id|nct_id|group_type|title|description
3036466|NCT00309166|Experimental|Cervarix Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
3036467|NCT00309166|Active Comparator|Engerix-B Group|Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
3036468|NCT00309244|Experimental|TI + Insulin glargine|Technosphere® Insulin Inhalation Powder + insulin glargine
3036469|NCT00309244|Active Comparator|BPR 70/30|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
3036470|NCT00309387|Experimental|Centrum|multivitamin-mineral supplement. RDA dosage. 1 tablet a day for the whole study duration.
3036471|NCT00309387|Placebo Comparator|placebo|placebo pills. One tablet a day for the whole study duration.
3036472|NCT00309452|Active Comparator|Treatment as usual|Referral to community providers.
3036473|NCT00309452|Experimental|STEP Care|Integrated and comprehensive treatment provided by a specialized team in a public mental health center.Interventions include pharmacotherapy, family education, cognitive behavioral group and individual psychotherapy and case management focused on vocational rehabilitation.
3036474|NCT00309465|Experimental|1|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
3036475|NCT00309465|Active Comparator|2|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose.
3036476|NCT00309465|Experimental|3|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
3036477|NCT00309608|Experimental|Linagliptin low dose|Patients receive Linagliptin low dose tablets once daily
3036478|NCT00309608|Experimental|Linagliptin medium dose|Patients receive Linagliptin medium dose tablets once daily
3036479|NCT00309608|Experimental|Linagliptin high dose|Patients receive Linagliptin high dose tablets once daily
3036480|NCT00309608|Placebo Comparator|Placebo|Patients receive tablets identical to those containing Linagliptin low, medium and high dose
3036481|NCT00309608|Active Comparator|Glimepiride|Patients receive Glimepiride tablets once daily
3036482|NCT00309738|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3036483|NCT00309738|Active Comparator|Simvastatin 40 mg QD|Simvastatin 40 mg once daily
3036484|NCT00309751|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3036485|NCT00309751|Active Comparator|Atorvastatin 20 mg QD|Atorvastatin 20 mg once daily
3036486|NCT00309777|Experimental|Pitavastatin 2 mg|Pitavastatin 2 mg once daily
3036487|NCT00309777|Active Comparator|Simvastatin 20 mg|Simvastatin 20 mg once daily
3036488|NCT00309777|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
3036489|NCT00309777|Active Comparator|Simvastatin 40 mg|Simvastatn 40 mg once daily
3036490|NCT00309842|Experimental|Unrelated UCBT for Blood Cancers|Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.
3036491|NCT00309907|Experimental|Etanercept and corticosteroid therapy|Patients receive etanercept IV (dose 0.4 mg/kg- max 25 mg) over 30 minutes on day 0 and subcutaneously (dose 0.4 mg/kg- max 25 mg) on days 3, 7, 10, 14, 17, 21, and 24. Treatment continues in the absence of an infectious pathogen, disease progression, or unacceptable toxicity. Patients also receive methylprednisolone (or corticosteroid equivalent) IV (dose 2.0 mg/kg/day) on days 0-2 and then orally with a taper beginning day 7. Dose on days 7-20 (1.0 mg/kg/day), days 21-34 (0.5 mg/kg/day), days 35-48 (0.25 mg/kg/day) and days 49-56 (0.25 mg/kg/every other day) discontinuing on day 56.
3036492|NCT00309946|Experimental|Treatment (enzyme inhibitor therapy)|Initial cediranib maleate dosing was 45 mg (once daily) during a 28-day cycle. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity. Due to substantial toxicity, the starting dose was subsequently lowered to 30 mg daily.
3036493|NCT00309959|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive ABI-007 IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3036494|NCT00309985|Experimental|Androgen-Deprivation Therapy and Docetaxel|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3036495|NCT00309985|Active Comparator|Androgen-Deprivation Therapy alone|Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration) alone.
3036496|NCT00310037|Experimental|Arm A maintenance therapy|Patients receive bortezomib 1.6 mg/m^2 IV on days 1, 8, 15, and 22 once daily for 4 weeks. There will be a 4 week rest period. One cycle is a total of 8 weeks. A total of 10 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
3036497|NCT00310037|Experimental|Arm B consolidation therapy|Patients receive bortezomib 1.3 mg/m^2 IV on days 1, 4, 8, and 11 once daily for 3 weeks. One cycle is a total of 3 weeks. A total of 4 cycles of bortezomib will be given in the absence of disease progression or unacceptable toxicity.
3036498|NCT00310050|Experimental|Pemetrexed in combination with concomitant radiotherapy|Patients will receive Pemetrexed plus Radiotherapy.
3036499|NCT00310076|Experimental|Chemo therapy followed by thalidomide|After cytoreductive surgery with intraperitoneal hyperthermic chemotherapy, patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
3178830|NCT00666159|Experimental|1|
3178831|NCT00666159|Active Comparator|2|
3178832|NCT00666185|Experimental|1|
3468742|NCT03892681|Other|contrast agents for liver MRI|
3468743|NCT03892837|Active Comparator|Control group|Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
3468744|NCT03892837|Experimental|PRP group|Procedure/Surgery: PRP PRP treatment following the conventional treatment Slow spray / inject autogenous PRP to cover the wound of stenosis. Procedure/Surgery: Conventional therapy of airway stenosis is including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
3036504|NCT00310310|Placebo Comparator|Usual Care|Usual sleep apnea and cpap care
3036505|NCT00310310|Experimental|Self-Management|sleep apnea self-management program - 4 sessions, group-based
3036506|NCT00310362|Experimental|Usual Care with nurse phone call|Usual Care--Nurses telephoned patients 7 days prior to appointment to remind patients about scheduled GI appointment and to answer any questions.
3036507|NCT00310362|Experimental|interactive voice response 3 days prior|Interactive voice response system was used to remind patients 3 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR3)
3036508|NCT00310362|Experimental|interactive voice response 7 days prior|Interactive voice response system was used to remind patients 7 days before a scheduled appointment and to educate them about preparation procedures for the appointment (IVR7)
3036509|NCT00310375|Experimental|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets - 50mg, 100mg or 300mg
3178833|NCT00666185|Active Comparator|2|
3036511|NCT00310401|Experimental|Albuterol|Albuterol sulfate 5 mg dissolved in normal saline administered every 4 hours by nebulization
3036512|NCT00310401|Placebo Comparator|Saline|Saline administered every 4 hours by nebulization
3036513|NCT00310427|Experimental|LY686017|Subjects received 50 mg of the NK1 antagonist LY686017 orally on a daily basis.
3036514|NCT00310427|Placebo Comparator|Placebo|Subjects received placebo orally on a daily basis
3036515|NCT00310440|Experimental|Bone graft substitute|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with P-15 synthetic osteoconductive bone substitute (investigational device).
3036516|NCT00310440|Active Comparator|Autologous Bone|Subjects will receive anterior cervical discectomy with fusion and instrumentation (anterior plate). Structural allograft ring will be used. The cavity of the ring will be filled with local autologous bone.
3036517|NCT00310466|Active Comparator|Sublingual immunotherapy|sublingual immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
3036518|NCT00310466|Placebo Comparator|Placebo|placebo sublingual drops
3036519|NCT00310791|Placebo Comparator|Sugar Pill|Placebo (sugar pill); identical to treatment medication capsule
3036520|NCT00310791|Experimental|DHEA + Hormone replacement therapy (estrogen/progestin)|Combined therapy of dehydroepiandrosterone (DHEA) and hormone replacement therapy (ERT). Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse (20 mg ethinyl estradiol + 0.1 mg levonorgestrel for 15 months). The estrogen/progestin component of the regimen has been chosen to maximize patient compliance, as patients with AN may experience bloating or nausea if higher estrogen doses (> 20 g) are initiated too rapidly. The DHEA capsule strength will be 50 mg, the total daily dose to be studied in combination with HRT. The micronized DHEA preparation achieves more constant DHEA and DHEA-S levels. Fifty milligrams appears to be a physiological replacement dose for these young women, determined both from our pilot (10) and longitudinal studies (7).
3036521|NCT00310804|Experimental|cTIV_lot 1|
3036522|NCT00310804|Experimental|cTIV_lot 2|
3036523|NCT00310804|Experimental|cTIV_lot 3|
3036524|NCT00310804|Active Comparator|TIV group|
3036525|NCT00310817|Experimental|MenACWY-CRM(Ad+) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine with adjuvant (Ad+) on day 1 and second dose at 28 days or at 6 months or at 12 months after the first vaccination.
3036526|NCT00310817|Experimental|MenACWY-CRM(Ad-) 12 to 35 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant (Ad-) on day 1 and second dose either at 28 days or at 6 months or at 12 months after the first vaccination.
3036527|NCT00310817|Experimental|MenACWY-CRM(Ad-) 36 to 59 Months|Subjects received one dose of MenACWY-CRM conjugate vaccine without adjuvant on day 1 and second dose on day 169 or day 337.
3036528|NCT00310817|Active Comparator|MenACWY-PS (36 to 59 Months)|Subjects received one dose of MenACWY polysaccharide (PS) vaccine on day 1 and second dose of MenACWY-CRM conjugate vaccine without adjuvant on day 169 or day 337.
3036529|NCT00310856|Experimental|MenACWY-CRM_6-12 M|Subjects received 2 doses of MenACWY-CRM (1 dose at 6 and 12 months of age). Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
3036530|NCT00310856|Experimental|MenACWY-CRM_12 M|Subjects received 1 dose of MenACWY-CRM at 12 months of age. Subjects also received routine vaccines: 2 doses of PC7 (1 dose at 6 and 12 months of age), 1 dose of DTaP-Hib-IPV (at 6 months of age) and 1 dose of MMR+Varicella (at 13 months of age)
3036531|NCT00310856|Experimental|MenC-CRM_12 M_MenACWY-CRM_18 M|"Subjects received 1 dose of MenC-CRM (at 12 months of age) and 1 dose of MenACWY-CRM (at 18 months of age).~Subjects also received routine vaccines: 1 dose of PCV7 (at 12 months), MMR+Varicella (at 13 months) and DTaP-Hib-IPV (at 18 months)"
3036532|NCT00311155|Experimental|1|"Olmesartan medoxomil oral tablets for 4 weeks followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets for 8 weeks, followed by, if necessary:~Olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets + amlodipine oral tablets for 8 weeks"
3036533|NCT00311168|Experimental|VIP On, Then VIP Off|Participants first have VIP programmed On after randomization until 3 months, followed by VIP programmed Off from 3 to 6 months.
3178834|NCT00666237|Experimental|Tube shunt surgery group|Participants in this group will receive a tube shunt surgery (Baerveldt Glaucoma implant).
3036534|NCT00311168|Experimental|VIP Off, Then VIP On|Participants first have VIP programmed Off after randomization until 3 months, followed by VIP programmed On from 3 to 6 months.
3036535|NCT00311181|Experimental|2.5/3.5/4.5 ms defibrillation waveform|
3036536|NCT00311246|Experimental|An open-label|Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52
3036537|NCT00311311|Active Comparator|1|Tacrolimus + MMF + Steroids
3036538|NCT00311311|Experimental|2|Tacrolimus + MMF + Steroids with conversion from Tacrolimus to Sirolimus at 3-4 months post-transplant
3036539|NCT00311363|Experimental|GEn (XP13512) 1200 mg|GEn (XP13512) 1200 mg
3036540|NCT00311363|Placebo Comparator|Placebo|Placebo
3036541|NCT00311376|Experimental|1|botulinum toxin Type A (200U)
3036542|NCT00311376|Experimental|2|botulinum toxin Type A (300U)
3036543|NCT00311376|Other|3|placebo; botulinum toxin Type A (200U)
3036544|NCT00311376|Other|4|placebo; botulinum toxin Type A (300U)
3036545|NCT00311402|Other|Aggrenox Capsule|
3036546|NCT00311402|Other|Acetylsalicylic Acid (ASA) 81 mg Tablet|
3036547|NCT00311584|Experimental|Disease measurable by CT or MRI scan (Irinotecan/Temozolomide)|Measurable by CT scan (Computed Tomography) or MRI scan (Magnetic Resonance Imaging). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3036548|NCT00311584|Experimental|Disease eval by bone marrow or MIBG (Irinotecan/Temozolomide)|Evaluation by bone marrow or MIBG scan (metaiodobenzylguanidine scan, a radiopharmaceutical). Patients receive irinotecan hydrochloride IV (10 mg/m2/dose) over 1 hour on days 1-5 and 8-12 and oral temozolomide (100 mg/m2/dose) on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3036549|NCT00311623|Active Comparator|Control group|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Receive no intervention on Days 1-14. Surgery performed on Day 15."
3036550|NCT00311623|Experimental|Low-dose Rapamycin (3mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
3036551|NCT00311623|Experimental|High-dose Rapamycin (6mg)|"Men >18years old with prostate cancer clinical stages T1c to T3, no metastases, Gleason sum of 7-10, multiple positive diagnostic cores, Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, candidates for radical prostatectomy.~Must have adequate hepatic, renal and bone marrow function, no allergy to rapamycins, avoid medications interfering with rapamycin metabolism, no active infection, no prior therapies for prostate cancer.~Will receive rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) oral (PO) once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15)."
3036552|NCT00311766|Placebo Comparator|1|Placebo comparator gel does not contain any active drug. Topical administration of 0.0% Thymosin Beta 4 gel, once a day (qd) up to 56 days
3036553|NCT00311766|Active Comparator|2|Topical Administration of 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel once a day (qd) up to 56 days
3036554|NCT00312195|Experimental|BTDS (5, 10 or 20)|Buprenorphine transdermal patch
3036555|NCT00312195|Placebo Comparator|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch
3036556|NCT00312208|Experimental|1|Doxorubicin in combination with cyclophosphamide followed by docetaxel (AC -> T)
3036557|NCT00312208|Experimental|2|Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
3036558|NCT00312221|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
3036559|NCT00312221|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
3036560|NCT00312221|Experimental|Oxycodone Immediate-Release (Oxy IR) 40 mg|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
3036561|NCT00312338|Experimental|Infected Patient treated with Vigamox|Conjunctivitis-Infected Patient receiving Vigamox 0.5% in both eyes three times daily for 7 days.
3036562|NCT00312338|No Intervention|Healthy Subjects|Healthy Subjects receiving no treatment
3036563|NCT00312377|Active Comparator|1|Docetaxel monotherapy
3036564|NCT00312377|Experimental|2|Vandetanib + Docetaxel
3036565|NCT00312494|Placebo Comparator|Placebo|
3036566|NCT00312494|Experimental|Ziprasidone 20-40mg twice a day (BID)|
3036567|NCT00312494|Experimental|Ziprasidone 60-80mg BID|
3036568|NCT00312572|Experimental|BTDS10/20|Initial doses (Level 1) of BTDS 10. Subjects were allowed to have their doses adjusted to BTDS 20 (Level 2) on or after day 4.
3036569|NCT00312572|Experimental|BTDS 20|Initial doses (Level 1) of BTDS 20.
3036570|NCT00312663|Experimental|10ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
3036571|NCT00312663|Experimental|50ug dose FMP011|Falciparum Malaria Protein 11 with AS01B adjuvant
3036572|NCT00312702|Experimental|10µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
3036573|NCT00312702|Experimental|50µg dose FMP011|Falciparum Malaria Protein 11 with AS02A adjuvant
3036574|NCT00312728|Experimental|bevacizumab|
3036575|NCT00312845|Experimental|Bortezomib + Rituximab|
3036576|NCT00312845|Active Comparator|Rituximab|
3036577|NCT00312858|Active Comparator|1|Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
3036578|NCT00312858|Active Comparator|2|Arm 2: ProQuad™ 0.5 mL injection (2 doses ~8 months apart), Prevnar™ 0.5 mL injection (one dose), both administered concomitantly, VAQTA™ 0.5 mL injection (2 doses 6 months apart) administered alone. 34 weeks of study duration.
3036579|NCT00312884|Active Comparator|Usual Care|Recieved usual hospital and community care
3036580|NCT00312884|Experimental|Intervention Arm|Recieved telemonitoring
3036581|NCT00312897|Placebo Comparator|corn oil|as stated
3036582|NCT00312897|Experimental|Omega 3 Fatty Acids|as stated
3036583|NCT00312923|Experimental|Policosanol|20 mg daily of policosanol
3036584|NCT00312923|Placebo Comparator|Placebo|20 mg of microcrystalline cellulose daily
3036585|NCT00313014|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
3036586|NCT00313014|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
3036587|NCT00313014|Experimental|Oxycodone Immediate-Release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
3036588|NCT00313170|Experimental|1|Fulvestrant 250 mg (intramuscular injection 250 mg)
3036589|NCT00313170|Experimental|2|Fulvestrant 250 mg (+ 250 mg loading regimen)
3036590|NCT00313170|Experimental|3|Fulvestrant 500 mg (intramuscular injection 500 mg)
3036591|NCT00313209|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: salmeterol 50 μg, twice daily, inhaled"
3036592|NCT00313209|Placebo Comparator|Placebo|"Placebo~underlying medication: salmeterol 50 μg, twice daily, inhaled"
3036593|NCT00313300|Active Comparator|A1|
3036594|NCT00313300|Experimental|A2|
3036595|NCT00313300|Placebo Comparator|A3|
3036596|NCT00313300|Experimental|A4|
3036597|NCT00313313|Experimental|Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)|Metformin 500-2500 mg (as needed)
3036598|NCT00313313|Experimental|Saxagliptin 5 mg + Glyburide 7.5 mg (B)|Metformin 500-2500 mg (as needed)
3036599|NCT00313313|Placebo Comparator|Placebo + Glyburide 7.5 mg (C)|Metformin 500-2500 mg (as needed)
3036600|NCT00313443|Experimental|Amiodarone, long-term|Unique arm: all patients were taking amiodarone for more than 6 months and all patietns underwent amiodarone dosage in blood and fat tissue samplings
3036601|NCT00313560|Experimental|Erlotinib and EBRT after pancreatectomy|"Adjuvant treatment with erlotinib 100 mg plus Capecitabine 800 mg/m2 PO BID (5 days on/ 2 days off regimen) and External Beam Radiation Therapy (EBRT) at doses of 50.4 Gy in 28 fractions after pancreatectomy (Dosing for capecitabine and erlotinib was amended after considering the toxicity profile of the first 6 patients).~Approximately 4-8 weeks after the conclusion of chemoradiation, it is recommended patients will continue treatment with 4 cycles of gemcitabine 1000 mg/m2 days 1, 8, and 15 every 28 days plus daily erlotinib 100 mg."
3036602|NCT00313586|Experimental|Arm A (azacitidine)|Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
3036603|NCT00313586|Experimental|Arm B (azacitidine, entinostat)|Patients receive azacitidine as in Arm A and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
3036604|NCT00313612|Experimental|Treatment (oxaliplatin plus topotecan)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and topotecan IV continuously on days 1-14. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed at 30 days.
3036605|NCT00313716|Active Comparator|Epo1 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger of 10gm/dl
3036606|NCT00313716|Active Comparator|Epo1 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, at 24 and 48 hrs after injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
3036607|NCT00313716|Active Comparator|Epo2 and TT10|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 10gm/dl
3036608|NCT00313716|Active Comparator|Epo2 and TT7|recombinant human erythropoietin, rhEpo administration (500 IU/kg within 6 hrs of injury, and at 9 and 16 days after injury) and hemoglobin transfusion trigger 7gm/dl
3036609|NCT00313716|Placebo Comparator|Placebo and TT10|Placebo administration and transfusion threshold 10 gm/dl
3036610|NCT00313716|Placebo Comparator|Placebo and TT7|Placebo administration and transfusion threshold 7 gm/dl
3036611|NCT00313729|Experimental|Temozolomide|Temozolomide
3036612|NCT00313781|Experimental|A|For patients treated with docetaxel and prednisone only, who progress during treatment, CP-751,871 will be added to the regimen to test reversibility of chemoresistance.
3036613|NCT00313781|Active Comparator|B|
3036614|NCT00313820|Active Comparator|Pregabalin|The change from in pain scores from baseline to endpoint among stroke subjects receiving pregabalin will be compared to change in pain scores from baseline to endpoint among stroke subjects receiving matched placebo.
3036615|NCT00313820|Placebo Comparator|Placebo|The change in pain scores from baseline to endpoint will be compared among the two treatment groups- ie subjects receiving 12 weeks of pregabalin treatment vs subjects receiving 12 weeks of placebo treatment.
3036616|NCT00313846|Experimental|BTDS|Buprenorphine transdermal patch 5, 10 or 20 micrograms/hour (mcg/h)
3036617|NCT00313846|Placebo Comparator|Placebo|Placebo to match BTDS 5, 10 or 20 mcg/h
3036618|NCT00313911|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
3036619|NCT00313911|Active Comparator|Group 2: Tritanrix-Hep B/Hib™+OPV|
3036620|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, prior IL-2|Patients that received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses).
3036621|NCT00314106|Experimental|TBI 1200 cGy + TIL +HD IL-2, no prior IL-2|Patients that have not received prior interleukin 2 (IL-2) therapy will receive a myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x 2 days intravenous (IV)), fludarabine (25mg/m^2/day IV X 5 days) and 1200 cGy total body irradiation (TBI). Following the lymphodepleting regimen, patient will receive intravenous adoptive transfer of tumor reactive lymphocytes (minimum 3 X 10 (9) and up to a maximum of 3 X 10(11) lymphocytes) followed by high-dose intravenous (IV) IL-2 (720,000 IU/kg/dose every 8 hours for up to 15 doses)
3036622|NCT00314132|Placebo Comparator|Placebo|All subjects received a single injection of placebo on Day 0.
3036623|NCT00314132|Experimental|ChimeriVax™ JE 4 log10 PFU Vaccine|All participants received a single injection of ChimeriVax™ JE 4 log10 Plaque-forming unit (PFU) Vaccine on Day 0.
3036624|NCT00314145|Experimental|ChimeriVax™-JE|Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
3036625|NCT00314145|Active Comparator|JE-VAX®|Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.
3036626|NCT00314236|Experimental|Microfracture with BST-CarGel|BST-CarGel applied to a Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
3036627|NCT00314236|Active Comparator|Microfracture without BST-CarGel|Microfractured lesion in repair of focal articular cartilage lesions on the femoral condyle
3036628|NCT00314249|Placebo Comparator|Placebo|Placebo, oral administration, twice daily for 12 weeks
3036629|NCT00314249|Experimental|Milnacipran|Milnacipran 100mg/day (50mg BID [twice a day])
3036630|NCT00314262|Experimental|Erlotinib & Celecoxib|
3036631|NCT00314340|Active Comparator|extended-release morphine|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On one of three study dates, subjects received ER morphine tablets, 45 mg (Mallinckrodt Pharmaceuticals, St. Louis, MO). The dose of ER morphine sulfate (45 mg) was selected because of its approximate equianalgesic effect to the dose of hydrocodone-acetaminophen (30/925 mg)."
3036632|NCT00314340|Active Comparator|hydrocodone|"Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity~On the day of the study session, patients received hydrocodone 30 mg plus N-acetyl-para-aminophenol 975 mg (APAP;Qualitest Pharmaceuticals Inc, Huntsville, AL)."
3036633|NCT00314340|Placebo Comparator|placebo|Subjects received a placebo pill if randomized to this arm. Both opioid medications and the placebo were administered in identical capsules.
3036634|NCT00314366|Active Comparator|Stem Cell Therapy|Subjects are randomized to receive Stem Cell Therapy (treatment) at the time of enrollment where cells are delivered after NOGA mapping and cells injected with the Myostar catheter.
3036635|NCT00314366|Placebo Comparator|Control|"Placebo patients will receive injections of plasma (control) instead of stem cells. Placebo patients are able to crossover and receive active treatment at 6 months if they meet the criteria.~At 6 months, subject is offered stem cell therapy and then followed for 12 months."
3036636|NCT00314574|Experimental|Xolair|"The subcutaneous dose of Xolair administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
3036637|NCT00314574|Placebo Comparator|placebo|"The subcutaneous dose of placebo administered in this study was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.~Participants maintained their high-dose inhaled corticosteroid (minimum of 500 µg of fluticasone dry powder inhaler twice a day or its ex-valve equivalent) and Long-Acting Beta-Agonist dose (either 50 µg salmeterol twice daily or 12 µg formoterol twice daily) throughout the study.~Participants were permitted to use albuterol as rescue medicine throughout the study."
3036638|NCT00314795|Experimental|Peginesatide|"Peginesatide 0.05 mg/kg injection, subcutaneously as a starting dose followed by peginesatide 0.1 mg/kg injection, subcutaneously once every 4 weeks for up to 6 months.~Individual dose of peginesatide injection was modified based on hemoglobin levels. Dose adjustments were made in order to achieve and maintain hemoglobin in the target range of 10.0-12.0 g/dL."
3036639|NCT00314808|Experimental|Dronabinol|
3036640|NCT00314951|Experimental|fidaxomicin|Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours [q12h] regimen) with intermittent matching placebo to fidaxomicin
3036641|NCT00314951|Active Comparator|Vancomycin|Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours [q6h] regimen).
3036642|NCT00315055|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|Participants will receive 3 vaccinations with Diphtheria (D) and tetanus (T) toxoids, acellular pertussis (2-component) (aP), recombinant Hepatitis B surface antigen (HBsAg), inactivated poliomyelitis virus (IPV), and Hemophilus influenzae type b (Hib) polysaccharide conjugated to tetanus protein (DTaP-IPV-Hep B-PRP~T); One dose each at 2, 3, and 4 months of age.
3036643|NCT00315055|Active Comparator|Group 2: PENTAXIM™ and ENGERIX B® PEDIATRIC|Participants will receive 3 vaccinations with DTaP-IPV-PRP~T (PENTAXIM™ ) and recombinant Hepatitis B (ENGERIX® PEDIATRIC) vaccines. One dose each at 2, 3, and 4 months of age.
3036644|NCT00315120|Other|A (Active OMT and active (UST)|Subjects in this group received active osteopathic manipulation and active ultrasound physical therapy
3036645|NCT00315120|Other|B (Sham OMT and active UST)|Subjects in this group received sham osteopathic manipulation and active ultrasound physical therapy
3036646|NCT00315120|Other|C (Active OMT and sham UST)|Subjects in this group received active osteopathic manipulation and sham ultrasound physical therapy
3036647|NCT00315120|Other|D (Sham OMT and sham UST)|Subjects in this group received sham osteopathic manipulation and sham ultrasound physical therapy
3036648|NCT00315146|Placebo Comparator|Hypocaloric diet (and placebo)|
3036649|NCT00315146|Active Comparator|Hypocaloric diet, resist. training to maximize power, placebo|
3036650|NCT00315146|Active Comparator|Hypocaloric diet and a PPAR- γ agonist (pioglitazone/Actos™)|
3036651|NCT00315146|Active Comparator|Hypocaloric diet,resistance training, pioglitazone/Actos™|
3036652|NCT00315302|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye
3036653|NCT00315302|Active Comparator|Atropine plus plano|Atropine 1% once each weekend day in the sound eye plus a plano lens for the sound eye
3036654|NCT00315328|Active Comparator|Patching|Patching 2 hours per day plus near activities for one hour while patching (with increase to 4 hours per day for moderate amblyopes and >4 hours per day for severe amblyopes at 5 weeks if acuity not improved at least 5 letters)
3178835|NCT00666237|Experimental|Trabeculectomy with Mitomycin C|Participants in this group will receive a Trabeculectomy surgery with Mitomycin C
3036655|NCT00315328|Active Comparator|Atropine|Atropine 1% once each weekend day in the sound eye plus near activities for at least one hour every day (with increase to daily atropine at 5 weeks if acuity not improved by at least 5 letters)
3036656|NCT00315341|Experimental|Buprenorphine/Nx|For the BUP/NX group, all participants will receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg buprenorphine increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
3036657|NCT00315341|Active Comparator|Methadone|For the MET group, all participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit. Investigators are encouraged to dose adequately to decrease craving and to obtain negative urine toxicology specimens.
3036658|NCT00315445|Placebo Comparator|Placebo|Placebo oxycodone (OXY)/acetaminophen (APAP) tablets and placebo transdermal patch (TDS) 5, 10, or 20
3036659|NCT00315445|Active Comparator|OXY/APAP|5 mg oxycodone/325 mg acetaminophen tablets
3036660|NCT00315445|Experimental|BTDS|Buprenorphine transdermal patch 5, 10, or 20 mcg/hour
3036661|NCT00315458|Experimental|BTDS|Buprenorphine transdermal patches 10 or 20 mcg/h
3036662|NCT00315458|Placebo Comparator|Placebo|Placebo to match buprenorphine transdermal patch 10 or 20
3036663|NCT00315588|Experimental|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
3036664|NCT00315614|Experimental|Islet Transplantation and Bone Marrow|Administration of islets and infusion of CD34 enriched Bone Marrow cells in subjects with type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemia.
3036665|NCT00315627|Experimental|islet transplantation|Islet Alone Transplantation under Alentuzumab (Campath1H) induction.
3036666|NCT00315705|Experimental|clofarabine, etoposide, cyclophosphamide|"Phase 1: escalating dosage of the three drugs delivered intravenously. Clofarabine dosage from 20-40 mg/m^2, etoposide dosage from 75-100 mg/m^2, cyclophosphamide dosage from 340-440 mg/m^2.~Phase 2: The recommended phase 2 doses (RP2D) were clofarabine 40 mg/m^2, etoposide 100 mg/m^2 and cyclophosphamide 440 mg/m^2 delivered intravenously"
3036667|NCT00315731|Experimental|tositumomab and iodine I 131 tositumomab|Subjects participating in this study will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I-131 tositumomab, immediately following an infusion of 450 mg of unlabeled tositumomab. Using the dosimetric data from three of the six imaging time points and the subject's weight, a patient-specific activity (mCi) of Iodine I-131 will be calculated to deliver the desired total body dose of radiation (75 cGy). All subjects will then receive an infusion of unlabeled tositumomab (450 mg) immediately followed by an infusion of the subject specific dose of tellurium-derived Iodine I-131 tositumomab (35 mg) to deliver a total body dose (TBD) of 75 cGy.
3036668|NCT00315822|Placebo Comparator|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
3036669|NCT00315822|Active Comparator|80% oxygen|Subject undergoing surgery will receive supplemental oxygen
3036670|NCT00315939|Experimental|Group A Order: SMBG, IBMF-1, IBMF-2|Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
3036671|NCT00315939|Experimental|Group B Order: IBMF-1, IBMF-2, SMBG|Group B began with Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.
3036672|NCT00316004|Experimental|7.5% hypertonic saline/6% dextran (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70
3036673|NCT00316004|Experimental|7.5% hypertonic saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline
3036674|NCT00316004|Placebo Comparator|0.9% normal saline (NS)|250 ml intravenous bolus administration of 0.9% saline
3036675|NCT00316017|Experimental|1|7.5% hypertonic saline/6% Dextran-70 (HSD)
3036676|NCT00316017|Experimental|2|7.5% hypertonic saline (HS)
3036677|NCT00316017|Placebo Comparator|3|0.9% normal saline
3036678|NCT00316082|Experimental|Saxagliptin 2.5 mg QAM (A)|PLUS open-label metformin (as needed as rescue medication)
3036679|NCT00316082|Experimental|Saxagliptin 2.5 mg titrated to 5 mg QAM (B)|PLUS open-label metformin (as needed as rescue medication)
3036680|NCT00316082|Experimental|Saxagliptin 5 mg QAM (C)|PLUS open-label metformin (as needed as rescue medication)
3036681|NCT00316082|Experimental|Saxagliptin 5 mg QPM (D)|PLUS open-label metformin (as needed as rescue medication)
3036682|NCT00316082|Placebo Comparator|Placebo (E)|PLUS open-label metformin (as needed as rescue medication)
3036683|NCT00316121|Experimental|1|
3036684|NCT00316121|Active Comparator|2|
3036685|NCT00316173|Experimental|Single-arm|HYCAMTIN at a dose of 2.0 - 2.5mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1, every 21 days
3036686|NCT00316186|Experimental|Single arm, open label|
3036687|NCT00316199|Experimental|A|
3036688|NCT00316225|Experimental|Pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) every 21 days for 6 cycles
3036689|NCT00316264|Experimental|Motavizumab followed by Palivizumab|2 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month)
3036690|NCT00316264|Experimental|Palivizumab followed by motavizumab|2 doses of palivizumab (15 mg/kg, administered as an intramuscular injection once/month) followed by 3 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
3036691|NCT00316264|Experimental|Motavizumab control|5 doses of motavizumab (15 mg/kg, administered as an intramuscular injection once/month)
3036692|NCT00316277|Experimental|Buprenorphine/Nx with EMM|
3036693|NCT00316277|Active Comparator|Buprenorphine/Nx with SMM|
3036694|NCT00316303|Experimental|1|Participants will receive screening, testing, immunization, and risk reduction. Screening and testing will take place at study entry, immunization will occur at entry and after 3 and 6 months, and risk reduction will take place at study entry and after 3 and 6 months.
3036695|NCT00316303|Placebo Comparator|2|Participants will receive enhanced treatment as usual.
3036696|NCT00316355|Active Comparator|Traditional CBT|Cognitive-behavioral therapy (CBT) that incorporates exposure with ritual prevention (EX/RP)
3036697|NCT00316355|Experimental|Stepped-Care CBT|Stepped-care CBT
3036698|NCT00316524|Experimental|GP 1: two x 1x10E08 TCID, MVA-BN® s.c., vaccinia naive|vaccinia naive subjects receiving two subcutanenous vaccinations with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID)
3036699|NCT00316524|Experimental|GP 2: 1x10E08 TCID, MVA-BN®, 1x Placebo, s.c., vaccinia naive|vaccinica naive subjects receiving one vaccination with 0.5ml MVA-BN® IMVAMUNE(1x10E08 TCID), followed by one vaccination Placebo (0.5ml Tris Buffer)
3036700|NCT00316524|Placebo Comparator|GP 3: two x Placebo, s.c., vaccinia naive|vaccinia naive subjects, receiving two subcutaneous vaccinations with Placebo (0.5ml Tris Buffer).
3036701|NCT00316524|Experimental|GP 4: 1x10E08 TCID, MVA-BN®, s.c., vaccinia experienced|vaccinia experienced subjects, receiving one subcutaneous vaccination with 0.5ml MVA-BN® IMVAMUNE (1x10E08 TCID).
3036702|NCT00316589|Experimental|Healthy subjects|Control group with and without a history of previous smallpox vaccination IMVAMUNE (MVA-BN)
3036703|NCT00316589|Experimental|HIV-infected, vaccinia-naive|Subjects without a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
3036704|NCT00316589|Experimental|HIV-infected, vaccinia-experienced|Subjects with a history of previous smallpox vaccination, IMVAMUNE (MVA-BN)
3036705|NCT00316602|Experimental|Healthy Participants|Healthy, vaccinia naive subjects without Atopic Dermatitis, receiving two doses of MVA-BN (IMVAMUNE)
3036706|NCT00316602|Experimental|Atopic Dermatitis Participants|"Vaccinia naive subjects with diagnosed Atopic Dermatitis. Diagnosed AD included subjects with either history of or subjects with currently active AD (defined as scoring AD [SCORAD] <= 30), receiving two doses of MVA-BN (IMVAMUNE)"
3036707|NCT00316693|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals HPV-16/18 vaccine (Cervarix™) according to a 0, 1, 6-month schedule.
3036708|NCT00316693|Active Comparator|Aimmugen Group|Subjects received 3 doses of Aimmugen™ (Hepatitis A [HAV] vaccine) according to a 0, 1, 6-month schedule.
3036709|NCT00316706|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals' HPV-16/18 Vaccine (Cervarix™) during the primary study (NCT00196924). Subjects from this group continued the long-term follow-up study until Month 48.
3036710|NCT00316706|Active Comparator|Havrix Group|Subjects received 3 doses of Havrix™ (hepatitis A vaccine [HAV]) during the primary study (NCT00196924). Subjects from the this group completed the study at Month 24.
3036711|NCT00316719|Experimental|Adefovir Dipivoxil (ADV)|
3036712|NCT00316719|Active Comparator|Lamivudine (LAM)|
3036713|NCT00316862|Experimental|Treatment (chemotherapy, chemoradiotherapy, surgery)|"INDUCTION CHEMOTHERAPY (COURSES 1-2): Patients receive cisplatin intravenously (IV) over 30 minutes and irinotecan hydrochloride IV over 30-90 minutes on days 1 and 8 of courses 1 and 2. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY (COURSES 3-4): Beginning 2 weeks after completion of induction chemotherapy, patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 1 and 8 of courses 3 and 4 and undergo radiotherapy daily 5 days a week in course 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Approximately 4-8 weeks after completion of chemoradiotherapy, patients undergo surgery to remove the tumor."
3036714|NCT00316888|Experimental|Arm I (closed to accrual as of 11/3/2008)|Patients receive cisplatin IV over 60 minutes on days 1, 29, 57, and 85 and fluorouracil IV continuously over 96 hours on days 1-4, 29-32, 57-60, and 85-88. Patients also receive cetuximab IV over 120 minutes on day 50 and then IV over 60 minutes on days 57, 64, 71, 78, 85, 92, and 99 and undergo radiotherapy once daily 5 days a week for 5 weeks, beginning on day 57. Treatment continues in the absence of disease progression or unacceptable toxicity.
3036715|NCT00316888|Experimental|Arm II (open to accrual on 8/18/2009)|Patients receive cetuximab IV over 120 minutes on day 1 and then IV over 60 minutes on days 8, 15, 22, 29, 36, 43, and 50. Patients also receive cisplatin IV over 60 minutes on days 1 and 36, fluorouracil IV continuously over 96 hours on days 8-11 and 36-39, and undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3036716|NCT00316914|Experimental|Ca/Mg|Patients receive calcium gluconate (Ca) and magnesium sulfate (Mg) IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
3036717|NCT00316914|Placebo Comparator|Placebo|Patients receive a placebo IV over 30 minutes immediately before and after each oxaliplatin administration (once every 2 weeks) of their assigned chemotherapy regimen.
3036718|NCT00317044|Experimental|Esomeprazole 40 mg twice daily|
3036719|NCT00317044|Experimental|Esomeprazole 40 mg once daily|
3036720|NCT00317044|Placebo Comparator|Placebo|
3036721|NCT00317109|Experimental|AC primed Group|
3036722|NCT00317109|Active Comparator|AC unprimed Group|
3036723|NCT00317226|Experimental|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
3036724|NCT00317239|Experimental|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
3036725|NCT00317239|Active Comparator|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
3036726|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 10ug|Subject vaccinated with 10 ug of FMP1/AS02A on days 0, 29 and 57
3036727|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 25 ug|Subject vaccinated with 25 ug of FMP1/AS02A on days 14, 42, and 70
3036728|NCT00317473|Experimental|FMP1/AS02A Malaria vaccine 50 ug|Subject vaccinated with 50 ug of FMP1/AS02A on days 28, 56 and 84
3036729|NCT00317473|Active Comparator|Imovax Rabies Vaccine|Subject vaccinated with Imovax Rabies Vaccine on corresponding FMP1/AS021 vaccination days
3178836|NCT00666250|No Intervention|Baseline|Baseline values off chocolate supplement
3178837|NCT00666250|Experimental|Low Dose|Low dose of dietary supplement 30 ml tid (Activ Xocai Drink)
3036730|NCT00317603|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
3036731|NCT00317642|Experimental|clofarabine (IV formulation) and cytarabine|"Participants received clofarabine (40 mg/m^2) administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Participants could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)~Complete induction cycle = 5 consecutive days of treatment~Re-induction cycle = 5 consecutive days of treatment at the original or modified dose~Consolidation cycle = 4 consecutive days of treatment at the original or modified dose"
3036732|NCT00317642|Experimental|placebo and cytarabine|Participants received placebo administered as a 1-hour infusion followed 3 hours later (from end of infusion) by cytarabine 1 g/m^2 administered as a 2-hour infusion. Patients could receive up to 3 cycles of treatment (induction, re-induction, and consolidation)
3036733|NCT00317720|Experimental|Trastuzumab + RAD001|Trastuzumab loading dose is 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle. Starting RAD001 dose 10 mg by mouth daily.
3036734|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject
3036735|NCT00317941|Experimental|IFNB-1b 250 mcg (Betaseron) via Betaject light|Interferon beta 1b ([IFNB-1b] Betaseron, BAY86-5046) 250 mcg (8 MIU) administered every other days by subcutaneous injection using Betaject Light
3036736|NCT00317941|Active Comparator|IFNB-1a 44 mcg (Rebif) via Rebiject II|Interferon beta-1a ([IFNB-1a] Rebif) 44 mcg (12 MIU) three times per week by subcutaneous injection using Rebiject II
3036737|NCT00318136|Experimental|Treated with Bevacizumab|
3036738|NCT00318149|Experimental|Fluarix 18-40 Y Group|Subjects (aged 18-40 years [Y]) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3036739|NCT00318149|Experimental|Fluarix ≥65 Y Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3036740|NCT00318149|Experimental|Fluarix-AS25 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS25, administered intramuscularly in the deltoid region of the non-dominant arm.
3036741|NCT00318149|Experimental|Fluarix-AS50 Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS50, administered intramuscularly in the deltoid region of the non-dominant arm.
3036742|NCT00318149|Experimental|Fluarix- AS01B Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01B, administered intramuscularly in the deltoid region of the non-dominant arm.
3036743|NCT00318149|Experimental|Fluarix- AS01E Group|Subjects (aged ≥ 65 years) received 1 dose of the Fluarix vaccine adjuvanted with AS01E, administered intramuscularly in the deltoid region of the non-dominant arm.
3036744|NCT00318292|Experimental|PLA|Active preemptive local analgesia.
3036745|NCT00318292|Placebo Comparator|Placebo|Placebo for preemptive local analgesia.
3036746|NCT00318357||CRT in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment plus CRT were compared to patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued ot follow up the original CARE-HF CRT group patients."
3036747|NCT00318357||Control in CARE-HF|"In the CARE-HF study patients treated with standard medical treatment. In the CARE-HF Long Term Follow-up part, almost all patients received CRT therapy on top of Optimal Medical Treatment. The CARE-HF LTFU study aims to further investigate mortality.~CARE-HF LTFU study continued to follow up the original CARE-HF control group patients."
3036748|NCT00318370|Experimental|Far Only|Farletuzumab only (Far Only): farletuzumab, 100 milligrams (mg)/square meter (m2).
3036749|NCT00318370|Experimental|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
3036750|NCT00318409|Active Comparator|Bupropion|buproprion XL 300mg daily
3036751|NCT00318409|Placebo Comparator|Placebo|placebo 300mg daily
3036752|NCT00318461|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3036753|NCT00318461|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3036754|NCT00318461|Experimental|Lira 1.8 + Met|Liraglutide 1.8 mg/day + glimepiride placebo + metformin 1.5-2.0 g/day
3036755|NCT00318461|Active Comparator|Met Mono|Metformin 1.5-2.0 g/day + liraglutide placebo + glimepiride placebo
3036756|NCT00318461|Active Comparator|Met + Glim|Glimepiride 4 mg/day + metformin 1.5-2.0 g/day + liraglutide placebo
3036757|NCT00318474|Active Comparator|Mycophenolate Mofetil (MMF)|Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
3036758|NCT00318474|Placebo Comparator|MMF Placebo|Subjects receive MMF placebo.
3036759|NCT00318565|Experimental|Navistar ThermoCool Catheter|
3036760|NCT00318591|Experimental|SpeediCath|hydrophilic-coated intermittent catheter
3036761|NCT00318591|Experimental|Conveen Uncoated|uncoated urinary intermittent catheter
3036762|NCT00318643|Experimental|Cohort 1: MMC plus Chemophase 20,000 U|Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
3036763|NCT00318643|Experimental|Cohort 2: MMC plus Chemophase 60,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
3036764|NCT00318643|Experimental|Cohort 3: MMC plus Chemophase 200,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
3178838|NCT00666250|Experimental|High-dose|High dose of dietary supplement 90 ml tid (Xocai Activ drink)
3036765|NCT00318643|Experimental|Cohort 4: MMC plus Chemophase 400,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
3036766|NCT00318643|Experimental|Cohort 5: MMC plus Chemophase 800,000 U|Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
3036767|NCT00318708|Experimental|clarithromycin + fluticasone|clarithromycin 500 mg twice daily (Biaxin) + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
3036768|NCT00318708|Active Comparator|placebo + fluticasone|placebo clarithromycin twice daily + fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
3036769|NCT00318812|Experimental|Heme Iron|Heme Iron Polypeptide 11mg PO tid for 6 months
3036770|NCT00318812|Active Comparator|Venofer|Venofer q month IV x 6 months
3036771|NCT00319020|Experimental|Bosentan|Bosentan was administered at 4 mg/kg twice daily (b.i.d.) until the end of the study. It could be down-titrated to 2 mg/kg b.i.d. if not well tolerated.
3036772|NCT00319046|Experimental|Open-label miglustat|Oral administration of miglustat 100 mg t.i.d. for a period of 2 years
3036773|NCT00319098|Experimental|GSK1562902A Group|Male and female subjects aged 18 or over received two intramuscular doses of the GSK1562902A study vaccine, at Day 0 and Day 21, into the non-dominant arm. The group was further stratified by age for analyses.
3036774|NCT00319098|Active Comparator|Fluarix+Placebo Group|Male and female subjects aged 18 or over received one dose of Fluarix™ vaccine at Day 0 and one dose of placebo at Day 21, intramuscularly into de non-dominant arm. The group was further stratified by age for analyses.
3036775|NCT00319111|Experimental|Bosentan|Open label bosentan treatment
3036776|NCT00319254|Experimental|Advanced breast cancer|
3036777|NCT00319436|Experimental|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
3036778|NCT00319436|Active Comparator|Standard Parent Education for Substance Using Mothers|This 12 session comparison intervention was designed to match the Maternal Mentalizing Therapy on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child care and child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
3036779|NCT00319449|Experimental|Ezetimibe 10 mg|Participants treated with 10 mg/day ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
3036780|NCT00319449|Placebo Comparator|Placebo 10 mg|Participants treated with 10 mg/day matching placebo to ezetimibe added to an ongoing treatment of 10 mg/day atorvastatin.
3036781|NCT00319501|Placebo Comparator|Placebo|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of placebo solution as a deep intramuscular injection in the mid to outer thigh. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of acute repetitive seizures (ARS).
3036782|NCT00319501|Experimental|Diazepam|During the Double-blind Period, participants received a single, age- and weight-appropriate dose of diazepam solution, ranging from 0.2 to 0.5 mg/kg, as a deep intramuscular injection in the mid to outer thigh. Additional doses were permissible during the Open-label Period. Drug was administered by a caregiver using a spring-driven, pressure-activated, prefilled autoinjector at the onset of an episode of ARS.
3036783|NCT00319553|Experimental|Adacel® Vaccine Group|
3036784|NCT00319553|Active Comparator|BOOSTRIX® Vaccine Group|
3036785|NCT00319592|Experimental|ChimeriVax™-JE|Subjects received 2 injections of placebo (normal saline), 1 each on Days 0 and 7, and 1 injection of ChimeriVax™-JE on Day 28.
3036786|NCT00319592|Active Comparator|JE-VAX®|Subjects received 1 injection of JE-VAX® each on Days 0, 7, and 28.
3036787|NCT00319644|Experimental|Minibal Arm|Using Mini bronchoalveolar lavage
3036788|NCT00319644|No Intervention|Tracheal Aspirates|standard of care for ICU.
3036789|NCT00319696|Experimental|Bosentan|Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
3036790|NCT00319735|Experimental|Investigational Treatment|"Cetuximab 400 mg/m2 IV over 120 minutes Day -14 (Loading Dose)~Cetuximab 250 mg/m2 IV over 60 minutes Day -7~Cetuximab 250 mg/m2 IV over 60 minutes Days 1, 8, 15, 22, 29 and 36~Combined with radiation therapy for six weeks.~Surgery for esophageal resection after 6 to 8 week rest period.~Subjects who consent will provide tissue samples."
3036791|NCT00319748|Experimental|Intent-To-Treat|Patients treated with at least one dose - 852A subcutaneous injection.
3036792|NCT00319748|Experimental|Evaluable Cohort|Patients who received all 24 doses of 852A per protocol.
3036793|NCT00319956|Active Comparator|Azithromycin Group|Group receives azithromycin
3036794|NCT00319956|Placebo Comparator|Placebo Group|Group receives placebo
3036795|NCT00319982|Experimental|I- Diltiazem|Diltiazem- study medication
3036796|NCT00319982|Placebo Comparator|II- Placebo|Placebo Comparator
3036797|NCT00320112|Experimental|Reciprocal Diabetes Peer Support program|peers are paired during the group visit and are encouraged to speak with their partner at least once a week for the 6 month duration of the study.
3036798|NCT00320112|Other|Nurse Case Management|patients are not paired in the NCM arm. they are provided with educational session on diabetes management and informed of case management services.
3036799|NCT00320190|Active Comparator|Dasatinib|Participants with chronic phase chronic myeloid leukemia (CML) who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
3036800|NCT00320190|Active Comparator|Imatinib|Participants with chronic phase CML who had only a suboptimal response after at least 3 months of therapy with imatinib, 400 mg.
3036801|NCT00320216|Placebo Comparator|Group I (Placebo)|Patients in the placebo group will receive placebo at Weeks 0, 1, 2, 3, and 16. At week 20, all patients will receive a single dose of ustekinumab 90 mg.
3036802|NCT00320216|Experimental|Group II (Ustekinumab 45 mg)|Patients will receive single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
3036803|NCT00320216|Experimental|Group III (Ustekinumab 90 mg)|Patients will receive 90 mg single dose ustekinumab at Week 0 and placebo at Weeks 1, 2, and 3. At Week 16 patients with PGA greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
3036804|NCT00320216|Experimental|Group IV|Patients will receive 45 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16, patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 45 mg. At week 20, all patients will receive placebo.
3036805|NCT00320216|Experimental|Group V|Patients will receive 90 mg of ustekinumab at Weeks 0, 1, 2, and 3. At Week 16 patients with Physician's Global Assessment (PGA) greater than or equal to 3 will receive ustekinumab 90 mg. At week 20, all patients will receive placebo.
3036806|NCT00320242|Active Comparator|1 mo baseline|1 mo baseline before visual cue: Cane or walker, no laserlight visual cue x 1 mo; + laserlight visual cue for 2nd mo
3036807|NCT00320242|No Intervention|2 month baseline|Cane or walker, no laserlight visual cue x 2 mo, + laserlight visual cue for 3rd mo
3036808|NCT00320255|Placebo Comparator|Cohort 1: Placebo|Participants received placebo tablets once daily
3036809|NCT00320255|Placebo Comparator|Cohort 1: Apixaban, 5 mg|Participants received apixaban as tablet, 5 mg, once daily
3036810|NCT00320255|Active Comparator|Cohort 1: Apixaban, 10 mg|Participants received apixaban as tablet, 10 mg, once daily
3036811|NCT00320255|Active Comparator|Cohort 1: Apixaban, 20 mg|Participants received apixaban as tablet, 20 mg, once daily
3036812|NCT00320255|Placebo Comparator|Cohort 2: Placebo|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received placebo once daily.
3036813|NCT00320255|Active Comparator|Cohort 2: Apixaban, 5 mg|Participants in this cohort were admitted to the trial following the addition of a protocol amendment (Amendment 5), which removed the prohibition of inclusion of patients receiving chemotherapy with concomitant antiangiogenic therapy with bevacizumab. Patients received apixaban as tablet, 5 mg, once daily.
3036814|NCT00320281|Placebo Comparator|placebo|Normal saline injections were used for placebo injections. Injections were based on treatment plan determined in clinical setting by study PI and physical therapist. 25 cc syringe was used and amount of saline injected was unit based on muscles to be injected according to the treatment plan.
3036815|NCT00320281|Active Comparator|Botulinum toxin A|Botulism toxin A dosage was based on plan developed in clinical setting with study PI and physical therapist. Drug was dosed in 25 cc syringe,diluted with normal saline and injections occured based on treatment plan.
3036816|NCT00320372||1. 500 VNS Patients|VNS Patients - Treatment-resistant depression patients treated with VNS Therapy.
3036817|NCT00320372||2. 300 Non-VNS Patients|Non-VNS Patients - Treatment-resistant depression patients not receiving VNS Therapy.
3036818|NCT00320385|Experimental|Arm 1: Lapatinib plus Trastuzumab|Lapatinib 1000mg once daily in combination with trastuzumab 4mg/kg loading dose followed by 2mg/kg weekly
3036819|NCT00320385|Experimental|Arm 2: Lapatinib|Lapatinib 1500mg once daily
3036820|NCT00320411|Experimental|Lapatinb|Lapatinib 1500mg QD
3036821|NCT00320489|Experimental|Olanzapine Pamoate Depot|Olanzapine pamoate depot
3036822|NCT00320489|Active Comparator|Olanzapine|Oral olanzapine
3036823|NCT00320515|Experimental|A|
3036824|NCT00320528|Experimental|Pure ADHD|Attention-Deficit/Hyperactivity Disorder (ADHD) alone. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3036825|NCT00320528|Experimental|ADHD+Internalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus internalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3036826|NCT00320528|Experimental|ADHD+Externalizing Disorders|Attention-Deficit/Hyperactivity Disorder (ADHD) plus externalizing disorders. Received atomoxetine: 0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
3036827|NCT00320541|Active Comparator|paclitaxel plus bevacizumab (PB)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
3036828|NCT00320541|Experimental|paclitaxel plus bevacizumab plus gemcitabine (PB+G)|paclitaxel 90 milligrams per meter squared (mg/m2) administered intravenously (IV) on days 1, 8, 15 every 28 days followed by gemcitabine 1500 mg/m2 IV on days 1 and 15 every 28 days followed by bevacizumab 10 milligrams per kilogram (mg/kg) administered IV on days 1 and 15 every 28 days
3036829|NCT00320593|Active Comparator|Progressive addition lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
3036830|NCT00320593|Active Comparator|Single vision lenses (SVLs)|Single vision lenses
3132835|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
3178839|NCT00666302|Experimental|1|
3036831|NCT00320606|Experimental|Immunosuppression Withdrawal|"Recipients of parental living donor liver transplants 4 or more years prior to trial enrollment, who also had stable allograft function during the preceding 6 months while taking a single immunosuppressive drug were permitted to undergo withdrawal of immunosuppression therapy. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.~Participants are carefully evaluated/monitored throughout the study by assessments including but not limited to liver biopsy, liver tests and clinic visits, alloantibodies, autoantibodies and quantitative immunoglobulin G test results."
3036832|NCT00320671|Experimental|Participants will take aripiprazole|Participants will take aripiprazole
3036833|NCT00320671|Experimental|Participants will take risperidone|Participants will take risperidone
3036834|NCT00320710|Experimental|Zoledronic acid every (q) 4 weeks|Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.
3036835|NCT00320710|Experimental|Zoledronic acid q 12 weeks|Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.
3036836|NCT00320710|Experimental|Placebo / zoledronic acid|Participants randomized to this arm received placebo but the arm was later dropped and participants in this arm were swithced to the zoledronic acid q 4 weeks according to a study amendment.
3036837|NCT00320749|Experimental|capecitabine, docetaxel, gemcitabine|Dose escalation study of mGTX using three dose levels (DL1-3). Patients received docetaxel on days 1 and 8, gemcitabine on days 8 and 15, and capcitabine on days 8 through 21. Gemcitabine fixed dose at 750 mg/m2 over 75 min, capecitabine twice daily and escalated from 500 to 650 mg/m2 at DL2 and docetaxel increased from 30 to 36 mg/m2 at DL3.
3036838|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q4|
3036839|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 0.5mg q12|
3036840|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q4|
3036841|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 2.0mg q12|
3036842|NCT00320788|Experimental|aflibercept injection (VEGF Trap-Eye, BAY86-5321) 4.0mg q12|
3036843|NCT00320801|Active Comparator|BTDS 5|Buprenorphine transdermal patch 5 mcg/h, applied for 7-day wear
3036844|NCT00320801|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h, applied for 7-day wear
3036845|NCT00321048|Experimental|ABC (Active Breathing coordinator)|Patients are randomized to ABC arm will receive radiation with ABC. Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the No ABC arm.
3036846|NCT00321048|No Intervention|No Active Breathing Coordinator|Patients randomized to the No ABC arm will receive radiation without ABC.Cardiac perfusion will be assessed at baseline and 6 months after treatment and the difference will be compared to that seen in the ABC arm.
3036847|NCT00321269|Active Comparator|Single Illness Managment|This intervention includes standard disease self-management coaching for heart failure and helps patients set goals for fluid management, restricted salt-intake, and medication adherence.
3036848|NCT00321269|Experimental|Comorbid Illness Management|This intervention includes the same self-management coaching found in the comparator arm, but also includes discussion of ways to cope and manage mood.
3036849|NCT00321373|Experimental|GSK1247446A-AS03 Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3036850|NCT00321373|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of non-adjuvanted GSK1247446A vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3036851|NCT00321373|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of the vaccination who received 1 dose of Fluarix vaccine. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3036852|NCT00321464|Active Comparator|zoledronic acid|
3036853|NCT00321464|Experimental|denosumab|
3036854|NCT00321555|Experimental|LMB-2 to Treat Hairy Cell Leukemia|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
3036855|NCT00321594|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3036856|NCT00321620|Active Comparator|zoledronic acid|
3036857|NCT00321620|Experimental|denosumab|
3036858|NCT00321646|Experimental|chemotherapy|docetaxel and bevacizumab prior to prostatectomy
3036859|NCT00321672|Experimental|NGX-4010, 60 minutes|
3036860|NCT00321672|Experimental|NGX-4010, 30 minutes|
3036861|NCT00321672|Other|0.04% conc. capsaicin patch, 60 min.|
3036862|NCT00321672|Other|0.04% conc. capsaicin patch, 30 min.|
3036863|NCT00321685|Experimental|Treatment (bevacizumab and chemoradiotherapy)|See Detailed Description
3036864|NCT00321698|Experimental|Phase I Dose 1-4|"Group 1=radiation only; Group 2=Docetaxel IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=Docetaxel IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
3036865|NCT00321698|Experimental|Phase II MTD Dose|"Phase II with no phase I dose-limiting toxicities=Docetaxel IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
3036866|NCT00321711|Active Comparator|Dose level 1 500 AMG 531 (Part A - azacitidine)|500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3036867|NCT00321711|Active Comparator|Dose level 1 750 AMG 531 (Part B - decitabine)|750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
3036868|NCT00321711|Active Comparator|Dose level 2 750 AMG 531 (Part A - azacitidine)|750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3178840|NCT00666302|Active Comparator|2|
3036869|NCT00321711|Placebo Comparator|Placebo (Part A - azacitidine)|Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
3036870|NCT00321711|Placebo Comparator|Placebo (Part B - decitabine)|Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
3036871|NCT00321737|Experimental|Dexlansoprazole MR 30 mg QD|
3036872|NCT00321737|Experimental|Dexlansoprazole MR 60 mg QD|
3036873|NCT00321737|Placebo Comparator|Placebo|
3036874|NCT00321763|Experimental|GSK1247446A Lot 1 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3036875|NCT00321763|Experimental|GSK1247446A Lot 2 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 2 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3036876|NCT00321763|Experimental|GSK1247446A Lot 3 Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 3 GSK1247446A vaccine adjuvanted with AS03 at Day 0. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3036877|NCT00321763|Experimental|GSK1247446A Pooled Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Lot 1, 2 or 3 GSK1247446A vaccines adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
3036878|NCT00321763|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of FluarixTM vaccine adjuvanted with AS03 at Day 0. The vaccines were administered intramuscularly into the deltoid region of the non-dominant arm.
3036879|NCT00321789|Experimental|Spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse developed a plan to support patient goal achievement.
3036880|NCT00321789|No Intervention|Usual care|Couples assigned to this arm received educational materials at baseline and usual care thereafter, with no contact from the study interventionist.
3036881|NCT00321828|Experimental|Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab|Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab
3036882|NCT00321854|Experimental|Early Pramipexole|Patients were treated with pramipexole for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
3036883|NCT00321854|Experimental|Delayed Pramipexole|Patients were treated with placebo for 6 to 9 months then up-titrated to target dose of pramipexole (2.25 mg/day).
3036884|NCT00321893|Experimental|Arm I: Budesonide|Inhaled Budesonide 800 ug twice daily for 1 year
3036885|NCT00321893|Placebo Comparator|Arm II: Placebo|Inhaled placebo twice daily for 1 year
3036886|NCT00321906|Active Comparator|Azathioprine|(tacrolimus,azathioprine/prednisone)
3036887|NCT00321906|Active Comparator|Sirolimus|tacrolimus/sirolimus/prednisone
3036888|NCT00321919|Experimental|Early Epoetin Beta Therapy|Participants received immediate epoetin beta therapy starting at 2000 IU, subcutaneously once weekly up to four years to reach a target Hb level of 13-15 g/dL; with an individual Hb increase of at least 2 g/dL within approximately 3 months.
3036889|NCT00321919|Active Comparator|Late Epoetin Beta Therapy|Participants received epoetin beta treatment starting at 2000 IU, subcutaneously once weekly up to four years only when a decline in Hb levels to <10.5 g/dL had occurred in order to reach a target Hb of 10.5-11.5 g/dL.
3036890|NCT00321932|Active Comparator|Arm I (control)|Patients receive oral cholecalciferol (vitamin D) and oral calcium once a day for 12 months.
3036891|NCT00321932|Experimental|Arm II (treatment)|Patients receive vitamin D and calcium as in arm I. Patients also receive zoledronic acid intravenously (IV) over 15-30 minutes at 28 days prior to stem cell transplantation and at 3 and 6 months after transplantation.
3036892|NCT00321971|Experimental|PST-MCI/AD Caregiving|The experimental Intervention (PST-MCI/AD Caregiving) focuses on training in adaptive problem-solving attitudes and skills (Problem-Solving Therapy or PST). It was adapted from a manualized protocol for PST use in primary care. Our adaptation sought to enhance problem-solving skill levels of family caregivers as they began to face a variety of potential caregiving stressor.
3036893|NCT00321971|Active Comparator|NT-MCI/AD Caregiving|"The comparison Intervention (Caregiver Nutritional Training (NT-MCI/AD) was based on the United States Department of Health and Human Services (USDHHS) 2005 My Pyramid Dietary Guidelines for Americans over Age 50. We chose a nutrition-based comparison intervention because information about dietary practices is not likely to affect mental health outcomes. The NT intervention was matched to the PST-based intervention in terms of number and duration of sessions."
3036894|NCT00321984|Experimental|Dexlansoprazole MR 30 mg QD|
3036895|NCT00321984|Experimental|Dexlansoprazole MR 60 mg QD|
3036896|NCT00321984|Placebo Comparator|Placebo|
3036897|NCT00322023|Experimental|D-serine 30 mg/kg|D-serine 30 mg/kg
3036898|NCT00322023|Experimental|D-serine 60 mg/kg|D-serine 60 mg/kg
3036899|NCT00322023|Experimental|D-serine 120 mg/kg|D-serine 120 mg/kg
3036900|NCT00322049|Experimental|Cohort A: Dengue Vaccine- Full Dose (T-DEN F17 )|"Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years;~DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection. All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection."
3036901|NCT00322049|Active Comparator|Cohort B: Control vaccines|Control vaccines: Hemophilus influenza type b (Hib) vaccine and varicella vaccine
3036902|NCT00322049|Experimental|Cohort C: Dengue Vaccine - 1/10 Dose (T-DEN F17 )|Dengue vaccine at Months 0 and 6 and booster follow-up at 3 years
3132836|NCT03456960|Experimental|Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).
3178841|NCT00666315||Harmonic|Group operated with Harmonic device
3036903|NCT00322101|Experimental|Arm I (Nonmyeloablative regimen)|"CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96."
3036904|NCT00322101|Experimental|Arm II (Myeloablative regimen)|"CONDITIONING: Patients are assigned to 1 of 2 treatment groups.~Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.~Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.~TRANSPLANTATION: Patients undergo PBSC infusion on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3036905|NCT00322153|Placebo Comparator|Placebo|Oral administration, once daily.
3036906|NCT00322153|Active Comparator|Memantine ER|28mg, once daily. Oral administration for 24 weeks.
3036907|NCT00322231|Experimental|ZOSTAVAX™ / Placebo|Zoster vaccine live on Day 1 (Period 1), placebo on Week 4 (Period 2)
3036908|NCT00322231|Experimental|Placebo / ZOSTAVAX™|Placebo on Day 1 (Period 1), zoster vaccine live on Week 4 (Period 2)
3036909|NCT00322309|Experimental|Mirtazapine|"Mirtazapine administration as follows:~Days 1-4 15mg of mirtazapine daily Days 5-9 30mg of mirtazapine daily Days 10-78 45mg of mirtazapine daily Days 79-81 30mg of mirtazapine daily Days 82-84 15mg of mirtazapine daily"
3036910|NCT00322309|Placebo Comparator|Placebo- Sugar pill|Matched Placebo given daily days 1-84
3036911|NCT00322335|Experimental|Menitorix/Pediarix Group|Subjects were primed with 3 doses of Pediarix™ co-administered intramuscularly with Menitorix™ in the right and left thigh respectively in the primary study (NCT00352963) at 2, 4 and 6 months of age. This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
3036912|NCT00322335|Active Comparator|Infanrix hexa (or IPV/Hib)/NeisVac-C/Engerix-B/Menitorix Group|Subjects were either primed in the primary study (NCT00352963) with 3 doses of Infanrix™ hexa administered intramuscularly in the right thigh at 2, 4 and 6 months of age and 2 doses of NeisVac-C™ administered intramuscularly in the left thigh at 2 and 4 months of age or with Engerix-B at birth intramuscularly in the right thigh, Infanrix™ hexa intramusculary in the right thigh at 2 and 6 months of age and NeisVac-C™ intramuscularly in the left thigh at 2 and 4 months of age, Infanrix™ IPV/Hib was administered intramuscularly in the right thigh at 4 months of age. All subjects were boosted with Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050. No vaccines were administered during this long-term persistence phase of the study.
3036913|NCT00322335|Active Comparator|Infanrix hexa/Meningitec Group|Subjects were primed with Infanrix™ hexa co-administered intramuscularly with Meningitec™ in the right and left thigh respectively at 2, 4 and 6 months of age during the primary study (NCT00352963), followed by a booster dose of Infanrix™ hexa intramuscularly in the right thigh between 13 and 14 months of age in study (NCT00323050). No vaccines were administered during this long-term persistence phase of the study.
3036914|NCT00322348|Experimental|ZOLADEX 10.8 mg|ZOLADEX (goserelin acetate) 10.8 mg intramuscular depot for injection every 12 weeks
3036915|NCT00322348|Experimental|ZOLADEX 3.6 mg|ZOLADEX (goserelin acetate) 3.6 mg intramuscular depot for injection every 4 weeks
3036916|NCT00322374|Experimental|25 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 25 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3036917|NCT00322374|Experimental|30 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 30 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3036918|NCT00322374|Experimental|35 mg/m^2 Ixabepilone plus 75 mg/m^2 Epirubicin|Participants received 35 mg/m^2 Ixabepilone as a 3-hour IV infusion following a 3- to 5-minute IV infusion of 75 mg/m^2 epirubicin every 21 days.
3036919|NCT00322387|Experimental|Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days.~Called 'Cohort A' in protocol, study report and publications."
3036920|NCT00322387|Experimental|Plerixafor AM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days.~Called 'Cohort B' in protocol, study report and publications."
3036921|NCT00322387|Experimental|Low CD34+ Count/ Plerixafor PM|"Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of >=10 cells/µL but <20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days.~Called 'Cohort C' in protocol, study report and publications."
3036922|NCT00322387|Experimental|Plerixafor After Chemo|"This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery.~Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached >= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms.~Called 'Investigational Cohort' in protocol, study report and publications."
3036923|NCT00322439||Etanercept|Participants received etanercept (Enbrel) treatment at the dose and regimen determined by the investigator and were evaluated for up to 5 years at 6-month intervals. During this period, participants may have discontinued etanercept therapy, may have switched to another anti-psoriatic therapy, may have used etanercept in combination with other anti-psoriatic therapies, or may have discontinued any or all antipsoriatic treatments.
3036924|NCT00322452|Experimental|1|gefitinib
3036925|NCT00322452|Active Comparator|2|Carboplatin/Paclitaxel
3036926|NCT00322465|Experimental|Doxycycline|Doxycycline 100 mg orally twice daily (2 pills/day = 200 mg/day) for 7 days plus placebo azithromycin orally single dose and placebo tinidazole.
3036927|NCT00322465|Experimental|Doxycycline + Tinidazole|Doxycycline 100 mg orally twice daily for 7 days plus placebo azithromycin single dose plus tinidazole 2 gm orally single dose (4 tablets at 500 mg each).
3036928|NCT00322465|Experimental|Azithromycin|Azithromycin 1 gram (gm) orally single dose (2 tablets at 500 milligrams (mg) each) plus doxycycline placebo twice daily for 7 days plus tinidazole placebo single dose.
3036929|NCT00322465|Experimental|Azithromycin + Tinidazole|Azithromycin 1 gm orally single dose (2 tablets at 500 mg each) plus doxycycline placebo twice daily for 7 days plus tinidazole single dose (4 tablets at 500 mg each).
3036930|NCT00322491|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3036931|NCT00322491|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3036932|NCT00322556|Experimental|IgPro10|See Intervention Description
3036933|NCT00322621|Experimental|Duloxetine|All subjects receive 30 mg once daily (QD), by mouth (per os - PO) for 1 week followed by duloxetine 60 mg QD, PO for 7 weeks, then maintenance at 60 mg QD, PO for responders to 6 months and rescue at 120 mg QD, PO for non-responders to 6 months. Patients beginning maintenance at the 60 mg QD dose could be increased to the 120 mg QD level if they did not maintain appropriate level of response throughout the maintenance period.
3036934|NCT00322777|Experimental|Spirituality Group|Arm where participants began the intervention (the Spirituality Teaching Program) upon recruitment for an 8 week period. Therefore, the program was initiated at week 1 of the trial.
3036935|NCT00322777|Active Comparator|Waitlist Control Group|Arm where participants began the intervention (the Spirituality Teaching Program) after an 8 week wait period. Therefore, the program was initiated at week 8 of the trial. Between week 1 and week 8, participants did not complete the program and were instructed to carry out their day to day activities as before.
3036936|NCT00322842|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3036937|NCT00322842|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3036938|NCT00322868|Experimental|Pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda
3036939|NCT00322881|Experimental|Carboplatin/Paclitaxel|Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
3036940|NCT00323037|Active Comparator|1|
3036941|NCT00323037|Active Comparator|2|
3036942|NCT00323063|Active Comparator|Arm I (Gemcitabine Hydrochloride)|Patients receive gemcitabine hydrochloride IV on days 3 and 10.
3036943|NCT00323063|Experimental|Arm II (Gemcitabine Hydrochloride + Imatinib)|Patients receive gemcitabine hydrochloride IV on days 3 and 10 and oral imatinib mesylate once daily on days 1-5 and 8-12.
3036944|NCT00323115|Experimental|Vaccine|
3036945|NCT00323193|Experimental|Arm 1|The intervention group completes approximately 8 individual level sessions with a MOVE specialist as well as approximately 8 group level intervention sessions.
3036946|NCT00323193|No Intervention|Arm 2|The control group offers basic information about diet and exercise every month for six months.
3036947|NCT00323258|Experimental|Intervention|Patients enrolled in the intervention arm received inpatient education on the importance of medication and assessment of barriers to adherence. A pill box, pocket medication card, and tips for remembering to take medications were provided. The community pharmacist was notified of the subject's enrollment. The community pharmacist was asked to reinforce importance of evidence-based medications and assess the subject's medication adherence every 6 weeks for 6 months. If a problem was noted, the subject's health care team will be notified.
3036948|NCT00323258|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the patient-care nurse and a letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations. Enrolled patients in the usual care arm were not disclosed to the community pharmacy until the end of the study period when refill records were requested.
3036949|NCT00323271|Experimental|Arm 1|Behavioral: Cognitive-behavior therapy
3036950|NCT00323271|Active Comparator|Arm 2|Interventional: Educational intervention
3036951|NCT00323284|Active Comparator|A--iStent plus Cataract Surgery|iStent plus Cataract Surgery
3036952|NCT00323284|Active Comparator|B--Cataract Surgery Only|Cataract Surgery only
3036953|NCT00323297|Placebo Comparator|placebo|
3036954|NCT00323297|Experimental|Active|
3036955|NCT00323310|Experimental|Gadobenate Dimeglumine|
3036956|NCT00323362|Experimental|Gemcitabine hydrochloride and imatinib mesylate|
3036957|NCT00323414|Active Comparator|Polyunsaturated fatty acid (Opti-EPA)|Polyunsaturated fatty acid will consist of purified EPA:DHA (360 mg EPA and 240 mg DHA) 6 gelcaps-3 capsules by mouth 2x per day x 48 weeks
3036958|NCT00323414|Placebo Comparator|Placebo|Gelcaps containing corn oil as placebo 6 capsules 3 capsules by mouth 2 x per day for 48 weeks
3036959|NCT00323427|Experimental|Arm 1|Group Aural Rehabilitation session, two hours in length, approximately 6 participants plus Group Facilitator
3036960|NCT00323427|Active Comparator|Arm 2|Veterans receive new VA issued digital hearing aids per Standard VA Audiology Hearing Aid services
3036961|NCT00323453|Experimental|Experimental Arm|The experimental arm will undergo open appendectomy utilizing the Alexis® retractor (wound protection device utilized intraoperatively), followed by standardized wound closure.
3036962|NCT00323453|Placebo Comparator|Control Arm|Open appendectomy and standardized wound closure
3036963|NCT00323492|Experimental|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization
3036964|NCT00323492|Active Comparator|Maintain Baseline Regimen|Maintain baseline regimen
3036965|NCT00323492|Experimental|Delayed Truvada|Truvada once daily with NNRTI or PI (participants from the comparator group who switched to Truvada during Study Phase 2)
3036966|NCT00323492|Experimental|All Truvada|Truvada once daily with NNRTI or PI (all participants who received Truvada during the study, i.e., participants in the Truvada and Delayed Truvada groups)
3036967|NCT00323557|Experimental|Pneumococcal Vaccine + GM-CSF|Vaccine subcutaneously + GM-CSF (3 Doses of 250 mg subcutaneously) given either Pre Vaccine at Day -7, Day -1 and Day 0 (day of pneumococcal vaccine) or Post Vaccine given at Day 0, Day +3 and Day +7.
3036968|NCT00323557|Experimental|Pneumococcal Vaccine Alone|First vaccine dose subcutaneously, Day 0.
3036969|NCT00323609|Active Comparator|Kyphoplasty|
3036970|NCT00323609|Active Comparator|Vertebroplasty|
3036971|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3036972|NCT00323622|Experimental|Cohort 1-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3036973|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 in the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3036974|NCT00323622|Experimental|Cohort 2-RTS,S/AS02A ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of RTS,S/AS02A (GSK 257049) vaccine at Months 0, 1 and 2 of the NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3036975|NCT00323622|Active Comparator|Cohort 1-Prevnar-Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3036976|NCT00323622|Active Comparator|Cohort 1-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study. Subjects in this group are part of the Cohort 1 of the study, which was followed for analysis of malaria infection.
3036977|NCT00323622|Active Comparator|Cohort 2-Prevnar- Hiberix <24M Group|Subjects, male and female, aged 12 to 24 months at first vaccination, were administered 2 doses of Prevnar™ vaccine at Months 0 and 2 and 1 dose of Hiberix® vaccine at Month 1 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3036978|NCT00323622|Active Comparator|Cohort 2-Engerix-B ≥24M Group|Subjects, male and female, aged between 24 and 48 months at first vaccination, were administered 3 doses of Engerix®-B vaccine at Months 0, 1 and 2 in the Primary NCT00197041 Study. Subjects in this group are part of the Cohort 2 of the study, which was followed for analysis of malaria disease. As Cohort 2 subjects, subjects in this group also received as part of the Primary NCT00197041 Study one dose of sulfadoxine-pyrimethamine and amodiaquine per day for 3 days 4 weeks prior to onset of surveillance, so as to clear any parasitemia. No additional dose of vaccine or drug was administered during this open follow-up NCT00323622 study.
3036979|NCT00323739|Experimental|Bevacizumab and RAD001|Bevacizumab 10mg/kg, IV infusion, every 2 weeks RAD001 10 mg by mouth daily
3178842|NCT00666315||Conventional|Group operated with Electrocauery and Clip/Suture
3178843|NCT00666341|Placebo Comparator|Placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
3036980|NCT00323869|Experimental|Bevacizumab + carboplatin + gemcitabine|"Bevacizumab in combination with carboplatin and gemcitabine:~•Carboplatin, administered IV at area under the curve (AUC) of 5, every 3 weeks on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles.~Carboplatin was administered before the gemcitabine infusion:~•Gemcitabine, administered 1000 mg/m² IV on days 1 and 8 of each 3-week cycle (twice per cycle) for up to 6 cycles~Bevacizumab was administered 1 hour after end of all chemotherapy infusions:~•Bevacizumab was administered 15 mg/kg IV on day 1 of each 3-week cycle (once per cycle) for up to 6 cycles in combination with chemotherapy, then continuing until evidence of progressive disease or significant treatment-related toxicity"
3036981|NCT00323882|Experimental|MDX-010|
3036982|NCT00323960|Active Comparator|Methylprednisolone pulse (MPDN)+PDN+CSA|MPDN= methylprednisolone pulse PDN= prednisone or equivalent CSA= cyclosporine A
3036983|NCT00323960|Active Comparator|MPDN+PDN+MTX|MPDN= methylprednisolone pulse PDN= prednisone or equivalent MTX= methotrexate
3036984|NCT00323960|Active Comparator|MPDN+PDN|MPDN= methylprednisolone PDN= prednisone or equivalent
3036985|NCT00324038|Experimental|buprenorphine transdermal system|Buprenorphine transdermal 7 day analgesic patch
3036986|NCT00324038|Active Comparator|codeine paracetamol tablets|codeine paracetamol combination tablets
3036987|NCT00324116|Experimental|Active|
3036988|NCT00324155|Experimental|Arm A: Ipilimumab and Dacarbazine|In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
3036989|NCT00324155|Active Comparator|Arm B: Placebo and Dacarbazine|
3036990|NCT00324168|Active Comparator|1|
3036991|NCT00324168|Placebo Comparator|2|
3036992|NCT00324233|Active Comparator|SC|Speedicath (SC) catheter is a catheter for intermittent catherisation
3036993|NCT00324233|Experimental|SCCM|SpeediCath Compact Male (SCCM) is a compact catheter for intermittent catherisation to be used by males
3036994|NCT00324259|Active Comparator|Arm 1 (6 mg estradiol)|6 mg of estradiol daily (2 mg tid).
3036995|NCT00324259|Active Comparator|Arm 2 (30 mg estradiol)|30 mg of estradiol. (10 mg tid)
3036996|NCT00324272|Experimental|Groin dissection: sealant used.|
3036997|NCT00324272|Active Comparator|Groin dissection: no sealant used.|
3036998|NCT00324272|Experimental|Axillary dissection: sealant used.|
3036999|NCT00324272|Active Comparator|Axillary dissection: no sealant used.|
3037000|NCT00324350|Active Comparator|1|intensive glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level below 6.0%)
3037001|NCT00324350|Active Comparator|2|standard glycemic control (therapeutic strategy that targets a glycosylated hemoglobin (HbA1c) level of 7 to 7.9%)
3037002|NCT00324415|Experimental|CMT with Radiation Therapy|"All patients will receive combined modality therapy (CMT) with 2 cycles of cisplatin and 5-FU chemotherapy, given concurrently with radiation therapy. CMT consists of:~Cetuximab 400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose).~Cisplatin 75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)~5-FU 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)"
3037003|NCT00324649|Experimental|Truvada|Truvada + NNRTI or PI.
3037004|NCT00324649|Active Comparator|Zidovudine/lamivudine|Zidovudine/lamivudine + NNRTI or PI.
3037005|NCT00324675|Active Comparator|Rosiglitazone|
3037006|NCT00324675|Placebo Comparator|placebo|
3037007|NCT00324701|Experimental|Telepsychology|therapy done at patients house
3037008|NCT00324701|Active Comparator|Face-to-face therapy|therapy delivered at the VAMC
3037009|NCT00324740|Experimental|Treatment (vorinostat and isotretinoin)|Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3037010|NCT00324753|Experimental|Intervention|Communication sheet
3037011|NCT00324753|Other|Control|Standard of care brochures
3037012|NCT00324805|Active Comparator|Arm I (chemotherapy)|"Patients receive one of the following. For all, treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~REGIMEN 1: Vinorelbine ditartrate 30 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV over 60 minutes on day 1 REGIMEN 2: Docetaxel 75 mg/m2 IV and cisplastin 75 mg/m2 IV on day 1 REGIMEN 3: Gemcitabine hydrochloride 1200 mg/m2 IV on days 1 and 8, cisplatin 75 mg/m2 IV on day 1 REGIMEN 4 (non-squamous histology only): Pemetrexed disodium 500mg/m2 IV and cisplatin 75 mg/m2 IV on day 1"
3037013|NCT00324805|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive chemotherapy as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab repeats every 21 days for up to 1 year.
3037014|NCT00324857|Placebo Comparator|Arm 1/Attention Control|Subjects randomized to the attention control arm received a patient educational booklet about OA published by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This booklet provides a brief educational program that summarizes how to live with knee OA but does not specifically mention joint replacement
3037015|NCT00324857|Active Comparator|Arm 2/Decision Aid (DA)|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
3037016|NCT00324857|Active Comparator|Arm 3/ Motivational Interview (MI)|Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain
3132837|NCT03456960|Experimental|Study 2,TAK-438ASA (Fasted + Fed condition)|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
3178844|NCT00666341|Experimental|20 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
3037017|NCT00324857|Active Comparator|Arm 4/ DA and MI|"Decision Aid Video: The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option.~Motivational Interviewing: The research intervention will conduct the fact-to-face MI session with the participant. This was used as a mechanism to help patients confront their thoughts about TKR and how to engage their primary care doctors about knee pain"
3037018|NCT00324870|Experimental|Arm I|"Phase I: Patients receive oral SAHA twice daily on days 1-14 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive SAHA at the MTD determined in phase I and bevacizumab as in phase I."
3037019|NCT00324896|Experimental|eszopiclone|eszopiclone. Those under 65yo received 3mg of eszoplicone ( or randomized to matching placebo)and those 65yo or older received 2mg of eszoplicone ( or randomized to matching placebo)taken each night at bedtime
3037020|NCT00324896|Placebo Comparator|placebo|Those randomly assigned to matching placebo, took their dose each night at bedtime
3037021|NCT00324961|Experimental|Single arm open label adefovir dipivoxil|adefovir dipivoxil once daily 10 mg orally
3037022|NCT00324987|Experimental|Arm I (CLOSED TO ACCRUAL 10/1/2009) (imatinib and bevacizumab)|Patients receive imatinib mesylate PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3037023|NCT00324987|Active Comparator|Arm II (CLOSED TO ACCRUAL 10/1/2009) (imatinib)|Patients receive imatinib mesylate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3037024|NCT00325039|Active Comparator|1|retropubic mid-urethral sling (TVT) The specific TVT used was the Tension-free Vaginal Tape (Gynecare)
3037025|NCT00325039|Active Comparator|2|"transobturator mid-urethral sling (TVT-O and the Monarc) Two transobturator slings were used: the Tension-free Vaginal Tape Obturator (Gynecare), which is placed starting inside the vagina and coming out through the obturator foramen (in-to-out) or the Monarc (American Medical System), which is placed starting in the groin area, passing through the obturator foramen, and then into the vagina (out-to-in)."
3037026|NCT00325078|Experimental|Treatment|Study drug (TNFa inhibitor-infliximab or adalimumab) treated group.
3037027|NCT00325078|No Intervention|Observation|Subjects with IBD without TNFa inhibitor treatment
3037028|NCT00325130|Experimental|Group 1|Concomitant Administration
3037029|NCT00325130|Experimental|Group 2|Non-concomitant administration
3037030|NCT00325143|Experimental|Infanrix Hexa Group|Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.
3037031|NCT00325156|Experimental|Group A|
3037032|NCT00325195|Experimental|q2 wks|8 mg pegloticase every 2 weeks
3037033|NCT00325195|Experimental|q4 wks|8 mg pegloticase every 4 weeks (alternating with placebo every 4 weeks)
3037034|NCT00325195|Placebo Comparator|placebo|placebo every 2 weeks
3037035|NCT00325234|Experimental|Pemetrexed/Carboplatin|"Pemetrexed 600 mg/m^2 was administered intravenously over approximately 10 minutes on Day 1.~Carboplatin was given over approximately 30 minutes on Day 1 beginning after the end of the Pemetrexed infusion, consistent with a target of AUC (Area under the plasma drug concentration versus time curve) 5.0 mg*min/mL. The cycle of treatment was 21 days."
3037036|NCT00325234|Active Comparator|Gemcitabine/Vinorelbine|Vinorelbine 30 mg/m^2 was given over approximately 6-10 minutes on Day 1 and Day 8. Gemcitabine 1200 mg/m^2 was given over approximately 30 minutes on Day 1 and Day 8 beginning after the end of the Vinorelbine infusion. The cycle of treatment was 21 days.
3037037|NCT00325403|Active Comparator|UT-15C (oral treprositnil)|Subjects receive UT-15C (oral treprostinil) twice daily.
3037038|NCT00325403|Placebo Comparator|Placebo|Subjects receive placebo (sugar pill) twice daily.
3037039|NCT00325416|Experimental|Age Group A - Melphalan and Topotecan plus Stem Cell Rescue|Participants 18 - 60 years of age. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
3037040|NCT00325416|Active Comparator|Age Group B - Melphalan and Topotecan plus Stem Cell Rescue|Participants 61 years of age or older. Intensive-Dose Melphalan and Topotecan (MT) followed by Stem Cell transplant.
3037041|NCT00325442|Active Comparator|Active|Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
3037042|NCT00325442|Placebo Comparator|Placebo Arm|Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
3037043|NCT00325468|Experimental|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
3037044|NCT00325598|Experimental|Cohort 1 (36 Gy)|36 Gy in 9 fractions BID x 4 1/2 treatment days
3037045|NCT00325598|Experimental|Cohort 2 (40 Gy)|40 Gy in 10 fractions BID over 5 treatment days
3037046|NCT00325754|Active Comparator|E-Cylinder|22-lb E-cylinder towed on a cart
3037047|NCT00325754|Active Comparator|Lightweight Cylinder|3.6-lb lightweight cylinder that can be carried
3037048|NCT00325780|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3037049|NCT00325819|Active Comparator|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
3037050|NCT00325819|Placebo Comparator|Placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
3037051|NCT00325897|Active Comparator|Azithromycin, 250 mg|Macrolide Antibiotic (Azithromycin)
3037052|NCT00325897|Placebo Comparator|Placebo|Inactive
3037053|NCT00326001|Experimental|Gold tip catheter|Gold tip catheter
3037054|NCT00326001|Active Comparator|Platinum-iridium tip catheter|Platinum-iridium tip catheter
3037055|NCT00326118|Active Comparator|Meningitec + Hiberix Group|Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
3037056|NCT00326118|Experimental|Menitorix Group|Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
3037057|NCT00326170|Experimental|VPA + 5-aza + ATRA|Daily for 7 days, Valproic acid (VPA) starting dose 75 mg/m^2 subcutaneously in combination with 5-azacytidine (5-aza) 50 mg/kg orally; and all-trans retinoic acid (ATRA) 45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3.
3037058|NCT00326183|Active Comparator|1|Arm 1: vaccine
3037059|NCT00326183|Active Comparator|2|Arm 2: Active comparator
3037060|NCT00326196|Active Comparator|PCI|Percutaneous coronary intervention
3037061|NCT00326196|Active Comparator|CABG|Coronary artery bypass graft (CABG)
3037062|NCT00326209|Experimental|Encapsulated Mesalamine Granules (eMG)|Participants will receive eMG 1.5 grams (4 capsules of eMG 0.375 grams each) QD orally in the morning for up to 24 months.
3037063|NCT00326417|Experimental|Cyclophosphamide 150mg|Fludarabine plus 150 mg/kg Cyclophosphamide (total dose)
3037064|NCT00326417|Experimental|Cyclophosphamide 100mg|Fludarabine plus 100 mg/kg Cyclophosphamide (total dose)
3037065|NCT00326417|Experimental|Cyclophosphamide 50mg|Fludarabine plus 50 mg/kg Cyclophosphamide (total dose)
3037066|NCT00326417|Experimental|Fludarabine|Fludarabine only (no Cyclophosphamide administered)
3037067|NCT00326495|Experimental|BAY 43-9006 & Cetuximab|BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID). Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2, followed by 250 mg/m^2 weekly starting on week 3
3037068|NCT00326599|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and oral AZD2171 once daily on days 1-21. Treatment repeats every 21 days for up to 6 courses. Patients achieving stable disease, partial response, or complete response after 6 courses of therapy receive AZD2171 alone as above. Treatment with AZD2171 repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3037069|NCT00326599|Active Comparator|Arm II|Patients receive gemcitabine and carboplatin as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3037070|NCT00326612|Active Comparator|Intranasal Midazolam 0.2mg/kg|GIve once for seizure longer than 5 minutes
3037071|NCT00326612|Active Comparator|Rectal Diazepam 0.3-0.5 mg/kg|Given once for seizure longer than 5 minutes
3037072|NCT00326625|Experimental|40 mg glatiramer acetate (GA)|Pre-filled syringe of 40 mg glatiramer acetate (GA) for injection, administered subcutaneously once a day.
3037073|NCT00326625|Placebo Comparator|Placebo|Pre-filled syringe of matching placebo, administered subcutaneously once a day.
3037074|NCT00326716|Experimental|Treatment|
3037075|NCT00326781|Active Comparator|Nicotine Nasal Spray|
3037076|NCT00326781|Active Comparator|Transdermal Nicotine patch|
3037077|NCT00326872|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for 26 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment beyond 26 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, prior to course 2, prior to course 4, and every 6 courses thereafter.
3037078|NCT00326885|Experimental|Catumaxomab|
3037079|NCT00326898|Experimental|Arm A (sunitinib malate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sunitinib malate PO QD for 4 weeks and placebo sorafenib tosylate PO QD or BID for 6 weeks.
3037080|NCT00326898|Experimental|Arm B (sorafenib tosylate, placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive sorafenib tosylate PO QD or BID for 6 weeks and placebo sunitinib malate PO QD for 4 weeks followed.
3037081|NCT00326898|Placebo Comparator|Arm C (placebo)|Beginning 4-12 weeks following radical or partial nephrectomy, patients receive placebo sorafenib tosylate as in Arm A and placebo sunitinib malate as in Arm B.
3037082|NCT00326911|Experimental|cetuximab + bevacizumab + gemcitabine|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks, and gemcitabine 1000 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks. All medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab, bevacizumab, and gemcitabine. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
3037083|NCT00326911|Active Comparator|cetuximab + bevacizumab|Cetuximab 400 mg/m2 weekly (over 120 minutes) on day 1 of cycle 1 with subsequent weekly infusions of 250 mg/m2 (over 60 minutes), followed by bevacizumab 10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks. Both medications will be administered by intravenous infusion on the same day. The order of study drug administration will be cetuximab and bevacizumab. On day 1 of cycle 1, one hour must elapse between administration of cetuximab and bevacizumab.
3037084|NCT00326924|Experimental|Biological|PRBCs that are less than 7 days old are considered 'fresh'.
3037085|NCT00326924|Experimental|Standard PRBCs|PRBCs 'stored' as per hospital policy.
3037086|NCT00326950|Experimental|1|
3037087|NCT00326963|Experimental|Enfuvirtide+PI+ARV's|"Eligible participants received Fuzeon® (enfuvirtide) 90 milligram (mg) subcutaneously (SC) two times a day (bid) for 24 weeks plus new protease inhibitor (PI) (darunavir/ritonavir) plus other investigator-choice antiretrovirals (ARVs). Participants selected their preferred injection device among the following three options: 27 gauge (G) ½ needle/syringe, 31G 8 millimeter (mm) needle/syringe or Biojector 2000 (B2000) needle-free injection device (NFID)."
3037088|NCT00327015|Experimental|Saxagliptin and Metformin (A)|PLUS open-label pioglitazone (as needed as rescue medication)
3037089|NCT00327015|Experimental|Saxagliptin and Metformin (B)|PLUS open-label pioglitazone (as needed as rescue medication)
3037090|NCT00327015|Experimental|Saxagliptin and Placebo (C)|PLUS open-label pioglitazone (as needed as rescue medication)
3037091|NCT00327015|Active Comparator|Metformin and Placebo (D)|PLUS open-label pioglitazone (as needed as rescue medication)
3037092|NCT00327171|Experimental|Aflibercept 2.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 2.0 mg/kg Aflibercept.
3037093|NCT00327171|Experimental|Aflibercept 4.0 mg/kg|Participants with advanced ovarian epithelial adenocarcinoma administered 4.0 mg/kg Aflibercept.
3037094|NCT00327340|Experimental|OGX-011 / mitoxantrone/prednisone|OGX-011 / mitoxantrone/prednisone: OGX-011 administered in combination with mitoxantrone and prednisone
3037095|NCT00327340|Experimental|OGX-011/docetaxel/prednisone|OGX-011/docetaxel/prednisone: OGX-011 administered in combination with docetaxel and prednisone
3037096|NCT00327444|Placebo Comparator|Placebo|"Participants with advanced ovarian cancer administered placebo in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to receive aflibercept or be withdrawn from the study."
3037097|NCT00327444|Experimental|Aflibercept|"Participants with advanced ovarian cancer administered aflibercept in the double-blind (DB) period.~In the open-label (OL) period, participants had the option to continue to receive aflibercept or be withdrawn from the study."
3037098|NCT00327470|Experimental|Open Label|
3037099|NCT00327717|Experimental|Zonisamide 100 mg tablet|
3037100|NCT00327717|Placebo Comparator|Placebo|
3037101|NCT00328016|Experimental|Device Guided Breathing|Individual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
3037102|NCT00328016|Placebo Comparator|Control Group|Control group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
3037103|NCT00328042|Experimental|Self-Management Workshop|
3037104|NCT00328042|Active Comparator|Information Only|
3037105|NCT00328094|Experimental|CII, Continuous Insulin Infusion|Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
3037106|NCT00328094|Active Comparator|IIB, Intermittent insulin boluses|Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
3037107|NCT00328172|Placebo Comparator|Placebo|Placebo tablets matching BI 1356
3037108|NCT00328172|Experimental|BI 1356 0.5 mg|BI 1356 dose 1 once daily
3037109|NCT00328172|Experimental|BI 1356 2.5 mg|BI 1356 dose 2 once daily
3037110|NCT00328172|Experimental|BI 1356 5.0 mg|BI 1356 dose 3 once daily
3037111|NCT00328172|Active Comparator|Metformin|Metformin
3037112|NCT00328198|Experimental|Dose escalation|Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated).
3037113|NCT00328198|Experimental|No escalation|Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered subcutaneously at alternating injection sites 3 times per week for up to 18 weeks.
3037114|NCT00328263|Experimental|1|Bio-K Cl1285 Bio-K Cl1285 contains 50 billion of live bacteria.
3037115|NCT00328263|Placebo Comparator|2|placebo devoid of bacteria
3037116|NCT00328510|Experimental|GTC Frame|Participant undergoes SRT using a GTC frame to immobilize the participant's heading during radiation therapy
3037117|NCT00328510|Experimental|BrainLab thermoplastic mask|Participant undergoes SRT using the BrainLab thermoplastic mask to immobilize the participant's head during radiation therapy
3037118|NCT00328562|Experimental|Iressa and RT|"Iressa plus thoracic RT at the following dose levels:~Level 1: 42.0 Gy in 10 fractions of 4.2 Gy~Level 2: 50.4 Gy in 12 fractions of 4.2 Gy~Level 3: 63.0 Gy in 15 fractions of 4.2 Gy"
3037119|NCT00328614|Experimental|Samarium-153 (0.25 mCi/kg)|Cohort 1: Patients receive 0.25 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037120|NCT00328614|Experimental|Samarium-153 (0.5 mCi/kg)|Cohort 2: Patients receive 0.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037121|NCT00328614|Experimental|Samarium-153 (0.75 mCi/kg)|Cohort 3: Patients receive 0.75 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037122|NCT00328614|Experimental|Samarium-153 (1.0 mCi/kg)|Cohort 4: Patients receive 1.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037123|NCT00328614|Experimental|Samarium-153 (1.5 mCi/kg)|Cohort 5: Patients receive 1.5 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037124|NCT00328614|Experimental|Samarium-153 (2.0 mCi/kg)|Cohort 6: Patients receive 2.0 mCi/kg of Samarium-153, hormonal therapy, and radiation therapy
3037125|NCT00328627|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3037126|NCT00328627|Experimental|Alogliptin 12.5 + Placebo|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3037127|NCT00328627|Experimental|Alogliptin 25 + Placebo|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3037128|NCT00328627|Active Comparator|Placebo + Pioglitazone 15|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3037129|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 15|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3037130|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 15|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 15 mg, tablets, orally, once daily for up to 26 weeks.
3037131|NCT00328627|Active Comparator|Placebo + Pioglitazone 30|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3178845|NCT00666341|Experimental|40 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
3037132|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 30|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3037133|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 30|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3037134|NCT00328627|Active Comparator|Placebo + Pioglitazone 45|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3037135|NCT00328627|Experimental|Alogliptin 12.5 + Pioglitazone 45|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3037136|NCT00328627|Experimental|Alogliptin 25 + Pioglitazone 45|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 45 mg, tablets, orally, once daily for up to 26 weeks.
3037137|NCT00328770|Experimental|Sirolimus based immunosuppression|Sirolimus given intravenously or orally to achieve serum level of 12-20ug/l
3037138|NCT00328783|Experimental|Active Breathing Coordinator|Patients breathe through the ABC device
3037139|NCT00328861|Experimental|NK Cells + IL-2: Melanoma|Melanoma (skin cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
3037140|NCT00328861|Experimental|NK Cells + IL-2: Renal Cell|Renal cell (kidney cancer). Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7. Fludarabine 25 mg/m^2 day intravenous on days -6 through -2. IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days. Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
3037141|NCT00328926|Active Comparator|Luveris® 75 IU|
3037142|NCT00328926|Active Comparator|Luveris® 25 IU|
3037143|NCT00328926|Placebo Comparator|Placebo|
3037144|NCT00329030|Active Comparator|Rituxan/BEAM|Autologous transplantation using rituxan/BEAM
3037145|NCT00329030|Experimental|Bexxar/BEAM|Autologous transplantation using Bexxar/BEAM
3037146|NCT00329238|Experimental|Dabigatran|Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
3037147|NCT00329238|Active Comparator|Warfarin (INR of 2.0-3.0)|Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
3037148|NCT00329303|Experimental|Certolizumab Pegol (CZP) 200 mg|Subcutaneous injections of 400 mg initial dose at Week 0 with 200 mg every 2 weeks thereafter.
3037149|NCT00329303|Experimental|Certolizumab Pegol (CZP) 400 mg|Subcutaneous injections of 400 mg every 2 weeks.
3037150|NCT00329407|Active Comparator|Topiramate Treatment|In this open label non-placebo controlled trial all subjects received topiramate, the active medication. Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
3037151|NCT00329420|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
3037152|NCT00329420|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
3037153|NCT00329420|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
3037154|NCT00329433|Active Comparator|Heparin|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
3037155|NCT00329433|Experimental|Desirudin (Iprivask™)|Both groups of patients will receive study drug three times a day (TID) for DVT prophylaxis. The current TID schedule is 0900, 1300, and 2100. Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
3037156|NCT00329524|Sham Comparator|Active versus Sham Treatment|Subjects randomly assigned to active and sham TMS separated by one week interval.
3037157|NCT00329550|Experimental|CZP 400 mg / Placebo|Certolizumab pegol (CZP) 400 mg in this extension study / Placebo in double-blind main study (NCT00291668)
3037158|NCT00329550|Experimental|CZP 400 mg / CZP 200 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 200 mg in double-blind main study (NCT00291668)
3037159|NCT00329550|Experimental|CZP 400 mg / CZP 400 mg|Certolizumab pegol (CZP) 400 mg in this extension study / Certolizumab pegol (CZP) 400 mg in double-blind main study (NCT00291668)
3037160|NCT00329602|Placebo Comparator|Double-blind for 12 to 26 Weeks|Double-blind (Ropinirole:Placebo) for 12 to 26 weeks
3037161|NCT00329602|Other|Open-label ropinirole for 40-Weeks|Open label ropinirole for 40 weeks
3037162|NCT00329641|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|"Patients receive carboplatin IV and paclitaxel IV once on day 1 and oral sorafenib twice daily on days 2-19. Treatment repeats every 21 days for up to 6 courses.* After 6 courses, patients continue to receive oral sorafenib alone twice daily in the absence of disease progression or unacceptable toxicity.~[Note: *If sorafenib is discontinued prior to course 6, patients may continue to receive carboplatin and paclitaxel for up to 6 courses; if carboplatin and paclitaxel are discontinued prior to course 6, patients may continue to receive sorafenib alone twice daily on days 1-21 of each course in the absence of disease progression or unacceptable toxicity. ]"
3037163|NCT00329719|Experimental|Group I (sorafenib tosylate, temsirolimus)|Patients receive sorafenib tosylate and temsirolimus as in Phase I.
3037164|NCT00329719|Experimental|Group II (sorafenib tosylate, temsirolimus, surgery)|Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
3037165|NCT00329719|Experimental|Group III (sorafenib tosylate, temsirolimus, anti-VEGF)|Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
3037166|NCT00329745|Experimental|Rotarix Group|During the primary study (NCT00197210) subjects received two oral doses of Rotarix™ vaccine.
3037167|NCT00329745|Placebo Comparator|Placebo Group|During the primary study (NCT00197210) subjects received two oral doses of placebo.
3037168|NCT00329771||Episodic migraineurs|Eligible subjects with episodic migraine (with or without aura)
3037169|NCT00329784|Experimental|Peanut Consumption Group|Participants on this arm will consume peanut protein.
3037170|NCT00329784|No Intervention|Peanut Avoidance Group|Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.
3037171|NCT00329797|Experimental|Zoledronic Acid|Zoledronic acid q 6 months plus Vitamin D and calcium supplement for 3 years in addition to concurrent radiation therapy and LHRH therapy.
3037172|NCT00329797|Active Comparator|Control|Vitamin D and calcium supplement everyday for 3 years in addition to concurrent radiation therapy and LHRH therapy.
3037173|NCT00329836||Subjects with cluster headache|Subjects with both episodic and chronic cluster (as defined by the International Headache Society-IHS) were enrolled.
3037174|NCT00329849|Experimental|MenACWY-CRM|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal conjugate vaccine (MenACWY-CRM)
3037175|NCT00329849|Active Comparator|MenACWY-PS|Subjects ≥2 to ≤10 years of age received one dose of a quadrivalent meningococcal polysaccharide (PS) vaccine (MenACWY-PS)
3037176|NCT00329901|Experimental|Tdap + MenACWY-CRM|Subjects received Tdap and MenACWY-CRM vaccines concomitantly, in separate arms
3037177|NCT00329901|Experimental|Tdap + saline|Subjects received Tdap vaccine and saline (placebo) concomitantly, in separate arms
3037178|NCT00329901|Experimental|MenACWY-CRM + saline|Subjects received MenACWY-CRM vaccine and saline (placebo) concomitantly, in separate arms
3037179|NCT00330161|Experimental|Treatment (vorinostat)|"Patients receive oral vorinostat (SAHA) once daily on days 1-21. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) after 4 courses receive an additional 3 courses. All other patients may continue treatment in the absence of disease progression or unacceptable toxicity.~Blood samples are taken on day 15 of course 1, day 1 of course 2, during the last week of course 4, and at completion of study treatment. Blood is examined for interleukin (IL)-6, IL-6 receptor, and gp130 levels."
3037180|NCT00330174|Experimental|1|Acamprosate tablets
3037181|NCT00330174|Placebo Comparator|2|Matching placebo tablets
3037182|NCT00330187|Experimental|Bupropion SR + Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
3037183|NCT00330187|Active Comparator|Placebo + Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management, with escalating rewards for abstinence (and re-sets for non-abstinence) at twice-weekly visits.
3037184|NCT00330187|Active Comparator|Bupropion SR + No Contingency Management|Bupropion SR capsules, with goal dose of 300 mg/day, for 6 weeks of treatment. Contingency Management is not provided in this arm.
3037185|NCT00330187|Placebo Comparator|Placebo + No Contingency Management|Placebo capsules, matched in appearance to Bupropion SR capsules, for 6 weeks of treatment. Contingency Management is not provided in this arm.
3037186|NCT00330343|Experimental|Naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
3037187|NCT00330382|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Patients receive oral Bowman-Birk inhibitor concentrate twice daily for 6 months
3037188|NCT00330382|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily for 6 months
3037189|NCT00330421|Experimental|Group I (sarcomas of extremity, closed accrual as of 5/30/07)|Patients receive oral sorafenib twice daily on days 1-14. Patients undergo surgical resection of the tumor on approximately day 15. Once patients recover from surgery (and radiotherapy if indicated), patients who demonstrate a clinically and pathologically significant response (≥ 25% reduction in tumor size or ≥ 25% necrosis in the surgical specimen) may continue sorafenib as above for a maximum of 6 months in the absence of disease progression or unacceptable toxicity and at the discretion of the principal investigator. Biopsy tissue and blood samples are examined for biomarkers and interstitial fluid pressure (IFP) is measured at baseline and immediately before surgery.
3037190|NCT00330421|Experimental|Group II (metastatic or inoperable sarcomas)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56.
3037191|NCT00330460|Active Comparator|Alendronate|Subjects in this arm will receive active ALN and placebo denosumab
3037192|NCT00330460|Experimental|Denosumab|Subjects in this arm will receive active denosumab and placbo ALN
3037193|NCT00330551|Experimental|Long-acting injectible risperidone|Participants who are randomly assigned to this arm will be administered the long-acting injectible form of risperidone (Risperdal Consta) every two weeks, plus group skills training and case management, for 12 months.
3037194|NCT00330551|Active Comparator|Oral risperidone|Participants who are randomly assigned to this arm will be treated with the oral version of risperidone (Risperdal) daily, plus group skills training and case management, for 12 months.
3037195|NCT00330564|Experimental|SU011248 (Sutent, Sunitinib Malate)|50 mg/day orally for 4 weeks
3037196|NCT00330668|Experimental|All rhIGF-1 Subjects|"All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms [μg]/ kilogram [kg] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study."
3037197|NCT00330681|Experimental|1|MCI-186
3037198|NCT00330681|Placebo Comparator|2|Placebo of MCI-186
3037199|NCT00330733|Placebo Comparator|Placebo|Matching placebo
3037200|NCT00330733|Active Comparator|Salsalate Therapy|Salsalate
3037201|NCT00330759|Active Comparator|zoledronic acid|denosumab placebo with active zoledronic acid
3037202|NCT00330759|Experimental|denosumab|active denosumab with zoledronic acid placebo
3037203|NCT00330863|Experimental|Injectable|Participants assigned to receive long-acting injectable risperidone
3037204|NCT00330863|Active Comparator|Oral|"Participants assigned to receive oral atypical antipsychotic medication"
3037205|NCT00330876|Experimental|Pitavastatin 2 mg QD|Pitavastatin 2 mg once daily
3037206|NCT00330876|Experimental|Pitavastatin 4 mg QD|Pitavastatin 4 mg once daily
3037207|NCT00330915|Experimental|A|
3037208|NCT00330928|Experimental|1|Subjects undergoing elective percutaneous coronary intervention
3037209|NCT00330967||Group 1|healthy subjects
3037210|NCT00330967||Group 2|healthy subjects different from group 1
3037211|NCT00331006|Experimental|Rituximab|Rituximab administered at a dose of 375 mg/m2 by slow intravenous infusion once per week for 4 weeks
3037212|NCT00331136|Experimental|Group A (Tablets)|Pyronaridine artesunate 6:2 mg/kg. The tablet strength is 48:16 mg oral PA, with the number of tablets depending on body weight.
3037213|NCT00331136|Experimental|Group B (Tablets)|Pyronaridine artesunate 9:3 mg/kg. The tablet strength is 72:24 mg oral PA, with the number of tablets depending on body weight.
3037214|NCT00331136|Experimental|Group C (Tablets)|Pyronaridine artesunate 12:4 mg/kg. The tablet strength is 96:32 mg oral PA, with the number of tablets depending on body weight.
3037215|NCT00331136|Experimental|Group D (Granules)|Pyronaridine artesunate 9:3 mg/kg. The sachet of granules strength is 60:20 mg PA, with the number of sachets depending on body weight, and is administered as a suspension with water.
3037216|NCT00331162|Active Comparator|1|Alemtuzumab
3037217|NCT00331162|Active Comparator|2|Anti-Thymocyte Globulin
3037218|NCT00331344|Experimental|Treatment (combination chemotherapy)|Patients receive mitoxantrone hydrochloride IV over 30 minutes and ixabepilone IV over 3 hours on day 1 and oral prednisone twice daily on days 1-21. Treatment repeats every 21 days for ≥ 3 courses in the absence of disease progression or unacceptable toxicity.
3037219|NCT00331409|Experimental|Everolimus and Imatinib Mesylate|Everolimus: 2.5 mg daily by mouth Imatinib Mesylate: 600 mg daily by mouth
3037220|NCT00331422|Experimental|Patients Who Received Treatment|All patients receiving treatment with Paclitaxel and Carboplatin followed by surgery to remove cancerous tissue.
3037221|NCT00331552|Experimental|Arm I|Patients receive oral cyclophosphamide once daily on days 1-28 and pegylated doxorubicin HCl liposome IV over 90 minutes on day 1. Treatment repeats every 4-6 weeks in the absence of disease progression or unacceptable toxicity. Some patients with HER2/neu 3+ disease may also receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks at the discretion of the treating physician.
3037222|NCT00331630|Experimental|Treatment arm|30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3037223|NCT00331682|Experimental|Treatment (docetaxel and alvocidib)|Patients receive docetaxel IV over 30 minutes followed 4-6 hours later by flavopiridol IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3037224|NCT00331760|Other|Endometrial Cancer: IMRT|Endometrial Cancer patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks.
3037225|NCT00331760|Other|Cervical Cancer: IMRT + Chemotherapy (cisplatin)|Cervical patients receive Intensity Modulated Radiation Therapy (IMRT) 28 fractions over 5.5 weeks and concurrent weekly cisplatin 40 mg/m^2 for five weeks.
3037226|NCT00331773|Active Comparator|Conventional 3D-CRT|Conventional 3D-CRT or IMRT to 73.8 Gy in 41 fractions
3037227|NCT00331773|Experimental|Hypofractionated 3D-CRT|Hypofractionated 3D-CRT or IMRT to 70 Gy in 28 fractions
3037228|NCT00331799|Active Comparator|1|Open label treatment with Duloxetine for 8 weeks with dosing from 30-60 mg.
3037229|NCT00331864|Experimental|Ranibizumab|Ranibizumab-naïve (Non-ANCHOR) patients received up to 12 intravitreal injections (Month 0 through Month 11). The dose of 0.3 mg ranibizumab was administered monthly for three consecutive months. From Month 3 through Month 11, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab were injected as individually needed based on re-treatment criteria described in the protocol. For patients who had participated in the ANCHOR study, either 0.3 mg ranibizumab or, after implementation of an amendment to the protocol, 0.5 mg ranibizumab was injected if the patient met re-treatment criteria described in the protocol. Ranibizumab was administered no sooner than 14 days after the previous treatment.
3037230|NCT00332163|Experimental|Pre-emptive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg once every 2 weeks (Q2W) or irinotecan and panitumumab 9 mg/kg once every 3 weeks (Q3W), and pre-emptive skin treatment which included skin moisturizer, sunscreen, 1% hydrocortisone cream, and an oral antibiotic for 6 weeks starting 24 hours prior to chemotherapy.
3037231|NCT00332163|Experimental|Reactive Skin Treatment|Participants received either FOLFIRI and panitumumab 6 mg/kg Q2W or irinotecan and panitumumab 9 mg/kg Q3W. Participants were treated for each individual skin toxicity occurrence according to prespecified guidelines and based on the type and severity. Treatment could include emollient, sunscreen, topical or oral steroids, antibiotics, or antihistamines, as required.
3037232|NCT00332202|Experimental|A|
3037233|NCT00332202|Placebo Comparator|B|
3037234|NCT00332241|Experimental|A1|Active Abilify
3037235|NCT00332241|Placebo Comparator|A2|
3037236|NCT00332332|Experimental|etanercept|Open label etanercept 50 mg twice weekly subcutaneously (SC) for 3 months followed by 50 mg twice a week week SC for 9 months, for a total treatment period of 12 months.
3037237|NCT00332462|Experimental|Cyclosporine (Sandimmun®)|Period 1: Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days followed by Period 2: Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
3037238|NCT00332488|Experimental|1|Technosphere Insulin
3037239|NCT00332488|Active Comparator|2|Metformin & Secretagogues
3037240|NCT00332488|Experimental|3|Technosphere & Metformin
3037241|NCT00332579|Active Comparator|A|Naltrexone
3037242|NCT00332579|Placebo Comparator|B|Placebo
3037243|NCT00332605|Experimental|Naltrexone plus N-Acetyl Cysteine|"Naltrexone tablets~N-Acetyl Cysteine: 600mg tablets, daily"
3037244|NCT00332605|Placebo Comparator|Placebo|
3037245|NCT00332644|Experimental|1|nicotine patch alone treatment
3037246|NCT00332644|Experimental|2|nicotine lozenge alone treatment
3037247|NCT00332644|Experimental|3|nicotine patch + lozenge combination treatment
3037248|NCT00332644|Experimental|4|bupropion alone treatment
3037249|NCT00332644|Experimental|5|bupropion + nicotine lozenge combination treatment
3037250|NCT00332644|Placebo Comparator|6|placebo control (no active medication) treatment
3037251|NCT00332696|Experimental|Octreotide|Participants received Octreotide long-acting release (LAR) 30 mg intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received immediate-release Octreotide 600 µg/day (administered subcutaneously 2 or 3 times a day or via continuous intravenous (IV) or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
3037252|NCT00332696|Placebo Comparator|Placebo|Participants received physiologic saline solution intramuscular injection every 28 days for 3 months beginning on Day 1. Participants also received physiologic saline solution (administered subcutaneously 2 or 3 times a day or via continuous intravenous or subcutaneous injection over a 24 hour period) and methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections) for the first 6 days.
3037253|NCT00332709|Experimental|Letrozole|Letrozole orally 2.5 mg/day for 3 years
3037254|NCT00332709|Experimental|Letrozole + Zoledronic Acid|Letrozole orally 2.5mg/day for 3 years; Zoledronic acid 4mg every 6 months by infusion
3037255|NCT00332722|Active Comparator|Group 1- without steroid|Cervical Facet Joint Nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
3037256|NCT00332722|Active Comparator|Group 2 - with steroid|Cervical Facet Joint nerve block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
3037257|NCT00332839|Active Comparator|Calcineurin Inhibitor (CNI) group|Participants received Cyclosporine A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids, or Tacrolimus A (CsA) plus Enteric Coated Mycophenolate Sodium (EC-MPS) plus corticosteroids.
3037258|NCT00332839|Experimental|Certican group|Participants were switched in a step-wise fashion from the CNI based regimen to Everolimus (RAD001).
3037259|NCT00333138|Experimental|Fingolimod (FTY720) 1.25 mg/day|Core study: patients received fingolimod 1.25 mg, once daily for 6 months. Extension: In dose -blind period and open label, fingolimod 1.25 mg once daily for 9-18 months (6 months to 24 months). Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3037260|NCT00333138|Placebo Comparator|Placebo/Fingolimod (FTY720)|Core study: patients received placebo, once daily for 6 months. Extension: In dose-blind period patients were re-randomized into either fingolimod 1.25 mg or 5.0 mg once per day for 6-15 months. In open-label period patients received fingolimod 1.25 mg once per day for 15 to 24 months. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3037261|NCT00333138|Experimental|Fingolimod (FTY720) 5.0 mg/day|Core study: patients received fingolimod 5.0 mg, once daily for 6 months. Extension: In dose-blind period fingolimod 5.0 mg once daily for 6-15 months. For open-label phase 15 to 24 months 1.25mg once daily. Later, all patients converted to fingolimod 0.5 mg, once daily for rest of the study participation.
3037262|NCT00333177|Experimental|Cog Remediation, risperidone injection|Participants will receive cognitive remediation training plus risperidone, administered via injection.
3037263|NCT00333177|Active Comparator|Healthy Behavior Training, risperidone injection|Participants will receive health behavior training plus risperidone, administered via injection.
3037264|NCT00333177|Experimental|Cog Remediation, oral risperidone|Participants will receive cognitive remediation training plus risperidone administered orally.
3037265|NCT00333177|Active Comparator|Healthy Behavior Training, oral risperidone|Participants will receive health behavior training plus risperidone administered orally.
3037266|NCT00333359|Experimental|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
3037267|NCT00333437|Experimental|Treatment|Mycophenolate Mofetil
3037268|NCT00333606|Experimental|Verum acupuncture|Acupuncture of specific acupuncture points
3037269|NCT00333606|Sham Comparator|Sham acupuncture|Acupuncture of non-specific acupuncture points
3037270|NCT00333619|Experimental|Nonpharmacological sleep intervention|The intervention will combine: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies.
3037271|NCT00333619|Active Comparator|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
3037272|NCT00333710|Experimental|Individual face-to-face contact|Individual face-to-face contact treatment
3037273|NCT00333710|Experimental|Individual telephone contact|Individual telephone contact treatment
3037274|NCT00333710|No Intervention|Control condition/treatment as usual|Control condition/treatment as usual
3037275|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus placebo|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3037276|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3037277|NCT00333775|Experimental|Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg|Participants received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
3037278|NCT00333788|Experimental|Certolizumab pegol 400 mg|400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
3037279|NCT00333801|Active Comparator|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP). VRP is the treatment as usual, which mostly consisted of transitional work program (TWP) in which client is placed in a set-aside noncompetitive job for time-limited period and then pursues competitive employment at time of discharge from VRP. Limited integration with treatment team and limited follow-along supports that are time-limited.
3037280|NCT00333801|Experimental|Individual Placement and Support (IPS)|Inidividual Placement and Support (IPS). IPS Supported Employment involves an IPS specialists working with client to identify job preferences, rapidly begin community-based job search, engage in competitive employment, sustain employment via open-ended IPS follow-along supports, and integrate IPS within the PTSD treatment team.
3037281|NCT00333814|Active Comparator|1|Dexamethasone 350 µg
3037282|NCT00333814|Active Comparator|2|Dexamethasone 700 µg
3037283|NCT00333814|Sham Comparator|3|Sham
3037284|NCT00333840|Experimental|imatinib (STI571)|In the first-line treatment period participants received imatinib 400 mg orally once daily in the morning. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to receive interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injection for 10 days every month. Maximum study duration was 11.5 years.
3037285|NCT00333840|Active Comparator|IFN-a+Ara-C|In the first-line treatment period participants received interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day. After the maximum tolerated dose of IFN-a was achieved, participants also received cytarabine (ARA-C) 20 mg/m^2/day (max 40 mg) SC injections for 10 days every month. Hydroxyurea was permitted in the first 6 months to keep the white blood cell count (WBC) below 20.0 X 10^9/liter. If protocol specific criteria applied, participants were eligible to crossover to the second-line treatment period to receive imatinib (STI571). IFN treatment was discontinued with protocol amendment 6. Maximum study duration was 8 years.
3037286|NCT00333866|Experimental|1|
3037287|NCT00333866|Experimental|2|
3037288|NCT00333866|Experimental|3|
3037289|NCT00333866|Placebo Comparator|4|
3037290|NCT00333879|Other|Virtual Sound System|Efficacy of using a virtual sound system to simulate street crossing conditions.
3037291|NCT00333970|Experimental|cognitive remediation|cognitive remediation
3037292|NCT00333970|No Intervention|treatment as usual|treatment as usual
3037293|NCT00333983|Experimental|Arm 1|Robot Exercise Group
3037294|NCT00333983|Active Comparator|Arm 2|Traditional Upper Extremity Exercise Group
3037295|NCT00334074|Experimental|Clofarabine and Cytarabine|Five consecutive days of clofarabine 40 mg/m^2 IVI over 1 hour followed 4 hours later by cytarabine 1000 mg/m^2 IVI over 2 hours
3037296|NCT00334113|Experimental|Arm 1|Participants in this arm will meet with an exercise physiologist and obtain an exercise prescription for a walking program. In addition, they will recieve an intervention that will be delivered over an automated telephone system (TLC-PED). These automated phone calls with voice response and voice recognition capabilities will occur weekly over a 6 month period. During these calls, participants' physical activity will be monitored, new physical activities goals will be set, information about physical activity and the associated health benefits will be provided, and barriers to physical activity will be explored.
3037297|NCT00334113|No Intervention|Arm 2|"This is the treatment as usual condition. Participants in this condition will also have 2 sessions with an exercise physiologist and will receive an exercise prescription for a home based walking program. The will not receive the automated phone calls each week that are designed to motivate physical activity."
3037298|NCT00334204|Other|Measure Platelet Function Analyser -100 (PFA-100)|measuring Platelet Function Analyser (PFA)-100 test (an in vitro platelet function test, in addition to the rest of the routine/uusal clinical care)
3037299|NCT00334282|Placebo Comparator|placebo arm|matching placebo (800 mg tablet) once daily
3037300|NCT00334282|Experimental|pazopanib arm|Oral pazopanib tablet 800 mg once daily continuously
3037301|NCT00334542|Experimental|Simvastatin|Simvastatin 40 mg for 24-28 weeks
3037302|NCT00334633|Active Comparator|control|metronidazole 500 BID for 7 days
3037303|NCT00334633|Active Comparator|tinidazole 500|tinidazole 500 BID for 7 days
3037304|NCT00334633|Active Comparator|tinidazole 1 gm|tinidazole 1 gm BID for 7 days
3037305|NCT00334737|Experimental|Darbepoetin alfa injection|Darbepoetin alfa 10 mics/kg/week subcutaneous injection x 10 weeks or until 35 completed weeks Drug: Darbepoetin alfa Other names: Aranesp Darbe SC injection
3037306|NCT00334737|Active Comparator|erythropoietin alfa injection|Epo 400 units/kg three times a week SC x 10 weeks or until 35 completed weeks Drug: erythropoietin other names: epogen Epo SC injection
3037307|NCT00334737|Placebo Comparator|placebo/control|Sham injection
3037308|NCT00334802|Experimental|A|
3037309|NCT00334815|Experimental|Group 1 (cisplatin, etoposide, radiotherapy)|Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
3037310|NCT00334815|Experimental|Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
3037311|NCT00334815|Experimental|Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)|Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
3037312|NCT00334893|Experimental|Treatment (chemotherapy)|Patients receive eribulin mesylate IV over 15 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3132838|NCT03456960|Experimental|Study 2,TAK-438ASA (Fed + Fasted condition)|One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).
3037313|NCT00334958|Placebo Comparator|Placebo|For 12-day Titration Phase and 12 week Maintenance Phase, placebo tablets matching to rufinamide 400 mg oral tablets will be administered according to the same regimen scheme as described for rufinamide. For 12-day Titration Phase, 1 matching placebo tablet will be administered twice daily and increased by 1 tablet every 3 days up to maximum of 4 matching placebo tablets twice daily (placebo tablet matched to rufinamide total daily dose of 3200 mg). For the 12 week maintenance phase, 4 placebo tablets matching to rufinamide maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Similar to the dose reduction permitted in the rufinamide group, participants in placebo group will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily.
3037314|NCT00334958|Active Comparator|Rufinamide|For the 12-day Titration Phase, rufinamide will be administered orally in doses starting with 400 milligram (mg) twice daily and increased every 3 days in 400 mg twice daily increments up to 1600 mg twice daily (total daily dose 3200 mg). For the 12 week Maintenance Phase, maintenance doses of 1600 mg twice daily (3200 mg total daily dose) will be administered. Participants unable to tolerate the target dose (3200 mg/day) will be allowed only during the Titration Phase to have the dose reduced to 3 tablets twice daily (corresponding to a dose of 2400 mg/day in the rufinamide group).
3037315|NCT00335140|Experimental|Rituximab + standard chemotherapy|Rituximab + high dose methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine. Patients with meningeal involvement will receive additional methotrexate and leucovorin.
3037316|NCT00335153|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants were to receive LCIG, via the NJ tube during the nasojejunal (NJ) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the Post-PEG-J Long-Term Treatment Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour), in most instances."
3037317|NCT00335257||1|Users of OCs containing DRSP
3037318|NCT00335257||2|Users of OCs containing other progestins
3037319|NCT00335283|Active Comparator|Lansoprazole|
3037320|NCT00335283|Placebo Comparator|Sugar Pill|
3037321|NCT00335322|Active Comparator|1|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin efavirenz)
3037322|NCT00335322|Active Comparator|2|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)
3037323|NCT00335322|Experimental|3|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)
3037324|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA high dose|
3037325|NCT00335452|Experimental|Clopidogrel high dose treatment regimen + ASA low dose|
3037326|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA high dose|
3037327|NCT00335452|Active Comparator|Clopidogrel standard treatment regimen + ASA low dose|
3037328|NCT00335478|Experimental|Daptomycin|
3037329|NCT00335504|Experimental|Arm I (atorvastatin calcium)|Patients receive oral atorvastatin once daily.
3037330|NCT00335504|Experimental|Arm II (sulindac)|Patients receive oral sulindac twice daily.
3037331|NCT00335504|Experimental|Arm III (oligofructose-enriched inulin)|Patients receive oral oligofructose-enriched inulin (Raftilose Synergy 1) twice daily.
3037332|NCT00335504|Placebo Comparator|Arm IV (placebo)|Patients receive an oral placebo twice daily.
3037333|NCT00335517|Experimental|10mg Depodur|
3037334|NCT00335517|Experimental|15mg DepoDur|
3037335|NCT00335556|Experimental|Surgery|Patients with completely resectable stage I-IV RCC undergo surgical resection. Patients with incompletely resectable stage III-IV RCC undergo treatment as per physician's choice.
3037336|NCT00335556|Experimental|Treatment (UH-1)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, and carboplatin. Patients whose primary tumors were initially resected undergo radiotherapy once daily 5 days a week for 4-5½ weeks beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13. Patients with unresectable clear cell sarcoma of the kidney (CCSK) receive no further study therapy.
3037337|NCT00335556|Experimental|Treatment (window/UH-1)|Patients receive vincristine IV on days 1 and 8 and irinotecan hydrochloride IV over 30 minutes on days 1-5 and 8-12 (course 1). Patients with progressive disease (PD) are treated with regimen UH-1. Patients with stable disease (SD), partial response (PR), or complete response (CR) receive another course of irinotecan hydrochloride/vincristine window therapy beginning on day 22. After the second course, patients with SD or PD are treated with regimen UH-1 and patients with PR or CR are treated with regimen UH-2.
3037338|NCT00335556|Experimental|Treatment (UH-2)|Patients receive combination chemotherapy comprising vincristine, doxorubicin hydrochloride, cyclophosphamide, etoposide, carboplatin, and irinotecan hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 7. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 7.
3037339|NCT00335556|Experimental|Treatment (regimen I)|Patients receive vincristine, doxorubicin hydrochloride, cyclophosphamide, and etoposide. Patients whose primary tumors were initially resected (except those with stage I CCSK) undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
3037340|NCT00335556|Experimental|Treatment (regimen DD-4A)|Patients receive dactinomycin, vincristine, and doxorubicin hydrochloride. Patients whose primary tumors were initially resected undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 1. Patients with delayed primary tumor resection undergo radiotherapy as in regimen UH-1 beginning on day 1 in week 13. If the primary tumor was not previously resected, patients undergo resection, if feasible, in week 13.
3037341|NCT00335725|Experimental|Fostimon|Fostimon is an highly purified FSH preparation.
3037342|NCT00335725|Active Comparator|Gonal-F|Gonal-F is a recombinant FSH preparation.
3037343|NCT00335738|Experimental|Group 1 (identified by central review as high risk)|Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.
3037344|NCT00335738|No Intervention|Group 2 (identified by central review as not high risk)|Patients undergo observation periodically for at least 5 years.
3037345|NCT00335764|Experimental|Group 1|Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28.
3037346|NCT00335764|Experimental|Group 2|Patients receive sorafenib tosylate as in group 1. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
3037347|NCT00335764|Experimental|Group 3|Patients receive sorafenib tosylate as in group 1. Patients also receive oral tipifarnib twice daily on days 1-21.
3037348|NCT00335777|Experimental|Migranal treatment first treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
3037349|NCT00335777|Experimental|Migranal second treatment phase|All subjects were asked to treat one headache at 1 hour (early) and one headache at 4 hours after onset of throbbing (late). Dose of nasal spray constant for both time points. The subject could determine the order in which they could treat the headaches (early (first treatment phase) then late (second treatment phase), or late (first treatment phase) then early (second treatment phase).
3037350|NCT00335829|Experimental|single arm, received bevacizumab and TACE|
3037351|NCT00335959|Experimental|Chemotherapy, Chemoradiation, Surgery|"Chemotherapy: Oxaliplatin, 130 mg/m2, 2 hour IV infusion on Days 1 and 22; Capecitabine 850 mg/m2/dose, PO q 12 hours on Days 1-14 and 22-35 Chemoradiation: Capecitabine 650 mg/m2/dose, PO q 12 hours on days 43-77; Radiation therapy 180 cGy/day, 5 days/week beginning on Day 43.~Surgery: Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy"
3037352|NCT00335972|Active Comparator|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
3037353|NCT00335972|Active Comparator|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
3037354|NCT00336024|Active Comparator|Arm I (induction+consolidation chemotherapy, autologous PBSC))|"Patients receive vincristine sulfate IV on days 1, 8, and 15; etoposide IV over 1 hour on days 1-3; cyclophosphamide IV over 1 hour on days 1 and 2; cisplatin IV over 6 hours on day 3. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
3037355|NCT00336024|Experimental|Arm II (induction+consolidation chemotherapy, autologous PBSC)|"Patients receive vincristine sulfate IV on days 1, 8, and 15; high-dose methotrexate IV over 4 hours on day 1; and leucovorin calcium IV or orally every 6 hours beginning on day 2 and continuing until methotrexate levels are in a safe range. Patients then receive etoposide IV over 1 hour on approximately days 4, 5, and 6, cyclophosphamide IV over 1 hour on approximately days 4 and 5, and cisplatin IV over 6 hours on approximately day 6. Treatment repeats every 3 weeks for 3 courses.~Within 6 weeks after completion of induction therapy, patients receive consolidation therapy comprising carboplatin IV over 2 hours and thiotepa IV over 2 hours on days 1 and 2 and filgrastim (G-CSF) IV or SC beginning on day 5 and continuing until blood counts recover. Patients also receive autologous PBSC IV on day 4. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity."
3037356|NCT00336232|Experimental|Diet Intervention|28 day diet low vitamin K, 28 day diet high vitamin K
3037357|NCT00336284|Active Comparator|Home Monitoring|Home Monitoring programmed on.
3037358|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off.
3037359|NCT00336323|Active Comparator|1|Laser photocoagulation at baseline
3037360|NCT00336323|Experimental|2|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
3037361|NCT00336323|Experimental|3|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
3037362|NCT00336323|Experimental|4|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
3037363|NCT00336323|Experimental|5|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
3037364|NCT00336479|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3037365|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3178846|NCT00666341|Experimental|80 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
3320825|NCT02014064|Experimental|Atomoxetine|Double-blind, Placebo controlled, 2-phase study the safety & efficacy of Atomoxetine
3037366|NCT00336479|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
3037367|NCT00336479|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
3037368|NCT00336492|Experimental|002|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
3037369|NCT00336492|Experimental|001|infliximab infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
3037370|NCT00336505|Active Comparator|Clarithromycin|
3037371|NCT00336505|Experimental|Cethromycin|
3037372|NCT00336544|Experimental|Cethromycin|
3037373|NCT00336544|Active Comparator|Clarithromycin|
3037374|NCT00336583|Experimental|Oxaliplatin, response|relapsed or refractory non-Hodgkin's lymphoma
3037375|NCT00336700|Experimental|Gemcitabine and Erlotinib|Erlotinib (oral) 150 mg/day x 12 months Gemcitabine 1500 mg/m2 IV over 150 minutes q 2 weeks x 4 months
3037376|NCT00336817|Active Comparator|Myfortic Group|Subjects in the Myfortic arm will receive Myfortic 360mg or 720 mg BID for 90 days
3037377|NCT00336817|Active Comparator|CellCept Group|Subjects in the CellCept arm will receive CellCept 500mg or 1000mg BID for 90 days
3037378|NCT00336856|Experimental|IRINOTECAN AND CETUXIMAB|Cetuximab will be administered at the dose of 500 mg/m2 intravenously (IV) over 120 minutes, followed by 500 mg/m2 every 2 weeks, IV over 2 hours at an infusion rate not to exceed 5 ml/min. Followed immediately by Irinotecan administered at a dose of 180 mg/m2 IV over 60 minutes every two weeks.
3037379|NCT00336895|Experimental|Liver Transplant Subjects|All subjects in this study will receive Myfortic 360mg or 720 mg BID for 90 days.
3037380|NCT00336973|Experimental|1|
3037381|NCT00337077|Experimental|Eribulin mesylate|Patients receive eribulin mesylate IV over 5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3037382|NCT00337103|Experimental|1|
3037383|NCT00337103|Active Comparator|2|
3037384|NCT00337129|Experimental|eribulin mesylate|eribulin mesylate
3037385|NCT00337168|Experimental|Induc, ReInduc, Consol, clofarabine, cytarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
3037386|NCT00337181||Vaccine Group|Received vaccination in RV144
3037387|NCT00337181||Placebo Group|Received placebo in RV144
3037388|NCT00337194|Experimental|Arm I (SGN-30, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
3037389|NCT00337194|Active Comparator|Arm II (placebo, chemotherapy)|"Participants receive one of the following regimens every cycle depending on history of prior stem cell transplant. Cycle is 21 days.~No prior stem cell transplant:~SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 20 mg/m^2 IV days 1 & 8, gemcitabine: 1000 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 15 mg IV days 1 & 8.~Prior stem cell transplant SGN-30: 12 mg/kg IV days 1 & 8, vinorelbine: 15 mg/m^2 IV days 1 & 8, gemcitabine: 800 mg/m^2 IV days 1 & 8, pegylated doxorubicin HCl liposome: 10 mg IV days 1 & 8."
3037390|NCT00337207|Experimental|Avastin|
3037391|NCT00337272|Placebo Comparator|1 (Placebo)|Patients will take placebo 30 minutes before bedtime days 1-28 of treatment period.
3037392|NCT00337272|Active Comparator|2 (Ramelteon)|Patients will take 8 mgs of ramelteon 30 minutes before bedtime days 1-28 of treatment period.
3037393|NCT00337285|Experimental|1|
3037394|NCT00337350|Active Comparator|rosiglitazone|rosiglitazone 4mg/day
3037395|NCT00337350|Placebo Comparator|placebo|matched placebo for 4mg rosiglitazone
3037396|NCT00337428|Experimental|Group 1|Concomitant/CMF
3037397|NCT00337428|Experimental|Group 2|Non-Concomitant/CMF
3037398|NCT00337428|Experimental|Group 3|Concomitant/FMF
3037399|NCT00337428|Experimental|Group 4|Non-Concomitant/FMF
3037400|NCT00337467|Experimental|A1|
3037401|NCT00337571|Experimental|A1|5 mg
3037402|NCT00337571|Experimental|A2|10 mg
3037403|NCT00337571|Experimental|A3|15 mg
3037404|NCT00337571|Placebo Comparator|B1|
3037405|NCT00337610|Experimental|sitagliptin 100 mg once a day (q.d.)/metformin ≥1500 mg a day|
3037406|NCT00337610|Placebo Comparator|sitagliptin 100 mg placebo q.d./ metformin ≥ 1500 mg/day|
3037407|NCT00337662|Experimental|1|Olanzapine for Not Early Onset response (NEO) patients
3037408|NCT00337662|Active Comparator|2|Risperidone for Not Early Onset response (NEO) patients
3037409|NCT00337662|Active Comparator|3|Risperidone for Early Onset response (EO) patients
3037410|NCT00337675|Active Comparator|Arm 1: drug + episodic supplemental placebo|Montelukast once a day (qd) + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
3037411|NCT00337675|Active Comparator|Arm 2: placebo comparator + episodic supplemental drug|Placebo qd + episode driven supplemental Montelukast qd for 12 days for a 52-wk treatment period
3037412|NCT00337675|Placebo Comparator|Arm 3: placebo comparator + episodic supplemental placebo|Placebo qd + episode driven supplemental placebo qd for 12 days for a 52-wk treatment period
3178847|NCT00666341|Experimental|120 μg rPhleum Immunotherapy|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
3178848|NCT00666354|Active Comparator|1|
3178849|NCT00666354|Active Comparator|2|
3037413|NCT00337727|Other|1|Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.
3037414|NCT00337727|Other|2|Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.
3037415|NCT00337779|Active Comparator|glatiramer acetate 40 mg|
3037416|NCT00337779|Active Comparator|glatiramer acetate 20 mg|
3037417|NCT00337818|Experimental|Cervarix New Process|Subjects aged 15 to 25 years received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process.
3037418|NCT00337818|Experimental|Cervarix Old Process Group|Subjects aged 15 to 25 years who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the old manufacturing process.
3037419|NCT00337818|Experimental|Cervarix Young/Lot 1 Group|Subjects aged 10 to 14 years, who received 3 doses (at Months 0, 1 and 6) of Cervarix™ (human papillomavirus [HPV]) produced with the new manufacturing process (Lot 1).
3037420|NCT00337935|Experimental|Epoetin Alfa|
3037421|NCT00337935|Other|Group 2|Standard treatment of anemia excluding use of erythropoetin stimulating agents (ESAs).
3037422|NCT00338039|Experimental|Chemotherapy + Chemoradation|Systemic chemotherapy followed by chemoradiation in locally advanced pancreatic cancer. Cetuximab 500 mg/m^2 intravenous (IV)/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy. Induction Therapy Gemcitabine 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses; Induction Chemotherapy Oxaliplatin 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses. Capecitabine Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation. Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
3037423|NCT00338104|Experimental|40% Glargine|Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.
3037424|NCT00338104|Experimental|60% Glargine|Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.
3037425|NCT00338104|Experimental|80% Glargine|Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.
3037426|NCT00338286|Experimental|001|epoetin alfa + packed RBC transfusion 40 000 IU SC once a week.
3037427|NCT00338286|Other|002|Standard supportive care (packed RBC transfusion) Per doctor prescription
3037428|NCT00338598|Experimental|Glycine|Glycine, 0.8 gr per kg given in two daily doses
3037429|NCT00338598|Placebo Comparator|placebo|placebo will be administered.
3037430|NCT00338728|Experimental|Treatment (imatinib mesylate, letrozole)|Participants receive imatinib mesylate PO BID and letrozole PO QD for 8 weeks in the absence of disease progression or unacceptable toxicity.
3037431|NCT00338741||1|Rebif exposed pregnancies
3037432|NCT00338741||2|Non-Rebif exposed pregnancies
3037433|NCT00338806|Experimental|Interpersonal Psychotherapy-Prevention|Participants will receive interpersonal psychotherapy for prevention with adolescents
3037434|NCT00338806|Active Comparator|Educational and Clinical Monitoring|Participants will receive educational clinical monitoring
3037435|NCT00338884|Experimental|SUNITINIB MALATE.|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
3037436|NCT00338949|Active Comparator|Control|Participants on risperidone or olanzapine who will remain on risperidone or olanzapine and do not switch to ziprasidone
3037437|NCT00338949|Experimental|Switch|Participants who enter on risperidone or olanzapine and switch to ziprasidone
3037438|NCT00338962|Active Comparator|Paroxetine and naltrexone|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
3037439|NCT00338962|Active Comparator|paroxetine and placebo|Paroxetine was started at 10 mg per day and the dose was gradually increased over 2 weeks to 40 mg per day.
3037440|NCT00338962|Active Comparator|Desipramine and naltrexone|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day. Naltrexone was started at 25 mg the first day and 50 mg per day for the rest of the treatment.
3037441|NCT00338962|Active Comparator|Desipramine and placebo|Desipramine was started at a dose of 25 mg per day. The dose was gradually increased over 2 weeks to 200 mg per day.
3037442|NCT00338988|Experimental|Capecitabine + Oxaliplatin|Combination of intravenous (IV) oxaliplatin 100 mg/m^2 Day 1 and oral (PO) capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m2) on Days 1-14.
3037443|NCT00339040|Active Comparator|Arm A: QHPV|QHPV at week 0, 8, 24, 96.
3037444|NCT00339040|Other|Arm B: Placebo/QHPV|Placebo at week 0, 8, 24; QHPV at week 96, 104, 120.
3037445|NCT00339079|Experimental|Cognitive Behavioral Therapy (CBT)|Patients in this arm only received Cognitive Behavioral Therapy (CBT). Six, 60 minute weekly sessions were followed by 4 bi-weekly sessions and 3 monthly booster sessions.
3037446|NCT00339079|Placebo Comparator|Placebo|Patients only received placebo pills accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
3037447|NCT00339079|Experimental|Fluoxetine|Patients only received the SSRI Fluoxetine. Medication was adminstered on a fixed-flexible dosing regimen, beginning at 10mg/day for 2 weeks, then 20 mg/day for 2 weeks, 40 mg/day for two weeks, 60 mg/day for 2 weeks, and 80 mg/day (the target dose) thereafter. This was accompanied by medication management supportive therapy; including non-specific encouragement, support and explanation similar to that provide in a physician's office.
3037448|NCT00339079|Experimental|Combined CBT and Fluoxetine|Patients in this arm received both CBT and the fluoxetine medication. Both interventions were administered in the same way as when adminstered alone in the other arms.
3037449|NCT00339144|Experimental|Dasatinib (100 mg)|
3037450|NCT00339144|Experimental|Dasatinib (150 mg)|
3037451|NCT00339144|Experimental|Dasatinib (200 mg)|
3037452|NCT00339183|Experimental|Panitumumab Plus FOLFIRI|Participants received panitumumab as an intravenous (IV) infusion at a dose of 6 mg/kg plus a standard chemotherapy regimen (FOLFIRI) consisting of 5-fluorouracil (5-FU), leucovorin and irinotecan. Treatment was administered in cycles every two weeks.
3037453|NCT00339183|Active Comparator|FOLFIRI Alone|Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
3037454|NCT00339833|Experimental|Salsalate|Salsalate (3g/day) for 7 days
3037455|NCT00339833|Placebo Comparator|Placebo|Placebo
3037456|NCT00340379|Active Comparator|Ziprasidone|Subjects in this arm received ziprasidone with a placebo to maintain the blind
3037457|NCT00340379|Active Comparator|Sertraline/Haloperidol|Subjects in this arm received a combination of sertraline and haloperidol with a placebo to maintain the blind. Sertraline dosage was 150-200mg/day and haloperidol was 6-8mg/day based on tolerance.
3037458|NCT00340678|Experimental|Normoalbuminuria Losartan|Subjects with normal urinary albumin excretion were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
3037459|NCT00340678|Placebo Comparator|Normoalbuminuria Placebo|Subjects with normal urinary albumin excretion were treated with placebo corresponding to each dose of losartan.
3037460|NCT00340678|Experimental|Microalbuminuria Losartan|Subjects with microalbuminuria were treated with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
3037461|NCT00340678|Placebo Comparator|Microalbuminuria Placebo|Subjects with Microalbuminuria were treated with placebo corresponding to each dose of losartan.
3037462|NCT00340704|Experimental|1. Low dose group|
3037463|NCT00340704|Experimental|2. Medium dose group|
3037464|NCT00340704|Experimental|3. High dose group|
3037465|NCT00340834|Experimental|Fingolimod 1.25 mg|
3037466|NCT00340834|Experimental|Fingolimod 0.5 mg|
3037467|NCT00340834|Active Comparator|Interferon β-1a 30 µg|
3037468|NCT00342355|Active Comparator|AZT+DDI+EFV|Zidovudine,Didanosine,Efavirenz ( Zidovudine 600 mg once daily,Didanosine <60 kg/125 mg twice daily or >60kg/200 mg twice daily,Efavirenz 600 mg once daily)
3037469|NCT00342355|Active Comparator|AZT+DDI+r/LPV|Zidovudine,Didanosine,Lopinavir/Ritonavir(AZT 600 mg once daily,DDI 100 mg twice daily,r/LPV 400mg/100mg twice daily)
3037470|NCT00342355|Active Comparator|d4T+3TC+EFV|Stavudine,Lamivudine,Efavirenz(d4T 40 mg twice daily,3TC 300 mg once daily,EFV 600 mg once daily)
3037471|NCT00342355|Active Comparator|d4T+3TC+r/LPV|Stavudine,Lamivudine,Lopinavir/Ritonavir(d4T 40m mg twice daily,3TC 300 mg once daily,r/LPV 400mg/100mg twice daily)
3037472|NCT00342563|Experimental|Mecamylamine- Smoker|
3037473|NCT00342563|Placebo Comparator|Placebo-Smoker|
3037474|NCT00342563|Experimental|Mecamylamine- Non-Smoker|
3037475|NCT00342563|Placebo Comparator|Placebo-Non-Smoker|
3037476|NCT00342628|Experimental|Vi-rEPA plus DTP|Vi-rEPA and DTP at 2, 4, 6 months, and Vi-rEPA at 12 months
3037477|NCT00342628|Active Comparator|Hib-TT plus DTP|Hib-TT and DTP at 2,4 and 6 months, Hib-TT at 12 months
3037478|NCT00342628|Active Comparator|EPI|DTP at 2,4 and 6 months
3037479|NCT00343044|Experimental|Treatment|Subjects received standard topotecan with the addition of bevacizumab. Cycles were 28 days and continued until toxicity, progression or subject wish to discontinue treatment. Topotecan administered 4 mg/m2 IV on days 1, 8 and 15 and bevacizumab IV 10 mg/kg, days 1 and 15 of each cycle.
3037480|NCT00343083|Experimental|Cetuximab comparison for Head and Neck Cancer|"To report the mature data of a prospective Phase II trial designed to evaluate the efficacy of an epidermal growth factor receptor inhibitor cetuximab (CTX) added to the concurrent therapy of weekly paclitaxel/carboplatin (PC) and daily radiation therapy (RT).~Both chemotherapy and radiation will be given on a weekly basis (see interventions for details)."
3037481|NCT00343252|Experimental|Teriparatide|Teriparatide 20 micrograms (ug)/day, subcutaneous, 18 months plus once weekly oral placebo
3037482|NCT00343252|Active Comparator|Risedronate|Risedronate 35 milligrams (mg)/once weekly, oral, 18 months plus daily subcutaneous injection placebo
3037483|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/6)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Paclitaxel 200 mg/m² on day 1 of every 3 week cycle~Carboplatin area under curve (AUC=6 min*mg/mL) on day 1 of every 3 week cycle~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3037484|NCT00343291|Active Comparator|Cetuximab + Bevacizumab + Paclitaxel + Carboplatin (6/3)|"Cycles 1-6:~Cetuximab 400 mg/m² initial dose on day 1 and then 250 mg/m² given every week~Bevacizumab 15 mg/kg given on day 8 of every 3 week cycle~Cycles 1-3:~Paclitaxel 200 mg/m² on day 1 of each 3 week cycle for the first 3 cycles~Carboplatin AUC=6 min*mg/mL on day 1 of each 3 week cycle for the first 3 cycles~Patients who demonstrate a response or stable disease after six cycles of therapy may continue on weekly cetuximab monotherapy until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3037485|NCT00343382|Experimental|Arm I|Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
3037486|NCT00343382|Experimental|Arm II|Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
3037487|NCT00343382|Placebo Comparator|Arm III|Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
3037488|NCT00343382|Placebo Comparator|Arm IV|Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
3037489|NCT00343460|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, placebo subcutaneously (SC), and dexamethasone IV on day 1 of chemotherapy course 1. Patients in the high-risk (level 5) stratum also receive oral dexamethasone on days 2-4 of all treatment courses.
3178850|NCT00666354|Active Comparator|3|
3037490|NCT00343460|Experimental|Arm II|Patients receive APF530 SC, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
3037491|NCT00343460|Experimental|Arm III|Patients receive APF530 SC at a higher dose, placebo IV, and dexamethasone IV on day 1 of chemotherapy course 1. Patients then receive APF530 SC (at the same higher dose) and dexamethasone IV on day 1 of chemotherapy courses 2-4. Patients in the high-risk (level 5) stratum also receive oral dexamethasone as in arm I.
3037492|NCT00343512|Experimental|Therapeutic Intervention|
3037493|NCT00343564|Experimental|Phase 1 Dose Escalation|Phase 1 dose escalation without and with GCSF support
3037494|NCT00343564|Experimental|Phase 2 Fixed Dose|Phase 2 fixed dose based on Phase I findings stratified by NHL type
3037495|NCT00343642|Experimental|Active Fructo-oligosaccharide|"Subjects received an active fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.~The fructo-oligosaccharide supplement was administered orally in a powder form two teaspoons daily."
3037496|NCT00343642|Placebo Comparator|Placebo Fructo-oligosaccharide|Subjects received a placebo fructo-oligosaccharide supplement and a diet following the 2005 Dietary Guidelines for Americans.
3037497|NCT00343642|Active Comparator|Dietary Therapy|Subjects received a placebo fructo-oligosaccharide supplement and a restrictive anti-inflammatory diet developed by the research team.
3037498|NCT00343785|Experimental|Treatment (conditioning regimen, transplant, GVHD prophylaxis)|Patients receive a conditioning regimen comprising cyclophosphamide IV on days -5 to -2 and anti-thymocyte globulin IV over 4-10 hours on days -4 to -2. Patients undergo allogeneic bone marrow transplantation on day 0. Patients then receive GVHD prophylaxis comprising methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1 hour or PO twice daily on days -1 to 50, followed by a taper until 6 months after grafting.
3037499|NCT00343863|Active Comparator|Dexamethasone + Ondansetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and ondansetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
3037500|NCT00343863|Experimental|Dexamethasone + Palonosetron IV on Day 1|"All patients receive doxorubicin hydrochloride IV on day 1 and oral cyclophosphamide on days 1-7.~Patients receive dexamethasone IV or orally and palonosetron IV on day 1 (prior to each dose of doxorubicin hydrochloride)."
3037501|NCT00343889|Experimental|Group 1: DTaP-Hep B-PRP-T + Oral Polio Vaccine (OPV) vaccine|Participants received 3 doses of the DTaP-Hep B-PRP~T concomitantly with Oral Polio Vaccine (OPV), 1 dose each at 6, 10, and 14 weeks of age.
3037502|NCT00343889|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of Tritanrix-Hep B/Hib™ concomitantly with Oral Polio Vaccine (OPV) at 6, 10, and 14 weeks of age.
3037503|NCT00343915|Experimental|2-Dose Engerix|subjects received 2 doses of adult (thiomersal-free) HBV formulation, one at 0 and 6 months, respectively and placebo (physiological saline) at 1 month.
3037504|NCT00343915|Active Comparator|3-Dose Engerix|subjects received 3 doses of paediatric (preservative-free) HBV formulation one at 0, 1 and 6 months, respectively.
3037505|NCT00344032|Experimental|Cervarix|Subjects who received 3 doses of HPV-16/18 VLP/AS04 Vaccine (Cervarix TM) (at 0, 1, 6 months).
3037506|NCT00344032|Placebo Comparator|Placebo|Subjects who received 3 doses of Placebo (at 0, 1, 6 months).
3037507|NCT00344175|Experimental|Pitavastatin 4 mg|Pitavastatin 4 mg once daily
3037508|NCT00344175|Active Comparator|Simvastatin 40mg/80mg|Simvastatin 40 mg or 80 mg once daily
3037509|NCT00344305|Experimental|Cohort 1: Participants Between 6 to < 24 Months Age|Participants received a single, intranasal dose of 0.2 millilitre (mL) (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 fluorescent focus units (FFU) of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
3037510|NCT00344305|Experimental|Cohort 2: Participants Between 24 to < 60 Months Age|Participants received a single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains namely, A/New Caledonia/20/99 (H1N1), A/Wyoming/03/2003 (H3N2) (A/Fujian/411/2002-like) and B/Jilin/20/2003 (B/Shanghai/361/2002-like).
3037511|NCT00344318|Experimental|Synflorix 1 Group|Subjects aged 6-12 weeks from the Philippines receiving Synflorix™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ vaccines at 6, 10, 14 weeks of age.
3037512|NCT00344318|Experimental|Synflorix 2 Group|Subjects aged 6-12 weeks from Poland receiving Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 2, 4, 6 months of age.
3037513|NCT00344318|Active Comparator|Prevenar 1 Group|Subjects aged 6-12 weeks from the Philippines receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Polio Sabin™ at 6, 10, 14 weeks of age.
3037514|NCT00344318|Active Comparator|Prevenar 2 Group|Subjects aged 6-12 weeks from Poland receiving the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ at 2, 4, 6 months of age.
3037515|NCT00344370|Experimental|Pitavastatin|Pitavastatin 4 mg QD
3037516|NCT00344370|Active Comparator|Atorvastatin|Atorvastatin 40 mg
3037517|NCT00344448|Experimental|Raptiva|At the beginning of the first (week 1) and second (week 13) phases, all patients will receive reduced dose of the study medication determined at 0.7 mg/kg/week. During all the subsequent administrations, all patients will receive full dose of the study medication determined at 1 mg/kg/week.
3037518|NCT00344448|Placebo Comparator|placebo|Weekly subcutaneous injection of a placebo (formulated to match the commercial vial of Raptiva in appearance and content except for the active ingredient) for the first 12 weeks of the study.
3037519|NCT00344461|Experimental|Nevirapine, FTC, Tenofovir|Open Label Drugs- Nevirapine 200 mg twice a day, FTC 200 mg once a day and Tenofovir 300 mg once a day for 96 weeks.
3037520|NCT00344500|No Intervention|Usual Care|Usual Care
3037521|NCT00344500|Active Comparator|Lifestyle Balance|Behavioral Weight Loss Program
3037522|NCT00344682|Experimental|memantine|memantine (5-20mg a day)
3037523|NCT00344682|Placebo Comparator|Placebo|placebo (5-20mg a day)
3037524|NCT00344773|Experimental|Gefitinib|Gefitinib 250mg tablet once daily
3037525|NCT00344968|Experimental|1|
3037526|NCT00344968|Experimental|2|
3037527|NCT00344968|Sham Comparator|3|
3037528|NCT00345033|Experimental|1|Participants will take aripiprazole 15mg/day for 8 weeks.
3037529|NCT00345033|Placebo Comparator|2|Participants will take placebo for 8 weeks.
3037530|NCT00345046|Active Comparator|Pred Forte 1%|Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
3037531|NCT00345046|Active Comparator|EconoPred Plus 1%|EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
3037532|NCT00345046|Active Comparator|Prednisolone Acetate 1%|Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.
3037533|NCT00345176|Active Comparator|Lutein/Zeaxanthin|lutein (10mg)/zeaxanthin (2 mg)
3037534|NCT00345176|Active Comparator|DHA/EPA|DHA (350 mg)/EPA (650 mg)
3037535|NCT00345176|Active Comparator|Lutein/Zeaxanthin + DHA/EPA|lutein (10 mg)/zeaxanthin (2 mg) + DHA (350 mg)/EPA (650 mg)
3037536|NCT00345176|Placebo Comparator|Placebo/Control|Considered control because all participants received the AREDS formulation
3037537|NCT00345254|Experimental|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
3037538|NCT00345254|No Intervention|Untouched cord|The cord was untouched after delivery of the anterior shoulder and prior to extraction of the body.
3037539|NCT00345293|Experimental|DC/PC3 vaccine|3 subcutaneous injections of ex vivo-generated autologous dendritic cell vaccine: 1) pulsed with apoptotic PC3 cells; 2) pulsed with apoptotic PC3-M1 cells, and 3) pulsed with keyhole limpet hemocyanin (KLH, control antigen)
3037540|NCT00345332|Placebo Comparator|1|Placebo
3037541|NCT00345332|Experimental|2|Botox
3037542|NCT00345345|Experimental|Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
3178851|NCT00666367|Active Comparator|1|Vitamin D (D-cure) will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3178852|NCT00666367|Placebo Comparator|2|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
3178853|NCT00666380|Experimental|10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
3178854|NCT00666380|Experimental|50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant|
3037547|NCT00345371|Active Comparator|Topiramate|Subjects will receive topiramate (in tablet form) up to 200 mg/day for 13 weeks.
3037548|NCT00345371|Placebo Comparator|Placebo Oral Tablet|After randomization subjects will receive topiramate matched placebo (in tablet form), up to 200 mg/day for 13 weeks.
3037549|NCT00345384|Placebo Comparator|Normal Saline|One group (placebo comparator) will receive a normal saline infusion, set at a rate as if it were the active drug.
3037550|NCT00345384|Active Comparator|Dexmedetomidine|The second group (the study group) will receive a continuous infusion of dexmedetomidine titrated from 0.1 - 0.5 mics/kg/h to control pain for up to 24 hours after they are admitted to an open nursing unit after discharge from the PACU or ICU
3037551|NCT00345397|Experimental|Subjects Receiving PEC Tube|Percutaneous Endoscopic Colostomy Tube (PEC) Placement
3037552|NCT00345540|Experimental|NOV-002 plus Carboplatin|NOV-002 is given by IV bolus on lead-in day -1 at cycle 1, and on day 1 at subsequent cycles, followed by Carboplatin AUC 5. NOV-002 is then continued via daily SC injection, with 28 day cycles.
3037553|NCT00345579|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and a fourth dose of Menhibrix vaccine at 12-15 months of age in the study NCT00345683. Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3037554|NCT00345579|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in the study NCT00345683. ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3037555|NCT00345592|Experimental|Device managed arm|Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
3037556|NCT00345592|Active Comparator|Traditional arm|Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.
3037557|NCT00345605|Experimental|HDA|"High Dose Arm~Wash-out then 7 days of:~Arg 500 mg/kg/d or 10 g/m2 BSA Placebo instead of NaPBA"
3037558|NCT00345605|Experimental|LDA|"Low Dose Arm~Wash-out followed by 7 days of:~Arg 100 mg/kg/d or 2 g/m2 BSA NaPBA 500 mg/kg/d or 10 g/m2 BSA"
3037559|NCT00345631|Active Comparator|Manual Compression|Manual compression (MC)
3037560|NCT00345631|Experimental|Vascular Closure Device|Vascular Closure Device (VCD)
3178855|NCT00666393|Experimental|001|
3178856|NCT00666432||1|Controls
3178857|NCT00666432||2|Patient Family
3178858|NCT00666432||3|Patients
3178859|NCT00666445||1|Patients diagnosed with Alzheimer's Disease
3178860|NCT00666445||2|Aged-matched normal controls
3178861|NCT00666471|Experimental|1|MICE
3178862|NCT00666471|Active Comparator|2|SPA ligation
3178863|NCT00666484|Experimental|Treatment Group 1: stages 1A, 1B, 2A: OEPA x 2|"OEPA (28day cycle):~Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15"
3320826|NCT02014064|Placebo Comparator|Placebo|"Control Group Schedule:~Day 1: 40mg @ 8:00am Day 2: 40mg @ 8:00am Day 3: 40mg @ 8:00am, 40mg @ 8:00pm Day 4: 40mg @ 8:00am, 40mg @ 8:00pm Day 5: 40mg @ 8:00am, 40mg @ 8:00pm Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
3037561|NCT00345683|Experimental|Menhibrix Group|Subjects received 3 doses of Menhibrix vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and a fourth dose of Menhibrix vaccine at 12-15 months of age in this study (study Month 10-13). Menhibrix was administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3037562|NCT00345683|Active Comparator|ActHIB Group|Subjects received 3 doses of ActHIB vaccine (at 2, 4 and 6 months of age, study Months 0, 2 and 4), co-administered with Pediarix/Infanrix penta as a primary vaccination course in the study NCT00345579 and 1 dose of PedvaxHib vaccine as a booster at 12-15 months of age in this study (study Month 10-13). ActHIB and PedvaxHib vaccines were administered intramuscularly in the upper right thigh and co-administered Pediarix/Infanrix penta vaccine was injected intramuscularly in the upper left thigh.
3037563|NCT00345839|Experimental|Cinacalcet|
3037564|NCT00345839|Placebo Comparator|Placebo|
3037565|NCT00345865|Experimental|NHL with irradiation|Non Hodgkin's Lymphoma patients treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
3037566|NCT00345865|Experimental|HL without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
3037567|NCT00345865|Experimental|NHL - HIV infected with irradiation|Non Hodgkin's Lymphoma patients infected with HIV, treated with cyclophosphamide, total body irradiation therapy, peripheral blood stem cell transplantation and G-CSF.
3037568|NCT00345865|Experimental|NHL - HIV infected without irradiation|Patients with Hodgkin's lymphoma treated with cyclosphosphamide, carmustine, etoposide, peripheral blood stem cell transplantation and G-CSF.
3037569|NCT00345865|Experimental|NHL without radiation and cyclosporine|Patients with non Hodgkin's lymphoma ineligible to receive total body irradiation because of prior radiation and are not candidates for high dose cyclophosphamide will be treated with carmustine, etoposide, cytarabine, and melphalan followed by peripheral blood stem cell transplantation and G-CSF (called BEAM conditioning).
3037570|NCT00345878|Experimental|Cervarix Group|Subjects received 3 doses of HPV-16/18 L1 VLP AS04 (Cervarix™) according to a 0, 1, 6-month schedule.
3037571|NCT00345878|Placebo Comparator|Placebo Group|Subjects received 3 doses of Placebo according to a 0, 1, 6-month schedule.
3037572|NCT00345969|Active Comparator|Transdermal Testosterone gel (1%)|Transdermal testosterone 1% gel (Androgel) provided as 2.5 gm and/or 5 gm gel packets with dose titration and monthly dose adjustments to achieve and maintain serum total testosterone level between 500-900 mg/dL. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
3037573|NCT00345969|Placebo Comparator|Placebo gel|Inactive topical gel identical in appearance to the active medication, provided in packets identical to the packaging for the active medication. Gel to be applied daily by participants. Participants are blinded to the contents of the gel packets. Participants in this arm also perform supervised exercise training for 6 months.
3037574|NCT00346034|Experimental|1|
3037575|NCT00346073|Experimental|Boostrix Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Boostrix® vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
3037576|NCT00346073|Experimental|Adacel Group|Subjects, male or female, between, and including, 19 and 64 years of age received a single dose of Adacel™ vaccine administered intramuscularly in the deltoid region of the non-dominant upper arm at Day 0.
3037577|NCT00346151|Experimental|Belatacept|Immunosuppressive protocol consisting of belatacept, glucocorticoids, antithymocyte globulin (ATG), and sirolimus.
3037578|NCT00346164|Experimental|Arm A: No adjuvant treatment|Patients with low-grade tumor with either negative or positive microscopic margins or high-grade tumor ≤ 5 cm (in maximum diameter) with negative microscopic margins are assigned to arm A: (observation only).
3037579|NCT00346164|Experimental|Arm B: Low risk; adjuvant radiotherapy|Patients with high-grade tumor ≤ 5 cm (in maximum diameter) with positive microscopic margins are assigned to arm B: (adjuvant radiotherapy). Beginning between 6-42 days after surgical resection, patients undergo a total of 31 fractions of adjuvant radiotherapy.
3037580|NCT00346164|Experimental|Arm C: Intermediate & High risk; adjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with high-grade, grossly resected primary tumor, with metastases are assigned to receive arm C: (adjuvant chemoradiotherapy). Patients receive ifosfamide IV; doxorubicin hydrochloride IV; beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy.
3037581|NCT00346164|Experimental|Arm D: Intermediate & High Risk; Neoadjuvant chemoradiotherapy|High risk [metastatic, resected, incompletely resected, or unresected disease] patients with unresected, high-grade metastatic tumor are assigned to receive treatment as in arm D: (neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy with or without radiotherapy): Patients receive ifosfamide IV; doxorubicin hydrochloride IV. Beginning in week 4, patients also undergo a total of 31 fractions of radiotherapy. Patients undergo surgical resection in week 13.
3037582|NCT00346216|Experimental|celecoxib|subject receives celecoxib and dummy (placebo) ibuprofen and naproxen
3037583|NCT00346216|Active Comparator|ibuprofen|subject receives ibuprofen and dummy (placebo) celecoxib and naproxen
3037584|NCT00346216|Active Comparator|naproxen|subject receives naproxen and dummy (placebo) celecoxib and ibuprofen
3037585|NCT00346268|Active Comparator|Morphine plus Parecoxib|
3037586|NCT00346268|Active Comparator|Morphine and Placebo|
3037587|NCT00346333|Experimental|Lutein plus 15,000 IU/d Vitamin A|Daily intake of 12mg of Lutein plus 15,000 IU/d of Vitamin A palmitate
3037588|NCT00346333|Placebo Comparator|Control plus 15,000 IU/d Vitamin A|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
3037589|NCT00346398|Experimental|Oral mucosal immunoprophylaxis (OMIP)|Participants are administered oral mucosal immunoprophylaxis (OMIP) daily for 12 months.
3037590|NCT00346398|Placebo Comparator|Placebo|Participants are administered, via the same route as the experimental group, an oral placebo solution daily for 12 months.
3037591|NCT00346476||Participants|Individuals in the Masiphumelele Township of Cape Town, South Africa, who have been potentially exposed to TB and/or HIV
3037592|NCT00346632|Experimental|KW-2449|Treatment with ascending doses of KW-2449
3037593|NCT00346697|Experimental|LOVAZA|4 g/d of omega-3 fatty acid esters, plus dietary counseling
3037594|NCT00346697|Placebo Comparator|Placebo|Corn oil placebo, plus dietary counselling
3037595|NCT00346905|Experimental|Single Arm|Those receiving Enteryx treatment
3037596|NCT00347009|Other|Adefovir Dipivoxil|10mg once daily in patients with CHB related advanced fibrosis/cirrhosis.
3037597|NCT00347022|Experimental|Xenetix|The patient receive one injection of Xenetix 300 (300 mg of iodine/ml)
3037598|NCT00347022|Active Comparator|Visipaque|The patient receive one injection of Visipaque 270 (270 mg of iodine/ml)
3037599|NCT00347269|Experimental|CALM Intervention|"Participant choice of:~Cognitive Behavioral Therapy (CBT) Psychotropic (anti-anxiety) medication optimization"
3037600|NCT00347269|Active Comparator|Treatment as Usual (TAU)|Participants assigned to TAU with their primary care provider (PCP)
3037601|NCT00347360|Experimental|lisinopril|lisinopril
3037602|NCT00347360|Experimental|carvedilol|carvedilol controlled release formulation
3037603|NCT00347438|Experimental|Capecitabine|Capecitabine will be given at 1000mg/m2 twice daily for 2 weeks x 8 cycles, with a one-week pause in-between cycles.
3037604|NCT00347776|Active Comparator|Control|topical tetracycline
3037605|NCT00347776|Active Comparator|Intervention 1|oral azithromycin, single 1g dose to subject
3037606|NCT00347776|Active Comparator|Intervention 2|single oral azithromycin dose to subject and immediate family members
3037607|NCT00347919|Experimental|monotherapy arm|1500 mg (6 x 250 mg tablets) oral lapatinib once daily
3037608|NCT00347919|Experimental|Cohort 1 combination arm|1000 mg (4 x 250 mg tablets) of oral lapatinib and 400 mg (4 x 100 mg tablets) of oral pazopanib taken together once daily
3037609|NCT00347919|Experimental|Cohort 2 combination arm|1500 mg (6 x 250 mg tablets) of oral lapatinib and 800 mg (1 x 500 mg tablets plus 3 x 100 mg tablets) of oral pazopanib taken together once daily
3037610|NCT00347932|Experimental|ISV-403|0.6% ISV-403 ophthalmic suspension
3037611|NCT00347932|Placebo Comparator|Vehicle|Vehicle of ISV-403 ophthalmic suspension
3037612|NCT00347958|Experimental|Adacel vaccine group|Participants 15 to 69 years of age who received a dose of Adacel vaccine in one of three previous studies (Td501, or Td502, or Td505), revaccinated in Study Td518.
3037613|NCT00348140|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
3037614|NCT00348140|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
3037615|NCT00348140|Placebo Comparator|Arm 3|Placebo
3037616|NCT00348205|Experimental|Technolas 217z Zyoptix System|Bausch & Lomb Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software.
3037617|NCT00348283|Placebo Comparator|Double Blind|Blinded study through Week 52. Adalimumab compared to placebo during blinded portion.
3037618|NCT00348283|Other|Open Label|Note: No comparator was used in Open-Label portion of study. From Week 8, subjects could have switched to open-label (OL) adalimumab 40mg administered subcutaneously (SC) every other week (eow)or OL adalimumab 40 mg SC every week (ew) dosing to treat disease flare or non-response. At Week 52, all remaining subjects were allowed to switch to the Open-Label portion of the study.
3037619|NCT00348309|Experimental|Arm 1|Rosiglitazone Extended Release 2mg OD
3037620|NCT00348309|Experimental|Arm 2|Rosiglitazone Extended Release 8mg OD
3037621|NCT00348309|Placebo Comparator|Arm 3|Placebo
3037622|NCT00348348|Active Comparator|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5%
3037623|NCT00348348|Experimental|Besifloxacin Suspension|Besifloxacin hydrochloride ophthalmic suspension 0.6%
3037624|NCT00348374|Active Comparator|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
3037625|NCT00348374|Experimental|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
3037626|NCT00348595|Active Comparator|1|5mg/day Arm: one 5 mg active Revlimid capsule and one 25 mg matched placebo capsules PO QAM (every morning) (at approximately the same time) days 1-21 days (28-day cycles).
3037627|NCT00348595|Active Comparator|2|25 mg/day Arm: one 25 mg active Revlimid capsule and one 5 mg matched placebo capsule PO QAM (every morning) (at approximately the same time) days 1-21 (28 day cycles).
3037628|NCT00348673|Experimental|Stage 1|
3037629|NCT00348673|Experimental|Stage 2|
3037630|NCT00348686|Experimental|Candesartan|Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.
3037631|NCT00348790|Experimental|Vatalanib|"Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached.~Patients who are responding may remain on study treatment for 12 months."
3037632|NCT00348816|Experimental|Docetaxel (Single Arm)|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Prednisone 5mg twice a day Radical prostatectomy as standard of care Radiation therapy will be used as standard of care Post radiation Doxcetaxel
3037633|NCT00348881|Experimental|Group 1: DTaP-Hep B-PRP-T + OPV vaccine|Participants received 3 doses of the DTaP-Hep B-PRP-T concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
3037634|NCT00348881|Active Comparator|Group 2: Tritanrix-HepB/Hib™ + OPV vaccine|Participants received 3 doses of the Tritanrix-HepB/Hib™ concomitantly with OPV vaccine, 1 dose each at 6, 10, and 14 weeks of age.
3037635|NCT00348933|Experimental|1|Participants will receive two daily doses of Metafolin, betaine, and creatine, and one daily dose of vitamin B12 for 12 months.
3037636|NCT00348946|Active Comparator|Oxandrolone|Androgen oxandrolone: Oxandrolone, 0.6 > mg/kg/day, orally, for 2 years.
3037637|NCT00348946|Placebo Comparator|Placebo|An inactive substance.
3037638|NCT00349336|Experimental|1|
3037639|NCT00349336|Experimental|2|
3037640|NCT00349349|Experimental|ofatumumab|Anti-CD20 antibody therapy
3037641|NCT00349388|Experimental|Asacol once a day dosing|Asacol total dose in mg/kg given once a day
3037642|NCT00349388|Active Comparator|Asacol BID/TID dosing|Asacol total dose split BID or TID
3037643|NCT00349466|Experimental|1|CF101 1 mg given orally every 12 hours for 12 weeks
3037644|NCT00349466|Placebo Comparator|2|Placebo given orally every 12 hours for 12 weeks
3037645|NCT00349622|Active Comparator|Ceftriaxone|"Two thirds of participants were assigned to 4 grams of ceftriaxone per day. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is a cephalosporin antibiotic and was administered intravenously via a central venous catheter twice a day."
3037646|NCT00349622|Placebo Comparator|Placebo|"One third of participants were assigned to placebo, or an inactive substance. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Pediatric multivitamin solution was used as the placebo in this study and was administered intravenously via a central venous catheter twice a day."
3037647|NCT00349713|Experimental|Cohort 1: 25ug FMP2.1 / AS02A|20 subject to receive 25ug of FMP2.1 vaccine in 0.25mL of GSK Biologicals' adjuvant AS02A
3037648|NCT00349713|Experimental|Cohort 2: 50ug FMP2.1 / AS02A|20 subjects to receive 50ug of FMP2.1 vaccine in 0.5mL of GSK Biologicals' adjuvant AS02A
3037649|NCT00349713|Active Comparator|Cohorts 1 and 2: Rabies vaccine (RabAvert)|"20 subjects to receive Rabies vaccine (RabAvert). 10 subjects from Cohort 1 and 10 subjects from Cohort 2~Rabies vaccine (RabAvert): RabAvert Rabies vaccine"
3037650|NCT00349752|Experimental|Certolizumab pegol 400 mg|Certolizumab pegol 400 mg
3037651|NCT00349752|Placebo Comparator|Placebo|Placebo
3037652|NCT00349778|Experimental|High-Dose Sequential Therapy|Cyclophosphamide + Etoposide + Melphalan + Carmustine with Filgrastim
3037653|NCT00349908|Experimental|Group 1: Atherosclerosis Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
3037654|NCT00349908|Active Comparator|Group 2: Aneurysm Arm|Implant of Cordis Neurovascular ENTERPRISE Self Expanding Stent System
3037655|NCT00349921|Active Comparator|clonidine first, then adenosine|clonidine given in first injection adenosine given in second injection
3037656|NCT00349921|Active Comparator|adenosine first, then clonidine|adenosine given in first injection clonidine given in second injection
3037657|NCT00349921|Placebo Comparator|clonidine given first, then placebo|placebo
3037658|NCT00349921|Placebo Comparator|adenosine given first, then placebo|placebo
3037659|NCT00349973|Experimental|1|Dipyridamole
3037660|NCT00349973|Active Comparator|2|Olanzapine
3037661|NCT00350025|Other|Cetuximab alone|Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy
3037662|NCT00350025|Other|Cetuximab with Paclitaxel|Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.
3037663|NCT00350142|Experimental|Stereotactic Body Radiotherapy|Patients will have a 4D pancreatic protocol CT and a FDG PET scan scan, both for planning purposes. An SBRT treatment plan will be developed based on tumor geometry and location. All patients will receive a single fraction of 25 Gy dose of Stereotactic Body Radiotherapy on Trilogy Linear Accelerator, followed by weekly Gemcitabine.
3037664|NCT00350220|Active Comparator|1|High Hemoglobin group; goal Hb >13g/dl. 10cc/kg RBCs are transfused for any hemoglobin value under 13g/dl regardless whether clinical indication for transfusion exists.
3037665|NCT00350220|Active Comparator|2|Low Hb transfusion group; goal to not transfuse unless the Hb <9.0 g/dl. 10cc/kg RBCs are transfused only if the Hemoglobin is under 9.0g/dl and clinical indications for transfusion exist.
3037666|NCT00350272|Experimental|Elvucitabine, Efavirenz,Tenofovir|"Elvucitabine (blinded) 10 mg/day in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
3037667|NCT00350272|Active Comparator|Lamivudine,Efavirenz,Tenofovir|"Lamivudine (blinded) 300 mg daily in combination with open-label efavirenz 600 mg daily and open-label tenofovir 300 mg daily, all administered orally, over 12 weeks. Eligible subjects continued with an additional 84 weeks of open-label treatment (through Week 96).~Subjects who experienced at least a 2 log10 decrease in HIV-1 RNA from Baseline or who had an HIV-1 RNA level of less than 400 copies/mL at Week 10 and had not experienced any Grade 3 or 4 hematological toxicity as of the Week 10 measurement were considered eligible for an additional 84 weeks of open-label treatment after Week 12."
3037668|NCT00350298|Experimental|GS-CDA1/MDX-1388|Biological: GS-CDA1/MDX-1388 One Intravenous dose
3037669|NCT00350298|Placebo Comparator|Placebo|Biological: normal saline (0.9% sodium chloride) One Intravenous dose
3037670|NCT00350337|Experimental|Pre-transfection F17|"4 monovalent vaccine lots: DEN type 1 45AZ5 PDK-27, Lot 1-1-90 DEN type 2 S16803 PDK-50, Lot 1-1-90 DEN type 3 CH53489 PDK-20 DEN type 4 341750 PDK-6, Lot 1-1-90 in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Freeze-dried monovalent dengue vaccines were rehydrated with sterile water for injection diluted to match viral concentration of the F17 Post vaccine"
3037671|NCT00350337|Experimental|Post-transfection F17|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2 : 5.3 log10 FFU/mL DEN type 3: 4.7 log10 FFU/mL DEN type 4: 5.0 log10 FFU/mL in 50% EMEM stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
3037672|NCT00350337|Experimental|Post-transfection F19|"4 monovalent vaccine lots: DEN type 1: 4.9 log10 FFU/mL DEN type 2: 5.2 log10 FFU/mL DEN type 3: 4.6 log10 FFU/mL DEN type 4: 4.4 log10 FFU/mL (1:10 dilution) in 50% EMEM-stabilizer, streptomycin, neomycin and vegetable-derived carbohydrates and amino acids stabilizers for injection.~Lyophilized, single dose vials and sterile water for injection"
3037673|NCT00350337|Placebo Comparator|Placebo|A sterile solution of the same EMEM, with phenol red (1:1) and the same virus stabilizer contained in the vaccine. The phenol red dye (phenolsulfonphthalein) is an FDA-accepted vaccine excipient used in vaccines as a pH indicator. The placebo was identical in appearance to the dengue vaccine.
3037674|NCT00350363|Active Comparator|1 hour gatifloxacin|presence of conjunctival bacteria 1 hour after administration of topical gatifloxacin
3037675|NCT00350402|Active Comparator|High Intensity Muscle Strength Training|This arm involved high intensity muscle strength training at 75% maximum inspiratory pressure (MIP). Training took place for 4 weeks, 5 days a week. Each daily session involved 5 sets of breathing exercises that required participants to take deep breaths (i.e., inspire) using use a breathing device. Settings on the breathing device were determined by obtaining the individual's maximal inspiratory pressure (MIP)using a specialized breathing gauge. The MIP was determined at the beginning of each week and the training device was adjusted and set at 75% MIP. Exercises took place in home setting, with weekly visit by staff. Participants kept daily exercise log.
3037676|NCT00350402|Sham Comparator|Sham MST|This arm (low intensity MST) was identical to the real intervention in all ways except that the training device was set at 5% maximum inspiratory pressure (MIP). Thus less muscle and breathing effort was required during this sham treatment.
3037677|NCT00350519|Experimental|PROCRIT (epoetin alfa)|Participants will receive PROCRIT (epoetin alfa).
3037678|NCT00350519|Experimental|STANDARD THERAPY|Participants will receive standard of care.
3037679|NCT00350532|Active Comparator|Neuropathic Pain Subjects|Chronic Pain Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
3037680|NCT00350532|Active Comparator|Healthy Subjects|Healthy Participants will be trained to accurately estimate pain by way of thermal heat testing. Next a small amount of spinal fluid will be withdrawn from each participant to measure the amounts of naturally-made chemicals in the participants' cerebrospinal fluid. Participants then will receive an injection of clonidine. After the injection, additional samples of spinal fluid will be taken to measure chemical changes in the fluid.
3037681|NCT00350545|Experimental|rituximab + prednisone arm|Rituximab will be given as an IV fusion as initial treatment, followed by predisone (given during registration) which will be continued through-out trial and tapered off by physician. Cyclosporine A and tacrolimus will be used if chances of new diagnosis of chronic GVHD occur. Both drugs have no interaction with Rituxan, but will be tapered off after predisone is completely tapered.
3037682|NCT00350636|Experimental|Oxybutynin topical gel|Oxybutynin topical gel
3037683|NCT00350636|Placebo Comparator|Placebo topical gel|placebo topical gel
3037684|NCT00350727|Experimental|Combination|Pazopanib and Lapatinib in combination. Subjects remain on treatment until disease progression or withdrawal from study.
3037685|NCT00350779|Experimental|1|Sitagliptin
3037686|NCT00350779|Placebo Comparator|2|Placebo
3037687|NCT00350792|Experimental|Pemetrexed + Carboplatin|"Pemetrexed: 500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles.~Carboplatin: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles."
3037688|NCT00350870|Placebo Comparator|Placebo|Placebo (plus Cognitive Behavioral Therapy- CBT)
3037689|NCT00350870|Active Comparator|Disulfiram|Disulfiram (plus CBT)
3037690|NCT00350870|Placebo Comparator|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
3037691|NCT00350870|Active Comparator|Disulfiram plus Contingency Management|Disulfiram plus Contingency Management for cocaine abstinence and medication compliance (in addition to CBT).
3037692|NCT00351039|Experimental|Bevacizumab, Erlotinib, Pemetrexed|Single Arm Phase II trial in elderly patients with advanced stage Non-Squamous Non-Small Cell Lung Cancer
3037693|NCT00351273|Active Comparator|Azithromycin and Rifampin|Participants received Azithromycin and Rifampin
3037694|NCT00351273|Active Comparator|Doxycycline and Rifampin|Participants received Doxycycline and Rifampin
3037695|NCT00351273|Placebo Comparator|received placebo|Participants received placebo
3037696|NCT00351299|Experimental|Infusion of dexmedetomidine|infusion 0.3-0.7 dexmedetomidine
3037697|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
3037698|NCT00351351|Experimental|A|Cyberwand
3037699|NCT00351351|Active Comparator|B|Currently available lithotripsy technology
3037700|NCT00351377|Experimental|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily in a dose that was equimolar to the dose of Mycophenolate mofetil the participant was taking at the time of study entry. The planned duration of treatment 6 to 8 weeks.
3037701|NCT00351416|Experimental|Aromatase inhibitor EFP|"Letrozole administration (20 mg) on day 2-4 (EFP; early follicular phase) of cycle 2 and~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
3037702|NCT00351416|Experimental|Aromatase inhibitor LFP|"Letrozole administration (20 mg daily x 2) at follicle size of > 16 mm (LFP; late follicular phase) in cycle 2.~Nal-Glu GnRH antagonist used to estimate the overall amount of GnRH secreted."
3037703|NCT00351468|Experimental|Eltrombopag|Open-label eltrombopag
3037704|NCT00351533|Experimental|1|Enteral fish oil
3037705|NCT00351533|Placebo Comparator|2|Enteral saline
3037706|NCT00351611|Experimental|Active|Active drug
3037707|NCT00351611|Placebo Comparator|Placebo|placebo comparator
3037708|NCT00351741|Experimental|High Frequency|Provide standard ventilatory support for burn patients utilizing high frequency percussive ventilation
3037709|NCT00351741|Active Comparator|Conventional|Standard ventilator support for non burned patients utilizing lung protective low tidal volume ventilation
3037710|NCT00351819|Active Comparator|Androgel (testosterone gel)|Testosterone replacement therapy
3037711|NCT00351819|Placebo Comparator|Placebo|Placebo gel
3037712|NCT00351936|Active Comparator|Aripiprazole|aripiprazole 15mg/day
3037713|NCT00351936|Placebo Comparator|placebo|matched placebo for aripiprazole 15mg/day
3037714|NCT00352001|Experimental|Lenalidomide and Azacitidine|
3037715|NCT00352027|Experimental|All Participants|Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
3037716|NCT00352053|Experimental|OBR + Tenofovir DF|Tenofovir DF administered orally, one tablet daily without regard to meals
3037717|NCT00352053|Placebo Comparator|OBR + Tenofovir DF Placebo|Placebo to match tenofovir DF administered orally, one tablet daily without regard to meals
3037718|NCT00352105|Experimental|Concurrent Chemotherapy and ZD1839|
3037719|NCT00352365|Experimental|Treatment (lenalidomide)|"INDUCTION THERAPY: Patients receive oral lenalidomide once daily on days 1-14, 1-21, or 1-28 (course 1). Patients undergo bone marrow biopsy on day 28 or 35 to assess treatment efficacy. Patients with stable or improving disease (i.e., a decrease in blast percentage) without progressive disease proceed to maintenance therapy.~MAINTENANCE THERAPY: Beginning within 42 days after completion of induction therapy, patients receive oral lenalidomide once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3037720|NCT00352417|Experimental|VIA-2291|
3037721|NCT00352417|Placebo Comparator|Placebo|Matching Placebo
3037722|NCT00352534|Experimental|Nephrectomy and re-evaluation (very low-risk disease)|Patients undergo nephrectomy only. If they meet criteria, they are then observed periodically for 5 years. Patients with recurrent disease undergo surgery (immediate or delayed) and receive chemotherapy as in stratum III. Patients with no metachronous renal disease receive radiotherapy. Patients with metachronous disease undergo renal-sparing surgery and chemotherapy as in stratum III, but no radiotherapy. Treatment continues for up to 25 weeks.
3037723|NCT00352534|Experimental|Nephrectomy, chemotherapy (standard-risk, stg I or II)|Patients undergo nephrectomy. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1, every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 doses of doxorubicin. Treatment continues for up to 25 weeks.
3037724|NCT00352534|Experimental|Nephrectomy/biopsy, chemotherapy (standard-risk, stage III)|Patients undergo nephrectomy, if feasible, or biopsy. For patients who undergo biopsy only, definitive surgery is undertaken at week 7 or 13. Between 9 and 14 days post-nephrectomy, patients receive vincristine IV beginning on day 1 every week for 10 weeks then every 3 weeks for a total of 15 doses. Patients receive dactinomycin IV beginning day 1, alternating every 3 weeks with doxorubicin hydrochloride IV for a total of 5 doses of dactinomycin and 4 dose of doxorubicin hydrochloride. Patients undergo radiotherapy over 5-7 days after nephrectomy. Treatment continues for up to 25 weeks.
3037725|NCT00352612|Placebo Comparator|cephalexin|
3037726|NCT00352612|Active Comparator|clindamycin|
3037727|NCT00352664|Active Comparator|Donepezil|Oral Donepezil 5 mg daily x 7 days
3037728|NCT00352664|Placebo Comparator|daily x 7 days|Placebo tablet daily x 7 days
3037729|NCT00352690|Other|Cohort 1 (first 12 eligible patients)|"Paclitaxel poliglumex 135 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
3037730|NCT00352690|Experimental|Cohort 2 (remaining patients)|"Paclitaxel poliglumex 175 mg/m2 IV on day 1 of each 21 day cycle for a total of 2 cycles.~Carboplatin AUC=5 IV over 30 minutes on day 1 of each 21 day cycle for a total of 2 cycles.~Thoracic radiation therapy starting day 1 consisting of 66 Gy delivered in 2 Gy daily fractions.~Paclitaxel poliglumex 175 mg/m2 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles.~Carboplatin AUC=6 IV beginning 3-5 weeks after completion of radiation therapy on day 1 every 21 days for a total of 2 cycles."
3037731|NCT00352755|Experimental|Peritonectomy + IP5FU + FOLFOX|"Surgical debulking with peritonectomy~IP 5FU 600 mg/m^2 over 30-60 minutes with patient rotating every 15 minutes. Repeated every 2 weeks for a total of 9 cycles.~FOLFOX (oxaliplatin, 5FU, leucovorin) will follow IP therapy. Oxaliplatin 85 mg/m^2 over 2 hours with leucovorin at 400 mg/m^2 and IV 5-FU at 2400 mg/m^2 over 46 hours. Repeated every 2 weeks for a total of 8 cycles."
3037732|NCT00352781|Experimental|Nicotine Replacement + Behaviour Therapy|Nicotine Replacement Therapy as per monograph & behavioural intervention
3037733|NCT00352794|Experimental|Lenalidomide + Prednisone|Lenalidomide oral 10 mg daily/days 1-21 of 28 day cycle. Prednisone starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
3037734|NCT00352846|Experimental|Vitamin D + Calcium Carbonate|Oral Vitamin D 400 mg daily + Calcium 1200 mg daily
3037735|NCT00352846|Experimental|Vitamin D + Calcium Carbonate + Zoledronic Acid|Oral Vitamin D 400 mg daily and Calcium 1200 mg daily; Zoledronic Acid 4 mg/m^2 intravenous at baseline and 6 months.
3037736|NCT00352885|Experimental|Escitalopram|Participants will receive escitalopram and IL-2 treatment
3037737|NCT00352885|Placebo Comparator|Placebo|Participants will receive placebo and IL-2 treatment
3037738|NCT00352911|Active Comparator|VGX-410 (Mifepristone)|150mg twice daily of VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of VGX-410 for 14 days
3037739|NCT00352911|Placebo Comparator|Placebo for VGX-410 (Mifepristone)|150mg twice daily of placebo for VGX-410 for 14 days and, if well tolerated, a dose escalation to 300mg twice daily of placebo for VGX-410 for 14 days
3037740|NCT00352976|Experimental|Treatment with TBI|Patients treated with total body irradiation, Fludarabine, Cyclophosphamide, Bone Marrow Transplantation, Mycophenolate Mofetil, and Sirolimus.
3037741|NCT00353119|Placebo Comparator|Placebo then etanercept|Patients randomized to initiate the study with placebo for the first 12 weeks - Group 1 then crossed over to etanercept 50mg twice weekly for weeks 12 to 24
3037742|NCT00353119|Active Comparator|Etanercept|Patients randomized to etanercept - Group 2. Patients received etanercept 50 mg subcutaneously twice weekly for 24 weeks
3037743|NCT00353262|Experimental|1|
3037744|NCT00353301|Experimental|Erlotinib and Sirolimus|"Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day.~Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day."
3037745|NCT00353366||Cohort Group|Subjects received two oral doses of the Rotarix vaccine at the age of 6 weeks
3037746|NCT00353418|Experimental|PEG-IFN Alfa-2a 180 μg + Ribavirin 800 mg|
3037747|NCT00353418|Active Comparator|PEG-IFN Alfa-2a 180 μg + Ribavirin 1000 or 1200 mg|
3037748|NCT00353431|Active Comparator|1|"Conventional insulin group:~In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician."
3037749|NCT00353431|Experimental|2|"Intensive insulin therapy algorithm:~The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake."
3037750|NCT00353496|Experimental|lanreotide (Autogel formulation)|
3037751|NCT00353496|Placebo Comparator|Placebo|
3037752|NCT00353522|Experimental|Dalcetrapib|Dalcetrapib 900mg po daily for 24 weeks
3037753|NCT00353522|Placebo Comparator|Placebo|Placebo po daily for 24 weeks
3037754|NCT00353652|Active Comparator|Study#1: chlorthalidone (CTD) first then spironolactone (SP)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months of chlorthalidone first (12.5-25 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with spironolactone (25-75 mg/d)without washout period for 3 months. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
3037755|NCT00353652|Active Comparator|Study #1: spironolactone (SP) first, then chlorthalidone (CTD)|Participants in study #1 only received 2 interventions. All subjects are randomized to receive 3 months spironolactone first (25-75 mg/d), using a single-blind 2-phase crossover design. Then, the subject is transitioned to treatment with chlorthalidone(12.5-25 mg/d) without washout period. Following 3 month treatment period, the procedures listed below were performed. After completion of the study procedures, the medication is discontinued.
3037756|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+ SP 2nd, CTD+IR 3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dosespironolactone (SP) 25 mg daily for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
3037757|NCT00353652|Active Comparator|Study# 2 CTD alone 1st, CTD+IR 2nd, CTD+SP3rd|Subjects are randomized to receive 3 months of fixed-dose chlorthalidone (CTD, 25 mg/d) alone first, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, followed by fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
3037758|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD alone 2nd, CTD+IR 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months. After completion of the study procedures, the medication is discontinued.
3037759|NCT00353652|Active Comparator|Study# 2 CTD+SP1st, CTD+IR 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, then fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
3037760|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD alone 2nd, CTD+SP 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD 25 mg/d alone for 3 months, then fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months. After completion of the study procedures, the medication is discontinued.
3037761|NCT00353652|Active Comparator|Study# 2 CTD+IR 1st, CTD+SP 2nd, CTD alone 3rd|Subjects are randomized to receive fixed-dose CTD 25 mg/d plus fixed-dose irbsesartan (IR, 150 mg daily) for 3 months, using a single-blind 3-phase crossover design. Then, subjects are treated with fixed-dose CTD (25 mg/d) plus fixed-dose spironolactone (SP) 25 mg daily for 3 months, followed by fixed-dose CTD 25 mg/d alone for 3 months. After completion of the study procedures, the medication is discontinued.
3037762|NCT00353704|Active Comparator|Pregabalin|150 mg Pregabalin per orally about one hour before surgery
3037763|NCT00353704|Placebo Comparator|Placebo|One capsule of saccharose (placebo) was administered orally about one hour before surgery.
3037764|NCT00353834|Active Comparator|Glargine insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve fasting blood glucose of 100 mg/dl and avoid hypoglycemia.
3037765|NCT00353834|Experimental|Exenatide|Exenatide 5ug twice daily for 4 weeks followed by 10 ug twice daily for 8 weeks.
3037766|NCT00353873|Active Comparator|Fluticasone propionate (FLIXOTIDE™)|Fluticasone propionate (FLIXOTIDE™) at a dose of 200μg twice daily
3037767|NCT00353873|Experimental|Fluticasone propionate/salmeterol (SERETIDE™)|Salmeterol/fluticasone propionate combination (SERETIDE™) at a dose of 50/100μg twice daily
3037768|NCT00353938|Experimental|Full Dose MDMA-assisted therapy (125 mg)|Three 8-hour sessions of MDMA-assisted therapy with 125 mg of MDMA, followed by a supplemental dose of 62.5 mg MDMA
3037769|NCT00353938|Active Comparator|Active Placebo MDMA-assisted therapy (25 mg)|Three 8-hour sessions of MDMA-assisted therapy with 25 mg of MDMA, followed by a supplemental dose of 12.5 mg MDMA
3037770|NCT00353977|Experimental|ALVAC-CMV (vCP260) Vaccinated group|Patients who were vaccinated with ALVAC-CMV (vCP260)
3037771|NCT00354029|Placebo Comparator|Placebo|Saline 0,9%
3037772|NCT00354029|Active Comparator|S (+) Ketamine|
3320827|NCT02014077|Active Comparator|Thoracostomy Tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube for traumatic haemothorax
3321396|NCT02018510|Experimental|Group 5B|HIV-infected individuals on ART, VL < 20 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3037773|NCT00354107|Experimental|Treatment (monoclonal antibody therapy, chemotherapy)|"Patients receive monoclonal antibody SGN-30 IV alone on day 1 in weeks 1-8. Beginning in week 5, patients receive ICE chemotherapy comprising ifosfamide IV over 2 hours on days 1-3, carboplatin IV over 1 hour on day 1, and etoposide IV over 1 hour on days 1-3. Treatment with ICE repeats every 3 weeks for 6 courses** in the absence of unacceptable toxicity. Patients also receive intrathecal therapy comprising methotrexate, cytarabine, and hydrocortisone once on day 29 (week 5).~Cohorts of 3-6 patients receive a pre-determined dose of monoclonal antibody SGN-30 with possible dose de-escalation to 1 dose level below in the event of ≥ 2 of 6 patients experience dose-limiting toxicity (DLT). The dose at which ≤ 1 of 6 patients experience DLT will be used in a phase II study."
3037774|NCT00354159|Experimental|Treatment Arm|Physicians have access to device-based hemodynamic monitor information to guide patient management
3037775|NCT00354159|Placebo Comparator|Control Arm|Physicians do not have access to device-based hemodynamic monitor information to guide patient management
3037776|NCT00354172|Experimental|Treated Patients|All patients receiving treatment with chemotherapy and radiation, along with natural killer cells, aldesleukin and umbilical cord blood transplant.
3037777|NCT00354224|Experimental|Oxaliplatin + Capecitabine|Patients will receive Oxaliplatin 85 mg/m2/d on day 1, given as a 2-hour infusion in 250 mL of dextrose 5% repeated every 2 weeks. Capecitabine will be administered orally at a dose of 850 mg/m2 twice a day.
3037778|NCT00354341|Experimental|Group 1 (Early Epoetin Beta)|Along with their standard treatment participants will receive epoetin beta at a starting dose of 2000 International Units (IU) subcutaneously (SC) once weekly to reach and maintain target hemoglobin (Hb) between 13 and 15 grams per deciliter (g/dL), for 15 months. Epoetin beta doses will be adjusted according to individual participant's Hb level. Standard treatment will be as per investigator discretion.
3037779|NCT00354341|Active Comparator|Group 2 (No/Late Epoetin Beta)|Participants will receive their standard treatment for 15 months but no treatment for anemia correction unless Hb level will be less than (<) 10.5 g/dL on 2 consecutive visits of 2 weeks interval or the Hb level will be <10 g/dL on a single determination. In such cases participants could receive epoetin beta at a starting dose of 2000 IU SC once weekly to reach and maintain a target Hb level of 10.5 to 11.5 g/dL. Standard treatment will be as per investigator discretion.
3037780|NCT00354432|Active Comparator|Arm I - Placebo|Patients receive oral placebo pill and oral placebo powder once daily.
3037781|NCT00354432|Active Comparator|Arm II - Soy|Patients receive oral placebo pill and oral soy protein/isoflavones powder once daily.
3037782|NCT00354432|Experimental|Arm III - Venlafaxine|Patients receive oral Venlafaxine pill and placebo powder once daily.
3037783|NCT00354432|Placebo Comparator|Arm IV - Soy + Venlafaxine|Patients receive oral Venlafaxine pill and soy protein/isoflavones powder once daily.
3037784|NCT00354484|Experimental|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
3037785|NCT00354484|Active Comparator|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
3037786|NCT00354601|Experimental|Weekly Docetaxel and Capecitabine|Weekly Docetaxel and Capecitabine
3037787|NCT00354640|Experimental|Anastrozole and Simvastatin|This is a pharmacological study for women on anastrozole as adjuvant therapy for breast cancer to receive concurrent simvastatin for up to 14 days.
3037788|NCT00354679|Experimental|Irinotecan, Cisplatin, Bevacizumab, Radiotherapy, & Surger|"Induction therapy: Patients receive cisplatin IV over 30 minutes and irinotecan hydrochloride IV over 30 minutes on days 1, 8, 22, and 29. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 22.~Combination therapy and radiotherapy: Patients receive cisplatin and irinotecan hydrochloride as in induction chemotherapy on days 43, 50, 64, and 71. Patients also receive bevacizumab IV over 30-90 minutes on days 43 and 64. Patients undergo external beam radiotherapy 5 days a week for 6 weeks beginning on day 43. Surgery: Patients undergo surgery 6-8 weeks after finishing combination therapy and radiotherapy.~Maintenance therapy: Approximately 6 weeks after surgery, patients receive bevacizumab IV over 30-90 minutes every 3 weeks for 6 months"
3037789|NCT00354744|Experimental|High Risk Rhabdomyosarcoma|Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients.
3037790|NCT00354770|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine
3037791|NCT00354770|Placebo Comparator|2|Placebo
3468745|NCT03892759|Other|Evaluation and Treatment|Subjects will be evaluated through inspection and palpation of the thoracic and lumbar spine, and other body regions as necessary. The provider will make a diagnosis of somatic dysfunction based off the TART (tissue texture change, asymmetry, restriction of motion, tenderness/pain) findings.
3468746|NCT03892876|Experimental|Schizophrenia TS+ve|Schizophrenia patients who receive auditory high frequency Tetanizing Stimulation
3037794|NCT00354887|Experimental|Oxaliplatin + Capecitabine|Intravenous Oxaliplatin 130 mg/m^2, Day 1 + Oral Capecitabine 750 mg/m^2 twice daily Days 1-14.
3037795|NCT00354913|Experimental|Imatinib mesylate+hydroxyurea|All patients receive imatinib mesylate and hydroxyurea orally on a daily, continuous basis. Dosing of imatinib mesylate is adjusted for patients who are also receiving p450-inducing anti-epileptic drugs.
3037796|NCT00354978|Experimental|FOLFIRI plus Bevacizumab|FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day cycle.
3468747|NCT03892876|Sham Comparator|Schizophrenia TS-ve|Schizophrenia patients who receive sham comparator
3468748|NCT03892876|Experimental|Control TS+ve|Healthy controls who receive auditory high frequency Tetanizing Stimulation
3468749|NCT03892876|Sham Comparator|Control TS-ve|Healthy controls who receive sham comparator
3468750|NCT03892772|Experimental|SAS0421a, SAS0421b and SAS0421c|Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.
3037797|NCT00355030|Experimental|1|
3037798|NCT00355030|Experimental|2|
3037799|NCT00355056|Sham Comparator|Medical Management|Will not receive the closure device, and will be treated with the current standard of care medical treatment. Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and simulate PFO closure procedure (sham procedure).
3037800|NCT00355056|Experimental|PFO Closure|Will undergo Intracardiac Echo (ICE) in cardiac catheterization lab and undergo PFO device closure procedure with the AMPLATZER PFO Occluder.
3037801|NCT00355082|Experimental|lamotrigine 300|300 mg/day treatment
3037802|NCT00355082|Experimental|lamotrigine 250|250 mg/day treatment
3037803|NCT00355121|Experimental|Group 1|DAPTACEL® + IPOL on Day 0 and Menactra on Day 30
3037804|NCT00355121|Experimental|Group 2|DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30
3037805|NCT00355121|Experimental|Group 3|Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30
3037806|NCT00355134|Experimental|Fingolimod 1.25 mg|"Participants received 1.25 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 1.25 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day."
3037807|NCT00355134|Experimental|Fingolimod 0.5 mg|Participants received 0.5 mg fingolimod orally once a day for up to 24 months during the core phase. In the Extension phase participants continued to receive 0.5 mg fingolimod orally once a day.
3037808|NCT00355134|Experimental|Placebo|"Participants received placebo capsules orally once a day for up to 24 months during the core phase. In the Extension phase participants received either 1.25 or 0.5 mg fingolimod orally once a day.~Note: Upon implementation of a protocol amendment all patients taking 1.25 mg fingolimod were switched to 0.5 mg fingolimod orally once a day. Upon implementation of a protocol amendment, all patients taking placebo were switched to 0.5 mg fingolimod orally once a day."
3037809|NCT00355147|Experimental|Arm 1 Secondary Risk Factor Management|Patient Secondary Stroke Risk Factor Program including Stroke Self Management and Stroke Peer Support and Physician Stroke Guideline Adherence
3037810|NCT00355147|Placebo Comparator|Attention Control Group|Received Phone Calls from Staff to Control for Attention
3037811|NCT00355199|Experimental|R-HDS|R-HDS : Rituximab supplemented high-dose (Cyclophosphamide,Ara-C, Methotrexate, Etoposide, Cis-Platin) sequential chemotherapy with autografting.
3037812|NCT00355199|Active Comparator|R-CHOP|Rituximab-CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone).
3037813|NCT00355264|Experimental|Single Arm on Active Drug|"5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels~Outcomes were also evaluated by the subject's type of BH4 deficiency either defects in the genes encoding the enzymes involved in biosynthesis or defects in the genes encoding the enzymes involved in recycling."
3037814|NCT00355342|Experimental|Salmeterol 50 mcg BID|Participants randomized to this arm received salmeterol 50 microgram (mcg), formulated with lactose via the DISKUS™ inhaler one inhalation twice daily (BID) one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication. DISCUS is registered trademark product of GlaxoSmithKline.
3037815|NCT00355342|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Participants randomized to this arm received Fluticasone propionate/salmeterol combination product 250/50 mcg, formulated with lactose via the DISKUS inhaler one inhalation BID, one inhalation in the morning and one inhalation in the evening for 156 Weeks. Each DISKUS contained 60 doses of study medication. Participant were provided with albuterol/salbutamol as relief medication.
3037816|NCT00355368|Active Comparator|Succinylcholine|
3037817|NCT00355368|Active Comparator|Rocuronium|
3037818|NCT00355394|Placebo Comparator|Placebo|Standard care including intravenous fluid, but no metoclopramide.
3037819|NCT00355394|Active Comparator|Metoclopramide|Standard care including intravenous fluid PLUS metoclopramide.
3037820|NCT00355472|Experimental|1|KW-0761
3037821|NCT00355615|Active Comparator|rosuva 5|rosuvastatin 5 mg
3037822|NCT00355615|Active Comparator|rosuva 10|rosuvastatin 10 mg
3037823|NCT00355615|Active Comparator|rosuva 20|rosuvastatin 20 mg
3037824|NCT00355615|Placebo Comparator|Placebo|Placebo
3037825|NCT00355615|Other|rosuva ol|rosuvastatin open label
3037826|NCT00355706|Active Comparator|Group I - without Steroids|Thoracic Facet Joint Nerve Blocks with Local Anesthetic(0.25% Bupivacaine)
3037827|NCT00355706|Active Comparator|Group II - with steroid|Thoracic Facet Joint Nerve Blocks with Local Anesthetic (0.25% Bupivacaine) and Sterioids(0.15 mg of non-particulate betamethasone)
3037828|NCT00355784|Other|Control|9 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and their plasma growth hormone concentration was allowed to decline naturally.
3037829|NCT00355784|Experimental|Growth Hormone Treatment|8 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received exogenous growth hormone treatment administered in 4 daily injections to mimic physiological growth hormone secretion throughout the 2-week overeating period.
3037830|NCT00355784|Experimental|High Growth Hormone Treatment|5 non-obese (initial body mass index 23.5 +/- 0.3 kg/m2), weight stable, relatively sedentary (physical activity </- 2h/week), healthy adults not taking any medications were admitted to the hospital for 2 weeks during which time they ate ~4000 kcal/day and received a relatively high daily dose of growth hormone.
3037831|NCT00355797|Active Comparator|Closed Loop Stimulation (CLS)|Pacemaker programmed with Closed Loop Stimulation rate adaptive technology for long-term follow-up data collection.
3037832|NCT00355797|Active Comparator|Standard Rate Adaptive Technology (R)|Pacemaker programmed with standard rate adaptive technology (R, accelerometer) for long-term follow-up data collection.
3037833|NCT00355797|Active Comparator|Non-rate adaptive pacing (DDD)|Pacemaker programmed with no rate adaption (DDD mode) for long-term follow-up data collection.
3037834|NCT00355914|Active Comparator|Group 1 Without Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin)
3037835|NCT00355914|Experimental|Group 2 With Steroids|Lumbar Facet Joint Nerve Block with Local Anesthetic (0.5 mL of 0.25% Bupivacaine with/without 0.5 mL of Sarapin) and 0.15 mg of non-particulate betamethasone)
3037836|NCT00356031|Experimental|Bevacizumab, Radiation, and Surgery|Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)
3037837|NCT00356057|Active Comparator|1|Biventricular pacing group with Closed Loop Stimulation rate adaptation (Protos CLS device)
3037838|NCT00356057|Active Comparator|2|Biventricular pacing group with accelerometer based rate adaption (Stratos LV device)
3037839|NCT00356057|Active Comparator|3|Right Ventricular pacing group with accelerometer based rate adaption (Stratos LV device)
3037840|NCT00356122|Experimental|Docetaxel/Oxaliplatin/Bevacizumab|Participants with advanced, recurrent, or metastatic Non Small Cell Lung Cancer (NSCLC), treated with the combination of docetaxel, followed by oxaliplatin, and then bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.
3037841|NCT00356135|Experimental|Prasugrel 10/10 mg|Open label (lead-in) dose of clopidogrel 75 milligram (mg) for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 10 mg and placebo, followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
3037842|NCT00356135|Experimental|Clopidogrel 75/75 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of clopidogrel 75 mg and placebo, followed by maintenance dose of clopidogrel 75 mg taken for 13 to 15 days.
3037843|NCT00356135|Experimental|Prasugrel 60/10 mg|Open label (lead-in) dose of clopidogrel 75 mg for 10 to 14 days. Upon completion, assignment to a single loading dose of prasugrel 60 mg and placebo followed by maintenance dose of prasugrel 10 mg taken for 13 to 15 days.
3037844|NCT00356148|Active Comparator|Prophylaxis Group|patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis
3037845|NCT00356148|No Intervention|No Prophylaxis Group|Patients who are BMI over 25 and do not receive antibiotic prophylaxis
3037846|NCT00356200|Experimental|Fluphenazine treated|Treated with fluphenazine
3037847|NCT00356200|Placebo Comparator|Placebo|Treated with Placebo
3037848|NCT00356265|Experimental|CKD|
3037849|NCT00356265|Active Comparator|Hypertension group|
3037850|NCT00356265|Active Comparator|Normotensive group|
3037851|NCT00356278|Experimental|A|Participants will receive VRE therapy and D-cycloserine
3037852|NCT00356278|Active Comparator|B|Participants will receive VRE therapy and alprazolam
3037853|NCT00356278|Placebo Comparator|C|Participants will receive VRE therapy and placebo
3037854|NCT00356304|Experimental|1|Participants will receive motivational interviewing in addition to their antidepressant therapy
3037855|NCT00356304|Active Comparator|2|Participants will receive treatment as usual
3037856|NCT00356369|Experimental|Nimenrix Group|Subjects receiving GSK Biologicals' meningococcal vaccine 134612
3037857|NCT00356369|Active Comparator|Mencevax Group|Subjects receiving Mencevax™ ACWY
3037858|NCT00356408|Experimental|CDP870 400 mg|Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2
3037859|NCT00356434|Active Comparator|1|Patients will have the Kendall, A-V foot impulse pump, model 6060 applied to their lower extremities to prevent DVT
3037860|NCT00356434|Active Comparator|2|Patients will have the Kendall,sequential compression device, model 9525 applied to the lower extremities to prevent DVT
3037861|NCT00356525|Experimental|Less Than One Year: Pemetrexed|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
3037862|NCT00356525|Experimental|Less Than One Year: Pemetrexed + Gemcitabine|Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
3037863|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Carboplatin|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
3037864|NCT00356525|Experimental|One Year or Greater: Pemetrexed + Gemcitabine|Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
3037865|NCT00356590|Other|1|
3037866|NCT00356603|Experimental|Sumatriptan|Sumatriptan
3037867|NCT00356759|Sham Comparator|12-weekly INR|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times
3037868|NCT00356759|No Intervention|Standard management|Dosing warfarin every 4 weeks, all INRs true values
3037869|NCT00356811|Experimental|Single arm|Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
3037870|NCT00356863|Experimental|Explanation on cardiac rehabilitation|Intervention: Increasing awareness to cardiac rehabilitation programs: Patients received a written and oral short explanation on the importance and benefits of cardiac rehabilitation (CR) participation, and information on available programs. They were telephoned 2 weeks after hospital discharge to encourage them to enroll at a cardiac rehabilitation program (CRP). In addition, physicians and nurses at the cardiothoracic units participated in a 1-hour seminar on CR. A recommendation to the general physician to refer the patient to CRP was added to the letter of discharge from hospital.
3037871|NCT00356863|No Intervention|Usual care with no intervention|Patients recruited to the study received the usual care without any additional explanation on cardiac rehabilitation, and no effort to increase their awareness or the ward's awareness to cardiac rehabilitation was done.
3132839|NCT03457103|Experimental|CATCH Group|A portable capnometer (CapnoTrainer, Better Physiology, Cheyenne, WY) will be used in-session to provide continuous visual feedback of RR, ETCO2, rhythm, and depth of breathing, and ratio of inspirations to expiration. CATCH will be once weekly for 6 weeks, for a total of 6 sessions; each session will be approximately 60 minutes duration. The principal investigator will implement the CATCH intervention
3132840|NCT03457103|Active Comparator|Control Group|Pulmonary Rehabilitation (PR). Patients in both treatment groups will participate in a 10-week (16 - 20 sessions) comprehensive PR program.
3132841|NCT03457116|Active Comparator|NSAIDS|400mg of Ibuprofen
3037872|NCT00356889|Experimental|Bevacizumab and Erlotinib Hydrochloride|"Patients receive 5 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15 and 150 mg oral erlotinib hydrochloride daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Tumor tissue and blood specimens are collected periodically for correlative studies. Specimens are examined by immunohistochemistry for epidermal growth factor receptor (EGFR) and P-EGFR protein levels; AKT p-AKT, mitogen-activated protein kinase (MAPK) and P-MAPK protein levels; and vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 protein levels. EGFR mutations are detected by laser capture microdissection. Enzyme-linked immunosorbent assay is used to measure total and free serum VEGF levels."
3037873|NCT00356915|Experimental|Itraconazole tablets|Itraconazole 200 mg tablets
3037874|NCT00356915|Active Comparator|Itraconazole capsules|Two Itraconazole 100 mg capsules were taken daily.
3037875|NCT00356915|Placebo Comparator|Placebo tablets|The itraconazole 200-mg tablets and placebo tablets exactly matched one another and were white to slightly grey in color, were oblong and biconvex in shape, and were melt-extrusion, film-coated.
3037876|NCT00356993|Experimental|NRT + Behavioural Support|Nicotine Replacement Therapy plus Behavioural Intervention
3037877|NCT00357006|Active Comparator|1|100 mcg Estradiol
3037878|NCT00357006|Active Comparator|2|200 mcg Estradiol
3037879|NCT00357006|Placebo Comparator|3|adjunctive transdermal placebo
3037880|NCT00357032|Experimental|Treatment (belinostat)|Patients receive PXD101 IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 6-12 months in the absence of disease progression or unacceptable toxicity.
3037881|NCT00357110|Active Comparator|1|Anastrozole monotherapy
3037882|NCT00357110|Experimental|2|Anastrozole + Fulvestrant
3037883|NCT00357162|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3037884|NCT00357214|Active Comparator|potassium bicarbonate|Participants will receive potassium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
3037885|NCT00357214|Active Comparator|Sodium bicarbonate|Participants will receive sodium bicarbonate in dosage of 67.5 mmol/d. This compound has no other name.
3037886|NCT00357214|Active Comparator|Potassium chloride|Participants will receive potassium chloride in dosage of 67.5 mmol/d. This compound has no other name.
3037887|NCT00357214|Placebo Comparator|microcrystalline cellulose|Participants will receive placebo is microcrystalline cellulose. This compound has no other name.
3037888|NCT00357331|Experimental|Potassium Citrate|Potassium Citrate 20 meq twice daily
3037889|NCT00357331|Placebo Comparator|Placebo|Placebo
3037890|NCT00357370|Experimental|Cohort 1|20 mg
3037891|NCT00357370|Experimental|Cohort 2 - Arm 1|10 mg
3037892|NCT00357370|Experimental|Cohort 2 - Arm 2|20 mg
3037893|NCT00357370|Placebo Comparator|Cohort 2 - Arm 3|
3037894|NCT00357396|Experimental|Chemo followed by DSCT|"Myeloablative preparative regimen: Patients receive busulfan IV over 2 hours every 6 hours on days -8 to -6, melphalan IV over 20 minutes on days -5 to -3, and thiotepa IV over 4 hours on day -2.~Allogeneic hematopoietic stem cell transplant: Patients undergo allogeneic bone marrow or T-cell depleted peripheral blood stem cell transplantation on day 0.~Graft-vs-host disease (GVHD) prophylaxis: Patients receive treatment according to institutional guidelines and are given treatment against infection.~After completion of study treatment, patients are followed periodically for at least 3 years."
3037895|NCT00357500|Experimental|5-drug metronomic antiangiogenic regimen|Thalidomide: Start at 3 mg/kg (rounded to nearest 50 mg), increasing dose weekly by 50 mg as tolerated to 24 mg/kg (max 1,000 mg); Celecoxib: < 20 kg at 100 mg; 20-50 kg at 200 mg; > 50 kg at 400 mg; Fenofibrate: 90 mg/m2 (max 200 mg); Etoposide: 50 mg/m2; Cyclophosphamide: 2.5 mg/kg (max 100 mg); Patients receive oral etoposide once daily on days 1-21 and 43-63 (weeks 1-3 and 7-9) and oral cyclophosphamide once daily on days 22-42 (weeks 4-6). Patients also receive oral thalidomide once daily, oral celecoxib twice daily, and oral fenofibrate once daily in weeks 1-9. Treatment repeats approximately every 9 weeks for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients receive alternating etoposide and cyclophosphamide pulses (i.e., etoposide-cyclophosphamide-etoposide during courses 1 and 3 and cyclophosphamide-etoposide-cyclophosphamide during course 2).
3037896|NCT00357552|Experimental|LPV/r monotherapy|Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) once a day will be added to their regimen.
3037897|NCT00357656|Experimental|BI|Bolus infusion of rAHF-PFM
3037898|NCT00357656|Experimental|CI|Continuous infusion of rAHF-PFM
3037899|NCT00357734|Experimental|Gefitinib (ZD1839)|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
3037900|NCT00357760|Experimental|Arm A (higher dose of VEGF Trap)|Patients receive a higher dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3037901|NCT00357760|Experimental|Arm B (lower dose of VEGF Trap)|Patients receive a lower dose of ziv-aflibercept (VEGF Trap) IV over 1 hour on day 1. In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, the dose of ziv-aflibercept (VEGF Trap) may be escalated to the higher dose in Arm A.
3037902|NCT00357877|Placebo Comparator|Placebo Dental Coating|Dental coating with all ingredients except Chlorhexidine topically applied by dental professional supragingivally to the full dentition
3037903|NCT00357877|Active Comparator|Active Dental Coating|10% w/v chlorhexidine acetate coating FDA IND #45466. Dental coating with all ingredients including Chlorhexidine topically applied by dental professional supragingivally to the full dentition
3037904|NCT00357903|Other|1|
3037905|NCT00357955|Experimental|MEDIC|Multidisciplinary education and diabetes intervention for cardiac risk reduction
3037906|NCT00357955|No Intervention|usual care|usual care
3037907|NCT00357968|Experimental|Prasugrel to Clopidogrel|One time oral loading dose (LD) of 60-mg Prasugrel and placebo matched to clopidogrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 10-mg Prasugrel and placebo matched to clopidogrel taken orally once a day for 14 days. Patients cross-over to 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for the next 14 days.
3037908|NCT00357968|Active Comparator|Clopidogrel to Prasugrel|One time oral LD of 600 mg clopidogrel and placebo matched to prasugrel (plus oral enteric coated aspirin 325 mg to 500 mg is recommended) followed by 150 mg clopidogrel and placebo matched to prasugrel taken orally once a day for 14 days. Patients cross-over to 10 mg prasugrel and placebo tablets matched to clopidogrel taken orally once a day for the next 14 days.
3037909|NCT00357994|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
3037910|NCT00357994|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
3037911|NCT00358007|Experimental|Cone Beam CT|
3037912|NCT00358150|Experimental|Eliglustat tartrate|
3037913|NCT00358215|Experimental|Darbepoetin alfa|Starting dose of 0.75 µg/kg subcutaneously every 2 weeks until hemoglobin concentrations reach 13.0 g/dL on 2 consecutive visits, then monthly dosing, titrated to achieve hemoglobin target of 13.0 g/dL, not to exceed 14.5 g/dL.
3037914|NCT00358215|Placebo Comparator|Placebo|Participants received dose and administration schedule (every 2 weeks or once a month) changes that simulated the changes for participants receiving darbepoetin alfa.
3037915|NCT00358332|Experimental|Group 1: FMP2.1/AS02A 10 mcg dose or rabies vaccine.|20 children will be randomized to receive either the 10 mcg dose of FMP2.1/AS02A (n=15) or rabies vaccine (n=5) on study days 0, 30 +/- 7, and 60 +/- 7.
3037916|NCT00358332|Experimental|Group 2: FMP2.1/AS02A 25 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 25 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
3037917|NCT00358332|Experimental|Group 3: FMP2.1/AS02A 50 mcg dose or rabies vaccine.|40 children will be randomized to receive either the 50 mcg dose of FMP2.1/AS02A (n=30) or rabies vaccine (n=10) on study days 0, 30 +/- 7, and 60 +/- 7.
3037918|NCT00358436|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
3037919|NCT00358436|Placebo Comparator|Placebo|Placebo by inhalation
3037920|NCT00358449|Experimental|Mepolizumab 0.55 mg/kg|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg) by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
3037921|NCT00358449|Experimental|Mepolizumab 2.5 mg/kg|Participants received mepolizumab 2.5 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
3037922|NCT00358449|Experimental|Mepolizumab 10 mg/kg|Participants received mepolizumab 10 mg/kg by IV infusion for 30 minutes on Day 1, Week 4 and Week 8.
3037923|NCT00358462|Active Comparator|Active azithromycin+placebo doxycycline|Active azithromycin (1g) and placebo doxycycline
3037924|NCT00358462|Active Comparator|Active doxycycline+placebo azithromycin|Active doxycycline and placebo azithromycin
3037925|NCT00358501|Experimental|Defibrotide|Defibrotide treatment
3037926|NCT00358501|No Intervention|Historical Control|Historical control group
3037927|NCT00358527|Experimental|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray 200 mcg, once daily.
3037928|NCT00358527|Placebo Comparator|Matching placebo nasal spray|
3037929|NCT00358579|Active Comparator|Adrenaline|
3037930|NCT00358579|Active Comparator|Vasopressin|
3037931|NCT00358644|Experimental|1|
3037932|NCT00358657|Experimental|Treatment (chemo, total-body irradiation, transplant)|See Detailed Description
3037933|NCT00358670|Active Comparator|Maintenance Infliximab|Infliximab 5 mg/kg by body weight every 8 weeks
3037934|NCT00358670|Experimental|Intermittent Infliximab|Infliximab 5 mg/kg by body weight at Weeks 0, 2, 6 and 14 following a 50% reduction in Psoriasis Area and Severity Index (PASI) from the Study P04271 Baseline
3037935|NCT00358735|Experimental|ActiveCare CECT|The ActiveCare CECT device is a mobile compression device used to prevent venous thromboembolic events, used after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery.
3037936|NCT00358735|Active Comparator|LMWH (Enoxaparin)|Enoxaparin (LMWH) will be used, following a protocol that is considered a standard of care for this patient population. 40mg QD for the remainder of the 10 days.
3037937|NCT00358826|Experimental|VIA-2291 25 mg|VIA-2291 25 mg
3037938|NCT00358826|Experimental|VIA-2291 50 mg|VIA-2291 50 mg
3037939|NCT00358826|Experimental|VIA-2291 100 mg|VIA-2291 100 mg
3037940|NCT00358826|Placebo Comparator|Placebo|Placebo
3037941|NCT00358917|Experimental|LPV/r 800/200 mg QD Tablet|
3037942|NCT00358917|Active Comparator|LPV/r 400/100 mg BID Tablet|
3037943|NCT00358956|Experimental|1|
3037944|NCT00359021|Experimental|001|TMC125 200 mg twice daily until commercially available
3037945|NCT00359073|Active Comparator|Montelukast|montelukast (10 mg everyday)
3037946|NCT00359073|Placebo Comparator|Placebo|Placebo comparator
3037947|NCT00359138|Experimental|Desloratadine 5 mg tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3037948|NCT00359138|Active Comparator|Desloratadine placebo tablet + Levocetirizine 5 mg capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3037949|NCT00359138|Placebo Comparator|Desloratadine placebo tablet + Levocetirizine placebo capsule|Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).
3037950|NCT00359203|Placebo Comparator|Dual chamber pacemaker|Dual chamber pacemaker programmed ODO (switched OFF)
3037951|NCT00359203|Active Comparator|Dual chamber pacemeker|Medtronic dual chamber pacemaker programmed ON and with Rate Drope Response programmed ON
3037952|NCT00359216|Experimental|Mometasone furoate nasal spray|
3037953|NCT00359216|Placebo Comparator|Placebo nasal spray|
3037954|NCT00359294|Experimental|Zalypsis (PM00104)|
3037955|NCT00359424|Active Comparator|intravenous (IV) rt-PA alone|Group one will receive the standard dose of intravenous (IV) rt-PA alone given over an hour.
3132842|NCT03457116|Active Comparator|Opiates|Norco (hydrocodone 5mg- acetaminophen 325mg)
3037956|NCT00359424|Experimental|Endovascular therapy|Group two will receive a lower dose or a standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose (based on the location and extent of the blood clot) a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery.
3037957|NCT00359619|Active Comparator|Cervarix Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037958|NCT00359619|Experimental|Cervarix 1 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 1 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037959|NCT00359619|Experimental|Cervarix 2 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 2 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037960|NCT00359619|Experimental|Cervarix 3 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 3 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037961|NCT00359619|Experimental|Cervarix 4 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 4 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037962|NCT00359619|Experimental|Cervarix 5 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 5 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037963|NCT00359619|Experimental|Cervarix 6 Group|Female subjects, aged 18 to 25 years at the time of first vaccination, received 3 doses of Cervarix vaccine formulation 6 at Months 0, 1 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3037964|NCT00359632|Experimental|Linezolid|Subjects have received at least 6 weeks of linezolid therapy (600 mg BID). Continued duration of linezolid treatment is based on treating physician's benefit/risk assessment. A matching control who did not receive linezolid will be selected for each linezolid treated subject.
3037965|NCT00359632|Active Comparator|Matched control|Control subjects individually matched to linezolid subjects (on age, gender and type of infection) who received at least 6 weeks of antibiotics other than linezolid. Control group assessed only at baseline visit to assess presence of background abnormalities in the study test panel.
3037966|NCT00359736|Experimental|Sildenafil|Sildenafil 20 mg tid orally
3037967|NCT00359736|Placebo Comparator|Placebo|Identical Placebo 20 mg tid orally
3037968|NCT00359762|Experimental|Exenatide|
3037969|NCT00359762|Active Comparator|Glimepiride|
3037970|NCT00359801|Experimental|Exubera|
3037971|NCT00359801|Active Comparator|Usual Diabetes Care|
3037972|NCT00359944|Experimental|AC-3933|AC-3933, 5mg twice daily
3037973|NCT00359944|Experimental|AC-3933, 20 mg twice daily|AC-3933, 20 mg twice daily
3037974|NCT00359944|Placebo Comparator|Placebo|Sugar Pill twice daily
3037975|NCT00359983|Experimental|MenHibrix 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of MenHibrix co-administered with Pediarix and Prevnar and a 4th dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3037976|NCT00359983|Active Comparator|ActHIB 4-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a 4th dose of ActHIB co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3037977|NCT00359983|Experimental|ActHIB 3-dose + MenHibrix 4th-dose group|Subjects received in the primary study (NCT00129129) 3 doses of ActHIB co-administered with Pediarix and Prevnar and a dose of MenHibrix co-administered with Prevnar. No vaccines were administered during this long-term persistence study.
3037978|NCT00360009|Active Comparator|STN DBS|Patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's disease (PD)
3037979|NCT00360009|Active Comparator|GPI DBS|Patients who underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi) to treat Parkinson's disease (PD)
3037980|NCT00360009|No Intervention|no DBS|non-DBS PD patient control group
3037981|NCT00360230|Experimental|SB257049 F2 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037982|NCT00360230|Experimental|SB257049 F1 0-1 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037983|NCT00360230|Experimental|SB257049 F2 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037984|NCT00360230|Experimental|SB257049 F1 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037985|NCT00360230|Experimental|SB257049 F2 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037986|NCT00360230|Active Comparator|SB257049 F1 0-1-7 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037987|NCT00360230|Active Comparator|Rabipur 0-1-2 M Group|Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
3037988|NCT00360243|Experimental|flibanserin 25 mg b.i.d|25 mg twice daily for 24 weeks
3037989|NCT00360243|Experimental|flibanserin 50mg qhs|50 mg taken once daily at bedtime for 24 weeks
3037990|NCT00360243|Experimental|flibanserin 50mg b.i.d.|50 mg twice daily for 24 weeks
3037991|NCT00360243|Placebo Comparator|placebo|twice daily for 24 weeks
3037992|NCT00360269|Experimental|Active|Atomoxetine plus Motivational Enhancement Therapy
3037993|NCT00360269|Placebo Comparator|Placebo|Placebo plus Motivational Enhancement Therapy
3037994|NCT00360282|Other|With Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
3037995|NCT00360282|Other|With Vertigo; Rizatriptan - Placebo|These subjects received Rizatriptan on visit 1 and placebo on visit 2.
3037996|NCT00360282|Other|Without Vertigo; Placebo - Rizatriptan|This group received placebo on visit 1 and Rizatriptan on visit 2.
3037997|NCT00360282|Other|Without Vertigo; Rizatriptan-Placebo|This group received Rizatriptan on visit 1 and placebo on visit 2.
3037998|NCT00360308|Placebo Comparator|Placebo|matching E2007 and matching entacapone
3037999|NCT00360308|Active Comparator|E2007|2 mg once daily in the evening, Weeks 0→2 (2 weeks) and 4 mg once daily in the evening, Weeks 2→18.
3038000|NCT00360308|Active Comparator|Entacapone|200 mg with each dose of Levodopa.
3038001|NCT00360334|Experimental|1|
3038002|NCT00360334|Active Comparator|2|
3038003|NCT00360360|Experimental|Bevacizumab/Paclitaxel/Carboplatin/Erlotinib|Bevacizumab 15mg/kg IV infusion,Day 1 Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1 Carboplatin AUC 6.0 IV Day 1 Erlotinib 150 mg by mouth daily
3038004|NCT00360399|Active Comparator|Escitalopram|Participants will receive treatment with escitalopram for 12 weeks
3038005|NCT00360399|Active Comparator|Duloxetine|Participants will receive treatment with duloxetine for 12 weeks
3038006|NCT00360399|Active Comparator|CBT|Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks
3038007|NCT00360412|Experimental|E2007|During the first two weeks of the study, Patients received 1 x 2mg E2007 tablet. At the week 2 visit, patients who tolerated the 2 mg/day dose were up-titrated to receive 4mg/day (2 x 2 mg E2007 tablets). Patients not tolerating the 4 mg dose were allowed to down titrate to 2 mg. Patients who did not tolerate the 2 mg dose were withdrawn from the study. Patients returned at week 4, if their tolerance to the 4 mg/day dose was acceptable they remained on this dose for the maintenance phase of the study. If at any time their tolerance declined, they were to return for an unscheduled visit and the daily dose was reduced to 2 mg. If at any stage, 2 mg day wass not tolerated, the patient was withdrawn from the study.
3038008|NCT00360490|Experimental|Levonorgestrel Intrauterine System (LNG IUS) 20µg per 24 hours|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
3038009|NCT00360490|Active Comparator|Medroxyprogesterone acetate (MPA)|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
3038010|NCT00360529|Experimental|fibanserin|flibanserin 50 mg q.h.s.
3038011|NCT00360529|Experimental|flibanserin|flibanserin 100 mg q.h.s.
3038012|NCT00360529|Placebo Comparator|placebo|placebo q.h.s.
3038013|NCT00360555|Experimental|flibanserin|flibanserin 25 mg b.i.d
3038014|NCT00360555|Experimental|flibanserin 50mg|flibanserin 50mg qhs/b.i.d
3038015|NCT00360555|Experimental|flibanserin 100mg|flibanserin 50mg b.i.d./100mg qhs
3038016|NCT00360555|Placebo Comparator|placebo|placebo comparator
3038017|NCT00360568|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).~Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances."
3038018|NCT00360672|Experimental|Revlimid|Revlimid 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
3038019|NCT00360685|Other|TAC + MMF|Tacrolimus and Mycophenolate
3038020|NCT00360685|Other|TAC+MTX|Tacrolimus and Methotrexate
3038021|NCT00360698|Other|insulin glulisine+insulin glargine+metformin+glimepiride|Bolus arm
3038022|NCT00360698|Other|insulin glargine+metformin+glimepiride|Control arm
3038023|NCT00360724|Experimental|duloxetine (cymbalta)|Duloxetine medication: a medication currently marketed in the USA that is reported to have pharmacological effects including reuptake blockage for serotonin and norepinephrine
3038024|NCT00360724|Placebo Comparator|Placebo treatment|placebo treatment: treatment with placebo capsules that match active medication capsules
3038025|NCT00360828|Experimental|Irinotecan Treatment|Participants were given irinotecan at a fixed dose: [350 mg/m2 in patients either not on anti-seizure drugs or on anti-seizure drugs which do not interfere with the metabolism of Irinotecan; 600 mg/m2 in patients on anti-seizure drugs which interfere with the metabolism of Irinotecan] once every 21 days. Depending on how many side effects were experienced with the first cycle [first 21 days], the dose of both drugs may remain the same or may be decreased to make the treatment better tolerated with less side effects. The irinotecan was given to through a vein over 90 minutes.
3038026|NCT00360971|Experimental|Palifermin|Concurrent radiation therapy, cisplatin, and palifermin followed by neck dissection for indicated patients.
3038027|NCT00360971|Placebo Comparator|Placebo|Concurrent radiation therapy, cisplatin, and placebo followed by neck dissection for indicated patients.
3038028|NCT00361140|Experimental|AUC 6000|"Busulfan AUC Level 1: 6000 +/- 600 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3038029|NCT00361140|Experimental|AUC 7500|"Busulfan AUC Level 2: 7500 +/- 750 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3038030|NCT00361140|Experimental|AUC 9000|"AUC Level 3: 9000 +/- 900 uM-min~Fludarabine 40mg/m2 IV over 1 hour"
3038031|NCT00361218|Other|open-label selective serotonin reuptake inhibitor (SSRI)|citalopram or escitalopram
3321397|NCT02018523|Experimental|Lenalidomide|Oral lenalidomide 10 mg daily until disease progression
3038032|NCT00361231|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|"The chemotherapy drugs are given twice every 28 days. This 28 day period is called a cycle of study treatment.~Bevacizumab will be administered by IV over 90 minutes on day 1 and day 15. Gemcitabine will be administered by IV over 1 hour and 40 minutes on days 1 and 15 of each cycle. Oxaliplatin will be administered by IV for 2 hours on days 1 and 15 of each cycle.~Participants will continue to receive cycles of study treatment as long as their disease does not progress and they are not experiencing any serious side effects."
3038033|NCT00361257|Experimental|Arm 1: Minocycline|100 mg orally every 12 hours
3038034|NCT00361257|Placebo Comparator|Arm 2: Matching placebo|orally every 12 hours
3038035|NCT00361270|Experimental|Arm 1 Hyp-8|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist without audio recordings
3038036|NCT00361270|Experimental|Arm 2 Hyp-8 w recordings|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour hypnosis with hypnotherapist with audio recordings
3038037|NCT00361270|Experimental|Arm 3 Hyp-2 w recordings|Single-site study at MEDVA-Houston Behavioral: 2 weeks 1-hour hypnosis with hypnotherapist with audio recordings
3038038|NCT00361270|Active Comparator|Arm 4 BIO|Single-site study at MEDVA-Houston Behavioral: 8 weeks 1-hour EMG biofeedback without audio recordings
3038039|NCT00361283|Other|atorvastatin|80mg of atorvastatin given once daily for 16 weeks
3038040|NCT00361296|Experimental|K562/GM-CSF cell vaccine|Vaccinations of 1x10^8 cells are given to participants at weeks 0, 3, 6, 9, and 17.
3038041|NCT00361335|Experimental|Group I: 2mg/kg Golimumab + MTX|Intravenous (IV) infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (an additional 2mg/kg IV infusion of golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of subcutaneous (SC) injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive methotrexate (MTX) at the same dose as that before study entry
3038042|NCT00361335|Experimental|Group II: 2mg/kg Golimumab only|IV infusions of 2mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX or switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules
3038043|NCT00361335|Experimental|Group III: 4mg/kg Golimumab + MTX|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter for a minimum of 48 weeks followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive MTX at the same dose as that before study entry.
3038044|NCT00361335|Experimental|Group IV: 4mg/kg Golimumab only|IV infusions of 4mg/kg golimumab at Week 0 and every 12 weeks thereafter with early escape (addition of MTX) and dose regimen adjustment (addition of MTX), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (initial treatment plus early escape and/or dose regimen adjustment) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition, patients will receive placebo (sham MTX) capsules.
3038045|NCT00361335|Placebo Comparator|Group V: IV Placebo + MTX|IV infusions of placebo at Week 0 and Week 12 with early escape (switch to 4mg/kg IV golimumab) and dose regimen adjustment (switch to 4mg/kg IV golimumab), depending on joint assessment results, at Week 16 and 24, respectively. The duration of the combined IV treatment period (placebo plus golimumab) will be a minimum of 48 weeks. The IV treatment period will be followed by the option of SC injections of 50mg golimumab every 4 weeks for a further 24 weeks (Extension Study). In addition patients will receive MTX at the same dose as that before study entry. Participants still receiving placebo injections at Week 48 are not eligible to enter the Extension Study.
3038046|NCT00361374|Experimental|EPA|Eicosapentaenoic acid (EPA) Omega-3, 1g/day
3038047|NCT00361374|Experimental|DHA|Docosahexaenoic acid (DHA) Omega-3, 1g/day
3038048|NCT00361374|Placebo Comparator|Placebo|Placebo capsule (980mg soybean oil)
3038049|NCT00361439|Active Comparator|Mometasone|Mometasone intranasal steroid therapy daily for 2 weeks
3038050|NCT00361439|Placebo Comparator|Placebo|2 puffs of placebo spray in each nostril once daily
3038051|NCT00361504|Experimental|Tapentadol (CG5503)|Tapentadol (CG5503) extended release (ER) 100 to 250 mg twice daily (BID) for up to one year.
3038052|NCT00361504|Active Comparator|Oxycodone|Oxycodone controlled release (CR) 20 to 50 mg twice daily (BID) for up to one year.
3038053|NCT00361569|Experimental|1|
3038054|NCT00361569|Experimental|2|
3038055|NCT00361569|Placebo Comparator|3|
3038056|NCT00361569|Placebo Comparator|4|
3038057|NCT00361595|Experimental|open label|5 mg zoledronic acid in a single 15 minute IV
3038058|NCT00361634|Experimental|Etanercept|Etanercept 50 mg administered by subcutaneous injection once weekly for up to 12 weeks.
3038059|NCT00361712|Experimental|Preemptive epidural analgesia|Parturients will receive epidural analgesia immediately upon arrival in the labor ward before onset of painful contractions (VAS<3).
3038060|NCT00361712|Active Comparator|Standard of care|Parturients with cervical dilatation and painful labor (VAS >5) will receive epidural analgesia as soon as possible
3038061|NCT00361842|Experimental|Irinotecan|
3038062|NCT00361972|Active Comparator|Lansoprazole therapy|Lansoprazole 30 mg orally twice daily
3038063|NCT00361972|Placebo Comparator|Placebo|placebo orally twice daily
3038064|NCT00362115|Experimental|Azilsartan Medoxomil 5 mg QD|
3038065|NCT00362115|Experimental|Azilsartan Medoxomil 10 mg QD|
3038066|NCT00362115|Experimental|Azilsartan Medoxomil 20 mg QD|
3038067|NCT00362115|Experimental|Azilsartan Medoxomil 40 mg QD|
3038068|NCT00362115|Experimental|Azilsartan Medoxomil 80 mg QD|
3038069|NCT00362115|Active Comparator|Olmesartan 20 mg QD|
3038070|NCT00362115|Placebo Comparator|Placebo QD|
3038071|NCT00362180|Experimental|Cohort A: mipomersen|Healthy volunteers treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3038072|NCT00362180|Placebo Comparator|Cohort A: placebo|Healthy volunteers treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3038073|NCT00362180|Experimental|Cohort D: mipomersen|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of mipomersen 200 mg over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3038074|NCT00362180|Placebo Comparator|Cohort D: placebo|Participants with impaired fasting glucose and mixed dyslipidemia who were treated with 6 injections of placebo over the course of 4 weeks. Injections were given subcutaneously (sc) on days 1, 4, 8, 11, 15 and 22.
3038075|NCT00362180|Experimental|Cohort E: mipomersen|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly mipomersen 200 mg injections for 13 weeks.
3038076|NCT00362180|Placebo Comparator|Cohort E: placebo|Participants with uncomplicated heterozygous familial hypercholesterolemia (HeFH) treated with weekly placebo injections for 13 weeks.
3038077|NCT00362180|No Intervention|Cohort F: no intervention|A reference group of participants with familial hypobetalipoproteinemia (FBHL) who did not receive a study intervention. Data gathered for 15 weeks.
3038078|NCT00362180|Experimental|Cohort G: mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with mipomersen 200 mg weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
3038079|NCT00362180|Placebo Comparator|Cohort G: placebo followed by mipomersen|Participants with well-controlled Type 2 diabetes mellitus, hypercholesterolemia, and normal triglyceride levels were treated with placebo weekly for 26 weeks, followed by open-label mipomersen 200 mg weekly for an additional 26 weeks.
3038080|NCT00362232|Experimental|Rivaroxaban 10 mg Once Daily (OD) ((Xarelto, BAY59-7939))|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening plus placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
3038081|NCT00362232|Active Comparator|Enoxaparin 30 mg twice a day (bid)|Placebo tablet of rivaroxaban administered once daily in the evening plus syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
3038082|NCT00362297|Active Comparator|Standard dose|
3038083|NCT00362297|Experimental|High-dose|
3038084|NCT00362336|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T|
3038085|NCT00362336|Experimental|Group 2: CombAct-HIB™ + OPV|
3038086|NCT00362336|Active Comparator|Group 3: DTaP-IPV-Hep B-PRP-T (ENGERIX B™ at birth)|
3038087|NCT00362375|Experimental|Healthy Love Workshop|Single-session, small-group HIV prevention intervention
3038088|NCT00362375|Active Comparator|HIV101|Single-session, small-group intervention providing facts regarding HIV/AIDS
3038089|NCT00362414|Experimental|Dual Growth Factor|All patients received erythropoietin and beta-hCG. This was the only treatment arm in the study, i.e., all enrollees received active therapy.
3038090|NCT00362440|Experimental|Leptin|Leptin replacement therapy
3038091|NCT00362440|Placebo Comparator|Pioglitazone or metformin|Diabetes treatment therapy
3038092|NCT00362453|Experimental|Tai Chi|The Tai Chi program was based on the classical Yang Style. Patients participated in 60-minute Tai Chi sessions twice a week for 12 weeks. Each session included warm up and review of Tai Chi principles and techniques; Tai Chi exercises; breathing techniques; and various relaxation methods. The classes were taught by a Tai Chi master with over 20 years' experience conducting Tai Chi Mind-Body exercise programs. Several modifications were developed to achieve the physical and mental goals of the study for knee OA, accommodate knee OA symptoms and limit dropouts. Subjects were instructed to practice Tai Chi at least 20 minutes a day at home and encouraged to maintain their usual physical activities, but not to participate in additional new strength training other than their Tai Chi exercises.
3038093|NCT00362453|Placebo Comparator|Wellness Education and Stretching|The wellness education and stretching program provided an active control for the attention being paid to the Tai Chi group. The control group attended two 60-minute class sessions per week for 12 weeks. Each session started with 40 minutes of didactic lessons on OA knowledge, nutrition, and physical and mental health education. The final 20 minutes consisted of stretching exercises involving the upper body, trunk and lower body, each stretch being held for 10 to 15 seconds. Participants were also instructed to practice at least 20 minutes of stretching exercises per day at home. They were encouraged to maintain their usual physical activities, but not to participate in additional strength and mind-body exercise programs other than their stretching exercise.
3038094|NCT00362466|Active Comparator|A|50-180 mg once daily (QD)
3038095|NCT00362466|Active Comparator|B|200-800 mg QD
3038096|NCT00362609|Active Comparator|Low dose|
3038097|NCT00362609|Active Comparator|High dose|
3038098|NCT00362648|Experimental|1|RotaTeq™
3038099|NCT00362648|Placebo Comparator|2|Placebo
3038100|NCT00362817|Experimental|Temozolomide & Intra-Arterial (IA) carboplatin|Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
3038101|NCT00362882|Experimental|Arm 1|Patients receive docetaxel IV over 60 minutes on day 1 and bortezomib IV over 3-5 seconds on days 1 and 8.
3038102|NCT00362882|Experimental|Arm 2|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 2 and 8.
3038104|NCT00363051|Experimental|Everolimus 10 mg|"Stratum 1 patients who were not receiving regular Octreotide Depot therapy. These patients were to receive everolimus monotherapy at 10 mg/day.~Stratum 2 patients who were to receive everolimus 10 mg/day in addition to continuing their entry dose of Octreotide Depot therapy.~Patients were instructed to take two 5 mg tablets of everolimus orally with a glass of water, once daily (preferably in the morning). Dosing was strongly recommended to occur at the same time every day."
3038105|NCT00363077|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of the GSK1247446A vaccine adjuvanted with AS03. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3038106|NCT00363077|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of vaccination received 1 dose of Fluarix™ vaccine. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3038107|NCT00363129|Experimental|Arm I|Patients receive oral vitamin E twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
3038108|NCT00363129|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning within 4 days of the start of chemotherapy course 1 and continuing until 1 month after completion of chemotherapy.
3038109|NCT00363142|Active Comparator|FPV/r200|Fosamprenavir/ritonavir (either 700/100mg BID or 1400/200mg QD)
3038110|NCT00363142|Experimental|FPV/r100|Fosamprenavir/ritonavir 1400/100mg QD
3038111|NCT00363168|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
3038112|NCT00363168|Experimental|B|0.5 mg/0.05 ml dose of ranibizumab
3038113|NCT00363246||Group 1|Older veterans who use a wheelchair for their primary means of mobility.
3038114|NCT00363298|Experimental|d-amphetamine|dextro-amphetamine capsules, 15 mg per capsule, in Bottles A and B, dose: one from Bottle A each morning and 1 from Bottle B each morning
3038115|NCT00363298|Sham Comparator|Sham comparison|caffeine in capsules identical to those containing d-amphetamine, with 200 mg of caffeine in Bottle A capsules, and 100 mg of caffeine in Bottle B capsules, dose was 1 capsule from Bottle A and 1 capsule from Bottle B each morning
3038116|NCT00363311|Active Comparator|Dutasteride|Dutasteride 0.5mg
3038117|NCT00363311|Placebo Comparator|Placebo|Matching placebo
3038118|NCT00363415|Experimental|A|
3038119|NCT00363415|Active Comparator|B|
3038120|NCT00363467|Other|Autologous Hematopoietic Progenitor Cell Transplantation|G-CSF Mobilization Leukepheresis Busulfan Stem Cell Reinfusion
3038121|NCT00363480|Experimental|SFC 50/250 mcg|Participants received the combination product, fluticasone 250 microgram (mcg) plus salmeterol 50 mcg (SFC 50/250 mcg) for 12 weeks. Study treatment was received using DISKUS™ powder inhalers, one dose in morning and evening. Study medication was dispensed at visits 3, 4, and 5 for 30 days each. The participants were provided with salbutamol rescue medication if they developed acute asthmatic symptoms. This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol. Use of rescue medications was recorded in the participant's asthma diaries. Stable dosages of other concomitant medications were allowed if they had no impact on the outcome criteria.
3038122|NCT00363545|Experimental|Liquid Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the liquid formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
3038123|NCT00363545|Experimental|Lyophilized Rotarix Group|Healthy male and female infants, between and including 6-12 weeks of age, who received two oral doses of the lyophilized formulation of the Rotarix™ vaccine, according to a 0, 2 month schedule.
3038124|NCT00363649|Experimental|Arm A|Patients will receive injections of interferon alfa and sargramostim once a day for 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm II.
3038125|NCT00363649|Experimental|Arm B|Patients will receive an injection of GM-K562 cell vaccine every 3 weeks for at least 6 months. Some patients may receive treatment for up to 1 year. After 1 year, some patients may receive treatment as in arm I. NOTE: Study Arm B is not available to newly accrued and enrolled subjects based on the interim analysis directing all new subjects to the combination of Interferon + sargramostim (Arm A).
3038126|NCT00363675|Experimental|All study participants|Children with hand burns
3038127|NCT00363766|Experimental|LY573636|
3038128|NCT00363779|Experimental|LGL Patients administered cyclosporine|Large Granular Lymphocyte Leukemia (LGL) is a low grade non-Hodgkins lymphoma characterized by tissue invasion of the marrow, spleen, and liver. Cyclosporine 5-10 mg/kg/day was administered as an oral preparation given every 12 hours. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml.
3038129|NCT00363805|Experimental|Green Tea|Patients receive green tea beverage and placebo capsules for 6 months.
3038130|NCT00363805|Experimental|Polyphenon E|Patients receive placebo beverage and Polyphenon E capsules daily for 6 months.
3038131|NCT00363805|Placebo Comparator|Placebo|Patients receive placebo beverage and placebo capsules daily for 6 months.
3038132|NCT00363883|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3038133|NCT00363896|Experimental|Aclidinium 200 μg once-daily|Aclidinium bromide 200 μg once-daily by inhalation
3038134|NCT00363896|Placebo Comparator|Placebo|Placebo once-daily via inhalation
3038135|NCT00364013|Experimental|FOLFOX + Panitumumab|Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.
3038136|NCT00364013|Active Comparator|FOLFOX|Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
3038137|NCT00364130|Active Comparator|Active Low Magnitude Mechanical Stimulus|Active Low Magnitude Mechanical Stimulus
3038138|NCT00364130|Placebo Comparator|Inactive Low Magnitude mechanical Stimulus|Inactive, or placebo low magnitude mechanical stimulus
3038139|NCT00364156|Experimental|Extended Patch Treatment|Participants in this treatment arm receive 24 weeks of 21mg nicotine patch in addition to 8 smoking cessation counseling sessions.
3038140|NCT00364156|Active Comparator|Standard Patch Treatment|Participants receive 8 weeks of 21mg nicotine patch followed by 16 weeks of placebo patch.
3038141|NCT00364182|Experimental|A|
3038142|NCT00364182|Experimental|B|
3038143|NCT00364286|Experimental|Dasatinib|Dasatinib 50mg Orally twice daily.
3038144|NCT00364351|Active Comparator|1|Erlotinib
3038145|NCT00364351|Experimental|2|Vandetanib
3038146|NCT00364377|Active Comparator|Sitagliptin|People with impaired fasting glucose randomized to treatment with sitagliptin 100 mg once daily.
3038147|NCT00364377|Placebo Comparator|Placebo|People with impaired fasting glucose randomized to treatment with placebo once daily.
3038148|NCT00364533|Placebo Comparator|003|Placebo Fixed Dose Matching placebo for 3 days
3038149|NCT00364533|Active Comparator|002|Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days
3038150|NCT00364533|Experimental|001|Tapentadol IR (CG5503) Fixed Dose 50, 75, & 100 mg BID for 3 days
3038151|NCT00364533|Other|004|Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
3038152|NCT00364611|Experimental|Docetaxel and Bevacizumab|Stratum 1: HER2 Negative participants with metastatic breast cancer treated with DB (docetaxel and bevacizumab) intravenously (IV) every 3 weeks (q3w) until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
3038153|NCT00364611|Experimental|Docetaxel, Bevacizumab and Trastuzumab|Stratum 2: HER2 Positive participants with metastatic breast cancer treated with DBT (docetaxel, bevacizumab, and trastuzumab) IV q3w until treatment discontinuation criteria (unacceptable toxicity, disease progression or death) are met
3038154|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 months to < 6 months|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3038155|NCT00364793|Experimental|EFV+ddI+FTC in patients >=6 months to < 2 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3038156|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 2 years to < 3 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3038157|NCT00364793|Experimental|EFV+ddI+FTC in patients >= 3 years to <= 6 years|EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle, or oral solution (30 mg/mL. In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.
3038158|NCT00364819|Experimental|1|rituximab 1000 mg IV on days 1 and 15, given over 5 - 6 hours
3038159|NCT00364832|Experimental|Cohort A (0.4/150, 1x/ Week)|Eligible participant will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) SC using a dose conversion factor of 0.4/150 microgram (mcg)/ kilogram (kg) of the previous weekly erythropoiesis stimulating agents (ESA) dose, (equal to 50% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038160|NCT00364832|Experimental|Cohort B (0.4/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038161|NCT00364832|Experimental|Cohort C (0.4/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.4/150 mcg/kg of the previous weekly ESA dose, (equal to 50% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038162|NCT00364832|Experimental|Cohort D (0.8/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038163|NCT00364832|Experimental|Cohort E (0.8/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038164|NCT00364832|Experimental|Cohort F (0.8/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 0.8/150 mcg/kg of the previous weekly ESA dose, (equal to 100% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038165|NCT00364832|Experimental|Cohort G (1.2/150, 1x/ Week)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once weekly up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038166|NCT00364832|Experimental|Cohort H (1.2/150, 1x/ 3 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every three weeks up to 19 weeks. After 19 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3038167|NCT00364832|Experimental|Cohort I (1.2/150, 1x/ 4 Weeks)|Eligible participant will be administered RO0503821 SC using a dose conversion factor of 1.2/150 mcg/kg of the previous weekly ESA dose, (equal to 150% assumed equi-effective dose) once every four weeks up to 21 weeks. After 21 weeks of core treatment period, participants will be followed-up for two optional treatment extension periods (54 weeks each).
3321398|NCT02018536|Experimental|Part 1, Cohort A|8 participants to receive a single oral dose of 30 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3038168|NCT00364845|Active Comparator|Darbepoetin alfa|Single-blind darbepoetin alfa administered by subcutaneous injection (SC) every other week until hemoglobin (Hgb) was stable (2 consecutive Hgb values between 120 and 135 g/L), then every month for up to 9 months.
3038169|NCT00364845|Placebo Comparator|Placebo|Single-blind placebo administered by subcutaneous injection (SC) every other week until week 16, then every month for up to 9 months.
3038170|NCT00364858|Other|Q2 Cerezyme|Patients receiving Cerezyme one infusion every 2 weeks (Q2).
3038171|NCT00364858|Other|Q4 Cerezyme|Patients receiving Cerezyme one infusion every 4 weeks (Q4).
3038172|NCT00365053|Experimental|Treatment (belinostat)|Patients receive PXD101 IV at 1000 mg/m2 over 30 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3038173|NCT00365105|Active Comparator|Zoledronic acid|Zoledronic acid, vitamin D and calcium supplements.
3038174|NCT00365105|Experimental|Zoledronic acid + Radiopharmaceuticals|Zoledronic acid, vitamin D and calcium supplements, plus Sr-89 or Sm-153.
3038175|NCT00365144|Experimental|Bevacizumab Plus Erlotinib Hydrochloride|"A treatment cycle is 21 days:~bevacizumab 15 mg/kg as a 60-90 min infusion once every 21 days, with erlotinib hydrochloride 150 mg by mouth daily"
3038176|NCT00365209|Experimental|2g (curcumin)|Patients receive 2 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
3038177|NCT00365209|Experimental|4g (curcumin)|Patients receive 4 grams of oral curcumin once daily. Treatment continues for up to 30 days in the absence of unacceptable toxicity or disease progression.
3038178|NCT00365261|Active Comparator|eszopiclone|active drug
3038179|NCT00365261|Placebo Comparator|placebo|placebo
3038180|NCT00365274|Experimental|SGN-30 + Combination Chemotherapy|"Monoclonal antibody SGN-30 monotherapy: SGN-30 12 mg/kg weekly intravenously(IV) over 2 hours once weekly for 3 weeks.~SGN-30 and CHOP chemotherapy: Beginning 1 week after completion of monoclonal antibody SGN-30 monotherapy, SGN-30 12 mg/kg IV over 2 hours on day 1 and CHOP chemotherapy comprising cyclophosphamide IV over 1 hour, doxorubicin hydrochloride IV over 15 minutes, and vincristine IV over 15 minutes on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 6-8 courses."
3038181|NCT00365300|Active Comparator|Pantoprazole|
3038182|NCT00365300|Placebo Comparator|Placebo|
3038183|NCT00365352|Experimental|XP13512 600MG|XP13512 600MG ONCE DAILY
3038184|NCT00365352|Experimental|XP13512 1200MG|XP13512 1200MG ONCE DAILY
3038185|NCT00365352|Placebo Comparator|Placebo|PLACEBO ONCE DAILY
3038186|NCT00365365|Experimental|Stratum 1 (AC->T + bevacizumab)|"HER2-negative participants administered~doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by~docetaxel (T) + bevacizumab for 4 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3038187|NCT00365365|Experimental|Stratum 2 (TAC + bevacizumab)|"HER2-negative participants administered~docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by~bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3038188|NCT00365365|Experimental|Stratum 3 (TCH + bevacizumab)|"All HER2-positive participants administered~docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab for 6 cycles followed by~bevacizumab and trastuzumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed"
3038189|NCT00365378|Experimental|1|HPV 16 L1 VLP vaccine
3038190|NCT00365378|Placebo Comparator|2|Placebo
3038191|NCT00365391|Experimental|Treatment (monoclonal antibody, enzyme inhibitor)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo laboratory studies to determine EGFR and phosphorylated-EGFR protein levels using initial diagnostic biopsy specimens by IHC for correlation with clinical outcome. Levels of proteins through which EGFR signals, including Akt, phosphorylated-Akt, MAPK, and phosphorylated-MAPK, are also determined using initial diagnostic biopsy specimens by IHC and correlated with clinical outcome. Total and free serum vascular endothelial growth factor levels are determined at the start of study and prior to course 3 by ELISA.
3038192|NCT00365417|Experimental|Doxorubicin+Cyclophosphamide+Bevacizumab|
3038193|NCT00365456|Experimental|PTH (1-84)|
3038194|NCT00365456|Active Comparator|Risedronate|
3038195|NCT00365508|Experimental|Arm I|Participants apply a transdermal nicotine patch at 3 different time periods during weeks 3-14; a higher-dose patch is applied for weeks 3-8, a medium-dose patch is applied for weeks 9-10, and a lower-dose patch is applied for weeks 11-14.
3038196|NCT00365508|Experimental|Arm II|Participants receive one oral nicotine lozenge every 1-2 hours in weeks 3-8 (≥ 9 lozenges per day), one lozenge every 2-4 hours in weeks 9-11 (≥ 5 lozenges per day), and 1 lozenge every 4-8 hours in weeks 12-14 (≥ 3 lozenges per day).
3038197|NCT00365547|Experimental|Patients Treated With Topotecan and Avastin in NSCLC|Weekly topotecan hydrochloride and bi-weekly Avastin (bevacizumab) in patients with non-small cell lung cancer (NSCLC) who have failed prior systemic chemotherapy.
3038198|NCT00365599|Experimental|Vorinostat and Tamoxifen|As outlined in Intervention descriptions
3038199|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 1 received a 20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3038200|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 2 received a 40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3038201|NCT00365716|Experimental|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 3 received a 80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
3321399|NCT02018536|Experimental|Part 1, Cohort B|8 participants to receive a single oral dose of 60 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3038202|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 225|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 4 received placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
3038203|NCT00365716|Experimental|Placebo (mcg) (Aluminum Adjuvant) 450|The Vaccination Period for the Base Study encompassed Day 1 through Month 7, during which time subjects in Group 5 received placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
3038204|NCT00365768|Experimental|Arm I: Glutamine|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral glutamine twice daily on days 1-21.
3038205|NCT00365768|Placebo Comparator|Arm II: Placebo|Beginning 1 week after administration of vincristine chemotherapy, patients receive oral placebo twice daily on days 1-21.
3038206|NCT00365794|Experimental|Single arm|Open label treatment without masking with each participant serving as his own control. Measurements are compared before and after treatment.
3038207|NCT00365846|Experimental|Campath 1H induction w/ Sirolimus immunosuppression|Campath 1H at day -1 and 0 of kidney transplant followed by long term CNI free immunosuppressive therapy with Sirolimus,
3038208|NCT00365859|Experimental|De Novo|De novo participants (those who did not participate in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) assigned to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3038209|NCT00365859|Experimental|Rollover Placebo|Participants who completed participation in protocol (CN138-178 [NCT00332241] or CN138-179 [NCT00337571]) on placebo treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3038210|NCT00365859|Experimental|Rollover Aripiprazole|Participants who completed participation in protocol CN138-178 [NCT00332241] or CN138-179 [NCT00337571] on aripiprazole treatment and continued to meet all of the inclusion criteria and none of the exclusion criteria. Assigned in this study to open-label aripiprazole (oral tablet), flexibly dosed (2 to 15 mg/day) taken once daily, started at 2 mg/day on Day 1. Target daily dose was 5 mg, 10 mg, or 15 mg; maximum dose, regardless of weight, was 15 mg. Dose increases were incremental (dose levels are 2 mg, 5 mg, 10 mg, and 15 mg), occurring no more often than every 4 days, and were based on assessment of efficacy and tolerability at the current dose. The dosage could be adjusted downward if the patient experienced intolerance at any time to the current dose.
3038211|NCT00365872|Experimental|EBRT + DC Injection + Resection|Single Arm: EBRT + DC Injection + Resection. Prior to the fourth DC Injection, participants were assigned to 3 cohorts as outlined in that intervention.
3038212|NCT00365976|Placebo Comparator|1|Placebo
3038213|NCT00365976|Active Comparator|2|Eszopiclone
3038214|NCT00365989|Experimental|ExAblate Enhanced Sonication Test Arm|The intervention to be administered is ExAblate Enhanced Sonication. The purpose of this study is to examine the safety profile of the ExAblate Enhanced Sonication mode to insure that no new safety issues are introduced compared to the normal focused ultrasound mode.
3038215|NCT00366028|Other|Organizational Model|Organizational Model: Participants in this arm of the study will receive information regarding the organizational model and work closely with the research team throughout the project to implement various aspects of the model. Participants in this arm of the study will be interviewed and participate in the data feedback portion of the study as well.
3038216|NCT00366028|Other|Data Feedback|Data Feedback Only: Participants in this arm will be interviewed periodically and participate in the data feedback portion of the study.
3038217|NCT00366249|Active Comparator|A|
3038218|NCT00366249|Active Comparator|B|
3038219|NCT00366275|Experimental|In vivo purging autotransplant|
3038220|NCT00366301|Placebo Comparator|Placebo pill|Placebo pill
3038221|NCT00366301|Active Comparator|Metformin Pill|Metformin pill
3038222|NCT00366301|Active Comparator|Insulin Glargine plus placebo pill|Insulin glargine plus placebo pill
3038223|NCT00366301|Active Comparator|Insulin Glargine plus metformin pill|Insulin Glargine plus metformin pill
3038224|NCT00366340|Experimental|1|13-valent pneumococcal conjugate vaccine
3038225|NCT00366340|Active Comparator|2|7-valent pneumococcal conjugate vaccine
3038226|NCT00366444|Experimental|1|
3038227|NCT00366444|Placebo Comparator|2|
3038228|NCT00366457|Other|Gemcitabine, Bevacizumab and Erlotinib|single-arm, no masking
3038229|NCT00366535|Active Comparator|Placebo first, then Neurotropin (G-1)|Double blind cross-over study: receive Placebo for 12 weeks and then Neurotropin for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others blind.
3038230|NCT00366535|Active Comparator|Neurotropin first, then Placebo (G-2)|Double blind cross-over study: receive Neurotropin for 12 weeks and then Placebo for 12 weeks (after at least 1 week washout period). Assignment to each group was in random order, selected by the pharmacy with all others
3038231|NCT00366548|Experimental|1|
3038232|NCT00366548|Active Comparator|2|
3038233|NCT00366626|Experimental|1.|Naltrexone one capsule a day
3038234|NCT00366626|Placebo Comparator|2|One capsule a day match to naltrexone
3038235|NCT00366678|Experimental|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine
3038236|NCT00366678|Active Comparator|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine
3038237|NCT00366899|Experimental|1|13-valent pneumococcal conjugate vaccine
3038238|NCT00366899|Active Comparator|2|7-valent pneumococcal conjugate vaccine
3038239|NCT00367003|Experimental|Deep Brain Stimulation|Participants with treatment resistant depression will have a device implanted for deep brain stimulation.
3038240|NCT00367016|Experimental|Omalizumab|Subjects will receive subcutaneous Omalizumab for 6 months. Prior to Omalizumab administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
3038241|NCT00367016|Experimental|Placebo|Subjects will receive subcutaneous placebo for 6 months. Prior to placebo administration, all subjects will undergo screening studies, including spirometry, blood test and skin test. Blood test includes comprehensive metabolic panel, CBC, and total and free IgE levels. Skin test will be done with a panel of 7 common allergens
3038242|NCT00367133|Active Comparator|1|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
3038243|NCT00367133|Experimental|2|Intravitreal injection of 1mg of triamcinolone acetonide
3038244|NCT00367133|Experimental|3|Intravitreal injection of 4mg of triamcinolone acetonide
3038245|NCT00367237|Experimental|Infliximab + methotrexate (IFX + MTX)|Remicade (infliximab [IFX]) 5 mg/kg infusions at Weeks 0, 2, 6, 14 and oral methotrexate (MTX) 15 mg/week
3038246|NCT00367237|Active Comparator|Methotrexate (MTX)|Oral methotrexate (MTX) 15 mg/week
3038247|NCT00367341|Other|Escitalopram|
3038248|NCT00367341|Other|Cognitive Behavioral Therapy|
3038249|NCT00367380|Experimental|Group 1|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 413ABM
3038250|NCT00367380|Experimental|Group 2|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 414WRR
3038251|NCT00367380|Experimental|Group 3|6 volunteers to be challenged with the infected with +/-3 mosquito bites from batch 418JAL
3038252|NCT00367432|Experimental|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
3038253|NCT00367458|Experimental|Atorvastatin, then Placebo|Patients were randomized to receive Atorvastatin first for 8 weeks, followed by 4 weeks wash out, and then cross over to placebo for 8 weeks.
3038254|NCT00367458|Experimental|Placebo, Then Atorvastatin|Patients were randomized to receive placebo first for 8 weeks, followed by 4 weeks wash out, and then cross over to 80 mg atorvastatin daily for 8 weeks.
3038255|NCT00367484|Experimental|Rebif® (clone 484-39)|Rebif® 44 mcg, three times per week (tiw), subcutaneously (s.c.) During the first 4 weeks of the study, subjects underwent a dose titration regimen of 40% of Rebif® 22 mcg or 20% of Rebif® 44 mcg tiw (8.8 mcg per injection) in the first and second week followed by 100% of Rebif® 22 mcg or 50% of Rebif® 44 mcg (22 mcg per injection) in the third and fourth week. After 4 weeks, subjects received 44 mcg injected s.c. tiw.
3038256|NCT00367601|Experimental|1|Bevacizumab + erlotinib; if no progressive disease observed, combination or single-agent treatment will continue until unacceptable toxicity or progressive disease.
3038257|NCT00367640|Experimental|100 IR|100 IR grass pollen allergen extract tablet
3038258|NCT00367640|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3038259|NCT00367640|Experimental|500 IR|500 IR grass pollen allergen extract tablet
3038260|NCT00367640|Placebo Comparator|Placebo|Placebo tablet
3038261|NCT00367679|Experimental|Single Arm|800 mg pazopanib oral daily
3038262|NCT00367744|Active Comparator|Rosigitazone arm|Rosiglitazone active 4 mg BID
3038263|NCT00367744|Placebo Comparator|Placebo arm|Matching Placebo BID
3038264|NCT00367770|Experimental|Tracleer|The starting dose for all patients will be 62.5 mg b.i.d. At the Week 4 visit, patients who were started on 62.5 mg b.i.d. will be uptitrated to 125 mg b.i.d. if the 62.5 mg b.i.d. dose was well-tolerated.
3038265|NCT00367835|Experimental|SPD503 (Guanfacine hydrochloride)|
3038266|NCT00367835|Placebo Comparator|Placebo|
3038267|NCT00367991|Active Comparator|A|recombinant human erythropoietin 200 U/kg IV daily for 3 days
3038268|NCT00367991|Placebo Comparator|B|Normal saline volume to match active treatment IV daily for 3 days
3038269|NCT00368069|Experimental|Keppra® XR|Keppra® extended release formulation -XR
3038270|NCT00368069|Placebo Comparator|Placebo|placebo
3038271|NCT00368108|Experimental|2 mg perampanel|The Perampanel 2mg dosage was fixed for the entire double-blind study. Subjects taking perampanel 2mg were to take the dose orally once every day in the evening.
3038272|NCT00368108|Experimental|4 mg perampanel|The Perampanel 4mg group first were subjected to a 4 week titration period, followed by a maintenance period for the remaining weeks. Subjects taking perampanel 4mg had a titration period of 4 weeks, starting at 2mg per day adding 1mg of perampel every two weeks up to 4mg. The dosages were to be taken orally once every day in the evening.
3038273|NCT00368108|Placebo Comparator|placebo|The placebo dosage was a fixed dosage for the entire double-blind study. Subjects receiving the placebo were to take one dose orally once every day in the evening.
3038274|NCT00368251|Placebo Comparator|Placebo|Placebo Placebo twice a day (bid), 14 weeks (2 week Up-Titration Period + 12 week Maintenance Period)
3038275|NCT00368251|Experimental|Brivaracetam 5 mg/day|Brivaracetam (BRV) 5 mg/day 5 mg twice a day (bid) using 2.5 mg tablets for 12 weeks (after 2 week Up- Titration Period)
3038276|NCT00368251|Experimental|Brivaracetam 150 mg/day|Brivaracetam (BRV) 150 mg/day 150 mg twice a day (bid) using 25 mg and 50 mg tablets for 12 weeks (after 2 week Up-Titration Period)
3038277|NCT00368277|Experimental|Aliskiren-based regimen|Aliskiren 150 mg; aliskiren 300 mg; aliskiren 300mg + hydrochlorothiazide 12.5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; aliskiren 300 mg + hydrochlorothiazide 25 mg + amlodipine 10 mg
3038278|NCT00368277|Active Comparator|Ramipril-based regimen|Ramipril 5 mg; Ramipril 10 mg; Ramipril 10 mg + hydrochlorothiazide 12.5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 5 mg; Ramipril 10 mg + hydrochlorothiazide 25 mg + amlodipine 10mg
3038279|NCT00368290|Experimental|1|modafinil plus CBT
3038280|NCT00368290|Placebo Comparator|2|placebo plus CBT
3038281|NCT00368316|Experimental|S. sonnei conjugate vaccine|Shigella sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa
3038282|NCT00368316|Experimental|S. flexneri 2a conjugate vaccine|Shigella flexneri 2a O-specific polysaccharide covalently bound to recombinant exoprotein A of pseudomonas aeruginosa
3038283|NCT00368355|Experimental|CLINIMACS Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device
3038284|NCT00368355|Experimental|ISOLEX Device|Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device
3038285|NCT00368459|Experimental|raloxifene|oral raloxifene 120 mg once daily
3038286|NCT00368459|Placebo Comparator|placebo|identical appearing oral placebo
3038287|NCT00368472|Experimental|Perampanel|Participants previously receiving placebo/perampanel in the double blind study, were titrated to receive perampanel 2 mg to 12 mg, once daily during the OLE study
3038288|NCT00368537|Active Comparator|1|Arm 1: Tigecycline
3038289|NCT00368537|Active Comparator|2|Arm 2: Ampicillin-Sulbactam or Amoxicillin-Clavulanate plus or minus a glycopeptide
3038290|NCT00368550|Experimental|1|Oral sertraline, cognitive-behavioral counseling to maintain abstinence from alcohol
3038291|NCT00368550|Placebo Comparator|2|Placebo, cognitive-behavioral counseling to maintain abstinence from alcohol
3038292|NCT00368641|Experimental|Intervention|peritoneal dialysis
3038293|NCT00368641|No Intervention|Standard of Care|
3038294|NCT00368745|Active Comparator|Pregabalin|Pregabalin treatment for GAD during 6 week taper/discontinuation from alprazolam treatment; followed by 6 weeks pregabalin treatment 'alprazolam free'.
3038295|NCT00368745|Placebo Comparator|Placebo|Placebo treatment of GAD during 6 week taper/discontinuation of alprazolam treatment followed by 6 weeks continuation of placebo treatment 'alprazolam free'.
3038296|NCT00368836|Experimental|BreathScreen PE + D-dimer|CO2/O2 ratio will be measured using the Breath Screen PE device. D-dimer levels will also be collected.
3038297|NCT00368849|Experimental|40 milligram twice a day atomoxetine|Participants received 40 milligram twice a day atomoxetine for 4 weeks.
3038298|NCT00368849|Placebo Comparator|Twice a day matching placebo|Participants received twice a day matching placebo for 4 weeks.
3038299|NCT00368875|Experimental|vorinostat, paclitaxel, bevacizumab|Vorinostat BID on days 1-3, 8-10, and 15-17, paclitaxel IV over 1 hour on days 2, 9, and 16, bevacizumab IV over 30-90 minutes on days 2 and 16, repeat every 28 days.
3038300|NCT00368927|Experimental|Arm I|Patients receive oral sulindac twice daily for 6 months.
3038301|NCT00368927|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
3038302|NCT00368940|Experimental|PATH|Participants will receive PATH for 12 weeks
3038303|NCT00368940|Active Comparator|ST-CI|Participants will receive ST-CI for 12 weeks
3038304|NCT00368966|Experimental|1|
3038305|NCT00368966|Active Comparator|2|
3038306|NCT00368979|Active Comparator|Dutasteride|
3038307|NCT00368979|Placebo Comparator|Placebo|
3038308|NCT00368992|Experimental|Treatment (cetuximab, paclitaxel, bevacizumab)|"INDUCTION THERAPY: Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cetuximab IV over 1 hour on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3038309|NCT00369122|Experimental|Treatment (radiation therapy, bevacizumab, cisplatin)|"Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45 Gy.~Some patients also undergo low-dose rate brachytherapy twice, 1-3 weeks apart, beginning >= 4 weeks after initiating EBRT or high-dose rate brachytherapy 5 times, >= 48 hours apart, beginning >= 2 weeks after initiating EBRT. EBRT and chemotherapy are halted on the day of high-dose rate brachytherapy. Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, and 35."
3038310|NCT00369161|Active Comparator|Very low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 1.5 and 3 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
3038311|NCT00369161|Active Comparator|Low dose tacrolimus|The first dose of everolimus was to be administered not later than 24 hours after transplantation with a starting dose of 1.5 mg bis in diem/twice a day (b.i.d.) thereafter adjusted to maintain the trough blood levels between 3 and 8 ng/ml. Tacrolimus was to be initiated within 24 hours after reperfusion of the graft with a starting dose of 0.1 mg/kg/day thereafter adjusted to maintain the trough blood levels between 4 and 7 ng/ml. Up to months three all patients received the same treatment and after three months patients in this arm received tacrolimus to reach a trough blood level between 4 and 7 ng/ml. All patients received two doses of 20 mg basiliximab, administered as an intravenous bolus injection. The first dose was given on the day of transplantation, with the second dose being administered on the fourth day post-transplant. Intravenous (i.v.) prednisone (or equivalent) was given pre- or intra-operatively according to center practice.
3038312|NCT00369226|Experimental|Bortezomib/Tacrolimus/Methotrexate post HSCT|
3038313|NCT00369278|Experimental|Intensified Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1-14: 2880 mg/day (2 x 1440 mg), then day 15-42: 2160 mg/day (2 x 1080 mg), then day 43-End of study (month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 180 days.
3038314|NCT00369278|Active Comparator|Standard Mycophenolate sodium|Enteric-coated mycophenolate sodium was given according to the following dosing regimen: Day 1 - End of Study(month 6): 1440 mg/day (2 x 720 mg). Total duration of treatment was 6 months.
3321400|NCT02018536|Experimental|Part 1, Cohort C|8 participants to receive a single oral dose of 120 mg of GSK2336805 (6 participants) or placebo (2 participants) on Day 1.
3038315|NCT00369317|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4. COURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.~COURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I~INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3038316|NCT00369343|Experimental|A|
3038317|NCT00369343|Placebo Comparator|B|
3038318|NCT00369382|Active Comparator|1|Group 1: Continuation of CNI regimen
3038319|NCT00369382|Experimental|2|Group 2: (CNI-Free) Conversion to SRL-based regimen
3038320|NCT00369486|Active Comparator|1|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study (ETDRS) technique)
3038321|NCT00369486|Experimental|2|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
3038322|NCT00369486|Experimental|3|Anterior peribulbar injection of 20 mg triamcinolone
3038323|NCT00369486|Experimental|4|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
3038324|NCT00369486|Experimental|5|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
3038325|NCT00369512|Experimental|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
3038326|NCT00369564|Experimental|Arm I Glutamic Acid|Patients receive oral glutamic acid 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
3038327|NCT00369564|Placebo Comparator|Arm II Placebo|Patients receive oral placebo 3 times daily beginning prior to the first dose of vincristine and continuing through week 5 (stratum 2) or week 10 (stratum 1).
3038328|NCT00369577|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, single dose
3038329|NCT00369577|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
3038330|NCT00369577|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
3038331|NCT00369590|Experimental|All Study Patients|"Patients receive VEGF Trap (ziv-aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis."
3038332|NCT00369629|Experimental|Cohort 1|"Pemetrexed at a dose of 400 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
3038333|NCT00369629|Experimental|Cohort 2|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 800 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
3038334|NCT00369629|Experimental|Cohort 3|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1000 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
3038335|NCT00369629|Experimental|Cohort 4|"Pemetrexed at a dose of 500 mg/m2 will be given to patients on day 1 and day 15 of 28 day cycle.~Gemcitabine at a dose of 1200 mg/m2 will be given following pemetrexed on day 1 and 15 of a 28-day cycle."
3038336|NCT00369655|Experimental|Treatment (ziv-afibercept)|Patients receive VEGF Trap IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3038337|NCT00369668|Experimental|High Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; four 90-minute sessions/week for 2 weeks.
3038338|NCT00369668|Active Comparator|Low Intensity|Bilateral training moving both arms coupled with neuromuscular electrical stimulation; two 90-minute sessions/week for 2 weeks.
3038339|NCT00369668|Active Comparator|Control|Bilateral training moving both arms coupled with sham neuromuscular electrical stimulation
3038340|NCT00369681|Experimental|R-ABVD|ABVD (doxorubicin; vinblastine; bleomycin; dacarbazine) given as standard for 6-8 cycles. Rituximab given 375 mg/m^2 Cycle 1 Days -6, 1, 8, 15, and 22. Rituximab given 375 mg/m^2 Cycles 2, 4, and 6 Day 1.
3038341|NCT00369707|Experimental|Bortezomib and Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
3038342|NCT00369746||Alcohol and major depression, citalopram|Patients with alcohol use disorder and major depression, treated with citalopram tablets, 20-60 mg, once daily, for 12 weeks
3038343|NCT00369746||Major Depression, citalopram|Patients with major depression, treated with citalopram tablets 20-60 mg daily, for 12 weeks
3038344|NCT00369785|Experimental|Arm I - Donepezil|Weeks 1-6: One 5 mg tablet orally donepezil hydrochloride Weeks 7-24: Two 5mg tablets per day
3038345|NCT00369785|Placebo Comparator|Arm II - Control|Weeks 1-6: One placebo tablet per day Weeks 7-24: Two placebo tablets per day
3038346|NCT00369824|Experimental|Cervarix + Boostrix/Menactra Group|Subjects received Cervarix and Boostrix at Month 0, Menactra and Cervarix at Month 1 and Cervarix alone at Month 6.
3038347|NCT00369824|Experimental|Cervarix + Menactra/Boostrix Group|Subjects received Menactra and Cervarix at Month 0, Boostrix and Cervarix at Month 1 and Cervarix alone at Month 6.
3038348|NCT00369824|Experimental|Cervarix + Boostrix + Menactra Group|Subjects received Boostrix, Menactra and Cervarix at Month 0 and Cervarix alone at Months 1 and 6.
3038349|NCT00369824|Experimental|Boostrix/Cervarix Group|Subjects received Boostrix at Month 0 and Cervarix at Months 1, 2 and 7.
3038350|NCT00369824|Experimental|Menactra/Cervarix Group|Subjects received Menactra at Month 0 and Cervarix at Months 1, 2 and 7.
3038351|NCT00369824|Experimental|Cervarix Group|Subjects received Cervarix at Months 0, 1 and 6.
3038352|NCT00369915|Experimental|Plac/Scop|Placebo then scopolamine
3038353|NCT00369915|Experimental|Scop/Plac|Scopolamine then placebo
3038354|NCT00369928|Placebo Comparator|Placebo|Placebo, oral dose, BID
3038355|NCT00369928|Experimental|25 mg PG-760564|25 mg BID, of oral PG-760564
3038356|NCT00369928|Experimental|100 mg PG-760564|100 mg BID, of oral PG-760564
3038357|NCT00369941|Experimental|MK-0518 400 mg b.i.d.|MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
3038358|NCT00369941|Active Comparator|Efavirenz 600 mg q.h.s.|Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
3038359|NCT00369967|Experimental|Quick start|Start contraceptive method (NuvaRing) day of enrollment
3038360|NCT00369967|Active Comparator|Traditional start|Start contraceptive method (NuvaRing) after next menses (per package insert)
3038361|NCT00370071|Experimental|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
3038362|NCT00370149|Active Comparator|Antibiotic-impregnated Catheters (M/R)|Interventions is insertion intra-operatively of catheters impregnated with minocycline and rifampin to determine if their is a therapeutic difference between this catheter and the placebo (non-impregnated) catheter. The catheters are sized to accommodate children in different size ranges: Cook Inc. Double Lumen 4 Fr., 8 cm long, (C-UDLM-401J-ABRM-HC), 5 Fr., 8 cm long, (C-UDLM-501J-ABRM-HC), and 5 Fr., 12 cm long, (C-UDLMY-501J-RSC-ABRM-HC).
3038363|NCT00370149|Placebo Comparator|Non-impregnated Catheter (C/S)|Intervention is insertion intra-operatively of conventional, non-impregnated catheters. There are two sizes to accommodate children in different size ranges: Cook Incorporated Double Lumen Polyurethane Central Venous Catheters, 4 Fr., 8 cm long, (C-UDLM-401J), 5 Fr., 8 cm long, (C-UDLM-501J), and 5 Fr., 12 cm long (C-UDLM-501J-RSC).
3038364|NCT00370292|Experimental|Pemetrexed - Before Protocol Amendment|
3038365|NCT00370292|Experimental|Pemetrexed - After Protocol Amendment|
3038366|NCT00370331|Experimental|Treatment arm plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
3038367|NCT00370331|Placebo Comparator|placebo plus standard of care|Subjects will initiate treatment with 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
3038368|NCT00370396|Experimental|Synflorix-Synflorix Group|This group consisted of subjects previously vaccinated with the Synflorix™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
3038369|NCT00370396|Active Comparator|Prevenar-Prevenar Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Prevenar™ vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Prevenar™ vaccine, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
3038370|NCT00370396|Experimental|Prevenar-Synflorix Group|This group consisted of subjects previously vaccinated with the Prevenar™ vaccine as part of a previous study by GSK Biologicals - the 10PN-PD-DIT-001 (105553) study (EuDRA-CT number: 2005-003300-11). As part of the 105553 study, subjects had received a 3-dose primary vaccination of Synflorix vaccine at 2, 3 and 4 months of age (injected intramuscularly [IM] in the right thigh) co-administered with Infanrix hexa™ vaccine, except for the second dose in France, which was co-administered with Infanrix™ IPV Hib, injected intramuscularly in the left thigh. As part of this study, at 12-18 months of age, subjects received a booster dose of Synflorix™, injected IM in the right thigh or deltoid, co-administered with Infanrix hexa™ vaccine, injected IM in the left thigh or deltoid.
3038371|NCT00370552|Experimental|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|
3038372|NCT00370552|Experimental|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|
3038373|NCT00370552|Active Comparator|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|
3038374|NCT00370682|Experimental|T-DEN F17|Full Dose (0.5 mL) 0 and 6 months
3038375|NCT00370682|Experimental|T-DEN F19|Full Dose (0.5 mL) at 0 and 6 months
3038376|NCT00370682|Placebo Comparator|Placebo Comparator|0.5 mL sterile buffer at 0 and 6, subcutaneous injection
3038377|NCT00370838|Experimental|Levetiracetam|"Levetiracetam (Keppra) is used in one phase of this cross-over study.~The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
3038378|NCT00370838|Active Comparator|Clonidine|"Clonidine is used in one phase of this cross-over study.~The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase."
3038379|NCT00370994|Active Comparator|Caudal epidural injection|Caudal epidural with placement of catheter in sacral canal with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 0.9% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
3038380|NCT00370994|Active Comparator|Percutaneous adhesiolysis|Pecutaneous adhesiolysis and targeted placement of Racz catheter with injection of 5 mL of 2% preservative-free lidocaine, followed by 6 mL of 10% sodium chloride solution and 6 mg of non-particulate Betamethasone and 1 mL of sodium chloride solution
3038381|NCT00371137|Placebo Comparator|1|
3038382|NCT00371137|Experimental|2|
3038383|NCT00371150|Experimental|Arm1|
3038384|NCT00371176|Experimental|D-Cycloserine|Brief imaginal exposure therapy plus DCS pill
3038385|NCT00371176|Placebo Comparator|Placebo|Brief imaginal exposure therapy plus Placebo pill
3038386|NCT00371254|Experimental|1|
3038387|NCT00371254|Experimental|2|
3038388|NCT00371267|Experimental|Arm 1: Telephone-delivered CBT|Telephone-delivered cognitive behavior therapy for pain management
3038389|NCT00371267|Active Comparator|Arm 2: Telephone patient education|Telephone-delivered patient education regarding management of chronic pain
3038390|NCT00371293|Active Comparator|1|Participants will receive CPAP therapy.
3038391|NCT00371293|Active Comparator|2|Participants will take part in a weight loss program.
3038392|NCT00371293|Experimental|3|Participants will receive CPAP therapy and take part in a weight loss program.
3038393|NCT00371345|Experimental|Dasatinib|Participants with either a Human epidermal growth factor (Her2/neu)-amplified tumor type or ER and/or PgR positive tumor types received oral dasatinib twice daily (BID).
3038394|NCT00371397|Experimental|Hatha yoga classes|Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3038395|NCT00371397|Sham Comparator|Movement Control|Non-Hatha yoga gentle movement. Groups consisted of novices or experts. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3038396|NCT00371397|No Intervention|Passive Video Control|Another control condition, a neutral video that did not include any music, allowed us to contrast the effects of yoga with no activity.The session included a sequence on how to design physics experiments for a high school classroom, as well as segments from two lectures on polymers and quantum mechanics. Groups were counterbalanced to ensure that equal number of novices and experts participated in each possible session combination, in a randomly assigned order.
3038397|NCT00371436|Active Comparator|Progressive Audiologic Tinnitus Management (PATM)|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment."
3038398|NCT00371436|Other|Usual Care (UC)|Typical audiologic care that would be received in a VA Audiology Clinic.
3038399|NCT00371449||hearing aid users|hearing aid users
3038400|NCT00371540|No Intervention|I|Routine care in the clinic
3038401|NCT00371540|Experimental|II|Follow-up in clinic every 3 months, home visits monthly
3038402|NCT00371566|Experimental|Lapatinib|
3038403|NCT00371566|Placebo Comparator|Placebo|
3038404|NCT00371631|Other|Arm 1|insertion of E. coli coated catheter
3038405|NCT00371644|Experimental|Arm 1|Participants receive 12 biweekly sessions of Cognitive Processing Therapy (CPT).
3038406|NCT00371644|Active Comparator|Arm 2|Participants receive 12 biweekly sessions of Present Centered Therapy (PCT).
3038407|NCT00371683|Active Comparator|A1|+ placebo
3038408|NCT00371683|Experimental|A2|+ placebo
3038409|NCT00371761|Experimental|PegIntron|PegIntron, 1.5 micrograms/kg weekly, for up to 24 weeks followed by a 48-week observation phase
3038410|NCT00371761|Active Comparator|Adefovir|Adefovir, 10 mg daily, for up to 48 weeks followed by a 24-week observation phase
3038411|NCT00371787|Experimental|soft contact lens|
3038412|NCT00371787|No Intervention|non-lens wear|control group
3038413|NCT00371826|Experimental|Calcineurin Inhibitor (CNI) Withdrawal|"Every randomized patient in this group received~Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone~Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day~Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day"
3038414|NCT00371826|Experimental|Steroid Withdrawal|"Every randomized patient in this group received~Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day~Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day~Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120.~Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol"
3038415|NCT00371826|Active Comparator|CNI+MPA+ Steroid|"Patients randomized to this group received:~Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36."
3038416|NCT00371839|Active Comparator|Mild Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 20-39 decibels hearing level (dBHL)
3038417|NCT00371839|Active Comparator|Moderate Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz of 40-49 decibels hearing level (dBHL)
3038418|NCT00371839|Active Comparator|Moderate-Severe Hearing Loss|Audiological Evaluation will show average hearing threshold at 500, 1000, 2000, and 4000 Hz greater than 50 decibels hearing level (dBHL)
3038419|NCT00371865|Active Comparator|Cognitive Behavioral Therapy|8 group-administered sessions of Cognitive-Behavioral Therapy
3038420|NCT00371865|Experimental|Acceptance-Based Therapy|8 group-administered sessions of Acceptance-based therapy
3038421|NCT00372060|Experimental|1|MK0431 + pioglitazone
3038422|NCT00372060|Placebo Comparator|2|Placebo/MK0431 + pioglitazone
3038423|NCT00372112|Active Comparator|100 mcg GW642444H|Twice daily in the morning.
3038424|NCT00372112|Active Comparator|400 mcg GW642444H|Twice daily in the morning.
3038425|NCT00372112|Active Comparator|50 mcg salmeterol|Twice daily.
3038426|NCT00372112|Placebo Comparator|placebo|Twice daily
3038427|NCT00372190|Experimental|Mesh surgery|Trocar guided tension free vaginal mesh insertion by Prolift mesh kit
3038428|NCT00372190|Active Comparator|Conventional vaginal surgery|Classical vaginal prolapse surgery (fascia plication)
3320828|NCT02014077|Active Comparator|VATS|patients selected for VATS after failure of first thoracostomy tube drainage of traumatic haemothorax will undergo a Video-Assisted Thoracoscopic clearance of the persistent/retained haemothorax
3038431|NCT00372255|Experimental|Influsplit SSW® 2005/2006 6-9 years Group|Subjects aged 6 to 9 years who received 2 doses of Influsplit SSW® 2005/2006 vaccine at an interval of 4 weeks (Day 0 and Day 28 ± 2).
3038432|NCT00372255|Active Comparator|Influsplit SSW® 2005/2006 10-13 years Group|Subjects aged 10 to 13 years who received 1 dose of Influsplit SSW® 2005/2006 vaccine at Day 0.
3038433|NCT00372385|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3038434|NCT00372385|Experimental|Telaprevir 12 Week +Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet orally thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks.
3038435|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 12 weeks.
3038436|NCT00372385|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a 12 Week|Single loading dose of telaprevir 1250 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 12 weeks.
3038437|NCT00372411|Experimental|Arm 1|Robot-Assisted Therapy - MIT-MANUS System
3038438|NCT00372411|Active Comparator|Arm 2|Intensive Comparison Therapy
3038439|NCT00372411|Other|Arm 3|Usual Care
3038440|NCT00372424|Experimental|1|Combination of SU011248 (37.5 mg once daily [Schedule 2/1]) with docetaxel (75 mg/m2 every 3 weeks) and trastuzumab (therapeutic dose)
3038441|NCT00372489|Experimental|Peginesatide|
3038442|NCT00372528|Experimental|pregabalin|open label treatment
3038443|NCT00372567|Experimental|A|
3038444|NCT00372567|Active Comparator|B|
3038445|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Pts w/out Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
3038446|NCT00372593|Experimental|Arm B: Experimental - with GMTZ, AML Pts w/out Down Syndrome|Pts receive IT ARA-C at diagnosis or on day 1 of treatment or twice a week for up to six doses. They also receive an infusion of ARA-C on days 1-10; a 6-hr infusion of daunorubicin on days 1, 3, & 5; a 4-hr infusion of etoposide on days 1-5; and a 2-hr infusion of GMTZ - gemtuzumab ozogamicin (Mylotarg) on day 6. After 3 wks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5. After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5. After 3 wks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hr infusion of mitoxantrone hydrochloride on days 3-6. They also receive a 2-hr infusion of gemtuzumab on day 7. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9.
3038447|NCT00372593|Active Comparator|Arm A: Standard Arm - No GMTZ, AML Patients with Down Syndrome|"Patients receive intrathecal (IT) cytarabine (ARA-C) at diagnosis or on day 1 of treatment or twice a week for up to 6 doses. They also receive an infusion of ARA-C on days 1-10; a 6-hour infusion of daunorubicin hydrochloride on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, patients receive IT ARA-C on day 1. They also receive an infusion of ARA-C on days 1-8; a 6-hr infusion of daunorubicin on days 1, 3, and 5; and a 4-hr infusion of etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1 and 1-hr infusions of ARA-C and etoposide on days 1-5.~After 3 weeks of rest, some patients receive IT ARA-C on day 1; a 2-hr infusion of ARA-C on days 1-4; and a 1-hour infusion of mitoxantrone on days 3-6. After 3 weeks of rest, they receive a 3-hr infusion of ARA-C on days 1, 2, 8, and 9 and an injection of asparaginase on days 2 and 9."
3038448|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in ALL patients.|Clofarabine 40 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038449|NCT00372619|Experimental|Clofarabine 40 mg/m² to assess feasibility in AML patients.|Clofarabine 40 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 40 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 40 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038450|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in ALL patients.|Clofarabine 52 mg/m² to assess feasibility in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038451|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in ALL patients.|Clofarabine 52 mg/m² to assess efficacy in ALL patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038452|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess feasibility in AML patients.|Clofarabine 52 mg/m² to assess feasibility in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038453|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy in AML patients|Clofarabine 52 mg/m² to assess efficacy in AML patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038454|NCT00372619|Experimental|Clofarabine 52 mg/m² to assess efficacy - ambiguous lineage pt|Clofarabine 52 mg/m² to assess efficacy in acute leukemia of ambiguous lineage patients. Patients receive Cycle 1 (14-42 days) Cytarabine IT (aged based dosage 1-1.99 30 mg, 2-2.99 50 mg, ≥ 3 years 70 mg on Day 0, Clofarabine IV (dosage 52 mg/m2/dose) on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Cycle 2 (14-42 days) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5. Maintenance cycles 1-10 (14-42 days each) Methotrexate IT (age based dosage 1-1.99 8 mg, 2-2.99 10 mg, ≥ 3 12 mg) on day 1, Clofarabine IV 52 mg/m2/dose on days 1-5, and High Dose Cytarabine IV 1000 mg/m2/dose on days 1-5.
3038455|NCT00372697|Experimental|Octreotide 30 mg every 21 days|Patients received octreotide 30 mg every 21 days intramuscularly (im) for 6 months, a total of 8 doses. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
3038456|NCT00372697|Experimental|Octreotide 60 mg every 28 days|Patients received octreotide 60 mg every 28 days intramuscularly (im) for 6 months, a total of 6 doses. Octreotide mg was administered as two 30 mg injections. At each study visit, octreotide was administered only after completion of all scheduled efficacy and safety evaluations for that visit. Octreotide was injected im into the right or left gluteal regions. The injections were initially administered by a trained and authorized member of the investigational team. When no study visit at the investigational site was required, the injections were given by a trained nurse or the family doctor.
3038457|NCT00372775|Experimental|Sunitinib|
3038458|NCT00372905|Experimental|bortezomib, Ibritumomab tiuxetan, rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
3320829|NCT02014090|Active Comparator|half supine bicycle Exercise|60 minutes of half supine bicycle exercise with submaximal workload
3038459|NCT00372957|Placebo Comparator|Placebo|Participants received two capsules of matching placebo orally once daily in the morning with 150 milliliter (mL) of water at least 15 minutes prior to breakfast for 7 Days.
3038460|NCT00372957|Experimental|GW823093C 15 mg|Participants received one 15 milligrams (mg) of GW823093C capsule and one placebo capsule orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
3038461|NCT00372957|Experimental|GW823093C 30 mg|Participants received 30 mg (2x15 mg) of GW823093C capsules orally once daily in the morning with 150 mL of water at least 15 minutes prior to breakfast for 7 Days.
3038462|NCT00372970|Active Comparator|Botulinum Toxin A|200 U of Botox injected endoscopically into pylorus
3038463|NCT00372970|Placebo Comparator|Placebo|saline into pylorus.
3038464|NCT00372996|Experimental|1|CP-751,871 + exemestane Treatment until progression or toxicity
3038465|NCT00372996|Active Comparator|2|
3038466|NCT00373113|Active Comparator|A|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
3038467|NCT00373113|Experimental|B|37.5 mg daily, continuous dosing
3038468|NCT00373256|Experimental|A|
3038469|NCT00373256|Active Comparator|B|
3038470|NCT00373269||Diabetic subject|Subjects with acute stroke, hyperglycemia and history of diabetes.
3038471|NCT00373269||Normoglycemic Control|Subjects with acute stroke and normal blood glucose.
3038472|NCT00373295|Experimental|Baclofen 60 mg, Placebo, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038473|NCT00373295|Experimental|Baclofen 90 mg, Placebo, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038474|NCT00373295|Experimental|Baclofen 60 mg, Baclofen 90 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038475|NCT00373295|Experimental|Baclofen 90 mg, Baclofen 60 mg, Placebo|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038476|NCT00373295|Experimental|Placebo, Baclofen 90 mg, Baclofen 60 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038477|NCT00373295|Experimental|Placebo, Baclofen 60 mg, Baclofen 90 mg|"Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3038478|NCT00373334|Experimental|1|
3038479|NCT00373334|Experimental|2|
3038480|NCT00373334|Sham Comparator|3|
3038481|NCT00373360|Experimental|1|
3038482|NCT00373386|Experimental|Growth Hormone|Growth hormone treatment 0.3 mg/kg/min
3038483|NCT00373399|Placebo Comparator|Inactive Marijuana (0, 1.8, or 3.9% THC)|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Inactive marijuana (0% THC) served as a placebo comparator. Participants received an inactive marijuana cigarette (0% THC; provided by NIDA) in 1 of the 3 outpatient sessions in randomized order.
3038484|NCT00373399|Experimental|Active Marijuana|In this randomized, placebo-controlled study, every participant received all 3 treatment interventions in randomized order. Participants received active marijuana cigarettes (1.8, or 3.9% THC; provided by NIDA) over 2 of 3 outpatient sessions in randomized order.
3038485|NCT00373425|Experimental|Erlotinib|Participants received 150 mg/day erlotinib orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
3038486|NCT00373425|Placebo Comparator|Placebo|Participants received matching placebo tablets orally for 2 years or until relapse, death, participant request or investigator decision to discontinue study drug, or intolerable toxicity.
3038487|NCT00373490|Experimental|Vorinostat 600 mg|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
3038488|NCT00373490|Experimental|Vorinostat 400 mg|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
3038489|NCT00373529|Experimental|Clofarabine|Participants received an induction cycle of clofarabine 30 mg/m^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m^2/day intravenous infusion for 5 consecutive days.
3038490|NCT00373685|Experimental|Celecoxib|dosing as per USPI label
3038491|NCT00373685|Active Comparator|NSAIDs|
3038492|NCT00373698|Experimental|Three Component Model|Three Component Model of Collaborative Care: Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
3320830|NCT02014090|Active Comparator|ECP|90 minutes of ECP
3038493|NCT00373698|No Intervention|Usual Care|"Patients randomized to Usual Care will receive care as usual by VA clinicians."
3038494|NCT00373880|Experimental|Aripiprazole (15mg) + Cocaine|Aripiprazole (15 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg).
3038495|NCT00373880|Placebo Comparator|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a smoked cocaine dose-response curve (0, 12, 25, 50 mg)
3038496|NCT00373958|Experimental|13vPnC vaccine|
3038497|NCT00373958|Active Comparator|7vPnC vaccine|
3038498|NCT00374088|Placebo Comparator|Placebo|These patients receive a placebo infusion of D5W prior to and after surgery
3038499|NCT00374088|Experimental|N-Acetylcysteine|These patients receive a loading dose of N-Acetylcysteine 100 mg/kg in D5W IV 1 hour prior to surgery. They receive a maintenance infusion of N-Acetylcysteine 10 mg/kg/hr in D5W IV for 24 hours after surgery.
3038500|NCT00374127|Experimental|marijuana blunt|marijuana blunt (0%, 1.8%, or 3.6% THC)
3038501|NCT00374127|Experimental|marijuana cigarette|marijuana cigarette (0%, 1.8%, or 3.6% THC)
3038502|NCT00374140|Experimental|RAD001 (Everolimus)|RAD001 (Everolimus)10 mg by mouth daily without interruption
3038503|NCT00374231|Experimental|Immunosuppression|All the patients who enroll in this study will receive the same medications (tacrolimus, mycophenolate mofetil, and a short course of steroids) to prevent rejection of the liver transplant. All participants will be gradually taken off prednisone if they are 90 days or longer post liver transplant and have not had a rejection in the last 30 days.
3038504|NCT00374244|Placebo Comparator|1|placebo pimozide
3038505|NCT00374244|Active Comparator|2|active pimozide
3038506|NCT00374322|Placebo Comparator|Placebo|6 tablets daily for 12 months
3038507|NCT00374322|Experimental|Lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
3038508|NCT00374335|Other|infants with cutaneous hemangiomas|
3038509|NCT00374452|Experimental|ATHENA-CDS-HTN plus Guideline Link|ATHENA-CDS-HTN plus Guideline Link. ATHENA-CDS-HTN display on the cover sheet of electronic health record, plus link to the guidelines
3038510|NCT00374452|Other|Guideline Link Only|Guideline Link Only. Link to The Seventh Report of the Joint National Committee on Prevention Detection and Treatment of High Blood Pressure (JNC7) and to VA-Department of Defense (DoD) hypertension guidelines
3038511|NCT00374556|Experimental|Eszopiclone|Eszopiclone 3mg capsules, once daily at bedtime for 12 weeks
3038512|NCT00374556|Placebo Comparator|Placebo|3mg placebo capsule, once daily at bedtime for 12 weeks
3038513|NCT00374803|Experimental|Mycophenolic Acid (Myfortic) Preload|Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
3038514|NCT00374803|Active Comparator|Mycophenolic Acid (Myfortic) Standard|Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day).
3038515|NCT00374842|Experimental|GSK1247446A Formulation 1 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a full dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3038516|NCT00374842|Experimental|GSK1247446A Formulation 2 Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the GSK1247446A vaccine adjuvanted with a half dose of adjuvant at Day 0. The adjuvanted GSK1247446A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3038517|NCT00374842|Active Comparator|Fluarix Group|Subjects aged 18 - 59 years at the time of enrolment received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3038518|NCT00374868|Experimental|Pemetrexed + Cisplatin|
3038519|NCT00374907|Experimental|Saxagliptin (A)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
3038520|NCT00374907|Placebo Comparator|Placebo (ST) / Metformin (LT) (B)|Metformin 500-1500 mg (open-label, as needed for rescue in LT)
3038521|NCT00375167|Experimental|Recovery Workbook Intervention|12-week Recovery Intervention: The intervention is a 12-week group-based intervention. The intervention is informed by the Recovery Workbook- a validated intervention for people with serious mental illness. The intervention includes 2 hour sessions for 12 weeks that focus on the following areas: Introduction to the intervention; Recovery; Knowledge and Control; Managing life stress; Enhancing personal meaning; Building personal support; and Setting personal goals. The total time period of the intervention is 24 hours. Participants in this arm also receive treatment as usual.
3038522|NCT00375167|No Intervention|Treatment as usual|The participants in the control arm will continue to receive treatment as usual. TAU is Assertive Community Treatment. Assertive Community Treatments are structured to meet set fidelity standards that are evidence-based. This arm did not receive any intervention.
3038523|NCT00375219|Experimental|omacetaxine|Treatment was the same for all cohorts: induction therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 14 consecutive days every 28 (±3) days for up to 6 cycles. Maintenance therapy was subcutaneous (SC) administration of omacetaxine at 1.25 mg/m^2 twice a day (BID), administered for 7 consecutive days every 28 (±3) days for up to 3 years.
3038524|NCT00375427|Experimental|Every 3 months|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
3038525|NCT00375427|Experimental|Every 4 weeks|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.
3038526|NCT00375492|Experimental|Group A|
3038527|NCT00375492|Placebo Comparator|Group B|
3038528|NCT00375505|Experimental|Zometa|Zoledronic acid 4mg as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
3038529|NCT00375505|Placebo Comparator|Placebo|Placebo as a 15-minute infusion every 3 months for a treatment period of 24 months (total of 8 infusions).
3038530|NCT00375518|Active Comparator|1|Atorvastatin
3038531|NCT00375518|Placebo Comparator|2|placebo
3038532|NCT00375609|Experimental|Betrixaban 15 mg|Betrixaban 15 mg oral twice daily for 10 to 14 days
3038533|NCT00375609|Experimental|Betrixaban 40 mg|Betrixaban 40 mg oral twice daily for 10 to 14 days
3038534|NCT00375609|Experimental|Enoxaparin|Enoxaparin 30 mg administered subcutaneously every 12 hours for 10 to 14 days
3038535|NCT00375674|Experimental|A|
3038536|NCT00375674|Placebo Comparator|B|
3038537|NCT00375713|Experimental|Levocetirizine|Levocetirizine + Cetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
3038538|NCT00375713|Active Comparator|Cetirizine|Cetirizine + Levocetirizine-Placebo + Standard Topical Steroid (1% hydrocortisone) Ointment for 14 days
3038539|NCT00375752|Active Comparator|Letrozole|Letrozole 2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvent treatment
3038540|NCT00375752|Experimental|Zolendronic Acid + Letrozole|2.5 mg/day oral letrozole for approximately 6.5 months neoadjuvant treatment plus zoledronic acid 4 mg i.v. q4w
3038541|NCT00375830|Experimental|Cohort 1 Pilot-WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Preliminary pilot assessment to confirm feasibility & improved diagnostic accuracy of the combined 18F-NaF CT & 18F-FDG PET scan procedures, as compared to the regular medical care procedure, 99mTc MDP bone scans.
3038542|NCT00375830|Experimental|Cohort 2 WB-MRI & Combined 18F-NaF-CT/18F-FDG-PET scans|Assessment to define the accuracy of the combined 18F-NaF CT & 18F-FDG PET/CT scan procedures compared to 99mTc MDP bone scan.
3038543|NCT00375830|Experimental|Cohort 3 Combined 18F-NaF / 18F-FDG PET/WB-MRI scan|Assessment to define the utility of 18F-NaF & 18F-FDG as the radiolabels in a single combined PET / WB-MRI procedure.
3038544|NCT00375934|Experimental|1|
3038545|NCT00375934|Placebo Comparator|2|
3038546|NCT00375973|Experimental|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
3038547|NCT00375973|Placebo Comparator|Placebo|Placebo comparator to Duloxetine
3038548|NCT00375999|Experimental|docetaxel and epirubicin|salvage docetaxel and epirubicin
3038549|NCT00376168|Experimental|prGCD 30 Units/kg|
3038550|NCT00376168|Experimental|prGCD 60 Units/kg|
3038551|NCT00376220|Experimental|1|"Drug: Riluzole Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.~Other Names:~• Rilutek"
3038552|NCT00376220|Placebo Comparator|2|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
3038553|NCT00376246|Other|Group 1|1st group will receive Ezetimibe for 2 weeks followed by washout (no medication) period for 4 weeks and followed by placebo for 2 weeks.
3038554|NCT00376246|Other|Group 2|2nd group will receive Ezetimibe and placebo in reverse order with interspaced 4-week washout period.
3038555|NCT00376259|Experimental|Combination therapy|Combination therapy: 600 mg of telbivudine (LdT) by mouth plus 10 mg of adefovir (ADV) by mouth once daily for 96 weeks.
3038556|NCT00376259|Active Comparator|Adefovir monotherapy|Adefovir monotherapy: 10 mg of adefovir by mouth once daily for 96 weeks.
3038557|NCT00376363|Active Comparator|Ahmed implant,1|Ahmed glaucoma drainage implant for intraocular pressure control
3038558|NCT00376363|Active Comparator|Baerveldt implant|Baerveldt glaucoma drainage implant for intraocular pressure control
3038559|NCT00376506|Experimental|Implanted Device|Implanted intramuscular neurostimulator device
3038560|NCT00376506|Active Comparator|External Device|External vibrotactile device
3038561|NCT00376532||ICD pacing or shock event|Subjects who experienced a device treatment, defined as a pacing event or a shock event
3038562|NCT00376532||No ICD pacing or shock event|Subjects who did not experience a treatment defined as a pacing event or a shock event
3038563|NCT00376558|Active Comparator|Contingency Management w/ CRA|Cocaine users: Contingency management w/ Community Reinforcement Approach
3038564|NCT00376558|No Intervention|Healthy Control|A group of healthy matched comparison subjects with no DSM-IV axis I Disorder was included; they were matched for cigarette smoking, gender, and ethnicity.
3038565|NCT00376597|Experimental|Arm I (lymphedema education)|Six weeks after surgery, patients receive a brief initial post-operative care session describing lymphedema risk and prevention through oral instruction and written materials. Patients complete physical assessments and questionnaires at 6 weeks and at 6, 12, and 18 months. Patients are also contacted by telephone at 9 and 15 months.
3038566|NCT00376597|Experimental|Arm II (lymphedema education, physical therapy)|Description Patients receive lymphedema education and complete physical assessments and questionnaires as in Arm I. Patients also complete a personalized physical therapy intervention, receive a refrigerator magnet, and a 15-minute video that reinforces information and exercises.
3038567|NCT00376675|Experimental|Arm I|Patients receive oral methylphenidate hydrochloride daily on days 1-28.
3038568|NCT00376675|Placebo Comparator|Arm II|Patients receive oral placebo daily on days 1-28.
3038569|NCT00376688|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3038570|NCT00376805|Experimental|All Treated Patients|All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.
3038571|NCT00376935|Placebo Comparator|1|Participants will receive palifermin placebo injection on Days 1, 2, and 3
3038572|NCT00376935|Experimental|2|Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
3038573|NCT00376935|Experimental|3|Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
3038574|NCT00376935|Experimental|4|Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
3038575|NCT00376948|Experimental|Novasoy®, Gemcitabine & Erlotinib|Novasoy® 396 mg (177 mg of Isoflavones) twice-daily starting daay -7 until day 28; Gemcitabine 1000 mg/m2 days 1, 8, & 15; Erlotinib 150 mg day 1 until day 28
3038576|NCT00376961|Experimental|R-CHOP + Velcade|6 21-day cycles of standard R-CHOP with 1.3 mg/m^2 Bortezomib given on days 1 and 4 of each cycle. This is followed by 8 3-month cycles of maintenance with 1.3 mg/m^2 Bortezomib on days 1, 4, 8 and 11 of each cycle.
3038577|NCT00377156|Active Comparator|Arm I|Patients undergo stereotactic radiosurgery (SRS)
3038578|NCT00377156|Experimental|Arm II|Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.
3038579|NCT00377234|Experimental|1|
3038580|NCT00377234|Active Comparator|2|
3038581|NCT00377260|Experimental|Amoxicillin-clavulanate|Reconstituted amoxicillin-clavulanate at 90/6.4 mg/kg/day in 2 divided doses for 10 days.
3038582|NCT00377260|Placebo Comparator|Placebo|Reconstituted placebo in 2 divided doses for 10 days.
3038583|NCT00377299|Experimental|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
3038584|NCT00377299|Placebo Comparator|Placebo|Placebo matching active medication.
3038585|NCT00377312|Experimental|Group 1|Parathyroid Hormone (PTH) (1-34) 2 picomols/kg/hr for one week.
3038586|NCT00377312|Experimental|Group 2|Parathyroid Hormone (PTH) (1-34)4 picomols/kg/hr for one week.
3038587|NCT00377364|Experimental|Acetaminophen|Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days.
3038588|NCT00377364|Placebo Comparator|Placebo|Participants will be given an identical appearing placebo (two 500 mg tablets) four times daily for 7 days.
3038589|NCT00377403|Experimental|Intervention Arm|Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
3038590|NCT00377403|Placebo Comparator|Symptomatic treatments only|Placebo for 10 days in addition to symptomatic treatments
3038591|NCT00377429|Experimental|catumaxomab|
3038592|NCT00377520|Experimental|Pemetrexed|
3038593|NCT00377572|Experimental|Omalizumab (Xolair) + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
3038594|NCT00377572|Placebo Comparator|Placebo + Conventional Therapy|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 60 weeks to participants classified as having moderate to severe asthma. Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP-II, 2002) guidelines, under the management of an asthma specialist health care provider.
3038595|NCT00377611|Experimental|FLUARIX 50-64 YEARS GROUP|Adult subjects aged between and including 50-64 years who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
3038596|NCT00377611|Experimental|FLUARIX 65+ YEARS GROUP|Elderly subjects aged 65 and over who received a single dose of Fluarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm, were enrolled for investigation of influenza and influenza-related complications.
3038597|NCT00377637|Experimental|Induction Phase: Mycophenolate mofetil|Participants received oral mycophenolate mofetil (MMF) 1.5 g twice a day and concomitant corticosteroids for the 24 weeks of the Induction Phase.
3038598|NCT00377637|Active Comparator|Induction Phase: Cyclophosphamide|Participants received monthly infusions of cyclophosphamide, 0.5 to 1.0 g per square meter of body surface area and concomitant treatment with corticosteroids for the 24 week Induction Phase.
3038599|NCT00377637|Experimental|Maintenance Phase: Mycophenolate mofetil|Participants received mycophenolate mofetil (MMF) 1.0 g orally twice a day, placebo to azathioprine orally once a day and corticosteroid for the 36 weeks Maintenance Phase.
3038600|NCT00377637|Active Comparator|Maintenance Phase: Azathioprine|Participants received azathioprine (AZA) 2 mg/kg/day orally once a day, placebo to mycophenolate mofetil orally twice a day and corticosteroid for the 36 weeks Maintenance Phase.
3038601|NCT00377676|Experimental|Usual Diabetes Therapy plus placebo|Usual diabetes therapy plus placebo
3038602|NCT00377676|Experimental|Drug Cycloset|
3038603|NCT00377741|Experimental|1|
3038604|NCT00377819|Experimental|denosumab|
3038605|NCT00377819|Active Comparator|alendronate|
3038606|NCT00377832|No Intervention|1|
3038607|NCT00377832|Active Comparator|2|Acetaminophen 975 mg once
3038608|NCT00377858|Experimental|Insulin Lispro Mid Mixture|Insulin lispro mid mixture (MM) up to three times a day (TID)
3038609|NCT00377858|Active Comparator|Insulin Glargine|Insulin glargine daily with insulin lispro at mealtime (up to 3 injections) as needed.
3038610|NCT00377962|Experimental|Everolimus + CNI reduction|Everolimus (3-8 ng/mL) + CNI reduction ± MPA/AZA ± steroids. Everolimus 0.75-1.5 mg twice daily. Dose adjusted to target blood concentration in the range 3-8 ng/mL. CNI reduction (reduced 50-70%): target of achieving a cyclosporine A (CsA) trough level < 75 ng/mL or a tacrolimus trough level < 4 ng/mL. MPA was reduced by 25%,upon CNI reduction. If participants were treated with AZA ( alternative to MPA) no dose reduction was needed. Steroid treatment was according to local practice.
3038611|NCT00377962|Active Comparator|Control|CNI ± MPA/AZA ± steroids. In the standard CNI arm, all immunosuppressants including mycophenolic acid (MPA) and azathioprine (AZA) continued unchanged as per local practice. Steroid treatment was according to local practice.
3038612|NCT00378014|Experimental|Everolimus|Basiliximab plus everolimus-based immunosuppressive regimen following the reduction and cessation of initial CNI regimen plus optional steroids according to local best practice
3468751|NCT03892772|Active Comparator|SAS0421a and SAS0421b|Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.
3038613|NCT00378014|Active Comparator|Calcineurin Inhibitor (CNI)|Basiliximab plus CNI-based immunosuppressive regimen according to local best practice plus optional steroids according to local best practice
3038614|NCT00378079|Experimental|3|
3038615|NCT00378079|Active Comparator|1|
3038616|NCT00378079|Experimental|2|
3038617|NCT00378105|Experimental|lenalidomide, dexamethasone, bortezomib combination|In this study each cycle will be 21 days and participants will begin the study medication in the clinic on Cycle 1 Day 1. Lenalidomide (capsules) will be taken daily for the first 2 weeks only (Day 1-14). Dexamethasone (tablets) will be taken on Day 1, 2, 4, 5, 8, 9, 11 and 12. Bortezomib will be given intravenously in the outpatient treatment clinic on Day 1, 4, 8 and 11. The third week is a rest period and no study medication will be given.
3038618|NCT00378209|Experimental|lenalidomide, dexamethasone, bortezomib combination|Participants took the study medication in the clinic on Cycle 1 day 1. Each treatment cycle lasted three weeks. They took the lenalidomide (capsules) every day for the first two weeks only (days 1-14). They took the dexamethasone (tablets) on Day 1, 2, 4, 5, 8, 9, 11 and 12 and came to the outpatient treatment center for intravenous bortezomib on Day 1, 4, 8 and 11. The third week of the cycle was a rest period and the participant did not take any study medication.
3038619|NCT00378326|Experimental|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
3038620|NCT00378352|Placebo Comparator|Dose Escalation Safety|The objective of the first phase is to evaluate the safety of escalating doses of Epoetin alfa in patients with STEMIs.
3038621|NCT00378352|Placebo Comparator|Single Dose Efficacy|Single parenteral administration of 60000 U of epoetin alfa. The objectives of the second phase are to investigate the effects of the highest safe dose on infarct size, left ventricular remodeling and endothelial progenitor cells.
3038622|NCT00378378|Experimental|MFNS 100 mcg QD for subjects 6 to less than 12 years|Mometasone Furoate nasal Spray (MFNS) 100 mcg once per day (QD) for subjects 6 to less than 12 years of age
3038623|NCT00378378|Placebo Comparator|Placebo QD for subjects 6 to less than 12 years|
3038624|NCT00378378|Experimental|MFNS 200 mcg QD for subjects 12 to less than 18 years|
3038625|NCT00378378|Experimental|MFNS 200 mcg BID for subjects 12 to less than 18 years|
3038626|NCT00378378|Placebo Comparator|Placebo QD for subjects 12 to less than 18 years|
3038627|NCT00378378|Experimental|MFNS 100 mcg BID for subjects 6 to less than 12 years|
3038628|NCT00378378|Placebo Comparator|Placebo BID for subjects 6 to less than 12 years|
3038629|NCT00378378|Placebo Comparator|Placebo BID for subjects 12 to less than 18 years|
3038630|NCT00378482|Experimental|1|Drug: CP-675,206 (Tremelimumab)
3038631|NCT00378508|Experimental|1|The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2 over a 14 day treatment period.
3038632|NCT00378508|Placebo Comparator|2|Normal saline infusion
3038633|NCT00378534|Experimental|T Cell Depletion Transplant Participants|Participants with hematological malignancies received a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90.
3038634|NCT00378534|Other|Stem Cell Donors|An HLA 6/6 identical family member will be co-enrolled into this study as a stem cell donor. The stem cell collection aspect of this protocol is not investigational.
3038635|NCT00378560|Placebo Comparator|1|Placebo
3038636|NCT00378560|Experimental|2|Vaccine
3038637|NCT00378573|Experimental|docetaxel, gemcitabine and bevacizumab|Single arm treatment with docetaxel, gemcitabine and bevacizumab
3038638|NCT00378599|Experimental|PEG-Intron plus Rebetol (RBV)|PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was >10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing <65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing >85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).
3038639|NCT00378703|Active Comparator|Arm A (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15.
3038640|NCT00378703|Experimental|Arm B (bevacizumab and temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and bevacizumab as in Arm A.
3038641|NCT00378703|Experimental|Arm C (bevacizumab and sorafenib tosylate)|Patients receive bevacizumab as in Arm A and sorafenib tosylate PO BID on days 1-5, 8-12, 15-19, and 22-26.
3038642|NCT00378703|Experimental|Arm D (sorafenib tosylate and temsirolimus)|Patients receive sorafenib tosylate PO BID on days 1-28 and temsirolimus as in Arm B.
3038643|NCT00378898|Active Comparator|EGD with proximal BRAVO capsule|Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
3038644|NCT00378898|Sham Comparator|EGD with sham BRAVO capsule placement|Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
3038645|NCT00379080|Experimental|Arm I - Feasibility|"Patients receive oral tandutinib twice daily for 7 days. Patients then undergo biopsy or surgery to remove the tumor. Within 2 weeks after biopsy or surgery, patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~conventional surgery~oral tandutinib~Pharmacological study~Tissue samples"
3038646|NCT00379080|Experimental|Arm 2 - Dose Escalation (Phase 1)|"Phase I: Patients receive oral tandutinib twice daily* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tandutinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.~the starting dose for tandtinib is 500mg BID~oral tandutinib~Pharmacological study~Tissue samples"
3038647|NCT00379080|Experimental|Arm 3 - Phase 2|"Patients receive tandutinib as in phase I at the MTD determined in phase I.~600mg was the determined MTD in Dose Escalation~oral tandutinib~Pharmacological study~Tissue samples"
3038648|NCT00379145|Experimental|Trabectedin|Trabectedin IV over 24 hours every 3 weeks
3038649|NCT00379197|Experimental|Naltrexone|Naltrexone 50 mg will be taken orally once a day every day of a 28 day treatment course (cycle 1) and continue for another identical 28 day treatment (cycle 2) . PET scan will be performed after cycle 1 and cycle 2 complete.
3038650|NCT00379210|Experimental|1|"Meditation training group-- received Mindfulness Based Stress Management from the Penn Program for Stress Management.~The meditation practice initially emphasized attention to a single focus. For most concentrative exercises, this focus was the breath. The sensations of breathing were to be examined closely, and when attention wandered it was to be redirected back to the breath. In other exercises, the focus of attention was to be directed to sensations within specific body parts (body scan exercise) and sensations of walking (walking meditation). During the 5th week of classes, the mindfulness training was expanded to include some explicit training in receptive attention."
3038651|NCT00379210|Active Comparator|2|"Nutrition education group~An active comparison condition involving nutrition education was offered. This course matched the mindfulness course in all dimensions including course duration, homework, psychosocial support, and teacher expertise. The course was taught by a nurse who had expertise in nutrition and offered a program described in the book, Nutrition for Life by Lisa Hark."
3038652|NCT00379236|Experimental|EUFLEXXA™ Double-blind|Each subject received 3 single-dose injections of EUFLEXXA™ into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
3038653|NCT00379236|Placebo Comparator|Placebo Double-blind|Each subject received 3 single-dose injections of placebo into the target knee; one injection per week at weeks 0, 1 and 2. Patients were followed for 26 weeks following the first injection.
3038654|NCT00379236|Experimental|EUFLEXXA™ Open Label|All patients who participated in the 26 week double-blind study (including participants randomized to the placebo treatment group) and elected to participate in the open label extension, received three injections of EUFLEXXA™ in the target knee. Injections were given once a week on weeks 26, 27 and 28.
3038655|NCT00379288|Experimental|MF/F 200/10 mcg BID|
3038656|NCT00379288|Experimental|MF/F 400/10 mcg BID|
3038657|NCT00379288|Active Comparator|F/SC 250/50 mcg BID|
3038658|NCT00379288|Active Comparator|F/SC 500/50 mcg BID|
3038659|NCT00379340|Experimental|Stage IV and rapid complete response (RCR) of lung metastases|Stage IV and rapid complete response (RCR) of lung metastases continuously treated with DD4A after 6 weeks of DD4A
3038660|NCT00379340|Experimental|Stage IV and slow incomplete response (SIR) of lung metastases|Stage IV and slow incomplete response (SIR) of lung metastases treated with Regimen M after 6 weeks of DD4A
3038661|NCT00379340|Other|Stage III/IV with LOH 1p and 16q treated with Regimen M|Stage III/IV with LOH 1p and 16q treated with Regimen M
3038662|NCT00379340|Other|Stage IV with non-lung disease treated with Regimen M|Stage IV with non-lung disease treated with Regimen M
3038663|NCT00379340|Other|Stage IV with lung metastases|Stage IV with lung metastases treated with DD4A for less than 6 weeks and/or response inevaluable at week 6
3038664|NCT00379353|Active Comparator|Group 1: Thalidomide|100 mg capsules orally, once a day for 14 days
3038665|NCT00379353|Placebo Comparator|Group 2: Placebo|Two placebo capsules orally, once a day for 14 days.
3038666|NCT00379574|Experimental|Bortezomib + CHOP every 2 weeks|Bortezomib + CHOP(Cycloophosphamide, vincristine, doxorubicin,and predinisolone) every 2 weeks
3038667|NCT00379639|Experimental|Romidepsin / Gemcitabine|Participants were to receive 7, 10 or 12 mg/m^2 of romidepsin intravenously on either Days 1, 8 and 15 (Schedule A) or Days 1 and 15 (Schedule B) of each 28-day cycle, followed by 800 or 1000 mg/m^2 of gemcitabine. Subsequent doses of both drugs were based on treatment-related toxicities. The planned duration of study therapy was 6 cycles or until disease progression occurred. Patients who responded could continue beyond 6 cycles until disease progression or until a withdrawal criterion was met.
3038668|NCT00379769|Experimental|rosiglitazone in addition to background metformin|Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3038669|NCT00379769|Experimental|rosiglitazone in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3038670|NCT00379769|Active Comparator|Sulfonylurea in addition to background metformin|Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3038671|NCT00379769|Active Comparator|Metformin in addition to background sulfonylurea|Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.
3038672|NCT00379795|Experimental|Ranibizumad 0.5 mg|Ranibizumab 0.5 mg intravitreal injection 0.5 mg in the study eye on an as needed basis no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Dosing interval was determined by the investigator, on the basis of clinical evaluations and judgment.
3038673|NCT00379808|Placebo Comparator|Placebo|1 lactose-containing capsule daily for 1 month
3038674|NCT00379808|Active Comparator|Montelukast 10 mg|1 montelukast 10 mg tablet (masked by capsule) daily for 1 month
3038675|NCT00379821|Experimental|CQ Monotherapy|N=160: treat with Chloroquine (CQ) alone.
3038676|NCT00379821|Experimental|CQ plus atovaquone proguanil|N=160: treat with CQ plus atovaquone proguanil.
3038677|NCT00379821|Experimental|CQ plus artesunate|N=160: treat with CQ plus artesunate.
3038678|NCT00379821|Experimental|CQ plus azithromycin|N=160: treat with CQ plus azithromycin.
3038679|NCT00379834|Active Comparator|Cosopt|Cosopt twice daily in both eyes
3038680|NCT00379899|Active Comparator|Control|Standard of care, without use of cinacalcet.
3038681|NCT00379912|Experimental|Investigational Arm A|Azacitidine + Erythropoietin
3038682|NCT00379912|Experimental|Investigational Arm B|Azacitidine
3038683|NCT00380029|Experimental|Erlotinib|erlotinib given before and after transurethral resection of a bladder tumor, TURBT
3038684|NCT00380068|Experimental|Ambrisentan|
3038685|NCT00380081|Experimental|placebo/zolpidem 3.5/zolpidem 1.75|
3038686|NCT00380081|Experimental|placebo/zolpidem 1.75/zolpidem 3.5|
3038687|NCT00380081|Experimental|zolpidem 3.5/placebo/zolpidem 1.75|
3038688|NCT00380081|Experimental|zolpidem 3.5/zolpidem 1.75/placebo|
3038689|NCT00380081|Experimental|zolpidem 1.75/placebo/zolpidem 3.5|
3038690|NCT00380081|Experimental|zolpidem 1.75/zolpidem 3.5/placebo|
3038691|NCT00380250|Experimental|Lubiprostone|8 mcg capsule twice daily (BID)
3038692|NCT00380250|Placebo Comparator|Placebo|Matching placebo capsule twice daily (BID)
3038693|NCT00380367|Experimental|Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)|Participants who enroll receive a total of 3 intramuscular injections of Quadrivalent HPV VLP vaccine (types 6, 11, 16, 18) given on Day 1, Month 2 and Month 6.
3038694|NCT00380393|Experimental|GSK257049 Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of GSK257049 vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
3038695|NCT00380393|Active Comparator|Rabipur Group|Male or female subjects between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine administered intramuscularly in the left deltoid muscle at Days 0, 30 and 60.
3038696|NCT00380588|Experimental|Gemcitabine + Cisplatin|"Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.~Cisplatin: 25 milligrams per square meter (mg/m2), intravenous (IV), day 1 and day 8 every 21 days x 16 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal."
3038697|NCT00380588|Experimental|Gemcitabine|Gemcitabine: 1000 milligrams per square meter (mg/m2), intravenous (IV), day 1,8 and 15 every 28 days x 12 maximum cycles or disease progression or unacceptable toxicity or patient withdrawal.
3038698|NCT00380692|Experimental|Atomoxetine|atomoxetine 0.5 mg/kg/day every day (QD), by mouth (PO) for 1 week, atomoxetine 0.8mg/kg/day QD, PO for 1 week, 1.2mg/kg/day QD, PO for 6 weeks then atomoxetine 0.5-1.2 mg/kg/day QD, PO for up to 20 weeks
3038699|NCT00380692|Placebo Comparator|Placebo|"placebo every day (QD), by mouth (PO) for 8 weeks~Then patients can take atomoxetine 0.5-1.2 mg/kg/day QD, PO up to 20 weeks"
3038700|NCT00380718|Experimental|Pemetrexed|
3038701|NCT00380744|Experimental|Part A LY2189102 0.1 mg/kg/wk|"Part A: 2 times (x) 0.1 milligrams/kilogram/week (mg/kg/wk) Loading dose, then 0.1 mg/kg/wk) X 4 weeks (wks), intravenous (IV)~Part B: 2 x 0.02 mg/kg/wk Loading dose, then 0.02 mg/kg/wk X 4 wks, IV"
3038702|NCT00380744|Experimental|Part A LY2189102 0.3 mg/kg/wk|"Part A: 2 x 0.3 mg/kg/wk Loading dose, then 0.3 mg/kg/wk X 4 wks, IV~Part B: 2 x 0.15 mg/kg/wk Loading dose, then 0.15 mg/kg/wk X 4 wks, IV"
3038703|NCT00380744|Experimental|Part A LY2189102 1.0 mg/kg/wk|"Part A: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV~Part B: 2 x 1.0 mg/kg/wk Loading dose, then 1.0 mg/kg/wk X 4 wks, IV"
3038704|NCT00380744|Experimental|Part A LY2189102 2.5 mg/kg/wk|"Part A: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV~Part B: 2 x 2.5 mg/kg/wk Loading dose, then 2.5 mg/kg/wk X 4 wks, IV"
3038705|NCT00380744|Placebo Comparator|Placebo|IV, once weekly x 4 wks
3038706|NCT00380861|Active Comparator|PFC Sigma RP-F|PFC® Sigma™ RP-F knee implant is a posterior stabilized cemented component cemented that is implanted with a standard posterior stabilized surgical technique.
3038707|NCT00380861|Active Comparator|PFC Sigma RP|P.F.C.® Sigma™ Rotating Platform (RP) Cruciate Retaining Knee System has a special insert that helps the knee move more like it did before the knee replacement.
3038708|NCT00380874|Experimental|1|flexible dosing
3038709|NCT00380874|Placebo Comparator|2|
3038710|NCT00380978|Active Comparator|early analgesia:combined-spinal epidural|
3038711|NCT00380978|Active Comparator|late analgesia (systemic)|
3038712|NCT00381004|Experimental|FCR + Sargramostim|Fludarabine + Cyclophosphamide + Rituximab (FCR) = Fludarabine - Course 1: 25 mg/m^2 IV Days 2-4; Course 2-6: 25 mg/m^2 IV Days 1-3. Cyclophosphamide - Course 1: 250 mg/m^2 intravenous (IV) Days 2-4; Course 2-6: 250 mg/m^2 Days 1-3. Rituximab - Course 1: 375 mg/m^2 IV over 2-6 hours Day 1; Course 2-6: 500 mg/m^2 IV Day 1. Sargramostim - Course 1: 250 mcg/m^2 subcutaneous (SQ) Days -1 and 5-11; Course 2-6: 250 mcg/m^2 SQ Days -1 and 4-10.
3038713|NCT00381043|Active Comparator|1- Acamprosate|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
3038714|NCT00381043|Placebo Comparator|2 - Sugar Pill - Placebo|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
3038715|NCT00381095|Experimental|1|flexible dosing
3038716|NCT00381095|Placebo Comparator|2|
3038717|NCT00381238|Experimental|rosiglitazone|Extended Release Tablets
3038718|NCT00381303|Experimental|001|darunavir 600mg bid for 48 wks,ritonavir 100mg bid for 48 wks
3038720|NCT00381485|Experimental|MF/F MDI 400/10 mcg BID|"Mometasone Furoate 400 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3038721|NCT00381485|Experimental|MF/F MDI 200/10 mcg BID|"Mometasone Furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3038722|NCT00381485|Active Comparator|MF MDI 400 mcg BID|"Mometasone Furoate 400 mcg taken twice daily~Participants received 2 to 3 weeks (approximately) of open-label, run-in medication with MF MDI 400 mcg BID prior to the 12-week double-blind treatment period"
3038723|NCT00381550|Experimental|Arm I|Patients receive 3-AP (Triapine®) IV over 4 hours followed by fludarabine phosphate IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3038724|NCT00381563|Other|Intervention to placebo|Participants will wear the patellofemoral realigning knee brace for 6 weeks, followed by the non-aligning knee brace for 6 weeks.
3038725|NCT00381563|Other|Placebo to intervetion|Participants will wear the non-aligning knee brace for 6 weeks, followed by the patellofemoral realigning knee brace for 6 weeks.
3038726|NCT00381615|Experimental|rMenB|"Infants received 4 doses of recombinant meningococcal serogroup B (rMenB) vaccine without outer membrane vesicle (OMV-NZ) at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of Diphtheria Tetanus Pertussis-Haemophilus influenzae type b-Inactivated Polio Vaccine (DTaP-Hib-IPV) (at 2, 3, and 4 months) and Heptavalent Pneumococcal Conjugate (PC7) (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and Measles Mumps Rubella (MMR) (at 13 months)."
3038727|NCT00381615|Experimental|rMenB+OMV|"Infants received 4 doses of rMenB vaccine with OMV-NZ at 2, 4, 6 and 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months)."
3038728|NCT00381615|Experimental|Routine|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine without OMV-NZ at 12 months of age."
3038729|NCT00381615|Experimental|Routine+OMV|"Infants received routine vaccines - 3 doses each of DTaP-Hib-IPV (at 2, 3, and 4 months) and PC7 (at 2, 4 and 13 months), 2 doses of MenC-CRM (at 3 and 5 months) and 1 dose each of MenC-Hib (at 12 months) and MMR (at 13 months).~Infants also received single dose of rMenB vaccine with OMV-NZ at 12 months of age."
3038730|NCT00381628||Stable subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro.
3038731|NCT00381628||Exacerbating subjects with CF|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) at the beginning and end of treatment for a pulmonary exacerbation. These cells will be studied in vitro.
3038732|NCT00381628||Stable subjects with asthma|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the disease control group.
3038733|NCT00381628||Healthy volunteers|These subjects will undergo epithelial cells and blood lymphocyte extraction. Nasal curettage will be performed to obtain nasal epithelial cells and blood will be obtained to isolate circulating lymphocytes one time from these subjects (age 15 years and above) when they are in their usual state of well-health. These cells will be studied in vitro. This is the control group
3038734|NCT00381641|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity
3038735|NCT00381680|Active Comparator|Regimen A: Standard vincristine dosing|See detailed description.
3038736|NCT00381680|Experimental|Arm B: Randomized High Dose Vincristine regimen|See detailed description. Closed to accrual as of 09/2010).
3038737|NCT00381706|Experimental|Arm A (ECF + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab IV on days 1, 8 and 15. Patients receive epirubicin 50 mg/m^2 IV after cetuximab on day 1 followed by cisplatin 60 mg/m^2 IV over 60 minutes. On days 1-21, patients receive 5-fluorouracil 200 mg/m^2/day continuous IV infusion. Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
3038738|NCT00381706|Experimental|Arm B (IC + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1, 8 and 15. Patients receive cisplatin 30 mg/m^2 IV over 30 minutes on days 1 and 8 after cetuximab. Patients also receive irinotecan 65 mg/m^2 IV over 90 minutes on days 1 and 8 after receiving cisplatin.Treatment repeats every 21 days in the absence of disease progression and unacceptable toxicity.
3038739|NCT00381706|Experimental|ARM C (FOLFOX + cetuximab)|Patients receive cetuximab 400 mg/m^2 IV over 120 minutes on day 1 of the first cycle, then 250 mg/m^2 IV over 60 minutes thereafter. Patients receive cetuximab on days 1 and 8. On Day 1, patients also receive oxaliplatin 85 mg/m^2 IV over 120 minutes and leucovorin 400 mg/m^2 IV over 120 minutes either concurrently with oxaliplatin via a separate infusion line or post oxaliplatin administration. Following leucovorin, patients will receive 5-fluorouracil 400 mg/m^2 IV bolus injection, then 5-fluorouracil 2400 mg/m^2 IV infusion over 46-48 hours. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3038740|NCT00381797|Experimental|Arm I|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and fludeoxyglucose F 18 positron emission tomography at baseline and periodically during treatment."
3038741|NCT00381810|Experimental|Rituximab 1000 mg|Participants will receive rituximab 1000 mg intravenously twice, 14 days apart at study entry and again 6 months later. Participants will also receive methylprednisolone 100 or 125 mg IV, acetaminophen 1000 mg orally, and diphenhydramine 50 mg orally prior to study drug infusion.
3038742|NCT00381849|Active Comparator|Cystone then sugar pill|Subject will take Cystone for 6 weeks, then have a 1 week wash out period followed by the sugar pill for another 6 weeks
3038743|NCT00381849|Placebo Comparator|Sugar pill then Cystone|Subject will take sugar pill for 6 weeks, then a 1 week wash out followed by the Cystone for another 6 weeks
3038744|NCT00381849|Experimental|Open-label Cystone|All subjects will receive Cystone for 46 weeks in the open-label period.
3038745|NCT00381862|Experimental|Aprepitant and Palonosetron|
3038746|NCT00381888|Experimental|Patients Treated with Fondaparinux|Patients treated with at least one dose of Fondaparinux (2.5 mg subcutaneous, Days 1-28 by mouth).
3038747|NCT00381940|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy)|"Patients receive ifosfamide IV continuously over days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, bortezomib IV on days 1, 4, and 8, and filgrastim (G-CSF) IV or subcutaneously beginning on day 6 and continuing until blood counts recover or PBSC are harvested. Treatment repeats every 21 days for up to 2 or 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo autologous PBSC harvesting according to institutional guidelines after the second course of therapy."
3038748|NCT00381966|Experimental|Robotic placement device|The intervention involves use of a robotic template to assist in placement of needles for prostate brachytherapy.
3038749|NCT00382018|Active Comparator|Group 1|Patients continue to receive regular treatment without change at the discretion of the physician. Patients are eligible for other first-line chemotherapy trials. No further blood is collected.
3038750|NCT00382018|Experimental|Group 2|Patients continue to receive their current chemotherapy regimen without change.
3038751|NCT00382018|Active Comparator|Group 3, Arm I|Patients continue with their current chemotherapy regimen without change.
3038752|NCT00382018|Experimental|Group 3, Arm II|Patients switch to a different chemotherapy regimen. Selection of a new chemotherapy regimen is made by the patient's doctor.
3038753|NCT00382031|Active Comparator|zalutumumab|Zalutumumab in combination with Best Supportive Care
3038754|NCT00382031|Other|Control|Best Supportive Care
3038755|NCT00382070|Experimental|Group 2 Letrozole|Patients receive oral letrozole once daily for up to 5 years.
3038756|NCT00382070|Placebo Comparator|Group 1 Placebo|Patients receive oral placebo once daily for up to 5 years.
3038757|NCT00382109|Experimental|Tacro-MTX/Sirolimus GVHD Prophylaxis Regimen|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors) and oral sirolimus (dose 2.5mg/m2/day - 4 mg max starting dose) daily starting on day 0 followed by a taper starting on day 180 through day 207.
3038758|NCT00382109|Active Comparator|Tacro-MTX GVHD Prophylaxis|Preparative regimen of total body irradiation (TBI) 200 cGy BID days -8,-7, & -6, Thiotepa IV (dose 5 mg/kg/day on days -5 & -4) & cyclophosphamide IV (dose 60 mg/kg/day on days -3 & -2). Tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally (when able) daily on day -2 with a taper starting on day 42 - day 98 (patients undergoing matched sibling donor transplantation) OR tacrolimus IV (dose 0.02 mg/kg/day) continuously or orally daily beginning on day -2 followed by a taper on day 100 through day 180 (patients undergoing other related, unrelated, or cord blood donor transplantation) in the absence of GVHD. Patients also receive methotrexate IV (5 mg/m2/dose) on days 1,3, & 6 (patients with matched sibling and umbilical cord blood donors) OR days 1,3 6, & 11 (patients with other related/unrelated bone marrow and peripheral blood stem cell donors).
3038759|NCT00382148|Experimental|1|
3038760|NCT00382174|Placebo Comparator|1|0.00% thymosin beta 4 w/w administered topically once daily for up to 84 days
3038761|NCT00382174|Active Comparator|2|3 doses of thymosin beta 4: 0.01% w/w, 0.02% w/w, and 0.1% w/w, administered topically once daily for up to 84 days
3038762|NCT00382265|Active Comparator|Tamsulosin|Tamsulosin 0.4mg PO qd for 28 days
3038763|NCT00382265|Placebo Comparator|Placebo|Placebo PO qd for 28 days
3038764|NCT00382291|Experimental|Regular Titration|Regular titration of Sertraline plus cognitive behavioral therapy. The titration schedule used a flexible upward titration from 25 mg/day to 200 mg/day over 9 weeks unless higher doses were not tolerated, after which the dosage was adjusted as a function of tolerability. If tolerated, maximum dose could be achieved in 5 weeks.
3038765|NCT00382291|Placebo Comparator|Placebo|Placebo plus cognitive behavioral therapy
3038766|NCT00382291|Experimental|Slow Titration|Slow titration of Sertraline plus cognitive behavior therapy. The titration schedule utilized a slower titration schedule relative to the RegSert arm. Unless unable to tolerate higher doses, children remained on 25mg/day for the first two weeks, 50mg/day from weeks 3-4, 75mg/day for weeks 5-6, 100mg/day for week 7, 150mg/day for week 8, and 200mg/day for week 9 until the end of the study.
3038767|NCT00382408|Experimental|Vaccine|Participants received a single tablet of both Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
3038768|NCT00382408|Placebo Comparator|Placebo|Participants received a single tablet of both placebos that matched the Type-4 and Type-7 adenovirus vaccines at study visit 1 (Day 0).
3038769|NCT00382590|Active Comparator|5-Aza + VPA|5-Azacytidine (5-Aza) 75 mg/m^2 subcutaneously daily + Valproic Acid (VPA) 50 mg/m^2 orally daily, each for 7 days
3038770|NCT00382590|Active Comparator|Ara-C|Low-Dose Ara-C 20 mg twice daily subcutaneously for 10 days.
3038771|NCT00382720|Experimental|TE (Taxotere and Eloxatin)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere and Eloxatin. Participants who received the optimal dose for Taxotere and Eloxatin were analyzed in this study."
3038772|NCT00382720|Experimental|TEF (Taxotere, Eloxatin and 5-FU)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and 5-FU (5-Fluorouracil). Each chemotherapy cycle was repeated every 14 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and 5-FU. Participants who received the optimal dose for Taxotere, Eloxatin and 5-FU were analyzed in this study."
3132843|NCT03457636|Experimental|doxycycline anhydrous and adapalene/benzoyl peroxide|All subjects will receive at Baseline doxycycline anhydrous 40 mg (Oracea) to be taken once daily and Adapalene-Benzoyl Peroxide Gel .3-2.5% (Epiduo) to be applied once daily for 12 weeks
3038773|NCT00382720|Experimental|TEX (Taxotere, Eloxatin and Xeloda)|"Docetaxel (Taxotere) in combination with Oxaliplatin (Eloxatin) and capecitabine (Xeloda). Each chemotherapy cycle was repeated every 21 days.~Participants received either the optimal or non-optimal dose for Taxotere, Eloxatin and Xeloda. Participants who received the optimal dose for Taxotere, Eloxatin and Xeloda were analyzed in this study."
3038774|NCT00382785|Experimental|moderated online support|12-week online support led by a healthcare professional
3038775|NCT00382785|Experimental|peer-led support|12-week online support group in a peer-led format
3038776|NCT00382824|Active Comparator|CoQ10|Half of the enrolled patients will be randomized into the the CoQ10 arm and will receive a dosage of 2400mg/day of Coenzyme Q10
3038777|NCT00382824|Placebo Comparator|Placebo|Half of the enrolled patients will be randomized into the the Placebo arm and will receive a matching dose of placebo that resembles the 2400mg/day dose of the CoQ10 arm.
3038778|NCT00382863|Experimental|Treatment|HeartNet and Optimal Medical/Device Therapy (e.g., medications and cardiac resynchronisation therapy)
3038779|NCT00382863|Active Comparator|Control|Optimal Medical/Device Therapy alone (e.g., medications and/or cardiac resynchronisation therapy) (Note: For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of angiotensin converting enzyme (ACE) inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy-defibrillator (CRT-D) for at least three months prior to study enrollment, when indicated.)
3038780|NCT00382928|No Intervention|Standard of Care Group|Patients will receive standard of care measures in case of cardiac arrest. They will not receive AECD monitoring or intervention
3038781|NCT00382928|Experimental|AECD Monitoring + Standard of Care Group|Patients will receive AECD monitoring and intervention in addition to standard of care in case of cardiac arrest during admission to the hospital. Defibrillation of pulseless VT/VF by AECD.
3038782|NCT00382967|Experimental|Datscan Product|
3038783|NCT00382967|No Intervention|Control|
3038784|NCT00382993|Other|Combination Product - Placebo|Combination Product (sumatriptan and naproxen sodium) [Attack 1] followed by Placebo [Attack 2]
3038785|NCT00382993|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
3038786|NCT00383019|Experimental|Xalatan|
3038787|NCT00383019|Experimental|Xalacom|
3038788|NCT00383071|Active Comparator|Cohort 1|H5N1 vaccine - 90 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3038789|NCT00383071|Active Comparator|Cohort 2|H5N1 vaccine - 120 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3038790|NCT00383071|Active Comparator|Cohort 3|H5N1 vaccine - 180 mcg IM every 4 week x 4 doses Apheresis - if HAI titer above 1:160
3038791|NCT00383071|Active Comparator|Cohort 4|H5N1 vaccine - 180 mcg IM every 4 weeks x 2 doses, injection site randomized to either deltoid or gluteus Apheresis - if HAI titer above 1:160
3038792|NCT00383084|Experimental|1|Group 1 participants will take part in 30 minutes total of self-selected lifestyle physical activity throughout the day, 5 to 7 days per week. Twice a month, they will attend group sessions designed to help participants develop and maintain a more physically active lifestyle. Goal setting, self-monitoring, and pain management will be discussed at these sessions.
3038793|NCT00383084|Active Comparator|2|Group 2 participants will attend monthly fibromyalgia educational sessions, which will focus on understanding the symptoms of FM, learning to manage pain and fatigue, and developing self-help strategies.
3038794|NCT00383110||Group 1|Adults (age 18 or older) with type 2 diabetes.
3038795|NCT00383123|Experimental|Fluarix Group|"Subjects in this group received Fluarix™ and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
3038796|NCT00383123|Active Comparator|Fluzone Group|"Subjects in this group received Fluzone and will be further stratified by 3 age groups~1:1 in 6 months to < 36 months~1:1 in 3 to < 5 years~3:1 in 5 to < 18 years"
3038797|NCT00383149|Experimental|Ixabepilone plus Cetuximab|All participants were administered ixabepilone at a starting dose of 32 mg/m^2 as a 3-hour intravenous (IV) infusion every 3 weeks. In addition, all participants were administered an initial dose of cetuximab (400 mg/m^2 IV over 2 hours) followed by a weekly lower dose (250 mg/m^2 IV over 1 hour).
3038798|NCT00383162|Other|Combination Product - Placebo|Combination product (sumatriptan and naproxen sodium) [Attack 1] followed by placebo [Attack 2]
3038799|NCT00383162|Other|Placebo - Combination Product|Placebo [Attack 1] followed by Combination Product (sumatriptan and naproxen sodium) [Attack 2]
3038800|NCT00383188|Placebo Comparator|1|
3038801|NCT00383188|Experimental|2|
3038802|NCT00383188|Experimental|3|
3038803|NCT00383188|Experimental|4|
3038804|NCT00383188|Experimental|5|
3038805|NCT00383240|Experimental|MF/F MDI 200/10 mcg BID|
3038806|NCT00383240|Experimental|MF MDI 200 mcg BID|
3038807|NCT00383240|Experimental|F MDI 10 mcg BID|
3038808|NCT00383240|Placebo Comparator|Placebo BID|
3038809|NCT00383266|Experimental|Pemetrexed + Carboplatin|"Pemetrexed 500 mg/m^2 IV over 10 minutes~Carboplatin AUC 5 IV over 30 minutes on day 1 of each cycle~Each cycle will last 21 days."
3038810|NCT00383292|Experimental|Tasisulam|
3038811|NCT00383331|Experimental|A|
3038812|NCT00383331|Experimental|B|
3038813|NCT00383435|Experimental|MF/F MDI 400/10 mcg BID|
3038814|NCT00383435|Experimental|MF/F MDI 200/10 mcg BID|
3038815|NCT00383435|Experimental|MF MDI 400 mcg BID|
3038816|NCT00383435|Active Comparator|Formoterol MDI 10 mcg BID|
3038817|NCT00383435|Placebo Comparator|Placebo MDI BID|
3038818|NCT00383448|Experimental|Treated Patients|Patients receiving chemotherapy (Hydroxyurea, Alemtuzumab, Clofarabine, Melphalan), Hematopoietic Stem Cell Transplantation and radiation therapy (Total body Irradiation) mycophenylate mofetil and cyclosporine A.
3038819|NCT00383500|Experimental|Flexitouch device|Participants will self-administer lymphedema management via daily use of the Flexitouch device, an intermittent pneumatic compression device (aka, lymphedema pump)
3038820|NCT00383500|Experimental|Manual Lymphatic Drainage (MLD)|Participants will self-administer lymphedema management via daily manual lymphatic massage therapy, using a Class 1 compression garment
3038821|NCT00383500|No Intervention|Observational Control (no intervention)|Control group, no intervention. No Flexitouch or manual massage therapy
3038822|NCT00383552|Experimental|MF/F MDI 100/10 mcg BID|
3038823|NCT00383552|Experimental|MF MDI 100 mcg BID|
3038824|NCT00383552|Experimental|F MDI 10 mcg BID|
3038825|NCT00383552|Placebo Comparator|Placebo BID|
3038826|NCT00383565|Experimental|Arm I|Patients receive FR901228 IV over 4 hours on days 1, 8, and 15.
3038827|NCT00383643|Placebo Comparator|Placebo|Eligible subjects randomized to this arm received placebo as gelatin capsule and a liquid capsule to fully maintain the blind.
3038828|NCT00383643|Active Comparator|Zolpidem tartrate|Eligible subjects randomized to this arm received zolpidem as gelatin capsule and a placebo liquid capsule to fully maintain the blind.
3038829|NCT00383643|Active Comparator|Sodium oxybate|Eligible subjects randomized to this arm received placebo as gelatin capsule and a sodium oxybate capsule to fully maintain the blind.
3038831|NCT00383721|Experimental|MF/F MDI 400/10 mcg BID|
3038832|NCT00383721|Experimental|MF/F MDI 200/10 mcg BID|
3038833|NCT00383721|Experimental|MF MDI 400 mcg BID|
3038834|NCT00383721|Active Comparator|Formoterol MDI 10 mcg BID|
3038835|NCT00383721|Placebo Comparator|Placebo MDI BID|
3038836|NCT00383747|Active Comparator|Nicotine Patch|
3038837|NCT00383747|Placebo Comparator|Placebo Nicotine Patch|
3038838|NCT00383760|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV on days 1 and 8.
3038839|NCT00383786|Experimental|GR205171|selective neurokinin-1 receptor antagonist, fixed 5 mg dose every day, for 8 weeks.
3038840|NCT00383786|Placebo Comparator|placebo|sugar pill
3038841|NCT00383942|Active Comparator|Misoprostol|Patients randomized to this arm will receive 25 micrograms of misoprostol every four hours.
3038842|NCT00383942|Experimental|EASI Catheter|Patients randomized to this arm will receive extra amniotic saline infusion (EASI) administered via catheter
3038843|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
3038844|NCT00384033|Experimental|Desvenlafaxine succinate sustained-release 100 mg|
3038845|NCT00384033|Placebo Comparator|Placebo|
3038846|NCT00384033|Other|Duloxetine 60mg|Active control to assess assay sensitivity
3038847|NCT00384059|Experimental|1|13-valent pneumococcal vaccine
3038848|NCT00384059|Active Comparator|2|7-valent pneumococcal vaccine
3038849|NCT00384085|Experimental|Lantus/Apidra-3|Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
3038850|NCT00384085|Experimental|Lantus/Apidra-1|Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
3038851|NCT00384085|Experimental|Novolog Mix 70/30|Premixed insulin (Novolog® Mix 70/30) added to oral agents.
3038852|NCT00384176|Active Comparator|1|Bevacizumab + FOLFOX
3038853|NCT00384176|Experimental|2|Cediranib + FOLFOX
3038854|NCT00384189|Active Comparator|Ciclesonide 40 µg|Placebo-matching ciclesonide, inhaled via a metered-dose inhaler (MDI) with 1,1,1,2-hydrofluoroalkane (HFA)-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 40 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3038855|NCT00384189|Active Comparator|Ciclesonide 80 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 80 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3038856|NCT00384189|Active Comparator|Ciclesonide 160 µg|Placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily, in the evening for 2 to 4 weeks in the Baseline period followed by ciclesonide 160 µg, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3038857|NCT00384189|Placebo Comparator|Placebo|Placebo-matching Ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 2 to 4 week in the Baseline period followed by placebo-matching ciclesonide, inhaled via a MDI with HFA-134a as propellant, once daily in the evening for 12 weeks. Salbutamol 100 μg/puff was available to be used as rescue medication if needed.
3038858|NCT00384241||Children|Children age 15-19, self reported as African American of European Origin, healthy non-smoker, with normal blood pressure, exposed to an activity to that results in induced stress
3038859|NCT00384241||Parents|Collection of buccal swab Parent of participants in the Children Arm
3038860|NCT00384332|Experimental|Arm 1|Orally disintegrating olanzapine
3038861|NCT00384332|Experimental|Arm 2|regular olanzapine
3038862|NCT00384397|Experimental|Group 1: Menactra® Vaccine|Participants will receive Menactra® vaccine at age 9 months and 12 months, respectively.
3038863|NCT00384397|Experimental|Group 2: Menactra® + MMRV|Participants will receive Menactra® at age 9 months followed by Menactra® and Measles-Mumps-Rubella-Varicella (MMRV) vaccines at Age 12 Months
3038864|NCT00384397|Experimental|Group 3: Menactra® + PCV|Participants will receive Menactra® at age 9 months followed by Menactra® and Pneumococcal Conjugate (PCV) vaccines at Age 12 Months
3038865|NCT00384449|Experimental|Lucentis (ranibizumab)|Lucentis (ranibizumab)
3038866|NCT00384670|Experimental|Dengue and Japanese Encephalitis vaccine|1 mL subcutaneous injection Dengue Vaccine Formulation 17 on Day 0 and Day 60. 0.5 mL subcutaneous injection Licensed Japanese Encephalitis (JE) Vaccine on months 7 and 7.5.
3038867|NCT00384748|Experimental|Tele-visit Group|TR intervention targets safe functional mobility within a home environment and consists of: 1) exercise targeting underlying stroke-related impairment and 2) adaptive strategies targeting external factors to help compensate for disability. TR uses a combination of tele-video visits, an in-home messaging device, and telephone contact over a 3-month study period. A video camera is used in the home to provide visual and audio to a therapist located at the base hospital. An interactive, in-home messaging device is used to facilitate adherence with treatment recommendations and to screen for depression, falls, and difficulty with self-care. This allows evaluations of problem areas during tele-visits, rapid response to new functional problems.
3038868|NCT00384748|Active Comparator|Usual Care Group|Patients randomized to the Usual Care group receive routine VA care, as directed by their physicians. Therapy services are tracked via a weekly diary for the entire 6 month study period. In this weekly diary, patients in both the usual care and intervention group will record receipt of therapy. Usual Care group will be asked whether they exercised, and if so how frequently. They will be administered telephone interviews at baseline, 3-and 6-months. The interview outcome measures are FONEFIM, Late-Life Function and Disability Instrument, Falls Self Efficacy Scale and Stroke Specific Patient Satisfaction with Care. In addition, sociodemographics, stroke severity, length of time since stroke onset, and depression at baseline will be measured.
3038869|NCT00384774|Experimental|Lasmiditan|Participants received escalating doses of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 45 mg of lasmiditan as intravenous injection.
3038870|NCT00384774|Placebo Comparator|Placebo|Participants received intravenous infusion of placebo solution.
3038871|NCT00384813|Experimental|1: Home-based family intervention|Home-based family intervention
3038872|NCT00384813|Active Comparator|2: ETAU|Enhanced Treatment As Usual (1 home visit)
3038873|NCT00384839|Experimental|1|azacitidine for injectable suspension
3038874|NCT00384865|Active Comparator|Aspirin 81 mg + Simvastatin 40 mg|"Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months~Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months"
3038875|NCT00384865|Active Comparator|Aspirin 81 mg + Placebo|"Aspirin: Aspirin 81 mg, taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
3038876|NCT00384865|Active Comparator|Placebo + Simvastatin 40 mg|"Placebo taken orally, once a day for 6 months~Simvastatin: Simvastatin 40 mg, taken orally, once a day for 6 months"
3038877|NCT00384865|Placebo Comparator|Placebo + Placebo|"Placebo taken orally, once a day for 6 months~Placebo taken orally, once a day for 6 months"
3038878|NCT00384930|Placebo Comparator|1|placebo tablet
3038879|NCT00384930|Active Comparator|2|2.5 mg tadalafil tablet
3038880|NCT00384930|Active Comparator|3|5 mg tadalafil tablet
3038881|NCT00384930|Active Comparator|4|10 mg tadalafil tablet
3038882|NCT00384930|Active Comparator|5|20 mg tadalafil tablet
3038883|NCT00384956|Experimental|Azacitidine|Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle. Patients that do not respond after two cycles will have the dose increased to 100 mg/m2. Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle. Individuals who demonstrate a loss of response will resume 28 day cycles.
3038884|NCT00385008|Other|Arm 1|open-label active drug
3038885|NCT00385008|Other|Arm 2|open-label active drug
3038886|NCT00385138|Experimental|Cangrelor|cangrelor bolus (30 mcg/kg) & infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + placebo capsules (to match) at end of PCI + active clopidogrel (600mg) immediately post infusion
3038887|NCT00385138|Active Comparator|Clopidogrel|placebo bolus & infusion (to match) + clopidogrel capsules (600 mg) at end of PCI + placebo capsules (to match) immediately post infusion
3038888|NCT00385216|Active Comparator|Nicotine nasal spray|In one sitting the subject will receive a nicotine nasal spray, 3 mg, one application.
3038889|NCT00385216|Placebo Comparator|Placebo spray|In one sitting the subject will receive a placebo nasal spray (0 mg), one application.
3038890|NCT00385255|Experimental|BOOSTRIX+FLUARIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Boostrix® vaccine co-administered with Fluarix® vaccine at Day 0, injected intramuscularly in the left and right upper deltoid regions, respectively.
3038891|NCT00385255|Experimental|FLUARIX BOOSTRIX GROUP|Healthy male or female adults, aged between 19 to 64 years of age inclusive and 65 years or older, who received Fluarix® vaccine at Day 0 and Boostrix® vaccine at Month 1, both injected intramuscularly in the upper left deltoid region.
3038892|NCT00385268|Experimental|Active medication Acamprosate|1998mg/day for 8 weeks
3038893|NCT00385268|Placebo Comparator|Placebo|placebo pills for 8 weeks
3038894|NCT00385515|Experimental|1|SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days
3038895|NCT00385515|Placebo Comparator|2|placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days
3038896|NCT00385541|Active Comparator|A|Patients receive morphine 1mg/dose PCA for postsurgical pain; max 10 mg/hr; lockout 6 minutes.
3038897|NCT00385541|Active Comparator|B|Patients receive hydromorphone 0.2mg/dose PCA for postsurgical pain; max 10mg/hr; lockout 6 minutes.
3038898|NCT00385580|Experimental|1|
3038899|NCT00385580|Experimental|2|
3038900|NCT00385671|Active Comparator|Pregabalin|Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US & Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US & Germany) or 150 mg BID (Canada), PO for 10 weeks.
3038901|NCT00385671|Experimental|Duloxetine|Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
3038902|NCT00385671|Experimental|Gabapentin + Duloxetine|Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.
3038903|NCT00385684|Experimental|A1: hydrocodone/APAP w placebo PRN|This is a fully crossed study, each participant serves as his own control. Phase A (closed label) has two arms: A1 is the experimental and A2 is the placebo comparator. Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
3038904|NCT00385684|Placebo Comparator|A2: placebo w hydrocodone/APAP PRN|This is a fully crossed study, each participant serves as his own control. Phase A: Participants are randomized to either A1 for 1 week then A2 for 1 week OR A2 for 1 week then A1 for one week. A1: hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID, with liquid placebo available PRN. A2: liquid placebo TID with hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid PRN.
3132844|NCT03457727|Experimental|Subjects receiving danirixin: Part A|Subjects will receive a single oral dose of 50 mg danirixin reference and test formulations with food and 240 mL of water in a cross-over manner.
3038905|NCT00385684|Active Comparator|B: Open label hydrocodone/acetaminophen|Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
3038906|NCT00385723|Experimental|1|1.25 g/d
3038907|NCT00385723|Experimental|2|2.496 g/d
3038908|NCT00385723|Placebo Comparator|3|
3038909|NCT00385736|Experimental|Adalimumab 80/40|
3038910|NCT00385736|Experimental|Adalimumab 160/80/40|
3038911|NCT00385736|Placebo Comparator|Placebo|
3038912|NCT00385788|Experimental|Gemcitabine + Fludarabine + Melphalan|Gemcitabine 800 mg/m^2 intravenous (IV) over 30 minutes for one day; Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
3038913|NCT00385788|Experimental|Fludarabine + Melphalan|Fludarabine 33 mg/m^2 IV for 4 days; Melphalan 70 mg/m^2 IV over 30 minutes for 2 days. Antithymocyte Globulin 2 mg/kg IV for 2 days before stem cell transplantation. If receiving transplant from matched unrelated donor (not blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant, infusion of stem cells on Day 0. Tacrolimus 0.03 mg/kg by vein over 24 hours following infusion; beginning Day +7 Filgrastim (G-CSF) injection under skin once daily and Methotrexate 5 mg/m2 by vein on Days +1, +3, +6, and +11.
3038914|NCT00385801|Placebo Comparator|Placebo|Identical placebo tablets and injections
3038915|NCT00385801|Active Comparator|risperidone consta|Risperidone 1-2 mg tablets and Risperidone 25 mg injections
3038916|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (CNTO 328) (Part 1)|In Part 1, mitoxantrone 12 milligram per square meter (mg/m^2) will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kilogram (mg/kg) intravenously as a 2 hour-infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3038917|NCT00385827|Experimental|Mitoxantrone+Prednisone+Siltuximab (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with siltuximab 6 mg/kg intravenously as a 2-hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year; and prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3038918|NCT00385827|Active Comparator|Mitoxantrone+Prednisone (Part 2)|In Part 2, mitoxantrone 12 mg/m^2 will be given intravenously as a 30-minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2) along with prednisone 5 mg orally twice daily starting with the first administration of mitoxantrone.
3038919|NCT00385840|Active Comparator|Fluarix Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the Fluarix™ vaccine in study NCT00321763, received 1 dose of Fluarix™ vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3038920|NCT00385840|Experimental|GSK1247446A Group|Subjects aged 60 years or older at the time of re-vaccination, who previously received 1 dose of the GSK1247446A vaccine in study NCT00321763, received 1 dose of adjuvanted GSK1247446A vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3038921|NCT00385918|Experimental|Lokomat training|Subjects will receive active exercise treatment in the Lokomat device 3 times per week for 3 months. Each session will last approximately 45 minutes.
3038922|NCT00385918|Active Comparator|Home stretching then Lokomat training|Patients will participate in a home stretching program for 3 months. They will then be crossed over to an active Lokomat treatment for a subsequent 3 months.
3038923|NCT00385944|Experimental|Prasugrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) prasugrel 10 mg and two placebo tablets, matched to clopidogrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of clopidogrel two 75 mg tablets and one placebo matched to prasugrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
3038924|NCT00385944|Active Comparator|Clopidogrel|Open label lead-in one time dose of Clopidogrel 900 mg oral tablets (a single or cumulative dose) and 250 mg to 500 mg aspirin loading dose (LD), either orally or intravenously. Patients are then assigned to maintenance dose (MD) Clopidogrel two 75 mg and one placebo tablet, matched to prasugrel, and 100 mg aspirin, all taken orally once a day for 14 days. Patients cross-over to MD of prasugrel one 10 mg tablet and two placebo tablets matched to clopidogrel and 100 mg aspirin, all taken orally once a day for the next 14 days.
3038925|NCT00385996|Experimental|Erlotinib|Erlotinib 150mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
3038926|NCT00386009|Placebo Comparator|1|Placebo
3038927|NCT00386009|Active Comparator|2|tadalafil
3038928|NCT00386022|Experimental|Young postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
3038929|NCT00386022|Experimental|Older postmenopausal women|intervention: graded doses of GnRH following NAL-GLU GnRH antagonist administration with or without transdermal estrogen patch
3038930|NCT00386100|Placebo Comparator|Metformin|MET began at a total daily dose of 500 mg and could be increased up to a maximum dose of MET 2000 mg. The dose level was to be increased unless a tolerability issue existed at the current dose level.
3038931|NCT00386100|Active Comparator|Avandamet (Rosiglitazone maleate/metformin hydrochloride)|AVM began at a total daily dose of 4 mg/500 mg and could be increased up to a maximum dose of AVM 8 mg/2000 mg
3038932|NCT00386152|Experimental|epoetin alfa (120,000 Units)|epoetin alfa (PROCRIT) 120,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
3038933|NCT00386152|Experimental|epoetin alfa (80,000 Units)|epoetin alfa (PROCRIT) 80,000 Units injected subcutaneously once every 3 weeks for up to 13 weeks
3038934|NCT00386152|Active Comparator|darbepoetin alfa (500 mcg)|darbepoetin alfa (ARANESP) 500 mcg injected subcutaneously the skin once every 3 weeks for up to 13 weeks
3038935|NCT00386243|No Intervention|Usual Care|Study subjects randomized to this arm would receive usual care from their provider(s). No study intervention is undertaken on subjects in this arm. Participants in Usual Care would complete the same four outcome assessments (surveys) throughout the course of the study that members of the intervention complete.
3038936|NCT00386243|Experimental|Stepped Care|Study subjects randomized to this arm would receive stepped care for their pain. Stepped care involves FDA-approved analgesic therapy, a 12-week pain self-management program, and if pain does not improve, a 12-week cognitive behavioral therapy program.
3038937|NCT00386256|Experimental|Health Buddy outpatient|Received home telehealth monitoring by Health Buddy
3038938|NCT00386256|Experimental|Telephone outpatient|
3038939|NCT00386256|Experimental|health buddy inpatient|
3038940|NCT00386256|Experimental|telephone inpatient|
3038941|NCT00386308|Experimental|1|
3038942|NCT00386308|Placebo Comparator|2|
3038943|NCT00386334|Placebo Comparator|Placebo|Week -2 to day 0 single blind one tablet placebo in the evening. Double blind period: Day 1 to Week 12 double blind one tablet placebo in the evening. Follow up period: two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
3038944|NCT00386334|Experimental|Eszopiclone|Week -2 to day 0 single blind one tablet placebo in evening. Double Blind period: Day 1 to Week 12 double blind one tablet 2 mg of eszopiclone in evening. Follow up period consists of two weeks (Weeks 13-14) single blind one tablet placebo in evening, and two weeks (Weeks 15-16) no drug washout.
3038945|NCT00386360|Placebo Comparator|Placebo|Placebo dose
3038946|NCT00386360|Experimental|Risedronate|35 mg risedronate, orally, once weekly
3038947|NCT00386425|Experimental|Standard therapy|24 microgram/kilogram/hour (mcg/kg/hr) for 24 hours, followed by 24 mcg/kg/hr for an additional 72 hours
3038948|NCT00386425|Experimental|Alternative therapy:moderate protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 24 mcg/kg/hr for an additional 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
3038949|NCT00386425|Experimental|Alternative therapy:severe protein C deficiency|24 mcg/kg/hr for 24 hours, followed by 30 or 36 mcg/kg/hr for 48 to 144 hours (original protocol) or an additional 72 to 144 hours (amended protocol)
3038950|NCT00386477|Experimental|Vag prep|Vagina cleansed prior to performing cesarean
3038951|NCT00386607|Experimental|Core Treatment|Oral pills of aliskiren 150 mg /valsartan 160 mg in combination for 2-weeks. The aliskiren 300 mg /valsartan 320 mg in combination for 52-weeks, optional addition of Hydrochlorothiazide (HCTZ) 12.5 mg starting from Week 10 if the blood pressure was uncontrolled (mean sitting Systolic Blood Pressure ≥ 140 and/or mean sitting Diastolic Blood Pressure ≥ 90 mmHg). The dose of Hydrochlorothiazide (HCTZ) 12.5 mg could be increased to 25 mg if blood pressure remained uncontrolled.
3038952|NCT00386607|Experimental|Extension Treatment|"For patients entering into extension, those previously treated with Hydrochlorothiazide (HCTZ) 12.5 or 25 mg in addition to aliskiren 300 mg/valsartan 320 mg were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 25 mg in the extension. Those patients who had not received HCTZ during the core study were treated with aliskiren 300 mg/valsartan 320 mg/HCTZ 12.5 mg.~The HCTZ 12.5 mg dose could be increased to HCTZ 25 mg if the mean sitting Systolic Blood Pressure (msSBP) was ≥140 mmHg and/or the mean sitting Diastolic Blood Pressure (msDBP) was ≥90 mmHg for 2 consecutive visits."
3038953|NCT00386776|Experimental|'Computer-based medical history|A computer-based medical history to take in their homes via the Internet. The history is divided into 24 modules- family history, social history, cardiac history, pulmonary history, and the like.
3038954|NCT00386880||Subjects with episodic migraine with allodynia|These are subjects with episodic migraine with allodynia
3038955|NCT00386880||Subjects with episodic migraine without allodynia|Subjects with episodic migraine without allodynia
3038956|NCT00387010|Experimental|fentanyl buccal tablets|Successful dose strength for each participant was determined during a titration period of no more than 10 days. Participants used the successful dose of 100, 200, 400, 600, or 800 mcg during the four week open-label treatment period.
3038957|NCT00387023|Experimental|Zevalin + Rituximab|Rituximab 250 mg/m^2 intravenous (IV) over 4-6 hours for 2 weeks, + Zevalin 5 millicurie (mCi)/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
3038958|NCT00387036|Other|1|Arm 1: drug, crossing over to Pbo comparator
3038959|NCT00387036|Other|2|Arm 2: Pbo comparator, crossing over to drug
3038960|NCT00387088|Other|Tiotropium|Tiotropium 5µg via Respimat® inhaler (2 inhalations of 2.5µg per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
3038961|NCT00387088|Other|Placebo|Placebo via Respimat® inhaler (2 inhalations per day) + usual maintenance treatment (only anticholinergic bronchodilators were excluded)
3038962|NCT00387127|Experimental|Lapatinib|1500mg lapatinib orally daily
3038963|NCT00387127|Placebo Comparator|Placebo|orally daily
3038964|NCT00387335|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3038965|NCT00387348|Placebo Comparator|Placebo-Placebo|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and placebo once daily for the second 4 weeks
3038966|NCT00387348|Other|Placebo-Escitalopram|Participants in this arm were randomized to receive placebo once daily for the first 4 weeks and escitalopram oxalate 10 mg once daily for the second 4 weeks
3038967|NCT00387348|Other|Escitalopram-Placebo|Participants in this arm were randomzied to receive escitalopram 10 mg once daily for the first 4 weeks and placebo once daily for the second 4 weeks
3038968|NCT00387426|Experimental|Arm I|Patients receive oral sunitinib malate once daily for 6 weeks.
3038969|NCT00387465|Experimental|Phase I - 30mg/m2 Azacitidine|Patients receive Azacitidine 30mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
3038970|NCT00387465|Experimental|Phase I - 40mg/m2 Azacitidine|Patients receive azacitidine 40mg/m2 SQ and entinostat 7mg PO on days 3 and 10 of each cycle.
3038971|NCT00387465|Experimental|Phase II Arm|Patients receive azacitidine 40mg/m2 subcutaneously (SQ) on days 1-6 and 8-10 and entinostat 7mg PO on days 3 and 10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3038972|NCT00387621|Experimental|Placebo First, then Nesiritide (Arm A)|In the first intervention period the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
3038973|NCT00387621|Experimental|Nesiritide First, then Placebo (Arm B)|In the first intervention period the subjects received subcutaneous nesiritide given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered. There was a 2 week washout period. In the second intervention period, the subjects received subcutaneous placebo given in the abdomen. After a lead in period of 15 minutes, the acute saline load was administered.
3038974|NCT00387647|Experimental|Azacitidine Treatment|Azacitidine 50 mg/m^2 subcutaneously daily for 5 days (Monday through Friday) on days 1 through 5, every 28 days for 6-12 cycles.
3038975|NCT00387660|Experimental|Metastatic SCLC|Irinotecan 200 mg/m2, every 21 days (intravenous) + Carboplatin AUC = 5 mg/ml x min (intravenous), every 21 days for 6 cycles
3038976|NCT00387660|Experimental|Relapsed SCLC|Irinotecan 150 mg/m2 (intravenous), every 21 days + Carboplatin AUC = 5 mg/ml x min (intravenous, every 21 days for 6 cycles
3038977|NCT00387712|Experimental|Velocity based treadmill training|6 month of progressive treadmill walking with treadmill speed gradually progressed to meet the training heart rate goals for moderate intensity aerobic exercise, when hemiparetic gait velocity can no longer be safely progressed, incline is added to achieve the heart rate training goals.
3038978|NCT00387712|Experimental|Duration based treadmill training|6 month of progressive treadmill walking with duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress.
3038979|NCT00387725|Experimental|Group A|20ug Experimental
3038980|NCT00387725|Experimental|Group 2|60ug Experimental
3038981|NCT00387725|Experimental|Group 3|200ug Experimental
3038982|NCT00387725|Active Comparator|Group 4|Active comparator
3038983|NCT00387751|Experimental|Arm I|Patients receive oral sorafenib tosylate on days 1-5, 8-12, 15-19, and 22-26 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
3038984|NCT00387764|Experimental|pazopanib arm|This was a single arm study, therefore no control arm.
3038985|NCT00387790|Experimental|Arm I|Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3038986|NCT00387829|Active Comparator|1|Use of DuraGen Plus Adhesion Barrier Matrix as an adhesion barrier in the spine
3038987|NCT00387829|No Intervention|2|Control arm is surgery alone (no adhesion barrier)
3038988|NCT00387881|Placebo Comparator|Placebo|
3038989|NCT00387881|Experimental|Treximet|
3038990|NCT00387894|Experimental|erlotinib hydrochloride (Tarceva)|During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
3038991|NCT00387959|Experimental|Unrelated Donor Umbilical Cord Transplant|Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilixal Cord Blood
3038992|NCT00388037|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3038993|NCT00388154|Experimental|Gemcitabine + Cisplatin|Gemcitabine 900 mg/m^2 by vein (IV) over 1 hour on Day 1 and Day 8. Cisplatin 30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
3038994|NCT00388297|Experimental|Levothyroxine for Subclinical Hypothyroidism|100 µg of Levothryoxine for participants with subclinical hypothyroidism
3038995|NCT00388297|Placebo Comparator|Placebo for Levothyroxine - Subclinincal Hypothyroidism|Placebo for Levothyroxine for participants with subclinical hypothyroidism
3038996|NCT00388297|Experimental|Levothyroxine for Hypothyroxinemia - Hypothyroxinemia|50 µg of Levothyroxine for participants with hypothyroxinemia
3038997|NCT00388297|Placebo Comparator|Placebo for Levothyroxine|Placebo for Levothyroxine for participants with hypothyroxinemia
3038998|NCT00388349|Experimental|Gemcitabine + Autologous HCT|Gemcitabine and high-dose chemotherapy followed by peripheral blood stem cell (PBSC) rescue. Chemotherapy includes Gemcitabine + Vinorelbine + Carmustine + Etoposide + Cyclophosphamide.
3038999|NCT00388362|Experimental|Sirolimus Therapy|Administration of Sirolimus and Prednisone
3039000|NCT00388414|Placebo Comparator|Placebo - sugar pill|
3039001|NCT00388414|Experimental|Duloxetine|
3039002|NCT00388453|Active Comparator|1|Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
3039003|NCT00388453|Experimental|2|subject is known to have GERD based on symptoms and previous positive response to PPI
3039004|NCT00388453|Experimental|3|subject is known to have EERD based on symptoms and previous positive response to PPI
3039005|NCT00388505|Experimental|Tobramycin inhalation powder (TIP)|Participants received four 28 mg capsules of tobramycin inhalation powder (TIP) delivered with the T-326 inhaler twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
3320831|NCT02014103|Other|Sequence 1|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 1: Formulation 3, 5, 6, 4, 2, 1.
3039006|NCT00388505|Active Comparator|Tobramycin solution for inhalation (TOBI)|Participants received one 300 mg (in 5 mL) ampoule of tobramycin solution for inhalation (TOBI) delivered with a nebulizer twice daily for 28 days followed by 28 days off therapy (one cycle) for a total of three cycles.
3039007|NCT00388583|Experimental|Fluzone Intradermal (ID) Vaccine Group|Participants received a dose of Fluzone Intradermal (ID) Influenza Vaccine
3039008|NCT00388583|Active Comparator|Fluzone Intramuscular (IM) Vaccine Group|Participants received a dose of Fluzone Intramuscular (IM) Influenza Vaccine.
3039009|NCT00388674||A|
3039010|NCT00388674||B|
3039011|NCT00388726|Experimental|1|
3039012|NCT00388726|Active Comparator|2|
3039013|NCT00388804|Active Comparator|RT Group 1|Radiation Therapy (RT) over 8 1/2 weeks: 42 treatments, 5 days per week with 2 days rest in between.
3039014|NCT00388804|Active Comparator|RT Group 2 + Hormone Therapy|Radiation Therapy over 8 1/2 weeks; + Hormone Therapy (Bicalutamide 50 mg orally/day or Flutamide 250 mg orally 3 times daily on first 21-30 Days) + Leuprolide (22.5 mg Intramuscularly (IM)/every 3 months or 7.5 mg IM monthly) or Goserelin (10.8 mg subcutaneously every 3 months or 3.6 mg subcutaneously monthly)
3039015|NCT00388947||1|AMS Prolapse Product (AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family)
3039016|NCT00389064|Experimental|Quetapine XR|Tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily.
3039017|NCT00389064|Placebo Comparator|Placebo|Matching placebo tablets orally administered once daily.
3039018|NCT00389168|Experimental|Irbesartan|Irbesartan per os titrated to 300 mg od, 48 weeks
3039019|NCT00389168|Active Comparator|Atenolol|Atenolol per os titrated to 100 mg od, 48 weeks
3039020|NCT00389207|Active Comparator|NVP bid|nevirapine (NVP) 200 mg BID in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3039021|NCT00389207|Experimental|NVP qd|nevirapine (NVP) 400 mg QD in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3039022|NCT00389207|Active Comparator|ATZ/r|ritonavir-boosted atazanavir in combination with emtricitabine (FTC) and tenofovir DF (TDF)
3039023|NCT00389324|Experimental|Immune Globulin Intravenous (Human)|Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified
3039024|NCT00389441|Experimental|A|
3039025|NCT00389467|Active Comparator|1 Mechanical Embolectomy|Participants will be randomized to receive mechanical embolectomy treatment either with the Merci Retriever or Penumbra System and standard medical care or treatment with standard medical care alone.
3039026|NCT00389467|No Intervention|2|standard medical care
3039027|NCT00389493|Active Comparator|1|Participants will receive treatment with risperidone
3039028|NCT00389493|Active Comparator|2|Participants will receive exposure and ritual prevention therapy (EX/RP)
3039029|NCT00389493|Placebo Comparator|3|Participants will receive treatment with the placebo
3039030|NCT00389519|Placebo Comparator|Placebo|once per day
3039031|NCT00389519|Experimental|ramipril low dose|0.3125, 0.625, or 1.25 mg once a day, based on subject weight
3039032|NCT00389519|Experimental|ramipril mid dose|1.25, 2.5, or 5 mg once a day, based on subject weight
3039033|NCT00389519|Experimental|ramipril high dose|5, 10, or 20 mg once a day, based on subject weight
3039034|NCT00389532|Experimental|1|aged 19 to 59 years
3039035|NCT00389532|Experimental|2|aged ≥ 60 years
3039036|NCT00389597|Experimental|1 Level|Cervical artificial disc (investigational device) at 1 level compared with control procedure (ACDF) at one level
3039037|NCT00389597|Experimental|2 Level|Cervical artificial disc (investigational device) at 2 levels compared with control procedure (ACDF) at two levels
3039038|NCT00389818|Experimental|DR-COP|Single arm interventional study: all subjects receive DR-COP regimen.
3039039|NCT00389831|Placebo Comparator|Placebo|Subjects receiving a single dose of placebo nasal spray on all 4 treatment days
3039040|NCT00389831|Experimental|Rotigotine Nasal Spray|Subjects receiving doses of placebo nasal spray on Day 1 or Day 2, Rotigotine nasal spray 62µg on Day 1 or Day 2, Rotigotine nasal spray 124µg on Day 3, and Rotigotine nasal spray 247µg on Day 4
3039041|NCT00389857|Experimental|Influenza vaccine-naive group|Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
3039042|NCT00389857|Experimental|Influenza vaccine-primed group|Participants have received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0.
3039043|NCT00389974|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily for 4 weeks. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or PR may receive 2 courses after CR or PR is reached.
3039044|NCT00390013|Active Comparator|Gabapentin|Gabapentin (Neurontin) titration and dosing for total of 8 weeks (Cross over)
3039045|NCT00390013|Placebo Comparator|Placebo oral capsule|Placebo titration and dosing for total of 8 weeks (Cross over)
3039046|NCT00390182|Experimental|Single Arm|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy."
3039047|NCT00390221|Placebo Comparator|Placebo|Participants will receive 3 subcutaneous (SC) injections of placebo every 4 weeks for up to 52 weeks.
3039048|NCT00390221|Experimental|150 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
3039049|NCT00390221|Experimental|300 mg DAC HYP|Participants will receive 3 SC injections every 4 weeks for up to 52 weeks.
3039050|NCT00390234|Experimental|Treatment (ziv-aflibercept)|Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3039051|NCT00390299|Experimental|Arm A (resection cavity administration)|Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by MV-CEA administered into the resection cavity.
3039052|NCT00390299|Experimental|Arm B (intratumoral and resection cavity administration)|Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA IT through the catheter over 10 minutes on day 1. Patients then undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
3039053|NCT00390325|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.
3039054|NCT00390416|Experimental|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
3039055|NCT00390429|Experimental|Phase I, Group I (completed)|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride once on days 2, 9, and 16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
3039056|NCT00390429|Experimental|Phase I, Group II (completed)|Patients receive docetaxel as in group I and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression. Patients may then continue to receive erlotinib hydrochloride alone in the absence of unacceptable toxicity or disease progression.
3039057|NCT00390429|Experimental|Phase II|Patients receive docetaxel IV over 1 hour on day 1 and oral erlotinib hydrochloride at the MTD determined in group II of phase I once daily on days 2-16. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then continue to receive erlotinib hydrochloride alone in the absence of disease progression or unacceptable toxicity.
3039058|NCT00390455|Experimental|Arm I (lapatinib)|Patients receive lapatinib ditosylate PO QD on days 1-28 and fulvestrant IM on days 1 and 15 of course 1 and on day 1 of each subsequent course. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3039059|NCT00390455|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28 and fulvestrant as in Arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3039060|NCT00390468|Experimental|Tandutinib (MLN518)|500 mg twice daily, a small-molecule inhibitor of the type III receptor tyrosine kinases. Tandutinib (MLN518) previously known as CT53518.
3039061|NCT00390546|Experimental|Propranolol|Single dose of 0.5 mg/kg per dose and increased to 1.0 mg/kg per dose ITD for the second and subsequent doses.
3039062|NCT00390546|Experimental|Digoxin|First 2 doses at 0.010 mg/kg per dose TID, then 0.0035 mg/kg per dose TID for the third and subsequent doses
3039063|NCT00390559|Experimental|ActiveP/ActiveC|21 mg patch/Nicotine-containing cigarette
3039064|NCT00390559|Experimental|PlaceboP/ActiveC|0 mg patch/nicotine-containing cigarette
3039065|NCT00390559|Experimental|Active P/PlaceboC|21 mg patch/no nicotine cigarette
3039066|NCT00390559|Experimental|PlaceboP/PlaceboC|0 mg patch/no nicotine cigarette
3039067|NCT00390572|Experimental|Sleep Specialty Consultation|Participants randomized to receive a one-time sleep consultation at beginning of study
3039068|NCT00390572|No Intervention|Treatment as Usual|Participants randomized to receive a one-time sleep consultation after completing study procedures (after 10 month study wait-list period).
3039069|NCT00390611|Active Comparator|Paclitaxel/Carboplatin/Sorafenib|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV, Day 1 Sorafenib 400mg PO bid
3039070|NCT00390611|Active Comparator|Paclitaxel/carboplatin|Paclitaxel 175 mg/m2 1-3 hour IV infusion, Day 1 Carboplatin AUC 6 infused over 20 minutes IV
3039071|NCT00390689|Experimental|Pramipexole 0.25 mg once daily|Pramipexole 0.25 mg given once daily
3039072|NCT00390689|Experimental|Pramipexole 0.5 mg once daily|Pramipexole 0.5 mg given once daily
3039073|NCT00390689|Experimental|Pramipexole 0.75 mg once daily|Pramipexole 0.75 mg given once daily
3039074|NCT00390780|Active Comparator|Clotrimazole|Clotrimazole troches, 10 mg, 5 times per day for 14 days
3039075|NCT00390780|Experimental|miconazole Lauriad|Miconazole Lauriad 50 mg mucoadhesive buccal tablet, once daily, for 14 days
3039076|NCT00390806|Experimental|topotecan plus radiation|topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.
3039077|NCT00390806|Active Comparator|Whole brain radiation|Whole brain radiation 3 Gy/day for 10 days
3039078|NCT00390858|Experimental|Deferasirox|Initial dose of 10 mg/kg, dose modifications of ± 5 or 10 mg/kg were based on participant response.
3039079|NCT00390884|Experimental|Fluzone®-Primed Group|Participants had received two doses of the 2005-2006 formulation of Fluzone® vaccine in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
3039080|NCT00390884|Experimental|Fluzone®-Naive Group|Participants had never received Influenza vaccine and had received two doses of placebo in the fall of 2005 (Study GRC28, NCT00242424), will receive 2 doses of Fluzone® Pediatric 2006-2007 formulation.
3039081|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group I|Very preterm infants born after a gestation period of 27-30 weeks (189-216 days)
3039082|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group II|Mild pretem infants born after a gestation period of 31-36 weeks (217-258 days)
3039083|NCT00390910|Experimental|Synflorix™ + Infanrix™ hexa Group III|Infants born after a gestation period of more than 36 weeks (more than 258 days)
3039084|NCT00390949|Experimental|Intervention arm|Peer education with female sex workers and potential male clients. Strengthened syndromic management of STIs with community-based promotion activities
3039085|NCT00390949|No Intervention|Control|Standard of care
3039086|NCT00391027|Active Comparator|Insulin Glargine (Lantus®)|
3039087|NCT00391027|Active Comparator|Inhaled Human Insulin (Exubera®)|
3039088|NCT00391053|Experimental|Study Group 1|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 1
3039089|NCT00391053|Experimental|Study Group 2|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 2
3039090|NCT00391053|Experimental|Study Group 3|Participants will receive the High-Dose Inactivated, Split-Virion Influenza Vaccine Lot 3
3039091|NCT00391053|Active Comparator|Group 4|Participants will receive the Standard Fluzone® vaccine
3039092|NCT00391079|Experimental|A|
3039093|NCT00391079|Placebo Comparator|B|
3039094|NCT00391092|Experimental|1|
3039095|NCT00391092|Active Comparator|2|
3039096|NCT00391118|Experimental|A (Part A)|"Enzastaurin: 1125 milligram (mg) loading dose then 500 mg oral tablet, daily for six 21-day cycles or up to 3 years~Carboplatin: Area under the concentration time curve (AUC) 5 intravenous (IV), every (q) 21 days for six 21-day cycles~Paclitaxel:175 milligrams/square meter (mg/m²) IV, q21 days for six 21-day cycles"
3039097|NCT00391118|Placebo Comparator|B (Part B)|"Carboplatin: AUC5 IV, q21 days for six 21-day cycles~Paclitaxel: 175 mg/m², IV, q21 days for six 21-day cycles~Placebo: oral tablet"
3039098|NCT00391222|Experimental|001|Risperidone Long Acting Injectable (LAI) Intramuscular injections of risperidone LAI (25 37.5 or 50 mg) every 2 weeks and oral placebo daily
3039099|NCT00391222|Placebo Comparator|002|Placebo Intramuscular injections of placebo every 2 weeks and oral placebo daily
3039100|NCT00391222|Active Comparator|003|Olanzapine Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
3039101|NCT00391274|Experimental|Pemetrexed|
3039102|NCT00391274|Active Comparator|Docetaxel|
3039103|NCT00391365||Group 1|Subjects undergoing ankle arthrodesis (fusion) for treatment of ankle arthritis
3039104|NCT00391365||Group 2|Subjects undergoing ankle arthroplasty (replacement) for treatment of ankle arthritis
3039105|NCT00391391|Experimental|1|Split, Inactivated, Trivalent Influenza Vaccine
3039106|NCT00391391|Experimental|2|Split, Inactivated, Trivalent Influenza Vaccine
3039107|NCT00391391|Active Comparator|3|Split, Inactivated, Trivalent Influenza Vaccine
3039108|NCT00391391|Active Comparator|4|Split, Inactivated, Trivalent Influenza Vaccine
3039109|NCT00391443|Experimental|Bosentan|Subjects receive bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg b.i.d (if body weight > 40 kg) or bosentan 62.5 mg b.i.d. (if body weight < 40 kg)
3039110|NCT00391443|Placebo Comparator|Placebo|Subjects receive placebo matching the bosentan treatment regimen
3039111|NCT00391469|No Intervention|control treatment|
3039112|NCT00391586|Experimental|Erlotinib followed by chemotherapy|"Erlotinib: 150 mg orally once daily,~Platinum-based chemotherapy regimen selections include:~Carboplatin (Carbo) area under the curve (AUC) 6, or cisplatin (Cis) 60-100 mg/m2, day (D)1, administered with one of the following:~Docetaxel 75 mg/m2, D1~Docetaxel 35 mg/m2, D1,8,15~Paclitaxel 200-225 mg/m2, D1~Paclitaxel 80-100 mg/m2, D1,8,15~Carbo AUC 5-6, or Cis 60-100 mg/m2, D1, administered with one of the following:~Etoposide 100 mg/m2 D1-3~Etoposide 200 mg/m2 orally D1-3~Pemetrexed 500 mg/m2, D 1~Irinotecan 50 mg/m2 D1,8,15~Other regimens:~Gemcitabine 1000 mg/m2-1250 mg/m2, D1,8 + Carbo AUC 6, or Cis 60-100 mg/m2, D1 or 8~Vinorelbine 25 mg/m2 D1,8 + Carbo AUC 5, or Cis 80 mg/m2 D1"
3039113|NCT00391599|Experimental|Study Group|a fleet enema (250 cc of sodium biphosphate 16 gr and sodium phosphate 6 gr per 100 cc) the night before cesarean section
3039114|NCT00391599|Active Comparator|Control Group|no preoperative intestinal preparation.
3039115|NCT00391625|Experimental|GA-GCB|15-60 U/kg every other week via intravenous infusion
3039116|NCT00391716|Experimental|gabapentin 900mg daily|900mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
3039117|NCT00391716|Experimental|gabapentin 1800mg daily|1800 mg gabapentin daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks
3039118|NCT00391716|Placebo Comparator|placebo daily|placebo capsules daily for 12 weeks and weekly concomitant manualized behavioral counseling for 12 weeks.
3039119|NCT00391768|Experimental|oseltamivir (Tamiflu®)|
3039120|NCT00391807|Experimental|study drug|Norethindrone/Ethinyl Estradiol
3039121|NCT00391846|Other|Guided by NT-proBNP|Treatment guided by clinical symptoms and signs + NTproBNP
3039122|NCT00391846|Other|Not Guided by NT-proBNP|Treatment guided by clinical symptoms and signs
3039123|NCT00391872|Active Comparator|Clopidogrel|Oral treatment
3039124|NCT00391872|Experimental|Ticagrelor|Oral treatment
3039125|NCT00391898|Experimental|Levodopa/carbidopa/entacapone|
3039126|NCT00391898|Active Comparator|Levodopa/carbidopa|
3039127|NCT00391976|Experimental|Tobramycin 300 mg for 28 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 28 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
3039128|NCT00391976|Experimental|Tobramycin 300 mg for 56 days|Patients inhaled tobramycin 300 mg bis in die (bid, twice a day) for 56 days using the PARI LC PLUS™ jet nebulizer and a suitable compressor. The 2 daily doses were taken approximately 12 hours apart and no less than 6 hours apart.
3039129|NCT00392015|Experimental|Dose-escalation|NMRC-M3V-Ad-PfCA
3039130|NCT00392015|Experimental|Regimen-comparison|NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA
3039131|NCT00392041|Experimental|Eszopiclone|
3039132|NCT00392041|Placebo Comparator|Placebo|
3039133|NCT00392054|Experimental|Catheter Ablation|Pulmonary vein isolation performed by catheter ablation for the prevention of recurrence of symptomatic atrial fibrillation
3039134|NCT00392054|Active Comparator|Antiarrhythmic Drug Therapy|Conventional antiarrythmic drug therapy for the prevention of recurrence of symptomatic atrial fibrillation
3039135|NCT00392171|Experimental|Temozolomide|Temozolomide will be administered at a dose of 50 mg/m^2 for cycles of 28 days for 12 months or until progression.
3039136|NCT00392210|No Intervention|Spontaneous Fill|
3039137|NCT00392210|Active Comparator|Retrograde Fill|
3039138|NCT00392223|Experimental|Treatment Group A|
3039139|NCT00392223|Experimental|Treatment Group B|
3039140|NCT00392236|Experimental|A|Participants will receive treatment as usual and a 2-way pager for 6 months
3039141|NCT00392236|Active Comparator|B|Participants will receive treatment as usual
3039142|NCT00392288|Placebo Comparator|Placebo MDI|double-blind
3039143|NCT00392288|Experimental|Ciclesonide MDI 40 µg BID|double-blind
3039144|NCT00392288|Experimental|Ciclesonide MDI 80 µg BID|double-blind
3132845|NCT03457727|Experimental|Subjects receiving danirixin without omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) in fasted or fed state in a cross-over manner.
3039145|NCT00392327|Active Comparator|Arm A (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD five days a week for 6 weeks. Patients also receive vincristine sulfate IV over 1 minute once weekly for 6 weeks. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive cisplatin IV over 6 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 8, and cyclophosphamide IV over 1 hour on days 2 and 3. Patients also receive filgrastim SC or IV beginning on day 4 and continuing until blood counts recover (at least 10 days).~Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity."
3039146|NCT00392327|Experimental|Arm B (chemoradiotherapy)|"CHEMORADIOTHERAPY: Patients receive vincristine sulfate and undergo radiation therapy as in Arm A. Patients also receive carboplatin IV over 15 minutes on each day of radiation therapy. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm A."
3039147|NCT00392327|Experimental|Arm C (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm A. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive isotretinoin PO BID on day 1 and days 16-28 and cisplatin, vincristine sulfate, cyclophosphamide, and filgrastim as in Arm A maintenance therapy. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive isotretinoin PO BID on days 15-28 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3039148|NCT00392327|Experimental|Arm D (chemoradiotherapy, isotretinoin-CLOSED TO ACCRUAL)|"CHEMORADIOTHERAPY: Patients undergo chemoradiotherapy as in Arm B. Six weeks after completion of chemoradiotherapy, patients proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive maintenance therapy as in Arm C. Patients then proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive continuation therapy as in Arm C."
3039149|NCT00392379|Experimental|A|4 mg nicotine lozenges for 3 months
3039150|NCT00392379|Placebo Comparator|B|Placebo nicotine lozenges for 3 months
3039151|NCT00392392|Experimental|Intervention|Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.
3039152|NCT00392444|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3039153|NCT00392496|Experimental|Arm I|This is a non-randomized, open-label, multicenter study. Patients receive sunitinib malate orally once daily on days 1-28. Treatment repeats every 4 weeks for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity.
3039154|NCT00392665|Active Comparator|Erlotinib + Bevacizumab|erlotinib plus bevacizumab
3039155|NCT00392665|Active Comparator|Erlotinib + Sulindac|erlotinib plus sulindac
3039156|NCT00392678|Placebo Comparator|Placebo|Placebo, appearance matched to active drug
3039157|NCT00392678|Active Comparator|3 gram|Salsalate 3.0 grams daily, divided
3039158|NCT00392678|Active Comparator|3.5 gram|Salsalate 3.5 g daily, divided
3039159|NCT00392678|Active Comparator|4 gram|Salsalate 4.0 g daily, divided
3039160|NCT00392704|Experimental|Intervention|"All patients initially received treatment with paclitaxel 200 mg/m2, 3 hour IV infusion days 1 and 22; carboplatin area under the curve (AUC) 6.0 IV, days 1 and 22; 5-fluorouracil (5-FU) 200 mg/m2 daily by 24-hour continuous IV infusion, days 1 to 43; bevacizumab 15 mg/kg IV infusion days 1 and 22.~One to three weeks after completing neoadjuvant therapy, patients began treatment with concurrent chemoradiation, bevacizumab, and erlotinib. Radiation therapy began on day 1, with 1.8-Gy single daily doses, Monday through Friday, to a total dose of 68.4 Gy. Paclitaxel 50 mg/m2 was administered by 1-hour IV infusion on days 1 and 22. Erlotinib 150 mg by mouth daily began concurrently with radiation therapy and continued daily during the 7-week course of radiation."
3039161|NCT00392769|Experimental|Cetuximab|400 mg/m^2 intravenous (IV) over 120 Minutes, followed by weekly infusions at 250 mg/m^2 IV over 60 minutes.
3039162|NCT00392782|Experimental|Natural Killer Cell Kir Epitope|
3039163|NCT00392808|Experimental|MENC-CRM/MENC-CRM|Children primed with 3 doses of MenC-CRM vaccine, Intervention: boosted with one dose of MenC-CRM vaccine
3039164|NCT00392808|Experimental|MENC-CRM/MENC-TT|Children Primed with three doses of MenC-CRM vaccine. Intervention: boosted with one dose of MenC-TT
3039165|NCT00392808|Experimental|MENC-TT/MENC-CRM|Children primovacccinated with two MenC-TT vaccine doses. Intervention: boosted with one dose MenC-CRM vaccine
3039166|NCT00392808|Experimental|MENC-TT/MENC-TT|Children primovacccinated with two MenC-TT vaccine doses. Intervention boosted with one dose MenC-TT vaccine
3039167|NCT00392821|Experimental|RAD001 and Sorafenib|RAD001 and Sorafenib
3039168|NCT00392834|Experimental|Regimen A (R-CODOX-M chemotherapy)|Patients receive rituximab IV and doxorubicin hydrochloride IV over 15 minutes on day 1, cyclophosphamide IV over 30-60 minutes on days 1 and 2, pegfilgrastim SC on day 3, vincristine IV on days 1 and 8, high-dose methotrexate IV over 2-4 hours on day 15, and leucovorin calcium IV beginning 24 hours after the start of methotrexate and continuing every 6 hours until level is adequate. Patients receive CNS prophylaxis of methotrexate IT, cytarabine IT, and hydrocortisone IT on day 1. Patients with high-risk disease receive an additional dose of cytarabine IT on day 3. Patients also receive G-CSF SC once daily on days 3-9. Once the methotrexate levels drops below 50 nmol/L, patients resume G-CSF SC once daily beginning on approximately day 18 and continuing until blood counts recover.
3132846|NCT03457727|Experimental|Subjects receiving danirixin with omeprazole: Part B|Subjects will receive a single oral dose of 50 mg danirixin formulation (selected in Part A) along with once daily 40 mg OMP capsule in fasted or fed state in a cross-over manner.
3132847|NCT03457909|Experimental|DS-MCE|outpatients who have esophagus symptoms will take DS-MCE and conventional endoscopy examination examination successively.
3132848|NCT03458702|Experimental|YogaFit then Quiet Rest|Participants participated in a 30 min YogaFit and then a session of 30 min of Quiet Rest on a separate day.
3039169|NCT00392834|Experimental|Regimen B (rituximab and IVAC chemotherapy)|Patients receive rituximab IV on day 1, ifosfamide IV continuously and etoposide IV continuously over 24 hours on days 1-5, and high-dose cytarabine IV over 1-3 hours twice daily on days 1-2. Patients receive CNS prophylaxis comprising methotrexate IT and hydrocortisone IT on day 5. Patients also receive pegfilgrastim SC once 24-48 hours after completion of chemotherapy OR G-CSF SC beginning on day 6 and continuing until blood counts recover. Patients with CNS involvement (leptomeningeal and/or intraparenchymal) at diagnosis do not receive CNS prophylaxis as above. Instead, these patients receive a combination of sequential liposomal cytarabine and methotrexate IT or via an Ommaya reservoir on day 1 and then every 14 days as tolerated until completion of systemic chemotherapy.
3039170|NCT00392925|Experimental|Placebo and Metreleptin|Placebo-pramlintide 600 microliters (µL) twice a day (BID) and metreleptin (recombinant-methionyl human leptin) 5 milligram (mg) BID, 20 weeks
3039171|NCT00392925|Experimental|Pramlintide Acetate and Placebo|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and placebo-metreleptin 1 mL BID, 20 weeks
3039172|NCT00392925|Experimental|Pramlintide Acetate and Metreleptin|Lead-in period: 2 weeks pramlintide acetate 180 mcg BID, then 2 weeks pramlintide acetate 360 mcg BID Study period: Pramlintide acetate 360 mcg BID and metreleptin (recombinant-methionyl human leptin) 5 mg BID, 20 weeks
3039173|NCT00392925|Other|Lead-In Period|During the Lead-In Period before a participant was randomized to a study arm, the participant received 180 mcg pramlintide acetate twice a day (BID) for 2 weeks, followed by 360 mcg pramlintide acetate BID for 2 weeks (total of 4 weeks in the Lead-In Period).
3039174|NCT00392951|Experimental|Sirolimus treatment|Sirolimus treatment
3039175|NCT00392990|Experimental|Alternating doxil/Magrath regimen & rituximab/Magrath regimen|Patients are stratified between high risk and low risk disease status. Low risk patients receive 3 cycles of rituximab (500 mg/m2) R-CODOX-M chemotherapy IV over 2-4 hours with intrathecal chemotherapy (Regimen A). High risk patients receive 1 cycle of R-CODOX-M chemotherapy IV followed by R-IVAC chemotherapy over 30 minutes(Regimen B); regimens A and B are then repeated.
3039176|NCT00393029|Experimental|Patients with metastatic melanoma|Melanoma is a serious form of skin cancer that develops in the skin cells that make our skin color (melanocytes).
3039177|NCT00393029|Experimental|Patients with other metastatic cancers|
3039178|NCT00393042|Experimental|Focalin XR then Adderall XR|Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.
3039179|NCT00393042|Experimental|Adderall XR then Focalin XR|Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.
3039180|NCT00393068|Experimental|Treatment|"Prior to surgery study treatment will be given over a 6 weeks (Days 1-42) period. Beginning Day 1 and continuing through Day 35 patients will receive a continuous infusion of 5-FU by vein. A small portable pump will be used to administer this drug into a tube that has been surgically inserted into the patient's vein. On Day 1 and 22 patients will also receive the drugs paclitaxel, carboplatin and bevacizumab by vein. Erlotinib is given by mouth beginning on Day 1 and continuing through Day 45. Patients will receive radiation therapy daily, Monday through Friday, beginning Day 1-35 (approximately 5 weeks).~Surgery will be performed approximately 12-14 weeks after beginning this combined treatment."
3039181|NCT00393094|Experimental|Bevacizumab & Irinotecan Patients|Bevacizumab - 10 mg/kg intravenous injection Irinotecan - 125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
3039182|NCT00393367|Placebo Comparator|Saline Placebo|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this placebo comparator arm will then receive 2 nebulized albuterol doses mixed with 8mL of normal saline. Finally, all patients will receive the second nebulized ipratropium dose.
3039183|NCT00393367|Experimental|Budesonide Inhalaiton Suspension|All subjects will receive 3 albuterol sulfate doses, 2 ipratropium bromide doses, and systemic corticosteroids. All patients will receive both the systemic corticosteroids and one dose of a mixture of albuterol and ipratropium bromide while guardians are approached for consent. Patients randomized to this intervention arm will then receive 2 nebulized albuterol doses mixed with 8mL of budesonide inhalation suspension (BIS). Finally, all patients will receive the second nebulized ipratropium dose.
3039184|NCT00393380|Experimental|Parathyroid Hormone (teriparatide)|Parathyroid hormone after double umbilical cord blood transplant.
3039185|NCT00393458|Experimental|Indacaterol 300 μg plus placebo to formoterol|Patients inhaled indacaterol 300 μg once daily via a single-dose dry-powder inhaler (SDDPI), placebo to indacaterol once daily via a SDDPI, and placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol, placebo to indacaterol, and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3039186|NCT00393458|Experimental|Indacaterol 600 μg plus placebo to formoterol|Patients inhaled indacaterol 600 μg (two 300 μg capsules) once daily via single-dose dry-powder inhalers (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3132849|NCT03458702|Experimental|Quiet Rest then YogaFit|Participants participated in a 30 min Quiet Rest session and then a session of 30 min of YogaFit on a separate day.
3132850|NCT03458871|Experimental|4-week TTNS home based protocol|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 4-week protocol.
3132851|NCT03459040|Experimental|alpha-1-antitrypsin (AAT)|16 doses of AAT through a catheter placed into a blood vessel over eight weeks.
3039187|NCT00393458|Active Comparator|Formoterol 12 μg plus placebo to indacaterol|Patients inhaled formoterol 12 μg twice daily via the manufacturer's proprietary inhalation device (Aerolizer®) plus placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI). Formoterol and placebo to indacaterol were taken in the morning between 8:00 and 10:00 AM; formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3039188|NCT00393458|Placebo Comparator|Placebo to indacaterol plus placebo to formoterol|Patients inhaled placebo to indacaterol once daily via a single-dose dry-powder inhaler (SDDPI) plus placebo to formoterol twice daily via the manufacturer's proprietary inhalation device (Aerolizer®). Placebo to indacaterol and placebo to formoterol were taken in the morning between 8:00 and 10:00 AM; placebo to formoterol was taken again 12 hours later in the evening between 8:00 and 10:00 PM. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3039189|NCT00393484|Experimental|Arm A|"Entecavir + Lamivudine placebo (0-96 weeks)~Entecavir (96-240 weeks)"
3039190|NCT00393484|Active Comparator|Arm B|"Lamivudine + Entecavir placebo (0-96 weeks)~Lamivudine (96-240 weeks)"
3039191|NCT00393510|Active Comparator|Traditional Chinese Medicine|12 herbals formulation was given as an adjuvant therapy for the patients orally twice a day.
3039192|NCT00393510|Placebo Comparator|Placebo|Placebo was made with starch and colouring materials. Given to patient orally twice a day
3039193|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine (Booster Dose)."
3039194|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 2)|"Participants had previously received a primary series of 3 doses of RECOMBIVAX HB™ (5 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a dose of 10µg/per 0.5 ml ENGERIX-B™ (Booster Dose)"
3039195|NCT00393523|Active Comparator|5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine, (Booster Dose)."
3039196|NCT00393523|Active Comparator|10 µg ENGERIX-B™ Booster (Group 4)|"Participants had previously received a primary series of 3 doses of ENGERIX-B™ (10 µg (micrograms) per dose) during the first year of life outside of the context of the study.~During this study, participants received a 10µg/0.5 ml dose of ENGERIX-B™ (Booster Dose)."
3039197|NCT00393523|Experimental|5 µg Modified Process Hepatitis B Vaccine (Group 5)|"Participants did not receive a prior vaccination with a hepatitis B vaccine.~During the study, participants received a 5µg/0.5 ml dose of Modified Process Hepatitis B Vaccine."
3039198|NCT00393705|Experimental|insulin lispro LM + insulin lispro MM|Three times per day subcutaneous injection of insulin lispro mid mixture (MM) with the possibility to change the evening injection of MM to insulin lispro low mixture (LM) if fasting blood glucose target is not achieved.
3039199|NCT00393705|Active Comparator|Insulin Biphasic Aspart 30/70 or Insulin Lispro LM|Twice daily subcutaneous injection of either insulin biphasic aspart 30/70 or insulin lispro low mixture (LM) (continuation of analogue formulation used before study enrollment).
3039200|NCT00393718|Experimental|Liraglutide|Liraglutide 0.9 mg + glibenclamide placebo
3039201|NCT00393718|Active Comparator|Glibenclamide|Glibenclamide 1.25-2.5 mg + liraglutide placebo
3039202|NCT00393796|Active Comparator|SUTENT|Study participants randomized to received SUTENT will receive a dose of 50 mg PO (capsules) as a single agent to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
3039203|NCT00393796|Placebo Comparator|Placebo|Study participants randomized to receive placebo will receive 50 mg/day PO (capsules) of an inactive substance to be taken once daily for four consecutive weeks followed by a two week rest period to form a complete cycle of six weeks.
3039204|NCT00393848|Experimental|Experiment 2 - Experimental Group|
3039205|NCT00393848|No Intervention|Experiment 1 - Standard of care Group|
3039206|NCT00393848|Experimental|Experiment 1 - Experimental Group|
3039207|NCT00393848|Placebo Comparator|Experiment 2 - Placebo Group|
3039208|NCT00393861|Experimental|oxaliplatin & bevacizumab|
3039209|NCT00393874|Active Comparator|Medication|Treatment will be conducted under double blind conditions and will last a total of 8 weeks. Participants will also receive printed educational material about sleep hygiene developed by the American Academy of Sleep Medicine. Items include going to bed when drowsy, avoiding clock watching while awake in bed, avoidance of caffeine and alcohol, engaging in moderate exercise, and ensuring comfortable sleep environment. Clinical ratings will be obtained weekly throughout the trial.Medications will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose. The research pharmacy will prepare each dose in identical gelatin capsules to prevent identification.
3039210|NCT00393874|Active Comparator|Behavioral|"Participants randomized to BSI will receive the intervention aimed at reducing nightmares, insomnia, and sleep avoidance behavior. The treatment will be administered over 8 weeks. The intervention sessions will consist of two individual, 45-minute treatment sessions, delivered on Weeks 1 and 3. A 45-minute booster session will be conducted on Week 5. Thirty-minute face-to-face contacts will be scheduled on other weeks (i.e., Weeks 2, 4, 6, 7 and 8) to address any difficulty with the treatment instructions and techniques, to answer questions that may have occurred, and to complete weekly clinical ratings (CGI-I/SR and ASES)."
3132852|NCT03459131|Other|BIOFINITY ENERGYS then BIOFINITY|Comfilcon A with Digital Zone Optics™ contact lenses worn first, followed by comfilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
3132853|NCT03459131|Other|BIOFINITY then BIOFINITY ENERGYS|Comfilcon A contact lenses worn first, followed by comfilcon A with Digital Zone Optics™ contact lenses. Each product will be worn bilaterally (in both eyes) for 7 days in a daily wear modality.
3039211|NCT00393874|Placebo Comparator|Placebo|Participants randomized to PLA will take 4 capsules each night, and capsule will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed. A placebo pill condition is included for several reasons. First, there is no approved treatment approach currently recognized as being effective for sleep disturbances associated with combat-related PTSD, and which is being withheld from subjects assigned to the placebo arm of the study. We will monitor subjects carefully and on a weekly basis.
3039212|NCT00393887|Experimental|1|Biodesign IHM Graft placement
3039213|NCT00393887|Active Comparator|2|Polypropylene mesh placement
3039214|NCT00393913||Continuous Positive Airway Pressure (CPAP)|Participants will use a CPAP machine if they are found to have sleep apnea.
3039215|NCT00393939|Experimental|A|
3039216|NCT00393939|Active Comparator|B|
3039217|NCT00393978|Placebo Comparator|Quetiapine and Placebo|Quetiapine and Placebo
3039218|NCT00393978|Active Comparator|Quetiapine and Topiramate|Quetiapine and Topiramate
3039219|NCT00394082|Experimental|ABI-007 plus Bevacizumab|ABI-007 is administered on days 1, 8 and 15 at 125 mg/m^2 and bevacizumab is administered on day 1 and 15 at 10 mg/kg of each 28 day cycle. Treatment continues until disease progression or intolerable toxicity. If a patient develops intolerable toxicity to only one of the drugs, the other drug may be continued as single agent therapy in the absence of progression, as long as the treating physician feels this is in the best interests of the patient.
3039220|NCT00394095|Experimental|Topiramate Group|Patients' initial dose of topiramate 25mg bid, which was titrated over 18 days to 150 mg bid (with flexibility to titrate to 200mg bid) as tolerated.
3039221|NCT00394095|Placebo Comparator|Placebo Group|Sugar pill
3039222|NCT00394212|Experimental|1|Transoral suturing of the dilated gastrojejunostomy
3039223|NCT00394212|Sham Comparator|2|Sham Endoscopy (suturing not performed)
3039224|NCT00394251|Experimental|AC --> ABI-007|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m^2 ABI-007 (Abraxane) plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
3039225|NCT00394251|Experimental|AC --> Taxol|Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 175 mg/m^2 Taxol plus Bevacizumab for four cycles (weeks 9-16); Bevacizumab (weeks 17-46).
3039226|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1200 mg|
3039227|NCT00394277|Experimental|PEG-IFN 180 µg + Ribavirin 1400/1600 mg|
3039228|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1200 mg|
3039229|NCT00394277|Experimental|PEG-IFN 360/180 µg + Ribavirin 1400/1600 mg|
3039230|NCT00394329|Experimental|Daily ICS + Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir®™ 90 mcg Inhalation Aerosol) rescue puffs as needed
3039231|NCT00394329|Active Comparator|Daily ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) one puff bid + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3039232|NCT00394329|Experimental|Rescue ICS|Beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed + albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3039233|NCT00394329|Placebo Comparator|Placebo|Albuterol sulfate administered via a hydrofluoroalkane (HFA) inhaler (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
3039234|NCT00394355|Experimental|Group 1|MF DPI 400 mcg once a day (QD) in the evening (PM)
3039235|NCT00394355|Experimental|Group 2|MF DPI 200 mcg QD PM
3039236|NCT00394355|Active Comparator|Group 3|Fluticasone propionate (FP) metered dose inhaler (MDI) 250 mcg twice a day (BID)
3039237|NCT00394355|Active Comparator|Group 4|ML 10 mg QD PM
3039238|NCT00394433|Experimental|Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA)|Patients received bevacizumab 10 mg/kg IV on day 1 every 3 weeks while on study. Additionally, they received docetaxel 30 mg/m2 IV over 30 minutes, followed by cisplatin 25 mg/m2 IV over 30 minutes, followed by irinotecan 50 mg/m2 IV over 30 minutes on days 1 and 8 of each 3-week cycle until disease progression or unacceptable toxicity. Dose reductions were not permitted for bevacizumab although treatment could be held up to 2 months. If bevacizumab was discontinued, treatment with other agents could continue. When docetaxel, cisplatin, or irinotecan was held on day 1 of a cycle, all agents were held.
3039239|NCT00394524|Experimental|Computer assisted IV insulin infusion|Subjects in this group will receive continuous intravenous (IV) Insulin Infusion using glucommander computer guided system. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
3039240|NCT00394524|Active Comparator|Standard insulin infusion algorithm|Subjects in this group will receive Insulin using Standard insulin infusion algorithm. All patients in the study will receive Glulisine(Apidra R ) a rapid acting insulin approved by Food and Drug Administration (FDA)
3039241|NCT00394589|Experimental|Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks
3039242|NCT00394589|Experimental|Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab, every 8 weeks
3039243|NCT00394589|Active Comparator|Control|Continuation of infliximab 3 mg/kg every 8 weeks
3039244|NCT00394654|Experimental|MEDI528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
3039245|NCT00394654|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
3039246|NCT00394706|Experimental|1|Use of Impedance Threshold Device (ITD)
3039247|NCT00394706|Sham Comparator|2|Sham ITD
3039248|NCT00394706|Other|3|Analyze early. Upon EMS (emergency medical services) arrival at the scene of a non-traumatic cardiac arrest, the EMS providers assess the cardiac rhythm as soon as possible. Approximately thirty seconds of CPR (cardiopulmonary resuscitation) may be done prior to an assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
3320832|NCT02014103|Other|Sequence 2|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 2: Formulation 3, 4, 6, 5, 1, 2.
3039249|NCT00394706|Other|4|Analyze late. Upon the EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is done prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
3039250|NCT00394771|Experimental|Low Dose DR-1031|42 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3039251|NCT00394771|Experimental|Midrange Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 42 days combination active tablets (25 mcg EE/ 150 mcg LNG) followed by 21 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3039252|NCT00394771|Experimental|High Dose DR-1031|21 days combination active tablets (20 mcg EE /150 mcg LNG) followed by 21 days combination active tablets (25 mcg EE/150 mcg LNG) followed by 42 days combination active tablets (30 mcg EE/ 150 mcg LNG) followed by 7 days of 10 mcg EE tablets.
3039253|NCT00394771|Active Comparator|Seasonale|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets.
3039254|NCT00394888|Other|Facial Hemangioma|Patients with large facial hemangioma.
3039255|NCT00394888|Other|Lumbosacral Hemangioma|Patients with lumbosacral hemangioma.
3039256|NCT00394888|Other|Multiple Hemangiomas|patients with multiple hemangiomas (>5)
3039257|NCT00394901|Placebo Comparator|Placebo|
3039258|NCT00394901|Experimental|Pregabalin 150mg/day|
3039259|NCT00394901|Experimental|Pregabalin 300mg/day|
3039260|NCT00394901|Experimental|Pregabalin 600mg/day|
3039261|NCT00394914|Experimental|Pleconaril|Participants will receive Pleconaril nasal spray 4 sprays per nostril twice daily (BID), 24 mg/day for 1 week during the Treatment Period for a total of 14 doses.
3039262|NCT00394914|Placebo Comparator|Placebo|Participants will receive placebo nasal spray 4 sprays per nostril BID for 1 week during the Treatment Period for a total of 14 doses.
3039263|NCT00394953|Experimental|MIRCERA|Eligible participants with anemia in CKD who were on hemodialysis will receive methoxy polyethylene glycol-epoetin beta (MIRCERA [RO0503821]) IV once every month up to 52 weeks. The starting dose of MIRCERA which will be administered during the treatment period will depend on the dose of darbepoetin alfa administered during screening period i.e., 120, 200 and 360 mcg for weekly darbepoetin alfa doses of <40, 40-80, and >80 mcg, respectively.
3039264|NCT00394953|Active Comparator|Darbepoetin Alfa|Eligible participants with anemia in CKD who were on hemodialysis will receive darbepoetin alfa (Aranesp) IV once every two weeks up to 26 weeks and darbepoetin alfa IV twice the dose than earlier, once every month from Week 27 up to Week 52.
3039265|NCT00395018|Experimental|entecavir|
3039266|NCT00395044|Experimental|Gabapentin|1200 mg/daily of Gabapentin
3039267|NCT00395044|Placebo Comparator|Placebo|1200mg/d of Placebo
3039268|NCT00395057|Experimental|AGN 211745 Solution 1000 ug|AGN 211745 Solution 1000 ug
3039269|NCT00395057|Experimental|AGN 211745 Solution 300 ug|AGN 211745 Solution 300 ug
3039270|NCT00395057|Experimental|AGN 211745 Solution 100 ug|AGN 211745 Solution 100 ug
3039271|NCT00395057|Active Comparator|Ranibizumab 500 ug|Ranibizumab 500 ug
3039272|NCT00395083|No Intervention|Group 1|Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
3039273|NCT00395083|Experimental|Group 2|The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care.
3039274|NCT00395135|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3039275|NCT00395135|Placebo Comparator|Matching Placebo BID|Matching placebo tablet each morning and evening
3039276|NCT00395161|Experimental|zinc selenium glutamine metoclopramide|metoclopramide, zinc, selenium, and glutamine
3039277|NCT00395161|Placebo Comparator|enteral whey protein and IV saline|saline, sterile water, whey protein
3039278|NCT00395226|Experimental|Zinc sulfate|220 mg of zinc sulfate
3039279|NCT00395226|Placebo Comparator|Lactose|270 mg lactose
3039280|NCT00395291|Experimental|MK-0677 then Placebo|MK-0677 and Placebo - All subjects were given MK-0677 for a 30 +/- 7 days and then they were given a placebo for 30 +/- 7 days.
3039281|NCT00395291|Experimental|Placebo then MK-0677|MK-0677 and Placebo - All subjects were given Placebo for a 30 +/- 7 days and then they were given MK-0677 for 30 +/- 7 days.
3039282|NCT00395304|Experimental|Sequence #1|fluticasone propionate + montelukast, followed by fluticasone propionate, followed by fluticasone propionate + salmeterol
3039283|NCT00395304|Experimental|Sequence #2|fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol, followed by followed by fluticasone propionate
3039284|NCT00395304|Experimental|Sequence #3|fluticasone propionate + salmeterol, followed by fluticasone propionate, followed by fluticasone propionate + montelukast
3039285|NCT00395304|Experimental|Sequence #4|fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast, followed by fluticasone propionate
3039286|NCT00395304|Experimental|Sequence #5|fluticasone propionate, followed by fluticasone propionate + salmeterol, followed by fluticasone propionate + montelukast
3039287|NCT00395304|Experimental|Sequence #6|fluticasone propionate, followed by fluticasone propionate + montelukast, followed by fluticasone propionate + salmeterol
3039288|NCT00395343|Experimental|1|sitagliptin
3039289|NCT00395343|Placebo Comparator|2|Placebo
3039290|NCT00395447||Straight-forward Device Replacement|Subject with a straight-forward device replacement without lead revisions or additions.
3039291|NCT00395447||Device Replacement with Upgrade|Subjects with a device replacement and planned lead upgrade, revision, or addition.
3039292|NCT00395460|Experimental|Gadobutrol 0.1 mmol/kg Body Weight (BW) (Gadavist, BAY86-4875)|Participant received 0.1 mmol/kg BW Gadobutrol (= 0.1 mL/kg BW by intravenous injection at a rate of 1.0 mL/sec)
3039293|NCT00395460|Active Comparator|GD 0.1 mmol/kg BW (Magnevist, BAY86-4882)|Participant received 0.1 mmol/kg BW Gadopentetate Dimeglumine (GD) (= 0.2 mL/kg BW by intravenous injection at a rate of 2.0 mL/sec
3039294|NCT00395486|Experimental|Rosuvastatin|
3039295|NCT00395486|Active Comparator|Atorvastatin|
3039296|NCT00395512|Experimental|Alogliptin 25 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 26 weeks.
3039297|NCT00395512|Active Comparator|Pioglitazone 30 mg QD|Pioglitazone 30 mg, tablets, orally, once daily and alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
3039298|NCT00395512|Experimental|Alogliptin 25 mg QD+ Pioglitazone 30 mg QD|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3039299|NCT00395512|Active Comparator|Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 26 weeks.
3039300|NCT00395538|Other|Biopsy|Subjects are randomized to have the second bone biopsy done 1,2, or 4 years after the start of PTH.
3039301|NCT00395629|Experimental|ICL670 (Deferasirox)|Three dose cohorts: 5 mg/kg/day, 10 mg/kg/day, 15 mg/kg/day
3039302|NCT00395642|Experimental|HM with weight and BP remote monitoring|Device based Home Monitoring and weight and blood pressure remote monitoring
3039303|NCT00395694|Experimental|lamictal|
3039304|NCT00395733|Experimental|Gadobutrol, then Gadopentate dimeglumine|Period 1: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged; Period 2: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged
3039305|NCT00395733|Experimental|Gadopentate, dimeglumine then Gadobutrol|Period 1: Participant received Gadopentate 0.5 M (iv), at a dose of 0.4 mL/kg BW, up to 0.6 mL/kg BW if 3 FOVs to be imaged; Period 2: Participant received Gadobutrol 1.0 M (iv: intravenous injection), at a dose of 0.2 mL/kg BW, up to 0.3 mL/kg BW if 3 Fields of View (FOVs) to be imaged
3039306|NCT00395746|Experimental|0.6 mg + SU|Liraglutide 0.6 mg + sulphonylurea
3039307|NCT00395746|Experimental|0.9 mg + SU|Liraglutide 0.9 mg + sulphonylurea
3039308|NCT00395746|Placebo Comparator|SU Mono - 1|Liraglutide placebo 0.6 mg + sulphonylurea
3039309|NCT00395746|Placebo Comparator|SU Mono - 2|Liraglutide placebo 0.9 mg + sulphonylurea
3039310|NCT00395850|Placebo Comparator|1|microcrystalline cellulose
3039311|NCT00395850|Experimental|2|disulfiram at 250 mg/day
3039312|NCT00395850|Experimental|3|Disulfiram at 375 mg/day
3039313|NCT00395850|Experimental|4|Disulfiram at 500 mg/day
3039314|NCT00395863|Active Comparator|MultiHance|0.5 M MultiHance at a single injection
3039315|NCT00395863|Active Comparator|Magnevist|0.5 M Magnevist at a single injection
3039316|NCT00395876|Placebo Comparator|Placebo + Tenecteplase + Tenecteplase (PTT)|
3039317|NCT00395876|Experimental|Tenecteplase + Tenecteplase + Placebo (TTP)|
3039318|NCT00395967|Experimental|All Patients|Patients who were predicted to be unable to mobilize a minimum number of cells (≥2*10^6 CD34+ cells/kg) in 3 apheresis days when given granulocyte colony-stimulating factor (G-CSF) alone and who were eligible for autologous peripheral blood stem cell transplantation.
3039319|NCT00395993|Experimental|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
3039320|NCT00395993|Active Comparator|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
3039321|NCT00396032|Experimental|1|
3039322|NCT00396032|Placebo Comparator|2|
3039323|NCT00396084|Experimental|Gatifloxacin|10 subjects to receive gatifloxacin 400 mg orally once daily for 7 days.
3039324|NCT00396084|Active Comparator|Isoniazid|20 subjects to receive isoniazid 300 mg orally once daily for 7days.
3039325|NCT00396084|Experimental|Levofloxacin|10 subjects to receive levofloxacin 1000 mg orally once daily for 7days.
3039326|NCT00396084|Experimental|Linezolid every 12 hours|10 subjects to receive linezolid 600 mg orally every 12 hours daily for 7 days.
3039327|NCT00396084|Experimental|Linezolid once daily|10 subjects to receive linezolid 600 mg orally once daily for 7days.
3039328|NCT00396084|Experimental|Moxifloxacin|10 subjects to receive moxifloxacin 400 mg orally once daily for 7 days.
3039329|NCT00396097|Active Comparator|Standard|Standard daily HGH treatment
3039330|NCT00396097|Active Comparator|Formula-based|Formula-based dose regimen
3039331|NCT00396162|Placebo Comparator|Placebo pill|Placebo pills on same schedule as active intervention.
3039332|NCT00396162|Active Comparator|Probiotic|L. rhamnosus R0011 strain
3039333|NCT00396201|Experimental|Participants with Hodgkin's Disease (HD)|Participants with Hodgkin's Disease who were eligible for autologous peripheral blood stem cell transplantation.
3039334|NCT00396253|Experimental|Tenecteplase|At each treatment, subjects had 2 mL (2 mg) of tenecteplase instilled into each lumen of their HD catheter. Subjects could receive up to three treatments with tenecteplase, the first two as part of the initial treatment course and one additional treatment as part of the retreatment (RT) course. The first treatment, followed by a 1-hour dwell time, was given to all subjects at Visit 1. At the end of hemodialysis at Visit 1, eligible subjects had a second treatment instilled for an extended dwell time until the start of Visit 2 (up to 72 hours).
3039335|NCT00396266|Experimental|Non-Hodgkin's Lymphoma (NHL)|Participants with NHL were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3039336|NCT00396266|Experimental|Multiple Myeloma (MM)|Participants with MM were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
3039337|NCT00396279|Experimental|Denosumab|Participants received denosumab 120 mg once every 4 weeks (Q4W), with an additional 120 mg doses on Days 8 and 15 of the first month of treatment. All participants were instructed to take daily supplements of at least 500 mg of calcium and 400 IU of vitamin D. Participants were to continue to receive denosumab until one of the following occurred: complete tumor resection, disease progression without clinical benefit, or decision by the participant to discontinue for any reason.
3039338|NCT00396292|Experimental|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
3039339|NCT00396292|Active Comparator|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
3039340|NCT00396318|Experimental|Tenecteplase|
3039341|NCT00396331|Experimental|G-CSF plus Plerixafor|
3039342|NCT00396383|Experimental|Participants with Multiple Myeloma (MM)|Participants with MM who were eligible for autologous peripheral blood stem cell transplantation.
3039343|NCT00396409|Experimental|Depigold+Omalizumab|Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
3039344|NCT00396409|Experimental|Depigoid+Placebo|Depigoid® (grass/rye pollen 50/50) + Placebo
3039345|NCT00396565|Experimental|ER OROS paliperidone|Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
3039346|NCT00396565|Placebo Comparator|Placebo|
3039347|NCT00396565|Active Comparator|Olanzapine|
3039348|NCT00396591|Experimental|Aflibercept|Participants with advanced ovarian epithelial cancer (including fallopian tube and primary peritoneal adenocarcinoma) treated with Aflibercept every 2 weeks until a criterion for treatment discontinuation was met
3039349|NCT00396630|Experimental|Rotarix Group|"All subjects received 2 oral doses of Rotarix vaccine at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
3039350|NCT00396630|Placebo Comparator|Placebo Group|"All subjects received 2 oral doses of placebo at Day 0 (Visit 1) and Week 7 (Visit 2).~Subjects aged less than 6 months at Visit 3 received one complimentary Rotarix vaccine dose at Week 13 (Visit 3)."
3039351|NCT00396656|Experimental|Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)|"After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning."
3039352|NCT00396656|Experimental|Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan|"After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.~After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning."
3039353|NCT00396812|Experimental|Rituximab|
3039354|NCT00396877|Placebo Comparator|Placebo|
3039355|NCT00396877|Experimental|Clopidogrel 0.2 mg/kg/day|
3039356|NCT00396981|Active Comparator|Matrix 2® Coils|Matrix 2® Coils for endovascular aneurysm occlusion
3039357|NCT00396981|Active Comparator|GDC® Coils|GDC® Coils for endovascular aneurysm occlusion
3039358|NCT00397020|Experimental|1 Divalproex ER|Divalproex ER
3039359|NCT00397020|Active Comparator|2 Quetiapine Fumarate|quetiapine fumarate
3039360|NCT00397033|Experimental|002|Paliperidone ER 12mg/day paliperidone er for 6 weeks
3039361|NCT00397033|Experimental|001|Paliperidone ER 6mg/day paliperidone er for 6 weeks
3039362|NCT00397033|Placebo Comparator|003|Placebo Placebo for 6 weeks
3039363|NCT00397046|Experimental|Neratinib 80 mg|
3039364|NCT00397046|Experimental|Neratinib 160 mg|
3039365|NCT00397046|Experimental|Neratinib 240 mg|
3039366|NCT00397046|Experimental|Neratinib 320 mg|
3039367|NCT00397150|Experimental|Intervention|Peer-support for exclusive breastfeeding
3039368|NCT00397150|No Intervention|No intervention|No intervention
3039369|NCT00397189|Experimental|Circadin|
3039370|NCT00397189|Placebo Comparator|placebo|
3039371|NCT00397215|Experimental|GSK1562902A 1 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
3039372|NCT00397215|Experimental|GSK1562902A 2 Group|Subjects aged 61 years or older at the time of first vaccination received 1 dose of GSK1562902A non-adjuvanted vaccine at Day 0. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm.
3039373|NCT00397215|Experimental|GSK1562902A 3 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
3039374|NCT00397215|Experimental|GSK1562902A 4 Group|Subjects aged 61 years or older at the time of first vaccination received 2 doses of GSK1562902A non-adjuvanted vaccine at Days 0 and 21. The vaccine was administered in the deltoid region of each arm.
3039375|NCT00397254|Active Comparator|Clinical Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a clinical limit of study medication received Rizatriptan 10mg ODT: 27 tablets per month."
3039376|NCT00397254|Active Comparator|Formulary Limit|"Eligible patients were randomized to one of two treatment regimens in a 1:1 ratio. Those randomized to receive a formulary limit of study medication received Rizatriptan 10mg ODT: 9 tablets per month."
3039377|NCT00397462|No Intervention|Control|No change to usual behavior
3039378|NCT00397462|Experimental|Low dose|Request that calf muscle pump stimulation be used less than four hours per day
3039379|NCT00397462|Experimental|High dose|Request that calf muscle pump stimulation be used at least four hours per day
3468752|NCT03892772|Active Comparator|SAS0421c|Participants will take SAS0421c for 3 days. Half doses will be given on the first night.
3039380|NCT00397488|Experimental|Sunitinib|This is a phase II trial of Sunitinib in patients with metastatic urothelial carcinoma. Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks followed by a two-week rest period for the initial population. A second cohort of patients will be enrolled, who will receive 37.5 mg of sunitinib orally, on a continuous dosing schedule. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Re-staging imaging studies will be performed after every cycle of treatment during the first 4 cycles and subsequently after every other cycle. Patients may continue on study as long as they are tolerating therapy and in the absence of disease progression.
3039381|NCT00397514||Congenital Heart Surgery Patients|Pacing protocol prior to patient's extubation with 20 min. of either conventional right ventricular (RV) or biventricular (BiV) pacing, preceded and followed by 10 min. of recovery time.
3039382|NCT00397540|Active Comparator|percutaneous ethanol injection therapy|Patients with hepatocellular carcinoma who will be treated with PEIT (percutaneous ethanol injection therapy)
3039383|NCT00397540|Active Comparator|radiofrequency thermal ablation|Patients with hepatocellular carcinoma who will be treated with RFTA (radiofrequency thermal ablation)
3039384|NCT00397579|Experimental|SL-401|Patients will be treated with a maximum of five doses of approximately 15min IV infusions of DT388IL3/SL-401 over a ten day period at a maximum of once daily.
3039385|NCT00397631|Experimental|1|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
3039386|NCT00397631|Active Comparator|2|sitagliptin 100 mg placebo q.d./pioglitazone 30 mg q.d.
3039387|NCT00397813|Experimental|Arm A - Dose Level 1|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039388|NCT00397813|Experimental|Arm A - Dose Level 2|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039389|NCT00397813|Experimental|Arm A - Dose Level 3|"Arm A - patients with MPD or MDS-RA/RARS Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039390|NCT00397813|Experimental|Arm B - Dose Level 1|"Arm B - patients with MDS-RAEB or CMML Dose Level 1 - 300 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039391|NCT00397813|Experimental|Arm B - Dose Level 2|"Arm B - patients with MDS-RAEB or CMML Dose Level 2 - 400 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039392|NCT00397813|Experimental|Arm B - Dose Level 3|"Arm B - patients with MDS-RAEB or CMML Dose Level 3 - 450 cGy TBI~NONMYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~PBSC TRANSPLANTATION: Patients undergo filgrastim-mobilized PBSC infusion after TBI on day 0.~IMMUNOSUPPRESSION:~Matched Related Donor: Patients receive cyclosporine PO BID on days -3 to 56, followed by a taper until day 180. Patients also receive MMF PO BID beginning 4-6 hours after transplantation on day 0 and continue until day 27.~Unrelated Donor: Patients receive cyclosporine PO BID on days -3 to 100, followed by a taper until day 180. Patients also receive MMF PO three times daily beginning 4-6 hours after transplantation on day 0 and continue until day 40, followed by a taper until day 96."
3039393|NCT00397839|Placebo Comparator|Placebo|
3039394|NCT00397839|Experimental|Ibandronate|
3039395|NCT00397878|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3039396|NCT00397891|Experimental|1|bapineuzumab 0.15 mg/kg or placebo
3039397|NCT00397891|Experimental|2|bapineuzumab 0.5 mg/kg or placebo
3039398|NCT00397891|Experimental|3|bapineuzumab 1.0 mg/kg or placebo
3468753|NCT03892772|Placebo Comparator|Placebo|Participants will take placebos for 3 days.
3039399|NCT00397904|Experimental|Cetuximab, Cisplatin, and Irinotecan|Cetuximab will be combined with weekly irinotecan and cisplatin. Patients will receive cetuximab 400 mg/m2 on day 1, week 1. Following this loading dose, patients will receive weekly cetuximab 250 mg/m2 (day 8, 15, 22, etc.) until disease progression or unacceptable toxicity. Patients will continue to receive irinotecan and cisplatin weekly on day 1 and day 8, on an every 21 day cycle. The standard maximum doses are irinotecan 65 mg/m2 and cisplatin 30 mg/m2.
3039400|NCT00397930|Experimental|Yoga Intervention (YOCAS)|Standardized Yoga for Cancer Survivors (YOCAS)
3039401|NCT00397930|Experimental|Standard Care Control Condition|Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.
3039402|NCT00397943|Experimental|M72/AS01B Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS01B vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3039403|NCT00397943|Experimental|M72/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of M72/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3039404|NCT00397943|Active Comparator|Mtb72F/AS02A Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator Mtb72F/AS02A vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3039405|NCT00397943|Active Comparator|Non-adjuvanted Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the comparator GSK Biologicals' candidate recombinant M. tuberculosis vaccine, non-adjuvanted, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3039406|NCT00397943|Placebo Comparator|Control Group|Healthy male or female subjects, between and including 18 to 50 years of age, who received 2 doses of the adjuvant system alone, administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 0 and Month 1.
3039407|NCT00397982|Experimental|Treatment (enzyme inhibitor, monoclonal antibody)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.
3039408|NCT00398047|Experimental|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine andHematopoietic Growth Factors
3039409|NCT00398073|Experimental|mouse gp100 DNA via PMED|patients will be randomized to mouse gp100 DNA delivered via gold particles using the PowderMed delivery system (ND10, described above). Two actuations/day will be administered every two weeks for 4 months for a total of 16 actuations. Each actuation consists of 2 μg of plasmid DNA coated onto 1000 μg of gold. The total dose of plasmid DNA given will be 32 μg DNA on 16,000 μg gold.
3039410|NCT00398073|Experimental|mouse gp100 DNA injections intramuscularly|patients will be injected with 1000 μg of mouse gp100 plasmid DNA intramuscularly. Two injections/day will be administered every two weeks for 4 months (4000 ug of mouse gp100 plasmid/month) for 16 vaccinations.
3039411|NCT00398086|Experimental|100 mg/m^2|Participants received albumin-bound paclitaxel 100 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level one). Treatment continued until progressive disease or unacceptable toxicity.
3039412|NCT00398086|Experimental|125 mg/m^2|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level two). Treatment continued until progressive disease or unacceptable toxicity.
3039413|NCT00398086|Experimental|150 mg/m^2|Participants received albumin-bound paclitaxel 150 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle (dose level three). Treatment continued until progressive disease or unacceptable toxicity.
3039414|NCT00398112|Experimental|Arm I|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3039415|NCT00398138|Experimental|vaccine|Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 & 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 & -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time & placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) & the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response & have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
3039416|NCT00398320|Experimental|Bevacizumab (Avastin), Oxaliplatin (Eloxatin)|
3039417|NCT00398398|Experimental|Capecitbine, oxaliplatin, cetuximab|Capecitbine, oxaliplatin and cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
3039418|NCT00398411|Experimental|Moxifloxacin|moxifloxacin 400 mg tablets once daily
3039419|NCT00398411|Placebo Comparator|Placebo|identical appearing placebo
3039420|NCT00398476|Active Comparator|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
3039421|NCT00398476|Active Comparator|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
3039422|NCT00398567|Experimental|Part 1 - dose level 1 (160 mg)|All subjects receiving HKI-272 dose level 1 in combination with trastuzumab
3039423|NCT00398567|Experimental|Part 1 - dose level 2 (240 mg)|All subjects receiving HKI-272 dose level 2 in combination with trastuzumab
3039424|NCT00398567|Experimental|Part 2 - expanded MTD cohort|All subjects receiving HKI-272 in combination with trastuzumab
3039425|NCT00398632|Experimental|Duloxetine|Duloxetine 60 mg, by mouth, once daily or twice daily (as needed to control symptoms of major depression)
3039426|NCT00398866|Active Comparator|1|Bupivicaine (local anesthetic)
3039427|NCT00398866|Active Comparator|2|Corticosteroid (trimcinolone (Kenalog) 40 mg)
3039428|NCT00398866|Experimental|3|Synvisc
3039429|NCT00398918|Experimental|Zonisamide|
3039430|NCT00398918|Placebo Comparator|Placebo|
3039431|NCT00398983|Experimental|Decitabine 20 mg/m^2|20 mg/m^2 intravenous (IV) daily for 5 days
3039432|NCT00398983|No Intervention|No Study Drug|Continue current therapy.
3039433|NCT00399035|Placebo Comparator|FOLFOX + placebo Cediranib|FOLFOX + placebo Cediranib
3039434|NCT00399035|Placebo Comparator|Xelox + placebo Cediranib|Xelox + placebo Cediranib
3039435|NCT00399035|Experimental|FOLFOX + Cediranib|FOLFOX + Cediranib
3039436|NCT00399035|Experimental|XELOX + Cediranib|XELOX + Cediranib
3039437|NCT00399308|Active Comparator|Control|Multi-layer compression bandaging (Profore)
3039438|NCT00399308|Experimental|Celaderm, Bi-Weekly|Celaderm, bi-weekly applications, up to a maximum of four applications
3039439|NCT00399308|Experimental|Celaderm, Weekly|Celaderm, applied weekly, up to a maximum of four applications
3039440|NCT00399360|Placebo Comparator|Group 1|No Lifestyle Modification and Placebo
3039441|NCT00399360|Active Comparator|Group 2|Lifestyle Modification and Placebo
3039442|NCT00399360|Active Comparator|Group 3|No Lifestyle Modification and Metformin
3039443|NCT00399360|Active Comparator|Group 4|Lifestyle Modification and Metformin
3039444|NCT00399490|Experimental|1|
3039445|NCT00399529|Experimental|Allo GM-CSF-secreting vaccine, Trastuzumab, Cyclophosphamide|"Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.~Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously~Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study"
3039446|NCT00399568|Experimental|IV acetaminophen 1 g/100 mL solution|
3039447|NCT00399568|Placebo Comparator|IV Placebo 100 mL solution|
3039448|NCT00399763|Placebo Comparator|1|placebo plus individual cognitive behavioral therapy
3039449|NCT00399763|Experimental|2|atomoxetine plus individual cognitive behavioral therapy
3039450|NCT00399802|Active Comparator|Single IV infusion of ZA 4 mg|Participants will receive a single IV infusion of ZA 4 mg at the start of treatment and a once-daily odanacatib matching placebo tablet for 4 weeks.
3039451|NCT00399802|Experimental|Odanacatib 5 mg|Participants will receive a once-daily odanacatib 5 mg tablet for 4 weeks and a single IV infusion of ZA matching placebo at the start of treatment.
3039452|NCT00399880|Experimental|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
3039453|NCT00399880|No Intervention|Usual care|
3039454|NCT00399893|Experimental|Octreotide|Octreotide to be administered by subcutaneous injection three times daily while on study
3039455|NCT00399893|Placebo Comparator|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
3039456|NCT00400153|Experimental|COMBIVENT Respimat 20/100 mcg|
3039457|NCT00400153|Experimental|COMBIVENT CFC-MDI 36/206 mcg|
3039458|NCT00400153|Experimental|Ipratropium Respimat 20 mcg|
3039459|NCT00400179|Active Comparator|A|In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).
3039460|NCT00400179|Active Comparator|B|In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.
3039461|NCT00400205|Experimental|Recipients of Docetaxel, Cisplatin, 5-Fluorouracil|Participants with squamous cell carcinoma receiving chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil.
3039462|NCT00400400|Experimental|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium tablets taken orally twice a day (in the morning and in the evening) at a dose equimolar to the dose of mycophenolate mofetil the participant was taking prior to start of the study + Placebo to mycophenolate mofetil capsules taken orally twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
3039463|NCT00400400|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil capsules taken orally twice a day (in the morning and in the evening) at the dose the participant was taking prior to study start + Placebo to mycophenolate sodium tablets taken twice a day for 30 days. Participants remained on their standard immunosuppressive regimen of calcineurin inhibitors (CNI) (Cyclosporin A or Tacrolimus) administered with or without corticosteroids throughout the study.
3039464|NCT00400439|Experimental|dalcetrapib (RO4607381)|
3039465|NCT00400439|Placebo Comparator|placebo|
3039466|NCT00400517|Experimental|GM-CSF Injections and Oral Thalidomide|taught to administer an injection of GM-CSF under your skin (subcutaneous injection) and will administer this medicine to yourself every Monday, Wednesday and Friday for 4 weeks at time. Thalidomide will be taken orally (by mouth) every evening at bed time. You will continue these injections 3 times a week and the daily oral medicine for up to 2 months if the therapy appears to be helping your disease.
3039467|NCT00400569|Experimental|Sunitinib Malate (SU011248) Treatment|Sunitinib malate, 50 mg daily, for 4 weeks every 6 weeks
3039468|NCT00400634|Experimental|1|Intracerebral administration of CERE-120
3039469|NCT00400634|Sham Comparator|2|Sham Neurosurgery
3039470|NCT00400686|Experimental|Epoetin Alfa - 80,000 U sc|Epoetin Alfa will be administered 80,000 units subcutaneously every week beginning on Day 1. On Day 28, the dose was adjusted based upon patients' Hemoglobin Levels
3039471|NCT00400712|No Intervention|Control|natural progression post-stroke
3039472|NCT00400712|Experimental|Intervention|two weeks of goal directed intensive physical rehabilitation therapy at 6 months (and one year)
3039473|NCT00400764|Experimental|Phase Ib: Dulanermin 4 mg/kg|Participants received 4.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3039474|NCT00400764|Experimental|Phase Ib: Dulanermin 8 mg/kg|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3039475|NCT00400764|Active Comparator|Phase II: Rituximab|Participants received rituximab administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
3039476|NCT00400764|Experimental|Phase II: Combination Therapy|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles. Participants also received rituximab administered by IV infusion at 375 mg/m^2 weekly for up to eight doses.
3039477|NCT00400764|Experimental|Phase II: Dulanermin|Participants received 8.0 mg/kg/day dose of dulanermin, administered by intravenous (IV) infusion for 5 consecutive days at the start of each 21-day treatment cycle for up to four cycles.
3039478|NCT00400803|Experimental|Patients with Stage IIIb/IV Non-Small Cell Lung Cancer|Patients treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
3039479|NCT00400829|Experimental|Arm I|Patients receive 1.4 mg/m2 eribulin mesylate IV over 1-2 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3039480|NCT00400881|No Intervention|Continuous PAP (CPAP)|CPAP (continuous positive airway pressure). 5 cm H2O.
3039481|NCT00400881|Experimental|Automatic tube compensation (ATC)|ATC is a new mode of ventilation being compared with traditional one (CPAP). ATC is a mode of ventilation of the same device (mechanical ventilator), not a new device. The pressure in this modes varies according the mechanical parameters of the respiratory system that are automatically calculated by this mode. This is the intervention arm.
3039482|NCT00400946|Active Comparator|Intramuscular native E coli L-asparaginase (IM-EC)|Patients in this arm were randomized to intramuscular native E coli L-asparaginase 25 000 IU/m2 weekly for 30 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
3039483|NCT00400946|Experimental|Intravenous PEG-asparaginase (IV-PEG)|Patients in this arm were randomized to intravenous PEG-asparaginase 2500 IU/m2 every 2 weeks for 15 doses. Protocol therapy was comprised of 5 phases: Induction, Consolidation I, CNS, Consolidation II, Continuation and varied dependent on risk classification. Patients who achieved complete remission after induction were eligible for post-induction asparaginase randomization. Further details are provided in the study description section.
3039484|NCT00400985|Other|Implantable Device diagnostics|All enrolled subjects were implanted with a device. Audible Device diagnostics turned on or off
3039485|NCT00401102|Other|Interpersonal psychotherapy|All participants received interpersonal psychotherapy adapted for self-injury
3039486|NCT00401193|Experimental|1|
3039487|NCT00401193|Experimental|2|
3039488|NCT00401193|Placebo Comparator|3|
3039489|NCT00401245|Active Comparator|A|
3039490|NCT00401245|Active Comparator|B|
3039491|NCT00401245|Active Comparator|C|
3039492|NCT00401245|Active Comparator|D|
3039493|NCT00401245|Active Comparator|E|
3039494|NCT00401245|Active Comparator|F|
3039495|NCT00401245|Active Comparator|G|
3039496|NCT00401245|Placebo Comparator|H|
3039497|NCT00401258|Other|1|12-week, open-label trial of duloxetine in subjects with IBS.
3039498|NCT00401375|Experimental|MNTX 12 mg|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) as an intravenous (IV) infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
3039499|NCT00401375|Experimental|MNTX 24 mg|Participants will receive MNTX 24 mg as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
3039500|NCT00401375|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX as an IV infusion over approximately 20 minutes for every 6 hours until one of the following occurs: 1) 24 hours elapsed after the first bowel movement and the participant was tolerating clear liquids, 2) the participant was discharged from the hospital, or 3) a maximum of 10 days elapsed. The first dose of study drug will be administered within the first 90 minutes after the end of surgery (defined as the time when the last skin suture or staple is placed in the participant).
3039501|NCT00401401|Experimental|Zalutumumab 4 mg/kg|Zalutumumab 8 weekly infusions
3039502|NCT00401401|Experimental|Zalutumumab 8 mg/kg|Zalutumumab 8 weekly infusions
3039503|NCT00401401|Experimental|Zalutumumab 12 mg/kg|Zalutumumab 8 weekly infusions
3039504|NCT00401401|Experimental|Zalutumumab 16 mg/kg|Zalutumumab 8 weekly infusions
3039505|NCT00401414|Experimental|Warfarin|We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
3039506|NCT00401518|Experimental|ACADIA®|Investigational surgical treatment using the ACADIA Facet Replacement system
3039507|NCT00401518|Active Comparator|Control Instrumented PLF|Control surgical treatment using an instrumented posterolateral fusion
3039508|NCT00401531|Experimental|Group 1: DTaP IPV Hep B PRP T + Prevnar™|
3039509|NCT00401531|Active Comparator|Group 2: Infanrix hexa™ + Prevnar™|
3039510|NCT00401544|Experimental|Darbepoetin alfa 300 μg plus IV Iron|Darbepoetin alfa 300 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3039511|NCT00401544|Experimental|Darbepoetin alfa 300 μg|Darbepoetin alfa 300 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3039512|NCT00401544|Experimental|Darbepoetin alfa 500 μg|Darbepoetin alfa 500 μg subcutaneous injection every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3039513|NCT00401544|Active Comparator|Darbepoetin alfa 500 μg plus IV Iron|Darbepoetin alfa 500 μg subcutaneous injection plus intravenous (IV) iron 400 mg, every three weeks (Q3W), for up to 15 weeks (a total of 5 doses).
3039514|NCT00401622|Experimental|OneTouch® Ultra®2 system|Test care group assigned to OneTouch® Ultra®2 system
3039515|NCT00401622|Active Comparator|Standard care|Control group receiving standard care with a traditional blood glucose monitoring system
3039516|NCT00401778|Active Comparator|1|RAD001 5 mg/day for 21 days sequentially.
3039517|NCT00401778|Active Comparator|3|RAD001 10 mg/day for 21 days sequentially.
3039518|NCT00401778|No Intervention|Control|Patients who are eligible for the study but choose not to receive RAD001 treatment.
3039519|NCT00401817|Experimental|Study Treatment Arm|Bevacizumab-R-CHOP therapy included bevacizumab administered at 15 mg/kg on day 1, and standard dose R-CHOP on day 3, for six 21-day cycles
3039520|NCT00401830|Placebo Comparator|Placebo|
3039521|NCT00401830|Experimental|Lacosamide|Lacosamide Tablet 400mg daily
3039522|NCT00401843|Experimental|Part 1: Siltuximab Plus Bortezomib|Siltuximab 6 milligram per kilogram (mg/kg) will be administered as intravenous infusion once every 2 weeks along with bortezomib 1.3 milligram per square meter (mg/m^2) during cycle 1.
3039523|NCT00401843|Experimental|Part 2: Bortezomib + Placebo|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with matching placebo administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with matching placebo once every 2 weeks during 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 milligram per day (mg/day) will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
3039524|NCT00401843|Experimental|Part 2: Bortezomib + Siltuximab|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period along with Siltuximab administered as intravenous infusion once every 2 weeks during 42-day treatment phase. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) along with Siltuximab administered as intravenous infusion once every 2 weeks for 35-day Maintenance Phase. Dexamethasone tablet will be administered at first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles.
3039525|NCT00401882|Active Comparator|Standard Of Care Drug Epinephrine|Additional doses of Epinephrine (1 mg) given as part of standard of care during cardiac arrest
3039526|NCT00401882|Active Comparator|IV Metoprolol instead Epinephrine|IV metoprolol 5 mg. up to 2 times (only) during cardiac arrest will be given instead of additional Epinephrine doses
3039527|NCT00401960|Experimental|Daptomycin adjunctive group|Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
3039528|NCT00401960|No Intervention|standard of care|Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician
3039529|NCT00401973|Experimental|Olanzapine|olanzapine plus behavioral information
3039530|NCT00401973|Experimental|Olanzapine + Amantadine|Olanzapine and Pharmacological Algorithm 1a - amantadine first plus behavioral information
3039531|NCT00401973|Experimental|Olanzapine + Metformin|Olanzapine and Pharmacological Algorithm 1b - metformin first plus behavioral information
3039532|NCT00401986||Alair Treatment|Alair Treated subjects from PREDECESSOR STUDY (NCT00214539).
3039533|NCT00402025|Experimental|Talimogene Laherparepvec|Participants received 3 doses of talimogene laherparepvec administered by direct injection 3 weeks apart. At the discretion of the investigator, treatment with talimogene laherparepvec could continue beyond the third dose until week 15 in a regimen of at least 3 weeks between doses.
3039534|NCT00402051|Experimental|Pemetrexed + Cisplatin|
3039535|NCT00402051|Experimental|Pemetrexed + Carboplatin|
3039536|NCT00402103|Experimental|Aliskiren/Amlodipine|
3039537|NCT00402103|Experimental|Aliskiren/Amlodipine/HCTZ|
3039538|NCT00402116|Experimental|A|The Phase 1 consisted of the dose escalation of enzastaurin in 2 cohorts of up to 6 patients to assess maximum tolerated dose (MTD). Cohort 1 = radiotherapy/enzastaurin 250 mg per day/temozolomide 75 mg/m^2 therapy. The 6 initial cohort patients were clinically evaluated for dose-limiting toxicities (DLT). If no more than 1 of 6 patients experienced a DLT or tumor progression, patients continued 1 complete adjuvant enzastaurin/temozolomide 28-day cycle. If there was no significant toxicity after the first adjuvant cycle, participants received subsequent adjuvant enzastaurin/temozolomide cycles. If no more than 1 of the 6 initial cohort participants treated at 250 mg of enzastaurin experienced a DLT during radiotherapy and the first adjuvant cycle, up to 6 more participants could be entered at 500 mg of enzastaurin. The Phase 2, using the MTD determined in the Phase 1 (250 mg), evaluated the combination's safety and measured OS.
3039539|NCT00402168|Experimental|A: Belatacept|
3039540|NCT00402168|Active Comparator|B: calcineurin inhibitor (CNI)-based immunosuppressive regimen|
3039541|NCT00402233|Other|Placebo|
3039542|NCT00402233|Other|Pramipexole 0.5 mg Tid|Pramipexole 0.5 mg tid (three times a day)
3039543|NCT00402233|Other|Pramipexole 0.5 mg Bid|Pramipexole 0.5 mg bid (bis in die (two times a day))
3039544|NCT00402233|Other|Pramipexole 0.75 mg Bid|Pramipexole 0.75 mg bid (bis in die (two times a day))
3039545|NCT00402246|Experimental|Remote Arm|Remote Management
3039546|NCT00402246|Active Comparator|In-office Arm|In-Office Care
3039547|NCT00402285|Active Comparator|lycopene supplement|Two 15mg lycopene capsules daily for 3 months.
3039548|NCT00402285|Active Comparator|fish oil supplement|1g fish oil capsule daily for 3 months.
3039549|NCT00402285|Placebo Comparator|placebo|placebos for lycopene and fish oil.
3039550|NCT00402298|Experimental|Full dose (125 mg) MDMA-assisted therapy|Participants will receive an initial dose of 125 mg MDMA followed 2.5 hours later by a supplemental dose of 62.5 mg MDMA during the course of two day-long therapy sessions.
3039551|NCT00402298|Active Comparator|Active Comparator (25 mg) MDMA-assisted therapy|Participants will receive an initial dose of 25 mg MDMA followed 2.5 hours later by a supplemental dose of 12.5 mg MDMA during the course of two day-long therapy sessions.
3039552|NCT00402324|Experimental|1|olanzapine and divalproex
3039553|NCT00402324|Placebo Comparator|2|placebo and divalproex
3039554|NCT00402337|Active Comparator|72 ug linaclotide acetate|
3039555|NCT00402337|Active Comparator|145 ug linaclotide acetate|
3039556|NCT00402337|Active Comparator|290 ug linaclotide acetate|
3039557|NCT00402337|Active Comparator|579 ug linaclotide acetate|
3039558|NCT00402337|Placebo Comparator|Matching Placebo|
3039559|NCT00402363|Experimental|omega-3-acid ethyl esters|
3039560|NCT00402363|Placebo Comparator|Placebo|
3039561|NCT00402597|Experimental|001|Rivaroxaban 1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
3039562|NCT00402597|Experimental|002|Rivaroxaban/Placebo 1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
3039563|NCT00402597|Placebo Comparator|003|Placebo 1 placebo tablet twice daily for 6 months.
3039564|NCT00402649|Experimental|1|All subjects will receive at least 2 and up to 3 doses of the vaccine approximately 28 days apart.
3039565|NCT00402688|Active Comparator|001|levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
3039566|NCT00402688|Active Comparator|002|levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.
3039567|NCT00402688|Active Comparator|003|levofloxacin 500mg tablet once daily for 4 weeks.
3039568|NCT00402714|Active Comparator|1|Extracorporeal photopheresis, pentostatin and total body irradiation
3039569|NCT00402714|Active Comparator|2|Pentostatin and total body irradiation
3039570|NCT00402727|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
3039571|NCT00402727|Active Comparator|PIP/TAZ-AMC|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
3039572|NCT00402779|Experimental|Erlotinib|Balanced randomization: Erlotinib 150 mg continuous administration for 1 year.
3039573|NCT00402779|Placebo Comparator|Placebo|Balanced randomization: Placebo continuous administration for 1 year.
3039574|NCT00402831|Experimental|Intramuscular ProQuad®|Participants will receive doses of ProQuad® by IM injection on Day 1 and Day 30 into the deltoid muscle perpendicular to the skin, with the first dose in the right arm and the second dose in the left arm.
3039575|NCT00402831|Active Comparator|Subcutaneous ProQuad®|Participants will receive doses of ProQuad® by SC injection on Day 1 and Day 30 in the deltoid area at a 45° angle to the skin, with the first dose in the right arm and second dose in the left arm.
3039576|NCT00402896|Experimental|ZD6474|300 mg/day orally for 10 weeks.
3039577|NCT00402987|Experimental|celecoxib 50 mg/50 mg|
3039578|NCT00402987|Experimental|celecoxib 100 mg/placebo|
3039579|NCT00402987|Experimental|celecoxib 100 mg/50 mg|
3039580|NCT00402987|Placebo Comparator|Placebo|
3039581|NCT00403117|Placebo Comparator|Placebo, Marijuana (0% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039582|NCT00403117|Experimental|Placebo, Marijuana (3.27% THC)|During each session, one capsule containing placebo was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039583|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039584|NCT00403117|Experimental|Naltrexone (12mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (12 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039585|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039586|NCT00403117|Experimental|Naltrexone (25mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (25 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039587|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039588|NCT00403117|Experimental|Naltrexone (50mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (50 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039589|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (0% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (0% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039590|NCT00403117|Experimental|Naltrexone (100mg), Marijuana (3.27% THC)|During each session, one capsule containing naltrexone (100 mg) was administered to the participant in a size 00 opaque capsule with lactose filler. A marijuana cigarette (3.27% THC; ca. 800 mg) provided by the National Institute on Drug Abuse, was administered 45 minutes post capsule administration.
3039591|NCT00403130|Experimental|Phase II 3-drug regimen|Gemcitabine + Paclitaxel + Bevacizumab
3039592|NCT00403234|Experimental|BTDS 10|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
3039593|NCT00403234|Experimental|BTDS 20|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
3039594|NCT00403234|Experimental|BTDS 30|Buprenorphine transdermal patch 30 mcg/h applied for 7-day wear
3039595|NCT00403234|Placebo Comparator|Placebo TDS|Placebo patches were similar to BTDS 10 and 20.
3039596|NCT00403260|Experimental|Pyronaridine - artesunate|Oral pyronaridine artesunate (180:60mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
3039597|NCT00403260|Active Comparator|Mefloquine plus artesunate|Mefloquine (250mg tablets) plus artesunate (100mg tablets) once a day for 3 consecutive days (Day 0, 1, and 2). Posology based on body weight ranges.
3039598|NCT00403273|Experimental|A|Single Intra-articular Injection of 100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
3039599|NCT00403273|Placebo Comparator|B|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
3039600|NCT00403390|Experimental|Brand name levothyroxine (Synthroid)|Dose previously demonstrated to normalize thyroid function given daily for 2 months
3039601|NCT00403390|Active Comparator|Generic formulation of Levothyroxine|Dosage previously determined to normalize thyroid function given daily for 2 months
3039602|NCT00403403|Placebo Comparator|Placebo+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
3039603|NCT00403403|Experimental|Bevacizumab+Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide
3039604|NCT00403455|Other|Paroxetine Arm|This is a single arm, single site, open-label clinical trial to treat veterans with PTSD. It is a 12-week trial to investigate the efficacy of paroxetine in reducing PTSD symptoms, with the primary outcome measure using CAPS. Genetic information is included to understand why some respond and some do not respond to paroxetine treatment.
3039605|NCT00403481|Experimental|Active treatment|Blood pressure (BP) measurements were taken every three weeks for 12 weeks. In accordance with their BP results, participants either stayed on their current medication or were started on the next higher regimen at the 3, 6, or 9 week visits. All participants began at 20 mg olmesartan, once daily for 3 weeks. The next higher regimen was olmesartan 40 mg, followed by olmesartan 40 mg + 12.5 mg hydrochlorothiazide, followed by olmesartan 40 mg + 25 mg of hydrochlorothiazide.
3039606|NCT00403494|Experimental|Sapropterin dihydrochloride|Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
3039607|NCT00403494|Placebo Comparator|Placebo|Subjects receive matching oral Placebo twice daily for 24 weeks.
3039608|NCT00403546|Experimental|High-Dose Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take ziprasidone oral capsule twice daily added to their regular open-label ziprasidone dose (total of 240 mg/d). After the first week, the study drug will be increased to a total ziprasidone dose of 320 mg/d for 7 weeks.
3039609|NCT00403546|Placebo Comparator|Placebo, Standard Treatment Ziprasidone|Participants with schizophrenia or schizoaffective disorder who remain symptomatic despite treatment with ziprasidone 160 mg/d for at least 3 weeks will be instructed to take matching placebo oral capsule twice daily added to their regular open-label ziprasidone dose of 160 mg/d. After the first week, the matching placebo will be increased to two capsules twice daily and their regular open-label ziprasidone will remain the same (160 mg/d) for 7 weeks.
3039610|NCT00403754|Experimental|Placebo-Ind 150 μg-Ind 300 μg-Ind 600 μg-Salmeterol|"In treatment period 1: patients received 2 placebo capsules; in treatment period 2: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 indacaterol 300 μg capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3132571|NCT03438045|Experimental|Partnered Intervention|The aspects of the partnering package of evidence-based intervention strategies are: (1) written agreements of collaboration for dental screening, health promotion, and incentives; (2) culturally-tailored and language-specific adaptation of materials; (3) demonstrations with role-playing of proper brushing with fluoride toothpaste and flossing techniques; and (4) CHW follow-up with patients of oral health care receipt and dental hygiene behaviors. Additionally, bilingual (English and Mandarin Chinese) CHWs will receive additional training in oral health promotion demonstration, oral health services and programs available at local clinics and hospitals, information about dental and health insurance, and evidence-based oral health behaviors.
3039611|NCT00403754|Experimental|Ind 150 μg-Ind 600 μg-Placebo-Ind 300 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 150 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 indacaterol 300 μg capsules; in treatment period 3: patients received 2 placebo capsules; and in treatment period 4: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3039612|NCT00403754|Experimental|Ind 300 μg-Placebo-Ind 600 μg-Ind 150 μg-Salmeterol|"In treatment period 1: patients received 1 indacaterol (Ind) 300 μg capsule + 1 placebo capsule; in treatment period 2: patients received 2 placebo capsules; in treatment period 3: patients received 2 indacaterol 300 μg capsules; and in treatment period 4: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation, device on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3039613|NCT00403754|Experimental|Ind 600 μg-Ind 300 μg-Ind 150 μg-Placebo-Salmeterol|"In treatment period 1: patients received 2 indacaterol (Ind) 300 μg capsules; in treatment period 2: patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3: patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4: patients received 2 placebo capsules. Two inhalation capsules of study drug were inhaled using a single dose dry powder inhaler (SDDPI) in the morning on day 1 of each treatment period at approximately the same time of day +/- 15 minutes. There was a washout period of 14-28 days between each treatment period. In open label treatment period 5: patients received 100 μg salmeterol (50 μg in the morning, 50 μg twelve hours post initial dose) inhaled via Diskus®, an inhalation device, on Day 1.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol was available for rescue use throughout the study."
3039614|NCT00403767|Experimental|Rivaroxaban|
3039615|NCT00403767|Active Comparator|Warfarin|
3039616|NCT00403845|Experimental|Placebo-indacaterol 150μg-indacaterol 300μg-indacaterol 600μg|In treatment period, 1 patients received 2 placebo capsules; in treatment period 2, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; and in treatment period 4, patients received 2 indacaterol 300 μg capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3039617|NCT00403845|Experimental|Indacaterol 150μg-indacaterol 600μg-placebo-indacaterol 300μg|In treatment period 1, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 indacaterol 300 μg capsules; in treatment period 3, patients received 2 placebo capsules; and in treatment period 4, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3039618|NCT00403845|Experimental|Indacaterol 300μg-placebo-indacaterol 600μg-indacaterol 150μg|In treatment period 1, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 2, patients received 2 placebo capsules; in treatment period 3, patients received 2 indacaterol 300 μg capsules; and in treatment period 4, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3039619|NCT00403845|Experimental|Indacaterol 600μg-indacaterol 300μg-indacaterol 150μg-placebo|In treatment period 1, patients received 2 indacaterol 300 μg capsules; in treatment period 2, patients received 1 indacaterol 300 μg capsule + 1 placebo capsule; in treatment period 3, patients received 1 indacaterol 150 μg capsule + 1 placebo capsule; and in treatment period 4 patients received 2 placebo capsules. There was a washout period of 14-28 days between each treatment period. Patients received each treatment only once. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3039620|NCT00404066|Experimental|Neoadjuvant Chemotherapy|Doxorubicin (Adriamycin) + cyclophosphamide (Cytoxan) with pegfilgrastim or filgrastim growth factor support every 2 weeks for 4 cycles, followed by docetaxel + lapatinib for four 21-day cycles, followed by surgery. Dexamethasone was administered twice-a-day for 3 days, starting 24 hours before the docetaxel infusions. After surgery +/- radiation, participants may receive trastuzumab (Herceptin) for a year.
3039621|NCT00404079|Experimental|Glucosamine Sulphate|
3039622|NCT00404079|Placebo Comparator|Placebo|
3039623|NCT00404092|Experimental|1st cohort|70mg caspofungin 1x/day
3039624|NCT00404092|Experimental|2nd cohort|100mg caspofungin 1x/day
3039625|NCT00404092|Experimental|3rd cohort|150mg caspofungin 1x/day
3039626|NCT00404092|Experimental|4th cohort|200mg caspofungin 1x/day
3039627|NCT00404235|Experimental|paclitaxel + carboplatin|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation (ABI-007) IV over 30 minutes followed by carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for at least 8 courses in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected periodically to evaluate secreted protein acidic and rich in cysteine (SPARC) content of tumor tissue by immunohistochemistry and to explore the impact of therapy on immune homeostasis. Samples are also analyzed by immunoenzyme techniques for angiogenesis markers.~After completion of study treatment, patients are followed periodically for up to 2 years."
3039628|NCT00404248|Active Comparator|With Enzyme-inducing antiseizure drugs (+EIASD)|"subjects on the +EIASD treatment arm were taking one of these antiseizure drugs: phenytoin, carbamazepine, phenobarbital, primidone and oxcarbazepine.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
3039629|NCT00404248|Active Comparator|With Non enzyme-inducing antiseizure drugs (-EIASD)|"Subjects in the -EIASD group were either not being treated with antiseizure drugs or were taking ones that did not significantly induce hepatic enzymes such as gabapentin, lamotrigine, valproic acid, levetiracetam, tiagabine, topiramate, zonisamide and felbamate.~Subjects will take terameprocol for 5 consecutive days each month by IV. Starting dose is 750mg/day. Dose escalation is 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, and 9300. NO intrasubject dose escalation.~PK (pharmacological study) data will be collected on day one of cycle one infusion"
3039630|NCT00404352|Active Comparator|RNF 44 mcg three times weekly|
3039631|NCT00404352|Active Comparator|RNF 44 mcg once weekly and placebo twice weekly for blinding|
3039632|NCT00404352|Placebo Comparator|Placebo three times weekly|
3039633|NCT00404495|Experimental|Temozolomide + Irinotecan|
3039634|NCT00404547|Active Comparator|Alvesco|Alvesco 320mcg / Alvesco 640mcg
3039635|NCT00404547|Active Comparator|Usual Care|
3039636|NCT00404651|Experimental|Group 1|Participants receive vaccine Batch A
3039637|NCT00404651|Experimental|Group 2|Participants receive vaccine Batch B
3039638|NCT00404651|Experimental|Group 3|Participants receive vaccine Batch C
3039639|NCT00404651|Active Comparator|Group 4|Participants receive Infanrix hexa™
3039640|NCT00404755|Experimental|escitalopram|escitalopram 10 mg/d for 1 week, then increasing by 10 mg/week if tolerated and not remitted to maximal dose of 40 mg/d
3039641|NCT00404755|Experimental|bupropion|bupropion extended release (XL) 150 mg/d for a week, then 300 mg/d for a week and then 450 mg/d; all dose increases if tolerated and not remitted
3039642|NCT00404755|Experimental|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then by 50 mg/week to a maximum dose of 300 mg/d; all dose increases if tolerated and not remitted
3039643|NCT00404768|Experimental|Treatment|GSK221149A
3039644|NCT00404768|Placebo Comparator|Placebo|Placebo
3039645|NCT00404820|Experimental|Zoledronic acid 5 mg|Patients received zoledronic acid 5 mg in 100 ml solution in a 15 minute intravenous (iv) infusion once per year. The peripheral iv infusion was preceded by and followed by a 10 ml normal saline flush of the intravenous line. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
3039646|NCT00404820|Active Comparator|Alendronate 70 mg|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal. Patients were to remain in an upright position for 30 minutes after swallowing the tablet. In addition to study therapy, all participants received 1200 mg elemental calcium and 800 IU of vitamin D daily. Calcium and vitamin D were supplied in a chewable tablet that was to be taken twice daily.
3039647|NCT00404924|Placebo Comparator|1|Best Supportive Care
3039648|NCT00404924|Experimental|2|Vandetanib + Best Supportive Care
3039649|NCT00405275|Active Comparator|Arm 1|Etanercept and Methotrexate. Participants also received placebo hydroxychloroquine and sulfasalazine
3039650|NCT00405275|Active Comparator|Arm 2|Hydroxychloroquine, sulfasalazine and methotrexate. Participants also received placebo etanercept.
3039651|NCT00405288||Proctofoam-HC®|Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
3039652|NCT00405288||Control|Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
3039653|NCT00405353|Experimental|crossover treatment with Androgel|6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone
3039654|NCT00405509||Confirmed respiratory virus|
3039655|NCT00405509||Unconfirmed respiratory infection|
3039656|NCT00405522|Experimental|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|
3039657|NCT00405522|Experimental|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|
3039658|NCT00405548|Active Comparator|BNP (nesiritide)|BNP 10 micrograms/Kg twice per day given subcutaneously for 12 weeks
3039659|NCT00405548|Placebo Comparator|Placebo|Saline solution given subcutaneously twice per day for 12 weeks (packaged to match active comparator)
3039660|NCT00405587|Experimental|PLX4032|Open-label, sequential dose escalation
3039661|NCT00405639|Active Comparator|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
3039662|NCT00405639|Placebo Comparator|Placebo|Subjects randomized to this arm will receive self administered SQ placebo (normal saline) injections to match those of the study drug group. That is, first dose on Day 1, second dose 12 hours after the first dose, third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
3039663|NCT00405652|Experimental|Enteric-coated Mycophenolate sodium|Enteric-coated Mycophenolate sodium (EC-MPS), administered orally twice a day to achieve a dose equimolar to the dose of Mycophenolate mofetil (MMF) the patient was taking at the time of study entry up to a maximum dose of 1440 mg.
3039664|NCT00405704|Active Comparator|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
3039665|NCT00405704|Placebo Comparator|Placebo|Cherry-flavored liquid suspension matched to active comparator.
3039666|NCT00405756|Experimental|MPR+R|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3039667|NCT00405756|Experimental|MPR+p|Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3039668|NCT00405756|Other|MPp+p|Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.
3039669|NCT00405821|Active Comparator|Acyclovir 400mg tablet twice daily|
3039670|NCT00405821|Placebo Comparator|Placebo tablet twice daily|
3039671|NCT00405912|Placebo Comparator|Placeo|Placebo pill was identical in appearance to the active medication.
3039672|NCT00405912|Experimental|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tablets, 3 times a day.
3039673|NCT00405912|Experimental|St. John's Wort-1800 mg/day|St. John's Wort - 600 mg 3 times per day
3039674|NCT00405938|Experimental|Bevacizumab/anastrozole|Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] and anastrozole (1 mg orally daily). Treatment will be given in 4-week cycles.
3039675|NCT00405938|Experimental|Bevacizumab/fulvestrant|Bevacizumab/fulvestrant (with trastuzumab in HER2+ patients). Bevacizumab 10mg/kg IV every 2 weeks [patients who are also receiving trastuzumab have the option to receive their bevacizumab at 15 mg/kg every 3 weeks instead of 10 mg/kg every 2 weeks (see Trastuzumab section below)] fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant). Treatment will be given in 4-week cycles.
3039676|NCT00405964|Experimental|5-mg Desloratadine tablet|
3039677|NCT00405964|Placebo Comparator|Placebo tablet|
3039678|NCT00406029|Experimental|Preladenant 1 mg BID|Participants received preladenant 1 mg twice daily (BID) during the 12-week treatment period.
3039679|NCT00406029|Experimental|Preladenant 2 mg BID|Participants received preladenant 2 mg BID during the 12-week treatment period.
3039680|NCT00406029|Experimental|Preladenant 5 mg BID|Participants received preladenant 5 mg BID during the 12-week treatment period.
3039681|NCT00406029|Experimental|Preladenant 10 mg BID|Participants received preladenant 10 mg BID during the 12-week treatment period.
3039682|NCT00406029|Placebo Comparator|Placebo BID|Participants received preladenant matching placebo BID during the 12-week treatment period.
3039683|NCT00406107|Active Comparator|Pegaptanib Sodium 0.3mg (Macugen)|Intravitreous injections of Macugen 0.3mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
3039684|NCT00406107|Active Comparator|Pegaptanib Sodium 1 mg (Macugen)|Intravitreous injections of Macugen 1.0mg given at baseline, week 6 and week 12 with subsequent injections at six weekly intervals at the discretion of the investigator until week 54.
3039685|NCT00406133|No Intervention|Standard intensive glucose monitoring|Patients in the control group were given blood glucose meters and test strips and asked to perform home blood glucose monitoring at least four times daily.
3039686|NCT00406133|Active Comparator|Continuous Glucose Monitoring (CGM)|Patients in the CGM group were instructed to use the CGM device on a daily basis and to verify the accuracy of the glucose measurement with a home blood glucose meter (provided by the study) before making management decisions (as per the regulatory labeling of the devices).
3039687|NCT00406276|Experimental|RAD001+Docetaxel|RAD001 in combination with Docetaxel.
3039688|NCT00406315|Other|A1|atypical antipsychotic for the treatment of schizophrenia
3039689|NCT00406354|Experimental|Atomoxetine Fast Titration|0.5 milligram per kilogram (mg/kg) daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 8 weeks
3039690|NCT00406354|Experimental|Atomoxetine Slow Titration|0.5 mg/kg daily dose taken orally for 1 week, then 0.8 mg/kg daily dose taken orally for 1 week, then 1.2 mg/kg daily dose taken orally for 7 weeks
3039691|NCT00406354|Placebo Comparator|Placebo|matching placebo daily dose taken orally
3039692|NCT00406367|Experimental|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection"
3039693|NCT00406367|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
3039694|NCT00406393|Active Comparator|Tacrolimus/Methotrexate|Patients will be given Tacrolimus and Methotrexate for GVHD prophylaxis.
3039695|NCT00406393|Experimental|Tacrolimus/Sirolimus|Patients will be given Tacrolimus and Sirolimus for GVHD prophylaxis.
3039696|NCT00406419|Placebo Comparator|Placebo × 2 IV + MTX|Participants received two intravenous (IV) infusion matching placebo to ocrelizumab on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 milligram (mg) was administered weekly.
3039697|NCT00406419|Experimental|Ocrelizumab 200 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 200 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
3039698|NCT00406419|Placebo Comparator|Ocrelizumab 500 mg × 2 IV + MTX|Participants received two IV infusion of ocrelizumab 500 mg on Day 1 and Day 15. A repeat course was administered at Weeks 24 and 26. Methotrexate 7.5-25 mg was administered weekly.
3039699|NCT00406640|Active Comparator|A|
3039700|NCT00406640|Active Comparator|B|
3039701|NCT00406653|Experimental|1|"4 arms for induction period~2 arms for maintenance period"
3039702|NCT00406653|Placebo Comparator|2|"4 arms for induction period~2 arms for maintenance period"
3039703|NCT00406653|Other|abatacept|1 arm for open-label extension phase
3039704|NCT00406692|Experimental|Zonisamide|In open-label non-placebo controlled trial subjects are treatment with zonisamide 400 mg during the maintenance phase of this study
3039705|NCT00406718|Experimental|PharmCAT|Participants will receive PharmCAT in addition to Treatment as usual, Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
3039706|NCT00406718|Active Comparator|Med-eMonitor|Participants will receive Med-eMonitor™ in addition to treatment as usual. Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
3039707|NCT00406718|Active Comparator|Treatment as Usual|Participants will receive standard treatment as usual which is medication management and limited case management provided by the CMHC.
3039708|NCT00406783|Experimental|5-mg Desloratadine tablet|
3039709|NCT00406783|Placebo Comparator|Placebo tablet|
3039710|NCT00406848|Experimental|Duloxetine|
3039711|NCT00406848|Placebo Comparator|Placebo|
3039712|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection"
3039713|NCT00407030|Experimental|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection"
3039714|NCT00407030|Placebo Comparator|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection
3039715|NCT00407355|Active Comparator|RBZ 0.3|RBZ at the 0.3 mg dose intravitreal injection
3039716|NCT00407355|Active Comparator|RBZ 0.5|RBZ dose level .5 for ITV injection
3039717|NCT00407381|Experimental|Ranibizumab|Ranibizumab (RBZ) intravitreal injection alone
3039718|NCT00407381|Active Comparator|Laser|Laser photocoagulation
3039719|NCT00407381|Experimental|Laser with Ranibizumab|Laser following intravitreal injection of RBZ
3039720|NCT00407420|Experimental|Mandometer|Active intervention - one meal eaten per day off Mandometer
3039721|NCT00407420|Active Comparator|Control|Nutritional and activity advice alone
3039722|NCT00407485|Experimental|Treatment (ziv-aflibercept)|Patients receive 4 mg/kg VEGF Trap IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3039723|NCT00407511|Experimental|Pregabalin|
3039724|NCT00407537|Experimental|Caduet|Open label caduet added to usual care regimen followed by investigators.
3039725|NCT00407550|Experimental|Gemzar x2|Treat subjects with 2 dosings/cycle of Gemzar x6 cycles.
3039726|NCT00407550|Experimental|Gemzar x1|Treat subjects with 1 dosing/cycle of Gemzar x9 cycles.
3039727|NCT00407654|Experimental|Arm I|Patients receive VEGF Trap (aflibercept) IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3039728|NCT00407745|Placebo Comparator|matched placebo|
3039729|NCT00407745|Experimental|pregabalin|flexible dosing over 4 weeks followed by 12 weeks maintenance and one week taper period
3039730|NCT00407797|Experimental|Pregabalin|
3039731|NCT00407888|Experimental|Arm I|Patients receive dose-intensive chemotherapy comprising doxorubicin hydrochloride IV over 10-15 minutes on day 1, oral cyclophosphamide once daily on days 1-7, and filgrastim subcutaneously on days 2-7. Courses repeat every 7 days for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Beginning 1 week later, patients then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once a week for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients with HER-2/neu positive disease also receive trastuzumab IV over 30-90 minutes once a week for 1 year in the absence of disease progression or unacceptable toxicity.
3039732|NCT00407966|Experimental|Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride)|"Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t[8;21], inv[16], or t[16;16]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator."
3132572|NCT03438266|Experimental|JUVÉDERM VOLUMA® XC Injectable Gel with Cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
3132573|NCT03438266|Other|JUVÉDERM VOLUMA® XC Injectable Gel with Needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
3039733|NCT00408005|Experimental|Group 0 Induction Therapy|All patients (T-ALL and T-LLy) receive cytarabine intrathecally (IT) on day 1; vincristine sulfate IV on days 1, 8, 15, and 22; prednisone IV or PO twice daily BID on days 1-28; pegaspargase IM (may give IV over 1 to 2 hours) on day 4, 5, or 6; daunorubicin hydrochloride IV on days 1, 8, 15 and 22; and methotrexate IT on days 8 and 29 (and days 15 and 22 for patients with CNS3 disease).
3039734|NCT00408005|Active Comparator|Group 1 Arm IV (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35.
3039735|NCT00408005|Active Comparator|Group I Arm I (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT. Patients with standard risk T-LLy received Arm I, and those with high risk T-LLy were randomized between Arm I and Arm II combination chemotherapy.
3039736|NCT00408005|Active Comparator|Group I Arm I (Delayed intensification chemotherapy|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10). Standard risk T-LLy patients were assigned to Arm I and those with high risk were randomized between Arm I and Arm II.
3039737|NCT00408005|Active Comparator|Group I Arm I (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL), all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
3039738|NCT00408005|Active Comparator|Group I Arm I (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31. Patients with DS also receive leucovorin calcium PO 48 and 60 hours after each methotrexate IT dose (DS patients excluded as of 09/29/10).~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on days 2, 4, 6, 8, 10, 12, 22, 24, 26, 28, 30, and 32."
3039739|NCT00408005|Active Comparator|Group I Arm II (Consolidation chemotherapy)|Patients receive nelarabine IV over 60 minutes on days 1-5 and 43-47; methotrexate IT on days 15, 22, 57, and 64; cyclophosphamide IV over 30 minutes on days 8 and 50; cytarabine IV over 15-30 minutes or SC on days 8-11, 15-18, 50-53 and 57-60; mercaptopurine PO on days 8-21 and 50-63; vincristine sulfate IV on days 22, 29, 64, and 71; and pegaspargase IM or IV over 1-2 hours on days 22 and 64. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 15, 22-26, and 29-33 (DS patients excluded as of 09/29/10). (Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT QD on days 22-28 and 29-35. Patients with high risk T-LLy were either randomized to Arm I or Arm II. Patients with T-LLy who failed induction therapy were assigned to Arm II.
3039740|NCT00408005|Active Comparator|Group I Arm II (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
3039741|NCT00408005|Active Comparator|Group I Arm II (Interim maintenance chemotherapy)|"Patients receive vincristine sulfate IV and escalating doses of methotrexate IV on days 1, 11, 21, 31, and 41; pegaspargase* IM or IV over 1-2 hours on days 2 and 22; and methotrexate IT on days 1 and 31.~Note: *Patients with an allergy to pegaspargase receive Erwinia asparaginase on Monday, Wednesday and Friday for two consecutive weeks starting the day of asparaginase substitution."
3039742|NCT00408005|Active Comparator|Group I Arm II (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
3132574|NCT03438383|Sham Comparator|Sham Bi-PAP|"Sham Bi-PAP was applied through nasal mask for 3 days postoperatively. Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of Bi-PAP. With this modality, also used on previous studies, the applied pressure by sham Bi-PAP was constant and equal to 2 centimeter of water (cm H2O)."
3320833|NCT02014103|Other|Sequence 3|Patients will be randomized to a sequence of administration of the various 6 tacrolimus formulations. Sequence 3: Formulation 4, 3, 5, 1, 6, 2.
3039743|NCT00408005|Active Comparator|Group I Arm III (Consolidation chemotherapy)|Patients receive methotrexate IT on days 1, 8, 15, and 22; cyclophosphamide IV over 30 minutes on days 1 and 29; cytarabine IV over 15-30 minutes or SC on days 1-4, 8-11, 29-32, and 36-39; mercaptopurine PO on days 1-14 and 29-42; vincristine sulfate IV on days 15, 22, 43 and 50; and pegaspargase IM or IV over 1-2 hours on days 15 and 43. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose. Patients with persistent testicular disease or with DS and testicular disease undergo testicular radiotherapy on days 11-12, 15-19, and 22-26. (DS patients excluded as of 09/29/10.) Patients with intermediate-risk or high-risk disease (CNS1 or CNS2) undergo prophylactic CRT (1,200 cGy/dose) QD on days 15-21 and 22-28. Patients with low-risk disease do not undergo CRT.
3039744|NCT00408005|Active Comparator|Group I Arm III (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, 43, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age and for patients with DS); doxorubicin hydrochloride IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6, AND day 43; methotrexate IT on days 1, 29, and 36; cyclophosphamide IV over 30 minutes on day 29; cytarabine IV over 15-30 minutes or SC on days 29-32 and 36-39; and thioguanine PO on days 29-42. Patients with DS also receive leucovorin calcium PO at 48 and 60 hours after each methotrexate dose (DS patients excluded as of 09/29/10).
3039745|NCT00408005|Active Comparator|Group I Arm III (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine sulfate IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
3039746|NCT00408005|Active Comparator|Group I Arm III (Maintenance chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; prednisone PO BID on days 1-5, 29-33, and 57-61; mercaptopurine PO QD on days 1-84; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; and methotrexate IT on day 1. Treatment repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 119) (for girls with T-ALL) and all patients with T-LLy, and 3 years from the start of interim maintenance therapy (approximately week 171) (for boys with T-ALL).
3039747|NCT00408005|Active Comparator|Group I Arm IV (Delayed intensification chemotherapy)|Patients receive vincristine sulfate IV on days 1, 8, 15, and 50; dexamethasone IV or PO BID on days 1-21 (for patients < 10 years of age) OR on days 1-7 and 15-21 (for patients >= 10 years of age); doxorubicin IV on days 1, 8, and 15; pegaspargase IM or IV over 1-2 hours on day 4, 5, OR 6 AND day 50; methotrexate IT on days 1, 36, and 43; nelarabine IV over 60 minutes on days 29-33; cyclophosphamide IV over 30 minutes on day 36; cytarabine IV over 15-30 minutes or SC on days 36-39 and 43-46; and thioguanine PO on days 36-49.
3039748|NCT00408005|Active Comparator|Group I Arm IV (Interim maintenance chemotherapy)|Patients receive HDMTX IV over 24 hours and vincristine IV on days 1, 15, 29, and 43; mercaptopurine PO on days 1-56; and methotrexate IT on days 1 and 29. Beginning 42 hours after the start of HDMTX, patients also receive leucovorin calcium IV or PO once every 6 hours for 3 doses.
3039749|NCT00408005|Active Comparator|Group I Arm IV (Maintenance chemotherapy)|Patients receive vincristine sulfate, prednisone, mercaptopurine, methotrexate PO, methotrexate IT, and nelarabine in Cycles 1, 2 and 3. Patients then receive treatment (without nelarabine) as follows: vincristine, prednisone, mercaptopurine, methotrexate PO, and methotrexate IT as in arm II. Treatment (without nelarabine) repeats every 84 days until the total duration of study treatment is 2 years from the start of interim maintenance therapy (approximately week 121) (for girls with T-ALL), and for those with T-LLY, and 3 years from the start of interim maintenance therapy (approximately week 173) (for boys with T-ALL).
3039750|NCT00408070|Experimental|I|This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
3039751|NCT00408200|Other|AAD:YES|Subjects receive membrane-active anti-arrhythmic medication after ablation. See intervention list below.
3039752|NCT00408200|Other|AAD:NO|Subjects do not receive membrane-active anti-arrhythmic medications after ablation.
3039753|NCT00408317|Experimental|Ultrase® MT20|
3039754|NCT00408317|Placebo Comparator|Placebo|
3039755|NCT00408408|Active Comparator|Arm 1A: Docetaxel then AC|Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
3039756|NCT00408408|Experimental|Arm 1B Docetaxel + Bev then AC + Bev|Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
3039757|NCT00408408|Experimental|Arm 2A: Docetaxel + Capecitabine then AC|Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
3039758|NCT00408408|Experimental|Arm 2B: Docetaxel + Cape + Bev then AC + Bev|Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
3039759|NCT00408408|Experimental|Arm 3A: Docetaxel + Gem then AC|Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
3039760|NCT00408408|Experimental|Arm 3B: Docetaxel + Gem + Bev then AC + Bev|Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
3039761|NCT00408421|Experimental|A|duloxetine 30 mg, daily (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 6 weeks then duloxetine 60 mg or 120 mg QD, PO for 6 weeks
3039762|NCT00408421|Placebo Comparator|B|placebo daily (QD), by mouth (PO) for 13 weeks
3039763|NCT00408434|Experimental|CS-7017|CS-7017 from 0.05 to 3.2 mg bid
3039764|NCT00408460|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive paclitaxel IV on days 3, 10, and 17 and imatinib mesylate PO QD on days 1-4, 8-11, and 15-18. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
3039765|NCT00408499|Experimental|Erlotinib + Cetuximab|Daily erlotinib combined with weekly cetuximab
3039766|NCT00408564|Experimental|Gemcitabine,Oxaliplatin and Cetuximab|"Gemcitabine will be given on day 1 of every 2 week cycle. Oxaliplatin will be given day 2 of every 2 week cycle. Cetuximab will be given every week for 12 weeks.~After chemotherapy, patient will be assessed for resectability. Patients will have either surgery or daily radiation and capceitabine Monday-Friday for a total of 5 and a half weeks."
3039767|NCT00408590|Experimental|Experimental Arm|
3039768|NCT00408603|Experimental|All study patients|All patients will receive voreloxin injection
3039769|NCT00408629|Experimental|adalimumab group|
3039770|NCT00408629|Experimental|placebo group|
3039771|NCT00408681|Experimental|Arm I|Patients receive oral lithium carbonate once or twice daily. Treatment continues for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
3039772|NCT00408694|Experimental|Treatment (bevacizumab, cisplatin, fluorouracil, IMRT, 3D-CRT)|"BEVACIZUMAB AND CHEMORADIOTHERAPY: Patients receive bevacizumab IV over 30-90 minutes and cisplatin IV over 20-30 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 1, patients also undergo three-dimensional conformal radiotherapy or intensity-modulated radiotherapy once daily 5 days a week for a total of 33 fractions.~ADJUVANT THERAPY: Beginning in week 10, patients receive fluorouracil IV continuously over 96 hours on days 1-4, cisplatin IV over 20-30 minutes on day 1 OR days 1 and 2, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3039773|NCT00408876|Experimental|Duloxetine 20 mg|duloxetine 20 mg once a day (QD), by mouth (PO) for 13 weeks
3039774|NCT00408876|Experimental|Duloxetine 60 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week then duloxetine 60 mg QD, PO for 12 weeks
3039775|NCT00408876|Experimental|Duloxetine 120 mg|duloxetine 30 mg once a day (QD), by mouth (PO) for 1 week followed by duloxetine 60 mg QD, PO for 1 week, then duloxetine 120 mg QD, PO for 11 weeks
3039776|NCT00408876|Placebo Comparator|Placebo|placebo once a day (QD), by mouth (PO) for 13 weeks
3039777|NCT00408902|Experimental|TandutinibTreatment|Patients receive oral tandutinib 500 mg twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3039778|NCT00408928|Experimental|Bortezomib for Treatment of GHVD|To determine if bortezomib (VELCADE®) will successfully inhibit T-cell responses in clinically acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
3039779|NCT00408993|Experimental|Duloxetine|60 mg every day (QD) (morning or evening), by mouth (PO) for 12 weeks (at week 2, dose can be increased to 120 mg at investigator discretion based on response)
3039780|NCT00408993|Placebo Comparator|Placebo|Placebo every day (QD), by mouth (PO) for 12 weeks
3039781|NCT00409006|Experimental|Pemetrexed/Cisplatin/Gefitinib|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by gefitinib 250 mg administered orally, once daily, until disease progression or unacceptable toxicity.
3039782|NCT00409006|Experimental|Pemetrexed/Cisplatin|Pemetrexed 500 milligrams per meters squared (mg/m2) plus cisplatin 75 mg/m2 administered by intravenous (IV) infusion once every 3 weeks for 4 cycles without progression followed by pemetrexed 500 mg/m2 administered by IV infusion (with optional cisplatin 75 mg/m2 for up to 2 additional cycles) until disease progression or unacceptable toxicity.
3039783|NCT00409175|Experimental|1.|Fx-1006A
3039784|NCT00409175|Placebo Comparator|2.|Placebo
3039785|NCT00409188|Experimental|Tecemotide (L-BLP25)|
3039786|NCT00409188|Placebo Comparator|Placebo|
3039787|NCT00409240|Experimental|MEDIC Intervention|Receives pharmacist-led behavioral and pharmacologic group intervention for cardiac risk reduction
3039788|NCT00409240|No Intervention|Usual Care|Patient continued on usual care
3039789|NCT00409292|Experimental|RAD001|"RAD001 was administered continuously at a dose of 10 mg daily by mouth until disease progression, unacceptable toxicity, or withdrawal of consent.~Four weeks of study drug was considered to be one cycle of treatment."
3039790|NCT00409409|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3039791|NCT00409409|Placebo Comparator|Placebo|Placebo tablet
3039792|NCT00409539|Placebo Comparator|1|Placebo run-in phase. 2 week duration.
3039793|NCT00409539|Placebo Comparator|2|To be taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
3039794|NCT00409539|Experimental|3|20mg dose of SMP-986 to be taken once daily for 8 week duration.
3039795|NCT00409539|Experimental|4|40mg dose of SMP-986 to be taken for 8 week duration.
3039796|NCT00409539|Experimental|5|80mg dose of SMP-986 to be taken for 8 week duration.
3039797|NCT00409539|Experimental|6|120mg dose of SMP-986 to be taken for 8 week duration.
3039798|NCT00409565|Experimental|Cetuximab plus bevacizumab|Cetuximab plus bevacizumab
3039799|NCT00409578|Placebo Comparator|Placebo|Placebo tablets and capsules
3039800|NCT00409578|Experimental|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
3039801|NCT00409578|Experimental|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.
3039802|NCT00409578|Experimental|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.
3039803|NCT00409617|Experimental|Open Label|
3039804|NCT00409682|Active Comparator|Open-label adalimumab (Week 0 to Week 4)|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
3039805|NCT00409682|Active Comparator|Low-Dose Adalimumab: 20 mg or 10 mg eow (Week 4 to Week 52)|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
3039806|NCT00409682|Active Comparator|High-Dose Adalimumab: 40 mg or 20 mg eow (Week 4 to Week 52)|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
3039807|NCT00409708|Active Comparator|1|
3039808|NCT00409708|Other|2|
3039809|NCT00409747|Experimental|Minocycline|
3039810|NCT00409773|Other|1|Arm 1: drug + comparator + Placebo
3039811|NCT00409773|Other|2|Arm 2: drug + comparator + Placebo
3039812|NCT00409773|Other|3|Arm 3: drug + comparator + Placebo
3039813|NCT00409773|Other|4|Arm 4: drug + comparator + Placebo
3039814|NCT00409773|Other|5|Arm 5: drug + comparator + Placebo
3039815|NCT00409825|Experimental|Part 1|Part 1 done after 4 weekly 17-OHPC injections completed, between 20 6/7 to 24 6/7 weeks gestation. 10 cc blood drawn pre-5th injection. 10 cc blood drawn 12 hours post-dose and 7 consecutive days. 24-hour urine collected days 4-5 within 7 days post-injection. Part 2 done 31 0/7 to 34 6/7 or at 35 0/7 weeks. 10 cc blood drawn pre weekly injection, 12 hours post-dose, and 7 consecutive days. 24-hour urine collected between days 4-5 within 7 days post-injection. A subject in whom Part 2 is performed during the last scheduled injection of 17-OHPC (at or around 35 0/7 weeks) will have the option to participate in Part 3, in which 10 cc of blood will be drawn serially over 21 days after completing Part 2. Blood will be drawn on days 9, 11, 14, 17, 20, 24, 28 after the last injection. Part 4: At the time of labor and delivery, subject will have 10cc of blood removed from a maternal peripheral vein. 10cc of blood will be collected from the placenta/umbilical cord after delivery.
3039816|NCT00409838|Experimental|Abatacept and Methotrexate|
3039817|NCT00409838|Placebo Comparator|Placebo and Methotrexate|(standard of care)
3039818|NCT00409838|Experimental|Abatacept - Open Label|Open-label extension phase
3039819|NCT00410046|Experimental|Etanercept (ETN)|Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
3039820|NCT00410059|Experimental|Erlotinib|Erlotinib 150 mg by mouth daily x 28 days.
3039821|NCT00410072|Experimental|TDF 0.5 mg|TDF=tenofovir
3039822|NCT00410072|Experimental|ETV 0.5 mg +TDF 300 mg|ETV=entecavir; TDF=tenofovir
3039823|NCT00410124|Experimental|RAD001 +BSC|The study drugs were self administered by the patients. Patients were instructed to take the study drug as specified in the protocol. Patients were instructed to take two tablets (5 mg each) by mouth every day. Tablets were to be taken one tablet after another with a glass of water, at the same time each day in a fasting state or with a light fat-free meal. If disease progression occurred, patients were unblinded and if they were receiving RAD001, they would discontinue the study. Otherwise, they would be given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
3039824|NCT00410124|Placebo Comparator|Placebo (plus BSC)|Patients received matching placebo of RAD001 tablets twice a day along with Best Supportive Care. With the documented disease progression, the investigator could unblind the patient. If unblinded patient was receiving placebo treatment, they were given the option to continue in the extension open label phase of 2 tablets of RAD001 5mg by mouth every day.
3039825|NCT00410150|Experimental|Group 1 (Heliox-powered albuterol)|Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox.
3039826|NCT00410150|Active Comparator|Group 2 (Oxygen-powered albuterol)|Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.
3039827|NCT00410163|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab every 4 weeks in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 500mg
3039828|NCT00410163|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 monthly infusions with ofatumumab in combination with fludarabine and cyclophosphamide. The first infusion will be 300mg followed by 5 infusions of 1000mg
3039829|NCT00410189|Experimental|ZD6474|ZD6474 300 mg by mouth daily for 28 Days.
3039830|NCT00410202|Active Comparator|Entecavir|With the option of adding tenofovir at week 48. (This does not apply to Korea)
3039831|NCT00410202|Active Comparator|Adefovir + Lamivudine|
3039832|NCT00410202|Active Comparator|Entecavir + Adefovir|
3039833|NCT00410280|Other|1|
3039834|NCT00410384|Placebo Comparator|Placebo|Placebo
3039835|NCT00410384|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
3039836|NCT00410384|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
3039837|NCT00410410|Experimental|Abatacept (ABA)|"Induction Period; 3 arms for Cohort 1: ABA 30/~10 mg/kg (ABA administered at 30 mg/kg followed by ABA at ~10 mg/kg), ABA ~10 mg/kg, ABA 3 mg/kg~Induction Period; 2 arms for Cohort 2: ABA 30/~10 mg/kg and Second Cohort ABA ~10 mg/kg~1 arm for maintenance period (ABA ~10 mg/kg)"
3039838|NCT00410410|Placebo Comparator|Placebo|"1 arm for induction period~1 arm for maintenance period"
3039839|NCT00410410|Other|abatacept|1 arm for open-label extension phase (ABA ~10 mg/kg)
3039840|NCT00410423|Experimental|Bortezomib 0.7mg/m^2|Bortezomib in combination with mitoxantrone, etoposide and cytarabine
3039841|NCT00410423|Experimental|Bortezomib 1.0mg/m^2|
3039842|NCT00410423|Experimental|Bortezomib 1.3mg/m^2|
3039843|NCT00410488|Active Comparator|Palonosetron - 1 Dose|"Arm 1: Palonosetron 0.25 mg intravenous (IV) for 1 dose (day 0).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
3039844|NCT00410488|Active Comparator|Palonosetron - 3 Doses|"Arm 2: Palonosetron 0.25 mg IV for 3 doses (days 0, 2, 4).~Dexamethasone: IV piggyback daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy. Chemotherapy treatment regimen: Zinecard: 750 mg/m2 as an IV bolus; Doxorubicin: 75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0. Mesna: 500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hours for days 0, 1, 2, and 3 (infusion completing on day 4); Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2); Vincristine: 2 mg IV by rapid administration on day 0 (for patients with small cell histology)."
3039845|NCT00410514|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.
3039846|NCT00410514|Experimental|Mirabegron 50 mg|Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.
3039847|NCT00410514|Experimental|Mirabegron 100 mg|Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.
3039848|NCT00410605|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, oral lenalidomide on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3039849|NCT00410761|No Intervention|1|Placebo vandetanib
3039850|NCT00410761|Experimental|2|Vandetanib
3039851|NCT00410813|Experimental|Arm I|Patients receive oral dasatinib once daily.
3039852|NCT00410813|Experimental|Arm II|Patients receive oral dasatinib twice daily.
3039853|NCT00410826|Experimental|Arm I (chemo, radiotherapy, enzyme inhibitor/radiosensitizer)|Patients receive cisplatin IV on days 1, 22, and 43 and undergo 3-dimensional conformal or intensity modulated radiotherapy once daily, 5 days per week, on days 1-47. Patients also receive erlotinib hydrochloride PO once daily on days -7 to 47.
3039854|NCT00410826|Active Comparator|Arm II (chemotherapy, radiotherapy)|Patients receive cisplatin and radiotherapy as in Arm I.
3039855|NCT00410891|Experimental|topical antibiotic|topical gatifloxacin 4 times per day
3039856|NCT00410904|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28 in course 1 and on days 1-21 in course 2 and all subsequent courses. Patients also receive pemetrexed disodium IV over 10 minutes on day 8 in course 1 and on day 1 in course 2 and all subsequent courses. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3039857|NCT00411086|Experimental|Rituximab + GM-CSF|Rituximab 375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22. Sargramostim (GM-CSF) 250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
3039858|NCT00411216|Experimental|exercises for gaze stabilization|Experimental group performed vestibular adaptation and substitution exercises
3039859|NCT00411216|Placebo Comparator|Control exercises|Saccadic eye movements against a Ganzfeld to prevent retinal slip error signal; no head movements
3039860|NCT00411398|Experimental|Memantine 5-20mg/d flexible dose|Memantine tablets 5-20mg/d flexible dose
3039861|NCT00411411|Placebo Comparator|Placebo|Placebo treatment, administered as tablets.
3039862|NCT00411411|Experimental|Januvia|Active treatment
3039863|NCT00411450|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until disease progression, intolerability, death, or study withdrawal.
3039864|NCT00411463|Experimental|Psychotherapy|Subjects randomized to the Psychotherapy arm will receive Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
3039865|NCT00411463|Experimental|Medication|Subjects randomized to the medication arm will receive the FDA approved medication Seroquel (quetiapine)
3039866|NCT00411554|Experimental|Sitagliptin 50 mg QD|sitagliptin 50 mg orally once daily (QD=once daily)
3039867|NCT00411554|Active Comparator|Voglibose 0.2 mg TID|voglibose 0.2 mg orally three times daily (TID= three times daily)
3039868|NCT00411619|Experimental|Everolimus|As this was a non-randomized, open-label, single arm study, all patients in the study received treatment with everolilmus
3039869|NCT00411632|Experimental|Bexarotene + Erlotinib|Bexarotene 400 mg/m^2 by mouth daily x 28 Days. Erlotinib 150 mg by mouth daily x 28 Days.
3039870|NCT00411645|Experimental|A|
3039871|NCT00411645|Placebo Comparator|B|
3039872|NCT00411671|Experimental|Sorafenib|Sorafenib 400 mg By Mouth Twice Daily for 28 Days.
3039873|NCT00411684|Experimental|CDB-2914|A Prospective, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of CBD-2914 as Emergency Contraception When Taken Between 48 Hours and 120 Hours of Unprotected Intercourse
3039874|NCT00411749|Experimental|V501|"V501 vaccination Quadrivalent HPV (Types 6, 11, 16,~18) L1 VLP Vaccine Injection~cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,~Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6."
3039875|NCT00411749|Placebo Comparator|Placebo|Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
3039876|NCT00411762|Experimental|PHY906 Administration|PHY906 800mg, orally, twice a day for days 1-4 and capecitabine 1500mg/m^2 days 1-7 of a 14-day cycle
3039877|NCT00411788|Experimental|sirolimus and trastuzumab|Patients received oral sirolimus 6 mg daily in combination with weekly trastuzumab administered intravenously with a loading dose of 4 mg/kg followed by 2 mg/kg weekly in a 28-day cycle. A subsequent amendment allowed trastuzumab to be administered every 3 weeks for patient convenience, with a loading dose of 8 mg/kg followed by a 6 mg/kg in a 21-day cycle. Sirolimus was administered at a 6 mg oral daily dose. Cycles were repeated on an every 21 or 28-day schedule until disease progression, unacceptable toxicity, or the development of any of the criteria for study removal. Doses were reduced or discontinued based on tolerability.
3039878|NCT00412061|Experimental|Octreotide+ Everolimus|Everolimus was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity. Each treatment cycle lasted 28 days. Patients received their first dose of everolimus at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1, Day 1.
3039879|NCT00412061|Placebo Comparator|Octreotide+ Placebo|Matching placebo was administered in accordance with a 10-mg daily dosing regimen (two 5-mg tablets) in conjunction with octreotide 30 mg intramuscularly (i.m.) every 28 days. Patients were treated until progression or unacceptable toxicity; Each treatment cycle lasted 28 days. Patients received their first dose of matching placebo at Cycle 1, Day 1. Administration of octreotide was performed every 28 days (± 4 days) starting on Cycle 1 Day 1.
3039880|NCT00412074|Active Comparator|Control 400 IU vitamin D3|400 IU vitamin D3/day given to lactating women and 400 IU vitamin D3/day given as oral supplement to infant in dyad
3039881|NCT00412074|Experimental|2400 IU vitamin D3 (cholecalciferol)|2400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 2000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
3039882|NCT00412074|Experimental|6400 IU vitamin D3 (cholecalciferol)|6400 IU vitamin D3 given to lactating mother: 400 IU vitamin D3 from a prenatal vitamin and 6000 IU vitamin D3 and 0 IU vitamin D3 (placebo) given to her breastfeeding infant
3039883|NCT00412087|Experimental|Cholecalciferol 2000 IU|Women at 12-16 weeks' gestation are enrolled into the study to receive 2000 IU/day vitamin D3 for one month. After the run-in dose, the subjects are randomized to one of two treatment groups: either 2000 or 4000 IU/day to be taken throughout pregnancy until delivery.
3039884|NCT00412087|Experimental|Cholecalciferol 4000 IU|Women are randomized to one of 2 treatment groups: 2000 or 4000 IU vitamin D3/day
3039885|NCT00412113|Active Comparator|Norvasc 5 mg|Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
3039886|NCT00412113|Experimental|Caduet 10/20mg|Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
3039887|NCT00412113|Active Comparator|Norvasc 10 mg|Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
3039888|NCT00412113|Experimental|Caduet 5/20mg|Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
3039889|NCT00412217|Experimental|Erlotinib|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive erlotinib tablets as 150 mg PO daily for 1 year until disease progression or intolerable toxicity.
3039890|NCT00412217|Placebo Comparator|Placebo|Participants treated with surgical resection and chemoradiotherapy or radiotherapy alone will receive placebo treatment for 1 year until disease progression or intolerable toxicity.
3039891|NCT00412243|Experimental|Clofarabine + Cyclophosphamide|Clofarabine 40 mg/m^2 daily for 3 Days + Cyclophosphamide starting 200 mg/m^2 every 12 hours for 3 days
3039892|NCT00412360|Experimental|Single Cord Blood Transplant|Unrelated donor, single umbilical cord blood unit transplant; conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
3039893|NCT00412360|Experimental|Double Cord Blood Transplant|Unrelated donor, double umbilical cord blood unit transplant; Conditioning regimen: Total Body Irradiation/cyclophosphamide/fludarabine; GVHD prophylaxis: Cyclosporine A/Mycophenolate Mofetil
3039894|NCT00412373|Experimental|001|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
3039895|NCT00412373|Experimental|003|Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
3039896|NCT00412373|Placebo Comparator|002|Placebo for 6 weeks
3039897|NCT00412425|Active Comparator|2 Days Palonosetron|2 Days Palonosetron 0.25 mg intravenous (IV)
3039898|NCT00412425|Active Comparator|3 Days Palonosetron|3 Days Palonosetron 0.25 mg IV
3039899|NCT00412451|Experimental|Ocriplasmin 25µg|25µg ocriplasmin intravitreal injection versus sham injection
3039900|NCT00412451|Experimental|Ocriplasmin 75µg|75µg ocriplasmin intravitreal injection versus sham injection
3039901|NCT00412451|Experimental|Ocriplasmin 125µg|125µg ocriplasmin intravitreal injection versus sham injection
3039902|NCT00412451|Sham Comparator|sham injection|Sham injection
3039903|NCT00412516|Other|Group 1|JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month
3039904|NCT00412516|Experimental|Group 2|JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently
3039905|NCT00412516|Other|Group 3|Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month
3039906|NCT00412529|Experimental|Telbivudine|
3039907|NCT00412529|Active Comparator|Entecavir|
3039908|NCT00412542|Experimental|Thalidomide + CPT-11|Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.
3039909|NCT00412607|Experimental|NaviStar ThermoCool Catheter|
3039910|NCT00412737|Experimental|Oseltamivir|
3039911|NCT00412737|Placebo Comparator|Placebo|
3039912|NCT00412750|Experimental|LdT+ PEG-INF|Telbivudine (LdT) 600 mg orally once a day for 104 weeks in combination with peginterferon alpha-2a (PEG-INF)180 μg subcutaneous injection once a week for 52 weeks.
3039913|NCT00412750|Experimental|LdT Monotherapy|Telbivudine (LdT) monotherapy: 600 mg orally once daily for 104 weeks.
3039914|NCT00412750|Active Comparator|PEG-INF Monotherapy|Peginterferon alpha-2a (PEG- INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.
3039915|NCT00412841|Experimental|Atorvastatin|Atorvastatin 40mg
3039916|NCT00412841|Placebo Comparator|Placebo|Tablets identical to atorvastatin 40mg
3039917|NCT00412867|Experimental|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
3039918|NCT00412893|Experimental|Isavuconazole|Participants received a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they reached a treatment endpoint or for a maximum of 84 days.
3039919|NCT00412893|Active Comparator|Voriconazole|Participants received a loading dose of voriconazole, 6 mg/kg every 12 hours IV for the first 24 hours, followed by a maintenance dose of 4 mg/kg every 12 hours by IV on Day 2. Beginning on Day 3, participants received 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they reached a treatment endpoint or for a maximum of 84 days.
3039920|NCT00412958|Experimental|Ocriplasmin 25µg|25µg of ocriplasmin intravitreal injection
3039921|NCT00412958|Experimental|Ocriplasmin 75µg|75µg of ocriplasmin intravitreal injection
3039922|NCT00412958|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
3039923|NCT00412958|Placebo Comparator|Placebo|Intravitreal injection of placebo
3039924|NCT00412971|Active Comparator|Hexvix cystoscopy group|
3039925|NCT00412971|Other|White light|Standard White light cystoscopy
3039926|NCT00412984|Active Comparator|1|
3039927|NCT00412984|Experimental|2|
3039928|NCT00413010|Placebo Comparator|Arm 2|
3039929|NCT00413010|Experimental|Arm 1|
3039930|NCT00413036|Experimental|lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
3039931|NCT00413049|Experimental|Valsartan/amlodipine 80/5 mg|
3039932|NCT00413049|Active Comparator|Amlodipine 5 mg|
3039933|NCT00413062|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3039934|NCT00413062|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3039935|NCT00413153|Active Comparator|1|Boosted Reyataz (300mg atazanavir + 100mg ritonavir)
3039936|NCT00413153|Active Comparator|2|Kaletra (pre-study dose)
3039937|NCT00413166|Experimental|Induction ATRA + ATO + Idarubicin|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATRA 45 mg/m2 daily by mouth beginning day 1; ATO 0.15 mg/kg by vein daily beginning on day 1; Idarubicin 12 mg/m2 x 1 dose; Methylprednisolone 50 mg daily for 5 days starting on day 1."
3039938|NCT00413166|Experimental|Maintenance|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO)~ATO 0.15 mg/kg by vein over 2 hours Monday-Friday for 4 weeks, then a 4-week break. ATRA 45 mg/m2 by mouth every day for 2 weeks, followed by 2 additional weeks of no study drug. Continue ATRA until treatment with ATO complete."
3039939|NCT00413166|Experimental|Induction ATRA + ATO + GO|"All-Trans Retinoic Acid (ATRA) + Arsenic Trioxide (ATO) + Gemtuzumab Ozogamicin (GO)~ATRA 45 mg/m2 daily po (in 2 divided doses) beginning day 1; ATO 0.15 mg/kg IV daily beginning on day 1; GO 9 mg/m2 on day 1 Methylprednisolone 50 mg daily for 5 days followed by rapid taper starting on day 1.~Theophylline 100mg p.o. bid days 1-3, 200 mg p.o. bid days 4-6, and 300 mg p.o. bid thereafter during periods when patient is receiving ATRA or ATO. Theophylline administration continues until therapy with ATO and ATRA is completed."
3039940|NCT00413192|Experimental|1|
3039941|NCT00413218|Experimental|Isavuconazole (ISA)|Participants received 3 intravenous (IV) loading doses of 200 mg of isavuconazole on days 1 and 2, followed by an IV maintenance dose of 200 mg once daily from day 3 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV to oral therapy. Oral therapy consisted of 200 mg isavuconazole twice daily.
3039942|NCT00413218|Active Comparator|Caspofungin (CAS)/Voriconazole|Participants received 1 intravenous (IV) loading dose of 70 mg CAS on day 1, followed by an IV maintenance dose of 50 mg CAS from day 2 to day 56. On day 11 at the discretion of the investigator, non-neutropenic patients could switch from IV CAS to oral voriconazole comprising of a loading dose of 400 mg twice daily (BID) on the first day of oral therapy followed by standard dosing of 200 mg BID thereafter.
3039943|NCT00413231|Experimental|Valiant Thoracic Stent Graft System|"160 subjects were enrolled into the study, including 157 subjects treated with the study device and three subjects classified as intent-to-treat who did not receive the study device.~There were no other arms for this study."
3039944|NCT00413244|Experimental|Androgel treatment|"Androgel 5 grams~Androgel treatment - subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
3039945|NCT00413244|Placebo Comparator|Placebo|Placebo - will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months.
3039946|NCT00413283|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3039947|NCT00413283|Experimental|Romiplostim 250 μg|Participants received romiplostim 250 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3039948|NCT00413283|Experimental|Romiplostim 500 μg|Participants received romiplostim 500 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3132854|NCT03459196|Experimental|Treatment Group|A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
3132855|NCT03459612|Placebo Comparator|Placebo|Placebo administered orally in one of four study periods.
3039949|NCT00413283|Experimental|Romiplostim 750 μg|Participants received romiplostim 750 μg administered subcutaneously on Day 2 of each chemotherapy cycle. Chemotherapy consisted of 21-day cycles of gemcitabine/carboplatin (gemcitabine and carboplatin on Day 1 and gemcitabine again on Day 8) or 21-day cycles of gemcitabine/cisplatin (gemcitabine and cisplatin on Day 1 and gemcitabine again on Day 8), up to a maximum of 5 cycles administered according to standard institutional practice.
3039950|NCT00413335|Active Comparator|1|Subject undergoes ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, NMR and DEXA scan. Subject then receives Rosiglitazone. Subjects are followed every 2 weeks. Imaging repeated at 2 months. 12 week follow up. And then all tests are repeated at 4 months.
3039951|NCT00413335|Placebo Comparator|2|Subject has ogtt, hyperinsulinemic-euglycemic clamp, abdominal and liver MRI, DEXA, NMR. Subject is randomized (double-blind) to placebo. Is followed every 2 weeks, repeats imaging at 2 months, is seen at 12 weeks and then repeats all tests at 2 months.
3039952|NCT00413374|Other|Enoxaparin|
3039953|NCT00413400|Placebo Comparator|Placebo|
3039954|NCT00413400|Active Comparator|Etanercept|
3039955|NCT00413413|Experimental|Valsartan/amlodipine 80/5 mg|
3039956|NCT00413413|Active Comparator|Valsartan 80 mg|
3039957|NCT00413413|Active Comparator|Valsartan 160 mg|
3039958|NCT00413478|Experimental|5-Azacytidine|5-Azacytidine 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
3039959|NCT00413582|Active Comparator|1|Epidural analgesia
3039960|NCT00413582|Experimental|2|IV narcotic analgesia
3039961|NCT00413634|Experimental|Younger Participants (18-50 years)|
3039962|NCT00413634|Experimental|Elderly Participants (≥65 years)|
3039963|NCT00413660|Experimental|CP 690,550 1 mg BID|
3039964|NCT00413660|Experimental|CP 690,550 10 mg BID|
3039965|NCT00413660|Experimental|CP 690,550 15 mg|
3039966|NCT00413660|Experimental|CP 690,550 3 mg BID|
3039967|NCT00413660|Experimental|CP 690,550 5 mg BID|
3039968|NCT00413660|Experimental|CP-690,550 20 mg QD|
3039969|NCT00413660|Placebo Comparator|Placebo|Dummy tablets
3039972|NCT00413777|Experimental|Tolvaptan 45/15 mg/day orally for up to 4 years|Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
3039973|NCT00413777|Experimental|Tolvaptan 60/30 mg/day orally for up to 4 years|Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.
3039974|NCT00413894|Experimental|1|
3039975|NCT00413920|Experimental|Without Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, but did not subsequently receive oral corticosteroids for the remainder of the study.
3039976|NCT00413920|Active Comparator|With Steroids|Patients received Enteric-coated Mycophenolate Sodium (EC-MPS), administered orally 2 times a day for 6 months. Patients also received cyclosporine and a dose of methylprednisolone immediately after transplantation, and subsequently continued to receive daily oral prednisone.
3039977|NCT00413959|Experimental|Velcade, Rituximab,Cyclophosphamide & Decadron|Velcade 375 mg/m^2 given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
3039978|NCT00413972|Experimental|Vytorin 10/10|Ezetimibe 10 mg with Simvastatin 10 mg
3039979|NCT00413972|Experimental|Vytorin 10/20|Ezetimibe 10 mg with Simvastatin 20 mg
3039980|NCT00413972|Experimental|Vytorin 10/40|Ezetimibe 10 mg with Simvastatin 40 mg
3039981|NCT00413972|Placebo Comparator|Placebo|
3039982|NCT00414011|Experimental|Moxifloxacin|Moxifloxacin eye drops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
3039983|NCT00414011|Experimental|Gatifloxacin|Gatifloxacin eyedrops; 1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
3039984|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 5 μg|Infants received a primary series of 3 doses of experimental vaccine (5 μg per dose) at 2, 4 and 6 months of age.
3039985|NCT00414050|Active Comparator|RECOMBIVAX HB™ Hepatitis B Vaccine|Infants received a primary series of 3 doses of currently licensed vaccine (5 μg per dose) at 2, 4 and 6 months of age.
3039986|NCT00414050|Experimental|Modified Process Hepatitis B vaccine 10 μg|Infants received a primary series of 3 doses of experimental vaccine (10 μg per dose) at 2, 4 and 6 months of age.
3039987|NCT00414050|Active Comparator|ENGERIX-B®|Infants received a primary series of 3 doses of currently licensed vaccine (10 μg per dose) at 2, 4 and 6 months of age.
3039988|NCT00414076|Active Comparator|Letrozole|Letrozole 2.5 mg Tablet By Mouth Daily for 12 Weeks.
3039989|NCT00414076|No Intervention|Standard of Care|Patients receive no treatment. Follow up every 3 months.
3039990|NCT00414167|Experimental|1|Bupropion
3039991|NCT00414167|Placebo Comparator|2|Placebo
3039992|NCT00414206|Active Comparator|1% mecamylamine|
3039993|NCT00414206|Active Comparator|0.3% mecamylamine|
3039994|NCT00414206|Placebo Comparator|Placebo|
3039995|NCT00414271|Experimental|Docetaxel and Capecitabine in gastric cancer|Intravenous docetaxel 60 mg/m2 on day 1 and oral capecitabine 900 mg/m2 two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
3039996|NCT00414310|Experimental|Decitabine|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days.
3039997|NCT00414310|Experimental|Decitabine + Valproic Acid|Decitabine 20 mg/m^2 intravenous (IV) over 1 hour daily for 5 days. Valproic Acid 50 mg/kg orally daily for 7 days.
3039998|NCT00414388|Experimental|Single agent Sorafenib|Oral Single agent Sorafenib 400mg twice daily
3039999|NCT00414440|Experimental|Everolimus|Patients in the everolimus group initially received 5 mg/day everolimus divided in 2 equal doses (i.e. 2.5 mg b.i.d.). Dose adjustments were performed to achieve a blood trough level of 3-8 ng/mL (maximum daily dose: 10 mg/day [5 mg b.i.d.]).
3040000|NCT00414440|Placebo Comparator|Placebo|Placebo tablets equivalent to the dosage of everolimus 5 mg/day, divided in 2 equal doses.
3040001|NCT00414466|Placebo Comparator|Placebo (0mg/day)|Intraspinal Placebo delivered continuously for 29 days via an implantable infusion system
3040002|NCT00414466|Active Comparator|Gabapentin Low (1mg/day)|Intraspinal Gabapentin Low delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3040003|NCT00414466|Active Comparator|Gabapentin Medium (6mg/day)|Intraspinal Gabapentin Medium delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3040004|NCT00414466|Active Comparator|Gabapentin High (30mg/day)|Intraspinal Gabapentin High delivered continuously for 22 days via an implantable infusion system followed by 7 days infusion at half dose
3040005|NCT00414518|Experimental|Treatment interruption|Oral Tenofovir disoproxil fumarate/Emtricitabine and Lopinavir/Ritonavir for 12 weeks followed by treatment interruption if CD4 count is 450 mm^3 or higher. When CD4 count is less than 350 mm^3 on two separate, consecutive measurements during treatment interruption, therapy will be resumed.
3040006|NCT00414518|Experimental|CD4 T cell guided therapy|Anti Retroviral Therapy initiated when AIDS-defining illness occurs or if CD4 count is confirmed at less than 350 mm^3 at two separate, consecutive measurements
3040007|NCT00414544|Experimental|CosmetaLife|Test Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
3040008|NCT00414544|Active Comparator|Restylane|Control Article was given at start and two week follow up if necessary, up to a maximum dose of 2 cc to achieve optimal correction as determined by investigator.
3040009|NCT00414596|Experimental|DRX Group|Patients using the device DRX9000™.
3040010|NCT00414609|Experimental|Aliskiren|"Core Study: Aliskiren ascending doses: 75 mg tablet for 1st week, 150 mg for 2nd week, 300 mg for next 34 weeks orally once daily in the morning.~Extension Study: Patients from both the core arms who completed core study and signed informed consent form were included in this arm of extension study.~Patients received 150 mg aliskiren tablet orally once a day for two weeks. Patients were then up-titrated to 300 mg aliskiren orally once a day at the discretion of the principal investigator based on their clinical condition for the duration of the study."
3040011|NCT00414609|Placebo Comparator|placebo|Core study: placebo for 36 weeks once daily in the morning
3040012|NCT00414635|Other|Control Arm with Week 24 Crossover|Subjects randomized to the control arm will remain on daily dosing of the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily for 24 weeks. After 24 weeks of daily therapy subjects on this arm may be eligible to cross over to the experimental arm regimen of the coformulated single tablet of 600 mg efavirenz +300 mg tenofovir df +200 mg of emtricitabine on the 5/2 intermittent dosing treatment schedule for the remainder of the study.
3040013|NCT00414635|Experimental|5/2 Intermitent Treatment Arm|Subjects randomized to the 5/2 intermittent dosing treatment schedule regimen will be prescribed the pre-study regimen of 600mg efavirenz and 1 coformulated tablet of 300mg tenofovir df + 200 mg emtricitabine by mouth daily, or the equivalent coformulated single tablet of 600mg efavirenz + 300mg tenofovir df + 200 mg emtricitabine by mouth daily, for 5 consecutive days per week followed by 2 days off of these medications, 600 mg efavirenz, 300 mg tenoforvir dt and 200 mg emtricitabine, for 48 weeks.
3040014|NCT00414661||Study group|All enrolled subjects
3040015|NCT00414700|Experimental|ChondroCelect|
3040016|NCT00414700|Active Comparator|Microfracture|
3040017|NCT00414726|Active Comparator|NBO (Normobaric Oxygen)|Oxygen, inhaled at 30-45L/min via a facemask for 8 hours
3040018|NCT00414726|Placebo Comparator|Room Air|Room Air, inhaled at 30-45L/min via a facemask for 8 hours
3040019|NCT00414765|Experimental|Aldesleukin|All participants were treated with aldesleukin 600,000 international units per kilogram [IU/kg] (0.037 milligram (mg)/kg) administered as a 15-minute intravenous (IV) infusion every 8 hours for a maximum of 14 doses for the first cycle (5-day cycle). Following 9 days of rest from therapy, the cycle was repeated for up to 14 doses (i.e., a total of up to 28 doses), if tolerated.
3040020|NCT00414817|Experimental|Automated Phone-Based Refill Reminders|Intervention Arm: Participants randomly assigned to this study arm may receive up to 8 automated phone calls from the BREATH EASY Medication Reminder Program over the course of the 19 month intervention period.
3040021|NCT00414817|No Intervention|Usual Care|"Usual Care: Participants randomly assigned to this arm received the same introductory letter as those in the intervention arm, giving them the opportunity to opt out, but were subsequently selected to be in the usual care study arm, and therefore, receive no intervention."
3040022|NCT00414908|Experimental|A|
3040023|NCT00414908|Placebo Comparator|B|
3040024|NCT00414960|Experimental|Enzastaurin|Treatment with enzastaurin 500 milligrams (mg) orally (po) once daily (QD) given as 4 tablets (125 mg each).
3040025|NCT00414960|Placebo Comparator|Placebo|Treatment with placebo po QD appearing identical to enzastaurin.
3040026|NCT00414973|Experimental|A|
3040027|NCT00414973|Active Comparator|B|
3040028|NCT00415051|Experimental|Single Group Assignment|RVF MP-12
3040029|NCT00415168|Experimental|Pemetrexed + Cisplatin|
3040030|NCT00415194|Experimental|Pemetrexed/Cisplatin|"Pemetrexed 500 milligrams per meter square (mg/m^2) administered intravenously (IV) plus cisplatin 75 mg/m^2 IV on Day 1 every 21 days. Pretreatment, Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment.~Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose. Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
3040031|NCT00415194|Placebo Comparator|Placebo/Cisplatin|"Placebo (approximately 100 mL normal saline) administered intravenously (IV) plus cisplatin 75 mg/m^2 on Day 1 every 21 days.~Pretreatment - Both Treatment Arms: Dexamethasone administered orally (po): 4 milligrams (mg) twice daily (BID) taken on the day before, the day of, and day after study treatment. Vitamin B12 administered intramuscularly (im): 1000 micrograms (μg) taken 1 to 2 weeks before treatment and every 9 weeks until 3 weeks after last treatment dose.~Folic Acid administered orally (po): 350 μg to 1000 μg taken 1 to 2 weeks before treatment and continue daily until 3 weeks after last treatment dose."
3040032|NCT00415363|Experimental|A|
3040033|NCT00415363|Placebo Comparator|B|
3040034|NCT00415493|Experimental|Order 1|Cold-dry air provocation followed (on a separate day) by Warm-moist air provocation
3040035|NCT00415493|Experimental|Order 2|Warm-moist air provocation followed (on a separate day) by Cold-dry air provocation
3040036|NCT00415506|Experimental|Scleritis|Subjects with Scleritis
3040037|NCT00415506|Experimental|Orbital Inflammation|Subjects with Orbital Inflammation
3040038|NCT00415519|Experimental|1|
3040039|NCT00415519|Placebo Comparator|2|
3040040|NCT00415532|Experimental|Romiplostim|Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10^9/L for up to 52 weeks.
3040041|NCT00415532|Other|Standard of Care|Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
3040042|NCT00415597|Experimental|ALO-01|Doses given once or twice daily
3040043|NCT00415610|Other|Tier 1|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 170 to 200 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3040044|NCT00415610|Other|Tier 2|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 140 to 170 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3040045|NCT00415610|Other|Tier 3|"Dose escalation:~The scientists will investigate the potential consequences of controlling blood pressure with intravenous nicardipine to a range between 110 to 140 mmHg. Treatment with nicardipine must begin within 6 hours of symptom onset and will continue for an estimated 18 - 24 hours, until SBP is stabilized. The assigned SBP range will be maintained for 24 hours. After 24 hours, management of blood pressure is at the discretion of the primary physician."
3040046|NCT00415623|Active Comparator|Amlodipine 5mg|
3040047|NCT00415623|Experimental|Amlodipine 10mg|
3040048|NCT00415636|Experimental|LY2603618 40 mg/m^2 (4.5-hour infusion)|LY2603618 40 milligrams per square meter (mg/m^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed.
3040049|NCT00415636|Experimental|LY2603618 40 mg/m^2 (1-hour infusion)|Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m^2 [4.5-hour infusion]), the LY2603618 40 mg/m^2 dose in Cohort 2 (LY2603618 40 mg/m^2 [1-hour infusion]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed.
3040050|NCT00415636|Experimental|LY2603618 70 mg/m^2|Beginning with Cohort 3 (LY2603618 70 mg/m^2), dose modifications were allowed. LY2603618 70 mg/m^2 was administered over the course of 1 hour.
3040051|NCT00415636|Experimental|LY2603618 105 mg/m^2|Cohort 4: LY2603618 105 mg/m^2 administered over the duration of 1 hour.
3040052|NCT00415636|Experimental|LY2603618 150 mg/m^2|Cohort 5: LY2603618 150 mg/m^2 administered over the duration of 1 hour.
3040053|NCT00415636|Experimental|LY2603618 195 mg/m^2|Cohort 6: LY2603618 195 mg/m^2 administered over the duration of 1 hour.
3040054|NCT00415857|Experimental|PR1 + Imatinib|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Continue receiving imatinib by mouth at the same dose received during the last 6 months. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
3040055|NCT00415857|Experimental|PR1 + Imatinib + Interferon|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses. Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination. GM-CSF 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
3040056|NCT00415870|Experimental|PACE|Received text messages and counseling calls
3040057|NCT00415870|No Intervention|Control|
3040058|NCT00415909|Experimental|TALL-104 + IM|TALL-104 cells and imatinib mesylate (IM) therapy
3040059|NCT00416078|Experimental|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
3040060|NCT00416078|Active Comparator|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
3040061|NCT00416182|Experimental|Pulmozyme|2.5 mg Pulmozyme (dornase alfa) delivered intranasally once daily
3040062|NCT00416182|Placebo Comparator|placebo|2.5 mg/2mL placebo administered intranasally once daily
3040063|NCT00416195|Experimental|E2007|2 mg E2007 once daily for 2 weeks (Days 1 to 14), then 4 mg E2007 once daily for 2 weeks (Days 15 to 28), then 6 mg E2007 once daily for 2 weeks (Days 29 to 42), then 8 mg E2007 once daily for 2 weeks (Days 43 to 56), then 10 mg E2007 once daily for 2 weeks (Days 57 to 70), then 12 mg E2007 once daily for 6 weeks (Days 71 to 112).
3040064|NCT00416195|Placebo Comparator|Placebo|Matching placebo once daily for 16 weeks (Days 1 to 112)
3040065|NCT00416312||Conventional & Patient-Specific Dosimetry|Tumor absorbed dose calculations determined using both conventional dosimetry and 3D-RD patient-specific dosimetry software.
3040066|NCT00416455|Experimental|Treatment (diagnostic scans, surgery, chemotherapy, radiation)|Patients receive fludeoxyglucose F 18 (FDG) IV followed 60 minutes later by positron emission tomography (PET)/CT scanning on day 1. Patients also receive ferumoxtran-10 IV over 30-45 minutes on day 1 (or 24-36 hours before MRI) and undergo MRI on day 2. Patients undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy with pelvic and abdominal lymph node biopsy within 2 weeks after PET/CT scan. Patients diagnosed with metastatic disease prior to lymph node biopsy proceed directly to primary treatment. Patients with cervical cancer undergo chemoradiotherapy within 4 weeks of PET/CT scan.
3040067|NCT00416494|Experimental|Initial Cohort|
3040068|NCT00416494|Experimental|Second cohort|
3040069|NCT00416520|Experimental|1|
3040070|NCT00416520|Placebo Comparator|2|
3040071|NCT00416520|Active Comparator|3|
3132856|NCT03459612|Experimental|100 milligrams (mg) Lasmiditan|100 mg lasmiditan administered orally in one of four study periods.
3040072|NCT00416572|Experimental|Education Intervention|Participants attended 4 2-hr education sessions. The overall goal of the sessions was to provide information that would reduce participants' uncertainty about their illness and its treatment, to enhance coping in productive ways with the issues and problems confronting them, and to facilitate communication between the participants and their partners.
3040073|NCT00416572|Experimental|Nutrition Education Intervention|Participants attended 4 2-hr nutrition education sessions. Each session provided information and encouragement on setting and attaining measurable goals for healthy eating and on the benefits of thinking positively about dealing adaptively with problems in life and living a healthy lifestyle.
3040074|NCT00416572|No Intervention|Control Condition|Participants received care as usual.
3040075|NCT00416598|Experimental|Treatment (chemotherapy, PBSC or bone marrow transplantation)|See Detailed Description.
3040076|NCT00416624|Experimental|Epoetin alfa - 40000 units|40,000 Units
3040077|NCT00416624|Experimental|Epoetin alfa - 80000 units|80,000 Units
3040078|NCT00416624|Experimental|Epoetin alfa - 120000 Units|120,000 Units
3040079|NCT00416624|Experimental|Darbepoetin alfa***|500 mcg
3040080|NCT00416715|Experimental|Treatment (letrozole)|Patients receive letrozole PO QD. Patients, who experience muscle pain, joint pain, or joint stiffness that requires an intervention and who are found to be vitamin D deficient, also receive calcium and vitamin D3 PO. Treatment continues for up to 28 weeks in the absence of disease progression or unacceptable toxicity.
3040081|NCT00416793|Experimental|Treatment|Patients receive bortezomib IV on days 1, 4, 8, and 11 and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3040082|NCT00416884|Experimental|TBI, Campath, Fludarabine T-cell Deplete|(Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
3040083|NCT00416949|Experimental|Patient-specific 3D-RD Dosimetry|Applied a patient-specific dosimetry calculation method to the imaging data collected to calculate tumor absorbed doses, using 3D-RD method.
3040084|NCT00417027|Active Comparator|2.5 mL bolused every 15 minutes|
3040085|NCT00417027|Active Comparator|5ml bolused every 30 minutes|
3040086|NCT00417027|Active Comparator|10ml bolused every 60 minutes|
3040087|NCT00417079|Active Comparator|Mitoxantrone + Prednisone|Mitoxantrone + Prednisone
3040088|NCT00417079|Experimental|Cabazitaxel + Prednisone|Cabazitaxel + Prednisone
3040089|NCT00417170|Experimental|Aliskiren 300 mg|Eligible participants received oral Aliskiren 300 mg + Placebo Amlodipine once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
3040090|NCT00417170|Active Comparator|Amlodipine 5 mg|Eligible participants received oral Amlodipine 5 mg + Placebo Aliskiren once daily for 12 weeks. Study medication was taken with 200 mL of water in the morning. Breakfast was eaten 1 hour after taking study medication. Study medication was swallowed whole, and not chewed.
3040091|NCT00417274|Experimental|Quinacrine|Uncontrolled treatment arm
3040092|NCT00417417|Experimental|Rilonacept|Rilonacept 320 mg subcutaneous at each treatment visit
3040093|NCT00417417|Sham Comparator|Placebo|Normal saline subcutaneously at each treatment visit.
3040094|NCT00417482|Other|Risperidone-risperidone|Risperidone for 16 weeks followed by risperidone for 16 weeks
3040095|NCT00417482|Other|Risperidone-Placebo|Risperidone for 16 weeks followed by placebo for 16 weeks
3040096|NCT00417482|Other|Placebo-Placebo|Placebo for 16 weeks followed by placebo for 16 weeks
3040097|NCT00417612|Experimental|1|Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
3040098|NCT00417612|Placebo Comparator|2|Participants given placebo capsule to match for comparison
3040099|NCT00417859|Active Comparator|TKA mobile|TKA mobile
3040100|NCT00417859|No Intervention|TKA|TKA fix
3040101|NCT00417885|Experimental|A|sunitinib + exemestane
3040102|NCT00417963|Experimental|stent placement in the carotid artery|placement of a bare metal stent for treatment of carotid artery stenosis
3040103|NCT00417976|Experimental|Bevacizumab|
3040104|NCT00417989|Experimental|722 sensor augmented pump|722 arm: MiniMed Paradigm REAL-Time System using NovoLog/NovoRapid for 1 year
3040105|NCT00417989|No Intervention|Multiple Daily Injections (MDI)|MDI arm: Continue with current MDI therapy using Lantus and NovoLog/NovoRapid for 1 year
3040106|NCT00418015||Labor analgesia|Labor analgesia receiving fentanyl labor analgesia
3040107|NCT00418015||Cesarean delivery analgesia|Cesarean delivery analgesia consisting of spinal fentanyl and morphine
3040108|NCT00418028|Active Comparator|A Cint|Capecitabine will be administered orally at a dose of 1250 mg/m2 twice-daily (in the morning and in the evening, the equivalent of a total daily dose of 2500 mg/m2) for 14 days, in 3 week cycles with a resting period of 7 days,until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
3040109|NCT00418028|Experimental|B Ccont|Capecitabine 800 mg/m2 orally twice-daily (in the morning and in the evening the equivalent of one dose of 1600 mg/m2) for 21 days, in 3 week cycles without resting period, until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
3040110|NCT00418093|Experimental|Chemotherapy|All patients received oxaliplatin, gemcitabine, and bevacizumab
3040111|NCT00418184|Experimental|1|
3040112|NCT00418184|Placebo Comparator|2|
3040113|NCT00418262|Experimental|Atomoxetine HCL (Strattera)|Teatment of children with fetal alcohol syndrome and ADHD with Atomoxetine HCL (Strattera)
3040114|NCT00418314|Experimental|QuickOpt (Treatment)|Frequent optimization using QuickOpt to optimize the AV/PV and VV Delays.
3040115|NCT00418314|Active Comparator|Control|Empiric programming or one-time optimization using a non-IEGM method.
3040116|NCT00418379|Experimental|300 IR (4M)|300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
3040117|NCT00418379|Experimental|300 IR (2M)|300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
3040118|NCT00418379|Placebo Comparator|Placebo|Placebo tablet
3040119|NCT00418457|Active Comparator|General anesthesia and opioid|General anesthesia followed by opioid administration
3040120|NCT00418457|Active Comparator|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral) combined with propofol
3040121|NCT00418522|Active Comparator|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
3040122|NCT00418522|Experimental|Exubera|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
3040123|NCT00418561|Experimental|Cohort 1|Metazym (Recombinant human arylsulfatase A (rhASA)): 25 U/kg as a single dose - hereafter 50 U/kg
3040124|NCT00418561|Experimental|Cohort 2|100 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
3040125|NCT00418561|Experimental|Cohort 3|200 U/kg Metazym (Recombinant human arylsulfatase A (rhASA))
3040126|NCT00418574|Experimental|Abagovomab|
3040127|NCT00418574|Placebo Comparator|Placebo|
3040128|NCT00418665|Active Comparator|750 mcg AMG 531|750 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3040129|NCT00418665|Placebo Comparator|Placebo Part B|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
3040130|NCT00418665|Placebo Comparator|Placebo Part A|Placebo weekly via subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3040131|NCT00418665|Active Comparator|500 mcg AMG 531|500 μg AMG 531 weekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part A)
3040132|NCT00418665|Active Comparator|750 mcg AMG531 Part B|750 μg AMG 531 biweekly by subcutaneous injection + lenalidomide (10 mg orally per day) for 16 weeks (Part B)
3040133|NCT00418691|Active Comparator|Immediate Release (IR) Methylphenidate|10 mg by mouth (PO) twice daily for 4 Weeks
3040134|NCT00418691|Active Comparator|Sustained Release (SR) Methylphenidate|200 mg PO once daily for 4 Weeks
3040135|NCT00418691|Active Comparator|Modafinil|18 mg PO once daily for 4 Weeks
3040136|NCT00418717|Experimental|1|Arm 1: Period A-25mg BW; Arm 1: Period B-50mg QW
3040137|NCT00418834|Active Comparator|1|
3040138|NCT00418834|Active Comparator|2|
3040139|NCT00418886|Placebo Comparator|1|Placebo Vandetanib + Pemetrexed
3040140|NCT00418886|Experimental|2|Vandetanib + Pemetrexed
3040141|NCT00418938|Experimental|Arm A|FOLFIRI + Panitumumab
3040142|NCT00418938|Experimental|Arm B|FOLFIRI + Bevacizumab
3040143|NCT00418951|Experimental|Liposomal amphotericin B: 3 mg/kg|3 mg/kg intravenously (IV) three times per week
3040144|NCT00418951|Experimental|Liposomal amphotericin B: 9 mg/kg|9 mg/kg IV once per week
3040145|NCT00418951|Experimental|Voriconazole: 400 mg|400 mg oral twice daily day 1 followed by 200 mg twice daily
3040146|NCT00418964|Experimental|Single bundle hamstring|
3040147|NCT00418964|Experimental|Double bundle hamstring|
3040148|NCT00418964|Active Comparator|Bone patellar tendon bone|
3040149|NCT00418977|Experimental|Family Based Therapy|Participants will receive family based therapy (FBT)
3040150|NCT00418977|Active Comparator|Individual Supportive Psychotherapy|Participants will receive individual supportive psychotherapy (ISP)
3040151|NCT00419003|Experimental|Lamotrigine Pre-Treatment|Patients who met enrolment criteria for phase 1 were randomly allocated to lamotrigine or placebo by a permuted block procedure consisting of blocks of two or four patients. The randomization list was created by a biostatistician with no patient contact. 300 mg of lamotrigine 2 hrs prior to ketamine infusion. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
3040152|NCT00419003|Placebo Comparator|Placebo Pre-Treatment|2 hours prior to ketamine infusion each patient received three capsules of placebo identical in size, weight, appearance, and taste to the lamotrigine tablets. Responders were randomized to one of two continuation pharmacotherapy groups, receiving either two capsules of riluzole 50 mg each (100 mg/d) or matching pill placebo under double-blind conditions.
3040153|NCT00419094|Experimental|Keppra XR 1000 mg/day|1000 mg/day once daily for 18 weeks (administered as two levetiracetam XR tablets and two placebo tablets once daily)
3040154|NCT00419094|Experimental|Keppra XR 2000 mg/day|2000 mg/day once daily for 18 weeks (administered as four levetiracetam XR tablets once daily)
3040155|NCT00419120|Experimental|Neo-bladder construction|Surgical implantation of autologous neo-bladder construct
3040156|NCT00419159|Experimental|Everolimus (RAD001) 70 mg/week|
3040157|NCT00419159|Experimental|Everolimus (RAD001) 10 mg/day|
3040158|NCT00419263|Experimental|Peramivir 150 mg|
3040159|NCT00419263|Experimental|Peramivir 300 mg|
3040160|NCT00419263|Placebo Comparator|Placebo|
3040161|NCT00419315|Experimental|Alcohol Care Management|Care management for alcohol dependence delivered in primary care
3040162|NCT00419315|Active Comparator|Usual Care|Usual care included a referral to specialty addiction treatment
3040163|NCT00419341|Experimental|IgPro20|Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
3040164|NCT00419380|Active Comparator|dornase alfa (Pulmozyme®)|dornase alfa - Pulmozyme®: 5 drops twice daily for 7 days to the affected ear.
3040165|NCT00419380|Active Comparator|Ofloxin|Ofloxin : 5 drops twice daily for 7 days to the affected ear.
3040166|NCT00419393|Experimental|Keppra XR (Levetiracetam XR)|1000 - 3000 mg/day Keppra XR (Levetiracetam XR), flexible dosing, throughout the duration of the study (planned: approximately 6 months-3 years)
3040167|NCT00419445|Active Comparator|GTS21 25 mg tid/Placebo 25 mg tid|
3040168|NCT00419445|Active Comparator|GTS21 75 mg tid/Placebo 75 mg tid|
3040169|NCT00419445|Active Comparator|GTS21 150 mg tid/Placebo 150 mg tid|
3040170|NCT00419562|Experimental|Oral Insulin|7.5 mg oral insulin capsules given before breakfast on a daily basis.
3040171|NCT00419562|Placebo Comparator|Placebo|Placebo capsule designed to match appearance of treatment capsule
3040172|NCT00419666|Experimental|Calcitriol 3mcg/g|Participants receive calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
3040173|NCT00419757|Active Comparator|Symbicort|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
3040174|NCT00419757|Active Comparator|Budesonide|budesonide HFA pMDI 160 μg x 2 actuations twice daily
3040175|NCT00419770|Experimental|B|Deferasirox
3040176|NCT00419770|Placebo Comparator|A|
3040177|NCT00419926|Experimental|Intensified Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the intensified Myfortic dosing regimen, the initial dose was 2-fold of the labeled dose (i.e. 2880 mg/day). The dosage was reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
3040178|NCT00419926|Active Comparator|Standard Mycophenolate Sodium (Myfortic) dosing regimen|In patients randomized to the standard Myfortic dosing regimen, the initial dose of 1440 mg/day had to be maintained throughout the whole study.
3040179|NCT00419952|Experimental|Symbicort|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
3040180|NCT00419952|Experimental|Budesonide|Budesonide HFA pMDI 160 ug x 2 actuations BID
3040181|NCT00420004|Experimental|LY2216684|"LY2216684: flexible dose of 3, 6, 9, or 12 milligrams (mg), tablets, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 3 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 3 mg/day; it could be increased 3 mg at a time (scheduled visit) to a maximum dose of 12 mg/day; or it could be decreased 3 mg at any time (scheduled or unscheduled visits) to a minimum dose of 3 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 3 mg/day and 6 mg/day of LY2216684 also received 1 LY2216684-matching placebo tablet + 2 escitalopram-matching placebo capsules. Participants on 9 mg/day and 12 mg/day of LY2216684 also received 2 escitalopram-matching placebo capsules."
3040182|NCT00420004|Placebo Comparator|Placebo|Placebo: tablet and capsule equivalents to LY2216684 and escitalopram, respectively, administered orally, once daily for 8 weeks.
3040183|NCT00420004|Active Comparator|Escitalopram|"Escitalopram: flexible dose of 10 or 20 milligram (mg), capsules, administered orally, once daily for 8 weeks.~For the first week of treatment, participants received a starting dose of 10 mg/day. Then, based on tolerability, for the next 7 weeks, the dose could remain at 10 mg/day; it could be increased up to a maximum dose of 20 mg/day; or it could be decreased back to 10 mg/day.~All participants were required to take an equal number of tablets (2) and capsules (2) per day. Therefore, participants on 10 mg/day of escitalopram also received 1 escitalopram-matching placebo capsule + 2 LY2216684-matching placebo tablets. Participants on 20 mg/day of escitalopram also received 2 LY2216684-matching placebo tablets."
3040184|NCT00420017|Experimental|Amiodarone|Intravenous amiodarone
3040185|NCT00420017|Other|Control|Control
3040186|NCT00420056|Experimental|PD-0332991|
3040187|NCT00420095|Active Comparator|1|Human insulin mix 30/70
3040188|NCT00420095|Experimental|2|Insulin lispro low mix
3040189|NCT00420147|Experimental|Wedged Orthosis|Subjects were given a wedged inshoe orthosis
3040190|NCT00420147|Placebo Comparator|Neutral Orthosis|Subjects were given a neutral inshoe orthosis.
3040191|NCT00420199|Active Comparator|Abatacept + Methotrexate (Double-blind period)|
3040192|NCT00420199|Placebo Comparator|Placebo + Methotrexate (Double-blind period)|
3040193|NCT00420212|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
3040194|NCT00420212|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
3040195|NCT00420212|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
3040196|NCT00420238|Experimental|A|
3040197|NCT00420238|Placebo Comparator|B|
3040198|NCT00420290|Active Comparator|Kineret|Interleukin-1 receptor antagonist
3040199|NCT00420290|Placebo Comparator|Placebo|
3040200|NCT00420303|Experimental|A|
3040201|NCT00420303|Placebo Comparator|B|
3040202|NCT00420316|Experimental|Rotarix Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two powdered oral doses of Rotarix™ vaccine in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
3040203|NCT00420316|Placebo Comparator|Placebo Group|Healthy children between and including 6 to 12 weeks of age at the time of first vaccination, who received two liquid oral doses of placebo in the Rota-036 primary vaccination study (102247), were subsequently followed-up for 6 months during their third year of age, in scope of the present study.
3040204|NCT00420342|Experimental|0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3040205|NCT00420342|Experimental|2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)|2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3040206|NCT00420342|Active Comparator|1.5 mg MPA / 0.3 mg CEE (Prempro)|1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)
3040207|NCT00420381|Experimental|A|
3040208|NCT00420407|Experimental|I|Vasopressin
3040209|NCT00420407|Placebo Comparator|2|bolus of NS (normal saline) followed by continuous infusion of NS, no vasopressin added
3040210|NCT00420420|Experimental|MK0249|
3040211|NCT00420420|Placebo Comparator|placebo|
3040212|NCT00420459|Experimental|Aripiprazole|
3040213|NCT00420511|Experimental|Sitagliptin|Sitagliptin 100mg once a day (od) by mouth (po)
3040214|NCT00420511|Placebo Comparator|Placebo arm|Placebo once a day (od) by mouth (po)
3040215|NCT00420628|Experimental|Loteprednol/Tobramycin|0.5% loteprednol etabonate with 0.3% tobramycin opthalmic suspension
3040216|NCT00420628|Placebo Comparator|Vehicle|Vehicle
3040217|NCT00420641|Experimental|GSK372475 Arm|GSK372475 1.0- 1.5 mg/day
3040218|NCT00420641|Experimental|Paroxetine Arm|Paroxetine 20-30 mg/day
3040219|NCT00420641|Other|Placebo|Placebo to Match
3040220|NCT00420745|Experimental|Rotarix Group|All subjects received 2 oral doses of Rotarix vaccine, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
3040221|NCT00420745|Placebo Comparator|Placebo Group|All subjects received 2 oral doses of placebo, 1 dose at Day 0 and 1 dose at Month 1 or 2 depending on the country.
3040222|NCT00420771|Experimental|Gabapentin|gabapentin treatment 1200 mg three times daily
3040223|NCT00420771|Placebo Comparator|Placebo|Placebo condition received pills identical in appearance to experimental arm.
3040224|NCT00420784|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Single loading dose of telaprevir 1125 milligram (mg) tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
3040225|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a,RBV 48 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3040226|NCT00420784|Experimental|Telaprevir 24 Week+Peg-IFN-alfa-2a 24 Week|Single loading dose of telaprevir 1125 mg tablet orally on Day 1 followed by 750 mg telaprevir tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection, for 24 weeks.
3040227|NCT00420784|Placebo Comparator|PBO 24 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir tablet orally thrice daily for 24 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3040228|NCT00420849|Experimental|Lenalidomide plus Dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
3040229|NCT00420927|Experimental|ADA+MTX/PBO+MTX (Arm 1)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, MTX monotherapy plus blinded placebo (PBO) during Period 2
3040230|NCT00420927|Experimental|ADA+MTX/ADA+MTX (Arm2)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1 and Period 2
3040231|NCT00420927|Experimental|ADA+MTX/OL ADA+MTX (Arm 3)|Combination therapy with methotrexate (MTX) and blinded adalimumab (ADA) during Period 1, open-label combination therapy with ADA + MTX during Period 2
3040232|NCT00420927|Experimental|PBO+MTX/PBO+MTX (Arm 4)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1 and Period 2
3040233|NCT00420927|Experimental|PBO+MTX/OL ADA+MTX (Arm 5)|Methotrexate (MTX) monotherapy plus blinded placebo (PBO) during Period 1, open-label combination therapy with adalimumab (ADA) and MTX during Period 2.
3040234|NCT00420992|Experimental|ALO-01|Up to 80 mg twice a day (bid)
3040235|NCT00420992|Placebo Comparator|Placebo|Twice a day (bid)
3040236|NCT00421148|Experimental|Sugammadex 0.5 mg/kg|Participants are to receive an intravenous (IV) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 0.5 mg/kg sugammadex is to be given.
3040237|NCT00421148|Experimental|Sugammadex 1 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 1 mg/kg sugammadex is to be given.
3040238|NCT00421148|Experimental|Sugammadex 2 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 2 mg/kg sugammadex is to be given.
3040239|NCT00421148|Experimental|Sugammadex 4 mg/kg|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single bolus dose of 4 mg/kg sugammadex is to be given.
3040240|NCT00421148|Placebo Comparator|Placebo|Participants are to receive an IV single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, an IV single 3-mL bolus dose of placebo (sodium chloride 0.9% solution) is to be given.
3040241|NCT00421174|Experimental|Etanercept|Etanercept plus corticosteroids
3040242|NCT00421174|Active Comparator|Placebo|Placebo plus Corticosteroids
3040243|NCT00421304|Placebo Comparator|Placebo|Participants will receive a single intravenous (IV) dose of placebo matched to motavizumab on Day 0 of the study.
3040244|NCT00421304|Experimental|Motavizumab 30 mg/kg|Participants will receive a single IV dose of motavizumab 30 mg/kg on Day 0 of the study.
3040245|NCT00421304|Experimental|Motavizumab 100 mg/kg|Participants will receive a single IV dose of motavizumab 100 mg/kg on Day 0 of the study.
3040246|NCT00421343|Other|Treatment for osteoporosis and falls|calcium, vitamin D, a weekly oral bisphosphonate, and falls prevention measures. No comparator group. All participants received the same intervention
3040247|NCT00421408|Experimental|Protein powder|Participants will receive a protein supplement daily (40 g whey protein supplement).
3040248|NCT00421408|Placebo Comparator|Placebo carbohydrate|Participants will receive a placebo supplement daily (40 g maltodextrin).
3040249|NCT00421603|Active Comparator|Adderall-XR and Topiramate|Adderall-XR (60 mg/day) and Topiramate (300mg/day)
3040250|NCT00421603|Placebo Comparator|Placebo|Placebo
3040251|NCT00421707|Experimental|GW876008|GW876008
3040252|NCT00421707|Placebo Comparator|Placebo|Placebo
3040253|NCT00421733|Active Comparator|Paricalcitol 1 mcg|One paricalcitol 1 mcg capsule and one matching placebo capsule per dose
3040254|NCT00421733|Active Comparator|Paricalcitol 2 mcg|Two paricalcitol 1 mcg capsules per dose
3040255|NCT00421733|Placebo Comparator|Placebo|Two placebo capsules per dose
3040256|NCT00421889|Experimental|Single arm|"Belinostat: 1000 mg/m2 days 1-5 in a 21 day cycle; IV Paclitaxel: Administered IV 2-3 hours after belinostat infusion on day 3 in a 21-day cycle~Carboplatin: Administered IV infusion after paclitaxel on day 3 in a 21-day cycle"
3040257|NCT00421928|Experimental|001|tapentadol (CG5503) 50 100 150 200 250mg twice a day (BID) during 15 weeks
3040258|NCT00421928|Active Comparator|002|oxycodone 10 20 30 40 50mg twice a day (BID) during 15 weeks
3040259|NCT00421928|Placebo Comparator|003|placebo matching placebo twice a day (BID) during 15 weeks
3040260|NCT00421993|Experimental|1|Adapalene/Benzoyl Peroxide Topical Gel
3040261|NCT00421993|Active Comparator|2|Adapalene Topical Gel
3040262|NCT00421993|Active Comparator|3|Benzoyl Peroxide Topical Gel
3040263|NCT00421993|Placebo Comparator|4|Topical Gel Vehicle
3040264|NCT00422032|Experimental|15 mg/m^2 Clofarabine|Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days
3040265|NCT00422032|Experimental|30 mg/m^2 Clofarabine|Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days
3040266|NCT00422058|Placebo Comparator|Lira placebo/Lira 2.4 mg/Lira 3.0 mg|Liraglutide placebo once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3040267|NCT00422058|Experimental|Lira 1.2 mg/Lira 3.0 mg|Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3040268|NCT00422058|Experimental|Lira 1.8 mg/Lira 3.0 mg|Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3040269|NCT00422058|Experimental|Lira 2.4 mg/Lira 3.0 mg|Liraglutide 2.4 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3040270|NCT00422058|Experimental|Liraglutide 3.0 mg|Liraglutide 3.0 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
3040271|NCT00422058|Active Comparator|Orlistat|Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal, weeks 0-20 (open-label) continued to receive Orlistat capsules 3 times daily (3 x 120 mg) in connection with each main meal in open-label extension period (weeks 20-104)
3040272|NCT00422084|Experimental|PA group|Pyronaridine artesunate (PA)
3040273|NCT00422084|Active Comparator|AL group|Arthemether lumefantrine (AL)
3040274|NCT00422097|Experimental|Ixabepilone, 5 mg/d|If none of first 3 participants experiences a dose-limiting toxicity (DLT) during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the maximum tolerated dose (MTD). If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040275|NCT00422097|Experimental|Ixabepilone, 10 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040276|NCT00422097|Experimental|Ixabepilone, 15 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040277|NCT00422097|Experimental|Ixabepilone, 20 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040278|NCT00422097|Experimental|Ixabepilone, 25 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040279|NCT00422097|Experimental|Ixabepilone, 30 mg/d|If none of first 3 participants experiences a DLT during the first 21-day cycle, a new cohort is opened at the next dose level (5-mg increments). If 2 or more of the first 3 participants experience a DLT within the first 21-day course, the dose level will be considered above the MTD. If 1 of the first 3 participants experiences a DLT, an additional 3 participants will be enrolled at this dose level for a total of 6 participants. If 2 or more of the 6 participants (or 1/3 or more of a cohort with more than 6 participants) experience a DLT, this dose level will be considered above the MTD.
3040280|NCT00422097|Experimental|Ixabepilone, 25 mg, with famotidine|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive famotidine, 40 mg on Day 1.
3040281|NCT00422097|Experimental|Ixabepilone, 25 mg, with food|Following identification of MTD, participants who completed Cycle 1 and treated at the ixabepilone MTD (25 mg/d) will crossover to Cycle 2 in which they receive a low-fat meal on Day 1.
3132857|NCT03459612|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally in one of four study periods.
3040282|NCT00422162|Experimental|Duloxetine Hydrochloride (60 mg)|"Up to Week 4: 60 milligrams (mg) every morning and placebo every evening, by mouth (PO).~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders received 60 mg every morning and 60 mg every evening added to the placebo"
3040283|NCT00422162|Experimental|Duloxetine Hydrochloride (120 mg)|"Up to Week 4: 60 mg every morning and 60 mg every evening, PO.~Week 4 to Week 8: Responders continued on same dose as before; Nonresponders continued as before with a placebo capsule added to the evening dose"
3040284|NCT00422201|Experimental|Prospective, open-label, study of mifepristone|Eligible subjects will start study treatment at the dose of 600 mg/day (given as one 200 mg tablet tid, per os). Total duration of treatment will not exceed 12 months. At the end of 12-month treatment, investigators may petition to extend treatment on a case-by-case basis.
3040285|NCT00422227|Active Comparator|1|Etanercept + Methotrexate
3040286|NCT00422227|Active Comparator|2|DMARD therapy Methotrexate + Sulfasalazine/Hydroxychloroquine/Leflunomide
3040287|NCT00422279|Experimental|supraalevolar|Bone inductive implant (Nobel Replace Tapered Groovy) placed in the supralveolar position
3040288|NCT00422279|Experimental|Other|Bone inductive implant (Nobel Replace Tapered Groovy) placed in extraction socket
3040289|NCT00422292|Experimental|Menactra® at 9 and 12 Months|Participants will received Menactra® vaccination at 9 and 12 months of age.
3040290|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + MMRV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus measles, mumps, rubella, varicella (MMRV) vaccine at 12 months of age
3040291|NCT00422292|Experimental|Menactra® at 9 Months and Menactra® + PCV at 12 Months|Participants will receive Menactra® at 9 months of age and Menactra® plus pneumococcal conjugate vaccine (PCV) at 12 months of age
3040292|NCT00422292|Active Comparator|MMRV + PCV at 12 Months|Participants who received no vaccination at 9 months of age and measles, mumps, rubella, varicella (MMRV) vaccine plus pneumococcal conjugate vaccine (PCV) at 12 months of age
3040293|NCT00422383|Experimental|1|
3040294|NCT00422383|Experimental|2|
3040295|NCT00422383|Experimental|3|
3040296|NCT00422422|Experimental|Brivaracetam|
3040297|NCT00422448|Experimental|Nevi from participants|Benign nevi dermoscopically sub-classified into 4 dermoscopic types (i.e., with globular, reticular, mixed pattern with globules in the center and mixed pattern with globules at the periphery) were excised from healthy volunteers for further genetical analysis
3040298|NCT00422461|Placebo Comparator|Placebo|
3040299|NCT00422461|Experimental|PF-00489791 20 mg titrated to 40 mg|
3040300|NCT00422461|Experimental|PF-00489791 4 mg|
3040301|NCT00422461|Experimental|PF-00489791 10 mg|
3040302|NCT00422513|Experimental|methoxy polyethylene glycol-epoetin beta|120-360 micrograms (iv) monthly, starting dose
3040303|NCT00422513|Active Comparator|Epoetin Alfa|As prescribed, (iv), 3 times weekly
3040304|NCT00422591|Experimental|Idarubicin + Cytarabine|Idarubicin 12 mg/m2 IV over 1 hour daily x 3 (days 1-3). Cytarabine 1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
3040305|NCT00422656|Experimental|Perifosine|Patients receive oral perifosine (150 mg) daily each cycle. Cycle duration is 28 days. After cycle 2, response is assessed and patients with stable or responding disease can continue for another 4 cycles or until disease progression (PD). Protocol treatment duration is 6 cycles but patients may receive perifosine maintenance per investigator discretion in absence of PD.
3040306|NCT00422695||HIV +|Groups divided according to CD4 counts
3040307|NCT00422695||Healthy Controls|HIV -ve subjects
3040308|NCT00422734|Placebo Comparator|1|Placebo
3040309|NCT00422734|Active Comparator|2|5 mg tadalafil
3040310|NCT00422799|Experimental|bortezomib and rituximab|bortezomib and rituximab
3040311|NCT00422812|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
3040312|NCT00422812|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
3040313|NCT00422812|Experimental|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
3040314|NCT00422812|Experimental|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
3040315|NCT00422903|Placebo Comparator|Letrozole plus placebo|Letrozole 2.5 mg administered orally fro 6 mos. plus placebo 1500 mg administered orally throughout the study until definitive surgery
3040316|NCT00422903|Experimental|Letrozole plus lapatininb|Letrozole 2.5 mg administered orally fro 6 mos. plus lapatinib 1500 mg administered orally throughout the study until definitive surgery
3040317|NCT00423046|Experimental|Cervarix Group|Subjects received 3 doses of GSK Biologicals human papillomavirus [HPV]16/18 vaccine 580299 (CervarixTM) at Months 0, 1 and 6 and a dose of placebo at Month 2. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
3040318|NCT00423046|Active Comparator|Gardasil Group|Subjects received 3 doses of Gardasil® (Merck's human papillomavirus [HPV] vaccine) at Months 0, 2 and 6 and a dose of placebo at Month 1. All doses were administered by intramuscular injection in the deltoid muscle of the upper arm.
3040319|NCT00423085|Placebo Comparator|Placebo|Participants received daily matching placebo patch for the duration of the 24-week double-blind treatment phase of the study.
3040320|NCT00423085|Experimental|rivastigmine 5 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks and thereafter daily rivastigmine 5 cm^2 patch. For patients who experienced intolerability, the dose was adjusted to rivastigmine 2.5 cm^2 daily. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3040321|NCT00423085|Experimental|Rivastigmine 10 cm^2|During the 16-week titration period patients received daily rivastigmine 2.5 cm^2 patch for the first 4 weeks, rivastigmine 5 cm^2 patch for the next 4 weeks, rivastigmine 7.5 cm^2 patch for the next 4 weeks and then rivastigmine 10 cm^2 patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3132858|NCT03459612|Active Comparator|Diphenhydramine|50 mg diphenhydramine administered orally in one of four study periods.
3132859|NCT03459794|Active Comparator|Ivermectin|Ivermectin will be administered once at 150mcg/kg, orally.
3132860|NCT03459794|Placebo Comparator|Control|An oral placebo will be administered once
3040322|NCT00423098|Experimental|Standard dose|Mycophenolate sodium was administered orally in combination with a standard dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 1 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
3040323|NCT00423098|Active Comparator|Low dose|Mycophenolate sodium was administered in combination with a reduced dose of corticosteroids (CS) administered as prednisone or prednisone equivalent (PRED). Mycophenolate sodium was administered in divided doses at a daily dose of 1440 mg during the first 2 weeks of the study and then at 2160 mg daily for the next 22 weeks. The dose of Prednisone was started at 0.5 mg per kg body weight and subsequently tapered according to the patient's weight. The planned treatment duration was 24 weeks.
3040324|NCT00423137|Placebo Comparator|Placebo - low dose|Twice daily (b.i.d.)
3040325|NCT00423137|Placebo Comparator|Placebo - high dose|Twice daily (b.i.d.)
3040326|NCT00423137|Experimental|BIBW2948 - low dose|Twice daily (b.i.d.)
3040327|NCT00423137|Experimental|BIBW2948 - high dose|Twice daily (b.i.d.)
3040328|NCT00423150|Experimental|Temozolomide|
3040329|NCT00423176|Experimental|MFNS + Antibiotic|Mometasone furoate nasal spray (MFNS) twice daily (BID) for 29 days, plus antibiotic. Appropriate antibiotic therapy amoxicillin/clavulanic acid BID.
3040330|NCT00423176|Placebo Comparator|Placebo|Matching placebo nasal spray BID for 29 days, plus amoxicillin/clavulanic acid BID
3040331|NCT00423189|Active Comparator|Ranibizumab only|drug - intravitreal ranibizumab
3040332|NCT00423189|Experimental|40% fluence PDT/procedure|40% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
3040333|NCT00423189|Experimental|20% fluence photodynamic therapy|20% fluence photodynamic therapy-PDT therapy with 0.5mg ranibizumab
3040334|NCT00423267|Experimental|Posaconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months.
3040335|NCT00423267|Active Comparator|Fluconazole|Eligible subjects will be stratified at Baseline by disease site (skeletal, lung, or soft tissue) and by immune status (immunocompromised or non-immunocompromised) and will then be randomly assigned to receive Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months. Fluconazole treatment or placebo only occurred during Period A.
3040336|NCT00423293|Other|5-FU + Mitomycin + IMRT|5-FU + Mitomycin + IMRT
3040337|NCT00423319|Active Comparator|Apixaban, 2.5 mg BID plus placebo|Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD)
3040338|NCT00423319|Experimental|Enoxaparin, 40 mg QD plus placebo|Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID
3040339|NCT00423332|Placebo Comparator|1|Cediranib placebo
3040340|NCT00423332|Experimental|2|Cediranib
3040341|NCT00423358|Active Comparator|vitamin D|ergocalciferol 50,000 IU Twice monthly
3040342|NCT00423358|Placebo Comparator|placebo|matching placebo tablet
3040343|NCT00423436|Experimental|IVR Assessment Plus Triage|Interactive Voice Response Telephone System (IVR) Plus Triage (Participants report symptoms to telephone system and doctor/nurse notified when symptom is severe) + Questionnaire
3040344|NCT00423436|Experimental|IVR Assessment Only|IVR (Phone calls twice weekly) + Questionnaire
3040345|NCT00423449|Experimental|Vorinostat + Gemcitabine + Platinum-based agent|
3040346|NCT00423488|Experimental|Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg|Participants were instructed to take one 10-mg ezetimibe tablet and one simvastatin placebo tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
3040347|NCT00423488|Active Comparator|Ezetimibe Placebo + Simvastatin 40 mg|Participants were instructed to take one ezetimibe placebo tablet and one simvastatin 20-mg tablet orally in the evening every day for six weeks in addition to their daily, oral, open-label, 20-mg simvastatin tablet.
3040348|NCT00423579|Experimental|Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment
3040349|NCT00423579|Active Comparator|Ezetimibe/Simvastatin placebo + Simvastatin 40 mg|Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.
3040350|NCT00423605|Experimental|1|
3040351|NCT00423657|Experimental|Ceftaroline fosamil for Injection|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
3040352|NCT00423657|Active Comparator|IV Vancomycin plus IV Aztreonam|Vancomycin 1 g administered over 60 minutes every 12 hours followed by aztreonam 1 g administered over 60 minutes every 12 hours.
3040353|NCT00423670|Active Comparator|Arm 1. PEG +RBV for 48 Wks (Part I)|"Participants treated with PegIntron (1.5 μg/kg, once weekly [QW]) and Ribavirin (800 to 1400 mg/day) for 48 weeks.~Participants with detectable HCV-RNA levels after 24 weeks of treatment had the option of crossing over to receive 24 weeks of PegIntron (1.5 μg/kg, QW), Ribavirin (800 to 1400 mg/day), and boceprevir (800 mg three times daily [TID]) for 24 additional weeks. The participants that crossed over to receive boceprevir formed Arm 8. The total treatment duration was up to 54 weeks."
3040354|NCT00423670|Experimental|Arm 2. PEG + RBV + BOC for 28 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 28 weeks.
3040355|NCT00423670|Experimental|Arm 3. PEG + RBV + BOC (from Wk 4) for 24 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 24 weeks.
3040356|NCT00423670|Experimental|Arm 4. PEG +RBV + BOC for 48 Wks (Part I)|Participants receiving boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 48 weeks.
3040357|NCT00423670|Experimental|Arm 5. PEG + RBV + BOC (from Wk 4) for 44 Wks (Part I)|Participants receiving a lead-in treatment with PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for 4 weeks, followed by boceprevir (800 mg TID) plus PegIntron (1.5 μg/kg QW) and ribavirin (800 to 1400 mg/day) for up to 44 weeks.
3040358|NCT00423670|Experimental|Arm 6. PEG + RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), ribavirin (800 to 1400 mg/day) and boceprevir (800 mg TID) for up to 48 weeks during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
3040359|NCT00423670|Experimental|Arm 7. PEG +Low-dose RBV + BOC for 48 Wks (Part II)|Participants receiving PegIntron (1.5 μg/kg QW), low-dose ribavirin (400 to 1000 mg/day) and boceprevir (800 mg TID) for up to 48 weeks (Arm 7) during Part II of the study. Part II was initiated after participants were fully enrolled for Part I.
3040360|NCT00423670|Experimental|Arm 8. PEG + RBV + BOC (from Wk 24) for 48 Wks (Part I)|"Participants that started in Arm 1 and had detectable HCV-RNA levels after 24 weeks of treatment had the option of receiving boceprevir (800 mg TID) with~PegIntron (1.5 μg/kg QW), and ribavirin (800 to 1400 mg/day). Participants that took the option of crossing over to receive PegIntron, ribavirin, and boceprevir (800 mg TID) for 24 additional weeks constitute Arm 8. The total treatment duration was up to 54 weeks."
3040361|NCT00423683|Experimental|1- Arixtra Alone|Arixtra Alone
3040362|NCT00423683|Active Comparator|2 Arixtra+ filter|Arixtra + filter
3040363|NCT00423722|Experimental|Hydration: Normal Saline (salt water)|Group 1: 1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily
3040364|NCT00423722|Placebo Comparator|Placebo: Lower Saline|Group 2: Lower Amount of Normal Saline (salt water); 100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
3040365|NCT00423735|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
3040366|NCT00423800|Experimental|Pegetron® - 24 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 16 weeks of treatment
3040367|NCT00423800|Active Comparator|Pegetron®- 48 Weeks|Participants are treated with Pegetron® (pegylated interferon alfa-2b and ribavirin) for 8 weeks and then randomized to an additional 40 weeks of treatment.
3040368|NCT00423813|Placebo Comparator|1|
3040369|NCT00423813|Experimental|2|
3040370|NCT00423852|Experimental|chemotherapy with Stem Cell Support|This is a phase I/II trial of sequential accelerated chemotherapy cycles with paclitaxel/ifosfamide and paclitaxel/ifosfamide and carboplatin administered with G-CSF and PBSC support. During phase I, carboplatin, ifosfamide, and paclitaxel will be dose escalated to determine the MTD. Additional patients will be enrolled in the Phase II portion of the study following the determination of the MTD of Ifosfamide and paclitaxel, to bring the total possible number of patients treated at the MTD to 38.
3040371|NCT00423878|Experimental|1|Participants will switch to aripiprazole with a cross-titration from the current antipsychotic over 3-4 weeks. Allowed final dosage range for aripiprazole was 5-30 mg/day
3040372|NCT00423878|Active Comparator|2|Participants will continue with their current antipsychotic treatment, either olanzapine 5-20 mg/day, quetiapine 200-1200 mg/day, or risperidone 1-16 mg/day.
3040373|NCT00423891|Experimental|Arm 1: Entecavir|
3040374|NCT00423917|Experimental|fulvestrant + bevacizumab|"Patients receive fulvestrant intramuscularly on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, prior to every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed every 3-6 months for 5 years."
3040375|NCT00423930|Experimental|IMRT + cisplatin + bevacizumab|This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.
3040376|NCT00423943|Experimental|D|modafinil
3040377|NCT00423943|Placebo Comparator|Placebo|placebo
3040378|NCT00424008|Experimental|MF/F MDI 200/10 mcg BID|Mometasone furoate 200 mcg and formoterol 10 mcg fixed dose combination taken twice daily.
3040379|NCT00424008|Active Comparator|F/SC DPI 250/50 mcg BID|Fluticasone propionate/salmeterol (F/SC) 250/50 mcg BID
3040380|NCT00424047|Experimental|CC-5013 plus dexamethasone|Arm A: Oral CC-5013 is initiated on Day 1 of Cycle 1 at a dose of 25 mg daily for 21 days every 28 days. Therefore, the subject will take a placebo identical in appearance to the CC-5013 capsule for week 4 of every 28 days. Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral CC-5013 placebo capsules will be administered for 28 days of every cycle.
3040381|NCT00424047|Experimental|Dexamethasone plus placebo|Arm B: Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
3040382|NCT00424177|Experimental|eltrombopag|
3040383|NCT00424190|Experimental|Ceftaroline for Injection|
3040384|NCT00424190|Active Comparator|IV Vancomycin and IV Aztreonam|
3040385|NCT00424255|Experimental|Lapatinib+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus lapatinib 1500 mg once daily for 6 to 7 weeks, followed by lapatinib 1500 mg once daily for one year.~Chemoradiotherapy=total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of radiotherapy. Lapatinib is also given at 1500 mg once daily for 3-7 days prior to the start of chemoradiotherapy."
3040386|NCT00424255|Placebo Comparator|Placebo+Chemoradiation|"Adjuvant concurrent chemoradiotherapy plus placebo once daily for 6 to 7 weeks, followed by placebo once daily for one year.~Chemoradiotherapy = total dose of 66Gy over 6-7 weeks plus cisplatin 100mg/m2 on days 1,2 and 43 of the course of treatment. Placebo is also given once daily for 3-7 days prior to the start of chemoradiotherapy."
3040387|NCT00424268|Active Comparator|Roflumilast|"Roflumilast 500 µg~underlying medication: tiotropium 18 µg, once daily, inhaled"
3040388|NCT00424268|Placebo Comparator|Placebo|"Placebo~underlying medication: tiotropium 18 µg, once daily, inhaled"
3040389|NCT00424294|Active Comparator|Celecoxib|Celecoxib with placebo therapy.
3040390|NCT00424294|Other|Methotrexate|Background Methotrexate taken in both CP-195,543/Celecoxib and Celecoxib only arms.
3040391|NCT00424294|Experimental|CP-195,543|CP-195,543 and Celecoxib dual therapy.
3040392|NCT00424346|Experimental|Canakinumab 600 mg IV + 300 mg q2wk|Participants received canakinumab 600 mg intravenous (IV) loading dose on Day 1 and 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg every 4 weeks.
3040393|NCT00424346|Experimental|Canakinumab 300 mg q2wk|Participants received canakinumab 300 mg subcutaneous injections every 2 weeks (q2wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3040394|NCT00424346|Experimental|Canakinumab 150 mg q4wk|Participants received canakinumab 150 mg subcutaneous injections every 4 weeks (q4wk) for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3040395|NCT00424346|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 12 weeks in the Core Phase. In the Extension Phase, participants received 300 mg canakinumab every 4 weeks subcutaneously, until a protocol amendment in January 2009 decreased the dose to 150 mg subcutaneous injection every 4 weeks.
3040396|NCT00424372|Experimental|pregabalin|
3040397|NCT00424385|Experimental|Arm 1|Only 1 arm for the study - this arm gets both drugs, gleevec and sorafenib
3040398|NCT00424398|Experimental|Bepreve|Bepotastine Besilate Ophthalmic Solution 1.5%
3040399|NCT00424398|Placebo Comparator|Placebo|sterile ophthalmic solution
3040400|NCT00424398|Experimental|Bepotastine Besilate|sterile ophthalmic solution 1.0%
3040401|NCT00424463|Experimental|1|
3040402|NCT00424463|Placebo Comparator|2|
3040403|NCT00424476|Placebo Comparator|Placebo|Placebo
3040404|NCT00424476|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg
3040405|NCT00424476|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg
3040406|NCT00424489|Experimental|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation will be performed after conditioning
3040407|NCT00424502|Experimental|1|
3040408|NCT00424515|Experimental|Treatment Arm|Imatinib
3040409|NCT00424528|Active Comparator|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
3040410|NCT00424528|Active Comparator|Tiotropium 18 mcg once daily|Tiotropium 18 mcg once daily/Placebo Inhalation Solution
3040411|NCT00424528|Experimental|Arformoterol /Tiotropium|Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily
3040412|NCT00424554|Experimental|Temozolomide treatment|
3040413|NCT00424554|No Intervention|No treatment|
3040414|NCT00424593|Experimental|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
3040415|NCT00424593|Placebo Comparator|Placebo|every day (QD), by mouth (PO), 13 weeks
3040416|NCT00424619|Active Comparator|1|50 000 IU Vitamin D2
3040417|NCT00424619|Active Comparator|2|100 000 IU Vitamin D2
3040418|NCT00424619|Placebo Comparator|3|Placebo
3040419|NCT00424632|Experimental|Single arm dose escalation|
3040420|NCT00424749|Experimental|Rituximab|375 mg/m^2/week for 4 weeks
3040421|NCT00424762|Experimental|rosiglitazone|4mg titrated to 8mg daily
3040422|NCT00424762|Placebo Comparator|Placebo|blinded matching placebo treatment
3040423|NCT00424827|Experimental|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of Gemcitabine/Fluorouracil with External Beam Radiation in patients with non-metastatic, locally advanced pancreatic carcinoma.
3040424|NCT00424840|Experimental|Bortezomib 1.3 mg/m2|Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
3040425|NCT00424840|Experimental|Bortezomib 1.6 mg/m2|Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
3040426|NCT00424840|Experimental|Bortezomib 1.8 mg/m2|Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF
3040427|NCT00425061|Experimental|1|
3040428|NCT00425061|Experimental|2|
3040429|NCT00425061|Placebo Comparator|3|
3040430|NCT00425100|Experimental|Open Label-fesoterodine|Single treatment study arm.
3040431|NCT00425113|Experimental|Metronidazole|Metronidazole added to background TB treatment regimen during initial 2 months
3040432|NCT00425113|Placebo Comparator|Placebo|Placebo added to background TB treatment regimen during initial 2 months
3040433|NCT00425269|Experimental|Intervention|The intervention group was divided into nine subgroups of ten to twelve women who were offered six educational sessions, each lasting 2 h, during a 7 +- 1-month period. The main focus was on the physiological importance of blood glucose and its regulation by diet and physical activity, and on knowledge about the Pakistani lifestyle in Pakistan and Norway
3040434|NCT00425269|No Intervention|Control|One lesson recieved after post-test
3040435|NCT00425308|Active Comparator|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|Everolimus dose has been adjusted to reach in Group 2, assessment of everolimus dose/trough level (C0), between 6 and 10 ng/ml plus Enteric-coated Mycophenolate Sodium (EC-MPS) 720 mg/d (360mg the morning and 360 mg the evening) plus steroids
3040436|NCT00425308|Active Comparator|Everolimus + Cyclosporine|Everolimus dose has been adjusted to reach in Group 1, assessment of everolimus dose/trough level (C0), between 3 and 8 ng/ml plus Cyclosporine in which Group 1 dose adjusted to reach, assessment of Cyclosporine dosage and blood concentration (C2), between 200 and 450 ng/ml plus steroids
3040437|NCT00425373|Experimental|Valsartan + amlodipine 40/2.5 mg|
3040438|NCT00425373|Experimental|Valsartan + amlodipine 40/5 mg|
3040439|NCT00425373|Experimental|Valsartan + amlodipine 80/2.5 mg|
3040440|NCT00425373|Experimental|Valsartan + amlodipine 80/5 mg|
3040441|NCT00425373|Active Comparator|Valsartan 40 mg|
3040442|NCT00425373|Active Comparator|Valsartan 80 mg|
3040443|NCT00425373|Active Comparator|Amlodipine 2.5 mg|
3040444|NCT00425373|Active Comparator|Amlodipine 5 mg|
3040445|NCT00425373|Placebo Comparator|Placebo|
3040446|NCT00425386|Experimental|Erlotinib and Sunitinib|"Drug: erlotinib hydrochloride Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily~Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off"
3040447|NCT00425477|Experimental|Bexarotene + GM-CSF|BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
3040448|NCT00425555|Experimental|Previously treated with oral bexarotene|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
3040449|NCT00425555|Experimental|No prior oral bexarotene treatment|Participants received Panobinostat 20 milligrams per day (mg/day) capsule orally, once a day (OD) on 3 days per week. (Monday, Wednesday and Friday or alternative Day 1, 3 and 5).
3040450|NCT00425607|Experimental|Lonafarnib|All subjects initiated oral Lonafarnib twice daily at a dose of 115mg/m2 and escalated to 150 mg/m2. Two subjects de-escalated to 115mg/m2 following toxicity.
3040451|NCT00425672|Experimental|Arm I|Patients receive ONTAK IV over 1 hour on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3040452|NCT00425698|Active Comparator|intravenous erythropoietin|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
3040453|NCT00425698|Placebo Comparator|intravenous placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
3040454|NCT00425750|Experimental|Treatment|"Docetaxel (40 mg/m2) IV Infusion over 30 minutes every 3 weeks (Day 1 and 8 of 21 day cycle)except the first dose is held on Day 1 of Cycle 1.~Bortezomib (1.6mg/m2) IV 3-5 second push every 3 weeks (Day 1 and 8 of 21 day cycle).Bortezomib is given as a single agent only on Day 1 of Cycle 1."
3040455|NCT00425802|Other|treatment|This is a phase 2 study of a treatment regimen consisting of a non-myeloablative (NMA) conditioning regimen incorporating low dose chemotherapy and low dose radiation as well as peri-transplant Rituximab and the transplantation of peripheral blood stem cells (PBSC) or bone marrow if PBSC collection not possible from an HLA compatible related or unrelated donor in patients with B cell lymphoid malignancies including diffuse large cell (DLC) and mantle cell non-Hodgkin's lymphoma (NHL), indolent B cell NHL, or chronic lymphocytic leukemia (CLL).
3040456|NCT00425854|Experimental|BIBW 2992|high dose once daily
3040457|NCT00425945|Placebo Comparator|Placebo|Placebo delivered as four tablets matching the active product once daily orally.
3040458|NCT00425945|Active Comparator|Pine Bark Extract|Flavangenol 200 mg Flavangenol is a brand of Pine Bark Extract manufactured by Toyo Shinyaku of Saga, Japan. Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day.
3040459|NCT00426127|Experimental|Docetaxel and Liposomal Doxorubicin Combined with Enoxaparin|Docetaxel 75 mg/m^2 + Doxil 30 mg/m^2 + Enoxaparin 1.5 mg/kg
3040460|NCT00426153|Active Comparator|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg) intramuscularly every 28 days (+/- 5 days) for one year
3040461|NCT00426153|Placebo Comparator|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
3040462|NCT00426231|Experimental|Patient Navigator intervention|Patient Navigator intervention
3040463|NCT00426231|Active Comparator|Information control|Information control
3040464|NCT00426270|Experimental|Octagam 10% 1 g/kg/day|Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.
3040465|NCT00426283|Experimental|Flovent 1760 mcg|Fluticasone propionate 880 mcg twice daily for 3 months
3040466|NCT00426283|Placebo Comparator|Placebo|Placebo twice daily for 3 months
3040467|NCT00426361|Experimental|Cervarix Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6.
3040468|NCT00426361|Experimental|Boostrix Polio → Cervarix Group|Subjects who received Boostrix™ Polio at Month 0 and GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 1, 2 and 7.
3040469|NCT00426361|Experimental|Cervarix + Boostrix Polio Group|Subjects who received GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM) at Month 0, 1 and 6 with co-administration of Boostrix™ Polio at Month 0.
3040470|NCT00426517|Experimental|Matched related donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 10 mg/kg total dose given intravenously over 2 days
3040471|NCT00426517|Experimental|Matched unrelated donor stem cell transplant|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
3040472|NCT00426517|Experimental|Matched unrelated donor stem cell transplant (MUD-non CGD)|Conditioning with ATG 40 mg/kg total dose over 4 days IV, Busulfan 5 mg/kg total dose over 2 days IV, and TBI 300 cGy in two fractions at day -2
3040473|NCT00426517|Experimental|Matched unrelated donor transplant (MUD-CGD) cord blood|Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days, Busulfan 5 mg/kg total dose given intravenously over 2 days, and Total Body Irradiation (TBI) 200 cGy in two fractions on the same day
3040474|NCT00426556|Experimental|Phase I - RAD001 5mg + PT, daily|Daily dosing schedule of EPT = Paclitaxel & Trastuzumab verolimus 5mg plus Paclitaxel plus Trastuzumab.
3040475|NCT00426556|Experimental|Phase I - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
3040476|NCT00426556|Experimental|Phase I - RAD001 30mg + PT, weekly|Weekly dosing schedule of Everolimus 30mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab.
3040477|NCT00426556|Experimental|Phase II - RAD001 10mg + PT, daily|Daily dosing schedule of Everolimus 10mg plus Paclitaxel plus Trastuzumab. PT = Paclitaxel & Trastuzumab
3040478|NCT00426660|Experimental|1|
3040479|NCT00426751|Active Comparator|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
3040480|NCT00426751|Experimental|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mcg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
3040481|NCT00426764|Experimental|Romidepsin|Participants received romidepsin 14 mg/m^2 administered intravenously over 4 hours on Days 1, 8, and 15 of a 28-day cycle. Participants continued on monthly cycles of romidepsin. The planned duration of study therapy was 6 cycles. Patients who responded could continue beyond 6 cycles until disease progression or other withdrawal criteria were met. For participants treated for 12 or more cycles, maintenance dosing (2 doses per cycle) was permitted.
3040482|NCT00426842|Experimental|Arm 1|Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.
3040483|NCT00426855|Experimental|Bendamustine and Bortezomib|Combination Chemotherapy of Bendamustine and Bortezomib as described in the intervention section
3040484|NCT00427011|Experimental|1|
3040485|NCT00427037|Placebo Comparator|Placebo|Placebo
3040486|NCT00427037|Active Comparator|Cholecalciferol|D3
3040487|NCT00427193|Experimental|Caloric Restriction (CR)|25% caloric restriction
3040488|NCT00427193|Active Comparator|Control, Ad libitum (AL)|Ad libitum energy intake
3040489|NCT00427297|Experimental|NVP-containing|Infants randomized to this arm will receive nevirapine-containing HAART regimen
3040490|NCT00427297|Active Comparator|NVP-sparing|Infants randomized to this arm will receive nevirapine-sparing HAART
3040491|NCT00427336|Experimental|Fludarabine + Cyclophosphamide + ATG|Fludarabine 30 mg/m^2/day by vein (IV), Cyclophosphamide IV 300 mg/m^2/day, ATG (Antithymocyte Globulin) IV 3.75 mg/kg/day
3040492|NCT00427349|Experimental|AMG 706+Octreotide|"Patients receive oral AMG 706 and octreotide acetate intramuscularly (IM) once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the morning. AMG 706 was taken daily without breaks in treatment.~One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles."
3040493|NCT00427557|Experimental|Cellular Therapy with Cord Blood Cells|Fludarabine 30 mg/m^2 intravenous (IV) for 4 Days + Melphalan 140 mg/m^2 IV for 1 Day + Rituximab 375 mg/m^2 IV once weekly + Cord Blood Transplantation + Stem Cell Transplantation Infusion
3040494|NCT00427648|Active Comparator|1|xylocaine
3040495|NCT00427648|Placebo Comparator|2|normal saline
3040496|NCT00427661|Other|AHCT in High Risk SCD|Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
3040497|NCT00427700|Active Comparator|Clomiphene|Uso of 100mg of clomiphene citrate during days 5-9 of the menstrual cycle
3040498|NCT00427700|Experimental|Raloxifene|Use of 100mg of raloxifene during days 5-9 of the menstrual cycle
3040499|NCT00427765|Experimental|Busulfan + Melphalan|Busulfan 32 mg/m^2 intravenous (IV) for 1 Day then 130 mg/m^2 IV for 4 Days; and Melphalan 70 mg/m^2 IV for 2 Days
3040500|NCT00427778|Experimental|Incontinence ring then no intervention|Participants first were fitted with an incontinence ring, which they wore continuously for 4 weeks. The ring wa then removed and a washout period of 2 weeks followed. Then the second 4-week period with no ring was completed.
3040501|NCT00427778|Experimental|No intervention then incontinence ring|Participants spend the first study 4-week period with no intervention. Then, a wasout period of 2 weeks followed. Participants were then fitted with an incontinence ring, which they wore continuously for 4 weeks.
3040502|NCT00427791|Experimental|Etoposide + Total Body Irradiation + Rituximab|Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
3040503|NCT00427791|Experimental|Etoposide + Total Body Irradiation|Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days
3040504|NCT00427804|Experimental|Calcitriol|Calcitriol 0.25 mcg orally twice a day for 7 days or calcitriol 0.50 mcg orally twice a day for 7 days.
3040505|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
3040506|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 1|Participants aged 60-64 years were given a 0.5 mL dose administered on day 1.
3040507|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 1|Participants aged 50-59 years given a 0.5 mL dose administered on day 1.
3040508|NCT00427895|Experimental|13vPnC Cohort 3, Vaccination 1|Participants aged 18-49 years given a 0.5 mL dose administered on day 1.
3040509|NCT00427895|Experimental|13vPnC Cohort 1, Vaccination 2|Participants aged 60-64 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
3040510|NCT00427895|Active Comparator|23vPS Cohort 1, Vaccination 2|Participants aged 60-64 years who received 23vPS at vaccination 1 receive a 0.5 mL dose of 23vPS administered 3-4 years after dose 1.
3040511|NCT00427895|Experimental|13vPnC Cohort 2, Vaccination 2|Participants aged 50-59 years who received 13vPnC at vaccination 1 receive a 0.5 mL dose of 13vPnC administered 3-4 years after dose 1.
3040512|NCT00427908|Experimental|Group A|All subjects received GSK Biolgicals' meningococcal vaccine 134612.
3040513|NCT00427908|Active Comparator|Group B|Subjects including and above two years of age received Mencevax™ ACWY, subjects below two years of age received Meningitec™.
3040514|NCT00427921|Experimental|1|Open Label
3040515|NCT00427934|Placebo Comparator|2|
3040516|NCT00427934|Experimental|1|This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.
3040517|NCT00427960|Active Comparator|rosuvastatin|rosuvastatin 5 mg
3040518|NCT00427960|Active Comparator|atorvastatin|atorvastatin 10 mg
3132861|NCT03460587|Experimental|Home-based Telerehabilitation|Home-based Telerehabilitation
3040519|NCT00427973|Experimental|AZD2171|Patients will receive AZD2171 (cediranib maleate) 30mg by mouth once a day. Treatment may continue for as long as benefit is shown. Patients will undergo MRI and CT scan of the liver before beginning treatment, 3 days after the first dose of AZD2171, and after finishing course one. Patients will also undergo blood collection periodically for laboratory studies. Laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, and pharmacological study will be performed.
3040520|NCT00427999|Experimental|STI571+ pioglitazone+ etoricoxib + dexamethasone + treosulfane|STI571 (imatinib) 400mg po daily + pioglitazone 60mg po daily + etoricoxib 60mg po daily + dexamethasone 1mg po daily + treosulfane 500mg po daily for 24 weeks
3040521|NCT00428090|Experimental|Rosiglitazone|XR (extended release) oral tablets
3040522|NCT00428090|Other|Placebo|Placebo (Double-Dummy to Match)
3040523|NCT00428116|No Intervention|Interrupted HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to interrupted treatment and followed for 18 months.
3040524|NCT00428116|Active Comparator|Continued HAART|After 24 months of treatment with HAART, half the eligible infants will be randomized to continued treatment with HAART for 18 months.
3040525|NCT00428220|Experimental|A|"Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.~The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible."
3040526|NCT00428246|Active Comparator|1|1 mcg paricalcitol
3040527|NCT00428246|Active Comparator|2|2 mcg paricalcitol
3040528|NCT00428246|Placebo Comparator|3|Placebo
3040529|NCT00428298|Experimental|Active Treatment Valacyclovir|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
3040530|NCT00428298|Placebo Comparator|Placebo Treatment|Subjects dispensed 500 mg capsules. Subjects take two 500 mg capsules twice daily for 16 weeks.
3040531|NCT00428389|Experimental|Immediate Switch|Patients randomized to the immediate switch group continued treatment with donepezil through the evening prior to Day 8 of the study. On Day 8, all patients began open-label treatment with 5 cm^2 rivastigmine patch formulation. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
3040532|NCT00428389|Experimental|Delayed Switch|Patients randomized to the delayed switch group were switched to 5 cm^2 rivastigmine patch formulation on Day 8, following a 7-day withdrawal period from donepezil. A new patch was applied daily for 4 weeks. Patients who completed the core phase had the option of entering the extension phase, in which they received open-label treatment with rivastigmine patch formulation for an additional 20 weeks. In the absence of any dose-limiting adverse events (AEs), the dose was increased to 10 cm^2 patch, and it remained the same through Week 25. Patients who experienced dose-limiting AEs had their dose reduced to 5 cm^2 patch and continued on their best tolerated dose for the remainder of the study.
3040533|NCT00428584|Experimental|1|interferon beta-1a
3040534|NCT00428584|Active Comparator|2|interferon beta-1b
3040535|NCT00428597|Experimental|A|
3040536|NCT00428597|Placebo Comparator|B|
3040537|NCT00428610|Experimental|LY573636|LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
3040538|NCT00428714|Experimental|Enzastaurin-Cohort 1|Chemo-naive participants who had androgen-independent prostate cancer with rising prostate-specific antigen (PSA) levels but no clinical or radiographic evidence of metastatic disease. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
3040539|NCT00428714|Experimental|Enzastaurin-Cohort 2|Participants with progressed, metastatic prostate cancer who had received prior treatment with a docetaxel-containing agent. Participants were given 1125 mg loading dose of enzastaurin on Day 1 of Cycle 1 (28-day cycle) only, and thereafter 500 mg enzastaurin once daily.
3040540|NCT00428792|Experimental|Very light breakfast (VLB) then standard breakfast (SB)|Very light breakfast (VLB) for one week then crossover to standard breakfast (SB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12.
3040541|NCT00428792|Experimental|Standard breakfast (SB) then very light breakfast (VLB)|Standard breakfast (SB) for one week then crossover to very light breakfast (VLB) for one week while taking either 1 or 2 20 mg capsules of methylphenidate once per day based on the dosage the child had taken in the month prior to study start. SB is defined as 450 kcal for girls age 6-9, 490 kcal for boys age 6-9, 550 kcal for girls age 10-12, and 600 kcal for boys age 10-12. VLB is defined as 150 kcal for children age 6-9 and 180 kcal for children age 10-12.
3040542|NCT00428844|Experimental|Daptomycin 6 mg/kg|Daptomycin (6 mg/kg every 24 hours [q24h]) as a 30 minute intravenous (IV) infusion for 6 weeks (± one week).
3040543|NCT00428844|Experimental|Daptomycin 8 mg/kg|Daptomycin (8 mg/kg q24h) as a 30 minute IV infusion for 6 weeks (± one week).
3040544|NCT00428844|Active Comparator|Comparator|Vancomycin was administered at 1 gram every 12 hours (q12h) as a 60-minute infusion and teicoplanin was administered 6 mg/kg q24h as a 30-minute infusion also for 6 weeks (±1 week). Semi-synthetic penicillin (nafcillin, oxacillin, or flucloxacillin) was administered according to standard of care for 6 weeks (±1 week).
3040545|NCT00428922|Experimental|Trastuzumab, Bevacizumab, and Docetaxel|Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]
3040546|NCT00428948|Experimental|Tolvaptan|Participants received the highest tolerated split-dose regimen (upon awakening and 9 hours later) of tolvaptan 45/15 mg, 60/30 mg, or 90/30 mg orally for 36 months.
3040547|NCT00428948|Placebo Comparator|Placebo|Participants received placebo (upon awakening and 9 hours later) orally for 36 months.
3040548|NCT00428974|Experimental|CF101 1 mg|
3040549|NCT00428974|Experimental|CF101 2mg|
3040550|NCT00428974|Experimental|CF101 4mg|
3040551|NCT00428974|Placebo Comparator|Placebo|
3040552|NCT00429104|Experimental|HER2+ Metastatic Breast Cancer|Herceptin 4 mg/kg IV Over 90 Minutes + GM-CSF 250 mcg/m^2 subcutaneously
3040553|NCT00429143|Experimental|Haploidentical Allogeneic Transplantation|Patients undergoing hematopoietic stem cell transplant from a partially matched related donor
3040554|NCT00429169|Active Comparator|Paroxetine|Participants will receive paroxetine for 8 weeks
3040555|NCT00429169|Active Comparator|Bupropion|Participants will receive bupropion for 8 weeks
3040556|NCT00429182|Experimental|High-dose chemotherapy|Carboplatin + Cyclophosphamide + Thiotepa
3040557|NCT00429273|Active Comparator|Group 1: Guan-Guan+Placebo|weeks 1-4: Guanfacine weeks 5-8: Guanfacine + Placebo
3040558|NCT00429273|Active Comparator|Group 2: Placebo-Placebo+DMPH|weeks 1-4: Placebo weeks 5-8: Placebo+DMPH
3040559|NCT00429273|Experimental|Group 3: Guan-Guan+DMPH (Comb)|weeks 1-4: Guanfacine weeks 5-8: Guanfacine+DMPH
3040560|NCT00429299|Active Comparator|Arm A|Chemotherapy plus trastuzumab
3040561|NCT00429299|Experimental|Arm B|Chemotherapy plus lapatinib
3040562|NCT00429299|Active Comparator|Arm C|Chemotherapy plus trastuzumab plus lapatinib
3040563|NCT00429364|Active Comparator|Atenolol|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.
3040564|NCT00429364|Active Comparator|Losartan|Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).
3040565|NCT00429403|Experimental|Goserelin|3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
3040566|NCT00429403|No Intervention|No Goserelin|
3040567|NCT00429416|Experimental|LLME to Decrease GVHD Following HSC T|To determine if an experimental agent, LLME, can decrease the incidence and severity of Graft-Versus-Host-Disease (GVHD) following hematopoietic stem cell transplantation (HSCT).
3040568|NCT00429494|Experimental|Leuprolide Acetate|Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.
3040569|NCT00429507|Experimental|Samarium 153-EDTMP + Stem Cell Transplant|Samarium 153-EDTMP tracer dose = 30 millicurie (mCi) by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose. Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP. Questionnaires taking about 15 minutes to complete.
3040570|NCT00429572|Experimental|Allogeneic Transplantation|Intravenous Fludarabine 30 mg/m^2 daily on days 1-5, and Melphalan 70 mg/m^2 on days 4 and 5 followed by blood stem cell transplant on day 7.
3040571|NCT00429585|Other|Randomized Treatment - Nail|Randomized Treatment - Nail
3040572|NCT00429585|Other|Randomized Treatment - Plate|Randomized Treatment - Plate
3040573|NCT00429663|Other|IM Nails|Reamed, Interlocking Intramedullary Nail - Randomized treatment
3040574|NCT00429663|Other|Plate Fixation|Locking Periarticular Plate - Randomized Treatment
3040575|NCT00429702|Experimental|Benadryl® Ativan® Decadron® (BAD) Pump|Patients receive ondansetron hydrochloride IV twice daily and saline IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive diphenhydramine hydrochloride, lorazepam, and dexamethasone by continuous infusion pump.
3040576|NCT00429702|Active Comparator|Control Arm Saline|Patients receive ondansetron hydrochloride IV twice daily and dexamethasone IV twice daily beginning 30-60 minutes prior to the start of chemotherapy. Patients also receive saline by continuous infusion pump.
3040577|NCT00429793|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3040578|NCT00429923|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days.
3040579|NCT00429923|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days.
3040580|NCT00429923|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
3040581|NCT00429949|Experimental|Dasatinib|"Dasatinib will be administered continuously at an oral dose of 70 mg BID on Days 1-28 of each 28 day cycle.~In patients with stable disease after 8 weeks on therapy the dasatinib will be increased to 100 mg BID on Days 1-28 on each 28 day cycle."
3040582|NCT00430092|Experimental|Difluprednate 0.05% BID|Difluprednate 0.05% 1 drop BID for 14 days
3040583|NCT00430092|Experimental|Difluprednate 0.05% QID|Difluprednate 0.05% 1 drop QID for 14 days
3040584|NCT00430092|Placebo Comparator|Placebo|Placebo for 14 days. Placebo was administered BID for 14 days and QID for 14 days. The outcomes of the 2 placebo groups were examined and were determined to be statistically indistinguishable so the placebo groups were pooled for comparison with the difluprednate groups.
3040585|NCT00430183|Experimental|Arm A: docetaxel + LHRH agonist + surgical intervention|"Patients receive six cycles of docetaxel administered every 3 weeks combined with 18-24 weeks of androgen deprivation therapy. During each cycle of chemotherapy, all patients should undergo premedication with dexamethasone 8 mg orally prior to docetaxel. Dexamethasone may also be given intravenously according to institutional guidelines.~Patients will also receive androgen deprivation for 18-24 weeks of an LHRH agonist (eg, leuprolide acetate, goserelin acetate). Additional premedication and antiemetics may be given at the physician's discretion and as defined by the protocol.~Patients will undergo standard surgical intervention. The surgical procedures will be performed within 60 days of the completion of neoadjuvant therapy. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. It must be initiated within 6 months of the date of surgery."
3040586|NCT00430183|Other|Arm B: surgical intervention|All patients undergo standard surgical intervention. The surgical procedures will be performed within 60 days of randomization. Patients are allowed to receive adjuvant external beam radiation at the discretion of the treating physician and as defined per the protocol. Adjuvant radiation must be initiated within 6 months of the date of surgery.
3040587|NCT00430248|Experimental|Febuxostat 40 mg QD|
3040588|NCT00430248|Experimental|Febuxostat 80 mg QD|
3040589|NCT00430248|Active Comparator|Allopurinol 200 mg or 300 mg QD|(dependent on renal function)
3040590|NCT00430300|Experimental|150mcg, 450mcg or 1350mcg|Active treatment given BID via a double pin monodose capsule inhaler device
3040591|NCT00430300|Placebo Comparator|Placebo|Placebo treatment given BID via a single pin monodose inhaler device
3040592|NCT00430352|Experimental|1|
3040593|NCT00430482|Experimental|1|Cognitive Behavioral Therapy
3040594|NCT00430482|Active Comparator|2|Individual Counseling
3040595|NCT00430495|Experimental|Atacicept 25 mg|
3040596|NCT00430495|Experimental|Atacicept 75 mg|
3040597|NCT00430495|Experimental|Atacicept 150 mg|
3040598|NCT00430495|Placebo Comparator|Placebo|
3040599|NCT00430508|Experimental|4|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3040600|NCT00430508|Experimental|1|olmesartan medoxomil (OM) /hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3040601|NCT00430508|Experimental|3|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
3040602|NCT00430508|Experimental|2|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
3040603|NCT00430521|Experimental|GSK1562902A V/I/6 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
3040604|NCT00430521|Experimental|GSK1562902A V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
3040605|NCT00430521|Experimental|GSK1562902A 2V/I/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 6.The vaccine was administered in the deltoid region of the non-dominant arm.
3040606|NCT00430521|Experimental|GSK1562902A 2V/V/6 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 6. The vaccine was administered in the deltoid region of the non-dominant arm.
3040607|NCT00430521|Experimental|GSK1562902A V/I/12 Group|Subjects received 1 dose of vaccine formulated from VT strain at Day 0 and 1 dose of the vaccine including IN strain at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
3040608|NCT00430521|Experimental|GSK1562902A V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Month 12. The vaccine was administered in the deltoid region of the non-dominant arm.
3040609|NCT00430521|Experimental|GSK1562902A 2V/I/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including IN strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
3040610|NCT00430521|Experimental|GSK1562902A 2V/V/12 Group|Subjects received 2 doses of vaccine formulated from VT strain, 1 at Day 0 and 1 at Day 21 and a 3rd dose of vaccine including VT strain at Month 12.The vaccine was administered in the deltoid region of the non-dominant arm.
3040611|NCT00430573|Experimental|DCS-augmented CBT-IC|D-cycloserine-augmented CBT-IC
3040612|NCT00430573|Placebo Comparator|Placebo-augmented CBT-IC|Placebo-augmented CBT-IC
3040613|NCT00430625|Experimental|VPRIV®-45 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase, GA-GCB)
3040614|NCT00430625|Experimental|VPRIV®-60 U/kg, IV, every other week|VPRIV® (velaglucerase alfa, Gene Activated® human glucocerebrosidase,GA-GCB)
3040615|NCT00430638|Experimental|Treatment|Olmesartan medoxomil, plus hydrochlorothiazide, if necessary
3040616|NCT00430638|Placebo Comparator|Placebo|Placebo tablets were taken once daily for 12 weeks
3040617|NCT00430677|Experimental|Abatacept 30 mg/kg+Corticosteroids+MMF|Short-term Period
3040618|NCT00430677|Experimental|Abatacept 10 mg/kg+Corticosteroids+MMF|Short-term Period
3040619|NCT00430677|Experimental|Placebo+Corticosteroids+MMF|Short-term Period
3040620|NCT00430677|Experimental|Abatacept 10mg/kg|Long-term Extension Period
3040621|NCT00430716|Experimental|Sildenafil High dose|
3040622|NCT00430716|Experimental|Sildenafil Low dose|
3040623|NCT00430716|Experimental|Sildenafil medium dose|
3040624|NCT00430716|Experimental|Sildenafil - Open label Phase|Open label extension from week 12 to week 24.
3040625|NCT00430755|Other|Inpatients of hospital|"All patients who were admitted to the departments of nephrology or cardiology in a tertiary hospital in Germany.~The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
3040626|NCT00430768|Experimental|Group 1 Low Dose|"rAAV1-CB-hAAT 6.9 x10e12 vector genomes (vg) administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3040627|NCT00430768|Experimental|Group 2 Middle Dose|"rAAV1-CB-hAAT 2.2 x 10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3040628|NCT00430768|Experimental|Group 3 High Dose|"rAAV1-CB-hAAT 6.0 x10e13 vg administered in a 9.9 ml volume of study agent in nine separate 1.1 mL injections in the deltoid muscle of the non-dominant side under ultrasound guidance"
3040629|NCT00430781|Experimental|Combination arm|Pazopanib plus lapatinib
3040630|NCT00430781|Active Comparator|Lapatinib monotherapy|Lapatinib
3040631|NCT00430781|Active Comparator|Pazopanib monotherapy|Pazopanib
3040632|NCT00430937|Experimental|Daptomycin|4 mg/kg intravenous (i.v.) once daily
3040633|NCT00430937|Active Comparator|Pooled Comparator|
3040634|NCT00430950|Experimental|1|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ) 40/25 mg + OM/HCTZ 20/25 mg matching placebo
3040635|NCT00430950|Experimental|2|olmesartan medoximil (OM)/ hydrochlorothiazide (HCTZ)20/25 mg + OM/HCTZ 40/25 matching placebo
3040636|NCT00430989|Other|70% Nitrous Oxide|General anaesthesia using 70% Nitrous Oxide with fraction of inspired oxygen at 30%
3040637|NCT00430989|Other|No Nitrous Oxide|General anaesthesia not containing Nitrous oxide with fraction of inspired oxygen at 30%
3040638|NCT00431041|Experimental|Solifenacin|Solifenacin succinate: 5 mg tablets, taken orally, once daily
3040639|NCT00431041|Active Comparator|Oxybutynin IR|Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day
3040640|NCT00431067|Experimental|BIBW 2992|BIBW 2992 (Afatinib) once daily until progression
3040641|NCT00431132|Experimental|Vagifem® 10 mcg|One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks
3040642|NCT00431184|Active Comparator|Pentazocine then Lorazepam|In the first leg of the study, pentazocine will be given to subjects randomly assigned to this group. On Day 1, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later. On Day 2, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later.
3040643|NCT00431184|Active Comparator|Lorazepam then Pentazocine|In the first leg of the study, lorazepam will be given to subjects randomly assigned to this group. On Day 3, subjects in this group will be given 0.25mg of Lorazepam followed by a second dose of 0.25mg two hours later. On Day 2, subjects will receive 50mg of pentazocine followed by a second dose of 50mg two hours later.
3040644|NCT00431444|Active Comparator|Zoledronic Acid|Zoledronic acid 5 mg (single i.v. infusion) + daily oral placebo for 6 months (zoledronic acid group)
3040645|NCT00431444|Active Comparator|Raloxifene|Placebo (single i.v. infusion) + oral raloxifene 60 mg/day for 6 months (raloxifene group)
3040646|NCT00431496|Experimental|Cinacalcet|Cinacalcet was administered orally at a starting dose of 30 mg/day for 23 weeks. Possible sequential doses during the study were 30, 60, 90, 120, and 180 mg. Dose escalation of cinacalcet occurred if the intact parathyroid hormone (iPTH) level from the previous study visit was > 31.8 pmol/L (300 pg/mL) unless the participant had either reached the maximum dose (180 mg/day), the serum corrected total calcium was < 2.1 mmol/L (8.4 mg/dL), or the participant experienced an adverse event that precluded a dose increase.
3040647|NCT00431626|Experimental|Laser TURP with dutasteride|Prior to and after standard treatment with laser TURP, dutasteride is applied to each patient
3040648|NCT00431626|Placebo Comparator|Laser TURP with placebo|Prior to and after standard treatment with laser TURP, placebo is applied to each patient
3040649|NCT00431847||Group 1|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war aggressively treated with regional anesthesia for pain control.
3040650|NCT00431847||Group 2|Soldiers with one or more severely injured, mangled or amputated limbs from the Iraq/Afghanistan war receiving standard treatment for pain control.
3040651|NCT00431951|Experimental|ST-246|250 mg, 400 mg or 800 mg of ST-246 given once daily for 21 days
3040652|NCT00431951|Placebo Comparator|placebo|Placebo to match ST-246
3040653|NCT00431964|Active Comparator|Active|azithromycin 250 mg tablets
3040654|NCT00431964|Placebo Comparator|Placebo|placebo tablets (matched to active drug in appearance)
3040655|NCT00432042|Experimental|ProQuad® + Infanrix® hexa|Pediatric (12 to 23 months of age) participants received ProQuad® and Infanrix® hexa (booster dose) concomitantly on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3040656|NCT00432042|Active Comparator|ProQuad®|Pediatric (12 to 23 months of age) participants received ProQuad® on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3040657|NCT00432042|Active Comparator|Infanrix® hexa|Pediatric (12 to 23 months of age) participants received Infanrix® hexa (booster dose) on Visit 1 (Day 0). Blood samples were taken on Visit 1 and Visit 2 (Day 42).
3040658|NCT00432159|Experimental|1-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level of the cervical spine, C3 to C7 inclusive.
3040659|NCT00432159|Active Comparator|1-level ACDF with plate|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at a single level of the cervical spine, C3 to C7 inclusive.
3040660|NCT00432159|Experimental|2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at two adjacent levels of the cervical spine, C3 to C7 inclusive.
3040661|NCT00432159|Active Comparator|2-level ACDF|Anterior Cervical Discectomy and Fusion with plate (ACDF with plate) using allograft spacer and the SLIM-LOC™ Anterior Cervical Plate System at two adjacent levels of the cervical spine, C3 to C7 inclusive.
3040662|NCT00432159|Experimental|Training: 1 & 2-level Cervical TDR|Cervical Total Disc Replacement (Cervical TDR) arthroplasty with the DISCOVER™ Artificial Cervical Disc at a single level or multiple levels of the cervical spine, C3 to C7 inclusive. Training cohort.
3040663|NCT00432172|Active Comparator|Group 1 (Luminal A) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
3040664|NCT00432172|Experimental|Group 1 (Luminal A) Selective treatment|"Selective treatment:~Postmenopausal patients: exemestane x 6 months Premenopausal patients: goserelin x 6 months + exemestane x 6 months"
3040665|NCT00432172|Active Comparator|Group 2 (Basal) Standard treatment|Standard treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.
3040666|NCT00432172|Experimental|Group 2 (Basal) Selective treatment|Selective treatment: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.
3040667|NCT00432237|Experimental|MK0974 50 mg|MK0974 50 mg; one orally-administered dose, plus an optional second dose (MK0974 50 mg) to treat a single moderate-to-severe migraine attack
3040668|NCT00432237|Experimental|MK0974 150 mg|MK0974 150 mg; one orally-administered dose, plus an optional second dose (MK0974 150 mg) to treat a single moderate-to-severe migraine attack
3040669|NCT00432237|Experimental|MK0974 300 mg|MK0974 300 mg; one orally-administered dose, plus an optional second dose (MK0974 300 mg or placebo) to treat a single moderate-to-severe migraine attack
3040670|NCT00432237|Placebo Comparator|Placebo|Placebo; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine attack
3040671|NCT00432276|Experimental|Alogliptin 25 mg + Pioglitazone 30 mg add-on to Metformin|Alogliptin 25 mg, tablets, orally, once daily; pioglitazone 30 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
3040672|NCT00432276|Active Comparator|Pioglitazone 45 mg add-on to Metformin|Alogliptin placebo-matching tablets, orally, once daily; pioglitazone 45 mg, tablets, orally, once daily; and the maximum tolerated dose of metformin, tablets, orally, for up to 52 weeks.
3040673|NCT00432341|Experimental|BOTOX®|Botulinum toxin type A (BOTOX®)
3040674|NCT00432341|Active Comparator|Dysport®|Botulinum toxin type A (Dysport®)
3040675|NCT00432380|Experimental|PLACEBO-ROTARIX-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Month 1 and Month 2, and a single oral dose of placebo at Day 0. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3040676|NCT00432380|Experimental|ROTARIX-PLACEBO-ROTARIX GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 2 oral doses of Rotarix™ liquid vaccine at Day 0 and Month 2, and a single oral dose of placebo at Month 1. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3040677|NCT00432380|Placebo Comparator|PLACEBO GROUP|Healthy male or female infants between, and including, 5 to 10 weeks of age, were administered 3 oral doses of placebo at Day 0, Month 1 and Month 2. Subjects also received routine infant vaccinations according to the Expanded Program of Immunization (EPI) recommendations in Philippines.
3040678|NCT00432458|Experimental|Arm I: Thal/ZLD|Thalidomide (Thal) + Zolendronic acid (ZLD)
3040679|NCT00432458|Experimental|Arm II: ZLD|Zoledronic acid (ZLD)
3040680|NCT00432601|Experimental|Arm 1|Patients will receive Michigan Cancer Consortium decision aid.
3040681|NCT00432601|Active Comparator|Arm 2|Patients will receive National Comprehensive Cancer Network decision aid.
3040682|NCT00432666|Experimental|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
3040683|NCT00432666|Placebo Comparator|Placebo|
3040684|NCT00432679|Experimental|arm 1|study drug
3040685|NCT00432744|Active Comparator|CoenzymeQ10|CoenzymeQ10: patients will be randomized to receive CoenzymeQ10 in either Period #1 (Months 0-6) or Period #2 (Months 7-12).
3040686|NCT00432744|Placebo Comparator|Placebo|Placebo: patients will be randomized to receive placebo either ion Period #1 (months 1-6) or Period #2 (months 7-12).
3040687|NCT00432809|No Intervention|Medical therapy|Intensive medical therapy for diabetes
3040688|NCT00432809|Active Comparator|Gastric Bypass|Procedure/Surgery: Bariatric surgery laparoscipic Roux-en-Y Gastric Bypass (RYGB) plus intensive medical therapy
3040689|NCT00432809|Active Comparator|Sleeve Gastrectomy|Procedure/Surgery: Bariatric surgery - laparoscopic sleeve gastrectomy plus intensive medical therapy
3040690|NCT00432835|Active Comparator|Gastric Stimulation Days1-4/Sham5-8|The sequence followed for patients in Group 1 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 1, then active stimulation for 72 consecutive hours, then a 1 day wash out, then the cross over, which entailed the device remaining inactive for the final 3 study days
3040691|NCT00432835|Active Comparator|Sham1-4/Gastric Stimulation Days5-8|The sequence followed for patients in Group 2 was: enrollment and acquisition of baseline data, then placement of electrode, then determination of mucosal EGG, then randomization to Group 2, then no stimulation whatsoever until Day 5, then the cross over,then active stimulation with the Gastric Electrical Stimulator for 72 consecutive hours.
3040692|NCT00432965|Experimental|VAC Therapy|Treatment of Diabetic Foot Ulcers with VAC Therapy
3040693|NCT00432965|Active Comparator|Moist Wound Therapy|Moist Wound Therapy (standard of care)
3040694|NCT00432991|Placebo Comparator|Saline Placebo|Drug: Saline Placebo 0.5 mL, IM (in the muscle), one time
3040695|NCT00432991|Experimental|IM Ephedrine|Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum] 25 mg, IM (in the muscle), one time
3040696|NCT00433004|No Intervention|1|No advance supply of emergency contraception
3040697|NCT00433004|Active Comparator|2|Advance supply of emergency contraception is given
3040698|NCT00433017|Experimental|Verteporfin + Ranibizumab|Verteporfin (6 mg/m^2) photodynamic therapy (PDT) and ranibizumab (0.5 mg). Patients received three consecutive monthly ranibizumab injections starting on Day 1, and then as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
3040699|NCT00433017|Active Comparator|Ranibizumab Monotherapy|Patients received three consecutive monthly ranibizumab injections starting on Day 1 and then as needed from Month 3 based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and CNV leakage assessed by fluorescein angiography (FA).
3040700|NCT00433147|Experimental|Afegostat tartrate 25 milligrams (mg) once per day|Afegostat tartrate was administered orally during the 4-week treatment period.
3040701|NCT00433147|Experimental|Afegostat tartrate 150 mg once per day|Afegostat tartrate was administered orally once per day during the 4-week treatment period.
3040702|NCT00433147|Experimental|Afegostat tartrate 150 mg once every four days|Afegostat tartrate was administered orally once every 4 days during the 4-week treatment period.
3040703|NCT00433147|Experimental|Afegostat tartrate 150 mg once every seven days|Afegostat tartrate was administered orally once every 7 days during the 4-week treatment period.
3040704|NCT00433160|Experimental|Teriparatide|20 micrograms for 104 weeks
3040705|NCT00433160|Placebo Comparator|Placebo|Placebo for 52 weeks. After 52 weeks, all patients on placebo can receive 20 micrograms teriparatide for 52 weeks
3040706|NCT00433199|Placebo Comparator|Placebo|Placebo
3040707|NCT00433199|Experimental|T-Gel 1.62%|Testosterone (T) gel 1.62%
3040708|NCT00433290|Experimental|A|
3040709|NCT00433290|Placebo Comparator|B|
3040710|NCT00433329|Experimental|Bosentan|Oral bosentan 62.5 mg twice daily (BID) first 4 weeks, followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated, with the addition of sildenafil 20 mg thrice daily (TID) in patients who do not reach the 6-MWT distance threshold at Week 16
3040711|NCT00433381|Experimental|Arm I (bevacizumab and temozolomide)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
3040712|NCT00433381|Experimental|Arm II (bevacizumab & irinotecan hydrochloride)|Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
3040713|NCT00433446|Experimental|CNTO 328|
3040714|NCT00433511|Active Comparator|Arm I (chemotherapy, placebo)|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV over 20-30 minutes, and placebo IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo IV over 30-90 minutes on day 1. Treatment with paclitaxel and placebo repeats every 3 weeks for 4 courses.
3040715|NCT00433511|Experimental|Arm II (chemotherapy, bevacizumab)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses.
3040716|NCT00433511|Experimental|Arm III (chemotherapy, bevacizumab monotherapy)|Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I and bevacizumab as in arm II. Treatment repeats every 2 or 3 weeks for 4 courses. Beginning 3 weeks later, patients then receive paclitaxel as in arm I and bevacizumab as in arm II. Treatment with paclitaxel and bevacizumab repeats every 3 weeks for 4 courses. Beginning 2 months later, patients then receive bevacizumab IV over 30-90 minutes on day 1. Treatment with bevacizumab alone repeats every 3 weeks for 10 courses.
3040717|NCT00433537|Experimental|VcR-CVAD induction followed by maintenance rituximab|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) subcutaneously (SC) or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Maintenance rituximab: Beginning 4-8 weeks after completion of induction therapy, patients receive rituximab IV over 3-4 hours once weekly for 4 weeks. Treatment repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3040718|NCT00433537|Experimental|VcR-CVAD induction followed by ASCT|"VcR-CVAD induction: Patients receive VcR-CVAD comprising bortezomib IV over 3-5 seconds on days 1 and 4; rituximab IV over 3-4 hours on day 1; doxorubicin hydrochloride IV over 48 hours on days 1 and 2; cyclophosphamide IV over 3 hours every 12 hours on days 1-3; vincristine IV over 3-5 seconds on day 3; and dexamethasone IV or orally once daily on days 1-4. Patients also receive filgrastim (G-CSF) SC or IV once daily beginning on day 5 or 6 and continuing until blood counts recover OR pegfilgrastim SC on day 5 or 6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~ASCT: After completion of induction therapy, patients who are eligible may have the option to receive consolidation therapy for autologous stem cell transplantation (off-study). These patients undergo stem cell harvest during courses 4, 5, or 6 of induction therapy."
3040719|NCT00433550|Experimental|Group 1 (6/6 UGT1A1 genotype)|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO BID on days 2-15
3040720|NCT00433550|Experimental|Group 2 (6/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride as in group 1. They also receive oxaliplatin and capecitabine as in group 1 but at lower doses.
3040721|NCT00433550|Experimental|Group 3 (7/7 UGT1A1 genotype)|Patients receive irinotecan hydrochloride, oxaliplatin, and capecitabine as in group 1 but at lower doses.
3040722|NCT00433654|Active Comparator|MRI group|The MRI group underwent a one-hour MRI scan at the 9-12 weeks post-implant follow-up.
3040723|NCT00433654|Other|Control group|The control group waited for one hour (no MRI) at the 9-12 weeks post-implant follow-up.
3040724|NCT00433745|Experimental|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
3040725|NCT00433771|Experimental|WallFlex Biliary Fully Covered stent|Single arm, biliary stenting, using WallFlex Biliary Fully Covered stent
3040726|NCT00433836|Experimental|Valsartan 80 mg|
3040727|NCT00433836|Experimental|Valsartan 160 mg|
3040728|NCT00433836|Experimental|Valsartan 320 mg|
3040729|NCT00433836|Active Comparator|Enalapril 10 mg|
3040730|NCT00433836|Active Comparator|Enalapril 20 mg|
3040731|NCT00433836|Active Comparator|Enalapril 40 mg|
3040732|NCT00433914|Experimental|rMenB|6-8 months-old infants received 3 doses of rMenB vaccine without OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
3040733|NCT00433914|Experimental|rMenB+OMV|6-8 months-old infants received 3 doses of rMenB vaccine with OMV-NZ at 6-8 months of age, 2 months later and 12 months of age.
3040734|NCT00433966|Active Comparator|Pharmacology Arm|"To establish the safety and efficacy of the use of bivalirudin in patients with acute myocardial infarction undergoing a primary angioplasty strategy by showing that compared to unfractionated heparin plus routine use of GP IIb/IIIa inhibitors, bivalirudin (with use of GP IIb/IIIa inhibitors reserved for angioplasty complications) results in:~reduced rates of major bleeding events at 30 days~similar rates of major adverse ischemic cardiac events at 30 days~reduced rates of the composite of major adverse ischemic cardiac events + major bleeding at 30 days."
3040735|NCT00433966|Active Comparator|Stent Arm|"To establish the safety and efficacy of the paclitaxel-eluting TAXUS™ stent by showing that compared to an otherwise identical bare metal EXPRESS2™ stent, the TAXUS™ stent results in:~reduced rates of target lesion revascularization for ischemia at 1 year~similar rates of death, reinfarction, stroke or stent thrombosis at 1 year~lower rates of analysis segment binary angiographic restenosis at 13 months"
3040736|NCT00433992||ABC/3TC|HIV-infected subjects were given Abacavir-Lamuvidine
3040737|NCT00433992||TDF/FTC|HIV-infected patients were given tenofovir DF-emtricitabine
3040738|NCT00434018|Other|Wheelchair Skills Training Program|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs. The WSP is a set of assessment and training protocols related to wheelchair skills. The WSP includes the Wheelchair Skills Test (WST), the Wheelchair Skills Training Program (WSTP) and related materials.
3040739|NCT00434018|Other|Basic Health Education|Basic health educational training sessions: Five sessions are held with subjects to provide them additional information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
3040740|NCT00434057|Other|Biopsied Pigmented Skin Lesions|Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto
3040741|NCT00434109|Experimental|Sunitinib Malate and Hepatic Artery Embolizations|Sunitinib Malate and Selective Hepatic Artery Embolizations: Sunitinib malate (Sutent) at a dose of 37.5mg. 1-3 selective hepatic artery embolizations.
3040742|NCT00434122|Experimental|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
3040743|NCT00434122|Placebo Comparator|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
3040744|NCT00434148|Experimental|Pasireotide 600 ug|At randomization, participants received 600 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 900ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
3040745|NCT00434148|Experimental|Pasireotide 900 ug|At randomization, participants received 900 ug subcutaneously (sc) twice daily (bid). Participants continued at this dose until month 6 if their month 3 mean urinary free cortisol (mUFC) was <= 2 x the upper limit of normal (ULN) and the mUFC was below or equal to their baseline mUFC. Participants not meeting the mUFC criteria at month 3 were unblinded and required to increase their dose to 1200 ug bid on an open label basis. Participants had the option to continue in the extension phase as long as they did not meet any discontinuation criteria or until pasireotide was available commercially in their country.
3040746|NCT00434161|Active Comparator|Palifermin before only|Subjects received palifermin before-high dose chemotherapy (total 3 doses) and matched placebo after-high dose chemotherapy (total 3 doses)
3040747|NCT00434161|Placebo Comparator|Placebo (suger pill)|Subjects received matched placebo before- and after-high dose chemotherapy
3040748|NCT00434161|Active Comparator|Palifermin before and after|Subjects received palifermin before- and after-high dose chemotherapy (total of 6 doses)
3040749|NCT00434213|Experimental|Methylphenidate Transdermal System|To characterize the dermal reactions seen with the use of DAYTRANA
3040750|NCT00434226|Experimental|Bevacizumab + Carboplatin/Paclitaxel + Sunitinib|
3040751|NCT00434226|Placebo Comparator|Bevacizumab + Carboplatin/Paclitaxel|
3040752|NCT00434252|Placebo Comparator|Carboplatin+Paclitaxel+Placebo|
3040753|NCT00434252|Experimental|Carboplatin+Paclitaxel+Bevacizumab|
3040754|NCT00434278|Placebo Comparator|Placebo|
3040755|NCT00434278|Experimental|Dornase alfa|
3040756|NCT00434304|Experimental|Ropinirole PR/XR|
3040757|NCT00434330|Experimental|Cohort 1, Q4W, SC, No Transition|
3040758|NCT00434330|Experimental|Cohort 2, Q4W, IV, No Transition|
3040759|NCT00434330|Experimental|Cohort 3, Q4W, SC, Transition|
3040760|NCT00434330|Experimental|Cohort 4, Q4W, IV, Transition|
3040761|NCT00434330|Experimental|Cohort 5, Q4W, SC, Transition|
3040762|NCT00434330|Experimental|Cohort 6, Q4W, IV, Transition|
3040763|NCT00434356|Experimental|1|
3040764|NCT00434356|Placebo Comparator|2|
3040765|NCT00434421|Experimental|German Cockroach Allergen Dosing Group|Glycerinated German Cockroach Allergenic Extract
3040766|NCT00434434|Experimental|1|
3040767|NCT00434434|Experimental|2|
3040768|NCT00434434|Placebo Comparator|3|
3040769|NCT00434512|Experimental|SB732461 adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040770|NCT00434512|Experimental|SB732461 adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040771|NCT00434512|Experimental|SB732461 adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040772|NCT00434512|Experimental|SB732461 non-adjuvanted_LD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted low-antigen dose [LD] (10 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040773|NCT00434512|Experimental|SB732461 non-adjuvanted_MD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted medium-antigen dose [MD] (30 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040774|NCT00434512|Experimental|SB732461 non-adjuvanted_HD Group|Healthy adult HIV seronegative subjects aged 18 to 40 years, who received two doses of the non-adjuvanted high-antigen dose [HD] (90 μg) SB732461 vaccine, intramuscularly, at Day 0 and Day 30.
3040775|NCT00434577|Experimental|GSK1437173A _LD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) low dose (LD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by intramuscular injection (IM) in the upper deltoid site of the left arm.
3040776|NCT00434577|Experimental|GSK1437173A _MD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) medium dose (MD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
3040777|NCT00434577|Experimental|GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
3040778|NCT00434577|Placebo Comparator|Placebo + GSK1437173A _HD Group|Healthy male or female subjects aged 60 years or older, who received a 1st dose of saline solution and a 2nd dose of GSK1437173A high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
3040779|NCT00434577|Active Comparator|GSK1437173A_MODIFIED GROUP|Healthy male or female subjects aged 60 years or older, who received 2 doses of GSK1437173A modified formulation vaccine reconstituted with saline solution, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
3040780|NCT00434642|Experimental|Carboplatin and gemcitabine + bevacizumab|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Bevacizumab 15 mg/kg was administered IV on Day 1 of each of the six 21-day treatment cycles. The bevacizumab dose was based on the patient's weight at baseline and remained the same throughout the study.
3040781|NCT00434642|Active Comparator|Carboplatin and gemcitabine + placebo|Carboplatin (AUC 4 mg/mL/minute) was administered intravenously (IV) on Day 1 of each of six 21-day treatment cycles. The carboplatin dose was calculated to reach a target area under the curve (AUC) of concentration x time according to the Calvert formula. Gemcitabine 1000 mg/m^2 was administered IV on Days 1 and Day 8 of each of the six 21-day treatment cycles. Placebo was administered by IV on Day 1 of each of the six 21-day treatment cycles.
3040782|NCT00434759|Active Comparator|SCP|SCP is a stepped-care program with a self-help module with minimal therapist contact (8 sessions) as first step, followed by therapist-guided intervention depending on status of remission (8 sessions up to a maximum of 16 sessions).
3040783|NCT00434759|Active Comparator|ST|A standard therapy which means a therapist-guided intervention with 16 sessions face-to-face therapy.
3040784|NCT00434876|Experimental|1|Quetiapine XR
3040785|NCT00434876|Placebo Comparator|2|Placebo
3040786|NCT00434954|Experimental|Exenatide Twice Daily (BID)|
3040787|NCT00434954|Active Comparator|Premixed Insulin Aspart Twice Daily (BID)|
3040788|NCT00434967|No Intervention|4|Placebo
3040789|NCT00434967|Active Comparator|2|Candesartan cilexetil
3040790|NCT00434967|Active Comparator|3|Hydrochlorothiazide (HCT)
3040791|NCT00434967|Experimental|1|Candesartan cilexetil + Hydrochlorothiazide Combination
3040792|NCT00434993|Active Comparator|Albuterol Sulfate|
3040793|NCT00434993|Placebo Comparator|Placebo|
3040794|NCT00435019|Experimental|insulin detemir|insulin detemir + insulin aspart
3040795|NCT00435019|Experimental|NPH insulin|NPH insulin + insulin aspart
3040796|NCT00435045|Active Comparator|atorvastatin arm|atorvastatin + placebo
3040797|NCT00435045|Experimental|Lovaza arm|Lovaza + atorvastatin
3040798|NCT00435162|Experimental|Low Dose|
3040799|NCT00435162|Experimental|Medium Dose|
3040800|NCT00435162|Experimental|High Dose|
3040801|NCT00435188|Experimental|Arm 1|Behavioral: Multi-component physical activity counseling program A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
3040802|NCT00435188|No Intervention|Arm 2|Usual care
3320834|NCT02014142|Experimental|Group A. L-PPDS single occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous single occlusion; L-PPDS will be inserted in the lower punctum and no plug will be inserted in the upper punctum of each eye; L-PPDS will remain for a period of 14 weeks.
3040805|NCT00435370|Experimental|Tropisetron|Tropisetron (10mg/day) + risperidone(6mg/day)
3040806|NCT00435370|Placebo Comparator|Placebo|Placebo + risperidone (6mg/day)
3040807|NCT00435409|Experimental|A|
3040808|NCT00435409|Active Comparator|B|
3040809|NCT00435487|Experimental|A|
3040810|NCT00435487|Active Comparator|B|
3040811|NCT00435539|Experimental|ocriplasmin 75µg single injection|Ocriplasmin 75µg single injection versus sham injection
3040812|NCT00435539|Experimental|ocriplasmin 125µg single injection|Ocriplasmin 125µg single injection versus sham injection
3040813|NCT00435539|Experimental|ocriplasmin 175µg single injection|Ocriplasmin 175µg single injection versus sham injection
3040814|NCT00435539|Experimental|ocriplasmin 125µg multiple injections|Ocriplasmin 125µg multiple injections. Subjects who did not achieve resolution of VMT by the day 28 visit (i.e. non-responders) were given an open-label injection of ocriplasmin 125µg. Subjects who still did not achieve resolution of VMT by the day 56 visit were given a second open-label injection of ocriplasmin 125µg.
3040815|NCT00435539|Sham Comparator|sham injection|sham injection
3040816|NCT00435591|Experimental|Dose Regimen 1|Placebo loading dose + 20mg/day continuous infusion conivaptan per ampoule
3040817|NCT00435591|Experimental|Dose Regimen 2|Conivaptan loading dose (20mg)+ 20mg/day continuous infusion conivaptan per ampoule
3040818|NCT00435591|Experimental|Dose Regimen 3|Placebo loading dose + 20mg/day continuous infusion conivaptan per premix bag
3040819|NCT00435591|Experimental|Dose Regimen 4|Conivaptan loading dose (20mg) + 20mg/day continuous infusion conivaptan per premix bag
3040820|NCT00435812|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
3040821|NCT00435812|Active Comparator|Engerix-B|1.0 mL Engerix-B
3040822|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_24 Weeks|Participants received 90 micrograms (μg) peginterferon alfa-2a subcutaneous once a week for 24 weeks.
3040823|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_24 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 24 weeks.
3040824|NCT00435825|Experimental|peginterferon alfa-2a 90 μg_48 Weeks|Participants received 90 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
3040825|NCT00435825|Experimental|peginterferon alfa-2a 180 μg_48 Weeks|Participants received 180 μg peginterferon alfa-2a subcutaneous once a week for 48 weeks.
3040826|NCT00435929|Experimental|1|
3040827|NCT00435929|Experimental|2|
3040828|NCT00435942|Experimental|1|Endovascular Treatment arm to be implanted with Relay device
3040829|NCT00435942|Active Comparator|2|Surgical Control, underwent open repair
3040830|NCT00435994|Other|Infants with viral lower respiratory infections|Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants
3040831|NCT00435994|Other|Healthy Control|Healthy infants between the ages of 2-24 month
3040832|NCT00435994|Other|Bronchiolitis-Nasal wash only|Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only
3040833|NCT00436007|Experimental|GSK 257049 1 Group|"Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib, Polio Sabin™ and GSK 257049 vaccines at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ vaccines at Month 7.~The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania."
3040834|NCT00436007|Experimental|GSK 257049 2 Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, 3 doses of GSK 257049 vaccine at Months 0, 1 and 7, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. Stamaril™ was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
3040835|NCT00436007|Active Comparator|Tritanrix™ HepB/Hiberix™ Group|Subjects aged 6 to 10 weeks at the time of first vaccination received 3 doses of Tritanrix™ HepB/Hib and Polio Sabin™ at Months 0, 1 and 2, and a single dose of Rouvax™ and Stamaril™ at Month 7. The GSK 257049 and Tritanrix™ HepB/Hib vaccines were administered intramuscularly in the left and right antero-lateral thigh, respectively. Rouvax™ and Stamaril™ were administered intramuscularly in the left and right arm respectively. Polio Sabin™ was administered orally. The Stamaril™ vaccine was not administered to subjects from Tanzania as this vaccine was not foreseen at the time to be introduced to the EPI vaccination schedule in Tanzania.
3040836|NCT00436046|Active Comparator|Group 1: 0.6 ml of IVV|30 subjects to receive 0.6 ml of inactivated influenza virus vaccine (IVV).
3040837|NCT00436046|Experimental|Group 3: 0.7 ml of IVV + 10M units of IFN|30 subjects to receive 0.7 ml of IVV containing 10M units of interferon (IFN).
3040838|NCT00436046|Experimental|Group 2: 0.6 ml of IVV + 1M unit of IFN|30 subjects to receive 0.6 ml of IVV containing 1M units of interferon (IFN).
3040839|NCT00436163|Experimental|Peginterferon Alfa-2a|Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.
3040840|NCT00436215|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (sorafenib) + Bevacizumab
3040841|NCT00436280|Experimental|Enzastaurin + Gemcitabine Rituximab Oxaliplatin (R-GEMOX)|
3040842|NCT00436332|Experimental|Erlotinib and Bevacizumab|
3040843|NCT00436345|Experimental|Remifentanil|remifentanil
3040844|NCT00436345|Active Comparator|Propofol|Propofol infusion
3040845|NCT00436436|Experimental|O6-benzylguanine & Temozolomide in Glioblastoma|Patients receive O6-benzylguanine intravenous over 1 hour and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3040846|NCT00436475|Other|1|Vitamin D3 2,000 IU daily plus Calcium Carbonate 400 mg twice daily
3040847|NCT00436475|Other|2|Vitamin D3 2,000 IU daily plus Calcium-Placebo twice daily
3040848|NCT00436475|Other|3|Vitamin D3-Placebo plus Calcium Carbonate 400 mg twice daily
3040849|NCT00436475|Other|4|Vitamin D3-Placebo plus Calcium-Placebo
3040850|NCT00436501|Experimental|Treatment (VEGF Trap, Docetaxel)|"Phase I (closed to accrual as of 3/14/2008): Patients receive VEGF Trap IV over 1 hour on day 1 of course 1. Patients then receive VEGF Trap IV over 1 hour and docetaxel IV over 1 hour on day 1 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of VEGF Trap until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 or 6 patients experience dose-limiting toxicity."
3040851|NCT00436501|Experimental|Phase II Treatment (VEGF Trap, Docetaxel)|Phase II (opened to accrual as of 5/9/2008): Patients receive VEGF Trap at the MTD determined in phase I and docetaxel as in phase I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3040852|NCT00436553|Experimental|Verteporfin With Standard Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin photodynamic therapy (PDT) with standard fluence (SF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
3040853|NCT00436553|Active Comparator|Ranibizumab Monotherapy|Patients received monthly ranibizumab injections for 12 months and thereafter as needed based on the retreatment criteria. These patients were also administered verteporfin placebo infusion with sham PDT on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. Retreatments were determined based on study specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA).
3040854|NCT00436553|Experimental|Verteporfin With Reduced Fluence Rate Plus Ranibizumab|Patients received three consecutive monthly ranibizumab injections on Day 1 and at Months 1 and 2, and thereafter as needed at intervals of at least 30 days based on retreatment criteria. These patients also received verteporfin PDT with reduced fluence (RF) rate on Day 1 and then as needed from Month 3 at intervals of at least 90 days based on the retreatment criteria. From month 3 onward, retreatments were determined based on study-specific retreatment criteria that included retinal thickness by Optical Coherence Tomography (OCT), sub-retinal hemorrhage evaluated by ophthalmoscopic examination, visual acuity assessed using Early treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart and choroidal neovascularization (CNV) leakage assessed by fluorescein angiography (FA). Patients received sham intravitreal injections for the first 12 months if retreatment with ranibizumab was not warranted based on the retreatment criteria.
3040855|NCT00436605|Experimental|Treatment (kinase inhibitor therapy)|Patients receive oral dasatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3040856|NCT00436618|Experimental|Relapsed aggressive non-Hodgkin lymphoma|Study 1. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3040857|NCT00436618|Experimental|Relapsed indolent non-Hodgkin lymphoma|Study 2. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3040858|NCT00436618|Experimental|Uncommon lymphomas|Study 3. Includes Hodgkin's lymphomas. Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
3040859|NCT00436644|Experimental|Lapatinib + Topotecan|Assess biological effects of topotecan and lapatinib in patients with epithelial ovarian cancer and primary peritoneal carcinoma.
3040860|NCT00436748|Experimental|Darbepoetin Alfa QW|Participants received darbepoetin alfa once a week (QW) for 24 weeks. The initial dose was 0.45 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
3040861|NCT00436748|Experimental|Darbepoetin Alfa Q2W|Participants received darbepoetin alfa every 2 weeks (Q2W) and a placebo every other 2 weeks to maintain the blind for 24 weeks. The initial dose was 0.75 μg/kg; thereafter, active doses were administered to achieve and then maintain hemoglobin levels within a target range of 10.0 to 12.0 g/dL. Participants not on dialysis or who were receiving peritoneal dialysis were administered darbepoetin alfa subcutaneously; participants receiving hemodialysis were administered darbepoetin alfa intravenously.
3178864|NCT00666484|Experimental|Treatment Group 2: stages 2AE, 2B, 3A: OEPA x 2 + COPP x 2|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
3178865|NCT00666484|Experimental|Treatment Group 3: stages 2BE, 3AE, 3B, 4: OEPAx2 + COPPx4|"OEPA (28 day cycle) Vincristine 1.5mg/m^2 iv d1,d8,d15 (capped at 2mg/dose) Etoposide 125mg/m^2 iv d1-5 Prednisolone 60mg/m^2 po d1-15 Adriamycin 40mg/m^2 iv d1 and 15~COPP (28 day cycle) Cyclophosphamide 500mg/m^2 iv d1 and 8 Vincristine 1.5mg/m^2 iv d1,8 (capped 2mg/dose) Procarbazine 100mg/m^2 po d1-15* Prednisolone 40mg/m^2 po d1-15"
3178866|NCT00666497|Experimental|A|Azacitidine
3178867|NCT00666497|Experimental|B|MGCD0103
3178868|NCT00666497|Experimental|C|Azacitidine + MGCD0103
3178869|NCT00666510||Bronchospasm|Patients who presented bronchospasm during anesthesia induction
3178870|NCT00666510||Asthma|Patients who presented bronchospasm during anesthesia induction and were identified as asthmatics
3178871|NCT00666510||Control|Patients who were submitted to anesthesia induction and showed no complications
3178872|NCT00666523|Experimental|1|
3178873|NCT00666523|Placebo Comparator|2|
3178874|NCT00666575|Experimental|Gabapentin|
3178875|NCT00666575|Placebo Comparator|Placebo|
3178876|NCT00666601|Experimental|Pilot study|3 subjects, open lable, microdialysis single dose.
3178877|NCT00666601|Experimental|Main Study|12 subjects, open label, single dose of 600 mg.
3178878|NCT00666614|Other|Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
3178879|NCT00666614|Other|Standard Care|Normal Hospital Environment
3178880|NCT00666627|Active Comparator|1|Ibandronate
3178881|NCT00666627|Active Comparator|2|Risedronate
3178882|NCT00666627|Active Comparator|3|Alendronate 70mg once weekly
3178883|NCT00666627|No Intervention|4|Young women control group
3040868|NCT00436852|Experimental|Measurable disease by CT or MRI scan (ABT-751 chemotherapy)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
3040869|NCT00436852|Experimental|Evaluable by I-MIBG scintigraphy (ABT-751)|Patients receive oral ABT-751 (200 mg/m2) once daily on days 1-7. Treatment repeats every 21 days for 52 courses in the absence of disease progression or unacceptable toxicity. Quality-of-life assessment at baseline and prior to each course of treatment. A pharmacological study (pharmacokinetic profile of ABT-751) will be determined.
3040870|NCT00436904|Experimental|Alemtuzumab + Rituximab|Alemtuzumab 30mg Monday, Wednesday, and Friday x 5 weeks, Rituximab 375/mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
3040871|NCT00436917|Experimental|zoledronic acid|4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.
3040872|NCT00436956|Experimental|AZD2171 in Prostate Cancer|Cohort 1 (n=35) received 20 mg AZD2171 (Cediranib) orally daily. Cohort 2 (n=23) received prednisone 10 mg orally daily with 20 mg AZD2171.
3040873|NCT00436969|Active Comparator|Control|Subjects randomized to the control arm injection of prescribed anesthetic and corticosteroid, shall receive an equivalent volume (8 mL's).
3040874|NCT00436969|Experimental|Investigational|Subjects randomized to the active treatment in this study will receive a one-time dose of 8 mL's of Orthovisc derived from non-animal source bacterial fermentation, S. Equi.
3040875|NCT00436982|Active Comparator|Cemented Triathlon total knee system|The Triathlon total knee system is the successor of the Duracon total knee system and was observed in a prospective randomised, parallel, double-blind study.
3040876|NCT00436982|Active Comparator|Cemented Duracon total knee system|The Duracon total knee system is the predecessor of the Triathlon total knee system and was observed in a prospective randomised, parallel, double-blind study.
3040877|NCT00437034|Experimental|Treatment (antiangiogenesis therapy)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3040878|NCT00437073|Experimental|lapatinib plus capecitabine|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
3040879|NCT00437073|Experimental|lapatinib + topotecan|A total of 55 isubjects will be enrolled into this arm. Subjects with progression of CNS and/or non-CNS disease will be considered progressors. At the time of radiographically-documented CNS and/or non-CNS disease progression, a subject randomized to this arm will be allowed to cross over to the alternative arm.
3040880|NCT00437125|Experimental|Duloxetine|Participants received duloxetine 30 milligram (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg orally QD for 11 weeks
3040881|NCT00437203|Experimental|1|
3040882|NCT00437268|Experimental|enzastaurin + irinotecan + cetuximab|
3040883|NCT00437268|Active Comparator|irinotecan + cetuximab|
3040884|NCT00437281|Placebo Comparator|Placebo|
3040885|NCT00437281|Experimental|Pregabalin|
3040886|NCT00437294|Experimental|Capecitabine + Enzastaurin|
3040887|NCT00437294|Placebo Comparator|Capecitabine + Placebo|
3040888|NCT00437489|Active Comparator|Control|
3040889|NCT00437489|Experimental|Experimental|
3040890|NCT00437645|Experimental|Valsartan/amlodipine 160/5 mg|Twelve (12) weeks treatment with the combination of valsartan/amlodipine 160/5 mg. Together with the active medication, patients received a placebo that matched amlodipine 5 mg. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
3040891|NCT00437645|Active Comparator|Amlodipine 10 mg|Eight (8) weeks of treatment with amlodipine 10 mg (two 5 mg capsules). Together with the active medication, the patients received a placebo that matched valsartan 160 mg. At Week 8, patients were switched and treated with the combination of valsartan/amlodipine 160/5 mg and a placebo that matched amlodipine 5 mg for an additional 4 weeks until the end of the study. The three capsules were taken by mouth with water once daily in the morning, regardless of meals. Patients were instructed not to take their study medication the morning of their study visits. Instead, they brought the study medication with them to the site and took it there as instructed by the investigator.
3040892|NCT00437658|Experimental|Elagolix 75 mg BID|Participants received elagolix 75 mg orally twice a day (BID) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
3040893|NCT00437658|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg orally once a day (QD) for 24 weeks and placebo to DMPA-SC by subcutaneous injection at weeks 1 and 12.
3040894|NCT00437658|Active Comparator|DMPA-SC|Participants received placebo to elagolix orally once a day for 24 weeks and DMPA-SC 104 mg by subcutaneous injection at weeks 1 and 12.
3040895|NCT00437983|Active Comparator|PS-Omega3|Phosphatidylserine-Omega3, 300mg/day 15 wk
3040896|NCT00437983|Placebo Comparator|Placebo|Cellulose tainted with fishy odor, 3 capsules/day
3040897|NCT00438100|Active Comparator|Capecitabine arm|Capecitabine (Xeloda): 1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
3040898|NCT00438100|Experimental|S-1 arm|S-1: 80 mg/m2 orally bid daily for day 1 through day28 followed by 14-day washout; repeat this as a course.
3040899|NCT00438191||1|Subjects who wear the splint whenever the feel the need.
3040900|NCT00438191||2|Subjects who wear the splint whenever possible.
3178884|NCT00666640||1|50 subjects who have suffered a hip fracture
3178885|NCT00666640||2|50 age matched controls
3178886|NCT00666692|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab
3178887|NCT00666744|Experimental|1|Exercise Intervention - additional lower limb exercises will be completed by the person with stroke with the assistance of his/her family for 35 minutes daily for a period of 8 weeks.
3040901|NCT00438204|Experimental|Bevacizumab, gemcitabine hydrochloride|"Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days~Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed disodium every 14 days~Pemetrexed 400 mg/m2 intravenously over 10 minutes every 14 days."
3040902|NCT00438256|Experimental|Group 1|10 Radiation Sessions over 2 weeks
3040903|NCT00438256|Experimental|Group 2|5 Radiation sessions: 3 in week 1 and 2 in week 2
3040904|NCT00438256|Experimental|Group 3|5 Radiation sessions: 4 in week 1 and 1 in week 2
3040905|NCT00438256|Experimental|Group 4|5 Radiation Sessions in one week
3040906|NCT00438360|Active Comparator|Cyclosporine A|Oral soft gelatin capsules of cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
3040907|NCT00438360|Placebo Comparator|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
3040908|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 1|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Wash-out up to 8 weeks~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
3040909|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 2|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
3040910|NCT00438399|Active Comparator|C. propionate-Wash out-Corticosteroid 3|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
3040911|NCT00438399|Active Comparator|Corticosteroid 1-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 1:~Dose or Concentration: Corticosteroid 1 Foam~Mode and Frequency of Administration:Twice daily, a golf-ball sized amount to be massaged into the affected area of the scalp~Duration of Treatment: 4 weeks as a maximum"
3040912|NCT00438399|Active Comparator|Corticosteroid 2-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 2:~Dose or Concentration: Corticosteroid 2 Lotion~Mode and Frequency of Administration: Twice daily, a thin film to be applied to the affected area of the scalp and massaged gently and thoroughly into the skin~Duration of Treatment: 4 weeks as a maximum"
3040913|NCT00438399|Active Comparator|Corticosteroid 3-Wash out-C. propionate|"Clobetasol propionate Shampoo:~Dose or Concentration: Clobetasol propionate 0.05% shampoo~Mode and Frequency of Administration: Topical Once daily to the dry scalp, to be lathered and rinsed after 15 minutes~Duration of Treatment: 4 weeks as a maximum~Corticosteroid 3:~Dose or Concentration: Corticosteroid 3 Scalp application~Mode and Frequency of Administration: Twice daily, a thin film to be applied into the affected area of the dry scalp and rubbed gently into the scalp~Duration of Treatment: 4 weeks as a maximum"
3040914|NCT00438451|Active Comparator|Levetiracetam|Levetiracetam
3040915|NCT00438451|Active Comparator|Carbamazepine|Carbamazepine
3040916|NCT00438451|Active Comparator|Lamotrigine|Lamotrigine
3040917|NCT00438464|Experimental|Arm I (Finasteride)|Finasteride 5 mg once daily for 4-6 weeks, then undergo prostatectomy.
3040918|NCT00438464|Placebo Comparator|Arm II (Placebo)|Placebo once daily for 4-6 weeks, then undergo prostatectomy.
3040919|NCT00438490|Experimental|recombinant human prolactin|Recombinant Human Prolactin 60 mcg/kg once daily subcutaneous injection
3040920|NCT00438490|Placebo Comparator|Placebo|Normal saline placebo subcutaneous injection
3040921|NCT00438633||Early Therapy|Subjects who begin therapy immediately after diagnosis of injury.
3040922|NCT00438633||Late Therapy|Subjects who delay therapy for 3 weeks after diagnosis of injury.
3040923|NCT00438659|Experimental|Mometasone|Patients apply 2.5 mL mometasone furoate cream once daily to the treatment area (breast or chest wall) for the duration of planned radiotherapy.
3040924|NCT00438659|Placebo Comparator|Placebo|Patients apply 2.5 mL of an identical-appearing placebo cream to the treatment area as in arm I.
3040925|NCT00438672|Active Comparator|Dequervains|The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.
3040926|NCT00438672|Active Comparator|Lateral Epicondylitis|
3040927|NCT00438672|Active Comparator|CMC Arthritis|The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.
3040928|NCT00438750|Experimental|Independent Home Exercises|Subjects who learn their therapy exercises from the surgeon and practice them independently at home.
3040929|NCT00438750|Experimental|Formal Therapy|Subjects who follow the conventional protocol of seeing a therapist to learn and guide them in their exercises.
3040930|NCT00438802|Experimental|alefacept|Determine both the maximum tolerated dose level as well as the optimal immunologic dose and toxicity.
3040931|NCT00438815|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.
3040932|NCT00438854|Experimental|Dasatinib treatment|All patients were treated with dasatinib pills by mouth as treatment.
3040933|NCT00438880|Experimental|Arm I|See Detailed Description
3040934|NCT00438932|Active Comparator|Lanthanum Carbonate and Low Phosphorus Diet|25% of subjects will receive binders plus a phosphate restricted diet.
3040935|NCT00438932|Active Comparator|Lanthanum Carbonate and Unrestricted Phosphorus Diet|25% binders + unrestricted phosphate diet.
3040936|NCT00438932|Active Comparator|Placebo and Low Phosphorus Diet|25% placebo + phosphate restricted diet.
3040937|NCT00438932|Active Comparator|Placebo and Unrestricted Phosphorus Diet|25% placebo + unrestricted phosphate diet.
3040938|NCT00438971|Experimental|Duloxetine|
3040939|NCT00439140|Experimental|botulinum toxin Type A 200U|Botulinum toxin Type A 200U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
3040940|NCT00439140|Experimental|botulinum toxin Type A 300U|Botulinum toxin Type A 300U injection into the detrusor on Day 1 followed by a repeat botulinum toxin Type A 300U injection after a minimum of 12 weeks (if applicable).
3040941|NCT00439140|Other|Placebo/botulinum toxin Type A 200U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 200U injection after a minimum of 12 weeks (if applicable).
3040942|NCT00439140|Other|Placebo/botulinum toxin Type A 300U|Placebo (Normal Saline) injection into the detrusor on Day 1 followed by a botulinum toxin Type A 300U injection (200U after discontinuation of 300U) after a minimum of 12 weeks (if applicable).
3040943|NCT00439179|Experimental|Cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
3040944|NCT00439179|Experimental|Cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
3040945|NCT00439179|Experimental|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
3040946|NCT00439179|Experimental|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
3040947|NCT00439218|Experimental|Subject Enrollments|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) approach and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
3040948|NCT00439231|Experimental|Lenalidomide (Revlimid) subjects|Lenalidomide regimen testing to determine efficacy for CLL/ SLL subjects
3040949|NCT00439244|Active Comparator|Zoledronic acid plus teriparatide|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion. Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
3040950|NCT00439244|Experimental|Zoledronic acid|Zoledronic acid 5.0 mg/100 mL was administered via a peripheral intravenous site at Visit 2 (once at randomization) as a slow 15-minute infusion.
3040951|NCT00439244|Active Comparator|Placebo zoledronic acid plus teriparatide|Placebo zoledronic acid 100 mL intravenous (i.v.) (once at randomization) plus teriparatide 20 μg (daily subcutaneous injections administered concurrently through 52 weeks). Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. The pen device delivers 20 μg of teriparatide concurrently as daily subcutaneous injections for 52 weeks.
3040952|NCT00439270|Active Comparator|Dasatinib, 50 mg + Docetaxel, 60 mg/m^2|Participants received dasatinib, 50 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 60 mg/m^2.
3040953|NCT00439270|Active Comparator|Dasatinib, 50 mg + Doxetaxel, 75 mg/m^2|Participants received dasatinib, 50 mg administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3040954|NCT00439270|Active Comparator|Dasatinib, 70 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 70 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3040955|NCT00439270|Active Comparator|Dasatinib, 100 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 100 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3040956|NCT00439270|Active Comparator|Dasatinib, 120 mg + Docetaxel, 75 mg/m^2|Participants received dasatinib, 120 mg, administered orally once daily. Docetaxel was administered every 3 weeks as an infusion at 75 mg/m^2.
3040957|NCT00439296|Experimental|Dose Level 1|"Treatment Dose of ABT-751 is 80 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040958|NCT00439296|Experimental|Dose Level 2|"Treatment Dose of ABT-751 is 100 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040959|NCT00439296|Experimental|Dose Level 3|"Treatment Dose of ABT-751 is 125 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040960|NCT00439296|Experimental|Dose Level 4|"Treatment Dose of ABT-751 is 150 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040961|NCT00439296|Experimental|Dose Level 5|"Treatment Dose of ABT-751 is 175 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040962|NCT00439296|Experimental|Dose Level 0|"Treatment Dose of ABT-751 is 65 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040963|NCT00439296|Experimental|Dose Level -1|"Treatment Dose of ABT-751 is 50 mg/m2/day~Tx Course 1:~• ABT-751, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, IT Methotrexate~Tx Course 2:~• Cyclophosphamide, 6-Thioguanine, IT Methotrexate, Cytarabine, PEG-asparaginase, ABT-751~Tx Courses 3-12 (maintenance courses):~• ABT-751, IT Methotrexate"
3040964|NCT00439309|Experimental|VascuSeal|Consists of two liquids that when mixed together in situ rapidly cross-link to form a biocompatible absorbable sealant that is tissue adherent. These liquids are sprayed onto tissues using the Dual Liquid Applicator. The formed Sealant remains intact for approximately 2 to 7 days. During this period the Sealant undergoes hydrolysis where it is absorbed into the circulatory system and is excreted through the kidneys.
3040965|NCT00439309|Active Comparator|GELFOAM/THROMBIN|GELFOAM/THROMBIN description - GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine Skin Gelatin USP Granulates and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids. Although not necessary, GELFOAM can be used either with or without thrombin to obtain hemostasis.
3040966|NCT00439335|Experimental|H5 HA IM|Vaccine group H5 HA IM: the subject will receive 0.1 mL of H5 HA by the IM route in one arm and 0.1 mL of saline placebo by the ID route in the other arm.
3040967|NCT00439335|Experimental|H5 HA ID|Vaccine group H5 HA ID: the subject will receive 0.1 mL of H5 HA by the ID route in one arm and 0.1 mL of saline placebo by the IM route in the other arm.
3040968|NCT00439374|Active Comparator|17 alpha-hydroxyprogesterone caproate|250 mg of 17 alpha-hydroxyprogesterone caproate given by weekly injection until 37 weeks gestation or delivery
3040969|NCT00439374|Placebo Comparator|Placebo|Placebo oil given by weekly injection until 37 weeks gestation or delivery.
3040970|NCT00439413|Active Comparator|Selegiline Transdermal Patch|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received Selegiline Transdermal System, 6mg -20cm(2) patch, one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
3040971|NCT00439413|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -4 week Screening/Baseline Phase.~During treatment, subjects received matched placebo 20cm(2) patch transdermal patch one time per day for 9 weeks~Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks"
3040972|NCT00439465|Other|Ex-vivo expanded effector cells|Infusing IL-2 and GM-CSF post-Hematopoietic Stem Cell Transplant (HSCT)
3040973|NCT00439517|Experimental|1|UFOX + Cetuximab
3040974|NCT00439517|Active Comparator|2|FOLFOX4 + Cetuximab
3040975|NCT00439556|Experimental|Treatment (chemotherapy, transplant, filgrastim, tacrolimus)|See Detailed Description
3040976|NCT00439608|Experimental|Treatment|Cetuximab, paclitaxel, and carboplatin weekly for 6 weeks with 50.4 Gy radiation.
3040977|NCT00439647|Experimental|Zoledronic Acid|5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
3040978|NCT00439647|Placebo Comparator|Placebo|100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
3040979|NCT00439725|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 20 mg oral tablet once daily
3040980|NCT00439725|Placebo Comparator|Placebo|Participants were to receive matching placebo oral tablet once daily
3040981|NCT00439738|Experimental|valsartan/HCTZ|
3040982|NCT00439738|Active Comparator|HCTZ +Amlodipine|
3040983|NCT00439777|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 15 mg rivaroxaban (oral) twice daily (b.i.d.) for 3 weeks, followed by 20 mg once daily (o.d.)
3040984|NCT00439777|Active Comparator|Enoxaparin/VKA|Participants received enoxaparin (subcutaneous) 1.0 mg/kg b.i.d. for minimal 5 days, plus vitamin K antagonist (VKA) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 - 3.0)
3040985|NCT00439946|Experimental|treprostinil|IV treprostinil continuous infusion via Crono Five infusion pump.
3040986|NCT00440011|Experimental|1|
3040987|NCT00440011|Active Comparator|2|
3040988|NCT00440037|Experimental|AMG 531|
3040989|NCT00440050|Experimental|1.|DHA
3040990|NCT00440050|Placebo Comparator|2.|Placebo
3040991|NCT00440115|Experimental|High intensity disease management|High intensity disease management, free nicotine replacement therapy or bupropion
3040992|NCT00440115|Experimental|Low intensity disease management|Low intensity disease management, free nicotine replacement therapy or bupropion
3040993|NCT00440115|Other|Comparison group|Comparison group, free nicotine replacement therapy or bupropion
3040994|NCT00440180|Placebo Comparator|Group B|Placebo
3040995|NCT00440180|Experimental|Group A|Anastrozole
3040996|NCT00440193|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants were to receive rivaroxaban 15 mg oral tablet twice daily for 3 weeks, followed by 20 mg once daily
3040997|NCT00440193|Active Comparator|Enoxaparin/VKA|Participants were to receive 1.0 mg/kg enoxaparin twice daily (subcutaneous) for at least 5 days, plus vitamin K antagonist (VKA) (oral) at individually titrated doses to achieve a target international normalized ratio (INR) of 2.5 (range: 2.0 to 3.0)
3040998|NCT00440232|Experimental|Frovatriptan|5.0 mg of Frovatriptan given as single dose
3040999|NCT00440232|Placebo Comparator|placebo|
3041000|NCT00440297|Experimental|Modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
3041001|NCT00440297|Active Comparator|ENGERIX-B™2|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
3041002|NCT00440310|Experimental|Litx + Chemotherapy|
3041003|NCT00440310|Active Comparator|Chemotherapy alone|
3041004|NCT00440401|Active Comparator|TachoSil®|
3041005|NCT00440401|Active Comparator|Standard Treatment|Standard Treatment of haemorrhage in cardiovascular surgery
3041006|NCT00440466|Experimental|001|epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
3041007|NCT00440466|Experimental|003|epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
3041008|NCT00440466|Experimental|002|epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
3041009|NCT00440505|Placebo Comparator|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
3041010|NCT00440505|Experimental|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
3041011|NCT00440505|Experimental|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
3041012|NCT00440518|Placebo Comparator|Placebo|Placebo
3041013|NCT00440518|Experimental|Lacosamide 100mg|100mg lacosamide
3041014|NCT00440518|Experimental|Lacosamide 300mg|300mg lacosamide
3041015|NCT00440531|Active Comparator|1|RECOMBIVAX HB™
3041016|NCT00440531|Experimental|2|Modified Process Hepatitis B Vaccine
3041017|NCT00440531|Active Comparator|3|ENGERIX-B™
3041018|NCT00440557|Experimental|TIW: Epoetin alfa 3 injections Weekly/Once Weekly|Participants will be administered with epoetin alfa 3 times weekly for 22 weeks (initial subcutaneous (SC) dose 50 IU/kg), then once weekly, for 22 weeks (initial SC dose 10,000 IU)
3041019|NCT00440557|Experimental|QW: Epoetin alfa once weekly|Participants will be administered with epoetin alfa once weekly for 44 weeks (initial subcutaneous dose 10,000 IU).
3041020|NCT00440557|Experimental|Q2W: Epoetin alfa once every two weeks|Participants will be administered with epoetin alfa once every 2 weeks for 44 weeks (initial subcutaneous dose 20,000 IU).
3041021|NCT00440596|Experimental|Mindfulness based stress reduction|Mindfulness based stress reduction
3041022|NCT00440596|Active Comparator|Progressive Muscle Relaxation|Progressive Muscle Relaxation
3041023|NCT00440700|Experimental|Patient-directed music|Patients select preferred music for listening through headphones whenever they like for as long as they like whenever feeling anxious, desire some rest and quiet time, or for listening enjoyment while mechanically ventilated in the ICU.
3041024|NCT00440700|Active Comparator|Headphones|Noise-canceling headphones only (no music) are applied by the patient to block out noise/sound in the ICU whenever desired.
3041025|NCT00440700|Other|Standard of Care|Patients receive usual care for the ICU and are encouraged to self-initiate rest periods twice daily.
3041026|NCT00440726|Experimental|Ph 1 Dose Escalation|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. 3+3 escalation design.
3041027|NCT00440726|Experimental|Ph 2 Efficacy and Safety|Intervention: Bortezomib with chemotherapy (dexamethasone, PEG-asparaginase, doxorubicin, cytarabine, methotrexate, and vincristine) and Triple IT therapy for patients who are CNS 2 or 3 at study entry. Patients receive bortezomib at maximum tolerated dose (as established in the Phase 1 portion of the study) and are assessed for response and toxicity.
3041028|NCT00440830|Experimental|Smokers-nicotine|Smokers who were treated with nicotine
3041029|NCT00440830|Experimental|Nonsmokers-nicotine|Nonsmokers who were treated with nicotine
3041030|NCT00440830|Placebo Comparator|Smokers-placebo|Smokers who were treated with placebo
3041031|NCT00440830|Placebo Comparator|Nonsmokers-placebo|Nonsmokers who were treated with placebo
3041032|NCT00440947|Other|Simplification|Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
3041033|NCT00440947|Other|Continuation|Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.
3041034|NCT00440999|Experimental|pyronaridine artesunate|The tablet strength is 180:60 mg oral PA plus chloroquine-placebo. Depending on their body weight, patients receive 1 to 4 tablets once a day, for 3 days. The actual dose-level range covered by this regimen is 7.2: 2.4 mg/kg to 13.8:4.6 mg/kg pyronaridine artesunate.
3041035|NCT00440999|Active Comparator|chloroquine|"The tablet strength is 155 mg oral chloroquine plus PA-placebo.~Patients receive:~For adults: 620 mg (i.e. 4 tablets) on Days 0 and 1 and 310 mg (i.e. 2 tablets) on Day 2. For children: 10 mg/kg on Days 0 and 1 and 5 mg/kg on Day 2."
3041036|NCT00441012|Experimental|1|Modified process Hib/Hep B vaccine
3041037|NCT00441012|Active Comparator|2|COMVAX™
3041038|NCT00441064|Experimental|Diet Sequence Low/High Sodium|Patients on low sodium diet ( <= 100 mmol/day) for the first 4 weeks and high sodium (>= 200 mmol/day) diet for the next 4 weeks. [with Aliskiren 300 mg]
3041039|NCT00441064|Experimental|Diet Sequence High/Low Sodium|Patients on high sodium (>= 200 mmol/day) diet for the first 4 weeks and on low sodium diet ( <= 100 mmol/day) for the next 4 weeks. [with Aliskiren 300 mg]
3041040|NCT00441090|Experimental|Avatrombopag tablets|"2.5, 5, 10 or 20 mg tablets~1 tablet taken orally once daily for 28 days"
3041041|NCT00441090|Placebo Comparator|Placebo tablet|"2.5, 5, 10, or 20 mg tablets~1 tablet taken orally once daily for 28 days"
3041042|NCT00441103|Experimental|Rebif® New Formulation (IFN-beta-1a, RNF)|
3041043|NCT00441103|Placebo Comparator|Placebo/RNF|
3041044|NCT00441116|Placebo Comparator|Dutasteride|Dutasteride
3041045|NCT00441129|Active Comparator|Conventional insulin pump therapy|Conventional insulin pump therapy or continuous subcutaneous insulin infusion (CSII)
3041046|NCT00441129|Experimental|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
3132575|NCT03438383|Active Comparator|Bi-PAP|Bi-PAP through nasal mask, at individualized IPAP/EPAP pressures, was applied for 3 days postoperatively. IPAP and EPAP in the Bi-PAP system were individualized for each patient in accordance with accepted values of SpO2, PaCO2, and patient synchronization and tolerability with the device.Individualized setting of pressures in patient group was applied gradually starting with 12/4 cm H2O (IPAP/EPAP) and up to 18/10 (IPAP/EPAP) with consecutive increases of 2 cm H2O.
3041047|NCT00441142|Active Comparator|Phase II: Arm A (Control Group: RT + TMZ)|"The Induction Phase:~Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given]."
3041048|NCT00441142|Experimental|Phase I + Phase II: Arm B (RT + TMZ + Vandetanib)|"The Induction Phase:~ZD6474 (Vandetanib) daily (to begin 5-7 days prior to starting participant's RT) Temozolomide (75 mg/m2 daily for 6 weeks) with concurrent fractionated radiation therapy for approximately 6 weeks (XRT must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy), followed by 4-6 weeks rest.~Followed by the Maintenance Phase:~12 cycles of adjuvant temozolomide [at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle; if 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given].~ZD6474 (Vandetanib) daily for the twelve (12) 28-day cycles of adjuvant temozolomide, with the option to continue until participant experiences an unacceptable toxicity or his/her tumor progresses."
3041049|NCT00441168|Active Comparator|VAD Treatment|vincristine in combination with adriamycin and dexamethasone
3041050|NCT00441168|Experimental|PAD Treatment|bortezomib in combination with adriamycin and dexamethasone
3041051|NCT00441259|Experimental|JE-CV Group|Participants will receive Japanese encephalitis chimeric virus vaccine (JE-CV)
3041052|NCT00441259|Active Comparator|MBDV Group|Participants will receive the mouse brain-derived vaccine (MBDV)
3041053|NCT00441285|Active Comparator|I. ABZ + ABZ Placebo + PZQ|Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
3041054|NCT00441285|Active Comparator|II.- ABZ + ABZ Placebo + PZQ Placebo|Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
3041055|NCT00441285|Active Comparator|III .- Albendazole + PZQ Placebo|"Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward."
3041056|NCT00441337|Experimental|0.3 mg/kg MDX-1106 drug|0.3 milligrams (mg) MDX-1106 drug (nivolumab) per kilogram (kg) of body weight (mg/kg) was administered in a single intravenous (IV) infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3041057|NCT00441337|Experimental|1 mg/kg MDX-1106 drug|1 mg MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3041058|NCT00441337|Experimental|3 mg/kg MDX-1106 drug|3 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3041059|NCT00441337|Experimental|10 mg/kg MDX-1106 drug|10 mgs MDX-1106 drug (nivolumab) per kg of body weight (mg/kg) was administered in a single IV infusion. If criteria were met, 2 additional doses could be administered (1 every 4 weeks).
3041060|NCT00441350|Active Comparator|OM 40|Olmesartanmedoxomil (OM)40 mg tablets.
3041061|NCT00441350|Experimental|OM/HCTZ 40/12.5|Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets.
3041062|NCT00441363|Active Comparator|Bromocriptine Mesylate|Bromocriptine mesylate 0.8 mg
3041063|NCT00441363|Placebo Comparator|Placebo|Bromocriptine mesylate 0.8 mg matching placebo
3041064|NCT00441441|Experimental|Fluticasone propionate/salmeterol 100/50 HFA|Fluticasone propionate/salmeterol 100/50 HFA (2 inhalations of 50/25mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate 100mcg HFA inhaler (2 inhalations) twice daily
3041065|NCT00441441|Experimental|Fluticasone propionate 100mcg HFA|Fluticasone propionate 100mcg HFA (2 inhalations of 50mcg), twice daily (strengths are ex-valve) and a placebo HFA inhaler matching the fluticasone propionate/salmeterol 100/50 HFA inhaler (2 inhalations ) twice daily
3041066|NCT00441467|Experimental|Glufosfamide|Glufosfamide
3041067|NCT00441480|Active Comparator|Plant sterol esters|plant sterols esterified to fish oil fatty acids
3041068|NCT00441480|Placebo Comparator|placebo|Corn oil
3041069|NCT00441545|Experimental|1|Fosrenol (Lanthanum carbonate)
3041070|NCT00441545|Active Comparator|2|Sevelamer hydrochloride
3041071|NCT00441558|Experimental|flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
3041072|NCT00441584|Experimental|PegIntron plus Rebetol|PegIntron 1.5 μg/kg/week plus Rebetol 800-1400 mg/day administered for 48 weeks
3041073|NCT00441701|Experimental|Part 1: Navarixin 3 mg|Cohort 1: Participants receive navarixin 3 mg (three 1 mg capsules) once daily (QD) for up to 12 weeks
3041074|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 3 mg|Cohort 1: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3041075|NCT00441701|Experimental|Part 1: Navarixin 10 mg|Cohort 2: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
3041076|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 10 mg|Cohort 2: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3041077|NCT00441701|Experimental|Part 1: Navarixin 30 mg|Cohort 3: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
3041078|NCT00441701|Placebo Comparator|Part 1: Placebo to navarixin 30 mg|Cohort 3: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3041079|NCT00441701|Experimental|Part 2: Navarixin 3 mg|Cohort 4: Participants receive navarixin 3 mg (three 1 mg capsules) QD for up to 12 weeks
3041080|NCT00441701|Experimental|Part 2: Navarixin 10 mg|Cohort 4: Participants receive navarixin 10 mg (one 10 mg capsule and two placebo capsules) QD for up to 12 weeks
3041081|NCT00441701|Experimental|Part 2: Navarixin 30 mg|Cohort 4: Participants receive navarixin 30 mg (three 10 mg capsules) QD for up to 12 weeks
3132576|NCT03438396|Experimental|Single arm|tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)
3041082|NCT00441701|Placebo Comparator|Part 2: Placebo to navarixin|Cohort 4: Participants receive placebo to navarixin (three capsules) QD for up to 12 weeks
3041083|NCT00441727|Experimental|Esomeprazole 40 mg|Esomeprazole 40 mg
3041084|NCT00441727|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg
3041085|NCT00441727|Placebo Comparator|Placebo|Placebo
3041086|NCT00441766|Experimental|AGN 203818 3 mg|Part A: AGN 203818 3mg capsule every 12 hours for 4 weeks
3041087|NCT00441766|Experimental|AGN 203818 20 mg|Part A: AGN 203818 20mg capsule every 12 hours for 4 weeks
3041088|NCT00441766|Experimental|AGN 203818 60 mg|Part A: AGN 203818 60mg capsule every 12 hours for 4 weeks
3041089|NCT00441766|Placebo Comparator|Placebo|Part A: Placebo capsule every 12 hours for 4 weeks
3041090|NCT00441792|Experimental|Etomidate|
3041091|NCT00441792|Experimental|midazolam|
3041092|NCT00441883|Experimental|PF-03187207 and Latanoprost Vehicle|One drop of each, once daily in study eye for 28 days
3041093|NCT00441883|Active Comparator|Latanoprost 0.005% and PF-03187207 Vehicle|One drop of each, once daily in study eye for 28 days
3041094|NCT00441974|Experimental|Single arm adefovir dipivoxil|adefovir dipivoxil once daily orally 10 mg
3041095|NCT00442013|Experimental|Lansoprazole|Participants in this group will receive lansoprazole on a daily basis for 6 months. There are two doses of Lansoprazole solutab provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
3041096|NCT00442013|Placebo Comparator|Matching placebo|Participants in this group will receive a matching placebo on a daily basis for 6 months. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
3041097|NCT00442117|Experimental|MF-DPI|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
3041098|NCT00442117|Active Comparator|BUD-DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
3041099|NCT00442169|Experimental|Group 1: WN02 Low Dose (Part 1)|Low Dose in healthy adults in Part 1 against a placebo control.
3041100|NCT00442169|Experimental|Group 2: WN02 Medium Dose (Part 1)|Medium dose level in part one healthy subjects against a placebo control.
3041101|NCT00442169|Experimental|Group 3: WN02 High Dose (Part 1)|High dose level in part one healthy subjects against a placebo control
3041102|NCT00442169|Placebo Comparator|Group 4: Placebo (Part 1)|Participants will receive a single dose of saline in Part 1 on Day 0
3041103|NCT00442169|Experimental|Group 5: WNO2 High Dose (Part 2)|Participants enrolled in Part 2 and received a single dose of West Nile Virus vaccine.
3041104|NCT00442169|Placebo Comparator|Group 6: Placebo (part 2)|Participants will receive a single dose of saline in Part 2 on Day 0
3041105|NCT00442286|Experimental|On|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
3041106|NCT00442286|Experimental|Off|Subject will be randomized to a 2:1 allocation to the Rheos ON or OFF arms at the time of Rheos System activation (time point 0). After the six month follow up evaluation, all subjects will have therapy activated, though subjects and treating physicians will not be informed of randomized treatment assignment.
3041107|NCT00442338|Experimental|Montelukast 7 mg|Montelukast 7 mg IV administration
3041108|NCT00442338|Experimental|Montelukast 14 mg|Montelukast 14 mg IV administration
3041109|NCT00442338|Active Comparator|Aminophylline 250 mg|Aminophylline 250 mg IV drip administration
3041110|NCT00442364|Experimental|1|Polidocanol (1%) Microfoam (Varisolve)
3041111|NCT00442416|Experimental|RO0503821|Eligible participants will be administered RO0503821 (methoxy polyethylene glycol-epoetin beta [Mircera]) subcutaneously (SC) every month for eight months (6 months of titration period [TP] and two months of evaluation period [EP] and 15-days following the final study visit (9 months post randomization). The first dose of Mircera (120, 200, or 360 mcg) will be based upon the dose of epoetin alfa received 1 to 2 weeks prior to administration of study drug, while subsequent doses will be adjusted to maintain haemoglobin (Hb) concentrations within target of >=10.0 gram per decilitre (g/dL) and <=12.0 g/dL. Participants who self-administered/visited to clinics for erythropoiesis stimulating agent (ESA) dosing prior to randomization will continue to do so.
3041112|NCT00442416|Active Comparator|Epoetin Alfa|Eligible participants will be administered epoetin alfa SC as per the standard of care for eight months (TP and EP), and will be followed-up for 15 days following the final study visit. Participants who self-administered/visited to clinics for ESA dosing prior to randomization will continue to do so.
3041113|NCT00442468||All participants|This is a cross-sectional, non-interventional study. All enrolled subjects were asked to complete a questionnaire and pulmonary function test to assess the prevalence of airflow obstruction.
3041114|NCT00442507|Experimental|1|Patients will be treated with erlotinib 150 mg oral daily and Avastin 15 mg/kg intravenously each cycle of therapy (each cycle is 21 days or every 3 weeks). The first infusion of Avastin will be administered over 90 minutes. If tolerated, the second infusion will be given over 60 minutes and in 30 minutes for the subsequent treatments. Treatment will be administered until disease progression or intolerable side effects.
3178888|NCT00666744|No Intervention|2|Participants in this group will receive routine exercise therapy following stroke
3178889|NCT00666770|Experimental|Gabapentin 250 mg|
3178890|NCT00666770|Experimental|Gabapentin 500 mg|
3041118|NCT00442559|Experimental|Montelukast|Participants were treated for 12 months after randomization: Participants 2 to 5 years of age took one 4 mg chewable tablet and 6 to 14 years of age took one 5 mg chewable tablet daily in the evening. If participants had exacerbated from mild to moderate within 12 weeks, inhaled corticosteroids (ICS) was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
3041119|NCT00442559|Active Comparator|Inhaled Corticosteroids (ICS)|Participants were treated for 12 months after randomization: Each participant's physician selected the ICS agent, dose, and regimen. If participants had exacerbated from mild to moderate within 12 weeks, ICS was added to Montelukast and ICS, respectively and those participants were excluded in the efficacy evaluation at 12 weeks.
3041120|NCT00442572|Experimental|PEGASYS|Participants received 4 treatment cycles of continuous intermittent treatment with PEGASYS® (Peginterferon alfa-2a) . Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
3041121|NCT00442572|No Intervention|No Intervention|Participants were on non- specific anti-viral treatment.
3041122|NCT00442598|Experimental|Glufosfamide q21 days|1-hour infusion of glufosfamide at a dose of 5,000 mg/m2 on Day 1 of a 21-day cycle
3041123|NCT00442598|Experimental|Glufosfamide q7 days low|1-hour infusion of glufosfamide at a dose of 1,660 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
3041124|NCT00442598|Experimental|Glufosfamide q7 days high|1-hour infusion of glufosfamide at a dose of 2,500 mg/m2 on Days 1, 8 and 15 of a 21-day cycle
3041125|NCT00442611|Experimental|Abatacept|Abatacept (dosed based upon weight) administered intravenously (IV) on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
3041126|NCT00442611|Placebo Comparator|IV fluid|Placebo to match abatacept (IV fluid) administered on days 1, 15, 30 and monthly thereafter for a total of 7 doses.
3041127|NCT00442689|Experimental|1|oral contraceptive (35 mg ethinyl estradiol)
3041128|NCT00442689|Experimental|2|Flutamide 250 mg twice daily
3041129|NCT00442689|Placebo Comparator|3|Placebo
3041130|NCT00442702|Experimental|Mircera|Participants received Mircera by subcutaneous injection once every month during the dose titration (7 months) and evaluation period (2 months). The starting dose was based on the weekly dose of darbepoetin alfa administered prior to the switch to Mircera, and was either 120, 200 or 360 µg Mircera per month. The dose was then adjusted to maintain Hemoglobin levels within the defined target range and also according to the need for red blood cell transfusions (due to worsening anemia), or for toxicity related to Mircera.
3041131|NCT00442702|Active Comparator|Darbepoetin alfa|Participants continued to receive the same dose of darbepoetin alfa as before screening by subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling during the dose titration (7 months) and the evaluation period (2 months).
3041132|NCT00442767|Active Comparator|Rapid acting Insulin therapy - before meal|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal
3041133|NCT00442767|Experimental|Pre-meal Pramlintide and Post-meal Insulin therapy|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
3041134|NCT00442897|Experimental|1|
3041135|NCT00442897|Active Comparator|2|
3041136|NCT00442936|Experimental|Telcagepant 150 mg|Participants receive telcagepant 150 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 150 mg or placebo) or one dose of non-study rescue medication.
3041137|NCT00442936|Experimental|Telcagepant 300 mg|Participants receive telcagepant 300 mg capsules, one capsule administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (telcagepant 300 mg or placebo) or one dose of non-study rescue medication.
3041138|NCT00442936|Active Comparator|Zolmitriptan 5 mg|Participants receive zolmitriptan 5 mg tablets, one tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
3041139|NCT00442936|Placebo Comparator|Placebo|Participants receive placebo matching capsules or tablets, one capsule or tablet administered orally at initial onset of moderate to severe migraine headache. If, after 2 hours post-dose, participants still have a moderate to severe migraine or migraine recurs, participants may receive an optional second dose of study drug (placebo) or one dose of non-study rescue medication.
3041140|NCT00442962|Experimental|EFV + FTC/TDF|Participants will efavirenz (600mg in pill form, taken orally, once daily) and emtricitabine/tenofovir disoproxil fumarate (200/300mg in pill form, taken orally, once daily), for 48 weeks
3041141|NCT00443053|Active Comparator|Fondaparinux 2.5mg|
3041142|NCT00443053|Placebo Comparator|Placebo|
3041143|NCT00443079|Experimental|Siliphos/Placebo|Received study medication first followed by placebo
3041144|NCT00443079|Experimental|Placebo/Siliphos|Received placebo first followed by study medicaiton
3041145|NCT00443118|Active Comparator|Neopuff TM with PEEP|Newborns ventilated for neonatal resuscitation using Neopuff TM with PEEP
3041146|NCT00443118|Active Comparator|Self Inflating Bag with PEEP|Newborns ventilated for neonatal resuscitation using Self Inflating Bag with PEEP valve attached
3041147|NCT00443118|Active Comparator|Self Inflating Bag without PEEP|Newborns ventilated for neonatal resuscitationusing Self Inflating Bag without PEEP valve attached
3041148|NCT00443209|Experimental|Telcagepant 280 mg/300 mg|Participants receive telcagepant 300 mg soft gel capsules or telcagepant 280 mg tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of telcagepant, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of telcagepant per month for up to 18 months.
3041149|NCT00443209|Active Comparator|Rizatriptan 10 mg|Participants receive rizatriptan tablets, administered orally as a single dose at onset of migraine. If still experiencing a migraine 2 hours after the first dose of rizatriptan, participants may take an optional second dose of study drug or non-study rescue medication. Participants may take up to 16 doses (for treatment of up to 8 migraines) of rizatriptan per month for up to 18 months.
3041150|NCT00443261|Experimental|1 (SCCHN)|Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Patients will receive Azacitidine and cisplatin.
3041151|NCT00443352|Experimental|Duloxetine|Duloxetine 120mg daily for 12 weeks.
3041152|NCT00443430|Active Comparator|Methotrexate Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus placebo etanercept and placebo prednisolone
3178891|NCT00666770|Placebo Comparator|Placebo|
3041153|NCT00443430|Active Comparator|Methotrexate-Etanercept-Prednisolone Arm|Methotrexate 0.5 mg/kg given by subcutaneous injection once per week, plus etanercept 0.8 mg/kg given by subcutaneous injection once per week, plus prednisolone by mouth daily with decreasing dose tapered over 16 weeks
3041154|NCT00443456|Experimental|Single|
3041155|NCT00443534|Experimental|1|
3041156|NCT00443547||1-level|Patients needing a single level cervical fusion with Vectra-T
3041157|NCT00443547||2-level|Patients needing cervical fusion at two consecutive levels with Vectra-T
3041158|NCT00443547||3-level|Patients needing cervical fusion at three consecutive levels with Vectra-T
3041159|NCT00443547||4-level|Patients needing cervical fusion at four consecutive levels with Vectra-T
3041160|NCT00443560||Instrumental Vaginal Delivery (IVD)|Instrumental vaginal delivery (IVD) is attempted to prevent fetal hypoxia if the second stage of labor is prolonged. It includes forceps and vacuum extractions.
3041161|NCT00443560||Spontaneous Vaginal Delivery (SVD)|The control group consisted of parturients who had a spontaneous vaginal delivery (SVD)in the same 24 hour period who were case-matched for gravidity and parity.
3041162|NCT00443599|Experimental|Insulin|Insulin was infused to target a blood glucose concentration of 80-110 mg/dL
3041163|NCT00443599|Active Comparator|Usual Care|Insulin was infused according to the discretion of the treating clinical team.
3041164|NCT00443651|Experimental|Rituximab 1000 mg (Stage I patients)|Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
3041165|NCT00443651|Experimental|Rituximab 500 mg (Stage II patients)|Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
3041166|NCT00443703|Experimental|1|Arm 1: MK0518 (raltegravir) + placebo to KALETRA™ (lopinavir (+) ritonavir )
3041167|NCT00443703|Active Comparator|2|Arm 2: KALETRA™ (lopinavir (+) ritonavir) + placebo to MK0518 (raltegravir)
3041168|NCT00443729|Experimental|1|Raltegravir & Placebo
3041169|NCT00443729|Active Comparator|2|Lopinavir (+) Ritonavir & Placebo
3041170|NCT00443755|Active Comparator|Insulin Sensitizer Therapy|Two insulin sensitizing drugs will be taken together for 3 months; metformin 1000 mg twice daily plus pioglitazone 45 mg daily.
3041171|NCT00443755|Placebo Comparator|Placebo|Placebo tablets were used to match the active comparator drugs and dosing regimen.
3041172|NCT00443781|Other|PD and F.A.D. diagnostic testing|
3041173|NCT00443820|Experimental|1|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks
3041174|NCT00443820|Placebo Comparator|2|Vehicle (placebo) for 48 weeks
3041175|NCT00443820|Experimental|3|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks
3041176|NCT00443820|Placebo Comparator|4|Vehicle (placebo) for 24 weeks
3041177|NCT00443846|Experimental|Group 1: Concomitant Administration|Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).
3041178|NCT00443846|Active Comparator|Group 2: Sequential Administration|Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.
3041179|NCT00443872|Other|orally disintegrating selegiline|This is a one arm open label study of patients who are experiencing a dopamine agonist (DA) related adverse effects (AE) of either one or more of the following: excessive daytime sleepiness, hallucinations, pedal edema, impulse control disorder. All subjects received orally disintegrating selegiline.
3041180|NCT00443898|Experimental|1|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 48 weeks
3041181|NCT00443898|Placebo Comparator|2|vehicle (placebo) applied once daily for 48 weeks
3041182|NCT00443898|Experimental|3|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) applied once daily for 24 weeks
3041183|NCT00443898|Placebo Comparator|4|vehicle (placebo) applied once daily for 24 weeks
3041184|NCT00444028|Experimental|Cohort A: Inhaled Loxapine 0.625 mg or Placebo|Single 0.625 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
3041185|NCT00444028|Experimental|Cohort B: Inhaled Loxapine 1.25 mg or Placebo|Single 1.25 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
3041186|NCT00444028|Experimental|Cohort C: Inhaled Loxapine 2.5 mg or Placebo|Single 2.5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
3041187|NCT00444028|Experimental|Cohort D: Inhaled Loxapine 5 mg or Placebo|Single 5 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
3041188|NCT00444028|Experimental|Cohort E: Inhaled Loxapine 10 mg or Placebo|Single 10 mg dose of inhaled loxapine or Single Placebo dose of inhaled loxapine
3041189|NCT00444067|Experimental|Spinal Sealant System|Spinal Sealant System
3041190|NCT00444067|Active Comparator|Standard of Care|Standard of care methods as an adjunct to sutured dural repair
3041191|NCT00444080|Active Comparator|Control Arm|Subjects undergoing trabeculectomy with the use of Mitomycin C
3041192|NCT00444080|Experimental|Treatment Arm|Subjects undergoing Ex-PRESS Under Scleral Flap implantation procedure with the use of Mitomycin C
3041193|NCT00444106|Experimental|Artemether-lumefantrine (Coartem)|Artemether-lumefantrine (Coartem) tablets containing 20 mg artemether and 120 mg lumefantrine twice a day for 3 days, dosage dependent on body weight.
3041194|NCT00444106|Active Comparator|Atovaquone-proguanil (Malarone)|Atovaquone-proguanil (Malarone) tablets containing 250 mg atovaquone and 100 mg proguanil hydrochloride once daily for 3 days, dosage dependent on body weight.
3041195|NCT00444106|Active Comparator|Artesunate-mefloquine|Artesunate-mefloquine tablets containing 50 mg artesunate (Plasmotrim) and 250 mg mefloquine (Mephaquin). Artesunate 4 mg/kg/day (for 3 days) and mefloquine 25 mg/kg/day (days 2 and 3) total dose was given once daily dependent upon body weight.
3041196|NCT00444145|Experimental|Patients with documented GERD or laryngopharyngeal reflux|Patients who have documented GERD as evidenced by erosive esophagitis or those patients who have newly diagnosed laryngopharyngeal reflux as diagnosed by endoscopy.
3041197|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (initial phase)|
3041198|NCT00444275|Experimental|Esomeprazole 40 mg Once Daily (initial phase)|
3041199|NCT00444275|Experimental|Esomeprazole 20 mg Once Daily (Maintenance Phase)|
3041200|NCT00444275|Experimental|Esomeprazole 20 mg on Demand (Maintenance Phase)|
3041201|NCT00444275|Experimental|Antacid Treatment (Maintenance Phase)|
3041202|NCT00444457|Experimental|1|
3041203|NCT00444457|Experimental|2|
3041204|NCT00444457|Experimental|3|
3041205|NCT00444457|Active Comparator|4|
3041206|NCT00444535|Experimental|Oral lapatinib tablets in combination with IV bevacizumab|1500 mg oral lapatinib (once daily) plus 10 mg/kg intravenous bevacizumab (every two weeks)
3041207|NCT00444587|Experimental|Trastuzumab + 2nd Line Chemotherapy|
3041208|NCT00444587|Active Comparator|Only Chemotherapy|
3041209|NCT00444600|Experimental|0.5mg Ranibizumab plus laser|
3041210|NCT00444600|Experimental|0.5 mg Ranibizumab plus deferred laser|
3041211|NCT00444600|Experimental|4 mg Triamcinolone plus laser|
3041212|NCT00444600|Active Comparator|Sham plus laser|
3041213|NCT00444626|Experimental|DGE|Participants received DGE in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period. Participants who continued into the Repeat Treatment period were treated with DGE as an open-label treatment.
3041214|NCT00444626|Active Comparator|Restylane|Participants received Restylane in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period.
3041215|NCT00444678|Experimental|Cetuximab, Capecitabine and Oxaliplatin|
3041216|NCT00444795||1|patients diagnosed as GIST after disease progression on or intolerance to imatinib mesylate
3041217|NCT00444795||2|patients diagnosed as advanced RCC
3041218|NCT00444795||3|patients diagnosed as unresectable, well-differentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma
3041219|NCT00444821|No Intervention|Surveillance|
3041220|NCT00444821|Experimental|Early Endovascular Repair|
3041221|NCT00444912|Experimental|G-CSF plus plerixafor|Participants with CD20- lymphoma
3041222|NCT00444912|Experimental|G-CSF plus plerixafor and rituximab|Participants with CD20+ lymphoma
3041223|NCT00444925|Experimental|Fesoterodine|Tablets
3041224|NCT00444925|Placebo Comparator|Placebo|Tablets and capsules
3041225|NCT00444925|Active Comparator|Tolterodine|Capsules
3041226|NCT00444951|Experimental|Menactra® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
3041227|NCT00444951|Experimental|Mencevax® group|Have received previously a dose of an A, C, Y, W 135 and at least one dose of bivalent A, C meningococcal polysaccharide vaccine, will receive a booster dose of Mencevax ACWY (serogroups A, C, Y, W-135) polysaccharide meningococcal vaccine.
3041228|NCT00444951|Experimental|Control group|Participants have not previously received any meningococcal vaccine, will receive a booster dose of Menactra® (Meningococcal [serogroups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate) vaccine.
3041229|NCT00444964|Experimental|Primary Cohort|Nutropin AQ
3041230|NCT00445003|Experimental|Sham injection plus laser|Sham injection at baseline and 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3041231|NCT00445003|Experimental|0.5mg Ranibizumab plus laser|Intravitreal injections of 0.5mg Ranibizumab at baseline and at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3041232|NCT00445003|Active Comparator|4-mg Triamcinolone Acetonide plus Laser|4-mg Triamcinolone Acetonide at baseline and sham injection at 4 weeks. Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
3041233|NCT00445068|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week on days: 1, 3 and 5, then 8, 10 and 12, then 15, 17 and 19 of each cycle, as part of a 3-week (21 days) treatment cycle. Participants could continue treatment until disease progression or unacceptable toxicity.
3041234|NCT00445146|Experimental|EVG+RTV|"EVG 85 mg or 150 mg + RTV + ARV regimen~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their ARV regimen will receive EVG 85 mg and all other participants will receive EVG 150 mg.~Some participants may receive EVG 300 mg during the course of protocol amendment 2."
3041235|NCT00445211|Active Comparator|Intra-Aortic balloon Pump with Heparin|Intra-Aortic Balloon Pump (IABP) with Heparin
3041236|NCT00445211|Active Comparator|Intra-Aortic balloon Pump without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin
3041237|NCT00445224|Experimental|Hip Progressive Resistive Exercises|Exercises targeting hip musculature such as hip abduction and hip external rotation that was progressed by increased resistance following typical progressive resistive exercise approach.
3041238|NCT00445224|Active Comparator|Quad Progressive Resistive Exercises|Exercises targeting quadriceps musculature such as quadriceps isometric setting, terminal knee extensions, and straight leg raises that was progressed by increased resistance following typical progressive resistive exercise approach..
3041239|NCT00445263|Experimental|Early Invasive strategy|Tirofiban and coronarography within 6 hours
3041240|NCT00445263|Active Comparator|Delayed invasive strategy|Coronarography after 6 hours
3041241|NCT00445302|Active Comparator|Normal renal function|Participants with normal renal function (creatinine clearance (CLcr) > 90 ml/min) who serve as the study control. Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3041242|NCT00445302|Experimental|Mild renal impairment|Participants have mild renal impairment (creatinine clearance (CLcr) = 51 to 80 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3041243|NCT00445302|Experimental|Moderate renal impairment|Participants have moderate renal impairment (creatinine clearance (CLcr) = 31 to 50 mL/min). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3041244|NCT00445302|Experimental|Severe renal impairment|Participants have severe renal impairment (creatinine clearance (CLcr) < 31 mL/min, not requiring dialysis). Participants treated with one dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection.
3041245|NCT00445315|Experimental|2|
3041246|NCT00445315|Experimental|3|
3041247|NCT00445315|Experimental|1|
3041248|NCT00445315|Experimental|4|
3041249|NCT00445315|Placebo Comparator|5|
3041250|NCT00445328|Active Comparator|B|
3041251|NCT00445328|Experimental|A|
3041252|NCT00445341|Experimental|Flavopiridol in lymphoma patients|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
3041253|NCT00445432|Experimental|DB Adalimumab 40 mg eow|Subjects received double-blind (DB) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the DB treatment period lasting 52 weeks.
3041254|NCT00445432|Placebo Comparator|Placebo eow|Subjects received placebo subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
3041255|NCT00445432|Experimental|OL Adalimumab 40 mg eow|Subjects received open-label (OL) 40 mg adalimumab subcutaneously (SC) every other week (eow) during the double-blind treatment period lasting 52 weeks.
3041256|NCT00445458|Experimental|HKI-272 dose level 1|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 160 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3041257|NCT00445458|Experimental|HKI-272 dose level 2|Part 1: Subjects with solid tumors receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3041258|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm A|Part 2: Subjects with metastatic breast cancer who have not received more than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3041259|NCT00445458|Experimental|HKI-272 expanded MTD cohort, arm B|Part 2: Subjects with metastatic breast cancer who have not received more than 3 prior cytotoxic chemotherapy treatment regimen for metastatic disease receiving HKI-272 (neratinib) 240 mg daily by mouth in combination with paclitaxel 80 mg/m^2 weekly IV.
3041260|NCT00445484|Experimental|Group 1|Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
3041261|NCT00445484|Experimental|Group 2|Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).
3041262|NCT00445549|Experimental|Vandetanib treatment|300 mg daily oral dose, 28 day cycle
3041263|NCT00445588|Experimental|Treatment|"Patients receive oral erlotinib hydrochloride 150mg once daily and oral sorafenib tosylate 400mg twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study"
3041264|NCT00445601|Experimental|Arm I|Patients receive intravesical gemcitabine hydrochloride over 1 hour.
3041265|NCT00445601|Placebo Comparator|Arm II|Patients receive intravesical placebo over 1 hour.
3041266|NCT00445679|Experimental|A|DVS SR 50mg/day
3041267|NCT00445679|Experimental|B|DVS SR 100mg/day
3041268|NCT00445679|Experimental|C|DVS SR 200mg/day
3041269|NCT00445679|Active Comparator|D|Paroxetine 20mg/day
3041270|NCT00445692|Experimental|Treatment (clarithromycin, dexamethasone, lenalidomide)|"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.~NOTE: *After one year of treatment, dexamethasone is tapered for an additional 4 weeks."
3041271|NCT00445705|Placebo Comparator|Placebo|Part A: Placebo every 12 hours for 4 weeks
3041272|NCT00445705|Experimental|AGN 203818 3 mg|Part A: 3 mg AGN 203818 every 12 hours for 4 weeks
3041273|NCT00445705|Experimental|AGN 203818 20 mg|Part A: 20 mg AGN 203818 every 12 hours for 4 weeks
3041274|NCT00445705|Experimental|AGN 203818 60 mg|Part A: 60 mg AGN 203818 every 12 hours for 4 weeks
3041275|NCT00445744|Experimental|Treatment (cyclophosphamide, busulfan, transplant)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV on days -7 and -6 and busulfan IV over 3 hours on days -5 to -2.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV or PO twice daily on days -1 to 200 with taper on day 56 and methotrexate on days 1, 3, 6, and 11."
3041276|NCT00445770|Experimental|1|
3041277|NCT00445770|Experimental|2|
3041278|NCT00445770|Active Comparator|3|
3041279|NCT00445848|Experimental|Erlotinib and Bevacizumab|
3041280|NCT00445887|Experimental|Arm I (levonorgestrel)|Patients receive oral levonorgestrel once daily.
3041281|NCT00445887|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily.
3041282|NCT00445939|Experimental|Adalimumab 160 mg/80 mg|
3041283|NCT00445939|Experimental|Adalimumab 80 mg/40 mg|
3041284|NCT00445939|Placebo Comparator|Placebo|
3041285|NCT00445978|Experimental|Sapropterin dihydrochloride|2.5, 5, 10, 20 mg/kg/day of sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks, with an optional extension phase at the highest tolerated dose for up to a total of 2 years.
3041286|NCT00446030|Experimental|Stratum 1: TAC + Bevacizumab|"Human epidermal growth factor receptor-2 (HER2) negative participants stratified at registration, were administered chemotherapy with docetaxel, doxorubicin and cyclosphosphamide (TAC) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
3041287|NCT00446030|Experimental|Stratum 2: TCH + Bevacizumab|"HER2 positive participants stratified at registration, were administered chemotherapy with docetaxel, carboplatin and trastuzumab (TCH) + bevacizumab for Cycles 1-6 (every 3 weeks), and followed with maintenance therapy with bevacizumab and trastuzumab every 3 weeks for a total of 52 weeks.~All participants were administered prophylactic recombinant Granulocyte Colony Stimulating Factor (G-CSF) during chemotherapy, based on a dose recommended by the manufacturer. For participants with estrogen receptor (ER) or progesterone receptor (PR) positive tumors, anti-estrogen therapy was recommended. Participants could receive radiation therapy at the discretion of the treating medical and radiation oncologist."
3041288|NCT00446095|Experimental|fostamatinib|
3041289|NCT00446134|Experimental|Group 1: Drug|Oral taribavirin tablet 20 mg/kg/day (Actual doses were 20-24 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3041290|NCT00446134|Experimental|Group 2: Drug|Oral taribavirin tablet 25 mg/kg/day (Actual doses were 25-29 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3041291|NCT00446134|Experimental|Group 3: Drug|Oral taribavirin 30 mg/kg/day (Actual doses were 30-34 mg/kg/day) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3041292|NCT00446134|Active Comparator|Group 4: Drug|Oral ribavirin 800 mg/day (body weight <65 kg), 1000 mg/day (body weight 65-84 kg), 1200 mg/day (body weight 85-104 kg) or 1400 mg/day (body weight greater than or equal to 105 kg) BID plus weekly subcutaneous injections of peginterferon alfa-2b (1.5 ug/kg/wk)
3041293|NCT00446147|Placebo Comparator|Placebo|one tablet twice per day, which is identical to pyridoxine
3041294|NCT00446147|Experimental|Pyridoxine|100 mg twice per day
3041295|NCT00446199|Experimental|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
3041296|NCT00446199|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
3041297|NCT00446199|Experimental|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
3041298|NCT00446199|Placebo Comparator|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
3041299|NCT00446264|Experimental|islet transplantation|Each participant received up to three sequential fresh islet infusions within three months.
3041300|NCT00446290|Experimental|Docetaxel, Capecitabine and Oxaliplatin|
3041301|NCT00446446|Experimental|Panitumumab|articipants received panitumumab as an intravenous infusion at a dose of 9 mg/kg every 21 days until disease progression, unacceptable toxicity, withdrawal of consent, death, or end of study.
3041302|NCT00446511|Experimental|CKD patients: Valsartan+enalapril|
3041303|NCT00446511|Active Comparator|CKD patients: Enalapril|
3041304|NCT00446511|Experimental|Non-CKD patients: Valsartan|
3041305|NCT00446511|Active Comparator|Non-CKD patients: Enalapril|
3041306|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 1|For the first 2 weeks, afegostat tartrate was administered orally at a dose of 225 milligrams (mg) once daily (QD) for 7 consecutive days, followed by no study medication for 7 consecutive days. After 2 weeks, participants then took 225 mg afegostat tartrate QD for 3 consecutive days, followed by no study medication for 4 consecutive days. This 3-days-on/4-days-off treatment regimen was followed for 22 weeks.
3041307|NCT00446550|Experimental|Afegostat Tartrate Treatment Regimen 2|Afegostat tartrate was administered orally at a dose of 225 mg QD for 7 consecutive days, followed by no study medication for 7 consecutive days. This 7-days-on/7-days-off treatment regimen was followed for 24 weeks.
3041308|NCT00446563|Experimental|Amlodipine + Valsartan|Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
3041309|NCT00446563|Active Comparator|Losartan + Hydrochlorothiazide|Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
3041310|NCT00446641|Experimental|1 Cilostazol|100mg of Cilostazol twice a day
3041311|NCT00446641|Placebo Comparator|Placebo|matching placebo to cilostazol
3041312|NCT00446654|Experimental|CGC-11047 once every 2 weeks|16.5 mg CGC-11047 as a subconjunctival injection once every two weeks.
3041313|NCT00446654|Experimental|CGC-11047 once every four weeks|16.5 mg CGC-11047 as a subconjunctival injection once every four weeks.
3041314|NCT00446797|Active Comparator|Non-Selective NSAIDS|nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.
3041315|NCT00446797|Experimental|Celecoxib|
3041316|NCT00446849|Experimental|MMX Mesalamine|
3041317|NCT00446966|Experimental|fish oil , corn oil|Highly purified pharmaceutical grade omega three polyunsaturated fatty acids
3041318|NCT00446966|Placebo Comparator|placebo|olive oil
3041319|NCT00446992|Experimental|Open Trial Group|The patients were newly diagnosed with psychosis and were recruited at their first clinical contact for psychosis.
3041320|NCT00447005|Experimental|Open|
3041321|NCT00447057|Experimental|Pemetrexed (Nonsquamous)|Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
3041322|NCT00447057|Experimental|Pemetrexed + Erlotinib (Nonsquamous)|Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
3041323|NCT00447057|Experimental|Pemetrexed (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed arm
3041324|NCT00447057|Experimental|Pemetrexed + Erlotinib (Squamous)|Group of participants with NSCLC of squamous histology who were assigned to Pemetrexed + Erlotinib arm
3041325|NCT00447083|Experimental|UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with UV. The dose of UV (time of exposure) will be progressively increased from 3 minutes to 9 minutes over the 6 visits to acclimate subjects to UV light. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive UVB tanning bed treatment first, then switch to the non-UVB treatment.
3041326|NCT00447083|Placebo Comparator|Non-UVB First|Subjects with fibromyalgia will undergo 6 tanning sessions (3/week x 2 weeks) at which they will be exposed in tanning beds with non-UV bulbs. The time of exposure will be progressively increased from 3 minutes to 9 minutes over the 6 visits to mirror UVB treatment. Before and after every tanning session the subject will complete the pain questionnaire. Subjects in this group will be randomized to receive non-UVB tanning bed treatment first, then switch to the UVB treatment.
3041327|NCT00447083|Experimental|UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of UVB.
3041328|NCT00447083|Placebo Comparator|Non-UVB|The subjects who complete the acclimation phase of the study will then be randomized to 3 times/week treatments for 6 weeks with a fixed dose (10 min) of non-UVB exposure
3041329|NCT00447122|Experimental|treatment|lapatinib, 1,500 mg/day, and Gemcitabine, 1 gm/m2/week for 3 weeks followed by 1 week off, until disease progression
3041330|NCT00447226|Experimental|Lapatinib Oral Tablets|
3041331|NCT00447226|Placebo Comparator|Placebo Control|
3041332|NCT00447265|Experimental|Etanercept|Participants in this group will self-administer 50 mg etanercept injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
3041333|NCT00447265|Placebo Comparator|Placebo|Participants in this group will self-administer 50 mg placebo injections once a week for 24 weeks. They will continue receiving their usual treatment with corticosteroids and either mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA).
3041334|NCT00447278|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
3041335|NCT00447278|Active Comparator|OEST|Other Early Standard Treatment (OEST): any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
3041336|NCT00447330|Experimental|1|
3041337|NCT00447382|Active Comparator|NN304|Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
3041338|NCT00447382|Experimental|NN729|Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks
3041339|NCT00447499|Experimental|Somatuline Autogel (lanreotide acetate)|Somatuline Autogel (lanreotide acetate) Injection
3041340|NCT00447590|Experimental|LAP-BAND|All subjects who received the LAP-BAND System.
3041341|NCT00447694|Experimental|deferasirox every day for 77 weeks|Participants received Deferasirox 30 milligrams per kilogram per day (mg/kg/day) orally once daily (OD), 30 minutes before breakfast, preferably around the same time every morning if possible. Deferasirox tablets were dropped into water or orange juice, or apple juice and stirred until completely dispersed. For doses less than 1 gram (g), tablets were dissolved in at least 100 milliliter (mL) of liquid; for doses of 1 to 3 g, tablets were dissolved in at least 200 mL. After tablets were fully disintegrated, the liquid was promptly consumed.
3041342|NCT00447772|Experimental|1|
3041343|NCT00447876|Experimental|Botulinum type A toxin (Dysport®)|
3041344|NCT00447876|Placebo Comparator|Placebo|
3041345|NCT00448019|Experimental|FCR + Bevacizumab|FCR = Fludarabine 25 mg/m^2 intravenous (IV) , Cyclophosphamide 250 mg/m^2 IV daily for 3 days, Rituximab 375 mg/m^2 IV Day 1, followed by 500 mg/m^2 IV. FCR daily for 3 days. Bevacizumab 10 mg/Kg IV on Day 3, course 1.
3041346|NCT00448123|Placebo Comparator|Placebo|Placebo
3041347|NCT00448123|Active Comparator|Tamsulosin|Intervention - Tamsulosin
3041348|NCT00448136|Experimental|1|
3041349|NCT00448136|Experimental|2|
3041350|NCT00448175|Experimental|Urgent PC treatment arm|
3041351|NCT00448201|Active Comparator|Methotrexate Only Arm|GVHD Prophylaxis with Methotrexate
3041352|NCT00448201|Active Comparator|2 Doses ATG + Methotrexate|GVHD prophylaxis with antithymocyte globulin (ATG) + Methotrexate
3041353|NCT00448201|Active Comparator|2 Doses ATG|GVHD prophylaxis with 2 doses ATG
3041354|NCT00448201|Active Comparator|3 Doses ATG|GVHD prophylaxis with 3 doses ATG
3041355|NCT00448227|Experimental|Famciclovir|Famciclovir was administered orally as a suspension in OraSweet® on Day 1. Patients received a single, individualized dose between 25-200 mg based on body weight.
3041356|NCT00448279|Active Comparator|Chemotherapy Alone|Chemotherapy, schedule and dose at the investigator's discretion.
3041357|NCT00448279|Experimental|Chemotherapy, Trastuzumab|Trastuzumab, at the investigator's discretion, either 2 milligrams per kilogram (mg/kg) intravenous (i.v.) every 7 days or 6 mg/kg i.v. every 3 weeks. Chemotherapy, schedule and dose at the investigator's discretion.
3041358|NCT00448344|Experimental|Arm 1|Family-supported smoking cessation
3041359|NCT00448344|Other|Arm 2|Standard smoking cessation
3041360|NCT00448357|Experimental|GVHD prophylaxis|"Subjects with matched-related donors (MRDs) were treated with tacrolimus and methotrexate with or without alemtuzumab for graft vs host disease prophylaxis Subjects also receive busulfan and fludarabine .~Matched unrelated donor (MUD) or mismatched related donor (MMRD) subjects receive GVHD prophylaxis with rabbit anti-thymocyte globulin (ATG) + Methotrexate Subjects also receive busulfan, fludarabine, and tacrolimus."
3041361|NCT00448435|Active Comparator|SLM+FP First|SLM(salmeterol) 25mcg + FP(fluticasone propionate) 50mcg twice daily in first intervention period and SFC(salmeterol/fluticasone propionate) 25/50mcg twice daily in second intervention period and (after washout period).
3041362|NCT00448435|Active Comparator|SFC First|SFC (Salmeterol/Fluticasone propionate combination) 25/50mcg twice daily in first intervention period and SLM (Salmeterol) 25mcg + FP (Fluticasone Propionate) 50mcg twice daily in second intervention period (after washout period).
3041363|NCT00448435|Experimental|SFC|SFC (salmeterol/fluticasone propionate combination) 25/50mcg twice daily in Extension period (after cross-over period).
3041364|NCT00448448|Active Comparator|Brace|This study involves full-time, rigid TLSO's only. Braced subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning. Orthotic evaluations are conducted every 6 months as as necessary to maintain brace fit and function.
3041365|NCT00448448|Active Comparator|Observation|Observation. Observed subjects are followed every six months with radiography, clinical exam and self-reported evaluations of health and functioning.
3041366|NCT00448539|Experimental|Rufinamide (Rufinamide During Core Study)|
3041367|NCT00448539|Experimental|Rufinamide (Placebo During Core Study)|
3041368|NCT00448591|Experimental|1|
3041369|NCT00448630||Atypical Antispychotics (or second generation antipsychotics)|Patients with schizophrenia who are currently receiving or are going to start a new treatment with atypical antipsychotics, ziprasidone, risperidone, quetiapine, olanzapine, aripiprazole, amisulpride.
3041370|NCT00448669|Active Comparator|TDF-FTC,condoms,adh/risk counseling|Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
3041371|NCT00448669|Placebo Comparator|Placebo,condoms,adh/risk counseling|Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
3041372|NCT00448708|Experimental|Vascular Wrap and Graft|Lifespan® ePTFE Vascular Graft and Vascular WrapTM Paclitaxel-Eluting Mesh: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access. The Vascular WrapTM Paclitaxel-Eluting Mesh is positioned on the vein and placed around the venous anastomosis to include both the toe and the heel of the anastomosis, and is sutured in place.
3041373|NCT00448708|No Intervention|Lifespan® ePTFE Vascular Graft|Lifespan® ePTFE Vascular Graft Only: The Lifespan® ePTFE Vascular Graft is implanted as an arteriovenous graft in an upper extremity to provide a hemodialysis access.
3041374|NCT00448747|Experimental|AEZS-130 ( formerly ARD-07)|A single oral administration of AEZS-130 (0.5 mg/kg po) as Growth Hormone Stimulation Test
3041375|NCT00448747|Active Comparator|L-ARG+GHRH|This trial was set up as a multi-center, randomized, cross-over study investigating AEZS-130 as a Growth Hormone Stimulation Tests in terms of safety and efficacy compared to L-ARG+GHRH. When GHRH became unavailable on the US market, this comparator arm was no longer available, which was addressed by Amendment No. 3 (version 27-March-2010). Control subject enrolled under Amendment No. 3 were not randomized as there was no cross-over due to unavailability of L-ARG+GHRH. These control subjects received only AEZS-130
3041376|NCT00448760|Experimental|Neoadjuvant + Adjuvant Chemotherapy|
3041377|NCT00448812|Experimental|Alair Treatment|Subjects from PREDECESSOR STUDY (NCT00214526) treated with conventional therapy with ICS+LABA (inhaled corticosteroid + long-acting beta-agonist) plus Bronchial Thermoplasty with the Alair System.
3041378|NCT00448812|No Intervention|Control|Control group subjects from PREDECESSOR STUDY (NCT00214526).
3041379|NCT00448864|Experimental|Ecallantide - Low Dose Regimen|Participants received a maximum of 15 milligrams (mg) ecallantide in stages. Intravenous (IV) infusion of 0.6 milligrams per milliliter (mg/mL) ecallantide was administered at 2.92 milliliters per minute (mL/min) for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of cardiopulmonary bypass (CPB), whichever came first. At the termination of the initial infusion, a second infusion of 0.4 mg/mL ecallantide was started at 38 milliliters per hour (mL/hr) for 4 hours.
3041380|NCT00448864|Experimental|Ecallantide - High Dose Regimen|Participants received a maximum of 91 mg ecallantide in stages. IV infusion of 0.6 mg/mL ecallantide was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, an infusion of normal saline was started at 38 milliliters per hour (mL/hr) for 4 hours.
3041381|NCT00448864|Placebo Comparator|Placebo|Participants received placebo in stages. IV infusion placebo was administered at 2.92 mL/min for 20 minutes. The infusion rate was then reduced to 0.583 mL/min for 160 minutes, or until the end of CPB, whichever came first. At the termination of the initial infusion, a second infusion of placebo was started at 38 mL/hr for 4 hours.
3041382|NCT00448916|Experimental|Pregabalin|Orally-administered pregabalin
3041383|NCT00449007|Active Comparator|1|fluoxetine -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
3041384|NCT00449007|Active Comparator|2|bupropion -- 6 months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention; patients will also be encouraged to attend daily Alcoholics Anonymous meetings
3041385|NCT00449033|Experimental|Sorafenib (Nexavar, BAY43-9006) + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with sorafenib. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: sorafenib 2 tablets (200 mg) taken orally (po) twice daily (bid). If the patient had radiological evidence of stable disease (SD) or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which sorafenib was administered 400 mg bid until criteria for withdrawal were met.
3132577|NCT03438539|Sham Comparator|Attentional Control with Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
3041386|NCT00449033|Placebo Comparator|Placebo + GC|Up to 6 cycles (21 days per cycle) of gemcitabine (G) and cisplatin (C) with placebo. Day 1: gemcitabine 1250 mg/ m^2 infusion (IV), followed by cisplatin 75 mg/ m^2 IV; Day 8: gemcitabine 1250 mg/ m^2 IV; Days 1-21: placebo 2 tablets po bid. If the patient had radiological evidence of SD or better after completing up to 6 cycles in the Chemotherapy Phase, the patient could continue to Maintenance Phase, during which 2 placebo tablets were administered bid until criteria for withdrawal were met.
3041387|NCT00449072|Placebo Comparator|Placebo|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of investigational product (IP) with the nasal spray bottle~Placebo in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
3041388|NCT00449072|Active Comparator|TAA-AQ|"3 to 9 year old participants with Perennial Allergic Rhinitis (PAR) administered~Placebo in the baseline/screening period to demonstrate administration of IP with the nasal spray bottle~Triamcinolone acetonide (TAA-AQ) in the double-blind treatment period~All participants were provided Children's Claritin® Syrup as a rescue medication."
3041389|NCT00449150|Experimental|Treatment Group A: CET 78 mg + 78 mg|"Treatment course 1: Cetrorelix 78 mg + 78 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: 26 mg CET(1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3041390|NCT00449150|Experimental|Treatment Group B: CET 78 mg + 52 mg|"Treatment course 1: Cetrorelix 78 mg + 52 mg~Week 0: 52 mg CET (2 injections)~Week 2: 26 mg CET (1 injection)~Treatment course 2:~Week 26: 52 mg CET (2 injections)~Week 28: Placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3041391|NCT00449150|Placebo Comparator|Treatment Group C: Placebo|"Treatment course 1:~Week 0: placebo (2 injections)~Week 2: placebo (1 injection)~Treatment course 2:~Week 26: placebo (2 injections)~Week 28: placebo (1 injection)~4 days with treatment, Day 1 of each indicated week, 6 injections in total per patient."
3041392|NCT00449163|Experimental|Combination Chemotherapy and Bevacizumab|"Treatment cycle is 6 weeks, 2 weeks of consecutive treatment followed by 1 week of rest and 2 weeks of treatment followed by one week of rest. Treatment will be administered weekly, 4 out 6 weeks, on days 1, 8, 22 and 29:~Bevacizumab: 7.5mg/kg via intravenous (IV) infusion on Days 1 and 22;~Irinotecan: 110 mg/m^2 via IV infusion on Days 1, 8, 22, 29;~Leucovorin: 500 mg/m^2 via IV infusion on Days 1, 8, 22 and 29;~Floxuridine: 120 mg/kg over continuous infusion on Days 1, 8, 22 and 29."
3041393|NCT00449176|Experimental|001|tapentadol (CG5503) ER 50 100 150 200 250 mg twice daily for 15 weeks
3041394|NCT00449176|Active Comparator|002|oxycodone CR 10 20 30 40 50 mg twice daily for 15 weeks
3041395|NCT00449176|Placebo Comparator|003|placebo matching placebo twice daily for 15 weeks
3041396|NCT00449540|Active Comparator|Active Transcranial Magnetic Stimulation (TMS) Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
3041397|NCT00449540|Sham Comparator|Sham TMS Device|Both arms of participants receive identical looking devices and were instructed use the same treatment protocol. Participants in each group were instructed to treat with the device within one hour of onset of migraine aura.
3041398|NCT00449644|Experimental|TMC207 Stage 1|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
3041399|NCT00449644|Placebo Comparator|Placebo Stage 1|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
3041400|NCT00449644|Experimental|TMC207 Stage 2|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
3041401|NCT00449644|Placebo Comparator|Placebo Stage 2|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.
3041402|NCT00449670|Experimental|H5N1 Adjuvanted Group|Subjects received 2 doses of H5N1 adjuvanted split virus vaccine (lot 1, 2, 3 or 4) containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 during Primary Phase. A subset of these subjects (Boosted sub-cohort) received a single dose of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 during Booster Phase. The remaining subjects (Non-Boosted sub-cohort) received a single booster dose at Month 12 or 36 after initial priming in study 111443 (NCT00652743).
3041403|NCT00449670|Active Comparator|H5N1 Un-adjuvanted Group|Subjects received 2 doses of a H5N1 non-adjuvanted split virus vaccine containing A/Vietnam/1194/2004 strain at Day 0 and Day 21 and two booster doses of heterologous H5N1 adjuvanted vaccine containing A/Indonesia/05/2005 strain at Month 6 and Month 6 + 21 days.
3041404|NCT00449696|Experimental|Gel-200|
3041405|NCT00449696|Placebo Comparator|PBS|
3041406|NCT00449748|Experimental|RAD001|Oral 10 mg daily for 30 days
3041407|NCT00449761|Experimental|Panobinostat|Participants received panobinostat 20 milligrams (mg) orally once daily (OD), three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat was administered at the same time each morning, and with an 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue this treatment until an unacceptable toxicity that precludes further treatment was experienced, or until disease progression.
3041408|NCT00449787|Active Comparator|Sumatriptan|Sumatriptan 100 mg tablet
3041409|NCT00449787|Active Comparator|Naproxen|Naproxen 500 mg tablet
3041410|NCT00449865|Placebo Comparator|Placebo|
3041411|NCT00449865|Active Comparator|creatine|
3041412|NCT00449930|Experimental|1|Drug
3041413|NCT00449930|Active Comparator|2|Active comparator
3041414|NCT00449956|Experimental|1|combination of dorzolamide hydrochloride and timolol maleate
3041415|NCT00449956|Active Comparator|2|Concomitant use of dorzolamide hydrochloride and timolol maleate
3041416|NCT00449956|Active Comparator|3|timolol maleate
3041417|NCT00450073|Active Comparator|Vitamin D3|Vitamin D3=cholecalciferol 50,000 IU weekly
3041418|NCT00450073|Active Comparator|vitamin D2|The intervention is an oral tablet of vitamin D2 (ergocaliferol 50,000 IU weekly) for 12 weeks.
3041419|NCT00450073|Active Comparator|Sunlamp|The intervention is the use of a Sunlamp (Sperti) to the skin 5 times a week for 12 weeks
3041420|NCT00450177|Experimental|Iron Group|Ferrous sulfate 325 mg either by capsule or oral solution three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
3041421|NCT00450177|Placebo Comparator|Placebo Group|Placebo capsule three times a day at 9 am, 1pm and 5 pm until hospital discharge or for 42 days, whichever occurs first.
3041422|NCT00450190|Experimental|Saizen® E-Device|
3041423|NCT00450216|Experimental|1|HZT-501: Ibuprofen 800mg/famotidine 26.6mg
3041424|NCT00450216|Active Comparator|2|Ibuprofen 800mg
3041425|NCT00450242|Experimental|5% Lidocaine cream|5% topical lidocaine cream.
3041426|NCT00450242|Placebo Comparator|Placebo cream|
3041427|NCT00450255|Experimental|Arm I|Patients receive Aflibercept IV at 4 mg/kg over 1 hour on day 1. Treatment repeats every 14 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3041428|NCT00450372|Experimental|ADI-PEG 20|
3041429|NCT00450385|Experimental|R-CHOP|"Patients will receive R-CHOP for 6 to 8 cycles:~Rituximab 375 mg/m2 on day 1~Cyclophosphamide 750 mg/m2 IV on day 1~Doxorubicin 50 mg/m2 on day 1~Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1~Prednisone 100 mg orally days 1-5, repeated every 21 days."
3041430|NCT00450411|Experimental|Brachytherapy|Prostate brachytherapy delivered using either 125-iodine (I-125) or 103-palladium (Pd-103)
3041431|NCT00450424|No Intervention|Counseling|Participants will be given one of two counseling interventions regarding MSI testing: standard counseling or a CD-ROM intervention.
3041432|NCT00450437|Active Comparator|Licensed Meningococcal Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
3041433|NCT00450437|Experimental|Novartis MenACWY Conjugate Vaccine|Novartis meningococcal ACWY conjugate Vaccine
3041434|NCT00450450|Experimental|Arm I|Patients undergo filgrastim (G-CSF)-stimulated allogeneic bone marrow transplantation on day 0.
3041435|NCT00450450|Active Comparator|Arm II|Patients undergo conventional allogeneic bone marrow transplantation on day 0.
3041436|NCT00450463|Active Comparator|Flutamide Alone|Patients receive flutamide orally 3 times a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising prostatic specific antigen (PSA) levels) without metastatic disease (as evidenced on scans), may receive vaccine treatment as defined in arm II beginning 4 weeks after flutamide therapy is discontinued.
3041437|NCT00450463|Experimental|Flutamide + Vaccine + Sargramostim|Patients receive flutamide orally 3 times a day on days 1-28. Patients also receive recombinant vaccinia PSA vaccine subcutaneously (SC) on day 1 of course 1 only and recombinant fowlpox PSA vaccine SC on day 1 of all subsequent courses. Patients receive sargramostim (GM-CSF) SC on days 1-4. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After 3 months of treatment, patients who do not develop clinical progression, but develop biochemical recurrence (e.g., rising PSA levels), discontinue flutamide but may continue to receive vaccine treatment.
3041438|NCT00450580|Experimental|Arm A|Fosamprenavir/ritonavir 1400mg/100mg QD + ABC/3TC FDC 600/300mg QD
3041439|NCT00450580|Active Comparator|Arm B|Fosamprenavir/ritonavir 700mg/100mg BID + ABC/3TC FDC 600/300mg QD
3041440|NCT00450619|Experimental|Arm A -EDTMP Alone|Patients receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg intravenous (IV) over 1 minute on day 8. Treatment repeats every 12 weeks in the absence of disease progression or unacceptable toxicity.
3041441|NCT00450619|Experimental|Arm B - 153SmEDTMP with vaccine|Patients receive recombinant vaccinia-TRICOM vaccine 2 x 10^8 PFU subcutaneously (SC) on day 1. Patients also receive recombinant fowlpox-TRICOM vaccine 1 x 10^9 PFU SC on days 15 and 29 and sargramostim (GM-CSF)100 mcg/injection SC x 4 days. Treatment with recombinant fowlpox-TRICOM vaccine and GM-CSF* repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive samarium Sm 153 lexidronam pentasodium 1 mCi/Kg as in arm I.
3041442|NCT00450658|Experimental|1|HZT-501: Ibuprofen 800mg/Famotidine 26.6mg
3041443|NCT00450658|Active Comparator|2|Ibuprofen 800mg
3041444|NCT00450723|Experimental|Sentinel Lymph Node Biopsy|
3041445|NCT00450749|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3041446|NCT00450749|Experimental|Arm II (low-dose lycopene)|Patients receive low-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3041447|NCT00450749|Experimental|Arm III (high-dose lycopene)|Patients receive high-dose lycopene PO QD for 4-7 weeks, and then undergo radical prostatectomy.
3041448|NCT00450801|Experimental|R-MACLO-IVAM-T|Rituximab, Methotrexate, Doxorubicin, Cyclophosphamide and Vincristine (cycle 1), followed by Rituximab, Ifosfamide (and Mesna), Etoposide and Cytarabine (cycle 2). These two cycles are repeated once, and patients achieving complete repose receive maintenance Thalidomide.
3041449|NCT00450814|Experimental|Stage 1 (MV-NIS alone)|Patients receive MV-NIS IV over 1 hour on day 1. (Closed to accrual on 12/17/2009 and reopened 10/13/2011)
3041450|NCT00450814|Experimental|Stage 2 (MV-NIS and cyclophosphamide)|Patients receive cyclophosphamide IV over 30 minutes and then MV-NIS IV over 1 hour 2 days later. (Temporarily closed to accrual on 10/13/11)
3041451|NCT00450866|Experimental|Epothilone B|
3041452|NCT00451035|Experimental|Panobinostat (LBH589)|Participants were administered panobinostat 20 milligram (mg) orally once a day (OD) three times a week as part of a 4 week (28 day) treatment cycle. Panobinostat were administered at the same time each morning with 8oz/240 milliliter (ml) of water after a fasting period of at least two hours (water was allowed). Participants could continue treatment until they experienced unacceptable toxicity or disease progression.
3041453|NCT00451048|Experimental|Arm I|Patients will receive sunitinib malate (SU11248) by mouth once a day. Treatment may continue for as long as benefit is shown.
3041454|NCT00451178|Experimental|R-CHOP and Enzastaurin|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
3041455|NCT00451178|Active Comparator|R-CHOP|R-CHOP includes rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment therapies.
3041456|NCT00451191|Active Comparator|1|100 units botulinum toxin type A (BoNT/A)
3041457|NCT00451191|Active Comparator|2|300 units botulinum toxin type A (BoNT/A)
3041458|NCT00451204|Active Comparator|Estriol plus Copaxone injections QD|Estriol Capsules (daily) plus Copaxone injections (daily). Progestin capsules given for 2 weeks every 3 months to avoid unopposed estrogens.
3041459|NCT00451204|Placebo Comparator|Placebo plus Copaxone injections QD|Placebo Capsules (daily) plus Copaxone injections (daily). A second placebo capsule given for 2 weeks every 3 months.
3041460|NCT00451217|Experimental|Rocuronium + Sugammadex|After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
3041461|NCT00451217|Active Comparator|Rocuronium + Neostigmine|After the last dose of rocuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
3041462|NCT00451217|Experimental|Vecuronium + Sugammadex|After the last dose of vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was administered
3041463|NCT00451217|Active Comparator|Vecuronium + Neostigmine|After the last dose of vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was administered
3041464|NCT00451282|Experimental|Stepped Preventive Care|Receiving Stepped Preventive Care intervention - at least 2 brief assessments with nurse and/or social worker (1) during hospital admission , and (2) approximately 2 weeks post-discharge. Additional interventions provided as needed, based on manual.
3041465|NCT00451282|No Intervention|Treatment as usual|Medical and psychosocial care per usual hospital protocols, which may include social work support.
3041466|NCT00451321|Experimental|otelixizumab|
3041467|NCT00451451|Experimental|BG00012 240 mg Twice Daily (BID)|Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
3041468|NCT00451451|Experimental|BG00012 240 mg 3 Times Daily (TID)|Participants received two 120 mg BG00012 capsules orally three times daily (TID)
3041469|NCT00451451|Placebo Comparator|Placebo|Participants received two placebo capsules orally three times daily (TID)
3041470|NCT00451451|Active Comparator|Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)|Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
3041471|NCT00451555|Experimental|Enzastaurin + Fulvestrant|"Participants received Enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 500 mg orally (QD) once daily in a 28-day cycle.~Participants received enzastaurin loading dose of 1125 mg, on Day 1 of Cycle 1 only then received Enzastaurin 250 mg orally (BID) twice daily in a 28-day cycle.~Fulvestrant was given intramuscularly at a loading dose of 500 mg on Day 1 and 250 mg on Day 15 in Cycle 1. Subsequent doses of Fulvestrant 250 mg were given on Day 1 of Cycle 2 and every 28 days thereafter."
3041472|NCT00451555|Placebo Comparator|Fulvestrant + Placebo|Participants received fulvestrant: 500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression. Then, participants received placebo, oral, daily.
3041473|NCT00451698|Placebo Comparator|3|acyanotic placebo
3041474|NCT00451698|Experimental|4|acyanotic erythropoietin
3041475|NCT00451906|Experimental|Bevacizumab + Chemotherapy|Participants with advanced or recurrent NSCLC will be administered bevacizumab infusions at a dose of 7.5 milligram per kilogram (mg/kg) or 15 mg/kg (investigator's choice) on Day 1 and then every 3 weeks, intravenously (IV) for a maximum of 6 cycles in combination with the standard of care NSCLC first-line chemotherapy in line with the licensed national prescribing information, during the treatment period. The initial dose of bevacizumab will be administered following chemotherapy; all subsequent doses could be given before or after chemotherapy.
3041476|NCT00451958|Experimental|Degarelix 80 mg / Degarelix 80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days for the rest of the study.
3041477|NCT00451958|Experimental|Degarelix 160 mg / Degarelix 160 mg|"The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent monthly degarelix maintenance dose of 160 mg (40 mg/mL) degarelix were administered as single 4 mL s.c. injections every 28 days.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3041478|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 80 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3041479|NCT00451958|Experimental|Leuprolide 7.5 mg / Degarelix 160 mg|"During the main CS21 study, leuprolide (Lupron Depot) 7.5 mg was injected into the muscle every 28 days for one year.~Starting one year after the first dose of leuprolide, degarelix doses were administered into the abdominal wall every 28 days. First, a starting dose of 240 mg (40 mg/mL) degarelix was administered as two 3 mL subcutaneous (s.c.) injections and one month later the participants received either subsequent monthly degarelix maintenance doses of 80 mg (20 mg/mL) or 160 mg (40 mg/mL) every 28 days for the rest of the study.~Following the implementation of a protocol amendment, all patients received a monthly degarelix maintenance dose of 80 mg (20 mg/mL) for the rest of the study."
3041480|NCT00452114|Active Comparator|Assignment to In-Exsufflator Cough Assist Device|In-Exsufflator Cough Assist Device augments the expiratory flow and force of the patient's cough with the addition of a cycle of positive and negative inspiratory pressure when used daily
3041481|NCT00452114|Active Comparator|Assignment to flutter valve device|flutter valve device delivers expiratory low-pressure vibratory pulse to the patient's airway when used daily
3041482|NCT00452335|Experimental|Lubiprostone 12 mcg QD|Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (<6 years of age and able to swallow capsules) who are at least 12 kg body weight
3041483|NCT00452335|Experimental|Lubiprostone 12 mcg BID|Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight
3041484|NCT00452335|Experimental|Lubiprostone 24 mcg BID|Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight
3041485|NCT00452348|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
3041486|NCT00452348|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
3041487|NCT00452374|Experimental|Oxaliplatin, Fludarabine, Cytarabine + Rituximab|Starting dose oxaliplatin 17.5mg/m^2/day intravenous (IV) for 4 days; Fludarabine 30 mg/m^2 IV and Cytarabine 1 g/m^2 IV for two days, + Rituximab 375 mg/m^2 IV on Day 3, Cycle 1 then Day 1 following cycles.
3041488|NCT00452413|Experimental|Enzastaurin and erlotinib combination therapy|"Enzastaurin:~Phase 1, Dose Level 1: 500 milligram (mg) oral loading dose Day 1, 250 mg oral, daily Day 2-28, 28-day cycle until disease progression~Phase 1, Dose Level 2: 1125 mg oral loading dose Day 1, 500 mg oral, daily until disease progression~Phase 2: Dose determined from Phase 1, oral, daily, 28-day cycles until disease progression~Erlotinib:~• 150 mg, oral, daily, 28-day cycles until disease progression"
3041489|NCT00452426|Experimental|Sedation System|Computer-Assisted Personalized Sedation (CAPS) device used for delivery of sedation
3041490|NCT00452426|Active Comparator|Current Standard of Care|Site's current standard used for delivery of sedation
3041491|NCT00452439|Active Comparator|Actonel|Actonel (Risedronate) + Vitamin D + Calcium
3041492|NCT00452439|Placebo Comparator|Placebo|Placebo + Vitamin D + Calcium
3041493|NCT00452452|Experimental|A|
3041494|NCT00452530|Experimental|Apixaban, 2.5 mg BID + Placebo|Participants received apixaban, 2.5-mg tablets twice daily (BID), plus a matching enoxaparin-placebo injection 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
3041495|NCT00452530|Active Comparator|Enoxaparin, 40 mg QD + Placebo|Participants received enoxaparin, 40-mg subcutaneous injection once daily (QD), plus a matching apixaban-placebo tablet 12 (±3) hours prior to hip-replacement surgery through 11 (±2) days after the day of surgery.
3041496|NCT00452543|Experimental|Escitalopram plus acamprosate|
3041497|NCT00452543|Placebo Comparator|Escitalopram plus placebo|
3041498|NCT00452673|Experimental|50 mg BID dasatinib + 825 mg/m^2 BID capecitabine|Twice a day (BID) for 2 weeks of a 3-week cycle
3041499|NCT00452673|Experimental|70 mg BID dasatinib + 825 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
3041500|NCT00452673|Experimental|70 mg BID dasatinib + 1000 mg/m^2 BID capecitabine|BID for 2 weeks of a 3-week cycle
3041501|NCT00452673|Experimental|100 mg QD dasatinib + 1000 mg/m^2 BID capecitabine|2 weeks of a 3-week cycle
3041502|NCT00452699|Active Comparator|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
3041503|NCT00452699|Active Comparator|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
3041504|NCT00452790|Experimental|A|
3041505|NCT00452790|Active Comparator|B|
3041506|NCT00452868|Experimental|Donepozil|Donepezil 5 milligrams a day for 6 weeks
3041507|NCT00453063|Experimental|MFNS 200 mcg QD|
3041508|NCT00453063|Placebo Comparator|Placebo|
3041509|NCT00453102|Experimental|Zevalin + Rituximab|Ibritumomab Tiuxetan (Zevalin) + Rituximab
3041510|NCT00453154|Experimental|Arm I (Combination Chemotherapy + Sunitinib Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m^2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start sunitinib at 150 mg on day 1, then 37.5 daily until disease progression."
3041511|NCT00453154|Active Comparator|Arm II (Combination Chemotherapy + Placebo Maintenance)|"Participants will receive the following combination chemotherapy for 4-6 cycles (21 days):~Cisplatin 80 mg/m^2 by IV over 1 hour on day 1 every cycle OR Carboplatin AUC = 5* by IV Etoposide 100 mg/m2 by IV over 1 hour on days 1, 2, and 3 every cycle~Maintenance: Following 4-6 cycles of combination chemotherapy, start placebo at 150 mg on day 1, then 37.5 daily until disease progression."
3041512|NCT00453180|Experimental|1|Target dose for n-acetylcysteine is 60 mg/kg/day. Capsules available in 300 mg and 600 mg strengths.
3041513|NCT00453180|Placebo Comparator|2|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
3041514|NCT00453193|Experimental|Alemtuzumab + Pentostatin|Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
3041515|NCT00453310|Experimental|sunitinib malate|The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks)
3041516|NCT00453336|Experimental|Single Arm|
3041517|NCT00453349|Experimental|Moxifloxacin|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
3041518|NCT00453349|Active Comparator|Levofloxacin plus Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
3041519|NCT00453362|Experimental|Erlotinib|"Erlotinib 150 mg/day taken orally at approximately the same time of day with 200 mL (6-8 Ounces) of water on an empty stomach. Participants received Erlotinib for 1 year or until they developed progressive disease or intolerable toxicity.~After 14 days and after 56 days of treatment with Erlotinib participants underwent FDG-PET and FLT-PET scans."
3041520|NCT00453388|Experimental|Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3041521|NCT00453388|Experimental|Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3041522|NCT00453388|Experimental|Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)|Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3041523|NCT00453388|Experimental|Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)|Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.
3041524|NCT00453895|Experimental|Sunitinib|"Sunitinib will be administered 50 mg per day for 4 weeks followed by 2 weeks off.~treatment will continue until progressive disease or unacceptable toxicity"
3041525|NCT00453921|Placebo Comparator|1|Placebo Capsule and Placebo Memory and Attention Training (Placebo as both conditions)
3041526|NCT00453921|Active Comparator|2|Methylphenidate capsules and Memory and Attention Training (Active Med/Active therapy)
3041527|NCT00453921|Active Comparator|3|Methylphenidate capsules and Placebo Memory and Attention Training (Active Med/Placebo therapy)
3041528|NCT00453921|Active Comparator|4|Placebo capsules and Memory and Attention Training (Placebo Med/Active therapy)
3041529|NCT00453973|Experimental|Maintenance Switch in Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were on dialysis and had been on Epoetin at study entry, and who were switched to peginesatide (NCT00434330). This group is categorized as Maintenance Switch in Dialysis Participants regardless of dialysis status at the start of or during this study."
3041530|NCT00453973|Experimental|Treatment Initiation in Non-Dialysis Participants|"Participants were from a prior Affymax peginesatide treatment study conducted in participants who were not on dialysis and not on erythropoiesis stimulating agents (ESAs), and who received peginesatide (NCT00228436). This group is categorized as Initiation of Treatment in Non-Dialysis Participants regardless of dialysis status at the start of or during this study."
3041531|NCT00453986|Experimental|Nimenrix A Group|subjects received 1 dose of Nimenrix™ Lot A at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3041532|NCT00453986|Experimental|Nimenrix B Group|subjects received 1 dose of Nimenrix™ Lot B at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3041533|NCT00453986|Experimental|Nimenrix C Group|subjects received 1 dose of Nimenrix™ Lot C at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm.
3041534|NCT00453986|Active Comparator|Mencevax ACWY Group|subjects received 1 dose of Mencevax™ ACWY vaccine at Month 0. Mencevax™ ACWY vaccine was administered by subcutaneous injection in the non-dominant upper arm.
3041535|NCT00453986|Experimental|Nimenrix+Fluarix Group|subjects received 1 dose of Nimenrix™ Lot A co-administered with Fluarix™ vaccines at Month 0. Nimenrix™ vaccine was administered by intramuscular injection in the deltoid region of the non-dominant arm. Fluarix™ vaccine was administered by intramuscular injection in the deltoid region of the dominant arm.
3041536|NCT00453999|Experimental|Arm 1: Peramivir 200 mg|Peramivir 200 mg administered intravenously once daily for 5 days (5 doses)
3041537|NCT00453999|Experimental|Arm 2: Peramivir 400 mg|Peramivir 400 mg administered intravenously once daily for 5 days (5 doses)
3041538|NCT00453999|Experimental|Arm 3: Oseltamivir|Oseltamivir 75 mg oral suspension administered orally twice daily for 5 days (10 doses)
3041539|NCT00454051|Active Comparator|Omalizumab|Omalizumab was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level.
3041540|NCT00454051|Placebo Comparator|Placebo|Placebo was injected subcutaneously every 2 weeks or every 4 weeks for 16 weeks.
3041541|NCT00454116|Placebo Comparator|1|FOLFIRI + placebo vandetanib
3041542|NCT00454116|Experimental|2|FOLFIRI + low dose vandetanib
3041543|NCT00454116|Experimental|3|FOLFIRI + high dose vandetanib
3041544|NCT00454142|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Pharmacological study will be done on Day 1 and Day 28. Computed tomography will be done at baseline and day 28."
3041545|NCT00454181|Experimental|IFN lozenges|500 IU Interferon-alpha lozenges for oral dissolution
3041546|NCT00454181|Placebo Comparator|placebo lozenges|200 mg lozenges containing anhydrous crystalline maltose
3041547|NCT00454194|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3041548|NCT00454194|Active Comparator|Arm II|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3041549|NCT00454207|Experimental|sildenafil citrate (UK-92,480)|sildenafil citrate 20 mg TID
3041550|NCT00454246|Experimental|methoxy polyethylene glycol-epoetin beta|"120-360 micrograms methoxy polyethylene glycol-epoetin beta subcutaneous (sc) monthly starting dose, for a minimum of 5 months to a maximum of 18 months.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3041551|NCT00454246|Active Comparator|Epoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of epoetin alfa subcutaneous once per week for a minimum of 5 months to a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3041552|NCT00454246|Active Comparator|Darbepoetin alfa|"Patients randomized to the reference arm continued to receive their standard of care dose and regimen of darbepoetin subcutaneous once every two weeks for a minimum of 5 months and a maximum of 18 months. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.~Dosage was adjusted to maintain a hemoglobin target range of ≥10 g/dL to ≤12 g/dL."
3041553|NCT00454324|Experimental|Arm A|Carboplatin + Abraxane (240mg/m2) on Day 1 of a 21 Day cycle, up to 6 cycles
3041554|NCT00454324|Experimental|Arm B|Carboplatin + Abraxane (80mg/m2)given on Days 1, 8 and 15 of a 21 Day Cycle, up to 6 cycles
3041555|NCT00454363|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3041556|NCT00454584|Experimental|CNTO 1275 45 mg|Patients will receive CNTO 1275 45 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on Physician's Global Assessment (PGA) response at Week 12 and initial treatment assignment.
3041557|NCT00454584|Experimental|CNTO 1275 90 mg|Patients will receive CNTO 1275 90 mg at the Weeks 0 and 4 visits. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
3041558|NCT00454584|Active Comparator|Etanercept 50 mg|Patients will receive Etanercept 50 mg twice weekly through Week 12. Treatment after Week 12 is dependent on PGA response at Week 12 and initial treatment assignment.
3041559|NCT00454636|Experimental|Cisplatin / Capecitabine|Cisplatin, 80 mg/m2/day, intravenous (IV), every 3 weeks; capecitabine, 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
3041560|NCT00454636|Experimental|Epirubicin / Cisplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2, orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
3041561|NCT00454636|Experimental|Epirubicin / Oxaliplatin / Capecitabine|Epirubicin, 50 mg/m2/day, IV, every 3 weeks; oxaliplatin, 130 mg/m2/day, IV, every 3 weeks; capecitabine, 625mg/m2 orally, twice daily per 3-week cycle. Study drugs were administered for at least 24 weeks.
3041562|NCT00454636|Experimental|Docetaxel / Cisplatin / Capecitabine|Docetaxel, 60 mg/m2/day, IV, every 3 weeks; cisplatin, 60 mg/m2/day, IV, every 3 weeks; capecitabine, 825 mg/m2, orally, twice daily for 2 weeks, followed by 1 week of rest in each cycle. Study drugs were administered for at least 24 weeks.
3041563|NCT00454649|Experimental|Axitinib [AG-013736] + chemotherapy combination|"The following separate groups were included:~axitinib~plus carboplatin/paclitaxel in three different schedules~plus paclitaxel~plus docetaxel/carboplatin~plus docetaxel~plus capecitabine~plus gemcitabine/cisplatin~plus pemetrexed/cisplatin"
3041564|NCT00454779|Experimental|Arm 1|Panitumumab + Docetaxel + Cisplatin
3041565|NCT00454779|Other|Arm 2|control
3041566|NCT00454805|Active Comparator|2|Fulvestrant Monotherapy
3041567|NCT00454805|Experimental|3|AZD2171 + Fulvestrant
3041568|NCT00454818|Experimental|MYDICAR Very Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1.4x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) only.
3041569|NCT00454818|Experimental|MYDICAR Low Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 6x10e11 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study)
3041570|NCT00454818|Experimental|MYDICAR Mid Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 3x10e12 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
3041571|NCT00454818|Experimental|MYDICAR High Dose|Single dose of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 1x10e13 DNAase resistant particles administered by antegrade epicardial coronary artery infusion. Used in MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study) and MYDICAR Phase 2 (Placebo-controlled, Randomized Study).
3041572|NCT00454818|Placebo Comparator|Placebo infusion|A single dose of placebo (Sodium Chloride Injection, USP) administered by antegrade epicardial coronary artery infusion.
3041573|NCT00454857||Patients with ITP|Participants with ITP and currently treated for ITP were followed prospectively for a period of 12 months.
3041574|NCT00454909|Experimental|Group A|Subjects aged 10 years (< 11 years) vaccinated with meningococcal vaccine GSK134612.
3041575|NCT00454909|Experimental|Group B|Subjects aged 11 to 25 years vaccinated with meningococcal vaccine GSK134612.
3041576|NCT00454909|Active Comparator|Group C|Subjects aged 11 to 25 years vaccinated with Menactra®.
3041577|NCT00454987|Experimental|Menitorix Group|Previously primed in infancy with Menitorix™ and Infanrix-IPV™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
3041578|NCT00454987|Active Comparator|Meningitec Group|Previously primed in infancy with Meningitec™ and Pediacel™ and boosted with Menitorix™ (Priorix™ co-administered). All UK subjects received a booster dose of Infanrix-IPV™ at 40 to 43 months of age, intramuscularly in the deltoid region.
3041579|NCT00454987|Active Comparator|Meningitec+Hiberix Group|"Previously primed (according to the routine UK immunisation schedule) with 3 doses of a Meningitec™ conjugate vaccine and a Hiberix™ containing vaccine before the age of 8 months without booster dose at 12 months of age (only for UK). All subjects received a booster dose of Infanrix-IPV™ and Menitorix™ at 40 to 43 months of age, intramuscularly in the deltoid region.~This group was added only at year 2 in UK (Meningitec+Hiberix Group) to comply with UK Hib Catch-up vaccination programme."
3041580|NCT00455013|Experimental|belatacept, mycophenolate mofetil (MMF)|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months; MMF 1g twice daily(bis in die, BID)
3041581|NCT00455013|Experimental|belatacept, sirolimus|thymoglobulin 1.5mg/kg for 4 days;IV belatacept: 10 mg/kg Days 1 and 5, then every other week through Month 3 (Weeks 2,4,6,8,10,12), and then every 4 weeks through Month 6 (Weeks 16, 20, 24),after 6 months, 5 mg/kg every 4 weeks until 12 months;sirolimus 5 mg/day on Day 1 (day of transplant)and continued through Day 2, dosing to be adjusted to keep pre-dose C0 levels at 7-12 ng/mL for first 6 months, followed by 5 - 10 ng/mL until 12 months.
3041582|NCT00455013|Other|tacrolimus, MMF|(IMPs as comparator regimen)thymoglobulin 1.5mg/kg for 4 days; oral tacrolimus 0.1 mg/kg/day in 2 divided doses with initial targeted trough level of 8-12 ng/mL for Days 1 - 30 with dose reduction to achieve 12 hour trough target of 5-10 ng/mL for 12 months; MMF (mycophenolate mofetil) 1g BID.
3041583|NCT00455195|Experimental|Alglucosidase Alfa/Alglucosidase Alfa|Participants who received alglucosidase alfa during the double-blind study and, if they completed the double-blind study, continued that treatment during the extension study. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) until their participation in both the AGLU02704 (NCT00158600) and AGLU03206 studies combined equaled a minimum of 104 weeks.
3041584|NCT00455195|Experimental|Placebo/Alglucosidase Alfa|Participants given placebo during the double-blind study, completed the double-blind study (study AGLU02704, NCT00158600), and qualified to continue into the extension study on alglucosidase alfa. Participants received an intravenous (IV) infusion of 20 mg/kg of alglucosidase alfa every other week (qow) for up to 52 weeks. Only the alglucosidase alfa treatment experience is included in this extension study.
3041585|NCT00455312|Experimental|Patients with DC|Patients with dyskeratosis congenita (DC). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, total body irradiation and stem cell transplantation.
3041586|NCT00455312|Experimental|Patients with SAA|Patients with severe aplastic anemia (SAA). Patients are treated with alemtuzumab (Campath 1H), Cyclophosphamide, Fludarabine, antithymocyte globulin, total body irradiation and stem cell transplantation.
3468754|NCT03892811||Infants referred for swallow study|"This is a within-subjects intervention study where each infant in the study will receive all three conditions.~The three study conditions are bottle-feeding with 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple."
3468755|NCT03892525|Experimental|treatment|
3041589|NCT00455429|Placebo Comparator|Placebo|
3041590|NCT00455429|Experimental|JNJ-26113100 (50 mg) once daily|
3041591|NCT00455429|Experimental|JNJ-26113100 (100 mg) once daily|
3041592|NCT00455429|Experimental|JNJ-26113100 (100 mg) twice daily|
3041593|NCT00455429|Experimental|JNJ-26113100 (250 mg) twice daily|
3041594|NCT00455455|Active Comparator|Optifree RepleniSH Multipurpose Disinfecting Solution|
3041595|NCT00455455|Active Comparator|ReNu Multiplus Multipurpose Solution|
3041596|NCT00455520|Placebo Comparator|Placebo|placebo matching placebo twice daily for 12 weeks
3041597|NCT00455520|Experimental|CG5503|CG5503 100, 150, 200, 250mg twice daily given for up to 15 weeks
3041598|NCT00455533|Experimental|A|
3041599|NCT00455533|Active Comparator|B|
3041600|NCT00455650|Active Comparator|Schizophrenia, Mecamylamine|
3041601|NCT00455650|Active Comparator|Schizophrenia, Varenicline|
3041602|NCT00455650|Placebo Comparator|Schizophrenia, Placebo|
3041603|NCT00455650|Active Comparator|Control, Mecamylamine|
3041604|NCT00455650|Active Comparator|Control, Varenicline|
3041605|NCT00455650|Placebo Comparator|Control, placebo|
3041606|NCT00455663|Experimental|Cognitive Adaptation Training|In home treatment using environmental supports such as signs, labels, alarms, checklists and the organization of belongings to bypass cognitive impairment, cue and sequence adaptive behavior and improve a wide range of functional outcomes.
3041607|NCT00455663|Experimental|Pharm-Cognitive Adaptation Training|Uses Supports from Cognitive Adaptation Training designed only to promote adherence to medication and treatment follow up.
3041608|NCT00455663|Active Comparator|Treatment As Usual|Medication follow up and limited case management provided by local mental health authority
3041609|NCT00455689|Experimental|Developed hot flashes|Subjects who developed hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
3041610|NCT00455689|Experimental|Did not develop hot flashes|Subjects who did not develop hot flashes after receiving leuprolide acetate (3.75 mg intramuscular injection)
3041611|NCT00455702|Experimental|D-cycloserine|50 mg d-cycloserine
3041612|NCT00455702|Placebo Comparator|Placebo|50 mg placebo
3041613|NCT00455741|Active Comparator|Young postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women.
3041614|NCT00455741|Active Comparator|Older postmenopausal women|Graded estradiol infusion to young postmenopausal women. Graded progesterone infusion to young postmenopausal women..
3041615|NCT00455858|Active Comparator|insulin detemir|
3041616|NCT00455923|Experimental|Seretide|Eligible participants received a starting dose of 50/100 mcg Seretide (combination of Sal/FP) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 50/250 mcg and 50/500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
3041617|NCT00455923|Experimental|Flixotide|Eligible participants received a starting dose of 100 mcg Flixotide (FP only) via Diskus inhaler, twice daily. During the first 6 months, when the asthma was unstable/uncontrolled, dose was increased in a stepwise fashion to 250 mcg and 500 mcg (if still unstable). After the initial 6 months, the treatment was fixed without further changes. The total treatment period was 18 months.
3041618|NCT00455962|Active Comparator|African American women 18-35 yo|intervention: estradiol steroid infusion and progesterone steroid infusion
3041619|NCT00455962|Active Comparator|Caucasian women 18-35 yo|intervention: estradiol steroid infusion intervention: progesterone steroid infusion
3041620|NCT00455975|Experimental|Weekly Avastin|Bevacizumab 15mg/kg IV weekly until progressive disease or toxicity
3041621|NCT00455975|Experimental|Bi-weekly Avastin|Bevacizumab 15mg/kg IV every 2 weeks until progressive disease or toxicity
3041622|NCT00456014|Experimental|1 - SSRI|Participants will receive standardized pharmacotherapy with the SSRI escitalopram over 8 weeks. Non-remitters after 8 weeks will be offered standardized pharmacotherapy with desipramine
3041623|NCT00456092|Experimental|Apremilast 40 mg QD|"Participants received 40 mg apremilast orally once a day (QD) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 40 mg apremilast QD for an additional 12 weeks.~The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 40 mg QD thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication."
3132862|NCT03460652|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
3041624|NCT00456092|Experimental|Apremilast 20 mg BID|Participants received 20 mg apremilast orally twice a day (BID) for 12 weeks in the Treatment Phase. Participants who entered the Extension Phase continued to receive 20 mg apremilast BID for an additional 12 weeks. The dose of apremilast was titrated starting at 10 mg QD during Days 1 to 3 followed by 20 mg QD during Days 4 to 7 and then 20 mg BID thereafter. A single dose reduction to 20 mg per day was allowed for participants who experienced intolerable adverse effects from study medication.
3041625|NCT00456092|Placebo Comparator|Placebo|Participants received matching placebo to apremilast orally BID for 12 weeks during the Treatment Phase. Participants who entered the Extension Phase were re-randomized on Day 85 to receive either 40 mg apremilast QD or 20 mg apremilast BID for 12 weeks.
3041626|NCT00456261|Experimental|Cohort A|Cohort A, will receive bevacizumab 10mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over 10 minutes followed by gemcitabine 1500 mg/m2 by vein over 30-60 minutes. This regimen will be given on day 1 and day 15 of each treatment cycle. Each cycle is 28 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 2 weeks as long as their disease does not worsen.
3041627|NCT00456261|Experimental|Cohort B|Cohort B, will receive bevacizumab 15mg/kg by vein over 30-90 minutes followed by pemetrexed 500 mg/m2 by vein over approximately 10 minutes followed by carboplatin AUC=5 by vein over 30-60 minutes. This regimen will be given on day 1 of each treatment cycle. Each cycle is 21 days long. As long as their disease does not worsen patients can receive up to a maximum of 6 cycles of this combination chemotherapy. Following that they can receive bevacizumab alone once every 3 weeks as long as their disease does not worsen.
3041628|NCT00456300|Experimental|Exenatide 1.25 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
3041629|NCT00456300|Experimental|Exenatide 2.5 mcg + Insulin|In each intervention arm the participant receives a different dose of Exenatide along with Insulin as a single subcutaneous injection
3041630|NCT00456300|Active Comparator|Insulin|Each subject received a baseline study with insulin alone
3041631|NCT00456365|Experimental|Pravastatin|Pravastatin
3041632|NCT00456365|Placebo Comparator|Placebo|Placebo
3041633|NCT00456495|Experimental|Subconjunctival ranibizumab|Patients will receive subconjunctival ranibizumab every 2-4 weeks.
3041634|NCT00456508|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.
3041635|NCT00456521|Experimental|NB32|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling
3041636|NCT00456521|Placebo Comparator|Placebo|Placebo with intensive group lifestyle modification counseling
3041637|NCT00456547||Postpartum hysterectomy|Women that require postpartum hysterectomy for post-delivery bleeding.
3041638|NCT00456547||Cesarean delivery case controls|Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
3041639|NCT00456599|Experimental|Oxaliplatin & gemcitabine with radiation|This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
3041640|NCT00456625|Experimental|Group Engerix™-B|Subjects received a dose of Hepatitis B vaccine approximately 20 years after the primary neonatal vaccination
3041641|NCT00456755|Active Comparator|Shi-Bi-Lin|Consist of 6 herbal. 7.5 g Xanthium sibiricum Patrin ex Widder (Asteraceae, Fructus), 20 g Angelica dahurica (Fisch. ex Hoffm.) Benth. (Apiaceae, Radix), 7.5 g Saposhnikovia divaricata (Turcz.) Schischk. (Apiaceae, Radix),15 g Magnolia biondii Pamp., (Magnoliaceae, Flos), 5 g Gentiana scabra Bunge (Gentianaceae, Radix) and 5 g Verbena officinalis L. (Verbenaceae, Herba).
3041642|NCT00456755|Placebo Comparator|Placebo|The placebo contained brown colored starch resembling the SBL powder
3041643|NCT00456807|Experimental|Cervarix Group|Subjects who received 3 doses of Cervarix during the primary study (NCT00294047).
3041644|NCT00456807|Placebo Comparator|Placebo Group|Subjects who received 3 doses of placebo during the primary study (NCT00294047).
3041645|NCT00456846|Experimental|ABI-007|100 mg/m^2 ABI-007 was administered by intravenous (IV) infusion over 30 minutes weekly for 3 weeks followed by 1 week rest. Therapy continued until disease progression or unacceptable toxicity.
3041646|NCT00456885|Placebo Comparator|Exenatide First|Started on Exenatide, 3 week washout, start placebo
3041647|NCT00456885|Experimental|Placebo First|Started on placebo, 3 week washout, start exenatide
3041648|NCT00457002|Experimental|Arm 1|"While hospitalized, Apixaban plus Placebo~Apixaban (Tablets, Oral, 2.5 mg), Placebo (Syringes, SC)~After hospital discharge, Apixaban~Apixaban (Tablets, Oral, 2.5 mg)"
3041649|NCT00457002|Active Comparator|Arm 2|"While hospitalized, Enoxaparin plus Placebo~Enoxaparin (Syringes, SC, 40 mg), Placebo (Tablets, Oral)~After hospital discharge: Placebo~Placebo (Tablets, Oral)"
3041650|NCT00457015|Experimental|DX-88 (ecallantide)|DX-88 (ecallantide) 30 mg given as three 10 mg/mL subcutaneous injections.
3041651|NCT00457015|Placebo Comparator|Placebo|Placebo, Phosphate Buffer Saline (PBS), pH 7.0 given as 3 subcutaneous injections.
3041652|NCT00457197|Placebo Comparator|Placebo|This group will be given placebo matching quetiapine for the course of the 12 weeks in the study.
3041653|NCT00457197|Active Comparator|Quetiapine|This group will be given 50mg Quetiapine per day baseline-week 1, 100mg Quetiapine per day week 1-week 2, 200mg Quetiapine per day week 2-week 3, 400mg Quetiapine per day week 3-week 4, and 600mg Quetiapine per day week 4 to week 12.
3041654|NCT00457249|Experimental|Adacel Vaccine Group|
3041655|NCT00457249|Active Comparator|DECAVAC Vaccine Group|
3041656|NCT00457301||Control|
3041657|NCT00457366|Active Comparator|Quetiapine|Quetiapine is being used in an ER setting on agitated patients, being administered orally.
3041658|NCT00457366|Active Comparator|Haloperidol|"Haloperidol is being used in an ER setting on agitated patients, administered IM. This is being used in combination with lorazepam and cogentin. We are comparing the use of this cocktail to quetiapine alone."
3468756|NCT03892928|Placebo Comparator|Propofol group|2-5 mg/kg.h propofol during the whole colonoscopy
3041659|NCT00457366|Active Comparator|Lorazepam|"Lorazepam is being used in an ER setting on agitated patients, administered IM.This is being used in combination with haloperidol, and cogentin. We are comparing the use of this cocktail to quetiapine alone."
3041660|NCT00457366|Active Comparator|Cogentin|"Cogentin is being used in an ER setting on agitated patients, administered IM.~This is being used in combination with haloperidol, and lorazepam. We are comparing the use of this cocktail to quetiapine alone."
3041661|NCT00457392|Experimental|1|
3041662|NCT00457392|Active Comparator|2|
3041663|NCT00457418|Experimental|PEG-Intron|"6 ug/kg/week, SC (first 8 weeks)~3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)"
3041664|NCT00457626|Experimental|Valsartan Open Label|Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.
3041665|NCT00457639|Experimental|Cholic Acid active capsules|Cholic Acid weight based dose for 6 months double-blind
3041666|NCT00457639|Placebo Comparator|Placebo for Cholic Acid|Placebo for Cholic Acid for 6 months double-blind
3041667|NCT00457665|Active Comparator|Nelfinavir (Viracept)|
3041668|NCT00457665|Active Comparator|Efavirenz (Sustiva)|
3041669|NCT00457691|Experimental|1|
3041670|NCT00457691|Placebo Comparator|2|
3041671|NCT00457730|Experimental|Duloxetine|subjects will be randomized to study drug (Duloxetine) or Placebo. Subjects will take 30 mg (10 capsules) titrate up to 60 mg( 40 capsules) and titrate back down to 30 mg.
3041672|NCT00457730|Placebo Comparator|placebo|matched placebo medication
3041673|NCT00457743|Experimental|SU011248|25 , 50 or 75 mg/day of SU011248
3041674|NCT00457795|Experimental|brimonidine 0.1%|brimonidine 0.1%
3041675|NCT00457821|Experimental|Ivacaftor Group A|Subjects in Part 1 who first received 25 mg or 75 mg of ivacaftor every 12 hours (q12h) for 14 days, then crossed over to receive the alternate dose for another 14 days.
3041676|NCT00457821|Experimental|Ivacaftor Group B|Subjects in Part 1 who first received 75 mg or 150 mg of ivacaftor q12h for 14 days then crossed over to receive the alternate dose for another 14 days.
3041677|NCT00457821|Experimental|Ivacaftor Group C|Subjects in Part 2 who received 150 mg or 250 mg of ivacaftor q12h for 28 days.
3041678|NCT00457821|Placebo Comparator|Placebo|Subjects who received placebo in Part 1 and subjects who received placebo in Part 2.
3041679|NCT00457977|Active Comparator|Pneumovax (PPSV23)|pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
3041680|NCT00457977|Active Comparator|Prevnar (PCV7)|diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose
3041681|NCT00458211|Experimental|Experimental|Open label change to ziprasidone
3041682|NCT00458237|Experimental|Ph I: Everolimus L1 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3041683|NCT00458237|Experimental|Ph I: Everolimus L2 + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3041684|NCT00458237|Experimental|PhII: Everolimus MTD + Trastuzumab|Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus at the MTD by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.
3041685|NCT00458302|Experimental|darunavir monotherapy|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
3041686|NCT00458302|Experimental|darunavir + 2 NRTI|darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
3041687|NCT00458341|Experimental|Ataluren 4, 4, and 8 mg/kg, then ataluren 10, 10, and 20 mg/kg|During Cycle 1, participants will receive ataluren at 4 mg/kg in the morning, 4 mg/kg at midday, and 8 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 10, 10, and 20 mg/kg) for Cycle 2.
3041688|NCT00458341|Experimental|Ataluren 10, 10, and 20 mg/kg, then ataluren 4, 4, and 8 mg/kg|During Cycle 1, participants will receive ataluren at 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by a 14-day follow-up period without treatment. Then, the participants will crossover to the other ataluren dose regimen (ataluren 4, 4, and 8 mg/kg) for Cycle 2.
3041689|NCT00458393|Experimental|TDF/FTC|Drug. Daily oral tablet of co-formulated 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate (TDF/FTC).
3041690|NCT00458393|Placebo Comparator|Placebo|Drug. Daily oral placebo
3041691|NCT00458406|Active Comparator|Bi-Flex|"Subjects randomized to this arm will undergo a clinical Bi-Flex sleep study. Following a baseline polysomnography, subjects in this arm will undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will be randomized to Bi-Flex or CPAP, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
3041692|NCT00458406|Active Comparator|CPAP|"Subjects randomized to this arm will undergo a clinical CPAP titration sleep study.~Subjects in this arm received standard continuous positive airway pressure (CPAP) therapy.~In this randomized, double-blinded clinical trial, patients with obstructive sleep apnea will randomized to CPAP or Bi-Flex, and repeat polysomnography will be performed on pressure at 3 months. Objective adherence data will be obtained at 1 and 3 months."
3041693|NCT00458484|Experimental|Series 1: Stereotactic radiosurgery|Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy.
3041694|NCT00458484|Experimental|Series 2: Stereotactic radiosurgery|Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each.
3041695|NCT00458536|Experimental|Cohort 1|Patients treated with DC/RCC vaccine to evaluate for treatment-limiting toxicity
3041696|NCT00458536|Experimental|Cohort 2|Patients treated with DC/RCC vaccine to evaluate response
3041697|NCT00458705|Experimental|Combination therapy|Combination therapy with bortezomib, pegylated liposomal doxorubicin and dexamethasone (BDD) followed by either thalidomide and dexamethasone (TD) or bortezomib, thalidomide and dexamethasone in patients with symptomatic untreated high-risk or primary resistant multiple myeloma. Three cycles of BDD will be administered. Patients who respond after three cycles will receive two cycles of TD. Patients with stable or progressive disease after three cycles of BDD receive two cycles of bortezomib, thalidomide and dexamethasone. If at any point during the study a patient achieves a complete response (CR), the patient will be given the option to discontinue treatment on-study.
3041698|NCT00458783|Active Comparator|Prolonged RBC storage|Transfusion with oldest available matching RBCs.
3041699|NCT00458783|Active Comparator|Short RBC storage|Transfusion with youngest available matching RBCs.
3041700|NCT00458822|Experimental|All Patients|All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis
3041701|NCT00458952|Experimental|Dose Escalation|Dosing of Ultratrace iobenguane I 131 began at 6.0 mCi/kg and escalated in 1.0 mCi/kg increments in order to establish the MTD. The MTD is the dose immediately below the level at which escalation stops due to dose-limiting toxicity (DLT). An additional 3 patients are to be treated at the MTD, for a total of 6.
3041702|NCT00459043|Active Comparator|1|Docetaxel Alone
3041703|NCT00459043|Active Comparator|2|Docetaxel with ZD6474
3041704|NCT00459056|Experimental|Carvediolol CR + Lisinopril, then Lisinopril + HCTZ|Subjects were randomly assigned to Carvedilol CR + Lisinopril for three months, then had a washout period of one month, and then were given Lisinopril + HCTZ for the final three months.
3041705|NCT00459056|Active Comparator|Lisinopril + HCTZ, then Carvedilol CR + Lisinopril|Subjects were randomally assigned to Lisinopril + HCTZ for three months, then had a washout period for one month, and then were given Carvedilol CR + Lisinopril for the final three months.
3041706|NCT00459108|Experimental|Oral Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3041707|NCT00459134|Experimental|Arm I: ArginMax|ArginMax® 3 pills twice daily
3041708|NCT00459134|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo 3 pills twice daily
3041709|NCT00459186|Experimental|RAD001 Followed by RAD001 + Docetaxel|RAD001 10 mg daily for 2 weeks, followed by RAD001 + Docetaxel at one of three doses: 5 mg RAD001 and docetaxel at 60 mg/m2, 10 mg RAD001 and docetaxel at 60 mg/m2, and 10 mg RAD001 and docetaxel at 70 mg/m2. RAD001 was given daily. Docetaxel was given every 3 weeks by intravenous infusion. Patients also received prednisone 5 mg by mouth twice daily.
3041710|NCT00459290|Experimental|Mifepristone 200 mg PO daily|Mifepristone 200 mg PO daily administered on a continuous basis (every 4 weeks is considered one cycle) until disease progression or adverse effects prohibit further therapy.
3041711|NCT00459303|Active Comparator|intraocular lens|patients with bilateral clinical significant cataract reisiceved cataract surgeries and recieved spherial intraocuar lens(SA60AT, Alcon) in one eye and aspherical intraocular lens(Tecnis Z9000, AMO)in the other respectively.
3041712|NCT00459316|Experimental|Group 1|Participants ≤11 to <25 years of age with CD4% at screening ≥15%. All received Quadrivalent meningococcal conjugate vaccine at entry, those who were eligible were randomized at week 24, with Group 1B receiving a second Quadrivalent meningococcal conjugate vaccine at week 24. Those who were eligible received a booster dose of Quadrivalent meningococcal vaccine at 3.5 years.
3041713|NCT00459316|Experimental|Group 2|Participants ≤11 to <25 years of age with CD4% at screening <15%; All receiving Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
3041714|NCT00459316|Experimental|Group 3|Participants >=2 to <11 years of age with CD4% at screening ≥ 25%; All received Quadrivalent meningococcal conjugate vaccine at entry, with those who were eligible receiving Quadrivalent meningococcal conjugate vaccine at week 24 and 3 years.
3041715|NCT00459342|Experimental|Arm I|Patients received oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3041716|NCT00459355|Experimental|Home Safety Toolkit|Intervention group receives home safety tool-kit with education and self-efficacy materials to promote competence to make home safety modifications.
3041717|NCT00459355|No Intervention|Conventional Safety Checklist|Comparison group received a conventional home safety checklist
3041718|NCT00459368|Experimental|I|In this cluster-randomized trial physicians practicing at intervention clinic sites will receive adherence information on their patients with asthma who are currently taking an inhaled corticosteroid medication. This information will be available to them via our electronic prescribing software to discuss with patients at the time of the visit. Physicians at these sites also receive standardized training in how to interpret and intervene when poor adherence is identified.
3041719|NCT00459368|Active Comparator|II|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
3041720|NCT00459381|Experimental|Treatment (pazopanib hydrochloride)|"Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
3041721|NCT00459537|Experimental|Terbinafine|10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.
3041722|NCT00459537|Active Comparator|Amorolfine|5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.
3041723|NCT00459667|Experimental|IFNB-1b 500 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 500 mcg administered s.c. every other day (double blind)
3041724|NCT00459667|Experimental|IFNB-1b 250 mcg|Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day (double blind)
3041725|NCT00459667|Experimental|IFNB-1b 250 mcg*|"Interferon beta 1b ([IFNB 1b] Betaseron) 250 mcg administered s.c. every other day~*(Subjects who were administered Copaxone and subjects who had prematurely discontinued medication during BEYOND study.)"
3041726|NCT00459706|Experimental|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
3041727|NCT00459706|Experimental|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
3041728|NCT00459732|Placebo Comparator|Placebo Capsule|placebo capsule, similar in size, shape and color to zinc capsule, taken once daily for 18 months
3041729|NCT00459732|Active Comparator|Zinc (25 mg/d)|25 mg of elemental Zinc as zinc sulphate taken once daily for 18 months
3041730|NCT00459862|Experimental|Arm I|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-21. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3041731|NCT00459875|Experimental|Sunitinib|The treatment will include Sunitinib malate 50 mg self-administered orally, once daily in the evening, without regard to meals, for 4 consecutive weeks (28 days) followed by 2 weeks (14 days) off, to comprise a complete cycle of 6 weeks.
3041732|NCT00459953|Experimental|Extended treatment|extended cognitive behavioral treatment for smoking cessation; Participants receive an additional 9 sessions of cognitive behavior therapy
3041733|NCT00459953|No Intervention|Control group|Monthly follow-up phone calls for assessment purposes and to control for potential therapeutic effects associated with continued contact
3041734|NCT00459979|Experimental|Sunitinib|
3041735|NCT00460031|Experimental|Ketoconazole Plus Lenalidomide|
3041736|NCT00460109|Experimental|rituximab + denileukin diftitox|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients also receive denileukin diftitox IV over 15-60 minutes on days 1-5. Treatment with denileukin diftitox repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3041737|NCT00460239|Experimental|Placebo|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041738|NCT00460239|Experimental|Morphine 15|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041739|NCT00460239|Experimental|Morphine 30|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041740|NCT00460239|Experimental|Buprenorphine 8|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041741|NCT00460239|Experimental|Buprenorphine 16|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041742|NCT00460239|Experimental|Buprenorphine 32|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041743|NCT00460239|Experimental|Buprenorphine 48|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041744|NCT00460239|Experimental|Buprenorphine 60|All participants are randomly assigned to receive an order of the 8 study drugs/doses (placebo, 2 doses of morphine, 5 doses of buprenorphine).
3041745|NCT00460265|Active Comparator|ARM 2|Arm 2 consists of Cisplatin and 5-FU
3041746|NCT00460265|Experimental|ARM 1|ARM 1 Consists of Panitumumab plus Cisplatin and 5-FU
3041747|NCT00460408||Observational study, no comparator|Observational study of patients with AMD treated with Macugen, no comparator
3041748|NCT00460421|Experimental|Palifermin Dose Escalation|A 3 dose escalation design. Sucessive cohorts of patient (9 patients per group) will each be administered Palifermin as an IV bolus injection (40, 60 or 80 µg) once daily for 3 consecutive days before the start of conditioning regimen (chemotherapy and total body irradiation) and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
3041749|NCT00460434|Experimental|1|Tension-free Vaginal Tape (TVT) surgery
3041750|NCT00460434|Sham Comparator|2|Sham Tension-free Vaginal Tape (TVT) surgery
3041751|NCT00460525|Active Comparator|Rabies Vaccine|Rabies vaccine administered on Days 0, 30, and 60.
3041752|NCT00460525|Experimental|FMP2.1/AS02A|50 mcg of FMP2.1 in 0.5 mL AS02A administered on Days 0, 30, and 60.
3041753|NCT00460551|Experimental|Zalutumumab 8 mg/kg|
3041754|NCT00460564|Active Comparator|High-Dose BTX|
3041755|NCT00460564|Placebo Comparator|High-Dose Placebo|
3041756|NCT00460564|Active Comparator|Low-Dose BTX|
3041757|NCT00460564|Active Comparator|Low-Dose Placebo|
3041758|NCT00460577|Active Comparator|Formoterol (Foradil®)|Formoterol (Foradil®) 12 micrograms administered through Aerolizer®.
3041759|NCT00460577|Active Comparator|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg|Fenoterol 0.5 mg + Ipratropium Bromide (Berodual®) 0.25 mg 20 drops in 3 mL of saline solution nebulized.
3041760|NCT00460603|Active Comparator|B|bevacizumab 5 mg/kg every 2 weeks + FOLFOX
3041761|NCT00460603|Experimental|C|AG-013726 5 mg bid+ bevacizumab 2 mg/kg every 2 weeks + FOLFOX
3041762|NCT00460603|Experimental|A|AG-013736 5 mg bid starting dose + FOLFOX
3041763|NCT00460655|Active Comparator|BTX|
3041764|NCT00460655|Placebo Comparator|Placebo|
3041765|NCT00460746|Experimental|001|TMC125, Darunavir; RitonavirTMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
3041766|NCT00460798||Non-Interventional Study|
3041767|NCT00460811|Active Comparator|72 ug linaclotide acetate|
3041768|NCT00460811|Active Comparator|145 ug linaclotide acetate|
3041769|NCT00460811|Active Comparator|290 ug linaclotide acetate|
3041770|NCT00460811|Active Comparator|579 ug linaclotide acetate|
3041771|NCT00460811|Placebo Comparator|Matching Placebo|
3041772|NCT00460993|Experimental|Group 1|Lunesta Active drug (eszopiclone) 1 mg during 1st week of active drug. If sleep efficiency does not improve does increases to 2 mg for 2nd week of active drug administration.
3041773|NCT00460993|Placebo Comparator|Group 2|"Sugar pill packaged and supplied by Sepracor. One pill weeks one and two of intervention.~Weeks 3 and 4 this Placebo group crosses over to active drug. 1 mg week 3 increasing to 2mg week 4 if sleep efficiency does not improve."
3041774|NCT00461032|Experimental|1|montelukast
3041775|NCT00461032|Placebo Comparator|2|Placebo
3041776|NCT00461045|Experimental|MRZ 0.5 mg/m^2|Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
3041777|NCT00461097|Experimental|Egg Oral Immunotherapy (OIT)|Subjects ingest egg white solid (EWS) on Visit 1 (initial day dose escalation up to 50 mg), followed by a build-up phase (escalating daily egg doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects are on a maximally tolerated daily egg dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects are given a 5 gm Oral Food Challenge (OFC) using EWS to identify desensitized [1] subjects. Subjects/study staff are unblinded following this OFC and either continue on their egg OIT maintenance dose of 2 gm/day or are allowed to attempt escalation up to 2 gm/day for the remainder of the study (1-3 years). A 10 gm OFC to identify desensitized [1] subjects occurs at specified intervals under prescribed conditions (yrs 2 - 4). Subjects who pass this 1st 10 gm OFC stop study therapy for 4-6 wks, then have a 2nd 10 gm OFC. Subjects that pass this 2nd 10 gm OFC are considered tolerant [2], stop EWS dosing and add egg to their diet.
3041778|NCT00461097|Placebo Comparator|Control Group|Subjects ingest placebo (cornstarch) during Visit 1 (initial day of dose escalation up to 50 mg), followed by a build-up phase (escalating daily placebo doses every 2 wks, achieving a maintenance dose by 32-40 wks). Thereafter, subjects were on a maximally tolerated daily placebo dose (306 mg to 2 gm) for ≥8 wks. After wk 44, subjects were given a 5 gm Oral Food Challenge (OFC) using egg white solid to identify desensitized [1] subjects. Subjects/study staff were unblinded following this initial 5 gm OFC. After unblinding, subjects discontinued further placebo dosing and continued on an egg-restricted diet. A 10 gm OFC was administered under prescribed conditions to subjects if their egg-specific serum IgE level was below 2 kUA/L. They were followed in the study up to 2 years. [1] Desensitized: Subject does not react to egg during OFC while taking daily doses of therapy. [2] Tolerant: Subject does not react to egg during OFC 4-6 wks after abstinence from egg consumption.
3041779|NCT00461123|Experimental|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
3041780|NCT00461123|Placebo Comparator|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
3041781|NCT00461175||1|Mirena®
3041782|NCT00461175||2|Copper IUD
3041783|NCT00461253||1|Breast Cancer Cases
3041784|NCT00461253||2|Matched Controls for Breast Cancer Cases
3041785|NCT00461292|Experimental|1|botulinum toxin Type A (200U)
3041786|NCT00461292|Experimental|2|botulinum toxin Type A (300U)
3041787|NCT00461292|Other|3|placebo; botulinum toxin Type A (200U)
3041788|NCT00461292|Other|4|placebo; botulinum toxin Type A (300U)
3041789|NCT00461305|Experimental|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
3041790|NCT00461305|Experimental|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
3041791|NCT00461331|Active Comparator|Insulin 1|Either insulin Aspart or insulin Lispro were randomized to be insulin 1.
3041792|NCT00461331|Active Comparator|Insulin 2|Between insulin Aspart and insulin Lispro, the one that was not used as insulin 1 was then used as the second insulin for the second arm of the study.
3041793|NCT00461513||Intervention|The PCDM intervention will include evaluation of CHF care by the collaborative care team, with diagnostic and therapeutic treatment recommendations based on current ACC/AHA national clinical practice guidelines, daily telemonitoring and patient self-care support utilizing the VA telemonitoring system, and screening and treatment for comorbid depression. The Collaborative Care (CC) team at each site will consist of a primary care provider, cardiologist, and psychiatrist, who are local opinion leaders, as well as a nurse site coordinator and pharmacist. For a given intervention patient, there will be an initial assessment of care by the CC team following the enrollment visit. Each intervention patient will be re-reviewed by the CC team a minimum of 2 additional times (at 6-weeks and 6 months). In addition, patients will have daily telemonitoring, and their care will be reviewed by the CC team if the telemonitoring data suggests clinical deterioration.
3041794|NCT00461513||Usual Care|Patients randomized to the usual care arm will continue to receive care at the discretion of their regular VA providers (for a given patient, this could include cardiology specialty care in addition to PCP care, participation in site-specific CHF programs such as CHF patient education classes, etc.), in direct continuity with the care they were receiving prior to enrollment. Patients in the usual care group will also be given information sheets that outline self-care for CHF, and will be provided with a scale, if needed, at the enrollment visit. Patients in the usual care group will have the same amount of interaction with the study team as the intervention patients (i.e. complete questionnaires at the same frequency; have the same study visits). PCPs of usual care patients will be notified of the results of all screening studies (patient survey results, lab tests) as we have done in previous studies.
3041795|NCT00461552|Active Comparator|Leptin|Leptin weight and gender based dose, sub-cutaneous, twice daily. Leptin versus placebo for entire 6 months double-blind.
3041796|NCT00461552|Placebo Comparator|Placebo|Placebo , sub-Q injection twice daily.
3041797|NCT00461591|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
3041798|NCT00461591|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
3041799|NCT00461630|Experimental|ER niacin/laropiprant|1 g ER niacin plus 20 mg laropiprant per tablet. 2 tablets orally per day. With either 40 mg simvastatin tablet or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
3041800|NCT00461630|Active Comparator|Placebo|Placebo (for ER niacin/laropiprant) 2 tablets orally per day. With either 40 mg simvastatin tablet orally per day or ezetimibe/simvastatin (10 mg/40 mg) in single tablet taken once daily
3178892|NCT00666783|Experimental|PAL|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
3178893|NCT00666783|Active Comparator|GRA|receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2)
3178894|NCT00666796|Placebo Comparator|A|
3041801|NCT00461708|Experimental|Rash, Grade <2|Participants with a rash graded less than (<) 2 according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version (v.) 3.0 received erlotinib, 100 milligrams (mg), orally (PO), once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
3041802|NCT00461708|Experimental|Rash, Grade ≥2|Participants with a rash graded greater than or equal to (≥) 2 according to the NCI-CTC v. 3.0 received erlotinib, 100 mg, PO, once per day until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment. Participants also received gemcitabine, 1000 mg/m^2, IV, over 30 minutes on Days 1, 8 and 15 in 4-week cycles until disease progression, unacceptable toxicity or refusal of patient to continue with the treatment.
3041803|NCT00461734|Active Comparator|RV Apex|
3041804|NCT00461734|Experimental|RV High Septum|
3041805|NCT00461773|Active Comparator|bevacizumab|brief exposure bevacizumab
3041806|NCT00461773|Active Comparator|bevacizumab and letrozole|brief exposure bevacizumab and letrozole
3041807|NCT00461786|Experimental|Pemetrexed|
3041808|NCT00461851|Experimental|Chemotherapy plus sorafenib|Gemcitabine 1000 mg/m2 weekly x 2 weeks plus carboplatin AUC (Area under curve) 5 every 3 weeks plus sorafenib x 6 cycles then maintenance sorafenib alone
3041809|NCT00461981|Experimental|FluMist, Influenza Virus Vaccine Live|FluMist, Influenza Virus Vaccine Live, Intranasal
3041810|NCT00461981|Active Comparator|TIV, Trivalent Inactivated Influenza Virus Vaccine|TIV, Trivalent Inactivated Influenza Virus Vaccine, Intramuscular
3041811|NCT00462020|Active Comparator|1|5 days of IV antibiotics after appendectomy
3041812|NCT00462020|Experimental|2|home on oral antibiotics to complete 7 days of treatment when tolerating PO's
3041813|NCT00462124|Other|Balloon|Implantation of a biodegradable balloon spacer (absorbable perirectal spacer)
3041814|NCT00462228|Experimental|Memantine|Subjects will be titrated up to 20 mg of memantine per day for 12 weeks, followed by placebo for 12 weeks
3041815|NCT00462228|Placebo Comparator|Placebo|Subjects will be titrated up to 20 mg of placebo per day for 12 weeks, followed by memantine for 12 weeks
3041816|NCT00462280|Experimental|Two matched nevi group - Lovastatin|Patients with two matched nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity.
3041817|NCT00462280|Placebo Comparator|Two Matched Nevi Group - Placebo|Patients with two matched nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3041818|NCT00462280|Experimental|One large nevi group - Lovastatin|Patients who have one large nevi received lovastatin PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3041819|NCT00462280|Placebo Comparator|One Large Nevi Group - Placebo|Patients who have one large nevi received placebo PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity
3041820|NCT00462306||Pregnant population|The study group consisted of pregnant women, presenting to Prentice Women's Hospital of Northwestern Memorial Hospital for spontaneous labor, induction of labor, and scheduled cesarean delivery.
3041821|NCT00462306||Non-Pregnant Population|The study group consisted of non-pregnant females, presenting to Northwestern Memorial Hospital for ambulatory surgery
3041822|NCT00462332|Experimental|High risk patientes|Category of risk will be defined according to biological features.
3041823|NCT00462332|Experimental|Low risk patients|Category of risk will be defined according to biological features.
3041824|NCT00462345|Experimental|Rituximab, Methotrexate|Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
3041825|NCT00462384|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 micrograms per kilogram (mcg/kg) body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
3041826|NCT00462423|Experimental|Single Arm, Open Label|Single Arm, Open Label trial of Abraxane and Avastin
3041827|NCT00462449|No Intervention|1|Individuals randomized into this group will only receive specialized therapy associated with this population.
3041828|NCT00462449|Experimental|2|In addition to appropriate therapy, this group will receive the FES device and be given instruction on how to complete specialized exercises utilizing this device.
3041829|NCT00462462|Experimental|1|Ethanol gel
3041830|NCT00462462|Active Comparator|2|Ethanol solution
3041831|NCT00462488|Active Comparator|Treatment Schedule A -|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 6 weeks. If free of disease at 12 weeks after the first instillation, the subject enters Maintenance dosing in which 30 mg of Vicinium is administered once per week for 3 weeks followed by 9 weeks of no therapy.~If the subject had histologically confirmed disease that is stage <T2, they repeat the Induction phase dosing. If the subject is free of disease, the subject enters the maintenance dosing phase of every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 51 (end-of-study [EOS])."
3132578|NCT03438539|Experimental|Inhibitory Control Training with Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
3178895|NCT00666796|Experimental|B|
3041832|NCT00462488|Active Comparator|Treatment Schedule B|"Induction Phase is a single intravesical dose of Vicinium at 30 mg in 40 mL PBS once per week for 12 weeks followed by 1 week of no therapy.~If 13 weeks after the first instillation of Vicinium the subject is free of disease, they have a break from therapy before entering Maintenance dosing in which 30 mg of Vicinium is administered once weekly for 3 weeks followed by 9 weeks of no therapy. If the subject is free of disease, additional maintenance cycle(s) are repeated every 12 weeks (3 weeks of therapy followed by 9 weeks of no therapy until disease recurrence is confirmed by positive biopsy or up to a maximum of Week 57 (EOS)."
3041833|NCT00462501|Experimental|Chemotherapy and Bevacizumab With or Without Radiation|FOLFOX/Bevacizumab will be given for 4 cycles over 8 weeks; FOLFOLX6 without Bevacizumab will be given for an additional 2 cycles over 4 weeks. Oxaliplatin will be given on Day 1 of each cycle over 2 hours at 85 mg/m2 IV. Leucovorin will be given Day 1 of each cycle over 2 hours at 400 mg/m2 IV. Fluorouracil will be given on Day 1 of each cycle at 400 mg/m2 IVP, then Fluorouracil will be given at 1200 mg/m2 IVCI over Day 1 and 2. Bevacizumab will be given at 5mg/kg over 10 minutes on day 1. Patients will undergo re-staging within 3 weeks of completing their 6th cycle of FOLFOX. If the reassessment reveals that there has been no disease progression as compared to the pre-treatment evaluation and the patient remains a candidate for an R0 resection. If the surgical oncologist's reassessment is that the patient is not a candidate for an R0 resection, the patient will proceed to standard pre-operative radiation with synchronous infusional 5-fluorouracil.
3041834|NCT00462605|Experimental|Arm I|Patients receive oral MS-275 on days 1, 8, 15, and 22. Patients also receive sargramostim (GM-CSF) subcutaneously once daily on days 1-42 in courses 3 and 5 and on days 1-35 in courses 1, 2, 4, and 6. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. After completion of 2 courses of study therapy, patients who achieve a complete or partial response may receive an additional 4 courses. Patients who maintain stable disease for more than 2 months after completion of 6 courses of study therapy may receive an additional 6 courses at the time of disease progression, provided they meet original eligibility criteria.
3041835|NCT00462644|Active Comparator|Etomidate|Etomidate Group patients were randomized to receive etomidate 0.3mg/kg IV plus succinylcholine 1mg/kg IV for RSI medications
3041836|NCT00462644|Active Comparator|Fentanyl-Midazolam|Fentanyl-Midazolam Group patients were randomized to receive 100ug fentanyl IV, plus 5 mg midazolam IV, plus 1mg/kg succinylcholine IV for RSI medications.
3041837|NCT00462670|Placebo Comparator|1|0mg
3041838|NCT00462670|Experimental|2|15mg OPC-41061
3041839|NCT00462709|Experimental|Open-label C1INH-nf|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 7 days.
3041840|NCT00462722|Placebo Comparator|Placebo pre and post exercise|placebo before and after musculoskeletal-loading exercise
3041841|NCT00462722|Experimental|Placebo pre and ibuprofen post exercise|placebo before and ibuprofen after musculoskeletal-loading exercise
3041842|NCT00462722|Experimental|Ibuprofen pre and placebo post exercise|ibuprofen before and placebo after musculoskeletal-loading exercise
3041843|NCT00462735|Experimental|Advanced Head and Neck Cancer|Patients with stage IVA and IVB or high-risk stage III squamous cell carcinomas of the head and neck
3041844|NCT00462748|Experimental|1|Arm 1: Drug
3041845|NCT00462748|Active Comparator|2|Arm 2: Active comparator
3041846|NCT00462748|Active Comparator|3|Arm 3: Active comparator
3041847|NCT00462761|Experimental|AC220|Determine safety, tolerability and pharmacokinetic (PK) parameters of AC220
3041848|NCT00462826|Experimental|Treatment (aflibercept)|Patients receive VEGF Trap IV over 1 hour on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3041849|NCT00462839|Experimental|Calibrated drapes viewed first|Caregivers were shown calibrated drape demonstrating level of blood and asked to estimate amount of blood in collection bag. These same individuals were then crossed over and shown non-calibrated drapes and asked to estimate the amount of blood they contained.
3041850|NCT00462839|Active Comparator|Non-calibrated drapes viewed first|Standard vaginal delivery drape (non-calibrated) was shown to caregiver who was asked to estimate amount of blood. These same individuals were then crossed over and shown calibrated delivery drapes and asked to estimate the amount of blood they contained.
3041851|NCT00462865|Experimental|Gemcitabine and Capecitabine and Avastin|Avastin administered concurrently with chemotherapy (Gemcitabine + Capecitabine) for six cycles followed by single agent Avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
3041852|NCT00462917|Experimental|Pleiotropic info, in-person disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed in-person during an APOE-based genetic risk assessment
3041853|NCT00462917|Experimental|AD-only info, phone disclosure|Alzheimer's disease risk information only is disclosed via telephone during an APOE-based genetic risk assessment
3041854|NCT00462917|Experimental|Pleiotropic info, phone disclosure|Incidental pleiotropic risk information, in addition to AD risk information, is disclosed via telephone during an APOE-based genetic risk assessment
3041855|NCT00462917|Active Comparator|AD-only info, in-person disclosure|Alzheimer's disease risk information only is disclosed in-person during an APOE-based genetic risk assessment
3468757|NCT03892928|Other|Dexmedetomidine group|0.1mcg/kg continuous infusion for 15min, 0.7-1mcg/kg.h during the whole colonoscopy
3041857|NCT00462982|Experimental|Sunitinib|Patients will be treated with 50 mg daily for four out of every six weeks.
3041858|NCT00463047|Experimental|Fentanyl Buccal Tablets (FBT)|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
3041859|NCT00463047|Active Comparator|Oxycodone|This study includes a screening period, 2 open-label dose titration periods (in randomized order), and 2 double-blind treatment periods (in randomized order).
3041860|NCT00463060|Experimental|Treatment|Participants treated with chemotherapy and radiotherapy
3041861|NCT00463151|Placebo Comparator|1|0mg rebamipide
3041862|NCT00463151|Experimental|2|60mg rebamipide
3041863|NCT00463151|Experimental|3|150mg rebamipide
3041864|NCT00463151|Experimental|4|300mg rebamipide
3178896|NCT00666796|Experimental|C|
3468758|NCT03892746|Active Comparator|Active tDCS + task oriented practice|
3468759|NCT03892746|Sham Comparator|Sham tDCS + task oriented practice|
3041865|NCT00463229|Experimental|Interprofessional Team Approach|Participants in the experimental group will receive home care services from a team of professional service providers [Community Care Access Centre (CCAC) Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist] and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
3041866|NCT00463229|No Intervention|Usual Home Care Services|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessment and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessment with clients.
3041867|NCT00463346|Experimental|Acamprosate|Acamprosate
3041868|NCT00463346|Placebo Comparator|placebo|placebo
3041869|NCT00463385|Experimental|Prednisone|"Participants received oral prednisone from Day 1-28 of each 28-day cycle for up to 3 cycles (84 days), 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day, and pomalidomide placebo tablets on Days 1-28 for up to 12 cycles in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants were discontinued from the study."
3041870|NCT00463385|Experimental|Pomalidomide|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and prednisone placebo tablets on Days 1-28 for the first 3 cycles in the Double-Blind Treatment Phase.~After the completion of Cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3041871|NCT00463385|Experimental|Pomalidomide 2 mg + Prednisone|"Participants received 2 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 2 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3041872|NCT00463385|Experimental|Pomalidomide 0.5 mg + Prednisone|"Participants received 0.5 mg oral pomalidomide daily from Day 1-28 of each 28-day cycle for up to 12 cycles (336 days), and oral prednisone tablets on Days 1-28 for the first 3 cycles, 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day in the Double-Blind Treatment Phase.~After the completion of cycle 12 and upon unblinding, participants determined to have a complete remission (CR), partial remission (PR) or clinical improvement (CI) using the International Working Group (IWG) Response Criteria in the study protocol, were eligible to participate in the extension phase and continue to receive oral pomalidomide 0.5 mg daily, from Days 1-28 of each cycle, until disease progression, unacceptable toxicity or voluntary withdrawal."
3041873|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Meningitec™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Wyeth's Men-C conjugate vaccine (Meningitec™) at 11-18 months of age.
3041874|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + NeisVac-C™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with GSK Biologicals' DTPa-combined vaccine (Infanrix™ hexa in Germany & Poland and Infanrix™ IPV Hib in Spain) and Baxter's Men-C conjugate vaccine (NeisVac-C™) at 11-18 months of age.
3041875|NCT00463437|Experimental|GSK's 10-valent Pneumococcal Vaccine 1024850A + Menitorix™|Subjects receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
3041876|NCT00463437|Active Comparator|Prevenar™ + Menitorix™|Subjects receiving a booster dose of Wyeth's pneumococcal conjugate vaccine (Prevenar™) co-administered with DTPa-combined vaccine (Infanrix™ penta in Germany & Poland and Infanrix™ IPV in Spain) and GSK Biologicals' combined Hib-MenC vaccine (Menitorix™) at 11-18 months of age.
3041877|NCT00463476|Experimental|2-year olds|Healthy children 2 years of age (±3 months) who had previously received all vaccinations recommended under the Sri Lankan childhood immunization schedule according to their age. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12 and 13 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
3041878|NCT00463476|Experimental|5-year olds|Healthy children 5 years of age (±3 months) that met all other eligibility criteria. Subjects must have previously received inactivated mouse brain-derived Japanese Encephalitis vaccine (IMBV) at the recommended 12, 13, and 24 months of age. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV).
3041879|NCT00463567|Experimental|Indacaterol 150 µg (Continued Into Stage 2)|"In the morning, Indacaterol 150 µg once daily orally inhaled via a single dose dry powder inhaler (SDDPI) + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily Inhaled Corticosteroid (ICS) monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3132863|NCT03460899|Experimental|Clamp Arm|All 14 subjects will undergo an Euglycaemic Clamp at Visit 2 as well as a Hyperinsulinaemic/Hypoglycaemic Clamp at Visit 3 with the Intervention of reaching certain plasma glucose levels for blood sampling regarding platelet activity parameters. Infusion of Dextrose and human soluble insulin (Actrapid) will be used to reach certain plasma glucose levels.
3178897|NCT00666796|Experimental|D|
3178898|NCT00666809|Active Comparator|Arm 1|
3041880|NCT00463567|Experimental|Indacaterol 300 µg (Continued Into Stage 2)|"In the morning, Indacaterol 300 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041881|NCT00463567|Active Comparator|Tiotropium 18 µg (Continued Into Stage 2)|"Tiotropium 18 µg dry powder capsules delivered (open label) via manufacturer's proprietary SDDPI, (Handihaler®). Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041882|NCT00463567|Placebo Comparator|Placebo (Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 and continued treatment up to 26 weeks in Stage 2. Placebo to Formoterol inhalation in the morning and in the evening was discontinued after Stage 1.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041883|NCT00463567|Experimental|Indacaterol 75 µg (Not Continued into Stage 2)|"In the morning, Indacaterol 75 µg once daily orally inhaled via a SDDPI + Placebo to Indacaterol delivered via SDDPI + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041884|NCT00463567|Experimental|Indacaterol 600 µg (Not Continued Into Stage 2)|"In the morning, 2 capsules of Indacaterol 300 µg once daily orally inhaled via two SDDPI devices + Placebo to Formoterol delivered via Aerolizer. In the evening, Placebo to Formoterol delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041885|NCT00463567|Active Comparator|Formoterol 12 µg (Not Continued Into Stage 2)|"In the morning, Placebo to Indacaterol delivered via two SDDPI devices + Formoterol 12 µg delivered via Aerolizer. In evening, Formoterol 12 µg delivered via Aerolizer. Participated in the 2 week Stage 1 but did not continue to Stage 2.~Daily ICS monotherapy (if applicable) was to remain stable and Salbutamol/albuterol was available for rescue use throughout study."
3041886|NCT00463580|Experimental|Infliximab|Participants in this arm will receive an infusion of infliximab.
3041887|NCT00463580|Placebo Comparator|Placebo|Participants in this arm will receive an infusion of normal saline.
3041888|NCT00463606|Experimental|ABT-335 and Rosuvastatin Calcium|ABT-335 135mg in combination with rosuvastatin calcium 5mg administered orally, once daily for 12 weeks
3041889|NCT00463606|Active Comparator|ABT-335|ABT-335 135mg monotherapy administered orally, once daily for 12 weeks
3041890|NCT00463606|Active Comparator|Rosuvastatin Calcium|Rosuvastatin calcium 5mg monotherapy administered orally, once daily for 12 weeks
3041891|NCT00463684|Experimental|All subjects|Healthy infants 9 months of age (plus or minus 2 weeks) that met the eligibility criteria. Subjects received one dose of Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV) and one dose of live, attenuated measles vaccine.
3041892|NCT00463788|Experimental|cisplatin and cetuximab|
3041893|NCT00463788|Active Comparator|cisplatin|
3041894|NCT00463801|Experimental|Daptomycin|350 mg of Daptomycin was supplied as sterile lyophilized powder in glass vials. Each vial was to be reconstituted with 7 mL of normal saline or water for injection, to give a 50 mg/mL drug concentration. Daptomycin was to be administered as a 30-minute intravenous infusion, once daily for at least 7 days, at the dose of 4 mg/Kg, up to a maximum of 14 days.
3041895|NCT00463840|Experimental|Oxaliplatin+ 5FU+ radiation (RT) /surgery /FOLFOX 6|"Concurrent chemoradiation before surgery and FOLFOX6 regimen after surgery~Radiation (RT) 180cGy daily x 5 days/week x 5 weeks, then additional 540 cGy in 3 fractions over a half week to pancreatic portal;~Combined with :~5FU 200 mg/m^2 daily by continuous intravenous infusion (CIV) x 5 weeks and weekly Oxaliplatin 60 mg/m^2, IV for 5 weeks (in Phase I, 30, 40, 50, and 60 mg/m^2 Oxaliplatin were tested).~Observation for 2 weeks to assess dose-limiting toxicity (DLT)/Response. Surgery if deemed resectable.~Then modified FOLFOX 6 for 6 cycles (2 weeks/cycle):~Day 1 hour 0: Oxaliplatin 85 mg/m^2 intravenously (IV) + Leucovorin 350 mg IV over 2 hours; hour 2: 5FU 400 mg/m^2 IV bolus followed by 2400 mg/m^2 IV over 46 hours."
3041896|NCT00464087|Active Comparator|Heparin|Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
3041897|NCT00464087|Active Comparator|Bivalirudin|Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
3041898|NCT00464204|Experimental|Voluven® Arm|
3041899|NCT00464204|Active Comparator|0.9 % NaCl|
3041900|NCT00464269|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period.
3041901|NCT00464269|Experimental|Brivaracetam 5 mg/day|Brivaracetam 5 mg/day, 2.5 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg /day in a double-blinded way for the 12-week Treatment Period.
3041902|NCT00464269|Experimental|BRV 20mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period.
3041903|NCT00464269|Experimental|BRV 50mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day. Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day, in a double-blinded way for the 12-week Treatment Period.
3041904|NCT00464308|Active Comparator|001|Esomeprazole 40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3041905|NCT00464308|Active Comparator|002|Esomeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3041906|NCT00464308|Active Comparator|003|Rabeprazole 20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
3041907|NCT00464334|Experimental|Placebo to V950/IMX 0 mcg|Participants receive Placebo to V950/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041908|NCT00464334|Experimental|Placebo to V950/IMX 16 mcg|Participants receive Placebo to V950/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041909|NCT00464334|Experimental|V950 0.5 mcg/IMX 0 mcg|Participants receive V950 0.5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041910|NCT00464334|Experimental|V950 0.5 mcg/IMX 16 mcg|Participants receive V950 0.5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041911|NCT00464334|Experimental|V950 0.5 mcg/IMX 47 mcg|Participants receive V950 0.5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041912|NCT00464334|Experimental|V950 0.5 mcg/IMX 94 mcg|Participants receive V950 0.5 mcg/IMX 94 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041913|NCT00464334|Experimental|V950 5 mcg/IMX 0 mcg|Participants receive V950 5 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041914|NCT00464334|Experimental|V950 5 mcg/IMX 16 mcg|Participants receive V950 5 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041915|NCT00464334|Experimental|V950 5 mcg/IMX 47 mcg|Participants receive V950 5 mcg/IMX 47 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041916|NCT00464334|Experimental|V950 50 mcg/IMX 0 mcg|Participants receive V950 50 mcg/IMX 0 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041917|NCT00464334|Experimental|V950 50 mcg/IMX 16 mcg|Participants receive V950 50 mcg/IMX 16 mcg, 0.5 mL intramuscular injection at Months 0, 2 and 6.
3041918|NCT00464438|Experimental|1|
3041919|NCT00464438|Active Comparator|2|
3041920|NCT00464464|Active Comparator|1|cognitive-behavioral therapy
3041921|NCT00464464|No Intervention|2|standard medical care
3041922|NCT00464490|No Intervention|Standard Hospital Ventilation Weaning Protocol|Control. Hospital weaning protocol
3041923|NCT00464490|Experimental|Dexmedetomidine for Extubation|Dexmedomidine infusion to facilitate extubation
3041924|NCT00464542|Other|Metronidazole|Observational before and after treatment Drug: Metronidazole 500 mg, taken by mouth, two times a day, 7 days
3041925|NCT00464620|Experimental|Dasatinib, 70 mg, twice daily|Patients take 70 mg of Dasatinib, twice daily, for 28 day cycles
3041926|NCT00464646|Experimental|1|"Cohort A: Women with unresected locally advanced breast cancer (clinical Stage IIIA, IIIB, and IIIC)~Cohort B: Women with resected pN2 or pN3 (pathologic Stage III) breast cancer"
3041927|NCT00464672|Experimental|Influenza virus vaccine|
3041928|NCT00464672|Active Comparator|Comparator influenza vaccine|
3041929|NCT00464685|Experimental|700 µg Dexamethasone Implant and Laser Photocoagulation|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
3041930|NCT00464685|Sham Comparator|Sham Implant and Laser Photocoagulation|Initial sham injection with up to 1 additional treatment based on re-treatment criteria. Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
3041931|NCT00464698|Experimental|All Study Participants|Duloxetine 30mg: Dose level 1 (Week 1) Duloxetine 60mg: Dose level 2 (Wks 2-4) Duloxetine 120mg: Dose level 3 (Wks 3-7)
3041932|NCT00464711|Other|Escitalopram|single arm
3041933|NCT00464737|Placebo Comparator|Placebo|Placebo
3041934|NCT00464737|Experimental|Rotigotine 4 mg|4 mg/24 hrs
3041935|NCT00464737|Experimental|Rotigotine 8 mg|8 mg/24 hrs
3041936|NCT00464815|Experimental|Group A|Subjects of 11-17 years of age who will receive GSK134612
3041937|NCT00464815|Active Comparator|Group B|Subjects of 11-17 years of age who will receive MencevaxTM ACWY
3041938|NCT00464945|Experimental|1|
3041939|NCT00464945|Active Comparator|2|
3041940|NCT00465088|Experimental|1|
3041941|NCT00465088|Experimental|2|
3041942|NCT00465101|Other|GreenLight HPS|
3041943|NCT00465179|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg by mouth daily for 4 weeks, then 2 weeks off.
3041944|NCT00465270|Experimental|Device|AMPLATZER PFO Occluder
3041945|NCT00465270|Active Comparator|Standard or Care - Medical Management|Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
3041946|NCT00465361|No Intervention|Baseline Performance|Observation of baseline performance
3041947|NCT00465361|Experimental|Post-intervention Performance|Observation of performance post-intervention
3041948|NCT00465530|Experimental|2|Saline plus Gentamycin
3041949|NCT00465530|Placebo Comparator|1|Saline
3041950|NCT00465569|Experimental|Active Treatment|Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians
3041951|NCT00465569|Placebo Comparator|Placebo|
3041952|NCT00465595|Experimental|Low Dose First, High Dose Second|The Low-Dose-1st Group received the low dose of psilocybin on the first session and the high dose on the second session
3041953|NCT00465595|Experimental|High Dose First, Low Dose Second|The High-Dose-1st Group received the high dose of psilocybin on the first session and the low dose on the second session
3041954|NCT00465647|Experimental|≥ 28 Days to < 13 Months|infant and toddler
3041955|NCT00465647|Experimental|≥ 13 months to < 5 years|young child
3041956|NCT00465647|Experimental|≥ 5 years to < 12 years|older child
3041957|NCT00465647|Experimental|≥ 12 years to < 17 years|adolescent
3041958|NCT00465738|Experimental|incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 5.0 mL resulted in a dose of 20 units per 1.0 mL."
3041959|NCT00465738|Active Comparator|incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 mL sterile of NaCl 0.9% solution without preservatives. Dilution with 2.0 mL resulted in a dose of 50 units per 1.0 mL."
3041960|NCT00465816|Experimental|Nimenrix + Twinrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
3041961|NCT00465816|Active Comparator|Nimenrix Group|Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
3041962|NCT00465816|Active Comparator|Twinrix Group|Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
3041963|NCT00465894|Active Comparator|Extended Release Tolterodine LA|An anti-muscarinic drug that is used for symptomatic treatment of urinary incontinence.
3041964|NCT00465894|Active Comparator|Intra Vaginal Estradiol Cream|For topical application to the vaginal area to treat symptoms of urgency or irritation with urination.
3041965|NCT00465972|Placebo Comparator|Placebo|Placebo
3041966|NCT00465972|Active Comparator|2|Doxepin
3041967|NCT00465972|Active Comparator|3|Temazepam
3041968|NCT00465985|Experimental|Part I, Part II-arm1, & Part III|
3041969|NCT00465985|Placebo Comparator|Part II - arm 2|
3041970|NCT00466167|Other|Pramipexole ER|
3041971|NCT00466167|Other|Pramipexole IR|
3041972|NCT00466167|Placebo Comparator|Placebo|
3041973|NCT00466193|Experimental|Zolpidem 3.5mg|
3041974|NCT00466193|Placebo Comparator|Placebo|
3041975|NCT00466206|Experimental|3MP - Treatment Arm|Magnetic Mini-Mover Procedure using the Magnimplant and Magnatract
3041976|NCT00466310|Active Comparator|Aripiprazole for 4 weeks|Blood is drawn for baseline. 20 Subjects are randomly assigned to receive Aripiprazole for weeks weeks with a starting dose of 10mg/day and the dose will be titrated to a maximum of 30mg /day based on effectiveness and tolerability. After 4 weeks of treatment, blood will be drawn again for metabolomics.
3041977|NCT00466310|Active Comparator|Risperidone for 4 weeks|Blood will be drawn for baseline evaluation. 20 Subjects will be randomly assigned to receive risperidone at a starting dose of 2mg/day, and can be increased to 6mg/day based on response of the subject. After 4 weeks of medication, blood is drawn again.
3041978|NCT00466310|Other|Healthy volunteers|Fasting blood samples will be drawn from healthy volunteers to match age, race and gender with the research subjects for comparison.
3041979|NCT00466323|Experimental|FMPO Condition|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
3041980|NCT00466323|Active Comparator|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
3041981|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin|Regimen A: docetaxel 75 milligrams per square meter (mg/m^2), intravenous (IV) is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 milligrams (mg) oral (po), twice daily (BID) every day. In Cycle 1, enzastaurin is given as a loading dose of 1125 mg on the day prior to docetaxel and prednisone therapy, followed by enzastaurin 500 mg po, daily (QD) for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
3041982|NCT00466440|Placebo Comparator|docetaxel + prednisone + placebo|Regimen B: docetaxel 75 mg/m^2, IV is administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, placebo is given as a loading dose on the day prior to docetaxel and prednisone therapy, followed by po, QD placebo for the remaining Period 2 (chemotherapy) and Period 3 (maintenance), until unblinding.
3041983|NCT00466440|Experimental|docetaxel + prednisone + enzastaurin (modified Regimen A)|Modified Regimen A, including pharmacokinetic (PK) characterization: Participants were treated with a modified investigational regimen with no dose escalation: docetaxel 75 mg/m2, IV was administered on Day 1 every 3 weeks for 6 cycles (maximum up to 10 cycles) and prednisone 5 mg po, BID every day. In Cycle 1, enzastaurin was given as a loading dose of 1125 mg starting on Day 4, followed by enzastaurin 500 mg po, QD for the remaining Period 2 (chemotherapy) and Period 3 (maintenance).
3041984|NCT00466505|Experimental|Therapeutic Intervention|
3041985|NCT00466661|Experimental|Acamprosate|666 mg p.o. TID
3041986|NCT00466661|Placebo Comparator|Placebo|Matching placebo
3041987|NCT00466687|Experimental|Therapeutic Intervention|"Tarceva and Avastin:~Tarceva: 150mg PO, days 1-28~Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course"
3041988|NCT00466752|Experimental|Treatment (enzyme inhibitor) 48hr stop|Patients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 days after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
3041989|NCT00466752|Experimental|Treatment (enzyme inhibitor) 24hr stop|tients receive sorafenib tosylate PO BID on days 1-14. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 day after completion of sorafenib tosylate, patients undergo radical prostatectomy on approximately day 43.
3041990|NCT00466817|Experimental|Valganciclovir|Six months of oral Valganciclovir.
3041991|NCT00466817|Placebo Comparator|Placebo|Six weeks of oral Valganciclovir followed by placebo to complete the six month time period.
3041992|NCT00466921|Experimental|Lenalidomide|
3041993|NCT00466947|Experimental|Synflorix Group|Subjects received 3 primary doses of Synflorix at 2, 4 and 6 months of age co-administered with Infanrix-hexa and booster dose of Synflorix at 15-18 months of age co-administered with Infanrix-IPV/Hib. All vaccines were administered intramuscularly in the right (Synflorix) or the left (Infanrix-hexa, Infanrix-IPV/Hib) thigh (primary dose) or deltoid (booster dose).
3041994|NCT00466947|Active Comparator|Control Group|Subjects received 3 doses of Engerix at 2, 4 and 6 months of age co-administered with Infanrix-IPV/Hib and 1 dose of Havrix co-administered with Infanrix-IPV/Hib at 15-18 months of age. All vaccines were administered in the right (Engerix, Havrix) or the left (Infanrix-IPV/Hib) thigh.
3041995|NCT00466960|Experimental|Treatment (colony stimulating factor and chemotherapy)|"INDUCTION THERAPY: Patients receive GM-CSF SC once daily on days 16-26. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 14 days after last GM-CSF injection, patients receive GM-CSF SC once daily on days 1-15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3041996|NCT00467038|Other|Dialectical Behavior Therapy|Dialectical Behavior Therapy
3041997|NCT00467038|No Intervention|Healthy Controls|Healthy controls
3041998|NCT00467051|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1 and ifosfamide IV over 1 hour on days 1-5. Beginning on day 6, patients receive filgrastim (G-CSF) subcutaneously or IV once daily until blood count returns to normal. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3041999|NCT00467077|Experimental|Gefitinib and PEG-IFNa Treatment|Gefitinib administered at a dose of 250 mg orally once daily for 12 weeks. PEG-IFNa at 4.0 µg/kg/wk administered subcutaneously once weekly for 6 weeks (cycle repeated once for a total of 2 cycles).
3042000|NCT00467259|Placebo Comparator|Placebo|28 cm² Placebo patch
3042001|NCT00467259|Experimental|Testosterone|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
3042002|NCT00467272|Experimental|Daptomycin|Daptomycin 6 mg/kg intravenous (IV) every 24 hours for at least 7-14 days, depending on the type of bacteria.
3042003|NCT00467285||Group 1|140 subjects with type 2 diabetes on pioglitazone.
3042004|NCT00467285||Group 2|140 subjects with type 2 diabetes not on pioglitazone.
3042005|NCT00467298|Experimental|Self-management|Novel intensive self-management education and exercise program of four weeks
3042006|NCT00467298|No Intervention|Usual care|Usual care- cardiac or pulmonary rehabilitation exercise program of 8 weeks duration
3042007|NCT00467350|Active Comparator|enema|Rectal enema containing mixture of milk and molasses
3042008|NCT00467350|Active Comparator|PEG 3350|Medication to be taken orally once each day for three consecutive days
3042009|NCT00467363|Active Comparator|Aspirin|81mg of low-dose aspirin plus 400micrograms of folic acid.
3042010|NCT00467363|Placebo Comparator|Placebo|400micrograms of folic acid.
3042011|NCT00467389|Experimental|Oral Placebo First|Three days of daily treatment with oral placebo, followed by three days of daily treatment with 5 mg of donepezil
3042012|NCT00467389|Experimental|Donepezil First|Three days of daily treatment with 5 mg of donepezil, followed by three days of daily treatment with oral placebo.
3042013|NCT00467519|Experimental|Group 1|DAPTACEL primed participants
3042014|NCT00467519|Experimental|Group 2|Pentacel primed participants
3042015|NCT00467558|Active Comparator|Naltrexone|Naltrexone 50mg-150mg by mouth per day.
3042016|NCT00467558|Placebo Comparator|Placebo|Placebo pills (1-3 pills daily) depending upon dose prescribed by study physician
3042017|NCT00467584|Active Comparator|High Dose Aspirin|High Dose Aspirin; 1300 milligrams of aspirin per day, taken by mouth as two tablets, twice per day for 8 weeks
3042018|NCT00467584|Active Comparator|Low Dose Aspirin|Low Dose Aspirin; 162 milligrams of aspirin per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
3042019|NCT00467584|Placebo Comparator|Placebo|Placebo tablets, matching the active aspirin tablets in appearance, taken by mouth twice per day for 8 weeks
3042020|NCT00467597||Group 1|
3042021|NCT00467610|Experimental|Panhematin|
3042022|NCT00467649|Experimental|Group A|
3042023|NCT00467649|Active Comparator|Group B|
3042024|NCT00467779|Experimental|Stage 1: Cobimetinib Dose Escalation (21/7 Schedule)|Participants will receive cobimetinib (GDC-0973/XL518) at the starting dose of 0.05 mg/kg via solution or capsule, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3042025|NCT00467779|Experimental|Stage 1A: Cobimetinib Dose Escalation (14/14 Schedule)|Participants will receive cobimetinib at the starting dose of 60 mg via solution or capsule, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3042026|NCT00467779|Experimental|Stage 2: Cobimetinib Expansion (21/7 Schedule)|Participants will receive cobimetinib at the maximum tolerated dose (MTD) established in Stage 1, once daily for Days 1-21 of each 28-day cycle (21 days on drug followed by 7 days off treatment [21/7 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3042027|NCT00467779|Experimental|Stage 2 A: Cobimetinib Expansion (14/14 Schedule)|Participants will receive cobimetinib at the MTD established in Stage 1A, once daily for Days 1-14 of each 28-day cycle (14 days on drug followed by 14 days off treatment [14/14 schedule]). Treatment will continue until progressive disease (PD) or unacceptable toxicity for up to 1 year at the discretion of investigator and beyond 1 year with the agreement of the sponsor.
3042028|NCT00467779|Experimental|Stage 3: Cobimetinib+Midazolam+Dextromethorphan|Participants will receive a single dose of midazolam (2 mg of midazolam syrup) and dextromethorphan (30 mg tablet) on Cycle 1 Day 1, in the absence of cobimetinib. After a 2-day washout period, participants will receive 21 consecutive daily doses of cobimetinib (60-mg) followed by a 7-day washout period. Participants will receive another single dose of midazolam and dextromethorphan on Cycle 1 Day 15, in the presence of steady-state cobimetinib concentrations. In Cycle 2 and beyond participants will receive cobimetinib alone, administered as a 60-mg daily dose for 21 consecutive days in 28-day cycles (21/7 schedule).
3042029|NCT00467818|Active Comparator|Omega 3 fatty Acids, drug|Omega 3 Fatty acids will be dispensed to subjects in the active experimental group of the study.
3042030|NCT00467818|Placebo Comparator|Placebo|The placebo will be dispensed to subjects in the control group
3042031|NCT00467831|Experimental|Multi-Drug Regimen|Losartan, 25 mg by mouth every night at bedtime; Zileuton, 1200 mg by mouth twice daily; N-acetylcysteine, 600 mg by mouth three times daily; Pravastatin, 20 mg by mouth every night at bedtime; Erythromycin, 333 mg by mouth three times daily.
3042032|NCT00467844|Experimental|1|1 mg GTx-024
3042033|NCT00467844|Experimental|2|3 mg GTx-024
3042034|NCT00467844|Placebo Comparator|3|Placebo
3042035|NCT00467857|Active Comparator|InteguSeal* and standard surgical preparation solutions|InteguSeal* microbial skin sealant was applied to surgical sites prior to incision after standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
3178899|NCT00666809|Placebo Comparator|Arm 2|
3042036|NCT00467857|Other|Standard surgical skin preparation alone|Prior to incision, standard surgical skin preparation in patients undergoing coronary artery bypass graft (CABG) surgery
3042037|NCT00467870|Experimental|1|750 mg dose of testosterone undecanoate
3042038|NCT00467870|Experimental|2|1000 mg dose testosterone undecanoate
3042039|NCT00467896|Experimental|Iloprost|The study enrolled patients who were already using iloprost (10 µg/mL) standard dose (5 µg) delivered by I-neb® Adaptive Aerosol Delivery (AAD) System with Power Disc-6 (PD-6) without any safety or tolerability concerns, thereby facilitating a direct comparison with the Power Disc-15 (PD-15). The single arm design allowed each patient to serve as his/her own control.
3042040|NCT00467961|Experimental|Miltenyi system transplant recipients|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach. Older subjects will receive a lower dose of irradiation to reduce the regimen intensity. Determine appropriate level of post transplant immunosuppression
3042041|NCT00468052|Active Comparator|fentanyl|fentanyl bolus 1ug.kg-1
3042042|NCT00468052|Experimental|dexmedetomidine|dexmedetomidine 2ug.kg-1 over 10 min followed by 0.7ug.kg-1.h-1
3042043|NCT00468104|Active Comparator|Alteplase, Placebo- intapleural instillation|Either 25 mg of Alteplase or Placebo instilled daily. Response to therapy after three days. cross over to the other drug if no response was noted.
3042044|NCT00468104|Active Comparator|Placebo, Alteplase -2nd arm|If the first arm fails then the 2nd arm ( cross over to either Placebo or Alteplase not used in the first arm) instilled intrapleurally daily for three days
3042045|NCT00468143|Experimental|Adderall Extended Release First|This group was treated with Adderall extended release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall immediate release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
3042046|NCT00468143|Experimental|Adderall Immediate Release First|This group was treated with Adderall immediate release, either during phase 2 of the trial, or during phase 3 (this subset received Adderall extended release during phase 2 and then underwent a washout period). This was a counterbalanced crossover study, with a washout period in between treatment periods. Participants were randomized in a 1:1 ratio to one of two schedules Adderall IR followed by Adderall XR, or Adderall XR followed by Adderall IR.
3042047|NCT00468169|Experimental|A: Cetuximab+FHX|Cetuximab [250mg/m2 (day 1, weekly x10)] + FHX (5-FU [CI: 600mg/m2/day; days 0-5 (120h total) every other week x5], Hydroxyurea [500 mg PO BID, days 0-5 (=11 doses), every other week x5] and twice-daily radiation [150 cGy per fraction - days 1-5, every other week x5 (70-72 Gy total dose)]). Total duration is 10 weeks.
3042048|NCT00468169|Experimental|B: Cetuximab + PX|Cetuximab [250 mg/m2 (day 1, weekly x7)] + PX (Cisplatin [100mg/m2 (week 1 & 4 on day 1 (or 2))], Accelerated fraction radiotherapy with concomitant boost [AFX-CB (72 Gy/42 F/6 W) (3-D or IMRT based)]). Total duration: 7 weeks.
3042049|NCT00468208|Experimental|1|Participants will receive abatacept intravenously at study visits on Days 1, 15, and 29, and then once a month thereafter.
3042050|NCT00468286|Experimental|A|Treatment group A: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
3042051|NCT00468286|Experimental|B|Treatment group B: Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months.
3042052|NCT00468299|Active Comparator|Misoprostol and placebo|Women in this arm receive placebo and misoprostol 800 mcg buccally
3042053|NCT00468299|Experimental|Mifepristone and misoprostol|Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally
3042054|NCT00468312|Experimental|Mometasone Furoate Nasal Spray (MFNS)|200 mcg daily
3042055|NCT00468312|Placebo Comparator|Placebo|Two sprays in each nostril in the morning
3042056|NCT00468481|Experimental|Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)|1 tablet 0.020 mg EE/3.0 mg DRSP/0.451 mg L-5-MTHF as calcium salt given orally/daily for 24 days followed by 1 tablet 0.451 mg L-5-MTHF as calcium salt given orally/daily for 4 days over a time period of 24 weeks
3042057|NCT00468481|Active Comparator|Drospirenone (DRSP)/Ethinylestradiol (EE)|1 tablet 0.020 mg EE/3.0 mg DRSP [YAZ] given orally/daily for 24 days followed by 1 placebo tablet given orally/daily for 4 days over a time period of 24 weeks
3042058|NCT00468546|Placebo Comparator|Placebo Plus Methotrexate|Participants will be administered placebo by intravenous infusion on Days 1 and 15 along with MTX 10-25 mg per os (p.o.) or parenterally once a week up to 24 weeks and will be followed up to Week 104.
3042059|NCT00468546|Experimental|Rituximab plus Methotrexate|Participants will be administered rituximab 1000 mg as intravenous infusion on Days 1 and 15 along with MTX 10-25 mg p.o. or parenterally once a week up to Week 24 and will be followed up to Week 104.
3042060|NCT00468559|Experimental|Open Label Esomeprazole|This is an open label, run-in phase. All patients received Esomeprazole.
3042061|NCT00468559|Experimental|Double Blind Esomeprazole|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
3042062|NCT00468559|Placebo Comparator|Double Blind Placebo|This is the double blind withdrawal phase. Patients are randomized to active drug or placebo.
3042063|NCT00468585|Experimental|1 Capecitabine and Bevacizumab|The Phase II trial has a Simon mini-max two-stage design. Twenty-seven patients will be enrolled to the first stage of the Phase II trial, with a target accrual of 40 patients. The treatment dose of capecitabine as determined in the Phase I portion of this trial will be administered orally in two divided doses daily on Days 1 through 7 and Days 15 through 21 in a 28 day cycle. Phase II patients will receive bevacizumab 10 mg/kg intravenously every 2 weeks concurrently with oral capecitabine. Patients will be evaluated for toxicity between Days 3 to 5 (complete blood count only), Day 8, Day 15, and Day 22 during cycle #1. Thereafter, toxicity will be assessed on Days 1 and 15. Efficacy will be assessed with every other week physical examination and radiographic scans of measurable disease every 12 weeks.
3178900|NCT00666874|Experimental|1|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
3042064|NCT00468650|Active Comparator|Open label|Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive Patrex® 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to Patrex® 100 mg PRN for the following four weeks.
3042065|NCT00468676|Active Comparator|B|Treatment as usual
3042066|NCT00468676|Experimental|A|Case management intervention
3042067|NCT00468728|Active Comparator|1|Vancomycin
3042068|NCT00468728|Experimental|2|PAR-101/OPT-80
3042069|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 6 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3042070|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 7 to 11 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3042071|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 12 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3042072|NCT00468819|Experimental|Gadobutrol (Gadavist, BAY86-4875) - age 2 to 17 years|Participants received Gadobutrol 0.1 mmol/kg body weight (BW) = 0.1 mL/kg BW as single intravenous bolus injection
3042073|NCT00468845|Experimental|1|
3042074|NCT00468845|Experimental|2|
3042075|NCT00468845|Placebo Comparator|3|
3042076|NCT00468858|Experimental|T-DEN-Post-Transfection F17|Post-Transfection F17, full dose
3042077|NCT00468858|Experimental|T-DEN-Post-Transfection F19|Post-Transfection F19, full dose
3042078|NCT00468858|Placebo Comparator|Placebo|Control
3042079|NCT00468910|Experimental|Arm I|Patients receive oral acetylsalicylic acid (aspirin) once daily.
3042080|NCT00468910|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
3042081|NCT00469014|Active Comparator|Arm 1: Busulfan + Fludarabine (30 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 30 mg/m^2 intravenous (IV) Daily + Fludarabine 30 mg/m^2 IV Daily; + Clofarabine 10 mg/m^2 IV Daily; Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
3042082|NCT00469014|Experimental|Arm 2: Busulfan + Fludarabine (20 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 20 mg/m^2 IV + Fludarabine 20 mg/m^2 IV Daily + Clofarabine 20 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
3042083|NCT00469014|Experimental|Arm 3: Busulfan + Fludarabine (10 mg/m^2) + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 10 mg/m^2 IV Daily + Fludarabine 10 mg/m^2 IV Daily + Clofarabine 30 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
3042084|NCT00469014|Experimental|Arm 4: Busulfan + Clofarabine|4-day Treatment Period Day -6 to Day -2: Busulfan 40 mg/m^2 IV Daily + Clofarabine 40 mg/m^2 IV Daily. Thymoglobulin Day -3 to Day -1, and Stem Cell Infusion Day 0.
3042085|NCT00469079|Active Comparator|1|Nicotine gum or nicotine lozenge; Dosage: 2 or 4 mg; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3042086|NCT00469079|Experimental|2|Taboka - oral tobacco product Dosage: 0.84 to 1.26 mg free nicotine per g dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3042087|NCT00469079|Experimental|3|Camel Snus - oral tobacco product Dosage: 6.09 to 9.16 mg dry weight; Frequency: Daily; Duration: 5 weeks of use of which 1 week is tapering.
3042088|NCT00469092|Experimental|BIAsp 30|
3042089|NCT00469092|Active Comparator|Glargine|
3042090|NCT00469144|Experimental|Fixed-Dose Busulfan + Fludarabine|Busulfan Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
3042091|NCT00469144|Experimental|Adjusted Dose Busulfan + Fludarabine|Busulfan Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day. Fludarabine 40 mg/m^2 IV Daily Over 1 Hour x 4 Days.
3042092|NCT00469209|Active Comparator|No Bortezomib|Arm 1: Melphalan 100 mg/m^2 intravenous (IV) days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3042093|NCT00469209|Active Comparator|Bortezomib 1.0 mg/m^2|Arm 2: Bortezomib (Level 1) 1.0 mg/m^2 IV push on Days -9, -6, and -3, Melphalan 100 mg/m^2 IV days -4,-3 + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3042094|NCT00469209|Active Comparator|Bortezomib 1.5 mg/m^2|Arm 3: Bortezomib (Level 2) 1.5 mg/m^2 IV push on Days -9, -6, and -3, Melphalan + Arsenic Trioxide 0.25 mg/kg IV for 7 days + Vitamin C IV daily
3042095|NCT00469274|Active Comparator|Antibiotic PEP|Subjects who did receive PEP following pertussis exposure
3042096|NCT00469274|No Intervention|No PEP|Subjects who did not receive PEP following pertussis exposure
3042097|NCT00469391|Experimental|GI Sleeve|medical device that mimics gastric bypass mechanism for weight-loss
3042098|NCT00469391|Sham Comparator|Sham Control|
3042099|NCT00469456|Active Comparator|1|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
3042100|NCT00469456|Placebo Comparator|2|Placebo oral administration twice daily for 12 weeks
3042101|NCT00469508|Active Comparator|Modafinil|Modafinil 400mg oral dose taken daily for 12 weeks
3042102|NCT00469508|Placebo Comparator|Placebo|Modafinil 0mg (sugar pill) oral dose taken daily for 12 weeks
3042103|NCT00469833|Experimental|Arm 1|Intervention: Insulin glargine treatment. The study is designed as a within subjects comparison of insulin secretion in type 2 diabetic patients before and after 2 months of insulin treatment to reduce blood glucose. Insulin secretion will be determined with a hyperglycemic clamp using 20% dextrose, and ingestion of an oral glucose solution (75 g).
3042104|NCT00469859|Experimental|Group 1 (Lestaurtinib dose 50 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
3042105|NCT00469859|Experimental|Group 2 (Lestaurtinib: Dose 62.5 mg/m2|"DOSE-FINDING PHASE:~COURSE 1: Patients receive cytarabine IV over 2 hours twice daily on days 1-4, idarubicin IV over 15 minutes on days 2-4, and oral lestaurtinib twice daily on days 5-28. Patients achieving complete or partial response proceed to course 2. Cohorts of 6 patients receive escalating doses of lestaurtinib until a TBAD is determined. The TBAD is defined as the dose at which no more than 2 of 6 patients experience DLT and biologic activity is confirmed by PIA assay.~COURSE 2: Patients receive high-dose cytarabine IV over 3 hours twice daily on days 1-4 and oral lestaurtinib (at the dose determined in course 1) twice daily on days 5-28. Patients achieving complete or partial response proceed to continuation therapy.~CONTINUATION THERAPY: Patients receive oral lestaurtinib twice daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Continued (see detailed description)"
3042106|NCT00469898|Experimental|Therapeutic Intervention|Lung cancer patients will be treated for four 3-week cycles (12 weeks) in the absence of progressive disease, unacceptable toxicity, or withdrawal of patient consent. Up to two additional cycles may be administered at the discretion of the treating physician. If at treatment withdrawal the disease has responded or is stable, the patient will continue to be followed for efficacy (i.e. until progressive disease)at 8 week intervals. Following the diagnosis of progressive disease, patients will be followed every two months for survival.
3042107|NCT00469911|Experimental|Magnetic Resonance Spectroscopy|Patients will have Magnetic Resonance Spectroscopy to measure in vivo accumulation of triglycerides in myocardial tissue
3042108|NCT00469911|Experimental|Ex vivo heart biopsy|Patients will have their normal routine clinical heart biopsy of myocardial heart tissue.
3042109|NCT00470054|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib twice daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3042110|NCT00470093|Experimental|Interleukin-6 and Interferon-α|Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.
3042111|NCT00470106|Active Comparator|Cognitive Remediation|cognitive remediation
3042112|NCT00470106|Experimental|Social Cognitive Skills Training|social cognitive skills training
3042113|NCT00470106|Active Comparator|Hybrid Intervention|combined social cognitive and cognitive remediation training
3042114|NCT00470106|Other|Skills Training|control training
3042115|NCT00470158|Experimental|combined iron and zinc|Iron and zinc together
3042116|NCT00470158|Experimental|Separate iron and zinc|Iron and zinc on separate days
3042117|NCT00470158|Experimental|iron alone|Iron
3042118|NCT00470158|Experimental|zinc alone|Zinc
3042119|NCT00470158|Placebo Comparator|placebo|
3042120|NCT00470184|Experimental|Chemo|Oxaliplatin 85 mg/m2 will be administered IV on days 1, 15 and 29. Capecitabine 1250 mg/m2 will be administered in 2 divided daily doses P0 or via enteral tube, on radiation days only (Monday- Friday/ weekly). Capecitabine will be continued until the final dose of radiotherapy
3042121|NCT00470262|Other|Fenofibrate 145 mg PO QD and Pioglitazone 45 mg PO QD|Treatment with pioglitazone and fenofibrate in subjects with pre diabetes
3042122|NCT00470262|Other|Fenofibrate 145 mg PO QD|Treatment with fenofibrate in subjects with pre diabetes
3042123|NCT00470275|Experimental|Cytarbine|Cytarabine IV every 12 hours days 1-5 of 21 day cycle. Response evaluation after 6 cycles of therapy.
3042124|NCT00470301|Experimental|Arm I|Tipifarnib plus sequential weekly paclitaxel followed by doxorubicin plus cyclophosphamide
3042125|NCT00470366|Experimental|Paclitaxel, Ifosfamide, and Cisplatin|-Paclitaxel is administered first, 120 mg/m2 on days 1 and 2 every three weeks for four cycles. Cisplatin is administered at 20 mg/m2 over approximately 30 minutes daily for five days every three weeks for four courses. -The ifosfamide is given last with 1200 mg/m2 daily for five days every three weeks for four cycles.
3042126|NCT00470392|Other|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
3042127|NCT00470392|Other|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
3042128|NCT00470418|Other|NIC5-15|Subjects with Alzheimer's Disease
3042129|NCT00470418|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease
3042130|NCT00470470|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral imatinib mesylate twice daily for up to 12 weeks in the absence of disease progression or unacceptable toxicity.
3042131|NCT00470535|Experimental|Arm 1 - Oral Erlotinib hydrochloride|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity
3042132|NCT00470548|Experimental|Phase I: Abraxane and Alimta|Three dose levels were tested. Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, and 260 mg/m2 every 21 days.
3042133|NCT00470548|Experimental|Phase II: Abraxane and Alimta|Pemetrexed 500mg/m2 day 1 and nab-paclitaxel day 1 at 260 mg/m2 every 21 days.
3042134|NCT00470600|Placebo Comparator|Normal Saline|250 milliliters normal saline as a placebo comparator was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
3042135|NCT00470600|Experimental|Intravenous ibuprofen|800 mg of intravenous ibuprofen diluted in 250 milliliters normal saline was administered every 6 hours for a total of five doses over the first 24 hours. Those patients who received the initial five doses could continue to receive additional doses as needed every 6 hours through the 120-hour treatment period.
3042136|NCT00470626|Experimental|1|Vena Cava Filter
3042137|NCT00470717|Other|Phone calling|Weekly telephone call. There are not two arms to the study. The primary intervention is phone calling weekly to assess ability to complete phone call and obtain feeding data.
3042138|NCT00470834|Experimental|Arm 1|50 mg bicalutamide and 3.5 mg Dutasteride (IP)
3042139|NCT00470834|Placebo Comparator|Arm 2|50 mg bicalutamide and placebo
3042140|NCT00470847|Other|Lapatinib,Whole Brain Radiation,Herceptin|Lapatinib before and during Whole Brain Radiation Therapy (WBRT), then Herceptin 4mg/kg IV weekly
3042141|NCT00471068|Experimental|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
3042142|NCT00471068|Active Comparator|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
3042143|NCT00471081|Experimental|Group A|Single dose GSK134612.
3042144|NCT00471081|Experimental|Group B|Two doses of GSK134612.
3042145|NCT00471107|Sham Comparator|Sham TDCS|
3042146|NCT00471107|Experimental|Surface-anodal direct current|0.08 mA/cm2
3042147|NCT00471107|Active Comparator|Surface-cathodal direct current|0.08 mA/cm2
3042148|NCT00471146|Experimental|A|
3042149|NCT00471146|Active Comparator|B|
3042150|NCT00471237|No Intervention|Placebo|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3042151|NCT00471237|Active Comparator|Alendronate|All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3042152|NCT00471237|Active Comparator|Teriparatide|Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study
3042153|NCT00471237|Experimental|Ronacaleret|4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.
3042154|NCT00471276|Experimental|1|
3042155|NCT00471315|No Intervention|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
3042156|NCT00471328|Experimental|Nilotinib|400mg twice daily in core and extension phases of the study.
3042157|NCT00471328|Active Comparator|Control/cross-over to Nilotinib|"In core study phase, patients in this arm received Best Supportive Care (BSC) with or without imatinib or sunitinib at the last tolerated dose or at the investigator's choice until documented disease progression followed by cross-over to nilotinib arm.~Patients entering the extension study on this control arm were permitted to cross over to nilotinib arm only upon documented disease progression."
3042158|NCT00471354|Experimental|Atomoxetine|0.5 mg/kg/day once a day (QD), by mouth (PO), starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
3042159|NCT00471380|Active Comparator|Crossover group ABB|"3 period, 2 treatment cross-over model:~Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)"
3042160|NCT00471380|Active Comparator|Crossover group BAA|"3 period, 2 treatment cross-over model:~Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)."
3042161|NCT00471445|Experimental|ketamine/amitriptyline NP-H cream|Patients apply 4 grams amitriptyline (4%) and ketamine (2%) hydrochloride topical analgesic cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
3042162|NCT00471445|Placebo Comparator|Placebo Cream|Patients apply a placebo cream twice daily to areas of pain, numbness, or tingling in the hands and/or feet.
3042163|NCT00471497|Experimental|nilotinib 300mg bid (investigating arm)|
3042164|NCT00471497|Experimental|Nilotinb 400 mg bid (investigating arm)|
3042165|NCT00471497|Experimental|imatinib 400mg QD (control arm)|
3042166|NCT00471536|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3042167|NCT00471705|Experimental|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
3042168|NCT00471705|Active Comparator|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
3042169|NCT00471705|Experimental|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
3042170|NCT00471718|Experimental|Phase I/II: Chemotherapy ABT-751|"Phase I: Patients receive oral ABT-751 twice daily on days 1-7 and 15-21.~Phase II: Patients receive ABT-751 twice daily"
3042171|NCT00471848|Experimental|Treatment Arm|Antithymocyte globuline with cyclosporin in first line treatment of patients with acquired severe aplastic anaemia and patients with non-severe aplastic anaemia who are transfusion dependent
3042172|NCT00471887|Experimental|Treatment-Single Arm|See intervention descriptions
3042173|NCT00472030|Experimental|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
3042174|NCT00472030|Active Comparator|Prednisone|The control arm of the study will receive standard prednisone therapy to a maximum dose of 0.5 mg/kg/day.
3132864|NCT03460990|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
3042175|NCT00472056|Experimental|BEAM + Standard Rituximab|"Arm 1 BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + Standard Rituximab with Standard Rituximab for Cohort 1 or 2~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Standard Rituximab: 375 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0."
3042176|NCT00472056|Experimental|BEAM + High Rituximab|"BEAM Chemotherapy (Carmustine, Etoposide, Cytarabine, Melphalan) + High Dose Rituximab~Cohort 1 for 65 years of age or younger BEAM: Carmustine 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~Cohort 2 for older than 65 years of age BEAM: Carmustine 300 mg/m2 IV over 1 hour on day -6, cytarabine 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), etoposide 100 mg/m2 IV twice a day on days -5 through -2 (total 8 doses), and melphalan 140 mg/m2 IV on day -1.~High Dose Rituximab: 1000 mg/m^2 IV Days +1, +8 after Stem Cell Infusion on Day 0"
3042177|NCT00472199|Experimental|Pramipexole|4 weeks of flexible dose-titration (to optimise efficacy and tolerability), starting at 0.125 mg once daily with the potential to increase or decrease the dose in steps to 0.25 mg, 0.5 mg and 0.75 mg, with the final dose level subsequently fixed for 22 weeks.
3042178|NCT00472199|Placebo Comparator|Placebo|4 weeks of flexible dose-titration as for the investigational product; with the dose subsequently fixed for 22 weeks.
3042179|NCT00472290|Experimental|Open Label Romiplostim (formerly AMG 531)|
3042180|NCT00472303|Placebo Comparator|Matching Placebo after Tapentadol in Titration Phase|Oral Tapentadol 100 mg to 250 mg twice daily. Participants randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off the tapentadol dose they had received in the Titration Phase. From the 4th day (Day 18) all participants received matching placebo in the maintenance (i.e. randomized withdrawal) phase.
3042181|NCT00472303|Active Comparator|Morphine Controlled Release|Oral Morphine 40 mg to 100 mg twice daily. Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Maintenance phase: continuing on dose level established in titration phase.
3042182|NCT00472303|Experimental|Tapentadol Prolonged Release|Oral Tapentadol 100 mg to 250 mg twice daily. Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses.
3042183|NCT00472420|Experimental|1|
3042184|NCT00472446|Experimental|cervical block before surgery|bilateral superficial cervical block, placed before surgery (just before skin incision)
3042185|NCT00472446|Placebo Comparator|placebo cervical block before surgery|placebo bilateral superficial cervical block with saline, placed before surgery (just before skin incision)
3042186|NCT00472446|Experimental|cervical block after surgery|bilateral superficial cervical block, placed after surgery (just after skin closure)
3042187|NCT00472446|Placebo Comparator|placebo cervical block after surgery|placebo bilateral superficial cervical block with saline, placed after surgery (just after skin closure)
3042188|NCT00472576|Experimental|Placebo then MK-0657|Double-blind crossover administration of placebo then MK-0657 (4-8 mg/day)
3042189|NCT00472576|Experimental|MK-0657 then Placebo|Double-blind crossover administration of MK-0657 (4-8 mg/day) then placebo
3042190|NCT00472641|Experimental|Ziprasidone/Geodon|Ziprasidone/Geodon up to 320 mg per day
3042191|NCT00472732||1|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD
3042192|NCT00472732||2|Healthy males or females without known medical or metabolic disorder (control group)
3042193|NCT00472797|Active Comparator|1|Rebif New Formulation - Non Titrated
3042194|NCT00472797|Active Comparator|2|Rebif New Formulation - Titrated
3042195|NCT00472849|Experimental|OFAR (Phase I)|Oxaliplatin starting dose 30 mg/m^2/day over 2 hours on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily intravenous (IV) over 30 minutes on days 2-3, 2-4, or 2-5 until maximum tolerated dose reached. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose (MTD) reached. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
3042196|NCT00472849|Experimental|OFAR MTD (Phase II)|Oxaliplatin 25 mg/m^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
3042197|NCT00473083|Experimental|Arm 1: Prophylactic Treatment|Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
3042198|NCT00473083|Experimental|Arm 2: Reactive Treatment|"Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:~Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade~Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.~Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.~Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln."
3042199|NCT00473083|Experimental|Arm 3: No Treatment Unless Severe (Grade 3)|This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
3042200|NCT00473265|Experimental|PTH(1-84)|100mcg of PTH1-84 every other day, every day, or every three days
3042201|NCT00473330|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042202|NCT00473330|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042203|NCT00473330|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042204|NCT00473382|Experimental|Ranibizumab 0.3 mg|Patients received ranibizumab 0.3 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042205|NCT00473382|Experimental|Ranibizumab 0.5 mg|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 36 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042206|NCT00473382|Sham Comparator|Sham injection/ranibizumab 0.5 mg|Patients received a sham intravitreal injection monthly for 24 months. Patients who had not discontinued treatment by Month 24 could choose to receive ranibizumab 0.5 mg monthly administered intravitreally for the subsequent 12 months. Patients who had not discontinued treatment by Month 36 could enter the open-label extension phase to receive ranibizumab 0.5 mg as needed (pro re nata [PRN]) for up to 24 additional months.
3042207|NCT00473434|Experimental|001|Paliperidone3mg or 6mg or 9mg or 12mg once daily for 52 weeks
3042208|NCT00473512|Experimental|Abiraterone acetate|Abiraterone acetate 250 mg up to a maximum of 2000 mg capsules will be given orally daily for 28-day treatment period to determine the MTD in Phase 1 of the study. Participants will receive MTD of abiraterone acetate for 12 cycles (28 day each) in Phase 2 of the study. Dexamethasone 0.5 mg will be given orally (If participants have disease progression) daily up to 12 cycles.
3042209|NCT00473564|Experimental|TORS Candidates|Participants who consented to undergo transoral robotic-assisted surgery using the da Vinci® Robotic System
3042210|NCT00473590|Experimental|Bortezomib + bevacizumab|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
3042211|NCT00473590|Active Comparator|Bortezomib + placebo|Participants received bortezomib 1.3 mg/m^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
3042212|NCT00473642|Experimental|1|Standard Fluence Photodynamic Therapy combined with ranibizumab
3042213|NCT00473642|Experimental|2|Verteporfin at 50% fluence photodynamic therapy combined with ranibizumab
3042214|NCT00473642|Active Comparator|3|Ranibizumab monotherapy
3042215|NCT00473668|Experimental|TRITANRIX-HEPB/HIBERIX KFT. GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ Kft. vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3042216|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX LD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ low-dose (LD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3042217|NCT00473668|Active Comparator|TRITANRIX-HEPB/HIBERIX HD GROUP|Subjects, male or female, aged 6 to 8 weeks received 3 doses of Tritanrix™-HepB/Hiberix™ high-dose (HD) formulation vaccine, administered intramuscularly in the anterolateral thigh at 6, 10 and 14 weeks of age.
3042218|NCT00473694|Experimental|rocuronium+sugammadex|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 post-tetanic counts (PTC) and after the last dose of rocuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
3042219|NCT00473694|Active Comparator|rocuronium+neostigmine|Participants received a single bolus dose of 0.60 mg/kg rocuronium prior to intubation. The neuromuscular block was maintained with 0.15 mg/kg rocuronium if needed. At 1-2 PTC and after the last dose of rocuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
3042220|NCT00473694|Experimental|vecuronium+sugammadex|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 4.0 mg/kg sugammadex was administered.
3042221|NCT00473694|Active Comparator|vecuronium+neostigmine|Participants received a single bolus dose of 0.1 mg/kg vecuronium prior to intubation. The neuromuscular block was maintained with 0.015 mg/kg vecuronium if needed. At 1-2 PTC and after the last dose of vecuronium, a single bolus dose of 70.0 μg/kg neostigmine (up to a maximum dose of 5 mg) was administered in combination with 14.0 μg/kg glycopyrrolate.
3042222|NCT00473746|Experimental|Phase I Dose Escalation|
3042223|NCT00473746|Experimental|Phase II Dose Treatment|
3178901|NCT00666874|Active Comparator|2|General information about healthy food choices and exercise
3042224|NCT00473824|Experimental|Civacir Treated|Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir], 18 infusions total, per schedule, of Civacir 300 or 400 mg/kg of body weight, with standard post-transplant site specific routine immunosuppressant therapy .
3042225|NCT00473824|No Intervention|Observational Control|Observation on standard post-transplant site specific routine immunosuppressant therapy without infusions of Hepatitis C Immune Globulin Intravenous (Human) 5% [Civacir].
3042226|NCT00473837|Active Comparator|Treatment|Subjects initially treated with Co-arthemeter, and then continued on weekly chloroquine till day 90
3042227|NCT00473837|Placebo Comparator|Control|Subjects initially treated with Co-arthemeter, and then continued on weekly placebo till day 90
3042228|NCT00473876|Active Comparator|1|Receiving Metformin for 4 months
3042229|NCT00473876|Placebo Comparator|2|Matched Placebo for 4 months
3042230|NCT00473889|Experimental|1|vorinostat; IV paclitaxel; IV carboplatin
3042231|NCT00473889|Placebo Comparator|2|Placebo; IV paclitaxel; IV carboplatin
3042232|NCT00474045|Experimental|Insulin detemir|Individually adjusted insulin detemir injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
3042233|NCT00474045|Active Comparator|Neutral Protamine Hagedorn (NPH) insulin|Individually adjusted NPH insulin injected subcutaneously as basal insulin + individually adjusted insulin aspart injected subcutaneously as bolus insulin from randomisation (gestational week 8-12) and continued until 6 weeks after delivery. If a subject was not pregnant at randomisation, treatment was given up to a maximum of 52 weeks. For subjects who became pregnant, randomised treatment was continued until 6 weeks after delivery. Subjects who were not pregnant at 52 weeks after randomisation were withdrawn
3042234|NCT00474058|Experimental|Rotigotine|Rotigotine transdermal patch
3042235|NCT00474058|Placebo Comparator|Placebo|Placebo transdermal patch
3042236|NCT00474123|Active Comparator|Simvastatin 80 mg|Patients were treated with simvastatin 80 mg for 6 weeks
3042237|NCT00474123|Active Comparator|Ezetimibe 10 mg / Simvastatin 20 mg|Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks
3042238|NCT00474175|Placebo Comparator|1|Placebo control
3042239|NCT00474175|Active Comparator|2|10% benzocaine gel formulation
3042240|NCT00474175|Active Comparator|3|20% benzocaine gel formulation
3042241|NCT00474201|Sham Comparator|Gemfibrozil PK without LPV/r|"Subjects received a single 600 mg dose of gemfibrozil without concurrent lopinavir-ritonavir 400mg/100mg; this is the control arm of a crossover study design."
3042242|NCT00474201|Experimental|Gemfibrozil PK after 2 weeks of LPV/r|Single dose (600 mg) Gemfibrozil pharmacokinetics (i.e. plasma concentrations collected over time to calculate area under the concentration vs. time curve) assessed after 14.5 days of lopinavir/ritonavir (400/100 mg twice daily) administration.
3042243|NCT00474240|Placebo Comparator|1|
3042244|NCT00474240|Active Comparator|2|
3042245|NCT00474240|Experimental|3|
3042246|NCT00474240|Experimental|4|
3042247|NCT00474240|Experimental|5|
3042248|NCT00474240|Experimental|6|
3042249|NCT00474253|Experimental|Rocuronium + Sugammadex|Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.
3042250|NCT00474253|Active Comparator|Succinylcholine|Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
3042251|NCT00474266|Experimental|Nimenrix + Priorix-Tetra Group|Subjects received 1 dose of Nimenrix vaccine and 1 dose of Priorix-Tetra vaccine on Day 0 and a second dose of Priorix-Tetra vaccine on Day 84.
3042252|NCT00474266|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
3042253|NCT00474266|Active Comparator|Priorix-Tetra Group|Subjects received 1 dose of Priorix-Tetra vaccine on Day 0, 1 dose of Meningitec vaccine on Day 42 and a second dose of Priorix-Tetra vaccine on Day 84.
3042254|NCT00474266|Active Comparator|Meningitec Group|Subjects received 1 dose of Meningitec vaccine on Day 0 followed by 2 doses of Priorix-Tetra vaccine, respectively 42 and 84 days later.
3042255|NCT00474383|Experimental|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) tablet or capsule will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study, along with prednisone/prednisolone 5 mg tablet orally twice daily or dexamethasone 0.5 mg tablet orally once daily.
3042256|NCT00474487|Experimental|Novartis MenACWY Vaccine (19 to 55 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
3042257|NCT00474487|Active Comparator|Licensed polysaccharide vaccine|Licensed meningococcal ACWY polysaccharide vaccine
3042258|NCT00474487|Active Comparator|Licensed Conjugate Vaccine|Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
3042259|NCT00474487|Experimental|Novartis MenACWY Vaccine (56 to 65 Years)|Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years
3042260|NCT00474526|Experimental|US1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042261|NCT00474526|Experimental|US1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042262|NCT00474526|Experimental|US2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042263|NCT00474526|Experimental|US3 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3178902|NCT00666887|Active Comparator|Minocycline|Minocycline 100 mg oral for up to 24 months
3042264|NCT00474526|Experimental|US4A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042265|NCT00474526|Experimental|US4B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042266|NCT00474526|Experimental|US4C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042267|NCT00474526|Experimental|LA1A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months Pneumococcal, HAV, and MMR-V: 12 months"
3042268|NCT00474526|Experimental|LA1B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 6, and 13 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042269|NCT00474526|Experimental|LA2 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042270|NCT00474526|Experimental|LA3A (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 16 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042271|NCT00474526|Experimental|LA3B (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 17 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 16 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042272|NCT00474526|Experimental|LA4 (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~DTaP, Hib: 15 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042273|NCT00474526|Experimental|LA5 (MenACWY-CRM + Infant Vaccines)|"Received vaccines:~MenACWY: 2, 4, 6, and 12 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042274|NCT00474526|Experimental|LA6A (Infant Vaccines Only)|"Received vaccines:~MenACWY: 12, and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042275|NCT00474526|Experimental|LA6B (Infant Vaccines Only)|"Received vaccines:~MenACWY: 13 and 15 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042276|NCT00474526|Experimental|LA6C (Infant Vaccines Only)|"Received vaccines:~MenACWY: 18 months~DTaP-IPV-HBV, Hib, rotavirus and pneumococcal conjugate vaccines: 2, 4, and 6 months~Pneumococcal, HAV, and MMR-V: 12 months"
3042277|NCT00474539|Experimental|1|
3042278|NCT00474539|Active Comparator|2|
3042279|NCT00474617|Experimental|Participants 18 to 64 years old|Participants to receive an intravenous (IV) single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of second twitch (T2) with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
3042280|NCT00474617|Experimental|Participants 65 to 74 years old|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
3042281|NCT00474617|Experimental|Participants 75 years and older|Participants to receive an IV single bolus dose of 0.6 mg.kg-1 rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg.kg-1 rocuronium were to be administered. After the intubation dose or the last maintenance dose of rocuronium, participants were to be reversed at reappearance of T2 with an intravenous single bolus dose of 2.0 mg.kg-1 of sugammadex.
3042282|NCT00474630|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/ day with ancillary therapy
3042283|NCT00474630|Placebo Comparator|Placebo|Placebo with ancillary therapy
3042284|NCT00474708|Experimental|1|1.Effexor XR Group
3042285|NCT00474708|Active Comparator|2|2.SSRI or Conventional Antidepressant Group
3042286|NCT00474760|Experimental|1|
3042287|NCT00474786|Experimental|1|
3042288|NCT00474786|Experimental|2|
3042289|NCT00474812|Experimental|Dasatinib Treatment|Patients receive oral dasatinib twice daily on days 1-28.
3042290|NCT00474851|Experimental|Norethindrone acetate + estrogens|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
3042291|NCT00474851|Placebo Comparator|norethindrone acetate + placebo|Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.
3042292|NCT00474903|Active Comparator|Arm I (placebo, esomeprazole magnesium)|Patients receive two oral placebos once daily and oral esomeprazole magnesium (40 mg, twice daily).
3042293|NCT00474903|Experimental|Arm II (low-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (81 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
3042294|NCT00474903|Experimental|Arm III (higher-dose aspirin, esomeprazole magnesium)|Patients receive both an oral placebo and acetylsalicylic acid (325 mg dose), once daily and oral esomeprazole magnesium (40 mg, twice daily).
3042295|NCT00474929|Experimental|Multiple Myeloma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
3178903|NCT00666887|Placebo Comparator|Placebo|Lactose Monohydrate NF (Spray-dried) 235 mg/cap Magnesium Stearate NF 1 mg/cap Croscarmellose Sodium NF 4 mg/cap Stearic Acid 10 mg/cap Placebo CAP Lt orange OP-Purple OP (APO 100)
3042296|NCT00474929|Experimental|Lymphoma|Phase I: Dose level 0: Sorafenib 200 mg twice daily, RAD001 5mg every other day; Dose level 1: Sorafenib 200 mg twice daily, RAD001 5mg every day; Dose level 2: Sorafenib 400 mg twice daily, RAD001 5mg every day; Dose level 3: Sorafenib 400 mg twice daily, RAD001 10mg every day; Phase II: Sorafenib 200 mg twice daily, RAD001 5mg every day;
3042297|NCT00474955|Experimental|Peginterferon Alpha-2a|Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton), 180 micrograms as a subcutaneous injection, once in a week, for 48 weeks. Participants with a calculated glomerular filtration rate of <15 milliliter /minute will be administered a reduced dose of 135 mcg as a subcutaneous injection, once in a week, for 48 weeks.
3042298|NCT00474968||Arm 1 - Experimental|e2 Cell Collector [SoftPAP(R)]
3042299|NCT00474968||Arm 2 - Control|Brush/spatula
3042300|NCT00474994|Experimental|Group A|Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3042301|NCT00474994|Experimental|Group B|High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3042302|NCT00474994|Experimental|Group C|Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.
3042303|NCT00475020|Experimental|Fludarabine + Busulfan + Thymoglobulin|Fludarabine 40 mg/m^2 by vein daily over 1 hour x 4 days. Busulfan test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days. Thymoglobulin 2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor.
3042304|NCT00475033|Experimental|1|
3042305|NCT00475033|Active Comparator|2|
3042306|NCT00475085|Active Comparator|Arm I|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
3042307|NCT00475085|Experimental|Arm II|Patients receive granisetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and another oral placebo once daily on days 2 and 3.
3042308|NCT00475085|Active Comparator|Arm III|Patients receive palonosetron hydrochloride IV and dexamethasone IV once on day 1, oral aprepitant once daily on days 1-3, and oral dexamethasone once daily and oral placebo twice daily on days 2 and 3.
3042309|NCT00475085|Experimental|Arm IV|Patients receive palonosetron hydrochloride IV, dexamethasone IV, and oral placebo once on day 1 and oral prochlorperazine 3 times daily and oral dexamethasone once daily on days 2 and 3.
3042310|NCT00475150|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral cediranib maleate QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3042311|NCT00475176|Experimental|S-Adenosyl Methionine|
3042312|NCT00475215|Experimental|Rocuronium + Sugammadex 2.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 2.0 mg/kg.
3042313|NCT00475215|Experimental|Rocuronium + Sugammadex 4.0 mg/kg|After the IV intubation dose (0.6 mg/kg) or last maintenance dose (0.15 mg/kg) of rocuronium, at reappearance of T2, participants will receive IV sugammadex 4.0 mg/kg.
3042314|NCT00475228|Experimental|Arm I|Levonorgestrel IUD will be inserted immediately after completion of D&E
3042315|NCT00475228|Active Comparator|Arm 2|Levonorgestrel IUD will be inserted at standard time post-procedure (3-6 weeks post D&E procedure)
3042316|NCT00475241|Experimental|Prolonged Exposure Therapy|Prolonged exposure therapy for PTSD
3042317|NCT00475241|Active Comparator|Present Centered Therapy|Present centered therapy for PTSD
3042318|NCT00475306|Active Comparator|Metoclopramide 20+diphenhydramine|Metoclopramide 20 mg + diphenhydramine, delivered intravenously over 15 minutes
3042319|NCT00475306|Active Comparator|Metoclopramide 20+placebo|Metoclopramide 20 mg + placebo, delivered intravenously over 15 minutes
3042320|NCT00475306|Active Comparator|Metoclopramide 10 + placebo|Metoclopramide 10mg + placebo, delivered intravenously over 15 minutes
3042321|NCT00475306|Active Comparator|Metoclopramide 10+diphenhydramine|Metoclopramide 10 mg + diphenhydramine 25 mg, delivered intravenously over 15 minutes
3042322|NCT00475319|Placebo Comparator|Placebo|0% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3042323|NCT00475319|Experimental|1% OPC-12759 ophthalmic suspension|1% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3042324|NCT00475319|Experimental|2% OPC-12759 ophthalmic suspension|2% OPC-12759 ophthalmic suspension received one drop to both eyes four times a day for 4 weeks.
3042325|NCT00475423|Experimental|1|
3042326|NCT00475501|Experimental|Arm 1|testosterone enanthate
3042327|NCT00475501|Experimental|Arm 2|finasteride
3042328|NCT00475501|Experimental|Arm 3|testosterone enanthate + finasteride
3042329|NCT00475501|Placebo Comparator|Arm 4|placebo
3042330|NCT00475644|Experimental|Enzastaurin|Enzastaurin: 1125 milligram (mg) loading dose then 500 mg, oral daily, up to 3 years
3042331|NCT00475670|Active Comparator|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose on Day 1, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death.
3042332|NCT00475670|Experimental|Trastuzumab, Taxane|Participant received an initial loading dose of 4 mg/kg trastuzumab i.v. on Day 1, followed by 2mg/kg i.v. weekly, or an initial loading dose of 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks, until disease progression, unacceptable toxicity, withdrawal or death; and concomitant taxane, which is either 100 milligrams per square meter (mg/m2) docetaxel i.v. every 3 weeks, or 75 mg/m2 weekly or 175 mg/m2 every 3 weeks paclitaxel for at least 18 weeks, or more at the discretion of the investigator.
3178904|NCT00666900|Experimental|1|
3178905|NCT00666900|Experimental|2|
3042333|NCT00475709|Experimental|Trifecta Aortic Heart Valve|All subjects enrolled into the study are implanted with the Trifecta Aortic Heart Valve.
3042334|NCT00475722|Active Comparator|1 Healthy Eating|Healthy People 2010 Diet using an exchange list
3042335|NCT00475722|Experimental|2 Mediterranean|Mediterranean Diet using an exchange list
3042336|NCT00475735|Experimental|MK-0249|Total time in the study will be ~10 weeks.
3042337|NCT00475735|Active Comparator|Concerta|Total time in the study will be ~10 weeks.
3042338|NCT00475735|Placebo Comparator|Placebo|Total time in the study will be ~10 weeks.
3042339|NCT00475787|Experimental|Spinal Manipulative therapy|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
3042340|NCT00475787|Sham Comparator|Detuned Ultrasound|"Detuned Ultrasound involves utilizing an ultrasound machine that is set to 0 w/cm2 and US gel is applied to the spine for 11 minutes."
3042341|NCT00475852|Experimental|001|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
3042342|NCT00475852|Placebo Comparator|002|Placebo matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
3042343|NCT00475865|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3042344|NCT00475865|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3042345|NCT00475865|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate (GA) for 24 weeks
3042346|NCT00475878|Placebo Comparator|placebo|
3042347|NCT00475878|Active Comparator|escitalopram|
3042348|NCT00475904|Active Comparator|amitriptyline 4% ketamine 2% cream, placebo capsules|Np-1 cream and placebo gabapentin
3042349|NCT00475904|Active Comparator|gabapentin capsules, placebo cream|gabapentin caps and placebo cream
3042350|NCT00475904|Placebo Comparator|placebo cream and capsules|placebo cream and capsules
3042351|NCT00475982|Experimental|Arm 1: Weight Loss|Weight Loss Group
3042352|NCT00475982|Active Comparator|Arm 2: No Weight Loss|No Weight Loss Group
3042353|NCT00476008|Placebo Comparator|Placebo|One tablet placebo morning and evening (BID) for 12 months
3042354|NCT00476008|Active Comparator|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months.
3042355|NCT00476021|Experimental|Postplacental IUD insertion|immediate postplacental levonorgestrel-releasing IUD (Mirena) insertion
3042356|NCT00476021|Active Comparator|Delayed IUD insertion|delayed levonorgestrel-releasing IUD (Mirena) insertion (6-8 weeks after delivery)
3042357|NCT00476047|Experimental|Treatment (monoclonal antibody therapy)|Patients receive tositumomab and iodine I 131 tositumomab IV over 90 minutes on day 0 and then again 7-14 days later over 30-60 minutes.
3042358|NCT00476086|Experimental|Oxaliplatin/ Gemcitabine Then Radiation|Patients rcvd IV chemotherapy on days 1 and 15 of a 4-week cycle: gemcitabine 1000 mg/m2 and oxaliplatin 65 mg/m2 for up to 3 cycles. Two dose reductions per study drug were permitted. On study, chemotherapy was followed by radiation therapy (RT) within 4-6 weeks of last chemotherapy. RT regimen was tumor-volume directed.
3042359|NCT00476151|Placebo Comparator|placebo cream|vehicle cream
3042360|NCT00476151|Active Comparator|amitriptyline 4% ketamine 2% cream|active topical cream
3042361|NCT00476229|Experimental|Radiation + Chemotherapy + BSCT|Total Lymphoid Irradiation (2 times) at 80 cGy daily for five days + Thymoglobulin 1.5 mg/kg intravenous 5 days + Rituximab 375 mg/m^2 intravenous on 4 different days + Blood stem cell transplant (BSCT)
3042362|NCT00476242|Experimental|Memantine and Vivitrol|intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
3042363|NCT00476242|Placebo Comparator|Placebo and Vivitrol|intramuscular injection of Vivitrol 380 mg and Placebo
3042364|NCT00476476|Experimental|Erlotinib|Patients rcvd oral erlotinib 150 mg/day. Cohort 1 pts would have at least 28 days and no more than 42 days of therapy in advance of definitive therapy (surgery or chemoradiation). Cohort 2 pts continued on therapy (28 days per cycle) until disease progression, unacceptable toxicity or withdrawal of consent. Two potential dose reductions were prescribed to 100 and 50 mg/day.
3042365|NCT00476593|Experimental|Diclofenac|Preservative- free Diclofenac Na 0.1 % eye drops were applied in one consecutively assigned eye of healthy volunteers four times a day for three days, after which macular thichness was measured in both subjects' eyes with the OCT .
3042366|NCT00476593|Experimental|Dexamethasone|Benzalkonium-reserved Dexamethasone Sodium Phosphate 0.1% was applied in one consecutively assigned eye of healthy volunteers six times a day for three days, after which macular thickness was assessed in both subjects's eyes with the OCT.
3042367|NCT00476645|Experimental|Fulvestrant|
3042368|NCT00476788|Experimental|Omnipod Device|Patients will be placed on an Omnipod insulin pump
3042369|NCT00476957|Active Comparator|1|Medtronic Endeavor® Zotarolimus Eluting Coronary Stent System
3042370|NCT00476957|Active Comparator|2|Cordis Cypher® Sirolimus-eluting Coronary Stent
3042371|NCT00476996|Experimental|Ocrelizumab 200 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 intravenous (IV) infusions of 200 milligram (mg) of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
3042372|NCT00476996|Experimental|Ocrelizumab 500 mg x 2 IV + Non-Biologic DMARD Therapy|Participants will receive 2 IV infusions of 500 mg of ocrelizumab, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
3042373|NCT00476996|Placebo Comparator|Placebo x 2 IV + Non-Biologic DMARD Therapy|Participants will receive ocrelizumab matching placebo IV in two infusions, separated by 14 days (Day 1 and Day 15) in combination with any non-biologic DMARD
3042374|NCT00477087|Experimental|GM-CSF Plus Mitoxantrone|GM-CSF at 250 micrograms/ m² / day subcutaneously 3 x week for 3 weeks. Participants will also receive mitoxantrone 14 mg/m² on Day 1 of each cycle. Each cycle of therapy consists 21 days.
3042375|NCT00477152|Experimental|HYLENEX-augmented subcutaneous (SC ) rehydration|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
3042376|NCT00477165|Experimental|Citalopram|One 20mg capsule per day for 4 weeks, then 2 capsules per day (40mg) for 4 weeks
3178906|NCT00666900|Placebo Comparator|3|
3042377|NCT00477165|Placebo Comparator|Placebo|Identical to citalopram 20mg capsule. One capsule per day for 4 weeks, then 2 capsules per day for 4 weeks
3042378|NCT00477191|Experimental|Etanercept|Etanercept
3042379|NCT00477204|Active Comparator|Simvastatin|Zocor(simvastatin)(20 mg)daily for 6 months along with Placebo (sugar pill)of active comparator (Vytorin [simvastatin] + Zetia [ezetimibe].
3042380|NCT00477204|Active Comparator|Ezetimibe/Simvastatin|Vytorin(simvastatin [Zocor} + ezetimibe [Zetia])(20 mg)daily for 6 months along with placebo (sugar pill)of comparator (Vytorin [simvastatin]).
3042381|NCT00477269|Experimental|STI571|STI571
3042382|NCT00477269|Placebo Comparator|Placebo|Placebo
3042383|NCT00477269|Experimental|All Patients|Open label extension
3042384|NCT00477295|Active Comparator|Zonisamide|
3042385|NCT00477295|Active Comparator|Carbamazepine|
3042386|NCT00477334|Experimental|1|Famciclovir 1000 mg; twice a day for one day.
3042387|NCT00477334|Placebo Comparator|2|Placebo; twice a day for one day.
3042388|NCT00477386|Experimental|Carboplatin combined with Decitabine|Decitabine at escalating dose levels will be given X 5 days followed by Carboplatin given on Day 8.
3042389|NCT00477451|Placebo Comparator|RCT Placebo|Subjects received inhaled placebo after 0.5 mg/kg doxapram IV in the randomized controlled trial
3042390|NCT00477451|Experimental|RCT Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the randomized controlled trial
3042391|NCT00477451|Experimental|Open Label Inhaled Alprazolam 1 mg|Subjects received 1 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the open label dose validation
3042392|NCT00477451|Experimental|Initial Inhaled Alprazolam 2 mg|Subjects received 2 mg inhaled Staccato alprazolam 10 s after 0.5 mg/kg doxapram IV in the initial open label dose assessment
3042393|NCT00477464|Experimental|Lapatinib+capecitabine|Lapatinib 1250mg once daily +capecitabine 2000mg/m^2 twice daily (14 days out of 21 days)
3042394|NCT00477490|Placebo Comparator|Placebo|Participants took a placebo 'melt' for 28 days to complete part 1 of the study. In part 2, placebo patients were randomized to one of the other 4 treatment arms based on assignments predetermined at the initial randomization, to receive active desmopressin melt for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3042395|NCT00477490|Experimental|desmopressin melt 10 μg|Participants took desmopressin melt 10 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3042396|NCT00477490|Experimental|desmopressin melt 25 μg|Participants took desmopressin melt 25 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3042397|NCT00477490|Experimental|desmopressin melt 50 μg|Participants took desmopressin melt 50 μg for 28 days to complete part 1 of the study. Participants continued on this dose in part 2 of the study for between 1 and 6 months (until the database for part 1 was locked and treatment was unblinded).
3042398|NCT00477490|Experimental|desmopressin melt 100 μg|Participants will take desmopressin melt 100 μg for 28 days to complete part 1 of the study. Participants will continue on this dose in part 2 of the study for between 1-6 months (until the database for part 1 is locked and treatment is unblinded).
3042399|NCT00477594|Experimental|Mipomersen 200 mg per week|Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
3042400|NCT00477594|Experimental|Mipomersen 200 mg every other week|Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years. Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
3042401|NCT00477607|Experimental|Arm 1|Receiving alpha-lipoic acid during cisplatin treatment.
3042402|NCT00477607|Placebo Comparator|Arm 2|Receiving placebo during cisplatin treatment
3042403|NCT00477633|Experimental|Norethindrone/ethinyl estradiol|1 tablet per day
3042404|NCT00477659|Experimental|Donepezil hydrochloride|
3042405|NCT00477672|Experimental|2|Pimavanserin tartrate (ACP-103), 10 mg, tablet, once daily by mouth, 6 weeks
3042406|NCT00477672|Experimental|3|Pimavanserin tartrate (ACP-103), 40 mg, tablet, once daily by mouth, 6 weeks
3042407|NCT00477672|Placebo Comparator|1|Placebo tablet, once daily by mouth, 6 weeks
3042408|NCT00477685||OculusGen Collagen Matrix|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
3042409|NCT00477750|Experimental|Treatment (Lenalidomide, Melphalan, Prednisone)|"Intervention: Drug: lenalidomide Dose determined by Phase I treatment schedule. Taken orally days 1-21 every 28 days until progression~Intervention: Drug: melphalan Dose determined by Phase I treatment schedule. Taken orally days 1-4 every 28 days until progression~Intervention: Drug: prednisone 60mg/m^2, orally days 1-4 every 28 days until progression"
3042410|NCT00477971|Active Comparator|Arm A|"Patients receive low-dose melphalan IV over 15-30 minutes on day~1 or orally once daily on days 1-7 and oral dexamethasone on days 1-4 and 22-25. Treatment repeats every 6 weeks for 10 courses.~Study treatment beyond one year is not allowed."
3042411|NCT00477971|Experimental|Arm B|Patients receive filgrastim (G-CSF) on days -7 to -3 and undergo autologous hematopoietic stem cell (HSC) collection. Patients receive high-dose melphalan IV over 1 hour on days -2 and -1 and undergo autologous HSC transplantation on day 0.
3042412|NCT00478023|Active Comparator|Morphine|
3042413|NCT00478023|Experimental|Tapentadol 50 mg immediate release|
3042414|NCT00478023|Experimental|Tapentadol 75 mg immediate release|
3042415|NCT00478023|Experimental|Tapentadol 100 mg immediate release|
3042416|NCT00478023|Placebo Comparator|Matched placebo|
3042417|NCT00478036|Active Comparator|Acular LS|Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
3042418|NCT00478036|Active Comparator|Pred Forte|Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
3042419|NCT00478036|Placebo Comparator|Refresh Tears|Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days
3042420|NCT00478140|Experimental|Trastuzumab|Participants receive trastuzumab loading dose 8 mg/kg intravenous (IV) over 30-90 minutes on day 1 and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3042421|NCT00478192|Experimental|Regimen 1 Conivaptan QD|20 mg conivaptan once a day
3042422|NCT00478192|Experimental|Regimen 2 Conivaptan BID|20 mg conivaptan two times a day
3042423|NCT00478192|Placebo Comparator|Regimen 3 Placebo|
3042424|NCT00478205|Experimental|1|
3042425|NCT00478205|Experimental|2|
3042426|NCT00478218|Experimental|Lenalidomide/Cyclophosphamide/Dexamethasone|
3042427|NCT00478231|Experimental|1|
3042428|NCT00478244|Experimental|Epidermolysis Bullosa (EB) Patients|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant.
3042429|NCT00478257|Active Comparator|1 Active Bright White Light Treatment|Intervention: Bright white light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
3042430|NCT00478257|Active Comparator|2 Comparator Red Light Treatment|Intervention: Dim red light, the intervention, was administered via a light box made by Litebook Inc for 30 minutes each morning during four cycles of chemotherapy
3042431|NCT00478335|Experimental|Active Therapy|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, calcitonin, sildenafil
3042432|NCT00478335|Placebo Comparator|Placebo Control|4-day treatment with hydrochlorothiazide/amiloride, indomethacin, placebo for calcitonin, placebo for sildenafil
3042433|NCT00478361|Experimental|Gemcitabine, Paclitaxel and Doxorubicin|Paclitaxel 135 mg/m^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m^2 IV over 90 min; Doxorubicin 40 mg/m^2 IV over 20 min; treatment may repeat every 2 weeks for up to nine courses. Injection of Pegfilgrastim on day 1.
3042434|NCT00478426|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3042435|NCT00478556|Active Comparator|1|Gastroview
3042436|NCT00478556|Experimental|2|Omnipaque
3042437|NCT00478569||Parathyroid Hormone (PTH) (1-84)|PTH(1-84) was prescribed in accordance with the terms of the marketing authorization. Participants were observed for 24 months.
3042438|NCT00478647|Experimental|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
3042439|NCT00478777|Experimental|lenalidomide plus dexamethasone|Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), dexamethasone was to be reduced to 40 mg QD for Days 1-4 of each 28 day-cycle.
3042440|NCT00478881|Experimental|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
3042441|NCT00478881|Placebo Comparator|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
3042442|NCT00478933|Experimental|ICD Therapy, blood sampling|Blood sampling Defibrillator, Dual Chamber ; Implantable
3042443|NCT00479037|Active Comparator|PTH(1-84)|
3042444|NCT00479037|Active Comparator|Strontium Ranelate|
3042445|NCT00479089|Active Comparator|Weekly Docetaxel|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy.
3042446|NCT00479089|Active Comparator|Weekly Docetaxel + ZD1839|Docetaxel 25 mg/m^2 IV over 30 minutes for 4 weeks with premedication with Dexamethasone, followed by 2 weeks off therapy. ZD1839 250 mg by mouth daily, without break.
3042447|NCT00479115|Experimental|AMD3100|
3042448|NCT00479154|Experimental|Botulinum Toxin A|Injection of onabotulinumtoxinA
3042449|NCT00479154|Placebo Comparator|Placebo (saline)|Injection of saline placebo
3042450|NCT00479232|Experimental|Cohort 1: Vorinostat (sequential)|"Vorinostat 400 mg capsules once daily given 7, 10 or 14 days in 28 day cycles. Up to 24 months of treatment.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
3042451|NCT00479232|Experimental|Cohort 2: Vorinostat (concurrent)|"Vorinostat 400 mg capsules once daily given 7 days, 14 days with 8 day break after first 7 days or 14 days without break, out of 28 day cycles.~Decitabine IV 20 mg/m^2 daily for 5 days in each 28 day cycle. Up to 24 months of treatment."
3042452|NCT00479336|Placebo Comparator|1|
3042453|NCT00479336|Experimental|2|
3042454|NCT00479336|Experimental|3|
3042455|NCT00479336|Experimental|4|
3042456|NCT00479388|Other|1|One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
3042457|NCT00479388|Active Comparator|2|Stable dose of simvastatin or atorvastatin (20mg to 40mg) for 12 weeks.
3042458|NCT00479401|Experimental|Pramipexole Extended Release (PPX ER)|
3042459|NCT00479401|Experimental|Pramipexole Immediate Release (PPX IR)|
3042460|NCT00479401|Placebo Comparator|Placebo|
3042461|NCT00479466|Experimental|MK0893 80 mg|MK0893 tablets totaling 80 mg once daily.
3042462|NCT00479466|Experimental|MK0893 60 mg|MK0893 tablets totaling 60 mg once daily.
3042463|NCT00479466|Experimental|MK0893 40 mg|MK0893 40 mg tablet once daily.
3042464|NCT00479466|Experimental|MK0893 20 mg|MK0893 20 mg tablet once daily.
3042465|NCT00479466|Active Comparator|Metformin|Metformin HCL 500 mg tablet twice daily BID titrating up to 1000 mg twice daily over 3 weeks.
3042466|NCT00479466|Placebo Comparator|Placebo|PLA tablets. 12 week treatment period.
3042467|NCT00479557|Active Comparator|1|arm 1: ACC-001 (Vanutide Cridificar)+ QS-21
3042468|NCT00479557|Active Comparator|2|arm 2: ACC-001
3042469|NCT00479557|Placebo Comparator|3|arm 3: QS-21
3042470|NCT00479557|Placebo Comparator|4|Drug: Phosphate Buffered Saline (PBS)
3042471|NCT00479674|Experimental|Abraxane, Carboplatin, Bevacizumab|Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15
3042472|NCT00479687|Active Comparator|Supartz|SUPARTZ® 3 injections over 2 weeks
3042473|NCT00479687|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline 3 injections over 2 weeks
3042474|NCT00479713|Experimental|1|Arm 1: drug
3042475|NCT00479713|Active Comparator|2|Arm 2: active comparator
3178907|NCT00666939|Experimental|A|
3178908|NCT00666939|Experimental|B|
3042476|NCT00479765|Experimental|1|OncoGel administered into remaining cavity after surgical resection. Each dose cohort will receive a different volume of OncoGel
3042477|NCT00479856|Experimental|Lapatinib plus Chemotherapy|Lapatinib is administered in combination with one of the following chemotherapies based on the discretion of the investigator : capecitabine, docetaxel or nab-paclitaxel.
3042478|NCT00479882|Experimental|Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg|After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.
3042479|NCT00479882|Experimental|Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.
3042480|NCT00479882|Experimental|Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg|After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.
3042481|NCT00479882|Experimental|Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg|After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.
3042482|NCT00480025|Experimental|GSK1572932 Group|Patients received up to 13 doses of GSK1572932, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
3042483|NCT00480025|Placebo Comparator|Placebo Group|Patients received up to 13 doses of placebo, 5 doses every 3 weeks followed by 8 doses every 12 weeks.
3042484|NCT00480077|Experimental|Access Arm|HF subjects managed with standard clinical assessment and using the audible OptiVol® Fluid status monitoring alert and the device Cardiac Compass Report
3042485|NCT00480077|Active Comparator|Control arm|HF subjects managed with standard clinical assessment
3042486|NCT00480324|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 month schedule.
3042487|NCT00480324|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 month schedule.
3042488|NCT00480441|Active Comparator|1|Dronabinol+ BRENDA therapy
3042489|NCT00480441|Placebo Comparator|2|Placebo+BRENDA therapy
3042490|NCT00480493|Experimental|Parent mentor contact|Parent mentor provides face-to-face social support
3042491|NCT00480493|Active Comparator|Control Arm|Parent is given a phone contact
3042492|NCT00480532|Experimental|Doxycycline 100bid x5 days|
3042493|NCT00480532|Placebo Comparator|placebo bid x 5 days|
3042494|NCT00480532|Experimental|Subantimicrobial doxycycline daily|
3042495|NCT00480532|Placebo Comparator|placebo daily|
3042496|NCT00480636||One cohort of patients treated with dalteparin.|About 100 patients with deep-vein thrombosis and with or without pulmonary embolism will be included in the study.
3042497|NCT00480740|Experimental|Cardiac Transplant|diagnostic cardiac catheterization in children with a transplanted heart
3042498|NCT00480740|Experimental|Fontan procedure|diagnostic cardiac catheterization in children with a transplanted ventricle
3042499|NCT00480740|Other|Normal Physiology|diagnostic cardiac catheterization in children with normal cardiac physiology
3042500|NCT00480779|Other|GLB Group|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
3042501|NCT00480779|Other|GLB DVD|The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study choose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
3042502|NCT00480857|Experimental|Docetaxel|
3042503|NCT00480987|Experimental|Oxaliplatin + Cytarabine + Fludarabine|Oxaliplatin 30 mg/m^2 intravenous (IV) days 1-4, Cytarabine 500 mg/m^2 by IV continuous infusion days 2-6, Fludarabine 30 mg/m^2 IV days 2-6
3042504|NCT00481065|Experimental|Concomitant alone|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1 then 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382.
3042505|NCT00481065|Experimental|Concomitant +Mixed|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042506|NCT00481065|Experimental|Concomitant +MF59-eH5N1|1 dose of MF59-eH5N1 into one arm and 1 dose of eTIV_a into the other arm on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042507|NCT00481065|Experimental|Mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1 and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042508|NCT00481065|Experimental|Mixed and mixed|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, day 22, and day 382
3042509|NCT00481065|Experimental|Mixed+MF59-eH5N1|1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042510|NCT00481065|Experimental|MF59-eH5N1+eTIV_a|1 dose of MF59-eH5N1 on day 1, 1 dose of eTIV_a on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042511|NCT00481065|Experimental|eTIV_a+MF59-eH5N1|1 dose of eTIV_a on day 1, 1 dose of MF59-eH5N1 on day 22, and 1 dose of MF59-eH5N1 mixed extemporaneously with eTIV_a on day 382
3042512|NCT00481078|Experimental|Arm I (vorinostat, paclitaxel, carboplatin)|Patients receive oral vorinostat (SAHA) at 400 mg once daily on days 1-14 and paclitaxel IV 200 mg/m2 over 3 hours and carboplatin IV dosed to achieve an area under the concentration versus time curve of 6 mg/mLXmin over 30 minutes on day 3.
3042513|NCT00481078|Active Comparator|Arm II (placebo, paclitaxel, carboplatin)|Patients receive an oral placebo once daily on days 1-14 and paclitaxel and carboplatin as in arm l.
3042514|NCT00481195|Active Comparator|Armodafinil|
3042515|NCT00481195|Placebo Comparator|Placebo|
3042516|NCT00481247|Experimental|Dasatinib|
3042517|NCT00481247|Active Comparator|Imatinib|
3042518|NCT00481351|Experimental|group1 ezetimibe|6 week wash out, followed by 06 week ezetimibe 10mg once a day e then 6 week ezetimibe 10mg plus sinvastatin 20mg for more 6 week.
3042519|NCT00481351|Active Comparator|group 2 simvastatin|6 week simvastatin 20mg once a day followed by 6 week simvastatin 80mg once a day.
3042520|NCT00481507|Placebo Comparator|Placebo|
3042521|NCT00481507|Experimental|Kefir|
3042522|NCT00481676|Experimental|Omalizumab 75-375 mg|Omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
3042523|NCT00481676|Placebo Comparator|Placebo to omalizumab|Placebo to omalizumab was dosed at 75 to 375 mg according to baseline IgE and body weight as described in dosing tables in the study protocol. Dosing occurred subcutaneously every 2 or 4 weeks depending on dose.
3042524|NCT00481767|Active Comparator|Cervarix Group|Healthy female subjects who received 3 doses of Cervarix at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
3042525|NCT00481767|Placebo Comparator|Placebo Group|Healthy female subjects who received 3 doses of placebo at Months 0, 1 and 6, administered intramuscularly into the deltoid region of the non-dominant arm. For some analyses the group was stratified by age into a 10-14 years of age group and a 15-25 years of age group.
3042526|NCT00481832|Experimental|T & B Cell Mobilization Auto & Allo HCT|A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.
3042527|NCT00481845|Experimental|Vandetanib + Anastrozole|Vandetanib and Anastrozole as neoadjuvant therapy
3042528|NCT00481845|Active Comparator|Anastrozole|Anastrozole as neoadjuvant therapy
3042529|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Sequential Days|
3042530|NCT00481871|Experimental|Pralatrexate & Gemcitabine - Same Day|
3042531|NCT00481988|Active Comparator|transcranial direct current stimulation|The active group of patients will receive active Iomed II Phoresor transcranial direct current stimulation for the first two weeks followed by another two weeks of active transcranial direct current stimulation.
3042532|NCT00481988|Sham Comparator|sham tDCS|The patients in the sham arm receive active Iomed II Phoresor transcranial direct current stimulation for the second two weeks of the clinical trial only. For the first two weeks the Iomed II Phoresor constant current generator is turned on for 10 seconds to produce the tingling sensation on the scalp experienced by the patients in the active arm but the generator is then turned off and the patients receive no stimulation for the remainder of the 20 minute session.
3042533|NCT00482001|Experimental|donepezil|donepezil, capsule, 5mg daily once daily for 14 days
3042534|NCT00482001|Placebo Comparator|placebo|placebo (cornstarch), capsule, once daily for 14 days
3042535|NCT00482014|Experimental|A: Pemetrexed + Carboplatin|Pemetrexed + Carboplatin
3042536|NCT00482014|Experimental|B: Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
3042537|NCT00482053|Experimental|Auto-HCT followed by Allo-HCT for Poor-risk DLBCL|"Participants will have peripheral blood stem cells (PBSC, aka progenitor / stem cells) mobilized to peripheral blood with rituximab, chemotherapy (cyclophosphamide or etoposide), and filgrastim; undergo apheresis to collect (self/autologous PBSC), and receive carmustine, etoposide, and cyclophosphamide as conditioning for PBSC infusion as a hematopoietic cell transplant (auto-HCT).~Then participants will receive allogeneic HCT (allo-HCT) transplant conditioning [total lymphoid irradiation (TLI) + anti-thymocyte globulin (ATG)] followed by allogenic PBSC (allo-HCT) obtained from a human leukocyte antigen (HLA)-matched or single mismatch filgrastim-mobilized donor. Participant allo-HCT transplant is to occur within 150 days of auto-HCT. Post-allo-HCT treatment includes cyclosporine + mycophenolate mofetil (MMF).~Subject's participation ends if donor is not identified within 150 days. Pre-medication includes acetaminophen; diphenhydramine; hydrocortisone; & methylprednisolone."
3042538|NCT00482170|Experimental|1|Arm 1: Enbrel 50 mg Prefilled Syringe
3042539|NCT00482170|Active Comparator|2|Arm 2 Enbrel 50 mg Autoinjector
3042540|NCT00482391|Experimental|AC, PACLITAXEL , TRASTUZUMAB & LAPATINIB|The regimen consists of AC (doxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 4 with pegfilgrastim, followed by weekly paclitaxel (80 mg/m2) x 12 + trastuzumab (H) + lapatinib (L). Pegfilgrastim 6mg is given subcutaneously (SQ) on day # 2 of each AC. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion. Trastuzumab will be administered weekly starting with paclitaxel treatment # 1. Near the completion of all chemotherapy, patients may receive trastuzumab on a q 3-weekly schedule, starting as early as with paclitaxel cycle # 12. The total duration of trastuzumab from beginning to end is 52 weeks. Lapatinib will be given orally at 1000 mg daily, starting with trastuzumab for a total duration of 52 weeks. Hormonal therapy such as tamoxifen or an aromatase inhibitor will be given to patients with hormone receptor positive disease at the physician's discretion. Radiation therapy to the breast or chest is recommended to patients as appropriate.
3042541|NCT00482547|Experimental|Silver-coated catheter|Bard Hydrogel Silver Salts Coated Latex Urinary Catheter System
3178909|NCT00666939|Placebo Comparator|C|
3178910|NCT00666952|Experimental|1|
3042542|NCT00482547|Placebo Comparator|Silicone-coated catheter|Bard silicone elastomer coated latex catheter system
3042543|NCT00482612|Experimental|Esmirtazapine 1.5 mg|Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
3042544|NCT00482612|Experimental|Esmirtazapine 3.0 mg|Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks
3042545|NCT00482612|Experimental|Esmirtazapine 4.5 mg|Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
3042546|NCT00482612|Placebo Comparator|Placebo|Placebo to esmirtazapine
3042547|NCT00482625|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD for 21-42 days. Patients then proceed to surgery.
3042548|NCT00482677|Active Comparator|Temozolomide|Temozolomide and short course radiation
3042549|NCT00482677|Active Comparator|Radiation|Short course radiation alone
3042550|NCT00482703|Experimental|A|
3042551|NCT00482703|Experimental|B|
3042552|NCT00482729|Experimental|1|Arm 1: drug
3042553|NCT00482729|Active Comparator|2|Arm 2: active comparator
3042554|NCT00482911|Experimental|Cohort 1-lenalidomide & cyclophosphamide|Participants first started on 2 Interventions (Dose A-QD) in Cycle 1, with 10 mg Lenalidomide (Len) once daily and 50 mg Cyclophosphamide (Cyc) once daily; 25 mg Sunitinib (Sun) was added once daily as a 3rd Intervention (Dose B-QD) from Cycle 2 onwards. Doses were adjusted in subsequent cycles depending on toxicity, including incremental step downs to 5/25/12.5 mg Len/Cyc/Sun once daily (Dose C-QD) or once every other day (Dose C-QOD).
3042555|NCT00482911|Experimental|Cohort 2-sunitinib & cyclophosphamide|2 participants started Cycle 1 with Dose B as described above and had adjusted-dosing as described for Cohort 1. The remaining 7 participants began Cycle 1 with 10 mg Len, 25 mg Cyc and 12.5 mg Sun once daily (Dose D-QD). Doses were adjusted in subsequent cycles depending on toxicity, including step up to 10/50/12.5 mg Len/Cyc/Sun once daily (Dose E-QD) and step down to Dose D once every other day (Dose D-QOD).
3042556|NCT00483002||Healthy smokers|
3042557|NCT00483041|Experimental|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
3042558|NCT00483041|Placebo Comparator|PLACEBO|Placebo administered as a single intravenous infusion
3042559|NCT00483184|Placebo Comparator|1|(placebo)0 IU IFNa
3042560|NCT00483184|Experimental|2|(Veldona)500 IU IFNα bid
3042561|NCT00483184|Experimental|3|(Veldona)1000 IU IFNα bid
3042562|NCT00483223|Experimental|Single Arm|Cisplatin or carboplatin (1 arm, 2 cohorts)
3042563|NCT00483262|Experimental|CCI779 and Bortezomib Phase I/II|In Phase I part, 15 or 25 mg temsirolimus (CCI-779)and 1·3 or 1·6 mg/m² bortezomib was given once a week.In Phase II, patients received intravenous temsirolimus once a week on days 1, 8, 15, 22, and 29 for a cycle of 35 days, and intravenous bortezomib once a week on days 1, 8, 15, and 22 for a cycle of 35 days, the MTD ascertained in the Phase I part.
3042564|NCT00483327|Experimental|Megestrol Acetate|80 mg (2 tablets) orally at breakfast, 80 mg at dinner for at least 12 weeks and up to 2 years.
3042565|NCT00483379|Experimental|alglucosidase alfa 20 mg/kg every week|Participants were treated with alglucosidase alfa 20 mg/kg every week for 52 weeks. This was the 'frequent dose' arm.
3042566|NCT00483379|Experimental|alglucosidase alfa 40 mg/kg every other week|Participants were treated with alglucosidase alfa 40 mg/kg every other week for 52 weeks. This was the 'high dose' arm.
3042567|NCT00483405|Other|Single Arm Trial|Single Arm Trial
3042568|NCT00483496|Experimental|V0096CR actives and vehicle|"Each patient received each one of the 8 test products on their respective randomly allocated sites on grid (grid to be applied on the back skin; 1 product by grid window).~Single application of the test materials at the dosage of 2mg/cm² (total of 8 treated sites), prior to irradiation using a solar simulator."
3042569|NCT00483509|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
3042570|NCT00483548|Experimental|Ziprasidone|Active treatment, double-blind, randomized treatment arm
3042571|NCT00483548|Placebo Comparator|Placebo|Inactive, placebo treatment, double-blind, randomized arm
3042572|NCT00483561|Experimental|Gefitinib plus Etoposide|"Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.~Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple)."
3042573|NCT00483574|Experimental|Group 1: Menactra® and Routine Pediatric Vaccines|Participants received Menactra® alone at age 9 months and Menactra® concomitantly with routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate [PCV], and hepatitis A [HepA]) at age 12 months.
3042574|NCT00483574|Other|Group 2: Routine Pediatric Vaccines|Participants received routine pediatric vaccines (measles-mumps-rubella-varicella [MMRV: ProQuad], pneumococcal conjugate[PCV], and hepatitis A [HepA]) at age 12 months.
3042575|NCT00483652|Placebo Comparator|Placebo|Placebo control
3042576|NCT00483652|Active Comparator|Fampridine-SR|10 mg b.i.d.
3042577|NCT00483704|Experimental|Telcagepant 140 mg|Telcagepant 140 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 140 mg or placebo.
3042578|NCT00483704|Experimental|Telcagepant 280 mg|Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
3042579|NCT00483704|Placebo Comparator|Control Group 1|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 4th). Telcagepant 140 mg will be administered for the 3rd migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
3042580|NCT00483704|Placebo Comparator|Control Group 2|Placebo, oral, tablet, across 3 migraine attacks (1st, 2nd, and 3rd). Telcagepant 140 mg will be administered for the 4th migraine attack. Participants will receive placebo for the optional second dose. For migraine attacks 2, 3, and 4, no study medication will be provided as an optional second dose.
3042581|NCT00483717|Placebo Comparator|Placebo|Intranasal Placebo
3042582|NCT00483717|Experimental|Ketorolac tromethamine|Intranasal ketorolac tromethamine
3042583|NCT00483756|Active Comparator|1|Treatment Arm 1 will also receive standard of care medications
3042584|NCT00483756|Experimental|2|Treatment Arm 2 will also receive standard of care medications
3042585|NCT00483756|Experimental|3|Treatment Arm 3 will also receive standard of care medications
3042586|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group A)|Participants with HCV RNA levels greater than (>) 15 international units per milliliter (IU/mL) at Week 4, HCV RNA greater than or equal to (>=) 15 IU/mL at Week 8, and either HCV RNA less than (<) 15 IU/mL or >=2 times logarithmic (2 log10) drop at Week 12, will receive pegylated-interferon alfa-2a (Pegasys) 180 micrograms (mcg) subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 milligrams (mg) orally daily for 48 weeks.
3042587|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group B)|Participants with HCV RNA levels >15 IU/mL at Week 4, HCV RNA >=15 IU/mL at Week 8, and either HCV RNA <15 IU/mL or >=2 log10 drop at Week 12, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 72 weeks, and ribavirin 1000 to 1400 mg orally daily for 72 weeks.
3042588|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group C)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 36 weeks, and ribavirin 1000 to 1400 mg orally daily for 36 weeks.
3042589|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group D)|Participants with HCV-RNA levels >15 IU/mL at Week 4, and HCV-RNA <15 IU/mL at Week 8, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3042590|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group E)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 24 weeks, and ribavirin 1000 to 1400 mg orally daily for 24 weeks.
3042591|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group F)|Participants with HCV-RNA levels <15 IU/mL at Week 4, will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3042592|NCT00483938|Experimental|Pegylated-interferon Alfa-2a + Ribavirin (Group NR)|Participants who do not have any change in HCV-RNA levels at Weeks 4, 8, and 12 will not be randomized (NR) to any of the other groups. Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for 48 weeks, and ribavirin 1000 to 1400 mg orally daily for 48 weeks.
3042593|NCT00484094||Rapamune|
3042594|NCT00484159|Experimental|1|Radiofrequency lumbar facet joint denervation only if positive response to 2 diagnostic facet blocks.
3042595|NCT00484159|Experimental|2|Radiofrequency lumbar facet joint denervation if positive response to single facet joint block.
3042596|NCT00484159|Experimental|3|Radiofrequency lumbar facet denervation without a diagnostic facet block.
3042597|NCT00484185||1|
3042598|NCT00484198|Placebo Comparator|1|
3042599|NCT00484198|Experimental|2|Rivoglitazone 1.0 mg
3042600|NCT00484198|Experimental|3|Rivoglitazone 1.5 mg
3042601|NCT00484198|Active Comparator|4|Pioglitazone 45 mg
3042602|NCT00484289|Experimental|Arm 1: Participants from Phase I study (IM101-034)|
3042603|NCT00484289|Experimental|Arm 2: Participants from Phase II study (IM101-071)|
3042604|NCT00484289|Experimental|Arm 3: New Participants with Methotrexate (MTX) Intolerance|
3042605|NCT00484315|Experimental|TAXUS Element|
3042606|NCT00484315|Active Comparator|TAXUS Express|
3042607|NCT00484354|Active Comparator|1|Bicarbonate administration
3042608|NCT00484354|Placebo Comparator|2|Normal saline administration
3042609|NCT00484393|Experimental|Tetracaine|Tetracaine 4% gel 1g applied to injection site
3042610|NCT00484393|Placebo Comparator|Placebo|Placebo cream (Aquatain) 1g applied to inejction site
3042611|NCT00484419|Experimental|colesevelam|colesevelam tablets 625 mg
3042612|NCT00484419|Active Comparator|rosiglitazone|rosiglitazone maleate 4mg
3042613|NCT00484419|Active Comparator|sitagliptin|sitagliptin phosphate tablets
3042614|NCT00484679|Experimental|1|Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.
3042615|NCT00484874|Experimental|A Single Dose of I-131 Tositumomab|I-131 Tositumomab therapeutic regimen given to patients with relapsed/refractory Hodgkin's lymphoma who have or have not undergone transplant.
3042616|NCT00484939|Experimental|Bevacizumab + capecitabine|Participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3-week treatment cycle. In addition, participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
3042617|NCT00484939|Active Comparator|Capecitabine|Participants received capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week treatment cycle.
3042618|NCT00485069|Experimental|Ropinirole Hydrochloride|
3042619|NCT00485134|Experimental|Stage 1: Group A, Dolphin 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of lipopolysaccharides (LPS). 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3042620|NCT00485134|Experimental|Stage 1: Group B, Dolphin 480 µg|480 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3042621|NCT00485134|Experimental|Stage 1: Group C, Dolphin 690 µg|690 Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. 230 μL of the formulated vaccine (or placebo, sterile saline) was added to a nasal spray applicator (DolphinTM).
3042622|NCT00485134|Other|Stage 1: Group D, Pipette 240 µg|240 µg Shigella flexneri 2a Invaplex 50 vaccine. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 mL glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. These subjects received 200 μL the vaccine via electronic pipette. This group is for lot bridging only, not included in dose-finding study.
3178911|NCT00666952|Active Comparator|2|
3468760|NCT03892590||Stable patient|Stable patients who admitted to ICU for observation.
3042623|NCT00485134|Other|Stage 2: Immunized / Challenge|The selected dose was to be administered with the Dolphin™ using the vaccination schedule from stage 1. Immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
3042624|NCT00485134|Placebo Comparator|Stage 2: Controls|A control was to be administered with the DolphinTM using the vaccination schedule from Stage 1. Non-immunized and challenged with Shigella challenge strain approximately 42 days after receiving the last vaccination following a 90-minute fast.
3042625|NCT00485173|Experimental|INFUSE® Bone Graft|In this arm, patients will receive implant with INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate.
3042626|NCT00485264|Experimental|Cohort I|"Participants between the ages of 12 and 18 years; receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily."
3042627|NCT00485264|Experimental|Cohort IIA|"Participants between the ages of 6 and 11 years, receiving raltegravir poloxamer film coated tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet."
3042628|NCT00485264|Experimental|Cohort IIB|"Participants between the ages of 6 and 11 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~8 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
3042629|NCT00485264|Experimental|Cohort III|"Participants between the ages of 2 and 5 years; receiving raltegravir chewable tablet:~Stage I starting dose: Weight based dose of ~6 mg/kg based on protocol dosing table, taken orally twice daily.~Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily."
3042630|NCT00485264|Experimental|Cohort IV|"Participants between the ages of 6 and 23 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
3042631|NCT00485264|Experimental|Cohort V|"Participants between the ages of 4 weeks and 5 months; receiving raltegravir oral granules for suspension (20 mg/mL):~Stage I starting dose: Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data."
3042632|NCT00485303|Experimental|Abiraterone|Abiraterone acetate 1000 milligram (mg) (4 oral tablets of 250 mg each) will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-days dosing cycle and will be continued until disease progression or unacceptable toxicity.
3042633|NCT00485433|Active Comparator|Bupivacaine HCl 105mg|Bupivacaine HCl given during hernia repair
3042634|NCT00485433|Experimental|SKY0402 low dose|SKY0402 low dose given during hernia repair
3042635|NCT00485433|Experimental|SKY0402 Middle dose|SKY0402 middle dose given during hernia repair
3042636|NCT00485433|Experimental|SKY0402 High dose|SKY0402 high dose given during hernia repair
3042637|NCT00485472|Experimental|Lacosamide|lacosamide (LCM)
3042638|NCT00485472|Placebo Comparator|Placebo|Placebo
3042639|NCT00485485|Experimental|Imatinib Mesylate + Docetaxel|Imatinib 400 mg orally daily; Docetaxel 60 mg/m^2 by vein over 1 hour every 3 weeks
3042640|NCT00485589|Placebo Comparator|Placebo|Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
3042641|NCT00485589|Experimental|Ocrelizumab 200 mg|Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
3042642|NCT00485589|Experimental|Ocrelizumab 500 mg|Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
3042643|NCT00485693|Active Comparator|Bupivacaine HCl|Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)
3042644|NCT00485693|Other|SKY0402|SKY0402 at various dosage levels. Single administration.
3042645|NCT00485732|Experimental|Cervarix Group|
3042646|NCT00485732|Placebo Comparator|Placebo Group|
3042647|NCT00485758|Other|1|Arm 1: One tablet of ER niacin/ laropiprant (1g) + one tablet of the run-in statin dose, advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study.
3042648|NCT00485758|Active Comparator|2|Arm 2: stable lipid-modifying regimen, adding Placebo ER niacin/laropiprant in week 4, for the duration of the study.
3042649|NCT00485836|Sham Comparator|Sham injection|
3042650|NCT00485836|Experimental|Ranibizumab injection 0.3 mg|
3042651|NCT00485836|Experimental|Ranibizumab injection 0.5 mg|
3042652|NCT00485953|Experimental|Active Medication Group|risedronate 35 mg weekly
3042653|NCT00485953|No Intervention|Placebo Group|Placebo
3042654|NCT00486018|Sham Comparator|Sham injection|
3042655|NCT00486018|Experimental|Ranibizumab injection 0.3 mg|
3042656|NCT00486018|Experimental|Ranibizumab injection 0.5 mg|
3042657|NCT00486031|Other|balsalazide disodium tablets,3.3 g BID,|
3042658|NCT00486044|Experimental|simvastatin|simvastatin 40 mg nightly for 1 month then 80 mg nightly for 8 months
3042659|NCT00486044|Placebo Comparator|Placebo|Matching placebo tablet nightly for 9 months
3042660|NCT00486226||1 Endovascular|All patients implanted with an CORDIS ENTERPRISE Vascular Reconstruction Device.
3042661|NCT00486252||This is N/A due to the above description.|This is N/A due to the above description.
3042662|NCT00486278|Experimental|vatreptacog alfa 5 mcg/kg|
3042663|NCT00486278|Experimental|vatreptacog alfa 10 mcg/kg|
3042664|NCT00486278|Experimental|vatreptacog alfa 20 mcg/kg|
3042665|NCT00486278|Experimental|vatreptacog alfa 40 mcg/kg|
3042666|NCT00486278|Experimental|vatreptacog alfa 80 mcg/kg|
3042667|NCT00486278|Experimental|rFVIIa 90 mcg/kg|
3042668|NCT00486291|Experimental|1|Phentermine 15mg/topiramate 100mg
3042669|NCT00486291|Placebo Comparator|2|Matched placebo
3042670|NCT00486330|Other|Buprenorphine plus Tipranavir/Ritonavir|
3042671|NCT00486434|Active Comparator|1|SMC021 Oral Calcitonin, 0.8 mg twice daily during 24 months
3042672|NCT00486434|Placebo Comparator|2|SMC021 Placebo, orally twice daily during 24 months
3042673|NCT00486447|Experimental|Imaging|General imaging subjects receiving CT exams
3042674|NCT00486525|Experimental|Arm I: Yoga Therapy|Patients participate in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients are also encouraged to practice yoga at home using the appropriate DVD/video segments for the month.
3042675|NCT00486525|No Intervention|Arm II: Wait-List|Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.
3042676|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 200 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT. Starting dose of HCQ is 200mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
3042677|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 400 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 400 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
3042678|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 600 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 600 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
3042679|NCT00486603|Experimental|Phase 1: RT+TMZ+HCQ 800 mg|"Phse I: daily hydroxychloroquine (HCQ) on 1st day of RT and concomitant temozolomide for 6wks during RT, 800 mg. After 6 wks, 4 wkd of HCQ alone daily. this will complete 10 week cycle. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~cohorts of three pts: dose levels: 200, 400, 800mg. NO dose escalation beyond 800mg.~Other: pharmacological study (PK)~pts continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 1~Radiation (RT)"
3042680|NCT00486603|Experimental|Phase 2: RT + TMZ + HCQ MTD|"Phse 2: daily hydroxychloroquine (HCQ) (MTD 600mg) on 1st day of RT and concomitant temozolomide for 6wks during RT. After 6 weeks, 4 weeks of HCQ alone daily. Complete 10 week cycle -Initiation Phase~Maintenance cycles 1-6 HCQ daily TMZ D 1-5 150-200mg/m2 every 28 days. Cycles 7+ mono therapy of HCQ daily, every 28 days.~Other: pharmacological study (PK)~Pts will continue on treatment until tumor progression. PKs - correlatives will be collected in Phase 2~Radiation (RT)"
3042681|NCT00486642|Experimental|Arm A (pazopanib hydrochloride)|"Patients receive pazopanib hydrochloride PO QD on days 1-28.~."
3042682|NCT00486642|Experimental|Arm B (pazopanib hydrochloride, bicalutamide)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Patients also receive bicalutamide PO QD on days 8-28 of course 1 and on days 1-28 in all subsequent courses.
3042683|NCT00486720|Experimental|1|vorinostat 400 mg
3042684|NCT00486720|Experimental|2|vorinostat 200 mg
3042685|NCT00486759|Experimental|Bevacizumab + rituximab + CHOP|Patients received bevacizumab 5 mg/kg/week on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
3042686|NCT00486759|Active Comparator|Placebo + rituximab + CHOP|Patients received placebo to bevacizumab on Day 1 of each cycle + rituximab 375 mg/m^2 intravenously (IV) on Day 1 of each cycle + CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone).
3042687|NCT00486811|Placebo Comparator|Matching Placebo (twice daily)|The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
3042688|NCT00486811|Experimental|Tapentadol ER (100 to 250 mg twice daily)|The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
3042689|NCT00486811|Active Comparator|Oxycodone CR (20 to 50 mg twice daily)|The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
3042690|NCT00486824|Active Comparator|Indomethacin|50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
3042691|NCT00486824|Active Comparator|Nifedipine|30 mg Nifedipine initially followed by 20 mg every 6 hrs for 48 hrs.
3042692|NCT00486837|Experimental|Group 1|Bronchial Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
3042693|NCT00486837|Experimental|Group 2|Peripheral Deposition Intervention: Alpha1-Proteinase Inhibitor (Human) Dosage: 25 mg in lungs, one inhalation per day over 4 weeks
3042694|NCT00486863|Placebo Comparator|Control|Placebo at 12-16 weeks gestation.
3042695|NCT00486863|Experimental|Praziquantel|Praziquantel at 12-16 weeks gestation.
3042696|NCT00486902|Experimental|Ketamine|Subjects receive IV ketamine 10 mg 5 minutes after infant delivery.
3042697|NCT00486902|Placebo Comparator|Placebo|Subjects receive IV Saline 20 mL 5 minutes after infant delivery
3042698|NCT00486954|Experimental|Paclitaxel plus Lapatinib|6 pills of lapatinib at 250 mg each once daily and infusion of paclitaxel at 80 mglm2 weekly
3042699|NCT00486954|Active Comparator|Paclitaxel alone|Infusion of paclitaxel at 80 mglm2 weekly
3042700|NCT00487084|Experimental|morphine - 2CP-saline (MCS)|morphine will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level; saline will be administered at skin incision
3042701|NCT00487084|Experimental|saline-2CP-morphine (SCM)|saline will be administered 30 min prior to epidural anesthesia; 2CP will be used to achieve a T4 level;morphine will be administered at skin incision
3042702|NCT00487084|Active Comparator|saline-lidocaine-morphine (SLM)|Saline will be administered 30 min prior to epidural anesthesia; lidocaine will be used to achieve a T4 level; morphine will be administered at skin incision
3042703|NCT00487188|Experimental|ENF + HAART|Participants received Enfuvirtide (ENF) 90 mg administered by subcutaneous injection twice a day for up to 48 weeks in addition to an oral highly active antiretroviral treatment (HAART) regimen for up to 48 weeks.
3042704|NCT00487188|Active Comparator|HAART|Participants received an oral highly active antiretroviral treatment (HAART) regimen, consisting of 3-5 antivirals for up to 48 weeks.
3042705|NCT00487240|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension twice daily
3042706|NCT00487240|Active Comparator|Detemir|Insulin Levemir (detemir) subcutaneous (SC) twice daily.
3042707|NCT00487279|Experimental|ICD Group|ICD (Implantable Cardioverter Defibrillator)
3042708|NCT00487279|Other|Control Group|Medial Therapy
3042709|NCT00487435|Experimental|001|Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
3042710|NCT00487539|Placebo Comparator|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
3042711|NCT00487539|Experimental|Golimumab 100 mg -> 50 mg|Golimumab 100 milligram (mg) subcutaneous injection administered at Week 0 and dose is decreased to 50 mg at Week 2.
3042712|NCT00487539|Experimental|Golimumab 200 mg -> 100 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 and dose is decreased to 100 mg at Week 2.
3042713|NCT00487539|Experimental|Golimumab 400 mg -> 200 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 and dose is decreased to 200 mg at Week 2.
3042714|NCT00487552|Experimental|1|palliative treatment of gastric outlet obstruction
3042715|NCT00487565|Other|LCS Complete Posterior Stabilized knee implant|Total knee arthroplasty with a posterior stabilized implant
3042716|NCT00487669|Experimental|Paclitaxel Poliglumex with Pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued.
3042717|NCT00487695|Active Comparator|CLE followed by standard EGD|Participants are randomized to have either confocal laser endomicroscopy (CLE) or standard endoscopy (EGD) first. Then 6 weeks later, they have the other procedure. This arm is for patients randomized to CLE followed by standard EGD
3042718|NCT00487695|Active Comparator|standard EGD followed by CLE|Patients are randomized to either have standard endoscopy (EGD)or confocal laser endomicroscopy (CLE) first. The second procedure is then completed 6 weeks later. This arm is for patients who had standard endoscopy first.
3042719|NCT00487721|Experimental|Silibin-Phytosome|Subjects in this group will take Silibin-Phytosome 13 grams daily, in three divided doses for 2-10 weeks.
3042720|NCT00487721|No Intervention|Control|Patients in this arm will not take any intervention.
3042721|NCT00487747|Experimental|Peginterferon Alfa-2a|
3042722|NCT00487825|Experimental|Canakinumab + Methotrexate|Canakinumab, human anti-interleukin-1beta monoclonal antibody plus Methotrexate (MTX). Intravenous (IV) Infusion of 600mg canakinumab on Day 1, 15 continuing every 4 weeks up to week 26. MTX was given as variable dosing regimen of 7.5 mg-15 mg weekly.
3042723|NCT00487825|Active Comparator|Methotrexate + placebo|Methotrexate (MTX) was given as variable dosing regimen of 7.5 mg-15 mg weekly. Intravenous (IV) Placebo Solution, given in the same mode of administration as the canakinumab solution.
3042724|NCT00487942|Active Comparator|50 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 50 mg/day armodafinil treatment arm for the double-blind treatment period of the study took one 50 mg armodafinil tablet plus three placebo tablets each morning.
3132865|NCT03460990|Experimental|VX-659/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
3132866|NCT03461146|Experimental|MT-6548|
3042725|NCT00487942|Active Comparator|100 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 100 mg/day armodafinil treatment arm for the double-blind treatment period of the study took two 50 mg armodafinil tablets plus two placebo tablets each morning. Subjects began taking 50 mg/day and then titrated to 100 mg/day on Day 2 of the first week of the double-blind treatment period.
3042726|NCT00487942|Active Comparator|200 mg/day armodafinil|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the 200 mg/day armodafinil treatment arm for the double-blind treatment period of the study took four 50 mg armodafinil tablet and no placebo tablets each morning. Subjects were titrated to this dose by starting treatment at 50 mg/day (1 tablet) and increasing by 50 mg increments on days 2, 4, and 6 until they were taking 200 mg/day.
3042727|NCT00487942|Placebo Comparator|Placebo|Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
3042728|NCT00488033|No Intervention|1|Standard of Care
3042729|NCT00488033|Other|2|CT Angiography
3042730|NCT00488059|Experimental|Phase I|Phase 1: ENF 90mg SC BID): In the first phase or cohort phase of day I-1 through Week I-12 of the trial all patients received enfuvirtide (ENF) 90 mg subcutaneously (SC) twice daily (BID) + Isentress® [raltegravir] (RAL) 400-mg orally (PO) BID + optimized background (OB) with at least 1 fully active antiretroviral (ARV) agent excluding nucleoside reverse transcriptase inhibitor (NRTIs).
3042731|NCT00488059|Experimental|Phase II|"In the randomized comparator Phase II of the trial- (Day II-1 through Week II-16): Virologic responders confirmed HIV-1 RNA ≤50 copies/mL from Phase I were randomized to 1 of 2 treatment arms of~(Phase II Arm A: Phase I then ENF 90mg SC BID): ENF 90 mg SC BID + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs or (Phase II Arm B: Phase I then ENF 180mg SC QD): ENF 180 mg SC once daily (QD) + RAL 400 mg PO BID + OB with at least 1 fully active ARV agent excluding NRTIs."
3042732|NCT00488293|Experimental|Arm 1|Store and forward teledermatology consult process
3042733|NCT00488293|No Intervention|Arm 2|Conventional consult process
3042734|NCT00488319|Experimental|001|Paliperidone ER1.5 to 12 mg tablet once daily for 6 months
3042735|NCT00488345|Experimental|A|0.75 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by central laboratory in acceptable condition for 10 to 12 patients in cohort. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3042736|NCT00488345|Experimental|B|1 mg/kg (up to a maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Escalation to next dose cohort will occur only after safety and tolerability at preceding dose have been established by sponsor (after tigecycline LDOT data are received) and if at least 5 of 6 PK samples per patient have been received by the central laboratory in acceptable condition for 10 to 12 patients in the cohort. Treatment period of tigecycline will be a minimum of 3 days (unless the patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3042737|NCT00488345|Experimental|C|1.25 mg/kg (up to maximum dose of 50 mg for each dose) of tigecycline every 12 hours infused over approximately 30 minutes. Treatment period of tigecycline will be a minimum of 3 days (unless patient is considered a treatment failure before this time) and a maximum of 14 days. On or after Day 4, based on investigator's decision, patients can switch to oral antibiotic therapy (to be chosen and provided by the investigator) and discharged after collection of planned PK samples.
3042738|NCT00488475||Patients with Rheumatoid Arthritis|
3042739|NCT00488488||A|
3042740|NCT00488514|Other|Active Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)
3042741|NCT00488592|Experimental|PR1/WT1 Vaccine Response in Participants With Low-Risk Myeloid Cancers|"Subjects were given 6 subcutaneous injects of PR1:169-177 in Montanide adjuvant and 6 subcutaneous injections of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
3042742|NCT00488618|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3042743|NCT00488618|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3042744|NCT00488631|Placebo Comparator|Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to placebo subcutaneous (under the skin) injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
3042745|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 50 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 50 mg or 100 mg subcutaneous injections every 4 weeks through Week 52.
3468761|NCT03892499|Experimental|Healthy Volunteers|Period 1: Single dose of olinciguat. Period 2: ITZ is dosed once daily (QD) for 10 days; a single dose of olinciguat is administered 1 hour after the fourth ITZ QD dose.
3468762|NCT03892603|Experimental|Strengthening exercises program|
3468763|NCT03892603|Experimental|Motor control exercises program|
3042746|NCT00488631|Experimental|GLM-I-Rsp-Golimumab 100 mg Maintenance|Participants in clinical response to golimumab at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and randomized to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631). Participants with loss of clinical response will be re-randomized to receive golimumab 100 mg or 200 mg subcutaneous injections every 4 weeks through Week 52.
3042747|NCT00488631|Placebo Comparator|Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance|Participants in clinical response to placebo at Week 6 of induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized. Participants with loss of clinical response will have their dose increased to golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52.
3042748|NCT00488631|Experimental|PBO-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to placebo at Week 6 induction study C0524T16 (NCT00488774) or C0524T17 (NCT00487539) and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
3042749|NCT00488631|Experimental|GLM-I-nonRsp-Golimumab 100 mg Maintenance|Participants not in clinical response to golimumab at Week 6 of induction study and received golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in maintenance study C0524T18 (NCT00488631); not randomized.
3042750|NCT00488644|Experimental|Levothyroxine + Liothyronine|Levothyroxine 75 mcg by mouth (PO) Daily for 8 Weeks + Liothyronine 15 mcg PO Daily for 8 Weeks
3042751|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 1)|Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 13 months), and 1 dose each of MMR and Hib (booster) at 13 months.
3042752|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 2)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months.~This group had an additional blood draw at the time of enrollment."
3042753|NCT00488683|Experimental|MenACWY-CRM and Routine Vaccines (Group 3)|"Infants received 2 doses of MenACWY-CRM (at 2 and 4 months) as a primary course of vaccination and third dose (at 12 months) as a booster. Infants also received routine vaccines - 3 doses of DTaP-Hib-IPV (at 2, 3, and 4 months), 3 doses of PCV (at 2, 4, and 12 months), and 1 dose each of MMR and Hib (booster) at 13 months of age.~This group had an additional blood draw at 6-7 days after third dose of MenACWY-CRM."
3042754|NCT00488774|Placebo Comparator|Placebo|Matching placebo for golimumab, intravenous (IV) (through a vein in the arm) infusion administered at Week 0
3042755|NCT00488774|Experimental|Golimumab 1 milligram (mg) per kilogram (kg)|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0.
3042756|NCT00488774|Experimental|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0.
3042757|NCT00488774|Experimental|Golimumab 4 mg per kg|Golimumab 4 mg per kg, intravenous (IV) infusion administered at Week 0.
3042758|NCT00488865|Other|Intravascular Filter Device|
3042759|NCT00488982|Experimental|Docetaxel + Observation|Intermittent docetaxel/prednisone with no maintenance therapy: Patients will discontinue docetaxel/prednisone and undergo observation until disease progression at which time they will re-initiate docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before subsequent discontinuation of chemotherapy
3042760|NCT00488982|Experimental|Docetaxel + GM-CSF|Intermittent docetaxel/prednisone with maintenance GM-CSF therapy: Patients will discontinue docetaxel/prednisone and will receive maintenance GM-CSF until disease progression at which time, they will discontinue GM-CSF and resume docetaxel/prednisone. Six cycles of docetaxel/prednisone will again be administered before discontinuation of chemotherapy and GM-CSF therapy is re-initiated. GM-CSF dose/schedule will be as previously described (250 mcg/m2 SQ daily, days 15-28 q28 days)
3042761|NCT00489086|Other|Tazarotene Cream|Open label
3042762|NCT00489216|Experimental|Efalizumab|All patients on study will receive a total of 8 injections of efalizumab
3042763|NCT00489255|Experimental|Trimethobenzamide (Tigan®)|
3042764|NCT00489255|Placebo Comparator|Inactive substance|
3042765|NCT00489268|Active Comparator|Phase I: 6 J/cm2|Subjects randomized to the energy density group of 6 J/cm2 through the HALO Ablation System.
3042766|NCT00489268|Active Comparator|Phase I: 8 J/cm2|Subjects randomized to the energy density group of 8 J/cm2 through the HALO Ablation System.
3042767|NCT00489268|Active Comparator|Phase I: 10 J/cm2|Subjects randomized to the energy density group of 10 J/cm2 through the HALO Ablation System.
3042768|NCT00489268|Active Comparator|Phase I: 12 J/cm2|Subjects randomized to the energy density group of 12 J/cm2 through the HALO Ablation System.
3042769|NCT00489268|Active Comparator|Phase II|All Halo 360 treatments performed at 10 J/cm2 through the HALO Ablation System. All Halo 90 treatments performed at 12 J/cm2 through the HALO Ablation System.
3042770|NCT00489281|Experimental|Transplant - 200 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
3042771|NCT00489281|Experimental|Transplant - 400 cGy|Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
3042772|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 1|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
3132868|NCT03461289|Experimental|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
3042773|NCT00489359|Experimental|Pemetrexed/Carboplatin Phase 2|"Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.~Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion."
3042774|NCT00489411|Experimental|Arm I/Group A (Duloxetine then Placebo)|Patients receive oral duloxetine hydrochloride once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive an oral placebo once or twice daily in weeks 8-13.
3042775|NCT00489411|Experimental|Arm II/Group B (Placebo then Duloxetine)|Patients receive an oral placebo once or twice daily in weeks 1-6. After a 1-week rest period, patients cross over to receive oral duloxetine hydrochloride once or twice daily in weeks 8-13.
3042776|NCT00489424|Experimental|Acetaminophen|2 capsules of acetaminophen 325 mg and 2 capsules of placebo (matching fluvastatin) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of acetaminophen 325 mg 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3042777|NCT00489424|Experimental|Fluvastatin|2 capsules of fluvastatin 40 mg and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to i.v. infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3042778|NCT00489424|Placebo Comparator|Placebo|2 capsules of placebo (matching fluvastatin) and 2 capsules of placebo (matching acetaminophen) administered 45 +/- 15 minutes prior to intravenous (i.v.) infusion of zoledronic acid 5 mg, then 2 capsules of placebo (matching acetaminophen) 4 times per day (including medication taken at study site at visit 2/day 1) over the next 3 days (not exceeding 8 capsules in a 24-hour period).
3042779|NCT00489476|Experimental|1.25 mg Staccato Loxapine|1.25 mg ADASUVE, single dose
3042780|NCT00489476|Experimental|2.5 mg Staccato Loxapine|2.5 mg ADASUVE, single dose
3042781|NCT00489476|Experimental|5 mg Staccato Loxapine|5 mg ADASUVE, single dose
3042782|NCT00489476|Experimental|Staccato Placebo|Staccato Placebo, 0 mg
3042783|NCT00489489|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3042784|NCT00489489|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3042785|NCT00489489|Placebo Comparator|Placebo + IFN-β|Placebo (for Teriflunomide) once daily concomitantly with Interferon-β (IFN-β) for 24 weeks
3042786|NCT00489541|Experimental|TAXUS Element Stent System|
3042787|NCT00489554|Experimental|Synflorix Vaccine Group|Subjects receiving Synflorix vaccine co-administered with DTPa-HBV-IPV/Hib (Infanrix hexa) vaccine at 2-4-6 months of age, and co-administered with HRV (Rotarix) vaccine at 2-4 months of age.
3042788|NCT00489736|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
3042789|NCT00489736|Active Comparator|Amiodarone 600mg/200mg od|over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
3042790|NCT00489827|Active Comparator|Intravenous glutamate|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
3042791|NCT00489827|Placebo Comparator|Saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
3042792|NCT00489853|Experimental|Symbicort then Formoterol then Placebo|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
3042793|NCT00489853|Experimental|Formoterol then Symbicort then Placebo|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
3042794|NCT00489853|Placebo Comparator|Placebo then Formoterol then Symbicort|Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily
3042795|NCT00489866|Experimental|Aripiprazole|
3042796|NCT00489866|Placebo Comparator|Placebo|
3042797|NCT00489918|Placebo Comparator|Macroflux® placebo|Macroflux® placebo patch
3042798|NCT00489918|Experimental|Macroflux® 20 mcg|Macroflux® 20 mcg patch
3042799|NCT00489918|Experimental|Macroflux® 30 mcg|Macroflux® 30 mcg patch
3042800|NCT00489918|Experimental|Macroflux® 40 mcg|Macroflux® 40 mcg patch
3042801|NCT00489918|Active Comparator|FORTEO®|FORTEO® 20 mcg injection
3042802|NCT00489970|Experimental|Boostrix Group|Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine [Tdap](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine [Tdap](GSK776423).
3042803|NCT00489970|Active Comparator|Adacel Group|Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine [Tdap](GSK776423).
3042804|NCT00489970|Active Comparator|Control group|Subjects received the first dose of Boostrix vaccine [Tdap](GSK776423) in this study at Year 9.
3042805|NCT00490009|Experimental|Bexxar + Total Body Irradiation (TBI)|Bexxar will be administered with pre-medications acetaminophen, diphenhydramine, and potassium iodide (KI).
3042806|NCT00490022|Active Comparator|1|DHT gel (70 mg/day) for one month
3042807|NCT00490022|Placebo Comparator|2|Placebo gel for one month
3042808|NCT00490035|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
3042809|NCT00490035|Experimental|Brivaracetam 20 mg/day|Brivaracetam 20 mg/day, 10 mg administered twice a day
3042810|NCT00490035|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
3042811|NCT00490035|Experimental|Brivaracetam 100 mg/day|Brivaracetam 100 mg/day, 50 mg administered twice a day
3042812|NCT00490061|Experimental|Radiotherapy and Lapatinib with DCE-MRI|DCE-MRI will precede radiotherpy before and after Lapatinib loading. 1500mg/d once daily oral Lapatinib will be administration for seven days prior to and throughout radiotherapy. Radiotherapy will be delivered as Intensity Modulated Radio Therapy (IMRT) using a G.E. Healthcare 1.5T MR, systems revision 12.0 M5 for a total dose of 70Gy delivered in 2-2.12 Gy/ fraction over the course of 6.5-7 weeks.
3042813|NCT00490100|Experimental|Treatment|Treatment
3042814|NCT00490139|Active Comparator|Arm 1: Trastuzumab|"Design 1: Trastuzumab 8mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab administered every 3 weeks (6mg/kg IV without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab 4mg/kg IV loading dose followed by 2mg/kg IV weekly. After completion of chemotherapy, trastuzumab (6mg/kg without loading dose) every 3 weeks for an additional 40 weeks (52 weeks total)."
3042815|NCT00490139|Experimental|Arm 2: Lapatinib|"Based on the IDMC results from 18 August 2011, any patient enrolled onto Arm 2 should be considered for a new treatment strategy based on discussion with their physician.~Design 1: Lapatinib 1500mg oral daily for a total of 52 weeks.~Design 2: Either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 IV every 3 weeks for 4 cycles administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, oral lapatinib administered at 1500mg daily for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with oral lapatinib at 750mg daily. After completion of chemotherapy, the dose of lapatinib will be increased to 1500mg oral daily for an additional 40 weeks (52 weeks total)."
3042816|NCT00490139|Experimental|Arm 3: Trastuzumab followed by Lapatinib|"Design 1: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) for 12 weeks administered concomitantly and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles; followed by a 6 week treatment-free interval followed by oral lapatinib 1500mg daily for 34 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concomitantly with trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV weekly) followed by a 6 week treatment-free interval followed by oral lapatinib 1500 mg daily for 28 weeks (52 weeks total)."
3042817|NCT00490139|Experimental|Arm 4: Lapatinib in combination with Trastuzumab|"Design 1: Oral lapatinib 1000 mg daily concurrent with trastuzumab 8 mg/kg IV loading dose followed by 6mg/kg IV every 3 weeks (52 weeks total).~Design 2: Trastuzumab (4mg/kg loading dose followed by 2mg/kg IV weekly) concurrent with oral lapatinib 750 mg daily and either paclitaxel 80mg/m2 IV weekly for 12 weeks OR docetaxel 75mg/m2 every 21 days for 4 cycles (12 weeks). After completion of chemotherapy, the dose of lapatinib will be increased to 1000mg daily concurrently with trastuzumab every 3 weeks (6mg/kg without loading dose) for an additional 40 weeks (52 weeks total).~Design 2B: Docetaxel 75mg/m2 and carboplatin AUC 6 every 3 weeks for 6 cycles (18 weeks) administered concurrently with oral lapatinib 750mg plus weekly trastuzumab (4mg/kg IV loading dose followed by 2mg/kg IV. After the completion of chemotherapy, trastuzumab will be administered every 3 weeks (6mg/kg without loading dose) concurrent with lapatinib 1000mg daily for an additional 40 weeks (52 weeks total)."
3042818|NCT00490256|No Intervention|Control|Arm 1 is the control arm. This arm will receive the standard cardiopulmonary bypass circuit.
3042819|NCT00490256|Active Comparator|Experimental|This arm is the modified selective perfusion arm. This arm will receive the modified cardiopulmonary circuit.
3042820|NCT00490269|Active Comparator|Dronabinol|
3042821|NCT00490269|Placebo Comparator|Placebo|
3042822|NCT00490282|Experimental|Image-Guided Adaptive Radiotherapy|Intensity Modulated Radiotherapy (IMRT) + Adaptive Radiotherapy (ART)
3042823|NCT00490451|Experimental|LY573636|
3042824|NCT00490477|No Intervention|CONVENTIONAL|
3042825|NCT00490477|Active Comparator|POLYMYXIN-B|an extracorporeal LPS removal
3042826|NCT00490490|Experimental|Tositumomab + XRT + KI|Tositumomab + external beam radiotherapy (XRT) + potassium iodide (KI)
3042827|NCT00490529|Experimental|CpG-MCL Vaccine|An autologous anti-tumor vaccine.
3042828|NCT00490542|Placebo Comparator|Placebo arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received sugar pills.
3042829|NCT00490542|Active Comparator|Geodon arm|Participants were instructed by a physician to take a study drug daily. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone. Participants were not informed whether they were receiving sugar pills or Geodon. Participants in this study arm received Geodon.
3042830|NCT00490555|Placebo Comparator|1|Placebo gel + Placebo pill + placebo injection
3042831|NCT00490555|Active Comparator|2|Testosterone 1% transdermal gel 10 g + placebo pill + placebo injection
3042832|NCT00490555|Active Comparator|3|Testosterone 1% transdermal gel 10 g + dutasteride 0.5 mg Orally + placebo injection
3042833|NCT00490555|Active Comparator|4|Testosterone 1% transdermal gel 10 g + placebo pill + DMPA 300 mg injection (IM)
3042834|NCT00490568|Experimental|Rosiglitazone XR|Investigational drug
3042835|NCT00490646|Experimental|Arm A|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
3042836|NCT00490646|Active Comparator|Arm B|trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.
3042837|NCT00490698|Experimental|Zoledronate + Atorvastatin|Zoledronate 4 mg intravenous (IV) once every 4 Weeks + Atorvastatin 20 mg orally (PO) daily
3468764|NCT03892603|Active Comparator|Education and advice|
3042838|NCT00490724|Experimental|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
3042839|NCT00490724|Experimental|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
3042840|NCT00490724|Experimental|Nesiritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
3042841|NCT00490802|Experimental|Intranasal Oxytocin|Subjects were given 24 IU intranasal oxytocin twice daily, in the morning and afternoon for 6 weeks.
3042842|NCT00490802|Placebo Comparator|Placebo|Subjects were given placebo twice daily, in the morning and afternoon for 6 weeks.
3042843|NCT00490815|Experimental|1|
3042844|NCT00490815|Experimental|2|
3042845|NCT00490841|Experimental|RX Herculink Elite|To evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in the treatment of suboptimal post-procedural percutaneous transluminal angioplasty (PTA) of atherosclerotic de novo or restenotic renal artery stenosis in patients with uncontrolled hypertension.
3042846|NCT00490919|Experimental|Double-blind BTDS 10 or 20|Buprenorphine transdermal system 10 or 20 mcg/h applied for 7-day wear
3042847|NCT00490919|Placebo Comparator|Double-blind Placebo TDS|Placebo transdermal system to match BTDS patches, applied for 7 days
3042848|NCT00490971|Experimental|Paliperidone ER|
3042849|NCT00490971|Placebo Comparator|Placebo|
3042850|NCT00490971|Active Comparator|Olanzapine|
3042851|NCT00491075|Experimental|Pemetrexed + Gemcitabine|Pemetrexed 500 mg/m^2 intravenous (IV) and Gemcitabine 1500 mg/m^2 IV on Day 1.
3042852|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 1|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks for HCV genotype 1
3042853|NCT00491179|Experimental|Pegylated IFN + RBV for HCV genotype 2|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks for HCV genotype 2
3042854|NCT00491244|Experimental|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
3042855|NCT00491244|Experimental|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
3042856|NCT00491322|Experimental|Ergocalciferol group|Ergocalciferol 50000 international units once a week for 12 weeks
3042857|NCT00491322|Placebo Comparator|Ergocalciferol Placebo group|Matching placebo once a week for 12 weeks
3042858|NCT00491374|Experimental|MFNS|
3042859|NCT00491374|Placebo Comparator|Placebo|
3042860|NCT00491491|Experimental|Z-BEAM|ibritumomab tiuxetan (zevalin) BEAM
3042861|NCT00491491|Active Comparator|standard BEAM|standard BEAM chemotherapy
3042862|NCT00491504|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg total dose (2 sprays each nostril)
3042863|NCT00491504|Placebo Comparator|Placebo|Placebo (2 sprays each nostril)
3042864|NCT00491530|Experimental|ABT-335 + rosuvastatin calcium|
3042865|NCT00491530|Experimental|ABT-335 + simvastatin|
3042866|NCT00491530|Experimental|ABT-335 + atorvastatin calcium|
3042867|NCT00491556|Experimental|Experimental Arm|Subjects in the experimental group will begin HAART consisting of TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r upon entry or to begin treatment under current DHHS guidelines. Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
3042868|NCT00491556|Other|Standard Care Arm|Subjects randomized to the standard care arm will begin HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care and will be followed for a total of three years. Under these guidelines and under current clinical standards, subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur.
3042869|NCT00491608|Experimental|1|rThrombin
3042870|NCT00491738|Experimental|1|
3042871|NCT00491738|Placebo Comparator|2|
3042872|NCT00491751|Experimental|Atorvastatin|Atorvastatin 40 or 80 mg/day
3042873|NCT00491751|Experimental|Ascorbic Acid|Ascorbic Acid 500 mg/day
3042874|NCT00491751|Placebo Comparator|Placebo|Placebo atorvastatin and Placebo ascorbic acid
3042875|NCT00491764|Experimental|Posaconazole 100 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
3042876|NCT00491764|Experimental|Posaconazole 200 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
3042877|NCT00491764|Experimental|Posaconazole 400 mg QD for 24 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
3042878|NCT00491764|Experimental|Posaconazole 400 mg QD for 12 weeks.|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
3042879|NCT00491764|Active Comparator|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
3042880|NCT00491764|Placebo Comparator|Placebo|Placebo for 24 weeks.
3042881|NCT00491829|Experimental|flibanserin|50 mg qhs
3042882|NCT00491829|Experimental|flibanserin 100mg|100 mg qhs
3042883|NCT00491829|Placebo Comparator|placebo|placebo qhs
3042884|NCT00491894|Other|Patients with Chronic Drooling|Arm receiving study drug
3042885|NCT00492024|Experimental|Moxifloxacin 400 mg|Moxifloxacin 400mg once daily for 5 days
3042886|NCT00492024|Placebo Comparator|Placebo|Matching placebo for 5 days
3042887|NCT00492063|Experimental|Cell culture-derived influenza vaccine (cTIV)|
3042888|NCT00492063|Active Comparator|Egg-derived influenza virus vaccine (TIV)|
3042889|NCT00492089|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3042890|NCT00492089|Placebo Comparator|Arm II|Patients receive placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3042891|NCT00492115|Active Comparator|"therapeutic CPAP Treatment (6 weeks)"|Intervention - The active comparator is an intervention of nightly therapeutic CPAP (continuous positive airway pressure) treatment for 6 weeks. Patients will use CPAP every night for the full duration of the study, i.e., 6 weeks
3042892|NCT00492115|Placebo Comparator|"Sham CPAP/therapetuic CPAP (6 weeks)"|"The placebo comparator is an intervention of placebo CPAP (continuous positive airway pressure) nightly for 3 weeks followed by therapeutic CPAP treatment nightly for 3 weeks.~Patients will use a sham CPAP (no real pressure) for 3 weeks and then will be switched to real CPAP for 3 weeks."
3042893|NCT00492206|Experimental|Cetuximab|"Cetuximab 400 mg/m2 IV week 0 only~External beam radiation weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly thereafter weeks 1 - 7~Cetuximab 250 mg/m2 IV weekly weeks 8 - 26~Carboplatin AUC = 6 IV Paclitaxel 200 mg/m2 IV Every 3 weeks x 3 Cycles"
3042894|NCT00492232|Experimental|Ramelteon 8 mg QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
3042895|NCT00492232|Placebo Comparator|Placebo QD and current Zolpidem therapy|Zolpidem therapy will be reduced by dose, frequency, or both for up to 10 weeks.
3042896|NCT00492284|Experimental|1/4 Fluence Triple Therapy|Very low fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3042897|NCT00492284|Experimental|1/2 Fluence Triple Therapy|Reduced-fluence Visudyne followed by intravitreal Lucentis-Dexamethasone triple therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3042898|NCT00492284|Experimental|1/2 Fluence Double Therapy|Reduced-fluence Visudyne followed by Lucentis double therapy [within 2 hours] administered on Day 0, and then as required every 2 months thereafter
3042899|NCT00492284|Experimental|Ranibizumab|Lucentis monotherapy administered on Day 0, Month 1 and Month 2, and then as required monthly thereafter
3042900|NCT00492297|Experimental|Sorafenib + Dacarbazine|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
3042901|NCT00492336|Active Comparator|Rasagiline|Treatment with Rasagiline
3042902|NCT00492336|Placebo Comparator|Inactive pill|Treatment with Placebo
3042903|NCT00492349|Experimental|1|Varenicline
3042904|NCT00492349|Placebo Comparator|2|Placebo
3042905|NCT00492401|Experimental|Treatment (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-10. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3042906|NCT00492531|Experimental|Sildenafil|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo.
3042907|NCT00492531|Placebo Comparator|Placebo|There was a balancing of treatment group assignment across Tricuspid Regurgitant Jet velocity(TRV)measured on Echo
3042908|NCT00492544|Experimental|Cervarix|Subjects received 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) according to a 0, 1, 6-month schedule.
3042909|NCT00492557|Experimental|13vPnC+TIV Followed by Placebo 1 month later|
3042910|NCT00492557|Active Comparator|Placebo+TIV Followed by 13vPnC 1 month later|
3042911|NCT00492583|Placebo Comparator|Placebo|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.
3042912|NCT00492583|Experimental|Bifidobacterium lactis (BB-12)|Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.
3042913|NCT00492622|Experimental|Immediate-release omeprazole release first|subjects receive immediate release omeprazole for 7 days then delayed release for 7 days
3042914|NCT00492622|Experimental|Delayed-release omeprazole first|subjects receive delayed release omeprazole for 7 days then immediate release for 7 days
3042915|NCT00492648|Experimental|GSK1437173A 18-30 Years Old Group|Subjects aged 18 to 30 years old receiving 2 doses GSK1437173A vaccine in the primary study.
3042916|NCT00492648|Experimental|GSK1437173A 50-70 Years Old Group|Subjects aged 50 to 70 years old receiving 2 doses GSK1437173A vaccine in the primary study.
3042917|NCT00492726|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects received placebo matching the comparator (Ertapenem dummy) and Moxifloxacin 400 mg in 250 mL for intravenous infusion every 24 hours.
3042918|NCT00492726|Active Comparator|Ertapenem|Subject received Ertapenem 1.0 g in 50 mL for intravenous infusion and placebo matching Moxifloxacin (Moxifloxacin dummy) every 24 hours.
3042919|NCT00492752|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib was administered orally at a dose of 400 mg (2 x 200 mg tablets) bid (twice daily); 2 dose reductions to predefined levels of 400 mg (2 x 200 mg tablets) once daily (od) and 400 mg (2 x 200 mg tablets) every 2 days were permitted for treatment-emergent adverse events related to study treatment.
3042920|NCT00492752|Placebo Comparator|Placebo|Placebo tablets matching in appearance were orally administered bid (twice daily).
3042921|NCT00492856|Experimental|Post-consolidation therapy arm I|Patients receive oral tretinoin twice daily on days 1-7, oral mercaptopurine once daily on days 1-14, and oral methotrexate on day 1. Treatment repeats every 2 weeks for up to 1 year.
3042922|NCT00492856|No Intervention|Post-consolidation therapy arm II|Patients receive no further chemotherapy. Patients are followed every 3 months for 1 year. (Randomization and observation arm closed as of 8/15/10)
3042923|NCT00492921|Experimental|Cyclophosphamide 50|Treatment with cyclophosphamide 50 mg/kg/d x 1 days.
3042924|NCT00492921|Experimental|Cyclophosphamide 100|Treatment with cyclophosphamide 50 mg/kg/d x 2 days.
3042925|NCT00492921|Experimental|Cyclophosphamide 150|Treatment with cyclophosphamide 50 mg/kg/d x 3 days.
3178912|NCT00666991|Experimental|Nanotax, 50 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 50 mg/m2 once every 28 days until progression or unacceptable toxicity
3042926|NCT00492973|Active Comparator|Control|Patients in the active comparator group will receive intraoperative injections containing bupivacaine HCl, morphine, epinephrine, clonidine, cefuroxime, and normal saline, as per the surgeon's standard of care.
3042927|NCT00492973|Experimental|Corticosteroid|Patients in the Corticosteroid group will have the same medications as the Control Group with the addition of a corticosteroid (methylprednisolone acetate)
3042928|NCT00493012|Experimental|vitamin D oil|oil containing vitamin D (Vigantol oil)
3042929|NCT00493012|Placebo Comparator|placebo oil|oil not containg vitamin D (Migliol oil)
3042930|NCT00493038|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
3042931|NCT00493038|Active Comparator|Amoxicillin/Clavulanate|Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
3042932|NCT00493064|Experimental|Prospective active treatment|Niacin 500mg TID PO for treatment of retinal vein occlusions.
3042933|NCT00493181|Experimental|Interleukin-11|Starting dose 10 mcg/kg subcutaneously 3 times a week
3042934|NCT00493220|Experimental|HYLENEX SC, Placebo SC, IV|subcutaneous HYLENEX and ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
3042935|NCT00493220|Experimental|HYLENEX SC, IV, Placebo SC|subcutaneous HYLENEX and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
3042936|NCT00493220|Experimental|Placebo SC, HYLENEX SC, IV|subcutaneous placebo and ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, IV ceftriaxone as 3rd intervention
3042937|NCT00493220|Experimental|Placebo SC, IV, HYLENEX SC|subcutaneous placebo and ceftriaxone as 1st intervention, IV ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
3042938|NCT00493220|Experimental|IV, HYLENEX SC, Placebo SC|IV ceftriaxone as 1st intervention, subcutaneous HYLENEX and ceftriaxone as 2nd intervention, subcutaneous placebo and ceftriaxone as 3rd intervention
3042939|NCT00493220|Experimental|IV, Placebo SC, HYLENEX SC|IV ceftriaxone as 1st intervention, subcutaneous placebo and ceftriaxone as 2nd intervention, subcutaneous HYLENEX and ceftriaxone as 3rd intervention
3042940|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 15 milligrams/kilogram (mg/kg)|Intravenous Acetaminophen administered 15 milligrams/kilogram (mg/kg) every 8 hours (q8h) or every 6 hours (q6h) based age of subject
3042941|NCT00493246|Experimental|Intravenous (IV) Acetaminophen 12.5 (mg/kg)|Intravenous Acetaminophen administered 12.5 milligrams/kilogram (mg/kg) every 6 hours (q6h) or every 4 hours (q4h)
3042942|NCT00493285|Active Comparator|1|MEDI-534 at 10^4 TCID50 at 0, 2, and 4 months (Nasal spray)
3042943|NCT00493285|Active Comparator|2|MEDI-534 at 10^5 TCID50 at 0, 2, and 4 months (Nasal Spray)
3042944|NCT00493285|Active Comparator|3|MEDI-534 at 10^6 TCID50 at 0, 2, and 4 months (Nasal Spray)
3042945|NCT00493311|Experimental|IV Acetaminophen|1 g of acetaminophen in 100 mL of intravenous solution
3042946|NCT00493311|Placebo Comparator|IV Placebo|100 mL of intravenous placebo solution
3042947|NCT00493454|Experimental|Ibritumomab tiuxetan + Rituximab|Rituximab 250 mg/m² intravenous (IV) Days 1 and 8, 111In Ibritumomab Tiuxetan (5mCi of 111In, 1.6 mg of Ibritumomab Tiuxetan) IV (over 10 minutes) on Day 1; and 90Y Ibritumomab Tiuxetan 0.3 or 0.4 mCi/kg IV (over 10 minutes) on Day 8 after the Day 8 of Rituximab.
3042948|NCT00493467|Experimental|Zevalin|Ibritumomab Tiuxetan (Zevalin) + Rituximab
3042949|NCT00493636|Active Comparator|A (Sorafenib + Gemcitabine or Capecitabine)|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
3042950|NCT00493636|Placebo Comparator|B (Placebo + Gemcitabine or Capecitabine)|Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
3042951|NCT00493649|Experimental|TC+H|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.
3042952|NCT00493779|No Intervention|1|Effect of Clopidogrel withdrawal on biomarkers will be assessed via blood draws
3042953|NCT00493805|Experimental|Interventional Study arm (with insulin resistance)|"HOMA IR (homeostasis model assessment-estimated insulin resistance) of > 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg by mouth (PO) administered twice daily (BID) for a variable period depending on their response to treatment."
3042954|NCT00493805|Experimental|Non interventional study arm (without insulin resistance)|"HOMA IR <= 2~These participants received PEG-Intron 1.5 μg /kg subcutaneously (SC) once weekly plus weight based Rebetol 800-1400 mg PO administered twice daily (BID) for 48 weeks. (Participants are treated according to~European labeling)."
3042955|NCT00493974|Active Comparator|Zileuton|Zileuton (Zyflo, 600 mg 4 times a day)
3042956|NCT00493974|Placebo Comparator|Placebo|Placebo
3042957|NCT00494013|Experimental|Insulin Lispro Protamine Suspension|Insulin Lispro Protamine Suspension: Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
3042958|NCT00494013|Active Comparator|Detemir|Detemir: Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
3042959|NCT00494026|Experimental|Pemetrexed + Carboplatin|
3042960|NCT00494091|Experimental|A.|
3042961|NCT00494091|Experimental|B.|
3042962|NCT00494143|Active Comparator|Conventional Prosthetic foot|A conventional prosthetic foot that has limited energy storage and return capabilities. It is standardized and used by all subjects in the study.
3468765|NCT03892447|Experimental|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
3042963|NCT00494143|Active Comparator|Prescribed Prosthetic foot|the Prosthetic foot that the subject had prescribed for them by their clinical providers and was worn prior to study initiation
3042964|NCT00494143|Experimental|CESR foot|the experimental CESR, controlled energy storage prosthetic foot
3042965|NCT00494221|Active Comparator|FOLFOX + Cediranib 20 mg|FOLFOX + Cediranib 20 mg
3042966|NCT00494221|Active Comparator|FOLFOX + Cediranib 30 mg|FOLFOX + Cediranib 30 mg
3042967|NCT00494221|Placebo Comparator|FOLFOX + Placebo Cediranib|FOLFOX + Placebo Cediranib
3042968|NCT00494234|Experimental|KU-0059436 (AZD2281) 100 mg BID|
3042969|NCT00494234|Experimental|KU-0059436 (AZD2281) 400 mg BID|
3042970|NCT00494299|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.
3042971|NCT00494299|Placebo Comparator|Placebo|Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).
3042972|NCT00494442|Experimental|KU-0059436 (AZD2281) 100 mg BID|
3042973|NCT00494442|Experimental|KU-0059436 (AZD2281) 400 mg BID|
3042974|NCT00494481|Placebo Comparator|1|Docetaxel + placebo vandetanib
3042975|NCT00494481|Experimental|2|Vandetanib + Docetaxel
3042976|NCT00494494|Active Comparator|Standard Treatment|topical antibiotic for 10 days and a topical corticosteroid for 1 month
3042977|NCT00494494|Experimental|Nepafenac|1 drop per study eye three times per day for 30 days in addition to standard care
3042978|NCT00494507|Active Comparator|HYP Dichlorphenamide|Hyperkalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3042979|NCT00494507|Placebo Comparator|HYP Placebo|Hyperkalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3042980|NCT00494507|Active Comparator|HOP Dichlorphenamide|Hypokalemic participants were randomized to Dichlorphenamide for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3042981|NCT00494507|Placebo Comparator|HOP Placebo|Hypokalemic participants were randomized to Placebo for a 9 week double-blind phase. All participants then received Dichlorphenamide for a 52 week open-label phase.
3042982|NCT00494585|Experimental|CEP-701|80 mg orally twice a day for 30 days
3042983|NCT00494676|Experimental|Real prism glasses first, then sham|Participants in this arm will receive high power (57 prism diopter) peripheral prism glasses in the first period of the crossover and low power sham peripheral prism glasses in the second period
3042984|NCT00494676|Experimental|Sham prism glasses first, then real|Participants in this arm will receive low power sham peripheral prism glasses in the first period of the crossover and high power (57 prism diopter) peripheral prism glasses in the second period
3042985|NCT00494780|Active Comparator|Active Comparator 1|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 500mg
3042986|NCT00494780|Active Comparator|Active Comparator 2|Each patient will receive a total of 6 infusions with ofatumumab in combination with CHOP every 3 weeks. The first infusion will be 300mg followed by 5 infusions of 1000mg
3042987|NCT00494806|Experimental|Rocking Group|Patients rocked in a rocking chair in 10-20 minute increments for at least one hour per day beginning on the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
3042988|NCT00494806|No Intervention|Standard Care|Standard care group got out of bed and sat in a non-rocking chair and ambulated beginning the first day after surgery. Activity was increased each day and continued until passage of first postoperative flatus.
3042989|NCT00494871|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
3042990|NCT00494871|Active Comparator|Warfarin|Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
3042991|NCT00494975|Experimental|NB-UVB|Narrow band-Ultraviolet B phototherapy
3042992|NCT00494975|Placebo Comparator|UVA|Ultraviolet A Phototherapy
3042993|NCT00495040|Experimental|Proton Radiotherapy|Proton radiotherapy 87.5 CGE with 2.5 Gy/fraction for 35 treatments.
3042994|NCT00495079|Experimental|Marqibo|Eligible subjects received study drug at 2.25 mg/m^2 intravenously via peripheral or central venous access over 60 minutes (± 10 minutes).
3042995|NCT00495131|Active Comparator|Peginterfron and ribavirin (24 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
3042996|NCT00495131|Active Comparator|Peginterferon and ribavirin (48 weeks)|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
3042997|NCT00495157|Experimental|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3042998|NCT00495157|Experimental|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3042999|NCT00495157|Experimental|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
3043000|NCT00495170|Experimental|Concurrent proton and Chemotherapy|Proton Radiotherapy + Carboplatin + Paclitaxel
3043001|NCT00495222|Experimental|Tissue plication|The Endoscopic Suturing System (ESS) is used for tissue apposition and reduction of the size of a dilated GJ anastomosis in subjects who are regaining weight after successful weight loss following gastric bypass
3043002|NCT00495391|Active Comparator|1|Oral 500 mg nitazoxanide twice daily for 4 weeks followed by oral 500 mg nitazoxanide twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
3043003|NCT00495391|Placebo Comparator|2|Oral placebo twice daily for 4 weeks followed by oral placebo twice daily plus weekly injections of peginterferon alfa-2a plus oral ribavirin (1000 mg if <75 kg body weight or 1200 mg if ≥75 kg body weight) in daily divided doses for 48 weeks.
3043004|NCT00495469|Experimental|GSK189075|Participants will receive GSK189075 for 12 weeks
3043005|NCT00495469|Placebo Comparator|Placebo|Participants will receive GSK189075 matching Placebo for 12 weeks
3043006|NCT00495495|Experimental|Ozone treatment|Ozone treatment of randomly selected study tooth for 60 seconds
3043007|NCT00495495|Placebo Comparator|Placebo, no ozone|Placebo treatment (no ozone) of randomly selected study tooth for 60 seconds.
3043008|NCT00495521|Experimental|Active|4-Aminosalicylic acid extended release granules (as volume equivalent of active product), 50 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 50 mg/kg orally two times daily for 2 weeks
3043009|NCT00495521|Placebo Comparator|Placebo|Placebo granules identical in appearance to the active arm (as volume equivalent of active product), 0 mg/kg orally three times daily for two weeks followed by (as volume equivalent) 0 mg/kg orally two times daily for 2 weeks
3043010|NCT00495586|Placebo Comparator|Placebo|Placebo pills t.i.d. for 8 days
3043011|NCT00495586|Active Comparator|Amoxycillin and clavulanic acid|Amoxycillin and clavulanate t.i.d. for 8 days
3043012|NCT00495612|Experimental|Omalizumab|Patients received omalizumab via subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. The dose administered and the dosing interval were determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.
3043013|NCT00495612|Placebo Comparator|Placebo|Patients received placebo as a subcutaneous injection either every 2 weeks or every 4 weeks for 16 weeks. Patients received injections at the same time intervals as the omalizumab group.
3043014|NCT00495625|Experimental|Sunitinib Malate (SUO11248) Treatment|
3043015|NCT00495677|Active Comparator|PF-00232798 40 mg|
3043016|NCT00495677|Active Comparator|PF-00232798 300 mg|
3043017|NCT00495677|Active Comparator|PF-00232798 400 mg|
3043018|NCT00495677|Active Comparator|PF-00232798 5 mg|
3043019|NCT00495677|Active Comparator|PF-00232798 20 mg|
3043020|NCT00495677|Active Comparator|PF-00232798 150 mg|
3043021|NCT00495755|Experimental|Campath (alemtuzumab)|
3043022|NCT00495794|Experimental|Pharmacist management|Eligible patients assigned to - adherence counseling and medication management delivered by a clinical pharmacist trained in behavioral counseling approaches (motivational interviewing)
3043023|NCT00495794|No Intervention|Usual care|Eligible patients receive usual care
3043024|NCT00495820|Experimental|Arm 1|Methylphenidate
3043025|NCT00495820|Placebo Comparator|Arm 2|Placebo
3043026|NCT00496015|Experimental|Synflorix I Group|Subjects were vaccinated with 3 primary vaccination doses of Synflorix™ vaccine with prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa along with prophylactic antipyretic treatment.
3043027|NCT00496015|Experimental|Synflorix II Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment
3043028|NCT00496015|Experimental|Synflorix PRE Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (before the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
3043029|NCT00496015|Experimental|Synflorix POST Group|Subjects were vaccinated with 3 primary vaccination doses of Synforix™ vaccine without prophylactic administration of paracetamol in study 10PN-PD-DIT-010 (107017), and received in this study (after the implementation of the protocol amendment) at 12-15 months of age a booster dose of Synforix™ vaccine, co-administered with Infanrix™ hexa without prophylactic antipyretic treatment.
3043030|NCT00496015|Active Comparator|Mencevax + Infanrix Hexa Group|Age-matched pneumococcal vaccine unprimed group receiving a single dose of Mencevax™ vaccine co-administered with Infanrix™ hexa vaccine.
3043031|NCT00496054|Experimental|RotaTeq™ Vaccine (V260)|Evaluation of Safety, Tolerability and Immunogenicity of Vaccination with RotaTeq™ in Healthy Infants in India.
3043032|NCT00496080|Experimental|DUAO Device|Doppler-guided uterine artery occlusion device (Single-arm study)
3043033|NCT00496197|Experimental|1.|Subjects receive anidulafungin IV followed by oral therapy with fluconazole or voriconazole.
3043034|NCT00496262|Experimental|Human Fibrinogen Concentrate|
3043035|NCT00496340|Experimental|Conditioning Followed by HCT|"Pentostatin/Busulfan/Rituximab/Allogeneic Hematopoietic Cell Transplant (HCT).~Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Conditioning:~Patients will receive anti-seizure prophylaxis with lorazepam 0.5 mg every 6 hours beginning day -6.~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Patient will then receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600.~Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.~Rituximab: Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
3043036|NCT00496366|Experimental|Capecitabine (Xeloda) + Lapatinib (Tykerb)|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Lapatinib will be taken daily continuously for 21 days (Days 1- 21)."
3043037|NCT00496379|Experimental|ZK219477|
3043038|NCT00496470|Active Comparator|Symbicort+TIO|Symbicort Turbuhaler® (budesonide/formoterol) 320/9 mcg, one inhalation twice daily and Spiriva® (tiotropium) 18 mcg, one inhalation once daily
3043039|NCT00496470|Active Comparator|Spiriva® + Placebo Turbuhaler|Spiriva® (tiotropium) 18 mcg, one inhalation once daily and placebo Turbuhaler one inhalation once daily
3043040|NCT00496483|Active Comparator|LCP-Tacro (tacrolimus)|Experimental: LCP Tacro; investigational product LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets.
3043041|NCT00496587|Experimental|Capecitabine + Gemcitabine + Bevacizumab|Capecitabine 800 mg/m^2 By Mouth Twice Daily On Days 1-21. Gemcitabine 900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15. Bevacizumab 10 mg/kg By Vein On Days 1 and 15.
3043042|NCT00496626|Experimental|1|V501 (Gardasil®)
3043043|NCT00496626|Placebo Comparator|2|Placebo
3043044|NCT00496730|Experimental|Vytorin®|simvastatin (+) ezetimibe 10/20 mg (Vytorin®) ; tablet, once daily, 8 Weeks
3043045|NCT00496730|Active Comparator|atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
3043046|NCT00496769|Experimental|Apixaban|
3043047|NCT00496769|Active Comparator|Acetylasalicylic acid|
3043048|NCT00496808|Experimental|Herceptin|8 mg/kg intravenously (IV) Over 90 Minutes
3043049|NCT00496834|Experimental|1|Losartan or Losartan/HCTZ
3043050|NCT00496834|Active Comparator|2|Carvedilol or Carvedilol/HCTZ
3043051|NCT00496873|Experimental|Cytoxan + Rituxan + Nipent|Cytoxan 600 mg/m^2 on Day 1 of 21-day cycle. Rituxan 375 mg/m^2 on Day 1 of 21 Day Cycle. Nipent 4 mg/m^2 on Day 1 of 21 Day Cycle.
3043052|NCT00496964|Experimental|1|Injection of Botulinum toxin A into vastus lateralis of study limb plus exercise program
3043053|NCT00496964|Placebo Comparator|2|Placebo injection + exercise
3043054|NCT00497055|Experimental|Aripiprazole|Aripiprazole 5mg daily for week one. Aripiprazole 10mg daily for week two. Aripiprazole 20mg daily for weeks three through twelve.
3043055|NCT00497055|Placebo Comparator|Placebo|Placebo (for Aripiprazole) 5mg daily for week one. Placebo (for Aripiprazole) 10mg daily for week two. Placebo (for Aripiprazole) 20mg daily for weeks three through twelve.
3043056|NCT00497081|Active Comparator|Mirtazapine|mirtazapine 30 mg daily
3043057|NCT00497081|Placebo Comparator|Placebo|placebo 30 mg daily
3043058|NCT00497146|Experimental|Paricalcitol|Participants received paricalcitol capsules 2 µg once a day (two 1 µg paricalcitol capsules), for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
3043059|NCT00497146|Placebo Comparator|Placebo|Participants received 2 placebo capsules once a day for up to 48 weeks. Participants who completed the 48-week Treatment Period could continue in the Long-term Follow-up Period for an additional 18 months. Participants did not receive study drug during the Long-term Follow-up Period.
3043060|NCT00497198|Experimental|MCI-196|
3043061|NCT00497198|Placebo Comparator|Placebo|
3043062|NCT00497289|Experimental|1|Lipidem 20 %
3043063|NCT00497289|Active Comparator|2|Lipofundin MCT/LCT 20%
3043064|NCT00497770||Caucasian|Caucasian patients receiving Alimta for 2nd line NSCLC
3043065|NCT00497770||African American|African American patients receiving Alimta for 2nd line NSCLC
3043066|NCT00497770||Asian American|Asian American patients receiving Alimta for 2nd line NSCLC
3043067|NCT00497770||Hispanic|Hispanic patients receiving Alimta for 2nd line NSCLC
3043068|NCT00497796|Experimental|1|
3043069|NCT00497796|Active Comparator|2|
3043070|NCT00497874|Experimental|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
3043071|NCT00497874|No Intervention|Usual care|Usual primary care treatment
3043072|NCT00498173|Experimental|Atomoxetine|Participants will receive flexibly dosed atomoxetine for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
3043073|NCT00498173|Placebo Comparator|Placebo|Participants will receive blinded, matched placebo for 8 weeks. Dosage can be increased over the first 4 weeks of study participation and will then be held constant for the remainder of the 8-week trial.
3043074|NCT00498186|Experimental|Rotigotine|Rotigotine trans-dermal patch
3043075|NCT00498355|Experimental|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
3043076|NCT00498368|Experimental|Rituximab Plus ACE/ARB|Intravenous Rituximab therapy, ACE/ARB combination therapy, and Omega-3 Fatty Acid Fish Oil Supplement
3043077|NCT00498368|Active Comparator|ACE/ARB|ACE/ARB therapy and Omega-3 Fatty Acid Fish Oil Supplement
3043078|NCT00498433|Experimental|Aliskiren|"Part 1: After a 1-2 weeks initial washout period, all eligible patients underwent a two week placebo run-in phase (period 1) consisting of treatment with one tablet of placebo to aliskiren once daily (o.d.). This was followed by a 4 week treatment phase (period 2) consisting of treatment with 300 mg aliskiren o.d..~Part 2: Eligible randomized patients in this arm received aliskiren 300 mg tablet o.d. and amlodipine placebo capsule o.d. for 12 weeks."
3043079|NCT00498433|Active Comparator|Amlodipine|"Part 1: After aliskiren treatment (period 2), each patient was entered into a second washout period (4 weeks) during which blood pressure was required to be ≤ 140/90 mmHg. If blood pressure exceeded 140/90 mmHg on two consecutive days (home monitoring) and was confirmed at the study center, the patient was entered into the amlodipine treatment period (period 3). In period 3, all patients received 5 mg amlodipine o.d.. The length of the amlodipine period varied from 4 to 7 weeks.~Part 2: Eligible patients randomized to part 2 received amlodipine 5 mg o.d. and aliskiren placebo for 12 weeks"
3043080|NCT00498485|Placebo Comparator|Placebo|Patients were randomized and these received placebo
3043081|NCT00498485|Active Comparator|Sodium Oxybate|Patients were randomized and these received the active drug
3043082|NCT00498550|Experimental|Clozapine|Clozapine, Clozaril
3043083|NCT00498550|Active Comparator|Treatment as usual|Treatment as usual with any antipsychotic other than Clozapine.
3043084|NCT00498602|Experimental|1|ACC-001
3043085|NCT00498602|Other|2|QS-21
3043086|NCT00498602|Other|3|Diluent: Phosphate Buffered Saline
3043087|NCT00498602|Experimental|4|ACC-001
3043088|NCT00498615|Experimental|Fasudil 80 mg|Subject is given a single dose of 80 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3043089|NCT00498615|Experimental|40 mg Fasudil|Subject is given a single dose of 40 mg of Fasudil ( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3043090|NCT00498615|Placebo Comparator|placebo|Subject is given a single dose of placebo( blinded to participant and researcher) a cold challenge is given 2 hrs after the dose.
3043091|NCT00498628|Experimental|1|Quetiapine fumarate plus medical management
3043092|NCT00498628|Placebo Comparator|2|Medical management plus placebo comparator
3043093|NCT00498706|Experimental|Telephone-administered CBT|Participants will receive telephone-administered cognitive behavioral therapy.
3043094|NCT00498706|Active Comparator|Face-to-face CBT|Participants will receive face-to-face cognitive behavioral therapy.
3043095|NCT00498927|Experimental|Temozolomide|Following diagnosis of tumor recurrence or progression, all patients will receive of daily low dose temozolomide given at 50mg/m2/d without interruption. Brain imaging will be performed at baseline and every 2 months (standard of care). The treatment will be administered until development of toxicity, evidence of progression of disease or death.
3043096|NCT00498940|Active Comparator|Biventricular Pacing|After weaning from bypass, patients received temporary biventricular pacing for 24 hours. Values obtained from optimization testing determined pacemaker settings (AVD, VVD, heart rate).
3043097|NCT00498940|Active Comparator|Standard of Care|No continuous pacing occurred about surgery. Patients underwent optimization testing.
3043098|NCT00499031|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 120 minutes on day 1.
3043099|NCT00499083|Experimental|Vaccine|Patients with HER-2/neu negative tumors will receive IT DCs one week after the first three of four cycles of dose dense T therapy and then four cycles of dose dense AC therapy will be given (i.e. T-AC).
3043100|NCT00499096|Experimental|Chronic Care Model for Bipolar Disorder|An intervention group of patients with bipolar disorder and 1 or more risk factor for cardiovascular disease; group will receive self-management group sessions, followed by phone contacts by the Care Manager. This is the chronic care model for bipolar disorder
3043101|NCT00499096|No Intervention|Enhanced Usual Care|A group of patients with bipolar disorder and one or more risk factors for cardiovascular disease will be randomized to receive enhanced usual care. This group will receive usual care, plus mailings on wellness topics (attention control), and their providers will receive information on guideline concordant care.
3043102|NCT00499109|Experimental|E. Dual Agent Chemotherapy|"Experimental Arm E.~Patients received treatment according to gene expression strata with four doublet regimens.~Low ERCC1 and Low RRM1 Group - Gemcitabine (G) and Carboplatin (Cb): GCb Group.~Low RRM1 and High ERCC1 Group - Gemcitabine (G) and Docetaxel (D): GD Group.~High RRM1 and Low ERCC1 Group - Docetaxel (D) and Carboplatin (Cb): DCb Group.~High ERCC1 and High RRM1 Group - Vinorelbine (V) and Docetaxel (D): DV Group."
3043103|NCT00499109|Active Comparator|C. Standard of Care Control Arm|"Control Arm C: Gemcitabine and Carboplatin (GCb).~All patients in arm C were treated with GCb regardless of gene expression levels. Patients received up to 6 cycles, and no maintenance therapy was allowed."
3043104|NCT00499122|Experimental|NOV-002 and Chemotherapy|"NOV-002:~Cycle 1, Day -1 only: 60 mg intravenously (IV) x 2, 3 hours (+/- 30 minutes) apart~Cycles 1 - 8, Day 1: 60 mg IV, 1 hour (+/- 30 minutes) prior to chemotherapy administration~Cycle 1 - 8, Days 2 - 21: 60 mg subcutaneous injections~Cyclophosphamide: 600 mg/m2 IV, Cycles 1 - 4, Day 1~Doxorubicin: 60 mg/m2 IV, Cycles 1 - 4, Day 1~Docetaxel: 100 mg/m2 IV, Cycles 5 - 8, Day 1"
3043105|NCT00499174|No Intervention|Active Surveillance|Active surveillance with radical intervention at the time one or more of the following occur: Biochemical progression; Grade progression; Clinical progression
3043106|NCT00499174|Active Comparator|Radical Intervention|Radical prostatectomy or radiotherapy based on patient and physician preference
3043107|NCT00499252|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation (Abraxane®) IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3043108|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 2 Growth Factors|Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)
3043109|NCT00499343|Experimental|Rituximab + Ifosfamide + Etoposide + 1 Growth Factor|Growth Factor = granulocyte-colony stimulating factor (G-CSF)
3043110|NCT00499369|Experimental|Arm I (chemotherapy, cetuximab)|Patients receive single-agent irinotecan hydrochloride IV or FOLFIRI IV. They also receive cetuximab IV over 1-2 hours on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3043111|NCT00499369|Experimental|Arm II (chemotherapy, cetuximab, bevacizumab)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive bevacizumab IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3043112|NCT00499369|Experimental|Arm III (closed to accrual as of 4/20/2009)|Patients receive single-agent irinotecan hydrochloride or FOLFIRI AND cetuximab as in arm I. Patients also receive a higher dose of bevacizumab (higher than in arm II) IV over 30 minutes on day 1. Courses repeat every 14-21 days (depending upon chemotherapy regimen) in the absence of disease progression or unacceptable toxicity.
3043113|NCT00499408|Experimental|Soy and Vitamin D|Patients will receive oral supplementation with both 2,000 IU per day of vitamin D (cholecalciferol) and soy (160 mg per day soy isoflavones). Serum PSA and plasma levels of vitamin D will be assessed monthly. Soy isoflavones levels will be assessed every three months.
3043114|NCT00499447|Experimental|Radiofrequency Ablation with External Beam Radiation|Radiofrequency Ablation (RFA)under computerized tomography guidance followed 3-4 weeks later with External Beam Radiation Therapy
3043115|NCT00499460|Other|Arm I|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
3043116|NCT00499460|Other|Arm II|Two 30-day treatment periods separated by a washout of at least 4 weeks. In Period 1, participants receive oral placebo twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29. In Period 2, participants receive oral garlic powder tablet twice daily on days 1-30, oral oxycodone on day 28, and a combination of oral midazolam and digoxin on day 29.
3043117|NCT00499473|Experimental|Stratum 1 (kinase inhibitor therapy)|Non-EIAC patients receive oral sunitinib malate once daily for 4 consecutive weeks followed by 2 weeks of rest.
3043118|NCT00499473|Experimental|Stratum 2 (kinase inhibitor therapy)|EIAC & OSU patients receive oral sunitinib malate as in stratum 1. Patients receive escalating doses of oral sunitinib malate until the maximum tolerated dose (MTD) is determined.
3043119|NCT00499486|Experimental|Sirolimus|Sirolimus 5mg. po QD continously (28 days=cycle)
3043120|NCT00499603|Experimental|Paclitaxel + FEC|Paclitaxel 80 mg/m^2 intravenously (IV) on day 1(+/- 2 days) of each week, followed by four cycles of combination 5-Fluorouracil at 500 mg/m^2, Epirubicin at 100 mg/m^2 and Cyclophosphamide at 500 mg/m^2 (FEC) on day 1 every 3 weeks (+/- 7 days).
3043121|NCT00499603|Experimental|Paclitaxel + RAD001 + FEC|Paclitaxel + RAD001 Followed by FEC (5-Fluorouracil + Epirubicin + Cyclophosphamide)
3043122|NCT00499616|Experimental|Group 2 (chemotherapy, surgery)|2 courses of initial chemotherapy (6 wks) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Partial response (PR) to chemo go to observation. No PR: 2-6 additional courses of chemo (beginning course 3 - cyclophosphamide, etoposide, filgrastim, carboplatin, doxorubicin hydrochloride). No PR after additional chemotherapy proceed to retrieval chemo: cyclophosphamide and topotecan hydrochloride on days 1-5. Treatment with retrieval chemotherapy repeats every 21 days for up to 6 courses. Some patients may also undergo surgery.
3043123|NCT00499616|Experimental|Group 3 (chemotherapy, surgery)|4 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, filgrastim. Patients with a PR after chemo proceed to observation. No PR receive 2-4 additional courses of chemotherapy (beginning with course 5) - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. No PR after additional chemo proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
3043124|NCT00499616|Experimental|Group 4 (chemotherapy, surgery, antineoplastic therapy)|8 courses of initial chemo - carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, filgrastim. Patients < 12 months of age with stg 3, 4, or 4S (not including liver metastases) disease who achieve a very good PR (VGPR) to chemo proceed to observation. Patients 12-18 months of age with stg 3 or 4 who achieve VGPR proceed to isotretinoin therapy. No VGPR proceed to retrieval chemo - cyclophosphamide and topotecan hydrochloride. Some patients may also undergo surgery.
3043125|NCT00499616|Experimental|Non-intermediate risk enrolled on intermediate risk trial|The no treatment group assignment patients may have received some treatment on ANBL0531 but they were not evaluable on this study due to being non-intermediate risk and hence did not receive a treatment assignment on ANBL0531.
3043126|NCT00499655|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily and oral placebo twice daily on days 1-28.
3043127|NCT00499655|Experimental|Arm II|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily on days 1-28.
3043128|NCT00499681|Experimental|Arm I|Patients receive Lapatinib and Letrozole once daily for two weeks, following tumor measurement patients receive Lapatinib and Letrozole once daily for 14 weeks.
3043129|NCT00499681|Experimental|Arm II|Patients receive Letrozole and placebo once daily for 2 weeks, following tumor measurement patients receive Letrozole and Lapatinib once daily for 14 weeks.
3043130|NCT00499694|Experimental|Bevacizumab and Satraplatin|"Bevacizumab 10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)~Satraplatin 80 mg/m(2), Orally, Days 1-5, every 35 days"
3043131|NCT00499746|Active Comparator|Tramadol|oral dose, once per day
3043132|NCT00499746|Placebo Comparator|Placebo|oral dose, once per day
3043133|NCT00499746|Active Comparator|hydromorphone|oral dose, once per day
3043134|NCT00499746|Active Comparator|methylphenidate|oral dose, once per day
3043135|NCT00499863|Experimental|Methylphenidate Transdermal System|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
3043136|NCT00499863|Placebo Comparator|2|Daily application of matching MTS Placebo Patch
3043137|NCT00499889|Experimental|Imatinib, Busulfan, Fludara + Antithymocyte Globulin|Oral Imatinib Mesylate 400 mg twice a day for 9 Days; Busulfan 130 mg/m^2 by vein (IV) daily for 2 Days; Fludara 40 mg/m^2 IV daily for 4 Days; Antithymocyte Globulin (ATG) 2.5 mg/kg IV daily for 3 Days; Tacrolimus levels maintained between 5-15 ng/dl, Day -2 to Day 180; Methotrexate 5 mg/m2 on days 1, 3, 6 and 11; and Donor bone marrow or blood stem cells infused on day 0 with possible donor lymphocyte infusion (DLI) for progressive disease.
3043138|NCT00499915|Experimental|Secondhand Smoke Reduction and Asthma Education|Parents of children in the experimental group will receive asthma education at NICU discharge as well as a secondhand smoke reduction program.
3043139|NCT00499915|Active Comparator|Asthma Education|Parents of children in the active comparator group will receive asthma education at NICU discharge.
3043140|NCT00500071|Experimental|1|
3043141|NCT00500110|Experimental|Hormonal Ablation, Imatinib + Docetaxel|Imatinib Mesylate 600 mg by mouth (PO) daily + Docetaxel 30 mg/m^2 by vein (IV) weekly + Hormonal Ablation (Goserelin Acetate or Leuprolide) injections every other month or every 3 months
3043142|NCT00500149|Experimental|1|
3043143|NCT00500149|Placebo Comparator|2|
3043144|NCT00500240|No Intervention|Conventional Care|Control Group: Conventional care using blood sugar management with regular human insulin.
3043145|NCT00500240|Other|Intensive Insulin|Intervention Group: Intense blood sugar management with Insulin Aspart + Insulin Glargine
3043146|NCT00500266|Experimental|1|13-valent Pneumococcal Conjugate Vaccine
3043147|NCT00500292|Placebo Comparator|1|FOLFOX + Placebo vandetanib
3043148|NCT00500292|Experimental|2|FOLFOX + low dose vandetanib
3043149|NCT00500292|Experimental|3|FOLFOX + high dose vandetanib
3043150|NCT00500318|Experimental|Aclidinium|
3043151|NCT00500318|Placebo Comparator|Placebo|
3043152|NCT00500331|Experimental|Arm 1|GSK189075
3043153|NCT00500331|Placebo Comparator|Arm 2|Placebo
3043154|NCT00500331|Other|Arm 3|pioglitazone (active control)
3043155|NCT00500370|Experimental|Group A|
3043156|NCT00500370|Placebo Comparator|Group B|
3043157|NCT00500448|No Intervention|No Treatment|No treatment was delivered to this arm. Participants went about activities of daily living
3043158|NCT00500448|Experimental|Electrical Stimulation|Neuromuscular electrical stimulation treatments 3 times per week for 4 weeks
3043159|NCT00500578|Experimental|1: Standard Schedule - Ribavirin|Aerosolized Ribavirin 6 grams over 18 hours every 24 hours
3043160|NCT00500578|Experimental|2: Modified Schedule - Ribavirin|Aerosolized Ribavirin 2 grams over 3 hours every 8 hours
3043161|NCT00500656|Experimental|Randomized controlled -Icatibant|"Subjects received S.C icatibant+ oral placebo~Icatibant Form: solution for injection, 3 mL, 10 mg/mL Single dose: 30 mg (3 mL)~Placebo Form: hard capsule Single dose: 2 capsules Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart"
3043162|NCT00500656|Active Comparator|Randomized controlled-Tranexamic acid|"Subjects received oral Tranexamic acid+ S.C. placebo~Tranexamic acid Form: over encapsulated film tablet Single dose: 1000 mg (2 capsules) Frequency: 3 x 2 capsules for 2 days, taken orally, 6 to 8 hours apart~Placebo Form: solution for injection, matched to icatibant for injection Single dose: 3 mL Frequency: one subcutaneous injection in the abdominal region"
3043163|NCT00500656|Experimental|Controlled Open-label / laryngeal attack|Patients with laryngeal symptoms at the baseline were not randomised but treated with icatibant open label during the controlled phase.
3043164|NCT00500656|Experimental|Untreated patients at the baseline|Patients who were screened and found eligible but did not experience an angioedema attack, or had an attack that was not severe enough to merit treatment while the controlled phase was ongoing were treated in the open label phase with icatibant
3043165|NCT00500682|Placebo Comparator|Placebo|
3043166|NCT00500682|Experimental|AST-120|
3043167|NCT00500760|Experimental|Panitumumab Plus Chemoradiation|Participants received standard radiation therapy for 7 weeks and cisplatin 75 mg/m^2 and panitumumab 9 mg/kg on Days 1, 22 and 43.
3043168|NCT00500760|Active Comparator|Chemoradiotherapy Alone|Participants received standard radiation therapy for 7 weeks and cisplatin 100 mg/m^2 on Days 1, 22, and 43.
3043169|NCT00500903|Experimental|PIC Dose Escalation|Alisertib 5, 10, 20, 40, 80, 110 or 150 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 7 to 21 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 51 cycles).
3043170|NCT00500903|Experimental|ECT Dose Escalation|Alisertib 10 or 20 mg, Enteric-coated Tablet (ECT) formulation, orally, once daily (QD) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 2 cycles).
3043171|NCT00500903|Experimental|Relative Bioavailability|Alisertib 40 mg ECT or PIC formulation, orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 1, followed by alisertib 40 mg in the opposite formulation (PIC or ECT) orally, twice daily (BID) for 7 days followed by a 14--day recovery period in cycle 2, followed by alisertib 50 mg PIC formulation orally, twice daily (BID) for 7 days followed by a 14--day recovery period in each cycle until disease progression or unacceptable alisertib--related toxicity (up to 9 cycles).
3043172|NCT00501007||Non-psychiatric smokers|Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
3043173|NCT00501007||Smokers with Schizophrenia|Smokers meeting criteria for schizophrenia or schizoaffective disorder
3043174|NCT00501046|Placebo Comparator|Placebo|
3043175|NCT00501046|Experimental|AST-120|
3043176|NCT00501059|Experimental|Acetylsalicylic acid (Aspirin, BAYE4465)|Participants received 1 tablet of enteric-coated acetylsalicylic acid [100 milligram (mg)] orally once daily.
3043177|NCT00501059|Placebo Comparator|Placebo|Participants received 1 tablets of matching placebo orally once daily.
3043178|NCT00501085||LAP-BAND|Patients who receive the LAP-BAND AP Adjustable Gastric Banding System.
3043179|NCT00501293|Experimental|1|Methylphenidate Transdermal System
3043180|NCT00501540|Experimental|Lithium|Lithium carbonate will be dosed on a flat scale of mg/day and not by weight or body surface area (BSA). Lithium carbonate will be provided as a 300mg tablet and will be taken daily without breaks in treatment.
3043181|NCT00501592|Active Comparator|25 mg INT-747|
3043182|NCT00501592|Active Comparator|50 mg INT-747|
3043183|NCT00501592|Placebo Comparator|Placebo|
3043184|NCT00501631|Active Comparator|VIVITROL 380 mg|Administered via intramuscular (IM) injection once every 4 weeks.
3043185|NCT00501631|Placebo Comparator|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
3043186|NCT00501644|Experimental|Chemoimmunotherapy|GM-CSF Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy + rIFN-g (Interferon Gamma) 0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle) + Paraplatin (Carboplatin) AUC of 5 by 1 hour IV infusion every 28 days
3043187|NCT00501852|Experimental|NVA237 12.5 µg|12.5 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3043188|NCT00501852|Experimental|NVA237 25 µg|25 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3043189|NCT00501852|Experimental|NVA237 50 µg|50 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3043190|NCT00501852|Experimental|NVA237 100 µg|100 µg daily via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3043191|NCT00501852|Placebo Comparator|Placebo|Placebo via single-dose dry-powder inhaler (SDDPI). At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3043192|NCT00501852|Active Comparator|Tiotropium 18 µg|18 µg od via Handihaler inhaler. Tiotropium was given open-label. At baseline visits for each of the 4 double-blind treatment periods, patients were randomized to one of 30 treatment sequences. There was a 7 day washout period between each sequence.
3132869|NCT03461757|Experimental|Arm 1: Rimegepant 75 mg|Participants were administered a single sublingual dose of 75 mg of rimegepant ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3043193|NCT00501891|Experimental|Bevacizumab and Metronomic Temozolomide|Patients will receive up to 12 cycles of bevacizumab (Avastin) and metronomic temozolomide (Temodar), and each cycle is 28 days. Bevacizumab will be administered at 10 mg/kg every other week beginning a minimum of 7 days after a biopsy or 28 days after a craniotomy. Temozolomide will be dosed at 50 mg/m2 daily in a 28-day cycle.
3043194|NCT00501943|Active Comparator|Riluzole|Riluzole + Avonex
3043195|NCT00501943|Placebo Comparator|Placebo|placebo + Avonex
3043196|NCT00501969|Experimental|Rotigotine|Rotigotine
3043197|NCT00501995|Experimental|IV Cyclophosphamide (50 mg/kg)|This is an open-labeled single arm study of Cyclophosphamide (50 mg/kg) administered intravenously over 1 hour daily for four consecutive days (200 mg/kg total) through a Hickman catheter .
3043198|NCT00502203|Experimental|Paclitaxel + Carboplatin|Paclitaxel 175 mg/m^2 intravenously (IV) over 3 hours and Carboplatin AUC 5 IV over 1 hour every 21 Days for 6 courses.
3043199|NCT00502216|Experimental|1|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
3043200|NCT00502216|Placebo Comparator|2|Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
3043201|NCT00502242|Active Comparator|A|Capsule - initial treatment is 5 mg (active)- oral - once per day
3043202|NCT00502242|Placebo Comparator|B|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
3043203|NCT00502307|Experimental|1|Tivozanib (AV-951) administered as a solid dosage form daily for three weeks per month
3043204|NCT00502307|Placebo Comparator|2|solid oral capsule containing excipients dosed daily for three weeks per month
3043205|NCT00502320|Experimental|Ramelteon|8 mg
3043206|NCT00502320|Placebo Comparator|Placebo|
3043207|NCT00502593|Experimental|GSK1562902A-A Lot 1 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043208|NCT00502593|Active Comparator|Fluarix-A 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043209|NCT00502593|Experimental|GSK1562902A-A Lot 1 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 1. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043210|NCT00502593|Active Comparator|Fluarix-A 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase A of this NCT00502593 study (or study 107066). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043211|NCT00502593|Experimental|GSK1562902A-B Lot 2 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043212|NCT00502593|Active Comparator|Fluarix-B 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043213|NCT00502593|Experimental|GSK1562902A-B Lot 2 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 2. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043214|NCT00502593|Active Comparator|Fluarix-B 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase B of this NCT00502593 study (or study 108498). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043215|NCT00502593|Experimental|GSK1562902A-C Lot 3 3-5Y Group|Subjects aged 3-5 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043216|NCT00502593|Active Comparator|Fluarix-C 3-5Y Group|Subjects aged 3-5 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043217|NCT00502593|Experimental|GSK1562902A-C Lot 3 6-9Y Group|Subjects aged 6-9 years received 2 doses of GSK1562902A vaccine, lot 3. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The GSK1562902A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043218|NCT00502593|Active Comparator|Fluarix-C 6-9Y Group|Subjects aged 6-9 years received 2 doses of Fluarix™ vaccine. These subjects were enrolled in the Phase C of this NCT00502593 study (or study 108500). The Fluarix™ vaccine was administered intramuscularly in the deltoid region of the non-dominant arm on Days 0 and 21.
3043219|NCT00502671|Experimental|1|
3043220|NCT00502697|Experimental|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic visits. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
3043221|NCT00502697|Other|Conventional prenatal/postpartum care|Women assigned to the control arm of the study received conventional prenatal and postpartum clinic care.
3043222|NCT00502801|Experimental|Doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
3043223|NCT00502840|Experimental|1|
3043224|NCT00502853|Experimental|1|
3468766|NCT03892447|Active Comparator|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d; Dopamine3～5 ug/kg·min,iv,3 h/d,14d
3043225|NCT00502905|Experimental|Busulfan + Fludarabine|Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours immediately after Fludarabine 40 mg/m^2 over 1 hour.
3043226|NCT00502944|Experimental|Counselor-based HIV screening|
3043227|NCT00502944|Active Comparator|Emergency staff member-based HIV screening|
3043228|NCT00502996|Experimental|Rituximab|Eligible participants receiving Rituximab (MabThera/Rituxan) 1 gram/dose (g/dose) intravenously (IV) on Day 1 and Day 15 followed by previous pre-medication (methylprednisolone 100 mg IV, antihistamine and antipyretic) and concomitant treatment of Methotrexate at least 15 mg per oris (PO) weekly were observed during the study period of 24 weeks. After treatment completion, participants were followed-up for safety up to 24 weeks.
3043229|NCT00503113|Experimental|1|
3043230|NCT00503113|Experimental|2|
3043231|NCT00503113|Active Comparator|3|
3043232|NCT00503308|Experimental|Abbreviated Consenting|
3043233|NCT00503308|No Intervention|Standard Consenting|
3043234|NCT00503399|Experimental|Teriparatide|Teriparatide 20 microgram (µg) subcutaneous (sc) injection once daily (QD).
3043235|NCT00503399|Active Comparator|Risedronate|Risedronate 35 milligrams (mg) oral (po) tablet once weekly (QW)
3043236|NCT00503425|Experimental|1|
3043237|NCT00503685|Experimental|IMC-A12|Administered every 2 weeks
3043238|NCT00503685|Experimental|IMC-A12 + cetuximab|Administered every 2 weeks
3043239|NCT00503685|Experimental|IMC-A12 + cetuximab [Kirsten rat sarcoma (K-ras) wild-type]|Participants who have experienced confirmed partial response (PR) or stable disease (SD) ≥ 24 weeks on a prior anti-EGFR-containing therapy followed by disease progression are enrolled in this arm.
3043240|NCT00503698|Experimental|Somatropin|Somatropin once daily from week 0 to end of trial
3043241|NCT00503698|Placebo Comparator|Placebo|Placebo once daily to end of trial
3043242|NCT00503750|Active Comparator|Trastuzumab and Abraxane followed Trastuzumab and Vinorelbine|Patients will be treated sequentially with preoperative trastuzumab and dose-dense ABI-007 followed by trastuzumab in combination with vinorelbine. Trastuzumab will be administered as a one-time loading dose of 4 mg/kg as a 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as a 30 minute infusion. ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8). Growth factor support with pegfilgrastim (Neulasta®) is required 24 to 48 hours following completion of each cycle of ABI-007. Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20). As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
3043243|NCT00503776|Active Comparator|Arm IA|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
3043244|NCT00503776|Active Comparator|Arm IB|Patients undergo SNT and low weight resistance training (LWRT).
3043245|NCT00503776|Experimental|Arm IIA|Patients receive amifostine subcutaneously (SC) 30-60 minutes prior to each dose of intensity-modulated radiotherapy (IMRT). Patients also undergo SNT as in arm IA.
3043246|NCT00503776|Experimental|Arm IIB|Patients receive amifostine SC 30-60 minutes prior to each dose of IMRT. Patients also undergo SNT and LWRT as in arm IB.
3043247|NCT00503867|Experimental|SIR-Spheres microspheres|SIR-Spheres microspheres
3043248|NCT00503906|Experimental|Abraxane, Avastin and Gemcitabine|"Each treatment cycle is 28 days. Participants will be treated until disease progression:~Gemcitabine: 1500 mg/m2 body surface area (BSA) intravenously (IV) over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Abraxane: 150 mg/m2 IV over 30 minutes (+/- 5 minutes) on days 1 and 15 of each cycle, followed by;~Avastin: 10 mg/kg IV on days 1 and 15 of each cycle."
3043249|NCT00503984|Experimental|Phase 1 - Aza + Doc|Phase 1 Azacitidine (Aza) and Docetaxel (Doc) with dose escalation/de-escalation design, and Prednisone, with growth factor support; GADD45α methylation and expression analysis, with optional growth factor support (pegfilgrastim/filgrastim).
3043250|NCT00503984|Experimental|Phase 2 - Aza + Doc RPTD|Recommended Phase Two Dose (RPTD) of Azacitidine and Docetaxel; and Prednisone; with optional growth factor support (pegfilgrastim/filgrastim).
3043251|NCT00503997|Experimental|drug therapy|
3043252|NCT00504023|Experimental|imiquimod|This is a pilot study of the use of a topical immunomodulatory agent, imiquimod, for the treatment of recurrent Extramammary Paget's disease (EMPD).
3043253|NCT00504075|Experimental|Gammaplex (intravenous immunoglobulin)|
3043254|NCT00504153|Experimental|Treatment (tyrosine Kinase Inhibitor)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3043255|NCT00504166|Active Comparator|alendronate sodium|alendronate sodium 70 mg tablet once a week for 24 months
3043256|NCT00504166|Placebo Comparator|placebo|placebo to match alendronate sodium
3043257|NCT00504231|Experimental|0.3 mL Influenza Vaccine ID|60% dose - 0.3 mL delivered intradermally with needle and syringe
3043258|NCT00504231|Experimental|0.15 mL twice Influenza Vaccine ID|60% dose - 0.15 mL delivered twice intradermally with needle and syringe
3043259|NCT00504231|Active Comparator|0.5 mL Influenza Vaccine by IM|100% dose - 0.5mL delivered intramuscularly with needle and syringe
3043260|NCT00504231|Experimental|0.3 mL Influenza Vaccine IM|60% dose - 0.3 mL delivered intramuscularly with needle and syringe
3043261|NCT00504257|Experimental|Avastin and Docetaxel|Combination Therapy: Immunotherapy (Avastin) and Chemotherapy (Docetaxel) as outlined in Intervention descriptions. Avastin: 15 mg/kg, In 100 ml normal saline (NS) IV infusion over 90 +/- 15 minutes, Day 1, every 21 day cycle. Docetaxel: 40 mg/m^2, In 250 ml 5% dextrose in pure water (D5W) or NS IV infusion over 1 hour in a non-pvc container and through a polyethylene-lined set, Day 1, 8, every 21 day cycle. Response assessment every 3 cycles (9 weeks).
3043262|NCT00504309|Experimental|4g P-OM3, then 1g P-OM3, then Placebo|4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
3043263|NCT00504309|Experimental|1g P-OM3, then 4g P-OM3, then Placebo|1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
3043264|NCT00504309|Experimental|Placebo, then 4g P-OM3, then 1g P-OM3|Corn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
3043265|NCT00504309|Experimental|4g P-OM3, then Placebo, then 1g P-OM3|4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
3043266|NCT00504309|Experimental|1g P-OM3, then Placebo, then 4g P-OM3|1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
3043267|NCT00504309|Experimental|Placebo, then 1g P-OM3, then 4g P-OM3|Corn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
3043268|NCT00504348|Experimental|Prospective investigation group|Tacrolimus treatment is to be initiated at the starting dose of 0.075mg/kg/day, adjusted to maintain its whole blood trough levels between 5 and 10 ng/mL for 52 weeks. All patients are to receive glucocorticoids with the starting doses equivalent to between 0.6 and 1.0 mg/kg/day of prednisolone which are to be continued for the first 28 days after which be subsequently tapered according to a predefined guideline. Up to two courses of pulse intravenous glucocorticoid therapy are allowed during that period.
3043269|NCT00504426|Placebo Comparator|1|
3043270|NCT00504426|Active Comparator|2|
3043271|NCT00504426|Active Comparator|3|
3043272|NCT00504426|Active Comparator|4|
3043273|NCT00504504|Experimental|Rituximab + ABVD Chemotherapy|Rituximab 375 mg/m^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m^2 IV, Bleomycin 10 U/m^2 IV, Vinblastine 6 mg/m^2 IV, DTIC 375 mg/m^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.
3043274|NCT00504556|Experimental|1|DU-176b 30mg tablet once daily
3043275|NCT00504556|Experimental|2|DU-176b 60mg once daily
3043276|NCT00504556|Experimental|3|DU-176b 30mg b.i.d.
3043277|NCT00504556|Experimental|4|DU-176b 60mg tablets two times a day
3043278|NCT00504556|Active Comparator|5|warfarin tablets
3043279|NCT00504582|Experimental|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
3043280|NCT00504582|No Intervention|No Fibrin Sealant|
3043281|NCT00504595|Experimental|ACZ885|"Healthy Volunteers: Single administration of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of ACZ885 (Canakinumab) Intravenous (IV) on Day 1, Day 15, and Day 43."
3043282|NCT00504595|Placebo Comparator|Placebo|"Healthy Volunteers: Single administration of 600 mg of Placebo Intravenous (IV) on Day 1.~Rheumatoid Arthritis (RA) Patients: Dose of 600 mg of Placebo Intravenous (IV) on Day 1, Day 15, and Day 43."
3043283|NCT00504660|Active Comparator|1: Anaplastic Tumors|Anaplastic Tumors - 6-TG 80 mg/m^2 orally (PO) every 6 hours Day 1-3; Temozolomide 150 mg/m^2 PO daily Days 4-8, after 6 day rest Capecitabine 825 mg/m^2 and Celebrex 400 mg PO every 12 hours Day 14-27 for 28 day course.
3043284|NCT00504660|Active Comparator|2: Anaplastic Tumors|"Anaplastic Tumors - 6-TG 80 mg/m^2 PO every 6 hours Day 1-3, Lomustine 100 mg/m^2 PO on Day 4; Capecitabine 825 mg/m^2 PO every 12 hours Days 11-24, and Celebrex 400 mg PO every 12 hours Days 11-24.~Participants if previously received Temozolomide but not Lomustine (CCNU) will receive Lomustine; or if had Gliadel wafers and Temozolomide with radiotherapy (XRT) will receive Temozolomide."
3043285|NCT00504660|Active Comparator|3: Glioblastoma Multiforme|"Glioblastoma Multiforme - 6-TG 80 mg/m^2 PO every 6 Hours Day 1-3; Capecitabine 825 mg/m^2 PO every 12 hours Days 14-27 and Celebrex 400 mg PO every 12 hours Day 11-24; Temozolomide 150 mg/m^2 PO daily Days 4-8 OR CCNU (Lomustine) 100 mg/m2 orally Day 4 of each 42-day cycle.~Participants receive Temozolomide if not had previous treatment and if had prior CCNU. Those previously treated with Temozolomide but not CCNU receive CCNU, and those that had Gliadel and Temozolomide with XRT receive Temozolomide."
3043286|NCT00504725|Experimental|Ketamine|Single bolus 0.5mg/kg ketamine IV after induction of anesthesia
3043287|NCT00504725|Placebo Comparator|Placebo|0.9 % saline bolus of equivalent volume
3043288|NCT00504751|Experimental|Study Treatment|This is a single arm study
3043289|NCT00504777|Experimental|1|
3043290|NCT00504829|Experimental|LCP-AtorFen|LCP-AtorFen 40/100mg fixed-dose combination tablet of 40mg atorvastatin and 145mg fenofibrate for treatment of mixed dyslipidemia
3043291|NCT00504829|Active Comparator|atorvastatin|atorvastatin 40mg tablet (Lipitor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
3043292|NCT00504829|Active Comparator|fenofibrate|fenofibrate 145mg tablet (Tricor), as an adjunct to diet and exercise for treatment of mixed dyslipidemia
3043293|NCT00504881|Placebo Comparator|Placebo|Matching Placebo tablets administered twice a day
3043294|NCT00504881|Experimental|Brivaracetam|A flexible dose of Brivaracetam tablets, administered twice a day, starting with a dose of 20 mg/day and could increase to 50 mg/day, 100 mg/day or 150 mg/day
3043295|NCT00504894|Placebo Comparator|Placebo|Placebo given in low dose to gauge subject's responses to visual stimuli.
3043296|NCT00504894|Active Comparator|Propofol|Propofol given at 0.90 μgml-1 to gauge subject's responses to visual stimuli.
3043297|NCT00504894|Active Comparator|Thiopental|Thiopental given at 3.0 μgml-1 to gauge subject's responses to visual stimuli.
3043298|NCT00505076|Experimental|MK-0777 8 mg|MK-0777 8 mg tablet by mouth twice daily for 4 weeks
3043299|NCT00505076|Experimental|MK-0777 3 mg|MK-0777 3 mg tablet by mouth twice daily for 4 weeks
3043300|NCT00505076|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 4 weeks
3043301|NCT00505284|Placebo Comparator|Placebo|
3043302|NCT00505284|Active Comparator|Perampanel 2mg|
3043303|NCT00505284|Active Comparator|Perampanel 4mg|
3043304|NCT00505284|Active Comparator|Perampanel 6mg|
3043305|NCT00505284|Active Comparator|Perampanel 8mg|
3043306|NCT00505362|Active Comparator|Rectus muscle closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure and reapproximation of the rectus muscles with three-interrupted sutures.
3043307|NCT00505362|No Intervention|Rectus muscle non-closure|Two-layer uterine closure, peritoneal closure, fascial and skin closure, and rectus muscles non-closure.
3043308|NCT00505375|Experimental|1|Intravenous infusions of CTLA-4 Ig
3043309|NCT00505375|Placebo Comparator|2|Intravenous infusions of placebo
3043310|NCT00505414|Placebo Comparator|Matching Placebo|Oral Tapentadol 100 mg to 250 mg twice daily. Followed by matching placebo in the maintenance (i.e. randomized withdrawal phase).
3043311|NCT00505414|Active Comparator|Morphine Controlled Release|Oral Morphine 45 mg to 90 mg twice daily.
3043312|NCT00505414|Experimental|Tapentadol Extended Release|Oral Tapentadol 100 mg to 250 mg twice daily.
3043313|NCT00505622|Experimental|E2007|E2007 2 mg (one 2 mg tablet taken daily in the evening), or 4 mg (two 2 mg tablets daily in the evening).
3043314|NCT00505635|Experimental|Biochemotherapy with Temozolomide|Temozolomide 250 mg/m^2 every 4 hours Day 1; Biochemotherapy of Velban 1.5 mg/m^2 intravenous (IV) Days 1-4; Cisplatin 20 mg/m^2 IV Days 1-4; + Interleukin-2 9 MIU/m^2 IV over 24 Hours for 4 Doses Days 1-4; Intron-A 5 mu/m^2 subcutaneously daily Days 1-5; + Oral Thalidomide 400 mg daily.
3043315|NCT00505661|Experimental|Letrozole|2.5 mg by mouth (PO) daily
3043316|NCT00505687|Experimental|Rotigotine|Rotigotine
3043317|NCT00505752|Experimental|AS900672-Enriched 50 mcg|
3043318|NCT00505752|Experimental|AS900672-Enriched 100 mcg|
3043319|NCT00505752|Experimental|AS900672-Enriched 150 mcg|
3043320|NCT00505752|Active Comparator|Follitropin alfa 150 IU|
3043321|NCT00505765|Experimental|AL-108, 30 mg/day|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
3043322|NCT00505765|Experimental|AL-108, 5 mg/day|AL-108, 5 mg/day- one spray in each nostril once per day
3043323|NCT00505765|Placebo Comparator|Placebo, 3 sprays BID|Placebo- 3 sprays in each nostril, twice per day
3043324|NCT00505765|Placebo Comparator|Placebo, 1 Spray Daily|Placebo- one spray in each nostril, once per day
3043325|NCT00505778|Active Comparator|Mesalamine (Asacol) Once-Daily|an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)
3043326|NCT00505778|Active Comparator|Mesalamine (Asacol) Twice-Daily|an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)
3043327|NCT00505895|Experimental|Fludarabine + Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous (IV) daily over 30 minutes for 4 Days (Beginning Day -4).~Melphalan 140 mg/m^2 IV over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 IV infused starting on day -5."
3043328|NCT00505895|Experimental|Fludarabine + Lower-Dose Melphalan + Stem Cell Infusion|"Fludarabine 30 mg/m^2 intravenous daily over 30 minutes for 4 Days (Beginning Day -4).~Lower-Dose Melphalan 100 mg/m^2 intravenous over 20 minutes on Day -1. Stem Cell Infusion on Day 0. Rituximab 375 mg/m^2 intravenous infused starting on day -5."
3043329|NCT00505921|Experimental|Campath-1H|"3 mg in vivo Day 1; 10 mg Day 2; 30 mg Days 3 and 10 of chemotherapy treatment. Transplantation on Day 0.~Preparative Regimen For Autologous Stem Cell Transplantation: BEAM (BCNU 300 mg/m2 intravenous (IV) over 1 hour on day -6, cytarabine 200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses), etoposide 200 mg/m2 IV twice on day -5 to -2 (total 8 doses), and Melphalan 140 mg/m2 IV on day -1. Beginning on day +5 G-CSF 10 mg/kg sc (in a.m.) and GM-SCF 250 m/m2 on Day +5 (in p.m.)~Preparative Regimen For Allogenic Stem Cell Transplantation: Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy day 0."
3043330|NCT00505934|Experimental|Levetiracetam|
3043331|NCT00506025|Active Comparator|Cranberry 2xday|Cranberry juice (C) two times daily, a.m. and p.m.
3043332|NCT00506025|Active Comparator|Cranberry + Placebo|De-Activated Cranberry juice in the am, then placebo (P) in the pm
3043333|NCT00506025|Placebo Comparator|Placebo 2xday|Placebo in the form of juice two times daily in the a.m. and p.m.
3043334|NCT00506077|Experimental|MK0249|
3043335|NCT00506077|Placebo Comparator|Placebo|
3043336|NCT00506129|Experimental|Fludarabine + Melphalan with PBPC|Fludarabine 25 mg/m^2 intravenous (IV) daily for 5 Days prior to Allogeneic Transplant, Melphalan 70 mg/m^2 IV daily for 2 Days prior to IV Allogeneic Transplant following Fludarabine & Melphalan. Thymoglobulin 2 mg/kg/day IV on days -3, -2 & -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
3468767|NCT03892551||patients admitted to emergency ward|all patients admitted to the emergency ward and awaiting triage are observed
3043337|NCT00506142|Experimental|Cohort 1|Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
3043338|NCT00506142|Experimental|Cohort 2|Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
3043339|NCT00506155|Experimental|Neoadjuvant Chemotherapy with M-VAC + Avastin|Avastin 10 mg/kg by vein over 90 minutes. Cisplatin 70 mg/m^2 by vein over 4 hours. Doxorubicin 30 mg/m^2 by vein over 15 minutes. Methotrexate 30 mg/m^2 by vein over 30 minutes. Vinblastine Sulfate 3 mg/m^2 by vein over 30 minutes.
3043340|NCT00506285|Experimental|A|This arm was 4 weeks long. Subjects were treated using Methylphenidate Transdermal System. Patients were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone contact. MTS was initiated using a 12.5 cm patch. The dose was increased during the first 2 weeks based on treatment response and side effects to the largest tolerated dose/patch size. It was held steady the last 2 weeks.
3043341|NCT00506285|Placebo Comparator|B|This arm was 4 weeks long. Placebo patch was initiated using a 12.5 cm patch and then increased to the largest tolerated patch size during the first 2 weeks and held steady the last two weeks. Subjects were seen weekly, phone contact was made between visits and dosing could be adjusted as a result of the phone visit.
3043342|NCT00506350|Experimental|GSK1562902A non-AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 1 (F1) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3043343|NCT00506350|Experimental|GSK1562902A non-AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3132870|NCT03461757|Placebo Comparator|Arm 2: Placebo|Participants were administered a single sublingual dose of matching placebo for rimegepant (75 mg) ODT on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3043344|NCT00506350|Experimental|GSK1562902A non-AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3043345|NCT00506350|Experimental|GSK1562902A non-AD F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of a non-adjuvanted (non-AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 4 (F4) in study 106750 (NCT00309634) receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3043346|NCT00506350|Experimental|GSK1562902A AD F1 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation1 (F1) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3043347|NCT00506350|Experimental|GSK1562902A AD F2 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 2 (F2) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3043348|NCT00506350|Experimental|GSK1562902A AD F3 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of an adjuvanted (AD) investigational H5N1 vaccine (A/Vietnam/1194/04 strain) Formulation 3 (F3)in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3043349|NCT00506350|Experimental|GSK1562902A AD Approved F4 Primed Group|Healthy male or female adults, between and including 19 to 61 years of age, primed with 2 doses of approved Formulation (F) of adjuvanted (AD) H5N1 vaccine (A/Vietnam/1194/04 strain) in study 106750 (NCT00309634) received 1 dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study at Day 0, administrated IM in the deltoid region of the non-dominant arm.
3043350|NCT00506350|Experimental|Control Group|Healthy male or female adults, between and including 19 to 61 years of age, unprimed receiving 2 doses of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, one at Day 0 and one at Day 21, administrated IM in the deltoid region of the non-dominant arm.
3043351|NCT00506389|Experimental|Esmirtazapine 3.0 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 3.0 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3043352|NCT00506389|Experimental|Esmirtazapine 4.5 mg|Participants took placebo tablets on Days -7 and -6, esmirtazapine 4.5 mg tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3043353|NCT00506389|Placebo Comparator|Placebo|Participants took placebo tablets on Days -7 and -6, placebo tablets on Days 1-42, and placebo tablets on Days 43-50. Tablets were taken by mouth once daily in the evening.
3043354|NCT00506415|Experimental|Open label: Rivastigmine (5 cm^2 / 10 cm^2)|Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.
3043355|NCT00506415|Experimental|Double blind: Rivastigmine (10 cm^2)|Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.
3043356|NCT00506415|Experimental|Double blind: Rivastigmine (15 cm^2)|Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.
3043357|NCT00506415|Experimental|Extended open label Rivastigmine (10 cm^2)|Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.
3043358|NCT00506441|Experimental|1|
3043359|NCT00506441|Placebo Comparator|2|
3043360|NCT00506454|Active Comparator|Lipidose|Dosage of 1.5 mL/kg of Lipidose over a 2-hour period.
3043361|NCT00506454|Placebo Comparator|Placebo|Dosage of 1.5 mL/kg of Placebo over a 2-hour period.
3043362|NCT00506519|Experimental|AT-150|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 125-175%
3043363|NCT00506519|Experimental|AT-250|Loading dose followed by maintenance IV infusion for 5 days to maintain antithrombin activity at the target level 225-275%
3043364|NCT00506519|Active Comparator|Control|The best standard treatment for the underlying condition only
3043365|NCT00506597|Experimental|Erwinase|6 doses of 25,000 Units/m^2 Erwinase® intramuscular/subcutaneously every other day to replace each dose of Pegylated Asparaginase
3043366|NCT00506662|Experimental|Insulin detemir|Individually adjusted dose of insulin detemir once daily
3043367|NCT00506662|Active Comparator|Insulin NPH|Individually adjusted dose of insulin NPH once daily
3043368|NCT00506675|Active Comparator|Intensive|42 hours per week of patching combined with atropine (1%) once daily in the sound eye, with spectacle correction (if needed)
3043369|NCT00506675|Active Comparator|Weaning|For patients currently patching, reduce patching to two hours daily for four weeks, then no treatment thereafter except spectacle correction (if needed). For patients currently using atropine, reduce atropine to once weekly for 4 weeks, then no treatment thereafter except spectacle correction (if needed)
3043370|NCT00506714|Experimental|Adult subjects with hip osteoarthritis|Walk with and without a single point cane at baseline and after four weeks
3043371|NCT00506714|No Intervention|Healthy Subjects|Healthy adults walking without a cane at baseline
3043372|NCT00506753|Experimental|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
3043373|NCT00506753|Experimental|RT/TU|Relaxation Training followed by Treatment as Usual
3043374|NCT00506779|Experimental|Phase I: Paclitaxel + Imatinib Mesylate|Phase I MTD using oral dose Imatinib Mesylate escalation 400, 500, 600 mg daily; Paclitaxel 175 mg/m^2 every 21 days
3132871|NCT03461965|Experimental|Education with 3D printed model|The experimental group will be educated on MMS with a standardized script in addition to a 3D MMS model
3043375|NCT00506779|Experimental|Phase II: Paclitaxel Alone or Pacliataxel + Imatinib Mesylate|"Intended randomization of Paclitaxel alone or Paclitaxel + Imatinib Mesylate; the study was terminated early due to poor enrollment and all patients are no longer being treated or followed. Single treatment arm MTD using oral dose Imatinib Mesylate escalation = 500 mg daily; Paclitaxel 175 mg/m^2 every 21 days~Phase II, (Arm 1) = Paclitaxel 175 mg/m^2 every 21 days Phase II, (Arm 2) Paclitaxel 175 mg/m^2 every 21 days+ Imatinib Mesylate MTD using oral dose Imatinib Mesylate escalation = 500 mg daily"
3043376|NCT00506831|Experimental|Imatinib mesylate|100 mg daily and increase by 100mg daily every 2 weeks to a maximum of 400 mg daily as tolerated
3043377|NCT00506857|Experimental|Busulfan + Fludarabine|Busulfan starting 0.8 mg/kg by vein (IV) every 6 hours for 12 doses; Fludarabine 30 mg/m^2 IV daily for 4 days.
3043378|NCT00506883|Experimental|High Dose Colchicine|After confirmation of a gout flare, patients were to begin standard dosing of colchicine 4.8mg (two capsules (1.8mg) initially followed by additional one capsule doses (0.6mg) every hour for an additional 6 doses).
3043379|NCT00506883|Experimental|Low Dose Colchicine|Within 12 hours of a confirmed gout flare, patients were to begin the low dose colchicine regimen consisting of a total dose of 1.8 mg - two colchicine capsules initially (1.2 mg)followed an hour later by a single additional capsule of active drug(0.6 mg)then by 5 additional hourly doses of an identical looking placebo capsules
3043380|NCT00506883|Placebo Comparator|Placebo|
3043381|NCT00506922|Experimental|No Pentostatin|Group 1: No Pentostatin
3043382|NCT00506922|Experimental|Pentostatin 0.5|Group 2: Pentostatin 0.5 mg/m^2
3043383|NCT00506922|Experimental|Pentostatin 1|Group 3: Pentostatin 1 mg/m^2
3043384|NCT00506922|Experimental|Pentostatin 1.5|Group 4: Pentostatin 1.5 mg/m^2
3043385|NCT00506922|Experimental|Pentostatin 2|Group 5: Pentostatin 2 mg/m^2
3043386|NCT00506948|Experimental|Thymoglobulin + Sirolimus + MMF|Thymoglobulin 1.5 mg/kg intravenous (IV) days -4, -3, -2, -1 before Stem Cell Transplant (Day 0); Sirolimus 6 mg IV on day -2 followed by 2 mg daily to maintain therapeutic levels and Mycophenolate Mofetil (MMF) 15 mg/kg IV or orally every 12 hours starting on day 0 until day+27.
3043387|NCT00507026|Experimental|A|DIC075V (IV diclofenac)
3043388|NCT00507026|Active Comparator|B|IV Ketorolac
3043389|NCT00507026|Placebo Comparator|C|Placebo
3043390|NCT00507130|Experimental|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3043391|NCT00507130|Experimental|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3043392|NCT00507130|Experimental|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3043393|NCT00507130|Placebo Comparator|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
3043394|NCT00507208|Experimental|Dynasplint|Participants randomized to this arm will be treated with the Dynasplint Trismus System
3043395|NCT00507208|Active Comparator|Control|Participants randomized to this arm will use tongue depressors for 3 months and if there is no improvement in their mouth opening at this timepoint, they will crossover to the Dynasplint Trismus System
3043396|NCT00507416|Experimental|Bortezomib and Dexamethasone (VD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus intravenous (IV) injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
3043397|NCT00507416|Experimental|Bortezomib, Thalidomide, and Dexamethasone (VTD)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11 and 12, and thalidomide 100 mg orally on Days 1-21 for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance) .
3043398|NCT00507416|Experimental|Bortezomib, Melphalan and Prednisone (VMP)|Participants received bortezomib (Velcade) 1.3 mg/m^2 administered as a bolus IV injection on Days 1, 4, 8, and 11, and melphalan 9 mg/m^2 orally on Days 1-4 every other cycle and prednisone 60 mg/m^2 orally on Days 1-4 every other cycle for eight 21-day treatment cycles (Induction). Participants then received bortezomib 1.6 mg/^2 IV on Days 1, 8, 15 and 22 for five 35-day cycles (Maintenance).
3043399|NCT00507429|Experimental|Arm 1: CA4P + Carboplatin + paclitaxel|Six 21-day cycles: CA4P (60 mg/m2 on Days 1, 8, 15), carboplatin (AUC 6) + paclitaxel (200 mg/m2) on Day 2
3043400|NCT00507429|Active Comparator|Arm 2: Carboplatin + Paclitaxel|Six 21-day cycles of Carboplatin (AUC 6) + paclitaxel (200 mg/m2) given on Day 1
3043401|NCT00507442|Experimental|VDR|VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
3043402|NCT00507442|Experimental|VDCR|VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
3043403|NCT00507442|Experimental|VDC|VELCADE (bortezomib), dexamethasone, cyclophosphamide
3043404|NCT00507442|Experimental|VDC-mod|Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
3043405|NCT00507455|Placebo Comparator|Placebo|Participants received once daily, oral doses of placebo matching solifenacin succinate and tamsulosin tablets for 12 weeks.
3043406|NCT00507455|Experimental|6 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 6 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
3043407|NCT00507455|Experimental|9 mg Solifenacin + 0.4 mg Tamsulosin|Participants received once daily, oral doses of 9 mg solifenacin succinate and 0.4 mg tamsulosin tablets for 12 weeks.
3043408|NCT00507507|Experimental|Tenofovir DF|Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
3043409|NCT00507507|Experimental|FTC+Tenofovir DF|Participants were randomized to receive FTC plus tenofovir DF once daily.
3043410|NCT00507546|Experimental|Ramelteon then placebo|8 mg nightly ramelteon for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of nightly placebo (cross-over)
3043411|NCT00507546|Experimental|Placebo then ramelteon|placebo nightly for three weeks, followed by two weeks of nightly placebo (washout), then three weeks of 8 mg nightly ramelteon (cross-over)
3043412|NCT00507559|Experimental|AAA Repair System|
3468768|NCT03892512|Active Comparator|dexmedetomedine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex .Pfizer CO ) .
3043413|NCT00507689|Experimental|FTC/TDF+HBIg|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF+HBIg in the randomized period.
3043414|NCT00507689|Experimental|FTC/TDF|Participants received FTC/TDF+HBIg for up to 24 weeks in the pre-randomization period; those who completed 24 weeks of treatment were then randomized to receive FTC/TDF in the randomized period.
3043415|NCT00507728|Experimental|Bupropion|Bupropion starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter).
3043416|NCT00507728|Experimental|Varenicline|Varenicline starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter).
3043417|NCT00507728|Placebo Comparator|Placebo|Placebo by mouth for 12 weeks.
3043418|NCT00507767|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO or via PEG tube BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3043419|NCT00507819|Active Comparator|Sildenafil, then Placebo|Sildenafil will be given at a dose of 20 mg three times-a-day for six weeks followed by a six week washout period followed by placebo for an additional six weeks.
3043420|NCT00507819|Active Comparator|Placebo, then Sildenafil|Placebo will be given for six weeks followed by a six week washout period followed by Sildenafil which will be given at a dose of 20 mg three times-a-day for six weeks
3043421|NCT00508001|Placebo Comparator|1|Best Supportive Care + Placebo
3043422|NCT00508001|Experimental|2|Best Supportive Care + ZD6474 100 mg
3043423|NCT00508001|Experimental|3|Best Supportive Care + ZD6474 300 mg
3043424|NCT00508027|Other|Simvastatin, Dose Escalation|There are no arms in this study. Simvastatin will be given in a dose-escalating fashion to 3 sequential dosage groups (20 mg/day, 40 mg/day, 80 mg/day).
3043425|NCT00508105|Active Comparator|subscapularis peel|
3043426|NCT00508105|Active Comparator|osteotomy|
3043427|NCT00508118|Experimental|1|Nicardipine
3043428|NCT00508118|Placebo Comparator|2|0.9% saline
3043429|NCT00508144|Experimental|Alimta|Alimta 500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks.
3043430|NCT00508157|Experimental|A|
3043431|NCT00508157|Active Comparator|B|
3043432|NCT00508183|Active Comparator|single row fixation|
3043433|NCT00508183|Active Comparator|double row fixation|
3043434|NCT00508261|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with Infanrix hexa™
3043435|NCT00508261|Experimental|Group B|Meningococcal vaccine GSK134612 followed one month later by Infanrix hexa™
3043436|NCT00508261|Active Comparator|Group C|Infanrix hexa™ followed one month later by Meningococcal vaccine GSK134612
3043437|NCT00508261|Active Comparator|Group D|Meningitec™ vaccination
3043438|NCT00508274|Experimental|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
3043439|NCT00508300|Other|A|Epidural Analgesia (EDA) An epidural catheter was inserted at thoracic level (Th8-Th10) before induction of anesthesia. A bolus of 5 mL of bupivacaine 0.5% was started as soon as the epidural catheter was in place, and a continuous perfusion of bupivacaine 0.5% at 5 mL/hr was initiated until the end of surgical procedure.
3043440|NCT00508300|Other|B|Patient controlled analgesia (PCA) was assured by fentanyl (morphine-based) as needed.
3043441|NCT00508391|Experimental|Simultaneous 1st, Optimized 2nd|Lumax HF-T device programmed to simultaneous biventricular pacing first for 30 days, followed by optimized biventricular pacing for 30 days.
3043442|NCT00508391|Experimental|Optimized 1st, Simultaneous 2nd|Lumax HF-T device programmed to optimized biventricular pacing first for 30 days, followed by simultaneous biventricular pacing for 30 days.
3043443|NCT00508404|Experimental|Panitumumab plus FOLFIRI|Participants received 6 mg/kg panitumumab intravenously (IV) once every 14 days in combination with FOLFIRI chemotherapy regimen consisting of irinotecan, infusional 5-fluorouracil, and leucovorin, until diagnosed with radiographic disease progression.
3043444|NCT00508469|Experimental|Travalert with travoprost/timolol fixed combination|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
3043445|NCT00508469|Experimental|Travalert with travoprost and timolol|One drop travoprost in the study eye at 9 p.m. and one drop of timolol in the study eye twice daily (9 a.m. and 9 p.m.) for six months using a separate Travalert device for each medication.
3043446|NCT00508482|Experimental|deep needling group|Acupoints of bilateral Tianshu (ST25), which were located according to WHO Standardized Acupuncture Points Location, were used. After sterilizing the skin, needles of the size of 0.35×0.75mm were inserted into ST25 vertically and slowly without manipulation for about 20~60mm until piercing into the muscle layer. Paired alligator clips of the electric acupuncture (EA) apparatus were attached transversely to the needle holders of bilateral ST25. EA stimulation lasted for 30 minutes with a dilatational wave of 2/15Hz and current intensity of 0.1~1mA. Participant's abdominal muscle twitching mildly showed the proper dose. Patients were treated once a day, five times a week for continuous 4 weeks.
3043447|NCT00508482|Active Comparator|lactulose group|Lactulose Oral Solution was taken orally at the dose of 20~30ml once every morning after breakfast for continuous 4 weeks. Patients should take lactulose for another 3 months if no severe adverse effect was showed.
3043448|NCT00508482|Active Comparator|shallow needling group|Bilateral ST25, the same acupoints as deep needling group, were used. After skin disinfection, needles of the size of 0.30×25mm penetrated the skin uprightly for about 5~9mm into the fat layer without manipulation. The usage of EA apparatus and treatment course were the same as deep needling group.
3043449|NCT00508521|Experimental|FES and Motor Learning Training|participants <6 months after first stroke who presented with arm dysfunction were trained using FES and Motor Learning
3043450|NCT00508521|Other|Control group|Subjects in this arm will receive standard care as prescribed by their physician and covered by their insurance
3043451|NCT00508651|Experimental|Cohort 1 MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM Luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
3043452|NCT00508651|Placebo Comparator|Cohort 1 Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM Luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
3043453|NCT00508716|No Intervention|A|Usual Care - Education about CHF by Primary Nurse on discharge. No teach-back is used in this arm.
3043454|NCT00508716|Experimental|B|"Tailored Intervention for patients with low health literacy and nurse-directed teachback: Educational leaflet which has been developed for low-health literacy patients. Adminstered by dedicated Nurse-educator. Nurse-educator asks Patient for teachback after Intervention. This means that the Patient repeats in his/her own words the Information received. Education ends once Patient has been able to repeat the Information back."
3043455|NCT00508742|Experimental|1|13 valent pneumococcal conjugate vaccine
3043456|NCT00508742|Active Comparator|2|7 valent pneumococcal conjugate vaccine
3043457|NCT00508755|Experimental|Arm 1|stroke
3043458|NCT00508820|Experimental|1|Romiplostim
3043459|NCT00508924|Experimental|ARG250|
3043460|NCT00508924|Experimental|ARG300|
3043461|NCT00508924|Experimental|ARG350|
3043462|NCT00508924|Placebo Comparator|Heparin|
3043463|NCT00509002|Experimental|Adenoid Cystic Salivary Gland Carcinoma Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
3043464|NCT00509002|Experimental|Other Carcinoma of Salivary Gland Group|Participants receive Gefitinib daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.
3043465|NCT00509028|Experimental|BUD - Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
3043466|NCT00509028|Active Comparator|CONV - Conventional Asthma Therapy|Conventional Asthma Therapy - according to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
3043467|NCT00509041|Experimental|Dasatinib|Use of dasatinib in treatment of pts with previously treated malignant mesothelioma
3043468|NCT00509067|Experimental|A|Participants assigned to receive galantamine and CDP-choline
3043469|NCT00509067|Placebo Comparator|B|Participants assigned to receive placebo
3043470|NCT00509093|Experimental|Imatinib Mesylate|
3043471|NCT00509106|Experimental|Ceftaroline fosamil for injection|Ceftaroline fosamil was administered in two consecutive 300 mg IV infusions over 30 minutes, every 12 hours (q12h).
3043472|NCT00509106|Active Comparator|IV Ceftriaxone|Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).
3043473|NCT00509145|Experimental|Laquinimod|Laquinimod 0.6 mg, oral
3043474|NCT00509145|Placebo Comparator|Placebo|Matching placebo
3043475|NCT00509171|Active Comparator|1-Standard reamer|Standard reamer
3043476|NCT00509171|Active Comparator|2-Use of the Reamer-Irrigator Aspirator|Use of the Reamer-Irrigator Aspirator
3043477|NCT00509197|Active Comparator|Active treatment group (A)|Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
3043478|NCT00509197|Placebo Comparator|Control group treated with placebo (B)|treatment with placebo
3043479|NCT00509223|Experimental|Group 1|Lifestyle counseling with Positive Airway Pressure (PAP) therapy
3043480|NCT00509223|Active Comparator|Group 2|Lifestyle counseling without Positive Airway Pressure (PAP) therapy
3043481|NCT00509236|Experimental|Sitagliptin 25 mg|
3043482|NCT00509236|Active Comparator|Glipizide 2.5 mg - 20 mg|
3043483|NCT00509249|Experimental|Arm I|Patients will receive aflibercept IV at 4 mg/kg over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3043484|NCT00509262|Experimental|Sitagliptin|Sitagliptin + Placebo for Glipizide
3043485|NCT00509262|Active Comparator|Glipizide|Glipizide + Placebo for Sitagliptin
3043486|NCT00509288|Experimental|anti-MART-1 F5 TCR PBL + HD IL-2|Patients treated with peripheral blood lymphocytes (PBL)
3043487|NCT00509288|Experimental|anti-MART-1 F5 TCR TIL + HD IL-2|Patients treated with TIL (tumor infiltrating lymphocytes).
3043488|NCT00509366|Active Comparator|Cisplatin Sensitive (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Cisplatin day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Cisplatin day 1, Pemetrexed day 1~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin sensitive arm, based on histology (squamous/non-squamous)."
3043489|NCT00509366|Active Comparator|Cisplatin Resistant (Post-Amendment)|"Assignment to Treatment Group based on histology and tumor genomics analysis:~Squamous Cell NSCLC-Docetaxel day 1, Gemcitabine days 1 & 8 Non-Squamous Cell NSCLC-Pemetrexed day 1, Gemcitabine days 1 & 8~Per an amendment dated 1/25/2010, post-amendment treatment assignment refers to the further separation of patients into sub-groups, within the cisplatin resistant arm, based on histology (squamous/non-squamous)."
3043490|NCT00509366|Active Comparator|Cisplatin Sensitive (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Cisplatin day 1, Gemcitabine days 1 & 8"
3043491|NCT00509366|Active Comparator|Cisplatin Resistant (Pre-Amendment)|"Assignment to Treatment Group based on tumor genomics analysis:~Pemetrexed day 1, Gemcitabine days 1 & 8"
3043492|NCT00509392|Active Comparator|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
3043493|NCT00509392|Active Comparator|Endovenous Laser|Treatment invention of venous disease with an Endovenous Laser.
3043494|NCT00509496|Experimental|anti-gp100:154-162 TCR PBL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered peripheral blood lymphocyte (PBL) cell preparation - minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes.~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
3043495|NCT00509496|Experimental|anti-gp100:154-162 TCR TIL + HD IL-2|"fludarabine phosphate-25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days~cyclophosphamide-60 mg/kg/day x 2 days intravenous~Anti-gp100:154-162 TCR-engineered tumor infiltrating lymphocytes (TIL) cell preparation- minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL or PBL. The cells are infused intravenously over 20-30 minutes~aldesleukin-720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)"
3043496|NCT00509587|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3043497|NCT00509665|Experimental|Gemcitabine+doxorubicin|
3043498|NCT00509769|Experimental|Trastuzumab emtansine 3.6 mg/kg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.
3043499|NCT00509795|Active Comparator|ranibizumab 0.5mg Q4|
3043500|NCT00509795|Experimental|aflibercept injection 2.0mg Q4|
3043501|NCT00509795|Experimental|aflibercept injection 0.5mg Q4|
3043502|NCT00509795|Experimental|aflibercept injection 2.0mg Q8|
3043503|NCT00509821|Experimental|Enzastaurin Once Daily (QD)|Enzastaurin given orally (PO) once daily (QD). 1125 mg loading dose D(-)7 then 500 mg PO,QD with concomitant radiotherapy.
3043504|NCT00509821|Experimental|Enzastaurin Twice Daily (BID)|Enzastaurin 1125 mg loading dose D(-)7 then 250 mg twice daily (BID) PO, with concomitant radiotherapy.
3043505|NCT00509873|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
3043506|NCT00509873|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
3043507|NCT00509899|Experimental|Ruxolitinib|All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.
3043508|NCT00509925|Experimental|Treatment period 1|Insulin detemir for 16 weeks (treatment period 1) followed by insulin NPH treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
3043509|NCT00509925|Experimental|Treatment period 2|Insulin NPH for 16 weeks (treatment period 1) followed by insulin detemir treatment for 16 weeks (treatment period 2) in addition to meal-time insulin aspart
3043510|NCT00510068|Experimental|Everolimus 10 mg/day|Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
3043511|NCT00510068|Placebo Comparator|Placebo|Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).
3043512|NCT00510146|Experimental|Olanzapine|During double-blind treatment, participants receive olanzapine at a dose of 5 milligram (mg) which is increased to 10 mg per day no later than 3-7 days after randomization (Baseline). Subsequent dose increases above 10 mg (up to a maximum of 20 mg per day) are permitted in 5 mg per day increments, based upon tolerability and symptoms. Dosing may be decreased by any number of decrements, however dosing below 5 mg requires study discontinuation.
3043513|NCT00510146|Placebo Comparator|Placebo|Matching placebo administered once daily, by mouth during double-blind treatment.
3043514|NCT00510146|Experimental|Olanzapine (open-label treatment period)|During open-label treatment, participants randomized to placebo in double-blind period will receive olanzapine 5 mg starting at Week 6. Participants randomized to olanzapine must be at a 5 mg olanzapine dose at Week 7. Those on higher doses will be reduced between Week 6 and Week 7 (10 mg reduced to 5 mg; 15 mg reduced to 10 mg and then to 5 mg at Week 7; 20 mg reduced to 15 mg and then 10 mg to dosing at 5 mg at Week 7). Dose increases beyond Week 7 are permitted and at the investigator's discretion.
3043515|NCT00510198|Active Comparator|Control Arm 1: SOC and CC with OptiVol|Standard of Care and Cardiac Compass with OptiVol as the Control. Intervention is standard of care, such as symptom assessment with the addition of viewing Cardiac Compass trends and the OptiVol diagnostic.
3043516|NCT00510198|Active Comparator|Control Arm 2: SOC|Intervention is Standard of Care alone, such as assessment of symptoms, only. Device trending information, but OptiVol is not allowed.
3043517|NCT00510224|Experimental|1|
3043518|NCT00510276|Experimental|Atomoxetine|
3043519|NCT00510276|Placebo Comparator|Placebo|
3043520|NCT00510289|Experimental|all patients|sorafenib
3043521|NCT00510458|Other|LFIT™Femoral Heads With X3® Insert|LFIT™ Femoral Heads With X3® Insert
3043522|NCT00510484|Experimental|A|
3043523|NCT00510484|Placebo Comparator|B|
3043524|NCT00510497|Experimental|Autologous HIV-1 ApB DC Vaccine|Subjects who will receive ApB Dendritic cell vaccine
3043525|NCT00510510|Experimental|NVA237 100 µg|
3043526|NCT00510510|Experimental|NVA237 200 µg|
3043527|NCT00510510|Placebo Comparator|Placebo|
3043528|NCT00510653|Experimental|Imatinib Mesylate|600 mg/day orally for 6 Weeks
3043529|NCT00510692|Experimental|2g/day Eicosapentanoic Acid (EPA)|"Eicosapentanenoic Acid (EPA) as the free fatty acid 2 capsules twice daily for 6 months.~Endoscopy and biopsies taken as described under intervention."
3043530|NCT00510692|Placebo Comparator|Placebo|Medium chain triglycerides 2 capsules twice daily for six months. Endoscopy and biopsies taken as described under intervention.
3043531|NCT00510718|Experimental|1|MDV3100
3043532|NCT00510744|Experimental|pancreatic enzyme supplementation|3 month supplementation in those gastric bypass patients shown to have a fat absorption less than 80%
3043533|NCT00510783|Active Comparator|Phenytoin/Fosphenytoin|Patients in the control arm will receive either IV Dilantin (1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals) or IV Fosphenytoin (1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals).
3043534|NCT00510783|Active Comparator|Levetiracetam|Patients in the intervention arm will receive IV Keppra (1 gram of Keppra added to 100 mL diluent infused over 15 minutes).
3043535|NCT00510809|Active Comparator|1|Policosanol 20mg daily
3043536|NCT00510809|Placebo Comparator|2|
3043537|NCT00510809|Active Comparator|3|Policosanol 20mg daily Plus Statin Therapy Already In Use
3132872|NCT03461965|Active Comparator|Verbal Counselling|Participants in the control group will be educated on MMS according to the current standard of care, verbal counselling, with a standardized script
3132873|NCT03462082|No Intervention|Baseline STN-DBS|Maintenance of baseline bilateral STN-DBS settings.
3043538|NCT00510835|Experimental|1|Early Goal Directed Therapy (EGDT) - The study team will insert a central venous catheter (CVC) for continuous monitoring of the subjects' central venous pressure (CVP) and central venous oxygen saturation (Scv02). The study team will use this information to give fluid, blood, and heart medications in a structured fashion. The CVC is FDA approved and routinely used in hospitals.
3043539|NCT00510835|Experimental|2|Protocolized Standard Care (PSC)- The study team will monitor the subjects' blood pressure and blood oxygen level with routine equipment. The study team will use this information to give fluid and heart medications in a structured fashion. CVCs will only be used when standard IVs are unable to give the proper amount of fluids and medicines. Blood transfusions will be given according to currently recommended guidelines.
3043540|NCT00510835|Active Comparator|3|Usual Care - The attending physicians will treat the subjects according to their standard treatment plan and without any influence from the study team. A member of the study team will simply observe and record what happens.
3043541|NCT00510874|Experimental|Pumarix Formulation 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 1 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043542|NCT00510874|Experimental|Pumarix Formulation 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 2 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043543|NCT00510874|Experimental|Pumarix Formulation 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 3 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043544|NCT00510874|Experimental|Pandemrix Formulation A Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation A of Pandemrix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043545|NCT00510874|Experimental|Pandemrix Formulation B Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation B of Pandemrix ™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043546|NCT00510874|Experimental|Pumarix Formulation 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 4 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043547|NCT00510874|Experimental|Pumarix Formulation 5 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of formulation 5 of Pumarix™ vaccine at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm (non-dominant arm for the first injection and dominant arm for the second one).
3043548|NCT00510887|Experimental|VR-FND|"Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum."
3043549|NCT00510952|Experimental|Lispro|Insulin Lispro protamine suspension: Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
3043550|NCT00510952|Active Comparator|Glargine|Insulin glargine: Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
3043551|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole -STD|Standard therapy of DEC (300mg) and albendazole (400mg) yearly
3043552|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole- HD1|High dose of DEC (300mg) and albendazole (800mg) yearly
3043553|NCT00511004|Active Comparator|Diethylcarbamazine/Albendazole-HD2|High dose of DEC (300mg) and albendazole (800mg) twice yearly (every 6 months)
3043554|NCT00511095|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) Intramuscular (IM) injection 0.5mL
3043555|NCT00511108|Experimental|1|Arm 1: drug
3043556|NCT00511108|Active Comparator|2|Arm 2: active comparator
3043557|NCT00511108|Experimental|3|Arm 3: drug + active comparator
3043558|NCT00511108|Placebo Comparator|4|Arm 4: placebo comparator
3043559|NCT00511134|Experimental|Zyban + Lunesta|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + Lunesta (3 mg qd x 6 weeks)
3043560|NCT00511134|Placebo Comparator|Zyban + Placebo|Zyban (150 mg qd x 7 days then 150 mg bid x 6 weeks) + placebo (1 pill per day x 6 weeks)
3043561|NCT00511147|Experimental|IGIV3I Grifols 10% (All Subjects)|All subjects with Chronic ITP
3043562|NCT00511173|Experimental|Clinician dosing of warfarin|Warfarin dose based on clinician dosing without the use of warfarin pharmacogenetics
3043563|NCT00511199|Experimental|NOMAC-E2|"Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2~monophasic combined oral contraceptive"
3043564|NCT00511199|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3043565|NCT00511238|Experimental|carfilzomib (A0)|
3043566|NCT00511238|Experimental|carfilzomib (A1)|
3043567|NCT00511342|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic COC
3043568|NCT00511342|Active Comparator|LNG-EE|Levonorgestrel (LNG) and Ethinyl Estradiol (EE), 0.150 mg LNG and 0.030 mg EE monophasic COC
3043569|NCT00511355|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3043570|NCT00511355|Active Comparator|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets (LNG-EE), 150 mcg LNG and 30 mcg EE
3043571|NCT00511433|Experimental|NOMAC-E2|Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
3043572|NCT00511433|Active Comparator|DRSP-EE|Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive
3043573|NCT00511472|Experimental|MK-0941|
3043574|NCT00511472|Placebo Comparator|Placebo|
3043575|NCT00511667|Experimental|MK0941|
3043576|NCT00511667|Placebo Comparator|Placebo|
3043577|NCT00511706|Experimental|dexamethasone and ranibizumab|Intravitreal injection of dexamethasone 700 µg at Day 1; ranibizumab 500 µg at Day -30 and Day 7-14.
3043578|NCT00511706|Sham Comparator|sham and ranibizumab|Sham injection at Day 1; ranibizumab 500 µg at day -30 and Day 7-14.
3043579|NCT00511797|Experimental|DRSP 1 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 1 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3043580|NCT00511797|Experimental|DRSP 2 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 2 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3043581|NCT00511797|Experimental|DRSP 3 mg/EE 20 μg|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 μg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle
3043582|NCT00511797|Placebo Comparator|Placebo|1 tablet per day placebo for 28 days in each 28-day cycle
3043583|NCT00511810|Experimental|Low Dose Fish Oil|Capsule omega-3 fatty acids 2.4g/day (4 capsules/day)
3043584|NCT00511810|Experimental|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
3043585|NCT00511836|Experimental|VIVITROL 380 mg|
3043586|NCT00511836|Placebo Comparator|Placebo|
3043587|NCT00511862|Experimental|TheraSphere|Single arm, TheraSphere Yttrium 90 glass microspheres at 120 Gy +/- 10%; stratified by type of disease (colorectal cancer, neuroendocrine cancer, non-colorectal/non-neuroendocrine cancer
3043588|NCT00511875|Experimental|Doxycycline Monohydrate|stratified equally to doxycycline monohydrate 50mg taken once daily for 24 months
3043589|NCT00511875|Placebo Comparator|Placebo|stratified equally to placebo taken once daily for 24 months
3043590|NCT00511901|Placebo Comparator|Placebo & Niferex|Placebo (for epoetin alpha) subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
3043591|NCT00511901|Active Comparator|epoetin alpha & Niferex|40,000 IU (initial dose) epoetin alpha subcutaneous injection weekly for 8 weeks and Niferex 150 mg twice a day for 8 weeks
3043592|NCT00511914|Experimental|cTIV (Adults)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
3043593|NCT00511914|Experimental|cTIV (Elderly)|Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).
3043594|NCT00511992|Experimental|Avastin|
3043595|NCT00512096|Experimental|Cisplatin + Ifosfamide + Paclitaxel|Cisplatin 25 mg/m^2 IV Days 1-3; Ifosfamide 1200 mg/m^2 IV Days 1-3; Paclitaxel 175 mg/m^2 IV Day 1
3043596|NCT00512135|Experimental|IncobotulinumtoxinA (Xeomin) (20 units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3043597|NCT00512148|Experimental|1|Receipt of autologous neo-bladder construct consisting of a device regenerated in the laboratory from the patient's own muscle and urothelial cells
3043598|NCT00512252|Experimental|Phase I Dose Escalation|"AMD3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d"
3043599|NCT00512252|Experimental|Phase II Dose Treatment|"AMD 3100 SQ on days 0-5~Mitoxantrone on days 1-5~Etoposide on days 1-5~Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)"
3043600|NCT00512278|Experimental|Infliximab|Infliximab: 48 weeks of therapy with the combination of PEG INF-2b/RBV plus adjuvant infliximab
3043601|NCT00512278|Placebo Comparator|Placebo|Placebo: 48 weeks of therapy with Placebo and PEG INF-2b/RBV
3043602|NCT00512707|Experimental|Active Testosterone Gel|Active Testosterone Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
3043603|NCT00512707|Placebo Comparator|Placebo Gel|Placebo Gel and on demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
3043604|NCT00512798|Experimental|Phase I|
3043605|NCT00512798|Experimental|Phase II|
3043606|NCT00512902|Experimental|Group 1|SSc patients receiving Imatinib (Gleevec, up to 600 mg) QD PO for up to 1 year.
3043607|NCT00513019|Active Comparator|1|Lamictal (lamotrigine)
3043608|NCT00513019|Placebo Comparator|2|Placebo
3043609|NCT00513071|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3043610|NCT00513240|Experimental|EPO group|Patients randomized to receive the 3 doses of erythropoetin.
3043611|NCT00513240|Placebo Comparator|Control group.|Patients randomized to receive 3 doses of normal saline control.
3043612|NCT00513292|Active Comparator|FEC-75 then Paclitaxel/trastuzumab|Patients receive FEC comprising fluoroucacil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks.
3043613|NCT00513292|Experimental|Paclitaxel/trastuzumab then trastuzumab/FEC-75|Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluoroucacil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I.
3132874|NCT03462082|Experimental|Asymmetric STN-DBS 1|Unilateral 50% reduction of voltage (e.g. right side)
3043614|NCT00513305|Active Comparator|Low-dose cytarabine plus arsenic trioxide|Cycle 1 cytarabine 10 mg/m^2 was administered subcutaneously (sc) twice daily (bid) on days 1-14. 0.25 mg/kg arsenic trioxide was administered intravenously (iv) on days 1-5 and days 8-12. Cycle 2 A second identical cycle of cytarabine and arsenic trioxide was given to patients with persistent disease. Patients who achieved complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine and arsenic trioxide with the doses and schedule identical to the initial cycle. A recovery period of up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of arsenic trioxide 0.25 mg/kg iv on days 1 and 4 and cytarabine 10 mg/m^2 sc bid on days 1 through 7 of a 28-day cycle.
3043615|NCT00513305|Active Comparator|Low-dose cytarabine alone|Cytarabine was administered at a dose of 10 mg/m^2 sc bid from days 1-14 of cycle 1. A second identical cycle of cytarabine was given to patients with persistent disease. Patients who achieved a complete remission (CR), complete remission with incomplete platelet count recovery (CRp), or partial remission (PR) after 1 or 2 cycles received a 14-day consolidation cycle of cytarabine with the doses and schedule identical to the initial treatment cycle. Recovery period up to 4 weeks between the attainment of CR, CRp, or PR and the initiation of consolidation treatment was allowed. Patients who completed consolidation treatment started maintenance treatment of cytarabine at 10 mg/m^2 sc bid on days 1-7 of a 28-day cycle. Patients started maintenance treatment within 42 days after platelet count recovery. Maintenance treatment continued for 2 years or until unacceptable toxicity or disease progression.
3043616|NCT00513344|Experimental|dark chocolate containing polyphenols|dark chocolate
3043617|NCT00513344|Experimental|Milk chocolate containing polyphenols|Bespoke milk chocolate
3043618|NCT00513344|Active Comparator|Control chocolate with no polyphenols|cocoa-free chocolate
3043619|NCT00513357|Experimental|Melatonin|20 mg of Melatonin before going to sleep at night for a period of 4 weeks.
3043620|NCT00513357|Placebo Comparator|Placebo|20 mg of Placebo before going to sleep at night for a period of 4 weeks.
3043621|NCT00513370|Experimental|1|
3043622|NCT00513409|Experimental|Synflorix Booster Group|Subjects previously primed with Synflorix™ and receiving in the current study Havrix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
3043623|NCT00513409|Experimental|Synflorix Catch-up Group|Subjects previously primed with Havrix™ co-administered with Infanrix™ hexa and receiving in the current study Synflorix™ co-administered with Infanrix™ hexa (Dose 1) and Synflorix™ (Dose 2).
3043624|NCT00513435|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO or by PEG tube QD on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3043625|NCT00513461|Experimental|Arm I (SAMe)|Patients receive SAMe PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
3043626|NCT00513461|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for weeks 1-4, PO BID for weeks 5-8, and PO TID for weeks 9-24 in the absence of disease progression or unacceptable toxicity.
3043627|NCT00513474|Experimental|Rasburicase Group|Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.
3043628|NCT00513474|Other|Control Group|Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.
3043629|NCT00513500|Experimental|1|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on rapid diagnostic test. For pneumonia, give one half tablet (250mg amoxicillin) for children weighing (5-9.9kg) and one tablet for children weighing (10-20kg) three times a day for five days.
3043630|NCT00513500|Active Comparator|2|Give one half tablet (20mg artemether, 120mg lumefantrine) to children weighing (5-9.9kg) and one tablet to children weighing (10-20kg) twice a day for three days for malaria based on clinical diagnosis. For pneumonia, refer to the nearest health facility
3043631|NCT00513526|Experimental|Gardasil|Quadrivalent HPV Vaccine (types 6, 11, 16, 18) for intramuscular injection at study entry, week 8, week 24, and week 128.
3043632|NCT00513604|Experimental|Cohort 1 - NMA, TIL, aldesleukin|"Cohort 1 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), & high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 1 = unselected TIL"
3043633|NCT00513604|Experimental|Cohort 2 - NMA, CD4+ TIL, aldesleukin|"Cohort 2 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 2 = CD4+ depleted (selected) TIL"
3132579|NCT03438539|Experimental|Working Memory Training with Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
3043634|NCT00513604|Experimental|Cohort 3 - NMA, total body irradiation|"Cohort 3 - Nonmyeloablative (NMA), total body irradiation (TBI):~Nonmyeloablative chemotherapeutic conditioning regimen and 2 gray units (Gy) of total body irradiation followed by cluster of differentiation 4 (CD4+) depleted tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL 2Gy (gray units) of total body irradiation (TBI) twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute using a linear accelerator in Radiation Oncology Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 3 = CD4 + depleted (selected) TIL + 600Gy radiation"
3043635|NCT00513604|Experimental|Cohort 4 - NMA, young TIL, aldesleukin|"Cohort 4 - Nonmyeloablative (NMA), tumor infiltrating lymphocytes (TIL), aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by bulk young tumor infiltrating lymphocytes and high dose (HD) aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. Bulk young TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 4 = unselected TIL - it is the SAME as cohort 1"
3043636|NCT00513604|Experimental|Cohort 5 - NMA, CD4+TIL, HD aldesleukin|"Cohort 5 - Nonmyeloablative (NMA), cluster of differentiation 4 (CD4+) tumor infiltrating lymphocytes (TIL), high dose (HD) aldesleukin:~Nonmyeloablative chemotherapeutic conditioning regimen followed by CD4+ depleted tumor infiltrating lymphocytes and high dose aldesleukin.~Cyclophosphamide 60 mg/kg intravenous (IV) daily x 2 days. Fludarabine 25 mg/m^2 intravenous (IV) daily x 5 days. CD4+ depleted TIL Aldesleukin 720,000 IU/kg intravenous (IV) (based on body weight) over 15 minutes every eight hours for up to 5 days.~Cohort 5 = CD4 + depleted TIL - it is the SAME as cohort 2"
3043637|NCT00513617|Active Comparator|Low Dose|0.05 g/kg/day Arginine
3043638|NCT00513617|Active Comparator|High Dose|0.10 g/kg/day Arginine
3043639|NCT00513617|Placebo Comparator|Placebo|No Arginine
3043640|NCT00513682|Experimental|Ultrase® MT20|
3043641|NCT00513695|Experimental|Treatment (neoadjuvant chemotherapy before surgery)|Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.
3043642|NCT00513708|No Intervention|Treatment As Usual (TAU)|"Treatment as Usual (TAU): Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during medically managed inpatient detoxification."
3043643|NCT00513708|Experimental|Motivational Enhancement Therapy (MET)|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Motivational Enhancement Therapy (MET) session delivered by a trained professional."
3043644|NCT00513708|Experimental|Peer-delivered Twelve Step Facilitation|"Participants randomized to this arm will receive usual care (i.e., pharmacotherapy to manage alcohol withdrawal, counseling and referral to treatment or self-help) during inpatient detoxification plus a 60-minute Peer-delivered Twelve Step Facilitation (P-TSF)session delivered by individuals from a common self-help program."
3043645|NCT00513747|Experimental|Arm I|Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
3043646|NCT00513747|Active Comparator|Arm II|Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
3043647|NCT00513799|Active Comparator|1: Hygiene Education|"Intensive education on prevention of skin infections through improvements in personal hygiene (also serves as control group)"
3043648|NCT00513799|Active Comparator|2: Hygiene education + mupirocin|Application of mupirocin in the nasal mucosa alone
3043649|NCT00513799|Active Comparator|Education + mupirocin + chlorhexidine|A combination of nasal application of mupirocin and chlorhexidine showers
3043650|NCT00513799|Active Comparator|4: Education + mupirocin + bleach baths|A combination of nasal application of mupirocin and bathing in dilute bleach water
3043651|NCT00514020|Experimental|Treatment|
3043652|NCT00514046|Experimental|Vandetanib|Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m^2/day.
3043653|NCT00514137|Experimental|Treatment (kinase inhibitor therapy)|Patients receive 37.5 mg oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3043654|NCT00514215|Experimental|Sargramostim, Flow Cytometry, Biopsy. Cryosurgery|Sargramostim-250 μg, inhaled, two times a day, on days 4-10 and days 36-42 Flow cytometry-Days 1 & 32 Immunoenzyme technique-Days 1 & 32 CT guided biopsy-Days 1 & 32 Cryosurgery-Days 1 and 32
3043655|NCT00514449|Experimental|Valacyclovir|1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
3043656|NCT00514449|Placebo Comparator|Sugar pill|2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.
3043657|NCT00514501|Experimental|Iodofiltic Acid I 123|
3043658|NCT00514514|Active Comparator|CNI standard regimen|Myfortic, Sandimmun Optoral and corticosteroids
3043659|NCT00514514|Experimental|CNI free regimen|"CNI free regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Myfortic, Certican 1.5 mg, Sandimmun Optoral (50% of standard dose) and corticosteroids Step 2 at BL2 + 8 days: Myfortic, Certican 3 mg and corticosteroids"
3132875|NCT03462082|Experimental|Asymmetric STN-DBS 2|Unilateral 50% reduction of voltage (e.g. left side)
3043660|NCT00514514|Active Comparator|CNI low regimen|"CNI low regimen: comprising the following steps for switching treatment:~Step 1 at BL2 + 1 day: Certican 1.5 mg, Sandimmun Optoral and corticosteroids Step 2 at BL2 + 8 days: Certican 1.5 mg, Sandimmun Optoral (low dose) and corticosteroids"
3043661|NCT00514540|Experimental|First-Line/Second-Line Chemotherapy|"First-Line (CD) Chemotherapy: Carboplatin area under the curve (AUC) = 5, intravenous (IV) over 30 minutes and Docetaxel 75 mg/m^2 IV over 60 minutes, Day 1. Repeated every 3 weeks.~Second-Line (EP) Chemotherapy: Etoposide 120 mg/m^2 daily for 3 days and Cisplatin 25 mg/m^2 for 3 days with adequate intravenous hydration mannitol diuresis and supportive care (antiemetics). Repeated every 3 weeks."
3043662|NCT00514592||All|All patients enter the same group
3043663|NCT00514683|Experimental|dose 1|low dose BIBF1120 once daily
3043664|NCT00514683|Experimental|dose 2|low dose BIBF 1120 twice daily
3043665|NCT00514683|Experimental|dose 3|intermediate dose BIBF 1120 twice daily
3043666|NCT00514683|Experimental|dose 4|high dose BIBF 1120 twice daily
3043667|NCT00514683|Placebo Comparator|placebo|placebo
3043668|NCT00514709|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
3043669|NCT00514709|Experimental|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
3043670|NCT00514735|Experimental|1|Ablation Management
3043671|NCT00514735|Active Comparator|2|Medical Management
3043672|NCT00514852|Experimental|1|Carboxymethylcellulose and Glycerin based artificial tear
3043673|NCT00514852|Active Comparator|2|Carboxymethylcellulose
3043674|NCT00514904|Experimental|Nimenrix Group|Subjects received 1 dose of Nimenrix vaccine at Month 0. Nimenrix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3043675|NCT00514904|Active Comparator|Mencevax ACWY Group|Subjects received 1 dose of Mencevax ACWY vaccine at Month 0. Mencevax ACWY vaccine was administered subcutaneously into the upper region of the non-dominant arm.
3043676|NCT00514917|Experimental|Docetaxel+Leuprolide+Bicalutamide|Participants received docetaxel 75 milligram per square meter (mg/m^2) intravenous infusion over 1 hour every 3 weeks up to 10 cycles (3 week cycle) along with leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
3043677|NCT00514917|Active Comparator|Leuprolide+Bicalutamide|Participants received leuprolide 22.5 mg injection subcutaneously every 12 weeks up to 18 months and bicalutamide 50 mg tablet orally once daily for first 4 weeks of treatment.
3043678|NCT00514943|Experimental|BIBW 2992|once daily taken orally
3043679|NCT00514943|Active Comparator|Cetuximab|once every week by intravenous injection
3043680|NCT00515008|Experimental|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi 18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
3043681|NCT00515008|Placebo Comparator|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
3043682|NCT00515021|Experimental|Daytime then nightime dosing|Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.
3043683|NCT00515021|Experimental|Nighttime then daytime dosing|Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.
3043684|NCT00515034|Experimental|001|Doripenem 1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
3043685|NCT00515034|Active Comparator|002|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
3043686|NCT00515034|Experimental|003|Doripenem 1 gram infused over 4 hours at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
3043687|NCT00515034|Active Comparator|004|Imipenem/cilastatin 1 gram infused over 1 hour at 8 hour intervals for patients with complicated intrabdominal infections (cIAI) for 5 to 14 days Vancomycin may be added as adjunctive therapy as per investigator discretion
3043688|NCT00515073|Experimental|Paclitaxel (Taxol) + Pelvic Radiation|"Paclitaxel (Taxol) 50 mg/m^2 intravenous (IV) weekly over 1 hour for 5 weeks. Radiation therapy to the pelvis daily for 25 treatments.~Both radiation therapy and paclitaxel chemotherapy on Day 1 or 2, followed by radiation alone for four days, repeated every week for a total of 5 weeks, giving a total dose of 45 Gy with external beam radiation to pelvis and 5 courses of paclitaxel 50 mg/m^2. Four-six weeks after pelvic radiation completed, 4 additional courses of paclitaxel 135 mg/m^2 alone given every 21 days. Vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for additional 3 days. No chemotherapy given with vaginal apex boost."
3043689|NCT00515086|Experimental|No Surgery (Everolimus 10 mg)|Participants with recurrent Glioblastoma Multiforme (GBM) not scheduled to undergo salvage surgical resection, received a daily oral dose of 10 mg Everolimus (RAD001) until evidence of disease progression or toxicity.
3043690|NCT00515086|Experimental|Everolimus 10 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 10 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3043691|NCT00515086|Experimental|Everolimus 5 mg + Surgery|Participants scheduled to undergo salvage surgical resection received a daily oral dose of 5 mg Everolimus for 7 days prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3043692|NCT00515086|Active Comparator|Everolimus 0 mg + Surgery|Participants scheduled to undergo salvage surgical resection received no treatment with Everolimus prior to surgery, then after recovery from surgery received a 10 mg daily oral dose of Everolimus until evidence of disease progression or toxicity.
3043693|NCT00515099|Experimental|Antithymocyte globulin|This group received a total of 6.5 mg/kg of antithymocyte globulin (e.g., Thymoglobulin®) divided into four doses as follows: Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
3043694|NCT00515099|Placebo Comparator|Placebo|This group received a saline solution to match the Thymoglobulin doses given to the active treatment group, on Day 1, 0.5 mg/kg; Day 2, 2 mg/kg; Day 3, 2 mg/kg; and Day 4, 2 mg/kg.
3043695|NCT00515177|Experimental|MBSR|A Mindfulness-Based Stress Reduction (MBSR) program that includes 8-weeks of group instruction in mindfulness meditation techniques followed by home practice and monitoring.
3043696|NCT00515177|Active Comparator|PCT Sleeping Pills|A pharmacotherapy control arm (PCT Sleeping Pills) consisting of a state-of-the-art prescription sedative hypnotic, eszopiclone - brand name LUNESTA(R), at a dose of one 3 milligram (mg) pill nightly for a duration of 8 weeks followed by use as needed (same dosage) for 3 months. This drug was approved by the Food and Drug Administration as a sedative for more than short term use.
3043697|NCT00515203|Placebo Comparator|II.|5 thrombocytopenic (as defined per protocol) subjects
3043698|NCT00515203|Experimental|I.|15 thrombocytopenic (as defined per protocol) subjects
3043699|NCT00515216|Experimental|Oxaliplatin/Leucovorin/5-FU|"Good risk patients with the TSER*2/*2 or *2/*3 genotype or low TS expression genotype received treatment of oxaliplatin, leucovorin given over 2 hours along with 5-FU given as intravenous push followed by 5-FU given as intravenous infusion of 46 hours. This treatment was repeated every 2 weeks."
3043700|NCT00515294|Experimental|1Caffeinated Alcoholic Beer|Caffeinated Alcoholic beer
3043701|NCT00515294|Active Comparator|2Non-Caffeinated Alcoholic Beer|Non-Caffeinated Alcoholic beer
3043702|NCT00515294|Active Comparator|3Caffeinated Non-Alcoholic Beer|Caffeinated Non-Alcoholic Beer
3043703|NCT00515294|Placebo Comparator|4Non-Caffeinated, Non-Alcoholic Beer|Non-Caffeinated, Non-Alcoholic Beer
3043704|NCT00515411|Active Comparator|Arm A, - Modified DCF|"Drug Dose (mg/m2) Schedule~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Arm A is repeated every 2 weeks, and a cycle will be considered 6 weeks (eg 3 treatments)."
3043705|NCT00515411|Active Comparator|ARM B - Parent DCF with G-CSF|"Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg"
3043706|NCT00515411|Active Comparator|Arm C - Modifid DCF + Trastuzumab|"Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes."
3043707|NCT00515437|Experimental|1|1500U Myobloc
3043708|NCT00515437|Experimental|2|2500U Myobloc
3043709|NCT00515437|Experimental|3|3500U Myobloc
3043710|NCT00515437|Placebo Comparator|4|pooled placebo
3043711|NCT00515463|Experimental|Denosumab - Vial|Participants received denosumab 60 mg subcutaneous injection using a standard vial on Day 1 and at Month 6.
3043712|NCT00515463|Experimental|Denosumab - Prefilled syringe|Participants received denosumab 60 mg subcutaneous injection using a pre-filled syringe on Day 1 and at Month 6.
3043713|NCT00515502|Active Comparator|Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: umeclidinium bromide (UMEC) 250 micrograms (µg), UMEC 500 µg, Tiotropium 18 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3043714|NCT00515502|Active Comparator|Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3043715|NCT00515502|Active Comparator|Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043716|NCT00515502|Active Comparator|Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, UMEC 500 µg, placebo and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043717|NCT00515502|Active Comparator|Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, UMEC 500 µg and UMEC 1000 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043718|NCT00515502|Active Comparator|Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043719|NCT00515502|Active Comparator|Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, Tiotropium 18 µg, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043720|NCT00515502|Active Comparator|Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, placebo, UMEC 250 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043721|NCT00515502|Active Comparator|Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg and placebo. Treatment periods were seperated by a washout period of at least 14 days.
3043722|NCT00515502|Active Comparator|Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Tiotropium 18 µg, UMEC 250 µg, placebo and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043723|NCT00515502|Active Comparator|Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: Placebo, UMEC 250 µg, Tiotropium 18 µg and UMEC 500 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043724|NCT00515502|Active Comparator|Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg|Participants received single doses of 4 treatments, over 4 treatment periods, in the following sequence: UMEC 250 µg, placebo, UMEC 500 µg and Tiotropium 18 µg. Treatment periods were seperated by a washout period of at least 14 days.
3043725|NCT00515528|Experimental|Vaccine Alone|Subjects received vaccine immunization injected intra-dermally or subcutaneously on day 1. The vaccine was an emulsification consisting of 250 mcg each of the following peptides: Melan-A, gp100, MAGE-3, and NA17 as well as GM-CSF 125 mcg and Montanide. A second and third vaccination was given at 2 weeks and 4 weeks after the first. If there was no evidence of cancer progression, additional courses of three vaccinations administered at 2 week intervals were administered until disease progression.
3043726|NCT00515528|Experimental|Vaccine plus Ontak|Subjects in Vaccine plus Ontak received the same vaccination strategy as Vaccine alone group but additionally received a single dose of denileukin diftitox(18 mcg/kg) 4 days prior to the first vaccine administration
3043727|NCT00515541|Active Comparator|A|Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.
3043728|NCT00515541|Active Comparator|B|Patient is on regular dose of Aspirin ( < or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza
3043729|NCT00515541|Active Comparator|C|Patient is taking regularly 75mg of clopidogrel daily and Aspirin (< or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza
3043730|NCT00515541|Active Comparator|D|Patient is regularly taking Warfarin daily and Aspirin (< or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza
3043731|NCT00515619|Experimental|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing
3468769|NCT03892512|Active Comparator|esmolol|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride . Baxter CO ).
3468770|NCT03892486|Experimental|The high PUFA diet group|This will receive detailed nutritional recommendations and will consume at least 4 table spoons of olive oil or 30 grams of nuts daily for 12 weeks.
3043734|NCT00515697|Experimental|Ramucirumab|Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.
3043735|NCT00515723|Active Comparator|Olanzapine|Participants in this group were randomized to flexibly-dosed treatment with olanzapine.
3043736|NCT00515723|Active Comparator|Risperidone|Participants in this group were randomized to flexibly-dosed treatment with risperidone.
3043737|NCT00515723|Active Comparator|Quetiapine|Participants in this group were randomized to flexibly-dosed treatment with quetiapine.
3043738|NCT00515723|Active Comparator|Ziprasidone|Participants in this group were randomized to flexibly-dosed treatment with ziprasidone.
3043739|NCT00515827|Experimental|Raltegravir then Placebo (Arm A)|400 mg raltegravir (MK-0518) administered twice daily in addition to optimized background regimen (OBR) from entry to Week 12; halt raltegravir at Week 12 and add placebo twice daily for 12 weeks
3043740|NCT00515827|Experimental|Placebo then Raltegravir (Arm B)|Placebo administered twice daily in addition to OBR from entry until Week 12; halt placebo at Week 12 and add 400 mg raltegravir tablet twice daily for 12 weeks
3043741|NCT00515879|Experimental|CBT plus d-cycloserine|Participants will receive cognitive behavioral therapy plus D-cycloserine
3043742|NCT00515879|Placebo Comparator|CBT plus placebo|Participants will receive cognitive behavioral therapy plus pill placebo
3043743|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Negative|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
3043744|NCT00516048|Experimental|Exenatide:Treatment-Emergent Antibody Positive|This arm will receive 5mcg exenatide for 4 weeks, followed by 10mcg exenatide for 20 weeks.
3043745|NCT00516074|Experimental|Exenatide Arm|This arm will receive 5mcg exenatide for 4 weeks, and then 10mcg exenatide for the remaining 8 weeks of the study.
3043746|NCT00516074|Placebo Comparator|Placebo Arm|This arm will receive placebo injection (volume equivalent to the exenatide injection in the experimental arm).
3043747|NCT00516139|Experimental|Lamotrigine|Open-label lamotrigine
3468771|NCT03892486|No Intervention|Control group|The Control group will receive general nutritional recommendations based on Human Nutrition Recommendations for Polish Population.
3468772|NCT03892473|Experimental|Flexible Assertive Community Treatment (FACT)|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
3468773|NCT03892473|Active Comparator|Care as usual (CAU)|Active Comparator: CAU (Care as usual) Patients with SMI receiving usual care, meaning mostly medical treatment
3468774|NCT03892434|Active Comparator|Bevacizumab|
3468775|NCT03892434|Active Comparator|Dexamethasone|
3043748|NCT00516165|Experimental|RAD001|Patients will receive RAD001 10 mg/day orally (6 weeks/cycle). Patients will be continued on treatment until disease progression, limiting toxicity, patient withdrawal of consent, or death.
3043749|NCT00516217|Experimental|Galaximab|Induction: 500 mg/m^2 by IV over 60 minutes days 1, 8, 15 & 22 Extended Induction: 500 mg/m^2 by IV every 4 weeks until disease progression or unacceptable toxicity
3043750|NCT00516269|Experimental|Methylphenidate then Placebo|Methylphenidate 18 mg oral daily for 2 weeks then Placebo oral daily for 2 weeks
3043751|NCT00516269|Experimental|Placebo then Methylphenidate|Placebo oral daily for 2 weeks then Methylphenidate 18 mg oral daily for 2 weeks
3043752|NCT00516295|Experimental|Arm I (Feasibility assessment of VTCB)|Patients receive bevacizumab IV over 30-90 minutes on day 1, vincristine sulfate IV on days 1, 8, and 15, and topotecan hydrochloride IV over 30 minutes and cyclophosphamide IV over 60 minutes on days 1-5. Treatment repeats every 21 days (except during weeks 14, 15 [course 5], 17, 18 [course 6], 26, 27 [course 9], 29, and 30 [course 10] when no chemotherapy is given) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3043753|NCT00516295|Experimental|Arm II (VTCB)|Patients receive bevacizumab, vincristine sulfate, topotecan hydrochloride, and cyclophosphamide as in Arm I.
3043754|NCT00516295|Active Comparator|Arm III (CTC)|Patients receive vincristine, topotecan hydrochloride, and cyclophosphamide as in arm I.
3043755|NCT00516386|Experimental|Insulin like growth factor- 1 (IGF-1)|Adolescent girls with AN meeting inclusion criteria were administered recombinant human (rh) rhIGF-1 at a dose of 35-40 mcg/k twice daily by subcutaneous injections for a 7-10 day period.
3043756|NCT00516503|Experimental|Arm I|Patients apply 1 spoonful of baclofen-amitriptyline hydrochloride-ketamine gel> topically to each> area of pain,> numbness,> and/or tingling> on the> feet and/or hands twice daily> for> 4 weeks.
3043757|NCT00516503|Placebo Comparator|Arm II|Patients apply 1 spoonful of placebo gel topically to each area of pain, numbness, and/or tingling on the feet and/or hands twice daily for 4 weeks.
3043758|NCT00516737|Experimental|1|Active Drug
3043759|NCT00516737|Placebo Comparator|2|Matching Pbo Comparator
3043760|NCT00516893|Experimental|Natalizumab High Titer|natalizumab high titer 300 mg administered as intravenous (IV) infusion over 60 minutes once every 4 weeks for up to 9 doses
3043761|NCT00516906|Placebo Comparator|Transparent Adhesive Dressing|Standard of Care Non-Antimicrobial Transparent Adhesive Dressing
3043762|NCT00516906|Experimental|CHG antimicrobial transparent dressing|Chlorhexidine gluconate antimicrobial transparent adhesive dressing
3043763|NCT00516919|Experimental|1|Xenical + behavioral intervention
3043764|NCT00516919|Active Comparator|2|Placebo + behavioral intervention
3043765|NCT00517010|Experimental|proton beam with ranibizumab|Intervention is 24Gy proton radiation in 2 fractions given within 6 weeks of first dose of intravitreal ranibizumab (0.5mg) drug combined with four monthly doses of intravitreal lucentis and monthly prn lucentis thereafter.
3043766|NCT00517296|Experimental|Adalimumab with EUS guided therapy|Patients will be randomized to adalimumab treatment with EUS guided therapy decisions. Colorectal surgeon will have access to EUS data prior to EUA with possible seton placement.
3043767|NCT00517296|Active Comparator|Adalimumab|Patients will be randomized to adalimumab treatment. Colorectal surgeon will not have access to EUS data prior to EUA with possible seton placement.
3043768|NCT00517413|Experimental|C.E.R.A|Participants with chronic renal anaemia who were on dialysis and previously treated with intravenous (IV) or subcutaneous (SC) epoetin alfa, epoetin beta or darbepoetin alfa received monthly treatment with Continuous Erythropoietin Receptor Activator (C.E.R.A.) (methoxy polyethylene glycol-epoetin beta [Mircera]). The initial dose of C.E.R.A. was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA); 120, 200, or 360 micrograms (mcg) C.E.R.A., IV or SC, every 4 weeks for 48 weeks.
3043769|NCT00517530|Experimental|Phase I, NHL|Participants in this NHL arm received multiple ascending doses between 50 and 2000 mg via intravenous infusion of obinutuzumab.
3043770|NCT00517530|Experimental|Phase I, CLL|Participants in this CLL arm received multiple ascending doses between 400 and 2000 mg via intravenous infusion of obinutuzumab.
3043771|NCT00517530|Experimental|400/400 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3043772|NCT00517530|Experimental|1600/800 mg - Phase II, iNHL|Participants in this iNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3043773|NCT00517530|Experimental|400/400 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 400 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 400 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3043774|NCT00517530|Experimental|1600/800 mg - Phase II, aNHL|Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
3043775|NCT00517530|Experimental|1000/1000 mg - Phase II, CLL|Participants in this CLL arm received an intravenous infusion of obinutuzumab 1000 mg on Days 1, 8, and 15 of Cycle 1 and obinutuzumab 1000 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
3043776|NCT00517530|Experimental|Retreated Participants|Participants who might benefit from retreatment who were allowed to be treated again via intravenous infusion of obinutuzumab at the request of the investigator.
3043777|NCT00517556|Experimental|study group (CCOCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for 168 continuous days through six cycles
3043778|NCT00517556|Active Comparator|control group (traditional OCP)|treatment with monophasic oral contraceptive (gestodene 0,075 mg /ethinyl estradiol 20 mcg) for traditional (21 active days/7 inactive days) regimen through six cycles.
3043779|NCT00517634|Experimental|Sequence 1: FP, SFC, Placebo|Fluticasone Propionate (FP) 100 micrograms (mcg) twice daily (BID) in the first treatment period: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 mcg BID in the second treatment period: Placebo in the third treatment period
3043780|NCT00517634|Experimental|Sequence 2: Placebo, SFC, FP|Placebo in the first treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
3043781|NCT00517634|Experimental|Sequence 3: SFC, FP, Placebo|Salmeterol/Fluticasone Propionate 50/100 Combination mcg BID in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Placebo in the third treatment period
3043782|NCT00517634|Experimental|Sequence 4: SFC, Placebo, FP|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the first treatment period: Placebo in the second treatment period: Fluticasone Propionate 100 mcg BID in the third treatment period
3043783|NCT00517634|Experimental|Sequence 5: FP, Placebo, SFC|Fluticasone Propionate 100 mcg BID in the first treatment period: Placebo in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
3043784|NCT00517634|Experimental|Sequence 6: Placebo, FP, SFC|Placebo in the first treatment period: Fluticasone Propionate 100 mcg BID in the second treatment period: Salmeterol/Fluticasone Propionate Combination 50/100 mcg BID in the third treatment period
3043785|NCT00517751|Experimental|X-STOP PEEK|In this arm, patients will undergo X-STOP PEEK surgery.
3043786|NCT00517829|Active Comparator|1- Docetaxel plus Oxaliplatin|Docetaxel as an intravenous (IV) infusion over 1 hour, followed by oxaliplatin IV over 2 hours
3043787|NCT00517829|Active Comparator|2- Docetaxel plus oxaliplatin plus cetuximab|Docetaxel 60 mg/m2 as an IV infusion over 1 ho ur, followed by oxaliplatin 130 mg/m2 IV over 2 hours, followed by cetuximab 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
3043788|NCT00517881|Experimental|C.E.R.A.|
3043789|NCT00517933|Active Comparator|Sildenafil|20 mg of sildenafil 3 times a day (TID) for 12 weeks followed by 20 mg of sildenafil TID for an additional 12 weeks
3043790|NCT00517933|Placebo Comparator|Placebo / Sildanafil|20 mg of placebo TID for 12 weeks followed by 20 mg of sildenafil citrate TID for an additional 12 weeks
3043791|NCT00518011|Experimental|Erlotinib + Gemcitabine|Participants received Erlotinib 150 mg/day orally as a continuous schedule with Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
3043792|NCT00518011|Active Comparator|Gemcitabine|Participants received Gemcitabine 1000 (mg/m^2)/day, IV on Days 1, 8, 15 and every 4 weeks for 6 cycles.
3043793|NCT00518089|Experimental|Gatifloxacin 0.5% Eye Drops|Gatifloxacin 0.5% Eye Drops
3043794|NCT00518089|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops
3043795|NCT00518154|Experimental|A|Patients will be taking oral Pyridostigmine 30mg tid, as well as their usual antiretroviral treatment
3043796|NCT00518180|Experimental|MenACWY + Tdap + HPV|Subjects received MenACWY concomitantly with Tdap and HPV at study month 0 followed by two injections of HPV at month 2 and 6
3043797|NCT00518180|Experimental|MenACWY →Tdap → HPV|Subjects received MenACWY at study month 0 followed by one injection of Tdap at month 1, followed by three injections of HPV at months 2, 4, and 8
3043798|NCT00518180|Experimental|Tdap →MenACWY → HPV|Subjects received Tdap at month 0 followed by one injection of MenACWY at month 1, followed by three injections of HPV at months 2, 4, and 8
3043799|NCT00518206|Experimental|Cohort 1|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
3043800|NCT00518206|Experimental|Cohort 2|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
3043801|NCT00518284|No Intervention|No Drug Treatment Control|Following revascularization, participants did not receive any study drug treatment.
3043802|NCT00518284|Experimental|Proximal to Lesion + IV|Participants received an initial intraarterial infusion (proximal to the lesion) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization, and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
3043803|NCT00518284|Experimental|During Flow Arrest|Participants received an initial intraarterial infusion (during flow arrest) of 45 mg/m^2 nanoparticle paclitaxel immediately following revascularization.
3043804|NCT00518284|Experimental|During Flow Arrest + IV|Participants received an initial intraarterial infusion (during flow arrest) of 45mg/m^2 nanoparticle paclitaxel immediately following revascularization and a follow-up intravenous injection of 45 mg/m^2 at 7 days.
3043805|NCT00518323|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
3043806|NCT00518323|Experimental|002|Paliperidone ER 3 mg or 6 mg tablet once daily for 6 weeks
3043807|NCT00518323|Experimental|003|Paliperidone ER 6 mg or 12 mg tablet once daily for 6 weeks
3043808|NCT00518323|Placebo Comparator|004|Placebo Once daily for 6 weeks
3043809|NCT00518336|Experimental|Cervarix Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of Cervarix at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
3043810|NCT00518336|Placebo Comparator|Placebo Group|Young adult women from the Brazilian cohort who participated in the primary study 580299/001 (NCT00689741) and follow-up study 580299/007 (NCT00120848) and received 3 doses of placebo at 0, 1 and 6 months intramuscularly into the deltoid region of the non-dominant arm during the primary study.
3043811|NCT00518349|Active Comparator|Prototype colonoscope|Colonoscopy using prototype colonoscope with passive bending function
3043812|NCT00518349|Placebo Comparator|Standard colonoscope|Colonoscopy using standard colonoscope with no passive bending function
3043813|NCT00518531|Other|Treatment Sequence B|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment Sequences. Subjects randomized to treatment sequence B will receive 70 mg oral alendronate QW for 1-year (Treatment period 1) followed by denosumab 60 mg Q6M SC for 1 year (Treatment Period 2).
3043814|NCT00518531|Other|Treatment Sequence A|When a subject meets all eligibility criteria and signs the informed consent, they will be randomized in a 1:1 allocation to one of the two treatment sequences. Subjects randomized to treatment sequence A will receive 60 mg denosumab Q6M SC for 1-year (Treatment period 1) followed by oral alendronate 70 mg QW for 1 year (Treatment period 2).
3043815|NCT00518622|Experimental|1|25 mg b.i.d. MK7009
3043816|NCT00518622|Experimental|2|75 mg b.i.d. MK7009
3043817|NCT00518622|Experimental|3|250 mg b.i.d. MK7009
3043818|NCT00518622|Experimental|4|500 mg b.i.d. MK7009
3043819|NCT00518622|Experimental|5|700 mg b.i.d. MK7009
3043820|NCT00518622|Experimental|6|125 mg q.d. MK7009
3043821|NCT00518622|Experimental|7|600 mg q.d. MK7009
3043822|NCT00518622|Experimental|8|Placebo
3043823|NCT00518687|Experimental|V710 60 µg|
3043824|NCT00518687|Placebo Comparator|Placebo|
3043825|NCT00518713|Experimental|Clobazam Low Dose|
3043826|NCT00518713|Experimental|Clobazam Medium Dose|
3043827|NCT00518713|Experimental|Clobazam High Dose|
3043828|NCT00518713|Placebo Comparator|Placebo|
3043829|NCT00518882|Experimental|Liraglutide|Liraglutide 1.8 mg once daily + subject's own OAD treatment
3043830|NCT00518882|Active Comparator|Exenatide|Exenatide 10 mcg twice daily + subject's own OAD treatment
3043831|NCT00518973|Placebo Comparator|Placebo|The primary outcome was to determine the effect of quetiapine compared with placebo in terms of reducing core eating disorder symptoms on the Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS) and the Eating Disorder Inventory-2 (EDI-2).
3043832|NCT00518973|Experimental|Quetiapine|Secondary outcomes were to determine if quetiapine is superior to placebo in reducing anxiety, depression and obsessionality assessed with the State Trait Anxiety Inventory (STAI), Hamilton Depression Rating Scale (HAM D) and Yale-Brown Obsessive Compulsive Scale, respectively. In addition, another secondary goal was to determine if quetiapine is superior to placebo in terms of weight gain. Adverse events were also determined.
3043833|NCT00518986|Active Comparator|1|armodafinil 200 mg/day
3043834|NCT00518986|Placebo Comparator|2|Placebo
3043835|NCT00519077|Experimental|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
3043836|NCT00519194|Experimental|Epicor Cardiac Ablation|
3043837|NCT00519285|Placebo Comparator|Placebo|Placebo added to standard chemotherapy with docetaxel plus prednisone or prednisolone
3043838|NCT00519285|Experimental|Aflibercept|Aflibercept added to standard chemotherapy with docetaxel plus prednisone or prednisolone
3043839|NCT00519376|Experimental|GW642444M 25mcg|
3043840|NCT00519376|Experimental|GW642444M 50mcg|
3043841|NCT00519376|Experimental|GW642444M 100mcg|
3043842|NCT00519376|Experimental|GW642444H 100mcg|
3043843|NCT00519376|Experimental|placebo|
3043844|NCT00519428|Experimental|escitalopram + bupropion|escitalopram plus bupropion extra long (XL) as dual treatment (i.e., this is not a SINGLE treatment arm; all patients assigned this arm received both medications)
3043845|NCT00519428|Active Comparator|escitalopram|escitalopram monotherapy
3043846|NCT00519428|Active Comparator|bupropion|bupropion extra long (XL) monotherapy
3043847|NCT00519532|Experimental|Rotigotine|Rotigotine Transdermal Patch
3043848|NCT00519584|Placebo Comparator|Ropivacaine/saline|Ropivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
3043849|NCT00519584|Active Comparator|Ropivacaine/dex|Ropivacaine and local steroid: 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic and 0.9% saline 2ml (systemic placebo) for intravenous injection with sedation for the block;
3043850|NCT00519584|Active Comparator|bupivacaine/dex|bupivacaine and systemic steroid: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block plus dexamethasone 8 mg (2 ml) administered intravenously with sedation administered for the block.
3043851|NCT00519584|Placebo Comparator|bupivacaine/Saline|bupivacaine 30ml 0.5% ropivacaine plus 2 ml 0.9% saline (local placebo) for interscalene block and 0.9% saline 2 ml (systemic placebo) for intravenous injection with sedation for the block
3043852|NCT00519623|Experimental|PassPort(R) Transdermal Insulin Delivery System|
3043853|NCT00519636|Active Comparator|FFNS, FPNS|fluticasone furoate nasal spray, fluticasone propionate nasal spray
3043854|NCT00519636|Active Comparator|FPNS, FFNS|fluticasone propionate nasal spray, fluticasone furoate nasal spray
3043855|NCT00519636|Placebo Comparator|placebo FFNS, placebo FPNS|placebo nasal spray matching fluticasone furoate nasal spray, placebo nasal spray matching fluticasone propionate nasal spray
3043856|NCT00519636|Placebo Comparator|placebo FPNS, placebo FFNS|placebo nasal spray matching fluticasone propionate nasal spray, placebo nasal spray matching fluticasone furoate nasal spray
3043857|NCT00519649|Experimental|Group Engerix|Subjects received a single challenge dose of Engerix™ (hepatitis-B [HBV] vaccine)
3043858|NCT00519779|Placebo Comparator|2|Placebo oral Omega-3 fish oil supplementation
3043859|NCT00519779|Experimental|1|oral Omega-3 fish oil supplementation
3043860|NCT00519818|Experimental|Cortef and Chronocort|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
3043861|NCT00519831|Experimental|Vinflunine + Cetuximab|Patients may receive more than 4 cycles of therapy if they continue to demonstrate response to therapy, have limited toxicity, and if the treating physician determines that they are deriving clinical benefit from the treatment. The decision of continuing therapy beyond 4 cycles must be discussed with the principal investigator.
3043862|NCT00519896|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis therapy)|Patients receive sunitinib malate PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
3043863|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (A): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 1 year."
3043864|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab then bevacizumab/erlotinib|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation (AE): Patients received bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle and oral erlotinib 150mg daily for 1 year."
3043865|NCT00520013|Experimental|carboplatin/paclitaxel/bevacizumab|"Induction (CTA): Patients received carboplatin IV AUC 5, paclitaxel IV 175 mg/m2 and bevacizumab IV 15 mg/kg on day 1 (+/- 3d) of a 21 day cycle for 6 cycles. Bevacizumab started with cycle 2.~Patients with disease progression based on radiographic evaluation after induction could not advance to the randomized consolidation phase.~Consolidation: None"
3043866|NCT00520039|Experimental|Standard Care Plus OMM|Subjects will receive active intervention with osteopathic manipulative medicine (OMM) using a prescribed standardized treatment protocol which is age appropriate. Subjects will also receive standard care for otitis media from their referring physician.
3043867|NCT00520039|No Intervention|Standard Care Only|Subjects will receive standard care only for otitis media from their regular referring physician
3043868|NCT00520130|Experimental|A - Tacrolimus, methotrexate, sirolimus (TMS) Arm|TMS Arm
3043869|NCT00520130|Experimental|B - Cyclosporine (AC) Arm|AC Arm
3043870|NCT00520234|Active Comparator|1 prophylaxis|Caspofungin 50 mg Intravenous (IV) daily up to 28 days of therapy
3043871|NCT00520234|Placebo Comparator|2 placebo|Normal Saline 100 cc IV daily
3043872|NCT00520286|Active Comparator|Modafinil|Participants will receive a Modafinil 200 mg or 400 mg tablet one time per day for 12 weeks
3043873|NCT00520286|Placebo Comparator|Placebo|Participants will receive a matching Modafinil placebo 200 mg or 400 mg tablet one time per day for 12 weeks
3043874|NCT00520299|Experimental|Cohort 1|Subjects received ADI-PEG 20 at a dose of 40 IU/m^2
3043875|NCT00520299|Experimental|Cohort 2|Subjects received ADI-PEG 20 at a dose of 80 IU/m^2
3043876|NCT00520299|Experimental|Cohort 3|Subjects received ADI-PEG 20 at a dose of 160 IU/m^2
3043877|NCT00520351|Active Comparator|1|
3043878|NCT00520351|Active Comparator|2|
3043879|NCT00520403|Experimental|1|
3043880|NCT00520468|Experimental|Cytokine-Immunotherapy|Erythropoietin 40,000 units subcutaneously (SQ) weekly; G-CSF 300 mcg SQ twice a week; Prednisone 60 mg/Day for 7 days, taper over 1 month; Cyclosporin A 300 mg orally daily
3043881|NCT00520481|Experimental|IMC-A12|Thirty-one participants will receive IMC-A12 at 10 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). An additional 10 participants will receive IMC-A12 at a dose of 20 mg/kg every three weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Radiographic evaluation of response will be performed every 8 weeks for the participants treated with intravenous (i.v.) IMC-A12 at 10 mg/kg and every 9 weeks for the participants treated with i.v. IMC-A12 at 20 mg/kg.
3043882|NCT00520494|Experimental|Vivaglobin|Vivaglobin: 16% (160 mg/mL) liquid formulation of human IgG for SC use. Loading dose: 100 mg/kg for 5 consecutive days; maintenance dose: 100 mg/kg 1 to 2 times a week for 24 weeks.
3043883|NCT00520533|Experimental|On Study|"Treatment (cycle 1):~cG250 10mg/m² IV weekly x 5 doses (1st & 5th doses trace-labelled with 124I)~Sunitinib 50 mg/day orally x 4 weeks commencing day 8~Followed by two-week break~Treatment (cycle 2 - investigator discretion):~cG250 10mg/m² IV weekly x4 doses~Sunitinib 50 mg/day orally x 4 weeks (commencing concurrently)~Followed by two-week break"
3043884|NCT00520546|Experimental|1|Patients with prostate carcinoma confirmed by needle biopsy, age >50 years, planned radical prostatectomy with lymph-node dissection, fasting for >12 hours before FEC-PET and an interval between biopsy and PET >3 weeks.
3043885|NCT00520572|Active Comparator|1|Etanercept 50mg, subcutaneous, once weekly
3043886|NCT00520572|Experimental|2|50mg oral, once daily
3043887|NCT00520572|Experimental|3|100 mg oral, once daily
3043888|NCT00520572|Experimental|4|200 mg oral, once daily
3043889|NCT00520572|Experimental|5|400mg once, daily
3043890|NCT00520572|Placebo Comparator|6|oral, once daily
3043891|NCT00520676|Experimental|pemetrexed plus carboplatin|"Drug: pemetrexed 500 milligrams per square meter (mg/m^2), intravenous (IV), every (q) 21 days x 6 cycles maximum~Drug: carboplatin Area Under the Curve (AUC) 5 milligram*minute/milliLiter (mg*min/mL), IV, q 21 days x 6 cycles maximum"
3043892|NCT00520676|Active Comparator|docetaxel plus carboplatin|"Drug: docetaxel 75 mg/m^2, IV, q 21 days x 6 cycles maximum~Drug: carboplatin AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum"
3043893|NCT00520741|Experimental|Lacosamide 400 mg/day|Lacosamide 400 mg/day
3043894|NCT00520741|Active Comparator|Lacosamide 300 mg/day|Lacosamide 300 mg/day
3043895|NCT00520767|Experimental|Melphalan, Dexamethasone, Bortezomib,|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4
3043896|NCT00520845|Experimental|Treatment Arm|Either docetaxel or pemetrexed given with celecoxib
3043897|NCT00520884|Placebo Comparator|Healthy 70+ Women Placebo Infusion|Healthy and Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
3043898|NCT00520884|Placebo Comparator|Frail 70+ Women Placebo Infusion|Frail Women 70 and Older Receive a 3 hour Placebo Infusion of Saline administered in a stepwise fashion in amounts equivalent to the ghrelin infusion.
3043899|NCT00520884|Active Comparator|Healthy 70+ Women Ghrelin Infusion|Healthy Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
3043900|NCT00520884|Active Comparator|Frail 70+ Women Ghrelin Infusion|Frail Women 70 and Older are administered a 3 hour graded Ghrelin Infusion (the first hour of the ghrelin infusion at a dose of 2.5 pmol/kg/min, increased to a dose of 5.0 pmol/kg/min for one hour, and then increased to the dose of 10 pmol/kg/min for the final hour of the infusion).
3043901|NCT00520910|Experimental|Polypodium leucotomos extract|Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
3043902|NCT00520910|No Intervention|No intervention|Subject is not given any treatment.
3043903|NCT00520936|Experimental|Pemetrexed|
3043904|NCT00520975|Active Comparator|Arm A (chemotherapy and placebo)|"INDUCTION THERAPY: Patients receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22 and paclitaxel IV over 60 minutes with or without carboplatin IV over 60 minutes on days 1, 8, and 15. Patients also receive placebo IV over 30-90 minutes on day 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and placebo IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3043905|NCT00520975|Experimental|Arm B (chemotherapy and bevacizumab)|"INDUCTION THERAPY: Patients receive trastuzumab and paclitaxel with or without carboplatin as in Arm A. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 1 week after the last dose of induction trastuzumab, patients receive trastuzumab IV over 30-90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3043906|NCT00521001|Experimental|everolimus + temozolomide|"Patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, 22-26, and 29-33 and oral temozolomide once a day on days 8-12 for course 1 only. For course 2 and all subsequent courses, patients receive oral everolimus once a day on days 1-5, 8-12, 15-19, and 22-26 and oral temozolomide once a day on days 1-5. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~All patients undergo blood sample collection periodically for correlative studies. Samples are analyzed for relative numbers of T, B, and NK cells via flow cytometry, quantitative immunoglobulin levels (IgG, IgM, and IgA), Tetramer/ELISPOT CTL frequencies to CMV/EBV immunodominant antigens, V beta T cell spectratyping, and VEGF levels via ELISA.~After completion of study treatment, patients are followed every 8 weeks."
3043907|NCT00521014|Experimental|GM-CSF and Rituximab After Autologous Stem Cell Transplant|"GM-CSF: 250 mcg (flat dose) three times per week for 8 weeks, administered on alternate days. Thus, 24 doses of GM-CSF will be administered.~Rituximab: 375 mg/m2/week for 4 weeks, beginning within 3 days after the first dose of GM-CSF; rituximab. The second course of GM-CSF and rituximab will be administered approximately 22-26 weeks (day +154 to +182) after ASCT."
3043908|NCT00521053|Experimental|PV-10|
3043909|NCT00521079|Experimental|vBloc|Subjects implanted with a functional Maestro System device that delivers therapy (Therapy ON).
3043910|NCT00521079|Sham Comparator|Placebo|Subjects implanted with a functional Maestro System device that does NOT deliver therapy (Therapy OFF).
3043911|NCT00521144|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive obatoclax mesylate IV over 3 hours on day 1 OR days 1 and 3 and topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
3043912|NCT00521339|Experimental|Apremilast 20 mg BID/ 30 mg BID|Apremilast 20 mg or 30 mg orally twice per day
3043913|NCT00521352|Active Comparator|Active rTMS|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
3043914|NCT00521352|Sham Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
3043915|NCT00521365|Experimental|Quetapine 600 mg|
3043916|NCT00521404|Experimental|CS-1008 + gemcitabine|CS-1008 + gemcitabine
3043917|NCT00521456|Experimental|1|
3043918|NCT00521456|Placebo Comparator|2|
3043919|NCT00521586|Other|1|arm 1 = TIV +13vPnC at visit 1, placebo at visit 2 then 13vPnC at year 5
3043920|NCT00521586|Other|2|arm 2 = TIV + placebo at visit 1, then 13vPnC at visit 2 and at year 5
3043921|NCT00521599|Experimental|MF DPI 2 x 100 mcg BID|2 inhalations of mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
3043922|NCT00521599|Experimental|MF DPI 1 x 200 mcg BID|1 inhalation of mometasone furoate dry powder inhaler (MF DPI) 200 mcg plus 2 inhalations of placebo matching MF DPI 100 mcg twice daily (BID) for 8 weeks
3043923|NCT00521599|Placebo Comparator|Placebo|2 inhalations of placebo matching mometasone furoate dry powder inhaler (MF DPI) 100 mcg plus 1 inhalation of placebo matching MF DPI 200 mcg twice daily (BID) for 8 weeks
3043924|NCT00521976||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
3043925|NCT00521989|Experimental|CRx-102 (2.7/90)|"2.7 mg prednisolone plus 90 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3043926|NCT00521989|Experimental|CRx-102 (2.7/180)|"2.7 mg prednisolone plus 180 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3043927|NCT00521989|Experimental|CRx-102 (2.7/360)|"2.7 mg prednisolone plus 360 mg dipyridamole~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM. The dipyridamole dose was divided equally between the two time points, 8AM and 1PM"
3043928|NCT00521989|Active Comparator|Prednisolone|"2.7 mg prednisolone~Subjects were dose twice daily through day 98. Prednisolone at 2.7 mg/d was administered as 1.8 mg at 8AM and 0.9 mg at 1PM."
3043929|NCT00521989|Placebo Comparator|Placebo|"Placebo~Subjects were dose twice daily through day 98."
3043930|NCT00522041|Experimental|Cellegesic (nitroglycerin 0.4%)|Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
3043931|NCT00522041|Placebo Comparator|Placebo 375 mg|Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.
3043932|NCT00522171||Electro Surgery|Electro Surgical instruments are used to cut and coagulate tissue using alternating electric current at the surgical site. In Electro Surgery, the patient is included in the circuit and current enters the patient's body.
3043933|NCT00522275|Experimental|Lacosamide|Up to 800 mg/day lacosamide (flexible dosing)
3043934|NCT00522379|Experimental|Rotigotine 2 mg/24 hr|
3043935|NCT00522379|Experimental|Rotigotine 4 mg/24 hr|
3043936|NCT00522379|Experimental|Rotigotine 6 mg/24 hr|
3043937|NCT00522379|Experimental|Rotigotine 8 mg/24 hr|
3043938|NCT00522379|Placebo Comparator|Placebo|
3043939|NCT00522392|Experimental|Arm A (VRD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib, dexamethasone and lenalidomide. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11; fixed dose of lenalidomide at 15 mg orally on days 1-14; and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15. Aspirin 325 mg/day orally on days 1-21 of each cycle was required unless the patient was treated with alternate prophylaxis of either low molecular weight heparin or coumadin.
3043940|NCT00522392|Active Comparator|Arm B (VD)|Patients were given consolidation therapy for 8 cycles (1 cycle = 21 days) with the combination bortezomib plus dexamethasone. Patients received each cycle: the standard dose of bortezomib (1.3 mg/m2) on days 1, 4, 8 and 11 and 3 days of dexamethasone at 40 mg total dose per day given on days 1, 8 and 15.
3043941|NCT00522418|Experimental|VNS Therapy|VNS Therapy + Best Medical Practice
3043942|NCT00522418|Active Comparator|Best Medical Practice|Best Medical Practice
3043943|NCT00522431|Experimental|1|2% testosterone gel
3043944|NCT00522548|Active Comparator|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) at a target dose of 720 mg orally twice daily for 6 months after transplant.
3043945|NCT00522548|Active Comparator|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent manufactured by Sandoz, at a target dose of 1000 mg orally twice daily for 6 months after transplant.
3043946|NCT00522626||Observational|Opioid exposed pregnancies
3043947|NCT00522795|Experimental|PPX with cisplatin and radiation|PPX 50mg/m2 wk and cisplatin 25mg/m2 wk for 6 weeks with 50.4 GY concurrent radiation
3043948|NCT00522873|Experimental|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
3043949|NCT00522873|Active Comparator|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
3043950|NCT00522925|Placebo Comparator|1|Matching Placebo
3043951|NCT00522925|Experimental|2|
3043952|NCT00522925|Experimental|3|
3043953|NCT00522951|Experimental|Gadobutrol 0.1 mmol/kg bw|Participants received first injection (intravenous [i.v.]) of gadobutrol 0.1 mmol/kg body weight (bw), corresponding to a dose of 0.1 mmol/kg bw
3043954|NCT00522951|Experimental|Gadobutrol 0.2 mmol/kg bw|Participants received second injection (i.v.) of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
3043955|NCT00522951|Experimental|Gadoteridol (ProHance)|Participants received two injections (i.v.) of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw. The interval of two bolus injections is 13-15 min
3043956|NCT00523302|Active Comparator|Active TMS|Since cortical stimulation can be performed non-invasively by active Transcranial Magnetic Stimulation (TMS), Participants in the active TMS group, receive five 20 minute active TMS treatment sessions per week for two weeks.
3043957|NCT00523302|Sham Comparator|Sham TMS|To prevent unwanted cortical activation, Sham TMS will be employed in the Sham TMS group. For the Sham TMS group, a specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active TMS coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials. Participants in the sham TMS group receive five 20 minute Sham TMS treatment sessions per week for two weeks.
3043958|NCT00523341|Experimental|Denosumab|Participants received a 60 mg subcutaneous injection of denosumab every 6 months for seven years.
3043959|NCT00523367|No Intervention|esomeprazole|
3043960|NCT00523419|Experimental|Pemetrexed|Participants received pemetrexed 500 milligrams per square meter (mg/m^2) by intravenous (IV) infusion of 10 minutes on Day 1 of each 21-day cycle.
3043961|NCT00523549|Experimental|Standard treatment regimen|(Valsartan + Amlodipine to target SBP of < 140 mmHg)
3043962|NCT00523549|Experimental|Intensive treatment regimen|(Valsartan + Amlodipine to target SBP < 130 mm Hg)
3043963|NCT00523614||1: Cases|
3043964|NCT00523614||2: Controls|
3043965|NCT00523640|Experimental|I|"Combination of gemcitabine, capecitabine, and bevacizumab~gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle"
3043966|NCT00523705|Experimental|escitalopram|Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
3043967|NCT00523705|Placebo Comparator|placebo|Placebo tablets matched to drug.
3043968|NCT00523718|Experimental|riluzole|Patients randomized to this arm will receive riluzole augmentation, at a standard, fixed dose (50 mg bid), in addition to the medication regimen they are on at enrollment
3043969|NCT00523718|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from riluzole, in addition to the medication regimen they are on at study enrollment.
3043970|NCT00523744|Experimental|Amlodipine(AML)+olmesartan, AML+valsartan, AML+valsartan+HCTZ|During the Treatment Phase 1, participants received 1 week of treatment with olmesartan 10 mg and amlodipine 5 mg once daily in free combination, followed by three weeks of treatment with olmesartan 20 mg plus amlodipine 10 mg once daily in free combination. During the treatment Phase 2 of the study participants received amlodipine 10 mg plus valsartan 160 mg for 4 weeks. During the Extension Phase, participants received 4 weeks treatment with amlodipine 10 mg plus valsartan 160 mg plus hydrochlorothiazide (HCTZ) 12.5 mg.
3043971|NCT00523848|Experimental|Arm 1|Patients receive low-dose oral thalidomide once a day on days 1-28, bortezomib IV on days 1, 4, 15, and 18, and doxorubicin hydrochloride liposome IV over 60-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity
3043972|NCT00523978|Experimental|Experimental|Experimental subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci. If necessary, experimental subjects were allowed a previously failed Study Atrial Fibrillation Drug (AF Drug).
3043973|NCT00523978|Active Comparator|Control|Control Subjects were treated with an AF Drug (flecainide, propafenone, or sotalol) that they had not previously failed.
3043974|NCT00523991|Placebo Comparator|placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
3043975|NCT00523991|Experimental|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
3043976|NCT00524017|Experimental|Arm I (treatment)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity.
3043977|NCT00524017|No Intervention|Arm II (control)|Patients receive regular follow-up care
3043978|NCT00524030|Experimental|1|
3043979|NCT00524030|Experimental|2|
3043980|NCT00524043|Experimental|001|Paliperidone ER 1.5 mg tablet once daily for 6 weeks
3043981|NCT00524043|Active Comparator|002|Paliperidone ER 6 mg tablet once daily for 6 weeks
3043982|NCT00524043|Placebo Comparator|003|Placebo Once daily for 6 weeks
3043983|NCT00524121|Experimental|Oral Erlotinib|Patients receive oral erlotinib hydrochloride once daily for 1 year
3043984|NCT00524173|Active Comparator|Tenofovir only|Tenofovir 300mg by mouth daily for 192 weeks
3043985|NCT00524173|Experimental|Tenofovir & emtricitabine|Tenofovir 300mg in combination with emtricitabine 200mg by mouth daily for 192 weeks
3043986|NCT00524225|Experimental|Neumega (Interleukin 11, IL-11)|Neumega (Oprelvekin, Interleukin 11, IL-11) 25 mcg/kg subcutaneously, given for 4 days preoperatively, and on day 5 preoperatively, and for up to 2 days postoperatively
3043987|NCT00524264|Experimental|1|
3043988|NCT00524264|Placebo Comparator|2|
3043989|NCT00524303|Active Comparator|Arm 1|Trastuzumab alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles and Paclitaxel for 4 (21 day) cycles then continued trastuzumab until time of definitive surgery
3043990|NCT00524303|Experimental|Arm 2|Lapatinib alone for 2 weeks then in combination with FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued lapatinib until time of definitive surgery
3043991|NCT00524303|Experimental|Arm 3|Trastuzumab + Lapatinib for 2 weeks then added FEC75 for 4 (21 Day) cycles followed by Paclitaxel for 4 (21 day) cycles then continued trastuzumab + lapatinib until time of definitive surgery
3043992|NCT00524316|Experimental|Sunitinib|oral sunitinib malate once daily on days 1-7 and 15-35 in course 1 and on days 1-28 in all subsequent courses
3043993|NCT00524342|Experimental|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
3043994|NCT00524368|Experimental|DRV/rtv 800/100 mg once daily|Two 400 mg darunavir (DRV) ie, TMC114 tablets + one 100 mg ritonavir (rtv) capsule once daily.
3043995|NCT00524368|Experimental|DRV/rtv 600/100 mg twice daily|One 600 mg TMC114 tablet + one 100 mg capsule of rtv twice daily.
3043996|NCT00524420|Experimental|Active rTMS|Active rTMS involves administration of real rTMS to the patient.
3043997|NCT00524420|Sham Comparator|Sham rTMS|Sham rTMS is a placebo or inactive form of rTMS for study control and comparison purposes.
3043998|NCT00524472|Experimental|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
3043999|NCT00524472|Other|Insulin at the standard of care levels|Group B will be administered insulin at the standard of care levels established by the participating institution.
3044000|NCT00524537||Adalimumab (Humira) Treatment|Adult patients with moderately to severely active CD treated with Humira in a routine clinical practice setting.
3044001|NCT00524576|Experimental|Engerix 2 Doses + Challenge Dose|Subjects received 2 doses of Engerix™-B (Month 0 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
3044002|NCT00524576|Experimental|Engerix 3 Doses + Challenge Dose|Subjects received 3 doses of Engerix™-B (Month 0, 1 and 6) in the primary study and a single dose of Engerix™-B during the booster study.
3044003|NCT00524589|Experimental|Dexamethasone and Calcitriol|Patients receive oral dexamethasone once on days 1 and 2 and calcitriol IV over 1 hour on day 2. Treatment repeats weekly.
3044004|NCT00524680|Experimental|Arm I|Patients receive 4,000 IU of oral cholecalciferol (vitamin D3) once daily.
3044005|NCT00524680|Experimental|Arm II|Patients receive 6,000 IU of vitamin D3 once daily.
3044006|NCT00524680|Experimental|Arm III|Patients receive 8,000 IU of vitamin D3 once daily.
3044007|NCT00524680|Experimental|Arm IV|Patients receive 10,000 IU of vitamin D3 once daily.
3044008|NCT00524745|Active Comparator|0,2,6 month vaccination schedule|
3044009|NCT00524745|Active Comparator|0,3,9 month vaccination schedule|
3044010|NCT00524745|Active Comparator|0,6,12 month vaccination schedule|
3044011|NCT00524745|Active Comparator|0,12,24 month vaccination schedule|
3044012|NCT00524771||1|Users of NuvaRing
3044013|NCT00524771||2|Users of combined oral contraceptives
3044014|NCT00524940|Experimental|Study Group|
3044015|NCT00525031|Experimental|Temozolomide (TMZ)|Temozolomide = TMZ - 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
3044016|NCT00525031|Experimental|Temozolomide (TMZ) + Pegylated Interferon-alpha 2b (PGI)|"Temozolomide = TMZ and PGI = Pegylated Interferon-alpha 2b~Temozolomide 150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks. Pegylated Interferon-alpha 2b 0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks."
3044017|NCT00525044|Placebo Comparator|Control|
3044018|NCT00525044|Experimental|Ambroxol|
3044019|NCT00525057|Experimental|Treatment (dalteparin)|Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.
3044020|NCT00525135|Other|1|If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.
3044021|NCT00525135|Other|2|If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.
3132876|NCT03462576|Experimental|Emricasan 25mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
3044022|NCT00525148|Experimental|BIBW 2992|Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs. After protocol amendment 2 (17 Dec 2008), the starting dose of BIBW 2992 was reduced to a medium dose, with 2 possible dose reductions if needed after discontinuation due to drug-related AEs.
3044023|NCT00525161|Experimental|Sorafenib & Endocrine Therapy|Sorafenib & Endocrine Therapy
3044024|NCT00525174|Active Comparator|Patching|2 hours daily patching of the sound eye plus one hour near activities while patching
3044025|NCT00525174|Active Comparator|Bangerter filters|Bangerter filter worn on sound eye spectacles lens full time plus at least one hour near activities
3044026|NCT00525265|Experimental|1|OPC-41061
3044027|NCT00525265|Placebo Comparator|2|placebo
3044028|NCT00525421|Experimental|Curcumin|Curcumin C3 Complex
3044029|NCT00525421|Placebo Comparator|Placebo|Placebo
3044030|NCT00525499|Placebo Comparator|1|Vehicle control cream applied topically to the face twice daily for 12 weeks
3044031|NCT00525499|Experimental|2|0.001% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3044032|NCT00525499|Experimental|3|0.005% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3044033|NCT00525499|Experimental|4|0.025% ASC-J9 cream applied topically to the face twice daily for 12 weeks
3044034|NCT00525512|Experimental|tiotropium 18mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
3044035|NCT00525512|Placebo Comparator|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
3044036|NCT00525525|Experimental|Efficacy Group|Patients treated with the combination of radiation plus temozolomide (75 mg/m2 daily during radiotherapy) plus bevacizumab (10 mg/kg IV every two weeks during radiotherapy) plus tarceva (dose based upon use of EIAED, either 200 mg daily or 500 mg daily; given daily); all treatment begins at the start of radiotherapy and continues until tumor progression, death or excessive toxicity
3044037|NCT00525525|Other|Safety Lead-in Group|"Fractionated radiotherapy in daily doses of 1.8-2.0 Gy delivered 5 days per week over ~6 weeks, to a total dose of 59.4 to 60 Gy.~Adjuvant temozolomide 200 mg/m^2/d x 5 d per 28-d cycle; Erlotinib 150-200 mg/d (or 500-600 mg/d for patients on enzyme-inducing antiepileptic drugs) on a continuous basis 7 days per week; Bevacizumab 10 mg/kg every 2 weeks"
3044038|NCT00525590|Experimental|1|
3044039|NCT00525603|Experimental|CFAR|CFAR = Cyclophosphamide 200 mg/m^2/day 3-5 intravenous (IV) 5-30 minutes, Fludarabine 20 mg/m^2/day 3-5 IV 5-30 minutes, Alemtuzumab 30 mg 1, 3,5 IV 2-4 hours, and Rituximab 375 mg/m^2/day 2 IV 4-6 hours
3044040|NCT00525629|Experimental|Walnut Diet|48 Grams of Walnuts Daily
3044041|NCT00525629|Placebo Comparator|Control Diet|Isocaloric Diet with No Walnuts
3044042|NCT00525733|Active Comparator|3-drug standard therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg/ +ritonavir 100 mg QD
3044043|NCT00525733|Experimental|5-drug experimental therapy|FTC 200 mg/TDF 300 mg QD + darunavir 800 mg + ritonavir 100 mg QD + Raltegravir 400 mg BID + Maraviroc 150 mg BID
3044044|NCT00525785|Experimental|5-Fluorouracil + Folinic Acid + Oxaliplatin|"PreOp Chemotherapy: 2 cycles (each cycle consisting of 4 weeks or 2 treatments) of chemotherapy with oxaliplatin, folinic acid and infusional 5-FU (FOLFOX-48). Oxaliplatin 100 mg/m^2 over 2 hours on day 1, folinic acid intravenous (IV) at 200 mg/m^2 over 30 minutes on day 1, and 5-FU 2,200 mg/m^2 over 48 hours as continuous infusion by outpatient pump starting on day 1. This therapy, FOLFOX-48 repeated every 2 weeks x 4 (8 weeks of induction chemotherapy).~PreOp Chemoradiotherapy begins 12 days after last dose of PreOp Chemo 5FU plus oxaliplatin; A total of 45 Gy (1.8 Gy fx/d) of radiotherapy concurrent to low-dose continuous infusion of 5-FU (300 mg/m^2/d Monday through Friday) & weekly oxaliplatin 45 mg/m^2 over 2 hours for 5 weeks (oxaliplatin administered on the first day of radiation week).~Surgical resection 4-6 weeks after completion of chemoradiotherapy"
3044045|NCT00525798|Active Comparator|1|SMC021 - Oral Calcitonin
3044046|NCT00525798|Placebo Comparator|SMC021- Placebo|SMC021 - placebo
3044047|NCT00525837|Other|varenicline|open label varenicline
3044048|NCT00525876|Experimental|Matched Sibling Transplant|Allogeneic Stem Cell Transplantation With Rituximab Containing Nonablative Conditioning Regimen: Cyclophosphamide 750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
3044049|NCT00525876|Experimental|Allo MUD & MM|Allo MUD & MM = Allogeneic Stem Cell Transplantation, Matched unrelated donor or mismatched sibling donor transplantations: Cyclophosphamide 1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine 30 mg/m^2 given intravenously on Days -5 and -3 before transplantation. Rituximab 375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation. Alemtuzumab 15 mg per day given intravenously days 1 through 3 after transplantation.
3044050|NCT00525902|Experimental|Adalimumab|
3044051|NCT00525915|Experimental|Arm A: Chemo with Radiation Treatment|For 5 weeks, Chemo of 5-FU 250 mg/m^2 intravenous (IV) over 24 hours for 5 days weekly with Oxaliplatin 40 mg/m^2 IV daily over 2 hours, and Radiation treatment every weekday; then surgery.
3044052|NCT00525915|Experimental|Arm B: Pre-Op Chemo + Chemo with Radiation Treatment|Pre-Operative Chemo 5-FU 2.2 mg/m^2 IV continuous infusion over 48 hours start on day 1 and 15, and Oxaliplatin 100 mg/m^2 IV on day 1 and 15; followed by Surgery + Chemo with Radiation Therapy (same as Arm A)
3044053|NCT00526058|Other|A (Secura then Futura)|The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
3044054|NCT00526058|Other|B (Futura then Secura)|The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.
3044055|NCT00526071|Experimental|Migalastat|Migalastat was administered orally, 150 mg QOD, 250 mg QD for 3 days, 4 days off per week for 2 months, or 500 mg QD for 3 days, 4 days off per week for up to 10 months, depending on the approval date of the protocol amendments at each site. Participants received migalastat for up to 56 months.
3044056|NCT00526097|Experimental|Bisacodyl 5 mg x 2 once daily|patient to receive two enteric-coated tablets containing 5 mg bisacodyl
3044057|NCT00526097|Placebo Comparator|Placebo|patient to receive two placebo-to-match enteric-coated tablets 5 mg bisacodyl
3044058|NCT00526110|Experimental|5-Fluorouracil + Docetaxel + Oxaliplatin|5-Fluorouracil 2.2 Gm/m^2 intravenously (IV) over 48 hours on Day 1. Docetaxel 20 mg/m^2 IV over 60 minutes. Oxaliplatin 85 mg/m^2 IV over 120 minutes on Day 1.
3044059|NCT00526123|Active Comparator|1|symmetric tip catheter
3044060|NCT00526123|Active Comparator|2|conventional split-tip catheter
3044061|NCT00526162|Experimental|Implantation of Consulta CRT-D|Patients have an implant attempt with a Bi-ventricular Implantable Cardioverter Defibrillator
3044062|NCT00526188|Experimental|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
3044063|NCT00526227|Experimental|Secura ICD implant|Secura ICD device implanted
3044064|NCT00526292|Experimental|natural killer (NK) cells with salvage chemotherapy|This is a Phase II study, designed to determine the efficacy of natural killer (NK) cells isolated from HLA-haploidentical related donors when infused following a salvage chemotherapy regimen into patients who have relapsed or persistent leukemia following an allogeneic HLA-compatible HSCT and who are ineligible for a second HSCT.
3044065|NCT00526474|Placebo Comparator|Placebo|1 placebo tablet, orally, daily for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
3044066|NCT00526474|Experimental|Vorapaxar|one 2.5 mg tablet daily, orally, for at least 1 year in addition to current treatment of atherosclerotic disease, which will be continued to be administered as per current standard of care.
3044067|NCT00526591|Experimental|Low-dose Everolimus Cohort|5mg Everolimus daily continuously for 8 weeks and conventional surgery
3044068|NCT00526591|Active Comparator|High-dose Everolimus Cohort|10mg Everolimus daily continuously for 8 weeks and conventional surgery
3044069|NCT00526630|Active Comparator|1. MPD|Randomized to receive active Methylphenidate first. At cross-over, participants will receive placebo.
3044070|NCT00526630|Placebo Comparator|2. Placebo|Randomized to receive placebo first. At cross-over, participants will receive the active Methylphenidate.
3044071|NCT00526656|Experimental|sunitinib malate|Drug
3044072|NCT00526799|Experimental|Phase I|Topotecan 3.5 mg/m^2 + Sorafenib dose escalation:
3044073|NCT00526799|Experimental|Phase II|Topotecan 3.5 mg/m^2 + Sorafenib 400 mg po daily.
3044074|NCT00526890|Experimental|CPSR|Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination with Radiation
3044075|NCT00526994|Experimental|Screened|Screened w/4 questions on intimate partner violence; if positive, receives referral information
3044076|NCT00526994|Active Comparator|Universal education|all participants receive partner violence referral information
3044077|NCT00526994|No Intervention|Control|no screen and no referral
3044078|NCT00527072|Experimental|001|infliximabOpen-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
3044079|NCT00527111|Experimental|Chemoradiotherapy plus Cetuximab|Pelvic irradiation plus 5-fluorouracil plus cetuximab
3044080|NCT00527111|Active Comparator|Chemoradiotherapy alone|Pelvic irradiation plus 5-fluorouracil
3044081|NCT00527124|Experimental|Arm I|Patients receive oral cediranib maleate once daily on days 1-21, docetaxel IV over 1 hour on day 1, and oral prednisone twice daily on days 1-21.
3044082|NCT00527124|Active Comparator|Arm II|Patients receive docetaxel and prednisone as in arm I.
3044083|NCT00527319|No Intervention|Group A, control group|Supportive care only
3044084|NCT00527319|Active Comparator|Group B, Low Dose VT-122|VT-122 (dose of etodolac: 400 mg/day) + supportive care
3044085|NCT00527319|Active Comparator|Group C, High Dose VT-122|VT-122 (dose of etodolac: 800 mg/day) + supportive care
3044086|NCT00527332|Active Comparator|A|Spinal anesthesia combined with intrathecal morphine. Spinal anesthesia applied in intervertebral space L3/L4 or L2/L3 with hyperbaric bupivacaine 20 mg and morphine 0.2 mg intrathecally. Sedation with propofol.
3044087|NCT00527332|Active Comparator|B|General anesthesia. General anesthesia induced with propofol, fentanyl and rocuronium, and maintained with propofol and oxygen in air. Rocuronium and fentanyl repeated when needed.
3044088|NCT00527397|Experimental|B|Type 2 Diabetes Mellitus (DM) who has not yet treated by Insulin
3044089|NCT00527397|Experimental|C|Type 2 DM who has already treated by Insulin
3044090|NCT00527397|Experimental|A|Type 1 DM
3044091|NCT00527423|Experimental|Intravitreal Aflibercept Injection (EYLEA, VEGF Trap-Eye)|
3044092|NCT00527475|Active Comparator|Group I|Group I will receive 0.5 mg. ranibizumab intraocularly initially. This will be repeated monthly for 3 months total and then as needed over the period of one year.
3044093|NCT00527475|Experimental|Group II|Group II will receive Reduced Fluence-PDT (25 Joules) followed by 0.5 mg. of ranibizumab intraocularly on the same day. The second group will receive the combination of ranibizumab and RF-PDT as needed over a period of one year.
3044094|NCT00527488|Experimental|Degarelix 16+16 mg|
3044095|NCT00527488|Experimental|Degarelix 32 mg|
3044096|NCT00527488|Experimental|Degarelix 32+32 mg|
3044097|NCT00527488|Experimental|Degarelix 64 mg|
3044098|NCT00527514|Experimental|1|
3044099|NCT00527566|Experimental|Mepolizumab|Subjects will receive open-label mepolizumab
3044100|NCT00527592|Experimental|Travoprost|Travoprost assigned to one eye, with latanoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
3044101|NCT00527592|Active Comparator|Latanoprost|Latanoprost assigned to one eye, with travoprost assigned to the fellow eye for intra-individual control. One drop, single dose. The eye, and the order in which the first test medicine was instilled (either travoprost or latanoprost), was randomly assigned.
3044102|NCT00527605|Experimental|A|dutasteride 0.5mg once daily orally
3044103|NCT00527605|Placebo Comparator|B|Placebo matched once daily orally
3044104|NCT00527618|Active Comparator|Standard-dose acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
3044105|NCT00527618|Experimental|High-dose valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
3044106|NCT00527644|Other|Spring Clips|Subjects will undergo laparoscopic cholecystectomy with commercially available 5 mm spring clips utilized for the ligation of the cystic duct and artery.
3044107|NCT00527722|Experimental|Pleural Plug|Experimental lung plug after the lung biopsy.
3044108|NCT00527722|Active Comparator|No Pleural Plug|The standard lung biopsy without placement of the plug.
3044109|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (concurrent)|
3044110|NCT00527735|Experimental|Ipilimumab/ placebo + paclitaxel + carboplatin (sequential)|
3044111|NCT00527735|Active Comparator|Ipilimumab placebo + paclitaxel + carboplatin|
3044112|NCT00527787|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
3044113|NCT00527787|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
3044114|NCT00527826|Active Comparator|arm 1|
3044115|NCT00527826|Active Comparator|arm 2|
3044116|NCT00527878|Experimental|Placebo/Ranitidine crossover|Patients took placebo for 12 months and then ranitidine for 12 months
3044117|NCT00527878|Experimental|Ranitidine/placebo crossover|Ranitidine for one year followed by placebo for one year
3044118|NCT00527904|Experimental|PN 400 (VIMOVO)|500 mg delayed release naproxen/20 mg immediate release esomeprazole
3044119|NCT00527943|Placebo Comparator|Placebo|Loading oral dose of one 40 mg vorapaxar placebo tablet on Day 1, then one 2.5 mg vorapaxar placebo tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
3044120|NCT00527943|Experimental|Vorapaxar|Loading oral dose of one 40 mg vorapaxar tablet on Day 1, then one 2.5 mg vorapaxar tablet daily, orally for at least 1 year in addition to current treatment of acute coronary syndrome, which will be continued to be administered as per current stand of care.
3044121|NCT00528021|Active Comparator|1|
3044122|NCT00528021|Active Comparator|2|
3044123|NCT00528021|Active Comparator|3|
3044124|NCT00528021|Placebo Comparator|4|
3044125|NCT00528112|Experimental|LCS12|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 12 microg/24 h in vitro
3044126|NCT00528112|Experimental|LCS16|Intrauterine levonorgestrel contraceptive system (LCS), releasing levonorgestrel (LNG) 16 microg/24 h in vitro
3044127|NCT00528190|Experimental|Itraconazole|Itraconazole 5mg/kg/day for 24 weeks
3044128|NCT00528190|Placebo Comparator|Placebo|Placebo/day for 24 weeks
3044129|NCT00528268|Experimental|Cohort 1|Family history of SMA type I 0-3 months old Confirmation of no more than 3 SMN2 copies
3044130|NCT00528268|Experimental|Cohort 2|Family history of SMA type II 0-6 months old Confirmation of no more than 4 SMN2 copies
3044131|NCT00528372|Experimental|Group 1: Dapagliflozin, 2.5 mg AM|Participants with hemoglobin A1c (HbA1c) ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each morning for up to 102 weeks.
3044132|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each morning for up to 102 weeks.
3044133|NCT00528372|Experimental|Group 1: Dapagliflozin 2.5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 2.5 mg, once each evening for up to 102 weeks.
3044134|NCT00528372|Experimental|Group 1: Dapagliflozin, 5 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each evening for up to 102 weeks.
3044135|NCT00528372|Experimental|Group 1: Dapagliflozin, 10 mg PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 10 mg, once each evening for up to 102 weeks.
3044136|NCT00528372|Experimental|Group 2: Dapagliflozin, 5 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3044137|NCT00528372|Experimental|Group 2: Dapagliflozin, 10 mg AM|Participants with HbA1c ≥10.1% and ≤12% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3044138|NCT00528372|Experimental|Group 1: Dapagliflozin placebo AM & PM|Participants with HbA1c ≥7% and ≤10% at enrollment received dapagliflozin placebo once each morning and evening for up to 102 weeks.
3044139|NCT00528372|Experimental|Group 1: Dapaglifozon, 5 mg AM|Participants with (HbA1c ≥7% and ≤10% at enrollment received dapagliflozin tablets, 5 mg, once each morning for up to 102 weeks.
3044140|NCT00528398|Experimental|Treatment (idarubicin, cytarabine)|Patients receive cytarabine IV over 3 hours every 12 hours on days 1-4 and idarubicin IV over 5-10 minutes on days 1-3. Patients undergo bone marrow aspirate and biopsy 7 days after completion of induction chemotherapy. Patients with > 25% cellular biopsy or > 10% abnormal cells on aspirate receive 4 more doses of cytarabine and 1 dose of idarubicin.
3044141|NCT00528411|Active Comparator|1|Aspirin + Placebo
3044142|NCT00528411|Active Comparator|2|Aspirin + clopidogrel
3044143|NCT00528411|Experimental|3|Aspirin + Ticagrelor
3044144|NCT00528424|Experimental|AA4500 0.58 mg|
3044145|NCT00528450|Experimental|Tretinoin and Arsenic Trioxide With or Without Idarubicin|See Outline for details
3044146|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 750 milligram (mg) orally administered every 8 hours (hr) for 12 weeks, in combination with standard treatment composed of pegylated interferon (Peg-IFN)-alfa-2a solution for subcutaneous injection at the dose of 180 microgram per week (mcg/week) and ribavirin (RBV) oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
3044147|NCT00528528|Experimental|Telaprevir 750 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 750 mg orally administered every 8 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kilogram/week (mcg/kg/week) and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
3044148|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2a/RBV tablet|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2a solution for subcutaneous injection at the dose of 180 mcg/week and RBV oral tablets at the dose of 1000-1200 mg/day up to 48 weeks.
3044149|NCT00528528|Experimental|Telaprevir 1125 mg with Peg-IFN-alfa-2b/RBV capsule|Telaprevir tablets at the dose of 1125 mg orally administered every 12 hr for 12 weeks, in combination with standard treatment composed of Peg-IFN-alfa-2b solution for subcutaneous injection at the dose of 1.5 mcg/kg/week and RBV oral capsules at the dose of 800-1200 mg/day up to 48 weeks.
3044150|NCT00528541|Active Comparator|BOTOX®|botulinum toxin type A (BOTOX®)
3044151|NCT00528541|Active Comparator|Dysport®|botulinum toxin type A (Dysport®)
3044152|NCT00528567|Experimental|Bevacizumab and Chemotherapy|Participants randomized to receive bevacizumab in combination with chemotherapy as prescribed.
3044153|NCT00528567|Active Comparator|Chemotherapy|Participants randomized to receive standard adjuvant chemotherapy as prescribed.
3044154|NCT00528580|Experimental|1|Simvastatin 80 mg once daily PO (or via NG or G-tube)
3044155|NCT00528580|Placebo Comparator|2|Identical-appearing placebo PO (or via NG or G-tube)
3044156|NCT00528606|Experimental|AA4500 0.58 mg|
3044157|NCT00528606|Placebo Comparator|Placebo|
3044158|NCT00528645|Experimental|Treatment (saracatinib)|Patients receive oral AZD0530 once daily for up to 2 years in the absence of disease progression or unacceptable toxicity. Blood samples are obtained at baseline and periodically during study to determine levels of circulating tumor cells for defined translational studies.
3044159|NCT00528788|Experimental|Pre and post doxicalciferol|ESRD: all patients with secondary hyperparathyroidism who are vitamin D naive will receive doxercalciferol 2 mcg or 4 mcg 3 times per week fopr 30 days (1 month). Blood work and vascular laboratory studies will be performed pre and post treatment.
3044160|NCT00528801||Cases (CLOSED)|These are patients diagnosed with sickle cell disease (confirmed by hemoglobin electrophoresis).
3044161|NCT00528801||Controls (CLOSED)|These are persons that do not have sickle cell disease (confirmed by hemoglobin electrophoresis); matched to cases by age, gender, and education level
3044162|NCT00528840|Experimental|AA4500 0.58 mg|
3044163|NCT00528866|Experimental|Androgen suppression + RT + docetaxel|LHRH agonist and oral antiandrogen (flutamide or bicalutamide), radiation therapy (RT), and docetaxel
3044164|NCT00528879|Placebo Comparator|Placebo + Metformin|Participants received dapagliflozin-matching placebo once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3044165|NCT00528879|Experimental|Dapagliflozin, 2.5 mg + Metformin|Participants received dapagliflozin, 2.5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3044166|NCT00528879|Experimental|Dapagliflozin, 5 mg + Metformin|Participants received dapagliflozin, 5 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3044167|NCT00528879|Experimental|Dapagliflozin, 10 mg + Metformin|Participants received dapagliflozin, 10 mg, once daily plus open-label metformin ≥1500 mg per day for up to 102 weeks
3044168|NCT00528931|Experimental|AA4500 0.58 mg|
3044169|NCT00528957|Experimental|Tenofovir DF|
3044170|NCT00528957|Active Comparator|stavudine or zidovudine|
3044171|NCT00528970|Experimental|MOA-728 12 mg|Participants will receive methylnaltrexone (MOA-728) 12 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
3044172|NCT00528970|Experimental|MOA-728 24 mg|Participants will receive MOA-728 24 mg as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
3044173|NCT00528970|Placebo Comparator|Placebo|Participants will receive placebo matching to MOA-728 as an IV infusion over approximately 20 minutes for approximately every 6 hours for a total of 4 doses in 24-hour period. The first dose of study drug will be administered within approximately 90 minutes after completion of the surgical procedure (defined as the time when the last skin suture or staple is placed in the participant). Dose administration will be continued for a maximum of 10 days.
3044174|NCT00528996|Placebo Comparator|Placebo|Matching Placebo
3044175|NCT00528996|Experimental|BEA 2180 BR low dose|Low dose
3044176|NCT00528996|Experimental|BEA 2180 BR medium dose|Medium dose
3044177|NCT00528996|Experimental|BEA 2180 BR high dose|High dose
3044178|NCT00528996|Experimental|Tiotropium Bromide|Tiotropium Bromide
3044179|NCT00529035|Experimental|Interleukin-2|"Interleukin-2 (IL-2) will be given daily through an injection under the skin for a period of 8 weeks. To determine the highest safest dose of IL-2, the dose participants receive will increase as lower doses are determined to be safe. There will be three dose levels:~Dose Level -A 0.3 x 106 (IU/m2/d) Dose Level -B 1 x 106 (IU/m2/d) Dose Level-C 3 x 106 (IU/m2/d)"
3044180|NCT00529087|Placebo Comparator|1|
3044181|NCT00529087|Experimental|2|
3044182|NCT00529087|Experimental|3|
3044183|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 1|Treatment included: radiation as 61-65 Gray (Gy) in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent pemetrexed intravenous (IV) bolus with doses escalating from 300 milligrams per square meter (mg/m^2) IV through 500 mg/m^2 IV on Days 1 and 22; concurrent cisplatin 25 mg/m^2 IV on Days 1-3 and 22-24 for Cohorts 1-3 and cisplatin 20 mg/m^2 IV on Days 1-5 and 22-26 for Cohort 4. Participants then received 2 additional consolidation cycles repeated every 3 weeks (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
3044184|NCT00529100|Experimental|Pemetrexed/Cisplatin/Radiation Phase 2|Treatment included: radiation, 61-65 Gy in 33-35 fractions if 2-phase treatment and 62-66 Gy in 31-33 fractions if 1-phase treatment; concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22 ; concurrent cisplatin 20 mg/m^2 IV as determined by Phase 1 trial with cycles commencing on Days 1 and 22; 2 additional consolidation cycles (q3 weeks) of pemetrexed 500 mg/m^2 IV and cisplatin 75 mg/m^2 IV.
3044185|NCT00529126|Experimental|SKY0402 high dose|SKY0402, single administration
3044186|NCT00529126|Experimental|SKY0402 middle dose|SKY0402, single administration
3044187|NCT00529126|Experimental|SKY0402 low dose|SKY0402, single administration
3044188|NCT00529126|Active Comparator|Bupivacaine HCl|Bupivacaine HCl
3044189|NCT00529152|Other|A|Ferriprox Oral Solution single treatment
3044190|NCT00529191|Experimental|Atorvastatin|Two out of every three patients will receive atorvastatin.
3044191|NCT00529191|Placebo Comparator|Placebo|One out of three subjects will receive a placebo.
3044192|NCT00529204|Experimental|Exenatide|exenatide 5 µg BID s.c. daily for 28 days, followed by 10 µg BID s.c. daily from day 29 to week 24
3044193|NCT00529217|Experimental|Open-Label Active rTMS|Active repetitive Transcranial Magnetic Stimulation (rTMS)
3044194|NCT00529243|Experimental|MK-0518 (raltegravir)|Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
3044195|NCT00529308|Active Comparator|Active|
3044196|NCT00529308|Sham Comparator|Sham|
3044197|NCT00529373|Experimental|Odanacatib|Participants receive 50 mg of blinded odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
3044198|NCT00529373|Placebo Comparator|Placebo|Participants receive blinded placebo to 50 mg of odanacatib weekly over the course of the base study and first extension study (5 years total), followed by 50 mg of open-label odanacatib weekly for 5 years. Participants also receive Vitamin D3 and open-label supplemental calcium so that total daily calcium intake (from both dietary and supplemental sources) is approximately 1200 mg.
3044199|NCT00529386|Experimental|Botox|300 IU botox
3044200|NCT00529399|Experimental|1|3 injections of GAD-Alum vaccine
3044201|NCT00529399|Experimental|2|2 injections of GAD-Alum vaccine and one injection with Aluminum hydroxide alone
3044202|NCT00529399|Placebo Comparator|3|3 injections of Aluminum hydroxide alone
3044203|NCT00529451|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily
3044204|NCT00529451|Experimental|Aliskiren 150 mg|Aliskiren 150 mg once daily
3044205|NCT00529451|Experimental|Aliskiren 75 mg|Aliskiren 75 mg once daily
3044206|NCT00529451|Active Comparator|Ramipril 5 mg|Ramipril 5 mg once daily
3044207|NCT00529516|Experimental|FluAS25 Group|Subjects aged 65 years and above, who had received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in study NCT00377585, received one dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A) in the current study.
3044208|NCT00529516|Active Comparator|Fluarix ≥ 65 years age Group|Subjects aged 65 years and above, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
3044209|NCT00529516|Active Comparator|Fluarix 18-40 years age Group|Subjects aged between 18 and 40 years, who had received one dose of Fluarix™ vaccine in study NCT00377585, received one dose of Fluarix™ vaccine in the current study.
3044210|NCT00529529|Experimental|Indacaterol 300 μg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 300 μg, patients received indacaterol and salmeterol placebo inhalations in the morning and salmeterol placebo inhalation in the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3044211|NCT00529529|Experimental|Indacaterol 600 μg|Patients received indacaterol 600 μg (2 x 300 μg capsules) delivered via single dose dry powder inhalers (SDDPI) once daily (od) in the morning (between 07:00 and 11:00 AM). In addition to indacaterol 600 μg, patients received salmeterol placebo inhalation in the morning and the evening (between 7:00 and 11:00 PM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3044212|NCT00529529|Active Comparator|Salmeterol 50 μg|Patients received salmeterol 50 μg delivered via the salmeterol proprietary dry powder inhalation device bis in die (bid, twice daily), once in the morning (between 07:00 and 11:00 AM) and once in the evening (between 7:00 and 11:00 PM). In addition to salmeterol 50 μg, patients received 2 indacaterol placebo inhalations in the morning. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3044213|NCT00529542|Experimental|Atorvastatin|
3044214|NCT00529542|Placebo Comparator|Placebo|
3044215|NCT00529555|Sham Comparator|Scaling and root planing + SHAM TX|sham treatment
3044216|NCT00529555|Placebo Comparator|Scaling and root planing + Vehicle|Placebo
3044217|NCT00529555|Active Comparator|Scaling & root planing + Periocline Gel|Minocycline HCL 2.1%
3044218|NCT00529568|Experimental|eltrombopag|active treatment arm
3044219|NCT00529568|Placebo Comparator|placebo|placebo control arm
3044220|NCT00529633|Active Comparator|Thalidomide|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive 100mg Thalidomide for a period of 4 weeks; if somnolence tolerated, dosage is increased to 200mg nightly for a period of 20 more weeks -- to total of 24 weeks on Thalidomide."
3044221|NCT00529633|Placebo Comparator|No Drug|"12 End stage renal disease (ESRD) patients on hemodialysis for at least 3 months~Serum C reactive protein level of ≥ 0.8 mg/dl~Serum albumin < 3.8 g/dl (BCG)~Patients will receive Placebo (Sugar pill) for a period of 24 weeks."
3044222|NCT00529659|Experimental|MK-0773|MK-0773
3044223|NCT00529659|Placebo Comparator|Placebo|Placebo
3044225|NCT00529789|Experimental|Duloxetine|
3044226|NCT00529802|Experimental|Everolimus (RAD001) 10mg daily|All patients were to receive 10mg everolimus (RAD001) daily.
3044227|NCT00529958|Active Comparator|Patellar Tendon (PT)|ACL reconstruction using a patellar tendon autograft
3044228|NCT00529958|Active Comparator|Hamstring (HT)|ACL reconstruction using a quadruple-strand semitendinosus/gracilis (hamstring) tendon single-bundle autograft
3044229|NCT00529958|Active Comparator|Double-Bundle (DB)|ACL reconstruction using a semitendinosus/gracilis (hamstring) tendon double-bundle autograft
3044230|NCT00530023|Active Comparator|1. 722|722 arm: MiniMed Paradigm REAL-Time System
3044231|NCT00530023|No Intervention|2. Multiple Daily Injections (MDI)|MDI arm: Continue with currently prescribed Multiple Daily Injection therapy. No change in treatment or regime for study.
3044232|NCT00530075|Experimental|1|Gusperimus
3044233|NCT00530088|Experimental|Porfimer Sodium|Patients receive porfimer sodium subcutaneously followed by photodynamic therapy (PDT) comprising laser light delivered by a single or a diffuser (i.e., for broad areas of dysplasia) fiberoptic lens fiber.
3044234|NCT00530218|Experimental|All Study Participants|Ganciclovir IV 5 mg/kg/bid x 7 days followed by Ganciclovir Oral 1000 mg tid 7 days per week x 5 weeks
3044235|NCT00530257|Placebo Comparator|Placebo|Placebo (sugar pill);Subjects will be equally randomized and will receive one week of treatment with placebo and compared to subjects who were randomized to receive one week of OROS-methylphenidate.
3044236|NCT00530257|Active Comparator|OROS-methylphenidate|Subjects will be equally randomized and will receive one week of treatment with the optimal dose of OROS methylphenidate compared with subjects randomized to receive one week of placebo.
3044237|NCT00530270|Active Comparator|Dexamethasone|
3044238|NCT00530270|Placebo Comparator|Placebo|
3044239|NCT00530335|Experimental|Atomoxetine|
3044240|NCT00530348|Experimental|Alemtuzumab|
3044241|NCT00530348|Active Comparator|Interferon Beta-1a|
3044242|NCT00530439|Experimental|Lifestyle intervention|physical activity, dietetic counselling
3044243|NCT00530439|No Intervention|Control|
3044244|NCT00530504|Experimental|Device|Device
3044245|NCT00530621|Experimental|Pemetrexed + Enzastaurin|
3044246|NCT00530621|Placebo Comparator|Pemetrexed + Placebo|
3044247|NCT00530634|Experimental|Gemcitabine + Cisplatin|Surgical resection followed by (within 60 days) by chemotherapy (Gemcitabine at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle and Cisplatin at 75 mg/m2 IV over 1 hour on day 8 of a 21 day cycle) followed by radiation therapy (treated using linear accelerator with photon beam energy of 6-21 MV) upon completion of 3 cycles of chemotherapy.
3044248|NCT00530712|Experimental|PTA and Stenting with EverFlex device|Qualified subjects undergo treatment of atherosclerotic lesions in the native SFA/SFA/PPA with PTA and stenting using the PROTÉGÉ® EverFlex™ Self-Expanding Stent System
3044249|NCT00530764|Experimental|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
3044250|NCT00530764|Experimental|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
3044251|NCT00530764|Experimental|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
3044252|NCT00530764|No Intervention|Placebo|Range of 1-16 sprays per day of placebo spray.
3044253|NCT00530777|Experimental|1|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
3044254|NCT00530777|Placebo Comparator|2|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
3044255|NCT00530790|Experimental|ropinirole CR-RLS|"Subjects will orally take ropinirole CR-RLS tablet(s) once daily 1-2 hours before the onset of RLS symptoms at about the same time of the day. The time of taking ropinirole must be after 16:00.Adjustment of the Ropinirole CR-RLS tablets should be completed after the Week 1 visit up to the Week 10 visit. The dose will be increased at intervals of at least one week until sufficient efficacy is obtained (use much improved as a guide) without safety problem. Dose escalation will start at the initial dose 0.5 mg/day to 1 mg/day; after 1 mg/day, the dose will be increased by 1 mg/day to the maximum 6 mg/day."
3044256|NCT00530803|Active Comparator|EMLA Cream|Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.
3044257|NCT00530803|Active Comparator|Synera Patch|Participants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.
3044258|NCT00530816|Experimental|Carfilzomib|"Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles.~Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles."
3044259|NCT00530855|Experimental|Lacosamide|Lacosamide tablets for dosing 100 -800 mg/day
3044260|NCT00530894|Experimental|1|Cohort A: Sapien Valve
3044261|NCT00530894|Active Comparator|2|Cohort A: other surgical valve
3044262|NCT00530894|Experimental|3|Cohort B: Sapien Valve
3044263|NCT00530894|Active Comparator|4|Cohort B: Medical therapy
3044264|NCT00530946|Active Comparator|CI-1038 2.5mg/5mg|
3044265|NCT00530946|Active Comparator|CI-1038 2.5mg/10mg|
3044266|NCT00530946|Active Comparator|CI-1038 5mg/5mg|
3044267|NCT00530946|Active Comparator|CI-1038 5mg/10mg|
3044268|NCT00531011|Active Comparator|XIENCE V|Patients randomized to receive the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS)
3044269|NCT00531011|Active Comparator|TAXUS® Liberté™|Patients randomized to receive the TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System
3044270|NCT00531050|Experimental|Part 1: Sequence A, Part 2: Sequence A|"Part 1: Sequence 'A' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus dry powder inhaler (DPI). Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'A' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3132580|NCT03438539|No Intervention|Attentional Control without Normative Feedback|Control training tasks will include completion of basic arithmetic problems for approximately 5 minutes. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
3044271|NCT00531050|Experimental|Part 1 : Sequence B, Part 2: Sequence B|"Part 1: Sequence 'B' consisted of - Period 1, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'B' consisted of - Period 1, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3044272|NCT00531050|Experimental|Part 1: Sequence C, Part 2: Sequence C|"Part 1: Sequence 'C' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received single dose of salmeterol 50μg via Diskus DPI. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'C' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device . In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3044273|NCT00531050|Experimental|Part 1; Sequence D, Part 2: Sequence D|"Part 1: Sequence 'D' consisted of - Period 1, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of salmeterol 50μg via Diskus DPI.~Part 2: Sequence 'D' consisted of - Period 1, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3044274|NCT00531050|Experimental|Part 1: Sequence E, Part 2: Sequence E|"Part 1: Sequence 'E' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device. Period 3, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device.~Part 2: Sequence 'E' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3044275|NCT00531050|Experimental|Part 1: Sequence F, Part 2: Sequence F|"Part 1: Sequence 'F' consisted of - Period 1, patient received single dose of salmeterol 50μg via Diskus DPI. Period 2, patient received single dose of indacaterol matching placebo via the Concept1 inhaler device. Period 3, patient received a single inhaled dose of indacaterol 300μg capsule administered via the Concept1 inhaler device.~Part 2: Sequence 'F' consisted of - Period 1, patients received morning and evening single inhalational dose of salmeterol 50μg via Diskus DPI. Period 2, patients received single inhalation dose of indacaterol matching placebo in morning and evening via Concept1 device. Period 3, patients received a morning single inhalational dose of indacaterol 300μg and an evening single inhalation dose of indacaterol matching placebo via the Concept1 inhaler device. In Part 2 of the study, at 20 minutes following each dose, patients received three doses of nebulized salbutamol 2.5 mg at 20 minute intervals."
3044276|NCT00531206||All participants|
3044277|NCT00531232|Experimental|Clofarabine 55 mg/day|Participants received Clofarabine 55 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
3044278|NCT00531232|Experimental|Clofarabine 35 mg/day|Participants received Clofarabine 35 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
3044279|NCT00531232|Experimental|Clofarabine 25 mg/day|Participants received Clofarabine 25 mg/day orally for 5 consecutive days of each 28-day treatment cycle until disease progression or death, whichever comes first (maximum study duration: up to 4 years).
3044280|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044281|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/27 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 27 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044282|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044283|NCT00531284|Experimental|Phase 2 Solid Tumors: Carfilzomib 20/36 mg/m² Bolus|Participants received carfilzomib 20 mg/m² administered by bolus intravenous infusion over 2-10 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044284|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 36 mg/m²|Participants received carfilzomib 36 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044285|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 45 mg/m²|Participants received carfilzomib 45 mg/m² administered by intravenous infusion over 30 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for at least 2 cycles. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044286|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044287|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044288|NCT00531284|Experimental|Phase 1B Solid Tumors: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044289|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/36 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 36 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044290|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/45 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044291|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044292|NCT00531284|Experimental|Phase 1b Multiple Myeloma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044293|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/56 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044294|NCT00531284|Experimental|Phase 1b Lymphoma: Carfilzomib 20/70 mg/m²|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 70 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044295|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/45 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 45 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044296|NCT00531284|Experimental|Phase 1b MM: Carfilzomib 20/56 mg/m² + Dexamethasone|Participants received carfilzomib 20 mg/m² administered by intravenous infusion over 30 minutes on Cycle 1 Days 1 and 2 only, then 56 mg/m² on Days 8, 9, 15 and 16 and thereafter for the remainder of treatment plus dexamethasone 40 mg weekly. All participants with stable disease or better after 2 cycles could continue treatment until progressive disease or unacceptable toxicity.
3044297|NCT00531427|Experimental|1|Buprenorphine transdermal system 10 and 20 applied for 7-day wear
3044298|NCT00531427|Placebo Comparator|2|Placebo transdermal system to match BTDS patches, applied for 7-day wear
3044299|NCT00531453|Experimental|1|bortezomib, dexamethasone, and thalidomide
3044300|NCT00531453|Experimental|2|bortezomib, dexamethasone, thalidomide, and cyclophosphamide
3044301|NCT00531479|Active Comparator|Voriconazole|Voriconazole monotherapy
3044302|NCT00531479|Experimental|Voriconazole and Anidulafungin|Combination therapy with voriconazole and anidulafungin
3044303|NCT00531518|No Intervention|Control group|This is the control arm. Participants will be offered only case management. Participants may seek outside treatment, without guidance from study staff.
3044304|NCT00531518|Experimental|Family-aided Assertive Community Treatment|This is the experimental intervention arm for high-risk-for-psychosis participants. The intervention includes psychiatric drugs (aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine), psychoeducational multifamily group treatment and supported employment and education .
3044305|NCT00531661|Active Comparator|TREATMENT Group|Standard of care HF management plus HF management based upon hemodynamic information obtained from the HF Pressure Measurement System
3044306|NCT00531661|Placebo Comparator|CONTROL Group|Standard of care HF management
3044307|NCT00531752|Experimental|Flexible Dose|
3044308|NCT00531752|Placebo Comparator|Placebo|
3044309|NCT00531752|Experimental|Fixed Dose|
3044310|NCT00531817|Experimental|Tocilizumab 8 mg/kg + DMARDs|
3044311|NCT00531817|Placebo Comparator|Placebo + DMARDs|
3044312|NCT00531843|Experimental|1A|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with Abbreviated Injury Scale (AIS) >=3). These patients will receive fondaparinux 2.5mg via subcutaneous administration (SubQ) daily.
3044313|NCT00531843|Active Comparator|1B|Patients at high risk for venous thromboembolism (criteria: age>=40, pelvic fracture, lower extremity fracture, shock on presentation, spinal cord injury, head injury with AIS >=3) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure with creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression.
3044314|NCT00531843|Experimental|2A|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors). These patients will receive fondaparinux 2.5mg SubQ daily and mechanical compression.
3044315|NCT00531843|Active Comparator|2B|Patients at very high risk for venous thromboembolism (criteria: major operative procedure, venous injury, ventilator days >3, 2 or more high risk factors) who also have a contraindication to anticoagulant(enoxaparin)administration such as renal failure creatine clearance <30 mL/min, head injury with head AIS >=3), uncontrolled hemorrhage, uncorrected coagulopathy, persistent thrombocytopenia. These patients will receive mechanical compression and possibly temporary inferior vena cava (IVC) filter(as determined by the patient's care givers).
3044316|NCT00531882|Experimental|1-pioglitazone|Pioglitazone
3044317|NCT00531882|Experimental|2-simvasatin|Simvastatin
3044318|NCT00531882|Active Comparator|3-Ibuprofen 1000-1600 mg/day|Ibuprofen 1000-16-- mg/day, maximum 3200 mg/day
3044319|NCT00531934|Experimental|1|
3044320|NCT00531934|Active Comparator|2|
3044321|NCT00531947|Experimental|EMSAM|Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
3044322|NCT00531947|Placebo Comparator|Placebo|Placebo Selegiline Transdermal System 6, 9 or 12
3044323|NCT00531960|Active Comparator|Bevacizumab, Chemotherapy|Participants received bevacizumab, 15 milligrams (mg) per (/) kilogram (kg), intravenously (IV), on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received 4 to 6 cycles of a standard platinum-containing regimen of chemotherapy: either gemcitabine, 1250 mg/ square meter (m^2), IV, on Days 1 and 8 of Cycles 1 through 4 or 6, and cisplatin 80 mg/m^2, IV, on Day 1 of Cycles 1 through 4 or 6; or paclitaxel, 200 mg/m^2, IV, and carboplatin area under the curve (AUC) 6 mg/ milliliter (ml) multiplied by (*) minute (min) on Day 1 of Cycles 1 through 4 or 6. The chemotherapy regimen and number of cycles was up to the discretion of the investigator.
3044324|NCT00531960|Experimental|Bevacizumab, Erlotinib|Participants received bevacizumab, 15 mg/kg, IV, on Day 1 of Cycles 1 through 7 until disease progression, unacceptable toxicity, death, or withdrawal. Participants also received erlotinib, 150 mg, orally (PO), daily until disease progression, unacceptable toxicity, death, or withdrawal.
3044325|NCT00532129|Experimental|Rituximab plus Chlorambucil|Participants will receive combination therapy of rituximab plus chlorambucil for first 6 cycles and then chlorambucil alone for a maximum of 6 additional cycles.
3044326|NCT00532155|Experimental|Placebo/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Placebo immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
3044327|NCT00532155|Placebo Comparator|Aflibercept/Docetaxel|Participants with Non-Small-Cell Lung Cancer (NSCLC) were administered Aflibercept immediately followed by Docetaxel every three weeks until disease progression, unacceptable toxicity, or participant's refusal.
3044328|NCT00532259|Experimental|CT-011|The monoclonal antibody termed CT-011 (currently, pidilizumab).
3044329|NCT00532298|Experimental|GSK576389A- 2006/2007 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 1 container.
3044330|NCT00532298|Experimental|GSK576389A - 2006/2007 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2006/2007 influenza season presented in 2 containers.
3044331|NCT00532298|Active Comparator|Fluarix 2006/2007 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
3044332|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 1 container Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 1 container.
3044333|NCT00532298|Experimental|GSK576389A - 2007/2008 Season - 2 containers Group|Subjects aged ≥ 65 years received adjuvanted influenza vaccine GSK576389A for the Northern Hemisphere 2007/2008 influenza season presented in 2 containers.
3044334|NCT00532298|Active Comparator|Fluarix 2007/2008 Season Group|Subjects aged ≥ 65 years received a single dose of Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
3044335|NCT00532441|Experimental|Erlotinib and Docetaxel: Biliary|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
3044336|NCT00532441|Experimental|Erlotinib and Docetaxel: Hepatocellular|"Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28~Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15"
3044337|NCT00532480|Other|Duolxetine|Open-label duloxetine 30 - 60 mg oral administration
3044338|NCT00532493|Active Comparator|Prazosin Group|Subjects randomized to this arm will be on prazosin.
3044339|NCT00532493|Placebo Comparator|Placebo Group|Subjects randomized to this arm will be on placebo.
3044340|NCT00532779|Experimental|NB16|Naltrexone SR 16 mg/Bupropion SR 360 mg /day with ancillary therapy
3044341|NCT00532779|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg /day with ancillary therapy
3044342|NCT00532779|Placebo Comparator|Placebo|Placebo with ancillary therapy
3044343|NCT00532844|Experimental|Sapropterin dihydrochloride|Sapropterin dihydrochloride 5 mg/kg twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
3132877|NCT03462576|Experimental|Emricasan 5mg|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
3044344|NCT00532844|Experimental|Sapropterin dihydrochloride+Vitamin C|Sapropterin dihydrochloride 5 mg/kg and 500 mg Vitamin C twice a day administered as whole tablets orally within 1 hour after morning and evening meals for 13 days and the last dose within 1 hour after a morning meal on Day 14 and Day 28.
3044345|NCT00532883|Placebo Comparator|Placebo Pills and Placebo Liquid|
3044346|NCT00532883|Active Comparator|Hydroxyurea Pills and Placebo Liquid|
3044347|NCT00532883|Active Comparator|Placebo Pills and Magnesium Pidolate Liquid|
3044348|NCT00532883|Active Comparator|Hydroxyurea Pills and Magnesium Pidolate Liquid|
3044349|NCT00532935|Experimental|1|Sitagliptin phosphate (+) metformin hydrochloride
3044350|NCT00532935|Active Comparator|2|pioglitazone
3044351|NCT00532948|Experimental|1|
3044352|NCT00533117|Experimental|Dialectical Behavior Therapy Fluoxetine|Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy (CBT) targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period,and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3044353|NCT00533117|Placebo Comparator|Dialectical Behavior Therapy placebo|Dialectal behavior therapy and placebo Dialectal behavior therapy (DBT) is a form of Cognitive behavior therapy targeting suicidal and non-suicidal self injury in borderline personality disorder and is delivered over a 12 month period, and placebo for fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3044354|NCT00533117|Experimental|Supportive therapy Fluoxetine|Supportive psychotherapy and fluoxetine Supportive therapy is a manualized psychotherapy aimed at strengthening coping skills and is delivered over a 12 month period, and fluoxetine, an SSRI that is given in standard dosing 20, 40, 60, 80 mg for 12 months.
3044355|NCT00533117|Active Comparator|Supportive therapy placebo|Supportive psychotherapy and placebo See above for descriptions.
3044356|NCT00533273|Experimental|AA4500 0.58 mg|
3044357|NCT00533273|Placebo Comparator|Placebo|
3044358|NCT00533429|Experimental|A|Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin
3044359|NCT00533429|Placebo Comparator|B|Pemetrexed + Carboplatin + Bevacizumab + Placebo
3044360|NCT00533442|Active Comparator|Tacrolimus plus MMF plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Mycophenolate Mofetil (MMF), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
3044361|NCT00533442|Experimental|Tacrolimus plus Rapamycin plus Steroids|Patients randomized to this arm were scheduled to receive maintenance therapy consisting of Tacrolimus, Rapamycin (Sirolimus), and Steroids. Patients in both treatment arms received dual induction therapy consisting of Rabbit Anti-thymocyte Globulin (Thymoglobulin) plus Daclizumab.
3044362|NCT00533507|Experimental|Synflorix group|Subjects receiving Synflorix co-administered with Infanrix™ hexa at 1.5, 3 and 6 months of age, and co-administered with Rotarix™ at 1.5 and 3 months of age.
3044363|NCT00533546|Experimental|Tier One|Participants will receive APC by intravenous injection, receiving 50% of dose as a bolus and the remainder as an infusion over one ho.
3044364|NCT00533702|Experimental|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab)
3044365|NCT00533702|Active Comparator|IMC-1121B (ramucirumab) + dacarbazine|IMC-1121B (ramucirumab) + dacarbazine
3044366|NCT00533845|Experimental|On-Q pain pump|Bupivacaine
3044367|NCT00533845|Placebo Comparator|Placebo/control|Saline
3044368|NCT00533897|Experimental|Abatacept|
3044369|NCT00533897|Placebo Comparator|Placebo|
3044370|NCT00533910|Placebo Comparator|Placebo|Will be given placebo and follow the exact procedures as the experimental section
3044371|NCT00533910|Experimental|Drug|
3044372|NCT00533949|Active Comparator|60 Gy RT|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3044373|NCT00533949|Experimental|74 Gy RT|74 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3044374|NCT00533949|Experimental|60 Gy RT + Cetuximab|60 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
3044375|NCT00533949|Experimental|74 Gy RT + Cetuximab|74 Gy Radiation therapy with concurrent cetuximab, paclitaxel, and carboplatin followed by consolidation cetuximab, paclitaxel, and carboplatin
3044376|NCT00534001|Experimental|Arm I (1-week run-in)|Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
3044377|NCT00534001|Experimental|Arm II (4-week run-in)|Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
3044378|NCT00534105||Gestational Diabetics|Patients with Gestational Diabetes
3044379|NCT00534105||2|Normal pregnant women without gestational diabetes
3044380|NCT00534118|Experimental|Infusion|Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
3044381|NCT00534209|Experimental|Arm I: Allogeneic B7.1/HLA-A1|"Patients will receive Allogeneic B7.1/HLA-A1 vaccine once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.~Given intradermally."
3044382|NCT00534209|Placebo Comparator|Arm II: Placebo|Patients receive a placebo vaccine intradermally once every other week for 2 courses over 12 weeks, for a maximum of 6 vaccines.
3044383|NCT00534235|Active Comparator|Posterolateral Fusion w/Pedicle Screws|Control: Posterolateral fusion and implantation of pedicle screws after decompression
3044384|NCT00534235|Active Comparator|coflex Interlaminar Technolgy|Investigative: Implantation of coflex Interlaminar Technology after decompression
3044385|NCT00534248|Experimental|Zostavax™|Participants randomized to receive Zoster Vaccine, Live (Zostavax™).
3044386|NCT00534248|Placebo Comparator|Placebo|Participants randomized to receive Placebo.
3132878|NCT03462576|Placebo Comparator|Placebo|The study treatment duration will be at least 48 weeks with study visits every 4 weeks up to Week 48 and every 8 weeks after Week 48.
3132879|NCT03462680|Active Comparator|niacin|Niacin 250 mg is compared to placebo tablet.
3044387|NCT00534313|Active Comparator|Abatacept (30/10)|Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg) thereafter.
3044388|NCT00534313|Active Comparator|Abatacept (10/10)|Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing <60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing >100 kg received 1000 mg).
3044389|NCT00534313|Active Comparator|Abatacept (3/3)|Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
3044390|NCT00534313|Placebo Comparator|Placebo|Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
3044391|NCT00534352|Experimental|001|TMC125; darunavir; ritonavirTMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
3044392|NCT00534365|Active Comparator|1|Tension-free vaginal tape procedure (TVT)
3044393|NCT00534365|Active Comparator|2|TVT-SECUR device
3044394|NCT00534404|Experimental|NRT Patch, Phone Counseling, Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches, contingent upon participation in proactive telephone counseling. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
3044395|NCT00534404|Active Comparator|Nicotine Patches and Internet|As adjuncts to internet-assisted tobacco treatment (iQuit Smoking website), research participants in this arm will have access to free 8-week supply of nicotine patches. Patch therapy will begin with the 21 mg patch for 4 weeks, followed by 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks.
3044396|NCT00534404|Placebo Comparator|Internet|Research participants in this arm will have free access to internet-assisted tobacco treatment (iQuit Smoking website).
3044397|NCT00534417|Experimental|Capecitabine and fulvestrant|"Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 kg.~Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days."
3044398|NCT00534495|Experimental|Group 1|Loading dose of rilonacept (4.4mg/kg) at Week 0, followed by rilonacept 2.2 mg/kg/week for the remainder of the study
3044399|NCT00534495|Placebo Comparator|Group 2|Placebo for 4 weeks, followed by rilonacept loading dose (4.4mg/kg), followed by rilonacept 2.2 mg/kg/week for the remainder of the study
3044400|NCT00534599|Other|1|Adjunctive Placebo Seroquel XR to anxiety treatment
3044401|NCT00534599|Experimental|2|Adjunctive Seroquel XR to anxiety treatment
3044402|NCT00534638|Experimental|Cervarix/Engerix-B A Group|The A group includes subjects from communities where 70% of male and female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate study participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated subjects were randomized to Cervarix). Finally, subjects from A group were either vaccinated with Cervarix, Engerix-B (control vaccine), or not vaccinated (enrolled control without vaccination). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3044403|NCT00534638|Experimental|Cervarix/Engerix-B B Group|The B group includes subjects from communities where 70% of female adolescents were to be vaccinated with Cervarix vaccine. To achieve a Cervarix vaccination coverage of 70%, a 9:1 ratio was used to allocate female participants to receive Cervarix vaccine versus control Engerix-B vaccine (meaning 90% of vaccinated females were randomized to Cervarix). In this group, all male adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from B group were either vaccinated with Cervarix (females) or Engerix-B/not vaccinated (males and females). Vaccines were administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3044404|NCT00534638|Active Comparator|Engerix-B Group|In this control group, all adolescents were to be vaccinated with Engerix-B control vaccine. Finally, subjects from this group were either vaccinated with Engerix-B or not vaccinated. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3044405|NCT00534703|Active Comparator|AAV1/SERCA2A|SERCA gene therapy
3044406|NCT00534703|Placebo Comparator|Placebo|Placebo (saline solution)
3044407|NCT00534794|Experimental|Elestat|
3044408|NCT00534794|Active Comparator|Pataday|
3044409|NCT00534833|Experimental|Group 1|DTaP-Hep B-PRP-T + OPV vaccine group
3044410|NCT00534833|Active Comparator|Group 2|Tritanrix-HepB/Hib™ + OPV vaccine group
3044411|NCT00534937|Active Comparator|Standard compression|Patients in this arm will receive current standard of care (once-weekly short-stretch compression wrapping).
3044412|NCT00534937|Experimental|Flexitouch|Patients in this arm will receive once-a-week short stretch compression wrapping AND once-daily Flexitouch pump application (including Flexitouch application once-a-week in the clinic setting).
3044413|NCT00534976|Experimental|Montelukast Sodium|"Participants 4-5 years: A single dose of 4 mg Montelukast chewable tablet daily, crossing over to matching placebo (Pbo) after a 3- to 7-day washout period (no participants 4-5 years were enrolled)~Participants 6-14 years: A single dose of 5 mg Montelukast chewable tablet daily, crossing over to matching Pbo after a 3- to 7-day washout period"
3132880|NCT03462680|Placebo Comparator|placebo|placebo
3178913|NCT00666991|Experimental|Nanotax, 82.5 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 82.5 mg/m2 once every 28 days until progression or unacceptable toxicity
3044414|NCT00534976|Experimental|Placebo|"Participants 4-5 years: A single dose of 4 mg Pbo chewable tablet daily, crossing over to Montelukast 4 mg chewable tablet after a 3- to 7-day washout period (no participants 4-5 years of age were enrolled)~Participants 6-14 years: A single dose of 5 mg Pbo chewable tablet daily, crossing over to Montelukast 5 mg chewable tablet after a 3- to 7-day washout period"
3044415|NCT00535002|Other|Cocaine Females, Yohimbine then Placebo|Cocaine dependent females, received yohimbine day 1 and placebo day 2
3044416|NCT00535002|Other|Cocaine Females, Placebo the Yohimbine|Cocaine dependent females, received placebo day 1 and yohimbine day 2
3044417|NCT00535002|Other|Cocaine Males, Yohimbine then Placebo|Cocaine dependent males, received yohimbine day 1 and placebo day 2
3044418|NCT00535002|Other|Cocaine Males, Placebo thenYohimbine|Cocaine dependent males, received placebo day 1 and yohimbine day 2
3044419|NCT00535002|Other|Control Females, Yohimbine then Placebo|Non-dependent females, received yohimbine day 1 and placebo day 2
3044420|NCT00535002|Other|Control Females, Placebo then Yohimbine|Non-dependent females, received placebo day 1 and yohimbine day 2
3044421|NCT00535002|Other|Control Males, Yohimbine then Placebo|Non-dependent males, received yohimbine day 1 and placebo day 2
3044422|NCT00535002|Other|Control Males, Placebo then Yohimbine|Non-dependent males, received placebo day 1 and yohimbine day 2
3044423|NCT00535132|Experimental|002|Oral Risperidone 4 or 6 mg MG once daily for 0-2 weeks
3044424|NCT00535132|Experimental|001|Paliperidone ER 6, 9 or 12 MG once daily for 4-6 weeks
3044425|NCT00535145|Experimental|001|Treatment as usual (TAU), Paliperidone ERTreatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
3044426|NCT00535223|Experimental|Group Based Exposure Therapy|"Behavioral:~GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking."
3044427|NCT00535223|Experimental|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus. This lasted for 16 weeks."
3044428|NCT00535236|Experimental|Autologous HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044429|NCT00535236|Placebo Comparator|Autologous HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044430|NCT00535236|Experimental|Allogeneic HCT-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044431|NCT00535236|Placebo Comparator|Allogeneic HCT-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044432|NCT00535236|Experimental|STM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044433|NCT00535236|Placebo Comparator|STM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044434|NCT00535236|Experimental|HM-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044435|NCT00535236|Placebo Comparator|HM-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044436|NCT00535236|Experimental|HIV-V212|Participants receive V212 as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044437|NCT00535236|Placebo Comparator|HIV-Placebo|Participants receive placebo as a 0.65 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3044438|NCT00535288|Placebo Comparator|Placebo|Participants receive encapsulated tablets, orally, once daily (QD) for up to 12 weeks.
3044439|NCT00535288|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine, 2.25 mg, encapsulated tablets, orally QD for up to 12 weeks.
3044440|NCT00535288|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine, 4.5 mg, encapsulated tablets, orally QD for up to 12 weeks.
3044441|NCT00535288|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine, 9 mg, encapsulated tablets, orally QD for up to 12 weeks.
3044442|NCT00535288|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine, 18 mg, encapsulated tablets, orally QD for up to 12 weeks.
3044443|NCT00535301|Placebo Comparator|Anterior Colporrhaphy (sutured repair)|Anterior vaginal prolapse repair with anterior colporrhaphy (no graft) using sutures.
3044444|NCT00535301|Active Comparator|Perigee (grafted repair)|Anterior vaginal prolapse repair with graft
3044445|NCT00535392|Experimental|Levetiracetam|
3044446|NCT00535405|Experimental|1|Each patient will receive 1 active treatment dose & 2 Placebo (Pbo) doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3044447|NCT00535405|Experimental|2|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3044448|NCT00535405|Experimental|3|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3044449|NCT00535405|Experimental|4|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3044450|NCT00535405|Experimental|5|Each patient will receive 1 active treatment dose & 2 Pbo doses or 2 active treatment doses & 1 Pbo dose at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 12 weeks.
3044451|NCT00535496|Experimental|1|sugammadex 1.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
3044452|NCT00535496|Experimental|2|sugammadex 1.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
3044453|NCT00535496|Experimental|3|sugammadex 4.0 mg/kg, TOF-Watch® SX (dominant forearm) and PNS (non-dominant forearm)
3044454|NCT00535496|Experimental|4|sugammadex 4.0 mg/kg, TOF-Watch® SX (non-dominant forearm) and PNS (dominant forearm)
3044455|NCT00535587|Experimental|1|
3044456|NCT00535587|Experimental|2|
3044457|NCT00535587|Experimental|3|
3044458|NCT00535587|Experimental|4|
3044459|NCT00535613|Experimental|1|propofol
3044460|NCT00535613|Sham Comparator|2|no propofol
3044461|NCT00535626|Other|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell used in revision total hip replacement
3044462|NCT00535652|Experimental|Ertapenem|Administration of 1 gram ertapenem I.V.
3044463|NCT00535730|Placebo Comparator|1|Placebo Comparator
3044464|NCT00535730|Experimental|2|vaccine
3044465|NCT00535743|Placebo Comparator|Arm A. Placebo; 3 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes (min) after the bolus intubation dose of 1 mg/kg Esmeron®.
3044466|NCT00535743|Experimental|Arm B. 2 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044467|NCT00535743|Experimental|Arm C. 4 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044468|NCT00535743|Experimental|Arm D. 8 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044469|NCT00535743|Experimental|Arm E. 12 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044470|NCT00535743|Experimental|Arm F. 16 mg/kg sugammadex; 3 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044471|NCT00535743|Placebo Comparator|Arm G. Placebo; 15 min after 1 mg/kg Esmeron®|Placebo (single intravenous (IV) bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044472|NCT00535743|Experimental|Arm H. 2 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044473|NCT00535743|Experimental|Arm I. 4 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044474|NCT00535743|Experimental|Arm J. 8 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044475|NCT00535743|Experimental|Arm K. 12 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044476|NCT00535743|Experimental|Arm L. 16 mg/kg sugammadex; 15 min after 1 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1 mg/kg Esmeron®.
3044477|NCT00535743|Placebo Comparator|Arm M. Placebo; 3 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044478|NCT00535743|Experimental|Arm N. 2 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044479|NCT00535743|Experimental|Arm O. 4 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044480|NCT00535743|Experimental|Arm P. 8 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044481|NCT00535743|Experimental|Arm Q. 12 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044482|NCT00535743|Experimental|Arm R. 16 mg/kg sugammadex; 3 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 3 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044483|NCT00535743|Placebo Comparator|Arm S. Placebo; 15 min after 1.2 mg/kg Esmeron®|Placebo (single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044484|NCT00535743|Experimental|Arm T. 2 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044485|NCT00535743|Experimental|Arm U. 4 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044486|NCT00535743|Experimental|Arm V. 8 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044487|NCT00535743|Experimental|Arm W. 12 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (12 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3044488|NCT00535743|Experimental|Arm X. 16 mg/kg sugammadex; 15 min after 1.2 mg/kg Esmeron®|Sugammadex (16 mg/kg; single IV bolus) administered 15 min after the bolus intubation dose of 1.2 mg/kg Esmeron®.
3178914|NCT00666991|Experimental|Nanotax, 125 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 125 mg/m2 once every 28 days until progression or unacceptable toxicity
3044489|NCT00535769|Placebo Comparator|Electronic monitor + no text message|The control or placebo comparator group of subjects will receive the study sunscreen with the attached electronic monitor. They will be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If the subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
3044490|NCT00535769|Experimental|Electronic monitor + Text message|The text message experimental group of subjects will receive the study sunscreen with the attached electronic monitor. In addition, this group will receive daily text messages on their cellular phone to remind them to apply the sunscreen. The text message will also contain the daily weather information. This group will also be instructed to apply sunscreen once a day in the morning to the sun-exposed areas of the body. If subjects are to have continuous sun exposure (for example, at a beach), they are to re-apply the sunscreen every 3 hours.
3044491|NCT00535782|Experimental|TCZ + MTX|Participants received 8 mg/kg tocilizumab (TCZ) by intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to Week 104, participants received open-label TCZ 8 mg/kg every 4 weeks plus 7.5-25 mg MTX weekly.
3044492|NCT00535782|Placebo Comparator|Placebo + MTX|Participants received placebo intravenous infusion (IV) every 4 weeks plus methotrexate (MTX) 7.5-25 mg (oral or parenteral) weekly for the first 24 weeks. From Week 24 to 104, participants received open-label tocilizumab (TCZ) 8 mg/kg every 4 weeks plus 7.5-25 mg MTX.
3044493|NCT00535821|Experimental|MiCHO|A 6-hour resuscitation protocol utilizing the esophageal Doppler monitoring (EDM)
3044494|NCT00535821|Active Comparator|EGDT|A 6-hour resuscitation protocol utilizing CVP/ScvO2
3044495|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 24 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 24 weeks.
3044496|NCT00535847|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a,RBV 48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks.
3044497|NCT00535847|Experimental|Other|"Subjects received telaprevir 750 mg tablet thrice daily in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects <75 kg and 1200 mg/day for subjects weighing >=75 kg, discontinued treatment before Week 12 in this study (VX06-950-107 [NCT00535847]) and had a partial response, viral breakthrough, or relapse in the parent study (VX05-950-104 [NCT00336479], VX05-950-104EU [NCT00372385] or VX06-950-106 [NCT00420784]) were included in Other reporting group."
3044498|NCT00535873|Experimental|Lenalidomide|Lenalidomide starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
3044499|NCT00535925|Active Comparator|Standard of Care (SoC) therapy|Control group patients will continue their SoC therapy. During the study such patients could receive all the therapeutic modifications according to the good medical practice of the specialist.
3044500|NCT00535925|Experimental|Multifactorial Intensified therapy|"An intensive multifactorial intervention according Scientific Guidelines is performed to achieve the goals for the following risk factors: hypertension, hyperglycaemia, lipids, anaemia.~In particular, new antihypertensive drugs will be added one by one until the achievement of blood pressure target (<130/80 mmHg)."
3044501|NCT00535938||Naïve to Botox® treatment|Initiating treatment with BOTOX® upon entry to the project.
3044502|NCT00535938||Non-naïve to Botox® treatment|Receiving ongoing treatment with BOTOX® upon entry to the project.
3044503|NCT00536107|Active Comparator|Docetaxel|docetaxel
3044504|NCT00536107|Experimental|Gefitinib|Gefitinib (IRESSA)
3044505|NCT00536120|Experimental|Tysabri Plus Vaccinations|Participants receive 9 monthly doses of Tysabri 300 mg intravenous (IV), and receive vaccinations with neoantigen and recall antigen (keyhole limpet hemocyanin [KLH] and tetanus diphtheria toxoid [Td], according to manufacturer's prescribing information) at Month 6 (following the 7th dose of Tysabri) for both KLH and Td, and 14 and 28 days later for KLH.
3044506|NCT00536120|Other|Vaccinations Only|Participants receive only vaccinations with neoantigen and recall antigen (KLH and Td, according to manufacturer's prescribing information) at Month 0 for both KLH and Td, and 14 and 28 days later for KLH. They do not receive any treatment for their MS and remain in the study through Month 2.
3044507|NCT00536172|Experimental|Escitalopram|Participants will receive treatment with escitalopram
3044508|NCT00536172|Placebo Comparator|Placebo|Participants will receive treatment with placebo
3044509|NCT00536198|Experimental|Sertraline|Participants will take sertraline that is dosed between 50 and 100 mgs during the symptomatic period. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
3044510|NCT00536198|Placebo Comparator|Placebo|Participants will take similar looking placebo during the symptomatic period.
3044511|NCT00536263|Active Comparator|PEG 1.0 mcg/kg weekly (QW) * 24 weeks|PegIntron 1.0 mcg/kg weekly (QW) * 24 weeks + 24 weeks follow-up
3044512|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 24 wks|PegIntron 1.5 mcg/kg QW * 24 wks + 24 wks follow-up
3044513|NCT00536263|Experimental|PEG 1.5 mcg/kg QW * 48 wks|PegIntron 1.5 mcg/kg QW * 48 wks + 24 wks follow-up
3044514|NCT00536341|Experimental|lenalidomide, fludarabine, rituximab|"Phase I Non-stratified, dose-escalation: >=3 patients per dose level. Safety and tolerability will be evaluated every 2 weeks during the active treatment. Doses of lenalidomide will be escalated, while the fludarabine and rituximab doses remain fixed.~Phase II The Phase II regimen will be chosen following a review of the Phase I data. Following selection of the Phase II schedule, 40 treatment naive patients will be enrolled and treated with the Phase II regimen every 28 days for up to 6 courses. For those patients achieving a CR after 3 cycles, one additional cycle of treatment will be administered beyond CR confirmation."
3044515|NCT00536380|Experimental|5-mg Desloratadine|5-mg Desloratadine once daily
3044516|NCT00536380|Experimental|10-mg Desloratadine|10-mg Desloratadine once daily
3044517|NCT00536380|Experimental|20-mg Desloratadine|20-mg Desloratadine once daily
3044518|NCT00536471|Experimental|A|duloxetine 60 milligrams (mg) every day (QD), by mouth (PO) for 3 months, after which may be increased to duloxetine 120 mg QD, PO for 6 months
3044519|NCT00536471|Placebo Comparator|B|placebo every day (QD), by mouth (PO) for up to 9 months, may be increased to duloxetine 60 mg QD, PO during the first 3 months
3044520|NCT00536484|Experimental|Fesoterodine (Double-Blind)|
3044521|NCT00536484|Placebo Comparator|Placebo (Double-Blind)|
3044522|NCT00536510|Experimental|1|laropiprant/niacin (MK0524A)
3044523|NCT00536510|Placebo Comparator|2|placebo
3044524|NCT00536575|Experimental|Intervention|The trial was designed as a single-arm Phase I/II study of sorafenib and bortezomib with dose optimization in initial patients. Phase I consisted of cohorts of 3 patients at each of three dose levels. Patients received bortezomib (Dose Level 1 - 1.3 mg/m2; Dose Level 2 - 1.6 mg/m2) by IV bolus on days 1, 8, 15, and 22 of each 5-week cycle with continuous oral dosing of sorafenib at 200 mg twice daily. Dose level 3 was planned as bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 with sorafenib 400 mg by mouth twice daily throughout each 5-week cycle.
3044525|NCT00536601|Experimental|Regimen CBV (patients with HL or NHL)|Patients receive etoposide intravenously (IV) continuously over 34 hours on day -8, cyclophosphamide IV over 2 hours on days -7 to -4, and carmustine IV over 2 hours on day -3. Patients undergo ASCT on day 0.
3044526|NCT00536601|Experimental|Regimen M200/M120 (patients with MM or amyloidosis)|Patients receive 200 or 120 mg/m^2 of melphalan IV over 30 minutes on day -2. Patients undergo ASCT on day 0.
3044527|NCT00536601|Experimental|Regimen BuC2iv (patients with ALL, AML, HL, or NHL)|Patients receive busulfan IV over 2 hours then every 6 hours on days -7 to -4 for 16 total doses and cyclophosphamide IV over 2 hours on days -3 and -2. Patients undergo ASCT on day 0.
3044528|NCT00536601|Experimental|Regimen CT6 (patients with ALL)|Patients receive cyclophosphamide IV over 2 hours on days -5 to -4. Patients then undergo TBI twice daily on days -3 to -1. Patients undergo ASCT on day 0.
3044529|NCT00536601|Experimental|Regimen CTtCp (patients with other solid tumors)|Patients receive cyclophosphamide IV continuously, carboplatin IV continuously, and thiotepa IV continuously over 24 hours on days -7 to -4. Patients undergo ASCT on day 0.
3044530|NCT00536601|Experimental|Regimen VCp (patients with testicular cancer)|Patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive etoposide IV over 2-3 hours and carboplatin IV over 30 minutes on days -6 to -4. Patients then undergo a second ASCT on day 0.
3044531|NCT00536601|Experimental|Regimen TtC1500/ECpM (patients with NBL or SRBCT)|Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 2 hours on days -5 to -2. Patients undergo ASCT on day 0. At least 4 weeks after the first transplant, patients receive carboplatin IV continuously over 24 hours on days -7 to -4, etoposide IV continuously over 24 hours on days -7 to -4, and melphalan IV over 30 minutes on days -7 to -5. Patients undergo a second ASCT on day 0.
3044532|NCT00536731|Active Comparator|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
3044533|NCT00536731|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
3044534|NCT00536731|Active Comparator|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
3044535|NCT00536744|Active Comparator|Active PACE application - 4 applications|Application of acoustical pulse energy (extracorporeal shockwaves) to target ulcer + standard of care
3044536|NCT00536744|Sham Comparator|Inactive, non-energy application|Non-energized (inactive - Sham)) application + standard of care
3044537|NCT00536809|Experimental|Phase I|Dose escalation of lapatinib along with capecitabine and oxaliplatin until the maximum tolerated dose is reached.
3044538|NCT00536809|Experimental|Phase II|Treatinng subjects at the maximum tolerated dose of lapatinib, capecitabine, and oxaliplatin
3044539|NCT00536874|Experimental|Gemcitabine And Oxaliplatin|A Phase II Study of Neoadjuvant Gemcitabine And Oxaliplatin In Patients With Potentially Resectable Previously Untreated Pancreatic Adenocarcinoma
3044540|NCT00536913|Experimental|With Spacer|Budesonide/formoterol pMDI 40/2.25ug + spacer
3044541|NCT00536913|Experimental|Without Spacer|Budesonide/formoterol pMDI 40/2.25 ug
3044542|NCT00536939|Experimental|Enzastaurin + Bevacizumab + Paclitaxel|"Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A)."
3044543|NCT00536939|Placebo Comparator|Bevacizumab + Paclitaxel + Placebo|Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.
3044544|NCT00536991|Experimental|Treatment (calcitriol, ketoconazole, hydrocortisone)|"PHASE I: Patients receive calcitriol PO QD on days 1-3, 8-10, 15-17, and 22-24. Patients also receive ketoconazole PO TID on days 1-24 and therapeutic hydrocortisone PO BID on days -1 to 24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive calcitriol and therapeutic hydrocortisone as in phase I. Patients also receive ketoconazole PO TID on days 4-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3044545|NCT00537017|Experimental|Preladenant 5 mg BID|Preladenant 5 mg twice daily (BID) given open-label for 36 weeks to participants with moderate to severe Parkinson's Disease who are on a long-term and stable L-dopa treatment regimen.
3044546|NCT00537030|Experimental|Treatment (chemotherapy)|Patients receive 6 doses of Erwinia asparaginase IM on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase remaining on the original treatment protocol. All other chemotherapy continues according to the original treatment protocol.
3044547|NCT00537056|Experimental|F-18 FDG PET/CT and DCE MRI|FDG PET CT F-18 Fluoro-deoxi-glucose: 15 mCi iv Gadolinium-DTPA: 0.1 mmol/kg Sunitinib: 50 mg/day po
3044548|NCT00537082|Experimental|FTY720 0.5 mg|FTY720
3044549|NCT00537082|Experimental|FTY720 1.25 mg|FTY720
3044550|NCT00537082|Placebo Comparator|Placebo|
3044551|NCT00537095|Experimental|vandetanib (ZD6474)|vandetanib (ZD6474) 300 mg per os once daily
3044552|NCT00537095|Placebo Comparator|Placebo|Placebo
3044553|NCT00537238|Active Comparator|B|
3044554|NCT00537238|Active Comparator|A|
3044555|NCT00537277|Experimental|BIAsp 30|Biphasic insulin aspart 30 administered once daily for 16 weeks. If HbA1c is higher than 7.0 % after 16 weeks of treatment, dose is increased to twice daily for another 16 weeks. If HbA1c is higher than 7.0 % after 32 weeks of treatment, dose is increased to three times daily until week 48 (end of trial).
3044556|NCT00537290|Experimental|Rituximab|All patients will receive 1000 milligrams of rituximab by intravenous infusion on Days 1 and 15.
3044557|NCT00537303|Experimental|Advanced|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the meals with the largest prandial increments and individually adjusted insulin aspart based mainly on postmeal SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
3044558|NCT00537303|Active Comparator|Basic|Insulin detemir once daily + oral anti-diabetic drugs (OADs) with addition of meal-time insulin aspart stepwise (1-2-3) at the largest meals and individually adjusted insulin aspart based mainly on pre-meal and bedtime SMPG (self monitored plasma glucose). The stepwise addition occurred if the treatment target of HbA1c below 7.0% was not reached after 12, 24 and 36 weeks, respectively.
3044559|NCT00537316|Experimental|Infliximab (IFX)|Part 1: IFX 5 mg/kg of body weight intravenous (IV) infusions was to be administered at Weeks 0, 2, and 6 and placebo to AZA was to be taken orally every day for 16 weeks. Responders to IFX at Week 8, were to receive one more IFX infusion at Week 14; non-responders to IFX were to receive placebo IFX infusions at Weeks 8 and 10 and an additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
3044560|NCT00537316|Active Comparator|Azathioprine (AZA)|AZA 2.5 mg/kg of body weight orally every day for 16 weeks. Responders to AZA monotherapy at Week 8 were to continue on AZA therapy and receive one placebo infusion at Week 14; non-responders to AZA at Week 8 would be eligible to receive an IFX infusion at Weeks 8, 10, and 14. Participants in steroid-free remission at Week 16 were to continue on AZA monotherapy and were to be followed up for safety in Part 2. Participants who experienced a relapse of disease after Week 16 were to continue daily AZA monotherapy and receive 3 infusions of IFX (induction therapy at Weeks 0, 2, and 6) followed by infusions every 8 weeks (maintenance therapy).
3044561|NCT00537316|Experimental|IFX/AZA|IFX 5 mg/kg of body weight IV infusions at Weeks 0, 2, and 6 plus AZA 2.5 mg/kg orally every day for 16 weeks. Responders to IFX/AZA at Week 8 were to receive one more IFX infusion at Week 14; non-responders to IFX/AZA were to receive placebo infusions at Weeks 8 and 10 and one additional IFX infusion at Week 14. Part 2: Participants in steroid-free remission at Week 16 of Part 1 were to be randomized to either maintenance (every 8 weeks [q8w]) or intermittent (upon relapse) open-label IFX (last IFX infusion administered at Week 86) plus double-blind oral AZA/placebo treatment as allocated in Part 1 (last dose at the final visit, Week 94). Responders at Week 16 who had not achieved steroid-free remission were to continue to receive IFX infusions every 8 weeks.
3044562|NCT00537316|Experimental|Maintenance IFX/AZA (during Part 2)|Participants randomized to maintenance IFX/AZA in Part 2 of the study were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) plus AZA 2.5 mg/kg of body weight daily. Four participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3044563|NCT00537316|Experimental|Maintenance IFX (during Part 2)|Participants randomized to maintenance IFX were to receive IFX 5 mg/kg of body weight IV infusions every 8 weeks (beginning at Week 22, Week 6 for direct entry) in Part 2 of the study. Placebo to AZA therapy was to continue as allocated in Part 1 of the study. All participants were from Part 1 of the study.
3044564|NCT00537316|Experimental|Intermittent IFX/AZA (during Part 2)|Participants randomized to intermittent IFX/AZA were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained) plus AZA 2.5 mg/kg of body weight daily in Part 2 of the study. Three participants were from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3044565|NCT00537316|Experimental|Intermittent IFX (during Part 2)|Participants randomized to intermittent IFX were to receive IFX 5 mg/kg of body weight IV infusions only upon relapse of disease (initiated at Weeks 0, 2, and 6 of individual treatment cycle and continued every 8 weeks until remission was regained). Placebo to AZA therapy was to continue as allocated in Part 1 of the study. One participant was from Part 1 of the study and 1 participant was enrolled directly into Part 2 of the study.
3044566|NCT00537329|Other|Open|This is an open-label, multi-center, non-comparative 12 week study evaluating the efficacy and safety of anidulafungin in subjects with candidemia.
3044567|NCT00537381|Active Comparator|Docetaxel + Prednisone + Placebo|Matching placebo as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 milligram per square meter (mg/m^2) as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
3044568|NCT00537381|Experimental|Docetaxel + Prednisone + Intetumumab|Intetumumab 10 mg per kilogram (mg/kg) as intravenous infusion every week for initial 6 weeks, then every 3 weeks; along with docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks and prednisone 5 mg orally twice daily were administered till 6 months or disease progression.
3044569|NCT00537394|Experimental|A|Regimen with higher predicted activity assigned by the study plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3044570|NCT00537394|Experimental|B|Regimen with higher predicted activity assigned by the study without NRTIs for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3044571|NCT00537394|Other|C|Regimen with lower predicted activity assigned plus at least 2 NRTIs (personalized choice from expert recommendation) for 96 weeks. A 3-4 drug regimen was selected from the drugs listed to the right.
3178915|NCT00666991|Experimental|Nanotax, 175 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 175 mg/m2 once every 28 days until progression or unacceptable toxicity
3044572|NCT00537407|Experimental|Treatment Arm A|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg subcutaneously (sc) once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3044573|NCT00537407|Experimental|Treatment Arm B|Debio 025 (alisporivir) 400 mg orally once daily for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3044574|NCT00537407|Experimental|Treatment Arm C|Debio 025 (alisporivir) 400 mg orally once daily + peg-IFNα2a 180 μg sc once weekly for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3044575|NCT00537407|Experimental|Treatment Arm D|Debio 025 (alisporivir) 800 mg orally once daily + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3044576|NCT00537407|Experimental|Treatment Arm E|Debio 025 (alisporivir) orally at a loading dose of 400 mg twice daily for 7 days followed by 400 mg/day for 22 days + peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally for 29 days followed by peg-IFNα2a 180 μg sc once weekly + ribavirin 1000 or 1200 mg/day orally administered for 44 or 68 weeks depending upon response
3044577|NCT00537485|Experimental|1|
3044578|NCT00537485|Placebo Comparator|2|
3044579|NCT00537511|Experimental|Dose-finding arm: Pomalidomide + Cisplatin + Etoposide|Oral pomalidomide 1 mg - 5 mg daily (QD) for 14 consecutive days of a 21-day cycle, in combination with intravenous (IV) cisplatin 25 mg/m^2 and IV etoposide 100 mg/m^2 on Days 1, 2 and 3 of each cycle during the dose-finding phase (Treatment and Extension Periods; 6 cycles in total). Dose escalation followed a standard phase 1 3+3 design. Participants continuing took only their pomalidomide dose (monotherapy) for an additional 3-week Recovery Period (14 days of consecutive dosing followed by 7 days of no study medication). Participants continuing took oral pomalidomide 5 mg QD as monotherapy for 14 consecutive days of each 21-day cycle until disease progression in the Maintenance Phase.
3044580|NCT00537576|Experimental|Low dose LACTIN-V applicator|Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10^8 CFU), administered vaginally once a day for 5 consecutive days
3044581|NCT00537576|Experimental|Medium dose LACTIN-V applicator|Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
3044582|NCT00537576|Experimental|High dose LACTIN-V applicator|High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10^9 CFU), administered vaginally once a day for 5 consecutive days
3044583|NCT00537576|Placebo Comparator|Low dose Placebo applicator|Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days
3044584|NCT00537576|Placebo Comparator|Medium dose Placebo applicator|Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days
3044585|NCT00537576|Placebo Comparator|High dose Placebo applicator|High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
3044586|NCT00537680|Experimental|1|mid dose Idebenone
3044587|NCT00537680|Experimental|2|high dose Idebenone
3044588|NCT00537680|Placebo Comparator|3|
3044589|NCT00537745|Experimental|Vivitrol|Vivitrol 380 mg/monthly, plus individual compliance enhancement therapy (Medication Management Therapy).
3044590|NCT00537771|Experimental|1|Anastrozole (ARIMIDEX)
3044591|NCT00537771|Active Comparator|2|Tamoxifen
3044592|NCT00537810|Experimental|Sibutramine|Sibutramine 15 mg daily
3044593|NCT00537810|Placebo Comparator|Placebo|Placebo Daily
3044594|NCT00537810|Experimental|Placebo/CBTsh|Placebo and Self-help CBT Placebo daily, Cognitive behavioral self-help manual for binge eating
3044595|NCT00537810|Experimental|Sibutramine/CBTsh|Sibutramine and Self-help CBT 15 mg daily Cognitive behavioral treatment manual for binge eating
3044596|NCT00537823|Experimental|Arm 1 - Wildtype|"Neoadjuvant therapy~Week 1~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8 *Cetuximab 250 mg/m^2 IV weekly~Weeks 3, 5, 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Week 1, 3, 5, 7, 9, 11, 13, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV Cetuximab 400 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2/day over 46 hours~Weeks 2, 4, 6, 8, 10, 12, 16~*Cetuximab 250 mg/m^2 IV weekly"
3044597|NCT00537823|Experimental|Arm 2 K-Ras 12/13 codon mutation|"Neoadjuvant Therapy~Weeks 1, 3, 5~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Wait 3-8 weeks after completion of therapy~Liver resection~Wait 4 weeks or until clinical status allows~Adjuvant Therapy~Weeks 1, 3, 5, 9, 11, 13~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~Bevacizumab 5 mg/kg IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2~Week 7, 15~Leucovorin 400 mg/m^2 IV~Oxaliplatin 85 mg/m^2 IV~5FU bolus 400 mg/m^2~5FU CIVI 1200 mg/m^2"
3044598|NCT00537940|Active Comparator|A|
3044599|NCT00537940|Active Comparator|B|
3044600|NCT00537979|Active Comparator|Paricalcitol injection|ABT-358 Zemplar
3044601|NCT00537979|Active Comparator|Paricalcitol capsules|ABT-358 Zemplar
3044602|NCT00538213|Experimental|Adjuvanted influenza vaccine GSK576389A Group|Subjects aged ≥ 66 years who previously received 1 dose of adjuvanted influenza vaccine GSK576389A in NCT00318149 and NCT00386698 studies were administered 1 dose of adjuvanted influenza vaccine GSK576389A.
3044603|NCT00538213|Active Comparator|Fluarix young Group|Subjects aged 19-42 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
3044604|NCT00538213|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years who previously received 1 dose of Fluarix vaccine in NCT00318149 and NCT00386698 studies were administered 1 dose of Fluarix vaccine.
3044605|NCT00538291|Experimental|Arm 1|Cetuximab 400mg/m2 IV on day 1 over 2 hours then 250 mg/m2 over 1 hour weekly + Xeloda(Capecitabine) 1000mg/m2 BID on days 1-14 repeated every 21 days.
3044606|NCT00538304|Experimental|1|bimatoprost eye drops
3044607|NCT00538304|Placebo Comparator|2|placebo
3044608|NCT00538434|Experimental|Reslizumab 1 mg/kg|reslizumab 1 mg/kg intravenous (IV) on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3044609|NCT00538434|Experimental|Reslizumab 2 mg/kg|reslizumab 2 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3044610|NCT00538434|Experimental|Reslizumab 3 mg/kg|reslizumab 3 mg/kg IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3044611|NCT00538434|Placebo Comparator|Placebo|saline placebo IV on Day 0 of each 28-day (+/-7 days) cycle, for up to 4 cycles
3044612|NCT00538473|Experimental|FluAS25 (GSK576389A) Group|Subjects received 1 dose of GlaxoSmithKline (GSK) Biologicals' AS25 adjuvanted influenza vaccine (GSK576389A).
3044613|NCT00538473|Active Comparator|Fluarix Group|Subjects received 1 dose of Fluarix™.
3044614|NCT00538512|Active Comparator|TIV|the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur
3044615|NCT00538512|Active Comparator|LAIV|live-attenuated influenza vaccine Flumist, manufactured by MedImmune
3044616|NCT00538512|Placebo Comparator|Placebo|Physiologic saline administered as a nasal spray or intramuscular injection
3044617|NCT00538590|Active Comparator|MITOMYCIN-C|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with Mitomycin-C.
3044618|NCT00538590|Experimental|ologen (Oculusgen)|20 patients will be recruited according to the enrollment acceptance criteria. Randomisation is performed and patients are allocated for trabeculectomy with ologen implant. The collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
3044619|NCT00538616|Active Comparator|Precedex-Propofol|Patients received an infusion of precedex for six hours and then a washout and then a propofol infusion for six hours.
3044620|NCT00538616|Active Comparator|Propofol- Precedex|Patients received an infusion of propofol for six hours and then a washout and then a precedex infusion for six hours.
3044621|NCT00538629||Schizophrenia|Patients with schizophrenia
3044622|NCT00538629||Bipolar disorder|Patients with bipolar disorder
3044623|NCT00538642|No Intervention|Stay on current antipsychotic|Subjects stay on same daily oral antipsychotic treatment as at baseline. Dose adjustments allowable as clinically indicated.
3044624|NCT00538642|Active Comparator|ziprasidone treatment|Subjects switch to daily oral ziprasidone from current antipsychotic(s). Dose titrated to clinically effective level.
3044625|NCT00538681|Experimental|Enzastaurin + Pemetrexed + Cisplatin|
3044626|NCT00538681|Placebo Comparator|Placebo + Pemetrexed + Cisplatin|
3044627|NCT00538733|Experimental|T-BiRD Therapy|"All patients were treated with the same regimen, starting with T-BIRD therapy (Cycles 1-4).~After 4 cycles, Patients with disease progression will be taken off study. Patients who achieve maximum response will receive maintenance. Patients who achieve VGPR or PR will be given T-BiRD for 2 cycles (cycles 5-6). After 6 cycles of T-BiRD, Patients who achieve maximum response will receive maintenance; those with disease progression will be taken off study; all other patients will receive BIRD.~Patients who progress on BiRD will reinitiate T-BiRD. If disease progression continues after 2 cycles, patients will be taken off study.~Patients in CR/sCR or that achieve a plateau of disease for > 2 cycles on BiRD or T-BiRD therapy will receive maintenance."
3044628|NCT00538759|Experimental|EBRT|External beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
3044629|NCT00538759|Sham Comparator|Control|Sham external beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty.
3044630|NCT00538785|Experimental|Motavizumab|Motavizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
3044631|NCT00538785|Active Comparator|Pailvizumab|Palivizumab was administered as an intramuscular injection at 15 mg/kg every 30 days during the RSV season for a maximum of 5 scheduled doses. Additionally, children who underwent cardiac surgery with cardiopulmonary bypass through Study Day 150 were to receive a protocol-specified replacement dose of study drug immediately following the surgery when determined by the physician to be medically stable for an IM injection.
3044632|NCT00538824|Experimental|DexTR (all patients)|All patients were treated with the DexTR (dexamethasone / thalidomide, lenalidomide (Revlimid®)), which consisted of lenalidomide 25mg/day during days 1-21, dexamethasone 40mg/day on days 1-4, 9-12, and 17-20, and thalidomide 50mg/day for the first 7 days, followed by 100mg/day for all subsequent days, for a total of 4 cycles of 28 days each.
3044633|NCT00538850|Experimental|Fentanyl sublingual spray|Participants received fentanyl sublingual spray 7 times or placebo 3 times in random order to treat up to a maximum of 2 breakthrough pain episodes per day with a minimum separation of 2 hours between treatments. Patients received a dose of 100 to 1600 µg determined in the open-label dose titration period of the current study.
3044634|NCT00538863|Experimental|Fentanyl sublingual spray titration|Patients received fentanyl sublingual spray to treat up to a maximum of 4 breakthrough pain episodes per day with a minimum separation of 4 hours between treatments. Patients started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 26 days was reached.
3044635|NCT00538863|Experimental|Fentanyl sublingual spray maintenance|Patients received fentanyl sublingual spray up to a maximum of 4 times per day with a minimum separation of 4 hours between treatments for 90 days. Patients received a dose of 100 to 1600 µg determined in a previous study (INS-05-001, NCT00538850) or in the open-label dose titration period of the current study. The dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects.
3044636|NCT00538902|Placebo Comparator|Placebo|Placebo administered subcutaneously every other week
3044637|NCT00538902|Experimental|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously every other week
3044638|NCT00538902|Experimental|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week
3044639|NCT00538915|Experimental|Nabi-IGIV Infused Every 3- or 4-Weeks|
3044640|NCT00539006|Active Comparator|FFNS, FPNS|active compound
3044641|NCT00539006|Active Comparator|FPNS, FFNS|active compound
3044642|NCT00539006|Placebo Comparator|placebo FFNS, placebo FPNS|placebo arm
3044643|NCT00539006|Placebo Comparator|placebo FPNS, placebo FFNS|placebo arm
3044644|NCT00539032|Experimental|Group 1: Menactra® Booster Group|Participants who had received 2 doses of quadrivalent (A, C, Y, and W-135) meningococcal polysaccharide vaccine before age 2 years received a booster vaccination with Menactra® vaccine.
3044645|NCT00539032|Experimental|Group 2: Menactra® Primary Vaccine (Control) Group|Participants who had not previously been given any meningococcal vaccine (meningococcal vaccine naive) received a primary vaccination with Menactra® vaccine.
3044646|NCT00539110|Experimental|zolpidem|zolpidem or ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
3044647|NCT00539110|Active Comparator|ramelteon|ramelteon or zolpidem dosed at 2200 and 0200 per the feeding tube depending on randomization
3044648|NCT00539188|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose (3000 mg daily), in addition to the medication regimen they are on at enrollment
3044649|NCT00539188|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3044650|NCT00539240|Placebo Comparator|Rabeprazole morning/evening placebo bedtime|AciPhex 20 mg BID and once daily placebo
3044651|NCT00539240|Placebo Comparator|Rabeprazole breakfast, placebo dinner and bedtime|AcipHex 20 mg once daily and BID placebo
3044652|NCT00539240|Active Comparator|Rabeprazole breakfast, placebo dinner, nortriptyline bedtime|AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
3044653|NCT00539253|Other|Gadobenate Dimeglumine (Multi Hance)|If patient did not participate in this study (by signing consent), they could receive any other contrast used routinely at this facility including the contrast used in this study
3044654|NCT00539279|Experimental|Prolonged Exposure Therapy (PE)|Prolonged Exposure Therapy (PE)
3044655|NCT00539279|Active Comparator|Relaxation Training (RT)|Relaxation Training (RT)
3044656|NCT00539305|Experimental|Study drug; testosterone transdermal gel|Dose will be adjusted as needed to maintain a target total T level of 500-900 ng/dl
3044657|NCT00539305|Placebo Comparator|2|
3044658|NCT00539500|Experimental|Transplantation CD133+ cells|Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan
3044659|NCT00539513|Experimental|N-Acetylcysteine|Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
3044660|NCT00539513|Placebo Comparator|placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3044661|NCT00539526|Experimental|1|bimatoprost 0.03%
3044662|NCT00539526|Active Comparator|2|travoprost 0.004%
3044663|NCT00539526|Active Comparator|3|latanoprost 0.005%
3044664|NCT00539539|Active Comparator|Feedback On|Automated real-time feedback on CPR Process activated
3044665|NCT00539539|No Intervention|Feedback Off|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
3044666|NCT00539591|Experimental|Temozolomide/peginterferon alfa-2b|"Stratum B: Resected Stage IIIC, unresectable Stage III, Stage IV, and recurrent patients~Stratum B is divided into 2 groups based on the presence (Stratum B1) or absence (Stratum B2) of measurable disease. Subjects will receive 8 weekly doses of peginterferon alfa-2b 0.5 mcg/kg/dose subcutaneously (SQ) in combination with temozolomide 75mg/m2/dose by mouth (PO) daily for 6 weeks followed by 2 week break. The duration of each treatment course will be 8 weeks. Strata B2 (no measurable disease) will proceed with 7 courses as outlined."
3044667|NCT00539591|Experimental|Peginterferon alfa-2b/non-pegylated interferon alfa-2b|Stratum A: Resected Stages IIC, IIIA, and IIIB patients will receive recombinant interferon alfa-2b 20 million units/m2/day intravenously (IV) 5 consecutive days per week for 4 weeks followed by peginterferon alfa-2b 1mcg/kg subcutaneously (SQ) once a week for 48 weeks.
3044668|NCT00539656|Experimental|Receive two cord blood units|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
3044669|NCT00539695|Experimental|IL2 Administration|"SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD"
3044670|NCT00539864|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2007-2008 formulation containing 45μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~135μg total"
3044671|NCT00539864|Active Comparator|TIV (Fluzone)|"Licensed Trivalent Influenza Vaccine (TIV): 2007-2008 formulation containing 15μg of each hemagglutinin derived from A/Solomon Islands/03/2006 (H1N1), A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004~45μg total~(Fluzone, sanofi pasteur)"
3044672|NCT00539942|Active Comparator|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
3178916|NCT00666991|Experimental|Nanotax, 225 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 225 mg/m2 once every 28 days until progression or unacceptable toxicity
3044673|NCT00539942|Experimental|Arixtra (fondaparinux sodium)|Patients randomized to treatment arm will initiate Arixtra (fondaparinux sodium) treatment on post-operative day 1 and continue treatment until post-operative day 22 (21 consecutive days). Subjects randomized to this arm are to receive the standard prophylactic dose for major abdominal surgery of 2.5 mg/day for a total of 21 consecutive days (including hospitalization time and after hospital discharge).
3044674|NCT00539981|Experimental|FluBlok (Lots A, B, C)|Participants received a single 0.5 milliliters (mL) dose of FluBlok vaccine from any of the Lots A, B, or C, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
3044675|NCT00539981|Placebo Comparator|Placebo|Participants received a single dose of placebo matched to FluBlok, intramuscularly on Day 0 (Visit 1). Participants were followed up to 6 months after vaccination.
3044676|NCT00539994|Experimental|Treatment B|200mg BID retapamulin 5 days
3044677|NCT00539994|Placebo Comparator|Treatment C|200mg BID placebo 5 days
3044678|NCT00539994|Experimental|Treatment A|200mg BID retapamulin 3 days and placebo BID 2 days for a total of 5 days
3044679|NCT00540007|Experimental|Cohort 1 - Lenalidomide daily on days 1-21|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-21 of a 28 day cycle."
3044680|NCT00540007|Experimental|Cohort 2 - Lenalidomide daily on days 1-28|"The first group of participants will be assigned to Cohort 1 and if no unacceptable toxicities occur in Cohort 1 then the second group of participants will be assigned to Cohort 2~Lenalidomide 25 mg per day PO daily on days 1-28 of a 28 day cycle."
3044681|NCT00540046|Active Comparator|A/Immediate|The patients in the immediate arm will have the Copper T 380A IUD inserted within 15 minutes after delivery of the placenta immediately following procedure
3044682|NCT00540046|Active Comparator|B/Delayed|The delayed group will have the Copper T 380A IUD inserted at the post-operative visit within 2-4 weeks following the procedure.
3044683|NCT00540124|Experimental|Tadalafil|
3044684|NCT00540124|Placebo Comparator|Placebo|
3044685|NCT00540124|Active Comparator|Tamsulosin|
3044686|NCT00540228|Experimental|GSK1247446A 1 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with a full dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3044687|NCT00540228|Experimental|GSK1247446A 2 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/2 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3044688|NCT00540228|Experimental|GSK1247446A 3 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/4 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3044689|NCT00540228|Experimental|GSK1247446A 4 Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of GSK1247446A with 1/8 dose of AS03 adjuvant at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3044690|NCT00540228|Active Comparator|Fluarix Group|Subjects aged 18-64 years at the time of enrolment received 1 dose of FluarixTM at Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3044691|NCT00540293|Experimental|Treatment group|this patient group consists of dyslipidemia patients with various CVD risk factors
3044692|NCT00540423|Experimental|SB-497115-GR group|Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.
3044693|NCT00540423|Placebo Comparator|placebo group|Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.
3044694|NCT00540436|Experimental|GSK1325760A|Single arm safety and efficacy
3044695|NCT00540449|Active Comparator|Efavirenz|Efavirenz 600mg once daily for 96 weeks
3044696|NCT00540449|Experimental|TMC278|TMC278 25 mg tablet once daily for 96 weeks
3044697|NCT00540514|Experimental|Albumin-bound paclitaxel + Carboplatin|Participants received albumin-bound paclitaxel (ABRAXANE®) 100 mg/m^2 administered as an intravenous infusion over 30 minutes on Days 1, 8, and 15 of each 21-day cycle. Carboplatin was given at an Area Under the Curve (AUC) = 6 mg*min/mL on Day 1 only of each 21-day cycle, beginning immediately after the completion of albumin-bound paclitaxel administration. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
3044698|NCT00540514|Active Comparator|Paclitaxel + Carboplatin|Participants received 200 mg/m^2 paclitaxel (Taxol®) administered by intravenous infusion followed by carboplatin at AUC = 6 mg*min/mL on Day 1 of a 21 day cycle. Participants could continue treatment at the investigator's discretion until disease progression, development of an unacceptable toxicity, or withdrawal of consent.
3044699|NCT00540579|Experimental|Intervention|All patients received gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of a 28 day cycle. Pomalidomide was administered orally on days 1-21 at doses escalated from 2 mg to 10 mg daily.
3044700|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 1 Group|Subjects aged ≥65 years received one dose of formulation 1 of the adjuvanted influenza vaccine GSK576389A.
3044701|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 2 Group|Subjects aged ≥65 years received one dose of formulation 2 of the adjuvanted influenza vaccine GSK576389A.
3044702|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 3 Group|Subjects aged ≥65 years received one dose of formulation 3 of the adjuvanted influenza vaccine GSK576389A.
3044703|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 4 Group|Subjects aged ≥65 years received one dose of formulation 4 of the adjuvanted influenza vaccine GSK576389A.
3044704|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 5 Group|Subjects aged ≥65 years received one dose of formulation 5 of the adjuvanted influenza vaccine GSK576389A.
3044705|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 6 Group|Subjects aged ≥65 years received one dose of formulation 6 of the adjuvanted influenza vaccine GSK576389A.
3044706|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 7 Group|Subjects aged ≥65 years received one dose of formulation 7 of the adjuvanted influenza vaccine GSK576389A.
3044707|NCT00540592|Experimental|Influenza vaccine GSK576389A formulation 8 Group|Subjects aged ≥65 years received one dose of formulation 8 of the adjuvanted influenza vaccine GSK576389A.
3044708|NCT00540592|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received one dose of Fluarix vaccine.
3044709|NCT00540592|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received one dose of Fluarix vaccine.
3044710|NCT00540644|Experimental|Revlimid, Cyclophosphamide, Prednisone|"Lenalidomide orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Cyclophosphamide twice daily, orally on Days 1-21 followed by 7 days rest, repeated every 28 days.~Prednisone every other day orally."
3044711|NCT00540722|Experimental|Treatment (R-(-)-gossypol acetic acid)|"Patients receive oral R-(-)-gossypol once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Patients undergo tumor tissue and blood sample collection at baseline and periodically during study for biomarker correlative studies. Archived tumor tissue samples, if available, are analyzed for Bcl-2 family protein expression (e.g., Bcl-2, Bcl-xL, MCl-1, Bax, Bak, and BH3 domain for BH3 members only) and MGMT gene methylation status. Blood samples are analyzed for apoptotic protein levels (Bcl-2) by enzyme-linked immunosorbent assay."
3044712|NCT00540982|Experimental|Normal Liver Function|
3044713|NCT00540982|Experimental|Mild Liver Dysfunction|
3044714|NCT00540982|Experimental|Moderate Liver Dysfunction|
3044715|NCT00540982|Experimental|Severe Liver Dysfunction|
3044716|NCT00540995|Experimental|Arm I: 1200cGy|"1200cGy = 150cGy x 8 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0.~GRAFT-VS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive GVHD prophylaxis that excludes methotrexate."
3044717|NCT00540995|Experimental|Arm II: 1350cGy|1350cGy = 150cGy x 9 doses: Patients receive busulfan IV once daily over 2 hours on days -15 and -13 and then every 6 hours on days -12 to -9. Patients also receive etoposide IV on day -3. Patients undergo image-guided intensity-modulated radiation therapy using helical tomotherapy on days -8 to -5.
3044718|NCT00541034|Experimental|cyclophosphamide, pentostatin & rituximab|Patients receive cyclophosphamide IV followed by pentostatin IV on day 1 in course 1. Beginning in course 2 and in all subsequent courses, patients receive cyclophosphamide IV on day 1, pentostatin IV on day 1, and rituximab IV on day 1 or on days 1 and 2. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3044719|NCT00541099|Experimental|Avastin & Docetaxel|Avastin 10.0 mg/kg on days 1 and 15; Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel; Docetaxel 35 mg/m2 on day 1, 8, 15
3044720|NCT00541190|Experimental|cystic fibrosis|Cystic fibrosis patients
3044721|NCT00541190|Experimental|healthy controls|Healthy control subjects
3044722|NCT00541229|Experimental|1|sitagliptin 100 mg
3044723|NCT00541229|Experimental|2|sitagliptin 200 mg
3044724|NCT00541229|Placebo Comparator|3|Placebo
3044725|NCT00541242|Active Comparator|1|bimatoprost 0.03% eye drops
3044726|NCT00541242|Active Comparator|2|latanoprost 0.005% eye drops
3044727|NCT00541307|Experimental|GORE VIABHAN Endoprothesis|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
3044728|NCT00541346|Experimental|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
3044729|NCT00541385|Experimental|PA group|"Oral pyronaridine/artesunate (PA, 60:20mg granules) once a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
3044730|NCT00541385|Active Comparator|AL group|"Oral artemether/lumefantrine (AL, 20:120mg crushed tablets) twice a day for 3 consecutive days (Days 0, 1, and 2).~Posology based on body weight ranges."
3044731|NCT00541450|Experimental|Sita/Met FDC|"In Phase A (Treatment Day 1 to Week 12), participants were administered 100 mg once daily (q.d.) of sitagliptin and matching placebo to 15 mg pioglitazone q.d. for 6 weeks followed by matching placebo to 30 mg pioglitazone for the next 6 weeks.~In Phase B (Treatment Week 12-Week 40), participants were switched to the Sita/Met Fixed-Dose Combination (FDC) at a dose of 50/500 mg twice a day (b.i.d.), which was increased to 50/1000 mg b.i.d. over a period of 4 weeks; as well as matching placebo to 45 mg pioglitazone."
3044732|NCT00541450|Active Comparator|Pioglitazone|"In Phase A (Treatment Day 1 up to Week 12), randomized participants in the pioglitazone group were administered 15 mg q.d. of pioglitazone and matching placebo to sitagliptin. At Week 6, participants were up-titrated to 30 mg pioglitazone q.d.~In Phase B (Treatment Week 12 to Week 40), participants were administered 45 mg pioglitazone q.d.; as well as matching placebo to Sita/Met FDC (50/500 increased to 50/1000 b.i.d. after 4 weeks)."
3044733|NCT00541593|Experimental|NOTES pancreatic pseudocystgastrostomy|Patients who undergo pancreatic pseudocystgastrostomy via a NOTES technique.
3044734|NCT00541658|Active Comparator|5 mg Before Breakfast|5 mg / Immediate-release Risedronate (At Least 30 Minutes Before Breakfast)
3044735|NCT00541658|Experimental|35 mg After Breakfast|35 mg / Delayed-release Risedronate (Immediately Following Breakfast)
3044736|NCT00541658|Experimental|35 mg Before Breakfast|35 mg / Delayed-release Risedronate (At Least 30 Minutes Before Breakfast)
3044737|NCT00541671|Placebo Comparator|1|Patients will then be randomized to receive placebo, consisting of 10ml of normal saline solution to be administered intravenously with the narcotic
3044738|NCT00541671|Active Comparator|2|Patients will be randomized to 6.25mg of promethazine, consisting of 0.25ml of promethazine diluted in 9.75ml of normal saline.
3044739|NCT00541775|Experimental|Sitagliptin|sitagliptin 100 mg
3044740|NCT00541775|Active Comparator|Rosiglitazone|rosiglitazone 8 mg
3044741|NCT00541775|Placebo Comparator|Placebo|placebo
3044742|NCT00541866|Experimental|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A:~Schedule B:~Expansion Phase~Schedule A:~Schedule B:"
3044743|NCT00541931|Other|Nonsmoker|Nonsmokers Intervention: Dietary Supplement: LifePak Nano
3044744|NCT00541931|Other|Smoker|Smoker arm Intervention: Dietary Supplement: LifePak Nano
3044745|NCT00541970|Experimental|Cervarix 1/Placebo Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 2, and 1 dose of placebo at Month 6. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3044746|NCT00541970|Experimental|Cervarix 1/Placebo/Cervarix 1 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 1, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3044747|NCT00541970|Experimental|Cervarix 2/Placebo/Cervarix 2 Group|Subjects received 2 doses of the Cervarix vaccine, formulation 2, at Month 0 and Month 6, and 1 dose of placebo at Month 2. The Cervarix vaccine and placebo were administered intramuscularly into the deltoid of the non-dominant arm.
3044748|NCT00541970|Experimental|Cervarix 2 Group|Subjects received 3 doses of the Cervarix vaccine, formulation 2, at Month 0, Month 2 and Month 6. The Cervarix vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
3044749|NCT00542178|Experimental|Intensive glycemia control|A strategy of intensive glycemia treatment to HbA1c less than 6%
3044750|NCT00542178|Active Comparator|Standard glycemia control|A strategy of multiple drugs to treat HbA1c to 7.0% - 7.9%
3044751|NCT00542178|Experimental|Intensive BP control|A strategy of BP treatment for SBP less than 120 mm Hg
3044752|NCT00542178|Active Comparator|Standard BP control|A strategy of BP treatment for SBP less than 140 mm Hg
3044753|NCT00542178|Experimental|Fibrate|Blinded fenofibrate + simvastatin 20-40 mg/d
3044754|NCT00542178|Placebo Comparator|Fibrate Placebo|Blinded placebo + simvastatin 20-40 mg/d
3044755|NCT00542191|Experimental|Neoadjuvant metronomic AC followed by weekly TC|Neoadjuvant chemotherapy with metronomic AC followed by weekly TC then surgery
3044756|NCT00542269|Experimental|Aliskiren / ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3044757|NCT00542269|Experimental|Aliskiren / amlodipine|6 weeks treatment with aliskiren 150 mg tablets, ramipril 5 mg placebo capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg tablets, ramipril 10 mg placebo capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3044758|NCT00542269|Active Comparator|Ramipril / amlodipine|6 weeks treatment with aliskiren 150 mg placebo tablets, ramipril 5 mg capsules, and amlodipine 5-10 mg tablets followed by an additional 6 weeks treatment with aliskiren 300 mg placebo tablets, ramipril 10 mg capsules, and amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
3044759|NCT00542308|Experimental|Zalutumumab 4-16 mg/kg|Zalutumumab iv infusion once weekly. The dose was titrated until grade 2 rash occurred.
3044760|NCT00542321|Experimental|Kinetic Therapy Bed|Kinetic Therapy Bed: Continuous automated turning to 45 degrees with head of the bed elevated 30 degrees or more for up to 7 continuous days
3044761|NCT00542321|Active Comparator|Manual Turn|Manual Turn: lateral rotation every 2 hours from back to left to back to right to back, with >/= 45 degree lateral rotation angle and 30 degree head of bed elevation
3044762|NCT00542386|Experimental|1|
3044763|NCT00542386|Placebo Comparator|2|
3044764|NCT00542425|Placebo Comparator|Placebo|
3044765|NCT00542425|Experimental|BA058 20 µg|
3044766|NCT00542425|Experimental|BA058 40 µg|
3044767|NCT00542425|Experimental|BA058 80 µg|
3044768|NCT00542425|Active Comparator|teriparatide|
3044769|NCT00542490|Experimental|Vaginal Cuff Brachytherapy|
3044770|NCT00542620|Experimental|Mixed injection|
3044771|NCT00542620|Active Comparator|Separate injection|
3044772|NCT00542750|Experimental|N-Acetylcysteine|All participants will receive N-Acetylcysteine 1200 mg twice daily during four weeks of participation. Tolerability, marijuana use, and reactivity to marijuana cues will be investigated.
3044773|NCT00542789|Placebo Comparator|1|Placebo
3044774|NCT00542789|Experimental|2|Esomeprazole 20 mg
3044775|NCT00542815|Experimental|1|
3044776|NCT00542815|Active Comparator|2|
3044777|NCT00542828|Experimental|Thymoglobulin|
3044778|NCT00542880|Experimental|Symbicort Turbuhaler First, then Seretide Diskus|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg First, then Seretide Diskus (salmeterol/fluticasone) 50/500 μg
3044779|NCT00542880|Experimental|Seretide Diskus First, then Symbicort Turbuhaler|Seretide Diskus (salmeterol/fluticasone) 50/500 μg First, then Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
3044780|NCT00542919|Experimental|T-Cell|T-Cell (TCL): Peripheral and cutaneous T-cell lymphoma (PTCL, CTCL). Participants received enzastaurin 1125 milligram (mg) loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
3044781|NCT00542919|Experimental|Indolent B-Cell|Indolent B-Cell (IBCL): Small lymphocytic lymphoma, follicular lymphoma (Grade 1 or 2) and marginal zone lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
3044782|NCT00542919|Experimental|Aggressive B-Cell|Aggressive B-Cell (ABCL): Primary central nervous system (CNS) lymphoma, follicular lymphoma (Grade 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma. Participants received enzastaurin 1125 mg loading dose then 500 mg, oral, daily until progressive disease or predefined criteria for discontinuation is met. Participants who progress within the first 28 days may remain on study treatment, provided that the participant is not in need of immediate treatment with another anticancer therapy. Study treatment occurs in cycles. 1 cycle = 28 days
3044783|NCT00542971|Experimental|Sorafenib + Idarubicin + Ara-C|Sorafenib starting dose 400 mg orally for 7 days; Idarubicin 12 mg/m^2 intravenous (IV) daily (days 1-3); and Ara-C 1.5 g/m^2 IV over 24 hours daily (days 1-4)
3044784|NCT00542997|Experimental|IgPro20|
3044785|NCT00543062|Other|Treatment Sequence ABCD|Treatment Sequence ABCD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
3044786|NCT00543062|Other|Treatment Sequence BDAC|Treatment Sequence BDAC where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
3044787|NCT00543062|Other|Treatment Sequence CABD|Treatment Sequence CABD where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
3044788|NCT00543062|Other|Treatment Sequence DCBA|Treatment Sequence DCBA where Treatment: A = Inhaled prochlorperazine (10 mg) + oral placebo, B = Inhaled prochlorperazine (5 mg) + oral placebo, C = Inhaled placebo + oral placebo, D = Inhaled placebo + oral moxifloxacin 400 mg
3044789|NCT00543101|Active Comparator|Switch to DRV/r|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
3044790|NCT00543101|Active Comparator|Continue on Current Dual Boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and are followed for an additional 24 weeks
3044791|NCT00543127|Experimental|Fulvestrant + Anastrozole|Fulvestrant loading dose regimen will consist of two 5 ml intramuscular injections on day 0 (500 mg), 250 mg single injection on days 14 and 28, and 250 mg single injection every 28 days thereafter for 3 years plus Anastrozole 1 mg PO once daily for 5 years
3044792|NCT00543127|Active Comparator|Anastrozole|Anastrozole 1 mg will be administered orally as one tablet daily for 5 years.
3044793|NCT00543140|Other|REALIZE™ Swedish Adjustable Gastric Band|All subjects have the REALIZE™ Swedish Adjustable Gastric Band. Single arm - no comparator.
3044794|NCT00543296|Experimental|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
3044795|NCT00543309|Experimental|I- nesiritide|Patients assigned to the nesiritide group will receive an intravenous loading dose of 2 mcg/kg followed by an infusion of 0.015 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
3044796|NCT00543309|Active Comparator|II- Milrinone|Patients assigned to the milrinone group will receive a bolus of 50 mcg/kg followed by an infusion of 0.5 mcg/kg/min, administered for at least 12 hours after CICU admission and up to five days unless prespecified lack of efficacy criteria are met.
3044797|NCT00543309|Placebo Comparator|III- placebo|Patients assigned to the placebo group will receive a 0.33 mL/kg bolus of 5% dextrose in water (D5W), followed by an infusion of D5W, administered for at least 12 hours after CICU admission and up to five days, unless prespecified lack of efficacy criteria are met.
3044798|NCT00543387|Experimental|MK-5108 200 mg BID (Panel 1)|Participants receive 200 mg of MK-5108 orally twice daily (BID) the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044799|NCT00543387|Experimental|MK-5108 400 mg BID (Panel 1)|Participants receive 400 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044800|NCT00543387|Experimental|MK-5108 800 mg BID (Panel 1)|Participants receive 800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044801|NCT00543387|Experimental|MK-5108 1200 mg BID (Panel 1)|Participants receive 1200 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044802|NCT00543387|Experimental|MK-5108 1500 mg BID (Panel 1)|Participants receive 1500 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044803|NCT00543387|Experimental|MK-5108 1800 mg BID (Panel 1)|Participants receive 1800 mg of MK-5108 orally BID the first 2 days of a 14-day cycle (cycle extended to 21 days if ≥Grade 2 toxicity observed).
3044804|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered intravenously (IV) the first 2 days of a 21-day cycle.
3044805|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
3044806|NCT00543387|Experimental|MK-5108 225 mg BID + 60 mg/m^2 Docetaxel (Panel 2)|Participants receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
3044807|NCT00543387|Experimental|MK-5108 100 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, one participant crossed over to Panel 2 per protocol following disease progression to receive 100 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
3044808|NCT00543387|Experimental|MK-5108 150 mg BID + 60 mg/m^2 Docetaxel (Crossover)|After receiving treatment in Panel 1, participants crossed over to Panel 2 per protocol following disease progression to receive 150 mg of MK-5108 orally BID in combination with 60 mg/m^2 Docetaxel administered IV the first 2 days of a 21-day cycle.
3044809|NCT00543400|Active Comparator|70 U/kg of unfractionated heparin given IV|Venous injection (IV) of 70 units per kilogram (U/kg) of unfractionated heparin prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3044810|NCT00543400|Experimental|50 IU/KG of M118|Venous injection of 50 international units per kilogram (IU/kg) of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3044811|NCT00543400|Experimental|75 IU/KG of M118|Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3044812|NCT00543400|Experimental|100 IU/KG of M118|Venous injection of 100 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
3044813|NCT00543439|Experimental|1|On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
3044814|NCT00543439|Experimental|2|Routine Prophylaxis Crossover
3044815|NCT00543543|Experimental|Low-dose V503|V503 (9-Valent Human Papillomavirus [HPV] Vaccine) low-dose 0.5 mL injection in a 3-dose regimen in the base study.
3044816|NCT00543543|Experimental|Mid-dose V503|V503 (9-Valent HPV Vaccine) mid-dose 0.5 mL injection in a 3-dose regimen in the base study. A subset of participants (Cohort 1) received a fourth V503 mid-dose vaccination in the extension study.
3044817|NCT00543543|Experimental|High-dose V503|V503 (9-Valent HPV Vaccine) high-dose 0.5 mL injection in a 3-dose regimen in the base study.
3044818|NCT00543543|Active Comparator|Gardasil|Gardasil (4-Valent HPV Vaccine) 0.5 mL injection in a 3-dose regimen in the base study. Participants (Cohort 2) were offered the V503 mid-dose 3-dose regimen in the extension study.
3044819|NCT00543569|Active Comparator|Tacrolimus/MMF/Basiliximab|Participants received tacrolimus at a starting dose of 0.20 mg/kg/day, mycophenolate mofetil (MMF) 750 or 1000 mg twice daily (BID), basiliximab administered as a 20 mg bolus injection 2 hours prior to transplantation on Day 0 and a 20 mg bolus injection on Day 3 and tapered corticosteroids for 6 months.
3044820|NCT00543569|Experimental|Alefacept QW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg intravenous (IV) bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly (QW) for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID and tapered corticosteroids for 6 months.
3044821|NCT00543569|Experimental|Alefacept QW/Tacrolimus|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 15 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.20 mg/kg/day, and tapered corticosteroids for 6 months.
3044822|NCT00543569|Experimental|Alefacept QOW/Tacrolimus/MMF|Participants received alefacept administered as a 7.5 mg IV bolus on Days 0 and 3; 30 mg subcutaneously on Day 7 then weekly for 12 weeks, then 15 mg subcutaneously monthly until the end of month 6, in addition to tacrolimus at a starting dose of 0.10 mg/kg/day, MMF 750 or 1000 mg BID, and tapered corticosteroids for 6 months.
3044823|NCT00543725|Active Comparator|002|efavirenz 600 mg tablet once daily for 96 weeks
3044824|NCT00543725|Experimental|001|TMC278 25 mg tablet once daily for 96 weeks
3044825|NCT00543764||Pre pathway|Pre pathway
3044826|NCT00543764||Post pathway|Post pathway
3044827|NCT00543777|Experimental|MRE + 2PD MRI|MRE - Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue. 2PD MRI - Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
3044828|NCT00543855|Experimental|3 mg Donepezil hydrochloride|
3044829|NCT00543855|Experimental|5 mg Donepezil hydrochloride|
3044830|NCT00543855|Experimental|10 mg Donepezil hydrochloride|
3044831|NCT00543855|Placebo Comparator|Placebo|
3044832|NCT00543985|Experimental|Stress Echocardiography|Echocardiography was performed prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
3044833|NCT00544076|Experimental|Sildenafil Citrate/Mo+Aprostadil/day|Patients receive intraurethral alprostadil once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
3044834|NCT00544076|Active Comparator|Sildenafil Citrate Monthly|Patients receive 3 doses of oral sildenafil citrate on 3 separate occasions at least 48 hours apart monthly for 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
3044835|NCT00544076|Experimental|Daily Sildenafil Citrate|Patients receive oral sildenafil citrate once daily for up to 9 months in the absence of disease progression or unacceptable toxicity. Patients also receive 3 doses of oral sildenafil citrate at least 48 hours apart monthly for up to 18 months. Patients on all three arms will have undergone robotic-assisted laparoscopic surgery. All patients will take part in the questionnaire administration and quality-of-life assessments.
3044836|NCT00544167|Experimental|Intervention|All patients received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 (AC) both administered intravenously day 1 every 3 weeks for four cycles, followed by paclitaxel 175 mg/m2 intravenously day 1 every 3 weeks for four cycles or 80 mg/m2 for twelve weeks (physician discretion), combined with sorafenib 400 mg orally twice daily. Sorafenib was held during radiation therapy where indicated and resumed once completed. Sorafenib was continued for a total of 12 months and in combination with adjuvant hormonal therapy where indicated.
3044837|NCT00544440|Experimental|Abiraterone acetate plus prednisone|Patients will be treated orally with abiraterone acetate 1000 mg daily and prednisone 5 mg twice a day until clinical disease progression.
3044838|NCT00544544|Experimental|Riluzole|Riluzole 50 mg twice daily for 2 weeks, increased to riluzole 50 mg in the morning and 100 mg in the evening for 1 week if tolerated, with a further increase to riluzole 100 mg twice daily if tolerated for 3 weeks.
3044839|NCT00544557||Patients with Ankylosing Spondylitis|
3044840|NCT00544648|Experimental|Treatment|nab-paclitaxel+ carboplatin + radiation
3044841|NCT00544674|Experimental|PR104|PR104 will be administered once every 21 days by IV
3044842|NCT00544713|Experimental|Carboxymethylcellulose and Glycerin based artificial tear|Carboxymethylcellulose and Glycerin based artificial tear
3044843|NCT00544713|Active Comparator|Carboxymethylcellulose based artificial tear|Carboxymethylcellulose based artificial tear
3044844|NCT00544778|Experimental|Arm 1|High-dose chemotherapy with doxorubicin at 120 mg/m2 and ifosfamide at 2 g/m2 followed by a prolonged schedule of CPT-11 at 20 mg/m2.
3044845|NCT00544817|Experimental|Combination Therapy|"In the combined modality portion of the study, patients were administered:~Radiation Therapy - 2 Gy/fraction, Single daily fractions M-F, to 60 Gy total Temozolomide - 75 mg/m2 by mouth once daily~Patients took a four week break before beginning follow-up systemic therapy:~Temozolomide - 150 mg /m2 by mouth on days 1-5 every 28 days for 6 cycles Sorafenib - 400 mg by mouth twice a day for 6 months"
3044846|NCT00544869|Experimental|1|
3044847|NCT00544882|Experimental|DR-1021|After randomization, participants received DR-1021 consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by EE 10 μg tablet once daily for 7 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
3044848|NCT00544882|Active Comparator|Mircette|After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
3044849|NCT00544908|Experimental|Dasatinib|Dasatinib 70 mg po bid (1 cycle=28 days)
3044850|NCT00545025|Experimental|GSK1247446A Group|Subjects aged between 18 and 60 years, having previously received one dose of the AS03-adjuvanted GSK1247446A vaccine in the primary study NCT00374842, received a single dose of GSK1247446A vaccine adjuvanted with a half dose of AS03 adjuvant at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Subjects in this group originated from either the GSK1247446A Formulation 1 or GSK1247446A Formulation 2 groups in study NCT00374862.
3044851|NCT00545025|Active Comparator|Fluarix Group|Subjects aged between 18 and 60 years, having previously received one dose of Fluarix™ vaccine during the primary study NCT00374842, received one dose of Fluarix™ vaccine at Day 0 of the current follow-up study NCT00545025. The vaccine was administered intramuscularly, in the deltiod region of the non-dominant arm. Subjects in this group originated from the Fluarix Group in study NCT00374862.
3044852|NCT00545051|Experimental|Ibandronate|Participants received monthly oral ibandronate (150 milligrams [mg]) for 12 months.
3044853|NCT00545051|Placebo Comparator|Placebo|Participants received monthly oral placebo for 12 months.
3044854|NCT00545077|Active Comparator|Arm A: Endocrine Therapy (ET)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
3044855|NCT00545077|Experimental|Arm B: ET with Bevacizumab (ET-B)|Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
3044856|NCT00545103|Experimental|SPD476 (1.2 g)|
3044857|NCT00545103|Experimental|SPD476 (2.4 g)|
3044858|NCT00545103|Experimental|SPD476 (4.8 g)|
3044859|NCT00545103|Placebo Comparator|Placebo|
3178917|NCT00666991|Experimental|Nanotax 275 mg/m2|Nanoparticulate paclitaxel (Nanotax) administered via intraperitoneal infusion at a dose of 275 mg/m2 once every 28 days until progression or unacceptable toxicity
3178918|NCT00667030|Experimental|Lifestyle Modification|Combined hypocaloric diet and aerobic exercise training
3044862|NCT00545155||Geriatric EMS Patients|Cohort for reliability and concurrent validity testing.
3044863|NCT00545168|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
3044864|NCT00545168|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
3044865|NCT00545168|Active Comparator|C - NIX|Nix Creme Rinse (permethrin 1%) applied according to OTC Instructions for Use
3044866|NCT00545181|Experimental|Metronidazole plus gel|Receive metronidazole plus vaginal gel
3044867|NCT00545181|Active Comparator|Control- metronidazole alone|Oral Metronidazole antibiotic therapy alone
3044868|NCT00545233|Experimental|PEG-INF alpha-2a + ribavirin+ pioglitazone|Participants received pioglitazone in a 16 week run-in period (30 mg per day orally for 8 weeks followed by 45 mg per day orally for 8 weeks). Participants then received piogliatzone 45 mg daily orally plus 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase. Participants received 45 mg of pioglitazone per day orally in the 24 week follow-up period.
3044869|NCT00545233|Active Comparator|PEG-INF alpha-2a + ribavirin|Participants received 18 μg of Peginterferon Alfa-2a (PEG-INF alpha-2a) subcutaneous (sc) once a week plus ribavirin (1000 - 1600 mg/day orally as a split dose in the morning and the evening based on the participant's body weight) for 48 weeks in the anti-HCV treatment phase followed by a treatment free 24 week follow-up period.
3044870|NCT00545272|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044871|NCT00545272|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044872|NCT00545272|Experimental|indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044873|NCT00545272|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044874|NCT00545272|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044875|NCT00545272|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3044876|NCT00545298|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only
3044877|NCT00545298|Experimental|B Same treatment for 6 weeks|200ppm NO gas 8hrs/day 6 weeks NO gas in nitrogen is delivered constantly to a patch over the wound
3044878|NCT00545298|Experimental|C - modified treatment, 5 wks lower dose|200 ppm No gas 8 hrs/day 1 wk, 20ppm 8hrs/day 5 weeks Gas is NO in nitrogen delivered constantly for 8 hours to a patch over the wound
3044879|NCT00545363|Experimental|Bone Marker Feedback (BMF) Participants|"Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants, in this arm, will receive BMF at Month 3. BMF will be given in terms of providing serum carboxy-terminal collagen crosslinks (CTX) level at Month 3. A BMF-form will be provided to the physicians to allow offering the bone marker result in an easy way. Participants will be informed if their results are within or outside of the desired range. In addition, participants will also supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake."
3044880|NCT00545363|Active Comparator|No BMF Participants|Postmenopausal women will receive ibandronate 150 milligrams (mg) once monthly (QM) orally for 6 months. Participants will be supported by PRP, to be carried out by supplying alarm devices, specifically designed to support the participant's regular drug intake.
3044881|NCT00545402|Experimental|MMF, Adjusted Dose; Tacrolimus; Corticosteroids|Participants received mycophenolate mofetil (MMF) 3 grams per day (g/d), orally (PO), twice per day (BID) with meals from Day 0 to Day 4; the dose was adjusted based on total exposure (AUC) using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12. Participants also received tacrolimus adjusted to a target trough level of 8 to (-) 12 nanograms per milliliter (ng/mL) from Day 0 to Month 1; the dose was adjusted to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 milligrams per kilogram (mg/kg), intravenously (IV), pre-operation on Day 0.
3044882|NCT00545402|Active Comparator|MMF, Standard Dose; Tacrolimus; Corticosteroids|Participants received MMF 2 g/d, PO, BID with meals from Day 0 to Month 12. Participants also received tacrolimus adjusted to a target trough level of 8-12 ng/mL from Day 0 to Month 1; the dose was reduced to reach a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12. Participants also received corticosteroids 10-15 mg/kg, IV, pre-operation on Day 0; followed by 20 mg/d, PO, 4 times per day (QDS) from Day 0 through Month 1; 15 mg/d, PO, 3 times per day (TID) from the end of Month 1 through Month 2; 10 mg/d, PO, BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
3044883|NCT00545441|Experimental|1|Surgisis® AFP
3044884|NCT00545441|Active Comparator|2|Flap
3044885|NCT00545532|Experimental|Conventional dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.
3044886|NCT00545532|Experimental|Double dose|Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.
3044887|NCT00545571|Experimental|Mircera in Renal Anemia|Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
3044888|NCT00545584|Experimental|Sitagliptin with Standard of Care|Subjects received sitagliptin 100 mg once daily for 26 Weeks, and: No specific intervention (standard recommendation) on physical exercise and diet.
3044889|NCT00545584|Experimental|Sitagliptin with Diet Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet which includes advice on diet with a leaflet and a diary"
3044890|NCT00545584|Experimental|Sitagliptin with Diet and Physical Activity Advice|"Subjects received sitagliptin 100 mg once daily for 26 Weeks,~and:~Intervention on diet + physical activity which includes advice on diet and physical activity with leaflets and diaries PLUS advice on physical activity with the utilization of a pedometer: subjects were asked to walk 10,000 steps per day 5 or more days per week."
3044891|NCT00545623|Active Comparator|ACU+RR|acupuncture + relaxation response CD
3044892|NCT00545623|Active Comparator|SHAM+RR|sham acupuncture + relaxation response CD
3044893|NCT00545623|Active Comparator|ACU+EDU|acupuncture+control CD
3044894|NCT00545623|Sham Comparator|SHAM+EDU|sham acupuncture+control CD
3044895|NCT00545662|Experimental|Placebo|Placebo tablets formulated to resemble the citicoline treatment.
3044896|NCT00545662|Experimental|Citicoline|Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
3044897|NCT00545688|Experimental|1|
3044898|NCT00545688|Experimental|2|
3044899|NCT00545688|Experimental|3|
3044900|NCT00545688|Experimental|4|
3178919|NCT00667043|Active Comparator|Study group 1|Midazolam and fentanyl; continuous intravenous infusions
3044901|NCT00545714|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter [mg/m^2] as intravenous [IV] infusion on Day 0 of Cycle 1 and 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m^2 on Days 1-3) and cyclophosphamide (250 mg/m^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
3044902|NCT00545740|Experimental|SPD476 (1.2 g)|
3044903|NCT00545740|Experimental|SPD476 (2.4 g)|
3044904|NCT00545740|Experimental|SPD476 (4.8 g)|
3044905|NCT00545740|Placebo Comparator|Placebo|
3044906|NCT00545753|Experimental|A - NatrOVA 1% - no nit combing|NatrOVA Creme Rinse (spinosad) 1% - no nit combing required
3044907|NCT00545753|Experimental|B - NatrOVA 1% - nit combing required|NatrOVA Creme Rinse (spinosad) 1% - nit combing regimen required
3044908|NCT00545753|Active Comparator|C - NIX|NIX Creme Rinse (permethrin 1%) applied to Over the Counter (OTC) Instructions for Use
3044910|NCT00545779|Experimental|Ibandronate|Participants completed Candidate Identification Questionnaire (CIQ) in Part A and received Ibandronate 150 milligram (mg) tablet orally once-monthly up to 6 months in Part B of the study.
3044911|NCT00545792|Experimental|Avastin|Avastin
3044912|NCT00545818|Experimental|Group-1, Implant length 6 mm|Subjects treated with OsseoSpeed™ implant, length: 6 mm
3044913|NCT00545818|Other|Group-2, Implant length 11 mm|Subjects treated with OsseoSpeed™ implant, length: 11 mm
3044914|NCT00545844|Experimental|1|montelukast sodium
3044915|NCT00545948|Other|Arm A-Vinorelbine|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of vinorelbine sensitivity were given cisplatin + vinorelbine.
3044916|NCT00545948|Other|Arm B-Pemetrexed|Resected tumor was used for genomic expression profiling. Patients with a genomic expression pattern suggestive of pemetrexed sensitivity were given cisplatin + pemetrexed.
3044917|NCT00545974|Experimental|1|Memantine 10mg BID
3044918|NCT00545974|Placebo Comparator|2|Placebo condition
3044919|NCT00546000|Experimental|1|Receive between 22 and 29 days of Cutivate lotion treatment
3044920|NCT00546052|Experimental|1|Losartan (MK0954) / Losartan + HCTZ (MK0954A)
3044921|NCT00546078|Experimental|Cervarix™ 4-Dose Group|Subjects who had received 3 doses of Cervarix™ in study 580299/001 (NCT00689741), received a 4th dose of Cervarix™ on Day 0 in the current study.
3044922|NCT00546078|Experimental|Cervarix™ 3-Dose Group|Subjects who had received 3 doses of placebo in study 580299/001 (NCT00689741), received 3 doses of Cervarix™ (Day 0, Month 1 and Month 6) in the current study.
3044923|NCT00546104|Experimental|Dasatinib|50- 100 mg PO BID
3044924|NCT00546117|Experimental|Lansoprazole (Prevacid)|Prevacid SoluTab (15 or 30 mg tab) once daily for 2 months
3044925|NCT00546117|Placebo Comparator|Placebo|Placebo SoluTab once daily for 2 months
3044926|NCT00546156|Active Comparator|HR+, HER2-|Patients with Hormone Receptor Positive, HER2 negative Breast Cancer. A single dose of Bevacizumab 10mg/kg, followed two weeks later by Adriamycin60 mg/m2 and Cyclophosphamide 600 mg/m2 with Bevacizumab 10mg/kg every 2 weeks x4, followed by Taxol 175 mg/m2 with Bevacizumab 10 mg/kg every 2 weeks x3, followed by Taxol 175 mg/m2 x1.
3044927|NCT00546156|Active Comparator|Triple Negative Breast Cancer Cohort|Hormone receptor negative, HER2 negative Cohort. Receive same drug protocol as Arm A.
3044928|NCT00546260|Placebo Comparator|1|Placebo for each Dose cohort: 10, 20, 40, and 60 mg
3044929|NCT00546260|Experimental|2|Experimental drug for each Dose cohort: 10, 20, 40, and 60 mg
3044930|NCT00546273|Experimental|RUTI 5 micrograms of FCMtb|RUTI dose: 5 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3044931|NCT00546273|Experimental|RUTI 25 micrograms of FCMtb|RUTI dose: 25 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3044932|NCT00546273|Experimental|RUTI 100 micrograms of FCMtb|RUTI dose: 100 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3044933|NCT00546273|Experimental|RUTI 200 micrograms of FCMtb|RUTI 200 micrograms of FCMtb (for fragmented cells of M. tuberculosis) (n=4)
3044934|NCT00546273|Placebo Comparator|placebo|placebo of the vaccine RUTI (total n=8, n=2 for each period)
3044935|NCT00546351|Experimental|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years.
3044936|NCT00546364|Experimental|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|
3044937|NCT00546364|Experimental|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|
3044938|NCT00546364|Active Comparator|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|
3044939|NCT00546377|Experimental|Mitoxantrone|
3044940|NCT00546390|Experimental|Ischemic Preconditioned Group (rIP)|A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
3044941|NCT00546390|No Intervention|No Cuff|No rIP
3044942|NCT00546429|Other|A|Monitoring of trochanteric fractures after treatment with the ATN system.
3044943|NCT00546481|Experimental|Correction Phase: CERA|
3044944|NCT00546481|Active Comparator|Correction Phase: Epoetin Beta|
3044945|NCT00546572|Experimental|1|Receives 13vPnC at year 0 and 13vPnC at year 1
3044946|NCT00546572|Active Comparator|2|Receives 23vPS at year 0 and 13vPnC at year 1
3044947|NCT00546637|Experimental|Fesoterodine 4mg or 8mg|
3044948|NCT00546637|Placebo Comparator|Placebo|
3044949|NCT00546715|Active Comparator|Dose Panel A|"Daclatasvir - 1 mg~Placebo - 0 mg"
3044950|NCT00546715|Active Comparator|Dose Panel B|"Daclatasvir - 10 mg~Placebo - 0 mg"
3044951|NCT00546715|Active Comparator|Dose Panel C|"Daclatasvir - 100 mg~Placebo - 0 mg"
3044952|NCT00546715|Active Comparator|Dose Panel D|"Daclatasvir - 0.5 - 200 mg (to be determined)~Placebo - 0 mg"
3178920|NCT00667043|Active Comparator|Study group 2|Propofol and remifentanil; continuous intravenous infusion
3044953|NCT00546728|Experimental|Exenatide|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
3044954|NCT00546728|Active Comparator|Metformin|Subjects were randomlly assigned to treatment arm: Exenatide 10 mcg twice daily vs. Metformin 500 mg twice daily.
3044955|NCT00546754|Experimental|1|Drug Arm
3044956|NCT00546754|Active Comparator|2|active comparator
3044957|NCT00546819|Experimental|ZOSTAVAX™|Participants administered ZOSTAVAX™ on Day 1.
3044958|NCT00546819|Placebo Comparator|Placebo|Participants administered Placebo on Day 1.
3044959|NCT00546884|Placebo Comparator|MI|The MI condition will expose participants to the provision of an advance directive and written instructions, roughly mimicking community standards and the requirements of the federal Patient Self Determination Act.
3044960|NCT00546884|Active Comparator|GI|Subjects randomized to the GI group will be invited to meet individually with a health care professional specializing in EOL care
3044961|NCT00546897|Experimental|Cohort 1|"Lenalidomide 50 mg/day oral for 14 days followed by 30 days of rest. Lenalidomide 50 mg/day oral for 21 days (this is Cycle 1 and Cycle 2).~If no progressive disease (PD) then lenalidomide 10 mg/day oral for 28 days for 12 cycles."
3044962|NCT00546897|Experimental|Cohort 2|"Cycle 1: Oral lenalidomide 50 mg/day x 28 days induction therapy. Treatment will then depend on the response to Cycle 1: if patients obtain a complete remission (CR) they will proceed to low dose lenalidomide therapy, if patients have a non-CR they will receive a second high dose cycle of lenalidomide 50 mg/day x 28 days (Cycle 2) Cycle 2 consists of lenalidomide 50mg/day x 28 days Further treatment will depend on the response to Cycle 2: if patients obtain a CR/partial remission (PR)/stable disease (SD) they will proceed to low dose lenalidomide therapy, if patients have PD they will be removed from the study.~Low Dose Cycles: low dose lenalidomide therapy consisting of 10 mg daily for a 28 day cycle.be 1) For patients that achieve a CR, 2 cycles of low dose lenalidomide will be administered, and then patients observed off therapy. For patients with PR/SD, low dose lenalidomide will continue for a total of 6 cycles and then patients will be observed off therapy."
3044963|NCT00546910|Experimental|Atomoxetine|0.5 milligram per kilogram (mg/kg) per day lead-in dose for 1 weeks followed by 7 weeks at 1.2 mg/kg per day dose.
3044964|NCT00546910|Placebo Comparator|Placebo|Placebo matched to 1 week lead-in and 7 week standard target dose of atomoxetine
3044965|NCT00547105|Experimental|erlotinib in combination with SBRT|Patients enrolled on the trial will have been receiving or will begin to receive erlotinib at standard doses (150 mg po per day). SBRT will commence within 4 weeks of the initiation of erlotinib
3044966|NCT00547118|Experimental|1|Rimonabant
3044967|NCT00547118|Placebo Comparator|2|Placebo
3044968|NCT00547157|Active Comparator|ARM 1 CRT|Cisplatin plus RT
3044969|NCT00547157|Experimental|ARM 2 PRT|Panitumumab plus RT
3044970|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of Synflorix™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ vaccines at 12-18 months of age.
3044971|NCT00547248|Active Comparator|Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group|Subjects in the Philippines, primary vaccinated at 6-10-14 weeks of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix™-HepB/ Hiberix™ and Polio Sabin™ at 12-18 months of age.
3044972|NCT00547248|Experimental|Synflorix + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of Synflorix™ vaccine co-administered with Tritanrix™-HepB/Hiberix™ and Poliorix™ vaccines at 12-18 months of age.
3044973|NCT00547248|Active Comparator|Prevenar + Tritanrix -HepB/ Hiberix + Poliorix Group|Subjects in Poland, primary vaccinated at 2-4-6 months of age, receiving booster dose of the Prevenar™ vaccine, co-administered with Tritanrix -HepB/ Hiberix and Poliorix™ at 12-18 months of age.
3044974|NCT00547365|Experimental|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
3044975|NCT00547378|Other|1|InterStim Therapy
3044976|NCT00547378|Active Comparator|2|Standard Medical Therapy
3044977|NCT00547521|Experimental|Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
3044978|NCT00547521|Experimental|SC Abatacept Monotherapy Cohort|In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.
3044979|NCT00547534|Experimental|Lymphoma Subjects receiving protocol therapy|Subjects that met all eligibility criteria and were treated with Bendamustine, Rituxan and Bortezomib.
3044980|NCT00547586|Placebo Comparator|Placebo|
3044981|NCT00547586|Experimental|150 mg|
3044982|NCT00547586|Experimental|300 mg|
3044983|NCT00547586|Experimental|450 mg|
3044984|NCT00547586|Experimental|600 mg|
3044985|NCT00547638|Experimental|Dermabond Protape|DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
3044986|NCT00547638|Active Comparator|Dermabond HVD|DERMABOND HVD Topical Skin Adhesive
3044987|NCT00547703|Active Comparator|Nortriptyline|Patients in this group will receive Nortriptyline 25mg at night for 8 weeks.
3044988|NCT00547703|Placebo Comparator|Sugar pill|Patients in this group will receive an identical placebo capsule at night for 8 weeks.
3044989|NCT00547729|Experimental|HeartPOD™ System|Implantation of HeartPOD™ Heart Failure Management System with DynamicRx®
3044990|NCT00547898|Experimental|Placebo|
3044991|NCT00547898|Experimental|Crofelemer 125 mg|
3044992|NCT00547898|Experimental|Crofelemer 250 mg|
3044993|NCT00547898|Experimental|Crofelemer 500 mg|
3132881|NCT03462745|Experimental|Cannulation with AccuVein AV 300|The AccuVein AV300 device helps in venepuncture and intravenous (IV) cannulation. It uses infrared light that can be absorbed by the blood hemoglobin so that veins location is clearly viewed on the skin's surface.
3178921|NCT00667056|Experimental|1|
3178922|NCT00667056|Placebo Comparator|2|
3044994|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + CAR; LDOPS + ENT|Each subject received 400 mg of droxidopa (LDOPS) with three separate interventions, i.e., LDOPS with 200 mg placebo, LDOPS with 200 mg carbidopa (CAR), and LDOPS with 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + CAR, followed by LDOPS + ENT.
3044995|NCT00547911|Experimental|LDOPS + Placebo; LDOPS + ENT; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + Placebo, followed by LDOPS + ENT, and lastly LDOPS + CAR.
3044996|NCT00547911|Experimental|LDOPS + CAR; LDOPS + Placebo; LDOPS + ENT|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + Placebo, and lastly LDOPS + ENT.
3044997|NCT00547911|Experimental|LDOPS + CAR; LDOPS + ENT; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + CAR, followed by LDOPS + ENT, and lastly LDOPS + Placebo.
3044998|NCT00547911|Experimental|LDOPS + ENT; LDOPS + Placebo; LDOPS + CAR|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + Placebo, and lastly LDOPS + CAR.
3044999|NCT00547911|Experimental|LDOPS + ENT; LDOPS + CAR; LDOPS + Placebo|There are three interventions that every subject orally received over the duration of the study; 400 mg of droxidopa (LDOPS) + 200 mg placebo, 400 mg of droxidopa (LDOPS) + 200 mg carbidopa (CAR), and 400 mg of droxidopa (LDOPS) + 200 mg entacapone (ENT). The order of the three interventions was randomly assigned prior to drug administration and each intervention was followed by a wash out period of at least two days to clear previous intervention from subject's systems. This arm received the three interventions in the order of: LDOPS + ENT, followed by LDOPS + CAR, and lastly LDOPS + Placebo.
3045000|NCT00548041|Other|Rapid HIV Tested|Subjects have HIV testing by oral swab performed.
3178923|NCT00667069|Other|A Relapse|Radiotherapy and Hormonotherapy only if relapse
3178924|NCT00667069|Experimental|B Immediate treatment|Radiotherapy and Hormonotherapy at randomization
3045003|NCT00548132|No Intervention|1|Patients in this arm will continue to get routine care
3045004|NCT00548132|Experimental|Chlorhexidine-impregnated foam dressing|Patient's catheters were cleaned with chlorhexidine-alcohol solution at least weekly before application of the Biopatch. These were evaluated daily and if the dressing was bloody, soiled or damaged, the dressing and the Biopatch were replaced prior to the 7-day period.
3045005|NCT00548145|Experimental|1|
3045006|NCT00548145|Active Comparator|2|
3045007|NCT00548171|Experimental|Boostrix I Group|Subjects who had received the Boostrix™ vaccine in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the same vaccine, intramuscularly in the deltoid region of the non-dominant arm.
3045008|NCT00548171|Active Comparator|Boostrix II Group|Subjects who had received the Td vaccines in the primary study 263855/002 (NCT01267058), were boosted in the current study with one dose of the Boostrix™ vaccine intramuscularly in the deltoid region of the non-dominant arm.
3045009|NCT00548184|Experimental|Single Group Assignment|Lapatinib Trastuzumab Endocrine
3045010|NCT00548197|Experimental|Intervention group|Intravitreal Bevacizumab will be injected 2.5 mg IVB 3-5 days before operation in diabetic patients who were candidates for vitrectomy before performing pars plana vitrectomy
3045011|NCT00548197|No Intervention|Control group|no injection before performing pars plana vitrectomy in diabetic patients who were candidates for vitrectomy
3045012|NCT00548249|Placebo Comparator|0 µg iron/dL of dialysate|Placebo 0 micrograms (µg) of iron/ deciliter (dL) of dialysate
3045013|NCT00548249|Experimental|5 µg iron/dL of dialysate|5 micrograms (µg) of iron/ deciliter (dL) of dialysate
3045014|NCT00548249|Experimental|10 µg iron/dL of dialysate|10 micrograms (µg) of iron/ deciliter (dL) of dialysate
3045015|NCT00548249|Experimental|12 µg iron/dL of dialysate|12 micrograms (µg) of iron/ deciliter (dL) of dialysate
3045016|NCT00548249|Experimental|15 µg iron/dL of dialysate|15 micrograms (µg) of iron/ deciliter (dL) of dialysate
3045017|NCT00548262|Experimental|1|
3045018|NCT00548340|Experimental|VEC-162 20 mg|VEC-162 (tasimelteon) 20 mg capsules PO daily for five weeks
3045019|NCT00548340|Experimental|VEC-162 50 mg|VEC-162 (tasimelteon) 50 mg capsules PO daily for five weeks
3045020|NCT00548340|Placebo Comparator|Placebo|Placebo capsules PO daily five weeks
3045021|NCT00548405|Experimental|Alemtuzumab 12 mg|Alemtuzumab (Lemtrada™) 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
3045022|NCT00548405|Experimental|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
3178925|NCT00667082|Experimental|NPI-0052 + Vorinostat Dose-Escalation|4 dose-escalation cohorts
3045023|NCT00548405|Active Comparator|Interferon Beta-1a|Interferon Beta-1a (Rebif®) 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
3045024|NCT00548418|Experimental|I|"Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle"
3045025|NCT00548431|Experimental|6 mercaptopurine arm|All patients received basic daily 6MP (6-mercaptopurine) (25 mg/m^2) and in addition high-dose methotrexate(HDM) every 3rd week (3 times HDM in total) and PEG-asparaginase every 14th day. Patients increased the dose of 6MP 2 weeks after each HDM if if the myelotoxicity had been acceptable. This means 2 increments since the study stopped 2 weeks after the last HDM
3045026|NCT00548470|Experimental|varenicline|open label varenicline 2mg/day
3045027|NCT00548548|Experimental|Bevacizumab|Participants received intravenous (IV) bevacizumab 7.5 mg/kg every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. Bevacizumab and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
3045028|NCT00548548|Placebo Comparator|Placebo|Participants received intravenous (IV) placebo infusion every 3 weeks, oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, or 5-fluorouracil (5-FU) at a dose of 800 mg/m˄2/day as a continuous IV infusion over the first 5 days of every 3 week cycle, and cisplatin 80 mg/m˄2 as an IV infusion every 3 weeks for a maximum of 6 cycles. The placebo and capecitabine/5-FU were administered until disease progression or unacceptable toxicity.
3045029|NCT00548652|No Intervention|1|standard nutrition counselling
3045030|NCT00548652|Experimental|2|MOVE -weight loss intervention
3045031|NCT00548652|Experimental|3|MOVE plus medical crisis counselling
3045032|NCT00548652|Experimental|4|MOVE plus methylphenidate
3045033|NCT00548652|Experimental|5|MOVE plus methyphenidate plus medical crisis counselling
3045034|NCT00548691|Experimental|Ferric Carboxymaltose (FCM)|Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
3045035|NCT00548691|Active Comparator|Standard Medical Care (SMC)|SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
3045036|NCT00548717|Experimental|Siro/MMF|Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF)
3045037|NCT00548717|Experimental|Siro/MMF/Bort|Sirolimus, Mycophenolate Mofetil, and Bortezomib as GVHD Prophylaxis Sirolimus (Rapamycin); Mycophenolate Mofetil (MMF) Bortezomib (Velcade) *added with study reopening in 2012
3045038|NCT00548808|Experimental|Insulin lispro low mixture|Insulin lispro low mixture (1, 2 or 3 daily injections)
3045039|NCT00548808|Active Comparator|Insulin glargine|Insulin glargine (alone or with 1, 2 or 3 daily injections of insulin lispro)
3045040|NCT00548847|Experimental|GM-CSF, Interferon-α-2b|
3045041|NCT00548860|Experimental|Ferric Carboxymaltose (FCM)|Undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg)
3045042|NCT00548860|Active Comparator|Standard Medical Care (SMC)|Varied as determined by the Investigator
3045043|NCT00549042|Experimental|OROS hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
3045044|NCT00549042|Placebo Comparator|placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
3045045|NCT00549055||1|Patients who obtained reimbursement of Macugen.
3045046|NCT00549172|Active Comparator|Operative (O)|Partial resection of degenerative tear of medial meniscus
3045047|NCT00549172|Sham Comparator|Conservative (K)|Arthroscopy (diagnostic)
3045048|NCT00549198|Experimental|ABC/3TC + EFV|
3045049|NCT00549198|Active Comparator|TDF/FTC + EFV|
3045050|NCT00549302|Active Comparator|20 mg tadalafil|20 milligram (mg) tadalafil taken once a day
3045051|NCT00549302|Active Comparator|40 mg tadalafil|40 mg tadalafil tablet taken once a day
3045052|NCT00549393|Experimental|1|Daily bathing with 2% chlorhexidine gluconate
3045053|NCT00549393|No Intervention|2|Standard bathing with soap and water basin or disposable cloth
3045054|NCT00549445||Azithromycin-treated|Participants in the COPD Network Macrolide Study who received azithromycin for 1 year.
3045055|NCT00549445||Placebo-treated|Participants in the COPD Network Macrolide Study who received placebo for 1 year.
3045056|NCT00549549|Active Comparator|1|
3045057|NCT00549549|Experimental|2|
3045058|NCT00549549|Experimental|3|
3045059|NCT00549549|Experimental|4|
3045060|NCT00549562|Other|Paliperidone ER|8-Week Open-Label
3045061|NCT00549601|Experimental|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|
3045062|NCT00549601|Experimental|Rivastigmine patch (9.5 mg/day)|
3045063|NCT00549601|Active Comparator|Rivastigmine capsules (6 mg to 12 mg/day)|
3045064|NCT00549640|Active Comparator|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
3045065|NCT00549640|Placebo Comparator|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
3045066|NCT00549718|Experimental|Lurasidone 40mg|
3045067|NCT00549718|Experimental|Lurasidone 80mg|
3045068|NCT00549718|Experimental|Lurasidone 120mg|
3045069|NCT00549718|Placebo Comparator|Sugar Pill|
3045070|NCT00549757|Experimental|Aliskiren|"In Core (Double Blind) phase, Aliskiren 150 mg once daily (o.d.) for 4 weeks; then patient was uptitrated to 300 mg o.d. at Visit 5/Week 4 (or 150 mg o.d. if patient could not tolerate target dose of study drug). Visits took place at 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment"
3178926|NCT00667108|Experimental|Gabapentin 250 mg|
3178927|NCT00667108|Experimental|Gabapentin 500 mg|
3045071|NCT00549757|Placebo Comparator|Placebo|"In Core (Double Blind) phase, placebo to match aliskiren 150 mg once daily (o.d.) for 4 weeks; from Visit 5/Week 4 placebo to match aliskiren 300 mg o.d. (or placebo to match aliskiren 150 mg if patient could not tolerate target dose of study drug). Visits took place 1, 4 , 5, 8 and 12 weeks after randomization (Visit 3/Week 0). Subsequent visits were planned every three months until end of core phase.~With the recommendation of Data Monitoring Committee (DMC), after discontinuation of study drug, a follow up was added as Extension Phase (9 months in average) with no active treatment."
3045072|NCT00549770|Experimental|LCZ696 100 mg|Participants received LCZ696 100 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045073|NCT00549770|Experimental|LCZ696 200 mg|Participants received LCZ696 200 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045074|NCT00549770|Experimental|LCZ696 400 mg|Participants received LCZ696 400 mg (200 mg LCZ696 for one week and then up-titration to 400 mg LCZ696 for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045075|NCT00549770|Active Comparator|Valsartan 80 mg|Participants received Valsartan 80 mg and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045076|NCT00549770|Active Comparator|Valsartan 160 mg|Participants received Valsartan 160 mg and matching placebo to LCZ696, Valsatan and AHU377 (5 tablets and 2 capsules) daily.
3045077|NCT00549770|Active Comparator|Valsartan 320 mg|Participants received Valsartan 320 mg (160 mg valsartan capsules for one week followed by 320 mg valsartan capsules for 7 weeks) and matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045078|NCT00549770|Experimental|AHU377 200 mg|Participants received AHU377 200 mg and matching placebo to LCZ696 and Valsartan (5 tablets and 2 capsules) daily.
3045079|NCT00549770|Placebo Comparator|Placebo|Participants received matching placebo to LCZ696, Valsartan and AHU377 (5 tablets and 2 capsules) daily.
3045080|NCT00549783|Active Comparator|Botulinum toxin type A 900kD|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
3045081|NCT00549783|Placebo Comparator|Placebo|First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit.
3045082|NCT00549822|Experimental|Intermittent letrozole therapy|Letrozole 2.5 mg administered by mouth daily during each 28 day treatment cycle. Treatment is intermittent with possible breaks between each 28 day treatment cycle based on CA 15-3 or CA 27.29 levels. Letrozole is administered until the participant has disease progression as determined by RECIST (Response Evaluation Criteria In Solid Tumors), experiences severe side effects, or decides to stop treatment.
3045083|NCT00549900|Experimental|Cervarix Group|Subjects received 3 doses of GSK580299 vaccine (Cervarix™, HPV -16/18 L1 VLP AS04 vaccine) according to a 0, 1, 6-month schedule.
3045084|NCT00549939|Placebo Comparator|Placebo|Matching placebo 0.1 mg/kg/day or 0.2 mg/kg/day
3045085|NCT00549939|Experimental|Alfuzosin 0.1 mg/kg/day|
3045086|NCT00549939|Experimental|Alfuzosin 0.2 mg/kg/day|
3045087|NCT00550043|Experimental|Cohort 1: Treatment Group A|INCB018424 15 mg twice daily (BID) or matching placebo
3045088|NCT00550043|Experimental|Cohort 2: Treatment Group B|INCB018424 5 mg BID or matching placebo
3045089|NCT00550043|Experimental|Cohort 2: Treatment Group C|INCB018424 25 mg BID or matching placebo
3045090|NCT00550043|Experimental|Cohort 2: Treatment Group D|INCB018424 50 mg once daily (QD) or matching placebo
3045091|NCT00550043|Placebo Comparator|Placebo|Matching placebo, oral
3045092|NCT00550147|Experimental|1|Oros Methylphenidate and Quetiapine
3045093|NCT00550173|Experimental|Pemetrexed + Erlotinib|Pemetrexed 500 milligrams per meter squared (mg/m^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
3045094|NCT00550173|Active Comparator|Erlotinib|Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
3045095|NCT00550173|Active Comparator|Pemetrexed|Pemetrexed 500 mg/m^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.
3045096|NCT00550238|Experimental|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
3045097|NCT00550277|Other|Treatment|LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
3045098|NCT00550290|Active Comparator|Cefazolin Preoperatively|Participants received Cefazolin 2 grams intravenously within 30 minutes prior to incision
3045099|NCT00550290|Experimental|Cefazolin Postoperatively|Participants received Cefazolin 2 gram intravenous within 30 minutes prior to incision and 1 gram Cefazolin every 8 hours for the first 24 hours post-op
3045100|NCT00550368|Experimental|Helicobacter pylori negative|Persons who tested negative for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
3045101|NCT00550368|Experimental|Helicobacter pylori positive|Persons who tested positive for H. pylori by both serology and Urea breath test. All participants will receive the Biological intervention: Enteropathogenic E. coli.
3045102|NCT00550394|Active Comparator|Quetiapine and Placebo|Quetiapine and Placebo
3045103|NCT00550394|Experimental|Quetiapine and Topiramate|Quetiapine and Topiramate
3045104|NCT00550407|Placebo Comparator|Placebo|
3045105|NCT00550407|Active Comparator|BW430C(lamotrigine)|
3045106|NCT00550420|Experimental|Arm 1|Rosiglitazone XR
3045107|NCT00550446|Active Comparator|1|
3045108|NCT00550446|Experimental|2|
3045109|NCT00550446|Experimental|3|
3045110|NCT00550446|Experimental|4|
3045111|NCT00550446|Experimental|5|
3045112|NCT00550446|Experimental|6|
3045113|NCT00550446|Placebo Comparator|7|
3045114|NCT00550459|Placebo Comparator|1|Placebo tablet given once a day for 21 days
3045115|NCT00550459|Active Comparator|2|Tolvaptan 15 mg-60 mg tablet given once a day for 21 days.
3045116|NCT00550537|Experimental|Treatment|Erlotinib followed by paclitaxel + carboplatin (+ bevacizumab in non-squamous) at the time disease progression.
3045117|NCT00550550|Placebo Comparator|Placebo|Matching Placebo
3045118|NCT00550550|Experimental|SCH 697243|Grass Sublingual Tablet (Phleum pratense extract)
3045119|NCT00550589|Experimental|Cidofovir|1.0% topical cidofovir cream
3045120|NCT00550615|Experimental|Dasatinib Dose Escalation|Phase 1 employed a standard 3+3 dose-escalation design to assess safety, MTD and dose-limiting toxicity (DLT). Maximum Tolerated Dose (MTD) was defined as the next lowest dose level below where ≥ 2/3 or ≥ 3/6 patients experience dose limiting toxicities in cycle 1.
3045121|NCT00550615|Experimental|Dasatinib Maximum Tolerated Dose|Once the maximum tolerated dose is determined, an additional patients will be enrolled into the Phase II portion of this trial.
3045122|NCT00550654|Experimental|Radiation Therapy in Metastatic Cancer|Patients undergo hypofractionated highly conformal radiotherapy with helical tomotherapy once every other day over 5 days for a total of 3 fractions.
3045123|NCT00550680|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia who have been previously treated with erythropoiesis-stimulating agent (ESA) therapy will receive IV Mircera every 4 weeks for a total of 24 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment. Subsequent doses will be adjusted to maintain Hb concentrations within target of 10.5 and 12.5 grams per deciliter (g/dL).
3045124|NCT00550732|Experimental|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
3045125|NCT00550745|Experimental|1|Arm 1: vaccine
3045126|NCT00550745|Placebo Comparator|2|Arm 2: Placebo Comparator
3045127|NCT00550771|Active Comparator|Doxorubicin Based Regimen|
3045128|NCT00550771|Experimental|Pegylated Liposomal Doxorubicin (PLD) Based Regimen|
3045129|NCT00550836|Active Comparator|Arm A: GE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
3045130|NCT00550836|Experimental|Arm B: PGE|Patients receive 1000 mg/m^2 gemcitabine hydrochloride IV on days 1, 8, and 15; 100 mg oral erlotinib hydrochloride on days 1 - 28; and 4.0 mg/kg panitumumab IV on days 1 and 15. Treatment repeats every 28 days for 2 courses. Patients achieving a CR after 2 courses receive 2 additional courses of treatment; patients achieving a PR receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride and panitumumab until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride, erlotinib hydrochloride, and panitumumab until second progression.
3045131|NCT00550862|Experimental|INT-747 10 mg|INT-747 10 mg once daily in combination with URSO for 12 weeks.
3045132|NCT00550862|Experimental|INT-747 25 mg|INT-747 25 mg once daily in combination with URSO for 12 weeks.
3045133|NCT00550862|Experimental|INT-747 50 mg|INT-747 50 mg once daily in combination with URSO for 12 weeks.
3045134|NCT00550862|Placebo Comparator|Placebo|Placebo once daily in combination with URSO for 12 weeks.
3045135|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 1|Influenza Virus Vaccine Formulation 1
3045136|NCT00551031|Experimental|Influenza Virus Vaccine Formulation 2|Influenza Virus Vaccine Formulation 2
3045137|NCT00551031|Active Comparator|Fluzone® Elderly Group|
3045138|NCT00551031|Active Comparator|Fluzone® High-dose Group|Participants enrolled at age ≥ 65 years
3045139|NCT00551031|Active Comparator|Fluzone® Adults Group|Participants enrolled at age 18-49 years.
3045140|NCT00551070|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3045141|NCT00551135|Experimental|3|
3045142|NCT00551135|Placebo Comparator|4|
3045143|NCT00551135|Experimental|2|
3045144|NCT00551135|Experimental|1|
3045145|NCT00551161|Experimental|single-arm|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 20 mg per day, in addition to their ongoing stable cholinesterase inhibitor treatment
3045146|NCT00551174|Experimental|1|
3045147|NCT00551174|Active Comparator|2|
3045148|NCT00551200|Active Comparator|BUPHENYL® to HPN-100 vs. HPN-100|Buphenyl treatment for one week was followed by dose escalation to HPN-100. Dose of Buphenyl was gradually decreased while HPN-100 dose was gradually increased until subject reached dosing of 100% HPN-100. HPN-100 at 100% of the dose was given for 1 week before subject was switched back to original Buphenyl treatment.
3045149|NCT00551213|Experimental|Robatumumab→Robatumumab|Participants receive 1 dose of robatumumab 0.3 mg/kg intravenously (IV) followed by 1 dose of robatumumab 10 mg/kg IV once every 2 weeks (Q2W) until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
3045150|NCT00551213|Active Comparator|Chemotherapy→Robatumumab|Participants receive 1 cycle of standard colorectal cancer chemotherapy currently approved and available on the market for use in colorectal cancer (to be selected by the Investigator based on participant's prior treatment) followed by 1 dose of robatumumab 10 mg/kg IV Q2W until disease progression. A cycle of robatumumab is defined as 2 weeks of treatment (i.e., 1 dose of robatumumab) with no recovery period between cycles.
3132882|NCT03462745|No Intervention|Standard insertion|Intravenous cannulation is an invasive procedure of inserting an intravenous catheter blindly through the skin, into the lumen of a peripheral vein.
3045151|NCT00551291|Experimental|Mycophenolate Mofetil + Prednisone + Erythropoietin Beta|Mycophenolate mofetil (MMF) 1 gm twice daily orally and prednisone 10 mg/day orally until the end of the study. Recombinant human erythropoietin beta 30,000 IU/week, subcutaneously for 6 weeks was added in case of no significant response at Week 12.
3045152|NCT00551369|Experimental|SBRT|Stereotactic body radiation therapy (SBRT)
3045153|NCT00551421|Experimental|Arm I|"Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I)."
3045154|NCT00551460|Experimental|Treatment|"Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year"
3045155|NCT00551525|Experimental|Radiotherapy + Samarium 153|Samarium 153 infusion followed by radiotherapy 12 weeks later
3045156|NCT00551642|Active Comparator|Inhaled Nitric Oxide (INO)|INO administered by nasal continuous positive airway pressure, nasal cannula or face mask at 5 parts per million (ppm) for between 7 and 21 days
3045157|NCT00551642|Placebo Comparator|Placebo|Placebo gas administered by nasal continuous positive airway pressure, nasal cannula or face mask, for a maximum of 21 days.
3045158|NCT00551707|Experimental|CRx-102 (2.7/180)|CRx-102 dose 1 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM titration dose (days 0-13) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM
3045159|NCT00551707|Experimental|CRx-102 (2.7/360)|CRx-102 Dose 2 total daily dose during treatment period (days 14-98) 2.7 mg prednisolone plus 360 mg dipyridamole administered as 1.8 mg prednisolone plus 180 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 2.7 mg prednisolone plus 90 mg dipyridamole administered as 1.8 mg prednisolone plus 45 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 2.7 mg prednisolone plus 180 mg dipyridamole administered as 1.8 mg prednisolone plus 90 mg dipyridamole at 8 AM and 0.9 mg prednisolone plus 90 mg dipyridamole at 1 PM
3045160|NCT00551707|Active Comparator|Prednisolone|treatment dose ( days 0-98) total daily dose of 2.7 mg prednisolone administered as 1.8 mg prednisolone at 8 AM and 0.9 mg prednisolone at 1 PM
3045161|NCT00551707|Active Comparator|Dipyridamole|total daily dose during treatment period (days 14-98) 360 mg dipyridamole administered as 180 mg dipyridamole at 8 AM and and 180 mg dipyridamole at 1 PM titration dose 1 (days 0-6) 90 mg dipyridamole administered 45 mg dipyridamole at 8 AM and 45 mg dipyridamole at 1 PM titration dose 2 (days 7-13) 180 mg dipyridamole administered as 90 mg dipyridamole at 8 AM and 90 mg dipyridamole at 1 PM
3045162|NCT00551707|Placebo Comparator|Placebo|placebo administered twice per day at 8 AM and 1 PM
3045163|NCT00551746|Active Comparator|1|Grape Juice
3045164|NCT00551746|Placebo Comparator|2|Grape Juice Placebo
3045165|NCT00551759|Experimental|Neoadjuvant therapy, Surgery, adjuvant therapy|"Neoadjuvant chemoradiotherapy and cetuximab: Patients (pts) receive oxaliplatin IV over 2 hours on days 1, 15, and 29, cetuximab IV over 1-2 hours on days 1, 8, 15, 22, and 29, and 5-FU IV over 24 hours on days 1-35. Pts also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Pts then proceed to surgery.~Surgery: Pts undergo surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab. Pts with an R0 or R1 resection proceed to adjuvant therapy. Pts whose tumors have not been completely resected or who have metastatic disease discontinue protocol therapy and receive further therapy at the discretion of the treating physician.~Adjuvant therapy: Within 4-8 weeks after surgery, pts receive docetaxel IV over 1 hour on days 1, 8, 15, 22, and 29 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
3045166|NCT00552032|Experimental|Mometasone Furoate nasal spray|
3045167|NCT00552032|Placebo Comparator|Placebo|
3045168|NCT00552058|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg for subcutaneous (sc) injection
3045169|NCT00552058|Placebo Comparator|Placebo|Placebo, saline solution for sc injection
3045170|NCT00552071|Experimental|Ultrasound-guided IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via ultrasound-guided IM gluteal injection every 28 days for 3 months.
3045171|NCT00552071|Active Comparator|Regular IM injections of octreotide LAR|Subjects received octreotide LAR 30 mg injection via regular IM gluteal injections every 28 days for 3 months
3045172|NCT00552084|Experimental|Fish Oil|4 grams fish oil daily for 24 weeks
3045173|NCT00552084|Placebo Comparator|Placebo|corn oil taken daily for 24 weeks
3045174|NCT00552110|Experimental|Combination1|Mometasone Furoate nasal spray (MFNS) with oxymetazoline nasal spray (OXY) 1 spray once daily
3045175|NCT00552110|Experimental|Combination3|MFNS with OXY 3 sprays once daily
3045176|NCT00552110|Active Comparator|Mometasone|MFNS once daily
3045177|NCT00552110|Active Comparator|Oxymetazoline|OXY twice daily
3045178|NCT00552110|Placebo Comparator|Placebo|Placebo nasal spray
3045179|NCT00552175|Experimental|Duloxetine 60|duloxetine 60 milligram (mg) taken orally every day
3045180|NCT00552175|Experimental|Duloxetine 40|Duloxetine 40 mg taken orally every day
3045181|NCT00552175|Placebo Comparator|Placebo|placebo comparator taken orally every day
3045182|NCT00552188|Experimental|VIA-2291|VIA-2291 100mg
3045183|NCT00552188|Placebo Comparator|Placebo|Matching placebo
3045184|NCT00552240|Active Comparator|NVP 200mg bis indie (BID)|after receiving nevirapine (NVP) 200 mg quaue die (QD) for 2 weeks, pt titrated to NVP 200 mg bis in die (BID) combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
3132883|NCT03462927|Experimental|MC2-01 Cream|MC2-01 cream (CAL and BDP, w/w 0.005%/ 0.064%).
3178928|NCT00667108|Placebo Comparator|Placebo|
3045185|NCT00552240|Active Comparator|Atazanavir 300 mg QD/ritonavir 100 mg QD|patients to receive atazanavir 300 mg QD boosted with ritonavir 100 mg QD combined with emtricitabine 200 mg QD/ tenofovir DF 300 mg QD (fixed dose combination Truvada) for 48 weeks
3045186|NCT00552279|Experimental|Cervarix-12 Group|Women received 3 doses of Cervarix TM (human papillomavirus (HPV) vaccine) administered according to a 0, 1, 12-month schedule
3045187|NCT00552279|Active Comparator|Cervarix-6 Group|Women received 3 doses of Cervarix TM (HPV vaccine) administered according to a 0, 1, 6-month schedule.
3045188|NCT00552305|Experimental|Lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing
3045189|NCT00552344|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg/vial; 400 mg subcutaneously at Week 0, 2 and 4, thereafter 400 mg subcutaneously at every 4 weeks.
3045190|NCT00552409|Experimental|Cholecalciferol|
3045191|NCT00552409|Placebo Comparator|Placebo|
3045192|NCT00552422|Experimental|Domperidone Arm|Study subjects will self-administer oral domperidone 10mg four times a day. If symptoms persist for more than 7 days, the investigator may increase the dose to 20mg four times a day. 20mg four times a day will be the maximal dose. Subjects with signiﬁcant renal impairment will received a starting dose of 10mg twice a day. The maximal dose in subjects with signiﬁcant renal impairment will be 20mg twice a day.
3045193|NCT00552448|Experimental|1|Use of the HFCC device in addition to standard therapy for status asthmaticus. The use of HFCC will not affect the therapy received
3045194|NCT00552448|No Intervention|2|This group will not use the VEST or HFCC. They will just have standard therapy for status asthmaticus. The standard therapy will not be affected if they are in this group.
3045195|NCT00552513|Other|Early Coronary Intervention|Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (within 24 hours of randomisation).
3045196|NCT00552513|Other|Delayed Coronary Intervention|Delayed intervention: Coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
3045197|NCT00552578|Active Comparator|Tapering doses of buprenorphine|Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
3045198|NCT00552578|Experimental|Steady doses of buprenrophine|Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.
3045199|NCT00552617|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
3045200|NCT00552617|Experimental|Rocuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
3045201|NCT00552617|Experimental|Rocuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
3045202|NCT00552617|Experimental|Rocuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
3045203|NCT00552617|Experimental|Rocuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
3045204|NCT00552617|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
3045205|NCT00552617|Experimental|Vecuronium + 0.5 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
3045206|NCT00552617|Experimental|Vecuronium + 1.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
3045207|NCT00552617|Experimental|Vecuronium + 2.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
3045208|NCT00552617|Experimental|Vecuronium + 4.0 mg/kg Sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
3045209|NCT00552669|Experimental|A--Oral Rapamycin plus BMS|Oral sirolimus plus bare metal stent implantation
3045210|NCT00552669|Active Comparator|B -- Drug Eluting Stent|Drug Eluting Stents
3045211|NCT00552695|Active Comparator|1|Lidocaine 70 mg/tetracaine 70 mg skin patch
3045212|NCT00552695|Placebo Comparator|2|
3045213|NCT00552760|Experimental|Ramelteon|8 mg
3045214|NCT00552760|Placebo Comparator|Placebo|
3045215|NCT00552786|Experimental|Acetin|
3045216|NCT00552786|Placebo Comparator|Glucose|
3045217|NCT00552812|Experimental|Stent therapy of aortic coarctation|Stenting of aortic coarctation
3045218|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
3132884|NCT03462927|Active Comparator|CAL/BDP combination|CAL/BDP ointment (w/w 0.005%/0.064%).
3132885|NCT03463031|Experimental|GSP 301 NS|Fixed dose combination of olopatadine hydrochloride 665 μg and mometasone furoate 25 μg NS
3045219|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
3045220|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
3045221|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
3045222|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
3045223|NCT00552929|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
3045224|NCT00552929|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
3045225|NCT00552929|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
3045226|NCT00552929|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
3045227|NCT00552929|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
3045228|NCT00553059|Experimental|Arm I: Palonosetron, Dexamethasone + Dronabinol|Palonosetron hydrochloride intravenous (IV) and dexamethasone IV 30 minutes before chemotherapy administration on day 1, and oral dronabinol 3 times a day for 5 days beginning 30 minutes before chemotherapy administration on day 1.
3045229|NCT00553059|Active Comparator|Arm II: Palonosetron + Dexamethasone|Palonosetron hydrochloride and dexamethasone as in arm I, and oral placebo 3 times a day for 5 days beginning 30 minutes before chemotherapy on day 1.
3045230|NCT00553098|Experimental|Treatment (chemotherapy, low dose radiation)|"CONDITIONING REGIMEN: *Patients with no life-threatening viral or fungal infections within 1 month before the planned HCT receive alemtuzumab IV over 6 hours on day -10 and fludarabine phosphate IV over 30 minutes on days -4 to -2. They also undergo low-dose TBI on day 0. Patients with HLH, IPEX syndrome, DiGeorge syndrome, or life-threatening viral or fungal infections within 1 month before the planned HCT receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo 2 low doses of TBI on day 0.~HEMATOPOIETIC CELL TRANSPLANTATION: Patients undergo HCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV or PO 2-3 times daily beginning on day -3 and continuing until day 100 followed by a taper until day 180. They also receive mycophenolate mofetil IV or PO 3 times daily beginning on day 0 and continuing until day 40 followed by a taper until day 96."
3045231|NCT00553150|Experimental|Everolimus (RAD001), Radiation (RT), Temozolomide (TMZ)|"Patients receive oral everolimus and oral temozolomide and 3D-conformal radiotherapy or IMRT as in phase I. Patients will undergo a 4-6 week rest period in course 2 and then proceed to adjuvant therapy.~Adjuvant therapy with everolimus and temozolomide (courses 3-8): Patients receive oral everolimus and oral temozolomide as in phase I.~Adjuvant therapy with everolimus alone (courses 9 and all subsequent courses): Patients receive oral everolimus as in phase I.~All patients undergo fludeoxyglucose (FDG)- or fluorothymidine-labeled PET/CT scans at baseline and periodically during treatment."
3045232|NCT00553163|Active Comparator|Gut-focussed hypnotherapy (GFH).|Gut-focussed hypnotherapy (GFH).
3045233|NCT00553163|Sham Comparator|Educational sessions|Regular sessions to learn about UC from research nurse
3045234|NCT00553202|Experimental|Treatment (chemotherapy and allogeneic SCT)|"Patients receive busulfan IV every 6 hours on days -9 to -6, high-dose cyclophosphamide IV over 1 hour on days -5 to -2, anti-thymocyte globulin IV once or twice daily over 4 hours on days -3 to -1, and methylprednisolone IV on days -3 to -1.~Patients undergo allogeneic hematopoietic stem cell transplantation (SCT) or allogeneic bone marrow transplantation (BMT) on day 0.~Patients receive cyclosporine or tacrolimus IV or orally beginning on day -2 and continuing until day 50, followed by a taper until week 24. Patients also receive methotrexate IV on days 1, 3, 6, and 11.~Blood samples will be collected periodically from both patients and donors for studies of natural killer cells in support of the pharmacological study objectives"
3045235|NCT00553254|Experimental|1|
3045236|NCT00553280|Experimental|pregabalin|
3045237|NCT00553319|Placebo Comparator|Placebo|Placebo
3045238|NCT00553319|Experimental|Adderall-XR 60 mg|Adderall-XR 60 mg
3045239|NCT00553319|Experimental|Adderall-XR 80 mg|Adderall-XR 80 mg
3045240|NCT00553332|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive oral selumetinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3045241|NCT00553358|Experimental|Arm 1 Lapatinib|1500 mg lapatinib for 6 weeks followed by lapatinib plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib.
3132886|NCT03463031|Placebo Comparator|GSP 301 Placebo NS|GSP 301 Placebo nasal spray
3178929|NCT00667134||1|Subjects with diffuse scleroderma
3178930|NCT00667134||2|Subjects with limited scleroderma
3045242|NCT00553358|Active Comparator|Arm 2 Trastuzumab|4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks followed by 2 mg/kg trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
3045243|NCT00553358|Experimental|Arm 3 Lapatinib plus Trastuzumab|1000 mg lapatinib plus 4 mg/kg IV loading dose followed by 2 mg/kg IV weekly trastuzumab for 6 weeks, followed by 750 mg lapatinib plus 2 mg/kg IV weekly trastuzumab plus weekly paclitaxel for an additional 12 weeks. After definitive surgery, 3 cycles of adjuvant FEC followed by 34 weeks of adjuvant lapatinib (1000 mg) in combination with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks).
3045244|NCT00553410|Active Comparator|Continuous letrozole|Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
3045245|NCT00553410|Experimental|Intermittent letrozole|Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
3045246|NCT00553436|Experimental|Enrolled Subjects treated with TAS device|All enrolled subjects treated with the Tissue Apposition System (TAS) device
3045247|NCT00553462|Experimental|paclitaxel + carboplatin + radiation + erlotinib|"Patients receive paclitaxel IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses. Patient with rapid disease progression outside of the chest after induction therapy are removed from study.~Patients with intrathoracic disease progression within the potential radiation field may continue protocol therapy at the discretion of the Study Chair. Patients with no disease progression outside the planned radiation field (either regional or distant) proceed to concurrent erlotinib hydrochloride and radiotherapy.~Beginning on day 43 (week 7), patients receive oral erlotinib hydrochloride once daily. Patients also undergo concurrent radiotherapy 5 days a week for up to 7 weeks (33 fractions) in the absence of rapid disease progression outside of the chest or unacceptable toxicity.~After completion of study therapy, patients are followed every 3 months for 1 year, and then every 6 months for up to 2 years"
3045248|NCT00553475|Placebo Comparator|Placebo|
3045249|NCT00553475|Experimental|Pregabalin 300 mg/day|
3045250|NCT00553475|Experimental|Pregabalin 600 mg/day|
3045251|NCT00553501|Experimental|Epratuzumab Plus Rituximab|"Induction Therapy (Month 1): Epratuzumab 360 mg/m^2 by IV days 1, 8, 15 & 22; Rituximab 375 mg/m^2 by IV day 3, 8, 15 & 22~Extended Induction (Weeks 12, 20, 28 & 36) Epratuzumab 360 mg/m^2 by IV weeks 12, 20, 28 & 36; Rituximab 375 mg/m^2 by IV weeks 12, 20, 28 & 36"
3045252|NCT00553514|Experimental|AS900672-Enriched 10 mcg|
3045253|NCT00553514|Experimental|AS900672-Enriched 20 mcg|
3045254|NCT00553514|Experimental|AS900672-Enriched 30 mcg|
3045255|NCT00553514|Experimental|AS900672-Enriched 40 mcg|
3045256|NCT00553514|Active Comparator|Follitropin alfa 75 IU|
3045257|NCT00553540|No Intervention|Control Group|Patients in this group will receive physical therapy and posture education for low back pain
3045258|NCT00553540|Active Comparator|Test Group|Patients in this group will receive spinal / back supports in addition to physical therapy and posture education for low back pain
3045259|NCT00553605|Active Comparator|I|Ketoprofen plus placebo parecoxib
3045260|NCT00553605|Active Comparator|II|Parecoxib plus placebo ketoprofen
3045261|NCT00553631|Experimental|GA-GCB|VPRIV™ ,velaglucerase alfa
3045262|NCT00553631|Active Comparator|imiglucerase|
3045263|NCT00553644|Experimental|Treatment (bortezomib, lenalidomide)|Patients receive induction therapy comprising bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response as best response after completion of induction therapy receive maintenance therapy comprising bortezomib IV on days 1 and 8 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 6 years in the absence of disease progression or unacceptable toxicity.
3045264|NCT00553696|Experimental|A|
3045265|NCT00553735|Active Comparator|Cyclosporine A 0.05%|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
3045266|NCT00553735|Placebo Comparator|Artificial Tear|"If patients pass the screening criteria, both eyes are randomized to therapy. One eye will receive Cyclosporine A 0.05% (Restasis) and the other eye will receive Placebo (Artificial Tear)~The objective signs will be corneal and conjunctival staining, Schirmer test (with and without anesthesia), and tear break-up time. The subjective endpoints will be the SANDE symptom global score."
3045267|NCT00553787|Experimental|VI-0521 Top|high dose experimental treatment
3045268|NCT00553787|Experimental|VI-0521 Mid|mid dose experimental treatment
3045269|NCT00553787|Placebo Comparator|Placebo|Placebo
3045270|NCT00553839|Other|Ketamine|Then a 2 mg/kg IV bolus of Ketamine hydrochloride will be given as part of general anesthesia for procedure
3045271|NCT00553969|Experimental|1|Coreg CR + lisinopril
3045272|NCT00553969|Experimental|2|Coreg CR + placebo
3045273|NCT00553969|Experimental|3|lisinopril + placebo
3045274|NCT00553969|Placebo Comparator|4|placebo + placebo
3045275|NCT00554099|Placebo Comparator|Placebo|Days 1 thru Days 10 to 14 (Visit 2): daily antibiotic therapy, dietary advice, and 6 placebo tablets (matching mesalamine) once a day. Visit 2 thru Week 12 : 1 placebo capsule (matching probiotic) and 6 placebo tablets (matching mesalamine) daily.
3045276|NCT00554099|Active Comparator|Mesalamine|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once a day. Visit 2 thru Week 12: 1 placebo capsule (matching probiotic) and 6 - 400 mg mesalamine tablets daily.
3045277|NCT00554099|Active Comparator|Mesalamine & Probiotic|Days 1 thru 10-14 (Visit 2): daily antibiotic therapy, dietary advice and 6 - 400 mg mesalamine tablets once daily. Visit 2 thru Week 12: 1- Bifidobacterium infantis 35624 capsule and 6 - 400 mg mesalamine tablets daily
3045278|NCT00554190|Experimental|1|AdvaCoat compared to Merogel Injectable Bioresorbable Nasal Dressing
3045279|NCT00554190|Active Comparator|2|Merogel Injectable Bioresorbable Nasal Dressing compared to AdvaCoat
3045280|NCT00554216|Experimental|VI-0521 Low|VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
3045281|NCT00554216|Experimental|VI-0521 Top|Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
3045282|NCT00554216|Placebo Comparator|Placebo|Placebo to match
3045283|NCT00554229|Experimental|ZD4054|ZD4054 10 mg oral tablet once daily
3045284|NCT00554229|Placebo Comparator|Placebo|Matching Placebo, oral tablets once daily
3045285|NCT00554294|No Intervention|Control group|Control schools had school curriculum as usual and did not receive environmental intervention.
3045286|NCT00554294|Experimental|Intervention group|Intervention schools received water dispensers, drinking bottles and lessons as intervention.
3045287|NCT00554372|Experimental|Low Dose|1e8 pfu (plaque forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
3045288|NCT00554372|Experimental|High Dose|1e9 pfu (plaque-forming units) total dose of JX-594 (recombinant vaccinia virus) on each of three (3) treatment days (2 weeks apart)
3045289|NCT00554463|Experimental|Combined Modality Therapy with Growth Factor Support|Concurrent radiation therapy, cisplatin, etoposide, and filgrastim followed by adjuvant cisplatin, etoposide, and pegfilgrastim.
3045290|NCT00554515|Experimental|HD IL2|Participants received high-dose (HD) IL2, 600,000 IU/kg/dose (Prometheus Laboratories Inc.) i.v. every 8 hours for 5 days (maximum of 14 doses) beginning on day 1 and again on day 15. One course generally consisted of 5 days of treatment, 9 days of rest, 5 more days of treatment, and 9 weeks of rest, followed by up to two additional courses of HD IL2 for patients who benefited and tolerated most of the planned IL2 doses. A treatment delay of up to 4 weeks was allowed for resolution of side effects between courses. Patients were eligible to receive a maximum of three courses of treatment.
3178931|NCT00667134||3|Subjects without a fibrosing or autoimmune disease.
3045292|NCT00554619|Experimental|GSK1325760A|
3045293|NCT00554671|Experimental|Pharmacist-led Group Visits|Algorithm driven medication titration, Behavioral: Monitoring, Behavioral: Group support, Behavioral: Self efficacy
3045294|NCT00554671|No Intervention|Usual Care|Patient continues on usual care for diabetes
3045295|NCT00554749|Other|1 Behavioral intervention|Behavioral intervention in all seven subjects Weekly sessions in the home and the kindergarten using defocused communication and stimulus fading interventions
3045296|NCT00554788|Experimental|Treatment (chemotherapy, radiotherapy, autologous SCI)|"INDUCTION: Patients receive vincristine IV; cisplatin IV; cyclophosphamide IV; and G-CSF SC beginning on day 3 and continuing until blood counts recover.~CONSOLIDATION (stage 4a or 4b disease only): Patients receive carboplatin IV; thiotepa IV; and etoposide IV.~AUTOLOGOUS STEM CELL INFUSION (stage 4a or 4b disease only): Patients undergo autologous stem cell infusion on day 0 and receive G-CSF SC beginning on day 1 and continuing until blood counts recover.~RADIOTHERAPY: Patients with stage 2 or 3 disease (orbital and/or regional involvement) undergo radiotherapy to sites that were initially involved beginning within 42 days after the start of course 4 of induction chemotherapy. Patients with stage 4a or 4b disease undergo radiotherapy to sites initially involved based on response beginning approximately 42 days after autologous stem cell infusion."
3045297|NCT00554801|Experimental|Blast|The study group includes soldiers who have recently been exposed to a high-explosive blast while stationed in Iraq or Afghanistan. They will be recruited at Walter Reed Army Medical Center, Washington, DC. They will undergo audiological testing.
3045298|NCT00554801|Active Comparator|Control|Control group are subjects matched to the experimental group by age, gender, and hearing loss, but who have not been exposed to a blast. They will undergo the same audiological testing as the experimental group
3045299|NCT00554840|Active Comparator|varenicline|
3045300|NCT00554840|Placebo Comparator|placebo|
3045301|NCT00554853|Other|Pioglitazone then placebo|Oral daily pioglitazone 30 mg tablets daily for 2 weeks, followed by 45 mg daily tablets until end of study for 3 months compared to placebo in tablets of equal presentation for 3 months, then crossover after a 2 month washout.
3045302|NCT00554853|Other|placebo then study drug (pioglitazone)|Oral daily placebo for 3 months compared to pioglitazone for 3 months, then crossover after a 2 month washout. Similar doses as mentioned above.
3045303|NCT00554970|Other|Treatment 1 then Treatment 2|Subjects received Treatment 1 in period 1 followed by a 7 day washout period and then Treatment 2 in period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
3045304|NCT00554970|Other|Treatment 2 then Treatment 1|Subjects received Treatment 2 in period 1 followed by a 7 day washout period and then Treatment 1 period 2. Treatment 1 was a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 2 was a single dose of Pulmicort Respules® 0.25mg dose delivered by nebulization twice daily for 7 days as per protocol.
3045305|NCT00554970|Other|Treatment 3 then Treatment 4|Subjects received Treatment 3 in period 1 followed by a 7 day washout period and then Treatment 4 period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
3045306|NCT00554970|Other|Treatment 4 then Treatment 3|Subjects received Treatment 4 in period 1 followed by a 7 day washout period and then Treatment 3 in period 2. Treatment 3 was a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol. Treatment 4 was a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol.
3045307|NCT00554996|Other|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
3178932|NCT00667147|Experimental|A|
3178933|NCT00667147|Experimental|B|
3045310|NCT00555048|Experimental|Alemtuzumab|Alemtuzumab given together with busulfan and cyclophosphamide followed by a donor stem cell transplant.
3045311|NCT00555061|Experimental|Arm 1|Single Arm Retapamulin 1% Ointment
3045312|NCT00555152|Experimental|Arm I (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
3045313|NCT00555152|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
3178934|NCT00667160|Experimental|1|
3178935|NCT00667160|Active Comparator|2|
3178936|NCT00667173|Experimental|1|
3045314|NCT00555217|Experimental|Combination of ARB and ACEI|Combination of an angiotensin converting enzyme inhibitor (ACEI) with an angiotensin receptor blocker (ARB)
3045315|NCT00555217|Active Comparator|Monotherapy ARB|Mono therapy arm. Standard treatment with angiotensin receptor blocker (ARB)
3045316|NCT00555321|Experimental|Group 1: Basiliximab+Belatacept (MI) + MMF|
3045317|NCT00555321|Experimental|Group 2: Belatacept (MI) + MMF|
3045318|NCT00555321|Experimental|Group 3: Belatacept Less Intensive (LI) + MMF|
3045319|NCT00555321|Other|Group 4: Tacrolimus + MMF|Other
3045320|NCT00555321|Active Comparator|Group 5: Tacrolimus|
3045321|NCT00555360|Experimental|Arm 1|Veterans with heart failure that can identify an out-of-home informal caregiver
3045322|NCT00555360|Active Comparator|Arm 2|Veterans with heart failure that can identify an out-of-home informal caregiver
3045323|NCT00555425|Active Comparator|1|Buprenorphine/naloxone maintenance (Mtn) is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services.
3045324|NCT00555425|Experimental|2|Buprenorphine/naloxone detoxification (Dtx) is identical to Mtn for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Buprenorphine/naloxone.
3045325|NCT00555438|Experimental|1|patients with renal impairment who received Fondaparinux 1.5 mg/l after major orthopaedic surgery
3045326|NCT00555464|Experimental|1|Vincristine is a drug that has been used to treat cancers in children (including infants). It has been effective in treating a small number of infants with hemangiomas, most of whom failed previous therapies including steroids. Vincristine must be administered into a vein. Given the encouraging response data and documented safety record, Vincristine is a good choice for a clinical trial treating infants with complicated hemangiomas.
3045327|NCT00555464|Active Comparator|2|The standard treatment for hemangioma at most centers is oral steroids (Prednisolone). Prednisolone has been used to stop the growth of infantile hemangiomas that are life threatening, that could harm important functions, or are likely to result in severe disfigurement (scarring) without treatment.
3045328|NCT00555477|Experimental|anastrozole|
3045329|NCT00555568|Experimental|Peer-led Groups|Arm 1 is a 3-month recovery-focused mental health education and support group led by peer facilitators
3045330|NCT00555568|Experimental|Clinician-led Groups|Arm 2 is a 3-month recovery-focused mental health education and support group led by a mental health clinician
3045331|NCT00555568|No Intervention|Treatment as Usual|Arm 3 is treatment as usual (no intervention)
3045332|NCT00555581|Experimental|400 mg daily of Imatinib Mesylate|All patients were treated with imatinib mesylate at a target dose of 400 mg daily by mouth for 12 months. Dose modifications and interruptions were made for AE and were recorded. After 12 months of treatment, imatinib was stopped for 3 months. Patients were reassessed and offered entrance to an extension phase of the trial.
3045333|NCT00555620|Experimental|A|
3045334|NCT00555620|Experimental|B|
3045335|NCT00555672|Experimental|A|
3045336|NCT00555750|Experimental|eszopiclone (3mg)|active medication (eszopiclone 3mg tablet) by mouth nightly 30 min before bed
3045337|NCT00555750|Placebo Comparator|placebo|identical placebo tablet by mouth nightly 30 min before bed
3045338|NCT00555880|Experimental|1|
3045339|NCT00555880|Placebo Comparator|2|
3045340|NCT00555893|Experimental|Active Drug|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
3045341|NCT00555893|Placebo Comparator|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
3045342|NCT00555906|Experimental|1|
3045343|NCT00555971|Placebo Comparator|Placebo Group|Subjects randomized to placebo
3045344|NCT00555971|Active Comparator|Omalizumab Group|Subjects randomized to omalizumab
3045345|NCT00555997|Active Comparator|1|Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.
3045346|NCT00555997|Active Comparator|2|Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.
3045347|NCT00555997|Placebo Comparator|3|Patients in Group 3 will receive placebo for the full 12 weeks of the study.
3045348|NCT00556049|Experimental|1|Sunitinib and gemcitabine
3045349|NCT00556140|Experimental|Major Depression with Psychotic Features|
3045350|NCT00556322|Experimental|1|
3045351|NCT00556322|Active Comparator|2|
3045352|NCT00556374|Experimental|Denosumab|Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
3045353|NCT00556374|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.
3045354|NCT00556374|Experimental|SubStudy: Zoledronic Acid|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive a single 5 mg intravenous dose of zoledronic acid 8 months after the last open-label dose of denosumab.
3045355|NCT00556374|Other|Substudy: Standard of Care|Eligible participants who completed the open-label phase could be enrolled into the zoledronic acid substudy and randomized to receive standard of care 8 months after the last open-label dose of denosumab.
3045356|NCT00556426|Experimental|Filter|All subjects enrolled to the study are in this arm. All subjects receive a filter.
3045357|NCT00556439|Experimental|A and C|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to abatacept at this point will be in Group A for giant cell arteritis and Group C for Takayasu arteritis.
3045358|NCT00556439|Placebo Comparator|B and D|This is a randomized withdrawal design protocol. All participants will receive abatacept and prednisone (a glucocorticoid) for the first 3 months. Abatacept will be given intravenously on selected days. Prednisone will be started at a dose of 40 to 60mg, then tapered to 20mg by Month 3, and finally further tapered until discontinuation is reached. At Month 3, participants who have achieved remission will be randomly assigned under double-blind conditions to receive monthly infusions of either abatacept or placebo. Participants who are assigned to placebo at this point will be in Group B for giant cell arteritis and Group D for Takayasu arteritis.
3045359|NCT00556452|Experimental|Clo/BU4|"Study will start at the 2nd dose level of three Clofarabine levels, in combination with Busulfan. The Clofarabine level that each subsequent patient is treated at is determined by a method using continual reassessment.~After pre-conditioning, subjects will receive a peripheral blood stem cell transplant."
3045360|NCT00556478|Active Comparator|Double-Blind Active|Double-blind Phase: Subjects will be randomised to PSD502 respectively if the patient meets all the entry criteria.
3045361|NCT00556478|Placebo Comparator|Double-Blind Placebo|Double-blind Phase: Subjects will be randomised to Placebo respectively if the patient meets all the entry criteria.
3045362|NCT00556478|Active Comparator|Open Label Phase|Subjects will all receive PSD502 if they wish to continue in the trial.
3045363|NCT00556491|Active Comparator|minocycline|
3045364|NCT00556491|Placebo Comparator|placebo|
3045365|NCT00556504|Experimental|TCM-700C|an add-on drug (2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3045366|NCT00556504|Placebo Comparator|Placebo|placebo add on(2 tablets/t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3045367|NCT00556543|Other|Treatment|
3045368|NCT00556673|Experimental|Indacaterol/mometasone - Placebo|In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
3045369|NCT00556673|Experimental|Placebo - indacaterol/mometasone|In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
3045370|NCT00556712|Experimental|Erlotinib|Participants received erlotinib, 150 milligrams (mg), orally (PO), daily from randomization until progressive disease (PD), death, or unacceptable toxicity.
3045371|NCT00556712|Placebo Comparator|Placebo|Participants received a placebo, PO, daily, from randomization until PD, death, or unacceptable toxicity.
3045372|NCT00556842|Active Comparator|1|Participants will undergo total hip arthroplasty.
3045373|NCT00556842|Active Comparator|2|Participants will undergo hemi-arthroplasty.
3045374|NCT00556894|Experimental|CF101 0.1 mg|CF101 0.1 mg was given orally q12h
3045375|NCT00556894|Experimental|CF101 1 mg|CF101 1 mg was given orally q12h
3045376|NCT00556894|Placebo Comparator|Placebo|Matched placebo was given orally q12h
3045377|NCT00556933|Experimental|Group 1|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
3045378|NCT00556933|Experimental|Group 2|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
3045379|NCT00556933|Experimental|Group 3|Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
3045380|NCT00556933|Experimental|Group 4|Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
3045381|NCT00556946|Other|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains
3045382|NCT00556972|Experimental|Fecal Incontinence management system|Fecal Incontinence Management System is based on the same principle as fecal pouches. A barrier around anus to ensure adhesion and prevent leakage.
3045383|NCT00556998|Experimental|1|
3045384|NCT00557076|Experimental|Familiar Auditory Sensory Training|FAST is a standardized passive auditory stimulation protocol. The patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. The FAST protocol is provided on compact discs (CDs), using portable players and noise cancelling headphones, while patients were awake (ie, eyes open). Speakers were used for one patient not tolerating his headphones. The CDs were identical according to track duration, labeling, and administration procedures.
3045385|NCT00557076|Sham Comparator|Sham Auditory Sensory Training|Placebo protocol is silence. Patients receive sham protocols for 10 minutes 4 times per day, with at least 2 hours in between, for 6 weeks.
3045386|NCT00557193|Experimental|Arm A (standard risk MLL-G)|Population Description: Eligible patients with MLL-G (germline, or non-rearranged)
3178937|NCT00667173|Placebo Comparator|2|
3178938|NCT00667173|Placebo Comparator|3|
3045387|NCT00557193|Active Comparator|Arm B (IR/HR MLL-R chemotherapy)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
3045388|NCT00557193|Experimental|Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)|Population Description: Eligible patients with MLL-R (rearranged). Considered Intermediate Risk (IR) if age >= 90 days at diagnosis and High Risk (HR) if age < 90 days at diagnosis.
3045389|NCT00557245|Active Comparator|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
3045390|NCT00557245|Active Comparator|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
3045391|NCT00557245|Placebo Comparator|Placebo|Placebo TDF + Placebo FTC/TDF orally, once daily.
3045392|NCT00557284|Experimental|1|Montelukast
3045393|NCT00557284|Placebo Comparator|2|
3045394|NCT00557310|Experimental|Teriparatide|20 micrograms (mcg) teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
3045395|NCT00557323||1|Patients being treated for hyperphosphatemia with any marketed product
3045396|NCT00557349|Active Comparator|Omeprazole|40 mg Omeprazole daily
3045397|NCT00557349|Active Comparator|Famotidine|40 mg Famotidine daily
3045398|NCT00557362|Active Comparator|1|Topical voriconazole with corneal de-epithelialization
3045399|NCT00557362|Active Comparator|2|Topical voriconazole without corneal de-epithelialization
3045400|NCT00557362|Active Comparator|3|Topical natamycin with corneal de-epithelialization
3045401|NCT00557362|Active Comparator|4|Topical natamycin without corneal de-epithelialization
3045402|NCT00557440|Experimental|Ind/M - FP/Salm - Pbo|"In Treatment Period 1 (Days 1 & 2) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via multi-dose dry powder inhaler (MDDPI), one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3045403|NCT00557440|Experimental|FP/Salm - Pbo - Ind/M|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3045404|NCT00557440|Experimental|Pbo - Ind/M - FP/Salm|"In Treatment Period 1 (Days 1 & 2) participants received 2 inhalations of placebo (Pbo) to indacaterol/mometasone via the TWISTHALER device in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 2 (Days 8 & 9) participants received indacaterol/mometasone (Ind/M) 500/400 μg via the TWISTHALER device (2 inhalations of 250/200 μg) in the evening and placebo to fluticasone/salmeterol via MDDPI, one inhalation in the evening and one inhalation the following morning.~In Treatment Period 3 (Days 15 & 16) participants received 2 inhalations of placebo to indacaterol/mometasone via the TWISTHALER device in the evening and fluticasone/salmeterol (FP/Salm) 250/50 μg via MDDPI, one inhalation in the evening and one inhalation the following morning.~Each treatment period was separated by a 6-day washout period."
3045405|NCT00557466|Experimental|indacaterol 62.5 μg|Indacaterol 62.5 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045406|NCT00557466|Experimental|indacaterol 125 μg|Indacaterol 125 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045407|NCT00557466|Experimental|Indacaterol 250 μg|Indacaterol 250 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045408|NCT00557466|Experimental|indacaterol 500 μg|Indacaterol 500 μg delivered by the TWISTHALER® device once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045409|NCT00557466|Active Comparator|formoterol|Formoterol 12 μg delivered by the AEROLIZER® device twice a day and placebo to indacaterol (placebo TWISTHALER® device) once a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045410|NCT00557466|Placebo Comparator|placebo|Placebo to indacaterol (placebo TWISTHALER® device) once a day and placebo to formoterol (placebo AEROLIZER® device) twice a day for 14 days. All participants were supplied with salbutamol/albuterol to use throughout the study as rescue medication.
3045411|NCT00557492|Experimental|Single Arm|"Intervention: Drug: Avastin (bevacizumab) 10 mg/kg, days 1, 15, 29 and 43~Intervention: Drug: Gemzar (Gemcitabine) On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).~Intervention:Radiation: external beam radiotherapy 3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy"
3045412|NCT00557505|Experimental|PF-03732010|Single Arm study
3045413|NCT00557622|Experimental|paroxetine|Drug 2 (20 mg/day or placebo) will be administered once daily after supper for the first two weeks after the run-in phase. If the investigator/subinvestigator judges that a sufficient response is achieved, Drug 2 will be continued for the remaining period. If a sufficient response is not achieved with Drug 2 but treatment is well tolerated, the dose will be titrated to one step higher level until a sufficient response is achieved [i.e., Drug 3 (30 mg/day or placebo) → Drug 4 (40 mg/day or placebo) → Drug 5 (50 m/day or placebo)] at intervals of at least two weeks by once daily administration after supper. Once a sufficient response is achieved, that dose will be continued.
3045414|NCT00557622|Placebo Comparator|placebo|placebo
3045415|NCT00557830|Active Comparator|Group A: Escalated Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
3045416|NCT00557830|Active Comparator|Group B: Standard Dose|Eligible patients will be randomized 2:1 to either Group A (escalated dose regimen) or Group B (standard dose regimen). Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
3045417|NCT00557856|Experimental|1|
3045418|NCT00557882|Active Comparator|mesh|Vaginal reconstructive surgery with synthetic polypropylene mesh
3045419|NCT00557882|Active Comparator|no mesh|Vaginal reconstructive surgery without mesh
3045420|NCT00557947|Experimental|I|Dermabond Protape-Incision segments are randomized & patient is own control
3045421|NCT00557947|Active Comparator|II|Intradermal Suture - Incision segments are randomized & patient is own control. Investigator selected suture on the basis of standard local practice.
3045422|NCT00558012|Experimental|Active Medication Group|One-time dose: Intravenous Zoledronic Acid 5.0 mg; Vitamin D (800 IU/daily); Calcium 1200 mg/daily (supplement plus diet)
3045423|NCT00558012|Placebo Comparator|Placebo|One-time dose: intravenous saline; Vitamin D (800 IU/daily); 1200 mg calcium (supplement plus diet)
3045424|NCT00558025|Experimental|Pramipexole Extended Release (ER)|Pramipexole Extended Release (ER) once daily
3045425|NCT00558025|Experimental|Pramipexole Immediate Release (IR)|Pramipexole Immediate Release (IR) once daily
3045426|NCT00558103|Active Comparator|arm 1|Lapatinib
3045427|NCT00558103|Active Comparator|arm2|Pazopanib monotherapy (open label)
3045428|NCT00558103|Experimental|arm3|Lapatinib+ pazopanib
3045429|NCT00558246|Experimental|I|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
3045430|NCT00558246|Active Comparator|II|On same patient, one breast is randomized to control and one breast is randomized to experimental arm. Patient is own control.
3045431|NCT00558259|Experimental|dabigatran etexilate 150 mg BID|Patient to receive dabigatran etexilatate capsules 150 mg twice daily
3045432|NCT00558259|Placebo Comparator|matching placebo twice daily (BID)|Patient to receive dabigatran extexilate matching placebo capsules twice daily
3045433|NCT00558272|Experimental|AZD0530 175 mg|AZD0530 (saracatinib) 175 mg once daily
3045434|NCT00558272|Experimental|Zoledronic Acid 4 mg|Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period
3045435|NCT00558285|Experimental|indacaterol/glycopyrrolate 600/100 μg|"Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3045436|NCT00558285|Experimental|indacaterol/glycopyrrolate 300/100 μg|"One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3045437|NCT00558285|Experimental|indacaterol/glycopyrrolate 150/100 μg|"One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3045438|NCT00558285|Active Comparator|indacaterol 300 μg|"One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3045439|NCT00558285|Placebo Comparator|placebo|"Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days.~The use of salbutamol/albuterol as rescue medication was permitted throughout the study."
3045440|NCT00558363|Experimental|Avodart|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
3045441|NCT00558363|Placebo Comparator|Placebo Arm|Patients will receive a 3-month supply of study drug or placebo. Patients will be instructed to take one capsule by mouth once daily. Study medication will be supplied at 3-month intervals during scheduled clinic visits for a total of 24 months.
3045442|NCT00558467|Other|Pramipexole|
3045443|NCT00558467|Placebo Comparator|Placebo|
3045444|NCT00558519|Experimental|Treatment (chemotherapy, radiotherapy)|"Patients are given a series of leukemia treatments that are divided into several sequential courses and different chemotherapy combinations of treatment. Please see the Detailed Description section for more information."
3045445|NCT00558571|Placebo Comparator|Placebo|
3045446|NCT00558571|Experimental|BI 10773 low dose|
3045447|NCT00558571|Experimental|BI 10773 medium dose|
3045448|NCT00558571|Experimental|BI 10773 high dose|
3045449|NCT00558636|Experimental|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
3321401|NCT02018536|Experimental|Part 2, Sequence 1|6 participants to receive Treatment A (TMC435 150 mg), D (TMC435 150 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), and C (TMC435 100 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3045450|NCT00558636|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
3045451|NCT00558701|Active Comparator|Microcurrent Stimulator + Silverlon|Patients receiving active electrical stimulation (15-50 microamps) during treatment of skin donor sites with Silverlon wound contact dressing. Intervention is active electrical stimulation via microcurrent stimulator.
3045452|NCT00558701|Sham Comparator|Silverlon alone|Patients receiving treatment of skin donor sites with Silverlon wound contact dressing alone (i.e., without active electrical stimulation)
3045453|NCT00558753|Placebo Comparator|1 Placebo|Half of the patients will receive PO placebo for 14 days
3045454|NCT00558753|Experimental|2 Pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
3045455|NCT00558792|Experimental|Isovue 370, 70 mL|iopamidol injection 370, 70 mL
3045456|NCT00558792|Experimental|Isovue 370, 80 mL|iopamidol injection 370, 80 mL
3045457|NCT00558792|Experimental|Isovue 370, 90 mL|iopamidol injection 370, 90 mL
3045458|NCT00558831|Active Comparator|Benzoyl Peroxide|Benzoyl Peroxide (BP) 2.5%
3045459|NCT00558831|Active Comparator|Benzoyl Peroxide plus moisturizing lotion|Benzyol Peroxide 2.5% plus moisturizing lotion
3045460|NCT00558844|Active Comparator|A|Arikayce™ at 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
3045461|NCT00558844|Placebo Comparator|B|Matching placebo for 560 mg Subjects randomized 2:1 to receive Arikayce 560 mg or Placebo.
3045462|NCT00558844|Active Comparator|C|Arikayce™ at 70 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
3045463|NCT00558844|Active Comparator|D|Arikayce™ at 140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
3045464|NCT00558844|Placebo Comparator|E|Matching placebo for 70 mg/140 mg Subjects randomized 1:1:1 to receive Arikayce 70 mg, Arikayce 140 mg or Placebo.
3045465|NCT00558896|Experimental|Relapsed Myeloma (<4 Prior Regimens)|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045466|NCT00558896|Experimental|Lenalidomide Refractory Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045467|NCT00558896|Experimental|Bortezomib/Lenalidomide Refractory/Relapsed Myeloma|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045468|NCT00558896|Experimental|Bortezomib/Lenalidomide Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045469|NCT00558896|Experimental|Relapsed Myeloma (< 4 Prior Regimens)|"Pomalidomide: 4 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045470|NCT00558896|Experimental|Relapsed/Refractory Myeloma|"Pomalidomide: 4 mg orally once daily, days 1-21 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045471|NCT00558896|Experimental|Relapsed Amyloidosis|"Pomalidomide: 2 mg orally once daily, days 1-28 of 28 day cycle~Dexamethasone: 40 mg on days 1, 8, 15 ad 22 of 28 day cycle"
3045472|NCT00559013|Active Comparator|1|PSD Veritas Collagen Matrix Reinforcement Arm
3045473|NCT00559104|Active Comparator|Irradiation in conditioning|total-body irradiation, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematologic stem cell transplantation, peripheral blood stem cell transplantation
3045474|NCT00559104|Active Comparator|Carmustine in conditioning|Carmustine, etoposide, cyclophosphamide, infusion of peripheral blood stem cells, granulocyte-colony stimulating factor (G-CSF), autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
3045475|NCT00559273|Experimental|Mircera|Participants will receive Mircera (Methoxy polyethylene glycol-epoetin beta), administered subcutaneously (SC) at a starting dose of 1.2 mcg/kg once every 4 weeks for 28 weeks.
3045476|NCT00559273|Active Comparator|Darbepoetin Alfa|Participants will receive darbepoetin alfa, administered SC once weekly or once every 2 weeks according to local labeling specifications for 28 weeks.
3045477|NCT00559364|Experimental|Viokase® 16|
3045478|NCT00559364|Placebo Comparator|Placebo|
3045479|NCT00559377|Experimental|Diagnostic FMISO AND FDG PET|Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.
3045480|NCT00559468|Experimental|Sugammadex + Sevoflurane|After receiving sevoflurane and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
3045481|NCT00559468|Experimental|Sugammadex + Propofol|After receiving propofol and the last dose of rocuronium, at the reappearance of first twitch (T1; 3-10% starting amplitude), a dose of 4.0 mg/kg sugammadex was administered.
3045482|NCT00559507|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3045483|NCT00559585|Active Comparator|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
3045484|NCT00559585|Active Comparator|Intravenous (IV) Abatacept|Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
3045485|NCT00559637|Experimental|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
3045486|NCT00559754|Experimental|1|
3045487|NCT00559845|Experimental|Bevacizumab|Participants will receive FEC, followed by paclitaxel, given concomitantly with bevacizumab for approximately 3-12 months.
3045488|NCT00559936|Experimental|Topical Avastin 1.0%|Each patient will receive topical Avastin in one eye.
3045489|NCT00559949|Experimental|Arm I|Patients receive oral selumetinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of unacceptable toxicity or disease progression.
3045490|NCT00559962|Placebo Comparator|1|Placebo
3045491|NCT00559962|Active Comparator|2|2.5 mg AEGR-733
3045492|NCT00559962|Active Comparator|3|5 mg AEGR-733
3045493|NCT00559962|Active Comparator|4|7.5 mg AEGR-733
3045494|NCT00559962|Active Comparator|5|10 mg AEGR-733
3045495|NCT00559962|Active Comparator|6|5 mg AEGR-733 + 20 mg atorvastatin
3045496|NCT00559962|Active Comparator|7|5 mg AEGR-733 + 145 mg fenofibrate
3045497|NCT00559962|Active Comparator|8|5 mg AEGR-733 + 10 mg ezetimibe
3045498|NCT00559988|Experimental|Home Monitoring Guided OAC|Home Monitoring is fully enabled and continuous remote surveillance data is available to investigators. Patients will be treated according to a predefined anticoagulation plan, which uses the total duration of AF/AFL combined with patients' CHADS2 score to determine the start, stop, and restart of OAC.
3045499|NCT00559988|Active Comparator|Physician-Directed OAC|"In Control (Group 2), Home Monitoring is active for Safety Net alerts, but the remote AF/AFL data is not revealed to the patient or treating physician. These patients receive physician-directed OAC consistent with current standards of care.~Safety Net data include:~ERI/EOS~Special Implant Status~Implant in Backup Mode (ROM)~VT/ VF Detection Inactive~Emergency Pacing~250 Ω > RV Pacing Impedance > 1500 Ω~Symptomatic VT/VF therapies including both ATP and shock~VT/VF storm~HM transmission failure >3 days"
3045500|NCT00560066|Experimental|cTIV|Subjects received one vaccination of cell culture-derived influenza vaccine
3045501|NCT00560066|Active Comparator|TIV|Subjects received one vaccination of egg-derived influenza vaccine
3045502|NCT00560105|Active Comparator|Acapella|The Active Comparator is the Acapella, a OPEP device
3045503|NCT00560105|Experimental|Lung Flute|The Active Comparator is the Lung Flute, a new indication of this device
3045504|NCT00560235|Experimental|1|
3045505|NCT00560313|Experimental|4CMenB|
3045506|NCT00560313|Experimental|MenACWY CRM|
3045507|NCT00560352|Experimental|Dasatinib + Bortezomib + Dexamethasone|Phase I dose escalation study
3045508|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 15 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3045509|NCT00560391|Experimental|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 70 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3045510|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 20 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3045511|NCT00560391|Experimental|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, 100 mg QD, lenalidomide, 25 mg QD, and dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22, in 28-day cycles.
3045512|NCT00560391|Experimental|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received a combination of dasatinib, lenalidomide, and dexamethasone in varying doses in 28-day cycles.
3045513|NCT00560404|Experimental|1|
3045514|NCT00560404|Active Comparator|2|
3045515|NCT00560417|Active Comparator|ILPS|Insulin Lispro Protamine Suspension (ILPS)
3045516|NCT00560417|Active Comparator|Glargine|Insulin Glargine
3045517|NCT00560508|Experimental|Pramipexole Extended Release|patient to receive a tablet containing 0.375 mg Pramipexole ER once a day plus containing 0.125 mg Pramipexole IR placebo twice a day -> a tablet containing 1.5 mg Pramipexole ER three times daily (TID) plus 0.5 mg Pramipexole IR placebo TID
3045518|NCT00560508|Active Comparator|Pramipexole Immediate Release|patient to receive a tablet containing 0.125 mg Pramipexole IR twice a day plus containing 0.375 mg Pramipexole ER placebo once a day -> a tablet containing 0.5 mg Pramipexole IR three times daily (TID) plus 1.5 mg Pramipexole ER placebo TID
3045519|NCT00560560|Experimental|1|Single arm study
3045520|NCT00560573|Experimental|1|
3045521|NCT00560612|Active Comparator|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
3045522|NCT00560612|Placebo Comparator|Placebo|
3045523|NCT00560703|Active Comparator|COL-101 (doxycycline, USP) capsules|COL-101
3045524|NCT00560703|Placebo Comparator|Placebo|Sugar capsule
3045525|NCT00560755|Experimental|ProQuad®|Healthy infants (12 to 22 months of age) received 2 doses of ProQuad® (Dose 1 on Day 1 and Dose 2 on Day 28 to 42) via subcutaneous injection into the deltoid muscle.
3045526|NCT00560794|Experimental|Blinatumomab|Participants received blinatumomab as continuous intravenous infusion at constant flow rate over 4 weeks followed by a 2 week treatment-free period (defined as one treatment cycle), for up to a maximum of 10 cycles. The initial dose was 15 μg/m^2/day. A dose increase to 30 μg/m^2/day was permitted with evidence for insufficient response to blinatumomab treatment.
3045527|NCT00560833|Placebo Comparator|Placebo|Participants receive placebo, encapsulated tablets, orally (PO), once daily (QD) for up to 12 weeks
3045528|NCT00560833|Experimental|Esmirtazapine 2.25 mg|Participants receive esmirtazapine 2.25 mg, encapsulated tablets, PO, QD for up to 12 weeks
3045529|NCT00560833|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg, encapsulated tablets, PO, QD for up to 12 weeks
3045530|NCT00560833|Experimental|Esmirtazapine 9 mg|Participants receive esmirtazapine 9 mg, encapsulated tablets, PO, QD for up to 12 weeks
3045531|NCT00560833|Experimental|Esmirtazapine 18 mg|Participants receive esmirtazapine 18 mg, encapsulated tablets, PO, QD for up to 12 weeks
3045532|NCT00560859|Active Comparator|Early AT Surgery|There will be removal of tonsils and adenoids that will be performed within 4 weeks of the baseline visit.
3045533|NCT00560859|Other|Watchful Waiting|Children will be closely monitored and re-evaluated for AT by an otolaryngologist after the primary 7 month monitoring period.
3045534|NCT00560885|Experimental|AtriCure Bipolar System|The AtriCure Synergy Bipolar Ablation system is used to create lesions outlined in the Maze IV procedure during a concomitant open cardiac surgical procedure.
3045535|NCT00560937|Active Comparator|1|Pregnenolone
3045536|NCT00560937|Placebo Comparator|2|Placebo
3045537|NCT00560950|Experimental|1st Revaccination Group|
3045538|NCT00560950|Experimental|2nd Revaccination Group|
3045539|NCT00561002|Experimental|Influenza vaccine Naive/Inadequately Primed|Participants had no more than one previous lifetime dose of influenza vaccine and received two doses of Fluzone®, on Days 0 and 14.
3045540|NCT00561002|Experimental|Influenza Vaccine Primed|Participants had previously received 2 injections of Influenza vaccine in the same season and received a single dose of Fluzone® on Day 0.
3045541|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 2|Participants who are never treated for chronic hepatitis C (inflammation of the liver) genotype 2 will receive telaprevir (TVR) 750 milligram (mg) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) from Day 15 to Week 26 (standard treatment phase). Each dose of pegylated interferon 180 microgram (mcg) will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
3045542|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3045543|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 2|Participants who are never treated for CHC genotype 2 will receive TVR matching placebo (Pbo) tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3045544|NCT00561015|Experimental|TVR then Peg-IFN-alfa-2a + RBV (T2 & PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15. Participants will then be treated with standard treatment regimen of Peg-IFN-alfa-2a and RBV from Day 15 to Week 26 (standard treatment phase). Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 26 weeks.
3045545|NCT00561015|Experimental|TVR with Peg-IFN-alfa-2a + RBV (T2/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 received TVR 750 mg tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3045546|NCT00561015|Active Comparator|Pbo with Peg-IFN-alfa-2a + RBV (Pbo/PR24) - Genotype 3|Participants who are never treated for CHC genotype 3 will receive TVR matching Pbo tablet orally 3 times a day during investigational treatment phase from Day 1 to Day 15 along with standard treatment regimen of Peg-IFN-alfa-2a and RBV which will be continued in the standard treatment phase from Day 15 to Week 24. Each dose of Peg-IFN-alfa-2a 180 mcg will be administered as a subcutaneous injection once a week. RBV will be taken orally as 400 mg tablets 2 times a day. Total duration of treatment will be 24 weeks.
3045547|NCT00561080|Experimental|Single Dose of Zostavax|Zostavax 0.65mL intramuscular injection administered on Day 0
3045548|NCT00561080|Experimental|Zostavax - Day 0 and Month 1|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 1
3045549|NCT00561080|Experimental|Zostavax - Day 0 and Month 3|Zostavax 0.65mL intramuscular injection administered on Day 0 and Month 3
3045550|NCT00561145|Experimental|Young men|Energy restriction period
3045551|NCT00561145|Experimental|Elderly men|Energy restriction period
3045552|NCT00561340|Experimental|1 Can of Pediasure Supplement Plus Nutritional Counseling|Pediasure and nutritional counseling
3045553|NCT00561340|Active Comparator|Counseling by the Provider on Ways to Encourage Caloric Intake|Behavioral intervention - Nutritional Counseling
3045554|NCT00561353|Experimental|TMC435 25 mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 25 mg once daily for 7 days followed by TMC435 25 mg once daily coadministered with peginterferon alpha-2a (PegIFNα-2a) (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 25 mg once daily coadministered with PR for 28 days (Panel B).
3045555|NCT00561353|Experimental|TMC435 75mg (Cohort 1/Panel A and B)|Treatment-naïve participants received TMC435 75 mg once daily for 7 days followed by TMC435 75 mg once daily for 21 days with PegIFNα-2a (P) and ribavirin (R) OR TMC435 75 mg once daily coadministered with PR for 28 days (Panel B).
3045556|NCT00561353|Placebo Comparator|Placebo (Cohort 1/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 25/75 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR and Placebo once daily coadministered with PR for 28 days (Panel B).
3045557|NCT00561353|Experimental|TMC435 200 mg (Cohort 2, Panel A and B)|Treatment-naïve participants received TMC435 200 mg once daily for 7 days followed by TMC435 200 mg once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR TMC435 200 mg once daily coadministered with PR for 28 days (Panel B).
3045558|NCT00561353|Placebo Comparator|Placebo (Cohort 2/Panel A and B)|Treatment-naïve participants received placebo (identical in appearance to TMC435 200 mg) once daily for 7 days followed by placebo once daily coadministered with PegIFNα-2a (P) and ribavirin (R) for 21 days (Panel A) OR placebo once daily coadministered with PR for 28 days (Panel B).
3045559|NCT00561353|Experimental|TMC435 75 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 75 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3045560|NCT00561353|Experimental|TMC435 150 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 150 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3045561|NCT00561353|Experimental|TMC435 200 mg (Cohort 4/Panel C)|Treatment-experienced non-responders received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3045562|NCT00561353|Placebo Comparator|Placebo (Cohort 4/Panel C)|Treatment-experienced non-responders received placebo once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3045563|NCT00561353|Experimental|TMC435 200 mg (Cohort 5/Panel D)|Treatment-experienced relapsers received TMC435 200 mg once daily coadministered with PegIFNα-2a and ribavirin for 28 days.
3045564|NCT00561392|Experimental|Rivastigmine 5 and 10 cm^2 patch|For the 1st 4 weeks of this 24 week study, patients were administered rivastigmine transdermally once daily via a 5 cm^2 patch. After the Week 4 assessment, patients were administered rivastigmine transdermally once daily via a 10 cm^2 patch, with adjustments as necessary for safety and tolerability.
3045565|NCT00561418|Experimental|Vorinostat (SAHA)|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles with the dose escalations.
3045566|NCT00561431|Active Comparator|1|Standard dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 20 ml/kg/hr
3045567|NCT00561431|Experimental|2|High dose Continuous Venovenous Hemodiafiltration (CVVHDF) at an effluent rate of 35 ml/kg/hr
3045568|NCT00561457|Experimental|Iliac Stenting|Stent placement in the iliac artery
3045569|NCT00561470|Placebo Comparator|Placebo/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Placebo followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
3045570|NCT00561470|Experimental|Aflibercept/FOLFIRI|Participants with Metastatic Colorectal Cancer administered Aflibercept followed by FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) starting on Day 1 of a 2-week cycle until a treatment discontinuation criterion was met
3045571|NCT00561574|Experimental|Esmirtazapine 1.5 mg|Participants receive esmirtazapine 1.5 mg tablets, one tablet administered orally once daily for up to 52 weeks
3045572|NCT00561574|Experimental|Esmirtazapine 3.0 mg|Participants receive esmirtazapine 3.0 mg tablets, one tablet administered orally once daily for up to 52 weeks
3045573|NCT00561600|Active Comparator|A|ASR™-XL Modular Acetabular Cup System stem
3045574|NCT00561600|Active Comparator|B|Pinnacle™ acetabular shell, with a 28mm or 36mm ULTAMET® metal liner, and a 28mm or 36mm Articul/eze M head.
3045575|NCT00561652|Active Comparator|Education + exercise|Education was provided in four, 1-hour sessions to improve patients' understanding of their back problem, reduce unwarranted concern about serious outcomes, & empower them to maintain normal activities & reduce risk of future back problems. Patients were taught that recovery depends on moving & restoring normal function & fitness. Patients were shown stretching & strengthening exercises to perform daily at home to enhance mobility & increase trunk endurance while minimizing spinal load. At follow-up, therapists reviewed exercise form & adherence. Participants allocated to no chiropractic care also were scheduled for 10 weekly 10-15 minute sessions to equalize provider attention vs. the group also receiving chiropractic care & not to provide education, exercise instruction, or therapy.
3045576|NCT00561652|Experimental|Education + exercise + chiropractic|In addition to education & exercise, all participants in this arm will be assigned chiropractic treatment. A minimum of 4 & up to 12 treatments will be provided over 6 weeks, based on patient response (i.e. treatments stopped if symptoms resolve). Each treatment visit will last 10-20 minutes. After 6 weeks, if the treating chiropractor determined that the patient's LBP was continuing to improve but hadn't reached therapy goals defined at baseline, the patient could receive up to 12 additional treatments over the next 6 weeks. Chiropractic treatment was delivered following standardized protocols. Treatment consisted of manual therapies, including SMT and mobilization techniques, with the assistance of light soft tissue techniques as indicated to facilitate the SMT.
3045577|NCT00561678|Experimental|Precedex|Precedex (Dexmedetomidine)
3045578|NCT00561678|Placebo Comparator|Placebo|Placebo - normal saline
3045579|NCT00561730||Pantoprazole|All patients enrolled
3045580|NCT00561821|Experimental|Esmirtazapine 0.5 mg|one placebo tablet daily for 14 days, followed by one 0.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3045581|NCT00561821|Experimental|Esmirtazapine 1.5 mg|one placebo tablet daily for 14 days, followed by one 1.5 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3045582|NCT00561821|Experimental|Esmirtazapine 3.0 mg|one placebo tablet daily for 14 days, followed by one 3.0 mg tablet Esmirtazapine daily for 16 days, and then one placebo tablet daily for 7 days
3045583|NCT00561821|Placebo Comparator|Placebo|one placebo tablet daily for 14 days, followed by one placebo tablet daily for 16 days, and then one placebo tablet daily for 7 days
3045584|NCT00561834|Experimental|Ranibizumab|To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.
3045585|NCT00561925|Experimental|nevirapine XR|400 mg QD
3045586|NCT00561925|Active Comparator|nevirapine IR|200 mg BID
3045587|NCT00561951|Experimental|Fesoterodine fumarate 4 mg (Double-Blind)|
3045588|NCT00561951|Placebo Comparator|Placebo (Double-Blind)|
3045589|NCT00561951|Experimental|Fesoterodine fumarate 8 mg (Double-Blind)|
3045590|NCT00561977|Active Comparator|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
3045591|NCT00561977|Active Comparator|Low Saturated Fat|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal per day.
3045592|NCT00561977|Active Comparator|Combination Diet|Combination low saturated fat (≤7% of total calories);high fiber (>30g fiber per day) -500 kcal from RMR, not less than 1200 kcal/day.
3045593|NCT00562094||Pantoprazole|
3045594|NCT00562120|Placebo Comparator|Placebo|
3045595|NCT00562120|Active Comparator|Allegra|
3045596|NCT00562120|Active Comparator|Allegra-D|
3045597|NCT00562120|Experimental|PF-03654746|
3045598|NCT00562159|Placebo Comparator|Placebo|Matching Placebo
3045599|NCT00562159|Experimental|SCH 697243|
3045600|NCT00562302|Experimental|Bio-Seal Group|Bio-Seal Plug Implanted
3045601|NCT00562302|No Intervention|Control Group|Control group with no intervention
3045602|NCT00562315|Other|FACBC PET-CT and ProstaScint CT|Participants diagnosed with localized prostate carcinoma with subsequent definitive therapy or suspicion of recurrent cancer will undergo an FACBC PET-CT scan and the ProstaScinct CT.
3045603|NCT00562328|Experimental|Alemtuzumab + Rituximab + GM-CSF|Alemtuzumab + Rituximab + GM-CSF
3045604|NCT00562354|Experimental|1|Stratum 1: >= 65 years of age
3045605|NCT00562354|Experimental|2|Stratum 2: 50 to 64 years of age
3045606|NCT00562484|Experimental|1|
3045607|NCT00562484|Other|2|
3045608|NCT00562627|Experimental|LIA IV|Local infiltration analgesia with ropivacaine and adrenaline and intravenous ketorolac and morphine
3045609|NCT00562627|Experimental|LIA IA|Local infiltration analgesia with ropivacaine, adrenaline and ketorolac and morphine
3045610|NCT00562627|Active Comparator|EDA|standard continuous epidural analgesia
3045611|NCT00562718|Experimental|Surgery and Chemotherapy|Eligible patients had undergone surgery and chemotherapy for high risk breast cancer, defined as either a T3 or T4 primary tumor, or N2 by either clinical or pathological criteria.
3045612|NCT00562861|Active Comparator|citalopram + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to citalopram.
3045613|NCT00562861|Placebo Comparator|placebo + mood stabilizer|All patients are on baseline mood stabilizers and are randomized to receive citalopram or placebo. In this arm, they are randomly assigned to placebo
3045614|NCT00562965|Experimental|A|Subjects will receive rituximab intravenously at a dose level of 375 mg/m² on day 1 of each cycle followed by inotuzumab ozogamicin administered intravenously at a dose level of 1.8 mg/m2 on day 2. The sequence will be repeated every 28 days.
3045615|NCT00562965|Active Comparator|B|Subjects will receive the investigator's choice from the following rituximab-containing regimens: R-CVP or R-FND. The investigator's choice of therapy will be administered every 21 days. Dosing for R-CVP will be intravenous rituximab at a dose of 375 mg/m2 on day 1, intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1, intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1, and oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5. Dosing for R-FND will be as follows: rituximab 375 mg/m2 intravenous on day 1, mitoxantrone 10 mg/m2 intravenous on day 2, fludarabine 25 mg/m2 intravenous on days 2 through 4 and oral dexamethasone 20 mg/day on days 1-5.
3045616|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
3045617|NCT00562978|Experimental|Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg|"Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10^6 /kg) proceed to radioimmunotherapy.~Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation.~Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV~AHSCT: Patients undergo reinfusion of PBSCs.~Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity."
3045618|NCT00563186|Experimental|A|Admission to a novel hospital ward (e.g. abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
3045619|NCT00563186|No Intervention|B|Hospital admission to a ward with traditional design features (eg. lack of sinks, predominance of 4-bed rooms [80%], shared bathrooms, curtains present)
3045620|NCT00563290|Experimental|Arm I (dasatinib 100 mg PO BID)|Patients receive 100 mg dasatinib PO BID on days 1-28
3045621|NCT00563290|Experimental|Arm II (dasatinib 70 mg PO BID)|Patients receive 70 mg dasatinib PO BID on days 1-28
3045622|NCT00563316|Experimental|Panitumumab + Irinotecan|Participants received panitumumab 6 mg/kg and irinotecan 180 mg/m² administered by intravenous (IV) infusion every 2 weeks until disease progression or intolerance of panitumumab, irinotecan or both.
3045623|NCT00563368|Experimental|VI-0521 Top|VI-0521; high dose phentermine/topiramate
3045624|NCT00563368|Experimental|VI-0521 Mid|VI-0521; mid dose phentermine/topiramate
3045625|NCT00563368|Active Comparator|TPM 46|mid dose topiramate
3045626|NCT00563368|Active Comparator|TPM 92|high dose topiramate
3045627|NCT00563368|Active Comparator|PHEN 7.5|mid dose phentermine
3045628|NCT00563368|Active Comparator|PHEN 15|high dose phentermine
3045629|NCT00563368|Placebo Comparator|Placebo|
3045630|NCT00563381|Active Comparator|Tiotropium + Placebo|patients inhale Tiotropium 18mcg once daily via HandiHaler and Placebo MDI twice daily
3045631|NCT00563381|Active Comparator|Salmeterol + Placebo|patients inhale Salmeterol 50mcg twice daily via MDI and Placebo HandiHaler once daily
3468776|NCT03892382|Active Comparator|Active rTMS|10 hertz (Hz) rTMS will be administered over the left dorsolateral prefrontal cortex. Therapy will include 10 daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 120% of the resting motor threshold intensity will be elicited.
3045634|NCT00563706|Experimental|1|
3045635|NCT00563706|Active Comparator|2|4mg/day
3045636|NCT00563706|Placebo Comparator|3|matching placebo
3045637|NCT00563784|Experimental|Erlotinib + Paclitaxel + Carboplatin|Oral Erlotinib 150 mg daily + Paclitaxel 45 mg/m^2 by vein weekly + Carboplatin 2 AUC by vein weekly and Radiation Therapy 63 GY/35 fractions for 7 weeks cycles
3045638|NCT00563797|Experimental|Mecamylamine|Mecamylamine is a noncompetitive, high-affinity nAChR antagonist with low selectivity for the alpha-7 receptor. Those receiving mecamylamine started at 2.5mg once daily (second dose was placebo). The dose was increased to 5.0 mg twice daily over 3 weeks.
3045639|NCT00563797|Placebo Comparator|Placebo|Placebo capsules were prepared by the pharmacy and were identical in size and color to the medication capsules.
3045640|NCT00564018|Experimental|Detemir|24 subjects randomized to therapy with a combination of insulins detemir and aspart at diagnosis of diabetes.
3045641|NCT00564018|Experimental|Glargine|24 subjects randomized to therapy with a combination of insulins glargine and aspart at diagnosis of diabetes.
3045642|NCT00564018|Experimental|NPH|24 subjects randomized to therapy with a combination of insulins NPH and aspart at diagnosis of diabetes.
3045643|NCT00564070|Active Comparator|Enhanced treatment as usual|Enhanced treatment as usual plus single-session life-steps treatment
3045644|NCT00564070|Experimental|CBT-AD|Enhanced treatment as usual plus multiple-session CBT treatment (CBT-AD)
3045645|NCT00564265||GIST|GIST from all gastrointestinal origins: esophagus, stomach, duodenum, jejunum, ileum, colon and rectum
3045646|NCT00564278|Active Comparator|Standard antidepressant therapy|Participants will receive standard antidepressant therapy, including selecting among 9 FDA-approved antidepressants from several classes.
3045647|NCT00564278|Experimental|Motivational antidepressant therapy|Participants will receive motivational antidepressant therapy, including selecting among the same list of 9 FDA-approved antidepressants from several classes as in the control arm.
3045648|NCT00564395|Experimental|Insulin Detemir+RAI, then Insulin Detemir and RAI separately|Participants first received, Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for 10 days. Then they received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for the next 10 days.
3045649|NCT00564395|Active Comparator|Insulin Detemir and RAI separately, then Insulin Detemir+RAI|Participants first received Insulin Detemir and RAI as separate subcutaneous injections, twice daily for 10 days. Then they received Insulin Detemir mixed with RAI, twice daily as subcutaneous injection for the next 10 days.
3045650|NCT00564447|Experimental|Azithromycin-30 minutes Post dose|
3045651|NCT00564447|Experimental|Azithromycin-2 hours post dose|
3045652|NCT00564447|Experimental|Azithromycin-12 hours post dose|
3045653|NCT00564447|Experimental|Azithromycin-24 hours post dose|
3045654|NCT00564447|Experimental|Moxifloxacin-30 minutes post dose|
3045655|NCT00564447|Experimental|Moxifloxacin-2 hours post dose|
3045656|NCT00564447|Experimental|Moxifloxacin-12 hours post dose|
3045657|NCT00564447|Experimental|Moxafloxacin-24 hours post dose|
3045658|NCT00564486|Placebo Comparator|IV Placebo 100 ml|IV Placebo 100 ml dosed every every 6 hours for 24 hours (4 doses total).
3045659|NCT00564486|Placebo Comparator|IV Placebo 65 ml|IV Placebo 65 ml dosed every every 4 hours for 24 hours (6 doses total).
3045660|NCT00564486|Experimental|IV Acetaminophen 1 gm|IV Acetaminophen 1 gm dosed every every 6 hours for 24 hours (4 doses total).
3045661|NCT00564486|Experimental|IV Acetaminophen 650 mg|IV Acetaminophen 650 mg dosed every every 4 hours for 24 hours (6 doses total).
3045662|NCT00564629|Experimental|IV acetaminophen plus oral placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive 1 g of acetaminophen in 100 ml of intravenous solution and oral placebo.
3045663|NCT00564629|Active Comparator|Oral acetaminophen plus IV placebo.|Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever. Randomization to receive oral acetaminophen 1 g plus 100 ml of intravenous placebo solution.
3045664|NCT00564681|Active Comparator|botulinum toxin Type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
3045665|NCT00564681|Active Comparator|botulinum toxin Type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
3045666|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
3045667|NCT00564681|Other|Placebo (Normal Saline) / botulinum toxin Type A Formulation 2|Intramuscular injections of the assigned study medication into the affected muscles (placebo for treatment cycle 1 and botulinum toxin Type A Formulation 2 for subsequent treatments). Maximum dose of 360 units. Subjects may receive up to three treatments.
3045668|NCT00564733|Experimental|Chemotherapy|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Patients undergo FDG PET/CT (fludeoxyglucose F 18 positron emission tomography/computed tomography) scan between days 18-21. The FDG PET/CT is an imaging biomarker analysis. Patients that are responding to treatment receive paclitaxel IV and carboplatin IV on day 1. Treatment repeats every 3 weeks for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.Patients that are not responding to chemotherapy per FDG PET then receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Non-responding patients undergo an additional FDG PET/CT scan between days 18-21 of course 2.
3045669|NCT00564850|Experimental|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|
3045670|NCT00564889|Experimental|CRD|"Lenalidomide 15mg daily (days 1-21)~Cyclophosphamide 300 mg/m^2 (days 1, 8, 15)~Dexamethasone 40 mg weekly"
3045671|NCT00564902|Placebo Comparator|Lutein|9 mg of Lutein for 12 months
3045672|NCT00564902|Active Comparator|Zeaxanthin and Lutein|3R 3'R Zeaxanthin 8 mg, Lutein 8 mg per day during 12 months
3045673|NCT00564902|Active Comparator|Zeaxanthin|3R 3'R Zeaxanthin 8 mg per day during 12 months
3045674|NCT00564954|Experimental|Dex-methylphenidate hydrochloride (Focalin XR)|20 mg capsule orally once a day for 7 days
3045675|NCT00564954|Placebo Comparator|Placebo|orally once a day for 7 days
3045676|NCT00565045|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Stimulation to finger and thumb extensors and flexors only in response to and with an intensity proportional to opening and closing of the contralateral unimpaired hand~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity~Therapy sessions are done with the subject being assisted by the CCFES system."
3045677|NCT00565045|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation.~Preprogrammed cycles of finger and thumb flexor and extensor stimulation repeatedly and automatically close and open the hand without any effort or voluntary intent required by the subject.~Subject instructed to relax, not attempt to assist the stimulation, and not to move the contralateral arm/hand during stimulation~Therapy sessions are done without the stimulation system"
3045678|NCT00565058|Experimental|Pilot|Pilot PD Study (Delayed GTI-2040) Group: In the Pilot PD Study Group, addition of GTI-2040 is delayed until 24 hours after initiation of HiDAC.
3045679|NCT00565058|Experimental|Phase II arm|Phase II PD Study (Early GTI-2040) Group: In the Phase II PD Study Group, GTI-2040 is given 24 hours prior to addition of HiDAC.
3045680|NCT00565084|Active Comparator|1|Ibuprofen
3045681|NCT00565084|Placebo Comparator|2|Placebo 1
3045682|NCT00565084|Placebo Comparator|3|Placebo 2
3045683|NCT00565110|No Intervention|Enhanced Usual Care|EUC patients receive medical center standard oncology care and supportive services routinely provided to all patients with cancer. In addition, EUC patients are given a patient focused and a family focused educational pamphlet on depression and cancer and a listing of financial and community resources (in Spanish for Spanish-speaking patients). With patient consent, as described in the informed written consent, the treating oncologist is informed via medical chart note if EUC patients screen positive for major depression. Treating oncology attending physicians, fellows and residents are invited to attend a didactic session led by the study psychiatrist on treating depression in cancer patients.
3045684|NCT00565110|Experimental|ADAPt-C intervention|Intervention patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
3045685|NCT00565136|Experimental|TOPAS|TOPAS AMS Pelvic Floor Repair System
3045686|NCT00565266|Experimental|"Tio + 1xICS || LABA + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045687|NCT00565266|Experimental|"TIO + 1xICS || 2xICS || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045688|NCT00565266|Experimental|"LABA + 1xICS || Tio + 1xICS || 2xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045689|NCT00565266|Experimental|"LABA + 1xICS || 2xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045690|NCT00565266|Experimental|"2xICS || Tio + 1xICS| || LABA + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045691|NCT00565266|Experimental|"2xICS || LABA + 1xICS || Tio + 1xICS"|"Participants will take part in three 16-week treatment periods, which will occur in the following order:~beclomethasone dipropionate 160 mcg twice daily (2xICS)~salmeterol xinafoate inhalation powder 50 mcg twice daily (LABA) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~tiotropium bromide inhalation powder 18 mcg once daily (Tio) plus beclomethasone dipropionate 80 mcg twice daily (1xICS)~Each of the three 16-week treatment periods will consist of 14 weeks of treatment followed by a 2-week washout period, in which participants will receive beclomethasone dipropionate 80 mcg twice daily (1xICS)."
3045692|NCT00565370|Experimental|A|XP+sorafenib
3045693|NCT00565370|Placebo Comparator|B|XP
3045694|NCT00565409|Active Comparator|1|
3045695|NCT00565409|Active Comparator|2|
3045696|NCT00565409|Placebo Comparator|3|
3045697|NCT00565448|Experimental|Docetaxel/Cisplatin/5-FU (TCF)|"Docetaxel 75 milligrams per square meter (mg/m²) over 1 hour on Day 1 every 3 weeks~Cisplatin 75 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 750 mg/m²/day continuous infusion Days 1 to 4 every 3 weeks as an induction therapy~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
3045698|NCT00565448|Active Comparator|Cisplatin/5-FU (CF)|"Cisplatin 80 mg/m² Day 1 over 6 hours every 3 weeks~5-Fluorouracil 1000 mg/m²/day continuous infusion Day 1 to 4 every 3 weeks as an induction therapy.~Consolidation treatment: radiation therapy for 7-8 weeks and 3 cycles of cisplatin 100 mg/m² every 3 weeks."
3178939|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-5kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (5kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3178940|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-25 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (25kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3178941|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-50 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (50kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3468777|NCT03892382|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
3045703|NCT00565604|Experimental|Short Catheter Delviery|Patients with duplex ultrasound documented incompetent perforator veins will be treated using a short catheter delivery system in conjunction with a Bright Tip Laser fiber.
3045704|NCT00565617|Experimental|Synergy, Epidural cortical stimulation|Epidural cortical stimulation (medial prefrontal cortex) for treatment resistant depression. The primary aim of this pilot study was to assess the feasibility and safety of EpCS in patients with treatment-resistant depression. Ultimately, for EpCS to be found effective, a much larger double blind placebo controlled study would be needed.
3045705|NCT00565643|Experimental|HA-CMC Group|Hyaluronic Acid-Carboxymethylcellulose placed as an adhesion barrier
3045706|NCT00565643|Placebo Comparator|Routine Closure Group|Routine Closure without placement of an adhesion barrier
3045707|NCT00565669|Experimental|Blink Tears|
3045708|NCT00565669|Experimental|Systane|
3045709|NCT00565721|Experimental|Fluciclatide Injection - (AH111585 (F18))|Using of the drug product named, AH111585 (F18) Injection. It's generic chemical name is Fluciclatide.
3045710|NCT00565747|Experimental|Test culture|Culture with GM-CSF
3045711|NCT00565747|Placebo Comparator|Control culture|Culture without GM-CSF
3045712|NCT00565773|Experimental|Immunosuppressive medications|"Renal transplant recipients will be given an experimental combination of immunosuppressive drugs. Participants will receive a single dose of alemtuzumab on the day of transplantation and will receive belatacept and sirolimus for 1 year.~At the time of transplant, all patients will receive a single dose of 500 mg of methylprednisolone IV over 30 minutes, followed within 1 hour by an IV infusion of 30 mg of alemtuzumab over 3 hours."
3045713|NCT00565812|Active Comparator|200 mg|High dose active comparator
3045714|NCT00565812|Active Comparator|50 mg|Low dose active comparator
3045715|NCT00565812|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
3468778|NCT03892330|Experimental|liposomal doxorubicin|Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
3468779|NCT03892330|Active Comparator|doxorubicin|Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
3468780|NCT03892330|Active Comparator|pharmorubicin|Drug: pharmorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
3468781|NCT03892330|Active Comparator|pirarubicin|Drug: pirarubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
3045720|NCT00565864|Experimental|1 (Low-normal TSH target)|Treatment arm 1 targets a thyroid stimulating hormone (TSH) of 0.28 -2.49 milliunits/liter (mU/L) (the theoretical optimal range). The intervention is as follows: Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses.
3045721|NCT00565864|Experimental|2 (High-normal TSH target)|"Treatment arm 2 targeting a TSH of 2.5 - 5.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
3045722|NCT00565864|Experimental|3 (Mildly elevated TSH target)|"Treatment arm 3 is targeting a TSH level o f 5.1-12.0 mU/L. The intervention is as follows:~Levothyroxine (L-T4) doses will be adjusted in this arm to achieve this target TSH range. L-T4 is the intervention. L-T4 is given once per day, in the morning, while fasted. Dose ranges for the study are calculated based on each subject's TSH levels monitored during the study. Duration of the intervention is the duration of the study, after which subjects return to taking their usual L-T4 doses."
3045723|NCT00565916|Experimental|estrogen plus progesterone|Hormone replacement therapy (HRT): estrogen plus progesterone
3045724|NCT00565916|Active Comparator|estrogen plus placebo|Hormone replacement therapy (HRT): estrogen plus placebo
3045725|NCT00566020|Experimental|Lamotrigine|study drug
3045726|NCT00566098|Experimental|ASCT+MILs|Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
3045727|NCT00566111|Active Comparator|A|
3045728|NCT00566111|Placebo Comparator|P|
3045729|NCT00566150|Active Comparator|Levetiracetam|
3045730|NCT00566150|Placebo Comparator|Placebo|
3045731|NCT00566228|Experimental|Immunologic autograft engineering|Patients' stem cells are collected according to modified Amicus settings (i.e., MNC OFFSET = 0.0 and RBC = 7.0). Patients undergo ASCT IV on the day of apheresis (lymphocyte enriched autograft).
3045732|NCT00566228|Active Comparator|Standard autograft collection|Patients' stem cells are collected according to standard Amicus settings (i.e., MNC OFFSET = 1.5 and RBC OFFSET = 5.0). Patients undergo ASCT IV on the day of apheresis.
3045733|NCT00566254|Placebo Comparator|Placebo|Participants had a starting dose of 1 mg/kg/day of placebo matching Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
3045734|NCT00566254|Experimental|Zonisamide|Participants had a starting dose of 1 mg/kg/day of Zonisamide. Dose was titrated upwards with weekly dose increases until a dose of 8 mg/kg/day was reached at the end of the Titration Period (Week 8). Dose during the Maintenance Period remained unchanged from Week 8.
3045735|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil SR 23 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326 (NCT00478205).
3045736|NCT00566501|Experimental|Donepezil SR 23 mg (Donepezil IR 10 mg in Study NCT00478205)|Donepezil SR 23 mg once daily orally for 12 months to participants who received donepezil 10 mg immediate release (IR) in the preceding double-blind study E2020-G000-326 (NCT00478205).
3045737|NCT00566527|Experimental|Arm 1: ProQuad® at 9 and 12 months|Pediatric participants received ProQuad® Dose 1 at 9 months of age and ProQuad® Dose 2 at 12 months of age.
3045738|NCT00566527|Experimental|Arm 2: ProQuad® at 11 and 14 months|Pediatric participants received ProQuad® Dose 1 at 11 months of age and ProQuad® Dose 2 at 14 months of age.
3045739|NCT00566527|Active Comparator|Arm 3: ProQuad at 12 and 15 months|Pediatric participants received ProQuad® Dose 1 at 12 months of age and ProQuad® Dose 2 at 15 months of age.
3045740|NCT00566540|Experimental|Treatment (neoadjuvant, adjuvant chemotherapy and radiation)|"PREOPERATIVE:Patients receive cisplatin IV over 2 hours three times weekly in week 1 once daily(QD),5 days a week, in weeks 1-2.~SURGERY:Patients undergo triple endoscopy and biopsy with submandibular gland transfer in week 3.~INTRAOPERATIVE: Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation.~POSTOPERATIVE: Patients receive paclitaxel IV over 3 hours in weeks 7-10 and cisplatin IV over 1-2 hours three times weekly in weeks 7 and 10. Patients also undergo Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation QD, 5 days a week, in weeks 7-10."
3045741|NCT00566579|Experimental|A|Double-freezing cryotherapy was done within one month after the primary hpv testing was positive. Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
3045742|NCT00566579|No Intervention|B|Pap smear and colposcopy were done at 6 months and 12 months. HPV testing was repeated again at 12 months.
3045743|NCT00566631|Experimental|Paliperidone Extended Release (ER)|
3045744|NCT00566696|Experimental|High-Risk Hematologic Malignancies|"Participants meeting eligibility criteria undergo haploidentical stem cell transplantation along with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (after January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.~Grafts from suitable haploidentical donors are processed using the CliniMACS system."
3045745|NCT00566709|Experimental|RBCT based on rSO2 value|Intervention: In the rSO2 - strategy group, patients will be transfused to attain a post-transfusion rSO2 values higher than 60%.
3045746|NCT00566709|Active Comparator|RBCT based on hemoglobin level value|Intervention: In the hemoglobin - strategy group, patients will be transfused to reach post-transfusion hemoglobin levels between 8.5 g/dL and 10 g/dL.
3045747|NCT00566722|Experimental|Open Label|
3045748|NCT00566735|Placebo Comparator|1|
3045749|NCT00566735|Active Comparator|2, Galantamine|
3045750|NCT00566813|Active Comparator|Group 1 (Islet Cell Transplant)|1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
3045751|NCT00566813|Active Comparator|Group 2 (Islet Cell Transplant plus)|1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily for I week, then up to 10-mcg twice daily for 6 months after the last islet transplant.
3045752|NCT00566852|Experimental|WBRT+Memantine|Whole brain radiation therapy (WBRT) and memantine
3045753|NCT00566852|Active Comparator|WBRT+Placebo|Whole brain radiation therapy (WBRT) and placebo
3045754|NCT00566930|No Intervention|1|
3045755|NCT00566930|Active Comparator|2|spinal manipulation
3045756|NCT00566930|Experimental|3|Spinal manipulation + exercises
3045757|NCT00566943|Active Comparator|Control|"Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple lines including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine). intestine or mesentery.~Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without buttress at the GJ anastomosis. Linear buttress at the stomach/pouch staple line is required."
3045758|NCT00566943|Experimental|PSD Veritas|"Linear Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas used as a staple line buttress at the stomach/pouch.~In addition to buttress of the stomach/pouch, patients may have PSD Veritas linear buttress at any of the following staple lines: intestine, mesentery, or anastomosis junction (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine).~Circular Peri-Strips Dry Veritas Group: Patients who have laparoscopic Roux-en-Y gastric by-pass surgery with PSD Veritas circular buttress used as a staple line buttress at the GJ anastomosis. Linear buttress at the stomach/pouch is required."
3045759|NCT00566969|Placebo Comparator|Sugar Pill|To be compared to active drug
3045760|NCT00566969|Active Comparator|Carvedilol 25 mg|To be compared to placebo and Carvedilol 50 mg
3045761|NCT00566969|Active Comparator|Carvedilol 50 mg|To be compared to placebo and Carvedilol 25 mg
3045762|NCT00566982|Experimental|Ospemifene 60 mg/day|Ospemifene will be taken orally, once daily, in the morning, with food for 52 weeks.
3045763|NCT00566982|Placebo Comparator|Placebo|Placebo will be taken once daily, in the morning, with food for 52 weeks.
3178942|NCT00667199|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)-100 kBq/kg|"Each patient received a single injection of radium-223 , based on the randomised dose level (100kBq/kg) and individual body weight.~A second injection of radium-223 set to 50 kBq/kg b.w. could be offered to patients in the Follow-up Period at the discretion of the investigator."
3045765|NCT00567008|Experimental|1|Varenicline (Chantix)
3045766|NCT00567008|Placebo Comparator|2|Placebo
3045767|NCT00567112|Experimental|DFC (fasted)|
3045768|NCT00567112|Experimental|OCT (fasted)|
3045769|NCT00567112|Experimental|OCT (after meal)|
3045770|NCT00567112|Active Comparator|OCT (before meal)|
3045771|NCT00567164|Experimental|Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
3045772|NCT00567164|Experimental|Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300)|Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
3045773|NCT00567164|Active Comparator|Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.
3045774|NCT00567190|Experimental|Pertuzumab + Trastuzumab + Docetaxel|Participants randomized to this arm received pertuzumab 420 milligrams (mg) intravenously (IV) once every 3 weeks (q3w) and trastuzumab 6 milligrams per kilogram (mg/kg) IV q3w, plus docetaxel 75 milligrams per square metre of body surface (mg/m^2) IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
3045775|NCT00567190|Placebo Comparator|Placebo + Trastuzumab + Docetaxel|Participants randomized to this arm received placebo IV q3w and trastuzumab 6 mg/kg IV q3w, plus docetaxel 75 mg/m^2 IV q3w (for at least 6 cycles; 1 cycle was 21 days). After Cycle 6, continuation of docetaxel treatment was at the discretion of the participant and treating physician. Participants remained in the treatment phase of the study until investigator-assessed radiographic or clinical evidence of disease progression, unmanageable toxicity, or study termination and were followed for survival until death, loss to follow-up, withdrawal of consent, or study termination.
3045776|NCT00567229|Experimental|Lenalidomide and Rituximab|This study will employ a Simon optimal two-stage design. Patients will receive lenalidomide 25 mg daily for days 1-21 of each 28 day cycle. Rituximab 375 mg/m2 will be given weekly for 4 weeks beginning 1 week after the start of lenalidomide therapy (weeks 2-5), and then once 8 weeks later (week 13). Patients with stable disease or better after 4 cycles (week 16, in the absence of delays for toxicity) will be able to continue on therapy on the same lenalidomide schedule and with rituximab 375 mg/m2 given once every 8 weeks.
3045777|NCT00567242|Experimental|Word-finding with intention component|Treats word-finding (picture naming, category member generation) with an intention manipulation (complex left-hand movement to initiate word-finding trials)
3045778|NCT00567242|Active Comparator|Word-finding with no intention component|Word-finding trials similar to intention mediated treatment, but without intention manipulation
3045779|NCT00567255|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day with ancillary therapy
3045780|NCT00567255|Placebo Comparator|Placebo|Placebo with ancillary therapy
3045781|NCT00567268||Gabapentin|Patients taking Gabapentin
3045782|NCT00567307|Experimental|The Red Heart Pill 2b (Polypill) (A)|The Polypill is composed of 75 mg aspirin, 20 mg simvastatin, 10 mg lisinopril and 12.5 mg hydrochlorothiazide
3045783|NCT00567307|Active Comparator|Standard Practice Group (B)|Standard Practice
3045784|NCT00567320|Active Comparator|Varenicline|
3045785|NCT00567320|Active Comparator|Sugar Pill or Placebo|Placebo is compared to active drug varenicline
3045786|NCT00567359|Experimental|Erlotinib|
3045787|NCT00567398|Active Comparator|non glucose sparing|Dianeal only
3045788|NCT00567398|Experimental|Glucose sparing|Physioneal, Extraneal, Nutrineal
3045789|NCT00567476|Active Comparator|Omalizumab + Conventional Therapy|Omalizumab was administered subcutaneously every 2 or 4 weeks over a period of 20 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of immunoglobulin E (IgE). Doses (mg) and dosing frequency were determined by serum total IgE level (IU/mL) and body weight (kg). Also, participants continued using their current formulation of inhaled corticosteroid (ICS) and long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
3045790|NCT00567476|Active Comparator|Conventional Therapy|Participants continued using their current formulation of inhaled corticosteroid (ICS) and a long-acting beta 2-adrenergic agonist (LABA). Home use of nebulized beta 2-agonist was allowed for the treatment of symptoms of intercurrent bronchospasm or during an asthma exacerbation if this treatment regimen was already established prior to screening visit.
3045791|NCT00567489|Active Comparator|Non glucose sparing|Dianeal only
3045792|NCT00567489|Experimental|glucose sparing|PEN solutions: Nutrineal, Extraneal, and Physioneal
3045793|NCT00567502||1|XAGRID® (anagrelide hydrochloride)
3045794|NCT00567502||2|Xagrid + Other cytoreductive
3045795|NCT00567502||3|Other cytoreductive
3045796|NCT00567541|Active Comparator|Active BBPM stimulation|Therapeutic Stimulation is applied via the Battery Powered Microneuromodulator (BBPM) which is programmed to deliver set stimulation parameters with approximate frequency of 30 Hz, current 5mA for 200 microseconds for the first 12 weeks of the study. The BBPM is implanted near the axillary nerve within the quadrilateral space.
3045797|NCT00567541|Placebo Comparator|Sham BBPM stimulation|The Battery Powered Microneuromodulator is implanted near the axillary nerve within the quadrilateral space. The BBPM is programmed for the first 12 weeks of the study to deliver short bursts of extremely low amplitude electrical stimulation at very wide time intervals to give appearance, impression, and sensation of therapeutic treatment. After 24 weeks, the device will be reprogrammed to deliver therapeutic stimulation over a 12 week period.
3468782|NCT03892642|Experimental|BCG + Avelumab|Combination of avelumab and intravesical BCG. One cycle = 12 weeks (84 days). A standard maintenance therapy regimen will be provided with BCG occurring at Month 3, 6, and 12. Avelumab treatment ends at the conclusion of Month 12 maintenance therapy.
3468783|NCT03892577||Patients with advanced hepatobiliary tumors|"2000 patients with advanced hepatobiliary tumors will be enrolled and the enroll patients should be treat with any type of the following three treatment program:~Monotherapy or combination therapy with the targeted drug related to genetic variation of the subject;~Treatment with pan-target anti-angiogenic drugs, such as sorafenib, regorafenib, lenvatinib, apatinib, etc;~Immunotherapy or immunotherapy combined with targeted therapy."
3045800|NCT00567580|Active Comparator|PBRT Alone|Prostate bed radiotherapy (PBRT) begins within 6 weeks (+/- 2 weeks) after registration.
3045801|NCT00567580|Experimental|PBRT + STAD|Prostate bed radiotherapy (PBRT) and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before radiotherapy (RT), and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
3045802|NCT00567580|Experimental|PLNRT + PBRT + STADT|Pelvic lymph node radiotherapy (PLNRT), prostate bed radiotherapy (PBRT), and short term androgen deprivation therapy (STAD) consisting of antiandrogen (AA) and luteinizing hormone-releasing hormone (LHRH) agonist therapy begins within 6 weeks (+/- 2 weeks) after registration. STAD starts first, 2 months (+/- 2 weeks) before RT, and lasts for 4-6 months. LHRH can last 4-6 months. AA starts at the same time as LHRH (or up to 2 weeks prior ), lasts approximately 4 months, and should end on the last day of RT (+/- 2 weeks).
3045803|NCT00567593|Other|Rosiglitazone|Rosiglitazone; 8mg tablet once a day for 14 days
3045804|NCT00567840|Experimental|1|PA-824 200 mg/qd
3045805|NCT00567840|Experimental|2|PA-824 600 mg/qd
3045806|NCT00567840|Experimental|3|PA-824 1000 mg/qd
3045807|NCT00567840|Experimental|4|PA-824 1200 mg/qd
3045808|NCT00567840|Active Comparator|5|Rifafour e-275 mg
3045809|NCT00567879|Experimental|Panobinostat with trastuzumab|Panobinostat intravenously (i.v.) or orally was given in combination with trastuzumab.
3045810|NCT00567892|Experimental|1. rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
3045811|NCT00567892|Sham Comparator|2. Sham rTMS|Sham rTMS appears identical to and mimics sounds and sensations of active magnet.
3045812|NCT00567996|Experimental|Indacaterol 150 μg|"Indacaterol 150 μg once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3045813|NCT00567996|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI). Placebo to Salmeterol delivered twice daily via a proprietary dry powder inhaler in the morning and in the evening.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3045814|NCT00567996|Active Comparator|Salmeterol 50 μg|"Salmeterol 50 μg twice daily delivered via a proprietary dry powder inhaler in the morning and in the evening. Placebo to Indacaterol daily in the morning, inhaled via a single dose dry powder inhaler (SDDPI).~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3045815|NCT00568022|Experimental|Ixabepilone + Capecitabine|
3045816|NCT00568061|Experimental|Inhaled Nitric Oxide|Inhaled Nitric oxide administered at 80 parts per million (ppm)
3045817|NCT00568061|Placebo Comparator|Placebo|Inhaled nitrogen gas (Placebo) administered at 80 ppm
3045818|NCT00568087|Active Comparator|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
3045819|NCT00568087|Placebo Comparator|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
3045820|NCT00568126|Experimental|Maca Root|Subjects in this arm will be given 3g/day of maca root for 12 weeks
3045821|NCT00568126|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo for 12 weeks.
3178943|NCT00667212|Active Comparator|2|Supportive Psychotherapy
3468784|NCT03892785|Experimental|Tocilizumab group|
3468785|NCT03892785|Active Comparator|Methotrexate group|
3045822|NCT00568178|Experimental|Losartan Double-Blind Base Study (12-weeks)|"Normotensive participants received losartan.~Hypertensive participants received either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo)."
3045823|NCT00568178|Active Comparator|Amlodipine Double-Blind Base Study (12-weeks)|Hypertensive participants were randomized to receive either active losartan (plus amlodipine placebo) OR active amlodipine (plus losartan placebo) for 12 weeks.
3045824|NCT00568178|Experimental|Losartan Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
3045825|NCT00568178|Active Comparator|Enalapril Open-Label Extension Phase (Month 36)|Participants were were carried over from the base study into the long-term safety extension. Participants in the extension were randomly assigned to either losartan or enalapril regardless of their previous randomized treatment. Dosing during the extension period (i.e. starting dose and any titration) was up to the investigator and varied by patient).
3045826|NCT00568321|Experimental|1|
3045827|NCT00568321|Active Comparator|2|
3045828|NCT00568321|Placebo Comparator|3|
3045829|NCT00568334|Experimental|VARILRIX HSA-FREE GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine produced without human serum albumin (HSA-Free), administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
3045830|NCT00568334|Experimental|VARILRIX GROUP|Healthy male or female children between, and including, 11 and 21 months of age, who received 2 doses of Varilrix™ vaccine, administered subcutaneously into the deltoid region of the left upper arm, at Day 0 and Day 43-57 (Week 6).
3045831|NCT00568386|Experimental|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop in each eye one time
3045832|NCT00568386|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each one time
3045833|NCT00568399|Experimental|Active Treatment|This is the only arm and involves active treatment with sodium thiosulfate in those subjects with high coronary artery calcium scores.
3045834|NCT00568451|Experimental|PC (previously treated)|Previously chemotherapy treated cohorts: Paclitaxel and Carboplatin (PC)
3045835|NCT00568451|Experimental|PC (chemo naive)|Chemotherapy-naive cohorts: Paclitaxel and Carboplatin (PC)
3045836|NCT00568451|Experimental|TMZ (previously treated)|Previously chemotherapy treated cohorts: Temozolomide (TMZ)
3045837|NCT00568451|Experimental|TMZ (chemo naive)|Chemotherapy-naive cohorts: Temozolomide (TMZ)
3045838|NCT00568555|Experimental|Low Dose Naltrexone first|LDN first, then placebo.
3045839|NCT00568555|Placebo Comparator|Placebo - sugar pill first|Placebo first, then LDN.
3045840|NCT00568633|Experimental|Allo-HSCT + TLI + ATG|"Participants achieving complete remission after consolidation therapy & who have 5 of 6 HLA-match sibling donor to provide PBSC harvest for transplant. Pre-transplant subjects receive:~Total lymphoid radiation (TLI) Days -11 to -7, and Days -4 to -1 (2 fractions on day -1)~Anti-thymocyte globulin (ATG) Days -11 to -7~Methylprednisolone Days -11 to -7~Cyclosporine (CSP) Days -4 to +2~5+ of 6 HLA-matched CD34+ cells on Day 0~Mycophenolate mofetil (MMF), Day 0 to Day +28"
3045841|NCT00568633|Active Comparator|Best Standard Care|"Regular medical care for participants who achieve complete remission after standard consolidation therapy, but do not have a 5 of 6 HLA-match sibling donor. Treatment may consist of:~Additional consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~Autologous transplantation~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~Umbilical cord blood transplantation~Haploidentical transplantation"
3045842|NCT00568685|Active Comparator|Atomoxetine 0.2 milligram per kilogram per day (mg/kg/day)|
3045843|NCT00568685|Active Comparator|Atomoxetine 0.5 mg/kg/day|
3045844|NCT00568685|Active Comparator|Atomoxetine 1.2 mg/kg/day|
3045845|NCT00568776|Placebo Comparator|1|
3045846|NCT00568776|Active Comparator|2|
3045847|NCT00568776|Active Comparator|3|
3045848|NCT00568776|Active Comparator|4|
3045849|NCT00568854|Active Comparator|Participants with diabetes|Persons with diagnosis of diabetes. Received biological intervention: BCG
3045850|NCT00568854|Active Comparator|Participants without diabetes|Persons with no diagnosis of diabetes and negative diabetes screening labs. Received biological intervention: BCG.
3045851|NCT00568958|Experimental|Naltrexone|Active naltrexone (25 mg daily +25 targeted)+ BASICS counseling
3045852|NCT00568958|Placebo Comparator|Placebo Naltrexone|Placebo Naltrexone (targeted + daily) + BASICS Counseling
3045853|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 0|"Group 1 = Low-Dose Ara-C + Azacitidine-Level 0~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days Azacitidine (AZA): 37.5 mg/m^2 intravenous (IV) Over 20-30 minutes Daily for 7 Days"
3045854|NCT00569010|Experimental|Low-Dose Ara-C + AZA-Level 1|"Group 2 = Low-Dose Ara-C + Azacitidine-Level 1~Low-Dose Ara-C: 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days AZA: Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
3045855|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 0|Group 3 = High-Dose Ara-C + Azacitidine-Level 0 High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65years) AZA: 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days
3045856|NCT00569010|Experimental|High-Dose Ara-C + AZA-Level 1|"Group 4 = High-Dose Ara-C + Azacitidine-Level 1~High-dose Ara-C: 1 g/m^2 Daily CIV for 4 days (age<65years) or 3 days (age>=65 years) AZA:Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days"
3045857|NCT00569127|Experimental|Arm I (octreotide acetate and bevacizumab)|Patients receive depot octreotide acetate IM and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3045858|NCT00569127|Experimental|Arm II (octreotide acetate and recombinant interferon alfa-2b)|Patients receive octreotide acetate IM as in arm I on day 1 and recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3045859|NCT00569166|Active Comparator|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3045860|NCT00569166|Active Comparator|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3045861|NCT00569166|Placebo Comparator|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
3045862|NCT00569192|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
3045863|NCT00569192|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
3045864|NCT00569192|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
3045865|NCT00569231|Experimental|Candida Antigen|
3045866|NCT00569270|Active Comparator|Tiotropium 18 µg capsule, bronchodilator|tiotropium 18 µg capsule for 1 month versus placebo. To study bronchodilation and effect following metronome paced hyperventilation and induced dynamic hyperinflation of active tiotropium versus placebo
3045867|NCT00569270|Placebo Comparator|2|placebo 18ug tiotropium for 1 month
3045868|NCT00569309|Experimental|Prevnar|The conjugate vaccine for Streptococcus pneumoniae will be administered during weeks 9, 17, and 25 after autologous HSCT - the study nurse will arrange for the vaccine to be administered at the specified time and the patient will be instructed to notify an investigator or study nurse of any side effects of vaccine administration. At the specified times, patients will fill out the quality-of-life assessment. All patients enrolled on this trial will have samples procured for all proposed laboratory correlative studies.
3045869|NCT00569530|Active Comparator|Treatment Surfactant (Infasurf) ONY, NY|Patients receive inhaled nitric oxide and scheduled doses of Infasurf on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
3045870|NCT00569530|Placebo Comparator|Sham (no treatment)|Infants receiving inhaled nitric oxide will receive Sham (no treatment) on study days 0, 3, 7, 10, and 14, if infant remains ventilated.
3045871|NCT00569582|Experimental|1|
3045872|NCT00569660|Experimental|Azacitidine|75 mg/m^2 Subcutaneous Daily for 7 days every 4 weeks
3045873|NCT00569777|Experimental|K-lens|etafilcon A contact lens with ketotifen.
3045874|NCT00569777|Placebo Comparator|Placebo|etafilcon A contact lens without ketotifen
3045875|NCT00569803|Active Comparator|Belatacept 50 mg Subcutaneous Injection|Belatacept 50 mg subcutaneous (SC) injection
3045876|NCT00569803|Active Comparator|Belatacept 100 mg Subcutaneous Injection|Belatacept 100 mg SC injection
3045877|NCT00569803|Active Comparator|Belatacept 125 mg Subcutaneous Injection|Belatacept 125 mg SC injection
3045878|NCT00569803|Active Comparator|Belatacept 150 mg Subcutaneous Injections|2 SC injections of 75 mg Belatacept
3045879|NCT00569803|Active Comparator|Belatacept 200 mg Subcutaneous Injections|2 SC injections of 100 mg Belatacept
3045880|NCT00569803|Active Comparator|Belatacept 250 mg Subcutaneous Injections|2 SC injections of 125 mg Belatacept
3045881|NCT00569803|Active Comparator|Belatacept 125 mg Intravenous Infusion|125 mg Belatacept intravenous (IV) injection
3045882|NCT00569803|Placebo Comparator|Placebo|SC injection of placebo solution
3045883|NCT00569855|Experimental|1|Receive phenoxybenzamine in preparation for cardiopulmonary bypass during open-heart surgery
3045884|NCT00569946|Experimental|AG-013736|
3045885|NCT00570037|Active Comparator|Immunization Program|Intervention Hospital - Standing postpartum vaccine orders, influenza vaccine clinic on postpartum ward for household contacts, mailed vaccine reminders
3045886|NCT00570037|No Intervention|No Immunization Program|Comparison Hospital - Receipt of vaccine through routine clinical care
3045887|NCT00570063|Placebo Comparator|1|PF-02545920 15 mg tablets taken twice a day by mouth for 21 days
3045888|NCT00570063|Placebo Comparator|2|Matching placebo tablets taken twice a day by mouth for 21 days
3045889|NCT00570089|Experimental|Study Drug Ranexa, Then Placebo|"Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.~After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet)."
3045890|NCT00570089|Experimental|Placebo, Then Study Drug Ranexa(Ranolazine)|"Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.~After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval."
3045891|NCT00570128|Active Comparator|Donepezil HCl|
3045892|NCT00570128|Placebo Comparator|Placebo|
3045893|NCT00570141|Active Comparator|OASIS Wound Matrix (Oasis)|This is a single arm study with only the test article Oasis used on all subjects
3045894|NCT00570232|Other|Tarceva|All patients will be prescribed erlotinib 150mg daily
3045895|NCT00570310|Active Comparator|A|Patients in Group A will remain on pregabalin (up to 600 mg/day po) treatment for the entire double-blind period.
3045896|NCT00570310|Placebo Comparator|B|Patients in Group B will be treated with placebo.
3045897|NCT00570323|Active Comparator|ARM A / Arimidex with Faslodex|Arimidex with Faslodex in postmenopausal women
3045898|NCT00570323|Active Comparator|ARM B Arimidex without Faslodex|Arimidex without Faslodex in postmenopausal women.
3045899|NCT00570349|Experimental|Low Dose Cohort|Subjects in the low dose cohort receive 20 part per million (ppm) of nitric oxide via nasal cannula over a 44 hour period.
3045900|NCT00570349|Experimental|High-Dose Cohort|Subjects in the high dose cohort receive 40 ppm of nitric oxide via nasal cannula over a 44 hour period.
3045901|NCT00570349|Placebo Comparator|Nitrogen|100% Nitrogen (placebo) will be administer at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
3045902|NCT00570401|Experimental|Dasatinib|"Beginning 1 week after completion of erlotinib hydrochloride or gefitinib therapy, patients receive oral dasatinib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.~Response is assessed by CT scan at 4 weeks, 8 weeks, and then every 8 weeks thereafter."
3045903|NCT00570492|Placebo Comparator|Placebo nasal spray|
3045904|NCT00570492|Experimental|Fluticasone furoate nasal spray|
3045905|NCT00570505|Experimental|LapBand|All subjects who receive the LAP-BAND System.
3045906|NCT00570661|Experimental|ITF2357|"ITF2357 hard gelatine capsules were administered orally, in fed conditions, at the cumulative daily dose of 1.5 mg/kg achieved by administration of 0.75 mg/kg at 12-hour interval for 4 weeks initially. The doses of 1.5 mg/kg/day were achieved by administration of an appropriate number of capsules of definite strength (dose strengths of 7.5, 10, 12.5, 15, 20 mg and 50 mg).~Treatment was further prolonged up to 12 weeks in total if so suggested by the observed benefits and the lack of treatment-limiting toxicity"
3045907|NCT00570674|Experimental|Phase I Dose Level 1: ACE-RT|Phase I Dose Level 1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. One dose (400 mg/m2 IV) of Erbitux was given prior to start of radiation, then weekly at 250 mg/m2 IV. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3045908|NCT00570674|Experimental|Phase I Dose Level -1: AC-RT|Phase I Dose Level -1 participants received Abraxane 20mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3045909|NCT00570674|Experimental|Phase I Dose Level 2: AC-RT|Phase I Dose Level 2 participants received Abraxane 30mg/m2 IV then carboplatin AUC 1.5 weekly IV during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3045910|NCT00570674|Experimental|Phase I Dose Level 3: AC-RT|Phase I Dose Level 3 participants received Abraxane 40mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3045911|NCT00570674|Experimental|Phase I Dose Level 4: AC-RT|Phase I Dose Level 4 participants received Abraxane 50mg/m2 IV then carboplatin AUC 1.5 IV weekly during the period of radiotherapy for a total of 7 weeks. Intensity-modulated radiotherapy (IMRT) was delivered 5 days per week with the prescribed dose of 70 Gy to the gross tumor volume, given in 2 Gy daily fractions for a total of 35 fractions.
3045912|NCT00570687|Experimental|1|Technosphere Insulin
3045913|NCT00570700|Experimental|Dasatinib|Patients receive oral dasatinib once daily in the absence of disease progression or unacceptable toxicity.
3045914|NCT00570713|Experimental|MORAb-009|MORAb-009 plus gemcitabine ('MORAb-009'): MORAb-009 was administered at 5 mg/kg on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
3045915|NCT00570713|Active Comparator|Placebo|Placebo plus gemcitabine ('Placebo') Placebo was administered on Day 1 of Weeks 1 through 7 during the first cycle and on Day 1 of Weeks 1 through 3 of subsequent cycles. Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
3045916|NCT00570739|Placebo Comparator|Diabetic Participants: Metformin HCl+Placebo for Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
3045917|NCT00570739|Experimental|Diabetic participants: Metformin HCl + Colesevelam|Participants will receive either 850 mg or 1700 mg of metformin HCl, depending on tolerability + 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
3045918|NCT00570739|Placebo Comparator|Pre-diabetic Participants: Colesevelam Placebo|Participants will receive 6 placebo tablets matching colesevelam 625 mg. Study medication is to be administered once daily for 16 weeks.
3045919|NCT00570739|Experimental|Pre-diabetes Participants: Colesevelam|Participants will receive 6 colesevelam tablets, 625 mg. Study medication is to be administered once daily for 16 weeks.
3045920|NCT00570765|Experimental|DB OCA 10 mg|OCA 10 mg for 3 months during the DB phase.
3045921|NCT00570765|Experimental|DB OCA 50 mg|OCA 50 mg for 3 months during the DB phase.
3045922|NCT00570765|Placebo Comparator|DB OCA Placebo|Matching placebo for 3 months during the DB phase.
3045923|NCT00570765|Experimental|LTSE OCA Total|After completion of the 3-month DB phase, all eligible participants were offered the opportunity to enter an open-label LTSE for up to 96 months beginning at 10 mg OCA. Doses up to 50 mg daily were evaluated.
3045924|NCT00570778|Experimental|indacaterol/glycopyrrolate 300/50 μg|One indacaterol/glycopyrrolate 300/50 μg capsule + 1 placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
3045925|NCT00570778|Active Comparator|indacaterol 600 μg|Two indacaterol 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
3045926|NCT00570778|Active Comparator|indacaterol 300 μg|One capsule indacaterol 300 μg + one placebo capsule inhaled once daily via a single dose dry powder inhaler for 7 days.
3045927|NCT00570778|Placebo Comparator|placebo|Two placebo capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
3045928|NCT00570908|Experimental|Study Group|capecitabine administered concurrently with WBRT followed by combination the combination of capecitabine with sunitinib
3045929|NCT00570921|Experimental|Fulvestrant + Everolimus|"Fulvestrant + Everolimus~Fulvestrant was administered intramuscularly (in the gluteus maximus) in a loading dose schedule as follows: 500 mg in two divided doses-one on each side on day 1, then 250 mg on day 14, and then 250 mg on day 28 and every 4 weeks ± 3 days thereafter. Everolimus was administered initially at a dose of 5 mg daily in the first 5-patient cohort for the first month of treatment and then increased to 10 mg PO daily after that."
3045930|NCT00570960|Experimental|1: Dextran 70|antibiotic therapy in addition to dextran 70, 1.0 g/kg on days one, two and three
3045931|NCT00570960|Active Comparator|2: Standard of Care Human Albumin|antibiotic therapy in addition to human albumin, 1.5 g/kg on day one and 1.0 g/kg on day three
3045932|NCT00571038|Experimental|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
3045933|NCT00571038|Active Comparator|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
3045934|NCT00571064|Experimental|1|
3045935|NCT00571103|Experimental|1 Open Label|Open Label. At visit 2, all participants were started on Acamprosate, 1,998 mg divided into 3 equal doses.
3045936|NCT00571259|Active Comparator|1|Catheter lock with heparin 1,000 units/mL
3045937|NCT00571259|Active Comparator|2|Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%
3045938|NCT00571324|Experimental|Exendin-(9-39) first, the Vehicle|Exendin-(9-39) will be administered intravenously (IV) after an overnight fast. Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. The following day, after another overnight fast, normal saline (control) vehicle infusion will be administered intravenously (IV) over 6 hours. During both infusions, blood glucose levels will be measured every 20 minutes.
3045939|NCT00571324|Placebo Comparator|Vehicle first, then Exendin-(9-39)|Normal saline vehicle infusion will be administered intravenously (IV) after an overnight fast. The infusion will be given over 6 hours. The following day, after another overnight fast, Exendin-(9-39) will be infused over 6 hours with the dose slowly escalating from 100pmol/kg/min for 2 hours, then 300pmol/kg/min for another 2 hours followed by 500pmol/kg/min for the last 2 hours of the infusion. During both infusions, blood glucose levels will be measured every 20 minutes.
3045940|NCT00571428|Experimental|15 mcg BID / 30 mcg QD|Arformoterol 15 microgram twice a day (BID) taken each morning and evening for one visit followed by Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for the next visit.
3045941|NCT00571428|Experimental|30 mcg QD / 15 mcg BID|Arformoterol 30 microgram once a day (QD) in the morning and placebo in the evening for one visit followed by Arformoterol 15 microgram twice a day (BID) in the morning and evening for the next visit.
3045942|NCT00571493|Experimental|Bortezomib Dose Escalation|"The phase I section of the study will follow a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of bortezomib when added to a standard BEAM (BCNU (carmustine), etoposide, cytarabine, melphalan) conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT).~After the MTD is defined, additional patients will enroll in Phase II to obtain preliminary estimates of survival using the Phase I regimen."
3045943|NCT00571519|Experimental|1|rivoglitazone HCl 0.5mg
3045944|NCT00571519|Experimental|2|rivoglitazone HCl 1.0 mg
3045945|NCT00571519|Experimental|3|rivoglitazone HCl 1.5 mg
3045946|NCT00571519|Placebo Comparator|4|placebo matching rivoglitazone HCl tablets
3045947|NCT00571519|Active Comparator|5|pioglitazone HCl 15 mg
3045948|NCT00571519|Active Comparator|6|pioglitazone HCl 30 mg
3045949|NCT00571519|Active Comparator|7|pioglitazone HCl 45 mg
3045950|NCT00571519|Placebo Comparator|8|matching placebo for pioglitazone
3045951|NCT00571649|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
3045952|NCT00571649|Active Comparator|Enoxaparin|Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days
3045953|NCT00571662|Experimental|Cohort I|Pentostatin to be administered intravenously on days - 10, -9, and -8 at a dose of 4mg/m2/day
3045954|NCT00571688|Experimental|Risperdal Consta|Risperdal Consta injection in conjunction with existing treatment
3045955|NCT00571688|Active Comparator|Treatment As Usual|Clinician and patient decide upon treatment, as in a non-research clinical setting. The only treatment exclusion is any form of risperidone.
3045956|NCT00571701|Active Comparator|celecoxib first, then placebo|Patients randomized to start celecoxib 6 months after enrollment. Then cross over to placebo after 1 year. Celecoxib dosing will be given orally 400mg once a day for adults, 200 mg once a day for pediatric patients between 12-25kg, 100mg once a day for pediatric patients < 12kg
3045957|NCT00571701|Placebo Comparator|Placebo first, then celecoxib|Patients randomized to start placebo 6 months after enrollment. One placebo capsule will be taken orally once a day. Placebo will match appearance of active celecoxib capsules. Cross over to 12 months of treatment with celecoxib after 1 year.
3045958|NCT00571948|Active Comparator|Babyfood with usual meat content and corn oil|Infants in the control group received vegetable-potato-meat-meals as part of complementary food containing common amounts of meat and corn oil marketed in Germany.
3045959|NCT00571948|Experimental|more meat and a vegetable oil rich in omega-3 fatty acids|Infants in the intervention group received vegetable-potato-meat-meals as part of complementary food containing higher amounts of meat than the control group and rapeseed oil instead of corn oil.
3045960|NCT00571961|Experimental|1|HIV negative subjects currently enrolled in a long-term buprenorphine maintenance therapy program for at least 3 months who have been on stable dose of buprenorphine for at least 3 weeks will be admitted to the General Clinical Research Center (GCRC) for pharmacokinetic (PK) blood draws at intervals over a 24-hour period. Subjects will then receive Kaletra and buprenorphine coadministered for 14 days. Subjects will be admitted to the GCRC for a second PK sampling day.
3045961|NCT00571974|Experimental|Phase 1 light dose escalation|"During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2."
3045962|NCT00571974|Experimental|Phase 2 - Treatment efficacy of PDT|"Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2."
3045963|NCT00571987|Other|1|This is a non-randomized one arm study, all subjects receive treatment (radiofrequency ablation).
3045964|NCT00572039|Experimental|PST|Problem Solving Treatment (PST)
3045965|NCT00572039|Placebo Comparator|ST|Supportive Therapy (ST)
3045966|NCT00572117|Placebo Comparator|Placebo (inert pill) Arm|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
3045967|NCT00572117|Experimental|Topiramate|Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. The pills will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
3045968|NCT00572156|Active Comparator|1. rhGH Alone|
3045969|NCT00572156|Experimental|2. Combination Dose|
3045970|NCT00572156|Experimental|3. Combination Dose|
3045971|NCT00572156|Experimental|4. Combination Dose|
3045972|NCT00572195|Experimental|Evaluation Group (stimulation ON)|Group of subjects that have an RNS® System implanted, completed the RNS® System Pivotal or Feasibility study, and elected to continue to receive RNS® System responsive stimulation for the long term.
3045973|NCT00572234|Experimental|Receiving Bupropion SR|receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)
3045974|NCT00572234|No Intervention|Treatment as Usual|Not receiving bupropion
3045975|NCT00572455|Experimental|Stage 1: PF-04217329 - Lowest Dose|
3045976|NCT00572455|Experimental|Stage 1: PF-04217329 - Low Dose|
3045977|NCT00572455|Experimental|Stage 1: PF-04217329 - Middle Dose|
3045978|NCT00572455|Experimental|Stage 1: PF-04217329 - High Middle Dose|
3045979|NCT00572455|Experimental|Stage 1: PF-04217329 - High Dose|
3045980|NCT00572455|Experimental|Stage 1: PF-02417329 - Highest Dose|
3045981|NCT00572455|Experimental|Stage 1: PF-04217329 - Vehicle|
3045982|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost Vehicle|
3045983|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost Vehicle|
3045984|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost Vehicle|
3045985|NCT00572455|Experimental|Stage 2: PF-04217329 - Low Dose + Latanoprost 0.005%|
3045986|NCT00572455|Experimental|Stage 2: PF-04217329 - Middle Dose + Latanoprost 0.005%|
3045987|NCT00572455|Experimental|Stage 2: PF-04217329 - High Dose + Latanoprost 0.005%|
3045988|NCT00572455|Experimental|Stage 2: PF-04217329 - Vehicle + Latanoprost 0.005%|
3045989|NCT00572468|Active Comparator|Simvastatin|Twenty-two men will be on the Statin arm and take 40 mg of simvastatin.
3045990|NCT00572468|Placebo Comparator|Placebo|Twenty-two men will be on the placebo arm.
3045991|NCT00572533|Active Comparator|Control|ESA Dose Adjustment per standard Anemia Management Protocol
3045992|NCT00572533|Experimental|Treatment|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"
3045993|NCT00572572|Experimental|Arm A: Aprepitant, Then Placebo|Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
3045994|NCT00572572|Experimental|Arm B: Placebo, Then Aprepitant|Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
3045995|NCT00572624|Experimental|Diet|Participants who received counseling and instruction about weight loss through diet and exercise
3045996|NCT00572624|Experimental|Gastric bypass surgery|Participants who received gastric bypass surgery
3045997|NCT00572728|Experimental|Diagnostic (18F-FLT)|Patients undergo 18F-FLT PET /CT at baseline (prior to chemotherapy, FLT-1), early therapy (5-10 days after the initiation of the first course of chemotherapy, FLT-2), and post therapy (within 3 weeks prior to surgery, FLT-3). Patients undergo standard surgical resection of residual tumor following completion of neoadjuvant chemotherapy.
3045998|NCT00572832|Active Comparator|6 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine according to the regular schedule of 0,2, and 6 months.
3045999|NCT00572832|Active Comparator|12 mon. 3rd dose of quadrivalent human papillomavirus vaccine|Receipt of three doses of quadrivalent human papillomavirus vaccine on a delayed schedule of 0,2, and 12 months.
3046000|NCT00572897|Experimental|Fludarabine, Melphalan +/- ATG|Fludarabine, Melphalan +/- ATG
3046001|NCT00572910|Experimental|V710 - Group 1|V710 (60 mcg without MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3046002|NCT00572910|Experimental|V710 - Group 2|V710 (60 mcg without MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
3046003|NCT00572910|Experimental|V710 - Group 3|V710 (60 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3046004|NCT00572910|Experimental|V710 - Group 4|V710 (60 mcg with MAA) on Day 1 and Placebo on Day 28 followed by third dose of V710 or placebo on Day 180.
3046005|NCT00572910|Experimental|V710 - Group 5|V710 (90 mcg with MAA) on Day 1 and Day 28 followed by third dose of V710 or placebo on Day 180.
3046006|NCT00572910|Placebo Comparator|Group 6|Placebo on Day 1, 28 and 180.
3046007|NCT00572936|Other|Latanoprost/Dorzolamide/Timolol|The participants received latanoprost at night and vehicle in the morning for two weeks, then 6 week washout, then Dorzolamide BID for two weeks, then 6 week washout, then Timolol BID for two weeks. The order in which the participants received the three different drugs was random.
3046008|NCT00573066|Experimental|Dosing level|A predetermined dose of Dexmedetomidine
3046009|NCT00573131|Experimental|Group 1|OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
3046010|NCT00573131|Active Comparator|Group 2|Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
3046011|NCT00573144|Placebo Comparator|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator).
3046012|NCT00573144|Active Comparator|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
3046013|NCT00573170|Other|TPB|TREXIMET® (Attack 1), placebo (Attack 2), BCM (Attack 3)
3046014|NCT00573170|Other|TBP|TREXIMET® (Attack 1), BCM (Attack 2), placebo (Attack 3)
3046015|NCT00573170|Other|BTP|BCM (Attack 1), TREXIMET® (Attack 2), placebo (Attack 3)
3046016|NCT00573170|Other|BPT|BCM (Attack 1), placebo (Attack 2), TREXIMET® (Attack 3)
3046017|NCT00573170|Other|PTB|placebo (Attack 1), TREXIMET® (Attack 2), BCM (Attack 3)
3046018|NCT00573170|Other|PBT|placebo (Attack 1), BCM (Attack 2), TREXIMET® (Attack 3)
3046019|NCT00573183|Experimental|STAGE-12|STAGE-12 received 3 individual and 5 group 12-step facilitation sessions focusing on 12-step principles plus an intensive referral in which counselors linked participants to community-based 12-step volunteers. These sessions took the place of 3 individual and 5 group sessions in the standard intensive outpatient drug treatment program and were integrated into treatment as usual.
3046020|NCT00573183|Active Comparator|Treatment as Usual|Treatment as usual received standard care provided in intensive outpatient drug treatment program without the STAGE-12 components.
3046021|NCT00573248|Experimental|4|
3046022|NCT00573261|Experimental|Pregabalin|Pregabalin medication
3046023|NCT00573261|Placebo Comparator|Placebo|Placebo
3046024|NCT00573287|Experimental|Clozapine|clozapine: clozapine--tablets, 12.5-100 mg, daily for 24 weeks
3046025|NCT00573287|Active Comparator|Risperidone|risperidone: risperidone--tablets, 0.5-5.0mg daily for 24 weeks
3046026|NCT00573313|Experimental|S-adenosylmethionine (SAMe)|Alcoholic liver disease patients receiving S-adenosylmethionine (SAMe)at 400 mg capsule three times daily for 24 weeks
3046027|NCT00573313|Placebo Comparator|Sugar pill|ALD subjects receiving Placebo three times daily for 24 weeks.
3046028|NCT00573430|Experimental|1|Candesartan Cilexetil
3046029|NCT00573430|Experimental|2|Candesartan Cilexetil
3046030|NCT00573430|Experimental|3|Candesartan Cilexetil
3046031|NCT00573443|Experimental|DM 30 mg/Q 10 mg|AVP-923-30/10 Capsules (30 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
3046032|NCT00573443|Experimental|DM 20 mg/ Q 10 mg|AVP-923-20/10 Capsules (20 mg dextromethorphan/10 mg quinidine)administered once daily for 1 week and then twice daily for 11 weeks
3046033|NCT00573443|Placebo Comparator|Placebo|Placebo Capsules once daily for 1 week and then twice daily for an additional 11 weeks
3046034|NCT00573469|Active Comparator|1|D9421-C 9 mg
3046035|NCT00573469|Active Comparator|2|D9421-C 15 mg
3046036|NCT00573469|Placebo Comparator|3|Placebo
3046037|NCT00573508|Active Comparator|Placebo|Matching placebo tablet taken once daily
3046038|NCT00573508|Experimental|Solifenacin Succinate|5mg or 10mg tablet taken once daily
3046039|NCT00573534|Experimental|Open Label Vyvanse|Open Label Vyvanse (lisdexamphetamine) in doses of 30-70 mgs over 8 weeks in younger siblings of substance abusing older siblings with a history of treatment for ADHD
3046040|NCT00573755|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3046041|NCT00573755|Active Comparator|Arm II|Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3046042|NCT00573768|Active Comparator|1|
3046043|NCT00573768|Placebo Comparator|2|
3046044|NCT00573768|Active Comparator|3|
3046045|NCT00573794|Experimental|Adalimumab 40 mg EOW/EW|Open-label adalimumab 40 mg every other week (EOW) or every week (EW). Participants who entered from an open-label cohort continued their previous dosing regimen of adalimumab EOW or EW; participants who entered from a double-blind cohort received adalimumab EOW.
3046046|NCT00573833|Experimental|HDR Brachytherapy|9.5 Gy HDR Brachytherapy for 4 fractions given over 2 days
3046047|NCT00573859|Experimental|ADHD medication versus placebo|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication (e.g., Dextroamphetamine; Amphetamine mixed salts; Atomoxetine; O-Methylphenidate; Lisdexamfetamine). For the placebo condition, a placebo pill was administered.
3046048|NCT00573872|Experimental|Spinal Radiosurgery|Patients will be fitted in a custom immobilization device. A CT simulation scan will then be performed to pinpoint intended radiosurgery target producing a computer optimized radiation plan to be confirmed by planning radiation physicist. Patient will then be placed in their immobilization device and aligned with the treatment planning position. Patient then receives radiosurgery. Treatment delivery will be divided into components of 3-5Gy with repeat CT based localization in between each of these components. For all patients, a nominal prescription dose of 24Gy will be entered into the tomotherapy cost function. Once the plan that provides maximal spinal sparing has been generated, the plan will be renormalized to produce no more than 8Gy (prior RT) or 10Gy (no prior RT) to 0.5cc of spinal cord by dividing the single fraction treatment into fractions of 3-5Gy.
3046049|NCT00573989|Experimental|Erlotinib|Erlotinib
3046050|NCT00574067|Experimental|Buprenorphine+OTP|Buprenorphine and counseling in prison and continued at opioid treatment program (OTP) upon release.
3046051|NCT00574067|Experimental|Buprenorphine+CHC|Buprenorphine and counseling in prison and continued at a community health center (CHC) upon release.
3046052|NCT00574067|Active Comparator|Counseling + OTP|Counseling only in prison and Buprenorphine upon release at a opioid treatment program (OTP)
3046053|NCT00574067|Active Comparator|Counseling + CHC|Counseling only in prisons and Buprenorphine upon release at a community health center (CHC)
3046054|NCT00574119|Experimental|Results with spironolactone|patients with heart failure due to nonischemic dilated cardiomyopathy will be studied by 11C acetate positron emission tomography and magnetic resonance imaging using vasodilator and gadolinium to judge myocardial blood flow, before and after 6 months' treatment with spironolactone.
3046055|NCT00574145|Experimental|Radiotherapy/Supportive Care (A)|Patients receive radiotherapy and healing touch therapy from a healing touch therapist once a week for the duration of their radiotherapy
3178944|NCT00667212|Active Comparator|1|Cognitive Behavioral Therapy (Cognitive Restructuring, Relaxation, and Coping Skills Training: CRCST)
3046056|NCT00574145|Sham Comparator|Control ARM (B)|Patients receive radiotherapy and sham healing touch therapy from a sham healing touch therapist once a week for the duration of their therapy
3046057|NCT00574171|Experimental|1|
3046058|NCT00574197|Other|Enteric-coated Mycophenolate Sodium (Myfortic)|1440mg/day (720mg by mouth, twice a day) of enteric-coated Mycophenolate Sodium (Myfortic) for 6 months
3046059|NCT00574236|Experimental|A|
3046060|NCT00574249|Active Comparator|adalimumab + placebo|adalimumab + placebo (vehicle ointment)
3046061|NCT00574249|Active Comparator|adalimumab + calcipotriol/betamethasone|adalimumab + calcipotriol/betamethasone ointment
3046062|NCT00574275|Placebo Comparator|Placebo and Gemcitabine|Participants with metastatic pancreatic cancer administered Placebo and 1000 mg/m^2 Gemcitabine.
3046063|NCT00574275|Experimental|Aflibercept and Gemcitabine|Participants with metastatic pancreatic cancer administered 4 mg/kg Aflibercept and 1000 mg/m^2 Gemcitabine.
3046064|NCT00574288|Experimental|Dose Escalation: Daratumumab|
3046065|NCT00574288|Experimental|Dose Expansion: Daratumumab|
3046066|NCT00574340|Active Comparator|Control study then antecedent hypoglycemia study group|Day 1 euglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to antecedent hypoglycemia study Day 1 hypoglycemia, Day 2 hypoglycemia
3046067|NCT00574340|Active Comparator|Antecedent Hypoglycemic clamp study|Day 1 hypoglycemia, day 2 hypoglycemia Hyperinsulinemic Hypoglycemic Clamp: hyperinsulinemic glucose clamp separated by 8 weeks then participants proceeded to control study Day 1 euglycemia, Day 2 hypoglycemia
3046068|NCT00574405|Active Comparator|1|MDI = 3-4+ insulin injections/day, using split-mix NPH insulin + regular insulin or Lantus + Novolog® (or Humalog®).
3046069|NCT00574405|Experimental|2|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
3046070|NCT00574548|Experimental|Group 1.1|Group 1.1 = 13vPnC then 13vPnC
3046071|NCT00574548|Experimental|Group 1.2|Group 1.2 = 13vPnC then 23vPS
3046072|NCT00574548|Experimental|Group 2|Group 2 = 23vPS then 13vPnC
3046073|NCT00574587|Experimental|Vorinostat Plus Paclitaxel|Vorinostat (PO days 1-3) plus weekly paclitaxel x 12 weeks (and trastuzumab if HER2-positive), followed by doxorubicin-cyclophosphamide every 2 weeks x 4 cycles, followed by surgery
3046074|NCT00574704|Experimental|1|
3046075|NCT00574704|Placebo Comparator|2|
3046076|NCT00574704|Experimental|3|
3046077|NCT00574704|Placebo Comparator|4|
3046078|NCT00574834|Active Comparator|Ramipril|Patients randomized to 6 months treatment of Ramipril.
3046079|NCT00574834|Active Comparator|HCTZ|PAtients randomized to 6 months treatment of HCTZ.
3046080|NCT00574834|Active Comparator|Ramipril+HCTZ|Patients randomized to 6 months treatment of Ramipril+HCTZ.
3046081|NCT00574847|Experimental|Escitalopram|Escitalopram treatment
3046082|NCT00574847|Placebo Comparator|Placebo|Placebo
3046083|NCT00574873|Experimental|1|Bosutinib
3046084|NCT00574873|Active Comparator|2|Imatinib
3046085|NCT00574912|Experimental|Placebo then Insulin Glargine|"Placebo: administer single dose of Placebo subcutaneously (SC) with blood glucose monitoring over 24 hours.~Then Insulin Glargine SQ 8 weeks later, in increasing doses (0.5, 1.0, 1.5, 2.0 u/kg body wt.) with blood glucose monitoring monitoring over a 24 hour period. Each dose is separated by 8 weeks (5 separate study visits)"
3046086|NCT00574951|Experimental|AMG 706|AMG 706 daily
3046087|NCT00574990||VA Physicians|VA providers who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3046088|NCT00574990||VA Nurses|VA nurses who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3046089|NCT00574990||VA Pharmacists|VA pharmacists who had worked at least one year in the VA and were familiar with the VA's electronic health record, CPRS.
3046090|NCT00575016|Experimental|1|botulinum toxin Type A (50U); botulinum toxin Type A (200U)
3046091|NCT00575016|Experimental|2|botulinum toxin Type A (100U); botulinum toxin Type A (200U)
3046092|NCT00575016|Experimental|3|botulinum toxin Type A (200U)
3046093|NCT00575016|Other|4|placebo; botulinum toxin Type A (200U)
3046094|NCT00575029|Experimental|megace treatment|Study subjects will be given 600mg of MA for oral ingestion per day for duration of 8 weeks. They will be monitored every week clinically for the development of adrenal insufficiency by review of symptoms, physical exam, body weight, pulse, and blood pressure. Subjects also will undergo biochemical evaluation of adrenal status every two weeks by measurement of serum electrolytes, serum cortisol, serum adrenocorticotropic hormone(ACTH) levels, and the adrenal response to a low dose ACTH (1µgm) stimulation test(see methods).
3046095|NCT00575042|Experimental|Patients treated with Fenofibrate|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) 160 mg table per day for 1 year
3046096|NCT00575146|Experimental|1|ketogenic diet
3046097|NCT00575159|Experimental|Arm a|GSK189075
3046098|NCT00575159|Placebo Comparator|Arm b|Placebo
3046099|NCT00575185|Active Comparator|Valomaciclovir|Valomaciclovir 2 grams orally twice daily for 21 days
3046100|NCT00575185|Placebo Comparator|placebo|placebo 2 tablets twice daily for 21 days
3046101|NCT00575328|Experimental|Maca Root|Subjects in this arm will be given 3g/day of Maca Root.
3046102|NCT00575328|Placebo Comparator|Placebo|Subjects in this arm will receive inactive placebo.
3046103|NCT00575367|Active Comparator|AzaSite|
3046104|NCT00575367|Active Comparator|Vigamox|
3046105|NCT00575380|Active Comparator|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days
3046106|NCT00575380|Active Comparator|Vigamox Eye Drops|One drop three times a day for seven days
3046107|NCT00575510|Experimental|Intervention|Culturally targeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
3046108|NCT00575510|Active Comparator|Active Control|nontargeted behavioral and normative beliefs + knowledge/skills + salience + environmental constraints/barriers counseling
3046109|NCT00575510|No Intervention|Standard Care Only|Clinical standard of care at time of study
3046110|NCT00575588|Experimental|Saxagliptin|
3046111|NCT00575588|Experimental|Glipizide|
3046112|NCT00575666|Experimental|A|Intranasal Insulin Treatment
3046113|NCT00575666|Placebo Comparator|B|Drug: Placebo
3046114|NCT00575887|Experimental|1|
3046115|NCT00575965|Experimental|Simvastatin|Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.
3046116|NCT00576056|Experimental|Tace and Sorafenib|Patients with unresectable HCC will be treated with TACE in combination with oral sorafenib administration. TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin. Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment.
3046117|NCT00576147|Experimental|CT scan|The standard head CT done to head trauma patients
3046118|NCT00576199|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks and within 24-48 hours prior to each transarterial chemoembolization (TACE) until disease progression or unmanageable toxicity. TACE was conducted for 4 sessions at 8-10 week intervals.
3046119|NCT00576251|Experimental|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
3046120|NCT00576251|Active Comparator|TOBRADEX|TOBRADEX 1 drop 4 times daily in both eyes
3046121|NCT00576303|Experimental|RO0503821 (C.E.R.A.), 1x/4weeks|Eligible participants started RO0503821 (Continuous Erythropoietin Receptor Activator [C.E.R.A]) intravenously, at a dose of 120, 200 or 360 microgram (µg) every four weeks. The dose of C.E.R.A was based on the epoetin alfa or beta dose of<8000, 8000-16000, or >16000 international units (IU)/week, administered during the stability verification period (SVP) of 4 weeks. The SVP period was followed by dose titration period (DTP) of 16 weeks, efficacy evaluation period (EEP) of 8 weeks and long term safety period (LTSP) of 28 weeks
3046122|NCT00576381|Experimental|A|Neonates will be administered a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours post cardiac surgery.
3046123|NCT00576407|Experimental|Cultured Thymus Tissue Implantation in Complete DiGeorge|"Participants with Complete DiGeorge Syndrome, who were eligible, received cultured thymus tissue implantation (CTTI).~No specific dose was assigned. There was a one time administration of the cultured thymus tissue."
3046124|NCT00576420|Experimental|FS VH S/D 500 s-apr - 60-Seconds|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time
3046125|NCT00576420|Experimental|FS VH S/D 500 s-apr - 120-Seconds|FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time
3046126|NCT00576420|Active Comparator|Control Group- Manual compression with surgical gauze pads|Treatment of the study-suture line will be manual compression with surgical gauze pads.
3046127|NCT00576472|Experimental|Treatment|
3046128|NCT00576576|Experimental|A|All patients in this arm are given atorvastatin therapy.
3046129|NCT00576628|Experimental|C.E.R.A|Participants received methoxy polyethylene glycol-epoetin beta (Continuous Erythropoietin Receptor Activator [C.E.R.A]) subcutaneously every four weeks for 44 weeks. The participants received initial dose of 1.2 microgram per kilogram (mcg/kg) of C.E.R.A. Once the Hemoglobin (Hb) concentration was attained within the target range of 11.0 and 13.0 gram per deciliter (g/dL), the dose was adjusted to maintain the Hb concentration within the target range.
3046130|NCT00576680|Experimental|Temozolomide with RAD001|
3046131|NCT00576693|Experimental|intensive medical management plus stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
3046132|NCT00576693|Experimental|intensive medical management alone|Intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
3046133|NCT00576732|Experimental|001|Risperidone low dose Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
3046134|NCT00576732|Experimental|002|Risperidone high dose Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
3046135|NCT00576732|Placebo Comparator|003|Placebo Oral solution qd or bid for 6 weeks
3046136|NCT00576758|Experimental|Obinutuzumab|Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
3046137|NCT00576758|Active Comparator|Rituximab|Participants received 375 mg/m^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
3046138|NCT00576823|Experimental|Alfuzosin solution - 2-7 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children 2-7 years of age.
3046139|NCT00576823|Experimental|Alfuzosin solution - 8-16 years|Alfuzosin solution, daily dose divided in 3 doses given at breakfast, lunch and dinner to children and adolescents 8-16 years of age who were not able to swallow tablets or preferred to take the solution or had a body weight < 30 kg.
3046140|NCT00576823|Experimental|Alfuzosin tablet - 8-16 years|Alfuzosin tablet, daily dose divided in 2 doses given at breakfast and dinner to children and adolescents 8-16 years of age who were able to swallow tablets and had a body weight ≥ 30 kg.
3178945|NCT00667264|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
3178946|NCT00667264|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
3178947|NCT00667290|Experimental|1|
3046141|NCT00576836|Experimental|Cultured Thymus Tissue Implantation w Parathyroid Transplant|"Cultured Thymus Tissue Implantation With Parathyroid Tissue Transplantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation with parathyroid transplantation, if eligible.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue and parathyroid tissue."
3046142|NCT00576836|Experimental|Cultured Thymus Tissue Implantation|"Cultured Thymus Tissue Implantation. Subjects who were enrolled in this arm underwent cultured thymus tissue implantation (CTTI) only.~No specific dose was assigned. The thymus tissue dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the recipient.~There was a one time administration of the cultured thymus tissue.~."
3046143|NCT00576901|Experimental|1|
3046144|NCT00576927|Experimental|Group1|SHI followed by Active Drug Ramelteon
3046145|NCT00576927|Placebo Comparator|Group 2|SHI Followed by Placebo
3046146|NCT00577005|Experimental|1|Levetiracetam tablets
3046147|NCT00577005|Placebo Comparator|2|matching placebo
3046148|NCT00577031|Experimental|1|
3046149|NCT00577083|Experimental|Initial cap-fitted|Initial cap-fitted colonoscopy for the first insertion
3046150|NCT00577083|Active Comparator|Initial regular|Initial regular no cap on the end of the colonoscope for the first insertion
3046151|NCT00577096|Experimental|Exercise|Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
3046152|NCT00577096|Active Comparator|usual care|Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
3046153|NCT00577122|Experimental|Cohort I (MPA)|Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.
3046154|NCT00577122|Experimental|Cohort II (MPA, low-dose chemotherapy)|"Medroxyprogesterone progesterone acetate (MPA) will be administered orally as a single daily dose.~Cyclophosphamide will be administered orally as a single daily dose. Methotrexate will be administered twice daily on days 1 and 2 of each week."
3046155|NCT00577135|Experimental|Q12 hour bolus|Furosemide-Q12 hour bolus
3046156|NCT00577135|Experimental|Continuous Infusion|Furosemide-Continuous Infusion
3046157|NCT00577135|Experimental|Low Intensification|Furosemide-Low Intensification
3046158|NCT00577135|Experimental|High Intensification|Furosemide-High Intensification
3046159|NCT00577382|Experimental|Sunitinib|"Cohort A participants received 50 mg sunitinib orally daily for 4 weeks followed by a two-week break from treatment. These 6-week cycles would be repeated until progression or unacceptable toxicity up to 1 year.~Cohort B participants received 37.5 mg sunitinib daily on a continuous basis until progression or unacceptable toxicity up to 1 year."
3046160|NCT00577408|Experimental|Depot Naltrexone|Depot Naltrexone. Vivitrol (380 mg)given monthly
3046161|NCT00577408|Active Comparator|Oral Naltrexone|Oral Naltrexone. For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday).
3046162|NCT00577460|Active Comparator|Pramipexole|Patients to receive Pramipexole ER 0.375 - 4.5 mg in tablet form daily
3046163|NCT00577460|Placebo Comparator|Placebo|Patients to receive placebo tablets identical to Pramipexole ER tablets only during transfer phase
3046164|NCT00577473|Active Comparator|1|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
3046165|NCT00577473|Experimental|2|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
3046166|NCT00577512|Experimental|HD DTPACE|DTPACE
3046167|NCT00577590|Placebo Comparator|Metformin Alone|Participants assigned to take Metformin alone.
3046168|NCT00577590|Experimental|Metformin and Rosiglitazone|Participants assigned to take Metformin and Rosiglitazone
3046169|NCT00577590|Experimental|Metformin and Lovaza|Participants assigned to take Metformin and Lovaza
3046170|NCT00577629|Experimental|Induction + Consolidation + Bexxar|Induction:Cyclophosphamide, Etoposide, and Rituxan (rituximab) followed by Consolidation: Cytarabine and Doxorubicin followed by radioimmunotherapy: Bexxar (tositumomab)
3046171|NCT00577642|Other|Single arm|Single arm biomarker study after a single dose of zoledronic acid
3046172|NCT00577655|Experimental|Albuterol|Albuterol-HFA-MDI 180 mcg, four times a day (total daily albuterol dose of 720 mcg) for 21 days. HFA-MDI refers to a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant.
3046173|NCT00577655|Placebo Comparator|Placebo|"A placebo of a metered-dose inhaler (MDI) utilizing a hydrofluoroalkane (HFA) propellant. (Hereafter noted as Placebo-HFA-MDI.)"
3046174|NCT00577707|Experimental|Patients With Stage IB-IIIA NSCLC With EGFR Mutations|This is a open label, single center, phase II trial for patients with clinical stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable tumors that harbor EGFR activating mutations. Patients will receive erlotinib x 3 weeks prior to initiation of concurrent erlotinib and chemotherapy.
3046175|NCT00577720|Active Comparator|35 mg IRBB|35 mg immediate release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
3046176|NCT00577720|Experimental|35 mg DRFB|35 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
3046177|NCT00577720|Experimental|50 mg DRFB|50 mg delayed release risedronate tablet, immediately following breakfast, once a week for 13 weeks
3046178|NCT00577720|Experimental|50 mg DRBB|50 mg delayed release risedronate tablet, 30 minutes prior to breakfast, once a week for 13 weeks
3046179|NCT00577824|Experimental|1|
3046180|NCT00577824|Experimental|2|
3046181|NCT00577824|Placebo Comparator|3|
3046182|NCT00577889|Experimental|Arm I (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on day 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3046183|NCT00577889|Experimental|Arm II (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 2 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3046184|NCT00577889|Experimental|Arm III (combination chemotherapy)|Patients receive 750 mg/m2 gemcitabine hydrochloride IV over 30 minutes on day 8 and 154 mg/m2 tanespimycin IV over 1 hour on days 1 and 9 of course one. Beginning with course two (and for all subsequent courses), all patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and tanespimycin IV over 1 hour on days 2 and 9.
3046185|NCT00577993|Active Comparator|1: FND + Rituximab Followed by Interferon|Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
3046186|NCT00577993|Active Comparator|2: FND Followed by Interferon & Rituximab|Fludarabine/Novantrone/Decadron Followed by Interferon & Rituximab
3046187|NCT00577993|Active Comparator|3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon|Cyclophosphamide/Vincristine/Doxorubicin/Bleomycin (1st Sequence) + Rituximab; Etoposide/Cisplatin/Ara-C/Methyl-Prednisol (2nd Sequence); Novantrone/Vincristine/Procarbazine/Prednisone + Rituximab (3rd Sequence) Followed by Interferon
3046188|NCT00578071|Experimental|Treatment|panitumumab, oxaliplatin, capecitabine and EBRT
3046189|NCT00578136|Active Comparator|1|1) One group will receive the rectus sheath block prior to Umbilical hernia repair.
3046190|NCT00578136|Active Comparator|2|2) The second group will receive local anesthetic infiltration of the surgical site at the end the umbilical hernia repair.
3046191|NCT00578175|Experimental|Group A|Subjects received refrigerator-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation A) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3046192|NCT00578175|Experimental|Group B|Subjects received freezer-stored Priorix-Tetra™ (MMRV vaccine 208136 formulation B) co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3046193|NCT00578175|Active Comparator|Group C|Subjects received ProQuad® co-administered with Havrix® and Prevnar® at Day 0 and a second dose of Havrix® at Day 180
3046194|NCT00578214|Active Comparator|Randomized Midazolam|Single-dose midazolam
3046195|NCT00578214|Placebo Comparator|Placebo|
3046196|NCT00578214|Experimental|Prospective Midazolam|
3046197|NCT00578227|Experimental|Cervarix™ & Twinrix™ Group|Subjects received 3 doses of Human Papilloma Virus (HPV) vaccine co-administered with combined Hepatitis A & Hepatitis B (HAB) vaccine (Months 0, 1 & 6).
3046198|NCT00578227|Experimental|Cervarix™ Group|Subjects received 3 doses of HPV vaccine (Months 0, 1 & 6).
3046199|NCT00578227|Active Comparator|Twinrix™ Group|Subjects received 3 doses of HAB vaccine (Months 0, 1 & 6).
3046200|NCT00578279|Other|A|subject randomized to 10ml of dehydrated alcohol
3046201|NCT00578279|Experimental|B|subject randomized to 20ml of dehydrated alcohol
3046202|NCT00578292|Experimental|Bone Marrow or Stem Cell Infusion|"Mesna, Cyclophosphamide, Busulfan, Fludarabine, Campath 1H~Bone Marrow or Stem Cell infusion with pre-meds to take place on Day 0.~Bone marrow dose/stem cell dose: To ensure the probability for bone marrow engraftment, 4 x 10e8 nucleated cells/kg patient weight or 5 x 10e6/kg of CD34+ cells/kg patient weight if the product is mobilized peripheral blood, will be the target to be obtained from the unrelated donor."
3046203|NCT00578305|Experimental|Rituximab 500 mg|Participants received rituximab 500 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3046204|NCT00578305|Experimental|Rituximab 1000 mg|Participants received rituximab 1000 mg iv on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants received further treatment courses on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3046205|NCT00578305|Placebo Comparator|Placebo|Participants received placebo intravenously (iv) on Day 1 and Day 15 of the main study. Participants received a second course of treatment on Day 1 and Day 15 after Week 24 of the main study, if they met eligibility criteria (see the Detailed Description). Participants were switched to receive rituximab 1000 mg iv on Day 1 and Day 15 at intervals of ≥ 6 months after Week 52 in the study extension phase, if they met eligibility criteria (see the Detailed Description). Throughout the study, participants received methylprednisolone 100 mg iv prior to infusion of the investigational drug, methotrexate 7.5 to 25 mg/week orally or parenterally, and folic acid or folate ≥ 5 mg/week orally.
3046206|NCT00578318|Experimental|Motivational Interviewing Active|Patients received a stepped progression of talk based treatment utilizing Motivational Interviewing as the basis.
3046207|NCT00578318|Active Comparator|Delayed Control|Patients received Treatment as usual (TAU) (i.e. no specific intervention and supportive check-ins from the study staff)
3046208|NCT00578331|Experimental|Olopatadine 0.6% Nasal Spray|2 sprays each nostril twice daily
3046209|NCT00578331|Placebo Comparator|Placebo Nasal Spray|2 sprays each nostril twice daily
3046210|NCT00578344|Experimental|Allogeneic BMT/SCT Transplant|"Busulfan, Campath 1H, Cyclophosphamide and MESNA:~Bone marrow infusion with pre-meds as per SOPs to take place on Day 0.~Bone marrow dose: To ensure the probability for bone marrow engraftment, 4 x 10^8 nucleated cells/kg patient weight will be the target at donor bone marrow harvest."
3046211|NCT00578383|Sham Comparator|Sham (inactive) Treatment BPD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
3046212|NCT00578383|Active Comparator|Active LFMS treatment in BPD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS)in bipolar depressed subjects
3178948|NCT00667290|No Intervention|2|
3046213|NCT00578383|Sham Comparator|Sham LFMS Comparator: in MD|20 minutes of sham treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
3046214|NCT00578383|Active Comparator|Experimental LFMS: in MD|20 minutes of active treatment with the Low Field Magnetic Stimulation Device (LFMS) in major depressed subjects
3046215|NCT00578448|Active Comparator|A|"10mg/kg~6 doses (Day 1, 5, week 2, 4, 8 and 12) for 12 weeks"
3046216|NCT00578448|Active Comparator|B|"5mg/kg~33 doses (every 4 weeks) for 144 weeks"
3046217|NCT00578461|Experimental|Stem Cell Transplant|patient's will be recieving a stem cell transplant on study Conditioning includes: Ara C, Cyclophosphamide, MESNA, TBI-Total Body Irradiation
3046218|NCT00578539|Experimental|Stem Cell Transplant|All patients will receive Ara C IV every 12 hours for 6 doses starting at 1400 hours on day -8. Cyclophosphamide IV once daily on day -7 and day -6 starting at 1400 hours. MESNA will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide. Campath 1h will be given on day -4, day -3, day -2 and day-1. TBI (Total Body Irradiation) will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1. Stem cell Infusion are infused on day 0.
3046219|NCT00578552|Placebo Comparator|Placebo|Non active placebo pill
3046220|NCT00578552|Active Comparator|Gabapentin - 1800 mg/day|Gabapentin - 1800 mg/day
3046221|NCT00578552|Active Comparator|Gabapentin - 2700 mg/day|Gabapentin - 2700 mg/day
3046222|NCT00578565|Experimental|1|open label, all subjects will receive rituximab
3046223|NCT00578617|Active Comparator|Pharmacologic Therapy|Pharmacologic Therapy Rate and/or Sinus Rhythm Control: Patients without other heart disease will receive beta or calcium channel blockers as first line rate control therapy. Patients with underlying coronary artery disease will receive beta-blockers, patients with limited ventricular hypertrophy not warranting exclusion would receive either beta- or calcium channel blockers, while patients with heart failure would be expected to receive carvedilol or metoprolol. Patients randomized to drug therapy may be started on a membrane active drug, in an approach consistent with the recommended Guidelines for Management of Subjects with AF. Each patient will be placed on an anti-arrhythmic drug for an appropriate period and the patient cardioverted to sinus rhythm if necessary. Patients will then be followed for a period of up to 3 months, during which dosage adjustment can be made or the drug replaced with a different anti-arrhythmic drug.
3046224|NCT00578617|Active Comparator|Ablation Therapy|Left Atrial Catheter Ablation: The specific choice of ablation catheters will be left to the investigator from the following list: Lifewire TC XLS, Therapy Dual/Thermocouple, NAVI-STAR/NAVI-STAR DS, Celsius Braided Tip, NAVI-STAR Thermo-Cool, Freezor/FreezorMax, Stinger, Blazer II RF/RPM/SteeroCath /XP, Chilli Cooled.
3046225|NCT00578643|Experimental|Allogeneic unrelated transplant|Conditioning from Day -9 to Day -1. Stem cells given on Day 0. Busulfan, alemtuzumab, cyclophosphamide, fludarabine, cyclosporine, stem cell infusion.
3046226|NCT00578669|Active Comparator|1|Sequential antidepressant pharmacotherapy with (20mg) fluoxetine, begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
3046227|NCT00578669|Placebo Comparator|2|Sequential placebo medication (dextrose), begun 8 weeks prior to and extended throughout brief (behavioral) standard smoking cessation treatment with transdermal nicotine patch.
3046228|NCT00578734|Experimental|Lucinactant|SURFAXIN® (lucinactant) for intratracheal instillation
3046229|NCT00578734|Sham Comparator|Sham Air|Sham air (placebo) instillation
3046230|NCT00578786|Experimental|Ambrisentan|2.5, 5 or 10 mg ambrisentan
3046231|NCT00578812|Experimental|PCM Cervical Disc - Investigational|PCM Cervical Disc replacement at one level from C3 to T1
3046232|NCT00578812|Active Comparator|ACDF - Control Group|Anterior cervical discectomy and fusion (ACDF) at one level from C3 to T1
3046233|NCT00578864|Experimental|Protracted Oral Etoposide|"Protracted oral etoposide for cycles 1, 2 and 4 of induction. Etoposide will be given in combination with IV cisplatin (a standard of care agent). If a subject does not respond after cycle 2, cycle 4 will be bolus etoposide in combination with IV cisplatin.~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
3046234|NCT00578864|Active Comparator|IV Bolus Etoposide|"IV bolus etoposide in combination with IV cisplatin will be given for cycles 1,2, and 4 of induction chemotherapy for patients who are not eligible for the experimental arm (e.g.require emergent treatment)~All patients will receive Adriamycin and cyclophosphamide for cycle 3 and 5 as a standard of care."
3046235|NCT00578877|Active Comparator|Arm 1|Gynol II (2% N-9 gel)
3046236|NCT00578877|Experimental|Arm 2|Buffer Gel
3046237|NCT00578903|Experimental|Patients|"Patients with a diagnosis of severe aplastic anemia who require an allogeneic stem cell transplant but lack an Human Leukocyte Antigen (HLA) identical family member.~Cytoxan, Campath, TBI-Total Body Irradiation, FK-506, Methotrexate, Stem Cell Infusion"
3046238|NCT00578929|Experimental|Olopatadine 0.6% 1 Spray|Olopatadine HCl 0.6% 1 spray per nostril twice daily
3046239|NCT00578929|Placebo Comparator|Vehicle 1 spray|Vehicle 1 spray per nostril twice daily
3046240|NCT00578929|Experimental|Olopatadine 0.6% 2 sprays|Olopatadine HCl 0.6% 2 sprays per nostril twice daily
3046241|NCT00578929|Placebo Comparator|Vehicle 2 sprays|Vehicle 2 sprays per nostril twice daily
3046242|NCT00578942|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
3046243|NCT00578968|Experimental|Tiotropium|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of 18 mcg tiotropium powder.
3046244|NCT00578968|Placebo Comparator|Placebo|Participants with chronic obstructive pulmonary disease randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose.
3046245|NCT00578968|No Intervention|Healthy Controls|Healthy age and gender matched controls were recruited for comparing cardiovascular responses to participants with chronic obstructive pulmonary disease prior to the intervention.
3046246|NCT00579059|Other|1|Maxim® Pop-Top® Tibia
3046247|NCT00579059|Other|2|Maxim® Regular Tibia
3046248|NCT00579098|Active Comparator|Atorvastatin|Lipitor (atorvastatin) 80 mg tablet taken once daily by mouth for 90 days
3046249|NCT00579098|Placebo Comparator|Placebo|Placebo (dummy) tablet taken once daily by mouth for 90 days
3046250|NCT00579111|Experimental|HLA-identical sibling transplant|Recipients of HLA identical sibling stem cell transplants
3046251|NCT00579111|Experimental|Unrelated Matched or Single Antigen Mismatched transplant|Recipients of unrelated matched or single antigen mismatched donor stem cell transplant or single antigen mismatched family donor stem cell transplants
3046252|NCT00579137|Experimental|Participants With SCID or Primary Immunodeficiency Disorder|all patient will receive an allogeneic transplant with the following conditioning regimen Campath -1H, Fludarabine, Anti-CD45
3046253|NCT00579280|Active Comparator|Quetiapine SR|Quetiapine SR (Quetiapine Sustained Release)
3046254|NCT00579280|Active Comparator|Divalproex Sodium ER|Divalproex Sodium ER (Divalproex Sodium Extended Release)
3046255|NCT00579280|Placebo Comparator|Placebo|placebo
3046256|NCT00579345|Experimental|cTIV|Cell culture derived seasonal trivalent influenza vaccine (cTIV)
3046257|NCT00579345|Active Comparator|eTIV_a|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a)
3046258|NCT00579345|Experimental|FLU (cTIV or eTIV_a)|Cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
3046259|NCT00579345|Active Comparator|FLU (cTIV or eTIV_a) + PV|23-valent Pneumococcal vaccine (PV) concomitantly administered with cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
3046260|NCT00579436|Active Comparator|Fish oil group|4g Lovaza (omega-3 fatty acid) daily.
3046261|NCT00579436|Placebo Comparator|Control group|placebo (4 non-active capsules daily)
3046262|NCT00579501|Experimental|Trabectedin|Trabectedin at a dose of 1.5 milligram per meter square (mg/m^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.
3046263|NCT00579527|Experimental|Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function.
3046264|NCT00579527|Experimental|CTTI with Parathyroid Transplantation w/immunosuppression|Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant.
3046265|NCT00579553|Active Comparator|Intramuscular Progesterone|Intramuscular Progesterone
3046266|NCT00579553|Experimental|Vaginal Progesterone|Vaginal Progesterone
3046267|NCT00579813|No Intervention|1|Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.
3046268|NCT00579813|Active Comparator|2|Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.
3046269|NCT00579826|Experimental|Letrozole|Letrozole, 2.5 mg daily for 6 months
3046270|NCT00579826|Placebo Comparator|Placebo|Placebo, daily for 6 months
3046271|NCT00579878|Active Comparator|1 Leflunomide alone vs combination therapy|Group A: Leflunomide alone
3046272|NCT00579878|Active Comparator|Methotrexate-Sulfasalazine-Hydroxychloroquine|Methotrexate, Sulfasalazine, Hydroxychloroquine.
3046273|NCT00579878|Active Comparator|3|Leflunomide-Sulfasalazine-Hydroxychloroquine
3046274|NCT00579982|Experimental|Arm 1|Lamictal orally disintegrating tablet (ODT)
3046275|NCT00580034|Experimental|Campath Purged Non-myeloablative ASCT|Campath Purged Non-myeloablative Allo Stem Cell Transplant (ASCT) in lymphoma, myeloma, or marrow failure: leukemia or myelodysplasia; and solid tumors
3046276|NCT00580034|Other|Donor Apheresis|"Donor must be a sibling, half sibling, parent, child or first cousin familial relationship and 3-5/6 Human Leukocyte Antigen matched related to subject. They must not have any medical condition which would make apheresis and G-CSF administration more than a minimal risk, and should have the following:~Adequate cardiac function by history and physical examination~bilirubin and hepatic transaminases < 2.5 x upper limit of normal~normal hematologic parameters Females should have a negative serum pregnancy test."
3046277|NCT00580047|Active Comparator|1|Zoledronic Acid 4mg intravenously once a year for 2 years
3046278|NCT00580047|Active Comparator|2|Alendronate 70mg orally once a week for 2 years
3046279|NCT00580047|Placebo Comparator|3|Combination drug entity: calcium 1200 mg with vitamin D 800 International Units daily
3046280|NCT00580073|Experimental|1|FOLFOX4 + Cetuximab
3046281|NCT00580138||Stroke or Head & Neck Cancer|Any subject who has suffered a stroke or has some form of head & neck cancer (non-laryngectomee) may be enrolled.
3046282|NCT00580151|Experimental|1|
3046283|NCT00580151|Placebo Comparator|2|
3046284|NCT00580229|Experimental|prednisone|Prednisone 40mg by mouth 30-60 minutes prior to rituximab.
3046285|NCT00580294|Experimental|oxymorphone|participants switched to oxymorphone extended release (ER) via both oral and intravenous patient-controlled analgesia (IV-PCA) oxymorphone. After 24 hours, participants were discharged with oral oxymorphone ER and oxymorphone immediate release (IR) as needed
3046286|NCT00580333|Experimental|Cisplatin/Avastin|Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
3178949|NCT00667303||1|
3046287|NCT00580372|Experimental|Study Treatment|Protocol therapy consists of a remission induction phase with mutually non-cross resistant combinations of vincristine, adriamycin, dexamethasone (VAD), high-dose cyclophosphamide with stem cell procurement and etoposide, dexamethasone, cytarabine, cisplatin (EDAP) followed by two courses of melphalan-based high-dose therapy supported by autologous stem cell transplants 4-6 months apart. Maintenance with interferon alpha will be administered until disease progression.
3046288|NCT00580398|No Intervention|Control|Usual care included physician advice to quit smoking.
3046289|NCT00580398|Experimental|Intervention|Intervention participants were provided with a cognitive-behavioral 12-week program consisting of varenicline (1mg bid, with initial titration up over week 1) and smoking cessation counseling targeted to the issues of thoracic cancer patients. We offered 7 counseling sessions but were flexible in offering additional counseling when needed. Counseling was delivered by a certified Tobacco Treatment Counselor using Motivational Interviewing (MI) techniques.
3046290|NCT00580502|Experimental|LAGB for low BMI patients|the LAP-BAND® Adjustable Gastric Band (LAGB®) for patients with BMI between 30-40 kg/m2 with co-morbidities
3046291|NCT00580606|Experimental|Low Dose Peanut SLIT (Double Blind to Open Label)|Subjects ingest peanut protein (glycerinated peanut allergenic extract) daily starting with 0.000165 mcg, followed by a build-up phase (escalating peanut doses every 2 weeks, achieving maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and continue on an open label peanut protein maintenance dose of 1,386 mcg/day or may attempt escalation up to this dose. Subjects who at the Week 116 OFC are unable to consume >= 5,000 mg peanut powder or 10-fold the amount of peanut powder compared to the baseline OFC will discontinue study therapy. SLIT=Sublingual Immunotherapy.
3046292|NCT00580606|Placebo Comparator|Placebo (DB) Crossed Over to High Dose Peanut SLIT (OL)|Subjects ingest placebo (glycerin) daily beginning with a dose of 0.000165 mcg, followed by a build-up phase (escalating placebo doses every 2 weeks, achieving a maintenance dose by 36 weeks). Thereafter, subjects are on a maximally tolerated maintenance dose (165 mcg to 1,386 mcg) for >= 8 weeks. After Week 44, subjects are given a 5,000 mg Oral Food Challenge (OFC) using peanut powder. Subjects/study staff are unblinded following this OFC and subjects no longer receive placebo dosing but are crossed over and receive open label high dose peanut SLIT; the study procedures and schedule are the same as for the Low Dose Peanut SLIT group, the only difference is the maximum maintenance dose is almost 3-fold higher at 3,696 mcg/day. DB=Double Blind, SLIT=Sublingual Immunotherapy, OL=Open Label.
3046293|NCT00580645|Experimental|varenicline|varenicline 1mg/day or 2mg/day
3046294|NCT00580645|Placebo Comparator|Placebo|Placebo Controlled
3046295|NCT00580671|Experimental|MET/CBT+CM/BPT|Integrated psychosocial counseling. 14 weekly session. Twice weekly urine testing. Abstinence-based incentives based on urine test results. 14 weekly behavioral parenting sessions.
3046296|NCT00580671|Experimental|MET/CBT+CM|Integrated psychosocial counseling. 14 weekly sessions. Twice weekly urine testing. Abstinence-based incentives based on urine test results.
3046297|NCT00580671|Active Comparator|MET/CBT|Integrated psychosocial counseling. 14 weekly sessions.
3046298|NCT00580723|Experimental|PRK 124|Topical PRK 124 (Pyratine-6)(0.125%) moisturizing lotion applied twice daily to the face for 48 weeks. Subjects will wash their faces prior to application. The applications will occur in the mornings and one hour before bedtime.
3046299|NCT00580788|Experimental|PTHrP(1-36) 2 pmol/kg/hr|PTHrP(1-36) at 2 picomoles/kg/hr for one week.
3046300|NCT00580788|Experimental|PTHrP (1-36) 4 pmol/kg/hr|PTHrP(1-36) at 4 picomoles/kg/hr for one week.
3046301|NCT00580788|Experimental|PTHrP(1-36) 5 pmol/kg/hr|PTHrP(1-36) at 5 picomoles/kg/hr for one week.
3046302|NCT00580788|Experimental|PTHrP(1-36) 6 pmol/kg/hr|PTHrP(1-36) at 6 picomoles/kg/hr for one week.
3046303|NCT00580801|Experimental|Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks and after that pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection [injected under the skin by way of a needle], once weekly) and ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 2 to 50.
3046304|NCT00580801|Experimental|Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
3046305|NCT00580801|Active Comparator|Placebo+Pegylated-interferon-alfa-2a+Ribavirin|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks along with pegylated-interferon-alfa 2a (180 mcg subcutaneous injection, once weekly) and ribavirin (1000-1200 mg as oral tablet daily), from Week 1 to 48.
3046306|NCT00580840|Active Comparator|Certolizumab pegol 400 mg and placebo|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
3046307|NCT00580840|Experimental|Certolizumab pegol 200 mg and placebo|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
3046308|NCT00580840|Placebo Comparator|Placebo|Placebo administered as two injections every 2 weeks
3046309|NCT00580853|Experimental|varenicline|varenicline 2mg/day
3046310|NCT00580853|Experimental|Bupropion|Bupropion 300mg/day
3046311|NCT00580853|Placebo Comparator|Placebo|Placebo Control
3046312|NCT00580866|Experimental|Joint Active Systems Brace (JAS Brace)|Elbow is placed in a brace to apply an extension force
3046313|NCT00580866|No Intervention|PT Only Group|No brace is used
3046314|NCT00580957|Experimental|Blocked|Active treatment arm. Transient autonomic blockade with Trimethaphan and blood pressure restoration with L-NMMA will be used during insulin clamp
3046315|NCT00580957|Placebo Comparator|Intact|Saline will be used instead of trimethaphan during insulin clamp
3046316|NCT00580970|Experimental|Lovastatin for 1 yr|Lovastatin (20-80 mg/d) was started on day 1 of radiation and continued for 12 months. Patients were followed for an additional 12 months. Lovastatin once per day for 1 year. After the implant, they are asked to return for checkups (study visits 4-13) 4 weeks, 8 weeks, 4 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months and 24 months after the procedure. At 8 weeks, 4 months, 6 months, 9 months and 12 months, will also have a blood test to check their liver.
3046317|NCT00580983|Experimental|Chemo-IMRT|"Chemotherapy:~Chemotherapy will consist of Paclitaxel 30mg/m² IV over 1 hour, followed by Carboplatin (AUC 1) IV over 30 minutes, or Carboplatin 100mg/m² per IV over 30 minutes or Cisplatin 100mg/m² per IV over 1 hour, or Cisplatin (80mg/m²) or Carboplatin (AUC 5) IV on day 1 and 5-Fluorouracil (1000mg/m²) as a 24-hour continuous infusion, daily x 4 days.~Intensity-modulated Radiation Therapy (IMRT):~Primary RT: 70 Gy to gross disease and 56-63 Gy to subclinical disease in 35 fractions.~Post-operative RT: 64 Gy to high-risk targets (postoperative tumor bed, first-echelon nodes) and 57.6 Gy to low-risk targets, in 32 fractions."
3046318|NCT00581048|Experimental|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
3046319|NCT00581061|Experimental|Vesicare Treatment|
3046320|NCT00581100|Active Comparator|1|etanercept 50 mg SC injection twice weekly for 12 weeks reducing to etanercept 50 mg once weekly to week 24
3046321|NCT00581100|Active Comparator|2|etanercept 50 mg SC once weekly for the complete 24 week treatment period
3046322|NCT00581230|Experimental|Laryngoscopy without RAMP|First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
3046323|NCT00581230|Experimental|Laryngoscopy with RAMP|Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.
3046324|NCT00581256|Experimental|1|Best Delivery-optimized radiotherapy technique (IMRT)
3046325|NCT00581256|Active Comparator|2|Best 3-dimensional standard PWTF technique
3046326|NCT00581308|Experimental|GORE® HELEX® Septal Occluder|Subjects who received a GORE® HELEX® Septal Occluder
3046327|NCT00581347|Other|Outreach|Receives outreach services
3046328|NCT00581347|No Intervention|Standard of Care|Receives standard medical care provided by primary care practice.
3046329|NCT00581360|Other|Bortezomib + Doxorubicin|Patients with incurable adenoid cystic carcinoma of the head and neck who receive doxorubicin and bortezomib
3046330|NCT00581386|Experimental|LTS-D|All the cases were divided into one of the group LTS-D, PLMA, and ETC
3046331|NCT00581386|Experimental|ProSeal Laryngeal Mask Airway|All patients were divided into either LTS-D, PLMA, or the ETC group.
3046332|NCT00581386|Experimental|Esophageal Tracheal Combitube (ETC)|All patients are divided into one of the group, LTS-D, PLMA, or the ETC.
3046333|NCT00581399|Experimental|NO-NUMO Chest Tube|The NO-NUMO™ High Vacuum Body Cavity Drainage System consist of disposable NO-NUMO™ body cavity drainage tubes, disposable Vario™ fluid management canisters Vario™ portable vacuum pump
3046334|NCT00581399|Active Comparator|Standard Chest Tube|Classic PVC Chest Tube
3046335|NCT00581529|Experimental|Radiotherapy|IMRT (Intensity-modulated Radiation Therapy), 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
3046336|NCT00581542|Active Comparator|Moxifloxacin Opthalmic solution|
3046337|NCT00581542|Active Comparator|Polymyxin B-trimethoprim opthalmic solution|
3046338|NCT00581555|Experimental|etanercept|Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
3046339|NCT00581555|Placebo Comparator|placebo|Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.
3046340|NCT00581581||1|Randomized to cooling (original randomized clinical trial): All children, now 6-8 years old who were randomized to cooling in the original trial were included in this arm. Cooling was achieved via the CoolCap system (Olympic Medical/Natus Corporation) in these babies.
3046341|NCT00581581||2|Randomized to standard care (original randomized clinical trial): All children, now 6-8 years old, who were treated using the standard of care at the time (normal temperature) were included in this arm. Infants' temperatures were monitored per standard of care. Most infants were cared for on an open wamer that was servo-controlled to normal body temperature (37 C) or in a standard bassinette.
3046342|NCT00581776|Experimental|VCR-CVAD with rituximab maintenance|Induction chemotherapy with Bortezomib, cyclophosphamide, rituximab, vincristine, doxorubicin, and dexamethasone. Subjects will receive 6 cycles of induction chemotherapy, of 21 days each. After completing induction, subjects will receive rituximab consolidation (4 weeks), and then rituximab maintenance therapy for up to 5 years.
3046343|NCT00581828|Experimental|1|Subjects received vitamin D (50,000 IU daily for 15 days) and maintenance dose vitamin D (50,000 IU twice monthly for 10 months).
3046344|NCT00581867|Experimental|Intranasal Insulin Aspart|Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
3046345|NCT00581867|Active Comparator|Intranasal Saline (placebo)|Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
3046346|NCT00581893|Experimental|1|Phenytoin administration
3046347|NCT00581893|Placebo Comparator|2|Placebo
3046348|NCT00581919|Experimental|Bort, Dex, and Dox with ALCAR|
3046349|NCT00581945|Experimental|Canakinumab|Participants received an initial dose of 1 mg/kg canakinumab (ACZ885) via intravenous infusion. Four weeks later, participants received a dose of 3 mg/kg canakinumab, and another dose of 3 mg/kg two weeks later. Thereafter, participants received doses of 6 mg/kg every four weeks until completion of the 45-week treatment period.
3046350|NCT00581945|Placebo Comparator|Placebo|Participants received a matching placebo intravenous infusion at weeks 1, 5, 7, and thereafter every four weeks until completion of the 45-week treatment period.
3046351|NCT00581971|Experimental|Celecoxib+Carboplatin/Paclitaxel+Radiation Therapy|
3046352|NCT00582010|Experimental|1. Experimental|iNO administration
3046353|NCT00582010|Placebo Comparator|2. Placebo|Placebo (nitrogen)
3046354|NCT00582075|Experimental|Radiosurgery 15-24 Gy + Adjuvant Temozolomide|
3046355|NCT00582114|Active Comparator|1|Atenolol
3046356|NCT00582114|Experimental|2|Lisinopril
3046357|NCT00582166|Experimental|Ibritumomab Tiuxetan (Zevalin) with Rituximab maintenance|
3046358|NCT00582205|Experimental|Paclitaxel, Cisplatin IP|There is only one arm for this study and it represents the participants receiving the intraperitoneal chemotherapy
3046359|NCT00582309|Active Comparator|Glucommander|Glucommander-Guided Intravenous Insulin Infusion
3046360|NCT00582309|Active Comparator|Standard|Standard Intravenous Insulin Infusion Algorithm consists of four levels (Algorithm 1-3 and a doubling of the insulin rate). Most patients begin in algorithm 1, where the insulin rate varies from 0.2 units per hour for BG in the range 70-109 mg/dl up to 6 units/hr for BG > 360 mg/dl. If algorithm 1 fails to bring the patient's BG into target range in 2 hrs, then the patient is moved up to algorithm 2, where the insulin rate varies from 0.5 to 12 units/hr; and if that fails, the patient moved up to algorithm 3, where insulin rate varies from 1 to 16 units/hr depending on the latest BG. Algorithm failure is a blood glucose outside the target range for 2 hrs, and the blood glucose does not decrease by at least 60 mg/dl within 1 hr. If algorithm 3 fails, the insulin rate is doubled.
3046361|NCT00582309|Active Comparator|Simple|Simple Calculated Intravenous Insulin Infusion consists of an initial insulin infusion rate varying from 0.5 units per hour for BG in the target range 80-120 mg/dl up to 8 units/hour for BG > 400 mg/dl. After the initial insulin rate and if BG is still > 120 mg/dl, then the insulin rate is increased by 1-2 units every 1 hour until BG is in the target range. If BG is still >120 mg/dl in 2 hours, then the insulin rate is doubled.
3046362|NCT00582361|Active Comparator|1, A|Group A patients will have a standard dressing applied following initial treatment of their open fracture.
3046363|NCT00582361|Experimental|2, B|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
3046364|NCT00582400|Experimental|I|
3046365|NCT00582426|Experimental|Octreotide Long Acting Release|Prevention of Chemotherapy Induced Diarrhea (CID)
3046366|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
3046367|NCT00582491|Experimental|I|Modafinil 400mg orally everyday for 16 days
3046368|NCT00582491|Placebo Comparator|II|Placebo orally everyday for 16 days
3046369|NCT00582517|Active Comparator|Group A External Brace|Group A will have a non-invasive range of motion external brace placed following surgery
3046370|NCT00582517|Experimental|Group B Compass Knee Hinge|Group B will have a Compass Knee Hinge placed
3046371|NCT00582556|Active Comparator|1|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
3046372|NCT00582556|Active Comparator|2|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given at mo 6
3046373|NCT00582556|Active Comparator|3|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
3046374|NCT00582608|Experimental|131I-8H9 and 8H9|This is an open-label single arm study of 131 I-8H9. injected intravenously at 10mCi/1.73m^2 dose [intended specific activity of '20mCi/mg protein] preceded by administration of 50mg/1.73m2 of unlabeled -8H9.
3046375|NCT00582660|Active Comparator|study drug BID for 7 days before surgery|400 mg Celecoxib the study drug will be given for 7 days before surgery
3046376|NCT00582660|Placebo Comparator|Placebo for 7 days before surgery|Placebo in a one to one randomization prior to surgery
3046377|NCT00582738|Active Comparator|CsA-TAC|Continuation of current immunosuppressive regimen (continuation of Calcineurin Inhibitor [CNI] with or without Enteric-coated mycophenolate sodium (myfortic) or mycophenolate mofetil(Cellcept)[MPA], with or without steroids) / no everolimus introduction.
3046378|NCT00582738|Experimental|everolimus|Initiation of everolimus with discontinuation of CNI/MPA, with or without steroids.
3046379|NCT00582790|Experimental|1|Interleukin-2 subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles in combination with Zoledronic acid IV on day 1 of every 4 week (28 days) cycle.
3046380|NCT00582816|Experimental|1|patients will undergo a standard pre-transplant evaluation, but will also have blood drawn to evaluate their HLA class I killer immunoglobulin-like receptor (KIR) ligand typing. Parents will undergo KIR genotyping and phenotyping, and a donor will be selected based on which parent shows the greatest degree of KIR receptor-ligand mismatching. Once the donor has been selected he/she will undergo a peripheral blood stem cell (PBSC) collection utilizing G-CSF and GM-CSF for stem cell mobilization. The PBSC collection will be performed utilizing standard procedures. The PBSC will then be processed in the UW BMT Laboratory in order to deplete the graft of T cells. This will be accomplished using the CliniMACS cell separation system. T cell depletion is a standard procedure for patients receiving haploidentical stem cell grafts. The resulting stem cell product will be analyzed for T cell, stem cell and NK cell content.
3046381|NCT00582894|Other|A|Preparative regimen of 1)Busulfex 3.2 mg/kg/day for 2 days, infused over 3 hours, on Day-6 and Day-5 2)Fludarabine 30 mg/m2/day for 5 days on Day-6 to D-2 and 3) Alemtuzumab 10 mg/day IV on days - 5 to -1
3046382|NCT00582907|Experimental|1|Treatment Arm A: Rilonacept (IL-1 Trap) at a dose of 2.2 mg/kg/wk (max 160 mg)given by subcutaneous injection for 3 months plus colchicine at a stable dose for those subjects already taking colchicine, or without colchicine for those intolerant or non-compliant with colchicine. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention
3046383|NCT00582907|Placebo Comparator|2|Treatment Arm B: Placebo given by subcutaneous injection weekly with or without colchicine for 3 months. Since the colchicine dose is stable throughout the study for each subject, at the prestudy dose, colchicine was not considered an intervention.
3046384|NCT00582933|Experimental|1|25 research participants with HLA Identical Related Donor using PBSC, 6 with BMT
3046385|NCT00582933|Experimental|2|70 research participants with HLA-Matched Unrelated Donor using PBSC, 17 with BMT
3046386|NCT00582933|Experimental|3|25 research participants with HLA-Mismatched Related Donor using PBSC, no BMT
3046387|NCT00582946|Experimental|Magnetic Contact Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss. Acute performance and safety assessed at 4 months compared to unaided baseline pre-treatment, followed by longer-term assessment of safety up to 10 months.
3046388|NCT00582972|Experimental|Experimental|Subjects will receive omeprazole 40 mg daily for 30 days
3046389|NCT00582998|Active Comparator|Standard Wound Dressing|Standard post-operative wound dressing
3046390|NCT00582998|Active Comparator|Vacuum Assisted Closure Device|Vacuum Assisted Closure (VAC) device
3046391|NCT00583011|Experimental|Local Anesthesia|Local anesthesia group. 2cc of 1% lidocaine with epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of 1% lidocaine to the depth of the peritoneum.
3046392|NCT00583011|Placebo Comparator|Placebo-Normal saline|Placebo normal saline group. 2cc of normal saline epinephrine administered 2 minutes before amniocentesis, using a 21 gauge needle initially as an intradermal wheal followed by a deeper infiltration of 2cc of normal saline to the depth of the peritoneum.
3046393|NCT00583050|Experimental|Endovascular Aneurysm Repair|Endovascular Aneurysm Repair of TAAA/AAA with Fenestrated/Branched Stent Grafts
3046394|NCT00583102|Experimental|Lovastatin followed by Cytarabine|The subject will receive high dose cytarabine as well as lovastatin. The subject will take doses of lovastatin twice a day, about 12 hours apart. On the third day, the subject will begin high-dose cytarabine IV over 3 hours, twice a day, starting 1 hour after the lovastatin dose for 5 days.
3046395|NCT00583219|Experimental|Botox/DMSO Solution|"Subjects received Botulinum-A toxin and Dimethyl sulfoxide solution. The first 3 subjects in Phase 1 underwent bladder instillation of 50 cc of the solution utilizing 200 units of botulinum-A toxin and 50cc DMSO. The next 6 subjects in the Phase 1 trial received 300 units of botulinum-A toxin and 50cc DMSO.~All subjects in the Phase 2 trial received 300 units of botulinum-A toxin and 50cc DMSO."
3046396|NCT00583362|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days.
3046397|NCT00583375|Active Comparator|Group 1|"Standard Rigid Fixation plus autograft~Standard of Care: Autologous Bone Graft"
3046398|NCT00583375|Experimental|Group 2|Standard Rigid Fixation plus Augment® Bone Graft
3046399|NCT00583414|Experimental|Endovascular Aneurysm Repair|Investigational stent-graft implant to exclude aneurysm
3046400|NCT00583453|Active Comparator|A|Celecoxib 200 mg tablets
3046401|NCT00583453|Placebo Comparator|B|Placebo with same dosing schedule as the active comparator arm
3046402|NCT00583492|Experimental|Ad5-yCD/mutTKSR39rep-ADP + IMRT|Gene Therapy + IMRT
3046403|NCT00583492|Active Comparator|IMRT Alone|IMRT: 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
3046404|NCT00583557|Experimental|Belimumab|
3046405|NCT00583596|Experimental|implant to close PDA|
3046406|NCT00583622|Experimental|Bevacizumab + High-Dose Chemotherapy|Bevacizumab 5 mg/kg by vein (IV) daily over 90 minutes for 2 Days + Carboplatin 333 mg/m^2 by vein over 2 hours for 3 Days + Docetaxel 300 mg/m^2 by vein over 2 hours for 1 Day + Gemcitabine 1,800 mg/m2 by vein over 3 hours for 4 Days + Melphalan 50 mg/m^2 by vein over 15 minutes for 3 Days + Stem Cell Transplant
3046407|NCT00583661|Experimental|EXCOR Pediatric|Implantation of the EXCOR Pediatric Ventricular Assist Device
3046408|NCT00583700|No Intervention|1|Control for study - watchful waiting.
3046409|NCT00583700|Experimental|2|Combined treatment with Pentoxifylline and Vitamin E.
3046410|NCT00583713|Experimental|Renal Group|Patients with moderate renal impairment
3046411|NCT00583713|Active Comparator|Healthy volunteers|Healthy volunteers
3046412|NCT00583713|Experimental|Hepatic Group|Patients with mild/moderate hepatic impairment.
3046413|NCT00583791|Experimental|Main Cohort|Device closure with the AMPLATZER Muscular VSD Occluder for patients with muscular ventricular septal defects which are hemodynamically significant and are either isolated or present in conjunction with other congenital heart defects.
3046414|NCT00583804|Experimental|Stimulation ON|Individuals implanted with stimulator/sensor device. Stimulator is turned on and is active.
3046415|NCT00583804|Active Comparator|Stimulation OFF|Function with stimulation turned off.
3046416|NCT00583908|Active Comparator|Group 1: lotrafilcon B/senofilcon A/balafilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. Period 1: lotrafilcon B /period 2: senofilcon A / period 3: balafilcon A / period 4: omafilcon A
3046417|NCT00583908|Active Comparator|Group 2 lotrafilcon B/omafilcon A/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: omafilcon A / period 3: senofilcon A / period 4: balafilcon A
3046418|NCT00583908|Active Comparator|Group 3 lotrafilcon B/balafilcon A/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: lotrafilcon B / period 2: balafilcon A / period 3: senofilcon A / period 4: omafilcon A
3046419|NCT00583908|Active Comparator|Group 4 senofilcon A/lotrafilcon B/omafilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: balafilcon A
3046420|NCT00583908|Active Comparator|Group 5 senofilcon A/omafilcon A/balafilcon A/lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: omafilcon A / period 3: balafilcon A / period 4: lotrafilcon B
3046421|NCT00583908|Active Comparator|Group 6 senofilcon A/balafilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: senofilcon A / period 2: balafilcon A / period 3: lotrafilcon B / period 4: omafilcon A
3046422|NCT00583908|Active Comparator|Group 7 omafilcon B/lotrafilcon B/senofilcon A/balafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: omafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: balafilcon A
3046423|NCT00583908|Active Comparator|Group 8 balafilcon A/lotrafilcon B/senofilcon A/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: senofilcon A / period 4: omafilcon A
3046424|NCT00583908|Active Comparator|Group 9 balafilcon A/lotrafilcon B/omafilcon A/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: lotrafilcon B / period 3: omafilcon A / period 4: senofilcon A
3046425|NCT00583908|Active Comparator|Group 10 balafilcon A/senofilcon A/lotrafilcon B/omafilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: lotrafilcon B / period 4: omafilcon A
3046426|NCT00583908|Active Comparator|Group 11 balafilcon A/senofilcon A/omafilcon A//lotrafilcon B|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: senofilcon A / period 3: omafilcon A / period 4: lotrafilcon B
3046427|NCT00583908|Active Comparator|Group 12 balafilcon A/omafilcon A/lotrafilcon B/senofilcon A|One intervention was worn during each study period, which consisted of lens insertion, followed by a 15 minute settling period prior to measurement. All four periods were conducted in one day. period 1: balafilcon A / period 2: omafilcon A / period 3: lotrafilcon B / period 4: senofilcon A
3046428|NCT00583947|Other|ARF/LEV|"Cross-over phase: one day active treatment with arformoterol 7.5 microgram per nebulization followed by a 7 day washout. Then a one day active treatment with levalbuterol 0.63 milligram per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
3046429|NCT00583947|Other|LEV/ARF|"Cross-over phase: one day active treatment with levalbuterol 0.63 milligram per nebulization followed by a 7 day washout. Then a one day active treatment with arformoterol 7.5 micrograms per nebulization.~Open-label phase: Following another 7 day washout, one day treatment with arformoterol 15 micrograms per nebulization."
3046430|NCT00584077||Stable lung transplant recipients|All enrolled subjects receive the same procedures; bronchoscopy with administration of mechanical and chemical irritants to the airway mucosa
3046431|NCT00584194|Experimental|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine, will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
3046432|NCT00584220|Other|senofilcon A toric / alphafilcon A toric|senofilcon A toric contact lenses worn daily during the first period, then alphafilcon A toric contact lenses worn daily during the second period
3046433|NCT00584220|Other|alphafilcon A toric / senofilcon A toric|alphafilcon A toric contact lenses worn daily during the first period, then senofilcon A toric contact lenses worn daily during the second period
3046434|NCT00584285||Corneal Topographer Fluorescein Patterns|Use corneal topography to evaluate fluorescein pattern of rgp contact lens. Used corneal topography to develop theoretical fluorescein patters on a virtual eye. Theoretical lens developed by the topographer was ordered to compare to the actual fluorescein pattern on the actual eye.
3046435|NCT00584402|Experimental|Contrast sonography|Contrast-enhanced sonography perflutren lipid microspheres
3046436|NCT00584415|Active Comparator|GP + PVI ablation|This study contains only one arm, which is GP ablation + PV antrum isolation. The intervention (GP ablation + PV isolation) was performed using ThermoCool Navistar catheters in all patients
3046437|NCT00584454|Experimental|Q Fever Vaccine (NDBR 105)|Volunteers will receive and intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase 1, MNLBR 110) in the volar aspect of the arm. Skin test will be evaluated; if erythema occurs after the skin test, it is medically contraindicated to vaccinate that volunteer. Volunteers with skin test reactions will not be vaccinated and withdrawn from the study.
3046438|NCT00584480|Active Comparator|1|Active Hyperbaric Oxygen Treatment (HBOT)
3046439|NCT00584558||1|Patients undergoing catheter ablation.
3046440|NCT00584701|Experimental|Risperidone|Risperidone was started at 0.5mg at bedtime for 4 days. If that dosage was tolerated and there were continued behavioral symptoms, the dose was increased to 1mg at bedtime for an additional 4 days. If tolerated and indicated, 0.5mg was added in the morning for a daily total of 1.5 mg.
3046441|NCT00584727|Active Comparator|senofilcon A/alphafilcon A/etafilcon A|First intervention:senofilcon A toric contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
3046442|NCT00584727|Active Comparator|alphafilcon A/etafilcon A/senofilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: senofilcon A toric contact lenses
3046443|NCT00584727|Active Comparator|etafilcon A/senofilcon A/alphafilcon A|First intervention: etafilcon A sphere contact lenses Second intervention:senofilcon A toric contact lenses Third intervention: alphafilcon A toric contact lenses
3046444|NCT00584727|Active Comparator|senofilcon A/etafilcon A/alphafilcon A|First intervention: senofilcon A toric contact lenses Second intervention: etafilcon A sphere contact lenses Third intervention: alphafilcon A toric contact lenses
3046445|NCT00584727|Active Comparator|alphafilcon A/senofilcon A/etafilcon A|First intervention: alphafilcon A toric contact lenses Second intervention: senofilcon A toric contact lenses Third intervention: etafilcon A sphere contact lenses
3046446|NCT00584727|Active Comparator|etafilcon A/alphafilcon A/senofilcon A|First intervention: etafilcon A sphere contact lenses Second intervention: alphafilcon A toric contact lenses Third intervention: senofilcon A toric contact lenses
3046447|NCT00584740|Experimental|AIN457|AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.
3046448|NCT00584740|Placebo Comparator|Placebo|Matching placebo to AIN457 was given as an infusion at day 1 and day 22.
3046449|NCT00584805|Experimental|Vaccination|Inactivated, Dried, TSI-GSD 104, EEE
3046450|NCT00584831|Active Comparator|Group 2 LSBO|contact lenses worn in this order: lotrafilcon B toric, senofilcon A toric, balafilcon A toric, omafilcon A toric
3046451|NCT00584831|Active Comparator|Group 3 LOSB|contact lenses worn in this order: lotrafilcon B toric, omafilcon A toric, senofilcon A toric, balafilcon A toric
3046452|NCT00584831|Active Comparator|Group 4 LBSO|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, senofilcon A toric, omafilcon A toric
3046453|NCT00584831|Active Comparator|Group 5 LBOS|contact lenses worn in this order: lotrafilcon B toric, balafilcon A toric, omafilcon A toric, senofilcon A
3046454|NCT00584831|Active Comparator|Group 6 SLOB|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, omafilcon A toric, balafilcon A toric
3046455|NCT00584831|Active Comparator|Group 7 SLBO|contact lenses worn in this order: senofilcon A toric, lotrafilcon B toric, balafilcon A toric, omafilcon A toric
3046456|NCT00584831|Active Comparator|Group 8 SOLB|contact lenses worn in this order: senofilcon A toric, omafilcon A toric, lotrafilcon B toric, balafilcon A toric
3046457|NCT00584831|Active Comparator|Group 9 SBLO|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, lotrafilcon B toric, omafilcon A toric
3046458|NCT00584831|Active Comparator|Group 10 SBOL|contact lenses worn in this order: senofilcon A toric, balafilcon A toric, omafilcon A toric, lotrafilcon B toric
3046459|NCT00584831|Active Comparator|Group 11 OSLB|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, lotrafilcon B toric, balafilcon A toric
3046460|NCT00584831|Active Comparator|Group 12 OSBL|contact lenses worn in this order: omafilcon A toric, senofilcon A toric, balafilcon A toric, lotrafilcon B toric
3046461|NCT00584831|Active Comparator|Group 13 OBLS|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, lotrafilcon B toric, senofilcon A toric
3046462|NCT00584831|Active Comparator|Group 14 OBSL|contact lenses worn in this order: omafilcon A toric, balafilcon A toric, senofilcon A toric, lotrafilcon B toric
3046463|NCT00584831|Active Comparator|Group 15 BLSO|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, senofilcon A toric, omafilcon A toric
3046464|NCT00584831|Active Comparator|Group 16 BLOS|contact lenses worn in this order: balafilcon A toric, lotrafilcon B toric, omafilcon A toric, senofilcon A toric
3046465|NCT00584831|Active Comparator|Group 17 BSOL|contact lenses worn in this order: balafilcon A toric, senofilcon A toric, omafilcon A toric, lotrafilcon B toric
3046466|NCT00584831|Active Comparator|Group 18 BOLS|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, lotrafilcon B toric, senofilcon A toric
3046467|NCT00584831|Active Comparator|Group 19 BOSL|contact lenses worn in this order: balafilcon A toric, omafilcon A toric, senofilcon A toric, lotrafilcon B toric
3046468|NCT00584831|Active Comparator|Group 1 LSOB|contact lenses worn in this order: lotrafilcon B toric/senofilcon A toric/omafilconA toric/balafilcon A toric
3046469|NCT00584844|Experimental|F tularensis Vaccine (0.0025 mL)|Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
3046470|NCT00584857|Experimental|Chemotherapy|Single
3046471|NCT00584870|Active Comparator|Naproxen|
3046472|NCT00584870|Placebo Comparator|Placebo|
3046473|NCT00584870|Experimental|RN624|
3046474|NCT00584909|Experimental|Open Label|
3046475|NCT00584922||AF ablation group|Patients undergoing catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.
3046476|NCT00584948|Experimental|Memantine|
3046477|NCT00584948|Placebo Comparator|Placebo|
3046478|NCT00584987|Placebo Comparator|Placebo FF + Placebo OXY|Placebo Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3046479|NCT00584987|Active Comparator|FF + Placebo OXY|Fluticasone furoate + Placebo Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3046480|NCT00584987|Active Comparator|Placebo FF + OXY|Placebo Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3046481|NCT00584987|Active Comparator|FF + OXY|Fluticasone furoate + Oxymetazoline, 2 puffs of each nasal spray in each nostril in the pm
3046482|NCT00585013|Experimental|Nitric Oxide Delivery Group|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
3046483|NCT00585013|No Intervention|Placebo|Placebo delivery of oxygen at standard dose.
3046484|NCT00585039|Experimental|A|levalbuterol nebulization
3046485|NCT00585052|Experimental|Paclitaxel and lovastatin|Paclitaxel given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly. Lovastatin self-administered at 80mg daily.
3046486|NCT00585078|Experimental|CAPOX|Participants self-administered capecitabine 1,000 mg/m2 orally twice daily (total daily dose 2,000 mg/m2), days 1-14 in 21-day cycles. Only 500 mg tablets were used, and doses were rounded to the nearest dose that could be administered with 500 mg tablets. Oxaliplatin 130 mg/m2 was administered intravenously on day 1 every 21 (±2) days. Treatment continued until tumor progression or toxicity requiring discontinuation of therapy.
3046487|NCT00585104|Experimental|1|All randomized patients receive drug.
3046488|NCT00585169|Experimental|memantine|10 to 30 mg/day memantine. The study consisted of 10 weeks of open-label memantine. All eligible study subjects were started at 10 mg/day for 2 weeks. The dose was increased to 20 mg/day after 2 weeks and then to 30 mg/day after 4 weeks unless remission of PG symptoms was attained at a lower dose.
3046489|NCT00585182|Experimental|1|
3046490|NCT00585195|Experimental|1|
3046491|NCT00585247|Experimental|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
3046492|NCT00585247|Placebo Comparator|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
3046493|NCT00585286|Experimental|Fractional carbon dioxide laser system|Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.
3046494|NCT00585312|Experimental|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
3046495|NCT00585312|Placebo Comparator|Placebo|Masked, placebo comparator
3046496|NCT00585325|Experimental|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
3178950|NCT00667316||A|Workers from companies and workers' health care organizations who go for their periodic medical checkup.
3046497|NCT00585325|Placebo Comparator|Instilled Placebo (0.9% Normal Saline)|receive .9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
3046498|NCT00585351|Experimental|I|Advanced Notification + Ranitidine
3046499|NCT00585351|Active Comparator|II|Advanced Notification + Placebo
3046500|NCT00585351|Active Comparator|III|No advanced notification + Ranitidine
3046501|NCT00585351|Placebo Comparator|IV|No advanced notification + Placebo
3046502|NCT00585377|Other|1|
3046503|NCT00585468|Experimental|Myfortic - Fed State|Mycophenolate sodium taken with a meal.
3046504|NCT00585468|Experimental|Myfortic - Fasting State|Mycophenolate sodium taken separately from food by 2 hours.
3046505|NCT00585494||Preoperative orthopedic|Patients undergoing elective total hip, knee and spinal surgery at University of Wisconsin hospital, having their preoperative visit between December 1, 2007 and November 30, 2008.
3046506|NCT00585533|Other|A|
3046507|NCT00585546|Experimental|LVAD and Clenbuterol|
3046508|NCT00585637|Active Comparator|1|No Vitamin D
3046509|NCT00585637|Active Comparator|2|1000 IU of Vitamin D
3046510|NCT00585637|Active Comparator|3|2000 IU of Vitamin D
3046511|NCT00585637|Active Comparator|4|4000 IU of Vitamin D
3046512|NCT00585650|Experimental|Treatment Group|Etanercept (Enbrel) 50mg twice weekly injections for 12 weeks
3046513|NCT00585650|Placebo Comparator|Placebo Group|Placebo Injections twice weekly for 12 weeks
3046514|NCT00585689|Experimental|Neoadjuvant ABI-007, Carboplatin, and Gemcitabine|Neoadjuvant ABI-007 (260 mg/m^2) on day 1, Carboplatin (Target AUC [Area under the curve] =5) on day 1, and Gemcitabine (800 mg^m2) on days 1 and 8, every 21 days.
3046515|NCT00585715|Experimental|Candela DCD with cooling|Laser treatment with Candela DCD cooling which produces a cryogenic fluid that cools the epidermis prior to each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will receive a coolant during the laser procedure.
3046516|NCT00585715|Active Comparator|Candela DCD without Cooling|Laser treatment without cooling before each laser pulse. Treatment will be conducted on either the left or the right thigh, which will also be randomly determined. The contra-lateral side will not be treated and will serve as a control. The laser system to be used in is Candela GentleYAG, a 1064nm Nd:YAG laser. This arm will not receive a coolant during the laser procedure.
3046517|NCT00585780|Active Comparator|High Alcohol Withdrawal on Prazosin|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
3046518|NCT00585780|Placebo Comparator|High Alcohol Withdrawal on PLA|High AW was determined by those scoring at or above the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. High AW were randomized to Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
3046519|NCT00585780|Active Comparator|Low Alcohol Withdrawal on Prazosin|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment. Low AW were randomized to Prazosin 16 mg/day (tid) administered for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
3046520|NCT00585780|Placebo Comparator|Low Alcohol Withdrawal on PLA|Low AW was determined by those scoring below the median on Clinical Institute of Withdrawal for Alcohol Revised (CIWA-Ar) assessment.Placebo tablets administered tid for 12 weeks with fish-bowl contingency management for weekly treatment attendance and manualized 12-Step relapse prevention counseling in a double blind manner.
3046521|NCT00585910|Experimental|1|Total treatment period is 7 weeks. Atomoxetine treatment will be initiated and maintained for 4 weeks. If the subject is a partial responder to atomoxetine treatment, OROS methylphenidate will then be added to his or her treatment regimen for the final 3 weeks of the study.
3046522|NCT00585923|Active Comparator|Usage of Fixed hole C-Tek™ Plate|Fixed Hole Plate - The fixed hole plate means that the screws do not move, restricting motion and providing additional stability
3046523|NCT00585923|Active Comparator|Usage of Slotted hole C-Tek™ Plate|Slotted Hole Plate - Bone screw translates while plate is stationary, which ultimately promotes grafts settling through load sharing.
3046524|NCT00585975|Experimental|Bromfenac Ophthalmic Solution 0.18%|
3046525|NCT00585975|Experimental|Xibrom 0.09%|
3046526|NCT00586001|Experimental|1|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders The UP is a form of transdiagnostic cognitive-behavioral therapy (CBT) for individuals diagnosed with anxiety disorders, depression and related disorders.
3046527|NCT00586001|No Intervention|2|Wait-list control: Participants were asked to wait 16 weeks before receiving treatment.
3046528|NCT00586066|Placebo Comparator|Placebo|Placebo-matching memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to placebo-matching memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to placebo-matching memantine 5 mg in the morning and placebo-matching memantine 10 mg in the evening in Week 3; dose increase if tolerated to placebo-matching memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
3046529|NCT00586066|Experimental|Memantine|Re-purposed Alzheimer's drug to treat cognitive dysfunction associated with bipolar disorder. Memantine 5 mg tablet once per day for 1 week; dose increase if tolerated to memantine 5 mg twice a day, in the morning and the evening in Week 2; dose increase if tolerated to memantine 5 mg in the morning and memantine 10 mg in the evening in Week 3; dose increase if tolerated to memantine 10 mg twice a day, in the morning and the evening Weeks 4 to 12.
3046530|NCT00586105|Experimental|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
3046531|NCT00586157|Active Comparator|Methylphenidate Transdermal System (MTS)|
3046532|NCT00586157|Placebo Comparator|Placebo|
3046533|NCT00586170|Experimental|EBI Bone Healing System + Surgery|Subject will be using the EBI Bone Healing System (active device) in conjunction with ORIF surgery of the nonunion site.
3046534|NCT00586170|Placebo Comparator|Placebo Device + Surgery|Subject will be using a placebo device in conjunction with ORIF surgery of the nonunion site.
3046535|NCT00586196|Active Comparator|1|
3046536|NCT00586196|Placebo Comparator|2|
3046537|NCT00586261|Placebo Comparator|Placebo|Placebo 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
3046538|NCT00586261|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily for 6 months, nitroglycerin was given to check the brachial reactivity.
3046539|NCT00586313|Experimental|a1: Tru-Cut biopsy for liver|Tru-Cut Biospy.
3046540|NCT00586326|Experimental|Women with DCIS|Women with DCIS
3046541|NCT00586339|Experimental|HIV+/Cervarix Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm, according to a 0, 1, 6-month schedule.
3046542|NCT00586339|Active Comparator|HIV+/Aluminium Hydroxide Group|Human immunodeficiency virus positive (HIV+) female subjects who received 3 doses of control Aluminium Hydroxide [Al(OH)3], administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3046543|NCT00586339|Experimental|HIV-/Cervarix Group|Human immunodeficiency virus negative (HIV-) subjects who received 3 doses of Cervarix vaccine administrated by intramuscular injection into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3046544|NCT00586469|Experimental|Old Bulk|This group receives a full dose of Fluviral made from aged bulk material
3046545|NCT00586469|Active Comparator|New Bulk|This group receives a full dose of Fluviral made from new material
3046546|NCT00586482|Active Comparator|Nicotine lozenge|"Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
3046547|NCT00586482|Placebo Comparator|Placebo lozenge|"Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day.~Subjects also received an abstinence advisement: a brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times."
3046548|NCT00586495|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
3046549|NCT00586508|Experimental|Enzastaurin + Bevacizumab|
3046550|NCT00586521|Experimental|rFVIII-FS (octocog-alfa), (Kogenate FS)|On-demand treatment was to follow the same treatment pattern the subject was using before entering the study. While on prophylactic treatment, all subjects were to be treated at a dose of 20-40 IU/kg, 3 times per week at a stable dose.
3046551|NCT00586573|Experimental|Namenda|
3046552|NCT00586612|Experimental|Preterm group|Subjects born after a gestation period of less than or equal to 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
3046553|NCT00586612|Active Comparator|Full-term group|Subjects born after a gestation period of more than 36 weeks and who received 3 doses (at 2, 4 and 6 months of age) of Menitorix™, Infanrix™ penta and Prevenar™ and a booster dose of Menitorix™, Infanrix™ IPV and Prevenar™ at 16-18 months of age.
3046554|NCT00586625|Experimental|Bepreve|bepotastine besilate ophthalmic solution 1.5%
3046555|NCT00586625|Placebo Comparator|Placebo|vehicle
3046556|NCT00586664|Experimental|Bepreve (Bepotastine Besilate Ophthalmic Solution) 1.5%|
3046557|NCT00586664|Experimental|Bepotastine Besilate Ophthalmic Solution 1.0%|
3046558|NCT00586664|Placebo Comparator|Placebo|
3046559|NCT00586690|Experimental|NK Cell Infusion|Natural Killer (NK) Cell infusion using CD56 monoclonal antibody
3046560|NCT00586690|Other|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
3046561|NCT00586703|Experimental|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors
3046562|NCT00586729|Experimental|Vashe|Vashe Wound Therapy applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
3046563|NCT00586729|Active Comparator|5% Mafenide Acetate|5% Mafenide Acetate applied to gauze dressing every 6 hours or as necessary to keep dressing moist for a total treatment duration of 5 days.
3046564|NCT00586820|Experimental|BQ-123|BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
3046565|NCT00586820|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
3046566|NCT00586846|Experimental|1|
3046567|NCT00586898|Experimental|1|
3178951|NCT00667329|Experimental|2CdA + Cyclophosphamide + Rituximab|2CdA 1.5 mg/m^2 subcutaneous injection three times daily x 7 days. Cyclophosphamide 40 mg/m^2 PO twice daily x 7 days. Rituximab 375 mg/m^2 IV once weekly x 4 weeks.
3178952|NCT00667407|Experimental|1|Levalbuterol 1.25 mg
3178953|NCT00667407|Active Comparator|2|Racemic Albuterol 2.5 mg
3178954|NCT00667433|Other|Single Arm|Single arm where subjects will receive Raltegravir 400 mg BID along with Truvada once a day for 104 weeks
3178955|NCT00667472|Experimental|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
3178956|NCT00667472|Experimental|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
3178957|NCT00667485|Experimental|Weekly Rapamcyin|Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks
3178958|NCT00667485|Experimental|Daily Rapamycin|Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks
3178959|NCT00667498|Experimental|1|
3178960|NCT00667498|Placebo Comparator|2|
3046574|NCT00587041|Placebo Comparator|Placebo|Participants received placebo for 6 weeks: 1 placebo packet daily and 1 placebo capsule twice daily
3046575|NCT00587041|Active Comparator|Oxadrop|Participants received Oxadrop for 6 weeks: Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis)
3046576|NCT00587041|Active Comparator|Agri-King Synbiotic|Participants received AKSB for 6 weeks: AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
3046577|NCT00587054|Experimental|Transplant Patients|
3046578|NCT00587067|Experimental|1|
3046579|NCT00587132|Experimental|New Onset Diabetes|"Adults diagnosed diabetes within two years, and at least one of the following: no family history of diabetes, abdominal discomfort, anorexia, weight loss, elevated serum cancer antigen 19-9 (CA 19-9), or those undergoing endoscopic ultrasound (EUS) with or without Fine Needle Aspiration (FNA) for pancreatic cancer screening.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3046580|NCT00587132|Experimental|Familial Pancreatic Cancer|"Adults age 35-99 with familial pancreatic cancer with two or more first degree relatives with pancreatic cancer.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3046581|NCT00587132|Experimental|Peutz-Jeghers Syndrome|"Adults age 35-99 with Peutz-Jeghers syndrome.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3046582|NCT00587132|Experimental|Clinical Symptoms of Pancreatic Cancer, Normal CT|"Adults age 35-99 with suspicious clinical symptoms of pancreatic cancer, but had normal CT of the abdomen with iodinated contrast within 2 weeks.~All subjects on this arm will receive Synthetic Human Secretin as a 0.2mcg/kg one time dose prior to CT imaging on Day 1 of the study."
3046583|NCT00587158|Other|Immunosuppression without paricalcitol (control)|Subjects will receive the standard immunosuppressive therapies consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®).
3046584|NCT00587158|Active Comparator|Immunosuppression with paricalcitol|Subjects will receive the standard immunosuppressive therapy consisting of induction therapy with Alemtuzumab (Campath®) and Methylprednisolone (Solumedrol®), then maintained with corticosteroid avoidance using Mycophenolate Mofetil (Cellcept®) and Tacrolimus (Prograf®). In addition, subjects will receive the study medication paricalcitol (Zemplar®).
3046585|NCT00587171|Active Comparator|Active|2 hours of daily patching combined with 1 hour daily of near activities (that includes 30 minutes of at-home active vision therapy) and weekly in-office active vision therapy
3046586|NCT00587171|Sham Comparator|Control|2 hours of daily patching combined with 1 hour of daily near activities (that includes 30 minutes of at-home control vision therapy) and weekly in-office control vision therapy
3046587|NCT00587288|Experimental|Reslizumab 3 mg/kg|Reslizumab 3 mg/kg intravenous (IV) on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
3046588|NCT00587288|Placebo Comparator|Placebo|Saline placebo IV on Day 0 of each 28-day (+/- 7 days) cycle, for 4 cycles
3046589|NCT00587431|Experimental|1|
3046590|NCT00587431|Active Comparator|2|
3046591|NCT00587457|Experimental|CAT-8015 5 microgram per kilogram (mcg/kg)|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3046592|NCT00587457|Experimental|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3046593|NCT00587457|Experimental|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
3046594|NCT00587483|Active Comparator|Lidocaine 1.5 mg /kg|Lidocaine is a class I (sodium channel block) antiarrhythmic drug.
3046595|NCT00587483|Active Comparator|Amiodarone 300 mg|Amiodarone is used to treat and prevent certain types of serious, life-threatening ventricular arrhythmias (a certain type of abnormal heart rhythm) when other medications did not help or could not be tolerated. Amiodarone is in a class of medications called antiarrhythmics. It works by relaxing overactive heart muscles.
3046596|NCT00587483|Placebo Comparator|placebo (saline)|
3046597|NCT00587587|Experimental|A|Apligraf (bilayered living cell therapy)
3178961|NCT00667524||I|
3178962|NCT00667537|Experimental|Radium-223 chloride|IV administrations of 100 kBq/kg b.w (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization). Two administrations took place with an interval of 6 weeks
3178963|NCT00667628|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
3178964|NCT00667628|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
3178965|NCT00667654|Experimental|100-200 µg CNTX-4975|single dose
3178966|NCT00667654|Experimental|300-425 µg CNTX-4975|Total dose delivered as two separate lower doses
3178967|NCT00667654|Experimental|600-700 µg CNTX-4975|Total dose delivered as two separate lower doses
3178968|NCT00667654|Experimental|800 µg CNTX-4975|Total dose delivered as two separate lower doses
3178969|NCT00667654|Experimental|900-1000 µg CNTX-4975|Total dose delivered as two separate lower doses
3046598|NCT00587587|Active Comparator|B|Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
3046599|NCT00587639|Experimental|rTMS Treatment|All subjects will have active rTMS treatment (10Hz, L-DLPFC - 3,000 Stimulations/treatment)
3046600|NCT00587678|Experimental|Randomized|Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
3046601|NCT00587678|Experimental|Ezetemibe|Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.
3046602|NCT00587769|Experimental|Bupropion SR & Varenicline|All 38 smokers will receive open-label bupropion SR and varenicline. Bupropion SR is an oral medication with recommended dosing of 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day. Varenicline is an oral medication with recommended dosing of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment. Subjects will quit on Day #8 after starting both medications.
3046603|NCT00587834|Experimental|1|Within-subject design: one side of the mouth receives Gintuit
3046604|NCT00587834|Active Comparator|2|Within-subject control: one side of mouth receives tissue harvested from the palate
3046605|NCT00587847|Other|Campath maintenance treatment|Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.
3046606|NCT00587860|Placebo Comparator|Placebo|
3046607|NCT00587860|Active Comparator|St. John's Wort|
3046608|NCT00587964|Experimental|Treatment|
3046609|NCT00587990|Experimental|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive lower dose mesenchymal stem cell injections for a total of 2 x 10^7 cells
3046610|NCT00587990|Experimental|Higher dose MSC injection|Participants will receive higher dose of mesenchymal stem cell injections for a total of 2 x 10^8 cells
3046611|NCT00587990|Placebo Comparator|(3) Placebo|Participants will receive placebo injections
3046612|NCT00588094|Experimental|Treatment|R-ICEesc will be administered with the intent of administering 2 cycles, each 21 days apart admixed with 4 doses of rituximab. G-CSF will be administered at 960 ug or 10 ug/kg if patient is > 100 kg after cycles one and two for PBPC collection for the first 10 patients enrolled. G-CSF will be administered in standard dosing for cycle one and then at 960 ug or 10 ug/kg (if patient is > 100 kg) after cycle two for PBPC collection for the remaining 22 patients. All responding patients who make at least 2 x 106 CD34+ cells/kg will receive high dose therapy and ASCT on other protocols.
3046613|NCT00588159|Experimental|Gabapentin preoperatively|Preoperative gabapentin 600 mg orally within 2 hours prior to surgery.
3046614|NCT00588159|Placebo Comparator|Active placebo|Diphenhydramine 12.5 mg orally 2 hours preoperatively.
3046615|NCT00588237|Experimental|1|Paclitaxel, Cisplatin, Bevacizumab
3046616|NCT00588341|Experimental|Treatment|
3046617|NCT00588354|Experimental|Clonidine|Transforaminal epidural clonidine injection
3046618|NCT00588354|Active Comparator|Steroid|Transforaminal epidural steroid injection
3046619|NCT00588380|Experimental|GLP-1|All participants recieved GLP-1 intravenously at 0.75 pmol/kg/min for the first hour and then at 1.5 pmol/kg/min for the next hour
3046620|NCT00588406|Experimental|B|Budesonide, 2mg, 4 doses, plus standard care
3046621|NCT00588406|Placebo Comparator|P|Placebo plus standard care
3046622|NCT00588445|Experimental|Treatment|
3046623|NCT00588536|Experimental|1|MTX, 6-TG, Leucovorin
3046624|NCT00588640|Experimental|Phase I, Group|This is an open label dose-ranging trial. The first cohort of 8 patients will receive 40mg of d-methadone every 12 hours.
3046625|NCT00588640|Experimental|Phase II, Group I|patients receiving around the clock opioid therapy-No patients were accrued to this group
3046626|NCT00588640|Experimental|Phase II, Group II|patients not receiving around the clock opioid therapy.No patients were accrued to this group
3046627|NCT00588666|Experimental|Bevacizumab, Carboplatin, Gemcitabine|Patients will initially receive bevacizumab 10 mg/kg followed by a 2 week treatment-free interval. Treatment will then begin with combination therapy. Gemcitabine 1000 mg/m2 will be administered intravenously on day 1 and 8 and carboplatin AUC 4.5 on day 1 with treatment recycled every 21 days. Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of each 21-day cycle. Restaging evaluations will be performed after every 3 cycles of treatment (approximately 9 weeks). Patients will receive a total of 6 cycles of chemotherapy unless disease progression or unacceptable toxicity occurs. Patients who achieve stable disease, a partial response, or a complete response after completion of 6 cycles, will be eligible to continue bevacizumab at the same dose and schedule until disease progression for a maximum of 18 additional doses.
3046628|NCT00588692|Active Comparator|SphygmoCor Unblinded|The use of the sphygmocor values will determine medication adjustments to optimize HF treatment.
3046629|NCT00588692|Placebo Comparator|SphygmoCor Blinded|Sphygmocor values will be blinded to the investigator.
3046630|NCT00588731|Experimental|Cannabidiol|
3046631|NCT00588731|Placebo Comparator|Placebo|
3046632|NCT00588770|Active Comparator|Arm IA (docetaxel, cisplatin)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046633|NCT00588770|Experimental|Arm IB (docetaxel, cisplatin, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and cisplatin as in Arm IA.
3046634|NCT00588770|Active Comparator|Arm IIA (docetaxel, carboplatin)|Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046635|NCT00588770|Experimental|Arm IIB (docetaxel, carboplatin, bevacizumab)|Patients receive bevacizumab as in Arm IB and docetaxel and carboplatin as in Arm IIA.
3046636|NCT00588770|Active Comparator|Arm IIIA (cisplatin, fluorouracil)|Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046637|NCT00588770|Experimental|Arm IIIB (cisplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm IIIA.
3046638|NCT00588770|Active Comparator|Arm IVA (carboplatin, fluorouracil)|Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3046639|NCT00588770|Experimental|Arm IVB (carboplatin, fluorouracil, bevacizumab)|Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm IVA.
3046640|NCT00588809|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1 -28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3046641|NCT00588822|Experimental|Rituximab|"Subjects will receive rituximab administered at the standard dose and schedule as an initial cycle of therapy, followed by a re-evaluation at 6 months. If the neuropathy is stable or responding at 6 months, the subject will receive Cycle 2 of rituximab, followed by a re-evaluation at 12 months.~Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22)."
3046642|NCT00588848|Experimental|Autoadjusting CPAP (VPAP auto)|The intervention will be the use of an Autoadjusting CPAP unit that will be applied to the subject during the 8 hours overnight the first night after surgery (study night). During this time, they will undergo a full night attended polysomnogram in their hospital room.
3046643|NCT00588848|Active Comparator|CPAP arm (usual care)|The intervention will be the use of the subject's own CPAP machine and this will be applied to the subject during the 8 hours overnight the first after surgery (study night). During the study night, they will undergo full polysomnography in their hospital room.
3178970|NCT00667667|Active Comparator|1|vertical vibration device (using Vibrafit whole body vibration platforms)
3178971|NCT00667667|Active Comparator|2|side-alternating vibration device (using Board 3000 whole body vibration platforms)
3046646|NCT00588900|Experimental|irinotecan + cediranib|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.~After completion of study therapy, patients are followed up every 3 months for up to 2 years from study entry."
3046647|NCT00588952|Experimental|Family History Positive|Subjects with a positive family history of alcoholism
3046648|NCT00588952|Experimental|Family History Negative|Subjects with a negative family history of alcoholism
3046649|NCT00588965|Placebo Comparator|1|Subjects are assigned to placebo.
3046650|NCT00588965|Active Comparator|2|Subjects will take propranolol LA 80 mg daily for one week then 160 mg for one week followed by the exercise test.
3046651|NCT00589056|Experimental|Single arm|Nelfinavir
3046652|NCT00589108|Active Comparator|Mobile-Bearing Knee|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
3046653|NCT00589108|Active Comparator|Modular-Metal-Backed Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
3046654|NCT00589108|Active Comparator|All-Polyethylene Knee|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray
3046655|NCT00589121|Experimental|Cohort A - Chemotherapy|Radiation therapy with neoadjuvant or adjuvant or concurrent or interdigitated chemotherapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
3046656|NCT00589121|Experimental|Cohort B - No Chemotherapy|Radiation therapy followed by surgery followed by, for patients with positive margins, radiation therapy boost
3046657|NCT00589277|Experimental|Gain-Framed counseling & Gain-framed materials|Novel messages for quitting smoking
3046658|NCT00589277|Placebo Comparator|Standard care counseling + standard materials|Standard care counseling + standard care print information
3046659|NCT00589290|Experimental|Belinostat Treatment|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
3046660|NCT00589303|Active Comparator|Drug Therapy|FDA approved rate and rhythm control drugs
3046661|NCT00589303|Active Comparator|Atrioventricular Node (AVN) Ablation / Pacing|AV Node ablation and device implant
3046662|NCT00589329|Experimental|A|"roup A will be assigned to receive antibiotics:~Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days."
3046663|NCT00589329|Placebo Comparator|B|Group B will not receive antibiotics for pregnancy prolongation, but will receive a matching masked placebo (IV saline and pill) regimen.
3046664|NCT00589472|Experimental|Treatment (Antihormone therapy and enzyme inhibitor therapy)|Patients receive bicalutamide PO QD for 1 month and leuprolide acetate IM or goserelin acetate SC once a month until surgery. Patients also receive vorinostat PO QD beginning on the first day of androgen depletion therapy and continuing for up to 8 weeks or until the day of surgery. Patients then undergo an open or laparoscopic radical prostatectomy. Patients with positive surgical margins undergo immediate adjuvant external beam radiotherapy to the prostatic fossa, based on the judgment of the treating physician.
3046665|NCT00589563|Experimental|Fludarabine/Melphalan Conditioning|"Fludarabine/Melphalan Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
3046666|NCT00589563|Experimental|FTBI/Cytoxan Conditioning|FTBI/Cytoxan Conditioning with Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis
3046667|NCT00589563|Experimental|FTBI/Etoposide Conditioning|"FTBI/Etoposide Conditioning with~Sirolimus, Tacrolimus and rabbit anti-thymocyte globulin (+/- methotrexate) for GvHD Prophylaxis"
3046668|NCT00589602|Experimental|T-Cell Depletion Transplant|"Our protocol is designed to attempt to improve the current results of matched unrelated donor (MUD) allo bone marrow transplant (BMT) and will be a major step towards the introduction and refinement of graft engineering. Our approach will address in a rational fashion all major technical and clinical aspects of MUD allo BMT.~Peripheral blood lymphocyte therapy; cyclophosphamide, tacrolimus, peripheral blood stem cell transplantation; total-body irradiation; 'allogeneic hematopoietic stem cell transplantation'"
3046669|NCT00589628|Active Comparator|1|5mg/kg/dose of infliximab IV every 4 weeks for 9 doses
3046670|NCT00589628|Active Comparator|2|10mg/kg/dose of infliximab IV every 4 weeks for 9 doses.
3178972|NCT00667667|Sham Comparator|3|wellness-control group
3178973|NCT00667680|Active Comparator|1|anodal tDCS
3046671|NCT00589667|Experimental|Treatment|Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle.
3046672|NCT00589693|Experimental|Doripenem|Doripenem from Days 1 to 7 and imipenem-cilastatin placebo from Days 1 to 10
3046673|NCT00589693|Active Comparator|Imipenem-Cilastatin|Imipenem-Cilastatin Days 1 to 10 and doripenem placebo from Days 1 to 7
3046674|NCT00589784|Experimental|Treatment|Sunitinib will be administered at a dose of 50 mg orally once daily for four consecutive weeks, followed by a two-week rest period. Intra-patient dose reduction may be required depending on the type and severity of individual toxicity encountered. Imaging studies will be performed after every other cycle. Patients may continue on study as long as they are tolerating treatment and in the absence of disease progression.
3046675|NCT00589797|Experimental|Investigational|Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
3046676|NCT00589797|Active Comparator|Control|Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
3046677|NCT00589836||Cardiac Pathologies|Patients with cardiomyopathy, ischemic heart disease, will have tissue Doppler echocardiograms performed
3046678|NCT00589849||1|
3046679|NCT00589888|Active Comparator|Intralipid 20%@ 20cc/hour|Intralipid 20% IV infusion at 20cc/hour
3046680|NCT00589888|Active Comparator|Intralipid 20% @ 40cc/hour|Intralipid 20% IV infusion at 40cc/hour
3046681|NCT00589888|Placebo Comparator|Normal Saline infusion @ 40cc/hour|Normal Saline continuous IV infusion at 40cc/hour for 8 hours
3046682|NCT00589888|Active Comparator|32-gram oral fat load|32-gram oral fat load once
3046683|NCT00589888|Active Comparator|64-gram oral fat load|64-gram oral fat load once
3046684|NCT00589914|Active Comparator|RISPERDAL CONSTA|RISPERDAL CONSTA 25-50 mg eq every 2 weeks
3046685|NCT00589914|Experimental|R092670|Paliperidone Palmitate 50-150 mg eq every 4 wks
3046686|NCT00589979|Experimental|Lidoderm (Lidocaine 5% Patch)|Lidoderm (lidocaine 5% patch) 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
3046687|NCT00589979|Placebo Comparator|Placebo Patch|Placebo Patch 10cm X 14cm patches each on the front and back of the index knee every 24 hours (q24h)
3046688|NCT00590005||Children with severe asthma|This group consists of children with severe asthma as defined per ATS workshop criteria (published in 2000).
3046689|NCT00590005||Children with non-severe asthma|This group includes children with asthma who do not meet the ATS criteria for severe asthma as outlined in the 2000 workshop report.
3046690|NCT00590018|Experimental|1|Subjects in this arm will receive a 5 day tapering course of hydrocortisone.
3046691|NCT00590018|Placebo Comparator|2|Subjects in this arm will receive 5 days of placebo.
3046692|NCT00590031|Experimental|1|External Beam Radiation Therapy, Cisplatin, Irinotecan
3046693|NCT00590044|Experimental|Insulin glargine+glulisine|Daily insulin glargine + glulisine before meals
3046694|NCT00590044|Active Comparator|Split-mixed NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
3046695|NCT00590161|Experimental|1|Pentoxifylline (PTX) 400 mg by mouth (PO) three times daily (TID)
3046696|NCT00590161|Placebo Comparator|2|Placebo three times daily (TID)
3046697|NCT00590226|Experimental|detremir + aspart insulin|Detemir insulin once daily + aspart insulin before meals three times a day at an initial total dose of 0.5 units/kg/day, subcutaneously
3046698|NCT00590226|Active Comparator|NPH + regular insulin|NPH insulin once a day + regular insulin before breakfast and dinner at an initial total dose of 0.5 units/kg/day, subcutaneously
3046699|NCT00590317|Active Comparator|Prochlorperazine|Patients receiving Prochlorperazine 10mg IV
3046700|NCT00590317|Active Comparator|Ondansetron|Patient receiving Ondansetron 4mg IV
3046701|NCT00590369|Active Comparator|1|KCI VAC type negative pressure wound therapy device
3046702|NCT00590369|Experimental|2|Versatile One (EZCare) negative wound therapy device
3046703|NCT00590395|Experimental|FDG-PET/CT to determine Cholecystitis|19 patients with suspected acute cholecystitis and a positive HIDA will be included in the study. This is purposely a highly selective population which most likely will have surgical proof of the findings. Subjects will receive an FDG PET/CT exam to determine the presence of gallbladder inflammation/infection(cholecystitis). Please note that 18FDG is an FDA approved radiopharmaceutical.
3046704|NCT00590460|Experimental|Single Arm Study: Stem Cell Transplant|CAMPATH-1H Anti-CD45 Fludarabine Stem Cell Infusion
3046705|NCT00590564|Experimental|1|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal.
3046706|NCT00590577|Experimental|001|Paliperidone palmitate 25 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8 36 64
3046707|NCT00590577|Experimental|002|Paliperidone palmitate 100 mg eq. Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8 36 64
3046708|NCT00590577|Experimental|003|Paliperidone palmitate 150 mg eq. Paliperidone palmitate 150 mg eq. i.m. Days 1 8 36 64
3046709|NCT00590577|Placebo Comparator|004|Placebo Placebo i.m. Days 1 8 36 64
3046710|NCT00590590|Placebo Comparator|3 (Placebo)|
3046711|NCT00590590|Experimental|1 (Lidocaine)|
3046712|NCT00590590|Experimental|2 (Lidocaine/Diphenhydramine)|
3046713|NCT00590681|Experimental|one|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
3046714|NCT00590707|Active Comparator|Deeper sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 0. This is the deeper sedation arm."
3178974|NCT00667680|Sham Comparator|2|Sham tDCS
3178975|NCT00667706|Active Comparator|1|Patients who will undergo Laparoscopic Sleeve Gastrectomy
3046715|NCT00590707|Active Comparator|Moderate sedation|"Patients randomly assigned to this arm will receive enough sedative drugs to keep their level of awareness during the hip fracture repair, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), at an OAA/S score of 4-5. This is the moderate sedation arm."
3046716|NCT00590720|Experimental|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
3046717|NCT00590720|Placebo Comparator|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
3046718|NCT00590759|Other|GORE TAG® Thoracic Endoprosthesis|
3046719|NCT00590772|Active Comparator|montelukast|montelukast 10 mg daily
3046720|NCT00590772|Placebo Comparator|Placebo|Placebo tablet
3046721|NCT00590824|Experimental|A|Hu14.18-IL2 -->Resection-->Hu14.18-IL2
3046722|NCT00590824|Experimental|B|Resection -->Hu14.18-IL2-->Hu14.18-IL2
3046723|NCT00590863|Active Comparator|SSRI + placebo|Participants will take escitalopram plus placebo.
3046724|NCT00590863|Active Comparator|Escitalopram + Bupropion SR|Participants will take escitalopram + bupropion-SR.
3046725|NCT00590863|Active Comparator|Venlafaxine XR + Mirtazapine|Participants will take venlafaxine-XR + mirtazapine.
3046726|NCT00590889|Other|St. Jude Medical (SJM) Conventional|St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff
3046727|NCT00590889|Other|St. Jude Medical (SJM) Silzone|St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating
3046728|NCT00590902|Experimental|1 - OSI-774|
3046729|NCT00590954|Experimental|Treatment|Following a diagnosis of tumor recurrence or progression, all patients will receive perifosine monotherapy until toxicity, progression, or death.
3046730|NCT00590967|Experimental|Treatment Group 1|"Pelvic Lymph Nodes Only Positive on FDG PET.~IMRT External Beam radiation to the para-aortic region (45 Gy)~Pelvis intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin 40 mg/m^2"
3046731|NCT00590967|Experimental|Treatment Group 2|"Para-Aortic Lymph Nodes Positive on FDG PET~IMRT (50.4 Gy to para-aortic lymph node bed with a 10.8 Gy boost to nodes)~IMRT external beam pelvic radiation therapy as appropriate for stage~Intracavitary brachytherapy (6 HDR treatments)~Weekly cisplatin (40 mg/m^2)"
3046732|NCT00590980||Observation|Patients with intracranial or extracranial vertebrobasilar occlusion or stenosis ≥ 50% presenting with vertebrobasilar distribution TIA or stroke.
3046733|NCT00591006|Experimental|Four Treatments Per Participant|This study has one arm due to a crossover design. All 17 subjects received 4 treatments: placebo then placebo, phenytoin then placebo, placebo then hydrocortisone, and phenytoin then hydrocortisone. Each treatment was randomly assigned and had a unique sequence out of 24 possible sequences.
3046734|NCT00591019|Active Comparator|modafinil|
3046735|NCT00591019|Placebo Comparator|Placebo|
3046736|NCT00591123|Experimental|FOLFOX, plus 5-FU and Erlotinib|single arm
3046737|NCT00591149|Experimental|1|"Patients will be treated with oxaliplatin 130 MG/M2 IV over 2 hours on day 1 and docetaxel 60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle. Cycles of treatment will be repeated every 3 weeks for a total of 4 cycles or until disease progression or intolerable toxicity.~Patients who were treated with 4 cycles of oxaliplatin and docetaxel and had a response or stable disease will be treated with cetuximab at 400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks, or until disease progression or intolerable toxicity."
3046738|NCT00591214|Experimental|MP-424|
3046739|NCT00591227|Active Comparator|1-aspart detemir|these subjects will be treated with insulin aspart every 2 hours if blood glucose is more than 200 mg/dl during their ER evaluation. If they are admitted to hospital then they will receive a weight-based dose of insulin detemir immediately prior to admission and then every 24 hours thereafter combined with mealtime doses of insulin aspart if they are eating.
3046740|NCT00591227|No Intervention|2 usual care|these subjects will receive no insulin per protocol during their ER stay or during a possible inpatient admission. The care for their diabetes will be solely determined by the physician(s) in the ER and by the physician(s) caring for them in the hospital if they are admitted. They may receive no therapy, oral agents or insulin per primary physician preference.
3046741|NCT00591240||Multiplex pathogen identification.|Urine samples of patients at risk for urinary tract infections were collected. Biosensor based assays were used to detect the most common uropathogens in these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
3046742|NCT00591240||Antimicrobial susceptibility testing.|Urine samples of patients at risk of urinary tract infections were collected. Biosensor based antimicrobial susceptibility test, in concert with pathogen identification assay was directly performed on these samples. Analytical validity of the biosensor assays was examined by comparing biosensor results to those obtained using standard clinical microbiology laboratory methods. No interventions were performed.
3046743|NCT00591253|Experimental|Azilsartan Medoxomil 40 mg QD|
3046744|NCT00591253|Experimental|Azilsartan Medoxomil 80 mg QD|
3046745|NCT00591253|Placebo Comparator|Placebo QD|
3046746|NCT00591266|Experimental|Azilsartan Medoxomil 40 mg QD and Amlodipine 5 mg QD|
3046747|NCT00591266|Experimental|Azilsartan Medoxomil 80 mg QD and Amlodipine 5 mg QD|
3046748|NCT00591266|Active Comparator|Amlodipine 5 mg QD|
3046749|NCT00591305|Experimental|PDL+DIM pill|once-time 585 nm pulsed dye laser (PDL) treatment on the lesions, immediately followed by 3-month oral taking diindolylmethane (DIM, at 1.2-1.75mg/kg/day), in 15 subjects
3046750|NCT00591305|Placebo Comparator|PDL+placebo pill|once-time PDL treatment on the lesions, then followed by 3-month oral taking DIM placebo, in other 15 subjects
3046751|NCT00591344|Active Comparator|Progressive resistance training|Subjects will perform between 60 and 90 minutes of progressive resistance training two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
3046752|NCT00591344|Active Comparator|Modified Fitness Counts|Subjects will perform between 60 and 90 minutes of modified Fitness Counts two times a week for two years at a local gym. These sessions will be supervised by a personal trainer two times a week for the first six months of training and then once a week for the remaining 18 months of training.
3046753|NCT00591370|Experimental|1 - Temozolomide (TMZ)|
3046754|NCT00591409|Placebo Comparator|Rocuronium + Placebo|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
3046755|NCT00591409|Experimental|Rocuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
3046756|NCT00591409|Experimental|Rocuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
3046757|NCT00591409|Experimental|Rocuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
3046758|NCT00591409|Experimental|Rocuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
3046759|NCT00591409|Placebo Comparator|Vecuronium + Placebo|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.
3046760|NCT00591409|Experimental|Vecuronium + 0.5 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
3046761|NCT00591409|Experimental|Vecuronium + 1.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
3046762|NCT00591409|Experimental|Vecuronium + 2.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
3046763|NCT00591409|Experimental|Vecuronium + 4.0 mg/kg sugammadex|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.04 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
3046764|NCT00591565|Experimental|1|acamprosate tablets
3046765|NCT00591578|Experimental|Azilsartan Medoxomil 40 mg QD|
3046766|NCT00591578|Experimental|Azilsartan Medoxomil 80 mg QD|
3046767|NCT00591578|Active Comparator|Valsartan 320 mg QD|
3046768|NCT00591591|Experimental|OSA|Persons with suspected obstructive sleep apnea (OSA) undergoning overnight sleep evaluation
3046769|NCT00591591|No Intervention|Controls|Healthy controls
3046770|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant + Rituximab|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
3046771|NCT00591630|Active Comparator|Zevalin + BEAM + Rituximab +Stem Cell Transplant|Zevalin + BEAM + Rituximab Followed by Stem Cell Transplant
3046772|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant + Rituximab|BEAM + Rituximab Followed by Stem Cell Transplant and Maintenance Rituximab
3046773|NCT00591630|Active Comparator|BEAM + Rituximab + Stem Cell Transplant|BEAM + Rituximab Followed by Stem Cell Transplant
3046774|NCT00591721|Experimental|Energy conservation education|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles
3046775|NCT00591721|Other|Wait list control|Participants received 6-70 minute group teleconference sessions with an occupational therapist facilitator. The intervention provided education, guided discussion, and peer support for learning about and applying energy conservation principles.
3046776|NCT00591734|Experimental|Intervention|All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.
3046777|NCT00591760|Experimental|GH|Patients will receive 6 months of substitutive somatotropin (growth hormone) therapy at a dose of 0.012 mg/kg every second day, added to their background optimized CHF therapy
3046778|NCT00591760|No Intervention|Placebo|PLacebo will be admistred with the same devices of GH, also on top of Optimal CHF treatment
3046779|NCT00591773|Experimental|Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD|
3046780|NCT00591773|Experimental|Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD|
3046781|NCT00591773|Active Comparator|Chlorthalidone 25 mg QD|
3046782|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the second twitch (T2) response to Train-of-four (TOF) stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
3046783|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
3046784|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
3046785|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
3178976|NCT00667706|Active Comparator|2|Patients who will undergo Laparoscopic Roux-en-Y Gastric Bypass
3046786|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Rocuronium)|After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.8 mg/kg sugammadex was administered IV.
3046787|NCT00591786|Experimental|Sugammadex 0.5 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 0.5 mg/kg sugammadex was administered IV.
3046788|NCT00591786|Experimental|Sugammadex 1.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 1.0 mg/kg sugammadex was administered IV.
3046789|NCT00591786|Experimental|Sugammadex 2.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 2.0 mg/kg sugammadex was administered IV.
3046790|NCT00591786|Experimental|Sugammadex 4.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 4.0 mg/kg sugammadex was administered IV.
3046791|NCT00591786|Experimental|Sugammadex 8.0 mg/kg (Vecuronium)|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.4 mg/kg vecuronium IV if necessary. At reappearance of the T2 response to TOF stimulation, a single dose of 8.0 mg/kg sugammadex was administered IV.
3046792|NCT00591825|Placebo Comparator|Non-Phobic Control - Placebo|Participants without phobia will be given one placebo administration.
3046793|NCT00591825|Active Comparator|Non-Phobic Control - DCS|Participants without phobia will be given one D-cycloserine (DCS) administration of 100mg.
3046794|NCT00591825|Placebo Comparator|Spider-phobic Placebo|Participants with phobia will be given one placebo administration.
3046795|NCT00591825|Experimental|Spider-phobic DCS|Participants with phobia will be given one D-cycloserine (DCS) administration of 100mg.
3046796|NCT00591838|Experimental|Phase I Dose Level A: SBRT 9Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 9Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
3046797|NCT00591838|Experimental|Phase I Dose Level B: SBRT 10Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 10Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
3046798|NCT00591838|Experimental|Phase I Dose Level C: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
3046799|NCT00591838|Experimental|Phase I Dose Level D: SBRT 12Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 12Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week.
3046800|NCT00591838|Experimental|Phase II: SBRT 11Gy x 5 fractions|-Stereotactic body radiation therapy (SBRT) dose of 11Gy for 5 fractions which is 5 total radiation treatments given over the course of about a week. The phase II dose was determined during the phase I portion of the study.
3046801|NCT00591851|No Intervention|1|single arm study
3046802|NCT00591942|Active Comparator|VivaGlass dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross over design. One dental crown cemented with VivaGlass Cement/subject. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
3046803|NCT00591942|Active Comparator|MultiLink dental cement|36 subjects (TOTAL) received two crowns each and another group of 11 subjects received a three-unit fixed dental bridge. Cross Over design. One dental crown per subject was cemented with Multilink Dental Cement. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
3046804|NCT00592072|Experimental|Medium chain fatty acid (Octanoic and Decanoic acid)|
3046805|NCT00592072|Placebo Comparator|Splenda (Placebo Control)|
3046806|NCT00592124|Experimental|1|Oral tenofovir disoproxil fumarate (TDF) for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
3046807|NCT00592124|Experimental|2|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and oral TDF and vaginal tenofovir gel application for Weeks 15 through 20
3046808|NCT00592124|Experimental|3|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, oral TDF for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
3046809|NCT00592124|Experimental|4|Oral TDF and vaginal tenofovir gel application for Weeks 1 through 6, vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
3046810|NCT00592124|Experimental|5|Oral TDF for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and vaginal tenofovir gel application for Weeks 15 through 20
3046811|NCT00592124|Experimental|6|Vaginal tenofovir gel application for Weeks 1 through 6, oral TDF and vaginal tenofovir gel application for Weeks 8 through 13, and oral TDF for Weeks 15 through 20
3046812|NCT00592176|Experimental|Bevacizumab|Bevacizumab injection: 0.1ml, 6 monthly doses plus baseline and 1 week post baseline
3046813|NCT00592319|Experimental|PDL+Celebrex|endoscopic treatment with once-time PDL radiation at 6.0-8.0 J on laryngeal papilloma, followed by oral taking of 9-month Celebrex (100mg, BID), in 15 subjects
3046814|NCT00592319|Active Comparator|standard surgery|"once-time and routine surgery, with either of carbon dioxide (CO2) laser radiation at 10.0-20.0 W or cold surgery with microinstruments, in 15 subjects"
3046815|NCT00592358|Experimental|1|
3046816|NCT00592384|Placebo Comparator|placebo|identically encapsulated placebo pills 37.5 - 300 mg/day for 12 weeks
3046817|NCT00592384|Experimental|venlafaxine XR|venlafaxine XR 37.5 - 300 mg/day for 12 weeks
3046818|NCT00592475|Experimental|Regimen 1 Conivaptan 12.5 mg|Conivaptan intravenous loading dose (10 mg) + 2.5 mg continuous infusion over 6.5 hours
3178977|NCT00667758|Experimental|1|Cetrorelix
3046819|NCT00592475|Experimental|Regimen 2 Conivaptan 25 mg|Conivaptan intravenous loading dose (20 mg) + 5 mg continuous infusion over 6.5 hours
3046820|NCT00592475|Placebo Comparator|Regimen 3 Placebo|Placebo continuous intravenous infusion over 6.5 hours
3046821|NCT00592488|Other|A|Placebo for first 6 hours then Acetyl-L-Carnitine (ALC) for 12 hours
3046822|NCT00592488|Other|B|Acetyl-L-Carnitine (ALC) for first 12 hours then placebo for next 6 hours
3046823|NCT00592501|Experimental|Proton/Photon Radiotherapy, Cisplatin, Fluorouracil|
3046824|NCT00592553|Experimental|High-Dose Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 20 milligrams/kilogram (mg/kg) at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for 48 weeks.
3046825|NCT00592553|Experimental|Low-Dose Ataluren|Participants will receive ataluren suspension orally TID, 10 mg/kg at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
3046826|NCT00592553|Placebo Comparator|Placebo|Participants will receive placebo matched to ataluren orally TID at morning, midday, and evening for 48 weeks.
3046827|NCT00592631|Experimental|CPAP|Subjects will use CPAP of 8-12 during days 2 through 6 of the study.
3046828|NCT00592631|Sham Comparator|SHAM|Subjects will use sham CPAP of 0-2 during days 2 through 6 of the study.
3046829|NCT00592683|Active Comparator|Aripiprazole plus Fish Oil|Subjects administered aripiprazole and randomized to receive fish oil
3046830|NCT00592683|Placebo Comparator|Aripiprazole plus Placebo|Subjects administered aripiprazole and randomized to receive placebo
3046831|NCT00592761|Experimental|Within subjects treatment, no-treatment|Within subject, treatment and no-treatment periods. Each participant served as his/her own control in this AABB/BBAA alternating treatment conditions design. Results were also compared across groups (treatment v. no-treatment).
3046832|NCT00592774|Placebo Comparator|Placebo Cohort 1|
3046833|NCT00592774|Experimental|Perampanel Cohort 1, 3-week Titration|
3046834|NCT00592774|Experimental|Placebo Cohort 2|
3046835|NCT00592774|Experimental|Perampanel Cohort 2, 1-week Titration|
3046836|NCT00592774|Experimental|Perampanel Cohort 2, 2- Week Titration|
3046837|NCT00592839|Experimental|1|0.3 mg SCE-B Daily
3046838|NCT00592839|Experimental|2|0.625 mg SCE-B Daily
3046839|NCT00592839|Placebo Comparator|3|Placebo
3046840|NCT00592852|Experimental|Fluoxetine|
3046841|NCT00592904|Experimental|1|
3046842|NCT00592943|Active Comparator|Armodafinil (100mg)|
3046843|NCT00592943|Active Comparator|Armodafinil (250 mg)|
3046844|NCT00593112|Experimental|OROS Methylphenidate|
3046845|NCT00593112|Other|Control|Healthy Volunteer Control group
3046846|NCT00593333|Active Comparator|1, A|Standard femoral intramedullary nail that utilizes a piriformis fossa portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur.
3046847|NCT00593333|Experimental|2, B|Trigen Trochanteric Femoral Nail (Smith & Nephew, Memphis)using a trochanteric insertion portal in the treatment of fractures of the subtrochanteric and diaphyseal shaft regions of the femur
3046848|NCT00593346|Experimental|Accelerated partial breast brachytherapy|Each patient will receive accelerated partial breast brachytherapy with multiple plane implant.
3046849|NCT00593372|Experimental|I|Drug Plus Behavioral Therapy
3046850|NCT00593372|No Intervention|II|Drug Therapy Only
3046851|NCT00593385|Other|iCAST covered stent|This is a one arm trial. All subjects received the iCAST covered stent.
3046852|NCT00593450|Active Comparator|1|Lucentis® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis® every 4 weeks or to variable dosing.
3046853|NCT00593450|Experimental|2|Avastin® on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin® every 4 weeks or to variable dosing.
3046854|NCT00593450|Experimental|3|Lucentis® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
3046855|NCT00593450|Experimental|4|Avastin® on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity.
3046856|NCT00593489|Experimental|Basal Insulin Initiation Strategy|"Basal Insulin Initiation Strategy which includes:~support by community pharmacist~support by diabetes specialist"
3046857|NCT00593489|No Intervention|Usual Practice|The physicians randomized to this group proceeded with their usual practice
3046858|NCT00593554|Active Comparator|1|Total body Irradiation; Thiotepa; Fludarabine; Rabbit ATG;
3046859|NCT00593554|Experimental|2|Palifermin; Total Body Irradiation; Thiotepa; Fludarabine; Rabbit ATG
3046860|NCT00593606|Experimental|Rotigotine|Patients were dispensed rotigotine patches up to 8mg/24h at a dose considered by the investigator to be equivalent to the dose of ropinirole that the subject was currently taking.
3046861|NCT00593645|Experimental|Arm 1: Non-myeloablative conditioning regimen|"Clofarabine 40mg/m2/day IV over two hours daily x 5 days on Days -6 thru -2~Cytarabine 1gm/m2/day IV over two hours daily x 5 days on Days -6 thru -2 after the START of Clofarabine.~Thymoglobulin 1.0mg/kg IV over 6 hours X 1 day on Day -4, then 2.5mg/kg/day x 2 days on Days -3 and -2.~Stem Cell Transplant - On day 0 a minimum of total CD34+ cell dose of 2 x10E6/kg (actual weight of recipient) will be infused."
3046862|NCT00593684|Experimental|Algidex patch|Infants in this group received the Algidex patch on top of the line insertion sites of any of the following lines: umbilical arterial line, umbilical venous line, peripheral arterial line, peripheral long line, and central venous line. This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2. Every 7 days, each insertion site was cleansed and then a new patch was placed and covered with a fresh occlusive dressing (Tegaderm, Opsite).
3046863|NCT00593684|No Intervention|Control group|Infants in this group served as the control group and received line-dressing changes every 7 days according to standard hospital protocol specific for the type of line inserted. Insertion sites were covered with only an occlusive dressing (Tegaderm, Opsite).
3046864|NCT00593736|Experimental|Ramelteon 1 mg QD|
3046865|NCT00593736|Experimental|Ramelteon 4 mg QD|
3046866|NCT00593736|Experimental|Ramelteon 8 mg QD|
3046867|NCT00593736|Placebo Comparator|Placebo QD|
3178978|NCT00667758|Placebo Comparator|2|NaCl solution
3046868|NCT00593827|Active Comparator|Arm 1|ixabepilone 16 mg/m^2 weekly for 3 weeks followed by 1 week rest
3046869|NCT00593827|Active Comparator|Arm 2|ixabepilone 40 mg/m^2 every 3 weeks
3046870|NCT00593840|Experimental|Intensity modulated radiation therapy (IMRT)|-This study provides guidelines for volume to be contoured during IMRT based on tumor site and stage of tumor site. The clinical tumor volume (CTV)1 will be treated to 66 Cy in 33 fractions or 60 Gy in 30 fractions. The CTV2 will be treated to 54 Gy in 33 fractions or 52 Gy in 30 fractions. The CTV3 will be modified based on tumor site and stage of tumor site in order to reduce volume.
3046871|NCT00593866|Experimental|Radiation Dose Escalation with Gemcitabine|"INTENSITY MODULATED RADIOTHERAPY~Radiation dose escalation:~Total dose Dose per fraction BED* Dose equivalent (1.8 Gy/fraction) Level 1 45.0 1.8 53.1 45.0 Level 2 50.0 2.0 60.0 50.4 Level 3 52.5 2.1 63.5 54.0 Level 4 55.0 2.2 67.1 57.0 Level 5 57.5 2.3 70.7 60.0 Level 6 60.0 2.4 74.4 63.0 Level 7 62.5 2.5 78.1 66.2 Level 8 65.0 2.6 81.9 69.4~BED=Biological Effective Dose; =10 Five fractions weekly, fraction size determined by dose level~Gemcitabine:~1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment"
3046872|NCT00593918||Toll-like Receptor 4 -2026/GG Genotype|Toll-like Receptor 4 (TLR4) -2026/GG Genotype of interest hypothesized to be associated with less inflammation during Respiratory Syncytial virus (RSV) infection
3046873|NCT00593918||Toll-like Receptor 4 -2026/AG and AA Genotypes|Toll-like Receptor 4 (TLR4) -2026/AG and AA control genotypes hypothesized to be associated with more inflammation during respiratory syncytial virus (RSV) infection
3046874|NCT00593957|Experimental|DM1( 0.25 mg/kg /day)|Dextromethorphan 0.25 mg/kg per day
3046875|NCT00593957|Experimental|DM2 (2.5 mg/kg/day)|Dextromethorphan 2.5 mg/kg/day
3046876|NCT00593957|Experimental|DM3 (5mg/kg/day)|Dextromethorphan 5mg/kg/day
3046877|NCT00594009|Experimental|Venovenous CO2 Removal (VVCO2R) in COPD|All patients enrolled in the trial will receive VVCO2R which consists of a circuit with a centrifugal pump, tubing, double lumen intravenous catheter and hollow fiber oxygenator
3046878|NCT00594022|Active Comparator|"Group 1- VirtuSom - Stim"|Normal sleepers (7.5 - 9.0 hours), MSLT (multiple sleep latency test) >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with active device (electric stimulation of the Vestibular nerve).
3046879|NCT00594022|Placebo Comparator|"Group 2- VirtuSom- Sham"|Normal sleepers (7.5 - 9.0 hours), MSLT >=14 min; phase-advance 5-hours studied under full polysomnogram (PSG) with placebo / sham device (NO electric stimulation of the Vestibular nerve).
3046880|NCT00594035|Experimental|1|Spinal Sealant
3046881|NCT00594035|Active Comparator|2|Standard of care
3046882|NCT00594061|Experimental|A|There is no arm to this study--(each participant serves ashis or her own control). Blinding or masking procedures are not included in the design, as it is not possible to conceal the presence or absence of a cochlear implant from device recipients and/or clinical investigators.
3046883|NCT00594100|Experimental|GFRS Pivotal Subjects|All non-training subjects using the GORE Flow Reversal System for embolic protection during carotid artery stenting (all subjects other than first two subjects accounted for in Training Cases).
3046884|NCT00594165|Experimental|Rotigotine|Rotigotine
3046885|NCT00594178|Experimental|A|Exercise group
3046886|NCT00594204|Active Comparator|varenicline|
3046887|NCT00594204|Placebo Comparator|placebo|
3046888|NCT00594230|Experimental|Panobinostat 20 mg|Treatment with LBH589 (Panobinostat) 20 mg
3046889|NCT00594230|Experimental|Panobinostat 30 mg|Treatment with LBH589 (Panobinostat) 30 mg
3046890|NCT00594256|Experimental|Sodium oxybate|Active treatment
3046891|NCT00594386|Experimental|Rotigotine|
3046892|NCT00594399|Experimental|Arm 1 Physical Activity counseling|Physical activity (PA) counseling program with the following components: baseline in-person counseling session; telephone calls, one physician endorsement of PA in a primary care clinic visit, monthly automated telephone calls from the primary care provider encouraging PA; and quarterly mailed materials providing personalized feedback.
3046893|NCT00594399|No Intervention|Arm 2|Usual care from primary, womens or geriatric clinics
3046894|NCT00594425|Experimental|1|PDT using MAL concentration A
3046895|NCT00594425|Experimental|2|PDT using MAL concentration B
3046896|NCT00594425|Placebo Comparator|3|PDT using Placebo cream
3046897|NCT00594464|Experimental|1|Rotigotine
3046898|NCT00594516|Experimental|001|tapentadol (CG5503) Immediate Release (IR) Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100 150 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second,tapentadol (CG5503) Immediate Release IR 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
3046899|NCT00594516|Experimental|002|tapentadol (CG5503) Extended Release (ER) During 2 double blind periods: Tapentadol ER 100 150 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
3046900|NCT00594568|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, placebo arm participants received LY450139 titrated up to 140 milligrams (mg) orally once daily until Week 88.
3046901|NCT00594568|Experimental|100 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily until Week 88.
3046902|NCT00594568|Experimental|140 mg LY450139|Participants received 60 mg LY450139 orally once daily for 2 weeks, followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
3046903|NCT00594646|Other|Group 1|TRUVADA + raltegravir
3046904|NCT00594659|Active Comparator|1|Therapist delivered cognitive behavioral treatment
3046905|NCT00594659|Experimental|2|Computerized Cognitive Behavioral treatment
3046906|NCT00594659|Active Comparator|3|Motivational enhancement therapy
3046907|NCT00594685||Isolated HIT|Hospitalized patients with isolated Heparin-Induced Thrombocytopenia (HIT), diagnosed by a fall in platelet count and a positive Platelet Factor 4 (PF4)-heparin Enzyme-Linked ImmunoSorbent Assay (ELISA) test
3046908|NCT00594815|Experimental|1|
3046909|NCT00594854|Experimental|PN400|PN 400 (esomeprazole/naproxen) dosed twice daily
3046910|NCT00594854|Active Comparator|Diclofenac/Misoprostol|diclofenac 75mg/misoprostol 200 mcg dosed twice daily
3046911|NCT00594880|Active Comparator|Pegasys 180 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 180 mcg/week sc
3046912|NCT00594880|Active Comparator|Pegasys 90 mcg/week|ART replacement treatment with Pegylated Interferon-alpha 2a, 90 mcg/week sc
3046913|NCT00594906|Active Comparator|Injection|30 participants will receive teriparatide (Forteo) injection pens.
3046914|NCT00594906|Placebo Comparator|Placebo|30 participants will receive placebo injection pens.
3046915|NCT00594932|Active Comparator|Arm I:|Participants randomly assigned to Arm I will receive mycophenolate mofetil in ascending doses during Month 1, and 3 grams/day (or less if there are tolerance issues) for Months 2 through 6. During Month 1 these participants receive the same number of pills as every other month, but with ascending doses of mycophenolate mofetil and descending numbers of placebo pills. Week one for a total of 1.5 gm/day of mycophenolate mofetil, Week two 2.0 gm/day, Week three 2.5 gm/day and Week 4 3 gm/day. Dose can be held or decreased for tolerance issues at any time.
3046916|NCT00594932|Placebo Comparator|Arm 2|Patients Randomly Assigned to Arm 2 will receive a placebo comparator. The placebo treatment will be structured so that they will undergo the same type of dosing in Month 1 that the ascending dose patient from Arm 1 undergo, but will have placebo in both bottles of pills. At the end of three months, after assessment of primary outcome, these patients enter open label treatment for three more months. During the fourth month this group continues to receive the same number of pills as they received before, with ascending doses of mycophenolate mofetil given vs descending placebo pills so that their induction is the same as those in Arm 1 at the first month.
3046917|NCT00594945|Experimental|Intranasal Clonazepam 2 mg|
3046918|NCT00594945|Experimental|Intranasal Clonazepam 3 mg|
3046919|NCT00594945|Experimental|Intranasal Clonazepam both Dose Groups 2 mg & 3 mg|
3046920|NCT00594958|Active Comparator|IC51 Group A|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3046921|NCT00594958|Active Comparator|IC51 Group B|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3046922|NCT00594958|Active Comparator|IC51 Group C|IC51 (JE-PIV) 6 mcg i.m. with 2 injections (days 0 and 28) with a vaccine produced from one out of three IC51 batches
3046923|NCT00594997|Experimental|Education|Students who receive an educational intervention which consists of a 45 minute interactive presentation as well as a 30 minute health education entertainment by a juggler.
3046924|NCT00594997|Active Comparator|Control|Students who fill out pre and post surveys and receive the intervention after the post-survey
3046925|NCT00595075|Experimental|1|Ramelteon 8 mg will be given once prior to a 2-hour nap
3046926|NCT00595075|Placebo Comparator|2|Placebo will be given once prior to a 2-hour nap
3046927|NCT00595088|Experimental|20 mg of BC-819/PEI|Six intravesical instillations of 20 mg of plasmid DNA (BC-819) complexed with PEI into the bladder of patients with intermediate-risk superficial bladder cancer [recurrent stages Ta (low or high grade) and T1 (low grade) TCC] who have failed prior intravesical therapies including BCG and/or chemotherapy.
3046928|NCT00595101|Experimental|PF-03187207 High Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3046929|NCT00595101|Experimental|Latanoprost 0.005% and PF-03187207 Vehicle|A single drop of each, once daily in study eye for 28 days
3046930|NCT00595101|Experimental|PF-03187207 Medium Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3046931|NCT00595101|Experimental|PF-03187207 Low Dose and Latanoprost Vehicle|A single drop of each, once daily in study eye for 28 days
3046932|NCT00595114||MIA 1|Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo
3046933|NCT00595114||MIA 2|Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin
3046934|NCT00595114||MIA 3|Participants from the MIA trial who are PCR positive and have received treatment with placebo
3046935|NCT00595114||MIA 4|Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin
3046936|NCT00595114||LEUKO 1|Participants from the LEUKO trial who have received treatment with placebo
3046937|NCT00595114||LEUKO 2|Participants from the LEUKO trial who have received treatment with zileuton
3046938|NCT00595127|Experimental|1|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein] preceded by administration of 50mg/1.73m^2 of unlabeled 8H9.
3046939|NCT00595153|Active Comparator|B|Asthmatics not on inhaled corticosteroids who will be put on an inhaled steroid during the study
3046940|NCT00595153|No Intervention|A|Healthy, non-asthmatics who will not be put on any intervention
3046941|NCT00595153|Active Comparator|C|Asthmatics, who are already on inhaled corticosteroids who will be put on standardized dose of inhaled corticosteroids
3046942|NCT00595231|Experimental|SYN111|500 mg 1 week, followed by 1000 mg for 7 weeks
3046943|NCT00595231|Placebo Comparator|Placebo|0 mg tablets
3046944|NCT00595270|Other|IC51|In study IC51-305, subjects who had received IC51 in study IC51-304 were tested for seroconversion 6 months after the first vaccination. Subjects who had protective titers were again tested for persistence of immunity at 12 months after the first immunization,whereas subjects who had titers below the seroconversion threshold by Month 6 received a booster dose of 1x6 mcg IC51 at Month 11. Their immune response was also assessed at Month 12. Thereafter, subjects who had no protective titer by Month 12 received a booster dose of 1x6 mcg IC51 at Month 23, regardless of prior treatment; and neutralizing antibody titers were reassessed at Month 24. Subjects who had protective titers at month 12 did not receive a booster at Month 23, and their neutralizing antibody titer was also assessed at Month 24.
3046945|NCT00595309|Active Comparator|A|
3046946|NCT00595335|Experimental|Rituximab|Rituximab 1000 mg IV twice at 2-week intervals, each preceded by Methylprednisolone 100 mg IV as premedication to the rituximab infusion.
3046947|NCT00595335|Placebo Comparator|Placebo|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
3046948|NCT00595361|Active Comparator|Arg/Arg|Arg/Arg subjects on 2 week salmeterol treatment
3046949|NCT00595361|Active Comparator|Gly/Gly|Gly/Gly subjects on 2 week salmeterol treatment
3046950|NCT00595413|Experimental|Atacicept 150 mg with loading dose|
3046951|NCT00595413|Experimental|Atacicept 150 mg without loading dose|
3046952|NCT00595413|Active Comparator|Adalimumab|
3046953|NCT00595413|Placebo Comparator|Placebo|
3046954|NCT00595465|Active Comparator|IC51 Batch A|
3046955|NCT00595465|Active Comparator|IC51 Batch B|
3046956|NCT00595465|Active Comparator|IC51 Batch C|
3046957|NCT00595478|Experimental|1|Motivational Enhancement Therapy (MET)/CBT+CM/BPT
3046958|NCT00595478|Active Comparator|2|Motivational Enhancement Therapy (MET)/CBT
3046959|NCT00595504|Experimental|1|Ramelteon 8mg/day
3046960|NCT00595504|Placebo Comparator|2|sugar pill
3046961|NCT00595517|Experimental|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
3046962|NCT00595530|Experimental|Ketamine|This group will receive ketamine
3046963|NCT00595556|Experimental|A|Zonisamide
3046964|NCT00595556|Placebo Comparator|B|placebo
3046965|NCT00595621|Active Comparator|MGP-1 ON|Experimental Pacemaker on for 6 weeks
3046966|NCT00595621|Active Comparator|MGP-1 OFF|Experimental Pacemaker on or off for 4 weeks
3046967|NCT00595764|Active Comparator|1|Physician Management
3046968|NCT00595764|Experimental|2|Physician Management plus Cognitive Behavioral Therapy
3046969|NCT00595790|Active Comparator|IC51 2 x 6 mcg|2 x 6 mcg (microgram)
3046970|NCT00595790|Active Comparator|IC51 1 x 12 mcg|1 x 12 mcg (microgram)
3046971|NCT00595790|Active Comparator|IC51 1 x 6 mcg|1 x 6 mcg (microgram)
3046972|NCT00595868|Experimental|Varenicline|
3046973|NCT00595868|Placebo Comparator|Placebo|
3046974|NCT00595881||Ultrasound|One group of patients will undergo emergency bedside ultrasound in addition to the clinical examination.
3046975|NCT00595946|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3046976|NCT00595946|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
3046977|NCT00595959|Experimental|Laser Treatment|CLiRpath Photoablation Atherectomy System
3046978|NCT00596011|Active Comparator|Polyphenon E Treatment|Polyphenon E, 200 mg epigallocatechin gallate (EGCG) twice a day (BID)
3046979|NCT00596011|Placebo Comparator|Placebo Administration|Matching placebo BID
3046980|NCT00596167|Experimental|Intravenous antibiotics|Intervention: administer intravenous vancomycin, gentamicin and levofloxacin. This study will determine the pharmacokinetics of intravenous vancomycin, gentamicin and levofloxacin in subjects receiving short-daily hemodialysis. There will not be a control arm for this study. The intervention for this arm will be to administer intravenous vancomycin, gentamicin and levofloxacin and draw blood samples at periodic intervals. The blood samples will be tested for these medications and pharmacokinetic analysis will be performed.
3046981|NCT00596271|Active Comparator|IC51 and Placebo|6 mcg i.m. IC51 with 2 injections (day 0 and 28)and placebo 0.5 mL with 1 injection (day 0)
3046982|NCT00596271|Active Comparator|HAVRIX and placebo|HAVRIX with 1 injection (day 0) and placebo 0.5 mL with 2 injections (day 0 and 28)
3046983|NCT00596271|Active Comparator|IC51 and HAVRIX|IC51 6 mcg i.m. with 2 injections (day 0 and 28) and HAVRIX with 1 injection (day 0)
3046984|NCT00596362|Experimental|1|AVASTIN
3046985|NCT00596427|Placebo Comparator|Placebo tablet 3 tablets 2x/day|Type-2 diabetes mellitus patients
3046986|NCT00596427|Experimental|Colesevelam HCL 625 mg: 3 tablets 2x/day|Type-2 diabetes mellitus patients
3046987|NCT00596440||1|Relatives of Cancer Patients
3046988|NCT00596440||2|Relatives of Orthopedic Patients
3046989|NCT00596453|Placebo Comparator|Placebo|
3046990|NCT00596453|Experimental|Ciprofloxacin hydrochloride|
3046991|NCT00596466|Experimental|1|
3046992|NCT00596622|Experimental|Bipolar Manic Subjects Treated|Bipolar mania picture response during fMRI before and after treatment with lithium
3046993|NCT00596622|Experimental|Bipolar Depressed Subjects Treated|Bipolar depression picture response during fMRI before and after treatment with lithium
3046994|NCT00596622|Experimental|Bipolar Euthymic Subjects Treated|Bipolar euthymia picture response before and after treatment with lithium
3046995|NCT00596635|No Intervention|Control Group|No cranberry capsules administered
3046996|NCT00596635|Active Comparator|One cranberry capsule|1 650mg cranberry capsule daily
3046997|NCT00596635|Active Comparator|Two cranberry capsules|1 650 mg cranberry capsule twice daily (bid)
3046998|NCT00596687|Experimental|1|Glargine once daily plus glulisine given before meals plus supplemental glulisine for BG > 140
3046999|NCT00596687|Active Comparator|2|Sliding scale regular insulin four-times daily achs.
3047000|NCT00596752|Experimental|Alprostadil|Prostavasin® 40 μg will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
3047001|NCT00596752|Placebo Comparator|Placebo|Placebo will be infused intravenously twice daily over 2 hours in 50 to 150 ml isotonic sodium chloride solution during a Treatment Phase of 4 weeks.
3047002|NCT00596817|Placebo Comparator|Placebo|
3047003|NCT00596817|Experimental|Vortioxetine: 5 or 10 mg|
3047004|NCT00596830|Experimental|A|Patients in Arm A will receive CP-751, 871 in combination with paclitaxel and carboplatin intravenously every 21 days for up to six cycles.'
3047005|NCT00596830|Active Comparator|B|Patient in Arm B will receive paclitaxel and carboplatin intravenously every 21 days for up to six cycles.
3047006|NCT00596934|Experimental|Metreleptin treatment group|Treatment group
3047007|NCT00596960|Experimental|Motivational Enhancement Therapy|Motivational enhancement therapy
3047008|NCT00596960|Active Comparator|Health Education|health education intervention
3047009|NCT00597012|Experimental|Surgical|Participants will undergo arthroscopic partial menisectomy (APM) surgery and offered postoperative rehabilitative physical therapy.
3047010|NCT00597012|Active Comparator|Nonoperative|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks.
3047011|NCT00597038|Experimental|Phase I Dose Escalation|Dasatinib and Dacarbazine (DTIC). The first cohort was a dasatinib dose of 50 mg by mouth (PO) twice a day (BID) given days 2-19 with DTIC given at a dose of 800 mg/m2 once every 3 weeks. The dose escalation was continued until MTD and a recommended Phase II dose was established.
3047012|NCT00597038|Experimental|Phase II Dose Treatment|Dasatinib and Dacarbazine (DTIC). The recommended phase II dose was dasatinib 70 mg BID with dacarbazine 800 mgm^2.
3047013|NCT00597116|Active Comparator|1|Vinorelbine
3047014|NCT00597116|Experimental|2|Vandetanib
3047015|NCT00597207|Experimental|1|Mechanical CPR with AutoPulse
3047016|NCT00597207|Other|2|Manual CPR
3047017|NCT00597246|Experimental|1|
3047018|NCT00597272|Experimental|1|Vaccine- KLH conjugates with GD2L and GD3L
3047019|NCT00597376|Experimental|1|On Cerefolin NAC and open-label multivitamin supplement
3047020|NCT00597376|Placebo Comparator|2|On placebo and open label multivitamin supplement
3047021|NCT00597402|Experimental|Avastin, radiation, temozolomide, and irinotecan|
3047022|NCT00597428|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3047023|NCT00597428|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
3047024|NCT00597493|Experimental|Sorafenib + Temozolomide|"Subjects receive 400mg of Sorafenib twice daily and 50mg/m^2 of Temozolomide once daily~Subjects continue to receive treatment until any of the following: progressive disease, unacceptable toxicity, non-compliance with study guidelines, withdrawal of patient consent, intercurrent non-cancer-related illness that prevents continuation of therapy or regular follow-up, general or specific changes in a subject's condition which render the patient unacceptable for treatment in the judgement of the investigator, or study closure"
3047025|NCT00597506|Experimental|Bevacizumab and Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28 10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
3047026|NCT00597519|Experimental|Treatment|Patients with hematopoietic malignancy at high-risk for relapse or with advanced disease will receive myeloablative conditioning with cyclophosphamide (Cy), low dose fludarabine (Flu) and total body irradiation (TBI) with post transplantation cyclosporine (CSA) and mycophenolate mofetil (MMF) for GVHD prophylaxis.
3047027|NCT00597545|Active Comparator|Conventional Shunt|"Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt only if it is indicated by EEG, by conventional management."
3047028|NCT00597545|Experimental|Prophylactic Shunt|Patients with diabetes mellitus (DM) undergoing carotid endarterectomy will receive a shunt even when by standard criteria they would not need to receive one.
3047029|NCT00597558|Experimental|Egg white protein|Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.
3047030|NCT00597584|Experimental|Peginesatide|
3047031|NCT00597584|Active Comparator|Epoetin|
3047032|NCT00597675|Placebo Comparator|Placebo|Oat flour ingested daily as a placebo
3047033|NCT00597675|Active Comparator|Peanut OIT|Peanut flour ingested daily as oral mucosal immunotherapy
3047034|NCT00597701|Active Comparator|Baclofen|Standard benzodiazepine therapy plus baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
3047035|NCT00597701|Placebo Comparator|Placebo|Standard benzodiazepine therapy plus placebo every eight hous as inpatients for 72 hours or until discharge if less than 72 hours.
3047036|NCT00597714|Experimental|Cohort A - Lymphoid Disease|Group A: Patients with a high chance of progressive lymphoid or myelomatous disease undergo Non-myeloablative Stem Cell Transplantation.
3047037|NCT00597714|Experimental|Cohort B - Myeloid Disease|Group B: Patients with a high chance of progressive myeloid diseases, marrow failure syndromes or myeloproliferative disorders undergo Non-myeloablative Stem Cell Transplantation.
3047038|NCT00597714|No Intervention|Donor|Donor priming and apheresis will include filgrastim 8 mcg/kg subcutaneously twice daily for 4 days prior to stem cell collection and continuing until pheresis is completed. Alternative mobilization strategies may be employed at the investigator's discretion.
3047039|NCT00597727|Active Comparator|Blinded Peanut SLIT|Blinded subjects who received peanut sublingual drops for the initial 12 month blinded phase of the study.
3047040|NCT00597727|Placebo Comparator|Blinded Placebo SLIT|Blinded subjects who received placebo sublingual drops for the initial 12 month blinded phase of the study.
3047041|NCT00597727|Other|Ext. maint. open label peanut SLIT|After completing the blinded phase of the study, subjects receiving Blinded Peanut SLIT continued on extended maintenance open-label peanut SLIT for the duration of the study. Subjects receiving Blinded Placebo SLIT were crossed over and underwent the 12 month buildup protocol on open label peanut SLIT and then continued on extended maintenance treatment for the duration of the study.
3047042|NCT00597727|Other|Early unblinded peanut SLIT|Subjects who were unblinded prematurely during the blinded phase of the study and then re-enrolled as an open label cohort.
3047043|NCT00597727|Other|Pilot peanut SLIT rollover cohort|Subjects from the original phase 1 study of peanut SLIT (NCT00429429) who were rolled over into the current protocol as an open label peanut SLIT cohort.
3047044|NCT00597753|Experimental|Peginesatide|
3047045|NCT00597753|Active Comparator|Epoetin alfa|
3047046|NCT00597766|Active Comparator|Low Dose|"Drug: Lidocaine (Neer's Test)~Drug: 20 mg Triamcinolone + Lidocaine"
3047047|NCT00597766|Active Comparator|Standard Dose|"Drug: Lidocaine (Neer's Test)~Drug: 40 mg Triamcinolone + Lidocaine"
3047048|NCT00597766|Experimental|High Dose|"Drug: Lidocaine (Neer's Test)~Drug: 60 mg Triamcinolone + Lidocaine"
3047049|NCT00597818|Placebo Comparator|Placebo|Participants receive matching placebo capsules for 20 months
3047050|NCT00597818|Experimental|Cobiprostone QD|Participants receive 18 mcg cobiprostone once daily (QD) for 20 months
3047051|NCT00597818|Experimental|Cobiprostone BID|Participants receive 18 mcg cobiprostone twice daily (BID) for 20 months
3047052|NCT00597818|Experimental|Cobiprostone TID|Participants receive 18 mcg cobiprostone three times daily (TID) for 20 months
3047053|NCT00597896|Experimental|Active pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
3047054|NCT00597896|Placebo Comparator|Placebo pramipexole|Day 1: Random assignment to drug or placebo and dosage starting at 0.125 mg BID, which will be increased every week to a target dose of 1.5 mg/day. Targeted maximum dose of 1.5 mg/day is expected to be reached by week 4, however, dosing will be flexible based upon side effects reported. The maximum dose will be 1.5 mg/day.
3047055|NCT00597935|Experimental|SSLF and PMT|Sacrospinous Ligament Fixation (SSLF) and Pelvic Muscle Training & Exercises (PMT)
3047056|NCT00597935|Experimental|ULS and PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) and Pelvic Muscle Training & Exercises (PMT)
3047057|NCT00597935|Experimental|SSLF without PMT|Sacrospinous Ligament Fixation (SSLF) without Pelvic Muscle Training & Exercises (PMT)
3047058|NCT00597935|Experimental|ULS without PMT|Uterosacral Vaginal Vault Ligament Suspension (ULS) without Pelvic Muscle Training & Exercises (PMT)
3047059|NCT00598078|Experimental|1|
3047060|NCT00598078|Experimental|2|
3047061|NCT00598078|Placebo Comparator|3|
3047062|NCT00598273|Experimental|Peginesatide 0.025 mg/kg|
3047063|NCT00598273|Experimental|Peginesatide 0.04 mg/kg|
3047064|NCT00598273|Active Comparator|Darbepoetin Alfa|
3047065|NCT00598442|Experimental|Peginesatide 0.025 mg/kg|
3047066|NCT00598442|Experimental|Peginesatide 0.04 mg/kg|
3047067|NCT00598442|Active Comparator|Darbepoetin alfa|
3047068|NCT00598481|Experimental|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with busulfan
3047069|NCT00598507|Experimental|Chemotherapy - ZK-EPO|ZK-EPO (ZK 219477) (Sagopilone), 16 mg/m^2, was administered intravenously over 3-hours every 21 days until progression or unacceptable toxicity.
3047070|NCT00598559|Experimental|1 g IV Acetaminophen|1 g q6h IV Acetaminophen
3047071|NCT00598559|Experimental|650 mg IV Acetaminophen|650 mg q4h IV Acetaminophen
3047072|NCT00598559|Other|Standard of Care|The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
3047073|NCT00598585|Experimental|sidenafil|sidenafil
3047074|NCT00598585|Placebo Comparator|placebo|placebo
3047075|NCT00598650|Experimental|1|
3047076|NCT00598663|Experimental|Off/On|"6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]~4 month wash out period~6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]"
3047077|NCT00598663|Experimental|On/Off|"6 month-Period On: Continuous Subcutaneous Insulin Infusion (CSII) + personal continuous glucose monitoring (personal CGM) [Device: Paradigm® Real-Time pump with Sensor On feature continuously]~4 month wash out period~6 month-Period Off: Continuous Subcutaneous Insulin Infusion (CSII) and Self Monitoring Blood Glucose [Device: Paradigm® Real-Time pump with Sensor Off feature]"
3047078|NCT00598689|Experimental|Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive 0.3% hypromellose ophthalmic solution prior to surgery.
3047079|NCT00598689|No Intervention|No Lubricant|Patients scheduled to receive LASIK surgery and randomized to receive no intervention of 0.3% hypromellose ophthalmic solution prior to surgery
3047080|NCT00598702|Experimental|IV Acetaminophen|40 to 75 mg/kg/day every 4 to 6 hours
3047081|NCT00598806|Experimental|Apaziquone|TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
3047082|NCT00598806|Placebo Comparator|Placebo|TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT
3047083|NCT00598819|Experimental|Healthy Volunteers|Healthy subjects testing the device.
3047084|NCT00598832|Experimental|Adapalene lotion 0.1%|
3047085|NCT00598832|Placebo Comparator|Adapalene Lotion vehicle|
3047086|NCT00598871|Placebo Comparator|2|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of eyedrops to the affected eye, identical to the active drug but with no thymosin beta 4 (0.00% thymosin beta 4, w/w), 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
3047087|NCT00598871|Active Comparator|1|There are 2 groups: active drug and placebo. The patients in the active comparator arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times a day (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
3047088|NCT00598975|Active Comparator|NKTR-102 100 mg/m2 + Cetuximab|"NKTR-102 100 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
3047089|NCT00598975|Active Comparator|NKTR-102 125 mg/m2 + Cetuximab|"NKTR-102 125 mg/m2 + Cetuximab Arm~All patients received NKTR-102 in combination with cetuximab. NKTR-102 was administered intravenously (IV) once every 3 weeks (q3w) over 90 minutes on Day 1. Patients were to be enrolled in one of the following sequential dosing cohorts of NKTR-102: 100, 125, 150, or 175 mg/m2. Only the 100 and 125 mg/m2 were enrolled."
3047090|NCT00599027|Experimental|Mometasone furoate nasal spray|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
3047091|NCT00599027|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
3047092|NCT00599053|Experimental|1|Early treatment with azithromycin
3047093|NCT00599053|No Intervention|2|Expectant (usual) management
3047094|NCT00599196|Experimental|Rotigotine|Rotigotine
3047095|NCT00599248|Experimental|1|TissueGene-C single intraarticular injection of 3x10e6 cells/joint
3047096|NCT00599248|Experimental|2|TissueGene-C single intraarticular injection of 1x10e7 cells/joint
3047097|NCT00599248|Experimental|3|TissueGene-C single intraarticular injection of 3x10e7 cells/joint
3047098|NCT00599248|Placebo Comparator|4|Placebo control single intraarticular injection
3047099|NCT00599313|Experimental|Sunitinib Malate|Sunitinib Malate (Sutent) (50 mg/day on Days 1-28 of 42-day cycles)
3047100|NCT00599326|Experimental|A|
3047101|NCT00599339||Neupro|Neupro at study onset
3047102|NCT00599339||Dopamine Agonist|Other Dopamine-Agonist at study onset
3047103|NCT00599339||L-Dopa|L-Dopa
3047104|NCT00599339||Neupro + L-Dopa|Neupro in combination with L-Dopa at study onset
3047105|NCT00599339||Dopamine Agonist + L-Dopa|Other Dopamine Agonist in combination with L-Dopa at study onset
3047106|NCT00599521|Experimental|Adapalene lotion 0.1%|
3047107|NCT00599521|Placebo Comparator|Adapalene Lotion vehicle|
3047108|NCT00599638|Active Comparator|1|
3047109|NCT00599638|Experimental|2|
3047110|NCT00599638|Placebo Comparator|3|
3047111|NCT00599755|Experimental|Gem/Cis or Gem/Carbo|
3047112|NCT00599872|Active Comparator|Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract administered via the sublingual oral route (27.6 to 77.3 Amb a 1 Units)
3047113|NCT00599872|Placebo Comparator|Placebo|Standardized Ragweed Allergenic Extract Placebo via the sublingual oral route
3047114|NCT00599924|Experimental|Single arm|"SU011248 [sunitinib] in combination with FOLFOX; FOLFOX is a chemotherapy regimen that combines oxaliplatin and leucovorin with bolus and infusion 5-FU. The modified FOLFOX 6 (mFOLFOX6) regimen is one of several different regimens of FOLFOX used in clinic, according to different dosages of the 4 drugs. mFOLFOX6 was administered every 2 weeks on Days 1 and 2 of each cycle.~25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in three different dosing regimens: schedule 2/2 (2 weeks on, 2 weeks off), schedule 4/2 (4 weeks on, 2 weeks off), and continuous daily dosing (every day); FOLFOX will be administered every 2 weeks, using the modified FOLFOX 6 (mFOLFOX6) regimen, consisting of: oxaliplatin 85 mg/m2 + leucovorin 400 mg/m2 as a 2-hr IV infusion; 5-FU 400 mg/m2 IV bolus, followed by - 5-FU 2400 mg/m2 as a 46-hr IV infusion"
3047115|NCT00600015|Experimental|Combination Therapy|Erlotinib + Sorafenib
3047116|NCT00600015|Placebo Comparator|Placebo|Erlotinib + Placebo
3047117|NCT00600028|Experimental|Experimental: Thalidomide, then placebo|Participants first received Thalidomide tablet for 12 weeks. After a washout period of two weeks, they then received placebo tablet for 12 weeks.
3047118|NCT00600028|Experimental|Experimental: Placebo, then Thalidomide|Participants first received Placebo tablet for 12 weeks. After a washout period of two weeks, they then received Thalidomide tablet for 12 weeks.
3047119|NCT00600067|Experimental|1|
3047120|NCT00600067|Placebo Comparator|2|
3047121|NCT00600080|Other|etafilcon A first nelfilcon A second|etafilcon A worn daily during week 1, nelfilcon A worn daily for week 2
3047122|NCT00600080|Other|nelfilcon A first, etafilcon A second|nelfilcon A worn daily during week 1, etafilcon A worn daily for week 2
3047123|NCT00600106|Active Comparator|Hormone replacement therapy|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
3047124|NCT00600106|Placebo Comparator|Placebo|1mg placebo
3047125|NCT00600119|Placebo Comparator|A|Placebo
3047126|NCT00600119|Experimental|B|NKTR-118
3047127|NCT00600171|Placebo Comparator|Placebo|Placebo Multi dose dry powder inhlaer
3047128|NCT00600171|Experimental|GW642444M|GW642444M
3047129|NCT00600340|Active Comparator|A Bev+Pac|Bevacizumab plus Paclitaxel
3047130|NCT00600340|Active Comparator|B Bev+Cap|Bevacizumab plus Capecitabine
3047131|NCT00600353|Experimental|Melphalan, dexamethasone, aprepitant, palonosetron|"Group A: Subjects with Multiple Myeloma~Conditioning regimen, over a 7 day period, includes:~Melphalan 70-100 mg, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Dexamethasone 4 mg IV and Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell infusion~Group B: Subjects with Lymphoma~Conditioning regimen, over a 7 day period, includes: (BEAC)~BCNU 300 mg/m2 IV x 1,Cytarabine 100 mg/m2 IV BID, Etoposide 100 mg/m2 IV BID, administer after, Cyclophosphamide 35 mg/kg QD, Dexamethasone 4 mg IV push, Aprepitant 125 mg PO, Palonosetron 0.25 mg IV over 30 seconds, Aprepitant 80 mg PO, Lorazepam 1 mg IV x 1 dose 30 minutes prior to stem cell transplant"
3047132|NCT00600613|Experimental|1|Patients going for treatment of liver metastases with radiation therapy.
3047133|NCT00600704|Active Comparator|RESTRICTED FLUIDS|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary Bypass
3047134|NCT00600704|Active Comparator|FREE FLUIDS|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
3047135|NCT00600743|Placebo Comparator|1 'Instructions to eat normally'|'Instructions to eat normally' Placebo 1 mg dose
3047136|NCT00600743|Active Comparator|2 'Instructions to eat normally'|'Instructions to eat normally' drug 1 mg dose 'GSKI181771X (CCK-1R agonist)'
3047137|NCT00600743|Placebo Comparator|3 'Instructions to eat normally'|'Instructions to eat normally' 2 mg placebo
3047138|NCT00600743|Active Comparator|4 'Instructions to eat normally'|'Instructions to eat normally' 2 mg drug 'GSKI181771X (CCK-1R agonist)'
3047139|NCT00600743|Placebo Comparator|5 'Instructions to eat normally'|'Instructions to eat normally' 4 mg placebo
3047140|NCT00600743|Active Comparator|6 'Instructions to eat normally'|'Instructions to eat normally' 4 mg drug 'GSKI181771X (CCK-1R agonist)'
3047141|NCT00600743|Placebo Comparator|7 Instructions to binge eat|Instructions to binge eat 4 mg placebo
3047142|NCT00600743|Active Comparator|8 Instructions to binge eat|Instructions to binge eat 4 mg drug 'GSKI181771X (CCK-1R agonist)'
3047143|NCT00600756|Experimental|Quetiapine XR|
3047144|NCT00600756|Active Comparator|Risperidone|
3047145|NCT00600821|Active Comparator|B|Bevacizumab will be administered in combination with carboplatin and paclitaxel.
3047146|NCT00600821|Experimental|A|AG-013736 will be administered in combination with carboplatin and paclitaxel.
3047147|NCT00600886|Experimental|Pasireotide LAR|Patients in this arm received Pasireotide LAR 40 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 20 or 60 mg, respectively. Patients who responded to Pasireotide LAR (i.e. the randomized treatment) at the end of the core (Month 12), continued Pasireotide LAR treatment in the extension. Patients who did not respond to Pasireotide LAR at the end of the core (Month 12) were allowed to switch to receive Octreotide LAR in the extension.
3047148|NCT00600886|Active Comparator|Octreotide LAR|Patients in this arm received Octreotide LAR 20 mg im depot injection, blinded, once every 28 days (± 2 days) for 12 months. Dose could be down- or up-titrated to 10 or 30 mg, respectively. Patients who responded to Octreotide LAR (i.e. the randomized treatment) at the end of the core (Month 12) continued Octreotide LAR treatment in the extension (up to 2 years of treatment). Patients who did not respond to Octreotide LAR at the end of the core (Month 12) were allowed to switch to receive Pasireotide LAR in the extension.
3047149|NCT00600925|Experimental|1|Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
3047150|NCT00600925|No Intervention|2|Standard of care, ie, no gentamicin-collagen sponge.
3047151|NCT00600938|Experimental|Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
3047152|NCT00600938|Active Comparator|Deferasirox Placebo|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
3047153|NCT00600938|Experimental|Extension: deferoxamine to deferasirox|"DFO to ICL (patients who switched from DFO to deferasirox in extension)"
3047154|NCT00600938|Experimental|Extension: deferasirox to deferoxamine|"ICL to DFO (patients who switched from deferasirox to DFO in extension)"
3047155|NCT00601107|Experimental|Doxercalciferol 2.5 mcg/day|Doxercalciferol 2.5 microgram (mcg) capsule orally once daily up to Week 24.
3047156|NCT00601107|Experimental|Doxercalciferol 5 mcg/day|Doxercalciferol 5 mcg capsules orally once daily up to Week 24.
3047157|NCT00601107|Experimental|Doxercalciferol 7.5 mcg/day|Doxercalciferol 7.5 mcg capsules orally once daily up to Week 24.
3047158|NCT00601107|Placebo Comparator|Placebo|Placebo matching to doxercalciferol capsules orally once daily up to Week 24.
3047159|NCT00601146|Experimental|Low-dose Chest CT screening|Annual low-dose Chest CT screening
3047160|NCT00601172|Placebo Comparator|Control|Placebo + standard antiemetics
3047161|NCT00601172|Experimental|Single Dose IV|Casopitant + standard antiemetics
3047162|NCT00601250|Experimental|Linagliptin|Patients receive linagliptin 5 mg tablets once daily
3047163|NCT00601250|Placebo Comparator|Placebo|Patients receive placebo tablets matching linagliptin 5 mg tablets once daily
3047164|NCT00601354|Experimental|Emotion Regulation Group therapy + alli|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program, plus 12 weekly sessions of guided self-help group psychotherapy
3047165|NCT00601354|Active Comparator|Orlistat/alli program meds only|Group taking the weight loss medication orlistat (alli), in conjunction with the alli weight loss program alone
3047166|NCT00601367|Experimental|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
3047167|NCT00601419||Somatropin|Patients administered Somatropin.
3047168|NCT00601458|Active Comparator|Arm 1: Pregabalin 300 mg|
3047169|NCT00601458|Active Comparator|Arm 2: naproxen sodium 550 mg|
3047170|NCT00601458|Placebo Comparator|Arm 3: Placebo|
3047171|NCT00601484|Experimental|1|
3047172|NCT00601484|Placebo Comparator|2|
3047173|NCT00601523|Active Comparator|Pramipexole|Patient to receive Pramipexole ER 0.375-4.5 mg tabl form daily
3047174|NCT00601523|Placebo Comparator|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
3047175|NCT00601627|Experimental|Panitumumab|"Chemotherapy concurrent with radiation: Radiation 5 days per week for 5½ weeks; Panitumumab on days 1, 15, and 29 of radiation therapy 5-fluorouracil (5FU) continuous infusion, starting on day 1 and through last day of radiation.~4-6 weeks after completion of radiation therapy: Gemcitabine on days 1, 8, and 15 of each cycle, for 3 cycles; Panitumumab on days 1 and 15 of each cycle, for 3 cycles. Maintenance therapy: Panitumumab on days 1 and 15 of each cycle, for 6 cycles."
3047176|NCT00601640|Experimental|Eflornithine HCL|Patients apply Eflornithine HCL ointment to their left forearm twice daily on days 1-90.
3047177|NCT00601640|Active Comparator|Diclofenac Na|Patients apply topical Diclofenac Na gel to their left forearm once daily on days 1-90.
3047178|NCT00601640|Experimental|Eflornithine HCL and Diclofenac Na|Eflornithine HCl ointment and Diclofenac Na gel applied twice and once daily, respectively on days 1-90.
3047179|NCT00601705|Experimental|Epirubicin, Oxaliplatin and Fluorouracil|
3047180|NCT00601718|Experimental|Treatment (enzyme inhibitor, monoclonal antibody, chemotherapy|Patients receive vorinostat PO QD on days 1-5, ifosfamide IV continuously over 24 hours and carboplatin IV over 1 hour on day 4, and etoposide IV over 1 hour on days 3-5. Patients who are CD20+ also receive rituximab IV once on day 3, 4, or 5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3047181|NCT00601731|Experimental|Adjuvanted MenACWY vaccine group|Blood test
3047182|NCT00601731|Active Comparator|Non-adjuvanted MenACWY vaccine group|Blood test
3047183|NCT00601796|Experimental|Combination Immunotherapy|Vaccine + Cytoxan + ATRA as outlined in Detailed Description
3047184|NCT00601835|Experimental|Canadian Td Vaccine Group|Participants received Canadian manufactured Td vaccine
3047185|NCT00601835|Active Comparator|United States Td Vaccine Group|Participants received US manufactured Td vaccine
3468786|NCT03892408|Experimental|Optiflow|100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand)
3468787|NCT03892408|No Intervention|Standard|standard anesthesia
3047188|NCT00601926|Experimental|Bevacizumab|15 mg/kg over 90 minutes
3132581|NCT03438539|Experimental|Inhibitory Control Training without Normative Feedback|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
3178979|NCT00667784||Anxiety Assessment|Minor Donors + Sibling Non-Donors + Parents or Legal Guardians
3468788|NCT03892421|Experimental|Modified DHAP|Rituximab 375 mg/m² day 1, i.v. Carboplatin AUC(Area Under Curve) 5 day 1, i.v. Cytarabine 2000 mg/m², on day 2 and 3, i.v. Dexamethasone 40 mg, days 1-4, i.v. Filgrastim 300 mcg, days 10-15, s.c.
3047189|NCT00601952|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
3047190|NCT00601952|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
3047191|NCT00601965|Experimental|CBT/Escitalopram|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
3047192|NCT00601965|Active Comparator|No CBT/escitalopram|12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks maintenance escitalopram at same dose as at end of first 12 weeks.
3047193|NCT00601965|Placebo Comparator|CBT/placebo|12 weeks open-label escitalopram (10-20mg/day as tolerated), followed by 16 weeks individual cognitive behavioral therapy plus continuation escitalopram at same dose as end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks. Up to 3 booster sessions of CBT allowed during the 28 week maintenance phase. CBT consists of 16 sessions of relaxation training, cognitive restructuring, and problem-solving skills training.
3047194|NCT00601965|Placebo Comparator|No CBT/placebo|"12 weeks open-label escitalopram, 16 weeks continuation escitalopram, 28 weeks pill placebo~12 weeks open-label escitalopram (10-20 mg/day as tolerated), followed by 16 weeks continuation escitalopram at same dose as at end of first 12 weeks, followed by 28 weeks of pill placebo. 28 weeks of pill placebo includes a taper period of a duration dependent on the initial dose of escitalopram, but in all cases taper to placebo is complete after 8 weeks."
3047195|NCT00602043|Experimental|Diagnostic (FES)|Patients undergo [^18F] FES PET scan. Patients also undergo standard clinical fludeoxyglucose F 18 (FDG)-PET or FDG-PET/CT scan up to 14 days prior to [^18F] FES PET scan.
3047196|NCT00602225|Experimental|Arm I|See Detailed Description
3047197|NCT00602290|Active Comparator|1 - Citalopram and placebo|Participants will take a combination of citalopram and placebo for 16 weeks
3047198|NCT00602290|Active Comparator|2 - Methylphenidate and placebo|Participants will take a combination of methylphenidate and placebo for 16 weeks
3047199|NCT00602290|Active Comparator|3 - Methylphenidate and Citalopram|Participants will take a combination of methylphenidate and citalopram for 16 weeks
3047200|NCT00602355|Placebo Comparator|1 (Placebo)|Participants receiving placebo pill with clinical management plus mothercrafting
3047201|NCT00602355|Active Comparator|2 (Sertraline)|Participants receiving active medication sertraline with clinical management plus mothercrafting
3047202|NCT00602355|Active Comparator|3 (IPT)|Participants receiving interpersonal psychotherapy (IPT) alone
3047203|NCT00602420|Experimental|Naproxen|Patients receive oral naproxen twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
3047204|NCT00602420|Placebo Comparator|Placebo|Patients receive an oral placebo twice daily beginning on the day pegfilgrastim is administered (day 2, 3, or 4) and continuing for 5-8 days.
3047205|NCT00602446|Experimental|Deferasirox Treated|Includes patients that were treated with deferasirox for 6 months.
3047206|NCT00602459|Active Comparator|Arm A (rituximab, fludarabine phosphate)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: Patients receive rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5.
3047207|NCT00602459|Experimental|Arm B (rituximab, fludarabine phosphate, lenalidomide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 1-4 hours on days 1 (50 mg/m^2), 3 (325 mg/m^2), and 5 (375 mg/m^2) of course 1 and on day 1 (375 mg/m^2) of all subsequent courses. Patients also receive fludarabine phosphate 25 mg/m^2/day IV over 30 minutes or PO on days 1-5. Participants without progression receive consolidation therapy lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6 PO QD on days 1-21 of 28 day cycle.
3047208|NCT00602459|Experimental|Arm C (rituximab, fludarabine phosphate, cyclophosphamide)|Participants receive induction therapy (every 28 days for up to 6 cycles) of: rituximab IV over 4 hours on days 1 (50mg/m^2) and 3 (325 mg/m^2) of course 1 and on day 1 (500 mg/m^2) of all subsequent courses. Patients then receive fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) followed by cyclophosphamide (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) IV piggyback over 30 minutes on days 1-3.
3047209|NCT00602459|Experimental|Arm D (rituximab, fludarabine, cyclophosphamide, lenalidomide)|Patients receive the first course of induction therapy as in Arm A or B before being re-assigned to Arm D. Beginning in course 2, patients receive rituximab IV (500 mg/m^2) on day 1 and fludarabine phosphate (age < 70: 25 mg/m^2/day; age >= 70: 20 mg/m^2/day) IV piggyback over 30 minutes or PO (32 mg/m^2/day) and cyclophosphamide IV (age < 70: 250 mg/m^2/day; age >= 70: 150 mg/m^2/day) piggyback over 30 minutes on days 1-3. Participants without progression receive consolidation therapy: lenalidomide 5mg/day cycle 1, 10 mg/day cycles 2-6PO QD on days 1-21 of 28 day cycle.
3047210|NCT00602472|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
3047211|NCT00602472|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
3047212|NCT00602537|Experimental|I|Antidepressant therapy
3047213|NCT00602537|Active Comparator|II|Mood stabilizer therapy
3178980|NCT00667797|Experimental|1|levalbuterol 1.25 mg
3178981|NCT00667797|Active Comparator|2|Racemic albuterol 2.5 mg
3047214|NCT00602641|Active Comparator|Arm I (thalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and thalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive thalidomide PO QD and continue in the absence of disease progression."
3047215|NCT00602641|Experimental|Arm II (lenalidomide)|"INDUCTION THERAPY: Patients receive melphalan PO and prednisone PO QD on days 1-4, and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression."
3468789|NCT03892356||Concussion Group|Participants (age group 18-60) who presents to the emergency department in the University Health Network within 7 days of concussion
3468790|NCT03892356||Healthy Controls Group|Participants (age group 18-60) with no previous history of concussions who are age, education and sex-matched to the patients' group will be recruited from the community.
3047219|NCT00602771|Experimental|Arm I|Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10.
3047220|NCT00602771|Experimental|Arm II (closed to accrual as of November 2008)|Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.
3047221|NCT00602797|Experimental|Treatment (vinorelbine tartrate, paclitaxel)|Patients receive vinorelbine tartrate IV over 6-10 minutes and paclitaxel IV over 1 hour once weekly for 6 weeks.
3047222|NCT00602836|Experimental|PCR-Lenalidomide|Pentostatin, Cyclophosphamide, Rituximab + Lenalidomide
3047223|NCT00602927|Placebo Comparator|Placebo|
3047224|NCT00602927|Active Comparator|Varenicline|
3047225|NCT00602953||Healthy volunteers|Normal weight and normal glucose tolerance.
3047226|NCT00602953||Pre-diabetes|Impaired fasting glucose of impaired glucose tolerance.
3047227|NCT00602953||Overweight|Overweight or obese volunteers, but with normal fasting and postprandial glucose levels.
3047228|NCT00602953||Type 2 diabetes|Patients with type 2 diabetes.
3047229|NCT00602953||Type 1 diabetes|Patients with type 1 diabetes.
3047230|NCT00602979|Other|Macintosh laryngoscope|Macintosh laryngoscope (control group/direct laryngoscopy) - current standard
3047231|NCT00602979|Other|Airtraq Optical Laryngoscope|Airtraq® Optical Laryngoscope (an experimental group/indirect laryngoscopy)
3047232|NCT00602979|Other|Storz DCI Video Laryngoscope|Storz DCI Video Laryngoscope® (an experimental group/indirect laryngoscopy)
3047233|NCT00602979|Other|GlideScope Video Laryngoscope|GlideScope® Video Laryngoscope (an experimental group/indirect laryngoscopy)
3047234|NCT00602979|Other|McGRATH Video Laryngoscope|McGRATH® Video Laryngoscope (an experimental group/indirect laryngoscopy)
3047235|NCT00603018|Experimental|Annorexia nervosa|Participants recovered from anorexia nervosa before and after administration of fluoxetine
3047236|NCT00603044|Active Comparator|Fluticasone furoate|55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
3047237|NCT00603044|No Intervention|No treatment|
3047238|NCT00603239|Experimental|Exenatide twice daily (BID)|
3047239|NCT00603239|Placebo Comparator|Placebo|
3047240|NCT00603265|Experimental|ADL5859|2 x 50 milligrams (mg) ADL5859 capsules administered orally once in the morning and once in the evening for 28 days
3047241|NCT00603265|Active Comparator|Duloxetine|2 x 30 mg duloxetine capsules administered orally once in the morning and 2 placebo capsules filled with lactose administered orally once in the evening for 28 days
3047242|NCT00603265|Placebo Comparator|Placebo|2 placebo capsules filled with lactose administered orally once in the morning and once in the evening for 28 days
3047243|NCT00603278|Placebo Comparator|Arm 1|
3047244|NCT00603278|Experimental|Arm 2|
3047245|NCT00603291|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
3047246|NCT00603291|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3047247|NCT00603291|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
3047248|NCT00603304|Placebo Comparator|Placebo|Participants will take one 320 mg placebo gelcap daily for 24 weeks one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
3047249|NCT00603304|Active Comparator|Saw Palmetto|Extract of Serenoa Repens 320 mg once daily for 24 weeks (one gelcap); followed by 640 mg daily for 24 weeks (two gelcaps) followed by 960 mg daily for 24 weeks (three gelcaps).
3047250|NCT00603382|Placebo Comparator|Placebo|
3047251|NCT00603382|Experimental|GW685698X|
3047252|NCT00603408|Experimental|Cisplatin + Radiation + Recommended Surgery|"Cisplatin 75 mg/m^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection"
3047253|NCT00603447|Experimental|Carfilzomib + Lenalidomide + Dexamethasone|Treatment during Cycles 1 through 12 consisted of carfilzomib (15, 20, or 20/27 mg/m²) on Days 1, 2, 8, 9, 15, and 16; lenalidomide (10, 15, 20, or 25 mg) on Days 1 to 21; and low-dose dexamethasone (40 mg) given 30 minutes to 4 hours before the carfilzomib dose on Days 1, 8, and 15, as well as on Day 22. For Cycles 13 and higher, carfilzomib could be omitted on Days 8 and 9 at the investigator's discretion.
3047254|NCT00603473|Experimental|gabapentin|
3047255|NCT00603512|Placebo Comparator|CP-690,550, 0mg|
3047256|NCT00603512|Experimental|CP-690,550, 10mg|
3047257|NCT00603512|Experimental|CP-690,550, 1mg|
3047258|NCT00603512|Experimental|CP-690,550, 3mg|
3047259|NCT00603512|Experimental|CP-690,550, 5mg|
3047260|NCT00603525|Experimental|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
3047261|NCT00603525|Placebo Comparator|1000 ml Saline|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
3047262|NCT00603538|Experimental|CP-751,871|
3047263|NCT00603564|Active Comparator|1|CPAP delivered by a helmet
3047264|NCT00603564|No Intervention|2|O2 administration via a conventional Venturi mask
3047265|NCT00603590|Experimental|Polypill|Fixed dose combination therapy with Aspirin 81mg, Hydrochlorothiazide 12.5mg, Enalapril 2.5mg and Atorvastatin 20mg
3047266|NCT00603590|Placebo Comparator|Control|Identical placebo
3047267|NCT00603642|Placebo Comparator|AMG 531|Double blinded placebo-controlled study
3047268|NCT00603642|Placebo Comparator|Placebo|
3047269|NCT00603720|Active Comparator|L-Name in Young|20 individuals age 18-35 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME.
3047270|NCT00603720|Active Comparator|Phenylephrine|25 individuals age 18-35 will be getting an infusion of phenylephrine (primarily an alpha agonist) during 3 separate PET study days
3047271|NCT00603720|Active Comparator|L-arginine in Young|20 individuals age 18-35 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
3047272|NCT00603720|Active Comparator|L-arginine in Old|20 individuals age 60-75 will be getting an infusion of L-arginine 125 mcg/kg/min for 120 to 140 minutes during 3 separate PET study days
3047273|NCT00603720|Experimental|L-NAME in Old|20 individuals age 60-75 will be getting an infusion of L-NAME (a nitric oxide inhibitor) during 3 separate PET study days, then a 10-minute infusion of L-arginine to reverse effects of L-NAME
3047274|NCT00603733|Experimental|Pentasa® modified extended release|5-ASA (5-Aminosalicylate)
3047275|NCT00603733|Active Comparator|Pentasa®|5-ASA (5-Aminosalicylate)
3047276|NCT00603746|Experimental|GW685698X|GW685698X
3047277|NCT00603798|Active Comparator|3.75% imiquimod cream|
3047278|NCT00603798|Active Comparator|2.5% imiquimod cream|
3047279|NCT00603798|Placebo Comparator|Placebo cream|
3047280|NCT00603837|Experimental|Blanket|This arm includes those Extremely low gestational age newborns (ELGANs) who are to be placed on a sodium acetate warming blanket after delivery.
3047281|NCT00603837|Experimental|Wrap|This arm includes those ELGANs randomized to be wrapped in polyethylene after delivery.
3047282|NCT00603889|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will have the same number of concentrations of the Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
3047283|NCT00603902|Experimental|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening
3047284|NCT00603902|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3047285|NCT00603902|Placebo Comparator|Matching Placebo|Matching placebo tablet each morning and evening
3047286|NCT00603915|Experimental|GC Plus Erlotinib|Eligible patients are treated with cisplatin/carboplatin and gemcitabine (GC) for 6 cycles of therapy followed by maintenance erlotinib. Those patients achieving SD or PR with chemotherapy will be started on maintenance erlotinib until disease progression. Those patients achieving CR with chemotherapy will be started on erlotinib for 6 cycles of treatment and those achieving CR on erlotinib will be treated with a maximum of 6 further cycles of erlotinib. Those patients with disease progression while on chemotherapy will be offered erlotinib 2 weeks following the last dose of chemotherapy until further disease progression.
3047287|NCT00603941|Experimental|Cohort 1; 0.15 mg CS-7017|Participants who received 0.15 mg twice daily (BID) oral CS-7017 and 135 [Dose Level 1a] or 175 [Dose Level 1b] mg/m^2 intravenous (IV) paclitaxel once every 3 weeks.
3047288|NCT00603941|Experimental|Cohort 2; 0.30 mg CS-7017|Participants who received 0.30 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
3047289|NCT00603941|Experimental|Cohort 3; 0.50 mg CS-7017|Participants who received 0.50 mg twice daily (BID) oral CS-7017 and 175 mg/m^2 IV paclitaxel once every 3 weeks.
3047290|NCT00603980|Other|Treatment sequence 1|Sequence 1: Q, 1, 2, 7, 3, 6, 4, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047291|NCT00603980|Other|Treatment sequence 2|Sequence Q, 2: 2, 3, 1, 4, 7, 5, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047292|NCT00603980|Other|Treatment sequence 3|Sequence 3: Q, 3, 4, 2, 5, 1, 6, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047293|NCT00603980|Other|Treatment sequence 4|Sequence 4: Q, 4, 5, 3, 6, 2, 7, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047294|NCT00603980|Other|Treatment sequence 5|Sequence 5: Q, 5, 6, 4, 7, 3, 1, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047295|NCT00603980|Other|Treatment sequence 6|Sequence 6: Q, 6, 7, 5, 1, 4, 2, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047296|NCT00603980|Other|Treatment sequence 7|Sequence 7: Q, 7, 1, 6, 2, 5, 3, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047297|NCT00603980|Other|Treatment sequence 8|Sequence 8: Q, 5, 4, 6, 3, 7, 2, 1; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047298|NCT00603980|Other|Treatment sequence 9|Sequence 9: Q, 6, 5, 7, 4, 1, 3, 2; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047299|NCT00603980|Other|Treatment sequence 10|Sequence 10: Q, 7, 6, 1, 5, 2, 4, 3; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047300|NCT00603980|Other|Treatment sequence 11|Sequence 11: Q, 1, 7, 2, 6, 3, 5, 4; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047301|NCT00603980|Other|Treatment sequence 12|Sequence 12: Q, 2, 1, 3, 7, 4, 6, 5; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047302|NCT00603980|Other|Treatment sequence 13|Sequence 13: Q, 3, 2, 4, 1, 5, 7, 6; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 1=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047303|NCT00603980|Other|Treatment sequence 14|Sequence 14: Q, 4, 3, 5, 2, 6, 1, 7; where Q=Qualifying sessions (2 mg oral alprazolam and placebo in random order), 11=placebo, 2=oral alprazolam 1 mg, 3= oral alprazolam 2 mg, 4= oral alprazolam 4 mg, 5= inhaled alprazolam 0.5 mg, 6= inhaled alprazolam 1 mg, 7= inhaled alprazolam 2 mg
3047304|NCT00603993|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg (same dose subject was receiving in preceding Study M03-651 [NCT 00235872]) subcutaneously (sc) administered every other week (eow) until approval of adalimumab in Japan
3047305|NCT00604019|Active Comparator|Dopamine|Patients that get Dopamine as an infusion for hypotension
3047306|NCT00604019|Active Comparator|Norepinephrine|Patients that get norepinephrine as an infusion for hypotension
3047307|NCT00604045|Experimental|1 Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
3047308|NCT00604045|Placebo Comparator|2 Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
3047309|NCT00604162|Experimental|PillCam COLON and Colonoscopy|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases, had capsule endoscopy with PillCam COLON after bowel preparation and before standard colonoscopy.
3047310|NCT00604175|Experimental|Stratum A|Participants with screening CD4 count >350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3047311|NCT00604175|Experimental|Stratum B|Participants with screening CD4 count >200 to <=350 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3047312|NCT00604175|Experimental|Stratum C|Participants with screening CD4 count <=200 cells/mm^3 received 0.5mL of quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3047313|NCT00604188|Experimental|Direct Suboxone Induction|Participants received 8 mg of Suboxone and placebo Subutex on Day 1, 16 mg of Suboxone and placebo Subutex on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
3047314|NCT00604188|Active Comparator|Subutex-to-Suboxone Induction|Participants received 8 mg Subutex and placebo Suboxone on Day 1, 16 mg Subutex and placebo Suboxone on Day 2, and all participants received open label Suboxone from Day 3 to Day 28. Suboxone dosage may be titrated from Day 4 to Day 28 up to 24 mg per day.
3047315|NCT00604201|Experimental|Co-infusion of UCB and Haploidentical CD34+ cells|Stem cell recipients received co-infusion of unrelated umbilical cord blood (UCB) and haploidentical CD34+ cells from a related donor following non-myeloablative conditioning for neutropenic patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with refractory anemia (RA)
3047316|NCT00604214|Experimental|Drotrecogin alfa (activated)|
3047317|NCT00604214|Placebo Comparator|Placebo|
3047318|NCT00604279|Experimental|Paliperidone palmitate|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
3047319|NCT00604279|Active Comparator|Risperidone long acting injection (LAI)|Risperidone LAI intramuscular at a dose of 25 milligram (mg) on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
3047320|NCT00604383|Experimental|Ruboxistaurin|
3047321|NCT00604383|Placebo Comparator|Placebo|
3047322|NCT00604461|Experimental|Dose Escalation Followed by Maintenance Therapy|"A: Tiered Dose Escalation/Phase II Dose -~Tier -1: Carboplatin AUC 4 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 1: Carboplatin AUC 5 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~Tier 2: Carboplatin AUC 6 + Bevacizumab 15 mg/Kg+Pemetrexed 500 mg/m^2.~B: Maintenance Therapy -~Patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first."
3047323|NCT00604500|Experimental|MF/F MDI 100/10 mcg BID with dose counter|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MFF MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
3047324|NCT00604552|Other|Lifeline Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by the Foundation of Society for the Vascular Surgery (SVS)
3047325|NCT00604552|Other|PS Registry|All comers registry for the on-label treatment of AAA with the AneuRx Stent Graft sponsored by Medtronic
3047326|NCT00604565|Experimental|SFP dialysate|dialysate with added soluble ferric pyrophosphate (SFP)
3047327|NCT00604565|Placebo Comparator|standard dialysate|standard dialysate without soluble ferric pyrophosphate (SFP)
3047328|NCT00604695|Active Comparator|1|Two (4mg) doses of tenecteplase
3047329|NCT00604695|Placebo Comparator|2|Two (4mL) doses of sterile saline
3047330|NCT00604708|Experimental|IC51|6 mcg (microgram) i.m. (intramuscular) on Day0, 14 and 28
3047331|NCT00604708|Active Comparator|JE-VAX|given s.c. on Day 0, 7 and 28
3047332|NCT00604721|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive a single dose of selumetinib on day 1 and undergo blood collection for PK sampling pre-dose (within 30 min of dosing), 15 and 30 minutes and 1, 2, 4, 8, 12, 24 and 48 hours post-dose. Beginning 48 hours after the initial dose and continuing until day 21, patients receive oral selumetinib twice daily. Patients also undergo blood collection for PK sampling on day 15 of course 1. In all subsequent courses, patients receive selumetinib on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3047333|NCT00604786|Experimental|Omalizumab subcutaneous|"This active are will receive treatment with omalizumab subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks"
3047334|NCT00604786|Placebo Comparator|Placebo Subcutaneous|"This placebo arm will receive identical treatment with placebo injections subcutaneously at the dose currently FDA-approved for the treatment of allergic asthma. There is a weight and IgE based dosing table in the and subjects receive therapy by subcutaneous injection every 2 or 4 weeks. The lower range of dosing is 150 mg q 4weeks ( one injection) with the upper range 375 mg every 2 weeks ( three injections).~The dosing is based on IgE levels and IGE and is given by subcutaneous injection every 2 to 4 weeks."
3047335|NCT00604812|Experimental|Panel A Rizatriptan|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
3047336|NCT00604812|Placebo Comparator|Panel A Placebo|"Subjects allocated to Panel A and randomized to receive a single dose of rizatriptan 5 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 20-39 kg were allocated to Panel A."
3047337|NCT00604812|Experimental|Panel B Rizatriptan|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
3047338|NCT00604812|Placebo Comparator|Panel B Placebo|"Subjects allocated to Panel B and randomized to receive a single dose of rizatriptan 10 mg orally disintegrating tablet (ODT) placebo on Day 1.~Subjects weighing 40 kg and above were allocated to Panel B."
3047339|NCT00604812|Experimental|Panel C Rizatriptan|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg dose and subjects weighing 40 kg and above received a 10 mg dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
3047340|NCT00604812|Placebo Comparator|Panel C Placebo|"Subjects allocated to Panel C and randomized to receive a single dose of rizatriptan ODT placebo on Day 1. Subjects in Panel C weighing 20-39 kg received a 5 mg placebo dose and subjects weighing 40 kg and above received a 10 mg placebo dose.~Panel C was added to the study by amendment to increase the number of male subjects in the 12-17 year old age group."
3047341|NCT00604825|Placebo Comparator|Placebo|Placebo
3047342|NCT00604825|Active Comparator|GSK232802|GSK232802
3047343|NCT00604825|Experimental|PREMARIN|PREMARIN
3047344|NCT00604890|Experimental|1|Active cream, 3% AM & PM
3047345|NCT00604890|Placebo Comparator|2|Placebo cream AM ; 3% active cream PM
3047346|NCT00604890|Placebo Comparator|3|Placebo cream AM; 1.5% active cream PM
3047347|NCT00604890|Placebo Comparator|4|Placebo AM and PM
3047348|NCT00604968|Experimental|Caelyx|
3047349|NCT00605033|Active Comparator|Suboxone|Double-blind, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) plus matching Subutex placebo during Week 1 followed by open-label, once-daily sublingual Suboxone (buprenorphine/naloxone 4 mg/1 mg to 24 mg/6 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
3047350|NCT00605033|Active Comparator|Subutex|Double-blind, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) plus matching Suboxone placebo during Week 1 followed by open-label, once-daily sublingual Subutex (buprenorphine 4 mg to 24 mg) during Weeks 2-4 with weekly access to take-home doses as of Week 2.
3047351|NCT00605072|Experimental|Candesartan|Angiotensin Receptor Blocker
3047352|NCT00605072|Experimental|Lisinopril|Angiotensin-Converting Enzyme (ACE) Inhibitor
3047353|NCT00605072|Active Comparator|HCTZ|Hydrochlorothiazide (diuretic)
3047354|NCT00605085|Experimental|1|IC51
3047355|NCT00605085|Placebo Comparator|2|Placebo
3047356|NCT00605150||Patients enrolled|Total number of patients enrolled
3047357|NCT00605176|Active Comparator|3.75% imiquimod cream|
3047358|NCT00605176|Active Comparator|2.5% imiquimod cream|
3047359|NCT00605176|Placebo Comparator|Placebo cream|
3047360|NCT00605189|Active Comparator|VAC NPWT|
3047361|NCT00605189|Active Comparator|Gauze-Based NPWT|
3047362|NCT00605189|Active Comparator|Moist Wound Therapy|
3047363|NCT00605202|Active Comparator|Licorice|
3047364|NCT00605202|Active Comparator|Licorice and HCTZ|
3047365|NCT00605267|Active Comparator|1|Tamoxifen
3047366|NCT00605267|Experimental|2|Anastrazole (Arimidex)
3047367|NCT00605280|Sham Comparator|Sham Control|
3047368|NCT00605280|Experimental|Macugen|
3047369|NCT00605293|Experimental|C.E.R.A|Participants received starting dose of 120, 200 or 360 mcg of C.E.R.A IV once monthly for 6 months. The starting dose was based on the dose of epoetin alfa administered in Week -1.
3178982|NCT00667823|Experimental|ACT-064992|ACT-064992
3178983|NCT00667914|Experimental|Orthogeriatric unit|Geriatric work-up on hip-fracture patients
3047370|NCT00605293|Active Comparator|Epoetin Alfa|Participants received IV injection of 6000 International Units (IU) of epoetin alfa every 3 weeks (q3wk) during the Stability Verification Period (SVP; Week -4 to -1), and 7443 IU of epoetin alfa q3wk during Dose Titration Period (DTP; Week 0 to 15), 7363 IU of epoetin alfa q3wk during Efficacy Evaluation Period (EEP; Week 16 to 23) up to 23 weeks.
3047371|NCT00605306|Experimental|indacaterol maleate/mometasone furoate|Participants received 2 inhalations of indacaterol maleate / mometasone furoate 250/400 μg once daily in the evening (full dose 500/800 μg) delivered via the Twisthaler device for 14 days.
3047372|NCT00605306|Placebo Comparator|Placebo|Participants received 2 inhalations of placebo to indacaterol maleate / mometasone furoate once daily in the evening delivered via the Twisthaler device for 14 days.
3047373|NCT00605319|Other|Toviaz (Fesoterodine)|Toviaz 4mg to 8mg
3047374|NCT00605345|Experimental|CERA Treatment Once Monthly|
3047375|NCT00605345|Active Comparator|Darbepoetin Alfa Once Biweekly|
3047376|NCT00605358|Active Comparator|Open Door Intervention|Subjects who receive the Open Door Intervention will work with the study counselor to identify barriers to participation in mental health treatment, set goals, and problem-solve, in addition to receiving a referral.
3047377|NCT00605358|No Intervention|Services Referral|"Subjects who do not receive the Open Door intervention will receive:~an evaluation~referral to a local mental health provider~booklet information on depression and mental health care, and will complete an application for HEAP, a Westchester County service that provides reduced rates from oil companies on heating to seniors."
3047378|NCT00605384|Experimental|1|
3047379|NCT00605384|Experimental|2|
3047380|NCT00605423|Active Comparator|1|Dose 0.2 ug/day Medidur implant
3047381|NCT00605423|Active Comparator|2|Dose 0.5 ug/day Medidur implant
3047382|NCT00605475|Experimental|Canakinumab|"Eligible participants were assigned to receive canakinumab in one of four cohorts; 1) Single IV infusion of canakinumab 0.3 mg/kg; 2) Singe IV infusion of canakinumab 10 mg/kg; 3) single IV infusion of canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
3047383|NCT00605475|Placebo Comparator|Placebo|"Eligible participants were assigned to receive placebo to canakinumab in one of four cohorts; 1) Single IV infusion of placebo to canakinumab 0.3 mg/kg; 2) Singe IV infusion of placebo to canakinumab 10 mg/kg; 3) single IV infusion of placebo to canakinumab 0.1 mg/kg or 0.3 mg/kg, or 1.5 mg/kg; 4) Single IV injection of placebo to canakinumab 0.03 mg/kg.~All participants were required to take a concomitant stable daily dose of metformin during the study."
3047384|NCT00605540||Study COPD population|Patients with diagnosis of mild to very severe chronic obstructive pulmonary disease
3047385|NCT00605566|Experimental|I|Patients will receive sorafenib and cyclophosphamide.
3047386|NCT00605644|Placebo Comparator|Placebo|Placebo
3047387|NCT00605644|Experimental|150 mg|MOA-728
3047388|NCT00605644|Experimental|300 mg|MOA-728
3047389|NCT00605644|Experimental|450 mg|MOA-728
3047390|NCT00605644|Experimental|600 mg|MOA-728
3047391|NCT00605657|Experimental|Valproic acid|Single arm study involving oral administration of valproic acid and monitoring of its efficacy by CT scans done before and after the intervention. Blood samples were also obtained to monitor safety labs and biomarkers.
3047392|NCT00605696|Experimental|1|Participants will receive insulin to target glucose 80-110 mg/dl within 6-12 hours after presenting to ED.
3047393|NCT00605696|Active Comparator|2|Participants will receive insulin to target 150-180 mg/dl for 48 hours after ICU admission followed by usual clinical care.
3047394|NCT00605722|Experimental|bevacizumab + erlotinib|Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression or unmanageable toxicity.
3047395|NCT00605813||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
3047396|NCT00605826|Experimental|Blinded injection of NASHA/Dx gel at randomization.|Blinded injection of NASHA/Dx (Solesta) Gel. For each treatment, a series of 4 equally spaced injections with 1 mL of Solesta into the anal canal. Subjects will be followed for 6 months during the blinded phase. During a subsequent open phase, these subjects will be followed to Month 36 (ie, for an additional 30 months).
3047397|NCT00605826|Sham Comparator|Blinded sham inject. at randomization|"Blinded sham injection (needle stick with empty syringes). For each treatment, a series of 4 equally spaced Sham injections (needle sticks) into the anal canal. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
3047398|NCT00605826|Other|Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.|"Blinded sham injection at randomization. Subjects will be followed for 6 months during the blinded phase.~Sham-treated subjects have the option to receive open-label injection of NASHA/Dx (Solesta) Gel at the 6-month time point following completion of the blinded phase (ie, blinded sham injection at randomization + NASHA/Dx Gel at 6 months). Following injection of NASHA/Dx gel at the start of the open phase, these subjects will be followed to Month 30 (ie, for an additional 24 months)."
3047399|NCT00605839|Experimental|Glucopak Care|Glucopak cell phone and intensive monitoring. This group will be given the experimental device, and placed in close communication with the clinic.
3047400|NCT00605839|Active Comparator|Cell Phone Care|Cell phone only, without the Glucopak. Participants will be given cell phones and encouraged to communicate more closely with the clinic, but will not use the Glucopak.
3047401|NCT00605839|Placebo Comparator|Usual Care|Usual care, without cell phone or glucopak
3047402|NCT00605865||Sertraline hydrochloride.|Patients taking Sertraline hydrochloride.
3047403|NCT00605904|Experimental|Acamprosate|Subjects received 3 tablets of 333mg acamprosate orally, three times daily (total dose of 999 mg) for a minimum of 2 weeks.
3047404|NCT00605904|Placebo Comparator|Placebo|Subjects received 3 tablets of placebo orally, three times daily, for a minimum of 2 weeks.
3047405|NCT00605917||Sertraline hydrochloride.|The patients of Panic disorder taking Sertraline hydrochloride.
3047406|NCT00606008|Experimental|Sutent Treatment|Sutent was administered daily for 4 weeks at a dose of 50 mg followed by a 2 week study drug free break.
3047407|NCT00606021|Experimental|A: Pemetrexed + Best Supportive Care|"Pemetrexed: 500 milligrams per square meter (mg/m²) , intravenous (IV), Day 1 of each 21-day cycle for 6 cycles~Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician."
3047408|NCT00606021|Active Comparator|B: Best Supportive Care|Best Supportive Care: Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
3047409|NCT00606034|Experimental|All subjects active|All subjects will receive the experimental treatment (U-500 insulin via Omnipod) since they have already failed all other previous insulin treatment regimens.
3047410|NCT00606047||Asymptomatic patients|Asymptomatic, healthy patients (without hip pain or prior hip disease) will be recruited. Patients will undergo a magnetic resonance imaging (MRI) of the hip joints to evaluate for the prevalence of femoroacetabular impingement (FAI).
3047411|NCT00606086|Experimental|1|GI-5005 monotherapy continuing on to triple therapy
3047412|NCT00606086|Active Comparator|2|Standard of care alone
3047413|NCT00606138|Experimental|Anti-VEGF injection|Intravitreal injection of 0.5-mg dose of ranibizumab
3047414|NCT00606138|Active Comparator|PRP Laser|Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
3047415|NCT00606177|Experimental|1|
3047416|NCT00606177|Placebo Comparator|2|
3047417|NCT00606229|Experimental|1|
3047418|NCT00606281|Experimental|1|
3047419|NCT00606281|Placebo Comparator|2|
3047420|NCT00606294|Experimental|Cohort 1 (closed to accrual)|Cohort 1 (closed to accrual) Cohort 1 (closed to accrual) There will be no change or intervention in a patient's treatment regime using chemoradiation where both the primary and the neck nodes receive 70Gy. This is currently one accepted standard of care. In a subcohort of patients in Cohort 1 with tumors that are positive for HPV who exhibited no evidence of hypoxia on their baseline 18F-FMISO PET/ CT scan or whose tumors have early resolution of hypoxia on their repeat early response 18F-FMISO PET/CT scan will undergo an alternative treatment where the primary tumor site receives 70Gy while the neck nodes receive 60Gy followed by a planned FDG PET/CT scan and observation.
3047421|NCT00606294|Experimental|Cohort 2 (closed to accrual)|Experimental: Cohort 2 (closed to accrual) Cohort 2 HPV+ tumors that demonstrate no evidence of hypoxia on an 18F-FMISO PET scan will receive 30Gy to the surgical bed and neck lymph nodes concurrent with standard chemotherapy followed by a 3-4 month post-treatment neck dissection. In patients who exhibit a complete response with this method of treatment, no further treatment is necessary. For patients within this select group who still have pathologic nodal disease, further standard chemoradiation will be given. All other patients in this cohort (i.e. those who are not in the select HPV+ tumor group outlined above) will receive standard of care treatment following their surgery.
3047422|NCT00606307|Experimental|ITF2357|Initial dose of 50 mg b.i.d. that was subsequently escalated to 50 mg t.i.d in case of lack of significant toxicity.
3047423|NCT00606320|Experimental|Aripiprazole|
3047424|NCT00606489|Placebo Comparator|1|
3047425|NCT00606489|Experimental|2|
3047426|NCT00606502|Experimental|Pralatrexate|Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
3047427|NCT00606502|Active Comparator|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
3047428|NCT00606554|Experimental|Computer-assisted weaning|Group assigned to the computer-assisted weaning program
3047429|NCT00606554|Active Comparator|Standard of care weaning|Group assigned to receive current, evidence-based, standard of care for discontinuation of mechanical ventilation.
3047430|NCT00606580|Experimental|WR 279,396 Topical Treament|WR 279,396 topical cream (15% paromomycin + 0.5% gentamicin topical cream)
3047431|NCT00606580|Experimental|Paromomycin Alone Topical treatment|Paromomycin Alone topical cream (15% paromomycin topical cream)
3047432|NCT00606580|Placebo Comparator|Vehicle Placebo Cream|The cream base without the addition of paromomycin or gentamicin
3047433|NCT00606593|Experimental|ABECD|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047434|NCT00606593|Experimental|BCADE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047435|NCT00606593|Experimental|CDBEA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047436|NCT00606593|Experimental|DECAB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047437|NCT00606593|Experimental|EADBC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047438|NCT00606593|Experimental|DCEBA|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047439|NCT00606593|Experimental|EDACB|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047440|NCT00606593|Experimental|AEBDC|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047441|NCT00606593|Experimental|BACED|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047442|NCT00606593|Experimental|CBDAE|5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
3047443|NCT00606632|Other|124-Iodine-cG250 (124I-cG250)|Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.
3047444|NCT00606684|Active Comparator|GW642444|GW642444
3047445|NCT00606684|Placebo Comparator|placebo|
3047446|NCT00606801|Active Comparator|Galantamine 8 mg/day|Galantamine 8 mg/day
3047447|NCT00606801|Placebo Comparator|Placebo|placebo
3047448|NCT00606892|Experimental|Placebo First, varenicline, + IV Nic|Subjects received a Placebo tablet once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg).After a minimum of a 5 day washout subjects then received varenicline tablet (1mg). once per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,0.7 mg per 70kg).
3047449|NCT00606892|Experimental|Varenicline first, placebo, + IV Nic|Subjects received Varenicline tablet (1 mg) per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1, 0.4, and 0.7 mg per 70 kg). After a washout of a minimum of 5 days subjects then received placebo tablet for per day for 4 days and then received a laboratory session where they were given ascending doses of Nicotine (0.1,0.4,, and 0.7mg per 70 kg).
3047450|NCT00606905|Active Comparator|1|IVIG, either Gamimune N (Talecris Biotherapeutics, Inc., Clayton, NC) or Gamunex 10% (Talecris Biotherapeutics, Inc., Clayton, NC), both as a 10% solution
3047451|NCT00606905|Placebo Comparator|2|normal saline
3047452|NCT00606931|Experimental|one arm|
3047453|NCT00606944|Experimental|ERP group|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
3047454|NCT00606944|No Intervention|control group|traditional, conventional care group
3047455|NCT00607022|Active Comparator|immediate load|immediate load of dental implant based on the bone quality determined by the insertion torque value
3047456|NCT00607022|Active Comparator|Loading at 6 weeks|delayed load (6 weeks post surgery) of dental implants based on bone quality determined by the insertion torque value
3047457|NCT00607022|Active Comparator|Loading at 12 weeks|traditional loading of dental implants (12 weeks post surgery) based on bone quality determined by the insertin torque value.
3047458|NCT00607048|Other|Schedule A|Schedule A (CP-870,893 administration schedule)
3047459|NCT00607048|Other|Schedule B|Schedule B (CP-870,893 administration schedule)
3047460|NCT00607087|Experimental|sequence 1|sequence 1: insulin glulisine / insulin aspart / insulin lispro.
3047461|NCT00607087|Experimental|Sequence 2|Sequence 2: insulin aspart / insulin lispro / insulin glulisine
3047462|NCT00607087|Experimental|Sequence 3|Sequence 3: insulin lispro / insulin glulisine / insulin aspart
3047463|NCT00607113|Experimental|Avastin|Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV)
3047464|NCT00607113|Experimental|Avastin + RAD001|Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks
3047465|NCT00607113|Experimental|RAD001|Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days
3047466|NCT00607126|Experimental|1|locomotor training using body weight support on a treadmill, using robotic device to provide locomotor training. Locomotor training will be done using the Lokomat device. the patient is suspended over a treadmill while their legs are in the Lokomat, which moves the legs on the treadmill.
3047467|NCT00607126|Active Comparator|2|resistive training using weights and therabands
3047468|NCT00607243|Experimental|Conventional dose group|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
3047469|NCT00607243|Experimental|Low dose group|Diluted CJ-50300 2.5 x 10000pfu/dose vaccination
3047470|NCT00607269|No Intervention|Control|Control condition receiving minimal incentives for service program attendance and participation.
3047471|NCT00607269|Experimental|Contingency Management|Contingency management (Voucher-Based Reinforcement Therapy) intervention providing positive reinforcement for service program participation and attendance, enactment of prosocial/health behavior, and/or clean urine samples (i.e., no illicit drug use) and clean breathalyzer tests (i.e., BA < 0.05).
3047472|NCT00607321|Experimental|1|Medtronic Bifurcation Stent System
3047473|NCT00607373|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3047474|NCT00607373|Placebo Comparator|Placebo|Participants received placebo as a subcutaneous injection once a week for 26 weeks.
3047475|NCT00607386|Other|Idursulfase|Open-label treatment with idursulfase
3047476|NCT00607594|Experimental|Treatment (kinase inhibitor therapy)|Patients receive saracatinib PO, at a dose of 175 mg QD in the absence of disease progression or unacceptable toxicity.
3047477|NCT00607620|Experimental|Intervention|Providers receive training in alcohol screening and brief interventions from study staff in compliance with American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
3047478|NCT00607620|No Intervention|Usual Care|Usual care for alcohol use problems after American College of Surgeons' Alcohol Screening and Brief Intervention Mandate
3047479|NCT00607672|Placebo Comparator|1|Patients are randomized to placebo prior to surgery
3047480|NCT00607672|Active Comparator|2|Patients are randomized to Ramipril prior to surgery
3047481|NCT00607672|Active Comparator|3|Patients are randomized to Candesartan (ARB) prior to surgery
3047482|NCT00607724|Experimental|Stage 1: GDC-0449 (150 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
3047483|NCT00607724|Experimental|Stage 1: GDC-0449 (270 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
3047484|NCT00607724|Experimental|Stage 1: GDC-0449 (540 mg)|Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
3047485|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (150 mg)]|Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3047486|NCT00607724|Experimental|Stage 2: BCC [GDC-0449 (270 mg)]|Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3047487|NCT00607724|Experimental|Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)]|Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3178984|NCT00667914|Active Comparator|Orthopedic care as usual|Traditional care in the orthopedic unit
3178985|NCT00667927|Other|1|
3047488|NCT00607724|Experimental|Stage 2: New Formulation [GDC-0449 (150 mg )]|Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
3047489|NCT00607789|Experimental|Duloxetine Group|Start with 30 mg duloxetine hydrochloride capsule/day to be increased up to 120 mg per day.
3047490|NCT00607789|Placebo Comparator|Placebo Group|Sugar pill with matching dosage as Duloxetine
3047491|NCT00607815|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy
3047492|NCT00607815|Active Comparator|Present Centered Therapy|Present Centered Therapy
3047493|NCT00607867|Active Comparator|Arm 1|A LoBAG30, weight maintenance diet will be given to subjects on metformin. All food will be provided for 5 weeks.
3047494|NCT00607867|Placebo Comparator|Arm 2|A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin. All food will be provided for 5 weeks.
3047495|NCT00607880|Active Comparator|Standard Port|Patients undergo insertion of the conventional vascular access port (C. R. Bard, Inc., Murray Hill, NJ). Patients then receive standard chemotherapy.
3047496|NCT00607880|Experimental|Vortex Implantable Access Port|Patients undergo insertion of the Vortex® implantable vascular access port (Horizon Medical Products, Manchester, GA). Patients then receive standard chemotherapy.
3047497|NCT00607893|Sham Comparator|Sham CPAP|Participants will receive sham continuous positive airway pressure (CPAP) for a 2 month period. Sham CPAP involves wearing a device that appears similar to a standard CPAP device, but administers a negligible pressure. Adherence will be tracked while the participant wears the device.
3047498|NCT00607893|Active Comparator|Treatment CPAP|Participants will receive continuous positive airway pressure for a 2 month period. The optimal treatment pressure will be identified during a titration study prior to trial enrollment. Adherence will be tracked while the participant wears the device.
3047499|NCT00607919|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 milligram/kilogram/day (mg/kg/day) given orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine
3047500|NCT00607919|Placebo Comparator|Placebo|Placebo will be packaged in the same way as experimental drug to enforce double-blind study design. Placebo will be administered orally once daily in the morning. All eligible patients who complete the double-blind study period will have the option of participating in a 16-week open-label extension period in which patients will be treated with atomoxetine.
3047501|NCT00607997|Experimental|All Study Patients|"Schedule A: 72 mg/m2 vosaroxin Days 1, 8 and 15~Schedule B: 72 mg/m2 vosaroxin on Days 1 and 8~Schedule C: 72 mg/m2 on Days 1 and 4, or~Schedule C: 90 mg/m2 on Days 1 and 4"
3047502|NCT00608023|Experimental|Tesamorelin 12 months (T-T)|Tesamorelin 2 mg/day for 12 months
3047503|NCT00608023|Experimental|Tesamorelin-Placebo (T-P)|Tesamorelin 2 mg/day for 6 months - Placebo for 6 months
3047504|NCT00608023|Experimental|Placebo-Tesamorelin (P-T)|Placebo 6 months - Tesamorelin 2 mg/day for 6 months
3047505|NCT00608062|Experimental|Pre1|Premenopausal - GnRHant plus estradiol
3047506|NCT00608062|Placebo Comparator|Pre2|Premenopausal - GnRHant plus placebo
3047507|NCT00608062|Experimental|Peri1|Perimenopausal (early) - GnRHant plus estradiol
3047508|NCT00608062|Placebo Comparator|Peri2|Perimenopausal (early) - GnRHant plus placebo
3047509|NCT00608062|Experimental|Peri3|Perimenopausal (late) - GnRHant plus estradiol
3047510|NCT00608062|Placebo Comparator|Peri4|Perimenopausal (late) - GnRHant plus placebo
3047511|NCT00608062|Experimental|Post1|Postmenopausal - GnRHant plus estradiol
3047512|NCT00608062|Placebo Comparator|Post2|Postmenopausal - GnRHant plus placebo
3047513|NCT00608140|Experimental|1|Participants will receive optimal medical therapy plus surgical mitral valve repair with complete annular ring placement
3047514|NCT00608140|Active Comparator|2|Participants will receive optimal medical therapy alone
3047515|NCT00608140|Experimental|3|Participants will receive optimal medical therapy plus 18-month delayed surgical mitral valve repair with complete annular ring placement
3047516|NCT00608205|Active Comparator|Arm A: Radiation with concurrent Cisplatin|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
3047517|NCT00608205|Experimental|Arm B: Radiation with concurrent 5-FU and Cisplatin|Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.
3047518|NCT00608244|Experimental|LCP-Tacro|"Prograf was administrated BID, doses per product labeling, with an interval of 12±1 hours between the morning and evening doses. Patients continued on the same dose from Day 0 through Day 7. On Day 8, all patients were converted to LCP Tacro QD for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro was administered orally once daily in the morning, with an interval of 24 ± 1 h between doses. Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL.~LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
3047519|NCT00608322|Experimental|1|Subjects receive inhaled nitric oxide (40 parts per million) for six hours.
3047520|NCT00608322|Sham Comparator|2|Subjects receive sham inhaled nitric oxide for six hours.
3047521|NCT00608426|No Intervention|Usual Care|Group who can elect to receive reactive (usual) care for smoking cessation.
3047522|NCT00608426|Experimental|Proactive Care|Group who will be proactively offered smoking cessation care with their choice of smoking cessation services (telephone care or in-person care).
3047523|NCT00608491|Active Comparator|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
3047524|NCT00608491|Experimental|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
3047525|NCT00608517|Experimental|Pediatric Myeloablative conditioning|Patients undergo total-body irradiation on days -7 to -4, and receive cyclophosphamide IV over 1 hour on days -3 and -2, methylprednisolone IV twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4 hours on days -3 to -1.
3047526|NCT00608517|Experimental|Adult Myeloablative conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -4, cyclophosphamide IV over 1 hour on days -5 and -4, and undergo total-body irradiation on days -3 to -1.
3047527|NCT00608517|Experimental|Reduced-intensity conditioning|Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on day -6 and undergo total-body irradiation on day -1.
3047528|NCT00608530|Experimental|Cognitive Behavioral Therapy-Psychologist-Delivered|10 hours of Cognitive Behavioral Training delivered by a psychologist over 8 weeks by telephone and face-to-face contact
3047529|NCT00608530|Active Comparator|Supportive Psychotherapy-Psychologist-Delivered|10 hours of Rogerian Psychotherapy delivered by a psychologist over 8 weeks by telephone and face-to-face contact
3047530|NCT00608530|Experimental|Cognitive Behavioral Therapy-Nurse-Delivered|10 hours of Cognitive Behavioral Training delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
3047531|NCT00608530|Active Comparator|Supportive Psychotherapy-Nurse-Delivered|10 hours of Rogerian Psychotherapy delivered by a primary care medical nurse over 8 weeks by telephone and face-to-face contact
3047532|NCT00608543|Other|Aripiprazole augmentation|This is a single arm trial in which all participants recieved open label aripiprazole augmentation of their current escitalopram, citalopram or sertraline treatment.
3047533|NCT00608569|Experimental|mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Modified directly observed therapy (mDOT) for the first 24 weeks and self-administration for the remaining 28 weeks.
3047534|NCT00608569|Active Comparator|non-mDOT arm|Oral FTC/TDF+LPV/rtv or TDF+ZDV+LPV/rtv for 52 weeks. Self-administration of the study treatment (non-mDOT) for 52 weeks.
3047535|NCT00608582|Experimental|Real rTMS|These patients receive a series of 10 Real Transcranial Magnetic Stimulation, Repetitive (rTMS), treatments, only. There is pre-testing, and post-testing at 2 months after the last Real rTMS treatment.
3047536|NCT00608582|Sham Comparator|Sham rTMS|Patients receive a series of 10 Sham Transcranial Magnetic Stimulation, Repetitive (rTMS) treatments, followed by a series of 10 Real rTMS treatments. Sham rTMS treatments are identical to the Real rTMS treatments, however, no magnetic pulse is released. There is pre-testing, and post-testing at 2 months after the last Sham rTMS treatment.
3047537|NCT00608634|Placebo Comparator|Placebo|Patients apply a placebo cream topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3047538|NCT00608634|Experimental|Low Dose POH 0.30%|Patients apply perillyl alcohol (POH) cream (0.3%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3047539|NCT00608634|Experimental|High Dose POH 0.76%|Patients apply perillyl alcohol (POH) cream (0.76%) topically to each dorsal forearm twice daily for 3 months in the absence of unacceptable toxicity.
3047540|NCT00608829|Experimental|GORE TAG® Thoracic Endoprosthesis|Gore 45mm TAG Thoracic Endograft Implantation
3047541|NCT00608842|Experimental|Deoxycholic Acid 1%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3047542|NCT00608842|Experimental|Deoxycholic Acid 2%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3047543|NCT00608842|Experimental|Deoxycholic Acid 4%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3047544|NCT00608842|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma, up to a maximum of 4.8 mL per treatment session, at 28-day intervals for up to a maximum of 4 treatments.
3047545|NCT00608881|Active Comparator|A - coenzyme Q10 2400 mg/day|Randomized to active treatment (coenzyme Q10 2400 mg/day)
3047546|NCT00608881|Placebo Comparator|B - Placebo|Randomized to placebo
3047547|NCT00608894|Experimental|LCP-Tacro|LCP-Tacro tablets(1,2,and 5mg tacrolimus)+ prednisone tablets(5mg)
3047548|NCT00608894|Active Comparator|Azathioprine|Azathioprine tablets(50mg)+ prednisone tablets(5mg)
3047549|NCT00608907|Experimental|VELCADE|Control arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.
3047550|NCT00608907|Experimental|VELCADE + rifampicin|Treatment Arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.
3047551|NCT00608907|Experimental|VELCADE + dexamethasone|Treatment arm, bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.
3047552|NCT00608959|Experimental|omiganan 1% gel|Omiganan has a rapid bactericidal and fungicidal effect which is under development for the prevention of infections arising from short-term central venous catheters, as well as for the prevention of surgical wound infections in contaminated wounds.
3047553|NCT00608959|Active Comparator|chlorhexidine 2%|
3047554|NCT00608985|Experimental|1|almorexant 200 mg
3047555|NCT00608985|Experimental|2|almorexant 100 mg
3047556|NCT00608985|Placebo Comparator|3|Placebo
3047557|NCT00608985|Active Comparator|4|zolpidem 10 mg
3047558|NCT00609128|Experimental|Olopatadine|one drop in one eye only two times per day at an interval of 6 to 8 hours for 1 week
3047559|NCT00609245|Experimental|Placebo then Valproic Acid (VPA)|all patients will have placebo on day 1 and VPA infusion on day 2
3047560|NCT00609271|Experimental|1|low carbohydrate diet
3047561|NCT00609271|Active Comparator|2|low fat diet
3047562|NCT00609336|Experimental|Treatment (chemotherapy, radiation, pancreaticoduodenectomy)|See Detailed Description
3047563|NCT00609362|Active Comparator|Rosiglitazone|25 women age 60 to 75 years receiving rosiglitazone 8 mg/day
3047564|NCT00609362|Placebo Comparator|Placebo|25 women 60 to 75 years of age receiving placebo once a day for 14 weeks
3047565|NCT00609466|Experimental|1|CG5503 IR 75mg 4 to 6 hourly for 72 hours
3047566|NCT00609466|Active Comparator|2|Morphine IR 30 mg 4 to 6 hourly for 72 hours
3047567|NCT00609466|Placebo Comparator|3|Matching placebo 4 to 6 hourly for 72 hours
3047568|NCT00609492|Experimental|Preterm I Group|Children born after a gestation period of 27-30 weeks
3047569|NCT00609492|Experimental|Preterm II Group|Children born after a gestation period of 31-36 weeks
3047570|NCT00609492|Active Comparator|Full term Group|Children born after a gestation period of more than 36 weeks
3047571|NCT00609518|Active Comparator|Standard Vitamin and Steroid Schedule + Pemetrexed|Standard vitamin and steroid schedule that is used with pemetrexed consisting of a minimum of 5 daily doses of folic acid before first pemetrexed dose and dexamethasone on day before, day of, and day after treatment.
3047572|NCT00609518|Experimental|Simplified Vitamin and Steroid Schedule + Pemetrexed|Simplified vitamin and steroid schedule to be used with pemetrexed consisting of 2 daily doses of folic acid before first pemetrexed dose and dexamethasone on day of treatment only.
3047573|NCT00609609|Experimental|Corticosteroids|Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
3047574|NCT00609609|Experimental|ECP + Corticosteroids|Extracorporeal Photopheresis (ECP) 8-9 treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60 + Methylprednisolone at a dose of 2 mg/kg/day with a taper to no less than 1 mg/kg/day by day 14, and no less than 0.4 mg/kg/day by day 28.
3047575|NCT00609622|Experimental|A|Treatment arm A - sunitinib plus mFOLFOX6
3047576|NCT00609622|Active Comparator|B|Treatment arm B - bevacizumab plus mFOLFOX6
3047577|NCT00609674|Experimental|fluticasone furoate nasal spray|
3047578|NCT00609674|Placebo Comparator|Placebo|
3047579|NCT00609739|Experimental|Cytarabine + Mitoxantrone|This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.
3047580|NCT00609804|Experimental|Sorafenib+Erlotinib|Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth
3047581|NCT00609804|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily by mouth.
3047582|NCT00609869|Experimental|Lenalidomide and Rituximab|"28 day cycles of Lenalidomide administered orally and Rituximab administered intravenously.~Lenalidomide: Escalating doses starting with of 2.5 mg daily on 28-days cycles.~Rituximab: at 375 mg/m^2 on a weekly basis for the first cycle starting on day 15."
3047583|NCT00609947|Experimental|Endeavor Zotarolimus-Eluting Coronary Stent|Zotarolimus-eluting stent (ZES) implanted using standard percutaneous coronary intervention (PCI) technique via the femoral approach
3047584|NCT00609973|Active Comparator|A|Ciprofloxacin 500 mg bid
3047585|NCT00609973|Placebo Comparator|B|Placebo bid
3047586|NCT00609986|Experimental|Intensive|The experimental group will receive the intravenous regular insulin infusion protocol for the maintenance of blood sugar levels 70-110 mg/dL while hospitalized up to 7 am post operative day #3 and after hospitalization will receive subcutaneous insulin to maintain blood sugar levels 70-140 mg/dL.
3047587|NCT00609986|Active Comparator|Control|The control group will receive subcutaneous insulin injections (NPH or glargine and aspartame) to maintain a blood sugar level between 70-180 mg/dL while hospitalized and after hospitalization subcutaneous insulin to maintain blood sugar levels 90-180 mg/dL.
3047588|NCT00610116|Other|LV lead electronically repositioning|Single arm study
3047589|NCT00610129|Experimental|1|MK-0646
3047590|NCT00610155|Placebo Comparator|1|
3047591|NCT00610155|Experimental|2|
3047592|NCT00610155|Experimental|3|
3047593|NCT00610168|Experimental|BOOSTRIX I GROUP|Subjects, who had received Boostrix™ vaccine in the primary study (263855/004), received one additional booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
3047594|NCT00610168|Experimental|BOOSTRIX II GROUP|Subjects, who had received Wyeth's (formerly Lederle) combined adult diphtheria and tetanus vaccine and GSK Biologicals' acellular pertussis vaccine in the primary study (263855/004), received one booster dose of Boostrix™ vaccine in this study, administered as an intramuscular injection into the deltoid region of the non-dominant arm.
3047595|NCT00610207|Experimental|AFP|Anal fistula plug placement performed during surgical procedure
3047596|NCT00610311|Experimental|ALVAC plus anti-gp100:154-162 TCR PBL + HD IL-2|"ALVAC plus anti-gp100:154-162 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin-2 (IL-2): ALVAC vaccine two hours prior to cell infusion patients will receive 0.5 ml containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6.4 to 107.9/mL of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL. This will be repeated on day 14.~Aldesleukin (IL2, Proleukin, Recombinant human interleukin 2)- 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)"
3047597|NCT00610363|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 16.
3047598|NCT00610363|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 16.
3047599|NCT00610428|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo
3047600|NCT00610428|Experimental|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
3047601|NCT00610428|Placebo Comparator|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
3047602|NCT00610441|Experimental|MK-8777 FD→PBO|Participants receive a fixed dose (FD) of MK-8777 100 mg twice each day (BID) for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of placebo (PBO) BID for 3 weeks (Treatment Period 2).
3047603|NCT00610441|Experimental|PBO→MK-8777 FD|Participants receive a fixed dose of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive a fixed dose of MK-8777 100 mg BID for 3 weeks (Treatment Period 2).
3047604|NCT00610441|Experimental|MK-8777 RD→PBO|Participants receive rising doses (RD) of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of placebo BID for 3 weeks (Treatment Period 2).
3047605|NCT00610441|Placebo Comparator|PBO→MK-8777 RD|Participants receive rising doses of placebo BID for 3 weeks (Treatment Period 1). After a 2-week placebo washout period, participants receive rising doses of MK-8777 100-300 mg BID for 3 weeks (Treatment Period 2).
3047606|NCT00610480|Active Comparator|Optive, then Systane Artificial Tears|Artificial Tears (Optive, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Systane, 40 microliters) will be administered using the same procedure protocol.
3047607|NCT00610480|Active Comparator|Systane, then Optive Artificial Tears|Artificial Tears (Systane, 40 microliters) will be administered at the first study visit, after baseline evaporation rate measurements have been taken. Evaporation rate measurements will be repeated 30 minutes later. At the next study visit, 2-14 days later, artificial tears (Optive, 40 microliters) will be administered using the same procedure protocol.
3047608|NCT00610649|Experimental|Part 1: Block A MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 16 days.
3047609|NCT00610649|Placebo Comparator|Part 1: Block A Placebo|Participants receive placebo BID for a total of 16 days.
3047610|NCT00610649|Experimental|Part 1: Block B MK-8777|Participants receive MK-8777 initiated at 200 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 13 days.
3047611|NCT00610649|Placebo Comparator|Part 1: Block B Placebo|Participants receive placebo BID for a total of 13 days.
3047612|NCT00610649|Experimental|Part 1: Block C MK-8777|Participants receive MK-8777 initiated at 300 mg BID and titrated to a maximum of 600 mg BID. Participants receive MK-8777 for a total of 10 days.
3047613|NCT00610649|Placebo Comparator|Part 1: Block C Placebo|Participants receive placebo BID for a total of 10 days.
3047614|NCT00610649|Experimental|Part 1: Block D MK-8777|Participants receive MK-8777 initiated at 100 mg BID and titrated to a maximum dose determined by the results of Block A. Participants receive MK-8777 for a total of 13 days.
3047615|NCT00610649|Placebo Comparator|Part 1: Block D Placebo|Participants receive placebo BID for a total of 13 days.
3047616|NCT00610649|Experimental|Part 2: MK-8777 200 mg|Participants receive MK-8777 100 mg BID for 27 days followed by one day of 100 mg QD. Participants receive MK-8777 for a total of 28 days.
3047617|NCT00610649|Experimental|Part 2: MK-8777 800 mg|Participants receive MK-8777 200 mg BID for 3 days followed by 400 mg BID for 24 days followed by one day of 400 mg QD. Participants receive MK-8777 for a total of 28 days.
3047618|NCT00610649|Placebo Comparator|Part 2: Placebo|Participants receive placebo BID for 27 days followed by one day of placebo QD. Participants receive placebo for 28 days.
3047619|NCT00610675|Experimental|Esmirtazapine|One tablet of Esmirtazapine, 4.5 mg orally, daily for up to 52 weeks
3047620|NCT00610688|Placebo Comparator|Prenatal Vitamin D3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a placebo tablet containing 0IU of Vitamin D
3047621|NCT00610688|Experimental|2|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3)along with a tablet containing 1600IU of Cholecalciferol (Vitamin D3)
3047622|NCT00610688|Experimental|3|Arm will receive prenatal vitamin with 400IU of cholecalciferol (Vitamin D3) along with a tablet containing 3600IU of Cholecalciferol (Vitamin D3).
3047623|NCT00610701|Experimental|Anterior pin placement|Anterior pin placement
3047624|NCT00610701|Experimental|Lateral pin placement|Lateral pin placement
3047625|NCT00610714|Active Comparator|Active Comparator|carboplatin plus paclitaxel
3047626|NCT00610714|Experimental|2|AZD0530 in combination with carboplatin plus paclitaxel
3047627|NCT00610727|Experimental|Inhaled prochlorperazine 0.625 mg vs IV|Prochlorperazine 0.5 mg IV over 5 sec crossover Inhaled prochlorperazine 0.625 mg
3047628|NCT00610727|Experimental|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato prochlorperazine 1.25 mg
3047629|NCT00610727|Experimental|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato prochlorperazine 2.5 mg
3047630|NCT00610727|Experimental|Inhaled prochlorperazine 5 mg|Inhaled Staccato prochlorperazine 5 mg
3047631|NCT00610727|Experimental|Inhaled prochlorperazine 10 mg|Inhaled Staccato prochlorperazine 10 mg
3047632|NCT00610727|Placebo Comparator|inhaled Placebo|inhaled Staccato Placebo (0 mg)
3047633|NCT00610740|Experimental|Patients Treated with CerviPrep™|CerviPrep™, a novel drug delivery device, was developed specifically for applying pharmaceuticals directly on the cervix. It consists of a syringe-like tube attached to a plastic cap that covers the cervix. Drug can be delivered through the tube, directly to the cervix without spillage onto vaginal or vulvar tissues.
3047634|NCT00610857|Experimental|Anti-CTLA4 monoclonal antibody and HDI|Specific Aim #1: Test the hypothesis that the combination of IFNa-2b and anti-CTLA-4 monoclonal antibody will improve the response rate in patients with recurrent inoperable AJCC stage III and stage IV melanoma. Our therapeutic target is achieving, with acceptable toxicity, a 20% or better rate of objective response, CR or PR by RECIST criteria, as compared to the 5% to 10% expected in patients eligible for study. Study size is planned in terms of our primary efficacy endpoint, objective response.
3047635|NCT00610883|Experimental|1 - LSA4|
3047636|NCT00610935|Placebo Comparator|Placebo|Placebo intramuscular injection
3047637|NCT00610935|Experimental|Peramivir|Single intramuscular injection of 300mg peramivir
3047638|NCT00610987|Active Comparator|Cefazolin|Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours after surgical repair of the closed limb fracture.
3047639|NCT00610987|Placebo Comparator|Placebo|Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo, after the intraoperative dose(s) of cefazolin
3047640|NCT00611026|Active Comparator|1|
3047641|NCT00611026|Placebo Comparator|2|
3047642|NCT00611026|Experimental|3|
3047643|NCT00611130|Experimental|1|3 Vigabatrin Tablets, 500 mg, bid, for 9 weeks
3047644|NCT00611130|Placebo Comparator|2|3 Placebo Tablets, bid, for 9 weeks
3047645|NCT00611247|Experimental|Methylated AGAT Promoter (Group 1)|Induction: 200 mg/m2/day oral Temozolomide x 7 days
3047646|NCT00611247|Experimental|Un-Methylated AGAT Promoter (Group 2)|Priming: 100 mg/m2/day oral Temozolomide x 14 days, followed by Induction: 200 mg/m2/day oral Temozolomide x 7 days
3047647|NCT00611325|Experimental|EIAED|Patients taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 2.5 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
3047648|NCT00611325|Experimental|Non-EIAED|Patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs). Avastin was administered intravenously at a dose of 15 mg/kg every 3 weeks. Bortezomib was adminstered intravenously at a dose of 1.7 mg/m2 on days 1, 4, 8, 11, 22, 25, 29, and 32 of a 42-day cycle.
3047649|NCT00611351|Experimental|Unrelated Donor Allogeneic|Matched unrelated donor allogeneic stem cell transplantation with a conditioning regimen of targeted busulfan, cyclophosphamide and thymoglobulin.
3047650|NCT00611403|Active Comparator|RESTASIS®|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
3047651|NCT00611403|Active Comparator|REFRESH ENDURA®|Artificial Tears (REFRESH ENDURA®)
3047652|NCT00611442|Active Comparator|1|split-dose PEG solution without dietary restrictions plus lubiprostone 24mcg gelcap pretreatment
3047653|NCT00611442|Placebo Comparator|2|split-dose PEG solution without dietary restrictions plus placebo pretreatment
3047654|NCT00611455|Experimental|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
3047655|NCT00611455|Placebo Comparator|1000 ml Saline|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
3047656|NCT00611468|Experimental|Intravenous Topotecan and Oral Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
3047657|NCT00611533|Active Comparator|Atomoxetine|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
3047658|NCT00611533|Placebo Comparator|Placebo|Subjects were enrolled into a double-blind, placebo-controlled cross over study where they will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks or placebo (PBO) for 6 weeks, followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week. Subjects undergo assessments of cognition, mood, and menopausal symptoms prior to randomization, after 6 weeks in the first treatment condition (ATX or PBO) and then finally after the second 6-week period of the alternate treatment condition. Subjects are monitored every other week to assess medication compliance and side effects. Subjects will be instructed to take one capsule of ATX 40mg/d or placebo per day. If tolerated, the number of pills of ATX will be increased to 2 per day at the end of Week 1 of both Trials A and B. Subjects will remain on two capsules per day for the remaining 5 weeks of Trials A and B.
3047659|NCT00611559|Experimental|Infanrix hexa Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ hexa
3047660|NCT00611559|Active Comparator|Infanrix hexa Preservative-Containing Formulation Group|Subjects received a booster dose of the preservative-containing formulation of Infanrix™ hexa
3047661|NCT00611559|Active Comparator|Infanrix penta Preservative-Free Formulation Group|Subjects received a booster dose of the preservative-free formulation of Infanrix™ penta.
3047662|NCT00611624|Experimental|Five Days of Mammosite Therapy|Five Days of Mammosite Therapy (Radiotherapy)
3047663|NCT00611715|Experimental|First line/hormone-therapy naive|
3047664|NCT00611715|Experimental|Second-line/prev hormone-therapy tx|
3047665|NCT00611767|Active Comparator|Family History Negative for Alcoholism|Family History Negative for Alcoholism subjects will receive 2 interventions
3047666|NCT00611767|Placebo Comparator|Family History Positive for Alcoholism|Family History Positive for Alcoholism subjects will receive 2 interventions
3047667|NCT00611806|Active Comparator|Folate with B12|Participants will take folic acid plus B12 for 18 weeks.
3047668|NCT00611806|Placebo Comparator|Placebo|Participants will take placebo for 18 weeks.
3047669|NCT00611858|Experimental|Cetuximab, 5-FU and Radiation|"Cetuximab: Participants first receive cetuximab at the initial dose of 400 mg/m2 intravenously (IV) administered over 120 minutes, followed by weekly infusions at 250 mg/m2 over 60 minutes. Cetuximab is given as single agent during the first 3 weeks on study and then in combination with 5-FU and radiation.~Radiation: Radiation therapy given as standard of care is initiated after the 3rd dose of cetuximab with a total dose of 50.4 Gray (Gy) in 28 fractions over approximately 5.5 weeks.~5-FU: Participants receive 5-Fluorouracil (5-FU) continuous infusion through central venous access at 225 mg/m2/day given 7 days a week starting day 1 of radiation (no later than 3 days) and lasting the duration of radiation therapy.~Duration of neoadjuvant therapy is estimated to be 9 weeks. Surgery follows at week 13-17. Sigmoidoscopy is performed for biopsy prior to the 1st dose and after 3rd dose of cetuximab before the initiation of radiation and/or 5-FU."
3047670|NCT00611884|Experimental|SIBA (D)|
3047671|NCT00611884|Experimental|SIBA (E)|
3047672|NCT00611884|Experimental|SIBA (D) M, W, F|
3047673|NCT00611884|Active Comparator|IGlar|
3047674|NCT00611897|Active Comparator|Arm I|The NAC capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after NAC administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
3178986|NCT00667940|Experimental|Workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
3047675|NCT00611897|Placebo Comparator|Arm II|The placebo capsules were administered orally in divided doses: 2000 mg followed by 1000 mg 2 hours later. Each morning, 165 min after placebo administration, subjects received a 1-min bolus of normal saline, followed by a 70-minlong saline infusion during which behavioral, cognitive, and ERP data were collected. Ketamine was administered intravenously as a bolus of .23 mg/kg over 1 min followed by .58 mg/kg for 30 min (SPM and RVP), and then .29 mg/kg for 40 min (P300 and MMN).
3047676|NCT00611923|Placebo Comparator|B|Participants will take placebo flutamide
3047677|NCT00611923|Experimental|A|Participants will take flutamide
3047678|NCT00611975|Experimental|A|Participants will receive treatment with fluoxetine for 2 months
3047679|NCT00611975|Experimental|B|Participants will receive treatment with bupropion for 2 months
3047680|NCT00612040|Experimental|SIBA (D)|
3047681|NCT00612040|Experimental|SIBA (E)|
3047682|NCT00612040|Experimental|IGlar|
3047683|NCT00612066|Experimental|Rosiglitazone|
3047684|NCT00612105|Experimental|1|Retigabine
3047685|NCT00612105|Placebo Comparator|2|Placebo
3047686|NCT00612222|Experimental|ALVAC plus anti-MART-1 F5 TCR PBL + HD IL-2|"ALVAC plus anti-MART-1 F5 T cell receptor (TCR ) peripheral blood lymphocytes (PBL) + high dose (HD) interleukin 2 (IL-2): ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 cell culture infectious dose 50% (CCID50) (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.~Aldesleukin - 720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days."
3047687|NCT00612235||Lamotrigine Monotherapy|Lamotrigine Monotherapy
3047688|NCT00612235||Levetiracetam Monotherapy|Levetiracetam Monotherapy
3047689|NCT00612235||Carbamazepine Monotherapy|Carbamazepine Monotherapy
3047690|NCT00612235||Normal control (no epilepsy)|Normal control (no epilepsy)
3047691|NCT00612313|Active Comparator|Continued medication alone|Participants will receive antidepressant treatment with fluoxetine for 30 weeks
3047692|NCT00612313|Experimental|Continued medication plus CBT|Participants will receive antidepressant treatment with fluoxetine for 30 weeks plus relapse prevention cognitive behavioral therapy for the last 24 weeks of treatment
3047693|NCT00612339|Experimental|Avastin and Temozolomide|Avastin administered at 10 mg/kg every 2 weeks beginning a minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide dosed at 200 mg/m2 daily for 5 days in a 28-day cycle.
3047694|NCT00612352|Active Comparator|Family HIstory Positive|Subjects with a positive family history of alcoholism.
3047695|NCT00612352|Active Comparator|Family History Negative|Subjects with a negative family history of alcoholism.
3047696|NCT00612430|Experimental|Bevacizumab + Etoposide|Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.
3047697|NCT00612456|Experimental|Arm 1|Pazopanib eye drops formulation 5 mg/mL daily for 28 days
3047698|NCT00612456|Experimental|Arm 2|Pazopanib eye drop formulation 5mg/mL TID for 28 days
3047699|NCT00612456|Experimental|Arm 3|Pazopanib eye drop formulation 2mg/mL TID for 28 days
3047700|NCT00612508|Active Comparator|Desogen|"Drug: ethinyl estradiol and desogestrel~1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol; secen inactive pills every 28 days.~Subjects receive baseline vaginal biopsy, followed by treatment with the OC for six cycles and repeat biopsy at 3 and after 6 cycles"
3047701|NCT00612508|Active Comparator|NuvaRing|"Intravaginal Contraception~ethinyl estradiol (0.15 mg/d) and etonogestrel (0.12 mg/d) Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring~Subjects had baseline vaginal biopsy followed by 6 cycles of ring use and repeat biopsy at 3 and after 6 cycles"
3047702|NCT00612534|Experimental|1|
3047703|NCT00612534|Experimental|2|
3047704|NCT00612534|Experimental|3|
3047705|NCT00612534|Placebo Comparator|4|
3047706|NCT00612560|Experimental|2|Flaxseed 25 mg per day and 1 placebo pill per day
3047707|NCT00612560|Experimental|3|25 mg flaxseed per day and 1 mg anastrozole pill per day
3047708|NCT00612560|Placebo Comparator|4|Placebo pill 1 per day
3047709|NCT00612560|Experimental|1|Anastrozole 1 mg pill per day
3047710|NCT00612573|Experimental|Doxycyline 0.6 mg/kg/day|Doxycycline dosed at 40 mg/day to subjects of appropriate weights
3047711|NCT00612573|Experimental|Doxycycline 1.2 mg/kg/day|Doxycycline dosed at 80 mg/day to subjects of appropriate weights
3047712|NCT00612573|Experimental|Doxycycline 2.4 mg/kg/day|Doxycycline dosed at 160 mg/day to subjects of appropriate weights
3047713|NCT00612573|Placebo Comparator|Placebo|
3047714|NCT00612586|Experimental|Enzastaurin + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with enzastaurin
3047715|NCT00612586|Placebo Comparator|Placebo + 5-FU/LV + Bev|5-fluorouracil/leucovorin (5-FU/LV) plus bevacizumab (Bev) in combination with placebo
3047716|NCT00612690|Experimental|Links to Learning|Participants received the community mental health consultation model program.
3047717|NCT00612690|Active Comparator|Services as Usual|Participants received treatment as usual and referrals.
3047718|NCT00612716|Experimental|Allogeneic Transplantation|Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.
3047719|NCT00612768|Experimental|T.R.U.E. Test allergens Fragrance Mix and Thimerosol|"Concordance (agreement) between positive patch reactions to~fragrance mix (0.43 mg/cm2) in polyvinylpyrrolidone (PVP) vs fragrance mix (0.43 mg/cm2) in hydroxypropylcellulose (HPC)~thimerosol (0.008 mg/cm2) in polyvinylpyrrolidone (PVP) vs thimerosol (0.008 mg/cm2) in hydroxypropylcellulose (HPC)~fragrance mix T.R.U.E. Test allergen vs fragrance mix reference allergen (petrolatum)~thimerosol T.R.U.E. Test allergen vs thimerosol reference allergen (petrolatum)~will be measured"
3047720|NCT00612807|Active Comparator|Control|Medication management with a study doctor every other week.
3047721|NCT00612807|Experimental|Combination|Medication management with a study doctor every other week plus weekly marital therapy.
3047722|NCT00612924|Experimental|Anaconda|
3047723|NCT00613015|Experimental|Modafinil/Stress|Participants received placebo for 2 days. modafinil on the third day and participated in the TRIER social stress task on the third day.
3047724|NCT00613015|Experimental|Modafinil/no stress|Participants received placebo for 2 days. modafinil on the third day and did not participate in the TRIER social stress task on the third day.
3047725|NCT00613015|Experimental|Guanfacine/stress|Participants received guanfacine for 3 days and participated in the TRIER social stress task on the third day.
3047726|NCT00613015|Experimental|Guanfacine/no stress|Participants received guanfacine for 3 days and did not participate in the TRIER social stress task on the third day.
3047727|NCT00613015|Placebo Comparator|Placebo/Stress|Participants received placebo for 3 days and participated in the TRIER social stress task on the third day.
3047728|NCT00613015|Placebo Comparator|Placebo/no stress|Participants received placebo for 3 days and did not participate in the TRIER social stress task on the third day.
3047729|NCT00613028|Experimental|Temo + Avastin|Patients treated with bevacizumab + temozolomide
3047730|NCT00613028|Experimental|VP-16 + Avastin|Patients treated with bevacizumab and VP-16 (etoposide)
3047731|NCT00613080|Other|IMRT + Chemotherapy , Resection, Postoperative Chemotherapy|Radiation therapy (intensity modulated radiation therapy [IMRT] + three dimensional conformal radiation therapy [3D-CRT]) + neoadjuvant chemotherapy (capecitabine and oxaliplatin) followed by resection and postoperative chemotherapy (FOLFOX)
3047732|NCT00613106|Experimental|HZT-501|HZT-501: ibuprofen 800mg/famotidine 26.6mg
3047733|NCT00613106|Active Comparator|Ibuprofen|Ibuprofen 800mg
3047734|NCT00613171|Experimental|ST1571|Participants received ST1571 100 mg tablets, orally, once daily. Initiated at an oral dose of 200 mg/day for 4 weeks then titrated up to 400 mg/day for 2 weeks followed by 600 mg/day until Week 24, if well tolerated.
3047735|NCT00613327|Experimental|Oxybutynin Chloride OROS|
3047736|NCT00613366|Experimental|Misoprostol|Cervical preparation with misoprostol prior to intrauterine device insertion
3047737|NCT00613366|Placebo Comparator|Placebo|Cervical preparation with placebo prior to intrauterine device insertion
3047738|NCT00613379|Experimental|Arm 1|10 mg/kg PRO 140, one IV dose (N=10)
3047739|NCT00613379|Experimental|Arm 2|5 mg/kg PRO 140, one IV dose (N=10)
3047740|NCT00613379|Placebo Comparator|Arm 3|Placebo, one IV dose (N=10)
3047741|NCT00613405|Experimental|Stress + cue exposure|Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
3047742|NCT00613405|Experimental|No stress + cue exposure|Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
3047743|NCT00613509|Experimental|Study Group 1: ALVAC melanoma vaccine|Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
3047744|NCT00613509|Active Comparator|Study Group 2: Interferon alpha-2b|Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.
3047745|NCT00613626|Placebo Comparator|Arm A: ZD6474 Matched Placebo|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
3047746|NCT00613626|Active Comparator|Arm B: ZD6474|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.
3047747|NCT00613626|Experimental|Safety Lead-In|Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator. The safety lead-in will be conducted to determine the safety of the combination of ZD6474 and cisplation + etopiside. If this combination is found to be unsafe, no patients will be randomized in the Phase II portion of the trial. If the combination is deemed safe according to the protocol, participants from the safety lead-in cohort will not be included in the efficacy analysis.
3047748|NCT00613821|Experimental|Lidocaine infusion|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
3047749|NCT00613821|Active Comparator|Paracervical block only|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
3047750|NCT00613834|Experimental|Lidocaine group|Participants receive transcervical instillation of 5 ml 4% lidocaine solution 3 minutes prior to transcervical tubal sterilization
3047751|NCT00613834|Placebo Comparator|Control group|Participants receive transcervical instillation of 5 ml saline 3 minutes prior to transcervical tubal sterilization
3047752|NCT00613925|Active Comparator|Pipelle Group|Women were randomized to have an endometrial biopsy collected using Pipelle de Cornier instrument.
3047753|NCT00613925|Active Comparator|Explora group|Women were randomized to have an endometrial biopsy collected using Explora curette instrument.
3047754|NCT00613938|Placebo Comparator|004|placebo 1 capsule q4-6 hrs for 3 days
3047755|NCT00613938|Active Comparator|003|oxycodone 10mg capsule q4-6 hrs for 3 days
3047756|NCT00613938|Experimental|001|Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
3047757|NCT00613938|Experimental|002|Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days
3047758|NCT00613951|Experimental|SIAC 30 (B)|
3047759|NCT00613951|Experimental|SIAC 45 (B)|
3047760|NCT00613951|Active Comparator|BIAsp 30|
3047761|NCT00614055|Active Comparator|Insulin glargine|
3047762|NCT00614055|Experimental|SIAC 30 (B)|
3047763|NCT00614055|Experimental|SIAC 45 (B)|
3047764|NCT00614120|Experimental|Lira 0.6 + Met|Liraglutide 0.6 mg + metformin + glimepiride placebo
3047765|NCT00614120|Experimental|Lira 1.2 + Met|Liraglutide 1.2 mg + metformin + glimepiride placebo
3047766|NCT00614120|Experimental|Lira 1.8 + Met|Liraglutide + metformin + glimepiride placebo
3047767|NCT00614120|Experimental|Glim + Met|Glimepiride 4.0 mg + metformin + liraglutide placebo
3047768|NCT00614198|Experimental|Gluten- and casein-free diet|Stage 1: Gluten- and casein-free dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If showed group significant improvements then progressed to stage 2 (continued on a gluten- and casein-free diet for a further 12 months).
3047769|NCT00614198|No Intervention|No dietary intervention|Stage 1: No special dietary intervention for first 8 or 12 months. 8 or 12 months: Interim analysis based on surpassing statistical thresholds. If gluten- and casein-free dietary group showed group significant improvements then progressed to stage 2 (introduction of a gluten- and casein-free diet for 12 months).
3047770|NCT00614315|Experimental|FLAIR Endovascular Stent Graft and Delivery System|
3047771|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (DB)|In double-blind (DB) Week 1, participants receive cetuximab 400 mg/m^2 intravenously (IV) loading dose and irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV one time each week (Q1W) maintenance dose, irinotecan IV Q1W and DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
3047772|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (OL)|In the open-label (OL) portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W + irinotecan Q1W at their pre-study dosage + OL dalotuzumab (loading dose of 15 mg/kg IV followed by a maintenance dose of 7.5 mg/kg 2 weeks later) to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
3047773|NCT00614393|Experimental|Dalotuzumab 10 mg/kg Q1W (OL)|In the OL portion of the study, ≥6 participants receive cetuximab 400 mg/m^2 Q1W+ irinotecan Q1W at their pre-study dosage + OL dalotuzumab 10 mg/kg IV Q1W to verify the safety of the regimen. In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 10 mg/kg IV Q1W for up to 32 months of treatment.
3047774|NCT00614393|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg Q2W (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. In DB Week 2, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV + DB dalotuzumab 15 mg/kg IV. In DB Week 3, participants receive cetuximab 250 mg/m^2 IV + irinotecan IV. Starting with DB Week 4, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB dalotuzumab 7.5 mg/kg IV Q2W for up to 32 months of treatment.
3047775|NCT00614393|Active Comparator|Placebo + Cetuximab + Irinotecan (DB)|In DB Week 1, participants receive cetuximab 400 mg/m^2 IV + irinotecan IV at their pre-study dosage. Starting with DB Week 2, participants receive cetuximab 250 mg/m^2 IV Q1W + irinotecan IV Q1W + DB normal saline (placebo) IV Q1W for up to 32 months of treatment.
3047776|NCT00614406|Experimental|1|
3047777|NCT00614406|Placebo Comparator|2|
3047778|NCT00614432||1|Women who are anticoagulated.
3047779|NCT00614432||2|Matched case controls.
3047780|NCT00614445|Experimental|Diclectin®|Diclectin® (doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg) delayed release tablet
3047781|NCT00614445|Placebo Comparator|Placebo|Placebo tablets identical in size, shape, taste, and color to the experimental treatment (Diclectin®)
3047782|NCT00614458|Experimental|Raltegravir and VPA to ART|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
3047783|NCT00614484|Experimental|Proton therapy with chemotherapy|"Induction Chemotherapy - Two cycles Taxol 200mg/m2 and Carboplatin AUC6 on day 1 and day 22. Weekly chemotherapy concurrent with radiotherapy Taxol 50mg/m2 and Carboplatin AUC 2 weekly for 5 weeks.~Proton therapy - 76 Gy in 5 weeks to lung tumor."
3047784|NCT00614523|Experimental|Romiplostim|Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
3047785|NCT00614523|Placebo Comparator|Placebo|Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
3047786|NCT00614575||BI-Sifrol® Tablets (Pramipexole)|BI-Sifrol® Tablets, pramipexole dose: 0.125 mg, 0.5 mg, No reference therapy
3047787|NCT00614614|Experimental|Menhibrix 1 Group|Subjects received 3 doses of Menhibrix vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age during the Primary Vaccination Phase. For the Booster Vaccination Phase, subjects were re-randomized and received either 1 dose of Nimenrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 1 Group] or a fourth dose of Menhibrix vaccine (at 12-15 months of age) and 1 dose of Infanrix vaccine (at 15-18 months of age) [Menhibrix 2 Group], or 1 dose of Nimenrix vaccine co-administered with 1 dose of Infanrix vaccine (at 15-18 months of age) [Nimenrix 2 Group].
3047788|NCT00614614|Active Comparator|ActHIB- Infanrix Group|Subjects received 3 doses of ActHIB vaccine and 3 doses of Pediarix vaccine at 2, 4 and 6 months of age and 1 booster dose of Infanrix vaccine at 15-18 months of age.
3047789|NCT00614744|Experimental|Whole-body Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
3047790|NCT00614744|Active Comparator|Normothermia|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
3047791|NCT00614822|Other|one arm for study|Carboplatin, Pemetrexed and Bevacizumab are given day 1 every 3 weeks for 6 cycles and will be continued if patient tolerates treatments and has stable disease. The Bevacizumab will be continued every 3 weeks for 1 year if the patient tolerates treatment and has stable disease.
3047792|NCT00614874|Experimental|1|Subjects took rosiglitazone 2 mg for 4 weeks, then 4mg for 4 weeks, then 8 mg for 4 weeks
3047793|NCT00614926|Experimental|Modafinil|Eligible patients will be treated at baseline through Week 4. Those who choose to continue will have additional in-person visits at Weeks 8 and 12 visits (and Week 16 for those starting modafinil at Week 4).
3047794|NCT00614926|Placebo Comparator|Placebo|Sugar pill equivalent to the active comparator. Dosing schedule will be the same as the dosing schedule for Modafinil.
3047795|NCT00614939|Experimental|Saxa|Saxagliptin
3047796|NCT00614939|No Intervention|Placebo|Placebo to match
3047797|NCT00614991|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID Period 3-Fosamprenavir 1400mg BID + Raltegravir 400mg BID
3047798|NCT00614991|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg BID
3047799|NCT00614991|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
3047800|NCT00614991|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Raltegravir 100mg BID
3047801|NCT00614991|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
3047802|NCT00614991|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3047803|NCT00615017|Experimental|AZD9773 cohort 1 (50 units/kg)|AZD9773: single infusion of 50 units/kg
3047804|NCT00615017|Experimental|AZD9773 cohort 2 (250 units/kg)|AZD9773: single infusion of 250 units/kg
3047805|NCT00615017|Experimental|AZD9773 cohort 3 (250/50 units/kg)|AZD9773: loading infusion of 250 units/kg then 9 maintenance doses of 50 units/kg q12hrs
3047806|NCT00615017|Experimental|AZD9773 cohort 4 (500/100 units/kg)|AZD9773: loading infusion of 500 units/kg then 9 maintenance doses of 100 units/kg q12hrs
3047807|NCT00615017|Experimental|AZD9773 cohort 5 (750/250 units/kg)|AZD9773: loading infusion of 750 units/kg then 9 maintenance doses of 250 units/kg q12hrs
3047808|NCT00615017|Placebo Comparator|Placebo|Placebo
3047809|NCT00615030|Experimental|Indacaterol Morning,Indacaterol Evening, Salmeterol|In period I, indacaterol 300 μg once a day in the morning delivered via single dose dry powder inhaler (SDDPI) with a placebo to salmeterol delivered via dry powder inhaler (DPI). Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, Salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and second dose in the evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047810|NCT00615030|Experimental|Indacaterol Evening,Indacaterol Morning, Placebo|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047811|NCT00615030|Experimental|Salmeterol, Placebo, Indacaterol Morning|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047812|NCT00615030|Experimental|Placebo, Salmeterol, Indacaterol Evening|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via dry powder inhaler (DPI). One of the two daily doses of salmeterol was administered in the morning and the second dose was in the evening along with placebo matching indacaterol delivered by SDDPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047813|NCT00615030|Experimental|Indacaterol Morning, Placebo, Indacaterol Evening|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, During morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, Patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3132887|NCT03463161|Experimental|Acquired Resistance Group|"Participants that have benefited from prior treatment with immunotherapy. Defined as response to prior treatment and/or stable disease lasting at least 5 months and disease worsening seen on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
3178987|NCT00667940|No Intervention|Delayed workshop|No specific intervention until after follow-up assessment, then receives same workshop.
3178988|NCT00667953|Experimental|Arm A:|
3047814|NCT00615030|Experimental|Indacaterol Evening,Salmeterol, Indacaterol Morning|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047815|NCT00615030|Experimental|Salmeterol, Indacaterol Evening, Placebo|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047816|NCT00615030|Experimental|Placebo, Indacaterol Morning, Salmeterol|In period I, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via dry powder inhaler DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047817|NCT00615030|Experimental|Indacaterol Morning, Salmeterol, Placebo|In period I, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period II, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period III, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047818|NCT00615030|Experimental|Indacaterol Evening, Placebo, Salmeterol|In period I, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via dry powder inhaler DPI. In period II, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period III, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047819|NCT00615030|Experimental|Salmeterol, Indacaterol Morning, Indacaterol Evening|In period I, salmeterol 50 μg twice daily delivered via DPI. One of the two daily doses of salmeterol was administered in the morning and the second dose in evening along with placebo matching indacaterol delivered by SDDPI. In period II, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. In period III, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047820|NCT00615030|Experimental|Placebo, Indacaterol Evening, Indacaterol Morning|In period, during morning and evening, placebo matching indacaterol was delivered via SDDPI and placebo matching salmeterol was delivered via DPI. In period II, patients were instructed to take morning doses of a placebo to indacaterol delivered via SDDPI and placebo to salmeterol delivered via DPI. Indacaterol 300 μg once a day in the evening delivered via SDDPI with placebo to salmeterol delivered via DPI. In period III, indacaterol 300 μg once a day in the morning delivered via SDDPI with a placebo to salmeterol delivered via DPI. Patients were also instructed to take evening doses of a placebo to indacaterol via SDDPI and placebo to salmeterol via DPI. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047821|NCT00615056|Active Comparator|B|Bevacizumab (avastin)
3047822|NCT00615056|Experimental|C|AG-013736 (axitinib)
3047823|NCT00615056|Experimental|A|AG-013736 (axitinib)
3047824|NCT00615056|Active Comparator|D|bevacizumab (avastin)
3047825|NCT00615069|Experimental|31 mm GORE EXCLUDER® Test Subjects|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
3047826|NCT00615199|Experimental|1mg BD|
3047827|NCT00615199|Experimental|5mg BD|
3047828|NCT00615199|Experimental|15mg BD|
3047829|NCT00615199|Placebo Comparator|Placebo BID|
3047830|NCT00615264|Experimental|DiaPep277|DiaPep277 1.0 mg + 40 mg Mannitol in 0.5 mL lipid emulsion.
3047831|NCT00615264|Placebo Comparator|Placebo|Mannitol 40 mg in 0.5 mL lipid emulsion.
3047832|NCT00615420|Experimental|Manuka Honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed
3047833|NCT00615420|Placebo Comparator|Placebo|Sugar-free placebo gel 5ml 4 times a day, swished and held in mouth for 30 secs then swallowed
3047834|NCT00615433|Experimental|Lurasdione 40mg tablets|
3047835|NCT00615433|Experimental|120mg|
3047836|NCT00615433|Active Comparator|15mg Olz|
3047837|NCT00615433|Placebo Comparator|Sugar pill|
3047838|NCT00615459|Experimental|Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg|In period I, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period II, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via single dose dry powder inhaler (SDDPI). In period III, indacaterol 150 μg once daily delivered via SDDPI and placebo to tiotropium was delivered once daily via the tiotropium inhalation device. Daily inhaled corticosteroid (ICS) monotherapy (where applicable) was provided to remain stable throughout study. The Short acting (beta) β2-agonist (SABA) was available for rescue use throughout the study.
3047839|NCT00615459|Experimental|Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium|In period I,indacaterol 300 μg once daily delivered via single dose dry powder inhaler (SDDPI)and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3047840|NCT00615459|Experimental|Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo|In period I, indacaterol 150 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period II, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. In period III, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3047841|NCT00615459|Experimental|Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg|In period I, tiotropium (18 μg) once daily delivered via inhalation device and matching placebo to indacaterol delivered once daily via SDDPI. In period II, placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium inhalation device. In period III, indacaterol 300 μg once daily delivered via SDDPI and matching placebo to tiotropium delivered once daily via tiotropium inhalation device. Daily ICS monotherapy (where applicable) was provided to remain stable throughout study. The SABA was available for rescue use throughout the study.
3047842|NCT00615472|Experimental|Group 1|Inhaled Anesthesia - isoflurane
3047843|NCT00615472|Experimental|Group 2|Intravenous Anesthesia - propofol, remifentanil
3047844|NCT00615550|Placebo Comparator|Placebo|placebo vaginal gel
3047845|NCT00615550|Active Comparator|Prochieve|Progesterone 8% Vaginal Gel
3047846|NCT00615589|Experimental|Flu-Bu4|Fludarabine Busulfan chemotherapy regimen(Flu-Bu4), followed by allogeneic stem cell transplant from best available, matched donor.
3047847|NCT00615719||ED patients undergoing coronary CTA|Emergency Department patients suspected of having acute coronary syndrome undergoing Coronary Computed Tomographic angiography.
3047848|NCT00615784|Experimental|A|
3047849|NCT00615836|Experimental|Desmopressin Melt 10 μg|Participants received desmopressin melt 10 μg once a day, placed under the tongue one hour before bedtime until they were re-randomized to one of the other doses of desmopressin Melt (25 μg, 50 μg, or 100 μg).
3047850|NCT00615836|Experimental|Desmopressin Melt 25 μg|Participants received desmopressin melt 25 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3047851|NCT00615836|Experimental|Desmopressin Melt 50 μg|Participants received desmopressin melt 50 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3047852|NCT00615836|Experimental|Desmopressin Melt 100 μg|Participants received desmopressin melt 100 μg once a day, placed under the tongue one hour before bedtime for up to 2 years and 2.5 months.
3047853|NCT00615901|Experimental|1|This is a pilot study using 8 cycles of CMF (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, and fluorouracil 600 mg/m2), at 14 day intervals supported by PEG-filgrastim for a cohort of 38 patients. A safety analysis will then be performed.
3047854|NCT00615927|Experimental|Astrocytoma|Grade II Astrocytoma
3047855|NCT00615927|Experimental|Oligodendroglioma|Grade II Oligodendroglioma or oligoastrocytomas
3047856|NCT00616018|Experimental|A|all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study
3047857|NCT00616109|Experimental|Maintenance Sunitinib|"Main interventional arm of study. Subjects who received maintenance sunitinib experimentally on this study were from a population of (consenting) patients with histologically or cytologically documented Extensive-State Small Cell Lung Cancer (ES-SCLC) who did not progress (were classified as Complete Response or CR, Partial Response or PR, or Stable Disease or SD) after an induction chemotherapy (Cisplatin and etoposide)"
3047858|NCT00616122|Experimental|Sunitinib, Cyclophosphamide, and Methotrexate|
3047859|NCT00616200|Experimental|A|
3047860|NCT00616239|Active Comparator|A|Subjects randomized to have the right side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
3047861|NCT00616239|Active Comparator|B|Subjects randomized to have the left side of the face peeled with salicylic acid every 2 weeks for a total of 4 peels (first 2 at 20% and last 2 at 30%). Subjects will apply 4% hydroquinone cream to affected areas on entire face for 14 weeks.
3047862|NCT00616421|Experimental|MenACWY-CRM (1 dose)|1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.
3047863|NCT00616421|Active Comparator|Licensed polysaccharide vaccine|1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1
3047864|NCT00616421|Experimental|MenACWY-CRM (2 doses)|2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.
3047865|NCT00616434|Experimental|Interferon beta-1a|Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks
3047866|NCT00616434|Placebo Comparator|Placebo|Placebo IM injection twice weekly for 12 weeks
3047867|NCT00616655|Active Comparator|1|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
3047868|NCT00616655|Active Comparator|2|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
3047869|NCT00616655|Placebo Comparator|3|Placebo total daily dose 0.9 mg
3047870|NCT00616772|Experimental|ABT-335 + Atorvastatin|ABT-335 (135 mg) and atorvastatin (up to 40 mg) once daily for 2 years.
3047871|NCT00616772|Placebo Comparator|Placebo + Atorvastatin|Placebo and atorvastatin (up to 40 mg) once daily for 2 years.
3047872|NCT00616902|Active Comparator|Paricalcitol Injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL given intravenously 3 times per week during dialysis
3047873|NCT00616902|Placebo Comparator|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
3047874|NCT00616928|Experimental|Influenza A (H5N1) 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047875|NCT00616928|Placebo Comparator|Placebo 18-64Y Group|Subjects aged 18-64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047876|NCT00616928|Experimental|Influenza A (H5N1) >64Y Group|Subjects aged > 64 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047877|NCT00616928|Placebo Comparator|Placebo >64Y Group|Subjects aged > 64 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047878|NCT00616928|Experimental|Influenza A (H5N1) Group|Pooled group of subjects aged >18 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047879|NCT00616928|Placebo Comparator|Placebo Group|Pooled group of subjects aged >18 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047880|NCT00616928|Experimental|Influenza A (H5N1) 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047881|NCT00616928|Placebo Comparator|Placebo 18-60Y Group|Subjects aged 18-60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047882|NCT00616928|Experimental|Influenza A (H5N1) >60Y Group|Subjects aged >60 years, who received 2 doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted vaccine formulations A. B, or C in approximately equal proportions, at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047883|NCT00616928|Placebo Comparator|Placebo >60Y Group|Subjects aged > 60 years, who received 2 doses of placebo at Days 0 and 21. The first dose was administered in the deltoid region of the non-dominant arm. The second dose was administered in the deltoid region of the dominant arm.
3047884|NCT00616941|Experimental|Cohort 1|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) once every 3 weeks for a total of 5 vaccinations.
3047885|NCT00616941|Experimental|Cohort 2|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 vegetable grade (VG) once every 3 weeks for a total of 5 vaccinations.
3047886|NCT00616941|Experimental|Cohort 3|Subjects received 4 synthetic peptides coded by the NY-ESO-1 gene (ie, NY-ESO-1 OLP4) in combination with Montanide ISA-51 VG and poly-ICLC once every 3 weeks for a total of 5 vaccinations.
3047887|NCT00616967|Active Comparator|Arm I|Patients receive carboplatin IV and paclitaxel albumin-stabilized nanoparticle formulation IV on day 1 and an oral placebo on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
3047888|NCT00616967|Experimental|Arm II|Patients receive carboplatin and paclitaxel albumin-stabilized nanoparticle formulation as in arm I and oral vorinostat on days 1-3. Treatment repeats weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.
3047889|NCT00617058|Experimental|1|metformin, 250mg-2000 mg/day, in BID to TID doses for 26 weeks. Open, flexibly adjusted.
3047890|NCT00617058|Experimental|2|Healthy lifestyle intervention. Additional meeting at each psychiatric visit to review weight changes, level of physical activity and healthy eating behaviors
3047891|NCT00617058|No Intervention|3|Self-selected patients will be followed at major timepoints to assess weight and related measures.
3047892|NCT00617084|Active Comparator|1. Resolute|Medtronic Endeavor Resolute
3047893|NCT00617084|Active Comparator|2. XIENCE V|Abbott Xience V
3047894|NCT00617097|Active Comparator|paracervical block with lidocaine|Subjects who receive pain control using paracervical block with lidocaine during first trimester surgical abortion
3047895|NCT00617097|Experimental|paracervical block with ketorolac and lidocaine|Subjects who receive pain control using paracervical block with ketorolac and lidocaine during first trimester surgical abortion
3047896|NCT00617123|Experimental|Vorapaxar|Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year
3047897|NCT00617123|Placebo Comparator|Placebo|Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year
3047898|NCT00617175|Experimental|Long NID|Programming a number of 30 out of 40 intervals to detect (NID)ventricular arrhythmia
3047899|NCT00617175|Active Comparator|Short NID|Programming a number of 18 out of 24 intervals to detect (NID)ventricular arrhythmia
3047900|NCT00617188|Experimental|Fulvestrant|Fulvestrant 500 milligrams (mg) Day 1; 250 mg Day 1, 29 and every 28 days thereafter.
3047901|NCT00617201|Experimental|1|Atomoxetine
3047902|NCT00617201|Placebo Comparator|2|Matched Placebo
3047903|NCT00617240|Experimental|1|metformin in doses from 250mg to 2000mg/day for 26 weeks
3047904|NCT00617240|Placebo Comparator|2|Matched placebo to metformin, doses between 250/0mg and 2000/0mg per day
3047905|NCT00617279|Active Comparator|GORE PROPATEN Vascular Graft:|
3047906|NCT00617279|Active Comparator|Disadvantaged Autologous Vein Graft|
3047907|NCT00617305|Experimental|Ambrisentan|Patients were assigned ambrisentan at open-label enrollment or randomization, and received at least one dose of ambrisentan plus an approved phosphodiesterase type-5 (PDE-5) inhibitor (PDE-5i; sildenafil or tadalafil).
3047908|NCT00617305|Active Comparator|Placebo|Patients were assigned placebo at randomization and received at least one dose of placebo plus an approved PDE-5i (sildenafil or tadalafil).
3047909|NCT00617344|Experimental|CYD Dengue Vaccine 5555 Formulation|Participants received 3 doses of CYD dengue vaccine (5555 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
3047910|NCT00617344|Experimental|CYD Dengue Vaccine 5553 Formulation|Participants received 3 doses of CYD dengue vaccine (5553 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
3047911|NCT00617344|Experimental|CYD Dengue Vaccine 4444 Formulation|Participants received 3 doses of CYD dengue vaccine (4444 formulation); one each at 0 (vaccination 1), 6 (vaccination 2), and 12 (vaccination 3) months.
3047912|NCT00617357|Experimental|1|Strattice Reconstructive Tissue Matrix
3047913|NCT00617396|Experimental|Quetiapine treatment group|All subjects will receive seroquel treatment for 8 weeks. Seroquel is the intervention.
3047914|NCT00617409|Active Comparator|Standard of Care|Arm A - Active Comparator: Observation (Standard of Care) + Second Line Chemotherapy
3047915|NCT00617409|Experimental|Ad.p53-DC Vaccines|Arm B - Experimental: Ad.p53-DC vaccines + Second Line Chemotherapy
3047916|NCT00617409|Experimental|Ad.p53-DC Vaccines + ATRA|Arm C - Experimental: Ad.p53-DC vaccines + All -trans Retinoic Acid (ATRA) + Second Line Chemotherapy
3047917|NCT00617461|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, 4 weeks treatment in either the first or second treatment period
3047918|NCT00617461|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, 4 weeks treatment in either the first or second treatment period
3047919|NCT00617539|Experimental|irinotecan and temozolomide|
3047920|NCT00617591|Experimental|Induction and Maintenance Therapy|"Induction Phase Followed by Maintenance Therapy.~Patients received lenalidomide 25 mg orally on days 1-21, dexamethasone 40 mg orally on days on 1-4, and Pegylated Liposomal Doxorubicin (PLD) 40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated). Cycles were repeated every 28 days.~At the best response (4-8 cycles of induction), patients could proceed with either high-dose therapy or maintenance with lenalidomide and dexamethasone at the tolerated doses on the same schedule until disease progression.~Dd-R: Lenalidomide (Revlimid®) combined with Pegylated Liposomal Doxorubicin (Doxil®) and Dexamethasone (Decadron®) as outlined in the Detailed Description."
3047921|NCT00617604|Placebo Comparator|Placebo|Participants received placebo administered intra-operatively as an intravenous (IV) bolus on Day 0, another IV bolus on Day 3 and weekly subcutaneous injections thereafter for 12 weeks. Participants also received tacrolimus, mycophenolate mofetil (MMF) and steroid treatment.
3047922|NCT00617604|Experimental|Alefacept|Participants received 7.5 mg alefacept administered intra-operatively as an IV bolus on Day 0, another 7.5 mg IV bolus on Day 3, and weekly subcutaneous injections of 15 mg alefacept thereafter for 12 weeks. Participants also received tacrolimus, MMF and steroid treatment.
3047923|NCT00617669|Active Comparator|Placebo + Docetaxel|placebo oral tablet once daily + docetaxel intravenous infusion every 3 weeks
3047924|NCT00617669|Experimental|ZD4054 + Docetaxel|ZD4054 10 mg oral tablet once daily + docetaxel intravenous infusion every 3 weeks
3047925|NCT00617708|Experimental|Arm I (erlotinib, gemcitabine, cixutumumab)|Patients receive erlotinib hydrochloride PO once daily on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3047926|NCT00617708|Active Comparator|Arm II (erlotinib, gemcitabine)|Patients receive erlotinib hydrochloride and gemcitabine hydrochloride as in arm I. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3047927|NCT00617734|Experimental|IMC-A12 (cixutumumab)|
3047928|NCT00617734|Experimental|IMC-A12 (cixutumumab) + cetuximab|
3047929|NCT00617773|Experimental|hu3S193|
3047930|NCT00617851|Experimental|Influenza virus vaccine (lot A)|Lot A of the investigational influenza virus vaccine
3047931|NCT00617851|Experimental|Influenza virus vaccine (lot B)|Lot B of the investigational influenza virus vaccine
3047932|NCT00617851|Experimental|Influenza virus vaccine (lot C)|Lot C of the investigational influenza virus vaccine
3047933|NCT00617851|Experimental|Influenza virus vaccine (pooled)|Pooled data of all three lots (Lot A, B and C) of the investigational influenza virus vaccine
3047934|NCT00617851|Active Comparator|Comparator influenza vaccine|A US licensed influenza virus vaccine
3047935|NCT00617890|Experimental|Group 1: 0.3 mg/kg|Participants received robatumumab 0.3 mg/kg intravenously (IV) as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 0.3 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
3178989|NCT00667966|Experimental|Vardenafil + Placebo|Subjects received single dose of 10 mg vardenafil followed by 20 mg vardenafil and then crossed over to 10 mg placebo followed by 20 mg placebo.
3047936|NCT00617890|Experimental|Group 1: 10 mg/kg|Participants who received robatumumab 10 mg/kg IV as a single dose on Day 1, followed by surgery on Day 10 to 14, and four weeks later, resumption of robatumumab 10 mg/kg on the same calendar day (± 3 days) once every 2 weeks until disease recurrence or up to 1 year of dosing. This group comprised participants with resectable osteosarcoma that relapsed within 6 months of prior definitive treatment (eg surgical metastasectomy) and having at least one prior chemotherapy regimen containing a platinum agent and doxorubicin.
3047937|NCT00617890|Experimental|Group 2: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with relapsed and unresectable osteosarcoma refractory to prior chemotherapy with a platinum- and doxorubicin-containing regimen.
3047938|NCT00617890|Experimental|Group 3: 10 mg/kg|Participants received robatumumab 10 mg/kg IV biweekly until disease recurrence or up to 1 year of dosing. This group comprised participants with Ewing sarcoma refractory to prior treatment with at least 3 of the following agents: ifosfamide, etoposide, cyclophosphamide, doxorubicin, or vincristine.
3047939|NCT00617903|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
3047940|NCT00617903|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
3047941|NCT00617929|Experimental|Conditioning for Graft Failure|Primary or secondary graft failure after hematopoietic stem cell transplantation defined as a > 50% loss of previously best donor chimerism or less than 25% donor chimerism beyond day +42 with pancytopenia and no evidence of relapse. Patients with any diagnosis, type of donor, hematopoietic cell graft or conditioning regimen should be considered for this study. Patients receive anti-thymocyte globulin, rituximab, and clofarabine.
3047942|NCT00617942|Experimental|Neo-adjuvant cohort 1|
3047943|NCT00617942|Experimental|Neo-adjuvant cohort 2|
3047944|NCT00617942|Experimental|Adjuvant cohort 1|
3047945|NCT00617942|Experimental|Adjuvant cohort 2|
3047946|NCT00617981|Experimental|1|ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
3047947|NCT00617981|Sham Comparator|2|Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
3047948|NCT00618072|Placebo Comparator|A: Study diet|EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of placebo metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day.
3047949|NCT00618072|Active Comparator|B: Study diet plus Metformin|"Metformin and Rosiglitazone Placebo~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of placebo rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
3047950|NCT00618072|Active Comparator|C: Study diet plus metformin and avandia|"Metformin and Rosiglitazone~EMPOWIR dietary intervention food exchange program; 40-45% carbohydrates, 35-40% protein, and 20% fat AND 4 week dosage escalation of metformin, 500 mg/day to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day added at weeks 3 and weeks 4 to a total dose of 4 mg/day."
3047951|NCT00618332|Active Comparator|1|2 weeks of treatment
3047952|NCT00618332|Placebo Comparator|2|2 weeks of treatment
3047953|NCT00618371|Experimental|Raltegravir intensification|Patients will be administered raltegravir 400 mg orally twice daily in addition to antiretroviral therapy
3047954|NCT00618410|Active Comparator|Carbon dioxide|nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
3047955|NCT00618410|Placebo Comparator|Placebo|nasal placebo administered 30 minutes prior to nasal challenge
3047956|NCT00618436|Active Comparator|Levetiracetam|Group 1 - The levetiracetam (Keppra®) group will receive a loading dose of 20 mg/kg IV over 15 minutes (rounded to the nearest 250mg) up to a maximum of 2000 mg, then started on maintenance dose (1000 mg, IV BID)as prophylaxis for 7 days.
3047957|NCT00618436|Active Comparator|Phenytoin|Group 2-The phenytoin group will receive a loading dose of 20 mg/kg IV to a maximum of 2000mg, then started on maintenance dose at 5 mg/kg/day (rounded to nearest 100mg dose, IV, divided into three doses a day) as prophylaxis for 7 days. Phenytoin levels are to be checked daily and dose adjusted as needed to maintain therapeutic levels of 10-20 µg/dL.
3047958|NCT00618449|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with 1 gm oral dose of Azithromycin; receive a second 1 gm oral dose of Azithromycin at Day 30; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
3047959|NCT00618449|Active Comparator|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); be treated at Day 30 with the WHO standard of care for trachoma - 1 gm oral dose of Azithromycin; be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60 and Day 360.
3047960|NCT00618514|Active Comparator|1|Bright Tip Laser Fiber - FDA-cleared study device
3047961|NCT00618514|Active Comparator|2|Standard bare tip Laser Fiber - Any commercially available laser device (the control)
3047962|NCT00618540|Experimental|Alemtuzumab|Patients administered with alemtuzumab, fludarabine phosphate, melphalan and donor stem cell transplantation in children with resistant Langerhans cell histiocytosis.
3047963|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/0.7 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047964|NCT00618618|Placebo Comparator|Placebo 0.2 mL/0.7 cm|Participants received placebo administered in 0.2 mL injections, 0.7 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047965|NCT00618618|Experimental|Deoxycholic Acid Injection 0.2 mL/1.0 cm|Participants received deoxycholic acid administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3178990|NCT00667966|Experimental|Placebo + Vardenafil|Subjects received single dose of 10 mg placebo followed by 20 mg placebo and then crossed over to 10 mg vardenafil followed by 20 mg vardenafil.
3047966|NCT00618618|Placebo Comparator|Placebo 0.2 mL/1.0 cm|Participants received placebo administered in 0.2 mL injections, 1.0 cm apart, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047967|NCT00618618|Experimental|Deoxycholic Acid Injection 0.4 mL/1.0 cm|Participants received deoxycholic acid administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047968|NCT00618618|Placebo Comparator|Placebo 0.4 mL/1.0 cm|Participants received placebo administered in 0.4 mL injections, 1.0 cm apart, up to 9.6 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047969|NCT00618722|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received 0.5% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (1 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047970|NCT00618722|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received 1.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (2 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047971|NCT00618722|Experimental|Deoxycholic acid Injection 4 mg/cm²|Participants received 2.0% deoxycholic acid administered in 0.2 mL injections, up to 4.8 mL (4 mg/cm²) per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047972|NCT00618722|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 4.8 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3047973|NCT00618748|Experimental|Pre-Olanzapine|Participants who received olanzapine 5-20 mg/day in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
3047974|NCT00618748|Experimental|Pre-Placebo|Participants who received placebo in acute phase of Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 24 weeks.
3047975|NCT00618748|Experimental|New Olanzapine|Participants who did not participate in Study HGMP (NCT#00510146), received olanzapine 5-20 mg/day, orally for 48 weeks.
3047976|NCT00618787|Active Comparator|Arm 1|
3047977|NCT00618787|Active Comparator|Arm 2|
3047978|NCT00618813|Experimental|Treatment (combination chemotherapy)|See Detailed Description
3047979|NCT00618826|Experimental|Treatment Period|Treatment will be administered once every 2 weeks. One cycle of therapy will consist of 14 days. Paclitaxel is administered first after appropriate premedications. Gemcitabine is administered second and Avastin is administered after chemotherapy, all given on day 1 of each cycle.
3047980|NCT00618839|Experimental|StrataGraft : cadaver allograft|All patients enrolled received StrataGraft skin tissue and an intrapatient control area treated with cadaver allograft in a split-wound design
3047981|NCT00618917|Experimental|Radiation + MnSOD PL + Paclitaxel + Carboplatin|MnSOD PL (0.3, 3, or 30 mg) + (Paclitaxel + Carboplatin (45mg/m^2)) + Radiation 1.9-2.1 Gy daily 5 times per week (4-6 hr after the first MnSOD PL dose). The total dose planned at 77.0 Gy with a range of 69-84Gy in 34-38 fractions over 7-8 weeks.
3047982|NCT00618956|Experimental|1|
3047983|NCT00618956|Placebo Comparator|2|
3047984|NCT00618982|Experimental|Sorafenib (Nexavar, BAY43-9006)|Intrapatient dose escalation of sorafenib from 400 mg orally twice daily (bid) for the first cycle, 600 mg bid for the second cycle and 800 mg bid until disease progression, unacceptable toxicity or withdrawal of consent. Dose reductions due to toxicities were allowed.
3047985|NCT00618995|Experimental|A|Arm A: ER niacin/laropiprant + Placebo to laropiprant
3047986|NCT00618995|Experimental|B|Arm B: ER niacin + Placebo to laropiprant
3047987|NCT00618995|Experimental|C|Arm C: laropiprant + Placebo to ER Niacin/laropiprant
3047988|NCT00618995|Placebo Comparator|D|Arm D: Placebo
3047989|NCT00619060|Experimental|Myristyl (right), Placebo (Left)|Participants apply topical myristyl nicotinate to the right forearm and topical placebo to the left forearm once daily for 4 weeks; Myristyl (Right), Placebo (Left) Topical Myristyl Nicotinate Cream and Placebo
3047990|NCT00619060|Experimental|Myristyl (Left), Placebo (Right)|Participants apply topical myristyl nicotinate to the left forearm and topical placebo to the right forearm once daily for 4 weeks; Myristyl (Left), Placebo (Right)Topical Myristyl Nicotinate Cream and Placebo
3047991|NCT00619073|Active Comparator|Clopidogrel + aspirin|The subjects will be randomized to clopidogrel 75 mg plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., clopidogrel) will then be discontinued and aspirin continued for another 43 days.
3047992|NCT00619073|Placebo Comparator|Placebo + aspirin|The subjects will be randomized to placebo plus aspirin 81 mg orally daily for 14 days. The study drug (i.e., placebo) will then be discontinued and aspirin continued for another 43 days.
3047993|NCT00619099|Experimental|1|
3047994|NCT00619099|Experimental|2|
3047995|NCT00619112|Experimental|Temozolomide|single arm trial; Patients treated with temozolomide at a dose of 150mg/m2 daily for seven consecutive days of every other week. One 28-day cycle will include treatment with temozolomide on days 1-7 and days 15-21 with no treatment on days 8-14
3047996|NCT00619190|Experimental|open aripipraprazole|Openly provided, flexibly dosed aripiprazole in doses from 1mg to 30mg
3047997|NCT00619190|No Intervention|no medication control|group of children whose parents do not want them to take medications for autism over the year following enrollment in the trial.
3047998|NCT00619229|Experimental|Alprostadil|Alprostadil
3047999|NCT00619229|Placebo Comparator|Placebo|Placebo
3048000|NCT00619255|Experimental|Intervention|Adolescent Trauma Support Program
3048001|NCT00619255|No Intervention|Control|Usual Care Control Condition
3048002|NCT00619307|Active Comparator|Transition with prophylactic ibuprofen|
3048003|NCT00619307|Active Comparator|Transition with PRN ibuprofen|
3048004|NCT00619359|Experimental|1|Arm 1: study medication
3048005|NCT00619359|Active Comparator|2|Arm 2: Active comparator
3048006|NCT00619385|Experimental|Proellex 100 mg|Proellex 100 mg daily for 7 days
3048007|NCT00619385|Experimental|Proellex 150 mg|Proellex 150 mg daily for 7 days
3048008|NCT00619385|Experimental|Proellex 200 mg|Proellex 200 mg daily for 7 days
3048009|NCT00619476|Placebo Comparator|Placebo|placebo
3048010|NCT00619476|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
3048011|NCT00619476|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
3048012|NCT00619476|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
3048013|NCT00619489|Experimental|Vedolizumab 2 mg/kg|Participants received vedolizumab, 2 mg/kg, intravenously (IV), on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
3048014|NCT00619489|Experimental|Vedolizumab 6 mg/kg|Participants received vedolizumab, 6 mg/kg, IV, on Days 1, 15 and 43, and thereafter once every 8 weeks for up to 78 weeks.
3048015|NCT00619502|Experimental|DTaP-IPV-Hep B-PRP~T Vaccine Group|Participants received a primary series of 3 vaccinations with DTaP-IPV-Hep B-PRP~T, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-HepB-PRP~T at 15 to 18 months of age in the present study
3048016|NCT00619502|Active Comparator|Pentaxim™ + Engerix B™ Vaccines Group|Participants received a primary series of 3 vaccinations with Pentaxim™ and Engerix B™ vaccines, with 1 dose each at 2, 3, and 4 months of age, in Study A3L10; they will receive a booster dose of DTaP-IPV-Hep B-PRP~T at 15 to 18 months of age in the present study.
3048017|NCT00619619|Experimental|A|
3048018|NCT00619645|Other|RIST for Heme malignancies|Busulfan 3.3 mg/kg over 3 hours on day -6 and day -5 Fludarabine 30 mg/m2 IV over 30 minutes on day -6 to day -2 followed by Transplant followed by Immunosuppressive/GVHD therapy
3048019|NCT00619684|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO on days 1-21. Courses repeat every 28 days for 2 years or longer in the absence of disease progression or unacceptable toxicity.
3048020|NCT00619723|Active Comparator|Citicoline|Participants will receive active medication throughout the study. Citicoline will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
3048021|NCT00619723|Placebo Comparator|Placebo|Participants will receive placebo identical in appearance to Citicoline throughout the study. Placebo will be given beginning at two capsules (500 mg/day) with an increase to four capsules (1000 mg/day) at week 2, six capsules (1500 mg/day) at week 4, and eight capsules (2000 mg/day) at week 6. Doses will be decreased, based on clinician judgment, due to side effects.
3048022|NCT00619801|Placebo Comparator|Placebo|
3048023|NCT00619801|Experimental|Levocetirizine|
3048024|NCT00619827|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3048025|NCT00619827|Placebo Comparator|Placebo|Placebo tablet
3048026|NCT00619866|Placebo Comparator|Placebo|Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
3048027|NCT00619866|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg QD for an additional 12 weeks.
3048028|NCT00619866|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
3048029|NCT00619892|Active Comparator|Quetiapine XR|Our target daily dose for quetiapine XR was 200 mg/day. The detailed quetiapine XR dosing guidelines were as follows: 50 mg 1 tab po at HS × 3 days, then, if 50 mg tolerated, increase to 50 mg 2 tabs at HS × 4 days; at the beginning of week 2, if the last dose was tolerated increase to 50 mg 3 tabs at HS × 3 days, then, if 150 mg tolerated, increase to 4 tabs at HS; at the beginning of week 3, if no efficacy & the 200 mg dose was well tolerated, increase to one 300 mg tab at HS-otherwise remain at 200 mg one tab at HS; at week 4 if still no improvement, & 300 mg was tolerable, increase to 200 mg tablet 2 at HS. From the beginning of week 5 to the end of the trial, quetiapine XR doses were held. We used quetiapine XR tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
3048030|NCT00619892|Placebo Comparator|Placebo|Subjects received identical-appearing placebo tablets provided by Astra Zeneca (50, 200, and 300 mg designations).
3048031|NCT00619918|Experimental|1|3% saline
3048032|NCT00619918|Placebo Comparator|2|Normal saline
3048033|NCT00619957|Placebo Comparator|1|Placebo tablet once a week for 2 years followed by once a week Risedronate for 2 years
3048034|NCT00619957|Experimental|Risedronate|35 mg risedronate tablet once a week for 2 years followed by open label 35 mg risedronate once a week for 2 years
3048035|NCT00619970|Active Comparator|Healthy Control|Healthy controls
3048036|NCT00619970|Active Comparator|Children receiving Rifaximin|2/3 Patients with CAP
3048037|NCT00619970|Placebo Comparator|Children receiving Placebo|1/3 patients with CAP
3048038|NCT00619983|Active Comparator|Donepezil|Donepezil 5 mg once per day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3048039|NCT00619983|Active Comparator|Duloxetine|Group 2: Will receive duloxetine 30 mg twice a day for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3048040|NCT00619983|Active Comparator|Donepezil + Duloxetine|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg for 12 weeks. Gabapentin will be titrated in all groups beginning at week 8.
3048041|NCT00619983|Placebo Comparator|Placebo|Group 4:Will receive placebo pills. Gabapentin will be titrated in all groups beginning at week 8.
3048042|NCT00620022|Experimental|Indacaterol 300 μg followed by placebo|Patients first received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received placebo delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048043|NCT00620022|Experimental|Placebo followed by indacaterol 300 μg|Patients first received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning for 3 weeks. After a 3-week washout period, patients received indacaterol 300 μg delivered od via a SDDPI in the morning for 3 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3178991|NCT00667979|Experimental|Arm 1|
3178992|NCT00667979|Placebo Comparator|Arm 2|
3178993|NCT00668005|Experimental|Arm 1|
3178994|NCT00668005|Placebo Comparator|Arm 2|
3048044|NCT00620035|Experimental|Radiopaque Etonogestrel Implant|"Radiopaque Etonogestrel Implant (drug) inserted with the Next Generation Applicator (NGA)~The Radiopaque Implant is a single rod contraceptive implant of 4 cm length and~2 mm in diameter which is placed at the inner side of the non-dominant upper-arm~about 8-10 cm above the medial epicondyle. The Radiopaque Implant contains~approximately 68 mg etonogestrel (ENG) dispersed in a matrix of ethylene vinyl acetate (EVA) copolymer and barium sulfate, surrounded by an EVA membrane. The barium-sulfate provides radio-opacity and allows detection by X-ray.~The ENG dose released from the implant amounts to about 60-70 mcg/day shortly after insertion and decreases to about 40 mcg/day at the start of the second year, and to about 25-30 mcg/day at the end of the third year."
3048045|NCT00620061|Experimental|All Participants|Lubiprostone: 24 mcg capsule twice daily (BID) for 36 weeks
3048046|NCT00620074|Experimental|combination 2|anidulafungin plus voriconazole
3048047|NCT00620074|Experimental|combination 1|anidulafungin plus voriconazole
3048048|NCT00620113|Placebo Comparator|Placebo|After an observation period of ~5 weeks, participants receive dose-matched placebo to odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 International Units (IU) vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3048049|NCT00620113|Experimental|Odanacatib 10 mg|After an observation period of ~5 weeks, participants receive 10 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3048050|NCT00620113|Experimental|Odanacatib 25 mg|After an observation period of ~5 weeks, participants receive 25 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3048051|NCT00620113|Placebo Comparator|Odanacatib 50 mg|After an observation period of ~5 weeks, participants receive 50 mg odanacatib once weekly for 52 weeks. Participants also receive weekly supplementation with open-label 5600 IU vitamin D3 and 500 mg of open-label daily calcium supplement (if calcium <1000 mg per day from dietary and other sources) throughout the observation and treatment periods.
3048052|NCT00620126|Experimental|Intervention|UC Home Automated Telemanagement
3048053|NCT00620126|Active Comparator|Control|Best Available Care
3048054|NCT00620191|Placebo Comparator|Matching Placebo|Placebo identical to metformin
3048055|NCT00620191|Experimental|Metformin|Metformin 1000 mg twice a day
3048056|NCT00620282|Experimental|Lira 1.8|Liraglutide 1.8 mg administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
3048057|NCT00620282|Placebo Comparator|Placebo|Placebo administered subcutaneously, once-daily, weeks 0-12 (100 uL/day, week 1; 200 uL/day, week 2; 300 uL/day, week 3-12)
3048058|NCT00620282|Active Comparator|Glimepiride|Glimepiride 4 mg administered orally, once-daily, open-label, weeks 0-12
3048059|NCT00620321|Experimental|LY2181308 sodium, idarubicin, cytarabine|
3048060|NCT00620373|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (20-mCi) Technetium (99mTc) sestamibi injection.
3048061|NCT00620464|Active Comparator|Radiopaque Implanon (ro imp)|The radiopaque rod (Radiopaque Implanon) is similar to the Implanon rod except for the addition of barium sulfate.
3048062|NCT00620464|Active Comparator|Implanon (imp)|"Implanon® (Org 32222) is a single rod contraceptive implant of 4 cm length and~2 mm in diameter. Implanon® contains approximately 68 mg etonogestrel (ENG) (Org 3236, 3-ketodesogestrel) dispersed in a matrix of ethylene vinyl acetate (EVA)copolymer, surrounded by an EVA membrane.~The ENG dose released by Implanon® amounts to about 60-70 μg/day shortly after~insertion and decreases to about 40 μg/day at the start of the second year, and to about 25-30 μg/day at the end of the third year."
3048063|NCT00620503|Experimental|Formulation A Fed|Single dose of Proellex 25 mg formulation A, fed
3048064|NCT00620503|Experimental|Formulation B Fed|Single dose of Proellex 25 mg formulation B, fed
3048065|NCT00620503|Experimental|Formulation B Fasted|Single dose of Proellex 25 mg formulation B, fasted
3048066|NCT00620542|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg distributed in 2-week run-in period
3048067|NCT00620542|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg distributed in 2-week run-in period
3048068|NCT00620542|Experimental|Rosuvastatin 40 mg|Rosuvastatin 40 mg distributed in core 2-year study
3048069|NCT00620542|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg distributed in core 2-year study
3048070|NCT00620555|Experimental|gabapentin|
3048071|NCT00620659|Experimental|1|Arm 1: Treatment period 1: MK0249; Treatment period 2: Placebo; Treatment period 3: modafinil
3048072|NCT00620659|Experimental|2|Arm 2: Treatment period 1: Placebo; Treatment period 2: modafinil; Treatment period 3: MK0249
3048073|NCT00620659|Experimental|3|Arm 3: Treatment period 1: modafinil; Treatment period 2: MK0249; Treatment period 3: Placebo
3048074|NCT00620659|Experimental|4|Arm 4: Treatment period 1: MK0249; Treatment period 2: modafinil; Treatment period 3: Placebo
3048075|NCT00620659|Experimental|5|Arm 5: Treatment period 1: Placebo; Treatment period 2: MK0249; Treatment period 3: modafinil
3048076|NCT00620659|Experimental|6|Arm 6: Treatment period 1: modafinil; Treatment period 2: Placebo; Treatment period 3: MK0249
3048077|NCT00620698||ALS patients|Patients with clinically established amyotrophic lateral sclerosis
3048078|NCT00620711|Experimental|1|Babies that meet criteria will be offered participation in feasibility trial, there are no other arms.
3048079|NCT00620750|Experimental|Extended release injectable naltrexone|
3048080|NCT00620763|Experimental|A|Dietary Intervention: High meat and high acid load diet followed by low meat and low acid load diet
3048081|NCT00620763|Experimental|B|Dietary Intervention: Low meat and low acid load diet followed by high meat and high acid load diet
3048082|NCT00620776|Experimental|Combined Treatment|Patients who receive combined cognitive behavioral therapy (CBT) plus medication (venlafaxine XR, flexibly dosed between 75-225 mg/day) treatment for GAD. CBT was once/week sessions for 12 weeks. Medication continued for the full 6 months.
3048083|NCT00620776|Active Comparator|Venlafaxine XR 75-225 mg alone|These patients receive only medication treatment for GAD. Patients take venlafaxine (flexibly dosed from 75-225 mg/day) as part of NCT00183274 and are assessed over a 6 month period. Medication continued for the full 6 months.
3048084|NCT00620815|Experimental|T/P-A|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Aflunov (A) on day 22
3048085|NCT00620815|Experimental|A/P-T|One dose of the Aflunov (A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by Tetravalent influenza vaccine (T) on day 22.
3048086|NCT00620815|Active Comparator|A/S-A|One dose of Aflunov (A) and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed Aflunov (A) on day 22.
3048087|NCT00620815|Experimental|T/P-A (V2 blood draw)|One dose of the tetravalent influenza vaccine (T) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by a blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
3048088|NCT00620815|Experimental|A/P-T (V2 blood draw)|One dose of the Aflunov(A) and concomitantly, but in a different arm, one dose of placebo (P) on day 1, followed by additional blood draw at visit 2 (V2) prior to the Tetravalent influenza vaccination (T) on day 22.
3048089|NCT00620815|Active Comparator|A/S-A (V2 blood draw)|One dose of Aflunov (A)and concomitantly, but in a different arm, one dose of licensed seasonal vaccine (S) on day 1, followed by an additional blood draw at visit 2 (V2) prior to Aflunov (A) vaccination on day 22.
3048090|NCT00620828|Placebo Comparator|Block Negative|Subjects receive intra-op saline injection per protocol
3048091|NCT00620828|Experimental|Block Positive|Subjects receive intra-op Ropivicaine 0.5% injection per protocol
3048092|NCT00620854|Experimental|rsCTA|Oral Tablet
3048093|NCT00620854|Experimental|rsCTB|Oral Tablet
3048094|NCT00620854|Active Comparator|Fortical|Nasal Spray
3048095|NCT00620945|Experimental|1|Treatment Group
3048096|NCT00621023|Experimental|1|Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid for MDS
3048097|NCT00621049|Experimental|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|
3048098|NCT00621049|Active Comparator|Docetaxel and Carboplatin|
3048099|NCT00621140|Experimental|linagliptin 5 mg|linagliptin 5 mg once daily
3048100|NCT00621140|Placebo Comparator|placebo|placebo matching linagliptin 5 mg tablets
3048101|NCT00621153|Active Comparator|1|Candesartan cilexetil 16mg monotherapy
3048102|NCT00621153|Experimental|2|Candesartan cilexetil 16mg/HCT combination therapy
3048103|NCT00621153|Active Comparator|3|candesartan cilexetil 32mg monotherapy
3048104|NCT00621153|Experimental|4|Candesartan Cilexetil 32 mg/HCT combination therapy
3048105|NCT00621179|Active Comparator|Group 1|Positive endometrial alpha v, beta 3 vitronectin expression. Standard controlled ovarian stimulation protocol followed by in vitro fertilization Intervention: No intervention
3048106|NCT00621179|Experimental|Group 2|Intervention: Positive endometrial alpha v beta 3 vitronectin expression, 3 months of leuprolide acetate in depot suspension administration prior to initiation of controlled ovarian stimulation followed by in vitro fertilization
3048107|NCT00621179|Experimental|Group 3|Negative endometrial alpha v, beta 3 vitronectin and administration of leuprolide acetate in depot suspension for 3 months prior to initiation of controlled ovarian stimulation
3048108|NCT00621179|Active Comparator|Group 4|Negative endometrial alpha v, beta 3 vitronectin expression and standard controlled ovarian stimulation protocol followed by in vitro fertilization. Intervention: No intervention
3048109|NCT00621192|Experimental|Meropenem|"These~Participants were subdivided into the following four groups based on Gestational Age (GA) and Postnatal Age (PNA):~Group 1: GA at birth below 32 weeks - PNA <2 weeks; Group 2: GA at birth below 32 weeks - PNA ≥2 weeks and <91 days; Group 3: GA at birth 32 weeks or older - PNA <2 weeks; Group 4: GA at birth 32 weeks or older - PNA ≥2 weeks and <91 days."
3048110|NCT00621244|Experimental|Arm 1, Group X|
3048111|NCT00621244|Experimental|Arm 1, Group Y|
3048112|NCT00621244|Experimental|Arm 2, Group X|
3048113|NCT00621244|Experimental|Arm 2, Group Y|Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.
3048114|NCT00621257|Active Comparator|Treatment A|2,000 IU/day of ergocalciferol orally for 6 weeks (control arm)
3048115|NCT00621257|Experimental|Treatment B|2,000 IU/day of cholecalciferol orally for 6 weeks
3048116|NCT00621257|Experimental|Treatment C|50,000 IU of ergocalciferol once a week orally for 6 weeks
3048117|NCT00621257|Active Comparator|Maintenance A|400 IU/day of ergocalciferol orally over 2 years (control arm)
3048118|NCT00621257|Experimental|Maintenance B|2,000 IU/day of ergocalciferol orally from November 1 to April 30, and 1,000 IU/day of ergocalciferol orally for the remainder of the year over 2 years
3048119|NCT00621296|Experimental|MP-424|
3048120|NCT00621309|Active Comparator|1|Subjects are given 300 mg / 7 days of rifampicin to induce CYP3A4. Midazolam clearance is measured on the 8th day.
3048121|NCT00621309|Active Comparator|2|Sulforaphane (SFN), a natural product derived from broccoli sprouts, is utilized as a putative inhibitor of ligand (Rifampin) activation of the Pregnane X-receptor. In this arm, both SFN (putative inhibitor of ligand binding to PXR) and Rifampin (strong activating ligand of PXR) are given together.
3048122|NCT00621309|Active Comparator|3|This arm involves the administration of Sulforaphane (SFN) alone, in the absence of the PXR ligand, rifampicin. The hypothesis is that SFN will have no effect on the expression of PXR-regulated genes. Alternatively, it is possible that SFN could inhibit as yet unidentified endogenous ligands to the PXR receptor, thereby causing down-regulations of genes regulated wholely or in part by PXR. SFN is administered as a broccoli sprout extract at a dose rate of 75 mg (~420 umoles) per day for 7 days.
3048123|NCT00621322|Placebo Comparator|Control Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the control GSK Biologicals' AS01B adjuvanted system, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3178995|NCT00668018|Experimental|Arm 1|
3178996|NCT00668031|Experimental|Arm 1|
3178997|NCT00668031|Placebo Comparator|Arm 2|
3178998|NCT00668044|Experimental|Arm 1|
3048124|NCT00621322|Active Comparator|GSK692342_F1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the non-adjuvanted GSK692342 vaccine formulation 1 (F1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3048125|NCT00621322|Experimental|GSK692342_F2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 2 (F2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3048126|NCT00621322|Experimental|GSK692342_F3 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 3, at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3048127|NCT00621322|Experimental|GSK692342_F4D1 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 1 (F4D1), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3048128|NCT00621322|Experimental|GSK692342_F4D2 Group|Healthy adults between and including 18 to 45 years of age at the time of first vaccination, who received 2 doses of the adjuvanted GSK692342 vaccine formulation 4 dosage 2 (F4D2), at Day 0, intramuscularly in the non-dominant arm and at Day 30, intramuscularly in the dominant arm.
3048129|NCT00621348|Active Comparator|Isotonic fluid group|Normal saline in 5% dextrose at standard maintenance rate
3048130|NCT00621348|Active Comparator|Fluid restriction group|Reduced volume (2/3 maintenance rate) of N/5 saline in 5% dextrose
3048131|NCT00621348|Active Comparator|Hypotonic fluid group|N/5 saline in 5% dextrose at standard maintenance rate
3048132|NCT00621504|Experimental|Ceftaroline fosamil for Injection|"Ceftaroline fosamil was administered in two consecutive 300-mg IV infusions over 30 minutes, every 12 hours (q12h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
3048133|NCT00621504|Active Comparator|IV Ceftriaxone|"Ceftriaxone was administered as a 1-g IV infusion over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h).~In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism."
3048134|NCT00621517|Experimental|1|Participants will receive 150MG Bupropion nightly.
3048135|NCT00621517|Placebo Comparator|2|Participants will receive matching placebo capsule nightly.
3048136|NCT00621530|Experimental|Ketorolac|ketorolac 2 mg ketorolac tromethamine opthalmic solution
3048137|NCT00621530|Placebo Comparator|Placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
3048138|NCT00621543|Experimental|Observation- All subjects|Women choosing intra-uterine contraception after medical abortion.
3048139|NCT00621621|Experimental|Freezor Catheter for AVNRT|Subjects with Atrio Ventricular Reentrant Tachycardia (AVNRT)will be treated with cryo (freezing) energy to ablate the slow pathway causing the arrythmia.
3048140|NCT00621621|Other|External Data Supporting the Study|This arm was taken from pier reviewed published reports that include adult subjects ablated with the Freezor catheter for AVNRT.
3048141|NCT00621686|Experimental|Sorafenib + Bevacizumab/Group A|"Patients receive oral sorafenib 400 mg (200 mg twice daily) days 1-5 and 8-12 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
3048142|NCT00621686|Experimental|Sorafenib + Bevacizumab /Group B|"Patients receive oral sorafenib 200 mg once daily on days 1-14 and 5 mg/kg bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days.~Patients undergo blood and plasma sample collection at baseline and then periodically during study treatment for translational research studies. Translational research studies include analysis of circulating endothelial cells and circulating endothelial progenitor cells by flow cytometry and measurement of angiogenic proteins in plasma by ELISA. DNA and buffy coat are extracted and collected from the blood samples for pharmacogenetic studies.~Quality of life is assessed at baseline, prior to every other treatment course, and at the end of treatment.~After completion of study treatment, patients are followed at 28-42 days, every 3 months for 5 years, and then annually for 10 years."
3048143|NCT00621751|Experimental|Carbamazepine|Carbamazepine 800 mg daily
3048144|NCT00621751|Placebo Comparator|Placebo|Placebo
3048145|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 1)|Participants aged 2 to 5 years at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
3048146|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 2)|Participants aged 2 to 5 years at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
3048147|NCT00621764|Experimental|JE-CV/Hepatitis A (Group 3)|Participants aged 12 to 24 months at enrollment; to receive Japanese encephalitis vaccine (Day 0) and Hepatitis A vaccine (Day 28)
3048148|NCT00621764|Experimental|Hepatitis A/JE-CV (Group 4)|Participants aged 12 to 24 months at enrollment; to receive Hepatitis A vaccine (Day 0) and Japanese encephalitis vaccine (Day 28)
3048149|NCT00621777|Active Comparator|Randomized Phase: Varenicline|Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
3048150|NCT00621777|Placebo Comparator|Randomized Phase: Placebo|
3048151|NCT00621842|Experimental|Open-Label Lamotrigine Treatment|
3048152|NCT00621855|Experimental|Dabigatran etexilate 50mg|twice daily dosing,
3048153|NCT00621855|Experimental|Dabigatran etexilate 75mg|twice daily dosing, patients with moderate renal impairment allocated 50mg bid
3048154|NCT00621855|Experimental|Dabigatran etexilate 110mg|twice daily dosing, patients with moderate renal impairment allocated 75mg bid
3048155|NCT00621855|Experimental|dabigatran etexilate 150mg|twice daily dosing, patients with moderate renal impairment allocated 110mg bid
3048156|NCT00621855|Placebo Comparator|placebo|matched placebo
3048157|NCT00621933||All Patients Receiving Cataract Surgery|All Patients Receiving Cataract Surgery
3048158|NCT00621946|Placebo Comparator|Placebo|Placebo Matching Escitalopram given orally daily (for a 12-week duration).
3048159|NCT00621946|Active Comparator|Escitalopram|Once daily oral administration (for a 12-week duration) of 10 mg escitalopram tablets with an increase to 20 mg in those with a less than 30% decrease in HAM-D scores at week 4.
3048160|NCT00621959|Placebo Comparator|Placebo|Matched placebo tablets once daily
3048161|NCT00621959|Experimental|LCTZ|5 mg levocetirizine dihydrochloride tablet
3048162|NCT00621985|Experimental|Experimental|Experimental therapy with nocturnal dexamethasone.
3048163|NCT00622180|Active Comparator|Daavlin Right vs. Excilite Left|Right hand treated with narrow-band UVB light and left hand treated with focal 308nm light.
3048164|NCT00622180|Active Comparator|Excilite Right vs. Daavlin Left|Right hand treated with focal 308-nm light and left hand treated with narrow-band UVB light
3048165|NCT00622284|Experimental|BI 1356 5mg, once daily|patient to receive a tablet containing 5mg BI 1356 plus one (two in US) inactive placebo capsule matching Glimepiride
3048166|NCT00622284|Active Comparator|Glimepiride|patient to receive 1mg or 2mg or 3mg (not in US) or 4mg Glimepiride capsule plus one inactive placebo tablet matching BI 1356 (plus one inactive placebo capsule in US)
3048167|NCT00622336|Experimental|Lenalidomide 25mg (CC-5013)|Oral 25mg daily on Days 1-21 every 28 days
3048168|NCT00622388|Experimental|Ofatumumab|8 weekly intra-venous (I.V.) infusions, 1 x 300mg and 7 x 1000mg
3048169|NCT00622401|Experimental|Group 1|Dendritic Cell/Tumor Fusion Vaccine Only
3048170|NCT00622401|Experimental|Group 2|Dendritic Cell/tumor fusion vaccine and low dose IL-12
3048171|NCT00622401|Experimental|Group 3|Dendritic Cell/tumor fusion vaccine and higher dose IL-12
3048172|NCT00622427|Experimental|Ramelteon then placebo|8 mg tablets every night for 2 weeks, then a 2 week washout,then crossover to placebo tablets for 2 weeks.
3048173|NCT00622427|Experimental|Placebo then Ramelteon|placebo tablets for every night for 2 weeks, then a 2 week washout, followed by 8 mg tablets every night for 2 weeks.
3048174|NCT00622440|Active Comparator|1|
3048175|NCT00622440|Placebo Comparator|2|
3048176|NCT00622466|Experimental|Sorfenib + Paclitaxel|Oral sorafenib tosylate twice daily on days 1-28 and paclitaxel IV over 1 hour on days 1, 8, and 15
3048177|NCT00622505|Experimental|Zoledronic acid|Participants received 4 milligrams (mg) or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes, every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine N-telopeptide of type 1 collagen (NTx) measurement (greater than or equal to [≥] 50 nanomoles per millimoles [nmol/mmol] creatinine or <50 nmol/mmol creatinine, respectively).
3048178|NCT00622518|Active Comparator|1|homeopathic ear drops in addition to standard care for otitis media
3048179|NCT00622518|No Intervention|2|No ear drops, standard care for otitis
3048180|NCT00622635|Experimental|Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048181|NCT00622635|Experimental|Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048182|NCT00622635|Experimental|Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048183|NCT00622635|Experimental|Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg|In treatment period 1, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received indacaterol 300 μg once daily for 14 days via SDDPI; and in treatment period 3, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI). There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3178999|NCT00668044|Experimental|Arm 2|
3048184|NCT00622635|Experimental|Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol|In treatment period 1, patients received indacaterol 300 μg once daily for 14 days via single-dose dry-powder inhaler (SDDPI); in treatment period 2, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); and in treatment period 3, patients received placebo to indacaterol once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048185|NCT00622635|Experimental|Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg|In treatment period 1, patients received salmeterol 50 μg twice daily for 14 days via multi-dose dry-powder inhaler (MDDPI); in treatment period 2, patients received placebo to indacaterol once daily for 14 days via single-dose dry-powder inhaler (SDDPI); and in treatment period 3, patients received indacaterol 300 μg once daily for 14 days via SDDPI. There was a washout period of 14 days between each treatment period. Indacaterol and placebo to indacaterol were administered double-blind; salmeterol was administered open-label. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048186|NCT00622700|Placebo Comparator|Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg|"Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally."
3048187|NCT00622700|Experimental|Teriflunomide 7 mg/7 mg|"Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally."
3048188|NCT00622700|Experimental|Teriflunomide 14 mg/14 mg|"Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally."
3048189|NCT00622726|Experimental|Bevacizumab for ROP|Intravitreal Bevacizumab Therapy is the Experimental Arm of this Study
3048190|NCT00622726|Active Comparator|Conventional Laser for ROP|Conventional Laser to the Peripheral Retina is the Control Arm of this Study
3048191|NCT00622739|Active Comparator|ziprasidone rapid dose|Rapid Dose Titration Group
3048192|NCT00622739|Active Comparator|ziprasidone slow dose|Slow Dose Titration Group
3048193|NCT00622869|Experimental|Everolimus + reduced tacrolimus|Low dose tacrolimus (tacrolimus reduced) + everolimus + corticosteroids.
3048194|NCT00622869|Experimental|Tacrolimus elimination|Low-dose tacrolimus (until Month 4, then tacrolimus eliminated) + everolimus + corticosteroids.
3048195|NCT00622869|Active Comparator|Tacrolimus control|Control dose tacrolimus + corticosteroids.
3048196|NCT00622895|Experimental|Treatment: allogeneic UCB after reduced intensity conditioning|Patients receive fludarabine phosphate IV on days -4, -3 and -2, cyclophosphamide IV over 1-2 hours on days -6, -5, 3, and 4, and undergo low-dose TBI on day -1. Patients receive hematopoietic cell transplantation on day 0.
3048197|NCT00622908|Experimental|ISV-403|ISV-403 0.6%
3048198|NCT00622908|Placebo Comparator|Vehicle|Vehicle of ISV-403
3048199|NCT00623012|Experimental|1|
3048200|NCT00623103|Experimental|Rivastigmine capsule|Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.
3048201|NCT00623103|Experimental|Rivastigmine patch|Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm^2 patch or the highest well tolerated dose was maintained until week 76.
3048202|NCT00623181|Experimental|Fluzone Intradermal First, Then Fluzone Intramuscular|
3048203|NCT00623181|Experimental|Fluzone Intramuscular First, Then Fluzone Intradermal|
3048204|NCT00623194|Experimental|insulin detemir|Insulin detemir up to twice daily plus insulin aspart at larger meals, doses are adjusted individually (treatment up to 104 weeks)
3048205|NCT00623233|Experimental|Gemcitabine + Bevacizumab|"Gemcitabine 2500 milligrams per square meter (mg/m^2) intravenous (IV) over 30 minutes given on Day 1 every 14 days (q 14 days) until disease progression (PD) or unacceptable toxicity.~Bevacizumab 10 milligrams per kilogram (mg/kg) initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
3048206|NCT00623363|Active Comparator|piclozotan|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of piclozotan administered at a plasma level of 30 ng/mL over 2 inpatient days.
3048207|NCT00623363|Placebo Comparator|0.9 % sodium chloride (normal saline)|Participants will be randomized to receive two 12-hour intravenous (IV) infusions of 0.9 % sodium chloride (normal saline) administered at a plasma level of 30 ng/mL over 2 inpatient days.
3048208|NCT00623428|Experimental|PEG-IFN alfa-2a + Ribavirin for 24 weeks|After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
3048209|NCT00623428|Active Comparator|PEG-IFN alfa-2a + Ribavirin for 48 weeks|After 24 weeks of treatment with PEG-IFN alfa-2a 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of HCV RNA at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA <15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, and continued treatment for another 24 weeks (for a total of 48 weeks of treatment). Participants were followed for an additional 24 weeks during the treatment-free follow-up period.
3048210|NCT00623467|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Participants were administered a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) bolus administration using a power injector via a peripheral vein (an antecubital vein was preferred). Gadobutrol was injected at a rate of 2 mL/second followed by a 20-mL 0.9% saline flush at the same rate.
3179000|NCT00668057|Experimental|Arm 1|
3179001|NCT00668057|Experimental|Arm 2|
3048211|NCT00623480|Experimental|Recombinant Factor VIII prophylaxis treatment|Participants received 25 IU/kg of Recombinant Factor VIII (Kogenate FS, BAY14-2222) intravenously (IV), 3 times per week. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) for patients exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
3048212|NCT00623480|Experimental|Recombinant Factor VIII on-demand treatment|Participants received Recombinant Factor VIII (Kogenate FS, BAY14-2222) IV for bleeds in accordance with package insert instructions and study physician recommendations.
3048213|NCT00623506|Active Comparator|1|Pregnenolone
3048214|NCT00623506|Placebo Comparator|2|Placebo
3048215|NCT00623545|Experimental|Exenatide|Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.
3048216|NCT00623597|Experimental|1|
3048217|NCT00623623|Experimental|Tenecteplase|Early tenecteplase, clopidogrel and enoxaparin followed by routine or rescue coronary intervention
3048218|NCT00623623|Other|primary PCI|Standard primary PCI
3048219|NCT00623636|Experimental|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks.
3048220|NCT00623636|Other|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks.
3048221|NCT00623714|Experimental|Arm 1|study medication + Pbo
3048222|NCT00623714|Experimental|Arm 2|Pbo + study medication
3048223|NCT00623727|Experimental|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight of BAY79-4980 1x/week plus 2 dummy injections/week (dummy = rFVIII (recombinant factor VIII)-FS (formulated with sucrose) excipient reconstituted in WFI (sterile water for injection))
3048224|NCT00623727|Active Comparator|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight of rFVIII-FS 3x/week (employing 1 percent POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine)-alone liposome (rFVIII-FS-POPC) as blinding agent used for first weekly injection and rFVIII-FS in WFI for 2nd and 3rd injection)
3048225|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-free patients|Participants who had not received corticosteroid therapy for at least 10 days before starting study drug received ipilimumab,10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
3048226|NCT00623766|Experimental|Ipilimumab, 10 mg/kg, IV in corticosteroid-dependent patients|Participants who were dependent on corticosteroid therapy received ipilimumab, 10 mg/kg, as a 90-minute intravenous (IV) infusion every 3 weeks (Weeks 1, 4, 7, and 10) during the Induction Phase. Those eligible (patients who did not discontinue due to toxicity, did not show progression at 24 weeks, and who remained clinically stable) for the Maintenance Phase continued to receive ipilimumab, 10 mg/kg IV, every 12 weeks, beginning at Week 24.
3048227|NCT00623805|Active Comparator|Bevacizumab+capecitabine+oxaliplatin|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
3048228|NCT00623805|Experimental|Bevacizumab(B)+capecitabine(C)+oxaliplatin followed by B+C|Participants received bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + oxaliplatin 130 mg/m^2 IV on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle for 6 cycles followed by bevacizumab 7.5 mg/kg intravenously (IV) on Day 1 of each 3-week cycle + capecitabine 1000 mg/m^2 orally twice a day on Days 1-14 of each 3-week cycle until disease progression.
3048229|NCT00623831|Experimental|Cohort 1|Subjects received MBV at a starting dose of 250 EU (dose level 1) twice weekly, with intrasubject dose escalations for each subsequent administration in the absence of a DLT until the desired pyrogenic effect was observed. The maximum possible dose to be investigated was 547,000 EU (dose level 8).
3048230|NCT00623831|Experimental|Cohort 2|Subjects received MBV twice weekly at the fixed dose (60,800 EU [dose level 6]) that was determined to be the pyrogenic dose level in Cohort 1.
3048231|NCT00623935|Experimental|Fludarabine plus Busulfan (CR)|Patients in CR will receive a reduced intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu2).
3048232|NCT00623935|Experimental|Fludarabine plus Busulfan (PR)|Patients in PR will receive a full intensity transplant regimen consisting of Fludarabine plus Busulfan (FluBu4).
3048233|NCT00624013|Placebo Comparator|Placebo|Placebo 50 mg up to 100 mg daily for 6 months
3048234|NCT00624013|Active Comparator|Sertraline (Zoloft)|Sertraline (Zoloft) 50 mg up to 100 mg daily for 6 months
3048235|NCT00624065|Experimental|carvedilol CR + lisinopril|
3048236|NCT00624065|Active Comparator|lisinopril + placebo|
3048237|NCT00624195|Experimental|CNS-targeted|"CNS-T will comprise two components: 1) initial selection of agents to optimize CNS penetration of the overall regimen; and 2) modification of the regimen if an interim pharmacokinetic (PK) assessment determines that plasma ARV exposure is not appropriate (overdosing, under dosing).~Possible regimens include combinations of these FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
3048238|NCT00624195|Active Comparator|non-CNS-targeted|"Subjects in the non-CNS-T (Comparison) arm will be randomized to receive a regimen (see list of FDA approved antiretrovirals listed below) designed to suppress plasma Viral Load, but not expected to have targeted CNS penetration.~Combinations of FDA approved antiretroviral agents: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
3048239|NCT00624221|Active Comparator|1|An Eye bank pre-cut the donor grafts used for the corneal transplant procedures.
3179002|NCT00668057|Experimental|Arm 3|
3048240|NCT00624221|Active Comparator|2|The surgeon dissected the donor grafts used for the transplant procedures.
3048241|NCT00624234|Experimental|NF-Tutoring Program 1|Tutoring Program I
3048242|NCT00624234|Experimental|NF-Tutoring Program 2|Tutoring Program II
3048243|NCT00624234|No Intervention|Typically Developing Readers|Control group
3048244|NCT00624234|Experimental|IRD-Tutoring Program 1|Tutoring Program I
3048245|NCT00624234|Experimental|IRD-Tutoring Program 2|Tutoring Program II
3048246|NCT00624234|No Intervention|Waitlist Control|Intervention Control Group (RD)
3048247|NCT00624286|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048248|NCT00624286|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3048249|NCT00624338|Experimental|Atacicept 75 mg|
3048250|NCT00624338|Experimental|Atacicept 150 mg|
3048251|NCT00624338|Placebo Comparator|Placebo|
3048252|NCT00624377||COPD patients|
3048253|NCT00624416|Other|Prednisolone and Isoproteronol Together|Beta-adrenergic agonists and corticosteroid
3048254|NCT00624442|Experimental|Cohort 1|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3048255|NCT00624442|Experimental|Cohort 2|4 treatment periods with a 2 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3048256|NCT00624442|Experimental|Cohort 3|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3048257|NCT00624442|Experimental|Cohort 4|4 treatment periods with a 24 hour infusion. The 4 treatment periods consist of 3 escalating dose levels of CK-1827452 and 1 placebo treatment randomized into the dose escalation sequence. Treatment periods occur at least 7 days apart.
3048258|NCT00624442|Experimental|Cohort 5|2 treatment periods with a 72 hour infusion. The 2 treatment periods are randomly assigned and consist of 1 dose level of CK-1827452 (with dose de-escalation possible depending on tolerability) and 1 placebo treatment. Treatment period 2 occurs at least 7 days after the conclusion of period 1.
3048259|NCT00624468|Experimental|Atacicept|
3048260|NCT00624468|Placebo Comparator|Placebo|
3048261|NCT00624520|Active Comparator|Cognitive Behavioral Stress Management|10 week program of Cognitive Behavioral Stress Management (CBSM) group sessions
3048262|NCT00624520|Active Comparator|Patient Education|10 week program of once weekly Patient Education group sessions
3048263|NCT00624559|Experimental|Celebrex; Low sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3048264|NCT00624559|Experimental|Celebrex, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a celebrex pill (100 mg twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3048265|NCT00624559|Placebo Comparator|Placebo, Low Sodium|Subject completes a normal sodium diet (3 days), a low salt diet (7 days), followed by a high salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3048266|NCT00624559|Placebo Comparator|Placebo, High Sodium|Subject completes a normal sodium diet (3 days), a high salt diet (7 days), followed by a low salt diet (7 days) while taking a placebo pill (twice a day for 17 day trial), randomized for trial order (drug versus placebo) and sodium diet order (low versus high sodium).
3048267|NCT00624585|Experimental|Dasatinib Dose Escalation|Patients will be started on dasatinib at a continuous oral daily dose of 100 mg per day. At 8 weeks, if the initial dose is well tolerated and patient has not achieved a partial response, the dose may be increased to 150 mg per day. All patients will be followed per protocol for a total core period of 16 weeks from the first dose. Responding patients will continue dasatinib treatment for up to 48 weeks in the absence of treatment failure, disease progression, limiting toxicity or death. Patients continuing after 48 weeks will be enrolled in a separate extension study for future follow up.
3048268|NCT00624780|Experimental|1|
3048269|NCT00624780|Active Comparator|2|
3048270|NCT00624780|Experimental|3|
3048271|NCT00624780|Placebo Comparator|4|
3048272|NCT00624806|Experimental|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers
3048273|NCT00624806|Active Comparator|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
3048274|NCT00624819|Experimental|Synflorix + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects primed with Synflorix vaccine in the 10PN-PD-DIT-001 (1105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Synflorix vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose of Synflorix vaccine at 12-18 months of age co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix) and/or against varicella (a single dose of Varilrix).
3179003|NCT00668057|Placebo Comparator|Arm 4|
3179004|NCT00668057|Placebo Comparator|Arm 5|
3179005|NCT00668057|Placebo Comparator|Arm 6|
3179006|NCT00668070|Experimental|ASP9831 Low Dose|
3048275|NCT00624819|Active Comparator|Prevenar + Infanrix + Havrix and/or Varilrix Group|This group consisted of subjects vaccinated with Prevenar vaccine in the 10PN-PD-DIT-001 (105553) and 007 (107046) studies. In 105553 study, subjects had been primed with 3 doses of Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In 107046 study, subjects had received a booster dose at 12-18 months of age of Prevenar vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 111347 study, subjects had received at Month 48 (4 years post Dose 1 in study 105553) one dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
3048276|NCT00624819|Experimental|Prevenar + Synflorix + Infanrix + Havrix and/or Varilrix|This group consisted of subjects vaccinated with Prevenar and Synflorix vaccines in the 10PN-PD-DIT-001 (105553) and 10PN-PD-DIT-007 (107046) studies. In 105553 study, subjects had been primed with 3 doses Prevenar vaccine at 2, 3 and 4 months of age co-administered with Infanrix related vaccines. In the 107046 study, subjects had received at 12-18 months of age a booster dose of Synflorix vaccine co-administered with Infanrix hexa vaccine. In this study, in the Year 4 (111347 study), subjects had received at Month 48 (4 years post Dose 1 in study 105553) one additional dose of Synflorix vaccine. In addition, subjects were also offered vaccination against hepatitis A (2 doses of Havrix and/or against varicella (a single dose of Varilrix).
3048277|NCT00624819|Experimental|Unprimed Group|"This group consisted of subjects between, and including, 64-68 months of age at the time of additional vaccination (primed subjects) or dose 1 (unprimed subjects), and for whom the investigator believed that their parents/guardians could and would comply with the requirements of the protocol. Subjects were not previously vaccinated with any pneumococcal vaccine and received 2 doses of Synflorix vaccine at 64-68 and 66-70 months of age (at Day 0 and Month 2).~The Unprimed Group was added only in Year 4 of the study."
3048278|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 30-300 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
3048279|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 700-2000 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 700- 2000 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
3048280|NCT00624832|Experimental|Xolair (Immunoglobulin E (IgE) = 301-699 IU/mL)|Patients with screening Immunoglobulin E (IgE) levels = 301- 699 IU/mL. Participants received subcutaneous injections of Xolair (Omalizumab) every 2 weeks; dosage dependent on IgE level and body weight.
3048281|NCT00624832|Placebo Comparator|Placebo|By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
3048282|NCT00624910|Experimental|1|A total of three 5 × 5-cm bupivacaine sponges implanted at specified layers in the wound prior to wound closure
3048283|NCT00624910|Placebo Comparator|2|A total of three 5 × 5-cm collagen sponges implanted at specified layers in the wound prior to wound closure
3048284|NCT00624910|No Intervention|3|The patient will recieve the standard of care, but no implant during surgery
3048285|NCT00624923|Experimental|1- Active Pharmacologic|Salsalate
3048286|NCT00624923|Placebo Comparator|2- Placebo|Placebo
3048287|NCT00625131|Active Comparator|Active Nicotine Patch Group|Transdermal nicotine patch
3048288|NCT00625131|Placebo Comparator|Placebo Patch Group|Transdermal placebo patch
3048289|NCT00625183|Experimental|Capecitabine, Oxaliplatin, Selenomethionine, Radiation Therapy|Oxaliplatin: 50 mg/m2 weekly x 5 Capecitabine 725 mg/m2BID on days of RT Selenomethionine: 4000mcg/m2 PO BID X 7 days prior to RT, then 4000mcg/m2 PO QD from first to last day of RT, including weekends
3048290|NCT00625365|Other|DEFINITY® (Perflutren Lipid Microsphere)|Patients who had undergone unenhanced echocardiography yielding suboptimal images and who were determined by the Principal Investigator to require DEFINITY-enhanced echocardiography
3048291|NCT00625391|Placebo Comparator|Placebo pill|24 weeks of placebo.
3048292|NCT00625391|Active Comparator|Green Tea Polyphenols (GTP)|24 weeks of green tea polyphenols
3048293|NCT00625391|Active Comparator|Placebo+Tai Chi (TC)|24 weeks of placebo plus Tai Chi exercise.
3048294|NCT00625391|Active Comparator|GTP+TC|24 weeks of green tea polyphenols plus Tai Chi exercise.
3048295|NCT00625404|Experimental|Truvada Arm|Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
3048296|NCT00625404|Placebo Comparator|Placebo Arm|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
3048297|NCT00625443|Experimental|Placebo (double-blind)|
3048298|NCT00625443|Experimental|Avatrombopag tablets (open-label)|
3048299|NCT00625443|Experimental|Avatrombopag tablets (double-blind)|
3048300|NCT00625729|Experimental|Treated Patients|Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with donor natural killer cells infusion, rituximab, aldesleukin and chemotherapy.
3048301|NCT00625807|Active Comparator|Program A - Relaxation Response (RR)|One of the 2 stress reduction courses
3048302|NCT00625807|Active Comparator|Program B - Mindfullness-based stress reduction (MBSR)|One of the 2 stress reduction courses
3048303|NCT00625820|Experimental|6R BH4|Subjects will receive 6R-BH4 400mg bid for 6 weeks, sequentially followed by 6R-BH4 plus Vitamin C 500mg bid for another 6 weeks. Patients will have scheduled visits at Weeks 0,3,6,9 and 12, with an exit-visit at week 16. Albuminuria will be assessed in 24-hour urine collections as well as early morning spot urine samples for albumin:creatinine ratio. Blood and urine will be tested for routine clinical laboratory tests, blood nitric oxide (NO), and also archived for later assays for special biomarkers. The primary outcome will be level of albuminuria as measured in a 24-hour urine collection at 6 and 12 weeks of therapy. Secondary outcomes will include urine albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), and blood pressure .
3179007|NCT00668070|Experimental|ASP9831 Higher Dose|
3048304|NCT00625846|Experimental|Cohort 1 (DTC)|Patients with differentiated thyroid cancer (DTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3048305|NCT00625846|Experimental|Cohort 2 (MTC)|Patients with medullary thyroid cancer (MTC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3048306|NCT00625846|Experimental|Cohort 3 (ATC)|Patients with anaplastic thyroid cancer (ATC) receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3048307|NCT00625846|Experimental|Expansion Cohort (DTC)|Patients with confirmed, differentiated thyroid cancer (DTC) who are thyroglobulin antibody negative receive 800 mg pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3048308|NCT00625872|Active Comparator|Treatment Group|Somatropin for 12 months
3048309|NCT00625872|Other|Control Group|In the first 6 months no intervention, afterwards Somatropin for 12 months
3048310|NCT00625989|Placebo Comparator|Diluent|Inhalation challenge preformed with diluent.
3048311|NCT00625989|Active Comparator|Allergen|Inhalation challenge preformed with allergen.
3048312|NCT00626028|Experimental|Nitric Oxide First, Oxygen Last|10 minute dose of Nitric Oxide (NO) at 80 ppm, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of 100% Oxygen on Day 1.
3048313|NCT00626028|Experimental|Oxygen First, Nitric Oxide Last|10 minute dose of 100% Oxygen, then 10 minute dose of NO plus Oxygen, then 10 minute washout, then 10 minute dose of NO at 80 ppm on Day 1.
3048314|NCT00626093|Other|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|Patients in the study who received a Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for it. It's a single arm study in which patients underwent defibrillation threshold (DFT) testing at implant and 6 months.
3048315|NCT00626197|Experimental|OCR 400 mg + SOC|Participants received Ocrelizumab 400 mg i.v. infusion on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
3048316|NCT00626197|Experimental|OCR 1000 mg + SOC|Participants received Ocrelizumab 1000 mg i.v. infusion on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks plus SOC regimen.
3048317|NCT00626197|Placebo Comparator|Placebo + SOC|Participants received placebo i.v. infusion on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks plus SOC regimen.
3048318|NCT00626210|Experimental|Modafinil|
3048319|NCT00626275|Experimental|ADL5859 -- 200 mg (Part A)|ADL5859: 200 milligrams (mg), capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
3048320|NCT00626275|Active Comparator|Naproxen -- 500 mg (Part A)|Naproxen: 500 mg, capsules, administered orally as a single dose during 1 of 3 Treatment Periods in Part A of the study
3048321|NCT00626275|Placebo Comparator|Placebo (Part A)|Matching placebo, capsules, administered orally, as a single dose during 1 of 3 Treatment Periods in Part A of the study
3048322|NCT00626275|Experimental|ADL5859 - 100 mg (Part B)|ADL5859: 100 mg, capsules, administered orally, twice daily (BID) for 2 weeks during Part B of the study
3048323|NCT00626275|Placebo Comparator|Placebo (Part B)|Matching placebo, capsules, administered orally, BID for 2 weeks during Part B of the study
3048324|NCT00626327|Experimental|MenACWY-CRM+ MMRV|
3048325|NCT00626327|Active Comparator|MMRV|
3048326|NCT00626327|Experimental|MenACWY-CRM|
3048327|NCT00626340|Active Comparator|MDD diagnosis and Estrogen treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen alone.
3048328|NCT00626340|Active Comparator|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
3048329|NCT00626340|Active Comparator|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
3048330|NCT00626340|Active Comparator|No depression and estrogen treatment|Non-depressed menopausal women between the ages of 40-70 receiving treatment with estrogen alone.
3048331|NCT00626366|Experimental|Nasal spray|This arm of the study will contain subjects who will spray 2-4 sprays of a nasal contrast solution in their nares. Following administration of the spray, the subjects will then have a Xoran mini-CAT scan of their sinuses.
3048332|NCT00626366|Experimental|Nasal drop|This arm will contain subjects who will place two drops of a nasal contrast solution in each nose. Following administration of the nasal contrast, the subjects will then have a Xoran miniCAT scan of their sinuses.
3048333|NCT00626392|Experimental|NER 500; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3048334|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3048335|NCT00626392|Experimental|NER 500; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 500 mg starting dose), daily during coadministration period (4 weeks)
3048336|NCT00626392|Experimental|NER 1000; ASA run-in, ASA coadmin|Aspirin (ASA) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3048337|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3048338|NCT00626392|Experimental|NER 1000; ASA Pbo run-in, ASA Pbo coadmin|Aspirin placebo (ASA Pbo) daily during run-in (1 week); ASA Pbo 30 min prior to niacin extended-release ([NER], 1000 mg starting dose), daily during coadministration period (4 weeks)
3048339|NCT00626405|Experimental|Arm I|Patients receive oral temozolomide on days 1-5 and bevacizumab IV over 30-90 minutes on days 1 and 15.
3048340|NCT00626405|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1.
3048341|NCT00626431|Experimental|Leuprolide acetate - Formulation A|Leuprolide acetate 45 mg, 6-month depot
3048342|NCT00626431|Experimental|Leuprolide acetate - Formulation B|Leuprolide acetate, 45 mg, 6-month depot
3048343|NCT00626522|Experimental|1|
3048344|NCT00626522|Experimental|2|
3048345|NCT00626522|Experimental|3|
3048346|NCT00626522|Placebo Comparator|4|
3048347|NCT00626522|Placebo Comparator|5|
3048348|NCT00626522|Placebo Comparator|6|
3048349|NCT00626548|Placebo Comparator|Placebo|Matching Placebo
3048350|NCT00626548|Experimental|ZD4054|ZD4054 (Zibotentan)
3048351|NCT00626574|Active Comparator|A|Group A will receive Procrit® intravenous injections (40,000U) once daily for 3 days (Study Days 1, 2, and 3). The first dose of Procrit® will be given within 36 hours of the initial SAH event / symptoms and immediately before the vascular clipping procedure.
3048352|NCT00626574|Placebo Comparator|B|Group B will receive Saline intravenous injections once daily for 3 days (Study Days 1, 2, and 3).
3048353|NCT00626626|Experimental|"Clofar, Cyclophos, Alemtuzumab"|"Phase 1: 1-3 patients will be treated in order to establish Cyclophosphamide and Clofarabine dose and to confirm reasonable safety and engraftment efficacy.~Drug - Clofarabine,Cyclophosphamide & Alemtuzumab - Clofar (30mg/m2) D -8 to -4; Cyclo (500mg/m2) D -8 & -7 & Alem (20mg over 2hrs)"
3048354|NCT00626626|Experimental|"Clofar, Cyclophos,Alemtuzumab(Ph II)"|"Phase II patients 4-9 will treat at the selected dose level of Clofarabine and Cyclophosphamide.~Drug - Clofarabine, Cyclophosphamide & Alemtuzumab Clofar (30mg/m2) D -8 to -4; Cyclo (1000mg/m2) D -8 & -7 & Alem (20mg)-pts."
3048355|NCT00626639|Placebo Comparator|Placebo|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of matching placebo. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of matching placebo after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
3048356|NCT00626639|Experimental|Palifermin|Three days before the start of radiotherapy (Day -3), participants received a single intravenous (IV) bolus injection of palifermin at 120 μg/kg. During radiotherapy (beginning on Day 1), participants received a weekly single IV bolus injection of palifermin at 120 μg/kg after the last radiation fraction of that week (usually on Fridays) until grade ≥3 oral mucositis occurred, or for a maximum 8 doses (completion of radiotherapy). Participants also received cisplatin 100 mg/m^2 on days 1, 22 and 43.
3048357|NCT00626743|Experimental|SK3530|Active Drug
3048358|NCT00626743|Placebo Comparator|Placebo|Tablet which has the same appearance and taste but doesn't contain active ingredient
3048359|NCT00626782|Experimental|A: Ranibizumab 0.5mg (0.05mL) injection|Ranibizumab 0.5mg (0.05mL) injection at end of trabeculectomy surgery. This intra-operative adjunct therapy was administered sub-conjunctivally 8-10mm posteriorly to the limbus as an antifibrotic agent.
3048360|NCT00626782|Active Comparator|B: Mitomycin C 0.4 mg/ml sponge|Mitomycin C 0.4 mg/ml soaked sponge applied to sclera (for up to 2 min) after flap is made during trabeculectomy surgery. This is the typical method used as an antifibrotic agent.
3048361|NCT00626795|Experimental|1|
3048362|NCT00626795|Experimental|2|
3048363|NCT00626795|Active Comparator|3|
3048364|NCT00626808||1|Children less than 24 months of age
3048365|NCT00626808||2|Children 24 to 59 months of age with a claim associated with a diagnosis of asthma
3048366|NCT00626808||3|Children 24 to 59 months of age without a claim associated with a diagnosis of asthma, but with dispensed medication for wheezing
3048367|NCT00626808||4|Children 24-59 months of age with immunosuppression
3048368|NCT00626821|Experimental|1|
3048369|NCT00626886|Experimental|1|Two, 5x5cm bupivacaine collagen sponges implanted during surgery
3048370|NCT00626886|Placebo Comparator|2|Placebo collagen sponge implanted during surgery
3048371|NCT00626912|Active Comparator|1|platinum coils
3048372|NCT00626912|Active Comparator|2|hydrogel coils
3048373|NCT00626925|Active Comparator|Total Topiramate Group|topiramate capsules beginning at 25 mg/day with gradual increase to a maximum of 200 mg orally)
3048374|NCT00626925|Placebo Comparator|Total Placebo Group|inactive placebo matched in appearance with topiramate capsules
3048375|NCT00627016|Experimental|Dexlansoprazole 30 mg QD|
3048376|NCT00627016|Placebo Comparator|Placebo|
3048377|NCT00627042|Experimental|Ramucirumab (IMC-1121B)|
3048378|NCT00627094|Experimental|Biatain Ibu|Biatain Ibu
3048379|NCT00627094|Active Comparator|Biatain|Biatain
3048380|NCT00627367|Experimental|Protocolized|"1mg IV hydromorphone followed by an additional 1mg at 15 minutes if the patient answer yes to the question, Do you want more pain medication?"
3048381|NCT00627367|Active Comparator|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clincian
3048382|NCT00627393|Experimental|1|Participants will receive granulocyte transfusions in addition to standard antimicrobial therapy
3048383|NCT00627393|Active Comparator|2|Participants will receive standard antimicrobial therapy alone
3048384|NCT00627393|Other|3|Participants will donate granulocytes after receiving a combination of two drugs, G-CSF and dexamethasone
3048385|NCT00627406|Experimental|A|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl)
3048386|NCT00627406|Active Comparator|B|More than 14 follicles with a diameter of > 11mm: triggering of ovulation with hCG (Pregnyl) 5.000 IU (s.c.)
3048387|NCT00627406|Experimental|C|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 0.5 mg GnRHa (Buserelin) (s.c.) + 1500 IU hCG (Pregnyl) (s.c.) at 35 hours and 1500 IU hCG (Pregnyl) (s.c.) 7 days after triggering of ovulation (OPU + 5)
3048388|NCT00627406|Active Comparator|D|14 or less follicles with a diameter of > 11mm: triggering of ovulation with 5000 IU hCG (Pregnyl) (s.c.)
3048389|NCT00627445|Experimental|BIAsp 50-50-30|Biphasic insulin aspart 50 administered before breakfast and lunch + biphasic insulin aspart 30 at dinner combined with metformin
3048390|NCT00627445|Active Comparator|BIAsp 30-30|Biphasic insulin aspart 30 administered before breakfast and dinner combined with metformin
3179008|NCT00668070|Placebo Comparator|Placebo|
3179009|NCT00668096|Placebo Comparator|Arm 2|
3048391|NCT00627458|Experimental|INFANRIX HEXA PF GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-free (PF) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3048392|NCT00627458|Experimental|INFANRIX HEXA PC GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the preservative-containing (PC) formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3048393|NCT00627458|Active Comparator|CONTROL GROUP|Healthy male and female subjects between, and including 16 and 20 months of age at the time of booster vaccination, who were given the licensed formulation of Infanrix Hexa™ in the primary vaccination study 106786, additionally received a single booster dose of Infanrix Hexa™ vaccine, administered intramuscularly into the anterolateral quadrant of the right thigh.
3048394|NCT00627497|Experimental|DIAM Group1|
3048395|NCT00627497|Active Comparator|Single-Level Posterior Decompression|
3048396|NCT00627497|Experimental|DIAM Group2|
3048397|NCT00627497|Active Comparator|Posterolateral Interbody Fusion|
3048398|NCT00627523|Experimental|Active|The active treatment arm
3048399|NCT00627523|Experimental|Control|Control
3048400|NCT00627679|Experimental|Treatment sequence: A, B, D, C|Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5
3048401|NCT00627679|Experimental|Treatment sequence: B, C, A, D|Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5
3048402|NCT00627679|Experimental|Treatment sequence: C, D, B, A|Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5
3048403|NCT00627679|Experimental|Treatment sequence: D, A, C, B|Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5
3048404|NCT00627705|Active Comparator|N-Acetyl Cysteine|active compound N-Acetyl Cysteine
3048405|NCT00627705|Placebo Comparator|Sugar pill|Placebo or sugar pill
3048406|NCT00627861|Experimental|Aliskiren and metoprolol succinate|
3048407|NCT00627926|Placebo Comparator|PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week|Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks.
3048408|NCT00627926|Experimental|Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
3048409|NCT00627926|Experimental|Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week|Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
3048410|NCT00627978|Experimental|Ixabepilone|Participants are treated with Ixabepilone.
3048411|NCT00627978|No Intervention|Control|
3048412|NCT00628030|Experimental|NOURISH|The first 2 waves and second 2 waves of participants will receive a 12 and 6 week face-to-face intervention (NOURISH), respectively. The interventions differ only in duration. They cover the same concepts which are grounded in Social Cognitive Theory (SCT). Throughout the interventions the influence of social learning on behavioral outcomes (e.g., parent's modeling of healthy behavior) will be emphasized. Weekly topics provide information about implementing healthy lifestyle behaviors, authoritarian parenting approaches, and strategies for overcoming barriers to change. Parents will receive pedometers for themselves and 1 of their children. A one-hour booster session will be available for all intervention participants 2 months after completion of the interventions.
3048413|NCT00628030|Placebo Comparator|Wellness Group|The placebo control group will attend a group session moderated by an independent interventionist. This interventionist will be blinded to the Specific Aims and hypotheses of this study. The session will address the role of diet and exercise in pediatric overweight. In addition, control parents will receive pedometers (and instructions on their use) for themselves and 1 of their children. Finally, control participants will be mailed publicly available brochures on pediatric overweight on 2 occasions during the study. Control participants will also be sent home one additional packet of information (essentially a review of previous mail outs) 2 months after post-testing.
3048414|NCT00628108|Placebo Comparator|Placebo|
3048415|NCT00628108|Experimental|Levocetirizine|
3048416|NCT00628134|Experimental|1|Subjects inhaled calfactant then isotonic saline
3048417|NCT00628134|Experimental|2|Subjects inhaled isotonic saline then calfactant
3048418|NCT00628147|Experimental|Narrow band imaging colonoscope|narrow band imaging colonoscope
3048419|NCT00628147|No Intervention|White Light|Conventional White Light Examination
3048420|NCT00628212|Experimental|Teneligliptin 10 mg|Teneligliptin 10 mg, orally, once daily
3048421|NCT00628212|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
3048422|NCT00628212|Experimental|Teneligliptin 40 mg|Teneligliptin 40 mg, orally, once daily
3048423|NCT00628212|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
3048424|NCT00628251|Experimental|1|AZD2281 Oral 200 mg BID
3048425|NCT00628251|Active Comparator|2|Liposomal Doxorubicin
3048426|NCT00628251|Experimental|3|AZD2281 Oral 400 mg BID
3048427|NCT00628355|Experimental|lidocaine injection|"Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.~Patients received lidocaine injections once a week for 4 weeks"
3048428|NCT00628355|Experimental|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
3048429|NCT00628394|Other|Atomox/CR|Patients are given the drug Atomoxetine and Cognitive Remediation training.
3048430|NCT00628394|Other|Atomox/Control|Patients are given the drug Atomoxetine and Remediation Control training.
3048431|NCT00628394|Other|Placebo/CR|Patients are given a Placebo and Cognitive Remediation training.
3048432|NCT00628394|Other|Placebo/Control|Patients are given Placebo and Remediation Control training.
3048433|NCT00628498|Experimental|Defibrotide|Defibrotide 25 mg/kg day given in 4 divided doses approximately every 6 hours
3048434|NCT00628589|Experimental|Inhaled Loxapine 5 mg|Inhaled Loxapine 5 mg, may repeat x 1 or 2 after 2 hours
3048435|NCT00628589|Experimental|Inhaled Loxapine 10 mg|Inhaled Loxapine 10 mg, may repeat x 1 or 2 after 2 hours
3048436|NCT00628589|Placebo Comparator|Inhaled placebo|Inhaled Loxapine placebo, may repeat x 1 or 2 after 2 hours
3048437|NCT00628628|Experimental|Group A|As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
3048438|NCT00628628|Experimental|Group B|Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily
3048439|NCT00628758|Experimental|Symbicort|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
3048440|NCT00628758|Experimental|Conventional BP|Conventional Best Practice for Treatment of Asthma
3048441|NCT00628862|Experimental|F 4.5 bid|Formoterol 4.5 ug twice daily (bid)
3048442|NCT00628862|Experimental|F 9.0 bid|Formoterol 9.0 ug bid
3048443|NCT00628862|Placebo Comparator|PBO|Placebo
3048444|NCT00628901|Experimental|Arm 1|
3048445|NCT00628901|Active Comparator|Arm 2|
3048446|NCT00628927||METH and/or cocaine dependent group|The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment. This group will be analyzed based on whether or not they completed treatment as defined by the study.
3048447|NCT00628927||Non METH and/or cocaine dependent group|The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
3048448|NCT00629018|Experimental|SC Group|"SC therapy,'Bone Marrow Stimulation','CD34+ autologous stem cell transplantation':~In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect"
3048449|NCT00629018|No Intervention|Controls|Patients receiving no cell therapy.
3048450|NCT00629083|Experimental|1|Bulkamid Hydrogel injection
3048451|NCT00629083|Active Comparator|2|Contigen injection
3048452|NCT00629122|Experimental|A: Tacrolimus and Nystatin Suspension|"Administer sublingual tacrolimus 2 mg every 12 hours (subject weight < 90 kg) or 3 mg every 12 hours (subject weight > 90kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Nystatin suspension 5 mL every 12 hours (study days 1 - 3 and 6 - 8)."
3048453|NCT00629122|Experimental|B: Tacrolimus and Clotrimazole Troche|"Administer sublingual tacrolimus 1 mg every 12 hours (subject weight < 90 kg) or 2 mg every 12 hours (subject weight > 90 kg) (study day 1 - 3). Tacrolimus capsules will be opened and the contents placed under the participants tongue. Oral tacrolimus at same dose every 12 hours (study day 6 - 8). Tacrolimus capsules will be administered by mouth.~Clotrimazole troche 10 mg every 12 hours (study day 1 - 3 and 6 - 8)."
3048454|NCT00629239|Experimental|1|AZD4818
3048455|NCT00629239|Placebo Comparator|2|Placebo
3048456|NCT00629265|Active Comparator|Active NMES + Swallowing Exercise|Active Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
3048457|NCT00629265|Sham Comparator|Sham NMES + Swallowing Exercise|Sham (inactive) Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES) therapy will be paired concomitantly with repeated effortful sallowing exercises, for 60 swallows, 2 times per day, 6 days per week, for 12 weeks.
3048458|NCT00629499|Experimental|Intervention|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle) in combination with 600 mg/m2 of IV cyclophosphamide once every 3 weeks for 4 cycles (i.e., a total treatment period of 12 weeks [84 days]). Patients with fluorescence in situ hybridization (FISH) HER2+ or IHC3+ breast cancer will also receive treatment with trastuzumab in addition to the nab paclitaxel / cyclophosphamide combination therapy. Maintenance therapy with trastuzumab will continue (for the HER2+ patients who are receiving trastuzumab) after the 12-week treatment period with combination nab paclitaxel/cyclophosphamide/trastuzumab. The total treatment time for trastuzumab will be 52 weeks rather than only 12 weeks.
3179010|NCT00668096|Experimental|Arm 1|
3048459|NCT00629525|Experimental|RAD001|RAD001 at a dose of 10 mg PO daily
3048460|NCT00629707|Active Comparator|1|Slower infusion rate: Patients in this arm will receive an initial intravenous fluid bolus of 10cc/Kg followed by rehydration calculated to replace a deficit of 7.5% of body weight over 48 hours.
3048461|NCT00629707|Active Comparator|2|More rapid infusion: Patients in this arm will receive an initial bolus of 20 cc/Kg of intravenous fluids followed by replacement of an estimated deficit of 10% of body weight over 36 hours plus replacement of 1/2 of urine output volume.
3048462|NCT00629772|Placebo Comparator|Placebo then infliximab|Placebo at weeks 0, 2, 6 during the first intervention period and infliximab 5mg/kg at weeks 14, 16 and 20 during second intervention period.
3048463|NCT00629772|Active Comparator|Infliximab|Infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22.
3048464|NCT00630032|Active Comparator|Docetaxel|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of D (100 mg/m² every 3 weeks)
3048465|NCT00630032|Experimental|Ixabepilone|3 cycles of FEC100 (F and C, each at 500 mg/m², E 100 mg/m², every 3 weeks) followed by 3 cycles of Ixabepilone (40 mg/m² every 3 weeks);
3048466|NCT00630058|Experimental|Group A (MP-424 High)|
3048467|NCT00630058|Experimental|Group B (MP-424 Low)|
3048468|NCT00630253|Experimental|Marrow Isolex|bone marrow processed using Isolex 300i (for patients enrolled through April 2010)
3048469|NCT00630253|Experimental|UCB|No processing Notes: sibling donor UCB is used as the stem cell source and co-enroll for unlicensed UCB registry
3048470|NCT00630253|Experimental|Marrow Clinimax|bone marrow processed using CliniMACS (for patients enrolled beginning with the August 2010 protocol version)
3048471|NCT00630305|Other|Session A|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session A only contains senofilcon A toric and alphafilcon A toric lenses.
3048472|NCT00630305|Other|Session B|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session B only contains senofilcon A toric and alphafilcon A toric lenses.
3048473|NCT00630305|Other|Session C|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session C only contains senofilcon A toric and lotrafilcon B toric lenses.
3048474|NCT00630305|Other|Session D|Subjects were first randomized to a session and then randomized to receive one of four lens sequences for that session. Each subject participated in all four sessions. Session D only contains senofilcon A toric and lotrafilcon B toric lenses.
3048475|NCT00630331|Experimental|CCI|Subjects received one dose of cell culture-derived influenza vaccine.
3048476|NCT00630331|Experimental|IVV|Subjects received one dose of the trivalent egg-derived influenza vaccine.
3048477|NCT00630331|Placebo Comparator|Placebo|Subjects received one dose of phosphate buffered solution (PBS).
3048478|NCT00630344|Experimental|RAD001 + Bicalutamide|"RAD001: once daily dose of 10 mg (5 mg tablets)~Bicalutamide: once daily dose of 50 mg (50 mg tablets)~1 cycle=28 days~Both agents are administered continuously until progression of disease or unacceptable toxicity."
3048479|NCT00630409|Experimental|Treatment|Patients will receive 3 cycles of therapy as an outpatient. Each 21-day cycle of therapy will comprise: Gemcitabine: IV on days 1 and 8. Doxil: on day 1. Patients with either responding or stable disease will continue to receive additional 3 cycles of therapy with gemcitabine and Doxil until there is radiological evidence of disease progression or they are unable or unwilling to continue treatment.
3048480|NCT00630539|Placebo Comparator|Subjects on placebo|Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks
3048481|NCT00630539|Experimental|Subjects on ospemifene 5 mg/day|Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks
3048482|NCT00630539|Experimental|Subjects on ospemifene 15 mg/day|Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks
3048483|NCT00630539|Experimental|Subjects on ospemifene 30 mg/day|Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks
3048484|NCT00630734|Experimental|SLCO1B1 Group 1|Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3048485|NCT00630734|Experimental|SLCO1B1 Group 2|Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3048486|NCT00630734|Experimental|SLCO1B1 Group 3|Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.
3048487|NCT00630747|Experimental|Idursulfase|
3048488|NCT00630786|Experimental|Panitumumab plus conatumumab|Participants received 10 mg/kg conatumumab and 6 mg/kg panitumumab administered on the same day by sequential intravenous (IV) infusions once every 2 weeks until progressive disease, intolerability, withdrawal, or death.
3048489|NCT00630812|Experimental|A|active treatment
3048490|NCT00630812|Placebo Comparator|B|
3048491|NCT00630825|Experimental|1.0/2.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 2.0 mg, SC injection, QW for 12 weeks
3048492|NCT00630825|Experimental|1.0/1.0 milligram (mg) LY2189265|LY2189265: 1.0 mg, subcutaneous (SC) injection, once weekly (QW) for 16 weeks
3048493|NCT00630825|Experimental|0.5/1.0 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC) injection, once weekly (QW) for 4 weeks; followed by 1.0 mg, SC injection, QW for 12 weeks
3048494|NCT00630825|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) injection, once weekly (QW) for 16 weeks
3048495|NCT00630838|Experimental|1|VSL#3 probiotic
3179011|NCT00668109|Experimental|Arm 1|
3179012|NCT00668109|Active Comparator|Arm 2|
3179013|NCT00668122|Experimental|Arm 1|
3179014|NCT00668122|Experimental|Arm 2|
3179015|NCT00668135|Experimental|Arm 1|
3048496|NCT00630838|Placebo Comparator|2|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
3048497|NCT00630864|Experimental|1|Fx-1006A 20mg soft gelatin capsules once daily for 12 months
3048498|NCT00630877|Experimental|NER/ASA|
3048499|NCT00630877|Experimental|NER/ASA Placebo|
3048500|NCT00630877|Experimental|NER Placebo/ASA Placebo|
3048501|NCT00630916|No Intervention|A|
3048502|NCT00630955|Experimental|1|20 mg memantine
3048503|NCT00630955|Experimental|2|40 mg memantine
3048504|NCT00630955|Placebo Comparator|3|
3048505|NCT00631007|Experimental|INT131 besylate 0.5 mg|INT131 besylate 0.5 mg once-daily administration and matching placebo to pioglitazone HCl.
3048506|NCT00631007|Experimental|INT131 besylate 1 mg|INT131 besylate 1 mg once-daily administration and matching placebo to pioglitazone HCl
3048507|NCT00631007|Experimental|INT131 besylate 2 mg|INT131 besylate 2 mg administered once-daily and matching placebo to pioglitazone HCl
3048508|NCT00631007|Experimental|INT131 besylate 3 mg|INT131 besylate 3 mg administered once-daily and matching placebo to pioglitazone HCl
3048509|NCT00631007|Active Comparator|pioglitazone HCl 45 mg|pioglitazone HCl 45 mg administered once-daily and matching placebo to INT131 besylate
3048510|NCT00631007|Placebo Comparator|placebo|placebo administered once-daily, matching placebo to INT131 besylate and matching placebo to pioglitazone HCl
3048511|NCT00631020|Experimental|CBME +/- NRT|6 weeks CBME with optional 4 weeks NRT
3048512|NCT00631163|Experimental|Deferasirox|Participants received initial dose of 20 milligrams per kilogram (mg/kg) Deferasirox tablets was administered orally once daily (OD) based on the Participants body weight. The dose of Deferasirox was adjusted to either 10 mg/kg or 30 mg/kg based on the volumes of blood transfusions being administered.
3048513|NCT00631189|Active Comparator|1|Rosuvastatin and Pravastatin
3048514|NCT00631189|Active Comparator|2|Rosuvastatin and Atorvastatin
3048515|NCT00631319|Experimental|OROS Hydromorphone|OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg
3048516|NCT00631319|Placebo Comparator|Placebo|Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).
3048517|NCT00631358|Experimental|Maxidex|Maxidex
3048518|NCT00631358|Sham Comparator|No treatment|Healthy normal control group receiving no treatment
3048519|NCT00631371|Experimental|1|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Temsirolimus 25 mg IV weekly
3048520|NCT00631371|Active Comparator|2|Bevacizumab 10 mg/kg intravenous (IV) q8wks + Interferon-Alfa 9MU SC TIW
3048521|NCT00631410|Experimental|A|
3048522|NCT00631410|Experimental|B|
3048523|NCT00631449|Active Comparator|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
3048524|NCT00631449|Placebo Comparator|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
3048525|NCT00631475|Experimental|1|"For patients who were administered bosentan during BUILD 3 (NCT00391443):~Same dose will continue~For patients who were administered placebo during BUILD 3 (NCT00391443):~Initial dose: 62.5 mg for 4 weeks Maintenance dose: 125 mg"
3048526|NCT00631488|Experimental|MK-0893 + Sitagliptin|
3048527|NCT00631488|Experimental|MK-0893 + Metformin|
3048528|NCT00631488|Active Comparator|Sitagliptin + Metformin|
3048529|NCT00631540|Experimental|1|renal artery stenting
3048530|NCT00631566|Experimental|1|
3048531|NCT00631566|Placebo Comparator|2|
3048532|NCT00631566|No Intervention|No MRSA colonization|
3048533|NCT00631657|Experimental|Esmirtazapine 4.5 mg|Participants receive esmirtazapine 4.5 mg tablets, administered once a day for 6 months
3048534|NCT00631657|Placebo Comparator|Placebo|Participants receive placebo tablets, administered once a day for 6 months
3048535|NCT00631670|Experimental|Single Treatment Group|15 Gy dose in one stereotactic body radiation treatment
3048536|NCT00631670|Experimental|25 Treatments Group|25 treatments, given once a day, Monday through Friday for about five weeks; Dose: 70 Gy at 2.8 Gy/treatment
3048537|NCT00631696|Experimental|1|
3048538|NCT00631696|Placebo Comparator|2|
3048539|NCT00631748|Experimental|Study Drug|Subjects randomized to the experimental arm of the study will be initially administered 50mg/day quetiapine fumarate (Seroquel XR) to be titrated up to 400mg/day by the end of the second week. Subjects will be stabilized at a dose of 400mg/day or alternatively 300, 200, 100, or 50mg/day or quetiapine fumarate as tolerated. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
3048540|NCT00631748|Placebo Comparator|Placebo|Subjects randomized to the placebo arm of the study will follow the same titration and dosing procedure as the experimental arm but will receive matched placebo tablets. During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
3048541|NCT00631852|Experimental|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
3048542|NCT00631917|Experimental|Aliskiren|For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
3179016|NCT00668135|Placebo Comparator|Arm 2|
3179017|NCT00668161|Experimental|1|Exercise
3179018|NCT00668161|No Intervention|2|Control
3179019|NCT00668174|Experimental|1|Exercise
3048543|NCT00631917|Active Comparator|Ramipril|For the first 2 weeks of the study participants received 5 mg ramipril orally once a day and were then forced titrated to ramipril 10 mg once a day for 52 weeks. Participants also received placebo to aliskiren for the duration of the study.
3048544|NCT00631969|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3048545|NCT00631969|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3048546|NCT00632021|No Intervention|1|Patients will receive usual care at hospital discharge, which generally includes physician reconciliation of medications and a nurse-provided explanation of how to take medications at the time of discharge.
3048547|NCT00632021|Experimental|2|Participants will receive pharmacist-led medication reconciliation, pharmacist counseling prior to discharge, a follow-up telephone call 1-4 days after discharge, and additional telephone support as needed.
3048548|NCT00632099|Placebo Comparator|Placebo|matched placebo
3048549|NCT00632099|Experimental|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day)
3048550|NCT00632125|Experimental|HX575 epoetin alfa i.v.|This post-authorization safety study was designed as a multi-center, multinational, prospective, single-arm clinical study with a 6-month HX575 (recombinant human) erythropoietin alfa treatment period. It was planned to include approximately 1,500 patients.
3048551|NCT00632203|Experimental|Temozolomide treatment|Subjects will receive temozolomide at a dose of 75 mg/m^2 orally (PO) daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
3048552|NCT00632203|No Intervention|Observation|Observation
3048553|NCT00632229|Experimental|Paliperidone|Recieves study medication called paliperidone
3048554|NCT00632229|Placebo Comparator|Pill placebo|Placebo comparator
3048555|NCT00632359|Experimental|Lenalidomide|Lenalidomide 10 mg daily given for 12 months.
3048556|NCT00632411|Experimental|Proactive group|Research study staff will contact participant to initiate the program. Half of participants will be randomized to the proactive condition and the other half to the reactive conditions.
3048557|NCT00632411|Experimental|Reactive group|Participant will contact the research study staff to initiate the program.
3048558|NCT00632424|Experimental|1|
3048559|NCT00632463|Experimental|1|Dose regimen 1
3048560|NCT00632463|Experimental|2|Dose regimen 2
3048561|NCT00632463|Placebo Comparator|3|Placebo
3048562|NCT00632489|Experimental|LBH589 with Capecitabine|MTD, LBH589 with Capecitabine
3048563|NCT00632489|Experimental|LBH589 and Lapatinib|LBH589 and Lapatinib
3048564|NCT00632489|Experimental|LBH589, Capecitabine and Lapatinib|LBH589, Capecitabine and Lapatinib (Breast Cancer Patients)
3048565|NCT00632502|Experimental|Navarixin|Navarixin (MK-7123, SCH 527123) 30 mg capsule, to be taken by mouth once daily in the morning for 4 weeks
3048566|NCT00632502|Placebo Comparator|Placebo|Placebo capsule to match navarixin, to be taken by mouth once daily in the morning for 4 weeks
3048567|NCT00632541|Experimental|Single Arm A|Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle
3048568|NCT00632619|Active Comparator|1|Participants will receive stimulant medication therapy and referrals to community-based psychosocial treatments.
3048569|NCT00632619|Experimental|2|Participants will receive stimulant medication therapy and group-based behavior therapy.
3048570|NCT00632632|Experimental|D-Cycloserine (DCS)|
3048571|NCT00632632|Placebo Comparator|Placebo|
3048572|NCT00632736|Active Comparator|Ropinirole XL (formerly CR)|Ropinirole XL (formerly CR)
3048573|NCT00632749|Experimental|Schedule A|BI 811283 on days 1 and 15 in combination with Cytarabine 20 mg twice daily on Days 1-10
3048574|NCT00632749|Experimental|Schedule B|BI 811283 on Day 1 in combination with Cytarabine 20 mg twice daily on Days 1-10
3048575|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg qw|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week [qw] (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
3048576|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), biw (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week [biw] (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
3048577|NCT00632814|Experimental|rFVIII-FS (Kogenate FS, BAY14-2222), tiw (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week [tiw] (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for participants in this group
3048578|NCT00632827|Experimental|Treatment Plan|(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days (D) 1, 8, Navelbine 20 mg/m2 D1, D8; Doxil 15 mg/m2 Days 1 and 8, G-CSF Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion (CIVI), days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day -6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion D0 (7) Post-transplant: Denileukin Diftitox (Ontak) 18 mcg/kg/day days 1- 5
3048579|NCT00632931|Experimental|A|Arm A: Drug/Placebo
3048580|NCT00632931|Experimental|B|Arm B: Placebo/Drug
3048581|NCT00632970|Experimental|Raltegravir plus Truvada|Raltegravir (400mg), 1 tablet, administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
3048582|NCT00632970|Active Comparator|Lopinavir/Ritonavir plus Truvada|Lopinavir/Ritonavir (400mg/100mg) (Kaletra), 2 tablets administered twice daily (BID) and Truvada (Emtricitabine/Tenofovir disoproxil fumarate) (200mg/300mg), 1 tablet administered once daily (QD)
3048583|NCT00633009|Active Comparator|LtSTA 15 ug|Naive volunteers tested with 15 ug injection of LtSTA. Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin tests were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3048584|NCT00633009|Active Comparator|LtSTA 30 ug|Naive volunteers tested with 30 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3048585|NCT00633009|Active Comparator|LtSTA 50 ug|Naive volunteers tested with 50 ug injection of LtSTA.Participants were skin tested on visits 3, 6 and 9 of the study. The results of the skin testes were read after 48 hours (+/- 6 hours) on visits 4, 7 and 10. A final evaluation was performed on visit 11, fourteen days after visit 10.
3048586|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG TWICE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod orally twice daily, each morning and evening for a period of 12 weeks
3048587|NCT00633022|Placebo Comparator|Placebo|Participants received 1 tablet of placebo matching Losmapimod orally twice daily, each morning and evening for a period of 12 weeks.
3048588|NCT00633022|Experimental|LOSMAPIMOD 7.5 MG ONCE DAILY|Participants received 1 tablet of 7.5 mg Losmapimod each morning once daily and placebo tablet each evening once daily orally for a period of 12 weeks.
3048589|NCT00633074|Experimental|Thiomersal-free FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal-free FluAS25 adjuvanted vaccine
3048590|NCT00633074|Experimental|Thiomersal reduced FluAS25 adjuvanted vaccine group|Subjects received 1 dose of thiomersal reduced FluAS25 adjuvanted vaccine
3048591|NCT00633126|Experimental|A|ceftaroline
3048592|NCT00633139|Experimental|Cohort 1|Cohort 1: 50 U/kg Recombinant human Arylsulfatase A (rhASA)
3048593|NCT00633139|Experimental|Cohort 2|Cohort 2: 100 U/kg Recombinant human Arylsulfatase A (rhASA)
3048594|NCT00633139|Experimental|Cohort 3|Cohort 3: 200 U/kg Recombinant human Arylsulfatase A (rhASA)
3048595|NCT00633152|Experimental|Ceftaroline|Intramuscular every 12 hours
3048596|NCT00633152|Active Comparator|linezolid plus optional aztreonam|Intravenous every 12 hours
3048597|NCT00633217|Active Comparator|arm 1|
3048598|NCT00633217|Experimental|arm 2|
3048599|NCT00633243|Experimental|Modified Directly Observed Therapy (mDOT)|Hepatitis C Virus (HCV) Treatment in Modified Directly Observed Therapy (mDOT) in Methadone Maintenance Treatment (MMT)
3048600|NCT00633243|Active Comparator|Self-Administered Therapy at Liver Specialty Clinic (SAT)|Hepatitis C virus (HCV) at a liver specialty clinic as self-administered therapy
3048601|NCT00633256|Experimental|Cycloserine|50 mg cycloserine
3048602|NCT00633256|Sham Comparator|Placebo|Matched placebo
3048603|NCT00633360|Experimental|Drospirenone and ethinyl estradiol|
3048604|NCT00633360|Placebo Comparator|Placebo|
3048605|NCT00633399|Experimental|1|Patients in group 1 will receive Ziprasidone for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Ziprasidone for 12 months.
3048606|NCT00633399|Placebo Comparator|2|Patients in group 2 will receive Placebo for the full 8 weeks of Phase 2. If they are in remission following phase two, and decide to enter phase three, they will continue on Placebo for 12 months.
3048607|NCT00633464|Experimental|Arm A (ixabepilone 40 mg^2)|ixabepilone 40 mg/m^2 every 3 weeks
3048608|NCT00633464|Experimental|Arm B (cetuximab 250 mg/m^2 + ixabepilone 40 mg/m^2)|cetuximab 400 mg/m^2 loading dose then 250 mg/m^2 weekly + ixabepilone 40 mg/m^2 every 3 weeks
3048609|NCT00633477|Experimental|Resatorvid 2.4 mg/kg/day|
3048610|NCT00633477|Placebo Comparator|Placebo|
3048611|NCT00633594|Experimental|rituximab/bortezomib/lenalidomide|"Patients in Phase I & II to receive treatment with rituximab, bortezomib and lenalidomide in 21-day cycles up to 6 cycles.~Phase I: Cohorts of 3 patients will be enrolled at escalating dose levels to determine the maximum tolerated dose (MTD). Doses may be de-escalated if necessary.~Phase II: patients will be treated with the MTD determined in Phase I."
3048612|NCT00633750|Experimental|Tarceva|
3048613|NCT00633867|Active Comparator|Intubation c McGrath videolaryngoscope|Tracheal Intubation using McGrath video-laryngoscope
3048614|NCT00633867|Active Comparator|Intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
3048615|NCT00633880|Experimental|Droxidopa|Double-blind
3048616|NCT00633880|Placebo Comparator|Placebo|Double-blind
3048617|NCT00633893|Experimental|1|2.5 mg
3048618|NCT00633893|Experimental|2|5.0 mg
3048619|NCT00633893|Active Comparator|3|0 mg
3048620|NCT00633919|Active Comparator|Active|SLITone Dermatophagoides Mix
3048621|NCT00633919|Placebo Comparator|Placebo|SLITone Placebo
3048622|NCT00633932|Experimental|1|Esomeprazole 20mg
3048623|NCT00633932|Experimental|2|Esomeprazole 40mg
3048624|NCT00633932|Active Comparator|3|Omeprazole 20mg
3048625|NCT00633945|Experimental|Lenalidomide|Open label lenalidomide received.
3048626|NCT00633945|Experimental|Lenalidomide 2|Open label lenalidomide received.
3048627|NCT00633984|Active Comparator|Cognitive Behavioral Group Therapy + D-Cycloserine|Participants received Cognitive Behavioral Group Therapy and 50mg D-Cycloserine.
3048628|NCT00633984|Placebo Comparator|Cognitive Behavioral Group Therapy + Placebo|Participants received Cognitive Behavioral Group Therapy and 50mg Placebo.
3048629|NCT00634036|Active Comparator|1|
3048630|NCT00634036|Placebo Comparator|2|
3048631|NCT00634049|Experimental|Isavuconazole|Administration of isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days followed by daily administration of isavuconazole (IV) or oral
3048632|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Dose Level 1
3048633|NCT00634088|Experimental|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Dose Level 2
3048634|NCT00634088|Experimental|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Dose Level 3
3048635|NCT00634088|Experimental|Ixabepilone + Lapatinib + Capecitabine|Triplet Combination
3048636|NCT00634101|Active Comparator|nefilcon A|Subjects randomized to this arm received the nelfilcon A lens throughout the entire duration of the study.
3048637|NCT00634101|Experimental|narafilcon A|Subjects randomized to this arm received the narafilcon A lens throughout the entire duration of the study.
3048638|NCT00634114|Experimental|1|Esomeprazole and Omeprazole
3048639|NCT00634114|Experimental|2|Esomeprazole
3048640|NCT00634166|Other|Historical Control|Treated within the last 5 years (if possible) with topical prophylactic therapies that did not include mafenide acetate or mafenide salt forms.
3048641|NCT00634166|Experimental|Prospective Patients/Active Drug|Prospective subjects with thermal injuries of 20-60% TBSA on the chest, abdomen, or proximal upper and lower extremities requiring meshed autografts on these areas will receive SS5% as the initial topical moist dressing over the meshed autograft(s) placed at the initial graft procedure (Day 1).
3048642|NCT00634179|Experimental|Treatment (VR-CHOP regimen)|"INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression.~MAINTENANCE: Patients achieving complete response (CR) receive rituximab IV once every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or partial response (PR) receive rituximab IV and bortezomib once weekly for 4 weeks every 6 months for up to 2 years in the absence of disease progression or unacceptable toxicity."
3048643|NCT00634244|Experimental|Arm A (carboplatin and topotecan hydrochloride)|Patients receive carboplatin and topotecan hydrochloride IV continuously over 24 hours on days 1-5.
3048644|NCT00634244|Experimental|Arm B (alvocidib, mitoxantrone, cytarabine)|Patients receive alvocidib IV over 4.5 hours QD on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9.
3048645|NCT00634244|Experimental|Arm C (sirolimus, mitoxantrone, etoposide, cytarabine)|Patients receive sirolimus PO QD on days 2-9, mitoxantrone hydrochloride IV over 15 minutes QD, etoposide IV over 1 hour QD, and cytarabine IV over 3 hours QD on days 4-8 or 5-9. (Closed to accrual)
3048646|NCT00634270|Experimental|Sirolimus|"Design~Sirolimus oral solution will be administered orally BID on a continuous dosing schedule (28 days = 1 treatment course) with pharmacokinetically-guided dosing.~Disease status will be evaluated using volumetric MRI analysis at regular intervals.~The plasma pharmacokinetics and pharmacodynamics of sirolimus will be evaluated, as will pharmacogenetic polymorphisms and their influence on the metabolism of sirolimus in this patient population.~Pain reduction and quality of life outcomes will also be assessed.~Toxicity of chronic sirolimus administered will be evaluated using physical and laboratory evaluations."
3048647|NCT00634283|Experimental|antidepressant-experienced|Subjects who had previously been exposed to active antidepressant medication (venlafaxine)
3048648|NCT00634283|Placebo Comparator|antidepressant-naive|Subjects who had previously been exposed to placebo only (and never to active antidepressant medication)
3048649|NCT00634504|Experimental|A|High-dose methotrexate, leucovorin, and Voraxaze
3048650|NCT00634504|Active Comparator|B|High-dose methotrexate and leucovorin without Voraxaze (glucarpidase)
3048651|NCT00634543|Experimental|Tramadol hydrochloride (HCl)/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3, 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
3048652|NCT00634543|Active Comparator|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
3048653|NCT00634569|Experimental|Flebogamma 5% DIF|
3048654|NCT00634647|Experimental|Satraplatin|satraplatin - 80 mg/m^2 days 1-5 of every 35 day cycle prednisone - 5 mg twice daily every 35 days
3048655|NCT00634751|Experimental|Phase I: 200mg Sorafenib+2DOC|"Cohort 1: 200mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
3048656|NCT00634751|Experimental|Phase I: 400mg Sorafenib BID+2DOC|"Cohort 2: 400mg Sorafenib+2DOC~Oxaliplatin + Oral Capecitabine + Sorafenib"
3048657|NCT00634751|Experimental|Phase II: Pancreatic Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
3048658|NCT00634751|Experimental|Phase II: Biliary Tract Cancer|Oxaliplatin + Oral Capecitabine + Sorafeni
3048659|NCT00634803|Experimental|CBT for POD|Integrated cognitive behavioral therapy for chronic pain and opioid dependence
3048660|NCT00634803|Active Comparator|Educational Counseling for POD|Educational Counseling is a didactic, lecture-discussion format to supplement the information and advice provided by physicians in physician management (PM)
3048661|NCT00634803|Active Comparator|Physician Management|PM is a relatively brief intervention that approximates the medically focused advice and brief counseling about medical issues that is typically provided by physicians to patients with chronic pain or other chronic medical conditions, such as diabetes or asthma.
3048662|NCT00634842|Experimental|FPG 70-90 mg/dL|Aggressive FPG (fasting plasma glucose) titration target range group
3048663|NCT00634842|Experimental|FPG 80-110 mg/dL|Conventional FPG (fasting plasma glucose) titration target range group
3048664|NCT00634907|Experimental|Pharmacogenetic-based warfarin dosing|"Pharmacogenetic-based warfarin dosing: Warfarin dosing based on formula that incorporates genetic testing results.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
3048665|NCT00634907|Active Comparator|Standard of care (control)|"Control or usual care warfarin dosing~NOTE: Standard of care (usual care) for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm, as noted above."
3179020|NCT00668174|No Intervention|2|Control
3048666|NCT00634920|Experimental|Everolimus (CNI-free)|Patients in this group were converted to everolimus immunosuppressive therapy. The patients in the everolimus group were treated with everolimus, off-label (CNI-free) use, and EC-MPS and corticosteroids in accordance with local practice and approved label. Conversion to everolimus was as follows: Day 1: begin everolimus 3 mg in the evening. Usual morning dose of CsA and 50% reduced evening dose of CsA Day 2: everolimus 2 mg in the morning and 2 mg in the evening, complete discontinuation of CsA Day 3 or 4, and onwards: everolimus according to trough level 6-10 ng/mL.The given total daily dose of the immunosuppressive drugs (everolimus) was divided into two (equal) doses, applied 12 hours apart.
3048667|NCT00634920|Active Comparator|Control (CsA)|Patients in the control group continued on an immunosuppressive regimen. The patients in this Control group were treated with CsA, EC-MPS and corticosteroids in accordance with local practice and approved label. The given total daily dose of the immunosuppressive drugs (CsA and EC-MPS) was divided into two (equal) doses, applied 12 hours apart.
3048668|NCT00634933|Experimental|Arm 1|Consists of Arms 1a and 1b
3048669|NCT00634933|Experimental|Arm 2|Consists of Arms 2a and 2b
3048670|NCT00634933|Placebo Comparator|Arm 3|Consists of Arms 3a and 3b.
3048671|NCT00635024|Experimental|Anti-thymocyte Globulin/Melphalan|Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m^2)
3048672|NCT00635050|Experimental|Doxil, Paclitaxel, Cyclophosphamide + Avastin|Two stage phase II single arm trial to evaluate the pathologic complete response rate to sequential dose dense chemotherapy using Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, in patients with locally advanced invasive breast cancer.
3048673|NCT00635089|Other|Open-Label Reslizumab|Open-label reslizumab intravenous (IV) infusion at an initial dose of 1 mg/kg monthly
3048674|NCT00635102|Active Comparator|Alcohol dependent|Alcohol dependent patients will receive 4 interventions
3048675|NCT00635102|Active Comparator|Healthy subjects|Healthy subjects will receive 4 interventions
3048676|NCT00635128|Experimental|BOOSTRIX-POLIO GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™-Polio vaccine in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3048677|NCT00635128|Experimental|BOOSTRIX + IPV MÉRIEUX GROUP|Healthy male or female subjects aged 9 to 13 years, who were given a single booster dose of Boostrix™ and IPV Mérieux® vaccines in the dTpa-IPV-001 (711866/001) study, additionally received a single booster dose of the Boostrix™-Polio vaccine, administered intramuscularly in the deltoid region of the non-dominant arm.
3048678|NCT00635154|Experimental|Anakinra with/without Dexamethasone|"Anakinra was given alone for 6 months at which time response was assessed.~If participants achieved a minor response or better they continued on Anakinra alone until disease progression.~If participants achieved stable disease, they added low dose Dexamethasone to Anakinra until progression.~If at any time a participant progresses, they were administered high dose Dexamethasone with Anakinra."
3048679|NCT00635219|Placebo Comparator|Placebo|
3048680|NCT00635219|Experimental|Vortioxetine: 2.5 mg|
3048681|NCT00635219|Experimental|Vortioxetine: 5 mg|
3048682|NCT00635219|Experimental|Vortioxetine: 10 mg|
3048683|NCT00635219|Other|Duloxetine: 60 mg|Active reference
3048684|NCT00635232|Active Comparator|Irbesartan 300mg|Irbesartan 300 mg once daily
3048685|NCT00635232|Placebo Comparator|Placebo|Blinded Placebo Treatment
3048686|NCT00635232|Experimental|PS433540 200mg|PS433540 200mg once daily
3048687|NCT00635232|Experimental|PS433540 400mg|PS433540 400mg once daily
3048688|NCT00635232|Experimental|PS433540 800mg|PS433540 800mg once daily
3048689|NCT00635349|Active Comparator|Non-steroidal Anti-inflammatory Drug (NSAIDs)|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numeric rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of NSAIDs to receive either meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 29 to Day 85.
3048690|NCT00635349|Experimental|Tramadol Hydrochloride Plus Acetaminophen|Participants will receive fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with meloxicam (7.5 mg or 15 mg once daily) or aceclofenac (100 mg twice daily) from Day 1 to Day 28. Participants who will have the numerical rating scale score 4 or less on Day 29 will be randomly assigned to the treatment of fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
3048691|NCT00635362|Experimental|postplacental insertion after cesarean|"Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
3048692|NCT00635362|Active Comparator|delayed insertion group|"Insertion of the LNG-IUS 4-8 weeks after cesarean delivery~Device of intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)"
3048693|NCT00635427|Experimental|VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039)|"This arm is the Overall velaglucerase alfa (VPRIV) 60 U/kg and includes patients from the following groups:~VPRIV 45 U/kg or 60 U/kg, IV, EOW for 51 weeks in parent study TKT032 (NCT00430625) and switched to 60 U/kg in HGT-GCB-044 to maintain blindness or 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)"
3048694|NCT00635427|Experimental|VPRIV 60 U/kg (Parent study-imiglucerase(60 U/kg) HGT-GCB-039)|imiglucerase 60 U/kg, IV, EOW for 39 weeks in parent study HGT-GCB-039 (NCT00553631)and switched 60 U/kg VPRIV in HGT-GCB-044
3048695|NCT00635427|Experimental|VPRIV 15-60 U/kg (Parent study VPRIV (15-60 U/kg) TKT034)|VPRIV 15- 60 U/kg, IV, EOW for 51 weeks in parent study TKT034 (NCT00478647) and continued in HGT-GCB-044 at the same dose as prescribed in TKT034
3132888|NCT03463161|Experimental|Suboptimal Benefit Group|"Participants that have not benefited from prior treatment with immunotherapy. Defined as stable disease lasting at least 5 months or suboptimal response (11-49% shrinkage of tumors). Disease continues to be stable on most recent imaging.~Participants will receive Pembrolizumab and Epacadostat."
3048696|NCT00635453|Experimental|I, Intervention|"Physicians, nurses and administrative staff of all intervention health centers participated in a training of Dietary Advice in January 2008 based on the Ten Steps for Healthy Feeding for Brazilian Children from Birth to Two Years of Age guideline.13 An experienced nutritionist conducted a standardized session for the health care team to outline the Ten Steps recommendations and strategies and to provide suggestions how best to incorporate these into the consultations. Printed materials were provided to the Health Care Centers for use by these professionals and for access to the Brazilian Ministry of Healthy Nutrition Department´s website. Health staff members received a pocket guide for use during the appointments and waiting room sessions."
3048697|NCT00635453|No Intervention|II, Control|Healthcare centers randomized to the non-intervention group continued their routine medical assistance without any involvement of the research team. No materials were provided to these clinics.
3048698|NCT00635479|Experimental|VAC Device placement|will have the VAC device used for post-operative management of acetabular fractures and pelvic fractures.
3048699|NCT00635479|Active Comparator|Gauze dressing|will receive current traditional surgical wound management with daily dressing changes in post operative management of acetabular fractures and pelvic fractures.
3048700|NCT00635492||1|exenatide
3048701|NCT00635492||2|insulin
3048702|NCT00635570|Active Comparator|Contraceptive vaginal ring|Contraceptive vaginal ring (NuvaRing)
3048703|NCT00635570|Active Comparator|Oral contraceptive pill|Oral contraceptive pill (Ortho Tri-cyclen Lo)
3048704|NCT00635609|Experimental|Doxycycline hyclate (Doryx)|
3048705|NCT00635609|Active Comparator|Doxycycline hyclate|
3048706|NCT00635648|Experimental|Caspofungin 50 mg Intravenous (IV)|
3048707|NCT00635700|Experimental|1|
3048708|NCT00635700|Placebo Comparator|2|
3048709|NCT00635739|Active Comparator|A, 1|
3048710|NCT00635739|Placebo Comparator|A, 2|
3048711|NCT00635778|Experimental|dalotuzumab 2.5/2.5 mg/kg|Participants received a loading dose of dalotuzumab 2.5 mg/kg administered by intravenous (IV) infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 2.5 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048712|NCT00635778|Experimental|dalotuzumab 5.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 5.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048713|NCT00635778|Experimental|dalotuzumab 10.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 10.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048714|NCT00635778|Experimental|dalotuzumab 15.0/5.0mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048715|NCT00635778|Experimental|dalotuzumab 20.0/5.0 mg/kg|Participants received a loading dose of dalotuzumab 20.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 5.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048716|NCT00635778|Experimental|dalotuzumab 15.0/10.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 10.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048717|NCT00635778|Experimental|dalotuzumab 15.0/15.0 mg/kg|Participants received a loading dose of dalotuzumab 15.0 mg/kg administered by IV infusion. Two weeks following completion of the loading dose, participants received a maintenance dose of dalotuzumab 15.0 mg/kg administered by IV infusion every two weeks for up to 18 months.
3048718|NCT00635804|Experimental|Pt 1: MK-3281 100 mg BID (Panel A)|Healthy male participants in this Part I serial panel receive 100 mg MK-3281 orally twice daily (BID) for 10 consecutive days for a total daily dose administered of 200 mg. The evening (PM) dose of MK-3281 was not administered on Day 10.
3048719|NCT00635804|Experimental|Pt 1: MK-3281 200 mg BID (Panel B)|Healthy male participants in this Part I serial panel receive 200 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 400 mg. The PM dose of MK-3281 was not administered on Day 10.
3048720|NCT00635804|Experimental|Pt 1: MK-3281 400 mg BID (Panel C)|Healthy male participants in this Part I serial panel receive 400 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 800 mg. The PM dose of MK-3281 was not administered on Day 10.
3048721|NCT00635804|Experimental|Pt 1: MK-3281 800 mg BID (Panel D)|Healthy male participants in this Part I serial panel receive 800 mg MK-3281 orally BID for 10 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 10.
3048722|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel E)|Genotype (GT)1 HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
3048723|NCT00635804|Experimental|Pt 2: MK-3281 800 mg BID (Panel F)|GT1a/GT1-nontypeable/GT3/GT1b HCV-infected male participants in this Part II serial panel receive 800 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 1600 mg. The PM dose of MK-3281 was not administered on Day 7.
3048724|NCT00635804|Experimental|Pt 2: MK-3281 1200 mg BID (Panel G)|GT1a (and/or GT1 nontypeable) and GT1b HCV-infected male participants in this Part II serial panel receive 1200 mg MK-3281 orally BID for 7 consecutive days for a total daily dose administered of 2400 mg. The PM dose of MK-3281 was not administered on Day 7.
3048725|NCT00635804|Placebo Comparator|Placebo|Participants receive dose-matched placebo to MK-3281 orally BID for 7 or 10 consecutive days depending on randomization. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
3048726|NCT00635817|Experimental|Leuprolide acetate 11.25 mg|There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
3132889|NCT03463512|Experimental|Racecadotril plus standard treatment oral rehydration solution|
3048727|NCT00635817|Experimental|Leuprolide acetate 30 mg|There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
3048728|NCT00635830|Experimental|1|Open Label
3048729|NCT00635882|Experimental|MF/F MDI 100/10 mcg|
3048730|NCT00635882|Experimental|MF/F MDI 200/10 mcg|
3048731|NCT00635882|Experimental|MF/F MDI 400/10 mcg|
3048732|NCT00635882|Experimental|MF DPI 200 mcg|
3048733|NCT00635882|Experimental|MF MDI 200 mcg|
3048734|NCT00635882|Experimental|Placebo|
3048735|NCT00635999|Experimental|Purely Behavioral therapy|Participants will receive treatment with progressive and applied relaxation and self-control desensitization.
3048736|NCT00635999|Experimental|Cognitive-Behavioral Therapy|Participants will receive treatment with cognitive therapy, progressive and applied relaxation, and self-control desensitization
3048737|NCT00635999|Experimental|Cognitive Therapy (CT)|Participants will receive purely cognitive therapy including identification of maladaptive thought processes and training in cognitive restructuring.
3048738|NCT00636077|Other|HD-C4 Big|3 consecutive treatments with the HD-C4 Big dialyzer.
3048739|NCT00636077|Other|HD-C4 Small|3 consecutive treatments with the HD-C4 Small dialyzer.
3048740|NCT00636077|Other|F160NR|3 consecutive treatments with the F160NR dialyzer.
3048741|NCT00636077|Other|F200NR|3 consecutive treatments with the F200NR dialyzer.
3048742|NCT00636155|Experimental|all patients|EL625 combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide)
3048743|NCT00636168|Active Comparator|A|
3048744|NCT00636168|Placebo Comparator|B|
3048745|NCT00636181|Active Comparator|Auto Aflex|auto adjusting positive pressure therapy with AFLEX
3048746|NCT00636181|Active Comparator|Auto CPAP|auto adjusting positive pressure therapy
3048747|NCT00636181|Active Comparator|CPAP|continuous positive airway pressure
3048748|NCT00636194|Experimental|B&L Multipurpose solution|Bausch & Lomb Multipurpose Contact Lens Solution
3048749|NCT00636194|Active Comparator|Alcon Multipurpose Solution|Alcon OptiFree Replenish Multipurpose Contact Lens Solution
3048750|NCT00636207|Experimental|Montelukast 0.1 mg|"Participants receive Montelukast inhalation powder, 0.1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
3048751|NCT00636207|Experimental|Montelukast 0.3 mg|"Participants receive Montelukast inhalation powder, 0.3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period."
3048752|NCT00636207|Experimental|Montelukast 1 mg|"Participants receive Montelukast inhalation powder, 1 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered once daily (QD) for 5 days followed by at least a 3-day washout period."
3048753|NCT00636207|Experimental|Montelukast 3 mg|"Participants receive Montelukast inhalation powder, 3 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3048754|NCT00636207|Experimental|Montelukast 10 mg|"Participants receive Montelukast inhalation powder, 10 mg.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3048755|NCT00636207|Placebo Comparator|Placebo|"Participants receive Placebo to Montelukast inhalation powder.~Part I: Administered as a single dose followed by at least a 3-day washout period.~Part II: Administered QD for 5 days followed by at least a 3-day washout period.~Part III: Administered QD for 10 days followed by at least a 7-day washout period."
3048756|NCT00636220||A, Observational|
3048757|NCT00636363|Experimental|Multipurpose Solution - Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
3048758|NCT00636363|Experimental|Multipurpose Solution - No Rub Care|Bausch & Lomb Multipurpose Solution for use with contact lens care
3048759|NCT00636363|Active Comparator|Ciba Vision Aquify Multipurpose Solution|Ciba Vision Aquify Multipurpose Solution for use with contact lens care
3048760|NCT00636389|Other|HD-C4 First, then 210H|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux HD-C4 dialyzer. Following the third treatment, the subjects will be switched to the Polyflux 210H dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
3048761|NCT00636389|Other|210H First, then HD-C4|Subjects will be randomly assigned to begin the first week of three consecutive treatments with the Polyflux 210H dialyzer. Following the third treatment, the subjects will be switched to the Polyflux HD-C4 dialyzer for a second week of three consecutive treatments. Therefore each subject will have a total of six consecutive dialysis treatments.
3048762|NCT00636441|Active Comparator|Guided Arm|"Genomically-guided treatment allocation.~This arm has the following cohorts:~AC sensitive patients [>60% probability of response to AC]~TC sensitive patients [>60% probability of response to TC]~Patients sensitive to neither AC nor TC; randomized to AC or TC"
3048763|NCT00636441|Active Comparator|Non-Guided Arm|"Non-genomically-guided treatment allocation.~This arm has the following cohorts:~In patients randomly assigned to AC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC~In patients randomly assigned to TC:~Patients sensitive to AC~Patients sensitive to TC~Patients sensitive to neither AC nor TC"
3048764|NCT00636506|Experimental|AMS 700 IPP 2005 Implant Group|Male subjects 21 years of age and older who are implanted with an AMS 700 IPP with MS (Momentary Squeeze) pump for erectile dysfunction.
3048765|NCT00636610|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily starting on Day 3 of each 2-week treatment cycle. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
3132890|NCT03463512|Active Comparator|ORS (standard treatment)|
3048766|NCT00636610|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily starting on Day 3 of each 2-week treatment. In addition, patients received either Modified FOLFOX (FOL=leucovorin calcium [folinic acid], F=fluorouracil, OX=oxaliplatin) + bevacizumab or FOLFIRI (FOL=leucovorin calcium [folinic acid] F=fluorouracil, IRI=irinotecan hydrochloride) + bevacizumab on Days 1-3 of each 2-week treatment cycle. The decision of which regimen (FOLFOX or FOLFIRI) to use was made by the treating physician and patient.
3048767|NCT00636636|Experimental|G-ER|Gabapentin - Extended Release
3048768|NCT00636636|Placebo Comparator|Placebo|Sugar pill
3048769|NCT00636649|Experimental|A|Escitalopram
3048770|NCT00636649|Placebo Comparator|B|Placebo
3048771|NCT00636675|Experimental|Fall QI|Falls QI includes quality improvement training about falls to be implement by indigenous nursing home staff with support of study personnel.
3048772|NCT00636675|Experimental|Connect & Falls QI|Connect is delivered, followed by Falls. Behavioral intervention to improve staff interaction for better care planning and execution. Connect will be delivered, followed by the Falls quality improvement intervention.
3048773|NCT00636701|Experimental|Primed rTMS|Receive 10 min. of 6-Hz rTMS Repetitive Transcranial Magnetic Stimulation at 90% RMT (3,600 pulses). Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
3048774|NCT00636701|Placebo Comparator|Unprimed rTMS)|Receive 10 min. of sham rTMS Repetitive Transcranial Magnetic Stimulation. Followed by 30 min. of 1-Hz rTMS at 95% RMT (1,880 pulses)
3048775|NCT00636792|Experimental|1|This is a phase 2, single-arm, open label, multicenter study evaluating the efficacy and safety of the combination of VELCADE, bendamustine, and rituximab in subjects with relapsed or refractory follicular lymphoma, who have received 4 or more doses of rituximab. Subjects may be sensitive or refractory to prior therapies, including rituximab.
3048776|NCT00636805|Experimental|1|Patient receives IV Aloxi
3048777|NCT00636818|Experimental|Atomoxetine|
3048778|NCT00636961|Experimental|Sequence 1: Indacaterol 300μg followed by Placebo|In period I, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
3048779|NCT00636961|Experimental|Sequence 2 : Placebo followed by Indacaterol 300μg|In period I, matching placebo was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. In period II, indacaterol 300μg was taken by inhalation once daily via the Concept 1 inhaler device for 2 weeks. For each treatment period and for each patient, the doses were to be administered between 7am and 12am. A period of at least 4 days but no more than 21 days separated each treatment period. Rescue medication (short-acting beta-agonist (SABA)) was prescribed by the investigator for the duration of the study.
3048780|NCT00636987|Other|Implanted with Biocor or Biocor Supra Valves|
3048781|NCT00637000|Experimental|Buprenorphine soluble film|"Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours."
3048782|NCT00637000|Experimental|Buprenorphine/naloxone soluble film|"Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours."
3048783|NCT00637156|Experimental|PRESTIGE LP Device|
3048784|NCT00637156|Other|ATLANTIS Cervical Plate System|
3048785|NCT00637195|Experimental|Cervarix™ & Engerix™ Group|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) (Months 0, 1 & 6) and 4 doses of Hepatitis B (Engerix™) vaccine (Months 0, 1, 2 & 12).
3048786|NCT00637195|Active Comparator|Engerix™ Group|Subjects received 4 doses of Hepatitis B (HBV) vaccine (Months 0, 1, 2 & 12).
3048787|NCT00637247|Experimental|imexon + gemcitabine|imexon + gemcitabine
3048788|NCT00637247|Active Comparator|Placebo + gemcitabine|Placebo in combination with gemcitabine
3048789|NCT00637273|Experimental|1|
3048790|NCT00637273|Active Comparator|2|
3048791|NCT00637273|Active Comparator|3|
3048792|NCT00637299|Active Comparator|Active osteopathic treatment (OMT+PR)|The examination was performed by osteopathic practitioners with emphasis on the neuromusculoskeletal system including palpatory diagnosis for somatic dysfunction and viscerosomatic change, in the context of total patient care. The examination was concerned with range of motion of all parts of the body, performed with the patient in multiple positions to provide static and dynamic evaluation.
3048793|NCT00637299|Sham Comparator|SOT + PR|Sham osteopathic treatment (manipulation)
3048794|NCT00637377|Active Comparator|Ranibizumab 0.5mg Q4|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3048795|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3048796|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3048797|NCT00637377|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
3048798|NCT00637494|Active Comparator|1|Mifepristone followed by an antidepressant
3048799|NCT00637494|Placebo Comparator|2|Placebo followed by an antidepressant
3048800|NCT00637572|Experimental|Megestrol acetate oral suspension nanocrystal dispersion|Megestrol acetate oral suspension nanocrystal dispersion formulation 115 mg/mL
3048801|NCT00637572|Active Comparator|Megestrol acetate oral suspension micronized formulation|Megestrol acetate oral suspension micronized formulation 60 mg/mL
3048802|NCT00637780|Experimental|1|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 6 days
3048803|NCT00637923|Experimental|1|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
3048804|NCT00637923|Placebo Comparator|2|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
3048805|NCT00638014|Active Comparator|1|Conventional wires only
3048806|NCT00638014|Experimental|2|Rapid Sternal Closure System supplemented with wires
3048807|NCT00638027|Experimental|1|Memantine 10 mg bid
3048808|NCT00638027|Placebo Comparator|2|Placebo
3048809|NCT00638157|Active Comparator|Daptomycin Alone|daptomycin 6 mg/kg q24h for treatment of right-sided infective endocarditis
3048810|NCT00638157|Experimental|Daptomycin plus gentamicin|daptomycin 6 mg/kg q24h with concomitant initial gentamicin dosed for the first 2 days of therapy for the treatment of right-sided infective endocarditis
3048811|NCT00638235||Phase I (IntePro, US only)|AMS Apogee™ with IntePro(Began May 2006 - Closed)
3048812|NCT00638235||Phase I (InteXen LP, US only)|AMS Apogee™ with InteXen LP (Began May 2006 - Closed)
3048813|NCT00638235||Phase II (France only)|AMS Perigee™ with IntePro (Began February 2007 - Closed)
3048814|NCT00638235||Phase III/IV (Perigee IntePro Lite, US only)|AMS Perigee™ with IntePro Lite (Began April 2007 - Closed)
3048815|NCT00638235||Phase III/IV (Apogee IntePro Lite, US only)|AMS Apogee™ with IntePro Lite (Began April 2007 - Closed)
3048816|NCT00638235||Phase V (Elevate Posterior IntePro Lite, US & EU)|AMS Elevate™ Apical & Posteiror with IntePro Lite (Began April 2008 - Closed)
3048817|NCT00638235||Phase V (Elevate Posterior InteXen, US only)|AMS Elevate™ Apical & Posteiror with IntXen LP (Began April 2008 - Closed)
3048818|NCT00638235||Phase VI (Elevate Anterior Gen 1, For Study Use Only, EU only)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 1, For Study Use Only, Began October 2008 - Closed)
3048819|NCT00638235||Phase VII (Elevate Anterior Gen 2, US & EU)|AMS Elevate™ Anterior & Apical with IntePro Lite (Generation 2, Began April 2009 - Closed)
3048820|NCT00638274|Active Comparator|Air|Air 3 ml used to identify epidural space
3048821|NCT00638274|Active Comparator|Saline|Saline 3 ml used to identify epidural space
3048822|NCT00638365|Experimental|1|KB001, a monoclonal antibody
3048823|NCT00638365|Placebo Comparator|2|Placebo
3048824|NCT00638378|Experimental|Ruxolitinib|Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
3048825|NCT00638404||1|Elective Cesarean Sections-this portion completed
3048826|NCT00638404||3|Any in-patient gynecologic procedure- this portion completed
3048827|NCT00638443|Other|Pregabalin then Diphenhydramine|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days; no drug for 7 days; diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
3048828|NCT00638443|Other|Diphenhydramine then Pregabalin|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days; no drug for 7 days; pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
3048829|NCT00638456|Active Comparator|1|oral viscous budesonide plus Prevacid
3048830|NCT00638456|Placebo Comparator|2|placebo plus Prevacid
3048831|NCT00638508|Active Comparator|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
3048832|NCT00638508|Experimental|Ketorolac with Ropivacaine|Patients will receive Ketorolac 5 mg and Ropivacaine 0.5% (Group 2) via an infusion catheter at the incision site
3048833|NCT00638651|Active Comparator|1|The tattoo will be treated with laser and imiquimod 5% cream
3048834|NCT00638651|Placebo Comparator|2|The tattoo will be treated with laser and placebo topical cream
3048835|NCT00638690|Experimental|Abiraterone acetate plus prednisone/prednisolone|
3048836|NCT00638690|Placebo Comparator|Placebo plus prednisone/prednisolone|
3048837|NCT00638716|Experimental|1|12 weekly doses of 1.5 mg CJC-1134-PC
3048838|NCT00638716|Experimental|2|4 weekly doses of 1.5 mg CJC-1134-PC followed by 8 weekly doses of 2.0 mg CJC-1134-PC
3048839|NCT00638716|Placebo Comparator|3|12 weekly doses of placebo
3048840|NCT00638820|Experimental|Intent-To-Treat|Patients enrolled and received study treatment.
3048841|NCT00638846|Experimental|senofilcon A toric|senofilcon A, daily wear, toric contact lens worn for two weeks
3048842|NCT00638846|Active Comparator|balafilcon A toric|balafilcon A, daily wear, toric contact lens worn for two weeks
3048843|NCT00638885||Group 1|
3048844|NCT00638924||Exercise Capacity|Individuals from the female gender; age range of 20 to 30 years old; considered healthy (i.e. with no diagnosed health condition; considered sedentary (i.e. performing less than 150 minutes of moderate intensity physical activity per week); will be asked to volunteer in the research and perform a exercise capacity test.
3048845|NCT00638937|Experimental|Treatment (saracatinib)|Patients receive saracatinib PO, at a dose of 175 mg QD on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
3048846|NCT00638963|Experimental|Temozolomide|
3048847|NCT00638963|No Intervention|Observational|
3048848|NCT00638989|Experimental|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
3048849|NCT00638989|Experimental|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
3048850|NCT00638989|Experimental|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
3048851|NCT00639002|Experimental|Ruxolitinib then Ruxolitinib + Dexamethasone|Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
3048852|NCT00639093|Experimental|1|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
3048853|NCT00639093|Active Comparator|2|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
3048854|NCT00639158|Active Comparator|ABT-335 + atorvastatin + ezetimibe|
3048855|NCT00639158|Placebo Comparator|Placebo + atorvastatin + ezetimibe|
3048856|NCT00639223|Active Comparator|Pravastatin|
3048857|NCT00639223|Experimental|Red yeast Rice|
3048858|NCT00639379|Experimental|senofilcon A|senofilcon A toric daily wear contact lenses
3048859|NCT00639379|Active Comparator|alphafilcon A|alphafilcon A toric daily wear contact lenses
3048860|NCT00639418||Participants 6 to 23 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 6 to 23 months of age
3048861|NCT00639418||Participants 24 to 59 months|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 24 to 59 months of age
3048862|NCT00639418||Participants 5 to 8 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 5 to 8 years of age
3048863|NCT00639418||Participants 9 to 17 years|Pediatric influenza vaccine coverage within practicing pediatricians' offices for participants 9 to 17 years of age
3048864|NCT00639457|Experimental|Pioglitazone|Pioglitazone (Actos; 30mg/day) for 16 weeks.
3048865|NCT00639457|Active Comparator|Pioglitazone + Exercise training|Pioglitazone (Actos; 30mg/day) plus progressive aerobic and weight lifting exercise training (1.5hr/day x 3 days/wk)supervised and monitored by a personal exercise trainer.
3048866|NCT00639509|Experimental|Treatment (monoclonal antibody therapy)|Patients receive anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
3048867|NCT00639678|Experimental|1|
3048868|NCT00639678|Experimental|2|
3048869|NCT00639678|Placebo Comparator|3|
3048870|NCT00639678|Placebo Comparator|4|
3048871|NCT00639717|Experimental|Etanercept and ECP|"Etanercept and ECP (Extracorporeal Photopheresis) in addition to standard GVHD prevention:~Etanercept will be given twice weekly by subcutaneous injection starting on the day of HSCT (Hematopoietic stem cell transplantation) conditioning until 8 weeks post transplant. ECP treatments will begin at once weekly starting at 4 weeks post transplant and continue at less frequent intervals until 6 months post transplant.~GVHD prophylaxis will consist of a standard two drug regimen: mycophenolate for 4 weeks and tacrolimus (titrated to a therapeutic level) for 8 weeks, then weaned over 4 months with discontinuation by 6 months post-transplant."
3048872|NCT00639769|Experimental|Therapeutic Intervention|
3048873|NCT00639860|Experimental|Placing OSSIX-Plus in Extraction Site|Placement of OSSIX-Plus, a resorbable collagen membrane, and the promotion of bone healing following exodontia.
3048874|NCT00640016|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
3048875|NCT00640016|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram per kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
3048876|NCT00640016|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
3048877|NCT00640016|Experimental|CAT-354 10 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56
3048878|NCT00640042|Experimental|1|
3048879|NCT00640133|Active Comparator|Active DBS|Participants will receive deep brain stimulation.
3048880|NCT00640133|Sham Comparator|Sham DBS|Participants will receive sham deep brain stimulation for several months and then active deep brain stimulation thereafter.
3048881|NCT00640146|Experimental|MNTX|Participants will receive methylnaltrexone (MNTX) 12 milligrams (mg) subcutaneously (SC) once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
3048882|NCT00640146|Placebo Comparator|Placebo|Participants will receive placebo matching to MNTX SC once daily for up to 4 or 7 days, depending upon the protocol version under which each participant is enrolled.
3048883|NCT00640224|Active Comparator|Rosiglitazone|Treatment naive overweight adolescent females with PCOS treated with Rosiglitazone
3048884|NCT00640224|Active Comparator|Drospirenone/ethinyl estradiol|Treatment naive overweight adolescent females with PCOS treated with Drospirenone/ethinyl estradiol
3048885|NCT00640224|No Intervention|Overweight/Obese without PCOS|Overweight adolescent females without PCOS to use as comparison of normal developmental changes. *No participants were enrolled in this Arm.
3048886|NCT00640224|No Intervention|Lean without PCOS|Lean healthy girls without PCOS to serve as controls for the cardiovascular markers. *No participants were enrolled in this Arm.
3048887|NCT00640250|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to either Disperse Blue 106 or Bronopol. Subjects must otherwise be healthy and fulfill entry criteria.
3048888|NCT00640289|Experimental|A|Treatment
3048889|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 1.0 mg|Participants received two single oral doses of 1.0 mg riociguat on study day 1 and study day 3.
3048890|NCT00640315|Experimental|Riociguat (Adempas, BAY63-2521) 2.5 mg|Participants received two single oral doses of 2.5 mg riociguat on study day 1 and study day 3.
3048891|NCT00640328|Experimental|Cohort 1.1|100mg ofatumumab then placebo
3048892|NCT00640328|Experimental|Cohort 1.2|placebo then 100mg ofatumumab
3048893|NCT00640328|Experimental|Cohort 2.1|300mg ofatumumab then placebo
3048894|NCT00640328|Experimental|Cohort 2.2|placebo then 300mg ofatumumab
3048895|NCT00640328|Experimental|Cohort 3.1|700mg ofatumumab then placebo
3048896|NCT00640328|Experimental|Cohort 3.2|placebo then 700mg ofatumumab
3048897|NCT00640341|Experimental|PureVision|PureVision Contact Lens
3048898|NCT00640341|Active Comparator|Acuvue Oasys|Acuvue Oasys Contact Lens
3048899|NCT00640341|Active Comparator|O2Optix|O2Optix Contact Lens
3048900|NCT00640393|Active Comparator|Part 1 - Etanercept|All participants received etanercept 50 mg twice a week for 12 weeks.
3048901|NCT00640393|Active Comparator|Part 2 - Etanercept and nbUVB|Participants who did not reach a 90 percent reduction in psoriasis area and severity index (PASI-90) after 12 weeks and were randomized to the narrow band ultra violet B (nbUVB) group. They received nbUVB treatments three times a week and 50 mg Etanercept once per week.
3048902|NCT00640393|Active Comparator|Part 2 - Etanercept|Participants who did not reach PASI-90 after 12 weeks and were randomized to the Etanercept group. They received 50 mg Etanercept once per a week.
3048903|NCT00640510|Experimental|IM olanzapine 10mg|Patients will receive at least one injection of Intramuscular (IM) olanzapine 10mg. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
3048904|NCT00640510|Placebo Comparator|IM placebo|Patients will receive at least one injection of Intramuscular placebo. If patients do not respond to the study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
3048905|NCT00640562|Experimental|Quetiapine Extended Release|
3048906|NCT00640562|Active Comparator|Risperidone|
3048907|NCT00640614|Experimental|Sensitives|Subjects with a clinical history and positive patch test (current or previous) to any of the seven allergens. Subjects must otherwise be healthy and fulfill entry criteria.
3048908|NCT00640614|Experimental|Consecutives|Subjects who are being seen for standard allergy patch testing, that are asked to participate in the study.
3048909|NCT00640653|Experimental|Abstinence-only|Participants will receive the abstinence-only HIV/STD risk-reduction intervention.
3048910|NCT00640653|Experimental|Safer-sex only|Participants will receive the safer-sex-only HIV/STD risk-reduction intervention.
3048911|NCT00640653|Experimental|Comprehensive-long|Participants will receive the 12-h long comprehensive HIV/STD risk-reduction intervention.
3048912|NCT00640653|Experimental|Comprehensive-short|Participants will receive the 8-h short comprehensive HIV/STD risk-reduction intervention.
3048913|NCT00640653|Active Comparator|Health-promotion control|Participants will receive the health promotion control intervention.
3048914|NCT00640822|Experimental|Calcipotriol plus Hydrocortisone ointment|Calcipotriol plus Hydrocortisone ointment once daily for up to 8 weeks
3048915|NCT00640822|Active Comparator|Tacalcitol|Tacalcitol once daily for up to 8 weeks
3048916|NCT00640822|Placebo Comparator|Calcipotriol plus Hydrocortisone ointment vehicle|Calcipotriol plus Hydrocortisone ointment vehicle once daily for up to 8 weeks
3048917|NCT00640835|Experimental|Sublingual administration|Buprenorphine/naloxone film strip administered sublingually
3048918|NCT00640835|Experimental|Buccal administration|Buprenorphine/naloxone film strip administered buccally
3048919|NCT00640926|Experimental|1|Radezolid 300 mg
3048920|NCT00640926|Experimental|2|Radezolid 450 mg
3048921|NCT00640926|Experimental|3|Radezolid 450 mg BID
3048922|NCT00640978|Experimental|Erlotinib + RAD001|Erlotinib 150 mg orally daily for 28 Days + RAD001 (Everolimus) 30 mg orally weekly for 4 Weeks
3048923|NCT00641043|Experimental|BI 1356 (5 mg)|BI 1356 5mg in initial combination therapy with pioglitazone 30 mg
3048924|NCT00641043|Placebo Comparator|Placebo matching BI 1356 5 mg|Placebo in initial combination therapy with pioglitazone 30 mg
3048925|NCT00641056|Experimental|1|
3048926|NCT00641056|Active Comparator|2|
3048927|NCT00641147|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 12 months. Laboratory Biomarker Analysis
3048928|NCT00641147|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 12 months. Laboratory Biomarker Analysis
3179021|NCT00668187||Gangliosidosis Diseases Study Population|This study observes one cohort: 42 infantile or juvenile Tay-Sachs disease, Sandhoff disease, or GM1 gangliosidosis affected subjects; and 10 late-onset gangliosidosis disease affected subjects.
3179022|NCT00668239|Active Comparator|1|Laser treatment: laser was applied to the macular region according to the modified grid technique in inverted C, preserving 500 μ of the foveolus and avascular zone, with 100μ diameter shots, energy varying from 0.2 to 0.5 joules, with a time of exposure between 0.2 and 0.4 seconds. One hundred and fifty to 200 shots were applied according to the size of the retinal area². ND YAG laser (Crystal Focus (EMERED®) was used
3179023|NCT00668239|Experimental|2|triamcinolone as previously described
3179024|NCT00668252||1|Non menopausal women
3179025|NCT00668252||2|age matched men
3179026|NCT00668252||3|Menopausal women
3179027|NCT00668252||4|age matched men
3179028|NCT00668278|Active Comparator|A|Laryngeal Mask Airway insertion
3048937|NCT00641563|Active Comparator|Dex/Remi followed by Mida/Remi|Sedation with dexmedetomidine and remifentanil followed by sedation with midazolam and remifentanil separated by one week
3048938|NCT00641563|Active Comparator|Mida/Remi followed by Dexa/Remi|Sedation with midazolam and remifentanil followed by sedation with dexmedetomidine and remifentanil separated by one week
3048939|NCT00641641|Experimental|antiretroviral therapy|tenofovir (TDF) + emtricitabine (FTC) as a fixed dose combination administered orally once per day and raltegravir (RAL) administered orally twice per day.
3048940|NCT00641667|Experimental|Fentanyl|
3179029|NCT00668278|Active Comparator|B|I-gel insertion
3048941|NCT00641706|Experimental|Stratum 1 (not undergoing surgery)|Patients receive oral vorinostat (SAHA) once daily on days 1-14 and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3048942|NCT00641706|Experimental|Stratum 2 (undergoing surgery)|Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
3048943|NCT00641719|Experimental|Duloxetine 40 mg|Duloxetine 40 milligrams (mg) once daily (QD), orally (PO), 1 year
3048944|NCT00641719|Experimental|Duloxetine 60 mg|Duloxetine 60 mg QD, PO, 1 year
3048945|NCT00641745|Experimental|1|Lurasidone
3048946|NCT00641745|Active Comparator|2|Risperidone
3048947|NCT00641797|Active Comparator|Arm 1, Conventional Therapy|Patients will receive standard conventional medication therapy (i.e., meclizine, diphenhydramine, lorazepam, ondansetron).
3048948|NCT00641797|Experimental|Arm 2, Epley Maneuver|Patients will receive vestibular rehabilitation (the Epley Maneuver).
3048949|NCT00641862|Active Comparator|Vitamin B12|Vitamin B12
3048950|NCT00641862|Placebo Comparator|Placebo|Placebo
3048951|NCT00642018|Active Comparator|A: Docetaxel|Standard of care (SOC) docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel therapy
3048952|NCT00642018|Experimental|B: LY2181308 + Docetaxel|LY2181308 administered with docetaxel 75 mg/m² intravenously every 3 weeks and prednisone 5 mg orally twice daily continuously while receiving docetaxel
3048953|NCT00642174|Experimental|Prasugrel|Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.
3048954|NCT00642174|Active Comparator|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.
3048955|NCT00642278|Experimental|Canagliflozin 50 mg daily|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3048956|NCT00642278|Experimental|Canagliflozin 100 mg daily|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3048957|NCT00642278|Experimental|Canagliflozin 200 mg daily|Each patient will receive 200 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3048958|NCT00642278|Experimental|Canagliflozin 300 mg daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily (in the morning) for 12 weeks with matching placebo capsule once daily (in the evening).
3048959|NCT00642278|Experimental|Canagliflozin 300 mg twice daily|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) twice daily for 12 weeks.
3048960|NCT00642278|Active Comparator|Sitagliptin 100 mg daily|Each patient will receive 100 mg of sitagliptin once daily (in the morning) for 12 weeks with matching placebo once daily (in the evening).
3048961|NCT00642278|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 12 weeks.
3048962|NCT00642304|Experimental|methoxy polyethylene glycol-epoetin beta|
3048963|NCT00642356|Experimental|Carbidopa/levodopa/entacapone|
3048964|NCT00642356|Active Comparator|Immediate release carbidopa/levodopa|
3048965|NCT00642369|Experimental|quetiapine fumarate|quetiapine fumarate was administered 25mg on the 1st day,738±41mg/day on the 14th day, and 738±48mg/day on the 28th day.
3048966|NCT00642369|Active Comparator|haloperidol|haloperidol was administered 2mg on the 1st day,16±7mg/day on the 14th day, and 18±6mg/day on the 28th day.
3048967|NCT00642460|Experimental|1|
3048968|NCT00642460|Placebo Comparator|2|
3048969|NCT00642473|Experimental|Prevention (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated at the same day as the start of erlotinib. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
3048970|NCT00642473|Experimental|Treatment (Erlotinib + Metronidazole Actavis)|Participants will receive erlotinib orally daily. Metronidazole actavis treatment will be initiated when participants develop rash. Metronidazole actavis 1% topical cream will be applied on the right side of the face and chest twice daily for 4 weeks. Left side of the face and chest was treated according to local standard procedures (ie, with non-active moisturizing cream).
3048971|NCT00642616|Experimental|Technosphere® Insulin (Asthma)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
3048972|NCT00642616|Active Comparator|Usual Care (Asthma)|Usual anti diabetic care in Diabetic participants with Asthma
3048973|NCT00642616|Experimental|Technosphere® Insulin (COPD)|Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
3048974|NCT00642616|Active Comparator|Usual Care (COPD)|Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
3048975|NCT00642642|Experimental|Double blinded active|Subject will receive autologous fibroblast treatment on either their left or right side of their face
3048976|NCT00642642|Placebo Comparator|Double blinded placebo|Subject will receive placebo treatment on the opposite side of the face from active treatment
3048977|NCT00642668|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants received methoxy polyethylene glycol-epoetin beta treatment monthly for 36 weeks with an efficacy evaluation period (EEP) during weeks 29-36 and followed by a 4 week follow-up period.
3048978|NCT00642694|Experimental|1|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Ramelteon (One 8 mg capsule at night)
3048979|NCT00642694|Placebo Comparator|2|Escitalopram tablets (starting dose of 10 mg with a maximum dose of 20 mg daily) + Matching Placebo (One capsule at night)
3048980|NCT00642707|Active Comparator|Arm 1|PRO 140 for three single SC doses: Days 1, 8, and 15
3048981|NCT00642707|Active Comparator|Arm 2|PRO 140 for three single SC doses: Days 1, 8 and 15
3048982|NCT00642707|Active Comparator|Arm 3|PRO 140 for two single SC doses: Days 1 and 15 plus one SC dose of PBO at Day 8
3048983|NCT00642707|Placebo Comparator|Arm 4|PBO for three single SC doses: Days 1, 8 and 15
3048984|NCT00642746|Experimental|FOLFOX with Erlotinib|Subjects received FOLFOX (Leucovorin, Fluorouracil, and Oxaliplatin) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFOX on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
3048985|NCT00642746|Experimental|FOLFIRI with Erlotinib|Subjects received FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan) and Erlotinib. Treatment consisted of a 28 day cycle. Subjects received FOLFIRI on days 1, 2, and 3, and 15-16, followed by Erlotinib on days 3-8, and 17-22.
3048986|NCT00642759|Experimental|Chemotherapy|Carboplatin, nab-paclitaxel, and bevacizumab
3048987|NCT00642772|Experimental|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
3048988|NCT00642811|Experimental|1|Aspirin + Ticagrelor
3048989|NCT00642811|Active Comparator|2|Aspirin + Clopidogrel
3048990|NCT00642850|Experimental|1|
3048991|NCT00642902|Experimental|Atacicept 25 mg|
3048992|NCT00642902|Experimental|Atacicept 75 mg|
3048993|NCT00642902|Experimental|Atacicept 150 mg|
3048994|NCT00642902|Placebo Comparator|Placebo|
3048995|NCT00642941|Experimental|Cohort 1: Ewings Sarcoma Primary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
3048996|NCT00642941|Experimental|Cohort 2: Ewings Sarcoma Secondary Cohort|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
3048997|NCT00642941|Experimental|Cohort 3: Ewings Sarcoma Expanded Cohort|Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
3048998|NCT00642941|Experimental|Cohort 4: Osteosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
3048999|NCT00642941|Experimental|Cohort 5: Synovial Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
3049000|NCT00642941|Experimental|Cohort 6: Rhabdomyosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
3049001|NCT00642941|Experimental|Cohort 7a: Alveolar Soft Part Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
3049002|NCT00642941|Experimental|Cohort 7b: Desmoplastic Small Round Cell Tumors.|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
3049003|NCT00642941|Experimental|Cohort 7c: Extraskeletal Myxoid Chondrosarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
3049004|NCT00642941|Experimental|Cohort 7d: Clear Cell Sarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
3049005|NCT00642941|Experimental|Cohort 7e: Myxoid Liposarcoma|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
3049006|NCT00642941|Experimental|Cohort 8: Diagnosis Not Specified|Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
3132891|NCT03463889|Experimental|Diagnostic (Gallium Ga 68-labeled PSMA-11, PET/MRI)|Participants receive 68Ga-PSMA IV over 1-2 minutes and then undergo PET/MRI 60 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
3179030|NCT00668291||CNC|Primary pigmented nodular adrenocortical disease (PPNAD) and the Carney complex (CNC)
3049007|NCT00642954|Experimental|Level 1: Vorinostat 300 mg + lenalidomide 10 mg|Participants will receive vorinostat 300 mg orally once-daily (QD) on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
3049008|NCT00642954|Experimental|Level 2: Vorinostat 400 mg + lenalidomide 10 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 10 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
3049009|NCT00642954|Experimental|Level 3: Vorinostat 400 mg + lenalidomide 15 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 15 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
3049010|NCT00642954|Experimental|Level 4: Vorinostat 400 mg + lenalidomide 20 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 20 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
3049011|NCT00642954|Experimental|Level 5: Vorinostat 400 mg + lenalidomide 25 mg|Participants will receive vorinostat 400 mg orally QD on Days 1-7 and Days 15-21; lenalidomide 25 mg orally QD on Days 1-21 and dexamethasone 40 mg orally QD on Days 1, 8, 15 and 22 of each 28-day cycle for up to 8 cycles. Qualified participants who don't have disease progression can continue treatment after 8 cycles at the same dose and schedule, until progressive disease or unacceptable toxicity.
3049012|NCT00642993|Experimental|SCH 497079|SCH 497079, administered orally, once daily
3049013|NCT00642993|Placebo Comparator|Placebo|Placebo capsules, administered orally, once daily
3049014|NCT00643006|Experimental|A. High intensive exercise|High intensive exercise
3049015|NCT00643006|Active Comparator|B. Low-intensive exercise|Low-to-moderate intensive supervised walks
3049016|NCT00643097|Experimental|Arm I (ACTIVATE)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)-specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, every 2 weeks starting 4 weeks after the completion of radiation. Subsequent vaccinations were given once a month until clinical or radiographic evidence of progression or death.
3049017|NCT00643097|Experimental|Arm II (ACT II STD)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 200 mg/m2 for the first 5 days of a 28 day cycle.
3049018|NCT00643097|Experimental|Arm III (ACT II DI)|Patients first receive 3 initial vaccinations of an epidermal growth factor receptor variant III (EGRRvIII)- specific peptide (PEP-3) keyhole limpet hemocyanin (KLH) conjugate vaccine and sargramostim (GM-CSF), referred to as PEP-3 vaccine, biweekly starting within 6 weeks of completing radiation. Additional vaccinations were given until clinical or radiographic evidence of progression or death. Patients subsequently receive temozolomide at a targeted dose of 100 mg/m2 for the first 21 days of a 28 day cycle.
3049019|NCT00643123|Experimental|Allopurinol|Subjects will be randomized to allopurinol at a fixed dose of 300 mg/day for the first week and then 600mg/day while continuing their current medications during the 7-week study. A battery of assessments will be administered at baseline and weeks 1, 2, 4, 6 after baseline. At each assessment, subjects will also be asked about side effects including potential side effects of allopurinol. Side effects will be assessed by the Treatment Emergent Side Effects Scale. Serum levels of lithium, valproic acid, carbamazepine, atypical antipsychotics or atypical antipsychotic metabolite, uric acid blood levels will be drawn at screen and at week 6 after baseline. Subjects taking only lithium, valproic acid, and/or carbamazepine will also have their serum levels drawn at week 2.
3049020|NCT00643123|Placebo Comparator|Placebo|Subjects will be randomized to placebo and will follow the same protocol as the allopurinol group.
3049021|NCT00643162|Experimental|Swedish Massage|Adding massage twice a week, for 8 weeks, and Lexapro in the treatment of depression.
3049022|NCT00643162|Sham Comparator|Light-Touch|Adding light touch twice a week, for 8 weeks, and Lexapro in the treatment of depression.
3049023|NCT00643201|Active Comparator|Apixaban|apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
3049024|NCT00643201|Experimental|Enoxaparin + Warfarin|Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.
3049025|NCT00643279|Experimental|CHRONICLE|Subjects randomized to the CHRONICLE group were managed using data from an implantable hemodynamic monitoring (IHM) device, including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The Chronicle IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
3049026|NCT00643279|Placebo Comparator|CONTROL|Subjects randomized to the CONTROL group implanted with the Chronicle implantable hemodynamic monitoring (IHM) device, but the intracardiac diagnostic information was blinded to both the patient and the physician during the randomized period of the study. Subjects were managed conventionally with standard of care. Physicians and patients have access to the intracardiac data after the randomized period of the study is over, at 6 months.
3049027|NCT00643448|Experimental|AZD1305 loading dose 250 mg + 125 mg|Tablets
3049028|NCT00643448|Experimental|AZD1305 loading dose 500 mg + placebo|Tablets
3049029|NCT00643448|Placebo Comparator|Placebo corresponding to AZD1305 loading dose|Tablets
3049030|NCT00643487||1|observation of the behavior of the infrapatellar plica
3049031|NCT00643565|Experimental|Bevacizumab + Chemotherapy|Participants received continuous IV infusion of bevacizumab (7.5 mg/kg every 3 weeks) on Day 1 of 3-week cycles followed by induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy) as per institutional practice for a total of 9 cycles during induction treatment phase. As per the investigator decision, local therapy (radiotherapy and /or surgery) was expected to start after 4 weeks of the last bevacizumab administration in the induction phase and resumed to bevacizumab in the maintenance phase at least 4 weeks after the last dose of local therapy. During maintenance treatment phase, participants received IV infusion of bevacizumab (5 mg/kg every 2 weeks) followed by vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Days 1 and 15 of 4-week cycles for a total of 12 cycles.
3049032|NCT00643565|Active Comparator|Chemotherapy|Participants received 9 cycles of induction chemotherapy (4 cycles of IVADo-containing chemotherapy followed by 5 cycles of IVA-containing chemotherapy administered every 3 weeks as per institutional practice. As per the investigator evaluation, participants had option to undergo local therapy (radiotherapy and /or surgery) during last 3 cycles of IVA (i.e. from Cycle 6 to Cycle 9). During maintenance treatment phase, participants received vinorelbine- and cyclophosphamide-containing chemotherapy (as per institutional practice) on Day 1 and 15 of 4-week cycles for a total of 12 cycles.
3049033|NCT00643578|Active Comparator|2|a single dose of 24 mcg of formoterol
3049034|NCT00643578|Active Comparator|1|a single dose of 12 mcg of formoterol
3049035|NCT00643604|Experimental|treprostinil sodium|all subjects had switched from IV epoprostenol to IV treprostinil sodium
3049036|NCT00643682|Experimental|A|Patients in this arm will be given an educational card in addition to the standard pre-endoscopy instructions.
3049037|NCT00643682|No Intervention|B|Patients in this arm will be given the standard pre-endoscopy instructions.
3049038|NCT00643760|Placebo Comparator|Placebo|Placebo
3049039|NCT00643760|Other|Pregabalin|Pregabalin 300mg/day (positive control), maintenance treatment 14 weeks
3049040|NCT00643760|Experimental|GEn 1200mg/day|gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
3049041|NCT00643760|Experimental|GEn 2400mg/day|gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
3049042|NCT00643760|Experimental|GEn 3600mg/day|gabapentin enacarbil 3600mg/day, maintanance treatment 14 weeks
3049043|NCT00643851|Experimental|Arm 1|Dapagliflozin (5 mg) + Metformin XR (up to 2000 mg)
3049044|NCT00643851|Experimental|Arm 2|Dapagliflozin (5 mg)
3049045|NCT00643851|Active Comparator|Arm 3|Metformin XR (500 mg up to 2000 mg)
3049046|NCT00643864|Other|Mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same therapist who performed the pretests."
3049047|NCT00643916|Experimental|Vaccinated at Age 9 and 12 Months|Participants received Menactra® vaccine at 9 and 12 Months of age
3049048|NCT00643916|Experimental|Vaccinated at Age 9 and 15 Months|Participants received Menactra® vaccine at 9 and 15 Months of age
3049049|NCT00643916|Experimental|Vaccinated at Age 12 and 15 Months|Participants received Menactra® vaccine at Age 12 and 12 Months of age
3049050|NCT00643916|Experimental|Vaccinated at Age 15 Months|Participants received Menactra® vaccine at 15 Months of age
3049051|NCT00643916|Experimental|Vaccinated at Age 18 Months|Participants received Menactra® vaccine at 18 Months of age
3049052|NCT00643916|Active Comparator|Vaccinated at Age 3 Years to <6 Years|Participants received Menomune® vaccine at Age 3 years to <6 years of age
3049053|NCT00644059|Experimental|TIV-adj|Adjuvanted trivalent inactivated subunit influenza vaccine
3049054|NCT00644059|Active Comparator|Flu-control|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine
3049055|NCT00644059|Sham Comparator|Non-flu Control|Novartis meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
3049056|NCT00644189|Other|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
3049057|NCT00644228|Active Comparator|Arm I (dexamethasone and lenalidomide)|Patients receive dexamethasone PO QD on days 1, 8, 15, and 22 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3049058|NCT00644228|Experimental|Arm II (dexamethasone, lenalidomide, bortezomib)|Patients receive dexamethasone PO QD on days 1, 2, 4, 5, 8, 9, 11, and 12; lenalidomide PO QD on days 1-14; and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3049059|NCT00644280|Active Comparator|Ranibizumab|Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at 3 time points: 9 days before Ahmed tube insertion for open-angle glaucoma, 1 month post-surgery, and 2 months post-surgery
3049060|NCT00644280|No Intervention|Usual care|Standard of care Ahmed tube insertion for open-angle glaucoma without injections of Ranibizumab
3049061|NCT00644358|Experimental|Vilazodone|Vilazodone titrated up to 40 mg/day for 1 year.
3049062|NCT00644423|Active Comparator|1|Omega-3 Fatty Acid
3049063|NCT00644423|Placebo Comparator|2|Placebo
3049064|NCT00644592|Active Comparator|1-Fenofibrate then Placebo|4 weeks of drug at 160 mg orally per day, 4 week washout, then 4 weeks of placebo
3049065|NCT00644592|Active Comparator|2 Placebo then Fenofibrate|4 weeks of placebo then 4 week washout then 4 weeks of Fenofibrate at 160 mg/day orally.
3049066|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14. Participants who met the predefined criteria at the end of Titration Phase enter the Double Blind Phase.
3179031|NCT00668291||MC-L|cardiac myxoma or isolated lentiginosis
3179032|NCT00668304|Experimental|Arm 1|
3049067|NCT00644787|Experimental|Fentanyl 1-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 1-day application transdermal patch and placebo matched to fentanyl 3-day application (JNS005) transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
3049068|NCT00644787|Active Comparator|Fentanyl 3-day transdermal patch (Double Blind Phase)|Participants who meet the predefined criteria at the end of Titration Phase and enter the Double Blind Phase receive fentanyl 3-day application transdermal patch and placebo matched to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
3049069|NCT00644878|Experimental|Nilotinib|
3049070|NCT00644917|Experimental|A|Drug
3049071|NCT00644917|Placebo Comparator|B|Placebo comparator
3049072|NCT00644917|No Intervention|C|Subjects serve as own controls.
3049073|NCT00644969|Placebo Comparator|Placebo Arm|Randomization 2:1 treatment to placebo
3049074|NCT00644969|Active Comparator|Treatment Arm|
3049075|NCT00644995|Active Comparator|Usual Care Control|Participants will receive usual care which includes advice to stop smoking and referral to standard care treatment available through participants' health insurance and health plan.
3049076|NCT00644995|Experimental|Step Up Intervention|Participants will receive the Step Up Wellness Program. The intervention is detailed below.
3049077|NCT00645047|Experimental|Telemedicine CBT|Cognitive behaviour therapy (CBT) delivered using videoconference telemedicine.
3049078|NCT00645047|Active Comparator|In-Person CBT|Cognitive behaviour therapy (CBT) delivered using in-person consultation.
3049079|NCT00645099|Experimental|001|paliperidone ER 6-mg or 9-mg tablet once daily flexible dosing for 6 months
3049080|NCT00645099|Active Comparator|002|olanzapine 10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
3049081|NCT00645164|Experimental|Xenaderm|Subject serves as own control
3049082|NCT00645333|Experimental|MK-0752, Docetaxel, Pegfilgrastim|MK-0752, Docetaxel, Pegfilgrastim in combination with escalating doses of MK-0752
3049083|NCT00645411|Experimental|Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV|All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3049084|NCT00645411|Active Comparator|Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV|All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.
3049085|NCT00645411|Experimental|Cohort 3 (3-8 Yrs) cTIV|All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3049086|NCT00645411|Active Comparator|Cohort 3 (3-8 Yrs) eTIV|All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere
3049087|NCT00645450|Experimental|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
3049088|NCT00645450|Placebo Comparator|Placebo|Weekly doses of placebo following recollection of traumatic memory
3049089|NCT00645528|Experimental|Insulin Education Class Participants|Participation in an insulin educational class at week 0 and again at week 2
3049090|NCT00645593|Active Comparator|Arm 1, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin, as described in the intervention
3049091|NCT00645593|Experimental|Arm 2, Cetuximab, Gemcitabine and Cisplatin|Gemcitabine and Cisplatin with Cetuximab, as described in the intervention
3049092|NCT00645671|Experimental|Loteprednol Etabonate|Loteprednol etabonate 0.5% ophthalmic ointment
3049093|NCT00645671|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ointment
3049094|NCT00645710|Experimental|Arm I|"Patients receive floxuridine as a continuous hepatic arterial infusion on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 9 and 11. Patients also receive yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV over 25 minutes on day 9. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients may receive an additional course of floxuridine in combination with systemic therapy at the discretion of the treating physician."
3049095|NCT00645762|Active Comparator|Balloon Dilation|Balloon dilation with FinESS device
3049096|NCT00645788|Experimental|32.50 mg Ciprofloxacin DPI (BAYQ3939)|32.50 mg ciprofloxacin DPI (Dry Powder for Inhalation) corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
3049097|NCT00645788|Experimental|48.75 mg Ciprofloxacin DPI (BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation Powder twice a day for 28 days
3049098|NCT00645788|Placebo Comparator|Matching Placebo for 32.50 mg|Inhalation of placebo powder formulation matching 32.50 mg ciprofloxacin DPI twice a day for 28 days
3049099|NCT00645788|Placebo Comparator|Matching Placebo for 48.75 mg|Inhalation of placebo powder formulation matching 48.75 mg ciprofloxacin DPI twice a day for 28 days
3049100|NCT00645827|Experimental|Insulin infusion conversion equation|Insulin infusion conversion equation is used to determine subcutaneous insulin dosing for first 24 hours after cessation of an IV insulin infusion.
3049101|NCT00645827|Active Comparator|Control|Judgment of patient's healthcare provider is used to determine subcutaneous insulin dosing for first 24 hours after cessation of IV insulin infusion.
3049102|NCT00645840|Experimental|Anakinra|After study enrollment, all subjects started anakinra (Kineret™; Amgen, Thousand Oaks, CA, USA) as a subcutaneous daily injection. Subjects weighing >25 kg at the time of enrollment received 100 mg daily, whereas those weighing <25 kg received 50 mg daily. Anakinra was continued for 28 d with no dose adjustment.
3049103|NCT00645853|Experimental|1|
3049104|NCT00645853|Active Comparator|2|
3049105|NCT00645944|Experimental|Eszopiclone Group|Participants assigned to this arm will receive Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
3049106|NCT00645944|Placebo Comparator|Placebo Group|"Participants assigned to this arm will receive placebo (an inactive substance or a sugar pill) to be taken each night for all weeks of the study."
3049107|NCT00645970||Group 1|
3049108|NCT00646048|Experimental|Arm 1|This arm is for patient that receive the TriVascular Stent-Graft System.
3049109|NCT00646113|Experimental|OsseoSpeed™ TX 3.0S (Dental implant)|OsseoSpeed™ TX 3.0S, Dental implants, 3.0 mm diameter, in lengths of 11, 13 and 15 mm
3049110|NCT00646399|Placebo Comparator|Placebo|Phosphate Buffered Saline
3049111|NCT00646399|Experimental|Pagibaximab 50 mg/mL|Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.
3049112|NCT00646451|Active Comparator|Pregabalin (Lyrica)|Pregabalin (Lyrica) 75 mg bid to a maximum dose of 300 mg bid
3049113|NCT00646451|Placebo Comparator|Placebo|Placebo to 4 capsules bid
3049114|NCT00646581|Placebo Comparator|Placebo (1)|Subjects are given a one-time, single dose of placebo intranasal spray
3049115|NCT00646581|Experimental|Single-Dose Intranasal Insulin|Subjects are given a one-time, single dose of intranasal insulin
3049116|NCT00646646|Active Comparator|propofol|active drug
3049117|NCT00646646|Active Comparator|dexmedetomidine|sedative
3049118|NCT00646646|Active Comparator|midazolam|Sedative
3049119|NCT00646646|Placebo Comparator|placebo|placebo control
3049120|NCT00646763|Active Comparator|Abdomen|These subjects will have their cytokine injections administered only to their abdomen.
3049121|NCT00646763|Active Comparator|Extremities|The extremity arm will have their injections administered to their upper and/or lower extremities.
3049122|NCT00646776|Active Comparator|A|
3049123|NCT00646776|Active Comparator|B|
3049124|NCT00646906|Experimental|Phase 1a: Acetaminophen 1000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smokers (n=8) will receive 81 mg aspirin at approximately 8 am followed by 1000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 1000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
3049125|NCT00646906|Experimental|Phase 1a: Acetaminophen 2000mg / aspirin|"All subjects in this arm (smokers (n=8) and non-smoking volunteers (n=8)) will receive 81 mg aspirin at approximately 8 am followed by 2000 mg acetaminophen at approximately 10 am during one crossover period (see Crossover Period: Aspirin first intervention). During the other crossover period, beginning after a 2 week washout, the order will be reversed and the subjects will receive 2000 mg acetaminophen at 8 am followed by 81 mg aspirin at 10 am (see Crossover Period: Aspirin last intervention). The occurrence of the two crossover periods will be randomized by order. Smokers and non-smokers will be matched for age and gender."
3049126|NCT00646906|Experimental|Phase 1b: Acetaminophen 1000 mg alone|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. They will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM (see Acetaminophen 1000 mg/d intervention). Study assessments will be performed on day 1 and on day 6. This is not a crossover design. Just one treatment period."
3049127|NCT00646906|Experimental|Phase 2: Acetaminophen vs. Ibuprofen|"Eight male and non-pregnant female subjects who are healthy and non-smoking will be recruited. In one period of this crossover study acetaminophen (1000 mg p.o.) will be administered orally at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Acetaminophen 4000 mg/d intervention). The last dose will be administered on day four at 8 AM In the other crossover period, after a washout period of at least 14 days, the subjects will receive ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days (see Crossover Period: Ibuprofen 800 mg/d intervention). The last dose will be administered on day four at 8 AM Study assessments will be performed on day 1 and day 4 of each crossover period. The occurrence of the two crossover periods will be randomized by order."
3049128|NCT00646958|Experimental|1|Radezolid 450 mg PO QD
3049129|NCT00646958|Experimental|2|Radezolid 450 mg PO BID
3049130|NCT00646958|Active Comparator|3|Linezolid 600 mg PO BID
3049131|NCT00647270|Placebo Comparator|Placebo|Placebo 12 weeks, 40mg adalimumab remaining 12 weeks
3049132|NCT00647270|Active Comparator|40 mg|40 mg every other week
3049133|NCT00647270|Active Comparator|80 mg|80 mg monthly
3049134|NCT00647296|Placebo Comparator|Part 1: Placebo or Dexpramipexole|During Part 1, subjects received twice daily doses of dexpramipexole (50 mg/day, 150 mg/day, or 300 mg/day) or matching placebo for approximately 12 weeks.
3049135|NCT00647296|Experimental|Part 2: Placebo washout|At the beginning of Part 2, subjects received twice daily doses of placebo for approximately 4 weeks.
3049136|NCT00647296|Experimental|Part 2: Dexpramipexole|Following the Part 2 placebo washout, subjects received dexpramipexole (50 mg/day or 300 mg/day), subjects received twice daily doses of placebo for up to 18 months.
3049137|NCT00647348|Active Comparator|1|Simvastatin 80mg OD
3049138|NCT00647348|Placebo Comparator|2|Placebo
3049139|NCT00647400|Experimental|Adalimumab 40 mg every other week|
3049140|NCT00647400|Experimental|Adalimumab 80 mg every other week|
3049141|NCT00647556|Active Comparator|adapalene|adapalene
3049142|NCT00647556|Active Comparator|tretinoin|Tretinoin
3049143|NCT00647699|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
3049144|NCT00647699|Sham Comparator|Control Group|riboflavin ophthalmic solution without UVA irradiation.
3049145|NCT00647998|Experimental|Darbepoetin|Patients received 1mg/kg IV Darbepoetin immediately prior to surgery
3049146|NCT00647998|Placebo Comparator|Standard care|No Darbepoetin
3049147|NCT00648037|Experimental|Rituximab|Patients following a T cell depleted HLA-mis-matched related or unrelated hematopoietic stem cell transplant (HSCT) will be treated with monthly Rituximab.
3049148|NCT00648115|Other|Basic Vocational Services|Veteran receives basic vocational services
3049149|NCT00648115|Active Comparator|Self-Study|Veteran participates in self-study vocational program
3049150|NCT00648115|Active Comparator|Group program|Group based vocational program
3049151|NCT00648167|Experimental|KRX-0502 (ferric citrate)|All patients will be switched from their current phosphate binder to Zerenex, and titrated to the maximum tolerated dose (up to about 12g/day) based on their serum phosphorus levels.
3049152|NCT00648375|Experimental|Propranolol|Participants will take propranolol for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
3049153|NCT00648375|Placebo Comparator|Placebo|Participants will take placebo for 14 weeks. Medication will be self-administered times they experience acute onset of hyperarousal symptoms, not more than twice per day.
3049154|NCT00648648|Experimental|MK-1775 325 mg Single Dose|Participants received MK-1775 325 mg, orally, on Day 1.
3049155|NCT00648648|Experimental|MK-1775 650 mg Single Dose|Participants received MK-1775 650 mg, orally, on Day 1.
3049156|NCT00648648|Experimental|MK-1775 1300 mg Single Dose|Participants received MK-1775 1300 mg, orally, on Day 1.
3049157|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an intravenous (IV) infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 100 mg single dose, orally, on Day 2 of each cycle.
3049158|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 in each 4-week cycle plus MK-1775 200 mg single dose, orally, on Day 2 of each cycle.
3049159|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
3049160|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
3049161|NCT00648648|Experimental|MK-1775 100 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin at an area under the time curve concentration of 5 mg/min/ml (AUC5) as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg single dose orally, on Day 2 of each cycle.
3049162|NCT00648648|Experimental|MK-1775 200 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg single dose orally, on Day 2 of each cycle.
3049163|NCT00648648|Experimental|MK-1775 325 mg Single Dose + Carboplatin AUC 5|Participants received carboplatin AUC5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg single dose orally, on Day 2 of each cycle.
3049164|NCT00648648|Experimental|MK-1775 25 mg BID x2.5 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4-week cycle plus MK-1775 25 mg orally twice daily (BID) for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each cycle.
3049165|NCT00648648|Experimental|MK-1775 50/25 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 doses of MK-1775 25 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
3049166|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given once weekly for 3 consecutive weeks of a 4 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the IV infusion of gemcitabine on Day 1 and followed by 4 additional doses of MK-1775 50 mg at approximately 12 hour intervals on Days 1-3, 8-9, and 15-17 of each 4 week cycle.
3049167|NCT00648648|Experimental|MK-1775 100 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 100 mg orally once daily (QD) on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
3049168|NCT00648648|Experimental|MK-1775 125 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 125 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
3049169|NCT00648648|Experimental|MK-1775 150 mg QD x2 Multi + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 150 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
3049170|NCT00648648|Experimental|MK-1775 175 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion given on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 175 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
3049171|NCT00648648|Experimental|MK-1775 200 mg QD x2 Multi Dose + Gemcitabine 1000 mg/ m^2|Participants received gemcitabine 1000 mg/m^2 as an IV infusion on Days 1, 8, and 15 of each 4 week cycle plus MK-1775 200 mg orally QD on Days 1, 2, 8, 9, 15, and 16 of each 4 week cycle.
3049172|NCT00648648|Experimental|MK-1775 50 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 50 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049173|NCT00648648|Experimental|MK-1775 100 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 100 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049174|NCT00648648|Experimental|MK-1775 125 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 125 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049175|NCT00648648|Experimental|MK-1775 150 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049176|NCT00648648|Experimental|MK-1775 200 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 200 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049177|NCT00648648|Experimental|MK-1775 250 mg BID x2.5 Multi Dose + Cisplatin 75 mg/ m^2|Participants received cisplatin 75 mg/ m^2 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 250 mg orally BID for 2.5 days, starting concomitantly with the administration of cisplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049178|NCT00648648|Experimental|MK-1775 75 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 75 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049179|NCT00648648|Experimental|MK-1775 150 mg BID x 2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 150 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049180|NCT00648648|Experimental|MK-1775 225 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 225 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049181|NCT00648648|Experimental|MK-1775 325 mg BID x2.5 Multi Dose + Carboplatin AUC 5|Participants received carboplatin AUC 5 as an IV infusion on Day 1 of each 3 week cycle plus MK-1775 325 mg orally BID for 2.5 days, starting concomitantly with the administration of carboplatin on Day 1 and then at 12 hour intervals on Days 1-3 of each 3 week cycle.
3049182|NCT00648739|Experimental|Samalizumab|All doses of samalizumab were individualized based on the participant's body surface area in mg/m^2 based on screening height and weight. Participants were assigned to a dose cohort, ranging from 50 to 600 mg/m^2, and received a single IV dose of samalizumab. Participants who tolerated the drug and demonstrated at least stable disease received up to 3 additional cycles of samalizumab at the same dose originally received at a minimum of 28-day intervals and beginning no sooner than 6 weeks after the initial dose. If no participants enrolled into a cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. If any 1 of the initial 3 participants in the cohort experienced a DLT, the cohort was expanded to at least 6 participants. Then, if less than one third of participants within the cohort experienced a DLT, escalation to the next dose level occurred with a new cohort. Dose cohorts were enrolled sequentially.
3049183|NCT00649220|Experimental|Memantine|
3049184|NCT00649389|Experimental|OM40/AML10|olmesartan medoxomil 40mg and amlodipine 10mg
3049185|NCT00649389|Active Comparator|OM40/HCTZ25|olmesartan medoxomil 40mg and hydrochlorothiazide 25mg
3049186|NCT00649389|Active Comparator|AML10/HCTZ25|amlodipine 10mg and hydrochlorothiazide 25mg
3049187|NCT00649389|Active Comparator|OM40/AML10/HCTZ25|olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg
3049188|NCT00649428|Experimental|Active|
3049189|NCT00649428|Placebo Comparator|Control|
3049190|NCT00649961|Experimental|Melatonin Open Label Single Arm|Infants born less than 31 weeks gestation who are less than 7 days old
3049191|NCT00650078|Experimental|NP01|Modified Release (MR) prednisone 5 mg
3049192|NCT00650078|Placebo Comparator|Placebo|
3049193|NCT00650091|Active Comparator|1|Participants will receive N-acetylcysteine (NAC) for 60 weeks.
3049194|NCT00650091|Placebo Comparator|2|Participants will receive placebo for 60 weeks.
3049195|NCT00650104|Active Comparator|Active|Open label medication - Ropinirole CR
3049196|NCT00650260|Experimental|vH2 System Group|The vital heat vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical. The vital heat vH2 System will be used for patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
3049197|NCT00650260|Active Comparator|Control Group|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket. The Bair Hugger System is the site's current approach to patient warming during these surgical procedures. Monitoring of core temperature via esophageal probe will be done for the purpose of data collection.
3049198|NCT00650546|Experimental|A pre treatment NAS score|liver biopsy score pre treatment with exenatide 5 micrograms SQ (sub-cutaneous) twice a day titrated to 10 mcg SQ twice a day as tolerated
3049199|NCT00650585|No Intervention|Control group|Did not receive Project ALERT
3049200|NCT00650585|Experimental|Treatment group|Received Project ALERT
3049201|NCT00650767|Experimental|ARRY-438162 (Schedule 1)|
3049202|NCT00650767|Experimental|ARRY-438162 (Schedule 2)|
3049203|NCT00650767|Experimental|ARRY-438162 (Schedule 3)|
3049204|NCT00650767|Placebo Comparator|Placebo|
3049205|NCT00650806|Experimental|Canagliflozin 50 mg|Each patient will receive 50 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3049206|NCT00650806|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3049207|NCT00650806|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin (JNJ-28431754) once daily for 12 weeks.
3049208|NCT00650806|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 12 weeks.
3049209|NCT00650845|Experimental|Dotarem®-enhanced MRI|Patients undergoing Dotarem®-enhanced MRI for diagnostic purposes
3049210|NCT00650845|Other|Non-enhanced MRI|Patients undergoing non-enhanced MRI for diagnostic purposes
3049211|NCT00650858|Active Comparator|0.3 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 0.3 mg dose arm or the 1.0 mg dose arm. Subjects in this arm (0.3 mg) received up to 8 doses of 0.3 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3049212|NCT00650858|Active Comparator|1.0 mg rt-PA|In stage 1 of the protocol, dose finding, subjects were randomized to either this 1.0 mg dose arm or the 0.3 mg dose arm. Subjects in this arm (1.0 mg) received up to 8 doses of 1.0 mg rt-PA every 12 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3049213|NCT00650858|Experimental|1.0 mg Rt-PA q8h|In stage 2 of the protocol, dose frequency, subjects received up to 8 doses of 1.0 mg of rt-PA (Cathflo) every 8 hours through the intraventricular catheter to treat intraventricular hemorrhage.
3049214|NCT00650936|Other|AMPLATZER Septal Occluder|Subjects were enrolled if the implant of the AMPLATZER Septal Occluder device was completed or was attempted (delivery system entered the subject's body).
3049215|NCT00651040|Active Comparator|Prednison|"Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms.~ARM 1 has only Prednisone"
3049216|NCT00651040|Active Comparator|Prednison + methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
3049217|NCT00651118|Active Comparator|fluticasone propionate|
3049218|NCT00651118|Experimental|azelastineHcl/fluticasone propionate|
3049219|NCT00651118|Placebo Comparator|Placebo|
3049220|NCT00651118|Active Comparator|azelastine Hcl|
3049221|NCT00651157|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus (Reolysin®) IV administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3049222|NCT00651261|Experimental|Induction and consolidation chemotherapy plus midostaurin|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and the experimental drug midostaurin. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with the experimental drug midostaurin. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with midostaurin for twelve (12) months.
3049223|NCT00651261|Active Comparator|Induction and consolidation chemotherapy plus placebo|Patients will receive a standard combination of chemotherapy drugs during remission induction therapy that includes cytarabine, daunorubicin, and placebo. Depending on the outcome of remission induction treatment, there may be a decision to discontinue the study treatment or a second remission induction cycle may be given. If remission induction therapy is successfully completed, patients will receive four courses of high-dose cytarabine consolidation chemotherapy plus dexamethasone together with placebo. All patients will undergo a bone marrow aspiration (and perhaps a biopsy) after the final course of remission consolidation chemotherapy. If the patient continues to respond to the treatment, the patient will receive continuation therapy with placebo for twelve (12) months.
3049224|NCT00651313|Active Comparator|Active|Lidocaine 10% (150mg) vaginal gel
3049225|NCT00651313|Placebo Comparator|Placebo|Placebo vaginal gel
3049226|NCT00651482|Experimental|Bevacizumab + RAD001 (everolimus)|"Study treatment, consisting of bevacizumab + everolimus, was administered as 28-day cycles~Bevacizumab 10 mg/kg administered by IV infusion every 14 days (dose suspension permitted, dose reduction not permitted)~Everolimus 10 mg daily was administered orally (dose reduction to 5 mg daily and then 5 mg every other day, was permitted as needed for toxicity or tolerability)"
3049227|NCT00651573|Active Comparator|Blood transfusion triggers of 24% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 24%. When the hematocrit value falls to less 24%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 24%, no further transfusions will be administered.
3049228|NCT00651573|Active Comparator|Blood transfusion triggers of 28% hematocrit value|Red blood cell transfusion will be given when hematocrit values fall below the assigned group 1 value which is 28%. When the hematocrit value falls to less 28%, a 1 unit RBC transfusion will be administered. Following administration of the 1 unit transfusion a repeat HCT is performed; if the hematocrit value responds to transfusion and is greater than or equal to 28%, no further transfusions will be administered.
3049229|NCT00651625|Experimental|1|The intervention is the use of the reciprocating procedure device (RPD) (AVANCA Re No. 1091001) (intervention) (Arm 1) with and without ultrasound guidance (intervention) in a syringe and needle procedure in comparison to a conventional syringe (BD Ref 309604) (control, Arm 2).
3049230|NCT00651625|Active Comparator|2|The conventional syringe (BD Ref 309604) is used to performed the syringe and needle procedure and outcome (effect of procedure (pain scores at 2 weeks and 6 months compared to preprocedural pain scores), and procedural pain (pain scores during procedure) are determined) and compared to Arm 1.
3049231|NCT00651664|Experimental|Alisertib 5 mg QD 7D|Alisertib 5 mg, capsules, orally, once daily (QD) for 7 days (D) followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 3 cycles).
3049232|NCT00651664|Experimental|Alisertib 80 mg QD 7D|Alisertib 80 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 4 cycles).
3049233|NCT00651664|Experimental|Alisertib 150 mg QD 7D|Alisertib 150 mg, capsules, orally, QD for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
3179033|NCT00668330|Active Comparator|Ibandronate+alfacalcidol+calcium|Bonviva
3049234|NCT00651664|Experimental|Alisertib 50 mg BID 7D|Alisertib 50 mg, capsules, orally, twice daily (BID) for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 29 cycles).
3049235|NCT00651664|Experimental|Alisertib 60 mg BID 7D|Alisertib 60 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 6 cycles).
3049236|NCT00651664|Experimental|Alisertib 75 mg BID 7D|Alisertib 75 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 8 cycles).
3049237|NCT00651664|Experimental|Alisertib 100 mg BID 7D|Alisertib 100 mg, capsules, orally, BID for 7 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 21 cycles).
3049238|NCT00651664|Experimental|Alisertib 50 mg QD 14D|Alisertib 50 mg, capsules, orally, QD for 14 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 25 cycles).
3049239|NCT00651664|Experimental|Alisertib 50 mg QD 21D|Alisertib 50 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 10 cycles).
3049240|NCT00651664|Experimental|Alisertib 70 mg QD 21D|Alisertib 70 mg, capsules, orally, QD for 21 days followed by a 14-day recovery period in each cycle until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
3049241|NCT00651755|Experimental|Aprepitant + CHOP/R-CHOP|Aprepitant 125 mg oral (PO) Day 1 of Cycle 1 followed by 80 mg PO Daily Days 2-3 with CHOP (steroid in CHOP) or R-CHOP plus Rituximab 375 mg/m^2 intravenous Day 1. CHOP or R-CHOP chemotherapy: (1) bolus or 48-hour infusion CHOP [cyclophosphamide 750 mg/m^2 IV Day 1, doxorubicin 25 mg/m^2/day IV given bolus or over 48 hours continuous infusion Days 1-2, vincristine 2 mg IV Day 1, prednisone PO 100 mg * 5 days]; or (2) Bolus or 48-hour infusion R-CHOP [Rituximab 375 mg/m^2 on Day 1 + CHOP as above]. [For patients receiving R-CHOP, CHOP may be administered starting on Day 2 at the discretion of the treating physician]
3049242|NCT00651755|Experimental|Standard of Care (Control) + CHOP/R-CHOP|Anti-emetics, Ondansetron 8 mg daily for 2 days, plus steroids in CHOP or R-CHOP regimen.
3049243|NCT00651794|Active Comparator|Control (NRP Curriculum with LFT and no team training)|Standard Neonatal Resuscitation Program (NRP) curriculum with no team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
3049244|NCT00651794|Experimental|NRP with LFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitation using low-fidelity simulators for low-fidelity training (LFT)
3049245|NCT00651794|Experimental|NRP with HFT and team training|Standard Neonatal Resuscitation Program (NRP) curriculum + team training; simulated resuscitations using high-fidelity simulators for high-fidelity training (HFT)
3049246|NCT00651820|Experimental|Collagenase Santyl Rate of Wound Closure|Dermatome-induced skin wounds treated with drug active (collagenase).
3049247|NCT00651820|Placebo Comparator|Vehicle Rate of Wound Closure|Dermatome-induced skin wounds treated with Vehicle alone.
3049248|NCT00651924|No Intervention|Phase 1|Review the materials and provide feedback regarding how understandable, engaging, and informative the materials are
3049249|NCT00651924|Experimental|Phase 2|Piloting the 'IVR-based Cognitive-behavior therapy' using the new materials
3049250|NCT00651937|Active Comparator|Standard Dose|Melphalan + Stem Cell Infusion (Standard Dose): Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 cluster of differentiation 34 (CD34)/kg on Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
3049251|NCT00651937|Active Comparator|High Dose|Melphalan + Stem Cell Infusion (High Dose): High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0. Melphalan 100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion. Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days. Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
3049252|NCT00652028|Other|Group 1|Dose level 1
3049253|NCT00652028|Other|Group 2|Dose level 2
3049254|NCT00652028|Other|Group 3|Dose level 3
3049255|NCT00652028|Other|Group 4|Dose level 4
3049256|NCT00652080|Experimental|1|Active Cream 3%; AM & PM
3049257|NCT00652093|Experimental|Opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
3049258|NCT00652093|Experimental|Opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
3049259|NCT00652093|Experimental|Placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
3049260|NCT00652093|Experimental|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
3049261|NCT00652093|Experimental|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
3179034|NCT00668330|Active Comparator|Placebo ibandronate+alfacalcidol+calcium|
3179035|NCT00668343|Active Comparator|1|
3179036|NCT00668343|Placebo Comparator|2|
3049262|NCT00652093|Experimental|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
3049263|NCT00652145|Experimental|Increase mesalamine dose by 2.4g/day|Increase dose of mesalamine by 2.4 gm per day
3049264|NCT00652145|No Intervention|Maintain mesalmine dose|Maintain current mesalamine dose at 2.4 g/day
3049265|NCT00652314|Experimental|1 - Thrombi-gel treatment|Thrombi-gel treatment
3049266|NCT00652314|Active Comparator|2 - Gelatin Sponge (Gelfoam)|Gelatin Sponge (Gelfoam) plus thrombin
3049267|NCT00652327|Experimental|Ezetimibe + Statin|
3049268|NCT00652327|Active Comparator|Double Statin|
3049269|NCT00652340|Experimental|A|
3049270|NCT00652340|Placebo Comparator|B|
3049271|NCT00652366|Active Comparator|Gemcitabine, Erlotinib Standard Dose|Participants received erlotinib, 100 milligrams (mg), orally (PO), once daily until disease progression or unacceptable toxicity. Participants also received gemcitabine, 1000 mg per (/) square meter (m^2), intravenously (IV), on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
3049272|NCT00652366|Experimental|Gemcitabine, Erlotinib Escalating Dose|Participants received erlotinib, beginning at 150 mg/day, PO, once daily, and increasing in increments of 50 mg every 2 weeks up to a maximum of 250 mg/day, until development of a grade 2 rash, or occurrence of other, non-rash, dose-limiting toxicity; treatment was continued until disease progression, unacceptable toxicity, death or withdrawal. Participants also received gemcitabine, 1000 mg/m^2, IV, on Days 1, 8, and 15 of consecutive 4 week cycles until disease progression or unacceptable toxicity.
3049273|NCT00652626|Experimental|Azacitidine 25 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 25 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3049274|NCT00652626|Experimental|Azacitidine 50 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 50 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3049275|NCT00652626|Experimental|Azacitidine 75 mg/m^2|Participants with normal renal function received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3049276|NCT00652626|Experimental|Azacitidine 100 mg/m^2|Participants with normal renal function received a single subcutaneous dose of azacitidine 100 mg/m^2 on Day 1. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3049277|NCT00652626|Experimental|Severe RI: azacitidine 75 mg/m^2|Participants with severe renal impairment (RI; defined as creatinine clearance < 30 mL/min/1.73 m^2) received subcutaneous doses of azacitidine 75 mg/m^2 on Days 1 to 5. Participants could continue treatment in the extension phase, which allowed up to 6 cycles of treatment with 75 mg/m^2 daily on Days 1-7 of each 28-day cycle.
3049278|NCT00652743|Experimental|GSK1562902A M6 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) and boosted 6 months (M6) after primary vaccination with one dose of Pandemic influenza candidate vaccine (GSK1562902A) in study 109630 (NCT00449670), administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3049279|NCT00652743|Experimental|GSK1562902A M12 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 12 Months (M12) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3049280|NCT00652743|Experimental|GSK1562902A M36 Group|Healthy male or female adults, primed with 2 doses of adjuvanted investigational H5N1 vaccine (A/Vietnam/1194/04 strain) in study 109630 (NCT00449670) receiving one dose of Pandemic influenza candidate vaccine (GSK1562902A) in this booster study, at 36 Months (M36) after the primary vaccination, administrated intramuscularly (IM) in the deltoid region of the non-dominant arm.
3049281|NCT00652834|Other|kidney recipients with GI symptoms|This was a four-week study designed to investigate GI mucosal lesions by SBCE in kidney transplant recipients who were using MMF, and to examine the changes in clinical symptoms and intestinal mucosa lesions 30 days after switching over from MMF to EC-MPS. The patient was switched from MMF to EC-MPS (Myfortic) on the equimola basis.
3049282|NCT00652899|Experimental|Total Body Irradiation|"This group includes patients that received all chemotherapy, infusion of natural killer (NK) cells and total body irradiation per protocol.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Radiation: total-body irradiation 200 cGy Day 1 preceding NK cell infusion. 5. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 6. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
3049283|NCT00652899|Experimental|No Total Body Irradiation|"This group includes patients that received chemotherapy and infusion of natural killer cells, but did not receive total body irradiation.~1. Allopurinol 300 mg by mouth daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post NK cell infusion. 2. Cyclophosphamide 60 mg/m^2 on Days 4 and 5 preceding NK cell infusion. 3. Fludarabine phosphate 25 mg/m^2 on Days 6 through 2 preceding NK cell infusion. 4. Allogeneic natural killer cells- Given day 0 - dose of 1.5-8.0 * 10^7/kg. 5. Aldesleukin 10 million units 3 times/week for a total of 6 doses beginning Day 0."
3049284|NCT00652938|Active Comparator|Cervarix & Engerix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) co-administered with Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
3049285|NCT00652938|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ (Human Papillomavirus [HPV] vaccine) according to a 0, 1, 6-month schedule.
3049286|NCT00652938|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix™ (Hepatitis B [HBV] vaccine) according to a 0, 1, 6-month schedule.
3179037|NCT00668356|Experimental|1|
3179038|NCT00668356|Active Comparator|2|
3049287|NCT00652951|Active Comparator|Synflorix + Infanrix hexa Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with Infanrix hexaTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (Infanrix hexaTM) thigh or deltoid.
3049288|NCT00652951|Experimental|Synflorix + Pediacel Group|Subjects received 3 doses of SynflorixTM vaccine co-administered with PediacelTM at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (SynflorixTM) or left (PediacelTM) thigh or deltoid.thigh or deltoid.
3049289|NCT00652951|Active Comparator|Prevenar + Pediacel Group|Subjects received 3 doses of PrevenarTM co-administered with PediacelTM vaccine at 2, 3 and 4 months of age (Study Months 0, 1, 2) and received a booster dose of each vaccine between 11 and 13 months of age (Study Month 9). All vaccines were administered intramuscularly in the right (PrevenarTM) or left (PediacelTM) thigh or deltoid.
3049290|NCT00653068|Experimental|Arm I (chemotherapy, autologous PBSC, 3D-CRT)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Within 2-6 weeks after induction therapy or radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment with consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. After consolidation therapy, patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks."
3049291|NCT00653068|Experimental|Arm II (chemotherapy, 3D-CRT, autologous PBSC)|"Patients receive vincristine IV on days 1, 8, and 15; high-dose methotrexate IV on day 1; leucovorin calcium orally or IV; etoposide IV on days 4, 5, and 6; cyclophosphamide IV on days 4 and 5; cisplatin IV on day 6, and G-CSF IV or SC on day 7 until ANC recovers.~Patients undergo 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks. Within 2-6 weeks after completion of radiation therapy, patients receive high-dose carboplatin IV and high-dose thiotepa IV on days 1 and 2 and undergo autologous PBSC rescue on approximately day 4. Patients also receive G-CSF IV or SC once daily until ANC recovers. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3049292|NCT00653133|Active Comparator|USPNB|Ultrasound imaging guided peripheral nerve block
3049293|NCT00653133|Active Comparator|NSPNB|Peripheral nerve stimulator guided peripheral nerve block catheter placement for continuous infusion of local anesthetic
3049294|NCT00653159|Active Comparator|Mirena IUD [LNG-IUS]|Participants in this arm had a Levonorgestrel-releasing intrauterine device (LNG-IUS), also known as the Mirena IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
3049295|NCT00653159|Active Comparator|Paragard IUD [Copper T380A]|Participants in this arm had a Copper T380A intrauterine device (CuT380A), also known as the Paragard IUD, inserted within the first 5 days of the adolescent's menstrual cycle, at least 7 weeks after a vaginal or cesarean delivery or second-trimester abortion or at least 3 weeks after a first-trimester abortion. For participants who had used depot-medroxyprogesterone acetate, insertions occurred at least 6 months after the participant's last injection. Participants were blinded to the device type; however, investigators and research assistants were not.
3049296|NCT00653224|Placebo Comparator|Placebo|Matched placebo tablets
3049297|NCT00653224|Experimental|LCTZ|5 mg tablet
3049298|NCT00653263||Methamphetamine dependent|Methamphetamine dependent participants admitted to Recovery Centers of Arkansas
3049299|NCT00653328|Experimental|Therapeutic Intervention|
3049300|NCT00653432|Experimental|Monovisc®|Injectable Hyaluronic Acid Gel
3049301|NCT00653432|Placebo Comparator|Saline|0.9% Sterile Saline
3049302|NCT00653523|Experimental|Ezetimibe + Simvastatin|Ezetimibe 10 mg + Simvastatin 20 mg
3049303|NCT00653861|Experimental|Juvederm with Lidocaine|Subjects receive Juvederm with Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in one nasolabial fold.
3049304|NCT00653861|Active Comparator|Juvederm|Subjects receive Juvederm without Lidocaine (either Ultra or Ultra Plus at investigator's discretion) in the other nasolabial fold.
3049305|NCT00653939|Active Comparator|Arm 1: Chemotherapy+Bevacizumab|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 months from randomization.
3049306|NCT00653939|Experimental|Arm 2: Active Comparator+Fosbretabulin|Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg), administered intravenously Day 1 of a 21-day cycle and fosbretabulin (60 mg/m2) on Days 7, 14, and 21 for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) on Day 1 and fosbretabulin on Days 1, 7 and 14 every 3 weeks until progression or until 12 months from randomization.
3049307|NCT00653991|Experimental|SOLVE-IT|Participants will receive the intervention SOLVE-IT. The SOLVE-IT intervention is a videogame designed to optimize self-regulation, reduce shame, and reduce risky choices for young men who have sex with men (YMSM).
3049308|NCT00653991|Active Comparator|Waitlist Control|Participants will receive the intervention, SOLVE-IT, a video game designed to optimize self-regulation reduce shame, and reduce risky sexual choices for YMSM, after a 6-month waitlist period.
3049309|NCT00654004||Subjects|Subjects are patients with a long-chain fatty acid oxidation disorder including CPT2, VLCAD, TFP or LCHAD deficiency.
3049310|NCT00654004||Controls|Subjects do not have a fatty acid oxidation disorder.
3049311|NCT00654030|Experimental|1650-G Vaccine|Patients receive 2 injections of 1650-G Vaccine given 4 weeks apart, for a total of 52 weeks on study.
3049312|NCT00654069|Placebo Comparator|Placebo|Tablet
3049313|NCT00654069|Active Comparator|Acurox 5/30mg|Oxycodone HCl 5mg/Niacin 30mg tablet
3049314|NCT00654069|Placebo Comparator|Acurox 7.5/30|Oxycodone HCl 7.5mg/Niacin 30mg tablet
3049315|NCT00654095|Experimental|Ezetimibe + Atorvastatin|Ezetimibe 10 mg + Atorvastatin 20 mg
3049316|NCT00654147|Active Comparator|Raltegravir & Lopinavir/ritonavir|Raltegravir 400 mg tablet and Lopinavir/ritonavir capsule by mouth, every 12 hours for 48 weeks
3049317|NCT00654147|Active Comparator|Raltegravir & emtricitabine/tenofovir|Raltegravir 400 mg tablet bu mouth, every 12 hours for 48 weeks and tenofovir/embritcitabine 200 mg/100 mg table by mouth, once daily for 48 weeks
3049318|NCT00654186|Experimental|1|
3049319|NCT00654238|Experimental|1|This is a single arm study.
3049320|NCT00654329|Experimental|Dexmedetomidine 1microgram/kilogram|Dexmedetomidine 1microgram/kilogram intranasal
3049321|NCT00654329|Experimental|Dexmedetomidine 2 micrograms/kilogram|Dexmedetomidine 2 micrograms/kilogram intranasal
3049322|NCT00654329|Active Comparator|Fentanyl 2 micrograms/kilogram|Fentanyl 2 micrograms/kilogram intranasal
3049323|NCT00654329|Placebo Comparator|Normal saline placebo|Normal saline placebo intranasal
3049324|NCT00654355|Experimental|Active Drug|tacrolimus ointment
3049325|NCT00654368|Active Comparator|Etanercept + Methotrexate|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to continue both etanercept plus methotrexate for an additional 18 months.
3049326|NCT00654368|Experimental|Etanercept Only|After six months of treatment with 50 mg/week subcutaneous etanercept added to existing methotrexate therapy of at least 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses) participants were randomized to discontinue methotrexate (tapered over 6 weeks) and continue etanercept alone for an additional 18 months.
3049327|NCT00654381|Active Comparator|voglibose 0.2 mg three times a day (TID)|patient to receive a tablet containing 0.2 mg voglibose TID plus 2 placebo tablets matching BI 1356
3049328|NCT00654381|Experimental|BI 1356 low dose|patient to receive a tablet containing BI 1356 and matching placebo plus 3 placebo tablets matching voglibose
3049329|NCT00654381|Experimental|BI 1356 high dose|patient to receive 2 tablets containing BI 1356 plus 3 placebo tablets matching voglibose
3049330|NCT00654381|Placebo Comparator|placebo|patient to receive 2 placebo tablets matching BI 1356 plus 3 placebo tablets matching voglibose
3049331|NCT00654420|Experimental|Ph I: Dalotuzumab 5 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 5 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
3049332|NCT00654420|Experimental|Ph I: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase I part of the study, participants receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily for 4 weeks. After 4 weeks of therapy, participants in Phase I who do not have disease progression and are satisfactorily tolerating study drug can continue to receive study drug.
3049333|NCT00654420|Experimental|Ph II: Dalotuzumab 10 mg/kg + Erlotinib|During the Phase II part of the study, participants are randomized to receive dalotuzumab intravenously (IV) at 10 mg/kg weekly plus open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
3049334|NCT00654420|Active Comparator|Ph II: Erlotinib|During the Phase II part of the study, participants are randomized to receive open-label erlotinib at 150 mg daily until disease progression or occurrence of unacceptable toxic effects.
3049335|NCT00654498|Other|Pramipexole|4 weeks of individual dose titration starting with Pramipexole 0.125 mg, next dose steps 0.25 mg, 0.5 mg and 0.75 mg, fixed dose for 2 weeks, once daily
3049336|NCT00654498|Other|Placebo|4 weeks of individual dose titration as for the investigational product, once daily
3049337|NCT00654511|Active Comparator|Fentanyl 1|Fentanyl 1 micrograms (mcg)/kilogram (kg)
3049338|NCT00654511|Active Comparator|Fentanyl 2|Fentanyl 2 micrograms (mcg)/kilogram (kg)
3049339|NCT00654511|Experimental|Dex 3|Dexmedetomidine 2 micrograms (mcg)/kilogram (kg)
3049340|NCT00654511|Experimental|Dex 4|Dexmedetomidine 4 micrograms (mcg)/kilogram (kg)
3049341|NCT00654615|Active Comparator|1|"Intramedullary Radius Fixation (Micronail) - Group 1~A new device was developed to provide intramedullary distal radius fracture fixation. This new device allows the placement of the orthopaedic hardware inside the medullary canal of the radius."
3049342|NCT00654615|Active Comparator|2|"Volar Plate Fixation - Group 2~Volar locking plates provide rigid external fixation and are placed on the outside of the radius. Volar plates are placed directly on the distal radius using a metal plate contoured to the shape of the distal radius."
3049343|NCT00654628|Experimental|1|Patients with intermediate or high risk dyslipidemia will be enrolled to receive treatment with Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks
3049344|NCT00654641|Experimental|Negative pressure wound closure|Negative Pressure wound closure
3049345|NCT00654641|Active Comparator|Standard wound closure|Standard Wound Closure
3049346|NCT00654654|Experimental|Active|
3049347|NCT00654732|Experimental|Arm A (rituximab, combination chemotherapy)|Participants receive rituximab intravenously IV over 7 hours on days 1, 8, 15, and 22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15. Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3049348|NCT00654732|Active Comparator|Arm B (combination chemotherapy)|Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine as in Arm A.
3049349|NCT00654745|Experimental|aml + olm + hctz|amlodipine; and olmesartan medoxomil, if required; and hydrochlorothiazide, if required.
3049350|NCT00654784|Experimental|1|
3049351|NCT00654784|Placebo Comparator|2|
3049352|NCT00654836|Experimental|Carboplatin, ABI-007 and Bevacizumab|Participants will receive combination carboplatin, nanoparticle albumin-bound paclitaxel (ABI-007-Abraxane), and bevacizumab (Avastin)
3049353|NCT00654875|Experimental|Aliskiren 300 mg (Once a Day)|Participants received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening for a total of 10 weeks.
3049354|NCT00654875|Experimental|Aliskiren 150 mg (Twice a Day)|Participants received Aliskiren 150 mg tablet + Placebo to Aliskiren matching 300 mg tablet daily in the morning and Aliskiren 150 mg tablet daily in the evening for the first 6 weeks then for the next 4 weeks received Aliskiren 300 mg tablet + Placebo to Aliskiren matching 150 mg tablet daily in the morning and Placebo to Aliskiren matching 150 mg tablet daily in the evening.
3049355|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 1|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3049356|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 2|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3049357|NCT00654901|Experimental|DTaP-IPV-Hep B-PRP~T Batch 3|Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3049358|NCT00654901|Active Comparator|Infanrix Hexa™|Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.
3049359|NCT00654940|Active Comparator|A|
3049360|NCT00654940|Placebo Comparator|B|
3049361|NCT00654953|Placebo Comparator|1|Placebo capsules
3049362|NCT00654953|Experimental|2|sertraline (200 mg/day)
3049363|NCT00654953|Experimental|3|sertraline (200 mg/day) plus gabapentin (1,200 mg/day)
3049364|NCT00654992|Active Comparator|EPO group|
3049365|NCT00654992|Placebo Comparator|Placebo group|
3049366|NCT00655083|Experimental|1|Nepadutant 0.1 mg/kg
3049367|NCT00655083|Experimental|2|Nepadutant 0.5 mg/kg
3049368|NCT00655356|Experimental|Active|
3049369|NCT00655356|Placebo Comparator|Placebo|
3049370|NCT00655473|Experimental|Dalcetrapib (RO4607381)|
3049371|NCT00655473|Placebo Comparator|Placebo|
3049372|NCT00655486|Experimental|Lacosamide|Lacosamide 100 to 800 mg/day, flexible dosing, administered twice daily throughout the duration of the study (up to 2 years)
3049373|NCT00655499|Experimental|Panitumumab + CPT11 (irinotecan hydrochloride)|1 cycle every 14 days (J1= J15)
3049374|NCT00655538|Experimental|Dalcetrapib|
3049375|NCT00655538|Placebo Comparator|Placebo|
3049376|NCT00655551|Experimental|Lacosamide 200 mg cohort|Single loading dose of intravenous (iv) lacosamide 200 mg followed by 6.5 days of oral lacosamide 100 mg twice daily
3049377|NCT00655551|Experimental|Lacosamide 300 mg combined cohorts|Single loading dose of intravenous (iv) lacosamide 300 mg dose followed by 6.5 days of oral lacosamide 150 mg twice daily
3049378|NCT00655551|Experimental|Lacosamide 400 mg cohort|Single loading dose of intravenous (iv) lacosamide 400 mg followed by 6.5 days of oral lacosamide 200 mg twice daily
3049379|NCT00655564|Experimental|Alefacept|Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
3049380|NCT00655629|Experimental|Vardenafil ODT (STAXYN, BAY38-9456)|Vardenafil 10 mg orodispersible tablet (ODT) taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3049381|NCT00655629|Placebo Comparator|Placebo|Matching placebo tablet taken on demand (PRN), approximately one hour before start of sexual activity, no more than one dose per day.
3049382|NCT00655642|Active Comparator|Ondansetron|Ondansetron 4 mg intravenous administration
3049383|NCT00655642|Active Comparator|Metoclopramide|Metoclopramide 10 mg intravenous administration
3049384|NCT00655642|Active Comparator|Promethazine|Promethazine 10 mg intravenous administration
3049385|NCT00655642|Placebo Comparator|Saline Placebo|Volume-matched saline placebo
3049386|NCT00655668|Experimental|Lenalidomide|Open-label, oral lenalidomide monotherapy
3049387|NCT00655707|Experimental|Autologous CD34+ cells|Autologous Cluster Designation 34+(CD34+) cells
3049388|NCT00655733|Experimental|HMPL-004|Subjects who fulfilled all entry criteria and randomized HMPL-004 arm will receive HMPL-004 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
3049389|NCT00655733|Placebo Comparator|Placebo|Subjects who fulfilled all entry criteria and randomized Placebo arm will receive matching placebo 400 mg 3 times daily 3 times daily for 56 days (8 weeks) with a 28-day (4-week) follow-up.
3049390|NCT00655746|Experimental|1|
3049391|NCT00655811|Active Comparator|Capsaicin|Capsaicin 0.1% cream application to the volar side of forearm.
3049392|NCT00655811|Placebo Comparator|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.) to the opposite forearm.
3049394|NCT00655850|Experimental|Paclitaxel and Gemcitabine + Avastin|Patients will be treated with metronomic chemotherapy with paclitaxel and gemcitabine weekly for 3 out of 4 weeks which constitutes one cycle (4 weeks). Avastin will be administered every 2 weeks. Treatment with metronomic chemotherapy and Avastin will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with Avastin will continue until disease progression, intolerable toxicity, or withdrawal of consent.
3049395|NCT00655863|Placebo Comparator|Placebo QD|
3049396|NCT00655863|Experimental|Alogliptin 25 mg QD|
3049397|NCT00655863|Experimental|Alogliptin 25 mg QD + Pioglitazone 30 mg QD|
3049398|NCT00655876|Experimental|Chemoradiation + Cetuximab|External beam radiation therapy (RT) with concurrent weekly paclitaxel, cisplatin, and cetuximab
3049399|NCT00655876|Active Comparator|Chemoradiation|External beam radiation therapy with concurrent weekly paclitaxel, and cisplatin
3049400|NCT00655889|Experimental|Active|
3049401|NCT00655928|Experimental|N-acetylcysteine|Participant received N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
3049402|NCT00655928|Placebo Comparator|Placebo|Participant received 0.9% saline 1 litre intravenous over 12 hours pre-operatively
3049403|NCT00655980|Experimental|Treatment|Vitamin B12 and folic acid
3049404|NCT00655980|Placebo Comparator|Comparator|Nitrous oxide and placebo
3049405|NCT00655980|Other|Standard of care|standard of care
3049406|NCT00656019|No Intervention|Normal Vitamin D Levels|No additional Vitamin D administered
3049407|NCT00656019|Experimental|Low-normal Vitamin D Levels|2000 IU dose of Vitamin D per day administered orally
3049408|NCT00656019|Experimental|Low Vitamin D Levels|4000 IU dose of Vitamin D per day administered orally
3049409|NCT00656019|Experimental|Very-low Vitamin D Levels|6000 IU dose of Vitamin D per day administered orally
3049410|NCT00656058|Experimental|Montelukast to Treat Bronchiolitis Obliterans|Montelukast for the treatment of BO following allogeneic or autologous stem cell transplant.
3049411|NCT00656084|Experimental|Experimental arm|Patients will be treated a maximum of 8 cycles or until the patient has evidence of a response, progressive disease, or until intolerable toxicity develops. Patients with a complete response will receive an additional 2 cycles of treatment (not to exceed 8 cycles). Drug order is gemcitabine, mitoxantrone, and rituximab.
3049412|NCT00656136|Placebo Comparator|Placebo|Patients receive placebo once daily
3049413|NCT00656136|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
3049414|NCT00656175|Active Comparator|Immediate|Immediate switch of PI or NNRTI to Raltegravir
3049415|NCT00656175|Active Comparator|Delayed|Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir
3049416|NCT00656201|Active Comparator|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
3049417|NCT00656201|Active Comparator|Intramuscular Progesterone|"Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.~."
3049418|NCT00656292|Placebo Comparator|Simvastatin|Subjects randomized to this arm will receive statin therapy (simvastatin 40 mg) two days before surgery -- allowing three doses of simvastatin before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of simvastatin therapy), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
3049419|NCT00656292|Experimental|Placebo|Subjects randomized to this arm will receive placebo two days before surgery -- allowing three doses of placebo before incision -- and these will be continued until patients are either discharged from the hospital or have completed a 3-day postoperative course (6 days of placebo), whichever occurs earlier. If patients are unable to take oral medications, the enteral route via nasogastric tube (at our institution, nasogastric tubes are routinely placed for both lumbar and thoracic instrumentation) will be used to deliver either placebo or the statin, as no parenteral form of this drug is currently available.
3049420|NCT00656305|Experimental|ExAblate Treatment Arm|
3049421|NCT00656305|Sham Comparator|ExAblate Sham Arm|
3049422|NCT00656370|Experimental|NS Infusion Group|Normal Saline (NS) and Hylenex
3049423|NCT00656370|Experimental|LR Infusion Group|Lactated Ringer's (LR) and Hylenex
3049424|NCT00656448|Experimental|Procrit Arm|Participants receive Procrit along with blood transfusions. Procrit 40,000 units subcutaneously every week starting within two weeks (before or after) from the start of induction chemotherapy.
3049425|NCT00656448|No Intervention|No Procrit: Standard Arm|Participants do not receive Procrit before receiving blood transfusions.
3049426|NCT00656474|Experimental|1|GLYC-101 Active Retro-auricular Site (1 per participant)
3049427|NCT00656474|Placebo Comparator|2 Comparator|"Placebo Retro-auricular Site (1 per participant)~This arm undergoes laser ablation with subsequent Placebo gel administration"
3049428|NCT00656487|Experimental|Cannabis-dependent rimonabant|Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
3049429|NCT00656487|Placebo Comparator|Cannabis-dependent placebo|Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
3049430|NCT00656487|No Intervention|Non-cannabis using control|Non-cannabis using demographically similar young adults followed for 28 days.
3049431|NCT00656513|Active Comparator|Pilocarpine: Phase III|
3049432|NCT00656513|Experimental|ALTENS: Phase III|
3049433|NCT00656513|Experimental|ALTENS: Phase II|
3049434|NCT00656617|Experimental|Idarubicin + Ara-C + Vorinostat|Idarubicin 12 mg/m^2 by vein (IV) over 1 hour daily for 3 days (days 4 to 6). Ara-C (Cytarabine) 1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7). Vorinostat initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
3049435|NCT00656630|Active Comparator|1|Acamprosate
3049436|NCT00656630|Active Comparator|2|Naltrexone
3049437|NCT00656630|Placebo Comparator|3|
3049438|NCT00656656|Other|Immunoadsorption/Dexamethasone/Rituximab|
3049439|NCT00656669|Experimental|1|The study will be conducted in 3 sequential treatment segments.
3049440|NCT00656799|Experimental|Sugammadex|IV single bolus dose of 4.0 mg/kg sugammadex
3049441|NCT00656851|Active Comparator|Pioglitazone|Pioglitazone (Actos, 30mg/day for 16 weeks)
3049442|NCT00656851|Active Comparator|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
3049443|NCT00656968|Active Comparator|10-day concomitant therapy|esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days
3049444|NCT00656968|Experimental|10-day sequential therapy|esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days
3049445|NCT00657020|Experimental|Nicotine lozenge|Nicotine lozenge containing 4 mg of nicotine to be placed in mouth and suck to dissolution.
3049446|NCT00657020|Placebo Comparator|Placebo lozenge|Placebo lozenge to be placed in mouth and suck to dissolution.
3049447|NCT00657046|Active Comparator|1|Droxidopa at 400 mg (2 capsules each containing 200 mg droxidopa plus one capsule with Placebo)
3049448|NCT00657046|Active Comparator|2|Droxidopa at 600 mg (3 capsules each containing 200 mg droxidopa)
3049449|NCT00657046|Placebo Comparator|3|Placebo (3 capsules with mannitol substituted for droxidopa)
3049450|NCT00657150|Experimental|Dabigatran etexilate|220 mg once daily
3049451|NCT00657150|Active Comparator|Enoxaparin|40 mg once daily
3049452|NCT00657267|Experimental|Single-Arm Study|
3049453|NCT00657280|Experimental|All subjects recieve Sitagliptin|All subjects are aware of what they are taking. Nobody is blinded in this study. study
3049454|NCT00657358|Experimental|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
3049455|NCT00657371|Experimental|Third Eye Retroscope|Colonoscopy exam using the Third Eye Retroscope device
3049456|NCT00657540|Experimental|Analatro|Antivenin Latrodectus (Black Widow) Equine Immune F(ab)2
3049457|NCT00657540|Placebo Comparator|Normal Saline Placebo|Normal Saline
3049458|NCT00657605|Experimental|Recombinant methionyl human leptin|Participants with congenital leptin deficiency will receive the Recombinant methionyl human leptin intervention subcutaneously, once a day with a dose of 0.02 to 0.04 mg/kg (adjusted according to weight loss).
3049459|NCT00657618|Experimental|Treatment only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Sodium Stibogluconate (SSG).
3049460|NCT00657657|Experimental|Group 1|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12, 60 (5 doses)
3049461|NCT00657657|Experimental|Group 2|Neonates from mother HBsAg (+) and HBeAg (+) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3049462|NCT00657657|Experimental|Group 4|Neonates from mother HBsAg (+) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3049463|NCT00657657|Experimental|Group 6|Neonates from mother HBsAg (-) and HBeAg (-) had received HBV vaccine at Month 0, 1, 2, 12 (4 doses)
3049464|NCT00657709|Experimental|rMenB Lot1|Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3049465|NCT00657709|Experimental|rMenB Lot2|Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3049466|NCT00657709|Experimental|rMenB Lot3|Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.
3049467|NCT00657709|Active Comparator|Routine|Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.
3049468|NCT00657709|Active Comparator|MenC + Routine|Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.
3049469|NCT00657917|Experimental|Paromomycin +Gentamicin topical cream|WR279,396 topically twice a day for 20 days
3049470|NCT00658021|Placebo Comparator|Placebo|Subcutaneous injection, twice a day
3049471|NCT00658021|Experimental|Exenatide 5 µg|Subcutaneous injection, twice a day
3049472|NCT00658021|Experimental|Exenatide 10 µg|Subcutaneous injection, twice a day
3049473|NCT00658112|Experimental|Benzoyl Peroxide 5%|Subjects will be given standard instructions in the use of topical benzoyl peroxide gel and will be provided with a supply of medication fitted with a Medication Event Monitoring System (MEMS) cap. This cap records dates and times the assembly is opened which can be downloaded at the final visit and tabulated with associated software. When the tubes are weighed, data from the MEMS Caps will be collected. Study coordinators will record adherence, while assessors are blinded to adherence rates. All subjects will be assigned to treatment with topical benzoyl peroxide to the entire face.
3049474|NCT00658138|Experimental|Adhesive A|
3049475|NCT00658138|Active Comparator|Adhesive B|
3049476|NCT00658320|Experimental|Everolimus + Reduced dose of cyclosporine|An initial everolimus dose of 0.75 mg orally twice daily (1.5 mg/day) was administered 24-36 hours from reperfusion after transplantation and dose adjustments based on everolimus trough level (target trough level 3-8 ng/mL). Reduced dose of cyclosporine was initiated either pre-transplantation or within 24 hours after transplantation following the local regimen. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study. Everolimus was available after 24 months for compassionate use.
3049477|NCT00658320|Active Comparator|Mycophenolate mofetil (MMF) + Standard dose of cyclosporine|Patients were treated with 1 gram twice a day (2 grams/day) of Mycophenolate mofetil (MMF) and standard dose of cyclosporine for 12 months post renal transplant. Patients were treated with antibody induction therapy using 20 mg basiliximab two hours prior to transplant and 20 mg basiliximab 4 days post transplant or according to local practice. Corticosteroids were administered according to local practice. Patients were treated for 12 months in the core study and 12 months in the extension study.
3049478|NCT00658333|Experimental|Enteric-coated Mycophenolate Acid|Equimolar dose of enteric-coated mycophenolate acid with mycophenolate mofetil placebo. 1000 mg mycophenolate mofetil = 720 mg enteric-coated mycophenolate acid (MPA equivalent dose). The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
3049479|NCT00658333|Active Comparator|Mycophenolate Mofetil|Mycophenolate mofetil therapy with placebo enteric-coated mycophenolate acid. The active and placebo study medications were dispensed in separate bottles identified as Bottle A and Bottle B.
3049480|NCT00658359|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications
3049481|NCT00658359|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive standard of care medications
3049482|NCT00658359|Experimental|Treatment Arm 3|Treatment Arm 3 will also receive standard of care medications
3049483|NCT00658385|Experimental|1|GCSF (human recombinant granulocyte colony stimulating factor)Neupogen(Amgen), Filgrastim, Central venous line placement, Stem cell Collection (leukapheresis)
3049484|NCT00658411|Experimental|All patients|Deferoxamine for >=2 weeks prior to stem cells
3049485|NCT00658515|Experimental|Dalcetrapib (RO4607381)|
3049486|NCT00658515|Placebo Comparator|Placebo|
3049487|NCT00658528|Experimental|1|
3049488|NCT00658528|Active Comparator|2|
3049489|NCT00658541|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
3049490|NCT00658541|Active Comparator|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
3049491|NCT00658567|Experimental|2|pimavanserin tartrate (ACP-103) 20 mg, tablet, once daily by mouth, 6 weeks
3049492|NCT00658567|Placebo Comparator|Placebo|Placebo tablet, once daily by mouth, 6 weeks
3049493|NCT00658567|Experimental|1|pimavanserin tartrate (ACP-103) 10 mg, tablet, once daily by mouth, 6 weeks
3049494|NCT00658606|Active Comparator|Alefacept alone|15 mg alefacept intramuscularly (IM) once weekly for 12 weeks
3049495|NCT00658606|Experimental|Alefacept + nbUVB|15 mg alefacept intramuscularly once weekly and narrow band Ultraviolet B (nbUVB) phototherapy 3 times per week for 12 weeks
3049496|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3049497|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 1|Stage 1: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3049498|NCT00658619|Other|400 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3049499|NCT00658619|Other|200 µg Brimonidine Tartrate Implant Stage 2|Stage 2: 200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1 and Month 6.
3049500|NCT00658619|Sham Comparator|Sham (no implant) Stage 2|Stage 2: sham in both eyes on Day 1 and Month 6.
3049501|NCT00658632|Experimental|1|
3049502|NCT00658632|Active Comparator|2|
3049503|NCT00658658|Experimental|Panitumumab|Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.
3049504|NCT00658684|Experimental|Fesoterodine fumarate|
3049505|NCT00658697|Experimental|Docetaxel, Bevacizumab, and ADT|"Docetaxel:~Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles~Bevacizumab:~Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles~ADT or Luteinizing hormone-releasing hormone agonist (LHRH):~Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)~Bicalutamide:~Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)"
3049506|NCT00658723|Experimental|1|
3049507|NCT00658723|Active Comparator|2|SURGICEL™ Absorbable Hemostat
3049508|NCT00658736|Experimental|1|EUS guided celiac block with bupivicaine and triamcinolone. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
3049509|NCT00658736|Placebo Comparator|2|EUS guided celiac block with bupivicaine only. Patient will undergo endoscopic ultrasound and celiac plexus blockade using an EUS needle inserted into the celiac plexus. 20 cc of injectate will be administered.
3049510|NCT00658775|Experimental|1|
3049511|NCT00658775|Active Comparator|2|
3049512|NCT00658788|Active Comparator|Study Treatment|"clobetasol propionate spray 0.05%~Other Names:~Clobex® Spray 0.05% clobetasol propionate spray, 0.05%, applied topically twice daily~calcitriol ointment~Other Names:~Calcitriol Ointment calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily"
3049513|NCT00658814|Experimental|Treatment (azacitidine, gemtuzumab)|See Detailed Description
3049514|NCT00658879||Somavert (Pegvisomant)|Patients taking Somavert (Pegvisomant).
3049515|NCT00658996|Experimental|SofLens DD Toric|Bausch & Lomb SofLens Daily Disposable Toric Contact Lens
3049516|NCT00658996|Active Comparator|Ciba Vision Toric Lens|Ciba Vision Focus Dailies Toric Contact Lens
3049517|NCT00659061|Active Comparator|Intervention|Multiple micronutrient fortificant (Sprinkles) and nutrition education given by LHWs.
3049518|NCT00659061|No Intervention|Control|Routine public health massages by Lady Health Workers (LHWs) during their community visits.
3049519|NCT00659165|Experimental|Insulin Detemir|Insulin Detemir
3049520|NCT00659165|Experimental|Insulin Glargine|Insulin Glargine
3049521|NCT00659230|Placebo Comparator|Placebo|Arm 1
3049522|NCT00659230|Active Comparator|Nepicastat|Arm 2
3049523|NCT00659269|Active Comparator|Multivitamin (MV)|1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)
3049524|NCT00659269|Experimental|Multivitamin + Vitamin B12 + Vitamin B6|"1 multivitamin pill will be taken orally, daily starting on the first day of chemotherapy and continuing for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts).~The patient will also take the following, starting on the first day of chemotherapy:~pyridoxine 50 mg three times per day, orally and continue for no more than 30 days past the cumulative chemotherapy dose (until the next cycle starts)~Vitamin B12 one mg injected intramuscularly, every 3 or 4 weeks, depending on the timing of the chemotherapy for 4 doses."
3049525|NCT00659295||Type 1 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
3179039|NCT00668369|Experimental|1|Liver transplant recipients with HCV infection fulfilling inclusion criteria.
3049526|NCT00659295||Type 2 diabetes|Prescription of insulin detemir (Levemir®) according to local approved labelling by prescribing physician in a normal clinical practice to patients with type 1 diabetes, including newly diagnosed patients who have never received insulin or analogue treatment.
3049527|NCT00659334|Active Comparator|1|Adults with brain tumor to receive Combidex infusion only
3049528|NCT00659334|Active Comparator|2|Adults with brain tumors to receive Combidex infusion and neurosurgery
3049529|NCT00659334|Other|3|Adults with brain tumors to receive neurosurgery only (NO Combidex)
3049530|NCT00659334|Active Comparator|4|Children with brain tumors to receive Combidex only
3049531|NCT00659334|Active Comparator|5|Children with brain tumors to receive Combidex and neurosurgery
3049532|NCT00659334|Other|6|Children with brain tumors to receive neurosurgery only, NO Combidex
3049533|NCT00659334|Active Comparator|7|Adults with Inflammatory lesions (stroke or MS) to receive Combidex only
3049534|NCT00659360|Experimental|Arm I|Patients receive oral AZD0530 (saracatinib ) at a dose of 175 mg, once daily, in the absence of disease progression or unacceptable toxicity.
3049535|NCT00659373|Active Comparator|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
3049536|NCT00659373|Experimental|T+OFS|Tamoxifen 20mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3049537|NCT00659373|Experimental|E+OFS|Exemestane 25mg orally daily for 5 years plus ovarian function suppression (OFS; triptorelin (GnRH analogue) 3.75 mg by im injection q28 days for 5 years; or surgical oophorectomy; or ovarian irradiation)
3049538|NCT00659425|Experimental|5 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049539|NCT00659425|Experimental|10 microgram per kilogram (mcg/kg)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049540|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049541|NCT00659425|Experimental|20 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049542|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema A|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049543|NCT00659425|Experimental|30 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049544|NCT00659425|Experimental|40 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049545|NCT00659425|Experimental|32 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
3049546|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema B|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
3049547|NCT00659425|Experimental|50 microgram per kilogram (mcg/kg): Schema C|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
3049548|NCT00659438|Experimental|1|Bicalutamide 150mg + ZD6474 300mg
3049549|NCT00659438|Placebo Comparator|2|Bicalutamide 150mg + placebo
3049550|NCT00659490|Experimental|AZD1940|AZD1940 800ug given predose
3049551|NCT00659490|Active Comparator|Naproxen|Naproxen 500mg given pre-surgery
3049552|NCT00659490|Placebo Comparator|Placebo|Placebo given pre-surgery
3049553|NCT00659529|Experimental|1|All subjects will receive oral sildenafil three times per day during the study. Study endpoints will be measured before the treatment period and at the end of the treatment period.
3049554|NCT00659581||Patients with hypertension|
3049555|NCT00659633|Experimental|Lidocaine|Intravenous lidocaine for neuropathic pain
3049556|NCT00659646|Experimental|A|Gentamicin sponge applied into wound plus levofloxacin, 750 mg by mouth (po) or intravenous (IV) every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
3049557|NCT00659646|Active Comparator|B|Levofloxacin, 750 mg po or IV every 24 hours or, if ulcer culture results show resistance to levofloxacin, alternative antimicrobial therapy as determined by susceptibility testing
3049558|NCT00659737|Placebo Comparator|Aprepitant|"Oral Aprepitant pill and placebo transdermal patch at least 1 hour prior to surgical procedure.~Emend (Aprepitant) + Placebo"
3049559|NCT00659737|Active Comparator|Scopolamine|Oral Aprepitant pill and Scopolamine transdermal patch at least 1 hour prior to surgical procedure.
3049560|NCT00659789|Experimental|Vacc-4x|Vacc-4x reconstituted in sterile water (0.1 mL) at a dose of 1.2mg per intradermal administration. Participants are given a total of 6 immunizations over 18 weeks (weeks 1, 2, 3, 4, 16, 18). Recombinant human granulocyte macrophage colony stimulating factor (rhuGM-CSF) Leukine (0.06mg in 0.1 mL) administered intradermally is used as a local adjuvant.
3049561|NCT00659789|Placebo Comparator|Placebo|Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
3049562|NCT00659802|Placebo Comparator|placebo|Matching dose of placebo will be given orally in capsules three times per day for 56 days.
3179040|NCT00668408|Other|LTOT group|Study group: optimal medical therapy plus LTOT = or > 15 hours pro die
3049563|NCT00659802|Experimental|HMPL-004 low dose|A total of 1200 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
3049564|NCT00659802|Experimental|HMPL-004 high dose|A total of 1800 mg of HMPL-004 per day in three divided doses will be given orally in capsules, 200 mg each, for 56 days.
3049565|NCT00659815|Active Comparator|ReNu in Currently Marketed Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.
3049566|NCT00659815|Experimental|ReNu in Clear Resin Bottle|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.
3049567|NCT00659828|Experimental|Recombinant Methionyl Human Leptin|Recombinant methionyl human leptin: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss).
3049568|NCT00659945|Active Comparator|1|Pre-op Aprepitant plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
3049569|NCT00659945|Placebo Comparator|2|Pre-op Placebo plus Ondansetron for PONV prophylaxis in patients undergoing outpatient plastic surgery
3049570|NCT00659984|Experimental|Ultratrace™ Iobenguane I 131|"Eligible patients received a diagnostic imaging dose of Ultratrace™ Iobenguane I 131 (1-5 mCi) within 7 days of study enrollment, followed by three dosimetry scans over 3-6 days. If the imaging dose demonstrated normal biodistribution and tumor uptake, then the patient received a therapeutic dose within 7-28 days of the diagnostic imaging dose, followed by a single imaging scan on Day 7 post therapy. As per protocol, therapeutic dosing was to begin at 12.0 mCi/kg and escalate to 15.0, 18.0, and 21.0 mCi/kg until the MTD was established or the 21.0 mCi/kg dose level was reached. Actual doses administered ranged from 8.8 to 18.6 mCi/kg. Based on actual doses administered, patients were grouped into 3 mean dose groups: 11.2, 15.5, and 18.2 mCi/kg.~The dosimetry dose was administered over a period of 1-3 minutes by injection; the therapeutic dose was diluted in up to 25 mL normal saline and infused intravenously over 30 to 60 minutes."
3049571|NCT00660010|Experimental|1|
3049572|NCT00660023|Experimental|Mircera in Renal Anemia|Participants with chronic renal anemia previously treated with ESA therapy will receive intravenous Mircera, also known as continuous erythropoietin receptor activator (CERA), every 4 weeks for a total of 52 weeks in this single-arm study. The first dose will be determined by the dose of ESA received prior to administration of study treatment, and subsequent doses will be adjusted to achieve target Hb concentrations.
3049573|NCT00660049|Experimental|SNaP application|"This is an open label pilot study of SNaP Advanced Wound Care System"
3049574|NCT00660075|Experimental|1|Sitagliptin 100 mg/d for 6 weeks
3049575|NCT00660075|Placebo Comparator|2|Placebo for 6 weeks
3049576|NCT00660179|Experimental|1|Macitentan (ACT-064992) tablet, 3 mg, once daily
3049577|NCT00660179|Experimental|2|Macitentan (ACT-064992) tablet, 10 mg, once daily
3049578|NCT00660179|Placebo Comparator|3|Matching placebo, once daily
3049579|NCT00660192|Placebo Comparator|Placebo|Subjects are randomized to receive Placebo which is inactive saline (sterile salt water solution). The Subjects are injected with a comparable amount of placebo solution (2cc-3cc) as received by those randomized to receive active study drug. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
3049580|NCT00660192|Active Comparator|Botox|Subjects are randomized to receive Active study drug Botox (onobotulinumtoxinA). The Botox is prepare by diluting 100units of toxin /1cc Saline. The Subjects are injected with 200-300units of units of Botox which is 2cc-3cc of solution. The randomization will be done in a double blinded manner where the investigator nor the subject knows which substance (Placebo vs. Botox) is being injected.
3049581|NCT00660309|Experimental|Aliskiren|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received aliskiren 300 mg tablets orally once a day for 14 days.
3049582|NCT00660309|Active Comparator|Irbesartan|On Day 1 participants received a single oral dose of 25 mg captopril. Starting on Day 2 participants received irbesartan 300 mg tablets orally once a day for 14 days.
3049583|NCT00660387|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG) + Placebo Capsules|Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG.
3049584|NCT00660387|Active Comparator|Placebo Gel + Levodopa-Carbidopa Capsules|Participants were randomized to placebo intestinal gel and oral levodopa-carbidopa (levodopa, 100 mg and carbidopa, 25 mg) Immediate Release (IR) capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of placebo.
3049585|NCT00660400|Experimental|Combined Therapy|5-azacitidine therapy followed Allogeneic Hematopoietic Cell Transplantation (HCT).
3049586|NCT00660504|Experimental|1|Amrubicin Hydrochloride-Cisplatin combined chemotherapy
3049587|NCT00660504|Active Comparator|2|Etoposide-Cisplatin combined chemotherapy
3049588|NCT00660517|Experimental|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray
3049589|NCT00660517|Active Comparator|azelastine Hcl 548 mcg|azelastine Hcl 548 mcg nasal spray
3049590|NCT00660517|Active Comparator|fluticasone propionate 200 mcg|fluticasone propionate 200 mcg nasal spray
3049591|NCT00660517|Placebo Comparator|placebo|placebo nasal spray
3049592|NCT00660530|Active Comparator|1|One week before the administration of crushed or chewed lanthanum, the subjects were instructed to discontinue their P-binding agents, if prescribed previously. At the end of the 1-week washout period, subjects whose serum P exceeded 5.5 mg/dL were randomized to receive, in a crossover fashion, lanthanum 1000 mg (Fosrenol, Shire US Inc., Wayne, PA, USA) 3 times daily to be chewed with meals (chewed LAN) or lanthanum 1000 mg crushed into a ﬁne powder and taken with meals 3 times daily (crushed LAN), for 4 weeks each. The lanthanum tablets were crushed into a ﬁne powder using a mortar and pestle by the investigators, individually wrapped in powder packets and dispensed to the subjects on a weekly basis. The subjects were instructed to empty the powder into a small plastic cup provided, mix with 2 tablespoonfuls of applesauce and take it with meals. After each treatment (chewed or crushed LAN), there was a 1-week washout period.
3049593|NCT00660530|Experimental|2|After the one-week washout period, the subject received the other lanthanum treatment (chewed or crushed) that they did not receive in the initial treatment period.
3179041|NCT00668408|Other|Non LTOT group|control group: optimal medical therapy without LTOT
3049594|NCT00660543|Experimental|Ferumoxytol|Patients receive ferumoxytol non-stoichiometric magnetite IV on day 2 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose). Ferumoxytol non-stoichiometric magnetite administration continues in the absence of unacceptable toxicity.
3049595|NCT00660543|Active Comparator|Gadoteridol|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
3049596|NCT00660543|Active Comparator|Gadoteridol Leakage Corrected|Patients receive gadoteridol IV on day 1 then undergo DSC MRI, and DCE MRI, DWI (day 1 only), and TOF MR angiography on days 1-3 at 4 time points: before radiation, 3 weeks after initiation of radiation plus temozolomide, at the end of radiation (6 weeks post first dose) and 6 weeks after radiation (12 weeks post first dose).
3049597|NCT00660660|Experimental|Nexium 20mg|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
3049598|NCT00660660|Placebo Comparator|Placebo|
3049599|NCT00660699|Experimental|Arm 1 (gemcitabine, docetaxel, 5FU, radiation)|"Gemcitabine 1000 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~Docetaxel 35 mg/m2 IV on Day 1 and Day 8 of a 21 day cycle for 2 cycles~5FU CIVI 225 mg/m2 per day throughout radiation (starts 3 weeks after start of cycle 2)~Radiation 5040 cGy or 5400 cGy for positive margins (starts 3 weeks after start of cycle 2). Daily dose of 1.8 Gy five days per week.~Gemcitabine 1000 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)~Docetaxel 35 mg/m2 IV on Days 1 and 8 of 21 day cycle for 2 cycles (this starts 4 weeks after radiation)"
3049600|NCT00660790||Patients with Type 2 Diabetes|diabetic subjects, above targets
3049601|NCT00660816|Active Comparator|Arm I|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
3049602|NCT00660816|Experimental|Arm II|Patients receive pemetrexed disodium IV over 10 minutes OR docetaxel IV over 60 minutes on day 1 and erlotinib hydrochloride PO once daily on days 2-19. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive standard chemotherapy with or without erlotinib hydrochloride in the absence of disease progression or unacceptable toxicity.
3049603|NCT00660829|Placebo Comparator|1|Placebo
3049604|NCT00660829|Active Comparator|2|0.15% Azelastine Hydrochloride
3049605|NCT00660907|Experimental|1|dapagliflozin plus metformin
3049606|NCT00660907|Active Comparator|2|glipizide plus metformin
3049607|NCT00660985|Experimental|Differin® Gel, 0.3%|Gel, 0.3%, 2g, once daily for 30 days
3049608|NCT00660985|Active Comparator|Differin® Gel, 0.1%|Gel, 0.1%, 2g, once daily for 30 days
3049609|NCT00661037||1|Patients having VF induction with shock termination at implant
3049610|NCT00661037||2|Patients not having VF induction at implant or during follow-up
3049611|NCT00661089|Experimental|Intramuscular OnabotulinumtoxinA|Injection of Botulinum Toxin type A - onabotulinumtoxinA into specified shoulder muscles at second visit
3049612|NCT00661089|Active Comparator|Intramuscular Placebo (Saline)|Injection of saline into specified shoulder muscles at Visit 2. Blind broken and subjects were offered study drug if initially in the placebo group, at week 12
3049613|NCT00661141|Experimental|Cohort 1: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 1.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
3049614|NCT00661141|Experimental|Cohort 2: Antizol 3.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 3.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol or 30 minutes after ethanol.
3049615|NCT00661141|Experimental|Cohort 3: Antizol 5.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 5.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
3049616|NCT00661141|Experimental|Cohort 4: Antizol 1.0 mg/kg|Participants receive alternating study treatment (oral fomepizole 7.0 mg/kg or placebo) on 2 sequential days (Study Day 1 and Study Day 2), administered 30 minutes prior to ethanol.
3049617|NCT00661193|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3049618|NCT00661193|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and oral erlotinib hydrochloride once daily on days 2-16. Treatment repeats every 21 days for 4 courses. Beginning in course 5 and for all subsequent courses, patients receive oral erlotinib hydrochloride alone on days 1-21. Courses with erlotinib hydrochloride repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3049619|NCT00661258|Experimental|Intervention|The intervention group patients were given their electronic drug monitoring feedback data at each monthly visit. The study coordinator would quickly calculate whether the patient's adherence was below 95% in the previous month. If so, that patient was flagged for enhanced counseling with a clinic doctor and this counseling was based on a printout containing the electronic drug monitoring data.
3049620|NCT00661258|No Intervention|Comparison|"The comparison group patients were not given the data from the electronic data monitoring feedback data. Instead, they filled out a self report form that all patients fill out. If they indicated in this report that their adherence in the previous was less than 95%, then they were flagged for enhanced counseling with a doctor. This counseling was based on the patient's self report. Thus both groups received enhanced counseling if they indicated poor adherence, but only the intervention group were given their electronic data output."
3049621|NCT00661271|Experimental|Mindfulness-Based Stress Reduction|8-week mindfulness-based stress reduction program with one retreat session
3049622|NCT00661271|Active Comparator|Healthy Topics|8-week health education program with one retreat session - based on a health curriculum developed by McGraw/Hill
3049623|NCT00661362|Experimental|1|Metformin + Saxagliptin
3049624|NCT00661362|Placebo Comparator|2|Metformin + Placebo
3049625|NCT00661388|Experimental|Continuous erythropoietin receptor activator (C.E.R.A.)|Eligible participants will be administered C.E.R.A subcutaneously, every 4 weeks for 44 weeks. The initial dose of C.E.R.A. will be 1.2 micrograms/kilogram. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin within the target range of 10.0 and 12.0 grams/deciliter.
3049626|NCT00661427|Active Comparator|Cetuximab 500 mg/m^2|Cetuximab 500 mg/m^2 IV over 2 hours every other week
3049627|NCT00661427|Active Comparator|Cetuximab 750 mg/m^2|Cetuximab 750 mg/m^2 IV over 3 hours every other week
3049628|NCT00661453|Experimental|1|All patients will receive VPA and carnitine.
3049629|NCT00661479|Experimental|400 µg Brimonidine Tartrate Implant Group B|400 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3049630|NCT00661479|Experimental|200 µg Brimonidine Tartrate Implant Group B|200 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3049631|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group B|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3049632|NCT00661479|Experimental|100 µg Brimonidine Tartrate Implant Group A|100 µg brimonidine tartrate implant in the study eye and sham in the fellow eye on Day 1.
3049633|NCT00661492|Experimental|Arm 1|Erbitux (cetuximab) and Novantrone (mitoxantrone)
3049634|NCT00661492|Experimental|Arm 2|Novantrone (mitoxantrone)
3049635|NCT00661505|Experimental|C.E.R.A. 120, 200, or 360 mcg|Eligible participants were administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) at a dose of 120, 200, or 360 microgram (mcg), intravenously (IV), every 4 weeks i.e. Weeks 4, 8, 12, 16 and 20 but not on Weeks 24 and 28. The initial dose of C.E.R.A.was based on the last dose of the previous Erythropoiesis Stimulating Agent (ESA). The ESA therapy was administered from enrollment to the 4 weeks stability verification period (SVP), weekly, either as epoetin (<8000 IU, 8000-16000 IU, or >16000 IU) or darbepoetin alpha (<40 mcg, 40-80 mcg, or >80 mcg). A telephone follow-up visit took place 4 weeks after the end of C.E.R.A. treatment (Week 28).
3049636|NCT00661531|Experimental|Estrace & Anastrozole|Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered
3049637|NCT00661544|Experimental|Arsenic Trioxide + Vitamin C + Melphalan|Arsenic Trioxide + Ascorbic Acid + Melphalan as a preparative regimen for autologous stem cell transplantation (delivered on Day 0)
3049638|NCT00661557|Experimental|Mencevax Primed Group|Subjects who were previously vaccinated with meningococcal vaccine Mencevax ACWY in study NCT00227422 received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
3049639|NCT00661557|Active Comparator|Mencevax Naive Group|Subjects who did not receive (or had not received in the preceding 10 years) any meningococcal vaccination received in the current study a single dose of meningococcal conjugate vaccine Nimenrix, administered intramuscularly in the deltoid muscle of the non-dominant arm.
3049640|NCT00661570|Experimental|Early feasability arm|
3049641|NCT00661583|Experimental|Ranibizumab alone|Treatment with ranibizumab 0.5 mg intravitreally injected (n=10)
3049642|NCT00661583|Experimental|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy (n=10)
3049643|NCT00661583|Active Comparator|MMC alone|MMC therapy alone (n=10)
3049644|NCT00661609|Experimental|AZD4877|Single agent AZD4877
3049645|NCT00661622|Experimental|Immunoembolization|Liver embolization treatment with injection of GM-CSF.
3049646|NCT00661622|Active Comparator|Plain embolization|Liver embolization with normal saline injected in place of GM-CSF
3049647|NCT00661661|Experimental|CP-690,550|
3049648|NCT00661674|Experimental|Sequence 1: Placebo, Combo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Palonosetron"
3049649|NCT00661674|Experimental|Sequence 2: Palonosetron, Combo, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron~Week 2: Palonosetron + Hydroxyzine Combo~Week 3: Placebo"
3049650|NCT00661674|Experimental|Sequence 3: Combo, Placebo, Palonosetron|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Placebo~Week 3: Palonosetron"
3132582|NCT03438539|Experimental|Working Memory Training without Normative Feedback|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task. Subjects assigned to not receive normative feedback will receive feedback on time spent doing a non-alcohol related activity as an attention/informational control (e.g., time spent watching television; LaBrie et al., 2013).
3049651|NCT00661674|Experimental|Sequence 4: Placebo, Palonosetron, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Placebo~Week 2: Palonosetron only~Week 3: Palonosetron + Hydroxyzine Combo"
3049652|NCT00661674|Experimental|Sequence 5: Combo, Palonosetron, Placebo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron + Hydroxyzine Combo~Week 2: Palonosetron only~Week 3: Placebo"
3049653|NCT00661674|Experimental|Sequence 6: Palonosetron, Placebo, Combo|"At T = 0 (minutes), healthy (non-opioid dependent, non-substance abuser) male volunteers (N=10) were pre-treated with either placebo (0.9% normal saline), palonosetron IV (0.75mg), or palonosetron IV (0.75mg) and hydroxyzine per os (PO) (100mg) in a crossover study design. This was followed at T = 30 by intravenous morphine (10mg/70kg). At T = 165, 10mg/70kg naloxone IV was given to precipitate opioid withdrawal. The objective opioid withdrawal score (OOWS) and subjective opioid withdrawal score (SOWS) were determined 5 and 15 minutes after naloxone administration (T = 170, 180, respectively). Baseline measurements were recorded at T = -30 and T = -15.~Week 1: Palonosetron only~Week 2: Placebo~Week 3:Palonosetron + Hydroxyzine Combo"
3049654|NCT00661687|Active Comparator|Purevision Contact Lens #1|PureVision Soft Contact Lens Design (currently marketed)
3049655|NCT00661687|Experimental|PureVision Contact Lens #2|Redesign of the currently marketed PureVision soft contact lens.
3049656|NCT00661713|Experimental|rMenB06|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
3049657|NCT00661713|Experimental|rMenB0|Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
3049658|NCT00661713|Experimental|rMenB016|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
3049659|NCT00661713|Experimental|rMenB01|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
3049660|NCT00661713|Experimental|rMenB026|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
3049661|NCT00661713|Experimental|rMenB02|Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
3049662|NCT00661713|Experimental|rMenB012|Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
3049663|NCT00661713|Experimental|rMenB6|Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
3049664|NCT00661726|Experimental|1|Participants will receive injected decitabine for 12 weeks.
3049665|NCT00661778|Experimental|Bevacizumab + cisplatin + docetaxel|Participants received bevacizumab 15 mg/kg intravenously (IV) followed by docetaxel 75 mg/kg IV in combination with cisplatin 75 mg/m^2 IV on Day 1 of each 3-week cycle for a maximum of 6 cycles. After completing the 6 cycles of combined chemotherapy, participants received bevacizumab 15 mg/kg IV until disease progression, unacceptable toxicity, or withdrawal of consent.
3049666|NCT00661830|Experimental|1|Gemcitabine + Sorafenib
3049667|NCT00661830|Placebo Comparator|2|Gemcitabine + Placebo
3049668|NCT00661895|Experimental|Intervention|Intervention group subjects will receive education and assistance from a Community Health Center or Cardiac Center nurse practitioner or physician, health educator, dietitian, social worker, and Cardiac Center-trained community members called Community Health Advocates (CHAs).
3049669|NCT00661895|Active Comparator|Control|No intervention
3049670|NCT00661960|No Intervention|1|HIV Negative volunteers
3049671|NCT00661960|Active Comparator|2|HIV-Positive volunteers taking raltegravir in combination with two other nucleoside reverse transcriptase inhibitors (NRTI) medications
3049672|NCT00661960|Active Comparator|3|HIV-Positive volunteers taking efavirenz or any other non-nucleoside reverse transcriptase inhibitors (NNRTI) in combination with two other nucleoside reverse transcriptase inhibitor (NRTI) medications
3049673|NCT00661999|Experimental|Arm I|Patients receive darbepoetin alfa subcutaneously and sodium ferric gluconate complex IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3049674|NCT00661999|Experimental|Arm II|Patients receive darbepoetin alfa as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3049675|NCT00661999|Experimental|Arm III|Patients receive darbepoetin alfa as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.
3049676|NCT00662012|Experimental|Sodium Stibogluconate (SSG) 20 mg/kg|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
3049677|NCT00662025|Experimental|1|
3049678|NCT00662038|Experimental|Treatment|pirfenidone
3132583|NCT03438578|Experimental|Efficacy Safety Score monitoring|Patients monitored with wireless vital signs and Efficacy Safety Score after discharge from the post-anesthesia care unit to an ordinary ward
3132584|NCT03438578|No Intervention|Regular|Patients receiving standard postoperative care after discharge from the post-anesthesia care unit to an ordinary ward
3049679|NCT00662129|Experimental|paclitaxel + gemcitabine + bevacizumab|"Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after every other course, and then after completion of treatment.~After completion of study treatment, patients are followed periodically for 5 years."
3049680|NCT00662155|Experimental|Continuous 1 (QHS-10)|continued nightly use with 10mg zolpidem
3049681|NCT00662155|Experimental|Partial Reinforcement (PRS-10)|partial reinforcement with 10mg zolpidem (PRS-10 [nightly pill use with 50% active meds and 50% placebos])
3049682|NCT00662155|Experimental|Intermittent (IDS-10)|intermittent dosing with 10mg zolpidem
3049683|NCT00662155|Experimental|Continuous 2 (QHS-5)|continued nightly use with 5mg zolpidem
3049684|NCT00662207|Experimental|Arm 1|Use a vibrator on the patient's bottom to determine if it will induce a bladder contraction; Use an anal dilator to determine if urethral relaxation will occur
3049685|NCT00662259|Experimental|alprazolam|Alprazolam, an FDA-approved drug, will be administered to 24 patients with generalized anxiety disorder.
3049686|NCT00662259|Placebo Comparator|placebo|A placebo comparator will be administered to 12 patients with generalized anxiety disorder
3049687|NCT00662298|Experimental|Severe Asthma|
3049688|NCT00662311|Experimental|Treatment (vorinostat with paclitaxel and radiotherapy)|Patients receive vorinostat PO QD, 5 days a week and paclitaxel IV over 1 hour once a week. Patients also undergo radiation therapy QD, 5 days a week. Treatment repeats every week for 7 courses in the absence of disease progression or unacceptable toxicity.
3049689|NCT00662363|Experimental|Lubiprostone and placebo Senna|Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon
3049690|NCT00662363|Active Comparator|Senna active plus Lubiprostone Placebo|Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID
3049691|NCT00662389|Experimental|A|
3049692|NCT00662532|Experimental|Minocycline HCl|1 mg microspheres of minocycline hydrochloride
3049693|NCT00662532|No Intervention|No Intervention|Control group receiving no drug intervention
3049694|NCT00662545|Experimental|A|Entecavir 1 mg for 24 weeks in addition to continued standard of care antiretroviral therapy containing tenofovir in addition to emtricitabine or lamivudine
3049695|NCT00662545|Active Comparator|B|continued standard of care antiretroviral therapy which will include tenofovir in addition to emtricitabine or lamivudine
3049696|NCT00662558|Experimental|celecoxib|
3049697|NCT00662558|Active Comparator|tramadol|
3049698|NCT00662649|Experimental|Fingolimod 1.25 mg|Patients continued the same dose to which they had been randomized in the Core study (CFTY720D2301/NCT00289978), fingolimod 1.25 mg/day, in this Extension study.
3049699|NCT00662649|Experimental|Fingolimod 0.5 mg|Patients continued the same dose to which they had been randomized in the Core study, fingolimod 0.5 mg/day, in this Extension study.
3049700|NCT00662649|Experimental|Placebo-fingolimod|Patients randomized to placebo in the Core study were re randomized to fingolimod (either 0.5 or 1.25 mg/day) in this Extension study.
3049701|NCT00662649|Experimental|Placebo-fingolimod 1.25 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 1.25 mg/day in this Extension study.
3049702|NCT00662649|Experimental|Placebo-fingolimod 0.5 mg|Patients randomized to placebo in the Core study were re randomized to fingolimod 0.5 mg/day in this Extension study.
3049703|NCT00662675|Experimental|001|Pancrease MT 10.5 or MT 21 Pancrease MT capsules for maximum dose of 10 000 lipase units / Kg / day
3049704|NCT00662675|Experimental|002|Placebo for Pancrease MT 10.5 or MT 21 Capsules with Pancrease MT excipients without the active enzymes
3049705|NCT00662818|Experimental|Telcagepant 300 mg→Acetaminophen/Paracetamol 1000 mg|Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
3049706|NCT00662818|Experimental|Placebo and APAP 1000 mg→Telcagepant 300 mg|Participants receive 1 dose of placebo to APAP and placebo to telcagepant for the first migraine attack and then up to 11 doses of APAP and placebo to telcagepant for up to 11 migraine attacks in Period 1 (6 weeks). Participants receive up to 12 doses of telcagepant and placebo to APAP for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
3049707|NCT00662831|Experimental|Active|Active study treatment
3049708|NCT00662831|Placebo Comparator|Placebo|Placebo
3049709|NCT00662857|Experimental|1: TI Inhalation Powder A|Technosphere® Insulin Inhalation Powder, two 15 U cartridges
3049710|NCT00662857|Experimental|2: TI Inhalation Powder B|Technosphere® Insulin Inhalation Powder, one 30 U cartridge
3049711|NCT00662857|Experimental|3: RAA Population|Rapid Acting Analogue subjects received 10 IU sc Insulin Lispro
3049712|NCT00662909|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
3049713|NCT00662909|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
3049714|NCT00662909|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 m tablets, orally once a day for 12 weeks
3049715|NCT00663026|Experimental|A|5 mg/week
3049716|NCT00663026|Experimental|B|10 mg/week
3049717|NCT00663026|Experimental|C|Placebo
3049718|NCT00663039|Experimental|Oxytocin, then Placebo|Participants first received 24IU of Oxytocin administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received placebo.
3132585|NCT03439072|Other|G-Pen followed by Lilly Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Lilly Glucagon at the second treatment visit
3049719|NCT00663039|Experimental|Placebo, then Oxytocin|Participants first received a placebo (saline nasal spray) administered intranasally with 6 total sprays (three in each nostril) on the morning and at midday of one study visit. Then, after at least month the participants returned for a second study day and received Oxytocin.
3049722|NCT00663117|Placebo Comparator|Placebo, Sugar pill|placebo for 3 months blinded then followed by an open-labelled study and all are treated with naltrexone 4.5 mg for 3 additional months
3049723|NCT00663117|Active Comparator|Naltrexone-HCl|Subjects are treated in a blinded fashion for 3 months with naltrexone 4.5 mg po for active Crohn's disease followed an open-labelled study where naltrexone is given an additional 3 months at 4.5 mg po; hence the total treatment interval in this arm is 6 months. The response to the intervention administered is measured in the activity index and mucosal healing by colonoscopy.
3049724|NCT00663169|Experimental|Canakinumab|Canakinumab 10 mg/kg intravenous infusion and placebo matching dexamethasone intravenous infusion on Day 1.
3049725|NCT00663169|Active Comparator|Dexamethasone|Dexamethasone 12 mg intravenous infusion and placebo matching canakinumab on Day 1.
3049726|NCT00663208|Active Comparator|Group 1|"Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily"
3049727|NCT00663208|Active Comparator|Group 2|"Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily"
3049728|NCT00663208|Active Comparator|Group 3|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3049729|NCT00663208|Active Comparator|Group 4|"Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3049730|NCT00663208|Active Comparator|Group 5|"Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3049731|NCT00663208|Active Comparator|Group 6|"Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily"
3049732|NCT00663234|Experimental|Age 10 to 14|Participants ages 10 to 14 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
3049733|NCT00663234|Experimental|Age 15 to 23|Participants ages 15 to 23 years receiving oral atorvastatin for 48 weeks while on a stable antiretroviral regimen
3049734|NCT00663260|Active Comparator|Dapagliflozin (10 mg)|
3049735|NCT00663260|Active Comparator|Dapagliflozin (5 mg)|
3049736|NCT00663260|Placebo Comparator|Placebo|
3049737|NCT00663702|Experimental|1|
3049738|NCT00663793|Experimental|Oral testosterone|"(Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
3049739|NCT00663793|Experimental|Finasteride plus Oral Testosterone|"(Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
3049740|NCT00663819|Active Comparator|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular staplers
3049741|NCT00663819|Other|Procedure/Surgery|Procedure/Surgery: colorectal, coloanal, and ileoanal anastomotic staple line without reinforcement
3049742|NCT00663858|Experimental|Cetrorelix 78+78|
3049743|NCT00663858|Experimental|Cetrorelix 78 + Placebo|
3049744|NCT00663858|Placebo Comparator|Placebo|
3049745|NCT00663871|Active Comparator|Fish Oil|Participants will take fish oil supplements daily for 4 months.
3049746|NCT00663871|Placebo Comparator|Placebo|Participants will take soybean oil (placebo) supplements daily for 4 months.
3049747|NCT00663923|Experimental|cross-cylinder|In this technique the laser is programmed with the axis and amount of cylinder,so that the steepest meridian is flattened with central cylindrical ablation and the flattest meridian steepens with paracentral ablation
3049748|NCT00663923|Active Comparator|single|In this technique ,cylinder is treated only on one meridian by performing an elliptical ablation to to flatten the steeper meridian to match the flatter meridian.
3049749|NCT00663962|Experimental|Perioperative pregabalin|Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=3) or Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-operatively (n=4).
3049750|NCT00663962|Placebo Comparator|Placebo control|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op. (N=8)
3049751|NCT00664105|Experimental|Therapeutic Intervention|
3049752|NCT00664209|Other|Active-placebo|These subject receive treatment with active triple therapy followed by treatment with placebo therapy.
3049753|NCT00664209|Other|Placebo-active|These subject receive treatment with placebo therapy followed by treatment with active triple therapy.
3049754|NCT00664326|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib 160 mg per os (po) every day (qd) for 3 weeks on 1 week off of every 4 week cycle
3049755|NCT00664430|Other|Calcitriol challenge followed by paricalcitol|Participants began a controlled calcitriol therapy period (calcitriol challenge) to confirm calcitriol resistance. After this period, those who failed to reduce PTH (according to parameters in protocol) initiated paricalcitol therapy.
3049756|NCT00664521|Experimental|Rituximab Plus Atacicept|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by atacicept 150 mg subcutaneously once a week from Week 7 to 32.
3049757|NCT00664521|Placebo Comparator|Rituximab Plus Placebo|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3, followed by placebo matched to atacicept subcutaneously once a week from Week 7 to 32.
3049758|NCT00664534|Active Comparator|Glargine|Glargine +/- 1,2 or 3 injections of insulin lispro plus oral antihyperglycemic medications (OAMs)
3049759|NCT00664534|Experimental|Premixed Insulin Lispro|Premixed Insulin Lispro (mid-mixture or low-mixture) 1,2 or 3 injections plus OAMs
3049760|NCT00664560|Experimental|ARM 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole
3049761|NCT00664560|Active Comparator|Arm 2 (celebrex)|Celecoxib 200 mg
3049762|NCT00664560|Placebo Comparator|Arm 3 (placebo)|sugar pill
3049763|NCT00664742|Experimental|Fluvastatin XL® Treatment|80 mg once daily, at bedtime.
3049764|NCT00664755|Experimental|Varenicline|Participant randomized to receive active varenicline and placebo transdermal nicotine patch.
3049765|NCT00664755|Active Comparator|Transdermal Nicotine Patch|Participant randomized to receive active transdermal nicotine patch and placebo varenicline.
3049766|NCT00664859|Experimental|Single|Open-label LCP-AtorFen
3049767|NCT00665002|Experimental|WT-1 Analog Peptide Vaccine|Participants received 6 bi-weekly vaccinations over 10 weeks. WT-1 vaccine was given with Montanide. Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
3049768|NCT00665132|Experimental|StimRouter (SR) for CTS|Percutaneous implantation of StimRouter System
3049769|NCT00665353|Experimental|PIO (step 1) then PIO+PEG-INF+RBV (step 2)|All participants in this study will receive pioglitazone therapy for 24 to 28 weeks. Participants will continue pioglitazone and add peginterferon and ribavirin to their treatment regimen for up to 48 additional weeks.
3049770|NCT00665366|Placebo Comparator|Placebo + valproate or lithium|Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
3049771|NCT00665366|Active Comparator|Aripiprazole + valproate or lithium|Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
3049772|NCT00665392|Experimental|cetuximab|Cetuximab by intravenous (IV) infusion over 1-2 h on day
3049773|NCT00665431|Experimental|Arm 1 PN 400 (VIMOVO)|PN400: 500 mg naproxen/20 mg esomeprazole bid
3049774|NCT00665431|Active Comparator|Arm 2 (Celebrex)|Celecoxib 200 mg
3049775|NCT00665431|Placebo Comparator|Arm 3 (Placebo)|sugar pill
3049776|NCT00665457|Experimental|Celecoxib|"•Neoadjuvant chemotherapy: Patients receive docetaxel IV over 1 hour on days 1, 8, and 15, oral capecitabine twice daily on days 1-14, and oral celecoxib twice daily on days 1-21. Courses repeat every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV once daily on day 1, oral celecoxib twice daily on days 1-14, and filgrastim subcutaneously once daily on days 3-10. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Celecoxib is stopped one week prior to surgery.~•Surgery: Patients undergo definitive surgery (either modified radical mastectomy or lumpectomy combined with axillary node dissection). Patients may also undergo adjuvant radiotherapy and hormonal therapy at the discretion of multidisciplinary breast team."
3049777|NCT00665470|Experimental|Cohort I - high dose Aldesleukin|Patients receive high-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
3049778|NCT00665470|Experimental|Cohort II - low dose Aldesleukin|Beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion, patients receive low-dose aldesleukin subcutaneous (SC) once daily 5 days a week for up to 6 weeks.
3049779|NCT00665561||Maraviroc exposed|
3049780|NCT00665561||Maraviroc unexposed|
3049781|NCT00665626|Experimental|Arm 1|Fostamatinib disodium (R935788) 100 mg tablet, orally, twice-a-day
3049782|NCT00665626|Placebo Comparator|Arm 2|Placebo, orally, twice-a-day
3049783|NCT00665652|Experimental|Lenalidomide|
3049784|NCT00665704|Experimental|Tobacco Tactics Website|Nine veteran smokers who will pilot test the Tobacco Tactics website
3049785|NCT00665847|Experimental|Etravirine (TMC125)|
3049786|NCT00665925|Experimental|1|R788, 100 mg tablet, orally, twice-a-day
3049787|NCT00665925|Experimental|2|R788, 150 mg tablet, orally, once a day
3049788|NCT00665925|Placebo Comparator|3|Placebo, orally, either once a day, or twice a day
3049789|NCT00666029|Active Comparator|Atorvastatin|Active arm atorvastatin 40 mg. o.d.
3049790|NCT00666029|Placebo Comparator|Placebo|Placebo arm dummy pill
3049791|NCT00666198||SILDENAFIL|Patients taking SILDENAFIL.
3049792|NCT00666211|Active Comparator|Standard of Care|Standard pain control drugs.
3049793|NCT00666211|Experimental|Opioid Titration|Pain will be Monitored and Medication Titrated
3049794|NCT00666224|Experimental|Glatiramer acetate|Glatiramer acetate 20 mg once daily by subcutaneous injection is administered in both the double-blind and open label periods.
3049795|NCT00666224|Placebo Comparator|Placebo (DB) to GA (OL)|Placebo matching glatiramer acetate once daily by subcutaneous injection during the double-blind period (DB). Glatiramer acetate (GA) 20 mg once daily by subcutaneous injection during the open-label period (OL).
3049796|NCT00666263|Experimental|IGIV, 10% Then Placebo|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: IGIV, 10% (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human)(Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg body weight (BW) per infusion cycle)."
3132586|NCT03439072|Other|Lilly Glucagon followed by G-Pen|1 mg Lilly Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
3049797|NCT00666263|Experimental|Placebo Then IGIV, 10%|"STUDY PART 1: Open-label stabilization on IGIV, 10% (Stabilization Phase 1) all participants. STUDY PART 2: Placebo (0.25% human albumin: BUMINATE 25% Albumin (Human) (Baxter Healthcare Corporation) used where licensed; otherwise Human Albumin 200 g/L Baxter Solution for Infusion was used) (double-blind treatment Cross-Over Period 1). STUDY PART 3: Between the two double-blind treatment cross-over periods, participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 2). STUDY PART 4: IGIV, 10% (double-blind treatment cross-over period 2). STUDY PART 5: Participants received open-label treatment/stabilization with IGIV, 10% (Stabilization Phase 3).~Each study part was 12 weeks in length. Participants received IGIV, 10% at the same equivalent dose per week administered prior to the study (0.4 to 2.0 g per kg BW per infusion cycle)"
3049798|NCT00666276||linezolid (Zyvox)|Patients taking Linezolid.
3049799|NCT00666328|Experimental|clevidipine|This will be a single-arm study with no reference therapy.
3049800|NCT00666406|Experimental|1|Advate rAHF-PFM
3049801|NCT00666406|Active Comparator|2|Recombinate rAHF
3049802|NCT00666458|Experimental|1|saxagliptin add-on to metformin
3049803|NCT00666458|Active Comparator|2|sitagliptin add-on to metformin
3049804|NCT00666536|Active Comparator|Aggressive treatment regimen (5/320 mg to 10/320 mg)|Valsartan + Amlodipine, daily: 320 mg + 5 mg (2 weeks); Valsartan + Amlodipine, daily: 320 mg + 10 mg (2 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 320 mg + 10 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
3049805|NCT00666536|Active Comparator|Moderate treatment regimen (5/160 mg)|Valsartan + Amlodipine, daily dose: 160 mg + 5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg (4 weeks); Valsartan + Amlodipine and Hydrochlorothiazide, daily: 160 mg + 5 mg and 12.5 mg or 25 mg (optional titration) (4 weeks)
3049806|NCT00666562|Placebo Comparator|Arm I (placebo)|Patients receive six oral placebo capsules once daily for 14-28 days.
3049807|NCT00666562|Experimental|Arm II (polyphenon E, placebo)|Patients receive four oral polyphenon E capsules and two oral placebo capsules once daily for 14-28 days in the absence of unacceptable toxicity.
3049808|NCT00666562|Experimental|Arm III (polyphenon E, trans-urethral resection or cystectomy)|Patients receive six oral polyphenon E capsules once daily for 14-28 days in the absence of unacceptable toxicity. After completion of study treatment, patients undergo trans-urethral resection of bladder tumor or cystectomy.
3049809|NCT00666588|Experimental|Bortezomib 1.3mg/m2-assess efficacy-low anthracycline exposure|Bortezomib 1.3mg/m2 to assess efficacy in low prior anthracycline exposure. Patients receive idarubicin IV (12 mg/m2/day) over 15 minutes on days 1-3, low-dose cytarabine IV (100 mg/m2/day) continuously over days 1-7, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (closed as of 08/01/10). Dosage modification based on age < 3 years old.
3049810|NCT00666588|Experimental|Bortezomib 1.0mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.0 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.0 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3049811|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess feasibility high anthracycline exp|Bortezomib 1.3 mg/m2 to assess feasibility in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity (dose-finding phase closed as of 10/10).
3049812|NCT00666588|Experimental|Bortezomib 1.3 mg/m2-assess efficacy high anthracycline exp|Bortezomib 1.3 mg/m2 to assess efficacy in high prior anthracycline exposure. Patients receive etoposide IV (150 mg/m2/dose) over 1 hour on days 1-5, high-dose cytarabine IV (1000 mg/m2/dose) over 1 hour twice daily on days 1-5, and bortezomib IV (1.3 mg/m2) on days 1, 4, and 8. All patients receive intrathecal cytarabine (30 mg - age 1-1.99 years, 50 mg - age 2-2.99 years, 70 mg - age ≥ 3 years) prior to courses 1 and 2. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity
3049813|NCT00666666|Experimental|AT101 (R-(-)-gossypol acetic acid)|Patients will receive Hormone therapy with at least one LHRH agent (Leuprolide Acetate or Goserelin) for 6 weeks and include bicalutamide. Patients will begin AT101 daily at 6 weeks for 3 weeks of every 4 weeks (4 weeks - 1 cycle) and continue for 8 cycles of combined therapy (combined AT101, and LHRH agonist). After 8 cycles patients will continue hormonal therapy.
3049814|NCT00666679|Active Comparator|1|mometasone
3049815|NCT00666679|Placebo Comparator|2|montelukast followed by placebo; or placebo followed by montelukast.
3049816|NCT00666705|Experimental|Maraviroc alone|
3049817|NCT00666705|Experimental|Maraviroc + Raltegravir|
3049818|NCT00666705|Experimental|Raltegravir alone|
3049819|NCT00666718|Active Comparator|Glargine|Glargine plus Insulin Lispro (2-3 injections)
3049820|NCT00666718|Experimental|ILPS|Insulin Lispro Protamine Suspension (ILPS) plus Insulin Lispro (2-3 injections)
3049821|NCT00666757|Experimental|duloxetine|study drug
3049822|NCT00666757|Active Comparator|citalopram|
3049823|NCT00666757|Active Comparator|fluoxetine|
3049824|NCT00666757|Active Comparator|paroxetine|
3049825|NCT00666757|Active Comparator|sertraline|
3049826|NCT00666835|Experimental|HX575 epoetin alfa Hexal AG|Eligible patients were switched from the comparator ERYPO®, to epoetin alfa HX575 Hexal AG in ratio 2:1 to be intravenously treated with HX575 in pre-filled syringes for 24 weeks (solution for injection i.v.). The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
3049827|NCT00666835|Active Comparator|ERYPO®, Janssen-Cilag|Eligible patients were randomized and continued to be treated with ERYPO® Janssen-Cilag in pre-filled syringes intravenously (solution for injection i.v.) for 24 weeks. The maximum weekly dose was 300 UI/kg body weight (given 1 to 3 times) to maintain hemoglobin levels between 10-13 g/dL.
3049828|NCT00666848|Placebo Comparator|2 (enalapril 5mg)|Subjects received Enalapril 5mg on study day and a placebo pill for 5 days prior or subjects received enalapril 5mg on study day and sitagliptin 100mg/day for 5 days prior .
3049829|NCT00666848|Placebo Comparator|1 (placebo)|Subjects received a placebo pill on study day and received a placebo pill for 5 days prior or subjects received a Placebo pill on study day and sitagliptin 100mg for 5 days prior.
3049830|NCT00666848|Placebo Comparator|3 (enalapril 10mg)|Subjects received Enalapril 10mg on study day and a placebo pill for 5 days prior, or subjects received Enalapril 10mg on study day and sitagliptin 100mg for 5 days prior.
3049831|NCT00666926|Experimental|1|
3049832|NCT00666926|Experimental|2|
3049833|NCT00666926|Experimental|3|
3049834|NCT00666926|Experimental|4|
3049835|NCT00666965|Placebo Comparator|1|inactive placebo
3049836|NCT00666965|Experimental|2|2.25 mg first week: 2.25 mg 1 sheet plus placebo 1 sheet 2nd to 6th week :2.25mg 1 sheet plus placebo 2 sheets
3049837|NCT00666965|Experimental|3|4.5 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 2 sheets pus placebo 1 sheet
3049838|NCT00666965|Experimental|4|6.75 mg/body first week : 2.25 mg 2 sheets 2nd to 6th week : 2.25 mg 3sheets
3049839|NCT00666978|Experimental|Bupropion Arm|Subjects undergo smoking cessation intervention and take bupropion.
3049840|NCT00666978|Placebo Comparator|Health Education Arm|Subjects receive counseling intervention and take placebo.
3049841|NCT00667004|Experimental|1|ecabet ophthalmic solution
3049842|NCT00667004|Placebo Comparator|2|Placebo comparator
3049843|NCT00667095|Experimental|Botox and DMSO instillation|Botulinum-A Toxin (Botox) 300 units in 50 cubic centimeters of Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution
3049844|NCT00667095|Placebo Comparator|DMSO instillation|Dimethyl Sulfoxide (DMSO) 50% w/w aqueous solution, 50 cubic centimeters
3049845|NCT00667186|Active Comparator|Targeted Screening|"Targeted Screening~Participants approached at ED for voluntary HIV counseling and testing based on risk for HIV"
3049846|NCT00667186|Active Comparator|Routine Screening|"Routine Screening~Participants approached at ED for voluntary HIV counseling and testing regardless of established risk according to age criteria"
3049847|NCT00667225|Placebo Comparator|I|Subjects in this group will have topical application of cantharidin's vehicle at each visit.
3049848|NCT00667225|Experimental|II|Subjects in this group will have topical application of cantharidin at each visit.
3049849|NCT00667251|Active Comparator|Lapatinib|Plus taxane based chemotherapy
3049850|NCT00667251|Active Comparator|Trastuzumab|Plus taxane based chemotherapy.
3049851|NCT00667277|Experimental|bevacizumab (Avastin)|Use of bevacizumab (Avastin) in the treatment of myelofibrosis.
3049852|NCT00667342|Experimental|Localized Resectable Disease (Stratum A)|Participants with localized resectable disease receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin, and doxorubicin, or methotrexate. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, or methotrexate.
3049853|NCT00667342|Experimental|Metastatic Disease (Stratum B)|Participants with metastatic disease (Stratum B) receive Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
3049854|NCT00667342|Experimental|Unresectable Disease (Stratum C)|Participants with unresectable disease (Stratum C) receive treatment identical to Stratum B: Cycle 1 of bevacizumab 3 days before chemotherapy with cisplatin and doxorubicin. Subsequent cycles consist of bevacizumab on the first day of chemotherapy, then cisplatin and doxorubicin, methotrexate or ifosfamide, and etoposide. If applicable, definitive surgery and assessment of histologic response will occur at week 10 followed by bevacizumab on the first day of chemotherapy with cisplatin and doxorubicin, methotrexate, or ifosfamide, and etoposide. Radiotherapy will be given post-operatively.
3049855|NCT00667355|Experimental|Adalimumab|Adalimumab 40 mg or 80 mg subcutaneously (SC) administered every other week (eow) until approval of adalimumab for Ankylosing Spondylitis (AS) in Japan. All subjects received 40 mg of adalimumab SC eow at Baseline. The subjects who completed 16 weeks of therapy and who failed to achieve Assessments in Ankylosing Spondylitis 20 (ASAS 20) response on or after Week 16, could increase the dose of adalimumab to 80 mg eow. When the dose was increased, the higher dose was to be continued during the rest of the study.
3049856|NCT00667368|No Intervention|Control|Bi-monthly testing for BV without treatment.
3049857|NCT00667368|Experimental|Intervention|Metronidazole 500mg twice daily for 7 days for Bacterial Vaginosis (BV) detection
3049858|NCT00667381|No Intervention|Control|The combination of anatomic landmarks and fluoroscopic localization of the femoral head will be used to guide femoral arterial access.
3049859|NCT00667381|Experimental|Ultrasound|Patients randomized to Ultrasound will have anatomic landmarks checked and real-time ultrasound guidance to aid femoral arterial access.
3049860|NCT00667394|Experimental|Tandutinib & Bevacizumab in GBM Patients|GBM (glioblastoma multiforme) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
3049861|NCT00667394|Experimental|Tandutinib & Bevacizumab in AG Patients|AG (anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic mixed oligoastrocytoma, and malignant astrocytoma NOS (not otherwise specified)) Tandutinib 500 mg by mouth daily dose twice a day. Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
3049862|NCT00667420|Experimental|EOXP chemotherapy|open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
3049863|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 11.25 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 months (3M) apart.
3049864|NCT00667446|Experimental|Leuprolide Acetate 3M Depot 30 mg|Twelve intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 months apart.
3049865|NCT00667459|Experimental|Investigational|PRESTIGE® LP Cervical Disc
3049866|NCT00667459|Active Comparator|Control|Control patients who received a ACDF fusion treatment from a previous IDE trial (NCT00642876)
3049867|NCT00667511|Active Comparator|Home Short Daily Hemodialysis|Intervention: Patients perform short daily hemodialysis (2 to 4 hour treatments) in the home setting using the NxStage System One.
3049868|NCT00667511|Experimental|Home Nocturnal Hemodialysis|Intervention: Patients perform nocturnal hemodialysis (6 to 10 hour treatments) in the home setting using the NxStage System One.
3049869|NCT00667563|Experimental|Gardasil Vaccination|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
3049870|NCT00667576|Experimental|Paricalcitol 2 µg ± 1 µg|Paricalcitol initial dosage 2 micrograms (µg) with incremental adjustment of 1 µg
3049871|NCT00667576|Experimental|Paricalcitol 2 µg ± 2 µg|Paricalcitol initial dosage 2 µg with incremental adjustment of 2 µg
3049872|NCT00667576|Experimental|Paricalcitol 4 µg ± 1 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 1 µg
3049873|NCT00667576|Experimental|Paricalcitol 4 µg ± 2 µg|Paricalcitol initial dosage 4 µg with incremental adjustment of 2 µg
3049874|NCT00667576|Other|Maxacalcitol 5 or 10 µg ± 2.5 µg|Maxacalcitol initial dosage 5 or 10 µg with incremental adjustment of 2.5 µg
3049875|NCT00667589|Experimental|urea 40% cream|
3049876|NCT00667589|Experimental|fluocinonide 0.05% cream|
3049877|NCT00667589|Experimental|tazarotene 0.1% cream|
3049878|NCT00667589|Experimental|bland emollient cream|
3049879|NCT00667602|Experimental|MenACWY-CRM197 (2 doses) + Concomitant Vaccines|Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.
3049880|NCT00667602|Experimental|MenACWY-CRM197 (1 dose) + Concomitant Vaccines|Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
3049881|NCT00667602|Active Comparator|MenC (1 dose) + Concomitant Vaccines|Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.
3049882|NCT00667615|Experimental|1|vorinostat in combination with cyclophosphamide, etoposide,prednisone and rituximab,peg-filgrastim or filgrastim
3049883|NCT00667693|Active Comparator|Macintosh laryngoscope|Intubation with a Macintosh laryngoscope
3049884|NCT00667693|Active Comparator|Pentax AWS|Intubation with a Pentax AWS
3049885|NCT00667719|Experimental|Aliskiren/Amlodipine/Hydrochlorothiazide|Participants received aliskiren 300 milligrams (mg) plus hydrochlorothiazide 12.5 mg for one week, at Week 1 followed by combination of aliskiren 300 mg plus amlodipine 5 mg plus hydrochlorothiazide 12.5 mg for one week, at Week 2. Following Week 2, participants were force titrated up to aliskiren 300 mg plus amlodipine 10 mg plus hydrochlorothiazide 25 mg for 26 to 52 weeks (Weeks 28 to 54). All study medications were taken orally with water, once daily in the morning.
3049886|NCT00667732|Active Comparator|1|Participants will receive exenatide as part of their diabetes treatment
3049887|NCT00667732|Placebo Comparator|2|Participants will receive placebo rather than exenatide as part of their diabetes treatment
3049888|NCT00667745|Experimental|1|Participants received lithium plus optimized medication treatment, as needed.
3049889|NCT00667745|Active Comparator|2|Participants only received optimized medication treatment, as needed; lithium was not be used.
3049890|NCT00667810|Experimental|Bapineuzumab 0.5 mg/kg|
3049891|NCT00667810|Experimental|Bapineuzumab 1.0 mg/kg|
3049892|NCT00667810|Placebo Comparator|Placebo|
3049893|NCT00667849|Active Comparator|Exogen 4000+|Single arm, Exogen 4000+
3049894|NCT00667849|Sham Comparator|Sham|Single arm, sham (identical device with the exception of administration of ultrasound).
3049895|NCT00667862|Experimental|Panobinostat|Participants with metastatic hormone refractory prostate cancer received 20 milligrams per meter square (mg/m^2) of panobinostat intravenously (i.v.) on Days 1 and 8 of a 21-day cycle. Treatment continued until disease progression as per investigator, intolerable toxicity, start of new cancer therapy, death, or withdrawal of consent.
3049896|NCT00667875|Placebo Comparator|1|
3049897|NCT00667875|Active Comparator|2|Naltrexone
3049898|NCT00667875|Active Comparator|3|Naltrexone + Aripiprazole
3049899|NCT00667888|Active Comparator|Intensity Modulated Radiotherapy (IMRT)|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
3049900|NCT00667888|Experimental|Hypofractionated Intensity Modulated Radiotherapy (HIMRT)|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
3049901|NCT00667992|Active Comparator|Budesonide Hydrofluoroalkane (HFA) 100|Budesonide Hydrofluoroalkane (HFA) 100 mcg twice daily for 2 weeks
3049902|NCT00667992|Active Comparator|Budesonide HFA 400|Budesonide HFA 400 mcg twice daily for 2 weeks
3049903|NCT00667992|Active Comparator|Budesonide Chlorofluorocarbon (CFC) 100|Budesonide Chlorofluorocarbon(CFC) 100 mcg twice daily for 2 weeks
3049904|NCT00667992|Active Comparator|Budesonide CFC 400|Budesonide CFC 400 mcg twice daily for 2 weeks
3049905|NCT00668148|Experimental|IMC-A12 (cixutumumab)|
3049906|NCT00668200|Other|zoledronic acid|5 mg of Reclast (ZOL446, zoledronic acid) injection in 100 mL ready to infuse solution administered intravenously via a vented line. The infusion time was to be not less than 15 minutes given over a constant infusion rate.
3049907|NCT00668317|Other|omeprazole and ranitidine|20 mg oralomeprazole oral tablet twice daily and ranitidine 300 mg oral tablet once daily nocte
3049908|NCT00668382|Experimental|Alpha-Gal Glycosphingolipid injection|Intervention: Intratumoral injection of a single dose of Alpha-Gal Glycosphingolipid (0.1 mg,1mg, 10mg)
3049909|NCT00668395|Other|CYP2B6*1/*1 genotype|Efavirenz clearance in this genotype was compared with the other genotypes
3049910|NCT00668395|Other|CYP2B6*1/*6|Efavirenz clearance in this genotype was compared with the other genotypes
3049911|NCT00668395|Other|CYP2B6*6/*6|Efavirenz clearance in this genotype was compared with the other genotypes
3049912|NCT00668434|Experimental|Prednisone|Participants will receive a 15-day tapering course of prednisone capsules.
3049913|NCT00668434|Placebo Comparator|Placebo|Participants will receive a 15-day course of placebo capsules.
3049914|NCT00668525|Active Comparator|2|Escitalopram low dose
3049915|NCT00668525|Experimental|3|Escitalopram high dose
3049916|NCT00668525|Placebo Comparator|1|Placebo
3049917|NCT00668564|Experimental|Intent-to-Treat|All patients treated with study regimen.
3049918|NCT00668707|Experimental|Melatonin|To receive 20 mg of melatonin nightly for 1 year post-surgery
3049919|NCT00668707|Placebo Comparator|Placebo|To receive 20 mg placebo nightly for 1 year post-surgery
3049920|NCT00668746|Experimental|Minocycline HCl microspheres|Minocycline HCl microspheres
3049921|NCT00668746|No Intervention|No drug intervention|No drug intervention
3049922|NCT00668811|Experimental|Treatment Arm - Sutent|Sutent 37.5 mg/day will be given orally.
3049923|NCT00668863|Experimental|1|
3049924|NCT00668902|Experimental|EM of CYP2C19|CYP2C19 enzyme activity in extensive metabolizers of CYP2C19 (CYP2C19*1/*1 genotype, or wild type) was measured by 13C)Pantoprazole breath test.
3049925|NCT00668902|Experimental|IM of CYP2C19|CYP2C19 activity in heterozygous for deficient CYP2C19 alleles (*2 and *3, IM of CYP2C19) was measured by (13C)Pantoprazole breath test.
3049926|NCT00668902|Experimental|PM of CYP2C19|Homozygous for CYP2C19 null alleles (*2/*2, *2/*3 or *3/*3, Poor metabolizers) was measured by (13C)Pantoprazole breath test.
3049927|NCT00669019|Experimental|Saracatinib|Patients receive saracatinib 175 mg oral once daily in the absence of disease progression or unacceptable toxicity.
3049928|NCT00669032|Experimental|hyaluronic acid|Cycles of 5 injections of hyaluronic acid at specified intervals
3049929|NCT00669032|Placebo Comparator|Placebo|Cycles of 5 injections of saline at specified intervals
3049930|NCT00669071|Active Comparator|IPL / Tri-Luma® Cream|
3049931|NCT00669071|Active Comparator|IPL/Cetaphil® Moisturizing Cream as Inactive Control|
3049932|NCT00669110|Experimental|A|
3049933|NCT00669162|Experimental|RT, Docetaxel, Hormonal Therapy|Radiation Therapy (RT) to 66 Gy in 33 treatment fractions at 2.0 Gy/fx Concurrent Docetaxel (with RT) at 20 mg/m2 weekly x 7 Casodex (50 mg po daily)x 6 months Zoladex (10.8 mg sc q 3 mos x 2) or Lupron (22.5 mg im q 3 mos x 2)
3049934|NCT00669214|Experimental|Efalizumab|
3049935|NCT00669214|Placebo Comparator|Placebo|
3049936|NCT00669240||1. Non-interventional|Patients prescribed varenicline in a non interventional manner.
3049937|NCT00669279|Experimental|Carvedilol CR|
3049938|NCT00669279|Experimental|Atenolol|
3049939|NCT00669318|Experimental|Treatment (Pentostatin, Alemtuzumab, Rituximab)|"Course 1: Patients receive:~2 mg/m^2 pentostatin IV on days 8 and 22;~3 mg alemtuzumab subcutaneously (SC) on day 3;~10 mg alemtuzumab SC on day 4;~30 mg alemtuzumab SC on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33;~6 mg Sargramostim (GM-CSF) SC on days 10-14. Patients then proceed to course 2.~Courses 2 and 3: Patients receive:~2 mg/m^2 pentostatin IV on days 1 and 15;~30 mg alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~20 mg/m^2 rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26;~6 mg GM-CSF SC on days 3-7. After completion of course 2, patients with a complete response proceed to observation. Patients with a partial response or stable disease receive another course of therapy (course 3)."
3049940|NCT00669331|Experimental|Mannitol|Inhaled mannitol 400mg
3049941|NCT00669331|Placebo Comparator|Control|Matched control - inhaled mannitol 50mg
3049942|NCT00669383|Active Comparator|A|Betamethasone (Celestone) 12 mg intramuscular q 24 hours x 2 doses
3049943|NCT00669383|Placebo Comparator|B|Placebo dose intramuscular q 24 hours x 2 doses
3049944|NCT00669396|Experimental|1|IUD
3049945|NCT00669396|Active Comparator|2|Oral levonorgestrel
3049946|NCT00669409|Experimental|10 mcg/kg|
3049947|NCT00669409|Experimental|100 mcg/kg|
3049948|NCT00669409|Experimental|200 mcg/kg|
3049949|NCT00669409|Experimental|25 mcg/kg|
3049950|NCT00669409|Experimental|50 mcg/kg|
3049951|NCT00669409|Placebo Comparator|Placebo|
3049952|NCT00669539||Combined-Mechanism Amblyopia|
3049953|NCT00669539||Strabismus-Only Amblyopia|
3049954|NCT00669552||Medtronic defibrillator|Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal.
3049955|NCT00669578|Experimental|CC-4047|
3049956|NCT00669617|Experimental|Ind 150μg, Salm/flut, Ind 300μg, Placebo, Salbut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Placebo, Salbutamol 200 μg (Salbut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3049957|NCT00669617|Experimental|Ind 300μg, Ind 150μg, Salbut, Salm/flut, Placebo|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo. At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3049958|NCT00669617|Experimental|Salm/flut, Placebo, Ind 150μg, Salbut, Ind 300μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salmeterol/fluticasone 50/500 μg (Salm/flut), Placebo, Indacaterol 150 μg (Ind 150μg), Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3049959|NCT00669617|Experimental|Salbut, Ind 300μg, Placebo, Ind 150μg, Salm/flut|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Salbutamol 200 μg (Salbut), Indacaterol 300 μg (Ind 300μg), Placebo, Indacaterol 150 μg (Ind 150μg), Salmeterol/fluticasone 50/500 μg (Salm/flut). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3049960|NCT00669617|Experimental|Placebo, Salbut, Salm/flut , Ind 300μg, Ind 150μg|Participants received a single dose of each treatment from Period I - V in the following order, separated by a washout period of 4-7 days: Placebo, Salbutamol 200 μg (Salbut), Salmeterol/fluticasone 50/500 μg (Salm/flut), Indacaterol 300 μg (Ind 300μg), Indacaterol 150 μg (Ind 150μg). At each treatment visit, participants received the specified treatment and 2 placebo inhalations (one inhalation from the SDDPI, and one inhalation from each of the two MDDPIs) to maintain blinding. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3049961|NCT00669669|Experimental|Treatment (chemotherapy, autologous stem cell transplant)|See Detailed Description
3049962|NCT00669682||Group A|The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance.
3049963|NCT00669864|Experimental|BIAsp 30-30|Individual adjusted dose of biphasic insulin aspart 30 administered before breakfast and dinner in combination with metformin 1000-2000mg, up to three times daily
3049964|NCT00669877|Experimental|Hyper-CVAD|Hyper-CVAD (odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses. Rituximab 375 mg/m2 days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses. Cyclophosphamide 300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3. Doxorubicin 50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses). Vincristine 2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses). Dexamethasone 40 mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses). G-CSF 10 mg/kg/day (rounded) until neutrophil recovery 1 x 10^9/L or higher can be substituted or can be added to pegfilgrastim if neutrophils have not recovered to 1 x 10^9/L by day 21.
3049965|NCT00669903|Experimental|1|AZD0328 low dose
3049966|NCT00669903|Experimental|2|AZD0328 Optimal dose
3049967|NCT00669903|Experimental|3|AZD0328 High dose
3049968|NCT00669903|Placebo Comparator|4|Placebo Comparator
3049969|NCT00669916|Experimental|AIN457|AIN457A 3mg/kg was administered intravenously as a single dose.
3049970|NCT00669916|Placebo Comparator|Placebo|Placebo was administered intravenously as a single dose.
3049971|NCT00669942|Experimental|Part 1 - AIN457A 0.3 mg/kg|AIN457A 0.3 mg/kg was administered intravenously as a single dose.
3049972|NCT00669942|Experimental|Part 1 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as a single dose.
3049973|NCT00669942|Experimental|Part 1 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
3049974|NCT00669942|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
3049975|NCT00669942|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
3049976|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3049977|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 3.0 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3049978|NCT00669942|Experimental|Parts 2 and 3 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3049979|NCT00669942|Placebo Comparator|Parts 2 and 3 - Placebo|Placebo to AIN457A was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3049980|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 3 mg/kg|AIN457A 3.0 mg/kg was administered intravenously as a single dose.
3049981|NCT00669942|Experimental|Part 1 - Healthy Volunteers - AIN457A 10 mg/kg|AIN457A 10 mg/kg was administered intravenously as a single dose.
3049982|NCT00669942|Placebo Comparator|Part 1 - Healthy Volunteers - Placebo|Placebo to AIN457A was administered intravenously as a single dose.
3049983|NCT00669955|Active Comparator|OAC 7 days|Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily
3049984|NCT00669955|Experimental|OBMT 10 days|OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.
3049985|NCT00670007|Experimental|Zemaira®|
3049986|NCT00670046|Other|Arm I (standard of care)|Patients undergo observation according to the standard of care. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
3049987|NCT00670046|Experimental|Arm II (valproic acid)|Patients receive oral valproic acid twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients complete quality of life questionnaires at baseline, 6 months, and 1 year.
3049988|NCT00670111|Experimental|RAP On then Off at 1 month visit|"Rate Adaptive Pacing (RAP) On for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) Off for second cardiopulmonary exercise test (CPX) at one month."
3049989|NCT00670111|Experimental|RAP Off then On at 1 month visit|"Rate Adaptive Pacing (RAP) Off for first cardiopulmonary exercise test (CPX) at one month.~Rate Adaptive Pacing (RAP) On for second cardiopulmonary exercise test (CPX) at one month."
3049990|NCT00670202|Experimental|Drug: Fasudil hydrochloride|Fasudil hydrochloride 40 mg three times a day X 14 days
3049991|NCT00670202|Placebo Comparator|Drug: Placebo oral tablet|Placebo 1 tablet three times daily x 14 days
3049992|NCT00670228|Active Comparator|Intensive Insulin Therapy (IIT)|In IIT arm, subjects received intravenous (IV) insulin glulisine and subcutaneous (sc) insulin glargine to maintain a Blood Glucose (BG) concentration between 90-130 mg/dL.
3049993|NCT00670228|Active Comparator|Standard Glycemic Care (SGC)|"In SGC arm subjects assigned to standard of care received subcutaneous regular insulin per sliding scale."
3049994|NCT00670241|Active Comparator|1|
3049995|NCT00670241|Active Comparator|2|
3049996|NCT00670241|Placebo Comparator|3|
3049997|NCT00670267|Experimental|Open Label treatment with oral Nadolol|Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.
3049998|NCT00670306|Experimental|Cetrorelix 78 mg|Drug: Cetrorelix 52 mg week 0, and 26 mg week 2, intra muscular-2 doses in 2 weeks and follow up to week 26.
3049999|NCT00670449|Experimental|Fingolimod 0.5 mg|Patients who received fingolimod 0.5 orally once daily in the core study continued on the same dose in this extension study.
3050000|NCT00670449|Experimental|Fingolimod 1.25 mg|Patients who received fingolimod 1.25 mg orally once daily in the core study continued on the same dose in this extension study.
3050001|NCT00670449|Experimental|Placebo-fingolimod|Patients who were randomized to placebo in the core study were re-randomized to either fingolimod 0.5 or 1.25 mg (1:1) orally once daily in this extension study.
3050002|NCT00670462|Active Comparator|Standard Behavioral Treatment (SBT)|"Standard Behavioral Treatment (SBT) for weight loss intervention introduces a core set of instructions on diet and exercise at the beginning of the intervention and then embellishes these instructions with suggested refinements of behavioral choices over time (e.g., different menus and amounts or types of physical activity)."
3050003|NCT00670462|Experimental|Maintenance-Tailored Treatment (MTT)|"Maintenance-Tailored Treatment (MTT) for weight loss intervention treats diet and exercise strategy embellishments as separate interventions with discrete and independent status. MTT differs from SBT in its emphasis on skills for long-term weight control, namely, the strategy of initiating varied weight-control strategies as a response to the demands of changing environmental challenges and to sustain effective cues and reinforcements needed to motivate weight-loss behaviors."
3050004|NCT00670488|Experimental|MK-2206 30 mg QOD|Participants receive 30 mg oral MK-2206 every other day (QOD) in repeating 4-week treatment cycles.
3050005|NCT00670488|Experimental|MK-2206 60 mg QOD|Participants receive 60 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
3050006|NCT00670488|Experimental|MK-2206 75 mg QOD|Participants receive 75 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
3050007|NCT00670488|Experimental|MK-2206 90 mg QOD|Participants receive 90 mg oral MK-2206 QOD in repeating 4-week treatment cycles.
3050008|NCT00670488|Experimental|MK-2206 90 mg QW|Participants receive 90 mg oral MK-2206 every week (QW) in repeating 4-week treatment cycles.
3050009|NCT00670488|Experimental|MK-2206 135 mg QW|Participants receive 135 mg oral MK-2206 QW in repeating 4-week treatment cycles.
3050010|NCT00670488|Experimental|MK-2206 200 mg QW|Participants receive 200 mg oral MK-2206 QW in repeating 4-week treatment cycles.
3050011|NCT00670488|Experimental|MK-2206 300 mg QW|Participants receive 300 mg oral MK-2206 QW in repeating 4-week treatment cycles.
3050012|NCT00670488|Experimental|MK-2206 250 mg QW|Participants receive 250 mg oral MK-2206 QW in repeating 4-week treatment cycles.
3050013|NCT00670488|Experimental|MK-2206 150 mg QW|Participants receive 150 mg oral MK-2206 QW in repeating 4-week treatment cycles.
3050014|NCT00670540||1|patients with suspected Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)
3050015|NCT00670709||1|Subjects with mild or moderate Huntington's Disease
3050016|NCT00670709||2|Normal Controls
3050017|NCT00670748|Experimental|#1 Anti-NY-ESO-1 TCR PBL+HD IL-2 Mel/RCC|Patients with melanoma or renal cell cancer (RCC) will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin.
3050018|NCT00670748|Experimental|#2 Anti-NY-ESO-1 TCR PBL+HD IL-2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by anti-NY ESO-1 TCR PBL and high dose (HD) aldesleukin
3050019|NCT00670748|Experimental|#3ESO1 TCR PBL+ALVAC ESO1+HD IL2 Mel/RCC|Patients with melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by replication-defective recombinant canarypox virus (ALVAC) NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
3050020|NCT00670748|Experimental|#4ESO1 TCR PBL+ALVAC ESO1+HD IL2 OtherCa|Patients with cancers other than melanoma or RCC will receive non-myeloablative lymphodepleting regimen of cyclophosphamide and fludarabine followed by ALVAC NY-ESO-1 vaccine, anti-NY ESO-1 TCR PBL and high dose aldesleukin
3050021|NCT00670774|Experimental|Eculizumab|Patients received eculizumab intravenously according to details provided in the intervention description.
3050022|NCT00670800|No Intervention|Normal Controls|Control subjects will have 5 visits (screening, oral glucose tolerance test (OGTT), neuropsychological testing, functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) as they will receive no treatment and will not have repeat studies. The baseline values obtained from the control subjects will be compared to the baseline values acquired from the PCOS affected subjects.
3132587|NCT03439124|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for IV administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
3050023|NCT00670800|Experimental|PCOS Affected Women-Metformin Treatment|Subjects with Polycystic Ovary Syndrome (PCOS) will be scheduled for 9 visits total: following the screening visit they will go through OGTT, neuro-psychological testing, fMRI and PET scan before and after 4 months of metformin use: 500mg tablets once daily with breakfast for 1 week, then increased to one tablet twice daily with breakfast & lunch for 1 week, then increased to one tablet three times daily with breakfast, lunch & dinner.
3050024|NCT00670930|Active Comparator|omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single use, 5 ml vial that was designed to deliver 150 mg of omalizumab for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The dose administered was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and the number of injections and injection volume was determined using protocol-specified dosing tables. Omalizumab 75 to 375 mg was administered SQ every 2 or 4 weeks depending on the dose for the 78 weeks duration of double-blinded treatment.
3050025|NCT00670930|Placebo Comparator|Placebo|Omalizumab matching placebo was supplied as lyophilized, sterile powder in a single-use, 5 ml vial that was designed to deliver omalizumab matching placebo for subcutaneous (SQ) administration upon reconstitution with 1.4 ml sterile water for injection. The number of injections and injection volume was individualized for each patient based on the patient's body weight and total serum Immunoglobulin E (IgE) level at Visit 1 and was determined using protocol-specified dosing tables. Placebo was administered SQ every 2 or 4 weeks for the 78 weeks duration of double-blinded treatment.
3050026|NCT00670956|Active Comparator|Active Study Group|STEROID: Betamethasone; 12 mg intramuscularly x 2 doses 24 hours apart
3050027|NCT00670956|Placebo Comparator|Placebo Group|PLACEBO: IM x 2 doses 24 hours apart
3050028|NCT00670982|Experimental|First line treatment|Patients with no prior therapy for metastatic breast cancer will receive bevacizumab intravenously every 2 weeks and vinorelbine intravenously once per week, and trastuzumab intravenously once per week
3050029|NCT00670982|Experimental|Second line treatment|Patients with 1 prior line for metastatic breast cancer will receive bevacizumab intravenously every two weeks, vinorelbine intravenously once per week, and trastuzumab intravenously once per week.
3050030|NCT00671034|Experimental|Arm I (combination chemotherapy)|Patients receive calaspargase pegol together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo radiation therapy to the head. Treatment may continue for up to 4 years.
3050031|NCT00671034|Active Comparator|Arm II (combination chemotherapy)|Patients receive pegaspargase together with combination chemotherapy. Patients receive chemotherapy PO, IV, SC, and IT. Some patients also undergo RT to the head. Treatment may continue for up to 4 years.
3050032|NCT00671060|Active Comparator|2|Women in Group 1 will be administered two tablets (2 100 mcg misoprostol tablets), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
3050033|NCT00671060|Placebo Comparator|1|Women in Group 1 will be administered two tablets (a 100 mcg misoprostol tablet and a placebo tablet made to resemble a 100 mcg misoprostol tablet), which she will be instructed to hold in her cheeks for 200 minutes, after which she will swallow any medication that remains. In cases where cervical dilation is not complete after six hours, women will be given a second dose of study drug. Study drug will continue to be administered at 6-hourly intervals through hour 42 after the study dose.
3050034|NCT00671177|Experimental|Water Immersion Colonoscopy|Water Immersion Colonoscopy
3050035|NCT00671177|Active Comparator|Standard Air Colonoscopy|Standard Air Colonoscopy
3050036|NCT00671437|Experimental|Arm 1|"Whole body FDG-PET/CT scan and CT scan of neck and chest (within 28 days of Day 1)~Cetuximab 400 mg/m2 intravenously (IV) over 2 hours on day 1 and 250 mg/m2 IV over 1 hour on days 8, 15, 22, 29, 36, 43, and 50.~Whole Body FDG-PET/CT scan and CT scan of neck and chest on Day 57 (prior to cetuximab infusion)~Cetuximab 250 mg/m2 IV over 1 hour on Day 57~Cetuximab 250 mg/m2 IV over 1 hour weekly until progressive disease"
3050037|NCT00671502|Experimental|Carisoprodol 700mg|tablet sustained release (SR)
3050038|NCT00671502|Experimental|Carisoprodol 500mg|sustained release(SR) tablet
3050039|NCT00671502|Placebo Comparator|Placebo|tablet
3050040|NCT00671515|Experimental|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
3050041|NCT00671528|Experimental|QUADRIDERME® cream|QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)
3050042|NCT00671528|Active Comparator|Betamethasone and Gentamicin|Combination of betamethasone diproprionate cream and gentamicin sulfate cream
3050043|NCT00671528|Active Comparator|Betamethasone|Betamethasone diproprionate cream
3050044|NCT00671554|Experimental|Melaxin and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million Colony Forming Units (CFU) of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration
3050045|NCT00671658|Experimental|HYPER-CVAD|Rituximab 375 mg/m^2 intravenous (IV), Cyclophosphamide (CTX) 300 mg/m^2 IV, Doxorubicin 50 mg/m^2 IV, Vincristine 2 mg IV, Dexamethasone 40 mg IV or oral (PO). Methotrexate (MTX) 12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7 - 200 mg/m^2 IV followed by 800 mg/m^2 for Courses 2,4,6,8. Cytarabine 100 mg intrathecal for Courses 1,3,5,7 - 3 gm/m^2 IV for Courses 2,4,6,8. G-CSF 10 ug/kg subcutaneous injection. Mesna 600 mg/m2 a day IV, Pegylated asparaginase 2000 International units/m^2 IV. Pegfilgrastim 6 mg (flat dose) within 72 hrs after completion of chemotherapy. Solumedrol 40 mg IV for Courses 2,4,6,8.
3050046|NCT00671671|Experimental|Cohort B|
3050047|NCT00671671|Experimental|Cohort A|Dose study drug in subjects who have previously failed to respond to interferon based therapies
3050048|NCT00671723|Placebo Comparator|Normal saline|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3050049|NCT00671723|Active Comparator|Hypertonic saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3050050|NCT00671723|Active Comparator|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
3050051|NCT00671749|Experimental|Study Treatment|"adapalene gel, 0.3%~Other Names:~Differin® Gel, 0.3% Applied once daily at bedtime~clindamycin/benzoyl peroxide gel~Other Names:~Duac® Gel Applied once daily in the morning"
3050052|NCT00671788|Experimental|Treatment (dasatinib)|Patients receive oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3050053|NCT00671853|Experimental|1|Quetiapine XR
3050054|NCT00671853|Placebo Comparator|2|Placebo for quetiapine XR
3050055|NCT00671879|Experimental|Carisprodol SR 700 mg|Carisoprodol 700 mg twice daily
3050056|NCT00671879|Experimental|Carisoprodol SR 500mg|Carisoprodol SR 500 mg twice daily
3050057|NCT00671879|Placebo Comparator|Placebo|Placebo
3050058|NCT00671918|Experimental|Lymphoseek, Lymphatic mapping, Injection|
3050059|NCT00671931|Active Comparator|I|Dexmedetomidine low infusion, Propofol low infusion
3050060|NCT00671931|Active Comparator|II|Dexmedetomidine high infusion, Propofol low infusion
3050061|NCT00671931|Active Comparator|IV|Dexmedetomidine high infusion, Propofol high infusion
3050062|NCT00671931|Active Comparator|V|Dexmedetomidine intermediate infusion, Propofol intermediate infusion
3050063|NCT00671931|Active Comparator|III|Dexmedetomidine low infusion, Propofol high infusion
3050064|NCT00671970|Experimental|Bevacizumab + Erlotinib|Bevacizumab + Erlotinib
3050065|NCT00672100|Active Comparator|A|Initial Bolus 5 ml Ropivacaine
3050066|NCT00672100|Active Comparator|B|Initial Bolus 10 ml Ropivacaine
3050067|NCT00672100|Active Comparator|C|Initial Bolus 20 ml Ropivacaine
3050068|NCT00672139|Experimental|Methylnaltrexone bromide|"Methylnaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study.~Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information."
3050069|NCT00672204|Experimental|1|Allogeneic islets of Langerhans
3050070|NCT00672243|Experimental|Erlotinib + Sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of erlotinib and 5mg of sirolimus for patients not on concurrent Cytochrome P450, family 3 (CY3PA)-inducing anti-epileptics (EIAEDS) and 400 mg of erlotinib and 10 mg of sirolimus for patients on concurrent EIAEDS.
3050071|NCT00672256|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
3050072|NCT00672438|Placebo Comparator|Saline placebo infusion|Subjects will receive an intravenous infusion of normal saline.
3050073|NCT00672438|Experimental|Alfentanil infusion|Subjects will receive an intravenous infusion of alfentanil.
3050074|NCT00672451|Experimental|rhubarb extract|will receive rhubarb extract
3050075|NCT00672451|Placebo Comparator|placebo|receive placebo
3050076|NCT00672477|Experimental|Methylnaltrexone|Methylnaltrexone subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL (12 mg) every other day if weight ≥ 62kg; or 0.4 mL (8 mg) every other day if weight between 38 and <62 kg. Subjects with impaired kidney function received reduced doses according to instructions in the Relistor prescribing information.
3050077|NCT00672477|Placebo Comparator|Placebo|Placebo subcutaneously every other day for 14 days (ie, 7 doses). Subjects received 0.6 mL every other day if weight ≥ 62kg; or 0.4 mL every other day if weight between 38 and < 62 kg. Subjects with impaired kidney function received reduced volumes of placebo solution to match the volumes used in the experimental group.
3050078|NCT00672490|Experimental|1|Quetiapine Fumarate - tablets
3050079|NCT00672490|Experimental|2|Quetiapine Fumarate - tablets and Lithium
3050080|NCT00672555|Experimental|Pilonidal Sinus T. With Limberg F.|All patients treated by excision and covering of the defect by a Limberg-flap, who gave their informed consent to participate in the study, as there is only one study group.
3050081|NCT00672594|Experimental|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
3050082|NCT00672620|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
3050083|NCT00672620|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.
3050084|NCT00672620|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.
3050085|NCT00672620|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3050086|NCT00672633|Experimental|A , Experimental|Lovaza, 4 grams/day orally for 6 months
3050087|NCT00672633|Placebo Comparator|Corn Oil Pill|Corn Oil Pill, 4 pills/day orally for 6 months
3050088|NCT00672646|Experimental|AZD1386|
3050089|NCT00672646|Active Comparator|Naproxen|
3050090|NCT00672646|Placebo Comparator|Placebo|Placebo matching AZD1386
3050091|NCT00672737||Males at risk for OSA|"Males at risk for obstructive sleep apnea were invited to have a sleep study either at home or at Stanford Sleep Center.~A week after their sleep study (Polysomnography), all volunteers underwent quantitative sensory testing in the laboratory, during which their pain thresholds and tolerances to heat (Heat pain threshold and tolerance) and cold (Cold pain threshold and tolerance) stimuli were assessed, under two different concentrations (1 and 2 mcg/mL, in randomized order) of remifentanil, a short-acting opioid, given as a computer-controlled infusion."
3050092|NCT00672841|Active Comparator|2|Standard care/empiric therapy group
3050093|NCT00672841|Experimental|1|Active surveillance/ preemptive therapy group
3050094|NCT00672854|Active Comparator|Intralipid 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving Intralipid 20% (soybean-based)
3050095|NCT00672854|Experimental|ClinOleic 20% Intravenous Emulsion|Subjects who require Total Parenteral Nutrition TPN receiving ClinOleic 20% (olive oil based)
3050096|NCT00672932|Experimental|raltegravir group|The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
3050097|NCT00672932|No Intervention|No augmented treatment|Subjects randomized not to receive augmented treatment will continue in the study with their regular antiretroviral regimen.
3050098|NCT00672958|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 6 weeks.
3050099|NCT00672958|Experimental|Vortioxetine|Vortioxetine 5 mg, encapsulated tablet, orally, once daily for up to 6 weeks.
3050100|NCT00672984|Experimental|Immediate-release Guanfacine HCl|
3050101|NCT00672984|Active Comparator|Moxifloxacin HCl|
3050102|NCT00672984|Placebo Comparator|Placebo|
3050103|NCT00673049|Experimental|Arm A|"The CP 751,871 treatment in combination with erlotinib will be given in three week cycles.~CP 751,871 (20 mg/kg) + erlotinib (150 mg/day) CP 751,871 will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter."
3050104|NCT00673049|Active Comparator|Arm B|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food)
3050105|NCT00673075|Active Comparator|1|Encapsulated Nebivolol
3050106|NCT00673075|Active Comparator|2|Encapsulated Carvedilol
3050107|NCT00673114|Other|Transplant Recipients|
3050108|NCT00673127|Experimental|KHAD|Ketoconazole, Hydrocortisone and Dutasteride Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Dutasteride: 0.5 mg once a day
3050109|NCT00673153|Experimental|Arm I|"REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .~CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.~MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses."
3050110|NCT00673231|Experimental|1|2.5mg
3050111|NCT00673231|Experimental|2|5mg
3050112|NCT00673231|Experimental|3|10mg
3050113|NCT00673231|Placebo Comparator|4|
3050114|NCT00673244|Experimental|1|
3050115|NCT00673257|Experimental|Pharmacokinetics of Daunorubicin chemotherapy patients|Patients receiving a chemotherapy regimen including daunorubicin hydrochloride administered as an infusion of any duration < 24 hours on a 1 or a 2 day schedule. Pre-study evaluations no greater than 14 days prior to daunomycin administration. If patients have had significant intercurrent illness or treatment that might affect organ function, laboratory work should be performed at an appropriately closer interval to daunomycin administration. A complete history and physical examination including height, weight and body surface area. Patients should be weighed with only light clothing; shoes must be removed before weight is measured. Patients height should be measured using a stadiometer after removing shoes. Laboratory evaluation: a) CBC with differential and platelet count. b) ALT, AST, bilirubin, creatinine, total protein, albumin, alkaline phosphatase, GGT.
3050116|NCT00673387|Placebo Comparator|Placebo-P + Placebo-M|Placebo matched to pramlintide BID plus placebo matched to metreleptin BID
3050117|NCT00673387|Experimental|Pramlintide 360 mcg + Placebo-M|360 mcg pramlintide given twice per day (BID) plus Placebo matched to Metreleptin given BID
3050118|NCT00673387|Experimental|Placebo-P + Metreleptin 5.0 mg|Placebo matched to pramlintide BID plus metreleptin 5.0 mg BID
3050119|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 2.5 mg|Pramlintide 180 mcg BID plus Metreleptin 2.5 mg BID
3050120|NCT00673387|Experimental|Pramlintide 180 mcg + Metreleptin 5.0 mg|Pramlintide 180 mcg BID plus Metreleptin 5.0 mg BID
3050121|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 1.25 mg|Pramlintide 360 mcg BID plus Metreleptin 1.25 mg BID
3050122|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 2.5 mg|Pramlintide 360 mcg BID plus Metreleptin 2.5 mg BID
3050123|NCT00673387|Experimental|Pramlintide 360 mcg + Metreleptin 5.0 mg|Pramlintide 360 mcg BID plus Metreleptin 5.0 mg BID
3050124|NCT00673400|Other|Stapled transanal rectum resection|patients operated with stapled transanal rectum resection
3050125|NCT00673439|Experimental|Fondaparinux|daily subcutaneous injection of fondaparinux (7.5-10 mg)
3050126|NCT00673452|Experimental|Duloxetine|60-120 mg, oral, every day, 12 weeks
3050127|NCT00673452|Placebo Comparator|Placebo|oral, daily, 12 weeks
3050128|NCT00673465|Experimental|Treatment sequence 1: SCH 497079 → Placebo → Metformin|Participants received SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks followed by metformin daily for 4 weeks.
3050129|NCT00673465|Experimental|Treatment sequence 2: Placebo → Metformin → SCH 497079|Participants received placebo daily for 4 weeks followed by metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
3050130|NCT00673465|Experimental|Treatment sequence 3: Metformin → SCH 497079 → Placebo|Participants received metformin daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by placebo daily for 4 weeks.
3050131|NCT00673465|Experimental|Treatment sequence 4: SCH 497079 → Metformin → Placebo|Participants received SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks followed by placebo daily for 4 weeks.
3050132|NCT00673465|Experimental|Treatment sequence 5: Placebo → SCH 49709 → Metformin|Participants received placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks followed by metformin daily for 4 weeks.
3050133|NCT00673465|Experimental|Treatment sequence 6: Metformin → Placebo → SCH 497079|Participants received metformin daily for 4 weeks followed by placebo daily for 4 weeks followed by SCH 497079 daily for 4 weeks.
3050134|NCT00673660||Statins|Patients with dyslipidemia who are taking or planning to take a statin treatment (Atorvastatin, Fluvastatin, Prevastatin, Rosuvastatin, Simvastatin or generics).
3050135|NCT00673673|Experimental|1|FOLFOX in combination with bevacizumab
3050136|NCT00673712|Experimental|Continuous Sternal Block|Continuous Sternal block with infusion of local anesthetic via ON-Q Painbuster Silver Soaker system
3050137|NCT00673712|Active Comparator|Opioid based analgesia|Opioid based analgesia including Patient controlled analgesia plus IM, Oral narcotics and other analgesics
3050138|NCT00673738|Experimental|Cetuximab Plus Radiotherapy|Concurrent Cetuximab plus Conformal Thoracic Radiotherapy (CTRT). Patients were treated with definitive radiotherapy (70 Gy in 35 fractions, per our currently-existing institutional standard) with concurrent cetuximab followed by 3 cycles of consolidation docetaxel plus cetuximab.
3050139|NCT00673764|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3050140|NCT00673764|Active Comparator|Optive|Optive Lubricant Eye Drops
3050141|NCT00673790|Active Comparator|Nebivolol|Nebivolol with concomitant losartan or lisinopril
3050142|NCT00673790|Active Comparator|Hydrochlorothiazide (HCTZ)|HCTZ with concomitant losartan or lisinopril
3050143|NCT00673790|Placebo Comparator|Placebo|Placebo with concomitant losartan or lisinopril
3050144|NCT00673816|Experimental|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
3050145|NCT00673855|Experimental|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye one time
3050146|NCT00673855|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye 1 time
3050147|NCT00673881|Experimental|Abt-335|ABT-335 (choline fenofibrate)
3050148|NCT00673894|Experimental|Glutamine+Sitagliptin|Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
3050149|NCT00673894|Placebo Comparator|Glutamine+Placebo|Glutamine 30 g/d (15 g with breakfast and dinner) + placebo
3050150|NCT00673920|Placebo Comparator|Placebo|"Participants received matching placebo:~on Day 15 of Cycle 1 (Participants who were administered OCR 400 mg on Day 1 of a Cycle 1 in combination with Methotrexate)~on both Days 1 and Day 15 of Cycle 1 (Participants who were randomized to the Placebo + Methotrexate group)"
3050151|NCT00673920|Experimental|Ocrelizumab 400mg|Participants received Ocrelizumab 400mg in combination with Methotrexate on Day 1, Cycle 1.
3050152|NCT00673920|Experimental|Ocrelizumab 200mg|Participants received Ocrelizumab 200 mg in combination with Methotrexate on Day 1 and Day 15, Cycle 1.
3050153|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 200mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
3050154|NCT00673920|Experimental|Ocrelizumab 200mg/ Ocrelizumab 400mg|Participants who received two 200 mg infusions of Ocrelizumab + Methotraxate during Cycle 1 were re-randomized (1:1 randomization ratio) to receive a single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
3050155|NCT00673920|Experimental|Ocrelizumab 400mg/ Ocrelizumab 400mg|Participants who received single 400mg infusions of Ocrelizumab + Methotraxate during Cycle 1 received a infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
3050156|NCT00673920|Experimental|Placebo/ Ocrelizumab 200mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive two infusions of 200 mg Ocrelizumab + Methotraxate during Cycle 2
3050157|NCT00673920|Experimental|Placebo/ Ocrelizumab 400mg|Participants who received placebo during Cycle 1 were re-randomized (1:1 randomization ratio) to receive single infusion of 400 mg Ocrelizumab + Methotraxate during Cycle 2
3050158|NCT00673933|Experimental|1|PDT using MAL crem
3050159|NCT00673933|Placebo Comparator|2|PDT using Placebo cream
3050160|NCT00673959|Experimental|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
3050161|NCT00673959|Active Comparator|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
3050162|NCT00674115|Experimental|Single Dose Zegerid for 1 or 7 days|Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension
3050163|NCT00674115|Active Comparator|Single Dose Prilosec 1 or 7 days|Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet
3050164|NCT00674115|Active Comparator|Sodium Bicarbonate|Sodium Bicarbonate 1680 mg Oral Suspension
3050165|NCT00674128|Experimental|Adhesive|Cyanoacrylate tissue adhesive.
3050166|NCT00674128|Active Comparator|Suture|Polyglactin 910 suture.
3050167|NCT00674154|Experimental|Vitamin D group|Cholecalciferol 1400 IU, 2 tablets once daily in 52 weeks
3050168|NCT00674154|Placebo Comparator|Placebo group|Placebo, two tablets daily in 52 weeks.
3050169|NCT00674206|Experimental|Gemcitabine and Oxaliplatin|All patients enrolled on clinical trial will receive Gemcitabine 1000mg/m^2 on Day 1 and Oxaliplatin 100 mg/m^2 intravenously over 2 hours on Day 2.
3050170|NCT00674219|Active Comparator|OCD group|OCD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
3050171|NCT00674219|Active Comparator|GAD group|GAD group - received 12 weeks of open-label memantine 10 mg twice daily, as either mono therapy or augmentation of their existing medication.
3050172|NCT00674297|Experimental|Fluvastatin|All patients will take Fluvastatin 40 mg daily for 3 months.
3050173|NCT00674323|Experimental|Verteporfin and Ranibizumab|Photodynamic therapy with verteporfin in combination with ranibizumab injection. Patients received one treatment at baseline with verteporfin photodynamic therapy (PDT) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3050174|NCT00674323|Active Comparator|Verteporfin monotherapy|Patients received one treatment at baseline with verteporfin photodynamic therapy in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab placebo (sham intravitreal injection) on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3321402|NCT02018536|Experimental|Part 2, Sequence 2|6 participants to receive Treatment B (GSK2336805 60 mg), A (TMC435 150 mg), C (TMC435 100 mg+GSK2336805 60 mg), and D (TMC435 150 mg+GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3050175|NCT00674323|Active Comparator|Ranibizumab monotherapy|Patients received one treatment at baseline with verteporfin placebo (with sham photodynamic therapy) in the study eye and thereafter based on re-treatment criteria at intervals of at least 90 days. Within 1-24 hours, patients also received Ranibizumab intravitreal injection on Day 1 and at Month 1 and 2 and thereafter according to the re-treatment criteria at intervals of at least 30 days through Day 150. From month 3 onward, re-treatments were determined based on study-specific re-treatment criteria that included evaluation of polyp progression on indocyanine green angiography (ICGA), and assessment of fluorescein angiograms and visual acuity.
3050176|NCT00674362|Experimental|Certolizumab pegol 200 mg (CDP870)|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
3050177|NCT00674362|Placebo Comparator|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
3050178|NCT00674466|Experimental|1|Twice-a-week dose of 1.5 mg CJC-1134-PC
3050179|NCT00674466|Experimental|2|Twice-a-week dose of 1.5 mg CJC-1134-PC for 4 weeks, then once-a-week dose of 2.0 mg CJC-1134-PC plus mid-week dosing of placebo
3050180|NCT00674466|Placebo Comparator|3|Twice-a-week placebo for CJC-1134-PC
3050181|NCT00674479|Experimental|INCB018424|The starting dose of INCB018424 will be 25 mg by mouth twice daily.
3050182|NCT00674492||Hepatitis C patients|patients who initiated antiviral treatment for hepatitis C
3050183|NCT00674570|Experimental|Arm 1: Hydrocortisone|Hydrocortisone
3050184|NCT00674570|Experimental|Arm 2: D-Cycloserine|D-Cycloserine
3050185|NCT00674570|Placebo Comparator|Arm 3: Placebo|Placebo
3050186|NCT00674583|Experimental|Nimenrix Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Nimenrix™ vaccine into the non-dominant deltoid region, at Day 0.
3050187|NCT00674583|Active Comparator|Menjugate Group|Healthy male or female subjects between, and including 2 and 10 years of age, intramuscularly received 1 dose of Menjugate® vaccine into the non-dominant thigh region, at Day 0.
3050188|NCT00674609|Placebo Comparator|Placebo|Placebo control
3050189|NCT00674609|Experimental|Sativex|Active treatment
3050190|NCT00674609|Experimental|THC Alone|Active treatment
3050191|NCT00674622|Experimental|Group 1-Prolotherapy|Deep injection with 15% dextrose in lidocaine
3050192|NCT00674622|Placebo Comparator|Group 2-Deep Saline/Lidocaine|Deep injection with saline/lidocaine
3050193|NCT00674622|Placebo Comparator|Group 3-Superficial Saline/lidocaine|Superficial injection with saline/lidocaine
3050194|NCT00674661|Active Comparator|Corneal Collagen Cross-linking (CXL) Treatment Group|riboflavin ophthalmic solution and UVA irradiation
3050195|NCT00674661|Sham Comparator|Control Group|riboflavin opthalmic solution without UVA irradiation
3050196|NCT00674700|Active Comparator|300 IR|300 IR house dust mites allergen extract tablet
3050197|NCT00674700|Active Comparator|500 IR|500 IR house dust mites allergen extract tablet
3050198|NCT00674700|Placebo Comparator|Placebo|Placebo tablet
3050199|NCT00674739|Experimental|imiquimod cream|2.5% imiquimod cream applied daily to wart area for up to 8 weeks
3050200|NCT00674739|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
3050201|NCT00674739|Placebo Comparator|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
3050202|NCT00674765|Experimental|1|Seroquel
3050203|NCT00674765|Placebo Comparator|2|Placebo
3050204|NCT00674817|Experimental|400 microgrammes GSK961081 and salbutamol|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
3050205|NCT00674817|Experimental|1200 microgrammes GSK961081 and salbutamol|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (3x 200 microgrammes at 20 min intervals, administered via spacer) of salbutamol at 1h, 12h and 24h of dosing.
3050206|NCT00674817|Experimental|400 microgrammes GSK961081 and ipratropium bromide|400 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
3050207|NCT00674817|Experimental|1200 microgrammes of GSK961081 and ipratropium bromide|1200 microgrammes of GSK961081 single-dose (via DISKUS MDPI) followed by cumulative doses (20 microgrammes, 20 microgrammes and 40 microgrammes at 20 min intervals, administered via spacer) of ipratropium bromide at 1h, 12h and 24h of dosing.
3050208|NCT00674817|Placebo Comparator|400 microgrammes of GSK961081 and placebo|400 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
3050209|NCT00674817|Placebo Comparator|1200 microgrammes of GSK961081 and placebo|1200 microgrammes of GSK961081 single-dose (via DISKUS Metered Dry Powder Inhaler/ MDPI) followed by cumulative doses (3 doses at 20 min intervals, administered via spacer) of placebo at 1h, 12h and 24h of dosing.
3050210|NCT00674973|Experimental|Erlotinib|Participants with advanced pancreatic carcinoma with Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
3050211|NCT00674973|Placebo Comparator|Placebo|Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received placebo matching to erlotinib 150 mg tablet orally once daily until disease progression, unacceptable toxicity, withdrawal, or death.
3050212|NCT00674986|Other|Active Control Group (ACG)|Participants in the Active Control Group received enhanced standard of care (more frequent clinic visits, free blood glucose meters and strips and point-of-care Hemoglobin A1c (HbA1c) test) for management of their Type 2 diabetes.
3050213|NCT00674986|Experimental|Structured Testing Group (STG)|Participants in the Structured Testing Group in addition to enhanced standard of care for the treatment of their Type 2 diabetes used the ACCU-CHEK® 360° View blood glucose analysis system (Tool) to monitor glucose levels at least quarterly.
3050214|NCT00675025|Experimental|Prior Donepezil-DB|All participants started with a dose of 2.5 mg/day (2.5 mL/day). Dose escalations occurred in 2.5 mg/day increments every 2 weeks (steady state levels assumed to have been reached) to a maximum dose of 10 mg/day, according to the participant's weight schedule and the Investigator's judgment of safety and tolerability. Re-titration was done to maintain the blinding of the double-blind study (E2020-A001-219). Doses could be decreased due to tolerability and could be increased or decreased to maintain a maximum dose of 0.1 to 0.2 mg/kg/day based on the participant's weight at clinic visits during the study duration.
3050215|NCT00675103|Experimental|pegloticase|
3050216|NCT00675259|Experimental|Neoadjuvant, Surgery, Adjuvant|Neoadjuvant chemotherapy : Nab-paclitaxel and carboplatin on days 1, 8, and 15 in combination with bevacizumab on days 1 and 15 administered every 28 days for 5 cycles followed by 1 cycle with Nab-paclitaxel and carboplatin on days 1, 8, and 15. Definitive surgery with either lumpectomy or mastectomy along with axillary lymph node dissection for all pre neo adjuvant chemotherapy node-positive patients approximately 4-5 weeks after the completion of NCT. Use of additional adjuvant chemotherapy and/or radiation therapy depends upon the treating physicians' judgment. Radiation therapy should begin no sooner than 6 weeks after breast cancer surgery. All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
3050217|NCT00675415|Active Comparator|Capnography|"Capnography: Subjects randomized to capnography-titration arm: The endoscopy team would be made aware of the capnographic abnormalities as they arise.~In this arm, the endoscopy team will have the graphic representation of respiratory activity (capnography) as well as end-epxiratory levels of carbon dioxide in addition to the normal physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography.~This observation phase would take place for a baseline prior to sedation, during the administration of sedation as well as throughout the procedure. Monitoring for the study would stop upon completion of the endoscopic procedure."
3050218|NCT00675415|No Intervention|Standard Monitoring|Subjects randomized to capnography-blinded arm: In this arm, the endoscopy team will not have the graphic representation of respiratory activity (capnography) as well as end-expiratory levels of carbon dioxide available. Only a standard of care physiologic monitoring portfolio of pulse oximetry, blood pressure and electrocradiography at the disposal of the endoscopy team to titrate the sedative medications.
3050219|NCT00675428|Experimental|Natalizumab 300 mg|Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.
3050220|NCT00675428|Experimental|Natalizumab 450 mg|Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.
3050221|NCT00675441|Experimental|Lenalidomide|Lenalidomide 10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
3050222|NCT00675506|Experimental|1|Participants will receive treatment with growth hormone releasing hormone 1-44 (TH9507).
3050223|NCT00675506|Placebo Comparator|2|Participants will receive treatment with placebo medication.
3050224|NCT00675558||Non-Obese (NO)|Patients with a BMI < 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.
3050225|NCT00675558||Morbidly Obese (MO)|Patients with a BMI > 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.
3050226|NCT00675558||Super-morbidly Obese (SMO)|"Patients with a BMI > 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.~10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study."
3050227|NCT00675584|Active Comparator|Placebo Budesonide|Participants will receive 0.5 mg of ICS (budesonide as Pulmicort Respules®) once a day at night, except during respiratory tract illnesses. During respiratory tract illnesses, participants will receive placebo each morning and 0.5 mg of budesonide each night for 7 days.
3050228|NCT00675584|Experimental|Budesonide|Participants will receive 1 mg of ICS (budesonide as Pulmicort Respules®) twice a day for 7 days at the onset of a respiratory tract illness; they will receive placebo ICS once a day at all other times during the study.
3050229|NCT00675597|Experimental|1|Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients with Resected Stage I-III Non-small Cell Lung Cancer
3050230|NCT00675766||Group 1|HIV-positive adults 50 and older/ HIV-positive adults 18-40 years old
3050231|NCT00675766||Group 2|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
3050232|NCT00675766||Group 3|HIV-negative controls 50 and older / HIV-negative controls 18-40 years old
3050233|NCT00675766||Group 4|HIV-negative controls 18-40 years old
3050234|NCT00675792|Experimental|Sugammadex|4 mg/kg sugammadex
3050235|NCT00675792|Active Comparator|Neostigmine|50 µg/kg neostigmine
3050236|NCT00675909|Active Comparator|Oral Midazolam|Oral midazolam 0.5mg/kg
3050237|NCT00675909|Experimental|Aerosolized intranasal midazolam|Intranasal midazolam 0.3mg/kg
3050238|NCT00675909|Experimental|Aerosolized buccal midazolam|Buccal midazolam 0.3mg/kg
3050239|NCT00675922|Experimental|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon 5% Solution and Silver Nitrate soaked dressings to two different burned area. Sites were then monitored for infections during hospitalization.
3050240|NCT00675948|Experimental|Sativex|Active treatment
3050241|NCT00675948|Experimental|GW-2000-02|Active treatment
3050242|NCT00675987|Active Comparator|Losartan|Losartan 100 mg 1 tab po QD
3050243|NCT00675987|Placebo Comparator|Placebo|Placebo 1 tab po QD
3050244|NCT00676013|Experimental|Alloderm, Integra, Homograft, Autograft|Burn debridement and grafting using interventions of 1) AlloDerm, 2) Integra, 3) Homograft and 4) Autograft on four separate sites on each patient
3050245|NCT00676052|Experimental|Arm 1|GSK233705 12.5mcg
3050246|NCT00676052|Experimental|Arm 2|GSK233705 25mcg
3050247|NCT00676052|Experimental|Arm 3|GSK233705 50mcg
3050248|NCT00676052|Experimental|Arm 4|GSK233705 100mcg
3050249|NCT00676052|Experimental|Arm 5|GSK233705 200mcg
3050250|NCT00676052|Placebo Comparator|Arm 6|Placebo
3050251|NCT00676065||1|Women who take oral contraceptives containing drospirenone
3050252|NCT00676065||2|Women who take oral contraceptives containing levonorgestrel
3050253|NCT00676065||3|Women who take oral contraceptives containing other progestogens
3050254|NCT00676091|Experimental|13vPnC|13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
3050255|NCT00676091|Active Comparator|7vPnC|7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).
3050256|NCT00676130|Active Comparator|Standard therapy|cephalexin plus placebo
3050257|NCT00676130|Experimental|Standard plus anti-CA-MRSA|cephalexin plus trimethoprim-sulfamethoxazole
3050258|NCT00676143|Experimental|Bapineuzumab 0.5 mg/kg|
3050259|NCT00676143|Placebo Comparator|Placebo|
3050260|NCT00676182||Arm 1: Telerehabilitation|telerehabilitation
3050261|NCT00676195|Experimental|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
3050262|NCT00676208|Experimental|Shared Medical Appointments|Medical students participated in shared medical appointments for patients with diabetes for one month.
3050263|NCT00676208|No Intervention|No shared medical appointments|Medical students in this arm did not participate in shared medical appointments.
3050264|NCT00676338|Experimental|Exenatide Once Weekly|
3050265|NCT00676338|Active Comparator|Metformin|
3050266|NCT00676338|Active Comparator|Sitagliptin|
3050267|NCT00676338|Active Comparator|Pioglitazone|
3050268|NCT00676364|Active Comparator|4% lidocaine topical anesthetic cream|This group received topical 4% lidocaine anesthetic cream under occlusive dressing for 15 minutes prior to needle stick.
3050269|NCT00676364|Placebo Comparator|Placebo|This group received matching placebo cream under occlusive dressing for 15 minutes prior to needle stick.
3050270|NCT00676403|Placebo Comparator|1|Placebo
3050271|NCT00676403|Experimental|2|investigational treatment
3050272|NCT00676403|Experimental|3|investigational treatment
3050273|NCT00676403|Experimental|4|investigational treatment
3050274|NCT00676403|Experimental|5|investigational treatment
3050275|NCT00676403|Experimental|6|investigational treatment
3050276|NCT00676520||1|Single-arm study
3050277|NCT00676572||Severe asthma|
3050278|NCT00676572||Non-severe asthma|
3050279|NCT00676585|Placebo Comparator|2|Normal Saline
3050280|NCT00676585|Experimental|1|Hydrocortisone 100mg every 8 hours.
3050281|NCT00676650|Experimental|A|Treatment Arm A - sunitinib + prednisone
3050282|NCT00676650|Placebo Comparator|B|Treatment Arm B - placebo + prednisone
3050283|NCT00676663|Experimental|Exemestane 25 mg + Entinostat 5 mg|Exemestane (Aromasin®) 25 mg tablets orally once daily plus an entinostat 5 mg tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
3050284|NCT00676663|Placebo Comparator|Exemestane 25 mg + Placebo|Exemestane (Aromasin®) 25 mg tablets orally once daily plus a placebo-matching entinostat tablet orally once per week on Days 1, 8, 15 and 22 of each 28-day treatment cycle until development of progressive disease (PD) or unacceptable toxicity or closure of the study by the Sponsor, whichever occurred first.
3050285|NCT00676676|Active Comparator|Testosterone|Testosterone patch delivering 300mcg daily for 8-weeks.
3050286|NCT00676689|Experimental|SAPIEN THV|
3050287|NCT00676715|Placebo Comparator|Placebo|Participants received two intravenous (IV) infusions of matching placebo separated by 14 days in Cycle 1, followed by two infusions of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4. Each cycle was of 168 days.
3050288|NCT00676715|Experimental|Ocrelizumab 600 mg|Participants two IV infusions of ocrelizumab 300 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 600 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
3050289|NCT00676715|Experimental|Ocrelizumab 1000 mg|Participants received two IV infusions of ocrelizumab 1000 mg separated by 14 days in Cycle 1, followed by an infusion of ocrelizumab 1000 mg on Day 1 and an infusion of placebo on Day 15 of Cycle 2. A single infusion of ocrelizumab 1000 mg was administered on Day 1 of Cycle 3 and a single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycle 4. Each cycle was of 168 days.
3050290|NCT00676715|Active Comparator|Avonex|Participants received weekly intramuscular injections of Avonex 30 microgram (mcg) in Cycle 1, followed by two infusions of OCR 300 mg separated by 14 days in Cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of Cycles 3 and 4. Each cycle was of 168 days.
3050291|NCT00676780|Experimental|ECGC Extract|Single arm for a phase II study
3050292|NCT00676793|Experimental|Polyphenon E|This is a single arm study comparing changes within patients before and after receiving the experimental drug Polyphenon E for the duration of the study, between recruitment and surgery for breast cancer.
3050293|NCT00676806|Experimental|Myeloablative conditioning|Umbilical cord blood for hematopoietic rescue following myeloablative conditioning
3050294|NCT00676806|Experimental|Reduced intensity conditioning|Umbilical cord blood for hematopoietic rescue following non-myeloablative conditioning
3050295|NCT00676897|Experimental|1|Simvastatin 40 mg PO or NGT
3050296|NCT00676897|Placebo Comparator|2|Placebo
3050297|NCT00677014|Active Comparator|Echo optimized AV delay|Echo optimized AV delay
3050298|NCT00677014|Active Comparator|Algorithm optimized AV delay|Algorithm optimized AV delay
3050299|NCT00677014|Active Comparator|Fixed AV Delay|Fixed AV Delay
3050300|NCT00677092|Experimental|Imatinib Mesylate (IM) Treatment|Imatinib mesylate 400 milligrams (mg) orally once daily for 4 months. Dosage was reduced to 200 mg if the participant developed gastrointestinal intolerance or alopecia.
3050301|NCT00677235|Experimental|FLAIR|FLAIR Endovascular Stent Graft
3050302|NCT00677235|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
3050303|NCT00677352|Experimental|1|
3050304|NCT00677352|Active Comparator|2|
3050305|NCT00677365|Placebo Comparator|Placebo|Placebo inhaled either once or twice daily via the PARI eFlow nebulizer for 28 days
3050306|NCT00677365|Experimental|MP-376 120 mg QD|MP-376 120 mg inhaled Once Daily (QD) via the PARI eFlow nebulizer for 28 days
3050307|NCT00677365|Experimental|MP-376 240 mg QD|MP-376 240 mg inhaled QD bia the PARI eFlow nebulizer for 28 days
3050308|NCT00677365|Experimental|MP-376 240 mg BID|MP-376 240 mg inhaled twice daily (BID) via the PARI eFlow nebulizer for 28 days
3050309|NCT00677534|Experimental|1|Cholecalciferol (Vitamin D)
3050310|NCT00677690|Active Comparator|NM+PR|Patients undergone to combination of neuromuscular stimulation and pulmonary rehabilitation (NM+PR)
3050311|NCT00677690|Placebo Comparator|SS+PR|Patients undergone to pulmonary rehabilitation
3050312|NCT00677807|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3050313|NCT00677807|Experimental|Indacaterol 300 µg|"Indacaterol 300 µg once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI).~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3050314|NCT00677807|Placebo Comparator|Placebo|"Placebo once-daily (o.d.) via SDDPI.~The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3050315|NCT00677820|Experimental|Trivalent influenza virus vaccine|Frozen trivalent vaccine containing new strains
3050316|NCT00677820|Placebo Comparator|Placebo|treatment with placebo
3050317|NCT00677833|Experimental|1|
3050318|NCT00677833|Experimental|2|
3050319|NCT00677898|Experimental|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
3050320|NCT00677898|Active Comparator|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
3050321|NCT00677924|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with Irinotecan
3050322|NCT00677924|Experimental|Zalutumumab 16 mg/kg|Zalutumumab in combination with Irinotecan
3050323|NCT00678015|Experimental|1|
3050324|NCT00678080|Experimental|Metformin|Metformin therapy as prescribed by their health care provider
3050325|NCT00678080|Active Comparator|Insulin|Insulin as prescribed by their health care provider
3050326|NCT00678210|Experimental|1|
3050327|NCT00678210|Experimental|2|
3050328|NCT00678210|Experimental|3|
3050329|NCT00678210|Placebo Comparator|4|
3050330|NCT00678249|Experimental|FLAIR|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft
3050331|NCT00678249|Active Comparator|PTA Only|Percutaneous Transluminal Angioplasty
3050332|NCT00678249|Experimental|FLAIR Roll-in Participants|Primary Patency followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
3050333|NCT00678301|Experimental|SYNFLORIX™ + ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Synflorix™ vaccine, according to a 3-dose schedule at 6-10-14 weeks of age co-administered with 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to the same schedule. The Synflorix™ and Zilbrix™ Hib vaccines were administered by intramuscular injection, in the right and left thigh respectively. The Polio Sabin™ vaccine was administered orally.
3050334|NCT00678301|Experimental|ZILBRIX™ HIB + POLIO SABIN™|Subjects in this group received 3 doses of Expanded Program on Immunization (EPI) vaccines Zilbrix™ Hib and Polio Sabin™ according to a 3-dose schedule at 6-10-14 weeks of age. The Zilbrix™ Hib vaccine was administered by intramuscular injection, in the left thigh. The Polio Sabin™ vaccine was administered orally.
3050335|NCT00678379|Placebo Comparator|Normal Saline|1.5 ml injection of Normal Saline into each tonsillar fossa pre-tonsillectomy
3050336|NCT00678379|Active Comparator|Lidocaine (1%) + Bupivacaine 0.5%|Submucosal injection of 1.5 mL Lidocaine (1%) + Bupivacaine 0.5% into the tonsillar fossa, pre-tonsillectomy
3050337|NCT00678379|Experimental|Lidocaine + Bupivacaine + Clondine|Submucosal injection of 1.5 mL Lidocaine 1% + Bupivacaine 0.5% + Clondine 25mcg into the tonsillar fossa, pre-tonsillectomy
3050338|NCT00678392|Experimental|Axitinib|
3050339|NCT00678392|Active Comparator|Sorafenib|
3050340|NCT00678418|Experimental|VIVITROL® 380 mg|
3050341|NCT00678418|Placebo Comparator|Placebo|
3050342|NCT00678444|No Intervention|Arm 1: Non-educational video self-cath|Randomized to not watching educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
3050343|NCT00678444|Experimental|Arm 2: Educational Video Self-cath|Randomized to watch educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
3050344|NCT00678470|Experimental|Single Arm|Investigational intervention without random assignment
3050345|NCT00678496|Experimental|1|CBT software delivered at home or in a primary care facility (n=12)
3050346|NCT00678496|Other|2|Treatment as usual (n=12)
3050347|NCT00678535|Experimental|Cetuximab plus Capecitabine plus Cisplatin|
3050348|NCT00678535|Active Comparator|Capecitabine plus Cisplatin|
3050349|NCT00678561|Experimental|2% CP-690,550 QD|
3050350|NCT00678561|Experimental|0.2% CP-690,550 QD|
3050351|NCT00678561|Experimental|0.02% CP-690,550 QD|
3050352|NCT00678561|Experimental|2% CP-690,550 BID|
3050353|NCT00678561|Experimental|0.2% CP-690,550 BID|
3050354|NCT00678561|Experimental|0.02% CP-690,550 BID|
3050355|NCT00678561|Placebo Comparator|Placebo Vehicle QD|
3050356|NCT00678561|Placebo Comparator|Placebo Vehicle BID|
3050357|NCT00678587|Placebo Comparator|Placebo|placebo, once daily, oral
3050358|NCT00678587|Active Comparator|Active|75 mg, once daily, oral
3050359|NCT00678639|Experimental|Emergency Department (ED) Observation unit|Emergency Department observation unit- Cardiac Magnetic Resonance Imaging (MRI) Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
3050360|NCT00678639|No Intervention|Usual care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
3050361|NCT00678652|Experimental|10 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 10 μg with Adjuvant
3050362|NCT00678652|Experimental|25 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 25 μg with Adjuvant
3050363|NCT00678652|Experimental|50 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 50 μg with Adjuvant
3050364|NCT00678652|Experimental|75 μg of Group B Meningococcal 8570 HOPS-G NOMV Vaccine|Three Injections, Given at 0, 6, and 12 Weeks, of Group B Meningococcal 8570 HOPS-G NOMV Vaccine Administered Intramuscularly to Healthy Subjects at 75 μg with Adjuvant
3050365|NCT00678691|Experimental|A,1|armodafinil
3050366|NCT00678691|Placebo Comparator|A,2|placebo
3050367|NCT00678795|Experimental|Sativex|Each 100 ul actuation contains 27 mg delta-9-tetrahydrocannabinol (THC) and 25 mg cannabidiol (CBD). A maximum of 48 actuations (130 mg of THC and 120 mg of CBD) was permitted in any 24 hour period.
3050368|NCT00678795|Placebo Comparator|Placebo|Each 100 ul actuation contains the colorants plus excipients. A maximum of 48 actuations was permitted in any 24 hour period.
3050369|NCT00678834|Active Comparator|Arm 1|To surgery patients, Tocotrienol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
3050370|NCT00678834|Active Comparator|Arm 2|To surgery patients, Tocopherol capsules. 200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
3050371|NCT00678834|Active Comparator|Arm 3|Tocotrienol to healthy subjects - 200 mg to take orally two times a day (400 mg a day).
3050372|NCT00678886|Experimental|otelixizumab|otelixizumab
3050373|NCT00678886|Placebo Comparator|placebo|Placebo
3050374|NCT00678899|Experimental|Surgery|Implantation with the Nucleus Hybrid L24 Cochlear Implant
3050375|NCT00679029|Experimental|Chemotherapy with Bevacizumab|"AC = Doxorubicin 60 mg /M2 followed by cyclophosphamide 600 mg/M2 will be given every 2 weeks for cycles 1-4.~TG = Paclitaxel 175 mg/M2 followed by gemcitabine 1500 mg/M2 will be given every 2 weeks for cycles 5-8.~Beginning cycle 5, B1= Avastin 10 mg/kg will be given as a single IV dose following each TG treatment every 2 weeks for cycles 5-7."
3050376|NCT00679042|Experimental|Treatment|All subjects will receive up to 3 transplantations of allogeneic human islets of Langerhans.
3050377|NCT00679055|Experimental|MK-0736|Participants will be orally administered 7 mg of MK-0736 once daily for 12 weeks
3050378|NCT00679055|Placebo Comparator|Placebo|Participants will be orally administered placebo once daily for 12 weeks.
3050379|NCT00679081|Experimental|CelTx|CelTx
3050380|NCT00679081|Active Comparator|Autologous CTG|Autologous sub-epithelial connective tissue graft
3050381|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 1|Dose of 5.0 x 10^9 colony forming units (CFU) S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
3050382|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 2|Dose of 7.5 x 10^9 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
3050383|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 3|Dose of 1.1 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
3050384|NCT00679172|Experimental|M01ZH09 Vaccine Candidate Cohort 4|Dose of of 1.7 x 10^10 CFU S. typhi (Ty2 aroC-ssaV-) ZH9 or placebo, administered as a single, oral dose
3050385|NCT00679211|Experimental|Trastuzumab emtansine|Trastuzumab emtansine (T-DM1) was administered to participants at a dose of 3.6 mg/kg by intravenous (IV) infusion every 3 weeks until documented disease progression, unmanageable toxicity, or study termination.
3050386|NCT00679263|Experimental|MN-221|
3050387|NCT00679263|Placebo Comparator|PLACEBO|Placebo intravenous infusion with dosing volume equivalent to active treatment.
3050388|NCT00679289|Experimental|Cohort 1|"KW2871: 5 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3050389|NCT00679289|Experimental|Cohort 2|"KW2871: 10 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3050390|NCT00679289|Experimental|Cohort 3|"KW2871: 20 mg/m^2 IV every 2 weeks until disease progression~HDI: 20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression"
3050391|NCT00679302|Placebo Comparator|placebo group|Maalox and bitter mixture
3050392|NCT00679302|Active Comparator|antibiotic group|Trimethoprim-sulfamethoxazole suspension
3050393|NCT00679341|Experimental|Trastuzumab emtansine|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) administered over 30-90 minutes every 3 weeks on Day 1 of each 21-day cycle.
3050394|NCT00679341|Active Comparator|Trastuzumab + docetaxel|Patients received a loading dose of trastuzumab 8 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of Cycle 1 followed by trastuzumab 6 mg/kg IV + docetaxel 75 or 100 mg/m^2 IV on Day 1 of all subsequent 21-day cycles.
3050395|NCT00679354|Experimental|Treatment (cilengitide)|Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3050396|NCT00679367|Experimental|Melphalan Revlimid and Dexamethasone|Melphalan Lenalidomide Dexamethasone
3050397|NCT00679380|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
3050398|NCT00679380|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus three placebo Entocort EC® overencapsulated capsules daily in the morning after breakfast.
3050399|NCT00679380|Active Comparator|3: Entocort EC® 3 mg|Three Entocort EC® 3 mg overencapsulated capsules plus one placebo budesonide MMX® tablet daily in the morning after breakfast.
3050400|NCT00679380|Placebo Comparator|4: Placebo|Three placebo Entocort EC® overencapsulated capsules plus one placebo Budesonide MMX® tablet daily in the morning after breakfast.
3050401|NCT00679432|Experimental|1: budesonide-MMX® 6 mg|One budesonide-MMX® 6 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3050402|NCT00679432|Experimental|2: budesonide-MMX® 9 mg|One budesonide-MMX® 9 mg plus two placebo Asacol® overencapsulated tablets daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3050403|NCT00679432|Placebo Comparator|3: Placebo|Two placebo Asacol® overencapsulated tablets plus one placebo Budesonide MMX® tablet daily in the morning after breakfast and two placebo Asacol® overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3050404|NCT00679432|Active Comparator|4: Asacol® 400 mg|Two Asacol® 400 mg overencapsulated tablets plus one placebo budesonide MMX® tablet daily in the morning after breakfast and two Asacol® 400 mg overencapsulated tablets daily after the mid-day meal and the evening meal for eight weeks.
3050405|NCT00679549|Experimental|DEVICE|Provided CPAP as an inpatient
3050406|NCT00679549|No Intervention|Control|No device provided
3050407|NCT00679627|Experimental|Galantamine|Galantamine 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
3050408|NCT00679627|Placebo Comparator|Placebo|Matching placeco
3050409|NCT00679783|Experimental|1|AZD2281, PARP inhibitor
3050410|NCT00679913|Active Comparator|1|standard pancreatoduodenectomy
3050411|NCT00679913|Active Comparator|2|extended pancreatoduodenectomy
3050412|NCT00679939|Active Comparator|Arm 1 Treatment A|rosiglitazone up to 8mg/day
3050413|NCT00679939|Active Comparator|Arm 2 Treatment B|metformin up to 2000mg/day
3050414|NCT00679952|Active Comparator|1|closed suction drainage group (CD group)
3050415|NCT00679952|Active Comparator|2|natural drainage group (ND group)
3050416|NCT00680017|Experimental|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
3050417|NCT00680017|Active Comparator|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
3050418|NCT00680043|Experimental|Peginesatide 0.04 mg/kg|
3050419|NCT00680043|Experimental|Peginesatide 0.08 mg/kg|
3050420|NCT00680043|Active Comparator|Epoetin Alfa|
3050421|NCT00680056|Active Comparator|1|Formoterol plus Placebo (Tiotropium)
3050422|NCT00680056|Experimental|2|Formoterol plus Tiotropium
3050423|NCT00680121|Placebo Comparator|Control Group|Placebo
3050424|NCT00680121|Experimental|Benfotiamine|Benfotiamine 600 mg
3050425|NCT00680186|Experimental|Dabigatran etexilate (150mg bid)|Patients will receive 1 capsule containing 150 mg dabigatran etexilate/matching placebo twice daily
3050426|NCT00680186|Active Comparator|Warfarin (INR 2.0-3.0)|Patients will receive tablets PRN warfarin/matching placebo to maintain a target INR of 2.0-3.0
3050427|NCT00680225|Experimental|Lucentis Injection|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
3050428|NCT00680368||Residents and Attending Physicians|This group contains the residents and the attending physicians who consented to participate in the study. They participated in a survey administered by a research assistant. Both physician resident and attending physicians were administered the survey twice within 24-hours and their test-retest responses were compared for reliability. Responses to attending and resident physicians covering the care for the patient and clinical care encounter were compared for accuracy.
3050429|NCT00680407|Experimental|silymarin 420 mg|420 mg Legalon (silymarin) three times daily
3050430|NCT00680407|Experimental|silymarin 700 mg|700 mg of Legalon (silymarin) three times daily
3050431|NCT00680407|Placebo Comparator|Placebo|Placebo (lactose pill)
3050432|NCT00680459|Experimental|1|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
3050433|NCT00680459|Placebo Comparator|2|heparin flush 10 units/ml lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. heparin flush solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
3050434|NCT00680524|Experimental|Phone Based Outreach Intervention Group|Open pilot trial
3050435|NCT00680628|Placebo Comparator|2|Saline + Enoxaparin
3050436|NCT00680628|Experimental|1|Tenecteplase + Enoxaparin
3050437|NCT00680706|Experimental|Thiamine|Receives thiamine
3050438|NCT00680706|Placebo Comparator|Control|
3050439|NCT00680745|Experimental|1|dapagliflozin 2.5mg + Glimepiride
3050440|NCT00680745|Experimental|2|dapagliflozin 5mg + Glimepiride
3050441|NCT00680745|Experimental|3|dapagliflozin 10mg + Glimepiride
3050442|NCT00680745|Placebo Comparator|4|Placebo + Glimepiride
3050443|NCT00680771||1|Primary Insomnia
3050444|NCT00680771||2|Good Sleepers
3050445|NCT00680797|Experimental|+T +E|+Testosterone, +Estrogen
3050446|NCT00680797|Experimental|+T -E|+Testosterone, -Estrogen
3050447|NCT00680797|Experimental|-T +E|-Testosterone, +Estrogen
3050448|NCT00680797|No Intervention|-T -E|-Testosterone, -Estrogen
3050449|NCT00680823|Experimental|Ropivacaine Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
3050450|NCT00680823|Placebo Comparator|Normal Saline Injections|Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
3050451|NCT00680823|No Intervention|Observation|Observation for 30 minutes.
3050452|NCT00680836|Active Comparator|Treatment Group|These patients have IBS and are receiving the rifaximin.
3050453|NCT00680836|Placebo Comparator|Placebo group|These patients have IBS and are receiving the placebo.
3050454|NCT00680862||Group 1|VA employees
3050455|NCT00680901|Experimental|CapeOx plus Lapatinib|CapeOx plus Lapatinib
3050456|NCT00680901|Placebo Comparator|CapeOx plus Placebo|CapeOx plus Placebo
3050457|NCT00680914|Experimental|Synflorix Group|Subjects received 3 doses of Synflorix vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
3050458|NCT00680914|Active Comparator|Prevenar Group|Subjects received 3 doses of Prevenar vaccine co-administered with Hiberix vaccine at Study Months 0, 2 and 4.
3050459|NCT00680953|Experimental|1|Denosumab (subcutaneously - every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
3050460|NCT00680953|Placebo Comparator|2|Placebo (subcutaneously every 6 months) + daily calcium and vitamin D supplements for 24 months, followed by a 12-month period of denosumab (subcutaneously - every 6 months).
3050461|NCT00680953|Active Comparator|3|Alendronate sodium hydrate oral tablets weekly + daily calcium and vitamin D supplements for 24 months (open label reference arm).
3050462|NCT00680992|Experimental|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
3050463|NCT00681031|Experimental|All Enrolled|Participants received a single dose (0.65 mL) of shingles (herpes zoster) vaccine (live) ZOSTAVAX® by subcutaneous injection at Visit 1 (Day 0)
3050464|NCT00681083|Experimental|1|Heated breathing tube
3050465|NCT00681083|Active Comparator|2|Non heated breathing tube
3050466|NCT00681109|Active Comparator|Treatment Arm 1|2.5% IL-1Ra
3050467|NCT00681109|Placebo Comparator|Placebo|Artificial Tear
3050468|NCT00681109|Active Comparator|Treatment Arm 2|5% IL-1Ra
3050469|NCT00681265|Experimental|glycerin|One eye will randomly receive a single instillation of one drop of a new formulation of an artificial tear containing glycerin 1% as an active with polylysine-graft-polyethylene glycol as an excipient.
3050470|NCT00681265|Active Comparator|polyethylene glycol 400/propylene glycol|The other eye will receive a single instillation of one drop of an artificial tear with propylene glycol (0.3%) and polyethylene glycol (0.4%) as active ingredients with hydroxypropyl-guar as a gelling agent.
3050471|NCT00681291|Active Comparator|1|lightweight polypropylene mesh
3050472|NCT00681291|Active Comparator|2|Strattice
3050473|NCT00681473|Experimental|Proton Radiation Therapy|Proton radiation therapy daily (Monday through Friday) for six weeks. This is a single arm study.
3050474|NCT00681538|Experimental|Sativex|"Contains Δ9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations (THC 32.4 mg:CBD 30 mg) in 24 hours"
3050475|NCT00681538|Placebo Comparator|Placebo|Contains no active drug but colourants and excipients. Subjects received placebo delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose was 12 actuations in 24 hours.
3050476|NCT00681564|Experimental|One-Stage Full-Mouth Disinfection|Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
3050477|NCT00681564|Active Comparator|Periodontal care|Basic oral hygiene instructions Supragingival plaque removal
3050478|NCT00681590|Active Comparator|1|vitamin D (cholecalciferol) 400 IU daily orally - low dose
3050479|NCT00681590|Active Comparator|2|vitamin D (cholecalciferol) 2000 IU daily orally - high dose
3050480|NCT00681668|Experimental|Quetiapine Fumarate 150 - 800mg|Quetiapine 150-800mg
3050481|NCT00681811|Experimental|HGT-1111 100 U/kg|
3050482|NCT00681811|Experimental|HGT-1111 200 U/kg|
3050483|NCT00681824|Experimental|FS VH S/D 500 s-apr|Application of FS VH S/D 500 s-apr on top of suture
3050484|NCT00681824|Active Comparator|Standard of Care (Control group)|The treatment of the control group consisted of Standard of Care (SoC) which was defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen based dura substitute.
3050485|NCT00681863|Active Comparator|pramipexole 0.0625 mg BID (twice daily)|all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
3050486|NCT00681863|Active Comparator|pramipexole 0.0625 mg QD (once daily)|patients to receive one tablet of pramipexole 0.0625 mg QD
3050487|NCT00681863|Active Comparator|pramipexole 0.125 mg BID|patients to receive one tablet of pramipexole 0.125 mg BID
3050488|NCT00681863|Active Comparator|pramipexole 0.125 mg TID (three times daily)|patients to receive one tablet of pramipexole 0.125 mg TID
3050489|NCT00681863|Active Comparator|pramipexole 0.25 mg BID|patients to receive one tablet of pramipexole 0.25 mg BID
3050490|NCT00681889|Experimental|Treatment Arm|10 Patients will receive treatment (Ranibizumab)
3050491|NCT00682357|Experimental|1|Methylprednisone 80 mg and Lidocaine 20 mg
3050492|NCT00682357|Experimental|2|Methylprednisolone 16 mg and Lidocaine 20 mg
3050493|NCT00682357|Placebo Comparator|3|Placebo and Lidocaine 20 mg
3050494|NCT00682435|Experimental|Hydromorphone|1 mg IV hydromorphone, + optional 1 mg IV hydromorphone 15 minutes later
3050495|NCT00682448|Active Comparator|1|Olanzapine plus metformin: olanzapine plus metformin 500 mg titrated up to but no greater than 2,000 mg based upon fasting blood glucose during study visits over six months.
3050496|NCT00682448|Placebo Comparator|2|Olanzapine plus Drug: Placebo. Subjects will remain on olanzapine plus placebo for 6 months.
3050497|NCT00682461|Active Comparator|Marketed formulation|Marketed nicotine replacement therapy product
3050498|NCT00682461|Experimental|prototype|Nicotine prototype
3050499|NCT00682539|Active Comparator|Avastin|15 patients with clinical significant macular edema receive an injection of 2,5 mg Avastin every month. After three initial injections of Avastin re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
3179042|NCT00668421|Experimental|CEP-701 (Lestaurtinib)|Subject is to receives Lestaurtinib, in Phase 1: standard cohort dose escalation; Phase 2: single stage design to estimate the percentage of subjects with a 15% or greater reduction in JAK2 V617F allele frequency in peripheral blood granulocytes in 6 months of treatment
3050500|NCT00682539|Active Comparator|Triamciolone|30 patients with a clinical significant diabetic macular edema receive an intraocular injection of 8mg triamcinolone at baseline under sterile conditions. 1 and 2 month after the baseline injection, patients receive a sham injection. After three month re-injection of 8mg Triamcinolone is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns patients will receive a sham injection. In between two injection of 8mg Triamcinolone must be an temporal interval of at least 3 months.
3050501|NCT00682539|Active Comparator|Lucentis|15 patients with clinical significant macular edema receive an injection of 0,5 mg Lucentis every month. After three initial injections of Lucentis re-injection is performed if the central retinal thickness measured with optical coherence tomography (Stratus OCT, Zeiss) stays more than 300 microns. If the Central retinal thickness decreases under 300 microns a sham injection is performed.
3050502|NCT00682565|Experimental|Mid Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
3050503|NCT00682565|Experimental|High Dose CK-1827452 or Placebo|CK-1827452 I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr or placebo, followed by 6 days three times a day oral dose and a final single oral dose
3050504|NCT00682617|Experimental|Waitlist Control|Delayed intervention. 3 months on waitlist, crossover to intervention (3 additional months)
3050505|NCT00682617|Experimental|3 Month Exercise Program|3 month exercise program
3050506|NCT00682643|Placebo Comparator|vehicle placebo nasal spray|
3050507|NCT00682643|Active Comparator|fluticasone furoate nasal spray|
3050508|NCT00682734|Active Comparator|1|Metoclopramide 10 mg+ diphenhydramine 25 mg. This medication was administered as an intravenous drip over 20 minutes
3050509|NCT00682734|Experimental|2|metoclopramide 20 mg + diphenhydramine 25 mg. Administered as an intravenous drip over 20 minutes.
3050510|NCT00682734|Experimental|3|metoclopramide 40 mg + diphenhdyramine 25mg. Administered as an intravenous drip over 20 minutes.
3050511|NCT00682786|Experimental|Good Risk (Thymidylate Synthase (TYMS)*2/*2, *2/*3, *2/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
3050512|NCT00682786|Experimental|Poor Risk (Thymidylate Synthase (TYMS)*3/*3, *3/*4)|"Radiation 45 Gy in 25 fractions to the pelvis.~5FU CIVI 225 mg/m2/day by CIVI during radiation~Irinotecan 50 mg/m2 IV weekly for 5 doses.~Surgery 6-10 weeks after completion of preoperative radiation if disease has become resectable."
3050513|NCT00682838|Experimental|Self-Management (SM)|Active Intervention - Self-management: Self-management Educational component focused on sleep apnea and CPAP from a self-management perspective
3050514|NCT00682838|Active Comparator|Telemonitored Care (TC)|Active Comparator - Telemonitored care: Telemonitored care Consists of CPAP therapist actively monitoring care at a distance, and acting on that data per a set protocol
3050515|NCT00682838|Experimental|SM + TC|Self-management and Telemonitored care: Combination of both SM + TC intervention
3050516|NCT00682838|No Intervention|Usual care (UC)|Control Group
3050517|NCT00682890|Placebo Comparator|1|Placebo tablet and birth control pill daily
3050518|NCT00682890|Active Comparator|2|metformin 2000 mg and birth control pill daily
3050519|NCT00682929|Active Comparator|1) Inhaled Cannabis|Inhaled cannabis is compared to oral placebo.
3050520|NCT00682929|Active Comparator|2) Oral THC|Inhaled placebo is compared to oral THC.
3050521|NCT00682929|Placebo Comparator|3) Placebo|Inhaled placebo is compared to oral placebo.
3050522|NCT00683020|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support.
3050523|NCT00683020|No Intervention|WAIT LIST Control|WAIT LIST Control: six month Wait List.
3050524|NCT00683046|Experimental|Drug Intervention|
3050525|NCT00683085|Experimental|Peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the safety and efficacy of this type of peptide.
3050526|NCT00683163|Active Comparator|A: 6 months both + 18 months oral only|Group A will receive 6 months of monthly oral ibandronate 150 mg, plus daily PTH 1-84, 1.4 mg; followed by 18 months of ibandronate only. Placebo injections will be given months 13-15. Calcium + Vitamin D supplements, plus multivitamins are provided.
3050527|NCT00683163|Active Comparator|B: (3 months injection + 9 months oral) x 2 years|Group B will receive 3 months of daily PTH 1-84, 1.4 mg; followed by 9 months of monthly oral ibandronate, 150 mg in year 1. In year 2, the group will receive another 3 months of daily PTH 1-84; followed by 9 months of monthly ibandronate. Placebo monthly pills will be given months 1-3 and months 13-15, and placebo injections will be given months 4-6. Calcium + Vitamin D supplements, plus multivitamins are provided.
3050528|NCT00683293|Active Comparator|1|Randomized group of patients receiving conventional laparoscopic hysterectomy
3050529|NCT00683293|Active Comparator|2|Randomized group of patients receiving robot-assisted laparoscopic hysterectomy
3050530|NCT00683332||A|
3050531|NCT00683384||1|
3050532|NCT00683410||1|
3050533|NCT00683449|Experimental|IV infusion of MN-221|MN-221 total dose of 240 mcg
3050534|NCT00683449|Placebo Comparator|MN-221 PLACEBO|i.v. infusion of MN-221 Placebo for 15 min
3050535|NCT00683475|Experimental|IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone|
3050536|NCT00683475|Experimental|IMC-A12 + Mitoxantrone + Prednisone|
3050537|NCT00683592|Experimental|1|vilazodone
3050538|NCT00683592|Placebo Comparator|2|
3050539|NCT00683618|Experimental|1|Rosuvastatin 5mg qd
3050540|NCT00683618|Experimental|2|Rosuvastatin 10mg qd
3050541|NCT00683618|Active Comparator|3|Atorvastatin 10mg qd
3050542|NCT00683644|Experimental|1 - zinc placebo|Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months. Washout 1 month. Placebo oral capsule taken once a day for 4 months.
3050543|NCT00683644|Experimental|2 - placebo zinc|Placebo oral capsule taken once a day for 4 months. Washout 1 month. Zinc sulfate (50 mg elemental zinc) taken once daily for 4 months.
3050544|NCT00683657|Experimental|Saxagliptin 5 mg + Metformin|
3050545|NCT00683657|Placebo Comparator|Placebo + Metformin|
3050546|NCT00683696|Experimental|CRT=ON|Cardiac Resynchronization Therapy activated.
3050547|NCT00683696|Active Comparator|CRT=OFF|Cardiac Resynchronization Therapy deactivated.
3050548|NCT00683774|Experimental|PCOS subjects|PCOS subjects given diazoxide
3050549|NCT00683774|Active Comparator|Normal subjects|Normal subjects given diazoxide
3050550|NCT00683800|Experimental|1|desvenlafaxine succinate (DVS) SR
3050551|NCT00683800|Placebo Comparator|2|Placebo
3050552|NCT00683826|Experimental|L-Leucine 4grams|This will be a triple arm design where subjects will be randomized into three groups. Arm #1 will be 4g of Leucine.
3050553|NCT00683826|Experimental|L-Leucine 8 grams|Arm number two of the study will be a dose of Leucine of 8g.
3050554|NCT00683826|Placebo Comparator|L-Leucine 0 grams|The third arm of the study will be composed of a control drink with no leucine in it.
3050555|NCT00683852|Active Comparator|Drug 2mg/Drug 5mg|patients randomly assigned to the drug/drug sequence, the dose of aripiprazole will be 2 mg/day during the first phase of the study, and 5 mg/day in the second phase.
3050556|NCT00683852|Active Comparator|Placebo/Drug 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study.
3050557|NCT00683852|Placebo Comparator|Placebo/Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study.
3050558|NCT00683878|Experimental|Arm 1|
3050559|NCT00683878|Experimental|Arm 2|
3050560|NCT00683878|Placebo Comparator|Arm 3|
3050561|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|
3050562|NCT00683904|Active Comparator|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|
3050563|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
3050564|NCT00683930|Experimental|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
3050565|NCT00683930|Placebo Comparator|Placebo|
3050566|NCT00684021|Active Comparator|1|Participants will receive active adult stem cell infusion 3 days after percutaneous coronary intervention (PCI).
3050567|NCT00684021|Active Comparator|2|Participants will receive active adult stem cell infusion 7 days after PCI.
3050568|NCT00684021|Placebo Comparator|3|Participants will receive placebo infusion (5% human serum albumin [HSA]) 3 days after PCI.
3050569|NCT00684021|Placebo Comparator|4|Participants will receive placebo infusion (5% HSA) 7 days after PCI.
3050570|NCT00684047|Experimental|FS Grifols Preliminary Part (I)|Open label administration of FS Grifols to all subjects
3050571|NCT00684047|Experimental|FS Grifols Primary Part (II)|Single-blind, randomized (2:1)
3050572|NCT00684047|Active Comparator|Manual Compression Primary Part (II)|Single-blind, randomized (2:1)
3050573|NCT00684060|Experimental|1|Participants will receive active stem cell infusion 2 to 3 weeks after a percutaneous coronary intervention (PCI).
3050574|NCT00684060|Placebo Comparator|2|Participants will receive placebo infusion (5% human serum albumin [HSA]) 2 to 3 weeks after a PCI.
3050575|NCT00684073|Experimental|Subutex®/Suboxone®|Subutex® for first two days of study followed by Suboxone® for last 3 days of study
3050576|NCT00684138|Experimental|ReSTOR Aspheric +3.0D|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
3050577|NCT00684138|Active Comparator|ReSTOR Aspheric +4.0D|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
3050578|NCT00684177|Experimental|Retapamulin Ointment, 1%|
3050579|NCT00684177|Placebo Comparator|Placebo Ointment|
3050580|NCT00684203|Experimental|Vorapaxar 20 mg/1 mg|Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3050581|NCT00684203|Experimental|Vorapaxar 20 mg/2.5 mg|Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3050582|NCT00684203|Experimental|Vorapaxar 40 mg/1 mg|Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3050583|NCT00684203|Experimental|Vorapaxar 40 mg/2.5 mg|Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine)
3050584|NCT00684203|Placebo Comparator|Placebo|Placebo loading dose + daily placebo maintenance dose + standard of care (Aspirin + Ticlopidine)
3050585|NCT00684242|Experimental|Lenalidomide|10 mg by mouth daily
3050586|NCT00684307|Experimental|1|AZD0837 450 mg
3050587|NCT00684307|Experimental|2|AZD0837 200 mg
3050588|NCT00684307|Experimental|3|AZD0837 300 mg
3050589|NCT00684307|Experimental|4|AZD0837 150 mg
3050590|NCT00684307|Active Comparator|5|Vitamin-K antagonist at INR 2-3
3050591|NCT00684320|Active Comparator|2 Placebo Condition (PC)|The placebo, group will complete the PC procedure, which is identical to the ADT procedure except that during the presentation of the trials where a disgust or angry face is present, the probe will appear with equal frequency in the position of disgust or angry and neutral face. Thus, disgust, angry nor neutral face will have signal value regarding the position of the probe.
3050592|NCT00684320|Experimental|1 Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
3132892|NCT03463915|Active Comparator|Bladder instillation WITH triamcinolone acetonide|Six weekly bladder instillations of standard cocktail plus triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
3050593|NCT00684411|Experimental|Imatinib mesylate|The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
3050594|NCT00684424||Outpatients with epilepsy|
3050595|NCT00684515|Experimental|Vorapaxar 2.5 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
3050596|NCT00684515|Experimental|Vorapaxar 1 mg + Aspirin|Vorapaxar oral tablets; once daily for 60 days + Aspirin.
3050597|NCT00684515|Placebo Comparator|Placebo + Aspirin|Placebo oral tablets; once daily for 60 days + Aspirin
3050598|NCT00684541|Experimental|Interpretation Modification Program|The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses. Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials. This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias. Participants completed two blocks of 110 training trials in each session. Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa. Each IMP session lasted approximately 20 min.
3050599|NCT00684541|Placebo Comparator|Interpretation Control Condition|The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials. This frequency was the same for benign interpretations. Thus, the control group was reinforced equally for making threat and benign interpretations. The ICC was not intended to change interpretation significantly in either direction.
3050600|NCT00684554|Active Comparator|Unobserved-at home|Buprenorphine Unobserved at home induction
3050601|NCT00684554|Active Comparator|Observed|Buprenorphine Observed in office induction
3050602|NCT00684567|Experimental|Single arm|It is the only arm of the study. Subjects receive a combination of radiotherapy and temozolomide, and then temozolomide monotherapy.
3050603|NCT00684593|Experimental|Navarixin|Navarixin 30 mg administered orally once daily for 28 days.
3050604|NCT00684593|Placebo Comparator|Placebo|Matching placebo to Navarixin administered orally once daily for 28 days.
3050605|NCT00684645||Patients treated with SUTENT®|Patients with metastatic or advanced renal cell carcinoma after failure of cytokines therapy.
3050606|NCT00684671|Experimental|Twinrix Group|Subjects received a single challenge dose of combined hepatitis A/hepatitis B vaccine (Twinrix).
3050607|NCT00684671|Active Comparator|Engerix + Havrix Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (Engerix) and hepatitis A vaccine (Havrix).
3050608|NCT00684671|Active Comparator|HB VAX PRO + Vaqta Group|Subjects received separate administration of a single challenge dose of hepatitis B vaccine (HB VAX PRO) and hepatitis A vaccine (Vaqta).
3050609|NCT00684723|Experimental|Lovastatin 40 mg Tablet|A single dose of Lovastatin 40 mg administered under fed conditions.
3050610|NCT00684723|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered under fed conditions.
3050611|NCT00684762|Experimental|Cilostazol|A single dose of cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
3050612|NCT00684762|Experimental|Pletal® (cilostazol)|A single dose of cilostazol (Pletal® 1 x 100 mg tablet) administered after an overnight fast of at least 10 hours.
3050613|NCT00684775|No Intervention|Work Plus Naltrexone Prescription|Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
3050614|NCT00684775|Experimental|Work Plus Naltrexone Contingency|Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.
3050615|NCT00684788|No Intervention|No Intervention|Participants were offered depot naltrexone injections and were not required to take scheduled injections to work.
3050616|NCT00684788|Experimental|Employment-based reinforcement|Participants were offered depot naltrexone injections and were required to take scheduled injections to work.
3050617|NCT00684814|Experimental|Zolpidem Tartrate 10 mg Tablets|A single dose of zolpidem tartrate 10 mg administered after an overnight fast of at least 10 hours.
3050618|NCT00684814|Experimental|Zolpidem Tartrate (Ambien®) 10 mg Tablets|A single dose of Ambien® 10 mg administered after an overnight fast of at least 10 hours.
3050619|NCT00684983|Active Comparator|Arm A (lapatinib ditosylate, capecitabine)|Patients receive capecitabine PO BID on days 1-14 and lapatinib ditosylate PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3050620|NCT00684983|Experimental|Arm B (cixutumumab, lapatinib ditosylate, capecitabine)|Patients receive capecitabine and lapatinib ditosylate as in Arm A. Patients also receive cixutumumab IV over 1 hour on days 1, 8, and 15. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3050621|NCT00684996|Active Comparator|Phase II Arm I|Patients receive bevacizumab (10mg/kg) IV over 30-90 minutes on days 1 and 15.
3050622|NCT00684996|Active Comparator|Phase II Arm II|Patients receive bevacizumab IV as in arm I at the RPTD determined in phase I, and humanized monoclonal antibody MEDI-522 (8mg/kg) IV over 30 minutes on days 1, 8, 15, and 22.
3050623|NCT00685035|Active Comparator|HFCWC with higher pressure/variable frequency settings|Half patients randomly assigned to perform HFCWC therapy first with a higher pressure/variable frequency protocol. This entailed performing a 30 minute session with pressure of 10 and 5 minutes each at frequencies of 8,9, and 10 Hz followed by pressure of 6 and 5 minutes each at frequencies of 18, 19, and 20 Hz. This group subsequently crossed-over to the lower-pressure/mid-frequency HFCWC protocol after a washout period of 2 days. This entailed performing a HFCWC session using a pressure of 5 and frequency of 12 Hz for the entire 30 minute session. The other half of subjects were randomly assigned to perform the lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency after the 2 day washout period
3050624|NCT00685035|Active Comparator|HFCWC with lower pressure/mid-frequency settings|lower-pressure/mid-frequency protocol first followed by the higher pressure/mixed-frequency
3050625|NCT00685139|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered after an overnight fast.
3050626|NCT00685139|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered after an overnight fast.
3050627|NCT00685165|Experimental|Primidone 50 mg Tablets|A single dose of primidone 50 mg administered after an overnight fast of at least 10 hours.
3050628|NCT00685165|Experimental|Primidone (Mysoline®) 50 mg Tablets|A single dose of Mysoline® 50 mg administered after an overnight fast of at least 10 hours.
3050629|NCT00685178|Experimental|1 topiramate + CR|topiramate and contingency reinforcement for urine sample confirming cocaine abstinence
3050630|NCT00685178|Experimental|2 topiramate + NonCR|Topiramate and random reinforcement irrespective of cocaine use
3050631|NCT00685178|Placebo Comparator|4 Placebo + NonCR|
3050632|NCT00685178|Active Comparator|3 Placebo + CR|Placebo and contingency reinforcement for urine sample confirming cocaine abstinence
3050633|NCT00685295|Experimental|Arm 1 / Fentora|"Intervention Group:~Subject receives:~placebo oral/swallowed pill~Fentanyl (Fentora) 100mcg rapidly dissolving transbuccal tablet"
3050634|NCT00685295|Active Comparator|Arm 2 / Percocet/Prevacid|"Active Comparator Group:~Subject receives:~Oxycodone/APAP (Percocet) 5/325 mg oral/swallowed pill~Lansoprazole 15 mg (Prevacid) comparator rapidly dissolving transbuccal tablet"
3050635|NCT00685334|Experimental|1|Participants will take olanzapine
3050636|NCT00685334|Active Comparator|2|Participants will take aripiprazole
3050637|NCT00685373|Experimental|Canakinumab (ACZ885)|Subcutaneous injection every 8 weeks based on participant's body weight. Body weight >40 kilogram (kg): 150 milligrams (mg) per injection and body weight <= 40 kg: 2 mg/kg per injection. For participants who did not experience sufficient symptomatic relief, an up-titration to the dose and/or more frequent doses were permitted as per protocol.
3050638|NCT00685399|Experimental|Cohort 1|Participants were administered with AIN457 (Sp2/0derived) 10 milligrams per kilogram (mg/kg) intravenous (i.v.) dose on Day 1 and Day 22.
3050639|NCT00685399|Experimental|Cohort 2|Participants were administered with AIN457 (Sp2/0 or Chinese hamster ovary cell (CHO) derived) 10 mg/kg, (CHO derived) 3 mg/kg or (CHO derived) 1 mg/kg i.v. dose on Day 1 and if needed a second dose of AIN457 10 mg/kg i.v. dose either on Day 15 or Day 22. 3 participants from cohort 1 rolled on into this cohort.
3050640|NCT00685399|Experimental|Cohort 3|Participants were administered with AIN457 10 mg/kg i.v. dose on Day 1 and Day 22.
3050641|NCT00685399|Experimental|Cohort 4|Extension period: Participants were administered with AIN457 10 mg/kg, i.v. (with or without a short course of corticosteroids) once a flare had occurred, or periodically at a frequency of not more than once per month at the discretion of the investigator.
3050642|NCT00685399|Experimental|Cohort 5|Participants were administered with AIN457 30 mg/kg single i.v. dose. A second dose was given when all 4 participants completed at least 29 days, and the 30 mg/kg dose was well tolerated by all.
3050643|NCT00685399|Experimental|Cohort 6 Arm 1|Participants were administered with AIN457 300 mg subcutaneously (s.c.) and saline i.v. infusion every two weeks (Days 1, 15, 29, and 43).
3050644|NCT00685399|Experimental|Cohort 6 Arm 2|Participants were administered with AIN457 10 mg/kg i.v. and s.c. saline injections every two weeks (Days 1, 15, 29, and 43).
3050645|NCT00685399|Experimental|Cohort 6 Arm 3|Participants were administered with AIN457 30 mg/kg i.v. and s.c. saline injections every 4 weeks (Days 1 and 29) and saline i.v. infusions and saline s.c. injections on Days 15 and 43 to maintain masking of treatment groups.
3050646|NCT00685477|Active Comparator|Experimental Sequence ABC|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
3050647|NCT00685477|Active Comparator|Experimental Sequence ACB|CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
3050648|NCT00685477|Active Comparator|Experimental Sequence BAC|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 60 minutes, with at least 2 days between each infusion
3050649|NCT00685477|Active Comparator|Experimental Sequence BCA|CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
3050650|NCT00685477|Active Comparator|Experimental Sequence CAB|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 15 minutes, followed by CCK-8 0.02 mg/kg 30 minutes, with at least 2 days between each infusion
3050651|NCT00685477|Active Comparator|Experimental Sequence CBA|CCK-8 0.02 mg/kg over 60 minutes, followed by CCK-8 0.02 mg/kg over 30 minutes, followed by CCK-8 0.02 mg/kg 15 minutes, with at least 2 days between each infusion
3050652|NCT00685516|Active Comparator|Arm I - Green Tea|Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
3050653|NCT00685516|Placebo Comparator|Arm II - Water|Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
3050654|NCT00685516|Active Comparator|Arm III - Decaffeinated black tea|Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
3050655|NCT00685659|Active Comparator|TAU only|Control condition that consists of treatment as usual, which is Intensive Outpatient Treatment (about 3 months long)
3050656|NCT00685659|Experimental|TMAC only|Adaptive telephone-based counseling
3050657|NCT00685659|Experimental|TMAC plus|Adaptive telephone-based counseling, plus incentives
3050658|NCT00685685|Experimental|Lovastatin 40 mg tablet|A single dose of Lovastatin 40 mg administered after an overnight fast of at least 10 hours.
3050659|NCT00685685|Experimental|Lovastatin (Mevacor®) 40 mg Tablet|A single dose of Lovastatin (Mevacor®) 40 mg administered after an overnight fast of at least 10 hours.
3050660|NCT00685698|Other|Nemonoxacin|Nemonoxacin 750 mg,oral administration, single-arm, once daily 7±1 and 14±1 days.
3050661|NCT00685750|Other|ME1|Patients with cutaneous metastatic melanoma receiving dacarbazine or temozolomide as first line treatment
3050662|NCT00685750|Other|ME2|Patients with cutaneous metastatic melanoma receiving first line treatment other than dacarbazine or temozolomide only
3050663|NCT00685750|Other|ME3|Patients with cutaneous metastatic melanoma receiving any second-or higherline chemotherapy treatment
3050664|NCT00685750|Other|ME4|Patients with cutaneous metastatic melanoma receiving local irradiation of cutaneous/subcutaneous tumor lesions
3050665|NCT00685750|Other|ME5|Patients with cutaneous metastatic melanoma receiving local imiquimod
3050666|NCT00685750|Other|NSC|Non-small cell lung cancer patients
3050667|NCT00685750|Other|ME6|Patients with cutaneous metastatic melanoma receiving ipilimumab
3050668|NCT00685763|Experimental|Proton radiation and chemotherapy|"Chemotherapy and Radiation Combination~Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks.~Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only.~Consolidation Chemotherapy starting 4 weeks after the completion of radiation~Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses."
3050669|NCT00685802|Experimental|Cilostazol 50 mg Tablets|A single dose of cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours.
3050670|NCT00685802|Experimental|Cilostazol (Pletal® ) 50 mg Tablets|A single dose of Cilostazol (Pletal® tablets, 2 x 50 mg ) administered after an overnight fast of at least 10 hours.
3050671|NCT00685919|Experimental|Carbidopa then Placebo|Carbidopa 200 mg every 6 hours orally for 5 doses followed by Placebo every 6 hours for 5 doses
3050672|NCT00685919|Experimental|Placebo then Carbidopa|Placebo matching carbidopa given every 6 hours orally for 5 doses followed by Carbidopa
3050673|NCT00685932|No Intervention|Control|This arm will be randomly assigned to have conventional retractions (ie Rich retractors and similar) used in the usual fashion during the cesarean procedure.
3050674|NCT00685932|Experimental|Mobius|This arm will be randomized to have the providers who are performing the cesarean section use the Mobius retractor during the cesarean section procedure after the peritoneal cavity is opened.
3050675|NCT00685945|Experimental|Control (bradykinin infusion)|Bradykinin (Clinalfa AG, Läufelfingen, Switzerland)
3050676|NCT00685945|Experimental|L-NMMA + bradykinin|N-monomethyl-L-arginine (L-NMMA, NO synthase inhibitor; Bachem, Torrance, CA)
3050677|NCT00685945|Experimental|Isosorbide + L-NMMA + bradykinin|Isosorbide (NO donor)
3050678|NCT00685945|Experimental|Sildenafil + L-NMMA + bradykinin|Sildenafil (phosphodiesterase type 5 (PDE5) inhibitor
3050679|NCT00686075|Experimental|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
3050680|NCT00686075|Placebo Comparator|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3050681|NCT00686075|Experimental|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3050682|NCT00686075|Placebo Comparator|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3050683|NCT00686075|Experimental|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
3050684|NCT00686075|Placebo Comparator|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
3050685|NCT00686075|Experimental|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3050686|NCT00686075|Placebo Comparator|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
3050687|NCT00686075|Experimental|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3050688|NCT00686075|Placebo Comparator|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
3050689|NCT00686127|Active Comparator|Lidocaine Patch|Drug: lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1 patch was applied topically to the affected site(s) for 12 hours each day.
3050690|NCT00686127|Placebo Comparator|Placebo Patch|Drug: placebo patch, 1 patch was applied topically to the affected site(s) for 12 hours each day.
3050691|NCT00686166|Experimental|Chemo + Chemo and radiation + Surgery|"Chemotherapy Cycle 1 (1 cycle is 35 days):~Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Cetuximab, 400 mg/m^2, IV, Day 1~Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2:~Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78~Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78~Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)~Radiation therapy: Planning target value 1: 4500 cGy (centigray) in 25 fractions; Planning target value 2 (stage T3 patients): Boost of 540 cGy in 3 fractions; Planning target value 2 (stage T4 patients): Boost of 900 cGy in 5 fractions.~Therapeutic Surgical procedure: Resection"
3050692|NCT00686205|Experimental|ABBOTT PRISM HIV O Plus assay for Specificity|All subjects will have their blood tested by the investigational HIV test.
3050693|NCT00686205|No Intervention|ABBOTT PRISM HIV O Plus Assay for Sensitivity|Samples collected from specimen vendors or from specimen collection studies were tested by the investigational HIV assay.
3050694|NCT00686231|Experimental|Dose Test 15mg NTG|Nitroglycerin 15mg (NTG) applied topically to one wrist and placebo to the other wrist at Visit 1
3050695|NCT00686231|Experimental|Dose Test 30mg NTG|Nitroglycerin 30mg applied topically to one wrist and placebo to the other wrist at Visit 1
3050696|NCT00686231|Experimental|Combination Test 20mg Lidocaine|Lidocaine 20mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 20mg + placebo applied to the other wrist, at Visit 2
3050697|NCT00686231|Experimental|Combination Test 40mg Lidocaine|Lidocaine 40mg + Nitroglycerin 30mg applied topically to one wrist, Lidocaine 40mg + placebo applied to the other wrist, at Visit 2
3050698|NCT00686257|Experimental|1|Patients receiving NPPV by the 'Total Face Mask'
3050699|NCT00686257|Active Comparator|2|Patients receiving NPPV by 'standard oronasal mask'
3179043|NCT00668447|Experimental|1|Soy protein and isoflavone tablets
3179044|NCT00668447|Active Comparator|2|Soy protein and placebo tablets
3179045|NCT00668447|Active Comparator|3|control protein and Isoflavone tablets
3050700|NCT00686335|Experimental|Lodotra|After the 4 week run-in period with immediate release prednisone (Cortancyl), patients were switched to the identical dose of modified release prednisone tablets (Lodotra). Study medication for the Lodotra treatment period consisted of Lodotra in 2 dose strengths (5 mg and 1 mg prednisone per tablet). Patients were to take their tablets with or after the evening meal (at 10 pm +/- 30 minutes) for 4 weeks.
3050701|NCT00686335|Active Comparator|Cortancyl|During the 4 week run-in period, patients remained on their respective pre-study dose of prednisone or equivalent. However, patients were standardized to 5 mg and 1 mg tablets of immediate release prednisone (Cortancyl). Patients were to take their tablets with or after the morning meal (at 8am +/- 30 minutes) for 4 weeks.
3320835|NCT02014142|Experimental|Group B. L-PPDS double occlusion|Latanoprost Punctal Plug Delivery System (L-PPDS) continuous double occlusion; L-PPDS will be inserted in the lower punctum and non-therapeutic (NT) plug will be inserted in the upper punctum of each eye and both will remain for a period of 14 weeks.
3050703|NCT00686517|Experimental|PEG-IFN 24|pegylated interferon alpha-2b 1.5 ug/kg/week for 24 weeks
3050704|NCT00686517|Experimental|PEG-IFN 12|pegylated interferon alpha-2b 1.5 ug/kg/week for 12 weeks
3050705|NCT00686517|Experimental|PEG-IFN + RVB 12|pegylated interferon alpha-2b 1.5 ug/kg/week in combination with ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
3050706|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 200 mg TID Days 9-15|POS 200 mg three times a day (TID) on Days 1-8 followed by continued randomized dosing regimen of POS 200 mg TID on Days 9-15, administered with food or oral nutritional supplements.
3050707|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg BID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg twice a day (BID) on Days 9-15, administered with food or oral nutritional supplements.
3050708|NCT00686543|Experimental|POS 200 mg TID Days 1-8 Followed by POS 400 mg TID Days 9-15|POS 200 mg TID on Days 1-8 followed by randomized dosing regimen of POS 400 mg TID on Days 9-15, administered with food or oral nutritional supplements.
3050709|NCT00686582|Experimental|Initially Vaccinia Naive, 2 dose primed, 1 booster dose|"Group 1 Initially Vaccinia Naive Subjects 2 doses of MVA-BN in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
3050710|NCT00686582|Experimental|Initially Vaccinia Naive, 1 dose primed, 1 booster dose|"Group 2 Initially Vaccinia Naive Subjects 1 dose of MVA-BN and 1x Placebo in prior study (POX-MVA-005)~1 booster dose of MVA-BN (POX-MVA-023) IMVAMUNE: 1x 10E8_TCID50"
3050711|NCT00686582|Other|Vaccinia Experienced, boosted, blood draw only|"Group 4 Vaccinia Experienced~1 booster dose of MVA-BN in prior study (POX-MVA-005) Blood draw, Screening Visit only (POX-MVA-023)"
3050712|NCT00686595|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg intravenous (IV) infusion administered at Baseline (Week 0), Visit 3 (Week 2), Visit 4 (Week 6), Visit 6 (Week 14), and Visit 8 (Week 22).
3050713|NCT00686634|Experimental|1|Sitagliptin 100 mg once daily
3050714|NCT00686686|Experimental|Infliximab 5 mg/kg|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
3050715|NCT00686699|Experimental|Preladenant 25 mg BID→Placebo BID|Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
3050716|NCT00686699|Placebo Comparator|Placebo BID→Preladenant 25 mg BID|Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.
3050717|NCT00686712|Experimental|1 - Insulin glargine QHS|Insulin glargine injected subcutaneously once daily at bedtime
3050718|NCT00686712|Experimental|2 - Insulin glargine QAM|Insulin glargine injected subcutaneously once daily in the morning
3050719|NCT00686712|Active Comparator|3 - NPH Insulin QHS|NPH insulin injected subcutaneously once daily at bedtime
3050720|NCT00686725|Active Comparator|Temozolomide + Radiation|"Standard therapy regimen:~Treatment will start 4 weeks after surgery. Temozolomide will be administered concomitantly with radiotherapy, at 75 mg/m^2/day orally for 42 days. Four weeks after completing concomitant radiotherapy, temozolomide will be administered for an additional six cycles. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m^2/day, and may be increased to 200 mg/m^2/day for Cycle 2 and subsequent cycles depending on nonhematological toxicity observed and neutrophil and platelet count values. Capsules containing 20 mg or 100 mg of temozolomide will be used.~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
3050721|NCT00686725|Experimental|Temozolomide alone, then Temozolomide + Radiation|"Early postsurgery temozolomide chemotherapy plus standard regimen:~Treatment with temozolomide alone will start 2 weeks after surgery at 75 mg/m^2/day orally for 14 days. Then, starting on Day 29 after surgery, temozolomide will be administered according to standard treatment as described for the temozolomide + radiation arm (standard therapy regimen).~Radiotherapy will be administered in combination with temozolomide. Radiotherapy will be administered for a total daily dose of 60 Gy in 30 fractions, 5 days a week for 6 weeks."
3050722|NCT00686777|Experimental|PEG-IFN + Ribavirin|Pegylated Interferon alfa-2b was administered to participants at 1.5 μg/kg subcutaneously once weekly for 48 weeks. Ribavirin was administered orally every day after morning and evening meals for 48 weeks at 400 mg/day.
3050723|NCT00686790|Experimental|PegIntron|All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.
3050724|NCT00686803|Experimental|PL3994 Dose A|PL3994 Dose A
3050725|NCT00686803|Experimental|PL3994 Dose B|PL3994 Dose B
3050726|NCT00686803|Experimental|PL3994 Dose C|PL3994 Dose C
3050727|NCT00686803|Experimental|PL3994 Dose D|PL3994 Dose D
3050728|NCT00686803|Experimental|PL3994 Dose E|PL3994 Dose E
3050729|NCT00686803|Placebo Comparator|Placebo|Placebo
3050730|NCT00686829|Experimental|VCV 30 mg|Participants take VCV 30 mg once daily.
3050731|NCT00686842|Experimental|VEGF Inhibitor PTC299|Single arm study - all subjects received PTC299
3050732|NCT00686855|Experimental|Tacrolimus|Tacrolimus Arm Closed to Accrual as of January 2012
3050733|NCT00686855|Experimental|Dexamethasone|
3050734|NCT00686881|Experimental|PegIFN-2b|Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
3050735|NCT00686881|Active Comparator|SNMC|Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.
3050736|NCT00686894|Experimental|Infliximab 5 mg/kg|Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6.
3050737|NCT00686920|Experimental|Rifaximin|Participants from a previous rifaximin HE study and new participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for at least 24 months, until regulatory approval of rifaximin for reduction in risk of overt HE recurrence, or until the sponsor closed the study.
3050738|NCT00686959|Experimental|Arm A: Pemetrexed + Cisplatin and TRT|"Participants were treated with Pemetrexed plus Cisplatin and concurrent thoracic radiation therapy (TRT) (Concurrent Phase) for three 21-day cycles, followed by a 3-5 week Recovery Period, then treated with consolidation chemotherapy with pemetrexed (Consolidation Phase) for up to four 21-day cycles~Concurrent Phase:~Pemetrexed: 500 milligrams per meter squared (mg/m^2), intravenous (IV) on Day 1 of each 21-day cycle for 3 cycles.~Cisplatin: 75 mg/m^2, IV on Day 1 of each 21-day cycle x 3 cycles. TRT: Beginning on Day 1 of chemotherapy, once daily fractions (2 Gray [Gy] per day), 5 days a week for 6 weeks and 3 days to target 66 Gy in 33 fractions.~Consolidation Phase:~Pemetrexed: 500 mg/m^2, IV on Day 1 of each 21-day cycle up to 4 cycles"
3050739|NCT00686959|Active Comparator|Arm B: Etoposide + Cisplatin and TRT|"Participants were treated with Etoposide plus Cisplatin and concurrent TRT (Concurrent Phase) for two 28-day cycles, followed by a 3-5 week Recovery Period, then received consolidation treatment with cytotoxic chemotherapy of choice (Consolidation Phase) for up to 2 cycles~Concurrent Phase:~Etoposide/Cisplatin (28-day cycle); Etoposide: 50 mg/m^2, IV on Days 1 to 5 and Days 29 to 33 and Cisplatin: 50 mg/m^2, IV on Days1, 8, 29, and 36~Consolidation Phase options:~Option 1: Continue the same treatment plan as Concurrent Phase Option 2: Vinorelbine/Cisplatin (21-day cycle); Vinorelbine: 30 mg/m^2, IV on Days 1, 8, 22, and 29; Cisplatin: 75 mg/m^2, IV on Days 1 and 22 Option 3: Paclitaxel/Carboplatin (21-day cycle); Paclitaxel: 200 mg/m^2, IV, on Days 1 and 22; Carboplatin: area under the concentration-time curve (AUC) = 6 (Carboplatin dosing based on calculated creatinine clearance), IV on Days 1 and 22"
3050740|NCT00686998|Experimental|AZD2624|AZD2624 40 mg
3050741|NCT00686998|Other|Olanzapine|Olanzapine 15 mg
3050742|NCT00686998|Placebo Comparator|Placebo|Matching Placebo
3050743|NCT00687076|Experimental|1|Participants will receive standard of medical care and treatment with intensive lipid modification using a statin plus Ezetimibe and Niaspan.
3050744|NCT00687076|Active Comparator|2|Participants will receive standard of medical care and treatment with standard lipid modifying medications plus placebo Ezetimibe and placebo Niaspan.
3050745|NCT00687102|Experimental|Star participants assigned to Tamoxifen|Participants in the parent study, STAR assigned to Tamoxifen who were 65 or older at time of enrollment.
3050746|NCT00687102|Experimental|Star participants assigned to Raloxifene|Participants in the parent study, STAR assigned to Raloxifene who were 65 or older at time of enrollment.
3050747|NCT00687167|Experimental|Zonisamide 100 mg Capsule|A single dose of zonisamide 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
3050748|NCT00687167|Experimental|Zonisamide (Zonegran® ) 100 mg Capsule|A single dose of Zonegran® 100 mg administered 30 minutes after initiation of a standardized, high fat breakfast.
3050749|NCT00687193|Placebo Comparator|Placebo|
3050750|NCT00687193|Experimental|CP-690,550, 10mg|
3050751|NCT00687193|Experimental|CP-690,550, 15mg|
3050752|NCT00687193|Experimental|CP-690,550, 1mg|
3050753|NCT00687193|Experimental|CP-690,550, 3mg|
3050754|NCT00687193|Experimental|CP-690,550, 5mg|
3050755|NCT00687219|Experimental|Peginterferon alfa-2b + Ribavirin|
3050756|NCT00687271|Experimental|MK-6213 160 mg + Atorvastatin 20 mg|1 MK-6213 160-mg tablet co-administered orally with 1 Atorvastatin 20-mg tablet once daily for 4 weeks
3050757|NCT00687271|Active Comparator|Atorvastatin 20 mg|1 Atorvastatin 20-mg tablet co-administered orally with 1 tablet of placebo for MK-6312 once daily for 4 weeks
3050758|NCT00687271|Experimental|MK-6213 160 mg|1 MK-6213 160-mg tablet co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg once daily for 4 weeks
3050759|NCT00687271|Placebo Comparator|Placebo|1 tablet of placebo for MK-6213 160 mg co-administered orally with 1 tablet of placebo for Atorvastatin 20-mg tablet once daily for 4 weeks
3050760|NCT00687297|Active Comparator|Vandetanib Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, vandetanib maintenance daily until progression.
3050761|NCT00687297|Placebo Comparator|Placebo Maintenance|Docetaxel day 1, carboplatin day 1 + vandetanib induction days 1 through 21 (daily) of a 28-day cycle for 4 cycles. If free of disease progression after 4 cycles, placebo maintenance daily until progression.
3050762|NCT00687323|Experimental|Temozolomide|Temozolomide capsules orally, once daily: 1 induction cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), 1 consolidation cycle (200 mg/m^2/day for 7 days in 1 28 day cycle), then 200 mg/m^2/day for 7 days each 28-day cycle or for 5 days each 28-day cycle (12 cycle maximum). Alternatively participants could have received 100 mg/m^2/day for 21 days of each 28-day cycle (12 cycle maximum).
3050763|NCT00687362|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
3050764|NCT00687401|Experimental|Infliximab 5 mg/kg|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6, and 14.
3050765|NCT00687440|Experimental|Caelyx, Docetaxel, Trastuzumab|"Stage 1: subjects will receive Caelyx one day every 3 weeks in combination with docetaxel one day every 3 weeks and trastuzumab once weekly during 6 cycles. At the end of this stage, based on the number of cardiac events, subjects will proceed to a second stage or restart with a lower dose of Caelyx.~Stage 2: subjects will be treated with the recommended dose of Caelyx (defined in the first stage) in combination with docetaxel and trastuzumab."
3050766|NCT00687453|Experimental|1|Insulin glargine at bedtime
3050767|NCT00687453|Active Comparator|2|NPH twice-daily
3050768|NCT00687531|Experimental|Mometasone Furoate|Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
3050769|NCT00687544|Experimental|PEG-IFN + RBV|PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
3050770|NCT00687609|Experimental|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
3050771|NCT00687674|Experimental|Sorafenib + Lenalidomide + Dexamethasone|
3050772|NCT00687713|Active Comparator|Bupropion|Subjects will receive bupropion 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
3050773|NCT00687713|Placebo Comparator|Placebo|Subjects will receive a matched bupropion placebo 150 mg tablet for 3 days then twice daily, for 12 weeks until dose taper during the last 3 days of week 12 at 150 mg per day.
3050774|NCT00687739|Placebo Comparator|1|GnRH agonist + placebo
3050775|NCT00687739|Active Comparator|2|GnRH agonist + placebo + exercise
3050776|NCT00687739|Experimental|3|GnRH agonist + Estradiol
3050777|NCT00687739|Experimental|4|GnRH agonist + Estradiol + exercise
3050778|NCT00687804|Experimental|Ranibizumab 0.5 mg|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3050779|NCT00687804|Experimental|Ranibizumab 0.5 mg + laser|"Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3050780|NCT00687804|Active Comparator|Laser|"Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met:~Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA > 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits.~Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes.~In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy."
3050781|NCT00687830|Active Comparator|Polythylene Glycol (PEG) in the evening|"Bowel preparation with Polyethylene Glycol given in the evening prior to the day of the afternoon colonoscopy.~'Polyethylene Glycol afternoon'"
3050782|NCT00687830|Experimental|Polythylene Glycol (PEG) in the Morning|"Bowel preparation with Polyethylene Glycol given on the morning of the day of the afternoon colonoscopy.~'Polyethylene Glycol morning'"
3050783|NCT00687856||LVAD Recipients|Participants who have had or are about to have a left ventricular assist device (LVAD) implanted
3050784|NCT00687908|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel once daily
3050785|NCT00687908|Placebo Comparator|2|Vehicle Gel once daily
3050786|NCT00687973|Experimental|Valsartan/amlodipine 160/10 mg|Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
3050787|NCT00687973|Active Comparator|Atenolol/amlodipine 100/10 mg|Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
3050788|NCT00688064|Experimental|1|Adapalene-BPO + Doxycyline
3050789|NCT00688064|Active Comparator|2|Vehicle + Doxycycline
3050790|NCT00688103|Active Comparator|ETN Alone|etanercept (25mg, twice/week, s.c.)
3050791|NCT00688103|Active Comparator|ETN+MTX|etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)
3050792|NCT00688155|Experimental|Physical Activity Training|The Physical Activity Training ((PAT) intervention consisted of center-based and home-based sessions comprised of aerobic, strength, flexibility, and balance training with a targeted duration of 150 mins/wk.
3050793|NCT00688155|Experimental|Cognitive Training|The Cognitive Training (CT) intervention was developed to improve consciously-controlled memory processing or recollection of episodic memory information.
3050794|NCT00688155|Experimental|Combined Intervention|"The Combined Intervention (PACT) was designed so that participants received both cognitive and physical activity training on the same day.~."
3050795|NCT00688155|Active Comparator|Healthy Aging Education|The Healthy Aging Education control intervention consisted of weekly lectures based on health education.
3050796|NCT00688181||Subjects treated with the Prefyx PPS System|All patients presenting to the institution for treatment of female Stress Urinary Incontinence (SUI), excluding those patients meeting any of the contraindications as noted in the Directions For Use.
3050797|NCT00688259|Experimental|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 6 months of weekly individual manualized cognitive-behavioral psychotherapy for psychosis in which participants set personal goals, identify problematic/ illness-related beliefs and experiences that may interfere with achieving those goals, evaluate the data supporting those beliefs, and then modify the beliefs or behavior as warranted by the data to make progress on those goals.
3050798|NCT00688259|Active Comparator|Supportive Therapy (ST)|approximately 6 months of weekly manualized supportive psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to the participants' lives and concerns
3050799|NCT00688324|Experimental|Single Arm|All subjects will have baseline measures, receive acamprosate for 2 weeks, then have measures repeated.
3050800|NCT00688376|Experimental|1|
3050801|NCT00688376|Placebo Comparator|2|
3050802|NCT00688467|Experimental|Navarixin → Placebo|Navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 2
3050803|NCT00688467|Experimental|Placebo → Navarixin|Matching placebo capsule to be taken once daily in the morning for 10 days in Treatment Period 1, followed by a 2-4 week washout period, followed by navarixin 30 mg capsule to be taken once daily in the morning for 10 days in Treatment Period 2
3050804|NCT00688519|Experimental|U0267 Foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3050805|NCT00688519|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3050806|NCT00688545||Celecoxib|Patients treated with celecoxib as per treating physician's judgement
3050807|NCT00688545||nsNSAIDs (nonselective nonsteroidal anti-inflammatory drugs)|Patients treated with nsNSAIDs as per treating physician's judgement
3050808|NCT00688597|Experimental|Cohort 1|Regimen 1: Low-dose duvoglustat (2.5 grams [g]) once a day (QD) for 3 days, followed by no drug for 4 days, for 11 weeks.
3050809|NCT00688597|Experimental|Cohort 2|Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks.
3050810|NCT00688597|Experimental|Cohort 3|Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks.
3050811|NCT00688623|Experimental|Everolimus|Everolimus
3050812|NCT00688636|Active Comparator|1|
3050813|NCT00688636|Placebo Comparator|2|
3050814|NCT00688662|Active Comparator|1.ERCP with sphincterotomy|ERCP with sphincterotomy: cutting the biliary sphincter muscle (sphincterotomy)
3050815|NCT00688662|Placebo Comparator|2.ERCP without sphincterotomy|ERCP without cutting the biliary sphincter muscle (sphincterotomy)
3050816|NCT00688688|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine extended release (ER) placebo capsules orally once a day for 12 months.
3050817|NCT00688688|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine ER placebo capsules orally once a day for 12 months.
3050818|NCT00688688|Active Comparator|Tolterodine ER 4 mg|Participants received tolterodine ER 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 months.
3050819|NCT00688701|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
3050820|NCT00688701|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
3050821|NCT00688701|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 12.
3050822|NCT00688701|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to Week 12.
3050823|NCT00688740|Experimental|TAC (Docetaxel)|docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
3050824|NCT00688740|Active Comparator|FAC (5-fluorouracil)|5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment
3050825|NCT00688753|Experimental|RAD001|two 5 mg tablets of everolimus orally, once daily
3050826|NCT00688844||PKU subjects - baseline|Male and female subjects with PKU at baseline starting KuvanTM therapy.
3050827|NCT00688870|Experimental|1|13vPnC
3050828|NCT00688870|Active Comparator|2|7vPnC
3050829|NCT00688909|Experimental|Letrozole|Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.
3050830|NCT00689026|Experimental|Experimental|The lubiprostone group will receive an additional two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
3050831|NCT00689026|Active Comparator|Control|All patients in the study will receive a standard oral dosing of 4L Polyethylene glycol with electrolytes colonoscopy preparation the day prior to their scheduled colonoscopy.
3050832|NCT00689078|Active Comparator|Pred acetate 1%|Prednisolone acetate 1.0% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
3050833|NCT00689078|Active Comparator|Pred acetate .12%|Prednisolone acetate 0.12% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
3050834|NCT00689078|Active Comparator|Lot Etab 0.2%|Loteprednol Etabonate 0.2% in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
3050835|NCT00689078|Placebo Comparator|Placebo|Tears Naturale (Artificial Tears) in each eye BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
3050836|NCT00689091|Experimental|BIS group|This group will have BIS values visible and will receive alerts when the value is >60.
3050837|NCT00689091|Active Comparator|MAC Alert|This group will receive an alert if total MAC (including intravenous infusions) is <0.5 age-adjusted.
3050838|NCT00689104|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets and matching tolterodine slow release (SR) placebo capsules orally once a day for 12 weeks.
3050839|NCT00689104|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
3179046|NCT00668447|Placebo Comparator|4|control protein and placebo tablets
3050840|NCT00689104|Experimental|Mirabegron 100 mg|Participants received mirabegron 100 mg tablets and matching tolterodine SR placebo capsules orally once a day for 12 weeks.
3050841|NCT00689104|Active Comparator|Tolterodine SR 4 mg|Participants received tolterodine SR 4 mg capsules and matching mirabegron placebo tablets orally once a day for 12 weeks.
3050842|NCT00689117|Experimental|1|CT Gel
3050843|NCT00689117|Active Comparator|2|Clindamycin Gel (clindamycin)
3050844|NCT00689117|Active Comparator|3|Tretinoin Gel (tretinoin)
3050845|NCT00689117|Placebo Comparator|4|Vehicle Gel
3050846|NCT00689221|Experimental|Cilengitide + Temozolomide + Radiotherapy|
3050847|NCT00689221|Active Comparator|Temozolomide + Radiotherapy|
3050848|NCT00689260|Active Comparator|1 - Log Aware|Dose Log Aware (patient is aware that the device records their injection information) Half the subjects in the log aware arm will complete a diary. The other half in the log aware arm will not complete the diary.
3050849|NCT00689260|Active Comparator|2 - Log Unaware|Dose Log Unaware (patient is not aware that the device records their injection information) Half the subjects in the log unaware arm will complete a diary. The other half in the log unaware arm will not complete the diary.
3050850|NCT00689273|Experimental|PF-04136309|
3050851|NCT00689273|Placebo Comparator|Placebo|
3050852|NCT00689299|Placebo Comparator|Dose Group C|Standardized Allergenic Extract, Cat Hair (Felis domesticus) placebo
3050853|NCT00689299|Active Comparator|Dose Group A|Standardized Allergenic Extract, Cat Hair (Felis domesticus) 0.21 Units
3050854|NCT00689299|Active Comparator|Dose Group B|Standardized Allergenic Extract, Cat Hair (Felis domesticus)2.1 units
3050855|NCT00689338|Experimental|Treatment Group|Option to treat with oral azole therapy following treatment with anidulafungin
3050856|NCT00689351|Experimental|1|13vPnC
3050857|NCT00689351|Active Comparator|2|7vPnC
3050858|NCT00689390|Other|Participants from Boceprevir Studies|Participants who previously participated in treatment studies in which boceprevir was administered were subsequently enrolled in Part 1 of the current follow-up study P05063 (NCT00689390). Participants may have received boceprevir or control peginterferon plus ribavirin (PR) in the previous treatment study. No treatment was administered in the current follow-up study.
3050859|NCT00689390|Other|Participants from Narlaprevir Studies|Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
3050860|NCT00689481|Experimental|U0267 foam|U0267 is a vitamin D3 analog (calcipotriene) foam. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3050861|NCT00689481|Placebo Comparator|Vehicle foam|Vehicle foam is the same as the U0267 foam except that it does not have the active ingredient. It is applied twice a day for 8 weeks to psoriasis lesions on the body.
3050862|NCT00689572|Experimental|Ondansetron|Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
3050863|NCT00689572|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
3050864|NCT00689611|Placebo Comparator|P|Half of patients will receive placebo for 9 weeks.
3050865|NCT00689611|Active Comparator|A|Half of patients will receive bupropion for 9 weeks.
3050866|NCT00689728|Experimental|30 milligram (mg) LY2127399|"Double-blind Treatment: 30 mg LY2127399 administered as a single intravenous (IV) infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
3050867|NCT00689728|Experimental|80 mg LY2127399|"Double-blind Treatment: 80 mg LY2127399 administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints, could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on initial randomized treatment up to Week 24.~Follow-up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
3050868|NCT00689728|Placebo Comparator|Placebo|"Double-blind Treatment: Placebo comparator administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.~Rescue: At Week 16 primary endpoint, participants without at least 20% improvement in either tender or swollen joint counts based on 28 joints could receive an additional (unblinded) 30 minute infusion of LY2127399 80 mg or remain on same initial randomized treatment up to Week 24.~Follow-Up: Optional visits beyond Week 24, if needed, to assess safety including B cell count recovery."
3050869|NCT00689793|Active Comparator|1|
3050870|NCT00689793|Placebo Comparator|2|
3050871|NCT00689819|Active Comparator|BP < 140/90 mmHg|This arm will target a blood pressure of < 140/90 mmHg (or < 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
3050872|NCT00689819|Experimental|BP < 120/80 mmHg|This arm will target a more aggressive blood pressure target of < 120/80 mmHg.
3050873|NCT00689871|Experimental|1|Primary augmentation
3050874|NCT00689871|Experimental|2|Primary reconstruction
3050875|NCT00689871|Experimental|3|Revision-augmentation
3050876|NCT00689871|Experimental|4|Revision-reconstruction
3050877|NCT00689936|Experimental|Lenalidomide / Dexamethasone until disease progression|Lenalidomide plus low-dose dexamethasone given until disease progression
3050878|NCT00689936|Experimental|Lenalidomide / Dexamethasone for 18 cycles|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
3050879|NCT00689936|Active Comparator|Melphalan, Prednisone, and Thalidomide (MPT) for 12 cycles|Combination of Melphalan, Prednisone and Thalidomide given for 12 six-week cycles
3050880|NCT00690040|Active Comparator|1|Ripening of the unfavorable cervix is done with Single balloon catheter (Foley catheter)
3050881|NCT00690040|Active Comparator|2|Ripening of the unfavorable cervix is done with double balloon catheter (Atad catheter)
3050882|NCT00690235|Other|Placebo|Patients will be given the Placebo for injection twice daily
3050883|NCT00690235|Other|Pramlintide|volunteers are given 180mg of pramlintide, twice daily
3050884|NCT00690274|Placebo Comparator|Placebo|Volunteers are given Placebo, up to 20mg per day
3050885|NCT00690274|Active Comparator|BF2.649|Volunteers are given BF2.649, up to 20mg per day
3050886|NCT00690339|Experimental|1|Augmentation
3050887|NCT00690339|Experimental|2|Reconstruction
3050888|NCT00690339|Experimental|3|Revision-augmentation
3050889|NCT00690339|Experimental|4|Revision-reconstruction
3050890|NCT00690378|Experimental|1|NXL/104 ceftazidime
3050891|NCT00690378|Active Comparator|2|comparator 4 x daily
3050892|NCT00690430|Active Comparator|Pasireotide LAR|Patients assigned to pasireotide LAR will receive a 60 mg dose of pasireotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 40 mg is permitted if tolerability issues arise. In addition, after 24 hours of the first LAR injections the patients were permitted to use pasireotide s.c. formulation for breakthrough symptoms as needed.
3050893|NCT00690430|Active Comparator|Octreotide LAR|Patients assigned to octreotide LAR will receive a 40mg dose of octreotide LAR i.m. depot injection once every 28 days (+/- 3 days) for 6 months at visits 2, 4, 5, 6, 7 and 8. A dose reduction to 30 mg is permitted if tolerability issues arise. Patients requiring a dose reduction are to return to the higher dose once the tolerability issue is resolved, if required for efficacy In addition, after 24 hours of the first LAR injections the patients were permitted to use octreotide s.c. formulation for breakthrough symptoms as needed.
3050894|NCT00690443|Active Comparator|2|2.5 mg AEGR 733 plus atorvastatin 20 mg weeks 1-4 followed by 5 mg AEGR 733 plus atorvastatin 20 mg weeks 5-8
3050895|NCT00690443|Active Comparator|1|Following 35-day washout + diet run-in, subjects receive atorvastatin 20 mg for 8 wks.
3050896|NCT00690482|Experimental|AZD1981|AZD1981 Oral tablet, twice daily
3050897|NCT00690482|Placebo Comparator|Placebo|Placebo Oral tablet, twice daily
3050898|NCT00690495|Experimental|1|Modified propofol (Propofol 0.5%)
3050899|NCT00690495|Active Comparator|2|Propofol 1%
3050900|NCT00690573|Experimental|Adalimumab|
3050901|NCT00690612|Experimental|1|investigator determines efficacious dose based on child's BP response.
3050902|NCT00690755||Group 1|type 2 diabetic individuals
3050903|NCT00690755||Group 2|type 1 diabetic individuals or those with diabetes secondary to pancreatic disease
3050904|NCT00690755||Group 3|non-diabetic individuals who are not considered to be overweight
3050905|NCT00690755||Group 4|non-diabetic individuals who are considered to be overweight
3050906|NCT00690755||Group 5|non-diabetic and type 2 diabetic individuals who will be subjected to an exercise study
3050907|NCT00690755||Group 6|individuals who have or are suspected of having glucose intolerance, including patients who have a history of gestational diabetes and patients who have polycystic ovary syndrome
3050908|NCT00690755||Group 7|healthy non-diabetic subjects who will receive one dose of metformin orally 1-2 hours before performing procedures
3050909|NCT00690794|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
3050910|NCT00690794|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
3050911|NCT00690820|Experimental|A|
3050912|NCT00690820|Placebo Comparator|B|
3050913|NCT00690833|Experimental|topical desonide hydrogel 0.05%|Approximately 40 male and female subjects (about 20 age 3 months to <13 years and 20 age 13 and up) with mild to moderate atopic dermatitis will apply desonate gel twice daily to ATD
3050914|NCT00690898|Experimental|Lanreotide autogel 120 mg|
3050915|NCT00690924|Experimental|Calcitriol|
3050916|NCT00691002|Experimental|LEO 80190|Calcipotriol 25 mcg/g plus 10 mg/g hydrocortisone ointment (LEO 80190)
3050917|NCT00691002|Placebo Comparator|LEO 80190 vehicle|Ointment Vehicle
3050918|NCT00691002|Active Comparator|Calcipotriol|Calcipotriol 25 mcg/g in the ointment vehicle
3050919|NCT00691002|Active Comparator|Hydrocortisone|Hydrocortisone 10 mg/g in the ointment vehicle
3050920|NCT00691015|Experimental|Chemotherapy or chemotherapy + total body irradiation|"Standard of care (SOC) chemotherapy or ( SOC) chemotherapy + total body irradiation (TBI) of one of the following regimens:~Regimen I: Patients receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen II: Patients undergo total body irradiation (TBI) twice daily for 8 fractions and receive etoposide IV;anti-thymocyte globulin IV.~Regimen III: Patients undergo TBI once or twice daily for 11 fractions and receive cyclophosphamide IV; anti-thymocyte globulin IV.~Regimen IV: Patients undergo TBI and receive fludarabine phosphate IV and busulfan IV; anti-thymocyte globulin IV.~Regimen V: Patients receive carmustine IV, etoposide IV, cytarabine IV, and melphalan IV. Some patients also receive rituximab IV; anti-thymocyte globulin IV.~Regimen VI: Patients receive fludarabine phosphate IV and melphalan IV. Some patients also undergo TBI; anti-thymocyte globulin IV."
3050921|NCT00691028|Experimental|TA-650 3 mg/kg|
3050922|NCT00691028|Experimental|TA-650 6 mg/kg|
3050923|NCT00691028|Experimental|TA-650 10 mg/kg|
3050924|NCT00691054|Experimental|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4.
3050925|NCT00691093||fesoterodine|
3050926|NCT00691132|Experimental|PEITC - Placebo (short-term trial)|Participants are asked to smoke only deuterated NNK cigarettes (provided by the study) and record the exact number of cigarettes smoked and alcoholic drinks consumed each day for 1 month. Participants receive oral phenethyl isothiocyanate (PEITC) four times daily for 5 days in week 2 and oral placebo four times daily for 5 days in week 4. Participants keep a diary of all food and beverages consumed on the days that PEITC or placebo are taken.
3050927|NCT00691132|Experimental|Placebo - PEITC (short-term trial)|Participants receive oral placebo four times daily for 5 days in week 2 and oral PEITC four times daily for 5 days in week 4. Participants are also asked to smoke only deuterated NNK cigarettes, record the number of cigarettes smoked and alcoholic drinks consumed each day, and keep a food and beverage diary as in arm I.
3050928|NCT00691197|Experimental|Carboxymethylcellulose sodium and Glycerin|Carboxymethylcellulose sodium and Glycerin based rewetting drop
3050929|NCT00691197|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium based rewetting drop
3050930|NCT00691210|Experimental|V/N: Level 1|Vorinostat: 400mg Niacinamide: 20 mg/kg rounded to 100mg
3050931|NCT00691210|Experimental|V/N: Level 2|Vorinostat: 400mg Niacinamide: 40 mg/kg rounded to 100mg
3050932|NCT00691210|Experimental|V/N: Level 3|Vorinostat: 400mg Niacinamide: 60 mg/kg rounded to 100mg
3050933|NCT00691210|Experimental|V/N: Level 4|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg
3050934|NCT00691210|Experimental|V/N: Level 5|Vorinostat: 400mg Niacinamide: 100 mg/kg rounded to 100mg
3050935|NCT00691210|Experimental|V/N/E: Level 1|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 25 mg/m2
3050936|NCT00691210|Experimental|V/N/E: Level 2|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 50 mg/m2
3050937|NCT00691210|Experimental|V/N/E: Level 3|Vorinostat: 400mg Niacinamide: 80 mg/kg rounded to 100mg Etoposide: 100 mg/m2
3050938|NCT00691301|Experimental|Pemetrexed and cisplatin|Pemtrexed plus cisplatin on day 1 every 21 days
3050939|NCT00691327|Experimental|1|Primary reconstruction
3050940|NCT00691327|Experimental|2|Revision-reconstruction
3050941|NCT00691327|Experimental|3|Revision-augmentation
3050942|NCT00691483|Placebo Comparator|placebo|
3050943|NCT00691483|Experimental|varenicline|
3050944|NCT00691600|Active Comparator|oral trimethoprim/sulfamethoxazole|subjects with abscesses less than 5cm will be randomized to either study med or placebo
3050945|NCT00691600|Placebo Comparator|placebo|Placebo after incision and drainage of abscess less than 5 cm.
3050946|NCT00691665|Experimental|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
3050947|NCT00691665|Active Comparator|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
3050948|NCT00691704|Experimental|High-risk Multiple Myeloma|Lenalidomide Induction (with Low Dose Dexamethasone) Therapy Followed by Low Dose Melphalan, Prednisone, Lenalidomide and Bortezomib Sequential Maintenance Therapy
3050949|NCT00691808|Experimental|High Dose|
3050950|NCT00691808|Experimental|Low Dose|
3050951|NCT00691808|Placebo Comparator|Placebo|
3050952|NCT00691938|Experimental|Level 1|"LBH589 10 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050953|NCT00691938|Experimental|Level 2|"LBH589 15 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050954|NCT00691938|Experimental|Level 3|"LBH589 20 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050955|NCT00691938|Experimental|Level 4|"LBH589 30 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050956|NCT00691938|Experimental|Level 5|"LBH589 40 mg/day three times a week on nonconsecutive days in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050957|NCT00691938|Experimental|Level 5B|"LBH589 40 mg/day three times a week on nonconsecutive days for the first 2 weeks in a 28 day cycle.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050958|NCT00691938|Experimental|Phase II|"LBH589 will be given in the dose and in the schedule that was found to work in the Phase I portion which was Level 5B.~Decitabine 20 mg/m^2 IV on days 1-5 in a 28 day cycle."
3050959|NCT00692185|Experimental|1|Participants will take olanzapine.
3050960|NCT00692185|Placebo Comparator|2|Participants will take matched placebo.
3050961|NCT00692198|Experimental|Supplemental oxygen therapy|Participants will receive treatment with supplemental oxygen therapy.
3050962|NCT00692198|No Intervention|No supplemental oxygen therapy|Participants will receive no supplemental oxygen therapy, unless the participant becomes severely hypoxemic at rest (e.g., meets conventional Medicare criteria for 24-hour supplemental oxygen due to severe hypoxemia at rest).
3050963|NCT00692211|Experimental|Arm 1: Fecal Immunochemical Tests|Mailed fecal immunochemical tests
3050964|NCT00692211|Experimental|Arm 2: Fecal Occult Blood Tests|Mailed fecal occult blood tests
3050965|NCT00692237|Active Comparator|1|Sildenafil 100 mg
3050966|NCT00692237|Placebo Comparator|2|Placebo 100 mg
3050967|NCT00692276|Experimental|1|Interspinous Process Spacer Device
3050968|NCT00692276|Active Comparator|2|Interspinous Process Spacer Device
3050969|NCT00692341|Experimental|Hepatic Function - Mild Impairment|Subjects with mild hepatic impairment (Child Pugh class A, score 5-6)
3050970|NCT00692341|Experimental|Hepatic Function - Moderate Impairment|Subjects with moderate hepatic impairment(Child Pugh class B,score 7-9)
3050971|NCT00692341|Experimental|Hepatic Function - Normal|"Group 1~1) subjects with normal hepatic function"
3050972|NCT00692406|Experimental|Smokers not interested in quitting smoking|Smokers were scanned 24 hours after quitting smoking, and scanned after smoking as usual.
3050973|NCT00692419|Experimental|Symptom management nurse intervention|This arm of the study will have a symptom management nurse facilitate the management of pain, sexual dysfunction and depression. The nurse will work with the patient's renal provider to implement appropriate symptom alleviating treatment. The intervention is patient specific and entirely dependent on the treatment recommendation made by the symptom management nurse.
3050974|NCT00692419|Active Comparator|Feedback intervention|This arm of the study will have pain, sexual dysfunction and depression assessed monthly with feedback given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider. The intervention on symptoms is at the discretion of the renal provider. The interventions implemented were patient specific and consisted of therapies the patient's renal provider decided to implement.
3050975|NCT00692692|Experimental|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
3050976|NCT00692692|Active Comparator|Standard of care|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
3050977|NCT00692770|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
3050978|NCT00692770|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
3050979|NCT00692913|Experimental|FOSAVANCE 5600|alendronate sodium (+) cholecalciferol
3050980|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians.
3050981|NCT00692978|Experimental|Asthma|Asthma patients
3050982|NCT00692978|Active Comparator|Healthy volunters|Healthy participants
3050983|NCT00693160|Experimental|Intrathecal Ketorolac|In the presence of a remifentanil infusion subject will receive a single intrathecal injection of ketorolac 2 mg Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
3050984|NCT00693160|Placebo Comparator|Placebo intrathecal injection|In the presence of remifentanil the subject will receive a single intrathecal injection of placebo (preservative-free normal saline) Each subject will receive the topical capsaicin model for hyperalgesia and allodynia assessment.
3050985|NCT00693225|Active Comparator|Omeprazole/sodium bicarbonate AM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken in the morning
3050986|NCT00693225|Experimental|Omeprazole/sodium bicarbonate PM dose|8 weeks of therapy with omeprazole/sodium bicarbonate oral suspension 40 mg, once per day, taken at bedtime
3050989|NCT00693303|Experimental|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
3050990|NCT00693420|Experimental|1|Bimatoprost 0.03% solution
3050991|NCT00693420|Placebo Comparator|2|Vehicle solution
3050992|NCT00693472|Experimental|Part 1: Preladenant|Preladenant 25 mg every 12 hours for 13 days
3050993|NCT00693472|Placebo Comparator|Part 1: Placebo|Placebo every 12 hours for 13 days
3050994|NCT00693472|Experimental|Part 2: Preladenant|Preladenant 25 mg every 12 hours for 13 days
3050995|NCT00693472|Active Comparator|Part 2: Standard of Care|Anticholinergic agents or Propranolol as standard-of-care dosing regimen (supplied by the study site)
3050996|NCT00693485|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3050997|NCT00693485|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3050998|NCT00693485|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
3050999|NCT00693498|Active Comparator|1|Standard leukoreduced irradiated blood cell transfusion group
3051000|NCT00693498|Experimental|2|Washed leukoreduced irradiated blood cell transfusion group
3051001|NCT00693654|Experimental|Sarna Lotion|1% pramoxine Sarna lotion
3051002|NCT00693654|Placebo Comparator|Placebo Cetaphil lotion|Placebo Cetaphil lotion
3051003|NCT00693693|Active Comparator|Cream-|topical hydrocortisone 17-butyrate 0.1% Cream preparation applied twice daily to all lesions of atopic dermatitis
3051004|NCT00693693|Active Comparator|Ointment|topical hydrocortisone 17-butyrate 0.1% Ointment preparation applied twice daily to all lesions of atopic dermatitis
3051005|NCT00693693|Active Comparator|Lipocream|topical hydrocortisone 17-butyrate 0.1% Lipocream preparation applied twice daily to all lesions of atopic dermatitis
3051006|NCT00693706|Experimental|GSK 1388442A Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of GSK 1388442A vaccine at Day 0. The GSK 1388442A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3051007|NCT00693706|Active Comparator|Fluarix Group|Subjects aged 18 to 49 years of age at the time of vaccination received 1 dose of Fluarix® vaccine at Day 0. The Fluarix® vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3051008|NCT00693719|Experimental|Etoposide and Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15. Etoposide 50 mg PO x14 days followed by 2 weeks off.
3051009|NCT00693784|Experimental|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
3051010|NCT00693992|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3051011|NCT00693992|Placebo Comparator|Arm II (placebo)|Patients receive placebo 37.5 mg PO once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3051012|NCT00694018|Active Comparator|Education and Standard Care|Received standard care and participated in an educational program for individuals with chronic back pain. Also received an uploading pedometer but no feedback or goals about their walking activity.
3051013|NCT00694018|Experimental|Internet Mediated Enhanced Pedometer|In addition to standard care and participating in an educational program, participants received an enhanced pedometer for uploading step information, e-mail messages with weekly step goals and access to a website that provided step goals and feedback, tailored motivational messages and on on-line community for communication asynchronously with staff and other participants.
3051014|NCT00694070||health care professionals and lay users|h= 8 health care professionals p= 43 lay users
3051015|NCT00694096|Experimental|1|
3051016|NCT00694109|Experimental|Mipomersen|Mipomersen Sodium once a week for up to 4 years (depending on participant's consent). Participants were followed for additional 24 week post-treatment.
3051017|NCT00694122|Active Comparator|Glargine (Lantus) insulin|"Long acting insulin, glargine, that subject currently used as an outpatient. SC injections. Dose given at 22:00 is based on past week blood glucose data during evening overnight hours and AM glucose. 20.2 +/- 11.7 units glargine (mean +/- SD).~Glargine (Lantus): Sanolfi Aventis~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the NPH insulin arm."
3051018|NCT00694122|Active Comparator|NPH insulin|"Long acting insulin, NPH, that participant was currently while an outpatient. SC injections. Dose (units) given at 22:00 is based on past week blood glucose during evening overnight period and AM glucose. 20.7 +/- 10.0 units NPH (mean +/- SD).~NPH: Eli Lilly~Hourly blood glucose from 22:00 to 08:00 while receiving glargine (Lantus) insulin will be compared with the glargine (Lantus) insulin arm."
3051019|NCT00694161|Experimental|Fx-1006A|
3051020|NCT00694304|Experimental|Vortioxetine|
3179047|NCT00668473||1|Subjects with diffuse scleroderma
3179048|NCT00668473||2|Healthy controls
3051021|NCT00694356|Experimental|Dalotuzumab 5 mg/kg|Participants receive dalotuzumab 5 mg/kg by intravenous (IV) infusion once each week for up to 1 year or until participant withdraws consent, experiences an adverse event (AE), progressive disease or major protocol violation, has moved or is lost to follow up.
3051022|NCT00694356|Experimental|Dalotuzumab 10 mg/kg|Participants receive dalotuzumab 10 mg/kg by IV infusion once each week for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
3051023|NCT00694356|Experimental|Dalotuzumab 15 mg/kg/7.5 mg/kg|Participants receive an initial dose of dalotuzumab 15 mg/kg by IV infusion followed by a maintenance dose of dalotuzumab 7.5 mg/kg by IV infusion once every 2 weeks for up to 1 year or until participant withdraws consent, experiences an AE, progressive disease or major protocol violation, has moved or is lost to follow up.
3051024|NCT00694369|Experimental|1|etoricoxib 90 mg
3051025|NCT00694369|Experimental|2|etoricoxib 120 mg
3051026|NCT00694369|Active Comparator|3|ibuprofen 2400 mg
3051027|NCT00694369|Active Comparator|4|acetaminophen 2400 mg/codeine 240 mg
3051028|NCT00694369|Placebo Comparator|5|Matching Placebo
3051029|NCT00694473|Experimental|Freestyle Navigator|Continuous monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
3051030|NCT00694551|Experimental|A. Level 100 mcg Peptide Vaccine|Peptide vaccine dose level 100 mcg + Poly IC-LC
3051031|NCT00694551|Experimental|B. Level 300 mcg Peptide Vaccine|Peptide vaccine dose level 300 mcg + Poly IC-LC
3051032|NCT00694551|Experimental|C. Level 1 mg Peptide Vaccine|Peptide vaccine dose level 1 mg + Poly IC-LC
3051033|NCT00694564|Experimental|Treatment|This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
3051034|NCT00694603|Experimental|Cetuximab|400mg/m2 IV x 1 and then 250mg/m2 IV weekly
3051035|NCT00694707|Placebo Comparator|Placebo|Participants received placebo orally once a day for 6 weeks.
3051036|NCT00694707|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
3051037|NCT00694707|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
3051038|NCT00694707|Experimental|Cariprazine 4.5 mg|Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
3051039|NCT00694707|Active Comparator|Risperidone 4.0 mg|Participants received risperidone 4.0 mg orally once a day for 6 weeks.
3051040|NCT00695019|Experimental|500 IU qd|500 IU Interferon-alpha lozenge taken once per day plus 2 placebo lozenges per day
3051041|NCT00695019|Experimental|500 IU tid|500 IU interferon-alpha lozenge taken 3 times per day
3051042|NCT00695019|Placebo Comparator|placebo|placebo lozenges taken 3 times per day
3051043|NCT00695097|Active Comparator|1|Rituximab Group: The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15) and followed up monthly for 1 year. Biopsy was done Baseline and Month 3 and other labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing). Physical exam and vital signs were done.
3051044|NCT00695097|Active Comparator|2|No Rituximab: received standard immunosuppression and was followed up monthly for 1 year. Labs (CBC/Diff, Platelets, HACA, PK, Serum Creatinine, 24-hour protein, HLA antibodies, flow cytometry, and serology testing) vital signs, and physical exam was done.
3051045|NCT00695110|Experimental|All study participants|"Treatment Period 1: Three capsules each containing 100 mg testosterone (T) as testosterone undecanoate (TU), twice daily (BID) for 7 days.~Treatment Period 2: Two capsules each containing 200 mg T as TU and testosterone enanthate (TE), BID for 7 days.~Treatment Period 3: Two capsules each containing 100 mg T as TU, BID for 8 days.~Treatment Period 4: Two capsules each containing 150 mg T as TU and TE, BID for 7 days."
3051046|NCT00695136|Experimental|Open label single arm|Single group study of Donepezil
3051047|NCT00695188|Other|Standard dose|Escalating dose
3051048|NCT00695188|Active Comparator|High dose|25 mg
3051049|NCT00695253|Other|Talent Endoluminal Spring Graft System|Single Arm study of the endoluminal treatment of Abdominal Aortic Aneurysms using the Talent Endoluminal Spring Graft System
3051050|NCT00695292|Experimental|Intervention|"Patients in the study will receive the following for the duration of the study: irinotecan 60 mg/m2 intravenously on Days 1, 8, and 15 and carboplatin AUC=4 on Day 1. The study will consist of 28-day cycles, to a maximum of 6 cycles of therapy with irinotecan and carboplatin. After treatment with irinotecan and carboplatin, sunitinib will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During sunitinib maintenance therapy, patients will receive sunitinib at 25 mg orally daily. Sunitinib maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study."
3051051|NCT00695318|Experimental|A, 2, I 0.2 µg/Day + Sham|0.2 µg/Day
3051052|NCT00695318|Experimental|A, 2, II 0.5 µg/Day + Sham|0.5 µg/Day
3051053|NCT00695396|Experimental|001|Epoetin alfa 40 000 IU subcutaneously once every week (1 mL dose) for 48 weeks
3051054|NCT00695396|Experimental|002|Epoetin alfa 80 000 IU subcutaneously once every week (2 mL dose) for 48 weeks
3051055|NCT00695396|Placebo Comparator|003|Placebo Matching volume 1 mL for 48 weeks
3051056|NCT00695396|Placebo Comparator|004|Placebo Matching volume 2 mLfor 48 weeks
3051057|NCT00695409|Experimental|Treatment (RIT, ZBEAM, ASCT)|RADIOIMMUNOTHERAPY: Patients receive yttrium Y 90 ibritumomab tiuxetan IV following rituximab IV on day -14. HIGH-DOSE COMBINATION CHEMOTHERAPY: Patients receive carmustine IV on days -7 and -6; etoposide IV over 1 hour twice daily and cytarabine IV over 2 hours twice daily on days -5 to -2; and melphalan IV on day -1. STEM CELL TRANSPLANTATION: Patients undergo autologous peripheral blood stem cell transplant on day 0. Patients also receive rituximab on day 8*. NOTE: * Some patients may also receive rituximab on day -1. Treatment continues in the absence of disease progression or unacceptable toxicity.
3051058|NCT00695435|Experimental|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension
3051059|NCT00695435|Active Comparator|TOBREX® Ophthalmic Solution|TOBREX® Ophthalmic Solution
3051060|NCT00695435|Active Comparator|TOBRADEX® Ophthalmic Suspension|TOBRADEX® Ophthalmic Suspension
3051061|NCT00695500|Experimental|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
3051062|NCT00695500|Placebo Comparator|Placebo|Placebo tablets, 0 mg per day for 3 weeks
3051063|NCT00695565|Placebo Comparator|Placebo Gel|Placebo Gel is vehicle without clonidine
3051064|NCT00695565|Active Comparator|Clonidine Topical Gel (ARC-4558)|Clonidine Topical Gel contains 0.1% clonidine hydrochloride
3051065|NCT00695578|Experimental|Biafin on left arm|Subjects were randomized to apply Biafine® to wounds on the left forearm and polysporin (standard of care) to wounds on the right forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
3051066|NCT00695578|Experimental|Biafin on right arm|Subjects were randomized to apply Biafine to wounds on the right forearm and Polysporin to wounds on the left forearm. Medications were applied three times a day for 4 weeks to the areas that have been treated with liquid nitrogen at the baseline visit.
3051067|NCT00695669|Experimental|Influenza A (H5N1) 1 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
3051068|NCT00695669|Experimental|Influenza A (H5N1) 2 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 14. The vaccine was administered intramuscularly in the deltoid region of the arm.
3051069|NCT00695669|Experimental|Influenza A (H5N1) 3 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 7. The vaccine was administered intramuscularly in the deltoid region of the arm.
3051070|NCT00695669|Experimental|Influenza A (H5N1) 4 Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0. The vaccine was administered intramuscularly in the deltoid region of the arm.
3051071|NCT00695786|Experimental|Schedule A (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 1-21 and rituximab IV over 4-8 hours on day 1 of courses 1-12. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity
3051072|NCT00695786|Experimental|Schedule B (lenalidomide, rituximab)|Participants receive lenalidomide PO on days 2-22 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1 and on day 1 of all subsequent courses. Courses repeat every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3051073|NCT00695864|Placebo Comparator|Placebo - sugar pill|Placebo - sugar pill
3051074|NCT00695864|Experimental|Ondansetron|Ondansetron
3051075|NCT00695903|Experimental|daptomycin 10 mg/kg|Daptomycin 10 mg/kg IV every 24 hours
3051076|NCT00695903|Experimental|vancomycin high-dose|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
3051077|NCT00695955|Experimental|Azilsartan Medoxomil|
3051078|NCT00696020|Experimental|BI 1744 CL low dose/tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3051079|NCT00696020|Experimental|BI1744CL medium dose/tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3051080|NCT00696020|Experimental|BI 1744 CL high dose/tiotropium bromide|BI 1744 CL high dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3051081|NCT00696020|Experimental|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3051082|NCT00696072|Active Comparator|A1|
3051083|NCT00696072|Active Comparator|A2|
3051084|NCT00696137|Experimental|BEMA Fentanyl|BEMA Fentanyl
3051085|NCT00696241|Experimental|Azilsartan Medoxomil 20 mg QD|
3051086|NCT00696241|Experimental|Azilsartan Medoxomil 40 mg QD|
3051087|NCT00696241|Experimental|Azilsartan Medoxomil 80 mg QD|
3051088|NCT00696241|Active Comparator|Olmesartan 40 mg QD|
3051089|NCT00696241|Placebo Comparator|Placebo QD|
3051090|NCT00696293|Experimental|1|"Duloxetine + clinical management~NOTE -- THIS WORK WAS CONDUCTED AS PART OF A CAREER DEVELOPMENT AWARD. THE CLINICALTRIALS.GOV DESCRIPTION OF THE STUDY WAS UPDATED 1/5/16 TO UPDATE THE OPEN LABEL NATURE OF THIS WORK. THIS IS WHAT IS REPORTED HERE AND HAS BEEN PEER REVIEWED AND PUBLISHED."
3051091|NCT00696384|Experimental|Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)|
3051092|NCT00696384|Experimental|Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)|
3051093|NCT00696384|Placebo Comparator|Placebo QD - Double-Blind Phase (Week 26- 32)|
3051094|NCT00696410|Experimental|CHF patients Given Zinc Acetate|Patients with CHF received zinc acetate 50 mg po TID. This is a pre-post study
3051095|NCT00696410|No Intervention|Healthy controls|Health controls; no zinc acetate administered.
3051096|NCT00696423|Experimental|Infanrix/Hib Single Injection Group|Subjects received 1 dose of Infanrix™ extemporaneously mixed with Hiberix™.
3051097|NCT00696423|Active Comparator|Infanrix + Hiberix Separate Injection Group|Subjects received two separate injections, one of Infanrix™ and one of Hiberix™.
3051098|NCT00696436|Experimental|Azilsartan Medoxomil 40 mg QD|
3051099|NCT00696436|Experimental|Azilsartan Medoxomil 80 mg QD|
3051100|NCT00696436|Active Comparator|Valsartan 320 mg QD|
3051101|NCT00696436|Active Comparator|Olmesartan 40 mg QD|
3051102|NCT00696436|Placebo Comparator|Placebo QD|
3051103|NCT00696449|Experimental|Frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
3051104|NCT00696449|Experimental|Electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
3051105|NCT00696449|Experimental|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
3051106|NCT00696449|Experimental|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
3051107|NCT00696488|Experimental|Fluorouracil 0.5%|each subject will receive the study medication: Carac® 0.5% Fluorouracil, a standard treatment for actinic keratoses. Carac® will be dispensed to the subjects in the original tube with MEMS electronic monitoring caps attached. Subjects will be asked to apply the medication daily to AK lesions
3051108|NCT00696618|Experimental|A|Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home(Stage 2), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3051109|NCT00696618|Experimental|B|Normosol-R enema (iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3051110|NCT00696618|Experimental|C|Fleet enema (hyper-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 1), Followed by Tap water enema (hypo-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 2), Followed by Normosol-R enema(iso-osmolar) administered rectally 125 mL one time in the clinic, then self-administered on three separate occasions at home (Stage 3)
3051111|NCT00696657|Experimental|A|
3051112|NCT00696657|Experimental|B|
3051113|NCT00696657|Experimental|C|
3051114|NCT00696657|Experimental|D|
3051115|NCT00696657|Experimental|E|
3051116|NCT00696657|Experimental|F|
3051117|NCT00696657|Placebo Comparator|G1|
3051118|NCT00696657|Placebo Comparator|G2|
3051119|NCT00696657|Placebo Comparator|G3|
3051120|NCT00696657|Placebo Comparator|G4|
3051121|NCT00696657|Placebo Comparator|G5|
3051122|NCT00696657|Placebo Comparator|G6|
3051123|NCT00696657|Experimental|H|
3051124|NCT00696657|Experimental|I|
3051125|NCT00696696|Experimental|Combination GES|Combination of Gemcitabine, Erlotinib, and Sorafenib
3051126|NCT00696709|Experimental|Part 1: Heat-treated Varicella-Zoster Virus (VZV) Vaccine|Participants received an 0.65 mL subcutaneous injection of heat-treated varicella zoster virus (VZV) vaccine A; 4-dose regimen administered ~30 days apart.
3051127|NCT00696709|Experimental|Part 1: Gamma- Irradiated VZV Vaccine A|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine A; 4-dose regimen administered ~30 days apart.
3051128|NCT00696709|Placebo Comparator|Part 1: Placebo|Participants received a 4-dose placebo regimen administered ~30 days apart.
3051129|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine B|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine B; 4-dose regimen administered ~30 days apart.
3051130|NCT00696709|Experimental|Part 2: Gamma- Irradiated VZV Vaccine C|Participants received an 0.65 mL subcutaneous injection of alternative inactivation method VZV vaccine C; 4-dose regimen administered ~30 days apart.
3051131|NCT00696761|Active Comparator|group1|Bladder outlet obstruction index(BOOI)≥ 20, Bladder contractility index(BCI)≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
3051132|NCT00696761|Active Comparator|group2|BOOI≥ 20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
3051133|NCT00696761|Active Comparator|group 3|BOOI<20, BCI≥ 100 Alfuzosin was administered daily (10 mg) for 12 month.
3051134|NCT00696761|Active Comparator|group 4|BOOI<20, BCI<100 Alfuzosin was administered daily (10 mg) for 12 month.
3051135|NCT00696774|Experimental|Duloxetine|Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.
3051136|NCT00696787|Placebo Comparator|Placebo|In the first stage, subjects were randomly assigned to receive placebo. Study was stopped after stage 1 by sponsor.
3051137|NCT00696787|Experimental|DVS SR|In the first stage, subjects were randomly assigned to receive DVS SR 200 mg/day. Study was stopped after stage 1 by sponsor.
3051138|NCT00696787|Active Comparator|Pregabalin|In the first stage, subjects were randomly assigned to receive Pregabalin 450 mg/day. Study was stopped after stage 1 by sponsor.
3051139|NCT00696800|Experimental|150 µg Corifollitropin Alfa|Participants received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (org 36286) on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recFSH; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were administered from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses.
3051140|NCT00696800|Active Comparator|200 IU recFSH|Participants received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Daily SC injections of Ganirelix were given from Stimulation Day 5 to the day of hCG; at which time a single dose of hCG was administered when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses.
3051141|NCT00696878|Experimental|Corifollitropin alfa 150 µg|Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after [rec]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.
3051142|NCT00697073|Experimental|1|high dose Idebenone
3051143|NCT00697112||A|
3051144|NCT00697190|Active Comparator|senofilcon A/galyfilcon A|senofilcon A silicone hydrogel toric contact lenses will be worn first. galyfilcon A silicone hydrogel toric contact lenses will be worn second.
3051145|NCT00697190|Active Comparator|galyfilcon A/senofilcon A|galyfilcon A silicone hydrogel toric contact lenses worn first. senofilcon A silicone hydrogel toric contact lenses worn second.
3051146|NCT00697203|Experimental|Dalcetrapib 300mg|
3051147|NCT00697203|Experimental|Dalcetrapib 600mg|
3051148|NCT00697203|Experimental|Dalcetrapib 900mg|
3051149|NCT00697203|Placebo Comparator|Placebo|
3051150|NCT00697255|Experimental|corifollitropin alfa + recFSH|Eligible participants will receive a subcutaneous (SC) injection of corifollitropin alfa (Stage 1a: 15mcg, Stage Ib/II: 30 mcg) the first, second, or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient, the participant will receive a second or third dose of corifollitropin alfa (Stage 1a: 15 mcg, Stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm, the participant will start daily SC injections with FSH (Stage 1A: 50 IU, Stage II: 75 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
3051151|NCT00697255|Experimental|corifollitropin alfa + hCG|Eligible participants will receive a SC injection of corifollitropin alfa (Stage Ia:15 mcg, Stage Ib/II: 30 mcg) the first, second or third day after onset of a progestagen-induced withdrawal bleeding. If the follicle growth is insufficient the participant will receive a second or third dose of corifollitropin alfa (Stage IA: 15 mcg, stage Ib/II: 20 mcg). As soon as the largest follicle reaches a size of ≥12 mm the participant will start daily SC injections with hCG (Stage Ib/II: 200 IU) the same day. A bolus injection of hCG (5000 IU) will be administered if at least one follicle is ≥18 mm and in total no more than two follicles ≥15 mm are observed.
3051152|NCT00697346|Experimental|Part 1: PIC Dose Escalation|Alisertib 25 or 35 mg, Powder-in-Capsule (PIC) formulation, orally, once daily (QD) for 21 days followed by a 7-day recovery period in 28-day cycles or alisertib 35, 45, 65 or 90 mg PIC, orally, (QD for 14 days followed by a 14-day recovery period in 28-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 14 cycles). All participants received an initial starting dosage of alisertib PIC 25 mg, orally, twice daily (BID) on Day 1 (loading dose), followed by their respective dosage assignment.
3051153|NCT00697346|Experimental|Part 1: ECT Dose Escalation|Alisertib 40 mg, Enteric-coated Tablet (ECT) formulation, orally, QD for 14 days followed by a 14-day recovery period in 28-day cycles, or alisertib 30, 40 or 50 mg ECT, orally BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 15 cycles).
3051154|NCT00697346|Experimental|Part 2: PTCL|Participants with peripheral T-cell lymphoma (PTCL) received alisertib 50 mg ECT, orally, BID for 7 days followed by a 14-day recovery period in 21-day cycles, until disease progression or unacceptable alisertib-related toxicity (up to 2 cycles).
3051155|NCT00697463|Experimental|Women with Idiopathic osteoporosis (IOP)|Each subject will receive 20 micrograms of Teriparatide (PTH 1-34) subcutaneously daily for 18 -24 months
3051156|NCT00697515|Active Comparator|Lisdexamfetamine Dimesylate (LDX, SPD489)|
3051157|NCT00697515|Placebo Comparator|Placebo|
3051158|NCT00697541|Experimental|A|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after four hours
3051159|NCT00697541|Active Comparator|B|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
3051160|NCT00697593|Experimental|Efalizumab|
3051161|NCT00697619|Experimental|Test Group|Zometa (zoledronic acid) 4 mg over 15 min IV infusion, every 4 week Anti-neoplastic therapy .Patients can receive concomitant cycles of chemotherapy or radiotherapy.
3051162|NCT00697619|No Intervention|Contorl Group|Anti-neoplastic therapy alone. Patients can receive concomitant cycles of chemotherapy or radiotherapy.
3051163|NCT00697697|Experimental|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
3051164|NCT00697697|Experimental|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
3051165|NCT00697788|Experimental|Ascending dose study|Ascending doses of dexmedetomidine (as per protocol)
3051166|NCT00697801|Experimental|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
3051167|NCT00697801|Experimental|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
3051168|NCT00697801|Placebo Comparator|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
3051169|NCT00697827|Experimental|1|In-Space
3051170|NCT00697827|Active Comparator|2|X STOP
3051171|NCT00698022|Experimental|Risperidone plus mifepristone|risperidone plus mifepristone daily for 28 days
3051172|NCT00698022|Placebo Comparator|risperidone plus mifepristone-matched placebo|risperidone plus mifepristone-matched placebo daily for 28 days
3051173|NCT00698022|Placebo Comparator|risperidone matched-placebo plus mifepristone|risperidone-matched placebo plus mifepristone daily for 28 days
3051174|NCT00698035|Active Comparator|Testosterone Cream|Testosterone Cream 1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
3051175|NCT00698035|Active Comparator|Estring|Estring 2mg ring inserted vaginally once every 12 weeks
3051176|NCT00698139|Active Comparator|Intervention first, then control|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, they will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. The rest of the protocol will be as described for the first encounter."
3051177|NCT00698139|Active Comparator|Control first, then intervention|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~On the first encounter, patients will come to clinic in the morning for baseline measurements.Subsequently, the control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.~On the second encounter, patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The rest of the protocol will be as described for the first encounter."
3051178|NCT00698139|Active Comparator|Intervention Only|"Ambulatory out-patients will be identified at Columbia-Presbyterian and New York University Medical Centers.~Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour."
3051179|NCT00698204|Experimental|I- Celecoxib|
3051180|NCT00698204|Placebo Comparator|II|
3051181|NCT00698451|Experimental|001|doxorubicin HCL liposome; bevacizumab; carboplatin30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
3051182|NCT00698516|Experimental|Open label, Single arm|Oral topotecan + IV Bevacizumab
3051183|NCT00698581|Experimental|Brivaracetam 50 mg|50 mg/day
3051184|NCT00698581|Experimental|Brivaracetam 100 mg|100 mg/day
3051185|NCT00698646|Active Comparator|Valsartan|(patients initiated on valsartan)
3051186|NCT00698646|Active Comparator|HCTZ|(patients initiated on HCTZ)
3051187|NCT00698646|Experimental|Valsartan + HCTZ|(patients initiated on Valsartan+HCTZ)
3051188|NCT00698685|Experimental|Preparative Regimen|"Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)~Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)~Followed by Allogeneic hematopoietic stem cell transplantation, related or unrelated donor, on day 0. Patients also receive cyclosporine intravenous (IV) continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper."
3051189|NCT00698815|Experimental|Arm I (pemetrexed)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive sunitinib malate as in Arm II as third-line therapy.
3051190|NCT00698815|Experimental|Arm II (sunitinib)|Patients receive sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive pemetrexed disodium as in Arm I as third-line therapy.
3051191|NCT00698815|Experimental|Arm III (pemetrexed and sunitinib)|Patients receive pemetrexed disodium 500 mg/m^2 IV over 10 minutes on day 1 and sunitinib malate at 37.5 mg PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may then receive third-line therapy at the discretion of the treating physician.
3320836|NCT02014155|Experimental|Group Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard desinsuflativo (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
3051195|NCT00698841|Experimental|Cetuximab|
3051196|NCT00698867||Discovery™ Elbow|Discovery™ Elbow minimally constrained
3051197|NCT00698932|Experimental|Saxagliptin 5mg|
3051198|NCT00698932|Placebo Comparator|Placebo|
3051199|NCT00698997|Experimental|1 Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
3051200|NCT00698997|Other|2 Standard Care available in the Community|Any intervention that were available and that families accessed in their communities
3051201|NCT00699010|Active Comparator|Acurox 5/30mg taken first|oxycodone HCl/Niacin 5/30mg tablets; 8 tablets per dose
3051202|NCT00699010|Active Comparator|Oxycodone 5mg taken first|oxycodone HCl 5mg tablets; 8 tablets per dose
3051203|NCT00699140|Experimental|1 treatment group with IGIV3I Grifols|"Open label, non-randomized treatment group with IGIV3I Grifols~Each patient received a total dose of 2 g/kg IGIV3I Grifols, given intravenously over either 2 days or 5 days in divided doses."
3051204|NCT00699153|Experimental|Loteprednol Etabonate|Loteprednol Etabonate 0.5%
3051205|NCT00699153|Placebo Comparator|Vehicle|Vehicle of Ophthalmic Loteprednol Etabonate
3051206|NCT00699192|Experimental|Amlodipine/Valsartan 5/80 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 80 mg once daily
3051207|NCT00699192|Active Comparator|Amlodipine/Valsartan 5/40 mg|1 capsule amlodipine 5 mg, 1 capsule valsartan 40 mg once daily
3051208|NCT00699192|Active Comparator|Amlodipine 5 mg|1 capsule amlodipine 5 mg, 1 capsule placebo to match valsartan once daily
3051209|NCT00699218|Experimental|rTMS treatment|Active rTMS treatment. Transcranial magnetic stimulation using a device called MagStim
3051210|NCT00699283|Experimental|Brivaracetam (BRV) 1|50 mg daily
3051211|NCT00699283|Experimental|Brivaracetam (BRV) 2|100 mg daily
3051212|NCT00699348|Experimental|C.E.R.A.|
3051213|NCT00699374|Experimental|Arm A|sunitinib arm
3051214|NCT00699374|Active Comparator|Arm B|sorafenib arm
3051215|NCT00699491|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22 (cixutumumab is given on days 8, 15, and 22 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3051216|NCT00699556|Experimental|patch+spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + nicotine nasal spray.
3051217|NCT00699556|Placebo Comparator|patch+placebo spray|Within subject design. All volunteers complete two laboratory sessions. In one session they receive nicotine patch + placebo nicotine nasal spray.
3051218|NCT00699582|Experimental|1|
3051219|NCT00699582|Experimental|2|
3051220|NCT00699582|Placebo Comparator|3|
3051221|NCT00699608|Experimental|Crossover|All subjects received all three treatments in a randomised order
3051222|NCT00699660|Experimental|CAPS/WHODAS|PTSD assessed using Clinical Assessment of PTSD Symptoms (CAPS) and WHODAS functional impairment structured evidence-based interview
3051223|NCT00699660|Active Comparator|Nonstructured Interview|Usual clinical interview to assess PTSD, without CAPS or WHODAS
3051224|NCT00699751|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received radium-223 50 kilo Becquerel (kBq)/kg body weight (b.w.) for 6 intravenous (IV) administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
3051225|NCT00699751|Placebo Comparator|Placebo|Participants received isotonic saline for 6 IV administrations separated by 4 weeks intervals plus Best Standard of Care (BSoC).
3051226|NCT00699803|Active Comparator|T-Pred|Tobramycin prednisolone acetate combination
3051227|NCT00699803|Active Comparator|Pred Forte|Prednisolone acetate
3051228|NCT00699816|Experimental|Immunotherapy Group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 16 times(4 treatments at a frequency of once per week, followed by 4 treatments every 2 weeks, then 4 treatments every 4 weeks, and finally 4 treatments every 8 weeks.
3051229|NCT00699816|No Intervention|Control Group|Patients who had undergone curative treatment(surgical resection, radiofrequency ablation[RFA], or percutaneous ethanol injection[PEI]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
3051230|NCT00699907|Active Comparator|Treatment Arm|Patients received oral flutamide (125 MG) once daily for 6 weeks in the absence of unacceptable toxicity. Patients then underwent risk-reducing salpingo-oophorectomy.
3051231|NCT00699907|No Intervention|High Risk Arm|High risk patients underwent risk-reducing salpingo-oophorectomy.
3051232|NCT00699907|No Intervention|Low Risk Arm|Low risk patients underwent salpingo-oophorectomy for a medical indication.
3051233|NCT00699972|Experimental|1|
3051234|NCT00699972|Experimental|2|
3051235|NCT00699972|Placebo Comparator|3|
3051236|NCT00699998|Experimental|Prasugrel|Prasugrel and Low-dose Commercially-available Aspirin
3051237|NCT00699998|Active Comparator|Clopidogrel|Clopidogrel and Low-Dose Commercially-available Aspirin
3051238|NCT00700011|Active Comparator|10 mg/m2 group|Patients were treated with Clofarabine 10 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
3051239|NCT00700011|Active Comparator|5 mg/m2 group|Patients were treated with Clofarabine 5 mg/m2 daily x 5 days per cycle. Cycles were intended on being every 28 days but this was flexible due to the bone marrow neding to recover from each cycle before strting the next one. Neulasta was given on day 5 of each cycle. Patients were treated until disease progression, or intolerable toxicities.
3051240|NCT00700063|Experimental|1|
3051241|NCT00700063|Experimental|2|
3051242|NCT00700063|Experimental|3|
3051243|NCT00700063|Placebo Comparator|4|
3051244|NCT00700063|Experimental|5|
3051245|NCT00700063|Experimental|6|
3051246|NCT00700063|Experimental|7|
3051247|NCT00700063|Placebo Comparator|8|
3051248|NCT00700102|Active Comparator|Chemotherapy|Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
3051249|NCT00700102|Experimental|Chemotherapy + Bevacizumab|Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
3051250|NCT00700115|Experimental|Kaletra + Isentress|Kaletra + Isentress
3051251|NCT00700115|Active Comparator|Standard HAART|Pre-study Antiretroviral regimen
3051252|NCT00700180|Experimental|1|
3051253|NCT00700180|Experimental|2|
3132893|NCT03463915|Placebo Comparator|Bladder instillation WITHOUT triamcinolone acetonide|Six weekly bladder instillations of standard cocktail without triamcinolone acetonide. Standard cocktail= heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
3051254|NCT00700271|Experimental|Morning Intake|After randomization, participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the morning between 6-10 am. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
3051255|NCT00700271|Experimental|Evening Intake|After randomization participants received a single daily oral dose of 5 mg amlodipine and 160 mg valsartan free combination therapy, taken in the evening between 6-10 pm. At week 4, uncontrolled patients (msSBP >= 140 mmHg and/or msDBP >= 90 mmHg or msSBP >= 130 mmHg and/or msDBP >= 80 mmHg in the case of diabetes or renal insufficiency measured by using conventional methods) received amlodipine/valsartan 10/160 mg for 4 additional weeks. Patients who were controlled at Week 4 (msSBP < 140 mmHg and msDBP < 90 mmHg or msSBP < 130 mmHg and msDBP < 80 mmHg in the case of diabetes or renal insufficiency) continued their amlodipine/valsartan 5/160 mg treatment for the remaining 4 weeks of the study.
3051256|NCT00700310|Active Comparator|1|
3051257|NCT00700310|Active Comparator|2|
3051258|NCT00700310|Active Comparator|3|
3051259|NCT00700310|Placebo Comparator|4|
3051260|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501: Phase 2|pemetrexed, cisplatin and CBP501
3051261|NCT00700336|Active Comparator|Pemetrexed and Cisplatin: Phase 2|pemetrexed and cisplatin
3051262|NCT00700336|Experimental|Pemetrexed, Cisplatin, and CBP501:Phase 1|MTD, which was equal to recommended dose for the Phase II part, was determined by 6 patients (3+3)
3051263|NCT00700375|Experimental|Sodium bicarbonate|
3051264|NCT00700375|Experimental|Sodium chloride|
3051265|NCT00700401||Peginterferon Alfa-2a + Ribavirin|
3051266|NCT00700427|Experimental|Atomoxetine|Atomoxetine 40-100 milligrams per day (mg/day) orally, once daily or twice daily for 24 weeks, followed by atomoxetine 80-100 mg/day orally, once daily or twice daily for 25 weeks.
3051267|NCT00700427|Placebo Comparator|Placebo|Atomoxetine 40-100 mg/day orally, once daily or twice daily for 24 weeks, followed by placebo orally, once daily for 25 weeks.
3051268|NCT00700440|Experimental|Cetuximab|400mg/m^2 intravenous infusion one week before radiotherapy, then 250mg/m^2 intravenous infusion weekly during radiotherapy
3051269|NCT00700570|Experimental|1|
3051270|NCT00700622|Experimental|TI + Insulin glargine|Technosphere Insulin Inhalation Powder in combination with Lantus (insulin glargine)
3051271|NCT00700622|Experimental|Insulin lispro + Insulin glargine|Humalog (insulin lispro) in combination with Lantus (insulin glargine)
3051272|NCT00700635|Experimental|Menactra® Group 1|Participants aged 2 to < 4 years
3051273|NCT00700635|Experimental|Menactra® Group 2|Participants aged 4 to < 6 years
3051274|NCT00700635|Active Comparator|Menactra® Group 3|Participants aged 6 to < 11 years
3051275|NCT00700713|Experimental|One-Dose Menactra Group|Participants received one dose of Menactra® in Study MTA26
3051276|NCT00700713|Experimental|Two-Dose Menactra Group|Participants received two doses of Menactra® in Study MTA26
3051277|NCT00700713|Active Comparator|Menactra vaccine-naïve Group|Participants had never received Menactra® vaccine.
3051278|NCT00700739|Other|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior Cervical Discectomy and Fusion with Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
3051279|NCT00700739|Active Comparator|Cervical Total Disc Replacement|DISCOVER™ Artificial Cervical Disc
3051280|NCT00700752|Active Comparator|senofilcon A/balafilcon A|senofilcon A silicone hydrogel contact lens worn during first 4-week period, balafilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
3051281|NCT00700752|Active Comparator|balafilcon A/senofilcon A|balafilcon A silicone hydrogel contact lens worn worn during first 4-week period, senofilcon A silicone hydrogel contact lens worn during the second 4-week period. Senofilcon A lenses worn daily on a 2-week replacement schedule; balafilcon A lenses worn daily on a 4-week replacement schedule. Lens replacement conducted in-office in a masked process.
3051282|NCT00700804|Experimental|High Calcium Diet|
3051283|NCT00700804|Experimental|Low Calcium Diet|
3051284|NCT00700817|Experimental|Lira 1.2 mg -> Lira 1.2 mg -> Lira 1.2 mg|Once-daily subcutaneous dose of liraglutide 1.2 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First week for up-titration of liraglutide from 0.6 mg to 1.2 mg. Subjects continued to receive liraglutide 1.2 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
3051285|NCT00700817|Experimental|Lira 1.8 mg -> Lira 1.8 mg -> Lira 1.8 mg|Once-daily subcutaneous dose of liraglutide 1.8 mg with at least 1500 mg metformin/day (tablets) for 26 weeks. First 2 weeks for up-titration of liraglutide from 0.6 mg to 1.8 mg. Subjects continued to receive liraglutide 1.8 mg once daily in extension period 1 (weeks 26-52) and extension period 2 (weeks 52-78).
3051286|NCT00700817|Active Comparator|Sita -> Sita|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52).
3051287|NCT00700817|Experimental|Sita -> Sita -> Lira 1.2 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.2 mg + metformin.
3051288|NCT00700817|Experimental|Sita -> Sita -> Lira 1.8 mg|Once-daily dose of sitagliptin 100 mg (tablets) with at least 1500 mg metformin/day (tablets) for 26 weeks. Subjects continued to receive 100 mg sitagliptin once daily in extension period 1 (weeks 26-52). In extension period 2 (weeks 52-78), subjects were randomised to liraglutide 1.8 mg + metformin.
3051289|NCT00700882|Experimental|Dasatinib|Patients receive oral dasatinib at 70 mg twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3051290|NCT00700973|Active Comparator|Arm 1|Substance use disorder usual care
3051291|NCT00700973|Experimental|Arm 2|Interpersonal violence prevention intervention
3051292|NCT00700999|Other|Arm 1|Intervention-Paroxetine
3051293|NCT00700999|No Intervention|Arm 2|No Intervention
3051294|NCT00701038|Experimental|Device|Provided with an auto adjusting bi-level positive airway pressure device
3051295|NCT00701038|No Intervention|Control|No device
3051296|NCT00701051|Active Comparator|Arm 1|Older adults, normal glucose tolerance
3051297|NCT00701051|Experimental|Arm 2|Older adults, impaired glucose tolerance
3051298|NCT00701064|Experimental|Bright Light Exposure|Bright Light (30 min/day)
3051299|NCT00701064|Placebo Comparator|Negative Ion Generator|Negative Ion Generator (30 min/day)
3051300|NCT00701090|Experimental|1|sitagliptin
3051301|NCT00701090|Active Comparator|2|glimepiride
3051302|NCT00701103|Experimental|Dalotuzumab 1.25 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 1.25 mg/kg (10 mg/mL) intravenous (IV) infusion 1 time every 1 week (Q1W).
3051303|NCT00701103|Experimental|Dalotuzumab 2.5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 2.5 mg/kg (10 mg/mL) IV infusion Q1W.
3051304|NCT00701103|Experimental|Dalotuzumab 5 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 5 mg/kg (10 mg/mL) IV infusion Q1W.
3051305|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 10 mg/kg (10 mg/mL) IV infusion Q1W.
3051306|NCT00701103|Experimental|Dalotuzumab 10 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 10 mg/kg (20 mg/mL) IV infusion Q1W.
3051307|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 15 mg/kg (10 mg/mL) IV infusion Q1W.
3051308|NCT00701103|Experimental|Dalotuzumab 15 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 15 mg/kg (20 mg/ mL) IV infusion Q1W.
3051309|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (10 mg/mL)|Participants received dalotuzumab 20 mg/kg (10 mg/mL) IV infusion Q1W.
3051310|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q1W (20 mg/mL)|Participants received dalotuzumab 20.0 mg/kg (20 mg/mL) IV infusion Q1W.
3051311|NCT00701103|Experimental|Dalotuzumab 20 mg/kg Q2W (20 mg/mL)|Participants received dalotuzumab 20 mg/kg (20 mg/mL) IV infusion 1 time every 2 weeks (Q2W).
3051312|NCT00701103|Experimental|Dalotuzumab 30 mg/kg Q3W (20 mg/mL)|Participants received dalotuzumab 30 mg/kg (20 mg/mL) IV infusion1 time every 3 weeks (Q3W).
3051313|NCT00701129|Experimental|Alglucosidase Alfa|Alglucosidase alfa (Myozyme®) 20 milligrams per kilogram (mg/kg) intravenous (IV) infusion every other week (qow) (or optionally 20 mg/kg IV infusion every week [qw]) beginning from Day 0 to a minimum of 18 months or if the patient was less than (<) 6 months of age at the time of enrollment, until the patient was 2 years of age, along with methotrexate 0.4 mg/kg subcutaneously for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab 375 milligrams per square meter (mg/m^2) (or 12.5 mg/kg for patients with body surface area less than or equal to 0.5 m^2) IV infusion qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
3051314|NCT00701311|Experimental|Study Drug CC-10004|Study drug CC-10004 20mg taken orally twice a day.
3051315|NCT00701363|Experimental|Lanreotide Autogel 120 mg|
3051316|NCT00701376|Other|liver function|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
3051317|NCT00701389|Experimental|Sequence 1: A→C→D→B|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A); Period 2: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 3: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D); Period 4: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B). Each dosing period is separated by a 5-day washout.
3051318|NCT00701389|Experimental|Sequence 2: B→D→C→A|Participants receive the following: Period 1: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 2: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D): Period 3: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C); Period 4:single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A). Each dosing period is separated by a 5-day washout.
3051319|NCT00701389|Experimental|Sequence 3: C→B→A→D|Participants receive the following: Period 1 :single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C), Period 2: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 3: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treatment A): Period 4: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D). Each dosing period is separated by a 5-day washout.
3051320|NCT00701389|Experimental|Sequence 4: D→A→B→C|Participants receive the following: Period 1: single oral dose of sumatriptan placebo/telcagepant placebo (Treatment D), Period 2: single oral dose of 100 mg sumatriptan/600 mg telcagepant (Treament A); Period 3: single oral dose of 100 mg sumatriptan/telcagepant placebo (Treatment B); Period 4: single oral dose of sumatriptan placebo/600 mg telcagepant (Treatment C). Each dosing period is separated by a 5-day washout.
3051321|NCT00701415|Experimental|Fabrazyme 0.5 mg/kg|Fabrazyme 0.5 mg/kg was administered every 2 weeks (up to 131 infusion) up to 260 weeks, the total infusion time was not less than 45 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
3051322|NCT00701415|Experimental|Fabrazyme 1.0 mg/kg|Fabrazyme 1.0 mg/kg was administered every 4 weeks (up to 66 infusion) up to 260 weeks, the total infusion time was not less than 90 minutes. In case of significant progression of Fabry disease, the dose was increased to 1.0 mg/kg every 2 weeks.
3051323|NCT00701441||Control group: healthy individuals without OSA|healthy individuals without OSA who are matched in weight and age to the participating OSA patients
3051324|NCT00701441||OSA group|Patients in the OSA group receive CPAP for 12 weeks as part of their care. patients with OSA provide measures at baseline and after 12 weeks of CPAP treatment.
3051325|NCT00701558|Experimental|Erlotinib + Gemcitabine|Participants received erlotinib 150 mg/day, orally (po) on a continuous schedule in combination with gemcitabine at 1000 mg/m^2 administered intravenously (iv) on days 1, 8, 15 of each 4 week cycle for 6 cycles as per standard medical care, or until disease progression or participant's withdrawal due to any reason or death.
3051326|NCT00701636|Experimental|Cases|The first 15 subjects enrolled will receive the intervention drug daptomycin as surgical antibiotic prophylaxis.
3051327|NCT00701636|No Intervention|Controls|15 subjects will be enrolled in the standard of care antibiotic group to serve as the controls. Controls will receive no experimental medications or treatments. The purpose of enrolling control patients was to serve as a reference group for intervention patients. Specifically cases and controls will be compared for changes in commonly collected hematologic parameters, creatinine, and CPK. Additionally, parameters collected during anesthesia will be compared. Controls will be matched to the intervention group by age (+/- 10 years), gender, and ethnicity.
3051328|NCT00701662|Experimental|Vivaglobin|Vivaglobin® is a 16% (160 mg/mL) liquid formulation of human normal immunoglobulin for subcutaneous infusion. Subjects will receive weekly infusions of Vivaglobin® at a weekly dosage calculated based on previous intravenous immunoglobulin treatment (between 0.1 to 0.5 g/kg body weight per week).
3051329|NCT00701675|Experimental|Sertraline 50mg|sertraline 50 mg daily
3051330|NCT00701675|Experimental|Sertraline 100mg|sertraline 100mg daily
3051331|NCT00701675|Placebo Comparator|Placebo|placebo 50 or 100mg
3051332|NCT00701701|Experimental|Regimen A: Alglucosidase alfa and Cyclophosphamide|Participants exhibiting clinical decline since starting alglucosidase alfa (Myozyme®) therapy and having inhibitory antibodies and/or a sustained high recombinant human acid alpha-glucosidase (rhGAA) antibody titer (defined as at least 2 titers greater than or equal to [>=] 25,600 obtained at least 1 month apart), regardless of their CRIM status, were assigned to Regimen A. In Regimen A, participants received alglucosidase alfa (Myozyme®) Intravenous (IV) infusion of 20 milligram per kilogram (mg/kg) every other week (qow) for a minimum of 18 months or, until the participant reached the age of 2 years (if the participant was less than [<6] months of age at the time of enrollment). In addition, cyclophosphamide 250 milligram per square meter (mg/m^2) IV infusion was administered every 4 weeks (q4w) after Myozyme® infusion for 6 months.
3051333|NCT00701701|Experimental|Regimen B: Alglucosidase alfa, Rituximab and Methotrexate|CRIM-negative participants were assigned to Regimen B if they either(1)exhibited clinical decline since starting alglucosidase alfa (Myozyme®)therapy and did not have inhibitory antibodies and/or a sustained rhGAA antibody titer(defined as at least 2 titers >=25,600 obtained at least 1 month apart),or(2) did not exhibit clinical decline since starting alglucosidase alfa(Myozyme®) therapy, regardless of their anti-rhGAA or inhibitory antibody status. Regimen B participants with CRIM-negative status received alglucosidase alfa(Myozyme®) IV infusion of 20 mg/kg qow for a minimum of 18 months or,until participant reached the age of 2 years (if participant was <6 months of age at time of enrollment). In addition,rituximab 375 mg/m^2 IV was administered weekly beginning the day after Myozyme® infusion for 4 weeks(an optional 2nd cycle could be administered at the discretion of the investigator) and biweekly methotrexate 15 mg/m^2 subcutaneous on the day after Myozyme® infusion for 6 months.
3051334|NCT00701714|Experimental|1|HX575, EPO HEXAL
3051335|NCT00701714|Active Comparator|2|ERYPO
3051336|NCT00701727|Experimental|1|ezetimibe (10mg/day)for 7 weeks
3051337|NCT00701727|Placebo Comparator|2|Placebo control
3051338|NCT00701779|Experimental|Dutasteride|"Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.~Subjects will self-administer the study medication once daily for up to 52 weeks (1 year). Subjects will return to the clinic at 13 week intervals during the treatment period. At each scheduled clinic visit (3, 6, and 9 months), the subjects will be counseled on withdrawal of Tamsulosin. The total study duration for each subject will be up to 52 weeks."
3051339|NCT00701805|Experimental|Paricalcitol 2 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3051340|NCT00701805|Experimental|Paricalcitol 2 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3051341|NCT00701805|Experimental|Paricalcitol 4 µg ± 1 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3051342|NCT00701805|Experimental|Paricalcitol 4 µg ± 2 µg|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 48 weeks in this study, combined with 12 weeks in the previous study, M10-309 (NCT00667576), for a total of 52 weeks of treatment.
3051343|NCT00701896|Other|Healthy Control - Non-smoking|Healthy Control arm with 51 subjects who are HIV negative and do not smoke
3051344|NCT00701896|Other|Healthy Control - Smoker|Healthy Control arm, includes 50 subjects who are HIV negative and are smokers.
3051345|NCT00701896|Active Comparator|HIV Smoking Cessation Arm|Includes up to 365 subjects who are HIV positive and initiate smoking cessation
3051346|NCT00701896|Experimental|Motivational Intervention|Includes up to 100 subjects who are HIV positive, do not wish to quit smoking but are willing to undergo one-on-one Motivational Intervention
3051347|NCT00701935|Placebo Comparator|1|
3051348|NCT00701935|Experimental|2|
3051349|NCT00702052|Experimental|Everolimus|Participants received everolimus tablets, 10 mg, orally, once daily during each 28 day cycle until determination of objective tumor progression or unacceptable toxicity, or death, or consent withdrawal, or discontinuation from the study for any other reason.
3051350|NCT00702143|Experimental|AD subjects|
3051351|NCT00702143|Experimental|MCI Subjects|MCI (mild cognitive impairment)
3051352|NCT00702143|Experimental|Healthy controls|
3051353|NCT00702208|Other|Single arm study|Paired laboratory results for clinician-collected and Screener collected specimens for cytology (and high-risk human papillomavirus testing for sub-sample)
3051354|NCT00702221|Experimental|ATV with CoVaccine HT™|Angiotensin Therapeutic Vaccine with CoVaccine HT™ adjuvant (an ingredient that may improve the immune response of the vaccine)
3051355|NCT00702221|Placebo Comparator|CoVaccine HT™ adjuvant alone|CoVaccine HT™ adjuvant alone
3051356|NCT00702234||Women/Expectant Mothers - Corifollitropin Alfa 150 µg|In base study P05714 (NCT00696878), up to 3 COS cycles were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of Gonadotropin Releasing Hormone (GnRH) antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin ([rec]hCG) (5,000-10,000 IU/250 µg). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone was administered for luteal phase support. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur. Participants with confirmed pregnancy at least 10 weeks after fresh embryo transfer in the base study were eligible for this follow-up study. In this follow-up study P05715, no study drugs were administered.
3051357|NCT00702273||150 µg Corifollitropin Alfa|Participants from the base study P05787 (NCT00696800), received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa (Org 36286) on menstrual cycle Day 2/3 (Day 1); 7 daily SC injections from Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG). Daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of oocyte pick up (OPU) daily doses of progesterone were started, for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
3051358|NCT00702273||200 IU RecFSH|Participants from the base study P05787 (NCT00696800), received a single SC injection of placebo Corifollitropin Alfa on menstrual cycle day 2/3 (Day 1); 7 daily SC injections with 200 IU recFSH from Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG. Multiple daily SC injections of Ganirelix were given from Day 5 to the day of hCG; at which time a single dose of hCG was given when 3 follicles >= 17 mm. On the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the base study were enrolled in follow up study P05716, where no study treatments were given, and embryos obtained in the base study underwent FTET cycles.
3051359|NCT00702299|Experimental|Receiving Treatment|Dose escalation of day 1 i.p. pemetrexed disodium accrued three patients to each of five dose levels (60-1,000 mg/m2), along with day 2 i.p. cisplatin (75 mg/m2) and day 8 i.p. paclitaxel (60 mg/m2) with a biologic sample preservation procedure
3051360|NCT00702325|Experimental|1|
3051361|NCT00702325|Active Comparator|2|
3051362|NCT00702338||corifollitropin alfa + recFSH Mothers|Eligible participants in Stage 1a of base study P05693 (NCT00697255) were administered injection(s) with subcutaneous (SC) corifollitropin alfa (15mcg) and daily SC injections with recFSH (50 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then to be followed for safety and efficacy on the current follow-up (FU) study (P05713) according to standard practice (no treatment administered).
3051363|NCT00702338||corifollitropin alfa + hCG Mothers|Eligible participants in Stage 1b of base study P05693 (NCT00697255) were administered injection(s) with SC corifollitropin alfa (30 mcg) and daily SC injections with hCG (200 IU) when the largest follicle reached a size of ≥12 mm. A bolus injection of hCG (5000 IU) was then administered if at least one follicle was ≥18 mm and in total no more than two follicles ≥15 mm were observed. Eligible mothers in this group with an ongoing pregnancy established in the base study (confirmed at ≥10 weeks after hCG bolus injection) were then followed for safety and efficacy on the current FU study (P05713) according to standard practice (no treatment administered).
3051364|NCT00702364|Experimental|Atomoxetine|40mg atomoxetine twice a day for 2 weeks
3051365|NCT00702364|Placebo Comparator|placebo|Placebo twice a day for two weeks
3051366|NCT00702377|Experimental|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops
3051367|NCT00702377|Active Comparator|OPTIVE|OPTIVE Lubricant Eye Drops
3051368|NCT00702403|Experimental|Treatment (prophylactic inhibition of BCR-ABL tyrosine kinase)|"Beginning after engraftment and blood count recovery (21 to 28 days after allogeneic stem cell transplant), patients with imatinib-sensitive leukemia receive imatinib mesylate PO QD until day 80 and then nilotinib PO BID on days 81-445. Patients with imatinib-resistant leukemia receive nilotinib PO BID beginning after engraftment and blood count recovery until day 445.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3051369|NCT00702468|Experimental|Sativex|Sativex
3051370|NCT00702468|Placebo Comparator|Placebo|Placebo
3051371|NCT00702507|Active Comparator|Miconazole Nitrate|
3051372|NCT00702520||Corifollitropin alpha 100 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily subcutaneous (SC) injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous luteinizing hormone (LH) and follicle stimulating hormone (FSH) was confirmed by estradiol (E2) and progesterone (P) measurements, a single dose of corifollitropin alpha 100 μg was administered in participants weighing <= 60 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recombinant follicle stimulating hormone (recFSH) injections (maximally 200 IU) up to and including the day of administration of human chorionic gonadotprophin (hCG). No study medications were administered in the present P05783 study (38834, NCT00702520).
3132894|NCT03463941|Experimental|African American church members|
3179049|NCT00668512|Experimental|Antimelanoma injection-GSL alpha-Gal|Intervention consists of injection of a single melanoma metastasis with two injections of GSL alpha-Gal separated by four weeks. Both injections done with the same dose of GSL alpha-GAL each time. Phase 1 dose escalating scheme: 0.1mg, 1 mg, 10mg
3179050|NCT00668551||1|Telemedicine care
3179051|NCT00668551||2|Standard of care
3179052|NCT00668590|Experimental|1|
3051373|NCT00702520||Corifollitropin alpha 150 ug|In the base study (P05788, 38833, NCT00702351), participants were pre-treated with daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase). After suppression of endogenous LH and FSH was confirmed by E2 and P measurements, a single dose of corifollitropin alpha 150 μg was administered in participants weighing >= 50 kg. From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG. No study medications were administered in the present P05783 study (38834, NCT00702520).
3051374|NCT00702546||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. But in base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3051375|NCT00702546||recFSH 150 IU|In this follow-up study, no medication or investigational product was administered. However, in base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3051376|NCT00702624||Corifollitropin alfa 100 μg|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants received single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants in base study P05690 also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3051377|NCT00702624||recFSH 150 IU|In follow-up study, no medication or investigational product was administered. In base study P05690 (NCT00702845), participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3051378|NCT00702650|Experimental|Testosterone MD-Lotion|"Participants received Testosterone Metered Dose (MD)-Lotion for 120 days. Participants started by receiving 3.0 mL (60 mg) of 2% Testosterone MD-Lotion, and based upon restoration to eugonadal levels, may have had their dose of testosterone adjusted upwards or downwards on Days 45 and 90.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 1 dose to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg) of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla).~6.0 mL (120 mg) of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
3051379|NCT00702689|Experimental|Imatinib mesylate in patients with cGVHD|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
3051380|NCT00702715|Experimental|Participants with severe renal impairment|Participants with severe renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Severe renal impairment was defined as creatinine clearance <30mL/min.
3051381|NCT00702715|Active Comparator|Participants with normal renal function|Participants with normal renal impairment will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC. Normal renal function was defined as creatinine clearance >=80mL/min.
3051382|NCT00702780|Experimental|Escitalopram|Escitalopram 20mg tablet by mouth once a day
3051383|NCT00702780|Placebo Comparator|Placebo|Placebo 20mg tablet by mouth once a day
3051384|NCT00702845|Experimental|corifollitropin alfa 100 µg|Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular [IM] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
3179053|NCT00668590|Active Comparator|2|
3179054|NCT00668603|Experimental|2|Postmenopausal women with severe vasomotor symptoms
3051385|NCT00702845|Active Comparator|recFSH 150 IU|Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.
3051386|NCT00702884|Experimental|Sunitinib|Sunitinib 37.5 mg daily for a 4 week cycle
3051387|NCT00702923|Experimental|1|Bicalutamide 150mg orally days 1-28 followed by CP-675,206 IV on day 29. Cycle is repeated once at month 3
3051388|NCT00702949|Experimental|Pregabalin75|Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
3051389|NCT00702949|Experimental|Pregabalin150|Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
3051390|NCT00702949|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 6 weeks.
3051391|NCT00703014||Mothers Corifollitropin Alfa 150 µg|Participants from the Base Trial P05787 who received a single subcutaneous (SC) injection of 150 µg Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections from Stimulation Days 1 to 7 with placebo-recombinant Follicle Stimulating Hormone (recFSH); followed by daily SC injections with 200 IU recFSH up to the day of human chorionogonadotropin (hCG); multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of oocyte pick up (OPU) daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
3051392|NCT00703014||Mothers recFSH 200 IU|Participants from the Base Trial P05787 who received a single SC injection of placebo Corifollitropin Alfa on day 2 or 3 of the menstrual cycle (Stimulation Day 1); 7 daily SC injections with 200 IU recFSH from Stimulation Days 1 to 7; followed by daily SC injections with 200 IU recFSH up to the day of hCG; multiple daily SC injections of Ganirelix from Stimulation Day 5 to the day of hCG; a single dose of hCG (5000 or 10,000 IU/USP) was administered when 3 follicles >= 17 mm were observed; and on the day of OPU daily doses of progesterone were started and continued for up to 6 weeks or menses. Eligible participants from the Base Trial were enrolled in Follow Up Trial P05712, where no study treatments were given, and pregnancy, delivery and neonatal outcome were monitored.
3051393|NCT00703053|Experimental|Group 1|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 7, A/Vietnam/04 90 mcg.
3051394|NCT00703053|Experimental|Group 9|100 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Vietnam/04 90 mcg.
3051395|NCT00703053|Experimental|Group 8|100 subjects: Day 0, A/Vietnam/04 90 mcg.
3051396|NCT00703053|Experimental|Group 7|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 180, A/Indonesia/05 90 mcg.
3051397|NCT00703053|Experimental|Group 6|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 180, A/Indonesia/05 90 mcg.
3051398|NCT00703053|Experimental|Group 5|50 subjects: Day 0, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg; Day 28, A/Vietnam/04 45 mcg + A/Indonesia/05 45 mcg.
3051399|NCT00703053|Experimental|Group 4|50 subjects: Day 0, A/Vietnam/04 90 mcg; Day 28, A/Indonesia/05 90 mcg.
3051400|NCT00703053|Experimental|Group 3|50 subjects: Day 0, A/Indonesia/05 90 mcg; Day 28, A/Indonesia/05 90 mcg.
3051401|NCT00703053|Experimental|Group 2|25 subjects: Day 0, A/Vietnam/04 90 mcg; Day 14, A/Vietnam/04 90 mcg.
3051402|NCT00703118|Experimental|Group A: T12/PR48|Participants will receive 12 weeks of 750 mg telaprevir eight hourly followed by 4 weeks of Placebo in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
3051403|NCT00703118|Experimental|Group B: T12(DS)/PR48|Participants will receive 4 weeks of Placebo followed by 12 weeks of 750 mg telaprevir eight hourly in combination with 48 weeks of Peg-IFN-alfa-2a and ribavirin at standard doses.
3051404|NCT00703118|Experimental|Group C: Pbo/PR48|Participants will receive placebo in combination with Peg- IFN-alfa-2a and ribavirin for 16 weeks. Participants will receive Peg- IFN-alfa-2a and ribavirin for next 32 weeks.
3051405|NCT00703157|Active Comparator|1|Arm 1: Catheter Ablation
3051406|NCT00703157|Active Comparator|2|Arm 2: Surgical Ablation.
3051407|NCT00703261|Active Comparator|10 mg Atorvastatin|10 mg atorvastatin + placebo
3051408|NCT00703261|Active Comparator|80 mg Atorvastatin|80 mg atorvastatin + placebo
3051411|NCT00703391|Experimental|1|Active Treatment
3051412|NCT00703391|Placebo Comparator|2|Placebo Treatment
3051413|NCT00703508|Experimental|Metformin|Metformin tablet, 500 mg/tablet, 2 tablets every twelve hours, 9 months duration
3051414|NCT00703664|Experimental|Treatment (vorinostat, bortezomib)|"Participants receive vorinostat orally (PO) once daily (QD) on days 1-5 and 8-12. Participants also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Vorinostat precedes bortezomib on days of concurrent administration. Courses repeat every 3 weeks in the absence of disease progression - or unacceptable toxicity. After completion of study therapy, participants are followed periodically.~Treatment arm consists of 3 cohorts, all receiving the same treatment:~A: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~B: Mantle Cell Lymphoma (MCL) - with no prior bortezomib.~C: Diffuse Large B-Cell Lymphoma (DLBCL) - with no prior bortezomib."
3051415|NCT00703677|Other|1|All participants will receive lithium. The dosage will be titrated over a 5-week period. Participants will then be followed prospectively for 6 months. Participants will be evaluated at the screening visit, baseline visit, and weeks 2 and 5 during the titration phase. Clinic study visits will then occur on alternate months through week 28. Telephone visits will occur between clinic study visits.
3051416|NCT00703729|Experimental|Cold Compression (CC)|The Game Ready device provides both active, continuous cold and intermittent, pneumatic compression to the post-op shoulder. The first group will use the Game Ready™ Device (CC) for one week following surgery and will use standard ice bags wrapped to the shoulder (IW) for the remainder of the study period.
3179055|NCT00668603|Experimental|1|Postmenopausal women without vasomotor symptoms
3179056|NCT00668616|Active Comparator|1|
3051417|NCT00703729|Active Comparator|Ice Wrap (IW)|The ice bag (IW)is secured to the shoulder using an elastic wrap. The second group will use standard ice bags wrapped to the shoulder (IW) for one week following surgery and will use the Game Ready™ Device (CC) for the remainder of the study period
3051418|NCT00703781|Experimental|Bromfenac|Bromfenac Ophthalmic Solution 0.09%, Dosed 1 Drop Daily
3051419|NCT00703781|Placebo Comparator|Placebo|Placebo, Dosed 1 Drop Daily
3051420|NCT00703820|Active Comparator|ADE|"Cytarabine + Daunorubicin + Etoposide~NK cells for infusion are prepared using the CliniMACS System."
3051421|NCT00703820|Active Comparator|Clo/AraC|"Clofarabine + Cytarabine~NK cells for infusion are prepared using the CliniMACS System."
3051422|NCT00703846|Other|KETOCONAZOLE|
3051423|NCT00703911||activated recombinant human factor VII|Male patients above 2 years of age with haemophilia A or B who have developed inhibitors and have been prescribed on-demand treatment of activated recombinant human factor VII at any dose for treatment of mild to moderate spontaneous bleeds
3051424|NCT00703924|Experimental|WR 279,396|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin
3051425|NCT00703924|Placebo Comparator|Placebo|Topical cream vehicle containing all of the components in WR 279,396 except the active ingredients.
3051426|NCT00703937|Experimental|Ferric Carboxymaltose (FCM)|750 mg of iron as undiluted FCM (15 mg/kg up to a maximum of 750 mg) at 100 mg per minute weekly until the calculated iron deficit dose has been administered (to a maximum cumulative dose of 2,250 mg).
3051427|NCT00703937|Active Comparator|Standard Medical Care (SMC) for the treatment of IDA|SMC as determined by the Investigator for the treatment of iron deficiency anemia (IDA).
3051428|NCT00703963|Active Comparator|Usual Care|Subjects will be having their INR tested by their Primary Care Provider as often as their Care Provider dictates. This study phase is twelve weeks long beginning at the day of discharge from our hospital.
3051429|NCT00703963|Active Comparator|Patient Self Testing|Subjects will be testing their INR at home using an FDA approved device (INRatio monitor by Hemosense) reporting their results to Quality Assured Services (QAS) via an 800 phone number; their Primary Care Provider will receive a fax with the INR result. We ask this group of patients to test at minimum one time a week, additional testing as requested by their Primary Care Provider. This phase lasts twelve weeks, beginning on the day of discharge from our hospital.
3051430|NCT00703976|Active Comparator|Cetuximab, Pemetrexed and Radiation therapy|"Cetuximab, Pemetrexed and Radiation therapy Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks"
3051431|NCT00703976|Experimental|Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab|"Cetuximab, Pemetrexed, Radiation Therapy plus Bevacizumab Cetuximab: Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.~Pemetrexed: Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.~Radiation therapy: Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks Bevacizumab: Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy."
3051432|NCT00704028|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
3051433|NCT00704028|Active Comparator|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
3051434|NCT00704132|Experimental|sitagliptin|Participants randomized to this arm will be administered sitagliptin 100mg daily, for six weeks.
3051435|NCT00704132|Placebo Comparator|Placebo|Participants randomized to this arm will be administered matching placebo, daily for six weeks.
3051436|NCT00704171|Experimental|PleuraSeal|PleuraSeal Lung Sealant System
3051437|NCT00704171|Active Comparator|Standard of Care|Standard tissue closure techniques (control) - sutures or staples only
3051438|NCT00704184|Placebo Comparator|Placebo + Peg-IFN/Ribavirin|Participants took double-blind Placebo + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3051439|NCT00704184|Experimental|Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 300 mg twice daily (b.i.d.) + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3051440|NCT00704184|Experimental|Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3051441|NCT00704184|Experimental|Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3051442|NCT00704184|Experimental|Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin|Participants took double-blind Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin from Week 1 to Week 4, followed by open-label Peg-IFN/Ribavirin from Week 5 to Week 48.
3051443|NCT00704262|Experimental|Calcipotriol plus hydrocortisone (LEO 80190)|
3051444|NCT00704340|Experimental|1|"DuraSeal Dural Sealant System - FDA Approved Device:~The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel."
3051445|NCT00704340|Active Comparator|2|"Standard of Care (control):~Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator."
3051446|NCT00704353|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
3051447|NCT00704353|Active Comparator|Standard Medical Care|Per product label
3179057|NCT00668616|Experimental|2|
3051448|NCT00704379|Placebo Comparator|Placebo|Placebo will be given in a double blind fashion via an equal number of tablets (identical to the sertraline tablets) administered once daily.
3051449|NCT00704379|Experimental|Sertraline|Sertraline will be given in a double blind fashion via tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention.
3051450|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) twice daily (b.i.d.) and Peg-IFN 180 mcg injection once weekly for 24 weeks.
3051451|NCT00704405|Experimental|24-wk Vaniprevir 600 mg + 24-wk PBO + Peg-IFN/RBV|Vaniprevir 600 mg (total daily dose) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 24 weeks, followed by PBO and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for an additional 24 weeks.
3051452|NCT00704405|Experimental|48-wk Vaniprevir 300 mg + Peg-IFN/RBV|Vaniprevir 300 mg (total daily dose, taken once daily [q.d.]) and RBV (1000 mg or 1200 mg total daily dose based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3051453|NCT00704405|Experimental|48-wk Vaniprevir 600 mg + Peg-IFN/RBV|Vaniprevir 600 mg and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3051454|NCT00704405|Placebo Comparator|48-wk PBO + Peg-IFN/RBV|PBO and RBV (1000 mg or 1200 mg based on body weight) b.i.d. and Peg-IFN 180 mcg injection once weekly for 48 weeks.
3051455|NCT00704418|Experimental|Bromfenac|Bromfenac ophthalmic solution 0.09%, dosed 1 drop daily
3051456|NCT00704418|Placebo Comparator|Placebo|Placebo, dosed 1 drop daily
3051457|NCT00704522||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.
3051458|NCT00704535||Subjects with hypercholesterolemia|Subjects with hypercholesterolemia that are using Ezetimibe either alone or in combination with a statin
3051459|NCT00704717||All Treated Patients|All patients participating in the study.
3051460|NCT00704730|Experimental|1|
3051461|NCT00704730|Placebo Comparator|2|
3051462|NCT00704769||1|Children with a history of perennial allergic rhinitis
3051463|NCT00704808||Patients|Patients with newly diagnosed and operated glioblastoma multiforme.
3051464|NCT00704847|Active Comparator|1|SMC021 Oral Calcitonin
3051465|NCT00704847|Placebo Comparator|2|SMC021 Placebo
3051466|NCT00704912|Active Comparator|Lifestyle intervention|Orlistat/Meal Replacement/Lifestyle Modification
3051467|NCT00704912|Active Comparator|Oral Contraceptives (OCP)|Loestrin 1/20
3051468|NCT00704912|Active Comparator|Lifestyle/OCP Combined|Combination of treatments
3051469|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Melanoma/RCC|Patients with melanoma and renal cell cancer will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
3051470|NCT00704938|Experimental|anti-p53 TCR PBL + DC + IL-2: Other histology|Patients with other histologies, such as breast cancer, will receive anti-p53 T cell receptor (TCR) peripheral blood lymphocytes (PBL) + dendritic cells (DC) + interleukin-2 (IL-2)
3051471|NCT00704964||All participants|Each site will be evaluated by a site questionnaire and assigned as either a high or low participant management site. Participants are not randomized to a group. However, treatment completion rates will be evaluated based on the high vs low participant management sites.
3051472|NCT00705003|Experimental|Active Drug Combination|BCI-024: over-encapsulated Buspirone tablet 15 mg at bedtime(QD) and BCI-049: over-encapsulated Melatonin tablet 3 mg QD
3051473|NCT00705003|Active Comparator|BCI-024 (Buspirone)|BCI-024: over-encapsulated Buspirone 15 mg QD
3051474|NCT00705003|Placebo Comparator|Matching placebo|Placebo: 1 capsule QD
3051475|NCT00705016|Experimental|Cilengitide 2000 mg once weekly+Cetuximab+5-FU+Cisplatin|
3051476|NCT00705016|Experimental|Cilengitide 2000 mg twice weekly+Cetuximab+5-FU+Cisplatin|
3051477|NCT00705016|Active Comparator|Cetuximab+5-FU+Cisplatin|
3051478|NCT00705081||Not previously treated|subjects with hypercholesterolemia, who had never been treated with any cholesterol-lowering agent, and received the combination of ezetimibe 10 mg and a statin as initiation therapy
3051479|NCT00705081||Previously treated with statin|subjects with hypercholesterolemia, who were previously treated with a statin, and received ezetimibe 10 mg as add-on therapy
3051480|NCT00705107||All Treated Patients|All patients participating in the study
3051481|NCT00705133|Experimental|Treprostinil-treated|Patients with pulmonary fibrosis with an advanced pulmonary hypertension phenotype will be treated with parenteral treprostinil in an open-label fashion
3051482|NCT00705146|Active Comparator|Comfort Cool Splint|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks.
3051483|NCT00705146|Active Comparator|Hybrid Custom-made splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks.
3051484|NCT00705159|Experimental|Loteprednol etabonate and tobramycin|Drug: Zylet (loteprednol etabonate and tobramycin)
3051485|NCT00705159|Active Comparator|Loteprednol etabonate|Drug: Lotemax (loteprednol etabonate)
3051486|NCT00705159|Active Comparator|Tobramycin|Drug: Tobramycin
3051487|NCT00705159|Placebo Comparator|Vehicle|Vehicle of Zylet
3051488|NCT00705224||Patients with chronic hepatitis C|Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia.
3051489|NCT00705250|Experimental|1|bendamustine hcl 120mg/m^2
3051490|NCT00705263||Patients with chronic hepatitis C|Patients with chronic hepatitis C who are treated with the PegIntron pen plus Rebetol will answer questions on the patient questionnaire.
3051491|NCT00705289||RA Subjects/ Infliximab 3 mg/kg|Subjects with rheumatoid arthritis (RA) in whom treatment with infliximab is started for the first time, in line with current clinical practice (and thus consistent with the European Summary of Product Characteristics [SPC] of Remicade®).
3051492|NCT00705341|Active Comparator|Low dose fluticasone for phase 2|For people with asthma, fluticasone at 250 mcg per day; phase 2 of study
3051493|NCT00705341|Active Comparator|High dose fluticasone for phase 2|For people with asthma, fluticasone at 1000 mcg per day; phase 2 of study
3051494|NCT00705341|No Intervention|Nonasthmatic controls for phase 1|People without asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
3051495|NCT00705341|No Intervention|Asthmatic controls for phase 1|People with asthma will be enrolled to perform 1 methacholine challenge test in phase 1 of the study
3051496|NCT00705367|Placebo Comparator|Placebo|
3051497|NCT00705367|Active Comparator|Abatacept, 30 mg/kg|
3051498|NCT00705367|Other|Abatacept, 10 mg/kg|Open-label long-term extension phase
3051499|NCT00705406|Experimental|Peramivir 600 mg|600 mg peramivir administered as bilateral 2-mL intramuscular injection.
3051500|NCT00705406|Placebo Comparator|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
3051501|NCT00705432|Placebo Comparator|1. Placebo + PEG + RBV|PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3051502|NCT00705432|Experimental|2. Boceprevir + PEG + RBV - 24 Weeks (RGT)|"PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up."
3051503|NCT00705432|Experimental|3. Boceprevir + PEG + RBV - 44 Weeks|PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3051504|NCT00705484||Remicade Group|Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
3051505|NCT00705484||Standard Therapy Group|Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
3051506|NCT00705523|Active Comparator|1|
3051507|NCT00705523|Placebo Comparator|2|
3051508|NCT00705536|Active Comparator|Humalog first, then Humalog + rHuPH20|"Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days"
3051509|NCT00705536|Active Comparator|Humalog + rHuPH20 first, then Humalog|"Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog~A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days"
3051510|NCT00705536|Active Comparator|Humulin-R first, then Humulin-R + rHuPH20|"Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20)~A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days"
3051511|NCT00705536|Active Comparator|Humulin-R + rHuPH20 first, then Humulin-R|"Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R~A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days"
3051512|NCT00705575|Experimental|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|
3051513|NCT00705575|Active Comparator|Aliskiren (300 mg)|
3051514|NCT00705614||Remicade Group|Particpiants with no prior exposure to Remicade, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who start on Remicade will constitute the Remicade Group, regardless of whether they continue with Remicade or switch to another treatment.
3051515|NCT00705614||Standard Therapy Group|Participants who are being treated with standard therapy and are not adequately maintained and will be offered an alternative treatment that does not include Remicade. Standard therapy participants must not have previously received Remicade.
3051516|NCT00705614||Switched to Remicade Group|Participants who started in the Standard Therapy Group but switched over to Remicade sometime during the follow-up period. Participants who switch to Remicade are evaluated in the Standard Therapy group until the time of the switch and are evaluated in the Switched to Remicade group thereafter.
3051517|NCT00705653|Experimental|PG-11047|
3051518|NCT00705666||PegIntron as monotherapy or in combination with Ribavirin.|Adult participants with chronic hepatitis C treated with PegIntron as monotherapy or in combination with ribavirin.
3051519|NCT00705679|Experimental|1|TDF 300 mg tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
3051520|NCT00705679|Experimental|2|TDF placebo tablet taken orally once daily and one FTC 200 mg/TDF 300 mg tablet taken orally once daily for 12 to 36 months
3051521|NCT00705679|Experimental|3|TDF placebo tablet taken orally once daily and one FTC/TDF placebo tablet taken orally once daily for 12 to 36 months
3051522|NCT00705679|Experimental|4|Application of tenofovir 1% vaginal gel once daily
3051523|NCT00705679|Experimental|5|Application of tenofovir placebo gel once daily
3051524|NCT00705718|Experimental|Endurant Bifurcated arm|The Bifurcated arm includes subjects who have received a bifurcated device. The Endurant Stent Graft System Bifurcated device is administered to treat patients with an Abdominal Aortic Aneurysm.
3051525|NCT00705718|Experimental|Endurant AUI arm|The AUI arm includes subjects who have received an AUI device. The Endurant Stent Graft System AUI device is administered to treat patients with an Abdominal Aortic Aneurysm.
3051526|NCT00705757|Active Comparator|Lumigan|Patients assigned to Lumigan/bimatoprost one drop before bedtime (qhs) to affected eye(s)
3051527|NCT00705757|Active Comparator|Xalatan|Patients assigned to Xalatan/latanoprost one drop before bedtime (qhs) to affected eye(s)
3051528|NCT00705757|Active Comparator|Travatan|Patients assigned to Travatan/travoprost one drop before bedtime (qhs) to affected eye(s)
3051529|NCT00705783|Experimental|Aripiprazole depot|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 52 weeks.
3051530|NCT00705783|Placebo Comparator|Placebo depot|Patients received placebo intramuscularly every 28 days for 52 weeks.
3051531|NCT00705874|Experimental|1|CGC-11047 in combination with Gemcitabine
3051532|NCT00705874|Experimental|2|CGC-11047 in combination with Docetaxel
3051533|NCT00705874|Experimental|3|CGC-11047 in combination with Bevacizumab
3051534|NCT00705874|Experimental|4|CGC-11047 in combination with Erlotinib
3051535|NCT00705874|Experimental|5|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
3051536|NCT00705874|Experimental|6|CGC-11047 in combination with 5-Flurouracil / Leucovorin
3051537|NCT00705874|Experimental|7|CGC-11047 in combination with Sunitinib
3051538|NCT00705939|Experimental|Naive 30 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
3051539|NCT00705939|Experimental|Naive 60 Units/kg|Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)
3051540|NCT00705939|Experimental|Switchover|Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)
3051541|NCT00706030|Experimental|neratinib 160 mg + vinorelbine|neratinib 160 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3051542|NCT00706030|Experimental|neratinib 240 mg + vinorelbine|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3051543|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, No Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3051544|NCT00706030|Experimental|neratinib 240 mg + vinorelbine, Prior Lapatinib|neratinib 240 mg tablets administered daily by mouth, vinorelbine 25 mg/m^2 administered IV on day 1 and day 8 of 21 day cycle
3051545|NCT00706095|Experimental|E7389 1.4 mg/m^2|
3051546|NCT00706095|Experimental|E7389 1.1 mg/m^2|
3051547|NCT00706095|Experimental|E7839 0.7 mg/m^2|
3051548|NCT00706121|Experimental|Vitamin E + selenium placebo|Vitamin E and selenium placebo daily for 7 - 12 years
3051549|NCT00706121|Experimental|Selenium + vitamin E placebo|Selenium and vitamin E placebo daily for 7 - 12 years
3051550|NCT00706121|Experimental|Vitamin E + selenium|Vitamin E and selenium daily for 7 - 12 years
3051551|NCT00706121|Placebo Comparator|Vitamin E placebo + selenium placebo|Vitamin E placebo and selenium placebo daily for 7 - 12 years
3051552|NCT00706134|Placebo Comparator|Placebo|
3051553|NCT00706134|Experimental|Aliskiren 75 mg|
3051554|NCT00706134|Experimental|Aliskiren 150 mg|
3051555|NCT00706134|Experimental|Aliskiren 300 mg|
3051556|NCT00706238|Experimental|GSK1203486A Group|"Patients received 4 cycles of MAGE-A3 product as follows:~Cycle 1: 6 doses, each given at a 2-week interval,~Cycle 2: 6 doses, each given at a 3-week interval~Cycle 3: 4 doses, each given at a 6-week interval~Cycle 4: 4 doses, each given at a 3-month interval followed by 4 doses, each given at a 6-month interval.~The MAGE-A3 product was administered intramuscularly in the deltoid or lateral regions of the thighs, alternately on the right and left sides."
3051557|NCT00706264|No Intervention|1|Expectant management
3051558|NCT00706264|Experimental|2|Placement of arabin pessary since 23 weeks until 37 weeks
3051559|NCT00706342|Experimental|1|
3051560|NCT00706355|Experimental|1|
3051561|NCT00706381|Experimental|1: Carb meal, fat meal, sincalide, placebo, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, and IV placebo + PO Ursodiol 15mg/kg day 5
3051562|NCT00706381|Experimental|2: Fat meal, carb meal, sincalide, placebo, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV sincalide 0.04mcg/kg + PO placebo day 3, IV placebo + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
3051563|NCT00706381|Experimental|3: Carb meal, fat meal, placebo, sincalide, urso|Participants randomized to consume a 100% carbohydrate meal day 1, then a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, then IV placebo + PO Ursodiol 15mg/kg day 5
3051564|NCT00706381|Experimental|4: Fat meal, carb meal, placebo, sincalide, urso|Participants randomized to consume a high fat (72% fat, 8% protein, 20% carbohydrate) meal day 1, then a 100% carbohydrate meal day 2, IV placebo + PO placebo day 3, IV sincalide 0.04mcg/kg + PO placebo day 4, the IV placebo + PO Ursodiol 15mg/kg day 5
3051565|NCT00706394|Experimental|A|Powerlink 34mm cuff stent graft
3051566|NCT00706407|Experimental|Fully integrated Uro-NIRS:UDS|
3051567|NCT00706433|Active Comparator|ALA 1000 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
3051568|NCT00706433|Active Comparator|ALA 500 seconds|Aminolevulinic acid HCL (ALA) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes and 20 seconds)
3051569|NCT00706433|Placebo Comparator|Vehicle 1000 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 1000 seconds (16 minutes and 40 seconds)
3051570|NCT00706433|Placebo Comparator|Vehicle 500 seconds|Vehicle (VEH) applied to the entire facial area 45 minutes prior to BLUE light treatment for 500 seconds (8 minutes 20 seconds)
3051571|NCT00706446|Experimental|1 - Tio/ICS in the Arg/Arg genotype|Tiotropium bromide 18 mcg qd plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
3051572|NCT00706446|Experimental|2 - Tio/ICS in the Arg/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
3051573|NCT00706446|Experimental|3 - Tio/ICS in the Gly/Gly genotype|Tiotropium bromide 18 mcg QD plus inhaled steroids, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly/Gly genotype
3051574|NCT00706446|Active Comparator|4 - LABA/ICS in the Arg/Arg genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Arg genotype
3051575|NCT00706446|Active Comparator|5 - LABA/ICS in the Arg/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Arg/Gly genotype
3051576|NCT00706446|Active Comparator|6 - LABA/ICS in the Gly/Gly genotype|Salmeterol 50 mcg 1 puff BID or Formoterol 12mcg 1 puff BID plus inhaled steroid, either Fluticasone propionate Diskus 100 mcg 1 puff bid, Fluticasone propionate aerosol 44 mcg 2 puffs bid, Fluticasone propionate aerosol 110 mcg 2 puffs bid, Fluticasone propionate aerosol 220 mcg 2 puffs qd, Budesonide 90 mcg 2 puffs bid, or Budesonide 180 mcg 2 puffs bid, in the Gly-Gly genotype
3051577|NCT00706485|Experimental|Dural brachytherapy plaque|Patients undergoing spine tumor resection will undergo dural plaque brachytherapy.
3051578|NCT00706511|Experimental|Group with OSA|Obese men and pre-menopausal women with OSA will receive 6 weeks of CPAP treatment, and assessed with a 3-day experimental protocol.
3051579|NCT00706511|No Intervention|Group without OSA|Obese men and pre-menopausal women without OSA will be characterized with a single 3-day experimental protocol
3051580|NCT00706550|Other|Immediate|"Arm 1 will receive PV (23-valent pneumococcal polysaccharide vaccine) prior to starting antiretroviral treatment and will receive PLACEBO after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
3051581|NCT00706550|Other|Delayed|"Arm 2 will receive PLACEBO prior to starting antiretroviral treatment and will receive PV (23-valent pneumococcal polysaccharide vaccine) after at least 6 months of starting antiretroviral treatment.~PV (23-valent pneumococcal polysaccharide vaccine): Currently commercially available pneumococcal polysaccharide vaccine"
3051582|NCT00706563|Experimental|Fluarix Adult Group|Subjects who are 18-40 years of age received one dose of Fluarix™.
3051583|NCT00706563|Experimental|Fluarix Elderly Group|Subjects who are ≥ 60 years of age received one dose of Fluarix™.
3051584|NCT00706589|Experimental|1|Aripiprazole 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
3051585|NCT00706589|Placebo Comparator|2|Placebo 2mg,5mg,10mg,15mg,20mg orally administrated Once a day (Titration according to the protocol)
3051586|NCT00706641|Experimental|Experimental: Neoadjuvant Dasatinib + Radical Cystectomy|Dasatinib 100 mg PO qd x 4 weeks followed by radical cystectomy 8-24 hours post last administered dasatinib dose
3051587|NCT00706654|Experimental|Aripiprazole depot 300 or 400 mg|Patients received aripiprazole 300 mg or 400 mg depot intramuscularly every 28 days for 38 weeks.
3051588|NCT00706654|Active Comparator|Aripiprazole 10-30 mg orally|Patients received aripiprazole 10-30 mg orally daily for 38 weeks.
3051589|NCT00706654|Experimental|Aripiprazole depot 25 or 50 mg|Patients received aripiprazole 25 mg or 50 mg depot intramuscularly every 28 days for 38 weeks.
3051590|NCT00706706|Experimental|sunitinib|single agent sunitinib, single arm
3051591|NCT00706719|Experimental|25 mg Androxal no wash out|1 capsule daily for 6 months of 25 mg of Androxal in men without a 3 month wash out period
3051592|NCT00706719|Active Comparator|Testim 1% (topical testosterone)|Testim 1% Gel applied topically for 6 months
3051593|NCT00706719|Experimental|25 mg Androxal wash out|1 x 25 mg Androxal capsule daily for 6 months in men with a previous 3 month washout period of topical testosterone
3051594|NCT00706784|Experimental|A|
3051595|NCT00706810|Experimental|All participants|
3051596|NCT00706823|Experimental|i-gel-SGA|Patients who received i-gel supraglottic device (i-gel airway) for intubation
3051597|NCT00706823|Active Comparator|LMA-Unique|Patients who received the Laryngeal Mask Airway-Unique (uLMA) for intubation
3051598|NCT00706836|Active Comparator|Pregabalin 50 mg|Pregabalin oral tablets (50 mg)
3051599|NCT00706836|Active Comparator|Pregabalin 200 mg|Pregabalin oral tablets (200 mg)
3051600|NCT00706836|Placebo Comparator|Placebo|Placebo
3051601|NCT00706849|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3051602|NCT00706849|Placebo Comparator|Placebo|Participants received a placebo subcutaneous injection once a week for 26 weeks.
3051603|NCT00706901|Experimental|Arm 1 GMI|Patients randomized to GMI received four structured 75-minute sessions consistent with the central principles and style of motivational interviewing (Miller & Rollnick, 2012). The goal of MI is to develop a sense of discrepancy between personal goals and current behavior and enhance change talk among participants, particularly for taking responsibility of one's substance use and being proactive for remaining in treatment.
3179058|NCT00668642|Experimental|A: Dutasteride During First Off-Cycle|Arm A patients received dutasteride (0.5 mg/day) during the first off-cycle and received placebo during the second off-cycle
3179059|NCT00668642|Placebo Comparator|B: Placebo During First Off-Cycle|Arm B patients received placebo during the first off-cycle and received dutasteride (0.5 mg/day) during the second off-cycle
3179060|NCT00668655||1|Female Subjects aged 20 to 75 inclusive, with a diagnosis of moderate (Global Severity Score of 3) Rosacea
3179061|NCT00668681|Active Comparator|Endorefix|Evaluation of EndoRefix Endovascular Delivery System and Staple
3051604|NCT00706901|Experimental|Arm 2 IHMD|Participants randomized to In-Home-Messaging Devices (IHMD) received a 27-day Care Coordination Home Telehealth (CCHT) program targeting their acute recovery from alcohol and other substance use disorder. Participants received their IHMD device through the Charleston VAMC CCHT program, including device accessories and a phone number to reach their CCHT provider. They were provided with specific instructions on how to set up their IHMD in their residence after discharge. The research associate followed-up with the patient one day after receiving the device to ensure that the device was successfully set up and to provide assistance as necessary. Participants received standard VA CCHT services.
3051605|NCT00706901|Active Comparator|Arm 3 TCC|Participants randomized to the Treatment Control Condition (TCC) received a psycho-educational group (e.g., addiction as a chronic disease, relapse prevention, developing a plan to prevent relapse) that was delivered with the aid of sequential standardized PowerPoint presentations. Group members were encouraged to ask questions and make comments. Therapists were encouraged to conduct the sessions using an instructional quality that minimized the use of GMI strategies. TCC consisted of four sessions, lasting 75 minutes, and was conducted on four consecutive days within the course of one week.
3051606|NCT00706914|Experimental|Once-daily aclidinium/formoterol|Aclidinium bromide 200 µg/ formoterol fumarate 12 µg fixed-dose combination (FDC) once-daily in the morning, plus placebo once-daily in the evening
3051607|NCT00706914|Experimental|Morning aclidinium/formoterol plus evening formoterol|Aclidinium bromide 200 µg/formoterol fumarate 12 µg FDC once-daily in the morning, plus formoterol fumarate 12µg once-daily in the evening
3051608|NCT00706914|Active Comparator|Formoterol BID|Formoterol fumarate 12 µg twice-daily (BID)
3051609|NCT00706966|Experimental|Dutasteride|Dutasteride was administered at a dose of 3.5 mg as an oral soft gelatin capsule once daily for 6 months
3051610|NCT00706979|Experimental|1|Practice Quit Attempt plus Nicotine Replacement Therapy
3051611|NCT00706979|Active Comparator|2|Practice Quit Attempt only
3051612|NCT00706992|Experimental|Arm I - Adj-4 A2 F5 cells|Patients receive anti-MART-1 F5 TCR-transduced peripheral blood lymphocytes (PBLs) intravenously (IV) over 20-30 minutes on day 0. 1 x 10e9 to 5 x 10e10 IV.
3051613|NCT00706992|Experimental|Arm II-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 subcutaneously (SC) on days 0 and 30. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously.
3051614|NCT00706992|Experimental|Arm III-Adj-4 A2 F5 cells + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
3051615|NCT00706992|Experimental|Arm IV-Adj-4 A2 F5 cells + MART-1:26-35(27L) Peptide+SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I, MART-1:26-35(27L) peptide vaccine emulsified in Montanide ISA-51 as in arm II, and aldesleukin as in arm III. 1 x 10e9 to 5 x 10e10 IV + 1.0 mg peptide subcutaneously + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.
3051616|NCT00706992|Experimental|Arm V-Adj-4 A2 F5 cells + ALVAC MART-1:26-35(27L) Vaccine|Patients receive anti-MART-1 F5 TCR-transduced PBLs IV over 20-30 minutes on day 0, and ALVAC-MART-1 vaccine SC on days 0 and 14. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
3051617|NCT00706992|Experimental|Arm VI-Adj-4 A2 F5 cells + ALVAC MART-1 VAccine + SQ IL-2|Patients receive anti-MART-1 F5 TCR-transduced PBLs and ALVAC-MART-1 vaccine as in arm V, and low-dose aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL)+ 125,000 IU/kg/day subcutaneously.
3051618|NCT00706992|Experimental|Arm VII-Adj-4 A2 ALVAC MART-1:26-35(27L) Vaccine|Patients receive ALVAC-MART-1 vaccine SC on days 0 and 14. ALVAC vaccine 0.5 ml containing target dose of 10e7 CCID50 (with a range of approximately 10^6.4 to 10^7.9/mL subcutaneously (total of 4 x 10e7 CCID50/2 mL).
3051619|NCT00707031|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3051620|NCT00707031|Active Comparator|Exenatide|1-step initiation regimen of exenatide: 5 mcg twice daily (BID) for 4 weeks, followed by 10 mcg BID up to the end of treatment.
3051621|NCT00707057|Experimental|Ibuprofen 600 mg ER group|One-hundred and sixty subjects will be randomly assigned to the Ibuprofen 600 mg ER treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
3051622|NCT00707057|Placebo Comparator|Placebo group|Eighty subjects will be randomly assigned to the Placebo treatment group based on gender and baseline pain intensity, as rated on an 11-point numerical rating scale (PI-NRS; 5-7 moderate pain, or 8-10, severe pain).
3051623|NCT00707174|Active Comparator|1|"Topical imiquimod group:~treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site."
3051624|NCT00707174|Experimental|2|"Topical imiquimod and topical tazarotene 0.1% cream group:~Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week."
3051625|NCT00707239|Experimental|A|
3051626|NCT00707239|Experimental|B|
3051627|NCT00707239|Active Comparator|C|
3051628|NCT00707343|Experimental|All patients|All participants enrolled.
3051629|NCT00707447|Placebo Comparator|1/Control|Control group received written information about diabetes risks with instructions about healthy eating and increasing physical exercise
3051630|NCT00707447|Experimental|2/PREDIAS|Intervention consists of a group programme (PREDIAS) aiming at modification of lifestyle
3051631|NCT00707486|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
3179062|NCT00668694|No Intervention|1|Anemia without stimulation.
3051632|NCT00707486|Active Comparator|Gauze with pressure and/or Gelfoam|Post operative care for oral surgery subjects consists of the subject biting on sterile cotton gauze to provide pressure to the extraction site. A common alternative practice involves the placement of Gelfoam (with or without antibiotic/steroid medication) into the extraction socket prior to application of the sterile gauze pressure dressing. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard of care for oral surgery subjects, including the use of cotton gauze and/or Gelfoam to control post operative bleeding.
3051633|NCT00707577|Experimental|Internet-based maintenance program|9-month Internet based self-monitoring maintenance program to track weight, exercise, and food logs
3051634|NCT00707577|No Intervention|Control|No maintenance program provided
3051635|NCT00707655|Experimental|Zalutumumab 4 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
3051636|NCT00707655|Experimental|Zalutumumab 8 mg/kg|Zalutumumab in combination with radiotherapy for 8 weeks. The treatment period of 8 weeks is followed by a 3 week follow-up period where all adverse events are collected and then additionally a 2 year follow-up period where only serious adverse events are collected.
3051637|NCT00707746|Placebo Comparator|Placebo|1 mL placebo saline, weekly subcutaneous injections for 26 weeks
3051638|NCT00707746|Experimental|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
3051639|NCT00707759|Experimental|A: withdrawal steroids|"Arms A: TAC + MMF + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
3051640|NCT00707759|Active Comparator|B|"Arms B: TAC + MMF + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
3051641|NCT00707863|Other|Depressed Subjects Age: 18 - 25 yrs|Subjects receiving Escitalopram (trade name: Lexapro) that are in the age range of 18-25
3051642|NCT00707863|Other|Depressed Subjects Age: 16 - 50 yrs|Subjects receiving Escitalopram (trade name: Lexapro) in the age range of 26-50
3051643|NCT00707915|Experimental|Dose reduction|The benzodiazepine dose will be discontinued in 4 weeks by a weekly 25% reduction. Participants will be observed for 8 weeks.
3051644|NCT00707954|Experimental|TA-7284|
3051645|NCT00707954|Placebo Comparator|Placebo of TA-7284|
3051646|NCT00707967|Experimental|Group A|Subjects receiving the candidate vaccine
3051647|NCT00707967|Placebo Comparator|Group B|Subjects receiving the adjuvant
3051648|NCT00707967|Placebo Comparator|Group C|Subjects receiving physiological saline
3051649|NCT00707980|Experimental|Vortioxetine|Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.
3051650|NCT00707993|Experimental|Alogliptin 25 mg QD|
3051651|NCT00707993|Active Comparator|Glipizide 5 mg QD|
3051652|NCT00708019|Experimental|Low dose|Low dose of the psychoeducational intervention (i.e., 8.0 hours with the intervention nurse over 10 weeks)
3051653|NCT00708019|Experimental|High dose|High dose of the psychoeducational intervention (i.e., 12.3 hours with the intervention nurse over 10 weeks)
3051654|NCT00708032|Other|spectacles|habitual spectacles worn daily for 12 months
3051655|NCT00708032|Experimental|narafilcon A soft contact lenses|narafilcon A soft contact lenses worn as daily disposable for 12 months
3051656|NCT00708071|Experimental|1|One side of the face is treated with FS VH S/D 4; the other side of the face is treated using standard of care.
3051657|NCT00708097|Experimental|NaF toothpaste(1450 ppmF)|Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.
3051658|NCT00708097|Active Comparator|NaF toothpaste (1400 ppmF)|Study toothpaste containing 1400 ppm F as NaF
3051659|NCT00708097|Active Comparator|NaMFP/NaF toothpaste (1450 ppmF)|Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF
3051660|NCT00708097|Active Comparator|NaF toothpaste (675 ppmF)|Study toothpaste containing 675 ppm F as NaF
3051661|NCT00708097|Placebo Comparator|Placebo toothpaste (0 ppmF)|Fluoride free placebo toothpaste (0 ppm F)
3051662|NCT00708110|Experimental|Treatment A|GSK1349572 2 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3051663|NCT00708110|Experimental|Treatment B|GSK1349572 10 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3051664|NCT00708110|Experimental|Treatment C|GSK1349572 50 mg or placebo every 24 hours for 10 days. Screening visit up to 30 days prior to first dose and follow-up for 11 days after last dose.
3051665|NCT00708123|Active Comparator|Sodium Fluoride (NaF) toothpaste[1350 parts per million(ppm)F]|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (1350 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3051666|NCT00708123|Experimental|NaF/Carbopol toothpaste (1400 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF and 0.5% carbopol toothpaste (1450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3051667|NCT00708123|Active Comparator|NaMFP/NaF toothpaste (1450 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaMFPand NaF toothpaste (1450 ppm F - 1000 ppm F as NaMFP and 450 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3051668|NCT00708123|Active Comparator|NaF toothpaste (250 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of NaF toothpaste (250 ppm F as NaF) for one timed minute, after removing their partial denture from their mouth.
3051669|NCT00708123|Placebo Comparator|Placebo toothpaste (0 ppm F)|Participants to brush their natural teeth twice daily with a full ribbon of fluoride free toothpaste (0 ppm F) for one timed minute, after removing their partial denture from their mouth.
3051670|NCT00708162|Experimental|Elvitegravir|"EVG 85 mg or 150 mg + RAL placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r) as part of their background regimen will receive EVG 85 mg; all other participants will receive EVG 150 mg."
3051671|NCT00708162|Active Comparator|Raltegravir|"RAL 800 mg (400 mg twice daily) + EVG placebo + background regimen in the Randomized Phase, followed by EVG 85 mg or 150 mg + background regimen in the Open-Label Phase.~Participants receiving LPV/r or ATV/r as part of their background regimen in the Open-Label Phase will receive EVG 85 mg; all other participants will receive EVG 150 mg."
3051672|NCT00708175|Experimental|Pioglitazone|
3051673|NCT00708175|Placebo Comparator|Placebo|
3051674|NCT00708201|Experimental|Alvimopan|"12 milligrams (mg)~Alvimopan, 12mg, capsule. Administered orally. One 30 minutes to 5 hours before the scheduled start of surgery on Day 0, and twice daily beginning on Postoperative Day 1 (POD 1) until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment"
3051675|NCT00708201|Placebo Comparator|Placebo|"300 mg polyethylene glycol in a capsule~Administered orally at least 30 minutes and no later than 5 hours before the scheduled start of surgery on Day 0. On Day 1, a single dose of placebo was given twice a day for a maximum of 7 days in hospital after surgery."
3051676|NCT00708214|Experimental|BIBW 2992|To study BIBW 2992 in association with letrozole in hormonoresistant metastatic breast cancer
3051677|NCT00708214|Other|Letrozole|Hormonotherapy for metastatic breast cancer
3051678|NCT00708227||Whites ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3051679|NCT00708227||Whites ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3051680|NCT00708227||African American ADRB2:ARG16ARG|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3051681|NCT00708227||African American ADRB2:GLY16GLY|All participants receive fluticasone for 2-weeks followed by fluticasone / salmeterol for 2-weeks at a dose commensurate with baseline inhaled corticosteroid dose. All participants receive ipratropium bromide for symptom rescue therapy.
3051682|NCT00708305|Experimental|NaF toothpaste (1450 parts per million [ppm] fluoride [F])|Participants brushed for one timed minute with 1.6g of NaF/silica and 0.4 percent carbopol toothpaste containing 1450ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3051683|NCT00708305|Active Comparator|NaF toothpaste (1400ppmF)|Participants brushed for one timed minute with 1.6g of NaF toothpaste containing 1400ppmF as NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3051684|NCT00708305|Active Comparator|Sodium monofluorophosphate (NaMFP)/ NaF toothpaste (1450ppmF))|Participants brushed for one timed minute with 1.6g of NaMFP/NaF toothpaste containing 1450ppmF from NaMFP and NaF. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3051685|NCT00708305|Placebo Comparator|Placebo toothpaste (0ppmF)|Participants brushed for one timed minute with 1.6g of fluoride free toothpaste. Participants then swished the slurry around their mouth for 10 seconds, expectorated, then rinsed with water for 10 seconds.
3051686|NCT00708422|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3051687|NCT00708422|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3051688|NCT00708435|Experimental|Beriplex® P/N|
3051689|NCT00708435|Active Comparator|Fresh frozen plasma|
3051690|NCT00708461|Experimental|Worksite Environmental Intervention|Changes to healthy food availability, physical activity opportunities and promotion, body weight scale access, and media enhancements to target weight gain prevention
3051691|NCT00708461|No Intervention|No-contact control|No-treatment control condition. Worksites were offered program materials upon completion of programs at intervention sites.
3051692|NCT00708500|Placebo Comparator|Placebo+PEG2b+RBV, x 44 weeks|Participants in Arm 1 (control) received pegylated interferon alfa 2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) for 4 weeks followed by boceprevir placebo + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3051693|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, Response Guided Therapy|"Participants in Arm 2 (experimental) were assigned either a 36-week or 48-week course of therapy based on their HCV-RNA status at Treatment Week 8.~PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 32 weeks, then:~36-week regimen: Participants who have undetectable HCV-RNA at Treatment Week 8 discontinue treatment and enter 36 weeks of post treatment follow-up.~48-week regimen: Participants who have detectable HCV-RNA at Treatment Week 8 are assigned an additional 12 weeks of therapy, followed by 24 weeks of post treatment follow-up. Placebo replaces boceprevir for the remaining 12 weeks of therapy, and this switch will occur in a blinded fashion."
3051694|NCT00708500|Experimental|Boceprevir+PEG2b+RBV, x 44 weeks|Participants in Arm 3 (experimental) received PEG2b + RBV (WBD) for 4 weeks followed by boceprevir + PEG2b + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
3051695|NCT00708526|Experimental|Phase 1 Recovery|Quick Emergence Device is in place for phase 1 anesthesia recovery
3051696|NCT00708526|Other|Standard of care|Tidal volume and respiratory rate are not changed during phase 1 recovery from anesthesia
3051697|NCT00708552|Experimental|SB-742457 - 15mg|SB-742457 - 15mg
3051698|NCT00708552|Placebo Comparator|Placebo|
3051699|NCT00708552|Experimental|SB-742457 - 35mg|SB-742457 - 35mg
3051700|NCT00708552|Active Comparator|Donepezil|
3051701|NCT00708643|Active Comparator|Habitual silicone hydrogel|Habitual contact lens wear.
3051702|NCT00708643|Experimental|narafilcon A|Silicone hydrogel daily disposable contact lens
3051703|NCT00708682|Experimental|A|
3051704|NCT00708708||A|Patients with moderate to severe plaque psoriasis
3051705|NCT00708721|Experimental|All patients|All participants enrolled.
3051706|NCT00708851|Active Comparator|NB-UVB Light Device (311-315 nm)|the subject will receive full body NB-UVB light therapy
3051707|NCT00708851|Experimental|LCD Solution with NB-UVB Phototherapy|on half of the body will receive LCD while the full body receives NB-UVB therapy
3051708|NCT00708877|Experimental|All participants|
3051709|NCT00708942|Active Comparator|1|HAL suppository (single administration, HAL 100mg), laser illumination (50J/cm2)
3051710|NCT00708942|Placebo Comparator|2|Placebo suppository (single administration), laser illumination (50J/cm2)
3051711|NCT00708942|No Intervention|3|
3051712|NCT00708942|Active Comparator|4|HAL ointment (5%, 100mg, single administration), LED diode illumination (50J/cm2)
3051713|NCT00708942|Placebo Comparator|5|Placebo ointment (single administration), no illumination
3051714|NCT00709059||PegIntron Plus Rebetol|Previously untreated patients infected with HCV genotype 1, 4, 5, or 6.
3051715|NCT00709098|Active Comparator|iloprost power 6|iloprost power 15
3051716|NCT00709098|Experimental|iloprost power 15|iloprost power 15
3051717|NCT00709111|Experimental|Maraviroc|Maraviroc (MVC) was taken for 24 weeks, in addition to the subject's current antiretroviral therapy (ART) drug regimen. At week 24, subjects discontinued MVC and were followed for an additional 24 weeks off MVC, but still on current ART drug regimen.
3051718|NCT00709124|Experimental|NMES|60 minute daily NMES sessions every day for the duration of subject's ICU stay.
3051719|NCT00709124|Sham Comparator|Sham|60 minute sham sessions every day for the duration of subjects ICU stay. No voltage will be applied to those receiving sham sessions.
3051720|NCT00709202|Active Comparator|1|Subjects assigned to this arm will receive Betahistine.
3051721|NCT00709202|Placebo Comparator|2|Subjects in this group will received placebo.
3051722|NCT00709228||PegIntron plus Rebetol|Those with chronic Hepatitis C infected with HCV LVL G1
3051723|NCT00709306|Placebo Comparator|Education|Participants were given a packet of standard skin cancer prevention educational brochures and handouts from major professional organizations to review independently for 10-15 minutes.
3051724|NCT00709306|Active Comparator|Motivational Interviewing|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. These sessions took about 22 minutes.
3051725|NCT00709306|Active Comparator|UV-detect photos|"Participants were shown a regular black and white photo and a black and white UV-filtered photo of their face. Participants were told that Any dark, spotted, freckled, wrinkled, uneven, or pitted areas indicate existing underlying skin damage that is difficult to reverse. However, protecting the skin from UV radiation can prevent future damage. Participants were asked what they noticed about the photos, what their reactions were, and how this might affect their behavior. These sessions took 12 minutes on average."
3051726|NCT00709306|Experimental|UV-detect photos & MI|Participants met with a trained counselor who reviewed any personalized feedback of risk derived from the baseline assessments (e.g., history of sunburns, self-reported UV exposure, protective behaviors). Counselors utilized the basic motivational interviewing skills of open-ended questions, reflection of participant statements, affirmations/positive feedback, and summation of major points throughout the discussion. In addition to baseline feedback, participants were also interviewed about the black & white and UV-filtered photos of their faces. These sessions took about 25 minutes.
3051727|NCT00709319||Primary|Subjects vitreomacular traction, visual acuity 20/63 to 20/400, retinal thickness >300 microns in the central subfield on OCT, and cataract extraction not being performed in conjunction with vitrectomy.
3051728|NCT00709592|Experimental|ATG 1.7 mg/kg, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 5.1 mg/kg in three divided doses (1.7 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive lower dose anti-thymocyte globulin IV on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
3051729|NCT00709592|Experimental|ATG 2.5 mg/kg/d, TBI, transplant|(Rabbit-ATG;Thymoglobulin,Genzyme) ATG 7.5 mg/kg in three divided doses (2.5 mg/kg/d) given over three days (day -9 to -7) followed by 450 cGy TBI and tacrolimus plus MMF GVHD prophylaxis. Patients receive higher dose anti-thymocyte globulin intravenously (IV) on days -9 to -7. Patients undergo total-body radiation (TBI) twice daily (BID) on day -1 and once daily (QD) on day 0. Patients then undergo peripheral blood stem cells or bone marrow transplant on day 0. GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: patients receive tacrolimus orally (PO) on days -2 to 90-120 with taper for 2 months, and mycophenolate mofetil (MMF) PO BID on days 0-30.
3051730|NCT00709696|Placebo Comparator|1|Placebo Varenicline
3051731|NCT00709696|Active Comparator|2|Varenicline
3051732|NCT00709722|Experimental|1|NKT-01
3051733|NCT00709735|Experimental|Reactivation Propranolol (RP)|"0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
3051734|NCT00709735|Active Comparator|Non-Reactivation Propranolol (NRP)|"0.67 mg/kg short-acting propranolol capsules then 1 mg/kg long-acting propranolol capsules 90 minutes later on Day 0 (non-reactivation) followed by 0.67 mg/kg short-acting placebo capsules then 1 mg/kg long-acting placebo capsules 90 minutes later on Day 2 (reactivation). All participants then underwent a script preparation session in which the investigator elicited five discrete personal memories, including two traumatic combat experiences."
3051735|NCT00709761|Experimental|Single Arm|Single arm combination therapy of Lap and NabPaclitaxel combination
3051736|NCT00709826|Experimental|apricoxib + gemcitabine + erlotinib|400mg apricoxib + 1000mg/m2 gemcitabine + 100mg erlotinib
3051737|NCT00709826|Placebo Comparator|placebo + gemcitabine + erlotinib|placebo + 1000mg/m2 gemcitabine + 100mg erlotinib
3179063|NCT00668694|Experimental|2|Anemia with stimulation
3051738|NCT00709852|Experimental|Gadobutrol then Gadoteridol|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous) in Period 1 and a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 2.
3051739|NCT00709852|Experimental|Gadoteridol then Gadobutrol|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v. in Period 1 and a single dose of gadobutrol 0.1 mmol/kg bw via i.v. in Period 2.
3051740|NCT00709878||L|Patients treated with lapatinib who developed skin toxicities and have been biopsied for skin rash.
3051741|NCT00709878||C|Patients treated with cetuximab who developed skin toxicities and have been biopsied for skin rash.
3051742|NCT00709878||P|Patients treated with panitumumab who developed skin toxicities and have been biopsied for skin rash.
3051743|NCT00709878||E|Patients treated with erlotinib who developed skin toxicities and have been biopsied for a skin rash.
3051744|NCT00709891|Experimental|cobas® 4800 HPV Test|The cobas 4800 human papillomavirus (HPV) Test combines in a single assay the identification of pooled high-risk oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), as well as genotypes 16 and 18 individually.
3051745|NCT00709956|Experimental|Active / placebo|Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3
3051746|NCT00709956|Placebo Comparator|Placebo / active|Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3
3051747|NCT00709995|Experimental|Part 1 Arm A: Enzastaurin + Sunitinib|"(Cohort 1): On cycle 1, day 1 a loading dose 125 milligram (mg) of Enzastaurin was administered by mouth orally, (BID) twice a day, followed by Enzastaurin 125 mg administered, twice a day, Days 2 through 42 of a 6-week cycle.~(Cohort 2): Cycle 1, Day 1 loading dose 375 mg of Enzastaurin administered po three times a day (TID), followed by 250 mg, po, BID continuously until disease progression, unacceptable toxicity, death, or discontinuation from the study for any other reason.~Sunitinib 50 mg was administered orally, once daily, Days 1-28, then rest (no drug given) days 29-42.~Phase 2 (Part 2): Randomized Double-Blind: Dosing was determined by Part 1. Part 2 was not activated per recommendation of safety review committee.~Enzastaurin: Cycle 1, Day 1 loading dose 375 mg administered orally, (TID) three times a day, followed by Part 1 dose twice a day on Days 2-42 of 6 week cycle.~Sunitinib: 50 mg administered orally, once daily, on Days 1-28, then rest Days 29-42."
3051748|NCT00709995|Placebo Comparator|Part 2 Arm B: Sunitinib + Placebo|"Part 2 was not activated per recommendation of safety review committee.~Sunitinib: 50 mg administered orally, once daily, Day 1-28, then rest Days 29-42.~Placebo: Cycle 1 Day 1 loading dose 3 tablets on Day 1, then 2 tablets daily, days 2-42."
3051749|NCT00710021|Experimental|vitamin D3 2000 IU|Participants in this arm take a vitamin D3 dose of 2000 international units (IU) daily by mouth for a duration of 12 weeks.
3051750|NCT00710021|Experimental|vitamin D3 4000 IU|Participants in this arm take a vitamin D3 dose of 4000 international units (IU) daily by mouth for a duration of 12 weeks.
3051751|NCT00710021|Placebo Comparator|vitamin D3 placebo|Participants in this arm take a vitamin D3 placebo daily by mouth for a duration of 12 weeks.
3051752|NCT00710034|Active Comparator|Nicotine Gum|Nicotine replacement therapy (4 mg nicotine gum) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute nicotine gum for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
3051753|NCT00710034|Experimental|Snus|Oral tobacco (Camel Snus) was provided to the participants for an 12 weeks. Participants were encouraged to completely substitute snus for cigarettes and asked to use at least 6-8 pieces a day or optimally every 1-2 h and more if necessary. They were advised to reduce consumption by half during weeks 7-9 and three-quarters during weeks 10-12.
3051754|NCT00710203|Active Comparator|Pulsed dye laser|Four lesions are selected on each subject for study. One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
3051755|NCT00710203|Active Comparator|Curettage|Four lesions are selected on each subject for study. A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
3051756|NCT00710203|Active Comparator|Electrodesiccation|Four lesions are selected on each subject for study. A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
3051757|NCT00710203|Active Comparator|No treatment|Four lesions are selected on each subject for study. A fourth lesion will not be treated and will serve as a control.
3051758|NCT00710385|Active Comparator|Heroin|Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051759|NCT00710385|Active Comparator|Naloxone|Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051760|NCT00710385|Experimental|Low Bup Dose|Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051761|NCT00710385|Experimental|Low Bup/Nal Dose|Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051762|NCT00710385|Experimental|High Bup Dose|Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051763|NCT00710385|Experimental|High Bup/Nal Dose|Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051764|NCT00710385|Placebo Comparator|Placebo|Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
3051765|NCT00710424|Experimental|Sativex|
3051766|NCT00710424|Placebo Comparator|Placebo|
3051767|NCT00710554|Experimental|Sativex|
3051768|NCT00710554|Placebo Comparator|Placebo|
3051769|NCT00710593|Active Comparator|A: HAART naive or no HAART in past 6 months|Participants who are ART naïve or, if ART-exposed, have not received highly active antiretroviral therapy (HAART) for at least the six months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
3051770|NCT00710593|Active Comparator|B: HAART atleast 6 months/ 2 viral loads <400 in last 6 months|Participants who have been receiving highly active antiretroviral therapy (HAART) for at least six months at the time of study entry, with two HIV-1 RNA plasma viral loads < 400 copies/ml on two previous clinical visits within the 6 months prior to study entry. All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
3051771|NCT00710606|Experimental|1- Obese Women /Nuvaring|Obese subjects (BMI 30-39.9)received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
3051772|NCT00710606|Active Comparator|2- Normal Weight / Nuvaring|Normal weight subjects (BMI 19-24.9) received two contraceptive hormonal rings. During the second cycle of ring use, subjects returned to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
3051773|NCT00710684|Experimental|DONEPEZIL + SB-742457 15 MG|SB-742457 - 15mg added to existing donepezil treatment
3051774|NCT00710684|Placebo Comparator|DONEPEZIL + PLACEBO|Placebo added to existing donepezil
3051775|NCT00710684|Experimental|DONEPEZIL + SB-742457 35 MG|SB-742457 - 35mg added to existing donepezil
3051776|NCT00710749|Experimental|Disposable device first, then Digital device|
3051777|NCT00710749|Experimental|Digital device first, then Disposable device|
3051778|NCT00710762|Experimental|BIBF1120|
3051779|NCT00710762|Placebo Comparator|Placebo|
3051780|NCT00710814|Experimental|Leptin - Placebo|Leptin self-administered subcutaneously twice each day for 16 weeks, then Placebo for 16 weeks.
3051781|NCT00710814|Placebo Comparator|Placebo - Leptin|Placebo self-administered subcutaneously twice each day for 16 weeks, then Leptin for 16 weeks.
3051782|NCT00710840|Experimental|1|
3051783|NCT00710840|Active Comparator|2|
3051784|NCT00710866|Experimental|1|2 doses 0.5mL VAXIGRIP® at months 0, 1
3051785|NCT00710866|Active Comparator|2|2 doses 0.25mL VAXIGRIP® at months 0, 1
3051786|NCT00710879|Experimental|Multipurpose Solution|Multi-purpose solution administered to adapted FDA group I soft contact lens wearers and FDA group IV soft contact lens wearers.
3051787|NCT00710905|Experimental|ReSTOR|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
3051788|NCT00710931|Experimental|ReSTOR +3 Multifocal Lens|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL)
3051789|NCT00710944|Experimental|Extraction Sockets|Immediate loading in extraction sockets.
3051790|NCT00710944|Experimental|Healed Ridges|Immediate loading in healed ridges.
3051791|NCT00710944|Experimental|Grafted Sites|Immediate loading of implants placed in grafted sites (four months healing after grafting).
3051792|NCT00710970|Experimental|Single Arm Receiving 25mg Tamoxifen|
3051793|NCT00710996||AcrySof Natural Intraocular Lens|"AcrySof Natural Intraocular Lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SN"
3051794|NCT00710996||AcrySof clear intraocular lens|"AcrySof clear intraocular lens (IOL) - Patients with previous bilateral implant of any Alcon lens model starting with the letters SA"
3051795|NCT00710996||Phakic patients|Phakic patients - Age matched patients who have not had cataract surgery
3051796|NCT00711009|Active Comparator|LPV/r + FTC/TDF|lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily
3051797|NCT00711009|Experimental|LPV/r + RAL|lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily
3051798|NCT00711022|Experimental|OsseoSpeed|
3051799|NCT00711100|Experimental|Camel Snus|Camel Snus (oral smokeless tobacco product). Dosage: 1.74-1.97 mg nicotine per portion.
3051800|NCT00711100|Experimental|Marlboro Snus|Marlboro Snus (oral smokeless tobacco product). Dosage: 0.14 - 0.38 mg nicotine per portion.
3051801|NCT00711100|Experimental|Stonewall|Stonewall (oral dissolvable tobacco product). Dosage: 0.28-0.57 mg nicotine per portion.
3051802|NCT00711100|Experimental|Ariva|Ariva (oral dissolvable tobacco product). Dosage: 0.24-0.25 mg nicotine per portion.
3051803|NCT00711100|Experimental|General Snus|General Snus (oral smokeless tobacco product); Dosage: 3.37 mg nicotine.
3051804|NCT00711113|Experimental|A|
3051805|NCT00711191|Experimental|single arm|
3051806|NCT00711243|Experimental|Cohort 1a|Docetaxel 25 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3051807|NCT00711243|Experimental|Cohort 2a|Docetaxel 30 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3051808|NCT00711243|Experimental|Cohort 3a|Docetaxel 40 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3051809|NCT00711243|Experimental|Cohort 4a|Docetaxel 50 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3051810|NCT00711243|Experimental|Cohort 5a|Docetaxel 60 mg/m2 + oxaliplatin 85 mg/m2 + 5-Fluorouracil 2.4 gm/m2
3051811|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 40mg|SM-13496 40 mg was administered orally once daily.
3051812|NCT00711269|Experimental|SM-13496 (lurasidone HCl) 80mg|SM-13496 80mg was administered orally once daily.
3051813|NCT00711269|Placebo Comparator|Placebo|Placebo was administered orally twice daily.
3051814|NCT00711269|Active Comparator|Risperidone|Risperidone was administered orally twice daily.
3051815|NCT00711347|Active Comparator|DisCoVisc|Alcon's DisCoVisc Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
3051816|NCT00711347|Active Comparator|Healon5|Abbott Medical Optic's (AMO) Healon5 Ophthalmic Viscosurgical Device (OVD) used at time of cataract surgery
3051817|NCT00711412|Experimental|Induction, Combination and surgery|"Weeks 1-6:~Capecitabine 1000mg/m2 twice daily Oxaliplatin 70mg/m2 on days 1 and 8~Weeks 7-12:~Capecitabine 825 mg/m2 twice daily Oxaliplatin 50mg/m2 weekly Radiation 1.8 Gy Monday-Friday~Evaluation for response and resection surgery"
3051818|NCT00711425|Experimental|A|
3051819|NCT00711464|Experimental|100 mg|modafinil 100 milligrams oral dose
3051820|NCT00711464|Experimental|200 mg|modafinil 200 mg oral dose
3051821|NCT00711464|Experimental|400 mg|modafinil 400 mg oral dose
3051822|NCT00711464|Placebo Comparator|Placebo|Single oral placebo capsule
3051823|NCT00711477|Experimental|NB32|Naltrexone SR 32 mg/bupropion SR 360 mg/day
3051824|NCT00711477|Placebo Comparator|Placebo|Placebo tablets
3051825|NCT00711490|Experimental|Sirolimus|The study eye was treated with sirolimus.
3051826|NCT00711516|Experimental|1|Armodafinil treatment (200 mg/day) - Study drug was supplied as 50 mg tablets and the dose was titrated from a starting dose of 50 mg taken once daily in the morning (before 0800), increasing to 100 mg/day on Day 2, 150 mg/day on day 5, and then 200 mg/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
3051827|NCT00711516|Placebo Comparator|2|Placebo comparator - Placebo tablets matching the armodafinil 50 mg tablets drug were supplied and the dose was titrated from a starting dose of one tablet taken once daily in the morning (before 0800), increasing to two tablets/day on Day 2, three tablets/day on day 5, and then four tablets/day beginning Day 8 and continuing through the end of the two week double-blind treatment period.
3051828|NCT00711529|Experimental|Hypnotherapy|"Patients randomized to the experimental arm were scheduled for three one-hour inductions by a single hypnotherapist, each one week apart. Standardized outlines were used for each induction. The second and third sessions also began with a standardized induction, followed by the establishment of an anchor, or physical reference point (forefinger to thumb), used to invoke images of coolness, which were individualized according to patient preference.~Patients were also instructed by the same hypnotherapist in self-hypnosis and guided imagery techniques to be used at home with the assistance of standardized audio compact disks. Participation lasted eight weeks."
3051829|NCT00711529|Active Comparator|Gabapentin|Patients randomized to the gabapentin arm were prescribed 900mg of the drug daily (300 mg by mouth three times daily).
3051830|NCT00711555|Experimental|Single arm study with Emend|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day."
3051831|NCT00711594|Experimental|BIBW 2992 MA2|Phase I step: Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally. Escalating doses of BIBW 2992 starting at 20mg daily.
3051832|NCT00711594|Experimental|BIBW 2992 QD|Phase II step: Patients start continuous once daily oral treatment of BIBW 2992 at high dose, until progression or undue Adverse Events (AEs) develop. Patients can be dose-reduced up to two times if needed after temporary discontinuation of treatment due to drug-related AEs.
3051833|NCT00711646|Experimental|Sativex|
3051834|NCT00711646|Placebo Comparator|Placebo|
3051835|NCT00711711|Experimental|Manual lymphatic drainage|this arm will receive 5 manual lymphatic drainage treatments from day 2 to day 7 post surgery
3051836|NCT00711711|Placebo Comparator|Relaxation|This arm will receive 5 relaxation treatments from day 2 to day 7 post surgery
3051837|NCT00711802|Experimental|Daptomycin|"Administered intravenously (IV) every 24 hours for up to 14 days at the following age-dependent dosages.~Participants ages 7 to 17 years: daptomycin was dissolved in a volume of 50 milliliters (mL) 0.9% sodium chloride for injection over 30 minutes (min) with an infusion rate of 1.67 mL/min.~Participants 1 to 6 years-old: daptomycin was dissolved in a volume of 25 mL 0.9% sodium chloride for injection over 60 min with an infusion rate was 0.42 mL/min.~Age Group 1 (for ages 12 to 17 years): 5 milligrams/kilogram (mg/kg)~Age Group 2 (for ages 7 to 11 years): 7 mg/kg~Age Group 3 (for ages 2 to 6 years): 9 mg/kg~Age Group 4 (for ages 1 to <2 years): 10 mg/kg"
3051838|NCT00711802|Active Comparator|Standard of Care (SOC)|The comparator agent for this study was the SOC treatment and dosage deemed appropriate by the Investigator. The recommended SOC agents were IV vancomycin, IV clindamycin, and IV semisynthetic penicillins every 24 hours for up to 14 days.
3051839|NCT00711828|Experimental|Treatment (R-CYBOR-D)|Patients receive rituximab IV on day 1and cyclophosphamide PO, bortezomib IV, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3051840|NCT00711867|Experimental|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
3051841|NCT00711867|Active Comparator|Bair Hugger|Arizant Bair Hugger temperature management system.
3051842|NCT00711880|Experimental|Sativex|
3051843|NCT00711880|Placebo Comparator|Placebo|
3051844|NCT00711958|Experimental|HX575 epoetin alfa Hexal AG|HX575 (erythropoietin alfa of the Sponsor Hexal AG). Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes. The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
3051845|NCT00711958|Active Comparator|ERYPO® Janssen-Cilag|ERYPO® Janssen-Cilag, Germany. Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range. Application of the drug required at least once per week and allowed maximum three times per week.
3051846|NCT00711971|Active Comparator|EPA-rich fish oil supplement|EPA-rich fish oil supplement
3051847|NCT00711971|Active Comparator|DHA-rich fish oil supplement|DHA-rich fish oil supplement
3051848|NCT00711971|Placebo Comparator|Soy Oil placebo|Soy oil
3051849|NCT00711997|Experimental|BC-819|Intratumoral administration of BC-819
3051850|NCT00712010|Experimental|Whey protein native|Whey protein native versus the 6 other arms
3051851|NCT00712010|Experimental|Whey protein microgels|Whey protein microgels versus the 6 other arms
3051852|NCT00712010|Experimental|Hydrolyzed whey protein|Hydrolyzed whey protein versus the 6 other arms
3051853|NCT00712010|Experimental|Casein native|Casein native versus the 6 other arms
3051854|NCT00712010|Experimental|Hydrolyzed casein|Hydrolyzed casein versus the 6 other arms
3051855|NCT00712010|Experimental|Total milk protein native|Total milk protein native versus the 6 other arms
3051856|NCT00712010|Experimental|Hydrolyzed milk protein|Hydrolyzed milk protein versus the 6 other arms
3051857|NCT00712075|Experimental|CBSST+PDA|PDA-Assisted Cognitive-Behavioral Social Skills Training (CBSST+PDA): The CBSST rehabilitation intervention will be combined with the use of a PDA to facilitate homework completion and progress towards recovery goal attainment in consumers.
3051858|NCT00712075|Active Comparator|CBSST|Cognitive Behavioral Social Skills Training (CBSST): CBSST is a psychosocial rehabilitation intervention that combines skills from cognitive behavioral therapy and social skills training to assist consumers in improving functioning and recovery goal attainment.
3051859|NCT00712075|Active Comparator|PDA-Only|PDA-only: To control of device contact, the PDA-only arm will not receive CBSST and will only carry a PDA with access to the basic features of the device.
3051860|NCT00712166|Placebo Comparator|Placebo three times daily (TID)|
3051861|NCT00712166|Experimental|AZLI 75 mg three times daily (TID)|
3051862|NCT00712179||Stroke Survivors|Subjects walked with or with therapists' assistance at different speeds and different amounts of body weight support across conditions.
3051863|NCT00712244|Active Comparator|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device during cataract surgery.
3051864|NCT00712244|Active Comparator|DuoVisc|Use of DuoVisc Viscoelastic System (Viscoat, Provisc) during cataract surgery.
3051865|NCT00712244|Active Comparator|Healon5|Use of Healon5 ophthalmic viscosurgical device (OVD) during cataract surgery.
3051866|NCT00712244|Active Comparator|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device during cataract surgery.
3051867|NCT00712270|No Intervention|Standard of Care|Screening and Baseline Procedures followed by Referral to Community Care. Baseline Procedures may be repeated at a later time if appropriate.
3051868|NCT00712270|Active Comparator|Drug: Aripiprazole|Screening and Baseline Procedures followed by 16 weeks of treatment with aripiprazole, followed by repeat of baseline procedures and referral to community care.
3051869|NCT00712270|Active Comparator|Risperidone|Screening and Baseline Procedures followed by 16 weeks of treatment with Risperidone,followed by repeat of baseline procedures and referral to community care.
3051870|NCT00712296|Experimental|ASHMI 4|ASHMI 4 capsules twice a day
3051871|NCT00712296|Experimental|ASHMI 12|ASHMI 12 capsules twice a day
3051872|NCT00712296|Placebo Comparator|Placebo|Placebo 6 capsules twice a day
3051873|NCT00712335|Experimental|1|"Asthmatic smokers treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
3051874|NCT00712335|Experimental|2|"Asthmatic smoker treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
3051875|NCT00712335|Active Comparator|3|"Non-smoking asthmatics treated with combination therapy:~Fluticasone propionate dosage - DPI 250 mcg BID for 3 months Salmeterol dosage - DPI 50 mcg BID for 3 months"
3051876|NCT00712335|Active Comparator|4|"Non-smoking asthmatic treated with Montelukast only:~Montelukast dosage: PO 10 mg QHS for 3 months"
3051877|NCT00712335|No Intervention|5|Normal controls
3051878|NCT00712348|Experimental|Taliglucerase alfa|Open label taliglucerase alfa treatment
3051879|NCT00712530|Experimental|1|"Single low-dose DermaVir immunization~0.1 mg pDNA/subject, 0.8 mL total volume of DermaVir~Administered topically with DermaPrep under two skin patches (0.4 mL/patch)"
3051880|NCT00712530|Experimental|2|"Single medium-dose DermaVir immunization~0.4 mg pDNA/subject, 3.2 mL total volume of DermaVir~Administered topically with DermaPrep under four skin patches (0.8 mL/patch)"
3051881|NCT00712530|Experimental|3|"Single high-dose DermaVir immunization~0.8 mg pDNA/subject, 6.4 mL total volume of DermaVir~Administered topically with DermaPrep under eight skin patches (0.4 mL/patch)"
3051882|NCT00712543|Experimental|1|Kristalose®, as prescribed, for 7 days.
3051883|NCT00712543|Experimental|2|Liquid lactulose, as prescribed, for 7 days.
3051884|NCT00712673|Experimental|Lixisenatide (Morning Injection)|2-step initiation morning regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3051885|NCT00712673|Experimental|Lixisenatide (Evening Injection)|2-step initiation evening regimen of lixisenatide: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3051886|NCT00712673|Placebo Comparator|Placebo (Morning Injection)|2-step initiation morning regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3051887|NCT00712673|Placebo Comparator|Placebo (Evening Injection)|2-step initiation evening regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3051888|NCT00712712|Experimental|Patient who has undergone radiofrequency ablation of bone metastases|Patient who has undergone radiofrequency ablation of bone metastases, localized, causing pain refractory to radiotherapy or not accessible to new irradiation, biphosphonates and well-conducted morphine analgesic treatment.
3051889|NCT00712725|Experimental|1|MK3207- 2.5 mg
3051890|NCT00712725|Experimental|2|MK3207- 5 mg
3051891|NCT00712725|Experimental|3|MK3207- 10 mg
3051892|NCT00712725|Experimental|4|MK3207- 20 mg
3051893|NCT00712725|Experimental|5|MK3207- 50 mg
3051894|NCT00712725|Experimental|6|MK3207- 100 mg
3051895|NCT00712725|Placebo Comparator|7|Placebo
3051896|NCT00712920|Placebo Comparator|1|Placebo
3051897|NCT00712920|Experimental|2|0.15% azelastine hydrochloride 1644 mcg/2 sprays per nostril 2 times a day for 4 weeks
3051898|NCT00712920|Experimental|3|0.1% azelastine hydrochloride 1096 mcg/2 sprays per nostril 2 times a day for 4 weeks
3051901|NCT00712959|Experimental|Group 1: Previous Tdap or Tdap-IPV Recipients|Participants received Tdap or Tdap-Inactivated Poliomyelitis Vaccine (IPV) in a previous study (TD9707 or TD9805)
3051902|NCT00712959|Active Comparator|Group 2: Tdap vaccine-naïve|Participants are age-balanced Tdap vaccine-naïve and will receive Tdap vaccine in the study at least 10 years after a previous tetanus, diphtheria and/or pertussis dose.
3051903|NCT00712959|No Intervention|Group 3|Past participants in Study TD9707 and TD9805 did not qualify for Tdap re-administration in this study or were unwilling to receive a second dose of Tdap. They were not included in the analysis for the study
3051904|NCT00712985|Experimental|Zometa (Zoledronic Acid) X 1 dose|Zometa (Zoledronic Acid) 5 mg IV X 1 dose
3051905|NCT00713206|Active Comparator|Dental implant (Osseotite)|Dental implants placed simultaneously with graft augmentation material.
3051906|NCT00713206|No Intervention|Control group|Dental implants placed into graft augmentation material that has four months to heal.
3051907|NCT00713219|Experimental|1|CHEMORADIATION
3051908|NCT00713284|Other|Study|All subjects who enroll in this study will be converted from their calcineurin inhibitor to sirolimus. There is no comparotor arm
3051909|NCT00713310|Experimental|Low-Dose|1.2 - 2.4 g/day Asacol dependent on body weight
3051910|NCT00713310|Experimental|High-Dose|2.0 - 4.8 g/day Asacol dependent on body weight
3051911|NCT00713323|Experimental|Sativex|Active treatment
3051912|NCT00713349|Other|1|Xenaderm Vehicle
3051913|NCT00713349|Placebo Comparator|2|Placebo Comparator
3051914|NCT00713427|Other|WallFlex Stent|All patients meeting eligibility criteria recieve the WallFlex™ Biliary Partially-Covered Stent, which has regulatory clearance in the areas in which the study is being conducted.
3051915|NCT00713479|Placebo Comparator|Sugar pill|Sugar pill (placebo) drug dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
3051916|NCT00713479|Active Comparator|Varenicline|Varenicline dosing will begin at 0.5 mg once daily for the first 3 days of condition and will be increased to 0.5 mg twice daily for days 5-6 of this condition, and increased to 1 mg twice daily on days 7-10 of this condition.
3051917|NCT00713544|Active Comparator|1|
3051918|NCT00713544|Experimental|2|20mg
3051919|NCT00713544|Experimental|3|50mg
3051920|NCT00713544|Experimental|4|100mg
3051921|NCT00713544|Experimental|5|150mg
3051922|NCT00713544|Placebo Comparator|6|
3051923|NCT00713583|Experimental|Levodopa pharmacotherapy|Levodopa pharmacotherapy (800mg levodopa and 200mg carbidopa per day), cognitive behavioral therapy (CBT), and contingency management (CM).
3051924|NCT00713583|Placebo Comparator|Placebo|Placebo, cognitive behavioral therapy (CBT), and contingency management (CM).
3051925|NCT00713609|Experimental|1|Benzoyl peroxide/clindamycin gel + tazarotene cream
3051926|NCT00713609|Active Comparator|2|Benzoyl peroxide/clindamycin gel + vehicle cream
3051927|NCT00713609|Active Comparator|3|Benzoyl peroxide gel + tazarotene cream
3051928|NCT00713609|Active Comparator|4|Clindamycin gel + tazarotene cream
3051929|NCT00713609|Active Comparator|5|Vehicle gel+ tazarotene cream
3051930|NCT00713609|Placebo Comparator|6|Vehicle gel + vehicle cream
3051931|NCT00713648|Experimental|rFXIII|
3051932|NCT00713661|Experimental|TachoSil®|
3051933|NCT00713700|Experimental|Device|
3051934|NCT00713817|Experimental|Sativex|
3051935|NCT00713817|Placebo Comparator|Placebo|
3051936|NCT00713830|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3051937|NCT00713830|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3051938|NCT00714051|Experimental|Fall Prevention Training|The falls prevention training group participated in four weekly training sessions on a custom-built treadmill that produced trip-simulating perturbations (movements). While harnessed overhead to prevent actual falls, the treadmill stopped or moved suddenly. The goal for the participant was to try and prevent a fall. Each week, the level of difficulty of the task was increased.
3051939|NCT00714051|Active Comparator|Attention Control|The attention control group participated in four weekly treadmill walking sessions at a self-selected speed.
3051940|NCT00714168|Active Comparator|1|Participants will take part in a standard behavioral weight loss program.
3051941|NCT00714168|Experimental|2|Participants will take part in a stepped-care weight loss program.
3051942|NCT00714233|Experimental|1|Metformin
3051943|NCT00714233|Experimental|2|Oral Contraceptive Pills
3051944|NCT00714233|Active Comparator|3|lifestyle modification program
3051945|NCT00714233|Placebo Comparator|4|placebo to active metformin arm
3051946|NCT00714259|Other|Non Myeloablative Treatment|"Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight."
3051947|NCT00714272|Experimental|A|Granulocytapheresis treatment
3051948|NCT00714272|Placebo Comparator|B|Sham device treatment
3051949|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3051950|NCT00714285|Experimental|Quadrivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3051951|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 1|Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3051952|NCT00714285|Active Comparator|Trivalent influenza vaccine GSK 2115160A Group 2|Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
3051953|NCT00714311|Active Comparator|TFP|Transference-Focused Psychotherapy
3051954|NCT00714311|Active Comparator|ECP|treatment by experienced community psychotherapists
3051955|NCT00714415||A|Patients with Hemophilia B
3051956|NCT00714493|Other|001|Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
3051957|NCT00714571|Active Comparator|MST healthy older adults Stage 1|Mnemonic strategy training
3051958|NCT00714571|Active Comparator|MST MCI Stage 1|Exposure training
3051959|NCT00714571|Active Comparator|XP healthy older adults Stage 1|XP healthy older adults Stage 1
3051960|NCT00714571|Active Comparator|XP MCI Stage 1|XP MCI Stage 1
3051961|NCT00714571|Active Comparator|MST healthy older adults Stage 2|MST healthy older adults Stage 2
3051962|NCT00714571|Active Comparator|SCT healthy older adults Stage 2|SCT healthy older adults Stage 2
3051963|NCT00714688|Experimental|001|prolonged release (PR) OROS methylphenidate 54 mg 18+36mg once daily for 13 weeks
3051964|NCT00714688|Experimental|002|prolonged release (PR) OROS methylphenidate 72 mg 2x36mg once daily for 13 weeks
3051965|NCT00714688|Placebo Comparator|003|Placebo 2xplacebo once daily for 13 weeks
3051966|NCT00714714|Experimental|Tretinoin and Adapalene gels|Adapalene facial gel and tretinoin facial gel applied daily for two weeks on opposite sides of the face (in a split-face model)
3051967|NCT00714753|Experimental|Intervention Group|Protocol treatment consists of either two high dose-rate (HDR) brachytherapy implantation sessions or one HDR brachytherapy session followed by external beam radiotherapy (EBRT). Each HDR session consists of two 9.5Gy fractions. After the first HDR session of two fractions, patients express a preference for: (1) a second HDR brachytherapy implantation session, or (2) EBRT. The second HDR session or EBRT will begin 2-4 weeks after the first HDR brachytherapy session.
3051968|NCT00714792||1|Subjects with urge incontinence due to overactive bladder
3051969|NCT00714792||2|women with no urge symptoms
3051970|NCT00714870|Other|1|intervention: this group will attend the nutrition and exercise program control group: this group will not attend the nutrition and exercise program
3051971|NCT00715026|Other|Trilogy AB Acetabular Hip Implant System|Post Approval Study of Device.
3051972|NCT00715078|Active Comparator|Cohort A|Sipuleucel-T with the concentration of 10 μg/mL PA2024 in a cell suspension of 1 x 10^7 peripheral blood mononuclear cells (PBMCs) per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3051973|NCT00715078|Active Comparator|Cohort B|Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3051974|NCT00715078|Active Comparator|Cohort C|Sipuleucel-T with the concentration of 2 μg/mL PA2024 in a cell suspension of 1 x 10^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3051975|NCT00715104|Experimental|Sipuleucel-T with Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, and then an additional booster infusion 13 weeks following RP.
3051976|NCT00715104|Experimental|Sipuleucel-T without Booster|Subjects were to receive 3 infusions of sipuleucel-T 12 weeks prior to RP, with no further sipuleucel-T treatment.
3051977|NCT00715117|Placebo Comparator|Sugar pill|Subjects will receive placebo for for the first 8 weeks administered orally one time daily. After 8 weeks placebo treated subjects are then crossed over to active drug naltrexone 0.1 mg/kg not to exceed 4.5 mg PO once daily for an additional 8 weeks.
3051978|NCT00715117|Experimental|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally either in capsules or liquid blinded for 8 weeks followed by open-labeled naltrexone for an additional 8 weeks. Safety and toxicity will be compared to placebo. Also change in Crohn's activity index scores of naltrexone to placebo are compared.
3051979|NCT00715208|Experimental|VELCADE R-CAP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 Intravenous on Day 1, cyclophosphamide 750 mg/m2 intravenous on Day 1, doxorubicin 50 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
3051980|NCT00715208|Experimental|VELCADE R-CP|VELCADE will be administered as a 3- to 5-second intravenous bolus injection, rituximab 375 mg/m2 intravenous on Day 1, cyclophosphamide 1000 mg/m2 intravenous on Day 1, VELCADE 1.6 mg/m2 intravenous on Days 1 and 8, prednisone 100 mg orally on Days 1 to 5 of a 21-day (3-week) cycle for 6 cycles.
3051981|NCT00715299|Other|Locomotor Training Group|persons who have sustained a stroke within greater than 6 months ago and less than 5 years.
3051982|NCT00715390||1-Children receiving anesthesia|The sample of patients screened will be the entire electronic anesthesia record database from 1998 until 2004 looking for subjects that have dysrhythmias.
3051983|NCT00715429|Experimental|vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks|Vitamin D arm
3051984|NCT00715429|Placebo Comparator|placebo x 10d, + placebo weekly 7 wks|placebo
3051985|NCT00715520|Experimental|Aim 1|Healthy adult female and male subjects will receive study drugs and TMS training to measure M1 excitability.
3051986|NCT00715520|Experimental|Aim 2|Healthy adult female and male subjects will receive repetitive TMS (rTMS) at different times or frequencies with respect to the training movement or sham stimulation.
3051987|NCT00715520|Experimental|Aim 3|Female and male subjects who have experienced a cerebral ischemic infarction, will receive study drugs and TMS to measure M1 excitability.
3051988|NCT00715559|Experimental|cysteamine bitartrate|Participants received cysteamine bitartrate by mouth up to 300 mg three times daily.
3051989|NCT00715624|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3051990|NCT00715624|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3179064|NCT00668694|No Intervention|3|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled without stimulation
3179065|NCT00668694|No Intervention|4|Non-anemic group: Hb >80-109 g/L ferritin levels >12 μg/L and TfR <6 will be enrolled with stimulation
3179066|NCT00668720|Experimental|1|
3179067|NCT00668720|Sham Comparator|2|
3321403|NCT02018536|Experimental|Part 2, Sequence 3|6 participants to receive Treatment C (TMC435 100 mg+GSK2336805 60 mg), B (GSK2336805 60 mg), D (TMC435 150 mg+GSK2336805 60 mg), and A (TMC435 150 mg) in a sequence with a 7 days washout period between each treatment sessions.
3051991|NCT00715650|Experimental|Arm 1|This counseling consists of four sessions each approximately 60 minutes each. The four sessions are organized as follows: a) Orientation to Benefits Counseling: Your Benefits and Your Goals b) Work and Claims c) Financial Review: Implications of Your Work Plan and d) Your Plans After the Benefits Notice. The first session focuses on the disability application process as a non-confrontational way to explore attitudes towards work. The second session more directly addresses the claimant's attitudes about work and beliefs about whether work will prevent receipt of disability benefits. The third session addresses the same issue as the second, ambivalence about work and disability, from a financial perspective. The fourth session occurs after the disability determination has been made, and it is possible the veteran may feel differently about a benefit that has been awarded.
3051992|NCT00715650|Active Comparator|Arm 2|This will consist of four-session orientation with the sessions organized as follows: a) overview of VHA services, b) Primary Care c) Pharmacy and laboratory services and d) specialty services. After the description of each service, participants will be invited to discuss which services they plan to utilize. The counselor will provide telephone numbers and directions to the sites at which these services are provided.
3051993|NCT00715676|Placebo Comparator|Group 1|
3051994|NCT00715676|Experimental|Group 2|220 ng
3051995|NCT00715676|Experimental|Group 3|440 ng
3051996|NCT00715728||1: Bair Hugger|Intraoperative warming with Bair Hugger forced air system
3051997|NCT00715728||2: Hot Dog|Intraoperative warming with Hot Dog resistive heating system
3051998|NCT00715741|Active Comparator|1|Group 1 will receive 30% oxygen plus PEEP + 3 to 5 cm Water duration of anesthesia and surgery
3051999|NCT00715741|Active Comparator|2|Group 2 will receive 30% oxygen without PEEP for the duration of anesthesia and surgery
3052000|NCT00715741|Active Comparator|3|Group 3 will receive > 90% oxygen plus PEEP + 3 to 5 cm of water for the duration of anesthesia and surgery
3052001|NCT00715741|Active Comparator|4|Group 4 will receive > 90% oxygen and no PEEP for the duration of anesthesia and surgery
3052002|NCT00715793|Experimental|Single Arm|
3052003|NCT00715884|Experimental|1|CYPHER® ELITE™ Sirolimus-Eluting Stent System.
3052004|NCT00715884|Active Comparator|2|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System
3052005|NCT00715910|Experimental|Nimenrix 1 Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
3052006|NCT00715910|Active Comparator|Menactra Group|Subjects 11-25 years of age who were previously vaccinated with 1 dose of Menactra vaccine at the time of vaccination
3052007|NCT00715910|Experimental|Nimenrix 2 Group|Subjects 10<11 years of age who were previously vaccinated with 1 dose of Nimenrix vaccine at the time of vaccination
3052008|NCT00715910|Experimental|Nimenrix Naive Group|Subjects 15 to <31 years of age at the time of primary vaccination with 1 dose of Nimenrix vaccine at year 5 of the current study
3052009|NCT00715910|Experimental|Nimenrix Pooled Group|Pooled group of subjects 10-25 years of age from Nimenrix 1 and Nimenrix 2 groups in the primary study (NCT00454909) who had received 1 dose of Nimenrix vaccine in that study and will receive a booster dose in this current study.
3052010|NCT00715910|Active Comparator|Menactra Booster Group|Subjects 11-25 years of age who had received 1 dose of Menactra vaccine in primary study (NCT00454909) and will receive 1 dose of Nimenrix vaccine in this current study.
3052011|NCT00715949||Mild Traumatic Brain Injury (MTBI) admits|admitted pediatric patients with mild traumatic brain injury (concussion)
3052012|NCT00715962|Active Comparator|Mobility Group|The Walking Intervention includes assistance to walk twice daily with or without a rolling walker. In addition, a behavioral intervention that included goal setting and discussion of how to overcome mobility barriers was used to encourage the mobility group to be more active throughout hospital stay. Participants will keep a diary of out of bed activity and will be encouraged to set goals for additional out of bed activity daily.
3052013|NCT00715962|Placebo Comparator|Control Group|The control group will receive twice daily friendly visits to counter the attention being paid to the intervention group. They will complete a diary but of visitors to their room.
3052014|NCT00716079|Other|Intensive BP lowering|Management policy to lower the systolic Blood pressure (BP) to a target of 140mmHg within 1 hour of randomization and sustained for 24 hours. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
3052015|NCT00716079|Other|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the American Heart Association (AHA) in 2007 and 2010. The attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, intravenous treatment may be started until the target systolic BP of 180 mmHg is achieved.
3052016|NCT00716092|Placebo Comparator|Placebo|Patients received placebo matching 5mg linagliptin and placebo matching 100mg sitagliptin.
3052017|NCT00716092|Experimental|Linagliptin|Patients received 5mg linagliptin, and placebo matching 100mg sitagliptin.
3052018|NCT00716092|Active Comparator|Sitagliptin|Patients received 100mg sitagliptin, and placebo matching 5mg linagliptin.
3052019|NCT00716144|Active Comparator|A|Talarozole 0.5 mg
3052020|NCT00716144|Active Comparator|B|Talarozole 1.0 mg
3052021|NCT00716144|Active Comparator|C|Talarozole 2.0 mg
3052022|NCT00716144|Placebo Comparator|D|Talarozole matching Placebo
3052023|NCT00716274|Experimental|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks (study period II). Participants who complete the study period II will be re-randomized in the study period III of 16-week duration to assess maintenance of benefit following discontinuation of treatment with atomoxetine. Participants assigned to atomoxetine during the study period II will be re-randomized to either atomoxetine or placebo whereas participants previously assigned to placebo will receive atomoxetine.
3052024|NCT00716274|Placebo Comparator|Placebo|Placebo will be packaged in the same way as active comparator to enforce double-blind study design
3052025|NCT00716417|Experimental|A. BIBW 2992-cisplatin-paclitaxel|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-paclitaxel
3052026|NCT00716417|Experimental|B. BIBW 2992-cisplatin-5FU|daily oral dose of BIBW 2992 combined with 3-weekly infusion of cisplatin-5FU
3052027|NCT00716443|Active Comparator|Pliaglis® Cream|tetracaine 4% / lidocaine 7% cream; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
3052028|NCT00716443|Active Comparator|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections; this was a randomized, split face study where Pliaglis® Cream was used on one side of the face and a compounded topical anesthetic ointment was used on the other side of the face. Restylane® was injected into both sides of the face.
3052029|NCT00716456|Experimental|1|In the phase I portion, patients will be enrolled in cohorts of 3-6 patients;receiving daily erlotinib 100 mg along with cetuximab given every 2 weeks beginning at 250mg/m2 IV. Following the initial dose, for dose levels 1 and 2 (250 mg/m2 and 375 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 60 minutes. For dose level 3 (500 mg/m2) patients will receive treatment every 2 weeks with cetuximab over 120 minutes. The infusion rate of cetuximab should never exceed 10 mg/minute (5 mL/min). The dose may subsequently be reduced for individual patients, depending on a patient's toxicity.
3052030|NCT00716586|Experimental|Trusopt (2% dorzolamide)|Intent to treat population. All participants assigned to Trusopt (2% dorzolamide)
3052031|NCT00716625||sunitinib malate|Patients taking sunitinib malate
3052032|NCT00716742||1|bimatoprost 0.03% latanoprost 0.005% travoprost 0.004%
3052033|NCT00716820||SUNITINIB MALATE|Patients taking Sutent.
3052034|NCT00716859|Active Comparator|Timolol|
3052035|NCT00716859|Experimental|latanoprost|
3052036|NCT00716963|Active Comparator|1|Fluticasone propionate (Flovent Diskus) 250 mcg
3052037|NCT00716963|Active Comparator|2|budesonide 400mcg
3052038|NCT00716963|Placebo Comparator|3|placebo
3052039|NCT00716976|Experimental|STS Arm (sodium thiosulfate treatment)|Patients receive sodium thiosulfate IV (dosage 16 g/m2 or 533 mg per kg for patients whose therapeutic protocol administers cisplatin on a per kg basis due to young age or small body) over 15 minutes beginning 6 hours after the completion of each cisplatin infusion. Treatment with sodium thiosulfate continues until the completion of cisplatin therapy.
3052040|NCT00716976|Experimental|Observation Arm (No sodium thiosulfate treatment)|Patients do not receive sodium thiosulfate.
3052041|NCT00717041||Presenting to the ED|Patients who present to the ED
3052042|NCT00717054|Active Comparator|Aprepitant and Scopolamine group|Patients receive aprepitant and scopolamine for prevention of postoperative nausea and vomiting then were followed through the post operative period looking for nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine placebo looking for a difference in incidence of events.
3052043|NCT00717054|Placebo Comparator|Aprepitant and Scopolamine Placebo Group|Patients receiving aprepitant and placebo scopolamine for prevention of postoperative nausea and vomiting then followed through the post operative period looking for signs of nausea, vomiting, composite, and rescue medication utilization. This was compared to patients receiving aprepitant and scopolamine looking for a difference in incidence of events.
3052044|NCT00717067|Experimental|Healthy Subjects|Subjects with Normal Renal Function (Creatinine Clearance > 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
3052045|NCT00717067|Experimental|Mild Renal Impairment|Subjects with Mild Renal Impairment (Creatinine Clearance >50 and ≤80 mL/min)
3052046|NCT00717067|Experimental|Moderate Renal Impairment|Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
3052047|NCT00717067|Experimental|Severe Renal Impairment|Subjects with Severe Renal Impairment (Creatinine Clearance <30 mL/min)
3052048|NCT00717067|Experimental|ESRD on Hemodialysis|Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance <30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
3052049|NCT00717093|Experimental|Active|
3052050|NCT00717093|Placebo Comparator|Placebo|
3052051|NCT00717197|Experimental|Capecitabine|Capecitabine (1,000-1,250 mg/m2) taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
3052052|NCT00717236|Experimental|Certolizumab pegol (CZP)|
3052053|NCT00717236|Placebo Comparator|Placebo|
3052054|NCT00717249|Experimental|Test Lens|galyfilcon A contact lens with a silver additive
3052055|NCT00717249|Active Comparator|Control Lens|galyfilcon A control contact lens
3052056|NCT00717288|Active Comparator|1|Detemir insulin dosed at 50% of calculated basal insulin infusion requirement injected once daily
3052057|NCT00717288|Active Comparator|2|Detemir insulin dosed at 65% of calculated basal insulin infusion requirement injected once daily
3052058|NCT00717288|Active Comparator|3|Detemir insulin dosed at 80% of calculated basal insulin infusion requirement injected once daily
3052059|NCT00717314|Experimental|MMF, 50% CNI Reduction|Participants received mycophenolate mofetil (MMF), 1.5 to 2.0 grams (g) daily, orally (PO), twice per day (BID) from baseline (BL) to Week 52. Participants also received a 50 percent (%) reduced dose of calcineurin inhibitor (CNI) from BL to Week 52.
3052060|NCT00717314|Experimental|MMF, ≥75% CNI Reduction|Participants received MMF, 1.5 to 2.0 g daily, PO, BID from BL to Week 52. Participants also received a 75% reduced dose of CNI from BL to Week 52.
3052061|NCT00717366|Experimental|MIRCERA Group 1: Intermediate-Conversion-Factor Group|Participants will receive methoxy polyethylene glycol-epoetin beta (MIRCERA) IV injection at a starting dose based on an intermediate conversion factor from their previous Erythropoiesis-stimulating Agent (ESA) dose (4 * previous weekly epoetin dose [international units {IU}]/250 or 4 * previous weekly darbepoetin alfa dose [micrograms {mcg}]/1.1) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with hemoglobin (Hb) level within ± 1 grams per deciliter (g/dL) of their baseline Hb level and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
3321404|NCT02018536|Experimental|Part 2, Sequence 4|6 participants to receive Treatment D (TMC435 150 mg+GSK2336805 60 mg), C (TMC435 100 mg+GSK2336805 60 mg), A (TMC435 150 mg) and B (GSK2336805 60 mg) in a sequence with a 7 days washout period between each treatment sessions.
3052062|NCT00717366|Experimental|MIRCERA Group 2: High-Conversion-Factor Group|Participants will receive MIRCERA IV injection based on a high conversion factor from their previous ESA dose (4 * previous weekly epoetin dose [IU]/125 or 4 * previous weekly darbepoetin alfa dose [mcg]/0.55) once every 4 weeks for 20 weeks. Participants who will complete the 20 weeks of treatment with Hb within ± 1 g/dL of their baseline Hb and within the target range of 10-12 g/dL will enter an optional 52-weeks safety extension period. During this period, the participants will continue to receive MIRCERA IV injection once every 4 weeks.
3052063|NCT00717405|Experimental|1|
3052064|NCT00717418||1|"cyclosporine ophthalmic emulsion 0.05%~artificial tears"
3052065|NCT00717522|Experimental|Pomalidomide|7 mg pomalidomide taken orally once daily (QD) on days 1 through 21 of each 28-day cycle
3052066|NCT00717574|Active Comparator|Sevoflurane group|Sevoflurane based general anesthesia
3052067|NCT00717574|Active Comparator|Propofol group|Propofol based general anesthesia
3052068|NCT00717626|Experimental|Daily administration of low dose FVIII|Low dose daily prophylaxis using FVIII products (e.g.Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS)
3052069|NCT00717756|Experimental|Lenalidomide|
3052070|NCT00717769|Experimental|SUN13834|
3052071|NCT00717769|Placebo Comparator|Placebo|
3052072|NCT00717860|Experimental|Caspofungin|caspofungin acetate (MK0991)
3052073|NCT00717860|Active Comparator|Micafungin|Micafungin sodium
3052074|NCT00717873|Experimental|HFCWO Arm|Airway clearance provided by the Vest Airway Clearance System
3052075|NCT00717873|No Intervention|CPT Arm|Airway clearance provided by manual CPT
3052076|NCT00717886|Experimental|1|Patients with documented axillary metastases (Stage II breast cancer) will undergo subdermal injection of technetium sulfur colloid (TSC) into the ipsilateral upper extremity approximately 3 hours before surgery.
3052077|NCT00717912|Experimental|Arm 1|Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup
3052078|NCT00717912|Experimental|Arm 2|Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Experimental sweetener syrup
3052079|NCT00717912|Experimental|Arm 3|Experimental sweetener syrup / Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup / Experimental sweetener syrup
3052080|NCT00717912|Experimental|Arm 4|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup / Classical sugar syrup / Classical sweetener syrup
3052081|NCT00717912|Experimental|Arm 5|Classical sugar syrup / Experimental sweetener syrup / Classical sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sugar syrup
3052082|NCT00717912|Experimental|Arm 6|Experimental sweetener syrup / Experimental sweetener syrup / Experimental sweetener syrup / Classical sugar syrup / Classical sweetener syrup / Classical sugar syrup / Classical sugar syrup
3052083|NCT00718042|Experimental|1|All subjects will have their blood tested by the investigational Chagas screening assay.
3052084|NCT00718042|Experimental|2|Testing of blood donor samples with the investigational Chagas screening assay. Samples that test positive will be also tested with the Chagas confirmatory assay.
3052085|NCT00718081|Experimental|1|Oral Sufentanil
3052086|NCT00718081|Experimental|2|Oral sufentanil
3052087|NCT00718081|Placebo Comparator|3|Oral dosage of placebo
3052088|NCT00718094|Experimental|Polyphenon E treatment|Polyphenon E® therapy was given for 56 days.
3052089|NCT00718094|Placebo Comparator|Placebo|Oral Placebo
3052090|NCT00718120|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years received a single dose of Fluviral® vaccine.
3052091|NCT00718120|Experimental|Fluviral Elderly Group|Subjects aged more than 60 years received a single dose of Fluviral® vaccine.
3052092|NCT00718159|Experimental|LY573636|
3052093|NCT00718237|Experimental|1|RotaTeq™
3052094|NCT00718237|Placebo Comparator|2|Placebo
3052095|NCT00718302|Experimental|Randomized treatment; antiglide plate|Randomized treatment; antiglide plate
3052096|NCT00718302|Experimental|Randomized treatment; lateral plate|Randomized treatment; lateral plate
3052097|NCT00718315|Experimental|1|
3052098|NCT00718315|Experimental|2|
3052099|NCT00718315|Experimental|3|
3052100|NCT00718328|Experimental|I|Simvastatin Group
3052101|NCT00718328|Placebo Comparator|II|Placebo Group
3052102|NCT00718419|Experimental|A: Enzastaurin|
3052103|NCT00718510|Active Comparator|L-arginine first/placebo second|Patients with diagnosis of schizophrenia will be randomised to receive L-arginine first/placebo second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
3052104|NCT00718510|Placebo Comparator|Placebo first/L-arginine second|Patients with diagnosis of schizophrenia will be randomised to receive placebo first/L-arginine second 3 grams bid (cross-over design) in addition to treatment as usual. The active treatment period will be 3 weeks, with a wash-out period of 5 days and re-commencing on the alternative arm of the randomization
3052105|NCT00718523|Placebo Comparator|A|Placebo plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of placebo administered on Day 1 of each 21-day cycle.
3052106|NCT00718523|Experimental|B|AMG 479 plus paclitaxel/carboplatin chemotherapy administered on Day 1 of each 21-day cycle for 6 cycles - then 6 additional cycles of AMG 479 single agent administered on Day 1 of each 21-day cycle.
3052107|NCT00718549|Experimental|Induction: Rituximab, Cladribine, Cyclophosphamide|Participants will receive rituximab at a dose of 375 milligrams per meter squared (mg/m^2) as intravenous (IV) infusion on Day 1, cladribine at a dose of 0.12 milligrams per kilogram per day (mg/kg/day) as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 in Cycle 1. Then, rituximab at a dose of 500 mg/m^2 as IV infusion on Day 1, cladribine at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4, and cyclophosphamide at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 will be administered in Cycles 2-6. Each cycle will be of 28 days in duration.
3052108|NCT00718549|Experimental|Maintenance Arm: Rituximab|Participants with PR or CR after induction phase who will be randomized to maintenance arm will receive rituximab treatment for 8 cycles. Twelve weeks after the last induction cycle, participants will receive rituximab at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle until disease progression (up to approximately 96 weeks).
3052109|NCT00718549|No Intervention|Observation Arm: No Intervention|Participants with PR or CR after induction phase who will be randomized to observation arm will not receive any intervention. Participants will be assessed every 4-weeks for the first 12 weeks and every 12-weeks afterwards up to 96 weeks.
3052110|NCT00718666|Experimental|Group A|Subjects who were previously vaccinated with one dose of GSK134612 at 12 months of age.
3052111|NCT00718666|Experimental|Group B|Subjects who were previously vaccinated with two doses of GSK134612, one each at 9 and 12 months of age.
3052112|NCT00718666|Experimental|Group C|Subjects aged 5-6 years not previously administered meningococcal vaccine.
3052113|NCT00718718|Experimental|Part A, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3052114|NCT00718718|Experimental|Part A, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 10) and later placebo (Week 12 to Week 22) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3052115|NCT00718718|Experimental|Part B, Group 1|Participants will receive placebo (Week 0 to Week 10) and later CNTO 136 100 mg (Week 12 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3052116|NCT00718718|Experimental|Part B, Group 2|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 2 weeks. Stable dose of methotrexate will be maintained through Week 24.
3052117|NCT00718718|Experimental|Part B, Group 3|Participants will receive CNTO 136 100 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6, 10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3052118|NCT00718718|Experimental|Part B, Group 4|Participants will receive CNTO 136 50 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3052119|NCT00718718|Experimental|Part B, Group 5|Participants will receive CNTO 136 25 mg (Week 0 to Week 24) every 4 weeks and placebo at interim visits (Weeks 2, 6,10, 14, 18, and 22). Stable dose of methotrexate will be maintained through Week 24.
3052120|NCT00718770|Experimental|Bexarotene|Open label - all patients receive intervention
3052121|NCT00718809|Experimental|Arm I|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3052122|NCT00718861|Placebo Comparator|Placebo|Matching placebo administered intravenously.
3052123|NCT00718861|Experimental|Zoledronic acid|
3052124|NCT00718887|Experimental|Entecavir, 0.5 mg QD|
3052125|NCT00718887|Other|Adefovir, 10 mg QD/Entecavir, 0.5 mg QD|Control
3052126|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F1-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 1 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3052127|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F2-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 182 and one dose of placebo (phosphate buffered saline, PBS) at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and Placebo vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, A/turkey H5N1 vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3052128|NCT00719043|Experimental|A/Indonesia primed-A/turkey Influenza (H5N1)-F3-Placebo Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 3 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 3 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3052129|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F1-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) vaccine formulation 1 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 1 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3052130|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F4-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 4 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 4 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3179068|NCT00668759|Experimental|1|"Vernakalant Injection:~In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes."
3052131|NCT00719043|Experimental|A/Indonesia primed-Placebo-A/turkey Influenza (H5N1)-F2-Group|Healthy subjects aged 18 years of age or older at the time of enrolment were primed with one dose of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) formulation 2 at Day 0, one dose of placebo (phosphate buffered saline, PBS) at Day 182 followed by one booster dose of A/turkey H5N1 vaccine formulation 2 at Day 549. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) and A/turkey H5N1 vaccines were administered intramuscularly in the deltoid region of the non-dominant arm while, Placebo vaccine was administered intramuscularly in the deltoid region of the dominant arm.
3052132|NCT00719043|Placebo Comparator|Naïve Placebo-A/turkey Influenza (H5N1)-F3-Group|Healthy subjects aged 18 years of age or older at the time of vaccination received one dose of placebo (phosphate buffered saline, PBS) at Day 0 followed by two doses of A/turkey H5N1 vaccine formulation 3, one dose administered at Day 182 and the other at Day 549. Placebo vaccine and one dose of A/turkey H5N1 vaccine (Day 549) was administered intramuscularly in the deltoid region of the non-dominant arm while the other dose of A/turkey H5N1 vaccine (Day 182) was administered intramuscularly in the deltoid region of the dominant arm.
3052133|NCT00719134|Experimental|1|Maxalt administration at onset of migraine
3052134|NCT00719134|Placebo Comparator|2|
3052135|NCT00719134|Experimental|3|
3052136|NCT00719134|Placebo Comparator|4|
3052137|NCT00719134|Experimental|5|
3052138|NCT00719134|Experimental|6|
3052139|NCT00719160|Placebo Comparator|Esomeprazole|
3052140|NCT00719160|Active Comparator|Placebo|
3052141|NCT00719186|Active Comparator|A|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
3052142|NCT00719186|Active Comparator|B|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
3052143|NCT00719212|Experimental|AMG 479|AMG 479 administered on day 1 of each 21-day cycle up to disease progression, unacceptable toxicity, withdrawal of consent or sponsor decision to stop the study.
3052144|NCT00719264|Experimental|bevacizumab, RAD001 (everolimus)|Participants received oral everolimus 10 mg qd plus intravenous bevacizumab 10mg/kg every 2 weeks
3052145|NCT00719264|Active Comparator|bevacizumab, interferon alfa-2a (IFN)|Participants received subcutaneous IFN dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3 of treatment and subsequently (if tolerated), 3 times per week plus intravenous bevacizumab 10 mg/kg every 2 weeks
3052146|NCT00719329|Experimental|A|Chlorhexidine cleansing of the cord for seven days
3052147|NCT00719329|Experimental|B|Chlorhexidine cleansing of the cord for 1 day
3052148|NCT00719329|Placebo Comparator|C|Dry cord care, as recommended by WHO
3052149|NCT00719355|Experimental|Walking with Poles|Patients were assigned to a 24 week walking with poles program of rehabilitation. The intervention was the additional of poles to the walking program.
3052150|NCT00719355|Active Comparator|Traditional walking program|Patients were assigned to a 24 week traditional walking program.
3052151|NCT00719472|Experimental|Rituximab 375 mg/m^2|Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m^2 administered by intravenous (IV) infusion on Day 1 of each cycle.
3052152|NCT00719537|Placebo Comparator|Aspirin plus Placebo Oral Tablet|Drug: Aspirin 81 mg, given orally once per day Drug: Placebo tablet given orally, once a day
3052153|NCT00719537|Active Comparator|Aspirin plus Progesterone|Drug: Aspirin 81mg, given orally once per day Drug: Progesterone 200mg given orally, once a day
3052154|NCT00719563|Experimental|Arm I|Patients receive oral American ginseng twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
3052155|NCT00719563|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 14 days. Treatment repeats every 2 weeks for 4 courses.
3052156|NCT00719576|Experimental|MACI|autologous cultured chondrocytes on porcine collagen membrane
3052157|NCT00719576|Active Comparator|Microfracture|Microfracture
3052158|NCT00719615||Thyroid Cancer in Remission Group|Thyroid Cancer-Remission Group & use of Vitamin D
3052159|NCT00719615||Thyroid Cancer with Active Disease Group|Thyroid Cancer-Active Group & use of Vitamin D
3052160|NCT00719615||Thyroid nodule group (no cancer) & Vit D|Thyroid nodule group without cancer and use of Vitamin D
3052161|NCT00719680|Experimental|IgPro20|The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)
3052162|NCT00719706|Active Comparator|1|1000-3000mg/day of acetyl-l-carnitine PLUS 600-1800mg/day of alpha-lipoic acid
3052163|NCT00719706|Placebo Comparator|2|
3052164|NCT00719732|Experimental|ReSTOR Aspheric +3|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
3052165|NCT00719810|Experimental|1|
3052166|NCT00719810|Experimental|2|
3052167|NCT00719810|Active Comparator|3|
3052168|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI|"Subjects with hematological malignancies with prior autologous transplant, >2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months.~Refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy."
3052169|NCT00719849|Experimental|Cyclophosphamide/Fludarabine/TBI/ATG|Subjects with hematological malignancies with prior autologous transplant >12 mos or <1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months
3052170|NCT00719862|Placebo Comparator|Placebo Nasal Spray|0mg Placebo Nasal Spray
3052171|NCT00719862|Active Comparator|0.15% azelastine hydrochloride nasal spray|0.15% azelastine hydrochloride
3052172|NCT00719901|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive obatoclax mesylate IV over 3 hours and bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3052173|NCT00720057|Experimental|Naproxen sodium ER (BAYH6689)|single dose (1 tablet) ER Naproxen sodium 660 mg with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
3052174|NCT00720057|Placebo Comparator|Placebo|Single dose (1 tablet) of placebo with a full glass of water (240ml) within 1 - 4 hours post dental surgery.
3052175|NCT00720096|Experimental|Liposomal Doxorubicin|Liposomal Doxorubicin - Chemotherapy single agent systemic.
3052176|NCT00720096|Experimental|Topotecan|Topotecan - Chemotherapy single agent systemic.
3052177|NCT00720109|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|See Detailed Description
3052178|NCT00720122|Experimental|Anorexia Nervosa Females|
3052179|NCT00720213|Active Comparator|Respironics BiPAP autoSV2, Then Respironics BiPAP autoSV3|Participants will be randomized to receive Respironics BiPAP autoSV2 first and Respironics BiPAP autoSV3 second.
3052180|NCT00720213|Experimental|Respironics BiPAP autoSV3, then Respironics BiPAP autoSV2|Participants will be randomized to receive Respironics BiPAP autoSV3 first and Respironics BiPAP autoSV2.
3052181|NCT00720226|Experimental|Losartan|Losartan 100 mg daily
3052182|NCT00720226|Placebo Comparator|Placebo|Placebo 1 pill daily
3052183|NCT00720278|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray
3052184|NCT00720278|Experimental|Astepro 0.1%|0.1% azelastine hydrochloride nasal spray
3052185|NCT00720278|Experimental|Astepro 0.15%|0.15% azelastine hydrochloride nasal spray
3052186|NCT00720330|Active Comparator|Ropivacaine|Paravertebral Group - A local anesthetic (ropivacaine) will be injected near the spine before surgery. Participants will also receive midazolam and fentanyl intravenously (through your vein) for sedation
3052187|NCT00720330|Active Comparator|Lidocaine/ketamine|Participant will receive general anesthesia through the vein before surgery. Lidocaine and ketamine will be administered intravenously throughout surgery and for 60 minutes after surgery.
3052188|NCT00720330|Placebo Comparator|Placebo|General anesthesia plus placebo. Placebo will be administered intravenously until 60 minutes after surgery
3052189|NCT00720356|Experimental|Treatment|erlotinib and bevacizumab
3052190|NCT00720369|Experimental|CoEnzyme Q10|Open Label Study
3052191|NCT00720369|No Intervention|Healthy Controls|Healthy controls completed all study procedures completed by the CoQ10 group but did not receive any study medication.
3052192|NCT00720382|Experimental|1|0.15% azelastine hydrochloride 1644 mcg
3052193|NCT00720382|Experimental|2|Mometasone furoate 200 mcg
3052194|NCT00720434|Experimental|A|500 mg BID
3052195|NCT00720434|Experimental|B|300 mg BID
3052196|NCT00720434|Experimental|C|200 mg BID
3052197|NCT00720434|Placebo Comparator|D|Placebo
3052198|NCT00720473|Other|A: Other|Open Label Study
3052199|NCT00720473|No Intervention|B: Healthy Controls|
3052200|NCT00720499|Experimental|BI 1744 CL low dose+tiotropium bromide|BI 1744 CL low dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3052201|NCT00720499|Experimental|BI 1744 CL medium dose+tiotropium bromide|BI 1744 CL medium dose plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
3052202|NCT00720629|Experimental|First Study Stage: Study Treatment|Visilizumab, Tacrolimus and Methotrexate.
3052203|NCT00720629|Active Comparator|Second Study Stage: Standard Treatment|Second Stage: Antithymocyte-globulin (ATG), Tacrolimus and Methotrexate. The study was closed during first stage and did not proceed to the second stage comparison to ATG in combination with tacrolimus/methotrexate as originally planned.
3052204|NCT00720759|Experimental|Arm 1|D-cycloserine + distributed treatment
3052205|NCT00720759|Sham Comparator|Arm 2|D-cycloserine + condensed treatment
3052206|NCT00720759|Placebo Comparator|Arm 3|Placebo + distributed treatment
3052207|NCT00720759|Placebo Comparator|Arm 4|Placebo + condensed treatment
3052208|NCT00720798|Experimental|Tocilizumab|Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.
3052209|NCT00720876|Experimental|Vorinostat and Rituximab|Vorinostat by mouth two times (2X) per day for two weeks followed by one week of rest. Rituximab intravenously once every three weeks .
3052210|NCT00720941|Active Comparator|Sunitinib|Control arm
3052211|NCT00720941|Experimental|Pazopanib|Experimental arm
3052212|NCT00721110|Active Comparator|Lidocaine|Intravenous Lidocaine Group - Lidocaine is administered intravenously throughout surgery and during the 24 hours following surgery
3052213|NCT00721110|Placebo Comparator|Placebo|A lidocaine placebo is administered intravenously throughout surgery and during the 24 hours after surgery.
3052214|NCT00721110|Active Comparator|Ketamine|Intravenous Ketamine Group - Ketamine is administered intravenously throughout surgery and during the 24 hours following surgery
3052215|NCT00721110|Active Comparator|ketamine + Lidocaine|both ketamine and Lidocaine are administered intravenously throughout surgery and during the 24 hours after surgery.
3052216|NCT00721123|Experimental|Tocilizumab 8 mg/kg|All participants received tocilizumab 8 mg/kg to a maximum of 800 mg, administered by intravenous (IV) infusion over one hour, every 4 weeks. Concomitant therapies were limited to dosage and administration constraints detailed in the protocol.
3052217|NCT00721136|Experimental|1|Moderate risk patients (afib, mechanical aortic valve) randomized to continue coumadin at their usual dose through the procedure.
3052218|NCT00721136|Active Comparator|2|Moderate risk patients randomized to hold their coumadin for 4-5 days prior to the procedure (to allow the INR to normalize).
3052219|NCT00721136|Experimental|3|High risk patients (mechanical mitral valve, prior stroke, current deep vein thrombosis, hypercoagulable syndrome) randomized to continue coumadin at the usual dose through the procedure.
3052220|NCT00721136|Active Comparator|4|"High risk patients randomized to holding coumadin for 4-5 days and using bridging anticoagulation with heparin while the coumadin is held."
3052221|NCT00721149|Experimental|NaviStar ThermoCool|
3052222|NCT00721162|Experimental|Ramucirumab|
3052223|NCT00721175|Experimental|SEMS|self-expandable metal stent group
3052224|NCT00721175|Active Comparator|PS|plastic stent group
3052225|NCT00721188|Experimental|Pharmacokinetic Population|All subjects who received study drug and completed Pharmacokinetic testing through 24 hours post-dose.
3052226|NCT00721214|Experimental|Arm A: 5-azacytidine|5-azacytidine as pre-transplant cytoreduction prior to allogeneic stem cell transplantation for High Risk Myelodysplatic Syndromes.
3052227|NCT00721227|Active Comparator|Anterior Curve|Reduction Gastroplasty by Gastric Plication on Anterior Curve
3052228|NCT00721227|Active Comparator|Greater Curve|Reduction Gastroplasty by Gastric Plication on Greater Curve
3052229|NCT00721253|Active Comparator|ReSTOR Aspheric +4|ACRYSOF ReSTOR Aspheric +4 Model SN6AD3
3052230|NCT00721253|Active Comparator|Tecnis MF|Abbott Medical Optics Tecnis Multifocal Intraocular Lens (IOL) Model ZM900
3052231|NCT00721253|Active Comparator|Acri.LISA|Meditec Acri.LISA Intraocular Lens (IOL) Model 366D
3052232|NCT00721357||Stroke|Stroke subjects
3052233|NCT00721357||Control|neurologically healthy subjects
3052234|NCT00721396|Experimental|B+R246|Subjects in this group received rMenB+OMV NZ vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations.
3052235|NCT00721396|Experimental|B246_R357|Subjects in this group received rMenB+OMV NZ vaccine at at 2, 4, and 6 months of age; routine infant vaccinations were administered at 3, 5 and 7 months of age.
3052236|NCT00721396|Experimental|B+R234|Subjects in this group received rMenB+OMV NZ vaccine at 2, 3, 4 months of age, administered concomitantly with routine infant vaccinations.
3052237|NCT00721396|Active Comparator|R234|Subjects in this group received routine infant vaccines administered at 2, 3 and 4 months of age.
3052238|NCT00721409|Experimental|Arm A|letrozole + PD 0332991
3052239|NCT00721409|Active Comparator|Arm B|letrozole
3052240|NCT00721500|Experimental|narafilcon A / etafilcon A - etafilcon A - narafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A contact lenses worn in both eyes.
3052241|NCT00721500|Experimental|narafilcon A / etafilcon A - narafilcon A - etafilcon A|First, narafilcon A and etafilcon A contact lenses worn contralaterally. Second, narafilcon A contact lenses worn in both eyes. Third, etafilcon A contact lenses worn in both eyes.
3052242|NCT00721500|Experimental|narafilcon A - etafilcon A - narafilcon A / etafilcon A|First, narafilcon A contact lenses worn in both eyes. Second, etafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
3052243|NCT00721500|Experimental|etafilcon A - narafilcon A - narafilcon A / etafilcon A|First, etafilcon A contact lenses worn in both eyes. Second, narafilcon A contact lenses worn in both eyes. Third, narafilcon A and etafilcon A contact lenses worn contralaterally.
3052244|NCT00721513|Experimental|TPFChemotherapy + Concomitant Cetuximab & RT|Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab & Radiation Therapy
3052245|NCT00721539|Other|Transoral Robotic Surgery|Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.
3052246|NCT00721578||1|
3052247|NCT00721617|Active Comparator|Obese subjects|Obese normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
3052248|NCT00721617|Active Comparator|Lean subjects|Lean normotensive subjects will receive 24 hour challenges on 3 separate occasions, in a random order, with IV Normal Saline at 20ml/hour, IV Intralipid (20% solution at 20 ml/hour and an oral fat load (96g/24 hours)
3052249|NCT00721630|Experimental|1|The regimen consists of capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily.
3052250|NCT00721734|Experimental|Carfilzomib|"Carfilzomib, 15 mg/m², was administered intravenously (IV) on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles for a maximum of 12 cycles.~If the 15 mg/m² dose was tolerated the dose could be increased to 20 mg/m² starting at Cycle 2. If 20 mg/m² was tolerated, an additional dose escalation to 27 mg/m² was allowed at Cycle 3 or at subsequent cycles."
3052251|NCT00721799|Experimental|FLT PET scan|"Subjects receive 2 18F-Fluorothymidine PET scans~Scan 1 at baseline (within 30 days prior to the start of chemotherapy and radiation therapy)~Scan 2 between fraction 5 and 6 of radiation therapy (after 10 Gray of radiation)"
3052252|NCT00721955|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo, may repeat after 2 hours x 2
3052253|NCT00721955|Experimental|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, may repeat after 2 hours x 2
3052254|NCT00721955|Experimental|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, may repeat after 2 hours x 2
3052255|NCT00721968|Active Comparator|1|Treatment Group (Group 1): Glaukos Trabecular Micro-Bypass Stent Model GTS400; implantation in conjunction with cataract surgery
3052256|NCT00721968|Placebo Comparator|2|Control Group (Group 2): Cataract surgery only
3052257|NCT00722007|Experimental|Cormet Hip Resurfacing Post-PMA Group|hip resurfacing
3052258|NCT00722020|Experimental|Vest Arm|HFCWO treatments 2-3 times daily 15 minutes per treatment via the VEST
3052259|NCT00722020|No Intervention|Control|Historical control for PICU asthma patients
3052260|NCT00722072|Experimental|Fulvestrant/ Sorafenib|"Fulvestrant: A loading dose will be administered intramuscularly to all subjects during cycle 1 of treatment as follows:~500 mg IM on Day 1~250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of Fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or unacceptable toxicity occurs requiring discontinuation.~Sorafenib: Subjects will take Sorafenib 800 mg/day administered as 400 mg bid (twice daily)each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until unacceptable toxicity occurs."
3052261|NCT00722111|Experimental|Arm 1|lingual press (high-intensity, oral, non-swallowing)
3052262|NCT00722111|Experimental|Arm 2|effortful swallowing (high-intensity swallowing)
3052263|NCT00722111|Experimental|Arm 3|natural swallowing (high frequency, low intensity swallowing)
3052264|NCT00722111|Sham Comparator|Arm 4|non-oral sham (control) exercise
3052265|NCT00722124|Active Comparator|SAMe 800|Each subject randomized to this arm will take a 400 mg pill of SAMe and one matching placebo pill in the AM and again in the PM
3052266|NCT00722124|Active Comparator|SAMe 1600|Each person randomized to this arm will take 2 400 mg pills of SAMe in the AM and again in the PM
3052267|NCT00722124|Placebo Comparator|Placebo|Each subject randomized to this arm will take 2 placebo pills in the AM and again in the PM
3052268|NCT00722137|Active Comparator|R-CHOP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, Vincristine 1.4 mg/m^2, and Prednisone 100 mg/m^2
3052269|NCT00722137|Experimental|VcR-CAP|Rituximab 375 mg/m^2, Cyclophosphamide 750 mg/m^2, Doxorubicin 50 mg/m^2, VELCADE 1.3 mg/m^2, and Prednisone 100 mg/m^2
3052270|NCT00722371|Experimental|Sitagliptin 100 mg|
3052271|NCT00722371|Experimental|Pioglitazone 15 mg|
3052272|NCT00722371|Experimental|Pioglitazone 30 mg|
3052273|NCT00722371|Experimental|Pioglitazone 45 mg|
3052274|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 15 mg|
3052275|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 30 mg|
3052276|NCT00722371|Experimental|Sitagliptin 100 mg/ Pioglitazone 45 mg|
3052277|NCT00722423|Experimental|Integrated Care Model|Integrated Care
3052278|NCT00722423|Experimental|Usual Care Model|Usual Care
3052279|NCT00722436|Experimental|Tranexamic acid|Tranexamic acid (100 mg/kg load, 10 mg/kg/hr) intravenous
3052280|NCT00722436|Placebo Comparator|Placebo|Saline was administered intravenously
3052281|NCT00722553|Other|Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)|"Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.~Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
3052282|NCT00722566|Experimental|1|VELCADE administered by subcutaneous injection
3052283|NCT00722566|Active Comparator|2|VELCADE administered by intravenous infusion
3052284|NCT00722722|Active Comparator|4 dose group|4 doses of bortezomib (1.3mg/m^2 of body surface area)
3052285|NCT00722722|Active Comparator|16 dose group|16 doses of bortezomib (1.3mg/m^2 of body surface area)
3052286|NCT00722722|Active Comparator|32 dose group|32 doses of bortezomib (1.3mg/m^2 of body surface area)
3052287|NCT00722761|Active Comparator|Drosperinone and Ethinyl estradiol|Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day
3052288|NCT00722761|Placebo Comparator|Placebo tablet|Placebo tablet once a day
3052289|NCT00722800|Experimental|A|drospirenone and ethinyl estradiol
3052290|NCT00722800|Placebo Comparator|B|Placebo
3052291|NCT00722865|Other|Avastin (Bevacizumab)|single-arm, open-label
3052292|NCT00723008|Experimental|A|Upon randomization, a double blinded Alpha Stim 100 device preset to the lowest effective setting (1/6) will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
3052293|NCT00723008|Experimental|B|Upon randomization, a double blinded Alpha Stim 100 device preset to no stimulation (0/6)will be applied to the earlobes of the subject for one hour per day for 5 days per week for 4 weeks; after the blinded period is completed the patient will wear a different Alpha Stim device that has not been blinded for one hour per day for 5 days per week for 4 weeks, with settings at the patient's preference (1 to 6/6). Report of pain, anxiety will be assessed before and after each daily session during the 8 week period.
3052294|NCT00723021|Experimental|PF-04191834 30mg|
3052295|NCT00723021|Experimental|PF-04191834 100mg|
3052296|NCT00723021|Experimental|PF-04191834 2000mg|
3052297|NCT00723021|Active Comparator|zileuton|
3052298|NCT00723021|Placebo Comparator|placebo|
3052299|NCT00723073||Caspofungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of caspofungin with an Absolute Neutrophil Count (ANC) < 500, for persistent febrile neutropenia from 11/1/2005 - 10/31/2006, as there first antifungal agent.
3052300|NCT00723073||Micafungin arm|All patients admitted to BWH/DFCI who received at least 2 doses of micafungin with an Absolute Neutrophil Count (ANC) < 500 for persistent febrile neutropenia from 11/1/2006 - 10/31/2007 as there first antifungal agent
3052301|NCT00723099|Experimental|Treatment (chemotherapy, transplant)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1-2 hours on day -6. Patients undergo a lower dose of TBI on day -1.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo donor umbilical cord blood infusion on day 0.~IMMUNOSUPRESSIVE THERAPIES: Patients receive cyclosporine IV over 1 hour every 8-12 hours on days 0 to +180 and mycophenolate mofetil IV or PO every 8 hours on days -3 to +96."
3052302|NCT00723125|Experimental|Cohort 1|"Avastin 10 mg/kg IV over 90 minutes day -14~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10~Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks"
3052303|NCT00723125|Experimental|Cohort 2|"Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7~Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7~Definitive surgery~Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks"
3052304|NCT00723177|Placebo Comparator|Placebo|This group will receive placebo drug
3052305|NCT00723177|Experimental|Low-dose AV411|This group will receive a low dose of AV411
3052306|NCT00723177|Experimental|High-dose AV411|This group will receive a high dose of AV411
3052307|NCT00723190|Experimental|Arm A|CLONICEL (Clonidine HCl sustained release)
3052308|NCT00723203|Experimental|Treatment (panobinostat)|"Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle"
3052309|NCT00723229|Active Comparator|1|
3052310|NCT00723229|No Intervention|2|
3052311|NCT00723255|Experimental|Treatment (bevacizumab, temsirolimus)|Patients receive bevacizumab IV on days 1 and 15 and temsirolimus IV on days 1, 8, 15, and 22.
3052312|NCT00723294|Experimental|Treatment (cryoablation)|A cryoprobe is inserted percutaneously under ultrasound guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively. Patients undergo surgical resection and sentinel lymph node biopsy and/or axillary dissection within 28 days after completion of cryoablation. Patients complete the Brief Pain Inventory before and after cryoablation and after surgery.
3052313|NCT00723398|No Intervention|Group 1: Control|Control, no intervention
3052314|NCT00723398|Experimental|Group 2: Raloxifene 60 Mg Oral Tablet|Raloxifene 60 mg Orally Daily
3052315|NCT00723398|Experimental|Group 3: Raloxifene 30 Mg Oral Tablet|Raloxifene 30 mg Orally Daily
3052316|NCT00723398|Experimental|Group 4: Lovaza 4 gm oral|Lovaza 4 gm/day Orally with Meals
3052317|NCT00723398|Experimental|Group 5: Lovaza 4gm & Raloxifene 30mg|Lovaza 4 gm/day oral capsule with meals plus Raloxifene 30 mg oral tablet daily
3052318|NCT00723450|Placebo Comparator|placebo|Placebo Controlled
3052319|NCT00723450|Experimental|lamictal|Flexible Dosing
3052320|NCT00723489|Experimental|YFV-17D (Right Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccine administration. In this arm, participants will receive a standard vaccine dose (5.5x10^4 Plaque Forming Units) of YFV-17D administered subcutaneously in the right deltoid and placebo vaccination transcutaneously (then covered with a semi-occlusive dressing) in the left deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administer assigned treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
3052321|NCT00723489|Experimental|YFV-17D (Left Deltoid)|Participants will be randomized within each atopic dermatitis (AD) severity subgroup or as non-atopic controls to either subcutaneous (SC) or transcutaneous (TC) vaccination. In this arm, participants will receive YFV-17D vaccination (1x10^3 Plaque Forming Units) by transcutaneous administration (then covered with a semi-occlusive dressing to optimize YFV-17D absorption) in the left deltoid and placebo by subcutaneous administration in the right deltoid. The site pharmacist will maintain the blind and an unblinded (i.e., masked) site coordinator will administered treatment: investigators, participants and assessors remain blinded to treatment assignments throughout the duration of the trial.
3052322|NCT00723528|Placebo Comparator|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
3052323|NCT00723528|Active Comparator|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3052324|NCT00723528|Active Comparator|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
3052325|NCT00723528|Placebo Comparator|Placebo A (After CP)|After the controlled period (that is [i.e.], during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3052326|NCT00723528|Placebo Comparator|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
3052327|NCT00723528|Active Comparator|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
3052328|NCT00723528|Active Comparator|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
3052329|NCT00723554|Experimental|Iloprost|"The study enrolled patients who were already using iloprost with PD-6 without any safety or tolerability concerns, thereby facilitating a direct comparison of the PD-15 to the PD-6.~The single-arm design allowed each patient to serve as his/her own control"
3052330|NCT00723580|Experimental|Sleep and Activity by Treatment Condition|Actigraphic measurements were obtained by attaching an actigraphic watch device to the child's non-dominant wrist. The measurements will include three separate three week periods beginning with a baseline period and the period in which the child's pharmacological treatment was initiated. Two additional three week actigraphic measurement periods will occur at 22 months post-baseline period and at 23 months post-baseline period. The resulting five treatment conditions were: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.). Sleep and activity will be evaluated by treatment conditions.
3052331|NCT00723606|Experimental|Intramuscular ziprasidone|
3052332|NCT00723606|Active Comparator|Intramuscular haloperidol|
3052333|NCT00723632||Peginterferon alfa-2b and ribavirin|All participants included in the study
3052334|NCT00723645||PEG IFN alfa-2b + RBV|Adult participants with chronic hepatitis C who were treated for the first time with pegylated interferon alfa-2b plus ribavirin and achieved end-of-treatment response prior to the study. Participants received no treatment during this study.
3052335|NCT00723697||Patients|Patients addicted to opiates and requiring replacement treatment. Patients in this non-interventional study were prescribed treatment as per usual clinical practice.
3052336|NCT00723710||Intron A|Patients with malignant melanoma who are free of disease post-surgery but at high risk for systemic recurrence.
3052337|NCT00723736||Pediatric Patients|Those with allergic rhinitis or chronic idiopathic urticaria.
3052338|NCT00723749||Suboxone|Patients for whom a drug dependence therapy with SUBOXONE® is planned and indicated, and who have already been pre-treated with SUBUTEX®, or another maintenance drug for at least 6 months.
3052339|NCT00723788|Experimental|Only one arm|All patients enrolled will receive an MRI of the abdomen with detailed views of the appendix
3052340|NCT00723801|Active Comparator|Subjects Randomized to Losartan|Losartan: 100 mg PO QD
3052341|NCT00723801|Active Comparator|Subjects Randomized to Atenolol|Atenolol: 50 mg PO QD
3052342|NCT00723827||All Participants|Participants with newly diagnosed glioblastoma multiforme (treat with temozolomide & radiotherapy) or participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy (treat with temozolomide).
3052343|NCT00723840||Crohn's Disease Participants|"Participants with Crohn's Disease for at least 6 months, who have a Crohn's Disease Activity Index (CDAI) score >= 150. The CDAI score evaluates Crohn's disease symptoms - a score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.~These participants have active disease despite drug therapy."
3052344|NCT00723892||PegIntron/Rebetol and psychotherapy support program|Participants receiving a psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
3052345|NCT00723892||PegIntron/Rebetol alone (no psychotherapy)|Participants receiving no psychotherapy support program during PegIntron/Rebetol therapy for hepatitis C.
3052346|NCT00723931||Participants with Chronic Hepatitis C|Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with Chronic Hepatitis C are generally treated.
3052347|NCT00723944|Active Comparator|Osseotite Certain Prevail|Dental implant with lateralized design
3052348|NCT00723944|Placebo Comparator|Osseotite Certain|Dental implant without the lateralized design
3052349|NCT00723957|Experimental|Ixabepilone, 32 mg/m^2 + Carboplatin (AUC 6)|
3052350|NCT00723957|Active Comparator|Paclitaxel, 200 mg/m^2 + Carboplatin (AUC 6)|
3052351|NCT00724009|Experimental|Clofarabine|Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
3052352|NCT00724061|Experimental|PEG-IFN-α-2b + UV therapy|Pegylated interferon α-2b in combination with UV therapy (either PUVA or NB-UVB).
3052353|NCT00724126|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3052354|NCT00724126|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3052355|NCT00724152|Experimental|Arm 1/Cognitive Behavioral Therapy|Participants randomly assigned to this experimental group received six weeks of tinnitus education plus cognitive behavioral therapy. Cognitive behavioral therapy for tinnitus participants addressed cognitive and behavioral skills targeting the management of tinnitus and the negative impacts of tinnitus. Long-term self-efficacy and self-sufficiency were emphasized. The major components of CBT for tinnitus included identification of individual responses and beliefs about tinnitus and hearing loss, re-conceptualization of the tinnitus experience as one in which the patient has personal control, presentation of skills to modify cognitions and change behaviors, and reinforcement of skills via goals setting, homework and activities. Skills related to attention control, sleep hygiene, relaxation training are provided. Tinnitus education also included causes, treatments, current research, etc.
3052356|NCT00724152|Active Comparator|Arm 2/Tinnitus Education|Participants randomly assigned to this group received six weeks of tinnitus education. Tinnitus education and skills related to attention control, sleep hygiene and relaxation training such as imagery techniques were provided. Tinnitus education included causes, treatments, current research, epidemiological information, basic anatomy of the ear and brain, and support resources.
3052357|NCT00724152|No Intervention|Arm 3/Standard Care|Participants randomly assigned to this control group received only standard care. Standard care involves audiological measurement and brief education during the standard care appointment.
3052358|NCT00724243||Rheumatoid Arthritis Patients in Slovakia|Rheumatoid arthritis patients in Slovakia who are starting treatment with infliximab for the first time, in accordance with normal clinical practice.
3052359|NCT00724308|Experimental|Arm 1|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
3052360|NCT00724308|Experimental|Arm 2|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state smoking cessation Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
3052361|NCT00724347|Experimental|Arm 1|Hearing impaired listeners with hearing aids underwent two months of consonant identification training in their homes.
3052362|NCT00724373||Participants with genotype 1 Hepatitis C Virus infection.|Participants with genotype 1 Hepatitis C Virus (HCV) infection who have been treated with pegylated interferon alfa-2b and ribavirin in the preceding 48 months
3052363|NCT00724451||Participants with Chronic Hepatitis C (CHC)|Peginterferon-naïve participants with CHC seen in general clinical practice in Italy and treated with either pegylated interferon alfa-2a or alfa-2b + ribavirin.
3052364|NCT00724464||Participants with Chronic Hepatitis C|Treatment-naïve participants with chronic hepatitis C, undergoing treatment with a standard treatment regimen of PegIntron and Rebetol in clinical practice at approximately 28 sites in Greece
3052365|NCT00724477||Subjects treated with INEGY|Subjects suffering from primary hypercholesterolemia that are not controlled by statins as a monotherapy, and are treated with INEGY
3052366|NCT00724503|Experimental|mFOLFOX6 + SIRT|A single injection of SIR-Spheres microspheres into the liver plus systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX)
3052367|NCT00724503|Active Comparator|mFOLFOX6|Systemic chemotherapy consisting of Oxaliplatin + Leucovorin + 5- Fluorouracil (FOLFOX).
3052368|NCT00724568|Experimental|Combination Drug Therapy|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11, Doxil at indicated doses on day 4, Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels, and Revlimid at indicated doses on days 1-14 in 3-week cycles for 4-8 cycles. To determine the MTD of the combination of Revlimid, Velcade, dexamethasone, and Doxil, four dose levels are planned.
3052369|NCT00724594|Experimental|N-acetylcysteine|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
3052370|NCT00724594|Active Comparator|Control|Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
3052371|NCT00724698||Group|Patients diagnosed with Allergic Rhinitis or Chronic Idiopathic Urticaria
3052372|NCT00724711|Experimental|FTC/TDF (Truvada [TVD]) + PI/r|Participants in this group received fixed-dose combination FTC 200 mg/TDF 300 mg (Truvada [TVD]) for 48 weeks. The prestudy ritonavir-boosted PI was continued unmodified through the 48 weeks of the study.
3052373|NCT00724711|Active Comparator|ABC/3TC + PI/r|Participants in this group continued their prestudy therapy - ABC 600 mg/3TC 300 mg administered as one tablet orally once daily (Epzicom) plus ritonavir-boosted PI regimen, given orally for 48 weeks.
3052374|NCT00724750|Experimental|G-SUC|Gauze suction (G-SUC) Negative Pressure Wound Therapy, continuous wall suction at 75 to 80 mm Hg was applied and dressings were changed daily.
3052375|NCT00724750|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Closure Device (VAC) Negative Pressure Wound Therapy, continuous suction at 75 to 125 mm Hg and the dressing was changed every 48 hours.
3052376|NCT00724815|Experimental|Sumatriptan|NP101 - sumatriptan iontophoretic transdermal patch
3052377|NCT00724815|Placebo Comparator|Placebo|Placebo iontophoretic transdermal patch
3052378|NCT00724854||Mono-infected with HCV|Participants infected with Hepatitis C Virus (HCV).
3052379|NCT00724854||Co-infected with HCV and HIV|Participants co-infected with HCV and Human Immunodeficiency Virus (HIV).
3052380|NCT00724867|Experimental|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV every 28 days
3052381|NCT00724867|Experimental|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV every 28 days
3052382|NCT00724893||Stage 1 Participants|Participants with CHC receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
3052383|NCT00724893||Stage 2 Participants|Participants with CHC Genotype 1 receiving PegIFN-2b using Redipen™ formulation (1.5 mcg/kg) once weekly and ribavirin capsules (800-1400 mg) daily according to routine medical practice at participating study sites.
3052384|NCT00724932|Experimental|Sugammadex|4.0 mg.kg-1 sugammadex at 1-2 PTC
3052385|NCT00724932|Experimental|Neostigmine|50 µg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2
3052386|NCT00724945|Active Comparator|senofilcon A / balafilcon A|senofilcon A multifocal lenses worn first, balafilcon A multifocal lenses worn second
3052387|NCT00724945|Active Comparator|balafilcon A/senofilcon A|balafilcon A multifocal lenses worn first, senofilcon A multifocal lenses worn second
3052388|NCT00724958||Remicade|Subjects with active luminal and/or fistulizing CD in the hospital or non-hospital setting.
3052389|NCT00724971|Experimental|Inotuzumab Ozogamicin + Rituximab|
3052390|NCT00724984|Experimental|1|
3052391|NCT00725010||Patients|Participants with newly diagnosed Glioblastoma multiforme who were prescribed temozolomide and radiotherapy as standard care.
3052392|NCT00725049|Active Comparator|Dental implant (Nanotite)|Dental implants of short length placed without sinus lifts
3052393|NCT00725049|No Intervention|Control group|Dental implants of standard length placed simultaneously with sinus augmentation
3052394|NCT00725075|Experimental|MK-8435 (Org 25935) 8-16 mg per day|Participants will be maintained on a stable dose of Second Generation Antipsychotic (SGA) and receive 4-8 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
3052395|NCT00725075|Experimental|MK-8435 (Org 25935) 24-32 mg per day|Participants will be maintained on a stable dose of SGA and receive 12-16 mg MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days. The dose of MK-8435 (Org 25935) can be titrated upward or downward within the specified dose range, as needed, up to Day 42 of the study. The dose must remain stable after Day 42 for the remainder of the study.
3052396|NCT00725075|Placebo Comparator|Placebo|Participants will be maintained on a stable dose of SGA and receive matching placebo for MK-8435 (Org 25935) BID, in the morning and the evening, as add-on treatment for up to 87 days.
3052397|NCT00725101||Fibromyalgia (FM) Participants|FM participants starting any new pharmacologic FM agent.
3052398|NCT00725153|Other|PureVision/Acuvue 2|PureVision contact lenses worn first, with Acuvue 2 contact lenses worn second. Both products worn for 10 hours each.
3052399|NCT00725153|Other|Acuvue 2/PureVision|Acuvue 2 contact lenses worn first, with PureVision contact lenses worn second. Both products worn for 10 hours each.
3052400|NCT00725205||Chronic hepatitis C participants|Untreated chronic hepatitis C (CHC) participants starting Peginterferon alfa-2b (injection pen) and Ribavirin combination therapy as their usual medical treatment according to the approved dosage/regimen were selected for this study.
3052401|NCT00725270|Placebo Comparator|Placebo|Patients will be randomized to placebo
3052402|NCT00725270|Experimental|Mifepristone|Patients will be randomized to mifepristone
3052403|NCT00725283|Experimental|GSK2130579A Group|Patients with cytologically proven AML, as defined by the World Health Organization classification, who were administered a standard dose of GSK2130579A treatment. Patients received 24 doses of the study treatment over a period of approximately 4 years.
3052404|NCT00725296||Remicade (Infliximab)|Participants with active and progressive PsA who have responded inadequately to disease-modifying anti-rheumatic drugs will receive induction infusions of Remicade at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. Whole observation period cannot exceed 102 weeks per participant if the maximal therapy interval of 16 weeks as defined in the Summary of Product Characteristics (SPC) is taken into consideration.
3052405|NCT00725322|Experimental|Placebo then Botox|
3052406|NCT00725322|Experimental|Botox then Placebo|
3052407|NCT00725361|Experimental|Active|Ambrisentan
3052408|NCT00725452||Infliximab|Subjects with plaque psoriasis will receive Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
3052409|NCT00725491|Experimental|1|ganirelix
3052410|NCT00725491|Active Comparator|2|triptorelin
3052411|NCT00725504|Experimental|Lidocaine infusion|Each participant will receive an intravenous infusion of lidocaine. Plasma concentrations will be increased gradually from 0-5 µg/ml.
3052412|NCT00725530|Active Comparator|balafilcon A / etafilcon A|Balafilcon A worn first, with etafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
3052413|NCT00725530|Active Comparator|etafilcon A / balafilcon A|Etafilcon A worn first, with balafilcon A worn second. Each product worn bilaterally in an extended wear (overnight) basis for 7 days.
3052414|NCT00725543||Remicade|Subjects with AS with severe axial symptoms and elevated serological markers of inflammatory activity will receive Remicade induction therapy consisting of 3 Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians. Whole observation period cannot exceed 102 weeks per subject if the maximal therapy interval of 16 weeks as defined in Summary of Product Characteristics (SPC) is taken into consideration.
3052415|NCT00725608||Patients|Opioid dependent patients currently in maintenance treatment with another medication who are switched to Suboxone (buprenorphine plus naloxone)
3052416|NCT00725621||Remicade|Patients with severe RA (indication according to Austrian labeling) will receive Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions. Remicade induction and maintenance therapy doses and intervals will be at the discretion of the physicians.
3052417|NCT00725712|Experimental|5-days on/9-days off|Dosing for first 5 days in every 14-day period.
3052418|NCT00725712|Experimental|daily dosing|dosed every day
3052419|NCT00725725|Experimental|4 mg Org 25935|Participants took a total of 3 doses of 4 mg Org 25935 prior to therapy sessions over a 2-week period.
3052420|NCT00725725|Experimental|12 mg Org 25935|Participants took a total of 3 doses of 12 mg Org 25935 prior to therapy sessions over a 2-week period.
3052421|NCT00725725|Placebo Comparator|Placebo|Participants took a total of 3 doses of placebo matched to Org 25935 prior to therapy sessions over a 2-week period.
3052422|NCT00725751||PegIFN-2b/ribavirin with substitution therapy|Participants in this cohort received antiviral treatment and substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
3052423|NCT00725751||PegIFN-2b/ribavirin without substitution therapy|Participants in this cohort received antiviral treatment but did not receive substitution therapy (opioid medicines with long-lasting effects [methadone + buprenorphine] or morphine)
3052424|NCT00725764|Experimental|Single Arm|Participants who qualified for study entry received 240 mg of GSK1363089 (foretinib) on a 5-day on 9-day off schedule every 2 weeks.
3052425|NCT00725842||Peg-IFN alfa-2b + ribavirin|Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).
3052426|NCT00725920|Experimental|Topiramate|patients receiving the active drug: topiramate
3052427|NCT00725920|Placebo Comparator|Placebo Control group|patients received pills content placebo, that were identical to the pills content active drug
3052428|NCT00725959|Experimental|Facebook Arm|Participants in this arm will have exposure to innovative, dynamic and regularly updated HIV Prevention messages on Facebook
3052429|NCT00725959|Active Comparator|Control arm|Participants in this arm will have exposure to static information on HIV prevention currently available online
3320837|NCT02014155|Experimental|Group TMI + Pulmonary Rehabilitation|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects. Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
3320838|NCT02014155|Experimental|Control Group|Inspiratory muscle training will be held three times a week for eight weeks
3320839|NCT02014155|Experimental|COPD group not rehabilitation|
3320840|NCT02014168|Experimental|Viroflu® and MVA-NP+M1|1 dose (0.5ml) of Viroflu® and 1 dose of 1.5 x10^8 pfu MVA-NP+M1 intramuscularly into the vastus lateralis muscle on day 0. The vaccines will be given side by side, with MVA NP+M1 being given immediately after the seasonal influenza vaccine.
3320841|NCT02014168|Placebo Comparator|Viroflu® and saline placebo|1 dose (0.5ml) of Viroflu® and 1 dose of a 0.9% saline placebo injected intramuscularly into the vastus lateralis muscle on day 0. The placebo will be administered immediately after the seasonal influenza vaccine.
3320842|NCT02014181|Experimental|Flaxseed|40 grams finely ground flaxseed powder daily for one month in patient with cystic fibrosis
3320843|NCT02014194|Placebo Comparator|attentional bias modification, placebo|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms). There are two arms with 15 OCD patients each one.
3179069|NCT00668759|Active Comparator|2|"Amiodarone Injection:~In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF."
3179070|NCT00668772|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
3320844|NCT02014194|Active Comparator|attentional bias modification, active group|Measure of attentional bias modification treatment after 10 sessions of attentional bias modification (two arms).
3320845|NCT02014207|Experimental|golden crinkle|
3320846|NCT02014207|Experimental|high blanch|
3320847|NCT02014207|Experimental|low blanche|
3320848|NCT02014207|Experimental|high chill|
3320849|NCT02014207|Experimental|low chill|
3320850|NCT02014220|Experimental|Atlantic Western chips|deep fried potato chips
3320851|NCT02014220|Experimental|Dakota Pearl chips|deep fried potato chips
3320852|NCT02014220|Experimental|Andover Ontario chips|deep fried potato chips
3320853|NCT02014220|Experimental|white bread with margarine|energy control
3320854|NCT02014220|Experimental|white bread|control
3320855|NCT02014233|Experimental|Omega-3|Participants will consume 5 mL of omega-3 (2333 mg essential fatty acids) with 1000 IU vitamin D3 for 21 days.
3320856|NCT02014233|Placebo Comparator|Olive oil|Participants will consume 5 mL of olive oil with 1000 IU vitamin D3 for 21 days.
3320859|NCT02014259|Experimental|Subjects with renal impairment|
3320860|NCT02014259|Active Comparator|Subjects with normal renal function|
3052442|NCT00726063|Experimental|Nanotite implant|Nanotite dental implant
3052443|NCT00726063|Active Comparator|Osseotite implant|Osseotite dental implant
3052444|NCT00726232|Experimental|Ruxolitinib 10 mg BID|Participants received 10 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3052445|NCT00726232|Experimental|Ruxolitinib 25 mg BID|Participants received 25 mg Ruxolitinib orally twice a day (BID) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3052446|NCT00726232|Experimental|Ruxolitinib 50 mg QD|Participants received 50 mg Ruxolitinib orally once a day (QD) for 56 days (two 28-day cycles) during the dose-ranging phase. After patients completed 2 cycles of treatment at the randomized dose, Investigators were permitted to adjust the dose/regimen on an individual basis to achieve an optimal balance of efficacy and safety. Treatment continued until a patient met a withdrawal criterion, had intolerable toxicity, progression of disease, or withdrew consent.
3052447|NCT00726323|Experimental|5/9 dosing|240 mg of foretinib on a 5 day on / 9 day off regimen every 14 days.
3052448|NCT00726323|Experimental|daily dosing|80 mg foretinib on a daily dosing regimen
3052449|NCT00726375|Experimental|Etanercept|a maximum of 8 SQ doses of 'Etanercept (Enbrel) at 0.4mg/kg per dose up to a maximum of 25 mg per dose
3052450|NCT00726388|Experimental|A|IV administration of multiple doses of DIC075V (intravenous diclofenac sodium) over multiple days
3052451|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
3052452|NCT00726414|Experimental|Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed|A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
3052453|NCT00726453|Experimental|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
3052454|NCT00726557||PegIntron + Rebetol|There will be a distinction between the patients depending on the type of substitution drug used (secondary parameters).
3052455|NCT00726609||Posaconazole (assigned by physician in normal practice)|"Treatment of invasive fungal infection.~Prophylaxis of invasive fungal infection."
3052456|NCT00726622|Active Comparator|Arm 1: Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection. The standard form of surgery is open laparotomy rectal resection. During open laparotomy, the surgeon makes a large incision or cut in the abdomen, and goes in through that cut to remove the tumor and lymph nodes from the rectum.
3179071|NCT00668772|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
3179072|NCT00668772|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
3320861|NCT02014285||Muscle Ultrasound/Sample|30 subjects enrolled from Wake Forest Baptist Health Intensive Care Units. Each study subject will undergo an ultrasound to examine the size and echogenicity of their muscles and a muscle biopsy from the rectus femoris. The muscles studied will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior.
3320862|NCT02014298|Other|Control|One area assessed as a control area, compared to the laser-treated area
3320863|NCT02014298|Active Comparator|Non-ablative Laser treatment|3 Non-ablative fractional laser treatments of one area
3320864|NCT02014311|Experimental|CTA+CTP guided treatment strategy|Patients with adenosine stress induced regional myocardial hypoperfusion (CT perfusion imaging) in combination with a corresponding epicardial coronary vessel with >50% stenosis (Coronary CT angiography) will be referred for invasive investigation within 30 days after study inclusion - CTP-INTERVENTION
3320865|NCT02014311|Active Comparator|CTA guided treatment strategy|Patients with at least one epicardial coronary artery stenosis >50% (Coronary CT angiography) will be referred for invasive investigation within 30 days after initial discharge from the hospital - CONTROL
3320866|NCT02014324||(suspected) NSCLC, mediastinal staging, endosonography|Patients with potentially medically operable and resectable NSCLC are eligible if there is an indication for pathological evaluation of mediastinal lymph nodes.
3320867|NCT02014337|Experimental|Mifepristone and Eribulin in combination|Single Arm
3320868|NCT02014350||DePuy Delta Xtend RTSA|
3320869|NCT02014389||Healthy subjects|Healthy subjects will be used as control group
3320870|NCT02014389||Patients|Patients with Glaucoma , Patients with retinal dystrophy
3320871|NCT02014415||Liver Biopsy|Participants will provide liver tissue specimens collected at the time of liver biopsy, to determine the rate of progression of liver injury in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3320872|NCT02014415||Known Severe Liver Disease|Participants will provide samples of serum, plasma, and DNA at defined time points to determine what genetic and environmental modifiers and biomarkers are associated with severe clinical liver disease, such cirrhosis, portal hypertension and liver failure in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3320873|NCT02014415||Post Liver Transplant|Participants will provide a DNA sample to determine what genetic and environmental modifiers are associated with the need for liver transplantation in adults with Pi-ZZ Alpha-1 Antitrypsin Deficiency.
3320874|NCT02014428|Experimental|Hyaluronic acid|220 mg hyaluronic acid per tablet (two tablets/day for 10 days, and subsequently one tablet/day for three months)
3052457|NCT00726622|Experimental|Arm 2: Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection. Laparoscopic-assisted rectal resection is performed using small instruments on long handles introduced into the abdomen through small ports called trocars in 3 - 6 positions on the abdomen through incisions measuring 5 -10 mm, under the guidance of a video camera. The abdominal wall is held up with carbon dioxide under pressure. The piece of bowel or intestine is removed through another incision (about 8 centimeters), and the ends of the intestine are reconnected to provide normal bowel function.
3052458|NCT00726661||Chemotherapy Cohort|Eligible participants with HER2-negative disease who received their first cytotoxic chemotherapy and/or targeted therapy were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
3052459|NCT00726661||Hormonal Therapy Cohort|Eligible participants with hormone receptor positive disease who received their first hormonal therapy for advanced disease were observed until death, withdrawal of consent, loss to follow-up, or until study closure, whichever was sooner (approximately 4.5 years).
3052460|NCT00726713|Experimental|1|Metanx
3052461|NCT00726713|Placebo Comparator|2|Placebo
3052462|NCT00726739|Experimental|Arm I - LMI + aldesleukin|Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3052463|NCT00726739|Active Comparator|Arm II (control) - aldesleukin|Patients receive aldesleukin SC on days 1 and 2. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over and receive treatment on arm I.
3052464|NCT00726739|Experimental|Arm III - Crossover Patients|"Patients who have progressive disease on Arm II were be offered crossover to Arm I provided they continued to meet all study criteria.~Patients receive allogeneic large multivalent immunogen vaccine (LMI) LP2307 intradermally on day 1 and aldesleukin subcutaneously (SC) on days 7 and 8. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity"
3052465|NCT00726752|Experimental|Axitinib|
3052466|NCT00726882|Other|HCV-infected Participants|"Hepatitis C virus (HCV)-infected participants who received ABT-333 at any dose level or matching placebo in a prior clinical study involving ABT-333.~Participants received no treatment in this follow-up study."
3052467|NCT00726895|Experimental|Quinine Sulfate Capsules 1 x 324 mg Dose|Quinine Sulfate 1 x 324 mg capsule dose.
3052468|NCT00726895|Experimental|Quinine Sulfate Capsules 2 x 324 mg Dose|Quinine Sulfate 2 x 324 mg capsules dose.
3052469|NCT00726986|Experimental|Sorafenib, Cisplatin, and Etoposide|
3052470|NCT00726999|Active Comparator|1|Gabapentin
3052471|NCT00726999|Placebo Comparator|2|Placebo Comparator -- pill matched in appearance to gabapentin
3052472|NCT00727064|Active Comparator|DVS/VEN|
3052473|NCT00727064|Active Comparator|VEN/DVS|
3052474|NCT00727090|Experimental|1|Conivaptan in addition to usual care at the discretion of the attending medical staff
3052475|NCT00727090|No Intervention|2|Usual care by the attending physician staff
3052476|NCT00727194|Experimental|1|eculizumab
3052477|NCT00727194|Placebo Comparator|2|Placebo
3052478|NCT00727220||Insulin Pump Therapy|Children starting insulin pump therapy
3052479|NCT00727220||Insulin Injections|Children remaining on insulin injections.
3052480|NCT00727246|Experimental|CDP-Choline|Treatment with CDP-Choline
3052481|NCT00727246|Placebo Comparator|Placebo|Treatment with Placebo
3052482|NCT00727259||Patients with chronic hepatitis C|Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.
3052483|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fasting|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
3052484|NCT00727272|Experimental|Quinine Sulphate Tabs 300 mg - Fasting|A single dose of quinine sulphate 300 mg administered with 240 mL of room temperature water after an overnight fast of at least 10 hours.
3052485|NCT00727272|Experimental|Quinine Sulfate Caps 324 mg - Fed|A single dose of quinine sulfate 324 mg administered with 240 mL of room temperature water thirty minutes after the initiation of a standardized, high-fat breakfast.
3052486|NCT00727298||Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
3052487|NCT00727311||PegIntron + Rebetol|Participants with chronic hepatitis C, who are either treatment-naïve or previously relapsed after receiving interferon monotherapy
3052488|NCT00727337|Experimental|LACE-DVD|Participants will complete the LACE training, however, not in an interactive computer mode but through a static DVD mode
3052489|NCT00727337|Experimental|LACE-COMPUTER|Participants will complete a computer-based auditory training program (i.e., LACE)
3052490|NCT00727337|Active Comparator|PLACEBO-DIRECTED LISTENING|Participants will complete a directed listening to books on CD treatment
3052491|NCT00727337|Active Comparator|CONTROL|Participants will be provided with hearing aids
3052492|NCT00727402||Observational|healthy patients fit into lotrafilcon A contact lenses for continuous wear
3052493|NCT00727441|Experimental|Arm A|Patients receive GVAX pancreatic cancer vaccine intradermally (ID) on day 1 of Cycle 1 and undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive an additional dose of the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1. Treatment with the vaccine repeats every 28 days for 4 additional cycles.
3179073|NCT00668772|Active Comparator|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
3179074|NCT00668772|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
3179075|NCT00668798||A|mother CMV positive
3179076|NCT00668798||B|mother CMV negative
3179077|NCT00668850|Experimental|1|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
3052494|NCT00727441|Experimental|Arm B|Patients receive low-dose cyclophosphamide IV on day 0 and GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive low-dose cyclophosphamide IV on day 0 and the vaccine on day 1. Treatment with cyclophosphamide and the vaccine repeats every 28 days for 4 additional cycles..
3052495|NCT00727441|Experimental|Arm C|Patients receive GVAX pancreatic cancer vaccine ID on day 1 of Cycle 1 and low-dose oral cyclophosphamide twice daily on days 1-7. Patients undergo pancreaticoduodenectomy on day 15. Approximately 6-10 weeks after surgery, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21 (Cycle 2). Beginning approximately 1 month after vaccination, patients receive standard adjuvant chemoradiotherapy comprising gemcitabine, fluorouracil or capecitabine, and radiotherapy over 26-28 weeks. Beginning approximately 4-8 weeks after the completion of chemoradiotherapy, patients receive the vaccine on day 1 and low-dose oral cyclophosphamide twice daily on days 1-7 and 15-21. Treatment with the vaccine and cyclophosphamide repeats every 28 days for 4 additional cycles.
3052496|NCT00727506|Experimental|BIBW 2992|BIBW 2992 once daily
3052497|NCT00727506|Active Comparator|TMZ|TMZ 21/28 days
3052498|NCT00727506|Experimental|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
3052499|NCT00727532|Experimental|Sorafenib|Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.
3052500|NCT00727558|Active Comparator|narafilcon A|spherical soft contact lens worn as a daily disposable modality for one week
3052501|NCT00727558|Active Comparator|nelfilcon A|spherical soft contact lens worn as a daily disposable modality for one week
3052502|NCT00727571||No CKD or Anemia|Chronic kidney disease (CKD) is based on estimated Glomerular Filtration Rate (GFR), calculated by the Modification of Diet in Renal Disease (MDRD) method, of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per World Health Organization (WHO) criteria. Participants completed the study after Week 1; data contributed to prevalence estimates.
3052503|NCT00727571||No CKD, but Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants completed the study at Week 2 and completed an anemia work-up; data contributed to prevalence estimates.
3052504|NCT00727571||CKD with Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed an anemia work-up, and mobility and physical performance assessments.
3052505|NCT00727571||CKD with no Anemia|CKD is based on estimated GFR calculated by the MDRD method of < 60 mL/min/1.73m^2. Anemia is defined as Hemogloblin <12 g/dL in women, < 13 g/dL in men per WHO criteria. Participants were observed for 26 weeks and completed mobility and physical performance assessments.
3052506|NCT00727597|Experimental|Arm A : Boosted Lexiva plus Epzicom|Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg).
3052507|NCT00727597|Experimental|Arm B: Efavirenz plus Epzicom|QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
3052508|NCT00727636|Experimental|Gardasil vaccine - Prospective Study|Prospective study participants received the Gardasil vaccine during the study
3052509|NCT00727636|No Intervention|Retrospective Study|Retrospective study participants had blood drawn in the study after they had received the Gardasil vaccine from their primary medical provider
3052510|NCT00727649|Active Comparator|Arm 1|Fiber (psyllium) powder
3052511|NCT00727649|Active Comparator|Arm 2|Loperamide
3052512|NCT00727740|Experimental|1|Indomethacin liquid suspension 100 mg (25 mg/5ml) which is 20 cc of suspension instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
3052513|NCT00727740|Placebo Comparator|2|Placebo suspension in the same volume (20 cc) which is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. The placebo suspension is also flushed with 5 cc of normal saline.
3052514|NCT00727844|Experimental|Delayed Start Linezolid|Subjects continued their existing regimen for 2 months after which LZD (600 mg once daily) was added. After 2 consecutive AFB negative sputum smears (not to exceed 4 months of LZD therapy), subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
3052515|NCT00727844|Experimental|Immediate Start Linezolid|Upon completion of entry criteria, subjects had LZD (600 mg once daily) added to their regimen. After 2 consecutive AFB negative sputum smears (or at 4 months) subjects were randomized to continue on 600 mg LZD once daily or to de-escalate to 300 mg once daily. Regardless of the dosage, subjects remained on LZD treatment for 18 months after sputum culture conversion or until they could no longer tolerate therapy.
3052516|NCT00727857|Experimental|Pioglitazone 15 mg /Metformin 850 mg BID|
3052517|NCT00727857|Active Comparator|Pioglitazone 15 mg BID|
3052518|NCT00727857|Active Comparator|Metformin 850 mg BID|
3052519|NCT00727909|Experimental|Hearing Aid Treatments|"Hearing aid treatments:~TC (Traditional Custom), RITA (Receiver-in-the Aid), and RITE (Receiver-in the-Ear)"
3052520|NCT00727961|Experimental|Arm 1|Caelyx Intravenous, 50 mg/m^2, given for 6 cycles
3052521|NCT00728130|Experimental|A|A neck dissection of at least the ipsilateral sub-level 1B will be performed in all patients
3052522|NCT00728182|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and a 11 amino acid domain than enables the peptide to cross the blood-brain barrier.
3052523|NCT00728182|Placebo Comparator|Placebo|
3179078|NCT00668850|Active Comparator|2|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
3052524|NCT00728260||Menactra Vaccine Recipients|"Children 2 years through 10 years of age who received Menactra vaccine within Kaiser Permanente during the study period. They served as their own controls for evaluation of acute (Days 0-30) events. Rates of events occurring during Days 0-30 following vaccination were compared to rates of events occurring during Days 31-60 following vaccination.~Six-month surveillance: For each individual receiving Menactra vaccine, the rate of an event in the 30-day follow-up period was compared with the rate of the same event in the 31-180-day follow-up period using age, sex, and seasonality as covariates in Cox regression analyses.~Menactra vaccine was administered according to routine clinical practice."
3052525|NCT00728416|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3052526|NCT00728416|Placebo Comparator|Arm 2|Matching placebo nasal spray
3052527|NCT00728468|Experimental|Treatment arm|
3052528|NCT00728481|Active Comparator|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks for subjects with positive 24 hour pH study (GERD)
3052529|NCT00728481|Active Comparator|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
3052530|NCT00728494||Treatment and Patient Assistance Program|Patient assistance program was provided to the participants treated with PegIntron/Rebetol. The support program consisted of training by physicians or specialized nurses on the significance of treatment compliance, methods for managing adverse events, and correct drug administration, as well as informational materials and assistance in the management of adverse events.
3052531|NCT00728494||Treatment Alone|PegIntron/Rebetol treatment only.
3052532|NCT00728507|Experimental|1|Two months of isoniazid, rifapentine, pyrazinamide and moxifloxacin (HPZM) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
3052533|NCT00728507|Active Comparator|2|Two months of isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) administered once daily. Pyridoxine (vitamin B6) will be given with each dose of isoniazid.
3052534|NCT00728689|Active Comparator|Group ST-246 Form I (followed by Form V)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
3052535|NCT00728689|Active Comparator|Group ST-246 Form V (followed by Form I)|Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
3052536|NCT00728728|Active Comparator|Arm 1: Pregnenolone|Pregnenolone
3052537|NCT00728728|Placebo Comparator|Arm 2: Placebo|Placebo
3052538|NCT00728754|Experimental|Dental implant Osseotite Prevail|Dental implant with lateralized design
3052539|NCT00728754|Active Comparator|Dental implant Osseotite|Dental implant without the lateralized design
3052540|NCT00728819|Active Comparator|1|Tapered PICC
3052541|NCT00728819|Active Comparator|2|Non-tapered PICC
3052542|NCT00728910|Active Comparator|Atorvastatin|atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
3052543|NCT00728910|Active Comparator|ABT335|ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
3052544|NCT00728910|Active Comparator|ER niacin|ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks
3052545|NCT00728923|Experimental|1|Minocycline (NPL-2003)
3052546|NCT00728936|Experimental|IMO-2125 0.04 mg/kg q week|IMO-2125 given weekly at 0.04 mg/kg
3052547|NCT00728936|Experimental|IMO-2125 0.08 mg/kg q week|IMO-2125 given weekly at 0.08 mg/kg
3052548|NCT00728936|Experimental|IMO-2125 0.16 mg/kg q week|IMO-2125 given weekly at 0.16 mg/kg
3052549|NCT00728936|Experimental|IMO-2125 0.32 mg/kg q week|IMO-2125 given weekly at 0.32 mg/kg
3052550|NCT00728936|Experimental|IMO-2125 0.48 mg/kg q week|IMO-2125 given weekly at 0.48 mg/kg
3052551|NCT00728936|Placebo Comparator|Placebo|Weekly saline placebo
3052552|NCT00728936|Experimental|IMO-2125 0.16 mg/kg twice a week|IMO-2125 given twice a week at 0.16 mg/kg
3052553|NCT00728949|Active Comparator|IMC-A12 (cixutumumab) + antiestrogen therapy|Participants will receive intravenous IMC-A12 10 mg/kg over 1 hour every 2 weeks, as well as the same dose and schedule of the last antiestrogen therapy to which their disease became refractory.
3052554|NCT00728949|Experimental|IMC-A12 (cixutumumab)|Participants will receive only IMC-A12 (10 mg/kg over 1 hour every 2 weeks).
3052555|NCT00728988|Experimental|Atorvastatin Group|
3052556|NCT00728988|Other|Usual Care Group|
3052557|NCT00729053|Active Comparator|Previous treatment, 0.16mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
3052558|NCT00729053|Active Comparator|Previous treatment, 0.64mg/kg|Patients will have clear cell renal carcinoma with previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
3052559|NCT00729053|Active Comparator|Treatment Naive, 0.16mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.16mg/kg
3052560|NCT00729053|Active Comparator|Treatment Naive, 0.64mg/kg|Patients will have clear cell renal carcinoma without previous treatment. Patients will receive weekly SC injections of IMO-2055 at a dose of 0.64mg/kg
3179079|NCT00668876|Active Comparator|1|Group A: perioperative immunonutrition
3179080|NCT00668876|Active Comparator|2|Group B: postoperative immunonutrition
3179081|NCT00668876|Active Comparator|3|Group C: control
3179082|NCT00668915||A|Primary arthroplasty
3320875|NCT02014428|Placebo Comparator|Placebo|two tablets/day for 10 days, and subsequently one tablet/day for three months
3052561|NCT00729157|Experimental|Treatment (ziv-aflibercept and fludeoxyglucose F 18)|Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients experiencing clear clinical benefit with aflibercept may continue treatment beyond 12 months, at the discretion of the study sponsor. Patients undergo FDG-PET scans at baseline and after 8 weeks of study therapy to evaluate changes in FDG avidity on FDG-PET scan. Blood samples are obtained at baseline and periodically during study for laboratory correlative studies. Samples are examined for pretreatment serum VEGF concentration, thyroglobulin levels (when elevated), serum pharmacokinetics of aflibercept by ELISA, and anti-aflibercept antibodies.
3052562|NCT00729183|Experimental|Odanacatib 50 mg|Participants receive 50 mg odanacatib and open-label 5600 IU vitamin D3 tablets once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
3052563|NCT00729183|Placebo Comparator|Placebo|Participants receive matching placebo to odanacatib and open-label 5600 IU vitamin D3 once weekly for 24 months. Participants also receive 500 mg of open-label daily calcium supplement as needed to ensure a total daily calcium intake of 1200 mg.
3052564|NCT00729326|Experimental|Sequence A|
3052565|NCT00729326|Experimental|Sequence B|
3052566|NCT00729378|Experimental|Exercise Intervention|Implementation of intervention program designed to provide skeletal loading through high impact activities. All activities performed by subjects in exercise intervention arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
3052567|NCT00729378|No Intervention|Control|Participants in this arm will not take part in exercise intervention. All activities performed by subjects in control arm will be assessed by physical activity questionnaire and use of pedometer. Have baseline anthropometric measurements, total body DXA scans and peripheral quantitative computed tomography (pQCT) scans of the tibia and femur.
3052568|NCT00729430|Experimental|Omega-3 Fatty Acids|Participants will receive a highly purified form of omega-3 fatty acids for 6 months.
3052569|NCT00729430|Placebo Comparator|Placebo|Participants will receive placebo for 6 months.
3052570|NCT00729469|Experimental|Ospemifene 60 mg/day and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of ospemifene 60 mg each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
3052571|NCT00729469|Placebo Comparator|Placebo and K-Y® lubricant|Subjects will receive a single, oral dose (1 tablet) of Placebo each morning with food for 12 weeks. All subjects will be provided vaginal lubricant (K-Y® Brand) and should use it as needed.
3052572|NCT00729482|Experimental|1|Treatment Arm (RAD001)
3052573|NCT00729521|No Intervention|Control|a control group receiving no special resources or guidance related to fall injury prevention or the community health improvement process;
3052574|NCT00729521|Active Comparator|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
3052575|NCT00729521|Experimental|Facilitative System|"a Facilitative System group receiving facilitative system support in addition to the resources provided the Standard Program group"
3052576|NCT00729586|Experimental|Arm I (temsirolimus)|Patients receive temsirolimus IV over 30 minutes once weekly for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3052577|NCT00729586|Experimental|Arm II (temsirolimus, megestrol acetate, tamoxifen citrate)|Patients receive temsirolimus as in Arm I and megestrol acetate PO BID for 3 weeks alternating with tamoxifen citrate PO BID for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3052578|NCT00729612|Experimental|Treatment (nab-paclitaxel, carboplatin)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and carboplatin IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3052579|NCT00729651|Experimental|1|Alendronate sodium/Cholecalciferol
3052580|NCT00729651|Active Comparator|2|Alendronate sodium
3052581|NCT00729690|Experimental|1 Multi-Dose Pregabalin|Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
3052582|NCT00729690|Experimental|2 single-dose pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
3052583|NCT00729690|Placebo Comparator|3 Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
3052584|NCT00729781|Experimental|Polyester Implants|There is one arm for this study. All subjects in this study will receive the investigational nasal implants. See the detailed description for procedure information.
3052585|NCT00729807|Experimental|Pentamidine|
3052586|NCT00729833|Experimental|CP-751,871 + Sunitinib|Escalating cohorts of CP-751,871 + Sunitinib
3052587|NCT00729846|Experimental|A|Patients will receive combination verteporfin with photodynamic therapy at reduced fluence [300mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
3052588|NCT00729846|Experimental|B|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
3052589|NCT00729859|Experimental|Group 1|Acyline 300 µg/kg injections every two weeks (2 doses) + placebo (no active ingredients) gel daily for 28 days + oral placebo pill daily for 28 days
3052590|NCT00729859|Experimental|Group 2|Acyline 300 µg/kg injections every two weeks (2 doses) + Testosterone gel 100 mg daily for 28 days + oral placebo pill daily for 28 days
3052591|NCT00729859|Experimental|Group 3|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
3052592|NCT00729924|Experimental|Open label oral raltegravir|Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.
3052593|NCT00729937|Experimental|TMP/SMX vs. Placebo|Subjects with an acute uncomplicated cutaneous abscess will be randomized to receive either Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or 4 placebo pills (twice per day).
3052594|NCT00729937|Experimental|TMP/SMX vs. Clindamycin|Subjects with an acute uncomplicated wound infection will be randomized to receive Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day, with alternating 1 identical placebo pill, twice per day) or clindamycin (300 mg, four times per day, with 3 placebo pills on alternating doses).
3052595|NCT00729937|Experimental|Cephalexin and TMP/SMX vs. Cephalexin|Subjects with acute uncomplicated cellulitis will be randomized to receive cephalexin (500 mg, four times per day) and Trimethoprim/Sulfamethoxazole (TMP/SMX) (4 single strength pills, 80 mg/400 mg each, twice per day) or cephalexin (500 mg, four times per day) and placebo (4 pills, twice per day).
3052596|NCT00730015|Experimental|145 μg linaclotide|
3052597|NCT00730015|Experimental|290 μg linaclotide|
3052598|NCT00730015|Placebo Comparator|Matching Placebo|
3052599|NCT00730028|Experimental|Limited Abscess|Limited abscess with or without cellulitis less than or equal to 5 cm in diameter will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA 300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children; or c) placebo two capsules three times daily.
3052600|NCT00730028|Experimental|Cellulitis or Larger Abscess|Subjects with cellulitis only or abscess > 5 cm in diameter, or with 2 or more sites of skin infection will be randomized to receive a 10-day course a) TMP-SMX 160/800 mg twice daily for adults; 8-10 mg/kg of TMP, 40-50 mg/kg of SMX twice daily for children; or b) CLINDA300 mg three times daily for adults; 25-30 mg/kg/day divided three times daily for children.
3052601|NCT00730041|Active Comparator|Palatal Implants|Pillar(R) Palatal Implants in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
3052602|NCT00730041|Sham Comparator|Sham procedure|Sham (procedure but no implants inserted) in combination with continuous positive airway pressure (CPAP) in subjects diagnosed with obstructive sleep apnea (OSA)
3052603|NCT00730132||New Statin|Group 1 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by transition to a new statin treatment
3052604|NCT00730132||Statin Dose Titration|Group 2 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) whose lipid-lowering therapy was modified by increasing the dose of ongoing statin treatment
3052605|NCT00730132||Ezetimibe added to existing statin|Group 3 - Patients with established diagnosis of CHD and hypercholesterolemia who did not achieve the target values for TC and LDL-C with existing statin therapy (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin) and whose lipid-lowering therapy was modified by the addition of ezetimibe to ongoing statin treatment
3052606|NCT00730158|Experimental|Arm A|irinotecan+ KD018
3052607|NCT00730158|Experimental|Arm B|irinotecan + placebo
3052608|NCT00730171|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator.
3052609|NCT00730236|Experimental|AEGR-733|
3052610|NCT00730275|Experimental|Sitagliptin 50 mg|Participants were randomized to sitagliptin 50 mg
3052611|NCT00730275|Experimental|Sitagliptin 100 mg|Participants were randomized to sitagliptin 100 mg
3052612|NCT00730275|Experimental|Sitagliptin 200 mg|Participants were randomized to a single dose of sitagliptin 200 mg
3052613|NCT00730275|Placebo Comparator|Placebo to sitagliptin|Participants were randomized to matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg
3052614|NCT00730327|Experimental|BIB®|Receives BioEnterics® Intragastric Balloon Intervention as well as diet and exercise counseling with the Behavioral Modification Intervention.
3052615|NCT00730327|Other|Control|Control arm receives the Behavioral modification intervention only.
3052616|NCT00730353|Experimental|1|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered in a 28-day treatment cycle. The 28 days of treatment with paclitaxel and sunitinib malate (plus the time required to recover if toxicity is encountered) is defined as a cycle.~Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.~Sunitinib malate 37.5 mg orally, daily. After 4 cycles, paclitaxel will be discontinued and patients will continue on sunitinib malate until disease progression, unacceptable toxicity, or physician discretion."
3052617|NCT00730405|Active Comparator|Albaconazole 100mg|Albaconazole for 36 weeks
3052618|NCT00730405|Active Comparator|Albaconazole 200mg|Albaconazole for 36 weeks
3052619|NCT00730405|Active Comparator|Albaconazole 400mg|Albaconazole for 36 weeks
3052620|NCT00730405|Active Comparator|Albaconazole 400mg 24 weeks, Placebo 12 weeks|Albaconazole for 24 weeks, Placebo for 12 weeks
3052621|NCT00730405|Placebo Comparator|Placebo 400 mg|Placebo for 36 weeks
3052622|NCT00730483|Experimental|DEB-TACE|PVA microporous hydrospheres loaded with doxorubicin hydrochloride used for the treatment of unresectable liver metastases from neuroendocrine tumors.
3052623|NCT00730522|Active Comparator|1|CPP-109 vigabatrin tablets
3052624|NCT00730522|Placebo Comparator|2|Matching Placebo Tablets
3052630|NCT00730691|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3052631|NCT00730691|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3052632|NCT00730691|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3052633|NCT00730691|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily, for 8 weeks, followed by placebo-matching capsules, orally, once daily, for 1 week.
3052634|NCT00730691|Active Comparator|Duloxetine 60 mg|Duloxetine 60 mg capsules, orally, once daily, for 8 weeks, followed by duloxetine 30 mg capsules, orally, once daily, for 1 week.
3052635|NCT00730730|Experimental|Complete SE Iliac Stent|Complete SE Iliac Stent
3052636|NCT00730756|Active Comparator|Arm A|Fluticasone Furoate Nasal Spray 110mcg intranasally once daily
3052637|NCT00730756|Placebo Comparator|Arm B|Matching placebo nasal spray intranasally once daily
3052638|NCT00730847|Experimental|Cervarix Group|Healthy female subjects who received three doses of the Cervarix vaccine, administered intramuscularly in the deltoid region according to a 0, 1 and 6-month schedule.
3052639|NCT00730912|Experimental|Pediatrics 3 to 6 years|Pediatrics 3 to 6 years
3052640|NCT00730912|Experimental|Pediatrics 7 to 15 years|Pediatrics 7 to 15 years
3052641|NCT00730912|Experimental|Adults 16 to 64 years|Adults 16 to 64 years
3052642|NCT00730925|Experimental|BIBW 2992|patient to receive tablets of BIBW 2992 once a day, starting at high dose until progression of the disease
3052643|NCT00730925|Experimental|BIBW 2992 + paclitaxel|patient whose disease progressed on treatment with BIBW 2992 monotherapy to receive tablet of BIBW 2992 once a day in combination with i.v. paclitaxel 3 weekly
3052644|NCT00730964|Other|Phase 4|Open Label
3052645|NCT00731042|Experimental|Avagard|3M Avagard Surgical and healthcare Personnel Hand Antiseptic with Moisturizers
3052646|NCT00731042|Active Comparator|Purell|Purell Surgical Scrub with Moisturizers
3052647|NCT00731055|Experimental|Intervention 1|"Each participant participates in 4 consecutive interventions in random order.~Placebo, 1 capsule before the session~0.5 mg varenicline, 1 capsule before the session 3.1 mg varenicline, 1 capsule before the session~4. 2 mg varenicline, 1 capsule before the session"
3052648|NCT00731055|Experimental|Intervention 2|Each participant participates in 4 consecutive interventions in random order. 1.0.5 mg varenicline, 1 capsule before the session 2. 1 mg varenicline, 1 capsule before the session 3.2 mg varenicline, 1 capsule before the session 4. Placebo, 1 capsule before the session
3052649|NCT00731055|Experimental|Intervention 3|Each participant participates in 4 consecutive interventions in random order. 1.1 mg varenicline, 1 capsule before the session 2. 2 mg varenicline, 1 capsule before the session 3.Placebo, 1 capsule before the session 4. 0.5 mg varenicline, 1 capsule before the session
3052650|NCT00731055|Experimental|Intervention 4|Each participant participates in 4 consecutive interventions in random order. 1.2 mg varenicline, 1 capsule before the session 2. Placebo, 1 capsule before the session 3. 0.5 mg varenicline, 1 capsule before the session 4. 1 mg varenicline, 1 capsule before the session
3052651|NCT00731094|Experimental|Physical Activity Intervention|Expert system-based physical activity counseling: Individualized baseline counseling and guided goal setting to increase physical activity gradually to at least 150 minutes/week of moderate intensity, with a 12-month follow-up via postal mail of 14 additional counseling contacts generated by responses to a physical activity questionnaire and individually tailored computer-generated expert system feedback messages for physical activity based on stages of the motivational readiness for change model
3052652|NCT00731094|No Intervention|Attention Control|Generalized baseline healthy lifestyle education and suggestion to increase physical activity, with a 12-month follow-up via postal mail of 14 wellness newsletters focused on health issues other than physical activity
3052653|NCT00731120|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3052654|NCT00731120|Experimental|Vortioxetine 2.5 mg|Vortioxetine 2.5 mg encapsulated tablets, orally, once daily for up to 8 weeks.
3052655|NCT00731120|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg encapsulated tablets, orally, once daily for up to 8 weeks.
3052656|NCT00731133|Other|Disulfiram|Disulfiram at 250 mg daily
3052657|NCT00731198|Experimental|1|Drotaverine hydrochloride
3052658|NCT00731198|Active Comparator|2|Hyoscine-N-butylbromide
3052659|NCT00731211|Experimental|Pazopanib|800 mg of pazopanib orally each day continuously
3052660|NCT00731341|Experimental|Hysteroscopic cryoablation|Women undergoing hysteroscopic ultrasound guided cryoablation for the treatment of uterine fibroids.
3052661|NCT00731484||Volunteer Patients/Subjects|These subjects should present the general population.
3052662|NCT00731549|Experimental|1|Active Treatment of aripiprazole IM depot (300mg or 400mg)
3052663|NCT00731588|Experimental|PPG1A - Adults|Phase I completed: Healthy male and post-menopausal female volunteers between the ages of 18 and 65. Volunteers must not have donated blood in the previous 8 weeks.
3052664|NCT00731588|Experimental|PPG1B - Infants|Phase II in progress: Newborns >= 24 weeks gestation who are patients in the Neonatal Intensive Care Unit at the University of Iowa Hospitals and Clinics that are being treated with the expectation of survival.
3052665|NCT00731614|Experimental|Arm 1|Cognitive Behavior Therapy + mirror retraining
3052666|NCT00731614|Active Comparator|Arm 2|Supportive psychotherapy
3052667|NCT00731640|Active Comparator|Monofocal|Patients unilaterally implanted with ReSTOR lens in one eye and previously implanted with monofocal Intraocular lens (IOL) (unspecified) in other eye
3052668|NCT00731640|Active Comparator|Phakic|Patients unilaterally implanted with ReSTOR lens in one eye and phakic in the other eye with no necessary cataract removal impending
3052669|NCT00731653|Experimental|1|BCI-024 and BCI-049
3052670|NCT00731666|Other|Titan® IPP|Subjects implanted with Titan® IPP
3052671|NCT00731679|Placebo Comparator|Placebo|Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3052672|NCT00731679|Experimental|Rifaximin|Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
3052673|NCT00731692|Experimental|FTY720D 0.5 mg|Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
3052674|NCT00731692|Placebo Comparator|Placebo|Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
3052675|NCT00731692|Experimental|FTY720D 1.25 mg switch to 0.5 mg|Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
3052676|NCT00731783|Active Comparator|Index patient only|Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
3052677|NCT00731783|Active Comparator|Household|All members of the household (over the age of 6 months) will be asked to follow the study protocol.
3052678|NCT00731874|Active Comparator|Arm 1 (6 to 8 ng/mL)|Target tacrolimus trough concentration of 6 to 8 ng/mL
3052679|NCT00731874|Active Comparator|Arm 2 (3 to 5 ng.mL)|Target tacrolimus trough concentration of 3 to 5 ng/mL
3052680|NCT00731939|Other|Titan® OTR IPP|Subjects implanted with Titan® One Touch Release (OTR) Inflatable Penile Prosthesis (IPP)
3052681|NCT00732030|Experimental|AcrySof Toric T3|Each enrolled eye receives AcrySof Toric Model SN60T3 Intraocular Lens (IOL)
3052682|NCT00732069|Active Comparator|Placebo, then ramipril, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3052683|NCT00732069|Active Comparator|Placebo, then valsartan, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3052684|NCT00732069|Active Comparator|Ramipril, then placebo, then valsartan|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3052685|NCT00732069|Active Comparator|Valsartan, then placebo, then ramipril|placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.
3052686|NCT00732069|Active Comparator|Ramipril, then valsartan, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
3052687|NCT00732069|Active Comparator|Valsartan, then ramipril, then placebo|placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.
3052688|NCT00732160|Experimental|HS-V/A; LS-V/A|High Sodium diet- Vehicle infusion then Aldosterone infusion Low Sodium diet- Vehicle infusion then Aldosterone infusion
3052689|NCT00732160|Experimental|HS-A/V; LS-A/V|High Sodium diet- Aldosterone infusion then Vehicle infusion Low Sodium diet- Aldosterone infusion then Vehicle infusion
3052690|NCT00732160|Experimental|LS-V/A; HS-V/A|Low Sodium diet- Vehicle infusion then Aldosterone infusion High Sodium diet- Vehicle infusion then Aldosterone infusion
3052691|NCT00732160|Experimental|LS-A/V; HS-A/V|Low Sodium diet- Aldosterone infusion then Vehicle infusion High Sodium diet- Aldosterone infusion then Vehicle infusion
3052692|NCT00732199|Other|Arm 1|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Young adults.
3052693|NCT00732199|Experimental|Arm 2|Determine the apneic threshold and carbon- dioxide reserve using noninvasive positive pressure ventilation during NREM sleep and determine the effect of episodic hypoxia on ventilatory long-term facilitation during NREM sleep in Older adults.
3052694|NCT00732212|Experimental|Doppler endoscopic probe hemostasis|In addition to stigmata of hemorrhage and visual cues, Doppler endoscopic probe will be used for detection of blood flow before and after standard endoscopic hemostasis. If residual blood flow in the lesion is found after standard treatment, further endoscopic treatment will be applied as deemed safe by the investigator-endoscopist.
3052695|NCT00732212|Active Comparator|Standard Endoscopic Hemostasis|Standard, visually guided endoscopic hemostasis based on visual cues of stigmata of hemorrhage and endoscopic control of bleeding or treatment of the stigmata according to current guidelines
3052696|NCT00732225|Active Comparator|DisCoVisc|Alcon DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate)
3052697|NCT00732225|Active Comparator|DuoVisc|Alcon DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate)
3052698|NCT00732225|Active Comparator|BioVisc|Sophia Lab BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate)
3052699|NCT00732225|Active Comparator|Healon5|AMO Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate)
3052700|NCT00732225|Active Comparator|Amvisc Plus|Bausch & Lomb Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate)
3052701|NCT00732238|Experimental|Arm 1|Removal of Bladder Catheter. Urine Culture Post Catheter Removal. Shorter Duration of Antibiotic Therapy.
3052702|NCT00732238|Active Comparator|Arm 2|Urinary Catheter Is Not Exchanged. Antibiotic Therapy Is Based On Culture Obtained From Existing Catheter. Longer Duration of Antibiotic Therapy.
3052703|NCT00732251|Experimental|Allopurinol|Using an open label, naturalistic design, subjects will continue with their current psychiatric medications during the study. Allopurinol will be given at a fixed dose of 300 mg/day for the first week and then 600mg/d for the remainder of the study. Subjects who cannot tolerate the 600mg dose will be given a dose of 300mg/d. Subjects will participate in monthly follow up visits for 24 months. Subjects who develop a substance abuse or substance dependence disorder during the study will be terminated from the study. Also, subjects who develop a medical condition which can affect their mood stability will be terminated from the study.
3052704|NCT00732303|Experimental|1|"Pemetrexed (Alimta) 500mg/m^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles~Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
3052705|NCT00732381|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3052706|NCT00732381|Placebo Comparator|Arm 2|Matching placebo nasal spray
3052707|NCT00732472|Experimental|7 day repeat dose|7 day repeat dose
3052708|NCT00732498|Experimental|ESHAP followed by Zevalin and Rituximab|Etoposide, Methylprednisolone, Cytarabine, Cisplatin (ESHAP) infusion X 2 Cycles followed by Rituximab and In-Zevalin or Y-Zevalin.
3052709|NCT00732615|Placebo Comparator|Placebo|Sterile water for injection
3052710|NCT00732615|Experimental|50, 75, 100 mcg NPSP558|Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response
3052711|NCT00732641|Experimental|Peginterferon α-2b|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
3052712|NCT00732641|No Intervention|No Treatment|Participants will be observed and will receive no treatment.
3052713|NCT00732654|Experimental|Sublingual Immunotherapy (SLIT)|"These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.~Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years."
3052714|NCT00732654|Experimental|SLIT/ Oral Immunotherpay (OIT) B|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years."
3052715|NCT00732654|Experimental|SLIT/ OIT A|"These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.~Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.~Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks."
3052716|NCT00732758|Experimental|Vitamin D3|Vitamin D3 1000 IU Tablet
3052717|NCT00732758|Placebo Comparator|Placebo|Placebo Tablet
3052718|NCT00732875|Experimental|Open Label Infliximab + Methotrexate|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
3052719|NCT00732901|Experimental|A (escitalopram)|Escitalopram
3052720|NCT00732901|Experimental|B (placebo)|Placebo
3052721|NCT00732940|Experimental|Belimumab Q2WKS|Every other week: 100 mg of belimumab (1 injection) subcutaneous (under the skin) on days 0, 7, and 14, then every other week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
3052722|NCT00732940|Experimental|Belimumab 3X/WK|Three times weekly: 200 mg of belimumab (2 injections of 100 mg each) subcutaneous (under the skin) on days 0, 2, and 4 then 100 mg three times a week until final evaluation at Week 24 with option to continue receiving belimumab at the same dose through 144 week continuation period.
3052723|NCT00732992|Experimental|CDD|
3052724|NCT00732992|Experimental|2/1|
3052725|NCT00733005|Experimental|Arm 1|Mometasone furoate nasal spray 200 mcg QD (once per day)
3052726|NCT00733005|Placebo Comparator|Arm 2|Matching placebo nasal spray
3052727|NCT00733096|Experimental|1|Epidural etanercept 4 mg, two doses 2 weeks apart
3052728|NCT00733096|Active Comparator|2|Epidural methylprednisolone 60 mg, two doses 2 weeks apart
3052729|NCT00733096|Placebo Comparator|3|Epidural saline, two doses 2 weeks apart
3052730|NCT00733135|Other|Atherectomy with embolic protection|All subjects were treated with atherectomy (with SilverHawk or TurboHawk device) in conjunction with embolic protection (SpiderFX device).
3052731|NCT00733226|Active Comparator|1 Broncho-Vaxom|The children received one capsule per oral, OM-85 BV (3.5 mg) per day for the first 10 consecutive days of each month for 3 consecutive months.
3052732|NCT00733226|Placebo Comparator|2 (Placebo OM-85 BV)|The children received one capsule per oral, placebo per day for the first 10 consecutive days of each month for 3 consecutive months.
3052733|NCT00733278|Experimental|Copper IUD|Copper IUD
3052734|NCT00733291|Active Comparator|Nelfilcon A soak / Nelfilcon A no-soak|Nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by nelfilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
3052735|NCT00733291|Active Comparator|Nelfilcon A no soak / nelfilcon A soak|Nelfilcon A contact lenses inserted directly from the blister package, followed by nelfilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
3052736|NCT00733291|Active Comparator|Etafilcon A soak / etafilcon A no soak|Etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution, followed by etafilcon A contact lenses inserted directly from the blister package. Each pair of lenses worn for 2 hours.
3052737|NCT00733291|Active Comparator|Etafilcon A no soak / etafilcon A soak|Etafilcon A contact lenses inserted directly from the blister package, followed by etafilcon A contact lenses inserted after being soaked overnight in a multi-purpose disinfecting solution. Each pair of lenses worn for 2 hours.
3052738|NCT00733304|Experimental|5 mg/ml TID|eligible participants received 5 mg/ml Pazopanib eye drops three times daily (TID)
3052739|NCT00733304|Experimental|2 mg/ml TID|eligible participants received 2 mg/ml Pazopanib eye drops three times daily
3052740|NCT00733304|Experimental|5 mg/ml QD|eligible participants received 5 mg/ml Pazopanib eye drops once daily (QD)
3052741|NCT00733330|Other|Conventional TKR arm|Patients to receive treatment with either a P.F.C. Sigma or L.C.S. knee using the conventional manual surgical technique
3052742|NCT00733330|Active Comparator|MiTKR CAS arm|Patients to receive treatment with either a P.F.C. or L.C.S. knees in chronological order into the CAS group which will use minimally invasive surgery and computer navigation
3052743|NCT00733343|Active Comparator|Treatment Group|treatment with Adaptive Servoventilation (Europe: AutoSet CS (USA: VPAP (Variable Positive Airway Pressure) Adapt SV)) + standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
3052744|NCT00733343|No Intervention|Control Group|standard medical therapy according to applicable guidelines (ESC, ACC/AHA)
3052745|NCT00733356|Experimental|Vyvanse Treatment|All subjects were tested at baseline before medication and then titrated to best dose and retested on Vyvanse Medication.
3052746|NCT00733369|Other|PFC Sigma RP-F|125 patients to be allocated to this arm according to blinding envelopes
3052747|NCT00733369|Active Comparator|PFC Sigma RP|125 patients to be allocated to this arm according to blinding envelopes
3052748|NCT00733408|Experimental|Tx (chemo, MoAb, and enzyme inhibitor)|"INDUCTION THERAPY: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving complete response, partial response, or stable disease after completion of induction therapy will receive bevacizumab IV over 30-90 minutes once every 14 or 21 days and erlotinib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity."
3052749|NCT00733421|Experimental|1|"Active study drug:~Etoricoxib 90 mg once daily"
3052750|NCT00733421|Active Comparator|2|Tramadol 100 mg slow release twice daily
3052751|NCT00733499|Other|LCS Complete Duofix|102 patients
3052752|NCT00733499|Active Comparator|LCS Complete Porocoat|104 patients
3052753|NCT00733512||ReSTOR|AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL)
3052754|NCT00733746|Experimental|Neoadjuvant therapy + Surgery + Adjuvant therapy|As part of neoadjuvant therapy, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 29, 36, and 43 and oral erlotinib hydrochloride once daily on days 1-43 in the absence of disease progression or unacceptable toxicity. Within 3-6 weeks after completion of neoadjuvant therapy, patients undergo pancreaticoduodenectomy and patients receive gemcitabine hydrochloride and erlotinib hydrochloride as in neoadjuvant therapy within 5-10 weeks post surgery.
3052755|NCT00733824|Experimental|Cohort 1|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~160 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3052756|NCT00733824|Experimental|Cohort 2|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~240 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3052757|NCT00733824|Experimental|Cohort 3|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~320 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3052758|NCT00733824|Experimental|Cohort 4|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~400 µg/kg IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3052759|NCT00733824|Experimental|Phase II|"240 µg/kg SC AMD3100 Day -5~10 µg/kg SC G-CSF Day -4 thru Day -1~MTD as determined in Phase I IV AMD3100 and 10 µg/kg SC G-CSF Day 1~Pheresis (this will be repeated on Day 2 through Day 4 until target of ≥5X106 CD34+ cell/kg is reached)"
3052760|NCT00733902|Experimental|Tanezumab 10 mg|
3052761|NCT00733902|Experimental|Tanezumab 5 mg|
3052762|NCT00733902|Experimental|Tanezumab 2.5 mg|
3052763|NCT00733902|Placebo Comparator|Placebo|
3052764|NCT00733954|Active Comparator|clobetasol propionate spray|clobetasol propionate spray 0.05%
3052765|NCT00733954|Active Comparator|clobetasol propionate ointment|clobetasol propionate ointment 0.05%
3052766|NCT00733980|Experimental|GSK561679 arm|Double blind GSK561679
3052767|NCT00733980|Placebo Comparator|placebo arm|Double blind placebo
3052768|NCT00733993|Experimental|1 Caffeine 150 mg|Caffeine 150 mg
3052769|NCT00733993|Placebo Comparator|2 Placebo|Placebo
3052770|NCT00733993|Experimental|3 Amphetamine|Amphetamine
3052771|NCT00733993|Experimental|4 Caffeine 300 mg|Caffeine 300 mg
3052772|NCT00734032|Placebo Comparator|Placebo Group|Matched Placebo
3052773|NCT00734032|Experimental|SB480848 40mg Group|SB480848 40mg/day
3052774|NCT00734032|Experimental|SB480848 80mg Group|SB480848 80mg/day
3052775|NCT00734032|Experimental|SB480848 160mg Group|SB480848 160mg/day
3052776|NCT00734071|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3052777|NCT00734071|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3052778|NCT00734097|Experimental|Nexium 40 mgs|
3052779|NCT00734149|Experimental|Bortezomib+Melphalan+Prednisone|Bortezomib 1.3 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 4, 8, and 11 of a 28 day cycle. Six cycles are planned. On days when both melphalan and bortezomib are given, melphalan is given at least one hour prior to bortezomib. Melphalan 6 mg/m2 is administered orally on an empty stomach daily on days 1-7 of each cycle. Prednisone 60 mg/m2 is administered orally daily on days 1-7 of each cycle.
3052780|NCT00734162|Experimental|Tenofovir disoproxil fumarate (TDF)|
3052781|NCT00734162|Placebo Comparator|Placebo|
3052782|NCT00734214|Experimental|0.9% NaCl|
3052783|NCT00734214|Active Comparator|0.45% NaCl|
3052784|NCT00734305|Experimental|Dose Escalation|Cohorts of escalating doses of MM-121 administered IV QW to determine MTD or RP2D + expansion cohort at MTD/RP2D
3052785|NCT00734344|Active Comparator|Arm 1|Raltegravir plus Truvada
3052786|NCT00734344|Active Comparator|Arm 2|Efavirenz plus Truvada
3052787|NCT00734409|Experimental|RASS plus (BIS)|Participants in this arm will receive sedation assessment with the RASS scale augmented with Bispectral Index (BIS) Monitor
3052788|NCT00734409|No Intervention|RASS only|Participants will receive sedation assessment only using the RASS scale which is the standard of care at our institution
3052789|NCT00734474|Experimental|3.0 mg LY2189265|"LY2189265 (Dulaglutide): 3.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052790|NCT00734474|Experimental|2.0 mg LY2189265|"LY2189265 (Dulaglutide): 2.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052791|NCT00734474|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052792|NCT00734474|Experimental|1.0 mg LY2189265|"LY2189265 (Dulaglutide): 1.0 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052793|NCT00734474|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052794|NCT00734474|Experimental|0.5 mg LY2189265|"LY2189265 (Dulaglutide): 0.5 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052795|NCT00734474|Experimental|0.25 mg LY2189265|"LY2189265 (Dulaglutide): 0.25 milligrams (mg), subcutaneous (SC) injection, once weekly for up to 104 weeks~Placebo: tablet, administered orally, once daily for up to 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for up to 104 weeks"
3052796|NCT00734474|Active Comparator|Sitagliptin|"Sitagliptin: 100-milligrams (mg) tablet, administered orally, once daily for 104 weeks~Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
3052797|NCT00734474|Placebo Comparator|Placebo/Sitagliptin (Baseline Through 104 Weeks)|"Placebo: solution, subcutaneous (SC) injection, once weekly for 104 weeks~Placebo: tablet, administered orally, once daily for 26 weeks~Sitagliptin: after 26 weeks, 100-milligrams (mg) tablet, administered orally, once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), administered orally for 104 weeks"
3052798|NCT00734500|Experimental|Treatment|Treatment
3052799|NCT00734539|Experimental|1|fluconazole 6mg/kg IV or PO twice weekly for 6 weeks
3052800|NCT00734539|Placebo Comparator|2|Placebo IV or PO twice weekly for 6 weeks
3052801|NCT00734578|Experimental|SPD503-AM|SPD503 (Guanfacine Extended Release)
3052802|NCT00734578|Experimental|SPD503-PM|SPD503 (Guanfacine Extended Release)
3052803|NCT00734578|Placebo Comparator|Placebo|
3052804|NCT00734591||Previously treated with Exubera|
3052805|NCT00734591||Previously treated with comparator|Subjects who had been treated with a comparator (other diabetes treatment such as injected insulin) in a prior Exubera controlled trial.
3052806|NCT00734604|Experimental|T(OaD)/S(PRN)/T(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
3052807|NCT00734604|Experimental|T(OaD)/T(PRN)/S(PRN)|Tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
3052808|NCT00734604|Experimental|S(PRN)/T(OaD)/T(PRN)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks
3052809|NCT00734604|Experimental|S(PRN)/T(PRN)/T(OaD)|Sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
3052810|NCT00734604|Experimental|T(PRN)/T(OaD)/S(PRN)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks
3052811|NCT00734604|Experimental|T(PRN)/S(PRN)/T(OaD)|Tadalafil 20 mg as needed [T(PRN)] for 8 weeks, 1 week washout, sildenafil citrate 100 mg as needed [S(PRN)] for 8 weeks, 1 week washout, tadalafil 5 mg once a day [T(OaD)] for 8 weeks
3052812|NCT00734617|Experimental|Less Dependent Smokers|
3052813|NCT00734617|Experimental|More Dependent Smokers|
3052814|NCT00734630|Active Comparator|Nebivolol|Nebivolol 5 mg, 5 mg nontrade tablets, oral administration Nebivolol 10 mg, 10 mg nontrade tablets, oral administration Nebivolol 20 mg, 20 mg nontrade tablets, oral administration Nebivolol 40 mg (two 20 mg nontrade tablets), oral administration
3052815|NCT00734630|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3052816|NCT00734656|Placebo Comparator|Placebo medication + placebo alcohol|
3052817|NCT00734656|Experimental|Placebo Medication + 0.8 gr/kg Ethanol|
3052818|NCT00734656|Experimental|4 mg Dutasteride + Placebo Alcohol|
3052819|NCT00734656|Experimental|4 mg Dutasteride + 0.8 gr/kg Ethanol|
3052820|NCT00734734|Experimental|1|
3052821|NCT00734747|Experimental|Medigus SRS Endoscopic Stapling System|Endoluminal fundoplication for the treatment of GERD
3052822|NCT00734799|No Intervention|2|Usual Care/Wait-List Control
3052823|NCT00734799|Experimental|1|Sleep Intervention for PTSD (SIP)
3052824|NCT00734851|Experimental|Multimodality|4 cycles of 70 mg/m2 Docetaxel + 37.5 mg daily Sunitinib for 14 days followed by a 7 day break for 3 cycles + external beam radiotherapy to 66 Gray over 6-7 weeks
3052825|NCT00734903|Experimental|A Woman's Path to Recovery (WPR)|A gender-focused approach to addiction recovery
3052826|NCT00734903|Active Comparator|12-Step Facilitation (TSF)|An evidence-based, non-gender-focused approach to addiction recovery
3052827|NCT00734929|Experimental|1|Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
3052828|NCT00734929|Active Comparator|2|Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia
3052829|NCT00734968|Experimental|Treatment|Patients randomly assigned to be treated with nitrofurantoin 100mg PO BID x 3 days post-operatively
3052830|NCT00734968|Placebo Comparator|Placebo|Arm randomly assigned to receive placebo 1 tablet PO BID x 3 days post-operatively.The incidence of UTI in this group will be compared with group one (1)
3052831|NCT00734994|Experimental|Hyperthermia system, Mitomycin C|Pilot study single arm study to test the safety, tolerability and clinical benefit of regional hyperthermia and mitomycin-C intravesical chemotherapy to treat non-invasive Transitional Cell carcinoma (TCC) of the bladder that has recurred after standard resection and adjuvant therapy.
3052832|NCT00735007|Experimental|1|
3052833|NCT00735072|Experimental|Maraviroc|Maraviroc (dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
3052834|NCT00735072|Placebo Comparator|Placebo|Placebo (dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens).
3052835|NCT00735306|Experimental|1|Avastin, Tarceva and Radiation Therapy
3052836|NCT00735371|Active Comparator|Lisdexamfetamine Dimesylate (LDX) 30 mg|
3052837|NCT00735371|Active Comparator|LDX 50 mg|
3052838|NCT00735371|Active Comparator|LDX 70 mg|
3052839|NCT00735371|Placebo Comparator|Placebo|
3052840|NCT00735397|Experimental|Perampanel|Participants previously receiving perampanel/placebo in the double blind-study, were titrated to receive perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years.
3052841|NCT00735436|Other|Gliadel/Avastin/CPT-11|Gliadel/Avastin/CPT-11
3052842|NCT00735449|Active Comparator|Combigan ®|Combigan® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%) adjunctive to Xalatan® (latanoprost 0.005%)
3052843|NCT00735449|Active Comparator|Timolol Maleate 0.5%|Timolol maleate 0.5% adjunctive to Xalatan® (latanoprost 0.005%)
3052844|NCT00735462|Experimental|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks
3052845|NCT00735462|Experimental|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
3052846|NCT00735462|Placebo Comparator|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks.
3052847|NCT00735475|Experimental|Afluria®|
3052848|NCT00735475|Active Comparator|Fluzone®|
3052849|NCT00735618|Experimental|Guided Relaxation|Heart rate variability (HRV) high frequency (HF) spectral analysis, before and after a 15 minute, one-time, guided relaxation program
3052850|NCT00735644|Experimental|JE-CV GPO MBP (Lot 1)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 1.
3052851|NCT00735644|Experimental|JE-CV GPO MBP (Lot 2)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 2.
3052852|NCT00735644|Experimental|JE-CV GPO MBP (Lot 3)|Participants 12 to 18 months of age received one dose of Japanese encephalitis chimeric virus vaccine (JE-CV) from Government Pharmaceutical Organization Mérieux Biological Products (GPO-MBP) Lot 3.
3052853|NCT00735644|Active Comparator|JE-CV WRAIR (Group 4)|Participants 12 to 18 months of age received one dose of JE-CV from Acambis at Walter Reed Army Institute of Research (WRAIR)
3052854|NCT00735644|Sham Comparator|Hepatitis A (Group 5)|Participants 12 to 18 months of age randomized to receive Hepatitis A vaccine
3052855|NCT00735670|Experimental|Venlafaxine|Venlafaxine HCl is classified as a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) and has been approved by the FDA for the treatment of major depressive disorder. The treatment group will receive a sub-therapeutic dose over a two week period, with a two week titration, starting at 37.5 mg up to a maximum dose of 150 mg per day. At the end of the treatment period, dosage was tapered down in a step-wise fashion over a period of three weeks; 75 mg. for two weeks and 37.5 mg. for one week. While this was the standard protocol, study drug tapering was individualized based on side effects and the clinical judgment of the prescriber.
3052856|NCT00735670|Placebo Comparator|Placebo|Placebo capsules were compounded by filling a matching gelatin capsule with lactose. Titration up and down followed the same schedule as the treatment group.
3052857|NCT00735696|Experimental|ramucirumab + paclitaxel + carboplatin|"Participants will receive ramucirumab in combination with paclitaxel and carboplatin until disease progression, the development of an unacceptable toxicity, or other withdrawal criteria, for up to six cycles (3 weeks per cycle).~In the absence of any withdrawal criteria, participants will continue to receive ramucirumab monotherapy every 3 weeks, provided there is ongoing evidence of benefit upon review every 6 weeks."
3052858|NCT00735709|Experimental|Vortioxetine 1 mg|Vortioxetine 1 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3052859|NCT00735709|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3052860|NCT00735709|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up 8 weeks.
3052861|NCT00735709|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3052862|NCT00735787|Placebo Comparator|Placebo/Adalimumab|"Loading dose of 2 placebo injections at Week 0 and placebo injections every other week (eow) from Week 1 through Week 15.~In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27."
3052863|NCT00735787|Active Comparator|Adalimumab|80 mg adalimumab loading dose at Week 0 and 40 mg adalimumab eow from Weeks 1 through 15. For subjects who continued in the second period of the study, subjects received 2 placebo injections at Week 16 to maintain the blind. Open-label 40 mg adalimumab eow was administered from Week 17 through Week 27.
3052864|NCT00735826|Experimental|Vorinostat 400 mg|Vorinostat will be administered orally once daily in an open-labeled unblinded manner to all subjects enrolled in the study. Subjects will received 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection.
3052865|NCT00735839|Experimental|V710|V710 vaccination (60 mcg) single dose on Day 1
3052866|NCT00735839|Placebo Comparator|Placebo|Placebo single dose on Day 1
3052867|NCT00735878|Experimental|ABT-751 100 mg and Carboplatin|100 mg BID ABT-751 orally for 7 days. Carboplatin AUC 4.5 once every 21 days.
3052868|NCT00735878|Experimental|ABT-751 125 mg and Carboplatin|125 mg BID ABT-751orally for 7 days. Carboplatin AUC 4.5 or 6 once every 21 days.
3052869|NCT00735878|Experimental|ABT-751 150 mg and Carboplatin|150 mg BID ABT-751orally for 7 days. Carboplatin AUC 6 once every 21 days.
3052870|NCT00735904|Experimental|AG-013736/Cisplatin/Gemcitabine|
3052871|NCT00735917|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive saracatinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3052872|NCT00736073|Active Comparator|1|aprepitant
3052873|NCT00736073|Placebo Comparator|2|Placebo
3052874|NCT00736099|Experimental|linagliptin 5 mg|open label
3052875|NCT00736099|Experimental|linagliptin 5 mg and pioglitazone 30 mg|open label
3052876|NCT00736125|Active Comparator|1|
3052877|NCT00736125|Active Comparator|2|
3052878|NCT00736190|Experimental|TDF|300-mg tablet (marketed formulation) taken orally once daily
3052879|NCT00736229|Experimental|Exenatide|0.05 µg/min liquid bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
3052880|NCT00736242||PEG-IFN alfa-2b + RBV|Participants received a combination of PEG-IFN alfa-2b plus RBV according to routine clinical practice and locally-approved product recommendations for a minimum of 12 weeks. No investigational medicinal product was provided by the sponsor.
3052881|NCT00736255|Experimental|Vyvanse and transdermal nicotine patch|The first group will receive LDX/SPD489 titrated up to 70 mg qd for 4 weeks after the identified quit date. Subjects will continue to receive NRT 21 mg at week 1 post quit date, then 14mg at week 2 post quit date and 7 at weeks 3 and 4 post quit date.
3052882|NCT00736255|Placebo Comparator|Placebo and transdermal nicotine patch|The second group will receive matching placebo and NRT after the quit date.
3052883|NCT00736333||Pegylated Liposomal Doxorubicin|Subjects with metastatic breast cancer
3052884|NCT00736450|Experimental|Arm I|See Detailed Description
3052885|NCT00736476|Experimental|1|
3052886|NCT00736476|Placebo Comparator|2|
3052887|NCT00736489|Experimental|crossover dose 1|AZD3199 120 microgram
3052888|NCT00736489|Experimental|crossover dose 2|AZD3199 480 microgram
3052889|NCT00736489|Experimental|crossover dose 3|AZD3199 1920 microgram
3052890|NCT00736489|Placebo Comparator|crossover dose 4|Placebo
3052891|NCT00736489|Active Comparator|crossover dose 5|Formoterol 9 microgram
3052892|NCT00736489|Active Comparator|crossover dose 6|Formoterol 36 microgram
3052893|NCT00736502||Patients HIV-1 positive|
3052894|NCT00736580|Active Comparator|Blunt Needles|Cesarean Delivery Performed with Blunt-tipped surgical Needles
3052895|NCT00736580|Placebo Comparator|Sharp Needles|Cesarean delivery performed with sharp surgical needles.
3052896|NCT00736632|Placebo Comparator|Placebo|Patients in the control group will receive placebo pills (instead of vitamin D) and calcium carbonate 500 mg twice daily.
3052897|NCT00736632|Active Comparator|Vitamin D|Patients in the vitamin D group will receive cholecalciferol 4000 units daily and calcium carbonate 500 mg twice daily.
3052898|NCT00736645|Experimental|Arm I|Patients receive oral selenomethionine and oral finasteride once daily for 4-5 weeks.
3052899|NCT00736645|Experimental|Arm II|Patients receive oral placebo and oral finasteride once daily for 4-5 weeks.
3052900|NCT00736645|Experimental|Arm III|Patients receive oral selenomethionine and oral placebo once daily for 4-5 weeks.
3052901|NCT00736645|Placebo Comparator|Arm IV|Patients receive two oral placebos once daily for 4-5 weeks.
3052902|NCT00736723||Patients non-septic shock|Postoperative/posttraumatic critically ill patients with non-septic shock
3052903|NCT00736723||Patients septic shock|Postoperative/posttraumatic critically ill patients with septic shock
3052904|NCT00736840|Other|CLD (chronic liver disease)|Chronic liver disease subjects with recent biopsy will be tested with a breath tests using a 13C enriched substrate metabolized by their liver
3052905|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|
3052906|NCT00736853|Experimental|Tramadol Hydrochloride Plus Acetaminophen (Double Blind)|
3052907|NCT00736853|Placebo Comparator|Placebo (Double-Blind)|
3052908|NCT00736879|Experimental|Dapagliflozin 1 mg|Dapagliflozin: 1 mg
3052909|NCT00736879|Experimental|Dapagliflozin 2.5 mg|Dapagliflozin: 2.5 mg
3052910|NCT00736879|Experimental|Dapagliflozin 5 mg|Dapagliflozin: 5 mg
3052911|NCT00736879|Placebo Comparator|Placebo|Placebo: 0 mg
3052912|NCT00736944|Experimental|1|"Induction chemotherapy followed by Radiation therapy plus Cisplatin~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cisplatin 100 mg/m2 IVPB on radiation day 1, 22, and 42."
3052913|NCT00736944|Experimental|2|"Induction chemotherapy followed by Radiation therapy plus Cetuximab~Induction chemotherapy:~Abraxane 100 mg/m2 IVPB, Day 1, 8, and 15 of cycles 1, 2, and 3. Cetuximab 400 mg/m2 IVPB, Day 1, cycle 1. Cetuximab 250 mg/m2 IVPB, Day 8 and 15 cycle 1, 2 and 3. Cisplatin 75 mg/m2 IVPB, Day 1, cycles 1, 2, and 3. 5-FU 750 mg/m2 CIVI, Day 1, 2 and 3, cycles 1, 2, and 3.~Post-Induction:~Radiation - Monday-Friday weeks 1-7 with concurrent Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB"
3052914|NCT00736957|Experimental|Tramadol HCL plus Acetaminophen|
3052915|NCT00736996|Experimental|Pioglitazone|"Pioglitazone~30 - 45mg tablet daily for 6 months"
3052916|NCT00736996|Active Comparator|Endurance Exercise Training|Endurance Exercise Training (EET) Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
3052917|NCT00736996|Placebo Comparator|Placebo|Placebo matching tablet sugar pill daily for 6 months
3052918|NCT00737048|Experimental|Tramadol plus Acetaminophen and Placebo|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively, along with two oral capsules of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed greater than or equal to (>=) 50.0 millimeter (mm) on the Visual Analog Scale (VAS), score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3052919|NCT00737048|Experimental|Tramadol and Placebo|Tramadol hydrochloride will be administered as single oral dosing of two capsules once at a dose of 75 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3052920|NCT00737048|Experimental|Acetaminophen and Placebo|Acetaminophen will be administered as single oral dosing of two capsules once at a dose of 650 milligram, along with two oral tablets of matching placebo, within 30 minutes after the intensity of pain associated with tooth extraction showed >= 50.0 mm on the VAS, score ranging from 0 mm (no pain) to 100 mm (worst possible pain).
3052921|NCT00737061|Experimental|Adiana Transcervical Sterilization System|Single arm treatment
3052922|NCT00737100|Experimental|Tiotropium Respimat 2.5 mcg|patient to receive low dose tiotropium once daily
3052923|NCT00737100|Experimental|Tiotropium Respimat 5 mcg|patient to receive high dose tiotropium once daily
3052924|NCT00737100|Placebo Comparator|Placebo Respimat|patient to receive placebo once daily
3052925|NCT00737178|Active Comparator|Immediate IUD insertion|Insertion of CuT380A at the routine medication abortion follow-up visit one week after initiation of a medication abortion
3052926|NCT00737178|Active Comparator|Delayed IUD insertion|Insertion of CuT380A four to six weeks after initiation of a medication abortion
3052927|NCT00737204|Experimental|Armodafinil|Participants will take armodafinil for 4 weeks. The dose will be titrated up from 50mg to 250mg per day as clinically indicated, using 50mg tablets. If responsive, participants will be offered 12 additional weeks of armodafinil.
3052928|NCT00737204|Placebo Comparator|Placebo|Participants will receive placebo pills for 4 weeks. Placebo tablets that match the 50mg active medication tablets will given following the same dosing strategy as Arm 1. The dose will be titrated from 1 placebo tablet daily to 5 tablets daily as clinically indicated. Non-responders to placebo will then be offered 16 weeks of active medication.
3052929|NCT00737243|Experimental|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib|Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
3052930|NCT00737243|Other|Treatment determined by physician|Other treatment determined by physician based on molecular profiling assay
3052931|NCT00737360|Experimental|1|
3052932|NCT00737438|Experimental|1|"Initial chemo for ALL pts (ECX + BEV): Epirubicin 50 mg/m2 d1 every 21 days Cisplatin 60 mg/m2 d1 every 21 days, Capecitabine 625 mg/m2 po bid days 2-21 (held for 48 hours prior to FDG-PET/CT in week 3) Bev 15 mg/kg d1 every 21 days (cycle 1 & cycle 2 only) Salvage chemotherapy for metabolic non-responders (DI + BEV): Docetaxel 30 mg/m2 d1, d8 every 21 days, CPT-11 50 mg/m2 d1, d8 every 21 days, Bev 15 mg/kg d1, cycle 2 only 2 cycles are planned prior to resection.~Pts who aren't Cisplatin candidates (i.e. Creatinine clearance 40-60/cc, older age, marginal PS,etc.) may get oxaliplatin instead of cisplatin after discus with the PI. Oxaliplatin will be admin at 130 mg/m2 on day 1 every 21 days. Pts who aren't able to get Capecitabine (i.e. insurance restriction, unable to swallow, etc.) may get infusional fluorouracil instead of capecitabine after discus with the PI. Fluorouracil will be admin at 200 mg/m2/d x 21 days (held for 48 hours prior to FDGPET/ CT scan in week 3 of cycle 1)."
3052933|NCT00737464|Experimental|Mircera|Participant with chronic renal anemia will receive methoxy polyethylene glycol-epoetin beta [Mircera] intravenously (IV) [(120, 200 or 360 micrograms (mcg)] every 4 weeks for 12 weeks.
3052934|NCT00737477|Experimental|Mircera in Renal Anemia|Participants will receive SC methoxy polyethylene glycol-epoetin beta (Mircera) every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
3052935|NCT00737529|Experimental|Lenalidomide|"Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but < 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal."
3052936|NCT00737568|Experimental|Tenofovir DF|TDF plus placebo to match FTC/TDF
3052937|NCT00737568|Experimental|FTC/TDF|FTC/TDF plus placebo to match TDF
3052938|NCT00737633|Experimental|16-Week population|Placebo subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
3052939|NCT00737633|Experimental|72-Week population|Active treatment subjects in OB-202 (NCT00486291) and DM-230 (NCT00600067)
3052940|NCT00737672|Experimental|VIABAHN Treatment Group|Use of GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface to revise arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Comparator Arm
3052941|NCT00737672|Active Comparator|PTA Treatment Group|Percutaneous Transluminal Angioplasty (PTA) in arteriovenous (AV) prosthetic grafts at the venous anastomosis in the maintenance or re-establishment of vascular access for hemodialysis as compared to Experimental Arm
3052942|NCT00737698|Experimental|Exercise|Exercise
3052943|NCT00737698|Experimental|Repetitive magnetic stimulation|Repetitive magnetic stimulation of femoral nerve
3052944|NCT00737698|No Intervention|Control|No active treatment
3052945|NCT00737711|Experimental|Mircera|
3052946|NCT00737737|Experimental|Opioid|Participants will receive MS Contin over a 4 week period starting at 15 mg bid. Doses will titrated upwards as tolerated by increments of 15-30 mg to a highest attained dose or a maximum dose of 90 mg
3052947|NCT00737737|Experimental|Placebo|Participants will receive a similar number of placebo tablets which match the study drug with regards to appearance over a period of 4 weeks
3052948|NCT00737893|Experimental|Erythropoietin (EPO)|20,000 units of EPO given on the day before surgery, the day of surgery, and the day after surgery.
3052949|NCT00737893|Placebo Comparator|Placebo|Placebo doses given the day before surgery, the day of surgery, and the day after surgery.
3052950|NCT00738023|Active Comparator|Diabetics|Obese, normotensive African-Americans with diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours, then normal saline 0.9% at 40 ml/hr intravenously for 48 hours, and then randomized to rosiglitazone for six weeks followed by Intralipid 20% at 40ml/hr intravenously for 48 hours
3052951|NCT00738023|Active Comparator|Non-Diabetic|Obese, normotensive African-Americans without diabetes received Intralipid 20% at 40ml/hr intravenously for 48 hours
3052952|NCT00738049|Active Comparator|Group 1|Group 1 will receive oral darusentan 100mg for 2 weeks during Phase 1 then placebo for 2 weeks during Phase 2.
3052953|NCT00738049|Active Comparator|Group 2|Group 2 will receive placebo for 2 weeks during Phase 1 then oral darusentan 100 mg for two weeks during Phase 2
3052954|NCT00738062|Active Comparator|Droxidopa|Study medication
3052955|NCT00738062|Placebo Comparator|Placebo|Placebo
3052956|NCT00738101|Experimental|Fish Oil Emulsion Arm|"In infants who meet the eligibility criteria for Fish Oil Emulsion arm will receive Fish Oil Emulsion after enrollment under the study.~Therapy with Fish Oil Emulsion (Omegaven) will be provided at a dose of 1 gm/kg/day (by continuous infusion) and will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If previously on Intralipid, it will be stopped prior to initiation of Fish Oil Emulsion.Fish oil emulsion will be provided as a continuous intravenous emulsion over 24 hours."
3052957|NCT00738361|Experimental|nab-paclitaxel|Administered via intravenous bolus at a dose of 150 mg/m2 weekly for 3 of 4 weeks every 28 days.
3052958|NCT00738374|Experimental|1|
3052959|NCT00738400|Experimental|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets PRN (pro re nata) for 4 weeks, Vardenafil 5 mg/10 mg/20 mg tablets PRN for consecutive 4 weeks
3052960|NCT00738400|Placebo Comparator|Placebo|Matching placebo tablets PRN (pro re nata) for 4 weeks, placebo tablets PRN for consecutive 4 weeks
3052961|NCT00738426|Active Comparator|Erchonia ML Scanner (MLS)|Red diode low level laser light energy
3052962|NCT00738426|Sham Comparator|Sham device|non-therapeutic sham light output
3052963|NCT00738530|Experimental|Bevacizumab + IFN-Alfa-2A|Bevacizumab infusions will be administered every 2 weeks at a dose of 10 milligram per kilogram (mg/kg) for 52 weeks or until disease progression or unacceptable toxicity. Interferon alfa-2a (IFN-Alfa-2A) will be administered 3 times per week as a subcutaneous injection at a dose of 9 million international units (MIU) for 52 weeks or until disease progression or major toxicity.
3052964|NCT00738530|Placebo Comparator|Placebo + IFN-Alfa-2A|Placebo matched with Bevacizumab infusions will be administered every 2 weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A will be administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.
3052965|NCT00738543|Experimental|Whole group of 48 volunteers|The arm is composed of 48 human volunteers to test 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City), Hypochlorite 10% of electrochemical production (Exsept 10% ®, Pisa, Guadalajara, Mexico), and control.
3052966|NCT00738673|Experimental|Degarelix|"Starting dose: 240 mg by subcutaneous (s.c.) injection in the abdomen on Day 0.~Maintenance dose: a maximum of 11 doses of 80 mg degarelix were given 28 days apart via single s.c. injections."
3052967|NCT00738699|Active Comparator|1|MORAb-003 (Farletuzumab) Plus Paclitaxel
3052968|NCT00738699|Placebo Comparator|2|Placebo Plus Paclitaxel
3052969|NCT00738881|Experimental|Arm I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3052970|NCT00738881|Experimental|Arm II (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3052971|NCT00738894|Active Comparator|Medical Management|Antiplatelet medical therapy alone
3052972|NCT00738894|Experimental|Device Closure|PFO closure with study septal occluder device plus antiplatelet medical therapy
3052973|NCT00739102|Experimental|1|S.M.A.R.T.® Nitinol Self-Expandable Stent System
3052974|NCT00739297|Placebo Comparator|1|montelukast Placebo
3052975|NCT00739297|Experimental|2|montelukast
3052976|NCT00739297|Experimental|3|montelukast
3052977|NCT00739297|Experimental|4|montelukast
3052978|NCT00739310|Experimental|Vest Treatment (HFCWO)|Patients will receive Vest treatments for airway clearance therapy 2 x daily for 12 months. These data will be compared to 12 months of data prior to Vest initiation.
3052979|NCT00739336|Experimental|A, 1|Intervention: Immediate 3 month program
3052980|NCT00739336|No Intervention|A, 2|Wait-List Control
3052981|NCT00739583|Active Comparator|1|Skin preparation for hip replacement with a Chlorhexidine based skin preparation solution, Chloraprep® (CHG 2% w/v and IPA 70% v/v; Enturia Inc., Leawood, KS, USA)
3052982|NCT00739583|Active Comparator|2|Skin preparation for hip replacement with an Iodine based skin preparation solution, Duraprep® (Iodophor 0.7% and IPA 74% w/w; 3M Healthcare, St. Paul, MN, USA.
3052983|NCT00739596|Experimental|Aliskiren Hydrochlorothiazide (HCTZ)|
3052984|NCT00739596|Active Comparator|Amlodipine|
3052985|NCT00739648|Placebo Comparator|Placebo|Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
3052986|NCT00739648|Experimental|MP-376 240 mg Twice Daily (BID)|MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
3052987|NCT00739661|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
3052988|NCT00739661|Placebo Comparator|Placebo to vismodegib|Patients received placebo to vismodegib orally once daily until radiographically confirmed disease progression, intolerable toxicity, or withdrawal from the study.
3052989|NCT00739674|Active Comparator|Losartan-Based Regimen Alone (L Group)|Losartan-based regimen, with sequential titration including HCTZ and CCB as needed to achieve target blood pressure.
3052990|NCT00739674|Experimental|Diet Management and Losartan-Based Regimen (DML Group)|Losartan with sequential titration including HCTZ and CCB as needed to achieve target blood pressure combined with low-salt intake diet.
3052991|NCT00739752|Experimental|Non-Framed-Offered|Non-Framed, Information Only Condition. Vaccine Offered.
3052992|NCT00739752|Experimental|Non-Framed-Recommended|Non-Framed, Information Only Condition. Vaccine Recommended.
3052993|NCT00739752|Experimental|Gain-Framed-Offered|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
3052994|NCT00739752|Experimental|Gain-Framed-Recommended|Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
3052995|NCT00739752|Experimental|Loss-Framed-Offered|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
3052996|NCT00739752|Experimental|Loss-Framed-Recommended|Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.
3052997|NCT00739765|Experimental|1 Interpersonal Psychotherapy (IPT)|Participants will receive interpersonal psychotherapy.
3052998|NCT00739765|Active Comparator|2 Prolonged Exposure (PE)|Participants will receive prolonged exposure therapy.
3052999|NCT00739765|Active Comparator|3 Relaxation therapy|Participants will receive relaxation therapy.
3053000|NCT00739908|Experimental|CX157 (TriRima)|
3053001|NCT00739908|Placebo Comparator|Placebo|
3053002|NCT00739934|Experimental|Children aged 2 to <12 years|Immunocompromised children aged 2 to <12 years who are at high risk for systemic fungal infection.
3053003|NCT00739960|Other|Abatacept|
3053004|NCT00739973|Placebo Comparator|Placebo|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 5 of the 5 pills taken were placebos.
3053005|NCT00739973|Experimental|Aliskiren 150 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053006|NCT00739973|Experimental|Aliskiren 300 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053007|NCT00739973|Experimental|Amlodipine 5 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053008|NCT00739973|Experimental|Amlodipine 10 mg capsule|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos. Amlodipine 10 mg arm starts with 1 week of Amlodipine 5 mg, then force titrated to 10 mg
3053009|NCT00739973|Experimental|Aliskiren/amlodipine 150/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053010|NCT00739973|Experimental|Aliskiren/amlodipine 150/10 mg tablet|150/5 for 1 week, then up-titrated to 150/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053011|NCT00739973|Experimental|Aliskiren/amlodipine 300/5 mg tablet|Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053012|NCT00739973|Experimental|Aliskiren/amlodipine 300/10 mg tablet|300/5 for 1 week, then up-titrated to 300/10 mg. Each dose was to be taken orally with water at approximately 8:00 A.M., except on the morning of the next office/clinic visit, when the study medication was to be taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of 4 tablets and 1 capsule of study medication throughout the study; 4 of the 5 pills taken were placebos.
3053013|NCT00739999|Other|1|6-10 years will be administered with atorvastatin tablet formulation with initial doses based on age cohort.
3053014|NCT00739999|Other|2|10-17 years will be administered 10-mg daily dose of atorvastatin tablet formulation.
3053015|NCT00740051|Experimental|Linagliptin|52 week treatment
3053016|NCT00740051|Placebo Comparator|Placebo|First 18 weeks of treatment
3053017|NCT00740051|Active Comparator|Glimepiride|Placebo patients switch to glimepiride week19-52
3053018|NCT00740129|Experimental|Zoledronic Acid 5 mg|Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.
3053019|NCT00740181|Experimental|Chemotherapy|Decitabine 20 mg/m2 IV over 1 hr days 1-5 Cytarabine 20 mg/m2 subcut days 1-5 G-CSF 5mcg/kg subcut days 1-5
3053020|NCT00740207|Active Comparator|Isovue 250|
3053021|NCT00740207|Active Comparator|VISIPAQUE 270|
3053022|NCT00740220||A|Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
3053023|NCT00740376|Experimental|Uniglide Mobile Bearing|Uniglide Mobile Bearing Unicondylar Knee System (MBK)
3053024|NCT00740376|Active Comparator|Uniglide Fixed Bearing|Uniglide Fixed Bearing Unicondylar Knee System (FBK)
3053025|NCT00740480||Surgical|Adult population (ages 18-65) with clinically significant nasal septum deviation.
3053026|NCT00740584|Experimental|Open Label, only arm|3%w/w SPL7013 vaginal gel (VivaGel)
3053027|NCT00740636|Experimental|75 mg/m2/day Temozolomide|75 mg/m2/day Temozolomide for 21 days (7 days off treatment). 28 day cycles.
3053028|NCT00740636|Experimental|200 mg/m2/day Temozolomide|200 mg/m2/day Temozolomide for 5 days (23 days off treatment). 28 day cycles.
3053029|NCT00740714|Experimental|A|Randomized to active treatment (Coenzyme Q10 2400 mg/day with vitamin E 1200 IU/day)
3053030|NCT00740714|Experimental|B|Randomized to active treatment (Coenzyme Q10 1200 mg/day with vitamin E 1200 IU/day)
3053031|NCT00740714|Placebo Comparator|C|Placebo (with vitamin E 1200 IU/day)
3053032|NCT00740727|Experimental|EASI|Subjects will undergo placement of EASI catheters. All subjects in whom EASI catheters are placed, will receive Human Recombinant Hyaluronidase (HRH) as part of the EASI placement. (No subject will receive HRH, other than as part of EASI catheter placement.)
3053033|NCT00740779|Experimental|Silodosin 4 mg|4 mg daily
3053034|NCT00740779|Experimental|Silodosin 8 mg|Silodosin 8 mg daily
3053035|NCT00740779|Placebo Comparator|Placebo|1 placebo capsule daily
3053036|NCT00740792|Experimental|azelastine HCl/fluticasone propionate|nasal spray
3053037|NCT00740792|Active Comparator|azelastine HCL|nasal spray
3053038|NCT00740792|Active Comparator|fluticasone propionate|nasal spray
3053039|NCT00740792|Placebo Comparator|placebo|nasal spray
3053040|NCT00740831|Experimental|A (PGL4001 5 mg)|Drug: PGL4001 5mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
3053041|NCT00740831|Experimental|B (PGL4001 10mg)|Drug: PGL4001 10 mg (oral tablets) and leuproreline matching placebo (intramuscular injection)
3053042|NCT00740831|Active Comparator|C (GnRH-agonist)|PGL4001 matching placebo (oral tablets) and leuprorelin 3.75 mg (intramuscular injection)
3053043|NCT00740857|Placebo Comparator|1|
3053044|NCT00740857|Active Comparator|2|
3053045|NCT00740857|Active Comparator|3|
3053046|NCT00740870|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
3053047|NCT00741013|Placebo Comparator|Placebo pill and placebo IV|
3053048|NCT00741013|Experimental|Lovastatin pill and placebo IV|
3053049|NCT00741013|Experimental|Placebo pill and rhAPC IV|
3053050|NCT00741026|Placebo Comparator|Placebo|Placebo
3053051|NCT00741026|Experimental|Olanzapine|Olanzapine 10mg po daily x 3 days
3053052|NCT00741039|Experimental|1,|Patients > or = to 65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23 valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly).
3053053|NCT00741039|Experimental|2|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly).
3053054|NCT00741091|Experimental|Registry|Registry to gather data on early clinical outcomes for the Carotid WALLSTENT Endoprosthesis and FilterWire EZ System in routine clinical practice.
3053055|NCT00741104||RA patients|Patients on maintenance therapy for RA with infliximab for >= the past 12 months.
3053056|NCT00741156|Experimental|Enalaprilat|enalaprilat 0.005-0.01 mg/kg intravenous x 1 dose
3053057|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Level 1)|Neratinib 160 mg and Capecitabine 1500 mg/m^2
3053058|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 2)|Neratinib 240 mg and Capecitabine 1500 mg/m^2
3053059|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 3)|Neratinib 240 mg and Capecitabine 2000 mg/m^2
3053060|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 4)|Neratinib 200 mg and Capecitabine 2000 mg/m^2
3053061|NCT00741260|Experimental|Neratinib and Capecitabine (Dose Group 5)|Neratinib 160 mg and Capecitabine 2000 mg/m^2
3053062|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 6)|Neratinib and Capecitabine Maximum Tolerated Dose without prior lapatinib
3053063|NCT00741260|Experimental|Neratinib and Capecitabine MTD (Dose Group 7)|Neratinib and Capecitabine Maximum Tolerated Dose with prior lapatinib
3053064|NCT00741273|Experimental|Proellex 25 mg healthy|Proellex 25 mg in healthy females
3053065|NCT00741273|Experimental|Proellex 25 mg Impaired|Proellex 50 mg in hepatically impaired females
3053066|NCT00741286|Placebo Comparator|Asprin (100mg) plus placebo|Asprin (100mg) plus placebo
3053067|NCT00741286|Active Comparator|Asprin (100mg) plus cilostazol (200mg)|Asprin (100mg) plus cilostazol (200mg)
3053068|NCT00741338|Experimental|Cohort 1|Tolerance Induction Period (TIP): Cyclosporine A (CsA) starting at 5 milligram per kilogram (mg/kg) orally three times daily until the target trough concentration of at least 350 nanogram per milliliter (ng/mL) (preferably 400 ng/mL) achieved along with azathioprine (Aza) 2.5 mg/kg/day orally. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly intravenous (IV) infusion (starting from Day 1) up to Week 12. CsA and Aza were gradually discontinued. Immune Challenge Period (ICP): following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 39.
3053069|NCT00741338|Experimental|Cohort 2|TIP: CsA starting at 6.7 mg/kg orally three times daily until the target trough concentration of at least 350 ng/mL (preferably 400 ng/mL) achieved along with Aza 5 mg/kg orally every other day. Once target CsA trough level achieved and maintained for at least 1 week, participants received laronidase 0.058 mg/kg (low-dose) once weekly IV infusion (starting from Day 1) up to Week 18. CsA and Aza were gradually discontinued. ICP: following TIP, laronidase dose increased to 0.12 mg/kg once weekly IV infusion for 1 week followed by 0.25 mg/kg once weekly IV infusion for 1 week and then 0.58 mg/kg (full-dose) once weekly IV infusion up to Week 45.
3053070|NCT00741390|Other|Arm A|In Visit 1 subjects tested BD/33G, OTM/33G, and OTM/28G devices. In Visit 2 subjects tested BD/33G and OTM/28G. See purpose for additional information.
3053071|NCT00741390|Other|Arm B|In Visit 1 subjects tested BD/33G, OTM/33G and OTU/28G devices. In Visit 2 subjects tested BD/33G and OTU/28G. See purpose for additional information.
3053072|NCT00741390|Other|Arm C|In Visit 1 subjects tested BD/33G, OTM/33G and ACC/28G devices. In Visit 2 subjects tested BD/33G and ACC/28G. See purpose for additional information.
3053073|NCT00741390|Other|Arm D|In Visit 1 subjects tested BD/33G, OTM/33G and OTM/28G devices. In Visit 2 subjects tested OTM/33G and OTM/28G. See purpose for additional information.
3053074|NCT00741455|Experimental|Study Treatment|Chemotherapy, stem cell transplantation, HLA-Matched related allogeneic stem cell transplantation, leukapheresis, G-CSF, peripheral blood stem cell transplant, fludarabine, cyclophosphamide, donor lymphocyte infusion, cyclosporine, methotrexate
3053075|NCT00741468|Experimental|All subjects|Proellex 50 mg CYP1A2 probe CYP2C9 probe CYP2C19 probe CYP2D6 probe CYP3A4 probe
3053076|NCT00741598|Experimental|Galantamine-ER|Participants will receive treatment with extended release galantamine
3053077|NCT00741598|Placebo Comparator|Galantamine placebo|Participants will receive treatment with placebo.
3053078|NCT00741611|Experimental|Mesh|Ablation with HD Mesh Ablation System
3053079|NCT00741611|Active Comparator|Drug|Treatment with anti-arrhythmic drugs
3053080|NCT00741819|Experimental|Inhaled treprostinil|Solution for oral inhalation treprostinil (0.6 mg/mL). Inhaled via an ultrasonic nebulizer which provides a dose of 6mcg of treprostinil per breath. Doses are titrated up to 12 breaths four times daily.
3053081|NCT00741858|Experimental|DuraGen (sutureless)|Duragen duraplasty - the Duragen patch is applied over the dural defect during Chiari decompression surgery. The Duragen represents sutureless technique of posterior fossa duraplasty. Rest of the treatment is as usual.
3053082|NCT00741858|Active Comparator|DuraGuard (suturable)|Duraguard duraplasty - the Duraguard patch is applied over the dural defect during Chiari decompression surgery and sutured to the dural edge. This represents suturable technique that theoretically provides better (water-tight) dural closure.
3053083|NCT00741936|Experimental|MaZiRenWan (MZRW)|MZRW granule, 7.5g/sachet
3053084|NCT00741936|Placebo Comparator|Placebo|Placebo granule, 7.5g/sachet
3053087|NCT00742001|Experimental|Mirasol Illumination Dose #1|Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)
3053088|NCT00742001|Experimental|Mirasol Illumination Dose #2|Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs
3053089|NCT00742001|Experimental|Mirasol Illumination Dose #3|Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs
3053090|NCT00742027|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, thrice every week (i.e. days 1, 3 and 5), in each cycle of 21 days until unacceptable toxicity, disease progression, start of new anti-cancer therapy or withdrawal of consent (up to approximately 48 months).
3053091|NCT00742053|Experimental|1|Male or female inpatients, age ≥ 18 and ≤ 80 years, who are in normal sinus rhythm and do not have a pacemaker or other indwelling intracardiac device and require PICC insertion for their routine care will be studied. Intervention: ECG-guided Power PICC placement.
3053092|NCT00742079|Experimental|1 D-cycloserine, placebo|Participants will receive D-cycloserine 1 hour before a cognitive behavioral therapy (CBT) session on Week 1, and they will receive placebo 1 hour before a CBT session on Week 2.
3053093|NCT00742079|Experimental|2 Placebo, D-cycloserine|Participants will receive placebo 1 hour before a CBT session on Week 1, and they will receive D-cycloserine 1 hour before a CBT session on Week 2.
3053094|NCT00742170|Active Comparator|Active electroacupuncture|In the active electroacupuncture condition, the current is set at 2 times threshold (approximately 6-10 mA), which typically produces muscle twitching.
3053095|NCT00742170|Sham Comparator|Sham electroacupuncture|In the sham electroacupuncture condition, the current is set at 1 mA, the lowest intensity possible before the HANS device shuts off; this is undetectable stimulation.
3053096|NCT00742183|Experimental|Mepilex® Ag|"Mepilex® Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film. Mepilex® Ag is an antimicrobial soft silicone foam dressing that absorbs exudate and maintains a moist wound environment.~Mepilex® Ag contains silver sulphate that releases silver ions to inactivate a wide range of wound related pathogens (bacteria and fungi), shown in vitro. By reducing the number of microorganisms, Mepilex® Ag may also reduce odour."
3053097|NCT00742183|Active Comparator|Silvadene® Cream 1%|Silvadene® Cream 1% (silver sulfadiazine) is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second-and third-degree burns.
3053098|NCT00742209|Placebo Comparator|Placebo|PBO
3053099|NCT00742209|Active Comparator|GSK 1838262 1200 mg/day|600 or 1200 mg/day
3053100|NCT00742209|Active Comparator|GSK 1838262 1800 mg/day|600 or 1200 or 1800 mg/day
3053101|NCT00742209|Active Comparator|GSK 1838262 2400 mg/day|600 or 1200 or 1800 or 2400 mg/day
3053102|NCT00742209|Active Comparator|GSK 1838262 3000 mg/day|600 or 1200 or 1800 or 2400 or 3000 mg/day
3053103|NCT00742235|Experimental|1|Vitamin D insufficient (treated with ergocalciferol 50,000 IU every other day x 5 doses)
3053104|NCT00742235|No Intervention|Vitamin D sufficient|Subjects who did not receive ergocalciferol and had a 25-OH vitamin D level >32 ng/ml
3053105|NCT00742274|Experimental|1|TAG+BMT
3053106|NCT00742274|Active Comparator|2|BMT alone
3053107|NCT00742313|Experimental|Arm A|Arm A has FloSeal Matrix applied to EVH wound bed.
3053108|NCT00742313|No Intervention|Arm B|Arm B does not have FloSeal Matrix applied to EVH wound bed.
3053109|NCT00742326|Experimental|Pioglitazone|pioglitazone 45 mg daily for 48 weeks
3053110|NCT00742326|Placebo Comparator|Placebo|one capsule daily for 48 weeks
3053111|NCT00742391|Active Comparator|1|PEP005 (ingenol mebutate) Gel
3053112|NCT00742391|Placebo Comparator|2|Vehicle gel
3053113|NCT00742417|Experimental|Albutein 5%|Patients allocated to this arm underwent plasma exchange with Albutein 5%.
3053114|NCT00742417|Sham Comparator|Control|
3053115|NCT00742469|Active Comparator|1|Rifaximin
3053116|NCT00742469|Placebo Comparator|2|Placebo
3053117|NCT00742508|Experimental|SK&F-105517-D group|SK&F-105517-D 10-80 mg/day
3053118|NCT00742508|Other|Carvedilol-IR group|Carvedilol-IR 5-20 mg/day
3053119|NCT00742560|Experimental|Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3053120|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3053121|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3053122|NCT00742560|Experimental|Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3053123|NCT00742560|Experimental|Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 2)|Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.
3053124|NCT00742573|Active Comparator|1 Texas Medication Algorithm|Participants will receive medication treatment according to the Texas Medication Algorithm (TMA) for depression
3053125|NCT00742573|Experimental|2 Patient Choice|Participants will be offered brief interpersonal psychotherapy (IPT-B) alone or combined with the TMA for depression
3053126|NCT00742625|Experimental|Treatment (daunorubicin hydrochloride and bortezomib)|See Detailed Description
3053127|NCT00742781|Experimental|Dietary supplement|Dietary supplement of vitamin D
3053128|NCT00742859|Experimental|Arm 1: Betrixaban|Betrixaban, 40 mg, orally, once daily for at least 3 months.
3053129|NCT00742859|Experimental|Arm 2: Betrixaban|Betrixaban, 60 mg, orally, once daily for at least 3 months
3053130|NCT00742859|Experimental|Arm 3: Betrixaban|Betrixaban, 80 mg, orally, once daily for at least 3 months
3053131|NCT00742859|Active Comparator|Arm 4: Warfarin|Warfarin will be prescribed by investigators according to the standard of care.
3053132|NCT00742872|Experimental|1|Mosapride
3053133|NCT00742872|Placebo Comparator|2|Placebo
3053134|NCT00742885|Experimental|Influenza A (H5N1) 20-40 Years Group|Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
3053135|NCT00742885|Experimental|Influenza A (H5N1) 41-64 Years Group|Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
3053136|NCT00742924|Experimental|Arm 1- Chemotherapy and 1.2 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery .~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3053137|NCT00742924|Experimental|Arm 2 - Chemotherapy and 2.3 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3053138|NCT00742924|Experimental|Arm 3 - Chemotherapy and 3.5 mg/m2 Zoledronic Acid|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3053139|NCT00742924|Experimental|Chemotherapy and 2.3 mg/m2 Zoledronic Acid after MTD|"(Weeks 1-11) Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; and G-CSF SC. (Week 12) Patients undergo therapeutic conventional surgery.~(Weeks 13-25): Patients receive etoposide IV; ifosfamide IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; G-CSF SC. (Week 26) Patients may undergo surgical procedure.~(Weeks 27-36): Patients receive dexrazoxane hydrochloride IV; doxorubicin hydrochloride IV; cisplatin IV; zoledronic acid IV; high-dose methotrexate IV; leucovorin calcium IV or orally; etoposide IV; ifosfamide IV; and filgrastim (G-CSF) SC.~See Detailed Description."
3053140|NCT00742963|Experimental|1|75 mg/m2 of Doxorubicin administered by bolus injection starting on Day 1 of a 21-day cycle.
3053141|NCT00743093|Experimental|acetaminophen|acetaminophen, 4 grams/day (1 gram every 4 hours for 4 doses)
3053142|NCT00743093|Placebo Comparator|placebo|placebo for acetaminophen 4 grams/day (2 caplets every 4 hours for 4 doses)
3053143|NCT00743106|Placebo Comparator|Placebo Comparator|Placebo (0.9% Nacl)infusion beginning during surgery and lasting for up to 24 hours
3053144|NCT00743106|Active Comparator|Fenoldopam Comparator|Fenoldopam (0.1 ~g/kg/min)infusion will commence after placing the patient in a lateral/flex position during the operation. The infusion will continue for a total of 24 hours.
3053145|NCT00743119|Placebo Comparator|Placebo + inactive marijuana (0% THC)|Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3053146|NCT00743119|Experimental|Dronabinol 10 mg + Marijuana (0% THC)|Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3053147|NCT00743119|Experimental|Dronabinol 20 mg + Marijuana (0% THC)|Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.
3053148|NCT00743119|Experimental|Placebo + Marijuana (1.98% THC)|Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.
3053149|NCT00743119|Experimental|Placebo + Marijuana (3.56% THC)|Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.
3053150|NCT00743145|Placebo Comparator|Placebo naltrexone + Inactive marijuana|Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
3053151|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (5.5% THC)|Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
3053152|NCT00743145|Placebo Comparator|Placebo naltrexone + Active marijuana (6.2% THC)|Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
3053153|NCT00743145|Experimental|Naltrexone + Active marijuana (5.5% THC)|Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
3053154|NCT00743145|Experimental|Naltrexone + Active marijuana (6.2% THC)|Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
3053155|NCT00743145|Placebo Comparator|Naltrexone + Inactive marijuana|Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
3053156|NCT00743249|Experimental|Canalicular stent, 10 mm|MINI MONOKA canalicular stent (tube), 10 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
3053157|NCT00743249|Experimental|Canalicular stent, 20 mm|MINI MONOKA canalicular stent (tube), 20 mm, inserted in the lower lacrimal canaliculus (tear duct) of one eye for up to 3 months
3053158|NCT00743275|Experimental|Study Group|Participants received one dose of Fluzone® vaccine on Day 0.
3053159|NCT00743288|Experimental|Melphalan and Panobinostat|"Schedule A: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 of a 28-day cycle and melphalan PO at 0.05 mg/kg on days 1-5 of week 1.~Toxicity led to the following changes in dose and schedule Schedule B1: 10mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule B2: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1-4 and 0.05 mg/kg melphalan POon days 1, 3 and 5 of week 1.~Schedule C: 20mg/daily of LBH589 PO on days 1, 3 and 5 of weeks 1 and 2 and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1 Schedule D1: 15 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D2: 15 mg/daily LBH589 PO and 0.10 mg/kg melphalan PO on days 1, 3 and 5 of week 1.~Schedule D3: 20 mg/daily LBH589 PO and 0.05 mg/kg melphalan PO on days 1, 3 and 5 of week 1."
3053160|NCT00743340|Experimental|Emtricitabine|Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
3053161|NCT00743366|Experimental|Quetiapine (200mg/day), Marijuana (6.2%, 0.0%)|"Quetiapine (200mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (200 mg) were administered 2 times per day ((1100 and 2300 hours).~Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use."
3053162|NCT00743366|Placebo Comparator|Placebo, Marijuana (6.2%, 0.0%)|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
3053163|NCT00743431||1|Women with advanced ovarian cancer
3053164|NCT00743444|Experimental|1|AZD3355
3053165|NCT00743444|Placebo Comparator|2|
3053166|NCT00743483|Experimental|rhBSSL|170 mg rhBSSL three times daily for 5 to 6 consecutive days
3053167|NCT00743509|Experimental|Oral Cyclophosphamide and Sirolimus (OCR)|Sarcoma patients were given oral Cyclophosphamide and Sirolimus (OCR) in 28 day cycles.
3053168|NCT00743574|Experimental|Vitamin D plus Calcium (Ca) supplementation|
3053169|NCT00743652|Experimental|Group1|Subjects 6 weeks to <10 months of age with 0 prior dose of Prevnar.
3053170|NCT00743652|Experimental|Group 2|Subjects <12 months of age with 1 prior dose of Prevnar.
3053171|NCT00743652|Experimental|Group 3|Subjects <12 months of age with 2 prior doses of Prevnar.
3053172|NCT00743652|Experimental|Group 4|Subjects ≥12 months to <2 years of age.
3053173|NCT00743652|Experimental|Group 5|Subjects ≥2 years to <5 years of age
3053174|NCT00743717|Experimental|1|
3053175|NCT00743717|Active Comparator|2|
3053176|NCT00743730|Active Comparator|I|Parent and Nurse Controlled Analgesics with basal
3053177|NCT00743730|Active Comparator|II|Parent and Nurse Controlled Analgesics without basal
3053178|NCT00743730|Active Comparator|III|"Intermittent opioid administered IV on an as needed basis"
3053179|NCT00744042|Other|asfotase alfa|asfotase alfa
3053180|NCT00744055|Experimental|Prazosin|prazosin (16mg/day)
3053181|NCT00744055|Placebo Comparator|Placebo|Placebo in identical looking capsule blister packs
3053182|NCT00744211|Placebo Comparator|Vehicle|Vehicle Group
3053183|NCT00744211|Experimental|ET-ARA 1mg/kg|ET-ARA 1 mg/kg
3053184|NCT00744211|Experimental|ET-ARA 2mg/kg|ET-ARA 2 mg/kg
3053185|NCT00744237|Experimental|1|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration~Open-label amlodipine may be given"
3053186|NCT00744237|Active Comparator|2|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration~Open-label amlodipine may be given"
3053187|NCT00744237|Active Comparator|3|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration~Open-label amlodipine may be given"
3053188|NCT00744263|Placebo Comparator|Placebo|
3053189|NCT00744263|Experimental|13-valent pneumococcal conjugate vaccine|
3053190|NCT00744328|Experimental|Transdermal Estradiol|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains transdermal estradiol ranging in dose from 50 to 200 mcg/day
3053191|NCT00744328|Active Comparator|Sertraline|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The skin patch contains no active ingredients, though packaging is designed to match active patches. The capsules contain sertraline ranging in dose from 25 to 200mg/day
3053192|NCT00744328|Placebo Comparator|Placebo|Women wear a skin patch that is changed weekly and take opaque capsules by mouth daily. The capsules for women in this arm do not contain any active ingredients. The skin patch contains no active ingredients, though packaging is designed to match active patches.
3053193|NCT00744380|Active Comparator|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4) as other sedatives are down titrated. Daily awakenings are used.
3053194|NCT00744380|Experimental|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)as other sedatives are down titrated. Daily awakenings are used.
3053195|NCT00744471|Experimental|Tanezumab 10 mg|Tanezumab 10 mg IV every 8 weeks
3053196|NCT00744471|Experimental|Tanezumab 5 mg|Tanezumab 5mg IV every 8 weeks
3053197|NCT00744471|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg IV every 8 weeks.
3053198|NCT00744471|Experimental|Placebo|Placebo
3053199|NCT00744497|Placebo Comparator|Placebo|Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
3053200|NCT00744497|Active Comparator|Dasatinib|Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily
3053201|NCT00744523|Experimental|Mo.ma cerebral protection device|Mo.Ma cerebral protection device
3053202|NCT00744627|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3053203|NCT00744627|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3053204|NCT00744653|Other|1|Patients with local-regional recurrence of breast cancer, lesion over 3 cm.
3053205|NCT00744692|Experimental|RIC Cord Blood Transplant|Reduced Intensity Conditioning for Umbilical Cord Blood Transplant
3053206|NCT00744757|Experimental|Decitabine|Decitabine 20 milligram per square meter (mg per m^2) will be administered intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
3053207|NCT00744796||DSAEK: Outcomes in patients with corneal edema|Best spectacle corrected visual acuity and anterior segment optical coherence tomography (OCT) at minimum will be performed in patients who have undergone DSAEK for corneal edema secondary to corneal endothelial dysfunction.
3053208|NCT00744848|Active Comparator|Bupivacaine HCl|"100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
3053209|NCT00744848|Other|SKY0402|"300 mg SKY0402 in a 40-mL injection volume.~A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration."
3053210|NCT00744861|Active Comparator|Exogen 4000+|Low intensity pulsed ultrasound (LIPUS) delivered via Exogen 4000+ (single transducer) device for a treatment duration of 20 minutes per fusion site per day.
3053211|NCT00744861|Sham Comparator|Exogen 4000+ sham|Non-active sham device identical to Exogen 4000+ (single transducer); treatment duration of 20 minutes per fusion site per day
3053212|NCT00744861|Active Comparator|Exospine|Low intensity pulsed ultrasound delivered via Exospine device (dual transducers); treatment duration of 20 minutes per day
3053213|NCT00744861|Sham Comparator|Exospine sham|Non-active sham device identical to Exospine (dual transducers); treatment duration of 20 minutes per day
3053214|NCT00744874|Experimental|Ablated Patients|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
3053215|NCT00744939||Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Participants received Magnevist in accordance with its labeling
3053216|NCT00744965|Active Comparator|Glyburide|Women with mild gestational diabetes will be started ADA diet and a low dose of Glyburide and their medication dosage will be titrated as necessary during the pregnancy to achieve glucose control.
3053217|NCT00744965|Placebo Comparator|Placebo|Women with mild gestational diabetes will be started ADA diet and placebo.
3053218|NCT00744978|Experimental|Varenicline|
3053219|NCT00744978|Placebo Comparator|Placebo|
3053220|NCT00744991|Experimental|Enzastaurin|Open Label
3053221|NCT00745095|No Intervention|SCI MoviPrep® (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI, GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (without neostigmine plus glycopyrrolate [NG])
3053222|NCT00745095|No Intervention|SCI PIEE (without NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation [PIEE] (without neostigmine plus glycopyrrolate [NG])
3053223|NCT00745095|No Intervention|Control MoviPrep® only|(Control, glomerular filtration rate (GFR)>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid (MoviPrep®) only (no NG)
3053224|NCT00745095|No Intervention|Control PIEE only|(Control, glomerular filtration rate (GFR)>=50ml/min), pulsed irrigation enhanced evacuation (PIEE) only (no NG)
3053225|NCT00745095|Experimental|SCI MoviPrep® (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)<=50ml/min and SCI GFR>=50ml/min) low-volume polyethylene glycol-electrolyte lavage with ascorbic acid [MoviPrep®] (with neostigmine plus glycopyrrolate [NG])
3053226|NCT00745095|Experimental|SCI PIEE (with NG)|(Spinal Cord Injury (SCI), glomerular filtration rate (GFR)>=50ml/min) pulsed irrigation enhanced evacuation (PIEE) (with neostigmine plus glycopyrrolate [NG])
3053227|NCT00745121|Experimental|Group-A, Osteoporosis/osteopenia|Patients with osteoporosis/osteopenia.
3053228|NCT00745121|Experimental|Group-B, Control|Control (non-osteoporotic/-osteopenic patients).
3053229|NCT00745251|Experimental|VI-0521|15 mg Phentermine and 92 mg Topiramate
3053230|NCT00745251|Placebo Comparator|Placebo|
3053231|NCT00745290|Active Comparator|Bupivacaine HCl|Single dose of 200 mg bupivacaine HCl administered intraoperatively via local infiltration
3053232|NCT00745290|Other|SKY0402|Single dose of 600 mg SKY0402 (study drug) administered intraoperatively via local infiltration
3053233|NCT00745368|Experimental|Raltegravir|Raltegravir 400 mg tablets twice daily
3053234|NCT00745420|Experimental|Hematopoietic Stem Cell Transplantation|Bone Marrow Transplant with GVHD Prophylaxis Regimen
3053235|NCT00745498|Experimental|Preop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 1 to 14 days before vitrectomy
3053236|NCT00745498|Experimental|Intraop IVB|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
3053237|NCT00745498|No Intervention|No IVB|Patients will not receive bevacizumab before nor during vitrectomy
3053238|NCT00745615|Experimental|Double-Blind: Laquinimod 0.3 mg|Participants who will be receiving laquinimod 0.3 milligram (mg) tablet once daily orally in double-blind core study, will continue to receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
3053239|NCT00745615|Experimental|Double-Blind: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally in double-blind core study, will continue to receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
3053240|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.3 mg|Participants who will be receiving placebo matching to laquinimod 0.3 mg tablet once daily orally in double-blind core study, will receive laquinimod 0.3 mg tablet once daily orally in double-blind extension period of this study for up to Week 36.
3053241|NCT00745615|Experimental|Double-Blind: Placebo/Laquinimod 0.6 mg|Participants who will be receiving placebo matching to laquinimod 0.6 mg (2 tablets of placebo) once daily orally in double-blind core study, will receive laquinimod 0.6 mg once daily orally in double-blind extension period of this study for up to Week 36.
3053242|NCT00745615|Experimental|Open-Label: Laquinimod 0.3 mg/Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.3 mg tablet once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
3053243|NCT00745615|Experimental|Open Label: Laquinimod 0.6 mg|Participants who will be receiving laquinimod 0.6 mg (2 tablets of 0.3 mg each) once daily orally either in double-blind core study or double-blind extension period, will receive laquinimod 0.6 mg capsule once daily orally in open-label extension period of this study until termination (as long as the Sponsor will continue the development of laquinimod 0.6 mg for RRMS) or early discontinuation (up to approximately 10.5 years).
3053244|NCT00745823|Active Comparator|Raltegravir 400 mg b.i.d.|
3053245|NCT00745823|Experimental|Raltegravir 800 mg q.d.|
3053246|NCT00745849|Experimental|1|esomeprazole 40mg po bid
3053247|NCT00745849|Placebo Comparator|2|
3053248|NCT00745875|Experimental|1|ZD4054 + Pemetrexed
3053249|NCT00745875|Placebo Comparator|2|ZD4054 matched placebo + pemetrexed
3053250|NCT00745940|Experimental|MBCT Intervention Group|The curriculum of our mindfulness intervention draws upon elements from the mindfulness-based stress reduction program, and Segal and colleagues manual for mindfulness-based cognitive therapy. It was modified by one of the investigators to address issues associated with traumatic brain injury (e.g., problems with attention, concentration, memory, fatigue). The intervention was increased to ten weeks with one and a half hour weekly sessions, along with a 20-30 minute daily meditation home practice. Further adaptations included simplified language, the use of repetition to reinforce concepts, and visual aids. More attention was paid to fostering learning conditions to encourage an environment of trust and non-judgement. Connections between learning activities was also made more explicit.
3053251|NCT00745940|No Intervention|MBCT Control Group|Control group waited.
3053252|NCT00746096|Experimental|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
3053253|NCT00746096|Placebo Comparator|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
3053254|NCT00746122|Other|Open repair|Immediate Open Surgery
3053255|NCT00746122|Experimental|Endovascular strategy|Endovascular strategy involves immediate computed tomography (CT) and emergency Endovascular aneurysm repair (EVAR), with open repair for patients anatomically unsuitable for EVAR
3053256|NCT00746187|Experimental|ASTRA TECH Implant System; Fixture ST|Ø 4.5 cm in lengths 9-13 mm
3053257|NCT00746187|Experimental|Biomet 3i; Osseotite® Implants|Ø 4.0 cm in lengths 8.5-13 mm
3053258|NCT00746252|Experimental|1|risperidone
3053259|NCT00746252|Experimental|2|aripiprazole
3053260|NCT00746330|Experimental|F12M - PL - F12D - MFF|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 4: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3179083|NCT00668941|Experimental|1|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a continuous regimen of daily teriparatide (20 mcg subcutaneously) for 48 months, in addition to alendronate. Biopsies will be performed at Week 7 or Month 7.5. The participants will then have the option to be followed while taking alendronate alone for 24-48 months.
3053261|NCT00746330|Experimental|F12D - F12M - MFF - PL|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 2: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3053262|NCT00746330|Experimental|MFF - F12D - PL - F12M|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 2: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI; Period 3: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 4: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3053263|NCT00746330|Experimental|PL - MFF - F12M - F12D|Participants received a single dose of each treatment in the following order, separated by a washout period of 6-7 days: Period 1: Placebo to formoterol fumarate / mometasone furoate via pMDI + placebo to formoterol fumarate via DPI; Period 2: Formoterol fumarate / mometasone furoate 10 μg / 100 μg via pMDI + placebo to formoterol fumarate via DPI; Period 3: Formoterol fumarate 12 μg via pMDI + placebo to formoterol fumarate via DPI; Period 4: Placebo to formoterol fumarate / mometasone furoate via pMDI + formoterol fumarate via DPI. Participants were allowed to continue their regular asthma maintenance inhaled corticosteroid medication throughout the study and were supplied with the short-acting β2-agonist (SABA) salbutamol as rescue medication.
3053264|NCT00746356|Experimental|Promote RF CRT-D|Patients with CRT-D device will have the autocapture features of the device tested.
3053265|NCT00746356|Experimental|Current RF ICD|Patients with ICD device will have the autocapture features of the device tested.
3053266|NCT00746395|Active Comparator|lubiprostone 24mcg single dose|lubiprostone 24mcg single dose po prior to capsule endoscopy
3053267|NCT00746395|Placebo Comparator|Sugar pill|Placebo (sugar pill) - matched single dose po prior to capsule endoscopy
3053268|NCT00746421|Experimental|1|Quetiapine XR 200-400 mg/day
3053269|NCT00746421|Placebo Comparator|2|Placebo one pill per day matching 200, 300, or 400 mg
3053270|NCT00746512|Experimental|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days
3053271|NCT00746512|Placebo Comparator|Placebo 15 mg|Prednisone 15 mg placebo tablets once daily for 15 days
3053272|NCT00746512|Experimental|Prednisone 7.5 mg|"Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
3053273|NCT00746512|Placebo Comparator|Placebo 7.5 mg|"Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days~As per adaptive dose-ranging design, this arm was added to the study because a difference between prednisone 15 mg and placebo was demonstrated during interim analysis."
3053274|NCT00746551|Active Comparator|Ferrous fumarate, Ferri-6®, Oral tablet|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
3053275|NCT00746551|Experimental|iron sucrose, Venofer®, intravenous drug|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
3053276|NCT00746564|Experimental|Open Label|SJM Confirm Device
3053277|NCT00746590|Experimental|1|
3053278|NCT00746668|Experimental|Control Group|Subjects randomly assigned to this group had their training delayed for 18 weeks. These subjects underwent four assessments: baseline and at three 6-week intervals' but, they were not given any training during this time. After this data collection period, these control subjects were given training on the three modules. However, their performance after each period of training was not assessed.
3053279|NCT00746668|Experimental|Group 1|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 3 (Reading Practice with RSVP)"
3053280|NCT00746668|Experimental|Group 2|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
3053281|NCT00746668|Experimental|Group 3|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 2 (Control of Reading Eye Movements)"
3053282|NCT00746668|Experimental|Group 4|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 2: Module 3 (Reading Practice with RSVP) Training Session 3: Module 2 (Control of Reading Eye Movements)"
3053283|NCT00746668|Experimental|Group 5|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 2 (Control of Reading Eye Movements) Training Session 2: Module 1 (Visual Awareness and Eccentric Viewing) Training Session 3: Module 3 (Reading Practice with RSVP)"
3053284|NCT00746668|Experimental|Group 6|"The subjects were trained in 6 weekly sessions of approximately 2 hours each, plus time for rest. This was followed by second assessments. The subjects were then trained on a second module for another 6 weeks, followed by third assessments. Finally, the subjects were trained on a third module for 6 weeks, followed by final assessments.~Subjects in this group were trained according to the following counterbalanced module order:~Training Session 1: Module 3 (Reading Practice with RSVP) Training Session 2: Module 2 (Control of Reading Eye Movements) Training Session 3: Module 1 (Visual Awareness and Eccentric Viewing)"
3053285|NCT00746694||Caelyx|Participants with metastatic breast or ovarian cancer treated with Caelyx as part of standard treatment and according to data sheet approved indications.
3053286|NCT00746733|Experimental|Vyvanse (LDX)|
3053287|NCT00746733|Experimental|Adderall XR (AXR)|
3053288|NCT00746785|Experimental|2.5 mg Olanzapine|"2.5 mg Olanzapine~1x per day for 12 weeks."
3053289|NCT00746785|Active Comparator|5mg Olanzapine|"5 mg Olanzapine~1x per day for 12 weeks."
3053290|NCT00746785|Placebo Comparator|Placebo|"Placebo~1x per day for 12 weeks."
3053291|NCT00746798|Experimental|ChimeriVax WN02 vaccine, low dose|Participants randomized to receive ChimeriVax WN02 vaccine, low dose
3053292|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, medium dose|Participants randomized to receive ChimeriVax-WN02 vaccine, medium dose
3053293|NCT00746798|Experimental|ChimeriVax-WN02 vaccine, high dose|Participants randomized to receive ChimeriVax-WN02 vaccine, high dose
3053294|NCT00746798|Placebo Comparator|Placebo|Participants randomized to receive Placebo (Saline)
3053295|NCT00746863|Experimental|1|Patients randomized to this arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
3053296|NCT00746863|No Intervention|2|Patients assigned to this arm will have the mid-urethral sling placed via the suprapubic approach in the standard fashion with no injection of Marcaine into the retropubic space.
3053297|NCT00746889|Active Comparator|Corticosteroid Injection|40 mg of intraarticular triamcinolone acetonide
3053298|NCT00746889|Placebo Comparator|Placebo Injection|Intraarticular injection of 0.9% saline
3053299|NCT00746941|No Intervention|Local standard of care|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants in this treatment arm had the option of adding 250 mg mefloquine by mouth at Week 4 (Day 28) or Week 8 (Day 56) daily for 3 days, and then weekly through Week 24."
3053300|NCT00746941|Experimental|Local standard of care plus mefloquine 250 mg|"All participants received local standard of care, which may have included any treatment or procedure that the Investigator would normally use in the treatment of a PML patient at their study site or hospital.~Participants received 250 mg mefloquine by mouth on Days 0, 1, and 2 and then weekly through Week 24."
3053301|NCT00746954|Other|Arm 1 BUS to PLA to ACET|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
3053302|NCT00746954|Other|ARM 2 ACET to BUS to PLA|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=3
3053303|NCT00746954|Other|ARM 3 PLA to ACET to BUS|Each patient will act as their own control, with comparisons over three nights, each night given buspirone (BUS 20mg), actetazolamide (ACET 250mg), or placebo (PLA) n=2
3053304|NCT00747006|Experimental|TI Inhalation Powder (original protocol)|Under the original protocol, subjects with Type 1 and Type 2 diabetes will have TI Inhalation Powder administered prandially during dose optimization visits and meal challenge visits (with meals of varying carbohydrate contents). Subjects with Type 2 diabetes will also use TI Inhalation Powder daily at each meal between visits.
3053305|NCT00747006|Other|TI Inhalation Powder and Humalog (Amendment 1)|Under Amendment 1, TI Inhalation Powder will be administered prandially to a new subset of subjects with Type 2 diabetes during TI dose optimization visits and TI meal challenge visits (with meals of varying carbohydrate contents). Subjects will be crossed over to administration of Humalog 15 minutes before meals during Humalog dose optimization visits and Humalog meal challenge visits (with meals of varying carbohydrate contents). Subjects will also use TI Inhalation Powder daily at each meal between visits.
3053306|NCT00747149|Experimental|Rosuvastatin 1|titrated
3053307|NCT00747149|Experimental|Rosuvastatin 2|Non-titrated
3053308|NCT00747214|Experimental|CRx-102 plus DMARD therapy|
3053309|NCT00747214|Placebo Comparator|Placebo plus DMARD therapy|
3053310|NCT00747227|Experimental|ZV9003|modified light transmission intraocular lens
3053311|NCT00747227|Active Comparator|ZA9003|monofocal acrylic intraocular lens
3053312|NCT00747344|Placebo Comparator|Placebo - Controlled Period (CP)|
3053313|NCT00747344|Experimental|Ustekinumab 45 mg - CP|
3053314|NCT00747344|Experimental|Placebo to ustekinumab 45 mg - after CP|
3053315|NCT00747344|Experimental|Ustekinumab 45 mg - after CP|
3053316|NCT00747435|Experimental|Original Audiological Criteria|"Inclusion Criteria:~Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition."
3053317|NCT00747435|Experimental|Expanded Audiological Criteria|"Pure-tone air-conduction threshold levels shall fall at or within the levels listed in the following chart.~Frequency (Hz): 250 500 750 1000 1500 2000 4000 8000 Lower Limit: 10 10 10 60 60 70 70 70 Upper Limit: 65 65 75 *110+ *110+*110+ *110+ *90+~Minimal benefit from optimally fit hearing aid/s, preferably bilateral, with monosyllabic word scores in quiet of ≤50% in the best-aided condition.~Study Arm 2 candidates are those who meet the inclusion criteria listed above with the exception that:~In the ear to be implanted, the pure-tone air conduction threshold(s) at 250, 500, and/or 750 Hz will be greater than or equal to 0 dB HL and less than 10 dB HL, and/or In the ear to be implanted, the pure-tone air conduction threshold(s) at 1000 and/or 1500 Hz will be greater than or equal to 0 dB HL and less than 60 dB HL and/or In their best-aided condition, they score 51-60% on monosyllabic word scores."
3053318|NCT00747474|Experimental|Lipotecan|Intravenous Lipotecan (TLC388 HCl for Injection)
3053319|NCT00747565|Experimental|Tecnis Multifocal IOL group|Subjects implanted bilaterally with the Tecnis Multifocal IOL. Participants were enrolled in this arm in the original study and also in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
3053320|NCT00747565|Active Comparator|CeeOn 911A monofocal control IOL group|Subjects implanted bilaterally with the CeeOn 911A monofocal IOL. Participants enrolled in this arm only in the original study; no control subjects were enrolled in the expansion study. Outcomes of the first eye of each subject were analyzed for the primary study endpoints.
3053321|NCT00747617|Active Comparator|PCOS group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
3053322|NCT00747617|Active Comparator|Control group|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of recombinant human chorionic gonadotropin administered iv on 5 separate occasions.
3053323|NCT00747643|Active Comparator|Varenicline|For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
3053324|NCT00747643|Placebo Comparator|Placebo|Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
3053325|NCT00747747|No Intervention|Control|No coadiuvant treatment. The subject is treated with the antibiotic only and forbidden to take any coadiuvant medicine as a remedy for the symptoms during the period of the study.
3053326|NCT00747747|Active Comparator|Saline solution|Saline solution sprayed according to the product indication. Only one brand/specific product has been selected.
3053327|NCT00747747|Experimental|Sinuclean treatment|Sinuclean DM Spray.
3053328|NCT00747812|Experimental|1|Stimulation on from activation to 12 weeks post-activation. Stimulation off from 12 weeks post-activation to 16 weeks post-activation. Stimulation on from 16 weeks post-activation to end of study.
3053329|NCT00747812|Sham Comparator|2|Sham Stimulation from activation of device to 12 weeks post-activation. Stimulation on from 12 weeks post-activation on.
3053330|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 5 seconds and then LoFric POBE Hydro-Kit II, 24 hours|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 5 seconds.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 24 hours."
3053331|NCT00748033|Experimental|LoFric POBE Hydro-Kit II, 24 hours and then LoFric POBE Hydro-Kit II, 5 seconds|"All subjects were first catheterizised with the reference catheter. After randomisation this group was first catheterizised with LoFric POBE Hydro-Kit II, activation time 24 hours.~Then the next test catheter was used LoFric POBE Hydro-Kit II, activation time 5 seconds."
3053332|NCT00748072|Placebo Comparator|Saline solution|patients treated with 1 ml of s.c. saline solution
3053333|NCT00748072|Experimental|DDAVP|treated with DDAVP (0.3 mcg/Kg s.c.) 1 hour before renal biopsy
3053334|NCT00748098|Other|GSK1838262:placebo|GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
3053335|NCT00748098|Other|Placebo:GSK1838262|Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2
3053336|NCT00748189|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3053337|NCT00748189|Active Comparator|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
3053338|NCT00748215|Experimental|Arm I: CASAD|Oral calcium aluminosilicate anti-diarrheal (CASAD) 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may receive CASAD for an additional 6 weeks.
3053339|NCT00748215|Placebo Comparator|Arm II: Placebo|Oral placebo 4 times daily for 6 weeks in the absence of disease progression or unacceptable toxicity. Participants who develop grade 3 or 4 diarrhea may then receive CASAD for 6 weeks.
3053340|NCT00748241|Experimental|Astra Tech Fixture ST|
3053341|NCT00748410|Experimental|7 Days Repeat Dose|
3053342|NCT00748540|Experimental|Implanted|Implanted with Vibrant Soundbridge
3053343|NCT00748553|Experimental|All patients|All participants enrolled.
3053344|NCT00748566|Experimental|Active treatment (switch to oral Ziprasidone)|
3053345|NCT00748657|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3053346|NCT00748709|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) for patients FISH positive for/or harboring EGFR or HER2 Mutation
3053347|NCT00748826||Infliximab -Rheumatoid Arthritis Participants|
3053348|NCT00748865|Experimental|Systane Ultra|Systane Ultra 1 drop each eye one time
3053349|NCT00748865|Active Comparator|Systane|Systane 1 drop each eye one time
3053350|NCT00748956|Experimental|Low dose NPY|Low dose, Receive 50 nmol dose of NPY
3053351|NCT00748956|Experimental|High dose NPY|High Dose, Receive 100 nmol dose of NPY
3053352|NCT00748956|Placebo Comparator|Placebo|Placebo comparator
3053353|NCT00748969|Experimental|Growth hormone treatmen|Growth hormone treatment arm. Somatropin (DNA origin)
3053354|NCT00748969|No Intervention|No growth hormone treatment in year 1|No growth hormone treatment in year 1; option for treatment in year 2 open-label period.
3053355|NCT00748982|Experimental|1|
3053356|NCT00748982|Placebo Comparator|2|
3053357|NCT00749073|Other|Percutaneous Lumbar Decompression procedure|mild percutaneous lumbar decompression procedure
3053358|NCT00749125|Experimental|1 Lexapro|The depressed participants in this arm will be given Lexapro.
3053359|NCT00749125|No Intervention|2 Control|The nondepressed participants in this arm will not be given any intervention for depression.
3053360|NCT00749203|Experimental|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
3053361|NCT00749203|Active Comparator|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
3053362|NCT00749268|Active Comparator|A|
3053363|NCT00749268|Active Comparator|B|
3053364|NCT00749398||Infliximab|Subjects with moderate-to-severe psoriasis who are treated with infliximab in daily clinics according to local country regulations and reimbursements.
3053365|NCT00749411|Experimental|Arm 1|
3053366|NCT00749411|Placebo Comparator|Arm 2|
3053367|NCT00749463|Experimental|Gum 2|Nicotine Gum 2 mg for subjects smoking less than 20 cigarettes per day; 2 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
3053368|NCT00749463|Experimental|Gum 4|Nicotine Gum 4 mg for subjects smoking 20 or more cigarettes per day; 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
3053369|NCT00749463|Experimental|Patch|Nicotine Patch; Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
3053370|NCT00749515|Experimental|Single Arm|All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring and HIDA scan. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).
3053371|NCT00749580|Experimental|1: Boosted PI+RAL|Group 1 Raltegravir 400 mg PO b.i.d. + their current boosted PI regimen Subjects in this study are HIV-Infected Patients who are on a stable boosted PI regimen; in this group are assigned to switched from their NRTIs as a Backbone to Raltegravir
3053372|NCT00749580|No Intervention|2: Boosted PI+NRTIs|Group 2 Continue the same regimen without change
3053373|NCT00749606|Experimental|Individual Telephone Intervention|Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
3053374|NCT00749606|Active Comparator|Group Telephone Intervention|Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.
3053375|NCT00749671|Active Comparator|ICD testing BIS|Bispectral Index Monitoring will be used to assess adequacy of moderate sedation during DFT.
3053376|NCT00749671|Active Comparator|ICD testing Ramsey|Ramsey Sedation Scale will be used to assess adequacy of moderate sedation during DFT
3053377|NCT00749684||Adults with malignant melanoma at high risk of relapse|"Adults with malignant melanoma of the following stages:~II and III (>/= 1.5 mm Breslow thickness without distant metastases~melanoma with lymph node metastases"
3053378|NCT00749749|Experimental|Bupivacaine collagen sponge|Three Bupivacaine sponges placed at different levels within the surgical cavity; one deep within the vault, one at the incision line in the peritoneum and one at the dermal incision line.
3053379|NCT00749749|Active Comparator|ON-ON-Q PainBuster Post-op Pain relief SystemQ system|Insertion of the ON-Q system catheter into the deep subcutaneous space overlying the fascia.
3053380|NCT00749775||Eplerenone|Subjects who are treated with Eplerenone tablet for hypertension disease
3053381|NCT00749879|Experimental|25 mg AMCC fed|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fed State"
3053382|NCT00749879|Experimental|25 mg AMCC fasting|"25 mg Proellex capsule formulated with AMCC coarse microcrystalline cellulose~Fasting State"
3053383|NCT00749879|Experimental|50 mg AMCC fed|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fed State"
3053384|NCT00749879|Experimental|50 mg AMCC fasting|"2, 25 mg Proellex capsules formulated with AMCC coarse microcrystalline cellulose~Fasting State"
3053385|NCT00749879|Experimental|50 mg SMCC fasting|"2, 25 mg Proellex capsules formulated with SMCC microcrystalline cellulose~Fasting State"
3053386|NCT00749892|Experimental|Treatment (erlotinib hydrochloride)|Participants receive erlotinib hydrochloride PO QD for 3-5 weeks in the absence of disease progression or unacceptable toxicity. Within 24 hours of the last dose, participants undergo cystectomy.
3053387|NCT00749931|Active Comparator|SOC|Standard of Care arm - standard of care lumpectomy procedure
3053388|NCT00749931|Experimental|Device + SOC|Use of the device in addition to the standard of care lumpectomy procedure.
3053389|NCT00749944|Experimental|varenicline|
3053390|NCT00749944|Placebo Comparator|placebo|
3053391|NCT00749957|Experimental|1|Subjects at least 6 y/o treated with a lower dose of the vector by subretinal injection
3053392|NCT00749957|Experimental|2|Subjects at least 6 y/o treated with a higher dose of the vector by subretinal injection
3053393|NCT00749996|Experimental|Investigational group|Single level herniectomy followed by placement of the DIAM™ Spinal Stabilization System
3053394|NCT00749996|Active Comparator|Control group|Single level herniectomy
3053395|NCT00750061|Placebo Comparator|Placebo|Placebo tablet
3053396|NCT00750061|Experimental|Lithium carbonate|Lithium Carbonate tablet, 250mg
3053397|NCT00750139|Experimental|1|Naftin 2% cream applied daily for 2 weeks
3053398|NCT00750139|Placebo Comparator|2|Placebo cream applied daily for two weeks
3053399|NCT00750139|Active Comparator|3|Active comparator applied daily for 4 weeks
3053400|NCT00750139|Placebo Comparator|4|placebo cream applied daily for 4 weeks
3053401|NCT00750152|Placebo Comparator|2|placebo
3053402|NCT00750152|Experimental|1|NAFT-500
3053403|NCT00750165|Experimental|Titration Night|Treatment with the Fisher & Paykel Sleep Style 200 Auto CPAP device
3053404|NCT00750191|Active Comparator|Intradiscal Biacuplasty|"On the day of the procedure, patients were given midazolam for relaxation and, if needed, fentanyl IV during the procedure. For treatment subjects, two TransDiscal probes were positioned under fluoroscopic guidance in the posterior annulus of the intervertebral disc. The probes were attached to the Radiofrequency generator and Radiofrequency energy was delivered. Placement of the probes within the disc annulus was confirmed using oblique, lateral, and anterior-posterior fluoroscopic images.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure."
3053405|NCT00750191|Placebo Comparator|Sham|"Sham procedures mimicked active treatment procedures, except that the probes were positioned just outside of the disc and no radiofrequency energy was delivered through the electrodes. Thus, sham patients were provided similar tactile, auditory and visual experiences as treatment patients, without receiving the active RF treatment.~Following completion of procedure the patient was transferred to recovery and monitored for 45 minutes then discharged home with instructions. It was expected that the patient limit their activities during the first week after the procedure.~The study will be unblinded at 6 months. If the patients in the IDB group show significant improvement compared to placebo they will be offered IDB."
3053406|NCT00750269|Experimental|Level 1: 8.0 Gy/FX|SBRT 40.0 Gy
3053407|NCT00750269|Experimental|Level 2: 8.5 Gy/FX|SBRT 42.5 Gy
3053408|NCT00750269|Experimental|Level 3: 9.0 Gy/FX|SBRT 45.0 Gy
3053409|NCT00750269|Experimental|Level 4: 9.5 Gy/FX|SBRT 47.5 Gy
3053410|NCT00750269|Experimental|Level 5: 10.0 Gy/FX|SBRT 50.0 Gy
3053411|NCT00750269|Experimental|Level 6: 10.5 Gy/FX|SBRT 52.5 Gy
3053412|NCT00750269|Experimental|Level 7: 11.0 Gy/FX|SBRT 55.0 Gy
3053413|NCT00750269|Experimental|Level 8: 11.5 Gy/FX|SBRT 57.5 Gy
3053414|NCT00750269|Experimental|Level 9: 12.0 Gy/FX|SBRT 60.0 Gy
3053415|NCT00750282|Experimental|Florbetaben (BAY94-9172)|
3053416|NCT00750308|Active Comparator|tadalafil, ramapril, combo, placebo|placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril + tadalafil, washout, placebo+placebo for three weeks
3053417|NCT00750308|Active Comparator|ramipril, tadalafil, placebo, combo|placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks
3053418|NCT00750308|Active Comparator|combo, placebo, tadalafil, ramipril|ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks
3053419|NCT00750308|Active Comparator|placebo, combo, ramipril, tadalafil|placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks
3053420|NCT00750308|Active Comparator|tadalafil, placebo, ramipril, combo|placebo+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks
3053421|NCT00750308|Active Comparator|ramipril, combo, tadalfil, placebo|placebo+ramipril for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo for three weeks
3053422|NCT00750308|Active Comparator|combo, ramipril, placebo, tadalafil|ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks
3053423|NCT00750308|Active Comparator|placebo, tadalafil, combo, ramipril|placebo+placebo for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+ramipril for three weeks
3053424|NCT00750308|Active Comparator|tadalafil, combo, placebo, ramipril|placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+placebo for three weeks, washout, placebo+ramipril for three weeks
3053425|NCT00750308|Active Comparator|ramipril, placebo, combo, tadalafil|placebo+ramipril for three weeks, washout, placebo+placebo for three weeks, washout, ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks
3053426|NCT00750308|Active Comparator|combo, tadalafil, ramipril, placebo|ramipril+tadalafil for three weeks, washout, placebo+tadalafil for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+placebo for three weeks
3053427|NCT00750308|Active Comparator|placebo, ramipril, tadalafil, combo|placebo+placebo for three weeks, washout, placebo+ramipril for three weeks, washout, placebo+tadalafil for three weeks, washout, ramipril+tadalafil for three weeks
3053428|NCT00750360|Experimental|Unprimed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who were previously not vaccinated against influenza (unprimed).
3053429|NCT00750360|Experimental|Unprimed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who were previously not vaccinated against influenza (unprimed).
3053430|NCT00750360|Experimental|Primed, > 6 to < 72 Months|Subjects aged > 6 months to < 72 months who previously received a vaccination against influenza (primed).
3053431|NCT00750360|Experimental|Primed, ≥ 72 to < 108 Months|Subjects aged ≥ 72 months to < 108 months who previously received a vaccination against influenza (primed).
3053432|NCT00750360|Experimental|Primed, ≥ 108 to < 216 Months|Subjects aged ≥ 108 months to < 216 months who previously received a vaccination against influenza (primed).
3053433|NCT00750360|Experimental|Primed, ≥ 216 Months|Subjects aged ≥ 216 months who previously received a vaccination against influenza (primed).
3053434|NCT00750373|No Intervention|Conventional|Conventional Treatment based on current guidelines
3053435|NCT00750373|Active Comparator|Surgery|Early surgery within 48 hours of randomization
3053436|NCT00750438|Experimental|Propionate ester|
3053437|NCT00750438|Placebo Comparator|Fermentable control|
3053438|NCT00750438|Placebo Comparator|Non fermentable control|
3053439|NCT00750737|Experimental|Posaconazole|Posaconazole 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
3053440|NCT00750737|Experimental|Amphotericin B Lipid Complex (ABLC)|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
3053441|NCT00750815|Experimental|A. Phase I - Dose Escalation|"Dose of Cyclophosphamide to depend on how many patients we treated:~Dose Level 1: Cyclophosphamide 250 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 2: Cyclophosphamide 500 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 3: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.0 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12~Dose Level 4: Cyclophosphamide 750 mg /m^2 IV Day 1; VELCADE, 1.3 mg/m^2 IV days 1,4,8, and 11; DOXIL 30 mg/m^2 Day 4; Dexamethasone 20 mg orally daily on days 1-2,4-5,8-9,11-12"
3053442|NCT00750815|Experimental|B. Phase II - Maximum Planned Dose (MPD)|Participants received Cyclophosphamide and VELCADE at Level 4 (the MPD) at the same schedule of the Phase I study. Pegylated doxorubicin and Dexamethasone were given at the same doses and schedule as the Phase I part of study.
3053443|NCT00750867|Experimental|1|Interventions included monthly infusions of intravenous immunoglobulin.
3053444|NCT00750880|Experimental|1|
3053445|NCT00750893||Rotarix Group|Subjects who received 2 oral doses of Rotarix. The first dose was administered before the age of 6 weeks and the second one at least 4 weeks after, preferably before the age of 16 weeks. The 2 doses had to be given before 24 weeks of age.
3053446|NCT00750919|Experimental|Esmirtazapine|Participants receive esmirtazapine 4.5 mg tablet, orally, once daily (QD) for up to 6 months.
3053447|NCT00751023|Experimental|1|Modafinil 400 mg daily
3053448|NCT00751023|Placebo Comparator|2|Placebo
3053449|NCT00751036|Experimental|Nilotinib|Patients who were assigned to this treatment group received 400 mg. nilotinib bid.
3053450|NCT00751036|Active Comparator|Imatinib|Patients who were assigned to this treatment group received 400 mg. imatinib bid.
3053451|NCT00751101|Experimental|Arm A: Prior to initiation of capecitabine|Patients apply a transdermal nicotine patch once every 24 hours beginning 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
3053452|NCT00751101|Experimental|Arm B: After hand-foot syndrome symptoms appear|Patients apply a transdermal nicotine patch once every 24 hours beginning with the course of chemotherapy initiated after hand-foot syndrome symptoms appear and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.
3053453|NCT00751114|Experimental|Insulin Glargine|Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL<FPG≤100mg/dL (3.9mmol/L<FPG≤5.5mmol/L).
3053454|NCT00751114|Active Comparator|Sitagliptin|Dose of 100 mg once a day administered with or without food.
3053455|NCT00751140|Experimental|Lymph Node Dissection at Time of Nephroureterectomy|A prospective single-arm two-stage phase II study to allow for analysis of the treatment-specific outcomes and disease-specific survival of patients treated with open or laparoscopic nephroureterectomy and bladder cuff excision along with a lymph node dissection (modified template retroperitoneal lymph node dissection).
3053456|NCT00751179|Active Comparator|Rocuronium - Sugammadex|Rocuronium - Sugammadex 4.0 mg/kg
3053457|NCT00751179|Active Comparator|Succinylcholine|Succinylcholine 1.0 mg/kg
3053458|NCT00751296|Experimental|Lenalidiomide|Lenalidomide target dose of 10 mg PO OD X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28-day cycle.
3053459|NCT00751348|Experimental|PRIORIX-TETRA GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix-Tetra® vaccine at Day 0, administered subcutaneously in the deltoid region of the left upper arm.
3053460|NCT00751348|Active Comparator|PRIORIX + VARILRIX GROUP|Healthy male and female subjects between, and including 11 and 24 months of age, who received one dose of Priorix™ vaccine together with one dose of Varilrix™ vaccine at Day 0, administered subcutaneously in the deltoid regions of the left or right upper arm, respectively.
3053461|NCT00751400|Experimental|Naproxen Sodium ER (BAYH6689)|subjects take one tablet Naproxen Sodium ER (extended release) every 24 hours while symptoms last for no more than 10 consecutive days for pain and no more than 3 consecutive days for fever
3053462|NCT00751530||Protease Inhibitor Group|Subjects who required a protease inhibitor in their new ART regimen
3053463|NCT00751530||Non-protease Inhibitor|Subjects who did not take a protease inhibitor in their regimen
3053464|NCT00751621|Experimental|IgPro20|Subcutaneous (SC) administration by the subject/parent/guardian with the planned weekly dose of IgPro20 to be the same as the subject's last dose recommended by the investigator in study ZLB06_001CR (NCT00542997).
3053465|NCT00751634|Experimental|A|Application of the Gaymar Rapr-Round device per approved use
3053466|NCT00751777|Experimental|Group 1: 37.5 µg LT patch|80 subjects will receive a two vaccination regimen with a LT patch.
3053467|NCT00751777|Placebo Comparator|Group 2: 0 µg LT patch (placebo)|40 subjects will receive a two vaccination regimen with a placebo patch.
3053468|NCT00751790|Experimental|Triptorelin|
3053469|NCT00751881|Experimental|Teriflunomide 7 mg / 14 mg|Core treatment period: Teriflunomide 7 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3053470|NCT00751881|Experimental|Teriflunomide 14 mg / 14 mg|Core treatment period: Teriflunomide 14 mg once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3053471|NCT00751881|Placebo Comparator|Placebo / Teriflunomide 14 mg|Core treatment period: Placebo (for teriflunomide) once daily. Extension treatment period: Teriflunomide 14 mg once daily.
3053472|NCT00751972|Experimental|HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
3053473|NCT00751998||Arm 1|Test of SpyGlass device
3053474|NCT00752089|Experimental|Sodium fluoride/potassium nitrate/Isopentane dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice containing active ingredients: 1450 ppm F as sodium fluoride (NaF) and 5% potassium nitrate (KNO3) and isopentane as an excipient ingredient.
3053475|NCT00752089|Experimental|NaF/KNO3 Dentifrice|Participants to brush their teeth for one timed minute twice daily with a gel to foam dentifrice, containing as active ingredients: 1450 ppm NaF and 5% KNO3 but no isopentane.
3053476|NCT00752089|Active Comparator|NaF Dentifrice|Participants to brush their teeth for one timed minute twice daily with a dentifrice containing 1450 ppm F as NaF.
3053477|NCT00752089|Placebo Comparator|Placebo Dentifrice|Participants to brush their teeth for one timed minute twice daily with a fluoride free dentifrice (0 ppm F).
3053478|NCT00752102|Active Comparator|Calcitriol|"Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. Calcitriol is available as capsules containing 0.25 mcg or 0.5 mcg calcitriol and as an oral solution containing 1 mcg/ml of calcitriol. All dosage forms contain butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) as antioxidants.~Subjects taking calcitriol started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels."
3053479|NCT00752102|Active Comparator|Paricalcitol|"Paricalcitol, USP, the active ingredient in Zemplar® Capsules, is a synthetically manufactured analog of calcitriol, the metabolically active form of vitamin D indicated for the prevention and treatment of secondary hyperparathyroidism in chronic kidney disease. Zemplar is available as soft gelatin capsules for oral administration containing 1 mcg, 2 mcg or 4 mcg of paricalcitol. Each capsule also contains medium chain triglycerides, alcohol, and butylated hydroxytoluene.~Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels."
3053480|NCT00752206|Active Comparator|Saracatinib|Saracatinib will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with saracatinib will be 13 cycles.
3053481|NCT00752206|Placebo Comparator|Placebo|Placebo will be administered as a once daily, oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of treatment with placebo will be 13 cycles.
3053482|NCT00752219|Experimental|NXL104/CAZ/MTZ|NXL104/ceftazidime + metronidazole
3053483|NCT00752219|Active Comparator|Meropenem|
3053484|NCT00752232|Experimental|ACC-001+QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
3053485|NCT00752232|Experimental|ACC-001|Active vaccine, IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
3053486|NCT00752232|Placebo Comparator|QS-21|Adjuvant, IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
3053487|NCT00752232|Placebo Comparator|PBS|Placebo, IM injection, Day 1, month 3, 6, 9, 12
3053488|NCT00752557|Experimental|1|rhBMP-2/CPM , 1.0 mg/mL
3053489|NCT00752557|Experimental|2|rhBMP-2/CPM , 2.0 mg/mL
3053490|NCT00752557|Active Comparator|3|Oral bisphosphonate therapy (standard of care)
3053491|NCT00752609|Experimental|Peginesatide|
3053492|NCT00752622|Experimental|Shortened interval|Infliximab 5 mg/kg, then Infliximab 5 mg/kg every 6 weeks
3053493|NCT00752622|Experimental|Increased dose|Infliximab 5 mg/kg, then Infliximab 7 mg/kg every 8 weeks
3053494|NCT00752726|Active Comparator|Orlistat|Orlistat 60 milligram (mg) capsules to be consumed orally with each meal 3 times per day
3053495|NCT00752726|Placebo Comparator|Placebo|Placebo to match Orlistat 60 mg capsules to be consumed orally with each meal 3 times per day.
3053496|NCT00752791|Experimental|Peginesatide|
3053497|NCT00752856|Experimental|1 - Kaletra + Isentress taken twice daily|Kaletra (lopinavir/ritonavir 400/100 mg) + Isentress (Raltegravir 400 mg) twice-daily
3053498|NCT00752856|Active Comparator|2 - Atripla taken once daily|Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily
3053499|NCT00752895|Experimental|Arm I - Ginseng|Patients receive oral American ginseng extract twice daily.
3053500|NCT00752895|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily.
3053501|NCT00752908||Obese patients|Obese patients
3053502|NCT00752908||Normal weight patients and volunteers|Normal weight patients and volunteers
3053503|NCT00752973|Experimental|Treatment arm|MALG treatment
3053504|NCT00753012|Experimental|Lisdexamfetamine|"Adults who meet DSM-IV-TR criteria for ADHD.~Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of <135/85."
3053505|NCT00753142|Active Comparator|Participants with ketosis-prone diabetes|Obese African Americans with type 2 diabetes with history of diabetic ketoacidosis (DKA) receiving Intralipid 20% and a glucose infusion.
3053506|NCT00753142|Active Comparator|Participants with ketosis-resistant diabetes|Obese African American with type 2 diabetes with hyperglycemia without ketosis receiving Intralipid 20% and a glucose infusion.
3053507|NCT00753142|Active Comparator|Non-diabetic control group|Obese African Americans without diabetes receiving a glucose infusion.
3053508|NCT00753220|Experimental|VDC2008|Cryoablation of prostate followed by dendritic cell injection (dose of 2.5 x 10^7, 7.5 x 10^7, or 1.0 x 10^8 cells depending on assigned cohort) into prostate and low dose cyclophosphamide therapy (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
3053509|NCT00753272|Experimental|FluNG Group|subjects received 2 doses (1 dose per season) of FluNG vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
3053510|NCT00753272|Active Comparator|Fluarix Group|subjects received 2 doses (1 dose per season) of Fluarix™ vaccine during the Northern Hemisphere (NH) vaccination periods. One dose at Day 0 of the Year 1 and one dose at Day 0 of the Year 2 (= Day 365 Year 1).
3053511|NCT00753298|Experimental|LoFric Primo (POBE) single-use urinary catheter|
3053512|NCT00753298|Active Comparator|LoFric Primo (PVC) single-use urinary catheter|
3053513|NCT00753337|Experimental|Assurant Cobalt Iliac Stent|Assurant® Cobalt Iliac Stent System
3053514|NCT00753363|Experimental|Arm 1|6 months of aerobic exercise training
3053515|NCT00753363|Experimental|Arm 2|6 months of weight loss
3053516|NCT00753415|Experimental|Part A: V935 LD|Two intramuscular (IM) injections of V935 low dose (LD), 1 given every other week over a 3-week period.
3053517|NCT00753415|Experimental|Part A: V934 LD(3)+V935 LD|Three electroporation (EP) injections of V934 (LD) , 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (LD) will be administered, 1 given every other week over a 3-week period.
3053518|NCT00753415|Experimental|Part A: V935 HD|Two IM injections of V935 high dose (HD), 1 given very other week over a 3-week period.
3053519|NCT00753415|Experimental|Part A: V934 HD(3)+V935 HD|Three EP injections of V934 (HD), 1 given every other week over a 5-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
3053520|NCT00753415|Experimental|Part A: V934 HD(5)+V935 HD|Five EP injections of V934 (HD), 1 given every other week over a 9-week period. Following a 4-week observation period, 2 IM injections of V935 (HD) will be administered, 1 given every other week over a 3-week period.
3053521|NCT00753415|Experimental|Part B: V935 LD/V934 Booster|Participants who completed Part A could enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster were administered, 1 given every 2 weeks.
3053522|NCT00753415|Experimental|Part B: V934 LD(3)+V935 LD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3053523|NCT00753415|Experimental|Part B: V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3053524|NCT00753415|Experimental|Part B: V934 HD(3)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3053525|NCT00753415|Experimental|Part B: V934 HD(5)+V935 HD/V934 Booster|Participants who complete Part A can enter Part B. Following a 12-week observation period, 3 EP injections of V934 booster will be administered, 1 given every 2 weeks.
3053526|NCT00753454|Experimental|CDP870|Patients having completed the week 34 assessment in C87077 (NCT00580840) or patients having been randomized at Week 18 and having met the pre-defined criteria for flare, will be given the option to enroll in C87084 and receive: 400 mg CZP at Entry, Week 2, and Week 4 followed by 200 mg every two weeks in combination with MTX until the drug is commercially available for the indication of RA in the patient's country or region (or until further notice from UCB).
3053527|NCT00753506|Active Comparator|Artemisinin|100 mg artemisinin capsule
3053528|NCT00753506|Placebo Comparator|Placebo|Identical looking placebo capsule
3053529|NCT00753519|Experimental|Real iTBS|iTBS is a novel form of excitatory rTMS that may induce larger and longer lasting changes that standard rTMS. iTBS consists of bursts of 3 pulses at 50 Hz repeated at 200 msec intervals. The 2 sec trains were repeated 20 times every 10 sec. iTBS was applied to the primary motor and the dorsolateral prefrontal cortex bilaterally.
3053530|NCT00753519|Sham Comparator|Sham iTBS|The sham coil was placed in the same areas, and made a similar sound as the rTMS but was without a magnetic pulse.
3053531|NCT00753545|Experimental|1|AZD2281
3053532|NCT00753545|Placebo Comparator|2|matching placebo
3053533|NCT00753623|Active Comparator|Ramelteon first, placebo second|"In a crossover design, a subject will be first assigned to the ramelteon arm and then switched over to the placebo arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night.The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
3053534|NCT00753623|Placebo Comparator|Placebo first, ramelteon second|"In a crossover design, a subject will be first assigned to the placebo arm and then switched over to the ramelteon arm. As this is a double-blind study, neither the subject nor the study staff will know which intervention the subject is randomly assigned. The ramelteon dose is 8mg once a night. The ramelteon and placebo will be blinded by the central pharmacy.~The subject is randomly assigned to first receive either ramelteon or placebo. The first intervention will be 14 days long. There is a 7 day washout period, and then the subject is assigned to the opposite intervention. The second intervention will be 14 days long."
3053535|NCT00753636|Experimental|Dynacirc CR (Isradipine)|Dynacirc CR (Isradipine) will start at 5mg dose and increased in increments of 5mg every 2 weeks
3053536|NCT00753649|Experimental|Aboriginal infants group|
3053537|NCT00753649|Active Comparator|Other Non-Aboriginal infants|
3053538|NCT00753675|Experimental|A|Vandetanib 300 mg as a once daily oral dose, from Day 1
3053539|NCT00753675|Experimental|B|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy)
3053540|NCT00753675|Placebo Comparator|C|Gemcitabine administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1 (after 6 cycles, in the absence of disease progression or unacceptable toxicity, Investigators remain at liberty to continue Gemcitabine plus Vandetanib / Placebo or to continue Vandetanib / Placebo monotherapy).
3053541|NCT00753688|Placebo Comparator|PLACEBO|matching placebo 800 mg once daily orally
3053542|NCT00753688|Experimental|PAZOPANIB|800 mg once daily orally
3053543|NCT00753714|Experimental|A|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with vandetanib alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
3053544|NCT00753714|Placebo Comparator|B|Gemcitabine administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to plus Vandetanib 100 mg Matching Placebo orally once-daily, from Day 1.Patients will receive gemcitabine for up to a maximum of 6 cycles, after which period patients should continue on daily oral dosing with placebo alone until progression. Once a patient has met the study criteria for disease progression on vandetanib/gemcitabine or placebo/gemcitabine, randomised treatment must be permanently discontinued.
3053545|NCT00753766|Experimental|Multifactorial Intervention|Mulitfactorial intervention - addressing glucose, blood pressure, lipids, smoking, nutrition and exercise.
3053546|NCT00753766|No Intervention|Usual care|Control group
3053547|NCT00753896|Experimental|1|
3053548|NCT00753922|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
3053549|NCT00753922|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
3053550|NCT00753922|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
3053551|NCT00753922|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
3053552|NCT00753935|Experimental|Enteric-coated aspirin|patients received enteric-coated aspirin 81 mg qd for 2 weeks
3053553|NCT00753935|Active Comparator|Chewable aspirin|Patients received chewable aspirin 81 mg qd for 2 weeks
3053554|NCT00753948|Experimental|Chronic Tetraplegia|Individuals with chronic tetraplegia
3053555|NCT00753948|Active Comparator|Mild Asthma|Individuals with diagnosed mild asthma
3053556|NCT00753948|Placebo Comparator|Healthy Control|Neurologically intact, otherwise healthy, age-matched control
3053557|NCT00754065|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 26 days, followed by one capsule placebo for 2 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
3053558|NCT00754065|Active Comparator|Ortho Tri-Cyclen Lo|Daily oral administration of one capsule Ortho Tri-Cyclen Lo [Ethinylestradiol (EE)/ Norgestimate (NGM)] for 21 days, followed by one capsule placebo for 7 days (28 days total per cycle) for 13 treatment cycles (treatment encapsulated)
3053559|NCT00754130|Experimental|Placebo/MK-0941 20mg|Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053560|NCT00754130|Experimental|MK-0941 5mg/Placebo|Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053561|NCT00754130|Experimental|MK-0941 5mg/MK-0941 20mg|Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053562|NCT00754130|Experimental|Placebo/MK-0941 40mg|Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053563|NCT00754130|Experimental|MK-0941 10mg/Placebo|Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053564|NCT00754130|Experimental|MK-0941 10mg/MK-0941 40mg|Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.
3053565|NCT00754156|Active Comparator|1 ABRA plus KCI ABThera or KCI VAC|ABRA Abdominal Wound Closure System in combination with KCI ABThera or KCI VAC
3053566|NCT00754156|Active Comparator|KCI V.A.C. Therapy or ABThera Alone|KCI V.A.C. Therapy ABThera Alone
3053567|NCT00754208|Other|methylpehnidate|open-label treatment with methylphenidate
3053568|NCT00754234|Experimental|MyPyramid Menu Days 1-7|Iron absorption measured from one of the 7 different USDA MyPyramid menus for 1 day each, in randomized order for each subject, separated by 2 weeks
3053569|NCT00754247|Experimental|Regimen A|0.5% hydrocortisone, silicone, vitamin E lotion
3053570|NCT00754247|Experimental|Regimen B|Onion extract gel
3053571|NCT00754247|Placebo Comparator|Regimen C|Cetearyl alcohol lotion
3053572|NCT00754325|Active Comparator|Arm 1 (Dasatinib +Fulvestrant)|
3053573|NCT00754325|Active Comparator|Arm 2 (Fulvestrant)|
3053574|NCT00754338|Active Comparator|Phase1 - Arm 1|
3053575|NCT00754338|Active Comparator|Phase1 - Arm 2|
3053576|NCT00754338|Active Comparator|Phase 2 - Arm 1|
3053577|NCT00754338|Active Comparator|Phase 2 - Arm 2|
3053578|NCT00754377||PBLI Curriculum group|To evaluate preliminary data on a PBLI curriculum grounded on QI system projects.
3053579|NCT00754377||Comparison group|Received a different curriculum.
3053580|NCT00754390|Experimental|Overall Study|Participants consumed 4 experimental diets for 4 weeks each in randomized order
3053581|NCT00754442|Active Comparator|teriparatide control|control subject
3053582|NCT00754442|Experimental|Teriparatide Patient|Patient with secondary hyperparathyroidism
3053583|NCT00754468|Experimental|Group 1: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 4 cycles x 10 seconds
3053584|NCT00754468|Experimental|Group 2: Cryo Spray Ablation|cryo spray ablation applied to healthy tissue 2 cycles x20 seconds
3053585|NCT00754494|Experimental|Erlotinib Hydrochloride (25 mg)|Patients receive 25mg of erlotinib hydrochloride PO and one 100 mg of placebo and one 25 mg of placebo PO QD.
3053586|NCT00754494|Experimental|Erlotinib Hydrochloride (50 mg)|Patients receive 50 mg of erlotinib hydrochloride PO and one 100 mg of placebo PO QD.
3053587|NCT00754494|Experimental|Erlotinib Hydrochloride (100 mg)|Patients receive 100 mg of erlotinib hydrochloride PO and two 25 mg of placebo PO QD.
3053588|NCT00754546|Active Comparator|Arformoterol tartrate|Bronchodilator therapy with arformoterol solution 15 mcg
3053589|NCT00754546|Placebo Comparator|Normal saline|Placebo using normal saline
3053590|NCT00754559|Experimental|Tocilizumab|
3053591|NCT00754572|Experimental|1|
3053592|NCT00754624|Experimental|TI Inhalation Powder|Technosphere® Insulin Inhalation Powder
3053593|NCT00754650|Experimental|Bevacizumab 15 mg/kg|Participants received bevacizumab 15 mg/kg intravenously on Day 1 of each 3-week cycle for 8 cycles.
3053594|NCT00754741|No Intervention|Usual care|All Physicians are given limited training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software when they see patients assigned to this arm
3053595|NCT00754741|Active Comparator|Adherence|
3053596|NCT00754741|Active Comparator|Adherence Plus|
3053597|NCT00754832|Experimental|1|Period 1 with Ginseng therapy intervention; Washout Period with no drug; Period 2 with placebo
3053598|NCT00754832|Experimental|2|Period 1 with placebo; Washout period with no drug; Period 2 with ginseng therapy intervention
3053599|NCT00754845|Experimental|Letrozole|Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
3053600|NCT00754845|Placebo Comparator|Placebo|Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity, disease recurrence, or development of a second malignancy.
3053601|NCT00754923|Experimental|Treatment: Sorafenib|Sorafenib will be administered at a dose of 400 mg taken twice daily, continuously on a 28 day cycle.
3053602|NCT00754936|Experimental|Escitalopram|12 week open label with 2 week placebo period (14 weeks total)
3053603|NCT00755040|Experimental|Ocular Cyclosporine (Restasis)|Patients receive cyclosporine ophthalmic emulsion (Restasis®) drops in each eye twice daily for up to 1 year after transplant.
3053604|NCT00755040|Placebo Comparator|Placebo|Patients receive placebo ophthalmic drops in each eye twice daily for up to 1 year after transplant.
3053605|NCT00755079|Placebo Comparator|Arm 1|group of persons with spinal cord injury will receive blinded placebo capsule
3053606|NCT00755079|Experimental|Arm 2|group of persons with spinal cord injury will receive blinded beta-2 adrenergic agonist capsule
3053607|NCT00755131|Experimental|Training Group|Postinfarction patients undergo 6-month exercise-based Cardiac Rehabilitation Program
3053608|NCT00755131|No Intervention|Control Group|Postinfarction patients NOT undergoing 6-months exercise-based Cardiac Rehabilitation program
3053609|NCT00755183|Experimental|testosterone ophthalmic solution|testosterone ophthalmic solution 0.03%
3053610|NCT00755183|Placebo Comparator|vehicle|vehicle of testosterone ophthalmic solution
3053611|NCT00755196|Active Comparator|1|AN2728 Ointment, 5%
3053612|NCT00755196|Placebo Comparator|2|AN2728 Ointment vehicle
3053613|NCT00755222|Experimental|AA4500|Clostridial collagenase for injection
3053614|NCT00755222|Placebo Comparator|Placebo|
3053615|NCT00755235|Experimental|1|Participants will receive depression care management by secure messaging.
3053616|NCT00755235|No Intervention|2|Participants will receive their usual care, with no additional education or care management services.
3053617|NCT00755274|Experimental|Group 1: Primed|Have received 2 or more lifetime Flu Vaccinations Prior to Visit 1
3053618|NCT00755274|Experimental|Group 2: Naive/Inadequately Primed|Never Received or Received Only 1 Lifetime Flu Vaccination Prior to Visit 1
3053619|NCT00755326|Active Comparator|Huo-Luo-Xiao-Ling|Active herb Huo-Luo-Xiao-Ling (HLXL) The subjects in the HLXL group received the medium dose of HLXL (10 capsules/day or 4,000mg/day) in the first 2 weeks to evaluate safety. If no adverse effects were observed, the dose was increased to 14 capsules per day (5,600 mg/day) for the subsequent 6 weeks.
3053620|NCT00755326|Placebo Comparator|Placebo|Placebo Huo-Luo-Xiao-Ling (HLXL): Subjects in the placebo group received an equal number of placebo capsule.
3053621|NCT00755417|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
3053622|NCT00755417|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
3053623|NCT00755417|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
3053624|NCT00755716|Placebo Comparator|Placebo (sugar pill)|Person receives an inactive placebo
3053625|NCT00755716|Active Comparator|Topiramate|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day for a total time of 10 weeks.
3053626|NCT00755716|Active Comparator|Topiramate and Nicotine patch|Subjects receive 10 weeks of topiramate with a dosage starting at 25 mg per day. At week two (quit date) subjects increase to 50 mg/day and gradually increase to 200 mg/day and one week taper for a total time of 10 weeks. On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
3053627|NCT00755755|Experimental|A (PGL4001 5mg)|PGL4001 5 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3053628|NCT00755755|Experimental|B (PGL4001 10mg)|PGL4001 10 mg (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3053629|NCT00755755|Placebo Comparator|C (placebo)|PGL4001 matching placebo (oral tablets) with concomitant oral administration of 1 tablet containing 80 mg Fe2+
3053630|NCT00755807|Placebo Comparator|Placebo|
3053631|NCT00755807|Experimental|Duloxetine|
3053632|NCT00755846|Experimental|Alogliptin 6.25 mg QD|
3053633|NCT00755846|Experimental|Alogliptin 12.5 mg QD|
3053634|NCT00755846|Experimental|Alogliptin 25 mg QD|
3053635|NCT00755846|Experimental|Alogliptin 50 mg QD|
3053636|NCT00755846|Experimental|Alogliptin 100 mg QD|
3053637|NCT00755846|Placebo Comparator|Placebo QD|
3053638|NCT00755911|Experimental|Tissue Repair Cells (TRC)|Subjects will receive Tissue Repair Cell (TRC) therapy plus Gelfoam carrier
3053639|NCT00755911|Sham Comparator|Control|Subjects will receive the control treatment, consisting of Gelfoam carrier without Tissue Repair Cell (TRC) therapy.
3053640|NCT00755937||Subjects receiving Remicade|Crohn's disease subjects receiving Remicade® per Product Monograph.
3053641|NCT00756002|Experimental|Ramelteon 4 mg QD|
3053642|NCT00756002|Placebo Comparator|Placebo QD|
3053643|NCT00756093|Experimental|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each one time
3053644|NCT00756093|Active Comparator|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
3053645|NCT00756093|Active Comparator|Blink Tears|Blink Tears 1 drop each eye one time
3053646|NCT00756093|Active Comparator|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops 1 drop each eye one time
3053647|NCT00756106|Experimental|Temozolomide and Radiation Therapy|
3053648|NCT00756236|Experimental|M-Group|Patients were randomly assigned to Metoprolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 1mg/ml Metoprolol. Investigators and patients were blinded to the group assignment.
3053649|NCT00756236|Experimental|E-Group|Patients were randomly assigned to Esmolol Group. The drug was dispensed in 60ml & 5ml syringes of 0.9% NaCl and 10mg/ml Esmolol. Investigators and patients were blinded to the group assignment.
3053650|NCT00756236|Placebo Comparator|P-Group|Patients were randomly assigned to this group. Patients received 0.9% NaCl only. To maintain the blind, 0.9% NaCl was also dispensed in 60ml & 5ml syringes.
3053651|NCT00756275|Active Comparator|Nicotine Replacement + PLA pill|Nicotine replacement treatment patch plus matched placebo pill
3053652|NCT00756275|Active Comparator|Varenicline + PLA patch|Varenicline plus matched placebo patches containing no nicotine
3053653|NCT00756314|Experimental|Personalized contraceptive counseling|All 123 allocated women for the intervention group received personalized counseling (face-to-face) and the contraceptive method chosen for free by a specialized trained doctor in family planning.
3053654|NCT00756314|No Intervention|Control|All 123 women allocated to control group received a standard care available at IMIP.Standard care is comprised of educational group counseling by specialized nursing staff in family planning discussing about contraceptive methods and side effects
3053655|NCT00756444|Active Comparator|Panitumumab plus Chemotherapy|Subjects receiving cisplatin and 5/FU and receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
3053656|NCT00756444|Active Comparator|Chemotherapy Alone|Subjects receiving cisplatin and 5/FU and not receiving Panitumumab who have with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
3053657|NCT00756457|Active Comparator|Active Treatment Group|Participants in Group A will undergo bracing and perform stretching exercises.
3053658|NCT00756457|Experimental|Passive Treatment Group|Participants in Group B will undergo bracing and perform stretching and strengthening exercises.
3053659|NCT00756470|Experimental|Neoadjuvant Lapatinib plus Chemotherapy|"Four cycles of Lapatinib and Paclitaxel followed by 4 cycles of Lapatinib plus 5-Fluorouracil, Cyclophosphamide, Epirubicin (FEC75). Cycle is 21 days.~Lapatinib alone at 1,000 mg orally once daily for a 2-week run-in period, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each.~Week 3 Paclitaxel 80 mg/m^2 weekly for 4 cycles (12 weeks) administered on Day 1, Day 8, and Day 15) of each cycle combined with Lapatinib 750 mg orally once daily.~Week 15, second combination treatment consisting of Lapatinib (1,000 mg orally once daily) combined with FEC75 (5-FU 500 mg/m^2, Epirubicin 75 mg/m^2, and Cyclophosphamide 500 mg/m^2 every 3 weeks for 4 cycles)."
3053660|NCT00756496|Experimental|1|
3053661|NCT00756548|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
3053662|NCT00756548|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
3053663|NCT00756574|Active Comparator|1. Surgical|surgical mask
3053664|NCT00756574|Active Comparator|2. N95 Respirator|N95 respirator
3053665|NCT00756600|Active Comparator|1|Regional Anesthesia
3053666|NCT00756600|Active Comparator|2|General Anesthesia
3053667|NCT00756613||465 VADT participants|The participants had previously participated in the VADT CSP #465 study
3053668|NCT00756652||MemoryGel Breast Implant Participants|MemoryGel Breast Implant Participants received Mentor Silicone Gel-Filled Breast Implants (MemoryGel) during their Breast Augmentation, Breast Reconstruction, or Revision surgery
3053669|NCT00756652||Saline Breast Implant Control Participants|Saline Breast Implant Control Participants received Saline Filled Breast Implants during their Breast Augmentation, Breast Reconstruction, or Revision surgery
3053670|NCT00756678|Active Comparator|1|Carboxymethylcellulose and Glycerin
3053671|NCT00756678|Active Comparator|2|Polyethylene glycol 400
3053672|NCT00756717|Experimental|MK-0752|Oral gamma-secretase inhibitor drug MK-0752, 350 mg for three days, four days off, then three days on, over a period of 10 days
3053673|NCT00756730|Other|Switch to DRV/r (800mg/100mg) QD|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
3053674|NCT00756730|Other|Switch to ATV/r (300mg/100mg QD)|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
3053675|NCT00756886|Active Comparator|Atorvastatin|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
3053676|NCT00756886|Placebo Comparator|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
3053677|NCT00756938|Experimental|Losartan potassium 0.1 to 1.4 mg/kg|Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3053678|NCT00756938|Experimental|Losartan potassium 0.3 to 1.4 mg/kg|Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3053679|NCT00756938|Experimental|Losartan potassium 0.7 to 1.4 mg/kg|Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved
3053680|NCT00756964|Active Comparator|Rasburicase|patients receiving rasburicase to lower serum uric acid
3053681|NCT00756964|Placebo Comparator|Placebo|patients will receive a placebo
3053682|NCT00756977|Experimental|1|multi-dose preparation for oral administration prior to colonoscopy
3053683|NCT00756977|Active Comparator|2|multi-dose preparation for oral administration prior to colonoscopy
3053684|NCT00757003|Experimental|Treatment Arm - Placement of TAG device|A TAG device will be used to repair the pathology in the thoracic aorta
3053685|NCT00757172|Other|Docetaxel + Cisplatin + Panitumumab + RT|Patients received docetaxel (40 mg/m^2), cisplatin (40 mg/m^2) and panitumumab (6 mg/kg) on weeks 1, 3, 5, 7, and 9 with radiotherapy (RT) (5040 cGy, 180 cGy/day x 28 days) beginning week 5. Resection was planned after completing chemotherapy (CRT).
3053686|NCT00757237|Experimental|AZLI 75 mg 3 times a day (TID)|
3053687|NCT00757237|Active Comparator|TIS 300 mg 2 times a day (BID)|
3053688|NCT00757588|Experimental|Saxagliptin, 5 mg + insulin|Saxagliptin, 5 mg, plus insulin, administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3053689|NCT00757588|Placebo Comparator|Placebo + insulin|Placebo administered to participants with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3053690|NCT00757601|Experimental|15 mg MK1006/Placebo/45 mg MK1006/60 mg MK1006/Placebo (Fed)|Participants received 15 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by placebo to MK1006 taken with food (Fed state) in Period 5.
3053691|NCT00757601|Experimental|Placebo/30mg MK1006/45mg MK1006/60mg MK1006/30mg MK1006 (Fed)|Participants received placebo to MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3053692|NCT00757601|Experimental|15mg MK1006/30mg MK1006/Placebo/60mg MK1006/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 60 mg MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3053693|NCT00757601|Experimental|15mg MK1006/30mg MK1006/45mg MK1006/Placebo/30mg MK1006 (Fed)|Participants received 15 mg MK1006 in Period 1, followed by 30 mg MK1006 in Period 2, followed by 45 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 30 mg MK1006 taken with food (Fed state) in Period 5.
3053694|NCT00757601|Experimental|60mg MK1006 / Placebo / 100mg MK1006 / 120mg MK1006 / Placebo|Participants received 60 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
3053695|NCT00757601|Experimental|Placebo/ 80mg MK1006/ 100mg MK1006/ 120mg MK1006/ 140mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5
3053696|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ Placebo/ 120mg MK1006/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 120 mg MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
3053697|NCT00757601|Experimental|60mg MK1006/ 80mg MK1006/ 100mg MK1006/ Placebo/ 140mg MK1006|Participants received 60 mg MK1006 in Period 1, followed by 80 mg MK1006 in Period 2, followed by 100 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 140 mg MK1006 in Period 5.
3053698|NCT00757601|Experimental|140mg MK1006 / Placebo / 200mg MK1006 / 230mg MK1006 / Placebo|Participants received 140 mg MK1006 in Period 1, followed by placebo to MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by placebo to MK1006 in Period 5.
3053699|NCT00757601|Experimental|Placebo/170mg MK1006/ 200mg MK1006/ 230mg MK1006/ 260mg MK1006|Participants received placebo to MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
3053700|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ Placebo/ 230mg MK1006/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by placebo to MK1006 in Period 3, followed by 230 mg MK1006 in Period 4, followed by 260 mg MK1006 in Period 5
3053701|NCT00757601|Experimental|140mg MK1006/170mg MK1006/ 200mg MK1006/ Placebo/ 260mg MK1006|Participants received 140 mg MK1006 in Period 1, followed by 170 mg MK1006 in Period 2, followed by 200 mg MK1006 in Period 3, followed by placebo to MK1006 in Period 4, followed by 260 mg MK1006 in Period 5.
3053702|NCT00757627|Experimental|1|Etoricoxib
3053703|NCT00757666|Active Comparator|Accelerometer|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with accelerometer (motion-based) sensor.
3053704|NCT00757666|Active Comparator|Minute Ventilation|Patients implanted with a Boston Scientific ALTRUA 60 pacemaker with minute ventilation sensor.
3053705|NCT00757705|Experimental|Paliperidone Extended-Release (ER)|
3053706|NCT00757783|Experimental|darunavir|darunavir 800 mg tablet once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg tablet once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
3053707|NCT00757783|Experimental|atazanavir|atazanavir 300 mg capsule once daily for 48 weeks,emtricitabine [FTC]/tenofovir [TDF] 200/300 mg once daily for 48 weeks,ritonavir 100 mg capsule or tablet once daily for 48 weeks
3053708|NCT00757822|Experimental|Arm 1|dronabinol
3053709|NCT00757822|Active Comparator|Arm 2|ondansetron
3053710|NCT00757848|Experimental|AZD9668|
3053711|NCT00757848|Placebo Comparator|Placebo|
3053712|NCT00758043|Experimental|T12PR24 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 12 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
3053713|NCT00758043|Experimental|T12PR48 (eRVR+)|Randomized Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects achieved an extended rapid viral response (eRVR+) and were randomized to this group
3053714|NCT00758043|Experimental|T12PR48 (eRVR-)|Assigned Group: Telaprevir + Peg-IFN-alfa-2a + RBV for 12 weeks, followed by Peg-IFN-alfa-2a + RBV for 36 weeks; subjects did not achieve an extended rapid viral response and were assigned to this group
3053715|NCT00758043|Experimental|Other|Other Group: Subjects who received at least 1 dose of study drug, but prematurely discontinued treatment before Week 20, were not randomized or assigned to a treatment regimen.
3053716|NCT00758069|Placebo Comparator|1|Placebo
3053717|NCT00758069|Experimental|2|Sitagliptin 100 mg
3053718|NCT00758069|Experimental|3|Sitagliptin 50 mg
3053719|NCT00758160|Experimental|OROS methylphenidate|Participants willl receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
3053720|NCT00758264|Experimental|Group A|Meningococcal vaccine GSK134612 co-administered with pneumococcal vaccine GSK1024850A.
3053721|NCT00758264|Active Comparator|Group B|Pneumococcal vaccine GSK1024850A followed one month later by meningococcal vaccine GSK134612.
3053722|NCT00758264|Active Comparator|Group C|Meningococcal vaccine GSK134612 followed one month later by pneumococcal vaccine GSK1024850A.
3053723|NCT00758290|Active Comparator|A|
3053724|NCT00758290|Experimental|B|
3053725|NCT00758342|Experimental|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
3053726|NCT00758342|Active Comparator|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
3053727|NCT00758394|Placebo Comparator|Fluoride - A|Fluoride only toothpaste
3053728|NCT00758394|Active Comparator|Total + Whitening toothpaste - B|Triclosan/fluoride toothpaste
3053729|NCT00758394|Experimental|Triclosan/fluoride/Amino Acid - C|toothpaste containing amino acid #1
3053730|NCT00758394|Experimental|Triclosan/fluoride/Cavistat -D|toothpaste containing amino acid/bicarbonate
3053731|NCT00758420|Active Comparator|1|Varisolve (polidocanol endovenous mircofoam)
3053732|NCT00758420|Placebo Comparator|2|Agitated saline
3053733|NCT00758459|Experimental|1|
3053734|NCT00758459|Placebo Comparator|2|
3053735|NCT00758485|Experimental|sugammadex|Participants receiving 4.0 mg.kg-1 Sugammadex at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
3053736|NCT00758485|Placebo Comparator|Placebo|Participants receiving Placebo (0.9% NaCl) at a target depth of NMB of 1-2 PTC after the last dose of rocuronium
3053737|NCT00758498|Experimental|1|armodafinil - dosage of 50 mg/day
3053738|NCT00758498|Experimental|2|armodafinil - dosage of 150 mg/day
3053739|NCT00758498|Placebo Comparator|3|matching placebo
3053740|NCT00758524|Experimental|Core Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, once daily (QD), with or without food for up to 8 weeks.
3053741|NCT00758524|Experimental|Core Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 8 weeks.
3053742|NCT00758524|Experimental|Core Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 8 weeks.
3053743|NCT00758524|Experimental|Core Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
3053744|NCT00758524|Active Comparator|Core Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 8 weeks.
3053745|NCT00758524|Placebo Comparator|Core Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 8 weeks.
3053746|NCT00758524|Experimental|Withdrawal Period: LCI699 0.25 mg QD|Participants received LCI699 0.25 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053747|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.25 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053748|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053749|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053750|NCT00758524|Experimental|Withdrawal Period: LCI699 1.0 mg QD|Participants received LCI699 1 mg capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053751|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 1.0 mg QD Placebo|Participants received LCI699 matching placebo capsules, orally, QD, with or without food for up to 1 week (Week 8 to Week 9).
3053752|NCT00758524|Experimental|Withdrawal Period: LCI699 0.5 mg BID|Participants received LCI699 0.5 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
3053753|NCT00758524|Placebo Comparator|Withdrawal Period: LCI699 0.5 mg BID Placebo|Participants received LCI699 matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
3053754|NCT00758524|Active Comparator|Withdrawal Period: Eplerenone 50 mg BID|Participants received eplerenone 50 mg capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
3053755|NCT00758524|Placebo Comparator|Withdrawal Period: Eplerenone 50 mg BID Placebo|Participants received eplerenone matching placebo capsules, orally, BID, with or without food for up to 1 week (Week 8 to Week 9).
3053756|NCT00758524|Placebo Comparator|Withdrawal Period: Placebo|Participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food for up to 1 week (Week 8 to Week 9).
3053757|NCT00758550|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
3053758|NCT00758550|Active Comparator|AcrySof Natural IOL|AcrySof Natural Intraocular Lens (IOL)
3053759|NCT00758563|Placebo Comparator|A|
3053760|NCT00758563|Active Comparator|B|
3053761|NCT00758576|Experimental|SN6AD1|AcrySof ReSTOR Model SN6AD1 Intraocular Lens
3053762|NCT00758589|Experimental|AZD1981 50 mg|AZD1981 50 mg Twice Daily (Bid)
3053763|NCT00758589|Placebo Comparator|Placebo|Placebo
3053764|NCT00758589|Experimental|AZD1981 400 mg|AZD1981 400 mg Twice Daily (Bid)
3053765|NCT00758589|Experimental|AZD1981 1000 mg|AZD1981 1000 mg Twice Daily (Bid)
3053766|NCT00758602|Active Comparator|MMF, Standard Dose Tacrolimus|Participants received mycophenolate mofetil (MMF) 0.75 to (-) 1 gram (g), orally (PO), twice daily (BID) from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 milligrams per kilogram (mg/kg), PO, BID to reach a target trough dose of 8-10 nanograms per milliliter (ng/mL) from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
3053767|NCT00758602|Experimental|MMF, Low Dose Tacrolimus|Participants received MMF 0.75-1 g, PO, BID from Day 0 through Month 12. Participants also received tacrolimus 0.1-0.15 mg/kg, PO, BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to 0.05-0.08 mg/kg, PO, BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12. Participants also received corticosteroids per center practice.
3053768|NCT00758667|No Intervention|Standard treatment|Standard treatment
3053769|NCT00758667|Experimental|Use of Mesna|Standard surgical procedure with Mesna
3053770|NCT00758680|Experimental|MK-1006 20 mg Once Daily (Panel A)|After a 2-week run-in/wash-off period, participants received single daily doses (q.d.) of 20 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the Clinical Research Unit (CRU).
3053771|NCT00758680|Experimental|MK-1006 40 mg Once Daily (Panel B)|After a 2-week run-in/wash-off period, participants received single daily doses of 40 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053772|NCT00758680|Experimental|MK-1006 80 mg Once Daily (Panel C)|After a 2-week run-in/wash-off period, participants received single daily doses of 80 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053773|NCT00758680|Experimental|MK-1006 120 mg Once Daily (Panel D)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053774|NCT00758680|Experimental|MK-1006 20 mg Twice Daily (Panel E)|After a 2-week run-in/wash-off period, participants received twice-daily doses (b.i.d.) of 120 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053775|NCT00758680|Experimental|MK-1006 30 mg Twice Daily (Panel F)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 30 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053776|NCT00758680|Experimental|MK-1006 50 mg Twice Daily (Panel G)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 10-day multiple-dosing period while remaining domiciled in the CRU.
3053777|NCT00758680|Experimental|MK-1006 120 mg Once Daily Outpatient (Panel H)|After a 2-week run-in/wash-off period, participants received single daily doses of 120 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
3053778|NCT00758680|Experimental|MK-1006 50 mg Twice Daily Outpatient (Panel I)|After a 2-week run-in/wash-off period, participants received twice-daily doses of 50 mg MK-1006 over a 7-day multiple-dosing period while remaining domiciled in the CRU. Participants were then discharged from the CRU and continued daily dosing of MK-1006 for an additional 21 days as outpatients.
3053779|NCT00758680|Placebo Comparator|Placebo|After a 2-week run-in/wash-off period, participants received dose-matched placebo to MK-1006 over a multiple-dosing period while remaining domiciled in the CRU.
3053780|NCT00758706|Experimental|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
3053781|NCT00758706|Placebo Comparator|Placebo|Dosing to match AZD1236
3053782|NCT00758745|Active Comparator|Model SN60WF|Implantation with the AcrySof Model SN60WF Intraocular Lens (IOL)
3053783|NCT00758745|Active Comparator|Model MA60AC|Implantation with the AcrySof Model MA60AC Intraocular Lens (IOL)
3053784|NCT00758758|Experimental|Experimental Arm 1|Hedrocel 1 level - No plate
3053785|NCT00758758|Experimental|Experimental Arm 2|Hedrocel 1 level with plate
3053786|NCT00758758|Experimental|Experimental Arm 3|Hedrocel 2 levels with plate
3053787|NCT00758758|Active Comparator|Control Arm 1|Autograft alone - Illiac crest
3053788|NCT00758758|Active Comparator|Control Arm 2|Autograft 1 level with plate
3053789|NCT00758758|Active Comparator|Control Arm 3|Allograft 1 level with plate
3053790|NCT00758758|Active Comparator|Control Arm 4|Autograft 2 levels with plate
3053791|NCT00758758|Active Comparator|Control Arm 5|Allograft 2 levels with plate
3053792|NCT00758771||Cystic Fibrosis|People who have been diagnosed with cystic fibrosis
3053793|NCT00758771||Healthy|People who do not have cystic fibrosis and who do not have any other lung conditions
3053794|NCT00758784|Experimental|bromfenac ophthalmic solution 0.06%|bromfenac ophthalmic solution 0.06% bilaterally twice a day
3053795|NCT00758836|Placebo Comparator|Placebo|Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine
3053796|NCT00758836|Experimental|Telcagepant 280 mg +Ibuprofen 400 mg|Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine
3053797|NCT00758836|Experimental|Telcagepant 280 mg +APAP 1000 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine
3053798|NCT00758836|Placebo Comparator|Telcagepant 280 mg|Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine
3053799|NCT00758862|Experimental|1|
3053800|NCT00759031|Placebo Comparator|A - Marketed fluoride toothpaste|
3053801|NCT00759031|Active Comparator|B -Triclosan/NaF/CoPolymer toothpaste|
3053802|NCT00759096|Experimental|Acrysof ReSTOR IOL|AcrySof ReSTOR Intraocular lens (IOL) implanted
3053803|NCT00759109|Experimental|Arm A - PegIntron|Participants randomized to Arm A received peginterferon α-2b (PegIntron), 50 μg, weekly, subcutaneously (SC), for a period of 3 years.
3053804|NCT00759109|Other|Arm B - Control|Participants randomized to Arm B were under observation and received no treatment.
3053805|NCT00759148|Experimental|Moxifloxacin AF|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, 1 drop in each eye twice daily for 3 days
3053806|NCT00759148|Placebo Comparator|Vehicle|Moxifloxacin AF vehicle, 1 drop in each eye twice daily for 3 days
3053807|NCT00759161|Active Comparator|1|AN2728 Ointment, 5%
3053808|NCT00759161|Placebo Comparator|2|AN2728 Ointment Vehicle
3053809|NCT00759174||Case Group|
3053810|NCT00759187|Placebo Comparator|A|
3053811|NCT00759187|Active Comparator|B|
3053812|NCT00759187|Active Comparator|C|
3053813|NCT00759330|Placebo Comparator|Placebo Tape (Arm 1)|Placebo tape remained on for 12 hours of continuous treatment per day.
3053814|NCT00759330|Experimental|Flurbiprofen Tape (Arm 2)|Flurbiprofen tape remained on for 12 hours of continuous treatment per day.
3053815|NCT00759330|Placebo Comparator|Placebo Tape (Arm 3)|Placebo tape remained on for 24 hours of continuous treatment per day.
3053816|NCT00759330|Experimental|Flurbiprofen Tape (Arm 4)|Flurbiprofen tape remained on for 24 hours of continuous treatment per day.
3053817|NCT00759356|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3053818|NCT00759356|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3053819|NCT00759395|Experimental|AZD2327|AZD2327 3mg BID
3053820|NCT00759395|Placebo Comparator|Placebo|Placebo BID
3053821|NCT00759408|Experimental|1|BQ-123
3053822|NCT00759473|Placebo Comparator|Placebo/Placebo/Placebo/Placebo|Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3053823|NCT00759473|Experimental|DCS/DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 3 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3053824|NCT00759473|Other|DCS/Placebo/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) at the first and third cue exposure sessions and a placebo at the second cue exposure and the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities.
3053825|NCT00759473|Experimental|DCS/DCS/Placebo|Participants were assigned to receive 50 mg of d-cycloserine (DCS) for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
3053826|NCT00759473|Active Comparator|Placebo/Placebo/Placebo|Participants were assigned to placebo for each of 2 cue exposure sessions and a placebo at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footage of cocaine-related activities. Cue exposure sessions were accompanied by instructions on coping with craving.
3053827|NCT00759525|Active Comparator|1|Glycyrrhetic Acid
3053828|NCT00759525|Placebo Comparator|2|Placebo
3053829|NCT00759564|Experimental|IV CP-70,429 and cross over to PF-03709270|
3053830|NCT00759603|Experimental|Lenalidomide + Rituximab|Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
3053831|NCT00759642|Experimental|Lapatinib|lapatinib
3053832|NCT00759655|Other|open label|
3053833|NCT00759668|Experimental|SN60D3|AcrySof Natural ReSTOR Intraocular Lens (IOL) Model SN60D3
3053834|NCT00759668|Active Comparator|SN60AT|AcrySof Natural Monofocal Intraocular Lens (IOL) Model SN60AT
3053835|NCT00759681|Active Comparator|Control|Gelfoam and Thrombin
3053836|NCT00759681|Experimental|Investigational Device|ArterX Surgical Sealant
3053837|NCT00759707|Experimental|1|ultrasound imaging of saphenous vein bypass graft following an ischemic stimulus, administration of sublingual nitroglycerin and intravenous administration of L-NMMA.
3053838|NCT00759759|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3053839|NCT00759759|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3053840|NCT00759772|Active Comparator|Teriparatide|
3053841|NCT00759772|Placebo Comparator|Placebo|
3053842|NCT00759785|Experimental|ER-positive Luminal B|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
3053843|NCT00759785|Experimental|Triple Negative|Single dose of dalotuzumab 20 mg/kg infused intravenously over 60-120 minutes.
3053844|NCT00759798|Experimental|Fludarabine, Cyclophosphamide, Rituximab|"Fludarabine 25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Cyclophosphamide 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond. Rituximab 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
3053845|NCT00759811|Experimental|Methotrexate|Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
3053846|NCT00759811|Placebo Comparator|Placebo|Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
3053847|NCT00759863|Experimental|Lifezig|Subjects watch personalized reminiscence video channels developed by program staff with the help of family members/caregivers (using the LifeZig system)
3053848|NCT00759863|No Intervention|Usual Care|Subjects follow routine activities applied by nurses or caregivers, such as traditional reminiscence, crafts, singing, recreational activities, and other activities.
3053849|NCT00759876|Experimental|Ataluren|Participants will receive ataluren 3 times per day with meals at doses of 20 milligrams per kilogram (mg/kg) (breakfast), 20 mg/kg (lunch), and 40 mg/kg (dinner) for up to 89 weeks.
3053850|NCT00759902|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3053851|NCT00759902|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3053852|NCT00759915|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3053853|NCT00759915|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3053854|NCT00759941|Experimental|Xalatan + Azopt|Xalatan dosed once a day at 10 pm, with Azopt dosed three times a day at 8 AM, 2 PM, and 10:05 PM as an adjunctive therapy for 3 months.
3053855|NCT00759941|Active Comparator|Xalatan + Placebo|Xalatan dosed once a day at 10 pm, with placebo dosed three times a day at 8 AM, 2 PM, and 10:05 PM concomitantly for 3 months.
3053856|NCT00759954|Other|1|Treatment A (test product) followed by Treatment B (reference product)
3053857|NCT00759954|Other|2|Treatment B (reference product) followed by Treatment A (test product)
3321405|NCT02018549|Experimental|Placebo|Inhalation through Chiesi NEXThaler DPI containing Placebo Dry Powder. Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
3321406|NCT02018575|Experimental|levels of lysine intake.|Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
3053858|NCT00759967|Active Comparator|Short daily hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of short daily hemodialysis(2 hours/day,6 days/week)B/P will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 month period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
3053859|NCT00759967|Active Comparator|Conventional hemodialysis|After a 3 month run-in period patients who are randomized to this arm will receive 3 months of conventional hemodialysis 3 days/week 3.5-4 hours/ treatment. BP will be monitored according to the Canadian hypertension guidelines both pre and post each dialysis session. Antihypertensive medication will be adjusted accordingly to maintain BP within the guidelines.At the end of this 3 moth period extracellular fluid volume (bioimpedance) will be measured using bioimpedance as well as sympathetic nerve activity using microneurography. Additionally Catecholamines as well as markers of oxidative stress will be collected.
3053860|NCT00760006|Active Comparator|Unasyn Antibiotic Arm|Unasyn® is a parenteral antibiotic that combines ampicillin with sulbactam, a beta-lactamase inhibitor. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. The study aims to assess the efficacy of the prophylactic antibiotic in cleft surgery to: decrease the incidence of surgical site infections, speed the progression of postoperative healing, improve the final quality of wound healing achieved, and decrease the rate of palatal fistula formation.
3053861|NCT00760006|Placebo Comparator|Saline Placebo Arm|Saline Placebo. All subjects enrolled in the study will receive a single dose of antibiotic or saline solution (placebo control) intravenously, as the IV will already be in place as standard of care for surgery. This will act as the placebo control.
3053862|NCT00760019|Active Comparator|Salsalate first, then Placebo|In this crossover study, this group was randomly allocated therapy with salsalate first, a 4 week washout, then 4 weeks of placebo therapy in a double-blinded fashion.
3053863|NCT00760019|Placebo Comparator|Placebo first, then Salsalate|In this crossover study, this group was randomly allocated therapy with placebo first, a 4 week washout, then 4 weeks of salsalate therapy in a double-blinded fashion.
3053864|NCT00760084|Experimental|A|Decitabine will be administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks.
3053865|NCT00760214|Experimental|Azilsartan Medoxomil 40 mg QD|
3053866|NCT00760214|Experimental|Azilsartan Medoxomil 80 mg QD|
3053867|NCT00760214|Active Comparator|Ramipril 10 mg QD|
3053868|NCT00760266|Experimental|Aliskiren/HCTZ 300/25 mg|
3053869|NCT00760266|Active Comparator|HCTZ 25 mg|
3053870|NCT00760383|Experimental|EAA+PT|20 g EAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
3053871|NCT00760383|Placebo Comparator|ALA+PT|20 g NEAA daily for 7 days prior to TKA surgery and for 14 days after surgery.
3053872|NCT00760435|Experimental|1|Infliximab plus Intravenous immunoglobulin (IVIG)
3053873|NCT00760435|Placebo Comparator|2|Placebo plus IVIG
3053874|NCT00760474|Experimental|Pregabalin, then placebo|
3053875|NCT00760474|Experimental|Placebo, then pregabalin|
3053876|NCT00760487|Experimental|AcrySof Toric IOL|AcrySof Toric Intraocular Lens (IOL)
3053877|NCT00760513|Active Comparator|Omega 3 fatty acid (fish oil)|OMACOR (alternative name: Lovaza) 4 grammes daily, oral capsule
3053878|NCT00760513|Placebo Comparator|dummy pill|4 grammes daily, oral capsule (olive oil)
3053879|NCT00760526|Active Comparator|1|continuous glucose monitoring
3053880|NCT00760526|Active Comparator|2|Standard glucose monitoring with a home glucose meter
3053881|NCT00760552|Active Comparator|Arm 1|VA patients with uncontrolled HTN.
3053882|NCT00760552|Active Comparator|Arm 2|VA patients with uncontrolled HTN.
3053883|NCT00760578|Placebo Comparator|Placebo|Microcrystaline cellulose once daily
3053884|NCT00760578|Active Comparator|Pioglitazone|Pioglitazone 45 mg once daily
3053885|NCT00760578|Experimental|MSDC-0160 90 mg|MSDC-0160 90 mg once daily
3053886|NCT00760578|Experimental|MSDC-0160 220 mg|MSDC-0160 220 mg once daily
3053887|NCT00760617|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥65 years received 1 dose of New generation influenza vaccine GSK2186877A
3053888|NCT00760617|Active Comparator|Fluarix elderly Group|Subjects aged ≥65 years received 1 dose of Fluarix vaccine
3053889|NCT00760617|Active Comparator|Fluarix young Group|Subjects aged 18-40 years received 1 dose of Fluarix vaccine
3053890|NCT00760669||Participants Receiving Infiximab|Participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PA) receiving infliximab injection will be observed.
3053891|NCT00760747|Experimental|Slow Switching Group|Slow Switching Group (switch from full stimulant dose to atomoxetine, 1.2 mg/kg/day, orally (PO), during 10 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
3053892|NCT00760747|Experimental|Fast Switching Group|Fast Switching Group (switch from full stimulant dose to atomoxetine 1.2 mg/kg/day, PO, during 2 weeks then continue treatment up to 1.8 mg/kg/day, PO to 14 weeks
3053893|NCT00760838|Experimental|Azithromycin|"Azithromycin 250 mg~1x/day during 5 days 3x/week afterwards"
3053894|NCT00760838|Placebo Comparator|placebo|"Placebo~1x/day during 5 days 3x/week afterwards"
3053895|NCT00760877|Experimental|Nilotinib|Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
3053896|NCT00760877|Active Comparator|Imatinib|Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
3053897|NCT00760929|Placebo Comparator|Placebo for R1507 (16mg/kg iv)|
3053898|NCT00760929|Placebo Comparator|Placebo for R1507 (9mg/kg iv)|
3053899|NCT00760929|Experimental|R1507 (16mg/kg iv)|
3053900|NCT00760929|Experimental|R1507 (9mg/kg iv)|
3053901|NCT00760994|Experimental|1 - Experiential Accepatance|Experiential acceptance
3053902|NCT00760994|Active Comparator|2 - Cognitive Restructuring|Cognitive restructuring
3053903|NCT00760994|Placebo Comparator|3 - Control|No-intervention control: Nutrition information
3053904|NCT00761007|Experimental|Ibodutant 10 mg|
3053905|NCT00761007|Experimental|Ibodutant 30 mg|
3053906|NCT00761007|Experimental|Ibodutant 60 mg|
3053907|NCT00761007|Placebo Comparator|Placebo|
3053908|NCT00761085|Active Comparator|Methadone-Children|Methadone comparison to standard of care for pain management
3053909|NCT00761085|Active Comparator|Morphine-Children|Morphine standard of Care pain management
3053910|NCT00761085|Active Comparator|Methadone-Adults|Methadone comparison to standard of care for pain management
3053911|NCT00761085|Active Comparator|Morphine-Adults|Morphine standard of Care pain management
3053912|NCT00761137|Experimental|Tropicamide placebo|subject received (blinded) each of the 4 drug doses at different visits - 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
3053913|NCT00761137|Experimental|Tropicamide 0.3 mg|subject received (blinded) each of the 4 drug doses at different visits - 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide
3053914|NCT00761137|Experimental|Tropicamide 1 mg|subject received (blinded) each of the 4 drug doses at different visits - 1 mg tropicamide, 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide
3053915|NCT00761137|Experimental|Tropicamide 3 mg|subject received (blinded) each of the 4 drug doses at different visits - 3 mg tropicamide, 0 mg tropicamide, 0.3 mg tropicamide, 1 mg tropicamide
3053916|NCT00761150|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
3053917|NCT00761150|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
3053918|NCT00761150|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
3053919|NCT00761189|Experimental|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
3053920|NCT00761202|Active Comparator|1|Optive Eyedrops
3053921|NCT00761202|Active Comparator|2|Hylocomod Eyedrops
3053922|NCT00761215|Experimental|TR-701 200 mg|
3053923|NCT00761215|Experimental|TR-701 300 mg|
3053924|NCT00761215|Experimental|TR-701 400 mg|
3053925|NCT00761267|Experimental|Anidulafungin IV|All subjects meeting screening criteria will receive IV anidulafungin.
3053926|NCT00761280|Experimental|trabedersen 10 µM|10 µM trabedersen (AP 12009), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
3053927|NCT00761280|Active Comparator|Chemotherapy|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle, up to 26 cycles; carmustine: i.v. administration, up to 200 mg/sqm/day, 1 day per cycle, up to 8 cycles; lomustine: capsules, 110 mg/sqm/day, 1 day per cycle, up to 8 cycles. Only 1 of these 3 drugs/interventions is administered per patient in the comparator arm.
3053928|NCT00761306|Experimental|Vortioxetine|
3053929|NCT00761319|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily for 90 days
3053930|NCT00761319|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily for 90 days
3053931|NCT00761345|Experimental|radiotherapy and chemotherapy|gemcitabine will be administered at 1000mg/m2 IV on days 1 and 8 of each 21 day cycle. erlotinib at either 100mg (cohort 1-3) or 150mg (cohort 4) PO daily. Low dose fractionated radiotherapy (LDRT) will be given BID on days 1 and 2 and 8 and 9 of each 21 day cycle
3053932|NCT00761462|Experimental|Ciprofloxacin|Subjects receiving Ciprofloxacin (group followed-up for 5 years)
3053933|NCT00761462|Active Comparator|Non-quinolone antibiotic|Subjects receiving non-quinolone antibiotic (group followed-up for 2 years)
3053934|NCT00761514|Experimental|1|All subjects will receive Adalimumab
3053935|NCT00761527||Participants with allergic rhinitis or idiopathic urticaria|Outpatient pediatric participants (ages 6 months-11 years) in the Philippines with a diagnosis of allergic rhinitis or chronic idiopathic urticaria.
3053936|NCT00761579|Experimental|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
3053937|NCT00761592|Active Comparator|1|
3053938|NCT00761592|Active Comparator|2|
3053939|NCT00761605|Experimental|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
3053940|NCT00761631|Experimental|Single|Open label
3053941|NCT00761657|Experimental|Roxadustat 0.7 mg/kg BIW|Participants will receive roxadustat 0.7 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
3053942|NCT00761657|Experimental|Roxadustat 0.7 mg/kg TIW|Participants will receive roxadustat 0.7 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
3053943|NCT00761657|Experimental|Roxadustat 1.0 mg/kg BIW|Participants will receive roxadustat 1.0 mg/kg BIW orally with doses administered at least 72 hours apart for 29 days.
3053944|NCT00761657|Experimental|Roxadustat 1.0 mg/kg TIW|Participants will receive roxadustat 1.0 mg/kg TIW orally with doses administered at least 48 hours apart for 26 days.
3053945|NCT00761657|Experimental|Roxadustat 1.5 mg/kg BIW|Participants will receive roxadustat 1.5 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
3053946|NCT00761657|Experimental|Roxadustat 1.5 mg/kg TIW|Participants will receive roxadustat 1.5 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
3053947|NCT00761657|Experimental|Roxadustat 2.0 mg/kg BIW|Participants will receive roxadustat 2.0 mg/kg BIW orally with doses administered at least 68 hours apart for 29 days.
3053948|NCT00761657|Experimental|Roxadustat 2.0 mg/kg TIW|Participants will receive roxadustat 2.0 mg/kg TIW orally with doses administered at least 46 hours apart for 26 days.
3053949|NCT00761657|Placebo Comparator|Placebo|Participants will receive placebo orally, matching to the roxadustat dose, number of days per week, and duration.
3053950|NCT00761735|Other|PEG-IFN + RBV: LTFU|Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
3053951|NCT00761748|Experimental|SenSura|SenSura Uro 2-piece. Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
3053952|NCT00761748|Active Comparator|Convatec|Convatec Uro 2-piece Is a urostomy bag with the intended use of collecting urine from a stoma. Consist of a base plate and a bag that is attached to the base plate.
3053953|NCT00761761|Experimental|1- Sensoril (Ashwagandha)|Sensoril (Ashwagandha) will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
3053954|NCT00761761|Placebo Comparator|2 - Placebo|Placebo will be administered using random assignment at a dose of 250 mg/day, increasing to a dose of 500 mg/day by the second week.
3053955|NCT00761774|Experimental|Brivaracetam|Brivaracetam at flexible dosing up to 200mg /day
3053956|NCT00761813|Experimental|Single Sliding Hip Screw|
3053957|NCT00761813|Experimental|Multiple Cancellous Screws|
3053958|NCT00761865|Active Comparator|Air Cast Stirrup Brace|50 patients will be randomly assigned to receive the Air Cast Stirrup Brace.
3053959|NCT00761865|Active Comparator|High Tide Fracture Boot|50 patients will be randomly assigned to the High Tide Fracture Boot.
3053960|NCT00761891|Experimental|Chewable aspirin|81 mg daily for 2 weeks
3053961|NCT00761930|Placebo Comparator|A|commercially available Fluoride toothpaste
3053962|NCT00761930|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
3053963|NCT00761930|Experimental|C|fluoride/herbal toothpaste
3053964|NCT00761956|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen CR-Flex Fixed Bearing Knee.
3053965|NCT00761956|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen CR Knee.
3053966|NCT00761969||PAB|Subjects with stable peripheral arterial disease; ankle-brachial pressure index on at least one leg =< 0.90.
3053967|NCT00761969||Control|Subjects without peripheral arterial disease (palpable pedal pulses and a normal ankle-brachial pressure index of 0.91-1.30), age- and sex-matched to the stuy group with PAD
3053968|NCT00762021|Experimental|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT
3053969|NCT00762021|Active Comparator|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF
3053970|NCT00762034|Experimental|Pem/Carbo/Bev|Pemetrexed (Pem), carboplatin (Carbo) and bevacizumab (Bev) followed by pemetrexed and bevacizumab
3053971|NCT00762034|Active Comparator|Pac/Carbo/Bev|Paclitaxel (Pac), carboplatin (Carbo) and bevacizumab (Bev) followed by bevacizumab
3053972|NCT00762073|Placebo Comparator|1|
3053973|NCT00762073|Experimental|2|Low Dose Group
3053974|NCT00762073|Experimental|3|Medium Dose Group
3053975|NCT00762073|Experimental|4|High Dose Group
3053976|NCT00762086|Active Comparator|Treatment Group|AngioPress Intermittent pneumatic compression (IPC) Device
3053977|NCT00762086|Other|Control Group|Aspirin/Clopidegrol and Standard walking exercises
3053978|NCT00762164|Active Comparator|1Vytorin 10/80 divided into 4|Vytorin 10/80 divided into 4
3053979|NCT00762164|Active Comparator|Simvastatin|Simvastatin 20 milligrams
3053980|NCT00762177|Placebo Comparator|A -Control|fluoride toothpaste
3053981|NCT00762177|Experimental|B Experimental toothpaste|Stannous fluoride toothpaste
3053982|NCT00762177|Active Comparator|C- positive control|fluoride/triclosan/copolymer toothpaste
3053983|NCT00762216|Other|Toric|Implantation with the AcrySof® Toric intraocular lens
3053984|NCT00762229|Active Comparator|Ezetimibe 10 mg|A whole ezetimibe 10 mg tablet
3053985|NCT00762229|Experimental|Ezetimibe 5 mg|"Ezetimibe 5 mg, formulated by splitting a 10 mg ezetimibe tablet in half"
3053986|NCT00762268|Experimental|SAMe|"SAMe: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
3053987|NCT00762268|Placebo Comparator|placebo|"Placebo: Placebo SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral pills for only 3 days per week, followed by a 4 day rest-period, before the round. The apparent dosage will be progressively increased each week to mimic a maximum of 1600 mg per day over a 4-week period."
3053988|NCT00762307|Experimental|Treatment Group 1|Cooling Intensity Factor = 33 Duration = 60 minutes
3053989|NCT00762307|Experimental|Treatment Group 2|Cooling Intensity Factor = 37 Duration = 30 minutes
3053990|NCT00762307|Experimental|Treatment Group 3|Cooling Intensity Factor = 37 Duration = 45 minutes
3053991|NCT00762307|Experimental|Treatment Group 4|Cooling Intensity Factor = 42 Cooling Duration = 30 minutes
3053992|NCT00762320|Experimental|Low dose Kaletra tablets|Patients will serve as their own controls as they are switched from the baseline treatment with liquid Kaletra to the study intervention treatment with Low Dose Tablet Kaletra (100mg/25mg)
3053993|NCT00762359|Experimental|Lansoprazole 15 mg QD|
3053994|NCT00762359|Active Comparator|Gefarnate 50 mg BID|
3053995|NCT00762372|Experimental|desflurane|
3053996|NCT00762372|Experimental|desflurane/N2O|
3053997|NCT00762372|Active Comparator|sevoflurane/N2O|
3053998|NCT00762385|Active Comparator|galyfilcon A/comfilcon A|galyfilcon A first, comfilcon A second
3053999|NCT00762385|Active Comparator|comfilcon A/galyfilcon A|comfilcon A first, galyfilcon A second
3054000|NCT00762411|Experimental|LY450139|Participants received 60 milligrams (mg) LY450139 orally once daily for 2 weeks followed by 100 mg LY450139 orally once daily for 2 weeks, then 140 mg LY450139 orally once daily until Week 88.
3054001|NCT00762411|Placebo Comparator|Placebo|Participants received placebo orally once daily for the first 76 weeks. At the end of 76 weeks, participants in the placebo arm received LY450139 titrated up to 140 mg orally once daily until Week 88.
3054002|NCT00762424|Active Comparator|Tamsulosin|
3054003|NCT00762424|Placebo Comparator|Placebo|
3054004|NCT00762450|Active Comparator|A- Positive Control|fluoride/triclosan/copolymer toothpaste
3054005|NCT00762450|Placebo Comparator|B - Silica control|fluoride only toothpaste
3054006|NCT00762450|Experimental|C- Experimental product|fluoride/triclosan/amino acid toothpaste
3054007|NCT00762463|Experimental|Celecoxib 200 mg QD|
3054008|NCT00762463|Active Comparator|Diclofenac SR 75 mg QD|
3054009|NCT00762476|Placebo Comparator|Placebo|
3054010|NCT00762476|Experimental|3804-250A|
3054011|NCT00762502|Active Comparator|senofilcon A toric bilaterally|senofilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
3054012|NCT00762502|Active Comparator|balafilcon A toric bilaterally|balafilcon A lenses worn daily bilaterally (in both eyes) for 3 months, replaced weekly.
3054013|NCT00762502|Active Comparator|senofilcon A/balafilcon A contralaterally|senofilcon A lens worn in one eye and balafilcon A lens worn in the other eye (contralaterally), daily for 3 months, replaced weekly.
3054014|NCT00762515|Placebo Comparator|A|commercially available Fluoride only toothpaste
3054015|NCT00762515|Active Comparator|B|Commercially available triclosan/copolymer/fluoride toothpaste
3054016|NCT00762528|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
3054017|NCT00762528|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
3054018|NCT00762606|Active Comparator|Phaco|Cataract extraction surgery utilizing Phacoemulsification
3054019|NCT00762606|Active Comparator|SICS|Small incision cataract surgery (SICS)
3054020|NCT00762619|Placebo Comparator|A -|fluoride toothpaste (Ultrabrite)
3054021|NCT00762619|Active Comparator|B - Postive control|fluoride/triclosan/copolymer toothpaste
3054022|NCT00762645|Experimental|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
3054023|NCT00762645|Active Comparator|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
3054024|NCT00762710|Experimental|1 - Prazosin Medication|Following randomization, participants in this arm will receive a 2-week titration of Prazosin followed by 10 weeks of stable dosing of Prazosin. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
3054025|NCT00762710|Placebo Comparator|2 - Placebo Medication|Following randomization, participants in this arm will receive a 2-week titration of placebo followed by 10 weeks of stable dosing of placebo. They will also attend study visits at least weekly for 12 weeks and will complete a final follow-up one month after discontinuation of the medication phase of the study at 16 weeks post-randomization.
3054026|NCT00762762|Active Comparator|A|
3054027|NCT00762762|Placebo Comparator|B|
3054028|NCT00762788|Active Comparator|senofilcon A contact lens|ACUVUE OASYS
3054029|NCT00762788|Active Comparator|lotrafilcon A contact lens|NIGHT&DAY
3054030|NCT00762788|Active Comparator|lotrafilcon B contact lens|O2Optix
3054031|NCT00762788|Active Comparator|balafilcon A contact lens|PureVision
3054032|NCT00762788|Active Comparator|comfilcon A contact lens|Biofinity
3054033|NCT00762788|Active Comparator|etafilcon A contact lens|ACUVUE 2
3054034|NCT00762853|Placebo Comparator|A|fluoride toothpaste from Thailand
3054035|NCT00762853|Active Comparator|B|fluoride/triclosan/copolymer toothpaste
3054036|NCT00762892|Active Comparator|Raltegravir|Raltegravir in combination with truvada (tenofovir and emtricitabine)
3054037|NCT00762892|Active Comparator|Atazanavir|Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
3054038|NCT00762931|Experimental|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation, all subjects will receive active treatment
3054039|NCT00762970|Experimental|Test Lens 1|Investigational soft contact lenses worn daily.
3054040|NCT00762970|Experimental|Test Lens 2|Investigational soft contact lenses worn daily.
3054041|NCT00762970|Active Comparator|Control lens|Spectacle lenses worn daily.
3054042|NCT00762996|Active Comparator|etafilcon A/etafilcon A|Period 1: etafilcon A, Period 2: etafilcon A
3054043|NCT00762996|Active Comparator|etafilcon A/omafilcon A|Period 1: etafilcon A, Period 2: omafilcon A
3054044|NCT00762996|Active Comparator|omafilcon A/etafilcon A|Period 1: omafilcon A, Period 2: etafilcon A
3054045|NCT00762996|Active Comparator|omafilcon A/omafilcon A|Period 1: omafilcon A, Period 2: omafilcon A
3054046|NCT00763035|Active Comparator|A|Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
3054047|NCT00763035|Active Comparator|B|Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.
3054048|NCT00763048|Placebo Comparator|A -Control|Fluoride toothpaste (Colgate Great Regular Flavor) is the control for this study. All study toothpastes contain fluoride. The study is evaluating the additional ingredients in the other toothpastes.
3054049|NCT00763048|Active Comparator|B|fluoride/triclosan/copolymer toothpaste (Colgate Total Toothpaste)
3054050|NCT00763061|Experimental|Travoprost 0.004%|Travoprost 0.004%
3054051|NCT00763061|Active Comparator|Timolol 0.5%|Timolol 0.5%
3054052|NCT00763139|Experimental|Placebo First|Placebo for first 8 weeks, then washout period for 4 weeks, and finally pioglitazone for 8 weeks.
3054053|NCT00763139|Experimental|Pioglitazone First|Pioglitazone for first 8 weeks, then washout period for 4 weeks, and finally placebo for 8 weeks.
3054054|NCT00763243|Experimental|Cogmed Working Memory Training|Cogmed Working Memory Training Program
3054055|NCT00763256|Active Comparator|A|
3054056|NCT00763256|Placebo Comparator|B|
3054057|NCT00763269|Experimental|A|sensitive toothpaste
3054058|NCT00763269|Active Comparator|B|Triclosan control toothpaste
3054059|NCT00763282|Experimental|SM+MI|Self Management (SM) + Motivational Interviewing (MI). Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. Motivational Interviewing (MI) is an evidence-based form of counseling to help individuals to engage in behavior change. Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
3321407|NCT02018588|Experimental|tryptophan intake|Graded levels of tryptophan will be given to each subject on different study days around the anticipated breakpoint.
3054060|NCT00763282|Active Comparator|ED|Education (ED). An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures. The ED intervention will differ only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
3054061|NCT00763321|Experimental|Open-label ABT-712|2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period).
3054062|NCT00763321|Experimental|Double-blind ABT-712|2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
3054063|NCT00763321|Placebo Comparator|Double-blind Placebo|2 placebo tablets, twice daily, for 4 weeks (double-blind period).
3054064|NCT00763360|Experimental|DisCoVisc®|DisCoVisc® Ophthalmic Viscosurgical Device
3054065|NCT00763360|Active Comparator|Healon|Healon
3054066|NCT00763360|Active Comparator|Amvisc Plus|Amvisc Plus
3054067|NCT00763386|Active Comparator|1|Study arm will consist of patients that are treated with the NexGen LPS-Flex Fixed Bearing Knee.
3054068|NCT00763386|Active Comparator|2|Study arm will consist of patients that are treated with the NexGen Legacy Posterior Stabilized Knee.
3054069|NCT00763412|Placebo Comparator|1 Placebo|1 pill before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance. Subjects were randomized to placebo or drug.
3054070|NCT00763412|Experimental|2. repaglinide|repaglinide 0.5 mg before each meal 3-4 times a day for 2 years. All subjects had abnormal glucose tolerance.Subjects were randomized to placebo or drug.
3054071|NCT00763451|Experimental|Lixisenatide (Two-Step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3054072|NCT00763451|Experimental|Lixisenatide (One-Step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
3054073|NCT00763451|Placebo Comparator|Placebo (Two-Step Titration)|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3054074|NCT00763451|Placebo Comparator|Placebo (One-Step Titration)|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, then 20 mcg QD up to the end of treatment.
3054075|NCT00763490|Experimental|Double cord blood transplant|'full intensity, double umbilical cord, stem cell transplant' with 'Flu/Bu4 conditioning regimen'
3054076|NCT00763698|Experimental|QuickFlex micro 1258T left heart lead|
3054077|NCT00763750|Experimental|PPX +TMZ+XRT|XRT 60Gy at 2 GY/fractions x 30 fractions TMZ 75mg/m2/day PPX 40mg/m2/week x 6 weeks Days 1,8,15,22,22,29,36
3054078|NCT00763815|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3054079|NCT00763815|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to the end of treatment.
3054080|NCT00763867|Placebo Comparator|Placebo|Placebo 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
3054081|NCT00763867|Experimental|Sildenafil|Sildenafil 20 mg three tid for 12 weeks followed by 60 mg tid for 12 weeks
3054082|NCT00763919|Experimental|Customized Adherence Enhancement (CAE)|"Participants, all of whom have a history of medication nonadherence, will be assigned to one or more treatment modules based on their individual profiles.~Treatment Modules:~Psychoeducation module Substance abuse module Improved communication/rapport with provider module Medication routines management module"
3054083|NCT00763958|Experimental|Buprenorphine|Active sublingual buprenorphine provided to participants; dose as clinically indicated up to 32 mg daily for up to 3 months
3054084|NCT00763958|Placebo Comparator|Placebo|Placebo sublingual medication provided to individuals randomized to control up to 3 months
3054085|NCT00763971|Experimental|Lisdexamfetamine Dimesylate (LDX)|Overencapsulated LDX 30, 50, or 70mg
3054086|NCT00763971|Active Comparator|Methylphenidate Hydrochloride|Overencapsulated Concerta 18, 36, or 54mg
3054087|NCT00763971|Placebo Comparator|Placebo|Overencapsulated Placebo
3054088|NCT00764309|Experimental|A1|
3054089|NCT00764322|Experimental|Tamoxifen 20|One arm, containing the ultra-rapid and extensive metabolizer genotypes, continues treatment with tamoxifen at 20mg.
3054090|NCT00764322|Active Comparator|Tamoxifen 40|This arm, containing the intermediate and poor metabolizer genotypes, receives escalated treatment with tamoxifen at 40mg.
3054091|NCT00764361|Experimental|NanoDOX™ Hydrogel|1.0% doxycycline gel
3054092|NCT00764361|Placebo Comparator|Placebo|placebo gel
3054093|NCT00764465|Active Comparator|Group A|Period 1-Maraviroc 300mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Maraviroc 300mg BID
3054094|NCT00764465|Active Comparator|Group B|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg BID
3054095|NCT00764465|Active Comparator|Group C|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID
3054096|NCT00764465|Active Comparator|Group D|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 700mg BID + Ritonavir 100mg BID + Maraviroc 300mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
3054097|NCT00764465|Active Comparator|Group E|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID
3054098|NCT00764465|Active Comparator|Group F|Period 1-Maraviroc 300mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Maraviroc 300mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3054099|NCT00764478|Experimental|Asenapine 5 mg BID|Participants were administered one 5 mg asenapine tablet, sublingually BID for 21 days
3054100|NCT00764478|Experimental|Asenapine 10 mg BID|Participants were administered one 10 mg asenapine tablet, sublingually BID for 21 days
3054101|NCT00764478|Placebo Comparator|Placebo BID|Participants were administered one asenapine-matched placebo tablet sublingually BID for 21 days
3054102|NCT00764491|Experimental|Optimesh 1500S|OptiMesh 1500S, filled with a mixture of demineralized bone matrix (DBM) and cortico-cancellous bone, placed into the interbody space from the posterior approach and supplemental pedicle screws.
3054103|NCT00764491|Active Comparator|Structural Allograft Spacer|Structural Allograft Spacer with pedicle screws.
3054104|NCT00764504|Experimental|Primary|Primary shoulder
3054105|NCT00764504|Experimental|Revision|Revision shoulder
3054106|NCT00764504|Experimental|Continued Access|Primary shoulder subjects enrolled at a later date in order to collect more data.
3054107|NCT00764517|Experimental|Previously untreated|"Patients enrolled with untreated, newly diagnosed mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) [Group I].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3054108|NCT00764517|Experimental|Relapsed|"Patients with relapsed disease including indolent Non-Hodgkins Lymphoma (NHL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) [Group II].~Patients receive vorinostat PO on days 1-14, cladribine IV over 2 hours on days 1-5, and rituximab IV on day 3 (weekly for the first course). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3054109|NCT00764660|Experimental|SCH 900435|Participants received SCH 900435 12 mg (as three SCH 900435 4 mg tablets) by mouth twice daily for 12 weeks.
3054110|NCT00764660|Placebo Comparator|Placebo|Participants received matching placebo tablets by mouth twice daily for 12 weeks.
3054111|NCT00764673|Other|Primary|Post market study
3054112|NCT00764738|Active Comparator|Monthly|Ranibizumab injections every month for 12 months.
3054113|NCT00764738|Active Comparator|As Needed|Ranibizumab injections monthly for 4 months then as needed thereafter.
3054114|NCT00764751|Experimental|1|
3054115|NCT00764751|Active Comparator|2|
3054116|NCT00764751|Placebo Comparator|3|
3054117|NCT00764790|Experimental|Fluarix Dose A Group|"Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3054118|NCT00764790|Experimental|Fluarix Dose B Group|"Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3054119|NCT00764790|Active Comparator|Fluzone Group|"Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age).~* Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses."
3054120|NCT00764868|Experimental|LDX|Lisdexamfetamine Dimesylate (LDX)
3054121|NCT00764881|Experimental|EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)|Daily oral administration of one capsule BAY86-5027 [estradiol valerate (EV) / dienogest (DNG)] for 28 days per cycle in the sequential 4-phasic regimen for 6 treatment cycles.
3054122|NCT00764881|Active Comparator|EE/LNG (Microgynon) + Placebo|Daily oral administration of one capsule ethinylestradiol (EE) / levonorgestrel (LNG) for 21 days, followed by 1 capsule placebo for 7 days (28 days total per cycle) for 6 treatment cycles.
3054123|NCT00764946|Experimental|1|raltegravir
3054124|NCT00765037||Encore RSP|Subjects who need treatment for rotator cuff deficiency or glenohumeral arthritis, received the Encore Reverse Shoulder Prosthesis and are willing to participate in the study.
3054125|NCT00765063|Experimental|Active|Active study treatment
3054126|NCT00765076|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 65 years receiving 1 dose of New generation influenza vaccine GSK2186877A at Day 0
3054127|NCT00765076|Active Comparator|Fluarix elderly Group|Subjects aged >= 65 years receiving 1 dose of Fluarix vaccine at Day 0
3054128|NCT00765076|Active Comparator|Fluarix young Group|Subjects aged 18-40 years receiving 1 dose of Fluarix vaccine at Day 0
3054129|NCT00765102|Experimental|Romidepsin + Bortezomib|"Romidepsin was given as an infusion on Days 1, 8 and 15 of each 28-day cycle. Bortezomib was administered twice a week for two consecutive weeks (Days 1, 4, 8 and 11) followed by a 17-day rest period.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
3054130|NCT00765128|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3054131|NCT00765128|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3054132|NCT00765193|Other|Skin cancer screening|
3054133|NCT00765206|Experimental|Zegerid|Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule
3054134|NCT00765206|Active Comparator|Prilosec|Omeprazole magnesium 20 mg OTC tablet
3054135|NCT00765232|Experimental|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3054136|NCT00765232|Placebo Comparator|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
3054137|NCT00765245|Experimental|Arm I: Lenalidomide|
3054138|NCT00765245|Experimental|Arm II: Lenalidomide and Rituximab IV|Patients receive lenalidomide as in arm I and rituximab IV on day 8 of courses 1, 3, 5, 7, 9, and 11 in the absence of disease progression or unacceptable toxicity.
3054139|NCT00765336|Active Comparator|Minocycline Extended-Release Tablets|
3054140|NCT00765336|Placebo Comparator|Placebo|
3054141|NCT00765362|Experimental|1|Subjects who are candidates for a total knee replacement and meet the inclusion/exclusion criteria of the study.
3054142|NCT00765375|Experimental|Botox and Placebo on each side of face|Botulinum Neurotoxin Type A (Botox, 1.5-3 units/lesion); Bacteriostatic saline solution (0.11 cc/lesion)
3054143|NCT00765388|Experimental|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
3054144|NCT00765388|Active Comparator|hollister Uro|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive
3054145|NCT00765570|Active Comparator|Treatment Group 1|Treatment Group 1-one treatment of Grid therapy followed by 15 treatments with standard radiation
3054146|NCT00765570|Active Comparator|Treatment Group-2|Treatment Group 2-15 treatments with standard radiation
3054147|NCT00765648|Active Comparator|1|nicardipine intravenous
3054148|NCT00765648|Active Comparator|2|Labetalol
3054149|NCT00765661|Experimental|LCP-Tacro|The initial dose starting at 0.14 mg/kg (the starting daily dose for African-American patients was 0.17 mg/kg), will be administered orally in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
3054150|NCT00765661|Active Comparator|Prograf (tacrolimus)|"Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
3054151|NCT00765674|Experimental|Aliskiren / amlodipine|Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3054152|NCT00765674|Experimental|Aliskiren / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3054153|NCT00765674|Experimental|Amlodipine / hydrochlorothiazide|Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3054154|NCT00765674|Experimental|Aliskiren / amlodipine / hydrochlorothiazide|Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
3054155|NCT00765726|Other|Moroctocog alfa(AF-CC)|
3054156|NCT00765817|Placebo Comparator|1|
3054157|NCT00765817|Experimental|2|
3054158|NCT00765843|Active Comparator|custom foot orthoses|Subjects will receive custom fabricated orthoses created from casts of the feet and according to individualized prescriptions. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
3054159|NCT00765843|Active Comparator|pre-fabricated orthoses|Subjects will be provided pre-fabricated (non-customized) orthoses. These orthoses are to be used in the standardized shoes provided to all subjects in the study. for use in their shoes.
3054160|NCT00765843|Sham Comparator|sham insoles|Subjects will receive sham orthoses that are soft and pliable, but not designed to relieve pain. These orthoses are to be used in the standardized shoes provided to all subjects in the study.
3054161|NCT00765856|Experimental|Oxymorphone ER|
3054162|NCT00765882|Experimental|1|Linaclotide 290 micrograms
3054163|NCT00765882|Experimental|2|Linaclotide 145 micrograms
3054164|NCT00765882|Placebo Comparator|3|Matching placebo
3054165|NCT00765895|Active Comparator|Nortriptyline|Nortriptyline Hydrochloride dose escalation from 10 mg to 75 mg
3054166|NCT00765895|Placebo Comparator|Placebo (for nortriptyline)|No treatment
3054167|NCT00765947|Experimental|Aliskiren-based regimen|All pts starting on aliskiren 150 mg (uptitrated to aliskiren 300 mg), followed by the addition of HCTZ 12.5 mg (uptitrated to 25 mg) and amlodipine 5 mg (uptitrated to 10 mg), as necessary to achieve the Blood Pressure goal.
3054168|NCT00765999|Experimental|Linaclotide|Linaclotide 290 μg/day capsules, administered orally once daily for up to 78 weeks in participants with either CC or IBS-C. Dose reduction to 145 μg/day was permitted at the discretion of the Investigator if a participant experienced AEs intolerable enough to prompt consideration of study withdrawal. After a temporary suspension of dosing, participants may have received either 145 μg/day or 290 μg/day of linaclotide, at the discretion of the Investigator. Subsequent dose adjustments (increases or decreases between 290 μg/day and 145 μg/day) were permitted also at the Investigator's discretion.
3321408|NCT02018601|Experimental|BRILMA&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1gr/6h
3321409|NCT02018601|Active Comparator|paravertebral block&dexketoprofen&paracetamol|dexketoprofen: 50 mg/8h paracetamol: 1g/6h
3054169|NCT00766038|Experimental|1|The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
3054170|NCT00766038|Placebo Comparator|2|Doses for participants receiving placebo will also be adjusted monthly to maintain the blinding.
3054171|NCT00766051|Experimental|Intervention Group|The infants in the intervention group were problem eaters with various diagnosis
3054172|NCT00766051|No Intervention|Matched Historical Comparison Group|The matched historical comparison group were also problem eaters and these infants did not receive the neurophysiologically based occupational therapy Intervention.
3054173|NCT00766090|Experimental|GW685698X|
3054174|NCT00766116|Experimental|Phase 1 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza 2 days then GO at 3 mg/m^2"
3054175|NCT00766116|Experimental|Phase 1 Dose Level 2|"5-Azacitidine, Gemtuzumab ozogamicin~75mg/m^2 5-Aza for 4 days then GO at 6 mg/m^2"
3054176|NCT00766116|Experimental|Phase I Dose Level 3|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
3054177|NCT00766116|Experimental|Phase 2 Dose Level 1|"5-Azacitidine, Gemtuzumab ozogamicin~75 mg/m^2 5-Aza for 6 days then GO at 6 mg/m^2"
3054178|NCT00766142|Experimental|Chemotherapy + Cetuximab|Surgery + Chemotherapy + Cetuximab
3054179|NCT00766363|Experimental|EVP-6124 (0.1 mg/day)|
3054180|NCT00766363|Experimental|EVP-6124 (0.3 mg/day)|
3054181|NCT00766363|Experimental|EVP-6124 (1.0 mg/day)|
3054182|NCT00766363|Placebo Comparator|Placebo|
3054183|NCT00766415|Experimental|AZD1981|
3054184|NCT00766415|Placebo Comparator|Placebo|
3054185|NCT00766467|Experimental|Group 1|Armodafinil
3054186|NCT00766467|Placebo Comparator|Group 2|Placebo
3054187|NCT00766493|Experimental|GORE® Embolic Filter|Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.
3054188|NCT00766506|Experimental|Fentanyl IONSYS|Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
3054189|NCT00766506|Active Comparator|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
3054190|NCT00766532|Experimental|aromatase inhibitor therapy|aromatase inhibitor therapy for six weeks
3054191|NCT00766597|Experimental|Vicriviroc in tablet form (20/30 mg) or liquid form (1 mg/ml)|HIV-1 Infected Antiretroviral Therapy Experienced Participants with CCR5-tropic Virus
3054192|NCT00766649|Experimental|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
3054193|NCT00766675|Experimental|Tramadol hydrochloride/acetaminophen|Tramadol hydrochloride/acetaminophen oral tablet will be administered as 37.5 /325 milligram respectively once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
3054194|NCT00766727|Experimental|GLYDe Dressing|Investigational Dressing
3054195|NCT00766727|No Intervention|Standard of Care|Standard of care comparator
3054196|NCT00766753|Experimental|Single|All consenting, eligible subjects receive the intervention
3054197|NCT00766831|Experimental|Hydromorphone OROS|Participants will receive hydromorphone OROS (8 milligram [mg] up to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
3054198|NCT00767000|Experimental|MK-0941 10 mg|
3054199|NCT00767000|Experimental|MK-0941 20 mg|
3054200|NCT00767000|Experimental|MK-0941 30 mg|
3054201|NCT00767000|Experimental|MK-0941 40 mg|
3054202|NCT00767000|Placebo Comparator|Placebo|
3054203|NCT00767039|Active Comparator|1|Surfactant (beractant, Survanta initial dose 100 mg/kg and subsequent doses 100 mg/kg phospholipids every 6-12 hours, as needed for up to 4 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
3054204|NCT00767039|Experimental|2|Surfactant (poractant, Curosurf initial dose 200 mg/kg and subsequent doses 100 mg/kg phospholipids every 12-24 hours as needed for up to 3 doses), intratracheal administration to very premature infants with RDS requiring mechanical ventilation
3054205|NCT00767104|Experimental|Silk-Like Pillowcase|Silk- Like pillowcase-One-half of subjects will be assigned to sleep on the study product, which is a standard size pillowcase made of a silk-like fabric every night for 12 weeks. The study pillowcases are fabricated from a light-weight plain-weave fabric woven of 100 percent synthetic yarns. The fabric is comprised of approximately 50% polyester and 50% nylon. The yarns in the fabric are formed from continuous-filament fibers, with no fibers projecting beyond the planar surface of the fabric. The antimicrobial technology used in the fabric is incorporated into the fibers during the finishing process and does not migrate out of the fabric or cause adverse reactions with skin contact.
3054206|NCT00767104|Placebo Comparator|Cotton Pillowcase|Placebo Comparator-One-half of subjects will be assigned to sleep on the placebo pillow case every night for 12 weeks. Placebo pillowcase is made of 100% cotton
3054207|NCT00767325|Experimental|Abatacept, 10 mg/kg|
3054208|NCT00767338|Active Comparator|No surgery + IUI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
3054209|NCT00767338|Active Comparator|No Surgery + TI|No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
3054210|NCT00767338|Active Comparator|Surgery + IUI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
3054211|NCT00767338|Active Comparator|Surgery + TI|Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
3054212|NCT00767364|Experimental|Infants with bowel resection|Infants with bowel resection who will receive the oral rotavirus vaccine, RotaTeq(R).
3054213|NCT00767364|Active Comparator|Healthy Infants|Healthy infants that are gest. age and age-matched controls within 14 days will be given the oral rotavirus vaccine, RotaTeq(R).
3054214|NCT00767455|Sham Comparator|Positive, Negative Controls|
3054215|NCT00767507|Experimental|Cangrelor|Cangrelor was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days.
3054216|NCT00767507|Placebo Comparator|Placebo|A placebo infusion was administered as a continuous IV infusion of 0.75µg/kg/min for a minimum of 48 hours and a maximum of 7 days, to maintain the blind.
3054217|NCT00767520|Active Comparator|A|
3054218|NCT00767520|Placebo Comparator|B|
3054219|NCT00767572|Experimental|atorvastatin|Patients are randomized to either atorvastatin or placebo once daily for 12 weeks. There is a 4 week washout, and then the groups are switched for 12 weeks. Brachial artery assessment will be performed before and after each 12 week period on therapy.
3054220|NCT00767572|Placebo Comparator|sugar pill|See above. Patients will be randomized to atorvastatin vs. placebo for 12 weeks and after a 4 week washout period the groups will be switched.
3054221|NCT00767624|Other|antidepressant + desensitization|Combined antidepressant medication (determined by an algorithm) plus desensitization therapy
3054222|NCT00767624|Other|antidepressant + cognitive behavioral|Combined antidepressant medication (determined by algorithm) plus cognitive behavioral therapy
3054223|NCT00767676|Other|1|
3054224|NCT00767767|Placebo Comparator|Placebos|Saline Infusion
3054225|NCT00767767|Active Comparator|Propofol 0.45mcg/mL|Anesthetic Drug Infusion
3054226|NCT00767767|Active Comparator|Propofol 0.90mcg/mL|Anesthetic Drug Infusion
3054227|NCT00767767|Active Comparator|Thiopental 1.5mcg/mL|Anesthetic Drug Infusion
3054228|NCT00767767|Active Comparator|Thiopental 3mcg/mL|Anesthetic Drug Infusion
3054229|NCT00767806|Experimental|Duloxetine|Participants received duloxetine 60 milligram by mouth once daily for 12 weeks of double-blind treatment
3054230|NCT00767806|Placebo Comparator|Placebo|Patients received placebo by mouth once daily for 12 weeks of double-blind treatment
3054231|NCT00767819|Experimental|Arm 1|Progressive or metastatic bone or soft tissue sarcomas
3054232|NCT00767819|Experimental|Arm 2|Progressive gastrointestinal stromal tumors (GIST) after failure of prior imatinib and sunitinib 1st and 2nd line
3054233|NCT00767819|Experimental|Arm 3|Progressive or metastatic alveolar soft part sarcoma (ASPS)
3054234|NCT00768053|Experimental|1|
3054235|NCT00768066|Experimental|1|Participants will receive an injection of 100 million or 200 million autologous human mesenchymal stem cells (hMSCs).
3054236|NCT00768066|Experimental|2|Participants will receive an injection of 100 million or 200 million autologous human bone marrow cells (hBMCs).
3054237|NCT00768066|Placebo Comparator|3|Participants will receive a placebo injection of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS).
3054238|NCT00768079|Placebo Comparator|Placebo|A single dose of placebo matched to benralizumab (MEDI-563) intravenous infusion over at least 30 minutes on Day 0.
3054239|NCT00768079|Experimental|Benralizumab 0.3 mg/kg|A single dose of benralizumab (MEDI-563) 0.3 milligram per kilogram (mg/kg) of body weight intravenous infusion over at least 30 minutes on Day 0.
3054240|NCT00768079|Experimental|Benralizumab 1.0 mg/kg|A single dose of benralizumab (MEDI-563) 1.0 mg/kg of body weight intravenous infusion over at least 30 minutes on Day 0.
3054241|NCT00768118|Experimental|Curcumin, Green Tea extract, Polygonum Cuspidatum & Soybean|Total number of visits: 2, pre-intervention blood draw and urine sample collection, post-intervention blood draw and urine sample collection and interview Length of each visit: 15-30 minutes Total expected duration of participants' involvement: 15 days During the two-week intervention, volunteers will take two 1/2g capsules of the combination capsule, twice daily immediately after morning and evening meals.
3054242|NCT00768144|Experimental|Sunitinib|Patients received oral Sunitinib at the daily dose of 37.5 mg continuously over a 28- day treatment cycle. Treatment continued until clinical or radiological evidence of progressive disease or excessive toxicity.
3054243|NCT00768222|Active Comparator|Chinese Silk Suture|Natural, non-absorbable silk suture made from entwined thread from silkworm larva, commercially available in China, used in a simple interrupted transdermal suture pattern
3054244|NCT00768222|Experimental|VICRYL* Plus Suture|Synthetic absorbable surgical suture composed of a copolymer of 90% glycolide and 10% L-lactide and containing triclosan antibacterial, used in a subcuticular closure technique
3054245|NCT00768261|No Intervention|Very Mild to Mild DAT Untreated|Group 1) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are untreated with either cholinesterase inhibitors or memantine
3054246|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/ Donepezil|Group 2) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with Donepezil (Aricept®).
3054247|NCT00768261|Active Comparator|Very Mild-Mild DAT Treated W/Combination|Group 3) subjects with very mild (CDR 0.5) to mild (CDR 1) DAT that are treated with the combination of Donepezil (Aricept®) and Memantine (Namenda®)
3054248|NCT00768261|No Intervention|Nondemented Comparison Subjects|Group 4) nondemented comparison subjects.
3054249|NCT00768287|Experimental|IB1001|
3054250|NCT00768287|Active Comparator|nonacog alfa|
3054251|NCT00768300|Experimental|Ambrisentan|
3054252|NCT00768300|Placebo Comparator|Placebo|
3054253|NCT00768430|Experimental|1|Ketamine
3054254|NCT00768430|Active Comparator|2|Midazolam
3054255|NCT00768469|Experimental|Nera 160 + Pac|Neratinib 160 mg + Paclitaxel 80 mg/m^2
3054256|NCT00768469|Experimental|Nera 240 + Pac|Neratinib 240 mg + Paclitaxel 80 mg/m^2
3054257|NCT00768521|Experimental|1|Part I, Sequence 1: tolterodine tartrate crossing over to matching placebo
3054258|NCT00768521|Experimental|2|Part I, Sequence 2: placebo crossing over to study drug 4 mg once a Day (qd)
3054259|NCT00768521|Experimental|3|Part II, Sequence 1: study drug crossing over to placebo
3054260|NCT00768521|Experimental|4|Part II, Sequence 2: placebo crossing over to study drug
3054261|NCT00768560|Active Comparator|Nifedipine (Adalat CR, BAYA1040) 40 mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
3054262|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 40 mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
3054263|NCT00768560|Experimental|Nifedipine (Adalat CR, BAYA1040) 80 mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
3054264|NCT00768599|Active Comparator|1|Econazole Nitrate Cream 1%
3054265|NCT00768599|Experimental|2|Econazole Nitrate Foam 1%
3054266|NCT00768599|Placebo Comparator|3|Vehicle Foam
3054267|NCT00768651|Experimental|One arm: Sitagliptin + Pantoprazole|"Intervention Details:~Sitagliptin 100 mg daily and Pantoprazole 40 mg bid for 6 months, followed by a three-month washout."
3054268|NCT00768664|Experimental|A|
3054269|NCT00768716|Experimental|White subjects|2 x 500 mg acetaminophen by mouth once
3054270|NCT00768716|Experimental|Black subjects|2 x 500 mg acetaminophen by mouth once
3054271|NCT00768755|Experimental|I|Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3054272|NCT00768755|Experimental|II|Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3054273|NCT00768755|Active Comparator|III|pemetrexed and cisplatin
3054274|NCT00768755|Experimental|IV|Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
3054275|NCT00768755|Active Comparator|V|pemetrexed and cisplatin
3054276|NCT00768898||2.5 microliters lissamine green|
3054277|NCT00768898||5.0 microliters lissamine green|
3054278|NCT00768898||10.0 microliters lissamine green|
3054279|NCT00768989|Experimental|Atazanavir + Raltegravir|Atazanavir 300 mg twice daily + Raltegravir 400 mg twice daily
3054280|NCT00768989|Active Comparator|Atazanavir + Ritonavir + Tenofovir /Emtricitabine|Atazanavir, 300 mg once daily, + Ritonavir, 100 mg once daily, + Tenofovir 300 mg/Emtricitabine, 200 mg once daily
3054281|NCT00769015|Experimental|BA-LVR|In BA-LVR, a low vision occupational therapist (OT) will deliver Behavior Activation (BA), a psychological treatment to prevent depression. This will be administered in the context of the standard of low vision care for OTs as defined by the American Occupational Therapy Association (AOTA). The OTs will collaborate with low vision optometrists, who will deliver the standard of low vision care as defined by the American Optometric Association. The optometrists will evaluate remaining vision and magnification needs, prescribe optical devices, and provide the OTs with initial care plans. The OTs will subsequently meet with subjects in their homes 6 times over 12 weeks to enhance device use, home modifications, and compensatory strategies.
3054282|NCT00769015|Placebo Comparator|ST-LVR|Subjects randomized to ST-LVR will receive clinic-based low vision optometry, in addition to 6 in-home Supportive Therapy (ST) sessions. ST is a placebo condition that controls for the attention that subjects in the active treatment arm will receive.
3054283|NCT00769067|Active Comparator|A|
3054284|NCT00769067|Experimental|B|
3054285|NCT00769119|Experimental|AZD9668 active treatment|
3054286|NCT00769119|Placebo Comparator|AZD9668 placebo treatment|
3054287|NCT00769132|Experimental|A|ER niacin/laropiprant + Placebo to laropiprant
3054288|NCT00769132|Active Comparator|B|ER niacin + Placebo to laropiprant
3054289|NCT00769132|Experimental|C|laropiprant + Placebo to ER niacin/laropiprant
3054290|NCT00769132|Placebo Comparator|D|Placebo
3054291|NCT00769184|Experimental|Corticosteroid + LCD|corticosteroid and LCD treatment (2 weeks), LCD alone treatment (4 weeks)
3054292|NCT00769184|Placebo Comparator|Corticosteroid + Placebo|corticosteroid and placebo treatment (2 weeks), placebo alone treatment (4 weeks)
3054293|NCT00769314|Experimental|1|Acyclovir Lauriad 50mg
3054294|NCT00769314|Placebo Comparator|2|
3054295|NCT00769392|Other|All Participants|All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
3054296|NCT00769483|Experimental|Phase I, Arm A|MK-0646 + Gemcitabine
3054297|NCT00769483|Experimental|Phase I, Arm B|MK-0646 + Gemcitabine + Erlotinib
3054298|NCT00769483|Experimental|Phase II, Arm A|Gemcitabine + Erlotinib
3054299|NCT00769483|Experimental|Phase II, Arm B|MK-0646 + Gemcitabine + Erlotinib
3054300|NCT00769483|Experimental|Phase II, Arm C|Gemcitabine + Erlotinib
3054301|NCT00769561|Experimental|BFB-CBT|"Biofeedback-based cognitive-behavioral treatment:~The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits."
3054302|NCT00769561|Active Comparator|Occlusal Splint (OS)|"Dental treatment with occlusal splints:~Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment."
3054303|NCT00769600|Active Comparator|Itraconazole with Pemetrexed|Pemetrexed IV every 21 days with oral Itraconazole 200mg daily.
3054304|NCT00769600|Active Comparator|Single agent pemetrexed|Pemetrexed IV on day 1 of 21-day cycle.
3054305|NCT00769704|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 days, followed by a 14-day rest period for 24 weeks. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, or lack of response by 12 months, for a maximum of 18 months.
3054306|NCT00769704|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec on Days 1 and 15 of each 28-day cycle for 24 weeks. The initial dose of talimogene laherparepvec was at a concentration of 10⁶ plaque forming units (PFU)/mL, injected into 1 or more skin, subcutaneous or nodal tumors. Subsequent doses began at least 3 weeks after the first dose and consisted of talimogene laherparepvec at a concentration of 10⁸ PFU/mL. Participants could continue treatment until clinically relevant disease progression, intolerability, withdrawal of consent, complete remission, lack of response by 12 months, or disappearance of all injectable lesions, for a maximum of 18 months.
3054307|NCT00769808|Experimental|Technolas 217z Excimer Laser|Bausch & Lomb Zyoptix Aspheric Algorithm for LASIK correction of myopia and myopic astigmatism.
3054308|NCT00769860|Active Comparator|1|Arimoclomol
3054309|NCT00769860|Placebo Comparator|2|
3054310|NCT00769886|Experimental|KetoNaph|KetoNaph (ketotifen fumarate 0.025%, naphazoline HCl 0.05%) ophthalmic solution
3054311|NCT00769886|Active Comparator|Naphazoline|Naphazoline HCl 0.05% ophthalmic solution
3054312|NCT00769886|Active Comparator|Ketotifen|Ketotifen fumarate 0.025% ophthalmic solution
3054313|NCT00769886|Placebo Comparator|Vehicle|Vehicle of KetoNaph ophthalmic solution
3054314|NCT00770029|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3054315|NCT00770029|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3054316|NCT00770120|Experimental|Everolimus|Daily oral Everolimus 10 mg/day
3054317|NCT00770133|Experimental|Ketotifen/naphazoline|Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3054318|NCT00770133|Placebo Comparator|Vehicle|Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3054319|NCT00770133|Active Comparator|Naphazoline|Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3054320|NCT00770133|Active Comparator|Ketotifen|Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.
3054321|NCT00770146|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a week for 26 weeks.
3054322|NCT00770146|Experimental|Mipomersen|Participants received mipomersen 200 mg as a subcutaneous injection once a week for 26 weeks.
3054323|NCT00770211|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3054324|NCT00770211|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3054325|NCT00770224|Experimental|R-CHOP, tositumomab and rituximab|"Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 IV Day 1 Prednisone 100 mg PO Days 1-5 Rituximab 375 mg/m2 IV Day 1 Q 21 Days x 6 Cycles~Patients are restaged by CT scan. Unlabeled tositumomab antibody 450 mg IV within 12 after Cycle 6 of CHOP. Dosimetric dose 35 mg IV after infusion of unlabeled tositumomab antibody. Unlabeled tositumomab antibody 450 mg IV 7-14 days after dosimetric dose. Therapeutic dose 35 mg IV after infusion of unlabeled tositumomab antibody.~Rituximab 375 mg/m2 IV q 3 months x 4 years beginning 1 year after registration."
3054326|NCT00770289||Single group|
3054327|NCT00770315|Experimental|SCH 39641 1.5 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 1.5 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3054328|NCT00770315|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 6 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3054329|NCT00770315|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergan extract (SCH 39641 12 Amb a 1-U) rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3054330|NCT00770315|Placebo Comparator|Placebo|Participants receive matching placebo rapidly dissolving sublingual tablets, administered once daily for approximately 52 weeks
3054331|NCT00770328|Experimental|Pentoxifylline|Patients receive Pentoxifylline 400 mg po TID for 8 weeks.
3054332|NCT00770328|Placebo Comparator|Placebo|Patients take a placebo TID for 8 weeks.
3054333|NCT00770341|Experimental|MK-3009 (daptomycin) 4 mg/kg|
3054334|NCT00770341|Active Comparator|Vancomycin|
3054335|NCT00770341|Experimental|MK-3009 (daptomycin) 6 mg/kg|
3054336|NCT00770367|Experimental|Pioglitazone then Placebo|18 volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take Pioglitazone for the first 12 week period of the study and then take the placebo for the final 12 weeks of the study.
3054337|NCT00770367|Experimental|Placebo then Pioglitazone|18 (other half of participants) volunteers that are Diabetic adults, 40-75 years that have higher ADMA levels as well as increased inflammation will take the placebo for the first 12 week period of the study and then take the Pioglitazone for the final 12 weeks of the study.
3054338|NCT00770432|Active Comparator|Polyethylene glycol 3350 powder for solution|MiraLAX® (polyethylene glycol 3350 powder for solution)
3054339|NCT00770432|Placebo Comparator|Placebo|MALTRIN 500® M500 (maltodextrin 500)
3054340|NCT00770484|Experimental|Propranolol then placebo|Active treatment
3054341|NCT00770484|Placebo Comparator|Placebo then propranolol|Placebo Treatment
3054342|NCT00770510|Experimental|Eszopiclone 1 mg|
3054343|NCT00770510|Experimental|Eszopiclone 2 mg|
3054344|NCT00770510|Experimental|Eszopiclone 3 mg|
3054345|NCT00770510|Placebo Comparator|Placebo|
3054346|NCT00770510|Active Comparator|Zolpidem Tartrate 10 mg|
3054347|NCT00770562|Active Comparator|Dexamethasone|Participants received 40 milligrams (mg) dexamethasone, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4). Participants in this treatment arm who failed to achieve a sustained response and had a platelet count of less than or equal to (≤)20 x 10^9 platelets per liter (L; from Day 30 up to end of 6 months) were treated with salvage treatment of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg per square meter (mg/m^2), intravenously (IV), with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28.
3054348|NCT00770562|Experimental|Dexamethasone plus Rituximab|Participants received dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV, with premedication of oral acetaminophen 500 mg and chlorpheniramine 10 mg IV on Days 7, 14, 21, and 28. Nonresponsive participants with platelets less than (<) 20 x10^9/L or with active bleeding could have also received an additional treatment course of dexamethasone 40 mg, orally, once per day for 4 consecutive days (Days 1, 2, 3, and 4) and rituximab 375 mg/m^2, IV on Days 7, 14, 21, and 28 administered with immunoglobulin (IgG) IV (at investigator discretion) and/or low/medium dose steroids (at investigator discretion) on Days 7, 14, 21, and 28.
3054349|NCT00770588|Experimental|gefitinib|Gefitinib (Iressa® 250 mg) 1 tablet daily
3054350|NCT00770588|Placebo Comparator|placebo|placebo 1 tablet daily
3054351|NCT00770601|Experimental|Canakinumab|Participants received body-weight stratified dosage of canakinumab treatment at 300 milligrams (mg) (for participants weighing more than 40 kilograms (kg)) and at 2 mg/kg (for participants weight less than or equal to 40 kg) subcutaneously every 4-8 weeks as per investigator discretion for a treatment period of 6 months. The first 3 Neonatal-Onset Multisystem Inflammatory Disease (NOMID) participants enrolled received a dose of 150 mg (>40 kg) and 2 mg/kg for children <40 kg. Since this dose was insufficient to fully control the symptoms of the disease the 300 mg / 4mg/kg dose was introduced by Protocol Amendment 2.
3054352|NCT00770653|Experimental|Pioglitazone 15 mg and Metformin 850 mg BID|
3054353|NCT00770653|Active Comparator|Glimepiride 2 mg and Metformin 850 mg BID|
3054354|NCT00770679|Experimental|High-Dose Statin|80 mg atorvastatin daily for 3 weeks
3054355|NCT00770692|Experimental|Eszopiclone 1 mg- Elderly|
3054356|NCT00770692|Experimental|Eszopiclone 2 mg- Elderly|
3054357|NCT00770692|Experimental|Eszopiclone 2 mg- Non-elderly|
3054358|NCT00770692|Experimental|Eszopiclone 3 mg- Non-elderly|
3054359|NCT00770757|Experimental|CC-4047 Arm|CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).
3054360|NCT00770770|Experimental|Fluocinolone Acetonide 0.2 µg/day|0.2 µg/day
3054361|NCT00770770|Experimental|Fluocinolone Acetonide 0.5 µg/day|0.5 µg/day
3054362|NCT00770809|Experimental|Arm I (THL)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 750 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity.
3054363|NCT00770809|Active Comparator|Arm II (TH)|Patients receive trastuzumab 2 mg/kg IV over 30-90 minutes and paclitaxel 80 mg/m^2 IV over 1 hour once weekly for 16 weeks in the absence of disease progression or unacceptable toxicity.
3054364|NCT00770809|Experimental|Arm III (TL)|Patients receive paclitaxel 80 mg/m^2 IV over 1 hour once weekly and lapatinib ditosylate 15000 mg PO once daily for 16 weeks in the absence of disease progression or unacceptable toxicity. (Discontinued as of 6-15-11)
3054365|NCT00770861|Active Comparator|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets, oral administration ; Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets, oral administration
3054366|NCT00770861|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3054367|NCT00770874|Experimental|1|S-1 + Cisplatin (arm A)
3054368|NCT00770874|Active Comparator|2|Cisplatin (arm B)
3054369|NCT00770913|Active Comparator|1|
3054370|NCT00770913|Experimental|2|
3054371|NCT00770913|Experimental|3|
3054372|NCT00770991|Experimental|Black Raspberry (BRB) Slurry plus BRB suppositories|20 grams BRB Slurry BID plus two, 730 mg BRB suppositories HS
3054373|NCT00770991|Experimental|Black Raspberry (BRB) Placebo Slurry plus BRB suppositories|20 grams BRB Placebo Slurry BID plus two, 730 mg BRB suppositories HS
3054374|NCT00771030|Placebo Comparator|Placebo SC (Cohorts 1-3)|Participants received placebo to brodalumab by subcutaneous (SC) injection once every 2 weeks for a total of six doses.
3054375|NCT00771030|Placebo Comparator|Placebo IV (Cohorts 5-6)|Participants received placebo to brodalumab by intravenous (IV) infusion every 4 weeks for a total of two doses.
3054376|NCT00771030|Experimental|Brodalumab 50 mg SC (Cohort 1)|Participants received 50 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
3054377|NCT00771030|Experimental|Brodalumab 140 mg SC (Cohort 2)|Participants received 140 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
3054378|NCT00771030|Experimental|Brodalumab 210 mg SC (Cohort 3)|Participants received 210 mg brodalumab by subcutaneous injection once every 2 weeks for a total of six doses.
3054379|NCT00771030|Experimental|Brodalumab 420 mg IV (Cohort 5)|Participants received 420 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
3054380|NCT00771030|Experimental|Brodalumab 700 mg IV (Cohort 6)|Participants received 700 mg brodalumab by IV infusion once every 4 weeks for a total of two doses.
3054381|NCT00771056|Experimental|Hydroxychloroquine|Hydroxychloroquine 400 mg po daily for up to one year.
3054382|NCT00771173|Active Comparator|Study Medication Group|Participants that are randomized to the phenazopyridine HCl group will receive the study medication (200 mg of phenzopyridine HCl orally) after leaving the operating room. We anticipate the first dose to be given after the patient has left the recovery area. We will continue use of study medication until it has been given up to 24 hours after the first VAS collection or catheter removal, whichever occurs first
3054383|NCT00771173|Placebo Comparator|Placebo tablet Group|For participants randomized to the placebo group will follow the same dosing schedule for the study medication, although they will receive an inert placebo tablet.
3054384|NCT00771238|Experimental|P500 Mattress|The new P500 Low Air Loss mattress will be used to replace the standard mattress for this study arm.
3054385|NCT00771238|No Intervention|Standard of Care Mattress|Cardiovascular ICU patients that receive standard of care mattress (Total Care Treatment Mattress) and standard pressure ulcer prevention care. All patients had daily skin assessments, as per normal care.
3054386|NCT00771264|Active Comparator|Urgent PC|
3054387|NCT00771264|No Intervention|Sham / Placebo|
3054388|NCT00771277|Experimental|Arm 1|Use of volunteer support teams to provide services
3054389|NCT00771407|Active Comparator|Strattice fascial inlay|Strattice will be placed as a fascial inlay to support the ostomy site
3054390|NCT00771407|Other|Standard ostomy construction|Ostomy will be created in the standard fashion
3054391|NCT00771472|Experimental|Vorinostat|
3054392|NCT00771537|No Intervention|Arm 1. Control PLUS Control|
3054393|NCT00771537|Experimental|Arm 2. Control PLUS 1-Sided|No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054394|NCT00771537|Experimental|Arm 3. Control PLUS 2-Sided Trivial|No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation.
3054395|NCT00771537|Experimental|Arm 4. Control PLUS 2-Sided Major|No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation.
3054396|NCT00771537|Experimental|Arm 5. 1-Sided PLUS Control|1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3054397|NCT00771537|Experimental|Arm 6. 1-Sided PLUS 1-Sided|1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054398|NCT00771537|Experimental|Arm 7. 1-Sided PLUS 2-Sided Trivial|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054399|NCT00771537|Experimental|Aim 8. 1-Sided PLUS 2-Sided Major|1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054400|NCT00771537|Experimental|Arm 9. 2-Sided Trivial PLUS Control|2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3054401|NCT00771537|Experimental|Arm 10. 2-Sided Trivial PLUS 1-Sided|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054402|NCT00771537|Experimental|Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054403|NCT00771537|Experimental|Arm 12. 2-Sided Trivial PLUS 2-Sided Major|2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054404|NCT00771537|Experimental|Arm 13. 2-Sided Major PLUS Control|2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation.
3054405|NCT00771537|Experimental|Arm 14. 2-Sided Major PLUS 1-Sided|2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054406|NCT00771537|Experimental|Arm 15. 2-Sided Major PLUS 2-Sided Trivial|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054407|NCT00771537|Experimental|Arm 16. 2-Sided Major PLUS 2-Sided Major|2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation.
3054408|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation A Group|Subjects previously primed in NCT00510874 study with formulation 1 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation A of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054409|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054410|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation B2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation B2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054411|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054412|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation C2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (Q-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation C2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054413|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D1 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054414|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation D2 Group|Subjects previously primed in NCT00510874 study with formulation 2 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation D2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054415|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E1 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E1 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054416|NCT00771615|Experimental|A/turkey H5N1 influenza Formulation E2 Group|Subjects previously primed in NCT00510874 study with formulation 3 of Influenza A (D-Pan H5N1) virus monovalent vaccine (A/Indonesia) were boosted with a single dose of formulation E2 of GSK A/turkey H5N1 Influenza vaccine in this study. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3054417|NCT00771667|Placebo Comparator|Placebo (IP)|
3054418|NCT00771667|Experimental|Ustekinumab 1mg/kg (IP)|
3054419|NCT00771667|Experimental|Ustekinumab 3 mg/kg (IP)|
3054420|NCT00771667|Experimental|Ustekinumab 6 mg/kg (IP)|
3054421|NCT00771667|Placebo Comparator|Placebo IV - Responder - Placebo SC (MP)|
3054422|NCT00771667|Placebo Comparator|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC|
3054423|NCT00771667|Placebo Comparator|Ustekinumab IV - Responder - Placebo SC (MP)|
3054424|NCT00771667|Experimental|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|
3054425|NCT00771667|Placebo Comparator|Ustekinumab IV - Nonresponder - Placebo SC (MP)|
3054426|NCT00771667|Experimental|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|
3054427|NCT00771745|Active Comparator|rATG 4 doses|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
3054428|NCT00771745|Active Comparator|rATG 3 doses|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
3054429|NCT00771758|Experimental|001|tapentadol IR 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 450 mg
3054430|NCT00771758|Experimental|002|oxycodone IR 5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days maximum daily dose 60 mg
3054431|NCT00771758|Placebo Comparator|003|placebo 1 capsule every 4 - 6 hr as needed for up to 10 days
3054432|NCT00771810|Placebo Comparator|Placebo|Combination gemcitabine and platinum-based chemotherapy with concurrent placebo
3054433|NCT00771810|Experimental|TXA127 100 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 100 ug/kg/day TXA127
3054434|NCT00771810|Experimental|TXA127 300 ug/kg|Combination gemcitabine and platinum-based chemotherapy with concurrent 300 ug/kg/day TXA127
3054435|NCT00771849|Experimental|Menactra® Vaccine Group|Participants receiving the tetravalent (A, C, Y, and W 135) meningococcal diphtheria toxoid conjugate vaccine
3054436|NCT00771849|Active Comparator|Hiberix® Vaccine Group|Participants receiving Haemophilus Influenzae Type b (Hib) vaccine
3054437|NCT00771875|Active Comparator|Rabbit Antithymocyte Globulin (RATG)|Rabbit Antithymocyte Globulin (RATG) All patients will receive RATG (Thymoglobulin) dosed based on CD3 count. Patients will be redosed when the cluster of differentiation 3 (CD3) count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily. 1.5mg/kg/day over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
3054438|NCT00771875|Experimental|RATG/Rituximab|Rabbit Antithymocyte Globulin (RATG) + Rituximab Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3); Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
3054439|NCT00771875|Experimental|RATG/Bortezomib|Rabbit Antithymocyte Globulin (RATG) + Bortezomib -Subjects will be given 1.5mg/kg/day of RATG over 6 hrs with 1st dose (D1) and over 4 hours for each dose thereafter. (day 1 then when CD3 levels > 25 cells/mm3). Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care. Bortezomib will be given at a dose of 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Methylprednisolone will be administered prior to each bortezomib dose. On days 2 and 5, administer methylprednisolone 100 mg intravenous push (IVP). On days 9 and 12, administer methylprednisolone 50 mg intravenous push (IVP). If thymoglobulin is administered the same day as bortezomib, the order of administration is- methylprednisolone, then bortezomib, then thymoglobulin.
3054440|NCT00771901|Placebo Comparator|Placebo|Subjects will be given a placebo rather than tauroursodeoxycholic acid.
3054441|NCT00771901|Experimental|tauroursodeoxycholic acid|Subjects will receive tauroursodeoxycholic acid for four weeks.
3054442|NCT00771901|Experimental|PBA|Subjects will receive sodium phenylbutyrate for four weeks.
3054443|NCT00771914|Experimental|Placebo, Lovaza, Aspirin, Both Aspirin and Lovaza|First Placebo, then 4 grams of Lovaza, then 81mg of Aspirin, then both 4 grams of Lovaza and 81 mg of Aspirin
3054444|NCT00771914|Experimental|Aspirin, Lovaza, Both Aspirin and Lovaza, Placebo|First 81mg of Aspirin, then 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo
3054445|NCT00771914|Experimental|Lovaza, Both Aspirin and Lovaza, Placebo, Aspirin|First 4 grams of Lovaza, then both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 81mg of Aspirin
3054446|NCT00771914|Experimental|Both Aspirin and Lovaza, Placebo, Lovaza, Aspirin|First both 81mg of Aspirin and 4 grams of Lovaza, then placebo, then 4 grams of Lovaza, then 81mg of Aspirin
3054447|NCT00771927||Lacosamide|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with add-on Vimpat
3054448|NCT00771927||Other AED|Epilepsy patients with partial-onset seizures who are uncontrolled on current therapy and are treated with other approved AED as add-on therapy
3054449|NCT00771953|Experimental|Apricoxib|Apricoxib 400mg once a day
3054450|NCT00771953|Placebo Comparator|Placebo|Placebo once a day
3054451|NCT00772005|Active Comparator|150 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3054452|NCT00772005|Active Comparator|200 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3054453|NCT00772005|Active Comparator|250 mg/day armodafinil|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3054454|NCT00772005|Placebo Comparator|Matching Placebo|At the baseline visit, patients were randomly assigned to 1 of 3 armodafinil treatment groups or to the placebo treatment group. Patients took 5 tablets orally each day, once daily in the morning. Study drug was titrated (using blister cards) during the double-blind treatment period starting with 50 mg/day of armodafinil or matching placebo. The dosage of armodafinil or matching placebo tablet was increased, as applicable, by 50 mg/day on days 2, 4, 6, and 8, up to the randomized dosage of 150, 200, or 250 mg/day. Patients remained at their randomized dosage for the duration of the study.
3054455|NCT00772031|Active Comparator|1|Participants will receive propranolol and topiramate.
3054456|NCT00772031|Placebo Comparator|2|Participants will receive a placebo and topiramate.
3054457|NCT00772070|Experimental|Previously received TetraMenD|Participants previously received one dose of a Meningococcal vaccine, TetraMenD in Study 603-02.
3054458|NCT00772070|Experimental|Meningococcal vaccine-naїve|Participants have never received a Meningococcal vaccine in the past.
3054459|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 1|Participants will receive a dose of Influenza intradermal vaccine Lot 1
3054460|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 2|Participants will receive a dose of Influenza intradermal vaccine Lot 2
3054461|NCT00772109|Experimental|Fluzone Intradermal Vaccine Lot 3|Participants will receive a dose of Influenza intradermal vaccine Lot 3
3054462|NCT00772109|Active Comparator|Fluzone Intramuscular Vaccine|Participants will receive a dose of influenza intramuscular vaccine
3054463|NCT00772148|Experimental|LCP-Tacro|LCP - Tacro™ tablets, once daily (LifeCycle Pharma A/S, Hørsholm DK)
3054464|NCT00772148|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
3054465|NCT00772304|Experimental|1|Olopatadine 0.6% / Azelastine 137 mcg
3054466|NCT00772330|Experimental|MIDI Arrow|Ab externo glaucoma drainage device with no reservoir
3054467|NCT00772382|Experimental|MCI-196|
3054468|NCT00772447|Experimental|AZ drug|Daptomycin
3054469|NCT00772447|Active Comparator|Comparator|Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin
3054470|NCT00772538|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3054471|NCT00772538|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3054472|NCT00772577|Experimental|1|Aliskiren Hydrochlorothiazide(HCTZ)
3054473|NCT00772577|Active Comparator|2|Ramipril
3054474|NCT00772590|Experimental|Raltegravir, bovine colostrum|Raltegravir and hyper-immune bovine colostrum
3054475|NCT00772590|Experimental|Hyper-immune bovine colostrum|Hyper-immune bovine colostrum and Raltegravir placebo
3054476|NCT00772590|Experimental|Raltegravir|Raltegravir and Hyper-immune Bovine Colostrum Placebo
3054477|NCT00772590|Placebo Comparator|Placebo|Raltegravir placebo and hyper-immune bovine colostrum placebo
3054478|NCT00772603|Placebo Comparator|Placebo|Placebo - four identical tablets taken orally once daily
3054479|NCT00772603|Active Comparator|2400 mg SPN-804|2400mg OXC XR taken orally once daily as four identical tablets
3054480|NCT00772603|Active Comparator|1200mg SPN-804|1200mg OXC XR taken orally once daily as four identical tablets
3054481|NCT00772629|Experimental|Group 1|Subjects naïve to any meningococcal vaccination
3054482|NCT00772629|Experimental|Group 2|Subjects who previously received unconjugated polysaccharide vaccine (either bivalent A and C or tetravalent A, C, Y, and W 135)
3054483|NCT00772668|Experimental|RCVELP|"Rituximab, Cyclophosphamide, Bortezomib, Prednisone (RCVELP):~Rituximab~Induction: 375 mg/m2 IV infusion on Day 1 of every 21 days cycle for 8 cycles~Maintenance: 375/m2 Days 1, 8, 15, 22 every 6 months for up to 4 cycles~Cyclophosphamide: 750 mg/m2 intravenous piggyback (IVPB) on Day 1 of every 21 day cycle for 8 cycles~Bortezomib: 1.6 mg/m2 IV push on Days 1 and 8 of every 21 days cycle for 8 cycles~Prednisone: 100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles"
3054484|NCT00772707|Experimental|Opti-Free Replenish|Multi-purpose contact lens solution for cleaning and disinfecting study contact lenses used on a daily basis for 30 days.
3054485|NCT00772772|Experimental|Vitamin D3|Vitamin D3 30,000 international units orally per week for 8 weeks
3054486|NCT00772889|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥66 years received one dose of New generation influenza vaccine GSK2186877A.
3054487|NCT00772889|Active Comparator|Fluarix elderly Group|Subjects aged ≥66 years received one dose of Fluarix vaccine.
3054488|NCT00772889|Active Comparator|Fluarix young Group|Subjects aged 19-43 years received one dose of Fluarix vaccine.
3054489|NCT00772915|Experimental|Lenalidomide with On-Demand Dexamethasone|"Lenalidmoide: 25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Dexamethasone: 10-40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression."
3054490|NCT00772928|Experimental|Pentacel™ concurrently with Prevnar®|Participants had Pentacel™ concurrently administered with Prevnar®
3054491|NCT00772928|Experimental|Pentacel™ staggered schedule with Prevnar®|Participants had Pentacel™ given at different times from Prevnar® (using a standardized, staggered schedule).
3054492|NCT00772941||Varenicline|Patients taking Varenicline.
3054493|NCT00772954|Placebo Comparator|Placebo vaccine group|Participants scheduled to receive a dose of placebo vaccine on Day 0, Day 28, and Day 56, respectively.
3054494|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 1|Participants scheduled to receive a dose of 50 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
3054495|NCT00772954|Experimental|Clostridium Difficile Vaccine Group 2|Participants scheduled to receive a dose of 100 μg Clostridium Difficile vaccine on Day 0, Day 28, and Day 56, respectively.
3054496|NCT00772967|Experimental|Placebo, Naproxen, Ultracet|Participants were treated with Placebo for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054497|NCT00772967|Experimental|Naproxen, Ultracet, Placebo|Participants were treated with Naproxen for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054498|NCT00772967|Experimental|Ultracet, Placebo, Naproxen|Participants were treated with Ultracet for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054499|NCT00772967|Experimental|Placebo, Ultracet, Naproxen|Participants were treated with Placebo for 3 days in Treatment Period 1, Ultracet for 3 days in Treatment Period 2, and Naproxen for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054500|NCT00772967|Experimental|Naproxen, Placebo, Ultracet|Participants were treated with Naproxen for 3 days in Treatment Period 1, Placebo for 3 days in Treatment Period 2, and Ultracet for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054501|NCT00772967|Experimental|Ultracet, Naproxen, Placebo|Participants were treated with Ultracet for 3 days in Treatment Period 1, Naproxen for 3 days in Treatment Period 2, and Placebo for 3 days in Treatment Period 3. The treatment periods were separated by a 4-6 day break.
3054502|NCT00773097|Experimental|MUC1 Poly-ICLC|
3054503|NCT00773136|Active Comparator|Bimatoprost Suspension|Intervention to be administered: Each subject was given two suspensions, one mixed with Bimatoprost and one mixed with normal saline. They were instructed to use each suspension to a pre-determined eyelash (prepared prior to study enrollment in double blind fashion and marked after randomization with right and left). The intervention was the one eye with the Bimatoprost.
3054504|NCT00773175|Active Comparator|Subcutaneous|Isotonic fluid rehydration by SC administration with hylenex (150 Units in 1 mL)
3054505|NCT00773175|Active Comparator|Intravenous|Isotonic fluid rehydration by IV
3054506|NCT00773253|Active Comparator|standard EMG-guided Botox injection|All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.
3054507|NCT00773253|Experimental|Multi-channel EMG-guided Botox injection|Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.
3054508|NCT00773279|Experimental|PDS290 --> FlexPen®|Subjects will receive trial drug with PDS290 for 12 weeks (treatment sequence 1) followed by FlexPen® for 12 weeks (treatment sequence 2)
3054509|NCT00773279|Experimental|FlexPen® --> PDS290|Subjects will receive trial drug with FlexPen® for 12 weeks (treatment sequence 1) followed by PDS290 for 12 weeks (treatment sequence 2)
3054510|NCT00773292|Experimental|ciclosporin|48 weeks treatment with ciclosporin
3054511|NCT00773370|Experimental|APA-Stroke|The APA-stroke exercise program designed specifically for individuals with hemiparetic gait deficits due to stroke. These progressive exercises focus on walking, balance and weight shifting and include an exercise homework component.
3054512|NCT00773370|Active Comparator|Sittercise|Sittercise is not stroke specific. This less vigorous exercise program consists of seated exercise, focusing on stretching to improve general range of motion and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework associated with this group.
3054513|NCT00773383|Experimental|1|
3054514|NCT00773422|Experimental|naltrexone + varenicline|naltrexone (25mg) + varenicline (2mg)
3054515|NCT00773422|Experimental|varenicline|varenicline 2mg
3054516|NCT00773422|Placebo Comparator|placebo|placebo control
3054517|NCT00773461|Experimental|1|
3054518|NCT00773461|Placebo Comparator|2|
3054519|NCT00773474|Experimental|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
3054520|NCT00773513|Active Comparator|Erythropoiesis Stimulating Agents|Participants will receive reference ESA according to approved label. The approved reference ESA compounds in the study will be darbepoetin alfa, epoetin alfa and epoetin beta.
3054521|NCT00773513|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants not currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta iv or sc once every 2 weeks for correction of renal anemia (target Hb 10-12 g/dL). Once corrected and in participants currently being treated with an ESA, methoxy polyethylene glycol-epoetin beta will be administered once monthly.
3054522|NCT00773604|Other|Treatment|Deep Brain Stimulation
3054523|NCT00773734|Experimental|Apremilast 10mg|Apremilast 10 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 10 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3054524|NCT00773734|Experimental|Apremilast 20mg|Apremilast 20 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 20 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3054525|NCT00773734|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally twice daily (BID) for 16 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for 8 weeks in the active treatment phase
3054526|NCT00773734|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 16 weeks during the placebo-controlled phase.
3054527|NCT00773734|Experimental|Placebo/Apremilast 20 mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 20 mg apremilast BID during the 8 week active treatment phase
3054528|NCT00773734|Experimental|Placebo/Apremilast 30mg|Participants initially randomized to receive placebo twice daily during the 16 week placebo controlled phase are re-randomized to 30 mg apremilast BID during the 8 week active treatment phase
3054529|NCT00773747|Experimental|Vorinostat + Bortezomib|Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
3054530|NCT00773747|Placebo Comparator|Placebo + Bortezomib|Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.
3054531|NCT00773786|Experimental|Arformoterol|Arformoterol twice daily for 1 week via nebulizer
3054532|NCT00773786|Placebo Comparator|Placebo|Placebo twice daily for 1 week
3054533|NCT00773838|Experimental|Vorinostat + Bortezomib|Participants receive vorinostat 400 mg, orally, once daily (QD) on Days 1-14 of each 21-day treatment cycle and bortezomib 1.3mg/m^2 intravenous (IV) injection QD on Days 1, 4, 8 and 11 of each 21-day treatment cycle for up to 26 cycles. Participants with progressive disease (PD) after 2 cycles of treatment or no change (NC) after 4 cycles of treatment receive additional treatment of Dexamethasone, 20 mg of total daily dose, orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle for up to 26 cycles. Eligible participants could receive additional treatment on an extension.
3054534|NCT00773955|Experimental|Treatment (R-(-)-gossypol)|Patients receive oral R-(-)-gossypol once daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3054535|NCT00773968|Experimental|Methoxy Polyethylene Glycol-Epoetin Beta|Participants will receive methoxy polyethylene glycol-epoetin beta once monthly by subcutaneous (SC) injection for 28 weeks.
3054536|NCT00774046|Experimental|Induction chemotherapy followed by stem cell transplant|Ara-C Mitoxantrone Etoposide Stem cell mobilization Autologous transplant
3054537|NCT00774163|Experimental|1|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
3054538|NCT00774163|Placebo Comparator|2|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
3054539|NCT00774202|Active Comparator|Rituximab, Cyclophosphamide, Vincristine, Prednisone|"'Standard Dose of Rituximab administered with C, V, P (CVP)'~Interventions: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses at standard rates and use of premedication. The schedule will be to give the first rituximab infusion 5 days (± 3 days) prior to first administration of CVP, and the following 3 infusions will be given on the same day as the 3 cycles of C, V, P. On those days, the IV Cyclophosphamide and Vincristine will be given first so that the administration of fluids with the rituximab can be used as post-cyclophosphamide hydration, Cyclophosphamide dosing will be 750mg/m2 (maximum 2000mg), vincristine 1.4 mg/m2 (up to 1.6 mg), prednisone 100mg po daily for 5 days."
3054540|NCT00774202|Active Comparator|Higher Dose of Rituximab|In this arm, Rituximab will be administered at a dose of 750 mg/m2 once a week x 4 consecutive weeks (4 infusions in total). We will perform EKG monitor tracings before, during and after Rituxan infusions. This will be a single-lead tracing that will allow us to look at the Q-T interval.
3054541|NCT00774267||1|
3054542|NCT00774267||2|
3054543|NCT00774267||3|
3054544|NCT00774267||4|
3054545|NCT00774397|Experimental|240 mg QD TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3054546|NCT00774397|Experimental|240 mg QD / LI-TN|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3054547|NCT00774397|Placebo Comparator|Placebo|Placebo once daily combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment-naive (TN) patients
3054548|NCT00774397|Experimental|120 mg QD / LI-TN|120 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in (LI) phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), followed by an additional 24 weeks of PegIFN/RBV in treatment naive (TN) patients
3054549|NCT00774397|Experimental|240 mg QD TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, followed by an additional 24 weeks of PegIFN/RBV in treatment experienced (TE) patients
3054550|NCT00774397|Experimental|240 mg QD / LI-TE|240 mg BI 201335 NA (Faldaprevir) once daily (QD) combined with PegIFN/RBV for 24 weeks, with a 3-day lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 (Faldaprevir) three days after first administration of PegIFN/RBV), success-dependently followed by re-randomisation to stop or to an additional 24 weeks of PegIFN/RBV in treatment-experienced (TE) patients
3054551|NCT00774397|Experimental|240 mg BID / LI-TE|240mg BI 201335 NA (Faldaprevir) twice daily combined with PegIFN/RBV for 24 or 48 weeks, with 3-day lead-in phase of PegIFN/RBV, in treatment-experienced patients
3054552|NCT00774566|Active Comparator|1|segmental PVI using an irrigated tip catheter
3054553|NCT00774566|Active Comparator|2|PVI using the Cryo-Balloon
3054554|NCT00774579||1|Patients with growth hormone (GH) deficiency starting GH replacement.
3054555|NCT00774579||2|Patients with growth hormone (GH) deficiency not starting GH replacement.
3054556|NCT00774748|Experimental|I|All participants in the study will use the subcutaneous catheter twice for a period of one week each to inject the enoxaparin. For the remainder of the study the participants will inject subcutaneously.
3054557|NCT00774787|Experimental|Imiquimod, treatment, topical cream|Imiquimod 5% cream, 1 packet (250 mg cream), applied to left or right treatment area on the face and/or balding scalp
3054558|NCT00774787|No Intervention|Control, Untreated|No treatment of treatment area on the other half of the face and/or balding scalp
3054559|NCT00774800|Experimental|First Humalog+PH20, then Humalog, Humulin-R+PH20, Humulin-R|"Humalog + Recombinant human hyaluronidase PH20 (rHuPH20) (Intervention 1): 24 units (U) of rHuPH20 per unit of Humalog, injected subcutaneously (SC), for up to 3 visits until an appropriate dose was identified.~Humalog alone (Intervention 2): a single SC injection of the appropriate identified dose of Humalog, delivered before a liquid meal.~Humulin-R + rHuPH20 (Intervention 3): 24 U of rHuPH20 per unit of Humulin-R, injected SC, for up to 2 visits until an appropriate dose was identified.~Humulin-R alone (Intervention 4): a single SC injection of the appropriate identified dose of Humulin-R, delivered before a liquid meal.~Appropriate dose of either Humalog or Humulin-R was that at which blood glucose following a liquid meal was <160 milligrams per deciliter (mg/dL) for more than 30 minutes during the first 4 hours after injection and never fell below 60 mg/dL.~All dose finding visits and interventions were separated by 3-10 days."
3054560|NCT00774852|Experimental|Treatment|Abatacept plus Euro-lupus regimen
3054561|NCT00774852|Placebo Comparator|Control|Abatacept placebo plus Euro-lupus regimen
3054562|NCT00774930|Experimental|Lanreotide Autogel (Somatuline Depot) 120 mg|"Subjects received deep s.c. lanreotide Autogel 120 mg every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for early roll over [ERO]) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
3054563|NCT00774930|Placebo Comparator|Placebo (DB) and lanreotide Autogel 120 mg in IOL and LTOLE|"Subjects received deep s.c. placebo every 4 weeks (±3 days) for 16 weeks (DB phase).~After completing the DB phase (or if they met criteria for ERO) the subjects entered the IOL phase during which they received lanreotide Autogel 120 mg deep s.c. every 4 weeks for 32 weeks. During the LTOLE phase, subjects continued treatment with lanreotide Autogel 120 mg deep s.c. every 4 weeks until at least 2 years after the last subject completed the IOL phase or when marketing approval for the treatment of symptoms of carcinoid syndrome was obtained [whichever occurred first])."
3054564|NCT00774995|Experimental|Engerix(4-dose)+HepatitisB(HB) Immunoglobulin (Ig)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3054565|NCT00774995|Experimental|Engerix(3-dose)+HBIg|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and HBIg concomitantly at Month 0, and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3054566|NCT00774995|Experimental|Engerix(4-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 and 60 months (4 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3054567|NCT00774995|Experimental|Engerix(3-dose)|Subjects who previously received HBV vaccine at 0, 1, 6 months (3 doses) and received a challenge dose of HBV vaccine after approximately 20 years (noted as Day 0) in the current study.
3054568|NCT00775021|Active Comparator|etafilcon A/nelfilcon A|etafilcon A contact lens worn first and nelfilcon A contact lens worn second
3054569|NCT00775021|Active Comparator|nelfilcon A/etafilcon A|nelfilcon A contact lens worn first and etafilcon A contact lens second.
3054570|NCT00775138|Experimental|Cohort 1 - 280 mg Arikayce™|Subjects in this arm of the cohort 1 will receive 280 mg of Arikayce™
3054571|NCT00775138|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of the cohort 1 will receive matching placebo.
3054572|NCT00775138|Experimental|Cohort 2 - 560 mg Arikayce™|Subjects in this arm of the cohort 2 will receive 560 mg of Arikayce™
3054573|NCT00775138|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of the cohort 2 will receive matching placebo
3054574|NCT00775203|Experimental|Trazodone Contramid Once A Day (OAD)|
3054575|NCT00775203|Placebo Comparator|Placebo|
3054576|NCT00775229|Active Comparator|1|Naltrexone
3054577|NCT00775229|Placebo Comparator|2|Placebo
3054578|NCT00775268|Experimental|Group A - Participants Scanned at Baseline & After Chemotherapy|Patients undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT) and fluorodeoxyglucose F 18 (FDG) PET/CT scans at baseline, after 2 courses of chemotherapy, and after completion of chemotherapy. Patients with residual FDG-positive mass after completion of therapy may be enrolled in group B.
3054579|NCT00775268|Experimental|Group B - Participants Scanned in the Evaluation of Residual Masses After Therapy|Patients who have completed treatment in whom FDG-PET shows a remaining tumor mass undergo an FLT PET/CT scan . Patients also undergo a biopsy or fine-needle aspiration, if clinically indicated.
3054580|NCT00775346||Polysomnography (PSG) Subjects|Subjects who have been prescribed with needing a polysomnography (PSG) will be enrolled into the study.
3054581|NCT00775411|Experimental|700 µg dexamethasone and ranibizumab|700 µg dexamethasone intravitreal injection at Day 1 in the study eye. Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
3054582|NCT00775437|Experimental|Adalimumab|Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
3054583|NCT00775450|Experimental|Group 1a: Fluzone ID After Fluzone ID|
3054584|NCT00775450|Experimental|Group 1b: Fluzone IM After Fluzone ID|
3054585|NCT00775450|Active Comparator|Group 2a: Fluzone IM After Fluzone IM|
3054586|NCT00775450|Experimental|Group 2b: Fluzone ID After Fluzone IM|
3054587|NCT00775450|Active Comparator|Group 3: Fluzone HD After Fluzone HD|
3054588|NCT00775463|Experimental|treprostinil diethanolamine|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
3054589|NCT00775463|Placebo Comparator|placebo (sugar pill)|Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
3054590|NCT00775528|Experimental|A|
3054591|NCT00775606|Active Comparator|ARM A/Lopinar/ritonavir|Subjects randomized to Arm A initiated Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
3054592|NCT00775606|Active Comparator|ARM B/Efavirenz|Subjects randomized to Arm B initiated Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
3054593|NCT00775645|Experimental|Arm I|Patients receive oral acetyl-L-carnitine hydrochloride 3 times daily for 24 weeks.
3054594|NCT00775645|Placebo Comparator|Arm II|Patients receive oral placebo 3 times daily for 24 weeks.
3054595|NCT00775658|Active Comparator|olopatadine then placebo|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
3054596|NCT00775658|Active Comparator|placebo then olopatadine|participants received olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day for 7 to 10 days followed by 7-10 day washout period. They then received a placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day for 7-10 days
3054597|NCT00775671|Active Comparator|Nebivolol|Nebivolol 5mg by mouth daily for 12 weeks.
3054598|NCT00775671|Active Comparator|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
3054599|NCT00775684|Experimental|Exenatide|Exenatide (Byetta®)-5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
3054600|NCT00775684|Experimental|Sitagliptin|Sitagliptin (Januvia®)-100 mg by mouth every morning
3054601|NCT00775684|Active Comparator|Glimepiride|Glimepiride (Amaryl®)-0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
3054602|NCT00775931|Active Comparator|marrow graft transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan, Fludarabine monophosphate, and total lymphoid irradiation followed by unrelated or matched related donor marrow graft transplantation (both peripheral blood and marrow) and a second CD34 cell infusion on Day 42.
3054603|NCT00775931|Active Comparator|cord blood transplant conditioning|Pre-transplant conditioning using Campath-1H, Busulfan and Cyclophosphamide followed by unrelated umbilical cord blood transplantation and a second smaller portion cord blood graft infusion on Day 42.
3054604|NCT00775944|Active Comparator|Standard support|Standard 'Together Programme' telephone support for smoking cessation & advice to obtain nicotine addiction treatment
3054605|NCT00775944|Active Comparator|Proactive telephone support|Proactive support & advice to obtain nicotine addiction treatment
3054606|NCT00775944|Active Comparator|Standard support & offer NRT|Reactive telephone support (i.e. Together Programme) and offer of voucher for cost free Nicotine Replacement Therapy
3054607|NCT00775944|Active Comparator|Proactive support & offer NRT|Proactive telephone support and offer of voucher for cost free NRT
3054608|NCT00775983|Active Comparator|laminaria|laminaria placed for cervical dilation; usual standard of care in study clinic
3054609|NCT00775983|Experimental|Dilapan-S|experimental treatment
3054610|NCT00776009|Experimental|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
3054611|NCT00776009|Active Comparator|Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg|Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
3054612|NCT00776009|Placebo Comparator|Placebo|Two Capsules taken orally once a day for 7 days
3054613|NCT00776230|Active Comparator|IC51 (~12 months post filling)|6 mcg (~12 months post filling)
3054614|NCT00776230|Active Comparator|IC51 (~18 months post filling)|6 mcg (~18 months post filling)
3054615|NCT00776230|Active Comparator|IC51 (~24 months post filling)|6 mcg (~24 months post filling)
3054616|NCT00776295|Experimental|adeno virus vectored p53|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
3054617|NCT00776594|Experimental|Group 1|Androgen Deprivation Therapy Plus Bevacizumab
3054618|NCT00776594|Experimental|Group 2|Androgen Deprivation Therapy Alone
3054619|NCT00776659||Observational|
3054620|NCT00776789|Experimental|skin to skin contact|Infants randomized to this group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. Mothers in both the groups received support for initiating breastfeeding, if required. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
3054621|NCT00776789|Experimental|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC. All mothers, regardless of the group allocation, were advised to give exclusive breastfeeding to their infants during the hospital stay. They were discouraged from giving supplemental feeds to their infants unless indicated by the duty registrar. All the mothers were counseled regarding the duration of exclusive breastfeeding at the time of discharge.
3054622|NCT00776919|Experimental|1|clindamycin / benzoyl peroxide gel
3054623|NCT00776919|Active Comparator|2|Clindamycin gel
3054624|NCT00776919|Active Comparator|3|BPO gel
3054625|NCT00776919|Placebo Comparator|4|vehicle gel
3054626|NCT00776984|Experimental|tiotropium 5mcg/day|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3054627|NCT00776984|Experimental|placebo|patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
3054628|NCT00776997|Other|Magnetic Sphincter Augmentation|Single-arm study: all subjects were treated with magnetic sphincter augmentation. A subject's baseline measurements prior to sphincter augmentation were compared to post-sphincter augmentation measurements. Subjects served as their own control.
3054629|NCT00777023|Experimental|G-ER 1200 mg|Gabapentin extended-release (G-ER) 1200 mg
3054630|NCT00777023|Experimental|G-ER 1800 mg|Gabapentin extended-release (G-ER) 1800 mg
3054631|NCT00777023|Placebo Comparator|Sugar Pill|Placebo 1200 mg or 1800 mg
3054632|NCT00777036|Experimental|Cohort 1: Imatinib-resistant/intolerant CP-CML|"Dasatinib 60 mg/m² tablet every day (QD) [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFSO) QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3054633|NCT00777036|Experimental|Cohort 2: Ph+ALL or AP- or BP-CML|"Dasatinib 80 mg/m² tablet QD [with a maximum dose of 140 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFSO QD [with a maximum dose of 170 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3054634|NCT00777036|Experimental|Cohort 3: Newly diagnosed, treatment naïve CP-CML|"Dasatinib 60 mg/m² tablet QD [with a maximum dose of 100 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFSO QD [with a maximum dose of 120 mg QD for subjects with high BSA] for minimum of 24 months, may continue as long as deriving clinical benefit"
3054635|NCT00777049|Experimental|ER+ and/or PgR+ (Arm I)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
3054636|NCT00777049|Experimental|ER- and PgR- (Arm II)|Panobinostat oral 40 mg (3 times a week) given every other week as part of a 28 day cycle.
3054637|NCT00777062|Experimental|1|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6
3054638|NCT00777062|Placebo Comparator|2|Placebo injection, 380 mg injection at the start of weeks 2 and 6.
3054639|NCT00777088|Experimental|Pipeline|Placement of Pipeline Embolization Device in the parent artery at the aneurysm location
3054640|NCT00777101|Experimental|Neratinib|
3054641|NCT00777101|Active Comparator|Lapatinib plus Capecitabine|
3054642|NCT00777153|Experimental|Cediranib 30mg|Cediranib 30mg
3054643|NCT00777153|Other|Cediranib 20mg + lomustine|Cediranib 20mg + lomustine
3054644|NCT00777153|Active Comparator|Lomustine and Placebo Cediranib|Lomustine and Placebo Cediranib
3054645|NCT00777179|Experimental|Vandetanib|
3054646|NCT00777179|Placebo Comparator|Placebo|
3054647|NCT00777205|Active Comparator|Enhanced Usual Care|Patients in the enhanced usual care arm received their usual mental health care, a copy of the Depression Helpbook, and bi-weekly study mailings with depression management tips.
3054648|NCT00777205|Experimental|Telephone-based peer support|Participants in the intervention arm received usual mental health care and biweekly study mailings. In addition, they had access to a telephone platform over which they could make free calls to their peer partner for mutual peer support over a 6-month period of time.
3054649|NCT00777257|Experimental|Study Group A|Tdap vaccine + placebo concomitantly on Day 0; Menactra® vaccine 28 days later
3054650|NCT00777257|Experimental|Study Group B|Tdap vaccine + Menactra® vaccine concomitantly on Day 0; placebo 28 days later
3054651|NCT00777257|Experimental|Study Group C|Menactra® vaccine + placebo concomitantly on Day 0; Tdap vaccine 28 days later
3054652|NCT00777296|Experimental|Cohort 1 - 280 mg ARIKACE™|Subjects in this cohort will receive 280 mg of ARIKACE™
3054653|NCT00777296|Placebo Comparator|Cohort 1 - Placebo|Subjects in this arm of cohort 1 will receive matching placebo
3054654|NCT00777296|Experimental|Cohort 2 - 560 mg ARIKACE™|Subjects in this cohort will receive 560 mg of ARIKACE™
3054655|NCT00777296|Placebo Comparator|Cohort 2 - Placebo|Subjects in this arm of cohort 2 will receive matching placebo
3054656|NCT00777335|Experimental|Panobinostat i.v.|
3054657|NCT00777335|Experimental|Panobinostat oral|
3179084|NCT00668941|Experimental|2|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will receive a cyclical regimen of teriparatide, in addition to alendronate. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an aption to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
3054658|NCT00777491|Experimental|5-FU and Cisplatin + BID Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction 5-fluorouracil, induction cisplatin, induction BID radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation 5-fluorouracil, consolidation cisplatin, consolidation BID radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine, adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
3054659|NCT00777491|Experimental|Gemcitabine + QD Irradiation|Within 8 weeks following pre-study transurethral resection (TUR) patients receive 2.5 weeks of induction chemoradiotherapy (induction gemcitabine and induction QD radiation therapy). Consolidation chemoradiotherapy begins 7-14 days following post-induction chemoradiotherapy endoscopic response evaluation. Patients achieving a complete response receive 1.5 weeks of consolidation chemoradiotherapy (consolidation gemcitabine and consolidation QD radiation therapy). Patients without a complete response undergo radical cystectomy. Outpatient adjuvant chemotherapy (adjuvant gemcitabine and adjuvant cisplatin) begins 4-5 weeks following the post-consolidation endoscopic evaluation or 8-12 weeks following radical cystectomy, and continues for 12 weeks.
3054660|NCT00777556|Experimental|DR-104|One tablet for emergency contraception
3054661|NCT00777608|Experimental|Donepezil 5-10 mg|There will be a 14 day period when all participants will receive placebo, followed by 5 mg donepezil, once daily for 14 days then titrated to 10 mg donepezil once daily for 70 days. Participants may then receive open-label donepezil for an additional 24 weeks.
3054662|NCT00777608|Placebo Comparator|Placebo|There will be a 14 day period when all participants will receive placebo. Participants will take placebo capsules orally, once daily for 84 days. Participants may then receive open-label donepezil for an additional 24 weeks.
3054663|NCT00777634||Binge eating disorder (BED)|Individuals who meet criteria for binge eating disorder.
3054664|NCT00777634||Without BED|Individuals who do not meet criteria for binge eating disorder.
3054665|NCT00777764|Experimental|Healthy Volunteers|Healthy participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and 1:1000, 1:100, 1:10 dilution and full concentrations of both omalizumab and omalizumab excipients.
3054666|NCT00777764|Experimental|Allergic Asthma Participants|Allergic asthma participants were tested sequentially in a skin prick test procedure with positive control (histamine 6 mg/mL), negative control (saline), and a succession of 1:1000, 1:100, 1:10 dilutions and full concentration of both omalizumab and omalizumab excipients.
3054667|NCT00777790|Experimental|Menactra® Group|Received Menactra® vaccine in Study MTA02
3054668|NCT00777790|Experimental|Menomune® Group|Received Menomune® vaccine in Study MTA02
3054669|NCT00777790|Experimental|Control Group|Meningococcal vaccine-naïve Control Group.
3054670|NCT00777803|Experimental|IncobotulinumtoxinA (Xeomin®/Bocouture®)|IncobotulinumtoxinA (Xeomin®/Bocouture®), 24 units; mode of administration: intramuscular injection.
3054671|NCT00777803|Active Comparator|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), 24 units; mode of administration: intramuscular injection.
3054672|NCT00777829|Experimental|zolpidem first, then placebo|Participants received one dose of zolpidem for one nap, then had a one week washout period, followed by once dose of placebo for one nap.
3054673|NCT00777829|Placebo Comparator|Placebo first, then zolpidem|Participants received one dose of placebo for one nap, then had a one week washout period, followed by once dose of zolpidem for one nap.
3054674|NCT00777855|Experimental|warfarin then warfarin plus rifampin|
3054675|NCT00777920|Experimental|Ambrisentan|Participants will receive ambrisentan 2.5 mg, 5 mg or 10 mg tablet orally once daily until such time as the investigator or participant chooses to stop ambrisentan treatment, ambrisentan becomes commercially available, or the sponsor stops the study.
3054676|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 5 mg|Participants received 1 Aliskiren/Amlodipine 300/5mg tablet + 1 Placebo to Aliskiren tablet once daily in the morning for 8 weeks.
3054677|NCT00777946|Experimental|Aliskiren 300 mg/Amlodipine 10 mg|Participants received 1 Aliskiren/Amlodipine 300/10 mg tablet + 1 Placebo to Aliskiren tablet orally once daily in the morning for 8 weeks.
3054678|NCT00777946|Active Comparator|Aliskiren 300 mg|Participants received 1 Aliskiren 300 mg tablet + 1 Placebo to Aliskiren/Amlodipine tablet orally once daily in the morning for 8 weeks.
3054679|NCT00778102|Experimental|1|
3054680|NCT00778102|Active Comparator|2|
3054681|NCT00778167|Experimental|Arm I (Enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.
3054682|NCT00778167|Experimental|Arm II (Enzyme inhibitor and monoclonal antibody therapy)|Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.
3054683|NCT00778258|Experimental|Milk-allergic; Non-consumption|Subjects in this arm reacted to the lowest baseline dose of baked milk (muffin) and will continue strict milk avoidance, returning for re-evaluation with laboratory tests at 12 and 24 months and baked milk challenge at 36 months. Individual participants may be challenged at 12 and or 24 months.
3054684|NCT00778258|Experimental|Tolerated Muffin, Reacted to Pizza|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin but react to ingesting the amount of baked milk in a standardized portion of pizza. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3054685|NCT00778258|Experimental|Reacted to Rice Pudding|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin and a standardized portion of pizza but react to a standardized dose of baked milk in rice pudding. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3054686|NCT00778258|Experimental|Reacted to Non-baked Milk|Subjects will be assigned to this arm, if they can tolerate ingesting a muffin, pizza and rice pudding but react to a standardized dose of non-baked milk. Within the arm, subjects will be randomized in 1:1 ratio to either return for re-evaluation at 6 months (Dose Escalation sub-arm) or 12 months (Maintenance sub-arm) to determine whether they might progress to ingesting higher amounts of baked milk protein.
3054687|NCT00778258|Experimental|Tolerant to Baked and Non-baked Milk|"Biological/Vaccine: Baked Milk At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.~Biological/Vaccine: Non-baked Milk Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk."
3054688|NCT00778258|No Intervention|Non-Interventional Comparison|Thirty subjects who fulfill inclusion criteria but are unwilling to participate in the full protocol will be enrolled as a comparison group to the active arms.
3054689|NCT00778310|Experimental|Concerta|The subject will be administered their usual dose of Concerta the morning of the FMRI scan in a double blind fashion
3054690|NCT00778310|Placebo Comparator|Placebo|The subject will be administered a placebo the morning of the FMRI scan in a double blind fashion
3054691|NCT00778336||Limb Ischemia|Patients presenting with limb ischemia for treatment
3054692|NCT00778336||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
3054693|NCT00778336||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
3054694|NCT00778336||Other Thrombotic Conditions|Patients presenting with thrombosed conditions other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment.
3054695|NCT00778375|Experimental|Clofarabine + Cytarabine + Decitabine|Clofarabine 20 mg/m^2 by vein (IV) as a 1- to 2-hour intravenous infusion daily for 5 days. Cytarabine 20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions. Decitabine 20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
3054696|NCT00778622|Experimental|A1|Normal Weight by Body Weight Index
3054697|NCT00778622|Experimental|A2|Overweight by Body Weight Index
3054698|NCT00778622|Experimental|A3|Obese by Body Weight Index
3054699|NCT00778648|Experimental|Juice Plus|
3054700|NCT00778648|Placebo Comparator|Placebo|
3054701|NCT00778817|Experimental|Arm II (Mitotane + IMC-A12)|Patients receive mitotane as in arm I and anti-IGF-1R recombinant monoclonal antibody IMC-A12 IV over 1 hour once every 2 weeks in the absence of disease progression or unacceptable toxicity.
3054702|NCT00778830|Experimental|Cetuximab plus FOLFIRI|
3054703|NCT00778830|Experimental|Cetuximab plus FOLFOX|
3054704|NCT00778869|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
3054705|NCT00778895|Experimental|Fluviral F1 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 1 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3054706|NCT00778895|Experimental|Fluviral F2 Group|Subjects 6 months to 3 years of age received if primed, 1 dose of formulation 2 of Fluviral vaccine at Day 0 and if unprimed, 2 doses of formulation 1 of Fluviral vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3054707|NCT00778895|Active Comparator|Vaxigrip Group|Subjects 6 months to 3 years of age received if primed, 1 dose of Vaxigrip vaccine at Day 0 and if unprimed, 2 doses of Vaxigrip vaccine at Day 0 and approximately Day 28. The vaccine was administered intramuscularly in the anterolateral part of the thigh (if the subject was less than 12 months) or in the deltoid region of the arm.
3054708|NCT00778921|Experimental|Amlodipine 10 mg|Amlodipine 10 mg
3054709|NCT00778921|Experimental|Aliskiren/Amlodipine 150/10 mg|Aliskiren/Amlodipine 150/10 mg
3054710|NCT00778921|Experimental|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg
3054711|NCT00778999|Active Comparator|Oral Contraceptive|Use of oral contraceptive pills prior to controlled ovarian stimulation
3054712|NCT00778999|No Intervention|Non-Oral Contraceptive|No use of oral contraceptive pills prior to controlled ovarian stimulation
3054713|NCT00779025|Active Comparator|MINE Alone|Female Personal Lubricant (PD-F-5254)
3054714|NCT00779025|Experimental|YOURS and MINE|Male Personal Lubricant (10855-096) used in conjunction with Female Personal Lubricant (PD-F-5254)
3054715|NCT00779103|Experimental|Histrelin Subcutaneous Implant (50 mg)|Subcutaneous implant designed to deliver histrelin continously for 12 months.
3054716|NCT00779116|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
3054717|NCT00779116|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
3054718|NCT00779142|Other|Methotrexate 25mg/ml|Methotrexate intravenous 25mg/ml: Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose to subjects with diabetic macular edema resistant to conventional therapies.
3054719|NCT00779155|Placebo Comparator|Inactive Resonator Therapy|Inactive magnetic resonance therapy
3054720|NCT00779155|Active Comparator|Active Resonator Therapy|active magnetic resonance therapy
3054721|NCT00779246|Active Comparator|1|Active surveillance cultures (ASC) (via nasal swabs) will be performed for all patients admitted to the medical intensive care unit (ICU) during the designated study period. All patients will be placed in contact isolation until nasal swabs return negative; otherwise will remain in isolation.
3054722|NCT00779246|Active Comparator|2|Chlorhexidine gluconate (CHG) cloths will be used to bathe patients daily instead of standard soap and water. Active surveillance cultures (ASC) will also be used in this arm, but results will be blinded and not used to determine whether patients should be in contact isolation.
3054723|NCT00779259|Active Comparator|Theophylline alone|baseline theophylline pharmacokinetics
3054724|NCT00779259|Active Comparator|Quinine alone|baseline quinine pharmacokinetics at steady state
3054725|NCT00779259|Experimental|Theophylline with steady state quinine|Theophylline pharmacokinetics in the presence of steady state quinine and quinine pharmacokinetics in the presence of theophylline.
3054726|NCT00779285|Experimental|Single-arm|Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles
3054727|NCT00779311|Experimental|Experimenal|All eligible patients will receive the mFOLFOX6 regimen at full dose followed by IV bevacizumab 5mg/kg on Day 1 of each treatment cycle. Sorafenib will be administered daily throughout treatment beginning on day 1
3054728|NCT00779324|Experimental|Amantadine|Amantadine 100 mg every morning and Noon
3054729|NCT00779324|Placebo Comparator|Placebo|Placebo tablets
3054730|NCT00779402|Experimental|Sipuleucel-T|Subjects received infusion of Sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3054731|NCT00779402|Placebo Comparator|Control|Subjects received infusion of control (autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen) at 2-week intervals, for a total of 3 infusions.
3054732|NCT00779467|Experimental|Bupivacaine with Neostimgine 8 mcg/ml|STUDY DRUG INFUSION WITH NEOSTIGMINE 8 MCG/ML
3054733|NCT00779467|Experimental|Bupivacaine and Neostigmine 4 mcg/ml|STUDY DRUG INFUSION CONC NEOSTIGMINE 4 MCG/ML
3054734|NCT00779467|Experimental|Bupivacaine with Neostigmine 2 mcg/ml|STUDY DRUG INFUSION NEOSTIGMINE 2 MCG/ML
3054735|NCT00779467|Active Comparator|BUPIVACAINE WITH FENTANYL 2 MCG/ML|Bupivacaine with fentanyl 2 mcg/ml. STANDARD INFUSION
3054736|NCT00779506|Experimental|Quetiapine Fumarate XR|Seroquel XR 400-800mg
3054737|NCT00779558|Active Comparator|Study drug|Heparin sulfate infusion at 10 units/kg/hour
3054738|NCT00779558|Placebo Comparator|Placebo|Placebo - normal saline infusion
3054739|NCT00779584|Experimental|MK-8776 10mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 10 mg/m^2 given as monotherapy as an intravenous (IV) infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054740|NCT00779584|Experimental|MK-8776 20mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 20 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054741|NCT00779584|Experimental|MK-8776 40mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 40 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054742|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054743|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 800mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 800 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054744|NCT00779584|Experimental|MK-8776 80mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 80 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054745|NCT00779584|Experimental|MK-8776 112mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 112 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054746|NCT00779584|Experimental|MK-8776 150mg/m^2+Gemcitabine 1000mg/m^2|Participants received MK-8776 150 mg/m^2 given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054747|NCT00779584|Experimental|MK-8776 200mg+Gemcitabine 1000mg/m^2|Participants received MK-8776 200 mg given as monotherapy as an IV infusion on Cycle 0 Day 1 and as combination therapy with gemcitabine 1000 mg/m^2 starting with Cycle 1 on Days 1 and 8 of a 21-day treatment cycle.
3054748|NCT00779675||Infliximab 5 mg/kg|
3054749|NCT00779701|Other|A|All subjects placed on insulin infusion.
3054750|NCT00779766|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix™ vaccine. Cervarix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3054751|NCT00779766|Placebo Comparator|Placebo Group|Subjects received 3 doses of placebo. Placebo was administered intramuscularly in the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3054752|NCT00779779||Rotarix Group|Subjects received 2 oral doses of Rotarix vaccine at an interval of at least 4 weeks between doses. The first dose was given from the age of 6 weeks and vaccination with both doses was to be completed by 24 weeks of age.
3054753|NCT00779857|Experimental|AtriCure LAA Exclusion System|AtriCure LAA Exclusion System
3054754|NCT00779870||1|healthy volunteers
3054755|NCT00779870||2|mild asthmatics
3054756|NCT00779870||3|moderately-severe asthmatics
3054757|NCT00779870||4|severe asthmatics
3054758|NCT00779909|Placebo Comparator|1- Placebo|placebo capsule once per day
3054759|NCT00779909|Experimental|2- Vitamin D3, 500 IU|vitamin D3, 500 IU capsule once per day
3054760|NCT00779909|Experimental|3- Vitamin D3, 2500 IU|vitamin D3, 2500 IU capsule once per day
3054761|NCT00779909|Experimental|4- Vitamin D3, 5000 IU|vitamin D3, 5000 IU capsule once per day
3054762|NCT00780026|Experimental|Strict Glycemic Control|strict glycemic control (80 to 110 mg/dl)
3054763|NCT00780026|No Intervention|Standard of Care Control|standard of care insulin dosing
3054764|NCT00780143|Experimental|Arm 1|Plitidepsin in combination with Cytarabine
3054765|NCT00780208|Other|Daytrana (methylphenidate patch)|Methylphenidate patch
3054766|NCT00780234|Experimental|Arm 1: pioglitazone|Current or former smokers receive 6 months of treatment with pioglitazone
3054767|NCT00780234|Placebo Comparator|Arm 2: placebo|Current or former smokers receive 6 months of treatment with placebo
3054768|NCT00780273|Experimental|Ankylos dental implants.|"3 Ankylos dental implants placed in platform switch configuration on one side of the mandible in support of a fixed restoration.~A total number of 19 subjects participated in this randomized, split mouth, masked, prospective, open, comparison, monocenter study. Participants were subjects with an edentulous mandible who recieved 3 implants on each side which were splinted for the delivery of a fixed prosthesis."
3054769|NCT00780273|Active Comparator|3i Prevail dental implants.|"Three 3i Prevail dental implants placed on the opposite side of the mandible from the Ankylos implants in support of fixed dental restoration.~After a baseline phase of 1 month the mandible sides of subjects were randomly assigned to one of the 2 parallel treatment groups: one side received ANKYLOS plus implants. The contralateral sde recieved Certain PREVAIL Implants. Abutments were installed and loaded immediately by a fixed temporary bridge. After 3 months the final prosthesis was incorporated."
3054770|NCT00780338|Experimental|1|Cohort 1: receives the Assets Getting To Outcomes intervention first. The AGTO intervention includes three types of assistance which are adapted to fit the needs and priorities of the individuals involved, as well as the inner and outer setting: (1) a manual of text and tools; (2) face-to-face training, and (3) onsite technical assistance (TA). These three types of assistance aim to improve the implementation process for each program. Two full-time, Maine-based staff, one with a master's and one with a bachelor's degree, provided AGTO tools, training, and TA to the intervention coalitions and programs during the two year intervention period. The tools are in the Search Institute-published manual, Getting To Outcomes with Developmental Assets: Ten steps to measuring success in youth programs and communities, which all intervention participants received.
3054771|NCT00780338|Active Comparator|2|Cohort 2: receives the Assets Getting To Outcomes intervention second, after Cohort 1 is done receiving the intervention.
3054772|NCT00780403|Active Comparator|RediTab/Zyrtec|Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference.
3054773|NCT00780403|Active Comparator|Zyrtec/RediTab|Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.
3054774|NCT00780416|Experimental|TRV/PEG/RBV|
3054775|NCT00780416|Active Comparator|PEG/RBV|
3054776|NCT00780442|Experimental|DCS|D-Cycloserine 50 mg is a partial glutamate agonist. Participants received DCS prior to cocaine cue exposure sessions.
3054777|NCT00780442|Placebo Comparator|Placebo|Saline comparator. Participants received placebo prior to cocaine cue exposure sessions.
3054778|NCT00780494|Experimental|bevacizumab+ carboplatin +capecitabine|Participants receive bevacizumab 15 mg/kg intravenously followed by carboplatin AUC 6 intravenously on Day 1 of a 21-day cycle, concurrently with capecitabine 850 mg/m2 twice-daily by mouth on Cycle Days 1-to-14, followed by a 1-week break.
3054779|NCT00780559|Other|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
3054780|NCT00780559|Other|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
3054781|NCT00780572|Experimental|Arm 1: ADE Alerts|Arm 1 is a random intervention group in which half of the patients admitted to the VASLCHCS during study time period will be randomly selected. Providers will see ADE alerts for all patient in the randomly selected experimental group
3054782|NCT00780572|No Intervention|Arm 2: Control/No Alerts|The second arm is the control. Alerts will not be displayed for these patients.
3054783|NCT00780676|Experimental|Dasatinib sensitivity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3054784|NCT00780676|Experimental|SRC pathway activity signature|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3054785|NCT00780676|Experimental|Dasatinib target index|Participants predicted to respond to Dasatinib (Sprycel) by predictive gene signature receive dasatinib 100 mg by mouth daily.
3054786|NCT00780676|Experimental|Selumetinib pathway predictor|Participants predicted to respond to selumetinib/AZD6244 by predictive gene signature (either MEK pathway activity predictor positive or MEK pathway predictor negative) receive selumetinib 75 mg by mouth twice daily (BID).
3054787|NCT00780715|Active Comparator|Gliclazide MR|
3054788|NCT00780715|Active Comparator|Sitagliptin|
3054789|NCT00780715|Active Comparator|Pioglitazone|
3054790|NCT00780715|Experimental|Metformin|
3054791|NCT00780741|Active Comparator|Immediate Office Probing|Probing to be performed in the office setting using topical anesthesia and infant restraint. Probing to be performed either the same day as randomization or within two weeks.
3054792|NCT00780741|Active Comparator|Deferred Facility Probing|Probing to be performed in a surgical facility under general anesthesia within four weeks after completion of the 26-week visit if any of the clinical signs persist.
3054793|NCT00780910|Experimental|MP-424|
3054794|NCT00780962|Experimental|N-Acetylcysteine group|Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
3054795|NCT00780962|Placebo Comparator|0.9% Sodium-chloride group|Subjects in this group will receive 500 cc Normal Saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 67 cc per hour of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
3054796|NCT00780975|Experimental|Arm 1|Aplidin (Plitidepsin)
3054797|NCT00781079|Experimental|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
3054798|NCT00781079|No Intervention|Care as Usual|Care as usual
3054799|NCT00781274|Experimental|MP-424|
3054800|NCT00781326|Other|Open Label Antidepressant|In Phase 1, all participants will be placed on antidepressant medication. In Phase 2, participants will continue with their antidepressant medication and also receive receive either nimodipine or placebo.
3054801|NCT00781365|No Intervention|Control|Patients in the control group will receive usual care from their primary care physicians at HealthPartners Medical Group clinics.
3054802|NCT00781365|Experimental|Telemonitors and pharmacy management|The telemonitoring intervention (TI) patients will receive a home blood pressure telemonitor and will work with a clinical pharmacist case manager to control elevated blood pressure. Patients will use their home telemonitors to read and send their blood pressures to their Pharmacist case manager, who will use phone meetings with the patient to make medication adjustments.
3054803|NCT00781391|Active Comparator|Warfarin/placebo edoxaban|Warfarin tablets plus placebo Edoxaban tablets
3054804|NCT00781391|Experimental|high dose edoxaban/placebo warfarin|Edoxaban tablets (60mg) plus warfarin placebo tablets
3054805|NCT00781391|Experimental|low dose edoxaban/placebo warfarin|Edoxaban tablets (30mg) plus warfarin placebo tablets
3054806|NCT00781456|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
3054807|NCT00781456|Placebo Comparator|Placebo|Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
3054808|NCT00781508|Experimental|sildenafil|Effect of oral administration of a single dose of sildenafil 50 mg on left ventricular filling pressures as evaluated 1 hr after sildenafil administration in patients with heart failure
3054809|NCT00781508|Placebo Comparator|placebo|Inactive placebo prepared to mimic the appearance of sildenafil.
3054810|NCT00781599|Active Comparator|1|Chantix for 3 months and Standard Counseling
3054811|NCT00781599|Experimental|2|Chantix for 3 months and Adherence Counseling
3054812|NCT00781768|Placebo Comparator|Standard PO (Zofran + Dexamethasone)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron (Zofran) 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion.
3054813|NCT00781768|Active Comparator|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
3054814|NCT00781859|Experimental|125µg Ocriplasmin|125µg intravitreal injection of ocriplasmin
3054815|NCT00781859|Placebo Comparator|Placebo|placebo intravitreal injection
3054816|NCT00781898|Active Comparator|Depot Naltrexone|
3054817|NCT00781898|Placebo Comparator|Placebo|
3054818|NCT00781911|Experimental|Carcinoid tumor|Participants with carcinoid tumor will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
3054819|NCT00781911|Experimental|Islet cell carcinoma|Participants with islet cell carcinoma will receive cixutumumab 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
3054820|NCT00781937|Experimental|Lira 3.0 mg|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide 3.0 mg, once daily, injected subcutaneously and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period. The starting dose of liraglutide was 0.6 mg, with weekly increments of 0.6 mg every 7 days until the target dose of 3.0 mg was reached
3054821|NCT00781937|Placebo Comparator|Placebo|A 12-week run-in period where screened subjects were treated with a low calorie diet. Randomised subjects (those who lost more than or equal to 5% of screening body weight) were treated with liraglutide placebo, once daily, injected subcutaneously for 56 weeks and instructed to follow a standard energy-restricted diet in the 56-week main trial period. Subjects discontinued treatment in the 12-week follow-up period
3054822|NCT00781950|Placebo Comparator|Placebo|Randomized, Blinded Controlled Arm of patients receiving placebo food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing a mixture of wheat and wheat bran to replace the flaxseed daily for one year.
3054823|NCT00781950|Experimental|Flaxseed|Randomized, Blinded group of patients that will be given food products (ie: bagels, muffins, bars, pasta, buns, and milled seeds) containing 30 g of milled flaxseed daily for one year
3054824|NCT00781963|Experimental|CBT-I|Manual-based cognitive behavioral therapy for insomnia (CBT-I) provided in 5 individual or group sessions by a non-clinician sleep coach.
3054825|NCT00781963|Active Comparator|Control|Non-directive sleep education provided in 5 group sessions by a health educator.
3054826|NCT00782067|Experimental|Midostaurin (PKC412)|Midostaurin was administered at a dose of 100 mg twice daily (bid) in continuous cycles of 28 days until disease progression, intolerable toxicity or withdrawal due to any cause, whichever occurred first.
3054827|NCT00782171|Active Comparator|Immediate Loading|SLActive dental implant(s) will be restored with a temporary restoration on the day of surgery.
3054828|NCT00782171|Active Comparator|Early Loading|Healing caps will be placed on the SLActive dental implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
3054829|NCT00782184|Experimental|ezetimibe/simvastatin 10/40|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, ezetimibe/simvastatin 10/40 was administered once daily in tablet form during the 6-week double-blind treatment period
3054830|NCT00782184|Active Comparator|atorvastatin 40 mg|Participants received 20 mg open-label atorvastatin during a 5-week run-in period. Following this run-in period, 40 mg atorvastatin was administered once daily in tablet form during the 6-week double-blind treatment period
3054831|NCT00782210|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3054832|NCT00782210|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3054833|NCT00782210|Placebo Comparator|Placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
3054834|NCT00782275|Experimental|bevacizumab and temsirolimus|"bevacizumab: given intravenously at a dose of 10mg/kg every 2 weeks (days 1 and 15)~temsirolimus: given intravenously at a dose of 25mg weekly on days 1, 8, 15, and 22~1 cycle=28-days~There were no dose reductions for bevacizumab allowed. If bevacizumab was held, the same dose would be used if treatment were resumed. If temsirolimus was held, the same or a reduced dose (15mg IV weekly) could be used upon resumption of therapy. Treatment was continued until the development of unacceptable toxicity or progression."
3054835|NCT00782288|Active Comparator|1|low dose 0.05mg digitoxin given once daily for 28 days
3054836|NCT00782288|Active Comparator|2|higher dose 0.1mg digitoxin daily for 28 days
3054837|NCT00782288|Placebo Comparator|3|placebo given daily for 28 days
3054838|NCT00782340|Active Comparator|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
3054839|NCT00782340|Placebo Comparator|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
3054840|NCT00782379|Experimental|Myeloablative Haploidentical Transplant|All patients will receive treatment using Fludarabine, Busulfan and Cyclophosphamide prior to receiving a haploidentical transplant followed by post-transplant cyclosphosphamide.
3054841|NCT00782418|Active Comparator|1|exenatide 5mcg
3054842|NCT00782418|Active Comparator|2|exenatide 1.5mcg
3054843|NCT00782418|Placebo Comparator|3|Placebo
3054844|NCT00782496|Experimental|Level1 Basic Meter Features|Adults with type 1 and type 2 diabetes use only basic features (Level 1) to test their blood. The CONTOUR meter has the basic features such as small meter size, easy to use , No Coding™ technology, 5-second test time, small sample size (0.6 µL), automatic control solution marking, 480 reading memory capacity.
3054845|NCT00782496|Experimental|Level 2 Advanced Meter Features|Adults with type 1 and type 2 diabetes additionally access and use more advanced meter features(Level 2)during blood glucose testing. The advanced features include ability to mark blood glucose values as obtained before or after meals or to set an audible reminder to test.
3054846|NCT00782509|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3054847|NCT00782509|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
3054848|NCT00782509|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3054849|NCT00782626|Experimental|everolimus|Patients rcvd oral everolimus 5.0 mg/m2/day for a 28-day treatment course up to a total of 12 courses (48 weeks) if a patient had stable disease except if toxicity was unacceptable. Two dose reductions were permitted (3.0 5.0 mg/m2/day and 2.0 mg/m2/day).
3054850|NCT00782639|Active Comparator|Iopamiro-370|
3054851|NCT00782639|Active Comparator|Visipaque 320|
3054852|NCT00782717|Experimental|NEVANAC|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
3054853|NCT00782717|Placebo Comparator|Nepafenac Vehicle|One drop three times a day starting on the day prior to cataract surgery (Day -1) and continuing on the day of surgery (Day 0) and for 90 days thereafter.
3054854|NCT00782756|Experimental|RT, with temozolomide and bevacizumab|This treatment regimen is novel in that it delivers the initial course of RT over 2 weeks instead of 6 weeks; also, the addition of bevacizumab during and after RT is a new approach.
3054855|NCT00782795|Active Comparator|Pioglitazone|30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
3054856|NCT00782795|Placebo Comparator|sugar pill (placebo)|1 sugar pill (placebo) taken once daily for 48 weeks.
3054857|NCT00782821|Active Comparator|Rabbit Antithymocyte Globulin (rATG)|Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.
3054858|NCT00782821|Experimental|RATG/Rituxan|Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.
3054859|NCT00782821|Experimental|RATG/Velcade|Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.
3054860|NCT00782821|Experimental|RATG/Rituxan/Velcade|"Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.~rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1."
3054861|NCT00783094|Experimental|Tadalafil 2.5 milligrams (mg)|2.5 mg tadalafil tablet by mouth once a day for 12 weeks followed by 5 mg tadalafil tablet by mouth once a day for 42 weeks.
3054862|NCT00783094|Experimental|Tadalafil 5 mg|5 mg tadalafil tablet by mouth once a day for 12 weeks then continue 5 mg tadalafil tablet by mouth once a day for 42 weeks.
3054863|NCT00783094|Placebo Comparator|Placebo|"Placebo tablet taken by mouth once a day for 12 weeks.~Then subjects may take 5 mg tadalafil tablet by mouth once a day for 42 weeks."
3054864|NCT00783198|Experimental|SCH 39641 6 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 6 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3054865|NCT00783198|Experimental|SCH 39641 12 Amb a 1-U|Participants receive Ambrosia artemisiifolia allergen extract (SCH 39641 12 Amb a 1-U) rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3054866|NCT00783198|Placebo Comparator|Placebo|Participants receive placebo matching ambrosia artemisiifolia allergen extract, rapidly dissolving tablets, administered once daily sublingually for approximately 52 weeks
3054867|NCT00783224|Placebo Comparator|Mometasone Furoate Placebo (PLAMF)|Placebo to mometasone furoate nasal spray, made to be indistinguishable from mometasone furoate nasal spray
3054868|NCT00783224|Placebo Comparator|Fluticasone Propionate Placebo (PLAFP)|Placebo to fluticasone propionate nasal spray, made to be indistinguishable from fluticasone propionate nasal spray
3054869|NCT00783224|Experimental|Mometasone Furoate (MF)|Mometasone furoate nasal spray 200 μg/day(QD)
3054870|NCT00783224|Active Comparator|Fluticasone Propionate (FP)|Fluticasone Propionate nasal spray 200 μg/day, twice per day (BID)
3054871|NCT00783263|Experimental|Rosuvastatin 5 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
3054872|NCT00783263|Active Comparator|Rosuvastatin 10 mg|Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
3054873|NCT00783263|Experimental|Rosuvastatin 10 mg + Ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
3054874|NCT00783263|Active Comparator|Rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
3054875|NCT00783289|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.
3054876|NCT00783289|Experimental|Benralizumab 25 mg|Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.
3054877|NCT00783289|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.
3054878|NCT00783289|Experimental|Benralizumab 200 mg|Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
3054879|NCT00783367|Experimental|Lenalidomide plus rituximab with dexamethasone|Lenalidomide-low dose dexamethasone plus rituximab
3054880|NCT00783432|Experimental|1|Astepro Nasal Spray (0.1% azelastine hydrochloride)
3054881|NCT00783432|Active Comparator|2|Astelin Nasal Spray (0.1% azelastine hydrochloride)
3054882|NCT00783614|Active Comparator|1|Start antiretroviral therapy (ART) immediately and initiate aspirin 325mg po daily
3054883|NCT00783614|Placebo Comparator|2|Start antiretroviral therapy (ART) immediately and initiate placebo pill daily
3054884|NCT00783614|Active Comparator|3|Defer antiretroviral therapy (ART) for 1 month and immediately initiate aspirin 325mg po daily
3054885|NCT00783614|Placebo Comparator|4|Defer antiretroviral therapy (ART) for 1 month and immediately initiate placebo pill daily
3054886|NCT00783692|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
3054887|NCT00783692|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
3054888|NCT00783705|Experimental|Arm I (inositol)|Patients receive oral inositol once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
3054889|NCT00783705|Experimental|Arm II (placebo)|Patients receive oral placebo once daily for 2 weeks and then twice daily for up to 6 months in the absence of unacceptable toxicity.
3054890|NCT00783718|Experimental|Vedolizumab|"In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase."
3054891|NCT00783718|Placebo Comparator|Placebo|In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.
3054892|NCT00783796|Experimental|2.25mm XIENCE V®|Patients receiving the 2.25 mm XIENCE V® stent
3054893|NCT00783835|Experimental|Methylphenidate|
3054894|NCT00783952|Other|1|Mixed venous oxygen saturation measurement obtained from blood drawn from a pulmonary artery catheter.Calculation of mixed venous oxygen saturation from the measurement of peripheral oxygen saturations using multiple Cerebral/Somatic Tissue Oximeter device probes
3054895|NCT00783965|Experimental|Arm I|Patients apply 0.1% tazarotene cream on months 0-12 and vehicle (placebo) on months 13-36 once daily to the chest.
3054896|NCT00783965|Experimental|Arm II|Patients apply, vehicle (placebo) on months 0-12 and 0.1% tazarotene cream on months 13-36 once daily to the chest.
3054897|NCT00784030|Other|Polycystic Kidney Disease Patients|Patients who present with polycystic kidney disease (PKD)
3054898|NCT00784030|Other|Healthy Patients|
3054899|NCT00784095|Experimental|Preparation and Completion|"Subjects in the first group (treatment) met with the facilitator three times for a period of forty-five minutes to one hour to discuss issues of life completion and preparation. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects discussed issues of heritage and legacy."
3054900|NCT00784095|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
3054901|NCT00784095|No Intervention|True Control|"Subjects in the third group (true control) were exposed to no intervention or attention control."
3054902|NCT00784134|Experimental|Alteplase|administration of alteplase via the intraventricular catheter
3054903|NCT00784134|Placebo Comparator|Saline Placebo|1 ml of normal saline administered via the intraventricular catheter
3054904|NCT00784147|Active Comparator|Ibalizumab 800 mg|every 2 weeks, combined with an Optimized Background Regimen
3054905|NCT00784147|Active Comparator|Ibalizumab 2000 mg|every 4 weeks, combined with an Optimized Background Regimen
3054906|NCT00784225|Experimental|Vitamin E + selenium placebo|vitamin E and selenium placebo daily for 7-12 years
3054907|NCT00784225|Experimental|Selenium + vitamin E placebo|selenium and vitamin E placebo daily for 7-12 years
3054908|NCT00784225|Experimental|Vitamin E + selenium|vitamin E and selenium placebo daily for 7-12 years
3054909|NCT00784225|Placebo Comparator|Vitamin E placebo + selenium placebo|vitamin E placebo and selenium placebo daily for 7-12 years
3054910|NCT00784238|Experimental|Paliperidone|Paliperidone Extended-Release (ER) oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
3054911|NCT00784277|Experimental|001|Tapentadol IR (CG5503) 50mg for 14 days
3054912|NCT00784277|Experimental|002|Tapentadol IR (CG5503) 75mg for 14 days
3054913|NCT00784277|Active Comparator|003|oxycodone IR 10mg for 14 days
3054914|NCT00784277|Placebo Comparator|004|placebo 1 capsule for 14 days
3054915|NCT00784277|Experimental|005|Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
3054916|NCT00784277|Active Comparator|006|oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
3054917|NCT00784277|Placebo Comparator|007|placebo Tablets and capsules 2 x a day for 28 days
3054918|NCT00784303|Experimental|DTC cohort|This arm will enroll participants with radioiodine (131 I)-refractory/resistant differentiated thyroid cancer.
3054919|NCT00784303|Experimental|MTC cohort|This arm will enroll participants with medullary thyroid cancer.
3054920|NCT00784368|Experimental|SFI (ITCZ Oral Solution Monotherapy)|Participants with deep-seated mycosis (Systemic Fungal Infection [SFI]) received itraconazole (ITCZ) oral solution in the dose range of 20 milliliter (ml) per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3054921|NCT00784368|Experimental|SFI (Switched Treatment)|Participants with SFI received 200 milligram (mg) twice daily itraconazole intravenous (into the vein) infusion (ITCZ-IV) for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3054922|NCT00784368|Experimental|FN (Switched treatment)|Participants with febrile neutropenia (FN) with suspected fungal infection received 200 mg twice daily ITCZ-IV for first 2 days followed by 200 mg per day ITCZ-IV up to 14 days. Participants then received ITCZ oral solution in the dose range of 20 ml per day to 40 ml per day for 12 weeks as per Investigator's discretion.
3054923|NCT00784459|Experimental|Treatment with Abatacept|Administration of Abatacept intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
3054924|NCT00784459|Placebo Comparator|Placebo|Administration of placebo (normal saline) intravenously 10 mg/kg every 2 weeks for 3 doses, followed by every 4 weeks for 2 doses.
3054925|NCT00784524|Experimental|LMI Vaccination + IL-2|Patients receiving allogeneic large multivalent immunogen breast cancer vaccine and aldesleukin.
3054926|NCT00784550|Experimental|ADVAIR DISKUS® inhlaer Plus SPIRIVA® HANDIHALER® inhaler|Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Plus Tiotropium Bromide 18 mcg QD
3054927|NCT00784550|Active Comparator|SPIRIVA® HANDIHALER® inhaler|Tiotropium Bromide 18mcg QD plus Placebo DISKUS BID
3054928|NCT00784563|Active Comparator|Continuous training|Aerobic walking using continuous heart rate training.
3054929|NCT00784563|Active Comparator|Interval training|Aerobic walking using interval heart rate training
3054930|NCT00784641|Experimental|Novel Bausch & Lomb Contact Lens|Novel Bausch & Lomb daily disposable contact lenses
3054931|NCT00784641|Active Comparator|SofLens|Bausch & Lomb SofLens daily disposable contact lenses
3054932|NCT00784641|Active Comparator|Acuvue|Johnson and Johnson 1-Day Acuvue Moist contact lenses
3054933|NCT00784654|Experimental|Lisdexamfetamine dimesylate (LDX)|Open-label 30, 50, or 70mg
3054934|NCT00784654|Placebo Comparator|Placebo|
3054935|NCT00784693|Experimental|Tanezumab|
3054936|NCT00784693|Placebo Comparator|Placebo|
3054937|NCT00784719|Experimental|Treatment 1|
3054938|NCT00784719|Experimental|Treatment 2|
3054939|NCT00784719|Experimental|Treatment 3|
3054940|NCT00784719|Experimental|Treatment 4|
3054941|NCT00784719|Active Comparator|Active comparator|
3054942|NCT00784719|Placebo Comparator|Placebo|
3054943|NCT00784758|Experimental|Fenzian Device|Subjects randomized to this arm will receive treatment with the Fenzian Device
3054944|NCT00784758|Sham Comparator|Sham Device|Subjects randomized to this arm will receive treatment with the sham device.
3054945|NCT00784784|Experimental|Influenza vaccine|Influenza vaccine, using Fluviral trivalent split virus vaccine
3054946|NCT00784784|Experimental|Antiviral prophylaxis|Zanamivir antiviral prophylaxis
3054947|NCT00784810|Experimental|Oxycodone/Naloxone Tablets|Oxycodone/Naloxone combination
3054948|NCT00784810|Active Comparator|Codeine/Paracetamol Tablets|Codeine/Paracetamol combination
3054949|NCT00784836|Experimental|Avonex|Avonex 30 mcg given subcutaneously, once weekly, for 18 months.
3054950|NCT00784849|Experimental|1|One arm diagnostic
3054951|NCT00784875|Experimental|Period A|2-week double-blind placebo lead-in period. Period A is the first of four 2-week treatment periods.
3054952|NCT00784875|Experimental|Period B|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period B is the second of four 2-week treatment periods.
3054953|NCT00784875|Experimental|Period C|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period C is the third of four 2-week treatment periods.
3054954|NCT00784875|Experimental|Period D|Patients will receive LY2624803, zolpidem or placebo in a sequence of four 2-week treatment periods. Period D is the fourth of four 2-week treatment periods.
3054955|NCT00784927|Experimental|Treatment|"Participants with symptomatic untreated low grade NHL will be treated according to a 28 day schedule for up to a maximum of 12 consecutive cycles:~375 mg/m^2 Rituximab IV on day 1. 20 mg Lenalidomide taken orally on days 1-21. 250 mg/m^2 Cyclophosphamide orally on days 1, 8, 15. 40 mg Dexamethasone orally on days 1, 8, 15, 22."
3054956|NCT00784979|No Intervention|CMVIG followed by PP|MMF or rapamycin was given with CMVIG for 4 weeks followed by plasmapheresis
3054957|NCT00785044||Group|No participants received any drug administration. No intervention conducted.
3054958|NCT00785213|Active Comparator|Rosiglitazone Alone|Baseline rosiglitazone pharmacokinetics.
3054959|NCT00785213|Experimental|Rosiglitazone with Steady State Quinine Sulfate|Rosiglitazone pharmacokinetics in the presence of steady state quinine sulfate.
3054960|NCT00785291|Active Comparator|Arm A (Paclitaxel)|Patients receive 90 mg/m^2 paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
3054961|NCT00785291|Experimental|Arm B (Nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15.
3054962|NCT00785291|Experimental|Arm C (Ixabepilone)|Patients receive ixabepilone IV over 60 minutes on days 1, 8, and 15. Patients may also receive 10 mg/kg bevacizumab IV over 30-90 minutes on days 1 and 15. (closed to accrual as of 7/18/11)
3054963|NCT00785486|Other|Midazolam alone|Baseline midazolam and 1-hydroxy-midazolam pharmacokinetics. One day 1 after a fast of at least 10 hours patients received a single oral dose of midazolam 2 mg. Blood was drawn at times sufficient to characterize the pharmacokinetics of midazolam and its main metabolite.
3054964|NCT00785486|Other|Qualaquin (quinine) alone steady state|On the morning of day 9 after taking Qualaquin (quinine) capsules 324 mg orally every 8 hours for the prior 5 days, and following a fast of at least 10 hours all study participants received their usual morning dose of Qualaquin (quinine) 324 mg. Blood was drawn at times sufficient to determine the steady state Cmax and AUC 0-tau for Qualaquin (quinine).
3054965|NCT00785486|Experimental|Midazolam with Qualaquin (quinine)|On day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen, all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg. Blood was drawn sufficient to characterize the steady state kinetics of quinine and the kinetics of midazolam and 1-hydroxy-midazolam in the presence of each other.
3054966|NCT00785512|Active Comparator|1|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
3054967|NCT00785512|Placebo Comparator|2|Matching placebo tablets, oral administration
3054968|NCT00785538|Experimental|IMC-A12|All participants will receive intravenous (I.V.) infusions of IMC-A12, with the dose depending on which cohort they are enrolled into. A minimum of three participants will be enrolled in each cohort. When all participants complete a cohort, dose escalation to the next cohort will occur.
3054969|NCT00785577|Placebo Comparator|Placebo|LY545694 placebo twice daily (BID) oral (po) for 5 weeks and pregabalin placebo capsules thrice daily (TID) po for 6 weeks
3054970|NCT00785577|Active Comparator|Pregabalin|"Pregabalin thrice daily (TID) oral for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
3054971|NCT00785577|Experimental|LY545694 21 mg|"LY545694 21 milligrams (mg) BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
3054972|NCT00785577|Experimental|LY545694 49 mg|"LY545694 escalated to 49 mg BID po during Week 2; possible titration down to 21 mg BID po within 1 week of escalation for remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
3054973|NCT00785577|Experimental|LY545694 105 mg|"LY545694 escalated to 105 mg BID po during Week 3 through Week 5; possible titration down to 49 mg BID po within 1 week of escalation for the remainder of study treatment.~Pregabalin placebo TID po for 6 weeks"
3054974|NCT00785629|Active Comparator|Calcium Acetate|667 mg with meals
3054975|NCT00785629|Active Comparator|Lanthanum Carbonate|500 mg with meals
3054976|NCT00785629|Active Comparator|Sevelamer Carbonate|800 mg with meals
3054977|NCT00785629|Placebo Comparator|Placebo|with meals
3054978|NCT00785707||cochlear implant|children less than 24 months at time of cochlear implantation
3054979|NCT00785772|Experimental|1: Patients with Cleatinine Clearance (CLcr) 5-14 mL/min|
3054980|NCT00785772|Experimental|2: Patients with CLcr 15-29 mL/min|
3054981|NCT00785772|Experimental|3: Patients with CLcr 30-59 mL/min|
3054982|NCT00785785|Experimental|Nilotinib|nilotinib 400 mg twice a day
3054983|NCT00785785|Active Comparator|Imatinib|imatinib 400 mg once daily
3054984|NCT00785798|Experimental|vorinostat doxil|Escalating doses of vorinostat 200mg to 400mg twice daily on days 1-7, and fixed-dose IV PLD 30mg/m2 on day 3 of a 21-day cycle
3054985|NCT00785928|Experimental|Placebo|
3054986|NCT00785928|Experimental|1 mg LY2127399|
3054987|NCT00785928|Experimental|3 mg LY2127399|
3054988|NCT00785928|Experimental|10 mg LY2127399|
3054989|NCT00785928|Experimental|30 mg LY2127399|
3054990|NCT00785928|Experimental|60 mg LY2127399|
3054991|NCT00785928|Experimental|120 mg LY2127399|
3054992|NCT00785980|Active Comparator|Quinine Sulfate|Baseline quinine sulfate pharmacokinetics
3054993|NCT00785980|Experimental|Quinine Sulfate with Ciprofloxacin|Quinine sulfate pharmacokinetics in the presence of steady state ciprofloxacin
3054994|NCT00786019|Experimental|Ascorbic acid|All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
3054995|NCT00786032||BCI Device|All participants will use the BCI System as a means of communication.
3054996|NCT00786188|Experimental|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg.
3054997|NCT00786188|Placebo Comparator|Placebo - Sugar Pill|Eligible subjects will be randomized to receive a sugar pill.
3054998|NCT00786409|Other|Gardasil|30 patients will receive 0.5 ml Gardasil vaccine at months 0,2, and 6.
3054999|NCT00786422|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|
3055000|NCT00786474|Placebo Comparator|Placebo|
3055001|NCT00786474|Experimental|Dalteparin|
3055002|NCT00786487|Experimental|lipid trained|20% lipid infusion in trained subjects
3055003|NCT00786487|Active Comparator|glycerol trained|glycerol infusion into trained subjects
3055004|NCT00786487|Experimental|lipid untrained|lipid infusion into untrained subjects
3055005|NCT00786487|Active Comparator|glycerol untrained|glycerol infusion into untrained subjects
3055006|NCT00786565|Experimental|Advanced Akreos Adapt|Advanced Akreos Adapt Aspheric Intraocular Lens (IOL).
3055007|NCT00786565|Experimental|Akreos Adapt|Akreos Adapt Spherical Intraocular Lens (IOL).
3055008|NCT00786643|Experimental|Stratum 1|Patients in stratum 1 have not received prior chemotherapy in the metastatic setting.
3055009|NCT00786643|Experimental|Stratum 2|Patients in stratum 2 have received 1-2 prior chemotherapy regimens in the metastatic setting.
3055010|NCT00786799|Active Comparator|Omega-3 Fatty Acids|
3055011|NCT00786799|Placebo Comparator|Placebo|
3055012|NCT00786825|Experimental|somatostatin|Type 1 diabetes and Hypoglycemia unawareness
3055013|NCT00786825|No Intervention|2|Healthy control subjects
3055014|NCT00786838|Experimental|Trabectedin|3-hour placebo intravenous infusion on Day 1 and trabectedin 1.3 mg/m2 3-hour intravenous infusion on Day 2 (single-blind). Patients may continue treatment with trabectedin until clinical benefit or drug is commercially available (open-label).
3055015|NCT00786864|Experimental|1. Experimental Group|Exercise Intervention Group
3055016|NCT00786864|No Intervention|2. Control Group|Control group - no intervention
3055017|NCT00786916|Placebo Comparator|Group A|Saline
3055018|NCT00786916|Active Comparator|Group B|Lidocaine 0.25 mg/kg
3055019|NCT00786916|Active Comparator|Group C|Lidocaine 0.5 mg/kg
3055020|NCT00786994|Experimental|1|Oleogel-S10 100 mg/g ointment for three months once a day (54 patients)
3055021|NCT00786994|Experimental|2|Oleogel-S10 100 mg/g ointment for three months twice a day (54 patients)
3055022|NCT00786994|Placebo Comparator|3|Placebo (petroleum jelly) for three months once a day (27 patients)
3055023|NCT00786994|Placebo Comparator|4|Placebo (petroleum jelly) for three months twice a day (27 patients)
3055024|NCT00787020||Ventriculostomy Open|Subjects are treated with near continuous cerebrospinal fluid (CSF) diversion by positioning the stopcock in the open position and the intracranial pressure (ICP) is monitored once each hour: CSF drains into an external ventricular drainage bag.
3055025|NCT00787020||Ventriculostomy Monitored|Subjects are treated with intermittent cerebrospinal fluid (CSF) diversion. Intracranial pressure (ICP) is monitored and CSF is drained only when the ICP exceeds a threshold dictated by the attending physician.
3055026|NCT00787137|Experimental|PG102 0.3 mg/kg|Lowest dose PG102
3055027|NCT00787137|Experimental|PG102 1 mg/kg|Second dose PG102
3055028|NCT00787137|Placebo Comparator|Placebo (phosphate-buffered saline)|Control
3055029|NCT00787150|Experimental|Apixaban 5mg BID|
3055030|NCT00787150|Experimental|Apixaban 2.5mg BID|
3055031|NCT00787150|Active Comparator|Warfarin|
3055032|NCT00787189|Active Comparator|The Hearing Laser|Active low level laser light therapy of 635 nanometers (nm)
3055033|NCT00787189|Placebo Comparator|Placebo Laser|inactive low level laser light therapy with no therapeutic output
3055034|NCT00787202|Experimental|15 mg BID|
3055035|NCT00787202|Experimental|10 mg BID|
3055036|NCT00787202|Experimental|3 mg BID|
3055037|NCT00787202|Experimental|0.5 mg BID|
3055038|NCT00787202|Placebo Comparator|Placebo|
3055039|NCT00787241||Mild preeclampsia|Preeclampsia without eclampsia or HELLP syndrome
3055040|NCT00787241||Severe preeclampsia|Severe preeclampsia with eclampsia and/or HELLP syndrome
3055041|NCT00787241||Mild preeclampsia superimposed on chronic hypertension|Mild preeclampsia in association with chronic hypertension
3055042|NCT00787254|Experimental|Lansoprazole 15 mg QD|
3055043|NCT00787254|Active Comparator|Gefarnate 50 mg BID|
3055044|NCT00787267|Experimental|Dasatinib|"After a biopsy is done to obtain fresh frozen tumor tissue (Stage I), dasatinib is to be administered as an oral dose of 70 mg twice daily on a continuous basis for 6 weeks. Every 6 weeks radiologic exam will be done to assess response. Treatment will continue until progression of disease, intolerable toxicity or patient withdrawal.~For Stage II, a biopsy to obtain fresh frozen tumor tissue will also be done. Depending on results from Stage I and results of biopsy, treatment with dasatinib will be determined."
3055045|NCT00787319||AMD|
3055046|NCT00787332|Experimental|Desirudin|Patients with suspected HIT without thrombosis syndrome (HIT/TS), randomized to SC Desirudin
3055047|NCT00787332|Active Comparator|Argatroban®|Patients randomized to IV Argatroban®
3055048|NCT00787527|Experimental|Zolinza + CHOP|Zolinza (vorinostat) + CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
3055049|NCT00787566|Experimental|0.5 mg of TRG (intranasal granisetron)|0.5 mg dose, intranasal powder, single spray, administered once
3055050|NCT00787566|Experimental|1.0 mg of TRG (intranasal granisetron)|1.0 mg dose, intranasal powder, songle spray, administered once
3055051|NCT00787566|Experimental|2.0 mg of TRG (intranasal granisetron)|2.0 mg dose, intranasal powder, single spray, administered once
3055052|NCT00787605|Active Comparator|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
3055053|NCT00787605|Experimental|Aliskiren / HCTZ|Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
3055054|NCT00787644|Active Comparator|1|
3055055|NCT00787644|Placebo Comparator|2|
3055056|NCT00787722|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation will be performed after conditioning regimen of cyclophosphamide, G-CSF, Mesna, rATG, rituximab, and methylprednisolone.
3055057|NCT00787761|Experimental|ATG, Cytoxan, Bu/Flu based Allogeneic Transplant|All patients will receive an ATG, Cyclosphosphamide, Busulfan and Fludarabine based Allogeneic Transplant
3055058|NCT00787787|Experimental|Treatment (sunitinib malate and capecitabine)|Patients receive sunitinib malate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence or disease progression or unacceptable toxicity.
3055059|NCT00787800|Active Comparator|Dual Chamber ICD|Dual chamber Implantable Cardioverter-Defibrillator (ICD): Atrial therapies and minimized ventricular pacing will be programmed on along with Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation.
3055060|NCT00787800|Active Comparator|Single Chamber ICD|Single chamber Implantable Cardioverter-Defibrillator: Optimally programmed Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) detection and therapies will be programmed on including use of detection enhancements.
3055061|NCT00787839||Group 1|Atlanta VA Medical Center patients who meet criteria for screening for prediabetes and early diabetes based on standard guidelines of the VA, the American Diabetes Association, and the National Institutes of Health
3055062|NCT00787852|Experimental|Group 1: Radiation, Paclitaxel, Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
3055063|NCT00787852|Experimental|Group 2: Radiation, Paclitaxel, carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
3055064|NCT00787891|Experimental|Rabeprazole 0.5 mg/kg|rabeprazole 0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
3055065|NCT00787891|Experimental|Rabeprazole 1.0 mg/kg|rabeprazole 1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
3055066|NCT00787904||Surgical Menopause|Pre-menopausal women undergoing total hysterectomy with oophorectomy rendering them post-menopausal
3055067|NCT00787904||Surgical Control|Pre-menopausal women undergoing abdominal surgery but without ovary removal
3055068|NCT00787904||Healthy|Healthy matched pre-menopausal controls
3055069|NCT00787930||Manic Subject with DWM Hyperintensities >2|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid) who had a BOYKO DWM Hyperintensity rating >2 and a YMRS <15 at week 3.
3055070|NCT00787930||Manic Subjects with DWM Hyperintensities <3|Subjects with acute mania who were treated with naturalistic protocol (starting with valproic acid)who had a BOYKO DWM Hyperintensity rating <3 and a YMRS <15 at week 3.
3055071|NCT00787943|Experimental|Left side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to left side of the face.
3055072|NCT00787943|Experimental|Right side of face|Topical benzoyl peroxide 10.0% cream - Formulation 2 or Topical benzoyl peroxide 10.0% cream - Formulation 1 is to be applied to right side of the face.
3055073|NCT00788008|Active Comparator|1|Inhalational anesthesia with isoflurane
3055074|NCT00788008|Active Comparator|2|total intravenous anesthesia with propofol
3055075|NCT00788073|Active Comparator|STX209|STX209 variable dose from 1mg bid to 10mg tid, capsule, oral, 4 weeks
3055076|NCT00788073|Placebo Comparator|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
3055077|NCT00788151|Experimental|CYD Dengue vaccine group|Participants received three injections of the CYD Dengue vaccine at 0, 6, and 12 months. Participants were followed for 6 months after the last vaccination (up to 18 months).
3055078|NCT00788151|Placebo Comparator|Control group|Participants received two injections of placebo, and one injection of pneumococcal polysaccharide vaccine (Pneumo23®) at 0, 6, and 12 months, respectively. Participants were followed for 6 months after the last vaccination (up to 18 months).
3055079|NCT00788255||All participants|"For each patient, 1 solution with citrated whole blood (control) and 3 solutions with citrated whole blood and exogenous oxytocin were prepared in separate vials using micropipettes as follows:~Citrated whole blood 1mL + 23μU oxytocin: final exogenous oxytocin concentration=22.5 μU/mL Citrated whole blood 1mL + 31μU oxytocin: final exogenous oxytocin concentration=30.1μU/mL Citrated whole blood 1mL + 34μU oxytocin: final exogenous oxytocin concentration=32.9μU/mL~After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation."
3055080|NCT00788372|Experimental|Fentanyl|Fentanyl transdermal patch will be applied once daily up to 4 weeks in Treatment period 1, releasing at the rate of 12.5 microgram per hour (mcg/hr), maintained for 2 days and for another 48 weeks in Treatment period 2. The dose will be increased as per Investigators' discretion in both treatment periods and the maximum applied dose will be 300 mcg/hr. Total duration of treatment is 52 weeks.
3055081|NCT00788593|Placebo Comparator|Placebo|
3055082|NCT00788593|Experimental|EUR-1008 (APT-1008) High Dose|
3055083|NCT00788593|Experimental|EUR-1008 (APT-1008) Low Dose|
3055084|NCT00788697|Other|Patients who received SonoVue|"Patients with at least 1 target lesion requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US): procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard"
3055085|NCT00788710|Experimental|Etoricoxib 120 mg|etoricoxib (MK0663) 120 mg (2 60 mg tablets) and 1 placebo tablet once daily on Days 1-5. Total treatment is 5 days.
3055086|NCT00788710|Experimental|Etoricoxib 90 mg|etoricoxib (MK0663) 90 mg tablet and 2 placebo tablets once daily on Days 1-5. Total treatment is 5 days.
3055087|NCT00788710|Placebo Comparator|Placebo|Placebo- 3 tablets once daily
3055088|NCT00788775|Experimental|Nilotinib|Nilotinib was given at a dose of 400 mg orally daily (200 mg pills twice per day). Patients received treatment up to 12 months as long as they were receiving clinical benefit.
3055089|NCT00788827|Experimental|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
3055090|NCT00788892|Experimental|Arm A: CPX-351|First induction: CPX-351 at 100u/m2 administered on days 1, 3 and 5 Second induction: CPX-351 at 100u/m2 administered on days 1 and 3 Consolidation: CPX-351 at 100u/m2 administered on days 1 and 3
3055091|NCT00788892|Active Comparator|Arm B: Cytarabine + Daunorubicin|First induction: Cytarabine at a dose of 100mg/m2/day on days 1-7, Daunorubicin at dose of 45 or 60mg/m2 on days 1-3 Second induction: Cytarabine at a dose of 100mg/m2/day on days 1-5, Daunorubicin at a dose of 45 or 60 mg/m2/day on days 1 and 2 Consolidation: Investigator's Choice
3055092|NCT00788957|Experimental|Part 1: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3055093|NCT00788957|Active Comparator|Part 2: Panitumumab Alone|Participants received panitumumab 6 mg/kg and placebo by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3055094|NCT00788957|Experimental|Part 2: Panitumumab + Rilotumumab|Participants received panitumumab 6 mg/kg and rilotumumab 10 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3055095|NCT00788957|Experimental|Part 2: Panitumumab + Ganitumab|Participants received panitumumab 6 mg/kg and ganitumab 12 mg/kg by intravenous infusion once every 2 weeks until progressive disease, intolerability, withdrawal, death or sponsor decision.
3055096|NCT00789074|Experimental|Varenicline pre-treatmemt|Participants will use varenicline (1mg BD) 4-weeks prior to quitting
3055097|NCT00789074|Placebo Comparator|Placebo|Participants will use 3 weeks of placebo, followed by 1 week of varenicline, prior to quitting
3055098|NCT00789113|Experimental|Extended Release Lamotrigine|Extended Release Lamotrigine
3055099|NCT00789191|Experimental|Comb|Combination therapy of insulin detemir once daily plus sitagliptin added to subject's own pre-trial metformin treatment
3055100|NCT00789191|Active Comparator|Sita|Monotherapy of sitagliptin once daily added to subject's own pre-trial metformin and/or sulphonylurea (SU) treatment
3055101|NCT00789256|Experimental|Study treatment|All patients will receive the following regimen: 1) Melphalan 2 mg orally, once daily. 2) Bortezomib 1.0 mg/M2 IV on days 1, 4, 8, 11.
3055102|NCT00789321|Experimental|1|amlodipine
3055103|NCT00789321|Placebo Comparator|2|Placebo to amlodipine
3055104|NCT00789360|Experimental|Inhaled Placebo crossed over to Inhaled Loxapine|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart; washout of at least 4 days; Inhaled Staccato Loxapine, 10 mg oses x 2, 8 hours apart
3055105|NCT00789360|Experimental|Inhaled Loxapine crossed over to Inhaled Placebo|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart; washout of at least 4 days; Inhaled Staccato Placebo, 2 inhalations, 8 hours apart;
3055106|NCT00789373|Experimental|pemetrexed + cisplatin followed by pemetrexed|pemetrexed plus cisplatin followed by pemetrexed plus best supportive care
3055107|NCT00789373|Placebo Comparator|pemetrexed + cisplatin followed by placebo|pemetrexed plus cisplatin followed by placebo plus best supportive care
3055108|NCT00789438||General Anesthesia|Patients undergoing short-term surgery (30-90 min) under general anesthesia
3055109|NCT00789438||Spinal|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia
3055110|NCT00789438||Spinal + Sedation|Patients undergoing short-term surgery (30-90 min) under spinal anesthesia with sedation
3055111|NCT00789477|Experimental|Intravitreal Aflibercept Injection .5Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) .5 mg every 4 weeks
3055112|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q4|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2 mg every 4 weeks
3055113|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2Q8|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by every 8 weeks
3055114|NCT00789477|Experimental|Intravitreal Aflibercept Injection 2PRN|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2mg every 4 weeks for 3 visits followed by PRN (as-needed) dosing according to the re-treatment criteria
3055115|NCT00789477|Active Comparator|Laser Photocoagulation|Focal laser at week 1, and one week after visits at which the participant met laser re-treatment criteria to the end of the study (week 52) starting at week 16; laser re- treatment was permitted no more than once every 16 weeks.
3055116|NCT00789529|Active Comparator|1|Opti-Free® RepleniSH® MPDS
3055117|NCT00789529|Active Comparator|2|Renu MultiPlus®
3055118|NCT00789555|Experimental|PATANASE|Olopatadine hydrochloride 0.6% nasal spray (PATANASE), two sprays in each nostril twice a day (morning and evening) for up to 12 months
3055119|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 3.7|Olopatadine nasal spray vehicle, pH 3.7, two sprays in each nostril twice a day (morning and evening) for up to 12 months
3055120|NCT00789555|Placebo Comparator|Patanase Vehicle, pH 7.0|Olopatadine nasal spray vehicle, pH 7.0, two sprays in each nostril twice a day (morning and evening) for up to 12 months
3055121|NCT00789581|Experimental|Doxorubicin/cyclophosphamide, ixabepilone|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by ixabepilone at 40 mg/m2 given for 4 cycles of 21 days each.
3055122|NCT00789581|Active Comparator|Doxorubicin/cyclophosphamide, paclitaxel|Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 administered for 4 cycles of 21 days each, followed by paclitaxel at 80 mg/m2 weekly for 12 weeks.
3055123|NCT00789672|Active Comparator|Lower Dose (3-1) levodopa/carbidopa|Oral levodopa 0.51 mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
3055124|NCT00789672|Active Comparator|Higher Dose (4.5-1) levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation) combined with 2 hours of daily patching, with a rapid taper of medication before a primary outcome exam 9 weeks after starting medication.
3055125|NCT00789685|Experimental|Interferon Beta|Interferon Beta
3055126|NCT00789698|Experimental|Lurasidone HC1|
3055127|NCT00789698|Active Comparator|Quetiapine|
3055128|NCT00789724|Experimental|Anakinra|Anakinra 100 mg given daily by subcutaneous injection for 14 days
3055129|NCT00789724|Placebo Comparator|Placebo|0.67 ml of NaCl 0.9% solution
3055130|NCT00789737|Experimental|Welchol|Welchol 625mg tablets
3055131|NCT00789737|Placebo Comparator|placebo|placebo
3055132|NCT00789750|Experimental|Colesevelam|Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
3055133|NCT00789750|Placebo Comparator|Placebo|Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
3055134|NCT00789776|Experimental|Treatment (non-myeloablative transplant)|"CONDITIONING: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total-body irradiation on day -1.~DONOR BONE MARROW TRANSPLANTATION: Patients undergo donor bone marrow transplantation on day 0.~POST-TRANSPLANTATION IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3 and mycophenolate mofetil PO TID on days 4 to 40, followed by a taper until day 84 in the absence of GVHD. Patients also receive tacrolimus IV continuously or IV QD over 1-2 hours or PO BID on days 4 to 84, followed by a taper until day 180 in the absence of GVHD.~NK CELL INFUSION: Patients undergo donor lymphocyte infusion of NK cells on day 7."
3055135|NCT00789802|Experimental|transdermal estradiol|participants will be randomized to transdermal estradiol
3055136|NCT00789802|Experimental|oral naproxen|participants will be randomized to oral naproxen
3055137|NCT00789802|Placebo Comparator|oral placebo|participants will be randomized to oral placebo
3055138|NCT00789815|Active Comparator|BIS-guided propofol infusion|In the study group, induction was started using alfentanil 4~5μg/kg bolus following repeated propofol boluses (0.5~1.5 mg/kg) until the BIS level reached 70. During maintenance, propofol infusion (3~12 mg/kg/hour) was given using a syringe pump (Injectomat Agilia, Fresenius Kabi, France), which was titrated to keep the BIS level between 65 and 75.
3055139|NCT00789815|Active Comparator|Clinical-judged midazolam administration|In the control group, induction was started using alfentanil 4~5μg/kg bolus following 2 mg midazolam bolus. After 2 minutes, if the patient was not well sedated, midazolam boluses were repeat by increments of 2 mg/2min until conscious sedation was achieved
3055140|NCT00789828|Experimental|Everolimus|Everolimus was administered orally at a starting dose of 4.5mg/m^2 daily and subsequently titrated to attain whole blood trough concentration of 5 to 15 ng/mL. Dose adjustments were permitted based on safety and whole blood trough concentrations.
3055141|NCT00789828|Placebo Comparator|Placebo|Matching Placebo administered orally.
3055142|NCT00789854|Active Comparator|Add-on Quetiapine XR+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or Venlafaxine from previous therapy + add-on treatment with quetiapine XR, 300mg tablet once daily (od).~From previous anti-depressant treatment 64% of the patients had SSRI and 35% had Venlafaxine at baseline."
3055143|NCT00789854|Active Comparator|Add-on Lithium+SSRI/Venlafaxine|"Selective serotonin reuptake inhibitors (SSRI) or venlafaxine from previous therapy + add-on treatment with lithium, approximately 900mg tablet once daily (od).~From previous anti-depressant treatment 67% of the patients had SSRI and 33% had Venlafaxine at baseline."
3055144|NCT00789854|Active Comparator|Monotherapy Quetiapine XR|Switch from previous treatment with SSRI or venlafaxine to quetiapine XR monotherapy, 300mg tablet once daily (od)
3055145|NCT00789867|Experimental|20ml pGM169/GL67A|Received a nebulized dose 20ml via an breath-actuated nebulizer
3055146|NCT00789867|Experimental|10ml pGM169/GL67A|Received a nebulized dose 10ml via an breath-actuated nebulizer
3055147|NCT00789867|Experimental|5ml pGM169/GL67A|Received a nebulized dose 5ml via an breath-actuated nebulizer
3055148|NCT00789880|Experimental|Vitamin D3|Subjects received a 21-day course of oral vitamin D3 (cholecalciferol, 4,000 international units [IU]
3055149|NCT00789880|Placebo Comparator|Placebo|Subjects received a 21-day course of oral vitamin D3-placebo
3055150|NCT00789958|Experimental|Adjuvant Chemo+ Chemoradiotherapy|"Adjuvant Chemotherapy~Capecitabine, 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Gemcitabine hydrochloride, 1000 mg/m^2, IV, Days 1 & 8 of each cycle~Chemoradiotherapy~-Capecitabine, 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT~Radiation (RT):~3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.~intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions."
3055151|NCT00789997|Experimental|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days.
3055152|NCT00789997|Active Comparator|Prednisone|prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg daily for 10 days.
3055153|NCT00790023|Experimental|80 mcg Ciclesonide|80 mcg Ciclesonide once daily
3055154|NCT00790023|Experimental|160 mcg Ciclesonide|160 mcg Ciclesonide once daily
3055155|NCT00790023|Placebo Comparator|Placebo|Placebo once daily
3055156|NCT00790036|Experimental|Everolimus|Participants who received Everolimus 10 mg (two 5 mg tablets), daily for 12 months
3055157|NCT00790036|Placebo Comparator|Placebo|Participants who received Everolimus placebo 10 mg (two 5 mg tablets), daily for 12 months
3055158|NCT00790062|Active Comparator|Oxytocin 10 units/500cc|1 dose only for prophylaxis given over 1 hour
3055159|NCT00790062|Experimental|Oxytocin 40 units/500cc|One dose only given over 1 hour. Per DSMB recommendations, this intermediate arm was stopped Jan 2010.
3055160|NCT00790062|Experimental|Oxytocin 80U/500cc|1 dose only given over 1 hour
3055161|NCT00790192|Experimental|Lurasidone 80mg|
3055162|NCT00790192|Experimental|Lurasidone 160mg|
3055163|NCT00790192|Active Comparator|Quetiapine XR|
3055164|NCT00790192|Placebo Comparator|Placebo|
3055165|NCT00790205|Experimental|Sitagliptin|Sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
3055166|NCT00790205|Placebo Comparator|Placebo|Placebo to sitagliptin tablet taken orally once daily in the morning for up to approximately 5 years.
3055167|NCT00790218|Experimental|CF102|An open-label trial (1, 5, and 25 mg BID) in 28-day cycles.
3055168|NCT00790270|Active Comparator|Cyclobenzaprine|
3055169|NCT00790270|Active Comparator|Ibuprofen|
3055170|NCT00790270|Experimental|Ibuprophen plus Cyclobenzaprine|
3055171|NCT00790296|Experimental|Thyrotropin releasing hormone (TRH)|TRH
3055172|NCT00790296|Placebo Comparator|Saline|Placebo
3055173|NCT00790335|Experimental|A-Intervention|PCDT with intrathrombus delivery of recombinant tissue plasminogen activator (rt-PA, maximum allowable total dose 35 mg) into the DVT over a period of up to 24 hours. Three methods of initial rt-PA delivery will be used: 1) Trellis-8 Peripheral Infusion System - maximum first-session rt-PA dose 25 mg; 2) AngioJet Rheolytic Thrombectomy System - maximum first-session rt-PA dose 25 mg; or 3) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole infusion catheter. Before and after PCDT, patients will receive standard DVT therapy as in the Control Arm
3055174|NCT00790335|No Intervention|B-Control|Initial anticoagulant therapy with unfractionated heparin, enoxaparin, dalteparin, or tinzaparin, for at least 5 days, overlapped with long-term oral warfarin (target international normalized ratio 2.0 - 3.0). Elastic compression stockings will be prescribed
3055175|NCT00790400|Experimental|Everolimus|Study drug was given by continuous oral daily dosing of two 5 mg tablets.
3055176|NCT00790400|Placebo Comparator|Placebo|Placebo was given by continuous oral daily dosing of two 5 mg tablets.
3055177|NCT00790556|Experimental|1|MK8245
3055178|NCT00790556|Placebo Comparator|2|Placebo Comparator
3055179|NCT00790569|Experimental|Arm I|Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
3055180|NCT00790569|Placebo Comparator|Arm II|Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
3055181|NCT00790569|Active Comparator|Arm III|Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
3055182|NCT00790582|Experimental|lithium carbonate|
3055183|NCT00790647|Experimental|Stem Cell Transplant with Bortezomib and Melphalan|Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion
3055184|NCT00790673|Experimental|1|CF102 1 mg qd
3055185|NCT00790673|Experimental|2|CF102 1 mg bid
3055186|NCT00790673|Experimental|3|CF102 1 mg bid; 16 weeks
3055187|NCT00790673|Placebo Comparator|5|
3055188|NCT00790699|Active Comparator|I-PORT|Treatment group
3055189|NCT00790699|Active Comparator|standard injections|control group
3055190|NCT00790738|Experimental|1|liothyronine (T3)
3055191|NCT00790738|Placebo Comparator|2|placebo
3055192|NCT00790751|Placebo Comparator|placebo|
3055193|NCT00790751|Experimental|avanafil 50 mg|
3055194|NCT00790751|Experimental|avanafil 100 mg|
3055195|NCT00790751|Experimental|avanafil 200 mg|
3055196|NCT00790790|Placebo Comparator|Placebo|Participants randomized to LY545694 placebo were given LY545694 placebo twice daily (BID) oral (po) for 5 weeks.
3055197|NCT00790790|Experimental|LY545694 49 mg|Participants randomized to LY545694 49 milligrams (mg) BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. Participants who were intolerant of this dose were titrated back down to 21 mg BID po for the remainder of study treatment.
3055198|NCT00790790|Experimental|LY545694 105 mg|Participants randomized to LY545694 105 mg BID po were first administered LY545694 21 mg BID po at Visit 3. After 1 week of dosing, participants were escalated to LY545694 49 mg BID po at Visit 4. At Visit 5, participants were titrated to the final dose of LY545694 105 mg BID po. Participants who were intolerant of this dose were titrated back down to LY545694 49 mg BID po for the remainder of study treatment.
3055199|NCT00790803|Other|Pegaptanib (Macugen)|Open label, non randomized, interventional controlled injection of 0.3mg of Pegaptanib (Macugen) every 6weeks with max of 5 injections over 30weeks.
3055200|NCT00790842|Experimental|Group A - CrCl 30-60 mL/min|Creatinine clearance 30 - 60 mL/min, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
3055201|NCT00790842|Experimental|Group B, CrCl < 30 mL/min|Creatinine clearance < 30 mL/min, not on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
3055202|NCT00790842|Experimental|Group C, CrCl < 30 mL/min, on dialysis|Creatinine clearance < 30 mL/min and on dialysis, lenalidomide dose determined in phase I, dexamethasone 40 mg orally days 1, 8, 15 and 22 of a 28 day cycle, and anticoagulants.
3055203|NCT00790855|Experimental|Bendamustine|Starting dose 50 mg/m^2 intravenously over 2 hours twice on Days 1-4 of every 4 week study cycle.
3055204|NCT00790868|Experimental|D-cycloserine|DCS-augmented CBT
3055205|NCT00790868|Placebo Comparator|Placebo|placebo-augmented CBT
3055206|NCT00790907|Experimental|Open label fondaparinux background and standard dose UFH|Subjects indicated for PCI and randomized to receive standard dose UFH
3055207|NCT00790907|Experimental|Open label fondaparinux background and low dose UFH|Subjects indicated for PCI and randomized to receive low dose UFH
3055208|NCT00790907|Other|Open label fondapaparinux|Subjects not indicated for PCI and not randomized
3055209|NCT00790933|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, 30-minute intravenous (IV) infusion every 4 weeks, starting at Week 0 for approximately up to 510 weeks.
3055210|NCT00791037|Experimental|Treatment (vaccine therapy)|"Patients receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. Beginning 2 weeks later, patients undergo leukapheresis to isolate and collect peripheral blood mononuclear cells for T-cell expansion.~Patients receive cyclophosphamide IV once on day -1 and autologous ex vivo-expanded HER2-specific T cell IV over 30 minutes on day 1. Treatment repeats every 7-10 days for up to three immunizations. Patients receive a booster HER2/neu peptide vaccine 1 month after the final T-cell infusion, followed by 2 additional booster vaccines at 2-month intervals."
3055211|NCT00791089|Experimental|Fish Oil, Ablation, Sinus Rhythm|Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
3055212|NCT00791089|Placebo Comparator|placebo, Ablation, sinus rhythm|Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.
3055213|NCT00791102|Active Comparator|1|Topical ASP-1001
3055214|NCT00791102|Placebo Comparator|2|Placebo for Topical ASP-1001
3055215|NCT00791128|Experimental|EndoBarrier GI Liner|22 patients were implanted with the GI Liner for a 52-week duration. Assessments were performed during the 6 months post-explant period.
3055216|NCT00791219|Experimental|Test|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
3055217|NCT00791219|Active Comparator|Reference|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
3055218|NCT00791219|Placebo Comparator|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
3055219|NCT00791258|Experimental|1|Azor tablets and hydrochlorothiazide tablets (if necessary) will be administered for up to 20 weeks
3055220|NCT00791323|Active Comparator|1|Ketorolac 0.4%
3055221|NCT00791323|Active Comparator|2|Mineral Oil Emollient
3055222|NCT00791388|Placebo Comparator|placebo|placebo capsule
3055223|NCT00791388|Experimental|50 mg PG 760564|50 mg PG 760564 active
3055224|NCT00791388|Experimental|100 mg PG 760564|100 mg PG 760564 active
3055225|NCT00791388|Experimental|200 mg PG 760564|200 mg PG 760564 active
3055226|NCT00791388|Experimental|400 mg PG 760564|400 mg PG 760564 active
3055227|NCT00791479|Experimental|0.1 milligram (mg) LY2189265|LY2189265: 0.1 milligram (mg), subcutaneous (SC), once weekly (QW)
3055228|NCT00791479|Experimental|0.5 milligram (mg) LY2189265|LY2189265: 0.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3055229|NCT00791479|Experimental|1.0 milligram (mg) LY2189265|LY2189265: 1.0 milligram (mg), subcutaneous (SC), once weekly (QW)
3055230|NCT00791479|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3055231|NCT00791479|Placebo Comparator|Placebo|Placebo: subcutaneous (SC) once weekly (QW)
3055232|NCT00791492|Experimental|Fx-1006A|
3055233|NCT00791518||No group|No group
3055234|NCT00791557|Experimental|Infliximab|Single arm open label IV Infliximab given at weeks 1,2,14,22
3055235|NCT00791648|Experimental|statin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
3055236|NCT00791648|Placebo Comparator|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
3055237|NCT00791661|Experimental|Panel A: MK-1006 15/30/45|Participants received a single rising dose of MK-1006 (dosed at 15 mg, 30 mg, and 45 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3055238|NCT00791661|Experimental|Panel B: MK-1006 60/80/60 fed|Participants received a single rising dose of MK-1006 (dosed at 60 mg, 80 mg, and 60 mg fed state) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3055239|NCT00791661|Experimental|Panel C: MK-1006 100/140/170|Participants received a single rising dose of MK-1006 (dosed at 100 mg, 140 mg, and 170 mg) or matching placebo to MK-1006 with a 7-day wash-out period between doses. Participants could have received both MK-1006 and matching placebo to MK-1006 over the 3 treatment periods.
3055240|NCT00791700|Experimental|Maraviroc|"Subjects will be stratified by age and formulation into one of the following cohorts:~Cohort 1: ≥2-<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-<18 years of age, maraviroc tablet formulation."
3055241|NCT00791765|Experimental|Placebo BIW/Etanercept 50 mg BIW|Participants received placebo subcutaneous injections twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg BIW.
3055242|NCT00791765|Experimental|Etanercept 50 mg BIW/Etanercept 50 mg QW|Participants received etanercept 50 mg by subcutaneous injection twice per week (BIW) for the first 12 weeks of the study. From Week 12 to Week 24, participants received etanercept 50 mg once per week (QW) and placebo once per week.
3055243|NCT00791778|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 sorafenib tablets (200 mg each) per oral twice daily (bid)
3055244|NCT00791778|Placebo Comparator|Placebo|Participants received 2 matching placebo tablets per oral twice daily
3055245|NCT00791817|Experimental|200 mg PG 760564, Subjects Fasted|200 mg PG 760564, Subjects Fasted, single dose
3055246|NCT00791817|Experimental|200 mg PG 760564, Subjects Fed|200 mg PG 760564, Subjects Fed high fat meal
3055247|NCT00791908|Experimental|electrodessication (ED)|Treatment over 6 weeks using electrodessication (ED) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3055248|NCT00791908|Experimental|pulsed dye laser (PDL)|Treatment over 6 weeks using pulsed dye laser (PDL) to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3055249|NCT00791908|Experimental|potassium titanyl phosphate (KTP) laser|Treatment over 6 weeks using potassium titanyl phosphate (KTP) laser to remove cherry angiomas. Each participant received treatment with PDL, KTP laser, and electrodesiccation to separate randomly selected areas on the torso, with each area bearing 4 cherry angiomata.
3055250|NCT00791921|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks
3055251|NCT00791921|Placebo Comparator|Placebo|Placebo of CDP870
3055252|NCT00791934|Experimental|Stratus Microflow Ethmoid Spacer|Temporary implantation of Ethmoid spacer with Triamcinolone Acetonide for 28 days.
3055253|NCT00791973|Active Comparator|Veramyst, then Placebo|fluticasone furoate (Veramyst) nasal spray once daily for a week, then one week washout period followed by placebo nasal spray once daily for a week
3055254|NCT00791973|Active Comparator|Placebo, then Veramyst|placebo nasal spray once daily for a week, then one week washout period followed by fluticasone furoate (veramyst) nasal spray once daily for a week
3055255|NCT00791999|Experimental|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks
3055256|NCT00791999|Experimental|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks
3055257|NCT00791999|Experimental|CDP870 400mg|400mg CDP870 given every 2 weeks
3055258|NCT00791999|Placebo Comparator|Placebo|Placebo given every 2 weeks
3055259|NCT00792077|Experimental|Sleep time|"Assessment of patients with chronic lymphocytic leukemia (CLL) experience severe cancer related fatigue (CRF):~Lenalidomide + Actigraph + Questionnaire + Sleep Test"
3055260|NCT00792103|Experimental|NP101|sumatriptan iontophoretic transdermal patch
3055261|NCT00792116|Experimental|Gum Chewing|
3055262|NCT00792116|No Intervention|Non-gum chewing|
3055263|NCT00792142|Experimental|Treatment (stem cell transplant, maintenance treatment)|Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.
3055267|NCT00792298|Experimental|Suvorexant 10 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 10 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3055268|NCT00792298|Experimental|Placebo → Suvorexant 10 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 10 mg suvorexant daily prior to bedtime during Treatment Period 2.
3055269|NCT00792298|Experimental|Suvorexant 20 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 20 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3055270|NCT00792298|Experimental|Placebo → Suvorexant 20 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 20 mg suvorexant daily prior to bedtime during Treatment Period 2.
3055271|NCT00792298|Experimental|Suvorexant 40 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 40 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3055272|NCT00792298|Experimental|Placebo → Suvorexant 40 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 40 mg suvorexant daily prior to bedtime during Treatment Period 2.
3055273|NCT00792298|Experimental|Suvorexant 80 mg → Placebo|After an ~1- to 2-week single-blind placebo run-in period, participants received 80 mg suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by dose-matched placebo to suvorexant daily prior to bedtime during Treatment Period 2.
3055274|NCT00792298|Experimental|Placebo → Suvorexant 80 mg|After an ~1- to 2-week single-blind placebo run-in period, participants received dose-matched placebo to suvorexant daily prior to bedtime for 4 weeks during Treatment Period 1, followed by a 1-week single-blind placebo washout period, followed by 80 mg suvorexant daily prior to bedtime during Treatment Period 2.
3055275|NCT00792428|Active Comparator|Real-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with real transcranial direct current stimulation (tDCS) over the motor region for up to 30 min.
3055276|NCT00792428|Sham Comparator|Sham-tDCS + PT-OT|Each subject will receive up to 5 days of traditional physical-occupational therapy for at least 1 hour per day in the stroke recovery laboratory in combination with sham (pretend) tDCS for up to 30 min. over the motor region.
3055277|NCT00792467|Experimental|ITF2357|"Patients received the following therapy cycle~ITF2357, 50 mg every 6 hours, per os, days 1 - 3;~Mechlorethamine, 6 mg/sqm, intravenously , day 4. Therapy was administered every 21 days as long as there was no evidence of progressive disease or unacceptable toxicity, but in any case for a maximum of 12 cycles.~The mean number of complete treatment cycles received by patients was 5.25, with a minimum of 1 cycle and a maximum of 12 cycles."
3055278|NCT00792571|Experimental|B.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, b.i.d (twice a day dosing)
3055279|NCT00792571|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablets, 60mcg, q.i.d (four times a day dosing)
3055280|NCT00792610|Experimental|Hepatitis B booster|They receive 3 doses of hepatitis B vaccine (Engerix-B Injection, recombinant HBsAg, 20mcg/ml/vial, GSK) at 0, 1st, 6th month during follow-up. Their anti-HBs status were checked at baseline, one week, one month, sixth month, and seven months later after the first dose of hepatitis B vaccine.
3055281|NCT00792623|Experimental|Varilrix Group|Subjects with autologous peripheral stem cell/bone marrow transplants, who received 2 doses of Varilrix vaccine subcutaneously in the deltiod region of the non-dominant upper arm, at 4.5 and 6.5 months post-transplantation.
3055282|NCT00792636|Experimental|sumatriptan and naproxen sodium combination|
3055283|NCT00792636|Active Comparator|sumatriptan|
3055284|NCT00792636|Active Comparator|naproxen sodium|
3055285|NCT00792688|Experimental|1|GLYC-101 Gel, 0.1% on one eyelid and Placebo Gel on the other eyelid
3055286|NCT00792688|Experimental|2|GLYC-101 Gel, 1.0% on one eyelid and Placebo Gel on the other eyelid
3055287|NCT00792688|Experimental|3|GLYC-101 Gel, 0.1% on one eyelid and GLYC-101 Gel, 1.0% on the other eyelid
3055288|NCT00792701|Experimental|Arm II|Beginning within 84 days after surgery, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3055289|NCT00792805|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055290|NCT00792805|Experimental|Indacaterol 300 μg|Patients inhaled indacaterol 300 μg via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055291|NCT00792805|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol via a single-dose dry-powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM) for 26 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055292|NCT00792909|Experimental|Synflorix™ Group 1|Subjects previously vaccinated with the Synflorix™ vaccine according to a 2+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
3055293|NCT00792909|Experimental|Synflorix™ Group 2|Subjects previously vaccinated with the Synflorix™ vaccine according to a 3+1 schedule, receiving one dose of Synflorix™ at 36-46 months of age.
3055294|NCT00792909|Active Comparator|Unprimed Group|Age-matched subjects not previously vaccinated with any pneumococcal vaccine receiving two doses of Synflorix™ at 36-46 and 38-48 months of age. Age-matching was ensured by the enrolment of subjects 36-46 months of age.
3055295|NCT00792922|Active Comparator|≥90% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
3055296|NCT00792922|Active Comparator|80%-89% coverage with azithromycin target|Selected communities will receive mass treatment annually for three years.
3055297|NCT00792922|Active Comparator|≥90% coverage with azithromycin , treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
3055298|NCT00792922|Active Comparator|80%-89% coverage with azithromycin : treatment based|"Treatment to be administered at baseline then continued yearly if trachoma prevalence is greater than 5%~In Niger, treatment will be every 6-months for children ages twelve and under."
3055299|NCT00792935|Experimental|MK-0941|
3055300|NCT00792935|Active Comparator|Glimepiride|
3055301|NCT00792948|Experimental|Treatment (chemotherapy, transplant, maintenance)|See Detailed Description
3055302|NCT00793104|Other|CR Plug|Placement of allograft CR Plug in primary injury site
3055304|NCT00793182|Active Comparator|1|Ioversol 320 mgI/mL
3055305|NCT00793182|Active Comparator|2|Iodixanol 320 mgI/mL
3055306|NCT00793325||Somatropin|Patients administered Somatropin.
3055307|NCT00793403||1|As per routine clinical care
3055308|NCT00793455|Experimental|Intervention Group|Received Educational Outreach
3055309|NCT00793455|No Intervention|Usual Care Control Group|Participants in this arm will receive normal care until outcome assessment is performed at 6 months following the placement of the order for the preventive service. They will be sent a letter reminding them to obtain the ordered preventive service test.
3055310|NCT00793546|Experimental|1|combination of bosutinib and exemestane
3055311|NCT00793546|Active Comparator|2|exemestane
3055312|NCT00793572|Experimental|Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy|See Detailed Description
3055313|NCT00793585|Experimental|Allopurinol|Allopurinol group:allopurinol, 100-300mg/d according to the levels of Scr(serum creatinine) and UA(uric acid), for those Scr < 1.5mg/dl (133 umol/L) at the baseline, allopurinol was given 100 mg three times daily.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
3055314|NCT00793585|Other|Control group|Control group:(patient in this group were received health education and were encouraged to adhere to a low-purine diet and continue their usual therapy.Patients diagnosed with hypertension received antihypertensive drugs with titration of CCB and β-blocker during the follow-up.The target of BP is less than 130/80mmHg.
3055315|NCT00793598|Experimental|Brincidofovir|"Under Amendments 1 and 2, subjects received 1 of 2 dose regimens of brincidofovir, as follows:~20 mg BCV once weekly (QW) on Days 0, 7, and 14; or~10 mg BCV twice weekly (BIW) BIW on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received 40 mg BCV QW for a total of 5 doses on Days 0, 7, 14, 21, and 28."
3055316|NCT00793598|Placebo Comparator|Placebo|"Under Amendments 1 and 2, subjects received placebo twice weekly (BIW) for a total of 5 doses on Days 0, 3, 7, 10, and 14.~Under Amendment 3, subjects received placebo once weekly (QW) for a total of 5 doses on Days 0, 7, 14, 21, and 28."
3055317|NCT00793611|Active Comparator|Behavioral therapy|"Behavioral Therapy standard of care (which consists of bladder drills, voiding diaries, timed voiding and pelvic floor exercises)"
3055318|NCT00793611|Experimental|hypnotherapy|patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatments for overactive bladder
3055319|NCT00793624|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3055320|NCT00793624|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3055321|NCT00793624|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3055322|NCT00793624|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3055323|NCT00793650|Active Comparator|Bortezomib before Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours before melphalan.
3055324|NCT00793650|Active Comparator|Bortezomib after Melphalan|Enrolled patients were randomized to receive a single escalating dose of bortezomib (1.0, 1.3, or 1.6 mg/m2) 24 hours after melphalan.
3055325|NCT00793780|Active Comparator|Naltrexone 25mg|
3055326|NCT00793780|Placebo Comparator|Placebo|
3055327|NCT00793793|Experimental|20mg|patient to receive 20mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3055328|NCT00793793|Experimental|48mg|patient to receive 48mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3055329|NCT00793793|Experimental|120mg|patient to receive 120mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3055330|NCT00793793|Experimental|240mg|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
3055331|NCT00793793|Placebo Comparator|Placebo|
3055332|NCT00793819|Experimental|1 Silodosin|
3055333|NCT00793819|Placebo Comparator|2 Placebo|
3055334|NCT00793871|Experimental|sunitinib|single agent sunitinib, single arm
3055335|NCT00793910|Active Comparator|Gabapentin|oral medication
3055336|NCT00793910|Placebo Comparator|placebo|
3055337|NCT00794040|Active Comparator|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
3055338|NCT00794040|Placebo Comparator|Add-on placebo after optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
3055339|NCT00794118||1.0|As per routinary clinical practice
3055340|NCT00794144|Experimental|1|Olopatadine Hydrochloride Nasal Spray 0.6%
3055341|NCT00794144|Placebo Comparator|2|Olopatadine Hydrochloride Nasal Spray Vehicle
3055342|NCT00794157|Experimental|Indacaterol 150 µg|Patients received indacaterol 150 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055343|NCT00794157|Experimental|Indacaterol 300 µg|Patients received indacaterol 300 μg delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055344|NCT00794157|Placebo Comparator|Placebo|Patients received placebo delivered via a single dose dry powder inhaler (SDDPI) once daily (od) in the morning (between 8:00 and 11:00 AM). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3055345|NCT00794170|Experimental|Telephone and print based intervention|The I-SIGHT intervention consists of twelve interactive voice recognition (IVR) phone calls over a nine-month period and accompanying printed materials that are mailed to participants following each call. The phone call messages and print materials are tailored to individuals' circumstances using data from the screening and baseline interviews. The intervention is based on theoretical constructs from Social Cognitive Theory and the Health Belief Model, and emphasizes self-efficacy, medication taking skills, outcome expectancies, facilitators and barriers to compliance, and social support. The treatment group receives the tailored telephone intervention and mailed, printed materials.
3055346|NCT00794170|No Intervention|Usual care|The control group received usual care at each clinical site and interacted with study personnel only for data collection.
3055347|NCT00794196|No Intervention|Usual Care|The control group will be receiving usual medical and pharmaceutical care.
3055348|NCT00794196|Experimental|Intervention Group|Intervention group will be receiving usual medical and pharmaceutical care plus a pharmaceutical support program.
3055349|NCT00794313|Experimental|Amantadine|
3055350|NCT00794313|Experimental|Amantadine plus Topiramate|
3055351|NCT00794313|Placebo Comparator|Sugar Pill|
3055352|NCT00794339|Experimental|Copper ATSM|pre-therapy pelvic 64Cu-ATSM-PET/CT with Pre- and post- therapy FDG PET/CT
3055353|NCT00794365||Open-label|
3055354|NCT00794417|Experimental|Phase 1: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
3055355|NCT00794417|Experimental|Phase 1: Aflibercept 2 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 2 milligrams per kilogram (mg/kg) followed by pemetrexed 500 mg/square meter (m^2) and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
3055356|NCT00794417|Experimental|Phase 1: Aflibercept 4 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 4 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) until disease progression, unacceptable toxicity, withdrawal of consent or if another study withdrawal criterion has been met.
3055357|NCT00794417|Experimental|Phase 2: Aflibercept 6 mg/kg and Pemetrexed and Cisplatin|Participants received intravenous infusion of aflibercept 6 mg/kg followed by pemetrexed 500 mg/m^2 and then cisplatin 75 mg/m^2 on Day 1 of each 3 week cycle (1 Cycle = 21 Days in this study) for 6 cycles.
3055358|NCT00794469||Water|obese children (body mass index > 95th percentile for age and sex) that will drink cold water
3055359|NCT00794508|Experimental|Retroviral-mediated ADA gene transfer|Transfer of the human ADA gene to isolated CD34+ cells from the bone marrow.
3055360|NCT00794547|Experimental|1|In the Phase I part of the study, we will test the safety of calcitriol along with standard chemotherapy. In addition, the goal is to see what effects (good and bad) it has on you and your type of Non-Small Cell Lung Cancer. This study is ongoing. In this portion of the study, we are testing increasing doses of calcitriol in combination with standard chemotherapy. If 2/3 patients at any dose level experience side effects that are limiting, we will call the dose level below that dose the maximum tolerated dose.
3055361|NCT00794547|Experimental|2|In the Phase II part of the study, we will find out the response of subjects' cancer has to the combination of a fixed dose of calcitriol (determined in the phase I study) with standard chemotherapy.
3055362|NCT00794560|Experimental|clinical setting: intervention|"Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital.~Intervention: patient education"
3055363|NCT00794560|No Intervention|clinical setting: standard care|Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
3055364|NCT00794560|Experimental|daily life setting: intervention|"Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists.~Intervention: patient education"
3055365|NCT00794560|No Intervention|daily life setting: standard care|Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
3055366|NCT00794573|Experimental|Varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
3055367|NCT00794573|Placebo Comparator|Sugar pill|placebo for 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
3055368|NCT00794664|Placebo Comparator|Placebo|Weekly subcutaneous injections for 26 weeks
3055369|NCT00794664|Experimental|Mipomersen|200 mg weekly subcutaneous injections for 26 weeks
3055370|NCT00794677|Placebo Comparator|Sugar Pill|Placebo medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
3055371|NCT00794677|Experimental|ezetimibe|10 mg medication will be taken orally once daily in the morning on rising either during the first intervention period or the second intervention period. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
3055372|NCT00794820|Experimental|FCR-Multiple Dose Rituximab|Fludarabine phosphate + Cyclophosphamide + Rituximab
3055373|NCT00794924|Experimental|Probiotics, VSL#3|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received commercially available probiotics (VSL#3) for 45 days.
3055374|NCT00794924|Placebo Comparator|Placebo|Acutely hospitalized elderly patients in a geriatric orthopedic rehabilitation department received placebo sachets for 45 days.
3055375|NCT00794950|Experimental|Sunitinib treatment|Intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma.
3055376|NCT00794963|Experimental|Integrated care|Provide on-site internal medicine evaluation, treatment and follow up of metabolic syndrome for patients in Clozapine Clinic
3055377|NCT00794963|Other|Usual Care|Follow the 8-month outcome of schizophrenia patients with metabolic syndrome treated in the community
3055378|NCT00795002|Experimental|Arm I|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
3055379|NCT00795002|Experimental|Arm II|Patients receive alvocidib IV over 30 minutes followed by alvocidib IV over 4 hours on days 1-3. Patients also receive cytarabine and mitoxantrone hydrochloride as in arm I.
3055380|NCT00795132|Active Comparator|Related BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor related to the participant/recipient
3055381|NCT00795132|Active Comparator|Unrelated BM PBSC|Bone Marrow Peripheral Blood Stem Cell (BM PBSC) from a donor unrelated to the participant/recipient
3055382|NCT00795132|Active Comparator|Unrelated Blood Cord|Blood Cord donated from a donor unrelated to the participant/recipient
3055383|NCT00795145|Placebo Comparator|Cohort 1: Placebo|
3055384|NCT00795145|Experimental|Cohort 1: 900 mg linezolid|
3055385|NCT00795145|Experimental|Cohort 1: 1200 mg linezolid|
3055386|NCT00795145|Placebo Comparator|Cohort 2: Placebo|
3055387|NCT00795145|Experimental|Cohort 2: 600 mg linezolid|
3055388|NCT00795145|Experimental|Cohort 2: 1200 mg linezolid|
3055389|NCT00795145|Active Comparator|Cohort 2: 400 mg Moxifloxacin|
3055390|NCT00795184|Other|Imaging Procedures HDWLE first NBI second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
3055391|NCT00795184|Other|Imaging Procedures NBI first HDWLE second and pCLE|All patients undergo both endoscopic imaging procedures and then the endomicroscopy procedure; the endoscopic imaging procedures being performed back to back by two endoscopists, blinded to each other.
3055392|NCT00795210|Experimental|GH 6mcg/kg/d|Recombinant human growth hormone 6mcg/kg SC once daily
3055393|NCT00795210|Experimental|GH 2mg daily|Recombinant human growth hormone 2mg SC once daily
3055394|NCT00795210|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks
3055395|NCT00795275|Experimental|Impaired Fasting Glucose|Treatment of people with impaired fasting glucose with Januvia (sitagliptin phosphate)
3055396|NCT00795275|Experimental|Normal glucose tolerance|Treatment of people with normal glucose tolerance with Januvia (sitagliptin phosphate)
3055397|NCT00795288|Experimental|Simvastatin, 80 mg/day|Simvastatin, 80 mg/day for 21 days
3055398|NCT00795288|Placebo Comparator|Placebo|Placebo
3055399|NCT00795340|Experimental|Arm I Cediranib|Patients receive oral cediranib once daily on days 1-21 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.
3055400|NCT00795340|Placebo Comparator|Arm II Placebo|Patients receive oral placebo once daily on days 1-21 and paclitaxel and carboplatin as in arm I.
3055401|NCT00795366|Active Comparator|AVP, arginine vasopressin|Vasopressin
3055402|NCT00795366|Active Comparator|Standard Catecholamine|levophed, dopamine, phenylephrine)
3055403|NCT00795509||Tolterodine tartrate.|Patients taking Tolterodine tartrate.
3055404|NCT00795600|Experimental|insulin detemir|Insulin detemir injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
3055405|NCT00795600|Active Comparator|insulin NPH|Insulin isophane (Neutral Protamine Hagedorn, NPH) injected subcutaneously (s.c.) in the evening in combination with insulin aspart injected s.c. as mealtime insulin for 26 weeks
3055406|NCT00795639|Experimental|Sitaxsentan|Monotherapy
3055407|NCT00795639|Placebo Comparator|Sitaxsentan Placebo|Monotherapy
3055408|NCT00795704|Placebo Comparator|Placebo|Control Group
3055409|NCT00795704|Active Comparator|Mulberry Leaf Extract|
3055410|NCT00795717|Active Comparator|Lovaza|Lovaza, dietary counseling
3055411|NCT00795717|Placebo Comparator|Placebo|Placebo, dietary counseling
3055412|NCT00795769|Experimental|Ondansetron therapy|Patients receive ondansetron IV once 30-60 minutes before undergoing autologous peripheral blood stem cell transplantation.
3055413|NCT00795821|Experimental|LY2216684|"10-week Acute Treatment Phase: Day after Week 0=start of 6 milligram (mg) once daily (QD) dosing; Week 1=all participants titrated to 9 mg QD; After Week 1=dose increased, maintained, or decreased to a minimum of 6 mg QD and maximum of 18 mg QD, depending on participant's tolerance of study drug.~1-year Long-term Extension Phase: Day after Week 10=start of same LY2216684 dose participant was taking at the end of acute treatment phase; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
3055414|NCT00795821|Placebo Comparator|Placebo|"10-week Acute Treatment Phase: 3 tablets QD for 10 weeks~1-year Long-term Extension Phase: Day after Week 10=6 mg LY2216684 dose; After 1 week=dose escalated to 9 mg QD; After Week 11=dose increased, maintained, or decreased to minimum of 6 mg QD and maximum of 18 mg QD based on investigator's judgment of safety and tolerability (up to Week 62)."
3055415|NCT00795886|Experimental|All participants|
3055416|NCT00795951|Experimental|TRUE Test panels 1.1, 2.1, 3.1|All subjects were patched with 3 T.R.U.E. Test panels containing 28 allergens and 1 negative control.
3055417|NCT00796003|Experimental|Phase I: JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
3055418|NCT00796003|Experimental|Phase I: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
3055419|NCT00796003|Experimental|Phase II: JNJ-30979754 20 mg/m2|JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
3055420|NCT00796120|Experimental|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
3055421|NCT00796120|Active Comparator|Doxorubicin plus Ifosfamide|Doxorubicin (as a monotherapy) 75 mg per m^2 will be given intravenously every 3 weeks or Doxorubicin 60 mg per m^2 will be given intravenously every 3 weeks followed by ifosfamide 6 to 9 gram (g)/m^2 every 3 weeks until disease progression.
3055422|NCT00796224|Active Comparator|1.|60 mg/kg azithromycin ER (Extended Release)arm
3055423|NCT00796224|Active Comparator|2.|30 mg/kg azithromycin IR (Immediate Release) arm
3055424|NCT00796302|Experimental|1|Children will receive active methylphenidate HCl and active risperidone. Parents will receive parent management training.
3055425|NCT00796302|Active Comparator|2|Children will receive methylphenidate HCl and placebo instead of the active risperidone. Parents will receive parent management training.
3055426|NCT00796315|Experimental|Doxylamine Succinate (USP)|Doxylamine Succinate United States Pharmacopeia (USP)
3055427|NCT00796328|Experimental|1|
3055428|NCT00796367|Placebo Comparator|Placebo|Placebo
3055429|NCT00796367|Experimental|VI-0521 Mid|7.5 mg phentermine and 46 mg topiramate
3055430|NCT00796367|Experimental|VI-0521 Top|15 mg phentermine and 92 mg topiramate
3055431|NCT00796419|Experimental|1|Intravenous 5% human albumin
3055432|NCT00796419|Experimental|2|Intravenous 6% hetastarch
3055433|NCT00796445|Experimental|MAGE-A3 Group|Patients who received up to 13 doses of recMAGE-A3 + AS15 ASCI. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of ASCI product at 3-week intervals, followed by 8 doses of ASCI product at 12-week intervals.
3055434|NCT00796445|Placebo Comparator|Placebo Group|Patients who received up to 13 doses of placebo. Study products were administered as intramuscular (IM) injections in the deltoid or the lateral region of the thigh (not in anatomical regions where lymph nodes had been excised): 5 doses of placebo at 3-week intervals, followed by 8 doses of placebo at 12-week intervals.
3055435|NCT00796523|Experimental|Happiest Baby videotape|videotape describing the Happiest Baby on the Block technique
3055436|NCT00796523|Placebo Comparator|control videotape|videotape with normal newborn instruction
3055437|NCT00796549|Experimental|BIBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
3055438|NCT00796562|Experimental|Myeloablative haploidentical BMT|"All participants except those with acute lymphoblastic leukemia and lymphoblastic lymphoma: Busulfan will be administered 1 mg/kg oral (or 0.8 mg/kg IV) four times per day for four days, followed by cyclophosphamide 50 mg/kg once per day for two days.~Participants with acute lymphocytic leukemia or lymphoblastic lymphoma: Cyclophosphamide will be administered 50 mg/kg once per day for two days, followed by total body irradiation at 300 cGy per day for four days."
3055439|NCT00796614|Placebo Comparator|Placebo|Participants received matching placebo to tamsulosin hydrochloride via opened capsules every day for 14 weeks
3055440|NCT00796614|Experimental|Low dose|Participants received 0.001 - 0.002 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3055441|NCT00796614|Experimental|Medium dose|Participants received 0.002 - 0.004 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3055442|NCT00796614|Experimental|High dose|Participants received 0.004 - 0.008 mg/kg tamsulosin hydrochloride via opened capsules every day for 14 weeks
3055443|NCT00796627|Sham Comparator|Healthy volunteers|"Healthy volunteers with no burn wounds Volunteers donate blood that will be studied in comparison to patients who have sustained burns. The circulating bone marrow stem cells will be counted and compared to the levels in burn patients. Six 12 ml tubes will be taken for the study. You will not be compensated. But you will be helping to advance science if you join the study."
3055444|NCT00796627|Active Comparator|Burn volunteer|To recruit burn wound patients with defined clinical criteria for study. A second-degree burn of at least 10 cm2 to up to 95% BSA; age = 14-75 years; BP > 100 mm Hg systolic; heart rate < 100 beats/minute; urine output > 30 ml/hour; area of burn < 20% of BSA; body temperature = 98.5-101 degrees Fahrenheit; serum albumin > 3 mg/ml; and informed consent. We will also obtain a history regarding the presence or absence of risk factors that may affect CAC numbers: hypertension > 1 year; smoking > 2 pack-years or within the last year; diabetes mellitus; and family history of premature coronary artery disease (men < 55 and women < 65 years of age).Six 12 ml tubes will be taken at 5 time points
3055445|NCT00796653|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3055446|NCT00796653|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3055447|NCT00796653|Active Comparator|Formoterol 12mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3055448|NCT00796653|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3055449|NCT00796666|Experimental|Sitaxsentan and Placebo|Monotherapy arm
3055450|NCT00796666|Experimental|Sitaxsentan and Sildenafil|Combination treatment
3055451|NCT00796705|Experimental|Adalimumab / Adalimumab Placebo|1 sub-cutaneous (SQ) injection of adalimumab or 1 SQ injection of placebo will be given in a blinded and alternating fashion for a total of 12 weeks
3055452|NCT00796705|Experimental|Etanercept|Participants will receive 1 SQ injection of etanercept each week for 12 weeks
3055453|NCT00796718|Experimental|Capecitabine|Capecitabine orally twice daily plus standard radiotherapy for 5 weeks, followed by surgery within 6 weeks after completion of treatment.
3055454|NCT00796744|Placebo Comparator|Placebo Vehicle Control|control placebo vehicle gel
3055455|NCT00796744|Active Comparator|0.03% DSC127|0.03 % DSC127 in Vehicle Control
3055456|NCT00796744|Active Comparator|0.01% DSC127|0.01% DSC127 in Vehicle Control
3055457|NCT00796757|Experimental|1|
3055458|NCT00796822|Experimental|1|Participants will receive pentoxifylline.
3055459|NCT00796822|Placebo Comparator|2|Participants will receive placebo.
3055460|NCT00796926|Experimental|Systane Ultra|Used four times a day topically to each eye
3055461|NCT00796926|Active Comparator|Refresh|Used four times a day topically to each eye
3055462|NCT00796978|Experimental|trastuzumab|
3055463|NCT00796991|Active Comparator|Arm A|
3055464|NCT00796991|Active Comparator|Arm B|
3055465|NCT00796991|Active Comparator|Arm C|
3055466|NCT00797108|Experimental|1|Loading dose of IV sulopenem with switch to oral PF-03709270
3055467|NCT00797108|Experimental|2|IV sulopenem with switch to oral PF-03709270
3055468|NCT00797108|Active Comparator|3|IV ceftriaxone with switch to oral amoxicillin/clavulanate potassium comparator
3055469|NCT00797212|Other|Subjects with diabetes|Subjects with diabetes use a new Apollo Blood Glucose Monitoring System with blood obtained from the palm and forearm
3055470|NCT00797225|Placebo Comparator|Placebo|Participants received placebo tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
3055471|NCT00797225|Experimental|Elagolix 150 mg|Participants received elagolix 150 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 150 mg for an additional 12 weeks.
3055472|NCT00797225|Experimental|Elagolix 250 mg|Participants received elagolix 250 mg tablets once a day and placebo intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants continued to receive elagolix 250 mg for an additional 12 weeks.
3055473|NCT00797225|Other|Leuprorelin|Participants received placebo tablets once a day and leuprorelin acetate 1-month depot 3.75 mg intramuscular injection once a month for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
3055474|NCT00797277|Experimental|IM olanzapine|Patients of this arm received 10 mg IM olanzapine after randomization
3055475|NCT00797277|Active Comparator|IM haloperidol plus lorazepam|Patients of this arm received 5 mg IM haloperidol plus 2 mg IM lorazepam after randomization
3055476|NCT00797316|Experimental|Aliskiren plus Hydrochlorothiazide|Aliskiren (150 mg) plus Hydrochlorothiazide (12.5 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg) plus Hydrochlorothiazide (25 mg). Medication was taken once daily in oral form.
3055477|NCT00797316|Active Comparator|Aliskiren|Aliskiren (150 mg) for one week. Subsequently up-titrated to Aliskiren (300 mg). Medication was taken once daily in oral form.
3055478|NCT00797459|Experimental|Restylane and Restylane with Lidocaine|This is a split-face design injecting both Restylane and Restylane-L injectable gels, administered once. Each subject received Restylane on one side of the face, and Restylane-L on the other. Subjects were blinded to which side of their face received Restylane or Restylane-L. The study was randomized and treatments successive.
3055479|NCT00797511|Experimental|Study Group|Participants will receive one dose of Tetanus, diphtheria (reduced antigen content), pertussis (acellular components) vaccine (TdcP-IPV, ADACEL Polio) on Day 0
3055480|NCT00797563|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system (BGMS) Apollo Blood Glucose Monitoring System with capillary blood; healthcare professionals use the new BGMS with subject capillary and venous blood.
3055481|NCT00797667|Experimental|Telcagepant 140 mg|Participants receive one telcagepant 140 mg tablet and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
3055482|NCT00797667|Experimental|Telcagepant 280 mg|Participants receive one telcagepant 280 mg tablet and one 140 mg telcagepant placebo, orally, twice daily for 12 weeks
3055483|NCT00797667|Placebo Comparator|Placebo|Participants receive one 140 mg telcagepant placebo and one 280 mg telcagepant placebo, orally, twice daily for 12 weeks
3055484|NCT00797732|Active Comparator|Active Acupuncture|The active intervention used a three-phase step-up protocol to gradually increase the body areas treated and needling intensity. Acupuncture needles (0.20x25mm) were inserted with a depth of 5-10 mm into predefined points based on a systematic literature review following the STRICTA guideline. Needles were stimulated to obtain the de qi sensation. An electroacupuncture (EA) device was connected at two acupoints. All needles remained in place for 30 minutes. The active acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; MacPherson H, Altman DG et al. PLoS Med 2010;7:e1000261]
3055485|NCT00797732|Sham Comparator|Sham Acupuncture|The sham intervention was designed to be maximally inert and minimally invasive, while simulating most aspects of the active protocol. Sham needles (0.12x30mm) were inserted at 14 locations paralleling the same body regions needled in the active group; however, all sham point locations were off the pathways of traditional Chinese medicine acupuncture meridians and points. An identical but deactivated EA device was used following sham protocols previously used. The sham acupuncture was administered once every 2 weeks for 24 weeks, starting 2 weeks into CRT and ending at 20 weeks after CRT. [Refs: Lu W, Wayne PM et al. Contemp Clin Trials 2012; 33; 700-711; Wayne PA, Krebs DE et al. Arch Phys Med Rehabil 2005;86:2248-2255]
3055486|NCT00797797|Experimental|Milnacipran Added|
3055487|NCT00797797|Experimental|No Treatment Added|
3055488|NCT00797823|Placebo Comparator|Insulin + Placebo|Glycemic control of subject participants was managed by the closed-loop system which delivered insulin and normal saline (instead of glucagon) as a placebo, based upon algorithm calculations.
3055489|NCT00797823|Active Comparator|Insulin + Glucagon|Glycemic control of subject participants was managed by the system which delivered insulin and glucagon based upon algorithm calculations.
3055490|NCT00797823|Experimental|Pilot Study|Pilot studies designed to assess safety of the system. Includes 6 participants undergoing 7 studies.
3055491|NCT00797862|Experimental|Aliskiren + Amlodipine|Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3055492|NCT00797862|Experimental|Aliskiren Start - Amlodipine Add-On|Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3055493|NCT00797862|Experimental|Amlodipine Start- Aliskiren Add-On|Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
3055494|NCT00797966|Experimental|1|OPC-34712 + ADT
3055495|NCT00797966|Placebo Comparator|2|Placebo + ADT
3055496|NCT00798018|Placebo Comparator|Air|air was used to inflate the cuff.
3055497|NCT00798018|Placebo Comparator|Normal Saline|Normal saline was used to inflate the cuff.
3055498|NCT00798018|Active Comparator|lidocaine|2% lidocaine was used to inflate the cuff.
3055499|NCT00798018|Experimental|tetracaine|1% tetracaine was used to inflate the cuff.
3055500|NCT00798096|Experimental|1|
3055501|NCT00798135|Experimental|itraconazole|Patients will receive oral itraconazole 200mg a day until disease progression.
3055502|NCT00798161|Experimental|BI 1356 + metformin|BI 1356 low dose + metformin 500 mg, twice daily
3055503|NCT00798161|Placebo Comparator|matching placebo|matching placebo
3055504|NCT00798161|Experimental|BI 1356+ Metformin|BI 1356 low dose + metformin 1000 mg, twice daily
3055505|NCT00798161|Active Comparator|Metformin|Metformin 500 mg, twice daily
3055506|NCT00798161|Active Comparator|metformin|Metformin 1000 mg, twice daily
3055507|NCT00798161|Experimental|BI 1356|BI 1356 high dose, once daily
3055508|NCT00798174|Experimental|Standard configuration vs. azygos coil|"The DFT with the standard Superior Vena Cava (SVC) coil vs. DFT with the azygos coil.~In this crossover study, each patient serves and own control, with defibrillation testing performed with and with the azygos coil"
3055509|NCT00798304|Experimental|1|Dose level 1 of meningococcal B rLP2086 vaccine and routine childhood vaccines
3055510|NCT00798304|Experimental|2|Dose level 2 of meningococcal B rLP2086 vaccine and routine childhood vaccines
3055511|NCT00798304|Experimental|3|Control group
3055512|NCT00798317|Experimental|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
3055513|NCT00798317|Placebo Comparator|Placebo|Intravitreal injection of placebo
3055514|NCT00798369|Experimental|Canakinumab 10 mg|Canakinumab 10 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3055515|NCT00798369|Experimental|Canakinumab 25 mg|Canakinumab 25 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3055516|NCT00798369|Experimental|Canakinumab 50 mg|Canakinumab 50 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3055517|NCT00798369|Experimental|Canakinumab 90 mg|Canakinumab 90 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3055518|NCT00798369|Experimental|Canakinumab 150 mg|Canakinumab 150 mg subcutaneous (s.c) once. The s.c. injection could be administered into the arm or thigh. Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
3055519|NCT00798369|Active Comparator|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg intramuscularly (i.m) once. The i.m. injection was recommended to be administered deeply into the gluteal muscle. Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
3055520|NCT00798434|Active Comparator|Placebo|Flexible dose regimen of placebo once daily. The dose can be increased after 4 weeks if clinically indicated. Subsequently the dose can be reduced to the original dose if clinically indicated.
3055521|NCT00798434|Active Comparator|Fesoterodine|Flexible dose regimen of fesoterodine fumarate 4mg once daily. The dose can be increased to 8mg once daily after 4 weeks if clinically indicated. Subsequently the dose can be reduced to 4mg if clinically indicated.
3055522|NCT00798486|Other|Subjects with and without Diabetes|Subjects participating in this study included 93 who had diabetes and 17 who did not have diabetes.
3055523|NCT00798577|Experimental|Vigamox|Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)
3055524|NCT00798577|Placebo Comparator|BSS Placebo|Balanced Salt Solution
3055525|NCT00798603|Experimental|pemetrexed + carboplatin + bevacizumab|Patients receive pemetrexed disodium IV over 10 minutes, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease or partial or complete response after 6 courses may continue to receive pemetrexed disodium and bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
3055526|NCT00798655|Experimental|Panitumumab, Cisplatin plus radiation|Standard radiation 60-66 Gy with 200 cGy daily fractions in 6-7 weeks Cisplatin* 30 mg/m2 IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements) Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses based upon radiation therapy dose requirements)
3055527|NCT00798694|Other|New to Meds|Naive to glaucoma therapy medical or surgical. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
3055528|NCT00798694|Other|Currently on Xalatan|Patients currently on Xalatan at least one month. All patients will receive Xalatan in the right eye and Travatan Z in the left eye.
3055529|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 25 mg|
3055530|NCT00798707|Experimental|Desvenlafaxine succinate sustained-release 50 mg|
3055531|NCT00798707|Placebo Comparator|Placebo|
3055532|NCT00798720|Experimental|Vorinostat + Bortezomib|Vorinostat 400 mg + Bortezomib 1.3 mg/m2
3055533|NCT00798759|Experimental|Travoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3055534|NCT00798759|Active Comparator|Latanoprost|One drop self-administered in the study eye(s) once daily at night for 12 weeks
3055535|NCT00798889|Experimental|Sunitinib|
3055536|NCT00798967|Experimental|Teduglutide|0.05 mg/kg/day sc dose of teduglutide
3055537|NCT00798967|Placebo Comparator|Placebo|Matching subcutaneous dose of placebo to teduglutide
3055538|NCT00799227|Experimental|700 µg Dexamethasone Implant|700 µg dexamethasone implant in the study eye at Day 1
3055541|NCT00799292|No Intervention|No injection|Patients did not receive an injection at cervix prior to beginning the procedure
3055542|NCT00799292|Experimental|Injection of vasopressin|Patients will be randomized to receive 20cc of dilute vasopressin (20units in 50cc normal saline)injected at cervix at beginning of the hysterectomy
3055543|NCT00799383|Experimental|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
3055544|NCT00799383|Placebo Comparator|Placebo|Placebo
3055545|NCT00799396|Experimental|Overall Study|Participants will receive clopidogrel treatment alone, followed by clopidogrel plus aspirin treatment on the last day of treatment.
3055546|NCT00799409|Experimental|1|CONCERTA (methylphenidate HCl) / Placebo Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
3055547|NCT00799409|Experimental|2|Placebo/ CONCERTA (methylphenidate HCl) Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
3055548|NCT00799422|Active Comparator|ReNu MultiPlus|ReNu MultiPlus used as specified in the protocol for contact lens care. In this crossover study, ReNu MultiPlus was dispensed in randomized order with Complete Easy Rub and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3055549|NCT00799422|Active Comparator|Complete Easy Rub|Complete Easy Rub used as specified in the protocol for contact lens care. In this crossover study, Complete Easy Rub was dispensed in randomized order with ReNu MultiPlus and Clear Care. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3055550|NCT00799422|Active Comparator|Clear Care|Clear Care used as specified in the protocol for contact lens care. In this crossover study, Clear Care was dispensed in randomized order with Complete Easy Rub and ReNu MultiPlus. Each product was used for one week with a fresh pair of Acuvue Oasys contact lenses. A 36-hour washout preceded each usage period.
3055551|NCT00799435|No Intervention|1|Participants will receive usual care for 12 weeks. The care will be dictated by the primary physician and/or diabetologist caring for the participant. Efforts will be made to ensure that all participants receive standard measures as indicated by guidelines, with a particular emphasis on blood pressure control and glucose control.
3055552|NCT00799435|Experimental|2|Participants will receive exenatide for 12 weeks.
3055553|NCT00799487|Experimental|1|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
3055554|NCT00799487|Experimental|2|CONCERTA (methylphenidate HCl) or placebo Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
3055555|NCT00799578|Experimental|Cystagon-EC|
3055556|NCT00799591||1|Intensive Care
3055557|NCT00799604|Experimental|clevidipine|"Patients were sequentially assigned to one of following three planned dose cohorts for Bolus 1 within the clevidipine arm:~Cohort 1: clevidipine 250 µg (0.5 mL)~Cohort 2: clevidipine 500 µg (1 mL)~Cohort 3: clevidipine 125 µg (0.25 mL or 0.5 mL of a 1:1 solution)"
3055558|NCT00799617|Active Comparator|AndroGel® (testosterone gel)|The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
3055559|NCT00799617|Placebo Comparator|Placebo gel|Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
3055560|NCT00799643|Active Comparator|1|Salsalate, 3.5 g/d orally, divided dosing
3055561|NCT00799643|Placebo Comparator|2|Salsalate Placebo, orally, divided dosing
3055562|NCT00799708|Placebo Comparator|1|Placebo
3055563|NCT00799708|Active Comparator|2|Estrace 0.5 mg
3055564|NCT00799708|Active Comparator|3|Estrace 2 mg
3055565|NCT00799812|Experimental|CHG Swabstick (3 @ once)|Chlorhexidine gluconate (CHG) 2% w/v CHG/isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied @ same time
3055566|NCT00799812|Experimental|CHG Swabstick sequential|Chlorhexidine gluconate (CHG) 2% w/v and isopropyl alcohol (IPA) 70% v/v - 3 swabsticks applied sequentially
3055567|NCT00799812|Active Comparator|Hibiclens|Chlorhexidine gluconate (CHG) 4% w/v in an aqueous base
3055568|NCT00799812|Placebo Comparator|Sterile water swab (3 @ once)|Sterile swabstick wetted with sterile deionized water - 3 swabsticks applied at the same time.
3055569|NCT00799812|Placebo Comparator|Sterile water swabstick (sequential)|Sterile swabstick wetted with sterile water--3 swabsticks applied sequentially.
3055570|NCT00799825|Experimental|Cervarix group|Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
3055571|NCT00799903|Experimental|Darapladib|Single daily oral tablet
3055572|NCT00799903|Placebo Comparator|Placebo|Single daily oral tablet
3055573|NCT00799981|Experimental|AABB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 7 cm then 10 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055574|NCT00799981|Experimental|ABAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055575|NCT00799981|Experimental|ABBA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 7 cm then 10 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055576|NCT00799981|Experimental|BAAB|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 7 cm then 7 cm then 10 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055577|NCT00799981|Experimental|BABA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then then 7 cm then 10 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055578|NCT00799981|Experimental|BBAA|"A=Coloplast SpeediCath Compact catheter, 7 cm B=Astra Tech POBE catheter, 10 cm 10 cm then 10 cm then 7 cm then 7 cm~Four catheterizations in total, two catheterizations with each study product in a randomized order."
3055579|NCT00800176|Placebo Comparator|Placebo|"During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast.~During the 12-week double-blind treatment period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test."
3055580|NCT00800176|Experimental|RO4998452 10mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 10 mg of RO4998452.
3055581|NCT00800176|Experimental|RO4998452 2.5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 2.5 mg of RO4998452.
3055582|NCT00800176|Experimental|RO4998452 20mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 20 mg of RO4998452.
3055583|NCT00800176|Experimental|RO4998452 40mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 40 mg of RO4998452.
3055584|NCT00800176|Experimental|RO4998452 5mg|During the single-blind run-in period, two placebo capsules were taken in the morning approximately 15 minutes prior to breakfast. During the 12-week double-blind treatment period, two capsules were taken in the morning approximately 15 minutes prior to breakfast, except on the days of the meal tolerance test. The two capsules combined contained 5 mg of RO4998452.
3055585|NCT00800202|Experimental|1|
3055586|NCT00800202|Experimental|2|
3055587|NCT00800254|Experimental|Neuromuscular Electrical Stimulation (NMES)|
3055588|NCT00800254|Active Comparator|Standard Rehabilitation Protocol|
3055589|NCT00800345|Experimental|Experimenal|Metronomic oral topotecan and oral pazopanib will be administered by mouth beginning on Cycle 1 Day 1. Patients will be enrolled and observed for dose limiting toxicity (DLT) for 1 cycle of treatment. Dose modification of the combination will depend on the number of patients experiencing DLT(s) at each dose level.
3055590|NCT00800384|Experimental|1|ICD implant without defibrillation testing
3055591|NCT00800384|Active Comparator|2|ICD implant with defibrillation testing
3055592|NCT00800436|Experimental|Part 1: Cohort 1|Healthy male participants will receive Herceptin 6 mg/kg IV on Day 1.
3055593|NCT00800436|Experimental|Part 1: Cohort 2|Female participants with HER2-positive breast cancer will receive Herceptin 6 mg/kg IV on Day 1.
3055594|NCT00800436|Experimental|Part 1: Cohort 3|Healthy male participants will receive Herceptin 6 mg/kg SC on Day 1.
3055595|NCT00800436|Experimental|Part 1: Cohort 4|Healthy male participants will receive Herceptin 10 mg/kg SC on Day 1.
3055596|NCT00800436|Experimental|Part 1: Cohort 5|Healthy male participants will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohorts 1, 2, 3, and 4.
3055597|NCT00800436|Experimental|Part 2: Cohort A|Female participants with HER2-positive breast cancer will receive Herceptin SC at the dose level determined in Part 1.
3055598|NCT00800436|Experimental|Part 2: Cohort B|Female participants with HER2-positive breast cancer will receive Herceptin SC at an adjusted dose level based on preliminary PK analysis of Cohort A.
3055599|NCT00800540|Other|AZARGA/COMBIGAN|AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
3055600|NCT00800540|Other|COMBIGAN/AZARGA|COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.
3055601|NCT00800683|Experimental|BI 1356|patient to receive a tablet containing BI 1356 once daily
3055602|NCT00800683|Placebo Comparator|placebo|patient to receive a tablet identical to BI 1356 once daily
3055603|NCT00800735|Experimental|Pegylated-interferon alfa-2a plus ribavirin|Participants received pegylated-interferon alfa-2a 180 µg/week subcutaneously plus ribavirin 1000 mg/day orally for patients weighing < 75 kg or 1200 mg/day for patients weighing ≥ 75 kg for 48 weeks.
3055604|NCT00800839|Experimental|Busulfan + Fludarabine + Cyclophosphamide|Busulfan starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
3055605|NCT00800865|Other|Biomarker Evaluation Group I|Biomarker evaluation before and after dosing with cytotoxic agent(s)
3055606|NCT00800865|Other|Biomarker Evaluation Group II|Biomarker evaluation before and after dosing with cytotoxic agent(s)
3055607|NCT00800982|Active Comparator|1 (Etanercept only)|Subjects will only be treated with etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months. No UVB will be given. Sham UVB will not be used because the subjects are not blinded because they often know they are receiving sham UVB due to differences in light intensity and heat.
3055608|NCT00800982|Experimental|2 (Etanercept + nb-UVB)|"Subjects will receive etanercept. This is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.~In addition, for months 3-6, subjects will receive Narrow Band Ultraviolet B phototherapy three times a week for 12 weeks in addition to the etanercept maintenance dose. The safety and efficacy of the combination therapy will be evaluated by the registered phototherapy nurses at each phototherapy visit and by the study investigator at monthly visits. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff."
3055609|NCT00801099|Experimental|Abx|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
3055610|NCT00801138|Placebo Comparator|Group 1|Group 1 Ropivacaine: 30 ml 0.5% ropivacaine plus 2 ml 0.9% saline for interscalene block
3055611|NCT00801138|Placebo Comparator|Group 2|Group 2 Bupivacaine: 30 ml 0.5% bupivacaine plus 2 ml 0.9% saline
3055612|NCT00801138|Active Comparator|Group 3|Group 3 Ropivacaine and dexamethasone: 30 ml 0.5% ropivacaine mixed with dexamethasone 8 mg (2 ml)
3055613|NCT00801138|Active Comparator|Group 4|Group 4 Bupivacaine and steroid: 30 ml 0.5% bupivacaine mixed with dexamethasone 8 mg (2 ml).
3055614|NCT00801229|Active Comparator|Vyvanse|Patients may be randomized to the active comparator arm. Participants randomized to this arm will receive 30, 50, or 70mg Vyvanse daily.
3055615|NCT00801229|Placebo Comparator|Placebo|Patients may be randomized to the placebo comparator arm. Those randomized to this arm will receive 30, 50, or 70mg placebo daily.
3055616|NCT00801242|Experimental|Degarelix 240 mg / 80 mg|
3055617|NCT00801398|Experimental|Oxymorphone IR|Open-Label, 2 part ascending-dose multicenter study
3055618|NCT00801632|Experimental|Kidney and Marrow Recipients|Combined kidney and bone marrow transplant
3055619|NCT00801684|Placebo Comparator|Placebo|Represents Dose A in the Dosing Sequence assignments.
3055620|NCT00801684|Experimental|TrIP-2D (100mcg)|Represents Dose B
3055621|NCT00801684|Experimental|TrIP-2SS (100mcg)|Represents Dose C
3055622|NCT00801684|Experimental|TrIP-2D (400mcg)|Represents Dose D
3055623|NCT00801684|Experimental|TrIP-2SS (100mcg) + Foradil (12mcg)|Represents Dose E. All subjects received Dose E as their final (5th) dose, after completing their initial 4 single doses according to their sequence assignment.
3055624|NCT00801723|Experimental|1: Budesonide MMX® 6 mg|One Budesonide-MMX® 6 mg tablet self-administered by the patients with a glass of water, in the morning after breakfast.
3055625|NCT00801723|Placebo Comparator|2: Placebo|One placebo tablet self-administered by the patients with a glass of water, in the morning after breakfast.
3055626|NCT00801801|Experimental|Metronomic Docetaxel + Sorafenib|"Subjects with advanced non-squamous cell non-small cell lung cancer with poor performance status will receive treatment in this non-randomized, open-label Phase II Study of Metronomic Chemotherapy (docetaxel) plus sorafenib as first-line therapy.~Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle."
3055627|NCT00801827|Experimental|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
3055628|NCT00801892|Active Comparator|1 subjects treated with CPAP|Continuous Positive Airway Pressure treatment (CPAP)
3055629|NCT00801892|Sham Comparator|2 subjects treated with sham-CPAP|Sham Continuous Positive Airway Pressure treatment (sham-CPAP)
3055630|NCT00801983|Experimental|A|Subject receives typical keyboard first for 6 months and alternative keyboard second for 6 months
3055631|NCT00801983|Experimental|B|Subject receives alternative keyboard first for 6 months and typical keyboard second for 6 months
3055632|NCT00802074|Active Comparator|Group A|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg BID Period 3- Fosamprenavir 1400mg BID + Raltegravir 400mg BID
3055633|NCT00802074|Active Comparator|Group B|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg BID + Raltegravir 400mg BID Period 3 Fosamprenavir 1400mg BID
3055634|NCT00802074|Active Comparator|Group C|Period 1-Raltegravir 400mg BID Period2- Fosamprenavir 700mg BID + Ritonavir 100mg BID Period 3- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID
3055635|NCT00802074|Active Comparator|Group D|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 700mg BID + Ritonavir 100mg BID + Raltegravir 400mg BID Period 3-Fosamprenavir 700mg BID + Ritonavir 100mg BID
3055636|NCT00802074|Active Comparator|Group E|Period 1-Raltegravir 400mg BID Period 2- Fosamprenavir 1400mg QD + Ritonavir 100mg QD Period 3- Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID
3055637|NCT00802074|Active Comparator|Group F|Period 1-Raltegravir 400mg BID Period 2-Fosamprenavir 1400mg QD + Ritonavir 100mg QD + Raltegravir 400mg BID Period 3-Fosamprenavir 1400mg QD + Ritonavir 100mg QD
3055638|NCT00802100|Experimental|Olanzapine|Participants will receive treatment with olanzapine and metformin, with the possible addition of simvastatin or benztropine, depending on side effects.
3055639|NCT00802100|Experimental|Perphenazine|Participants will receive treatment with perphenazine and benztropine, with the possible addition of simvastatin or metformin, depending on side effects.
3055640|NCT00802100|Experimental|Aripiprazole|Participants will receive treatment with aripiprazole, with the possible addition of simvastatin, metformin, or benztropine, depending on side effects.
3055641|NCT00802113|Experimental|Arm A - Family Donor|Fludarabine and Busulfan: Patients who have a matched family (allogeneic) donor will go on to receive non-ablative therapy, followed by an infusion of donor stem cells; this is called an allogeneic peripheral blood stem cell transplant. The non-ablative therapy will be busulfan and ﬂudarabine, Usually large (myeloablative) doses of these drugs are used for an allogeneic transplant. However, in this study lower doses (non-ablative) of chemotherapy will be given. In patients who still have evidence of disease after allogeneic transplant, additional donor immune cells (donor lymphocyte infusion) (DLI) will be given twice to further treat the lymphoma.
3055642|NCT00802113|Experimental|Arm B - Unrelated Cord Blood or Adult|Fludarabine, Busulfan and ATG: For patients who don't have a matched family donor, a cord blood search and unrelated adult search will be done at all of the cord blood banks and adult donor registries in the world. If a closely matched cord blood donor or unrelated adult donor is found, non-ablative chemotherapy with busulfan, ﬂudarabine and antithymocyte globulin (ATG) followed by the infusion of matched unrelated cord blood cells or adult donor stem cells or bone marrow to restore the bone marrow will be given.
3055643|NCT00802204|Active Comparator|Lean controls|Lean complete baseline outcome measures only
3055644|NCT00802204|Experimental|Obese|Obese completing baseline and post-VLCD outcome measures
3055645|NCT00802360|Experimental|Menopur/Endometrin|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055646|NCT00802360|Experimental|Menopur/Progesterone in Oil|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055647|NCT00802360|Active Comparator|Follistim/Endometrin|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progestrone vaginal insert (Endometrin®) starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055648|NCT00802360|Active Comparator|Follistim/Progesterone in Oil|"Follitropin beta (Follistim®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in Oil injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055649|NCT00802412|Other|Topiramate|The subjects for the proposed study will be 180 currently smoking, treatment-seeking male veterans with alcohol and nicotine dependence. Ninety subjects will be randomized to the topiramate arm and 90 subjects will be randomized to the placebo group.
3055650|NCT00802412|Placebo Comparator|Placebo|90 participants, will receive matching placebo
3055651|NCT00802438|Experimental|Mepolizumab|up to 3 monthly doses of 750mg i.v. mepolizumab
3055652|NCT00802464|Experimental|GSK1437173A formulation 1 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 1 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3055653|NCT00802464|Experimental|GSK1437173A formulation 2 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) GSK1437173A formulation 2 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3055654|NCT00802464|Experimental|GSK1437173A formulation 3 Group|Male or female subjects, 50 years of age or above, who received 2 doses of GSK1437173A (gE/ASO1B and gE/ASO1E) formulation 3 vaccine, administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3055655|NCT00802464|Placebo Comparator|Control Group|Male or female subjects, 50 years of age or above, who received 2 doses of saline solution (placebo), administered intramuscularly in the upper deltoid region of the non-dominant arm on a 0, 2 month schedule.
3055656|NCT00802503|Experimental|SPN group|"experimental arm: Supplemental Parenteral Nutrition (SPN) is added to enteral nutrition (EN) to reach 100% of their predicted energy needs from ICU day 4.~In the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line. Nutritional products as currently used in our institution. SPN is composed of EN and PN, both techniques being currently used in our institution."
3055657|NCT00802503|No Intervention|Control gr|EN : start EN at 20-30 ml/h per day up to maximal 150 ml/h per day; or day1: 500 ml, day2: 1000 ml, day3: 1500 ml of EN dependant on gastrointestinal tolerance (gastric residue volume more than 500ml). Nutritional products as currently used in our institution.
3055658|NCT00802529|Experimental|Steroid (Methylprednisolone)|Steroid (Methylprednisolone)
3055659|NCT00802529|Active Comparator|Gentamicin|Gentamicin
3055660|NCT00802633|Active Comparator|Stapling device|Efficacy of stapling device during radical cystectomy
3055661|NCT00802633|Active Comparator|Ligasure Device|Efficacy of ligasure tissue sealing device during radical cystectomy
3055662|NCT00802672|Experimental|Test Product|Ciclopirox Olamine Cream 0.77%
3055663|NCT00802672|Active Comparator|Reference Product|Loprox Cream 0.77%
3055664|NCT00802672|Placebo Comparator|Vehicle Product|placebo of test product
3055665|NCT00802685|Experimental|early ibuprofen|"Drug: Early ibuprofen~IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to early treatment will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
3055666|NCT00802685|Other|Late Ibuprofen expectant group (placebo)|"Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to late expectant group will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, late ibuprofen or expectant)."
3055667|NCT00802737|Experimental|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
3055668|NCT00802841|Experimental|Nilotinib|Participants received 400 mg nilotinib twice daily (BID).
3055669|NCT00802841|Active Comparator|Imatinib|Participants received 600 mg imatinib once daily (QD).
3055670|NCT00802867|Experimental|1|Subjects in Study 494-01 and Study 494-03 who had received 4 doses of Pentacel™ vaccine.
3055671|NCT00802880|Experimental|Dacarbazine|Dacarbazine 850 mg/m^2 IV Day 1 of each 21 day cycle.
3055672|NCT00802919|Experimental|Varenicline|Varenciline 1-2 mg/day
3055673|NCT00802919|Placebo Comparator|Matched Placebo|placebo for varenicline
3055674|NCT00802945|Experimental|NKTR-102 q14d|NKTR-102
3055675|NCT00802945|Experimental|NKTR-102 q21d|NKTR-102
3055676|NCT00802997|Active Comparator|1|Treatment with Sinergy system
3055677|NCT00802997|Placebo Comparator|2|placebo controlled
3055678|NCT00803010|Active Comparator|Tacrolimus / Rapamycin (TAC/RAPA)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Rapamycin: given the day before transplant and continued daily for at least one year."
3055679|NCT00803010|Active Comparator|Tacrolimus / Methotrexate (TAC/MTX)|"Tacrolimus: beginning 3 days before transplant and given for at least 50 days.~Methotrexate: given on days 1, 3, 6 and 11, after transplant."
3055680|NCT00803023|Experimental|1|Sodium Oxybate Oral Solution (4.5 grams)
3055681|NCT00803023|Experimental|2|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (4.5 grams)
3055682|NCT00803023|Experimental|3|Sodium Oxybate Oral Solution (6 grams)
3055683|NCT00803023|Experimental|4|Sodium Oxybate taken as a combination of an Oral Solution and Placebo Tablets (6 grams)
3055684|NCT00803049|Experimental|Placebo/Teriflunomide 7 mg|Participants who completed treatment of placebo (for teriflunomide) tablet once daily (QD) for 108 weeks in EFC6049 study, received teriflunomide tablet 7 mg QD for 288 weeks in this extension study.
3055685|NCT00803049|Experimental|Teriflunomide 7 mg/7 mg|Participants who completed treatment of teriflunomide 7 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 7 mg tablet QD for 288 weeks in this extension study.
3055686|NCT00803049|Experimental|Placebo/Teriflunomide 14 mg|Participants who completed treatment of placebo (for teriflunomide) tablet QD for 108 weeks in EFC6049, study received teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
3055687|NCT00803049|Experimental|Teriflunomide 14 mg/14 mg|Participants who completed treatment of teriflunomide 14 mg tablet QD for 108 weeks in EFC6049 study, continued their treatment with teriflunomide 14 mg tablet QD for 288 weeks in this extension study.
3055688|NCT00803062|Active Comparator|Arm I (paclitaxel and cisplatin)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV on day 1 or 2.
3055689|NCT00803062|Experimental|Arm II (paclitaxel, cisplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours or 24 hours on day 1 and cisplatin IV and bevacizumab IV over 30-90 minutes on day 1 or 2.
3055690|NCT00803062|Experimental|Arm III (topotecan hydrochloride and paclitaxel)|Patients receive paclitaxel IV over 3 hours on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
3055691|NCT00803062|Experimental|Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 3 hours and bevacizumab IV over 30-90 minutes on day 1 and topotecan hydrochloride IV over 30 minutes on days 1-3.
3055692|NCT00803101|Experimental|Beriplex® P/N|
3055693|NCT00803101|Active Comparator|Fresh frozen plasma|
3055694|NCT00803114|Experimental|Epidural Morphine|2.5 mg dose of epidural morphine given within one hour following vaginal delivery
3055695|NCT00803114|Placebo Comparator|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
3055696|NCT00803205|Experimental|Ataluren|Participants will receive ataluren 3 times per day (TID): 10 milligrams (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
3055697|NCT00803205|Placebo Comparator|Placebo|Participants will receive placebo TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total daily dose 40 mg/kg). Treatment will continue for 48 weeks, after which participants will be followed for 4 weeks.
3055698|NCT00803244|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3055699|NCT00803244|Placebo Comparator|Placebo|Placebo tablet
3055700|NCT00803270|Active Comparator|Surgical Treatment|Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
3055701|NCT00803270|Active Comparator|Non Surgical Treatment|"The non-surgical treatment will include two components:~Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~Behavioral therapy."
3055702|NCT00803361|Experimental|Duloxetine|
3055703|NCT00803361|Placebo Comparator|Placebo|
3055704|NCT00803400|Active Comparator|Alprazolam|Patients assigned to the pharmacological plan
3055705|NCT00803400|Active Comparator|Alprazolam + Aerobic exercise|Patients assigned to mix plan
3055706|NCT00803413|Other|Back School|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
3055707|NCT00803413|Other|Supervised Walking|Participants received weekly sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group
3055708|NCT00803413|Other|Back School and Walking|Participants received weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening); 30 minutes of on-place supervised walking in group
3055709|NCT00803413|Other|Control Group|Participants received weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
3055710|NCT00803452|Active Comparator|Doxycycline|Oral doxycycline
3055711|NCT00803452|Active Comparator|azithromycin|Topical azithromycin daily to the conjunctival culdesac
3055712|NCT00803517||Photodynamic therapy (PDT)|
3055713|NCT00803517||Focal laser photocoagulation (focal)|
3055714|NCT00803543|Active Comparator|Valacyclovir|This is the arm taking Valacyclovir
3055715|NCT00803543|Placebo Comparator|Placebo|This is the arm taking the placebo
3055716|NCT00803569|Experimental|ALVAC(2)-NY-ESO-1(M)/TRICOM + GM-CSF|Patients received SC injections with ALVAC(2)-NY-ESO-1(M)/TRICOM (0.5 mL) on Day 1 and the GM-CSF sargramostim (100 μg) on Days 1 through 4 in continuous 28-day cycles for up to 6 cycles.
3055717|NCT00803595|Experimental|CS-8958 Low Dose|CS-8958 powder to be inhaled - low-dose arm
3055718|NCT00803595|Experimental|CS-8958 High Dose|CS-8958 powder to be inhaled - high-dose arm
3055719|NCT00803595|Active Comparator|Oseltamivir phosphate|oseltamivir phosphate oral capsules
3055720|NCT00803634|Experimental|Clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was administered intravenously via a single dedicated line to all patients randomized to the clevidipine arm. Clevidipine was infused at an initial rate of 2 mg/h for the first 3 minutes. If blood pressure was not in the target range at 3 minutes, clevidipine was titrated to effect thereafter by doubling the dose every 3 min, per physician discretion and as tolerated by the patient until the desired effect until the SBP target range was attained. Once target range was achieved, the infusion rate could be increased or decreased as needed to maintain blood pressure for minimum of 30 minutes and a maximum duration of 96 hours. The minimum infusion rate was 1 mg/h and maximum infusion rate was 32 mg/h.
3055721|NCT00803634|Active Comparator|Standard of Care IV antihypertensive|For patients randomized to standard of care (SOC) IV antihypertensive treatment, a continuous infusion of an intravenous antihypertensive agent represented standard of care. The selection of treatment was at the discretion of the investigator. The infusion was to be administered according to the institution's treatment practice.
3055722|NCT00803647|Experimental|treatment|mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab
3055723|NCT00803686|Experimental|Part 1 Double Blind Oral rsCT Tablet|Intervention: Oral rsCT tablet given once 4 hours after evening meal.
3055724|NCT00803686|Placebo Comparator|Part 1, Double-blind Oral Placebo Tablet|Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
3055725|NCT00803686|Experimental|Part 2 Open label, Oral rsCT tablet|Intervention: Oral rsCT tablet given once 2 hours after evening meal.
3055726|NCT00803686|Active Comparator|Part 2, Open Label Fortical Nasal Spray|Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
3055727|NCT00803712|Experimental|Cinacalcet Group|Cinacalcet plus low dose active Vitamin D (if prescribed)
3055728|NCT00803712|Active Comparator|Control Group|Flexible active vitamin D dosing
3055729|NCT00803738|Experimental|Test Product|Terconazole Vaginal Suppository
3055730|NCT00803738|Active Comparator|Reference Product|Terazol Vaginal Suppository
3055731|NCT00803751|Experimental|Truview intubation|Receive laryngoscopy with Truview first and is immediately followed by laryngoscopy and intubation with Macintosh
3055732|NCT00803751|Active Comparator|Macintosh intubation|Macintosh blade will be used first followed by laryngoscopy and intubation with the truview
3055733|NCT00803777|Experimental|Intended Users of the Monitoring System|Subjects with type 1 diabetes and healthcare professionals (HCP) used a new blood glucose monitoring system (BGMS) with subject capillary blood. Any subject under age 18 was accompanied by a parent or guardian, who assisted subject if applicable.
3055734|NCT00803790|Experimental|Sequence 1- alendronate+vitamin D combination then alendronate|Participants in Part 1 received 70mg alendronate+5600 International Units (IU) vitamin D combination tablet in Period 1 followed by 70mg alendronate tablet in Period 2. A washout of at least 12 days separated each treatment period.
3055735|NCT00803790|Experimental|Sequence 2 alendronate then alendronate+vitamin D combination|Participants in Part 1 received 70mg alendronate tablet in Period 1 followed by 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
3055736|NCT00803790|Experimental|Sequence 3 alendronate+vitamin D combination then vitamin D|Participants in Part 2 received 70mg alendronate+5600 IU vitamin D combination tablet in Period 1 followed by a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 2. A washout of at least 12 days separated each treatment period.
3055737|NCT00803790|Experimental|Sequence 4- vitamin D then alendronate+vitamin D combination|Participants in Part 2 received a single dose of 5600 IU vitamin D, administered as two 2800 IU tablets in Period 1 followed by a 70mg alendronate+5600 IU vitamin D combination tablet in Period 2. A washout of at least 12 days separated each treatment period.
3055738|NCT00803959|Active Comparator|No UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation only.
3055739|NCT00803959|Active Comparator|UDS|Women desiring surgery for diagnosed, uncomplicated predominant stress urinary incontinence (UI) who receive a basic office evaluation with preoperative urodynamic studies prior to surgery.
3055740|NCT00804141|Experimental|MOA-728 12 mg QD|Participants will receive MOA-728 12 milligrams (mg) SC once daily (QD) for 48 weeks. Dosing could be adjusted to an as needed (PRN) basis with a minimum 1 dose per week and maximum 1 dose per day.
3055741|NCT00804193|Experimental|Test Product|Ciclopirox Olamine Topical Suspension
3055742|NCT00804193|Active Comparator|Reference Product|Loprox® Topical Suspension 0.77%
3055743|NCT00804193|Placebo Comparator|Vehicle Product|placebo of test product
3055744|NCT00804570|Experimental|LY2196044|
3055745|NCT00804570|Placebo Comparator|Placebo|
3055746|NCT00804596|Other|Subjects with diabetes|Subjects with diabetes use a new blood glucose monitoring system with subject capillary blood.
3055747|NCT00804609|Active Comparator|DepoDur following epidural lidocaine|Epidural DepoDur was administered 60 minutes after an epidural Lidocaine top-up for surgical anesthetic in cesarean section patients.
3055748|NCT00804609|Active Comparator|DepoDur following spinal anesthetic|Epidural DepoDur was administered 60 minutes after a standard spinal anesthetic. No prior epidural local anesthetic was used prior to DepoDur in this group assignment.
3055749|NCT00804648|Active Comparator|hemihydrate/maleate/maleate gel|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate 0.5% Period three - Timolol maleate gel forming solution 0.5%
3055750|NCT00804648|Active Comparator|maleate/maleate gel/hemihydrate|Period one - Timolol maleate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol hemihydrate 0.5%
3055751|NCT00804648|Active Comparator|maleate gel/hemihydrate/maleate|Period one - Timolol maleate gel forming solution 0.5% Period two - Timolol hemihydrate 0.5% Period three - Timolol maleate 0.5%
3055752|NCT00804648|Active Comparator|hemihydrate/maleate gel/maleate|Period one - Timolol hemihydrate 0.5% Period two - Timolol maleate gel forming solution 0.5% Period three - Timolol maleate 0.5%
3055753|NCT00804648|Active Comparator|maleate/hemihydrate/maleate gel|Period 1 - Timolol maleate 0.5% Period 2 - Timolol hemihydrate 0.5% Period 3 - Timolol maleate gel forming solution 0.5%
3055754|NCT00804648|Active Comparator|maleate gel, maleate, hemihydrate|Period 1 - Timolol maleate gel forming solution 0.5% Period 2 - Timolol maleate 0.5% Period 3 - Timolol hemihydrate 0.5%
3055755|NCT00804687|Experimental|JNJ-39220675 then Pseudoephedrine then Placebo|Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055756|NCT00804687|Experimental|JNJ-39220675 then Placebo then Pseudoephedrine|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055757|NCT00804687|Experimental|Placebo then JNJ-39220675 then Pseudoephedrine|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055758|NCT00804687|Experimental|Placebo then Pseudoephedrine then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055759|NCT00804687|Experimental|Pseudoephedrine then JNJ-39220675 then Placebo|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055760|NCT00804687|Experimental|Pseudoephedrine then Placebo then JNJ-39220675|Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period.
3055762|NCT00804843|Experimental|Statin 80 mg + Niacin extended-release (ER)|Participants in Russia and Brasil will receive 80 mg Simvastatin + niacin. All other participants will receive 80 mg Atorvastatin + niacin.
3055763|NCT00804843|Active Comparator|Statin 10 mg|Participants in Russia and Brasil will receive 10 mg Simvastatin. All other participants will receive 10 mg Atorvastatin.
3055764|NCT00804908|Placebo Comparator|Placebo for ABT-888 BID + TMZ QD|Placebo for ABT-888 twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3055765|NCT00804908|Active Comparator|ABT-888 20 mg BID + TMZ QD|ABT-888 20 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3055766|NCT00804908|Active Comparator|ABT-888 40 mg BID + TMZ QD|ABT-888 40 mg twice daily (BID) for 7 days every 28 days plus temozolomide (TMZ; by body surface area) 150 mg/m2 once daily (QD) for 5 days every 28 days.
3055767|NCT00804973|Experimental|1|
3055768|NCT00804973|Placebo Comparator|2|
3055769|NCT00804973|Active Comparator|3|
3055770|NCT00804986|Experimental|0.5 mg LY2428757|Once weekly, subcutaneous injection of 0.5 milligram (mg) LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055771|NCT00804986|Experimental|2.0 mg LY2428757|Once weekly, subcutaneous injection of 2.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055772|NCT00804986|Experimental|6.2 mg LY2428757|Once weekly, subcutaneous injection of 6.2 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055773|NCT00804986|Experimental|12.0 mg LY2428757|Once weekly, subcutaneous injection of 12.0 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055774|NCT00804986|Experimental|17.6 mg LY2428757|Once weekly, subcutaneous injection of 17.6 mg LY2428757 for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055775|NCT00804986|Placebo Comparator|Placebo|Once weekly, subcutaneous injection of placebo for 12 weeks. All injections were administered by study site personnel who were blinded to treatment assignment.
3055776|NCT00804999|Placebo Comparator|Placebo 1|Subjects that have never worn contacts with no ocular problems were selected. A baseline HRT was performed. Trial contact lenses were soaked in clear care solution for 10 hours. After 10 hours of the lenses soaking in clear care the subject returned. The contacts lenses that were soaked in clear care were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contact lenses were removed. An HRT was performed immediately after removing the contact lenses. The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3055777|NCT00804999|Active Comparator|Renu|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in ReNu contact solution for 10 hours. After 10 hours of the lenses soaking in ReNu the subject returned. The contacts were inserted onto the patients eyes. The patient then wore the contacts for two hours. After two hours the contacts lenses were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3055778|NCT00804999|Active Comparator|Optifree|Subjects that had worn contacts for at least two weeks without incident were selected. A baseline HRT was performed.Trial contacts lenses were soaked in Optifree Replenish contact solution for 10 hours. After 10 hours of the lenses soaking in Optifree Replenish the subject returned. The contacts were inserted onto the patients eyes. The patient wore contacts the for two hours. After two hours the contacts were removed. An HRT both with and without sodium fluorescein was performed immediately after removing the contact lenses.The HRT scans were analyzed for dendritic cell migration, basal cell epithelial density and nerve density and tortuosity.
3055779|NCT00805025|Experimental|AZLI|Participants were evaluated beginning 14 days prior to starting a 28-day course of AZLI (Day 0 to Day 28), followed by post-treatment assessments every 14 days through Day 56, for a total of 70 days of participation in the study.
3055780|NCT00805038|Placebo Comparator|Control|Usual care
3055781|NCT00805038|Experimental|Intervention|Navigator will assist patients in completing steps in transplant process
3055782|NCT00805142|Experimental|Opioid-Naive Participants (Tapentadol PR)|Opioid-naive participants are defined as those who had moderate to severe cancer pain that is not controlled sufficiently with non-opioid medications. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in the maintenance period. Treatment will be initiated with tapentadol prolonged release (JNS024PR, PR) 25 milligram (mg) oral tablet twice daily. Dose will be increased or decreased as per Investigator's discretion up to Day 14. Maximum dose limit will be 500 mg per day. Participants will then be assigned to the treatment in the maintenance period (15-19 days). The maintenance period is duration between the first dose and the final assessment in the maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at the same dose used on last day of titration period.
3055783|NCT00805142|Experimental|Opioid-Switch Participants (Tapentadol PR)|Opioid-switching participants are defined as those who had moderate to severe cancer pain that is controlled sufficiently with opioid therapy. Treatment period comprises of Titration and Maintenance period. Titration period (3-14 days) is duration between start of treatment to day before initial dose in maintenance period. Initial dose of tapentadol PR is selected according to daily dose of opioid (morphine sustained release [SR] preparation, oxycodone hydrochloride [HCl] SR tablet or fentanyl patch). Equivalent dose of tapentadol PR oral tablet twice daily is given depending on daily dose of opioid at completion of Screening period. Maximum dose limit is 500 mg per day. Participants will then be assigned to treatment in maintenance period (15-19 days). Maintenance period is defined as duration between first dose and final assessment in maintenance period. Participants will receive tapentadol PR oral tablet twice daily for 5 days at same dose used on last day of titration period.
3055784|NCT00805194|Experimental|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
3055785|NCT00805194|Placebo Comparator|Placebo plus docetaxel|Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
3055786|NCT00805207|Experimental|Progesterone - PCOS|Women with obesity and polycystic ovary syndrome
3055787|NCT00805207|Experimental|Testosterone - premenopausal women|Healthy premenopausal women.
3055788|NCT00805207|Experimental|Continuous positive airway pressure|Women and men with obesity and obstructive sleep apnea
3055789|NCT00805207|Experimental|Glucocorticoid|Lean and obese healthy women, and obese men
3055790|NCT00805207|Experimental|Estrogen|Postmenopausal women
3055791|NCT00805207|Other|control|Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits
3055792|NCT00805207|No Intervention|control - baseline testing only|Healthy men and women
3055793|NCT00805207|Experimental|Progesterone - Postmenopausal women|Postmenopausal women
3055794|NCT00805207|Experimental|Testosterone - Postmenopausal women|Postmenopausal women
3055795|NCT00805285|Experimental|Combination Oral Budesonide and Rectal Hydrocortisone|See intervention
3055796|NCT00805389|Experimental|GSK223192A 1 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 1, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3055797|NCT00805389|Experimental|GSK223192A 2 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 2, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3055798|NCT00805389|Experimental|GSK223192A 3 Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of GSK223192A vaccine, lot 3, at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The GSK223192A vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3055799|NCT00805389|Experimental|Fendrix Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Fendrix™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Fendrix™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3055800|NCT00805389|Active Comparator|Engerix-B Group|Subjects aged between, and including, 18 and 45 years at the time of first vaccination received 2 doses of Engerix-B™ vaccine at Days 0 and 30. 2 subsets of subjects within the group - subjects identified with either a pre-defined Human Leukocytes Antigen (HLA) Class I subtype (Subset 1) or a pre-defined HLA Class II subtype (Subset 2) - additionally received 1 booster dose of Hepatitis B surface antigens (HBsAg) at Day 360. The Engerix-B™ vaccine and HBsAg antigens were administered intramuscularly into the deltoid muscle of the non-dominant arm.
3055801|NCT00805441|Placebo Comparator|Placebo|
3055802|NCT00805441|Experimental|LY686017|
3055803|NCT00805467|Experimental|1|R935788 50 mg tablet, orally, twice-a-day
3055804|NCT00805467|Experimental|2|R935788 100 mg tablet, orally, twice-a-day
3055805|NCT00805467|Experimental|3|R935788 100 mg tablet, orally, once-a-day
3055806|NCT00805467|Experimental|4|R935788 150 mg tablet, orally, once-a-day
3055807|NCT00805480|Experimental|AIN457 3 mg/kg|Participants randomized to this arm received AIN457 3 mg/kg on day 1, and then matching placebo on days 15 and 29.
3055808|NCT00805480|Experimental|AIN457 10 mg/kg|Participants randomized to this arm received AIN457 10 mg/kg on day 1, and then matching placebo on days 15 and 29.
3055809|NCT00805480|Experimental|AIN457 10 mg/kg x3|Participants randomized to this arm received AIN457 3 mg/kg on days 1, 15 and 29.
3055810|NCT00805480|Placebo Comparator|Placebo|Participants randomized to this arm received matching placebo to AIN457 on days 1, 15 and 29
3055811|NCT00805493|No Intervention|Medication Taper|All participants begin with gradual tapering to the point of discontinuing medication
3055812|NCT00805493|No Intervention|Random assignment to placebo|Once they are medication-free, 50% of participants are randomized to placebo
3055813|NCT00805493|Active Comparator|Random assignment to riluzole|One they are medication-free, 50% of participants are randomized to riluzole
3055814|NCT00805532|Experimental|Behavioral Activation|Behavioral Activation (BA), modified to be delivered in 6-8, 60 minute sessions to address PTSD-related problems.
3055815|NCT00805532|Active Comparator|Treatment as Usual|Treatment As Usual for PTSD (TAU) within VA PTSD specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system.
3055816|NCT00805545|Experimental|A|Group of patients that will receive antibiotics 30-60 minutes prior to incision
3055817|NCT00805545|Active Comparator|B|Group of patients that will receive antibiotics immediately after clamping the umbilical cord
3055818|NCT00805675|Experimental|Telbivudine 600 mg monotherapy|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3055819|NCT00805675|Active Comparator|Tenofovir disproxil fumarate 300 mg monotherapy|All patients in this arm were randomized to receive Tenofovir disoproxil fumarate 300 mg(equivalent to tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3055820|NCT00805675|Active Comparator|Telbivudine 600 mg and Tenofovir 300 mg|All patients in this arm were randomized to receive Telbivudine (LDT) 600 mg QD and Tenofovir (TDF) 300 mg (equivalent to Tenofovir disoproxil 245 mg)QD. Patients were randomized prior to the first dose of study medication, which was defined as the study Baseline (Day 1) Visit. Subsequently, patients returned to the clinic at Days 2, 4, 6, 8, 11, 15 (Wk 2), 22 (Wk 3), 29 (Wk 4), 43 (Wk 6), 57 (Wk 8), and 85 (Wk 12) during the 12 weeks treatment phase.
3055821|NCT00805740|Experimental|Anidulafungin arm|
3055822|NCT00805740|Experimental|Caspofungin arm|
3055823|NCT00805766|Experimental|TA-650|
3055824|NCT00805792|Experimental|Donepezil|Participants received treatment with donepezil within 24 hours after the onset of ischemic stroke symptoms. Participants received donepezil 5 mg/day for 30 days, followed by an increase to 10 mg/day for 60 days.
3055825|NCT00805870|Experimental|Fish Oil|Lovaza, 3 grams/day for 65 days
3055826|NCT00805870|Placebo Comparator|Control|Wheat Germ Oil, 3 grams/day for 65 days
3055827|NCT00805935|Experimental|Menotropin/Progesterone vaginal insert|"Highly purified menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 100 mg starts on the day following oocyte retrieval and continues for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055828|NCT00805935|Experimental|Menotropin/Progesterone in oil|"Menotropin (Menopur®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055829|NCT00805935|Active Comparator|Follitropin beta/Progesterone vaginal insert|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone vaginal insert (Endometrin®) 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055830|NCT00805935|Active Comparator|Follitropin beta/Progesterone in oil|"Follitropin beta (Follistim Pen®) 225 IU from day 1-6 of menstrual cycle. May be adjusted up to 450 IU daily for more days until human chorionic gonadotropin (hCG) criteria are met.~Progesterone in oil 50 mg injections start on the day following oocyte retrieval and continue for a total duration of 10 weeks or until a negative pregnancy test is obtained."
3055831|NCT00805948|Experimental|DeNovo|Prospectively enrolled subjects treated with the Talent Thoracic Stent Graft System following U.S. market approval of the device.
3055832|NCT00805948|No Intervention|Valor|Historical control arm, consisting of 195 subjects from the VALOR Test Group (PMA P070007) that were followed for 5 years per the VALOR protocol. The data from these subjects will be combined with the data from the subjects implanted after commercial release (DeNovo) to comprise the final analysis cohort for the THRIVE Study
3055834|NCT00806026|Experimental|PBO/PGB 300 mg|
3055835|NCT00806026|Active Comparator|PBO/PPX 0.25 mg|
3055836|NCT00806026|Active Comparator|PBO/PPX 0.5 mg|
3055837|NCT00806026|Experimental|PGB 300 mg|
3055838|NCT00806026|Active Comparator|PPX 0.25 mg|
3055839|NCT00806026|Active Comparator|PPX 0.5 mg|
3055840|NCT00806078|Experimental|1|Single dose intact capsules 2 x 324 mg
3055841|NCT00806078|Experimental|2|Single dose contents of two capsules (2 x 324 mg) opened and mixed in 120 mL of chocolate pudding
3055842|NCT00806156|Experimental|NKTR-102 q14d|NKTR-102 was administered as an intravenous (IV) infusion over 90 ± 10 minutes, on Day 1 of each 2-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 4 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
3055843|NCT00806156|Experimental|NKTR-102 q21d|NKTR-102 was administered as an IV infusion over 90 ± 10 minutes, on Day 1 of each 3-week [± 2 days] cycle at a dose of 170 mg/m^2 for the first 6 patients enrolled and at a dose of 145 mg/m^2 for the remainder of the patients.
3055844|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Non-Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - infants who only provided SAEs (Serious Adverse Events) and medically attended AEs (Adverse Events)."
3055845|NCT00806195|Active Comparator|Routine Vaccines (Non-Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR: 12 months.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3055846|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (Detailed)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
3055847|NCT00806195|Active Comparator|Routine Vaccines (Detailed)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6 months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs."
3055848|NCT00806195|Experimental|MenACWY-CRM197 + Routine Vaccines (All)|"Infants received one vaccination of MenACWY-CRM197 vaccine at 2, 4, 6 and 12 months of age and one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3055849|NCT00806195|Active Comparator|Routine Vaccines (All)|"Infants received one vaccination of routine vaccines (according to the local vaccination schedule) - DTaP: 2, 4, 6, 15 months, IPV: 2, 4, 6, months, Hib: 2, 4, 6, 15 months, Pneumococcal conjugate: 2, 4, 6, 12 months, MMR, Varicella, and Hepatitis A: 12 months. HBV and rotavirus vaccines should be administered according to ACIP guidelines during the first year of life.~Routine vaccines given to subjects in these arms will be consistent with the US ACIP recommended vaccines.~All (Detailed and Non-Detailed subjects): Detailed - subjects who provided Reactogenicity and all AEs for 7 days, SAEs and medically attended AEs; Non-Detailed - subjects who only provided SAEs and medically attended AEs."
3055850|NCT00806221|Experimental|Emollient|Skin barrier protection from birth
3055851|NCT00806234|Active Comparator|1|Participants will continue on current antipsychotic medication.
3055852|NCT00806234|Experimental|2|Participants will undergo a staggered switch from current antipsychotic medication to aripiprazole or perphenazine.
3055853|NCT00806234|Experimental|3|Participants will add metformin to current antipsychotic medication treatment.
3055854|NCT00806260|Experimental|Treatment 1|Dosed first with alcohol, then active VI-0521, and last, VI-0521 placebo
3055855|NCT00806260|Experimental|Treatment 2|First dosed with alcohol placebo (fruit juice), then active VI-0521, and last, placebo VI-0521
3055856|NCT00806260|Experimental|Treatment 3|First dosed with alcohol, then VI-0521 placebo, and last, active VI-0521
3055857|NCT00806260|Experimental|Treatment 4|First dosed with alcohol placebo, then VI-0521 placebo, and last, active VI-0521
3055858|NCT00806286|Experimental|CS-7017 with Paclitaxel and Carboplatin|
3055859|NCT00806286|Placebo Comparator|Paclitaxel and Carboplatin|
3055860|NCT00806351|Experimental|Anidulafungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
3055861|NCT00806351|Experimental|Caspofungin Arm|Subjects were randomized 2:1 (anidulafungin:caspofunin).
3055862|NCT00806403|Active Comparator|thrombolysis|
3055863|NCT00806403|Active Comparator|invasive|
3055864|NCT00806416|Experimental|Sequence 1|alendronate/vitamin D combination then alendronate
3055865|NCT00806416|Experimental|Sequence 2|alendronate then alendronate/vitamin D combination
3055866|NCT00806416|Experimental|Sequence 3|alendronate/vitamin D combination then vitamin D
3055867|NCT00806416|Experimental|Sequence 4|vitamin D then alendronate/vitamin D combination
3055868|NCT00806442|Experimental|1: Borage Seed Oil and Echium Seed Oil|Borage/Echium plant seed oils: 2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
3055869|NCT00806442|Placebo Comparator|2: Placebo Comparator|Placebo comparator: 9 g/day corn oil
3055870|NCT00806494|Experimental|Treatment Arm|Fesoterodine 4mg, escalating to 8mg as required
3055871|NCT00806546|Experimental|NP101|sumatriptan iontophoretic transdermal patch
3055872|NCT00806585|Experimental|MK-0736 0.5 mg|One MK-0736 0.5 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
3055873|NCT00806585|Experimental|MK-0736 2.0 mg|One MK-0736 2.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will then be switched to MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
3055874|NCT00806585|Experimental|MK-0736 8.0 mg|One MK-0736 8.0 mg tablet, orally, once daily for 24 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for 52 weeks (Phase B).
3055875|NCT00806585|Active Comparator|HCTZ 12.5 mg → MK-0736 8.0 mg|one 12.5 mg hydrochlorothiazide (HCTZ) tablet daily, orally, for 12 weeks. Participant then switched to MK-0736 8.0 mg for 12 weeks (Phase A). Participant will continue to receive MK-0736 8.0 mg, once daily for an additional 52 weeks (Phase B).
3055876|NCT00806585|Placebo Comparator|Placebo|One placebo tablet daily, orally, for 24 weeks (Phase A). Participant will continue to receive placebo, once daily for 52 weeks (Phase B)
3055877|NCT00806598|Experimental|Thymoglobulin + Cyclosporin|Combination of Thymoglobulin 3.5 or 2.5 mg/kg/day intravenous (IV) for 5 days + Methylprednisone 1 mg/kg/day IV for 5 days, before each dose Thymoglobulin + Cyclosporin 5 mg/kg orally for 6 months following Thymoglobulin + Granulocyte - Colony Stimulating Factor (G-CSF) 5 microgram/kg subcutaneously daily up to 3 months
3055878|NCT00806624|Experimental|2|DU-176b tablets: high-dose
3055879|NCT00806624|Active Comparator|3|Warfarin tablets
3055880|NCT00806624|Experimental|1|DU-176b tablets: low-dose
3055881|NCT00806676|Other|1. Chronic Kidney Disease, NKF Stage 1-4|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with chronic kidney disease will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3055882|NCT00806676|Other|2. ESRD (dialysis)|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with ESRD will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3055883|NCT00806676|Other|3. Kidney Transplant Recipient|Gardasil vaccine series will be administered according to FDA-approved schedule, as recommended by the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Geometric antibody titers among those with a kidney transplant will be compared to titers in the general population measured during Phase III clinical studies by Merck & Co, Inc, to prove efficacy of the vaccine and obtain FDA approval.
3055884|NCT00806819|Experimental|nintedanib (BIBF1120) plus pemetrexed|nintedanib (BIBF1120) along with standard therapy of pemetrexed
3055885|NCT00806819|Placebo Comparator|Placebo plus pemetrexed|Pemetrexed standard therapy
3055886|NCT00806819|Experimental|nintedanib (BIBF1120) monotherapy|nintedanib (BIBF1120) monotherapy only for patients who discontinue pemetrexed
3055887|NCT00806819|Active Comparator|pemetrexed monotherapy|pemetrexed monotherapy only for patients who discontinue nintedanib (BIBF1120) or placebo
3055888|NCT00806819|Placebo Comparator|placebo monotherapy|placebo monotherapy only for patients who discontinue pemetrexed
3055889|NCT00806988|Active Comparator|Mitral Valve Repair|Participants will undergo CABG and a mitral valve repair procedure.
3055890|NCT00806988|Active Comparator|CABG|Participants will undergo CABG.
3055891|NCT00807001|Experimental|Cohort A|Subjects randomized 8:2 (active:placebo) to receive one 25 milligrams (mg) capsule of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3055892|NCT00807001|Experimental|Cohort B|Subjects randomized 8:2 (active:placebo) to receive two 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3055893|NCT00807001|Experimental|Cohort C|Subjects randomized 8:2 (active:placebo) to receive three 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3055894|NCT00807001|Experimental|Cohort D|Subjects randomized 8:2 (active:placebo) to receive four 25 mg capsules of IDX184 per day for 3 days. Fourteen days after treatment, subjects were offered a course of pegylated interferon and ribavirin according to local standard of care.
3055895|NCT00807014|Experimental|Duac Gel|Duac Gel
3055896|NCT00807014|Active Comparator|Differin gel|Differin gel
3055897|NCT00807040|Active Comparator|Mitral Valve Repair with Annuloplasty|Participants will undergo mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
3055898|NCT00807040|Active Comparator|Mitral Valve Replacement|Participants will undergo mitral valve replacement and complete preservation of the sub-valvular apparatus.
3055899|NCT00807092|Experimental|BIAsp 30|BIAsp 30 (biphasic insulin aspart 30) administered subcutaneously (under the skin) twice daily (before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BIAsp 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
3055900|NCT00807092|Experimental|BHI 30|BHI 30 (biphasic human insulin 30) administered subcutaneously (under the skin) twice daily (30 minutes before breakfast and dinner) + metformin. Initial total daily dose of 0.3 U or IU/kg body weight followed by individual dose adjustment for BHI 30 was performed over the first 4 weeks (titration period) to achieve the pre-meal blood glucose target of 4.4-6.1 mmol/l. The achieved dose was maintained for the last 2 weeks of treatment unless hypoglycaemia occurred.
3055901|NCT00807144|Experimental|Prolonged-Release Tacrolimus|Transplant maintenance immunosuppression with Prolonged-release Tacrolimus monotherapy
3055902|NCT00807144|Active Comparator|Standard-Release tacrolimus|Transplant maintenance immunosuppression with Standard-release Tacrolimus monotherapy
3055903|NCT00807209|Experimental|High Dose SKY0402|
3055904|NCT00807209|Active Comparator|Standard of Care|
3055905|NCT00807209|Experimental|Low Dose SKY0402|
3055906|NCT00807235|Experimental|Regimen 1|
3055907|NCT00807235|Experimental|Regimen 2|
3055908|NCT00807248|Placebo Comparator|Escitalopram placebo and gaboxadol placebo|
3055909|NCT00807248|Active Comparator|Escitalopram 20 mg and gaboxadol placebo|
3055910|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 5 mg|
3055911|NCT00807248|Experimental|Escitalopram 20 mg and gaboxadol 10 mg|
3055912|NCT00807456|Experimental|ASTRA TECH Implant System, OsseoSpeed™|
3055913|NCT00807495|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
3055914|NCT00807560|Experimental|FBT-PO|Family Based Therapy for Pediatric Overweight.
3055915|NCT00807560|Active Comparator|NEC-control|Nutritional Educational Control Condition (NEC).
3055916|NCT00807573|Experimental|Paclitaxel, Bevacizumab & Pemetrexed|During each 28-day cycle, paclitaxel, pemetrexed and bevacizumab will be given intravenously on days 1 and 15. Paclitaxel will be administered at 90mg/m^2 over 60 minutes on days 1 and 15. Pemetrexed 500mg/m^2 will be administered over 10 minutes on days 1 and 15. Bevacizumab will be given at 10mg/kg over 20 minutes on days 1 and 15
3055917|NCT00807586|Experimental|Steroid|
3055918|NCT00807586|Placebo Comparator|Placebo|
3055919|NCT00807599|Experimental|Stem cell transplant x 1 or x 2|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone, saving stem cell transplant for a later time."
3055920|NCT00807599|Experimental|Continue lenalidomide and dexamethasone|"All patients on this study start with the same treatment, lenalidomide and dexamethasone by mouth. After patients have received 4 cycles of lenalidomide and dexamethasone and are within 2 weeks of completing stem cell collection, they are randomized (like the toss of a coin) to either :~stem cell transplant right after collection~continue lenalidomide and dexamethasone~saving stem cell transplant for a later time."
3055921|NCT00807664|Experimental|1|Biatain Ag dressing
3055922|NCT00807664|Active Comparator|2|Biatain dressing
3055923|NCT00807742|Experimental|Contingency Management (CM)|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
3055924|NCT00807742|Active Comparator|Noncontingent Reinforcement (NR)|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
3055925|NCT00807768|Active Comparator|Arm I (pelvic radiation therapy)|Patients undergo conventional or intensity-modulated pelvic radiation therapy once daily, 5 days a week, for 5-6 weeks (total of 25-28 fractions) in the absence of disease progression or unacceptable toxicity. Patients with stage II disease or stage I disease with a confirmed diagnosis of clear cell and/or papillary serous histology may also undergo 1 or 2 intravaginal (i.e., vaginal cuff) brachytherapy boost treatments.
3055926|NCT00807768|Experimental|Arm II (brachytherapy, paclitaxel, carboplatin)|Patients undergo vaginal cuff brachytherapy comprising 3-5 high-dose rate brachytherapy treatments over approximately 2 weeks or 1 or 2 low-dose rate brachytherapy treatments over 1-2 days. Beginning within 3 weeks after initiating brachytherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Chemotherapy repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3055927|NCT00807846|Experimental|Celecoxib|
3055928|NCT00807846|Experimental|Naproxen|
3055929|NCT00807885|Experimental|Tegaderm-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with Tegaderm
3055930|NCT00807885|Experimental|Tape-secured 24 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, Teflon angiocatheter secured with a tape double chevron
3055931|NCT00807885|Experimental|Tegaderm-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with Tegaderm
3055932|NCT00807885|Experimental|Tape-secured 24 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 24-gauge, 0.75 inch long, polyurethane angiocatheter secured with a tape double chevron
3055933|NCT00807885|Experimental|Tegaderm-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with Tegaderm
3055934|NCT00807885|Experimental|Tape-secured 20 ga Teflon catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, Teflon angiocatheter secured with a tape double chevron
3055935|NCT00807885|Experimental|Tegaderm-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with Tegaderm
3055936|NCT00807885|Experimental|Tape-secured 20 ga polyurethane catheter|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a 20-gauge, 1.0 inch long, polyurethane angiocatheter secured with a tape double chevron
3055937|NCT00807885|Experimental|SC button with 27 ga X 9 mm needle|subcutaneous administration of a single 150 U dose of hylenex, followed by subcutaneous infusion (delivered by large volume infusion pump) of 1000 mL Lactated Ringer's solution, both delivered through a button-type subcutaneous delivery system (with a 27-gauge, 9 mm long metal needle)
3055938|NCT00807937|Experimental|A|AZD7325 5mg twice daily
3055939|NCT00807937|Experimental|B|AZD7325 15mg twice daily
3055940|NCT00807937|Active Comparator|C|Lorazepam 2mg twice daily
3055941|NCT00807937|Placebo Comparator|D|Placebo
3055942|NCT00807989|Active Comparator|Carbamazepine|Carbamazepine
3055943|NCT00807989|Experimental|Lamotrigine/Valproate|Lamotrigine and Valproate combination therapy
3055944|NCT00808015||Patients in routine practice|Patients prescribed Champix by treating physician and then entered into trial
3055945|NCT00808028|Experimental|1|dose level 1 rLP2086 vaccine
3055946|NCT00808028|Experimental|2|dose level 2 rLP2086 vaccine
3055947|NCT00808028|Experimental|3|dose level 3 rLP2086 vaccine
3055948|NCT00808028|Placebo Comparator|4|normal saline (placebo)
3055949|NCT00808067|Experimental|dabigatran dose 1|dabigatran high dose twice daily
3055950|NCT00808067|Experimental|dabigatran dose 2|dabigatran low dose twice daily
3055951|NCT00808132|Experimental|1|bazedoxifene 20 mg/conjugated estrogens 0.45 mg
3055952|NCT00808132|Experimental|2|bazedoxifene 20 mg/conjugated estrogens 0.625 mg
3055953|NCT00808132|Experimental|3|bazedoxifene 20 mg
3055954|NCT00808132|Active Comparator|4|Prempro
3055955|NCT00808132|Placebo Comparator|5|Placebo
3055956|NCT00808210|Experimental|Ocrelizumab 200mg|Participants received two intravenous (IV) infusions of 200 mg ocrelizumab administered on Day 1 and Day 15 and placebo IV infliximab infusions administered on Day 1, Day 15, Week 6, and Week 14. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
3055957|NCT00808210|Active Comparator|Infliximab 5mg/kg|Participants received four IV infusions of 5 mg/kg infliximab administered on Day 1, Day 15, Week 6, and Week 14 and placebo ocrelizumab infusions administered on Day 1 and Day 15. In addition to the study medication, all patients were to receive methotrexate at a stable dose of 7.5-25 mg/week and folic acid or equivalent at a dose of 5 mg/week to minimize methotrexate toxicity.
3055958|NCT00808236|Experimental|RhinoChill|Intra-arrest cooling with the RhinoChill during advanced cardiac life support
3055959|NCT00808236|Other|Control|Advanced cardiac life support, only
3055960|NCT00808249|Experimental|A-AZD7325 2mg|AZD7325 2mg BID
3055961|NCT00808249|Experimental|B-AZD7325 5mg|AZD7325 5mg BID
3055962|NCT00808249|Experimental|C-AZD7325 10mg|AZD7325 10mg QD
3055963|NCT00808249|Experimental|D-Placebo|Placebo
3055964|NCT00808340|Active Comparator|senofilA test/senofilA prod/balafilconA|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, senofilcon A production worn second, and balafilcon A worn third.
3055965|NCT00808340|Active Comparator|senofilcon A test/balafilcon A/senofilcon A prod|Subjects wear 3 multifocal contact lenses: senofilcon A test worn first, balafilcon A worn second, and senofilcon A production worn third.
3055966|NCT00808340|Active Comparator|senofilcon A prod/senofilcon A test/balafilcon A|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, senofilcon A test worn second, and balafilcon A worn third.
3055967|NCT00808340|Active Comparator|senofilcon A prod/ balifilcon A/ senofilcon A test|Subjects wear 3 multifocal contact lenses: senofilcon A production worn first, balafilcon A worn second, and senofilcon A test worn third.
3055968|NCT00808340|Active Comparator|balafilcon A/senofilcon A test/senofilcon A prod|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A test worn second, and senofilcon A production worn third.
3055969|NCT00808340|Active Comparator|balafilcon A/senofilcon A prod/senofilcon A test|Subjects wear 3 multifocal contact lenses: balafilcon A worn first, senofilcon A production worn second, senofilcon A test worn third.
3055970|NCT00808405|Active Comparator|acyclovir|
3055971|NCT00808405|Placebo Comparator|placebo|
3055972|NCT00808444|Experimental|Synflorix Clinical Lot & Infanrix Group|Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
3055973|NCT00808444|Experimental|Synflorix Commercial Lot Infanrix Group|Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
3055974|NCT00808470|Experimental|Nutrients|Subjects in University of Florida music player study who are assigned to nutrient condition(beta-carotene, vitamins C and E, magnesium). Nutrient tablets are consumed for 4 days.
3055975|NCT00808470|Placebo Comparator|Placebo for nutrients|Subjects in University of Florida music player study who are assigned to control (placebo) condition. Placebo tablets are consumed for 4 days.
3055976|NCT00808483|Experimental|Walking skill training group|Participation in the supervised walking skill training program.
3055977|NCT00808483|No Intervention|Control group|No participation in the supervised walking skill training program
3055978|NCT00808509|Active Comparator|Adalimumab + MTX|Participants continued treatment with adalimumab 40 mg subcutaneously every other week plus methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
3055979|NCT00808509|Experimental|Methotrexate|Participants discontinued adalimumab and continued to receive methotrexate (at least 10 mg/week orally or subcutaneously) for 52 weeks. Participants with a significant increase in RA disease activity were re-instituted to adalimumab 40 mg every other week (rescue arm). After Week 52 an observational extension period ensued where participants were treated at the discretion of the investigator.
3055980|NCT00808639|Experimental|Dose Dense MVAC|Chemo therapy with methotrexate, vinblastine, Adriamycin, Cisplatin
3055981|NCT00808665|Experimental|Dexmedetomidine|At the beginning of spinal surgery, patients will receive 1 hour dexmedetomidine intravenous bolus of 0.7 mcg/kg, followed by infusion of dexmedetomidine at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of dexmedetomidine at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
3055982|NCT00808665|Placebo Comparator|Saline|Since this is a blinded study, at the beginning of spinal surgery, patients will receive a 1 hour 0.9% saline intravenous bolus at a rate and volume commensurate with a 0.7 mcg/kg/hour bolus of dexmedetomidine. Similarly, this will be followed with a saline infusion at a rate of 0.5 mcg/kg/hour for 2 hours, followed by an infusion of saline at a rate of 0.2 mcg/kg/hour for the duration of the procedure and for 4 hours after the procedure.
3055983|NCT00808808||Arm A (Control)|A control arm of usual care offering TIV with baseline advertisement
3055984|NCT00808808||Arm B (Choice)|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
3055985|NCT00808808||Arm C (Choice Plus)|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
3055986|NCT00808834|Other|Senofilcon A / Lotrafilcon A|Senofilcon A, followed by Lotrafilcon A
3055987|NCT00808834|Other|Lotrafilcon A / Senofilcon A|Lotrafilcon A, followed by Senofilcon A
3055988|NCT00809055|Experimental|High dose caffeine|Loading dose 40mg/kg IV caffeine citrate, followed 12 hours later by 20mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate, followed 12 hours later by 10mg/kg IV caffeine citrate.
3055989|NCT00809055|Active Comparator|Standard dose caffeine|Loading dose 20mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo, followed 12 hours later with 10mg/kg IV caffeine citrate, followed 12 hours later with D5W placebo.
3055990|NCT00809094|Placebo Comparator|Placebo|Placebo was administered oral tablet TID for 24 weeks.
3055991|NCT00809094|Active Comparator|N-Acetylcysteine|Participants received 900 mg of oral N-acetylcysteine TID for 24 weeks.
3055992|NCT00809133|Experimental|Part A|BIBW2992 + Paclitaxel
3055993|NCT00809133|Experimental|Part B|BIBW2992 + Paclitaxel + Bevacizumab
3055994|NCT00809133|Experimental|Part C|BIBW2992 + Carboplatin
3055995|NCT00809133|Experimental|Part D|BIBW2992 +Paclitaxel + Carboplatin
3055996|NCT00809146|Active Comparator|Intramuscular (IM) anticonvulsant|This group gets active treatment with an anticonvulsant by the intramuscular route of administration.
3055997|NCT00809146|Active Comparator|Intravenous (IV) anticonvulsant|This group gets active treatment with an anticonvulsant by the intravenous route of administration.
3055998|NCT00809159|Experimental|Part 1 - AIN457A 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as a single dose.
3055999|NCT00809159|Placebo Comparator|Part 1 - Placebo|Placebo to AIN457A was administered intravenously as a single dose
3056000|NCT00809159|Experimental|Parts 1 and 2 - AIN457A 1.0 mg/kg|AIN457A 1.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3056001|NCT00809159|Experimental|Part 1 and 2 - AIN457 0.1 mg/kg|AIN457A 0.1 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3056002|NCT00809159|Experimental|Part 1 and 2 - AIN457 10 mg/kg|AIN457A 10.0 mg/kg was administered intravenously as 2 doses 21 days apart, i.e. the first dose on day 1 and the second dose on day 22.
3056003|NCT00809185|Experimental|RAD001 (everolimus)|RAD001 (everolimus) at 10mg/day with Bone marrow aspirate/biopsy and other laboratory biomarker analysis
3056004|NCT00809328|Experimental|Azithromycin|Azithromycin switch therapy (switch from intravenous to oral)
3056005|NCT00809354|Active Comparator|IV Placebo + NSAID|Oral NSAID
3056006|NCT00809354|Experimental|Tanezumab 5 mg|IV tanezumab 5 mg every 8 weeks (through Week 48)
3056007|NCT00809354|Experimental|Tanezumab 10 mg|IV tanezumab 10 mg every 8 weeks (through Week 48)
3056008|NCT00809354|Experimental|Tanezumab 5 mg + NSAID|IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
3056009|NCT00809354|Experimental|Tanezumab 10 mg + NSAID|IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
3056010|NCT00809445|Experimental|HIV rapid test & counseling|Participants will be offered an oral fluid HIV rapid test (via oral swab) and brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach (Project RESPECT-2 counseling). Prior to receiving testing, study participants must first provide consent for HIV testing. Consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test.
3056011|NCT00809445|Experimental|HIV rapid test and info|Participants will be offered an oral fluid HIV rapid test (via oral swab). Prior to receiving testing, study participants must first provide consent for HIV testing. Again, consent for testing will be obtained through a second consent form required of all participants who wish to proceed with the HIV test. Participants will receive rapid HIV testing and test results after signing the consent to be tested. In both Groups 1 and 2, participants who test reactive (preliminary positive) will be counseled on the sexual risk behaviors associated with transmission of HIV and the acquisition of STDs, as is current clinical practice with those testing HIV positive. Confirmed positives will be linked to HIV primary care.
3056012|NCT00809445|Active Comparator|HIV testing referral|Participants randomized to group 3 will receive a referral list for HIV community-testing agencies. Each CTP site will have previously prepared an extensive referral list of testing sites in the surrounding geographic area. By virtue of their status as patients in the CTPs, they will receive whatever HIV testing and HIV education referrals the CTPs normally provide to their patients. This is the standard of care at CTPs that do not provide on-site testing.
3056013|NCT00809471|Placebo Comparator|placebo|
3056014|NCT00809471|Experimental|avanafil 100 mg|
3056015|NCT00809471|Experimental|avanafil 200 mg|
3056016|NCT00809523|Experimental|Inactivated negative ion generator|Equivalent exposure to inactivated Negative Ion Generator
3056017|NCT00809523|Experimental|LED light treatment device|Light-emitting photodiode light treatment device, used for 30 min before 8 am
3056018|NCT00809614|Experimental|AIN457 (2x 10mg/kg)|Each patient received 10 mg/kg AIN457 intravenously, on Day 1 and Day 22.
3056019|NCT00809614|Placebo Comparator|Placebo|Each patient received 10 mg/kg of matching placebo intravenously, on Day 1 and Day 22.
3056020|NCT00809757|Experimental|1|90 ug Levalbuterol (2 actuations)
3056021|NCT00809757|Active Comparator|2|0.31 ug Levalbuterol UDV TID
3056022|NCT00809757|Placebo Comparator|3|Placebo
3056023|NCT00809783|Experimental|Tanezumab 10 mg|Tanezumab 10 mg
3056024|NCT00809783|Experimental|Tanezumab 5 mg|Tanezumab 5 mg
3056025|NCT00809783|Experimental|Tanezumab 2.5 mg|Tanezumab 2.5 mg
3056026|NCT00809809|Active Comparator|Zinc gluconate|Oral swabs containing homeopathic Zinc gluconate
3056027|NCT00809809|Placebo Comparator|Placebo|placebo
3056028|NCT00809835|No Intervention|Standard Treatment As Usual (TAU)|Standard Treatment plus placebo for cocaine abusing or dependent methadone-maintained individuals. This consists of daily methadone visits plus one individual and one group session per week, and patients may participate in additional treatments such as HIV education and treatment. The counseling program's theoretical orientation is described as client-centered.
3056029|NCT00809835|Experimental|TAU Plus Galantamine|Standard treatment plus Galantamine. In this study, we will use 8 mg galantamine extended release (ER). Galantamine ER is used once daily. The recommended initial dose is 8 mg/day and the maintenance dose is 16-24 mg/day.
3056030|NCT00809835|Experimental|TAU plus Computer Assisted Cognitive Behavioral Therapy (CBT)|TAU plus computer assisted CBT plus placebo. All participants assigned to this condition will also be offered up to 60 minutes per week to work with the CBT for CBT program, onsite at the clinic, in a private space and using a computer provided by the research project. Patients will have the choice of how they choose to use the computer, that is, in two 30-minute sessions or one one-hour session.
3056031|NCT00809835|Experimental|TAU plus CBT plus galantamine|Standard treatment, plus computer assisted cognitive behavioral therapy, plus galantamine.
3056032|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
3056033|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
3056034|NCT00809848|Experimental|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
3056035|NCT00809848|Active Comparator|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
3056036|NCT00809848|Placebo Comparator|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
3056037|NCT00809926|Experimental|Valsartan/aliskiren|
3056038|NCT00809926|Active Comparator|Valsartan|
3056039|NCT00809965|Experimental|Rivaroxaban 2.5 mg bid|One 2.5 mg rivaroxaban tablet twice daily for up to 6 months
3056040|NCT00809965|Experimental|Rivaroxaban 5 mg bid|One 5 mg rivaroxaban tablet twice daily for up to 6 months
3056041|NCT00809965|Placebo Comparator|Placebo|One placebo tablet twice daily for up to 6 months
3056042|NCT00810043|Active Comparator|Curette-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, curettage was performed prior to use of inflatable bone tamps.
3056043|NCT00810043|Active Comparator|IBT-First|All of patients in the study were treated with Balloon Kyphoplasty. During Balloon Kyphoplasty, two inflatable bone tamps (IBTs) are placed into the vertebral body bilaterally via a transpedicular or extrapedicular approach under fluoroscopic guidance. In this arm, inflatable bone tamps were used prior to curettage, then followed by a second inflation of the bone tamps.
3056044|NCT00810069|Experimental|Early Intervention|Escitalopram 10 milligrams per day for 4 weeks (one 10 milligram [mg]-capsule) followed by Duloxetine flexible dose (60 or 120 mg daily) for 12 weeks.
3056045|NCT00810069|Experimental|Delayed Intervention|Escitalopram 10 mg per day for 4 weeks (one 10 mg-capsule) followed by Escitalopram 10 to 20 mg per day for 4 weeks (one or two 10 mg capsule[s]). Then, non-responders switched to Duloxetine 60 or 120 mg per day for 8 weeks , and responders continued on Escitalopram 10 to 20 mg per day for 8 weeks.
3056046|NCT00810082|Active Comparator|Group A|Standard physical therapy for fall prevention
3056047|NCT00810082|Experimental|Group B|Physical therapy for fall prevention that includes ActiveStep
3056048|NCT00810095|Experimental|Treatment Arm|
3056049|NCT00810108|Experimental|Whole Then Crushed Tablets|These subjects will take whole lopinavir tablets at Study Visit 1, and crushed tablets at Study Visit 2.
3056050|NCT00810108|Experimental|Crushed Then Whole Tablets|These subjects will take crushed tablets at Study Visit 1, and whole tablets at Study Visit 2.
3056051|NCT00810199|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
3056052|NCT00810199|Placebo Comparator|Tocilizumab + Placebo|Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
3056053|NCT00810264||Data Collection Group|
3056054|NCT00810277|Experimental|1|
3056055|NCT00810303|Experimental|whole study group|A study with a duration of 34 days with 4 periods (= 4 pharmakokinetics) on 12 healthy subjects.
3056056|NCT00810342|Experimental|1- physical activity tailored|Tailored telephone counseling about how to become more physically active and goal setting. Email feedback on physical activity progress. Website listing resources new mothers can use to become more active.
3056057|NCT00810342|Active Comparator|2 - physical activity standard|Standard Website resources / information on physical activity
3056058|NCT00810355|Active Comparator|Arm 1|Support group
3056059|NCT00810355|Experimental|Arm 2|Cognitive Behavior Therapy
3056060|NCT00810355|Experimental|Arm 3|Cognitive Behavior Therapy and Cognitive Remediation
3056061|NCT00810368|Active Comparator|Carnosine treatment group|Carnosine treatment group
3056062|NCT00810368|Placebo Comparator|Placebo control group|Placebo control group
3056063|NCT00810394|Experimental|Sorafenib|Dose Re-Escalation Following a Dose Reduction
3056064|NCT00810407||rifabutin|Patients administered Rifabutin.
3056066|NCT00810459|Experimental|Trilogy ventilator|Trilogy ventilator
3056067|NCT00810459|Active Comparator|Standard of Care|Participants currently prescribed ventilator
3056068|NCT00810498|Experimental|Trilogy|Trilogy Device
3056069|NCT00810498|Active Comparator|Standard of Care|Participants prescribed ventilator
3056070|NCT00810511|Experimental|Lotrafilcon A|Investigational, spherical, silicone hydrogel contact lenses
3056071|NCT00810511|Active Comparator|Comfilcon A|Commercially marketed, spherical, silicone hydrogel contact lenses
3056072|NCT00810576|Experimental|Vorinostat + Bortezomib|Vorinostat 200 mg orally twice on Days 1-14 + Bortezomib 1.3 mg/m^2 intravenous (IV) on Days 1, 4, 8, 11.
3056073|NCT00810602|Experimental|Vorinostat prophylaxis|Vorinostat,combined with standard GVHD prevention medications(tacrolimus, mycophenolate) for adults who received a reduced intensity, related donor stem cell transplant
3056074|NCT00810615|Sham Comparator|Sham treatment|Subject will breathe air at less than 1.3 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at less that 1.3 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
3056075|NCT00810615|Experimental|Hyperbaric oxygen 2.4 ATA|Subject will breathe 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
3056076|NCT00810641|Active Comparator|Gufoni maneuver|Gufoni maneuver for apogeotropic HC-BPPV
3056077|NCT00810641|Active Comparator|Headshaking maneuver|headshaking maneuver for apogeotropic HC BPPV
3056078|NCT00810641|Sham Comparator|sham maneuver|sham maneuver for apogeotropic HC BPPV
3056079|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
3056080|NCT00810693|Experimental|Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
3056081|NCT00810693|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks
3056082|NCT00810719|Experimental|Gemcitabine and Erlotinib|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.Erlotinib will be dosed at 150mg orally (tablets) on days 2-5, 9-12, and 16-26 of a 28 day cycle.
3056083|NCT00810771|Experimental|Preference-tailored (PT) intervention|"Intervention:~Behavioral: Standard Information Behavioral: Preference-tailored Information"
3056084|NCT00810771|Active Comparator|Standard information (SI) intervention|Behavioral: Standard Information
3056085|NCT00810771|No Intervention|Usual Care|Due to budget and time constraints this group was not powered as a true study arm but was used to assess the impact of our baseline physician information letter and to control for any other interventions of system-wide initiatives that may occur during the study timeframe and impact rated of CRC screening. Data was not collected on every participant in this arm.
3056086|NCT00810797|Experimental|Treatment (exemestane)|Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3056087|NCT00810810|Active Comparator|1|Blood components with no additional treatment
3056088|NCT00810810|Experimental|2|Blood components leukoreduced
3056089|NCT00810810|Experimental|3|Blood components leukoreduced and irradiated
3056090|NCT00810888|Active Comparator|Group 1-Recombinant activated factor VII|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) randomized to receive rFVIIa at 80 mcg/kg (max dose 21.3 mL)."
3056091|NCT00810888|Placebo Comparator|Group 2 - Placebo|"Participants with ICH determined by CTA to be high risk for hemorrhage growth (spot sign positive for contrast leakage within the brain hematoma) will be randomized to receive placebo."
3056092|NCT00810888|No Intervention|Group 3 - Observation Only Arm|"Participants with ICHdetermined by CTA not to be at high risk for hemorrhage growth (CTA spot sign negative) enrolled into a prospective observational group."
3056093|NCT00810901|Experimental|Organ Donor|Intervention used a DVD, text messaging, emails, a website, US Mail, and telephone calls to educate teens about their choice to become a designated organ donor on their first driver's license application.
3056094|NCT00810901|Active Comparator|Alcohol Prevention|Intervention used a DVD and text messages, to educate teens about the laws that prohibit underage minors purchasing and consuming alcohol
3056095|NCT00811018|Experimental|Sitaxsentan|Sitaxsentan
3056096|NCT00811057|Active Comparator|1 Magnesium Sulfate|
3056097|NCT00811057|Active Comparator|2 Nifedipine|Participants randomized to this group will receive the medication nifedipine orally.
3056098|NCT00811057|Active Comparator|3 Indomethacin|Participants randomized to this arm will receive the medication indomethacin per rectum and orally.
3056099|NCT00811070|Experimental|1|
3056100|NCT00811135|Experimental|1|
3056101|NCT00811174|Experimental|Octagam 10%|
3056102|NCT00811187|Experimental|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
3056103|NCT00811187|Placebo Comparator|Saline placebo injection|5cc Normal Saline injection in each paracervical region
3056104|NCT00811252|Placebo Comparator|Placebo|
3056105|NCT00811252|Experimental|Vortioxetine 5 mg|
3056106|NCT00811252|Other|Duloxetine 60 mg|Active reference
3056107|NCT00811317|Experimental|Closed-loop|Type 1 diabetic subjects under closed-loop blood glucose control
3056108|NCT00811382|Experimental|1: Access to HMSC (Home Monitoring Service Center)|Full functionality of the Home Monitoring System for an early optimization of CRT and management of AF with a full access for the treating physician to the HMSC
3056109|NCT00811382|Active Comparator|2: No access to HMSC|Limited access of the treating physician to the HMSC where only events regarding implant and lead status will be generated and sent to the physician.
3056110|NCT00811395|Placebo Comparator|Placebo + IFN-β|Placebo (for teriflunomide) once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3056111|NCT00811395|Experimental|Teriflunomide 7 mg + IFN-β|Teriflunomide 7 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3056112|NCT00811395|Experimental|Teriflunomide 14 mg + IFN-β|Teriflunomide 14 mg once daily concomitantly with interferon-β [IFN-β] for 24 additional weeks
3056113|NCT00811395|Placebo Comparator|Placebo + GA|Placebo (for teriflunomide) once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3056114|NCT00811395|Experimental|Teriflunomide 7 mg + GA|Teriflunomide 7 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3056115|NCT00811395|Experimental|Teriflunomide 14 mg + GA|Teriflunomide 14 mg once daily concomitantly with glatiramer acetate [GA] for 24 additional weeks
3056116|NCT00811434|Active Comparator|Lactulose|3 months of Lactulose therapy based on pt. weight
3056117|NCT00811434|Placebo Comparator|placebo|1.5 ml/kg day po of sugar water placebo for three months
3056118|NCT00811473|Experimental|Quetiapine XR|
3056119|NCT00811473|Placebo Comparator|Placebo|
3056120|NCT00811564|Active Comparator|1|Fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution
3056121|NCT00811564|Active Comparator|2|Latanoprost 0.005% ophthalmic solution
3056122|NCT00811577|Experimental|AZX100-placebo|Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
3056123|NCT00811577|Placebo Comparator|Placebo-only|Three trocar sites on each patient received one dose of placebo (saline).
3056124|NCT00811642|Experimental|Posaconazole|Posaconazole 400 mg twice a day (BID) oral suspension for 12 weeks
3056125|NCT00811655|Experimental|Pre-Operative SRS|SRS pre-operatively with the planned target volume defined as the tumor plus a 3-mm margin.
3056126|NCT00811720|Placebo Comparator|Placebo|
3056127|NCT00811720|Experimental|Nalmefene|
3056128|NCT00811733|Experimental|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
3056129|NCT00811798|Experimental|Cervarix Group|
3056130|NCT00811850|Active Comparator|Combigan®|Combigan® (fixed combination of brimonidine tartrate 0.2%/timolol maleate 0.5% ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
3056131|NCT00811850|Active Comparator|Cosopt®|Cosopt® (fixed combination of dorzolamide hydrochloride - timolol maleate ophthalmic solution). One drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks.
3056132|NCT00811928|Active Comparator|Posaconazole|Posaconazole oral suspension 200 mg three times a day (TID)
3056133|NCT00811928|Active Comparator|Fluconazole|Fluconazole 400 mg once daily (QD)
3056134|NCT00811941|Placebo Comparator|Placebo|
3056135|NCT00811941|Experimental|Nalmefene|
3056136|NCT00811954|Experimental|Arm A: ATV/RTV + FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily.
3056137|NCT00811954|Experimental|Arm B: RAL + FTC/TDF|FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily.
3056138|NCT00811954|Experimental|Arm C: DRV/RTV + FTC/TDF|FTC/TDF, darunavir (DRV), and RTV, orally, once daily.
3056139|NCT00812006|Experimental|A|Treatment Sequence A: rizatriptan, rizatriptan, placebo
3056140|NCT00812006|Experimental|B|Sequence B: rizatriptan, placebo, rizatriptan
3056141|NCT00812006|Experimental|C|Sequence C: placebo, rizatriptan, rizatriptan
3056142|NCT00812097|Other|Primary Augmentation|The Primary Augmentation cohort will include patients who wish general breast enlargement receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
3056143|NCT00812097|Other|Primary Reconstruction|The Primary Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants.
3056144|NCT00812097|Other|Revision Augmentation|The Revision Augmentation cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast augmentation surgery.
3056145|NCT00812097|Other|Revision Reconstruction|The Revision Reconstruction cohort will include patients receiving MENTOR® MemoryShape™ (formerly known as Contour Profile Gel [CPG]) Breast Implants during a revision surgery to correct or improve the result of a primary breast reconstruction surgery.
3056146|NCT00812253|Experimental|Intravenous Insulin|
3056147|NCT00812253|Active Comparator|Subcutaneous Insulin|Basal bolus insulin (4 injections per day)
3056148|NCT00812331|Experimental|Genotype 2|Participants with chronic genotype 2 hepatitis C virus (HCV) infection
3056149|NCT00812331|Experimental|Genotype 3|Participants with chronic genotype 3 HCV infection
3056150|NCT00812331|Experimental|Genotype 4|Participants with chronic genotype 4 HCV infection
3056151|NCT00812331|Experimental|Genotype 5|Participants with chronic genotype 5 HCV infection
3056152|NCT00812331|Experimental|Genotype 6|Participants with chronic genotype 6 HCV infection
3056153|NCT00812461|Placebo Comparator|Placebo|
3056154|NCT00812461|Experimental|Nalmefene|
3056155|NCT00812487|Experimental|Intravenous insulin|
3056156|NCT00812487|Active Comparator|Subcutaneous Insulin|4 injections of insulin/day
3056157|NCT00812565|Placebo Comparator|Placebo every 2 weeks|Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
3056158|NCT00812565|Experimental|0.1 g/kg octagam 10% every 2 weeks|Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
3056159|NCT00812565|Experimental|0.25 g/kg octagam 10% every 2 weeks|Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
3056160|NCT00812565|Experimental|0.4 g/kg octagam 10% every 2 weeks|Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
3056161|NCT00812565|Placebo Comparator|Placebo every 4 weeks|Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
3056162|NCT00812565|Experimental|0.2 g/kg octagam 10% every 4 weeks|Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
3056163|NCT00812565|Experimental|0.5 g/kg octagam 10% every 4 weeks|Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
3056164|NCT00812565|Experimental|0.8 g/kg octagam 10% every 4 weeks|Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
3056165|NCT00812604|Experimental|Ping On Ointment|Ping On Ointment
3056166|NCT00812604|Placebo Comparator|Vaseline|Vaseline with minor trace of Ping On ointment to give medicinal smell
3056168|NCT00812812|Experimental|paroxetine group|paroxetine 10-40mg/day
3056169|NCT00812812|Placebo Comparator|placebo group|matched placebo to paroxetine
3056170|NCT00812838|Experimental|100 units of Botulinum Toxin Type A|Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
3056171|NCT00812838|Placebo Comparator|Normal saline|"Injection solution will consist of 10 cc preservative free normal saline~Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.~Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16."
3056172|NCT00812877|Active Comparator|Mineral Trioxide Aggregate|Pulp capping agent, Mineral Trioxide Aggregate used as a direct pulp cap
3056173|NCT00812877|Active Comparator|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide used as a direct pulp cap
3056174|NCT00812916||RF ablation|RF Ablation using specialized CFAE software
3056175|NCT00812929|Placebo Comparator|Placebo|
3056176|NCT00812929|Experimental|GSK2190915 10 mg|
3056177|NCT00812929|Experimental|GSK2190915 50 mg|
3056178|NCT00812929|Experimental|GSK2190915 100 mg|
3056179|NCT00812929|Experimental|GSK2190915 200 mg|
3056180|NCT00812955|Experimental|A - ABT-143 capsules 5/135 mg|ABT-143 capsules 5/135 mg - ABT-143 (rosuvastatin 5 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3056181|NCT00812955|Experimental|B - ABT-143 capsules 10/135 mg|ABT-143 capsules 10/135 mg - ABT-143 (rosuvastatin 10 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3056182|NCT00812955|Experimental|C - ABT-143 capsules 20/135 mg|ABT-143 capsules 20/135 mg - ABT-143 (rosuvastatin 20 mg in combination with fenofibric acid 135 mg) once daily for 8 weeks
3056183|NCT00812955|Active Comparator|D - Simvastatin capsules 40 mg|Simvastatin capsules 40 mg daily for 8 weeks
3056184|NCT00812968|Experimental|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
3056185|NCT00812981|Experimental|1562902A NP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the new-processed (NP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
3056186|NCT00812981|Experimental|1562902A CP GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the comparative-processed (CP) 1562902A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Days 0 and 21.
3056187|NCT00813098|Experimental|High dose|A high dose of LX1031; daily oral intake for 28 days
3056188|NCT00813098|Experimental|Low Dose|A low dose of LX1031; daily oral intake for 28 days
3056189|NCT00813098|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake
3056190|NCT00813111|Experimental|SKY0402|A single local administration of 300 mg in a 20-mL volume into each breast implant pocket for a total dose of 600 mg (i.e., a total of 40 mL)
3056191|NCT00813111|Active Comparator|Bupivacaine HCl|A single local administration of 100 mg in a 20-mL volume into each breast implant pocket for a total dose of 200 mg (i.e., a total of 40 mL)
3056192|NCT00813124|Experimental|Azacytidine Maintenance after allotx|Busulfan + Fludarabine + ATG + Azacytidine after allogeneic stem cell transplantation (allotx)
3056193|NCT00813150|Experimental|Vd (bortezomib + dexamethasone)|"Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days~1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle."
3056194|NCT00813150|Active Comparator|Vcd (bortezomib + low-dose dexamethasone + cyclophosphamide)|Participants received bortezomib at a dose of 1.3 mg/m² body surface area (BSA) for eight 3-week cycles. Within each cycle it was administered twice weekly (on Days 1, 4, 8, and 11) followed by a 10-day rest period (Days 12 through 21). They received single oral doses of 20 mg dexamethasone on Days 1 and 2, 4 and 5, 8 and 9, and 11 and 12 of each cycle and single oral doses of 50 mg cyclophosphamide on a once daily basis from Day 1, Cycle 1 continuously until Day 21, Cycle 8.
3056195|NCT00813176|Active Comparator|Double Lumen Endotracheal Tube|We used a device called a double lumen tube ( DLT Broncho-Cath®). It is a bifurcated endotracheal tube designed to independently collapse the operated lung.
3056196|NCT00813176|Active Comparator|Arndt Bronchial Blocker|We used a device called a bronchial blocker (9 Fr Arndt® blocker) along with a standard single-lumen tracheal tube (8.0-9.0 mm ID). The Arndt bronchial blocker is a single device, with a distal balloon that is passed thru the single lumen endotracheal once the patient is intubated. The Arndt bronchial blocker is designed to collapse the operated lung.
3056197|NCT00813293|Experimental|Sorafenib|Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
3056198|NCT00813293|Placebo Comparator|Placebo|Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip, 70 ± 2º C, 5 min).
3056199|NCT00813319|Experimental|1 - Girls OnGuard/HPV awareness|Adolescents will watch a short (10 min), interactive DVD designed to promote HPV awareness and initial GARDASIL vaccination and receive a keepsake to help them remember to return to the clinic for their second and third vaccine doses.
3056200|NCT00813319|No Intervention|2 - General health promotion|Adolescents will watch an equally short (10 min) DVD on healthy lifestyles and behaviors. HPV awareness and vaccination will not be addressed.
3056201|NCT00813358|Experimental|Endovascular repair|treatment
3056202|NCT00813488|Experimental|Fentanyl buccal tablet first then immediate release oxycodone|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
3056203|NCT00813488|Experimental|Immediate Release Oxycodone first then FBT|This crossover study includes a screening period, two titration periods, two double-blind treatment periods during which subjects will be randomized to receive fentanyl buccal tablet (FBT) plus placebo during the first treatment period and then immediate release oxycodone plus placebo during the second treatment period or vice versa, then followed by a 12-week open-label treatment period with FBT or an alternative short acting opioid.
3056204|NCT00813592|Experimental|All participants|
3056205|NCT00813709|Active Comparator|RNF 44 mcg thrice weekly|
3056206|NCT00813709|Active Comparator|RNF 44 mcg once weekly and placebo|
3056207|NCT00813709|Active Comparator|Placebo/RNF 44 mcg thrice weekly|
3056208|NCT00813761|Other|02Optix CL and ReNu MPS with SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
3056209|NCT00813761|Other|Proclear CL and ReNu MPS with SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
3056210|NCT00813761|Other|02Optix CL and Clear Care LCS with SICS|O2Optix contact lens and Clear Care lens care solution subject
3056211|NCT00813761|Other|Proclear CL and Clear Care LCS with SICS|Proclear contact lens and Clear Care lens care solution
3056212|NCT00813761|Other|02Optix CL and ReNu MPS without SICS|O2Optix contact lens and ReNu MultiPlus Multi-Purpose Solution
3056213|NCT00813761|Other|Proclear CL and ReNu MPS without SICS|Proclear contact lens and ReNu MultiPlus Multi-Purpose Solution
3056214|NCT00813761|Other|02Optix CL and Clear Care LCS without SICS|O2Optix contact lens and Clear Care lens care solution
3056215|NCT00813761|Other|Proclear CL and Clear Care LCS without SICS|Proclear contact lens and Clear Care lens care solution
3056216|NCT00813800|Experimental|Varenicline|Open-label; subjects will receive a behavioral intervention in addition to Varenicline.
3056217|NCT00813813|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3056218|NCT00813865|Experimental|Afegostat Tartrate Treatment Regimen 1|Afegostat tartrate was administered orally at a dose of 225 mg QD for 3 or 7 consecutive days followed by no study medication for 4 or 7 consecutive days (consecutive 3-days-on/4-days-off or 7-days-on/7-days-off, respectively). Amendment 2 added a MWF 3-days-on/4-days-off regimen. After Amendment 2 was implemented, all participants were assigned to one of the two 3-days-on/4-days-off regimens. Amendment 4 removed the consecutive 3-days-on/4-days-off regimen, and all participants were assigned to the MWF 3-days-on/4-days-off regimen. Participants were to receive afegostat tartrate for 30 months and be followed for 6 months after EOT.
3056219|NCT00813904|Experimental|rThrombin, 1000 IU/mL|
3056220|NCT00813917|Active Comparator|varenicline|
3056221|NCT00813917|Placebo Comparator|Placebo|
3056222|NCT00813943|Experimental|Cilengitide (2-times weekly) + Temozolomide + Radiotherapy|
3056223|NCT00813943|Experimental|Cilengitide (5-times weekly) + Temozolomide + Radiotherapy|
3056224|NCT00813943|Active Comparator|Temozolomide + Radiotherapy|
3056225|NCT00813982|Experimental|Experimental Lotrafilcon A Contact Lens|Lotrafilcon A experimental contact lens randomly assigned to one eye
3056226|NCT00813982|Active Comparator|Commercial Lotrafilcon A Contact Lens|Lotrafilcon A commercial contact lens randomly assigned to one eye
3056227|NCT00813995|Experimental|Sitagliptin|
3056228|NCT00813995|Placebo Comparator|Placebo|
3056229|NCT00814138|Active Comparator|1|Methotrexate
3056230|NCT00814138|Placebo Comparator|2|Placebo
3056231|NCT00814164|Experimental|Clorafarbine with daunorubicin|Patients receive clofarabine IV over 1 hour on days 1-5 and daunorubicin hydrochloride IV over 5 minutes on days 1, 3, and 5.
3056232|NCT00814177|Experimental|No change|Intervention Drug warfarin no change in the dose is performed
3056233|NCT00814177|Active Comparator|Change|Intervention Drug Warfarin One dose increased if subtherapeutic level; one dose deleted or reduced if supratherapeutic level
3056234|NCT00814255|Experimental|2|Conservative medical therapy plus adalimumab
3056235|NCT00814255|Active Comparator|1|Conservative medical therapy (lisinopril, losartan, atorvastatin)
3056236|NCT00814255|Experimental|conservative medical therapy plus galactose|drug: galactose 0.2 g /kg/dose (maximum dose 15g) po BID
3056237|NCT00814307|Experimental|Active 5mg|
3056238|NCT00814307|Experimental|Active 10 mg|
3056239|NCT00814307|Placebo Comparator|Placebo Sequence 1|
3056240|NCT00814307|Placebo Comparator|Placebo Sequence 2|
3056241|NCT00814320|Experimental|1|Efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
3056242|NCT00814320|Experimental|2|Pharmacokinetics of intravenous (IV) infusions of immune globulin intravenous (IGIV), 10% and efficacy and tolerability of subcutaneous (SC) infusions of immune globulin intravenous (IGIV), 10% with hyaluronidase (rHuPH20) after ramp-up
3056243|NCT00814346|Active Comparator|EGb 120 mg|
3056244|NCT00814346|Placebo Comparator|Placebo|
3056245|NCT00814463|Active Comparator|Post-operative SRS|All patients will undergo SRS with the planned target volume (PTV) defined as the resection cavity plus a 3-mm margin after surgical resection of a single brain metastasis. Dose will be prescribed to the maximum isodose line completely encompassing the PTV using the guidelines established in RTOG 9005. All patients will be evaluated for neurocognitive function via Mini-Mental State Examination (MMSE), Quality of Life (QOL) via FACT-Br, and for local recurrence via MRI every 3 months over the course of the study.
3056246|NCT00814489|Experimental|GSK2254233A Group|Subjects received 2 doses of adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254233A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3056247|NCT00814489|Experimental|GSK2254232A Group|Subjects received 2 doses of non-adjuvanted Non-Typable Haemophilus influenza and pneumococcal vaccine GSK2254232A at Months 0 and 2. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3056248|NCT00814489|Active Comparator|Engerix Group|Subjects received 3 doses of Engerix vaccine at Months 0, 2 and 6. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3056249|NCT00814502|Active Comparator|Zolpidem CR|Subjects randomized to Zolpidem CR
3056250|NCT00814502|Placebo Comparator|Placebo|Subjects randomized to Placebo
3056251|NCT00814580|Experimental|001|Tapentadol IR First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1 if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
3056252|NCT00814580|Active Comparator|002|Oxycodone IR First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1 if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
3056253|NCT00814632|Experimental|Study Drug CC 10004|Study drug CC-10004 20mg taken orally twice a day.
3056254|NCT00814658|Experimental|Galantamine + Nimodipine|
3056255|NCT00814658|Experimental|Galantamine + Placebo|
3056256|NCT00814671|Experimental|RPT450|Rifapentine 450mg daily
3056257|NCT00814671|Active Comparator|RIF 600|Rifampin 600mg daily
3056258|NCT00814671|Experimental|RPT 600|Rifapentine 600mg daily
3056259|NCT00814697|Experimental|Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Coil Stimulation (rTMS) treatment in Alzheimer's disease. The Magstim Rapid2 stimulator with a peak magnetic field of 0.5-3.5 Tesla at 100% output was used over the right and left dorsolateral prefrontal cortex. Patients received 4 sessions of rTMS over 2 weeks, lasting approximately 30 minutes, 2 consecutive days a week for 2 weeks.
3056260|NCT00814710|Experimental|Synflorix & Tritanrix-HebB/Hib Group|Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
3056261|NCT00814710|Active Comparator|Hiberix group & Tritanrix-HebB Group|Subjects received HiberixTM intramuscularly in the right thigh co-administered with TritanrixTM-HepB intramuscularly in the left thigh at 6-10-14 weeks of age (=study month 0, 1, 2)
3056262|NCT00814775|Active Comparator|Group 1|Fastrach Laryngeal Mask Airway intubation
3056263|NCT00814775|Active Comparator|Group 2|Intubation of difficult airway using CTrach Laryngeal Mask
3056264|NCT00814788|Experimental|Bicalutamide + Everolimus|Patients receive oral bicalutamide and oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3056265|NCT00814801|Placebo Comparator|Placebo|
3056266|NCT00814801|Experimental|Galantamine 16 mg/day|
3056267|NCT00814801|Experimental|Galantamine 24 mg/day|
3056268|NCT00814879|Active Comparator|a.|N(t)RTI(s) based backbone & PI/r
3056269|NCT00814879|Experimental|b.|Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
3056270|NCT00814970|Experimental|Complete SE Vascular Stent System|COMPLETE SE Vascular Stent System - implantation of study device in native SFA and/or PPA for subjects with symptomatic ischemic peripheral arterial disease in the superficial femoral artery or proximal popliteal arteries with an occlusion or lesion greater or equal to 50 percent with lesions located above the knee and amenable to percutaneous treatment with angioplasty and vascular stent implantation.
3056271|NCT00815035|Active Comparator|Peanut OIT|Subjects randomized to receive active treatment with peanut protein flour.
3056272|NCT00815035|Placebo Comparator|Placebo|Subjects randomized to receive placebo in the form of oat flour.
3056273|NCT00815087|Experimental|Functional Electrical Stimulation (FES)|Functional electrical stimulation: Experimental
3056274|NCT00815087|Active Comparator|Home Rehabilitation Program (HRP)|Exercise home program
3056275|NCT00815191|Active Comparator|Vital Heat|Vital HEAT (vH2) Temperature Management System
3056276|NCT00815191|Active Comparator|Forced air|Forced-air warming
3056277|NCT00815295|Experimental|Cetuximab + sorafenib|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib will be given at 200mg/m2 twice daily.
3056278|NCT00815308|Experimental|cetuximab, concurrent chemo-radiotherapy|Cetuximab, injection, loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8) Paclitaxel, injection,45 mg/m^2 (Day 1, every week for Weeks 2-8) Cisplatin, injection,20 mg/m^2 (Day 1, every week for Weeks 2-8) radiation therapy, 59.4 Gy, 1.8 Gy/33 fractions,1 fraction daily, Days 1-5 every week for Weeks 2-7, and Days 1-3 for Week 8
3056279|NCT00815347|Other|1 Crossover|
3056280|NCT00815360|Experimental|Treatment group|"single intravitreal injection of ranibizumab (0.5 mg in 0.1 cc)~peripheral laser to areas of retinal nonperfusion on ultra-widefield fluorescein angiography"
3056281|NCT00815360|Active Comparator|Control Group|"single intravitreal injection of triamcinolone acetonide (4.0 mg in 0.1 cc)~macular laser per treatment criteria"
3056282|NCT00815490|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3056283|NCT00815516|Experimental|Micafungin|Infants received micafungin at a dose of 10 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
3056284|NCT00815516|Active Comparator|Amphotericin B deoxycholate|Infants received amphotericin B deoxycholate (CAB) at a dose of 1.0 mg/kg per day by intravenous infusion for a minimum of 21 days to a maximum of 28 days for infants without end-organ dissemination or for a maximum of 42 days for infants with end-organ dissemination.
3056285|NCT00815659|Experimental|Rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
3056286|NCT00815685|Experimental|Eicosapentaenoic Acid|
3056287|NCT00815698|Active Comparator|no suture|self-adhesive mesh, i.e. no suture for mesh fixation
3056288|NCT00815698|Experimental|Suture|Suture for mesh fixation
3056289|NCT00815776|Experimental|1|Treatment group receiving the CID
3056290|NCT00815776|Active Comparator|2|Group assigned a mouth splint
3056291|NCT00815776|Active Comparator|Exercise Control Group|Group who received no device but were instead assigned a study-specified jaw exercise program
3056292|NCT00815919|Experimental|Velcade (bortezomib)|
3056293|NCT00815997|Sham Comparator|6-Fr TRI (transradial coronary intervention)|TRI will be performed using a 6-Fr guiding catheter.
3056294|NCT00815997|Active Comparator|4-Fr TRI|TRI will be performed using a 4-Fr guiding catheter.
3056295|NCT00816023|Experimental|Ecallantide Low Dose|target steady state concentration of 0.15 mg/L
3056296|NCT00816023|Experimental|Ecallantide Medium Dose|target steady state concentration of 0.75 mg/L
3056297|NCT00816023|Experimental|Ecallantide High Dose|target steady state concentration of 2.25 mg/L
3056298|NCT00816023|Placebo Comparator|Placebo|placebo
3056299|NCT00816036|No Intervention|Arm 1|Baseline Period
3056300|NCT00816036|Experimental|Arm 2|Intervention Period
3056301|NCT00816062|Experimental|Treatment|Patients diagnosed with an abdominal aortic or aorto-iliac aneurysm that are considered candidates for endovascular repair, per the FDA approved IFU.
3056302|NCT00816101|Experimental|PROCELLERA™Antimicrobial Dressing|Dressing changes every 3 days, more frequently if needed
3056303|NCT00816101|Active Comparator|Mepilex® Border Lite|Dressing changes every 2-3 days, more frequently if needed
3056304|NCT00816101|Active Comparator|Band-Aid® Adhesive Bandage|Dressing changes every 2-3 days, more frequently if needed.
3056305|NCT00816166|Experimental|Stent Group|"Medical therapy + PHAROS Vitesse neurovascular stent (Stent Group)"
3056306|NCT00816166|Active Comparator|Medical Therapy Group|"Medical therapy alone (Medical Therapy Group)"
3056307|NCT00816348|Other|Omegaven|All subjects will receive Omegaven
3056308|NCT00816361|Experimental|MEDI-573 0.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 0.5 milligram per kilogram (mg/kg) as a 60-minute intravenous (IV) infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056309|NCT00816361|Experimental|MEDI-573 1.5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 1.5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056310|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Escalation|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056311|NCT00816361|Experimental|MEDI-573 10 mg/Kg QWk Dose Escalation|Participants received MEDI-573 10 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056312|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Escalation|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056313|NCT00816361|Experimental|MEDI-573 30 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 30 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056314|NCT00816361|Experimental|MEDI-573 45 mg/Kg Q3Wk Dose Escalation|Participants received MEDI-573 45 mg/kg as a 90-minute IV infusion once every 21 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056315|NCT00816361|Experimental|MEDI-573 5 mg/Kg QWk Dose Expansion|Participants received MEDI-573 5 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056316|NCT00816361|Experimental|MEDI-573 15 mg/Kg QWk Dose Expansion|Participants received MEDI-573 15 mg/kg as a 60-minute IV infusion once every 7 days until unacceptable toxicity, documentation of disease progression, or other reason for participant withdrawal.
3056317|NCT00816400|Experimental|MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)|Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056318|NCT00816400|Experimental|MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)|MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056319|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056320|NCT00816400|Experimental|MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)|MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056321|NCT00816400|Experimental|MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)|MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056322|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056323|NCT00816400|Experimental|MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)|MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056324|NCT00816400|Experimental|MEDI-575, 9.0 mg/kg QWk Expansion Phase|MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056325|NCT00816400|Experimental|MEDI-575, 25 mg/kg Q3Wk Expansion Phase|MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
3056326|NCT00816556|Active Comparator|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3056327|NCT00816556|Active Comparator|Estradiol|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3056328|NCT00816556|Placebo Comparator|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
3056329|NCT00816595|Experimental|Arm A: Pentostatin, Cyclophosphamide, Rituximab, and Avastin|Patients receive 15 mg/kg bevacizumab IV over 30-90 minutes on day 1 of courses 1-5 and on days 1, 22, and 43 of course 6; 375 mg/m^2 rituximab IV over 2-4 hours on days 2 and 3 of course 1 and on day 1 of courses 2-6; and 2 mg/m^3 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 2 of course 1 and on day 1 of courses 2-6. Patients also receive 6 mg pegfilgrastim subcutaneously (SC) on day 3 of course 1 and on day 2 of courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3056330|NCT00816595|Experimental|Arm B: Pentostatin, Cyclophosphamide, and Rituximab|Patients receive 100 mg rituximab IV over 2-4 hours on day 1 and 375 mg/m^2 on day 2 of course 1 and 375 mg/m^2 on day 1 of courses 2-6. They receive 2 mg/m^2 pentostatin IV over 30 minutes and 600 mg/m^2 cyclophosphamide IV over 30 minutes on day 1. Patients also receive 6 mg pegfilgrastim SC on day 2. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3056331|NCT00816751|Active Comparator|1|
3056332|NCT00816751|Experimental|2|
3056333|NCT00816829|Placebo Comparator|1|Fenofibrate-matching placebo tablet
3056334|NCT00816829|Experimental|2|145 mg NanoCrystal fenofibrate tablet
3056335|NCT00816907|Experimental|Metformin|Encapsulated metformin 1000-2000 mg/day
3056336|NCT00816907|Placebo Comparator|Placebo|Matching placebo capsules 2-4 daily
3056337|NCT00817063|Experimental|Alitretinoin|Patients will receive alitretinoin 30mg capsule for up to 24 weeks
3056338|NCT00817063|Experimental|Placebo|Patients will receive placebo 30mg capsule for up to 24 weeks
3056339|NCT00817089|Placebo Comparator|Group 1 Asn40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
3056340|NCT00817089|Active Comparator|Group 2 Asn40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
3056341|NCT00817089|Placebo Comparator|Group 3 Asp40 Placebo Placebo|Each alcohol session preceded by pretreatment with placebo oral tablet
3056342|NCT00817089|Active Comparator|Group 4 Asp40 Placebo Naltrexone|The first alcohol session preceded by pretreatment with placebo oral tablet. The second alcohol session preceded by pretreatment with naltrexone 50 mg as a single dose.
3056343|NCT00817206|Experimental|LCP-Tacro|LCP-Tacro tablets™, once daily (LifeCycle Pharma A/S, Hoersholm DK)
3056344|NCT00817206|Active Comparator|Prograf (tacrolimus)|Prograf® capsules, twice daily (Astellas Pharma US, Deerfield IL)
3056345|NCT00817219|Experimental|TACLONEX ointment|
3056346|NCT00817336|Experimental|D-serine|60 mg/kg/day
3056347|NCT00817336|Placebo Comparator|Placebo|
3056348|NCT00817414|Experimental|Cohort A: LCI699 0.5 mg QD|Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks.
3056349|NCT00817414|Experimental|Cohort A: LCI699 1.0 mg QD|Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
3056350|NCT00817414|Experimental|Cohort B1: LCI699 1.0 mg BID|Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks.
3056351|NCT00817414|Experimental|Cohort B1: LCI699 2.0 mg QD|Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks.
3056352|NCT00817414|Placebo Comparator|Placebo|Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.
3056353|NCT00817479|Active Comparator|Dexamethasone|20 mg of dexamethasone
3056354|NCT00817479|Placebo Comparator|Placebo [Saline]|Saline
3056355|NCT00817531|Experimental|All subjects take open label Dasatinib|Dasatinib / Sprycel 100 mg
3056356|NCT00817635|Experimental|LCI699 0.25 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.25 mg, capsules, orally, twice daily (BID), with or without food for up to 8 weeks.
3056357|NCT00817635|Experimental|LCI699 1 mg QD|Following a 2-week placebo run-in period, participants received LCI699 1 mg, capsules, orally, once daily (QD), with or without food for up to 8 weeks.
3056358|NCT00817635|Experimental|LCI699 0.5 mg followed by LCI699 1 mg BID|Following a 2-week placebo run-in period, participants received LCI699 0.5 mg, capsules, orally, BID, with or without food for up to 4 weeks, followed by LCI699 1 mg, capsules, orally, BID with or without food for up to 4 weeks.
3056359|NCT00817635|Active Comparator|Eplerenone 50 mg BID|Following a 2-week placebo run-in period, participants received eplerenone 50 mg, capsules, orally, BID, with or without food for up to 8 weeks.
3056360|NCT00817635|Placebo Comparator|Placebo|For a 2-week placebo run-in period, followed by 8 weeks of the treatment period, participants received LCI699-matching placebo or eplerenone-matching placebo, capsules, orally, QD or BID, with or without food.
3056361|NCT00817778|Experimental|AZD1656|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3056362|NCT00817778|Placebo Comparator|Placebo|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3056363|NCT00817804|Experimental|V60 then Conventional|Study device first
3056364|NCT00817804|Experimental|Conventional then V60|Conventional device first
3056365|NCT00817843|Experimental|First Simva 80mg then Simvai/Eze10/10mg|First 6 weeks of Simvastatin 80mg, then 6 weeks of Simvastatin/Ezetimibe 10/10mg after 6 weeks of placebo washout
3056366|NCT00817843|Experimental|First Simva/Eze 10/10mg then Simva 80mg|First 6 weeks of Simvastatin/Ezetimibe 10/10mg, then 6 weeks of Simvastatin 80mg after 6 weeks of placebo washout
3056367|NCT00817999|Experimental|Loading Dose|Participants received a 300 mg dose of clopidogrel with or without GFJ.
3056368|NCT00817999|Experimental|Maintenance Dose|Participants received clopidogrel 75 mg/day for 7 days with or without GFJ
3056369|NCT00818116|Experimental|ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL)
3056370|NCT00818168||Infliximab|Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)
3056371|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|A subject randomized to the intervention group will be eligible for smoking cessation treatment (SCT) reimbursement during the 26-week period following the randomization.
3056372|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|Subjects in the control group choosing to quit using an SCT method will not be eligible for smoking cessation treatment (SCT) reimbursement and, thus, will have to purchase their treatment out of pocket.
3056373|NCT00818246|Sham Comparator|Sham light|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with a Sham light on the experimental periorbital area
3056374|NCT00818246|Experimental|LED-treated|one side of the face was treated three times weekly for four consecutive weeks (12 treatments) with 660 nm Light emitting diode (LED) on the experimental periorbital area
3056375|NCT00818259|Experimental|Part IA-fosaprepitant 115 mg/aprepitant|Day 1, fosaprepitant intravenous (IV) at a dose of 115 mg and Days 2 and 3, aprepitant 80 mg orally (PO), prior to chemotherapy for participants from 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3056376|NCT00818259|Experimental|Part IB-fosaprepitant 150 mg|Day 1, fosaprepitant, IV at a dose of 150 mg, prior to chemotherapy for participants 12 to 17 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3056377|NCT00818259|Experimental|Part IIA-aprepitant 80 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 6 months to <12 years of age - 47 mg/m^2; 4 months to <6 months of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3056378|NCT00818259|Experimental|Part IIB-aprepitant 125 mg equiv.|Day 1, aprepitant PO prior to chemotherapy at the dosing regimens listed for the following age ranges: 2 years to <12 years of age - 74 mg/m^2; 6 months to <2 years of age - 1.3 mg/kg; 4 months to <6 months of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; birth to <1 month of age - 0.75 mg/kg. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3056379|NCT00818259|Active Comparator|Part III-ondansetron|Ondansetron administered IV per local standard of care on Days 1, 2, and 3 prior to chemotherapy for participants from birth to <12 years of age. The use of IV dexamethasone is optional with the exception of the birth to one year old cohort.
3056380|NCT00818259|Experimental|Part IV-aprepitant regimen|Day 1, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 3.0 mg/kg; 1 month to <4 months of age - 1.5 mg/kg; Birth to <1 month of age - 0.75 mg/kg; Days 2 and 3, aprepitant, PO, prior to chemotherapy at the dosing regimens listed for the following age ranges: 4 months to <12 years of age - 2.0 mg/kg; 1 month to <4 months of age - 1.0 mg/kg; Birth to <1 month of age - 0.5 mg/kg. Participants also receive ondansetron IV as per local standard of care. The use of dexamethasone IV is optional with the exception of the birth to one year old cohort.
3056381|NCT00818259|Experimental|Part V-fosaprepitant regimen|Day 1, fosaprepitant, IV at a dose of 3 mg/kg prior to chemotherapy for participants 6 months to <12 years of age. Participants also receive ondansetron IV as per local standard of care, with or without dexamethasone IV.
3056382|NCT00818272||Remicade (infliximab)|Participants with confirmed diagnosis of active Crohn's disease.
3056383|NCT00818324|Experimental|OPC-12759 Ophthalmic suspension|Instillation, 4times/day
3056384|NCT00818337|Active Comparator|Aspirin 81mg|Resistant
3056385|NCT00818363|Experimental|Group 1: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
3056386|NCT00818363|Placebo Comparator|Group 2: SABER-Placebo|5.0 mL SABER-Placebo/Once
3056387|NCT00818389|Active Comparator|1|Participants randomized to lithium/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
3056388|NCT00818389|Placebo Comparator|2|Participants randomized to placebo/riluzole (randomization is 1:1 lithium/riluzole to placebo/riluzole, i.e., participants have an equal chance of getting randomized to lithium vs. placebo).
3056389|NCT00818441|Experimental|Cohort A|Dacomitinib (PF-00299804) in patients with EGFR mutated NSCLC or clinical characteristics defined above to enhance for EGFR mutated NSCLC
3056390|NCT00818441|Experimental|Cohort B|Dacomitinib in patients with HER2 mutated or amplified NSCLC
3056391|NCT00818519|Experimental|EE20/Drospirenone (YAZ, BAY86-5300)|In the active treatment group, participants received 24 consecutive days of active tablets followed by 4 consecutive days of inactive tablets. The active tablet contained 3 mg DRSP (Drospirenone) and 20µg EE (Ethinyl estradiol).
3056392|NCT00818519|Placebo Comparator|Placebo|The participants of the placebo group received inert but identical-appearing, color-matched tablets.
3056393|NCT00818623|Experimental|Degarelix 120 mg (20 mg/mL)|Degarelix 120 mg (20 mg/mL)
3056394|NCT00818623|Experimental|Degarelix 120 mg (40 mg/mL)|Degarelix 120 mg (40 mg/mL)
3056395|NCT00818623|Experimental|Degarelix 160 mg (40 mg/mL)|Degarelix 160 mg (40 mg/mL)
3056396|NCT00818623|Experimental|Degarelix 200 mg (40 mg/mL)|Degarelix 200 mg (40 mg/mL)
3056397|NCT00818623|Experimental|Degarelix 200 mg (60 mg/mL)|Degarelix 200 mg (60 mg/mL)
3056398|NCT00818623|Experimental|Degarelix 240 mg (40 mg/mL)|Degarelix 240 mg (40 mg/mL)
3056399|NCT00818623|Experimental|Degarelix 240 mg (60 mg/mL)|Degarelix 240 mg (60 mg/mL)
3056400|NCT00818623|Experimental|Degarelix 320 mg (60 mg/mL)|Degarelix 320 mg (60 mg/mL)
3056401|NCT00818649|Experimental|Velcade + Vorinostat|This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.
3056402|NCT00818662|Experimental|IGIV, 10% 400mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
3056403|NCT00818662|Experimental|IGIV, 10% 200mg/kg|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
3056404|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 4 mL/kg|0.25% human albumin solution infused at 4 mL/kg/2weeks
3056405|NCT00818662|Placebo Comparator|Human Albumin 0.25% Solution - 2 mL/kg|0.25% human albumin solution infused at 2 mL/kg/2weeks
3056406|NCT00818753|Experimental|Dabigatran 110 mg|experimental drug therapy in this indication
3056407|NCT00818753|Experimental|Dabigatran 150 mg|experimental drug therapy in this indication
3056408|NCT00818753|Active Comparator|Unfractionated Heparin|standard therapy in this indication as comparator
3056409|NCT00818766|Active Comparator|Antibiotic|Participants received intravenous (IV) cefazolin or vancomycin (for participants allergic to cephalosporin) immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
3056410|NCT00818766|Placebo Comparator|Placebo|Participants received IV placebo-matching antibiotics immediately following surgery for 48 hours or until all chest tubes were removed, whichever occurred first.
3056411|NCT00818779|Experimental|Aliskiren|Aliskiren 150-300 mg once daily
3056412|NCT00818779|Active Comparator|Amlodipine|5-10 mg amlodipine once daily
3056413|NCT00818805|Experimental|Olopatadine 0.1% one eye|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
3056414|NCT00818805|Experimental|Tranilast 0.5% one eye|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
3056415|NCT00818805|Placebo Comparator|Placebo (Olopatadine)|Patients received one drop Olopatadine 0.1% in one eye and 1 drop Olopatadine placebo in contralateral eye
3056416|NCT00818805|Placebo Comparator|Placebo (Tranilast)|Patients received one drop Tranilast ophthalmic solution 0.5% in one eye and 1 drop tranilast placebo in contralateral eye
3056417|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD|
3056418|NCT00818883|Experimental|Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD|
3056419|NCT00818961|Other|Hematopoietic Stem Cell Transplantation|All patients receive a hematopoietic stem cell transplant using one of two chemotherapy regimens based on donor type
3056420|NCT00819013|Experimental|Study Group 1|ACAM-FLU-A low dose + Adjuvant 1
3056421|NCT00819013|Experimental|Study Group 2|ACAM-FLU-A low dose + Adjuvant 2
3056422|NCT00819013|Experimental|Study Group 3|ACAM-FLU-A low dose
3056423|NCT00819013|Placebo Comparator|Study Group 4|Saline placebo
3056424|NCT00819039|Experimental|Part 1: Oral Aprepitant|In Study Part 1, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
3056425|NCT00819039|Experimental|Part 2: Oral Aprepitant|In Study Part 2, participants aged 6 months to 17 years received a single oral dose of aprepitant on Day 1.
3056426|NCT00819039|Active Comparator|Part 2: Intravenous Ondansetron|In Study Part 2, participants aged 6 months to 17 years received a single intravenous dose of ondansetron on Day 1.
3056427|NCT00819052|Active Comparator|NVP IR|200 mg orally twice a day (po BID)
3056428|NCT00819052|Experimental|NVP XR|400 mg orally once a day (po QD)
3056429|NCT00819091|Active Comparator|BI 1356|5 mg orally (po) once daily
3056430|NCT00819091|Placebo Comparator|Placebo|one tablet once daily
3056431|NCT00819156|Experimental|Degarelix 200/80|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
3056432|NCT00819156|Experimental|Degarelix 200/120|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
3056433|NCT00819156|Experimental|Degarelix 200/160|Cycle 1 was an initial 200 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
3056434|NCT00819156|Experimental|Degarelix 240/80|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 80 milligrams each of Degarelix. Each cycle was 28 days.
3056435|NCT00819156|Experimental|Degarelix 240/120|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 120 milligrams each of Degarelix. Each cycle was 28 days.
3056436|NCT00819156|Experimental|Degarelix 240/160|Cycle 1 was an initial 240 milligram dose of Degarelix. Cycles 2-13 were maintenance doses of 160 milligrams each of Degarelix. Each cycle was 28 days.
3056437|NCT00819182|Experimental|Paced respiration|The paced respiration intervention group received a compact disc with paper booklet. The booklet reinforced instructions on the first audio track for how to accomplish a target breath rate of 6-8 breaths per minute, practice twice per day for 15 minutes, and apply the breathing at the onset of each hot flash. Women were instructed to do slow, deep, abdominal breathing in through the nose and out through the mouth as per international recommendations (4). They were also instructed to practice twice per day for 15 minutes as per the small, laboratory-based studies (5, 6). The second and third tracks contained specially composed, digitally recorded music to help entrain the breath rate and structure the length of practice.
3056438|NCT00819182|Sham Comparator|Sham comparator: Fast, shallow breathing|The sham comparator group received a digital videodisc with paper booklet. The booklet reinforced voice-over and video demonstration to practice twice per day and apply the fast shallow breathing at the onset of each flash. A previously published report provides additional details and data indicating this program was a suitable attention control.
3056439|NCT00819182|No Intervention|Control: Usual Care|The usual care group received an investigator-signed letter explaining they were not selected to receive any study materials during the 16-week follow-up. These participants received paced respiration materials by mail after study completion.
3056440|NCT00819234|Placebo Comparator|1|
3056441|NCT00819234|Experimental|2|Pramlintide and 1.25mg Metreleptin
3056442|NCT00819234|Experimental|3|Pramlintide and 2.5mg Metreleptin
3056443|NCT00819234|Experimental|4|Pramlintide and 5.0mg Metreleptin
3056444|NCT00819247|Experimental|Degarelix 80/80 + 40|Loading doses of Degarelix 80 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
3056445|NCT00819247|Experimental|Degarelix 40/40 + 40|Loading doses of Degarelix 40 mg (20 mg/mL) on Days 0 and 3. Maintenance doses of 40 mg (20 mg/mL) given on days 28, 56, 84, 112 and 140.
3056446|NCT00819247|Experimental|Degarelix 80 + 20|Loading dose of Degarelix 80 mg (20 mg/mL) on Day 0. Maintenance doses of 20 mg (10 mg/mL) given on days 28, 56, 84, 112 and 140.
3056447|NCT00819260|Experimental|Harmonic Reduced Breast|harmonic scalpel used to reduce breast on that side
3056448|NCT00819260|Active Comparator|Electrocautery Reduced Breast|Electrocautery (current practice = control) used to reduce breast on that side
3056449|NCT00819286|Active Comparator|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
3056450|NCT00819286|Experimental|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates.
3056451|NCT00819390|Experimental|A: Chloroquine then Placebo for Off-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
3056452|NCT00819390|Experimental|B: Placebo then Chloroquine for Off-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
3056453|NCT00819390|Experimental|C: Chloroquine then Placebo for On-ART Participants|Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
3056454|NCT00819390|Experimental|D: Placebo then Chloroquine for On-ART Participants|Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
3056455|NCT00819403|Active Comparator|simvastatin|Simvastatin 40 mg daily
3056456|NCT00819403|Active Comparator|simvastatin/ezetimibe|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
3056457|NCT00819507|Experimental|Vanos Cream|glucocorticoid cream
3056458|NCT00819585|Experimental|Core study: Canakinumab 25 mg|Canakinumab 25 mg subcutaneously (sc) once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056459|NCT00819585|Experimental|Core study: Canakinumab 50 mg|Canakinumab 50 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056460|NCT00819585|Experimental|Core study: Canakinumab 100 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056461|NCT00819585|Experimental|Core study: Canakinumab 200 mg|Canakinumab 100 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056462|NCT00819585|Experimental|Core study: Canakinumab 300 mg|Canakinumab 300 mg sc once at Day 1, placebo sc at Days 29, 57, and 85 plus daily placebo capsules for 16 weeks. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3179085|NCT00668941|Active Comparator|3|Participants in this group will have been treated with alendronate for at least 1 year prior to study entry. Upon study entry, they will continue taking alendronate alone. Biopsies will be performed at Week 7 and then participants in this group will be offered teriparatide as part of Group 2 or 3.
3056463|NCT00819585|Experimental|Core study: Canakinumab q4wk|Canakinumab 50 mg sc at Days 1, and 29 followed by canakinumab 25 mg sc on Days 57, and 85 plus daily placebo capsules for 16 weeks, repeated every 4 week (q4wk). Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056464|NCT00819585|Active Comparator|Core study: Colchicine 0.5 mg|Colchicine 0.5 mg capsule orally once daily throughout the whole treatment phase of 16 weeks plus placebo matching canakinumab s.c. at Days 1, 29, 57, and 85. Allopurinol treatment was initiated at the latest at baseline (Visit 2) according to the patient's renal function / estimated creatinine clearance at screening (Visit 1). Allopurinol was administered orally to all randomized patients once daily (100 mg-300 mg) for 24 weeks.
3056465|NCT00819585|Experimental|Extension study: Group A|Participants who were randomized to canakinumab in the core study and were treated with canakinumab for at least 1 flare in the extension study.
3056466|NCT00819585|Experimental|Extension study: Group B|Patients who were randomized to canakinumab in the core study but did not receive treatment with canakinumab in the extension study.
3056467|NCT00819585|Experimental|Extension study: Group C|Patients who were randomized to colchicine in the core study and were treated with canakinumab for at least 1 flare in the extension study.
3056468|NCT00819585|Experimental|Extension study: Group D|Patients who were randomized to colchicine in the core study but did not receive treatment with canakinumab in the extension study.
3056469|NCT00819637|Experimental|Arformoterol 3 doses|
3056470|NCT00819637|Experimental|Arformoterol 1 dose, placebo 2 doses|
3056471|NCT00819637|Active Comparator|Levalbuterol 3 doses|
3056472|NCT00819741|Experimental|Repaglinide + metformin|Initial dose of repaglinide 1mg plus metformin 500mg once daily. During the dose titration period of 6 weeks, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily.
3056473|NCT00819741|Active Comparator|Repaglinide|Initial dose of repaglinide 1 mg three times daily. During the dose titration period of 6 weeks, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 1 mg three times daily.
3056474|NCT00819767|Experimental|Aliskiren|For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
3056475|NCT00819767|Active Comparator|Valsartan|For the first week of the 8 week treatment period, patients received valsartan 160 mg, placebo to valsartan, and 2 tablets of placebo to aliskiren. For the remaining 7 weeks of the study, patients received valsartan 320 mg (two 160 mg capsules) and 2 tablets of placebo to aliskiren. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
3056476|NCT00819780|Experimental|Panitumumab Plus mFOLFOX6|Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2) and 5-fluorouracil (5-FU) (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
3056477|NCT00819780|Active Comparator|Bevacizumab Plus mFOLFOX6|Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m^2), leucovorin (400 mg/m^2), followed by 5-FU (2400 mg/m^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
3056478|NCT00819793|Experimental|CentriMag Ventricular Assist System|All patients meeting the patient selection criteria will be treated with the CentriMag Ventricular Assist System.
3056479|NCT00819910|Active Comparator|Rosiglitazone + Placebo|Rosiglitazone 8 mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
3056480|NCT00819910|Active Comparator|Fenofibrate + Placebo|Fenofibrate 145mg daily + Placebo (Rosiglitazone) 8mg daily for 12weeks
3056481|NCT00819910|Experimental|Rosiglitazone +Fenofibrate|Rosiglitazone 8mg daily + Fenofibrate 145mg daily for 12 weeks
3056482|NCT00819910|Placebo Comparator|Placebo Therapy Daily|Placebo (Rosiglitazone) 8mg daily + Placebo (Fenofibrate) 145 mg daily for 12 weeks
3056483|NCT00820027|Experimental|Etoricoxib 90 mg|Participants received etoricoxib 90 mg once daily, matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
3056484|NCT00820027|Experimental|Etoricoxib 120 mg|Participants received etoricoxib 120 mg once daily, matching placebo to etoricoxib 90 mg once daily, and matching placebo to ibuprofen 600 mg every 8 hours for 7 days.
3056485|NCT00820027|Active Comparator|Ibuprofen 1800 mg|Participants received ibuprofen 600 mg every 8 hours, matching placebo to etoricoxib 120 mg once daily, and matching placebo to etoricoxib 90 mg once daily for 7 days.
3056486|NCT00820027|Placebo Comparator|Placebo|Participants received matching placebo to etoricoxib 90 mg and matching placebo to etoricoxib 120 mg once daily, and matching placebo to ibuprofen every 8 hours for 7 days.
3056487|NCT00820040|Experimental|Permacol|
3056488|NCT00820170|Experimental|dasatinib and paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.~The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel."
3056489|NCT00820222|Experimental|Lapatinib plus capecitabine|Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
3056490|NCT00820222|Active Comparator|Trastuzumab plus capecitabine|trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
3056491|NCT00820235|Experimental|A|
3056492|NCT00820235|Active Comparator|B|
3056493|NCT00820235|Active Comparator|C|
3056494|NCT00820248|Active Comparator|Arm I|Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
3056495|NCT00820248|Experimental|Arm II|Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.
3056496|NCT00820443|Experimental|Ceramic on metal prosthesis|Ceramic on metal prosthesis
3056497|NCT00820534|Experimental|Penciclovir|Penciclovir
3056498|NCT00820534|Placebo Comparator|Placebo|Placebo
3056499|NCT00820573|Placebo Comparator|Placebo|Placebo to be provided for 6 weeks
3056500|NCT00820573|Experimental|Sitagliptin|Sitagliptin to be provided for 6 weeks
3056501|NCT00820573|Experimental|Metformin|Metformin to be provided for 6 weeks
3056502|NCT00820573|Experimental|Sitagliptin+Metfromin|Sitagliptin + Metformin combined will be provided for 6 weeks
3056503|NCT00820599|Experimental|TAVR|Transaortic Valve Replacement
3056504|NCT00820612|Active Comparator|1|Indomethacin suppository
3056505|NCT00820612|Placebo Comparator|2|Placebo suppository
3056506|NCT00820664|Active Comparator|17β-estradiol 2.0 milligrams|Estrace 2.0 mg tablet
3056507|NCT00820664|Active Comparator|17β-estradiol 0.5 milligrams|Estrace 0.5 mg tablet
3056508|NCT00820664|Placebo Comparator|3|Placebo
3056509|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy|
3056510|NCT00820755|Active Comparator|Cetuximab 500 mg/m^2 every 2 weeks|
3056511|NCT00820755|Active Comparator|Cetuximab 250 mg/m^2 weekly|
3056512|NCT00820872|Experimental|docetaxel + carboplatin + trastuzumab + lapatinib|"Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1, trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15, and oral lapatinib ditosylate on days 1-21 (TCHL). Treatment with TCHL repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30-90 minutes on day 1 and oral lapatinib ditosylate on days 1-21 (days 1-7 of course 12 only) (LT). Treatment with LT repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for 2 years and then annually for up to 8 years."
3056513|NCT00820898|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3056514|NCT00821015|Experimental|Experimental|All study subjects will undergo cryoablation. This is a non-randomized trial.
3056515|NCT00821041|No Intervention|Waiting list control|
3056516|NCT00821041|Experimental|CBT|A 6 weeks online course. Each week participants log on to view videos and read information that focus on a variety of intervention techniques. These include relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training. Participants also monitor their sleep using an online sleep diary and respond to questions regarding their adherence to the program.
3056517|NCT00821093|Experimental|Indacaterol 150 µg|Patients inhaled indacaterol 150 μg once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Patients also inhaled placebo to salmeterol twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3056518|NCT00821093|Active Comparator|Salmeterol 50 µg|Patients inhaled salmeterol 50 μg twice daily, once in the morning between 8:00 and 11:00 AM and once in the evening between 8:00 and 11:00 PM via the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]) for 12 weeks. Patients also inhaled placebo to indacaterol once daily in the morning between 8:00 and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3056519|NCT00821119|Active Comparator|NCPAP|preterm infants with nasal positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome will be compared to preterm infants with nasal intermittent positive pressure ventilation
3056520|NCT00821119|Experimental|NIPPV|preterm with nasal intermittent positive pressure ventilation as a primary mode of respiratory support in preterm infants with respiratory distress syndrome
3056521|NCT00821184|Active Comparator|Vesicare|Vesicare alone
3056522|NCT00821184|Active Comparator|Vesicare/behavioral modification|Vesicare plus behavioral modification
3056523|NCT00821236|Active Comparator|Wavelight|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
3056524|NCT00821236|Active Comparator|AMO/VISX CustomVue|AMO/VISX CustomVue™
3056525|NCT00821236|Active Comparator|LADARVision 4000 excimer laser|LADARVision 4000 excimer laser
3056526|NCT00821327|Experimental|Study Arm|Gemcitabine, Cisplatin, Sunitinib
3056527|NCT00821431|Experimental|Compression device|The electrical compression device is operated from battery or a main adaptor. It is based upon the use of inflatable pneumatic cuffs that apply controlled compression to the foot, ankle and calf.
3056528|NCT00821431|Active Comparator|Profore, 4-layer bandage|A high compression 4-layer bandage (Profore, Trademark of Smith and Nephew). This is a four-layer system that can be purchased either separately or as a package: a wound contact layer (Knitted viscose), a sub-compression wadding bandage, two layers of elastane bandage plus a top cohesive layer.
3056529|NCT00821509|Active Comparator|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent hand washing in office and at home
3056530|NCT00821509|Active Comparator|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
3056531|NCT00821509|No Intervention|Control|No change in hygiene behaviour
3056532|NCT00821587|Active Comparator|Tacrolimus|Tacrolimus
3056533|NCT00821587|Active Comparator|Cyclosporine|Cyclosporine
3056534|NCT00821626|Active Comparator|Rapid test|Returning travelers with fever will have a rapid flu test
3056535|NCT00821626|Sham Comparator|Comparator|Returning travelers with fever will benefit of the usual medical care, without rapid flu test
3056536|NCT00821678|Experimental|Arm 1 Telemedicine Outreach for PTSD|Telemedicine-Based Collaborative Care
3056537|NCT00821678|No Intervention|Arm 2 Treatment as usual|Usual Care
3056538|NCT00821795|Active Comparator|NPH/Regular 70/30 mix|transition insulin therapy with NPH/Regular 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
3056539|NCT00821795|Active Comparator|Aspart insulin analog biphasic mix|transition insulin therapy with Aspart insulin analog 70/30 mix for outpatient glycemic control following a hospitalization for non-critical acute illness
3056540|NCT00821821|Experimental|MCI-186|
3056541|NCT00821821|Placebo Comparator|Placebo Group|
3056542|NCT00821873|Experimental|CR Plug BackFill|Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site
3056543|NCT00821886|Experimental|Ixabepilone/Trastuzumab/Carboplatin|Neoadjuvant treatment with Ixabepilone, Trastuzumab and Carboplatin, followed by surgery, peri-operative treatment and post-operative (adjuvant) treatment if patient deemed to be a surgical candidate
3056544|NCT00821951|Experimental|Vorinostat and Radiotherapy|
3056545|NCT00821964|Experimental|Treatment (biological therapy, chemo)|Patients receive Abraxane IV over 30 minutes on days 1, 8, and 15 and apply topical imiquimod to cutaneous lesions QD on days 1-4, 8-11, 15-18, and 22-25. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
3056546|NCT00822094|Experimental|CPX-351 (Arm A)|First induction: 100 units/m2 on Days 1, 3, and 5 by 90-minute IV infusion Second induction: 100 units/m2 on Days 1 and 3 by 90-minute IV infusion Consolidation(s): 100 units/m2 on Days 1 and 3 by 90-minute IV infusion
3056547|NCT00822094|Active Comparator|Salvage Therapy (Arm B)|First induction: Investigator's choice salvage therapy administered according to local practice Second induction: Investigator's choice salvage therapy administered according to local practice Consolidation(s): Investigator's choice consolidation therapy administered according to local practice
3056548|NCT00822107|Experimental|Thiazide Response|Hydrochlorothiazide 50 mg will be administered by mouth once.
3056549|NCT00822120|Experimental|HIV Positive, PET Positive: BEACOPP standard|Etoposide 100 mg/m2 IV Days 1, 2, 3 Dox 25 mg/m2 IV Day 1 Cyclo 650mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 Q 21 Days x 6 cycles
3056550|NCT00822120|Experimental|HIV Negative, PET Positive: BEACOPP escalated|Etoposide 200 mg/m2 IV Days 1, 2, 3 Dox 35 mg/m2 IV Day 1 Cyclo 1,250 mg/m2 IV Day 1 Procarb 100 mg/m2 PO Days 1-7 Pred 40 mg/m2 PO Days 1-14 Bleo 10u/m2 IV Day 8 Vincristine 1.4 mg/m2 IV Day 8 G-CSF 5mcg/kg/day SQ Days 8-14 Q 21 Days x 6 cycles
3056551|NCT00822120|Active Comparator|HIV Positive, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
3056552|NCT00822120|Active Comparator|HIV Negative, PET Negative: ABVD|Doxorubicin 25 mg/m2 IV Bleomycin 10u/m2 IV Vinblastine 6mg/m2 IV Dacarbazine 375 mg/m2 IV Days 1, 15 Q 28 Days x 2
3056553|NCT00822172|Active Comparator|Cilostazol + L-Carnitine|1 tablet cilostazol 100 mg PO BID and 3 capsules L-carnitine 334 mg PO BID
3056554|NCT00822172|Placebo Comparator|Cilostazol + Placebo|1 tablet cilostazol 100 mg PO BID and 3 capsules placebo PO BID
3056555|NCT00822185|Experimental|vatreptacog alfa, 5 mcg/kg|
3056556|NCT00822185|Experimental|vatreptacog alfa, 10 mcg/kg|
3056557|NCT00822185|Experimental|vatreptacog alfa, 20 mcg/kg|
3056558|NCT00822185|Experimental|vatreptacog alfa, 30 mcg/kg|
3056559|NCT00822237|Experimental|VARIVAX 2007 process + M-M-R II|
3056560|NCT00822237|Active Comparator|VARIVAX 1999 process + M-M-R II|
3056561|NCT00822328|Experimental|1|Fermented milk with Lactobacillus casei strain Shirota 100ml per day
3056562|NCT00822328|Placebo Comparator|2|Unfermented milk without Lactobacillus casei strain Shirota 100ml per day
3056563|NCT00822354|Experimental|1|Subjects will receive tadalafil 20mg every other day for the first month, and then placebo for the second month.
3056564|NCT00822354|Experimental|2|Subjects will receive placebo for the first month, and tadalafil 20mg orally every other day for the second month.
3056565|NCT00822510|Experimental|Telephone Interpersonal Counseling|Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
3056566|NCT00822510|Active Comparator|Telephone delivered education only|Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.
3056567|NCT00822523|Experimental|Botulinum toxin type A, 20 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 20 units
3056568|NCT00822523|Experimental|Botulinum toxin, type A, 2 units|Single intramuscular (into extensor digitorum brevis muscle of the foot) dose of Botulinum toxin type A, 2 units
3056569|NCT00822523|Placebo Comparator|Placebo|Saline, Single dose, Intramuscular injection into right EDB
3056570|NCT00822588|Experimental|1|
3056571|NCT00822588|No Intervention|2|
3056572|NCT00822692|Active Comparator|Bactrim DS|Trim/sulfa (800/160) two tablets orally (PO) twice a day (BID) x 7 days
3056573|NCT00822692|Placebo Comparator|matched placebo|matched placebo 2 pills orally (PO) twice a day (BID) x 7 days
3056574|NCT00822757|Experimental|1|V710
3056575|NCT00822757|Placebo Comparator|2|Placebo
3056576|NCT00822770|Experimental|Phase I|ATG + Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
3056577|NCT00822770|Experimental|Phase II|ATG + MTD Plerixafor (AMD3100) + G-CSF (Filgrastim) + Fludarabine + Busulfan + Allogeneic blood stem cell transplant
3179086|NCT00668941|Experimental|4|Participants in this group will receive a continuous regimen of teriparatide (20 mcg delivered subcutaneously) daily for 48 months. Biopsies will be performed at Week 7 or Month 7.5. At 24 months the participants will then have the option of taking alendronate and remaining in the study for another 24 months.
3056578|NCT00822900|Experimental|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone will be combined with a 20% Intralipid mixture for infusion.
3056579|NCT00822900|Placebo Comparator|Placebo|"Placebo stock solution was the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid was based on the same mg/kg/hr volume that would be required if PROG had been in the vial. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid was administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table was used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 72 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The placebo will be combined with a 20% Intralipid mixture for infusion."
3056580|NCT00822926|Experimental|Placebo then Botox|Injection 1: Saline- Subcutaneous injection of saline into scar tissue Injection 2: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
3056581|NCT00822926|Experimental|Botox then Placebo|Injection 1: Botulinum Toxin Type A- Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue Injection 2: Saline- Subcutaneous injection of saline into scar tissue
3056582|NCT00823043||Timolol hemihydrate|Subjects currently prescribed timolol hemihydrate 0.5% solution.
3056583|NCT00823043||Timolol maleate|Subjects currently prescribed timolol maleate in sorbate.
3056584|NCT00823069|Other|Perlane and Perlane-L|This is a split-face design injecting both Perlane and Perlane-L injectable gels, administered once. Each subject received Perlane-L on one side of the face, and Perlane on the other. Subjects were blinded to which side of their face receive Perlane or Perlane-L. The study was randomized and treatments successive.
3056585|NCT00823082|Experimental|Antithrombin III treatment group|Preoperative ATIII supplementation administered immediately after anesthesia induction
3056586|NCT00823082|No Intervention|Control group|No preoperative ATIII supplementation administered
3056587|NCT00823134|Other|AL + polysomnography|Participant wears an Apnea Link sleep apnoea screening device during the polysomnography to detect apnoeas (obstructive, central).
3056588|NCT00823199|Experimental|Allopurinal treatment|Allopurinal 300mg once daily by mouth for four weeks
3056589|NCT00823212|Active Comparator|PROMUS|Patients who received the PROMUS (XIENCE V) Everolimus-Eluting Coronary Stent
3056590|NCT00823212|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
3056591|NCT00823264|Experimental|Multiple Doses of Activated Charcoal|Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
3056592|NCT00823264|No Intervention|Control|Will not receive activated charcoal. Serum levels will be followed.
3056593|NCT00823303|Experimental|Paricalcitol|titrated to achieve 40-60% PTH suppression
3056594|NCT00823303|Active Comparator|Calcitriol|titrated to achieve 40-60% PTH suppression
3056595|NCT00823459|Experimental|Single-Arm Everolimus|Single-arm study with patients receiving Everolimus orally once daily dosing of 10 mg continuously from Day 1 of study until progression of disease or unacceptable toxicity. In addition archival tissue will be analysed for markers of P13K/mTOR pathway activation.
3056596|NCT00823472|Experimental|Start rFSH cycle day 2|
3056597|NCT00823472|Experimental|Start rFSH on cycle day 5|
3056598|NCT00823615|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
3056599|NCT00823615|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
3056600|NCT00823719|Experimental|ofatumumab + DHAP or ICE chemotherapy regimen|This study is a single arm study, but the Investigators are required to prospectively choose to treat all of their subjects with either ICE or DHAP chemotherapy regimens in combination with ofatumumab. Regardless of whether the subject receives ICE or DHAP chemotherapy, all subjects will receive the same ofatumumab regimen and dose.
3056601|NCT00823797|Experimental|Treatment (bendamustine hydrochloride)|Patients receive bendamustine hydrochloride IV over 30-90 minutes on days 1-2. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3056602|NCT00823823|Active Comparator|Bivalved cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a bivalved cast
3056603|NCT00823823|Active Comparator|Circumferential cast|Patients with a displaced distal radius or mid-diaphyseal forearm fracture requiring closed reduction will be immobilized in a circumferential cast
3056604|NCT00823836|Experimental|ropinirolePR-PR group|
3056605|NCT00823836|Active Comparator|ropiniroleIR-PR group|
3056606|NCT00823901|Experimental|Clindamycin/Tretinoin Gel|Participants applied Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel on entire face (forehead, nose, chin, cheeks) once daily at night for 12 weeks
3056607|NCT00823901|Placebo Comparator|Placebo gel|Participants applied Placebo gel with no active medication on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks.
3056608|NCT00823966||Delavirdine Mesilate|Patients administered.
3056609|NCT00823979|Experimental|UK- 453,061 Dose One|
3056610|NCT00823979|Experimental|UK- 453,061 Dose Two|
3056611|NCT00823979|Active Comparator|Comparator|
3056612|NCT00824005|Placebo Comparator|Placebo Injections|Participants will receive placebo injections.
3056613|NCT00824005|Experimental|Active Stem Cell Injections|Participants will receive active stem cell injections.
3056614|NCT00824044|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.
3056615|NCT00824044|Active Comparator|Escitalopram|Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression
3056616|NCT00824070|Experimental|Besifloxacin|Besifloxacin ophthalmic suspension
3056617|NCT00824070|Active Comparator|Moxifloxacin|Vigamox (moxifloxacin ophthalmic solution, 0.5%)
3056618|NCT00824070|Active Comparator|Gatifloxacin|Zymar (gatifloxacin ophthalmic solution, 0.3%)
3056619|NCT00824161|Experimental|1|TAS-109
3056620|NCT00824265|Experimental|Ofatumumab, Fludarabine, Cyclophosphamide|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
3056621|NCT00824265|Active Comparator|Fludarabine, Cyclophosphamide|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
3056622|NCT00824291|Placebo Comparator|1|
3056623|NCT00824291|Experimental|2|
3056624|NCT00824369|No Intervention|Anti-retroviral therapy|Anti-retroviral therapy
3056625|NCT00824382|Experimental|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation
3056626|NCT00824382|Experimental|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation
3056627|NCT00824382|Placebo Comparator|Placebo|2 puffs
3056628|NCT00824382|Experimental|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation
3056629|NCT00824408|Experimental|BI 6727 +pemetrexed|BI 6727 plus 500 mg/^m2 pemetrexed i.v. on day 1 of 21 day cycle
3056630|NCT00824408|Active Comparator|pemetrexed|500 mg/m^2 i.v. on day 1 of a 21 day cycle
3056631|NCT00824421|Experimental|UK- 453,061 Dose One|UK 453,061 Dose One plus Truvada
3056632|NCT00824421|Experimental|UK-453,061 Dose Two|UK 453,061 Dose Two plus Truvada
3056633|NCT00824421|Active Comparator|Efavirenz + Truvada|Efavirenz + Truvada
3056634|NCT00824434|Experimental|Experimental Stent|
3056635|NCT00824460|Experimental|1.25 g PA21|
3056636|NCT00824460|Experimental|5.0 g PA21|
3056637|NCT00824460|Experimental|7.5 g PA21|
3056638|NCT00824460|Experimental|10.0 g PA21|
3056639|NCT00824460|Experimental|12.5 g PA21|
3056640|NCT00824460|Experimental|Sevelamer hydrochloride - active control|
3056641|NCT00824473|Placebo Comparator|1|Placebo
3056642|NCT00824473|Active Comparator|2|0.15% azelastine hydrochloride
3056643|NCT00824512|Experimental|EGb 761® 120 mg|
3056644|NCT00824512|Placebo Comparator|Placebo|
3056645|NCT00824538|Experimental|sunitinib|Study to evaluate the effect of sunitinib (37.5 mg/day orally for 6 months) on occult tumor cells in the bone marrow of patients with high risk early stage breast cancer
3056646|NCT00824564|Experimental|A|Tranexamic Acid plus standard of care
3056647|NCT00824564|Other|B|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss.
3056648|NCT00824616|Placebo Comparator|Placebo|Participants receiving placebo tablets three times daily plus insulin injection once daily
3056649|NCT00824616|Experimental|MK-0941|Participants receiving MK-0941 tablets three times daily plus insulin injection once daily
3056650|NCT00824655|Experimental|Group 1|
3056651|NCT00824655|Experimental|Group 2|
3056652|NCT00824720|Experimental|High Dose Device|device worn continuously for 14 days
3056653|NCT00824720|Experimental|Low Dose Device|device worn continuously for 14 days
3056654|NCT00824720|Placebo Comparator|Placebo Device|device worn continuously for 14 days
3056655|NCT00824733|Experimental|Arm I: Treatment (PF03512676 in combination with Trastuzumab)|12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.
3056656|NCT00824746|Experimental|Gefitinib retreatment group|Gefitinib retreatment
3056657|NCT00824824|Experimental|Brimonidine 0.2%-timolol 0.5% arm|Patients using timolol were switched to brimonidine tartrate / timolol maleate 0.2%/05% 1 get BID OU for six weeks.
3056658|NCT00824824|Active Comparator|Dorzolamide 2%-timolol 0.5% arm|Patients using timolol were switched ti dorzolamide hydrochloride / timolol 0.5% 2%/0.5% bid OU for six weeks
3056659|NCT00824850|Experimental|1|Subjects received Prevnar in study D118-P8
3056660|NCT00824850|Experimental|2|Subjects received MnCC in study D118-P8
3056661|NCT00824993|Experimental|Ibandronate + Calcium + Vitamin D|Ibandronate infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant. Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
3056662|NCT00824993|Experimental|Calcium + Viatmin D|Calcium 500 mg by mouth everyday for 12 months. Vitamin D 400 units by mouth 2 times a day for 12 months.
3056663|NCT00825162|Experimental|Cohort A|Participants aged 6 months to less than 3 years
3056664|NCT00825162|Experimental|Cohort B|Participants aged 3 years to less than 9 years
3056665|NCT00825162|Experimental|Cohort C|Participants aged 9 years to less than 18 years
3056666|NCT00825175|Active Comparator|1|Treadmill Training in infants with Down syndrome only
3056667|NCT00825175|Experimental|2|Treadmill Training and supramalleolar orthoses use for infants with Down syndrome
3056668|NCT00825266|Active Comparator|bosentan|Bosentan 62.5 twice daily for 4 weeks, then 125 mg twice daily.
3056669|NCT00825266|Active Comparator|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration of the study.
3056670|NCT00825305|Experimental|Zagreb (2-1-1)|Rabies PCEC vaccine was applied according Zagreb schedule with 2 vaccinations on day 0, 1 vaccination on day 7 and day 21, respectively
3056671|NCT00825305|Active Comparator|Essen (1-1-1-1-1)|Rabies PCEC vaccine was applied according Essen schedule, i.e. 1 vaccination on day 0, day 3, day 7, day 14 and day 28, respectively.
3056672|NCT00825318|Experimental|Daily ultrafiltration|During the treatment phase of the study, the subject will undergo ultrafiltration 6 times a week and hemodialysis 2 times a week.
3056673|NCT00825344|Experimental|1|Etanercept 50 mg preoperatively
3056674|NCT00825344|Placebo Comparator|2|Subcutaneous saline preoperatively
3056675|NCT00825370|Experimental|Protocolized|"1 mg IV hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
3056676|NCT00825370|Active Comparator|Discretionary Care|Patients receive an IV opioid the type and dose of which is determined by the treating physician
3056677|NCT00825500|Placebo Comparator|Inhaled Placebo|Inhaled Staccato Placebo (0 mg)
3056678|NCT00825500|Active Comparator|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
3056679|NCT00825500|Experimental|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 2.5 mg, single dose
3056680|NCT00825565|Experimental|Alwextin cream|8 subjects enrolled in this single study arm. All 8 subjects completed the study.
3056681|NCT00825630|Active Comparator|Lansoprazole (Lanton)|Patients with H.pylori infection will take one tablet a day of 20 mg Lansoprazole for 14 days orally in the morning
3056682|NCT00825630|Active Comparator|Omeprazole (Losec)|Patients with H.pylori infection will take one tablet of 30 mg a day of Omeprazole for 14 days orally in the morning
3056683|NCT00825630|Active Comparator|Pantoprazole (Controloc)|Patients with H.pylori infection will take one tablet a day of 40 mg of Pantoprazole for 14 days orally in the morning
3056684|NCT00825630|Active Comparator|Esomeprazole(Nexium)|Patients with H.pylori infection will take one tablet a day of 20 mg Esomeprazole for 14 days orally on the morning
3056685|NCT00825682|Experimental|1|20 breast cancer patients scheduled for adjunctive radiation treatment will be recruited for this study to receive reflexology treatment initiated at the beginning of radiation therapy, once a week, for 10 weeks.
3056686|NCT00825682|No Intervention|2|20 breast cancer patients, scheduled for adjunctive radiation treatment, matched by age to the intervention group will receive treatment as usual, and will be evaluated by the same measures as the intervention group.
3056687|NCT00825734|Experimental|Dose Level 1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (40mg/m^2)
3056688|NCT00825734|Experimental|Dose Level -1|Sorafenib PO BID (200mg), Ixabepilone IV every 21 days (32mg/m^2)
3056689|NCT00825734|Experimental|Dose Level 1a|Sorafenib PO BID (400mg), Ixabepilone IV every 21 days (32mg/m^2)
3056690|NCT00825786|Active Comparator|Group 1|combined group: ropivacaine and mepivacaine mixture: 1:1 volume mixture of 1.5% mepivacaine and 0.5% ropivacaine in 2 syringes (labeled 1 and 2) with 15 mL in each (total, 30 mL) injected in immediate sequence;
3056691|NCT00825786|Active Comparator|Group 2|sequential group: mepivacaine followed by ropivacaine: syringe 1 containing 15 mL of 1.5% mepivacaine, syringe 2 containing 15 mL of 0.5% ropivacaine (total, 30 mL); syringe 2 was injected with a 90-sec delay after injection of syringe 1.
3056692|NCT00825812|Experimental|Sugammadex in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
3056693|NCT00825812|Active Comparator|Neostigmine in Caucasian Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
3056694|NCT00825812|Experimental|Sugammadex in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 2.0 mg.kg-1 sugammadex was administered.
3056695|NCT00825812|Active Comparator|Neostigmine in Chinese Subjects|At reappearance of T2 after the last dose of rocuronium, 50 μg.kg-1 neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
3056696|NCT00825825|Active Comparator|Escitalopram|One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.
3056697|NCT00825825|Active Comparator|Citalopram|One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.
3056698|NCT00825825|Placebo Comparator|Placebo|Two weeks of placebo in healthy volunteers.
3056699|NCT00825916|Experimental|High Dose|
3056700|NCT00825916|Placebo Comparator|Placebo|
3056701|NCT00825916|Experimental|Low Dose|
3056702|NCT00825994|Experimental|Omega-3|omega-3 fatty acids, 2grams qd [every day] (2 x 1 gram tablets), PO [by mouth]
3056703|NCT00826020|Experimental|Omegaven™|This study will be a prospective, non-randomized, open-label study of Omegaven™ for provision of parenteral lipid calories. The study cohort, receiving the parenteral nutrition (PN) lipid at 1g/kg/day, will be compared to historical controls at University of Nebraska Medical Center (UNMC) where parenteral lipid calories were provided exclusively through soybean-based formulations. The study is planned to enroll 100 patients. The Intestinal Rehabilitation Program at UNMC sees between 20 and 30 new pediatric patients per year, with almost all being PN-dependent and over 75% presenting with a bilirubin ≥ 2mg/dL. Based on these calculations, we estimate 4-5 years to enroll 100 patients.
3056704|NCT00826111|Active Comparator|Eszopiclone|Lexapro for 10 weeks together with eszopiclone.
3056705|NCT00826111|Placebo Comparator|Placebo|Lexapro for 10 weeks together with placebo.
3056706|NCT00826150|Experimental|BC-819|BC-819 60, 120 and 240 mg IP administration
3056707|NCT00826176|Experimental|Sugammadex in Caucasian Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Caucasian subjects living in Europe.
3056708|NCT00826176|Experimental|Sugammadex in Chinese Subjects|At 1-2 post-tetanic counts (PTC) after the last dose of rocuronium, 4.0 mg.kg-1 sugammadex was to be administered. Chinese subjects living in China.
3056709|NCT00826202|Experimental|D serine|60 mg/kg/day
3056710|NCT00826202|Placebo Comparator|Placebo|
3056711|NCT00826228|Experimental|PTH/Weight-Bearing|
3056712|NCT00826241|Experimental|Temozolomide + Lapatinib|Temozolomide starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle. Lapatinib starting dose 1250 mg daily by mouth.
3056713|NCT00826267|Experimental|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
3056714|NCT00826267|Active Comparator|Lapatinib|Lapatinib tablets 1500 mg daily.
3056715|NCT00826267|Active Comparator|Trastuzumab|Trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly.
3056716|NCT00826280|Placebo Comparator|Placebo plus Regadenoson|Two placebo capsules plus 0.4 mg regadenoson per 5mL intravenous (IV) bolus injection
3056717|NCT00826280|Experimental|Caffeine 200 mg plus Regadenoson|One 200 mg Caffeine capsule and one placebo capsule plus 0.4 mg regadenoson per 5mL intravenous bolus injection
3056718|NCT00826280|Experimental|Caffeine 400 mg plus Regadenoson|Two 200 mg Caffeine capsules plus 0.4 mg regadenoson per 5mL intravenous bolus injection
3056719|NCT00826449|Experimental|Phase I|Dasatinib + Erlotinib
3056720|NCT00826514|Experimental|Tanezumab|
3056721|NCT00826514|Placebo Comparator|Placebo|
3056722|NCT00826540|Experimental|Treatment (sorafenib tosylate and bevacizumab)|Patients receive sorafenib tosylate orally twice daily on days 1-5 and 8-12 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Blood samples are collected at baseline and then periodically during study treatment for laboratory biomarker and pharmacogenetic studies
3056723|NCT00826618|Experimental|Ranibizumab|
3056724|NCT00826748|Experimental|Treated Smokers|The treatment with inhaled beclomethasone will be administered to this cohort from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days.
3056725|NCT00826748|No Intervention|Non-Treated Smokers|This cohort will act as control and include healthy smokers who receive no treatment.
3056726|NCT00826748|No Intervention|Non-Smokers|This cohort will act as control and include healthy non-smokers who receive no treatment.
3056727|NCT00826800|Experimental|Neoadjuvant FOLFOX Plus Bevacizumab|FOLFOX and bevacizumab will be given to colon cancer patients for 4 cycles over 8 weeks; an additional 2 cycles of FOLFOX without bevacizumab will be given for a total of 12 weeks of pre-operative chemotherapy.Restaging will be performed within 3 weeks of the 6th chemotherapy cycle. Colon surgery will be performed between weeks 3 and 6 subsequent to the 6th cycle of FOLFOX. Patients receiving preoperative chemotherapy without radiation will wait a minimum of 3 weeks from their last dose of chemotherapy, and 6 weeks from their last dose of bevacizumab, before proceeding to surgery. Specifically, it is intended that patients will undergo surgery between 3-6 weeks from completion of their neoadjuvant therapy as deemed clinically appropriate by their surgeon and medical oncologist. This permits a 7-10 week interval between the 4th bevacizumab administration and colon surgery.
3056728|NCT00826943|Active Comparator|Levocetirzine|5 mg daily x 7 days (note = cross over = all participants receive active comparators and placebo)
3056729|NCT00826943|Active Comparator|cetirizine|10 mg daily x 7 days. Note = crossover study, so all participants recieve all active comparators and placebo.
3056730|NCT00826943|Placebo Comparator|placebo|one tablet daily x 7 days; note that this is a crossover study so all participants receive all active comparators and placebo
3056731|NCT00827073|Active Comparator|Tetracaine 0.5% drop|Tetracaine 0.5% drop of betadine will be used on the operative eye after Tetracaine has been administered
3056732|NCT00827073|Active Comparator|Lidocaine 2% Jelly|Lidocaine 2% Jelly drop of betadine will be used on the operative eye after Lidocaine 2% Jelly has been administered
3056733|NCT00827112|Experimental|Arm A|maraviroc (Selzentry, Celsentri) 150 mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100mg QD Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir (Reyataz) in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir (Prezista)/ritonavir (Norvir)((800/100 mg) QD or lopinavir/ritonavir (Kaletra, Aluvia)(400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir (Prezista)/ritonavir (Norvir) or lopinavir/ritonavir (Kaletra, Aluvia)(, then the subject must be discontinued from the study.
3056734|NCT00827112|Experimental|Arm B|"emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD~Subjects experiencing unconjugated hyperbilirubinemia attributable to atazanavir (Reyataz) /ritonavir (Norvir) without any other etiology of hyperbilirubinemia, responding to the therapy without virologic failure, but expressing cosmetic concerns because of the jaundice or scleral icterus (associated with bilirubin elevations) and wish to discontinue atazanavir in spite of reassurances by the investigator, will be permitted on a single occasion only to switch to another protease inhibitor either darunavir/ritonavir (800/100 mg) QD or lopinavir/ritonavir (400/100mg) BID and remain in the study. If the investigator decides to switch to a protease inhibitor other than darunavir/ritonavir or lopinavir/ritonavir, then the subject must be discontinued from the study."
3056735|NCT00827242|Experimental|Tadalafil|
3056736|NCT00827242|Placebo Comparator|Placebo|
3056737|NCT00827255||Patients who received Restasis®|Patients who received Restasis® (cyclosporine ophthalmic emulsion 0.05%)
3056738|NCT00827359|Experimental|Treatment|This is a single-arm study. All patients will receive everolimus.
3056739|NCT00827372|Experimental|Pazopanib Treatment|Pazopanib 800 mg orally once each day (maximum total duration of treatment = 24 weeks)
3056740|NCT00827541||1|Patients hospitalized because of cIAI or cSSTI
3056741|NCT00827606|Experimental|Atorvastatin|All subjects will be treated with atorvastatin
3056742|NCT00827632|Active Comparator|Normal Weight group|Participants with a BMI of 19-24.9 kg/m^2
3056743|NCT00827632|Active Comparator|Obese group|Participants with a BMI of 30-39.9 kg/m^2
3056744|NCT00827775|No Intervention|Control|Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
3056745|NCT00827775|Active Comparator|Intervention|Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
3056746|NCT00827827|Experimental|Arm 1|Participants in this group undergo lower-extremity strength training on three pneumatic resistance machines (Keiser Leg Press, Keiser Leg Extension, and Keiser Leg Curl). Training sessions happen 3 times per week (M,W,F) and last approximately 45 minutes to 1 hour. Participants in this group exercise each limb individually to account for the large discrepancies in strength between legs in stroke survivors.
3056747|NCT00827827|Active Comparator|Arm 2|Participants in this group receive equal exposure to study staff compared with the experimental ST group (approximately 45 minutes to 1 hour 3 times per week). Exercise sessions for this group involve a full battery of active and passive...upper and lower body...stretching and range of motion exercises performed on raised padded tables.
3056748|NCT00827918|Experimental|MK-8998|MK-8998, 6 mg twice a day (BID) for Days 1 to 7, and 8 mg BID thereafter for a 4-week total treatment period
3056749|NCT00827918|Active Comparator|Olanzapine|Olanzapine, 5 mg BID for Day 1 to 7, and 15 mg (5 mg in the morning and 10 mg in the evening) thereafter for a 4-week total treatment period
3056750|NCT00827918|Placebo Comparator|Placebo|Placebo Comparator to MK-8998 or olanzapine
3056751|NCT00827931|Experimental|A|end of the operation and on the mornings of the first, second, fourth and seventh postoperative days.
3056752|NCT00827931|Other|B|Standard of Care
3056753|NCT00827944|Active Comparator|1|Parietex ProGrip
3056754|NCT00827944|Active Comparator|2|Low weight polypropylene mesh
3056755|NCT00827983|Experimental|Progesterone SC|
3056756|NCT00827983|Active Comparator|Progesterone Vaginal gel|
3056757|NCT00828009|Experimental|Tecemotide/bevacizumab after chemoradiation|"Concomitant Chemoradiotherapy: Patients (pts) receive paclitaxel intravenously (IV) over 1 hour and carboplatin IV over 15-30 minutes weekly for 6 weeks. Pts also receive radiotherapy 5 days a week for 6½ weeks. Pts with CR, PR, or SD proceed to consolidation chemotherapy.~Consolidation chemotherapy: Pts receive paclitaxel IV over 3 hours and carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression (PD) or unacceptable toxicity. Pts with CR, PR, or SD proceed to maintenance therapy.~Maintenance therapy: Pts receive a single dose of cyclophosphamide IV over 15-30 minutes 3 days before the first dose of bevacizumab and tecemotide. Pts then receive bevacizumab IV over 30-90 minutes on day 1 and tecemotide subcutaneously on days 1, 8, and 15 of courses 1 and 2 and on day 1 of every other course beginning in course 4. Treatment repeats every 21 days for up to 34 courses in the absence of PD or unacceptable toxicity."
3056758|NCT00828061|Placebo Comparator|A|placebo
3056759|NCT00828061|Active Comparator|B|10 mg prednisone
3056760|NCT00828061|Active Comparator|C|25 mg prednisone
3056761|NCT00828074|Experimental|Treatment (vinorelbine tartrate and sorafenib tosylate)|Patients receive sorafenib tosylate PO twice daily on days 1-28 and vinorelbine ditartrate IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3056762|NCT00828113|Experimental|Extended treatment|52-week varenicline therapy + individual smoking cessation counseling
3056763|NCT00828113|Active Comparator|Standard treatment|13 weeks of varenicline therapy + individual smoking cessation counseling
3056764|NCT00828139|Experimental|Arm I (ziv-aflibercept, topotecan hydrochloride)|Patients receive ziv-aflibercept IV over 1 hour on day 1 and topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive ziv-aflibercept IV on day 1 and topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3056765|NCT00828139|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after 4 courses may then receive topotecan hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3056766|NCT00828178|Active Comparator|Omega-3|3 g of Omega-3 (1.8 g eicosapentaenoic acid, 1.2 g docosahexaenoic acid ethyl esters); flow-mediated dilation of the brachial artery
3056767|NCT00828178|Placebo Comparator|corn starch|corn starch; flow-mediated dilation of the brachial artery
3056768|NCT00828191|Experimental|Progesterone SC|
3056769|NCT00828191|Active Comparator|Progesterone Tablets|
3056770|NCT00828204|Experimental|Avonex Single-Use Autoinjector|"Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes.~In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks."
3056771|NCT00828295|Experimental|1 mcg/kg arm|Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg)
3056772|NCT00828295|Experimental|3 mcg/kg arm|Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg)
3056773|NCT00828308|Experimental|Ixabepilone|"Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.~Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***"
3056774|NCT00828321|Experimental|1|
3056775|NCT00828321|Active Comparator|2|
3056776|NCT00828347|Other|1.0 μg/day Alfacalcidol|Alfacalcidol 1.0 μg capsule by mouth, every day for 6 months
3056777|NCT00828347|Other|0.25 μg/day Alfacalcidol|Alfacalcidol 0.25 μg capsule by mouth, every day for 6 months
3056778|NCT00828412|Active Comparator|1|EpiCeram Skin Barrier Emulsion
3056779|NCT00828412|Active Comparator|2|Desonide Cream 0.05%
3056780|NCT00828451|Experimental|Preterm Infants for EGF Profiles|Premature infants born at < 32 weeks gestation who are 7 days old or less. Infants received and intravenous infusion of [5,5,5-2H3]leucine (stable isotope labeled leucine) with sampling of blood, urine and saliva.
3056781|NCT00828464|Experimental|clobetasol propionate foam|All subjects receive clobetasol propionate
3056782|NCT00828516|Experimental|Usual treatment plus acupuncture|Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment
3056783|NCT00828542|Experimental|etonogestrel implant|Etonogestrel releasing contraceptive implant (Implanon®, NV Organon, Oss, The Netherlands) inserted 24-48 h after delivery. It is compounded by 68mg of etonogestrel, 3years of duration.
3056784|NCT00828542|Active Comparator|depot medroxyprogesterone acetate|At the 6th week postpartum, this group received intramuscular 150 mg of depot medroxyprogesterone acetate (Contracept®, EMS Sigma Pharma, Hortolandia, Brazil).
3056785|NCT00828568|Experimental|Imiquimod 5% Taro|Imiquimod 5% manufactured by Taro applied for 16 weeks
3056786|NCT00828568|Active Comparator|Aldara - Imiquimod 5%|Aldara, Imiquimod 5% applied for 16 weeks
3056787|NCT00828568|Placebo Comparator|Vehicle|Imiquimod vehicle applied for 16 weeks
3056788|NCT00828672|Active Comparator|AXE (ARM 1)|Oxaliplatin, Bevacizumab and Capecitabine concurrently with radiotherapy.
3056789|NCT00828672|Active Comparator|AX (ARM 2)|Bevacizumab and Capecitabine concurrently with radiotherapy
3056790|NCT00828711|Experimental|MVI 100|MVI 100 mcg vaginal insert
3056791|NCT00828711|Experimental|MVI 150|MVI 150 mcg vaginal insert
3056792|NCT00828711|Experimental|MVI 200|MVI 200 mcg vaginal insert
3056793|NCT00828750|Experimental|Treatment|Eltrombopag oral tablets once daily
3056794|NCT00828841|Active Comparator|Paclitaxel, Carboplatin, Cetuximab (Arm A)|Patients with squamous or non-squamous histologies will receive carboplatin and paclitaxel for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion.
3056795|NCT00828841|Active Comparator|Platinum, Gemcitabine, Cetuximab (Arm B)|Patients with squamous or non-squamous histologies will receive gemcitabine with either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion.
3056796|NCT00828841|Active Comparator|Platinum, Pemetrexed, Cetuximab (Arm C)|Patients with squamous histology will receive pemetrexed and either carboplatin or cisplatin for a minimum of four and a maximum of six 21-day cycles, plus cetuximab, and then enter a maintenance phase with single-agent cetuximab. Cetuximab will be given on Day 1, and weekly during chemotherapy, followed by biweekly administration during the maintenance period. The choice of delivering four, five or six cycles of chemotherapy is at the investigator's discretion. The choice of platinum-based chemotherapy is also at the investigator's discretion. Patients with non-squamous histology are not eligible for this arm.
3056797|NCT00828945||Hyperlipidemic Patients|
3056798|NCT00828984|Experimental|Arm A (high-dose PEG 3350)|Patients receive high-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3056799|NCT00828984|Experimental|Arm B (low-dose polyethylene glycol)|Patients receive low-dose macrogol 3350-based oral osmotic laxative PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3056800|NCT00828984|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD. Treatment continues for up to 6 months in the absence of unacceptable toxicity.
3056801|NCT00829010|Experimental|HIV+/+ Group|Infants born from a HIV positive mother and confirmed as HIV infected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered intramuscularly in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3056802|NCT00829010|Experimental|HIV+/- Group|Infants born from a HIV positive mother and confirmed as HIV exposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3056803|NCT00829010|Experimental|HIV- (3+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected. Subjects received 3 primary doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3056804|NCT00829010|Experimental|HIV- (EPI) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 3 primary doses of Synflorix™ vaccine (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3179087|NCT00668941|Experimental|5|Participants in this group will receive a cyclical regimen of teriparatide. Teriparatide will be administered subcutaneously in 20-mcg doses daily for 3 months. They will receive no teriparatide for the following 3 months, and then teriparatide treatment will continue for the 3 months after that. This schedule will continue for 24 months with an option to all participants to continue cyclic teriparatide for another 24 months. Biopsies will be performed at Week 7 or Month 7.5.
3056805|NCT00829010|Experimental|HIV- (2+1) Group|Infants born from a HIV negative mother and confirmed as HIV unexposed uninfected.Subjects received 2 primary doses (at 6 & 14 weeks of age at study Months 0 and 2) and 1 booster dose of Synflorix™ vaccine (at 9 months of age, at study Month 8). Subjects in the group also received 3 primary vaccine doses (at 6, 10 & 14 weeks of age, at study Months 0, 1 and 2) and 1 booster vaccine dose (at 15-18 months of age, at study Month 14) of Tritanrix™-HepB/Hib, 2 vaccine doses of Rotarix™ (at 10 & 14 weeks of age, at study Months 1 and 2), and 2 doses of measles vaccine (9-10 months of age & 15-18 months of age, at study Months 8 and 14). Measles vaccine was not considered as a study vaccine. The Synflorix™ vaccine was administered IM in the right thigh, the Tritanrix™-HepB/Hib vaccine was administered IM in the left anterolateral thigh during the primary vaccination and in the left anterolateral thigh or left deltoid region during booster vaccination. Rotarix™ was given orally.
3056806|NCT00829036|Experimental|Wayfinding Prototype|A Wayfinding Prototype is evaluated in terms of the time it takes subjects to use this device to walk to specific indoor locations versus baseline walking time.
3056807|NCT00829049|Active Comparator|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
3056808|NCT00829049|Active Comparator|Adapalene Gel 0.3%|1 pea-size amount, QD x 16 weeks
3056809|NCT00829166|Experimental|Trastuzumab emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
3056810|NCT00829166|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
3056811|NCT00829244|Experimental|CONSORT Dosing|GONAL-f® dose based on subject baseline characteristics determined according to the CONSORT calculator
3056812|NCT00829244|Active Comparator|Standard Dosing|GONAL-f® at a standard dose of 150 IU per day
3056813|NCT00829283|Active Comparator|1|Standard Care
3056814|NCT00829283|Experimental|2|Stepped-care
3056815|NCT00829296|Experimental|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
3056816|NCT00829296|Active Comparator|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
3056817|NCT00829309|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
3056818|NCT00829309|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
3056819|NCT00829387|Experimental|Behavioral|Cognitive behavioral therapy - Ten sessions of individual treatment delivered by a doctoral level psychologist.
3056820|NCT00829387|Active Comparator|Educational|Diabetes Education - Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator
3056821|NCT00829413|Other|Patients who received SonoVue|"Patients with at least one target lesions requiring work-up for characterization to undergo~Unenhanced ultrasound of the target lesion (UE-US): gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion using commercially available ultrasound equipment and standard techniques (B-mode or Harmonic imaging) to study the anatomy of the target lesion and surrounding parenchyma;~SonoVue-enhanced ultrasound of the target lesion (CE-US):procedures described in protocol Section 7.5.1.2, to study the lesion vascularity in comparison to the surrounding parenchyma; and~Truth standard~2.4 mL of sulfur hexafluoride microbubbles (SonoVue®) will be administered as a bolus injection in a peripheral vein."
3056822|NCT00829426|Experimental|Alprazolam|Alprazolam 3mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
3056823|NCT00829426|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (reference) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
3056824|NCT00829439|Experimental|Levodopa/Carbidopa|"Other Names:~Sinemet L-dopa~Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
3056825|NCT00829452|Experimental|1|
3056826|NCT00829452|Active Comparator|2|
3056827|NCT00829504|Experimental|1|
3056828|NCT00829504|Active Comparator|2|
3056829|NCT00829530|Experimental|1|
3056830|NCT00829530|Active Comparator|2|
3056831|NCT00829621|Active Comparator|75 mmHg suction|IVAC suction 75 mmHg
3056832|NCT00829621|Experimental|125 mmHg suction|IVAC suction 125 mmHg
3056833|NCT00829673|Experimental|1|
3056834|NCT00829673|Active Comparator|2|Focalin®
3056835|NCT00829686|No Intervention|No intervention|No antibiotic
3056836|NCT00829686|Active Comparator|Septra DS|Septra DS (800/160) two pills PO BID x 7 days
3056837|NCT00829712|Experimental|1|
3056838|NCT00829712|Active Comparator|2|Focalin®
3056839|NCT00829738||Group 1|All patients enrolled
3056840|NCT00829764|Experimental|1|Doxycycline Monohydrate
3056841|NCT00829764|Active Comparator|2|Vibramycin Monohydrate®
3056842|NCT00829790|Experimental|1|Doxycycline Monohydrate
3056843|NCT00829790|Active Comparator|2|Vibramycin Monohydrate®
3056844|NCT00829829|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3056845|NCT00829829|Active Comparator|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
3056846|NCT00829829|Active Comparator|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3056847|NCT00829868|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
3056848|NCT00829868|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
3056849|NCT00829933|Experimental|1|DU-176b low dose
3056850|NCT00829933|Experimental|2|DU-176b intermediate dose
3056851|NCT00829933|Experimental|3|DU-176b high dose
3056852|NCT00829933|Active Comparator|4|Warfarin
3056853|NCT00829985|Experimental|Glycerinated German Cockroach Allergenic Extract|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume [w/v]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
3056854|NCT00829985|Placebo Comparator|Placebo|Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume [w/v]) was achieved.
3056855|NCT00829998|Experimental|Zaleplon|Zaleplon 10 mg Capsule (test) dosed in first period followed by Sonata® 10 mg Capsule (reference) dosed in second period
3056856|NCT00829998|Active Comparator|Sonata®|Sonata® 10 mg Capsule (reference) dosed in first period followed by Zaleplon 10 mg Capsule (test) dosed in second period
3056857|NCT00830024|Experimental|Alprazolam (test)|Alprazolam 3 mg ER Tablet (test) dosed in first period followed by Xanax XR® 3 mg Tablet (reference) dosed in second period
3056858|NCT00830024|Active Comparator|Xanax XR®|Xanax XR® 3 mg Tablet (test) dosed in first period followed by Alprazolam 3 mg ER Tablet (test) dosed in second period
3056859|NCT00830037|Experimental|IV Iron|
3056860|NCT00830037|Active Comparator|Oral Iron|
3056861|NCT00830063|Experimental|1|
3056862|NCT00830063|Experimental|2|
3056863|NCT00830063|Active Comparator|3|
3056864|NCT00830063|Placebo Comparator|4|
3056865|NCT00830076|Experimental|Sitagliptin + placebo metformin|
3056866|NCT00830076|Experimental|Metformin + placebo sitagliptin|
3056867|NCT00830076|Experimental|Sitagliptin + metformin|Co-administration of sitagliptin and metformin
3056868|NCT00830076|Placebo Comparator|Placebo sitagliptin + placebo metformin|Co-administration of placebo to sitagliptin and placebo to metformin
3056869|NCT00830115||Pantoprazole|All patients enrolled
3056870|NCT00830128|Experimental|pregabalin (Lyrica)|
3056871|NCT00830167|Placebo Comparator|Placebo|
3056872|NCT00830167|Experimental|Pregabalin|
3056873|NCT00830180|Experimental|Anti-NGF AB|
3056874|NCT00830206|Experimental|Azithromycin (test)|Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
3056875|NCT00830206|Active Comparator|Zithromax® (reference)|Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin Oral Suspension 200 mg/5 mL (test) dosed in second period
3056876|NCT00830219|Experimental|1|
3056877|NCT00830219|Active Comparator|2|
3056878|NCT00830232|Active Comparator|Closed-cell stent (Xact stent)|For patients randomized to the closed-cell stent group, the Xact closed-cell stents were used. The Xact stent is a FDA approved device.
3056879|NCT00830232|Active Comparator|Open-cell stent (Acculink carotid)|For patients randomized to the open-cell stent group, the Acculink carotid stent was used. The Acculink stent is a FDA approved device.
3056880|NCT00830258|Experimental|Pravastatin|Pravastatin 80 mg Tablet (test) dosed in first period followed by Pravachol® 80 mg Tablet (reference) dosed in second period
3056881|NCT00830258|Active Comparator|Pravachol®|Pravachol® 80 mg Tablet (reference) dosed in first period followed by Pravastatin 80 mg Tablet (test) dosed in second period
3056882|NCT00830284|Experimental|Recruitment|Patients with hypoxic respiratory failure
3056883|NCT00830310|Experimental|Customized Adherence Enhancement (CAE)|"Participants will be assigned to receive one or more of the study interventions based upon the participant's responses on the Attitudes toward Mood Stabilizers Questionnaire (AMSQ) and reasons for non-adherence on the Rating of Medication Influences (ROMI).~Individuals will participate in a series of 4 60-minute sessions over a 4-week period, with the study therapist who will implement the module-based intervention. The number of modules may differ depending on the baseline adherence profile of the participant.~An intervention manual developed by the investigators will provide explicit guidelines regarding how modules may be co-administered in single or multiple sessions to minimize redundancy as well as time and effort burden on study participants. The manual for each module will specifically address how any module could be combined with the other modules."
3056884|NCT00830336|Experimental|Azithromycin (test)|Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in first period followed by Zithromax® Oral Suspension 200 mg/5 mL (reference) dosed in second period
3056885|NCT00830336|Active Comparator|Zithromax® (reference)|Zithromax® for Oral Suspension 200 mg/5 mL (reference) dosed in first period followed by Azithromycin for Oral Suspension 200 mg/5 mL (test) dosed in second period
3056886|NCT00830362|Active Comparator|Propranolol 40mg|
3056887|NCT00830362|Placebo Comparator|Placebo|
3056888|NCT00830375|Experimental|Memantine|10-30mg, memantine
3056889|NCT00830388|Experimental|Ketoconazole 2% Foam|Open-label study
3056890|NCT00830440|Experimental|EndoBarrier Device|EndoBarrier Device and Diet & Lifestyle Counseling
3056891|NCT00830440|Active Comparator|Control|Diet & Lifestyle Counseling
3056892|NCT00830518|Experimental|Alisertib|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period, in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
3056893|NCT00830596|Active Comparator|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
3056894|NCT00830596|Active Comparator|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
3056895|NCT00830596|Placebo Comparator|Sham Intervention|Light effleurage and a sham mechanically-assisted chiropractic treatment for 2 weeks followed by full spine manipulation for 4 weeks
3056896|NCT00830765|Placebo Comparator|1 Placebo|The participant will receive a weekly injection of placebo from the time of enrollment up until 34 weeks' gestation or delivery, whichever occurs first.
3056897|NCT00830765|Active Comparator|Progesterone|The participant will receive weekly injections of 100mg of OHP17 from the time of enrollment until 34 weeks' gestation or delivery, whichever occurs first.
3056898|NCT00830791|Experimental|MK-0941 20 mg Mild Renal Insufficiency|MK-0941 20 mg administered to participants with mild renal insufficiency and type 2 diabetes.
3056899|NCT00830791|Experimental|MK-0941 20 mg Moderate Renal Insufficiency|MK-0941 20 mg administered to participants with moderate renal insufficiency and type 2 diabetes.
3056900|NCT00830791|Experimental|MK-0941 5 mg Severe Renal Insufficiency|MK-0941 5 mg administered to participants with severe renal insufficiency and type 2 diabetes.
3056901|NCT00830791|Experimental|MK-0941 20 mg Matched Controls|MK-0941 20 mg administered to age-, gender-, race-, body mass index (BMI)-, and hemoglobin A1C (HbAIc)-matched control subjects with normal renal function and type 2 diabetes.
3056902|NCT00830791|Experimental|MK-0941 5 mg Matched Controls|MK-0941 5 mg administered to age-, gender-, race-, body mass index (BMI)-, and HbAIc-matched control subjects with normal renal function and type 2 diabetes.
3056903|NCT00830804|Experimental|RAL + DRV/RTV|Raltegravir (400 mg BID) plus Darunavir/Ritonavir (800 mg/100 mg QD) for 52 weeks
3056904|NCT00830869|Experimental|Part 1: Ixazomib 0.125 milligram per square meter (mg/m^2)|Ixazomib (MLN9708) 0.125 mg/m^2, injection, intravenously (IV), once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056905|NCT00830869|Experimental|Part 1: Ixazomib 0.25 mg/m^2|Ixazomib (MLN9708) 0.25 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056906|NCT00830869|Experimental|Part 1: Ixazomib 0.5 mg/m^2|Ixazomib (MLN9708) 0.5 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056907|NCT00830869|Experimental|Part 1: Ixazomib 1 mg/m^2|Ixazomib (MLN9708) 1 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056908|NCT00830869|Experimental|Part 1: Ixazomib 1.33 mg/m^2|Ixazomib (MLN9708) 1.33 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056909|NCT00830869|Experimental|Part 1: Ixazomib 1.76 mg/m^2|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study.
3056910|NCT00830869|Experimental|Part 1: Ixazomib 2.34 mg/m^2|Ixazomib (MLN9708) 2.34 mg/m^2, injection, IV, once on Day 1, 4, 8 and 11 followed by 10 days of rest in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity during Part 1 of the study. Once the MTD will be established, participants with NSCLC, Head and Neck Cancer (H&N), Soft Tissue Sarcoma (STC) or Prostate Cancer (PC) will be included in MTD disease expanded cohort. An additional tumor pharmacodynamics expansion cohort (TPEC) will enroll participants with any type of solid tumor that can be biopsied for tissue analysis before and after treatment with ixazomib.
3056911|NCT00830869|Experimental|Part 2:Ixazomib 1.76 mg/m^2-NSCLC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with NSCLC during Part 2 of the study.
3056912|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-H&N|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with H&N during Part 2 of the study.
3056913|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-STC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with STC during Part 2 of the study.
3056914|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-PC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with PC during Part 2 of the study.
3056915|NCT00830869|Experimental|Part 2: Ixazomib 1.76 mg/m^2-TPEC|Ixazomib (MLN9708) 1.76 mg/m^2, injection, IV, once on Day 1, 4, 8, and 11 followed by 10 days of rest period in 21-day treatment cycles for a maximum of 12 cycles, or until progressive disease or unacceptable toxicity in participants with various types of solid tumors suitable for biopsy in tumor pharmacodynamic expansion cohort (TPEC) during Part 2 of the study.
3056916|NCT00830947|Experimental|OrthoAccel Device|Device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
3056917|NCT00830947|Sham Comparator|Sham Device (inactive device)|Sham device will look identical to active devices but will not deliver vibration to the patient.
3056918|NCT00830960|Experimental|Prasugrel 60/10 Primary|Loading dose 60 mg followed by maintenance dose 10 mg/day
3056919|NCT00830960|Experimental|Prasugrel 30/7.5 Primary|Loading dose 30 mg followed by maintenance dose 7.5 mg/day
3056920|NCT00830960|Experimental|Prasugrel 30/5 Primary|Loading dose 30 mg followed by maintenance dose 5 mg/day
3056921|NCT00830960|Active Comparator|Clopidogrel 300/75 Primary|Loading dose 300 mg followed by maintenance dose 75 mg/day
3056922|NCT00830960|Experimental|Prasugrel 30/5 Low Weight/Elderly|Loading dose 30 mg followed by maintenance dose 5 mg/day
3056923|NCT00830960|Active Comparator|Clopidogrel 300/75 Low Weight/Elderly|Loading dose 300 mg followed by maintenance dose 75 mg/day
3056924|NCT00831129|Active Comparator|Simvastatin + Placebo Rosiglitazone|Subjects will receive 40 mg Simvastatin + 1 tab Placebo Rosiglitazone daily
3056925|NCT00831129|Active Comparator|Simvastatin + rosiglitazone|Subjects will receive 40 mg Simvastatin + 4 mg Rosiglitazone once daily
3056926|NCT00831181|Experimental|Preoperative Chemoradiation|Preoperative Chemoradiation with oxaliplatin/5-FU followed by mesorectal excision and 5-FU / leucovorin (FOLFOX 6)
3056927|NCT00831233|Experimental|Degarelix 240 mg/80 mg|Degarelix 240 mg (40 mg/mL) + 80 mg (20 mg/mL)
3056928|NCT00831233|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|Goserelin (3.6 mg) + bicalutamide (50 mg)
3056929|NCT00831272|Experimental|Naltrexone|50mg/day of naltrexone
3056930|NCT00831272|Placebo Comparator|Placebo|Placebo
3056931|NCT00831311|Experimental|1|DTaP IPV HB-PRP~T vaccine group
3056932|NCT00831311|Active Comparator|2|PENTAXIM™ and ENGERIX B® vaccines group
3056933|NCT00831389|Experimental|Closed Loop (CL) Phase|Closed Loop (CL) Phase
3056934|NCT00831389|No Intervention|Standard of Care (OL) Phase|Standard of Care (OL) Phase or Open Loop Phase
3056935|NCT00831415|Experimental|1|DVS SR
3056936|NCT00831428||Scottish swimming team|
3056937|NCT00831441|Active Comparator|Apixaban|
3056938|NCT00831441|Placebo Comparator|Placebo|
3056939|NCT00831480|Experimental|1|All subjects will take everolimus
3056940|NCT00831493|Experimental|Vorinostat + Radiation Therapy|Vorinostat starting dose 200 mg orally once daily, Monday to Friday, Weeks 1 to 6; Radiation Therapy Dose of 50.4 Gray (Gy) in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
3056941|NCT00831675|Experimental|Infants <12 Months|Participants aged ≥ 6 to < 12 months at enrollment and received 2 doses of Fluzone® Vaccine
3056942|NCT00831675|Experimental|Toddlers ≥12 Months|Participants aged ≥ 12 to < 36 months at enrollment and received 2 doses of Fluzone® vaccine
3056943|NCT00831701|Active Comparator|Tamsulosin|Tamsulosin treatment
3056944|NCT00831701|Placebo Comparator|Placebo|Placebo treatment
3056945|NCT00831753|Experimental|Group 1|DTaP-IPV-Hep B-PRP~T vaccine group
3056946|NCT00831753|Active Comparator|Group 2|Infanrix® Hexa vaccine group
3056947|NCT00831766|Experimental|Phase I: Dose Escalation|"Induction: A dose escalation plan for induction therapy using a standard 3x3 design with dose escalation of Lenalidomide only, to determine maximum tolerated dose (MTD). Idarubicin and cytarabine doses will be fixed.~Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: According to dose escalation levels. Level 1: 5 mg/d; Level 2: 10 mg/d; Level 3: 15 mg/d; Level 4: 20 mg/d; Level 5: 25 mg/d."
3056948|NCT00831766|Experimental|Phase II: Treatment at MTD|"Idarubicin: 12 mg/m^2.~Cytarabine: 200 mg/m^2.~Lenalidomide: Maximum Tolerated Dose (MTD)."
3056949|NCT00831779|Experimental|Dapagliflozin|
3056950|NCT00831779|Placebo Comparator|Placebo|
3056951|NCT00831792|Experimental|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day). Following an initial 4-week cycle at a starting dose of 400 mg 5 days- on and 2 days off, TKI258 may be escalated to 500 mg/day 5 days-on/2 days off if no significant Grade3/4 AEs or laboratory abnormalities are observed.
3056952|NCT00831844|Experimental|Group 1 - Recurrent or Refractory Hepatoblastoma|Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056953|NCT00831844|Experimental|Group 2 - Recurrent or Refractory Synovial Sarcoma|Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056954|NCT00831844|Experimental|Group 3 - Recurrent or Refractory Rhabdomyosarcoma|Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056955|NCT00831844|Experimental|Grp 4-Recurrent or Refractory Adrenocortical Carcinoma|Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056956|NCT00831844|Experimental|Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056957|NCT00831844|Experimental|Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease|Group 6 - Recurrent or Refractory Neuroblastoma -meta-iodobenzylguanidine (MIBG) Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056958|NCT00831844|Experimental|Grp 7-Neuroblastoma with measurable disease|Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056959|NCT00831844|Experimental|Group 8 - Recurrent Osteosarcoma|Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056960|NCT00831844|Experimental|Group 9 - Recurrent or Refractory Wilms Tumor|Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056961|NCT00831844|Experimental|Group 10 - Recurrent or Refractory Retinoblastoma|Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3056962|NCT00831987|Experimental|Fluzone® Vaccine Group - Age 18-59 Years|Participants aged 18 to 59 years at enrollment and received 1 dose of Fluzone® Vaccine
3056963|NCT00831987|Experimental|Fluzone® Vaccine Group - Age ≥ 60 Years|Participants aged at least 60 years or older at enrollment and received 1 dose of Fluzone® Vaccine
3056964|NCT00832000|Experimental|1|Participants will receive mexiletine for 4 weeks, then no intervention for 1 week, and finally placebo for 4 weeks.
3056965|NCT00832000|Experimental|2|Participants will receive placebo for 4 weeks, then no intervention for 1 week, and finally mexiletine for 4 weeks.
3056966|NCT00832078|Other|Group A|SCCM (SpeediCath Compact Male catheter) then SC (SpeediCath cathter) on test day 1. SC then SCCM on test day 2
3056967|NCT00832078|Other|Group B|SC (SpeediCath cathter)then SCCM (SpeediCath Compact Male catheter) on test day 1. SCCM then SC on test day 2
3056968|NCT00832091|Active Comparator|1|There are 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were 3 concentrations used for topical administration to the active drug groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
3056969|NCT00832091|Placebo Comparator|2|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
3056970|NCT00832117|Experimental|Escalation and Expansion|
3056971|NCT00832130|Experimental|Manual Mini System|Treatment with experimental Manual Mini System
3056972|NCT00832130|Active Comparator|Warm Compress Therapy|Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase
3056973|NCT00832338|Experimental|Docetaxel with Cytoxan|Patients will be treated with docetaxel at 75 mg/m² concomitantly with cytoxan 600 mg/m² (TC) IV D1 every 3 weeks for 6 cycles. Due to known toxicity of docetaxel, all patients require dexamethasone 4 mg twice daily (BID) PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel to minimize hypersensitivity reactions and fluid retention.
3056974|NCT00832377|Experimental|Timolol/Dorzolamide|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
3056975|NCT00832390|Experimental|1|sitagliptin
3056976|NCT00832416|Experimental|1 Tramadol Once A Day 100mg|
3056977|NCT00832416|Experimental|2: Tramadol Once A Day 200mg|
3056978|NCT00832416|Experimental|3: Tramadol Once A Day 300mg|
3056979|NCT00832416|Experimental|4: Placebo|
3056980|NCT00832455|Experimental|Montelukast|
3056981|NCT00832585|Experimental|Alefacept|"Amevive® has been shown to be a safe and effective agent in the treatment of psoriasis but may prove useful in treating atopic dermatitis at a dose of 15mg IM every week for 12 weeks. Unlike other biologics for the treatment of skin diseases, the use of alefacept is not associated with increased infection, congestive heart failure, demyelinating disorders or lupus- like syndromes."
3056982|NCT00832637|Experimental|Gemcitabine, Cisplatin, Erlotinib|A combination of Cisplatin at 40 mg/m2 + Gemcitabine at 1000 mg/m2, every 28 days + Erlotinib 100 mg daily, orally. Cycles will be repeated every four weeks.
3056983|NCT00832650|Experimental|Fesoterodine|Tablets
3056984|NCT00832650|Placebo Comparator|Placebo|Tablets
3056985|NCT00832650|Active Comparator|Solifenacin|Tablets
3056986|NCT00832767|Active Comparator|SILS Port|SILS™ Port Laparoscopic Cholecystectomy
3056987|NCT00832767|Active Comparator|Four Port|Four Port Laparoscopic Cholecystectomy
3056988|NCT00832780|Experimental|Stereotactic Body Radiation (SBRT)|60 Gy using 12 Gy per fraction over 5 fractions, to be given within 10 calendar days
3056989|NCT00832819|Experimental|E7080 (Dose Escalation Cohort)|This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin.
3056990|NCT00832819|Experimental|E7080 (Expansion Cohort)|Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.
3056991|NCT00832871|Experimental|Mifepristone|200 mg RU-486 (Mifepristone) daily
3056992|NCT00833027|Experimental|1|Sitagliptin
3056993|NCT00833040|Experimental|Titration of sufentanil, the DBL sufentanil & PBO|"During the Titration Phase, patients titrated to the effective dosage of sublingual sufentanil NanoTab™(20, 30, 40, 60 or 80 mcg). One sublingual sufentanil NanoTab™ was taken as needed for breakthrough pain.~During the Double-Blind Phase, patients were then randomized to one of six treatment sequences, each of which included seven active doses of sublingual sufentanil (dosage determined in Titration Phase) and three placebo doses taken in random order. One NanoTab™ was taken as needed for breakthrough pain."
3056994|NCT00833053|Experimental|IFX q 6 weeks|
3056995|NCT00833053|Experimental|IFX + MTX|
3056996|NCT00833092|Placebo Comparator|Sugar pill|Sugar Pill
3056997|NCT00833092|Active Comparator|magnesium|300 milligrams of magnesium daily
3056998|NCT00833105|Experimental|AMES treatment|The subject will receive 25 treatment sessions, conducted 2-3 times per week on the AMES device. Each session will consist of testing followed by 30 minutes of wrist and finger rehabilitation using the AMES device.
3056999|NCT00833248|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
3057000|NCT00833248|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"On Day 0, the participants began once-daily oral (p.o.) treatment with bicalutamide as anti-androgen flare protection. This treatment continued for 2 weeks after the first dose of goserelin (i.e. 17 days in total).~On Day 3, the first goserelin implant was inserted s.c. into the abdominal wall. The second and third doses of goserelin were administered on Days 31 and 59, respectively."
3057001|NCT00833261|Experimental|Single Arm: Chemotherapy with Concurrent Radiation therapy|Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy intensity-modulated radiation therapy
3057002|NCT00833365|Active Comparator|Early treatment|Infants randomized to this group will receive their initial dose of ibuprofen prior to reaching 96 hrs old
3057003|NCT00833365|Active Comparator|Late treatment|Infants randomized to this group will receive their initial dose of ibuprofen after infant has reached 96 hrs old but before the infant reaches 10 days old.
3057004|NCT00833417|Experimental|Vismodegib 150 mg|Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.
3057005|NCT00833443|Active Comparator|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days.
3057006|NCT00833443|Placebo Comparator|Sugar Pill|
3057007|NCT00833469|Experimental|Escitalopram|Flexible dose escitalopram 10mg
3057008|NCT00833482|Active Comparator|Voriconazole, 200 mg BID (EM)|
3057009|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100 QD (EM & PM)|
3057010|NCT00833482|Active Comparator|Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)|
3057011|NCT00833482|Active Comparator|Voriconazole, 50 mg BID (PM)|
3057012|NCT00833482|Active Comparator|Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)|
3057013|NCT00833521|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
3057014|NCT00833521|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
3057015|NCT00833547|Experimental|Eszopiclone|3mg of eszopiclone on two consecutive nights
3057016|NCT00833547|Placebo Comparator|placebo|placebo capsule that looks identical to eszopiclone capsule on two consecutive nights
3057017|NCT00833560|Experimental|Cyclophosphamide + Bortezomib + Dexamethasone|Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
3057018|NCT00833586|Experimental|Terbinafine|Terbinafine HCl 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
3057019|NCT00833586|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
3057020|NCT00833638|Experimental|Tadalafil 2.5 mg|No drug during baseline period, 2.5 mg for 14 days, then will continue at 5 mg for 14 days.
3057021|NCT00833638|Experimental|Tadalafil 5 mg|No drug during baseline period, 5 mg for 14 days, then will continue at 5 mg for 14 days.
3057022|NCT00833638|Placebo Comparator|Placebo|No drug during baseline period, placebo for 14 days, then will continue tadalafil at 5 mg for 14 days.
3057023|NCT00833664|Experimental|Terbinafine|Terbinafine 250 mg Tablet (test) dosed in first period followed by Lamisil® 250 mg Tablet (reference) dosed in second period
3057024|NCT00833664|Active Comparator|Lamisil®|Lamisil® 250 mg Tablet (reference) dosed in first period followed by Terbinafine 250 mg Tablet (test) dosed in second period
3057025|NCT00833690|Placebo Comparator|[A:]|Placebo to produce no urate elevation
3057026|NCT00833690|Experimental|[B:]|"Inosine to produce a mild urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL"
3057027|NCT00833690|Experimental|[C.]|"Inosine to produce a moderate urate elevation~500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL"
3057028|NCT00833703|Placebo Comparator|Placebo|0.2 mL/kg/day matching placebo solution once daily.
3057029|NCT00833703|Experimental|Clopidogrel 0.2 mg/kg/day|0.2 mL/kg/day Clopidogrel reconstituted solution at 1mg/mL once daily.
3057030|NCT00833755|Active Comparator|Opioid - Ketamine|This group consists of 16 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
3057031|NCT00833755|Active Comparator|Non-opioid - Ketamine|This group consists of 22 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a ketamine treatment during the study. They were given an intravenous infusion of ketamine (0.05mg/kg) diluted in 50 ml normal saline over 30 minutes.
3057032|NCT00833755|Placebo Comparator|Opioid - Placebos|This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
3057033|NCT00833755|Placebo Comparator|Non-opioid - Placebos|This group consists of 23 subjects who have chronic pain conditions but were not on an opioid regimen over the last 3 months. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
3057034|NCT00833781|Active Comparator|mRNA-transfected dendritic cells|Participants in this arm/group received mRNA-transfected autologous dendritic cells
3057035|NCT00833781|Placebo Comparator|Dendritic cells without mRNA|Participants in this arm/group received autologous dendritic cells with no mRNA transfection
3057036|NCT00833794|Experimental|1 Tramadol Once A Day|
3057037|NCT00833794|Placebo Comparator|2 Placebo|
3057038|NCT00833833|Experimental|Phase 1: 2 mg pomalidomide|Pomalidomide 2 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3057039|NCT00833833|Experimental|Phase 1: 3 mg pomalidomide|Pomalidomide 3 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3057040|NCT00833833|Experimental|Phase 1: 4 mg pomalidomide|Pomalidomide 4 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3057041|NCT00833833|Experimental|Phase 1: 5 mg pomalidomide|Pomalidomide 5 mg daily on days 1-21 of each 28-day cycle. Participants with progressive disease (PD) had the option of adding dexamethasone 40 mg on Days 1, 8, 15, 22 of each 28-day cycle to the pomalidomide treatment, or discontinuing study treatment.
3057042|NCT00833833|Experimental|Phase 2: pomalidomide + dexamethasone|Combination therapy of 4 mg pomalidomide given once per day on Days 1-21 of each 28-day cycle and the starting dose of dexamethasone (determined by age) on days 1, 8, 15, and 22 of each 28-day cycle. The starting dose of dexamethasone was 40 mg for participants who were ≤ 75 years of age and 20 mg for participants who were > 75 years of age. Dose reduction steps for dexamethasone were provided for drug-related toxicities.
3057043|NCT00833833|Experimental|Phase 2: pomalidomide|4 mg pomalidomide was given once per day on Days 1-21 of each 28-day cycle until PD. Participants in the single agent pomalidomide treatment arm who developed confirmed PD at any time had the option to receive oral dexamethasone on days 1, 8, 15, and 22 of each 28-day cycle at the starting dose of 20 or 40 mg depending on age in addition to their current dose of pomalidomide, or to discontinue treatment.
3057044|NCT00833898|No Intervention|Caregiver Control|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care.
3057045|NCT00833898|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation Paced Respiration and Relaxation (PEPRR), which included one-on-one psychoeducation, stress management intervention, with paced respiration.
3057046|NCT00833911|Experimental|Tramadol Contramid® OAD|
3057047|NCT00833924|Other|1|Treatment with Endovascular Graft
3057048|NCT00833937|Experimental|Zolpidem|Zolpidem Tartrate 10 mg Tablet (test) dosed in first period followed by Ambien® 10 mg Tablet (reference) dosed in second period
3057049|NCT00833937|Active Comparator|Ambien®|Ambien® 10 mg Tablet (reference) dosed in first period followed by Zolpidem Tartrate 10 mg Tablet (test) dosed in second period
3057050|NCT00833976|Experimental|open-label Lovaza (omega-3 fatty acids)|4g per day (4g once a day or 2g two times a day) for 16 weeks
3057051|NCT00833989|Placebo Comparator|PLACEBO|
3057052|NCT00833989|Experimental|ACTIVE|
3057053|NCT00834041|Experimental|Aliskiren 2 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 2 mg/kg body weight once each morning
3057054|NCT00834041|Experimental|Aliskiren 6 mg/kg|Oral mini-tablets (3.125 mg) of aliskiren dosed at 6 mg/kg body weight once each morning
3057055|NCT00834067|Experimental|1|
3057056|NCT00834067|Active Comparator|2|
3057057|NCT00834080|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
3057058|NCT00834106|Experimental|qHPV|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine administered by intramuscular injection on Day 1, Month 2, and Month 6
3057059|NCT00834106|Placebo Comparator|Placebo|Placebo administered by intramuscular injection on Day 1, Month 2, and Month 6
3057060|NCT00834132|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
3057061|NCT00834132|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
3057062|NCT00834171||1|Loteprednol etabonate ophthalmic suspension 0.5%
3057063|NCT00834171||2|Loteprednol etabonate (0.5%) and tobramycin (0.3%)
3057064|NCT00834197|Experimental|1|
3057065|NCT00834197|Active Comparator|2|
3057066|NCT00834210|Active Comparator|1|Dapsone Gel 5% and Tazarotene Cream 0.1%
3057067|NCT00834210|Active Comparator|2|Tazarotene Cream 0.1%
3057068|NCT00834236|Experimental|gastric cancer|gastric cancer patients
3057069|NCT00834236|Active Comparator|normal subject|healthy subject
3057070|NCT00834249|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
3057071|NCT00834249|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
3057072|NCT00834275|Experimental|1|
3057073|NCT00834275|Active Comparator|2|
3057074|NCT00834288|Experimental|1: 1x200 mg Tramadol HCl OAD tablet daily|
3057075|NCT00834288|Active Comparator|2: 1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly|
3057076|NCT00834340|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
3057077|NCT00834340|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
3057078|NCT00834366|Experimental|Tramadol HCl 200 mg Film-coated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet based on randomization schedule.
3057079|NCT00834366|Experimental|Tramadol HCl 200 mg Uncoated Tablets|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Uncoated Tablet based on randomization schedule.
3057080|NCT00834405|Experimental|Leflunomide|Leflunomide 20 mg Tablet
3057081|NCT00834405|Active Comparator|Arava®|Arava® 20 mg Tablet
3057082|NCT00834418|Experimental|Leflunomide|Leflunomide 20 mg Tablet
3057083|NCT00834418|Active Comparator|Arava™|Arava™ 20 mg Tablet
3057084|NCT00834431|Experimental|1|
3057085|NCT00834431|Active Comparator|2|
3057086|NCT00834444|Experimental|1|
3057087|NCT00834444|Active Comparator|2|
3057088|NCT00834483|Experimental|1|Knotless suture for wound closure
3057089|NCT00834483|Active Comparator|2|Layered traditional wound closure (monocryl)
3057090|NCT00834522|Experimental|Granisetron|Granisetron 2 x 1 mg Tablet (test) dosed in first period followed by Kytril® 2 x 1 mg Tablet (reference) dosed in second period
3057091|NCT00834522|Active Comparator|Kytril®|Kytril® 2 x 1 mg Tablet (reference) dosed in first period followed by Granisetron 2 x 1 mg Tablet (test) dosed in second period
3057092|NCT00834535|Experimental|1|
3057093|NCT00834535|Active Comparator|2|
3057094|NCT00834561|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
3057095|NCT00834561|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
3057096|NCT00834574|Experimental|1|
3057097|NCT00834574|Active Comparator|2|
3057098|NCT00834587|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip™ 5/500 mg Tablet (reference) dosed in second period
3057099|NCT00834587|Active Comparator|Metaglip™|Metaglip™ 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
3057100|NCT00834613|Experimental|1|
3057101|NCT00834613|Active Comparator|2|
3057102|NCT00834626|Other|Surgery group|Interventional study of the effects of a novel metabolic procedure of Ileal Interposition with Sleeve Gastrectomy
3057103|NCT00834639|Experimental|1|
3057104|NCT00834639|Active Comparator|2|
3057105|NCT00834652|Experimental|1|Participants will receive sertraline and metformin.
3057106|NCT00834652|Placebo Comparator|2|Participants will receive sertraline and placebo.
3057107|NCT00834678|Experimental|Bendamustine and Erlotinib|Bendamustine 100 or 120 mg/m2 IV on days 1 and 2 and erlotinib 100 or 150 mg po on days 5 - 21 of each 28 day cycle.
3057108|NCT00834717|Experimental|Granisetron|Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period
3057109|NCT00834717|Active Comparator|Kytril®|Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period
3057110|NCT00834743|Experimental|1|
3057111|NCT00834743|Active Comparator|2|
3057112|NCT00834756|Experimental|Azithromycin|Azithromycin 600 mg tablet (test) dosed in first period followed by Zithromax® 600 mg tablet (reference) dosed in second period
3057113|NCT00834756|Active Comparator|Zithromax®|Zithromax® 600 mg tablet (reference) dosed in first period followed by Azithromycin 600 mg tablet (test) dosed in second period
3057114|NCT00834795|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
3057115|NCT00834795|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
3057116|NCT00834808|Experimental|1: Tramadol HCl 100mg|
3057117|NCT00834808|Experimental|2: Tramadol HCl 200mg|
3057118|NCT00834808|Experimental|3: Tramadol HCl 300mg|
3057119|NCT00834834|Active Comparator|Fluoxetine|Participants will receive fluoxetine with clinical management, which may involve switching medication to citalopram, another SSRI.
3057120|NCT00834834|Active Comparator|Dialectical behavior therapy|Participants will receive dialectical behavioral therapy (DBT).
3057121|NCT00834873|Experimental|Carvedilol|Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period
3057122|NCT00834873|Active Comparator|Coreg®|Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period
3057123|NCT00834886|Active Comparator|Combination|Bright light 10.000 lux + melatonin 3 mg
3057124|NCT00834886|Active Comparator|Melatonin|Melatonin 3 mg + placebo red light 400 lux
3057125|NCT00834886|Active Comparator|Bright light|Bright light 10.000 lux + placebo capsule 3 mg rice flour
3057126|NCT00834886|Placebo Comparator|Placebo|Placebo Red light 400 lux + placebo capsule 3 mg rice flour
3057127|NCT00834899|Experimental|1|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the eptifibatide arm will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
3057128|NCT00834899|Placebo Comparator|2|As soon as eligible patients are identified and provide consent to participate in the study, patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
3057129|NCT00834912|Experimental|1: Tramadol HCl (Confab Laboratories) fasting|
3057130|NCT00834912|Experimental|2: Tramadol HCl (Confab Laboratories) fed|
3057131|NCT00834912|Experimental|3: Tramadol HCl (Trillium Healthcare) fasting|
3057132|NCT00834964|Experimental|Venlafaxine|Venlafaxine 25 mg Tablet (test) dosed in first period followed by Effexor® 25 mg Tablet (reference) dosed in second period
3057133|NCT00834964|Active Comparator|Effexor®|Effexor® 25 mg Tablet (reference) dosed in first period followed by Venlafaxine 25 mg Tablet (test) dosed in second period
3057134|NCT00834977|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
3057135|NCT00834977|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsules (test) dosed in second period
3057136|NCT00834990|Experimental|1|
3057137|NCT00834990|Active Comparator|2|
3057138|NCT00835003|Active Comparator|1|Elective caesarean section at 38 weeks and 3 days of gestation
3057139|NCT00835003|Active Comparator|2|Elective caesarean section at 39 weeks and 3 days of gestation
3057140|NCT00835042|Experimental|1|
3057141|NCT00835042|Active Comparator|2|
3057142|NCT00835068||BeneFIX|
3057143|NCT00835081|Experimental|1|
3057144|NCT00835081|Active Comparator|2|
3057145|NCT00835120|Experimental|Pioglitazone|Pioglitazone has been approved by the U.S. Food and Drug Administration (FDA) to help people who are diagnosed with diabetes
3057146|NCT00835146|Experimental|1|
3057147|NCT00835146|Active Comparator|2|
3057148|NCT00835159|Experimental|Rivastigmine Patch|Group receiving Rivastigmine Patch
3057149|NCT00835159|Placebo Comparator|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
3057150|NCT00835172|Experimental|Glimepiride|Glimepiride 4 mg Tablet (test) dosed in first period followed by Amaryl® 4 mg Tablet (reference) dosed in second period
3057151|NCT00835172|Active Comparator|Amaryl®|Amaryl® 4 mg Tablet (reference) dosed in first period followed by Glimepiride 4 mg Tablet (test) dosed in second period
3057152|NCT00835185|Experimental|IMC-11F8 (necitumumab) /mFOLFOX-6 regimen|Participants will receive IMC-11F8 (necitumumab) once every 2 weeks in combination with the mFOLFOX-6 regimen (oxaliplatin/5-FU/FA)
3057153|NCT00835198|Active Comparator|1|Dapsone gel 5% and Tretinoin gel 0.025%
3057154|NCT00835198|Active Comparator|2|Tretinoin gel 0.025%
3057155|NCT00835211|Experimental|1|
3057156|NCT00835211|Active Comparator|2|
3057157|NCT00835224|Experimental|Midodrine|A drug to treat low blood pressure.
3057158|NCT00835224|Experimental|L-Name|L-Name: A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
3057159|NCT00835224|Placebo Comparator|Placebo|Placebo: A pill with an inactive substance that looks like the study drug.
3057160|NCT00835237|Experimental|Boostrix Group|Subjects received a single dose of Boostrix™ (tetanus toxoids, reduced diphtheria toxoids and acellular pertussis vaccine)
3057161|NCT00835237|Active Comparator|Decavac Group|Subjects received a single dose of Decavac™ (tetanus and diphtheria toxoids vaccine)
3057162|NCT00835263|Experimental|Lamotrigine|Lamotrigine 200 mg Tablet (test) dosed in first period followed by Lamictal® 200 mg Tablet (reference) dosed in second period
3057163|NCT00835263|Active Comparator|Lamictal®|Lamictal® 200 mg Tablet (reference) dosed in first period followed by Lamotrigine 200 mg Tablet (test) dosed in second period
3057164|NCT00835276|Experimental|1|
3057165|NCT00835276|Active Comparator|2|
3057166|NCT00835341||p16-methylated|patients with mild or moderate oral epithelial dysplasia containing methylated p16 CpG island.
3057167|NCT00835341||p16-unmethylated|patients with mild or moderate oral epithelial dysplasia NOT containing methylated p16 CpG island.
3057168|NCT00835354|Experimental|1|
3057169|NCT00835354|Active Comparator|2|
3057170|NCT00835367|Experimental|Amlodipine Benazepril|Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in first period followed by Lotrel® 10mg-20mg Capsule (reference) dosed in second period
3057171|NCT00835367|Active Comparator|Lotrel®|Lotrel® 10mg-20mg Capsule (reference) dosed in first period followed by Amlodipine Benazepril 10mg-20mg Capsule (test) dosed in second period
3057172|NCT00835380|Experimental|1|VAQTA™
3057173|NCT00835406|Experimental|Alendronate Sodium First|70 mg Alendronate Sodium Tablets test product dosed in first period followed by 70 mg Fosamax® Tablets reference product dosed in second period
3057174|NCT00835406|Active Comparator|Fosamax® First|70 mg Fosamax® Tablets reference product dosed in first period followed by 70 mg Alendronate Sodium Tablets test product dosed in second period.
3057175|NCT00835484|Experimental|1|
3057176|NCT00835484|Active Comparator|2|
3057177|NCT00835497|Experimental|Glipizide Metformin|Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in first period followed by Metaglip® 5/500 mg Tablet (reference) dosed in second period
3057178|NCT00835497|Active Comparator|Metaglip®|Metaglip® 5/500 mg Tablet (reference) dosed in first period followed by Glipizide Metformin Hydrochloride 5/500 mg Tablet (test) dosed in second period
3057179|NCT00835510|Experimental|Butenafine cream 1% (Taro)|Butenafine cream manufactured by Taro applied for 7 days
3057180|NCT00835510|Active Comparator|Lotrimin Ultra (butenafine) 1%|Lotrimin Ultra (butenafine) applied for 7 days
3057181|NCT00835510|Placebo Comparator|Vehicle|Butenafine vehicle applied for 7 days
3057182|NCT00835536|Experimental|1|
3057183|NCT00835536|Active Comparator|2|
3057184|NCT00835549|Experimental|1|
3057185|NCT00835549|Active Comparator|2|
3057186|NCT00835575|Experimental|1|
3057187|NCT00835575|Active Comparator|2|
3057188|NCT00835588|Experimental|Pantoprazole|Pantoprazole Sodium 40 mg DR Tablet (test) dosed in first period followed by Protonix® 40 mg DR Tablet (reference) dosed in second period
3057189|NCT00835588|Active Comparator|Protonix®|Protonix 40 mg DR Tablet (reference) dosed in first period followed by Pantoprazole Sodium 40 mg DR Tablet (test) dosed in second period
3057190|NCT00835614|Experimental|1|
3057191|NCT00835614|Active Comparator|2|
3057192|NCT00835640|Experimental|1|
3057193|NCT00835640|Active Comparator|2|
3057194|NCT00835666|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
3057195|NCT00835666|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
3057196|NCT00835692|Experimental|Clarithromycin Tablets|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
3057197|NCT00835692|Active Comparator|Biaxin® Tablets|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
3057198|NCT00835705|Experimental|Amoxicillin Clavulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 400-57 mg Chewable Tablet (reference) dosed in second period
3057199|NCT00835705|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (reference) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in second period
3057200|NCT00835731|Experimental|1|400mcg buccal misoprostol
3057201|NCT00835731|Experimental|2|Dilapan-S, control: vitamin B-12 administered sublingually
3057202|NCT00835770|Experimental|BG00012 plus placebo|In the first phase, participants will receive BG00012 240 mg (two 120 mg capsules) twice a day (BID) and 2 placebo capsules once a day. In the second phase participants will receive open-label BG00012 240 mg BID, for atleast 8 years.
3057203|NCT00835770|Experimental|BG00012|In the first phase participants will receive BG00012 240 mg (two 120 mg capsules) three times a day (TID). In the second phase participants will receive open-label BG00012 240 mg BID for atleast 8 years.
3057204|NCT00835796|Experimental|Finasteride|Finasteride 5 mg Tablet (test) dosed in first period followed by Proscar® 5 mg Tablet (reference) dosed in second period
3057205|NCT00835796|Active Comparator|Proscar®|Proscar® 5 mg Tablet (reference) dosed in first period followed by Finasteride 5 mg Tablet (test) dosed in second period
3057206|NCT00835861|Experimental|Metformin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
3057207|NCT00835861|Active Comparator|Insulin|Women who enter pregnancy with a diagnosis of non insulin dependent/Type 2 Diabetes that is controlled with diet or an oral hypoglycemic agent, and women who demonstrate abnormal glucose tolerance prior to 20 weeks of gestation by abnormal 3 hour glucose challenge testing will be offered study participation. After informed consent, they will be randomized 1:1 to either the Metformin or Insulin group.
3057208|NCT00835900|Experimental|varenicline|drug plus counseling.
3057209|NCT00835900|Active Comparator|placebo|placebo plus counseling
3057210|NCT00835926|Experimental|Fluzone® Vaccine Group 1|Participants aged 18 to 59 years at enrollment - Fluzone® Group
3057211|NCT00835926|Experimental|Fluzone® Vaccine Group 2|Participants aged 60 years and older at enrollment - Fluzone® Group
3057212|NCT00835978|Other|A|Randomized arm
3057213|NCT00835978|Other|B|Randomized arm
3057214|NCT00835978|Other|C|Non-randomized arm
3057215|NCT00835991|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
3057216|NCT00835991|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
3057217|NCT00836004|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
3057218|NCT00836004|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
3057219|NCT00836017||BOTOX®|Patients received BOTOX® (onabotulinumtoxinA) treatment as standard of care in clinical practice as prescribed by the physician. No intervention was administered as part of the study.
3057220|NCT00836056|Experimental|Clindamycin (test)|Clindamycin 300 mg Capsule (test) dosed in first period followed by Cleocin® 300 mg Capsule (reference) dosed in second period
3057221|NCT00836056|Active Comparator|Cleocin® (reference)|Cleocin® 300 mg Capsule (reference) dosed in first period followed by Clindamycin 300 mg Capsule (test) dosed in second period
3057222|NCT00836095|Other|Supreme LMA|"Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
3057223|NCT00836095|Active Comparator|Proseal LMA|"Proseal is a multiple use, variant of the laryngeal mask airway.~The choice of the airway device will be randomized by opening a sealed envelope immediately before induction. The airway device will be blindly inserted by an experienced attending anesthesiologist."
3057224|NCT00836186|Other|Radiation therapy|Women with non-metastatic breast cancer status post lumpectomy to negative margins and who are receiving whole breast irradiation as per standard treatment plan.
3057225|NCT00836277|Experimental|Irinotecan plus panitumumab|"Irinotecan 100 mg/m2 IV Day 1 and Day 8~+ Panitumumab 9mg/kg IV Day 1 Cycle = 21 days"
3057226|NCT00836342||Previous history of SCC|Participants had previous history of SCC
3057227|NCT00836342||Previous history of BCC|Participants had previous history of BCC
3057228|NCT00836342||Control|Participants had no previous history of squamous cell carcinoma or basal cell carcinoma
3057229|NCT00836407|Experimental|Arm 1: Ipilimumab Alone|Ipilimumab alone
3057230|NCT00836407|Experimental|Arm 2: Ipilimumab + Pancreatic Cancer Vaccine|Ipilimumab + Pancreatic Cancer Vaccine
3057231|NCT00836433|Active Comparator|FALLS only|Traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
3057232|NCT00836433|Experimental|CONNECT and FALLS|CONNECT educational intervention is designed to improve relationship-building and communication. The intervention includes 2 in-class session, group mapping exercise, individual relationship mapping exercises, Self-monitoring of interactions, individual staff coaching sessions. FALLS is a traditional falls educational intervention, including self-study modules, audit and feedback, falls team training, academic detailing, and toolkit.
3057233|NCT00836472|Experimental|Glyburide Metformin|Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in first period followed by Glucovance® 5/500 mg Tablet (reference) dosed in second period
3057234|NCT00836472|Active Comparator|Glucovance®|Glucovance® 5/500 mg Tablet (reference) dosed in first period followed by Glyburide Metformin 5/500 mg Film-Coated Tablet (test) dosed in second period
3057235|NCT00836498|Experimental|Part I, RotaTeq|3 doses of RotaTeq
3057236|NCT00836498|Placebo Comparator|Part I, placebo|3 doses of placebo
3057237|NCT00836498|Experimental|Part II, RotaTeq|3 doses of RotaTeq
3057238|NCT00836498|Experimental|Part II, RotaTeq and placebo|1 dose of RotaTeq and 2 doses of placebo
3057239|NCT00836498|Placebo Comparator|Part II, placebo|3 doses of placebo
3057240|NCT00836589||Data Collection Group|
3057241|NCT00836641|Active Comparator|pneumococcal immunization (2 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 2 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
3057242|NCT00836641|Active Comparator|pneumococcal immunization (10 mo)|one dose of pneumococcal conjugate vaccine (prevenar) followed after 10 months by one dose of pneumococcal polysaccharide vaccine (pneumovax)
3057243|NCT00836693|Experimental|Tadalafil|
3057244|NCT00836693|Placebo Comparator|Placebo|
3057245|NCT00836706|Experimental|Clarithromycin (test)|Clarithromycin 500 mg Tablet (test) dosed in first period followed by Biaxin® 500 mg Tablet (reference) dosed in second period
3057246|NCT00836706|Active Comparator|Biaxin®|Biaxin® 500 mg Tablet (reference) dosed in first period followed by Clarithromycin 500 mg Tablet (test) dosed in second period
3057247|NCT00836719|Experimental|Polyphenon E|Standarized green tea extract containing 50% EGCG
3057248|NCT00836745||1|Non Interventional
3057249|NCT00836758|Experimental|CPAP Device|Breathing event detection (AED) by the CPAP device will be compared to breathing event detection by a simultaneous PSG (manual PSG scoring).
3057250|NCT00836810|Experimental|Timed Release Tablet Prednisone|12 patients will be taking the intervention night time timed release tablet (TRT) prednisone at a dose of 7mg a day over 2 weeks.
3057251|NCT00836810|Active Comparator|Standard Prednisolone|12 patients will be taking morning Prednisolone at a dose of 7mg over 2 weeks.
3057252|NCT00836875|Experimental|1|Children from 2 to 17 years who have possible, probable or proven invasive aspergillosis, or other rare mold infection (eg, Scedosporium and Fusarium).
3057253|NCT00836888|Experimental|Cohort|
3057254|NCT00836901|Experimental|Amoxicillin Calvulanic Acid|Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period
3057255|NCT00836901|Active Comparator|Augmentin®|Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period
3057256|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-5|Ridaforolimus 10 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus intravenous (IV) infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3057257|NCT00836927|Experimental|Ridaforolimus 10 mg Days 1-6|Ridaforolimus 10 mg administered orally once daily on Days 1-6 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3057258|NCT00836927|Experimental|Ridaforolimus 20 mg Days 1-5|Ridaforolimus 20 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3057259|NCT00836927|Experimental|Ridaforolimus 30 mg Days 1-5|Ridaforolimus 30 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3057260|NCT00836927|Experimental|Ridaforolimus 40 mg Days 1-5|Ridaforolimus 40 mg administered orally once daily on Days 1-5 per week. Participants may continue ridaforolimus IV infusion at the same dose from the parent trial before being switched to ridaforolimus oral tablet.
3057261|NCT00836953|Experimental|Study Group|Participants received 2 doses of Fluzone® vaccine
3057262|NCT00837031|Experimental|Intervention|"The study began with a lead-in portion to confirm the tolerability of lenalidomide (25mg PO days 1-21) in combination with gemcitabine (1000mg/m2 IV days 1, 8, and 15).~After completion of the lead-in phase, all subsequent patients received lenalidomide 25mg PO on days 1-21 and gemcitabine 1000mg/m2 IV days 1, 8, and 15 of 28-day treatment cycles. Patients were instructed to take lenalidomide at approximately the same time each morning. Patients were permitted to continue treatment until disease progression or intolerable toxicity occurred."
3057263|NCT00837096|Experimental|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distrubtes negative pressre across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
3057264|NCT00837096|Active Comparator|Moist Wound Therapy (MWT)|t wound therapy (MWT) is a widely used treatment modality that demonstrates benefit through the facilitation of a moist wound environment, which is known to promote faster relative wound healing compared to wounds exposed to air.
3057265|NCT00837148|Experimental|Sorafenib and Dacarbazine|This study is an open label, single arm, Simon two stage, phase 2 trial of continuous, daily oral sorafenib, with intravenous dacarbazine administered every three weeks for patients with synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumor.
3057266|NCT00837161|Experimental|Philips MR guided HIFU system|Patient receiving HIFU treatment
3057267|NCT00837200|Experimental|Oncaspar, Doxil, Decadron Regimen|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
3057268|NCT00837213|Active Comparator|BPO with clindamycin foam|Benzoyl peroxide (BPO) wash with clindamycin foam
3057269|NCT00837213|Active Comparator|BPO + clindamycin foam + doxycycline|Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules
3057270|NCT00837252|Experimental|Finasteride|
3057271|NCT00837330|Experimental|Ranibizumab 0.5 mg/ 0.05 cc|Intraocular injection of 0.5 mg/ 0.05 cc ranibizumab
3057272|NCT00837330|Experimental|Ranibizumab 0.3 mg/ 0.05 cc|Intraocular injection of 0.3 mg/ 0.05 cc ranibizumab
3057273|NCT00837434|Experimental|Etanercept|Participants receive a subcutaneous injection of etanercept once every week for 24 weeks
3057274|NCT00837434|Experimental|Adalimumab|Participants receive a subcutaneous injection of adalimumab once every 2 weeks for 24 weeks
3057275|NCT00837447|Active Comparator|NexGen CR knee prosthesis|side of knee operated with total knee replacement with Nexgen CR prosthesis
3057276|NCT00837447|Active Comparator|NexGen CR-Flex knee prosthesis|side of knee operated with total knee arthroplasty using Nexgen CR-flex prosthesis
3057277|NCT00837473|Other|Plexur-P Bone Void Filler|Single arm. Open Label.
3057278|NCT00837486|Active Comparator|Active Group - Active Stimulation|Receive active stimulation with Reclaim™ DBS System
3057279|NCT00837486|Sham Comparator|Control Group - Sham Stimulation|Receive sham stimulation with Reclaim™ DBS System
3057280|NCT00837512|Experimental|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
3057281|NCT00837512|Active Comparator|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
3057282|NCT00837577|Experimental|Sitagliptin/Sitagliptin|
3057283|NCT00837577|Experimental|Placebo/Sitagliptin|
3057284|NCT00837590|Experimental|Acute Salsalate|Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
3057285|NCT00837590|Experimental|Chronic Salsalate - Obese|Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
3057286|NCT00837590|Experimental|Chronic Salsalate - Lean|Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.
3057287|NCT00837616|Active Comparator|Group A|Group A will receive the oral estradiol for 12 months
3057288|NCT00837616|Active Comparator|Group B|Group B will receive the transdermal estradiol for 12 months
3057289|NCT00837694||1|Non-obese/0 kcal
3057290|NCT00837694||2|Non-obese/100 kcal
3057291|NCT00837694||3|Non-obese/300 kcal
3057292|NCT00837694||4|Obese/0 kcal
3057293|NCT00837694||5|Obese/100 kcal
3057294|NCT00837694||6|Obese/300 kcal
3057295|NCT00837759|Other|T1D group|This study was terminated prior to full subject accrual because of changes to study personnel. The original study design was changed from a double-blind, placebo-controlled study to an open-label pilot study in order to collect safety data on enrolled subjects prior to study termination.
3057296|NCT00837811|Experimental|LY2127399|
3057297|NCT00837824|Experimental|Fabrazyme 1mg/kg every 2 weeks|Fabrazyme 1.0 mg/kg every 2 weeks
3057298|NCT00837824|Experimental|Fabrazyme 3mg/kg every 2 weeks|Fabrazyme 3.0 mg/kg every 2 weeks
3057299|NCT00837876|Experimental|Treatment|Sorafenib + Erlotinib
3057300|NCT00837902|Experimental|Atenolol|"There is only 1 arm to this study. Intervention: All participants received atenolol. Genotyping for GRK5 was performed to identify if participants were GLN/GLN, GLN/LEU, or LEU/LEU.~Heart rates were measured at rest, and as participants performed graded incremental exercise on a supine bicycle ergometer (at 25, 50, and 75 W for 2 minutes each) twice, once before and once 2.5 hours after taking 25 mg of atenolol."
3057301|NCT00837967|Experimental|First Symbicort, then Terbutaline|Symbicort Turbuhaler 160/4.5μg for 3 days First , then Terbutaline Turbuhaler 0.4 mg for 3 days
3057302|NCT00837967|Experimental|First Turbuhaler, then Symbicort|Terbutaline Turbuhaler 0.4 mg for 3 days First, then Symbicort Turbuhaler 160/4.5μg for 3 days,
3057303|NCT00838006|Experimental|Biofeedback training|Heart rate variability biofeedback training and iPod with Breath Pacer app
3057304|NCT00838006|Experimental|Cognitive bias modification training|Cognitive bias modification training and iPod with cognitive bias training app
3057305|NCT00838006|Sham Comparator|Control Group|No additional resilience training and iPod with no resilience training apps
3057306|NCT00838097||Darbepoetin alfa|Participants with chronic kidney disease who received darbepoetin alfa for the treatment of anaemia as part of routine clinical practice.
3057307|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 1)|
3057308|NCT00838110|Placebo Comparator|Placebo TID (Cohort 1)|
3057309|NCT00838110|Experimental|Dimebon 20 mg TID (Cohort 2)|
3057310|NCT00838110|Placebo Comparator|Placebo TID (Cohort 2)|
3057311|NCT00838136|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
3057312|NCT00838136|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
3057313|NCT00838162|Experimental|TMC310911/rtv 75/100 mg twice daily|TMC310911 75 mg + ritonavir 100 mg twice daily on Days 1 to 14
3057314|NCT00838162|Experimental|TMC310911/rtv 150/100 mg twice daily|TMC310911 150 mg + ritonavir 100 mg twice daily on Days 1 to 14
3057315|NCT00838162|Experimental|TMC310911/rtv 300/100 mg twice daily|TMC310911 300 mg + ritonavir 100 mg twice daily on Days 1 to 14
3057316|NCT00838162|Experimental|TMC310911/rtv 300/100 mg once daily|TMC310911 300 mg + ritonavir 100 mg once daily on Days 1 to 14
3057317|NCT00838201|Experimental|Arm 1|
3057318|NCT00838279|Experimental|Lamotrigine|Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in first period followed by Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in second period
3057319|NCT00838279|Active Comparator|Lamictal®|Lamictal® 2 x 25 mg Chewable Tablet (reference) dosed in first period followed by Lamotrigine 2 x 25 mg Chewable Tablet (test) dosed in second period
3057320|NCT00838331|Experimental|Fresh blood, then aged blood|
3057321|NCT00838435|Experimental|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
3057322|NCT00838513|Experimental|eculizumab|
3057323|NCT00838526|Experimental|1|
3057324|NCT00838526|Active Comparator|2|
3057325|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 1)|Neratinib 120 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057326|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 2)|Neratinib 120 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057327|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 3)|Neratinib 120 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057328|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 4)|Neratinib 120 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057329|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 5)|Neratinib 160 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057330|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 6)|Neratinib 160 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057331|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 7)|Neratinib 160 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3179088|NCT00668941|Active Comparator|6|Participants in this group will take only calcium and vitamin D supplements. Biopsies will be performed at Week 7. Participants will then be offered the standard care for osteoporosis or they may enter the study in Group 4 or 5.
3179089|NCT00668954|Active Comparator|Pomegranate Juice|
3057332|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 8)|Neratinib 160 mg and Temsirolimus 75 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057333|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 9)|Neratinib 200 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057334|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 10)|Neratinib 200 mg and Temsirolimus 25 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057335|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 11)|Neratinib 200 mg and Temsirolimus 50 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057336|NCT00838539|Experimental|Neratinib and Temsirolimus (Dose level 12)|Neratinib 240 mg and Temsirolimus 15 mg: Neratinib 40 mg tablets administered orally daily for as long as tolerated and the disease under study does not worsen. Temsirolimus administered intravenously once weekly for as long as tolerated and the disease under study does not worsen
3057337|NCT00838565|Placebo Comparator|Placebo|
3057338|NCT00838565|Experimental|PF-04236921|
3057339|NCT00838578|Experimental|KRN330 + Irinotecan|open label, single arm
3057340|NCT00838630|Experimental|1|
3057341|NCT00838630|Active Comparator|2|
3057342|NCT00838682|Experimental|rabeprazole sodium|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
3057343|NCT00838682|Active Comparator|Omeprazole|Intravenous Omeprazole 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
3057344|NCT00838695|Experimental|African Americans|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
3057345|NCT00838695|Experimental|Caucasians|Subjects' hand veins will be measured for maximum constriction while being infused with phenylephrine, and then mental stress and cold pressor testing
3057346|NCT00838903|Experimental|albiglutide + metformin|Albiglutide + metformin + placebo sitagliptin + placebo glimepiride
3057347|NCT00838903|Active Comparator|sitagliptin + metformin|Sitagliptin + metformin + placebo albiglutide + placebo glimepiride
3057348|NCT00838903|Active Comparator|glimepiride + metformin|Glimepiride + metformin + placebo albiglutide + placebo sitagliptin
3057349|NCT00838903|Active Comparator|metformin + placebo|Metformin + placebo albiglutide + placebo sitagliptin + placebo glimepiride
3057350|NCT00838916|Experimental|albiglutide weekly injection|albiglutide weekly subcutaneous injection
3057351|NCT00838916|Active Comparator|insulin glargine|insulin glargine daily injection
3057352|NCT00838929|Experimental|Vorinostat (200 mg) and radiation|Cohort 1: Patients receive 200 mg of Vorinostat and radiation
3057353|NCT00838929|Experimental|Vorinostat (300 mg) and radiation|Cohort 2: Patients receive 300 mg of vorinostat and radiation
3057354|NCT00838929|Experimental|Vorinostat (400 mg) and radiation|Cohort 3: Patients receive 400 mg of vorinostat and radiation
3057359|NCT00839072|Experimental|Trazodone Contramid OAD|
3057360|NCT00839072|Active Comparator|Desyrel|
3057361|NCT00839098|No Intervention|Control Group|Control Group
3057362|NCT00839098|Experimental|Instruction Group|Instruction Group
3057363|NCT00839098|Experimental|Instruction and Virtual Coach Group|Instruction and Virtual Coach Group
3057364|NCT00839241|Experimental|Autologous Blood Transfusion|
3057365|NCT00839241|Active Comparator|Allogenic Blood Transfusion|
3057366|NCT00839254|Experimental|10Pn3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3057367|NCT00839254|Experimental|10Pn2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3057368|NCT00839254|Active Comparator|Ctrl3+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3179090|NCT00668954|Placebo Comparator|Placebo Juice (non-Pomegranate)|
3179091|NCT00668967|Other|Reference|marketed extended release verapamil tablet
3179092|NCT00668967|Other|Test|reformulated extended release verapamil tablet
3179093|NCT00668980||Study group|20 infants with Down syndrome
3057369|NCT00839254|Active Comparator|Ctrl2+1-6W-6M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3057370|NCT00839254|Experimental|10Pn7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3057371|NCT00839254|Active Comparator|Ctrl7-11M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (7-11M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3057372|NCT00839254|Active Comparator|10Pn12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3057373|NCT00839254|Experimental|Ctrl12-18M/053 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-053 (NCT00839254 - EUDRACT 2008-006551-51) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3057374|NCT00839306|Experimental|1|
3057375|NCT00839306|Active Comparator|2|
3057376|NCT00839319|Experimental|Acyline plus Placebo|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous placebo hCG injection (inj) every other day (5 doses) for 10 days
3057377|NCT00839319|Experimental|Acyline plus 15 IU hCG|Acyline 300 ug/kg (SQ) inj(s) on Day 1 plus subcutaneous 15 IU hCG injection (inj) every other day (5 doses) for 10 days
3057378|NCT00839319|Experimental|Acyline plus 60 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 60 IU hCG injection (inj) every other day (5 doses) for 10 days
3057379|NCT00839319|Experimental|Acyline plus 125 IU hCG|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus subcutaneous 125 IU hCG injection (inj) every other day (5 doses) for 10 days
3057380|NCT00839319|Experimental|Acyline plus Testosterone gel|Acyline 300 ug/kg subcutaneous (SQ) injections on Day 1 plus Testosterone gel 75 mg/day daily for 10 days
3057381|NCT00839332|Experimental|LY2603618 + Gemcitabine|"Participants participated in Phase 1 or 2.~LY2603618 (Phase 1): 70 to 250 milligrams/meter squared (mg/m^2) LY2603618 as a 1-hour continuous intravenous (IV) infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression (DP). Participants received LY2603618 as part of the dose escalation cohort (dose of 70, 105, 150, 200, or 250 mg/m^2) or the expansion cohort (flat dose of 200 mg or 230 mg).~LY2603618 (Phase 2): 230 mg LY2603618 as a 1-hour continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP.~Gemcitabine (Phase 1 and 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until DP. Participants received gemcitabine 24 hours prior to LY2603618 administration."
3057382|NCT00839332|Active Comparator|Gemcitabine|"Participants participated in Phase 2 only.~Gemcitabine (Phase 2): 1000 mg/m^2 gemcitabine as a 30-minute continuous IV infusion once per week for 3 weeks, followed by 1 week of rest. This 28-day cycle was repeated for a minimum of 2 cycles and/or until disease progression."
3057383|NCT00839423|Placebo Comparator|Placebo|
3057384|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 5 mg|
3057385|NCT00839423|Experimental|Vortioxetine (Lu AA21004) 10 mg|
3057386|NCT00839423|Other|Venlafaxine XL 225 mg|Active Reference
3057387|NCT00839436|Experimental|3 microgram/kg CYT107|3 microgram/kg CYT107
3057388|NCT00839436|Experimental|10 microgram/kg CYT107|10 microgram/kg CYT107
3057389|NCT00839436|Experimental|20 microgram/kg CYT107|20 microgram/kg CYT107
3057390|NCT00839527|Active Comparator|metformin + glimepiride + pioglitazone + albiglutide placebo|Metformin + glimepiride + pioglitazone + matching albiglutide placebo
3057391|NCT00839527|Experimental|metformin + glimepiride + pioglitazone placebo + albiglutide|Metformin + open-label glimepiride + pioglitazone matching placebo + albiglutide
3057392|NCT00839527|Active Comparator|met + glimepiride + pioglitazone placebo + albiglutide placebo|metformin + open-label glimepiride + pioglitazone placebo + albiglutide placebo
3057393|NCT00839540|Active Comparator|micafungin 100|Patients receive Micafungin 100 mg qd
3057394|NCT00839540|Active Comparator|micafungin 200|Patients receive 200 mg Micafungin qd
3057395|NCT00839540|Active Comparator|Caspofungin|Patients receive caspofungin 70 mg LD followed by 50 mg qd
3057396|NCT00839800|Experimental|1|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
3057397|NCT00839800|Active Comparator|2|Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
3057398|NCT00839852|Experimental|Cariprazine 1.5mg|Participants received cariprazine 1.5 mg capsule once, twice or three times a day depending on their response and tolerability
3057399|NCT00839917|Experimental|ProQuad™|
3057400|NCT00839917|Active Comparator|M-M-R™ II and Varivax™|
3057401|NCT00839930|Experimental|Cilostazol (test)|Cilostazol 50 mg Tablet (test) dosed in first period followed by Pletal® 50 mg Tablet (reference) dosed in second period
3057402|NCT00839930|Active Comparator|Pletal® (reference)|Pletal® 50 mg Tablet (reference) dosed in first period followed by Cilostazol 50 mg Tablet (test) dosed in second period.
3057403|NCT00839956|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib IV on days 2 and 5 and vorinostat PO QD on days 1-14. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3057404|NCT00839982|Experimental|Treatment (chemotherapy)|Patients receive clofarabine PO QD on days 1-5 and low-dose cytarabine SC BID on days 1-10 or SC QD on days 1-14. Treatment repeats every 21-28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3057405|NCT00840034|Experimental|LY2216684|
3057406|NCT00840034|Placebo Comparator|Placebo|
3057407|NCT00840060|Experimental|AMALS|Addressing multiple aspects of language simultaneously
3057408|NCT00840060|Experimental|DTA|Discrete Trial Approach
3057409|NCT00840073|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
3057410|NCT00840073|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
3057411|NCT00840086|Experimental|rFVIII|
3057412|NCT00840099|Experimental|1|
3057413|NCT00840099|Active Comparator|2|
3057414|NCT00840177|Experimental|treatment|"Induction (1 cycle):~pravastatin 1280 mg/d PO D 1-8 idarubicin 12 mg/m2/d IV D 4-6 cytarabine 1.5 g/m2/d continuous IV D 4-7~Consolidation (up to 2 cycles):~pravastatin 1280 mg/d PO D 1-6 idarubicin 12 mg/m2/d IV D 4-5 cytarabine 1.5 g/m2/d continuous IV D 4-5"
3057415|NCT00840203|Experimental|Mesalamine|Mesalamine 4gm/60mL Rectal Enema (test) dosed in first period followed by Rowasa® 4gm/60mL Rectal Enema (reference) dosed in second period
3057416|NCT00840203|Active Comparator|Rowasa®|Rowasa® 4gm/60mL Rectal Enema (reference) dosed in first period followed by Mesalamine 4gm/60mL Rectal Enema (test) dosed in second period
3057417|NCT00840216|Experimental|1|
3057418|NCT00840216|Active Comparator|2|
3057419|NCT00840281|Experimental|1|
3057420|NCT00840281|Active Comparator|2|
3057421|NCT00840294|No Intervention|Observation|Observation only for 2 weeks
3057422|NCT00840294|Active Comparator|Antibiotic|Ciprofloxacin 500 mg twice daily for 2 weeks
3057423|NCT00840411|Experimental|Clarithromycin (test) First|
3057424|NCT00840411|Active Comparator|Biaxin® XL (reference) First|
3057425|NCT00840450|Experimental|Paclitaxel + Imatinib Mesylate (Gleevec)|
3057426|NCT00840463|Active Comparator|1|
3057427|NCT00840463|Placebo Comparator|2|
3057428|NCT00840476|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
3057429|NCT00840476|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
3057430|NCT00840632|Experimental|Trandolapril|Trandolapril 4 mg Tablet (test) dosed in first period followed by Mavik® 4 mg Tablet (reference) dosed in second period
3057431|NCT00840632|Active Comparator|Mavik®|Mavik® 4 mg Tablet (reference) dosed in first period followed by Trandolapril 4 mg Tablet (test) dosed in second period
3057432|NCT00840658|Placebo Comparator|Group A|Didactic safer injection & sexual activity education: In each city, 75 women will participate in a 60 minute lecture-format presentation and printed materials on safer sex and safer injection based on CDC guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). In this component, there will be no theory-driven active skill building elements oriented towards safer sex or safer injection.
3057433|NCT00840658|Active Comparator|Group B|"Interactive injection risk intervention and didactic safer sex education: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] counseling session. This one-on-one intervention incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared. In addition, participants will be provided a lecture-format presentation on safer sex. However, in this component, there will be no theory-driven active skill building elements oriented towards safer sex."
3057434|NCT00840658|Active Comparator|Group C|"Interactive sexual risk intervention and didactic safer injection education: In each city, 75 women will participate in the 60 minute Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one on one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of unsafe sex and condom use with clients. In addition, participants will be provided a lecture format presentation on safer injection sharing. However, in this component, there will be no theory-driven active skill building elements oriented towards safer injection behavior."
3057435|NCT00840658|Experimental|Group D|"Interactive injection and sexual risk intervention: In each city, 75 women will participate in the 60 minute Di No a las Jeringas Contaminadas ['Say No to Contaminated Syringes'] and Di No Al Sexo Inseguro [Say No to Unsafe Sex'] counseling session. This one-on-one intervention incorporates elements of MI and principles of Social Cognitive Theory and Theory of Reasoned Action (SCT/TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy)."
3057436|NCT00840749|Experimental|CyberKnife Stereotactic Radiotherapy|
3057437|NCT00840749|Active Comparator|Surgery|
3057438|NCT00840840|Experimental|1|
3057439|NCT00840840|Active Comparator|2|
3057440|NCT00840866|Experimental|1|
3057441|NCT00840866|Active Comparator|2|
3057442|NCT00840879|Experimental|Meloxicam|Meloxicam 15 mg Tablet (test) dosed in first period followed by Mobic® 15 mg Tablet (reference) dosed in second period
3057443|NCT00840879|Active Comparator|Mobic®|Mobic® 15 mg Tablet (reference) dosed in first period followed by Meloxicam 15 mg Tablet (test) dosed in second period
3057444|NCT00840970|Active Comparator|Efficacy Unilateral Control|Non-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the active comparator following FESS (control arm)
3057445|NCT00840970|Experimental|Efficacy Unilateral Treatment|Drug-coated splint placed unilaterally in the ethmoid sinus opening randomized to receive the intervention following FESS (treatment arm)
3057446|NCT00840970|Experimental|Safety/PK Bilateral Treatment|Drug-coated splints placed bilaterally in both ethmoid sinus openings following FESS
3057447|NCT00840996|Placebo Comparator|Placebo|Perioperative placebo IV infusion besides the standard anesthesia care, including general anesthesia and postoperative patient controlled analgesia.
3057448|NCT00840996|Active Comparator|Lidocaine|Perioperative intravenous lidocaine infusion besides the standard anesthesia care, including general anesthesia plus and post operative patient controlled analgesia.
3057449|NCT00841087|Experimental|SIBA|
3057450|NCT00841087|Active Comparator|Insulin Detemir|
3057451|NCT00841100|Experimental|Acute 24 Hour Component|Participants will receive one dose of Kuvan 20 mg/kg on Day 1 and assessed for Acute 24 hour Kuvan response.
3057452|NCT00841100|Experimental|Phase 1 Group|After completion of acute 24 hour component, participants can enroll in Phase 1 and will receive Kuvan 20 mg/kg by mouth once daily for 28 consecutive days
3057453|NCT00841100|Experimental|Phase 2 Group|Participants in Phase 1 that was not responsive will continue on to the Phase 2 of the study. Positive response is defined as a decrease of blood phenylalanine of 30% or greater from baseline taken from morning blood serum. The Phase 2 component of the study will be a 2 week period of dietary restriction.
3057454|NCT00841100|Experimental|Phase 3 Group|Participants in Phase 2 that achieves a fasting blood phenylalanine of less than 600 umol/l after 2 week dietary restriction will be retreated with Kuvan 20 mg/kg by mouth once daily for a period of 28 consecutive days.
3057455|NCT00841204|Experimental|Arm I|Participants receive oral sulindac twice daily for 8 weeks
3057456|NCT00841204|Placebo Comparator|Arm II|Participants receive oral placebo twice daily for 8 weeks
3057457|NCT00841269|Experimental|Uridine|Uridine 500 mg by mouth twice daily for 6 weeks
3057458|NCT00841269|No Intervention|Healthy Comparison|Healthy comparison participants were seen for baseline and week 6 MRI scans. No treatment was administered to participants enrolled as healthy comparisons.
3057459|NCT00841321|Active Comparator|Arm 1|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to take the intervention or placebo.
3057460|NCT00841321|Placebo Comparator|Arm 2|Subjects with multiple sclerosis and documented cognitive impairment will be randomized to receive the placebo.
3057461|NCT00841412|Experimental|Immediate Intervention Group|Immediate Intervention: Long term care units assigned to the Immediate Intervention group were first to receive the staff training and management intervention to improve nutritional care processes.
3057462|NCT00841412|Active Comparator|Delayed Intervention Group|Delayed Intervention: Long term care units assigned to the Delayed Intervention group were monitored under usual care conditions to serve as a control for the Immediate Intervention group. Then, these units received the staff training and management intervention at a later date.
3057463|NCT00841542|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
3057464|NCT00841542|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
3057465|NCT00841555|Experimental|Hypofractionation Radiotherapy+Temozolomide|Patients will receive temozolomide PO daily for 5 weeks. Beginning week 1 after initiation of temozolomide therapy, patients undergo HIMRT times a week for a total of 15 fractions.
3057466|NCT00841568|Experimental|1|
3057467|NCT00841659|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
3057468|NCT00841659|Active Comparator|Paxil®|Paxil® 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
3057469|NCT00841672|Experimental|Aliskiren/amlodipine 300/10 mg tablet|Aliskiren/amlodipine treatment regimen: At randomization, patients were treated with aliskiren/amlodipine 150/5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive aliskiren/amlodipine 300/10 mg.
3057470|NCT00841672|Active Comparator|Amlodipine 10 mg capsule|Amlodipine treatment regimen: At randomization, patients were treated with amlodipine 5 mg for one week. For the remaining 7 weeks of the study, patients were force-titrated to receive amlodipine 10 mg.
3057471|NCT00841698|Experimental|Paroxetine|Paroxetine HCl 40 mg Tablet (test) dosed in first period followed by Paxil® 40 mg Tablet (reference) dosed in second period
3057472|NCT00841698|Active Comparator|Paxil®|Paxil 40 mg Tablet (reference) dosed in first period followed by Paroxetine HCl 40 mg Tablet (test) dosed in second period
3057473|NCT00841763|Experimental|TIV + aH5N1|First dose of the non-adjuvanted trivalent influenza virus vaccine (TIV) followed by two doses of the adjuvanted monovalent influenza virus vaccine (aH5N1).
3057474|NCT00841763|Active Comparator|PL + aTIV|First dose of placebo (PL-saline) followed by two doses of the adjuvanted trivalent influenza virus vaccine (aTIV).
3057475|NCT00841776|Active Comparator|Duac gel|Clindamycin and benzoyl peroxide gel
3057476|NCT00841776|Active Comparator|Ziana gel|Clindamycin and tretinoin gel
3057477|NCT00841815|Experimental|Amlodipine Besylate|Amlodipine Besylate 10 mg tablet (test) dosed in first period followed by Norvasc® 10 mg tablet (reference) dosed in second period
3057478|NCT00841815|Active Comparator|Norvasc®|Norvasc® 10 mg tablet (reference) dosed in first period followed by Amlodipine Besylate 10 mg tablet (test) dosed in second period
3057479|NCT00841828|Experimental|Experimental|Epirubicin + Cyclophosphamide -> Docetaxel + Lapatinib
3057480|NCT00841828|Active Comparator|Control|Epirubicin + Cyclophosphamide -> Docetaxel + Trastuzumab
3057481|NCT00841906|Other|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
3179094|NCT00668980||Control Group|15 typically developing children
3179095|NCT00668993|Experimental|A, B|A is treatment group B is waitlist group
3057482|NCT00841906|Other|Alice PDx with written and verbal instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device.
3057483|NCT00841971|Experimental|anidulafungin|anti-fungal agent
3057484|NCT00841971|Active Comparator|Fluconazole|anti-fungal agent
3057485|NCT00842023|Experimental|Nesiritide Infusion|Nesiritide: 2 mcg/kg bolus (optional) followed by 0.01 mcg/kg/min infusion for 48 hours.
3057486|NCT00842023|Active Comparator|Nitroglycerin Infusion|Nitroglycerin was initiated at 10 mcg/min initial starting dose titrated every 5-10 minutes until symptom relief, SBP<or= 90 mm Hg, or up to a maximum rate of 200 mcg/min plus standard treatment.
3057487|NCT00842075|Experimental|1 Symlin|Subcutaneous injection of pramlintide prior to each meal with reduction of mealtime bolus insulin
3057488|NCT00842075|No Intervention|2 Usual Regimen|Usual bolus insulin dose at each meal
3057489|NCT00842153|Experimental|Clobetasol Propionate Foam|Topical foam formulation that includes clobetasol propionate (Steroid)
3057490|NCT00842153|Placebo Comparator|Vehicle Foam|Vehicle foam is the same as the clobetasol propionate foam except it does not include the active drug.
3057491|NCT00842231||Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
3057492|NCT00842244|Experimental|A|
3057493|NCT00842257|Experimental|Panitumumab|Panitumumab administered by a central line infusion on days 1 and 15 of each 4 week cycle.
3057494|NCT00842296|Experimental|Seg. RF Ablation with CLF catheter|Single Arm with CLF Catheter
3057495|NCT00842309|Active Comparator|D-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
3057496|NCT00842309|Placebo Comparator|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
3057497|NCT00842335|Experimental|JI-101|
3057498|NCT00842348|Experimental|Lanreotide (Autogel formulation)|Patients from the preceding DB study (Study 726) were treated with open label lanreotide Autogel 120 mg by deep subcutaneous injections every 28 days. Patients were included if they had been treated with lanreotide (Autogel formulation) or placebo in DB Study 726 and had stable disease at the end of the 96-week treatment period, or if they had received placebo and had disease progression at any time during Study 726. Safety data were based on the safety population patients who received lanreotide in Study 729). The main efficacy analysis was based on the ITT population (patients randomised in Study 726 regardless of whether they continued into Study 729).
3057499|NCT00842361|Active Comparator|Mix30|
3057500|NCT00842361|Experimental|SIAC|
3057501|NCT00842530|Experimental|CYD Dengue Vaccine Group|Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 injection each at 0, 6, and 12 months.
3057502|NCT00842530|Placebo Comparator|Control Group|Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.
3057503|NCT00842543|Experimental|Overweight|Overweight Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
3057504|NCT00842543|Experimental|Lean|Lean Boys receiving either Fruit and Vegetable Juice Concentrate (FVJC) or Placebo, 1 capsule, twice a day, for 6 months
3057505|NCT00842608|Experimental|Haloperidol Eligible Intervention|0.5-1mg Haloperidol Q8h for 7 days, reduced exposure to anticholinergics, reduced exposure to benzodiazepines
3057506|NCT00842608|Active Comparator|Haloperidol Eligible Usual Care|Usual care
3057507|NCT00842608|Experimental|Haldol-Ineligible Arm|"Haldol-Ineligible arm for patients with contraindications for Haldol, unresolvable prolonged QTc, history of torsades de pointes, or history of seizures.~Patients are randomized and will still receive:~reduced exposure to anticholinergics, reduced exposure to benzodiazepines"
3057508|NCT00842608|Active Comparator|Haldol Ineligible Usual Care|Usual Care
3057509|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Gem|
3057510|NCT00842712|Experimental|Safety run-in part: Cil (1000 mg) + Cetuximab + Cis + Vin|
3057511|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Gem|
3057512|NCT00842712|Experimental|Safety run-in part: Cil (2000 mg) + Cetuximab + Cis + Vin|
3057513|NCT00842712|Experimental|Randomized part: Cil (Once Weekly) + Cetuximab + Chemotherapy|
3057514|NCT00842712|Experimental|Randomized part: Cil (Twice Weekly) + Cetuximab + Chemotherapy|
3057515|NCT00842712|Active Comparator|Randomized part: Cetuximab + Chemotherapy|
3057516|NCT00842751|Placebo Comparator|Testosterone Undecanoate + placebo finasteride|Acyline 300mcg/kg subcutaneous on days 1, 15 and 29 + Testosterone Undecanoate (TU)200mg twice daily, orally for 7 days + placebo finasteride twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
3057517|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 0.5mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 0.5mg twice daily, orally for 7 days during one of the three intervention periods (First Intervention, Second Intervention or Third Intervention)
3057518|NCT00842751|Experimental|Testosterone Undecanoate + Finasteride 1mg|Acyline 300mcg/kg subcutaneous on days 1, 15 & 29 + testosterone undecanoate 200mg, twice daily orally for 7 days + finasteride 1mg twice daily, orally for 7 days during one of the three intervention periods ((First Intervention, Second Intervention or Third Intervention)
3057519|NCT00842764|Experimental|Holmium: YAG laser|Subjects will go under minimally invasive Holmium: YAG laser blepharoplasty
3057520|NCT00842829|Experimental|FBT 100 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 100 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
3179096|NCT00669006||1|New patients with a diagnosis of Neuropathic Pain
3179097|NCT00669097|Experimental|TKI258|
3179098|NCT00669123|Placebo Comparator|2|
3057521|NCT00842829|Active Comparator|FBT 200 mcg|During the Titration Period, participants took fentanyl buccal tables (FBT) with a starting dose of 200 mcg until they reached an effective dose, with a maximum dose of 800 mcg and a maximum timeframe of 7 days. Participants who reached an effective dose entered the Open-label Treatment Period, whose length depended on how long was needed to treat up to 8 episodes of breakthrough pain (BTP) with FBT (maximum of 8 days). The length of the Continuation Period (when applicable) varied from country to country, up to until FBT was commercially available in that country.
3057522|NCT00842946|Experimental|Exposure w/ Acceptance-Based Rationale|Behavioral exposure within the context of psychological acceptance.
3057523|NCT00842946|Active Comparator|Exposure w/ Habituation-Based Rationale|Behavioral exposure within the context of habituation.
3057524|NCT00842985|Other|drug condition|Participants received each drug condition in sequential order across 4 test days. Not all participants received the interventions in the same order.
3057525|NCT00843024|Experimental|Sumatriptan and Naproxen 1|Sumatriptan succinate and naproxen sodium combination 10mg/60mg
3057526|NCT00843024|Experimental|Sumatriptan and Naproxen 2|Sumatriptan succinate and naproxen sodium combination 30mg/180mg
3057527|NCT00843024|Experimental|Sumatriptan and Naproxen 3|Sumatriptan succinate and naproxen sodium combination 85mg/500mg
3057528|NCT00843024|Placebo Comparator|Placebo|Placebo to match
3057529|NCT00843115||Observational|This study was non-interventional and simply followed for 3 months patients initiating a treatment with donepezil
3057530|NCT00843167|Experimental|Sulforaphane Supplement|Patients receive oral broccoli sprout extract supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
3057531|NCT00843167|Placebo Comparator|Placebo|Patients receive oral placebo supplementation three times daily for 2-8 weeks in the absence of unacceptable toxicity.
3057532|NCT00843180|Experimental|massage|
3057533|NCT00843180|No Intervention|control|usual care only as control arm
3057534|NCT00843193|Experimental|GSK679586|Subjects will receive three, once monthly intravenous administration of 10 mg/kg of GSK679586, according to randomization
3057535|NCT00843193|Placebo Comparator|PLACEBO|Subjects will receive three, once monthly intravenous administration of saline, according to randomization
3057536|NCT00843284||Patients with neuropathic pain|
3057537|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC|dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
3057538|NCT00843349|Active Comparator|Ad Libitum Diet-LC|no dietary intervention + phosphorus binder (Lanthanum Carbonate)
3057539|NCT00843349|Active Comparator|900 mg Phosphate Diet-LC Placebo|dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
3057540|NCT00843349|Placebo Comparator|Ad Libitum Diet-LC Placebo|no dietary intervention + placebo
3057541|NCT00843466|Active Comparator|Mild moisturizing Hand Cleanser|The test group will be provided with a mild moisturizing hand cleanser for all hand cleansing needs during the duration of the study.
3057542|NCT00843466|No Intervention|Current Hand Cleanser|The control group will continue to use their current cleanser for all hand washing.
3057543|NCT00843479||Elderly NGT|Normoglycemic subjects 65-80 years old
3057544|NCT00843479||Middle-age NGT|Middle-age normoglycemic subjects 35 to 50 years old.
3057545|NCT00843492|Active Comparator|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
3057546|NCT00843492|Experimental|Fondaparinux|After randomization (Day 1), subjects will receive subcutaneously, once daily, fondaparinux 2.5 mg (1.5 mg in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days. Patients will then be followed up to five weeks (± one week) after the cast or brace removal.
3057547|NCT00843518|Experimental|LY451395|3 milligram (mg) LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
3057548|NCT00843518|Placebo Comparator|Placebo|Placebo orally twice daily for 12 weeks
3057549|NCT00843531|Experimental|RAD001 and erlotinib|"Each 28 day cycle:~RAD001: 5 mg per day by mouth (self-administered) Erlotinib: 100 mg per day by mouth (self-administered)"
3057550|NCT00843622|Experimental|1|Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants
3057551|NCT00843622|Placebo Comparator|2|Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants
3057552|NCT00843635|Experimental|Arm A - Tadalafil 10mg|Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
3057553|NCT00843635|Experimental|Arm B - Tadalafil 20mg|Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
3057554|NCT00843635|Placebo Comparator|Arm C - Placebo|Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
3057555|NCT00843713|Placebo Comparator|Placebo|For subjects assigned to the placebo group, patients will take a matching placebo pill of 400 mg by mouth twice daily for 24 weeks in addition to taking their current HIV medication
3057556|NCT00843713|Active Comparator|Raltegravir|For subjects assigned to the active comparator group, they will receive raltegravir at 400 mg by mouth twice daily for 24 weeks in addition to continuing to take their current HIV medication
3057557|NCT00843726|Experimental|Arm I|Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
3057558|NCT00843726|Experimental|Arm II|Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
3057559|NCT00843778|Experimental|Certolizumab Pegol|Certolizumab Pegol 200 mg every two weeks at the hospital by a nurse. Certolizumab Pegol 200 mg every two weeks at the patient's home done by patient (self-injection).
3057560|NCT00843843|Active Comparator|9 hour sleep, then 3 hour nap and 6 hour sleep|
3057561|NCT00843843|Active Comparator|3 hour nap and 6 hour sleep, then 9 hour sleep|
3057562|NCT00843856|Active Comparator|tacrolimus|Intervention type -drug tacrolimus therapy 2mg bd adjust to obtain levels of 5-12ng/L
3057563|NCT00843856|Active Comparator|tacrolimus and mycophenolate mofetil|tacrolimus 2mgs bd (adjusted to obtain levels 5-12mg/L and mycophenolate mofetil 500mg bd adjusted to obtain levels 1.5-3mg/L
3057564|NCT00843882|Active Comparator|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21.
3057565|NCT00843882|Experimental|Arm B (lenalidomide, epoetin alfa)|Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.
3057566|NCT00844051|No Intervention|No Intervention|No school-based influenza vaccination program
3057567|NCT00844051|Active Comparator|Intervention|School-based Influenza Vaccination Program
3057568|NCT00844090|Placebo Comparator|Arm 1|placebo tablets
3057569|NCT00844090|Experimental|Arm 2|methylphenidate tablets
3057570|NCT00844194|Other|DPNP with depression (1)|Patients that have diabetic polyneuropathy and depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
3057571|NCT00844194|Other|DPNP with depression (2)|Patients that have diabetic polyneuropathy and depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
3057572|NCT00844194|Other|DPNP without depression (1)|Patients that have diabetic polyneuropathy and no depression and are responder to 60 mg duloxetine QD (>30% pain reduction after week 6)
3057573|NCT00844194|Other|DPNP without depression (2)|Patients that have diabetic polyneuropathy and no depression and are non-responder to 60 mg duloxetine QD (<30% pain reduction after week 6)
3057574|NCT00844298|Experimental|Nilotinib+mVPD|Patients who were Philadelphia-positive, newly-diagnosed adult ALL and treated with nilotinib + mVPD treatment plan
3057575|NCT00844376|Other|Test|Extemporaneous preparation suspension Atorvastatin prototype formulation
3057576|NCT00844376|Other|Reference|Commercial atorvastatin tablet (Lipitor®)
3057577|NCT00844415|Experimental|dabigatran etexilate|open label; patient to receive dabigatran etexilate BID for three days
3057578|NCT00844428|Experimental|Eculizumab|
3057581|NCT00844519|Active Comparator|Maraviroc|For subjects assigned to the maraviroc group, subjects will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medication. For subjects on ritonavir, the dose of maraviroc will be 150mg by mouth twice daily.
3057582|NCT00844519|Placebo Comparator|Placebo|
3057583|NCT00844532|Experimental|Absolute Pro™ Peripheral Self-Expanding Stent System|Arm includes both Absolute Pro™ and Absolute Pro™ Long Lesion (LL) Peripheral Self-Expanding Stent Systems
3057584|NCT00844545|Experimental|Eculizumab|
3057585|NCT00844558|Experimental|Gait Training|Gait Training Intervention Group Participants
3057586|NCT00844558|Placebo Comparator|Control|Gait Training Control Group Participants
3057587|NCT00844597|Experimental|Cohort 1 - 0.5 mg/kg/wk|Subjects in this group will receive a 0.5 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057588|NCT00844597|Experimental|Cohort 2 - 1.0 mg/kg/wk|Subjects in this group will receive a 1.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057589|NCT00844597|Experimental|Cohort 3 - 2.0 mg/kg/wk|Subjects in this group will receive a 2.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057590|NCT00844597|Experimental|Cohort 4 - 4.0 mg/kg/wk|Subjects in this group will receive a 4.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057591|NCT00844597|Experimental|Cohort 5 - 10.0 mg/kg/wk|Subjects in this group will receive a 10.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057592|NCT00844597|Experimental|Cohort 6 - 20.0 mg/kg/wk|Subjects in this group will receive a 20.0 mg/kg/wk dose of AVI-4658 over 12 weekly IV infusions in 50 mL of normal saline solution over a 60-minute period
3057593|NCT00844649|Experimental|Albumin-bound paclitaxel (ABI-007)/Gemcitabine|ABI-007 125 mg/m2 administered in combination with gemcitabine 1000 mg/m2 weekly for 3 weeks followed by one week of rest.
3057594|NCT00844649|Active Comparator|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks followed by a week of rest (Cycle 2 onward).
3057595|NCT00844714|Experimental|Rituxan|
3057596|NCT00844753|Active Comparator|1|Atomoxetine + Parent Management Training
3057597|NCT00844753|Active Comparator|2|Atomoxetine without Parent Management Training
3057598|NCT00844753|Placebo Comparator|3|Placebo + Parent Management Training
3057599|NCT00844753|Placebo Comparator|4|Placebo without Parent Management Training
3057600|NCT00844805|Experimental|Infliximab + Naproxen|Infliximab administered at a dose of 5 mg/kg intravenously on Day 1 of Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks during the 28-week treatment phase.
3057601|NCT00844805|Placebo Comparator|Placebo + Naproxen|Placebo administered intravenously on Day 1 at Weeks 0, 2, 6, 12, 18, and 24, combined with naproxen administered at a daily dose of 1000 mg for 28 weeks, during the 28-week treatment phase.
3057602|NCT00844805|Experimental|Naproxen Only (Follow-Up)|For participants who achieved partial remission during 28-week treatment phase, naproxen was continued at a daily dose of 1000 mg administered orally for an additional 24 weeks in the follow-up phase.
3057603|NCT00844805|No Intervention|No Treatment (Follow-Up)|For participants who achieved partial remission during Treatment phase, no treatment was administered for an additional 24 weeks in the follow-up phase.
3057604|NCT00844831|Experimental|Treatment with lubiprostone|Subjects receive lubiprostone and bacteria is measured before and after
3057605|NCT00844844|Experimental|Eculizumab|
3057606|NCT00844857|Experimental|Olanzapine/Fluoxetine Combination|
3057607|NCT00844857|Placebo Comparator|Placebo|
3057608|NCT00844883|Experimental|sorafenib and drug eluting beads|single arm
3057609|NCT00844896|Active Comparator|DEF-only|Distress Emotional Support and Family Assessment Treatment
3057610|NCT00844896|Experimental|DEF + COPE|Distress Emotional Support and Family Assessment Treatment and Creating Opportunities for Parent Empowerment Treatment
3179099|NCT00669123|Experimental|1|Chondroitin sulphate
3057611|NCT00845000|Experimental|SCH 420814 10 mg→SCH 420814 100 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057612|NCT00845000|Experimental|SCH 420814 100 mg→Placebo→ SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057613|NCT00845000|Experimental|Placebo→SCH 420814 10 mg→SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057614|NCT00845000|Experimental|SCH 420814 10 mg→ Placebo→ SCH 420814 100 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057615|NCT00845000|Experimental|SCH 420814 100 mg→ SCH 420814 10 mg→Placebo|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057616|NCT00845000|Experimental|Placebo→ SCH 420814 100 mg→SCH 420814 10 mg|Participants were to receive their assigned experimental treatment based on randomly assigned treatment sequence at Hour 0 following an overnight withdrawal of their antiparkinsonian medications of each treatment period. The levodopa infusion was to be started at Hour 1 and was to run for 2 hours. The participants were to also receive 25 mg of carbidopa at the following times: Hours 0, 2, and 4. Treatment periods were to be separated by at least 7 days but not more than 28 days washout between each dose.
3057617|NCT00845039|Active Comparator|Cetuximab + Irinotecan|Participants in Treatment Group 1 will receive intravenous infusions of Cetuximab 500 milligrams per square meter (mg/m²) and Irinotecan 180 mg/m².
3057618|NCT00845039|Experimental|Cetuximab + IMC-A12 + Irinotecan|Participants in Treatment Group 2 will receive intravenous infusions of Cetuximab 500 mg/m², IMC-A12 10 milligrams/kilogram (mg/kg) and Irinotecan 180 mg/m².
3057619|NCT00845065|Placebo Comparator|Arm 1 (Control Arm)|Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by placebo (800 mg three times a day [TID] PO, using placebo matching SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks with 24 weeks post-treatment follow-up.
3057620|NCT00845065|Experimental|Arm 2 (Boceprevir Arm)|"Peginterferon alfa-2a (180 μg/week subcutaneously [SC]) plus ribavirin (1000 to 1200 mg/day orally [PO]) for 4 weeks followed by boceprevir (800 mg three times a day [TID] PO, using SCH 503034 200-mg capsules) + peginterferon alfa-2a 180 μg/week SC plus ribavirin 1000 to 1200 mg/day PO divided twice daily (BID) for 48 weeks~with 24 weeks post-treatment follow-up."
3057621|NCT00845130|Experimental|Diabetic Type II Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
3057622|NCT00845130|Experimental|Healthy Subjects|Subjects received ascorbic acid (Vitamin C) infusion 1 g/kg (maximum 100gm
3057623|NCT00845182|Active Comparator|Pioglitazone|Pioglitazone: 15 Patients will be randomized to Pioglitazone only arm
3057624|NCT00845182|Experimental|Exenatide|Exenatide: 15 subjects will be randomized to receive Exenatide
3057625|NCT00845182|Experimental|Drug Pioglitazone and Drug Exentatide|Pioglitazone and Exenatide: 15 subjects will be randomized to Pioglitazone and Exenatide
3057626|NCT00845195|Experimental|Olopatadine HCl Nasal Spray, 0.6%|
3057627|NCT00845195|Active Comparator|Azelastine HCl Nasal Spray, 0.1%|
3057628|NCT00845429|Experimental|Group 1: Standard-dose Cell-based Influenza Vaccine|Participants will receive a single dose of standard-dose cell-based influenza virus vaccine.
3057629|NCT00845429|Experimental|Group 2: High-dose Cell-based Influenza Vaccine|Participants will receive a single dose of high-dose cell-based influenza virus vaccine.
3057630|NCT00845429|Active Comparator|Group 3: Licensed Fluzone® Influenza Vaccine|Participants will receive a single dose of licensed Fluzone® influenza vaccine.
3057631|NCT00845481|Experimental|all patients apply all products|
3057632|NCT00845507|Experimental|Exenatide Group|Exenatide dstarted at 5 mcg subcutaneously twice daily within one hour before the morning and evening meals, and increased (as tolerated) to 10 mcg.
3057633|NCT00845507|Placebo Comparator|Placebo Group|Placebo: Sterile solution in equivalent doses as Exenatide
3057634|NCT00845520|Experimental|Lens implantation +1.00 diopter (D) postop target|Lens implant power calculated for postoperative MRSE target of +1.00 D
3057635|NCT00845520|Experimental|Lens implantation -1.00 D postop target|Lens implant power calculated for postoperative MRSE target of -1.00 D
3057636|NCT00845520|Experimental|Lens implantation 0.00 D postop target|Lens implant power calculated for postoperative MRSE target of 0.00 D
3057637|NCT00845650|Experimental|AIGIV 3.5 mg/kg (Cohort A)|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
3057638|NCT00845650|Other|Gamunex 90 mg/kg (Cohort A)|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
3057639|NCT00845650|Experimental|AIGIV 7.0 mg/kg (Cohort B)|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
3057640|NCT00845650|Other|Gamunex 180 mg/kg (Cohort B)|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
3057641|NCT00845650|Experimental|AIGIV 14.0 mg/kg (Cohort C)|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
3057642|NCT00845650|Other|Gamunex 360 mg/kg (Cohort C)|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
3057643|NCT00845663|Active Comparator|Pre-filled Syringe|pre-filled syringe (reference)
3057644|NCT00845663|Experimental|Auto-injection Device|Auto-injection device (test)
3057645|NCT00845676|Experimental|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a + Ribavirin
3057646|NCT00845728|Experimental|Indacaterol|Indacaterol 150 µg o.d. delivered via single-dose dry powder inhaler (SDDPI)
3057647|NCT00845728|Active Comparator|Tiotropium|Tiotropium 18 µg o.d. delivered via the handihaler®
3057648|NCT00845832|Experimental|1|
3057649|NCT00845832|Active Comparator|2|
3057650|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 10 mg|
3057651|NCT00845858|Active Comparator|Metoclopramide Nasal Spray 14 mg|
3057652|NCT00845858|Placebo Comparator|Placebo Nasal Spray|
3057653|NCT00845871|Experimental|Deferasirox|Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
3057654|NCT00845897|Placebo Comparator|1|Placebo (saline) injections into 6 sites in the calf muscle
3057655|NCT00845897|Active Comparator|2|Total 200 units of Botulinum Toxin injected into 6 sites into the calf muscles.
3057656|NCT00845897|Active Comparator|3|300 units of botulinum toxin injected into 6 sites in the calf muscle
3057657|NCT00845975|Active Comparator|Erchonia Hearing Lasers #1 & #2|"Erchonia Hearing Laser #1 is a dual laser system composed of a pulsed red 7.5 milliwatts (mW) laser of 635 nm +/- 5 nm and a pulsed green 7.5 mW laser of 532 nm, both lasers in simultaneous operation when the laser is activated.~Erchonia Hearing Laser #2 is a single diode laser that in pulsed mode emits 4.9 mW of red 635 nm +/- 5 nm light."
3057658|NCT00845975|Placebo Comparator|Placebo Lasers|Inactive lasers that do not emit any therapeutic light.
3057659|NCT00846027|Experimental|Bevacizumab + paclitaxel + gemcitabine|Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
3057660|NCT00846040|Experimental|Obese RF then RC|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive an 85% reduction of baseline dietary fat (RF) for 2 weeks. After a washout period of 2 weeks, they then received a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks
3057661|NCT00846040|Experimental|Obese RC then RF|Obese adult volunteers (BMI above 30 kg/m2) randomized to receive a 60% reduction of baseline dietary carbohydrate (RC) for 2 weeks. After a washout period of 2 weeks, they then received an 85% reduction of baseline dietary fat (RF) for 2 weeks.
3057662|NCT00846040|Active Comparator|Lean Control|Lean adult volunteers (BMI below 30kg/m2) placed on a weight-maintenance diet using a standard diet composition of 50% carbohydrate, 35% fat, and 15% protein on an out-patient basis
3057663|NCT00846053|Other|Stable lung function|* Group S (n = 14) will consist of CF patients, aged 12-21 years old, who underwent FDG-PET with stable lung function during the past 4 years, defined as less than 2% decline per year. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
3057664|NCT00846053|Other|Rapidly deteriorating lung function|* Group R (n = 14) will contain CF patients, aged 12-21 years old, who underwent FDG-PET with rapidly deteriorating lung function during the past 4 years with greater than 4% per year decline. There is no therapeutic intervention and FDG-PET scan will be performed in both cohorts.
3057665|NCT00846066|Experimental|Hands on Training|Hands on Training by a pediatric dentist
3057666|NCT00846066|Active Comparator|Web Based Training|Web Based Training for all residents before randomization
3057667|NCT00846287|Active Comparator|Drug Subjects|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. BROVANA (arformoterol tartrate) Inhalation Solution is supplied as 2 mL of arformoterol tartrate solution packaged in 2.1 mL unit-dose, low-density polyethylene (LDPE) unit-dose vials. Each unit-dose vial contains 15 mcg of arformoterol (equivalent to 22 mcg of arformoterol tartrate) in a sterile, isotonic saline solution, pH-adjusted to 5.0 with citric acid and sodium citrate. After administration of the drug, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
3057668|NCT00846287|Placebo Comparator|Saline|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the placebo (nebulized saline solution) will be administered (2.1 mL). After administration of the placebo, three additional bags of hyperpolarized helium-3 will be administered, again with five to ten minutes between each bag.
3057669|NCT00846365|Experimental|Azilsartan Medoxomil 20-40mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
3057670|NCT00846365|Experimental|Azilsartan Medoxomil 40-80mg plus Chlorthalidone 12.5-25 mg QD|(dependant on blood pressure)
3057671|NCT00846365|Active Comparator|Olmesartan medoxomil 20-40mg/hydrochlorothiazide 12.5-25mg QD|(dependant on blood pressure)
3057672|NCT00846391|Experimental|MK8245 5 mg b.i.d.|MK8245
3057673|NCT00846391|Experimental|MK8245 50 mg b.i.d.|MK8245
3057674|NCT00846391|Placebo Comparator|Placebo|Placebo
3057675|NCT00846482|Experimental|Resected or metastatic CRC|All patients with advanced or stage II or III colorectal cancer being treated with oxaliplatin
3057676|NCT00846495|Active Comparator|topiramate|Subjects randomized to Group A at Visit 2 were provided with topiramate, titrated over 4 weeks to a maximum dose of 100 mg daily. One dosage adjustment was allowed with a minimum dose of 50 mg daily.
3179100|NCT00669136|Other|1|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
3179101|NCT00669149|Experimental|1|group without anticoagulant therapy
3057677|NCT00846495|Active Comparator|frovatriptan|Subjects randomized to Group B at Visit 2 were provided with frovatriptan 5 mg to treat during prodrome at the point they were confident a disabling migraine would occur (before the onset of headache).
3057678|NCT00846521|Experimental|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
3057679|NCT00846547|Experimental|Arbaclofen|
3057680|NCT00846573|Experimental|Asthmatic Participants|This population is made up of only confirmed asthmatics. Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
3057681|NCT00846573|Experimental|Healthy|"This population is made up of subjects who are considered clinically healthy. This means that there are no records of any chronic disorders or pulmonary history.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3057682|NCT00846573|Experimental|COPD Patients|"This population is made up of only confirmed COPD patients. Diagnosis must be confirmed through their doctor prior to enrollment.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3057683|NCT00846573|Experimental|Cystic Fibrosis Patients|"This population is made up entirely of confirmed cystic fibrosis patients. Diagnosis must be confirmed through their physician.~Participants will inhale Hyperpolarized Helium-3: Participants will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans."
3057684|NCT00846586|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3057685|NCT00846586|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single dose dry powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3057686|NCT00846651|Experimental|colloid, then phenylephrine infusion|colloid administration; with 0.5 L Hydroxyethylstarch solution at a rate of 17 ml/min and completed over 30 min. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
3057687|NCT00846651|Active Comparator|crystalloid, then phenylephrine infusion|crystalloid administration; The patients received 1.5 L Ringer's lactate infusion at a rate of 50 ml/min and completed over 30 min prior to spinal anesthesia for cesarean section. A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
3057688|NCT00846742|Experimental|Treatment|Participants receive Stanford V Chemotherapy with or without radiation therapy. Patients receive doxorubicin hydrochloride IV and vinblastine IV on day 1 of weeks 1, 3, 5, and 7; mechlorethamine hydrochloride IV on day 1 of weeks 1 and 5; vincristine sulfate IV and bleomycin IV on day 1 of weeks 2, 4, 6, and 8; etoposide IV on day 1 of weeks 3 and 7; and prednisone orally (PO) three times daily every other day of weeks 1-8. Beginning 2-3 weeks after completion of chemotherapy, patients not achieving complete response undergo radiation therapy to individual nodal sites (tailored fields)
3057689|NCT00846807||Patients 75 years or younger|
3057690|NCT00846846|Experimental|Endeavor® Zotarolimus Eluting Coronary Stent|Endeavor® Zotarolimus Eluting Coronary Stent System
3057691|NCT00846885|Experimental|1|
3057692|NCT00846885|Active Comparator|2|
3057693|NCT00847015|Experimental|Gemcitabine, Cisplatin, and Sunitinib|This is a phase II study of GCS (Gemcitabine, Cisplatin, and Sunitinib) as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder. Patients with muscle invasive urothelial carcinoma who are candidates for radical cystectomy will be enrolled.
3057694|NCT00847132|Experimental|Collaborative Care|Collaborative Care Treatment: A study care manager provides depression education, consults with study psychiatrist to develop individualized treatment recommendations, and collaborates with patient and medical team to implement those recommendations
3057695|NCT00847132|Active Comparator|Usual Care|Usual Care Treatment: Primary medical providers are informed that the patient has depression and that treatment is recommended.
3057696|NCT00847145|Experimental|12B12M (1a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age,respectively. These subjects received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3057697|NCT00847145|Experimental|12B13M (1b)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ and routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received a booster (fourth) dose at 12 months and one dose of MMRV vaccine at 13 months of age in the present study.
3057698|NCT00847145|Experimental|12M13B15B (2a)|Previously in the present study subjects had received routine vaccine at 2, 4 and 6 months of age respectively. These subjects received MMRV vaccine at 12 months of age and two catch-up doses of rMenB+OMV NZ vaccine at 13 and 15 months of age in the present study.
3057699|NCT00847145|Experimental|12M12B14B (2b)|Previously in the parent study subjects ahd received three doses of routine vaccine at 2, 4 and 6 months of age, respectively. These subjects received two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age and one dose of MMRV vaccine given concomitantly at 12 months of age in the present study.
3057700|NCT00847145|Experimental|12B12M (3a)|Previously in the parent study subjects had received three doses of rMenB+OMV NZ at 2, 4 and 6 months of age respectively. These subjects had received one booster (fourth) dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3057701|NCT00847145|Experimental|12B13M (3b)|Previously in the present study subjects had received three doses of rMenB+OMV NZ at 12 months of age respectively. These subjects one booster (fourth) dose of rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
3057702|NCT00847145|Experimental|12B12M_C (4a)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age respectively. These subjects had received one single dose of rMenB+OMV NZ at 12 months of age concomitantly with one dose of MMRV vaccine in the present study.
3057703|NCT00847145|Experimental|12B13M_C (4b)|Previously in the parent study subjects had received three doses of Meningococcal C vaccine and routine vaccine at 2, 4 and 6 months of age. These subjects received one single dose o rMenB+OMV NZ at 12 months of age and one dose of MMRV vaccine at 13 months of age in the present study.
3057704|NCT00847171|Experimental|Trastuzumab, Cyclophosphamide, and a Breast Tumor Vaccine|Participants receive Trastuzumab (T), Cyclophosphamide (CY), and an allogeneic GM-CSF-secreting whole cell breast cancer vaccine
3057705|NCT00847197|Experimental|1|MK1903
3057706|NCT00847197|Placebo Comparator|2|Placebo to MK1903
3057707|NCT00847210|Experimental|Dexlansoprazole MR 30 mg QD|
3057708|NCT00847210|Experimental|Dexlansoprazole MR 60 mg QD|
3057709|NCT00847288|Experimental|Monthly Review Arm|Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly
3057710|NCT00847288|Active Comparator|Quarterly Review Arm|Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months
3057711|NCT00847301||Renal Impairment|
3057712|NCT00847379|Experimental|Overall Participants: High-Dose Ataluren|All participants will receive ataluren suspension orally three times a day (TID), 20 mg/kg at morning, 20 mg/kg at midday, and 40 mg/kg at evening (total daily dose 80 mg/kg) for up to 96 weeks in this study. Any participant who was receiving a reduced dose of ataluren at the end of treatment visit in study PTC124-GD-007-DMD, will be initiated ataluren therapy in this extension study at the 5-, 5-, and 10-mg/kg dose level; dose will be increased to 10, 10, and 20 mg/kg at Week 6 and to 20, 20, and 40 mg/kg at Week 12, if the preceding dose level is well tolerated.
3057713|NCT00847405|Experimental|1|
3057714|NCT00847405|Active Comparator|2|
3057715|NCT00847522|Experimental|All patients|All participants enrolled.
3057716|NCT00847535|Other|1|Transurethral dose escalation
3057717|NCT00847535|Other|2|Periurethral dose escalation
3057718|NCT00847561|Experimental|Family-based CBT|Family-based CBT. Participants will receive family-based cognitive behavioral therapy. Families in this group will learn about how to identify the signs and symptoms of anxiety, ways to cope with anxiety, relaxation techniques, and problem-solving skills. They will participate in 8, one-hour sessions, once/week with trained clinicians and 3 monthly booster sessions to reinforce what they learned.
3057719|NCT00847561|Placebo Comparator|Information Monitoring|Information Monitoring. Participants will receive a packet of information about anxiety. Participants in this group will be called monthly to monitor symptoms of anxiety.
3057720|NCT00847587|Experimental|1|Early postpartum insertion
3057721|NCT00847587|Active Comparator|2|Standard postpartum insertion
3057722|NCT00847613|Experimental|Sequence 1|
3057723|NCT00847613|Experimental|Sequence 2|
3057724|NCT00847613|Placebo Comparator|Sequence 3|
3057725|NCT00847613|Placebo Comparator|Sequence 4|
3057726|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD|
3057727|NCT00847626|Experimental|Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD|
3057728|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD|
3057729|NCT00847626|Experimental|Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD|
3057730|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD|
3057731|NCT00847626|Experimental|Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD|
3057732|NCT00847626|Active Comparator|Chlorthalidone 12.5 mg QD|
3057733|NCT00847626|Active Comparator|Chlorthalidone 25 mg QD|
3057734|NCT00847626|Experimental|Azilsartan medoxomil 20 mg QD|
3057735|NCT00847626|Experimental|Azilsartan medoxomil 40 mg QD|
3057736|NCT00847626|Experimental|Azilsartan medoxomil 80 mg QD|
3057737|NCT00847665|Active Comparator|Turning every 4 hours|The four-hours repositioning group patients were turned every four hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
3057738|NCT00847665|Experimental|Turning every 2 hours|The two-hours repositioning group patients, were turned every two hours following the next sequence: left side, back with a 30º elevation of the head end and the foot end of the bed, right side using the 30º tilt, back.
3057739|NCT00847704|Experimental|Test treatment group|Device: Assisted movement and enhanced sensation
3057740|NCT00847730|Experimental|VAC GranuFoam Bridge Dressing|This is a medical device foam dressing allowing placement away from wound site. It is designed to simplify the bridging application. It is used in combination with the V.A.C. Negative Pressure Wound Therapy System. For each subject, the dressing was applied in compliance with the IFU for 48-72 hours.
3057741|NCT00847808|Experimental|1|
3057742|NCT00847886|Experimental|LX3305|Daily oral intake of LX3305 for 14 days.
3057743|NCT00847886|Placebo Comparator|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
3057744|NCT00847912|Experimental|Arm 1: 5-fluorouracil|Group assigned to blinded 5-FU (5-fluorouracil) cream applied to face and ears twice daily for maximum of 56 doses
3057745|NCT00847912|Placebo Comparator|Arm 2: Placebo|Group assigned to blinded placebo, vehicle control cream applied to face and ears twice daily for maximum of 56 doses
3057746|NCT00847938|Active Comparator|1|neostigmine 0.04 mg.kg associated with atropine 0.02 mg/kg
3057747|NCT00847938|Active Comparator|2|neostigmine 0.02 mg.kg associated with atropine 0.01 mg/kg
3057748|NCT00847938|Active Comparator|3|neostigmine 0.1 mg.kg associated with atropine 0.05 mg/kg
3057749|NCT00847938|No Intervention|4|no injection of neostigmine
3057750|NCT00848016|Experimental|Treatment (R-(-)-gossypol acetic acid)|Patients receive 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3057751|NCT00848042|Active Comparator|AuroShell-3.5|Group treated with the lowest treatment level with 4.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 3.5 watts. Device: AuroLase Therapy
3057752|NCT00848042|Active Comparator|AuroShell-4.5|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 4.5 watts. Device: AuroLase Therapy
3057753|NCT00848042|Active Comparator|AuroShell-5.0|Group treated with up to 7.5 ml/Kg of AuroShell particles concentrated to 100 optical density and 5.0 watts. Device: AuroLase Therapy
3057754|NCT00848081|Placebo Comparator|Placebo|
3057755|NCT00848081|Experimental|Tadalafil|
3057756|NCT00848107|Experimental|Treprostinil|Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose (MTD).
3057757|NCT00848120|Experimental|1|
3057758|NCT00848172|Active Comparator|Octanoic Acid|
3057759|NCT00848172|Placebo Comparator|Placebo|
3057760|NCT00848185||Antagonist-hCG for triggering|Protocol with antagonist and hCG to trigger oocyte maturation
3057761|NCT00848185||Antagonist-aGnRH for triggering|Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
3057762|NCT00848185||Long protocol-hCG for triggering|Long Protocol and hCG to trigger oocyte maturation
3057763|NCT00848198||Normal|Subjects with no objective signs of Dry Eye Disease
3057764|NCT00848198||Dry Eye Disease|Subjects with objective signs of Dry Eye Disease
3057765|NCT00848211|Placebo Comparator|Placebo|
3057766|NCT00848211|Experimental|TUTI-16 0.03 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3057767|NCT00848211|Experimental|TUTI-16 0.1 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3057768|NCT00848211|Experimental|TUTI-16 0.6 mg|Subcutaneous injection on Day 0, Day 28, and Day 84
3057769|NCT00848237|Experimental|Treatment|All Patients with Barrett's esophagus or Intestinal metaplasia which is visible endoscopically or histologically may be treated with the Radiofrequency ablation system.
3057770|NCT00848250|Experimental|ACE inhibitor|Patients already on an ACE inhibitor will continue it until the day of surgery
3057771|NCT00848250|Experimental|No ACE inhibitor|Patients on ACE inhibitors who are randomized to stop their ACE inhibitor 48 hours prior to surgery
3057772|NCT00848354|Experimental|Phase 1 Etanercept + methotrexate|Phase 1: Etanercept + methotrexate
3057773|NCT00848354|Active Comparator|Phase 1 Conventional DMARD (SSZ or HCQ) + MTX|Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate
3057774|NCT00848367|Experimental|High attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
3057775|NCT00848367|Experimental|Low attachment anxiety condition|16 weeks of Group Psychodynamic Interpersonal Psychotherapy for patients with Binge Eating Disorder, matching them by attachment anxiety dimensions in order to enhance the impact of the therapy. It is hypothesized that by optimally matching patients to groups, they will have better clinical and health outcomes.
3057776|NCT00848393|Active Comparator|Fentanyl (High Dose)|This arm will receive a total of 25 mcg/kg of Fentanyl (High Dose) in two divided doses. First half-dose given at induction and second half-dose given before incision.
3057777|NCT00848393|Active Comparator|Fentanyl (Low Dose)|This arm will receive a total of 10 mcg/kg of Fentanyl (Low Dose). First half-dose will be given at induction and second half -dose given before incision.
3057778|NCT00848393|Active Comparator|Fentanyl (Low Dose) + Dexmedetomidine|This arm will receive10 mcg/kg of Fentanyl (Low Dose) -2 divided doses. Dexmedetomidine (Dex) loading dose-1 mcg/kg over 10 min, then Dex infusion at 0.5mcg/kg/hr.
3057779|NCT00848484|Experimental|1|MK5757
3057780|NCT00848484|Placebo Comparator|2|Placebo
3057781|NCT00848497|Active Comparator|Testim® + Viagra®|Testim® gel (50 mg of testosterone) once daily + Viagra® 25 mg tablet every night
3057782|NCT00848497|Placebo Comparator|Placebo Testim® + Viagra®|Placebo Testim® gel once daily + Viagra® 25 mg tablet every night
3057783|NCT00848510|Experimental|EMD 525797|
3057784|NCT00848536|Experimental|TRAVATAN APS|One drop once daily in the evening for 3 months
3057785|NCT00848536|Active Comparator|TRAVATAN|One drop once daily in the evening for 3 months
3057786|NCT00848549|Active Comparator|ZNS|
3057787|NCT00848549|Active Comparator|CBZ|
3057788|NCT00848718|Experimental|MK-2206 + carboplatin + paclitaxel|MK-2206 combined with carboplatin and paclitaxel
3057789|NCT00848718|Experimental|MK-2206 + docetaxel|MK-2206 combined with docetaxel plus pretreatment with a corticosteroid
3057790|NCT00848718|Experimental|MK-2206 + erlotinib|MK-2206 combined with erlotinib
3057791|NCT00848744|Experimental|topical salicylic acid 1.0% cream|
3057792|NCT00848783|Experimental|A-with IP Floxuridine|"Induction treatment:~Cisplatin 25 mg/m^2 and Irinotecan 75 mg/m^2 once a week for 4 weeks, both intravenous; Two weeks without treatment; Repeat the course once.~Re-evaluation, surgery if complete response, partial response or stable disease, or off the protocol if progression of disease.~Randomization~Surgery.~Postoperative IP treatment:~Day 1,2,3: Floxuridine 3 gm/day, IP; Day 3: Cisplatin 60 mg/m^2, IP; 2 weeks without treatment; repeat the course once~Postoperative systemic treatment: courses 1-9: Capecitabine 2,000 mg/m^2/day x14 every 3 weeks/course, Oral"
3057793|NCT00848783|Experimental|B-Without IP Floxuridine|Same as Arm A except no postoperative IP treatment.
3057794|NCT00848926|Experimental|Brentuximab vedotin|
3057795|NCT00848965|Placebo Comparator|Placebo|
3057796|NCT00848965|Experimental|Fluticasone propionate 25ug|
3057797|NCT00848965|Experimental|Fluticason propionate 50ug|
3057798|NCT00848965|Experimental|Fluticasone propionate 100ug|
3057799|NCT00848965|Experimental|Flutciasone propionate 200ug|
3057800|NCT00849017|Experimental|albiglutide|albiglutide weekly injection
3057801|NCT00849017|Placebo Comparator|placebo|albiglutide matching placebo
3057802|NCT00849017|Experimental|albiglutide up-titration|albiglutide weekly injection uptitration at week 12
3057803|NCT00849056|Placebo Comparator|placebo + pioglitazone (with or without metformin)|Placebo albiglutide weekly injection + pioglitazone (with or without metformin)
3057804|NCT00849056|Experimental|albiglutide + pioglitazone (with or without metformin)|albiglutide weekly injection + pioglitazone (with or without meformin)
3057805|NCT00849108|Experimental|Cohort 1: dose range and dose interval|Patients to receive either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during pharmacological or exercise stress, over a 1-day or 2-day period.
3057806|NCT00849108|Experimental|Cohort 2: Pharm&exercise stress Efficacy|"Patients to receive 2 IV bolus injections of BMS747158:1 at rest and 1 at stress~For the Pharmacologic (Adenosine) Stress:~Doses at rest to range between 2.9 and 3.4 mCi.~Doses under stress to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
3057807|NCT00849121|Experimental|1|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then every 12 weeks until disease progression.
3057808|NCT00849121|Experimental|2|Intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant given every 2 weeks for the first 12 weeks, then given every 2-week, 4-week, or 3-month intervals as dictated by cellular immune response measurement.
3057809|NCT00849147|Experimental|Haploidentical Bone Marrow Transplant|Participants will receive a human leucocyte antigen (HLA) haploidentical bone marrow transplantation using a non-myeloablative preparative regimen, GVHD prophylaxis.
3057810|NCT00849186|Experimental|Arm 1|
3057811|NCT00849212|Experimental|1|
3057812|NCT00849251|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive cyclophosphamide IV or PO over 1 hour, bortezomib IV over 3 minutes, and dexamethasone IV or PO on days 1, 8, and 15. Patients also receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3057813|NCT00849290|Experimental|APC8015F|
3057814|NCT00849381|Experimental|Cervarix Compliance Issue Centre Group|Subjects from one centre where compliance issues were discovered, who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study
3057815|NCT00849381|Experimental|Cervarix All Centres Group|Subjects from all study centres who received the Hepatitis A control vaccine in the primary study (NCT00122681) and the Cervarix vaccine in the current study.
3057816|NCT00849472|Experimental|Treatment Arm|"Preoperative~Cycles 1-4 Doxorubicin 60 mg/m2 IV over 15 minutes + Cyclophosphamide 600 mg/m2 IV over 30 minutes of Day 1 every 21 days~followed by:~Cycles 5-8 Paclitaxel 80 mg/m2 IV over 60 minutes (Days 1, 8, and 15) every 28 days in combination with pazopanib (800 mg) PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning on Day 1 of the first paclitaxel cycle Until 7 days before surgery~Followed by Surgery~Postoperative Pazopanib 800 mg PO once daily (2 tablets taken at the same time each day either 1 hour before or 2 hours after a meal) Daily beginning 4-6 weeks after surgery 6 months from first postoperative dose"
3057817|NCT00849485|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra® 750 mg Tablet (reference) dosed in second period
3057818|NCT00849485|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
3057819|NCT00849680|Placebo Comparator|Placebo|Participants receiving 1.0 ml of placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine or the placebo to the MRKAd5 HIV-1 gag vaccine injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26 or a 2-dose regimen at Day 1 and Week 26 or Day 1 and Week 4.
3057820|NCT00849680|Experimental|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Participants receiving 1.0 ml of the Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057821|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057822|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057823|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057824|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057825|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26, or in a 2-dose regimen at Day 1 and Week 4 (with no vaccine administered at Week 26) or Day 1 and Week 26 (with placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine administered at Week 4)
3057826|NCT00849680|Experimental|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Participants receiving 1.0 ml of Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose) injected intramuscularly in a 3-dose regimen at Day 1, Week 4 and Week 26.
3057827|NCT00849693|Placebo Comparator|Placebo|
3057828|NCT00849693|Active Comparator|Fluoxetine|
3057829|NCT00849693|Experimental|Duloxetine 60 mg|
3057830|NCT00849693|Experimental|Duloxetine 30 mg|
3057831|NCT00849797|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
3057832|NCT00849797|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
3179102|NCT00669149|Active Comparator|2|group with heparin
3179103|NCT00669149|Active Comparator|3|group with enoxaparin
3057833|NCT00849810|Experimental|Metoprolol to nebivolol|metoprolol 25-200mg at a stable daily dose for 4 weeks, then change to nebivolol at a comparable stable dose (5-20 mg) for 4 -5 weeks.
3057834|NCT00849862|Experimental|Levetiracetam|Levetiracetam 750 mg Tablet (test) dosed in first period followed by Keppra 750 mg Tablet (reference) dosed in second period
3057835|NCT00849862|Active Comparator|Keppra®|Keppra® 750 mg Tablet (reference) dosed in first period followed by Levetiracetam 750 mg Tablet (test) dosed in second period
3057836|NCT00849875|Experimental|Group A|All patients are to receive the same treatment consisting of 24 injections of the immunotherapeutic GSK2132231A combined with a course of 8 cycles of dacarbazine given at the beginning of the treatment
3057837|NCT00849901|Placebo Comparator|Placebo|
3057838|NCT00849901|Active Comparator|Fluoxetine|
3057839|NCT00849901|Experimental|Duloxetine|
3057840|NCT00849940|Experimental|CAS NIRS FORE-SIGHT oximeter|Pediatric patients presenting for cardiac catheterization.
3057841|NCT00850031|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
3057842|NCT00850070|Experimental|sapropterin, 100 mg capsules|Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
3057843|NCT00850070|Placebo Comparator|Placebo, matching active drug|The placebo was supplied as a 100 mg tablet, and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks.
3057844|NCT00850096|Placebo Comparator|Placebo for Nasulin|Placebo for Nasulin Spray
3057845|NCT00850096|Active Comparator|Nasulin|Nasulin (intranasal insulin spray 1%)
3057846|NCT00850135|Other|Continuous Glucose Monitor in pregnancy|The Seven Continuous Glucose Monitoring System: Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
3057847|NCT00850174|Experimental|Oxcarbazepine|Oxcarbazepine 600 mg Tablet (test) dosed in first period followed by Trileptal® 600 mg Tablet (reference) dosed in second period
3057848|NCT00850174|Active Comparator|Trileptal®|Trileptal® 600 mg Tablet (reference) dosed in first period followed by Oxcarbazepine 600 mg Tablet (test) dosed in second period
3057849|NCT00850200|Experimental|Proton Radiation Plan|
3057850|NCT00850200|Active Comparator|Conventional Photon Radiation Plan|
3057851|NCT00850200|Active Comparator|Intensity Modulated Radiation Plan|
3057852|NCT00850343|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3057853|NCT00850343|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3057854|NCT00850395||1|Non-Interventional
3057855|NCT00850460|Placebo Comparator|Placebo|Lactose placebo pill
3057856|NCT00850460|Active Comparator|Statins|Statin medications
3057857|NCT00850473|Experimental|Positron Emitting Image|Patient will have a PET/CT imaging study to determine cardiac stenosis, F-18 FDG and heparin/intralipid infusion and Contrast Dye.will be administered.
3057858|NCT00850499|Experimental|VELCADE and fludarabine (Group A)|VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
3057859|NCT00850499|Active Comparator|fludarabine and rituximab (Group B)|fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle
3057860|NCT00850564|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone (Tesamorelin) 2mg by subcutaneous injection once daily
3057861|NCT00850603|Active Comparator|Group 1|0.5 mL Subcutaneous arm (Menomune® )
3057862|NCT00850603|Experimental|Group 2|0.1 mL Subcutaneous arm (Menomune®)
3057863|NCT00850603|Experimental|Group 3|0.05 mL Intradermal arm (Menomune®)
3057864|NCT00850603|Experimental|Group 4|0.1 mL Intradermal arm (Menomune®)
3057865|NCT00850603|Experimental|Group 5|0.15 mL Intradermal arm (Menomune®)
3057866|NCT00850642|Placebo Comparator|Placebo|12 day repeat dosing with placebo
3057867|NCT00850642|Experimental|GSK2190915 100mg|12 day repeat dosing treatment phase with 100mg GSK2190915.
3057868|NCT00850759|Experimental|virtual reality|street-crossing training in a virtual pedestrian environment
3057869|NCT00850759|Active Comparator|computer and video|exposure to training in pedestrian safety via computer software, internet games, and television videos
3057870|NCT00850759|Active Comparator|streetside training|one-on-one training in street-crossing skills by an adult, at a streetside location
3057871|NCT00850759|No Intervention|no-contact control|no-contact control group.
3057872|NCT00850889|Active Comparator|1|Juvederm Ultra Injectable Gel with Lidocaine
3057873|NCT00850889|Active Comparator|2|Restylane Injectable Gel
3057874|NCT00850993|Experimental|Cohort 1: Stannsoporfin 1.5 mg/kg|Participants receive a single dose of 1.5 mg/kg by intramuscular (IM) injection, along with PhotoTherapy (PT) if and when needed.
3057875|NCT00850993|Experimental|Cohort 2: Stannsoporfin 3.0 mg/kg|Participants receive a single dose of 3.0 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
3057876|NCT00850993|Experimental|Cohort 3: Stannsoporfin 4.5 mg/kg|Participants receive a single dose of 4.5 mg/kg by intramuscular (IM) injection, along with PT if and when needed.
3057877|NCT00850993|Placebo Comparator|Cohort 4: Placebo|Participants receive a single dose of placebo (sterile saline solution) by IM injection, along with PT if and when needed.
3057878|NCT00851006|Experimental|Open-Label Creatine|Creatine Monohydrate 4 grams daily by mouth
3057879|NCT00851084|Active Comparator|mFOLFOX6 only|modified FOLFOX6 chemotherapy regimen
3057880|NCT00851084|Experimental|mFOLFOX6 + aflibercept|modified FOLFOX6 chemotherapy regimen in combination with aflibercept
3057881|NCT00851253|Experimental|Group 1 (CK SRS boost therapy)|Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.
3057882|NCT00851253|Experimental|Group 2 (CK SRS salvage therapy)|Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.
3057883|NCT00851279|Experimental|Magnetic irrigated ablation catheter|Patients with documented VT and prior MI, in whom an ICD was implanted either for primary or secondary prevention, were recruited for endocardial mapping/ablation during VT (entrainment mapping, activation mapping) and/or substrate mapping in sinus rhythm (elimination of fractionated/late potentials, endocardial scar homogenization) with remote magnetic navigation (Niobe, Stereotaxis Inc.,St Louis, USA) and irrigated RF ablation (NaviStar RMT ThermoCool, Biosense Webster,California, USA).
3057884|NCT00851318|Experimental|Certolizumab pegol 200 mg|Participants received 200 mg certolizumab pegol by subcutaneous injection once every 2 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3057885|NCT00851318|Experimental|Certolizumab pegol 400 mg|Participants received 400 mg certolizumab pegol by subcutaneous injection once every 4 weeks in combination with methotrexate for up to 52 weeks or until approval of certolizumab pegol for rheumatoid arthritis in Japan.
3057886|NCT00851357|Experimental|Active patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of nicotine patches
3057887|NCT00851357|Placebo Comparator|Placebo patches and telephone counseling|Proactive Telephone Counseling and 8-weeks of placebo patches
3057888|NCT00851357|Active Comparator|Telephone counseling|Proactive Telephone Counseling
3057889|NCT00851357|Active Comparator|Active patches and materials|8-weeks of nicotine patches and materials
3057890|NCT00851357|Active Comparator|Placebo patches and materials|8-weeks placebo patches and materials
3057891|NCT00851357|Active Comparator|Materials|Self-help materials
3057892|NCT00851409|Other|Recombinant Human C1 Inhibitor|Weekly administration of 50 IU/kg Recombinant Human C1 Inhibitor
3057893|NCT00851630|Experimental|Early|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 2 weeks after commencing antituberculous therapy
3057894|NCT00851630|Experimental|Delayed|Initiation of fixed dose combination zidovudine/lamivudine/abacavir 8 weeks after commencing antituberculous therapy
3057895|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase A Control|Quadrivalent Human Papillomavirus (qHPV) (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 15 mcg ISCOMATRIX™ (IMX) / Aluminum Hydroxyphosphate Sulfate (AAHS) and Octavalent HPV with 30 mcg IMX / AAHS during Phase A.
3057896|NCT00851643|Experimental|Octavalent HPV with 15 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg AAHS and 15 mcg IMX.
3057897|NCT00851643|Experimental|Octavalent HPV with 30 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 30 mcg IMX.
3057898|NCT00851643|Active Comparator|qHPV (GARDASIL™) - Phase B Control|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™). This is the control for the Octavalent HPV with 60 mcg IMX / AAHS and Octavalent HPV with 120 mcg IMX / AAHS during Phase B.
3057899|NCT00851643|Experimental|Octavalent HPV with 60 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 60 mcg IMX.
3057900|NCT00851643|Experimental|Octavalent HPV with 120 mcg IMX / AAHS|Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 VLP Vaccine Adjuvanted With 281 mcg AAHS and 120 mcg IMX.
3057901|NCT00851721|Experimental|Prophylaxis arm|
3057902|NCT00851721|Active Comparator|On-demand arm|
3057903|NCT00851786|Experimental|1|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of ZOSTAVAX (Zoster Vaccine Live) at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted.
3057904|NCT00851786|Placebo Comparator|2|Participants with CD4 cell counts of 200 cells/uL or greater in Stages 1 and 2, stratified by CD4 cell counts (200-349 cells/uL vs. >=350 cells/uL), will be given one dose of placebo at Day 0 and Week 6 and will be followed for at least 42 days after each vaccination after which a safety assessment will be conducted
3057905|NCT00851799||Cohort A|"ATV/RTV + FTC/TDF~Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), ritonavir (RTV), and atazanavir (ATV) to be taken orally, once daily."
3057906|NCT00851799||Cohort B|"RAL + FTC/TDF~FTC/TDF orally, once daily, and raltegravir (RAL) orally, twice daily."
3057907|NCT00851799||Cohort C|"DRV/RTV + FTC/TDF~FTC/TDF, darunavir (DRV), and RTV, orally, once daily."
3057908|NCT00851877|Experimental|arm one|Nab-Paclitaxel, Cisplatin, Cetuximab, intensity-modulated radiation therapy
3057909|NCT00851890|Experimental|ABT-333 (300 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 300 mg ABT-333 BID for 2 days followed by 300 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3057910|NCT00851890|Experimental|ABT-333 (600 mg) twice daily (BID) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 600 mg ABT-333 BID for 2 days followed by 600 mg ABT-333 BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3057911|NCT00851890|Experimental|ABT-333 (1200 mg) once daily (QD) + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naive participants received 1200 mg ABT-333 QD for 2 days followed by 1200 mg ABT-333 QD with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3179104|NCT00669149|Active Comparator|4|group with bivalirudin
3179105|NCT00669201||1|healthy young volunteers Inclusion: age 18-40, Exclusion: wrist trauma/surgery
3179106|NCT00669201||2|"patients with know osteoarthritis wrist changes according to pre-existing x-rays No age limits~exclusion: previous wrist surgery"
3057912|NCT00851890|Placebo Comparator|Placebo + pegIFN/RBV|Hepatitis C virus (HCV) positive, treatment-naïve participants received matching placebo once daily (QD) or twice daily (BID) for 2 days followed by placebo QD or BID with pegylated interferon/ribavirin (pegIFN/RBV) for 26 days. Pegylated interferon was administered at 180 μg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3057913|NCT00851903|Experimental|Combination insulin glargine and sitagliptin|"Insulin glargine administered once a day, in the evening, at dinner or at bedtime. Starting dose: - last dose administered in the core study for patients previously treated with insulin glargine, - 0.2 U/Kg of body weight for patients previously treated with sitagliptin. Monitoring of blood glucose and titration: all patients, irrespective of their previous treatment group in the core study were empowered to adjust their insulin doses, under strict investigator's supervision. The goal was to achieve through a force titration 70 < Fasting Plasma Glucose (FPG) ≤ 100 mg/dL (3.9 <FPG ≤ 5.5 mmol/L).~Sitagliptin: stable dose of 100 mg once a day administered with or without food."
3057914|NCT00852137|Experimental|PEP005 (ingenol mebutate) Gel, 0.05%|
3057915|NCT00852137|Placebo Comparator|Vehicle Gel|
3057916|NCT00852202|Experimental|1|0.25 - 0.75 mg/day cariprazine capsules, oral administration, once daily dosing.
3057917|NCT00852202|Experimental|2|1.5 - 3.0 mg/day cariprazine capsules, oral administration, once daily dosing.
3057918|NCT00852202|Placebo Comparator|3|Matching placebo capsules, oral administration, once daily dosing.
3057919|NCT00852397|Experimental|Apixaban 2.5 mg|
3057920|NCT00852397|Experimental|Apixaban 5.0 mg|
3057921|NCT00852397|Placebo Comparator|Placebo|
3057922|NCT00852475|Placebo Comparator|MUFA|Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
3057923|NCT00852475|Active Comparator|PUFA|Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
3057924|NCT00852527||Subjects with mild TBI|Presence of mild TBI defined by positive reference test
3057925|NCT00852527||Subjects without mild TBI|Absence of mild TBI defined by negative reference test
3057926|NCT00852540|Experimental|Retapamulin|
3057927|NCT00852540|Active Comparator|Linezolid|
3057928|NCT00852592|Active Comparator|Active Comparator|7000lux broad-spectrum light
3057929|NCT00852592|Placebo Comparator|Inactive Comparator|50lux dim red light
3057930|NCT00852644|Experimental|56 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057931|NCT00852644|Experimental|62 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057932|NCT00852644|Experimental|68 Gray (LESS than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057933|NCT00852644|Experimental|56 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 56 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057934|NCT00852644|Experimental|62 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 62 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057935|NCT00852644|Experimental|68 Gray (MORE than 3 centimeter cohort)|"Intervention:~Procedure/Surgery: computed tomography Standard CT scans~Intervention:~Radiation: fludeoxyglucose F 18 standard doses with CT scans~Radiation: hypofractionated radiation therapy 4 doses over 2 weeks - 68 Gray~Radiation: stereotactic radiosurgery CyberKnife radiosurgery"
3057936|NCT00852761|Experimental|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam
3057937|NCT00852761|Active Comparator|Clobex lotion|Clobex (clobetasol propionate 0.05%) lotion.
3057938|NCT00852917|Experimental|1: Tramadol Once A Day 100mg|
3057939|NCT00852917|Experimental|2: Tramadol Once A Day 200mg|
3057940|NCT00852917|Experimental|3: Tramadol Once A Day 300mg|
3057941|NCT00852917|Placebo Comparator|4: Placebo|
3057942|NCT00852930|Experimental|laser alone|The intervention was therapist administered low level laser therapy using low level laser, number of sessions based upon patient response
3057943|NCT00852930|Active Comparator|mld alone|The intervention was therapist administered manual lymphatic drainage (mld) using standard massage techniques,number of sessions based upon patient response
3057944|NCT00852930|Experimental|laser and mld combined|The intervention was therapist administered low level laser and mld using low level laser and standard massage techniques, number of sessions based upon patient response
3057945|NCT00852969|Active Comparator|Niacin|
3057946|NCT00852969|Placebo Comparator|Placebo|
3057947|NCT00852995|Experimental|A - Low Q7D|Low dose HP802-247, applied at each visit
3057948|NCT00852995|Experimental|B - Low Q14D|Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
3057949|NCT00852995|Experimental|C - High Q7D|High dose HP802-247, applied at each visit
3057950|NCT00852995|Experimental|D - High Q14D|High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
3057951|NCT00852995|Placebo Comparator|E - Vehicle|Placebo (Vehicle), applied at each visit
3057952|NCT00853021|Experimental|Bevacizumab and Aldesleukin|
3057953|NCT00853047|Experimental|Telotristat Etiprate 150 mg Core Phase|Telotristat etiprate capsules,150 mg orally 3 times daily for 28 days in the double-blind treatment period (core phase) in combination with stable-dose octreotide long-acting release (LAR) depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
3057954|NCT00853047|Experimental|Telotristat Etiprate 250 mg Core Phase|Telotristat etiprate capsules, 250 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
3057955|NCT00853047|Experimental|Telotristat Etiprate 350 mg Core Phase|Telotristat etiprate capsules, 350 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
3057956|NCT00853047|Experimental|Telotristat Etiprate 500 mg Core Phase|Telotristat etiprate capsules, 500 mg orally 3 times daily for 28 days in the double-blind treatment period in combination with a stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to enter the optional open-label extension period.
3057957|NCT00853047|Experimental|Placebo Core Phase|Placebo-matching telotristat etiprate capsules, orally 3 times daily for 28 days in the double-blind treatment period in combination with stable-dose octreotide LAR depot therapy given once per month. Upon completion of 28-days of treatment, participants were eligible to receive telotristat etiprate in the optional open-label extension period.
3057958|NCT00853047|Experimental|Telotristat Etiprate Open-Label Extension Phase|Telotristat etiprate at assigned dose level for 8 weeks in combination with stable-dose octreotide LAR depot therapy given once per month in the open-label extension period. Upon completion of the 8-week period, participants could enter an additional extension period of 172 weeks, receiving telotristat etiprate at the assigned dose or maximum tolerated dose (500 mg 3 times daily).
3057959|NCT00853073|Active Comparator|Bevacizumab|subjects will receive 1.0mg (0.04cc of 25 mg/ml) subconjunctival bevacizumab either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
3057960|NCT00853073|Placebo Comparator|balanced salt solution|patients randomized to treatment B are given 0.04cc of balanced salt solution injected in identical fashion either temporal or nasal to the bleb following bleb needling procedure in addition to 0.1 cc mitomycin C.
3057961|NCT00853099|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3057962|NCT00853099|Experimental|Adalimumab 80 mg/40 mg|Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3057963|NCT00853099|Experimental|Adalimumab 160 mg/80 mg|Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period received open-label adalimumab 40 mg every other week, with the possibility to escalate to 80 mg every other week, until drug approval.
3057964|NCT00853112|Experimental|PF-00489791 1 mg|
3057965|NCT00853112|Experimental|PF-00489791 2 mg|
3057966|NCT00853112|Experimental|PF-00489791 4 mg|
3057967|NCT00853112|Experimental|PF-00489791 10 mg|
3057968|NCT00853112|Experimental|PF-00489791 20 mg|
3057969|NCT00853112|Placebo Comparator|Placebo|
3057970|NCT00853112|Active Comparator|Sildenafil|Observational comparator arm
3057971|NCT00853125|Experimental|Sunitinib plus Irradiated Allogeneic Lymphocytes|
3057972|NCT00853151|Experimental|LY2428757 plus TT223 3 milligrams (mg)|Weekly LY2428757 plus 3 milligrams (mg) daily TT223
3057973|NCT00853151|Experimental|LY2428757 plus TT223 2mg|Weekly LY2428757 plus 2 mg daily TT223
3057974|NCT00853151|Experimental|LY2428757 plus placebo|Weekly LY2428757 plus daily TT223 placebo
3057975|NCT00853151|Placebo Comparator|Placebo plus Placebo|Weekly LY2428757 placebo plus daily TT223 placebo
3057976|NCT00853242|Placebo Comparator|Placebo|Placebo matched to Genz-644470 tablet orally three times a day (TID) with meals for 3 weeks.
3057977|NCT00853242|Experimental|Genz-644470 2.4 Grams Per Day (g/day)|Genz-644470 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
3057978|NCT00853242|Experimental|Genz-644470 4.8 g/day|Genz-644470 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
3057979|NCT00853242|Experimental|Genz-644470 7.2 g/day|Genz-644470 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
3057980|NCT00853242|Active Comparator|Sevelamer Carbonate 2.4 g/day|Sevelamer Carbonate 2.4 g/day tablets dosed orally TID with meals for 3 weeks.
3057981|NCT00853242|Active Comparator|Sevelamer Carbonate 4.8 g/day|Sevelamer Carbonate 4.8 g/day tablets dosed orally TID with meals for 3 weeks.
3057982|NCT00853242|Active Comparator|Sevelamer Carbonate 7.2 g/day|Sevelamer Carbonate 7.2 g/day tablets dosed orally TID with meals for 3 weeks.
3057983|NCT00853307|Experimental|Alisertib 50 mg|Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 26 Cycles).
3057984|NCT00853333|Active Comparator|Propofol|Administration via an IV
3057985|NCT00853333|Active Comparator|Midazolam|Administration via an IV
3057986|NCT00853333|Active Comparator|Dexmedetomidine|Administration via an IV
3057987|NCT00853372|Experimental|Trebananib 10 mg/kg + Sunitinib|Trebananib 10 mg/kg intravenously (IV) once weekly (QW) plus sunitinib 50 mg orally (PO) once daily (QD) 4 weeks on/2 weeks off
3057988|NCT00853372|Experimental|Trebananib 15 mg/kg + Sunitinib|Trebananib 15 mg/kg IV QW plus sunitinib 50 mg PO QD 4 weeks on/2 weeks off
3057989|NCT00853385|Experimental|5mg|
3057990|NCT00853385|Experimental|10 mg|
3057991|NCT00853385|Placebo Comparator|Placebo Sequence 1|
3057992|NCT00853385|Placebo Comparator|Placebo Sequence 2|
3057993|NCT00853385|Active Comparator|adalimumab|
3057994|NCT00853489|Experimental|recombinant bone morphogenetic protein 2|The patient will receive rhBMP-2 plus allograft chips in the bone defect site. Intervention type: surgical
3057995|NCT00853489|Active Comparator|Autogenous iliac crest bone graft|Bone will be harvested from the iliac crest and placed in the bone defect.
3057996|NCT00853580|Placebo Comparator|2|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
3057997|NCT00853580|Experimental|1|This is a prospective multi-centre randomized, placebo-controlled Phase II study to determine the efficacy of Lovastatin ™ on visual spatial learning and/or attention abilities of children with NF1 aged between 8 and less than 16 years. In addition, the effect of Lovastatin ™ on secondary measures of executive function, visual spatial skills, behavior and quality of life will be assessed. Participants will be randomized to 16-weeks of treatment with Lovastatin ™ or a matched placebo.
3057998|NCT00853593|Experimental|Model 4396 LV Lead|Non-randomized study.
3057999|NCT00853606|Experimental|avanafil|
3058000|NCT00853645|Experimental|Subcutaneous implantable cardioverter defibrillator (S-ICD) System|Single-arm with 6 patients implanted with an S-ICD System
3058001|NCT00853658|Experimental|Combination Aliskiren / Enalapril|Aliskiren / Enalapril combination therapy-150 mg/10 mg titrated to 300 mg/ 10 mg film-coated tablets and administered orally.
3058002|NCT00853658|Experimental|Aliskiren|Aliskiren monotherapy - 150 mg titrated to 300 mg film-coated tablets and administered orally.
3058003|NCT00853658|Active Comparator|Enalapril|Enalapril monotherapy -10 mg film-coated tablet and administered orally.
3058004|NCT00853671|Experimental|Adenosine Stress Dual-source CTP|A multiphase adenosine Stress Dual-source stress perfusion computed tomography imaging test, as described above, will be performed in all patients.
3058005|NCT00853723|Experimental|PTHrP 400 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months.
3058006|NCT00853723|Experimental|PTHrP 600 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months.
3058007|NCT00853723|Active Comparator|PTH 20 mcg/day|Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months.
3058008|NCT00853749|Other|Single|All subjects will receive a single dose of 13vPnC
3058009|NCT00853762|Experimental|Atacicept 25 mg (With Loading)|
3058010|NCT00853762|Experimental|Atacicept 75 mg (With Loading)|
3058011|NCT00853762|Experimental|Atacicept 150 mg (With Loading)|
3058012|NCT00853762|Experimental|Atacicept 150 mg (Without Loading)|
3058013|NCT00853827|Placebo Comparator|1|
3058014|NCT00853827|Experimental|2|Aliskiren 300 mg
3058015|NCT00853840|Experimental|1.|Maraviroc + Vardenafil
3058016|NCT00853840|Placebo Comparator|2.|Maraviroc + Placebo
3058017|NCT00853905|Experimental|Treatment 1(Triesence)|glaucoma surgery with 0.2cc Triesence adjunct.
3058018|NCT00853905|Active Comparator|Treatment 2 (balanced salt solution BSS)|glaucoma surgery with balanced salt solution, the standard technique.
3058019|NCT00853957|Experimental|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
3058020|NCT00853957|Active Comparator|Amlodipine|Amlodipine 5mg titrated to 10 mg
3058021|NCT00853970|Experimental|Bromfenac ophthalmic solution 0.09%|dosed 1 drop daily in study eye for 2 weeks
3058022|NCT00853970|Placebo Comparator|Placebo|dosed 1 drop daily in study eye for 2 weeks
3058023|NCT00853996|Experimental|Prevention (acolbifene hydrochloride)|Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.
3058024|NCT00854061|Experimental|T-Pred|Tobramycin prednisolone acetate combination
3058025|NCT00854061|Active Comparator|Pred Forte|Prednisolone acetate
3058026|NCT00854087|Active Comparator|Fuzheng Huayu|Pill with Fuzheng Huayu
3058027|NCT00854087|Placebo Comparator|Placebo|Pill without Fuzheng Huayu (sugar pill)
3058028|NCT00854100|Placebo Comparator|Placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo
3058029|NCT00854100|Experimental|Cariprazine 0.1 - 0.3 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR)+ cariprazine low dose
3058030|NCT00854100|Experimental|Cariprazine 1.0 - 2.0 mg|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine high dose
3058031|NCT00854113|Experimental|EGT0001474|Ascending doses of EGT0001474
3058032|NCT00854113|Placebo Comparator|Placebo|Placebo
3058033|NCT00854308|Experimental|MetMAb + Erlotinib|MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.
3058034|NCT00854308|Placebo Comparator|Placebo + Erlotinib|Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.
3058035|NCT00854360|Experimental|BDP HFA 80 µg/day|During the 2-week double-blind Treatment Period participants self-administered two actuations (one per nostril) of 40 micrograms (µg) BDP HFA and two actuations of placebo HFA once daily.
3058036|NCT00854360|Experimental|BDP HFA 160 µg/day|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of 40 µg BDP HFA once daily.
3058037|NCT00854360|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
3058038|NCT00854360|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
3058039|NCT00854373|Experimental|1|Bravelle
3058040|NCT00854373|Placebo Comparator|2|Saline
3179107|NCT00669201||3|Mixed group of 50 patients that perform routine MRI of the wrist for various indications
3179108|NCT00669227|Active Comparator|1|autologous stem cells, Ficoll preparation, intracoronary administration at the same day of bone marrow cell aspiration
3058041|NCT00854581|Experimental|Induction (Up to Day 21)|"For one cycle, up to Day 21. All participants are enrolled to induction therapy phase, then move to the maintenance therapy phase if they achieve complete response (PR) or partial response (PR). Participants who achieve a clinical CR at Day 14 response assessment will go on to Part 1 maintenance therapy. Patients who achieve a PR will receive 7 more days of induction therapy and then go on to Part 1 Maintenance Therapy.:~Zidovudine:~Days 1-2: 1.5 grams intravenously (IV) twice daily~Days 3-21: 1.5 grams IV twice daily~Interferon alfa-2b (IFN):~5 10 million units (mu) intravenously twice daily"
3058042|NCT00854581|Experimental|Part 1 Maintenance (Up to Day 60)|"From Treatment Day 14 or 21 to start of Month 3 (Day 60). Study participants move on to Part 1 Maintenance Therapy only if they achieve complete response (CR) or partial response (PR) after induction therapy. Restaging and molecular evaluation of disease at start of Month 3:~Zidovudine: 600 mg orally twice daily in all phases of Maintenance Therapy~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly~Participants then proceed to Part 2 maintenance."
3058043|NCT00854581|Experimental|Part 2A Maintenance (Up to 12 Months)|"Participants achieving a CR with undetectable clonal disease. Participants will receive therapy for as long as response is maintained:~Zidovudine: 600 mg orally twice daily~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly"
3058044|NCT00854581|Experimental|Part 2B Maintenance (Up to 12 Months)|"Participants achieving a CR with minimal residual disease (by multiplex PCR) or PR in Part 1:~Zidovudine: 600 mg or 300 mg orally twice daily, per protocol~PEG-Interferon alfa-2b: 1.5 ug/kg subcutaneously (SQ) once weekly, per protocol~Valproic acid, 250 mg orally twice daily, per protocol"
3058045|NCT00854594|No Intervention|Control|Control sites will receive the baseline measures pre and post. These sites will receive traditional diabetes education, which includes teleconsultation.
3058046|NCT00854594|Experimental|ReSPECT Intervention|Intervention sites will receive baseline measures pre and post, but also in-depth Shared Medical Appointments (SMA)(The Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT) intervention) and at 15 months SMA video conferences. At the end of the 18 months the randomly selected patients and providers will be asked to take part in a qualitative interview.
3058047|NCT00854607||Invasive Aspergillosis|Observational
3058048|NCT00854620|Experimental|Sorafenib|"Cycle 1: 400 mg BID sorafenib~Cycle 2: 600 mg BID sorafenib~Cycle 3+: 800 mg BID sorafenib"
3058049|NCT00854724|Active Comparator|Puerarin|
3058050|NCT00854724|Placebo Comparator|Placebo|Sugar beet filler in capsule
3058051|NCT00854828|Active Comparator|Surgical Intervention|
3058052|NCT00854828|Active Comparator|Non-Operative Intervention|
3058053|NCT00854906||Keratometric Tear Breakup Time|These are the study participants whose tear break up times were measured with a keratometer.
3058054|NCT00854906||Fluorescein Break Up Time|These are the study participants whose tear break up times were measured with with fluorescein dye.
3058055|NCT00855010|Experimental|pioglitazone|pioglitazone tablet 45 mg once daily
3058056|NCT00855010|Placebo Comparator|placebo pill|placebo pill once daily (look-alike pill which contains no active ingredients)
3058057|NCT00855062|Active Comparator|Minocycline|Minocycline 100 mg orally every 12 hours
3058058|NCT00855062|Placebo Comparator|Placebo|Placebo minocycline capsules every 12 hours
3058059|NCT00855166|Experimental|A|Dapagliflozin 10 mg plus Metformin
3058060|NCT00855166|Placebo Comparator|B|Placebo plus Metformin
3058061|NCT00855218|Experimental|Sorafenib (Nexavar, BAY43-9006) + TACE|Sorafenib was to be orally administered as 2 x 200 mg tablets bid (twice daily). Patients were then also treated with Transarterial Chemoembolization (TACE) performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of sorafenib, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
3058062|NCT00855218|Placebo Comparator|Placebo + TACE|Placebo was to be orally administered as 2 tablets bid (twice daily). Patients were then also treated with TACE performed with DC Bead (300 to 500 microns) and doxorubicin (150 mg) between 3 to 7 days after the first dose of placebo, TACE was also performed on Days 1 (+ 4 days) of cycle 1, 3, 7, 13 and then every 6 cycles thereafter (an optional TACE procedure could be performed between Day 1 of Cycle 7 and Cycle 13 and between Day 1 of Cycles 13 and 19, if deemed necessary by the Investigator.)
3058063|NCT00855309|Experimental|Arm I|Patients receive weight-based IV acyclovir sodium every 8 or 12 hours.
3058064|NCT00855309|Experimental|Arm II|Patients receive low-dose IV acyclovir sodium every 8 or 12 hours.
3058065|NCT00855335|Experimental|Group 1: Darunavir 600 /Ritonavir 100|TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.
3058066|NCT00855335|Experimental|Group 2: Darunavir 800/Ritonavir 100|TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.
3058067|NCT00855335|Experimental|Group 3: Etravirine|TMC125 (etravirine) 200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
3058068|NCT00855335|Experimental|Group 4: Rilpivirine|TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.
3058069|NCT00855335|Experimental|Group 5: Darunavir 800/Cobicistat 150|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
3058070|NCT00855413|Other|Darunavir/Ritonavir and Etravirine|"Darunavir/Ritonavir 800 mg/100 mg orally once daily.~ETR will be given 200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen."
3058071|NCT00855439|Experimental|Exenatide|Subjects will take exenatide by subcutaneous injection twice daily for 18 months
3058072|NCT00855439|Active Comparator|glargine|Subjects will take 1 daily injection of insulin glargine for 18 months.
3058073|NCT00855465|Experimental|Riociguat (Adempas, BAY63-2521)_individual dose titration|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 16 weeks
3058074|NCT00855465|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 16 weeks
3058075|NCT00855582|Experimental|Tadalafil 2.5 mg|
3058076|NCT00855582|Experimental|Tadalafil 5 mg|
3058077|NCT00855582|Placebo Comparator|Placebo|
3058078|NCT00855595|Experimental|Azelaic acid (Finacea, BAY39-6251) plus Doxycycline (Oracea)|Participants received topical azelaic acid gel 15% twice daily and doxycycline 40 mg once daily for 12 weeks
3058079|NCT00855595|Active Comparator|Metronidazole (Metrogel) plus Doxycycline (Oracea)|Participants received topical metronidazole 1% gel once daily and doxycycline 40 mg once daily for 12 weeks
3058080|NCT00855738|Other|1.0|
3058081|NCT00855816|Experimental|Breathing training|relaxation training
3058082|NCT00855816|No Intervention|Treatment as usual|treatment as usual
3058083|NCT00855842|Experimental|osmotic dilator|osmotic dilator
3058084|NCT00855894|Experimental|Pertuzumab + erlotinib|Patients received pertuzumab 840 mg intravenously (IV) 1 time (loading dose) followed by 420 mg IV (maintenance dose) every 3 weeks (q3w) plus erlotinib 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
3058085|NCT00855920|Active Comparator|Placebo (for Rilonacept) and Indomethacin|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 with Indomethacin orally thrice a day (TID) for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
3058086|NCT00855920|Active Comparator|Rilonacept and Indomethacin|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
3058087|NCT00855920|Active Comparator|Rilonacept and Placebo (for Indomethacin)|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 with Placebo (for Indomethacin) orally TID for 12 days.
3058088|NCT00855933|No Intervention|Control - no flossing|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily.
3058089|NCT00855933|Experimental|Experimental Floss|Subjects brushed thoroughly for one minute with Crest® Cavity Protection toothpaste and an Oral-B® Indicator soft, manual toothbrush once daily. Subjects flossed once daily with the experimental floss.
3058090|NCT00855959|Experimental|1|Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily
3058091|NCT00855959|Experimental|2|Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)
3058092|NCT00856024||Group 1: Naïve patients|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had not been treated with peginterferon alfa-2b.
3058093|NCT00856024||Group 2: Re-treatment|Patients, from Brazil, with confirmed chronic hepatitis C and who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin and who previous to this treatment had been considered nonresponders or relapsing to prior treatment for chronic hepatitis C.
3058094|NCT00856024||Group 3: HIV/HCV co-infected patients|Patients, from Brazil, with confirmed chronic hepatitis C and infected with Humman Immunodeficiency Virus (HIV) who completed 12 weeks of treatment with peginterferon alfa-2b and ribavirin.
3058095|NCT00856050|Experimental|letrozole|single arm trial - all patients received letrozole 2.5mg by mouth per day
3058096|NCT00856180|Experimental|Bevacizumab then Cyclophosphamide with Bevacizumab|Patients were given a regimen of sequential antiangiogenic blockade and disease assessed serologically and radiologically every 2 cycles/6 weeks. Patients started with bevacizumab 15 mg/kg IV every 3 weeks until they experienced progressive disease (PD) [RECIST 1.0 or Rustin criteria] or significant toxicity. If clinically stable as assessed by their treating physician, patients then received cyclophosphamide 50 mg orally (PO) daily continuously with bevacizumab treatment. If second PD occurred, patients discontinued the combination treatment.
3058097|NCT00856193|Placebo Comparator|Placebo then NVA237 50μg|Placebo 50 μg capsules followed by NVA237 50 μg capsules for inhalation once daily with Concept 1 device.
3058098|NCT00856193|Experimental|NVA237 50μg then placebo|NVA237 50 μg capsules followed by matching placebo 50 μg capsules for inhalation once daily with Concept 1 device.
3058099|NCT00856206|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3058100|NCT00856206|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3058101|NCT00856232|No Intervention|Standard therapy|Standard emergency department evaluation and treatment for headache
3058102|NCT00856232|Placebo Comparator|Medical Air|Air inhalation at 15L / min x 15 minutes followed by standard emergency department evaluation and treatment for headache
3058103|NCT00856232|Experimental|Oxygen|Oxygen inhalation at 15 L/min for 15 minutes followed by standard emergency department evaluation and treatment for headache
3058104|NCT00856245|Other|Rituximab|Patients will be treated IV with rituximab at the rate of 50 milligrams per hour (mg/hour) for 1 hour. If patient tolerates the infusion, the rate is increased by increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. If patient has a severe reaction, the infusion is stopped temporarily and the infusion rate is decreased by 50%. Subsequent infusions are started at the rate of 100 mg/hour, increased by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour if tolerated. Vital signs are monitored every 15 minutes for 2 hours and every 30 minutes thereafter.
3058105|NCT00856284|Experimental|Metformin + Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
3058106|NCT00856284|Experimental|Metformin + Alogliptin 25 mg|Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.
3058107|NCT00856284|Active Comparator|Metformin + Glipizide|Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.
3058108|NCT00856297|Experimental|MenACWY-CRM|Subjects received one primary dose of MenACWY-CRM conjugate vaccine in the parent study and were followed for persistence in the present study.
3058109|NCT00856297|Active Comparator|Licensed comparator|Subjects received one primary dose of a quadrivalent meningococcal conjugate vaccine with diphtheria toxoid as the protein carrier in the parent study and were followed for persistence in the present study at 5 years postvaccination.
3058110|NCT00856297|Other|Naive|Subjects who were age-matched to the other study groups and had not received any previous meningococcal vaccinations.
3058111|NCT00856297|Experimental|MenACWY-CRM/MenACWY-CRM|Subjects received one primary dose of the MenACWY-CRM conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
3058112|NCT00856297|Experimental|Licensed comparator/MenACWY-CRM|Subjects received one primary dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine in the parent study and one booster dose of MenACWY-CRM conjugate vaccine at 3 years after primary vaccination.
3058113|NCT00856323|Experimental|PEP/CM|Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
3058114|NCT00856349||Analysis cohort|Enrolled subjects who met study eligibility criteria and contributed data toward study endpoints.
3058115|NCT00856375|Experimental|NKTR-102|NKTR-102 IV every 3 weeks
3058116|NCT00856375|Active Comparator|irinotecan|irinotecan IV every 3 weeks
3058117|NCT00856388|Experimental|Treatment (Reduced intensity allogeneic stem cell transplant)|"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.~Note: *Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan."
3058118|NCT00856414|Experimental|1|botulinum toxin Type A 20U
3058119|NCT00856492|Experimental|Arm 1|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 and bevacizumab IV over 30- to 90-minutes on day 1 of weeks 1-12. Patients then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
3058120|NCT00856492|Active Comparator|Arm 2|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 1-12, and then receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 14, 16, 18, 20, 22, and 24.
3058121|NCT00856492|Active Comparator|Arm 3|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1 and pegfilgrastim SC on day 2 of weeks 1, 3, 5, 7, 9, and 11, and then receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on day 1 of weeks 14-25.
3058122|NCT00856518|Active Comparator|Arm 1: EMST|The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
3058123|NCT00856518|Sham Comparator|Arm 2: Sham group|The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load
3058124|NCT00856544|Experimental|Active 5 mg|
3058125|NCT00856544|Experimental|Active 10 mg|
3058126|NCT00856544|Placebo Comparator|Placebo Sequence 1|Placebo non-responders advance to 5 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 5 mg CP-690,550 at Month 6 visit.
3058127|NCT00856544|Placebo Comparator|Placebo Sequence 2|Placebo non-responders advance to 10 mg CP-690,550 at Month 3 visit. All patients in this treatment arm advance to 10 mg CP-690,550 at Month 6 visit.
3058128|NCT00856557|Experimental|Seminar and Practicum|Seminar and practicum that occurs over 4 week period for internal medicine residents, designed to provide a systematic approach to identifying and addressing contextual factors essential to planning patient care.
3058129|NCT00856557|No Intervention|No intervention|No educational intervention.
3058130|NCT00856583|Experimental|Sertindole|Normally in the range of 4 to 20 mg/day
3058131|NCT00856583|Active Comparator|Risperidone|Normally in the range of 2 to 8 mg/day
3058132|NCT00856609|Active Comparator|Exenatide|10 micrograms subcutaneously twice
3058133|NCT00856609|Placebo Comparator|Placebo|Twice daily
3058134|NCT00856635|Experimental|Glatiramer acetate|Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.
3058135|NCT00856635|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a day for up to 6 months.
3058136|NCT00856661|Experimental|Desmoteplase|
3058137|NCT00856661|Placebo Comparator|Placebo|
3058138|NCT00856726|Experimental|PTH infusion|(1-34) PTH infusion at a rate of 0.055 ug/kg/hour for six hours
3058139|NCT00856739||Group 1|
3058140|NCT00856778|Other|Virtue® Male Sling|Subjects implanted with Virtue® Male Sling
3058141|NCT00856791|Experimental|ON 01910.Na|3200 mg ON 01910.Na administered intravenously over 2 hours on days 1, 4, 8, 11, 15, and 18 of 28-day cycle
3058142|NCT00856830|Experimental|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin.~This study has only one arm but it incorporates two phases. Phase I utilizes a combination of bendamustine and irinotecan for Regimen A followed by etoposide and carboplatin for Regimen B."
3058143|NCT00856843|Active Comparator|Polyethylene glycol 3350 based bowel preparation|Polyethylene glycol 3350 based bowel preparation
3058144|NCT00856843|Experimental|BLI800|BLI800
3058145|NCT00856856|Experimental|Absorb stent|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
3058146|NCT00856908|Experimental|1|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3058147|NCT00856908|Placebo Comparator|2|Dose titration of oral suspension during 4 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 24 days
3058148|NCT00856934|No Intervention|Control|Wounds covered with standard dressings: three layers of paraffin gauze, standard bandages, elastic bandage.
3058149|NCT00856934|Experimental|PRP|PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
3058150|NCT00856934|Experimental|PRP+K|Keratinocytes suspended in PRP sprayed onto the wound bed with Calcium Choride. Wounds covered with same standard dressings used in control group.
3058151|NCT00856973|Experimental|Low dose eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
3058152|NCT00856973|Experimental|High dose eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
3058153|NCT00856973|Placebo Comparator|Placebo|Placebo 6-17 years
3058154|NCT00856986|Experimental|Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
3058155|NCT00856986|Experimental|Insulin detemir + Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects were randomised to continue to receive liraglutide 1.8 mg once daily + metformin in addition to individually adjusted insulin detemir for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was at least 7.0%
3058156|NCT00856986|Experimental|Non-Randomised Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Subjects continued to receive liraglutide 1.8 mg once daily + metformin for 26 weeks plus 26 weeks extension, when the HbA1c assessment after run-in period was below 7.0%
3058157|NCT00856986|Other|Early Withdrawals Lira 1.8|Subcutaneous administration of liraglutide 1.8 mg once daily in a forced 12 week run-in period + subject's own pre-trial metformin treatment at an unchanged dose and frequency (at least 1500 mg daily). Initial dose of liraglutide 0.6 mg/day with weekly increments of 0.6 mg until final dose of 1.8 mg/day was reached. Due to withdrawals in the run-in period, subjects did not receive any further treatment in trial
3058158|NCT00856986|Other|Intensified group|Intensification of treatment with insulin detemir was offered at Weeks 26 and 38 for subjects with an HbA1c ≥ 8.0% in the randomised Lira 1.8 group and non-randomised liraglutide treatment group.
3058159|NCT00856999|Experimental|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
3058160|NCT00857207|Experimental|Arm 1: Treatment Goal Management Training|Treatment Goal Management Training
3058161|NCT00857207|No Intervention|Arm 2: Control-Brain Health Workshop|Control-Brain Health Workshop
3058162|NCT00857220|Experimental|2mg eszopiclone (6-11yrs), 3mg eszopiclone (12-17yrs)|
3058163|NCT00857233|Experimental|Memantine|
3058164|NCT00857246|Experimental|Induction/ surgery/ chemoRT|"Induction treatment (3 weeks/cycle x 4 cycles): Cisplatin and Irinotecan on days 1 and 8; Cetuximab on days 1, 8, and 15.~Surgery (starts 3-4 weeks after induction treatment).~Chemoradiation treatment (starts 4-6 weeks after surgery):~weeks 1-19: Cetuximab on day 1 of every week; week 1: 5-FU and Leucovorin (LV) x 5 days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU+ LV on days 1-4; week 9: 5-FU+ LV on days 1-3; weeks 14 and 19: 5-FU+LV x 5days"
3058165|NCT00857259|Experimental|Everolimus 5 mg|5 mg orally once daily plus sham ocular injection on Day 1 (Baseline) until Day 28
3058166|NCT00857259|Active Comparator|Ranibizumab 0.5 mg|Ranibizumab intra-vitreal therapy (IVT) 0.5 mg on Day 1 (baseline)
3058167|NCT00857259|Active Comparator|Oral Everolimus (5mg) and Ranibizumab (0.5mg)|Everolimus orally 5 mg once daily plus Ranibizumab Intra-vitreal therapy (IVT) 0.5 mg on day 1 (baseline)
3058168|NCT00857272|Active Comparator|HalfLytely with 10mg bisacodyl|Active control
3058169|NCT00857272|Experimental|HalfLytely with 5mg bisacodyl|Investigational dose
3058170|NCT00857285|Experimental|1|olmesartan medoxomil
3058171|NCT00857285|Active Comparator|2|losartan potassium
3058172|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^9 vp/dose|Participants administered MRKAd5 HIV-1 gag vaccine 1x10^9 viral particles (vp)/dose (V520), on Day 1, Week 4, and Week 26.
3058173|NCT00857311|Experimental|MRKAd5 HIV-1 gag vaccine 1x10^10 vp/dose|"Participants were to be administered MRKAd5 HIV-1 gag 1x10^10 vp/dose (V520) on Day 1, Week 4, and Week 26.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in the group MRKAd5 HIV-1 gag 1x10^10 vp/dose."
3058174|NCT00857311|Experimental|Placebo|Participants administered placebo to MRKAd5 HIV-1 gag vaccine (V520) on Day 1, Week 4, and Week 26.
3058175|NCT00857311|Sham Comparator|Open Label Tetanus and Diptheria Toxoids Adsorbed|"Participants were to be administered open label tetanus and diptheria toxoids adsorbed (Td) at Day 1 only.~Per a letter dated 30-Aug-2005 all sites were notified that due to recruitment challenges enrollment would be halted as of 01-Oct-2005. Consequently, no participants were enrolled in this group."
3058176|NCT00857389|Experimental|Thio-Clo-Bu with Allo SCT|"Pre-transplant conditioning regimen:~Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF~Post haploidentical stem cell transplant participants:~Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses."
3058177|NCT00857415|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy.
3058178|NCT00857415|Experimental|Specificity Cohort|Younger healthy controls presumed to be devoid of beta-amyloid plaques.
3132347|NCT03419403|Experimental|Standard Steroids + Vasoconstrictor + Cold Compress|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
3058179|NCT00857454|Experimental|Testosterone MD-lotion|"In this open-label extension of the MTE08 trial, participants received Testosterone Metered Dose (MD)-Lotion for 60 days (dosing from Day 121 of the MTE08 trial to Day 180 of the MTE09 trial). Participants in MTE08 initially received 3.0 milliliters (mL) (60 micrograms [mg]) of 2% Testosterone MD-Lotion, and may have had their dose of testosterone adjusted upwards or downwards.~Doses could be titrated to one of the following:~1.5 mL (30 mg) of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to one axilla).~3.0 mL (60 mg)of 2% Testosterone MD-Lotion applied daily by 2 doses to the axilla (1.5 mL to each axilla).~4.5 mL (90 mg)of 2% Testosterone MD-Lotion applied daily by 3 doses to the axilla (2 x 1.5 mL to one axilla and 2 x 1.5 mL to the other axilla).~6.0 (120 mg)of 2% Testosterone MD-Lotion applied daily by 4 doses to the axilla (2 x 1.5 mL to each axilla)."
3058180|NCT00857493|Experimental|Group 1|
3058181|NCT00857493|Experimental|Group 2|
3058182|NCT00857532|Experimental|Normal cognitive performance|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores of ≥9, indicating normal cognitive performance.
3058183|NCT00857532|Experimental|Mild cognitive deficits|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores between 6 and 8, inclusive, indicating mild cognitive deficits.
3058184|NCT00857532|Experimental|Severe cognitive impairment|Subjects with age-and education-adjusted standardized Mattis Dementia Rating Scale scores below 5, indicating moderate to severe cognitive impairment.
3058185|NCT00857545|Experimental|Arm I (vaccine therapy and adjuvant)|Patients receive polyvalent antigen-KLH conjugate vaccine and immunological adjuvant OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 11, 23, 35, 47, 59, 71, and 83 in the absence of disease progression or unacceptable toxicity.
3058186|NCT00857545|Experimental|Arm II (adjuvant)|Patients receive immunological adjuvant OPT-821 SC as in arm I.
3058187|NCT00857584|Experimental|Quetiapine Extended Release|Lithium or valproate at stable doses within seric therapeutic levels
3058188|NCT00857584|Active Comparator|Sertraline|Lithium or valproate at stable doses within seric therapeutic levels
3058189|NCT00857623|Experimental|1|
3058190|NCT00857623|Placebo Comparator|2|
3058191|NCT00857649|Experimental|Memantine|
3058192|NCT00857649|Placebo Comparator|Placebo|
3058193|NCT00857727|Experimental|Drug|Dexmedetomidine
3058194|NCT00857727|Placebo Comparator|Control|Normal Saline IV solution
3058195|NCT00857766|Active Comparator|ADVAIR DISKUS|Subjects receive blinded Fluticasone Propionate/Salmeterol. At 4 months subjects will receive open label SPIRIVA HANDIHALER
3058196|NCT00857766|Placebo Comparator|Placebo|Subjects will receive placebo ADVAIR DISKUS. At 4 months subjects will receive open label SPIRIVA HANDIHALER
3058197|NCT00857792|Other|Open Label|
3058198|NCT00857818|Experimental|Aripiprazole|
3058199|NCT00857818|Active Comparator|Control group (Oanzapine, risperidone, or quetiapine)|
3058200|NCT00857857|Experimental|13 day repeat dose|
3058201|NCT00857896|Experimental|Fesoterodine once daily|
3058202|NCT00857948|Experimental|0.15% ivermectin|Participant on 0.15% ivermectin treatment conditioner
3058203|NCT00857948|Experimental|0.25% ivermectin|Participants on 0.25% ivermectin treatment conditioner
3058204|NCT00857948|Experimental|0.50% ivermectin|Participants on 0.50% ivermectin treatment conditioner
3058205|NCT00857948|Placebo Comparator|Placebo|participants on Placebo (Vehicle control)
3058206|NCT00857961|Experimental|3 mL (30 mg) of 1% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
3058207|NCT00857961|Experimental|1.5 mL (30 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to one axilla. All study participants are randomized to each of the 4 study treatments.
3058208|NCT00857961|Experimental|3 mL (60 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days to both axilla (1.5 mL to each axilla). All study participants are randomized to each of the 4 study treatments.
3058209|NCT00857961|Experimental|4.5 mL (90 mg) of 2% Testosterone MD-Lotion|Applied once daily for 7 days by three doses to both axilla (2 x 1.5 mL to one axilla and 1 x 1.5 mL to the other axilla). All study participants are randomized to each of the 4 study treatments.
3058210|NCT00858013|Active Comparator|Nateglinide|Nateglinide 90~120mg three times a day
3058211|NCT00858013|Active Comparator|Glimepiride|Glimepiride 1~2mg once a day
3058212|NCT00858117|Experimental|Alemtuzumab and Rituximab|Administration of Alemtuzumab combined with Rituximab to test the feasibility of combining these two monoclonal antibodies as a first line therapy in patients with B-cell chronic lymphocytic leukemia.
3058213|NCT00858130|Experimental|Veinoplus|Every subject enrolled in study will be in this experimental arm. VeinoPlus device will be used by all enrolled subjects.
3058214|NCT00858143||1|
3058215|NCT00858208||Patients with neovascular Age-Related Macula Degeneration|
3058216|NCT00858234|Experimental|Vorinostat + Bortezomib|Participants undergo up to 3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg once daily [QD] on Days 1 through 14) + bortezomib (1.3 mg/m^2 intravenous [IV] on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m^2 IV on Days 1, 4, 8, and 11).
3058217|NCT00858247|Experimental|Vitamin D3-low dose|Vitamin D3 400 IU capsule, one capsule daily for 12 weeks.
3058218|NCT00858247|Experimental|Vitamin D3-high dose|Vitamin D3 2000 IU capsule, one capsule daily for 12 weeks.
3058219|NCT00858364|Placebo Comparator|Placebo|Participants received placebo once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
3058220|NCT00858364|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg once every 3 weeks (Q3W) administered subcutaneously until 3 weeks after the completion of chemotherapy or upon determination of disease progression, whichever occurred first.
3058221|NCT00858390|No Intervention|1 standard care|organ donors receiving standard care
3058222|NCT00858390|Experimental|2 Enteral Feeding|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
3058223|NCT00858403|Experimental|Treatment with Dasatinib|Dasatinib 140 mg orally (po) every day starting Day #1, continuous dosing. This dose was chosen based on the current experience in patients with solids tumors who have had prior chemotherapy.
3058224|NCT00858442|Experimental|With PRP|Each patient received a single dose of 5cc PRP before the graft.
3058225|NCT00858442|No Intervention|Without PRP|Control patients did not receive any intervention before the graft.
3058226|NCT00858468|Experimental|Group 1|Participants aged 6 to 12 Weeks at enrollment
3058227|NCT00858468|Experimental|Group 2|Participants aged 24 to 36 Weeks at enrollment
3058228|NCT00858494|Experimental|homeopathic cold remedy|
3058229|NCT00858507|Experimental|Personal Health Assessment/RN Brief Intervention|RN-based medical outreach, administration of a personal health assessment and brief intervention
3058230|NCT00858507|Placebo Comparator|Social Work-Administered Outreach|Social work based outreach (usual care)
3058231|NCT00858637|Experimental|1 MCI-196|
3058232|NCT00858637|Placebo Comparator|2 Placebo of MCI-196|
3058233|NCT00858637|Active Comparator|3 Simvastatin|
3058234|NCT00858637|Placebo Comparator|4 Placebo of Simvastatin|
3058235|NCT00858689|Experimental|minocyline 50 mg or 100 mg PO BID|open label treatment with minocycline low or high dose, 50 mg or 100 mg PO (by mouth) BID (twice a day), added to existing medication regimen for 8 weeks
3058236|NCT00858702|Experimental|1|olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks
3058237|NCT00858702|Experimental|2|olmesartan medoxomil and a diuretic tablet (of the thiazide class)
3058238|NCT00858780|Active Comparator|1|50mg once weekly + methotrexate
3058239|NCT00858780|Active Comparator|2|25mg once weekly + methotrexate
3058240|NCT00858780|Placebo Comparator|3|once weekly + methotrexate
3058241|NCT00858832|Experimental|Methergine|Methergine group received Methergine 0.2mg po every 6 hours for two days, plus routine postpartum care.
3058242|NCT00858832|No Intervention|No treatment|No treatment group received only routine postpartum care.
3058243|NCT00858845|Experimental|Clonidine patch|Participants assigned to wear a clonidine patch.
3058244|NCT00858845|Placebo Comparator|Placebo|Participants assigned to wear a matching placebo patch.
3058245|NCT00858858|Experimental|Arm 1|All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.
3058246|NCT00858962|Experimental|Bup/Ral|Buprenorphine and Raltegravir co-administration
3058247|NCT00858988|Experimental|Rifaximin|
3058248|NCT00858988|Placebo Comparator|Placebo|
3058249|NCT00859014|Experimental|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.
3058250|NCT00859027|Experimental|Risedronate|35 mg by mouth every week as directed
3058251|NCT00859027|Placebo Comparator|risedronate placebo tablet|Calcium and vitamin D
3058252|NCT00859040|Experimental|SOM230C|Monthly SOM230C (pasireotide LAR) - 60 mg intramuscularly (Single-Arm Trial)
3058253|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh A|
3058254|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh B|
3058255|NCT00859053|Active Comparator|BMS-790052 in Child-Pugh C|
3058256|NCT00859053|Active Comparator|BMS-790052 in Healthy Subjects|
3058257|NCT00859131|Active Comparator|Thymoglobulin|Subjects receiving Thymoglobulin as induction agent in renal transplantation
3058258|NCT00859131|Active Comparator|Zenapax|subject who will receive daclizumab or basiliximab as induction agent in renal transplantation
3058259|NCT00859222|Experimental|Phase I Cohort 1: Bevacizumab +LBH589 20 mg every week|Phase I Cohort 1 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the original starting LBH589 dose of 20 mg/day orally, 3x per week, every week (days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26). Participants were treated until disease progression or unacceptable toxicity.
3058260|NCT00859222|Experimental|Phase I Cohort 2: Bevacizumab + LBH589 20 mg every other week|Phase I Cohort 2 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and the amended starting LBH589 dose of 20 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3058261|NCT00859222|Experimental|Phase I Cohort 3: Bevacizumab + LBH589 30 mg every other week|Phase I Cohort 3 participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3058262|NCT00859222|Experimental|All Phase I Participants|All phase I participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
3058263|NCT00859222|Experimental|Phase II GBM: Bevacizumab + LBH589 30 mg every other week|Phase II glioblastoma (GBM) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3058264|NCT00859222|Experimental|Phase II AG: Bevacizumab + LBH589 30 mg every other week|Phase II Anaplastic Glioma (AG) participants received the regimen established in the Phase I study (Feb 2011). Phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3058265|NCT00859222|Experimental|All Phase II Participants|All phase II participants received bevacizumab 10 mg/kg intravenously (IV) on days 1 and 15 of each 28 day cycle and LBH589 30 mg/day orally, 3x per week, every other week (Days 1, 3, 5, 15, 17, 19). Participants were treated until disease progression or unacceptable toxicity.
3058266|NCT00859313|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3058267|NCT00859339|Experimental|Experimental Treatment|Neoadjuvant cisplatin, gemcitabine and sunitinib malate followed by radical cystectomy
3058268|NCT00859430|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
3058269|NCT00859430|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
3058270|NCT00859456|Experimental|Sunitinib|Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi's sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
3058271|NCT00859469|Experimental|Oxaliplatin and Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin 100 mg/m² IV infusion over 2 hours repeated for 14 days up to 6 cycles
3058272|NCT00859495|Experimental|Multimodal lung sparing regimen|"Intrapleural chemotherapy plus systemic chemotherapy:~Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy."
3058273|NCT00859508|Experimental|SyntheCel|
3058274|NCT00859508|Active Comparator|other FDA cleared dura replacements|
3058275|NCT00859521|Experimental|Levetiracetam|Levetiracetam 1000 mg Tablet (test) dosed in first period followed by Keppra® 1000 mg Tablet (reference) dosed in second period
3058276|NCT00859521|Active Comparator|Keppra®|Keppra® 1000 mg Tablet (reference) dosed in first period followed by Levetiracetam 1000 mg Tablet (test) dosed in second period
3058277|NCT00859547|Experimental|Recombinant thrombin (rThrombin), 1000 IU/mL|
3058278|NCT00859573|Active Comparator|1. Modafinil|
3058279|NCT00859573|Placebo Comparator|2: Placebo|Placebo
3058280|NCT00859586|Experimental|Miltenyi Magnetic cell sorter for CD3|"Miltenyi Magnetic cell sorter device will be used for CD3 selection of granulocyte colony stimulating factor mobilized allogeneic PBSCT. In stage 1, subjects will receive 1 x 10 to the eight power CD3 cells/kg. In stage II, the dose of CD3+ cells will be increased to 2 x 10 to the eight power cells/kg.~This phase II clinical trial is designed to evaluate a novel non-myeloablative but highly immunosuppressive disease specific conditioning regimen and infusion of unmanipulated lymphocytes from a haplo-identical familial donor in subjects with relapsed disease following matched sibling stem cell transplantation who are not candidates for alternative treatment options. The clinical trial will evaluate recipient survival at six months post-relapse of disease."
3058281|NCT00859638|Experimental|Intervention Group|Rehabilitation self-management group, on-line self monitoring of physical function, and organizational capacity building.
3058282|NCT00859638|No Intervention|Case matched controls|Usual care in primary health care.
3058283|NCT00859651|Active Comparator|20,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 20,000 IU weekly, for one year.~Cholecalciferol 20,000 IU (2 active capsules + 1 matching placebo capsule)"
3058284|NCT00859651|Active Comparator|30,000 IU weekly|"Postmenopausal women who are at increased risk for breast cancer development receiving vitamin D3, oral cholecalciferol 30,000 IU weekly, for one year.~Cholecalciferol 30,000 IU (3 active capsules)"
3058285|NCT00859833|Experimental|myocardial perfusion reserve|Myocardial perfusion reserve will be measured by quantifying myocardial blood flow using MRI at rest and then with each of 2 coronary vasodilators. Measurements are performed with first pass gadolinium perfusion (i.v. bolus injection of 0.02 or 0.03 mmol/kg of gadolinium). Each of the 2 drugs is given sequentially (30 minutes apart) in the same sequence in every patient. The shorter acting drug (adenosine) is given first so it has time to wear off before giving the second drug. It is ideal to measure MPR with each drug during the same imaging session so that there are no other clinical variables that change between the administration of the 2 agents. See below.
3058286|NCT00859898|Experimental|Dapagliflozin + Metformin XR|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks~Metformin XR: Tablets, Oral, up to 2000 mg, once daily, 24 weeks"
3058287|NCT00859898|Experimental|Dapagliflozin + Placebo|"Dapagliflozin: Tablets, Oral, 10 mg, once daily, 24 weeks.~Placebo: Metformin HCl Modified Release matching placebo tablets, once daily, 24 weeks."
3058288|NCT00859898|Active Comparator|Metformin XR + Placebo|"Metformin XR: Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks~Placebo: Dapagliflozin matching placebo tablets once daily, 24 weeks"
3058289|NCT00859937|Experimental|Arm I|Patients receive dasatinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3058290|NCT00859950|Active Comparator|Sleep Apnea|Subjects found to have Obstructive Sleep Apnea (OSA) with Intermittent Hypoxemia (IH). This arm will undergo a pre-treatment blood draw, one month of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw.
3058291|NCT00859950|No Intervention|Normal Control|Subject found to have no evidence of Obstructive Sleep Apnea (OSA) after Nocturnal Polysomnography (NPSG). These subjects will only undergo a blood draw and will not have the Continuous Positive Airway Pressure (CPAP) treatment.
3058292|NCT00859976|Active Comparator|Plasma-sprayed shell|Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
3058293|NCT00859976|Experimental|BoneMaster coated shell|Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
3058294|NCT00860015|Experimental|Alimta/Gemcitabine|IV administration of drugs for 14 days for up to 4 cycles
3058295|NCT00860028|Experimental|Extended Varenicline Pretreatment|Arm 1 (Experimental) = 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.
3058296|NCT00860028|Experimental|Short-term Varenicline Pretreatment|Arm 2 (Experimental) = 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
3179109|NCT00669227|Placebo Comparator|2|placebo is visually indistinguishable from verum due to integration of autologous erythrocytes, intracoronary administration the same day of bone marrow aspiration
3179110|NCT00669253|Experimental|1|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
3058297|NCT00860067|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson (BD) Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
3058298|NCT00860067|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attentuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])a B strain of the Yamagata lineage.
3058299|NCT00860067|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria(trivalent influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature-sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004])a B strain of the Victoria lineage.
3058300|NCT00860171|Experimental|Treatment (iodine I 131 monoclonal antibody B, autologous HCT)|Patients receive a dosimetric dose of iodine I 131 monoclonal antibody BC8 IV on day -20 and a therapeutic dose on day -11. Before day -20, patients may also receive up to 2 additional dosimetric doses of iodine I 131 monoclonal antibody BC8 IV approximately 1-2 weeks apart. Patients then undergo autologous stem cell transplantation on day 0.
3058301|NCT00860262|Experimental|telmisartan and amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3058302|NCT00860262|Active Comparator|amlodipine|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3058303|NCT00860262|Active Comparator|telmisartan|telmisartan and amlodipine used in combination vs amlodipine or telmisartan
3058304|NCT00860314|Active Comparator|AP Position|Cardioversion with antero-posterior electrode position
3058305|NCT00860314|Active Comparator|AL Position|Cardioversion with antero-lateral electrode position
3058306|NCT00860379|Placebo Comparator|Placebo|Placebo
3058307|NCT00860379|Experimental|Selenium1|Subject will receive 2 ug/kg of IV selenium per day
3058308|NCT00860379|Experimental|Selenium2|Subject will receive 4 ug/kg of IV selenium per day
3058309|NCT00860405|Experimental|1|Investigational drug: HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion)
3058310|NCT00860405|Active Comparator|2|Control drug: Human serum albumin (HSA 50g/L)
3058311|NCT00860457|Experimental|Chemotherapy|Fludarabine/Rituximab followed by Lenalidomide
3058312|NCT00860470|Active Comparator|1|Iron (27 mg) and folic acid (600 ug)
3058313|NCT00860470|Experimental|2|Multiple micronutrient
3058314|NCT00860535|Experimental|Ph+ CML or Ph+ ALL|GFS biomarker evaluation
3058315|NCT00860574|Experimental|Treatment (allogeneic transplantation)|CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -6 to day -2 and treosulfan IV over 2 hours on days -6 to day -4. Patients also undergo total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation or bone marrow transplantation on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously or PO BID on days -1 to 56, followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11.
3058316|NCT00860743|No Intervention|Arm 1|"We plan to study 10 males and 10 females with moderate obstructive sleep apnea (OSA), and 10 healthy males and 10 healthy females. The males and the females will be matched based on age, race, sex and body mass index. The OSA and control participants will be exposed to intermittent hypoxia and sham intermittent hypoxia during wakefulness and sleep."
3058317|NCT00860743|Experimental|ANTIOXIDANT COCKTAIL|We plan to study 10 male participants with moderate obstructive sleep apnea (OSA) and 10 male control participants matched for age, race and body mass index. The OSA and control participants will be exposed to intermittent hypoxia during wakefulness and sleep following administration of an antioxidant or a placebo cocktail that will be presented in a randomized fashion.
3058318|NCT00860795|Active Comparator|Echinacea|
3058319|NCT00860795|Placebo Comparator|placebo|
3058320|NCT00860847|Active Comparator|Aged Garlic Extract and Coenzyme Q10|"AGE (1200 mg) and CoQ10 (120 mg)~This is a combination of aged garlic extract and co-enzyme Q10"
3058321|NCT00860847|No Intervention|Placebo|placebo pills will be given
3058322|NCT00860938|Active Comparator|Budesonide|
3058323|NCT00860938|Placebo Comparator|Placebo|
3058324|NCT00860951|Other|Brain Computer Interface Keyboard|What effect does the environment (BCI, AT device, Computer) have on the accuracy of typing using a BCI keyboard?
3058325|NCT00861146|Experimental|1 concurrent smoking cessation|smoking cessation delivered concurrent with intensive alcohol treatment
3058326|NCT00861146|Active Comparator|2 deferred smoking cessation|smoking cessation delivered 12 weeks after intensive alcohol treatment
3058327|NCT00861198||ERCP|Patients who have a medical indication for ERCP with cholangioscopy and/or pancreatoscopy and are referred for the procedure as part of their standard medical care will be considered for the study.
3058328|NCT00861263|Other|spiral overtube|Any subject that has been referred for spiral enteroscopy will be asked to participate in this study. The purpose is to gather data about the technical aspects of the procedure,diagnostic capability and treatment as well as long term follow up.
3058329|NCT00861341|Experimental|Pioglitazone with or without Aspirin|Blood samples will be taken at time 0 to measure platelet aggregation. 30mg Pioglitazone will be ingested and another blood sample will be obtained 90-180 minutes later for platelet aggregation. After 6-9 days, subjects will ingest 81mg of aspirin. Another blood sample will be obtained 2-24 hours later for baseline determination of platelet aggregation and activation after taking aspirin. Subjects will then ingest 30mg pioglitazone and a final blood sample will be obtained 90-180 minutes later to measure platelet aggregation.
3179111|NCT00669253|Active Comparator|2|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods (ultrasonic and manual means)
3058330|NCT00861380|Experimental|10Pn3+1-6W- 6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3058331|NCT00861380|Experimental|10Pn2+1-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks, followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3058332|NCT00861380|Active Comparator|Ctrl-6W-6M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 6 weeks to 6 months at enrolment. Subjects received the Engerix B vaccine (called also HBV vaccine) according to either a 3-dose primary vaccination schedule with an interval of at least 4 weeks between doses followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (3+1 Infant Schedule), or according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (2+1 Infant Schedule). The vaccine was administered intramuscularly in the thigh.
3058333|NCT00861380|Experimental|10Pn7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3058334|NCT00861380|Active Comparator|Ctrl7-11M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 7 to 11 months at enrolment. Subjects received the Engerix B (called also HBV) vaccine according to a 2-dose primary vaccination with an interval of at least 8 weeks followed by a booster dose of the same vaccine with an interval of preferably 6 months since the previous vaccine dose (minimum 4 months) (11-17M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3058335|NCT00861380|Experimental|10Pn12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Synflorix (called also 10Pn-PD-DiT, 10Pn or GSK1024850A) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3058336|NCT00861380|Active Comparator|Ctrl12-18M/043 Group|Subjects in this group were subjects enrolled in the 10PN-PD-DIT-043 (NCT00861380 - EUDRACT 2008-005149-48) study, aged 12 to 18 months at enrolment. Subjects received the Havrix (called also HAV) vaccine according to a 2-dose vaccination with an interval of at least and preferably 6 months between doses (12-18M Schedule). The vaccine was administered intramuscularly in the thigh or in the deltoid region of upper arm, provided the muscle size was adequate.
3058337|NCT00861471|Experimental|Docetaxel +Gleevec|
3058338|NCT00861601|Experimental|low dose|eltrombopag 12.5 mg/day
3058339|NCT00861601|Experimental|middle dose|eltrombopag 25 mg/day
3058340|NCT00861601|Experimental|high dose|eltrombopag 37.5 mg/day
3058341|NCT00861614|Active Comparator|Ipilimumab|
3058342|NCT00861614|Placebo Comparator|Placebo|
3058343|NCT00861692|Experimental|Argatroban|
3468791|NCT03892122|Other|Propofol group|"Sleep endoscopy will be performed by a Target Controlled Infusion system (BRAUN perfusion system) using Schneider model in effect-site (cerebral) targeted infusion 50-ml prefilled syringe of 1% propofol. Schneider system is a complex pharmacokinetic/pharmacodynamic (PK/PD) model that allows to obtain different rates of drug from the values of age, height, weight and lean body mass of the patient~. The starting dose of propofol will be 2-2,5 mcg ml-1 and increments of 0.2 mcg ml-1 took place when the new cerebral concentration of propofol will be reached, and never before 5 minutes. In this way, the investigators will be realized a slow technique of TCI propofol infusion according to European working group"
3468792|NCT03892122|Other|Dexmedetomidine group|For the D-DISE group, dexmedetomidine will be administered with an IV infusion at 1 mcg/kg over 10 minutes, followed by a maintenance rate of 0,7 mcg/kg/h.
3058348|NCT00861744|Experimental|Priorix 1 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 1) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3058349|NCT00861744|Experimental|Priorix 2 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 2) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3179112|NCT00669253|Active Comparator|3|Surgery at baseline for all deep pockets using conventional methods (ultrasonic and manual means)
3179113|NCT00669266||Tumor|Tumor material and corresponding biosamples from patients with adrenal tumors
3179114|NCT00669266||control group|Biomaterial from patients without adrenal tumor
3058350|NCT00861744|Experimental|Priorix 3 Group|Subjects between 12 and 15 months of age at the time of study vaccination who received one dose of Priorix investigational vaccine (Lot 3) subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3058351|NCT00861744|Active Comparator|MMR-II Group|Subjects between 12 and 15 months of age at the time of study vaccination who randomly received one dose of one of three different commercially-available lot of M-M-R II (Merck and Co.) vaccine subcutaneously in the right upper arm. Subjects concomitantly received one dose of Havrix and Prevnar vaccines intramuscularly in the left and the right thigh, respectively and one dose of Varivax vaccine subcutaneously in the left upper arm. Subjects had previously received three doses of Prevnar vaccine within the first year of life with the third dose administered at least 30 days prior to enrollment and vaccination with study vaccines.
3058352|NCT00861757|Placebo Comparator|Placebo|
3058353|NCT00861757|Experimental|2.5 mg Tadalafil|
3058354|NCT00861757|Experimental|5.0 mg Tadalafil|
3058355|NCT00861757|Active Comparator|0.2 mg Tamsulosin|
3058356|NCT00861913|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3058357|NCT00862082|Experimental|PR104 + Sorafenib|PR104 will be administered IV once every four weeks, in addition to 400mg sorafenib PO twice daily
3058358|NCT00862121|Experimental|Mesalazine|Mesalazine (Mesalamine) 2 g sachet; 6 g daily
3058359|NCT00862121|Placebo Comparator|Placebo|Placebo to Mesalazine (Mesalamine) 2 g sachet; 6 g daily
3058360|NCT00862134|Active Comparator|Docetaxel 75 mg/m^2|Subjects randomized to the docetaxel arm will be administered 75 mg/m^2, IV, every 21 days (an approved dose and schedule)
3058361|NCT00862134|Experimental|PR104 + 60 mg/m^2 docetaxel|Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m^2 docetaxel, IV, every 21 days plus 770 mg/m^2 PR104, IV, every 21 days and prophylactic G-CSF.
3058362|NCT00862186|Other|Self-Management Arm|Behavioral: 'Fatigue Facts & Fixes'
3058363|NCT00862251|Experimental|Ezetimibe/simvastatin|
3058364|NCT00862251|Active Comparator|Doubling statin dose|
3058365|NCT00862251|Active Comparator|Rosuvastatin|
3058366|NCT00862277||Group 1: Menactra® from Previous Studies|Subjects previously received only one dose of meningococcal vaccine, Menactra® in Study MTA04, MTA12, MTA19, or MTA21.
3058367|NCT00862277||Group 2: Menomune® from Previous Study|Subjects previously received only one dose of meningococcal vaccine, Menomune® in Study MTA04
3058368|NCT00862277||Group 3: Control|Meningococcal vaccine-naive age matched subjects
3058369|NCT00862446|Experimental|Treatment|All infants will receive Omegaven
3058370|NCT00862459|Experimental|Gadobutrol~0.03 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg body weight (BW) of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3058371|NCT00862459|Experimental|Gadobutrol~0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3058372|NCT00862459|Experimental|Gadobutrol~0.3 mmol/kg BW (Gadavist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol and one dose of 0.1 mmol/kg BW of OptiMARK. The order in which the participants received Gadobutrol and OptiMARK was randomized. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
3058373|NCT00862537||Active Resonator magnetic field therapy|Administration of active magnetic fields with the Resonator Device
3058374|NCT00862563|Experimental|Zonisamide|Encapsulated zonisamide with a target maintenance doses of 400 mg/day administered as 4 capsules per day.
3058375|NCT00862563|Experimental|Levetiracetam|Encapsulated levetiracetam with a target maintenance doses of 2000 mg/day administered as 4 capsules per day .
3058376|NCT00862563|Active Comparator|Topiramate|Encapsulated topiramate with a target maintenance doses of 300 mg/day administered as 4 capsules per day .
3058377|NCT00862563|Placebo Comparator|Sugar Pill|Encapsulated sugar pill with a target maintenance dose administered as 4 capsules per day.
3058378|NCT00862641|Placebo Comparator|Placebo - Asthma|Matching intravenous (IV) bolus injection, subjects with Asthma
3058379|NCT00862641|Experimental|Regadenoson - Asthma|0.4mg / 5mL intravenous bolus injection, subjects with Asthma
3058380|NCT00862641|Placebo Comparator|Placebo - COPD|Matching intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
3058381|NCT00862641|Experimental|Regadenoson - COPD|0.4mg / 5mL intravenous bolus injection, subjects with Chronic Obstructive Pulmonary Disease (COPD)
3058382|NCT00862654|Experimental|C propionate 4/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
3058383|NCT00862654|Experimental|C propionate 2/week + Ketoconasole 2/week|Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
3058384|NCT00862654|Experimental|C propionate 2/week|Clobetasol propionate shampoo 0.05% (2/week)
3058385|NCT00862654|Active Comparator|Ketoconazole 2/week|Ketoconazole shampoo 2% (2/week)
3058386|NCT00862719|Experimental|Sitagliptin once per day|600 mg sitagliptin once per day orally starting on Day -1 for a total of 4 doses
3058387|NCT00862719|Experimental|Sitagliptin twice per day|600 mg sitagliptin twice per day orally starting on Day -1 for a total of 8 doses
3058388|NCT00862719|Experimental|Sitagliptin three times per day|600 mg sitagliptin three times per day orally starting on Day -1 for a total of 12 doses
3058389|NCT00862745|Experimental|Active|fesoterodine 4 mg (1 tablet) for 2 weeks with the option to increase to fesoterodine 8 mg or stay at fesoterodine 4 mg for 10 weeks for a total of 12 weeks of study medication.
3058390|NCT00862745|Placebo Comparator|Control|placebo (an identical pill that contains no medication) 1 tablet daily for 2 weeks followed by the option to increase the placebo pill daily for 10 weeks for a total of 12 weeks of study placebo medication.
3058391|NCT00862784|Experimental|IMC-1121B (ramucirumab) + mFOLFOX-6|This regimen will be repeated every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
3058392|NCT00862810|Other|Received HPV vaccine first|
3058393|NCT00862810|Other|Received concomitant vaccines first|
3058394|NCT00862823|Active Comparator|Atripla Tablet|Drug exposure after administration of Atripla Tablet
3058395|NCT00862823|Experimental|Atripla Liquid|Drug exposure after administration of an extemporaneously prepared liquid formulation of Atripla
3058396|NCT00862836|Experimental|1|Vandetanib added to standard therapy (pegliposomal doxorubicin)
3058397|NCT00862849|Experimental|Insulin Lispro, Regular Human Insulin, rHuPH20|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C).~Intervention A: a single, subcutaneous (SC) injection of 0.15 units per kilogram (U/kg) insulin lispro with 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase (rHuPH20)~Intervention B: a single, SC injection of 0.15 U/kg regular human insulin (RHI) with 3.75 ng/kg rHuPH20~Intervention C: a single, SC injection of 0.15 U/kg insulin lispro alone~There was a washout period of 3 to 14 days between interventions.~The treatment sequence (ABC, ACB, BAC, BCA, CAB, or CBA) was repeated once so that each participant received up to 6 injections."
3058398|NCT00862940|Experimental|Memantine|
3058399|NCT00862940|Placebo Comparator|Placebo|
3058400|NCT00862979|Active Comparator|CNI-regimen|CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
3058401|NCT00862979|Experimental|CNI-free-regimen|CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids
3058402|NCT00862992|Experimental|1|
3058403|NCT00862992|Experimental|2|
3058404|NCT00862992|Experimental|3|
3058405|NCT00863057|Experimental|1|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone, (Period 3, Weeks 11 to 14) duloxetine and methadone, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone placebo
3058406|NCT00863057|Experimental|2|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone, (Period 2, Weeks 6 to 9) duloxetine placebo and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine and methadone
3058407|NCT00863057|Experimental|3|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine and methadone, (Period 2, Weeks 6 to 9) duloxetine and methadone placebo, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone placebo, (Period 4, Weeks 16 to 19) duloxetine placebo and methadone
3058408|NCT00863057|Experimental|4|Participants will receive treatment in the following order: (Period 1, Weeks 1 to 4) duloxetine placebo and methadone placebo, (Period 2, Weeks 6 to 9) duloxetine and methadone, (Period 3, Weeks 11 to 14) duloxetine placebo and methadone, (Period 4, Weeks 16 to 19) duloxetine and methadone placebo
3058409|NCT00863109||PEG + RBV (Standard Clinical Practice)|Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.
3058410|NCT00863122|Experimental|lapatinib|Subjects will receive lapatinib for 10 days prior to surgery for vestibular schwannoma resection.
3058411|NCT00863122|No Intervention|control|Control subjects will not receive any intervention prior to surgery for vestibular schwannoma resection.
3058412|NCT00863265|Experimental|Crossover order ABC|The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
3058413|NCT00863265|Experimental|Crossover order BCA|The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
3058414|NCT00863265|Experimental|Crossover order BAC|The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
3058415|NCT00863265|Experimental|Crossover order ACB|The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
3058416|NCT00863265|Experimental|Crossover order CAB|The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
3058417|NCT00863265|Experimental|Crossover order CBA|The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).
3058418|NCT00863304|Experimental|1|
3058419|NCT00863304|Experimental|2|
3058420|NCT00863304|Active Comparator|3|
3058421|NCT00863304|Placebo Comparator|4|
3058422|NCT00863317|Experimental|montelukast sodium|4mg granules PO QD for 14 days
3058423|NCT00863317|Placebo Comparator|Placebo|Sucrose granules PO QD for 14 days
3058424|NCT00863343||All|Anyone presenting with influenza-like-illness
3058425|NCT00863356|Experimental|Epistaxis Group|"Subjects presenting with epistaxis that have not been controlled by traditional nasal packing, or that recurred immediately upon removal of the nasal packing will be included in this study. Subject will be evaluated during the packing period to determine the effect of hemostasis. Chitosan coated packing will be removed after 48 hours. Subjects' nasal cavities will be examined endoscopically to evaluate bleeding control, morphological changes induced by the chitosan coated packing.~One week after the removal of the packing, the patients will be endoscopically examined to assess the healing of the packed area, to monitor control of bleeding, and observe any potential delayed reaction to the packing material."
3058426|NCT00863434|Experimental|Treatment (colony stimulating factor and chemotherapy)|Patients receive G-CSF SC QD on days 1-5 and clofarabine IV over 1 hour and cytarabine IV on days 2-5. Beginning approximately 1 month later, patients may receive one additional course of treatment in the absence of disease progression or unacceptable toxicity.
3058427|NCT00863551|Experimental|Trospium Chloride Extended Release, 60 mg|Trospium Chloride Extended Release, 60 mg
3058428|NCT00863655|Experimental|Everolimus + Exemestane|Everolimus 10 mg daily in combination with exemestane 25 mg daily
3058429|NCT00863655|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
3058430|NCT00863681|Experimental|Arm 1|
3058431|NCT00863707|Placebo Comparator|Placebo|Matching intravenous (IV) bolus injection
3058432|NCT00863707|Experimental|Regadenoson|0.4 mg/5 mL intravenous bolus injection
3058433|NCT00863746|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (BID)
3058434|NCT00863746|Placebo Comparator|Placebo|Participants received 2 tablets of placebo orally twice daily (BID)
3058435|NCT00863772|Experimental|Tanezumab 5 mg|
3058436|NCT00863772|Experimental|Tanezumab 10 mg|
3058437|NCT00863772|Placebo Comparator|Placebo|
3058438|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 10 mg|
3058439|NCT00863798|Experimental|Desvenlafaxine succinate sustained release 50 mg|
3058440|NCT00863798|Placebo Comparator|Placebo|
3058441|NCT00863928|No Intervention|Control Arm|No suppository given
3058442|NCT00863928|Experimental|B & O suppository|B & O suppository, belladonna 16.2 mg and opium 60 mg suppository (Paddock Laboratories, Minneapolis, MN)
3058443|NCT00864032|Experimental|Phase I|
3058444|NCT00864084|Experimental|Pulmonary rehabilitation|People with respiratory disease
3058445|NCT00864097|Experimental|Tanezumab 10 mg + diclofenac|IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3058446|NCT00864097|Experimental|Tanezumab 5 mg + diclofenac|IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3058447|NCT00864097|Experimental|Tanezumab 2.5 mg + diclofenac|IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3058448|NCT00864097|Placebo Comparator|IV placebo + diclofenac|IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)
3058449|NCT00864123|Active Comparator|Cognitive-behavioral therapy + placebo|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of placebo. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
3058450|NCT00864123|Experimental|Cognitive-behavioral therapy + D-cycloserine|Involves receiving cognitive-behavioral treatment of OCD symptoms for 10 sessions. One hour prior to sessions 4-10, the child will take either 1 or 2 pills containing 25mg of D-cycloserine. The number of pills depends on the child's weight (e.g., about 46kgs takes 2 capsules).
3058451|NCT00864253|Experimental|ABI-007|Treatment Arm A (ABI-007): Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
3058452|NCT00864253|Active Comparator|Dacarbazine|Treatment Arm B (dacarbazine): Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
3058453|NCT00864383|Placebo Comparator|Regimen 1 - 2EHRZ/4HR (control regimen)|"Eight weeks of chemotherapy with Ethambutol, Isoniazid, Rifampicin and Pyrazinamide plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin plus the Moxifloxacin placebo, followed by~Nine weeks of Isoniazid and Rifampicin only."
3058454|NCT00864383|Experimental|Regimen 2 - 2MHRZ/2MHR|"Eight weeks of chemotherapy with Moxifloxacin, Isoniazid, Rifampicin and Pyrazinamide plus the Ethambutol placebo, followed by~Nine weeks of Moxifloxacin, Isoniazid and Rifampicin, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo."
3058455|NCT00864383|Experimental|Regimen 3 - 2EMRZ/2MR|"Eight weeks of chemotherapy with Ethambutol, Moxifloxacin, Rifampicin and Pyrazinamide plus the Isoniazid placebo, followed by~Nine weeks of Moxifloxacin and Rifampicin plus the Isoniazid placebo, followed by~Nine weeks of the Isoniazid placebo and the Rifampicin placebo"
3058457|NCT00864513|Experimental|chemotherapy|pemetrexed
3058458|NCT00864539|Experimental|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 mL
3058459|NCT00864539|Active Comparator|plain milk|daily intake of 200 mL plain milk
3058460|NCT00864539|Experimental|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium
3058461|NCT00864539|Active Comparator|plane juice|subjects receiving plain orange juice
3058462|NCT00864539|Experimental|vitamin D-Ca supplement|Subjects receiving daily supplement containing 500 mg + 200 IU vitamin D
3058463|NCT00864539|Placebo Comparator|Placebo|Subjects receiving daily placebo containing 1g starch
3058464|NCT00864682|Placebo Comparator|Placebo|Saline pretreatment, saline admixture
3058465|NCT00864682|Active Comparator|Lidocaine pretreatment|Lidocaine pretreatment / saline-propofol admixture
3058466|NCT00864682|Active Comparator|Lidocaine-Propofol admixture|saline pretreatment / Lidocaine-propofol admixture
3058467|NCT00864708|Experimental|Arm 1|radio frequency-controlled (RF) Microstimulator (RFM) Gait System
3058468|NCT00864721|Experimental|Sunitinib Malate|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
3058469|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, every other week|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every other week for 52 weeks.
3058470|NCT00864851|Active Comparator|Replagal 0.2 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.2 mg/kg via intravenous infusion every week for 52 weeks.
3058471|NCT00864851|Active Comparator|Replagal 0.4 mg/kg, IV, weekly|Patients randomized to receive Replagal 0.4 mg/kg via intravenous infusion every week for 52 weeks.
3058472|NCT00864916|Experimental|1|Participants will receive pentoxifylline and combination antiretroviral therapy (cART).
3058473|NCT00864916|Active Comparator|2|Participants will receive placebo and cART.
3058474|NCT00865020|Experimental|Aliskiren 300 mg|Aliskiren tablets starting at a dose of 150 mg taken orally daily for 2 weeks followed by a dose of 300 mg taken orally for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Aliskiren: 1 tablet for the first 2 weeks and 2 tablets during the one week withdrawal period.
3179115|NCT00669305||Cohort 1|Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental models
3058475|NCT00865020|Active Comparator|Telmisartan 80 mg|Telmisartan capsules starting at a dose of 40 mg taken orally daily for 2 weeks followed by a dose of 80 mg taken orally daily for 10 weeks and placebo (withdrawal) for one week. Participants took Placebo to Telmisartan: 1 capsule for the first 2 weeks and 2 capsules during the one week withdrawal period.
3058476|NCT00865046|Experimental|PST + PST boosters|PST once a week for 10 weeks, then tapering over 6 months
3058477|NCT00865046|Active Comparator|PST + control-PST boosters|PST once a week for 10 weeks, then control-PST tapering over 6 months
3058478|NCT00865046|Placebo Comparator|Control-PST|control-PST for 10 weeks
3058479|NCT00865098|Experimental|Cetuximab With Radiotherapy|
3058480|NCT00865124|Experimental|Spironolactone (mineralocorticoid receptor [MR] blockade)|
3058481|NCT00865124|Active Comparator|Hydrochlorothiazide + potassium|
3058482|NCT00865124|Placebo Comparator|Placebo capsule|
3058483|NCT00865189|Experimental|Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy)|In this arm, participants will undergo 3 phases of treatment. During the Phase 1, participants will receive induction chemotherapy with 6 two-week cycles of bevacizumab + Folfox-4 (5-FU + oxaliplatin + folinic acid) for 12 weeks followed by a treatment-free interval of 3 to 4 weeks. The Phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (intravenous [IV] infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The Phase 3 will be surgery involving a radical rectal excision using the total mesorectal excision (TME) technique.
3058484|NCT00865189|Experimental|Arm B (Bevacizumab, Chemoradiotherapy)|In this arm, participants will receive the Phase 2 and Phase 3 treatments only. The phase 2 will include 7 weeks of bevacizumab + chemoradiotherapy (IV infusion of bevacizumab alone, 2 weeks before administration of the first cycle of chemoradiotherapy, then 5 one-week cycles of chemoradiotherapy [5-FU + radiotherapy], with administration of bevacizumab every two weeks [Cycles 1, 3 and 5]) followed by a treatment-free interval of 6 to 8 weeks. The phase 3 will be surgery involving a radical rectal excision using the TME technique.
3058485|NCT00865202|Experimental|L-Tryptophan|L-tryptophan supplementation (1 gram enterally three times per day) starting post-operatively and continuing for a maximum of 9 doses or the time of discharge from ICU (whichever occurs first)
3058486|NCT00865202|Placebo Comparator|Placebo|Similar appearing placebo administered post-operatively (1 enterally three times per day) for a total of nine doses or discharge from ICU (whichever occurs first)
3058487|NCT00865280|Experimental|PTK 0796|PTK 0796 100 mg for injection; PTK 0796 tablet, 300 mg (2 x 150 mg tablets)
3058488|NCT00865280|Active Comparator|Linezolid|Gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; Gram negative treatment: moxifloxacin 400 mg tablet and moxifloxacin 400 mg IV infusion solution
3058489|NCT00865306|Experimental|Active CBT|"Seven parent-only and 8-13 child-only sessions focusing on CBT for anxiety disorders using the Being Brave protocol."
3058490|NCT00865306|No Intervention|No intervention (wait-list controls)|Control children received no intervention.
3058491|NCT00865566|Experimental|1|Participants will receive a recombinant DNA plasmid vaccine injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
3058492|NCT00865566|Placebo Comparator|2|Participants will receive a recombinant DNA plasmid vaccine placebo injection at study entry and on Days 28 and 56, followed by a recombinant adenoviral serotype vector vaccine placebo injection on Day 168. As of April 2013, all vaccinations in this study have been stopped.
3058493|NCT00865709|Experimental|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
3058494|NCT00865709|Placebo Comparator|Matching placebo + mFOLFOX6|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
3058495|NCT00865904|Placebo Comparator|Placebo|Placebo matched to VX-809 capsule orally once daily for 28 days.
3058496|NCT00865904|Experimental|VX-809, 25 mg|VX-809, 25 milligram (mg) capsule orally once daily for 28 days.
3058497|NCT00865904|Experimental|VX-809, 50 mg|VX-809, 50 mg capsule orally once daily for 28 days.
3058498|NCT00865904|Experimental|VX-809, 100 mg|VX-809, 100 mg capsule orally once daily for 28 days.
3058499|NCT00865904|Experimental|VX-809, 200 mg|VX-809, 200 mg capsule orally once daily for 28 days.
3058500|NCT00865969|Experimental|Belinostat|Belinostat 1000 mg/m^2 administered as a 30 minute IV infusion on Days 1-5 of every 3-week cycle until disease progression or unmanageable treatment-related toxicities.
3058501|NCT00866034|Experimental|CD2|Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.
3058502|NCT00866034|Experimental|CD6|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.
3058503|NCT00866047|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion
3058504|NCT00866177|Experimental|Arm I|Patients receive oral MEK inhibitor AZD6244 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3058505|NCT00866281|Experimental|30 mg/m^2 bid|Participants received bodyweight and body surface area (BSA) stratified dose of midostaurin 30 mg/m^2 twice daily (bid) through oral route. The total daily dose in 30 mg/m^2 bid cohort was 60 mg/m^2.
3058506|NCT00866281|Experimental|60 mg/m^2 bid|Participants received bodyweight and BSA stratified dose of midostaurin 60 mg/m^2 bid through oral route. The total daily dose in 60 mg/m^2 bid cohort was 120 mg/m^2.
3058507|NCT00866294|Experimental|paroxetine CR group|controlled-release (CR) of paroxetine 12.5 to 50mg/day
3058508|NCT00866294|Other|paroxetine IR group|Immediate-release (IR) of paroxetine 10 to 40mg/day as a reference arm
3058509|NCT00866294|Placebo Comparator|placebo group|matched placebo to both paroxetine CR and paroxetine IR
3058510|NCT00866307|Experimental|Arm I (HR-average)|See Detailed Description.
3058511|NCT00866307|Experimental|Arm II (HR-high)|See Detailed Description.
3058512|NCT00866320|Experimental|Sorafenib|Chemotherapy single agent systemic. Sorafenib given up to 600mg orally every 12 hours for up to 10 months (40 weeks).
3058513|NCT00866333|Experimental|Entinostat|"Regimen determined by protocol version.~Regimen 1: entinostat 10 mg (two 5 mg tablets) orally, once every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 2: entinostat 10 mg (two 5 mg tablets) orally on Day 1, increased to 15 mg (three 5 mg tablets) beginning on Day 15 of Cycle 1 for participants who had not experienced treatment-related adverse events with severity grade ≥2 (moderate), then continue 15 mg every two weeks (Days 1 and 15) in a 28-day cycle until disease progression or unacceptable toxicity.~Regimen 3: entinostat 15 mg (three 5 mg tablets), orally, once weekly for 3 weeks followed by a 1-week break in a 4-week (28-day) cycle until disease progression or unacceptable toxicity."
3058514|NCT00866359|Active Comparator|A. Apremilast|
3058515|NCT00866359|Placebo Comparator|B. Placebo Comparator|
3058516|NCT00866606|Experimental|Benefix|Subjects received on-demand treatments with BeneFIX over a 6-month (calendar day) period.
3058517|NCT00866619|Experimental|GSK257049 [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine, according to a 0-1-2 Month schedule, followed by either a booster dose of the same GSK257049 vaccine or a dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
3058518|NCT00866619|Experimental|GSK257049 [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of the GSK257049 malaria vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by either a booster dose of the GSK257049 and Polio Sabin vaccines or a booster dose of Menjugate and Polio Sabin vaccines, at Month 20. All vaccines have been administered intramuscularly in the interolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
3058519|NCT00866619|Active Comparator|VeroRab Comparator [5-17M] Group|Male or female children between and including 5 to 17 months of age [5-17M], who received a 3-dose primary vaccination course of the VeroRab vaccine, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate vaccine, at Month 20. Both vaccines have been administered intramuscularly into the left deltoid.
3058520|NCT00866619|Experimental|Menjugate Comparator [6-12W] Group|Male or female children between and including 6 to 12 weeks of age [6-12W], who received a 3-dose primary vaccination course of Menjugate vaccine co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, according to a 0-1-2 Month schedule, followed by a booster dose of Menjugate and Polio Sabin vaccines, at Month 12. All vaccines have been administered intramuscularly in the left thigh for children under 1 year and left deltoid for children above 1 year of age (Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine), except for the Polio Sabin vaccine, which has been given orally.
3058521|NCT00866658|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3058522|NCT00866658|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3058523|NCT00866697|Placebo Comparator|Placebo|matched placebo tablet administered orally once daily for up to 24 months
3058524|NCT00866697|Experimental|Pazopanib|Pazopanib tablet administered orally at 800 mg once daily for up to 24 months
3058525|NCT00866723|Experimental|bevacizumab|Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.
3058526|NCT00866749|Experimental|Augmented BFM Therapy|Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
3058527|NCT00866775|Experimental|Eslicarbazepine 1600 mg QD|"Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD (Day 0) to 1200 mg QD (Week 1) to 1600 mg QD (Weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
3058528|NCT00866775|Experimental|Eslicarbazepine 1200 mg QD|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day 0) to 800 mg QD (week 1) to 1200 mg QD (weeks 2-18)~Subjects may continue in an open-label extension study with a starting dose of 1600 mg QD, or taper off study drug at the completion of this study The treatment period for subjects entering the open label extension study is up to 9 study visits over 18 weeks. The treatment period for subjects not entering the open-label extension study is up to 10 study visits over 19 weeks."
3058529|NCT00866788|Experimental|Omalizumab 75 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.).
3058530|NCT00866788|Experimental|Omalizumab 300 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3058531|NCT00866788|Experimental|Omalizumab 600 mg|Omalizumab (Xolair) was administered subcutaneously on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria (CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3058532|NCT00866788|Placebo Comparator|Placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study. Participants remained on stable doses of their pre-allocation Chronic Idiopathic Urticaria CIU) H1 antihistamine treatment throughout the study, and were provided diphenhydramine as rescue medication for pruritus relief on an as-needed basis.
3179116|NCT00669344|Placebo Comparator|II|Placebo
3058533|NCT00866814||Ventrio Group|Patients diagnosed with a ventral hernia requiring an open surgery for repair.
3058534|NCT00866879|Active Comparator|Control|Group 1 will continue immunosuppression medication per standard of care (SOC) at Northwestern by taking mycophenolate mofetil and tacrolimus.
3058535|NCT00866879|Experimental|Transition to Sirolimus Group|Group 2 will switch immunosuppression medication to taking mycophenolate mofetil and sirolimus
3058536|NCT00866879|Other|Donors|Data and blood samples from the donors are collected in this study to contribute to the general knowledge to be used in assessing the two donor recipient groups, which are the target of this study.
3058537|NCT00866905|Experimental|Ixabepilone/Cyclophosphamide|Systemic Therapy followed by surgery and possible radiation therapy
3058538|NCT00866918|Experimental|Standard Risk (WBC < 10000/uL)|See Detailed Description
3058539|NCT00866918|Active Comparator|High Risk (WBC > 10000/uL)|See Detailed Description
3058540|NCT00867009|Experimental|Induction/maintenance Therapy|pemetrexed, cisplatin and cetuximab followed by pemetrexed and cetuximab
3058541|NCT00867035|Active Comparator|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions from investigator: twice a day a tongue scraper was used with 4 or more strokes, followed by 20ml of 0.12% chlorhexidine gluconate mouthwash used for 30 sec, for one week.
3058542|NCT00867035|Experimental|Chlorine dioxide and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.1% stabilized chlor8ine dioxide rinse for 30sec, for one week.
3058543|NCT00867087|Experimental|Rituximab 375 mg/m^2 + Inotuzumab Ozogamicin 1.8 mg/m^2|Inotuzumab ozogamicin, in combination with rituximab, will be administered to patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma prior to an autologous stem cell transplant (aSCT).
3058544|NCT00867100|Placebo Comparator|Placebo|Placebo treatment
3058545|NCT00867100|Experimental|140 mg SC|140 mg SC PsO
3058546|NCT00867100|Active Comparator|350 mg SC|350 mg SC PsO
3058547|NCT00867100|Experimental|700 mg IV|700 mg IV PsO
3058548|NCT00867113|Experimental|Imatinib|All subjects received in tablet form imatinib (STI571) 400 mg once daily.
3058549|NCT00867139|Experimental|TCAD-Randomized Arm|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
3058550|NCT00867139|Active Comparator|Neuraminidase Monotherapy Arm|Zanamivir or Oseltamivir
3058551|NCT00867139|Other|TCAD Open Label Arm|TCAD for subjects who cannot tolerate or are ineligible to receive zanamivir
3058552|NCT00867165|Experimental|Ezetimibe|Ezetimibe 10-mg tablet once daily for 12 weeks
3058553|NCT00867165|Placebo Comparator|Placebo|Placebo to match ezetimibe 10-mg tablet once daily for 12 weeks
3058554|NCT00867217|Experimental|High Dose Vitamin D|High Dose Vitamin D3 capsule (3 x 10,000 IU capsules weekly). All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
3058555|NCT00867217|Placebo Comparator|Placebo|Placebo matched for High Dose Vitamin D3 capsules. All subjects also received standard dose vitamin D3 (600 IU daily) and letrozole (2.5 mg daily).
3058556|NCT00867308|Experimental|Lenalidomide 15 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 15 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
3058557|NCT00867308|Experimental|Lenalidomide 50 mg|"Patients diagnosed with high risk Myelodysplastic syndrome (MDS), regardless of 5q deletion status, will receive lenalidomide 50 mg per day orally, on days 1-28 of a 42 day cycle for 2 cycles. At this point, patients meeting protocol specified response criteria will proceed to Continuing Therapy on a reduced dose of lenalidomide until progression.~Patients not achieving response will receive 2 additional cycles of treatment, whereupon response will again be assessed. Patients achieving response at this point will proceed to Continuing Therapy as described.~Patients without evidence of response after 4 cycles will be taken off-study."
3058558|NCT00867321|Experimental|Arm I (Phase II)|Patients receive oral sorafenib tosylate on days 1-28 twice daily and bevacizumab IV on days 1 and 15.
3058559|NCT00867321|Experimental|Arm II (Phase II)|Patients receive oral sorafenib tosylate twice daily on days 1-28.
3058560|NCT00867334|Experimental|Imatinib mesylate and panitumumab|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 1. Each participant assigned to Arm 1 will receive imatinib mesylate for 28 days, followed by a combination of imatinib mesylate and panitumumab.
3058561|NCT00867334|Active Comparator|Panitumumab (standard-of-care)|Subjects whose initial liver biopsy samples meet certain lab values will be placed in Arm 2. Participants in Arm 2 will receive standard-of-care treatment with panitumumab.
3058562|NCT00867360|Experimental|Mifepristone|Receive mifepristone for 8 days
3058563|NCT00867360|Placebo Comparator|Placebo|Receive placebo rather than mifepristone
3058564|NCT00867451|Experimental|Immediate Treatment|Children will receive behavioral sleep interventions and, if needed, melatonin, to improve sleep functions.
3058565|NCT00867451|Experimental|Delayed Treatment|Children will only receive sleep behavior interventions for the first four weeks of the trial. Treatment with study drug will be delayed to the 5th week.
3058566|NCT00867490|Experimental|Candesartan+HCTZ, aliskiren+HCTZ, aliskiren+HCTZ+amlodipine|
3058567|NCT00867503|Experimental|bendamustine|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
3058568|NCT00867529|Experimental|Treatment (rituximab pre- and post-transplant)|Patients receive rituximab IV, pre- and post-transplant, on days -3, 10, 24, and 38. Patients undergo donor peripheral blood stem cell transplant on day 0. Treatment continues in the absence of disease progression or unacceptable toxicity.
3058569|NCT00867568|Experimental|TPI 287|
3058570|NCT00867659|Experimental|Cetrotide acetate|oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.
3058571|NCT00867789|Experimental|Trimethoprim-sulfamethaxazole|Incision and drainage of the abscess and treatment with oral TMP-SMX (100 patients)
3058572|NCT00867789|Placebo Comparator|Sugar pill|Incision and drainage of the abscess and treatment with oral placebo (100 patients)
3058573|NCT00867815|Other|Arm 1|
3058574|NCT00867932|Experimental|Eculizumab|Eculizumab was administered as an IV infusion for 12 weeks. All participants weighed more than 45 kg and received the following weight-based dosing regimen: induction/loading = 600 milligram (mg) weekly x 4; maintenance = 900 mg at Week 5; 900 mg every 2 weeks.
3058575|NCT00868101|Experimental|Preconditioning|Children who received the preconditioning stimulus
3058576|NCT00868101|No Intervention|Control|Children who did not receive the preconditioning stimulus
3058577|NCT00868140|Experimental|1/Pioglitazone|Pioglitazone in pill form at 45mg twice per day for 6 months
3058578|NCT00868140|Placebo Comparator|2/Placebo|Placebo control to arm 1 in pill form identical to treatment form also twice per day for 6 months
3058579|NCT00868166|Experimental|Olesoxime|2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid
3058580|NCT00868166|Placebo Comparator|Placebo Comparator|2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
3058581|NCT00868192|Experimental|Pemetrexed and bevacizumab|"Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle~Bevacizumab 15 mg/kg IV on Day 1 of each 21 day cycle"
3058582|NCT00868218|Active Comparator|1|30µg HA vaccine Intramuscularly administered
3058583|NCT00868218|Active Comparator|2|1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3058584|NCT00868218|Active Comparator|3|7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3058585|NCT00868218|Active Comparator|4|30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
3058586|NCT00868231|Experimental|Aclidinium 400 μg bid|Aclidinium bromide 400 μg twice-daily by inhalation
3058587|NCT00868231|Active Comparator|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily by inhalation
3058588|NCT00868231|Placebo Comparator|Placebo|Placebo
3058589|NCT00868296|Active Comparator|Low dose|
3058590|NCT00868296|Active Comparator|High dose|
3058591|NCT00868309|Experimental|Anavip|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 30 minutes for Anavip
3058592|NCT00868309|Active Comparator|CroFab|The initial dose of study drug was administered in a total volume of 500 mL (initial doses only) IV over 60 minutes for CroFab, or as permitted by IV access.
3058593|NCT00868348|Placebo Comparator|Saline|
3058594|NCT00868348|Active Comparator|Ketorolac|
3058595|NCT00868374|Experimental|1|Quetiapine XR
3058596|NCT00868374|Placebo Comparator|2|
3058597|NCT00868439|Active Comparator|patiromer|
3058598|NCT00868439|Placebo Comparator|placebo|
3058599|NCT00868452|Experimental|Lurasidone|
3058600|NCT00868452|Placebo Comparator|Placebo|
3058601|NCT00868517|Experimental|True Group Auricular Acupuncture|Received true group auricular acupuncture twice weekly for a period of two months.
3058602|NCT00868517|Sham Comparator|Sham Group Auricular Acupuncture|Received sham group auricular acupuncture twice weekly for a period of two months.
3058603|NCT00868517|Other|Wait-List Control Group|Served as wait list control. Did not receive any acupuncture during the study period.
3058604|NCT00868530|Experimental|Xyntha|This trial was an open-label and included assessments of safety, clinical efficacy, and Factor VIII (FVIII) recovery in Chinese subjects with hemophilia A. Subjects received on-demand treatments with Xyntha over a 6-month (calendar day) period.
3058605|NCT00868608|Experimental|inotuzumab ozogamicin|inotuzumab ozogamicin
3058606|NCT00868699|Experimental|lurasidone low arm|
3058607|NCT00868699|Placebo Comparator|Placebo|
3058608|NCT00868699|Experimental|lurasidone high arm|
3058609|NCT00868712||1|Warfarin use < 6 months
3058610|NCT00868712||2|Warfarin use 6-24 months
3058611|NCT00868712||3|Warfarin use >24 months
3058612|NCT00868751|Experimental|Tocilizumab|Single arm study - treatment only
3058613|NCT00868790|Experimental|PLA→MK-3577 QD AM→MK-3577 QD PM→MK-3577 BID (Arm 1)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3058614|NCT00868790|Experimental|MK-3577 QD AM→PLA→MK-3577 BID→MK-3577 QD PM (Arm 2)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3058615|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 BID→PLA→MK-3577 QD AM (Arm 3)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed MK- 3577 25 mg BID for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
3058616|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD PM→MK-3577 QD AM→PLA (Arm 4)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3058617|NCT00868790|Experimental|PLA→MK-3577 BID→MK-3577 QD AM→MK-3577 QD PM (Arm 5)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
3058618|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 QD PM→PLA→MK-3577 BID (Arm 6)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4.
3058619|NCT00868790|Experimental|MK-3577 QD PM→MK-3577 QD AM→MK-3577 BID→PLA (Arm 7)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3058620|NCT00868790|Experimental|MK-3577 BID→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 8)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4.
3058621|NCT00868790|Experimental|PLA→MK-3577 QD PM→MK-3577 BID→MK-3577 QD AM (Arm 9)|Participants were to receive oral treatment with dose-matched placebo to MK-3577 for 4 weeks during Period 1, followed by MK-3577 6 mg QD PM for 4 weeks during Period 2, followed by MK-3577 25 mg BID for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3058622|NCT00868790|Experimental|MK-3577 QD AM→MK-3577 BID→MK-3577 QD PM→PLA (Arm 10)|Participants were to receive oral treatment with MK-3577 10 mg QD AM for 4 weeks during Period 1, followed by MK-3577 25 mg BID for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 4.
3058623|NCT00868790|Experimental|MK-3577 QD PM→PLA→MK-3577 QD AM→MK-3577 BID (Arm 11)|Participants were to receive oral treatment with MK-3577 6 mg QD PM for 4 weeks during Period 1, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 25 mg BID for 4 weeks during Period 4. Domiciled participants were also to receive placebo to metformin during Period 1 and Period 2.
3058624|NCT00868790|Experimental|MK-3577 BID→MK-3577 QD AM→PLA→MK-3577 QD PM (Arm 12)|Participants were to receive oral treatment with MK-3577 25 mg BID for 4 weeks during Period 1, followed by MK-3577 10 mg QD AM for 4 weeks during Period 2, followed by dose-matched placebo to MK-3577 for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4.
3058625|NCT00868790|Experimental|PLA→METF→MK-3577 QD AM→MK-3577 QD PM (Arm 13)|Domiciled participants were to receive oral treatment with dose-matched placebo to metformin (METF) for 4 weeks during Period 1, followed by metformin 1000 mg BID for 4 weeks during Period 2, followed by MK-3577 10 mg QD AM for 4 weeks during Period 3, followed by MK-3577 6 mg QD PM for 4 weeks during Period 4. Participants in this arm were administered metformin placebo during Period 1 and active metformin during Period 2.
3058626|NCT00868790|Experimental|METF→PLA→MK-3577 QD PM→MK-3577 QD AM (Arm 14)|Domiciled participants were to receive oral treatment with metformin 1000 mg BID for 4 weeks during Period 1, followed by dose-matched placebo to metformin for 4 weeks during Period 2, followed by MK-3577 6 mg QD PM for 4 weeks during Period 3, followed by MK-3577 10 mg QD AM for 4 weeks during Period 4. Participants in this arm were administered active metformin during Period 1 and metformin placebo during Period 2.
3058627|NCT00868959|Experimental|lurasidone|
3058628|NCT00869024|Experimental|Stem Cell therapy|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells in Patients with Severe LV Dysfunction and LVAD Support
3058629|NCT00869024|Placebo Comparator|Placebo|Intramyocardial Delivery Placebo solution into Patients with Severe LV Dysfunction and LVAD Support
3058630|NCT00869050|Experimental|Capecitabine and Temozolomide|Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg and Temozolomide 150-200 mg/m2/day (PO divided BID).
3058631|NCT00869089|Experimental|CC-10004|"CC-10004 treament:~30mg,oral medication, BID, for 24 weeks (60mg total DAILY)"
3058632|NCT00869128|Other|Placebo First|Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
3058633|NCT00869128|Other|Circadin first|Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.
3058634|NCT00869141|Experimental|Research arm (postop IOP>10)|Receive glaucoma medications if the eye pressure more than 10 mmHg after AHmed valve implantation
3058635|NCT00869141|Active Comparator|Standard of care arm (postop IOP>17)|Receive glaucoma medication if eye pressure more than 17 mmHg after Ahmed valve implantation
3058636|NCT00869167|Experimental|1: Ramelteon|
3058637|NCT00869167|Placebo Comparator|2: Placebo|
3058638|NCT00869206|Experimental|Arm I (zoledronic acid every 4 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3058639|NCT00869206|Experimental|Arm II (zoledronic acid every 12 weeks)|Patients receive zoledronic acid IV over at least 15 minutes every 12 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3058640|NCT00869323|Experimental|Treated Patients|This group includes patients receiving Bortezomib and Rituximab for post-transplant lymphoproliferative disorders (PTLD).
3058641|NCT00869349|Experimental|IFS Intervention Group|
3058642|NCT00869349|Active Comparator|Education Group|
3058643|NCT00869362|Experimental|Diabetes Management Team|Evaluation and management by diabetes management team
3058644|NCT00869362|No Intervention|Control|Patients receive usual care for diabetes
3058645|NCT00869375|Active Comparator|CLEARWAY GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous in situ thrombolysis (local thrombolytic plus low pressure balloon angioplasty) with Clearway balloon
3058646|NCT00869375|Active Comparator|ANGIOJET GROUP|Endovascular peripheral intervention - Percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy with AngioJet Rheolytic Thrombectomy System
3058647|NCT00869401|Experimental|Group 1 (Phase II) dasatinib + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only dasatinib post cycle 8 until progressive disease, unacceptable adverse events or refusal.
3058648|NCT00869401|Active Comparator|Group 2 (Phase II) placebo + radiation + temozolomide|Patients receive concomitant chemotherapy and radiation for cycle one for a total of 42 days, then patients receive adjuvant chemotherapy 28-42 days post cycle one treatment. Patients receive only placebo post cycle 8 until progressive disease, unacceptable adverse events or refusal.
3058649|NCT00869440|Experimental|1: Remimazolam (CNS 7056) 0.10 mg/kg|Remimazolam (CNS 7056) 0.10 mg/kg iv
3058650|NCT00869440|Experimental|2: Remimazolam (CNS 7056) 0.15 mg/kg|Remimazolam (CNS 7056) 0.15 mg/kg iv
3058651|NCT00869440|Experimental|3: Remimazolam (CNS 7056) 0.20 mg/kg|Remimazolam (CNS 7056) 0.20 mg/kg iv
3058652|NCT00869440|Experimental|4: Midazolam 0.075 mg/kg|Midazolam 0.075 mg/kg iv
3058653|NCT00869518|Active Comparator|Rifabutin|Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
3058654|NCT00869518|Placebo Comparator|Placebo|Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
3058655|NCT00869557|Experimental|Stribild|
3058656|NCT00869557|Active Comparator|Atripla|
3058657|NCT00869609|Active Comparator|GLB Traditional Maintenance (TM)|Group Lifestyle Balance (GLB) program Traditional Maintenance: After completion of the GLB 12 core sessions, participants who are randomly assigned to GLB program Traditional Maintenance (TM) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions.
3058658|NCT00869609|Active Comparator|GLB-Carb-focused Maintenance (CF)|Group Lifestyle Balance (GLB) program Carb-focused Maintenance: After completion of the GLB 12 core sessions, participants randomly assigned to GLB Carb-focused Maintenance (CF) will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information regarding healthy carbohydrate intake and hunger management.
3058659|NCT00869622|Active Comparator|Risedronate|Active drug
3058660|NCT00869622|Placebo Comparator|Placebo + Calcium and Vitamin D|All patients both on placebo and active bisphosphonate to receive calcium and vitamin D
3058661|NCT00869778|Experimental|εPA-44 900μg|Inject εPA-44 900μg at week 0, 4, 8, 12, 20, 28.
3058662|NCT00869778|Experimental|εPA-44 600μg+Placebo 300μg|Inject εPA-44 600μg+Placebo 300μg at week 0, 4, 8, 12, 20, 28.
3058663|NCT00869778|Placebo Comparator|Placebo 900μg|Inject Placebo 900μg at week 0, 4, 8, 12, 20, 28.
3058664|NCT00869791|Other|Sequence 1|"Treatment Period 1:~IPX066 - 7 days; Washout Period - 7 days;~Treatment Period 2:~IR CD-LD- 7 days"
3058665|NCT00869791|Other|Sequence 2|"Treatment Period 1:~IR CD-LD - 7 days; Washout period - 7 days;~Treatment Period 2:~IPX066- 7 days"
3058666|NCT00869947|Experimental|Prosthesis|Powered ankle-foot prosthesis and passive-elastic prosthesis
3058667|NCT00869947|Experimental|Non-amputee|Non-amputee
3058668|NCT00869960|Experimental|Antiretroviral therapy|Healthy volunteers received two doses of Tenofovir, Emtricitabine, Atazanavir and Ritonavir administered twice (on day 6 - 10 and day 20 - 25 after day of Follicular phase); with pharmacokinetic measurements at 6 - 10 days after menses and then again at day 20 - 25 after menses.
3058669|NCT00870103|Experimental|Vigadexa eye drops|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
3058670|NCT00870194|Experimental|1|
3058671|NCT00870194|Placebo Comparator|2|
3058672|NCT00870233||GYN pts undergoing surgery|This study will assess patient use of WEBCORE, an online system designed for cancer patients to self-record toxicity-related symptoms based on NCI Common Terminology Criteria for Adverse Events and global quality of life (QoL) by European Organization for Research and Treatment of Cancer (EORTC QLQ-C30).
3058673|NCT00870363|Active Comparator|1|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3058674|NCT00870363|Active Comparator|2|maraviroc PLUS raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3058675|NCT00870363|Active Comparator|3|efavirenz or other NNRTI (non-nucleoside reverse transcriptase inhibitor) in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
3058676|NCT00870363|No Intervention|4|HIV-negative
3058677|NCT00870467|Placebo Comparator|DB Placebo|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058678|NCT00870467|Experimental|DB adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058679|NCT00870467|Experimental|DB Adalimumab/OL Adalimumab|Participants received double-blind adalimumab administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants also received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058680|NCT00870467|Experimental|DB Placebo/OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) for 26 weeks followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058681|NCT00870467|Experimental|DB Adalimumab/RE OL Adalimumab|Participants received double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058682|NCT00870467|Experimental|DB Placebo/RE OL Adalimumab|Participants received double-blind placebo administered subcutaneously (SC) every other week (eow) and then open-label adalimumab 40 mg SC eow as rescue treatment (as eligible at Week 12 or after) to complete 26 weeks, followed by open-label adalimumab 40 mg SC eow for up to 26 weeks. Participants received concomitant methotrexate 6 to 8 mg administered orally weekly.
3058683|NCT00870545|Experimental|Telephone support|12 telephone support group sessions based on the letters of the word BATTLEMIND
3058684|NCT00870584|Experimental|Omalizumab|The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.
3058685|NCT00870584|Placebo Comparator|Placebo|Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.
3058686|NCT00870688||1|epilepsy patients
3058687|NCT00870727|Experimental|Arm 1. Aripiprazole oral product|Participants will receive Aripiprazole oral product with a minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
3058688|NCT00870727|Placebo Comparator|Arm 2. Placebo oral capsule|Participants will receive matching (identical in size and appearance to study drug) placebo oral capsules over 8-weeks of treatment.
3058689|NCT00870740|Experimental|Group 1: DAC HYP 150 mg|Participants who received placebo in 205MS201 receive DAC HYP 150 mg subcutaneous (SC) injection every 4 weeks for a total of 13 doses.
3058690|NCT00870740|Experimental|Group 1: DAC HYP 300 mg|Participants who received placebo in 205MS201 receive DAC HYP 300 mg SC injection every 4 weeks for a total of 13 doses.
3058691|NCT00870740|Experimental|Group 2: Washout then DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 150 mg SC every 4 weeks for a total of 8 doses.
3058692|NCT00870740|Experimental|Group 2: DAC HYP 150 mg|Participants who received DAC HYP 150 mg SC injection in 205MS201 receive DAC HYP 150 mg SC every 4 weeks for a total of 13 doses.
3058693|NCT00870740|Experimental|Group 3: Washout then DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 undergo a washout period (placebo SC every 4 weeks for a total of 5 doses) and then receive DAC HYP 300 mg SC every 4 weeks for a total of 8 doses.
3058694|NCT00870740|Experimental|Group 3: DAC HYP 300 mg|Participants who received DAC HYP 300 mg SC in 205MS201 receive DAC HYP 300 mg SC every 4 weeks for a total of 13 doses.
3058695|NCT00870870|Experimental|GCiC + IMC-A12 (Gemcitabine/Cisplatin/Cetuximab + Cixutumumab)|"Cycles repeat every 3 weeks for first 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. Gemcitabine/Carboplatin/Cetuximab (GCC) plus cixutumumab will change to Gemcitabine/Cisplatin/Cetuximab (GCiC) plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
3058696|NCT00870870|Active Comparator|GCiC (Gemcitabine/Cisplatin/Cetuximab)|"Cycles repeat every 3 weeks for 6 cycles (18 weeks) and then once every 2 weeks (maintenance therapy) until disease progression, intolerable toxicity, withdrawal of consent or other withdrawal criteria met~*Cisplatin will replace Carboplatin. GCC plus cixutumumab will change to GCiC plus cixutumumab (participants enrolled subsequent to this change will receive gemcitabine, cisplatin and cetuximab, plus cixutumumab)"
3058697|NCT00870896|Experimental|Tiotropium|Cough reflex measured by capsaicin Inhalation Challenge will follow Dicpinigaitis performed at 1 and 3 months. Solutions prepared to make a stock solution of 0.01 Mol diluted with physiologic saline to yield 11 doubling concentrations from 0.98 to 1,000 uMol/L. Final diluted capsaicin concentrations are: 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, and 1000 uMol/L. Then, place 1 ml of the first concentration into nebulizer. Subjects inhale single breath of capsaicin aerosol. Single breaths are delivered in ascending order, with normal saline randomly interspersed to increase blindness, until two or more coughs (C2) and five or more coughs (C5) are reached. The different concentrations are delivered at 2 minute intervals.
3058698|NCT00871000|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Boostrix Polio™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Boostrix Polio™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
3058699|NCT00871000|Active Comparator|TETRAVAC GROUP|Healthy male or female children, between and including 5 to 6 years of age, who were primed with three doses of Infanrix™ vaccine according to the Italian 3-5-11 month vaccination schedule, additionally received a single booster dose of Tetravac™ vaccine co-administered with a single dose of Priorix Tetra™ vaccine at Day 0. Tetravac™ vaccine was administered intramuscularly in the deltoid region of the left upper arm, while the Priorix Tetra™ vaccine was administered subcutaneously in the deltoid region of the right upper arm.
3058700|NCT00871117|Experimental|Kinrix + M-M-R II + Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II and Varivax each, subcutaneously in the deltoid of the right upper and lower arm, respectively.
3058701|NCT00871117|Active Comparator|Kinrix + M-M-R II -> Varivax|Subjects received at Day 0 one dose of Kinrix, intramuscularly in the deltoid region of the left upper arm, co-administered with one dose of M-M-R II, subcutaneously in the deltoid of the right upper arm. At Day 30 they received one dose of Varivax subcutaneously in the deltoid region of the right upper arm.
3058702|NCT00871143|Experimental|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
3058703|NCT00871143|Active Comparator|Non Specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
3058704|NCT00871169|Experimental|Irinotecan, oxaliplatin, and cetuximab|The goal is to administer at least 4 cycles to each patient, but treatment may stop earlier if the treating physician deems stopping to be in the best interest of the patient. Repeated treatment may be given to patients who benefit (either complete or partial response or stabilization of disease)
3058705|NCT00871260|Other|Open Label|Approximately 25 healthy volunteers will be recruited as controls. Scan will be done with regadenoson contrast.
3058706|NCT00871286|Experimental|CT scan (sinus) pre-tx|Sinus CT scan performed at initial otolaryngology (ear, nose, and throat)visit
3058707|NCT00871286|Other|CT scan (sinus) post-tx|Sinus CT scan performed after 3-4 weeks of antibiotic treatment and any other indicated medical treatment(s), per insurance company guidelines
3058708|NCT00871338|Experimental|GSK2197870A Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2197870A vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2 and a booster dose of Menitorix™ vaccine at Month 10. All vaccines were administered intramuscularly. GSK2197870A and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh.
3058709|NCT00871338|Active Comparator|Pediacel Group|Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
3058710|NCT00871351|Experimental|Ezetimibe + Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3058711|NCT00871351|Active Comparator|Atorvastatin|Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3058712|NCT00871351|Active Comparator|Rosuvastatin|Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
3058713|NCT00871377|Placebo Comparator|Placebo|Corn Oil Placebo (n-6 fatty acids)
3058714|NCT00871377|Experimental|High Dose Fish Oil|2160 mg of EPA + DHA
3058715|NCT00871377|Experimental|Low Dose Fish Oil|1060 mg of EPA + DHA
3058716|NCT00871403|Experimental|Arm 1|Investigational treatment (pazopanib and pemetrexed)
3058717|NCT00871403|Active Comparator|Arm 2|Standard treatment (pemetrexed and cisplatin)
3058718|NCT00871494|Experimental|Azithromycin switch therapy (switch from intravenous to oral).|
3058719|NCT00871572|Placebo Comparator|Placebo|
3058720|NCT00871572|Experimental|LY2409021 10 milligrams (mg)|
3058721|NCT00871572|Experimental|LY2409021 30 mg|
3058722|NCT00871572|Experimental|LY2409021 60 mg|
3058723|NCT00871624|Active Comparator|Dexmedetomidine|Subjects received active dexmedetomidine 0.2 -0.7 mcg/kg/hr
3058724|NCT00871624|Placebo Comparator|Placebo|Subjects received placebo saline solution 0.2-0.7 mcg/kg/hr
3058725|NCT00871689|Experimental|UCBT With Post-Transplant IL-2|Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
3058726|NCT00871715|Experimental|ASAP|A focused, intense, evidence-based, upper extremity rehabilitation program, administered during the early post-acute outpatient interval. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence.
3058727|NCT00871715|Active Comparator|DEUCC|Dose-equivalent usual and customary arm therapy administered early post-acutely in the outpatient setting. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
3058728|NCT00871715|Other|UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group with treatment dose administered in accordance with usual and customary practices.
3058729|NCT00871728|Experimental|Itraconazole|
3058730|NCT00871741|Experimental|GSK2202083A GROUP|Subjects in this group were to receive three doses of GSK2202083A vaccine at 3, 5 and 11 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
3058731|NCT00871741|Active Comparator|INFANRIX + MENJUGATE GROUP|Subjects in this group were to receive three doses of Infanrix™ hexa vaccine at 3, 5 and 11 months of age, and two doses of Menjugate® vaccine at 3 and 5 months of age, as an intramuscular injection in the anterolateral quadrant of the right thigh.
3058732|NCT00871780|Experimental|Natalizumab|natalizumab 300 mg IV every 4 weeks for 48 weeks
3058733|NCT00871819|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
3058734|NCT00871845|No Intervention|LEAN (non obese, naive)|Patients naive to hepatitis C therapy with body mass index (BMI) <25
3058735|NCT00871845|Other|OVERWEIGHT (obese, naive, control)|Patients naive to hepatitis C therapy with BMI ≥ 25, received Dietary and Lifestyle modification educational sessions (one-time 15 minute weight loss instruction and pamphlet and enrolled into weight management program with 5 weekly one-hour nutrition and physical exercise education sessions after initial evaluation followed by monthly follow up.)
3058736|NCT00871858|Active Comparator|Arm A (ANA)|Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.
3058737|NCT00871858|Experimental|Arm B (FULV)|Patients receive fulvestrant intramuscularly ( 250 mg/5 ml solution) on days 1, 14, and 28 and then once a month thereafter until 6 months.
3058738|NCT00871871|Experimental|Part I, Placebo-HCTZ|Placebo in Period 1 followed by HCTZ in Period 2
3058739|NCT00871871|Experimental|Part I, HCTZ-Placebo|HCTZ in Period 1, followed by placebo in Period 2
3058740|NCT00871871|Experimental|Part II, Placebo-ISMN|Placebo in Period 1, followed by ISMN in Period 2
3058741|NCT00871871|Experimental|Part II, ISMN-Placebo|ISMN in Period 1, followed by placebo in Period 2
3058742|NCT00871923|Experimental|Tarceva + RT|Tarceva (Erlotinib hydrochloride) + Radiation Therapy. Tarceva 150 mg by mouth every day beginning Day 1. Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
3058743|NCT00871975|Experimental|Urodynamics + Tetra|All patients were recruited to the same arm and receive Urodynamics testing as part of the routine diagnostic work-up, plus the Tetra-NIRS intervention.
3058744|NCT00872001|Active Comparator|Acadesine|Acadesine intravenous (IV) infusion, plus cardioplegia solution with acadesine, and priming solution with acadesine in the heart lung machine during cardiopulmonary bypass (CPB)
3179117|NCT00669344|Experimental|I|Rivastigmine
3058745|NCT00872001|Placebo Comparator|Placebo|Normal saline, IV infusion, plus cardioplegia solution with added normal saline, and priming solution with added normal saline in the heart lung machine during CPB
3058746|NCT00872027|Experimental|1|Participants will receive 8 weeks of escitalopram treatment.
3058747|NCT00872027|Placebo Comparator|2|Participants will receive 8 weeks of placebo pills.
3058748|NCT00872079|Active Comparator|Genomics|"Aim 1: Collect historical data on warfarin dosing in subjects at the VA. Aim 2: Collect genotype information on up to 300 subjects receiving warfarin anticoagulation.~Aim 3: Develop a computer model incorporating the information from Aim 1 and 2. Aim 4: Conduct randomized clinical trial."
3058749|NCT00872170|Active Comparator|Intervention|Participants with thalassemia who have pulmonary hypertension will receive sildenafil for 12 weeks.
3058750|NCT00872170|No Intervention|Control|Participants with thalassemia who do not have pulmonary hypertension will be part of a control group and will only be undergoing screening/baseline assessments.
3058751|NCT00872339||transfusion-dependant|People with transfusion-dependant thalassemia who received at least 8 transfusions in the past year.
3058752|NCT00872339||non-transfusion-dependant|People with non-transfusion-dependant thalassemia who received no transfusions in the past year.
3058753|NCT00872339||intermittently transfused|Intermittently transfused patients- individuals who received at least one but fewer than eight transfusions in the last year
3058754|NCT00872430|Active Comparator|Placebo/Laxative tea crossover|This arm received placebo in the first period and laxative tea in the second period (after washout period of 9 days).
3058755|NCT00872430|Active Comparator|Laxative tea/Placebo crossover|This arm received laxative tea in the first intervention period and placebo in the second intervention period (after washout period of 9 days).
3058756|NCT00872521|Experimental|bortezomib; doxorubicin; dexamethasone|PAD induction Open Label Treatment: Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1 4 8 & 11) Doxorubicin 20 mg/m2 i.v. (D1 & 4) Dexamethasone 20 mg p.o. (D1 2 4 5 8 9 11 & 12)
3058757|NCT00872534|Experimental|PL-2200|PL-2200 is an NSAID product containing 325mg of acetylsalicylic acid and phosphatidylcholine in a neutral lipid matrix.
3058758|NCT00872534|Active Comparator|Aspirin|Immediate release 325mg aspirin
3058759|NCT00872599|Placebo Comparator|Placebo, then fenofibrate|Randomized study of fenofibrate versus placebo during high salt diet
3058760|NCT00872599|Placebo Comparator|Fenofibrate, then placebo|Randomized study of fenofibrate versus placebo during high salt intake.
3058761|NCT00872729|Active Comparator|Cystagon®|Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
3058762|NCT00872729|Experimental|RP103|Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
3058763|NCT00872833||age 18-29|People age groups 18-29 with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
3058764|NCT00872833||age 30+|People age groups 30+ years with transfusion-dependent thalassemia who have reported at least mild degrees of pain during the main Assessment of Pain study.
3058765|NCT00872898|Experimental|1|Once daily oral administration of memantine for 12 weeks.
3058766|NCT00872898|Placebo Comparator|2|Once daily oral administration of placebo for 12 weeks.
3058767|NCT00872989|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who progress also receive oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of a second disease progression or unacceptable toxicity.
3058768|NCT00872989|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and oral vandetanib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3058769|NCT00873015|Experimental|Nitrite|Continuous intravenous infusion of Sodium Nitrite
3058770|NCT00873015|Placebo Comparator|Vehicle control|Continuous intravenous infusion of saline
3058771|NCT00873041|Experimental|5 mg/kg/day deferasirox|Participants received a starting dose of 5 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3058772|NCT00873041|Experimental|10 mg/kg/day deferasirox|Participants received a starting dose of 10 mg/kg/day deferasirox tablets orally each day in the morning for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3058773|NCT00873041|Placebo Comparator|5 mg/kg/day placebo|Placebo tablet matching 5 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3058774|NCT00873041|Placebo Comparator|10 mg/kg/day placebo|Placebo tablet matching 10 mg/kg/day orally in the morning each day for 52 weeks. After 24 weeks of treatment Liver Iron Concentration (LIC) was assessed. Based on the LIC and change from baseline in LIC participants were eligible for dose escalation. In the Extension Study participants received deferasirox once daily (dose based on LIC) for 52 weeks.
3058775|NCT00873093|Experimental|Pre-B ALL Relapse<18 mths from diagnosis (chemo) age<=21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3058776|NCT00873093|Experimental|Pre-B ALL Relapse 18-36 mths from diagnosis (chemo) age<=21 yr|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3058777|NCT00873093|Experimental|Pre-B ALL Relapse<36 mths from diagnosis (chemo) age>21 yrs|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3179118|NCT00669435|Active Comparator|1|Amlodipine and Simvastatin
3058778|NCT00873093|Experimental|T-cell ALL (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3058779|NCT00873093|Experimental|T-cell Lymphoblastic Lymphoma (LL) (Chemotherapy)|Re-Induction Block 1 patients receive vincristine sulfate, Prednisone, pegaspargase, Doxorubicin hydrochloride. Re-Induction Block 2 patients receive Cyclophosphamide, Etoposide phosphate, and Methotrexate. Re-Induction Block 3 patients receive Cytarabine.
3058780|NCT00873119|Experimental|Arm A - BelCaP|Group A: belinostat 1000 mg/m² administered as a 30 minute IV infusion once daily on days 1, 2 and 3, with at least 18 hours between infusions, followed by belinostat 2000 mg administered orally once daily on days 4 and 5, every 3-weeks, in combination with paclitaxel 175 mg/m² administered as an IV infusion following the infusion of belinostat on cycle day 3, and carboplatin (AUC 6) administered as a 30-60 minute IV infusion directly after the paclitaxel administration on cycle day 3.
3058781|NCT00873119|Active Comparator|Arm B - CaP|Group B: paclitaxel 175 mg/m² administered as an IV infusion directly followed by carboplatin (AUC 6) administered as a 30-60 minute IV infusion on cycle day 1 of a 3-weekly cycle.
3058782|NCT00873327|Active Comparator|1|Open label -- 6 interval doses
3058783|NCT00873457|Experimental|Perifosine|Perifosine 50 mg twice a day for a total of six 28-day cycles.
3058784|NCT00873730|Experimental|1|
3058785|NCT00873730|Active Comparator|2|
3058786|NCT00873782|Experimental|1|Participants will undergo retrograde high pressure transvenous limb perfusion with normal saline.
3058787|NCT00873821|Experimental|1|MK-0941
3058788|NCT00873821|Placebo Comparator|2|Placebo Comparator
3058789|NCT00873860|Placebo Comparator|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3058790|NCT00873860|Experimental|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3058791|NCT00873860|Experimental|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3058792|NCT00873860|Experimental|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
3058793|NCT00873873||Persistent obstruction|(pattern of asthma progression)
3058794|NCT00873873||Late obstruction|(pattern of asthma progression)
3058795|NCT00873873||Late normal|(pattern of asthma progression)
3058796|NCT00873873||Persistent normal|(pattern of asthma progression)
3058797|NCT00873912|Experimental|Monovalent influenza virus vaccine|Frozen monovalent vaccine containing new strain
3058798|NCT00873912|Placebo Comparator|Placebo|Placebo
3058799|NCT00874029|Experimental|Halt Procedure|In this single-arm study, subjects who have symptomatic uterine fibroids will have the Halt Procedure in which intra-abdominal ultrasound will guide RF ablation of uterine fibroids using the Halt System.
3058800|NCT00874094|Active Comparator|platelet rich fibrin matrix|Both nasolabial folds treated with 0-2 cc of autologous platelet rich fibrin matrix,sufficient to efface nasolabial fold
3058801|NCT00874120|Experimental|Phenylephrine HCl Extended-Release tablets 30 mg|Phenylephrine HCl Extended Release tablets 30 mg
3058802|NCT00874120|Placebo Comparator|Placebo|Placebo
3058803|NCT00874237|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058804|NCT00874237|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058805|NCT00874237|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058806|NCT00874237|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058807|NCT00874237|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058808|NCT00874237|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg
3058809|NCT00874250|Experimental|GORE CTAG Device|The primary endpoint of this study is freedom from a Major Device Event (MDE) through 1 month post-treatment in subjects treated with the GORE® Conformable TAG® Thoracic Endoprosthesis.
3058810|NCT00874276|Experimental|No EGT Allele, slow metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
3058811|NCT00874276|Experimental|1+ EGT Allele, fast metabolizers for DCA|Individuals were genotyped at the beginning of the study and their haplotypes were defined. Dichloroacetate 2.5.ug/kg (non-clinical dose) will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
3058812|NCT00874432|Active Comparator|Chronic Kidney Disease-ACE-I|ace inhibitor
3058813|NCT00874432|Placebo Comparator|Chronic Kidney Disease|
3058814|NCT00874432|Active Comparator|Age matched control-ACE-I|ace-inhibitor
3058815|NCT00874432|Placebo Comparator|Age matched control|Placebo
3058816|NCT00874497|Experimental|1 Tetomilast|
3058817|NCT00874497|Placebo Comparator|2 Placebo|
3058818|NCT00874510|No Intervention|Standard Schedule|interns work standard schedule, being on duty for 30 continuous hours
3058819|NCT00874510|Experimental|Mandatory Naps|interns on overnight extended duty shifts have mandatory sign out of cell phones and cross-coverage responsibilities for 5 hours roughly between 12 and 5 am. For Year 2, this will be two 3 hour shifts, the first between 12am-3am and the 2nd between 3am-6am.
3058820|NCT00874549|Active Comparator|Group 1: Menomune Day 0|Participants received a single dose of Menomune® vaccine on Day 0.
3058821|NCT00874549|Experimental|Group 2: Menactra® Day 0 x 2|Participants received two single-dose injections of Menactra® vaccine on Day 0
3058822|NCT00874549|Experimental|Group 3: Menactra® Day 0 and 14|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14
3058823|NCT00874549|Experimental|Group 4: Menactra® Day 0 and 28|Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28.
3058824|NCT00874614|Experimental|Ultratrace® Iobenguane I 131 Treatment|
3058825|NCT00874731|Experimental|Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg|[Pt 1, Day 1]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. [Pt 1, Day 2]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. [Pt 2]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.
3058826|NCT00874770|Experimental|Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A)|Active Comparator
3058827|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (B)|Active Comparator
3058828|NCT00874770|Experimental|Daclatasvir, Peginterferon alpha-2a, ribavirin (C)|Active Comparator
3058829|NCT00874770|Active Comparator|Placebo, Peginterferon alpha-2a, ribavirin (D)|
3058830|NCT00874822||Berlin|Patients diagnosed with obstructive sleep apnea by polysomnography after being screened with the Berlin questionnaire.
3058831|NCT00874848|Experimental|Imprime PGG|Imprime PGG Injection + Cetuximab + Paclitaxel/Carboplatin
3058832|NCT00874848|Active Comparator|Control|Cetuximab + Paclitaxel/Carboplatin
3058833|NCT00874887|Active Comparator|Vigamox®|moxifloxacin 0.5% (m mg/mL), boric acid, sodium chloride, and purified water
3058834|NCT00874887|Active Comparator|Zymar®|gatifloxacin 0.3% (3 mg/mL), benzalkonium chloride 0.005%, edetate disodium; purified water and sodium chloride
3058835|NCT00875017|Experimental|Meal + Lanthanum|
3058836|NCT00875017|Active Comparator|Meal + Sevelamer|
3058837|NCT00875017|No Intervention|Meal Only|
3058838|NCT00875017|No Intervention|Fasting|
3058839|NCT00875056|Experimental|Follicular Lymphoma (FL)|Participants with relapsed/refractory FL received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
3058840|NCT00875056|Experimental|Indolent non-FL B-NHL or MCL|Participants with indolent non-follicular lymphoma (FL) B-cell non-Hodgkin's lymphoma (B-NHL), or with mantle cell Lymphoma (MCL) received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol.
3058841|NCT00875056|Experimental|Other Disease|Participants with disease other than relapsed/refractory follicular lymphoma (FL), non-FL B-cell non-Hodgkin's lymphoma (B-NHL), or mantle cell Lymphoma (MCL), as assessed by the Independent Central Pathological Committee, received 200 mg of vorinostat (MK-0683) twice daily (200 mg x 2/day) for 14 consecutive days followed by 1 week (7 days) rest in a 21-day cycle, until they met the per-participant discontinuation criteria specified by the protocol. This group was created to include participants who enrolled, but whose later diagnoses by the Independent Central Pathological Committee excluded them from analysis in the FL and non-FL B-NHL/MCL groups because they had different disease than those prespecified in the protocol.
3058842|NCT00875212|Experimental|dentifrice intervention|4 types of dentifrices were used in 4 different periods in a crossover study design.
3058843|NCT00875277|Experimental|LEO 29102 cream|LEO 29102 2.5 mg/g cream applied topically twice daily for 4 weeks
3058844|NCT00875277|Placebo Comparator|LEO 29102 Cream Vehicle|LEO 29102 cream vehicle applied topically twice daily for 4 weeks.
3058845|NCT00875277|Experimental|Betamethasone Dipropionate Cream|Betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
3058846|NCT00875277|Experimental|LEO 29102 Plus Calcipotriol Cream|LEO 29102 2.5 mg/g plus calcipotriol 50mcg/g cream applied topically twice daily for 4 weeks.
3058847|NCT00875277|Experimental|LEO 29102 Plus Betamethasone Dipropionate|LEO 29102 2.5 mg/g plus betamethasone 0.5 mg/g (as dipropionate) cream applied topically twice daily for 4 weeks.
3058848|NCT00875277|Active Comparator|Daivobet® Ointment|Daivobet® ointment, combination of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) applied topically twice daily for 4 weeks.
3058849|NCT00875329||Group 1|A convenience sample of 97VHA patients who served during the OEF or OIF era, who are targeted in CPRS as requiring the TBI Clinical reminder will be included. This includes all ages, both sexes, and all races and ethnicities.
3058850|NCT00875342|Experimental|D-cycloserine|100 mg on days of therapy session
3058851|NCT00875342|Placebo Comparator|Placebo|Sugar pill
3058852|NCT00875420|Experimental|RAD1901 10 mg|Oral once a day for 28 days
3058853|NCT00875420|Experimental|RAD1901 25 mg|Oral once a day for 28 days
3058854|NCT00875420|Experimental|RAD1901 50 mg|Oral once a day for 28 days
3058855|NCT00875420|Experimental|RAD1901 100 mg|Oral once a day for 28 days
3058856|NCT00875420|Placebo Comparator|Placebo|Oral once a day for 28 days
3058857|NCT00875433|Experimental|Monotherapy|BIBW 2992 high dose, once daily, continuous, monotherapy
3058858|NCT00875485|Experimental|Twinrix Adult Group|Subjects received 2 doses of Twinrix™ Adult intramuscularly according to a 0, 6 month schedule in the primary study
3058859|NCT00875485|Experimental|Twinrix Junior Group|Subjects received 3 doses of Twinrix™ Junior (= half dose Twinrix™ Adult) intramuscularly according to a 0, 1, 6 month schedule in the primary study
3058860|NCT00875524|Experimental|CYD Dengue Vaccine Group|Participants who received CYD dengue vaccine as first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections. Participants were followed for 4 years after the third injection.
3058861|NCT00875524|Sham Comparator|Control Vaccine Group|Participants who received the Meningococcal Polysaccharide Vaccine A + C, placebo, and Typhoid Vi polysaccharide vaccine as the first (Day 0), second (Day 0 + 6 months), and third (Day 0 + 12 months) injections, respectively. Participants were followed for 4 years after the third injection.
3058862|NCT00875550|Active Comparator|Dexmedetomidine Low Dose|
3058863|NCT00875550|Active Comparator|Dexmedetomidine High dose|
3058864|NCT00875563|Experimental|1|Zenith(R) Fenestrated AAA Endovascular Graft
3058865|NCT00875589||Control|Control subjects with no Mild Traumatic Brain Injury (MTBI) and no Post-Traumatic Stress Disorder (PTSD)
3058866|NCT00875589||MTBI|Subject with a diagnosis for Mild Traumatic Brain Injury (MTBI)
3058867|NCT00875615|Experimental|Cisplatin or Carboplatin + Sorafenib|
3058868|NCT00875641||HRV cohort|HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).
3058869|NCT00875641||Concurrent Control cohort|Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).
3058870|NCT00875641||Recent Historical Control cohort|Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.
3058871|NCT00875667|Experimental|Lenalidomide|Lenalidomide
3058872|NCT00875667|Active Comparator|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, Fludarabine
3058873|NCT00875706|Other|Training Feasibility|"4 sites will receive the training intervention to determine the feasibility of the train-the trainer approach.~The educational intervention is included in this arm."
3058874|NCT00875706|Other|Data Collection - Survey|Survey data collection tools will be piloted to assess feasibility of survey administration and development of the survey for future studies. This tools were piloted in sites where the educational intervention was administered.
3058875|NCT00875706|Other|Data Collection - Interview|Interview data collection tools will be piloted to assess feasibility of interview administration and development of the interview protocol for future studies. This tools were piloted in sites where the educational intervention was administered.
3058876|NCT00875797|Active Comparator|parentral glutamine|parenteral glutamine given in central venous line in dose up to 30 g par day
3058877|NCT00875797|Experimental|entral glutamine|enteral glutamine given through gastric tube in a dose up to 30 g per day
3058878|NCT00875836|Experimental|Buspirone|Buspirone
3058879|NCT00875836|Placebo Comparator|Placebo|Placebo
3058880|NCT00875979|Experimental|Trastuzumab emtansine 3.0 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.0 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
3058881|NCT00875979|Experimental|Trastuzumab emtansine 3.6 mg/kg + pertuzumab 420 mg|Patients received trastuzumab emtansine 3.6 mg/kg intravenously (IV) on Day 1 of every 3 week cycle until progressive disease, intolerable toxicity, initiation of another anti-cancer therapy, or patient discontinuation. Patients also received a loading dose of 840 mg of pertuzumab IV on Day 1 of Cycle 1 followed by pertuzumab 420 mg IV on Day 1 of every subsequent 3 week cycle.
3058882|NCT00876018|No Intervention|No intervention|No intervention
3058883|NCT00876018|Experimental|Nutritional supplement|Fortified nutritional powder
3058884|NCT00876018|Placebo Comparator|Placebo|Un-fortified nutritional powder
3058885|NCT00876187|Experimental|Tanezumab 20 mg IV|
3058886|NCT00876187|Experimental|Tanezumab 10 mg IV|
3058887|NCT00876187|Experimental|Tanezumab 5 mg IV|
3058888|NCT00876187|Active Comparator|Naproxen|
3058889|NCT00876187|Placebo Comparator|Placebo|
3058890|NCT00876200|Experimental|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
3058891|NCT00876200|Placebo Comparator|Placebo|Placebo = lactose
3058892|NCT00876265|Experimental|Belotero|
3058893|NCT00876265|Active Comparator|Zyplast|
3058894|NCT00876343|Experimental|1|Fixed dose
3058895|NCT00876343|Experimental|2|Titration dose
3058896|NCT00876343|Placebo Comparator|3|Placebo
3058897|NCT00876395|Experimental|Everolimus + Paclitaxel + Trastuzumab|Everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
3058898|NCT00876395|Placebo Comparator|Placebo + Paclitaxel + Trastuzumab|Placebo of everolimus 10 mg daily in combination with paclitaxel 80mg/m2 weekly on days 1, 8, 15 and trastuzumab 2mg/kg weekly on days 1, 8, 15, 22
3058899|NCT00876447|Experimental|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
3058900|NCT00876447|Experimental|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
3058901|NCT00876460|Experimental|BIBF 1120 + docetaxel|Low, medium and high dose of BIBF 1120 and 60 mg/m2, 75 mg/m2 docetaxel every 3 weeks
3058902|NCT00876694|Experimental|Indacaterol 300 µg|Indacaterol 300 μg once a day (o.d.) delivered via single dose dry powder inhaler (SDDPI). Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
3058903|NCT00876694|Active Comparator|Salmeterol 50 µg|Salmeterol 50 μg twice a day (b.i.d.) delivered via Diskus®. Daily ICS monotherapy, if needed, was allowed to remain stable throughout study. Salbutamol was available for rescue use throughout study.
3058904|NCT00876733||HIV treatment|
3058905|NCT00876915|Experimental|High Risk for VTE recieving dalteparin|Patients assigned at random to receive prophylactic dalteparin injections
3058906|NCT00876915|No Intervention|High Risk for VTE No therapy|No prophylactic therapy for VTE prevention given (Subjects receiving standard of care)
3058907|NCT00876915|No Intervention|Low Risk for VTE|Used as a control for the secondary outcome of evaluating tissue factor in collected blood samples
3058908|NCT00876928|Placebo Comparator|Placebo|Subjects with low vitamin D levels and pre-diabetes
3058909|NCT00876928|Experimental|vitamin D|Subjects with low vitamin D levels and pre-diabetes
3058910|NCT00876993|Experimental|Dose Level 0|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 75 mg/m^2 PO
3058911|NCT00876993|Experimental|Dose Level 1|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 125 mg/m^2 PO
3058912|NCT00876993|Experimental|Dose Level 2|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 175 mg/m^2 PO
3058913|NCT00876993|Experimental|Dose Level 3|Bevacizmuab 10 mg/kg IV Irinotecan 125 mg/m^2 IV Temozolomide 200 mg/m^2 PO
3058914|NCT00876993|Experimental|Dose Level 4|Bevacizmuab 10 mg/kg IV Irinotecan 150 mg/m^2 IV Temozolomide 200 mg/m^2 PO
3058915|NCT00877006|Experimental|Bendamustine and Rituximab (BR)|Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
3058916|NCT00877006|Active Comparator|R-CHOP/R-CVP|"Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles.~R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5~R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5"
3058917|NCT00877032|Experimental|Arm 1|
3058918|NCT00877058|Experimental|1.Preventive home visit|Preventive home visits: This intervention included a single home visit made by either a nurse, a physiotherapist, a qualified social worker or an occupational therapist. Participants received verbal and written information/advice about what the districts could provide. The preventive home visit was guided by a protocol, which included an opportunity for individuals to further elaborate on certain elements. The visit lasted between one and a half to two hours.
3058919|NCT00877058|Experimental|2. Senior meetings|The senior meetings comprised four weekly meetings with about six participants in each group. The main purpose was to focus on two different topics: 1) information about the ageing process and its consequences and 2) provision of tools and strategies for solving problems that can arise in the home environment. A follow-up home visit took place two to three weeks after the group sessions were completed. The group meetings were led either by an occupational therapist, a registered nurse, a physiotherapist or a qualified social worker, all of whom spoke about their particular dimension of aging.
3058920|NCT00877058|No Intervention|3. Control group|The control group had access to the ordinary range of services if requested from the urban districts for the aged. The aim of the municipal provision of care for the older persons is to ensure the ability to live as independently as possible. This includes remaining in their homes. When an older person in Sweden has difficulties managing independently, she or he can apply for assistance from the district. The extent of such support is subject to an assessment of needs and includes meals on wheels, help with cleaning and shopping, assistance with personal care, safety alarms and transportation service. The older person are also offered healthcare, provided either by municipal home help or home medical care services.
3058921|NCT00877370|Experimental|ertapenem|subjects will receive ertapenem while receiving CVVHD
3058922|NCT00877383|Experimental|Indacaterol 150 μg and tiotropium 18 μg|Patients inhaled indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3058923|NCT00877383|Active Comparator|Tiotropium 18 μg|Patients inhaled placebo to indacaterol 150 μg and tiotropium 18 μg once daily in the morning between 8:00 AM and 11:00 AM for 12 weeks. Placebo to indacaterol was delivered blinded via a single-dose dry-powder inhaler (SDDPI). Tiotropium was delivered open-label via the manufacturer's proprietary inhalation device (HandiHaler®). Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3058924|NCT00877448|Experimental|Multimeric-001 250 Mcg|Multimeric-001 250 Mcg in PBS
3058925|NCT00877448|Experimental|Adjuvanted Multimeric-001 250 Mcg|250 Mcg in montanide
3058926|NCT00877448|Placebo Comparator|Phosphate Buffered saline|Non-adjuvanted placebo
3058927|NCT00877448|Placebo Comparator|Adjuvanted PBS|Adjuvant was montanide
3058928|NCT00877448|Experimental|Multimeric-001 500 Mcg|Multimeric-001 in PBS
3058929|NCT00877448|Experimental|Adjuvanted Multimeric-001 500 Mcg|Adjuvant was montanide
3058930|NCT00877448|Experimental|Multimeric-001 125 Mcg|Multimeric-001 in PBS
3058931|NCT00877487|Experimental|SPD489|
3058932|NCT00877487|Placebo Comparator|Placebo|
3058933|NCT00877604|Experimental|TUDCA|tauroursodeoxycholic acid di-hydrate
3058934|NCT00877604|Placebo Comparator|placebo|excipient lactose
3058935|NCT00877773|Experimental|Temsirolimus|Temsirolimus 25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
3058936|NCT00877799|Experimental|CR845|CR845 administered as a single 15-min i.v. infusion at doses of 0.008 or 0.024 mg/kg on the day after surgery (Cohort 1), or at a dose of 0.040 mg/kg immediately after surgery (Cohort 2)
3058937|NCT00877799|Placebo Comparator|Placebo|Matched placebo administered as a single 15-min i.v. infusion on the day after surgery (Cohort 1), or the immediately after surgery (Cohort 2)
3058938|NCT00877877|Other|Cervarix Group|Subjects in the Cervarix Group of the primary study (NCT00196924), who had then received 3 doses of Cervarix™ vaccine intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 month vaccination schedule.
3058939|NCT00877890|Experimental|1|
3058940|NCT00877890|Active Comparator|2|
3058941|NCT00877929|Experimental|Telmisartan 80 / Amlodipine 10|Telmisartan 80 / Amlodipine 5 for two weeks, then forced titration to Telmisartan 80 / Amlodipine 10 Fixed Dose Combination
3058942|NCT00877929|Active Comparator|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
3058943|NCT00878072|Experimental|Famciclovir|
3058944|NCT00878189|Experimental|1|
3058945|NCT00878215|Experimental|Phase 1:Localize Anatomical Points on Liver Surface|-The surgeon will use image-guided surgery equipment to create the mapping with 3-D pictures of the participants liver. Laser range scanning will also be used to take 3-D pictures of the liver surface. The participant will then have planned standard surgery.
3058946|NCT00878215|Experimental|Phase 2: Ceramic bead|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. During the surgery, a ceramic bead will be placed in a pre-operatively determined target location within the tumor using image-guided surgery. Standard surgical procedures will then be used to remove the tumors. Magnetic resonance (MR) images of the resected liver will confirm targeting accuracy.
3058947|NCT00878215|Experimental|Phase 3: Ablative therapy|-The surgeon will use image-guided surgery to create the mapping with 3-D pictures of the liver. The liver tumors will be ablated using image-guided surgery. Standard surgical procedures will then be used to remove the portion of the liver that has the ablated tumors. The accuracy of the ablation will be confirmed via pathology sectioning.
3058948|NCT00878215|Experimental|Phase 4: Ablative therapy (not liver resection candidates)|-This phase is for patients who otherwise do not qualify to have a portion of their liver to be surgically removed. The surgeon will use image-guidance to create the mapping with 3-D pictures of the liver. The tumors will be ablated using image-guided therapy.
3058949|NCT00878228|Experimental|Study Group|The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).
3058950|NCT00878228|Placebo Comparator|Control Group|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).
3058951|NCT00878436|Experimental|Arm A (120 mg/week)|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~40 mg Panobinostat 3 times per week (120 mg per week) for 2 consecutive weeks with one week rest"
3058952|NCT00878436|Experimental|Arm B (60 mg/week)-Closed to accrual|"Each treatment cycle has 21 days:~Bicalutamide (Casodex®) 50mg P.O. daily, continuously, with the addition of:~20 mg Panobinostat 3 times per week (60 mg per week) for 2 consecutive weeks with one week rest"
3058953|NCT00878501|Experimental|AZD1386, 90 mg|
3058954|NCT00878501|Experimental|AZD1386, 30 mg|
3058955|NCT00878501|Placebo Comparator|Placebo|
3058956|NCT00878553|Placebo Comparator|Placebo|Two placebo tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3058957|NCT00878553|Experimental|10 mg SKP-1041|One 10 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3058958|NCT00878553|Experimental|15 mg SKP-1041|One 15 mg SKP-1041 controlled release zaleplon tablet plus one placebo tablet administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3058959|NCT00878553|Experimental|20 mg SKP-1041|Two 10 mg SKP-1041 controlled release zaleplon tablets administered orally at bedtime for two consecutive nights to each patient per crossover randomized sequence
3058960|NCT00878644|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
3058961|NCT00878644|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
3058962|NCT00878709|Experimental|Neratinib|240 mg orally daily for one year
3058963|NCT00878709|Placebo Comparator|Placebo|orally daily for one year
3058964|NCT00878722|Experimental|Arm A|"PXD101 administered as a 30-minute intravenous (IV) infusion of 1000 mg/m²/d for five consecutive days every 3 weeks.~Idarubicin administered on day 5 (first steps) or days 4 and 5 (later steps). Patients will be treated in a 21-day cycle for a minimum of 2 cycles and a maximum of 6 cycles (depending on cumulated idarubicin dose)."
3058965|NCT00878722|Experimental|Arm B|PXD101 administered by continuous intravenous infusion over 24-48 hours and idarubicin (in the later steps) added after the first 24 hours. The second cycle will start on day 15 but under observation of possible toxicity. Further cycles will be administered q 14 d for up to 6 cycles. The first dose steps will be carried out with PXD101 alone for safety reasons.
3058966|NCT00878800|Experimental|Experimental: PXD101 and doxorubicin (BelDox)|5-day PXD101 IV schedule with dose escalation combined with 1 day doxorubicin dose escalation IV
3058967|NCT00878826|Active Comparator|Enoxaparin 40 mg per day|
3058968|NCT00878826|Active Comparator|Enoxaparin 1 mg per kg daily|
3058969|NCT00878826|Active Comparator|Pre prescribed regimen of Enoxaparin|Current enoxaparin dose at time of first prenatal visit.
3058970|NCT00878878|Experimental|Arm A|
3058971|NCT00878878|Experimental|Arm B|
3058972|NCT00878995|Placebo Comparator|Standard of Care Therapy + Placebo Testosterone|Patients receive standard of care chemotherapy and/or radiation plus placebo testosterone intramuscularly (IM) weekly for 7 weeks.
3058973|NCT00878995|Active Comparator|Standard of Care Therapy + Testosterone|Patients receive standard of care chemotherapy and/or radiation plus testosterone (Testosterone Enanthate 100mg/ml) intramuscularly (IM) weekly for 7 weeks.
3058974|NCT00879034|Experimental|Zoledronic Acid,Pravastatin,and Lonafarnib|Lonafarnib;Zoledronic acid;Pravastatin
3058975|NCT00879060|Experimental|Spironolactone|Experimental group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to experimental group will be initiated on 25mg of spironolactone. If at week 4, serum potassium is <5.5 mmol/L and serum creatinine-baseline creatinine is <0.5 mg/dl, the study drug will be increased to the target dose of 50mg once daily.
3058976|NCT00879060|Placebo Comparator|Placebo Control|Placebo group includes individuals diagnosed with HCM between the ages of 18-55 (up to 50 for men). At time of randomization subjects randomized to placebo group will be initiated on an inactive placebo pill.
3058977|NCT00879190|Active Comparator|Unasyn (ampicillin/sulbactam)|
3058978|NCT00879190|Active Comparator|Ampicillin/gentamicin|
3058979|NCT00879229|Experimental|Ambrisentan|Participants were randomized to receive ambrisentan treatment at an initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 52 weeks
3179119|NCT00669435|Experimental|2|Losartan and Simvastatin
3179120|NCT00669474|Other|1|Suction curettage
3179121|NCT00669474|Active Comparator|2|Treatment with Botox
3058980|NCT00879229|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ambrisentan for 48 weeks, then transition to ambrisentan treatment at the initial dose of 5 mg for 4 weeks, followed by ambrisentan at the target dose of 10 mg for an additional 4 weeks.
3058981|NCT00879255|Experimental|Videoteleconferencing CPT|"The experimental arm is the group condition that received the CPT treatment via videoteleconferencing modality as compared to the experimental condition which is via face-to-face traditional modality.~Cognitive Processing Therapy Group Videoteleconference is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference."
3058982|NCT00879255|Active Comparator|Face-to-Face CPT|"The control arm is the group condition that received the CPT treatment via face-to-face traditional modality as compared to the experimental condition which is via videoteleconferencing modality.~Cognitive Processing Therapy Group In-Person is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference."
3058983|NCT00879333|Experimental|Everolimus + BSC|All patients were randomized to receive everolimus + BSC. All patients orally took two 5 mg tablets of everolimus once daily. Therefore, all patients in the everolimus arm took a total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
3058984|NCT00879333|Placebo Comparator|Placebo + BSC|All patients were randomized to receive placebo + BSC. All patients orally took two 5 mg tablets of matching placebo once daily. Therefore, all patients in the placebo receive matching tablets of total daily dose of 10 mg. Best supportive care was in accordance with the local practice of an individual institution or center, and specifically excluded anti-cancer treatments.
3058985|NCT00879359|Experimental|I|
3058986|NCT00879398||OAB-Toviaz|All patients who enrolled in this study
3058987|NCT00879411||arterial hypertension|
3058988|NCT00879437|Experimental|valproic acid and radiation, followed by valproic acid and bevacizumab|radiation phase (week 1-6): daily valproic acid and radiation, for approximately 6 weeks post-radiation phase (week 7-10): valproic acid daily maintenance phase (starting week 11): daily valproic acid, and bevacizumab once every 2 weeks; to continue for a maximum duration of 2 years
3058989|NCT00879645|Experimental|Sodium Sulfide - Mild Cohort|Mild renal impairment (RI) Cohort administered 1.5 mg/kg/hr infusion of Sodium sulfide intravenously for 3 hours.
3058990|NCT00879645|Experimental|Sodium Sulfide - Healthy Cohort|Healthy subjects received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
3058991|NCT00879645|Experimental|Sodium Sulfide - Moderate Cohort|Moderate RI cohort received sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
3058992|NCT00879645|Experimental|Sodium Sulfide - Severe Cohort|Severe RI cohort received sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
3058993|NCT00879658|Experimental|BAF312 10mg (period 1)|
3058994|NCT00879658|Experimental|BAF312 2 mg (period 1)|
3058995|NCT00879658|Experimental|BAF312 0.5 mg (period 1)|
3058996|NCT00879658|Experimental|BAF312 dose between 0.1 to 8 mg period 2|
3058997|NCT00879658|Experimental|BAF312 dose between 0.1 - 8 mg period 2|
3058998|NCT00879658|Placebo Comparator|Placebo (period 1, 2)|
3058999|NCT00879684|Experimental|1|
3059000|NCT00879697|Active Comparator|Strength training|Patients who performed strength training. The strength training program was composed by 8 exercises for whole body performed at sub-maximal intensity prescribed according to the patients self-perceived effort
3059001|NCT00879697|Active Comparator|Walking training|Patients who performed walking training. The walking training was performed in a treadmill using sub-maximal intensity prescribed based in patients self perceived effort
3059002|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
3059003|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 1|"Half the subjects will start with arm (i.e. every other subject in order)~Simvastatin 40 mg tablet by month daily for 6 weeks,~4 weeks washout period~Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks~4 weeks washout period~Simvastatin 40 mg tablet by month daily for 6 weeks"
3059004|NCT00879710|Other|Subjects with type 1 diabetes mellitus, option 2|"Half the subjects will start with arm (i.e. every other subject in order)~Ezetimibe 10 mg by month for 6 weeks,~4 weeks washout period"
3059005|NCT00879710|Other|Subjects with type 2 diabetes mellitus option 2|"Half the subjects will start with arm (i.e. every other subject in order) Ezetimibe 10 mg by month for 6 weeks,~•4 weeks washout period"
3059006|NCT00879775|Experimental|Caffeine|Intravenous injections of 200mg of caffeine with 100ml of normal saline over 1 hour
3059007|NCT00879775|Placebo Comparator|Placebo|Intravenous injections of 100ml of normal saline over 1 hour
3059008|NCT00879814|Experimental|1|rLP2086 vaccine 60 mcg
3059009|NCT00879814|Experimental|2|rLP2086 vaccine 120 mcg
3059010|NCT00879814|Experimental|3|rLP2086 vaccine 200 mcg
3059011|NCT00879814|Active Comparator|4|Tdap vaccine - normal saline - normal saline
3059012|NCT00879879|Experimental|Losartan|50 mg tablets of losartan taken daily by mouth for 1 year
3059013|NCT00879970|Active Comparator|pioglitazone|PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.
3059014|NCT00879970|Active Comparator|rosiglitazone|RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.
3059015|NCT00879970|Placebo Comparator|TZD placebo|Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years
3059016|NCT00879970|Active Comparator|Vitamin D|Active comparator
3059017|NCT00879970|Placebo Comparator|Vitamin D placebo|Placebo Comparator
3059018|NCT00879996|Active Comparator|1|Methadone 10-60 mg per day in 2-4 divided doses for 6 months
3059019|NCT00879996|Experimental|2|Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)
3059020|NCT00880009|Experimental|1|Combination of Bosutinib and Letrozole
3059021|NCT00880009|Active Comparator|2|Letrozole
3059022|NCT00880022|Active Comparator|arm compression only|Intervention of arm compression only by Flexitouch System
3059023|NCT00880022|Experimental|arm, trunk and chest compression|Intervention of arm, trunk and chest compression by Flexitouch System
3059024|NCT00880048|Experimental|orvepitant 30 mg|orvepitant 30 mg (low dose)
3059025|NCT00880048|Experimental|orvepitant 60 mg|orvepitant 60 mg (high dose)
3059026|NCT00880048|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 mg and 60 mg dosage forms
3059027|NCT00880087|Experimental|Therapeutic Hypothermia|Participants will receive therapeutic hypothermia after experiencing cardiac arrest.
3059028|NCT00880087|Active Comparator|Therapeutic Normothermia|Participants will receive therapeutic normothermia after experiencing cardiac arrest.
3059029|NCT00880100|Experimental|Ultrase® MT12|
3059030|NCT00880165|Active Comparator|Arm 1|In-laboratory testing followed by continuous positive airway pressure treatment
3059031|NCT00880165|Active Comparator|Arm 2|Home unattended testing followed by continuous positive airway pressure treatment
3059032|NCT00880191|Experimental|Arm I|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral gabapentin once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral gabapentin either two or three times daily on days 2-5 of chemotherapy.
3059033|NCT00880191|Experimental|Arm II|Patients receive oral dexamethasone with 5HT3 receptor antagonist and oral placebo once daily on day 1 of chemotherapy. Patients then receive oral dexamethasone twice daily with or without 5HT3 receptor antagonist on days 2-4, and oral placebo either two or three times daily on days 2-5 of chemotherapy.
3059034|NCT00880230|Experimental|Scuba Iliac Stent System|Device: Scuba™ iliac stent
3059035|NCT00880256|Experimental|MBSR|Patients who undergo mindfulness-based stress reduction will fill out measures of IBS severity before and after the mindfulness course.
3059036|NCT00880269|Experimental|Stratum A|patients with refractory acute myelogenous leukemia (AML) initially diagnosed as de novo AML received 60 mg of panobinostat per day on three discontinuous days per week.
3059037|NCT00880269|Experimental|Stratum B|patients with refractory AML initially diagnosed as AML secondary to myelodysplastic syndrome (MDS)/antecedent hematologic disorder (AHD) received 60 mg of panobinostat per day on three discontinuous days per week.
3059038|NCT00880334|Experimental|vandetanib & Docetaxel|vandetanib orally and Docetaxel intravenously
3059039|NCT00880334|Active Comparator|Placebo and Docetaxel|Placebo orally and docetaxel intravenously
3059040|NCT00880360|Experimental|Ontak|Administration of Ontak IV for treatment of epithelial ovarian cancer
3059041|NCT00880399|Placebo Comparator|Placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
3059042|NCT00880399|Experimental|Orvepitant 30 mg|30 mg/day (low dose)
3059043|NCT00880399|Experimental|Orvepitant 60 mg|60 mg/day (high dose)
3059044|NCT00880425||Participants with continuous headache|
3059045|NCT00880425||Participnts with non-continuous headache|
3059046|NCT00880464|Experimental|Vaccine|"Vaccinations will be administered on days 1,8,15 and every two weeks thereafter until the supply of vaccine has been exhausted or the patient is removed from study. As indicated in 5.2.5, vaccine cell dosage will be approximately 1x10 7 , 4x10 6 ,~1x10 6 , or 1x10 5 depending on the final cell yield."
3059047|NCT00880555||Arm 1: Non-Dementia Memory Disorder|Elderly patients with non-dementia memory disorder (mild cognitive impairment)
3059048|NCT00880555||Arm 2: Control|Elderly controls without memory impairment
3059049|NCT00880555||Arm 3: Mild Alzheimer Disease|Patients with mild Alzheimer disease (but preserved routine activities of daily living)
3059050|NCT00880568|Experimental|MK-1496 20 mg (21-Day Cycle)|Participants receiving MK-1496 20 mg on Day 1 of each 21-day cycle
3059051|NCT00880568|Experimental|MK-1496 40 mg (21-Day Cycle)|Participants receiving MK-1496 40 mg on Day 1 of each 21-day cycle
3059052|NCT00880568|Experimental|MK-1496 80 mg (21-Day Cycle)|Participants receiving MK-1496 80 mg on Day 1 of each 21-day cycle
3059053|NCT00880568|Experimental|MK-1496 120 mg (21-Day Cycle)|Participants receiving MK-1496 120 mg on Day 1 of each 21-day cycle
3059054|NCT00880568|Experimental|MK-1496 20 mg (28-Day Cycle)|Participants receiving MK-1496 20 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3059055|NCT00880568|Experimental|MK-1496 40 mg (28-Day Cycle)|Participants receiving MK-1496 40 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3059056|NCT00880568|Experimental|MK-1496 80 mg (28-Day Cycle)|Participants receiving MK-1496 80 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3059057|NCT00880568|Experimental|MK-1496 100 mg (28-Day Cycle)|Participants receiving MK-1496 100 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3059058|NCT00880568|Experimental|MK-1496 120 mg (28-Day Cycle)|Participants receiving MK-1496 120 mg on Days 1, 3, 8, 10, 15, and 17 of each 28-day cycle
3059059|NCT00880581|Experimental|PF-3512676|Patients will be treated with 18 mg PF-3512676 by intratumoral injection on day 2 following local radiotherapy, then weekly for a total of 10 injections over 10 weeks.
3059060|NCT00880607|Active Comparator|Intrathecal morphine|Receives a single dose of intrathecal morphine
3059061|NCT00880607|Experimental|Extended Release Epidural Morphine|Receives DepoDur extended release epidural morphine for pain management
3059062|NCT00880620|Placebo Comparator|Placebo|One Placebo capsule was given TID for the first 21 days. Two placebo capsules were given TID on days 22 till end of study (week 30).
3059063|NCT00880620|Experimental|IPX066 145 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-21. One IPX066 145 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
3059064|NCT00880620|Experimental|IPX066 245 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. One IPX066 245 mg LD and one placebo capsule were given TID on days 22 till end of study (week 30).
3179122|NCT00669487|Experimental|1. GPO-VIR S 1 pill orally every 12 hours|
3179123|NCT00669487|Experimental|2 GPO-VIR Z 1 pill orally every 12 hours|
3179124|NCT00669487|Experimental|3 Truvada 1 pill oral q 24 hr and NVP 1 pill oral q 12 hr|
3059065|NCT00880620|Experimental|IPX066 390 mg LD|One IPX066 95 mg LD was given TID on days 1-3. One IPX066 145 mg LD was given TID on days 4-7. One IPX066 195 mg LD was given TID on days 8-14. One IPX066 245 mg LD was given TID on days 15-21. Two IPX066 195 mg LD capsules were given TID on days 22 till end of study (week 30).
3059066|NCT00880685|Experimental|Memantine|Memantine 10-30mg
3059067|NCT00880698|Experimental|HIV-uninfected RotaTeq|HIV-1 uninfected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
3059068|NCT00880698|Placebo Comparator|HIV-uninfected Placebo|HIV-1 uninfected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
3059069|NCT00880698|Experimental|HIV-infected RotaTeq|HIV-1 infected participants receiving 3 doses of RotaTeq vaccine at intervals of 4-10 weeks with the third dose administered by 32 weeks of age.
3059070|NCT00880698|Placebo Comparator|HIV-1 infected Placebo|HIV-1 infected participants receiving 3 doses of placebo at intervals of 4-10 weeks with the third dose administered by 32 weeks of age
3059071|NCT00880750|Experimental|Lanthanum carbonate granules|Lanthanum carbonate granulated formulation crossover to chewable tablet formulation
3059072|NCT00880750|Experimental|Lanthanum carbonate chewable tablets (Fosrenol)|Lanthanum carbonate chewable table formulation crossover to granulated formulation
3059073|NCT00880763|Experimental|Vaniprevir 200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 100 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3059074|NCT00880763|Experimental|Vaniprevir 600 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 300 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3059075|NCT00880763|Experimental|Vaniprevir 1200 mg + peg-IFN + ribavirin|Participants will receive vaniprevir 600 mg twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3059076|NCT00880763|Placebo Comparator|Placebo + peg-IFN + ribavirin|Participants will receive placebo twice daily in combination with peg-IFN and ribavirin for 28 days. Participants will continue peg-IFN and ribavirin through Week 6 or, at the investigators discretion, up to Week 72.
3059077|NCT00880893|Experimental|CYD Dengue Vaccine Group|Participant's received the CYD Dengue Vaccine at 0, 6, and 12 months as first, second, and third vaccinations, respectively.
3059078|NCT00880893|Sham Comparator|Placebo Group|All participants received a placebo at first vaccination (Month 0). Participants <12 years received hepatitis A at second (Month 6) and third (Month 12) vaccinations. Participants >= 12 years received influenza vaccine of Northern and Southern hemisphere formulations at second (Month 6) and third (Month 12) vaccinations.
3059079|NCT00880906|Active Comparator|A|Group A receives steroids and PPI, (SOC) and esophageal dilation.
3059080|NCT00880906|Sham Comparator|B|Receives steroids and PPI only- Does not have esophageal dilation.
3059081|NCT00880919|Active Comparator|1|Seroquel XR 150mg oral tablets taken daily for 8 weeks.
3059082|NCT00880919|Active Comparator|2|Seroquel XR 300mg oral tablets taken daily for 8 weeks.
3059083|NCT00880919|Placebo Comparator|3|Equivalent number of placebo oral tablets taken daily for 8 weeks.
3059084|NCT00880997|Experimental|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both groups were tapered off doxazosin or placebo over study weeks 14-17."
3059085|NCT00880997|Placebo Comparator|placebo|A sugar pill to mimic the experiment drug, doxazosin, will be administered in the same manner as the experimental drug through the study duration.
3059086|NCT00881335|No Intervention|control group|
3059087|NCT00881335|Experimental|intervention|Intervention group were given flutter valve mucus clearance devices to do pulmonary function exercise
3059088|NCT00881361|Other|Study cohort|Patients who plan to receive or have received neoadjuvant chemotherapy are eligible. Patients undergo examination for breast and axilla lymph adenopathy and then undergo ultrasound of the axillary nodes at baseline and after completion of neoadjuvant chemotherapy. Within 12 weeks of completing neoadjuvant chemotherapy, patients undergo a mastectomy or lumpectomy (per surgeon discretion) including both sentinel lymph node surgery and axillary lymph node dissection.
3059089|NCT00881465|Experimental|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks. The first session will be held face-to-face to foster rapport. Sessions 1-4 will be held twice weekly; thereafter sessions will be held weekly. Sessions 1-3 are devoted to psychoeducation, treatment discussion, and hierarchy development. Sessions 4-10 involve CBT exercises specific to each youth.
3059090|NCT00881465|Placebo Comparator|Waitlist|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
3059091|NCT00881504|Experimental|"FOLFOX6 and Bevacizumab"|"Intervention = bevacizumab in combination with chemotherapy~Treatment of biliary system carcinoma using Bevacizumab in combination with modified FOLFOX6."
3059092|NCT00881530|Active Comparator|Sitagliptin|100 mg
3059093|NCT00881530|Active Comparator|Metformin|2000 mg
3059094|NCT00881530|Experimental|BI 10773 X mg|lower dose
3059095|NCT00881530|Experimental|BI 10773 Y mg|higher dose
3059096|NCT00881569|Experimental|1|CS-7017 tablets twice daily at strength ranging from 0.5 mg to 0.75 mg
3059097|NCT00881621|Experimental|Lapatinib and Capecitabine|Treatment
3059098|NCT00881647|Experimental|1|Participants will receive an 8-week course of cognitive behavioral therapy for insomnia.
3059099|NCT00881647|No Intervention|2|Participants will be placed on a waitlist for 8 weeks.
3059100|NCT00881712|Experimental|PET positive nodal disease measuring 15 mm or greater|Proton radiation with concomitant chemotherapy
3179125|NCT00669513|No Intervention|1|
3059101|NCT00881712|Experimental|PET positive nodal disease measuring less than 15 mm|Proton radiation
3059102|NCT00881712|Experimental|Patients considered resectable|Proton radiation plus surgery
3059103|NCT00881751|Experimental|Arm 1: bevacizumab and erlotinib|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral erlotinib hydrochloride once daily on days 1-28.
3059104|NCT00881751|Active Comparator|Arm 2: sorafenib tosylate|Patients receive oral sorafenib tosylate twice daily on days 1-28.
3059105|NCT00881868|Active Comparator|Clobex Spray|
3059106|NCT00881868|Placebo Comparator|Vehicle spray|
3059107|NCT00881894|Experimental|Sequence A-B (Test: PR2.1.1 - Reference: PR1.0)|Two single applications of rotigotine patches from two different manufacturing processes in the order A-B separated by a washout phase of at least 5 days
3059108|NCT00881894|Experimental|Sequence B-A (Reference: PR1.0 - Test: PR2.1.1)|Two single applications of rotigotine patches from two different manufacturing processes in the order B-A separated by a washout phase of at least 5 days
3059109|NCT00881959|Experimental|Group 1: Puros Dermis|Experimental treatment group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
3059110|NCT00881959|Active Comparator|Group 2: Alloderm|Control group of subjects who each have a single non-adjacent Miller's Class I or II gingival recession defect, greater than or equal to 2 mm, located on the buccal aspect of the maxillary incisor, canine, or premolar.
3059111|NCT00882102|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 by vein (IV) over 1-1/2 hours daily for 5 days. Gemtuzumab ozogamicin 3 mg/m^2 by vein on day 5.
3059112|NCT00882115|Experimental|DEP challenge in subjects consuming BSE|DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.
3059113|NCT00882206|Experimental|Decitabine / Vorinostat|This is a therapeutic trial investigating the combination of decitabine 15 mg/m2 and vorinostat 230 mg/m2 (maximum daily dose not to exceed 400 mg) in relapsed/refractory ALL/LL patients prior to induction chemotherapy.
3059114|NCT00882362|Experimental|1|
3059115|NCT00882440|Placebo Comparator|1|Placebo
3059116|NCT00882440|Experimental|2|Losartan 10 mg
3059117|NCT00882440|Experimental|3|Losartan 25 mg
3059118|NCT00882440|Experimental|4|Losartan 50 mg
3059119|NCT00882440|Experimental|5|Losartan 100 mg
3059120|NCT00882440|Experimental|6|Losartan 150 mg
3059121|NCT00882440|Active Comparator|7|Enalapril 20 mg
3059122|NCT00882518|Experimental|1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)
3059123|NCT00882518|Active Comparator|2-Chlorpromazine|Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)
3059124|NCT00882557|Experimental|A|9 mg/kg of daptomycin administered during the last 30 minutes of a hemodialysis session.
3059125|NCT00882557|Experimental|B|Post dialysis dosing
3059126|NCT00882583|Experimental|Dasatinib/Cetuximab/RT|"In Cohort A , there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort A will consist of patients with AJCC stage II (T2N0) and III (T1-2N1) SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx. Treatment will be dasatinib at specific dose level in combination with cetuximab 250mg/m2 IV and radiation therapy (RT) 70Gy at 2Gy/fn."
3059127|NCT00882583|Experimental|Dasatinib/Cetuximab/cisplatin/RT|"In Cohort B, there will be an initial run-in period of single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8 and oral dasatinib at specific dose level from day 8-14.~Cohort B will include patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0) squamous cell carcinoma of Oral Cavity, Oropharynx, Hypopharynx, and Larynx. Treatment will be daily dasatinib at specific dose level, in combination with q 3 week cisplatin 75mg/m2, weekly cetuximab 250mg/m2 IV and RT 70Gy ( 2gy per fraction)."
3059128|NCT00882661|Experimental|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
3059129|NCT00882661|Active Comparator|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
3059130|NCT00882687|Experimental|0.1% Lifitegrast|
3059131|NCT00882687|Experimental|1.0% Lifitegrast|
3059132|NCT00882687|Experimental|5.0% Lifitegrast|
3059133|NCT00882687|Placebo Comparator|Placebo|
3059134|NCT00882713|Experimental|C.E.R.A.|Eligible participants will be administered continuous erythropoietin receptor activator (C.E.R.A.[Mircera]) intravenously (IV) every 4 weeks for 44 weeks. The starting dose of 120, 200, or 360 micrograms (mcg) will be based on the dose of epoetin alfa or beta administered in the week preceding the switch to C.E.R.A. Subsequent doses will be adjusted to maintain the individual participant's hemoglobin (Hb) within a range of +/- 1.0 grams per deciliter (g/dL) of the reference hemoglobin (Hb) concentration and between 10.50 and 12.50 g/dL.
3059135|NCT00882778||activated recombinant human factor VII|Male patients diagnosed with haemophilia A or B with inhibitors, who were prescribed activated recombinant human factor VII (rFVIIa) for at least 30 days. All direction for rFVIIa medication usage was at the sole discretion of the physician in accordance within their usual practice. Data was collected for approximately 6 months of pre-prophylaxis, while the prophylaxis period had no limits.
3059136|NCT00882908|Experimental|TMC435 75 mg 12 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3059137|NCT00882908|Experimental|TMC435 75 mg 24 Wks + PR 24/48|Participants will receive TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3179126|NCT00669513|Experimental|2|Partial sleep deprivation
3059138|NCT00882908|Experimental|TMC435 150 mg 12 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3059139|NCT00882908|Experimental|TMC435 150 mg 24 Wks + PR 24/48|Participants will receive TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
3059140|NCT00882908|Placebo Comparator|Placebo 24 Wks + PR48|Participants will receive Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
3059141|NCT00882921||Elaprase|Idursulfase 0.5 mg/kg Weekly
3059142|NCT00882999|Placebo Comparator|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks (Weeks 0, 4, 8, 12, 16, and 20) for a total of 6 doses. Every 4 weeks in the LY2127399 arms [4 milligrams (mg) LY2127399 / 12 weeks and 120 mg LY2127399 / 12 weeks] for 24 weeks (except Week 0 and Week 12).
3059143|NCT00882999|Experimental|4 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
3059144|NCT00882999|Experimental|40 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
3059145|NCT00882999|Experimental|120 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
3059146|NCT00882999|Experimental|4 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
3059147|NCT00882999|Experimental|120 mg LY2127399 / 12 weeks|"Drug: LY2127399 Injection: 2 doses, one every 12 weeks for 24 weeks.~Drug: Placebo Injection: Every 4 weeks for 24 weeks (except Week 0 and Week 12)."
3059148|NCT00882999|Experimental|12 mg LY2127399 / 4 weeks|Injection: 6 doses, one every 4 weeks for 24 weeks.
3059149|NCT00883051|Experimental|50 mg Lasmiditan|50 mg lasmiditan administered orally (PO)
3059150|NCT00883051|Experimental|100 mg Lasmiditan|100 mg lasmiditan administered orally (PO)
3059151|NCT00883051|Experimental|200 mg Lasmiditan|200 mg lasmiditan administered orally (PO)
3059152|NCT00883051|Experimental|400 mg Lasmiditan|400 mg lasmiditan administered orally (PO)
3059153|NCT00883051|Placebo Comparator|Placebo|Placebo administered orally (PO)
3059154|NCT00883090|Experimental|FXIII|All subjects treated with Factor XIII Concentrate (Human) (FXIII)
3059155|NCT00883103|Active Comparator|Lidocaine|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
3059156|NCT00883103|Placebo Comparator|Aqueous gel|Plain aqueous gel as placebo will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
3059157|NCT00883116|Experimental|Ixabepilone, 40 mg/m^2, intravenously (IV)|Participants received ixabepilone, 40 mg/m^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
3059158|NCT00883116|Active Comparator|Control chemotherapy (Paclitaxel or Doxorubicin)|Participants received either paclitaxel, 175 mg/m^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m^2.
3059159|NCT00883129|Experimental|Mycophenolate Arm|Participants will receive oral mycophenolate mofetil for 2 years.
3059160|NCT00883129|Experimental|Cyclophosphamide Arm|Participants will receive oral cyclophosphamide for 1 year, followed by placebo for 1 year.
3059161|NCT00883168|Placebo Comparator|placebo|
3059162|NCT00883168|Active Comparator|azelastine Hcl|
3059163|NCT00883168|Active Comparator|fluticasone propionate|
3059164|NCT00883168|Experimental|azelastine Hcl /fluticasone propionate|
3059165|NCT00883233|Experimental|1|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
3059166|NCT00883233|Experimental|2|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
3059167|NCT00883233|Experimental|3|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
3059168|NCT00883233|Active Comparator|4|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
3059169|NCT00883246|Other|Atherectomy|All patients enrolled in this single-arm study were treated with directional atherectomy.
3059170|NCT00883337|Experimental|Teriflunomide 7 mg / 14 mg|Teriflunomide 7 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
3059171|NCT00883337|Experimental|Teriflunomide 14 mg / 14 mg|Teriflunomide 14 mg once daily (core treatment period) and teriflunomide 14 mg once daily (extension treatment period).
3059172|NCT00883337|Active Comparator|IFN-β-1a / 14 mg|Interferon β-1a 3 times a week (core treatment period) and teriflunomide 14 mg once daily (extended treatment period).
3059173|NCT00883389||Safe Kidney Care|Patients with Chronic Kidney Disease (eGFR < 60 ml/min/1.732)and not expected to need dialysis within 6 months of enrollment
3059174|NCT00883493|Experimental|Quetiapin fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
3059175|NCT00883493|Experimental|Quetiapin fumarate XR+Lithium carbonate|Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
3179127|NCT00669526|Active Comparator|SMHC referral|Referral to local Specialty Mental Health Care Services
3179128|NCT00669526|Experimental|BCBT|Brief Cognitive Behavioral Therapy
3179129|NCT00669591|Experimental|1|Patients will receive up to six (6) 28-day cycles of docetaxel plus weekly bavituximab during the treatment phase. During the follow-up phase, patients will continue to receive weekly bavituximab until disease progression
3059176|NCT00883558|Experimental|INSULIN-PH20 NP / Insulin Lispro|"All enrolled participants underwent a 1-month dose titration period and received 100 units per milliliter (U/mL) insulin lispro, injected subcutaneously (SC) pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~INSULIN-PH20 NP (Treatment A): 100 U/mL non-preserved (NP) formulation of regular human insulin with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine or maintained their usual regimen through an insulin pump."
3059177|NCT00883675|Experimental|Treatment|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin Area Under the Curve 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
3059178|NCT00883688|Experimental|Bevacizumab + Lapatinib|"Bevacizumab 10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle). Lapatinib Pills of 700 mg/m^2/dose given orally 2 times each day."
3059179|NCT00883740|Experimental|Lyrica|flexible dosing Lyrica 300-450mg/day
3059180|NCT00883740|Placebo Comparator|Placebo|Placebo
3059181|NCT00883753|Experimental|tocilizumab|Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
3059182|NCT00883779|Experimental|1|
3059183|NCT00883779|Placebo Comparator|2|
3059184|NCT00884039|Active Comparator|30 mg anecortave acetate|
3059185|NCT00884039|Active Comparator|15 mg anecortave acetate|
3059186|NCT00884052|Experimental|levetiracetam dose escalation|6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day
3059187|NCT00884065|Experimental|Intervention Group|The intervention group was treated with a single session of DF following the procedure as described by the authors.
3059188|NCT00884065|Placebo Comparator|Control Group|The control group was treated with a single placebo session of DF.
3059189|NCT00884117||Participants Infected with Influenza|Participants with a positive diagnostic test of influenza and/or displaying symptoms suggestive of influenza-like illness will be enrolled and followed for up to 10 days after informed consent for virological surveillance and assessment of clinical outcomes. Participants may receive treatment including oseltamivir, other treatment/medication, or no treatment.
3059190|NCT00884221|Experimental|Highly Purified Menotrophin|
3059191|NCT00884221|Active Comparator|Recombinant FSH|
3059192|NCT00884273|Experimental|Degarelix 240 mg/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
3059193|NCT00884273|Active Comparator|Goserelin (3.6 mg) + bicalutamide (50 mg)|"Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.~On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin."
3059194|NCT00884286|Experimental|Arm One|Aplidin® given as a 1-hour weekly IV infusion
3059195|NCT00884312|Experimental|Carfilzomib|Participants received carfilzomib administered intravenously, using the same method, frequency, and dose level as in the last cycle of the participant's previous carfilzomib study. Treatment was continued until confirmation of disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or commercial availability of carfilzomib.
3059196|NCT00884325|Experimental|Xyzal|
3059197|NCT00884325|Placebo Comparator|Placebo|
3059198|NCT00884377|Active Comparator|Sodium stibogluconate intravenous|20 mg/kg/day Sodium stibogluconate intravenous
3059199|NCT00884377|Experimental|ThermoMed device|ThermoMed device, single heat treatment at 50 degrees Celsius
3059200|NCT00884390|Experimental|ReFacto AF|
3059201|NCT00884585|Experimental|Cyclosporine Ophthalmic Solution (COS) followed by COS|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
3059202|NCT00884585|Other|Placebo followed by COS|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months followed by cyclosporine ophthalmic solution 0.010% up to 9 additional months; at Month 9 the dose may be adjusted to 2 times a day.
3059203|NCT00884611|Experimental|Predictive Low Glucose Suspend|The pump suspension system consists of the Revel CGM device communicating with a laptop computer that contains the hypoglycemia prediction algorithm. During the 21 night study period, the laptop is placed at the bedside and turned on by the participant at bedtime and off on arising in the morning.The laptop contains a randomization schedule (2:1) that indicats whether the hypoglycemia prediction algorithm will be in operation that night (Predictive Low Glucose Suspend Algorithm ON) or will not be activated (Predictive Low Glucose Suspend Algorithm OFF), to which the participant is blinded.
3059204|NCT00884650|Active Comparator|Oral Analgesic Only|Group 1 will receive oral analgesic only
3059205|NCT00884650|Active Comparator|anesthetic continuous-infusion + oral analgesia|Group 2: anesthetic continuous-infusion device, e.g. intravenous analgesic per pump, with supplemental oral analgesia
3059206|NCT00884741|Active Comparator|Arm I (radiation therapy, temozolomide, placebo)|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks and receive temozolomide PO QD for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5. Treatment with temozolomide repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients also receive placebo IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemotherapy and radiation therapy and continuing until the completion of temozolomide.
3059207|NCT00884741|Experimental|Arm II (radiation therapy, temozolomide, bevacizumab)|Patients undergo radiation therapy and receive temozolomide as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes once every 2 weeks beginning in week 4 of chemoradiotherapy and continuing until the completion of adjuvant temozolomide.
3059208|NCT00884754|Experimental|rigid GlideScope Specific Stylet|
3059209|NCT00884754|Active Comparator|90º curvature, malleable stylet|
3059210|NCT00884793|Experimental|intensification with raltegravir +/- NNRTI or PI|Intensification with raltegravir 400mg PO BID +/- a study PI or NNRTI
3059211|NCT00884806|Experimental|FID 114675A|FID 114675A used for 7 days, per protocol-specified instructions. Silicone hydrogel or hydrogel contact lenses worn bilaterally on a daily wear basis, one brand only.
3059212|NCT00884832|Experimental|Oral Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
3059213|NCT00884832|Placebo Comparator|Oral Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
3059214|NCT00884897|Experimental|Oxytocin|We will purchase OT from PharmaWorld, an international pharmacy located in Switzerland; the preparation of intranasal OT is manufactured by Novartis and sold under the trade name: Syntocinon. We have obtained an IND (number 78,246) for Syntocinon (intranasal oxytocin) manufactured by Novartis.
3059215|NCT00884897|Placebo Comparator|Placebo|We will be purchasing oxytocin placebo nasal spray through LABOSWISS located in Davos, Switzerland and distributed through PharmaWorld. LABOSWISS will manufacture the matching the placebo under GDP guidelines. The placebo will be in every way identical to the oxytocin formulation but will not contain OT.
3059216|NCT00884949|Experimental|BMN 110|Within-patient Dose-Escalation
3059217|NCT00885079|Experimental|Rebamipide|Instillation,4 times/day for 4 weeks
3059218|NCT00885079|Active Comparator|Hyaluronate|Instillation,6 times/day for 4 weeks
3059219|NCT00885092|Other|FID 114675A / RepleniSH|FID 114675A in Period 1; RepleniSH in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
3059220|NCT00885092|Other|RepleniSH / FID 114675A|RepleniSH in Period 1; FID 114675A in Period 2. Each solution was used for 7 days for cleaning, rinsing, conditioning, disinfecting, and storing silicone hydrogel contact lenses, per protocol-specified instructions. A new pair of silicone hydrogel contact lenses was dispensed at the start of each period and worn bilaterally on a daily wear basis.
3059221|NCT00885105|Experimental|Fluzone® Vaccine-Primed Group|Participants received 2 doses of Fluzone® vaccine at 2 months (in Study GRC 27)
3059222|NCT00885105|Active Comparator|Influenza Vaccine-Naive Group|Participants who have never received influenza vaccine (and not in Study GRC27)
3059223|NCT00885118|Experimental|BI 10773 low dose quaque die (QD)|patient to receive a BI 10773 low dose tablet and a placebo tablet once daily
3059224|NCT00885118|Experimental|BI 10773 mid-low dose QD|patient to receive a BI 10773 middle dose tablet and a placebo tablet once daily
3059225|NCT00885118|Experimental|BI 10773 mid-high dose QD|patient to receive two tablets of BI 10773 middle dose once daily
3059226|NCT00885118|Experimental|BI 10773 high dose QD|patient to receive a BI 10773 high dose tablet and a placebo tablet once daily
3059227|NCT00885118|Placebo Comparator|Placebo|patient to receive two tablets of placebo once daily
3059228|NCT00885170|Experimental|Odanacatib 50 mg|Odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
3059229|NCT00885170|Placebo Comparator|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months. Vitamin D3 (dietary supplement), two 2800 IU tablets, taken once weekly for 24 months. Participants received calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
3059230|NCT00885352|Experimental|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
3059231|NCT00885352|Placebo Comparator|Placebo|Placebo to sitagliptin orally once daily for 26 weeks.
3059232|NCT00885365|Experimental|Bramitob|tobramycin / Bramitob administered 300mg twice a day for 4 weeks
3059233|NCT00885365|Active Comparator|TOBI|tobramycin / TOBI administered 300mg twice a day for 4 weeks
3059234|NCT00885378|Active Comparator|Saxagliptin plus metformin IR|
3059235|NCT00885378|Placebo Comparator|Placebo plus metformin IR|
3059236|NCT00885482|Experimental|Single arm|"Treatment simplification from a standard combined antiretroviral therapy including 2 NRTIs and Atazanavir with Ritonavir to Lamivudine plus Atazanavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy."
3059237|NCT00885534|Experimental|Chemotherapy|This is a single institution phase II trial in stage III or IV melanoma patients with measurable disease but no prior cytotoxic chemotherapy and not thought to be curable by surgery.Before starting the chemotherapy, you may need to have a fresh biopsy of your tumor. If you have already had a tumor biopsy that we can use, you may not need another biopsy. Your study doctor will review with you the biopsies you have had. We will try to obtain biopsy material that already exists but if we cannot, you will need another biopsy.
3059238|NCT00885638|Placebo Comparator|Placebo|A placebo tablet is given before ingestion of macronutrients
3059239|NCT00885638|Active Comparator|Sitagliptin|Sitagliptin is given before ingestion of macronutrients
3059240|NCT00885677|Active Comparator|Study Group|Patients of the study arm are CRT-D patients followed-up by means of a remote disease management system (Medtronic Carelink® Network), for which an automatic alerting system is enabled for fluid accumulation, AT/AF episodes and system integrity.
3059241|NCT00885677|No Intervention|Control Group|Patients are CRT-D patients managed according to current standard clinical practice, based on routinely performed in-office visits.
3059242|NCT00885703|Experimental|Stage 1, Fluconazole 1200mg|Participants receive Fluconazole 1200mg induction dose in Stage 1
3059243|NCT00885703|Experimental|Stage 1, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 1
3059244|NCT00885703|Experimental|Stage 1, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 1
3059245|NCT00885703|Active Comparator|Stage 1, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 1
3059246|NCT00885703|Experimental|Stage 2, Fluconazole 1600mg|Participants receive Fluconazole 1600mg induction dose in Stage 2
3059247|NCT00885703|Experimental|Stage 2, Fluconazole 2000mg|Participants receive Fluconazole 2000mg induction dose in Stage 2
3059248|NCT00885703|Active Comparator|Stage 2, Ampho B|Participants receive Amphotericin B followed by Fluconazole in Stage 2
3059249|NCT00885742|Experimental|FXIII|All subjects who received a dose of Factor XIII (FXIII) Concentrate (Human).
3059250|NCT00885755|Experimental|1|
3059251|NCT00885768||A|patients with renal artery stenosis
3059252|NCT00885846|Active Comparator|Qigong Therapy|
3059253|NCT00885846|Active Comparator|PRT|
3059254|NCT00885846|No Intervention|Control|
3059255|NCT00886015|Experimental|TT Clamp|The TT clamp will be used in trichiasis surgery.
3059256|NCT00886015|Active Comparator|Standard BLTR Technique|Standard BLTR technique will be used in trichiasis surgery.
3059257|NCT00886119|Other|Lotrafilcon B / Omafilcon A|Lotrafilcon B, followed by Omafilcon A
3059258|NCT00886119|Other|Omafilcon A / Lotrafilcon B|Omafilcon A, followed by Lotrafilcon B
3059259|NCT00886145|Other|Vibration and No Vibration|Vibration: Right Leg and No Vibration: Left Leg.
3059260|NCT00886236|Active Comparator|1 Preoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
3059261|NCT00886236|Experimental|2 Preoperative and Postoperative Gabapentin Liquid|Preoperative Gabapentin Elixir (1200 mg) AND Postoperative Gabapentin Elixir (300 mg x 6 doses)
3059262|NCT00886236|Placebo Comparator|3 Preoperative and Postoperative Placebo Liquid|Preoperative Placebo Liquid (1200 mg) AND Postoperative Placebo Elixir (300 mg x 6 doses)
3059263|NCT00886262|Experimental|Vasopressin|
3059264|NCT00886262|Placebo Comparator|Normal saline placebo|
3059265|NCT00886288||Telmisartan|
3059266|NCT00886288||Telmisartan + hydrochlorothiazide|
3059267|NCT00886340|Active Comparator|Enhanced standard care|
3059268|NCT00886340|Experimental|Lifestyle counseling|
3059269|NCT00886379|Active Comparator|1|Mongolian milk without D
3059270|NCT00886379|Experimental|2|Mongolian milk with vitamin D
3059271|NCT00886379|Experimental|3|Ultra High Temperature (UHT) milk
3059272|NCT00886379|Experimental|4|Milk Substitute
3059273|NCT00886379|Experimental|5|Seasonal D
3059274|NCT00886379|Experimental|6|Daily D
3059275|NCT00886483|Active Comparator|Active neurofeedback|In the active neurofeedback condition, the intervention is active neurofeedback (actual neurofeedback) either twice weekly or three times a week (randomized to frequency), with the same amount of total treatment over 40 sessions, varying only in frequency. Neurofeedback will be via the CyberLearning technology, using videogame race car speed and steering as feedback governed by EEG theta-beta ratio through the interface. the game controller is used in the usual fashion, but maximal speed is capped by the threshold theta-beta ratio, which changes from minute-to-minute by fuzzy logic based on the previous minute's ratio. If theta power exceeds a threshold, the rumble function of the controller comes on as a warning. The feedback is transparent to the patient, who just plays the videogame.
3059276|NCT00886483|Sham Comparator|Sham Neurofeedback|The sham condition will appear identical to the neurofeedback in all aspects: equipment, duration, frequency, and videogame choices. The only difference is that the interface module will be pre-programmed to give random feedback rather than contingent on the participant's brainwave power spectrum.
3059277|NCT00886587|Experimental|11054-010|F# 11054-010 Investigational Device
3059278|NCT00886587|Active Comparator|10495-053|F# 10495-053 Atopiclair
3059279|NCT00886600|Placebo Comparator|1|Placebo
3059280|NCT00886600|Experimental|2|losartan 50 mg q.d.
3059281|NCT00886600|Experimental|3|losartan 100 mg q.d.
3059282|NCT00886600|Experimental|4|losartan 50 mg b.i.d.
3059283|NCT00886613|Experimental|V212|Participants randomized to receive V212 (heat treated VZV Vaccine)
3059284|NCT00886613|Active Comparator|Zostavax™|Participants randomized to receive Zostavax™ (Zoster Vaccine, live)
3059285|NCT00886613|Placebo Comparator|Placebo|Participants randomized to receive placebo
3059286|NCT00886626|Experimental|Exenatide|Exenatide
3059287|NCT00886626|No Intervention|Control|Control - no intervention
3059288|NCT00886639|Other|First of 2 6-minute-walking test with oxygen|Continuous flow of 2 liters per minute First with oxygen, second with medical air
3059289|NCT00886639|Other|First of 2 6-minute-walking tests with medical air|Medical air is compressed room air. First test with medical air, second with oxygen
3059290|NCT00886691|Experimental|Arm I (bevacizumab and everolimus)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and everolimus PO QD on days 1-28.
3059291|NCT00886691|Experimental|Arm II (bevacizumab and placebo)|Patients receive bevacizumab as in Arm I and placebo PO QD on days 1-28.
3059292|NCT00886704|Active Comparator|Convenience drink with EPA and DHA|Daily consumption of 200 ml convenience drink, containing 0.5 g EPA and DHA (Omega-3 Fatty Acids)
3059293|NCT00886704|Placebo Comparator|Convenience drink without EPA and DHA|Daily consumption of 200 ml convenience drink, not containing 0.5 g EPA and DHA (Omega-3 Fatty Acids), but containing 1.0 g of Omega-6 Fatty Acids (e.g. corn oil)
3059294|NCT00886743|Other|Oprelvekin as subcutaneous injection (50 mg/kg once daily)|Open label treatment with oprelvekin
3059295|NCT00886769|Experimental|Canakinumab|Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients>37.5 kg) received two sc injections.
3059296|NCT00886769|Placebo Comparator|Placebo|Patients received a single dose matching placebo of canakinumab on day 1.
3059297|NCT00886795|Experimental|Abatacept|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 weeks, and 8 weeks.
3059298|NCT00886821|Experimental|1|
3059299|NCT00886834|Experimental|Misoprostol|Misoprostol 400 micrograms inserted vaginally or buccally, per the participants desire.
3059300|NCT00886834|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
3059301|NCT00886899|Experimental|BridgePoint Medical System|Attempt to cross CTO with the BridgePoint Medical System after an attempt to cross the CTO with a currently marketed guidewire
3059302|NCT00886938|Experimental|rTMS to DLPF, pilot study|rTMS to the dorsolateral prefrontal cortex for patients with tinnitus
3059303|NCT00887068|Experimental|Azacitidine|Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
3059304|NCT00887068|No Intervention|No Azacitidine|Standard treatment post allogeneic transplant is supportive care only.
3059305|NCT00887159|Active Comparator|Arm A (CE)|Patients receive cisplatin IV over 1-2 hours on day 1 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3059306|NCT00887159|Experimental|Arm B (CE + GDC-0449)|Patients receive cisplatin and etoposide as in Arm A and vismodegib PO QD on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive vismodegib alone QD in the absence of disease progression or unacceptable toxicity.
3059307|NCT00887159|Experimental|Arm C (CE + IMC-A12)|Patients receive cisplatin and etoposide as in Arm A and cixutumumab IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cixutumumab alone once weekly in the absence of disease progression or unacceptable toxicity.
3059308|NCT00887198|Placebo Comparator|Placebo + prednisone|Placebo plus prednisone
3059309|NCT00887198|Experimental|Abiraterone + prednisone|Abiraterone acetate plus prednisone
3059310|NCT00887224|Experimental|Desvenlafaxine succinate sustained release 50 mg|
3059311|NCT00887224|Placebo Comparator|Placebo|
3059312|NCT00887250|Placebo Comparator|1|Placebo
3059313|NCT00887250|Experimental|2|Losartan 50 mg for 12 weeks
3059314|NCT00887250|Experimental|3|Losartan 50 mg titrated to 100 mg after 6 weeks
3059315|NCT00887341|Experimental|1|
3059316|NCT00887341|Active Comparator|2|
3059317|NCT00887354|Experimental|Teriparatide|"20 micrograms (mcg) a day by subcutaneous injection throughout study.~Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only."
3059318|NCT00887354|Active Comparator|Risedronate|"35 milligrams (mg) risedronate sodium orally once weekly throughout study.~Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only."
3059319|NCT00887432|Experimental|Arm I (cholecalciferol and placebo)|Patients receive cholecalciferol PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm II.
3059320|NCT00887432|Experimental|Arm II (placebo and cholecalciferol)|Patients receive placebo PO QD for 9 months in the absence of disease progression or unacceptable toxicity. After a wash-out period of 3 months, patients cross-over to Arm I.
3059321|NCT00887458|Active Comparator|Low Dose|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
3059322|NCT00887458|Active Comparator|High Dose|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
3059323|NCT00887471||Children who underwent PITA|Children who underwent partial intracapsular tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
3059324|NCT00887471||Children who underwent T&A|Children who underwent total tonsillectomy and adenoidectomy between July 2003 and January 2008 for treatment of pediatric sleep-disordered breathing documented by positive preoperative polysomnography.
3059325|NCT00887484|Experimental|Clindoxyl Gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
3059326|NCT00887484|Active Comparator|Epiduo gel|Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.
3059327|NCT00887510|Active Comparator|Thiazide First|Participants will receive 25 mg of hydrochlorothiazide (HCTZ) each day for 6 weeks, followed by 25 mg of HCTZ every day plus 4 mg of trandolapril each day for 6 weeks, followed by 4 mg trandolapril each day for 6 weeks.
3059328|NCT00887510|Active Comparator|Trandolapril First|Participants will receive 4 mg of trandolapril each day for 6 weeks, followed by 4 mg of trandolapril for 6 weeks plus 25 mg of HCTZ each day for 6 weeks, followed by 25 mg of HCTZ each day for 6 weeks.
3059329|NCT00887549|Experimental|Pemetrexed|
3059330|NCT00887562|Experimental|Idebenone 900 mg/day|Idebenone 900 mg/day
3059331|NCT00887562|Experimental|Idebenone 2250 mg/day|Idebenone 2250 mg/day
3059332|NCT00887562|Placebo Comparator|placebo|Placebo
3059333|NCT00887575|Experimental|Dose Level I|"Neoadjuvant - Paclitaxel IV (70 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.~Maintenance - Sunitinib PO (25mg) daily"
3059334|NCT00887575|Experimental|Dose Level II|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 5) day 1 of every cycle and Sunitinib PO (25mg) daily.
3059335|NCT00887575|Experimental|Dose Level III|Paclitaxel IV (80 mg/m^2) days 1, 8 and 15 of each cycle, Carboplatin IV (AUC = 6) day 1 of every cycle and Sunitinib PO (25mg) daily.
3059336|NCT00887588|Experimental|LCZ696|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 50 mg LCZ696 for 1- 2 weeks, then uptitrated to 100 mg bid for 1 -2 weeks, and thereafter, uptitrated to 200 mg bid.
3059337|NCT00887588|Active Comparator|Valsartan|During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
3059338|NCT00887640|Experimental|Temsirolimus 25 mg|Temsirolimus 25mg was administered by IV infusion each week (days 1, 8, 15, and 22 of each 28 day cycle). The infusion was to be administered over a period not less than 30 minutes and was to be completed within 60 minutes. Subjects were premedicated with 25 to 50 mg IV or PO diphenhydramine (or an alternative antihistamine in case of allergies) 30 minutes prior to the infusion.
3059339|NCT00887653|Experimental|Raltegravir|This is a single arm study where HIV-infected individuals virologically suppressed on current regimen will be switched to raltegravir +optimized back ground regimen for 6 months
3059340|NCT00887679|Experimental|Escitalopram|Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Open label, rater-blinded, prospective, 6-week trial of escitalopram.Subjects received escitalopram 10-20mg. Escitalopram was started at 10mg per day and augmented weekly in 10mg per day increments, the maximum dose being 20mg per day.
3059341|NCT00887744|Other|Aperius Treatment Arm|Single Arm
3059342|NCT00887783|Experimental|B: 66Gy/33F+Navelbine oral 150 mg q3w|"Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 66 Gy (2 Gy x 30, 5 F á weeks).~Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization"
3059343|NCT00887783|Active Comparator|A: 60Gy/30F+Navelbine oral 150 mg q3w|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks concomitant with curatively intended irradiation to 60 Gy (2 Gy x 30, 5 F á weeks) Radiation technique: 3D, 4D og VMAT techniques. The patients all had 2 cycles of carboplatin and vinorelbine before randomization
3059344|NCT00887809|Experimental|gemcitabine and docetaxel with bevacizumab|Patients will receive bevacizumab at 15 mg/kg on day 1 of each 21-day cycle intravenously over 30 minutes followed by a one hour (+30/-15 min) break. For cycles 1 through 6, gemcitabine will be administered at 900 mg/m2 over 90 minutes on day 1 and 8 of a 21-day cycle. Docetaxel will be administered at 75 mg/m2, over 60 minutes, on day 8. This will be followed by either 5 days of filgrastim or a single injection of pegfilgrastim. For cycles 7 and beyond, gemcitabine will be given at 800 mg/m2 over 30 minutes on day 1 and 8; docetaxel will be given at 35 mg/m2 over 30 minutes, also on days 1 and 8.
3059345|NCT00887822|Experimental|Bevacizumab, Capecitabine and Cisplatin|Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
3059346|NCT00887822|Placebo Comparator|Placebo, Capecitabine and Cisplatin|Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
3059347|NCT00887926|Experimental|IMC-EB10 5 milligrams/kilogram (mg/kg)|All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
3059348|NCT00887965|Other|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
3059349|NCT00887978|Placebo Comparator|Placebo|Identical placebo tablets to UT-15C, doses were titrated in the same manner
3059350|NCT00887978|Experimental|UT-15C SR|Doses were initiated at 0.25 mg BID and increased by 0.25 mg BID every three days (as clinically indicated based on tolerability and symptoms of PAH), to a max dose of 16 mg BID.
3059351|NCT00888134|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3059352|NCT00888173|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3059353|NCT00888238|Experimental|Sitagliptin/Sitagliptin/Placebo|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3059354|NCT00888238|Experimental|Sitagliptin/Placebo/Sitaglipitin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3059355|NCT00888238|Experimental|Placebo/Sitagliptin/Sitagliptin|Sitagliptin in 2 of 3 treatment periods and Placebo in 1 of 3 treatment periods
3059356|NCT00888329|Experimental|Aprepitant|40 mg aprepitant
3059357|NCT00888329|Placebo Comparator|Placebo|Placebo
3059358|NCT00888355|Placebo Comparator|1|Placebo
3059359|NCT00888355|Experimental|2|Losartan 50 q.a.m.
3059360|NCT00888355|Experimental|3|Losartan 25 b.i.d.
3059361|NCT00888355|Experimental|4|Losartan 25 q.a.m.
3059362|NCT00888381|Experimental|Adults|Healthy volunteers aged 18 to 59 years
3059363|NCT00888381|Experimental|Older Adults|Healthy volunteers aged 60 years or older
3059364|NCT00888433|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications
3059365|NCT00888433|No Intervention|Control|Maintenance of anti-hypertensive medications with option for cross-over treatment after 6-months
3059366|NCT00888459|Active Comparator|active|Self-help counseling material and 4 mg nicotine lozenges
3059367|NCT00888459|Placebo Comparator|2|self help counseling material and placebo nicotine lozenges
3059368|NCT00888511|Experimental|1|
3059369|NCT00888615|Experimental|Treatment (paclitaxel, elesclomol sodium)|Patients receive paclitaxel IV over 1 hour and elesclomol sodium IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients who are currently on treatment must not be dosed with elesclomol sodium after 12/31/2015. All other study procedures, with the exception of elesclomol sodium administration and paclitaxel administration, should continue in accordance with protocol requirements. Any treatment given after 12/31/2015, including continuation of paclitaxel, will be considered off study.
3059370|NCT00888628|Experimental|Islet transplant|"Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving insulin independence.~For the first islet transplant, patients will receive induction therapy with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance immunosuppression regimen already in place for their renal allograft.~Induction therapy for subsequent transplants will be 2 doses of basiliximab.~All patients will receive Etanercept to promote engraftment."
3059371|NCT00888654|Experimental|B-Dim, Radical Prosatectomy|"B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)~Radical Prostatectomy"
3059372|NCT00888849|Experimental|Stapling|
3059373|NCT00888849|Active Comparator|Suturing|4 layered hand-sutured anastomosis
3059374|NCT00888927|Experimental|Phase 1 Cohort 1|First course: 0.1 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.1 mg/kg over 1 hour every other week
3059375|NCT00888927|Experimental|Phase 1 Cohort 2|First course: 0.3 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 0.3 mg/kg over 1 hour every other week
3059376|NCT00888927|Experimental|Phase 1 Cohort 3|First course: 1.0 mg/kg once a week over 1 hour for 4 weeks Subsequent courses: 1.0 mg/kg over 1 hour every other week
3059377|NCT00888927|Experimental|Phase 2|First course: Maximum tolerated dose once a week over 1 hour for 4 weeks Subsequent courses: Maximum tolerated dose over 1 hour every other week
3059378|NCT00888940|Experimental|ecallantide|
3059379|NCT00888940|Active Comparator|Cyklokapron(R)|
3059380|NCT00888979|Experimental|Nicotrol with Behavioral Counseling|Nicotrol Inhaler: 10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
3059381|NCT00889005|Experimental|Cognitive Behavioral Therapy|Five sessions of trauma-focused, telephone based cognitive behavioral therapy, followed by assessment and referral to clinical treatment if needed.
3059382|NCT00889005|No Intervention|Waitlist control group|Five weeks without active intervention, followed by assessment and referral to clinical treatment if needed.
3059383|NCT00889187|Experimental|Phase 1 Cohort 1: Photon Rad (30 Gy/12 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 1, a total dose of 30 Gy in 10 fractions (3 Gy/day) was prescribed to the 95% isodose and administered 5 days per week over 12 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3059384|NCT00889187|Experimental|Phase I Cohort 2: Photon Rad (25 Gy/11 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 2, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 11 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3059385|NCT00889187|Experimental|Phase I Cohort 3: Photon Rad (25 Gy/5 days)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~At dose level 3, a total dose of 25 Gy in 5 fractions was prescribed to the 95% isodose and administered at 5 Gy per fraction over 5 days.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3059386|NCT00889187|Experimental|All Phase I: Photon Rad+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~All Phase I participants received the radiation regimen according to the established dose escalation schedule.~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3059387|NCT00889187|Experimental|Phase II: Photon Rad (MTD)+Capecitabine|"Neoadjuvant Short-Course Photon Radiation:~Phase II participants received the radiation regimen established in the Phase I study (MTD).~Chemotherapy:~Capecitabine was given orally 825 mg/m2 BID (total 1650 mg/m2 per day) for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy.~Patients underwent resection of their pancreatic cancer 1-3 weeks after the completion of chemoradiation. It was recommended that patients undergoing R0 or R1 resections receive adjuvant treatment with 4-6 cycles of gemcitabine-based therapy per institutional policy, to start 4 to 10 weeks after the operation."
3059388|NCT00889200|Experimental|Open-label Eszopiclone|Standard dosing of drug for 6 weeks for insomnia
3059389|NCT00889226|Experimental|Pitavastatin Group|
3059390|NCT00889226|Active Comparator|Atorvastatin Group|
3059391|NCT00889252|Experimental|K-Lens|Ketotifen combination drug-device product: contact lens (device) and anti-allergy drug
3059392|NCT00889252|Placebo Comparator|Placebo Lens|Placebo lens
3059393|NCT00889265|Experimental|CopiOs Pericardium Membrane|Subject's study site must exhibit a partially edentulous ridge of the maxilla or mandible with at least one tooth-span in length and less than 5.5mm in its smallest buccolingual dimension as measured by ridge-mapping calipers.
3059394|NCT00889330|Experimental|alcaftadine ophthalmic solution|active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
3059395|NCT00889330|Placebo Comparator|inactive ophthalmic solution vehicle|Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
3059396|NCT00889512|Active Comparator|Luveris Fixed dose|Participants in this arm will take Gonal F® and the same dose of Luveris® throughout the cycle. Their dose of Gonal F® will be adjusted throughout the cycle based on their response to the medication. The Luveris® dose will remain constant throughout.
3059397|NCT00889512|Experimental|Luveris increasing dose|Patients assigned to this group will gradually reduce the Gonal F® dose while increasing the Luveris® dose during the cycle, which more closely mimics the natural menstrual cycle.
3059398|NCT00889603||1|
3059399|NCT00889681|Experimental|Ablation|All study subjects will be receive cryo ablation with the experimental devices and, optionally, an Atrial Fibrillation Drug.
3059400|NCT00889707|Experimental|Active Drug|PRX302
3059401|NCT00889707|Placebo Comparator|Placebo|Placebo
3059402|NCT00889720|Other|Smoking cessation tratment including varenicline|
3059403|NCT00889824|Experimental|prosthesis group|balance prosthesis
3059404|NCT00889863|Experimental|Canakinumab|In Part I participants received open label 4 mg/kg canakinumab subcutaneous injection every 4 weeks for up to 32 weeks. For the first 8 weeks Part Ia (4 weeks) and Ib (4 weeks) patients maintained a stable oral steroid dose (prednisone or equivalent) followed by Ic an up to 20 week steroid tapering period and then Id a 4 week stable steroid dose period. Participants were then randomized to receive either 4 mg/kg canakinumab subcutaneous injection or placebo comparator in Part II and remained on the stable oral steroid dose for 24 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤ 0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤ 0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
3059405|NCT00889863|Placebo Comparator|Placebo|Participants in Part II received placebo matching canakinumab subcutaneous injection every 4 weeks. At 24 weeks in Part II participants with a >0.2 mg/kg and ≤0.5 mg/kg and no flare could restart steroid tapering. If the steroid dose was ≤0.2 mg/kg participants continued to maintain their current dose for the remainder of Part II.
3059406|NCT00889915|Active Comparator|1|Participants will receive methylphenidate transdermal system.
3059407|NCT00889915|Active Comparator|2|Participants will receive lisdexamfetamine dimesylate.
3059408|NCT00889915|Active Comparator|3|Participants will receive osmotic-release oral system methylphenidate (OROS MPH).
3059409|NCT00889915|Active Comparator|4|Participants will receive mixed amphetamine salts extended release.
3059410|NCT00889928|Experimental|cholecystectomy|transvaginal cholecystectomy
3059411|NCT00890045|Active Comparator|Control graft|Conventional ePTFE hemodialysis graft
3059412|NCT00890045|Experimental|HeRO Vascular Access Device|HeRO Vascular Access Device
3059413|NCT00890084||Group1|
3059414|NCT00890097|Experimental|AL-8309B 1.0%|AL-8309B 1.0% Ophthalmic Solution, 1 drop in each eye twice daily for 30 months, up to a maximum of 36 months
3059415|NCT00890097|Experimental|AL-8309B 1.75%|AL-8309B 1.75% Ophthalmic Solution, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
3059416|NCT00890097|Placebo Comparator|Vehicle|AL-8309B Vehicle, 1 drop in each eye twice daily, for 30 months up to a maximum of 36 months
3059417|NCT00890162|Active Comparator|Omalizumab|Subjects will receive two doses of Omalizumab while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
3059418|NCT00890162|Placebo Comparator|Placebo|Subjects will receive two doses of placebo while hospitalized, followed by continued outpatient therapy, every 2 to 4 weeks, for up to 6 months.
3059419|NCT00890201||Normal Gallbladder|"Patients with normal gallbladder (without gallstones) evidenced by preoperative ultrasonography (and postoperative biopsy) submitted to elective gastroesophageal surgery (gastrectomy for gastric cancer, bariatric surgery or esophageal surgery such as Nissen plicature or miotomy for achalasia).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography. Preoperative values of amylase and lipase must be normal."
3059420|NCT00890201||Gallbladder with gallstones|"Patients submitted to elective cholecystectomy for diseased gallbladders (gallbladder with gallstones evidenced by preoperative ultrasound).~The pancreaticobiliary junction must be normal as evidenced by intraoperative cholangiography and the preoperative amylase and lipase levels must also be normal."
3059421|NCT00890396||Active Follow-up|An active follow-up involved the performance of many of the laboratory tests and procedures done during BABY HUG clinical trials study. These included, but not limited to, serial laboratory parameters that were not part of routine clinical care such as Hgb F levels, pitted cell count, Howell-Jolly Body determination, a liver-spleen scan, diethylenetriaminepentaacetic acid (DTPA) glomerular filtration rate (GFR) measurement, creatinine clearance, Cystatin C, urine concentrating ability, transcranial Doppler, and neuropsychological testing.
3059422|NCT00890396||Passive Follow-up|A passive follow-up involved the abstraction of clinical data from the medical record. Results of physical examinations and laboratory tests performed as part of routine clinical care were recorded.
3059423|NCT00890409|No Intervention|Normothermia|Rectal temperature was maintained at 36.0-37.5 degree C.
3059424|NCT00890409|Experimental|Hypothermia|The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
3059425|NCT00890552|Experimental|Lenalidomide+Melphalan+Dexamethasone|Patients received lenalidomide 10 mg/day orally on days 1-21, melphalan 0.18 mg/kg orally on days 1-4, and dexamethasone 40 mg orally once weekly of a 28-day cycle (MDR treatment).
3059426|NCT00890591|Experimental|Treatment|
3059427|NCT00890617|Experimental|Prednisone & Cryotherapy|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
3059428|NCT00890656|Experimental|Augmented Hyper-CVAD|Hyper-CVAD (courses 1, 3, 5, and 7) alternated with high-dose methotrexate/ara-C (courses 2, 4, 6, and 8) administered on day 21; Hyper-CVAD = Cyclophosphamide, Vincristine, Doxorubicin, Decadron + Pegaspargase.
3059429|NCT00890682|Experimental|Sky0402|Injection of Study Drug
3059430|NCT00890682|Placebo Comparator|Placebo|Injection of study drug
3059431|NCT00890695|Active Comparator|Ready to use supplementary food (RUSF)|The RUSF intervention consists of a food paste made of maize, soya, sorghum, vegetable oil, sugar, dried skim milk and vitamin/mineral premix, prepared by VALID Nutrition in collaboration with Insta Products, Kenya in accordance with composition specified by the latest WHO expert consultation in 2008. Children in the intervention arm receive 4 weeks supply of RUSF. The amount supplied is based on the child's weight to give energy supplement of 100kcal per kg per day, equivalent to 25g RUSF per kg per day.
3059432|NCT00890695|No Intervention|Normal diet (standard of care)|For equity, parents or guardians of children in the usual diet arm will be given 2 bags of maize meal(4Kg) for family consumption instead of RUSF. All parents and carers in both arms will also receive standard nutritional advice as specified in the current WHO IMCI handbook.
3059433|NCT00890721|Experimental|SKY0402|During the hemorrhoidectomy, 30cc of SKY0402 is injected into the wound.
3059434|NCT00890721|Placebo Comparator|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
3059435|NCT00890825|Active Comparator|AZD6244 + Docetaxel|AZD6244 75 mg bd + Docetaxel 75 mg/m^2
3059436|NCT00890825|Placebo Comparator|Placebo + Docetaxel|Placebo + Docetaxel 75 mg/m^2
3059437|NCT00890916|Experimental|Neuroprosthesis System|Receives implanted device for hand function.
3059438|NCT00890929|Experimental|Azacitidine followed by lenalidomide|Dose escalation then dose expansion
3059439|NCT00890981|Other|Arm 1|Participants who were randomized to either denosumab or placebo in Study 20050179 and at least 12 months had elapsed from their 20050179 end-of-study visit had dual energy X-ray absorptiometry (DXA) of the forearm and HR-pQCT of the tibia and radius on Day 1 of this study. No study drug was administered.
3059440|NCT00891020|Experimental|Tocilizumab 8 mg/kg Monotherapy|Participants received Tocilizumab 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3059441|NCT00891020|Experimental|Tocilizumab 4 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 4 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants not achieving a 20% improvement from baseline in tender and swollen joint counts at Week 8 were to have their dosage increased to 8 mg/kg, per protocol. Beginning at Week 12 dosage increase to 8 mg/kg was at the discretion of the investigator. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3059442|NCT00891020|Experimental|Tocilizumab 8 mg/kg + DMARD|Participants received Tocilizumab (TCZ) 8 mg/kg as a 60 minute intravenous infusion every 4 weeks for a total of 6 infusions plus non-biologic disease-modifying antirheumatic drug (DMARD) of the investigator's choice for 24 weeks. Participants who completed the 24 week treatment period were offered the option of entering a long-term extension phase at the investigator's discretion.
3059443|NCT00891046|Experimental|Canakinumab|Canakinumab
3059444|NCT00891176|Experimental|Synflorix-Meningitec Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age 2 primary doses of Meningitec intramuscularly into the lower left thigh at 2 and 4 months of age. 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Meningitec at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
3059445|NCT00891176|Experimental|Synflorix-NeisVac-C Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 2 primary doses of Neis-Vac-C intramuscularly into the lower left thigh at 2 and 4 months of age and 3 primary doses of Infanrix hexa intramuscularly into the upper left thigh at 2, 4 and 6 months of age. (In Poland subjects were offered a third dose of Neis-Vac-C at 7 months of age to comply with national recommendations). During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV/Hib was given instead of Infanrix hexa.
3059446|NCT00891176|Experimental|Synflorix-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Synflorix intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
3059447|NCT00891176|Active Comparator|Prevenar-Menitorix Group|Subjects who received concomitantly in the primary study (NCT00334334): 3 primary doses of Prevenar intramuscularly into the right thigh at 2, 4 and 6 months of age, 3 primary doses of Menitorix intramuscularly into the lower left thigh at 2, 4 and 6 months of age and 3 primary doses of Infanrix penta intramuscularly into the upper left thigh at 2, 4 and 6 months of age. During the booster study (NCT00463437) subjects received the same vaccines as during the primary study at 11-18 months of age, with the exception of Spain, where Infanrix IPV was given instead of Infanrix penta.
3059448|NCT00891202|Experimental|Active|Eliglustat
3059449|NCT00891202|Placebo Comparator|Placebo|Placebo
3059450|NCT00891228|Placebo Comparator|Testosterone Gel 10 g and Nestorone® 0 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
3059451|NCT00891228|Experimental|Testosterone Gel 10 g and Nestorone® 8 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
3059452|NCT00891228|Experimental|Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day|Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
3059453|NCT00891293|Experimental|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
3059454|NCT00891319|Experimental|CCFES|"CCFES - Contralaterally Controlled Functional Electrical Stimulation~Electrical stimulator~Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand.~A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity.~Therapy sessions are done with the subject being assisted by the CCFES system."
3059455|NCT00891319|Active Comparator|cNMES|"cNMES - Cyclic NeuroMuscular Electrical Stimulation~Electrical stimulator~Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand.~Subject instructed to not move the contralateral arm/hand during stimulation.~Therapy sessions are done without the stimulation system."
3059456|NCT00891371|Experimental|lanreotide (Autogel formulation) Autogel 120mg|lanreotide (Autogel formulation) Autogel 120mg
3059457|NCT00891436|Placebo Comparator|Placebo nasal spray|
3059458|NCT00891436|Active Comparator|Fluticasone furoate nasal spray|
3059459|NCT00891462|Experimental|1|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
3059460|NCT00891462|Experimental|2|Aclidinium bromide dose, inhaled, for 12 weeks of treatment
3059461|NCT00891462|Placebo Comparator|3|Inhaled placebo for 12 weeks
3059462|NCT00891527|Experimental|Avastin and/or Gleevec|Patients were all treated with Gleevec (imatinib mesylate) and those without congenital heart disease and those who progressed were also treated with Avastin (bevacizumab).
3059463|NCT00891618|Experimental|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
3059464|NCT00891657|Experimental|SprayShield™|SprayShield™
3059465|NCT00891657|No Intervention|Control|No adhesion barrier administered.
3059466|NCT00891735|Experimental|Ranibizumab 0.5 mg monthly|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 24 months.
3059467|NCT00891735|Experimental|Ranibizumab 2.0 mg monthly|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 24 months.
3059468|NCT00891735|Experimental|Ranibizumab 0.5 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 0.5 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 0.5 mg administered intravitreally.
3059469|NCT00891735|Experimental|Ranibizumab 2.0 mg as-needed (pro re nata [PRN])|Patients received ranibizumab 2.0 mg monthly administered intravitreally for 3 months. Thereafter, patients' visual acuity and eye disease activity were assessed monthly for an additional 21 months. If study defined criteria were met at a monthly assessment, patients received ranibizumab 2.0 mg administered intravitreally.
3059470|NCT00891774|Experimental|Device|Treatment with EVOLENCE®
3059471|NCT00891813|Experimental|Zemplar (paracalcitol)|
3059472|NCT00891839|Experimental|Bendamustine+Rituximab|Patients receive bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2, and 375 mg/m^2 of rituximab by iv on day 1 of each 28-day cycle. Six 28-day cycles were planned and up to 8 cycles permitted for patients who do not have progressive disease and who have not achieved a complete response (CR).
3059473|NCT00891878|Experimental|Arm I|Patients receive oral capecitabine twice daily on days 1-14. Patients experiencing disease progression may crossover to arm II at the physician's discretion.
3059474|NCT00891878|Experimental|Arm II|Patients receive oral capecitabine as in arm 1 and oral sunitinib malate once daily on days 1-21.
3059475|NCT00891930|Experimental|Panitumumab|Participants received panitumumab (6 mg/kg starting dose) with irinotecan (starting dose of 180 mg/m²) every 2 weeks (Q2W) during Part 1. Upon radiographically confirmed disease progression, participants proceeded to Part 2 of the study and received treatment with panitumumab (6 mg/kg starting dose) and ganitumab (12 mg/kg starting dose) Q2W.
3059476|NCT00891982|Experimental|CTGel plus BPO wash|Benzoyl peroxide (BPO) Wash in the morning and CTGel in the evening
3059477|NCT00891982|Active Comparator|CTGel|Soap Free Cleanser in the morning and CTGel in the evening
3059478|NCT00891995|Experimental|Intensive Treatment|closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
3059479|NCT00891995|Active Comparator|Standard Treatment|home glucose monitoring (2 years)
3059480|NCT00892008||Open-Label|This study was open-label with only one treatment group. Pregabalin was prescribed in accordance with usual clinical practice.
3059481|NCT00892047|Experimental|1: venlafaxine plus aripiprazole|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
3059482|NCT00892047|Experimental|2: Placebo Comparator|antidepressant (venlafaxine) plus aripiprazol or venlafaxine plus placebo
3059483|NCT00892099|Experimental|High Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol weekly
3059484|NCT00892099|Experimental|Low Dose Ergocalciferol|Receives 50,000 IU of ergocalciferol per month
3059485|NCT00892099|Placebo Comparator|Placebo|Receives no ergocalciferol
3059486|NCT00892151|Experimental|Intended Users of the Software|10 Healthcare Professionals and 40 persons with diabetes (of which 6 were parents/legal guardians of children with diabetes) using a diabetes data management program.
3059487|NCT00892177|Experimental|Arm I|Patients receive bevacizumab on Day 1 and dasatinib on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3059488|NCT00892177|Active Comparator|Arm II|Patients receive bevacizumab on Day 1 and placebo on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3059489|NCT00892281|Other|Oracea® as monotherapy|Oracea as monotherapy
3059490|NCT00892281|Other|Oracea® as add-on therapy|Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides
3059491|NCT00892437|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo +ATV+FTC/TDF for 48 weeks
3059492|NCT00892437|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo +ATV+FTC/TDF for 48 weeks
3059493|NCT00892606|Experimental|Methadone|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine and 0.2 mg/kg of methadone IV with induction of general anesthesia.
3059494|NCT00892606|Active Comparator|Control|Patients received 2 µg/kg fentanyl, 0.2 mg/kg ketamine, and 0.2 mg/kg morphine (standard of care)
3059495|NCT00892697|Experimental|Arm|15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin
3059496|NCT00892710|Experimental|Pemetrexed/Bevacizumab|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days"
3059497|NCT00892710|Experimental|Pemetrexed/Bevacizumab/Carboplatin|"Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days~Bevacizumab 15 mg/kg IV every 21 days~Carboplatin AUC=5 IV every 21 days"
3059498|NCT00892710|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV given over 10 minutes every 21 days
3059499|NCT00892723|Experimental|Low Dose|
3059500|NCT00892723|Experimental|High Dose|
3059501|NCT00892723|Placebo Comparator|Placebo|
3059502|NCT00892775|Experimental|Priorix-Tetra new WS Group|Subjects received 2 doses of Priorix-Tetra vaccine formulated with new measles and rubella working seeds at Day 0 and Week 12.
3059503|NCT00892775|Experimental|Priorix-Tetra current WS Group|Subjects received 2 doses of Priorix-Tetra vaccine manufactured with current working seed virus at Day 0 and Week 12.
3059504|NCT00892957|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr will be applied to the study suture line.
3059505|NCT00892957|Active Comparator|Manual compression with surgical gauze pads|Dry gauze pads will be positioned to cover the complete study suture line.
3059506|NCT00893074|Other|0, 30, 60, and 120mg dronabinol|0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing
3059507|NCT00893113|Placebo Comparator|Placebo, Then Alfuzosin|Participants first received 1 Placebo tablet once daily for 12 weeks. Participants then received a 10 mg tablet of Alfuzosin daily for 12 weeks.
3059508|NCT00893113|Experimental|Alfuzosin, Then Placebo|Participants first received a 10 mg tablet of Alfuzosin once daily for 12 weeks. Participants then received 1 Placebo tablet once daily for 12 weeks.
3059509|NCT00893152||Group 1|Male veterans (focus groups and individual interviews)
3059510|NCT00893152||Group 2|Female veterans (focus groups and individual interviews)
3059511|NCT00893152||Group 3|Family members of participating veterans (focus groups and individual interviews)
3059512|NCT00893464|Experimental|IXAZOMIB|
3059513|NCT00893737|Experimental|Treximet|Treximet (a combination of sumatriptan 85 mg and naproxen sodium 500 mg) 1 tablet to be administered as soon as patient has headache indicative of migraine. Patient may treat up to 16 migraine attacks in 2 month study period.
3059514|NCT00893763|Experimental|Pre-intubation CHX|Chlorhexidine applied to oral cavity prior to intubation
3059515|NCT00893763|Active Comparator|Control|No chlorhexidine applied to oral cavity prior to intubation
3468793|NCT03892109|Active Comparator|Gingitrac|The gingitrac cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the selected abutment. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
3059520|NCT00893971|Experimental|1|Inhaled PT001 18 μg
3059521|NCT00893971|Experimental|2|Inhaled PT005 2.4 μg
3059522|NCT00893971|Experimental|3|Inhaled PT003 (PT001 18 μg / 2.4 μg PT005)
3059523|NCT00893971|Experimental|4|PT001 18 μg + PT005 2.4 μg
3059524|NCT00893984|Experimental|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
3059525|NCT00893997|Experimental|PR-1 vaccine|4 injections of 0.5 mg PR1 peptide vaccine every 3 weeks.
3059526|NCT00894127|Experimental|CyPath Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from two cohorts, including (1) high-risk control group comprised of individuals not diagnosed but at high risk for lung cancer (n=102) and, (2) cancer group comprised of individuals with confirmed lung cancer diagnosis (n=26), was labeled in exact manner with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
3059527|NCT00894166|Active Comparator|Nicotine Replacement Therapy Responder|Nicotine Responders
3059528|NCT00894166|Active Comparator|Pre-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
3059529|NCT00894166|Active Comparator|Pre-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
3059530|NCT00894166|Active Comparator|Pre-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
3059531|NCT00894166|Active Comparator|Post-Quit Rescue to Bupropion & Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
3059532|NCT00894166|Active Comparator|Post-Quit Rescue to Varenicline|Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
3059533|NCT00894166|Active Comparator|Post-Quit Rescue to Nicotine|Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
3059535|NCT00894322|Experimental|Cohort 1: Healthy Participants|A single 10-mg dose of exenatide once weekly suspension given to healthy participants via 3 subcutaneous (SC) injections at Day 1.
3059536|NCT00894322|Experimental|Cohort 2: Diabetes Participants|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of exenatide suspension for 12 weeks.
3059537|NCT00894322|Placebo Comparator|Cohort 2: Diabetes Participants Placebo|On Day 1, participants with type 2 diabetes mellitus treated with diet and exercise alone or with a stable regimen of metformin, thiazolidinedione (TZD), or a combination of metformin or TZD were randomized to receive weekly injections of medium-chain triglycerides (MCT)-diluent placebo for 12 weeks.
3059538|NCT00894361|Active Comparator|rotating-platform design TKA|patients who were randomized to receive the rotating platform mobile-bearing TKA design
3059539|NCT00894361|Active Comparator|all-polyethylene tibia design TKA|patients who were randomized to receive the all-polyethylene tibial component design
3059540|NCT00894387|Experimental|Aliskiren|Randomized patients in this arm received, Aliskiren 150 mg once daily for 2 weeks. From week 2 upto 6 months , patients who could tolerate study medication were up-titrated to aliskiren 300 mg once daliy.
3059541|NCT00894387|Placebo Comparator|Placebo|Randomized patients in this arm received matching placebo of Aliskiren. At week 2, Patients who could tolerate study medication were up-titrated to matching placebo of 300 mg aliskiren.
3059542|NCT00894413|Placebo Comparator|Placebo|
3059543|NCT00894413|Experimental|Tadalafil|Tadalafil 20 mg once per day
3059544|NCT00894465|Experimental|Versed|Both patients who are VCUG naive and patients who have had a previous VCUG are given oral midazolam prior to undergoing the VCUG.
3059545|NCT00894465|Placebo Comparator|Placebo|Both patients who are VCUG naive and patients who have had a previous VCUG are given an oral placebo prior to undergoing the VCUG.
3059546|NCT00894504|Experimental|Panitumumab/Gemcitabine/Carboplatin|Systemic therapy
3059547|NCT00894517|Experimental|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
3059548|NCT00894517|Placebo Comparator|Placebo (saline)|Placebo (saline) injected into the prostate on Day 1.
3059549|NCT00894543|Active Comparator|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI)
3059550|NCT00894543|Placebo Comparator|Placebo|Inactive pill
3059551|NCT00894556|Experimental|Treatment Sequence A|Rizatriptan - Rizatriptan - Placebo
3059552|NCT00894556|Experimental|Treatment Sequence B|Rizatriptan - Placebo - Rizatriptan
3059553|NCT00894556|Experimental|Treatment Sequence C|Placebo - Rizatriptan - Rizatriptan
3059554|NCT00894556|Other|Baseline Phase|Sumatriptan
3059555|NCT00894647|Placebo Comparator|2|placebo cream in 250mg/packet, up to 2 packets applied daily
3059556|NCT00894647|Active Comparator|imiquimod cream|Imiquimod 3.75% cream, 250 mg single-use packets, up to 2 packets applied daily
3059557|NCT00894686|Experimental|All subjects|Assessment of seropersistence of TBE antibodies at yearly intervals from approximately 3 years (38 months) to 10 years (118 months) after the first booster vaccination (in Study 700401), as well as antibody response to a second booster vaccination with either FSME-IMMUN 0.25 mL Junior or FSME-IMMUN 0.5 mL, depending on the subject´s age. Timing of the second booster vaccination will depend on the level of serum TBE antibodies detected at the defined assessment time points. Subjects who are not protected against TBE for an entire further season (NT titer <= 20 and/or ELISA value <=126 VIE U/mL) will be invited to receive the second booster vaccination at either the 40, 48, 60, 72, 84, 96, 108, or 120-month time point.
3059558|NCT00894699|Active Comparator|1|single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
3059559|NCT00894699|Placebo Comparator|2|single dose of sublingual Placebo NanoTab™
3059560|NCT00894738||antipsychotic treated|Children with psychiatric diagnoses who are currently treated with antipsychotic medications.
3059561|NCT00894738||healthy control|Age- and gender-matched children who do not have a psychiatric diagnosis, are not taking antipsychotic medications, and are otherwise healthy.
3059562|NCT00894803|Active Comparator|rt-PA only|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA given over 60 minutes. One out of 6 subjects will be in this group.
3059563|NCT00894803|Experimental|rt-PA and Eptifibatide|Subject will receive the standard dose (0.9mg/kg) of IV rt-PA. This IV dose will be discontinued at 40 minutes. The subject will immediately receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours. Five out of six subjects will be in this group.
3059564|NCT00894933|Experimental|Continuum|Verify the consistency of performance of the AMS CONTINUUM device in facilitating a sustainable anastomosis following a radical prostatectomy using updated Device design elements and Physician training materials on Device implant technique.
3059565|NCT00895011|Placebo Comparator|Placebo|
3059566|NCT00895011|Experimental|Avanafil 100 mg|
3059567|NCT00895011|Experimental|Avanafil 200 mg|
3059568|NCT00895037||1|Patients treated with Refacto AF
3059569|NCT00895154|Active Comparator|General Tutoring Group|Participants will receive general tutoring in the subject of his/her choice.
3059570|NCT00895154|Experimental|Tutoring + Memory Training Group|Participants will receive tutoring and memory training.
3059571|NCT00895180|Experimental|Group 1|Patients receive ramucirumab IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3059572|NCT00895180|Experimental|Group 2|Patients receive olaratumab IV over 60-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3059573|NCT00895193|Active Comparator|Apple-pectin 2000mg|Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3059574|NCT00895193|Active Comparator|Regular Non-enteric coated aspirin 325mg|Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3059575|NCT00895193|Active Comparator|Apple pectin + aspirin|Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3059576|NCT00895193|Placebo Comparator|Placebo Comparator|Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.
3059577|NCT00895232|Experimental|Cohort I|500 mg dose Venofer over 4 hours
3059578|NCT00895232|Experimental|Cohort II|500 mg Venofer infusion over 4-6 hours on Day 0 and repeated on Day 2 to 7
3059579|NCT00895232|Experimental|Cohort III|500 mg Venofer over 6 hours, followed within 24 hours by 500 mg Venofer over 6 hours
3059580|NCT00895245|Experimental|Arm I|"Patients receive cisplatin IV on day 1. Treatment repeats every 21 days for up to 3 courses. Patients also undergo radiotherapy once daily 5 days a week for up to 7 weeks.~Patients receive fosaprepitant dimeglumine IV, palonosetron hydrochloride IV, and dexamethasone IV on day 1.Patients then receive oral dexamethasone on days 2-4. Patients with no emesis or requirement for rescue anti-emetics in the first 120 hours after cisplatin infusion continue to receive the anti-emetic regimen as above with the second and third courses of cisplatin.~Patients complete an emesis diary daily for 5 days after each cisplatin infusion. Patients also complete a Functional Living Index-Emesis Questionnaire on day 8 after each cisplatin infusion."
3059581|NCT00895310|Experimental|Ketoconazole and Hydrocortisone|Ketoconazole 200mg PO TID + Hydrocortisone 20mg PO Qam, 10mg PO Qpm
3059582|NCT00895414|Experimental|Doxorubicin alone first, then Doxorubicin with Enalapril|Patients receive doxorubicin hydrochloride IV over 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2.
3059583|NCT00895414|Experimental|Doxorubicin with Enalapril first, then Doxorubicin alone|Patients receive doxorubicin hydrochloride IV on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
3059584|NCT00895453|Active Comparator|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid).
3059585|NCT00895453|Active Comparator|itraconazole + lactobacilli agent|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid). Additionally, Lactobacillus vaginal tablets monthly given through 6 days.
3059586|NCT00895453|Active Comparator|classic homeopathy (CH)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
3059587|NCT00895531|Active Comparator|Peripheral Nerve group|Group will receive sciatic catheter placed before or after surgery by subgluteal approach with the use of ultrasound. The ischial tuberosity will be identified with the ultrasound probe and its midpoint marked. A catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
3059588|NCT00895531|Experimental|Depodur Group|patients will have an L2-L3 epidural placed while they are in the sitting position before or after femoral catheter placement. They will receive 7.5 mg Depodur via the epidural catheter. All of these patients will receive Singular 10 mg and Claritin 10 mg before the epidural Depodur is placed, as per our protocol of patients receiving EREM.
3059589|NCT00895583|Experimental|Group I - Planned transition to sirolimus from tacrolimus|
3059590|NCT00895583|Active Comparator|Group II - Continuation of tacrolimus|
3059591|NCT00895622|No Intervention|Low Risk|No treatment given.
3059592|NCT00895622|Experimental|Intermediate Risk|54 Gy radiotherapy
3059593|NCT00895622|Experimental|High Risk|60 Gy radiotherapy
3059594|NCT00895661|Other|rituximab|single-arm, open-label, interventional
3059595|NCT00895752|Experimental|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
3059596|NCT00895817|Active Comparator|Swallowed fluticasone|
3059597|NCT00895817|Active Comparator|Esomeprazole|
3059598|NCT00895830|Placebo Comparator|1|
3059599|NCT00895830|Experimental|2|0.3mg dose level
3059600|NCT00895830|Experimental|3|1mg dose level
3059601|NCT00895830|Experimental|4|2mg dose level
3059602|NCT00895830|Experimental|5|3mg dose level
3059603|NCT00895843|Active Comparator|Conventional ibuprofen|
3059604|NCT00895843|Experimental|Brufen retard|
3059605|NCT00895895|Placebo Comparator|1|Placebo
3059606|NCT00895895|Experimental|2|SAM-531 1.5 mg
3059607|NCT00895895|Experimental|3|SAM-531 3.0 mg
3059608|NCT00895895|Experimental|4|SAM-531 5.0 mg
3059609|NCT00895895|Active Comparator|5|Donepezil
3059610|NCT00895921|Active Comparator|Aripiprazole|Participants will receive an injection of aripiprazole during the tracer-clamp study.
3059611|NCT00895921|Active Comparator|Olanzapine|Participants will receive an injection of olanzapine during the tracer-clamp study.
3059612|NCT00895934|Experimental|Phase 1 - Dose Finding|Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. Includes cohorts 1-3.
3059613|NCT00895934|Experimental|Phase 2 - Treatment at Selected Dose|Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, gemtuzumab ozogamicin 3 mg/m2/day on days 4 and 8.
3059614|NCT00895947|Experimental|Interferon-alpha|150 international units of interferon-alpha
3059615|NCT00895947|Placebo Comparator|placebo|placebo lozenges
3059616|NCT00896012|Experimental|1. Low-dose tacrolimus arm|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months). All patients will undergo a second protocol biopsy at 12 months.
3059617|NCT00896012|Experimental|2. Rapamune conversion arm:|Patients in this group will undergo a gradual conversion from tacrolimus to Rapamune therapy. Tacrolimus will be withdrawn progressively over a period of 7-10 days. Dosage adjustments will be made with the aim of reducing the blood levels of tacrolimus by 25% every other day until tacrolimus is discontinued. Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
3059618|NCT00896038|Experimental|Aprepitant|Following a 1-week placebo lead-in period subjects were given 125 mg of Aprepitant orally daily for 21 days
3059619|NCT00896038|Placebo Comparator|Placebo|Subjects received oral placebo during the 1-week placebo lead-in and then daily for 21 days
3059620|NCT00896051|Experimental|ATV/rtv 300/100 mg (Treatment A)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pre-treatment followed by ATV/rtv 300/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will receive TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
3059621|NCT00896051|Experimental|ATV/rtv 400/100 mg (Treatment B)|Treatment-experienced human immunodeficiency virus - type 1 (HIV-1) infected participants will take by mouth atazanavir (ATV)/low-dose ritonavir (rtv) 300/100 mg once daily + 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 2 weeks pretreatment followed by ATV/rtv 400/100 mg once daily + etravirine (ETR) 200 mg twice daily + 1 NRTI for 48 weeks. If particpating in an optional substudy to assess the effect of adding tenofovir disoproxil fumarate (TDF) for 7 days on ATV and ETR pharmacokinetics, participants will take TDF 300 mg once daily for 7 days in addition to their antiretroviral regimen (ETR+ATV/rtv+NRTI).
3059622|NCT00896064|Experimental|Formulation 1|
3059623|NCT00896064|Experimental|Formulation 2|
3059624|NCT00896168|Experimental|Infliximab + Methotrexate (Moderate RA)|Participants with moderate RA (score greater than 3.2, but less than 5.1 on the disease activity score [DAS] 28) received infliximab 3 milligram per kilogram (mg/kg) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) at Week 0, 2, 6, 14 and 22 along with oral MTX IN a stable dose of 7.5 to 20 mg per week (equal to the dose used before participation in the study) for 22 weeks.
3059625|NCT00896168|Experimental|Infliximab + Methotrexate (Severe RA)|Participants with severe RA (score greater than 5.1 on the DAS 28) received infliximab 3 mg/kg intravenous infusion at Week 0, 2, 6, 14 and 22 along with oral MTX in a stable dose of 7.5 to 20 mg per week (mg/week) equal to the dose used before participation in the study) for 22 weeks.
3059626|NCT00896181|Experimental|Chemoradiation for Nasopharyngeal Carcinoma|"INDUCTION THERAPY: Patients receive docetaxel intravenously (IV) over 60 minutes on Day 1; cisplatin IV over 1 to 3 hours (or carboplatin IV over 30 minutes) on Day 1; and fluorouracil IV continuously over 24 hours on Days 1 to 5. Each cycle is 21 days, with treatment consisting of up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMO-RADIOTHERAPY: Beginning within 3 to 6 weeks after initiating the last course of induction chemotherapy, patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily for 6.5 to 7 weeks. Patients also receive cisplatin IV over 1 hour (or carboplatin IV over 30 minutes) once weekly in weeks 1 to 6 in the absence of disease progression or unacceptable toxicity."
3059627|NCT00896233|Experimental|MRE|
3059628|NCT00896298|Active Comparator|1 Leptin|Active Comparator for 4 months, then for 8 months.
3059629|NCT00896298|Placebo Comparator|2 Sugar pill|Placebo for 4 months, then active comparator for 8 months.
3059630|NCT00896337|Experimental|ORION|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with iliac artery stenting with the Epic™ Nitinol Stent System.
3059631|NCT00896363|Active Comparator|Active|Parallel Group - High Dose Arm, Low Dose Arm
3059632|NCT00896363|Placebo Comparator|Placebo|Parallel Group
3059633|NCT00896389|Other|Salt-loading and thiazide diuretic (HCTZ)|Salt loading:2 L of 0.9% NaCl. HCTZ:12.5/ 25 mg of HCTZ for 1 week
3059634|NCT00896441|Experimental|Depressed patients|Depressed patients assigned in an open-label study of citalopram
3059635|NCT00896441|No Intervention|Controls|Healthy controls used as a comparison (no intervention) group for change in resting-state fMRI over time
3059636|NCT00896454|Experimental|denosumab|Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
3059637|NCT00896480|Experimental|GSK2132231A Group|Subjects, male or female, 18 years of age or older, received up to 24 doses of GSK2132231A intramuscularly in 4 cycles. In Cycle 1 (ending Week 13) 6 doses were administered at 2-week intervals; in Cycle 2 (ending Week 32) 6 doses at 3-week intervals; in Cycle 3 (ending Week 54) 4 doses at 6-week intervals and in Cycle 4 4 doses at 12-week intervals, starting 12 weeks after end of Cycle 3, followed by, after an interruption of treatment of 6 months, 4 doses at 24-week intervals.
3059638|NCT00896532|Placebo Comparator|Placebo|"Participants received placebo matching to romosozumab once a month (QM) or once every 3 months (Q3M) administered subcutaneously (SC) for up to 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059639|NCT00896532|Active Comparator|Alendronate|"Participants received open-label alendronate (ALN) 70 mg orally (PO) every week (QW) for 12 months. At month 12 participants transitioned to receive romosozumab 140 mg subcutaneously every month for an additional 12 months (months 12 to 24).~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. At month 36 participants ended study participation."
3059640|NCT00896532|Active Comparator|Teriparatide|Participants received open-label teriparatide 20 μg subcutaneously every day (QD) for 12 months. At month 12 participants ended study participation.
3059641|NCT00896532|Experimental|Romosozumab 70 mg QM|"Participants received double-blind romosozumab 70 mg subcutaneously every month for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059642|NCT00896532|Experimental|Romosozumab 140 mg Q3M|"Participants received double-blind romosozumab 140 mg subcutaneously once every 3 months for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059643|NCT00896532|Experimental|Romosozumab 140 mg QM|"Participants received double-blind romosozumab 140 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059644|NCT00896532|Experimental|Romosozumab 210 mg Q3M|"Participants received double-blind romosozumab 210 mg Q3M subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059645|NCT00896532|Experimental|Romosozumab 210 mg QM|"Participants received double-blind romosozumab 210 mg QM subcutaneously for 24 months.~Participants were then rerandomized to receive denosumab 60 mg or placebo to denosumab subcutaneously every 6 months from months 24 to 36. From months 36 to 48 participants received romosozumab 210 mg SC QM. At month 48 eligible participants received a single dose of open-label zoledronic acid 5 mg intravenously, or no intervention."
3059646|NCT00896649|Experimental|positron emission mammography|questionnaire administration digital mammography positron emission mammography
3059647|NCT00896779|Other|ranibizumab Group 1|Group 1: 3 monthly injections of 0.5mg then prn
3059648|NCT00896779|Other|ranibizumab Group 2|Group 2: 6 monthly injections of 0.5 mg then prn
3059649|NCT00897104|Experimental|1|Rizatriptan
3059650|NCT00897104|Experimental|2|Sumatriptan
3059651|NCT00897104|Placebo Comparator|3|Placebo
3059652|NCT00897390|Other|Arm A|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fasted conditions
3059653|NCT00897390|Other|Arm B|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fasted conditions
3059654|NCT00897390|Other|Arm C|Co-administration of single oral doses of a 2.5 mg tablet of saxagliptin and a 1000 mg tablet of metformin IR under fed conditions with a standard meal
3059655|NCT00897390|Other|Arm D|Single oral dose of a FDC tablet consisting of 2.5 mg saxagliptin/ 1000 mg metformin IR under fed conditions with a standard meal
3059656|NCT00897676|Other|Vehicle first, then Exendin-(9-39)|An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.
3059657|NCT00897676|Other|Exendin-(9-39) first then Vehicle.|"An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.~."
3059658|NCT00897715|Active Comparator|Interleukin-1 receptor antagonist|active drug
3059659|NCT00897715|Placebo Comparator|Placebo|matching placebo
3059660|NCT00897897|Other|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure receive a treatment with the Philips MRI-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
3059661|NCT00897949|Experimental|Rizatriptan 10 mg|
3059662|NCT00897949|Experimental|Rizatriptan 5 mg|
3059663|NCT00897949|Placebo Comparator|Placebo|
3059664|NCT00898222|Experimental|aspirin|Low dose daily aspirin in healthy volunteers for two weeks
3059665|NCT00898443|Other|Spinal Anesthetic Group|This group will receive spinal anesthetic for the surgical procedure and will serve as the control group for this study.
3059666|NCT00898443|Experimental|Epidural Anesthetic Group|This is the experimental group for this study.
3059667|NCT00898560|Other|Microginon®|A single oral dose of a combined oral contraceptive containing 30ug ethinyloestradiol and 150ug levonorgestrel (Microginon ®).
3059668|NCT00898560|Experimental|ESL and Microginon®|15-day treatment with ESL 800 mg once daily, with co administration of a single oral dose of Microginin® on Day 14 of the relevant dosing period, to assess impact of ESL on pharmacokinetics of the combined oral contraceptive.
3059669|NCT00898677|Experimental|1|rizatriptan 5 mg
3059670|NCT00898677|Experimental|2|rizatriptan 10 mg
3059671|NCT00898677|Active Comparator|3|sumatriptan 100 mg
3059672|NCT00898677|Placebo Comparator|4|placebo
3059673|NCT00898807|Experimental|Citalopram and psychosocial intervention|Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
3059674|NCT00898807|Placebo Comparator|Placebo and psychosocial intervention|Matching placebo, oral, and psychosocial intervention
3059675|NCT00899353|Experimental|Omega 3 supplement|Omega 3 supplement will be added to diet, 3 capsules per day for one month then 6 capsules per day for one month then 9 capsules per day as tolerated
3059676|NCT00899379|Experimental|Treatment Sequence 1|Placebo-Rizatriptan-Rizatriptan-Rizatriptan
3059677|NCT00899379|Experimental|Treatment Sequence 2|Rizatriptan-Placebo-Rizatriptan-Rizatriptan
3059678|NCT00899379|Experimental|Treatment Sequence 3|Rizatriptan-Rizatriptan-Placebo-Rizatriptan
3059679|NCT00899379|Experimental|Treatment Sequence 4|Rizatriptan-Rizatriptan-Rizatriptan-Placebo
3059680|NCT00899379|Experimental|Treatment Sequence 5|Rizatriptan-Rizatriptan-Rizatriptan-Rizatriptan
3059681|NCT00899392|Experimental|Electronic Assisted Consent|Standard procedural consent performed by pediatric gastroenterologist plus assistance from computerized emmi module.
3059682|NCT00899392|No Intervention|Control Consent|Standard procedural consent as performed by pediatric gastroenterologists
3059683|NCT00899431|Active Comparator|Group 1: Lenalidomide|Chemotherapy, Plus Lenalidomide - Lenalidomide starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months. Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine). Allopurinol 300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
3059684|NCT00899431|Active Comparator|Group 2: No Lenalidomide|Chemotherapy Treatment, No Lenalidomide - Fludarabine 30 mg/m^2 intravenously daily on days -5, -4, -3. Rituximab 375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8. Thymoglobulin 1.0 mg/kg intravenously over 4 hours (day -2 and -1). On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes. Bendamustine 130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
3059685|NCT00899470|Experimental|S+ M, (fasted)> S/M (fed)> S/M (fasted)>S+M (fed)|Participants were randomized to receive oral co-administration of a 2.5 mg tablet of saxagliptin plus a 500 mg tablet of metformin immediate release (IR) under fasted conditions (S + M [fasted]) followed by a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions (S/M [fed]) followed by S/M under fasting conditions (S/M [fasted]) followed by S + M under fed conditions (S + M [fed])
3059686|NCT00899470|Experimental|S/M (fasted)> S+M (fasted)> S+M (fed)> S/M (fed)|Participants were randomized to receive S/M (fasted) followed by S + M (fasted) followed by S + M (fed) followed by S/M (fed)
3059687|NCT00899470|Experimental|S+M (fed)> S/M (fasted) >S/M (fed)> S+M (fasted)|Participants were randomized to receive S + M (fed) followed by S/M (fasted) followed by S/M (fed) followed by S+M (fasted)
3059688|NCT00899470|Experimental|S/M (fed)> S+M (fed)> S+M (fasted)> S/M (fasted)|Participants were randomized to receive S/M (fed) followed by S+M (fed) followed by S+M (fasted) followed by S/M (fasted)
3059689|NCT00899548||Metastatic breast cancer patients|DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis
3059690|NCT00899574|Experimental|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
3059691|NCT00899600|Placebo Comparator|Normal saline|
3059692|NCT00899600|Experimental|Ketamine|
3059693|NCT00899678|Active Comparator|Maintenance High-Dose|Maintenance High-Dose group: 400 mg Certolizumab Pegol for subjects ≥ 40 kg or 200 mg Certolizumab Pegol for subjects 20 to < 40 kg
3059694|NCT00899678|Active Comparator|Maintenance Low-Dose|Maintenance Low-Dose group: 200 mg Certolizumab Pegol for subjects ≥ 40 kg or 100 mg Certolizumab Pegol for subjects 20 to < 40 kg
3059695|NCT00899717|Experimental|A|
3059696|NCT00899717|Placebo Comparator|B|
3059697|NCT00899847|Experimental|Autologous-Allogeneic Peripheral Blood Stem Cell Transplant|Study treatment is a high-dose sequential chemotherapy approach to hematopoietic stem cell (HSC) transplant that uses an autologous peripheral blood stem cell (auto-PBSC) transplant followed by allogeneic peripheral blood stem cell (allo-PBSC) transplant to evaluate improved graft vs host disease (GvHD) control. Participant auto-PBSC are mobilized with cyclophosphamide (also to provide cytoreduction) and filgrastim, followed by melphalan as an auto-PBSC conditioning agent, then auto-PBSC infusion. For the allo-PBSC transplant, donors are mobilized with filgrastim, and participants receive a regimen of total lymphoid irradiation and anti-thymocyte globulin (TLI/ATG), followed by infusion of donor allo-PBSC. Solumedrol, diphenhydramine, acetaminophen, and hydrocortisone are administered as premedications, and rabbit anti-thymocyte globulin (ATG) plus mycophenolate mofetil (MMF) are administered for post-allo-PBSC immunosuppression.
3059698|NCT00900029||No HP802 Treatment|Treatment received in Study 802-247-09-015 was HP802
3059699|NCT00900029||No HP802 Vehicle Treatment|Treatment received in Study 802-247-09-015 was HP802 Vehicle
3059700|NCT00900146|Experimental|Canakinumab 5 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 5 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3059701|NCT00900146|Experimental|Canakinumab 15 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 15 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3059702|NCT00900146|Experimental|Canakinumab 50 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 50 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3059703|NCT00900146|Experimental|Canakinumab 150 mg + Metformin|"In 4-Month Dose-finding period, patients visited the clinic monthly and had 150 mg Canakinumab injected in the clinic at each visit and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations). During this period, patients with consecutive morning fasting glucose >200 mg/dL were treated with a daily injection of insulin glargine as add-on therapy.~The intermediate period began after patients completed their 4-month visit and lasted until the primary analysis was completed and the optimal dose was selected. Patients continued on their randomized treatment and made brief visits to the clinic every month. From this point onward, patients with consecutive HbA1c >7.5% were treated with a daily injection of insulin glargine as add-on therapy."
3059704|NCT00900146|Placebo Comparator|Placebo + Metformin|In 4 month dose finding period as well as during intermediate period, patients received one injection of canakinumab matching placebo monthly and continued on a stable dose of metformin ≥ 1000 mg daily (or lower dose if required by local regulations).
3059705|NCT00900159|Experimental|eszopiclone|Treatment with eszopiclone
3059706|NCT00900159|Placebo Comparator|matching placebo|Treatment with matching placebo
3059707|NCT00900237|Active Comparator|Eslicarbazepine acetate|Eslicarbazepine acetate (ESL) 600 mg QD morning from Day 1-3 and 1200 mg ESL QD morning from Day 4-9
3059708|NCT00900237|Active Comparator|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 and oxcarbazepine 600mg BID from Day 4-9
3059709|NCT00900562|Experimental|Arm 1|Zalypsis (PM00104)
3059710|NCT00900601|Experimental|Sacroilliac fusion|Pastient are treated with sacroiliac joint arthrodesis to the sacroiliac joint and symphysis
3059711|NCT00900627|Experimental|1|AZD8931 plus Paclitaxel
3059712|NCT00900627|Placebo Comparator|2|Placebo plus Paclitaxel
3059713|NCT00900666|Placebo Comparator|Saline injection|
3059714|NCT00900666|Experimental|Botulinum toxin injection|
3059715|NCT00900731|Experimental|Indacaterol 150 µg|Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
3059716|NCT00900731|Active Comparator|Tiotropium 18 µg|Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
3059717|NCT00900757|Experimental|Palonosetron|Single Arm trial of Palonosetron for the prevention of RINV in primary malignant glioma patients receiving radiation therapy (RT) and concomitant temozolomide (TMZ)
3059718|NCT00900796||1|Patients diagnosed with active AS who start anti-TNF therapy according to standard clinical practice.
3059719|NCT00900822|Experimental|Straumann Bone Ceramic|StraumannBone Ceramic is used as bone grafting material in sinus augmentation procedures
3059720|NCT00900822|Active Comparator|BioOss|BioOss is used as a bone grafting material in sinus augmentation procedure
3059721|NCT00901017|Active Comparator|Straumann BoneCeramic|Straumann BoneCeramic
3059722|NCT00901017|Active Comparator|Bio-Oss|Geistlich Bio-Oss
3059723|NCT00901186|Experimental|RFB002|RFB002 0.5 mg was administered to the study eye with a single monthly intravitreal injection on day 1, day 30 and day 60. After day 90, if stable vision was not achieved, a monthly injection of RFB002 0.5 mg was administered until stable vision was achieved.
3059724|NCT00901186|Active Comparator|Laser photocoagulation|At least one treatment of laser photocoagulation was applied on day 1. The maximum number of laser photocoagulation treatments was 4.
3059725|NCT00901199|Experimental|Deferasirox (Exjade) and Deferoxamine (DFO)|All subjects received Deferasirox (Exjade) and Deferoxamine (DFO) dosing based on the iron overload at baseline.
3059726|NCT00901225|Experimental|G-CSF plus Plerixafor|Patients who were unable to mobilize a minimum number of cells (CD34+ cell count <20 cells/ul)following 5 days of G-CSF mobilization.
3059727|NCT00901316|Experimental|Routine Measures|
3059728|NCT00901316|Experimental|Bleach Baths|
3059729|NCT00901342|Experimental|Sipuleucel-T|Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
3059730|NCT00901394|Experimental|Treatment 1|B12-Folic acid, nitrous oxide
3059731|NCT00901394|Active Comparator|Treatment 2|Nitrous oxide (NO) and placebo
3059732|NCT00901394|Placebo Comparator|Control group|oxygen nitrogen
3059733|NCT00901459|Active Comparator|rTMS 90% MT - Low frequency rTMS|Intervention type: device. Intervention description: low frequency rTMS was administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues using 90% MT (Motor Threshold) 1 Hz rTMS Dose on Superior Frontal Gyrus
3059734|NCT00901459|Active Comparator|Location Control|rTMS Dosing: 90% MT (Motor Threshold) 1 Hz rTNS Location: Motor Cortex
3059735|NCT00901459|Active Comparator|Frequency Control|rTMS Dosing: 90% MT (Motor Threshold) 10 Hz rTNS Location: Superior Frontal Gyrus
3059736|NCT00901485|Experimental|autotitrating NIV|approximately 6 weeks using domiciliary nocturnal autotitrating non-invasive ventilation
3059737|NCT00901485|Active Comparator|Standard non-invasive ventilation|approximately 6 weeks using domiciliary nocturnal standard non-invasive ventilation
3059738|NCT00901576|Experimental|SPD503|
3059739|NCT00901576|Active Comparator|Concerta|
3059740|NCT00901576|Active Comparator|SPD503 + Concerta|
3059741|NCT00901628|Experimental|Periarticular Injection group|Periarticular injection with ropivacaine, morphine, ketorolac, epinephrine, cefuroxime
3059742|NCT00901628|No Intervention|No Injection group|usual postoperative care without periarticular injection
3059743|NCT00901901|Experimental|Sorafenib (Nexavar, BAY43-9006) + Erlotinib (Tarceva)|Participants received sorafenib 400 mg twice daily (bid) and erlotinib 150 mg tablet once daily (qd)
3059744|NCT00901901|Active Comparator|Sorafenib (Nexavar, BAY43-9006) + Placebo|Participants received sorafenib 400 mg twice daily (bid) and matching erlotinib placebo 150 mg tablet once daily (qd)
3059745|NCT00901927|Experimental|Bendamustine + Mitoxantrone + Rituximab|Bendamustine starting dose 90 mg/m^2 intravenously (IV) over 30-60 minutes on Days 1 and 2 of each 8-day cycle. Mitoxantrone 10 mg/m^2 IV over 15 minutes on Day 2 of each cycle. Rituximab 375 mg/m^2 IV over several hours on Day 1 of each cycle.
3059746|NCT00902018|Experimental|eltrombopag|10 ITP patients were treated with daily oral eltrombopag 75mg for 2 weeks and complete testing was done at weekly intervals 3 times they then were allowed to receive long-term eltrombopag
3059747|NCT00902018|Experimental|romiplostim|3 of the patients who received eltrombopag were also treated with romiplostim 10 micrograms/kg weekly for 2 weeks with the same complete testing done at weekly intervals three times after a washout period > 1 month they then resumed long-term eltrombopag
3059748|NCT00902018|Sham Comparator|healthy controls|no intervention single blood draw with complete studies
3059749|NCT00902161|Experimental|Propanolol + Placebo > Propanolol + MK0893|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8).
3059750|NCT00902161|Placebo Comparator|Propanolol + MK0893 > Propanolol + Placebo|Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8).
3059751|NCT00902174|Experimental|imatinib mesylate|Imatinib mesylate (QTI571) 200 mg once daily for two weeks, increased to 400 mg once daily if well tolerated. If 400 mg dose was not well tolerated, a down titration to 200 mg once daily was permitted.
3059752|NCT00902174|Placebo Comparator|Placebo|Placebo to imatinib mesylate taken once daily. Participants receiving placebo were allowed to receive already approved PAH treatments.
3059753|NCT00902226|Experimental|Escitalopram|
3059754|NCT00902265||desmopressin|"Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria.~Drug given by prescription."
3059755|NCT00902278|Active Comparator|Flulaval|
3059756|NCT00902278|Active Comparator|Fluvirin|
3059757|NCT00902278|Active Comparator|Fluzone|
3059758|NCT00902278|Active Comparator|Fluarix|
3059759|NCT00902278|Active Comparator|Affluria|
3059760|NCT00902304|Active Comparator|Usual care|Physicians applied their usual pattern of patient visits and treatment strategies to achieve individualized blood pressure target
3059761|NCT00902304|Experimental|Monotherapy (initial monotherapy arm)|Physicians utilized valsartan 160mg per day for 6 weeks, followed by (if required) dose titrations every 4 weeks thereafter until week 14 (valsartan 320mg per day, then valsartan 320mg plus hydrochlorothiazide (HCTZ) 12.5mg per day, then valsartan 320mg plus HCTZ 25mg per day (maximal dose)). For patients not at blood pressure target at week 18, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
3059762|NCT00902304|Experimental|Combination (initial combination therapy arm)|Physicians initially utilized single tablet combination products of either valsartan plus hydrochlorothiazide (HCTZ) or valsartan plus amlodipine for an initial 6 weeks of therapy (based on the treating physician's preference), with dose titrations (if required) every 4 weeks thereafter until week 10. The maximum dose for the HCTZ combination was valsartan 160mg plus HCTZ 25mg per day. The maximum dose for the amlodipine combination was valsartan 160mg plus amlodipine 10mg per day. For patients who were not at blood pressure target at week 14, physicians were requested to consider triple or alternative therapy at their own discretion for the remainder of the study.
3059763|NCT00902330|Experimental|Arm I (cranial microcurrent electrical stimulation [CES])|Patients receive a CES unit (Alpha-Stim® 100 Microcurrent Stimulator) that passes microcurrent levels of biphasic electrical stimulation via ear-lobe electrodes. The CES unit is preset to provide 1 hour of 100 μA (sub-sensory level), modified square-wave biphasic stimulation on a 50% duty cycle at .05 Hz, and to automatically turn off at the end of 1 hour. Patients use their CES unit once daily in weeks 1-18.
3059764|NCT00902330|Sham Comparator|Arm II (sham CES)|Patients receive a CES unit as in arm I, but the ear-lobe electrodes do not pass electrical current. Patients use their CES unit once daily in weeks 1-18.
3059765|NCT00902486|Experimental|INCB028050 4 mg QD|INCB028050 4mg Once daily (QD)
3059766|NCT00902486|Experimental|INCB028050 7 mg QD|INCB028050 7mg QD
3059767|NCT00902486|Experimental|INCB028050 10 mg QD|INCB028050 10mg QD
3059768|NCT00902486|Placebo Comparator|Placebo|Placebo group may 'cross-over' following 3 months of treatment to receive either active arm #2 (7mg QD) or active arm #3 (10mg QD) of INCB028050 capsules.
3059769|NCT00902538|Experimental|Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg|The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.
3059770|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.
3059771|NCT00902538|Experimental|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.
3059772|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)|Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.
3059773|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
3059774|NCT00902538|Experimental|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)|Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4
3059775|NCT00902564|Experimental|Escitalopram|
3059776|NCT00902577|Experimental|Diagnostic (MRI and PET using FMISO)|Two weeks before initiation of chemoradiotherapy with temozolomide, patients undergo MRI (DSC, DCE,DWI and MRS) and PET scan using FMISO. A subset of 15 patients undergo FMISO PET scans approximately 1 week before chemoradiotherapy.
3059777|NCT00902746|Experimental|NPC-01|Norethisterone, Ethinyl Estradiol
3059778|NCT00902850|Experimental|SofLens Daily Disposable|SofLens Daily Disposable Lenses
3059779|NCT00902850|Active Comparator|Marketed 1 Day Contact Lens|Marketed 1 Day Contact Lens
3059780|NCT00903032|Experimental|Arm 1|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
3059781|NCT00903032|Active Comparator|Arm 2|Patients will receive usual care following ACS hospital discharge
3059782|NCT00903162|Experimental|Letrozole-Leuprolide|Patients will receive 2.5mg oral letrozole daily and either 7.5mg monthly of Leuprolide IM or 22.5mg every three months of Leuprolide IM. Zoledronic acid 4mg IV every 6 months x 4 will also be offered optionally.
3059783|NCT00903175|Experimental|everolimus 1L/sunitinib 2L|everolimus First Line: 10 mg orally, once daily, (two 5 mg tablets), continuous treatment. sunitinib Second Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2)
3059784|NCT00903175|Active Comparator|sunitinib 1L/everolimus 2L|sunitinib First Line: 50 mg orally, once daily, 4 weeks on treatment followed by 2 weeks off (4/2) everolimus Second Line: 10 mg orally, once daily (two 5 mg tablets), continuous treatment
3059785|NCT00903201|Experimental|Treatment A|20 mg of SB656933
3059786|NCT00903201|Experimental|Treatment B|50 mg of SB656933
3059787|NCT00903201|Experimental|Placebo|Placebo
3059788|NCT00903331|Experimental|ACT-064922|ACT-064922 tablet (macitentan), 10 mg, once daily
3059789|NCT00903331|Placebo Comparator|Placebo|Matching placebo, once daily
3059790|NCT00903344|Experimental|Vitamin D|4000IU Vitamin D3 in tablet taken daily with multivitamin
3059791|NCT00903344|Active Comparator|Multivitamin|Multivitamin with 400IU vitamin D tablet
3059792|NCT00903357|Experimental|Montelukast first, then placebo|The group received active medication (montelukast 4 mg or 5mg once daily) for 8 weeks followed by a crossover to 8 weeks of placebo after 2-weeks washout period.
3059793|NCT00903357|Experimental|Placebo first, then Montelukast|The group received placebo medication (ascorbic acid) for 8 weeks followed by a crossover to 8 weeks of active medication (montelukast 4 mg or 5mg once daily) after 2-weeks washout period.
3059794|NCT00903370|Active Comparator|MVS|All participants will undergo mitral valve surgery with ligation/excision of left atrial appendage.
3059795|NCT00903370|Experimental|Ablation|Participants will undergo mitral valve surgery with ligation/excision of left atrial appendage plus surgical ablation with pulmonary vein isolation or biatrial lesion set.
3059796|NCT00903383|Experimental|Low Dose|A low dose of LX3305; daily oral intake for 12 weeks
3059797|NCT00903383|Experimental|Mid Dose|A mid dose of LX3305; daily oral intake for 12 weeks
3059798|NCT00903383|Experimental|High Dose|A high dose of LX3305; daily oral intake for 12 weeks
3059799|NCT00903383|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
3059800|NCT00903409|Experimental|"Simvastatin + Lovaza® (Non-switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + Lovaza® in the double-blind trial, hence in this open-label extension, they are termed Non-switchers"
3059801|NCT00903409|Experimental|"Simvastatin + Lovaza® (Switchers)"|"Open label Simvastatin + Lovaza® (omega-3-acid ethyl esters) NOTE: this group was originally assigned to Simvastatin + placebo in the double-blind trial, hence in this open-label extension, they are termed Switchers"
3059802|NCT00903448|Experimental|A|Prilosec OTC
3059803|NCT00903448|Active Comparator|B|Prevacid
3059804|NCT00903617|Experimental|Part A Treatment A|5 mg of GSK256073
3059805|NCT00903617|Experimental|Part A Treatment B|50 mg of GSK256073
3059806|NCT00903617|Experimental|Part A Treatment C|150 mg of GSK256073
3059807|NCT00903617|Placebo Comparator|Part A Treatment D|placebo
3059808|NCT00903617|Placebo Comparator|Part B Treatment A|placebo
3059809|NCT00903617|Active Comparator|Part B Treatment B|1500 mg Niaspan
3059810|NCT00903617|Experimental|Part B Treatment C|x mg dose of GSK256073 based on data from Part A
3059811|NCT00903617|Experimental|Part B Treatment D|optional dose of GSK256073 based on data from Part A
3059812|NCT00903630|Experimental|Phase 1 - Dose Level 1|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 10 mg daily on Days 1-28 every 28 days
3059813|NCT00903630|Experimental|Phase I - Dose Level 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: 15 mg daily on Days 1-28 every 28 days
3059814|NCT00903630|Experimental|Phase 2|liposomal doxorubicin: 40mg/m2 IV Day 1 every 28 days plus lenalidomide: maximum tolerated dose from Phase I portion of the study (10mg) daily on Days 1-28 every 28 days
3059815|NCT00903682|Experimental|etravirine|etravirine (ETR TMC125) 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
3059816|NCT00903682|Active Comparator|efavirenz|efavirenz (EFV) 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
3059817|NCT00903695|Experimental|Memory XL|"Subjects will take 2 Memory XL pills daily for 12 months (a vitamin nutriceutical developed by Thomas Shea, Ph.D.).~Mild Cognitive Impairment (MCI) patients, who met inclusion/exclusion criteria, were assessed initially using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting pills assigned to them by VAMC Research Pharmacist. Each 3 months thereafter, they returned to lab to be reassessed using same instruments, and to receive the next batch of study pills from the Pharmacist. The last assessment was when the patient had just finished 12 months of pill ingestion."
3059818|NCT00903695|Placebo Comparator|placebo|"Subjects diagnosed with MCI took two placebo pills daily for 12 months; these pills are formulated to look and taste the same as the nutriceutical being studied, Memory XL, so study was double-blind. Procedures for this arm are exactly the same as the MEMORY XL arm.~MCI subjects were assessed using 3 cognitive tests and 4 behavioral questionnaires, before they began ingesting the pills assigned to them by the Research Pharmacist at VAMC. Each 3 months thereafter, they returned to lab to be reassessed using the same instruments, and to receive next batch of study pills. Last assessment was when patient had completed 12 months of pill ingestion."
3059819|NCT00903760|Experimental|Decitabine + Clofarabine|Drug delivery intravenously (IV) in alternating series of cycles (Decitabine 20 mg/m^2 for 5 days first 3 cycles, then Clofarabine 10 mg/m^2 five days for next 3 cycles), pattern repeats for up to 24 cycles.
3059820|NCT00903760|Experimental|Decitabine|Decitabine 20 mg/m^2 IV daily for 5 days for a total of 24 courses.
3059821|NCT00903786|Experimental|Perampanel|"Participants were treated with the perampanel dose that was administered in maintenance period of Study E2007-J081-231 (Study 231) [NCT00849212]. In some instances, a 1-step down-titration from the viewpoint of safety and up-titration to the maintenance dose of Study 231 was allowed. In general, 1 to 6 tablets of perampanel was administered orally as a 2-milligram (mg) tablet (2 mg to 12 mg) once daily before bedtime (under fed conditions as much as possible).~The investigator, or subinvestigator, was allowed to complete the treatment by tapering the study drug after end of treatment or discontinuation (Follow-up Period), as appropriate. The taper period was 4 weeks at the longest."
3059822|NCT00903877|Experimental|Placebo followed by T3|Participants receive placebo for 4 weeks. Following placebo, participants begin T3 treatment at 25 mcg per day, for 4 weeks. Following this, participants begin T3 treatment at 50 mcg per day, for 4 more weeks.
3059823|NCT00903929|Experimental|Eltrombopag|
3059824|NCT00903968|Experimental|Phase I Dose Level 1|Phase I Dose Level 1 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059825|NCT00903968|Experimental|Phase I Dose Level 2|Phase I Dose Level 2 patients received plerixafor 160ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059826|NCT00903968|Experimental|Phase I Dose Level 3|Phase I Dose Level 3 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.0 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059827|NCT00903968|Experimental|Phase I Dose Level 4|Phase I Dose Level 4 patients received plerixafor 240ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059828|NCT00903968|Experimental|Phase I Dose Level 5|Phase I Dose Level 5 patients received plerixafor 320ug/kg by injection on days 1-6 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059829|NCT00903968|Experimental|Phase I Dose Level 5B|Phase I Dose Level 5B patients received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059830|NCT00903968|Experimental|Phase I Dose Level 6|Phase I Dose Level 6 patients received plerixafor 400ug/kg by injection on days 1, 2, 3, 6, 10, and 13 and bortezomib 1.3 mg/m2 intravenously days 3, 6, 10, and 13 of each 21 day cycle until disease progression or unacceptable toxicity.
3059831|NCT00903968|Experimental|All Phase I Participants|All Phase I participants received plerixafor by injection and bortezomib intravenously according to the established dose escalation schedule. Participants were treated until disease progression or unacceptable toxicity.
3059832|NCT00903968|Experimental|All Phase II Participants|All Phase I participants received plerixafor 320ug/kg by injection on days 1, 2, 3, 6, 10, and 13, bortezomib 1.3 mg/m2 intravenously or subcutaneously days 3, 6, 10, and 13, and dexamethasone 40mg orally days 3, 6, 10, and 13 of each 21 day cycle during induction. In maintenance, participants received plerixafor, bortezomib, and dexamethasone days 1, 8, 15, and 22 of each 35 day cycle. Participants were treated until disease progression or unacceptable toxicity.
3059833|NCT00904007|Experimental|SE Game Cohort|Will receive ISE intervention.
3059834|NCT00904007|No Intervention|Control Cohort|The control cohort will receive identical content online (with no ISE)
3059835|NCT00904033|Active Comparator|Multivitamin|Multivitamin used as control group.
3059836|NCT00904033|Experimental|Exercise|Exercise consisting of progressive walking and resistance band training.
3059837|NCT00904033|Experimental|Calcitriol|Calcitriol pill taken once per week.
3059838|NCT00904033|Experimental|Calcitriol and Exercise|Calcitriol pill taken once per week plus Exercise consisting of progressive walking and resistance band training.
3059839|NCT00904150||1 Menstrual migraine|Caucasian women with a current or past history of menstrual migraine (MM = pure menstrual migraine or menstrually-related migraine) attending the City of London Migraine Clinic
3059840|NCT00904150||2 No migraine|Caucasian women with no personal history of migraine
3059841|NCT00904345|Experimental|Treatment|
3059842|NCT00904371||Patients with arterial hypertention|
3059843|NCT00904488|Active Comparator|Addition of PO Thiazide Diuretic|Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.
3059844|NCT00904488|Active Comparator|IV furosemide dose escalation|Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.
3059845|NCT00904618|Experimental|TVT-SECUR|This study arm consisted of 48 women operated from January 2007 to October 2008. All patients underwent the implantation of the TVT-SECUR for the treatment of stress urinary incontinence or stress predominant mixed urinary incontinence. The surgery was done under local anesthesia by one high-volume surgeon.
3059846|NCT00904670|Experimental|Active|
3059847|NCT00904670|Placebo Comparator|Comparator|
3059848|NCT00904722|Experimental|CT-011 in combination with Rituximab|Combination of the immunotherapy drugs, CT-011 and rituximab.
3059849|NCT00904748|Experimental|Test 1|
3059850|NCT00904748|Experimental|Test 2|
3059851|NCT00904748|Active Comparator|Reference|
3059852|NCT00904813|Active Comparator|1. Short-course RT (5x5 Gy) + surgery within 1 week (SRT)|RT=Preoperative radiotherapy Gy=Gray
3059853|NCT00904813|Active Comparator|2. Short-course RT (5x5 Gy) + surgery after 4-8 weeks (SRT-delay)|RT=Preoperative radiotherapy Gy= Gray
3059854|NCT00904813|Active Comparator|3. Long-course RT (25x2 Gy) + surgery after 4-8 weeks (LRT-delay)|RT= Preoperative radiotherapy Gy= Gray
3059855|NCT00904826|Experimental|Eculizumab|The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks. Subjects will receive therapy for a total of 12 months.
3059856|NCT00904839|Experimental|BIBF 1120 + mFolfox6|BIBF1120 medium dose twice daily
3059857|NCT00904839|Active Comparator|Bevacizumab + mFolfox6|Bevacizumab 5mg/kg once daily every other week
3059858|NCT00904917|Experimental|Adapted PIP|"Participants (both mother and children) participated in an adapted cognitive family prevention program for the families of children with a depressed African American mother.~The intervention was the Prevention Intervention Project."
3059859|NCT00904917|Active Comparator|Lecture|"Mothers received psychoeducation about depression.~The intervention was psychoeducation."
3059860|NCT00904943|Experimental|Test First|Topiramate Capsules, 25 mg
3059861|NCT00904943|Active Comparator|Reference First|Topamax® Capsules, 25 mg
3059862|NCT00904969|Experimental|AMS Transobturator Male Sling System|
3059863|NCT00904982|Other|1 Usual Care Group/Control|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant and can confirm when medication is taken correctly.
3059864|NCT00904982|Experimental|2Med-eMonitor/Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled.
3179130|NCT00669643|Active Comparator|R-MDT PB|R-MDT PB group: standard/regular treatment recommended by WHO - All patients presenting fewer than 6 skin lesions will receive the standard treatment regimen for paucibacillary patients as the intervention; Intervention - PB 6 doses of rifampicin and dapsone
3059865|NCT00904982|Experimental|3 Incentive Group/Lottery|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication. The MM can display messages to the participant. This group will also be entered into a daily lottery in which he/she can win money. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
3059866|NCT00904982|Experimental|4 Combined Group/Lottery and Reminder|Participants in this study arm will be given an electronic medication monitoring system called a Med-eMonitor(MM) to use at home. This machine will measure the participant's adherence to taking their medication and will be set on active mode for this group. The MM will display messages of encouragement to participants and education on the importance of taking their warfarin medication. The Med-eMonitor also features an alarm that will sound to remind participants to take their medication as scheduled. Participants in this group will also be entered into a daily lottery. On any given study day, participants have a 1 in 10 chance of winning $10 and 1 in 100 chance of winning $100 when taking their warfarin medication as prescribed. Participants must take their dose correctly in order to be eligible for the daily lottery.
3059867|NCT00904995|Experimental|Group 1 - Oral|Voriconazole Starting oral dose of 400 mg pills twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
3059868|NCT00904995|Experimental|Group 2 - IV + Oral|Voriconazole 6 mg/kg by vein (IV) first dose then 200 mg pills two times a day thereafter.
3059869|NCT00905021|Experimental|Exemestane plus Sutent|"All patients enrolled on the study will receive treatment as follows:~Exemestane 25 mg by mouth every day.~Sunitinib 37.5 mg by mouth every day."
3059870|NCT00905034|Experimental|MOAD|Chemotherapy regimen of methotrexate, rituximab, vincristine, pegylated L-asparaginase and dexamethasone (MOAD).
3059871|NCT00905060|Experimental|Protein Peptide-Complex (HSPPC-96)|Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study), 3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
3059872|NCT00905125|Experimental|Arm 2, Fluarix®|Single 0.5 mL intramuscular injection of Fluarix®.
3059873|NCT00905125|Experimental|Arm 1, Fluzone®|Single 0.5 mL intramuscular injection of Fluzone®.
3059874|NCT00905151||HIV Positive|Across-sectional analysis of 200 HIV+ patients with varying levels of kidney function
3059875|NCT00905164|Experimental|Test First|Topiramate Capsules, 25 mg
3059876|NCT00905164|Active Comparator|Reference First|Topamax® Capsules, 25 mg
3059877|NCT00905255|Experimental|Lixisenatide (Two-step Titration)|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to end of treatment.
3059878|NCT00905255|Experimental|Lixisenatide (One-step Titration)|1-step initiation regimen of lixisenatide: 10 mcg QD for 2 weeks, then 20 mcg QD up to end of treatment.
3059879|NCT00905268|Experimental|Group A: Idebenone|Patients under/equal 45 kg: idebenone 180 mg/day Patients over 45 kg: idebenone 360 mg/day
3059880|NCT00905268|Experimental|Group B: Idebenone|Patients under/equal 45 kg: idebenone 450 mg/day Patients over 45 kg: idebenone 900 mg/day
3059881|NCT00905268|Experimental|C: Idebenone|Patients under/equal 45 kg: idebenone 1350 mg/day Patients over 45 kg: idebenone 2250 mg/day
3059882|NCT00905268|Placebo Comparator|D: Placebo|placebo
3059883|NCT00905307|Experimental|1|OPC-34712 0.25 mg arm
3059884|NCT00905307|Experimental|2|OPC-34712 low-dose arm
3059885|NCT00905307|Experimental|3|OPC-34712 mid-dose arm
3059886|NCT00905307|Experimental|4|OPC-34712 high-dose arm
3059887|NCT00905307|Placebo Comparator|5|
3059888|NCT00905307|Active Comparator|6|Aripiprazole arm
3059889|NCT00905346|Experimental|Test First|Topiramate Capsules 25 mg
3059890|NCT00905346|Active Comparator|Reference First|Topamax® 25 mg Capsule
3059891|NCT00905359|Active Comparator|Aperius™ PercLID™ System|Aperius™ PercLID™ System arm. Patients randomized to this arm will undergo treatment with the Aperius™ PercLID™ System.
3059892|NCT00905359|Active Comparator|Standalone Decompressive Surgery|Patients randomized to this arm will receive Standalone Decompressive Surgery, defined as decompressive surgery without instrumentation or fusion.
3059893|NCT00905424|Experimental|Active|Antidepressant + SPD489
3059894|NCT00905424|Placebo Comparator|Placebo|Antidepressant + placebo
3059895|NCT00905437|Placebo Comparator|Placebo|Placebo as an adjunct to standard of care
3059896|NCT00905437|Active Comparator|Pregabalin|Pregabalin as an adjunct to standard of care
3059897|NCT00905450|Experimental|BOL-303242-X|BOL-303242-X (Mapracorat)
3059898|NCT00905450|Placebo Comparator|Vehicle|Vehicle for BOL-303242-X (Mapracorat)
3059899|NCT00905489|Experimental|Nevirapine IR / Nevirapine XR|In this pharmaco-kinetic (PK) cross-over design trial, all patients initially receive nevirapine immediate release and then all patients are switched to nevirapine extended release 200 mg, 300 mg or 400 mg QD. After completing the PK phase patients had the option of continuing treatment with nevirapine XR in the Optional Extension Phase (OEP).
3059900|NCT00905515|Active Comparator|Control Group Cyclosporine|Maintain on Cyclosporine (CsA) at target trough level of 50-250 ng/mL.
3059901|NCT00905515|Active Comparator|Low Trough Level Prograf Group|Convert to Prograf (TAC) at target trough levels of 3.0-5.9 ng/mL.
3059902|NCT00905515|Active Comparator|High Trough Level Prograf Group|Convert to TAC at target trough levels of 6.0-8.9 ng/mL.
3059903|NCT00905554|Experimental|warm water|warm water irrigation during the insertion phase of colonoscopy
3059904|NCT00905554|Active Comparator|air|air insufflation during the insertion phase of colonoscopy
3059905|NCT00905567|Experimental|Test First|Topiramate 2 x 25 mg Tablet
3059906|NCT00905567|Active Comparator|Reference First|Topamax® Tablet 2 x 25 mg
3059907|NCT00905580|Placebo Comparator|Placebo|Patients receive oral Placebo 150 mg 1 hour prior to surgery, and 12 hours later
3059908|NCT00905580|Experimental|Pregabalin|Patients receive oral pregabalin 150 mg 1 hour prior to surgery, and 12 hours later
3059909|NCT00905606|Experimental|1|Topiramate Tablets, 25 mg
3059910|NCT00905606|Active Comparator|2|Topamax® Tablets, 25 mg
3059911|NCT00905632|Experimental|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
3059912|NCT00905632|Experimental|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
3059913|NCT00905632|Experimental|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
3059914|NCT00905632|Placebo Comparator|Placebo + SOC|Placebo tid +SOC
3059915|NCT00905827|Experimental|Intervention 1: in person CAMS|In person Collaborative Assessment and Management of Suicidality (CAMS) training for providers
3059916|NCT00905827|Experimental|Intervention 2: e-learning CAMS|Online Collaborative Assessment and Management of Suicidality (CAMS) training for providers
3059917|NCT00905827|No Intervention|Control: no training|Control Group: no training
3059918|NCT00905840|Active Comparator|Titanium Zircon implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
3059919|NCT00905840|Placebo Comparator|Titanium Grade IV implant|Intervention: each subject will receive two Straumann bone level implants, one implant is fabricated with Titanium Zircon and the other is a grade IV Titanium implant. Both implants will be randomly placed in the interforaminal region of the edentulous mandible, one on the right half and the other in the left part. Both implants will be treated the same way.
3059920|NCT00906074||Case|Cases will be defined as patients with elective or emergency abdominal surgery who develop severe surgical site infection (deep incisional or organ cavity type; see Center for Disease Control (CDC) criteria for definition in the Appendix), within 0-30 days of surgery.
3059921|NCT00906074||Control|Surgeon-matched controls will be patients with elective or emergency abdominal surgery who are free of surgical site infection (SSI) after 30 days from the surgery.
3059922|NCT00906087|Other|Cosopt|Intraocular pressure and blood pressure measurements will be compared under the following conditions: 1) after washout of clinical treatment, 2) after treatment with Cosopt, and 3) after another washout of Cosopt.
3059923|NCT00906165|Active Comparator|1- Immediately provisionalized|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will be immediately provisionalized upon placement, i.e. impressions will be taken directly after implant installation in order to fabricate screw-retained resin crowns within 48 hours after implant placement. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
3059924|NCT00906165|Active Comparator|2- Delayed Loading|The Straumann® Bone Level SLActive Implant (4.1mm diameter) will not be immediately provisionalized, instead there will be delayed implant loading. i.e. the patient will receive a removable prosthesis if necessary and the impressions for the final restoration will be taken 12-14 weeks after implant installation. At 16 weeks, the final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration.
3059925|NCT00906178|Experimental|CyberSenga|6-module HIV prevention program tailored for adolescents in Uganda
3059926|NCT00906178|No Intervention|Control|"treatment as usual - the sexual health education adolescents currently receive in secondary school"
3059927|NCT00906204|Experimental|Single-dose Thymoglobulin|Biological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
3059928|NCT00906204|Active Comparator|Divided-dose Thymoglobulin|Biological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4
3059929|NCT00906243|Experimental|CV9103|CV9103 will be applied intradermally on three (3) or five (5) time points. Treatment with CV9103 is administered over a period of either seven (7) or twenty-three (23) weeks.
3059930|NCT00906282|Experimental|Pemetrexed/Carboplatin|"4 cycles of preoperative treatment (1 Cycle = 21 days):~Pemetrexed: 500 mg/m2 intravenously (IV) for 10 minutes on Day 1 each cycle; Carboplatin: AUC 6.0 by IV on Day 1 each cycle."
3059931|NCT00906347|Active Comparator|Oxytocin augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive intravenous oxytocin.
3059932|NCT00906347|Active Comparator|Misoprostol augmentation|Women with hypotonic labor and a clinical decision to proceed with labor augmentation will receive oral misoprostol.
3059933|NCT00906373|Active Comparator|Cohort 1, IMC A12 - 10 mg/kg|Treatment cycles will repeat until there is evidence of progressive disease (PD), toxicity, or withdrawal. If any participant experiences a dose-limiting toxicity (DLT), an additional 3 participants will be enrolled at this dose level (for a total of 6). If no further DLTs, enrollment into Cohort 2 will occur.
3059934|NCT00906373|Active Comparator|Cohort 2, IMC A12 20 - mg/kg|Treatment cycles will repeat until there is evidence of PD, toxicity, or withdrawal.
3059935|NCT00906399|Placebo Comparator|Placebo|Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
3059936|NCT00906399|Experimental|Peginterferon Beta-1a Q2W|125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
3059937|NCT00906399|Experimental|Peginterferon Beta-1a Q4W|125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).
3059938|NCT00906425|Active Comparator|Submerged healing|The Straumann Bone Level Implant(s) will be placed using a submerged healing treatment
3059939|NCT00906425|Active Comparator|Trans-mucosal healing|The Straumann Bone Level Implant(s) will be placed using a trans-mucosal healing treatment
3059940|NCT00906503|Experimental|PET/Computed Tomography (CT)|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan; Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
3059941|NCT00906698|Experimental|BIBW 2992 and vinorelbine i.v|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine i.v.
3059942|NCT00906698|Experimental|BIBW 2992 and vinorelbine per os|Daily low (20mg), medium (40mg) and high (50mg) dosages of BIBW 2992 with standard dosage of vinorelbine per os.
3059943|NCT00906776|Active Comparator|Emdogain PLUS|Straumann Emdogain in combination with Straumann BoneCeramic
3059944|NCT00906776|Active Comparator|Autogenous bone|Autogenous bone from the patient
3059945|NCT00906789||Radiologists|Radiologists who have certification by the American Board of Radiology
3059946|NCT00906945|Experimental|Dose Level 1|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 240 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059947|NCT00906945|Experimental|Dose Level 2|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 320 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059948|NCT00906945|Experimental|Dose Level 3|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 420 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059949|NCT00906945|Experimental|Dose Level 4|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 560 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059950|NCT00906945|Experimental|Dose Level 5|"G-CSF 10 mcg/kg SQ on Days 1-8~Plerixafor 750 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059951|NCT00906945|Experimental|MTD - Phase II|"G-CSF MTD determined in Phase 1 SQ on Days 1-8~Plerixafor MTD determined in Phase 1 mcg/kg/d IV qd~Mitoxantrone 8 mg/m2/day IV once over 30 minutes daily on days 4-8~Etoposide 100 mg/m2/day IV once over 60 minutes daily on days 4-8~Cytarabine 1000 mg/m2/day IV once over 60 minutes daily on days 4-8"
3059952|NCT00906958|Experimental|Nexus Flow Generator|Participants were randomised to Nexus Flow Generator group for one night.
3059953|NCT00906958|Active Comparator|VPAP Flow Generator 25|Participants were randomised to VPAP Flow Generator 25 group for one night.
3059954|NCT00906971|Active Comparator|Laxatives|Magnesium hydroxide for which the dosage varied according to individual needs (a minimum of 2 ml/kg), and received guidance regarding fiber-rich foods, water and toilet training. Patients attended weekly consultations with a pediatric gastroenterologist.
3059955|NCT00907088|Active Comparator|1|
3059956|NCT00907088|Experimental|2|
3059957|NCT00907101|Experimental|Study Treatment|"Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)~Other Names:~Epiduo® Gel Apply once daily"
3059958|NCT00907153|Experimental|Vitamin D|
3059959|NCT00907153|Placebo Comparator|Placebo|
3059960|NCT00907257|Experimental|Same time of day|5% benzoyl peroxide wash and 0.04% tretinoin gel used at same time of day
3059961|NCT00907257|Active Comparator|Different times of day|5% benzoyl peroxide wash used in the morning and 0.04% tretinoin gel used in the evening
3059962|NCT00907296|Placebo Comparator|Placebo|Participants received subcutaneous injections of matching placebo on day 1 and at weeks 2, 6, and 12.
3059963|NCT00907296|Experimental|Romosozumab 70 mg: 2 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
3059964|NCT00907296|Experimental|Romosozumab 70 mg: 3 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
3059965|NCT00907296|Experimental|Romosozumab 70 mg: 4 Doses|Participants received subcutaneous injections of 70 mg romosozumab on day 1 and weeks 2, 6, and 12.
3059966|NCT00907296|Experimental|Romosozumab 140 mg: 2 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
3059967|NCT00907296|Experimental|Romosozumab 140 mg: 3 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
3059968|NCT00907296|Experimental|Romosozumab 140 mg: 4 Doses|Participants received subcutaneous injections of 140 mg romosozumab on day 1 and weeks 2, 6, and 12.
3059969|NCT00907296|Experimental|Romosozumab 210 mg: 2 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and week 2, and matching placebo at weeks 6 and 12.
3059970|NCT00907296|Experimental|Romosozumab 210 mg: 3 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2 and 6, and matching placebo at week 12.
3059971|NCT00907296|Experimental|Romosozumab 210 mg: 4 Doses|Participants received subcutaneous injections of 210 mg romosozumab on day 1 and weeks 2, 6, and 12.
3059972|NCT00907335|Experimental|Retin-A Micro|Retin-A Micro 0.04% facial acne treatment used once daily
3059973|NCT00907335|Placebo Comparator|Vehicle Control|Color matched facial gel vehicle control used once daily
3059974|NCT00907374|Active Comparator|Low dose inhibition of RAS|Standard low dose inhibition of the RAS with 10 mg of benazepril orally daily to treat microalbuminuria
3059975|NCT00907374|Experimental|Agressive inhibition of the RAS|40-80 mg benazepril plus 25-100 mg losartan both orally once or twice daily
3059976|NCT00907426|Experimental|Bimatoprost 0.03% Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3059977|NCT00907426|Other|Bimatoprost 0.03% Followed by Vehicle|Treatment period one (0-6 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3059978|NCT00907426|Other|Vehicle Followed by Bimatoprost 0.03%|Treatment period one (0-6 months), once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin). For treatment period two (6-12 months), once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin.
3059979|NCT00907478|Experimental|Romiplostim|"Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years.~The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L."
3059980|NCT00907517|Experimental|MK-8776 10 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 10 mg/m^2 intravenously (IV) on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour continuous intravenous infusion (CIV) on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3059981|NCT00907517|Experimental|MK-8776 20 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 20 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3059982|NCT00907517|Experimental|MK-8776 40 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 40 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3059983|NCT00907517|Experimental|MK-8776 56 mg/m^2 + Cytarabine 2 g/m^2|Participants received MK-8776 56 mg/m^2 IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3059984|NCT00907517|Experimental|MK-8776 140 mg + Cytarabine 2 g/m^2|Participants received MK-8776 140 mg flat dose IV on Days 2 and 3 and again on Days 11 and 12 PLUS cytarabine 2 g/m^2 IV via 72-hour CIV on Days 1 through 3 and repeated on Days 10 through 12 of a treatment cycle. The duration of one treatment cycle was to be approximately 4 to 6 weeks (until hospital discharge).
3059985|NCT00907621|Experimental|Acupuncture|"Acupuncture with Seirin 020x15 mm sterile acupuncture needle:~Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36 on infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks."
3059986|NCT00907621|No Intervention|Control|"Infants born after 36th week of gestation and weighing over 2500 grams at birth, and who qualify according to Wessels definition:~Paroxystical, uncontrolled crying in an otherwise healthy child under 3 months of age, and with more than 3 hours of crying 3 days per week for 3 weeks.~The Control group will have no intervention."
3059987|NCT00907738|Experimental|Vorinostat|
3059988|NCT00907777|Experimental|Pn Group|Subjects receiving GSK 1024850A vaccine.
3059989|NCT00907777|Active Comparator|Prev Group|Subjects receiving Prevenar™ vaccine.
3059990|NCT00907803|Experimental|ST-246 400 mg|ST-246 400mg (2 x 200 mg Capsules) Orally Once Daily for 14 days
3059991|NCT00907803|Experimental|ST-246 600 mg|ST-246 600 mg (3 x 200 mg Capsules) Orally Once Daily for 14 days
3059992|NCT00907803|Placebo Comparator|Placebo|Matching Placebo capsules, Orally Once Daily for 14 days
3059993|NCT00907881||All participants|Participants with type 2 diabetes mellitus (T2DM) who had sulfonylurea treatment added to an on-going regime of oral hypoglycemic agent(s).
3059994|NCT00907907|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3059995|NCT00907907|Active Comparator|Cellcept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3059996|NCT00908011|Active Comparator|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)
3059997|NCT00908011|Active Comparator|Standard Care|Increased dose of rosuvastatin to 20mg/day
3059998|NCT00908037|Experimental|eltrombopag plus standard of care|eltrombopag
3059999|NCT00908037|Placebo Comparator|placebo plus standard of care|placebo
3060000|NCT00908076|Active Comparator|amitiza|Amitiza
3060001|NCT00908076|Placebo Comparator|Placebo|Matching Placebo
3060002|NCT00908115||Infanrix Group|Subjects received one dose of Infanrix™ at 2, 4 and 6 months of age (primary vaccination), one dose at 15-18 months of age (booster vaccination) and one dose at 4-6 years of age (booster vaccination).
3060003|NCT00908128|Experimental|Mycophenolate Mofetil (test) First|Mycophenolate Mofetil Tablets, 500 mg dosed in first period followed by CellCept® Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3060004|NCT00908128|Active Comparator|CellCept® (reference) First|CellCept® Tablets, 500 mg dosed in first period followed by Mycophenolate Mofetil Tablets, 500 mg dosed in second period; sequence repeated in third and fourth periods.
3060005|NCT00908141|Experimental|Arm I: sargramostim (days1-14)|Patients receive sargramostim (GM-CSF) subcutaneously (SC) on days 1-14. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3060006|NCT00908141|Experimental|Arm II: sargramostim (3xweek)|Patients receive GM-CSF SC three times weekly for 4 weeks. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3060007|NCT00908232|Experimental|Stable Disease: VD|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
3060008|NCT00908232|Experimental|Stable Disease: VDC|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
3060009|NCT00908232|Experimental|Stable Disease: VDL|Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
3060010|NCT00908232|Experimental|Complete to Partial Response: VD|Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
3060011|NCT00908310|Other|Omniscan|
3060012|NCT00908349|Other|Oxcarbazepine XR|Open Label Study
3060013|NCT00908375|Active Comparator|Pregabalin|A 75mg pregabalin capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
3060014|NCT00908375|Placebo Comparator|Surgar Pill|One Sugar pill capsule will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 Sugar pill capsules twice a day. The total duration of the treatment will be 3 weeks.
3060015|NCT00908388|Experimental|GORE Conformable TAG® Device Surgical Implant|
3060016|NCT00908466|Experimental|Intravitreal Injection|Will receive intravitreal injections of sirolimus 352 µg in study eye on Days 0, 60, and 120.
3060017|NCT00908466|Experimental|Subconjunctival Injection|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
3060018|NCT00908544|Experimental|PHI-patients|"Patients with primary HIV infection (PHI) (see also Eligibility) are immediately treated with 2 NRTI + 1 PI/r + Maraviroc + Raltegravir"
3060019|NCT00908544|Experimental|CHI-patients|"Patients with chronic HIV infection (CHI) and with suppressed plasma viral load for at least three years under continuous HAART (2 NRTI + 1 PI/r see also Eligibility) intensified by Maraviroc + Raltegravir"
3060020|NCT00908583|Experimental|Phase 1, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day 32. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3060021|NCT00908583|Experimental|Phase 2, two stages|Patients will receive 1 dose of rituximab, 4 doses of bortezomib and plasmapheresis. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 32, 35, 39, 42. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3060022|NCT00908583|Experimental|Phase 3, two stages|Patients will receive 1 dose of rituximab and 4 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, and 11. For those patients who go on to Stage 2 of desensitization, bortezomib will be administered via IV push over 3-5 seconds during the pre-transplant period on days 23, 26, 30 and 33. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3060023|NCT00908583|Experimental|Phase 4, single stage|Patients will receive 1 dose of rituximab and 6 doses of bortezomib. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patients will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered during the pre-transplant period on days 1, 4, 8, and 11, 14, and 17. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3060024|NCT00908583|Experimental|Phase 5, single stage|Phase 5 evaluated even greater bortezomib dosing density by eliminating the inter-cycle dosing interval. Phase 5 evaluated eight consecutive doses of bortezomib with one dose of rituximab. Rituximab will be given at a dose of 375 mg/m2 on day -7. Patient will receive 1.3 mg/m2 of bortezomib via intravenous push (IVP) over 3-5 seconds. Bortezomib will be administered on days 1, 4, 8, 11, 14, 17, 20, and 23. Methylprednisolone will be administered within 30 minutes of each bortezomib administration in both stages of desensitization. With the first and second doses, administer methylprednisolone 100mg via IV push. With the third and fourth doses, administer methylprednisolone 50mg IVP.
3060025|NCT00908596|Experimental|Gadoxetic acid disodium (Primovist/Eovist, BAY86-4873)|Participants received Primovist at a dose of 0.025 mmol/kg body weight (BW) intravenously.
3060026|NCT00908648|No Intervention|1|standard white light
3060027|NCT00908648|Experimental|2|Narrow Band Imaging
3468794|NCT03892109|Active Comparator|traxodent|The traxodent cartridge was attached to the automixing gun and then the mixing syringe with intraoral tip was placed into the gingival sulcus and gingival retraction material was applied all around the tooth. After injecting the retraction material ,the corresponding comprecap was placed on to the abutment to push the material deep into the gingival sulcus. After 4 min, the comprecap with the set retraction material attached to it was removed from the patient mouth.
3468795|NCT03892109|Experimental|Ultrapk cord|the cord packed into the gingival sulcus around the tooth
3468796|NCT03892109|Placebo Comparator|nocord|used directly in the tray
3468797|NCT03892226||1, no myocardial injury|normal troponin level (hs-troponin T ≤ 99. percentile, i.e. 14ng/ml)
3060034|NCT00908791|Experimental|CLA|open-label, single-institution proof of principle study of oral CLA in patients with newly diagnosed adenocarcinoma of the breast.
3060035|NCT00908830||Cystic fibrosis|Lung transplant patients with cystic fibrosis. Measuring MPA levels in cystic fibrosis lung transplant patients for pharmacokinetic parameters.
3060036|NCT00908830||Non-cystic fibrosis lung transplant|Non-cystic fibrosis lung transplant patients. Non-cystic fibrosis lung transplant patients will have MPA levels drawn after their dose to determine pharmacokinetic parameters.
3060037|NCT00908882|Experimental|Enhanced PTSD Health Buddy and Motivational Interviewing|Veterans with PTSD who smoke are exposed to an intervention which included a 90-day smoking cessation curriculum that is integrated into the PTSD Health Buddy Program and weekly motivational interviewing counseling by a nurse plus usual smoking cessation care
3060038|NCT00908882|No Intervention|Usual PTSD Health Buddy Care|Veteran with PTSD who smoke randomly assigned to this arm received standard of care for smoking cessation and used the standard PTSD Health Buddy
3060039|NCT00908895|Experimental|Radio-radial fixator|Patients are operated on using a radio-radial fixator (Distal radius fixator, Synthes)
3060040|NCT00908895|Active Comparator|Percutaneous pinning|Two K-wires inserted on a percutaneous way (dorsally and from the styloid), with a cast for 6 weeks
3060041|NCT00908908|Experimental|1|
3060042|NCT00908947|Experimental|Overall Study|PTA plus stenting with the LifeStent® Vascular Stent System
3060043|NCT00908960|Experimental|High TFMP: Enoxaparin|Patients received enoxaparin 40 mg subcutaneously once daily for 2 months (60 days).Only patients with high TFMP status at baseline were randomized to treatment or observation.
3060044|NCT00908960|No Intervention|High TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Only patients with high TFMP status at baseline were randomized to treatment or observation.
3060045|NCT00908960|No Intervention|Low TFMP: Observation|Patients undergo observation until evaluation with a lower extremity ultrasound at 2 months (day 60). Patients with low TFMP status at baseline were directly assigned to observation.
3060046|NCT00909064|Experimental|Arixtra|Effect of Arixtra on would drainage and length of stay for the patients with hip and knee replacement
3060047|NCT00909090|Active Comparator|Intervention|10 mg FloraGlo lutein + 2 mg Optisharp zeaxanthin
3060048|NCT00909090|Placebo Comparator|Placebo|visually identical placebo
3060049|NCT00909155|Active Comparator|Depressed; Venlafaxine treatment|Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
3060050|NCT00909155|Active Comparator|Depressed; Fluoxetine treatment|Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
3060051|NCT00909155|No Intervention|Control|Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication
3060052|NCT00909181|Experimental|Oxybutynin Gel 56 mg/day|
3060053|NCT00909181|Experimental|Oxybutynin Gel 84 mg/day|
3060054|NCT00909181|Placebo Comparator|Placebo Gel|
3060055|NCT00909220||Current Major Depressive Disorder|Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores > 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
3060056|NCT00909220||Healthy Participants|Another 36 participants with no lifetime psychiatric symptoms and scores < 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.
3060057|NCT00909324|Experimental|Pre-LASIK 0.3% hypromellose|
3060058|NCT00909324|Active Comparator|Post-LASIK 0.3% hypromellose|
3060059|NCT00909363|Experimental|WAS patients receiving Promacta|Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets. For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used. PfOS is only available for investigational use at 20mg. Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
3060060|NCT00909363|Experimental|WAS patients for blood drawing only|WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
3060061|NCT00909363|Placebo Comparator|healthy children for blood drawing only|healthy children having blood obtained once as controls for platelet parameters study
3060062|NCT00909389||Filipino Patients with Hypercholesterolemia|
3060063|NCT00909428|Experimental|Solifenacin Succinate|The intervention for this study is 10mg daily solifenacin. Patients with overactive bladder syndrome will take this study drug for 30 days.
3060064|NCT00909480|Experimental|IDet|Individually adjusted insulin detemir once daily + metformin at least 1500 mg/day
3060065|NCT00909480|Active Comparator|IGlar|Individually adjusted insulin glargine once daily + metformin at least 1500 mg/day
3060066|NCT00909532|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
3060067|NCT00909532|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
3060068|NCT00909545|Active Comparator|Isradipine CR 5mg|Isradipine CR 5mg/day
3060069|NCT00909545|Active Comparator|Isradipine CR 10mg|Isradipine CR 10mg/day
3060070|NCT00909545|Active Comparator|Isradipine CR 20mg|Isradipine CR 20mg/day
3060071|NCT00909545|Placebo Comparator|Placebo|Placebo
3060072|NCT00909610|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg (test) dosed in first period followed by Urso Forte™ Tablets, 500 mg dosed in second period.
3060073|NCT00909610|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg (reference) dosed in first period followed by Ursodiol Tablets, 500 mg (test) dosed in second period.
3060074|NCT00909649|Active Comparator|1 fibrin glue|8 ml of fibrin glue was sprayed on the surgical area with Y canula ( doubleject application system).One milliliter of fibrin glue contains 70-100 mg. fibrinogen, 10-50 u factor 8 aprotinin 3000k iu/ml, 2-9 mg fibronectin,40-120 ug plasminogen ,4 Iu/ml thrombin, 40 mmol cocl2/L (immuno AG/austrial)
3060075|NCT00909649|No Intervention|2 non fibrin glue|after good haemostasis the same sized drain was applied in axillary and breast area and incision was closed. Followed by external compression for 10 minutes in both groups. Drains were left in places until the drainage for the preceding 24 h was less than 20 ml.
3060076|NCT00909727|Placebo Comparator|Placebo|Subjects who received placebo every 12 hours (q12h) for up to 48 weeks.
3060077|NCT00909727|Experimental|150 mg Ivacaftor q12h|Subjects who received 150 mg of ivacaftor q12h for up to 48 weeks.
3060078|NCT00909753|Experimental|Ursodiol (test) First|Ursodiol Tablets, 500 mg
3060079|NCT00909753|Active Comparator|Urso Forte™ (reference) First|Urso Forte™ Tablets, 500 mg
3060080|NCT00909779|Experimental|Arformoterol 15 mcg twice daily|Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
3060081|NCT00909779|Placebo Comparator|Placebo twice daily|Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.
3060082|NCT00909792|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B, followed by Senofilcon A
3060083|NCT00909792|Other|Senofilcon A / Lotrafilcon B|Senofilcon A, followed by Lotrafilcon B
3060084|NCT00909844|Experimental|Triptorelin|
3060085|NCT00909857|Experimental|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID (BAY86-5027) plus one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles
3060086|NCT00909857|Active Comparator|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet placebo plus one tablet SH D593B (Miranova) for 28 days without tablet-free interval for 3 treatment cycles
3060087|NCT00909870|Experimental|1|Weekly applications of Dermagraft and compression dressings, in combination with systematic surgical wound debridement.
3060088|NCT00909870|Active Comparator|2|Weekly application of compression dressings only, in combination with systematic surgical wound debridement.
3060089|NCT00910000|Experimental|Dose Level 1A|"Vorinostat: 200 mg taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 100 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060090|NCT00910000|Experimental|Dose Level 2A|"Vorinostat: 300mg, taken orally once a day for the first two weeks of each three-week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060091|NCT00910000|Experimental|Dose Level 1B|"Vorinostat: 200mg, taken orally twice a day for days 1-3 and days 8-10 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 1 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 1 and day 8 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060092|NCT00910000|Experimental|Dose Level 1C|"Vorinostat: 200mg, taken orally twice a day for days 1, 2, 8 and 9 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060093|NCT00910000|Experimental|Dose Level 1D|"Vorinostat: 300mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060094|NCT00910000|Experimental|Dose Level 2D|"Vorinostat: 400mg, taken orally once a day for days 1 and 2 of every three week cycle~Carboplatin: AUC 4, given intravenously on day 2 of every three week cycle~Gemcitabine: 1000 mg/m2, given intravenously on day 2 and day 9 of every three week cycle~Participants received up to 8 cycles of therapy without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision."
3060095|NCT00910039|Experimental|Sunitinib malate|"Oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo neuropsychological battery testing at baseline and periodically during study to assess cognitive function (memory, verbal fluency, visual-motor speed, executive function, and motor dexterity), activities of daily living, and quality of life."
3060096|NCT00910091|Experimental|A- BN 83495- 40mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
3060097|NCT00910091|Active Comparator|B- MA - 160mg|After eligibility is confirmed, subjects will be randomised at baseline. The randomisation number and associated treatment for the total study will be allocated by an Interactive Voice Response System (IVRS) service
3060098|NCT00910208|Experimental|Patient-controlled analgesia 1 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.0 mg morphine demand dosing every 6 minutes
3060099|NCT00910208|Experimental|Patient-controlled analgesia 1.5 mg demand dose|0.1 mg/kg morphine loading dose plus PCA with 1.5 mg morphine demand dosing every 6 minutes
3060100|NCT00910208|Active Comparator|Non-Patient-controlled analgesia comparison group|0.1 mg/kg morphine loading dose plus additional analgesia as needed
3060101|NCT00910247|Experimental|eslicarbazepine acetate|Open-label treatment with eslicarbazepine acetate will be at doses between 800 and 2400 mg QD
3060102|NCT00910273|Experimental|1|etanercept 50 mg/week
3060103|NCT00910299|Experimental|Prasugrel|
3060104|NCT00910299|Active Comparator|Clopidogrel|
3060105|NCT00910429|Experimental|Arm 1|
3060106|NCT00910481|Experimental|Elective IABP Insertion|
3060107|NCT00910481|No Intervention|No Planned IABP Insertion|
3060108|NCT00910520|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
3060109|NCT00910520|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
3468798|NCT03892226||2, chronic myocardial injury|elevated, but stable troponin level; (hs-troponin T> 99. percentile and rise/fall ≤ 20% in the control)
3060110|NCT00910624|Experimental|BOC + PEG/RBV|Participants who enrolled within 2 weeks after the last dose of PEG/RBV in previous protocol received boceprevir (BOC) + peginterferon/ribavirin (PEG/RBV) for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who did not enroll within 2 weeks after the last dose of PEG/RBV in previous protocol received PEG/RBV for 4 weeks followed by BOC + PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.
3468799|NCT03892226||3, acute myocardial injury|dynamic troponin elevation; (hs-troponin T> 99. percentile and rise/fall >20% in the control)
3060112|NCT00910663|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by Cellcept® 250 mg Capsule dosed in second period.
3060113|NCT00910663|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
3060114|NCT00910689|Placebo Comparator|1|Optimal Acute Therapy plus Beta Blocker Placebo
3060115|NCT00910689|Active Comparator|2|Optimal Acute Therapy plus Beta Blocker (propranolol or nadolol)
3060116|NCT00910689|Active Comparator|3|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker placebo
3060117|NCT00910689|Active Comparator|4|Optimal Acute Therapy plus Behavioral Migraine Management plus Beta Blocker (propranolol or nadolol)
3060118|NCT00910715|Active Comparator|EM-10 days doxycycline|
3060119|NCT00910715|Active Comparator|EM-doxycycline 15 days|
3060120|NCT00910715|Placebo Comparator|controls|
3060121|NCT00910728|Experimental|1|AZD1480
3060122|NCT00910845|Experimental|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable).
3060123|NCT00910845|Other|placebo/onabotulinumtoxinA|Placebo (normal saline) injected into the detrusor at Day 1, followed by an injection of onabotulinumtoxinA (botulinum toxin Type A) 100 U after a minimum of 12 weeks (if applicable).
3060124|NCT00910858|Experimental|10 mg Lenalidomide|"Participants in the Pharmacokinetic Phase received a single 10 mg oral dose of lenalidomide on Day -7. During the Monotherapy Phase participants received 10 mg oral lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure.~During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 10 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment."
3060125|NCT00910858|Experimental|15 mg Lenalidomide Non-del 5q|Following the enrollment of the first 25 patients into the Monotherapy Phase, a second group of 15 patients with low- or intermediate-1-risk MDS not associated with a del 5q (non-del 5q) cytogenetic abnormality were enrolled to receive 15 mg of lenalidomide once daily. Erythroid responders could continue lenalidomide monotherapy in the absence of limiting toxicity, disease progression, or erythroid failure. During the Combined Treatment Phase participants who were erythroid nonresponders and erythroid responders who had developed an erythroid relapse continued treatment with 15 mg lenalidomide in conjunction with recombinant human erythropoietin (rhu EPO) 40,000 units administered weekly by subcutaneous injection for 8 weeks. Responding patients could continue combined treatment.
3060126|NCT00910871|Experimental|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks in addition to Background Regimen (BR) for the treatment of multi-drug resistant tuberculosis (MDR-TB).
3060127|NCT00910910|Experimental|1 - Lenalidomide|1 - Lenalidomide
3060128|NCT00910910|Active Comparator|2- Chlorambucil|2- Chlorambucil
3060129|NCT00910962|Experimental|Treatment A|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
3060130|NCT00910962|Experimental|Treatment B|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg twice daily for 12 weeks
3060131|NCT00910962|Placebo Comparator|Treatment C|Placebo twice daily for 12 weeks
3060132|NCT00910988|Active Comparator|olanzapine|olanzapine injection in healthy control
3060133|NCT00910988|Active Comparator|ziprasidone|ziprasidone injection in healthy control
3060134|NCT00910988|Placebo Comparator|saline|saline injection in healthy control
3060135|NCT00911144|Experimental|Synflorix Group|Subjects previously primed (NCT00680914) with 3 doses of Synflorix and Hiberix in the first year of life receiving a booster dose of the same vaccines in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
3060136|NCT00911144|Active Comparator|Prevenar Group|Subjects previously primed (NCT00680914) with 3 doses of Prevenar and Hiberix in the first year of life receiving a booster dose of Prevenar and Hiberix in the second year of life by intramuscular injection into the right and the left thigh or deltoid, respectively.
3060137|NCT00911157|Experimental|Fondaparinux|
3060138|NCT00911157|Other|unfractionated heparin|
3060139|NCT00911170|Placebo Comparator|Placebo|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2, and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus placebo subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
3060140|NCT00911170|Placebo Comparator|Pegfilgrastim|Participants received standard chemotherapy (FOLFOX or FOLFIRI) on Days 1-2 and bevacizumab 5 mg/kg intravenous (IV) infusion on Day 1 of each 14-day cycle plus pegfilgrastim 6 mg administered as a single subcutaneous injection once per cycle, for a maximum of 4 cycles, 24 hours after chemotherapy (Day 4).
3060141|NCT00911274|Experimental|Test (mycophenolate mofetil) First|Mycophenolate Mofetil 250 mg Capsule dosed in first period followed by CellCept® 250 mg Capsule dosed in second period.
3060142|NCT00911274|Active Comparator|Reference (CellCept®) First|CellCept® 250 mg Capsule dosed in first period followed by Mycophenolate Mofetil 250 mg Capsule dosed in second period.
3060143|NCT00911300|Active Comparator|Arm 1: fondaparinux|
3060144|NCT00911300|Active Comparator|Arm 2: unfractionated heparin + Vitamin-K-Antagonist|
3060145|NCT00911443|Experimental|Dacarbazine + Interferon alpha + thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3060146|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3060147|NCT00911443|Experimental|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3060148|NCT00911443|Experimental|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3060149|NCT00911443|Active Comparator|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
3060150|NCT00911495|Experimental|GMI-1070|
3060151|NCT00911508|Active Comparator|Left Atrial Ablation|Pulmonary vein isolation using a circumferential ablative approach in the left atrium. Ablation may be performed using circular mapping catheter-guided ablation, antral isolation using a circular guided approach, or wide area circumferential ablation.
3060152|NCT00911508|Active Comparator|Rate or Rhythm Control Therapy|Current state-of-the-art drug therapy for atrial fibrillation (rate control or rhythm control). Treating physicians will be encouraged to follow the American College of Cardiology / American Heart Association / European Society of Cardiology Atrial Fibrillation Guidelines with regard to drug therapy for atrial fibrillation. The specific choice of rate control versus rhythm control drug therapy and the specific drugs to be used will ultimately be left to the discretion of the treating physician.
3060153|NCT00911534|Experimental|1|
3060154|NCT00911534|Placebo Comparator|2|
3060155|NCT00911547|Experimental|1|Montelukast + Beclomethasone
3060156|NCT00911547|Experimental|2|Montelukast + Placebo inhaler
3060157|NCT00911547|Experimental|3|Placebo tablet + Beclomethasone
3060158|NCT00911547|Placebo Comparator|4|Placebo tablet + Placebo inhaler
3060159|NCT00911586|Experimental|Testosterone Undecanoate|Oral testosterone undecanoate, 200 mg testosterone (T) as TU, twice daily for 28 days.
3060160|NCT00911612|Experimental|Colesevelam|Participants received colesevelam 1.875 g twice daily
3060161|NCT00911612|Placebo Comparator|Placebo|Participants received an inert capsule matching the study drug twice daily, as prepared by the Mayo Clinic research pharmacy
3060162|NCT00911625|Active Comparator|0.5 units/kg|Participants randomized to this arm will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
3060163|NCT00911625|Experimental|0.25 units/kg|Participants randomized to this arm will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
3060164|NCT00911742|Experimental|1 Tramadol Contramid Once A Day|
3060165|NCT00911742|Active Comparator|2 Zytram (R)|
3060166|NCT00911768|Experimental|Korean Red Ginseng group|The brand name of experimental drug is 'Capsule of Korean Red Ginseng Powder'. It consists of the powder of steamed root of Panax ginseng made by Korean Ginseng Corp.
3060167|NCT00911768|Placebo Comparator|Corn-starch powder with ginseng flavor|The placebo of this study is corn-starch powder with Korean Red Ginseng flavor. It has the same shape, color and flavor like experimental drug.
3060168|NCT00911807|Experimental|Cerebrolysin + donepezil|
3060169|NCT00911807|Experimental|Cerebrolysin + placebo|
3060170|NCT00911807|Active Comparator|Donepezil + placebo|
3060171|NCT00911820|Active Comparator|Arm A: PCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally, on days 1 and 8 of each cycle, patients received cisplatin 30 mg/m2 IV over 30 minutes and then irinotecan 65 mg/m2 IV over 30 minutes of each 3-week cycle. Treatment could continue until disease progression or unacceptable toxicity.
3060172|NCT00911820|Active Comparator|Arm B: TPCA|Patients first received bevacizumab 10 mg/kg IV on day 1 of every cycle (cycle length=21 days) at approximately 0.5 mg/kg/minute. Additionally on days 1 and 8 of each cycle, patients received docetaxel 30 mg/m2 IV over 30 minutes followed by cisplatin 25 mg/m2 IV over 30 minutes and then irinotecan 50 mg/m2 IV over 30 minutes of each 3-week cycle.
3060173|NCT00911859|Experimental|Part 1: VMP+Siltuximab 11 mg/kg|Siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP (Velcade+Melphalan+Prednisone). Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally (by mouth).
3060174|NCT00911859|Experimental|Part 2, Arm A: VMP+Siltuximab 8.3 mg/kg or 11 mg/kg|Siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks along with VMP. Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
3060175|NCT00911859|Active Comparator|Part 2, Arm B: VMP|Velcade 1.3 mg/m2 will be administered as an intravenous bolus injection according to the current approved package inserts. Melphalan 9 mg/m2 and prednisone 60 mg/m2 will be taken orally
3060176|NCT00911898|Experimental|MM-111|
3060177|NCT00911937|Experimental|Fesoterodine|
3060178|NCT00911937|Placebo Comparator|Placebo|
3060179|NCT00911989|Other|Transvaginal Sleeve Gastrectomy|Transvaginal Sleeve Gastrectomy using Steerable Flex Trocar (SFT) for transvaginal endoscope placement (endoscopic visualization)
3060180|NCT00912002|Experimental|MK-0941|MK-0941
3060181|NCT00912015|Experimental|Tramadol OAD 200mg|
3060182|NCT00912015|Experimental|Tramadol OAD 300mg|
3060183|NCT00912015|Experimental|Tramadol OAD 400mg|
3060184|NCT00912015|Other|Tramadol OAD 100mg|Despite provision in the protocol that the minimum daily dose was 200 mg, 2 patients took 100 mg against instructions.
3060185|NCT00912028|Active Comparator|senofilcon A|contact lens
3060186|NCT00912028|Active Comparator|lotrafilcon B|contact lens
3060187|NCT00912028|Active Comparator|balafilcon A|contact lens
3060188|NCT00912028|Active Comparator|methafilcon A|contact lens
3060189|NCT00912028|Active Comparator|vifilcon A|contact lens
3060190|NCT00912093|Placebo Comparator|Placebo|Single subcutaneous injection of matching placebo
3060191|NCT00912093|Experimental|Icatibant|Single subcutaneous injection of icatibant, 30 mg
3060192|NCT00912158|Active Comparator|CPAP + ST|Continuous positive airway pressure (CPAP) and Standard medical therapy (ST)
3060193|NCT00912158|Active Comparator|BiPAP + ST|Bilevel positive airway pressure (BiPAP) and standard medical therapy (ST)
3060194|NCT00912158|Active Comparator|ST|Standard Medical therapy (ST)
3060195|NCT00912197|Experimental|Oligofructose|Participants received 10g of Oligofructose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals.The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
3060196|NCT00912197|Placebo Comparator|Cellulose and maltodextrin|Participants received 10g of Cellulose powdered supplements in sachets each containing 10 g dietary fiber) three times per day. Volunteers were instructed to take the supplement with their main meals. Maltodextrin was added to the cellulose supplement. The 8-week supplementation period took place between visits 3 and 4 and included a 2-week run-in period to allow the bowel to adapt to the 30 g of dietary fiber.
3060198|NCT00912288|Experimental|Dimebon|
3060199|NCT00912288|Placebo Comparator|Placebo|
3060200|NCT00912301|Experimental|NaCDC 500 mg|Participants randomized to this arm received 500 mg NaCDC per day for 4 days.
3060201|NCT00912301|Experimental|NaCDC 1000 mg|Participants randomized to this arm received 1000 mg NaCDC per day for 4 days.
3060202|NCT00912301|Placebo Comparator|Placebo|Participants randomized to this arm received a placebo capsule each day for 4 days.
3060203|NCT00912340|Experimental|Trastuzumab|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and continue to receive their most recent hormone therapy. Patients achieving disease progression receive everolimus PO daily in combination with trastuzumab and hormone therapy.
3060204|NCT00912340|Experimental|Everolimus|Patients receive everolimus PO daily and continue their most recent hormone therapy. Patients achieving disease progression receive trastuzumab IV over 30-90 minutes once every 3 weeks in combination with everolimus and hormone therapy.
3060205|NCT00912340|Experimental|Trastuzumab and everolimus (ARM REMOVED)|Patients receive trastuzumab IV over 30 minutes once every 3 weeks and everolimus PO daily while continuing to receive their most recent hormone therapy.
3060206|NCT00912405|Experimental|Sinexus Intranasal Splint|Patient receives a drug-coated intranasal splint
3060207|NCT00912509|Active Comparator|30 minute light duration|30 minute treatment with UVX light
3060208|NCT00912509|Active Comparator|45 minute light duration|45 minute treatment with UVX light
3060209|NCT00912743|Experimental|1|MSI - H arm
3060210|NCT00912782|Placebo Comparator|Placebo|Placebo one time per week for 3 weeks
3060211|NCT00912782|Experimental|Cholecalciferol|Vitamin D 200,000 IU per week for 3 weeks
3060212|NCT00912795|Experimental|SMS Turkey|6-week smoking cessation program delivered via daily text messages
3060213|NCT00912795|No Intervention|Brochure control|7-page brochure that provided general information and tips on how to quit smoking
3060214|NCT00912808|Experimental|Donepezil|
3060215|NCT00912808|Placebo Comparator|Sugar Pill|
3060216|NCT00912873|Active Comparator|0.1% Ropivicaine|Patients will be given 0.1% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
3060217|NCT00912873|Experimental|0.4% Ropivicaine|Patients will be given 0.4% ropivicaine provided via infusion pump which will be attached intraoperatively and will remain connected until patient is ready to leave the hospital. In this time a physical therapist will work with the patient to assess outcome measures.
3060218|NCT00912912|Experimental|Sunitinib Malate|Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
3060219|NCT00912925|Placebo Comparator|Placebo|Patients in the placebo-control group were administered a solution of 100 millimolar (mM) sodium phosphate, 150 mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over approximately 4 hours once weekly for 26 weeks.
3060220|NCT00912925|Active Comparator|Aldurazyme treatment|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 Units/kg (approximately 0.58 mg/kg = labeled dose) administered intravenously over approximately 4 hours once weekly for 26 weeks.
3060221|NCT00912964|Placebo Comparator|Placebo|Participants received matching mirabegron placebo tablets orally once a day for 12 weeks.
3060222|NCT00912964|Experimental|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks.
3060223|NCT00912964|Experimental|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks.
3060224|NCT00912990|Placebo Comparator|Normal saline|Normal saline volume calculated to be equal to the volume of cisatracurium 0.2mg/kg
3060225|NCT00912990|Active Comparator|Cisatracurium|Subjects in this arm will be given Cisatracurium 0.2mg/kg IV dose one time prior to intubation.
3060226|NCT00913003|Placebo Comparator|Placebo|Group B using saline as a placebo.
3060227|NCT00913003|Active Comparator|Lidocaine|Group A lidocaine infusion and bolus.
3060228|NCT00913068|Experimental|TAP arm|in the experimental arm, the procedure will consist of the staff urologist injecting local anesthetic into the anterior abdominal wall bilaterally from the inside of the abdomen at the end of their surgery
3060229|NCT00913068|Active Comparator|standard post operative pain control|Our current post operative analgesic strategy involves a multi-modal approach, using local injectable anesthetic around the incision and systemic medications (i.e. non-steroidal anti-inflammatories, acetaminophen and break-through doses of opiates). Some of the more common adverse reactions are reparatory depression, sedation, confusion, delirium, nausea, pruritis, constipation, hypotension and bradycardia. Often it is these resulting side effects that extend the length of in hospital rehabilitation, and decrease a patient's overall satisfaction.
3060230|NCT00913081|Experimental|Quercetin 500 mg|Quercetin 500 mg once, administered one hour before 500 mg immediate-release niacin
3060231|NCT00913081|Experimental|Quercetin 1000 mg|Quercetin 1000 mg once, administered one hour before 500 mg immediate-release niacin
3060232|NCT00913081|Experimental|Quercetin 2000 mg|Quercetin 2000 mg once, administered one hour before 500 mg immediate-release niacin
3060233|NCT00913081|Placebo Comparator|Placebo|Placebo once, administered one hour before 500 mg immediate-release niacin
3060234|NCT00913133|Experimental|Desirudin|desirudin 15 mg twice daily for a minimum of 5 days
3060235|NCT00913263|Experimental|2-Hydroxyflutamide|Single injection of 2-Hydroxyflutamide (2-8mL ready-made paste)in one prostate lobe
3060236|NCT00913380|Experimental|Low-dose CT|
3060237|NCT00913380|Active Comparator|Standard-dose CT|
3060238|NCT00913458|Experimental|1|etanercept + methotrexate; etanercept + methotrexate
3060239|NCT00913510|Experimental|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
3060240|NCT00913510|Active Comparator|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, i.e. Drug.
3060241|NCT00913523|Experimental|Tampon with GML|Regular and Super Tampon with GML added to the cover
3060242|NCT00913523|Sham Comparator|Tampon without GML|Regular and Super Tampon without GML
3060243|NCT00913523|Sham Comparator|Tampon Normally Used|Type and Size of Tampon Normally Used by Subjects
3060244|NCT00913627|Experimental|1|1 x 600 mg ibuprofen IR/ER-roller compaction caplet
3060245|NCT00913627|Experimental|2|1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
3060246|NCT00913627|Active Comparator|3|1x 220 mg naproxen sodium (Aleve caplet)
3060247|NCT00913627|Placebo Comparator|4|1 x placebo caplet
3060248|NCT00913744|Experimental|Ocriplasmin|
3060249|NCT00913744|Sham Comparator|Sham injection|
3060250|NCT00913770|No Intervention|SC|Standard Care
3060251|NCT00913770|Experimental|SBIRT|Screening, Brief Intervention and Facilitated Referral to Treatment
3060252|NCT00913770|Experimental|SBI+Bup|Screening, Brief Intervention and Buprenorphine initiation
3060253|NCT00913835|Experimental|Olaratumab and Liposomal Doxorubicin|Olaratumab and Liposomal Doxorubicin
3060254|NCT00913835|Active Comparator|Liposomal Doxorubicin: Optional Olaratumab Monotherapy|Liposomal Doxorubicin Monotherapy until disease progression. Upon disease progression the participant had the option to receive Olaratumab monotherapy.
3060255|NCT00913913|Experimental|bevacizumab,IL-2, IFN, DC vaccine|Patients will be dosed with bevacizumab (10mg/kg) intravenously every two weeks beginning four weeks prior to the first vaccine. Each treatment week includes ultrasound guided intranodal DC-vaccine injection (1 X 107 cells/1mL), followed by 5 days of continuous intravenous infusion of IL-2 (18 MiU/m2), and three subcutaneous injections of IFNa-2b (6 MiU) (every other day)
3060256|NCT00913978|Active Comparator|Group 1: VitaHeat|Patients in group one will be warmed perioperatively with the VitaHeat mattress and IV fluid warmers once they are in the operating room.
3060257|NCT00913978|Active Comparator|Group 2: Bair Hugger|Patients in group two will be warmed perioperatively with the upper body bair hugger and IV fluid warmers once they are in the operating room.
3060258|NCT00914069|Experimental|RIVS vascular access|RIVS vascular access
3060259|NCT00914069|Active Comparator|Conventional vascular access|Conventional vascular access
3060260|NCT00914186|Placebo Comparator|Vehicle|
3060261|NCT00914186|Experimental|TS-022 0.005% lotion|
3060262|NCT00914186|Experimental|TS-022 0.010% lotion|
3060263|NCT00914186|Experimental|TS-022 0.020% lotion|
3060264|NCT00914316|Active Comparator|Phase 1-Ranolazine, Phase 2-Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
3060265|NCT00914316|Active Comparator|Phase 1 -Ranolazine, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise program and will additionally receive ranolazine 1000 mg orally, twice daily, by mouth. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
3060266|NCT00914316|Active Comparator|Phase 1 -Placebo, Phase 2 -Ranolazine|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and also receive ranolazine 1000 mg orally twice daily by mouth.
3060267|NCT00914316|Placebo Comparator|Phase 1 -Placebo, Phase 2 -Placebo|This group will participate in the Phase 1 -12 week supervised exercise regimen and will receive a sugar pill in place of the study drug. In Phase 2, the group will exercise independently and will receive a sugar pill in place of the study drug.
3060268|NCT00914459|Other|Moroctocog alfa (AF-CC)|Open Label
3060269|NCT00914485|Other|Provider Communication Skills Training|Provider clinical communication training intervention
3060270|NCT00914589|Experimental|FXIII17.5IU/Kg|Recombinant factor XIII at a single dose of 17.5 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
3060271|NCT00914589|Experimental|FXIII35IU/Kg|Recombinant factor XIII at a single dose of 35 IU/kg lean body mass (LBM) was administered via slow i.v. push at a rate not exceeding two mL per minute.
3060272|NCT00914589|Placebo Comparator|Placebo|Recombinant factor XIII placebo was administered as a single dose via slow i.v. push at a rate not exceeding two mL per minute.
3060273|NCT00914628|Experimental|A|HSV-TK engineering donor Lymphocytes
3060274|NCT00914628|Active Comparator|B|T-cell depleted or T-cell replete strategies
3060275|NCT00914732|Experimental|Group B, liquid, subcutaneous|Group B: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) liquid formulation by the subcutaneous route on Day 0 and 28.
3060276|NCT00914732|Experimental|Group C, liquid, intradermal|Group C: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (2x10^7 TCID50/0.1mL per dose) liquid formulation by the intradermal route on Day 0 and 28.
3060277|NCT00914732|Experimental|Group A, lyophilized, subcutaneous|Group A: 165 subjects will receive a 2 dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) lyophilized formulation by the subcutaneous route on Day 0 and 28.
3060278|NCT00914810|Experimental|Vitamin D|Cholecalciferol (2000 I.U. daily)
3060279|NCT00914810|Placebo Comparator|Placebo|Placebo capsule (sugar pill daily)
3060280|NCT00914849|Experimental|Arm 1 - Donor|"Day 1~AMD3100 320 ug/kg IV~Leukopheresis~Day 2 (if peripheral blood stem cell (PBSC) collected is not sufficient)~AMD3100 320 ug/kg IV~Leukopheresis"
3060281|NCT00914849|Experimental|Arm 2 - Recipient|"Standard of care and physician choice myeloablative or non-myeloablative chemotherapy with or without total body irradiation (permitted = cyclophosphamide and single dose total body irradiation (TBI) / fludarabine and busulfan / fractionated TBI and cyclophosphamide / fractionated TBI, etoposide, and cyclophosphamide / busulfan and cyclophosphamide / fludarabine, busulfan, and ATGAM~Day 0 = Stem Cell Transplant"
3060282|NCT00914862|Experimental|Children Ramelteon 4 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single 4 mg oral dose of ramelteon.
3060283|NCT00914862|Experimental|Children Ramelteon 8 mg|Children 6 to 11 years of age who had insomnia associated with ADHD received a single oral 8 mg dose of ramelteon.
3060284|NCT00914862|Experimental|Adolescents Ramelteon 4 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 4 mg ramelteon.
3060285|NCT00914862|Experimental|Adolescents Ramelteon 8 mg|Adolescents 12 to 17 years of age with insomnia received a single oral dose of 8 mg ramelteon.
3060286|NCT00914862|Active Comparator|Healthy Adult Ramelteon 8 mg|Healthy adults (18 to 50 years old) received a single oral dose of 8 mg ramelteon.
3060287|NCT00914927|Experimental|1|
3060288|NCT00914927|Experimental|2|
3060289|NCT00914927|Placebo Comparator|3|
3060290|NCT00914940|Experimental|Arm 1|"CONDITIONING: Patients undergo total-body irradiation twice daily on days -10 to -7. Patients also receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine IV over 30 minutes on days -6 to -2. TRANSPLANTATION: Patients undergo infusion of CD34+ enriched allogeneic peripheral blood stem cells (PBSC) followed by CD45RA+ T-cell-depleted allogeneic PBSC on day 0.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Cohort A: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 50 followed by standard taper in the absence of grade II-IV acute GVHD. Cohort B: Patients receive tacrolimus IV continuously or orally twice daily beginning on day -1 and continuing until day 30 followed by rapid taper in the absence of grade II-IV acute GVHD."
3060291|NCT00914966|Experimental|CINRYZE|"There were 3 potential dose escalation steps:~Step 1: 1500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 2: 2000 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks~Step 3: 2500 Units of CINRYZE (C1 inhibitor [human]) administered by IV infusion twice per week for 12 weeks"
3060292|NCT00915005|Experimental|Group 1|"Group 1: Photon Therapy - 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3060293|NCT00915005|Experimental|Group 2|"Group 2: Proton Therapy - 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3060294|NCT00915005|Experimental|Group 3|"Group 3: Receives either photon or proton therapy, whichever participant's doctor decides is better, for for 6-7 1/2 weeks.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3060295|NCT00915005|Experimental|Group 4|"Photon Therapy - Highest practical dose (74 CGE, 66 CGE) radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.~Paclitaxel 50 mg/m2 by vein 1 time each week for 7 weeks.~Carboplatin AUC 2 by vein 1 time each week for 7 weeks."
3060296|NCT00915018|Experimental|neratinib plus paclitaxel|
3060297|NCT00915018|Active Comparator|trastuzumab plus paclitaxel|
3060298|NCT00915031|Active Comparator|Hypothermia Only OR|Use of Hypothermia Cooling device only in the operating room. Intervention is Hypothermia Cooling Device.
3060299|NCT00915031|Active Comparator|Hypothermia in OR + Recovery|Use of hypothermia cooling device in the operating room and up to five hours after surgery is intervention.
3060300|NCT00915148||Ultrasound examination|Women with prolonged Labour; Primi gravidae, single pregnancy, >37 weeks, fetus alive, cephalic presentation.
3060301|NCT00915278|Experimental|PF-04605412|
3060302|NCT00915343|Experimental|Novel once daily modified release|"Test drug: hydrocortisone (modified release), oral tablet, available as 20 mg and 5 mg.~The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state"
3060303|NCT00915343|Active Comparator|Conventional TID hydrocortisone|Reference drug: hydrocortisone, oral tablet, 10 mg. The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM)in the same total daily dose as the experimental drug. The morning dose was administered in the fasting state.
3060304|NCT00915356|Experimental|1|AZD1305 iv infusion
3060305|NCT00915356|Placebo Comparator|2|Placebo iv infusion
3060306|NCT00915473|Experimental|Active Injection|Subjects randomized to this arm will receive 2.5 mL 0.5% bupivicaine plus 0.5 mL 20 mg methylprednisolone injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
3060307|NCT00915473|Placebo Comparator|Placebo Injection|Subjects randomized to this arm will receive 2.75 mL normal saline plus 0.25 mL 1% lidocaine injected over the ipsilateral (unilateral headache) or bilateral (bilateral headache) occipital nerve.
3060308|NCT00915499|Active Comparator|ASV mode|
3060309|NCT00915499|Active Comparator|CPAP mode|
3060310|NCT00915525|Experimental|botulinum toxin Type A 100U|Botulinum toxin Type A 100U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
3060311|NCT00915525|Experimental|botulinum toxin Type A 150U|Botulinum toxin Type A 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
3060312|NCT00915538|Other|Group 1 / use of pMDI as approved|The intervention in this group will use inhalation from the pMDI containing budesonide/formoterol pMDI 160/4.5 2 inhalations as approved. (FDA approved product information) without a spacer. The pulmonary function tests (PFTs) will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of budesonide /formoterol; pMDI160/5.
3060313|NCT00915538|Experimental|Group 2 / pMDI with Aerochamber Plus|The intervention in this group will use the pMDI budesonide/formoterol 160/4.5 with a valve holding chamber spacer device, Aerochamber Plus which is the intervention being studied The PFTs will be collected at baseline and for a period of 12 hours post inhalation of 2 inhalation of Symbicort 160/5. This is the intervention to be studied for comparison to the non-spacer inhalations..
3060314|NCT00915551|Experimental|PEP005 (Ingenol Mebutate) gel|
3060315|NCT00915551|Placebo Comparator|Vehicle gel|
3060316|NCT00915590|Experimental|Placebo first, then IL-1RA|It is our intent that 10 patients will complete a course of treatment with placebo, followed by a course of treatment with 5% custom made topical IL-1Ra.
3060317|NCT00915590|Experimental|IL-1RA first, then Placebo|It is our intent that 10 patients will complete a course of treatment with 5% custom made topical IL-1Ra, followed by a course of treatment with placebo
3060318|NCT00915603|Active Comparator|paclitaxel/bevacizumab/everolimus|Systemic Therapy
3060319|NCT00915603|Placebo Comparator|paclitaxel/bevacizumab/placebo|Systemic Therapy
3060320|NCT00915655|Experimental|DRV/rtv (darunavir/ritonavir)|Patients will receive darunavir tablets 2 x 400 mg in combination with ritonavir capsule 100 mg once daily for 48 weeks along with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) ie, either zidovudine/lamivudine or abacavir/lamivudine
3060321|NCT00915759|Active Comparator|ProKera|
3060322|NCT00915759|Placebo Comparator|Bandage contact lens|
3060323|NCT00915772|Experimental|Linagliptin + metformin bid|Linagliptin low dose + metformin 500 mg, bid
3060324|NCT00915772|Experimental|Linagliptin+ metformin bid|Linagliptin low dose + metformin 1000 mg bid
3060325|NCT00915772|Active Comparator|Metformin bid|Metformin 1000 mg bid
3060326|NCT00915798||Smokers with ADHD|Smokers with ADHD participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
3060327|NCT00915798||Nonsmokers with ADHD|Nonsmokers with ADHD participated in one condition.
3060328|NCT00915798||Control smokers|Control smokers participated in one overnight abstinence condition (withdrawal) and one smoking condition (smoking the first cigarette of the morning).
3060329|NCT00915798||Control nonsmokers|Control nonsmokers participated in one condition.
3060330|NCT00915876|Active Comparator|Paricalcitol|
3060331|NCT00915876|Placebo Comparator|Placebo|
3060332|NCT00915902|Experimental|Omega-3-acid ethyl esters (Lovaza)|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. GlaxoSmithKline supplied the study drug and the placebo. The study drug, Omega-3-acid ethyl esters (Lovaza) was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week treatment period. The study drug contained minimally 1.5 g DHA (docosahexaenoic acid) and 1.86 g EPA (eicosapentaenoic acid).
3060333|NCT00915902|Placebo Comparator|Placebo|This randomized, double-blind, placebo, crossover trial consisted of two 8-week treatment periods, separated by a 4-week washout. Eligible patients were randomized to receive either fish oil 4 g daily or corn oil placebo during the first 8-week treatment period; patients received the alternate treatment during the next treatment period. The corn oil placebo was given to patients PO daily as two, 1 g capsules taken twice daily during the duration of their 8-week non-treatment (placebo) period.
3060334|NCT00915928|Active Comparator|ACE inhibitor|patients randomized to this arm will be treated with ACE inhibitors after surgery
3060335|NCT00915928|Placebo Comparator|Placebo|patients randomized to this arm will be treated with placebo after surgery
3060336|NCT00915954|Active Comparator|Active Acromegaly|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
3060337|NCT00915954|Active Comparator|Type 2 Diabetes Mellitus(DM)|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
3060338|NCT00915954|Active Comparator|Heathy Controls|Placebo, oral glucose tolerance test, and subcutaneous administration of recombinant human IGF-1 will be given at visits 2, 3, and 4 respectively. All visits will be performed within a 4 week period.
3060339|NCT00915967|Experimental|Vancomycin|Subjects in the experimental group will receive Vancomycin injected directly into the wound pocket.
3060340|NCT00915967|Placebo Comparator|Saline|Subjects in the saline group will receive a Saline injection directly into the wound pocket.
3060341|NCT00916006|Experimental|PEP005 gel|PEP005 gel, 0.015% applied once daily for three consecutive days
3060342|NCT00916006|Placebo Comparator|Vehicle gel|Vehicle gel applied once daily for three consecutive days
3060343|NCT00916032|Active Comparator|1|One infusion using a 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent followed by a second infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total)
3060344|NCT00916032|Active Comparator|2|One infusion of two 1500 IU potency vials of Advate dissolved in 5 mL diluent each (administered in 10 mL diluent in total) followed by a second infusion of one 3000 IU potency vial of Advate dissolved and administered in 5 mL diluent
3060345|NCT00916058|Experimental|Dose Level 1|Dose Level 1; Bendamustine 30 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060346|NCT00916058|Experimental|Dose Level 2|Dose Level 2; Bendamustine 60 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060347|NCT00916058|Experimental|Dose Level 3|Dose Level 3; Bendamustine 90 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060348|NCT00916058|Experimental|Dose Level 4|Dose Level 4; Bendamustine 120 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060349|NCT00916058|Experimental|Dose Level 5|Dose Level 5; Bendamustine 150 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060350|NCT00916058|Experimental|Dose Level 6|Dose Level 6; Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060351|NCT00916058|Experimental|Phase 2|Bendamustine 225 mg/m^2 total, Melphalan 200 mg/m^2 total (140 mg/m^2 total for patients with Creatinine Clearance <70 ml/min)
3060352|NCT00916136|Active Comparator|Cutaneous Traction|Applied by using a strap on boot that attaches to the leg. A rope is attached to the boot. Weight is attached to the rope to use gravity to pull traction. The traction is left in place until patient is taken to surgery for reduction of the femur fracture.
3060353|NCT00916136|Active Comparator|Skeletal Traction|A small incision is made on the inside of the knee and a pin is surgically inserted through the bone. Weights are then attached that will pull traction on the broken femur. This traction pin will stay in until patient is taken to surgery for reduction of the femur fracture.
3060354|NCT00916149|Active Comparator|Levetiracetam|12 individuals with epilepsy, 6 of whom experience infrequent focal epileptiform discharges and 6 of whom experience frequent focal discharges. These individuals will be treated with levetiracetam (LEV). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LEV on discharge frequency, discharge duration, and cognitive task performance.
3060355|NCT00916149|Active Comparator|Lamotrigine|12 individuals with epilepsy, 6 of whom experience infrequent generalized discharges and 6 of whom experience frequent generalized discharges. These individuals will be treated with lamotrigine (LMT). They will complete repeated EEG/cognitive testing pre- and post-treatment to assess the effects of LMT on discharge frequency, discharge duration, and cognitive task performance.
3060356|NCT00916149|No Intervention|No treatment|15 healthy subjects, not receiving anticonvulsant medication, will undergo repeated EEG/cognitive testing as a control.
3060357|NCT00916279|Experimental|Lutonix Catheter|
3060358|NCT00916305|Experimental|Modified Audio video|Participants will listen to an audio video modified to mimic noise induced hearing loss after one night at a loud club
3060359|NCT00916305|Active Comparator|Unmodified Audio video|Participants will listen to the same music as the other arm, but only the track with unaltered music.
3060360|NCT00916344|Experimental|Pacemaker therapy|
3060361|NCT00916357|Active Comparator|Humalog, Then Humalog + rHuPH20, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout period), followed by a SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3 to 14 day washout period.
3060362|NCT00916357|Active Comparator|Humalog, Then Humulin-R + rHuPH20, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog alone for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 nanograms/kilogram (ng/kg) recombinant human hyaluronidase PH20 (rHuPH20). The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3060363|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humalog, Then Humulin-R + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) recombinant human hyaluronidase PH20(rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humulin-R + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3060364|NCT00916357|Active Comparator|Humalog + rHuPH20, Then Humulin-R + rHuPH20, Then Humalog|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humalog + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humalog + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humulin-R + rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog following a 3- to 14-day washout period.
3060365|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog, Then Humalog + rHuPH20|A subcutaneous (SC) injection of up to 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog alone. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20 following a 3- to 14-day washout period.
3060366|NCT00916357|Active Comparator|Humulin-R + rHuPH20, Then Humalog + rHuPH20, Then Humalog|A subcutaneous (SC) injection of 0.3- to 0.5-units per kilogram (U/kg) of Humulin-R + 3.75 nanograms per kilogram (ng/kg) of recombinant human hyaluronidase PH20 (rHuPH20) for up to 3 dose-finding (DF) visits (each visit separated by a 3- to 14-day washout), followed by a single SC injection of the appropriate dose of Humulin-R + rHuPH20. After a 3- to 14-day washout period, the DF process and injection of appropriate dose was repeated with 0.3- to 0.5-U/kg Humalog + 3.75 ng/kg rHuPH20. The DF process and injection of appropriate dose was then repeated with 0.3- to 0.5-U/kg Humalog alone following a 3- to 14-day washout period.
3060367|NCT00916370|Experimental|Core size registry (CSR)|Core size indicates the range of diameters of the stents used.
3060368|NCT00916370|Experimental|Long lesion registry (LLR)|Use of long lesion stents.
3060369|NCT00916383|Experimental|Upper Back|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of the upper back.
3060370|NCT00916383|Experimental|Upper Arm|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite arms.
3060371|NCT00916383|Experimental|Side of Torso|350 mg Donepezil Transdermal Patch (active) and placebo patch, each applied to opposite sides of torso.
3060372|NCT00916539|Experimental|Cast that immobilizes the thumb|Cast that immobilizes the thumb
3060373|NCT00916539|Active Comparator|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
3060374|NCT00916578|Experimental|Radiation Therapy + Capecitabine|"Capecitabine 825 mg/m2 twice a day. One of the two daily doses of capecitabine should be taken approximately 2 hours before receiving radiotherapy. The first day of Capecitabine is same day that radiotherapy is started, and last day that Capecitabine is given is last day of radiotherapy. Capecitabine administered only on days patient receives radiation therapy.~Radiation therapy dose 50-57 Gy to initial clinical target volume (CTV, gross disease + tissue at risk for micrometastatic disease including margin around gross disease and draining regional lymphatics)."
3060375|NCT00916617|Experimental|1|5 mg/week
3060376|NCT00916643|Experimental|H.E.L.P. Secura|"The H.E.L.P. System is a device composed of multiple modules and their associated disposables which can selectively and continuously remove LDL-cholesterol from plasma by precipitating the LDL-cholesterol with high concentrations of heparin in an acidic buffer and returning the plasma to the patient. Procedure steps:~Flushing the system with normal saline.~Filtering whole blood through a 0.2 micron plasma filter for continuous plasma removal.~Mixing the plasma with an equal volume of acetate buffer containing heparin.~Precipitation of LDL as a complex with heparin.~Removing the LDL-heparin precipitate by continuous circulation through a filter.~Removing heparin with use of a heparin adsorber.~Bicarbonate dialysis and ultrafiltration to produce an LDL-free plasma without excess heparin.~Re-mixing the LDL-free plasma with blood coming from the plasma filter and returning the reconstituted blood to the patient."
3060377|NCT00916721|Active Comparator|Propranolol|propranolol
3060378|NCT00916721|Placebo Comparator|Placebo|sugar pill
3060379|NCT00916929|Other|Implantable Cardioverter Defibrillator (ICD)|Impedance Monitoring Feature in an Implantable Cardioverter Defibrillator (ICD).
3060380|NCT00916929|Other|Cardiac Resynchronization Therapy (CRT-D)|Impedance Monitoring Feature in a Cardiac Resynchronization Therapy (CRT-D) device.
3060381|NCT00917124|Active Comparator|INVOS|INVOS : Cerebral oxygenation (rSO2) monitoring with INVOS. If rSO2 decreased for more than 20% from patient's baseline value, simple interventions were performed to prevent brain injury. These interventions included: repositioning of head or perfusion cannulae, increasing arterial carbon dioxide tension, increasing oxygen inspiration concentration, increasing arterial blood pressure, adjusting pump flow rate, temperature decreasing, increasing of anesthetic depth and blood transfusion.
3060382|NCT00917124|No Intervention|CONTROL|The CONTROL arm did not have INVOS or any other cerebral oxygenation monitoring, so interventions to control cerebral oxygenation were not performed.
3060383|NCT00917150|Experimental|OPC-6535 12.5mg|
3060384|NCT00917150|Experimental|OPC-6535 25mg|
3060385|NCT00917150|Experimental|OPC-6535 50mg|
3060386|NCT00917150|Placebo Comparator|placebo|
3060387|NCT00917267|Experimental|1|
3060388|NCT00917267|Active Comparator|2|
3060389|NCT00917384|Experimental|ramucirumab|Participants receive ramucirumab, administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), and best supportive care (BSC) as determined appropriate by the investigator(s). Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
3060390|NCT00917384|Placebo Comparator|Placebo|Participants receive injection for intravenous infusion every 2 weeks plus BSC as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel will be blinded as to assignment to active therapy versus placebo, the volume of placebo to be administered will be calculated as if it were active product with a dose of 8 mg/kg. Treatment will continue until there is evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
3060391|NCT00917462|Experimental|Sorafenib|Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer.
3060392|NCT00917501|Placebo Comparator|Placebo|Placebo to the Omega-3 given in other group taken twice a day.
3060393|NCT00917501|Active Comparator|Omega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA & will be taken twice a day.
3060394|NCT00917553|Experimental|doxycycline monohydrate|
3060395|NCT00917553|Placebo Comparator|Placebo|Placebo
3060396|NCT00917579|Other|Reference|10 mg atorvastatin
3060397|NCT00917579|Experimental|Test|New 10 mg atorvastatin tablet
3060398|NCT00917644|Other|Reference|80 mg atorvastatin tablets
3060399|NCT00917644|Experimental|Test|New 80 mg atorvastatin tablets
3060400|NCT00917735|Experimental|Green tea extract|Green tea extract capsules containing 80.7 % total catechins (51.7 % EGCG)
3060401|NCT00917735|Placebo Comparator|Sugar pill|Placebo capsules containing 50% maltodextrin, 49.5 % cellulose, and 0.5 % magnesium stearate
3060402|NCT00917852|Experimental|GORE Conformable TAG® Thoracic Endoprosthesis|
3060403|NCT00917865|Experimental|FACBC Imaging|Dynamic FACBC PET of primary prostate carcinoma.
3060404|NCT00918125||White educational video|Patients will view an educational video that contains White physicians and patients.
3060405|NCT00918125||African-American educational video|Patients will view an educational video that contains African-American physicians and patients.
3060406|NCT00918125||Usual care|Patients will receive counseling about their condition and treatment options.
3060407|NCT00918138|Experimental|Saxagliptin + Metformin XR + matching Metformin XR placebo|(Saxagliptin 5 mg plus Metformin XR 1500 plus matching Metformin XR 500 mg placebo)
3060408|NCT00918138|Active Comparator|Metformin XR + Metformin XR + matching Saxagliptin placebo|(Metformin XR 500 mg plus Metformin XR 1500 mg plus matching Saxagliptin 5 mg placebo)
3060409|NCT00918203|Active Comparator|Paclitaxel + Carboplatin|"(Initial 4-6 cycles) Paclitaxel 200 milligram/square meter (mg/m2) over 3 hrs (Day 1) Carboplatin Area Under Concentration (AUC)=6 (Day 1) of each 21-day cycle (Initial 4-6 cycles) Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants who experience progressive disease may cross over to olaratumab monotherapy."
3179131|NCT00669643|Experimental|U-MDT PB|U-MDT PB group: a unified treatment for all patients - All patients presenting fewer than 6 lesions (WHO PB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - PB 6 doses of rifampicin, clofazimine and dapsone
3060410|NCT00918203|Experimental|Olaratumab + Paclitaxel + Carboplatin|"(Initial 4-6 cycles)~Olaratumab 15 milligrams/kilogram (mg/kg) over 30 mins (Days 1 and 8) plus Paclitaxel 200 mg/m2 over 3 hrs (Day 1) Carboplatin AUC=6 (Day 1) of each 21-day cycle~Participants can remain on study after completing chemotherapy and receive olaratumab monotherapy on Days 1 and 8, provided there is ongoing evidence of clinical benefit."
3060411|NCT00918229|Other|balloon implantation|implantation of an absorbable perirectal spacer balloon
3060412|NCT00918255|Experimental|Adalimumab 40 mg qwk|Initial dose of adalimumab 160 mg at Week 0, adalimumab 80 mg at Week 2, followed by 40 mg weekly (qwk) starting at Week 4 through Week 15.
3060413|NCT00918255|Experimental|Adalimumab 40 mg eow|Initial dose of adalimumab 80 mg at Week 0, followed by adalimumab 40 mg eow (every other week) starting at Week 1 through Week 15.
3060414|NCT00918255|Placebo Comparator|Placebo|Matching placebo for adalimumab, administered weekly starting at Week 0 through Week 15.
3060415|NCT00918281|Experimental|Fluciclatide Injection|Fluciclatide Injection
3060416|NCT00918333|Experimental|Treatment (panobinostat and everolimus)|Patients receive panobinostat PO QD or on days 1, 3, 5, 15, 17, and 19 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3060417|NCT00918346|Experimental|Tafluprost 0.0015% preserved formulation|
3060418|NCT00918346|Experimental|Tafluprost 0.0015% unpreserved formulation|
3060419|NCT00918385|Active Comparator|1|High Androgen Receptor (AR) activity
3060420|NCT00918385|Active Comparator|2|Low Androgen Receptor (AR) activity
3060421|NCT00918567|Experimental|Combined therapy|atomoxetine plus behavior therapy
3060422|NCT00918567|Active Comparator|Drug therapy|atomoxetine alone
3060423|NCT00918580|Experimental|1|
3060424|NCT00918671||Medication-overuse headache|Chronic daily headache combined with medication overuse
3060425|NCT00918684|Experimental|Escitalopram|12-week open label with 2 week placebo period (14 weeks total)
3060426|NCT00918723|Experimental|Treatment (induction and maintenance chemotherapy)|"INDUCTION THERAPY: Patients receive vorinostat PO once daily on days 1-5 and 8-12; cyclophosphamide IV over 30-60 minutes and fludarabine phosphate IV over 30-60 minutes on days 1-3; and rituximab IV on day 1, 2, 3, 4, or 5. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning 3 months after the completion of induction therapy, patients receive vorinostat PO on days 1-14 and rituximab IV on day 1. Treatment repeats every 3 months for 2 years in the absence of disease progression or unacceptable toxicity."
3060427|NCT00918736|Experimental|hyaluronate injection|All patients with unilateral ankle OA received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
3060428|NCT00918749|Active Comparator|150 mg|150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
3060429|NCT00918749|Experimental|75 mg|75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
3060430|NCT00918749|Experimental|100 mg|100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
3060431|NCT00918866|Experimental|Low Pulmonary Arterial Pressure|Subjects with pulmonary arterial pressure (PAP) of < or = to 35 mmHg.
3060432|NCT00918866|Experimental|Elevated Pulmonary Arterial Pressure|Subjects with a PAP of > or = to 35 mmHg.
3060433|NCT00918879|Experimental|1|Saxagliptin
3060434|NCT00918879|Placebo Comparator|2|
3060435|NCT00918931|Experimental|Obatoclax Mesylate|30 mg by vein over 3 hours Days 1-3, 14-day cycle
3060436|NCT00918957|Experimental|TIP (Tobramycin Inhalation Powder)|Tobramycin 28 mg powder. The TIP dose of 112 mg twice a day (bis in diem = b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment.
3060437|NCT00918957|Placebo Comparator|Placebo|Placebo 20 mg powder capsules. The dose regimen for the reference product was inhaling the contents of four capsules twice a day (bis in diem = b.i.d.), in the morning and in the evening for 28 days (on treatment), followed by 28 days of no study treatment (off treatment).
3060438|NCT00919035|Experimental|Torisel|Single Agent Temsirolimus (Torisel®)
3060439|NCT00919061|Experimental|Gemcitabine and Cisplatin plus Sorafenib|This is a non-randomized, open label, single institution, phase II study of gemcitabine and cisplatin plus sorafenib for the treatment of patients with advanced or biliary tract carcinomas naïve to systemic therapy.
3060440|NCT00919100|Other|Standard Care|venipuncture with vapocoolant spray offered
3060441|NCT00919100|Experimental|Buzzy|Vibrating device with cold pack held to arm with tourniquet proximal to venipuncture site, optional distraction cards.
3060442|NCT00919113|Experimental|8 weekly bladder instillations of Uracyst|20 mL Uracyst (2% sodium chondroitin sulfate) per instillation; 8 instillations over a 7-week period
3060443|NCT00919113|Placebo Comparator|8 weekly bladder instillations of inactive control|20 mL inactive control buffer (phosphate-buffered saline); 8 instillations over a 7-week period
3060444|NCT00919126|Experimental|Group A|Xenon 50% (45%-55%) in Oxygen (45%-55%),
3060445|NCT00919126|Experimental|Group B|Xenon 70% (65%-75%) in Oxygen (25%-35%)
3060446|NCT00919126|Active Comparator|Group C|Medical Air in Oxygen (45%-55%)
3060447|NCT00919191|Experimental|Two interventions in split-face model|"Once daily use in a split face model:~Tretinoin gel~Adapalene Benzoyl peroxide"
3060448|NCT00919503|Experimental|Regimen A (PBSCT and BMT)|"CONDITIONING REGIMEN A : Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1.~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing bone marrow or PBSC transplantation receive tacrolimus IV continuously or PO twice daily on days -1 to 50 followed by a taper until day 180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3060449|NCT00919503|Experimental|Regimen B (UBCT)|"CONDITIONING REGIMEN B: Patients receive treosulfan IV on days -6 to -4 and fludarabine phosphate IV on days -6 to -2. Patients receive anti-thymocyte globulin IV on days -4 to -2. Patients undergoing umbilical cord blood transplantation will also receive low dose total-body irradiation on day -1 .~TRANSPLANTATION: Patients receive either bone marrow, peripheral blood stem cells (PBSC), or umbilical cord blood from the donor on day 0. The use of either bone marrow, PBSC, or umbilical cord blood will depend on the donor status.~Patients undergoing UCB transplantation receive cyclosporine IV over 1 hour every 8-12 hours on days -3 to 100 followed by a taper until day 180 in the absence of GVHD. Patients also receive mycophenolate mofetil IV or PO every 8 hours on days 0 to 40 followed by a taper until day 96 in the absence of GVHD."
3060450|NCT00919633|Experimental|Group 1: interferon alfa-2b (dose 1)|continuous subcutaneous infusion for 48 weeks
3060451|NCT00919633|Experimental|Group 2: interferon alfa-2b (dose 2)|continuous subcutaneous infusion for 48 weeks
3060452|NCT00919633|Experimental|Group 3: interferon alfa-2b (dose 3)|continuous subcutaneous infusion for 48 weeks
3060453|NCT00919633|Active Comparator|Group 4: peginterferon alfa-2b (1.5 μg/kg)|subcutaneous weekly for 48 weeks
3060454|NCT00919711|Experimental|Denosumab 60 mg|
3060455|NCT00919711|Active Comparator|Risedronate 150 mg QM|
3060456|NCT00919724||HIV-Infected|HIV-infected participants who are not currently receiving antiretroviral medications
3060457|NCT00919724||HIV-Uninfected|HIV-uninfected participants matched in age, sex, smoking status, and height to the HIV-infected participants
3060458|NCT00919763|Experimental|CD 2027|Topical Ointment
3060459|NCT00919763|Placebo Comparator|CD 2027 Vehicle|Topical Ointment
3060460|NCT00919802|Active Comparator|Oxytocin|Oxytocin, 40 IU intranasally, once
3060461|NCT00919802|Placebo Comparator|Saline as a nasal spray|Saline, 4ml intranasally, once
3060462|NCT00919854|Experimental|Darunavir (DRV)+Ritonavir (rtv)|Before dose adjustment, oral darunavir suspension (100 mg/mL): 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg. After dose adjustment, 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg twice daily if weight more than or equal to 15 kg. Before dose adjustment, oral ritonavir solution (80 mg/mL): 3 mg per kg body weight twice daily and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
3060463|NCT00919867|Active Comparator|A: SPD503 (4mg)|
3060464|NCT00919867|Active Comparator|B: VYVANSE (50mg)|
3060465|NCT00919867|Active Comparator|C: SPD503 (4mg) + VYVANSE (50mg)|
3060466|NCT00919893|Active Comparator|Cernilton|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
3060467|NCT00919893|Placebo Comparator|Placebo|Men with inflammatory chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS)
3060468|NCT00919932|Active Comparator|Paper and pen homework|Treatment as usual: therapy homework is completed by paper and pen.
3060469|NCT00919932|Experimental|Text-message homework|Experimental treatment: therapy homework is completed by text messaging.
3060470|NCT00920023|Experimental|SPIO MRI|
3060471|NCT00920075||1 Alendronate for 12 months, post study|Participants earlier were treated with alendronate for 12 months either in an open label study (without control) or double blind study with placebo control. These studies were completed. In this post study evaluation, available participants will be scheduled for one clinic visit to assess their current status of the bone density and no treatment is involved.
3060472|NCT00920140|Experimental|Phase I|"The proposed treatment schedule of GSK1120212 is continuous daily dosing. At the initiation of dosing, a loading dose will be given prior to starting continuous dosing (maintenance dose).~Alterations to the dose and schedule will be based on emerging PK, PD, and tolerability data. The goal will be to define a regimen that is well tolerated and provides adequate PK and PD. This will be the recommended Phase II schedule."
3060473|NCT00920140|Experimental|Phase II|A dose determined by Phase I to further evaulate the safety profile, PK, PD, and clinical activity of GSK1120212.
3060474|NCT00920218|Experimental|GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 1 (F1) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3060475|NCT00920218|Experimental|GSK 1437173A F2 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of GSK 1437173A formulation 2 (F2) vaccine, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3060476|NCT00920218|Experimental|Placebo-GSK 1437173A F1 Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 1 dose of the placebo followed by 2 doses of GSK 1437173A F1 vaccine. For some safety analyses, this Group was split into Placebo 1D Group (results following placebo administration) and GSK 1437173A 2D Group (results following HZV administration). All vaccines were administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3060477|NCT00920218|Placebo Comparator|Placebo Group|Male or female subjects, 18 years of age or older at the time of the first vaccination, received 3 doses of placebo, administered intramuscularly in the upper deltoid region of non-dominant arm according to a 0,1,3-months schedule.
3060478|NCT00920231|Experimental|Arm 1 initial system|"8 blind subjects are asked to use a prototype computer vision system to determine the challenges facing computer vision based indoor navigation.~Subjects are asked to travel through the hallways of a large hospital from the front entrance to a side entrance. The pathway consists of 9 segments including corners, four-way intersections, and doorways, and the total length of the route was approximately 200 meters. This challenging route was designed to stress the capabilities of the navigation system. It is a route that even sighted persons may find difficult to follow without practice. Pedestrian traffic was present throughout the route and lighting conditions could change in two of the segments where there were windows and doors."
3060479|NCT00920231|Experimental|Arm 2 modified system|The system is redesigned in response to problems identified from the first phase of the study. The redesigned system is tested by a second set of 8 blind subjects in the same indoor path as used in Arm 1.
3060480|NCT00920374|Experimental|Fluarix Adult Group|Subjects who are 18-60 years of age received one dose of Fluarix™
3060481|NCT00920374|Experimental|Fluarix Elderly Group|Subjects who are > 60 years of age received one dose of Fluarix™
3060482|NCT00920426|Experimental|GSK1265744 30 mg|GSK1265744 30 mg
3060483|NCT00920426|Experimental|Placebo|Placebo to match GSK1265744
3060484|NCT00920426|Experimental|GSK1265744 5 mg|GSK1265744 5 mg
3060485|NCT00920439|Experimental|POLIORIX GROUP|Healthy male or female subjects between, and including, 18 and 24 months of age, received a single booster dose of Poliorix™ vaccine that was administrated into the upper right thigh by intramuscular injection (IM).
3060486|NCT00920556|Experimental|Treatment|"5.0 g SRT501 will be administered for 20 consecutive days in a 21 day cycle for a maximum of 12 cycles. SRT501 will be administered at the same time each morning (approximately 15-30 minutes after breakfast) on all dosing days. No SRT501 administration will occur on Day 21 of each cycle.~After the first two cycles of SRT501, any subject who exhibits stable disease or better with SRT501 monotherapy (5.0 g/day) will continue for an additional two cycles. If, after the first two cycles, a subject exhibits PD, that subject will receive bortezomib (1.3 mg/m2 on Day 1, Day 4, Day 8, and Day 11 in a 21 day cycle) in conjunction with SRT501. Bortezomib will be administered prior to breakfast and SRT501 administration.~If after two additional cycles of SRT501 monotherapy (4 cycles total), the subject exhibits a MR or better, they they will remain on SRT501 therapy. If PD or SD are exibited, they are to undergo bortezomib regiment listed above."
3060487|NCT00920621|Experimental|Vitamin D treatment|vitamin D treatment plus prenatal multivitamins
3060488|NCT00920621|Placebo Comparator|placebo|placebo plus prenatal multivitamins
3060489|NCT00920647|Other|Control|Untreated Patients
3060490|NCT00920647|Experimental|Idursulfase -IT (1 mg)|monthly using an intrathecal drug delivery device (IDDD)
3060491|NCT00920647|Experimental|Idursulfase-IT (10 mg)|monthly using an intrathecal drug delivery device (IDDD)
3060492|NCT00920647|Experimental|Idursulfase -IT (30 mg)|monthly using an intrathecal drug delivery device (IDDD)
3060493|NCT00920686|Experimental|NXN-188|NXN-188, 600 mg, PRN
3060494|NCT00920686|Active Comparator|sumatriptan succinate 100 mg|Sumatriptan, 100 mg, PRN
3060495|NCT00920686|Placebo Comparator|placebo|matching, PRN
3060496|NCT00920699|Experimental|600 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day of CoQ10 in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3060497|NCT00920699|Experimental|1200 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3060498|NCT00920699|Experimental|2400 mg per day of CoQ10|All participants will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
3060499|NCT00920790|Experimental|KW-0761|
3060500|NCT00920816|Experimental|A|
3060501|NCT00920816|Active Comparator|B|
3060502|NCT00920829|Active Comparator|A118G A/A with Naltrexone|Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3060503|NCT00920829|Placebo Comparator|A118G A/A with Placebo|Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
3060504|NCT00920829|Active Comparator|A118G Any G with Naltrexone|Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3060505|NCT00920829|Placebo Comparator|A118G Any G with Placebo|Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
3060506|NCT00920855|Experimental|Bendamustine and Bortezomib|Bendamustine in escalating doses of 50, 70 or 90 mg/m^2 as combination therapy with bortezomib at 1.0 mg/m^2/dose administered for up to eight 28 day cycles.
3060507|NCT00920907|Experimental|Ipilimumab (Process B)|Reference
3060508|NCT00920907|Experimental|Ipilimumab (Process C)|Test
3060509|NCT00921024|Experimental|1|CXA-101
3060510|NCT00921024|Active Comparator|2|Ceftazidime
3060511|NCT00921115|Experimental|Arimidex + Faslodex|"Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.~On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery."
3060512|NCT00921310|Experimental|Phase I Dose Level 1 (pemetrexed + temsirolimus)|"-Dose Level 1~Pemetrexed 500mg/m^2 intravenous (IV) on Day 1 of each 21 day cycle~Temsirolimus 15 mg IV on Days 1,8 and 15 of each 21 day cycle"
3060513|NCT00921310|Experimental|Phase I Dose Level -1 (pemetrexed + temsirolimus)|"Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
3060514|NCT00921310|Experimental|Phase 2 (pemetrexed + temsirolimus)|"Phase 2 dose will be the maximum tolerated dose found in the Phase I portion of the study.~Pemetrexed (375 mg/m^2) IV on Day 1 of each 21 day cycle~Temsirolimus (15 mg) IV on Days 1,8 and 15 of each 21 day cycle"
3060515|NCT00921518|Placebo Comparator|Normal Saline|This group will receive isotonic saline at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
3060516|NCT00921518|Active Comparator|Sodium Bicarbonate|This arm two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
3060517|NCT00921557|Experimental|1A: Alendronate/Alendronate|Participants received alendronate for 96 weeks and calcium carbonate/vitamin D for 144 weeks
3060518|NCT00921557|Experimental|1B: Alendronate/Placebo|Participants received alendronate for 48 weeks followed by placebo for 48 weeks and calcium carbonate/vitamin D for 144 weeks
3060519|NCT00921557|Experimental|2: Placebo/Alendronate|Participants received placebo for 48 weeks followed by alendronate for 48 weeks and calcium carbonate/vitamin D for 144 weeks
3060520|NCT00921687|Experimental|Multifactorial intervention|The multifactorial intervention will consist of a CKD lecture, the CKD reference card, academic detailing, and access to the CKD registry.
3060521|NCT00921687|Active Comparator|Education only|Providers in the education only arm will receive a CKD lecture and be given a CKD reference card.
3060522|NCT00921843|Experimental|Methadone 0.1mg/kg|Methadone 0.1mg/kg
3060523|NCT00921843|Experimental|Methadone 0.2mg/kg|Methadone 0.2mg/kg
3060524|NCT00921843|Experimental|Methadone 0.3mg/kg|Methadone 0.3mg/kg
3060525|NCT00921843|Placebo Comparator|Control|No methadone
3060526|NCT00921895|Experimental|Device Testing|Patients with conjunctivitis will be tested with the RPS Adeno Detector IV
3060527|NCT00921934||Vitamin C|Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.
3060528|NCT00921947|Experimental|VAX102 IM|VAX102 given as 1 µg intramuscular (i.m.)
3060529|NCT00921947|Experimental|VAX102 SC|VAX102 given as a 2 µg subcutaneous (s.c.) dose
3060530|NCT00922116|Experimental|1|
3060531|NCT00922207|Experimental|1|
3060532|NCT00922207|Experimental|2|
3060533|NCT00922207|Placebo Comparator|3|
3060534|NCT00922233|Experimental|Levonorgestrel|0.75 mg of levonorgestrel within 24 hours of sex
3060535|NCT00922272|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3060536|NCT00922272|Placebo Comparator|Placebo|Placebo
3060537|NCT00922428||Observational group|Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.
3060538|NCT00922441|Experimental|Fimasartan 1|Fimasartan 60 mg group
3060539|NCT00922441|Experimental|Fimasartan 2|Fimasartan 120 mg group
3060540|NCT00922441|Active Comparator|Valsartan|Reference (Valsartan 80 mg) group
3060541|NCT00922480|Active Comparator|2|Losartan group
3060542|NCT00922480|Active Comparator|1|Fimasartan 60mg, 120mg
3060543|NCT00922623|Experimental|Belotero®|
3060544|NCT00922636|Active Comparator|Methylphenidate|Extended-release methylphenidate 18 milligrams per day (mg/day) to 54 mg/day, based on weight, given once daily (QD) and orally (po) as a capsule for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
3060545|NCT00922636|Placebo Comparator|Placebo|
3060546|NCT00922636|Experimental|LY2216684 (0.1 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of placebo in the taper phase.
3060547|NCT00922636|Experimental|LY2216684 (0.2 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
3060548|NCT00922636|Experimental|LY2216684 (0.3 mg/kg/day)|Taken in tablet form QD po for the 8-week double-blind treatment phase, followed by 2 weeks of tapering in the taper phase.
3060549|NCT00922701|Experimental|Peritoneal Dialysis Solution|
3060550|NCT00922766||1.0|
3060551|NCT00922779|Experimental|1|
3060552|NCT00922883|Experimental|Eltrombopag|Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.
3060553|NCT00922935|Experimental|Cresco early loading|The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) at 10 days of post surgery
3060554|NCT00922935|Experimental|Cresco late loading|"Healing caps will be placed until loading. The minimum waiting time is 4 weeks, but not before try ins to ensure a perfect fit. The implants must be restored (loaded) with a permanent screw retained fixed partial denture (FPD) within 42-56 days (6 to 8 weeks) of surgery."
3060555|NCT00922935|Active Comparator|Straumann system late loading|Straumann components loading at 6-8 weeks post surgery
3060556|NCT00922974|Experimental|Radiosurgery/SBRT|
3060557|NCT00922974|Active Comparator|External Beam Radiation Therapy|
3060558|NCT00922987||Lyrica|Adult patients with partial seizures (type of epilepsy). Inclusion criteria according to Summary of Product Characteristics
3060559|NCT00923078|Experimental|Auditory-Visual Train Order|4 weeks (20 sessions) of auditory cognitive training (Brain Fitness) followed by 4 weeks (20 sessions) of visual cognitive training (Insight)
3060560|NCT00923078|Experimental|Visual-Auditory Train Order|4 weeks (20 sessions) of visual cognitive training (Insight) followed by 4 weeks (20 sessions) of auditory cognitive training (Brain Fitness)
3060561|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 20mg/5mg/12.5mg|olmesartan medoxomil 20mg / amlodipine besylate 5 mg / hydrochlorothiazide 12.5mg
3060562|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/12.5mg|
3060563|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/5mg/25mg|
3060564|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/12.5mg|
3060565|NCT00923091|Experimental|olmesartan/amlodipine/hydrochlorothiazide 40mg/10mg/25mg|
3060566|NCT00923091|Experimental|olmesartan/amlodipine 20mg/5mg|olmesartan medoxomil 20mg / amlodipine besylate 5mg
3060567|NCT00923091|Experimental|olmesartan/amlodipine 40mg/5mg|
3060568|NCT00923091|Experimental|olmesartan/amlodipine 40mg/10mg|
3060569|NCT00923117|Experimental|Bevacizumab resistant patients|Patients who had tumor progression while treated with bevacizumab.
3060570|NCT00923117|Experimental|Bevacizumab naive patients|Patients with progressive tumor who have not been treated with bevacizumab.
3060571|NCT00923130|Experimental|Bevacizumab with Ixabepilone|Bevacizumab 15mg/kg every 3 weeks Ixabepilone given on days 1,2,3,4 and 5 of each three week cycle at a dose of 6mg/m(2)/day
3060572|NCT00923156|Experimental|Aliskiren|In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1. In double blind phase (Period 2), patients received aliskiren (150 mg once daily) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site and matching placebo of ramipril capsules.
3060573|NCT00923156|Experimental|Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (Period 2), patients received ramipril 10 mg capsule o.d and matching placebo of aliskiren tablet."
3060574|NCT00923156|Experimental|Aliskiren plus Ramipril|"In open label run-in phase (period 1), patients started with ramipril 2.5 mg or 5.0 mg capsule once daily (o.d) depending on previous treatment with RAAS blockers and up-titrated to ramipril 10 mg capsule o.d by end of period 1.~In double blind phase (period 2), patients received ramipril (10 mg once daily capsule) and aliskiren (150 mg once daily tablet) up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site"
3060575|NCT00923195|Experimental|TBI 600cGy + PBL + HD IL-2+gp100:154-162|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
3060576|NCT00923195|Experimental|TBI 600cGy+PBL+HD IL-2+MART-1:26-35(27L)|Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population). One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14. Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).Radiation: 2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute.
3320876|NCT02014454|Experimental|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularization, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP Cooperative Group."
3060580|NCT00923260|Experimental|Roux-en-Y Gastric Bypass/Omentectomy|Laparoscopic Roux-en-Y Gastric Bypass with omentectomy
3060581|NCT00923260|Active Comparator|Roux-en-Y Gastric Bypass alone|
3060582|NCT00923273|Experimental|Treatment level 1 - 3mg load|Sirolimus 3mg load/1mg/day; Pemetrexed 375mg/m^2
3060583|NCT00923273|Experimental|Treatment level 2 - 6 mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
3060584|NCT00923273|Experimental|Treatment level 3 - 6mg load|Sirolimus 6mg load/2mg/day; Pemetrexed 375mg/m^2
3060585|NCT00923273|Experimental|Treatment level 4 - 10 mg load|Sirolimus 10mg load/3mg/day; Pemetrexed 500mg/m^2
3060586|NCT00923273|Experimental|Treatment level 5 - 15 mg load|Sirolimus 15mg load/5mg/day; Pemetrexed 500mg/m^2
3060587|NCT00923351|Experimental|Arm A - Participants who did not receive rhIL-7|Six patients with Ewings sarcoma family or tumors (ESFT) participants will receive cytotoxic/lympholytic therapy with cyclophosphamide and fludarabine (if cluster of differentiation 4 (CD4) count > 200 cells/mcl). Participant will receive Tumor lysate/keyhole limpet hemocyanin (KLH) pulsed dendritic cell vaccine followed by Infusion of 8H9/CD25 depleted autologous lymphocyte infusion on Day 1, followed by Tumor lysate/KLH pulsed dendritic cell vaccine on week 4, 6, 8, 10, and 12.
3060588|NCT00923351|Experimental|Arm B - Participants who received rhIL-7|"Eight patients with rhabdomyosarcoma, fifteen patients with Ewings sarcoma family or tumors (ESFT), two patients with desmoplastic small round cell tumor, and one patient with synovial cell sarcoma participants will receive CYT107 20 mcg/kg/dose subcutaneous (SQ) (approx. 48h prior to vaccine[Day 0]), Tumor lysate/KLH pulsed dendritic cell vaccine followed by Infuse 8H9/CD25 depleted autologous lymphocyte infusion on Day 2, followed by CYT107 20 mcg/kg/dose SQ on days 14, 28 and 42 (± 7 days), and Tumor lysate/KLH pulsed dendritic cell vaccine on Days 16, 30, 44, 56, and 70 (± 7 days).~Apheresis/flow cytometry/delayed type of hypersensitivity (DTH) responses for immune endpoint monitoring (skin tests) will be performed on Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (+/- 7 days) (Arm B); and radiographic studies for clinical restaging will be performed on Week 8 and 20 (Arm A) and Days 42 and 126 (+/- 7 days) (Arm B)."
3060589|NCT00923364|Experimental|Recipients and Healthy Related Donors|Hematopoietic Stem Cell Transplant for MonoMAC: 10/10 Human Leukocyte Antigen (HLA) Matched Related Donor (MRD) or Unrelated Donor (URD) Transplant. 9/10 HLA Matched Related Donor or Unrelated Donor Transplant. Haploidentical Related Donor Transplant. Umbilical Cord Blood Transplant.
3060590|NCT00923481|Experimental|Multi-kinase inhibitor Fostamatinib Disodium (R935788)|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
3060591|NCT00923559|Experimental|Mother-Infant Psychoanalytic treatment;MIP|MIP intervention
3060592|NCT00923559|Active Comparator|TAU at Child Health Centres|Regular nurse visits at Child Health Centres according to Swedish infant health care.
3060593|NCT00923598|Active Comparator|1) 0.1% Ropivicaine on Right Leg|Patients will be randomized ot 0.1% Ropivicaine infusion on the right leg and therefore 0.4% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
3060594|NCT00923598|Active Comparator|2) 0.4% Ropivicaine on Right Leg|Patients will be randomized ot 0.4% Ropivicaine infusion on the right leg and therefore 0.1% Ropivicain in fusion for the left leg for pain due to bilateral TKA. The outcome measures will be measured on both legs, starting with the right leg each time. The infusion will last for the two days following surgery, that the patient is staying in the hospital.
3060595|NCT00923845|Other|Donors|A sibling who is 6/6 HLA --matched with the recipient. Donors undergo donor lymphocyte harvest and stem cell mobilization and harvest.
3060596|NCT00923845|Other|Recipients|Recipients undergo induction therapy, allogeneic stem cell therapy and GVHD prophylaxis.
3060597|NCT00923910|Other|Donors|Related and unrelated donors undergo lymphapheresis to prepare cellular vaccines and to donate lymphocytes for infusion.
3060598|NCT00923910|Experimental|Recipients|Participants receive donor lymphocytes and vaccines prepared from donors.
3060599|NCT00923936|Active Comparator|KS;classic/HIV+not improved on antiviral|Kaposi's Sarcoma (KS) in patients who are Human immunodeficiency virus (HIV) Negative, HIV infected with stable disease for one year despite antiretroviral therapy or progressive disease despite 4 months of antiretroviral therapy.
3060600|NCT00923936|Active Comparator|All other advanced HIV-asociated KS|All other patients with advanced acquired immune deficiency syndrome (AIDS)-associated KS
3060601|NCT00923949|Experimental|Pioglitazone|45 mg tablet daily by mouth for six weeks
3060602|NCT00923975|Other|Intended Users of the Software|Young adults, parents/guardians of young people under age 18, and healthcare professionals who work with this population would be intended users of the data management program. The DIDGET World Reports software is used to upload blood glucose results from the DIDGET Blood Glucose Monitoring System so that intended users can identify patterns in their diabetes management.
3060603|NCT00924001|Experimental|Metastatic Melanoma|Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.
3060604|NCT00924040|Experimental|BL22 Immunotherapy|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
3060605|NCT00924053|Experimental|EGT0001474|
3060606|NCT00924053|Placebo Comparator|Placebo|
3060607|NCT00924066|Experimental|Squamous and Nonsquamous participants|"Squamous cell carcinoma is a histologic subtype of cervical cancer. Squamous cell carcinoma of the cervix (80%) is much more common than adenocarcinoma of the cervix.~Non squamous carcinoma is a histologic subtype of cervical cancer. It is the second most common form of cervical cancer; consists of adenocarcinoma, adenosquamous and non squamous (not otherwise specified) subtypes.~All participants in both arms received ixabepilone 6 mg/m^2 x 5 days, each cycle."
3060608|NCT00924118|Experimental|Sodium Nitrite|Dose escalation of sodium nitrite.
3060609|NCT00924118|No Intervention|Open Control|Standard therapy
3060610|NCT00924170|Experimental|Fludarabine and Cyclophosphamide/LMB-2|Administer cycle 1 with Fludarabine and Cyclophosphamide (FC) alone. Two weeks after starting cycle 1, begin up to 6 cycles of FC plus LMB-2 at minimum 20-day intervals.
3060611|NCT00924209|Experimental|Stage IIIA lung cancer patients|Non-squamous cell non small cell lung cancer treated with 1250 mg/m^2 gemcitabine dose for two doses on day 1 and day 8 every 21 days,80 mg/m^2 cisplatin day 1 every 21 days for 3 cycles, 7.5 mg/kg bevacizumab on day 1 every 21 days for first 2 cycles only, and 100 mg/m^2 intravenous, and 100 mg/m^2 etoposide intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
3060612|NCT00924287|Experimental|Metastatic Cancer|Cancer that has invaded other parts of the body
3060613|NCT00924313|Experimental|11C-acetate for Prostate Cancer Patients|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
3060614|NCT00924326|Experimental|1x10^9-1x10^10+ high dose Interleukin-2|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + cryopreserved anti-CD19-CAR PBL
3060615|NCT00924326|Experimental|1x10^9-1x10^10 + high dose Retreat|
3060616|NCT00924326|Experimental|0.5x10^7 cells/kg|
3060617|NCT00924326|Experimental|2.5x10^6 cells/kg|
3060618|NCT00924326|Experimental|1.0x10^6 cells/kg|
3060619|NCT00924326|Experimental|1.0x10^6 cells/kg (Reduced chemo)|
3060620|NCT00924326|Experimental|2.0x10^6 cells/kg (Reduced chemo)|
3060621|NCT00924326|Experimental|6.0x10^6 cells/kg (Reduced chemo)|
3060622|NCT00924326|Experimental|2.0x10^6 cells/kg (Moderate chemo)|
3060623|NCT00924326|Experimental|2.0x10^6 cells/kg (9-12 days culture)|
3060624|NCT00924352|Experimental|Ixabepilone + Dasatinib|"Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level - 1;12 mg/m2,Dose Level - 2;12 mg/m2.~Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level - 1;100 mg QD,Dose Level - 2;70 mg QD."
3060625|NCT00924404|Experimental|Xylitol|isotonic xylitol for sinus rinse
3060626|NCT00924404|Active Comparator|Saline|saline for sinus rinse
3060627|NCT00924443|Experimental|Clofarabine|Clofarabine 30 mg/m^2/day intravenously over 1 hour for 5 days every 28 to 42 days (one cycle), then 20mg/m^2/day intravenously over 1 hour for 5 days every 29 to 43 days for the second and subsequent cycles, up to a maximum of 3 cycles.
3060628|NCT00924469|Experimental|Abiraterone plus leuprolide plus prednisone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day up to Week 24. Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks up to Week 24. Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks.
3060629|NCT00924469|Active Comparator|Leuprolide then abiraterone plus leuprolide plus prednisone|Leuprolide acetate will be administered at a dose of 22.5 mg as intramuscular injection once every 12 weeks up to Week 24. From Week 13 to 24, abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day with prednisone tablets administered orally as 5 mg once daily.
3060630|NCT00924482|Other|Single Arm - Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery
3060631|NCT00924508|Experimental|Patch + cream, patch alone, cream alone|This is a single arm study. Each subject will have 3 target lesions; one treated with TAC 0.1% cream and hydrogel patch (occlusion), the second treated with cream alone, and the third treated with occlusion alone.
3060632|NCT00924560|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received a 91-day regimen consisting of 84 consecutive days of active combination tablets containing 150 μg levonorgestrel (LNG)/30 μg ethinyl estradiol (EE), followed by 7 days of 10 μg EE tablets for a total of 52 weeks (4 consecutive 91-day cycles).
3060633|NCT00924560|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received a 28-day regimen consisting of 21 consecutive days of active combination tablets containing 100 μg LNG/20 μg EE followed by 7 days of placebo tablets for a total of 52 weeks (13 consecutive 28-day cycles).
3060634|NCT00924560|No Intervention|Untreated Control|Participants received no oral contraceptives during the study.
3060635|NCT00924612|Experimental|Fasting (Treatment A)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered orally in a fasted state
3060636|NCT00924612|Experimental|Very low fat diet (Treatment B)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with very low fat (6-10% fat).
3060637|NCT00924612|Experimental|Low fat diet (Treatment C)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with low fat (20% fat).
3060638|NCT00924612|Experimental|Normal diet (Treatment D)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with normal fat (30% fat).
3060639|NCT00924612|Experimental|High fat diet (Treatment E)|Single dose of oral testosterone undecanoate (containing 300 mg T) administered, 30 minutes after the initiation of protocol-defined breakfast of ~800 calories with high fat (50% fat).
3060640|NCT00924638|Active Comparator|Continuous Monitoring|Continuous cardiac monitoring by the Reveal® XT Insertable Cardiac Monitor
3060641|NCT00924638|No Intervention|Control Arm|Follow-up at the same frequency, but with no Insertable Cardiac Monitor
3060642|NCT00924651|Experimental|Standard Care + EXCAP|Personalized exercise prescription
3060643|NCT00924651|No Intervention|Standard Care|Wait list control
3060644|NCT00924664|Experimental|Tanezumab 20 mg|
3060645|NCT00924664|Experimental|Tanezumab 10 mg|
3060646|NCT00924703|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses dependent on safety and efficacy.
3060647|NCT00924729|Active Comparator|Moxifloxacin 0.5% ophthalmic solution|
3060648|NCT00924729|Active Comparator|Besifloxacin 0.6% ophthalmic suspension|
3060649|NCT00924781|Experimental|MK2578 1 mcg for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment every week (QW).
3060650|NCT00924781|Experimental|1 mcg of MK2578 for every 600 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3060651|NCT00924781|Experimental|MK2578 1 mcg for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
3060652|NCT00924781|Experimental|1 mcg of MK2578 for every 350 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3060653|NCT00924781|Experimental|MK2578 1 mcg for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QW.
3060654|NCT00924781|Experimental|1 mcg of MK2578 for every 200 U of Epogen at Baseline|Participants were randomized to receive treatment QM.
3060655|NCT00924820|Experimental|Bevacizumab|Bevacizumab 10 mg/kg by vein over about 1 hour, every 2 weeks.
3060656|NCT00924833|Placebo Comparator|placebo|Placebo tablets. One tablet twice daily.
3060657|NCT00924833|Active Comparator|2: Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
3060658|NCT00924833|Active Comparator|3: Nebivolol|Nebivolol 5 mg tablets. One nebivolo tablet daily. One placebo tablet daily.
3060659|NCT00924885|Experimental|Thin Follicle Aspiration Needle|Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the RN needle that had an outer diameter of 0.9 mm (20 gauge) and inner diameter of 0.6 mm for the last 50 mm from the tip of the needle and an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg.
3060660|NCT00924885|Active Comparator|Standard Follicle Aspiration Needle|"Transvaginal oocyte retrieval was performed under local anaesthesia and under guidance of ultrasound with the SN needle that had an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the remaining length of the needle. or the SN with an outer diameter of 1.4 mm (17 gauge) and inner diameter of 1 mm for the whole length of the needle.~The puncture procedure was performed according to each clinic's standard routine. Aspiration pressure was kept at a negative pressure between 90 and 120 mmHg."
3060661|NCT00924898|Experimental|Acute HIV Treatment Group|Single arm, open label study in which all participants received the same study treatment with efavirenz, emtricitabine, and tenofovir DF
3060662|NCT00924950|Active Comparator|Taclonex Ointment/Hydrogel Patch Applied Topically Once Daily|Taclonex ointment once daily used to treat one psoriatic plaque, along with the Hydrogel Patch used once daily.
3060663|NCT00924950|Active Comparator|Taclonex Ointment Topically Once Daily|
3060664|NCT00925002|Active Comparator|Open-Label|
3060665|NCT00925015|Experimental|Cetux/Irin - Dmab 10 mg/kg|After treatment with Cetuximab (Cetux) and Irinotecan (Irin), Dalotuzumab (Dmab) was administered as an intravenous infusion at 10 mg/kg in Cycle 1 on Days 22, 29 and 36; followed in subsequent cycles by treatment with 10 mg/kg on Days 1, 8, 15, 22, 29 and 36. Each cycle was 6 weeks long.
3060666|NCT00925015|Experimental|Cetux/Irin - Dmab 15/7.5 mg/kg|After treatment with Cetux/Irin, Dmab was administered as an intravenous infusion at 15 mg/kg in Cycle 1 on Days 8, 22 and 36; followed in subsequent cycles by treatment with 7.5 mg/kg on Days 8, 22 and 36. Each cycle was 6 weeks long.
3060667|NCT00925015|Experimental|Dmab 10 mg/kg - Cetux/Irin (DDI)|Dmab was administered in each cycle as an intravenous infusion at 10 mg/kg once weekly on Days 1, 22 and 29; followed by treatment with Cetux/Irin. For Drug-Drug Interaction (DDI). Each cycle was 6 weeks long.
3060668|NCT00925054|Experimental|rAvPAL-PEG 0.001 mg/kg|Subjects will start on rAvPAL-PEG 0.001 mg/kg
3060669|NCT00925054|Experimental|rAvPAL-PEG 0.003 mg/kg|Subjects will start on rAvPAL-PEG 0.003 mg/kg
3060670|NCT00925054|Experimental|rAvPAL-PEG 0.01 mg/kg|Subjects will start on rAvPAL-PEG 0.01 mg/kg
3060671|NCT00925054|Experimental|rAvPAL-PEG 0.03 mg/kg|Subjects will start on rAvPAL-PEG 0.03 mg/kg
3060672|NCT00925054|Experimental|rAvPAL-PEG 0.1 mg/kg|Subjects will start on rAvPAL-PEG 0.1 mg/kg
3060673|NCT00925119|Experimental|Atenolol|Participants will receive atenolol for 8 weeks.
3060674|NCT00925132|Experimental|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
3060675|NCT00925288|Active Comparator|Regular schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,2,6 months
3060676|NCT00925288|Experimental|Modified Schedule|Duration: Gardasil HPV vaccine administered intramuscularly at 0,3,6 months
3060677|NCT00925301|Experimental|Migalastat|Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.
3060678|NCT00925301|Placebo Comparator|Placebo|Placebo capsule taken orally QOD for 6 months.
3060679|NCT00925353|Experimental|lidocaine gel|
3060680|NCT00925522|Experimental|Therapy Cool Path Duo Cardiac Ablation System|All patients who are eligible receive cardiac ablation procedure for Ischemic Ventricular Tachycardia
3060681|NCT00925587|Active Comparator|Q2W|Q2W administration of darbepoetin alfa.
3060682|NCT00925587|Active Comparator|QM|QM administration of darbepoetin alfa
3060683|NCT00925600|Placebo Comparator|Placebo|Participants received placebo administered by subcutaneous injection on Day 1 and at Month 6.
3060684|NCT00925600|Experimental|Denosumab|Participants received denosumab 60 mg administered by subcutaneous injection on Day 1 and at Month 6.
3060685|NCT00925704|Active Comparator|Calcitriol|
3060686|NCT00925704|Experimental|Lanthanum carbonate + calcitriol|
3060687|NCT00925704|Experimental|Sevelamer carbonate + calcitriol|
3060688|NCT00925756|Experimental|Maraviroc 150 mg, 300 mg, or 600 mg twice daily|"This was a single arm study where Maraviroc was added for 24 weeks.~Maraviroc was dose-adjusted for concomitantly administered HIV medications according to the manufacture's recommendations:~150 mg twice daily with strong CYP3A4 inhibitors, including:~Protease inhibitors (except tipranavir/ ritonavir)~Delavirdine~ketoconazole, itraconazole, clarithromycin, nefazadone, telithromycin~Darunavir/r + etravirine~300 mg twice daily with non-inducers/ non-inhibitors of CYP3A4, including:~Tipranavir/ ritonavir~Nevirapine~All NRTIs~Enfuvirtide~600 mg twice daily with strong CYP3A4 inducers, including:~Efavirenz, etravirine~rifampin"
3060689|NCT00925769|Experimental|1|
3060690|NCT00925782|Other|Melphalan-Alkeran|Subjects begin with treatment Melphalan and crossover to treatment Alkeran
3060691|NCT00925782|Other|Alkeran-Melphalan|Subjects begin with treatment Alkeran and crossover to treatment Melphalan.
3060692|NCT00925899|Experimental|Melatonin|20 mg
3060693|NCT00925899|Placebo Comparator|Placebo|
3060694|NCT00925938|Experimental|Misoprostol vaginal priming insert (MVPI)|One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
3060695|NCT00925938|Placebo Comparator|MVPI Placebo|One vaginal insert of placebo administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit.
3060696|NCT00925990|Experimental|CTS-1027 + ribavirin|Study drug plus ribavirin
3060697|NCT00925990|Experimental|CTS-1027 + placebo|Study drug plus placebo for ribavirin
3060698|NCT00926003|Experimental|Full Computerized Cognitive Training|Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. Each training game become more difficult as the child gains proficiency.
3060699|NCT00926003|No Intervention|Control|Passive Control with no intervention training (computer cognitive games) for 8 weeks.
3060700|NCT00926003|Active Comparator|Limited computerized cognitive training|"Intervention is a Computer Cognitive Rehabilitation Training delivered in 24 sessions over 8 weeks (3 times/week). A training session lasts about an hour and consists of 9 training games or programs, 3 pertaining to improving attention, 3 pertaining to improving visual-spatial memory, and 3 pertaining to improving reasoning/planning. In this arm, however, the training games do NOT become progressively more difficult as the child gains proficiency, but rotates randomly among simpler to moderate levels of difficulty for each game. The purpose to to give children int he limited CCRT arm comparable exposure to the cognitive games training as with the full CCRT arm, with the exception of the titrating nature of the game training."
3060701|NCT00926029|Placebo Comparator|Fluoride control -A|Winterfresh Gel
3060702|NCT00926029|Active Comparator|Triclosan/Fluoride - B|Positive control (Total toothpaste)
3060703|NCT00926029|Experimental|Triclosan/fluoride/metal salt- C|test toothpaste
3060704|NCT00926185|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
3060705|NCT00926185|Experimental|0.1% Lifitegrast|Lifitegrast
3060706|NCT00926185|Experimental|1.0% Lifitegrast|Lifitegrast
3060707|NCT00926185|Experimental|5.0% Lifitegrast|Lifitegrast
3060708|NCT00926211|Experimental|Computer-Assisted|Hair harvest using the computer-assisted system
3060709|NCT00926211|Active Comparator|Manual Harvest|Hair harvesting via manual technique
3060710|NCT00926237|Experimental|Sham followed by active 1Hz, then active 10Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 1Hz and then active rTMS at 10 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
3060711|NCT00926237|Experimental|Sham followed by active 10Hz and active 1Hz rTMS|Subjects assigned to this arm received sham rTMS followed by active rTMS at 10 Hz and then active rTMS at 1 Hz. Each treatment consisted of a four-day trial with no less than 21 days separating each condition. Subjects receive sham stimulation first to prevent carry forward effects of the active treatment condition into the sham condition.
3060712|NCT00926263|Experimental|10 mg/kg cohort|
3060713|NCT00926263|Experimental|20 mg/kg cohort|
3060714|NCT00926263|Experimental|20/20 mg/kg cohort|
3060715|NCT00926289|Active Comparator|Telmisartan|Telmisartan 80 mg
3060716|NCT00926289|Experimental|Telmisartan/hydrochlorothiazide|Telmisartan80mg/Hydrochlorothiazide25mg
3060717|NCT00926328|Active Comparator|A -Experimental toothpaste|triclosan/copolymer/fluoride toothpaste
3060718|NCT00926328|Placebo Comparator|B - control toothpaste|sodium fluoride only toothpaste (placebo)
3060719|NCT00926367|Experimental|Clinidamycin/ Benzoyl Peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).
3060720|NCT00926367|Active Comparator|Benzoyl peroxide and adapalene|Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene
3060721|NCT00926380|Experimental|denosumab ONLY|
3060722|NCT00926380|Experimental|teriparatide (Forteo®) ONLY|
3060723|NCT00926380|Experimental|denosumab and teriparatide (Forteo®)|
3060724|NCT00926393|Active Comparator|Quetiapine Immediate Release (IR)|Quetiapine 25, 100, 200 and 300 mg
3060725|NCT00926393|Active Comparator|Quetiapine Extended Release (XR)|Quetiapine 50, 200, 300
3060726|NCT00926497|Experimental|Procalcitonin group|Antibiotic therapy is discontinued when two consecutive Procalcitonin values are below predefined age-adjusted cut-off values. Antibiotic therapy could be prolonged despite fulfilled Procalcitonin criteria at the discretion of the attending physician.
3060727|NCT00926497|No Intervention|Standard group|Standard treatment for suspected neonatal early-onset sepsis based on conventional laboratory parameters
3060728|NCT00926536|Experimental|C-arm CT + DSA as needed'|In the group of subjects randomized in this group, the image guidance component of the procedure will be conducted by the acquisition of 3D CT-like images during a trans-hepatic arterial injection of iodinated contrast agent for road mapping the tumor feeding vessels and supplemented by DSA as needed by the operating physician as imaging guidance for planning tumor(s) treatment approach.
3060729|NCT00926536|Active Comparator|DSA only|In the group of subjects randomized in this group, present standard of care, i.e DSA imaging only will be used by the operating physician to map out the tumor vessels and used for treatment approach. Additional 3D CT-like images will be obtained, but only used if the operator cannot perform adequate planning using DSA alone.
3060730|NCT00926588|Experimental|Stepped Care|Patients received automated pain monitoring. A nurse care manager partnering with a physician pain specialist decide on treatment changes collaborating with primary care physicians. Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are used.
3060731|NCT00926588|No Intervention|Usual Care|Patients receive usual care for pain from their primary care physician
3060732|NCT00926783|Active Comparator|(1) targeted CFAE ablation|
3060733|NCT00926783|Active Comparator|(2) generalized CFAE ablation|
3060734|NCT00926796|Experimental|Regimen B: gemifloxacin plus azithromycin|Gemifloxacin 320 mg by mouth one time plus azithromycin 2 gm by mouth one time.
3060735|NCT00926796|Experimental|Regimen A: gentamicin plus azithromycin|Gentamicin 240 mg intramuscular (IM) one time for patients greater than 45 kg or 5 mg/kg IM one time for patients less than or equal to 45 kg plus azithromycin 2 gm by mouth one time.
3060736|NCT00926848|Experimental|PaTH intervention group|"The PaTH intervention group for patients and partners consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions~18 educational sessions. The intervention consisted of patients and partners participating together in a formal cardiac rehabilitation program when typically just patients participate. In addition, partners were asked to make the same healthy eating and exercise changes that patients did to meet guidelines for health."
3060737|NCT00926848|Active Comparator|Usual care group|"The usual care group intervention for patients only consisted of participation in a structured and formal cardiac rehabilitation program:~18-36 exercise sessions and 18 educational sessions~Partners participated in the 18 educational sessions only."
3060738|NCT00926887|Sham Comparator|Placebo Laser|Placebo Laser is an inactive light
3060739|NCT00926887|Active Comparator|Erchonia EML Laser|Erchonia EML Laser uses two 7mW red 635nm wavelength light emitting CSRH Class IIIb laser diodes. The energy delivered is 1.5 J/cm2.
3060740|NCT00926952|Experimental|MAL-PDT 90 min incubation, no occlusion|Patients had 2-4 g of Methylaminolevulinate (MAL) spread on the entire face without occlusion and waited 90 minutes prior to photodynamic therapy (PDT) using red light.
3060741|NCT00927069|Experimental|Group A|Patients who have shown an unsatisfactory response to 3 months of etanercept 50 mg twice a week without dose reduction prior to screening.
3060742|NCT00927069|Experimental|Group B|Patients who showed a satisfactory response to 3 months or more of etanercept 50 mg twice a week followed by a loss of response after dose reduction to 50 mg etanercept once a week prior to screening.
3060743|NCT00927069|Experimental|Group A dose increase at Week 12|Patients in group A who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
3060744|NCT00927069|Experimental|Group B dose increase at Week 12|Patients in group B who - after 12 weeks of adalimimab 40 mg every other week in this study - failed to reach a physician's global assessment (PGA) of clear or almost clear and had a dose increase to 40 mg adalimimab every week for another 12 weeks.
3060745|NCT00927082|Experimental|PEG-IFN 90mcg 24 Wks|Participants received Pegasys (Pegylated interferon alfa-2a [PEG-IFN]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
3060746|NCT00927082|Experimental|PEG-IFN 180mcg 24 Wks|Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
3060747|NCT00927082|Experimental|PEG-IFN 90mcg 48 Wks|Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
3060748|NCT00927082|Experimental|PEG-IFN 180mcg 48 Wks|Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
3060749|NCT00927095|Active Comparator|Continuous OC (EE/DROS)|Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)
3060750|NCT00927095|Active Comparator|Intermittent OC (EE/DROS)|Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)
3060751|NCT00927095|Placebo Comparator|Placebo|Continuous daily oral placebo
3060752|NCT00927160||MACE group|Elderly patients admitted to the Mobile Acute Care of the Elderly Unit.
3060753|NCT00927160||Usual Care group|Elderly patients admitted to the general medicine service in the hospital
3060754|NCT00927186|Experimental|Teriparatide|
3060755|NCT00927186|Active Comparator|Zoledronic Acid|
3060756|NCT00927251|Experimental|Model 4296 LV Lead|Non-randomized study
3060757|NCT00927264|Experimental|Behavioral|"Motivational Interviewing Intervention Plus Education~Caregivers will receive a home-based motivational interviewing intervention for ETS reduction plus an educational program for ETS reduction."
3060758|NCT00927264|Active Comparator|Education Only|Caregivers will receive only educational program for ETS reduction.
3060759|NCT00927355|Active Comparator|Pioglitazone|half of the diabetic patients will be randomized to pioglitazone treatment for 6 months starting out with 15mg qd for 4 weeks and dose increased to 30mg (2 tablets) qday if no adverse effects noted at the four week mark by study physician.
3060760|NCT00927355|Placebo Comparator|Placebo|"The other half will be randomized to placebo for 6 months. The placebo pills also start out with one 15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
3060761|NCT00927368|Active Comparator|Ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
3060762|NCT00927368|Active Comparator|Ultrasound guidance needle stimulation|For the ultrasound guidance and needle stimulation arm, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation
3060763|NCT00927368|Active Comparator|Ultrasound guidance+catheter stimulation|For the ultrasound guidance and catheter stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
3060764|NCT00927394|Experimental|Combination Therapy: Aliskiren + Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 weeks. Forced titrated to: 2 tablets of Aliskiren 150 mg + 2 capsules of Valsartan 160 mg daily for 6 weeks
3060765|NCT00927394|Active Comparator|Monotherapy: Valsartan|To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day) for 8 weeks. 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 2 weeks. Forced titrated to: 2 capsules of Valsartan 160 mg + 2 tablets of placebo Aliskiren 150 mg daily for 6 weeks.
3060766|NCT00927472|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
3060767|NCT00927472|Active Comparator|Nix Creme Rinse|Nix applied to scalp for 10 minutes
3060768|NCT00927485|Experimental|Curcumin|Curcumin
3060769|NCT00927485|Placebo Comparator|Placebo|Placebo (sugar pills)
3060770|NCT00927563|Experimental|Tolcapone|Tolcapone 100-300mg/day
3060771|NCT00927576||Control subjects|Control subjects = 237. These subjects underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
3060772|NCT00927576||TBI patients|TBI patients N = 28. These patients underwent extensive testing with computerized neuropsychological tests including digit span testing, spatial span testing, simple reaction time testing, choice reaction time testing, finger tapping, verbal fluency, design fluency, verbal list learning, questionnaire completion, and the trail making test.
3060773|NCT00927589|Experimental|1|
3060774|NCT00927758|Active Comparator|Sequence 1: Flu/Sal- 250mcg/50mcg ->100mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3060775|NCT00927758|Active Comparator|Sequence 2: Flu/Sal- 500mcg/50mcg ->250mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3060776|NCT00927758|Active Comparator|Sequence 3: Flu/Sal- 100mcg/50mcg ->250mcg/50mcg->500mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3060777|NCT00927758|Active Comparator|Sequence 4: Flu/Sal- 250mcg/50mcg ->500mcg/50mcg->100mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3060778|NCT00927758|Active Comparator|Sequence 5: Flu/Sal- 500mcg/50mcg ->100mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3320877|NCT02014493|Active Comparator|HFNC first|4 hours with High Flow Nasal Cannulae (HFNC) 6 l/pr.min, then 4 hours with Continuous Positive Airway Pressure (CPAP) 6l/pr.min.
3060779|NCT00927758|Active Comparator|Sequence 6: Flu/Sal- 100mcg/50mcg ->500mcg/50mcg->250mcg/50mcg|"Treatment cycle 1: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 100mcg/50mcg once daily for 7 days.~Treatement Cycle 2 : Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 500mcg/50mcg once daily for 7 days.~Treatment Cycle 3: Patient randomized to Fluticasone Propionate/Salmeterol (Flu/Sal) received 250mcg/50mcg once daily for 7 days.~There were 14 days washout period between cycles."
3060780|NCT00927784|Sham Comparator|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media alone (placebo).
3060781|NCT00927784|Experimental|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs in sequential cohorts.
3060782|NCT00927810|Experimental|canakinumab|
3060783|NCT00927823|Experimental|PF-04691502 Treatment|
3060784|NCT00927849|Active Comparator|surgical group lateral sphincterotomy|underwent closed lateral internal sphincterotomy (LIS) under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
3060785|NCT00927849|Active Comparator|Glycerin trinitrate group|all were instructed to apply the Glycerin trinitrate group (GTN) ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
3060786|NCT00927849|Active Comparator|botulinum toxin injection|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
3060787|NCT00927862|Active Comparator|Standard IWPC warfarin dosing algorithm|Standard International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm.
3060788|NCT00927862|Experimental|Modified IWPC warfarin dosing algorithm|Modified International Warfarin Pharmacogenetics Consortium (IWPC) warfarin dosing algorithm
3060789|NCT00927862|Other|Historical controls|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records database of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic (PG)-guided cohorts (July 2008 through December 2010). Patients ≥18 years old initiating warfarin therapy with a baseline and at least 1 follow-up international normalized prothrombin time ratio (INR) level between days 3-14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG based.
3060790|NCT00927888|Active Comparator|1 - Bupivacaine Block|3 ml of 0.25% Bupivacaine with Epi 1:100,000 (A block)
3060791|NCT00927888|Placebo Comparator|2 - Placebo|Normal saline with Epi 1:100,000 (B block)
3060792|NCT00927901|Experimental|Indacaterol (ind) maleate-placebo-ind xinafoate-ind acetate|In treatment period 1, patients received indacaterol maleate 400 μg; in treatment period 2, patients received placebo to indacaterol; in treatment period 3, patients received indacaterol xinafoate 400 μg; and in treatment period 4, patients received indacaterol acetate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060793|NCT00927901|Experimental|Indacaterol (ind) xinafoate-ind maleate-ind acetate-placebo|In treatment period 1, patients received indacaterol xinafoate 400 μg; in treatment period 2, patients received indacaterol maleate 400 μg; in treatment period 3, patients received indacaterol acetate 400 μg; and in treatment period 4, patients received placebo to indacaterol 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060794|NCT00927901|Experimental|Indacaterol (ind) acetate-ind xinafoate-placebo-ind maleate|In treatment period 1, patients received indacaterol acetate 400 μg; in treatment period 2, patients received indacaterol xinafoate 400 μg; in treatment period 3, patients received placebo to indacaterol; and in treatment period 4, patients received indacaterol maleate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060795|NCT00927901|Experimental|Placebo-indacaterol (ind) acetate-ind maleate-ind xinafoate|In treatment period 1, patients received placebo to indacaterol; in treatment period 2, patients received indacaterol acetate 400 μg; in treatment period 3, patients received indacaterol maleate 400 μg; and in treatment period 4, patients received indacaterol xinafoate 400 μg. Patients received each treatment once daily for 7 days via the Concept1 single-dose dry-powder inhaler. There was a washout period of at least 7 days between each treatment period. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060796|NCT00927927|Experimental|SD 0.0002 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
3060797|NCT00927927|Experimental|SD 0.0012 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
3060798|NCT00927927|Experimental|SD 0.007 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
3060799|NCT00927927|Experimental|SD 0.035 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
3060800|NCT00927927|Experimental|SD 0.175 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
3060801|NCT00927927|Experimental|SD 0.7 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
3060802|NCT00927927|Experimental|SD 2.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
3060803|NCT00927927|Experimental|SD 7.5 mg/kg|Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
3060804|NCT00927927|Experimental|SD Placebo|Subjects were injected once with placebo
3060805|NCT00927927|Experimental|MD 0.02 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
3060806|NCT00927927|Experimental|MD 0.3 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
3060807|NCT00927927|Experimental|MD 1.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
3060808|NCT00927927|Experimental|MD 1.6 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
3060809|NCT00927927|Experimental|MD 4.0 mg/kg|Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
3060810|NCT00927927|Experimental|MD Placebo|Subjects were injected biweekly four times with placebo
3060811|NCT00927940|Experimental|Drug Eluting Stent|All patients may have one or two lesions, if the two lesions are located in separate coronary arteries. A patient with one or two lesions treated with stents of diameter 2.5mm - 3.5mm will be designated in this study.
3060812|NCT00927953|Experimental|MGAWN1|30 mg/kg single intravenous infusion of MGAWN1
3060813|NCT00927953|Placebo Comparator|Placebo - Normal Saline|single intravenous infusion of saline placebo
3060814|NCT00927992||Patients with haemophilia who undergo liver transplantation|Patients with haemophilia who underwent liver transplantation and who have been followed up at any site in Spain.
3060815|NCT00928018|Active Comparator|Sirolimus-Containing Regimen|"The Sirolimus containing arm will consist of the following drugs:~Experimental Arm: tacrolimus + sirolimus + low-dose methotrexate~Tacrolimus: Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Sirolimus:Given as a loading oral dose of 12 mg on day -3, then as a daily maintenance dose of 4 mg starting on day -2.~Methotrexate: Administered by intravenous bolus infusion, per institutional standard, at a dose of 5 mg/m2 on days +1, +3 and +6."
3060816|NCT00928018|Active Comparator|Sirolimus-Free regimen|"There are two choices for the Sirolimus free arm:~Control Arm 1: tacrolimus + methotrexate~Tacrolimus:Administered orally at a dose of 0.05 mg/kg based on ABW bid starting on day -3.~Methotrexate:Administered by intravenous bolus infusion at a dose of 5 mg/m2 on days +1, +3 and +6. For patients receiving stem cells from unrelated donors, an additional dose will be given on day +11.~Control Arm 2: cyclosporine + MMF~Cyclosporine: administered orally at a dose of 6 mg/kg based on ABW bid starting on day -3.~MMF:administered at a dose of 3gm daily orally (or intravenously if the patient cannot tolerate oral administration) divided in 2 or 3 doses (bid or tid) depending on physician preference starting on day 3."
3060817|NCT00928057|Experimental|4 mm / 8 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 8mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
3060818|NCT00928057|Experimental|4 mm / 5 mm PN|Subjects randomized to this study arm used either the 4mm PN or the 5mm PN for 3 weeks, then switched to the alternate PN for another 3 weeks. Order of PN use was randomly determined.
3060819|NCT00928070|Experimental|Fesoterodine|
3060820|NCT00928070|Placebo Comparator|Placebo|
3060821|NCT00928083|Experimental|Part A - 50 mg Single Dose|OZ439 Single doses of 50mg (capsules)
3060822|NCT00928083|Experimental|Part A - 100mg Single Dose|OZ439 Single doses of 100mg (capsules)
3060823|NCT00928083|Experimental|Part A - 200mg Single Dose|OZ439 Single doses of 200mg (capsules)
3060824|NCT00928083|Experimental|Part A - 400mg Single Dose|OZ439 Single doses of 400mg (capsules)
3060825|NCT00928083|Experimental|Part A - 400mg Single Dose + Food|OZ439 Single doses of 400mg (capsules) administered with food.
3060826|NCT00928083|Experimental|Part A - 400mg AD Single Dose|OZ439 Single doses of 400mg (aqueous dispersion)
3060827|NCT00928083|Experimental|Part A - 800mg Single Dose|OZ439 Single doses of 800mg (capsules)
3060828|NCT00928083|Experimental|Part A - 800mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
3060829|NCT00928083|Experimental|Part A - 1200mg Single Dose|OZ439 Single doses of 1200mg (capsules)
3060830|NCT00928083|Experimental|Part A - 1600mg AD Single Dose|OZ439 Single doses of 800mg (aqueous dispersion)
3060831|NCT00928083|Placebo Comparator|Part A - Placebo|Placebo control for Single rising Part A
3060832|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fed|Single dose of OZ439 800mg aqueous dispersion administered under fed conditions
3060833|NCT00928083|Experimental|Part B - 800mg AD Single Dose Fast|Single dose of OZ439 800mg aqueous dispersion administered under fast conditions
3060834|NCT00928083|Experimental|Part C - 200mg AD Multiple Dose|200mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3060835|NCT00928083|Experimental|Part C - 400mg AD Multiple Dose|400mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3060836|NCT00928083|Experimental|Part C - 800mg AD Multiple Dose|800mg aqueous solution OZ439 or placebo once daily for 3 days fasted
3060837|NCT00928083|Placebo Comparator|Part C - Placebo|Placebo control for Multiple rising Part C
3060838|NCT00928135|Active Comparator|7% Hypertonic saline|5 ml of 7% saline twice daily
3060839|NCT00928135|Experimental|Hypertonic xylitol|5 ml of 15% xylitol twice daily
3060840|NCT00928174|Experimental|Single Arm|Fluorine-18 fluorocholine IV in conjunction with PET/CT imaging, up to 3 doses.
3060841|NCT00928187|Active Comparator|Arm A|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)
3060842|NCT00928187|Active Comparator|Arm B|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)
3060843|NCT00928187|Active Comparator|Arm C|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
3060844|NCT00928200|Experimental|Single Arm|All patients receive Vincristine, Dexamethasone, Doxorubicin, and Cytarabine. Dexrazoxane optional on Day 1. Erwinase is started between Days 3-5 and is given every M-W-F for a total of 10 doses. Patients with CNS 1 or 2 receive Methotrexate intrathecally on Day 15. Patients with CNS 3 receive Triple Intrathecal Therapy (Methotrexate, Cytarabine and Hydrocortisone) on Days 8, 15, and 22.
3320878|NCT02014493|Active Comparator|CPAP first|4 hours Continuous Positive Airway Pressure (CPAP) 6 l/pr.min, then 4 hours High Flow Nasal Cannulae (HFNC) 6 l/pr.min.
3320879|NCT02014506|Experimental|HAPLO|
3060849|NCT00928252|Experimental|Received 18F-fluorocholine PET/CT|IV fluorine-18 labeled methylcholine before PET/CT
3060850|NCT00928304|Experimental|Florbetaben (BAY94-9172)|
3060851|NCT00928395|Active Comparator|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
3060852|NCT00928408||Cinacalcet|
3060853|NCT00928421|Experimental|Varisolve 0.125%|
3060854|NCT00928434|Experimental|DI (Degarelix Intermittent)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL on Day 0 administered subcutaneously (s.c.) into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Six maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 168 were administered.~During Phase B of the trial, If a patient had Prostate Specific Antigen (PSA) ≥2 ng/mL at any visit, additional doses of degarelix 240 mg followed by 80 mg maintenance dose(s) were administered."
3060855|NCT00928434|Experimental|DC (Degarelix Continuous)|"Patients in this arm received degarelix with a starting dose of 240 mg at a concentration of 40 mg/mL administered on Day 0 (Visit 1) s.c. into the anterior abdominal wall via two equivalent injections of 120 mg (3 mL) each.~Thirteen maintenance doses of degarelix 80 mg per month at a concentration of 20 mg/mL (4 mL) at Days 28 to 364, administered s.c. into the anterior abdominal wall"
3060856|NCT00928434|Active Comparator|LC (Leuprolide Continuous)|"Patients in this arm received leuprolide 7.5 mg one-month depot injection on Day 0, administered intramuscular (i.m.) into a large muscle, as per manufacturer's labeling directions.~One injection of 22.5 mg leuprolide 3-month depot was administered i.m. as per manufacturer's labeling directions at Day 28 and every 3 months afterwards for 4 additional doses (i.e at Days 112, 196, 280, and 364, respectively).~On Investigator's discretion, patients in the arm could take bicalutamide (Casodex®) for a maximum of 28 days to alleviate increased signs and symptoms due to initial upsurge in testosterone levels."
3060857|NCT00928486|Experimental|Lenalidomide and Dexamethasone|Lenalidomide 25mg by mouth (PO) once daily (QD) on Days 1-21 of each 28 day cycle; When creatinine (CrCl) clearance <60 mL/min, the initial dose was 10mg and the dose could be increased to 15mg after 2 cycles if the investigator judged therapeutic effect was insufficient and tolerability was acceptable. Dexamethasone 40 mg by PO once QD on days 1-4, 9-12 and 17-20 of each 28 day cycle for the first 4 cycles and Days 1-4 for the remaining cycles beginning at Cycle 5.
3060858|NCT00928512|Experimental|Secukinumab 25mg|Secukinumab 25mg s.c. q4wk
3060859|NCT00928512|Experimental|Secukinumab 75mg|Secukinumab 75mg s.c. q4wk
3060860|NCT00928512|Experimental|Secukinumab 150mg|Secukinumab 150mg s. c. q4wk
3060861|NCT00928512|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c. q4wk
3060862|NCT00928512|Placebo Comparator|Secukinumab Placebo|Secukinumab Placebo s.c. q4wk
3060863|NCT00928564|Active Comparator|Pudendal Block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
3060864|NCT00928564|Placebo Comparator|Placebo|5ml of saline at each block site
3060865|NCT00928642|Experimental|Oral Imatinib plus intravenous gemcitabine|"All research subjects receive oral imatinib 400mg days 1-5 and 8-12 of a 21 day cycle.~All research subjects received IV gemcitabine 1000mg/m2 days 3 and 10 of a 21-day cycle. .~All subjects had epithelial ovarian cancer or primary peritoneal carcinomatosis and had failed to respond to prior chemotherapy or progressed after prior chemotherapy."
3060866|NCT00928668|Experimental|Olodaterol (BI1744) Low|Single dosing of low dose Olodaterol inhaled orally from Respimat Device
3060867|NCT00928668|Experimental|Olodaterol (BI1744) Medium Low|Single dosing of medium low dose Olodaterol inhaled orally from Respimat Device
3060868|NCT00928668|Experimental|Olodaterol (BI1744) Medium High|Single dosing of medium high dose Olodaterol inhaled orally from Respimat Device
3060869|NCT00928668|Experimental|Olodaterol (BI 1744) High|Single dosing of high dose Olodaterol inhaled orally from Respimat Device
3060870|NCT00928668|Placebo Comparator|Placebo|Single dosing of Olodaterol placebo inhaled orally from Respimat Device
3060871|NCT00928694|Active Comparator|1|Fenofibrate U.S. Formulation
3060872|NCT00928694|Active Comparator|2|Fenofibrate UK Formulation
3060873|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_1|50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
3060874|NCT00928707|Experimental|GIVINOSTAT + MTD Hydroxyurea (HU)_2|50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy
3060875|NCT00928720|Active Comparator|CES device|Participants will use the device for 60 minutes each day for 8 weeks.
3060876|NCT00928720|Sham Comparator|Sham device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The sham device will look the same as the active CES device; however, no electrical stimulation will be present in the sham device.
3060877|NCT00928720|No Intervention|Usual care alone|No intervention; participants will receive usual medical care
3060878|NCT00928746|Other|ATROVENT 42mcg|
3060879|NCT00928772|Active Comparator|Alpha-Stim intervention|One hour Alpha-Stim intervention with sham midazolam
3060880|NCT00928772|Sham Comparator|Sham Alpha-Stim with midazolam|Sham Alpha-Stim intervention with real midazolam administration
3060881|NCT00928772|Placebo Comparator|Placebo|No Alpha-Stim and only topical anesthetics
3060882|NCT00928889|Experimental|Nateglinide 120 mg|Nateglinide was taken orally 3 times daily, 10 minutes before meals for 4 weeks.
3060883|NCT00928889|Active Comparator|Acarbose 50 mg|Acarbose 50 mg was taken orally 3 times daily, with the first bite of food at meals for 4 weeks.
3060884|NCT00928954|Active Comparator|Gabapentin|Increasing dose to 300 mg four times per day (total of 1200 mg/day)
3060885|NCT00928954|Active Comparator|Memantine|Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
3060886|NCT00929071|Experimental|Pain assessment for Evolence/topical anesthetic|Assess injection pain severity for a one time 1.0 mL injection of Evolence with 0.2 ml of topical anesthetic, applied 30 minutes prior to injection, to the left nasolabial fold of each participant .
3060887|NCT00929071|Experimental|Pain assessment for Evolence/Lidocaine|Assess injection pain severity for a one time 1.0 mL injection of Evolence mixed with 0.18 mL of 2% lidocaine (0.3% final lidocaine-HCl) in the right nasolabial fold of each participant.
3060888|NCT00929110|Experimental|Glycopyrronium bromide 50 μg|Patients inhaled glycopyrronium bromide 50 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060889|NCT00929110|Placebo Comparator|Placebo to glycopyrronium bromide|Patients inhaled placebo to glycopyrronium bromide once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060890|NCT00929110|Active Comparator|Tiotropium 18 μg|Patients inhaled tiotropium 18 μg once daily in the morning between 8:00 AM and 10:00 AM via a single-dose dry-powder inhaler (SDDPI) for 52 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3060891|NCT00929162|Experimental|ZD4054 + paclitaxel + carboplatin|ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
3060892|NCT00929162|Placebo Comparator|Placebo + paclitaxel + carboplatin|Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks
3060893|NCT00929201|Active Comparator|Sita + Met then Sita/Met FDC|Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
3060894|NCT00929201|Active Comparator|Sita/Met FDC then Sita + Met|Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
3060895|NCT00929240|Active Comparator|Avastin (bevacizumab)|
3060896|NCT00929240|Experimental|Avastin (bevacizumab) + Xeloda (capecitabine)|
3060897|NCT00929305|Placebo Comparator|Placebo laser|inactive laser light
3060898|NCT00929305|Active Comparator|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 milliWatt (mW) of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
3060899|NCT00929331|Experimental|Fluviral Adult Group|Subjects aged between 18 and 60 years who received one dose of Fluviral® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
3060900|NCT00929331|Experimental|Fluviral Elderly Group|Subjects over 60 years of age who received one dose of Fluviral ® (2009-2010 season) intramuscularly in the deltoid region of the non-dominant arm
3060901|NCT00929344|Experimental|Duloxetine|
3060902|NCT00929344|Experimental|Pregabalin|
3060903|NCT00929344|Placebo Comparator|Placebo|
3060904|NCT00929357||1|DMARDs
3060905|NCT00929357||2|Biologics
3060906|NCT00929500|Experimental|MAST program|Mixed Aerobic and Strength Training program (MAST): Each exercise session consisted of 10 minutes of warm-up, 15-30 minutes of interval aerobic training by cycle ergometer according to the program, 20 minutes of strength training exercises, and 10 minutes of cool-down by stretching.
3060907|NCT00929500|No Intervention|UC|Usual Care (UC) with Educational Lectures: No exercise sessions.
3060908|NCT00929526|Experimental|Cervarix Group|subjects received 3 doses of Cervarix™ vaccine in primary vaccination study NCT00316693.
3060909|NCT00929526|Placebo Comparator|Aimmugen Group|subjects received 3 doses of Aimmugen ™ vaccine in primary vaccination study NCT00316693.
3060910|NCT00929578|Placebo Comparator|Placebo|The sterile placebo: Bacteriostatic Sodium Chloride for Injection.
3060911|NCT00929578|Active Comparator|Fluphenazine|This will be an ascending dose study with the first cohort of 5 subjects dosed at 100 µg/mL, followed by cohorts at 500 and 2500 µg/mL. Dosing will be on Days 0, 7 and 14 and will consist of 5, or 10, 100 µL injections into the psoriatic lesion. The number of injections will depend on the lesion size. As this is a vehicle controlled study, subjects will receive intralesional injections of both drug and placebo, each into a separate target plaque, in a randomized fashion.
3060912|NCT00929643||1|
3060913|NCT00929656|Experimental|Real rTMS|Real rTMS + unimanual paretic UE training
3060914|NCT00929656|Active Comparator|Sham rTMS|Sham rTMS + unimanual paretic UE training
3060915|NCT00929669|Experimental|Pasireotide LAR|80 mg IM once monthly
3060916|NCT00929695|Experimental|Arm I (Low-dose)|Patients receive low-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
3060917|NCT00929695|Active Comparator|Arm II (Standard-dose)|Patients receive standard-dose prednisone or methylprednisolone once or twice daily in the absence of disease progression or unacceptable toxicity.
3060918|NCT00929708|Experimental|1|AZD3199 low dose
3060919|NCT00929708|Experimental|2|AZD3199 intermediate dose
3060920|NCT00929708|Experimental|3|AZD3199 high dose
3060921|NCT00929708|Active Comparator|4|Formoterol 2x4.5 microgram bid
3060922|NCT00929708|Placebo Comparator|5|Placebo
3060923|NCT00929734|Experimental|Rosuvastatin|
3060924|NCT00929734|Placebo Comparator|Placebo|
3060925|NCT00929773|Active Comparator|Erchonia PL2000 Laser|Low level laser light energy comprised of 1 milliWatts (mW) of red light (635 nm).
3060926|NCT00929773|Placebo Comparator|Placebo laser|inactive light
3060927|NCT00929838|Experimental|Diabetes Knowledge/Information Arm|Subjects randomized to the diabetes knowledge/information arm will complete 12 diabetes education modules over a 12-week period. The educational materials were developed based on guidelines for diabetes education by the American Diabetes Association. The content is based on the principles of the Adult Learning Theory. The information is designed to be relevant, person centered, and presented in a non-threatening manner. The modules are designed to be delivered via telephone in 10-15 minutes, so that the maximum contact time per telephone call including introduction and closing would not exceed 30 minutes.
3320880|NCT02014532|Active Comparator|Montelukast|Patients in Test Group were given Leukotriene receptor antagonist, Montelukast 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3060928|NCT00929838|Experimental|Motivation/Behavioral Skills Arm|The motivation/behavioral skills intervention consists of patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks. The behavioral skills training will be focused on 4 behaviors - physical activity, diet, medication adherence, and glucose self-monitoring. Guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks (4 behaviors over 12 weeks).
3060929|NCT00929838|Experimental|Combined Intervention Arm|The combined intervention group will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The behavioral skills training will be focused on 4 behaviors and guided by subjects' current problem areas and preferences, subjects will be asked to choose 1 of 4 behaviors to focus on every 3 weeks. The combined intervention group telephone sessions will last for 30 minutes.
3060930|NCT00929838|Sham Comparator|Usual Care Arm|The usual care group will receive weekly telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention. Patients in the usual care group will continue to receive any usual diabetes education provided by the clinic staff; however, they will not receive targeted diabetes knowledge/information, activation, empowerment, or behavioral skills training.
3060931|NCT00929864|Active Comparator|Abatacept|
3060932|NCT00929864|Active Comparator|Adalimumab|
3060933|NCT00929981||Oral Methylprednisolone|
3060934|NCT00929994||Exercise|Following a 3 month non intervention period, participants will participate in Cardiac Rehabilitation, carrying out an exercise program which will last 6 months and combine both resistance and aerobic training.
3060935|NCT00930046|Active Comparator|Ropivacaine group|Patients in this group will receive ropivacaine via the wound catheter for the first 48hrs after surgery
3060936|NCT00930046|Placebo Comparator|Normal Saline Group|Will receive an infusion of normal saline for 48hrs post-operatively via the wound catheter.
3060937|NCT00930059|Experimental|PF-04447943|
3060938|NCT00930059|Placebo Comparator|Placebo|
3060939|NCT00930176|Experimental|Human Coagulation FACTOR X|
3060940|NCT00930293|Experimental|Personalized Depression Care|Participants will receive interpersonal psychotherapy for depression with panic and anxiety symptoms (IPT-PS) and standard antidepressant medication (citalopram) treatment.
3060941|NCT00930293|Active Comparator|Standard Depression Care|Participants will receive brief supportive psychotherapy (BSP) and standard antidepressant medication (citalopram) treatment.
3060942|NCT00930553|Experimental|Previously treated with alemtuzumab|Alemtuzumab 12 mg per day administered through IV, once a day for 3 consecutive days (participants might receive additional cycles of alemtuzumab upon documented evidence of resumed disease activity, but not within same 12-month period)
3060943|NCT00930553|Experimental|Previously treated with interferon beta-1a (Rebif®)|Alemtuzumab 12 mg per day administered through IV, once a day for 5 consecutive days during the first cycle and 12 mg per day administered through IV, once a day for 3 consecutive days during the second cycle, 12 months later. Participants might qualify for as-needed retreatment (12 mg per day administered through IV, once a day for 3 consecutive days) after their second fixed annual cycle.
3060944|NCT00930644|Experimental|teduglutide|0.05 mg/kg/day
3320881|NCT02014532|Placebo Comparator|Placebo|Patients in Control Group were given placebo drug 1 tablet twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3060946|NCT00930761|No Intervention|Control|
3060947|NCT00930761|Experimental|Music therapy|
3060948|NCT00930774|Experimental|FM System|Provision of FM assistive device
3060949|NCT00930774|Experimental|Auditory Training|Provision of auditory training
3060950|NCT00930774|Experimental|FM System and Auditory Training|Provision of FM assistive device and auditory training
3060951|NCT00930774|No Intervention|Standard-of-Care|Standard-of-care informational counseling
3060952|NCT00930813|Experimental|Lutonix Catheter|Paclitaxel coated Balloon Catheter
3060953|NCT00930813|Active Comparator|Standard uncoated Balloon Angioplasty Catheter|uncoated angioplasty balloon
3060954|NCT00930930|Experimental|Cisplatin and Paclitaxel + RAD001|Cisplatin 25 mg/m2 IV weekly + RAD001 5 mg PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + RAD001 5 mg PO daily for 11 weeks
3060955|NCT00930930|Active Comparator|Cisplatin and Paclitaxel + Placebo|Cisplatin 25 mg/m2 IV weekly + placebo PO daily for 1 week followed by Cisplatin 25 mg/m2 IV + Paclitaxel 80 mg/m2 IV weekly + placebo PO daily for 11 weeks
3060956|NCT00930982|Experimental|Ciprofloxacin Inhale (BAYQ3939)|32.5 mg ciprofloxacin hydrated corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation Powder twice daily
3060957|NCT00930982|Placebo Comparator|Placebo|Inhalation of matching placebo twice a day
3060958|NCT00931164|Experimental|Sodium oxybate|"The study is an open-label, Phase I/II trial designed to obtain additional safety and pharmacokinetic parameters for use of sodium oxybate in children and adolescents afflicted with AHC.~Given the limited number of children carrying the diagnosis of AHC, typical controls will not be available for our study. In lieu of this, the subjective recording of ictal episodes in the 6 week period prior to drug initiation will serve as reference in determining drug efficacy."
3060959|NCT00931242|Experimental|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
3060960|NCT00931255|Active Comparator|Tacrolimus|Tacrolimus will be continued with target 12-hour trough level 7-10 ng/ml (tandem mass spectrometry) during the first year and 5-8 during second year.
3060961|NCT00931255|Active Comparator|Sirolimus|5 mg, PO , daily
3060962|NCT00931268|Other|Macrolane VRF 30|Open label, baseline-controlled, one treatment session with injection of Macrolane VRF30 to each buttock, not exceeding 400 ml per subject.
3060963|NCT00931307|Experimental|Lotrafilcon A|
3060964|NCT00931359|Experimental|Treatment with DTS-G2 System|Subjects receive treatment with the DTS-G2 System (an energy-based medical device) in both axilla. Multiple treatment sessions may be used.
3060965|NCT00931359|Sham Comparator|Sham treatment|All elements of the treatment are given except that no energy is delivered. Multiple treatment sessions may be used.
3060966|NCT00931385|Experimental|BI 1744 (Olodaterol) Low Dose|BI1744 Low Dose once daily
3060967|NCT00931385|Experimental|BI 1744 (Olodaterol) Med Dose|BI 1744 Med Dose once daily
3060968|NCT00931385|Placebo Comparator|Placebo|Placebo once daily
3060969|NCT00931385|Active Comparator|Foradil|Foradil 12 mcg twice daily
3060970|NCT00931411|Experimental|Formulation 609580 20 then 609209|Formulation 609580 20 cream is applied topically to the entire body twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609209 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
3060971|NCT00931411|Active Comparator|Formulation 609209 then 609580 20|Formulation 609209 cream is applied topically to entire body, twice a day, morning and evening, after bathing for 42 days. This is followed by the same application of formulation 609580 20 for 2 weeks. Dosage is at the discretion of the parent applying the cream to the child.
3060972|NCT00931463|Active Comparator|Ritonavir-boosted lopinavir and 2N(t)RTI|This is the current standard of care for second line therapy following failure of standard first-line NNRTI+2N(t)RTIs according to WHO guidelines.
3060973|NCT00931463|Experimental|Ritonavir-boosted lopinavir and raltegravir|This is an experimental arm which is likely to be fully active in the presence of N(t)RTI mutations and which preliminary evidence suggests should be potent and durable.
3060974|NCT00931489|Active Comparator|Wet AMD Patients Responders|Dilated eye exam once a month for 7 months; visual acuity and OCT once a month for 7 months; Lucentis(R)/ranibizumab injection once each month for the Baseline and Month 1-3 visits, then as needed at Month 4 and 5; 3 Tbls. blood draw at Baseline, Month 3 and Month 6 visits.
3060975|NCT00931489|No Intervention|Normal Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
3060976|NCT00931489|Active Comparator|Wet AMD Patients Acute Non-responders|Participants in this Group will have not responded to 4 prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. Dilated eye exam at Month 4; visual acuity and OCT at Months 4-6; injection of anti-VEGF treatment as needed at Months 4 and 5; 3 Tbls. blood draw at Month 4
3060977|NCT00931489|No Intervention|Dry AMD Population|Dilated eye exam and 3 Tbls. blood draw at first and only study visit.
3060978|NCT00931489|Active Comparator|Wet AMD Patients Chronic Non-responderes|Participants in this Group will have not responded to 4 or more prior injections of Lucentis(R)/ranibizumab or other anti-VEGF treatment. One visit at Month 4: Dilated eye exam with visual acuity and OCT; injection of anti-VEGF as needed; 3 Tbls. blood drawn
3060979|NCT00931515|Experimental|NuBac|NuBac device implanted at the L4/5 level
3060980|NCT00931515|Active Comparator|Prodisc-L|Prodisc-L implanted at the L4/5 level.
3060981|NCT00931528|Experimental|Tadalafil|Tadalafil
3060982|NCT00931528|Placebo Comparator|Placebo|Placebo
3060983|NCT00931632|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3060984|NCT00931632|Placebo Comparator|Placebo|Nitrogen Placebo
3060985|NCT00931710|Experimental|Valsartan/amlodipine/HCTZ|Valsartan/amlodipine-based regimen: at randomization (Visit 3) patients were treated with valsartan/amlodipine 160/5 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks, and a second forced titration at Visit 5 (Week 6) to valsartan/amlodipine/HCTZ 320/10/25 mg for the remaining 6 weeks of the study.
3060986|NCT00931710|Active Comparator|Losartan/HCTZ|Losartan-based regimen: at randomization (Visit 3) patients were treated with losartan 100 mg for 3 weeks, followed by a forced titration at Visit 4 (Week 3) to losartan/HCTZ 100/25 mg. At Visit 5 (Week 6) patients were switched to valsartan/amlodipine/HCTZ 160/5/25 mg for 3 weeks and, at Visit 6 (Week 9), patients were force titrated to valsartan/amlodipine/HCTZ 320/10/25 mg for the final 3 weeks of the study.
3060987|NCT00931723|Active Comparator|1|Seroquel XR and Lithium
3060988|NCT00931723|Placebo Comparator|2|Seroquel XR and placebo
3060989|NCT00931762|Experimental|Panobinostat|Participants received panobinostat 40 mg, capsules, orally, with or without food, three times a week on Monday, Wednesday, and Friday for up to 6 treatment cycles (each cycle of 28-days) with dose adjustments possible.
3060990|NCT00931801|Experimental|Intervention Arm No.1|
3060991|NCT00931801|Experimental|Intervention Arm No.2|
3060992|NCT00931801|Active Comparator|Control Arm|Continue baseline regimen
3060993|NCT00931879|Placebo Comparator|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
3060994|NCT00931879|Active Comparator|omega-3-ethyl esters 4g|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.
3060995|NCT00931892|Experimental|Low gluten group|Subjects will eat 3g of gluten per day
3060996|NCT00931892|Experimental|High gluten group|Subjects will eat 10g of gluten per day
3060997|NCT00931918|Active Comparator|RCHOP|RCHOP [rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
3060998|NCT00931918|Experimental|Vc-RCHOP|Vc-RCHOP [bortezomib (VELCADE®), rituximab, cyclophosphamide, doxorubicin, prednisone] administered as follows: bortezomib (VELCADE ®) 1.3 mg/m^2 administered intravenous (IV) push on Days 1 and 4 of each cycle with RCHOP administered as follows: rituximab 375 mg/m^2 intravenous (IV) infusion, cyclophosphamide 750 mg/m^2 IV infusion, doxorubicin 50 mg/m^2 IV injection and vincristine 1.4 mg/m^2 (maximum total dose 2 mg) IV injection on Day 1 with prednisone orally on Days 1 through 5 of a 21-day (3-week) cycle for 6 cycles.
3060999|NCT00931944|Experimental|KNS-760704 300 mg/day|Open-label KNS-760704 (150 mg Q12H)
3061000|NCT00931996|Experimental|Antipsychotic|Antipsychotic
3061001|NCT00932022|Experimental|trospium chloride XR 60 mg|Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
3061002|NCT00932022|Placebo Comparator|placebo|Placebo capsule taken orally once daily for 14 weeks.
3061003|NCT00932035|Experimental|Arm I (reverse mapping guided axillary lymph node dissection)|Patients receive isosulfan blue dye SC and then undergo reverse mapping-guided axillary lymph node dissection.
3061004|NCT00932035|Active Comparator|Arm II (control)|Patients undergo standard axillary lymph node dissection and then receive isosulfan blue dye SC.
3061005|NCT00932113|Active Comparator|Adalimumab|Dosing will be on day 1 and then weekly. For the injections, dosing will occur according to product recommendations. Patients will receive 80mg adalimumab (2 pre-filled syringes, each with 40mg) on day 1, and then 40mg on week 1 and then every 2 weeks (from week 1 through week 15).
3061006|NCT00932113|Active Comparator|Methotrexate (MTX)|Patients will be dosed according to the CHAMPION study in single weekly doses of methotrexate: 7.5mg at week 0, 10mg at week two, and 15mg at week 4 for all patients. For each subject if the PASI did not decrease by at least 50% from baseline (PASI-50) at week 8, dosing will be increased to 20mg per week; the dose will be maintained at 15mg per week if PASI-50 was achieved at week 8. If PASI-50 was not achieved at week 12, dosing will be increased to 25mg per week; the dose will be maintained at 20mg per week if the PASI-50 was achieved at week 12. All patients on methotrexate will also receive a dietary supplement of oral folate (5mg per week). Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
3061007|NCT00932126|Experimental|1|
3061008|NCT00932165||Exemestane|Patients taking Exemestane Tablets.
3061009|NCT00932282|Active Comparator|12 month maintenance of PnOIT|"Randomized subjects who will stay on the maintenance dose of oral peanut immunotherapy (PnOIT) for 12 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
3061010|NCT00932282|Active Comparator|24 month maintenance of PnOIT|"All subjects will be on the same intervention until Randomization. Randomized subjects who will stay on the maintenance dose of peanut oral immunotherapy (PnOIT) for 24 months.~The study has 4 phases: anti-IgE therapy before immunotherapy (Omalizumab), an initial desensitization day(s), a buildup period, and a daily home maintenance phase with a final dose of 8000mg peanut flour (~50% peanut protein). Then all subjects will be randomized to an additional 1 or 2 years (12 or 24 months) of maintenance OIT. An OFC will be performed at the end of the long-term maintenance in all groups."
3061011|NCT00932321|Experimental|24 Day NA/EE|Norethindrone acetate 1 mg /ethinyl estradiol 20 mcg for 24 days of each 28 day cycle
3061012|NCT00932321|Active Comparator|21 Day NA/EE|Norethindrone acetate 1 mg/ethinyl estradiol 20 mcg for 21 days of each 28 day cycle
3061013|NCT00932360|Experimental|Active TENS Placebo TENS No TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor
3061014|NCT00932360|Experimental|Placebo TENS Active TENS No TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Participants wore a TENS unit that was turned off for blinding of the outcome assessor
3061015|NCT00932360|Experimental|No TENS Active TENS Placebo TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
3061016|NCT00932360|Experimental|Active TENS No TENS Placebo TENS|Active TENS: 100 Hz, 200 μs at maximal tolerable intensity No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off
3061017|NCT00932360|Experimental|Placebo TENS No TENS Active TENS|Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Participants wore a TENS unit that was turned off for blinding of the outcome assessor Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
3061018|NCT00932360|Experimental|No TENS Placebo TENS Active TENS|No TENS: Participants wore a TENS unit that was turned off for blinding of the outcome assessor Placebo TENS: 100 Hz, 200 μs on for 45 seconds and then ramped off Active TENS: 100 Hz, 200 μs at maximal tolerable intensity
3061019|NCT00932373|Experimental|1|
3061020|NCT00932399||Group 1|Underwent a procedure at a VA medical facility in VISN 20 for a lower limb amputation between 1997 and 2008
3061021|NCT00932399||Group 2|No history of lower limb amputation
3061022|NCT00932425|Experimental|Outpatient cardiac monitoring|Patients will be assigned to wear a portable outpatient cardiac telemetry device for 21 days
3061023|NCT00932425|No Intervention|Control|Patients will be discharged home with standard clinical follow-up
3061024|NCT00932438|Experimental|LC Beads loaded with Irinotecan and FOLFOX6|"Device: LC Beads loaded with 100mg Irinotecan~Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician"
3061025|NCT00932438|Active Comparator|FOLFOX6 and Bevacizumab|Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
3061026|NCT00932451|Experimental|PF-0231066|
3061027|NCT00932477|Experimental|Artificial Tear Formulation 1|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
3061028|NCT00932477|Experimental|Artificial Tear Formulation 2|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear
3061029|NCT00932477|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
3061030|NCT00932620|Active Comparator|Simvastatin 40 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
3061031|NCT00932620|Active Comparator|Simvastatin 10 mg plus ezetimibe 10 mg|All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
3061032|NCT00932646|Experimental|BI1744 (Olodaterol)|Medium Dose once Daily
3061033|NCT00932646|Experimental|BI 1744 (Olodaterol)|Low Dose once Daily
3061034|NCT00932646|Placebo Comparator|Placebo|Placebo once Daily
3061035|NCT00932646|Active Comparator|Foradil|12 mcg twice daily
3061036|NCT00932659||Hemodialysis patients|This is a single arm observational study. The single arm consists of adult hemodialysis patients without a prior history of cardiac arrhythmias who will be implanted with a continuous cardiac monitoring device (REVEAL, Medtronic) for an FDA approved indication.
3061037|NCT00932698|Experimental|Dose Escalation Cohort 1: Ixazomib 0.24 mg/m^2|Ixazomib 0.24 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 220 days).
3061038|NCT00932698|Experimental|Dose Escalation Cohort 2: Ixazomib 0.48 mg/m^2|Ixazomib 0.48 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 270 days).
3061039|NCT00932698|Experimental|Dose Escalation Cohort 3: Ixazomib 0.8 mg/m^2|Ixazomib 0.8 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 137 days).
3061040|NCT00932698|Experimental|Dose Escalation Cohort 4: Ixazomib 1.2 mg/m^2|Ixazomib 1.2 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1436 days).
3061041|NCT00932698|Experimental|Dose Escalation Cohort 5: Ixazomib 1.68 mg/m^2|Ixazomib 1.68 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 456 days).
3061042|NCT00932698|Experimental|Dose Escalation Cohort 6: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 1621 days).
3061043|NCT00932698|Experimental|Dose Escalation Cohort 7: Ixazomib 2.23 mg/m^2|Ixazomib 2.23 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months (Up to 2434 days).
3061044|NCT00932698|Experimental|Relapsed and Refractory Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months, Participants must also be refractory to their most recent therapy as evidenced by PD while on therapy or within 60 days after their last dose of therapy (Up to 1621 days).
3061045|NCT00932698|Experimental|Velcade-Relapsed (VR) Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy but have relapsed after previous Velcade exposure and were not treated with any other proteasome inhibitors (Up to 1573 days).
3061046|NCT00932698|Experimental|Proteasome Inhibitor-Naive Expansion Cohort: Ixazomib 2 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants with relapsed or refractory disease after >=1 prior therapy which must include thalidomide (or lenalidomide) and corticosteroid, but who never received a proteasome inhibitor (Up to 550 days).
3061047|NCT00932698|Experimental|Carfilzomib Expansion Cohort: Ixazomib 2.0 mg/m^2|Ixazomib 2.0 mg/m^2, capsule, orally, on Days 1, 4, 8 and 11 during a 21-day treatment cycle until progressive disease (PD) or unacceptable toxicity up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months. Participants who previously received carfilzomib and had relapsed or refractory disease (Up to 123 days).
3061048|NCT00932828|Experimental|Peanut oral immunotherapy|Newly diagnosed allergic children receiving peanut flour as oral immunotherapy for the treatment of peanut allergy.
3061049|NCT00932893|Experimental|PF-02341066|
3061050|NCT00932893|Active Comparator|Pemetrexed or Docetaxel|Investigator selection of either pemetrexed or docetaxel as the active comparator
3061051|NCT00933166|Experimental|Lotrafilcon A|Investigational contact lens worn in both eyes for three months
3061052|NCT00933244|Other|High Dose Vitamin D3|"Loading Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take daily for 15 days and placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: 50,000 International Units vitamin D3 gel-caps (yellow) to take two times a month for 350 days and placebo gel-caps (white) to take daily for 350 days."
3061053|NCT00933244|Other|Low Dose Vitamin D3|"Loading Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 15 days plus placebo gel-caps (yellow) to take daily for 15 days.~Maintenance Dose: 800 International Units vitamin D3 gel-caps (white) to take daily for 350 days plus placebo gel-caps (yellow) to take two times a month for 350 days."
3061054|NCT00933244|Placebo Comparator|Placebo|"Loading Dose: Placebo gel-caps (yellow) to take daily for 15 days plus placebo gel-caps (white) to take daily for 15 days.~Maintenance Dose: Placebo gel-caps (yellow) to take two times a month for 350 days plus placebo gel-caps (white) to take daily for 350 days."
3061055|NCT00933270|Experimental|SUPERA® Nitinol Stent System|Implantation of SUPERA nitinol stent using the SUPERA® Nitinol Stent System
3061056|NCT00933335|Experimental|Single Arm|Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.
3061057|NCT00933491||Diabetic|Type II Diabetes
3061058|NCT00933491||Control|Non-diabetics
3061059|NCT00933543|Experimental|Visonac cream with PDT|Active treatment, Light dose 37 J/cm2.
3061060|NCT00933543|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 J/cm2.
3061061|NCT00933608|Experimental|memantine|after a period of gradual dose increase from 5 mg/day, participants will be asked to take memantine (20mg/day) for 16 weeks 10 mg in the morning, 10 mg at night
3061062|NCT00933608|Placebo Comparator|Placebo|dose increase to match active drug, after that 1 tablet in the morning, 1 tablet at night, to match active drug
3061063|NCT00933686|Active Comparator|Saizen®|
3061064|NCT00933686|Active Comparator|Placebo + Saizen®|
3061065|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Specificity|Specimens collected from normal apparently healthy individuals at low risk for HIV infection will be tested by the investigational HIV test and FDA-licensed HIV test.
3061066|NCT00933933|No Intervention|ARCHITECT HIV Ag/Ab Combo Sensitivity|Specimen with confirmed positive HIV Antigen, HIV-1 antibody, or HIV-2 antibody will be tested by the investigational HIV test.
3061067|NCT00933933|Experimental|ARCHITECT HIV Ag/Ab Combo Reactivity|Specimen collected from individuals at risk for HIV infection will be tested by the investigational HIV test.
3061068|NCT00934024|Other|Abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was abstinent after 5 weeks of varenicline treatment.."
3061069|NCT00934024|Other|Non-abstinent|"All participants received varenicline. A priori determined analysis was between participants who quit smoking and those who continued to smoke.~This arm was participants who continued to smoke after 5 weeks of varenicline treatment."
3061070|NCT00934050|Experimental|ELND005|
3061071|NCT00934089|Experimental|PF-04217329 + placebo|Active study drug + latanoprost vehicle
3061072|NCT00934089|Experimental|PF-04217329 + latanoprost|Active study drug + latanoprost
3061073|NCT00934102|Active Comparator|Lotrafilcon A|Lotrafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3061074|NCT00934102|Active Comparator|Narafilcon A|Narafilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3061075|NCT00934102|Active Comparator|Galyfilcon A|Galyfilcon A, silicone hydrogel, spherical contact lens randomly assigned to one eye, worn on an extended wear basis.
3061076|NCT00934128|Experimental|Group 1: BiPAP then Vapotherm|Bilevel positive airway pressure device (BiPAP) then Vapotherm air delivery.
3061077|NCT00934128|Experimental|Group 2: Vapotherm then BiPAP|Vapotherm air delivery then BiPAP.
3061078|NCT00934141|Experimental|Interest Circle Call + Website|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach.
3061079|NCT00934141|Experimental|Coaching + Website|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
3061080|NCT00934141|Experimental|Full: LS, Coaching, ICC, Website|Learning Session, Coaching, Interest Circle Calls, Website, see descriptions above
3061081|NCT00934141|Experimental|Learning Session + Website|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives-to help agencies learn and gather support from each other and from outside experts.
3061082|NCT00934180|Experimental|Ondansetron|Ondansetron HCl 8 mg OD Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
3061083|NCT00934180|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg OD Tablet (test) dosed in second period
3061084|NCT00934362|Other|Lucinactant first, then placebo|Active treatment first, then washout period, then placebo treatment
3061085|NCT00934362|Other|Placebo treatment first, then lucinactant treatment|0.9% NaCl vehicle treatment first, then washout period, then lucinactant treatment
3061086|NCT00934375|Experimental|1|
3061087|NCT00934375|Placebo Comparator|2|
3179132|NCT00669643|Experimental|R-MDT MB|R-MDT MB group: standard/regular treatment recommended by WHO - All patients presenting 6 skin or more lesions will receive the standard treatment regimen for multibacillary patients as the intervention; Intervention - MB 12 doses of rifampicin, clofazimine and dapsone
3179133|NCT00669643|Experimental|U-MDT MB|U-MDT MB group: a unified treatment for all patients - All patients presenting 6 lesions or more (WHO MB) will receive 6 doses of rifampicin, clofazimine and dapsone as the intervention; Intervention - MB 6 doses of rifampicin, clofazimine and dapsone
3179134|NCT00669656|Experimental|Prostate Health Cocktail|
3061088|NCT00934440|Experimental|Dose Escalation: 5-azacitidine|A traditional 3+3 dose escalation trial was implemented. Successive cohorts of patients (3 participants/cohort) received bevacizumab at the standard dose of 10mg/kg in combination with escalating doses of 5-azacitidine. If no dose limiting toxicity (DLT) is seen, subsequent patients will be treated at the next dose level. If one DLT is seen, an additional three patients will be accrued at that dose level. If two or more DLTs are seen at one dose level, then the previous dose level will be chosen for phase IIA. If two DLT's are seen at dose level 1, the trial will end. The standard 5-azacitidine dose is 75mg/m2/day for 7 days. If no DLT is seen at dose level 3, then we will proceed with the phase IIA portion of the study.
3061089|NCT00934544|Experimental|Ruxolitinib|5 mg tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
3061090|NCT00934544|Active Comparator|Best Available Therapy (BAT)|"Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.~Patients randomized to BAT were eligible to cross over to receive open-label ruxolitinib after a qualifying progression event, if they met the safety criteria. After the primary analysis in January 2011, patients randomized to receive BAT were allowed to cross over to receive ruxolitinib and move to the extension phase of the study without a qualifying progression event."
3061091|NCT00934596|Experimental|Lund de-airing|Lund de-airing technique
3061092|NCT00934596|Active Comparator|Carbon-dioxide insufflation|carbon-dioxide insufflation will be provided to the open mediastinal wound in a standardized manner
3061093|NCT00934622|Experimental|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL)
3061094|NCT00934635|Active Comparator|002|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 2 hours
3061095|NCT00934635|Active Comparator|003|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 2 hours
3061096|NCT00934635|Active Comparator|004|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 2 hours
3061097|NCT00934635|Active Comparator|005|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 24 hours
3061098|NCT00934635|Active Comparator|006|Paliperidone ER 9 mg tablet once a day followed by PET scan in approximately 24 hours
3061099|NCT00934635|Active Comparator|007|Oral risperidone 4 mg tablet once a day followed by PET scan in approximately 24 hours
3061100|NCT00934635|Active Comparator|008|Oral risperidone 6 mg tablet once a day followed by PET scan in approximately 24 hours
3061101|NCT00934635|Other|009|PET Scan PET Scan
3061102|NCT00934635|Active Comparator|001|Paliperidone ER 6 mg tablet once a day followed by PET scan in approximately 2 hours
3061103|NCT00934648|Experimental|1|
3061104|NCT00934661|Experimental|Extended Release Epidural Morphine|Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline
3061105|NCT00934661|Placebo Comparator|Placebo Group|The epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
3061106|NCT00934843|Experimental|Single dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive ONE dose intravenous methylprednisolone (IVMP) prior to heart surgery.
3061107|NCT00934843|Experimental|Two Dose steroid|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB) machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
3061108|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 75 mg/m^2 (over 2 days)|Participants with human epidermal growth factor receptor 2 (HER2)-positive MBC will receive docetaxel (Doc) 75 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 and T-DM1 2.4 milligrams per kilogram (mg/kg) IV infusion on Day 2 of Cycle 1 followed by T-DM1 75 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 75 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3061109|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (over 2 days)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion on Day 1 and T-DM1 2.4 mg/kg IV infusion on Day 2 of Cycle 1 followed by T-DM1 60 mg/m^2 and docetaxel 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3061110|NCT00934856|Experimental|MBC: T-DM1 2.4 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3061111|NCT00934856|Experimental|MBC: T-DM1 3.6 mg/kg + Doc 60 mg/m^2 (same day)|Participants with HER2-positive MBC will receive docetaxel 60 mg/m^2 IV infusion and T-DM1 3.6 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m^2 will be stopped and T-DM1 3.6 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
3061112|NCT00934856|Experimental|LABC: T-DM1 + Doc (Doublet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg IV infusion and docetaxel 60/75/100 mg/m^2 IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
3061113|NCT00934856|Experimental|LABC: T-DM1 + Doc + Pertuzumab (Triplet Regimen)|Participants with HER2-positive LABC will receive T-DM1 3.6 mg/kg Iv infusion, docetaxel 60/75 mg/m^2 IV infusion, and pertuzumab 840 mg (for Cycle 1) or 420 mg (for remaining cycles) IV infusion on Day 1 of each 3-week cycle, for 6 cycles. Study treatment will be administered for up to 6 cycles or until unacceptable toxicity, and prior to surgery.
3061114|NCT00934921|Experimental|Ondansetron|Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in first period followed by Zofran® 8 mg ODT (reference) dosed in second period
3061115|NCT00934921|Active Comparator|Zofran®|Zofran® 8 mg ODT (reference) dosed in first period followed by Ondansetron HCl 8 mg Orally Disintegrating Tablet (test) dosed in second period
3061116|NCT00934934|Placebo Comparator|Placebo|Saline will serve as the placebo solution since the active comparator is clear and colourless.
3061117|NCT00934934|Active Comparator|Antifungal|Patient will receive a dose daily for a total of 14 days
3061118|NCT00934947|Placebo Comparator|Sugar pill|
3061119|NCT00934947|Experimental|Propranolol, Propanolol ER|
3061120|NCT00935012|Experimental|Open-Label|
3061121|NCT00935064|Active Comparator|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
3061122|NCT00935064|Placebo Comparator|Placebo|
3061123|NCT00935220|Experimental|linagliptin|Pharmacokinetic (PK)/Pharmacodynamic (PD) investigation
3061124|NCT00935259|Experimental|Simvastatin 40 mg first, then placebo|Simvastatin 40 mg tablets once daily for 2 weeks followed by placebo for 2 weeks
3061125|NCT00935259|Placebo Comparator|Placebo first, then simvastatin 40 mg once daily|Placebo for 2 weeks followed by simvastatin 40 mg once daily for 2 weeks
3061126|NCT00935272|Experimental|Treatment|Restylane® Treatment
3061127|NCT00935272|No Intervention|Non-Treatment|Non-Treatment Arm
3061128|NCT00935311|Experimental|ABT-712|1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
3061129|NCT00935311|Active Comparator|Hydrocodone/Acetaminophen|2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
3061130|NCT00935311|Placebo Comparator|Placebo|2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
3061131|NCT00935493|Experimental|Guanfacine 0.1 mg po qhs|
3061132|NCT00935493|Experimental|Guanfacine 0.5 mg po qhs|
3061133|NCT00935493|Placebo Comparator|Placebo po qhs|
3061134|NCT00935532|Experimental|exenatide once weekly|
3061135|NCT00935532|Active Comparator|insulin glargine|
3061136|NCT00935584|Other|PACE Study|"The study utilized a quasi-experimental pre-post intervention design. The intervention provided was physician education to improve EMR use and communication.~Physician training in patient-centered EMR use was developed. The conceptual model of patient-centered communication will provide the underlying framework for the training aimed at improving physicians interviewing and communication skills."
3061137|NCT00935701|Experimental|Acupuncture and Acupressure|In Phase 1, 10 children with ASD will receive acupressure for four weeks. At week 5, they will be introduced to acupuncture which will be continued throughout the rest of the study as tolerated. In Phase 2, 40 children with ASD will receive acupressure twice weekly for 12 weeks. Parents will be trained in the acupressure techniques and will be asked to do this daily, at bedtime, and/or as requested by the child or deemed needed by the parent. Children will begin to be assessed for their ability to participate in acupuncture treatment between weeks 5 and 7 at the discretion of the acupuncturist. By week 7, all children will have been introduced to acupuncture/needling. If needling is still refused at this time, acupressure will continue for the remainder of the study.
3061138|NCT00935766|Placebo Comparator|Sugar Pill|4 tabs of placebo dependent on randomization
3061139|NCT00935766|Active Comparator|Omega 3|omega-3-acid ethyl esters and instructed to take 4 1 mg capsules daily
3061140|NCT00935792|Experimental|Arm I|Patients receive oral everolimus thrice weekly for 9 weeks and alemtuzumab subcutaneously thrice weekly for 8 weeks.
3061141|NCT00935818|Active Comparator|varenicline and buproprion SR|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and bupropion SR (150 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
3061142|NCT00935818|Placebo Comparator|varenicline and placebo|Everyone randomized to this arm will receive varenicline (up to 1mg bid) and placebo (0 mg bid)for 12 weeks. They will be followed up by study for an additional 9 months post end of medication - for a total of 1 year study participation. Everyone will receive behavioral counseling for the full year.
3061143|NCT00935857|Experimental|Balloon Colonoscopy|Colonoscopy using the single balloon colonoscopy system (novel endoscope to facilitate difficult colonoscopy).
3061144|NCT00935857|Active Comparator|Standard Colonoscopy|Colonoscopy using a standard adult colonoscope
3061145|NCT00935883|Placebo Comparator|Saline|Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator
3061146|NCT00935883|Active Comparator|Eculizumab|Randomized patients in the drusen or the GA cohort will receive active treatment with eculizumab
3061147|NCT00936065|Active Comparator|Group A|
3061148|NCT00936065|Experimental|Group B|
3061149|NCT00936065|Active Comparator|Group C|
3061150|NCT00936117|Experimental|Posaconazole|Posaconazole 200 mg (liquid) by mouth 3 times per day.
3061151|NCT00936208||Essential hypertensive men and women|
3061152|NCT00936221|Active Comparator|1|AZD6244 in combination with dacarbazine
3061153|NCT00936221|Placebo Comparator|2|Placebo in combination with dacarbazine
3061154|NCT00936299|Active Comparator|Bupropion + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive bupropion + CBT.
3061155|NCT00936299|Placebo Comparator|Placebo + cognitive behavioral therapy|Adolescents with ADHD, nicotine dependence, and cannabis use disorders receive placebo + CBT.
3061156|NCT00936351|Experimental|Arm 1|Mindfulness Meditation
3061157|NCT00936351|Active Comparator|Arm 2|Support Group that involves discussion of work-related issues in which participants are facilitated to assist each other with problem solving and offer support
3061158|NCT00936377|Experimental|Dexmedetomidine, low dose|Dexmedetomidine 0.4 µg/kg per hour administered for a maximum duration of five days
3061159|NCT00936377|Experimental|Dexmedetomidine, high dose|Dexmedetomidine 1.2 µg/kg per hour administered for a maximum duration of five days
3061160|NCT00936377|Placebo Comparator|Placebo|Normal saline
3061161|NCT00936455||Telemedicine|Telemedicine evaluated patients
3061162|NCT00936455||Telephone|Telephone evaluated patients
3061163|NCT00936481||Healthy controls|18 years or older with body mass index between 25-45
3061164|NCT00936481||Obstructive Sleep Apnea Group|Age 18 years or older with body mass index between 25 and 45
3061165|NCT00936611|Experimental|LBH589|"30 mg three days a week (Mondays, Wednesdays and Fridays).~1 cycle was 28 days~Dose modifications for attributable toxicities allowed for reduction to:~25 mg, 20 mg three times a week every week~Or 20 mg three times a week every other week. No dose re-escalation was allowed.~The protocol was amended on 6/15/2010 because of concerns of toxicity to allow a starting dose of 25 mg; 12/36 (33%) patients were enrolled on the 25 mg dose."
3061166|NCT00936663|Experimental|Sitagliptin 100 mg daily|sitagliptin 100 mg daily
3061167|NCT00936663|Placebo Comparator|placebo|placebo
3061168|NCT00936702|Experimental|Treatment (carboplatin, paclitaxel, and everolimus)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Patients also receive everolimus PO QD on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061169|NCT00936715|Experimental|FTC/TDF|
3061170|NCT00936741|Experimental|Mifepristone|Mifepristone 300mg to 1200mg once daily
3061171|NCT00936858|Experimental|Arm A|RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
3061172|NCT00936884|Experimental|Methylnaltrexone double-blind|Methylnaltrexone once every other day.
3061173|NCT00936884|Placebo Comparator|Placebo|Placebo once every other day.
3061174|NCT00936884|Other|Methylnaltrexone open-label|Subjects who completed the double-blind period had the option to receive methylnaltrexone once every other day during a 12-week, open-label extension period.
3061175|NCT00936897|Active Comparator|Ibandronate|Ibandronate 150mg PO QM (tablet)
3061176|NCT00936897|Experimental|Denosumab|denosumab 60mg Subcutaneous Q6M (pre-filled syringe)
3061177|NCT00936910|Experimental|Antifungal lock-treated patients|Intestinal failure and other patients with poor IV access and central line fungal-related infections will receive intravenous systemic antifungal therapy plus the instillation of Ambisome locks into the infected catheter.
3061178|NCT00936975|Experimental|18F-Fluoride PET|Patients undergo fluorine F 18 sodium fluoride PET scan at baseline and then at 12 weeks after initiation of treatment with dasatinib. Dasatinib was administered under a concurrent protocol and was not considered part of the intervention on this protocol
3061179|NCT00937040|Experimental|001|OROS MPH Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
3061180|NCT00937040|Placebo Comparator|002|Placebo Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
3061181|NCT00937105|Active Comparator|ReNu Multiplus and lotrafilcon A lenses|ReNu Multiplus contact lens care solution
3061182|NCT00937105|Active Comparator|Clear Care solution and lotrafilcon A lenses|Clear Care Contact Lens Care Solution
3061183|NCT00937118||Injury Management|Patients with full thickness duodenal laceration undergoing laparotomy and surviving more then 72 hours at our level 1 trauma center in the years 1989-2009. Patients requiring pancreaticoduodenectomy were excluded.
3061184|NCT00937157|Other|1|Patients diagnosed with multiple sclerosis who have the presence of at least 1 or more Gd enhancing lesions and/or acute relapse.
3061185|NCT00937235|Experimental|Integrated Treatment|Prolonged Exposure + Varenicline + Medication Management Counseling
3061186|NCT00937235|Active Comparator|Varenicline|Varenicline + Medication Management Counseling
3061187|NCT00937326|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight placebo capsules per day.~Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3061188|NCT00937326|Active Comparator|Arm1 - 0.25g|"The 0.25g SRT2104 treatment group will be administered one SRT2104 capsules with 7 placebo capsules, for a total of 8 capsules per day.~0.25g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3061189|NCT00937326|Active Comparator|Arm2 - 0.5g|"The 0.5g SRT2104 treatment group will be administered two SRT2104 capsules with 6 placebo capsules, for a total of 8 capsules per day.~0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3061190|NCT00937326|Active Comparator|Arm3 - 1g|"The 1g SRT2104 treatment group will be administered four SRT2104 capsules with four placebo capsules, for a total of 8 capsules per day.~1g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3061191|NCT00937326|Active Comparator|Arm4 - 2g|"The 2g SRT2104 treatment group will be administered eight SRT2104 capsules per day.~2g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every morning, 15 minutes following consumption of a standardized meal and should be administered with approximately 1 to 2 glasses of water."
3061192|NCT00937378|Experimental|SER120|
3061193|NCT00937378|Placebo Comparator|Placebo|
3061194|NCT00937391|Experimental|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
3061195|NCT00937404|Experimental|IPV Group|Healthy male or female subjects between, and including, 60 and 90 days of age at the time of the first vaccination, receive 3 doses of Poliorix at 2 (Study Day 0, Visit 1), 3 (Study Month 1, Visit 2) and 4 (Study Month 2, Visit 3) months of age, administered intramuscularly into the upper right side of the thigh.
3179135|NCT00669695|Placebo Comparator|Stat/CPAP|Atorvastatin and CPAP treatments
3179136|NCT00669695|Placebo Comparator|Stat/sham CPAP|Atorvastatin and sham CPAP treatments
3061196|NCT00937495|Experimental|Treatment (vorinostat, bortezomib)|Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061197|NCT00937521|Other|1|Vaccine candidate formulation I
3061198|NCT00937521|Other|2|Vaccine candidate formulation II
3061199|NCT00937521|Other|3|Vaccine candidate formulation III
3061200|NCT00937521|Other|4|Vaccine candidate formulation IV
3061201|NCT00937521|Other|5|Vaccine candidate formulation V
3061202|NCT00937521|Other|6|Vaccine candidate formulation VI
3061203|NCT00937521|Other|7|Control
3061204|NCT00937521|Other|8|Vaccine candidate formulation I with antipyretic
3061205|NCT00937560|Experimental|Bevacizumab + paclitaxel + carboplatin|Participants received 6-8 (at the investigator's discretion) 3-week cycles of bevacizumab 7.5 mg/kg intravenously (iv) on Day 1 of each cycle, paclitaxel 80 mg/m^2 iv on Days 1, 8, and 15 of each cycle, and carboplatin iv to an area under the curve of 6 on Day 1 of each cycle. The initial dose of carboplatin was calculated according to the Calvert formula (mg = [glomerular filtration rate + 25] x 6). Following the combination treatments, participants received up to 17 3-week cycles of bevacizumab 7.5 mg/g iv alone.
3061206|NCT00937768|Experimental|Arm A (antihormone therapy)|Patients receive leuprolide acetate IM on day 1 OR goserelin acetate SC on day 1. Courses repeat every 3 months for 9 months in the absence of disease progression or unacceptable toxicity.
3061207|NCT00937768|No Intervention|Arm B (no antihormone therapy)|Patients undergo observation every 3 months for 9 months.
3061208|NCT00937794||No treatment|This is a screening study designed to evaluate the behavioral, physical, and neurodevelopmental status in pediatric patients with Hunter syndrome who have early signs and symptoms of CNS involvement and who are currently receiving treatment with Elaprase.
3061209|NCT00937833|Experimental|Urethrovesical Sling|Surgisis Male Sling placed at the time of prostatectomy
3061210|NCT00937833|Active Comparator|Control|Prostatectomy
3061211|NCT00937859|Experimental|SER120|SER120
3061212|NCT00937859|Placebo Comparator|Placebo|
3061213|NCT00937950|Other|HPV-052 study subjects Group|The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
3061214|NCT00938015||PsA Patients (New)|New patients
3061215|NCT00938015||PsA Patients|CU patients
3061216|NCT00938041|Experimental|Retreatment of NHL with Iodine-131 Anti-B1 Antibody|Patients with non-Hodgkin's lymphoma who previously responded with a duration of response of at least 3 months to Iodine-131 Anti-B1 Antibody therapy will undergo two phases of study. In the first phase, patients will receive a dosimetric dose of unlabeled Anti-B1 Antibody (450 mg) followed by Anti-B1 Antibody (35 mg) which has been radiolabeled with 5 mCi of Iodine-131. Whole body gamma camera scans will be obtained after the dosimetric dose and data from three imaging time points will be used to calculate a patient-specific dose to deliver the desired total body dose of radiotherapy. In the second phase, patients will receive the therapeutic dose of unlabeled Anti-B1 Antibody (450 mg) followed by 35 mg of Anti-B1 Antibody labeled with the patient-specific dose to deliver the desired whole body dose of radiation. Patients will be treated with thyroid blocking medication at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion.
3061217|NCT00938314|Experimental|NTx®-265 Low Dose|hCG 385 µg (10,000 international unit [IU]), subcutaneously (SC), on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, intravenously (IV), on Day 7, 8, and 9 of study participation
3061218|NCT00938314|Experimental|NTx®-265 Medium Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
3061219|NCT00938314|Experimental|NTx®-265 High Dose|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
3061220|NCT00938314|Placebo Comparator|Saline Placebo|
3061221|NCT00938327||Rotarix Group|Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
3061222|NCT00938340|Experimental|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
3061223|NCT00938340|Experimental|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
3061224|NCT00938340|Experimental|Walnut oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
3061225|NCT00938340|Experimental|Walnut skins|Separated, ground walnut skins incorporated into inert food carrier
3061226|NCT00938366|Experimental|Cladribine followed by Cladribine + Pantoprazole|Subjects will receive a single dose of cladribine10 milligram (mg) orally on Day 1. After a wash out period of 10-25 days, subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose.
3061227|NCT00938366|Experimental|Cladribine + pantoprazole followed by Cladribine|Subjects will receive pantoprazole 40 mg orally for 2 consecutive days. On Day 2 of the pantoprazole administration, a single dose of cladribine 10 mg will be administered orally 3 hours after the second pantoprazole dose. After a wash out period of 10-25 days, subjects will receive a single dose of cladribine 10 mg orally.
3061228|NCT00938392|Experimental|FluNG Aged Group|Subjects receiving 1 dose of an aged lot of FLU NG vaccine (GSK2186877A).
3061229|NCT00938392|Experimental|FluNG Fresh Group|Subjects receiving 1 dose of a fresh lot of FLU NG vaccine (GSK2186877A).
3061230|NCT00938431|Experimental|Lacosamide - Age 5 - 11 years|Cohort 1 (Age 5 - 11 years); up to 8 mg/kg/day
3061231|NCT00938431|Experimental|Lacosamide - (Age 12 - 17 years)|Cohort 2 (Age 12 - 17 years); 12 mg/kg/day.
3061232|NCT00938431|Experimental|Lacosamide (Age 2 - 4 years)|Cohort 3 (Age 2 - 4 years); 12 mg/kg/day.
3061233|NCT00938431|Experimental|Lacosamide (Age 5 - 11 years)|Cohort 4 (Age 5 - 11 years); 12 mg/kg/day.
3061234|NCT00938431|Experimental|Lacosamide (Age 1 month - < 2 years)|Cohort 5 (Age 1 month to < 2 years); 12 mg/kg/day
3061235|NCT00938457|Experimental|Arm I|Patients undergo either percutaneous placement of metallic fiducial markers within the liver or respiratory-correlated cone-beam computed tomography for stereotactic targeting and planning. Patients then undergo single-fraction stereotactic body radiotherapy over approximately 1 hour within 1 week of the marker placement.
3061236|NCT00938470|Experimental|Arm I (combination chemotherapy, radiation therapy, surgery)|Patients receive docetaxel IV over 1 hour and oxaliplatin IV over 2 hours on day 1. Patients also receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. After completion of the second course, patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity. Approximately 4-12 weeks after completion of radiotherapy, patients undergo surgery.
3061237|NCT00938470|Active Comparator|Arm II (oxaliplatin, fluorouracil, radiation, and surgery)|Patients receive fluorouracil IV continuously on days 1-5 and oxaliplatin IV over 2 hours on days 1, 15, and 29. Patients also undergo radiotherapy and then surgery as in Arm I.
3061238|NCT00938548|Placebo Comparator|Placebo|Patients receive oral Placebo 1 hour prior to surgery, and 12 hours later
3061239|NCT00938548|Experimental|Pregabalin|Patients receive oral pregabalin 1 hour prior to surgery, and 12 hours later
3061240|NCT00938639|Experimental|CSL425 (15 mcg)|15 mcg of haemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3061241|NCT00938639|Experimental|CSL425 (30 mcg)|30 mcg of haemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3061242|NCT00938704|Active Comparator|1|carboxymethylcellulose 0.5%, glycerin 0.9%
3061243|NCT00938704|Active Comparator|2|sodium hyaluronate 0.18%
3061244|NCT00938717|Placebo Comparator|Placebo|
3061245|NCT00938717|Experimental|290 μg Linaclotide|
3061246|NCT00938782|Active Comparator|Active Monitoring with SEDLine Monitor|Patient group randomized to active monitoring with SEDLine monitor for titration of anesthesia.
3061247|NCT00938782|No Intervention|Blinded monitoring with SeEDLine Monitor|Patient group randomized to blinded monitoring with SEDLine monitor for titration of anesthesia. Data captured but not used for titration of anesthesia.
3061248|NCT00938860|Experimental|Neoral|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
3061249|NCT00938860|Active Comparator|tacrolimus|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
3061250|NCT00938886|Experimental|Naltrexone|50 mg daily naltrexone for 10 weeks
3061251|NCT00938886|Placebo Comparator|Placebo|Daily matched placebo pill
3061252|NCT00938964|Experimental|Lidocaine|Lidocaine infusion for 48 hours
3061253|NCT00938964|Placebo Comparator|Placebo|Normal saline infusion for 48 hours
3061254|NCT00939003|Experimental|Adalimumab|
3061255|NCT00939003|Placebo Comparator|Placebo|
3061256|NCT00939003|Experimental|Open-label Adalimumab|
3061257|NCT00939029|Active Comparator|Active|2 nicotine patches each at 21 mg/day for a total of 42 mg/day for 8 weeks
3061258|NCT00939029|Placebo Comparator|placebo|2 patches (containing non active ingredients) per day for 8 weeks
3061259|NCT00939055|Experimental|StomaphyX|Post-Roux-en-Y revisional surgery using the StomaphyX device.
3061260|NCT00939055|Sham Comparator|Sham Procedure|No intervention
3061261|NCT00939094|Experimental|A|
3061262|NCT00939094|Placebo Comparator|B|
3061263|NCT00939107|Experimental|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
3061264|NCT00939107|Active Comparator|Spinal manipulation|Spinal manipulation in combination with information of clinical findings and advice about back care
3061265|NCT00939120|Experimental|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
3061266|NCT00939120|Placebo Comparator|placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
3061267|NCT00939159|Experimental|LBH589|LBH589 20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
3061268|NCT00939185||Azithromycin group|
3061269|NCT00939198|Experimental|Na-ASP-2 Hookworm Antigen Skin Test|All participants will be skin tested with Na-ASP-2 skin test reagent applied to their arms, using both the prick-puncture and intradermal techniques.
3061270|NCT00939211|Experimental|AZD9164 100 mcg First, then Placebo for Spririva|1 x AZD9164 solution for inhalation through nebulisation 100 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3061271|NCT00939211|Experimental|AZD9164 400 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 400 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3061272|NCT00939211|Experimental|AZD9164 1200 mcg First, then Placebo for Spiriva|1 x AZD9164 solution for inhalation through nebulisation 1200 mcg (lung deposited dose) + 1 x placebo for Spiriva dry powder for inhalation
3061273|NCT00939211|Active Comparator|Spiriva 18 mcg First, then Placebo for AZD9164|1 x Spiriva dry powder for inhalation 18 mcg + 1 x placebo for AZD9164 (sodium chloride)
3061274|NCT00939211|Placebo Comparator|Placebo for Spiriva First, then Placebo for AZD9164|1 x placebo Spiriva dry powder for inhalation + 1 x placebo for AZD9164 (sodium chloride)
3061275|NCT00939341|Experimental|1|Symbicort Turbuhaler 160/4.5 µg delivered dose
3061276|NCT00939367|Experimental|Test|Torrent's Zolpidem TartrateTablets 10 mg
3061277|NCT00939367|Active Comparator|Reference|Sanofi-Synthelabo Inc's Ambient® Tablets 10 mg
3061278|NCT00939393|Active Comparator|FESS in OR with or without balloons|Functional Endoscopy Sinus Surgery
3061279|NCT00939393|Active Comparator|Balloon sinuplasty in physician office|Balloon Sinuplasty in physician office using Acclarent devices
3061280|NCT00939471|Other|Relieva™ Balloon Sinuplasty™ System|Balloon Dilation of sinus ostium
3179137|NCT00669695|Sham Comparator|Placebo/CPAP|Placebo and CPAP treatments
3061281|NCT00939484|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO once daily on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3061282|NCT00939510|Experimental|Lenalidomide (RevlimidTM ) and GM-CSF|
3061283|NCT00939523|Experimental|Lapatinib|All participants will be asked to take Lapatinib daily for a total of six months during the research study.
3061284|NCT00939536|Experimental|Torrent's Zolpidem Tartrate Tablets 10 mg|Normal Healthy Human Subjects receiving Torrent's Zolpidem Tartrate Tablets 10 mg
3061285|NCT00939536|Active Comparator|Sanofi-Synthelabo's Ambien® 10 mg Tablets|Normal Healthy Human Subjects receiving Sanofi-Synthelabo's Ambien® 10 mg Tablets
3061286|NCT00939562|Experimental|doxycycline monohydrate tablet|
3061287|NCT00939562|Active Comparator|doxycycline carragenate tablet|
3061288|NCT00939627|Placebo Comparator|Arm I (cetuximab and placebo)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral placebo twice daily on days 1-21.
3061289|NCT00939627|Experimental|Arm II (cetuximab and sorafenib tosylate)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, and 15 and oral sorafenib tosylate twice daily on days 1-21.
3061290|NCT00939640|Experimental|Dietary intervention|Diet patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet includes higher quantities of fresh fruits and vegetables, whole grain products, and low-fat dairy products than the standard American diet. The target sodium content is 50 mmol per 2100 kcal, and the caloric content is intended to maintain body weight. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants.
3061291|NCT00939653|Experimental|Single Arm - Clofarabine with Chemo|All patients receive the same treatment regimen consisting of clofarabine, etoposide, cyclophosphamide, cytarabine, and filgrastim. Up to 4 courses of therapy may be given.
3061292|NCT00939692|Experimental|Torrent Topiramate|tablet containing 25 mg of topiramate (Torrent Pharmaceuticals)
3061293|NCT00939692|Active Comparator|Topamax|tablet containing 25 mg of topiramate (Topamax®, Ortho-McNeil Neurologics, Inc.)
3061294|NCT00939705|Experimental|Torrent Topiramate|
3061295|NCT00939705|Active Comparator|Topamax|
3061296|NCT00939731|Experimental|PIC|
3061297|NCT00939731|Experimental|IRT|
3061298|NCT00939770|Experimental|Treatment (crizotinib)|Patients receive crizotinib PO BID on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3061299|NCT00939783|Experimental|Dimebon 20 mg TID|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
3061300|NCT00939796|Experimental|Tympanostomy Tube Delivery System (TTDS)|Tympanostomy tube placement with Acclarent tube delivery system
3061301|NCT00939809|Experimental|Treatment (urokinase-derived peptide A6)|Patients receive A6 subcutaneously once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3061302|NCT00939822|Experimental|Simvastatin|40 mg. Simvastatin/day
3061303|NCT00939822|Placebo Comparator|Placebo|Matching Placebo
3061304|NCT00939874|Experimental|Raltegravir|
3061305|NCT00939900|Experimental|aclasta|aclasta group
3061306|NCT00939900|No Intervention|control|control group
3061307|NCT00939952|Active Comparator|ertapenem 500 mg IV x1|All patients will receive ertapenem 500 mg IV once.
3061308|NCT00939991|Experimental|1|Phase I- Bevacizumab will be administered intravenously every other week. Temozolomide will be administered on a continuous daily dosing schedule. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen.
3061309|NCT00940017|Experimental|1|
3061310|NCT00940108|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3061311|NCT00940108|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3061312|NCT00940290|Other|GRADE system|A clinical recommendation built and graded with the GRADE working group system
3061313|NCT00940290|Other|SIGN grading system|A clinical recommendation built and graded with the Scottish Intercollegiate Guidelines Network system
3061314|NCT00940290|Other|NICE grading system|A clinical recommendation built and graded with National Institute of Clinical Excellence grading system
3061315|NCT00940290|Other|CEBM-Oxford|A clinical recommendation built and graded with the Centre for Evidence-Based Medicine grading system
3061316|NCT00940316|Experimental|Arm A: Erlotinib + Panitumumab + Irinotecan|Patients receive oral erlotinib hydrochloride once daily on days 1-14, panitumumab IV over 30-90 minutes on day 1, and irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3061317|NCT00940316|Experimental|Arm B: Erlotinib + Panitumumab|Patients receive oral erlotinib hydrochloride once daily on days 1-14 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients receive irinotecan hydrochloride as in arm A.
3061318|NCT00940316|Experimental|Arm C: Erlotinib + Panitumumab|Patients receive erlotinib hydrochloride and panitumumab as in arm B.
3061319|NCT00940342|Experimental|Treated and Relapsed - Group 1|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3061320|NCT00940342|Experimental|Treated and High-Risk for Progression - Group 2|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3061321|NCT00940342|Experimental|70 Years of Age and Refused Chemo - Group 3|Participants receive one (1) course of therapy. One course of therapy consists of four (4) doses of Rituximab 375 mg/m2, administered once weekly by vein for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly for 8 weeks.
3061322|NCT00940446|Experimental|Insorb staples|Subcuticular Absorbable staples
3061323|NCT00940446|Active Comparator|Control|Metal staple wound closure
3061324|NCT00940485|Experimental|Peginterferon alfa-2a + entecavir|Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
3061325|NCT00940485|Active Comparator|Entecavir|Participants received entecavir 0.5 mg orally once daily for 48 weeks.
3061327|NCT00940537||NAFLD|Non-diabetic, obese with diagnosed NAFLD (HTGC greater or equal to 5.5%)
3061328|NCT00940537||Non-NAFLD|Non-diabetic, obese with no previous diagnosis of NAFLD
3061329|NCT00940576|Experimental|mare´s milk|oral intake of of 250 ml mare´s milk
3061330|NCT00940576|Placebo Comparator|placebo drink|oral intake of of 250 ml placebo drink
3061331|NCT00940589|Experimental|Circadin|Drug
3061332|NCT00940589|Placebo Comparator|Placebo|drug
3061333|NCT00940602|Experimental|Deferasirox|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
3061334|NCT00940602|Placebo Comparator|Placebo|10 mg/kg/day (once daily) for the first 2 weeks of treatment, followed by 20 mg/kg/day (once daily) from Week 2 to End of Treatment. After 3 months of treatment at 20 mg/kg/day, the dose was allowed to be adjusted by 5 or 10 mg/kg/day up to 40 mg/kg/day based on serum ferritin responses. When a target serum ferritin level was reached (usually between 500 and 1000 µg/L), the dose could be reduced by 50% to maintain the serum ferritin within the target range.
3061335|NCT00940771|Experimental|boosted Atazanavir|Boosted Atazanavir was switched for the PI or NNRTI in the patients regimen
3061336|NCT00940823|Active Comparator|Ahmed FP7 Valve|Ahmed valve glaucoma drainage device implant for treatment of refractory glaucoma.
3061337|NCT00940823|Active Comparator|Baerveldt-350 Tube|Baerveldt tube glaucoma drainage device implant for treatment of refractory glaucoma.
3061338|NCT00940875|Experimental|1|
3061339|NCT00940875|Active Comparator|2|
3061340|NCT00940888||No treatment: ICD/CRTD-indicated|
3061341|NCT00940901|Experimental|sildenafil|Participants assigned to this arm were given sildenafil 50 mg tablet daily for 16 weeks.
3061342|NCT00940901|Placebo Comparator|placebo|Participants assigned to this arm were given a placebo pill for the first 8 weeks, and then Sildenafil 50 mg for weeks 9-16.
3061343|NCT00940992|Experimental|DER 45 EV Gel, 1%|DER 45 EV Gel, 1% topically applied once daily to face for 12 weeks
3061344|NCT00940992|Placebo Comparator|Vehicle|Placebo Gel applied topically once a day for 12 weeks
3061345|NCT00940992|Experimental|DER 45 EV Gel, 5%|DER 45 EV Gel, 5% applied topically once a day for 12 weeks
3061346|NCT00941005|Experimental|Electroacustimulation|Received electroacustimulation at the wrist using a small, battery-powered electroacustimulation device.
3061347|NCT00941005|Sham Comparator|Control|Received a device that was not turned on.
3061348|NCT00941031|Experimental|Induction Single Dose|"Induction with single injection - Single: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12"
3061349|NCT00941031|Experimental|Induction Monthly Dose|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12"
3061350|NCT00941031|Experimental|Induction Early Loading Dose|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12"
3061351|NCT00941031|Placebo Comparator|Placebo Dose|Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12
3061352|NCT00941070|Experimental|Treatment (cisplatin, triapine, radiation therapy)|"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.~Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression."
3061353|NCT00941304|Active Comparator|Standard Opioid|Oxycodone 5-mg oral capsule and 2 buccal placebo films
3061354|NCT00941304|Experimental|High Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 1, buccal placebo film, and oral placebo capsule
3061355|NCT00941304|Experimental|Mid Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.5-mg modified formulation 2, buccal placebo film, and oral placebo capsule
3061356|NCT00941304|Experimental|Low Dose buprenorphine HCl buccal film|Buprenorphine HCl buccal film 0.25-mg modified formulation 2, buccal placebo film, and oral placebo capsule
3061357|NCT00941304|Placebo Comparator|Placebo|Oral placebo capsule and 2 buccal placebo films
3061358|NCT00941330|Experimental|A: Exemestane|ARM A: Patients will be treated with exemestane.
3061359|NCT00941330|Active Comparator|B: Docetaxel and Cytoxan|ARM B: Patients will be treated with docetaxel and cytoxan.
3061360|NCT00941603|Experimental|SCH 900271 15 mg|Participants receive SCH 900271 15 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3061361|NCT00941603|Experimental|SCH 900271 10 mg|Participants receive SCH 900271 10 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3061362|NCT00941603|Experimental|SCH 900271 5 mg|Participants receive SCH 900271 5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3061363|NCT00941603|Experimental|SCH 900271 2.5 mg|Participants receive SCH 900271 2.5 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3061364|NCT00941603|Experimental|SCH 900271 1 mg|Participants receive SCH 900271 1 mg tablet and placebo tablet once daily in the morning with water in a fasted state for 8 weeks
3061365|NCT00941603|Placebo Comparator|Placebo|Participants receive two placebo tablets once daily in the morning with water in a fasted state for 8 weeks
3061366|NCT00941655|Experimental|Surgery + HIPEC + Systemic Chemotherapy|"Surgery -gastric resection, metastasectomy, and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes. Leucovorin 20 mg/m^2 IV and Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours."
3061367|NCT00941655|Experimental|Systemic Chemotherapy Alone|Irinotecan 165 mg/m^2 IV over 90 minutes, Oxaliplatin 85 mg/m^2 over 120 minutes, Leucovorin 200 mg/m^2 IV 120 minutes, 5FU 3200 mg/m^2 continuous IV infusion over 48 hours.
3061368|NCT00941668|Active Comparator|Total Toothpaste|Triclosan/Copolymer/fluoride toothpaste
3061369|NCT00941668|Placebo Comparator|Fluoride toothpaste|sodium monofluorophosphate toothpaste
3061370|NCT00941681|Experimental|Cohort 1: MR 50 mg BID|Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days.
3061371|NCT00941681|Experimental|Cohort 2: IR 37.5 mg TID|Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days.
3061372|NCT00941681|Experimental|Cohort 3: MR 100 mg BID|Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days
3061373|NCT00941720|Experimental|Busulfan Treatment|
3061374|NCT00941733|Experimental|Drug Eluting Balloon|Intervention: IN.PACT Amphirion™
3061375|NCT00941733|Active Comparator|Standard PTA|Intervention: Standard PTA
3061376|NCT00941798|Experimental|QMF149 Twisthaler® 500/400|QMF149 Twisthaler® (indacaterol maleate 500 µg/mometasone furoate 400 µg), once daily (QD)
3061377|NCT00941798|Active Comparator|Mometasone Twisthaler®|Mometasone Twisthaler®, 400 µg QD
3061378|NCT00941863|Experimental|Sorafenib 100 mg (50-mg tablet)|Dose-escalation cohort 1: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3061379|NCT00941863|Experimental|Sorafenib 200 mg (50-mg tablet)|Dose-escalation cohort 2: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3061380|NCT00941863|Experimental|Sorafenib 400 mg (50-mg tablet)|Dose-escalation cohort 3: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet). Treatment were planned until primary completion date (PCD).
3061381|NCT00941863|Experimental|Sorafenib 400 mg (200-mg tablet)|Dose-escalation cohort 4: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet). Treatment were planned until primary completion date (PCD).
3061382|NCT00941863|Experimental|Sorafenib 400 mg (Expansion)|Dose-expansion cohort: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion. Treatment were planned until primary completion date (PCD). 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib until 18 Sep 2008.
3061383|NCT00941889|Placebo Comparator|Placebo|Patients who are in the control group received a placebo of saline in the upper extremity at initial visit, 2 months and 6 months after enrollment.
3061384|NCT00941889|Active Comparator|Gardasil|The treatment group received a 0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity at initial visit, and again at two months and six months after enrollment.
3061385|NCT00941993|Experimental|local anesthesia|tympanic membrane local anesthesia delivery system
3061386|NCT00942084|Active Comparator|Protocol V2&up-Grp1-Acyclo10 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age < 14 days Dosage 10 mg/kg IV q12 Number of Infants 8
3061387|NCT00942084|Active Comparator|Protocol V2&up-Grp2_Acyclo20 mg/kg IVq12|Gestational Age 23-29 weeks Postnatal Age 14-44 days Dosage 20 mg/kg IV q12 Number of Infants 8
3061388|NCT00942084|Active Comparator|Protocol V2&up-Grp3-Acyclo20 mg/kg IVq8|Gestational Age 30-34 weeks Postnatal Age <45 days Dosage 20 mg/kg IV q8 Number of Infants 4
3061389|NCT00942084|Other|Protocol V1-Grps1-4-Acyclo 500 mg/m2 IVq8h|All patients in protocol V1 were to be dosed with 500 mg/m2 IV q8h. Protocol V1 Group 1: Gestational Age: 23-29 Weeks; PNA: <14 days; Protocol V1 Group 2: Gestational Age: 30-42 Weeks; PNA: <14 days; Protocol V1 Group 3: Gestational Age: 23-29 Weeks; PNA: 14-60 days; Protocol V1 Group 4: Gestational Age: 30-42 Weeks; PNA: 14-60 days
3061390|NCT00942149|Experimental|Daptomycin cohort|
3061391|NCT00942162|Experimental|GSK2132231A GS+ Group|Patients with the pre-specified gene signature (GS), who received intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
3061392|NCT00942162|Experimental|GSK2132231A GS- Group|Patients without the pre-specified gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE-A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
3061393|NCT00942162|Experimental|GSK2132231A GS-unknown Group|Patients with unknown gene signature (GS), planned to receive intramuscularly up to 24 doses of MAGE_A3 ASCI (the study product), in 4 cycles. Gene-signature sub-grouping was based on patients having a potentially predictive gene signature, as assessed at screening.
3061394|NCT00942175|Other|Regimen A|Clopidogrel 75 mg QD
3061395|NCT00942175|Other|Regimen B|Clopidogrel 75 mg QD and Lansoprazole 30 mg QD
3061396|NCT00942175|Other|Regimen C|Clopidogrel 75 mg QD and Dexlansoprazole 60 mg QD
3061397|NCT00942175|Other|Regimen D|Clopidogrel 75 mg QD and Omeprazole 80 mg QD
3061398|NCT00942175|Other|Regimen E|Clopidogrel 75 mg QD and Esomeprazole 40 mg QD
3061399|NCT00942188|Experimental|0.6 milligrams (mg) LY2189102|
3061400|NCT00942188|Experimental|18 mg LY2189102|
3061401|NCT00942188|Experimental|180 mg LY2189102|
3061402|NCT00942188|Placebo Comparator|Placebo|0.9% Sodium Chloride
3061403|NCT00942266|Experimental|Arm I|Patients receive low-dose oral vorinostat once daily on days 1-3, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV over 46 hours on days 2 and 3. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3061404|NCT00942266|Experimental|Arm II|Patients receive high-dose oral vorinostat once daily on days 1-3 and leucovorin calcium and fluorouracil as in arm I. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3061405|NCT00942305|Placebo Comparator|Placebo|"Cohort 1 = 40 mg of matching placebo administered once weekly (QW)~Cohort 2 = 100 mg of matching placebo administered QW~Cohort 3 = 200 mg of matching placebo administered QW~Cohort 4 = 200 mg of matching placebo administered twice weekly (BIW)~Cohort 4A = 100 mg of matching placebo administered BIW"
3061406|NCT00942305|Experimental|Brincidofovir|"Cohort 1 = 40 mg brincidofovir (BCV) administered once weekly (QW)~Cohort 2 = 100 mg BCV administered QW~Cohort 3 = 200 mg BCV administered QW~Cohort 4 = 200 mg BCV administered twice weekly (BIW)~Cohort 4A = 100 mg BCV administered BIW"
3061407|NCT00942331|Active Comparator|Arm I (gemcitabine hydrochloride, cisplatin, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and cisplatin IV and placebo IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive placebo IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3061408|NCT00942331|Experimental|Arm II (gemcitabine hydrochloride, cisplatin, bevacizumab)|Patients receive gemcitabine hydrochloride and cisplatin as in arm I. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3061409|NCT00942357|Experimental|Arm I (cisplatin, radiation therapy, paclitaxel, carboplatin)|Patients receive cisplatin IV on days 1 and 29. Patients also undergo radiation therapy QD, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3061410|NCT00942357|Active Comparator|Arm II (paclitaxel and carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3061411|NCT00942422|Experimental|defined green tea catechin extract / correlative analysis|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3061412|NCT00942448|Experimental|Diclofenac HPBCD s.c. 25mg/ml|
3061413|NCT00942448|Experimental|Diclofenac HPBCD s.c. 50mg/ml|
3061414|NCT00942448|Active Comparator|Diclofenac HPBCD s.c. 75mg/ml|
3061415|NCT00942448|Placebo Comparator|Placebo s.c. (1ml)|
3061416|NCT00942578|Experimental|Single Arm - 4 Drug Combination|A two dose level escalation of Lenalidomide from 15mg to 20mg to 25mg- standard 3+3 dose escalation approach in combination with docetaxel, Bevacizumab and prednisone.
3061417|NCT00942604|Active Comparator|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
3061418|NCT00942604|Placebo Comparator|Vehicle gel|Vehicle gel once daily for 2 consecutive days
3061419|NCT00942708|Other|Fluoxetine|Fluoxetine will be added starting at 20 mg and titrated as tolerated to 80 mg daily.
3061420|NCT00942734|Experimental|RAD001 + Erlotinib|RAD001 1 tablet (5 mg) by mouth every day of each 28 day study cycle. Erlotinib one tablet (150 mg) by mouth every day of each 28 day study cycle.
3061421|NCT00942786||No treatment|Consecutive patients undergoing emergency surgery
3061422|NCT00942825|Experimental|A CBP501 +Cisplatin + Pemetrexed|CBP501 25 mg/m2 + Cisplatin 75 mg/m2 + Pemetrexed 500mg/m2
3061423|NCT00942825|Active Comparator|B Cisplatin + Pemetrexed|Cisplatin + Pemetrexed
3061424|NCT00942851|Experimental|active|AH-8 containing topical intervention
3061425|NCT00942851|Placebo Comparator|placebo|topical intervention WITHOUT AH-8
3061426|NCT00942877|Experimental|Cediranib (AZD2171) Treatment|"Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~Pediatric participants (<16 years old) will be treated with 12 mg/m^2/day once a day for 28 days (28-day cycles)."
3061427|NCT00942890|Experimental|NMES plus Standard Rehab Protocol|"NMES (EMPI 300PV stimulator) plus standard of care intervention. NMES is to the quadriceps muscle of the residual and intact limb plus rehabilitation. Therapy is 12-wks of NMES home training w/ the EMPI 300PV muscle stimulator. Participants perform training at home for 5days/wk; sessions consisted of 15 to 20 min. of NMES to each leg eliciting15 contractions/leg (10 seconds on:50 seconds off), plus a 5-minute patient treatment log, 5x/wk for 12-wks. Each contraction will be elicited by an electrical impulse generated by a battery-operated device. Two 3 X 5 electrodes are placed over the quadriceps muscle group. Participants will train at 30-40% of MVC during weeks 1-6, and 40-50% of MVC during weeks 7-12; incremental increases will be made at the study visits."
3061428|NCT00942890|Active Comparator|Standard Rehab Protocol|TMARP standard of care intervention: 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1 week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
3061429|NCT00942903|Experimental|Compliant HME users|Laryngectomized patients who are currently compliant (24/7) users of a Provox HME
3061430|NCT00942968|Experimental|1|
3061431|NCT00942994|Experimental|Triple Therapy (Aliskiren/Amlodipine/HCTZ)|At week 0 patients were randomized to aliskiren/amlodipine 150/5 mg. At week 1, patients were force titrated to aliskiren/amlodipine/HCTZ 150/5/12.5 mg. At week 2, patients were force titrated to aliskiren/amlodipine/HCTZ 300/5/25 mg. At week 4, patients were force titrated to aliskiren/amlodipine/HCTZ 300/10/25 mg.
3061432|NCT00942994|Active Comparator|Dual Therapy (Aliskiren/Amlodipine)|At week 0 patients were randomized to amlodipine 5 mg. At week 1, patients were force titrated to aliskiren/amlodipine 150/5 mg. At week 2, patients were force titrated to aliskiren/amlodipine 300/5 mg. At week 4, patients were force titrated to aliskiren/amlodipine 300/10 mg.
3061433|NCT00943072|Experimental|VEGF Trap-Eye|Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
3061434|NCT00943072|Sham Comparator|Sham|Monthly Sham IVT injection until Week 24 Primary Endpoint
3061435|NCT00943098|Experimental|Diclofenac HPBCD s.c. 75mg/ml|
3061436|NCT00943098|Active Comparator|Voltarol 75mg/3ml i.m.|
3061437|NCT00943111|Experimental|Investigational|Eliglustat tartrate
3061438|NCT00943111|Active Comparator|Imiglucerase|
3061439|NCT00943124|Experimental|MK0524B then Simvastatin + MK0524A|"Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).~Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets."
3061440|NCT00943124|Experimental|Simvastatin + MK0524A then MK0524B|"Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.~Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg)."
3061441|NCT00943150|Experimental|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
3061442|NCT00943150|Active Comparator|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
3061443|NCT00943202|Experimental|Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine; Day 42: TIV.
3061444|NCT00943202|Experimental|Group 2: Day 0-H1N1+TIV; Day 21-H1N1|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine + TIV; Day 21: 15 mcg H1N1 vaccine.
3061445|NCT00943202|Experimental|Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1|150 subjects to receive-Day 0: TIV; Day 21: 15 mcg H1N1 vaccine; Day 42: 15 mcg H1N1 vaccine.
3061446|NCT00943202|Experimental|Group 3: Day 0-H1N1; Day 21-H1N1+TIV|150 subjects to receive-Day 0: 15 mcg H1N1 vaccine; Day 21: 15 mcg H1N1 vaccine + TIV.
3061447|NCT00943306|Experimental|lomitapide|Maximum tolerated dose of lomitapide in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
3061448|NCT00943319|Experimental|Busulfan and fludarabine|Intravenous busulfan (Busulfan®) in combination with fludarabine
3061449|NCT00943384|Experimental|chronOS Strip|This is a single arm, outcome study for treatment of patients with degenerative disc disease (DDD), with or without stenosis, with interbody fusion, posterolateral pedicle screw system, and the study device (chronOS Strip).
3061450|NCT00943397|Experimental|1|Montelukast
3061451|NCT00943397|Active Comparator|2|Usual Care
3061452|NCT00943436|Active Comparator|Active males|Males who participate in at least 30 minutes of physical activity on 5 or more days per week for the last month.
3061453|NCT00943436|Active Comparator|Inactive males|Males who participate in less than 1 hour of physical activity per week for the last month.
3061454|NCT00943488|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
3061455|NCT00943488|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
3061456|NCT00943579|Experimental|Kuvan®|Kuvan® (sapropterin) will be administered to all subjects at 20 mg/kg/day for 16 weeks.
3061457|NCT00943592|Experimental|Treatment|
3061461|NCT00943631|Experimental|Group 2: H1N1 Vaccine 30 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 30 mcg of H1N1 vaccine on Days 0 and 21.
3061462|NCT00943631|Experimental|Group 1: H1N1 Vaccine 15 mcg|200 subjects (100 subjects ages 18-64 and 100 subjects greater than or equal to age 65) to receive 15 mcg of H1N1 vaccine on Days 0 and 21.
3061463|NCT00943670|Experimental|T-DM1 / T-DM1 + pertuzumab|"Trastuzumab emtansine (T-DM1) was administered to participants by intravenous (IV) infusion on Day 1 of every 3 week cycle at a dose of 3.6 mg/kg.~From Cycle 4, participants with early progressive disease (demonstrated prior to the end of Cycle 6) could receive combined pertuzumab and trastuzumab emtansine. Pertuzumab was administered after trastuzumab emtansine by IV infusion at a loading dose of 840 mg on Day 1, starting at the cycle after tumor progression was determined, followed by 420 mg IV infusion every 3 weeks in subsequent cycles.~Participants who met criteria for ongoing clinical benefit were allowed to continue study treatment in the absence of disease progression or unacceptable toxicity for up to 1 year."
3061464|NCT00943683|Experimental|1|Montelukast
3061465|NCT00943683|Placebo Comparator|2|Placebo
3061466|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3061467|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 2)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 2.
3061468|NCT00943722|Experimental|9- to 15-Year-Old Females (Lot 3)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 3.
3061469|NCT00943722|Experimental|9- to 15-Year-Old Males (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3061470|NCT00943722|Experimental|16- to 26-Year-Old Females (Lot 1)|9-valent human papillomavirus (9vHPV) L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lot 1.
3061471|NCT00943735||Fesoterodine arm|subjects who present with OAB symptoms during medical office visits and who appear to be candidates for fesoterodine therapy
3061472|NCT00943761|Experimental|Vaniprevir 300 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 300 mg twice daily (b.i.d.) in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
3061473|NCT00943761|Experimental|Vaniprevir 600 mg b.i.d. + peg-IFN + RBV|Participants received vaniprevir 600 mg b.i.d. in combination peg-IFN 180 mcg weekly and ribavirin (1000 or 1200 mg) administered as a divided dose twice daily.
3061474|NCT00943787|Other|SMBG followed by clamp|One month of self-monitored blood glucose (SMBG) field data was used to calculate measures of glucose variability and risk of hypoglycemia, while the hyperinsulinemic, euglycemic and hypoglycemic clamp procedure was used to evaluate insulin sensitivity and epinephrine response during induced hypoglycemia.
3061475|NCT00943800|Experimental|Good Risks patients|For patients transplanted in remission.
3061476|NCT00943800|Experimental|High Risk Patients eligible for radiation|
3061477|NCT00943800|Experimental|High Risk Patients not eligible for radiation|
3061478|NCT00943826|Experimental|Bevacizumab + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy (RT) in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and bevacizumab 10 mg/kg IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they receive six 28-day cycle of bevacizumab 10 mg/kg IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive bevacizumab 15 mg/kg IV q3w until disease progression/unacceptable toxicity.
3061479|NCT00943826|Placebo Comparator|Placebo + RT + Temozolomide|In the Concurrent Phase participants will receive radiotherapy in daily fractions of 2 Gy to be given 5 days per week for 6 weeks and temozolomide 75 mg/m^2 daily from the first day to the last day of radiotherapy (it may continue for a maximum of 49 days in case of delay to the end of radiation therapy) and placebo IV every 2 weeks for 6 weeks. There will be a 4 week treatment break. Participants will then enter the Maintenance Phase where they will receive six 28-day cycle of placebo IV q2w and temozolomide 150 to 200 mg/m^2 daily in the first 5 days of each cycle. The participants will then enter the Monotherapy Phase where they will receive placebo IV q3w until disease progression/unacceptable toxicity.
3061480|NCT00943852|Active Comparator|1|losartan 100 mg
3061481|NCT00943852|Active Comparator|2|ISMN 60 mg
3061482|NCT00943852|Active Comparator|3|losartan 100 mg + ISMN 15 mg
3061483|NCT00943852|Active Comparator|4|losartan 100 mg + ISMN 60 mg
3061484|NCT00943852|Placebo Comparator|5|Placebo
3061485|NCT00943878|Experimental|Group 3: H1N1+placebo; H1N1+TIV; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); and Day 42, placebo.
3061486|NCT00943878|Experimental|Group 1: H1N1+placebo; H1N1+placebo; TIV|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, trivalent influenza vaccine (TIV).
3061487|NCT00943878|Experimental|Group 2: H1N1+TIV; H1N1+placebo; placebo|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, 15 mcg H1N1 Vaccine + trivalent influenza vaccine (TIV); Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, placebo.
3061488|NCT00943878|Experimental|Group 4: TIV+placebo; H1N1+placebo; H1N1|200 subjects (100 ages 18-64 years and 100 aged greater than or equal to 65 years) to receive: Day 0, trivalent influenza vaccine (TIV) + placebo; Day 21, 15 mcg H1N1 Vaccine + placebo; and Day 42, 15 mcg H1N1 vaccine.
3061489|NCT00943904|Experimental|Interstim stimulation|Patients who receive the interstim implant in order to evaluate effectiveness of treatment
3061490|NCT00943917|Experimental|ITCA 650 20 mcg/day|
3061491|NCT00943917|Experimental|ITCA 650 40 mcg/day|
3061492|NCT00943917|Active Comparator|Exenatide Injection|
3061493|NCT00943917|Experimental|ITCA 650 20/20|
3061494|NCT00943917|Experimental|ITCA 650 20/60|
3061495|NCT00943917|Experimental|ITCA 650 40/40|
3061496|NCT00943917|Experimental|ITCA 650 40/80|
3061497|NCT00943917|Experimental|Ex Inj/ITCA 650 40|
3061498|NCT00943917|Experimental|Ex Inj/ITCA 650 60|
3061499|NCT00944021|Experimental|PA-824 50 mg/qd|
3061500|NCT00944021|Experimental|PA-824 100mg/qd|
3061501|NCT00944021|Experimental|PA-824 150mg/qd|
3061502|NCT00944021|Experimental|PA-824 200mg/qd|
3061503|NCT00944021|Active Comparator|Rifafour e-275mg|
3061504|NCT00944034|Experimental|B+R246_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
3061505|NCT00944034|Experimental|B+R246_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
3061506|NCT00944034|Experimental|B+R246_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
3061507|NCT00944034|Experimental|B246_12|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age.
3061508|NCT00944034|Experimental|B246_18|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age.
3061509|NCT00944034|Experimental|B246_24|Previously received 3 doses of rMenB+OMV NZ vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 24 months of age.
3061510|NCT00944034|Experimental|B+R234_12|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ at 12 months of age.
3061511|NCT00944034|Experimental|B+R234_18|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age.
3061512|NCT00944034|Experimental|B+R234_24|Previously received rMenB+OMV NZ vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age.
3061513|NCT00944034|Experimental|B12 14|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 12 and14 months of age.
3061514|NCT00944034|Experimental|B18 20|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 18 and 20 months of age.
3061515|NCT00944034|Experimental|B24 26|Previously received two catch-up doses of rMenB+OMV NZ vaccine at 24 and 26 months of age.
3061516|NCT00944047|Experimental|Intervention Arm|Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
3061517|NCT00944073|Experimental|Group 2: 30 mcg H1N1 Vaccine|300 subjects to receive 30 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
3179138|NCT00669695|Active Comparator|Placebo/sham CPAP|Placebo and sham CPAP treatments
3061518|NCT00944073|Experimental|Group 1: 15 mcg H1N1 Vaccine|300 subjects to receive 15 mcg of Inactivated H1N1 Vaccine on Day 0 and Day 21.
3061519|NCT00944125|Active Comparator|Dual Site LV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
3061520|NCT00944125|Active Comparator|BiV Pacing|Prospective randomized blinded crossover study of patients meeting current CRT-D indication implanted with Dual LV pacing leads compared to BiV pacing.
3061521|NCT00944450|Active Comparator|1|Sitagliptin anhydrous formulation
3061522|NCT00944450|Active Comparator|2|Sitagliptin monohydrate FMI formulation
3061523|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 1|A single 15 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3061524|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 2|A single 18 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3061525|NCT00944528|Experimental|Single dose radiosurgery: Dose Level 3|A single 21 Gy dose of radiation given in radiosurgery technique about 10 days before lumpectomy.
3061526|NCT00944554|Placebo Comparator|Placebo|Group given placebo.
3061527|NCT00944554|Experimental|Varenicline|Experimental group given varenicline dosing.
3061528|NCT00944645|Active Comparator|A|MK0524A Source 1 (Phase III manufacturing site)
3061529|NCT00944645|Active Comparator|B|MK0524A Source 2 (commercial manufacturing site)
3061530|NCT00944658|Placebo Comparator|Placebo|placebo twice a day for 12 weeks, 4 weeks follow up
3061531|NCT00944658|Active Comparator|Apremilast|30 mg twice a day for 12 weeks, 4 weeks follow up
3061532|NCT00944671|Active Comparator|A|Famotidine/antacid combination tablet with water
3061533|NCT00944671|Experimental|B|Famotidine/Antacid EZ Chew tablet without water
3061534|NCT00944671|Experimental|C|Famotidine/Antacid EZ Chew tablet with water
3061535|NCT00944697|Placebo Comparator|Tablets|A placebo tablet to match the active reference treatment
3061536|NCT00944697|Active Comparator|Tablet|Oxycodone Naloxone tablets
3061537|NCT00944710|Active Comparator|Intensified treatment|Weekend atropine 1% with plano lens over the sound eye
3061538|NCT00944710|Active Comparator|Control|Weekend atropine 1%
3061539|NCT00944749|Experimental|Single Arm|
3061540|NCT00945009|Experimental|Arm 1 (Bilateral Wilms Tumors)|Patients start with three drug chemotherapy (Regimen VAD; vincristine, dactinomycin and doxorubicin) and are evaluated and six and 12 weeks for feasibility of undergoing a partial nephrectomy/renal sparing surgery. At week 12 definitive surgery takes place followed by chemotherapy and radiation therapy based on histology and stage. Treatment continues for 25 or 31 weeks depending on histology. Patients are followed for up to 10 years following end of therapy.
3061541|NCT00945009|Experimental|Arm 2 (Unilateral High Risk tumors bilaterally predisposed)|Patients start with either 2 drug or three drug chemotherapy (Regimen VA, VAD) and are evaluated a 6 and 12 weeks for feasibility of undergoing a partial nephrectomy. At week 12 definitive surgery takes place followed by chemotherapy.
3061542|NCT00945009|Experimental|Arm 3 (DHPLN)|Patients with this rare disease are diagnosed based on cross-sectional imaging characteristics and undergo 2 drug chemotherapy (Regimen;VA). Patients are reassessed at 6 weeks and 12 weeks. If disease has responded or stayed stable chemotherapy is completed for 19 weeks (Regimen EE4A). If disease has progress a biopsy is performed to assess histology and adjust therapy based on the biopsy. This therapy may include, nephrectomy, chemotherapy or radiation therapy.
3061543|NCT00945035|Active Comparator|A|Etoricoxib, 20% tablet
3061544|NCT00945035|Active Comparator|B|Etoricoxib, 30% tablet
3061545|NCT00945061|Experimental|Intraoperative radiation therapy|Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.
3061546|NCT00945061|Experimental|Intracavitary balloon brachytherapy|Patients undergo partial breast irradiation delivered as MammoSite® brachytherapy consisting of 10 fractions over 5 days.
3061547|NCT00945100|Active Comparator|Control|2 hours daily patching
3061548|NCT00945100|Active Comparator|Intensified treatment|42 hours per week of patching (averaging 6 hours daily)
3061549|NCT00945139|Experimental|Single Arm: Doxil and Avastin|Patients receive both agents, doxil and Avastin.
3061550|NCT00945191|Experimental|CS-1008 with paclitaxel and carboplatin|CS-1008 will be administered with paclitaxel and carboplatin.
3061551|NCT00945243|Other|Treatment|Treatment of cervical DDD with the Zero-P device
3061552|NCT00945256|Active Comparator|Young Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
3061553|NCT00945256|Active Comparator|Elderly Aerobic Exercise|45 minutes of treadmill walking at 40% VO2 peak
3061554|NCT00945256|Active Comparator|Young Sodium Nitroprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
3061555|NCT00945256|Active Comparator|Elderly Sodium Nitoprusside|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
3061556|NCT00945256|Active Comparator|Elderly Sodium Nitroprusside and Amino Acid Drink|Sodium Nitroprusside given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min and 7.5g amino acid drink taken orally
3061557|NCT00945282|Experimental|Cohort 1|In Cohort 1 subjects will receive either GSK2248761 30 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART.
3061558|NCT00945282|Experimental|Cohort 2|In Cohort 2 subjects will receive either GSK2248761 in the range of 10 mg - 20 mg or 40 mg - 90 mg or placebo once a day for 7 days. On Day 8 subjects will receive either Kaletra or HAART for 28 days. The doctor will choose the most appropriate medications for HAART. The dose for Cohort 2 will be determined following evaluation of results from Cohort 1. Cohort 2 may not be done.
3061559|NCT00945295|Active Comparator|Cohort #1|Cohort 1 will receive BoNT-A plus rehabilitation therapy for the duration of the study (for up to 2 injections of BoNT-A).
3061560|NCT00945295|Active Comparator|Cohort #2|Cohort 2 will receive BoNT-A alone
3061561|NCT00945321|Active Comparator|1|aprepitant 165 mg
3061562|NCT00945321|Active Comparator|2|aprepitant 185 mg
3061563|NCT00945321|Experimental|3|fosaprepitant 150 mg
3061564|NCT00945321|Experimental|4|aprepitant with food
3061565|NCT00945334|Experimental|Group 1|Group 1 will receive neomycin (500 mg po bid) and placebo (tid) for 14 days
3061566|NCT00945334|Experimental|Group 2|Group 2 will receive neomycin (500 mg po bid) and rifaximin (550mg po tid) for 14 days
3061567|NCT00945477|Experimental|Advanced prostate cancer, treatment, pazopanib|Pazopanib
3061568|NCT00945555||All participants|Participants with febrile neutropenia who received antibacterial treatment per investigator's judgment
3061569|NCT00945594|Experimental|Flexible cystoscopy|16F flexible cysto urethroscope (Storz, Culver city, CA)
3061570|NCT00945594|Experimental|Rigid cystoscopy|17F, 70° scope (Storz, Culver city, CA)
3061571|NCT00945659|Active Comparator|Standard Care|"Standard Care constitutes intensified diabetes management, an enrollment criterion for the study, consisting of either continuous subcutaneous insulin infusion (insulin pump) or multiple daily injections using a basal-bolus approach. All patients must be using carbohydrate counting and have prescribed correction factors for targeted insulin bolus dose adjustments."
3061572|NCT00945659|Active Comparator|Continuous Glucose Sensor|Patients will have the same diabetes management regimen as those in the Standard Care group. In addition they will be given a continuous glucose sensor, receive expert instruction in its use, and be guided by a physician and diabetes educator in achieving glycemic benefits through retrospective and real-time interpretation of CGS results and by learning to respond judiciously to the various CGS alarms.
3061573|NCT00945659|Experimental|CGS + Behavior Therapy|Patients in the use group will receive the same medical management as the Continuous Glucose Sensor group above. In addition, they will have 6 scheduled encounters with a behavior therapist that are designed to reduce or eliminate typical behavioral and/or psychological barriers to optimal use of CGS as part of diabetes care.
3061574|NCT00945750|Experimental|Sequence 1: FCT with water → CT without water → CT with water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
3061575|NCT00945750|Experimental|Sequence 2: CT without water → CT with water → FCT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
3061576|NCT00945750|Experimental|Sequence 3: CT with water → FCT with water → CT without water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
3061577|NCT00945750|Experimental|Sequence 4: FCT with water → CT with water → CT without water|Participants received famotidine 20 mg FCT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 3).
3061578|NCT00945750|Experimental|Sequence 5: CT without water → FCT with water → CT with water|Participants received famotidine 20 mg CT as a single dose without water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose with 120 mL of water (Period 3).
3061579|NCT00945750|Experimental|Sequence 6: CT with water → CT without water → FCT with water|Participants received famotidine 20 mg CT as a single dose with 120 mL of water (Period 1), followed by a 5- to 7-day washout, followed by famotidine 20 mg CT as a single dose without water (Period 2), followed by a 5- to 7-day washout, followed by famotidine 20 mg FCT as a single dose with 120 mL of water (Period 3).
3061580|NCT00945815|Experimental|treatment|AraC 1 g/m2/d IV Days 1-5 clofarabine 40 mg/m2/d IV Days 2-6 epratuzumab 360 mg/m2/d IV Days 7, 14, 21, 28 acetaminophen 650 mg/d PO Days 7, 14, 21, 28 diphenhydramine 50 mg/d IV Days 7, 14, 21, 28 IT methotrexate 12 mg IT at least 1 wk apart during induction All give 1 cycle
3061581|NCT00945854|Active Comparator|Wholegrain cereal diet|Treatment with a diet based on wholegrain cereals and foods with low glycemic index
3061582|NCT00945854|Active Comparator|Refined cereal diet|Treatment with a diet based on refined cereals and foods with high glycemic index
3061583|NCT00945893|Experimental|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414 - Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 fluorescent focus units (FFU) of live, attenuated influenza virus reassortant A/California/7/2009 strain that was propagated in chicken eggs. H1N1 monovalent influenza vaccine (MEDI3414) contained no preservatives and no adjuvants.
3061584|NCT00945893|Placebo Comparator|Placebo|Placebo -Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
3061585|NCT00945906|Experimental|FXIII|Subjects were administered FXIII Concentrate (Human) by intravenous (IV) infusion approximately every 28 days to maintain a trough FXIII level of approximately 5 to 20%.
3061586|NCT00945945|Experimental|DLX30-PLA|Per the protocol, patients randomized to the duloxetine group were to receive duloxetine for the entire 13-week acute treatment period. Patients were to start at a 30 mg daily (QD) dose of duloxetine for 1 week, then increase to 60 mg QD of duloxetine for the following 12 weeks. However, due to a study drug labeling error, patients randomized to this group received 30 mg of duloxetine for the initial 1-week, but received placebo instead of receiving 60 mg QD of duloxetine for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as DLX30-PLA throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive 30 mg QD of duloxetine during that week, and that did occur per protocol.
3179139|NCT00669708|Active Comparator|1|ph5 Eucerin Lotion with cooling compound
3179140|NCT00669708|Placebo Comparator|2|ph5 Eucerin Lotion
3179141|NCT00669721|Experimental|A|This patients start a run in period with LMWH schedule as hemodialysis circuit anticoagulation. Then they'll undergo hemodialysis with LMWH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to UFH schedule. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
3061587|NCT00945945|Placebo Comparator|PLA-DLX60|Per the protocol, patients randomized to the placebo group were to receive placebo for the entire 13-week acute treatment period. Patients were to start on placebo for the first week, then continue on placebo for the following 12 weeks. However, due to a study drug labeling error, patients in this group received placebo for the initial 1-week, but received 60 mg QD of duloxetine instead of receiving placebo for the next 12 weeks. The resulting unintended, mixed treatment group was labeled as PLA-DLX60 throughout this document. Per protocol, the last week of the study (week 14) was intended to be a 1-week taper period. Patients in this treatment group were to receive placebo that week, and that did occur per protocol.
3061588|NCT00945958|Experimental|SPARC0913|
3061589|NCT00946023|Experimental|Transplant|Non-myeloablative allogeneic bone marrow transplant (BMT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD (graft vs host disease) prophylaxis. Rituximab will be given as post-transplant maintenance.
3061590|NCT00946088|Active Comparator|Progesterone|Progesterone 400mg per vagina qhs.
3061591|NCT00946088|Placebo Comparator|Polyethylene glycol&hydrogenated vegetable oil|Polyethylene glycol&hydrogenated vegetable oil per vagina
3061592|NCT00946101|Active Comparator|MEDI3414 [Influenza A (H1N1) vaccine]|MEDI3414- Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of influenza virus type A/California/07/2009.
3061593|NCT00946101|Placebo Comparator|Placebo|Placebo - Placebo was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer
3061594|NCT00946153|Experimental|Lenvatinib|
3061595|NCT00946192|Experimental|Estrogen Patch|17Beta-estradiol transdermal patch twice weekly application for 12 months
3061596|NCT00946192|Active Comparator|Estrogen Pill|One pill containing estrogen and progesterone taken daily for 21 days followed by placebo pills only for 7 days; regimen repeated for 12 months.
3061597|NCT00946192|Sham Comparator|Control|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
3061598|NCT00946270|Experimental|Group 3 CC-4047 + Prednisone|CC-4047 0.5 mg orally daily starting on day 1 through 28. Prednisone given during first 3 cycles of therapy. It will be dosed orally at the dose of 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
3061599|NCT00946270|Experimental|Group 1 CC-4047|CC-4047 3.0 mg orally daily starting on day 1 through 21.
3061600|NCT00946270|Experimental|Group 2 CC-4047|CC-4047 0.5 mg orally daily starting on day 1 through 28.
3061601|NCT00946296|Active Comparator|Potassium Iodide|8 drops of Potassium Iodide in a glass of water, by mouth, daily for 7 days prior to operation.
3061602|NCT00946296|No Intervention|No Treatment|The experimental group receives no treatment.
3061603|NCT00946309|Experimental|High Sulforaphane Extract|
3061604|NCT00946309|Placebo Comparator|Placebo|
3061605|NCT00946322|Experimental|Arm 1: CTAP|Couple-Based Treatment for Alcohol Use Disorders and PTSD
3061606|NCT00946348|Experimental|Dronabinol|Dronabinol 10mg or 15 mg
3061607|NCT00946348|Active Comparator|Cannabis|Cannabis cigarette
3061608|NCT00946478|Active Comparator|Pimecrolimus|
3061609|NCT00946478|Sham Comparator|Vehicle cream|
3061610|NCT00946530|Experimental|Bright Light|received bright light
3061611|NCT00946530|Placebo Comparator|Control|received regular light
3061612|NCT00946647|Experimental|Panobinostat + 5-Azacytidine|"In phase I: Panobinostat : Escalating doses starting with 20 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In phase II: Panobinostat : Rapid Phase II doses at 30 mg delivered orally at Day 3, Day 5, Day 8, Day 10, Day 12, Day 15.~In both phases, dose of 5-Azacytidine was 75 mg/m^2, subcutaneously Daily for Day 1 to Day 7."
3061613|NCT00946647|Active Comparator|5-Azacytidine|"The dose of 5-Aza was fixed at 75 mg/m2/day for 7 days in Week 1 of each cycle. 5-Aza was sourced locally, except in 4 countries (Hungary, Switzerland, UK, and Spain, for which a central purchase was used by Novartis.~Dose of 5-Azacytidine : 75 mg/m^2 subcutaneously daily from Day 1 to Day 7."
3061614|NCT00946712|Experimental|Arm I (chemo +/- bevacizumab)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes with or without bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients receiving bevacizumab may continue to receive bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
3061615|NCT00946712|Experimental|Arm II (chemo, cetuximab, +/- bevacizumab)|Patients receive paclitaxel and carboplatin with or without bevacizumab as in Arm I. Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients may continue to receive cetuximab with or without bevacizumab (as above) in the absence of disease progression or unacceptable toxicity.
3061616|NCT00946881|Experimental|WST11 (TOOKAD® Soluble)|WST11-mediated-VTP The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers using 753 nm laser light at escalating fixed energy doses
3061617|NCT00946920|Experimental|Degarelix 240 mg/480 mg|
3061618|NCT00946920|Active Comparator|Goserelin acetate|
3061619|NCT00946998|Active Comparator|Sertraline|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
3061620|NCT00946998|Placebo Comparator|Placebo|Patients with predialysis Chronic Kidney Disease stages 3-5 and with major depressive episode
3061621|NCT00947115|Experimental|Cervarix 15-25 years group|Women, aged 15 to 25 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
3061622|NCT00947115|Experimental|Cervarix 26-45 years group|Women, aged 26 to 45 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
3061623|NCT00947115|Experimental|Cervarix 46-55 years group|Women, aged 46 to 55 at the time of primary vaccination, who were vaccinated with Cervarix intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule in the primary study HPV-014 (NCT00196937).
3061624|NCT00947154|Experimental|Open-label aripiprazol|Aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
3061625|NCT00947167|Experimental|Pertuzumab and Erlotinib|
3061626|NCT00947193|Experimental|Ataluren Overall Study|Ataluren was provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren was taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren was 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening or 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days, followed by an interval of 14 days without treatment.
3061627|NCT00947219|Active Comparator|HairMax LaserComb 2009, 12 Beam|Low Level Laser Medical Device 2009 with 12 laser beams
3061628|NCT00947219|Active Comparator|HairMax LaserComb 2009 9 Beam|Low Level Laser Mecial Device 2009 with 9 laser beams
3061629|NCT00947219|Active Comparator|Control device|The control device appears identical to the active device, but utilizes 9 LED lights instead of laser lights. The randomized devices are blinded to the study investigator and distributed in a blinded manner to the participants.
3061630|NCT00947271|Experimental|DVD 1 plus assessment 1|Participants will view educational DVD 1 and complete the first version of the study assessment.
3061631|NCT00947271|Experimental|DVD 1 plus assessment 2|Participants will view educational DVD 1 and complete the second version of the study assessment.
3061632|NCT00947271|Experimental|DVD 2 plus assessment 1|Participants will view educational DVD 2 and complete the first version of the study assessment.
3061633|NCT00947271|Experimental|DVD 2 plus assessment 2|Participants will view educational DVD 2 and complete the second version of the study assessment.
3061634|NCT00947297|Experimental|HPN-100|Patients who were treated with HPN-100
3061635|NCT00947310|Experimental|A|Standard ICD Programming
3061636|NCT00947310|Experimental|B|High rate cutoff
3061637|NCT00947310|Experimental|C|Long ICD duration delay
3061638|NCT00947349|Experimental|BI 201335 NA low TN|patient to receive a capsule containing low dose of BI 201335 NA/Drug for treatment-naive (TN) patients
3061639|NCT00947349|Experimental|BI 201335 NA high TN|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-naive (TN )patients
3061640|NCT00947349|Experimental|BI 201335 NA high TE|patient to receive a capsule containing high dose of BI 201335 NA/Drug for treatment-experienced (TE) patients
3061641|NCT00947349|Placebo Comparator|Placebo in Treatment Naive (TN) Patients|
3061642|NCT00947427|Placebo Comparator|Placebo|Placebo solution given by subcutaneous injection on monthly basis for 12 months
3061643|NCT00947427|Experimental|Canakinumab|Subcutaneous injection of canakinumab at dose of 2.0 mg/kg given monthly of 12 months
3061644|NCT00947505|Active Comparator|HairMax LaserComb 2009, 7 Beam|Lower level laser phototherapy medical device with 7 laser beams
3061645|NCT00947505|Active Comparator|Control Device|Identical to the Active device, but with 7 LED's instead of lasers
3061646|NCT00947518|Experimental|Chlorhexidine skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
3061647|NCT00947518|Placebo Comparator|Saline skin cleansing|Wiping the skin (except the face) once immediately after birth using baby wipes containing normal saline
3061648|NCT00947518|No Intervention|No skin cleansing|No skin application
3061649|NCT00947531|Experimental|Cerebrolysin|
3061650|NCT00947531|Placebo Comparator|0.9% Saline Solution|
3061651|NCT00947544|Experimental|HPN-100 and NaPBA|1 week of NaPBA treatment followed by 1 week of HPN-100 treatment.
3061652|NCT00947661|Experimental|SPARC0912|Test drug
3061653|NCT00947661|Experimental|Reference0912|Reference drug
3061654|NCT00947752|Active Comparator|F1 Glatiramer acetate 20mg/1.0ml|
3061655|NCT00947752|Experimental|F2 Glatiramer acetate 20mg/0.5ml|
3061656|NCT00947765|Experimental|Autologous blood injection group|This is the study group in whom autologous blood injection was injected at lateral epicondylitis site.
3061657|NCT00947765|Active Comparator|Local corticosteroid injection group|This is the control group in whom the commonly used treatment modality-local corticosteroid injection was given at lateral epicondyle site.
3061658|NCT00947856|Experimental|BV Retreatment|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (retreatment after relapse)
3061659|NCT00947856|Experimental|BV Extension|Brentuximab vedotin 1.2 or 1.8 mg/kg every 3 weeks by IV infusion (continued treatment)
3061660|NCT00947882|Placebo Comparator|Placebo|
3061661|NCT00947882|Experimental|Degarelix 10 mg|
3061662|NCT00947882|Experimental|Degarelix 20 mg|
3061663|NCT00947882|Experimental|Degarelix 30 mg|
3061664|NCT00948025|Active Comparator|Avance Nerve Graft|Commercially available Avance Nerve Graft for repair of nerve gap
3061665|NCT00948025|Active Comparator|Hollow Tube Conduit|Commercially available hollow tube conduit for repair of nerve gap.
3061666|NCT00948064|Experimental|Vorinostat with Azacitidine|ARM A: Azacitidine 75 mg/m^2/day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Vorinostat 200 mg by mouth three time a day with food for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
3061667|NCT00948064|Experimental|Azacitidine|ARM B: Azacitidine 75 mg/m^2 /day by vein over 15 - 30 minutes daily for 5 days (Days 1 - 5). Courses repeated every 3 to 8 weeks.
3061668|NCT00948090|Experimental|IV Busulfan|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
3061669|NCT00948155|Experimental|Varenicline before placebo|"Drug (Varenicline (Chantix)): Placebo~Intervention to be administered is: participants will receive standard dosing regimen of Varenicline for 21 days total, followed by 14-day washout and 21 days of placebo. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21."
3061670|NCT00948155|Experimental|Placebo then Varenicline|"Placebo: Drug Varenicline (Chantix)~Intervention to be administered is: participants will receive 21 days of placebo, followed by 14-day washout and standard dosing regimen of Varenicline for 21 days total. Standard dosing: 0.5 mg days 1-3; 0.5 mg bid days 4-7; 1.0 mg bid days 8-21.~Intervention 'Drug (Varenicline (Chantix)): Placebo'"
3061671|NCT00948246||Easyband|Subjects who had the Easyband device implanted laparoscopically.
3061672|NCT00948298|Placebo Comparator|Placebo|
3061673|NCT00948298|Experimental|Vitamin D|
3061674|NCT00948389|Active Comparator|Dasatinib|
3061675|NCT00948389|Active Comparator|Lomustine|
3061676|NCT00948428|Active Comparator|Generic Imiquimod|imiquimod cream, 5%
3061677|NCT00948428|Active Comparator|Aldara™|Aldara™ (imiquimod) cream, 5%
3061678|NCT00948428|Placebo Comparator|Vehicle cream|Vehicle cream (Actavis)
3061679|NCT00948441|Experimental|Group 1|25% ethanol for 12 weeks; wash out period for 4 weeks; heparin lock for 12 weeks
3061680|NCT00948441|Experimental|Group 2|heparin lock for 12 weeks; wash out period for 4 weeks; 25% ethanol lock for 12 weeks
3061681|NCT00948506|Placebo Comparator|1% topical cidofovir|1% topical cidofovir to one side of the face and placebo to the other side of the face
3061682|NCT00948506|Placebo Comparator|3% topical cidofovir|3% topical cidofovir to one side of the face and placebo to the other side of the face
3061683|NCT00948610|Placebo Comparator|Placebo|Placebo-participant will receive placebo saline solution via IV route.
3061684|NCT00948610|Active Comparator|Remicade|Remicade-Participant will be given 10 mg/kg of drug via IV route.
3061685|NCT00948675|Experimental|Pemetrexed + Carboplatin + Pemetrexed|Pemetrexed and Carboplatin followed by Pemetrexed
3061686|NCT00948675|Active Comparator|Paclitaxel + Carboplatin + Bevacizumab|Paclitaxel, Carboplatin, and Bevacizumab followed by Bevacizumab
3061687|NCT00948688|Experimental|Vorinostat, 5-FU, Radiation Therapy|Vorinostat at varying doses; orally, days 1-7, weeks 1-6 5-FU 225 mg/m2/day; intravenous; days 1-5, weeks 1-6 until completion of radiation therapy; Radiation therapy; 180cGy daily Monday-Friday; 28 days of treatment (6 weeks)
3061688|NCT00948766|Experimental|Rivastigmine 13.3 mg/24 h transdermal patch|In the core study, patients were titrated to the rivastigmine 13.3 mg/24 h dose in 2 steps. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-8, patients received rivastigmine 9.5 mg/24 h and placebo. For Weeks 9-24, patients received rivastigmine 13.3 mg/24 h and placebo. In the extension study, all patients were switched to rivastigmine 9.5 mg/24 h for a 4-week titration period and were then titrated up to 13.3 mg/24 h for a further 20 weeks of treatment.
3061689|NCT00948766|Active Comparator|Rivastigmine 4.6 mg/24 h transdermal patch|In the core study, patients received rivastigmine 4.6 mg/24 h daily. For Weeks 1-4, patients received rivastigmine 4.6 mg/24 h. For Weeks 5-24, patients received rivastigmine 4.6 mg/24 h and placebo. No patients received this treatment in the extension study.
3061690|NCT00948792|Active Comparator|Long transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of two hours.
3061691|NCT00948792|Experimental|Short transfusion group|This group of thrombocytopenic neonates who (as determined by the attending physician) are in need of a platelet transfusion will receive the transfusion over a period of 30 minutes.
3061692|NCT00948818|Experimental|Linaclotide|Linaclotide 290 micrograms
3061693|NCT00948818|Placebo Comparator|Placebo|Matching placebo
3061694|NCT00948857|Experimental|DHEA active treatment|Dehydroepiandrosterone 25 mg tid po
3061695|NCT00948857|Placebo Comparator|DHEA Placebo|Blinded placebo
3061696|NCT00948896|Experimental|1|
3061697|NCT00948896|Experimental|2|
3061698|NCT00948896|Experimental|3|
3061699|NCT00948896|No Intervention|4|
3061700|NCT00948922|Other|A: Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.
3061701|NCT00948922|Other|B: Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.
3061702|NCT00948922|Other|BE: Group B Expansion|Group B Expansion on Bortezomib Maintenance: Autologous Only.
3061703|NCT00948935|Experimental|Chemotherapy|Gemcitabine (Days 1, 8), irinotecan (days 1, 8) and panitumumab (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
3061704|NCT00948974|Active Comparator|cognitive therapy|cognitive therapy and exposure
3061705|NCT00948974|Active Comparator|acceptance and committment therapy|acceptance and commitment therapy and exposure
3061706|NCT00949078|Experimental|Open Label Omalizumab Group A|Omalizumab was dosed according to package insert. Patients who have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
3061707|NCT00949078|Experimental|Open Label Omalizumab Group B|Omalizumab was dosed according to package insert. Patients who do not have a decrease in peanut allergen induced basophil histamine release (Pn-BHR) to less than 20% of baseline will be assigned to this group.
3061708|NCT00949117|Experimental|Arm I- cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
3061709|NCT00949117|Experimental|cyproheptadine HCl & PediaSure or Ensure|Patients receive oral cyproheptadine hydrochloride twice daily and oral PediaSure (2 to 10 years of age) or Ensure (> 10 years of age) twice daily for up to 24 weeks in the absence of weight loss or unacceptable toxicity.
3061710|NCT00949234|Other|Open-Label|This was an open-label demonstration project. Therefore, medications were not blinded and participants were made aware of the regimen they received for PEP.
3061711|NCT00949325|Experimental|temsirolimus plus liposomal doxorubicin|Single arm study: Dose escalation of temsirolimus plus constant dose of liposomal doxorubicin.
3061712|NCT00949533|Experimental|Standard Dose|Oseltamivir capsule will be administered orally at a dose of 75 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 milligrams/ milliliter [mg/mL]) based on their body weight with a starting dose of 30 mg BID to a maximum dose of 75 mg BID; for 5 days.
3061713|NCT00949533|Active Comparator|Double Dose|Oseltamivir capsule will be administered orally at a dose of 150 mg BID in adult participants and children will receive oseltamivir powder for oral suspension dose (at 12 mg/mL) based on their body weight with a starting dose of 60 mg BID to a maximum dose of 150 mg BID; for 5 days.
3061714|NCT00949650|Experimental|BIBW 2992|BIBW 2992 tablet once daily until progression
3061715|NCT00949650|Active Comparator|Cisplatin/Pemetrexed|Cisplatin and Pemetrexed IV once every 3 weeks for up to 6 cycles
3061716|NCT00949702|Experimental|Single arm|
3061717|NCT00949715|Active Comparator|RV Mid-Septal Pacing|Pacing lead located in the right ventricle at the middle of the muscle separating the right and left sides of the heart
3061718|NCT00949715|Active Comparator|RV Apical Pacing|Pacing lead located at the bottom of the right ventricle of the heart, in the right ventricular apex
3061719|NCT00949884|Experimental|Olmesartan|Olmesartan 20 mg once daily for four weeks followed by 40mg one daily for four weeks.
3061720|NCT00949884|Placebo Comparator|Placebo followed by Olmesartan|Placebo capsule of olmesartan once daily for 2 weeks, followed by olmesartan 20 mg once daily for two weeks, followed by olmesartan 40 mg for 4 weeks
3061721|NCT00949884|Active Comparator|Losartan|Losartan 50 mg once daily for four weeks, followed by losartan 100 mg once daily for four weeks
3061722|NCT00949910|Experimental|Erlotinib|Erlotinib will be given as a single agent in this expanded access program (EAP) to participants with inoperable, locally advanced, recurrent, or metastatic NSCLC. Treatment will continue until unacceptable toxicity, disease progression, or withdrawal for any other reason.
3061723|NCT00949975|Active Comparator|1|AZD9668 active treatment
3061724|NCT00949975|Active Comparator|2|AZD9668 active treatment
3061725|NCT00949975|Active Comparator|3|AZD9668 active treatment
3061726|NCT00949975|Placebo Comparator|4|AZD9668 placebo treatment
3061727|NCT00950170|Experimental|1|The investigator treats subjects with ReFacto AF in the usual care setting.
3061728|NCT00950235|Other|Usual Care|This arm will receive one additional nutrition counseling session that typically received in the health system. This arm will be compared to our intervention group
3061729|NCT00950235|Experimental|Weight Management Counseling|In-person and group session counseling
3061730|NCT00950248|Active Comparator|Idebenone|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
3061731|NCT00950248|Placebo Comparator|Placebo|Placebo tablets administered orally as five tablets, three times per day with food.
3061732|NCT00950300|Active Comparator|Herceptin IV + Chemotherapy|Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
3061733|NCT00950300|Experimental|Herceptin SC + Chemotherapy|Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
3061734|NCT00950352|Experimental|Citicoline|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
3061735|NCT00950352|Placebo Comparator|Placebo|In a double-blind randomization design, subjects with methamphetamine dependence will be treated with citicoline or placebo for 8-9 weeks.
3061736|NCT00950365|Active Comparator|Arm A (pemetrexed)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061737|NCT00950365|Experimental|Arm B (pemetrexed disodium, erlotinib hydrochloride)|Patients receive pemetrexed disodium IV as in Arm A and erlotinib hydrochloride PO QD on days 2-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3061738|NCT00950599|Experimental|Saxagliptin (2.5 mg)|
3061739|NCT00950599|Experimental|Saxagliptin (5 mg)|
3061740|NCT00950599|Experimental|Saxagliptin (10 mg)|
3061741|NCT00950599|Experimental|Saxagliptin (20 mg)|
3061742|NCT00950599|Experimental|Saxagliptin (40 mg)|
3061743|NCT00950599|Experimental|Saxagliptin (100 mg)|
3061744|NCT00950599|Placebo Comparator|Placebo|
3061745|NCT00950612|Experimental|Group A|
3061746|NCT00950612|Placebo Comparator|Group B|
3061747|NCT00950651|Experimental|1 Tramadol HCl Contramid® Once A Day|
3061748|NCT00950651|Active Comparator|2 Tramadol HCl Twice a day (SR)|
3061749|NCT00950664|Experimental|Dysport® to Botox®|Dysport® injection in first intervention period and Botox® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
3061750|NCT00950664|Experimental|Botox® to Dysport®|Botox® injection in first intervention period and Dysport® in second intervention period (after washout period) cross over injection of Dysport® (abobotulinumtoxinA) and Botox® (onabotulinumtoxinA)
3061751|NCT00950729|Active Comparator|Driving with Running Shoes|
3061752|NCT00950729|Active Comparator|Driving with Plaster cast|
3061753|NCT00950729|Active Comparator|Driving with Aircast|
3061754|NCT00950742|Experimental|BIBW 2992 + Trastuzumab|Find maximum tolerated dose of the non-marketed substance:BIBW 2992 given orally with fixed weekly infusion doses of 2mg/kg Herceptin. Escalating doses of BIBW 2992 starting at 20mg daily.
3320882|NCT02014545|Active Comparator|WBRT + Lucanthone|Treatment will consist of WBRT given in a dose of 30 Gy in ten fractions with lucanthone given as an adjunct. Lucanthone will be administered as 25 mg and 100 mg tablets to be swallowed. Dosage will be one of the following: 250 mg bid, 250 tid, or 375 mg tid.
3061755|NCT00950755|Experimental|Tositumomab and Iodine I 131 Tositumomab (anti-B1 antibody)|In the first phase (dosimetric dose) patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of Anti B1 Antibody (35 mg) which has been trace-labeled with 5 mCi of Iodine 131. Whole body gamma camera scans will be obtained following the dosimetric dose. Using the dosimetric data, a patient-specific dose of Iodine 131 Anti B1 Antibody to deliver the desired total body dose of radiotherapy will be calculated. In the second phase, (radioimmunotherapeutic dose), patients will receive an infusion of unlabeled Anti B1 Antibody (450 mg) followed by an infusion of 35 mg Anti B1 Antibody labeled with the patient-specific dose of Iodine 131 to deliver a whole body dose of 75 cGy. Patients will be treated with saturated solution potassium iodide, Lugol's solution, or potassium iodide tablets starting at least 24 hours prior to the first infusion and continuing for 14 days following the last infusion of Iodine 131 Anti B1 Antibody.
3061756|NCT00950807|Placebo Comparator|Placebo|Placebo
3061757|NCT00950807|Active Comparator|Tiotropium|Tiotropium
3061758|NCT00950807|Experimental|Arm 1|GSK573719 1000mcg once daily
3061759|NCT00950807|Experimental|Arm 2|GSK573719 500mcg once daily
3061760|NCT00950807|Experimental|Arm 3|GSK573719 250mcg once daily
3061761|NCT00950807|Experimental|Arm 4|GSK573719 125mcg once daily
3061762|NCT00950807|Experimental|Arm 5|GSK573719 62.5 mcg once daily
3061763|NCT00950807|Experimental|Arm 6|GSK573719 250mcg twice daily
3061764|NCT00950807|Experimental|Arm 7|GSK573719 125mcg twice daily
3061765|NCT00950807|Experimental|Arm 8|GSK573719 62.5mcg twice daily
3061766|NCT00950833|Active Comparator|AP-AP Group|subjects from the AP-AP group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015, receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
3061767|NCT00950833|Active Comparator|NAP-pre Group|subjects from the NAP-pre group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in study NCT00496015 receiving an additional dose of pneumococcal conjugate vaccine GSK1024850A for immune memory assessment
3061768|NCT00950833|Active Comparator|Unprimed Group|Age-matched subjects from the unprimed group of the NCT00496015 study, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
3061769|NCT00950859|Experimental|GSK1349572 Cohort I|Single Arm, Cohort I
3061770|NCT00950859|Experimental|GSK1349572 Cohort II|Single Arm, Cohort II
3061771|NCT00950872|Experimental|Duet TRS|Subjects receive Duet TRS
3061772|NCT00950911|Experimental|1|
3061773|NCT00950937||HIV Group|HIV infected persons
3061774|NCT00950937||Control Group|Non HIV-infected persons
3061775|NCT00950950|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
3061776|NCT00950950|Experimental|Romosozumab|Participants were randomized to receive 3 mg/kg romosozumab administered by subcutaneous injection once every 4 weeks (Q4W) for 3 months.
3061777|NCT00950963|Experimental|Phone Counseling|The telephone outreach intervention was considered an adjunct to usual care. The study nurse focused on optimizing lipids utilizing published guidelines through phone contact.
3061778|NCT00950963|Active Comparator|Standard Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
3061779|NCT00951015|Experimental|10 mg GSK1349572|subjects will receive GSK1349572 10mg once daily blinded to dose
3061780|NCT00951015|Experimental|25mg GSK1349572|subjects will receive GSK1349572 25mg once daily blinded to dose
3061781|NCT00951015|Experimental|50mg GSK1349572|subjects will receive GSK1349572 50mg once daily blinded to dose
3061782|NCT00951015|Other|efavirenz control|efavirenz will serve as the internal control arm
3061783|NCT00951041|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
3061784|NCT00951041|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine. The first vaccine dose was administered intramuscularly in the deltoid region of the non-dominant arm at Day 0, and the second vaccine dose was administered intramuscularly in the deltoid region of the dominant arm at Day 21.
3061785|NCT00951080|Experimental|SNaP Wound Care System|
3061786|NCT00951080|Active Comparator|Traditional NPWT System|
3061787|NCT00951093||Patients assessed for GERD|Patients who had an open gastric bypass were assessed for GERD before and after surgery following the Montreal Consensus through a validated questionnaire in Portuguese language
3061788|NCT00951171|Experimental|Cervical occulsion|Insemination Eliptosphere catheter filled with 1cc of air for 15 minutes. H/S Eliptosphere by Copper surgical (U.S. Patent No. 5,624,399)
3061789|NCT00951171|Active Comparator|Standard IUI|Insemination with TOmcat catheter
3061790|NCT00951275|Experimental|1|
3061791|NCT00951379|Experimental|Arm I (Pioglitazone Hydrochloride)|Three (3) Pioglitazone 15 mg capsules by mouth once daily for 24 weeks
3061792|NCT00951379|Placebo Comparator|Arm II (Placebo)|Three (3) placebo capsules by mouth once daily for 24 weeks
3061793|NCT00951483|Experimental|Intervention Cohort|Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks.
3061794|NCT00951483|No Intervention|Healthy Control|Participants without major depressive disorder or anxiety are enrolled as a comparison group without intervention.
3320883|NCT02014545|Placebo Comparator|WBRT + Placebo|Patients will receive prophylactic cranial irradiation at 3 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 30 Gy.
3061795|NCT00951496|Experimental|Arm I (paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1 in courses 2-6. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone in courses 7-22 in the absence of disease progression or unacceptable toxicity.
3061796|NCT00951496|Experimental|Arm II (paclitaxel, bevacizumab, carboplatin IP)|Patients receive paclitaxel as in Arm I and carboplatin IP on day 1. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
3061797|NCT00951496|Experimental|Arm III (paclitaxel IP, bevacizumab, cisplatin IP)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IP on day 2, and paclitaxel IP on day 8. Patients also receive bevacizumab as in Arm I. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone as in Arm I.
3061798|NCT00951509||Condition 1 (PC Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3061799|NCT00951509||Condition 2 (PC Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3061800|NCT00951509||Condition 3 (VR Screens with No Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3061801|NCT00951509||Condition 4 (VR Screens with Rollers)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3061802|NCT00951509||Condntion 5 (Real-world driving)|All subjects (Repeated - measures study design): All subjects were evaluated with the Power Mobility Road Test (PMRT).
3061803|NCT00951561|Experimental|Vipon|
3061804|NCT00951561|Active Comparator|Ibuprofen|
3061805|NCT00951665|Experimental|Phase lb Regimen 1|Participants received trastuzumab emtansine (T-DM1) every three weeks (Q3W) + paclitaxel weekly (QW) intravenously.
3061806|NCT00951665|Experimental|Phase Ib Regimen 2|Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.
3061807|NCT00951665|Experimental|Phase Ib Regimen 3|Participants received T-DM1 QW + paclitaxel QW intravenously.
3061808|NCT00951665|Experimental|Phase Ib Regimen 4|Participants received T-DM1 QW + paclitaxel QW + pertuzumab Q3W intravenously.
3061809|NCT00951665|Experimental|Phase IIa Group A|Participants received maximum tolerated dose (MTD) from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW intravenously.
3061810|NCT00951665|Experimental|Phase IIa Group B|Participants received MTD from Phase 1b i.e. T-DM1 3.6mg/kg Q3W + paclitaxel 80mg/m^2 QW + pertuzumab Q3W intravenously.
3061811|NCT00951808|Active Comparator|Blood Transfusion Trial Cohort|Twenty participants will receive a blood transfusion while in the hospital.
3061812|NCT00951808|Active Comparator|Standard Care Trial Cohort|Twenty participants will not receive a blood transfusion and will receive standard care.
3061813|NCT00951808|Active Comparator|Standard Care Observational Cohort|Approximately 300 participants who are ineligible for or decline the blood transfusion part of the study will participate in the observational portion of the study and receive standard care.
3061814|NCT00951821|Experimental|Concurrent treatment|Concurrent treatment - experimental condition: Adolescent participants and their parents will receive concurrent cognitive behavioral therapy.
3061815|NCT00951821|Active Comparator|Adolescent treatment only|Adolescent treatment only - Active Comparator: Only adolescent participants will receive cognitive behavioral therapy.
3061816|NCT00951899|Experimental|Colesevelam|Treatment with colesevelam hydrochloride in addition to Metformin and Diet
3061817|NCT00951899|Placebo Comparator|Placebo|Treatment with placebo in addition to Metformin and Diet
3061818|NCT00951912|Placebo Comparator|Placebo|10g soy protein isolated powder patch by mouth everyday for 6months
3061819|NCT00951912|Experimental|Daidzein|10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months
3061820|NCT00951912|Experimental|Genistein|10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months
3061821|NCT00952068|Experimental|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
3061822|NCT00952081|Experimental|clevidipine,brain tumor,hypertension|21 or older, Clevidipine in brain tumor resection, epilepsy focus resection during acute hypertension under general anesthesia
3061823|NCT00952120|Experimental|GSUC|Gauze-based wall suction negative pressure wound therapy for 4-5 days
3061824|NCT00952120|Active Comparator|Vacuum-assisted closure|Vacuum-assisted closure (VAC) negative pressure wound therapy using commercially available device (KCI, Inc) for 4-5 days
3061825|NCT00952133|Experimental|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery.
3061826|NCT00952133|Placebo Comparator|Palonosetron only|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Intravenous Palonosetron and Saline solution
3061827|NCT00952211|Active Comparator|CPAP|CPAP at therapeutic pressure
3061828|NCT00952211|Sham Comparator|sub-therapeutic CPAP|CPAP administered at sub-therapeutic pressure
3061829|NCT00952276|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1 (with adjuvant)
3061830|NCT00952276|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2 (with adjuvant)
3061831|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
3061832|NCT00952276|Active Comparator|A/H1N1 Vaccine Group 4|Participants will receive A/H1N1 vaccine formulation 4
3061833|NCT00952276|Placebo Comparator|Placebo Group 5|Participants will receive a placebo vaccine
3179142|NCT00669721|Active Comparator|B|The patients randomized to receive UFH will start a run in period with this heparin schedule. Then they'll undergo hemodialysis with UFH for a second period of two weeks: in this checking phase samples will be collected during the midweek hemodialysis sessions. After the checking phase the patients will be crossed to LMWH. A wash out period of two weeks with UFH will be done. At the end of this period two weeks of checking phase will starts.
3061834|NCT00952289|Experimental|Ruxolitinib|Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count > 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
3061835|NCT00952289|Placebo Comparator|Placebo|Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.
3061836|NCT00952315|Active Comparator|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
3061837|NCT00952315|Active Comparator|Lithoclast Select|Lithoclast Select will be used to breakup and remove kidney stone. Duration will be timed and documented.
3061838|NCT00952315|Active Comparator|Cyberwand|The dual probe Cyberwand device will be used to fragment and remove the kidney stone. Duration will be timed and documented.
3061839|NCT00952341|Experimental|Aprepitant (MK-0869)|
3061840|NCT00952341|Placebo Comparator|Standard Therapy|
3061841|NCT00952367||Per-protocol population|In all, 3641 participants were enrolled; however, 38 were excluded because of violation of inclusion/exclusion criteria and 3 participants were excluded for unavailability of nasopharyngeal swab sample. The record presents demographic and result data for 3600 participants in the per-protocol population. These participants completed collection of the nasopharyngeal swab sample, the Epidemiology questionnaire, and 24 hours safety observation.
3061842|NCT00952380|Other|Single Arm|Single arm open-label
3061843|NCT00952393|Other|Pharmacokinetic|This single arm examines the pharmaco-kinetics of the release of 3-2,4 dimethoxy-benzilidene anabaseine in a hypomellose sustained release formulation.
3061844|NCT00952419|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
3061845|NCT00952419|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
3061846|NCT00952419|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3061847|NCT00952484|Active Comparator|2 mg/kg|2 mg/kg subcutaneous injection three times per week.
3061848|NCT00952484|Active Comparator|3 mg/kg|3 mg/kg subcutaneous injection three times per week.
3061849|NCT00952523|Experimental|Tretinoin & Adapalene-Benzoyl Peroxide|Tretinoin and Adapalene-Benzoyl Peroxide facial gels applied once daily in a split face model
3061850|NCT00952588|Experimental|AZD1152 1200 mg|AZD1152 1200 mg, iv, 7 day infusion monotherapy
3061851|NCT00952588|Active Comparator|LDAC 20 mg|LDAC 20 mg, sc, bd, 10 days (400mg per cycle)
3061852|NCT00952614|Experimental|Retisert for Retinal Vein Occlusion|0.59 mg Fluocinolone Acetonide (Retisert implant) for Retinal Vein Occlusion
3061853|NCT00952653|Experimental|DVS SR|
3061854|NCT00952705|Experimental|Q/LAIV-BFS (MEDI8662)|Q/LAIV-BFS (quadrivalent influenza vaccine) (MEDI8662) was supplied in the blow-fill-seal delivery system that delivers a nominal dose of 0.2 mL into a single nostril. Each dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), B/Victoria (B/Malaysia/2506/2004), and B/Yamagata (B/Florida/4/2006).
3061855|NCT00952705|Active Comparator|FluMist/B/Yamagata|FluMist/B/Yamagata was administered intranasally using a Becton Dickinson Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Yamagata (B/Florida/4/2006)
3061856|NCT00952705|Active Comparator|FluMist/B/Victoria|FluMist/B/Victoria was administered intranasally using a BD Accuspray™ device. A total volume of 0.2 mL was administered intranasally (approximately 0.1 mL into each nostril). Each dose contained 10^7.0 ± 0.5 FFU of each of 3 cold-adapted, temperature-sensitive, attenuated, 6:2 reassortant influenza virus strains: A/H1N1 (A/South Dakota/6/2007), A/H3N2 (A/Uruguay/716/2007), and B/Victoria (B/Malaysia/2506/2004).
3061857|NCT00952718|No Intervention|Control|No intervention.
3061858|NCT00952718|Experimental|Inspiratory muscle training|With intervention.
3061859|NCT00952731|Experimental|oral placebo, afimoxifene|4-hydroxytamoxifen gel 2mg/breast applied daily. Oral placebo taken daily.
3061860|NCT00952731|Active Comparator|tamoxifen citrate, placebo gel)|Placebo gel applied to the breasts daily. 20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules).
3061861|NCT00952822|Experimental|1|ADVATE reconstituted in 2 mL sterile water for infusion
3061862|NCT00952822|Active Comparator|2|ADVATE reconstituted in 5 mL sterile water for infusion
3061863|NCT00952848|Experimental|MC5-A Scramble instrument|Treatment of chronic neuropathic pain with the MC5-A device
3061864|NCT00953017|Active Comparator|Miralax plus Amitiza|106 patients randomized to Miralax plus Amitiza will take one 24mcg gelcap of Amitiza at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3061865|NCT00953017|Active Comparator|Miralax plus Dulcolax|107 patients randomized to Miralax plus Dulcolax will take two 5mg tablets of Dulcolax at noon the day prior to their colonoscopy. On the day prior to the colonoscopy, the patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3061866|NCT00953017|Active Comparator|Miralax|106 patients will mix 255gm of Miralax with 64 oz. of Gatorade and drink 32 oz. of the solution at 4 p.m. The remaining 32 oz. of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy.
3061867|NCT00953017|Active Comparator|Golytely (polyethylene glycol)|106 patients will take 1 gallon of golytley (Polyethylene glycol) and drink 1/2 of the solution at 4 p.m. The remaining 1/2 of the solution will be completed the morning of the procedure, approximately 4-6 hours prior to the scheduled start time of the colonoscopy
3061868|NCT00953043|Active Comparator|Lubiprostone|Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
3061869|NCT00953043|Placebo Comparator|Placebo|Subjects randomized to this arm received placebo medication for three days.
3061870|NCT00953056|Experimental|Cohort I - RotaTeq™, Adults|Adults randomized to receive a single dose of RotaTeq™.
3061871|NCT00953056|Placebo Comparator|Cohort I - Placebo, Adults|Adults randomized to receive a single dose of matching placebo to RotaTeq™.
3061872|NCT00953056|Experimental|Cohort II - RotaTeq™, Children|Children randomized to receive a single dose of RotaTeq™.
3061873|NCT00953056|Placebo Comparator|Cohort II - Placebo, Children|Children randomized to receive a single dose of matching placebo to RotaTeq™.
3061874|NCT00953056|Experimental|Cohort III - RotaTeq™, Infants|Infants randomized to receive 3 doses of RotaTeq™.
3061875|NCT00953056|Placebo Comparator|Cohort III - Placebo, Infants|Infants randomized to receive 3 doses of matching placebo to RotaTeq™.
3061876|NCT00953121|Experimental|Cohort A-Grade IV No Failure|Recurrent GBM patients who have not previously failed bevacizumab, irinotecan, or carboplatin
3061877|NCT00953121|Experimental|Cohort B-Grade III No Failure|Recurrent Grade 3 malignant glioma patients who have not previously failed either bevacizumab, irinotecan or carboplatin
3061878|NCT00953121|Experimental|Cohort C-Failed Prior Therapy|Recurrent Grade IV GBM patients who have failed prior bevacizumab therapy, but not prior CPT-11 or carboplatin therapies
3061879|NCT00953147|Experimental|Ciclesonide HFA 80 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 40 mcg canister, to be administered as 1 puff in each nostril (80 mcg per day).
3061880|NCT00953147|Experimental|Ciclesonide HFA 160 mcg once daily|Ciclesonide HFA nasal aerosol will be supplied in a 80 mcg canister, to be administered as 1 puff in each nostril (160 mcg per day).
3061881|NCT00953147|Placebo Comparator|Placebo once daily|The placebo HFA nasal aerosol is identical to active drug, but does not contain ciclesonide.
3061882|NCT00953160|Experimental|RF treatment|Abdomen, flank or thigh treated with RF device
3061883|NCT00953173||LapBand|Patients who have already consented to receive the LAP-BAND AP® Adjustable Gastric Banding System
3061884|NCT00953199|Experimental|Lidocaine|Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
3061885|NCT00953199|Active Comparator|Normal Saline|The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
3061886|NCT00953212|Active Comparator|Group A|Beta Blockers, Ascorbic Acid and Amiodarone
3061887|NCT00953212|Active Comparator|Group B|Beta Blockers and Ascorbic Acid
3061888|NCT00953212|Active Comparator|Group C|Beta Blockers and Amiodarone
3061889|NCT00953212|Active Comparator|Group D|Beta Blockers alone
3061890|NCT00953225|Experimental|Vitamin D3|4,000 IU vitamin D3 daily for one year
3061891|NCT00953225|Placebo Comparator|Placebo|Placebo daily for one year
3061892|NCT00953290|Experimental|Treated Thigh|The thigh treated with the RF device
3061893|NCT00953290|No Intervention|Untreated Thigh|The untreated thigh
3061894|NCT00953407|Experimental|Nelfilcon A|Nelfilcon A contact lens
3061895|NCT00953407|Active Comparator|Narafilcon A|Narafilcon A contact lens
3061896|NCT00953407|Active Comparator|Etafilcon A|Etafilcon A contact lens
3061897|NCT00953407|Active Comparator|Omafilcon A|Omafilcon A contact lens
3061898|NCT00953407|Active Comparator|Hilafilcon B|Hilafilcon B contact lens
3061899|NCT00953524|Experimental|A/H1N1 Vaccine Group 1|Participants will receive A/H1N1 vaccine formulation 1
3061900|NCT00953524|Experimental|A/H1N1 Vaccine Group 2|Participants will receive A/H1N1 vaccine formulation 2
3061901|NCT00953524|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Vaccine formulation 3
3061902|NCT00953524|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3061903|NCT00953576|Experimental|Phase I Dose Level 1 (DL1): KHAD+L (250 mg)|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 250 mg orally 1x day~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
3061904|NCT00953576|Experimental|Phase I Dose Level 2 (DL2): KHAD+L (500 mg)|"For the initial four weeks (1 cycle=28 days), participants will receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants will start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: 500 mg orally 1x day"
3061905|NCT00953576|Experimental|All Phase I Participants|"For the initial four weeks (1 cycle=28 days), participants receive KHAD treatment.~Ketoconazole: 400 mg orally 3x day Hydrocortisone: 30 mg (a.m.) and 10 mg (p.m.) orally 2x day Dutasteride: 0.5 mg orally 1x day~Participants start KHLAD on day 29 or d1 of cycle 2/ week 5. Lapatinib: according to the established dose escalation schedule~Participants are treated until unacceptable toxicity, disease progression or withdrawal."
3061906|NCT00953654|Experimental|Strength Training|Lower-body strength training exercise twice weekly for 6 weeks at an intensity progressing from 50% to 75% predicted one-repetition maximum
3061907|NCT00953654|Experimental|Endurance Training|Six-week lower-body dynamic cycling exercise condition completed twice weekly and matched to the strength training arm on total work completed, total time actively engaged in exercise and load progression.
3061908|NCT00953654|No Intervention|Waiting List Control|Waiting list control condition in which participants will maintain their current lifestyle and will not enter a six-week exercise training intervention, but will complete outcome measures along the same time progression as the intervention arms.
3061909|NCT00953667|Experimental|Niacin and Endotoxin|All subjects are expected to have the same interventions- Niacin and Endotoxin.
3061910|NCT00953680|Active Comparator|losartan /HCTZ combination tablet|single dose losartan 100 mg/HCTZ 12.5 mg combination tablet
3061911|NCT00953680|Active Comparator|losartan tablet + HCTZ capsule|Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule
3061912|NCT00953706|Placebo Comparator|Placebo|Placebo matched to ivacaftor tablet orally every 12 hours (q12h) for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
3061913|NCT00953706|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally q12h for 16 weeks during Part A (double-blind treatment period), followed by ivacaftor 150 mg tablet orally q12h for 96 weeks during Part B (open-label extension period).
3061914|NCT00953719|Active Comparator|36 mm|36 mm ceramic head on ceramic acetabular liner
3061915|NCT00953719|Other|28 mm ceramic-on-polyethylene|28 mm ceramic-on-polyethylene historical control
3061916|NCT00953745|Active Comparator|Depressed Participants|"Subjects with treatment-resistant depression (TRD) will be administered the Hamilton Depression Rating Scale (HAM-D 17) for entry and will receive escitalopram combined with an adjunctive placebo capsule for 8 weeks.~Subjects who fail to respond will continue to receive escitalopram and additionally change to receive a placebo tablet resembling the active augmentation agent Aripiprazole (ARP) for 2 weeks.~Subjects who fail to respond to escitalopram after the 2 phase placebo treatment will enter the ARP augmentation phase of the study and will receive escitalopram augmentation with ARP.~Subjects will have 3 neuroimaging scans: F-DOPA PET, raclopride PET, and functional MRI conducted after 10 weeks of treatment and repeated after 6 weeks of ARP treatment."
3061917|NCT00953745|No Intervention|Control Participants|Non-depressed, age- and sex-matched subjects without a DSM-IV Axis I diagnosis will serve as controls. They will not receive antidepressant, ARP, or any drug augmentation and will be used as quality control to compare the pre-ARP and post-ARP treatment brain images.
3061918|NCT00953849|Experimental|Arm 1: Celecoxib|Celecoxib treatment prior to surgery
3061919|NCT00953849|Experimental|Arm 2: Calcitriol|Treatment with Calcitriol prior to surgery
3061920|NCT00953849|Experimental|Arm 3: Celecoxib plus Calcitriol|Treatment with Celecoxib plus Calcitriol prior to surgery.
3061921|NCT00953849|No Intervention|Arm 4: No Treatment|no treatment prior to surgery
3061922|NCT00953862|Experimental|Atomoxetine Treatment Arm|Patients who were identified as having adult ADHD on the ACDS were offered an open label treatment trial with atomoxetine, up to 120 mg/day over 10 weeks. Atomoxetine was titrated over a period of four weeks based upon clinical response and observed side-effects. All patients receiving atomoxetine gave written informed consent prior to participation and were assessed for ADHD symptoms via the Adult Investigator Adult ADHD Symptom Rating Scale (AISRS) every 1-2 weeks. All patients received a physical exam, review of systems and routine blood work prior to treatment. Data were analyzed for patients completing at least 2 weeks of atomoxetine therapy. Treatment response was pre-hoc defined as having a >=30% reduction in total AISRS scores from baseline.
3061923|NCT00953927|Experimental|Investigational Vaccine|MVA85A/AERAS-485; subset into cohorts to explore different safety and immunogenicity tests.
3061924|NCT00953927|Placebo Comparator|Control Group|Candida Skin Test Antigen control; subset into cohorts to explore different safety and immunogenicity tests.
3061925|NCT00954109|Experimental|Exercise|exercise - supervised exercise (treadmill walking or cycle ergometer use)
3061926|NCT00954122|Experimental|Quetiapine XR|Quetiapine XR 300 mg on day 1, 600 mg on day 2, and 400-800 mg (at investigator's discretion) on day 3 and onwards.
3061927|NCT00954174|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1.
3061928|NCT00954174|Experimental|Arm II (paclitaxel, ifosfamide)|Patients receive ifosfamide IV over 1 hour on days 1-3 followed by paclitaxel as in Arm I.
3061929|NCT00954356|Experimental|XPF-001|
3061930|NCT00954356|Placebo Comparator|Placebo|
3061931|NCT00954421|Experimental|Deep Brain Stimulation|Multiple Sclerosis Tremor treated with VIM and VO Deep Brain Stimulation
3061932|NCT00954447|Experimental|Linagliptin|patient receives a tablet with intended final marketed dose
3061933|NCT00954447|Placebo Comparator|Placebo|patient receives a tablet identical to those containing Linagliptin
3061934|NCT00954512|Experimental|Regimen A: FOLFIRI (± Cetuximab) + Robatumumab|Participants with colorectal adenocarcinoma receive FOLFIRI (Irinotecan 180 mg/m^2+ folinic acid 400 mg/m^2+ 5-fluorouracil [5-FU] 400 mg/m^2 bolus followed by 2400 mg/m^2 intravenous [IV] infusion over 46 hours) (± cetuximab initial dose of 400 mg/m^2 IV followed by once-weekly doses of 250 mg/m^2 IV) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 2-week cycle.
3061935|NCT00954512|Experimental|Regimen B: Carboplatin + Paclitaxel + Robatumumab|Participants with non-small cell lung cancer receive carboplatin administered at an area under the curve (AUC) of 6 mg/mL/min IV PLUS paclitaxel 225 mg/m^2 IV PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
3061936|NCT00954512|Experimental|Regimen C: Epirubicin + Cisplatin + 5-FU + Robatumumab|Participants with gastric adenocarcinoma receive epirubicin 50 mg/m^2 IV PLUS cisplatin 60 mg/m^2 IV PLUS 5-FU 200 mg/m^2/day administered via a 21-week continuous IV infusion PLUS robatumumab 15 mg/kg IV on Day 1 of each 3-week cycle.
3061937|NCT00954512|Experimental|Regimen D: Trastuzumab + Robatumumab|Participants with human epidermal growth factor receptor 2 positive (Her2+) breast cancer receive trastuzumab 4 mg/kg IV once every week PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
3061938|NCT00954512|Experimental|Regimen E: mTor Inhibitor (Everolimus) + Robatumumab|Participants with renal cell cancer receive mammalian target of rapamycin (mTor) inhibitor (everolimus) 10 mg orally once per day PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle.
3061939|NCT00954512|Experimental|Regimen F: Gemcitabine (± Erlotinib) + Robatumumab|Participants with pancreatic adenocarcinoma receive gemcitabine 1000 mg/m^2 IV on Days 1, 8, 15, 22, 29, 36, and 43 in Cycle 1 and on Days 1, 8 and 15 in subsequent cycles (± erlotinib 100 mg per day orally) PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 4-week cycle. (Cycle 1 is 8 weeks.)
3061940|NCT00954538|Experimental|Part I, Healthy Participants|Healthy participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
3061941|NCT00954538|Experimental|Part II, HE and AD Participants|HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
3061942|NCT00954538|Experimental|Part III, HE and AD Participants|HE and AD participants will receive two separate IV doses of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
3061943|NCT00954681|Experimental|quetiapine treatment|Open label treatment with quetiapine
3061944|NCT00954707|Placebo Comparator|12m DAPT Group|
3061945|NCT00954707|Active Comparator|30m DAPT Group|
3061946|NCT00954733|Experimental|All participants|All participants, one arterial blood draw
3061947|NCT00954824|Experimental|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
3061949|NCT00954941|Experimental|Group 1: Ondansetron|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
3061950|NCT00954941|Active Comparator|Group 2: Ondansetron + Aprepitant|Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
3061951|NCT00954993|Experimental|Vaniprevir 600 mg - 300 mg|For each participant in period 1, 600 mg of Vaniprevir was taken twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg was taken on Day 4. Period 1 was followed by a minimum 30-day, up to approximately 140 day, washout interval. In period 2, 300 mg of Vaniprevir was taken twice daily by each participant on Days 1-3 and a single dose of Vaniprevir 300 mg was taken on Day 4.
3061952|NCT00955032|Experimental|High-Frequency Repetitive Transcranial Magentic Stimulation|High-Frequency repetitive transcranial magnetic stimulation patients randomized to this treatment will receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of Motor Evoked Potential (MEP) threshold, respectively.
3061953|NCT00955032|Sham Comparator|Sham Repetitive Transcranial Magentic Stimulation|Sham repetitive transcranial magnetic stimulation patients randomized to receive the sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
3061954|NCT00955110|Experimental|Oxymorphone ER 15 mg|15mg
3061955|NCT00955110|Active Comparator|Oxycodone CR 30 mg|30mg
3061956|NCT00955110|Placebo Comparator|Placebo|
3061957|NCT00955110|Experimental|Oxymorphone ER 30mg|30mg
3061958|NCT00955110|Active Comparator|Oxycodone CR 60mg|60mg
3061959|NCT00955201|No Intervention|Arm 1|Sedentary Control Group
3061960|NCT00955201|Experimental|Arm 2|Aerobic Exercise Group
3061961|NCT00955201|Experimental|Arm 3|Isokinetic Strength Exercise Group
3061962|NCT00955201|Experimental|Arm 4|Combined Aerobic and Isokinetic Strength Exercise Group
3061963|NCT00955253|Experimental|Guanfacine (Day 2) then Placebo (Day 4)|All patients received a single dose of guanfacine on Day 2 and a single dose of placebo on Day 4.
3061964|NCT00955253|Experimental|Placebo (Day 2) then Guanfacine (Day 4)|All patients received a single dose of placebo on Day 2 and a single dose of guanfacine on Day 4.
3061965|NCT00955266|Active Comparator|Calcium Chloride|Calcium chloride, 10mg/kg
3061966|NCT00955266|Placebo Comparator|Placebo|Normal saline
3061967|NCT00955279|Placebo Comparator|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
3061968|NCT00955279|Experimental|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
3061969|NCT00955279|Experimental|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
3061970|NCT00955305|Active Comparator|Arm A (CPB)|Patients receive carboplatin intravenously (IV) over 30 minutes, paclitaxel IV over 3 hours, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab may continue in the absence of disease progression or unacceptable toxicity.
3061971|NCT00955305|Experimental|Arm B (CPB+cixutumumab)|Patients receive carboplatin, paclitaxel, and bevacizumab as in Arm A. Patients also receive cixutumumab (IMC-A12) IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Treatment with bevacizumab and cixutumumab may continue in the absence of disease progression or unacceptable toxicity.
3061972|NCT00955357|Experimental|First Add-on|Lacosamide added to first adequate monotherapy (no history of Antiepileptic Drug [AED] polytherapy) and epilepsy diagnosis < or = 24 months at Screening.
3061973|NCT00955357|Experimental|Later Add-on|Lacosamide added to 1 to 3 Antiepileptic Drugs (AEDs) (with tentatives of at least 2 prior AED treatment regimens) and epilepsy diagnosis > or = 5 years at Screening.
3061974|NCT00955409|Experimental|ACC-001(3µg) + QS21|ACC-001(3µg) + QS21
3061975|NCT00955409|Experimental|ACC-001(10µg) + QS21|ACC-001(10µg) + QS21
3061976|NCT00955409|Experimental|ACC-001(30µg) + QS21|ACC-001(30µg) + QS21
3061977|NCT00955474|Experimental|Quetiapine|Patients assigned to receive Quetiapine
3061978|NCT00955474|Active Comparator|Quetiapine and SSRI|Patients assigned to receive Quetiapine and SSRI
3061979|NCT00955487|Experimental|Inhaled Nitric Oxide (iNO)|Participants will receive a low concentration of iNO until they are 30 weeks corrected gestational age or for 14 days if they were born at 29 weeks or more.
3061980|NCT00955487|Placebo Comparator|Nitrogen (placebo)|Participants will receive nitrogen (placebo) while in the hospital.
3061981|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel twice a day|drug
3061982|NCT00955513|Experimental|diclofenac diethylamine gel 2.32% gel three times a day|drug
3061983|NCT00955513|Placebo Comparator|placebo|placebo
3061984|NCT00955617|Experimental|Dotarem / Gadovist|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Dotarem in period 1 then with Gadovist in period 2
3061985|NCT00955617|Experimental|Gadovist / Dotarem|Contrast-enhanced MRA - Imaging examination contrast enhanced-MRA first with Gadovist in period 1 then with Dotarem in period 2
3061986|NCT00955682|Experimental|Group A|Subjects who received GSK vaccine 134612 in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
3061987|NCT00955682|Active Comparator|Group B|Subjects who received Meningitec™ vaccine in the primary vaccination study 109069 and will be boosted 4 years after primary vaccination with the same meningococcal vaccine as given in the primary study.
3061988|NCT00955708||Implants|Patients successfully implanted with the ACUITY Spiral Lead
3061989|NCT00955721|Experimental|Phase 1: GEMOX + Sorafenib|"Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib.~Gemcitabine: 1000 or 750 mg/m2, IV, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: 100 or 75 mg/m2, IV, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: 200 mg, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
3061990|NCT00955721|Experimental|Phase 2 - RPTD GEMOX + Sorafenib|"Recommended Phase Two Dose (RPTD) of Gemcitabine and Oxaliplatin (GEMOX) and Sorafenib:~Gemcitabine: Recommended Phase II Dose determined from Phase I, Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.~Oxaliplatin: Recommended Phase II Dose determined from Phase I, Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.~Sorafenib: Recommended Phase II Dose determined from Phase I, Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops."
3061991|NCT00955747|Placebo Comparator|Sugar Substitute Splenda|1.5 g Sugar Substitute Splenda, dissolved in 125 ml of water three times per day. If intestinal problems occur, the dose should be reduced to 1 g dissolved in water tid or additionally reduced to 0.5 g dissolved in 125 ml of water tid if problems still persisted, until patients adapted to treatment.
3061992|NCT00955747|Experimental|Tagatose|15 g Tagatose dissolved in 125 ml of water three times a day. The Tagatose dosage will be decreased to 10 g dissolved in 125 ml of water tid or decreased additionally to 5 g Tagatose dissolved in 125 ml of water tid, if needed due to gastrointestinal effects, until patients adapt to the treatment
3061993|NCT00955825|Experimental|300 IR|300 IR grass pollen allergen extract tablet
3061994|NCT00955825|Placebo Comparator|Placebo|Pacebo tablet
3061995|NCT00955877|Experimental|DepoDur80|DepoDur will be administered at 80μg/kg (not to exceed 5 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
3061996|NCT00955877|Experimental|DepoDur120|DepoDur will be administered at 120μg/kg (not to exceed 10 mg total/patient) under direct vision in the L1 laminectomy defect prior to wound closure.
3061997|NCT00955877|Placebo Comparator|Control|Preservative-free normal saline (2.5ml) will be placed in the L1 laminectomy defect and also dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter prior to wound closure.
3061998|NCT00955903|Experimental|Weight Loss|Participants receive Exercise and Reduced Calorie Diet Interventions
3061999|NCT00955903|Active Comparator|Control|Participants receive Exercise Intervention
3062000|NCT00955903|Active Comparator|Weight Maintenance|Participants receive Exercise and a Weight Maintenance Diet Interventions
3062001|NCT00955916|Experimental|CLAG Regimen with Gleevec®|Combined chemotherapy treatment (CLAG regimen) with Gleevec® (imatinib mesylate).
3062002|NCT00955955|Experimental|6(S)-5-MTHF(Deplin)|"Participants will receive 15 mg/day of Deplin, a medical food, for 8 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3062003|NCT00955955|Experimental|Placebo/Deplin|"Participants will receive placebo for the first 4 weeks, and then 15 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3062004|NCT00955955|Experimental|Placebo/Placebo|"Participants will receive placebo for both phases of the study.~The SPCD approach, is modified and conducted as follows:~The phase II dataset of interest is limited to patients treated with placebo during phase I who completed phase I, who did not experience a clinical response according to the HDRS-17 during phase I and entered phase II. Drug is compared to placebo in phase II for this patient subset alone.~The ITT/LOCF data comparing drug and placebo during phase I is combined with the data comparing drug and placebo according to the SPCD model for phase II (see steps 2 and 3 above), and analyzed using the statistical model as described in Fava et al, 2003"
3062005|NCT00955968|Experimental|Continue HAART|Continue receiving HAART within 0-42 days after delivery or other pregnancy outcome.
3062006|NCT00955968|Active Comparator|Stop HAART|Stop receiving HAART within 0-42 days after delivery or other pregnancy outcome and resume HAART when protocol specified criteria were met.
3062007|NCT00956020|Experimental|Treatment|Skin injection with platelet rich fibrin matrix on the inner aspect of the upper arm, with biopsies over a period from 30 minutes to 12 weeks after treatment.
3062008|NCT00956085|Experimental|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
3062009|NCT00956254|Experimental|Fentanyl sublingual spray 100 µg|Participants received a single administration of fentanyl sublingual spray 100 µg sublingually.
3062010|NCT00956293|Active Comparator|Control group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.
3062011|NCT00956293|Experimental|Everolimus group|During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.
3062012|NCT00956540|Experimental|Deflating|Deflating tracheal cuff (total air suction under negative pressure using a syringe) during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support. During ventilatory support the tracheal cuff remain pressurized (30 mmHg).
3062013|NCT00956540|No Intervention|Not deflating|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support
3062014|NCT00956540|Experimental|Deflating 2|Deflating tracheal cuff during periods of disconnection from mechanical ventilation in the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
3062015|NCT00956540|No Intervention|Not deflating 2|The tracheal cuff remain inflated all the time during the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate mange the airway.
3062016|NCT00956592|Active Comparator|CMAC Video laryngoscope|Subjects will have their intubation attempted first with the CMAC video laryngoscope
3062017|NCT00956592|Active Comparator|Macintosh blade|Patients will have their first intubation attempted utilizing the conventional Macintosh design laryngoscope blade
3062018|NCT00956631|Other|interlaminar decompression|Commercially available product (mild® Device Kit) used to perform interlaminar decompression
3062019|NCT00956709|Active Comparator|Levobupivacaïne 0,5 %|
3062020|NCT00956709|Active Comparator|Ropivacaïne 0,5%|
3062021|NCT00956761|Experimental|1|
3062022|NCT00956813|Experimental|Arm I|Patients receive oral flaxseed in the form of a bar similar to a granola bar once daily.
3062023|NCT00956813|Placebo Comparator|Arm II|Patients receive oral placebo bar once daily.
3062024|NCT00956839|Active Comparator|Group A|IM Vitamin D3 3,00,000 Units single dose
3062025|NCT00956839|Active Comparator|Group B|IM vitamin D3 6,00,000 Units single dose
3062026|NCT00956839|Active Comparator|Group C|Oral vitamin D3 500 Units/ day
3062027|NCT00956930|Experimental|Arm I (radioembolization)|Patients undergo radioembolization with yttrium Y 90 glass microspheres by hepatic artery infusion for approximately 1-3 courses.
3062028|NCT00956930|Experimental|Arm II (transarterial chemoembolization [TACE])|Patients undergo TACE with mitomycin C, doxorubicin hydrochloride, and cisplatin by hepatic artery infusion for approximately 1-3 courses.
3062029|NCT00956943|Active Comparator|21mg transdermal nicotine + placebo patch|21mg transdermal nicotine + placebo patch
3062030|NCT00956943|Experimental|42mg transdermal nicotine|42mg transdermal nicotine
3062031|NCT00957008|Experimental|A - GWL|Group Weight Loss Program (GWL) - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator.
3062032|NCT00957008|Experimental|B - GWL+SWA|Group weight loss program plus use of the Senseware Armband - Participants in this group attended a 14-session group weight loss program administered by trained facilitators plus 6 one-on-one telephone sessions with a facilitator and wore a SenseWear Armband. The SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
3062033|NCT00957008|Experimental|C - SWA Alone|Use of the senseware armband alone program - The intervention for the SWA Alone group was the SenseWear system includes the Armband, a real-time display device, and a personalized Weight Management Solutions web account. Participants received training in using the Armband and were asked to wear it at least 16 hours per day.
3062034|NCT00957008|No Intervention|D - Standard Care|Standard Care - Participants in this group received a self-directed weight loss manual that focused on cognitive and behavior change principles and learning activities based on Active Living Every Day and Healthy Eating Every Day
3062035|NCT00957021|Other|Triathlon® PS Total Knee System|Triathlon® PS Total Knee System
3062036|NCT00957047|Experimental|ESL 400 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400 mg tablets for Part I
3062037|NCT00957047|Experimental|ESL 800 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 800-mg tablets for Part I
3062038|NCT00957047|Experimental|ESL 1200 mg once daily|Eslicarbazepine acetate (ESL) was supplied in 400-mg and 800-mg tablets for Part I
3062039|NCT00957047|Placebo Comparator|placebo|Placebo tablets matching the 400-mg and 800-mg active substance tablets were supplied
3062040|NCT00957047|Experimental|ESL - Part II|All patients in Part II (Open-label Extension ) received ESL on an open-label basis, starting at 800 mg once daily.
3062041|NCT00957229|Placebo Comparator|Sugar pill|placebo pill by mouth once daily
3062042|NCT00957229|Experimental|GDC-0449|vismodegib 150MG by mouth once daily
3062043|NCT00957242|Active Comparator|warfarin|Oral warfarin titrated to an international normalization ratio (INR) of 2-3
3062044|NCT00957242|Placebo Comparator|placebo|Oral placebo (1mg or 2.5mg)
3062045|NCT00957268|Experimental|Alogliptin 12.5 mg (age 10 to < 14 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
3062046|NCT00957268|Experimental|Alogliptin 25 mg (age 10 to < 14 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3062047|NCT00957268|Experimental|Alogliptin 12.5 mg (age 14 to < 18 years)|Alogliptin 12.5 mg, tablets, orally, 1 dose only.
3062048|NCT00957268|Experimental|Alogliptin 25 mg (age 14 to < 18 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3062049|NCT00957268|Experimental|Alogliptin 25 mg (age 18 to 65 years)|Alogliptin 25 mg, tablets, orally, 1 dose only.
3062050|NCT00957333||case|ketamine + Cystitis
3062051|NCT00957359|Experimental|Psilocybin|Drug intervention
3062052|NCT00957359|Active Comparator|Niacin|Active control
3062053|NCT00957372|Experimental|ESL 800 mg daily (Part I)|ESL 800mg daily
3062054|NCT00957372|Experimental|ESL 1200 mg daily (Part I)|ESL 1200mg daily
3062055|NCT00957372|Placebo Comparator|placebo (Part I)|placebo
3062056|NCT00957372|Experimental|ESL - Open-label Extension (Part II)|All patients were treated with only ESL during Part II.
3062057|NCT00957424|Other|Overall|Single-armed study
3062058|NCT00957528|Placebo Comparator|Placebo|Weekly placebo treatment for a duration of 5 months.
3062059|NCT00957528|Experimental|Monthly Cycled Testosterone|A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
3062060|NCT00957528|Experimental|Continuous Testosterone|Weekly testosterone treatment for a duration of 5 months
3062061|NCT00957580|Experimental|Regimen 1 (Part 1)|
3062062|NCT00957580|Experimental|Regimen 2 (Part 1)|
3062063|NCT00957580|Experimental|Regimen 3 (Part 1)|
3062064|NCT00957580|Experimental|Regimen 1 (Part 2)|
3062065|NCT00957580|Experimental|Regimen 2 (Part 2)|
3062066|NCT00957593|Active Comparator|Oxytocin|Continuation of oxytocin per protocol once the patient reaches active labor
3062067|NCT00957593|Active Comparator|Oxytocin discontinuation|Oxytocin will be stopped once the patient reaches active labor
3062068|NCT00957658|Other|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem Study Device
3062069|NCT00957671|Experimental|Human Growth Hormone|recombinant human growth hormone (rhGH) self administered daily for one year
3062070|NCT00957684|Experimental|ESL 400 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3062071|NCT00957684|Experimental|ESL 800 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3062072|NCT00957684|Experimental|ESL 1200 mg once daily|ESL was supplied in 400-mg and 800-mg tablets
3062073|NCT00957684|Placebo Comparator|placebo|Placebo matching tablets
3062074|NCT00957684|Experimental|ESL - PART II|During Part II of the study all patients received Eslicarbazepine Acetate (ESL), including those who had been treated with placebo during Part I. ESL was supplied as scored 800 mg tablets; once daily administration by oral route.
3062075|NCT00957723|Other|Triathlon® CR Total Knee System|Participants receive the Triathlon® CR Total Knee System
3062076|NCT00957801|Active Comparator|Testosterone injection|Testosterone enanthate given as a single 100 mg Intramuscular (IM) injection
3062077|NCT00957801|Active Comparator|Testosterone gel|Testosterone topical gel (Androgel 1%) 10 mg administered daily for seven days
3062078|NCT00957801|Active Comparator|Testosterone injection and Medrol 6 day dose pack|Testosterone enanthate given as a single 100mg Intramuscular (IM) injection. Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
3062079|NCT00957801|Active Comparator|Medrol 6 day dose pack|Medrol 6 day dose pack was administered as directed with daily doses decreasing by 4mg per day with an additional 4mg given on day 7. Day one dose: 24mg, day two dose: 20mg, day three dose: 16mg, day four dose: 12mg, day five dose: 8mg, day six dose: 4 mg, day seven dose: 4mg.
3062080|NCT00957853|Experimental|Group 1: Cetuximab|Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes
3062081|NCT00957853|Experimental|Group 2: IMC-A12|IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3.
3062082|NCT00957853|Experimental|Group 3: Cetuximab + IMC-A12|"Cetuximab: 400 mg/m2 i.v. over 120 minutes on week 1, and 250 mg/m2 on week 2 and 3 i.v. over 60 minutes.~IMC-A12: 6 mg/kg/week i.v. over 1 hour on weeks 1 and 2 and 3."
3062083|NCT00957905|Experimental|Part A (alvocidib and oxaliplatin)|Patients receive alvocidib IV over 1 hour and oxaliplatin IV over 2 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3062084|NCT00957905|Experimental|Part B (alvocidib and FOLFOX)|Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours followed by fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3062085|NCT00957931|Experimental|Mesenchymal stromal cells|
3062086|NCT00957944|Experimental|Sequence A-B (Test: PR 2.1.1 WCL - Reference: PR 2.1.1 AND)|Two single applications of rotigotine patches from two different manufacturing sites in the order A-B separated by a washout phase of at least 5 days
3062087|NCT00957944|Experimental|Sequence B-A (Reference: PR 2.1.1 AND - Test: PR 2.1.1 WCL)|Two single applications of rotigotine patches from two different manufacturing sites in the order B-A separated by a washout phase of at least 5 days
3062088|NCT00957996|Experimental|Peramivir 300 mg|Peramivir 300 mg twice daily
3062089|NCT00957996|Experimental|Peramivir 600 mg|Peramivir 600 mg once daily
3062090|NCT00958035|Experimental|LATISSE®|bimatoprost ophthalmic 0.03% solution
3062091|NCT00958035|Placebo Comparator|Placebo|vehicle sterile solution
3062092|NCT00958074|Experimental|Cohort I (>=65 years old)|200 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
3062093|NCT00958074|Experimental|Cohort II (<65 years old)|400 mg vorinostat PO QD on days 1-28. Treatment repeats every 28 days for 6 courses. Dose escalation by 100mg per day increments to maximum dose of 500mg per day in the absence of dose limiting toxicity.
3062094|NCT00958126|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3062095|NCT00958126|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose. 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
3062096|NCT00958126|Experimental|CSL425 (30 mcg)|30 mcg of hemagglutinin antigen per dose. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21
3062097|NCT00958126|Placebo Comparator|Placebo|Vaccine diluent. 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and Day 21.
3062098|NCT00958165|Experimental|EAS-AC|PVI with EAS-AC
3062099|NCT00958191|Other|Trident® X3 Polyethylene Insert|Participants who received the Trident® X3 Polyethylene Insert.
3062100|NCT00958217|Experimental|Cognitive Processing Therapy-Modified|12 individually delivered sessions of Cognitive Processing Therapy-Modified (CPT-M) provided once weekly following initial group delivery of 12 sessions of Integrated Cognitive Behavioral Therapy
3062101|NCT00958217|Active Comparator|Integrated Cognitive Behavioral Therapy|12 individually delivered sessions of Integrated Cognitive Behavioral Therapy (ICBT) once weekly following initial group delivery of 12 sessions of ICBT
3062102|NCT00958217|No Intervention|Integrated Cognitive Behavioral Group Therapy|All participants were enrolled in an initial group-delivered Integrated Cognitive Therapy Group, consisting of 12 sessions over approximately 12 weeks prior to randomization to one of the study individually delivered interventions (CPT-M or ICBT). Individuals who were no longer participating in the study at the end of group sessions were not randomized.
3062103|NCT00958243|Placebo Comparator|Placebo|Placebo
3062104|NCT00958243|Experimental|CSL425 (7.5 mcg)|7.5 mcg of hemagglutinin antigen per dose
3062105|NCT00958243|Experimental|CSL425 (15 mcg)|15 mcg of hemagglutinin antigen per dose
3062106|NCT00958256|Experimental|Bortezomib with Cyclophosphamide and Rituximab|Bortezomib 1.3 mg/m^2 intravenously (IV) on Days 1, 4, 8, and 11 of the cycle; Cyclophosphamide 300 mg/m^2 IV every 12 hours on Days 2, 3, and 4, and Rituximab 375 mg/m^2 IV on Day 1. Mesna 600 mg/m^2 for 3 days, G-CSF 5 micrograms/kg subcutaneously daily for 7 days after last dose of Bortezomib. Cycles repeated every 21 days for up to six cycles.
3062107|NCT00958282|Active Comparator|lisdexamfetamine/Behavior Therapy|lisdexamfetamine 70mg/day plus Behavior Therapy
3062108|NCT00958282|Placebo Comparator|placebo|Placebo Comparator once per day
3062109|NCT00958308|Placebo Comparator|Placebo|Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3062110|NCT00958308|Active Comparator|BIO-K+ CL-1285|Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3062111|NCT00958308|Other|BIO-K+ CL-1285® & placebo|One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
3062112|NCT00958334|Experimental|Proellex 25 mg|Two Proellex® 12.5 mg capsules once daily
3062113|NCT00958334|Experimental|Proellex 12.5 mg|One Proellex® 12.5 mg capsules once daily
3062114|NCT00958334|Placebo Comparator|Placebo|Capsule once a day
3062115|NCT00958360|Experimental|Arm 1|Interdisciplinary Low Vision Rehabilitation: Low vision examination, prescription and dispensing of low vision devices, low vision therapy and homework.
3062116|NCT00958360|Active Comparator|Arm 2|Basic Low Vision Care: Low vision examination, prescription and dispensing of low vision devices without low vision therapy or assigned homework.
3062117|NCT00958412|Experimental|Proellex®|25 mg Proellex®
3062118|NCT00958438|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Rilonacept ) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
3062119|NCT00958438|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.
3062120|NCT00958438|Experimental|Rilonacept 160 mg|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.
3062121|NCT00958477|Experimental|EMD 525797|
3062122|NCT00958568|Experimental|Olanzapine and Fluoxetine combination (OFC)|
3062123|NCT00958568|Active Comparator|Fluoxetine|
3062124|NCT00958581|Placebo Comparator|Normal Saline|Patients infused with normal saline before and during the surgical procedure as a placebo.
3062125|NCT00958581|Experimental|Tranexamic acid|Patients receive TXA before and during the surgical case.
3062126|NCT00958581|Experimental|Epsilon Aminocaproic Acid|Patients will receive EACA before and during the surgical case.
3062127|NCT00958711|Experimental|Biologic - Unite Biomatrix|
3062128|NCT00958711|Active Comparator|Saline and Gauze|
3062129|NCT00958724|Experimental|Neratinib and Vinorelbine|Neratinib: 240 mg administered daily by mouth continuously, Vinorelbine: 25 mg/m^2 administered IV on Day 1 and 8 of 21 day cycle
3062130|NCT00958776|Experimental|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
3062131|NCT00958776|Placebo Comparator|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
3062132|NCT00958789|Other|Triathlon TS Knee|Triathlon TS Knee System
3062133|NCT00958828|Other|Nelfilcon A / Narafilcon A|Nelfilcon A contact lenses, then Narafilcon A contact lenses
3062134|NCT00958828|Other|Narafilcon A / Nelfilcon A|Narafilcon A contact lenses, then Nelfilcon A contact lenses
3062135|NCT00958841|Experimental|pasireotide LAR 60mg|Patients received pasireotide LAR at 60 mg approximately once every 28 days for 6 months during the core treatment period and additional treatment cycles up to a total of 48 months during the extension phase.
3062136|NCT00958880|Placebo Comparator|Sugar Pill|Participants will receive placebo (sugar pill) augmented Group Cognitive Behavioral Therapy
3062137|NCT00958880|Experimental|Yohimbine Hydrochloride|Participants will receive Yohimbine Hydrochloride augmented Group Cognitive Behavioral Therapy
3062138|NCT00958919|Experimental|naloxone|
3062139|NCT00958919|Placebo Comparator|normal saline|
3062140|NCT00959049|Experimental|Afluria Cohort A|Age 6 months to < 3 years
3062141|NCT00959049|Experimental|Afluria Cohort B|Age 3 to < 9 years
3062142|NCT00959049|Experimental|Afluria Cohort C|Age 9 to < 18 years
3062143|NCT00959049|Active Comparator|Fluzone Cohort A|Age 6 months to < 3 years
3062144|NCT00959049|Active Comparator|Fluzone Cohort B|Age 3 to < 9 years
3062145|NCT00959049|Active Comparator|Fluzone Cohort C|Age 9 to < 18 years
3062146|NCT00959166|Other|HIV/acute HCV coinfection|Subjects with HIV/acute HCV coinfection (aHCV cases) were required to have acute HCV, defined by a new positive plasma HCV RNA test within 12 months of a negative HCV RNA test.
3062147|NCT00959166|Other|HIV mono|HIV-infected individuals without hepatitis C co-infection
3062148|NCT00959192|Experimental|ACC-001 + QS-21|Active vaccine + adjuvant, IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
3062149|NCT00959192|Placebo Comparator|QS-21|Adjuvant, IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
3062150|NCT00959374|Active Comparator|V-loc and Monocryl|Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.
3062151|NCT00959647|Experimental|Vismodegib 150 mg|Participants received 150 mg vismodegib orally once a day until disease progression, intolerable toxicity, or withdrawal from the study. If a participant had been receiving combination chemotherapy and/or biotherapy (FOLFOX, FOLFIRI, bevacizumab) in a parent study, the same combination chemotherapy and/or biotherapy as specified in the parent study could be continued in this study at the discretion of the investigator.
3062152|NCT00959660|Active Comparator|Exercise Training|Exercise participants will undergo a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
3062153|NCT00959660|Active Comparator|Dietary Intervention|A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb) weight loss per week.
3062154|NCT00959660|Active Comparator|Attention control|Attention control participants will be provided a counseling session regarding general health education at baseline and will be contacted by staff via telephone every 2 weeks to discuss general health status.
3062155|NCT00959660|Active Comparator|Diet and Exercise|A hypocaloric diet will be developed to achieve a 2450 kcal/week deficit in addition to undergoing a 1-hour supervised exercise program 3 times per week for 20 weeks consisting primarily of walking exercise using an individualized exercise prescription based on the initial exercise stress testing results.
3062156|NCT00959699|Placebo Comparator|PegIFN-2b + RBV|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA <9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
3062157|NCT00959699|Active Comparator|PegIFN-2b + RBV + Boceprevir|PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.
3062158|NCT00959751|Experimental|NXN-188 600 mg|3 x 200 mg capsules, PRN
3062159|NCT00959751|Placebo Comparator|Placebo|3 x 0 mg capsules, PRN
3062160|NCT00959764|Experimental|Oral calcitonin and placebo nasal spray|Intervention: Oral calcitonin tablet (along with placebo intranasal spray)
3062161|NCT00959764|Active Comparator|Intranasal calcitonin & oral placebo|Intervention: Commercially available, active comparator, intranasal calcitonin-salmon (plus matching oral placebo tablet).
3062162|NCT00959764|Placebo Comparator|Placebo: tablet & intranasal spray|Intervention: Both oral matching placebo tablets and matching intranasal placebo spray
3062163|NCT00959842|Experimental|Lovaza|Lovaza was given as the only agent; there was no comparator agent or arm
3062164|NCT00959894|Experimental|Etravirine 400 mg once daily|Etravirine 400 mg once daily with fixed dose tenofovir/emtricitabine (Truvada) one tablet once daily
3062165|NCT00959907|Active Comparator|BoNT A1 (4U)|BoNT A1 (4U): Botulinum toxin A (Dysport®)4 units
3062166|NCT00959907|Active Comparator|BoNT-A2 (2U)|BoNT-A2(2U): Botulinum toxin A (Botox®) 2 units
3062167|NCT00959920|Active Comparator|Indwelling foley catheter|Insertion of an indwelling foley catheter when bladder emptying is necessary. The indwelling catheter will remain in place until the time of delivery.
3062168|NCT00959920|Active Comparator|Intermittent straight catheterization|Intermittent straight catheterization will be performed as needed during labor.
3062169|NCT00959946|Experimental|1|In part 1 (phase 1), ascending and descending multiple oral doses of bosutinib + capecitabine. Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14 + bosutinib 200 mg QD; capecitabine 625 mg/m2 BID on days 1-14 + bosutinib 300 mg QD. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID and bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
3062170|NCT00959985|No Intervention|Group 1A|Mild Lymphedema: Only required to meet with the lymphedema physical therapist
3062171|NCT00959985|Active Comparator|Group 1B|Mild Lymphedema: Fitted for compression sleeve
3062172|NCT00959985|Active Comparator|Group 2A|Moderate lymphedema: Fitted with a compression sleeve
3062173|NCT00959985|Active Comparator|Group 2B|Moderate Lymphedema: Fitted with compression sleeve and instructed to wear a short-stretch compression bandage
3062174|NCT00960011|Experimental|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
3062175|NCT00960011|Active Comparator|POLYPROPYLENE|Use of Polypropylene mesh for open inguinal hernia repair
3062176|NCT00960063|Experimental|Temozolomide+Irinotecan+Robatumumab|Participants receive temozolomide 100 mg/m^2/day intravenously (IV) on Days 1-5 PLUS irinotecan 10 mg/m^2/day IV on Days 1-5 and Days 8-12 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3062177|NCT00960063|Experimental|Vincristine+Doxorubicin+Cyclophosphamide+Robatumumab|Participants receive vincristine 2 mg/m^2 (maximum 2 mg) IV on Day 1 PLUS cyclophosphamide 1200 mg/m^2 IV on Day 1 PLUS doxorubicin hydrochloride 75 mg/m^2 IV continuously over 48 hours PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3062178|NCT00960063|Experimental|Ifosfamide+Etoposide+Robatumumab|Participants receive ifosfamide 1800 mg/m^2 per day IV PLUS etoposide 100 mg/m^2 per day IV on Days 1-5 PLUS robatumumab 10 mg/kg or 20 mg/kg IV on Day 1 of each 3-week cycle.
3062179|NCT00960076|Experimental|1|Saxagliptin
3062180|NCT00960076|Active Comparator|2|Metformin Extended Release
3062181|NCT00960115|Experimental|Tecemotide (L-BLP25) + Cyclophosphamide|Active
3062182|NCT00960115|Placebo Comparator|Placebo + Saline|Control
3062183|NCT00960141|Experimental|1|montelukast
3062184|NCT00960141|Active Comparator|2|loratadine
3062185|NCT00960141|Placebo Comparator|3|placebo
3062186|NCT00960193|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
3062187|NCT00960193|Experimental|Colchicine with Seville Orange Juice|colchicine pharmacokinetics in presence of Seville orange juice
3062188|NCT00960206|Experimental|Trident®System|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
3062189|NCT00960206|Experimental|ABC System|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
3062190|NCT00960206|Active Comparator|Control|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
3062191|NCT00960323|Active Comparator|Colchicine Alone|baseline colchicine pharmacokinetics
3062192|NCT00960323|Experimental|Colchicine with Atorvastatin|Colchicine pharmacokinetics in the presence of atorvastatin at steady state.
3062193|NCT00960375|Experimental|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
3062194|NCT00960375|Active Comparator|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide test at the start of each group meeting. StSST groups provide education about smoking and support for quitting.
3062195|NCT00960440|Experimental|Sequence 1|
3062196|NCT00960440|Experimental|Sequence 2|
3062197|NCT00960440|Placebo Comparator|Sequence 3|
3062198|NCT00960440|Placebo Comparator|Sequence 4|
3062199|NCT00960505|Experimental|Alternate day fasting (ADF)|Fast day diet: 25% energy intake, Feast day diet: Ad libitum energy intake (alternating days)
3062200|NCT00960505|Experimental|Calorie restriction (CR)|75% energy intake every day
3062201|NCT00960505|Active Comparator|Control|Usual diet
3062202|NCT00960531|Experimental|ACC-001 (3mcg) + QS-21|ACC-001 (3mcg) + QS-21
3062203|NCT00960531|Experimental|ACC-001 (10mcg) + QS-21|ACC-001 (10mcg) + QS-21
3062204|NCT00960531|Experimental|ACC-001 (30mcg) + QS-21|ACC-001 (30mcg) + QS-21
3062205|NCT00960570|Active Comparator|Efavirenz Alone|Baseline Efavirenz pharmacokinetics.
3062206|NCT00960570|Experimental|Efavirenz with Steady State Fenofibric Acid|Efavirenz pharmacokinetics in the presence of steady state Fenofibric Acid.
3062207|NCT00960622|Experimental|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
3062208|NCT00960622|Active Comparator|Combivir or Trizivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months or Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
3062209|NCT00960661|Experimental|Exenatide (BET)|Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET)
3062210|NCT00960661|Active Comparator|Insulin Lispro (BBT)|Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT)
3062211|NCT00960687|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered 30 minutes after the initiation of a standard breakfast.
3062212|NCT00960687|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered 30 minutes after the initiation of a standard breakfast.
3062213|NCT00960778|Experimental|Women- denicotinized cigarette|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
3062214|NCT00960778|Experimental|Men- denicotinized cigarette|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues after four days of denicotinized cigarette (less than 0.5 gram nicotine) use.
3062215|NCT00960778|Experimental|Women -nicotine patch|Treatment-seeking nicotine-dependent women will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
3062216|NCT00960778|Experimental|Men- nicotine patch|Treatment-seeking nicotine-dependent men will participate in functional magnetic resonance imaging (fMRI) with the presentation of smoking-related cues under after receiving three days of a 21 mg nicotine patch.
3062217|NCT00960804|Experimental|Tanezumab 5 mg|
3062218|NCT00960804|Experimental|Tanezumab 10 mg|
3062219|NCT00960804|Placebo Comparator|Placebo|
3062220|NCT00960843|Active Comparator|Conventional Adjustment Group|Subject whose band adjustments will be made via conventional standard of care (e.g., volume, hunger).
3062221|NCT00960843|Active Comparator|Intraband Pressure Arm|Subjects whose band adjustments will be guided by intraband pressure readings.
3062222|NCT00960856|Experimental|Fenofibric Acid 105 mg - Low-Fat Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
3062223|NCT00960856|Experimental|Fenofibric Acid 105 mg - Standard Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a standard breakfast.
3062224|NCT00960856|Experimental|Fenofibric Acid 105 mg - High-Fat/High-Calorie Meal|Fenofibric Acid 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
3062225|NCT00960856|Experimental|Fenofibric Acid 105 mg - Fasted State|Fenofibric Acid 105 mg tablet administered after an overnight fast of at least 10 hours
3062226|NCT00960869|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole dosed once daily (QD)
3062227|NCT00960869|Active Comparator|EC-Aspirin 325 mg|EC-Aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole) dosed once daily (QD)
3062228|NCT00960934|Experimental|MK-5442 2.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 2.5 mg of MK-5442 for a duration of at least 6 months.
3062229|NCT00960934|Experimental|MK-5442 5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 5 mg of MK-5442 for a duration of at least 6 months.
3062230|NCT00960934|Experimental|MK-5442 7.5 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 7.5 mg of MK-5442 for a duration of at least 6 months.
3062231|NCT00960934|Experimental|MK-5442 10 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 10 mg of MK-5442 for a duration of at least 6 months.
3062232|NCT00960934|Experimental|MK-5442 15 mg|Following a 2-week open-label placebo run-in, participants received a daily oral dose of 15 mg of MK-5442 for a duration of at least 6 months.
3062233|NCT00960934|Placebo Comparator|Placebo|Following a 2-week open-label placebo run-in, participants received a daily oral dose of placebo dose-matched to MK-5442 for a duration of at least 6 months.
3062234|NCT00960986|Experimental|Duloxetine 60 mg with food|Duloxetine 60 milligram (mg) capsule oral (po), once daily (QD) with food for 8 weeks
3062235|NCT00960986|Experimental|Duloxetine 60 mg without food|Duloxetine 60 mg capsule po QD without food for 8 weeks
3062236|NCT00960986|Experimental|Duloxetine 30 mg with food|Duloxetine 30 mg capsule po QD with food for 1 week, then 60 mg with food for 7 weeks
3062237|NCT00960986|Experimental|Duloxetine 30 mg without food|Duloxetine 30 mg capsule po QD without food for 1 week, then 60 mg without food for 7 weeks
3062238|NCT00960999|Experimental|Single-fraction SBRT (34 Gy)|Single-fraction stereotactic body radiation therapy (SBRT) of 34 Gy
3062239|NCT00960999|Experimental|Multiple-fraction SBRT (48 Gy)|Multiple-fraction stereotactic body radiation therapy (SBRT) given in four daily 12 Gy fractions for a total dose of 48 Gy
3062240|NCT00961051|Experimental|Investigational MPS|Investigational multipurpose disinfecting solution (study MPS)
3062241|NCT00961051|Active Comparator|Predicate MPS|Opti-Free RepleniSH multipurpose disinfecting solution (predicate MPS)
3062242|NCT00961064|Experimental|1|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
3062243|NCT00961116|Experimental|Fenofibric Acid (Fibricor™)|1 x 105 mg fenofibric acid (Fibricor™)tablet administered after an overnight fast of at least 10 hours
3062244|NCT00961116|Experimental|Fenofibrate (Tricor®)|1 x 145 mg fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
3062245|NCT00961181|Experimental|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
3062246|NCT00961220|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour and apply topical carmustine to the total skin surface (excluding the lips, eyelids, and ulcerated lesions) 1 hour after completing O6-benzylguanine infusion on days 1-2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3062247|NCT00961233|Experimental|inhaled/swallowed budesonide|
3062248|NCT00961233|Active Comparator|viscous/swallowed budesonide|
3062249|NCT00961259|Experimental|Fenofibric Acid 35 mg (1 x 35 mg tab)|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
3062250|NCT00961259|Experimental|Fenofibric Acid 105 mg (3 x 35 mg tab)|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
3062251|NCT00961259|Experimental|Fenofibric Acid 105 mg (1 x 105 mg tab)|1 x 105 mg tablet administered after an overnight fast of at least 10 hours
3062252|NCT00961298|Experimental|Duloxetine|Two weeks of placebo run in followed by 12 weeks of Duloxetine.
3062253|NCT00961311|Experimental|Trial Arm|All patients with systematic ischemic heart disease with stenotic lesions that are amenable to percutaneous treatment.
3062254|NCT00961350|Experimental|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
3062255|NCT00961350|Active Comparator|EC Aspirin|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
3062256|NCT00961402|Experimental|Wellness Control|Participants will receive health and wellness information and no exercise information.
3062257|NCT00961402|Experimental|Exercise Intervention|Intervention will include motivational telephone-based intervention to increase exercise to 5 days per week for 30 minutes or more each session.
3062258|NCT00961415|Experimental|Part 1|
3062259|NCT00961415|Experimental|Part 2A|
3062260|NCT00961415|Active Comparator|Part 2B|
3062261|NCT00961441|Experimental|Children 12-16 years old|
3062262|NCT00961441|Experimental|Adults 18-55 years old|
3062263|NCT00961532|Experimental|DDAVP|DDAVP 0.4 mcg/kg intravenously in 250 mL NS over 30 minutes
3062264|NCT00961571|Experimental|sunitinib and cepecitabine|Administration of sunitinib and capecitabine
3062265|NCT00961636|Experimental|ERN/LRPT|"One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg~tablets daily (2g/40 mg total) for 28 weeks"
3062266|NCT00961636|Experimental|ERN/LRPT then ERN|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks then Two 1g tablets ERN (2g total) once daily for 12 weeks.
3062267|NCT00961636|Placebo Comparator|Placebo|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks.
3062268|NCT00961649|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3062269|NCT00961649|Active Comparator|Brinz|Brinzolamide ophthalmic suspension, 1% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3062270|NCT00961649|Active Comparator|Brim|Brimonidine tartrate ophthalmic solution, 0.2% and Vehicle: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3062271|NCT00961649|Active Comparator|Brinz+Brim|Brinzolamide ophthalmic suspension, 1% and brimonidine tartrate ophthalmic solution, 0.2%: 1 drop each instilled in both eyes 3 times a day for 6 weeks. A time lapse of at least 10 minutes was required between instillations of each study drug.
3062272|NCT00961662|Experimental|2.5 active|2.5 Active - 2.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3062273|NCT00961662|Active Comparator|5.0 mid dose|5.0 mid dose - 5.0 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3062274|NCT00961662|Active Comparator|7.5 high dose|7.5 high dose - 7.5 g D-tagatose given orally, three times daily, immediately prior to meals for 6 months.
3062275|NCT00961805|Experimental|Dance Group|Belly dance
3062276|NCT00961805|No Intervention|Control Group|Waiting list
3062277|NCT00961896|Active Comparator|LDE225 (applied in parallel with vehicle) [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
3062278|NCT00961896|Placebo Comparator|Vehicle cream (applied in parallel with LDE225 [Part I]|Participants were exposed to both topically applied 0.75% LDE225 cream and LDE225 vehicle cream twice daily for 28 days where each treatment was randomized to two different test areas on each participant.
3062279|NCT00961896|Active Comparator|LDE225 0.25% [Part II]|Participants were exposed to topically applied 0.25% LDE225 cream twice daily for 6 weeks.
3062280|NCT00961896|Active Comparator|LDE225 0.75% [Part II]|Participants were exposed to topically applied 0.75% LDE225 cream twice daily where some basal cell carcinomas (BCCs) were teated for 6 weeks and some BCCs were treated for 9 weeks.
3062281|NCT00961961|Other|Lithium plus Fluoxetine Phase I|All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.
3062282|NCT00961961|Other|Lithium plus Placebo Phase I|No participants began their participation on Lithium plus Placebo.
3062283|NCT00961961|Experimental|Lithium plus Fluoxetine Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.
3062284|NCT00961961|Placebo Comparator|Lithium plus Placebo Phase II|Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.
3062285|NCT00962000|Other|600 mL/min|Dialysis Flow Rate Start 600mL/min Subject starting dialysis flow rate set at 600mL/min. ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
3062286|NCT00962000|Other|800 mL/min|Dialysis Flow Rate Start 800mL/min Subject starting dialysis flow rate set at 800mL/min. BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
3062287|NCT00962013|Other|Restoration® Modular|All subjects were enrolled into a single arm and received the Restoration® Modular Revision Hip System to replace the femoral portion of a failed previous implant.
3062288|NCT00962039|Experimental|Citalopram|Citalopram was initiated at 10 mg daily for one week, with dosage increased to 20 mg daily during week 2, with an optional increase to 40 mg daily at week 4 or thereafter if response was judged to be suboptimal (CGI-I or CGI-S > 2).
3062289|NCT00962039|Placebo Comparator|Placebo|Placebo administered in capsules identical to those containing citalopram using microcrystalline cellulose.
3062290|NCT00962065|Experimental|Low Dose|A low dose of LX4211; daily oral intake for 28 days
3062291|NCT00962065|Experimental|High Dose|A high dose of LX4211; daily oral intake for 28 days
3062292|NCT00962065|Placebo Comparator|Placebo|Matching placebo dosing with daily oral intake for 28 days
3062293|NCT00962078|Other|interval training|interval training in lung transplant candidates
3062294|NCT00962078|Other|Continuous Training|continuous training in lung transplant candidates
3062295|NCT00962091|Experimental|Dose Escalation|A single dose of alisertib 15 mg, oral solution (OS) was administered on Day 1, followed by alisertib 40 mg, powder-in-capsule (PIC), orally, twice a day (BID) on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, was administered on Cycle 2 Day 1 followed by alisertib 40 mg on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Subsequent cycles, alisertib 40 or 50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062296|NCT00962091|Experimental|Part A: Relative Bioavailability OS/PIC (Sequence A)|A single dose of alisertib 25 mg, OS, administered on Day 1, followed by alisertib 40 mg PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. A single dose of alisertib 50 mg PIC, orally, administered on Cycle 2 Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles, alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062297|NCT00962091|Experimental|Part A: Relative Bioavailability PIC/OS (Sequence B)|A single dose of alisertib 50 mg, PIC, orally administered on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 25 mg, OS, once on Day 1, followed by alisertib 40 mg, PIC, orally, BID on Days 3 through 9, followed by a 14-day rest period in a 23-day cycle. Subsequent cycles followed by alisertib 40-50 mg (individual dosage based on tolerability in Cycles 1 and 2), PIC, orally, BID on Days 1 through 7, followed by a 14-day rest period in Cycle 3, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062298|NCT00962091|Experimental|Part B: OS Food Effect Fed/Fasted (Sequence A)|Alisertib 35 mg (35 mg = relative bioavailability estimate in Part A as dose of OS that was calculated to yield the area under the concentration time curve of a 50-mg PIC dose): A single dose of alisertib 35 mg oral solution (OS), in fed state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in Cycle 1, in a 23-day cycle. Cycle 2 Day 1 alisertib 35 mg administered, OS, in fasted state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg, PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted, based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062299|NCT00962091|Experimental|Part B: OS Food Effect Fasted/Fed (Sequence B)|A single dose of alisertib 35 mg, OS, in fasted state, administered on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 2 Day 1 alisertib 30 mg, OS administered in fed state, once on Day 1, followed by alisertib 30 mg, OS, BID on Days 3-9, followed by a 14-day rest period in a 23-day cycle. Cycle 3 onwards, participants received alisertib 40 mg PIC, orally, BID on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062300|NCT00962091|Experimental|Part C: ECT Food Effect Fed/Fasted (Sequence A)|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 40 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2 in a 23-day cycle. Cycle 3 onwards, participants were administered alisertib 40 mg BID ECT on Days 1-7 with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062301|NCT00962091|Experimental|Part C: ECT Food Effect Fasted/Fed (Sequence B)|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 40 mg, ECT, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 1 in a 23-day cycle, followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 40 or 50 mg, ECT, orally, BID on Days 3 through 9, followed by a 14-day rest period in Cycle 2, a 23-day cycle. Cycle 3 onwards participants were administered alisertib 40 mg BID ECT on Days 1-7, with dose reduction to 30 mg BID or escalation to 50 mg BID permitted based on individual tolerance, followed by a 14-day rest period, in 21-day cycles until disease progression, occurrence of an unacceptable alisertib-related toxicity, or the start of another anticancer therapy.
3062302|NCT00962104|Experimental|Atomoxetine|
3062303|NCT00962104|Placebo Comparator|Placebo|
3062304|NCT00962208|Experimental|orthokeratology lenses|Children wearing orthokeratology at night for correcting of refractive error will be study group
3062305|NCT00962208|Other|single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
3062306|NCT00962247|Experimental|Sedentary; usual, 25% reduced, 50% reduced|The initial 3 weeks of the study, children were asked to maintain their usual targeted sedentary behaviors (TV, video game, computer use) measured by a television reduction device (TV Allowance). The following 3 weeks children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 25% from the usual sedentary condition using a television reduction device (TV Allowance). The final 3 weeks of the study, children were asked to reduce their targeted sedentary behaviors (TV, video game, computer use) by 50% from the usual sedentary condition using a television reduction device (TV Allowance)
3062307|NCT00962390|Experimental|150mg S-equol|
3062308|NCT00962390|Experimental|50mg S-equol|
3062309|NCT00962390|Experimental|10 mg S-equol|
3062310|NCT00962390|Placebo Comparator|Placebo|
3062311|NCT00962585|Placebo Comparator|Placebo|Placebo
3062312|NCT00962585|Experimental|S-equol 10 mg BID|S-equol 20 mg total daily dose
3062313|NCT00962585|Experimental|S-equol 50 mg BID|S-equol 100 mg total daily dose
3062314|NCT00962585|Experimental|S-equol 150 mg BID|S-equol 300 mg total daily dose
3062315|NCT00962598|Placebo Comparator|Corn Oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
3062316|NCT00962598|Experimental|Omega-3 Fatty Acids|The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
3062317|NCT00962650|Experimental|NOTES Toolbox|Multiple devices designed for trans-orifice use during surgical procedures; used for transvaginal cholecystectomy in this trial
3062318|NCT00962741|Experimental|1|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
3062319|NCT00962754|No Intervention|physician insight fluid balance|physician has insight in fluid balance chart, this is standard practice
3062320|NCT00962754|Experimental|fluid balance data masked to physician|physician no insight in the fluid balance chart
3062321|NCT00962780|Experimental|1|3 doses of 13vPnC and 1 dose of 23vPS, each dose given approximately 1 month apart
3062322|NCT00962871|Active Comparator|1|
3062323|NCT00962871|Experimental|2|
3062324|NCT00962871|Experimental|3|
3062325|NCT00962871|No Intervention|4|
3062326|NCT00962949|Experimental|Control|Healthy controls
3062327|NCT00962949|Experimental|Postural Tachycardia Syndrome|Patients with Postural Tachycardia Syndrome
3062328|NCT00963105|Experimental|Lenalidomide 5 mg|"Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
3062329|NCT00963105|Experimental|Lenalidomide 10 mg|"Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
3062330|NCT00963105|Experimental|Lenalidomide 15 mg|"Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability.~Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug"
3062331|NCT00963157|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3062332|NCT00963157|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3062333|NCT00963157|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3062334|NCT00963157|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3062335|NCT00963157|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3062336|NCT00963235|Experimental|1|
3062337|NCT00963430|Experimental|Group 2: 30 mcg H1N1 vaccine|60 subjects to receive 30 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
3062338|NCT00963430|Experimental|Group 1: 15 mcg H1N1 vaccine|60 subjects to receive 15 mcg of inactivated H1N1 vaccine on Day 0 and Day 21.
3062339|NCT00963469|Experimental|1|montelukast
3062340|NCT00963469|Active Comparator|2|loratadine
3062341|NCT00963469|Placebo Comparator|3|placebo
3062342|NCT00963482|Experimental|Intervention group|Cognitive-behavioural smoking cessation program
3062343|NCT00963482|Other|Control group|Autogenic training
3062344|NCT00963508|Experimental|Malathion Gel|Malathion gel 0.5% 30 minute application
3062345|NCT00963508|Active Comparator|Nix Crème Rinse|Nix Crème Rinse applied to scalp for 10 minutes
3062346|NCT00963547|Experimental|Pt. 1: MK-2206 45mg, QOD + Trastuzumab|Participants in Part 1 (Pt. 1) receive MK-2206 45 mg every other day (QOD), taken orally. In combination with MK-2206, trastuzumab is administered by intravenous (IV) infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg every 3 weeks (q3wk).
3062347|NCT00963547|Experimental|Pt. 1: MK-2206 60mg, QOD + Trastuzumab|Participants in Pt. 1 receive MK-2206 60 mg QOD, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
3062348|NCT00963547|Experimental|Pt. 1: MK-2206 135mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 135 mg once weekly (QW), taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
3062349|NCT00963547|Experimental|Pt. 1: MK-2206 200mg, QW + Trastuzumab|Participants in Pt. 1 receive MK-2206 200 mg QW, taken orally. In combination with MK-2206, trastuzumab is administered by IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk.
3062350|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 500mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the maximum tolerated dose defined in Part 1 (Pt. 1 MTD). MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 500 mg taken orally once daily (QD).
3062351|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 750mg, QD|Participants in Pt. 2 receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 750 mg taken orally QD.
3062352|NCT00963547|Experimental|Pt. 2: MK-2206 (Pt.1 MTD) + Trastuzumab + Lapatinib 1000mg, QD|Participants in Part 2 (Pt. 2) receive MK-2206 (dosed either QOD or QW) taken orally at the Pt. 1 MTD. MK-2206 is administered in combination with trastuzumab (IV infusion at an initial dose of 8 mg/kg (loading dose) followed by 6 mg/kg q3wk) as well as lapatinib 1000 mg taken orally QD.
3062353|NCT00963560|Experimental|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lens (IOL)
3062354|NCT00963560|Active Comparator|Crystalens HD|Bilateral implantation of Crystalens HD Intraocular Lens (IOL)
3062355|NCT00963560|Active Comparator|Crystalens AO|Bilateral implantation of Crystalens AO Intraocular Lens (IOL)
3062356|NCT00963599|Experimental|1|montelukast/loratadine
3062357|NCT00963599|Experimental|2|loratadine
3062358|NCT00963599|Experimental|3|montelukast
3062359|NCT00963599|Placebo Comparator|4|placebo
3062360|NCT00963638|Experimental|MagTabSR|
3062361|NCT00963638|Placebo Comparator|Sugar Pill|
3062362|NCT00963677|Experimental|Intubation without difficulty|The patients are not predicted for difficult intubation
3062363|NCT00963677|Experimental|Difficult intubation|The patients will be anticipated for difficult intubation without difficult ventilation
3062364|NCT00963807|Experimental|Treatment|Patients receive docetaxel IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo FDG PET/CT, FLT PET/CT, and thoracic CT at baseline and the end of cycles 1 and 2 and then undergo surgery.
3062365|NCT00963820|Experimental|0.24 mg/m^2|Ixazomib citrate, 0.24 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate
3062366|NCT00963820|Experimental|0.48 mg/m^2|Ixazomib citrate, 0.48 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062367|NCT00963820|Experimental|0.80 mg/m^2|Ixazomib citrate, 0.80 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062368|NCT00963820|Experimental|1.20 mg/m^2|Ixazomib citrate, 1.20 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period.
3062369|NCT00963820|Experimental|1.68 mg/m^2|Ixazomib citrate, 1.68 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062370|NCT00963820|Experimental|2.23 mg/m^2|Ixazomib citrate, 2.23 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062371|NCT00963820|Experimental|2.97 mg/m^2|Ixazomib citrate, 2.97 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062372|NCT00963820|Experimental|3.95 mg/m^2|Ixazomib citrate, 3.95 mg/m^2, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the dose escalation period. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062373|NCT00963820|Experimental|Relapsed and Refractory (RR)|Ixazomib citrate, 2.97 mg/m^2 established Maximum Tolerated Dose (MTD), capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the Relapsed and Refractory (RR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062374|NCT00963820|Experimental|VELCADE-Relapsed (VR)|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the VELCADE-relapsed (VR) expansion cohort. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062375|NCT00963820|Experimental|PI naïve|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in expansion cohort of participants who were proteasome inhibitor-naïve (PI naïve). All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062376|NCT00963820|Experimental|Carfilzomib|Ixazomib citrate, 2.97 mg/m^2 established MTD, capsules, orally, once weekly on Days 1, 8, and 15 of a 28-day cycle in the expansion cohort of participants who received their last dose of carfilzomib between 21 and 60 days prior to the first dose of ixazomib citrate. All dose amounts are expressed as the dose of ixazomib, the biologically active moiety of ixazomib citrate.
3062377|NCT00963859|Experimental|Robotic-assisted laparoscopic surgery|Robotic-assisted laparoscopic extended pelvic lymph node dissection
3062378|NCT00963872|Experimental|Complement Fragment 3A - Small Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.
3062379|NCT00963872|Experimental|Complement Fragment A - Larger Cell Dose|Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.
3062380|NCT00963911|Experimental|Included patients|Screening tests (G8 and VES-13)
3062381|NCT00963924|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
3062382|NCT00963924|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before the first cognitive remediation session of the week, for eight weeks.
3062383|NCT00963937|Active Comparator|Sumatriptan 25 mg|
3062384|NCT00963937|Active Comparator|Sumatriptan 50 mg|
3062385|NCT00963937|Placebo Comparator|Placebo|
3062386|NCT00963989|Experimental|Penumbra Device Arm|
3062387|NCT00964028|Experimental|INFANRIX-IPV/HIB M2-M3-M4 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age (M2-M3-M4), administered intramuscularly into the upper right side of the thigh.
3062388|NCT00964028|Experimental|INFANRIX-IPV/HIB M3-M4-M5 GROUP|Healthy male or female subjects between and including 60 and 90 days of age at the time of the first vaccination, received 3 doses of Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age (M3-M4-M5), administered intramuscularly into the upper right side of the thigh.
3062389|NCT00964158|Experimental|Group A|
3062390|NCT00964223|Experimental|Duac gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
3062391|NCT00964223|Active Comparator|Epiduo gel|Subjects will apply Duac gel once a day to one-half of their face and and apply Epiduo gel on the other side of their face once daily for the first 2 weeks.
3062392|NCT00964353|Active Comparator|Clinically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on clinical data algorithms
3062393|NCT00964353|Experimental|Pharmacogenetically Guided Cohort|Estimated Effective Warfarin dosing calculations are based on genetic and clinical data algorithms.
3062394|NCT00964366|Experimental|Clindamycin/BPO gel|Once-daily applications of clindamycin/BPO gel to the randomized side of the face either left or right.
3062395|NCT00964366|Active Comparator|Dapsone gel|Twice-daily applications of dapsone gel to one side of the face.
3062396|NCT00964392|Experimental|More-Experienced Physicians (MEP)|Physicians who perform greater than or equal to 50 atrial fibrillation ablation procedures per year.
3062397|NCT00964392|Experimental|Less-Experienced Physicians (LEP)|Physicians who perform less than 50 atrial fibrillation ablation procedures per year.
3062398|NCT00964431|Experimental|Indomethacin Test (lower dose)|
3062399|NCT00964431|Experimental|Indomethacin Test (upper dose)|Single dose
3062400|NCT00964431|Active Comparator|Celecoxib 400 mg|
3062401|NCT00964431|Placebo Comparator|Placebo|
3062402|NCT00964496|Active Comparator|Thalidomide Group|
3062403|NCT00964496|Other|Iron-controlled Group|
3062404|NCT00964548|Experimental|Dantrolene (low dose)|
3062405|NCT00964548|Experimental|Dantrolene (high dose)|
3062406|NCT00964678|Experimental|carvedilol|Carvedilol is titrated from a dose of 3.125mg twice daily to a maximal dose of 25mg twice daily over 24 weeks. Patients are evaluated to their response with 6 minute walk testing, echocardiography, and cardiac MRI
3062407|NCT00964743|Experimental|Intrathecal DepoCyt and Oral Sorafenib|This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
3062408|NCT00964782|Active Comparator|Sildenafil crossover to placebo|Sildenafil dosage (0.5mg/kg (max 20mg)) administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2, placebo drug administered before the exercises.
3062409|NCT00964782|Placebo Comparator|Placebo crossover to sidenafil|Patient will receive a look-alike placebo administered at the time of enrollment followed by a battery of exercise tests. After a washout period, the process will be repeated with treatment 2 Sildenafil dosage will be 0.5mg/kg (max 20mg) administered before the exercises.
3062410|NCT00964795|Experimental|Open-label Intravitreal Aflibercept Injection|Open-label Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) 2mg (40 mg/mL) was administered no more frequently than every 4 weeks, but no less frequently than every 12 weeks until amendment 4. Starting with amendment 4, Intravitreal Aflibercept Injection was administered no less frequently than every 8 weeks. Within these limits, the investigator would determine the interval of Intravitreal Aflibercept Injection administration on an as-needed basis according to the protocol-suggested re-treatment criteria, however the injections must have occurred at least every 12 weeks prior to amendment 4, and at least every 8 weeks starting from amendment 4 as noted above.
3062411|NCT00964860|No Intervention|Brushing Only|Brushing Only with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice
3062412|NCT00964860|Experimental|Brushing + Flossing|Brushing with an Oral B manual toothbrush and Crest Cavity Protection, sodium fluoride dentifrice, plus flossing with Glide floss
3062413|NCT00964886|Experimental|Arm 1|desipramine hydrochloride
3062414|NCT00964886|Experimental|Arm 2|cognitive behavioral therapy
3062415|NCT00964886|Experimental|Arm 3|desipramine hydrochloride and cognitive behavioral therapy
3062416|NCT00964886|Placebo Comparator|Arm 4|anticholinergic medication; active placebo
3062417|NCT00965081|Experimental|Duloxetine|
3062418|NCT00965081|Placebo Comparator|Placebo|
3062419|NCT00965094|Experimental|Everolimus|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients were switched to the CNI-free regimen. Everolimus was added to the patients immunosuppressive regimen and tacrolimus was removed successively.
3062420|NCT00965094|Active Comparator|Reference Therapy|At BL1, all study patients received induction therapy with basiliximab (Simulect®; 2x20mg on day 0 - 2 hours prior to transplantation, and on day 4 after transplantation) and commenced an immunosuppressive regimen consisting of MPA (Myfortic®; target dose: 1440 mg/day, which was also the maximum daily dose) + tacrolimus (Prograf®; based on C0-h levels; Table 9-2) and with corticosteroids. AT BL2 [Month 3 (+1 week) after transplantation], eligible patients were randomized, using living and cadaveric donation as stratum. Patients continued on the prior immunosuppressive regimen consisting of MPA + tacrolimus with corticosteroids.
3062421|NCT00965185|Experimental|Atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
3062422|NCT00965185|Placebo Comparator|placebo|
3062423|NCT00965237|Other|Multifocal CL / Single vision CL + reading glasses|Lotrafilcon B multifocal contact lenses (CL) worn first, with lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
3062424|NCT00965237|Other|Single vision CL + reading glasses / Multifocal CL|Lotrafilcon B single vision contact lenses (CL) and over-reader spectacles worn first, with lotrafilcon B multifocal contact lenses (CL) worn second. Both contact lens products worn bilaterally on a daily wear basis; over-reader spectacles worn on an as-needed basis.
3062425|NCT00965250|Experimental|Thymoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
3062426|NCT00965250|Experimental|Thymic Carcinoma|Patients will receive IMC-A12 at a dose of 20 mg/kg intravenously once every three weeks. The most common tumors of the thymus are thymomas (well differentiated neoplasms and moderately differentiated neoplasms) and thymic (poorly differentiated neoplasms) carcinomas.
3062427|NCT00965263|Experimental|Low dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 82ul
3062428|NCT00965263|Experimental|High Dose Vaccine|All participants were vaccinated four times: in week 1, 3, 5, and 9. Dose: 360ul
3062429|NCT00965341|Active Comparator|Testosterone|Testosterone Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
3062430|NCT00965341|Placebo Comparator|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
3062431|NCT00965419|Experimental|Edivoxetine|All enrolled participants were administered starting dose of 0.1 milligram per kilogram per day (mg/kg/day), or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
3062432|NCT00965458|Experimental|Alefacept|Subjects in this group receive weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
3062433|NCT00965458|Placebo Comparator|Placebo|Subjects in this group received weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
3062434|NCT00965484|Experimental|Genotropin pen|All subjects will receive genotropin pen to use for 2 months.
3062435|NCT00965497|Experimental|Escitalopram|All patients will receive escitalopram 20 mg daily.
3062436|NCT00965523|Experimental|Eribulin Mesylate|
3062437|NCT00965562|Active Comparator|I|Fluoxetine
3062438|NCT00965562|Active Comparator|II|Calcium
3062439|NCT00965562|Placebo Comparator|III|
3062440|NCT00965575|Experimental|Melatonin|Subjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
3062441|NCT00965575|Placebo Comparator|Placebos|Subjects will take a placebo 30 minutes before bedtime for four weeks
3062442|NCT00965731|Active Comparator|Erlotinib|
3062443|NCT00965731|Experimental|Erlotinib + PF-02341066|
3062446|NCT00965848|Experimental|Nosocomial Pneumonia|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with nosocomial pneumonia up to maximum of 14 days.
3062447|NCT00965848|Experimental|Complicated Intra-Abdominal Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated intra-abdominal infections up to maximum of 14 days.
3062448|NCT00965848|Experimental|Complicated Urinary Tract Infections|Doripenem will be administered as 1 or 4 hours intravenous infusion at a dose of 500 mg every 8 hours in participants with complicated urinary tract infections up to maximum of 10 days.
3062449|NCT00966186|Active Comparator|Standard technique|Proseal laryngeal mask airway was inserted according to the manufacture's instruction manual (insertion with help of index finger insertion)
3062450|NCT00966186|Experimental|Rotational technique|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was fel
3062451|NCT00966238|Experimental|VAX125|HA1 influenza vaccine
3062452|NCT00966264|Active Comparator|LNG-IUS|Levonorgestrel releasing intrauterine system
3062453|NCT00966264|Other|Hysterectomy|Hysterectomy
3062454|NCT00966277|Experimental|Group 1: Dalteparin|Dalteparin 5000 units subcutaneous, by injection under the skin, daily for 16 weeks.
3062455|NCT00966277|No Intervention|Group 2: Control|No study drug.
3062456|NCT00966355|Active Comparator|Terlipressin|treat with terlipressin IV for 5 days and endoscopic treatment
3062457|NCT00966355|Active Comparator|Somatostatin|treat with somatostatin IV for 5 days and endoscopic treatment
3062458|NCT00966355|Active Comparator|Octreotide|treat with octreotide IV for 5 days and endoscopic treatment
3062459|NCT00966433|Experimental|Spontaneous ventilation|Pt's will be allowed to breathe spontaneously through the PLMA during surgery without the assistance of positive pressure ventilation.
3062460|NCT00966433|Experimental|Pressure support ventilation|Pt's will receive positive pressure assistance with each spontaneous breath through the PLMA.
3062461|NCT00966433|Active Comparator|Pressure control ventilation|Pt.'s will be placed on the ventilator and ventilated with pressure control. through the PLMA.
3062462|NCT00966446|Experimental|Unsupervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided.
3062463|NCT00966446|Experimental|Supervised Decolonization|Households undergo decolonization for MRSA. The intervention includes applying Mupirocin ointment twice daily for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Study staff is in contact with household members during this intervention to ensure compliance.
3062464|NCT00966446|No Intervention|No Intervention|Households do not undergo active MRSA decolonization protocol
3062465|NCT00966550|Active Comparator|Tomato|Tomato with high carb/fat meal
3062466|NCT00966550|Placebo Comparator|Non-Tomato|Non-tomato with high carb/fat meal
3062467|NCT00966641|Experimental|PL 3100|Active experimental drug
3062468|NCT00966641|Active Comparator|Naproxen|Active comparator
3062469|NCT00966693|Experimental|Treatment (lenalidomide, thalidomide, dexamethasone)|"Participants receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Participants also receive dexamethasone PO QD on days 1-4, 9-12, and 17-20 of courses 1-2, and days 1, 8, 15, and 22 of subsequent courses. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Participants who have stable or responding disease to treatment receive lenalidomide PO on days 1-21 and thalidomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants may receive dexamethasone at the discretion of the investigator."
3062470|NCT00966719|Active Comparator|Lactation Consultant|"In hospital meeting with lactation consultant~1 to 3 follow up visits at weekly intervals with lactation consultant"
3062471|NCT00966719|No Intervention|current treatment for jaundice|Babies will receive current standard of care for jaundice (IV fluids and phototherapy)
3062472|NCT00966823|Experimental|Detachable balloon|Intervention: Fetuses treated with endoscopic tracheal occlusion
3062473|NCT00966849|Experimental|Conditional Cash Transfer|Vulnerable households in this arm will receive conditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3062474|NCT00966849|Experimental|Unconditional Cash Transfer|Vulnerable households in this arm will receive unconditional cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3062475|NCT00966849|Other|Control|Vulnerable households in this arm will not receive cash transfers. A standard agricultural package (e.g. seeds, fertiliser etc) will be made available. Parenting skills classes will also be made available. Standard social services will continue in the area.
3062476|NCT00966875|Experimental|3 mg LY2439821 (bDMARD-naive population)|3 milligrams (mg) LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)]
3062477|NCT00966875|Experimental|10 mg LY2439821 (bDMARD-naive population)|10 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062478|NCT00966875|Experimental|30 mg LY2439821 (bDMARD-naive population)|30 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062479|NCT00966875|Experimental|80 mg LY2439821 (bDMARD-naive population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062480|NCT00966875|Experimental|180 mg LY2439821 (bDMARD-naive population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062481|NCT00966875|Experimental|80 mg LY2439821 (TNFa-IR population)|80 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60. [Tumor Necrosis Factor Alpha-Inadequate Responder (TNFα-IR)]
3062482|NCT00966875|Experimental|180 mg LY2439821 (TNFa-IR population)|180 mg LY2439821 at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062483|NCT00966875|Placebo Comparator|Placebo (bDMARD-naive population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062484|NCT00966875|Placebo Comparator|Placebo (TNFa-IR population)|Placebo at Weeks 0, 1, 2, 4, 6, 8 and 10, followed by 160 mg LY2439821 in Part B (optional) at Weeks 16, 18, 20 and every 4 weeks thereafter through Week 60.
3062485|NCT00966940|Other|Travoprost-to-tafluprost|Travoprost first, with tafluprost second. Each product dosed for six weeks.
3062486|NCT00966940|Other|Tafluprost-to-travoprost|Tafluprost first, with travoprost second. Each product dosed for six weeks.
3062487|NCT00966953|Placebo Comparator|Fluoride Toothpaste|fluoride control
3062488|NCT00966953|Active Comparator|Total/Whitening|positive control
3062489|NCT00966953|Experimental|antibacterial plant extract 1|Honokiol
3062490|NCT00966953|Experimental|antibacterial plant extract 2|magnolol
3062491|NCT00967005|Experimental|N Acetyl Cysteine|The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers.
3062492|NCT00967005|Placebo Comparator|Sugar Pill|
3062493|NCT00967018|Experimental|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. For patients treated with goserelin in the previous trials (CS28, CS30 and CS31),a starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to the end of the trial. For patients treated with degarelix in the previous trials, maintenance doses of 80 mg (20 mg/mL) degarelix were continued and were administered as single 4 mL s.c. injections at 28 day intervals to the end of the trial.
3062494|NCT00967044|Experimental|Panobinostat + Everolimus|Panobinostat (LBH589) Plus Everolimus (RAD001)
3062495|NCT00967226|Experimental|propranolol for treatment of hemangiomas|Assessing efficacy and tolerability of propranolol in management of symptomatic hemangiomas
3062496|NCT00967226|Active Comparator|Prednisolone|Assessing efficacy and tolerability of prednisolone in management of symptomatic hemangiomas and comparing to propranolol.
3062497|NCT00967330|Experimental|1|
3062498|NCT00967330|Active Comparator|2|
3062499|NCT00967343|Experimental|ATIR|
3062500|NCT00967369|Experimental|Arm A (bortezomib, ifosfamide, carboplatin, etoposide)|ARM A: Patients receive bortezomib IV over 5 seconds on days 1 and 4, ifosfamide IV continuously over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on days 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3062501|NCT00967369|Active Comparator|Arm B (ifosfamide, carboplatin, etoposide)|Patients receive ifosfamide, carboplatin and etoposide as in Arm A. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3062502|NCT00967473|Experimental|Toric Intraocular Lens|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Models SN60T9/SN60T8
3062503|NCT00967486|Active Comparator|Routine Shunt|These patients are called routine as the routine method of carotid endarterectomy is used.
3062504|NCT00967486|Active Comparator|Selective Shunt|These patients are selectively used for shunting or not shunting based on systolic pressure < 40mmHg. This group is further used as subgroup analysis.
3062505|NCT00967499|Active Comparator|1|
3062506|NCT00967499|Active Comparator|2|
3062507|NCT00967551|Active Comparator|Micronutrient Sprinkles without zinc|Micronutrient sprinkles without zinc
3062508|NCT00967551|Experimental|Micronutrient sprinkles with zinc|Micronutrient sprinkles with zinc gluconate
3062509|NCT00967616|Active Comparator|FOLFIRI|"Participants who received irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). FOLFIRI was administered by intravenous (IV) injection once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
3062510|NCT00967616|Experimental|CS7017+FOLFIRI|"Participants who received CS7017 plus irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI). Two CS-7017 tablets were administered by mouth (PO) twice a day (BID) every 12 hours. FOLFIRI was administered IV once every 2 weeks. The FOLFIRI regimen consisted of:~Irinotecan, 180 mg/m^2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m^2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m^2/day x 2 days (total 2400 mg/m^2 over 46 to 48 hours continuous infusion)"
3062511|NCT00967668|Experimental|ASPIRE-Phone Lifestyle Coaching|Phone-based coaching using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
3062512|NCT00967668|Experimental|ASPIRE-Group Lifestyle Coaching|On-site weekly group visits using small change approach to improve physical activity and diet. Initial treatment of 3 months, followed by 21 months of follow-up phone support (phone-only ASPIRE-VA).
3062513|NCT00967668|Active Comparator|MOVE! Usual Care|Usual care MOVE!, which consists of weekly on-site group visits that follow MOVE! protocols with unstructured follow-up phone support
3062514|NCT00967694|Experimental|Nitrous oxide administration|All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baseline and then intervention values of IOP measurement.
3062515|NCT00967798|Experimental|Sitagliptin|"CF patients receiving Sitagliptin.~Intervention: Dose is 100 mg taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
3062516|NCT00967798|Placebo Comparator|Sugar pill|"CF patients receiving placebo.~Intervention: Placebo is taken orally once a day in the morning with breakfast. Duration is one year or until converted to CF diabetes, whichever comes sooner."
3062517|NCT00967941||Ancef|
3062518|NCT00967941||Vancomycin and Cefazolin|
3062519|NCT00967941||Daptomycin and Cefazolin|
3062520|NCT00967993||KRX-0502 (ferric citrate)|"KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate. All patients initiated on study drug will start with a fixed dose of KRX-0502 (ferric citrate) of 6 caplets per day.~Patients will be titrated at Visits 4, 5, and 6 based on serum phosphorus lab results. If serum phosphorus levels go below normal, there will be a decrease in pills; if serum phosphorus levels go above normal, there wil be an increase in pills. The maximum number of KRX-0502 (ferric citrate) caplets per day will be 12, or 12 g/day of ferric citrate.~Patients will take study drug orally with meals or snacks or within one hour after their meals or snacks."
3062521|NCT00968019||Presillion stent|Patients treated with the Presillion stent in up to two de novo coronary artery lesions
3062522|NCT00968071|Experimental|Decitabine + Gemtuzumab Ozogamicin|Decitabine 20 mg/m^2 intravenously (IV) over an hour and half daily for 5 days, Gemtuzumab Ozogamicin 3 mg/m^2 IV on day 5.
3062523|NCT00968149|Experimental|1|Montelukast
3062524|NCT00968149|Placebo Comparator|2|Placebo
3062525|NCT00968201|Experimental|1|Montelukast
3062526|NCT00968201|Placebo Comparator|2|Placebo
3062527|NCT00968227|Experimental|Transfusion|
3062528|NCT00968253|Experimental|Phase I: RAD001 + Combination Chemo|"Optimal dose finding of Everolimus (RAD001) beginning dose 5 mg + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Cytarabine (Ara-C) during Cycles 2, 4, 6, & 8.~First chemotherapy combination Hyper-CVAD = Cyclophosphamide, Vincristine, Adriamycin (doxorubicin), and Dexamethasone; Second chemotherapy combination Methotrexate and Ara-C."
3062529|NCT00968253|Experimental|Phase II: MTD RAD001 + Combination Chemo|MTD dose of Everolimus + two different chemotherapy combinations during alternating cycles, Hyper-CVAD on Cycles 1, 3, 5, & 7 and Methotrexate & Ara-C during Cycles 2, 4, 6, & 8.
3062530|NCT00968344|Experimental|Leucine|3-4 g Leucine added to daily meals during bed rest
3062531|NCT00968344|Placebo Comparator|Placebo|3-4 g Alanine added to daily meals during bed rest
3062532|NCT00968526|Experimental|GSK2340272A 2D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received two doses (2D) of GSK2340272A vaccine, one administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and the other one, administered intramuscularly in the deltoid region of the dominant arm at Day 21.
3062533|NCT00968526|Experimental|GSK2340272A 1D Group|Healthy male or female adults, aged 18 to 60 years (18-60y) and above (>60y), who received a single dose (1D) of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
3062534|NCT00968539|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3062535|NCT00968539|Experimental|GSK2340269A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3062536|NCT00968617|Experimental|MK2578 1.0 mcg/kg|MK2578
3062537|NCT00968617|Experimental|MK2578 2.0 mcg/kg|MK2578
3062538|NCT00968617|Experimental|MK2578 3.6 mcg/kg|MK2578
3062539|NCT00968617|Active Comparator|Darbepoetin alfa|darbepoetin alfa
3062540|NCT00968669|Experimental|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3062541|NCT00968669|Experimental|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3062542|NCT00968669|Experimental|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
3062543|NCT00968669|Experimental|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
3062544|NCT00968708|Experimental|Placebo|Alogliptin placebo matching tablets, orally, once daily. Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
3062545|NCT00968708|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for participants with normal or mildly impaired renal function as defined by estimated glomerular filtration rate (eGFR) ≥ 60 mL/min). Alogliptin 12.5 mg, tablets, orally, once daily for participants with moderately impaired renal function (eGFR ≥30 and <60 mL/min). Alogliptin 6.25 mg, tablets, orally, once daily for participants with severely impaired renal function or end stage renal disease (eGFR <30 mL/min). Participants continued to receive standard of care for cardiovascular disease and diabetes according to regional guidelines.
3062546|NCT00968799|Experimental|HIPEC treatment|"Cytoreduction~Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with cisplatin~Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution. Perfusion volume depends on body size (3 - 6 l).~If cisplatin amount exceeds the equivalent of 62.5 mg/m² body surface, cisplatin is dosed by body surface (62.5 mg/m²)(safety margin).~Perfusion is performed with the open or Coliseum technique for 90 min."
3062547|NCT00968812|Active Comparator|Glimepiride|Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
3062548|NCT00968812|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
3062549|NCT00968812|Experimental|Canagliflozin 300 mg|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
3062550|NCT00968838|Experimental|Non-radiated White Blood Cell Transfusion|Four (4) non-radiated white blood cell transfusions. Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
3062551|NCT00968838|Experimental|White Blood Cell Transfusion|Four (4) standard white blood cell transfusions (with radiation). Each transfusion given daily and taking from 1 hour to several hours depending on toleration of the treatment.
3062552|NCT00968864|Experimental|CliniMACS® (T cell depletion)|Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
3062553|NCT00968890|Experimental|Pandemrix+Fluarix and Pandemrix+Placebo|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with Fluarix™ on Day 0 and with a placebo on Day 21 intramuscularly in the deltoid region of the dominant arm.
3062554|NCT00968890|Experimental|Pandemrix+Placebo and Pandemrix+Fluarix|Subjects received two doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm co-administered with a placebo on Day 0 and with Fluarix™ on Day 21 intramuscularly in the deltoid region of the dominant arm.
3062555|NCT00968968|Experimental|Arm 1: Lapatinib plus Trastuzumab|
3062556|NCT00968968|Active Comparator|Arm 2: Trastuzumab|
3062557|NCT00968981|Experimental|A|
3062558|NCT00968981|Experimental|B|
3062559|NCT00968981|Experimental|C|
3062560|NCT00969124|Experimental|Third Eye Retroscope|All subjects underwent the same intervention, consisting of examination of the colon using a colonoscope along with the Third Eye Retroscope device, with removal of any polyps that were detected during the procedure.
3062561|NCT00969150|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
3062562|NCT00969150|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
3062563|NCT00969228|Experimental|Rotarix Group|Subjects received 2 oral doses of Rotarix according to a 0, 1 or 2-month schedule.
3062564|NCT00969228|Placebo Comparator|Placebo Group|Subjects received 2 oral doses of placebo according to a 0, 1 or 2-month schedule.
3062565|NCT00969280|Experimental|Standardized Acupuncture group|
3062566|NCT00969280|Placebo Comparator|Non-acupoint shallow penetration group|
3062567|NCT00969332|Experimental|Omegaven|0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
3062568|NCT00969436|Experimental|Priorix-Tetra Group|Subjects received 2 doses of Priorix-Tetra® vaccine, 1 at Day 0 and 1 at Month 6, administered subcutaneously in the left anterolateral thigh.
3062569|NCT00969436|Experimental|Priorix/ Priorix-Tetra Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix-Tetra® vaccine at Month 6, both administered subcutaneously in the left anterolateral thigh.
3062570|NCT00969436|Active Comparator|Control Group|Subjects received 1 dose of Priorix™ vaccine at Day 0 and 1 dose of Priorix™ vaccine co-administered with Varilirix™ vaccine at Month 6, administered subcutaneously in the left and right anterolateral thigh.
3062571|NCT00969501|Experimental|EUFLEXXA|ACTIVE CONTROL
3062572|NCT00969540|Active Comparator|Active Mattress Cover|Subjects in this arm will be given the placebo mattress cover followed active mattress cover .
3062573|NCT00969540|Placebo Comparator|Placebo Mattress Cover|Subjects in this arm will be given the active mattress cover followed by the placebo mattress cover.
3062574|NCT00969553|Experimental|BI 6727|Schedule A
3062575|NCT00969618|Experimental|Atomoxetine|
3062576|NCT00969709|Experimental|1|40 mg Levomilnacipran ER capsules, low dose, oral administration, once daily.
3062577|NCT00969709|Experimental|2|80 mg Levomilnacipran ER capsules, medium dose, oral administration, once daily dosing
3062578|NCT00969709|Experimental|3|120 mg Levomilnacipran ER capsules, high dose, oral administration, once daily dosing
3062579|NCT00969709|Placebo Comparator|4|Matching placebo capsules, oral administration, once daily.
3062580|NCT00969761|Experimental|A. BI 6727-cisplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to cisplatin
3062581|NCT00969761|Experimental|B. BI 6727-carboplatin|patient to receive 3-weekly infusion escalating dose of BI 6727 combined to carboplatin
3062582|NCT00969878|Placebo Comparator|Placebo injection|TA-CD placebo will be administered intra muscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
3062583|NCT00969878|Experimental|TA-CD Vaccination|TA-CD 400 μg will be administered intramuscular. A total of 5 injections will be given over 12 weeks (i.e., at Day 1 and at the beginning of Weeks 3, 5, 9 and 13).
3062584|NCT00970073|Experimental|Delayed CNI Group 1|Thymoglobulin 3mg total, administered on Days 0 and 2 (after transplant), plus MMF and corticosteroids. CNI administration delayed until 10 days post transplant. tacrolimus 3-8 (trough concentration)
3062585|NCT00970073|Experimental|Delayed CNI Group 2|Thymoglobulin 4.5mg total, plus MMF and corticosteroids. CNI therapy delayed until 10 days post transplant.tacrolimus 3-8 (trough concentration)
3062586|NCT00970073|Active Comparator|Early CNI / Control Arm|Standard post liver transplant therapy to include: tacrolimus 8-12 (trough concentration) initiated within 48 hours post-transplant, plus mycophenolate mofetil (MMF) and corticosteroids to be administered within 24 hours after transplant (Day 0).
3062587|NCT00970203|Experimental|Cohort A|"3 months of androgen ablation followed at PSA progression by 3 months of the combination of androgen ablation + DC1 vaccine~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
3062588|NCT00970203|Experimental|Cohort B|"3 months of the combination of androgen ablation + DC1 vaccine followed at PSA progression by 3 months of androgen ablation~AA: Lupron 22.5 mg or Zoladex 10.8 mg DC vaccine: intradermal (id) vaccine of 3-5 x 10e6 cells"
3062589|NCT00970268|Experimental|1|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
3062590|NCT00970268|Experimental|2|Aclidinium bromide dose, inhaled, for 52 weeks of treatment
3062591|NCT00970281|Experimental|10 mg Olanzapine|
3062592|NCT00970281|Placebo Comparator|Placebo|
3062593|NCT00970294|Experimental|Health Promotion Program|Supervised exercise, educational sessions, dietary counseling
3062594|NCT00970307|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of GSK2202083A vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. GSK2202083A and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3062595|NCT00970307|Active Comparator|INFANRIX HEXA + MENJUGATE GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 3 and 4 months of age, 2 doses of Menjugate® vaccine at 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Menjugate® vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3062596|NCT00970307|Active Comparator|INFANRIX HEXA + SYNFLORIX GROUP|Healthy male and female infants between and including 8 to 12 weeks at the time of the first vaccination, who received 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccine at 2, 3 and 4 months of age and 2 doses of Rotarix™ vaccine at 2 and 3 months of age. Infanrix hexa™ and Synflorix™ vaccines were administered intramuscularly into the right and left thigh, while Rotarix™ vaccine was administered orally.
3062597|NCT00970320|No Intervention|Control group, RCT2|Participants reporting anal incontinence 6 months postpartum receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
3062598|NCT00970320|Active Comparator|Intervention group, RCT 2|Participants reporting anal incontinence 6 months postpartum receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
3062599|NCT00970320|No Intervention|Control group, RCT3|Women with obsteric anal sphincter injury receiving written information only for 6 months. After 6 months they are offered the same intervention as the intervention group, i.e. PFMT for 6 months.
3062600|NCT00970320|Active Comparator|Intervention group, RCT 3|Women with obsteric anal sphincter injury receiving pelvic floor muscle training (PFMT) for 6 months (+6 months).
3062601|NCT00970320|No Intervention|Prevalence Study|1571 primiparae delivering at Ostfold Hospital Trust or St. Olav's Hospital during the period May 2009 to December 2010.
3062602|NCT00970359|Experimental|pts with thyroid cancer with and without BRAF mutation|Patients receive selumetinib orally (PO) twice daily (BID) for 4 weeks. Within 1 month, patients with adequate RAI uptake may receive 131I per standard of care and continue selumetinib until 2 days following 131I.
3062603|NCT00970489|Experimental|Omega-3 fatty acid capsules|
3062604|NCT00970489|Placebo Comparator|Olive Oil capsule|
3062605|NCT00970502|Experimental|erlotinib + celecoxib|
3062606|NCT00970593|Placebo Comparator|OAP-189|
3062607|NCT00970593|Placebo Comparator|2|
3062608|NCT00970632|Placebo Comparator|Placebo|Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks
3062609|NCT00970632|Experimental|Tadalafil 5 milligram (mg)|Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks
3062610|NCT00970632|Active Comparator|Tamsulosin 0.4 mg|Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks
3062611|NCT00970684|Experimental|Bevacizumab, Docetaxel, and Gemcitabine|Treatment repeats every 21 days for up to 6 courses.
3062612|NCT00970814|Active Comparator|Levetiracetam XR|Group received Levetiracetam
3062613|NCT00970814|Placebo Comparator|Sugar Pill|Placebo
3062614|NCT00970853|Active Comparator|Control|Control group
3062615|NCT00970853|Experimental|MOM Program home visiting|Mixed professional support home visiting program.
3062616|NCT00970944|Experimental|Amantadine HCL|100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4.
3062617|NCT00970944|Placebo Comparator|Placebo|
3062618|NCT00971048|Experimental|HP828-101|
3062619|NCT00971048|Active Comparator|Standard of Care|For DFU SoC is a hydrogel. For PU SoC is a hydrocolloid gel.
3062620|NCT00971178|Active Comparator|Local Dexmedetomidine|
3062621|NCT00971178|Placebo Comparator|Normal Saline|
3062622|NCT00971178|Active Comparator|IV dexmedetomidine|
3062623|NCT00971204|Experimental|Treatment with HeartLight System|Treatment of paroxysmal atrial fibrillation (PAF) with HeartLight System
3062624|NCT00971243|Experimental|MP-513 Lowest Dose and Metformin|
3062625|NCT00971243|Experimental|MP-513 Low Dose and Metformin|
3062626|NCT00971243|Experimental|MP-513 Medium Dose and Metformin|
3062627|NCT00971243|Experimental|MP-513 High Dose and Metformin|
3062628|NCT00971243|Placebo Comparator|Placebo and Metformin|
3062629|NCT00971282|Experimental|intra-individual comparison|
3062630|NCT00971295|Experimental|Treatment Sequence A|Eslicarbazepine acetate + Metformin period followed by washout period followed by Metformin period
3062631|NCT00971295|Experimental|Treatment Sequence B|Metformin period followed by washout period followed by Eslicarbazepine acetate + Metformin period
3062632|NCT00971321|Experimental|GSK 2340272A F1 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 1 (F1) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
3062633|NCT00971321|Experimental|GSK 2340272A F2 Group|Healthy male or female children, between and including 6 and 35 months of age, who received 2 doses of GSK2340272A Formulation 2 (F2) vaccine according to a 0, 21-day schedule, intramuscularly administered in the deltoid region of the arm or in the anterolateral region of the thigh if the subject was less than (<) 12 months at study entry.
3062634|NCT00971425|Experimental|Placebo-Pandemrix-Fluarix Group|Subjects received one dose of placebo intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21, and 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day 42.
3062635|NCT00971425|Experimental|Fluarix-Pandemrix-Placebo Group|Subjects received 1 dose of Fluarix intramuscularly in the deltoid region of the dominant arm at Day -21, 2 doses of Pandemrix (GSK2340272A) intramuscularly in the deltoid of the non-dominant arm at Day 0 and 21, and 1 dose of placebo intramuscularly in the deltoid of the non-dominant arm at Day 42.
3062636|NCT00971620|Experimental|BTX-A|BTX-A intralesional injection
3062637|NCT00971620|Experimental|Placebo/Saline|Saline intralesional injection
3062638|NCT00971633|Experimental|1|Treatment Sequence A-B-C
3062639|NCT00971633|Experimental|2|Treatment Sequence B-C-A
3062640|NCT00971633|Experimental|3|Treatment Sequence C-A-B
3062641|NCT00971633|Experimental|4|Treatment Sequence A-C-B
3062642|NCT00971633|Experimental|5|Treatment Sequence B-A-C
3062643|NCT00971633|Experimental|6|Treatment Sequence C-B-A
3062644|NCT00971737|Active Comparator|Cyclophosphamide and Vaccine only|Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
3062645|NCT00971737|Experimental|Cyclophosphamide, Vaccine and Trastuzumab|Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.
3062646|NCT00971750||Ultrasound Study Group|Patients with no history of gallbladder surgery who are undergoing elective laparoscopic roux-en-Y gastric bypass that have consented to undergo a preoperative transabdominal ultrasound in addition to routine preoperative assessment for surgery.
3062647|NCT00971789|Experimental|Sirolimus Patients|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects.
3062648|NCT00971841|Experimental|Paclitaxel|One hour intravenous infusion on Days 1, 8, 15, 22, 29, 36, followed by 1 week of rest (6 weeks on, 1 week off). One treatment course consists of 49 days. Day 1 dose same level as last dose of original Study CA139-540 (100mg/m2, 80 mg/m2, or 60 mg/m2). Treatment to continue until disease progression or unacceptable toxicity apparent.
3062649|NCT00971932|Experimental|Cetuximab + Cisplatin/Carboplatin + Fluorouracil (5-FU)|
3062650|NCT00971945|Experimental|Paclitaxel|
3062651|NCT00971997|Experimental|Lispro 50/50|
3062652|NCT00972088|Other|capsule endoscopy|patients eligible according to inclusion criteria who underwent a capsule endoscopy
3062653|NCT00972153|No Intervention|No device used|
3062654|NCT00972153|Sham Comparator|Device attached, not activated|
3062655|NCT00972153|Experimental|Device deployed and activated|
3062656|NCT00972205|Experimental|Paclitaxel and CBT-1|
3062657|NCT00972244|Experimental|1|1mg dapagliflozin
3062658|NCT00972244|Experimental|2|2.5mg dapagliflozin
3062659|NCT00972244|Experimental|3|5mg dapagliflozin
3062660|NCT00972244|Experimental|4|10mg dapagliflozin
3062661|NCT00972244|Placebo Comparator|5|Placebo
3062662|NCT00972283|Experimental|IDeg OD|
3062663|NCT00972283|Active Comparator|IGlar OD|
3062664|NCT00972322|Experimental|MK-8245 50 mg|MK-8245, 50 mg, twice daily for 28 days
3062665|NCT00972322|Placebo Comparator|Placebo|Placebo to MK-8245, 50 mg, twice daily
3062666|NCT00972335|Experimental|Combination Therapy|"Everolimus; this drug will be dosed at 10 mg orally DAILY for the duration of the study.~Bevacizumab; this drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study"
3062667|NCT00972374|Experimental|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
3062668|NCT00972374|Experimental|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
3062669|NCT00972374|Sham Comparator|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
3062670|NCT00972439|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
3062671|NCT00972439|Active Comparator|Ovcon Fe®|Ovcon Fe® is an oral contraceptive that contains less progestin.
3062672|NCT00972478|Experimental|Treatment (combination chemotherapy)|Patients receive vorinostat PO once daily on days 1-5 or 1-9 (according to dose level), rituximab IV, cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 3. Patients also receive prednisone PO once daily on days 3-7. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
3062673|NCT00972504|Active Comparator|GSK835726 (10mg)|10mg oral dose
3062674|NCT00972504|Active Comparator|GSK1004723 (1000mcg)|1000mcg nasal spray solution
3062675|NCT00972504|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
3062676|NCT00972504|Placebo Comparator|placebo|placebo
3062677|NCT00972517|Experimental|Group A|Subjects receiving alternative dose of GSK23440272A vaccine
3062678|NCT00972530|No Intervention|Activity|Normal activity without restrictions
3062679|NCT00972530|Active Comparator|immobilisation|48 hours postinjection rest
3062680|NCT00972543|Active Comparator|Raptiva|Double-blind phase, Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
3062681|NCT00972543|Placebo Comparator|Placebo|Double-blind phase, Placebo for 12 weeks.There then follows an open label extension of Raptiva 0.7mg/kg followed by Raptiva 1mg/kg/wk for a further 12 weeks
3062682|NCT00972595|Experimental|A|clinical trial formulation
3062683|NCT00972595|Active Comparator|B|non-U.S. marketed formulation
3062684|NCT00972621|Experimental|Vitrax II|Investigational dispersive viscoelastic
3062685|NCT00972621|Active Comparator|Viscoat|Marketed control dispersive viscoelastic
3062686|NCT00972725|Experimental|GSK732461+Nivaquine Group|Subjects received a single dose of Nivaquine® tablets orally, 2 days prior to receiving a booster dose of the GSK732461 vaccine.
3062687|NCT00972725|Active Comparator|GSK732461 Group|Subjects received a booster dose of the GSK732461 vaccine intramuscularly, in the deltoid region of the non-dominant arm.
3062688|NCT00972738|Experimental|1|montelukast
3062689|NCT00972738|Active Comparator|2|loratadine
3062690|NCT00972738|Placebo Comparator|3|placebo
3062691|NCT00972777|Experimental|Besifloxacin|0.6% ophthalmic suspension
3062692|NCT00972777|Placebo Comparator|Vehicle|
3062693|NCT00972816|Experimental|3.75_(50)MF59|3.75 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3062694|NCT00972816|Experimental|7.5_(0) MF59|7.5 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3062695|NCT00972816|Experimental|7.5_(50) MF59|7.5 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3062696|NCT00972816|Experimental|7.5_(100) MF59|7.5 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
3062697|NCT00972816|Experimental|15_(0) MF59|15 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3062698|NCT00972816|Experimental|15_(50)MF59|15 μg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22
3062699|NCT00972816|Experimental|15_(100) MF59|15 μg A/H1N1 antigen with 100% MF59 adjuvant administered on study day 1 and day 22
3062700|NCT00972816|Experimental|30_(0) MF59|30 μg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22
3062701|NCT00972959|Experimental|Bortezomib/Dexamethasone/Zoledronic Acid|"For this study, Velcade will be administered at the standard dose of 1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle.~Dexamethasone will be administered at a dose of 12 mg/m2 p.o., on days 1-2, 4-5, 8-9 and 11-12 of the same cycle.~Zoledronic acid will be administered at a dose of 4 mg, iv (15-minute infusion), every 28 days for up to 8 cycles, and then every 28 days for the next 18 months"
3062702|NCT00973102|Experimental|Premarin IV|Patients who were randomized to receive a single dose of 0.5 mg/kg Premarin® IV.
3062703|NCT00973102|Placebo Comparator|Placebo|Patients who were randomized to receive a single dose of 0.5 mg/kg placebo. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with hemorrhagic shock.
3062704|NCT00973349|Experimental|3.75_(50)MF59|50% of MF59 with 3.75 µg A/H1N1 antigen
3062705|NCT00973349|Experimental|7.5 w/o MF59|0% of MF59 with 7.5 µg A/H1N1 antigen
3062706|NCT00973349|Experimental|7.5_(50)MF59|50% of MF59 with 7.5 µg A/H1N1 antigen
3062707|NCT00973349|Experimental|7.5_(100)MF59|100% of MF59 with 7.5 µg A/H1N1 antigen
3062708|NCT00973349|Experimental|15 w/o MF59|0% of MF59 with 15 µg A/H1N1 antigen
3062709|NCT00973349|Experimental|15_(50)MF59|50% of MF59 with 15 µg A/H1N1 antigen
3062710|NCT00973349|Experimental|15_(100)MF59|100% of MF59 with 15 µg A/H1N1 antigen
3062711|NCT00973349|Experimental|30 w/o MF59|0% of MF59 with 30 µg A/H1N1 antigen
3062712|NCT00973362|Other|Adjunct (i.e. Normal Pap)|The Adjunct study will evaluate APTIMA HPV Assay clinical performance for detecting high-risk HPV types in female subjects 30+ years of age with negative (NILM) cytology results from routine Pap testing. This will be accomplished by evaluating the assay performance compared to known cervical disease status at baseline and after a 3-year follow-up period. A comparator FDA-Approved HPV DNA test is reported.
3062713|NCT00973362|Other|ASC-US|The ASC-US study will evaluate the APTIMA HPV Assay clinical performance for detecting high-risk HPV types in subjects with ASC-US Pap test results from routine Pap testing and known cervical disease status (based on colposcopic biopsy results). A comparator FDA-Approved HPV DNA test is reported. There is no follow-up period.
3062714|NCT00973479|Experimental|Group I: Placebo + Methotrexate (MTX)|Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
3062715|NCT00973479|Placebo Comparator|Group II: Golimumab + Methotrexate (MTX)|Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
3062716|NCT00973622|Experimental|Smokers|Healthy adult smokers aged 19-55 who are not currently interested in quitting smoking.
3062717|NCT00973622|Experimental|Non-smokers|Healthy adult non-smokers aged 19-55
3062718|NCT00973674|Experimental|Premarin IV|Patients randomized to receive a single dose of 0.5 mg/kg Premarin® IV
3062719|NCT00973674|Placebo Comparator|Placebo|Patients randomized to receive a single dose of placebo IV. Due of the faint yellow color of the reconstituted Premarin®, the placebo dose will be prepared with 0.14 ml of Vial 1 of Infuvite Adult Multivitamin and 14 ml of sterile water to generate a similar color and volume. This aliquot will be used only for those study patients who are randomized to the placebo arm. The placebo volume will be approximately equal to the volume which the patient would have received had the patient been randomized to the Premarin arm Considering the small amount of IV multivitamin needed for fluid tinting, it is not expected that the IV multivitamin will have any effect on patients with traumatic brain injury.
3062720|NCT00973700|Experimental|2x7.5adj|Two doses of MF59 adjuvanted (adj) A/H1N1
3062721|NCT00973700|Experimental|7.5adj_1_8|MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
3062722|NCT00973700|Experimental|7.5adj_1_22|MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
3062723|NCT00973700|Experimental|15_1_22|A/H1N1 on study days 1 and 22
3062724|NCT00973700|Experimental|2x15_1_22|Two doses of A/H1N1 (one in each arm) on study days 1 and 22
3062725|NCT00973739|Experimental|Lapatinib|"Lapatinib PO dosed according to age:~Children/adolescents (less than 18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO twice daily~Adults (18 years of age or older): 1,500 mg PO once daily~Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment."
3062726|NCT00973752|Experimental|Experimental|All patients treated on same arm
3062727|NCT00973765|Active Comparator|bactrim DS (800/160) 2 pills po BID x 7 days|active comparator
3062728|NCT00973765|Placebo Comparator|Matched placebo 2 pills po BID x 7 days|placebo
3062729|NCT00973921||Stent deployment evaluation|The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
3062730|NCT00973973|Experimental|Elagolix 150 mg|Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
3062731|NCT00973973|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.
3062732|NCT00974051|Active Comparator|Control|Subjects complete the same exercise routine, however no treatment is given at 9:00pm.
3062733|NCT00974051|Experimental|Terbutaline|Subjects complete same exercise routine. At 9:00pm, an oral dose of 2.5 mg of Terbutaline is administered.
3062734|NCT00974051|Experimental|20% Basal Insulin Reduction|All subjects complete the same exercise session. At 9:00pm, subject's basal rate is decreased by 20% for six hours.
3062735|NCT00974090|Placebo Comparator|Placebo / Teneli + SU|
3062736|NCT00974090|Experimental|Teneli / Teneli + SU|
3062737|NCT00974142|Experimental|Cyclosporine|
3062738|NCT00974142|Placebo Comparator|Placebo|
3062739|NCT00974220|Placebo Comparator|placebo|nebulized 0.9% saline placebo
3062740|NCT00974220|Experimental|fentanyl|nebulized fentanyl citrate (50 mcg)
3062741|NCT00974233|Experimental|Induction/Maintenance chemotherapy|Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy
3062742|NCT00974246|Experimental|COPD, ECF residents, Advair diskus|open label treatment with Advair diskus in COPD patients
3062743|NCT00974259|Experimental|pBrO2 and ICP management|Treatment protocol based on pBrO2 and ICP values.
3062744|NCT00974259|Active Comparator|ICP management|Treatment protocol based on ICP values only.
3062745|NCT00974311|Experimental|Enzalutamide|Formerly MDV3100
3062746|NCT00974311|Placebo Comparator|Placebo|
3062747|NCT00974350|Experimental|Group 1: SABER-Bupivacaine|2.5 mL SABER-Bupivacaine/Once
3062748|NCT00974350|Experimental|Group 2: SABER-Bupivacaine|5.0 mL SABER-Bupivacaine/Once
3062749|NCT00974350|Placebo Comparator|Group 3: SABER-Placebo|2.5 mL or 5.0 mL SABER-Placebo/Once
3062750|NCT00974363|Experimental|Group A|Subjects who received GSK Biologicals' meningococcal vaccine 134612 in the primary vaccination study 109069.
3062751|NCT00974363|Active Comparator|Group B|Subjects who received MencevaxTM ACWY in the primary vaccination study 109069.
3062752|NCT00974376|Experimental|Gabapentin 1200mg/day|1200mg/day of gabapentin for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
3062753|NCT00974376|Placebo Comparator|Placebo|1200mg/day of placebo for 12 weeks given in conjunction with 12 weeks of manual-guided behavioral counseling.
3062754|NCT00974480|Experimental|Redermic|Cream was applied twice a day every day, morning and evening for 24 weeks.
3062755|NCT00974480|Active Comparator|Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Hydrating cream was applied to the face in the morning every day for 24 weeks.
3062756|NCT00974480|Active Comparator|Combination of Redermic and Rejuva-A|Week 1, Rejuva-A cream was applied to face in the evening twice a week. Weeks 2 & 3, Rejuva-A cream was applied to the face in the evening three times a week. Weeks 4-24, Rejuva-A cream was applied to the face in the evening every other day. In cases of intolerance, returned to the previous dosage and remained there until the end of study. Redermic was applied every evening when Rejuva-A™ was not applied, as well as every morning.
3062757|NCT00974493|Active Comparator|Oral antibiotics|
3062758|NCT00974493|Active Comparator|Intravenous antibiotics|
3062759|NCT00974571|Experimental|1|montelukast
3062760|NCT00974571|Active Comparator|2|cetirizine
3062761|NCT00974571|Placebo Comparator|3|placebo
3062762|NCT00974675|Experimental|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3062763|NCT00974675|Experimental|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3062764|NCT00974675|Experimental|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
3062765|NCT00974675|Placebo Comparator|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
3062766|NCT00974818|Experimental|pts getting Mitomycin C (MMC)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of MMC, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
3062767|NCT00974818|Experimental|pts getting Bacillus Calmette-Guerin (BCG)|Patients will receive a induction course of 6 cycles of weekly intravesical therapy of either BCG, followed by a maintenance schedule consisting of 3 weekly cycles of the same drug at 3, 6, 12, 18, and 24 months.
3062768|NCT00974974|Experimental|IPX066|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IPX066.
3062769|NCT00974974|Active Comparator|IR CD-LD|Following IR CD-LD dose adjustment and conversion to IPX066, subjects were assigned to Investigational product IR CD-LD (active comparator).
3062770|NCT00975000|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
3062771|NCT00975000|Placebo Comparator|Placebo|Participants received placebo orally once daily for 52 weeks.
3062772|NCT00975130|Experimental|SC-GLM50|In Part 1 of the study, participants received subcutaneous golimumab treatment at a dose of 50 mg once monthly for 6 months in combination with background DMARD treatment.
3062773|NCT00975130|Experimental|IV GLM 2 mg/kg + GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive intravenous (IV) golimumab at a dose of 2 mg/kg once monthly for a period of 6 months or until remission is achieved. Participants will receive IV GLM at a dose of 2 mg/kg at the start of Month 7, and then at the start of Month 8 and Month 10 if the subject has not achieved remission at any of these IV administration visits. If remission is achieved, participants were switched to subcutaneous golimumab at a dose of 50 mg once monthly until study end, in combination with background DMARD treatment.
3062774|NCT00975130|Experimental|GLM50-SC|After 6 months of treatment in study Part 1, participants with good or moderate response but not in remission will receive subcutaneous golimumab at a dose of 50 mg once monthly for a period of 6 months, in combination with background DMARD treatment.
3062775|NCT00975143|Experimental|CIP-Isotretinoin|
3062776|NCT00975143|Active Comparator|Isotretinoin|
3062777|NCT00975156|Experimental|Lokomat Intervention|Lokomat gait training (five days a week for eight weeks for a total of 40 sessions).
3062778|NCT00975156|Active Comparator|Standard of Care|Conventional physical therapy focusing on gait training for five days a week for eight weeks for a total of 40 sessions.
3062779|NCT00975195|Experimental|fluticasone high dose|fluticasone priopionate high dose and tiotropium inhalation and salmeterol xinafoate
3062780|NCT00975195|Experimental|fluticasone medium & low doses|fluticasone priopionate medium and high doses; and tiotropium inhalation; and salmeterol xinafoate; and placebo matched to fluticasone priopionate
3062781|NCT00975221|Experimental|Cinacalcet|Participants received cinacalcet at a starting dose of 30 mg orally BID and were eligible for a dose titration once every 3 weeks during the 12-week dose-titration phase based on corrected total serum calcium concentration and safety assessments. Participants continued to receive cinacalcet for another 16 weeks during the efficacy assessment phase and then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
3062782|NCT00975221|Placebo Comparator|Placebo|Participants received placebo orally twice a day (BID) for 12 weeks during the dose titration phase and for another 16 weeks during the efficacy assessment phase. Participants then continued into the open-label extension phase and received cinacalcet at a starting dose of 30 mg BID for 24 weeks. The dose of cinacalcet could have been increased or decreased as needed to maintain a corrected total serum calcium concentration within the normal range through Week 52.
3062783|NCT00975286|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3062784|NCT00975286|Placebo Comparator|Placebo|2-step initiation regimen of volume matching placebo: 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3062785|NCT00975416|Placebo Comparator|Methadone|Intranasal oxytocin administered in the context of cognitive behavioral therapy to methadone dependent outpatients
3062786|NCT00975416|Placebo Comparator|Outpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent outpatients
3062787|NCT00975416|Placebo Comparator|Inpatient Cocaine|Intranasal oxytocin administered in the context of cognitive behavioral therapy to cocaine dependent inpatients
3062788|NCT00975481|Experimental|dimebon 20 mg|
3062789|NCT00975481|Experimental|dimebon 40 mg|
3062790|NCT00975481|Experimental|dimebon 60 mg|
3062791|NCT00975481|Placebo Comparator|placebo|
3062792|NCT00975481|Active Comparator|alprazolam 1 mg|
3062793|NCT00975481|Active Comparator|alprazolam 3 mg|
3062794|NCT00975507|Experimental|1|ProQuad™ (V221) + Placebo Followed by ProQuad™
3062795|NCT00975507|Active Comparator|2|M-M-R™ II + VARIVAX™
3062796|NCT00975585|Active Comparator|senofilcon A both eyes|soft contact lens worn daily for 2 weeks, with a 2-week replacement regimen.
3062797|NCT00975585|Active Comparator|lotrafilcon B both eyes|soft contact lens worn daily for 4 weeks, with a 4-week replacement regimen
3062798|NCT00975637|Experimental|140 mg SC|140 mg SC
3062799|NCT00975637|Experimental|70 mg SC|70 mg SC
3062800|NCT00975637|Experimental|280 mg SC|280 mg SC
3062801|NCT00975637|Placebo Comparator|210 mg SC|210 mg SC
3062802|NCT00975637|Experimental|Placebo|Placebo
3062803|NCT00975650|Experimental|Test 8.0, Ref 5.0, Test 14.0, Test 11.0|Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days;
3062804|NCT00975650|Experimental|Test 11.0, Test 8.0, Ref 5.0, Test 14.0|Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
3062805|NCT00975650|Experimental|Test 14.0, Test 11.0, Test 8.0, Ref 5.0|Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days;
3062806|NCT00975650|Experimental|Ref 5.0, Test 14.0, Test 11.0, Test 8.0|Treatment D: 5.0 mg Androderm® (Positive Control)-Patch, q.d. for 7 days; Treatment C: 14.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment B: 11.0 mg Nasobol® (2 syringes), b.i.d. for 7 days; Treatment A: 8.0 mg Nasobol® (2 syringes), b.i.d. for 7 days
3062807|NCT00975676|Experimental|Triptorelin plus tamoxifen|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years.
3062808|NCT00975676|Experimental|Triptorelin plus exemestane|Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
3062809|NCT00975715|Experimental|TRI476|Participants received TRI476 based on body weight with titration up to the maintenance dose, in addition to their traditional antiepileptics dosage.
3062810|NCT00975715|Placebo Comparator|Placebo|Participants received placebo to TRI476 without any adjustment to the dosing regimen, in addition to their traditional antiepileptics dosage.
3062811|NCT00975780|Experimental|enhanced oral care|
3062812|NCT00975780|Active Comparator|Usual care|The usual oral care provided at the nursing home
3062813|NCT00975806|Experimental|Cohort A|Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle
3062814|NCT00975806|Experimental|Cohorts F and G|Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 mg on days 1 to 14 or days 1 to 21 of each 21-day cycle
3062815|NCT00975884|Experimental|GSK2340272A (D21) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21 (D21).
3062816|NCT00975884|Experimental|GSK2340272A (M6) GROUP|Healthy male or female adults, above 18 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Month 6 (M6).
3062817|NCT00975923|Experimental|Collaborative Group|Quality Improvement Virtual Learning Collaborative with Interactive Teleconferences and Tool Kit
3062818|NCT00975923|Active Comparator|Tool Kit Group|Tool Kit of Evidence-Based Guidelines, Education Seminars, and Aide for Quality Improvement Methods
3062819|NCT00975975|Experimental|Basiliximab|Basiliximab will be given by IV on Day +7 post transplant for recipients of matched unrelated cells. Basiliximab will be given by IV on Day +9 post transplant for recipients of matched related cells.
3062820|NCT00976027|Experimental|Fluzone® High Dose Group|
3062821|NCT00976027|Active Comparator|Fluzone® Group|
3062822|NCT00976183|Experimental|Vorinostat|All study patients will receive the indicated dose of Vorinostat in conjunction with paclitaxel and carboplatin.
3062823|NCT00976209|Experimental|Phenylephrine Hydrochloride Extended Release Tablets, 30 mg|
3062824|NCT00976209|Active Comparator|Phenylephrine Hydrochloride Immediate Release Tablets, 10 mg|
3062825|NCT00976248|Experimental|RAD001|RAD001, oral, 10 mg, daily
3062826|NCT00976274|Placebo Comparator|starch capsule|
3062827|NCT00976274|Experimental|Korea red ginseng|
3062828|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 1|rAAV1-CMV-GAA (study agent) Administration: 1.0 x 10e12 vector genomes. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
3062829|NCT00976352|Experimental|rAAV1-CMV-GAA administration-cohort 2|rAAV1-CMV-GAA (study agent) Administration: 5.0 x 10e12 vector genomes Cohort 2 = 6 subjects. The following study assessments/interventions will be completed: Respiratory Muscle Strength Training (RMST), Safety labs, pulmonary function testing.
3062830|NCT00976391|Active Comparator|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
3062831|NCT00976391|Active Comparator|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
3062832|NCT00976404|Active Comparator|Maraviroc + raltegravir intensification|ART Intensification (addition of raltegravir and maraviroc to suppressive ART for 56 weeks)
3062833|NCT00976404|Experimental|Maraviroc + raltegravir intens. plus DNA + HIV-rAd5 vaccine|ART Intensification (addition of raltegravir and maraviroc for 56 weeks) PLUS immunomodulation therapy with DNA prime vaccine (Weeks 8,12,16) + HIV-recombinant Ad5-based vaccine (Week 32)
3062834|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed|Bevacizumab + Pemetrexed
3062835|NCT00976456|Active Comparator|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab + Pemetrexed + Carboplatin
3062836|NCT00976482||Pacemaker|Patients currently implanted with permanent Pacemaker according to guidelines
3062837|NCT00976495|Experimental|Dapagliflozin|
3062838|NCT00976495|Active Comparator|Hydrochlorothiazide|
3062839|NCT00976508|Experimental|1|
3062840|NCT00976521|Experimental|Local infusion, thrombus aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter following thrombus aspiration.
3062841|NCT00976521|Experimental|Local infusion, no aspiration|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter and no aspiration
3062842|NCT00976521|Active Comparator|No local infusion, thrombus aspiration|No local infusion of abciximab, thrombus aspiration.
3062843|NCT00976521|Active Comparator|No local infusion, no aspiration|No local infusion abciximab and no thrombus aspiration
3062844|NCT00976560|Experimental|GW856553|GW856553 7.5 mg BID
3062845|NCT00976560|Placebo Comparator|Placebo|Matching Placebo BID
3062846|NCT00976573|Experimental|Arm I (bevacizumab, paclitaxel, and carboplatin)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3062847|NCT00976573|Experimental|Arm II(bevacizumab, paclitaxel, carboplatin, and everolimus)|Patients receive bevacizumab, paclitaxel, and carboplatin as in Arm I. Patients also receive everolimus PO QD on 3 days a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3062848|NCT00976599|Experimental|CP-690,550 + methotrexate|
3062849|NCT00976599|Placebo Comparator|Placebo + methotrexate|
3062850|NCT00976664|Active Comparator|Orthotic group|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
3062851|NCT00976664|Other|Shoe Orthotic Wait group|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.
3062852|NCT00976677|Active Comparator|Arm I|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes (with or without bevacizumab IV over 30-90 minutes) on day 1. Patients also receive placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive placebo (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
3062853|NCT00976677|Experimental|Arm II|Patients receive paclitaxel and carboplatin (with or without bevacizumab) as in arm I. Patients also receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, patients with stable or responding disease may continue to receive erlotinib hydrochloride (with or without bevacizumab) as above in the absence of disease progression or unacceptable toxicity.
3062854|NCT00976703|Active Comparator|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
3062855|NCT00976703|Active Comparator|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
3062856|NCT00976716|Experimental|Celecoxib|
3062857|NCT00976820|Experimental|Arepanrix/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh [for children under (<) 12 months of age]. The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3062858|NCT00976820|Experimental|Arepanrix/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of Arepanrix™-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3062859|NCT00976820|Experimental|GSK2340273A/F1 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 1 (F1) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3062860|NCT00976820|Experimental|GSK2340273A/F2 Group|Subjects, aged 6 months - 9 years, male or female, received 2 doses of GSK2340273A-formulation 2 (F2) vaccine administered at a 21-day interval. The first dose was administered intramuscularly in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) or left anterolateral thigh (for children < 12 months of age). The second vaccine dose was administered in the deltoid region of the dominant arm (or right arm) or right anterolateral thigh (children < 12 months of age).
3062861|NCT00976898|Experimental|Proton Beam Irradiation|This is a single arm study. All study participants will receive proton radiation therapy.
3062862|NCT00976911|Active Comparator|1|
3062863|NCT00976911|Experimental|2|
3062864|NCT00976937|Experimental|Lixisenatide|2-step initiation regimen of lixisenatide along with sitagliptin placebo: lixisenatide 10 microgram (mcg) once daily (QD) for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24 along with placebo matching to sitagliptin 100 milligram (mg) capsule orally QD up to Week 24.
3062865|NCT00976937|Active Comparator|Sitagliptin|Sitagliptin along with 2-step initiation regimen of volume matching lixisenatide placebo: sitagliptin 100 mg capsule orally QD up to Week 24 along with volume matching lixisenatide placebo 10 mcg QD for 1 week, followed by 15 mcg QD for 1 week, then 20 mcg QD up to Week 24.
3062866|NCT00976950||Patients with HIV-1 infection|
3062867|NCT00976989|Experimental|T+P Concomitant Anthracycline-based chemotherapy|5-Fluorouracil, epirubicin with cyclophosphamide (FEC), trastuzumab (T) and pertuzumab (P) every three weeks for three cycles, followed by docetaxel, trastuzumab and pertuzumab every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
3062868|NCT00976989|Experimental|T+P Sequential Anthracycline-based chemotherapy|FEC every three weeks for three cycles, followed by docetaxel, trastuzumab (T) and pertuzumab (P) every three weeks, for three cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 21 as adjuvant therapy post-surgery.
3062869|NCT00976989|Experimental|T+P Concomitant Non-Anthracycline chemotherapy|Trastuzumab, carboplatin, docetaxel (TCH) and pertuzumab (P) every three weeks, for six cycles as neoadjuvant therapy. Trastuzumab every three weeks from Cycle 7 up to Cycle 17 as adjuvant therapy post-surgery.
3062870|NCT00977080|Active Comparator|IV Paricalcitol|Participants in the IV stratum received intravenous (IV) paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at 0.07 mcg/kg with titration every 2 weeks.
3062871|NCT00977080|Active Comparator|Cinacalcet (at sites with IV paricalcitol)|Participants in the IV stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (doxercalciferol IV 1 mcg 3 times weekly (TIW) at sites in the US and alfacalcidol capsules 0.25 mcg daily at sites in Russia).
3062872|NCT00977080|Active Comparator|Oral paricalcitol|Participants in the oral stratum received oral paricalcitol and, if hypercalcemia (calcium >= 10.5 mg/dL), received 30 mg of oral cinacalcet. Paricalcitol was dosed at mcg = IPTH/60 3 times weekly (TIW) with titration every 2 weeks.
3062873|NCT00977080|Active Comparator|Cinacalcet (at sites with oral paricalcitol)|Participants in the oral stratum received 30 mg of oral cinacalcet daily with a low-dose vitamin D receptor activator (VDRA) (alfacalcidol capsules 0.25 mcg daily).
3062874|NCT00977106|Experimental|1|
3062875|NCT00977106|Placebo Comparator|2|
3062876|NCT00977106|Experimental|3|
3062877|NCT00977171|Experimental|Droxidopa|
3062878|NCT00977184|Experimental|Real rTMS|
3062879|NCT00977184|Sham Comparator|Sham rTMS|
3062880|NCT00977197|Active Comparator|Pregabalin|"Subjects randomized to this arm will receive the following dosage:~75 mg (one tablet) twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study."
3062881|NCT00977197|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo matching the study drug.
3062882|NCT00977314|Experimental|SoundBite Hearing System|The objective of this study was to assess the safety and effectiveness of the SoundBite hearing system by Sonitus Medical and to support its intended use for the treatment of unilateral hearing loss. The SoundBite hearing system is a Bone Conduction Device (BCD) and is occasionally referred to as such in the protocol and within this report.
3062883|NCT00977379|Active Comparator|WBRT Followed by Standard of Care|Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system [CNS] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
3062884|NCT00977379|Experimental|WBRT+Capecitabine Followed by Capecitabine Maintenance|Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).
3062885|NCT00977431|Experimental|Regimen U|BIBW2992 + Radiotherapy
3062886|NCT00977431|Experimental|Regimen M|BIBW2992 + Temozolomide + Radiotherapy
3062887|NCT00977470|Experimental|Erlotinib|Erlotinib 150 mg oral daily
3062888|NCT00977470|Experimental|Erlotinib and Hydroxychloroquine|Erlotinib 150 mg oral daily plus Hydroxychloroquine (HCQ) 1000 mg oral daily
3062889|NCT00977548|Experimental|Erlotinib Treatment|Erlotinib was given as an oral 150 mg daily dose for 16 weeks. The dose was adjusted for diarrhea, rash and pulmonary toxicity.
3062890|NCT00977561|Experimental|Arm A|Figitumumab (CP-751,871) Plus Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
3062891|NCT00977561|Active Comparator|Arm B|Chemotherapy [Cisplatin (Or Carboplatin) And Etoposide] All drugs to be administered on a 21 day cycle
3062892|NCT00977613|Other|life style counseling|Treated stage 2 and 3 colorectal cancer patients were counseled to exercise at least to the equivalent of 18 metabolic hours per week and were assessed over 6 months.
3062893|NCT00977665|Experimental|rasagiline mesylate|rasagiline tablet, 1 mg/day for up to 48 weeks.
3062894|NCT00977665|Placebo Comparator|placebo|placebo tablet for up to 48 weeks.
3062895|NCT00977691|Experimental|Cohort 1|PBSC transplant with no post-transplant cyclophosphamide (PT-Cy)
3062896|NCT00977691|Experimental|Cohort 2|PBSC transplant with 50 mg/kg post-transplant cyclophosphamide (PT-Cy)
3062897|NCT00977691|Experimental|Cohort 3|PBSC transplant with 100 mg/kg post-transplant cyclophosphamide (PT-Cy)
3062898|NCT00977704|Active Comparator|Restylane and Perlane|Restylane and Perlane administered by injection. Recommended volume of 6.0 mL. Injection on study day 1 with an optional touch up on study day 14.
3062899|NCT00977769|Experimental|carbetocin 100 µg|Carbetocin injection, 100µg, single injection
3062900|NCT00977769|Active Comparator|oxytocin 5 u|Oxytocin 5U, injection, single injection
3062901|NCT00977769|Placebo Comparator|placebo (NaCl)|Saline single injection
3062902|NCT00977808|Experimental|Closed-Loop Model Predictive Control (MPC)|Insulin dosing was performed by a model-predictive control (MPC) algorithm.
3062903|NCT00977808|Placebo Comparator|Open-Loop|Insulin dosing was performed by the patient (using their normal routine and personal insulin pump) under a physician's supervision.
3062904|NCT00977938|Placebo Comparator|12m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
3062905|NCT00977938|Active Comparator|30m DAPT Study Arm|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine treatment in addition to aspirin.
3062906|NCT00978029|Placebo Comparator|Placebo|Matching placebo tablet sublingual, once daily
3062907|NCT00978029|Experimental|SCH 39641 6 Amb a 1-U|6 Units Short Ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) in an AIT, sublingual, once daily
3062908|NCT00978029|Experimental|SCH 39641 12 Amb a 1-U|12 Amb a 1-U in an AIT, sublingual, once daily
3062909|NCT00978042|Experimental|VOLUMA® XC Treatment Arm|Participants treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs) at study start. Participants were eligible for re-treatment if applicable.
3062910|NCT00978042|Other|Control Arm_No Treatment then VOLUMA® XC|No treatment for 6 months, then participants were treated with JUVÉDERM® VOLUMA® XC Injectable Gel, volume determined by the investigator (up to 12 mLs). Participants were eligible for re-treatment if applicable.
3062911|NCT00978068|Active Comparator|Lopinavir/ritonavir (LPV/r) +2 NRTI|Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
3062912|NCT00978068|Active Comparator|Nevirapine (NVP) or Efavirenz (EFV) +2 NRTI|Nevirapine (NVP) or Efavirenz (EFV) +2 nucleoside reverse transcriptase inhibitor (NRTI)
3062913|NCT00978120|Experimental|H1N1 vaccine high dose|Participants will be stratified according to asthma severity and will receive the high dosage of the H1N1 vaccine.
3062914|NCT00978120|Experimental|H1N1 vaccine low dose|Participants will be stratified according to asthma severity and will receive the low dosage of the H1N1 vaccine.
3062915|NCT00978250|Experimental|5-Fluro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)|FdCyd (100 mg/m(2)) + THU (350 mg/m(2)) administered 5 days/week for 2 weeks in 28-day cycles
3062916|NCT00978341|Experimental|Pregabalin|
3062917|NCT00978341|Other|Placebo|
3062918|NCT00978380|Experimental|A|
3062919|NCT00978432|Experimental|Arm 1a (RAD001 followed by LBH589)|"Part 1a: Sequential single agent therapy with RAD001 and LBH589. Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
3062920|NCT00978432|Experimental|Arm 1b (LBH589 followed by RAD001)|"Part 1b: Sequential single agent therapy with LBH589 and RAD001 . Each agent will be given for four-six 28-day cycles.~Subjects with less than a CR after 4 cycles of study drug should proceed to the next study drug(s) after the prescribed washout period.~Subjects with a CR may receive up to 6 cycles of study drug and will not receive the next study drug(s) until there is evidence of progressive disease.~There will be a 1-6 week 'washout' period between stopping and starting each agent in Part 1, unless rapid progression suggests holding therapy would not be in the patient's best interest."
3062921|NCT00978432|Experimental|Doublet (Combination RAD001 and LBH589)|Subjects will receive the doublet of RAD001 and LBH589 given in two to thirteen, 28-day cycles. Subjects will be evaluated for the disease status after completion of cycle two and then after every 4 cycles. Subjects with progressive disease will stop after 2 cycles. Subjects with stable disease or better may receive up to 13 cycles. LBH589 will start at 15mg po three days a week at least 2 days apart such as on days M/W/F or T/Th/Sat and RAD001 will start at 7.5mg po daily.
3062922|NCT00978445|Experimental|Home/Standard|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was at home first then in clinic INR and interaction with a care giver.
3062923|NCT00978445|Experimental|Standard/Home|all participants recieved vMetric protocol at home and in clinical setting, in this ARM the standard protocol was an in clinic INR and interaction with a care giver, then the Home protocol was as described.
3062924|NCT00978562|Experimental|Diagnostic (DSC-MRI with ferumoxytol, DCE-MRI with gadolinium)|Patients receive ferumoxytol and gadolinium IV and then undergo DSC-MRI and DCE-MRI. An optional MRI without injection of a contrast agent may be obtained after 20-24 hours at the discretion of the clinician. Patients may receive up to 3 more scans at least 3 weeks apart over up to 2 years.
3062925|NCT00978627|Experimental|IDegAsp OD|
3062926|NCT00978627|Active Comparator|IDet|
3062927|NCT00978731|Experimental|Dasatinib|
3062928|NCT00978757|Experimental|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
3062929|NCT00978757|Placebo Comparator|Placebo|Placebo: saline solution
3062930|NCT00979017|Experimental|Avastin in combination with temozolomide and irinotecan|Avastin 10 mg/kg every 14 days. Temozolomide 200 mg/m2 daily x 5 days in a 28-day cycle. Irinotecan dose depends on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). EIAED 340 mg/m2 every other week and no EIAED 125 mg/m2 every other week. Irinotecan dose also depends on if the patient has the UGT 1A1 polymorphism (7/7). If so, they do not metabolize the irinotecan normally, so these patients will start out at a two dose level reduction. EIAED starting dose will be 275 mg/m2 and no EIAED starting dose will be 75 mg/ m2.
3062931|NCT00979069|Experimental|Aerobic Group|12 weeks of aerobic exercise 3 times a week
3062932|NCT00979069|No Intervention|Control Group|No contact control
3062933|NCT00979121|Active Comparator|Rosuvastatin|"Half of the subjects were randomized to the active drug (Rosuvastatin).~Dosage, Form, and Frequency: drug was provided as 10mg tablets and administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). An initial 40mg loading dose was administered followed by a daily 20 mg maintenance dose. Maintenance dosing was adjusted for renal failure not compensated by renal replacement therapy.~Duration: drug was administered daily until:~28 days after randomization or 3 days after ICU discharge (whichever comes first),~Discharge from study hospital,~Death"
3062934|NCT00979121|Placebo Comparator|Placebo|"Half of the subjects were randomized to placebo.~10mg tablets identical to active drug were administered through an enteral feeding tube or orally (following extubation when patients were able to safely take oral medications). Dosage, frequency, and duration was provided in the same manner as the active drug."
3062935|NCT00979134|Experimental|Part A|Ascending doses of AZD4547 administered orally to patients to define the maximum tolerated dose (MTD) and/or a continuous, tolerable Recommended Dose (RD)
3062936|NCT00979134|Experimental|Part B|Dose expansion phase, at the RD defined in Part A
3062937|NCT00979134|Experimental|Part C|Expansion phase in patients with FGFR1 and FGFR2 amplified tumours commencing at the RD defined from Part A
3062938|NCT00979199|Other|Non invasive cardiac imaging|Intervention: Non invasive cardiac imaging. 'Anatomical' information provided by CTCA is obtained in every patient together with the 'functional' information provided by stress radionuclide cardiac imaging (SPECT or PET), to assess myocardial perfusion, and/or by stress MRI or ECHO imaging to assess myocardial contraction.
3062939|NCT00979212|Active Comparator|Induction CT+RT|Chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
3062940|NCT00979212|Experimental|Induction CT+RT+Panitumumab|Panitumumab plus chemotherapy (paclitaxel and carboplatin) plus radiation therapy followed by surgery (if operable) followed by consolidation chemotherapy (paclitaxel and carboplatin)
3062941|NCT00979303|No Intervention|Control Group|Control Patients - Undergo ablation procedures with radiation/fluoroscopy only
3062942|NCT00979303|Experimental|Study Group|Study Group Patients - Undergo ablation procedures using intracardiac echocardiography and 3D navigational system in addition to radiation.
3062943|NCT00979407|Experimental|GSK2340272A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3062944|NCT00979407|Experimental|GSK2340274A GROUP|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340274A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3062945|NCT00979420||HIV treatment|
3062946|NCT00979459|Experimental|MK-1006 80 mg DFC|Participants received a single dose of four 20 mg dry filled capsules of MK-1006
3062947|NCT00979459|Experimental|MK-1006 80 mg FCT|Participants received a single dose of two 40 mg film coated tablets of MK-1006
3062948|NCT00979576|Experimental|BIBF 1120 BID + Pemetrexed|Phase I part: Find MTD by using low, medium or high BIBF 1120 twice daily and 500mg/m^2 pemetrexed once every 3 weeks
3062949|NCT00979576|Experimental|BIBF 1120 BID (RD) + Pemetrexed|PHase II part: Study arm
3062950|NCT00979576|Experimental|BIBF 1120 BID(Placebo) + Pemetrexed|Phase II part: Comparator arm
3062951|NCT00979602|Experimental|GSK2340274A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the adjuvanted GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
3062952|NCT00979602|Experimental|GSK2340273A Group|Healthy male or female subjects between and including 18 to 60 years of age and older (>60 years) and between 18 to 64 years of age and older (>64 years), who received one dose of the unadjuvanted GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm.
3062953|NCT00979615|Experimental|1|Olopatadine HCL Nasal Spray, 0.6%
3062954|NCT00979615|Active Comparator|2|Azelastine HCl Nasal Spray, 137 mcg
3062955|NCT00979628|Experimental|Basal Plus Regimen|glargine subcutaneously once daily plus corrective doses of glulisine subcutaneously before meals and bedtime as needed
3062956|NCT00979628|Experimental|Basal Bolus|glargine subcutaneously once daily plus glulisine subcutaneously before meals (plus corrective doses of glulisine as needed)
3062957|NCT00979628|Active Comparator|sliding scale regular insulin (SSRI)|sliding scale regular insulin subcutaneously four-times daily in patients with T2DM admitted to general medicine and surgery wards.
3062958|NCT00979654|Experimental|Sifalimumab (MEDI-545) 500 or 600 milligram (mg)|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
3062959|NCT00979732|Active Comparator|GSE beverage active|grape seed extract beverage 150 mg/BID
3062960|NCT00979732|Placebo Comparator|GSE beverage placebo|grape seed extract placebo beverage 150 mg/BID
3062961|NCT00979745|Experimental|Afamelanotide|
3062962|NCT00979745|Placebo Comparator|Placebo|
3062963|NCT00979875|Experimental|Lispro+PH20, Lispro, Glulis+PH20, Glulis, Aspart+PH20, Aspart|"All participants were randomized to 1 of 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, or CBA), each of which was comprised of the same 3 interventions (A, B, and C). Each intervention was separated by a 3- to 14-day washout.~Intervention A: Participants received a single, subcutaneous (SC) injection of 95 units per milliliter (U/mL) Lispro + 5 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (PH20) and a single, SC injection of 95 U/mL Lispro alone 3 to 14 days apart.~Intervention B: Participants received a single, SC injection of 95 U/mL Glulisine (Glulis) + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Glulis alone 3 to 14 days apart.~Intervention C: Participants received a single, SC injection of 95 U/mL Aspart + 5 µg/mL PH20 and a single, SC injection of 95 U/mL Aspart alone 3 to 14 days apart."
3062964|NCT00979901|Experimental|1|montelukast
3062965|NCT00979901|Experimental|2|loratadine
3062966|NCT00979901|Placebo Comparator|3|placebo
3062967|NCT00979901|Experimental|4|montelukast/loratadine
3062968|NCT00979940|No Intervention|No atorvastatin|Patients do not receive Atorvastatin prior to PCI in cath lab
3062969|NCT00979940|Experimental|atorvastatin|Atorvastatin 80mg po given prior to PCI in cath lab
3062970|NCT00979953|Experimental|ADL5859|One 50-milligrams (mg) ADL5859 capsule, one 100-mg ADL5859 capsule, and 2 placebo capsules administered orally twice daily (BID) for 14 days
3062971|NCT00979953|Experimental|ADL5747|One 150-mg ADL5747 capsule and 3 placebo capsules administered orally BID for 14 days
3062972|NCT00979953|Active Comparator|Oxycodone CR|"One 10-mg Oxycodone controlled release (CR) capsule and 3 placebo capsules administered orally BID Days 1 through 4~One 20-mg Oxycodone CR capsule and 3 placebo capsules administered orally BID Days 5 through 14"
3062973|NCT00979953|Placebo Comparator|Placebo|Four placebo capsules administered orally BID for 14 days
3062974|NCT00979992|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3062975|NCT00980005|Experimental|Flulaval Group|"subjects received Flulaval™ vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Flulaval vaccine was administered intramuscularly into the non-dominant deltoid."
3062976|NCT00980005|Active Comparator|Fluzone Group|"subjects received Fluzone® Sanofi Pasteur's vaccine according to their priming status and age:~3-8 years: primed subjects 1 dose at Day 0; unprimed subjects 1 dose at Day 0 and a second dose at Day 28~9-17 years: 1 dose at Day 0 Fluzone vaccine was administered intramuscularly into the non-dominant deltoid."
3062977|NCT00980018|Experimental|nilotinib|Participants received two 150 [a total of 300 mg at each dosing] mg nilotinib capsules twice daily (bid) orally every morning and every evening approximately 12 hours apart and two 200 mg capsules [a total of 400 mg at each dosing] for patients enrolled prior to Protocol Amendment 1).
3062978|NCT00980044|Experimental|Tramadol 200 mg then placebo|Tramadol 200 mg daily for 1 week then placebo given for 1 week
3062979|NCT00980044|Placebo Comparator|Placebo for two weeks|Medication
3062980|NCT00980044|Experimental|Tramadol 600 mg then placebo|Tramadol 600 mg daily given for 1 week given then placebo given for 1 week
3062981|NCT00980057|Experimental|Adaptive CRT (aCRT) arm|Intervention: Cardiac resynchronization therapy (CRT-D) with Adaptive CRT algorithm ON
3062982|NCT00980057|Active Comparator|Echo-optimized arm|Intervention: Cardiac resynchronization therapy (CRT-D) with standard biventricular pacing (Adaptive CRT algorithm OFF)
3062983|NCT00980148|Experimental|Arm2|Doxycycline 100 mg oral twice a day (BID) for 7 days; 153 subjects
3062984|NCT00980148|Experimental|Arm 1|Azithromycin 1 gm oral single dose; 153 subjects
3062985|NCT00980174|Placebo Comparator|2|Subjects will receive placebo for denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab (SC injection every 6 months) for 1 year (open-label phase)
3062986|NCT00980174|Experimental|1|60 mg denosumab (SC injection every 6 months) for 1 year (double-blind phase) followed by 60 mg denosumab(SC injection every 6 months) for 1 year (open-label phase). These subjects will be on denosumab for a total of 2 years.
3062987|NCT00980200|Experimental|C/E/A/B/D|GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD/GW642444 Dose 3 QD
3062988|NCT00980200|Experimental|D/C/E/A/B|GW642444 Dose 3 QD/GW642444 Dose 2 QD/GW642444 Dose 4 QD/placebo/GW642444 Dose 1 BD
3062989|NCT00980200|Experimental|A/B/C/D/E|placebo/GW642444 Dose 1 BD/GW642444 Dose 2 QD/GW642444 Dose 3 QD/GW642444 Dose 4 QD
3062990|NCT00980200|Experimental|B/A/D/E/C|GW642444 Dose 1 BD/placebo/GW642444 Dose 3 QD/GW642444 Dose 4 QD/GW642444 Dose 2 QD
3062991|NCT00980200|Experimental|E/D/B/C/A|GW642444 Dose 4 QD/GW642444 Dose 3 QD/GW642444 Dose 1 BD/GW642444 Dose 2 QD/placebo
3062992|NCT00980278|Active Comparator|sinus lift plus dental implant|"Transalveolar sinus augmentation will be performed. After 4 months dental implants will be delivered only if primary stability can be achieved.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: N/A; only sinus augmentation and dental implant"
3062993|NCT00980278|Experimental|sinus lift plus BRCs and dental implant|"transalveolar sinus augmentation will be performed. A unit dose of BRC (10 ml) will be mixed with a commercially available β-TCP (Cerasorb), which will be used as a carrier to deliver the cells.~Intervention (Procedure/Surgery): Sinus lift augmentation and dental implant transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.~Biological/Vaccine: Aastrom BRCs, sinus augmentation, BRC application, dental implant"
3062994|NCT00980330|Experimental|TMC435 100 mg 12 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo with PR for 36 weeks.
3062995|NCT00980330|Experimental|TMC435 100 mg 24 Wks + PR48|Participants willl receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed by Placebo with PR for 24 weeks.
3062996|NCT00980330|Experimental|TMC435 100 mg 48 Wks + PR48|Participants will receive TMC435 100 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3062997|NCT00980330|Experimental|TMC435 150 mg 12 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo and PR for 36 weeks.
3062998|NCT00980330|Experimental|TMC435 150 mg 24 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks followed Placebo and PR for 24 weeks.
3062999|NCT00980330|Experimental|TMC435 150 mg 48 Wks + PR48|Participants will receive TMC435 150 mg once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3063000|NCT00980330|Placebo Comparator|Placebo 48 Wks + PR48|Participants will receive Placebo once daily with Peg-IFN-alfa-2a (P) once weekly and ribavirin (R) twice daily for 48 weeks.
3063001|NCT00980343|Experimental|Arm I (pre-surgery vismodegib)|"Patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily for 7 days before therapeutic conventional surgery. Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: pharmacological study; laboratory biomarker analysis"
3063002|NCT00980343|Experimental|Arm II (no vismodegib pre-surgery)|"Patients do not receive treatment before therapeutic conventional surgery.~Beginning within 28 days after surgical resection, all patients receive oral Hedgehog antagonist GDC-0449 (vismodegib) once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Other: laboratory biomarker analysis"
3063003|NCT00980395|Experimental|VCR (Velcade, Cladribine and Rituximab)|"Rituximab 375 mg/m2 IV day1~Cladribine 4 mg/m2 IV over 2 hours days 1-5~Bortezomib 1.3 mg/m2 IV days 1 and 4~Repeat every 28 days for a maximum of 6 cycles"
3063004|NCT00980590|Experimental|Airway Scope|Intubation with Airway Scope
3063005|NCT00980590|Active Comparator|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
3063006|NCT00980642|Other|General anesthesia|Temperature is measured by Draeger double-sensor and esophageal stethoscope temperature sensor every 5-min during the surgery.
3063007|NCT00980642|Other|Regional anesthesia|Temperature is measured by Draeger double-sensor and Foley catheter temperature sensor every 5-min during the surgery.
3063008|NCT00980655|Experimental|1|
3063009|NCT00980681|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg.
3063010|NCT00980681|Other|Time Of Flight|Each subject will undergo a TOF Magnetic Resonance Angiography
3063011|NCT00980746|Experimental|ESL 400 mg BID|ESL 400 mg twice daily (BID)
3063012|NCT00980746|Experimental|ESL 800 mg QD|ESL 800 mg once-daily (QD)
3063013|NCT00980746|Experimental|ESL 600 mg BID|Eslicarbazepine 600 mg twice daily
3063014|NCT00980746|Experimental|ESL 1200 mg QD|Eslicarbazepine acetate 1200 mg once daily
3063015|NCT00980746|Experimental|ESL 800 mg BID|Eslicarbazepine acetate 800 mg twice daily
3063016|NCT00980746|Placebo Comparator|Placebo|Placebo
3063017|NCT00980785|Placebo Comparator|Placebo|Matching Placebo
3063018|NCT00980785|Experimental|Active|Ramipril 5mg/day
3063019|NCT00980798|Experimental|001|OROS hydromorphone HCl 4 to 32 mg taken orally once daily for 16 weeks
3063020|NCT00980798|Placebo Comparator|002|Placebo placebo tablet once daily for 16 weeks
3063021|NCT00980980|No Intervention|Arm 1: Usual Care-Active Surveillance|Active Surveillance in All Adult ICUs, Contact Precautions for MRSA+
3063022|NCT00980980|Active Comparator|Arm 2: Targeted Decolonization|Continue Active Surveillance (AS), MRSA decolonization based on AS, Continue Contact Precautions for MRSA+
3063023|NCT00980980|Active Comparator|Arm 3: Universal Decolonization|Chlorhexidine bath and nasal mupirocin for all, Discontinuation of Active Surveillance, Continuation of Contact Precautions for MRSA+
3063024|NCT00981019||mortality*incidence*5-year survival*early stage|Physicians will be faced in scenarios about screening with information on mortality and 5-year survival, followed by information on mortality*incidence and 5-year survival*early stage in a random order.
3063025|NCT00981045|Experimental|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
3063026|NCT00981045|Active Comparator|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
3063027|NCT00981058|Experimental|Necitumumab + Gemcitabine + Cisplatin|
3063028|NCT00981058|Active Comparator|Gemcitabine + Cisplatin|
3063029|NCT00981084|Experimental|armodafinil and placebo|All participants will receive one dose of armodafinil and one dose of placebo in a cross-over design
3063030|NCT00981149|Experimental|duloxetine study drug|Drug
3063031|NCT00981149|Placebo Comparator|Placebo|Placebo
3063032|NCT00981175|Experimental|Study Group 1: ChimeriVax™-JE Vaccine first, then Placebo|Participants received ChimeriVax™-JE on Day 0 and ChimeriVax diluent on Day 28
3063033|NCT00981175|Experimental|Study Group 2: Placebo first, then ChimeriVax™-JE Vaccine|Participants received ChimeriVax diluent on Day 0 and ChimeriVax™-JE on Day 28.
3063034|NCT00981214|Experimental|EUR-1008 (APT-1008)|
3063035|NCT00981227|Experimental|ESL 400 mg twice-daily|ESL 400 mg twice-daily
3063036|NCT00981227|Experimental|ESL 800 mg once-daily|ESL 800 mg once-daily
3063037|NCT00981227|Experimental|ESL 600 mg twice daily|ESL 600 mg twice daily
3063038|NCT00981227|Experimental|ESL 1200 mg once daily|ESL 1200 mg once daily
3063039|NCT00981227|Experimental|ESL 800 mg twice daily|ESL 800 mg twice daily
3063040|NCT00981227|Placebo Comparator|placebo|placebo
3063041|NCT00981253|Experimental|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation with weekly stress management training for 12 weeks.
3063042|NCT00981253|Active Comparator|Standard Cardiac Rehabilitation|Standard cardiac rehabilitation consisting of supervised exercise for 12 weeks.
3063043|NCT00981292|Active Comparator|135mg EGCG|
3063044|NCT00981292|Active Comparator|270mg EGCG|
3063045|NCT00981292|Placebo Comparator|0mg EGCG|
3063046|NCT00981305|Experimental|Lactate-containing Vaginal Lubricant|apply 3cc of lactate-containing vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
3063047|NCT00981305|Placebo Comparator|Placebo|apply 3cc of placebo vaginal lubricant before sexual intercourse or sleeping for 8wks (at least 3 times per week)
3063048|NCT00981409|Experimental|Fondaparinux|
3063049|NCT00981409|Other|unfractionated heparin|
3063050|NCT00981435|Experimental|Artificial Tears|Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3063051|NCT00981435|Experimental|Non-steroidal anti-inflammatory|Topical ketorolac 0.5% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3063052|NCT00981435|Experimental|Steroid|Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
3063053|NCT00981461|Active Comparator|LLT Device 2009 9 Beam|HairMax LaserComb
3063054|NCT00981461|Sham Comparator|control device|control device
3063055|NCT00981474|Active Comparator|Control|Blood pressure targets during cardiopulmonary bypass based on institutional standards of empiric management.
3063056|NCT00981474|Experimental|Intervention|Blood pressure management based on cerebral autoregulation data.
3063057|NCT00981526|Experimental|A: Telmisartan|(existing Clozapine or Olanzapine treatment) + (Telmisartan)
3063058|NCT00981526|Placebo Comparator|B: Placebo|(existing Clozapine or Olanzapine treatment) + (Placebo)
3063059|NCT00981578|Experimental|ExAblate 2100 Treatment|ExAblate 2100 ablation for the treatment of painful bone metastases.
3063060|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 1|Participants received ChimeriVax™-JE (Japanese Encephalitis) a dose of 3.0 log10 Plaque-forming units (PFU) on Day 0.
3063061|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 2|Participants received ChimeriVax™-JE a dose of 4.0 log10 PFU on Day 0.
3063062|NCT00981630|Experimental|ChimeriVax™-JE Dose Level 3|Participants received ChimeriVax™-JE a dose of 5.0 log10 PFU on Day 0.
3063063|NCT00981630|Placebo Comparator|Placebo|Participants received ChimeriVax diluent, 0.5 mL on Day 0.
3063064|NCT00981669|Experimental|rotavirus vaccine|3 doses with 6 weeks interval
3063065|NCT00981669|Placebo Comparator|placebo|3 doses with 6 weeks interval
3063066|NCT00981682|Experimental|SER120 (desmopressin)|
3063067|NCT00981747|Experimental|All study participants|Study participants are patients that have been diagnosed with idiopathic pulmonary fibrosis (IPF).
3063068|NCT00981799|Experimental|Nelarabine Dose Level 1|The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
3063069|NCT00981799|Experimental|Nelarabine Dose Level 2|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 330 mg/m2 Cyclophosphamide.
3063070|NCT00981799|Experimental|Nelarabine Dose Level 3|Patients in this arm will be administered Nelarabine at 650 mg/m2 (100% of single agent MTD) and 400 mg/m2 Cyclophosphamide
3063071|NCT00981799|Experimental|Nelarabine Dose Level 0|Patients in this arm will be administered Nelarabine 325 mg/m2 (50% of single agent MTD) and 330 mg/2 Cyclophosphamide. Patients will only enter this arm if the MTD at Dose Level 1 has been exceeded. If the MTD is exceeded at Dose Level 0, the study will be closed.
3063072|NCT00981812|Experimental|PEM Breast Biopsy|All patients underwent PEM biopsy.
3063073|NCT00981825|Placebo Comparator|A|fluoride toothpaste control
3063074|NCT00981825|Active Comparator|B|triclosan/fluoride toothpaste
3063075|NCT00982007|Experimental|Cohort 1 (Group A) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
3063076|NCT00982007|Active Comparator|Cohort 1 (Group B) - Ferrous Sulfate|Oral iron - Ferrous Sulfate tablets
3063077|NCT00982007|Active Comparator|Cohort 2 (Group D) - IV Iron (standard of care)|Other IV iron
3063078|NCT00982007|Experimental|Cohort 2 (Group C) - Ferric Carboxymaltose (FCM)|Intravenous (IV) iron
3063079|NCT00982020|Experimental|Olanzapine/standard behavioral weight intervention|
3063080|NCT00982020|Experimental|Olanzapine/intense behavioral weight intervention|
3063081|NCT00982033|Active Comparator|Aliskiren|50 % of subjects participating in this trial will be on the active medication, Aliskiren 300mg qd, the other 50% will be on placebo.
3063082|NCT00982033|Placebo Comparator|Placebo|50% of subjects will be randomized to placebo.
3063083|NCT00982072|Active Comparator|prednisolone|prednisolone tablets
3063084|NCT00982072|Experimental|tacrolimus|tacrolimus tablets
3063085|NCT00982111|Experimental|Necitumumab + Pemetrexed + Cisplatin|Necitumumab + Pemetrexed + Cisplatin
3063086|NCT00982111|Active Comparator|Pemetrexed + Cisplatin|Pemetrexed + Cisplatin
3063087|NCT00982137|Experimental|ChimeriVax™-JE then STAMARIL®|Participants will receive ChimeriVax™-JE on Day 0 and STAMARIL® on Day 30
3063088|NCT00982137|Experimental|STAMARIL® then ChimeriVax™-JE|Participants will receive STAMARIL® on Day 0 and ChimeriVax™-JE on Day 30
3063089|NCT00982137|Experimental|ChimeriVax™-JE and STAMARIL®, then Diluent|Participants will receive ChimeriVax™-JE and STAMARIL® on Day 0 and diluent on Day 30.
3063090|NCT00982137|Experimental|Diluent then ChimeriVax™-JE and STAMARIL®|Participants will receive Diluent on Day 0 and ChimeriVax™-JE and STAMARIL® on Day 30.
3063091|NCT00982189|Experimental|Lisinopril|Lisinopril 10mg once daily
3063092|NCT00982189|Placebo Comparator|Lisinopril Placebo|Placebo pill (matched to lisinopril) once daily
3063093|NCT00982189|Experimental|Pravastatin|Pravastatin 20mg once daily
3063094|NCT00982189|Placebo Comparator|Pravastatin placebo|Placebo pill (matched to pravastatin) once daily
3063095|NCT00982228|Experimental|IDeg OD|
3063096|NCT00982228|Active Comparator|IGlar OD|
3063097|NCT00982280|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3063098|NCT00982319|Experimental|Broccoli sprout extract|Patients will be randomized to 14 day intervention of broccoli sprout extract and mango juice consisting of a dose of 100 µmols of sulforaphane dissolved in 150 mL mango juice once a day.
3063099|NCT00982319|Placebo Comparator|Mango juice|Patients will be randomized to 14 day intervention of 150 mL mango juice without broccoli sprout extract extract once a day.
3063100|NCT00982345|Other|Open label Quetiapine|Open-label Quetiapine XL 50 - 400 mg daily treatment 8 weeks
3063101|NCT00982397|Experimental|Single-chamber detetction|Patients implanted with a Protecta VR-ICD.
3063102|NCT00982397|Experimental|Dual-chamber detection|Patients implanted with a Protecta DR-ICD or CRT-D.
3063103|NCT00982410|Experimental|Arm 1|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
3063104|NCT00982410|Placebo Comparator|Arm 2|educational supportive group
3063105|NCT00982423|Experimental|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
3063106|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Chronic phase|Participants with chronic phase disease continued on the previous study dose of dasatinib, ranging from 50 mg once daily (QD) to 120 mg twice daily (BID).
3063107|NCT00982488|Other|Imatinib, 400 mg BID, Chronic phase|Participants with chronic phase disease received 400 mg of imatinib twice BID.
3063108|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, AP|Participants with advanced phase disease, accelerated phase (AP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3063109|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, MBP|Participants with advanced phase disease, myeloid blast cell (MBP), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3063110|NCT00982488|Other|Dasatinib, 50 mg QD to 120 mg BID, Advanced phase, Ph+ ALL|Participants with advanced phase disease, Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), continued on the previous study dose of dasatinib, ranging from 50 mg QD to 120 mg BID.
3063111|NCT00982553|Experimental|Phase 1_ribavirin|Treatment with Single dose ribavirin (800 mg) administered on day 1
3063112|NCT00982553|Experimental|Phase2_raltegravir|Treatment with Raltegravir (400 mg twice daily) administered from days 15-19
3063113|NCT00982553|Experimental|Phase3_ribavirin+raltegravir|Treatment with Ribavirin (800 mg) and Raltegravir (400 mg) administered day 20
3063114|NCT00982592|Experimental|Arm I (FOLFOX regimen and placebo)|Patients receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil bolus and then IV over 46-48 hours on day 1. Patients also receive placebo PO QD on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
3063115|NCT00982592|Experimental|Arm II (FOLFOX regimen and vismodegib)|Patients receive FOLFOX chemotherapy as in arm I. Patients also receive vismodegib PO on days 1-14. Courses repeat every 2 weeks in the absence of unacceptable toxicity or disease progression.
3063116|NCT00982644|Experimental|IDeg OD|
3063117|NCT00982644|Active Comparator|IGlar OD|
3063118|NCT00982657|Experimental|Cohort 1|CVX-060 + sunitinib
3063119|NCT00982657|Experimental|Cohort 2|CVX-060 + sunitinib
3063120|NCT00982657|Experimental|Cohort 3|CVX-060 + sunitinib
3063121|NCT00982657|Experimental|Expanded cohort|CVX-060 + sunitinib
3063122|NCT00982657|Experimental|Phase II - Arm A|CVX-060 + sunitinib
3063123|NCT00982657|Active Comparator|Phase II - Arm B|sunitinib alone
3063124|NCT00982865|Experimental|MSC1936369B Regimen 1|Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
3063125|NCT00982865|Experimental|MSC1936369B Regimen 2|"MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.~MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2."
3063126|NCT00982865|Experimental|MSC1936369B Regimen 3 once daily|Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
3063127|NCT00982865|Experimental|MSC1936369B Regimen 3 twice daily (BID)|Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
3063128|NCT00982878|Experimental|Maraviroc|
3063129|NCT00982930|Experimental|Tobramycin Inhalation Powder (TIP)|Participants received 112 mg (four 28 mg capsules) of TIP administered by the T-326 Inhaler, twice a day (b.i.d.), given in a cycle of 28 days on treatment followed by 28 days off treatment (one cycle = 56 days) for up to 3 cycles.
3063130|NCT00983073|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol IR tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3063131|NCT00983216|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3063132|NCT00983216|Experimental|Colchicine with Steady-State Ketoconazole|-colchicine pharmacokinetics in presence of steady-state ketoconazole
3063133|NCT00983242|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3063134|NCT00983242|Experimental|Colchicine with Verapamil HCl ER|colchicine pharmacokinetics in presence of steady-state verapamil
3063135|NCT00983281||Hextend|Patients that received Hextend as part of their fluid resuscitation.
3063136|NCT00983281||Standard of Care|Patients that received standard fluid resuscitation but no Hextend.
3063137|NCT00983294|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3063138|NCT00983294|Experimental|Colchicine with steady-state Azithromycin|colchicine pharmacokinetics in presence of steady-state azithromycin
3063139|NCT00983307|Experimental|Erlotinib and radiotherapy|Patients will be treated with Erlotinib and hypofractionated radiotherapy.
3063140|NCT00983346|Experimental|All patients|All participants enrolled.
3063141|NCT00983359|Experimental|Treatment (conformal stereotactic radiation therapy)|Patients undergo conformal stereotatic radiation
3063142|NCT00983372|Active Comparator|Colchicine alone|-colchicine baseline pharmacokinetics
3063143|NCT00983372|Experimental|Colchicine with steady-state Diltiazem|-colchicine pharmacokinetics in presence of steady-state diltiazem
3063144|NCT00983385|Experimental|Tapentadol|Tapentadol PR was given orally twice a day. A maximum of 2 oral Tapentadol immediate release (IR) tablets per day, with a minimum of a 4 hour interval between doses, were taken if there were acute pain episodes. The total daily dose of Tapentadol PR and IR were not permitted to exceed 500 mg per day.
3063146|NCT00983476|Experimental|Arm 1|in-person MOVE! SMI
3063147|NCT00983476|Experimental|Arm 2|web-based MOVE! SMI
3063148|NCT00983476|No Intervention|Arm 3|usual care + educational handouts regarding weight loss
3063149|NCT00983489|Active Comparator|counselling|counselling: Breast feeding counselling will be done to mothers
3063150|NCT00983489|Active Comparator|Video demonstration|Video demonstration to mothers on the advantages of exclusive breast feeding
3063151|NCT00983489|No Intervention|Standard Care|Standard care includes the routine care provided to the neonates as per hospital protocol
3063152|NCT00983515|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3063153|NCT00983515|Experimental|Colchicine with Ritonavir|-colchicine pharmacokinetics in presence of steady-state ritonavir
3063154|NCT00983541|Experimental|All patients|All participants enrolled.
3063155|NCT00983580|Experimental|Arm I (acetylsalicylic acid and eflornithine)|Patients receive acetylsalicylic acid PO once daily and eflornithine PO twice daily on days 1-28.
3063156|NCT00983580|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO three times daily on days 1-28.
3063157|NCT00983619|Experimental|Part A-MEDI-551 0.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063158|NCT00983619|Experimental|Part A-MEDI-551 1 mg/kg|Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063159|NCT00983619|Experimental|Part A-MEDI-551 2 mg/kg|Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063160|NCT00983619|Experimental|Part A-MEDI-551 4 mg/kg|Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063161|NCT00983619|Experimental|Part A-MEDI-551 8 mg/kg|Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063162|NCT00983619|Experimental|Part A-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063163|NCT00983619|Experimental|Part B-MEDI-551 6 mg/kg|Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063164|NCT00983619|Experimental|Part B-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063165|NCT00983619|Experimental|Part B-MEDI-551 24 mg/kg|Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
3063166|NCT00983619|Experimental|Part C-MEDI-551 8 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
3063167|NCT00983619|Experimental|Part C-MEDI-551 12 mg/kg + rituximab|Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
3063168|NCT00983619|Experimental|Part D-MEDI-551 12 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
3063169|NCT00983749|Experimental|Full-pressure ECP|"Patients in the Full-pressure ECP arm receive a 1-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner up to 300mmHg, while assessments are made."
3063170|NCT00983749|Sham Comparator|Sham-pressure ECP|A 1-hour treatment of ECP at an inactive pressure (75mmHg)
3063171|NCT00983801|Experimental|Ixabepilone|
3063172|NCT00983827|Experimental|Aquatic treadmill training|Aquatic treadmill training (ATT) is a pool-based treadmill training that combines the three concepts of unweighting the body, treadmill training, and the resistance effects of water into one modality.
3063173|NCT00983853|Experimental|Part A|The dose of ribavirin used (fixed versus weight-based) is region dependent
3063174|NCT00983853|Experimental|Part B|The dose of ribavirin used (fixed versus weight-based) is region dependent
3063175|NCT00983892|Experimental|CarePartners+|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive the intervention (Intervention = access to a caregiver Web site that updates them on patient's symptoms and provides tailored problem solving advice).
3063176|NCT00983892|No Intervention|CarePartners-|Patients receive automated telephonic symptom assessment and symptom management advice; caregivers receive nothing (i.e. no access to the caregiver website, or 'intervention').
3063177|NCT00983905|Active Comparator|Theophylline alone|baseline theophylline kinetics
3063178|NCT00983905|Experimental|Theophylline with steady-state Colchicine|theophylline pharmacokinetics upon administration with colchicine at steady-state
3063179|NCT00983918|Active Comparator|Desflurane|General Anesthesia with Desflurane
3063180|NCT00983918|Active Comparator|Sevoflurane|General Anesthesia with Sevoflurane
3063181|NCT00983918|Active Comparator|Isoflurane|General Anesthesia with Isoflurane
3063182|NCT00983918|Active Comparator|Propofol|General Anesthesia with Propofol
3063183|NCT00983931|Active Comparator|Colchicine alone|-baseline colchicine pharmacokinetics
3063184|NCT00983931|Experimental|Colchicine with Cyclosporine|-colchicine pharmacokinetics in presence of cyclosporine
3063185|NCT00983957|Experimental|BMS-790052 plus Ortho Tri-Cyclen®|
3063186|NCT00983983|Experimental|High fat/high calorie|High fat/high calorie diet: Oxepa
3063187|NCT00983983|Active Comparator|High calorie|High calorie diet: Jevity 1.5
3063188|NCT00983983|Placebo Comparator|Control|Control diet: Jevity 1.0
3063189|NCT00984009|Active Comparator|Colchicine alone|baseline colchicine pharmacokinetics
3063190|NCT00984009|Experimental|Colchicine with Grapefruit Juice|colchicine pharmacokinetics in presence of grapefruit juice
3063191|NCT00984022|Active Comparator|Iodoform dressing|Iodoform dressing for cutaneous abscess
3063192|NCT00984022|Active Comparator|Aquacel dressing|Aquacel dressing for cutaneous abscess
3063193|NCT00984061|Experimental|colchicine alone|colchicine baseline pharmacokinetics
3063194|NCT00984061|Experimental|colchicine with clarithromycin|colchicine pharmacokinetics in presence of clarithromycin
3063195|NCT00984126|Experimental|Turoctocog alfa|
3063196|NCT00984139|Experimental|Engerix-B Group|Subjects who were vaccinated with 3 doses of Engerix-B in infancy and who received a single challenge dose of Engerix-B , intramuscularly in the deltoid region of the non-dominant arm, at 12-13 years of age (Day 0).
3063197|NCT00984165|Experimental|Donor Lymphocyte Infusion/Radiation|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 1 after radiation (single, 8-Gy fraction to the maximum number of lesions).
3063198|NCT00984165|Active Comparator|Radiation/No Donor Lymphocyte Infusion|Subjects will receive radiation (single, 8-Gy fraction to the maximum number of lesions).
3063199|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Control|Subjects will receive a unmanipulated donor lymphocyte infusion (DLI) on Day 0.
3063200|NCT00984165|Active Comparator|Donor Lymphocyte Infusion - Donor|Healthy subjects who donated lymphocytes for infusion on a treatment Arm.
3063201|NCT00984204|Experimental|Treatment arm|
3063202|NCT00984256|Experimental|Drug|"5 groups, each group receiving Malarone tablet(s) (250/100mg)prior to challenge.~Group 1 - 1 tablet 1 day before challenge Group 2 - 1 tablet 4 days before challenge Group 3 - 1 tablet 7 days before challenge Group 4 - 2 tablets 7 days before challenge Group 5 - 4 tablets 7 days before challenge"
3063203|NCT00984256|Placebo Comparator|Control -no prophylaxis|
3063204|NCT00984282|Experimental|Sorafenib (Nexavar, BAY43-9006)|Participants received 2 tablets of Sorafenib (2×200 mg) orally twice daily (12 hours apart without food), 28 days comprise a cycle
3063205|NCT00984282|Placebo Comparator|Placebo|Participants received 2 tablets of Sorafenib-matching placebo orally twice daily (12 hours apart without food), 28 days comprise a cycle
3063206|NCT00984295|Experimental|1|ProQuad + Tripedia + Comvax at Day 0 (Concomitant)
3063207|NCT00984295|Experimental|2|ProQuad at Day 0, Tripedia + Comvax at Day 42(Nonconcomitant)
3063208|NCT00984295|Active Comparator|3|Varivax + M-M-R II at Day 0, Tripedia + Comvax at Day 42 (Control)
3063209|NCT00984308|Experimental|Intervention|The intervention group received unattended polysomnography and auto-titrating CPAP if sleep apnea was diagnosed
3063210|NCT00984308|Other|Control|The control group received usual clinical care which may include receipt of sleep diagnostic and therapeutic services
3063211|NCT00984334|Placebo Comparator|Capsules with no active drug|Placebo capsules once daily for three weeks then twice daily for three weeks.
3063212|NCT00984334|Active Comparator|Naloxone SR 2.5 mg capsules|Naloxone SR 2.5 mg capsules once daily for three weeks then twice daily for three weeks.
3063213|NCT00984334|Experimental|Naloxone SR 10mg capsules|Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
3063214|NCT00984334|Experimental|Naloxone SR 20 mg capsules|Two Naloxone SR 10 mg capsules once daily for three weeks then twice daily for three weeks.
3063215|NCT00984334|Experimental|Naloxone SR 5mg capsules|Naloxone SR 5 mg capsules once daily for three weeks then twice daily for three weeks.
3063216|NCT00984542|Experimental|Bendamustine|
3063217|NCT00984568|Experimental|Top-Hold|Level 1: Infliximab IV 5 mg/kg at Weeks 0, 2, and 6, and every 8 weeks thereafter. Level 2: Infliximab IV 5 mg/kg every 4 weeks. Level 3: Prednisolone induction + AZA 2.0-2.5 mg/kg/day.
3063218|NCT00984568|Active Comparator|Step-Up|Level 1: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral 5-aminosalicylic acid (5-ASA) 2 g/day. Level 2: Oral prednisolone (40 mg/day or 1 mg/kg/day in the case of non-response) + oral azathioprine (AZA) at a dose of 2.0-2.5 mg/kg/day. Level 3: Infliximab 5 mg/kg at Weeks 0, 2, and 6 and every 8 weeks thereafter.
3063219|NCT00984594|Other|Primary injury site|CR-Plug will be placed in the site of the primary injury
3063220|NCT00984594|Other|Backfill site|Autograft will be placed in the site of the primary injury; CR Plug will be placed in the harvest site
3063221|NCT00984620|Experimental|short arm|patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
3063222|NCT00984620|Experimental|long arm|patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)
3063223|NCT00984659|Experimental|FSC|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day
3063224|NCT00984659|Experimental|SAL|Salmeterol 50mcg DISKUS twice a day
3063225|NCT00984659|Placebo Comparator|Placebo|Placebo DISKUS twice a day
3063226|NCT00984698|Experimental|Structured Therapy|Cognitive Behavioral Social Rhythm Group Therapy is designed to improve mood and sleep by stabilizing social rhythms, increasing exposure to ambient light, changing dysfunctional bed/bedtime associations, activating the imagery system by changing nightmare content, and challenging dysfunctional automatic thoughts that might contribute to behavioral inactivation and nonadherence to the therapy protocol. There is no discussion of past traumatic events.
3063227|NCT00984698|Active Comparator|Unstructured Therapy|Present Centered Group Therapy includes education about the typical symptoms and features associated with PTSD and MDD, with a focus on how these symptoms affect interpersonal relationships. It uses the group format to decrease isolation, normalize symptoms, and provide the experience of giving and receiving support. Some relaxation training is provided early in therapy. There is no discussion of past traumatic events.
3063228|NCT00984815|Experimental|HZT-501|Open-label treatment with HZT-501
3063229|NCT00984867|Active Comparator|1|Dapagliflozin 10 mg tablet
3063230|NCT00984867|Placebo Comparator|2|Matching placebo tablet
3063231|NCT00985088|Experimental|GSK2340274A F1_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 1 (F1) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063232|NCT00985088|Experimental|GSK2340274A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340274A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063233|NCT00985088|Experimental|GSK2340274A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063234|NCT00985088|Experimental|GSK2340274A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340274A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline placebo at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063235|NCT00985088|Experimental|GSK2340273A F1_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 1 (F1) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063236|NCT00985088|Experimental|GSK2340273A F2_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 2 (F2) of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063237|NCT00985088|Experimental|GSK2340273A F2_1D Group|Healthy male or female subjects, above and including 18 years of age, who received one dose of Formulation 2 (F2) of GSK2340273A vaccine at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and one dose of saline at Day 21, administered intramuscularly into the deltoid region of the dominant arm. Subjects above (>) 60 years old received an additional dose of Formulation 2 (F2) of GSK2340273A vaccine after Day 42, administered into the deltoid region of the non-dominant arm.
3063238|NCT00985088|Experimental|GSK2340273A F3_2D Group|Healthy male or female subjects, above and including 18 years of age, who received 2 doses of Formulation 3 of GSK2340273A vaccine: at Day 0, administered intramuscularly into the deltoid region of the non-dominant arm and at Day 21, administered intramuscularly into the deltoid region of the dominant arm.
3063239|NCT00985114|Experimental|Device|EndoBarrier implanted for 6 months. Subject followed for 6 months after device was explanted.
3063240|NCT00985114|Active Comparator|Diet + Lifestyle counseling|Multidisciplinary lifestyle and nutritional counseling for 12 months
3063241|NCT00985140||12 Gy TSEBT|Prospective assignment to receive 12 Gy total skin electron beam therapy (TSEBT) for mycosis fungoides
3063242|NCT00985153|Experimental|1|ProQuad Lot 1
3063243|NCT00985153|Experimental|2|ProQuad Lot 2
3063244|NCT00985153|Experimental|3|ProQuad Lot 3
3063245|NCT00985153|Active Comparator|4|M-M-R II + Varivax
3063246|NCT00985166|Experimental|1|ProQuad + Placebo
3063247|NCT00985166|Active Comparator|2|M-M-R II + Placebo
3063248|NCT00985166|Active Comparator|3|M-M-R II + Varivax
3063249|NCT00985192|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-14. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity
3063250|NCT00985231|Experimental|PureVision Multi-Focal contact lenses|
3063251|NCT00985231|Active Comparator|SofLens59 contact lens|
3063252|NCT00985257|Other|Subjects with diabetes|Subjects with diabetes (or parents/guardians, if applicable)and healthcare professionals (HCPs) use a new blood glucose monitoring system. Subjects were 4 to 24 years of age with type 1 and type 2 diabetes.
3063253|NCT00985426|Experimental|HEPLISAV-B|0.5 mL HEPLISAV-B and 0.5 mL Placebo
3063254|NCT00985426|Active Comparator|Engerix-B|2.0 mL Engerix-B
3063255|NCT00985439|Experimental|Diclofenac Test (lower dose)|One 18-mg Diclofenac Test Capsule and 1 placebo capsule
3063256|NCT00985439|Experimental|Diclofenac Test (upper dose)|One 35-mg Diclofenac Test Capsule and 1 placebo capsule
3063257|NCT00985439|Active Comparator|Celecoxib 400 mg|
3063258|NCT00985439|Placebo Comparator|Placebo|
3063259|NCT00985465|Experimental|Pn-Pn group|subjects from the Pn-Pn group, previously vaccinated with pneumococcal conjugate vaccine GSK1024850A in the Malian centre of study NCT00678301, receiving a booster dose of pneumococcal conjugate vaccine GSK1024850A
3063260|NCT00985465|Experimental|Zil-Pn group|subjects from the unprimed group of the NCT00678301 Malian study centre, not previously vaccinated with any pneumococcal vaccine, receiving two doses of pneumococcal conjugate vaccine GSK1024850A
3063261|NCT00985491|Experimental|Device|All patients will be implanted with the Endobarrier Liner device.
3063262|NCT00985504|Experimental|Duloxetine|
3063263|NCT00985504|Active Comparator|Escitalopram|
3063264|NCT00985517|Experimental|Phase 1: Cohort 1|CERE-120 9.4 x 10^11 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
3063265|NCT00985517|Experimental|Phase 1: Cohort 2|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
3063266|NCT00985517|Experimental|Phase 2: CERE-120|CERE-120 2.4 x 10^12 vg, injected by a neurosurgeon directly in the substantia nigra and in the putamen
3063267|NCT00985517|Sham Comparator|Phase 2: Sham Surgery|Neurosurgical procedure that mimics the procedure for CERE-120 delivery. No injections were administered during sham surgery.
3063268|NCT00985543|Active Comparator|LPV/r 400/100 mg|Lopinavir/ritonavir 400/100 mg twice daily (2 heat-stable 200/50 mg tablets twice daily (BID))
3063269|NCT00985543|Experimental|LPV/r 200/150 mg|Lopinavir/ritonavir 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID)
3063270|NCT00985543|Experimental|LPV/r 200/50 mg|Lopinavir/ritonavir 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID)
3063271|NCT00985621|Experimental|1|
3063272|NCT00985621|Experimental|2|
3063273|NCT00985621|Active Comparator|3|
3063274|NCT00985621|Placebo Comparator|4|
3063275|NCT00985673|Experimental|Flulaval/placebo/unadjuvanted Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063276|NCT00985673|Experimental|Flulaval/placebo/Arepanrix Group|subjects received co-administration of Flulaval vaccine and saline placebo on Day 0 followed the administration of Arepanrix vaccine on Day 21 and Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063277|NCT00985673|Experimental|Flulaval/unadjuvanted Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and the unadjuvanted formulation of Arepanrix vaccine on Day 0 followed by the administration of the unadjuvanted formulation of Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063278|NCT00985673|Experimental|Flulaval/Arepanrix/placebo Group|subjects received co-administration of Flulaval vaccine and Arepanrix vaccine on Day 0 followed by Arepanrix vaccine on Day 21 and saline placebo on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063279|NCT00985673|Experimental|Unadjuvanted Arepanrix/placebo/Flulaval Group|subjects received co-administration of the unadjuvanted formulation of Arepanrix vaccine and saline placebo on Day 0 followed by the unadjuvanted formulation of Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063280|NCT00985673|Experimental|Arepanrix/placebo/Flulaval Group|subjects received co-administration of Arepanrix vaccine and saline placebo on Day 0 followed by Arepanrix vaccine on Day 21 and Flulaval vaccine on Day 42. All vaccines were administered intramuscularly in the deltoids of the dominant or non dominant arm. At Day 0 the two vaccines were administered each in a separate arm, at Day 21 in the dominant arm and at Day 42 in the non-dominant arm.
3063281|NCT00985686|Experimental|Study Arm|Arm where participants began the LEAP Project intervention upon recruitment for an 8 week period.
3063282|NCT00985686|Active Comparator|Waitlist Arm|"Arm where participants received the LEAP Project intervention after an 8 week wait period.~At 8 weeks, the results from the wait-list arm (no intervention) were compared to the results of the study arm (intervention completed)."
3063283|NCT00985712|Experimental|HumaPen Luxura|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Luxura daily for 24 weeks
3063284|NCT00985712|Experimental|HumaPen Memoir|Participant's insulin dose of Insulin Lispro or Huminsulin Normal is delivered subcutaneously via HumaPen Memoir daily for 24 weeks
3063285|NCT00985725|Experimental|Active|SPD489
3063286|NCT00985725|Placebo Comparator|Placebo|Placebo
3063287|NCT00985751|Experimental|Group 1|
3063288|NCT00985751|Experimental|Group 2|
3063289|NCT00985751|Experimental|Group 3|
3063290|NCT00985751|Experimental|Group 4|
3063291|NCT00985751|Experimental|Control Group|
3063292|NCT00985790|Experimental|GSK2321138A Group|"Subjects aged between 18 and 47 months received the GSK2321138A. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the GSK2321138A-Primed Group) received 1 dose of GSK2321138A vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the GSK2321138A-Unprimed Group) received 2 doses of GSK2321138A vaccine at Days 0 and 28. The GSK2321138A vaccine was administered intramuscularly in the deltoid of the right arm."
3063293|NCT00985790|Active Comparator|Fluarix Group|"Subjects aged between 18 and 47 months received the Fluarix™ vaccine. Primed subjects (subjects who had received a 2-dose priming immunization with Fluarix™ vaccine in study NCT00764790 - or the Fluarix-Primed Group) received 1 dose of Fluarix™ vaccine at Day 0. Unprimed subject (subjects who had not received any 2-dose priming influenza immunization in any previous year - or the the Fluarix-Unprimed Group) received 2 doses of Fluarix™ vaccine at Days 0 and 28. The Fluarix™ vaccine was administered intramuscularly in the deltoid of the right arm."
3063294|NCT00985829|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3063295|NCT00985907|Experimental|Doxil® + Melphalan + Velcade (DMV)|
3063296|NCT00985946|Experimental|panobinostat|This is a single arm trial. All patients will take panobinostat
3063297|NCT00985959|Experimental|Phase I: JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles.
3063298|NCT00985959|Experimental|Phase I: JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
3063299|NCT00985959|Experimental|Phase I: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 4 cycles
3063300|NCT00985959|Experimental|Phase II: JNJ-26866138 1.3 mg/m2|JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5-9 cycles. Melphalan 9 mg/m2 and Prednisolone 60 mg/m2 on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
3063301|NCT00985985|Experimental|2mg nicotine lozenge|2 mg nicotine lozenge
3063302|NCT00985985|Placebo Comparator|2 mg placebo|2 mg placebo
3063303|NCT00985985|Experimental|4 mg nicotine lozenge|4 mg nicotine lozenge
3063304|NCT00985985|Placebo Comparator|4 mg placebo|4 mg placebo
3063305|NCT00986102|Other|001|doripenem 500mg vial by injection every 8 hours for 5 to 14 days
3063306|NCT00986154|Experimental|heparin/edoxaban tosylate|
3063307|NCT00986154|Active Comparator|heparin/warfarin|
3063308|NCT00986180|Experimental|001|NUCYNTA 50 75 or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
3063309|NCT00986180|Active Comparator|002|Oxycodone IR 5 10 or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
3063310|NCT00986232|Experimental|1|ProQuad (low dose)
3063311|NCT00986232|Experimental|2|ProQuad (middle dose)
3063312|NCT00986232|Experimental|3|ProQuad (high dose)
3063313|NCT00986232|Active Comparator|4|M-M-R II + PUVV
3063314|NCT00986245|Active Comparator|Ropinirole PR QD first, then BID|Give Roipinirole prolonged release (PR) once-daily (QD) dose first, then twice-daily (BID) dosing
3063315|NCT00986245|Active Comparator|Ropinirole PR BID first, and then QD|Give Ropinirole prolonged release (PR) twice-daily (BID) dosing, and then once-daily (QD) dosing
3063316|NCT00986258|Experimental|Tapentadol Prolonged Release|"Other Names:~Nucynta~Palexia"
3063317|NCT00986349|Experimental|Diabetes|Single Arm
3063318|NCT00986362|Experimental|Ocriplasmin|
3063319|NCT00986362|Placebo Comparator|Placebo|
3063320|NCT00986401|Experimental|Glucophage® then Sanctura XR® (AB)|Treatment Period 1: Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD) for 4 days + Glucophage® (500 mg, BID) for 3.5 days.
3063321|NCT00986401|Experimental|Sanctura XR® then Glucophage® (BA)|Treatment Period 1: Sanctura XR® (60 mg, QD) for 10 days followed by Sanctura XR® (60 mg, QD for 4 days) + Glucophage® (500 mg, BID) for 3.5 days. Washout: There will be a washout period of 3 days between each treatment period. Treatment Period 2: Glucophage® (500 mg, BID) for 3.5 days.
3063322|NCT00986427|Active Comparator|1|Subjects will apply Restasis® to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
3063323|NCT00986427|Placebo Comparator|2|Subjects will apply Refresh® Dry Eye therapy to the target nails for 24 weeks. Additionally, there is a 12 week follow up period post the treatment period.
3063324|NCT00986440|Experimental|CS-7017|
3063325|NCT00986440|Placebo Comparator|Placebo|Placebo matching CS-7017
3063326|NCT00986453|Experimental|PlasmaBlade arm|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
3063327|NCT00986453|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3063328|NCT00986479|Experimental|AZD6765 (150 mg) / Placebo|Patients randomized to receive a single intravenous (iv) infusion of AZD6765 (150 mg) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of placebo (saline solution) over 60 minutes during the second period.
3063329|NCT00986479|Placebo Comparator|Placebo / AZD6765 (150 mg)|Patients randomized to receive a single intravenous (iv) infusion of placebo (saline solution) over 60 minutes during the first period, followed by a 7-day drug-free period, followed by a single iv infusion of AZD6765 (150 mg) over 60 minutes during the second period.
3063330|NCT00986544|Sham Comparator|Absence of drain|
3063331|NCT00986544|Active Comparator|Drain|drain positioned in the subhepatic space after laparoscopic cholecystectomy
3063332|NCT00986570|Experimental|Xeomin®|Botulinum Toxin A
3063333|NCT00986583|Other|Statin use group|Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
3063334|NCT00986583|Other|non statin use|Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.
3063335|NCT00986674|Experimental|Arm I (carboplatin, paclitaxel, cetuximab)|Patients receive carboplatin IV over 15-30 minutes and paclitaxel IV over 3 hours on days 1 and 22 and cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab alone on days 1, 8, 15, 22, 29, and 36. Treatment with cetuximab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
3063336|NCT00986674|Experimental|Arm II (carboplatin, paclitaxel, cixutumumab)|Patients receive carboplatin and paclitaxel as in arm I. Patients also receive cixutumumab IV over 1 hour on days 1, 15, and 29. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cixutumumab alone on days 1, 15, and 29. Treatment with cixutumumab repeats every 42 days in the absence of disease progression or unacceptable toxicity.
3063337|NCT00986674|Experimental|Arm III (carboplatin, paclitaxel, cetuximab, cixutumumab)|Patients receive carboplatin, paclitaxel, and cetuximab as in arm I. Patients also receive cixutumumab as in arm II. Treatment repeats every 42 days for 2 courses. Patients with stable or responding disease after 2 courses proceed to maintenance therapy with cetuximab as in arm I and cixutumumab as in arm II.
3063338|NCT00986830|Experimental|Balloon Dilation|Balloon dilation of the maxillary sinuses using the FinESS Sinus Treatment device.
3063339|NCT00986856|Experimental|Fucidin® cream|
3063340|NCT00986856|Placebo Comparator|Fucidin® cream vehicle|
3063341|NCT00986921|Experimental|mifepristone|women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
3063342|NCT00986921|Active Comparator|Osmotic dilator insertion|Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure
3063343|NCT00986973|Experimental|Sapropterin (KUVAN)|All subjects will receive Sapropterin (KUVAN) therapy at a dose of 20/mk/kg/day for four months.
3063344|NCT00986986|Experimental|Active Drug (extended release niacin)|Subjects in this arm will be given 12 weeks of extended release niacin. Intervention: extended release niacin (Niaspan) starting at 500 mg by mouth daily and titrated to a maximum dose of 1500 mg by mouth daily. Titration will depend on patient tolerability.
3063345|NCT00986986|No Intervention|Observation|Subjects in this arm will be monitored for 12 weeks and will not receive extended release niacin
3063346|NCT00987337|Experimental|Arm A|"Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
3063347|NCT00987337|Experimental|Arm B|"Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)~- or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)"
3063348|NCT00987337|Placebo Comparator|Arm C|Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
3063349|NCT00987389|Experimental|Plasma Exchange with Standard Glucocorticoids|Participants in this arm undergo plasma exchange and take a standard glucocorticoid dose.
3063350|NCT00987389|Active Comparator|No Plasma Exchange with Standard Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a standard glucocorticoid dose.
3063351|NCT00987389|Experimental|Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm undergo plasma exchange and take a reduced glucocorticoid dose.
3063352|NCT00987389|Active Comparator|No Plasma Exchange with Reduced-Dose Glucocorticoids|Participants in this arm do not undergo plasma exchange and take a reduced glucocorticoid dose.
3063353|NCT00987402|Active Comparator|Plain soap and water|Surgical hand preparation with plain soap and water
3063354|NCT00987402|Active Comparator|Alcohol based hand rubs|Surgical hand preparation with alcohol based alcohol hand rub
3063355|NCT00987415|Active Comparator|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
3063356|NCT00987415|Placebo Comparator|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
3063357|NCT00987467|Experimental|Cyclosporine 0.05% ophthalmic|cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control
3063358|NCT00987480|Experimental|chemotherapy-based cytoreductive regimen plus a CD34+ selected|This phase II trial is designed to investigate the safety and efficacy of a chemotherapy-based cytoreductive regimen plus a CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for the treatment of patients with Fanconi anemia and severe hematologic disease.
3063359|NCT00987558|Experimental|Treatment Sequence A|Simvastatin 80mg treatment period followed by Simvastatin 80 mg + eslicarbazepine acetate 800 mg treatment period
3063360|NCT00987558|Experimental|Treatment Sequence B|Simvastatin 80mg + eslicarbazepine acetate 800 mg treatment period followed by Simvastatin 80 mg treatment period
3063361|NCT00987623|Experimental|nelfilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
3063362|NCT00987623|Active Comparator|narafilcon A|Commercially marketed contact lens worn in both eyes on a daily wear, daily disposable basis for one week.
3063363|NCT00987727|Experimental|1|carboxymethylcellulose 0.5% and glycerin 0.9% (OPTIVE® MD)
3063364|NCT00987727|Active Comparator|2|sodium hyaluronate 0.18% (VISMED® Multi)
3063365|NCT00987831|Experimental|Blood drawing only Group C|Healthy controls, age, sex and ethnicity matched to the active study participants were recruited for two time blood donation as controls for the biomarker studies
3063366|NCT00987831|Experimental|Group A SLE prospective study|In Group A SLE patients enter with active disease. Any immune suppressant (e.g. methotrexate, azathioprine or mmf) is withdrawn and after blood drawing, depomedrol up to 160 mg IM is given. This may be repeated for a maximum of 160mg up to four times total in the first two weeks. Depomedrol is expected to last 1-3 months, serial biomarkers will be drawn until time of flare, at which time biomarkers will be drawn, patient is defined as meeting endpoint and new treatment initiated. Patients may elect to continue to donate blood samples per protocol up to one year.
3063367|NCT00987831|Experimental|Group B SLE one blood donation|SLE patients who meet the same entry criteria as Group A could elect to donate blood one time and not to continue in the prospective protocol. No extra intervention was performed other than blood draw and medical records review. This allowed an extension of cross sectional comparisons between biomarker changes related to background treatments by combining Group A baseline data with Group B data.
3063368|NCT00987935|Experimental|Nintedanib (BIBF 1120)|Phase I dose escalation and phase II using dose determined in phase I
3063369|NCT00987935|Active Comparator|Sorafenib|Twice daily dosing in phase II
3063370|NCT00987948|Experimental|Maraviroc|
3063371|NCT00988000|Other|Agree to the alternative study invitation|Agree with alternative of telephone consultation (instead of face to face) offered as an initial consultation to new referrals
3063372|NCT00988000|Other|Decline the alternative study invitation|Decline, no respond to the alternative of telephone consultation
3063373|NCT00988000|Other|Comparator|Choose and book
3063374|NCT00988013|Experimental|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day (total of 3Gy).
3063375|NCT00988013|Experimental|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days (for a total of 6Gy).
3063376|NCT00988013|Experimental|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days (for a total of 9Gy).
3063377|NCT00988013|Experimental|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days (for a total of 12Gy).
3063379|NCT00988065|Experimental|Sugammadex 4 mg/kg|Participants were to receive one dose of sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3063380|NCT00988065|Experimental|Sugammadex 16 mg/kg|Participants were to receive one dose of sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3063381|NCT00988065|Placebo Comparator|Placebo|Participants were to receive one dose of placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study.
3063382|NCT00988091|Placebo Comparator|IA-SA|Each participant received a single intra-articular (IA) injection of buffered saline (SA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they could receive a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and be followed for an additional 26 weeks.
3063383|NCT00988091|Experimental|IA-BioHA|Each participant received a single intra-articular (IA) injection of 1.2% sodium hyaluronate (BioHA) into the target knee, and was followed for a total of 26 weeks in the double-blind period. Participants had the option of continuing into the open-label period in which they received a single intra-articular injection of 1.2% sodium hyaluronate (IA-BioHA) into the target knee and were followed for an additional 26 weeks.
3063384|NCT00988117|Experimental|Rivastigmine Patch 9.5 cm2|
3063385|NCT00988143|Experimental|Study Group 1|Participants will receive the 2009-2010 Trivalent Influenza Vaccine (TIV) (Pediatric dose have no preservatives)
3063386|NCT00988143|Active Comparator|Study Group 2|Participants will receive the 2008-2009 Trivalent Influenza Vaccine (TIV)
3063387|NCT00988143|Active Comparator|Study Group 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV)
3063388|NCT00988156|Active Comparator|Eslicarbazepine acetate|To receive Eslicarbazepine acetate in addition to concomitant therapy
3063389|NCT00988156|Placebo Comparator|Placebo|To receive placebo in addition to concomitant therapy
3063390|NCT00988169|Experimental|oral erlotinib and pulsed doses of oral AT-101|This will be an open-label, single institution, phase II trial. The study will assess the efficacy of the combination of the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and the novel pan-Bcl-2 inhibitor, AT-101, in treatment-naïve advanced (Wet Stage IIIB and IV)NSCLC patients with EGFR activating mutations A planned pause of 21 days will be performed after enrollment of the 10th and 20th patient to assess for excessive toxicity.
3063391|NCT00988208|Experimental|Docetaxel, Prednisone, Lenalidomide (DPL)|25 mg lenalidomide orally once each day on Days 1-14; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice daily on each day of the treatment cycle
3063392|NCT00988208|Experimental|Docetaxel and Prednisone (DP)|Oral placebo once each day on Days 1-14 of the treatment cycle; 75 mg/m2 docetaxel intravenously on Day 1; 5 mg prednisone orally twice each day on each day of the treatment cycle
3063393|NCT00988221|Experimental|Tocilizumab 10 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 10 mg/kg intravenously every 4 weeks.
3063394|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing < 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
3063395|NCT00988221|Experimental|Tocilizumab 8 mg/kg in patients weighing ≥ 30 kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks.
3063396|NCT00988221|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks.
3063399|NCT00988325|Experimental|Oseltamivir 3 mg|infants 3 to <12 months
3063400|NCT00988325|Experimental|Oseltamivir 2.5 mg|infants 1 to <3 months of age
3063401|NCT00988325|Experimental|Oseltamivir 2 mg|infants 0 to 30 days (post natal) of age
3063402|NCT00988351|Active Comparator|PSG CPAP titration then CPAP treatment|Patients diagnosed with sleep apnea will have a continuous positive airway pressure (CPAP) titration with polysomnography (PSG) followed by continuous positive airway pressure (CPAP) Treatment
3063403|NCT00988351|Active Comparator|Auto-Adjusting Positive Airway Pressure|Following diagnosis of obstructive sleep apnea patients will be have auto-adjusting positive airway pressure treatment without a titration.
3063404|NCT00988429|Active Comparator|800 mg QD Eslicarbazepine acetate|tablets
3063405|NCT00988429|Active Comparator|1200 mg QD Eslicarbazepine acetate|tablets
3063406|NCT00988429|Placebo Comparator|Placebo|tablets
3063407|NCT00988442|Experimental|Enhanced nursing telephone support with standard care|Participants received enhanced nursing telephone support plus care as usual.
3063408|NCT00988442|Active Comparator|Standard care|Participants received care as usual.
3063409|NCT00988533|Experimental|0.5% Ivermectin Cream|
3063410|NCT00988559|Experimental|PMED Delivery - groups 1 and 2|Subjects will receive pNGVL4a-CRT/E7(detox) via gene gun at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3063411|NCT00988559|Experimental|IM injections - groups 5 and 6|Subjects will receive pNGVL4a-CRT/E7(detox) intramuscularly at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3063412|NCT00988559|Experimental|Intralesional delivery - group 3 and 4|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3063413|NCT00988559|Experimental|Intralesional delivery + imiquimod - group 7|Subjects will receive pNGVL4a-CRT/E7(detox) intra-mucosally and imiquimod applied to the cervix at weeks 0, 4, 8 prior to therapeutic resection of their lesion at week 15.
3063414|NCT00988598|Active Comparator|PF-04447943|
3063415|NCT00988598|Placebo Comparator|Placebo|
3063416|NCT00988637|Other|1) Vectical™ Ointment and Clobex® Spray|Vectical™ Ointment weekdays & Clobex® Spray weekends regimen
3063417|NCT00988637|Other|2) Clobex® Spray and Vectical™ Ointment|Clobex® Spray morning and Vectical™ Ointment evening regimen
3063418|NCT00988832||Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
3063419|NCT00988858|Experimental|LY2603618 and Pemetrexed|
3063420|NCT00988884|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
3063421|NCT00988884|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Menactra™ and Adacel™ each given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
3063422|NCT00989014|Experimental|CD07805/47 0.5% Topical Gel|0.5% Topical Gel
3063423|NCT00989014|Experimental|CD07805/47 0.18% Topical Gel|0.18% Topical Gel
3063424|NCT00989014|Experimental|CD07805/47 0.07% Topical Gel|0.07% Topical Gel
3063425|NCT00989014|Placebo Comparator|CD07805/47 Vehicle Topical Gel|Vehicle Topical Gel
3320884|NCT02014558|Experimental|Gilteritinib 20 mg in Escalation Phase|Participants received a single dose of 20 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 20 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3063426|NCT00989092|Other|Observational Group|Participants in the observation group were evaluated once every 2 weeks for the first 12 weeks (test period). No darbepoetin alfa was administered to the observation group during this period. Darbepoetin alfa could be initiated at a dose of 3.0 μg/kg once every 2 weeks beginning with the first visit after the test period at which the participants hemoglobin concentration was less than or equal to 11.0 g/dL. The dose of darbepoetin alfa could be increased to 5.0 μg/kg once every 2 weeks after 6 weeks of darbepoetin alfa treatment in participants with a hemoglobin change from baseline of less than 1.0 g/dL.
3063427|NCT00989092|Active Comparator|21 week treatment group|Participants in the treatment group received darbepoetin alfa subcutaneously (SC) at a dose of 3.0 μg/kg once every 2 weeks for 21 weeks. The dose of darbepoetin alfa could be increased at week 7 (to 5.0 μg/kg once every 2 weeks) or at week 13 (to 9.0 μg/kg once every 2 weeks) in participants with a hemoglobin change from baseline of less than 1.0 g/dL who dose escalated at week 7.
3063428|NCT00989157|Experimental|Active drug|All subjects received drug. Single arm.
3063429|NCT00989196|Experimental|Human-cl rhFVIII|
3063430|NCT00989196|Active Comparator|Kogenate FS|
3063431|NCT00989235|Active Comparator|Abatacept (10 mg/Kg)|
3063432|NCT00989235|Active Comparator|Abatacept (5 mg/Kg)|
3063433|NCT00989261|Experimental|Cohort 1; ≥60 years of age|"Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
3063434|NCT00989261|Experimental|Cohort 2; ≥18 years of age|"Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib.~Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-)~After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day."
3063435|NCT00989287|Experimental|GSK2340272A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3063436|NCT00989287|Experimental|GSK2340269A Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of GSK2340269A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3063437|NCT00989573|Placebo Comparator|Placebo|oral administration of placebo once-daily for 8weeks
3063438|NCT00989573|Experimental|OPC-6535 25 mg|oral administration of OPC-6535 25 mg once-daily for 8 weeks
3063439|NCT00989573|Experimental|OPC-6535 50 mg|oral administration of OPC-6535 50mg once-daily for 8 weeks
3063440|NCT00989586|Experimental|Phase I|Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
3063441|NCT00989586|Experimental|Phase II|Patients will receive veltuzumab IV weekly for 4 doses and milatuzumab IV weekly on day 2 of week 1 and on day 4 of weeks 2-4 for 4 total doses during induction therapy. Patients may continue on therapy to receive extended induction therapy provided they do not experience significant toxicity or rapid disease progression during the initial 4 week induction.
3063442|NCT00989612|Experimental|GSK2340274A GROUP|Healthy subjects, aged 20 to 64 years, male and female, received 2 doses of GSK2340274A vaccine, injected intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3063443|NCT00989664|Experimental|open-label single arm|Tositumomab and Iodine-131 Tositumomab radioimmunotherapy for chemotherapy-refractory low-grade B-cell lymphomas and low-grade lymphomas that have transformed to higher grade histologies.
3063444|NCT00989768|Experimental|Botulinum toxin type - A|Dysport® compared to Botox®
3063445|NCT00989781|Experimental|PCOS women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
3063446|NCT00989781|Experimental|Normal women|"Each subject will undergo pelvic 3D ultrasound followed by an iv recombinant human chorionic gonadotropin (r-hCG) stimulation test. One month later the r-hCG test will be repeated 24 hr after an injection of recombinant human follicle stimulating hormone (FSH).~After 1 month, subjects will receive a 7 hr dose-response infusion of adrenocorticotropin (ACTH) with blood sampling. Dexamethasone will be given prior to ACTH.~After 1 month, subject will receive r-hCG as described above followed the next day by an oral glucose tolerance test (OGTT). Subsequently, subjects will take Diazoxide 3 times a day for 2 weeks. At weekly intervals (2 weeks), the r-hCG stimulation test will be repeated followed the next day by an OGTT as described above."
3063447|NCT00989833|Active Comparator|A|budesonide 400yg + terbutaline 0.4 mg as-needed
3063448|NCT00989833|Active Comparator|B|placebo + terbutaline 0.4 mg as-needed
3063449|NCT00989833|Active Comparator|C|placebo + budesonide/formoterol 160/4.5 yg as-needed
3063450|NCT00989911|Experimental|Bosentan|Bosentan
3063451|NCT00989950|Experimental|Daytrana 9 hr wear|
3063452|NCT00989950|Experimental|Daytrana 10 hr wear|
3063453|NCT00989950|Experimental|Daytrana 11 hr wear|
3063454|NCT00989950|Experimental|Daytrana 12 hr wear|
3063455|NCT00989963|Experimental|Maximum Tolerated Dose (MTD)|Patients in the MTD treatment group will dose escalate weekly by 60µg b.i.d. until they reach the maximum dose of 600µg b.i.d. or they reach an intolerable dose which requires them to down-titrate by 60µg b.i.d. In these instances and at the Investigator's discretion, further attempts at dose escalation may be made.
3063456|NCT00989963|Experimental|Low Fixed Dose|The low dose group will receive 60µg twice a day(b.i.d.)
3063457|NCT00989963|Experimental|High Fixed Dose|Patients in the high dose group will dose escalate weekly by 60µg twice a day (b.i.d.) until they reach the fixed dose of 240µg b.i.d. Once patients in these treatment groups have reached their assigned maximum dose of active drug,
3063458|NCT00989989|Experimental|Adjunctive treatment|Adjunctive administration of ranibizumab 0.5 mg intravitreal injections and active laser.
3063459|NCT00989989|Experimental|Monotherapy treatment|Monotherapy ranibizumab 0.5 mg intravitreal injections plus sham laser.
3063460|NCT00989989|Active Comparator|Laser control|Active laser treatment plus sham intravitreal injections.
3063461|NCT00990093|Experimental|test intermittent catheter|CH 12 hydrophilic coated catheter
3063462|NCT00990093|Experimental|intermittent catheter|CH 12 hydrophilic coated catheter
3063463|NCT00990106|Active Comparator|prazosin hydrochloride|"prazosin Pfizer Minipress~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
3063464|NCT00990106|Placebo Comparator|placebo|"placebo~oral capsules~Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose."
3063465|NCT00990184|Experimental|Colesevelam Hydrochloride|
3063466|NCT00990236|Active Comparator|Enoxaparin 30 mg BID|standard dose enoxaparin thromboprophylaxis (30 mg twice daily)
3063467|NCT00990236|Experimental|Enoxaparin dose adjusted based on TEG|enoxaparin dose modified based on TEG results
3063468|NCT00990249|Experimental|Busulfan + Clofarabine + Stem Cell Transplant|"Busulfan test dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.~Clofarabine 40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3. Thymoglobulin 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors.~Stem cell infusion on Day 0."
3063469|NCT00990288|Experimental|Hemostatic Matrix|2 vials of Floseal applied once at the end of surgery
3063470|NCT00990288|No Intervention|Control|No intervention.
3063471|NCT00990314|Experimental|B.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, B.I.D (twice a day dosing)
3063472|NCT00990314|Experimental|Q.I.D|Beraprost Sodium Modified Release Tablet, 60mcg, q.i.d (four times a day dosing)
3063473|NCT00990340|Active Comparator|Tev-Tropin® needle-free|needle-free injection method (T-jet®)for 14 days before cross-over to other arm
3063474|NCT00990340|Active Comparator|Tev-Tropin® by Needle-syringe|needle-syringe injection method for 14 days before cross-over to other arm
3063475|NCT00990509|Experimental|Albumin|
3063476|NCT00990509|Placebo Comparator|Placebo|
3063477|NCT00990561|Active Comparator|Twice Daily Ultravate|Patients will apply both Ultravate ointment and LacHydrin lotion twice daily
3063478|NCT00990561|Active Comparator|Once daily Ultravate|Patients will apply Ultravate ointment once daily, but will use LacHydrin lotion twice daily
3063479|NCT00990652|Experimental|Bortezomib + Temozolomide|Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
3063480|NCT00990665|Experimental|CRT-D and LV lead|
3063481|NCT00990704|Experimental|Paricalcitol|2 mcg adjusted by +/- 1 mcg, up to a maximum of 7 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
3063482|NCT00990704|Active Comparator|Maxacalcitol|5 or 10 mcg adjusted by +/- 2.5 mcg, up to a maximum of 20 mcg, administered 3 times per week through intravenous catheter immediately before completion of dialysis
3063483|NCT00990769|Experimental|"High-normal BIS (Lighter anesthesia)"|Depth of anesthesia is titrated to a BIS of 55-60
3063484|NCT00990769|Experimental|"Low-normal BIS (Deeper anesthesia)"|Depth of anesthesia is maintained at a BIS level of 40-45
3063485|NCT00990782|Experimental|Single Arm|PillCam ESO Capsule Endoscope - all patients receive capsule endoscopy before and after RFA procedure.
3063486|NCT00990821|Experimental|Part I, Panel A|100 mg MK-0517 (nonpolysorbate 80 formulation [non-PS80]) or placebo → 150 mg MK-0517 (non- PS80) or placebo → 125 mg aprepitant
3063487|NCT00990821|Experimental|Part I, Panel B|100 mg MK-0517 (PS80 formulation [PS80]) or placebo → 150 mg MK-0517 (PS80) or placebo → 125 mg aprepitant
3063488|NCT00990821|Experimental|Part I, Panel C|40 mg MK-0517 (non-PS80) or placebo → 40 mg aprepitant
3063489|NCT00990821|Experimental|Part II|2 mg midazolam → 100 mg MK-0517 (PS80) + 2 mg midazolam
3063490|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 1|125 mg aprepitant → 90 mg MK-0517 (PS80)
3063491|NCT00990821|Experimental|Part III, Panel 1, Treatment Sequence 2|40 mg MK-0517 (non-PS80) → 125 mg aprepitant
3063492|NCT00990821|Experimental|Part III, Panel 2|40 mg MK-0517 (non-PS80)
3063493|NCT00990821|Experimental|Part IV|40 mg MK-0517 (non-PS80 formulation)
3063494|NCT00990821|Experimental|Part V, Treatment Sequence 1|125 mg aprepitant → 100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80 formulation)
3063495|NCT00990821|Experimental|Part V, Treatment Sequence 2|100 mg MK-0517 (PS80) → 115 mg MK-0517 (PS80) → 125 mg aprepitant
3063496|NCT00990821|Experimental|Part V, Treatment Sequence 3|115 mg MK-0517 (PS80) → 125 mg aprepitant → 100 mg MK-0517 (PS80)
3063497|NCT00990821|Experimental|Part V, Treatment Sequence 4|125 mg aprepitant → 115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80)
3063498|NCT00990821|Experimental|Part V, Treatment Sequence 5|100 mg MK-0517 (PS80) → 125 mg aprepitant → 115 mg MK-0517 (PS80)
3063499|NCT00990821|Experimental|Part V, Treatment Sequence 6|115 mg MK-0517 (PS80) → 100 mg MK-0517 (PS80) → 125 mg aprepitant
3063500|NCT00990938|Placebo Comparator|Saline|If randomized to placebo the patient will receive a subcutaneous injection once per week for 4 weeks
3063501|NCT00990938|Experimental|IMO-2125|If randomized to receive the experimental treatment, IMO-2125, the patient will receive a subcutaneous injection once per week for 4 weeks
3063502|NCT00991029|Active Comparator|clopidogrel|Patients assigned to clopidogrel in addition to aspirin
3063503|NCT00991029|Placebo Comparator|placebo|Patients assigned to placebo in addition to aspirin
3063504|NCT00991081|Active Comparator|Standard treatment|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling.~A self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail~A standard 8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
3063505|NCT00991081|Experimental|Genetic feedback plus standard treatment|"In addition to the standard treatment, participants in this arm received the following interventions:~Genetic feedback, verbal - During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment~Genetic feedback, printed - After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype"
3063506|NCT00991276|Experimental|pregabalin|
3063507|NCT00991276|Placebo Comparator|placebo|
3063508|NCT00991276|Active Comparator|pramipexole|
3063509|NCT00991289|Experimental|NTZ/PEG/RBV|Participants received nitazoxanide (NTZ) alone for 4 weeks followed by 48 weeks of NTZ with pegylated interferon (PEG) and ribavirin (RBV). Participants who did not achieve early virologic response (EVR) at Week 16 or had detectable hepatitis C virus (HCV) viral load at Week 28 discontinued treatment.
3063510|NCT00991302|Experimental|CAP-IT|"Participants received the modified CAP-IT adherence intervention in addition to standard care.~Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)"
3063511|NCT00991302|No Intervention|Standard care|Participants received standard care.
3063512|NCT00991341|Active Comparator|Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
3063513|NCT00991341|Active Comparator|Longer-storage red blood cell units|Red blood cell units stored >= 21 days
3063514|NCT00991406|Experimental|Arm 1: FES|Case-control study: pre- and post-stimulation (FES).
3063515|NCT00991458|Experimental|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3063516|NCT00991458|Experimental|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3063517|NCT00991458|Placebo Comparator|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
3063518|NCT00991510|Experimental|Reference/Test/Test|"The reference product was CellCept® and test product was Myfenax®. In period I, participants received CellCept on Days 1-14. In period II, participants crossed-over to receive Myfenax on Days 15-28. In period III, participants received Myfenax until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
3063519|NCT00991510|Experimental|Test/Reference/Reference|"The test product was Myfenax® and the reference product was CellCept®. In period I, participants received Myfenax on Days 1-14. In period II, participants crossed-over to receive CellCept on Days 15-28. In period III, participants received CellCept until the end of the study (Days 29-112).~Doses of mycophenolate mofetil were at least 500 mg twice daily, morning and evening."
3063520|NCT00991809|Experimental|Alfentanil|Subjects received a series of acute alfentanil administrations each session (15 mcg/kg IM per session), with sessions spaced at 3-4 day intervals.
3063521|NCT00991809|Active Comparator|Diphenhydramine|Subjects received a series of acute diphenhydramine administrations each session (25 mg IM per session), with sessions spaced at 3-4 day intervals.
3063522|NCT00991887|No Intervention|No Radiation Therapy (XRT)|This group will not receive radiation therapy after surgery.
3063523|NCT00991887|Active Comparator|Radiation Therapy (XRT)|Radiotherapy will be administered no later than 72 hours postoperatively.
3063524|NCT00991939|Experimental|High dose pulse dexamethasone|
3063525|NCT00991939|Active Comparator|Standard prednisone therapy|
3063526|NCT00991952|Experimental|Arm A (irinotecan hydrochloride, alvocidib)|Patients receive irinotecan hydrochloride IV over 30 minutes and alvocidib IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3063527|NCT00991952|Active Comparator|Arm B (irinotecan hydrochloride)|Patients receive irinotecan hydrochloride as in Arm A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3063528|NCT00992017|Experimental|H1N1 vaccine|Pregnant women enrolled received two doses of H1N1 vaccine, administered 21 days apart.
3063529|NCT00992056|Experimental|Metoprolol/Nebivolol|Metoprolol/Nebivolol: Metoprolol 50 mg titrated to 100 mg then nebivolol 5 mg titrated to 10 mg
3063530|NCT00992056|Experimental|Nebivolol/Metoprolol|Metoprolol 50 mg titrated to 100 mg then Nebivolol 5 mg titrated to 10 mg
3063531|NCT00992108|Active Comparator|Lidocaine|lidocaine injection group
3063532|NCT00992108|Experimental|Botulinum|
3063533|NCT00992186|Experimental|Carlumab|
3063534|NCT00992225|Experimental|LY573636-sodium|
3063535|NCT00992264|Experimental|Message Tone|"Prescriptive or Motivational~Persons are randomized to receive intervention content written in either a prescriptive or motivational tone."
3063536|NCT00992264|Experimental|Testimonials|Persons are randomized to receive a personally tailored testimonial or not.
3063537|NCT00992264|Experimental|Navigation|"Dictated or Non-Dictated~Persons are randomly assigned to be able to freely navigate the website or to have their navigation of the website pre-determined based on their baseline readiness to quit smoking."
3063538|NCT00992264|Experimental|Proactive Outreach|"Email or No-Email communication~Persons are randomized to receive periodic email reminders to return to the intervention website or not."
3063539|NCT00992394|Other|Arm 1|Subjects randomized to arm 1 stop their etanercept treatment on entry into the study and may be retreated by etanercept 50 mg once weekly after medical review and agreement between the subject and the investigator
3063540|NCT00992394|Other|Arm 2|Subjects randomized to arm 2 in which subjects continue on treatment with etanercept at 25 mg once weekly, but with the option to have their drug treatment increased to 50 mg once weekly after medical review and agreement between the subject and the investigator
3063541|NCT00992407|Experimental|Risperidone long acting injectables|
3063542|NCT00992407|Active Comparator|Risperidone tablets|
3063543|NCT00992433|Experimental|Group 2, 30 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 30 mcg H1N1 vaccine on Day 0 and Day 21.
3063544|NCT00992433|Experimental|Group 1, 15 mcg|CD4<200, n=60; CD4 greater than or equal to 200, n=60. 15 micrograms (mcg) H1N1 vaccine on Day 0 and Day 21.
3063545|NCT00992446|Experimental|Treatment (chemotherapy, ASCT, bortezomib, vorinostat))|All patients receive carmustine IV over 3 hours on day -7; cytarabine IV BID over 3 hours and etoposide IV BID over 2 hours on days -6 to -3; and melphalan IV over 30 minutes on day -2. Only patients with history of CD20+ NHL receive additional rituximab IV on days -19 and -12. Patients undergo ASCT on day 0. Patients then receive bortezomib IV on days 2 and 8, and vorinostat PO QD on days 1-14. Treatment with bortezomib and vorinostat repeats for total of 12 courses in the absence of disease progression or unacceptable toxicity.
3063546|NCT00992459|Experimental|Buphenyl (NaPBA) /HPN 100 Placebo|Subjects in Arm A were randomly assigned to receive NaPBA + HPN 100 placebo for 2 weeks and then crossed over to receive HPN 100 + NaPBA Placebo for 2 weeks.
3063547|NCT00992459|Experimental|HPN-100/NaPBA Placebo|Subjects in Arm B were randomly assigned to receive HPN-100 + NaPBA placebo for 2 weeks and then crossed over to receive NaPBA + HPN 100 placebo for 2 weeks.
3063548|NCT00992511|Experimental|GSK2340272A New 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the New process-manufactured (New 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
3063549|NCT00992511|Experimental|GSK2340272A New 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the New process-manufactured (New 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3063550|NCT00992511|Experimental|GSK2340272A INI 1D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received one dose of the Initial process-manufactured (INI 1D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
3063551|NCT00992511|Experimental|GSK2340272A INI 2D Group|Healthy male or female adults, between and including 18 to 60 years of age, who received two doses of the Initial process-manufactured (INI 2D) GSK2340272A vaccine, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3063552|NCT00992589|Experimental|Rabeprazole sodium 5 mg|
3063553|NCT00992589|Experimental|Rabeprazole sodium 10 mg|
3063554|NCT00992589|Placebo Comparator|Placebo|
3063555|NCT00992602|Experimental|Treatment (liposomal cytarabine, high-dose methotrexate)|See Detailed Description
3063556|NCT00992719|Active Comparator|Group 3: Non-pregnant Women: 15 mcg H1N1 Vaccine|100 non-pregnant women to receive 15 mcg inactivated H1N1 vaccine.
3063557|NCT00992719|Experimental|Group 2: Pregnant Women: 30 mcg H1N1 Vaccine|100 pregnant women to receive 30 mcg inactivated H1N1 vaccine.
3063558|NCT00992719|Experimental|Group 1: Pregnant Women: 15 mcg H1N1 Vaccine|100 pregnant women to receive 15 mcg inactivated H1N1 vaccine.
3063559|NCT00992784|Experimental|New generation influenza vaccine GSK2186877A Group|Subjects aged ≥ 66 years receiving 1 dose of New generation influenza vaccine GSK2186877A
3063560|NCT00992784|Active Comparator|Fluarix elderly Group|Subjects aged ≥ 66 years receiving 1 dose of Fluarix vaccine
3063561|NCT00992784|Active Comparator|Fluarix young Group|Subjects aged 19-43 years receiving 1 dose of Fluarix vaccine
3063562|NCT00992836|Experimental|Influenza A (H1N1) 2009 monovalent vaccine|All participants received two doses of the H1N1 influenza virus vaccine, administered 21 days apart.
3063563|NCT00992927|Experimental|CPIHD|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
3063564|NCT00992927|Active Comparator|CRIHD|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
3063565|NCT00992992|Experimental|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Tositumomab and Iodine I 131 Tositumomab followed by CHOP
3063566|NCT00993031|Experimental|Group A|ZDV 300mg/3TC 150mg/LPV 200mg/r 50mg
3063567|NCT00993031|Active Comparator|Group B|ZDV 300mg/3TC 150mg/EFV 600mg
3063568|NCT00993044|Experimental|Single Arm|
3063569|NCT00993148|Experimental|Maraviroc plus darunavir/ritonavir|Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks
3063570|NCT00993187|Experimental|Sitagliptin/Metformin FDC|Participants in the Sitagliptin/Metformin Fixed- Dose Combination (Sita/Met FDC) group received tablets of Sita/Met FDC and placebo tablets matching glimepiride for 30 weeks. The dose for Sita/Met FDC was 50/500 mg twice daily (b.i.d.) starting Day 1 and increased to 50/1000 mg b.i.d. over a period of 4 weeks.
3063571|NCT00993187|Active Comparator|Glimepiride|Participants in the Glimepiride group received 2 placebo tablets matching Sita/Met FDC and glimepiride tablets (1 mg or 2 mg) for 30 weeks. The dose for glimepiride was 1 mg once daily (q.d.) starting Day 1 and up-titrated as considered appropriate by the investigator based upon the results of participant's self-monitored blood glucose levels but not to exceed 6 mg/day.
3063572|NCT00993200|Active Comparator|Warfarin, control|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by usual care dosing.
3063573|NCT00993200|Experimental|Warfarin: PERMIT|Subjects naive to warfarin therapy with anticipated warfarin duration of at least 12 weeks managed by warfarin pharmacogenetic dosing (warfarin dosing using genetic information incorporated into the PERMIT algorithm).
3063574|NCT00993226|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
3063575|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
3063576|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
3063577|NCT00993226|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
3063578|NCT00993226|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
3063579|NCT00993226|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
3063580|NCT00993265|Experimental|N-acetylcysteine (NAC)|Patients randomized to this arm will receive N-Acetylcysteine, at a standard dose titrated to 2400 mg. They will receive NAC in addition to the medication regimen they are on at enrollment.
3063581|NCT00993265|Placebo Comparator|Placebo|Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.
3063582|NCT00993291|No Intervention|Baseline frequency|Baseline DBS frequency
3063583|NCT00993317|Placebo Comparator|Placebo of CDP870+MTX|
3063584|NCT00993317|Experimental|CDP870 200mg+MTX|
3063585|NCT00993421|Placebo Comparator|placebo|
3063586|NCT00993421|Experimental|LY377604 (75 mg)|
3063587|NCT00993421|Active Comparator|sibutramine (30 mg)/metoprolol (200 mg)|
3063588|NCT00993421|Experimental|LY377604 (40 mg)/sibutramine (30 mg)|
3063589|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (30 mg)|
3063590|NCT00993421|Experimental|LY377604 (15 mg)/sibutramine (30 mg)|
3063591|NCT00993421|Experimental|LY377604 (75 mg)/sibutramine (15 mg)|
3063592|NCT00993447|Experimental|CYD Dengue Vaccine Group|Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
3063593|NCT00993447|Sham Comparator|Control Vaccine Group|
3063594|NCT00993473|Experimental|Lantus (insulin glargine)|Lantus given as basal insulin once a day in the morning by subcutaneous injection
3063595|NCT00993473|Active Comparator|NPH insulin|Neutral Protamine Hagedorn (NPH) human insulin given as basal insulin either once or twice per day generally in the morning and /or at bedtime by subcutaneous injection
3063596|NCT00993499|Experimental|BIBW 2992 + Sirolimus|Dose escalation of the combination BIBW 2992 plus Sirolimus.
3063597|NCT00993616|Experimental|Treatment|Patients receive belinostat IV over 30 minutes on days 1-5 and carboplatin IV over 30-60 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are clinically responding or who, in the opinion of their physician, would continue to benefit from treatment may continue treatment beyond 6 courses.
3063598|NCT00993655|Active Comparator|IV carboplatin + IV paclitaxel|ARM 1: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intravenous day 1; Paclitaxel 60 mg/m2 intravenous day 8. Cycles given Q 21 days x 3 cycles
3063599|NCT00993655|Active Comparator|IP cisplatin + IV/IP paclitaxel|ARM 2: Paclitaxel 135 mg/m2 intravenous day 1 plus Cisplatin 75 mg/m2 intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles (Phase II cisplatin arm closed to accrual on 2014-FEB-03)
3063600|NCT00993655|Active Comparator|IP carboplatin + IV/IP paclitaxel|ARM 3: Paclitaxel 135 mg/m2 intravenous day 1 plus Carboplatin AUC 5 if measured GFR or AUC6 if estimated GFR intraperitoneal day 1; Paclitaxel 60 mg/m2 intraperitoneal day 8. Cycles given Q 21 days x 3 cycles
3063601|NCT00993668|Placebo Comparator|Placebo|Placebo
3063602|NCT00993668|Experimental|Cimzia|Certolizumab pegol
3063603|NCT00993798|Experimental|SABER-Bupivacaine Treatment 1a|double-blind
3063604|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 1b|double-blind
3063605|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 1c|double-blind
3063606|NCT00993798|Experimental|SABER-Bupivacaine Treatment 2a|double-blind
3063607|NCT00993798|Placebo Comparator|Placebo SABER-Bupivacaine Treatment 2b|double-blind
3063608|NCT00993798|Active Comparator|Bupivacaine HCl Treatment 2c|double-blind
3063609|NCT00993824|Placebo Comparator|Welchol then Placebo|3.75 grams of colesevelam HCl (Welchol) at evening meal for 12 weeks, and then crossover to placebo at evening meal for 12 weeks.
3063610|NCT00993824|Placebo Comparator|Placebo then Welchol|Placebo taken for 12 weeks at evening meal, and then crossover to 3.75 grams of colesevelam HCl taken at evening meal fro 12 weeks.
3063611|NCT00993915||Main group|Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
3063612|NCT00993928|Experimental|Arm A: Home-based sleep intervention with Device #1|Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
3063613|NCT00993928|Active Comparator|Arm B: Home-based sleep intervention with Device #2|Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.
3063614|NCT00993954|Experimental|Nurse Reduction|Patients randomized to reduction by nurse.
3063615|NCT00993954|Active Comparator|Physician Reduction|Patients randomized to treatment by Emergency Department Physician in traditional ED manner
3063616|NCT00993967|Experimental|Idebenone|1350 mg/day or 2250 mg/day for patients weighing ≤45 kg or >45 kg, respectively.In case of poor tolerability, dose reduction to 450 mg/day or 900 mg/day, respectively, were allowed.
3063617|NCT00994110|Experimental|SOM230|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
3063618|NCT00994110|Placebo Comparator|placebo|This is a randomized, double-blind, placebo controlled phase III trial of SOM230 vs. saline placebo in patients undergoing pancreaticoduodenectomy or distal pancreatectomy with or without splenectomy at Memorial Sloan-Kettering Cancer Center.
3063619|NCT00994123|Experimental|Phase 1: Dose-Escalation|Escalating doses of MM-121 (QOW IV) and erlotinib (daily PO)
3063620|NCT00994123|Active Comparator|Phase 2: Control|Erlotinib (daily)
3063621|NCT00994123|Experimental|Phase 2: Treatment|MM-121 (QOW IV) and erlotinib (daily PO)
3063622|NCT00994175|Experimental|Pioglitazone, Then Placebo|Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.
3063623|NCT00994175|Experimental|Placebo, Then Pioglitazone|Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.
3063624|NCT00994214|Experimental|BIM 23A760 1 mg|
3063625|NCT00994214|Experimental|BIM 23A760 2 mg|
3063626|NCT00994214|Experimental|BIM 23A760 4 mg|
3063627|NCT00994214|Experimental|BIM 23A760 6 mg|
3063628|NCT00994240|Active Comparator|ED&C times 3 cycles|
3063629|NCT00994240|Active Comparator|ED & C times 1 cycle|
3063630|NCT00994279|Active Comparator|Arm 1: Yoga Intervention|Yoga Intervention
3063631|NCT00994279|Active Comparator|Arm 2: Educational Wellness Group|Educational Wellness Group
3063632|NCT00994318|Experimental|FCM (high ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
3063633|NCT00994318|Experimental|FCM (low ferritin target)|Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
3063634|NCT00994318|Active Comparator|Oral Iron|Ferrous sulphate 100 mg iron twice daily, continuous
3063635|NCT00994422|Experimental|0.5% ivermectin cream|
3063636|NCT00994422|Placebo Comparator|vehicle control|
3063637|NCT00994448|Experimental|Bupropion|
3063638|NCT00994448|Placebo Comparator|Placebo (sugar pill)|
3063639|NCT00994461|Experimental|Celecoxib|
3063640|NCT00994461|Active Comparator|Loxoprofen|
3063641|NCT00994461|Placebo Comparator|Placebo|
3063642|NCT00994604|Experimental|broccoli sprout extract|This a before and after treatment study. The subjects will consumer broccoli sprout extract (BSE) for two weeks (14d). Lung function and Chest CT will be performed before and after BSE consumption.
3063643|NCT00994643|Experimental|Treatment (Interleukin Therapy, Monoclonal Antibody)|Patients receive interleukin-2 SC twice weekly and rituximab IV once weekly in weeks 5-8 and 25-28. Courses repeat every 4 weeks for up to 7 months in the absence of disease progression or unacceptable toxicity.
3063644|NCT00994682|Active Comparator|Pioglitazone|After all patients receive dietary counseling at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
3063645|NCT00994682|Placebo Comparator|Placebo|After dietary counseling to all patients at the research unit (CTSA), patients with prediabetes or type 2 diabetes mellitus (T2DM) and NASH will be started on pioglitazone (or placebo) in a randomized, double-blind,placebo-controlled study design. Pioglitazone will be given at 30 mg/day for the first 2 months and titrated to 45 mg/day thereafter (if well tolerated).
3063646|NCT00994760||GENISIS|
3063647|NCT00994890|Experimental|Tanezumab 2.5 mg|
3063648|NCT00994890|Experimental|Tanezumab 5 mg|
3063649|NCT00994890|Experimental|Tanezumab 10 mg|
3063650|NCT00994929|Experimental|Neumega (Oprelveken, Interleukin 11)|Neumega (Oprelveken, interleukin-11 (IL-11) 25 microgram/kilogram by subcutaneou injection once daily for four days, followed on day 4 DDAVP 0.3 microgram/kilogram intravenously 30 minutes after neumega
3063651|NCT00995007|Active Comparator|Group 2|Sequential Group (carboplatin followed by vandetanib)
3063652|NCT00995007|Active Comparator|Group 1|Combo Group (both drugs together)
3063653|NCT00995020|Experimental|SWETZ|The intervention administered in this arm is the straight wire excision of the transformation zone, a electrosurgical method to perform a cone biopsy using a 1 cm straight wire of 0.20 mm wire. The activated wire is used in much the same way as a cold knife or laser beam fashioning the surgical specimen to achieve two centimeters cm at cervical canal..
3063654|NCT00995020|Active Comparator|LLETZ cone|The intervention administered in this arm is the large loop excision of transformation zone as a cone biopsy, performed using a large loop electrode of 2 cm depth, applied to the cervix to achieving two centimeters at cervical canal .
3063655|NCT00995072|Experimental|Arm A|Nebivolol 5 mg daily for 12 weeks followed by Metoprolol succinate 100 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to metoprolol.
3063656|NCT00995072|Experimental|Arm B|Metoprolol succinate 100 mg daily for 12 weeks followed by nebivolol 5 mg daily for 12 weeks. A two week washout (no medication) is completed prior to switching to nebivolol.
3063657|NCT00995085|Experimental|Metadoxine SR|Metadoxine is a pyrolate salt of Pyridoxine
3063658|NCT00995215|Experimental|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
3063659|NCT00995345|Experimental|Dose 1: KRP-104 40 mg|Tablet, once-daily for 24 weeks
3063660|NCT00995345|Experimental|Dose 2: KRP-104 80 mg|Tablet, once-daily for 24 weeks
3063661|NCT00995345|Experimental|Dose 3: KRP-104 100 mg|Tablet, once-daily for 24 weeks
3063662|NCT00995345|Experimental|Dose 4: KRP-104 20/120mg|Tablet, once-daily for 24 weeks (dose switch from 20 to 120 mg at week 12)
3063663|NCT00995345|Placebo Comparator|Placebo|Tablet, once-daily for 24 weeks
3063664|NCT00995371|Active Comparator|Vertos mild® Minimally-Invasive Lumbar Decompression|Patients in the Vertos mild® treatment group will be treated by appropriately trained physicians in accordance with the product labeling and indications for use.
3063665|NCT00995371|Active Comparator|Epidural Steroid Injection|Patients in the Epidural Steroid Injection (ESI) group will have ESI performed by appropriately trained physicians in accordance with product labeling and indications for use.
3063666|NCT00995410|Experimental|PA32540 tablet|325 mg enteric coated (EC) ASA and 40 mg omeprazole to be taken by mouth once daily
3063667|NCT00995436|Active Comparator|Extraoral anchorage|The intervention is the placement of Headgear, to be worn 100 hours per week
3063668|NCT00995436|Active Comparator|Miniscrews|The intervention is the of miniscrews to supplement anchorage
3063669|NCT00995436|Active Comparator|Nance palatal arch|Anchorage supplemented by Nance palatal arch fixing molars together with an arch
3063670|NCT00995449|Experimental|KB003 70 mg|
3063671|NCT00995449|Experimental|KB003 200 mg|
3063672|NCT00995449|Experimental|KB003 600 mg|
3063673|NCT00995449|Placebo Comparator|Placebo|
3063674|NCT00995475|Experimental|Inhaled corticosteroid, Then placebo|FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks. After a washout period of 2 weeks, they then received FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks.
3063675|NCT00995475|Placebo Comparator|Placebo control, Then inhaled corticosteroid|FP matched placebo pMDI one puff twice daily for two weeks then FP four puffs twice daily for two weeks. After a washout period of 2 weeks, they then received FP 250μg per actuation pMDI one puff twice daily (total daily dose 500μg) for two weeks then FP 250μg per actuation pMDI four puffs twice daily (total daily dose 2000μg) for two weeks.
3063676|NCT00995488|Experimental|ABI-007|ABI-007 combined with Carboplatin, and Gemcitabine
3063677|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3063678|NCT00995501|Active Comparator|Intensive Glucose Control, Dexamethasone, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3063679|NCT00995501|Active Comparator|Intensive Glucose Control, placebo, Light anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3063680|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3063681|NCT00995501|Active Comparator|Intensive Glucose Control, Placebo, Deep anesthesia|"Intensive Glucose Control The target range for blood glucose will be 80-110 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3063682|NCT00995501|Active Comparator|Conventional Glucose Control, Dexamethasone, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Dexamethasone Dexamethasone administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3063683|NCT00995501|Active Comparator|Conventional Glucose Control, Placebo, Light anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Light anesthesia target BIS of 55"
3063684|NCT00995501|Placebo Comparator|Conventional Glucose Control, Placebo, Deep anesthesia|"Conventional Glucose Control The target range for blood glucose will be 180-200 mg/dl~Placebo Placebo administered at 8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning.~Deep anesthesia target BIS of 35"
3063685|NCT00995553|Experimental|Cognitive Remediation|A 48-session working memory focused cognitive remediation program is conducted. Training tasks have been selected from 3 software programs, PSS CogRehab, BrainTrain, and custom made N-back tasks.
3063686|NCT00995553|Placebo Comparator|Computer Skills|This is a 48-session, time matched comparison group in which participants practice keyboarding skills and the fundamentals of Microsoft Office Word, Powerpoint, and Excel programs.
3063687|NCT00995566||Thelin Registry Patients|
3063688|NCT00995670|Experimental|Sevoflurane and Glucose|"Endothelial function will be measured via forearm blood flow (FBF). Subjects may get I/R injury (ischemia) without glucose or sevoflurane (placebo); I/R with glucose only (glucose trial); I/R with sevoflurane only (sevo trial); I/R with glucose and sevoflurane (combo trial). Baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Glucose: 5% dextrose will be infused at 12 ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 1 hr to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent I/R injury.~Sevoflurane: 1 minimum alveolar concentration (MAC) for 20 min (after 1 hr glucose and before I/R) 26 volunteers were studied 67 times in this arm."
3063689|NCT00995670|Experimental|Vitamin C and Glucose|"To determine if vitamin C can restore the impairment of the endothelium (FBF) caused by the glucose (dextrose infusion). All subjects received glucose and I/R injury (ischemia), either with or without vitamin C. Control baseline FBF was taken in every trial before any intervention, and FBF was taken during intervention and post I/R.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Vitamin C: 1 gm iv bolus injection 5 min before I/R injury 16 volunteers were studied 25 times in this arm."
3063690|NCT00995670|Experimental|Statins and Glucose|"Volunteers ingested a 40 mg simvastatin (statin) pill for the two evenings prior to study day and the morning of the study to determine the effect of simvastatin on modulating the I/R injury during hyperglycemia (high glucose). Volunteers were studied with statin alone and with statin and glucose.~Placebo data were the placebo studies from the Sevoflurane and Glucose arm, when appropriate; new subjects (not enrolled in Sevoflurane and Glucose arm) underwent a separate placebo trial.~Glucose: 5% dextrose will be infused at 12ml/hr to a target of 200 mg/dl blood concentration in the experimental forearm for 60 min.~Statin: 40 mg of simvastatin 17 volunteers were studied 31 times in this arm."
3063691|NCT00995709|Experimental|AIN457C 300 mg every 2 week dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
3063692|NCT00995709|Experimental|AIN457C 300 mg monthly dosage regimen|AIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
3063693|NCT00995709|Placebo Comparator|Placebo|Placebo was administered in 2 s.c. injections every 2 weeks
3063694|NCT00995722|Experimental|Prednisone + Pyridostigmine|Corticosteroid
3063695|NCT00995722|Placebo Comparator|Placebo + Pyridostigmine|Matched, inactive substance
3063696|NCT00995761|No Intervention|biweekly schedule|docetaxel 40mg/m2 on day 1,15 every 4weeks cisplatin 40mg/m2 on day 1,15 every 4weeks
3063697|NCT00995774|Experimental|Robotic then Conventional|robotic arm therapy first, conventional therapy second
3063698|NCT00995774|Experimental|Conventional then Robotic|conventional therapy first, robotic therapy second
3063699|NCT00995865|Active Comparator|High dose|
3063700|NCT00995865|Active Comparator|Mid Dose|
3063701|NCT00995865|Placebo Comparator|Placebo|NaCl Injectable 0.9%
3063702|NCT00995904|Experimental|Treatment A, then Treatment B, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3063703|NCT00995904|Experimental|Treatment A, then Treatment C, then Treatment B|Study visits were separated by 3-7 day intervals. Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3063704|NCT00995904|Experimental|Treatment B, then Treatment A, then Treatment C|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4
3063705|NCT00995904|Experimental|Treatment B, then Treatment C, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
3063706|NCT00995904|Experimental|Treatment C, then Treatment A, then Treatment B|"Study visits were separated by 3-7 day intervals.~Treatment C: 21ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 2; Treatment A: 84ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 3; Treatment B: 42ug MAP0020 (unit dose budesonide delivered by Aeroneb® Go) at Visit 4"
3063707|NCT00995904|Experimental|Treatment C, then Treatment B, then Treatment A|Study visits were separated by 3-7 day intervals. Treatment C: 21ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 2; Treatment B: 42ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 3; Treatment A: 84ug of unit dose budesonide delivered by Aeroneb® Go (MAP0020) at Visit 4
3063708|NCT00995930|Placebo Comparator|Placebo|subcutaneous (SQ) monthly
3063709|NCT00995930|Experimental|ACZ885|150 mg SQ monthly
3063710|NCT00996034|Experimental|Healthy Smoker|There is only one arm to the study. All subjects will receive NicVax, [123I]5-I-A-85380,and Nicotine bitartrate.
3063711|NCT00996125|Experimental|Cervarix Group|Subjects received 3 doses of Cervarix vaccine. Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3063712|NCT00996125|Experimental|Placebo Group|Subjects received 3 doses of placebo. Placebo vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1, 6-month schedule.
3063713|NCT00996164|Experimental|flibanserin 100 mg|flibanserin 100mg po qd
3063714|NCT00996164|Placebo Comparator|Placebo|placebo 1 tab po qd
3063715|NCT00996203|Experimental|1|
3063716|NCT00996216|Experimental|Open-label eltrombopag|Open-label eltrombopag with dose titrations to support adequate platelet counts.
3063717|NCT00996281|Experimental|Azilsartan Medoxomil and Chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily for up to 52 weeks.~For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of azilsartan medoxomil 80 mg and chlorthalidone 25 mg."
3063718|NCT00996281|Active Comparator|Olmesartan Medoxomil and Hydrochlorothiazide QD|"Participants in the United States:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg.~Participants in Europe:~Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablet, orally, once daily for up to 52 weeks. For participants who did not achieve target blood pressure by Week 4, titration to a maximum dose of Olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg."
3063719|NCT00996307|Experimental|3.75_(50)MF59|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
3063720|NCT00996307|Experimental|7.5_(0)MF59|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
3063721|NCT00996307|Experimental|7.5_(50)MF59|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
3063722|NCT00996307|Experimental|15_(0)MF59|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
3063723|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 1|"Arm 1, Level 1: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 15 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3063724|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 1, Level 2|"Arm 1, Level 2: Irinotecan intravenously at 80 mg/m2 + Temsirolimus intravenously at 20 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3063725|NCT00996346|Experimental|Irinotecan&Temsirolimus:Arm 2, Level 1|"Arm 1, Level 2: Irinotecan intravenously at 50 mg/m2 + Temsirolimus intravenously at 25 mg on a weekly basis for 3 consecutive doses followed by one week of rest.~One cycle is four weeks."
3063726|NCT00996372|Experimental|flibanserin 100mg|flibanserin 100mg po qd
3063727|NCT00996372|Placebo Comparator|placebo|placebo one tablet po qd
3063728|NCT00996437|Placebo Comparator|Saline Injection|Saline injection at baseline, 4 and 8 weeks
3063729|NCT00996437|Active Comparator|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
3063730|NCT00996476|Experimental|TMC12/PR24 50 mg|Participants received TMC435 50 mg once daily with PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24 Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3063731|NCT00996476|Experimental|TMC12/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 12 weeks followed by PR until Week 24. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3063732|NCT00996476|Experimental|TMC24/PR24 50 mg|Participants received TMC435 50 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435, PR) at Week 24. All other participants continued PR until Week 48.
3063733|NCT00996476|Experimental|TMC24/PR24 100 mg|Participants received TMC435 100 mg once daily plus PegIFNa-2a and ribavirin (PR) for 24 weeks. Participants who achieved plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.4 log10 IU/mL at Week 4 and had undetectable plasma HCV RNA at Weeks 12, 16 and 20, discontinued all study treatment (TMC435 and PR) at Week 24. All other participants continued PR until Week 48.
3063734|NCT00996476|Experimental|PR48 Control|Participants received PegIFNa-2a and ribavirin (PR) for 48 weeks (PR48 control group)
3063735|NCT00996489|Experimental|Coaptite|
3063736|NCT00996580|Experimental|DR-103|"Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by;~21 days combination therapy of 25 mcg EE/150 mcg LNG followed by;~21 days combination therapy of 30 mcg EE/150 mcg LNG followed by;~7 days of 10 mcg EE."
3063737|NCT00996593|Experimental|open-label, single arm|
3063738|NCT00996606|Experimental|Tocilizumab in Active RA|Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.
3063739|NCT00996632|Experimental|A|Patients were operated using an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
3063740|NCT00996632|Active Comparator|B|Patients were operated using a conventional diarthermy knife
3063741|NCT00996658|Experimental|Linagliptin|Linagliptin tablets once daily
3063742|NCT00996658|Placebo Comparator|Placebo|Placebo tablets once daily
3063743|NCT00996736|Active Comparator|Topical Natamycin|
3063744|NCT00996736|Experimental|Topical Voriconazole|
3063745|NCT00996775|Active Comparator|standard care only|standard care only - harmful effects of alcohol use and NIAAA limits
3063746|NCT00996775|Experimental|Brief alcohol intervention|Group receiving brief alcohol intervention
3063747|NCT00996801|Placebo Comparator|Placebo|Participants received either matching placebo to alendronate (administered orally, once-weekly) or matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063748|NCT00996801|Experimental|MK-5442 5 mg|Participants received 5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063749|NCT00996801|Experimental|MK-5442 7.5 mg|Participants received 7.5 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063750|NCT00996801|Experimental|MK-5442 10 mg|Participants received 10 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063751|NCT00996801|Experimental|MK-5442 15 mg|Participants received 15 mg of MK-5442 (orally, once-daily) plus matching placebo to alendronate (administered orally, once-weekly) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063752|NCT00996801|Active Comparator|Alendronate 70 mg|Participants received 70 mg alendronate (orally, once-weekly) plus matching placebo to MK-5442 (administered orally, once-daily) for 12 months. Participants also received supplemental vitamin D3 and calcium (as needed) during treatment.
3063753|NCT00996840|Experimental|Cohort 1 - SB-681323 Intravenous 3mg|3mg SB-681323 Intravenous administration, infused over 4 hours
3063754|NCT00996840|Experimental|Cohort 2 - SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
3063755|NCT00996840|Experimental|Cohort 3 - SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
3063756|NCT00996840|Experimental|Cohort 4 - SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
3063757|NCT00996840|Experimental|Combined Placebo|Placebo to match intervention
3320885|NCT02014558|Experimental|Gilteritinib 40 mg in Escalation Phase|Participants received a single dose of 40 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 40 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3063758|NCT00996892|Experimental|Dose Escalation Stage 1: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 20 milligrams [mg]) and pictilisib capsules (at a starting dose of 80 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3063759|NCT00996892|Experimental|Dose Escalation Stage 1A: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D.Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3063760|NCT00996892|Experimental|Dose Escalation Stage 1B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules (at a starting dose of 40 mg) and pictilisib capsules (at a starting dose of 130 mg) from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3063761|NCT00996892|Experimental|Dose Expansion Stage 2: Cobimetinib + Pictilisib|Participants will received cobimetinib capsules and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutant non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; and KRAS mutant colorectal cancer (CRC).
3063762|NCT00996892|Experimental|Dose Expansion Stage 2A: Cobimetinib + Pictilisib|Participants received cobimetinib capsules on Days 1, 4, 8, 11, 15, and 18 and pictilisib capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1A. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant NSCLC; EGFR T790M mutant and EGFR inhibitor-progressing NSCLC; pancreatic adenocarcinoma; KRAS mutant CRC, and KRAS mutant endometrioid carcinoma.
3063763|NCT00996892|Experimental|Dose Expansion Stage 2B: Cobimetinib + Pictilisib|Participants will receive cobimetinib capsules and pictilisib capsules from Days 1 to 7 and then from Days 15 to 21 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1B. Participants will be off study drugs from Days 8 to 14 and from Days 22 to 28. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with KRAS mutant endometrioid carcinoma.
3063764|NCT00996918|Experimental|Bapineuzumab 0.5 mg/kg|bapineuzumab
3063765|NCT00996918|Experimental|Bapineuzumab 1.0 m/kg|bapineuzumab
3063766|NCT00996931|Experimental|Lenalidomide|
3063767|NCT00996944|Experimental|Ropinirole IR|
3063768|NCT00996944|Placebo Comparator|Placebo|
3063769|NCT00996996|Experimental|open-label, single arm|Tositumomab and Iodine I 131 Tositumomab
3063770|NCT00997035|Active Comparator|Oral Voriconazole|
3063771|NCT00997035|Placebo Comparator|Placebo|
3063772|NCT00997113|Active Comparator|Propofol|propofol only for deep procedural sedation
3063773|NCT00997113|Active Comparator|Propofol/alfentanil|Propofol with alfentanil for deep procedural sedation
3063774|NCT00997126|Active Comparator|Propofol|Propofol 1m g/kg IV followed by 0.5 mg/kg IV prn sedation
3063775|NCT00997126|Active Comparator|Alfentanil|Sedation using alfentanil 10 ug/kg followed by 5 ug/kg prn sedation
3063776|NCT00997204|Experimental|Icatibant- Naive Treatment Phase|Single subcutaneous injection of icatibant, 30 mg
3063777|NCT00997204|Experimental|icatibant- Self administration Phase|Single subcutaneous injection of icatibant, 30 mg
3063778|NCT00997243|Experimental|5-azacytidine and Lintuzumab|"Cycle 1- 5-azacytidine (Vidaza, AZA) 75mg/m2 IV/SC(subcutaneous)daily on days 1-7.~Subsequent Cycles (cycles to be repeated every 28 days) AZA 75mg/m2 IV/SC daily on days 1-7."
3063779|NCT00997321|Active Comparator|Propofol|propofol 1 milligram per kilogram intravenous bolus followed by 0.5 millligrams per kilogram as needed for mooderate procedural sedation
3063780|NCT00997321|Active Comparator|Ketamine|ketamine 1 milligram per kilogram followed by 0.5 millgram per kilogram as needed for moderate procedural sedation
3063781|NCT00997334|Experimental|Erlotinib|Erlotinib was given at a dose of 150mg orally once per day for 28 days (+/- 3 days); Patients are treated until disease progression or until unaccepted drug toxicity.
3063782|NCT00997373|Experimental|Letrozole|letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
3063783|NCT00997373|No Intervention|control|no treatemtn prior to hysterectomy
3063784|NCT00997425|Experimental|Door Cover/Floor Cover|Baseline One (14 days), First Intervention (14 days), Baseline Two (14 days), Second Intervention (14 days)
3063785|NCT00997438|Experimental|MS - Secondary Progressive|1200 mg of Lipoic acid supplement
3063786|NCT00997438|Experimental|MS - Relapsing Remitting|1200mg of Lipoic acid supplement
3063787|NCT00997438|Experimental|Healthy Controls|1200 mg of Lipoic acid supplement
3063788|NCT00997516|Experimental|SILS appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
3063789|NCT00997516|Active Comparator|Conventional laparoscopic appendectomy|The study population will consist of patients who come to the emergency room with acute abdominal pain and are found to have acute appendicitis on the basis of clinical evaluation and CT of the abdomen/pelvis.
3063790|NCT00997555|Experimental|bronchoscopy intervention group|Group undergoing scheduled bronchoscopy.
3063791|NCT00997555|No Intervention|Control group|Standard treatment without scheduled bronchoscopy.
3063792|NCT00997594|Active Comparator|Adrenal radiofrquency (RF) ablation|Patients who wll receive adrenal RF ablation.
3063793|NCT00997594|Active Comparator|Abdominal RF ablation other than adrenal gland|Patients who will receive abdominal radiofrequency ablation other than adrenal gland.
3063794|NCT00997620|Placebo Comparator|Placebo|Placebo treatment given as a once daily dose intranasally.in subjects with active seasonal allergic rhinitis.
3063795|NCT00997620|Experimental|Fluticasone Furoate|IFluticasone Furoate 110 mcg given intranasly once daily in am as an active treatment of seasonal allergic rhinitis
3063796|NCT00997672|Experimental|Lithium CARBONATE 150 and/or 300 mg|
3063797|NCT00997672|Placebo Comparator|Placebo|Placebo comparator
3063798|NCT00997893|Experimental|Estradiol/Medroxyprogesterone Acetate|1 mg/d oral Estradiol pill and 0 mg/d oral placebo pill for 12 weeks, followed by 10 mg/d oral medroxyprogesterone acetate (MPA) pill, for 10 days.
3063799|NCT00997893|Experimental|Soy Phytoestrogen|55 mg/twice daily oral Novasoy®/Soy Phytoestrogen pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
3063800|NCT00997893|Placebo Comparator|Placebo|0 mg tablet/twice daily oral placebo pill for 12 weeks, followed by 0 mg/d oral placebo pill, for 10 days.
3063801|NCT00997932|Other|Complete Cohort|The complete cohort of all women enrolled and stated they wanted an LNG-IUS between 48 and 72 hours of vaginal delivery.
3063802|NCT00997984|Experimental|Extended-release Guanfacine Hydrochloride (SPD503) AM|
3063803|NCT00997984|Experimental|placebo|
3063804|NCT00997984|Experimental|SPD503 PM|
3063805|NCT00998010|Experimental|Experimental|Patients receive bortezomib IV on days 1, 4, 8, 11, 29, 32, 36, and 39 and oral temozolomide on days 1-42.Patients undergo external-beam fractionated regional radiotherapy 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.2-6 weeks after radiotherapy, patients receive bortezomib IV on days 1, 4, 8, and 11 and oral temozolomide on days 1-5.Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3063806|NCT00998023|Experimental|Mynx VCD|Mynx Vascular Closure Device
3063807|NCT00998023|Active Comparator|AngioSeal VCD|AngioSeal Vascular Closure Device
3063808|NCT00998049|Experimental|Plerixafor|"Plerixafor 160mg/kg/dose by IV on days 5-8~Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8."
3063809|NCT00998205|Other|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micrograms/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micrograms/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate. If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
3063810|NCT00998296|Experimental|BIBW 2992 + BIBF 1120|This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
3063811|NCT00998309||Azithromycin SR|Patients taking Azithromycin.
3063812|NCT00998335|Active Comparator|Insulin detemir only|Patients with uncontrolled T2DM are treated with insulin detemir for 6 months. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl. This group will receive Long-acting bedtime insulin detemir (Levemir).
3063813|NCT00998335|Experimental|Insulin detemir plus aspart|After baseline evaluations, insulin detemir will be given at bedtime and titrated to achieve a fasting plasma glucose between 80-100 mg/dl. After 3 months patients will be admitted to assess the metabolic effects of intervention. After this, insulin aspart (insulin detemir plus aspart) will be added before breakfast, lunch and dinner titrated to normalize the postprandial plasma glucose. After another 3 months patients are readmitted and all study procedures repeated. This group will receive Insulin detemir and pre-meal insulin aspart.
3063814|NCT00998374||Pyloric-sparing vs. non-pyloric sparing|Pyloric: SG & DS Non-pyloric: RYGB
3063815|NCT00998400|No Intervention|Clinical Management|Control group
3063816|NCT00998400|Experimental|CBT + WBT|Patients treated with Cognitive-Behavioral Therapy in combination with Well-Being Therapy and lifestyle modification
3063817|NCT00998426|Experimental|All study participants|Study procedures will occur one timebetween post-op day 1 and post-op day 7. Study procedures to include blood glucose monitoring prior to and after (various time points for 2 hours after) infusion with HBIG.
3063818|NCT00998517|Active Comparator|Soy/peanut fortified spread|
3063819|NCT00998517|Experimental|Milk fortified corn/soy blend|
3063820|NCT00998517|Active Comparator|Supplementary Plumpy®|
3063821|NCT00998582|Active Comparator|Abacavir|Participants randomized to this arm will continue abacavir and their other HIV medications with no changes
3063822|NCT00998582|Experimental|Tenofovir|Participants randomized to this arm will switch from taking abacavir (co-formulated with lamivudine as Epzicom) and start taking tenofovir (co-formulated with emtricitabine as Truvada), and continue their other HIV medications
3063823|NCT00998660|Experimental|Patients receiving an Activa RC implant|
3063824|NCT00998764|Experimental|Bapineuzumab 0.5 mg/kg|
3063825|NCT00998790|Experimental|AMS AdVance Sling Group|European Male subjects >40 years old who were implanted with the AMS AdVance Male Sling to treat Stress Urinary Incontinence.
3063826|NCT00998868||hemiplegia|patients with hemiplegia, without other musculoskeletal disorders of the shoulder
3063827|NCT00998881|Experimental|Teneligliptin 20 mg|Teneligliptin 20 mg, orally, once daily
3063828|NCT00998881|Placebo Comparator|Placebo|Teneligliptin placebo-matching tablets, orally, once daily
3063829|NCT00998946|Experimental|Pralatrexate|"Participants received pralatrexate at an initial dose of 30 mg/m^2, as IV push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline on Days 1, 8 and 15 of a 4-week cycle (weekly for 3 weeks with 1 week of rest) until criteria for discontinuation per protocol were met. The initial dose of 30 mg/m^2 may be reduced to 20 mg/m^2 weekly, permitted per protocol defined criteria. If pralatrexate 20 mg/m^2/week was not tolerated, pralatrexate had to be discontinued. Dose re-escalation was not allowed once dose reduction was done.~Participants had dietary supplement of vitamin B12 and folic acid along with pralatrexate. Vitamin B12, given as 1mg IM, within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days post last dose of pralatrexate. Folic acid was given 1mg daily, orally, for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days post last dose of pralatrexate."
3063830|NCT00998985|Experimental|400 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 400 mg Grazoprevir or Placebo
3063831|NCT00998985|Experimental|600 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 600 mg Grazoprevir or Placebo
3063832|NCT00998985|Experimental|800 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 800 mg Grazoprevir or Placebo
3063833|NCT00998985|Experimental|400 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 400 mg Grazoprevir or Placebo
3063834|NCT00998985|Experimental|600 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 600 mg Grazoprevir or Placebo
3063835|NCT00998985|Experimental|800 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 800 mg Grazoprevir or Placebo
3063836|NCT00998985|Experimental|200 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 200 mg Grazoprevir or Placebo
3063837|NCT00998985|Experimental|100 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 100 mg Grazoprevir or Placebo
3063838|NCT00998985|Experimental|50 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 50 mg Grazoprevir or Placebo
3063839|NCT00998985|Experimental|200 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 200 mg Grazoprevir or Placebo
3063840|NCT00998985|Experimental|100 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 100 mg Grazoprevir or Placebo
3063841|NCT00998985|Experimental|50 mg Grazoprevir - GT3|GT3 HCV-infected Participants: 50 mg Grazoprevir or Placebo
3063842|NCT00998985|Experimental|30 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 30 mg Grazoprevir or Placebo
3063843|NCT00998985|Experimental|10 mg Grazoprevir - GT1|GT1 HCV-infected Participants: 10 mg Grazoprevir or Placebo
3063844|NCT00999037|Experimental|Renvela|Daily renvela with meals for 12 weeks
3063845|NCT00999037|Placebo Comparator|placebo|
3063846|NCT00999102|Experimental|Nebivolol, followed by Metoprolol|Participants first received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 9-16 in total).
3063847|NCT00999102|Experimental|Metoprolol, followed by Nebivolol|Participants first received Metoprolol at a dose of 50 mg daily for 4 weeks, followed by 100 mg daily for another 4 weeks (i.e., weeks 1-8 in total). The participants then received Nebivolol at a dose of 5 mg daily for 4 weeks, followed by 10 mg daily for another 4 weeks (i.e., weeks 9-16 in total)
3063848|NCT00999141|Experimental|FS VH S/D 4 s-apr|One side of face will be treated with the investigational product (FS VH S/D 4 s-apr) as an adjuvant to the standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
3063849|NCT00999141|No Intervention|Standard of Care (SoC)|Other side of face will receive standard of care. Please note: Each subject will participate in both arms (investigational product and standard of care) simultaneously, and will serve as his/her own control.
3063850|NCT00999167|Experimental|HPN-100|
3063851|NCT00999167|Placebo Comparator|Placebo|
3063852|NCT00999466|Experimental|1|AZD8848 (30 μg PILOT part and 60 μg MAIN part)
3063853|NCT00999466|Placebo Comparator|2|Placebo
3063854|NCT00999518|Experimental|Group 1|
3063855|NCT00999518|Experimental|Group 2|
3063856|NCT00999518|Experimental|Group 3|
3063857|NCT00999518|Experimental|Group 4|
3063858|NCT00999518|Placebo Comparator|Group 5|
3063859|NCT00999544|Experimental|Placebo aprepitant/0 mg oxycodone IN PO|Placebo aprepitant/Placebo oxycodone IN/PO
3063860|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 15 IN 0 PO|Placebo aprepitant/ oxycodone 15 IN 0 PO
3063861|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 30 IN 0 PO|Placebo aprepitant/ oxycodone 30 IN 0 PO
3063862|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 20 PO|Placebo aprepitant/ oxycodone 0 IN 20 PO
3063863|NCT00999544|Experimental|Placebo aprepitant/ oxycodone 0 IN 40 PO|Placebo aprepitant/ oxycodone 0 IN 40 PO
3063864|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 0 PO|Aprepitant 40 mg/ oxycodone 0 IN 0 PO
3063865|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 20 PO|Aprepitant 40 mg/ oxycodone 0 IN 20 PO
3063866|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 0 IN 40 PO|Aprepitant 40 mg/ oxycodone 0 IN 40 PO
3063867|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 15 IN 0 PO|Aprepitant 40 mg/ oxycodone 15 IN 0 PO
3063868|NCT00999544|Experimental|Aprepitant 40 mg/ oxycodone 30 IN 0 PO|Aprepitant 40 mg/ oxycodone 30 IN 0 PO
3063869|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 0 PO|Aprepitant 200 mg/ oxycodone 0 IN 0 PO
3063870|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 20 PO|Aprepitant 200 mg/ oxycodone 0 IN 20 PO
3063871|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 0 IN 40 PO|Aprepitant 200 mg/ oxycodone 0 IN 40 PO
3063872|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 15 IN 0 PO|Aprepitant 200 mg/ oxycodone 15 IN 0 PO
3063873|NCT00999544|Experimental|Aprepitant 200 mg/ oxycodone 30 IN 0 PO|Aprepitant 200 mg/ oxycodone 30 IN 0 PO
3063874|NCT00999596||FFDM (Full Field Digital Mammography)|Mammograms from the Philips Digital System
3063877|NCT00999687|Experimental|Indigo naturalis extract in oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
3063878|NCT00999687|Placebo Comparator|Olive oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
3063879|NCT00999713|Experimental|Calfactant|Endotracheal calfactant administration
3063880|NCT00999713|Placebo Comparator|Placebo (air)|Endotracheal air administration
3063881|NCT00999804|Experimental|24-week arm|Participants will receive 24-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
3063882|NCT00999804|Active Comparator|12-week arm|Participants will receive 12-weeks of lapatinib plus trastuzumab. Participants who are estrogen receptor (ER) and/or progesterone receptor (PR) positive will also receive endocrine therapy.
3063883|NCT00999830|Experimental|IPH 2101 0.2 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 0.2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
3063884|NCT00999830|Experimental|IPH2101 2.0 mg/kg|One infusion of IPH2101 every 4 weeks at the dose of 2 mg/kg by intravenous route over 1 hour, for 4 or up to 8 cycles.
3063885|NCT00999908|Experimental|Indacaterol 150 μg-tiotropium 18 μg-placebo|Patients received indacaterol 150 μg once. After a 5-9 days washout period, patients received tiotropium 18 μg once. After a second 5-9 days washout period, patients received placebo (matching indacaterol) once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3063886|NCT00999908|Experimental|Tiotropium 18 μg-placebo-indacaterol 150 μg|Patients received tiotropium 18 μg once. After a 5-9 days washout period, patients received placebo (matching indacaterol) once. After a second 5-9 days washout period, patients received indacaterol 150 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3063887|NCT00999908|Experimental|Placebo-indacaterol 150 μg-tiotropium 18 μg|Patients received placebo (matching indacaterol) once. After a 5-9 days washout period, patients received indacaterol 150 μg once. After a second 5-9 days washout period, patients received tiotropium 18 μg once. All treatments were delivered via a single dose dry powder inhaler (SDDPI). The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3063888|NCT00999921|Experimental|Tamoxifen|10 mg once daily from 5th day to 25th day of menstrual cycle for 3 months
3063889|NCT00999921|Experimental|Evening Primrose Oil|1000 mg daily for 3 months
3063890|NCT01000025|Active Comparator|PF-00299804|Patients receive oral PF-00299804 once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3063891|NCT01000025|Placebo Comparator|Placebo|Patients receive oral placebo once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3063892|NCT01000051|Experimental|Eltrombopag|Starting dose 50 mg/day orally for 8 weeks
3063893|NCT01000051|Placebo Comparator|Placebo|Once a day orally for 8 weeks
3063894|NCT01000064|Active Comparator|Vyvanse|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
3063895|NCT01000064|Placebo Comparator|Placebo|"Vyvanse capsule, 30-70 mg, each morning for 6 weeks.~Placebo capsule each morning for 6 weeks.~Brain scans (fMRI) performed at baseline, 6th week visit and 12th week visit."
3063896|NCT01000155|Experimental|Vorinostat|Patients received vorinostat in a pulsed fashion, once a day for 3 consecutive days every week to a maximum dose of 400 mg per dose (1200 mg/wk), for 12 to 16 weeks at the maximum dose. The first 3 patients were enrolled in an intrapatient dose escalation schedule of 100 mg/d, then 200 mg/d, each for 3 consecutive days a week for 4 weeks, and then 400 mg/d, 3 consecutive days per week for 16 weeks. The last 2 patients were enrolled to receive 400 mg/d, 3 consecutive days per week for 12 weeks, without an initial dose escalation.
3063897|NCT01000285|Experimental|Arm 1|"Bortezomib 1.0 mg/m2 intravenous (IV) Days 1-4~Etoposide 50 mg/m2/d 96 hour continuous intravenous infusion (CIVI) on Days 1-4~Vincristine 0.4 mg/m2/d 96 hour CIVI on Days 1-4~Doxorubicin 10 mg/m2/d 96 hour CIVI on Days 1-4~Prednisone 60 mg/m2/d PO on Days 1-5~Cyclophosphamide 375 mg/m2 IV on Day 5~Raltegravir 400 mg PO twice per day (BID) every day starting with cycle 2 therapy for the entire duration of the cycle.~Cycles will be repeated every 21-28 days for 2 cycles beyond best response, or a maximum of 6 cycles."
3063898|NCT01000311|Experimental|MenACWY-CRM + Routine Vaccines|"Infants received 3 doses of MenACWY-CRM at 2, 4 and 6 months as a infant series vaccination and a toddler dose at 12 months of age.~Infants also received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months."
3063899|NCT01000311|Experimental|Routine Vaccines|"Infants received routine vaccines - 3 doses each of DTaP-IPV/Hib, HBV and PCV at 2, 4 and 6 months; and 1 dose each of PCV and MMR at 12 months.~In addition subjects were offered a dose of MenACWY-CRM at 18 months as a benefit of participating in this study. However, blood was not drawn for immunogenicity analysis after this dose."
3063900|NCT01000324|Experimental|Twinrix Group|Pooled group of subjects from groups who were vaccinated with either Lot 1, Lot 2 or Lot 3 of Twinrix in the primary study according to a 0, 1, 6-Month schedule
3063901|NCT01000337|Active Comparator|sevoflurane|Volatile anesthetic
3063902|NCT01000337|Active Comparator|Propofol|Intravenous anesthetic
3063903|NCT01000376|Experimental|Group 1|
3063904|NCT01000376|Experimental|Group 2|
3063905|NCT01000480|Experimental|Pemetrexed|Pemetrexed and cisplatin are given as induction therapy followed after by pemetrexed and cisplatin with concurrent radiotherapy.
3063906|NCT01000493|Experimental|Orvepitant 60 mg|60 mg/day
3063907|NCT01000493|Placebo Comparator|Placebo|
3063908|NCT01000506|Active Comparator|Mepolizumab 750mg|Mepolizumab 750mcg i.v. every 4 weeks
3063909|NCT01000506|Active Comparator|Mepolizumab 250mg|Mepolizumab 250mcg i.v. every 4 weeks
3063910|NCT01000506|Active Comparator|Mepolizumab 75mg|Mepolizumab 75mcg i.v. every 4 weeks
3063911|NCT01000506|Placebo Comparator|Placebo|Placebo saline every 4 weeks i.v.
3063912|NCT01000610|Experimental|single arm|
3063913|NCT01000636|Experimental|Metvix PDT|
3063914|NCT01000649|Experimental|FE 202158 1.25|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 1.25 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3063915|NCT01000649|Experimental|FE 202158 2.5|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 2.5 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3063916|NCT01000649|Experimental|FE 202158 3.75|"Patients in the arm received an intravenous infusion for up to 7 days of FE 202158 at an initial rate of 3.75 ng/kg/min.~FE 202158 was provided as an isotonic acetate buffered stock solution of pH 4.0 in vials appropriately diluted with isotonic saline prior to use."
3063917|NCT01000649|Placebo Comparator|PLCBO|Patients in the arm received an intravenous infusion for up to 7 days of placebo.
3063918|NCT01000662|Active Comparator|ARM 1 daily boost|Radiation Therapy
3063919|NCT01000662|Active Comparator|ARM 2 weekly boost|Radiation Therapy
3063920|NCT01000727|Experimental|Darapladib 160 mg|Single daily oral tablet
3063921|NCT01000727|Placebo Comparator|Placebo|Single daily oral tablet
3063922|NCT01000805|Experimental|Duloxetine|
3063923|NCT01000805|Placebo Comparator|Placebo|
3063924|NCT01000818|Experimental|Period 1|MK0518
3063925|NCT01000818|Experimental|Period 2|famotidine + MK0518
3063926|NCT01000818|Experimental|Period 3|omeprazole + MK0518
3063927|NCT01000961|Experimental|RP103 Q12H|
3063928|NCT01000961|Active Comparator|Cystagon® Q6H|
3063929|NCT01000974|Experimental|Hiberix Group|Pooled group of subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of 3 different lots of Hiberix® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age The Hiberix® vaccine was administered intramuscularly in the right thigh. Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
3063930|NCT01000974|Active Comparator|ActHIB Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of ActHIB® vaccine co-administered with 3 doses of Pediarix® and Prevnar13® vaccines at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The ActHIB® vaccine was administered intramuscularly in the right thigh. The Pediarix® vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally.
3063931|NCT01000974|Active Comparator|Pentacel Group|Subjects, male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination, who received 3 doses of Pentacel® vaccine co-administered with 3 doses of Prevnar13® vaccine, 2 or 3 doses of Engerix™-B vaccine at 2, 4 and 6 months of age and 2 doses of Rotarix® vaccine at 2 and 4 months of age. The Pentacel® vaccine was administered intramuscularly in the right thigh. The Engerix™-B vaccine was administered intramuscularly in the left thigh. The Prevnar13® vaccine was administered intramuscularly in the left thigh or deltoid. The Rotarix® vaccine was administered orally. If subjects in the Pentacel Group had received a birth dose of Hepatitis B vaccine then they were to receive Engerix™-B vaccine only at 2 and 6 months of age.
3063932|NCT01000987|Experimental|varenicline|varenicline 1mg/day or 2mg/day
3063933|NCT01000987|Placebo Comparator|placebo|placebo
3063934|NCT01001052|Experimental|Colcrys™ - young subjects (18-30 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
3063935|NCT01001052|Experimental|Colcrys™ - elderly subjects (≥60 yrs)|One single dose of Colcrys™ 0.6mg taken by mouth on day 1
3063936|NCT01001078|Active Comparator|I-Gel supraglottic airway device|Group in which the I-Gel will be used in the first and second attempts to secure the airway. If a third attempt is needed, the LMA Supreme will be used. If the third attempt fails, a standard endotracheal tube will be used.
3063937|NCT01001078|Active Comparator|LMA Supreme supraglottic airway device|Group in which the LMA Supreme will be used in the first and second attempts to secure the airway. If a third attempt is needed, the I-Gel will be used. If the third attempt fails, a standard endotracheal tube will be used.
3063938|NCT01001078|Active Comparator|Standard endotracheal tube|A Standard endotracheal tube will be inserted in case both other airway devices (LMA Supreme and iGel) devices fail to provide adequate ventilation.
3063939|NCT01001104|Experimental|0.75 mg LY2189265|
3063940|NCT01001104|Experimental|0.5 mg LY2189265|
3063941|NCT01001104|Experimental|0.25 mg LY2189265|
3063942|NCT01001104|Placebo Comparator|Placebo|
3063943|NCT01001169|Experimental|GSK2340274A_F1 6M-9Y GROUP|Healthy male or female Japanese children, between and including 6 months to 9 years of age, who received two doses of GSK2340274A vaccine (formulation 1), administered intramuscularly into the deltoid region of the arm (intramuscularly into the anterolateral part of the thigh for subjects below 12 months of age at the entry of the study), according to 0, 21-day schedule. Within this group, enrolment of subjects was stratified by age into two subgroups, from 6 to 35 months and from 3 to 9 years.
3063944|NCT01001169|Experimental|GSK2340274A_F2 10Y-17Y GROUP|Healthy male or female Japanese children, between and including 10 to 17 years of age, who received two doses of GSK2340274A vaccine (formulation 2), administered intramuscularly into the deltoid region of the arm, according to 0, 21-day schedule.
3063945|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3063946|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3063947|NCT01001195|Experimental|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3063948|NCT01001195|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
3063949|NCT01001208|Experimental|Etanercept Plus Methotrexate|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received active methotrexate titrated as follows: 7.5 mg per week (3 capsules) for weeks 1 and 2, 10 mg per week (4 capsules) for weeks 3 and 4, and then up to 15 mg per week (6 capsules) or the maximum tolerated dose for the remainder of the 24-week treatment period.
3063950|NCT01001208|Active Comparator|Etanercept Plus Placebo|Participants received 50 mg etanercept twice weekly (BIW) for the first 12 weeks and then 50 mg etanercept once weekly (QW) for the second 12 weeks. Participants also received oral placebo that was the same number of capsules per week as the methotrexate dosing regimen.
3063951|NCT01001221|Experimental|Cabazitaxel + gemcitabine|"Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.~On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel."
3063952|NCT01001234|Experimental|Stage 1: rizatriptan|
3063953|NCT01001234|Placebo Comparator|Stage 1: placebo|
3063954|NCT01001234|Experimental|Stage 2: rizatriptan|
3063955|NCT01001234|Placebo Comparator|Stage 2: placebo|
3063956|NCT01001299|Experimental|Single arm|
3063957|NCT01001325|Experimental|Seasonal influenza vaccination|Receipt of Fluviral seasonal (2009-2010, Canadian) influenza vaccination as per manufacturers specification
3063958|NCT01001325|Placebo Comparator|Placebo|0.5 mL normal saline
3063959|NCT01001377|Active Comparator|Cetuximab|"Cetuximab 400 mg/m^2 as an initial dose, followed by 250 mg/m^2 intravenously (IV) every 7 days.~Participants were treated until disease progression, intolerability, withdrawal of consent, or death."
3063960|NCT01001377|Experimental|Panitumumab|Panitumumab 6 mg/kg IV every 14 days. Participants were treated until disease progression, intolerability, withdrawal of consent, or death.
3063961|NCT01001403|Experimental|nafamostat|The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.
3063962|NCT01001403|Placebo Comparator|Control|The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.
3063963|NCT01001429|Active Comparator|Propofol|propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
3063964|NCT01001429|Experimental|dexmedetomidine infusion|Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
3063965|NCT01001442|Experimental|BT062|BT062 was to be administered as single-dose IV infusions via a 0.22 μm in-line filter preferably in a forearm vein, according to medically accepted procedures on Days 1, 8, and 15 of each 28-day cycle. Alternatively BT062 may have been administered through a central venous line or a peripherally inserted central catheter (PICC). Other administration routes were only to be allowed after approval from Biotest. Each subject was to be monitored carefully for the effects of exposure to BT062. No subject was to have received more than 3 doses of BT062 per 28-day treatment cycle.
3063966|NCT01001494|Experimental|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation
3063967|NCT01001494|Experimental|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation
3063968|NCT01001494|Placebo Comparator|Placebo|Placebo
3063969|NCT01001520|Placebo Comparator|Placebo (Sugar Pill)|11-day placebo-controlled medication period
3063970|NCT01001520|Active Comparator|Tolcapone|11-day phase, tapered dosing scheduled (Day 1: 100mg three times daily, Days 2-8: 200mg three times daily, Day 9: 200mg twice daily, Day 10: 200mg once daily, Day 11: 100mg once daily); oral dosing; medication is encapsulated by the University of Pennsylvania's Investigational Drug Service (IDS)
3063971|NCT01001546|Experimental|Arm 1|Internet-based smoking cessation
3063972|NCT01001546|Other|Arm 2|Clinic-based smoking cessation
3063973|NCT01001559||Deplin + antidepressant|Deplin in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI)
3063974|NCT01001559||Antidepressant alone|SSRI or SNRI alone
3063975|NCT01001572|Active Comparator|Valsartan 160 mg|One capsule Valsartan 160 mg and 1 tablet placebo to Valsartan/Amlodipine taken orally once daily at approximately 9:00 AM for 8 weeks
3063976|NCT01001572|Experimental|Valsartan/amlodipine 160/5 mg|One film-coated tablet Valsartan/amlodipine 160/5 mg and 1 capsule Placebo to Valsartan taken orally once daily at approximately 9:00 AM for 8 weeks
3063977|NCT01001572|Other|Single-Blind Run-In Valsartan 160 mg|Single-Blind Run-In treatment with one capsule Valsartan 160 mg taken orally once daily at approximately 9:00 AM for 4 weeks.
3063978|NCT01001598|Other|danazol|Subjects with either Fanconi anemia or Dyskeratosis congenita
3063979|NCT01001702|Experimental|Oral Aripiprazole|Flexible dose of oral aripiprazole between 5 mg and 30 mg once daily for 72 months.
3063980|NCT01001767|Active Comparator|Lovaza|Lovaza 1 gram by mouth twice a day for 24 weeks.
3063981|NCT01001767|Placebo Comparator|Placebo|Placebo capsule by mouth twice a day x 24 weeks.
3063982|NCT01001806|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
3063983|NCT01001806|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
3063984|NCT01001806|Active Comparator|Nevanac|One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
3063985|NCT01001832|Active Comparator|Subcutaneous (SC) abatacept, 125 mg|
3063986|NCT01001832|Active Comparator|Intravenous (IV) abatacept, 125 mg|
3063987|NCT01001910|Experimental|Treatment (pemetrexed disodium, carboplatin)|Patients receive pemetrexed disodium IV over 8-15 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3063988|NCT01001975|Experimental|SPF Testing|Following Food and Drug Administration (FDA) guidelines for SPF testing, exposure control and product-protected site erythema responses are scored after 16 to 24 hours post-exposure to full spectrum light (Ultraviolet B radiation [UVB] and UVA).
3063989|NCT01001975|Experimental|UVA Protection Testing|Determination of Ultraviolet A Protection Factor (PFA). Following FDA guidelines, test sites exposed to UVA are scored for pigmentation responses 2 to 4 hours post-exposure.
3063990|NCT01001988|Experimental|Study group|Participants received a single dose of JE-CV administered in Study JEC02. In Study JEC05 there were yearly visits with blood samples taken for immunogenicity assessment.
3063991|NCT01002105|Experimental|Baclofen|The study was a double-blind, placebo-controlled, randomized trial comparing 50 mg/day of baclofen to placebo over 12 weeks, in addition to a low-intensity psychosocial intervention program, with 26-week and 52-week follow-up observations.
3063992|NCT01002105|Other|Psychosocial intervention|Intervention of the addition of placebo to low-intensity psychosocial intervention program. This was the control group
3063993|NCT01002118|Placebo Comparator|Placebo|4 capsules inert oil Placebo each day for 16 weeks
3063994|NCT01002118|Active Comparator|Omega-3 Fatty Acid Ethyl Esters|4 capsules Omega-3 Fatty Acid Esters each day for 16 weeks
3063995|NCT01002287|Experimental|SprayShield Adhesion Barrier|SprayShield Adhesion Barrier
3063996|NCT01002287|Sham Comparator|Control|Good Surgical Technique Alone
3063997|NCT01002339|Experimental|Tacrolimus with rapid steroid withdrawal|Basiliximab induction. Tacrolimus plus Mycophenolate mofetil (MMF), and corticosteroids with rapid withdrawal after one week.
3063998|NCT01002339|Active Comparator|Tacrolimus with steroids minimization|Basiliximab induction.Tacrolimus plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
3063999|NCT01002339|Experimental|CsA with steroid minimization|Basiliximab induction. Ciclosporin A (CsA) plus Mycophenolate mofetil (MMF) and low-dose corticosteroids for 6 months with subsequent removal
3064000|NCT01002456|Other|Level 1: site-specific information|provide site-specific information on nonadherence
3064001|NCT01002456|Other|Level 2: site-, patient-specific info|provide site- and patient-specific information on nonadherence
3064002|NCT01002482|Experimental|CGAO-based Glucose Control|Use of a Computerized Protocol fot Tight Glycemic Control named CGAO software in order to maintain Blood Glucose Levels between 4.4 and 6.1 mmol/l.
3064003|NCT01002482|Active Comparator|Standard-Care Glucose Gontrol|Use of Standard-Care Methods for Glucose Control targeting Blood Glucose Levels inferior to 10 mmol/l.
3064004|NCT01002547|Placebo Comparator|Arm 1|Diabetic with proven NASH by biopsy
3064005|NCT01002547|Active Comparator|Arm 2|Diabetic with proven NASH by biopsy
3064006|NCT01002547|Other|Arm 3|Diabetic with proven NASH by biopsy
3064007|NCT01002573|Experimental|ibuprofen|Ibuprofen, 10 mg/kg
3064008|NCT01002573|Active Comparator|Acetaminophen|Acetaminophen, 10mg/kg
3064009|NCT01002742|Experimental|Placebo|Corticosteroids with placebo
3064010|NCT01002742|Experimental|Mycophenolate Mofetil|Corticosteroids with Mycophenolate Mofetil
3064011|NCT01002755|Experimental|Treatment (lenalidomide, ofatumumab)|Participants receive ofatumumab IV over 4 hours on days 1, 8, 15, and 22 of course 1, day 1 of courses 2-6, and day 1 of every even course beginning course 8. Beginning day 9 of course 1, participants also receive lenalidomide PO daily. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3064012|NCT01002989||All eligible patients|"Subjects assessed for hypertension, were subjected to the measurement of ankle brachial index (ABI) by two methods:~Doppler~WatchBP Office oscillometric The order for performing the two methods was randomized."
3064013|NCT01003067|No Intervention|No Mesh|
3064014|NCT01003067|Experimental|Mesh Implementation|
3064015|NCT01003080|Experimental|TKA with the Aquamantys for hemostasis|This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.
3064016|NCT01003080|Active Comparator|TKA without the Aquamantys for hemostasis|This group will receive total knee arthroplasty using the standard treatment for hemostasis.
3064017|NCT01003106|Experimental|BRVO- Ranibizumab 0.5mg alone|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation.
3064018|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab with laser|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
3064019|NCT01003106|Experimental|BRVO- Ranibizumab 2.0mg alone|Branch retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
3064020|NCT01003106|Experimental|BRVO- Pro re nata (prn) ranibizumab|Branch retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
3064021|NCT01003106|Experimental|CRVO- Ranibizumab 0.5mg alone|Central retinal vein occlusion patients randomized to this group will receive 0.5mg of ranibizumab alone as per protocol without laser photocoagulation
3064022|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab with laser|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, and additional laser photocoagulation if required.
3064023|NCT01003106|Experimental|CRVO- Ranibizumab 2.0mg alone|Central retinal vein occlusion patients randomized to this group will receive 2.0mg of ranibizumab alone as per protocol without laser photocoagulation.
3064024|NCT01003106|Experimental|CRVO- Pro re nata (prn) ranibizumab|Central retinal vein occlusion patients randomized to this group will receive 0.5mg/2.0mg of ranibizumab as per protocol, without additional laser photocoagulation.
3064025|NCT01003184|Experimental|1|
3064026|NCT01003184|Active Comparator|2|
3064027|NCT01003210|Experimental|Homeopathic ear drops|Commercially available homeopathic ear drops
3064028|NCT01003210|No Intervention|standard therapy|standard therapy for otitis media, no ear drops
3064029|NCT01003249|Active Comparator|Baclofen, Then Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
3320886|NCT02014558|Experimental|Gilteritinib 80 mg in Escalation Phase|Participants received a single dose of 80 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 80 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3064030|NCT01003249|Placebo Comparator|Placebo, Then Baclofen|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. There will be a washout period after three week. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group. Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg
3064031|NCT01003275|Active Comparator|Paricalcitol followed by placebo|Participants will receive paricalcitol for 8 weeks, then an 8-week wash-out, then placebo for 8 weeks.
3064032|NCT01003275|Active Comparator|Placebo followed by paricalcitol|Participants will receive placebo for 8 weeks, then an 8-week wash-out, then paricalcitol for 8 weeks.
3064033|NCT01003288|Experimental|Pandemic influenza H1N1 vaccine|Influenza vaccine
3064034|NCT01003301|Experimental|Omalizumab|Active treatment: Experimental This arm will receive treatment with omalizumab at the dose FDA-approved for the treatment of allergic asthma.
3064035|NCT01003301|Placebo Comparator|Placebo|This arm will receive treatment with a placebo injections based on the FDA-approved dosing schedule approved for omalizumab for the treatment of allergic asthma.In general injection number and frequency are determined by a subject's weight and IgE level.
3064036|NCT01003418|Experimental|GSK2340272A Group 1|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-28 day schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
3064037|NCT01003418|Experimental|GSK2340272A Group 2|Healthy male or female children, between and including 8 and 12 weeks of age at the time of first vaccination, received 2 primary doses of GSK2340272A vaccine, according to a 0-4 month schedule. Subjects also received routine infant immunisation (Infanrix™-IPV/Hib) and Prevenar™ vaccine at Day 14, Month 3 and Month 10. All vaccines were administered intramuscularly into the anterolateral region of the thigh.
3064038|NCT01003639|Active Comparator|Acetazolamide|Acetazolamide given in escalating doses
3064039|NCT01003639|Placebo Comparator|Sugar pill|"Given in escalating dose (number of pill)"
3064040|NCT01003769|Experimental|Treatment (lenalidomide in combination with AT-101)|Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.
3064041|NCT01003886||Open Label|Adult male diagnosed with BPH and prescribed with Doxazosin mesylate GITS
3064042|NCT01003899|Experimental|afatinib (BIBW 2992)|patient to receive afatinib(BIBW 2992) po QD in an open-label manner
3064043|NCT01003938|Experimental|topotecan and erlotinib|Topotecan 0.4 mg/m^2/day administered via continuous infusion for 9 days beginning on Day 1, every 21 days cycle; erlotinib 150 mg daily for 9 days every 21 days cycle. Both drugs will be given for a minimum of 2 cycles.
3064044|NCT01003990|Experimental|Atazanavir|
3064045|NCT01003990|Experimental|Atazanavir/Ritonavir|
3064046|NCT01003990|Active Comparator|Lopinavir/Ritonavir|Ritonavir-boosted Lopinavir (LPV/RTV 400/100 mg) administered twice a day (BID) with Tenofovir/ Emtricitabine (TDF/FTC).
3064047|NCT01004003|Experimental|BIBF 1120|Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
3064048|NCT01004003|Active Comparator|Sorafenib|
3064049|NCT01004029|Placebo Comparator|Vehicle|Castor Oil
3064050|NCT01004029|Active Comparator|Hydroxyprogesterone Caproate Injection (HPC), 250 mg/mL|HPC 250 mg/mL in oil
3064051|NCT01004042|Active Comparator|Depressed subjects|Diagnosis of depression (diagnostic criteria from DSM-IV-TR and MINI International Neuropsychiatric Interview - Brazilian version 5.0.)They must be using a therapeutic dose of antidepressant for at least 2 months before the intervention prescribed by a psychiatrist.
3064052|NCT01004042|Active Comparator|Non Depressed subjects|Subjects with no diagnosis of depression
3064053|NCT01004107|Experimental|Radiesse Injectable Dermal Filler|Device: Radiesse Injectable Dermal Filler
3064054|NCT01004107|Active Comparator|Delayed Treatment|Cross over to treatment with Radiesse Injectable Dermal Filler at 3 Months
3064055|NCT01004146|Placebo Comparator|Control group|Patients assigned to the control group were educated on the proper technique of using the incentive spirometer and were instructed to use it for 3 breaths once per day to become able to use the device properly and consistently.
3064056|NCT01004146|Experimental|Experimental Group|Patients assigned to the experimental group were instructed to use the spirometer by inhaling as slowly and deeply as possible in a set of 10 times and to repeat the process at least 5 times every day until the day of surgery.
3064057|NCT01004159|Experimental|cetuximab with irinotecan|
3064058|NCT01004172|Experimental|carboplatin, bevacizumab, trastuzumab (if HER2+)|"Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.~carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle~bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle~trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only~*8mg/kg loading dose in cycle 1 for some participants~HER-2: human epidermal growth factor receptor 2"
3064059|NCT01004185|Experimental|High Dose|2.0 - 4.8 g/day Asacol dependent on body weight
3064060|NCT01004185|Experimental|Low Dose|1.2 - 2.4 g/day Asacol dependent upon body weight
3064061|NCT01004250|Experimental|Study Treatment|
3064062|NCT01004263|Experimental|Rizatriptan|Rizatriptan benzoate
3064063|NCT01004354|Experimental|Vitamin D|
3064064|NCT01004393|Experimental|Methylnaltrexone bromide|A single dose of methylnaltrexone will be administered subcutaneously to eligible subjects based on weight at the study entry. Since we will include subjects at all stages of cancer management, administering this study drug is considered experimental. We will use the dose approved by FDA, i.e., 0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg.
3064065|NCT01004406|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent
3064066|NCT01004406|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
3064067|NCT01004432|Experimental|Open-label (OL) Overall Group: Golimumab 50 mg SC + MTX|All enrolled and dosed participants receive golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks + Methotrexate (MTX) from Week 0 to Week 12.
3064068|NCT01004432|Experimental|Double blind (DB) Group 2a: Golimumab 50mg SC & Placebo IV+MTX|Participants, who do not achieve Disease Activity Score in 28 joints (DAS28) good response at Week 16, will be randomly assigned to receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48, along with placebo matched to golimumab intravenous infusion (IV) at Week 16, 20, 28, 36, and 44.
3064069|NCT01004432|Experimental|DB Group 2b: Golimumab 2mg/kg IV & Placebo SC + MTX|Participants, who do not achieve DAS28 good response at Week 16, will be randomly assigned to receive golimumab 2 milligram per kilogram (mg/kg) intravenous infusion (IV) + MTX, at Week 16, 20, 28, 36 and 44, along with placebo matched to golimumab SC injection every 4 weeks from Week 16 to Week 48.
3064070|NCT01004432|Experimental|OL Group 1: Golimumab 50 mg SC + MTX|Participants, who achieve DAS28 good response at Week 16, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 16 to Week 48.
3064071|NCT01004432|Experimental|OL Study Extension Group: Golimumab 50 mg SC + MTX|Participants who complete the main study (Week 0 to Week 52), do not meet lack of efficacy criteria, and participate in the OL study extension, will receive golimumab 50 mg SC injection every 4 weeks + MTX from Week 52 to Week 72.
3064072|NCT01004614|Experimental|Cohort 1|24 subjects (12 subjects per sequence) will receive treatment A) one 5 mg amlodipine 3rd OD tablet (test) with water and treatment B) one 5 mg amlodipine 2nd OD tablet (reference) with water.
3064073|NCT01004614|Active Comparator|Cohort 2|24 subjects (12 subjects per sequence) will receive treatment C) one 5 mg amlodipine 3rd OD tablet (test) without water, and treatment D) one 5 mg amlodipine 2nd OD tablet (reference) without water
3064074|NCT01004705|Experimental|Fixed Dose Combination Pill|Once daily oral dose of combination of acetylsalicylic acid, simvastatin, and ramipril (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 or 10 mg ramipril)
3064075|NCT01004705|Active Comparator|Simvastatin|Once daily oral dose of Simvastatin 40 mg
3064076|NCT01004718|Experimental|Fludeoxyglucose F18 (FDG) PET/CT scans|Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans and 180 minutes after FDG administration.
3064077|NCT01004744|Experimental|Presurgical oral anastrozole|1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.
3064078|NCT01004770|Experimental|1 (AH113111 Injection)|
3064079|NCT01004770|Active Comparator|2 (Visipaque Injection)|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
3064080|NCT01004822|Experimental|Active Drug|Weekly infusions of CVX-241 at specified doses
3064081|NCT01004848|Experimental|Peer-Led Lifestyle Education on Weight Loss|"Project HEED (Help Educate to Eliminate Diabetes), a community-based, peer-led weight loss program for overweight adults with pre-diabetes.~The intervention group will participate in an 8-session course held over a 10-week period. Project HEED (Help Educate to Eliminate Diabetes), led by trained peer educators, aims to help participants lose weight, thereby preventing their progression to diabetes."
3064082|NCT01004848|Placebo Comparator|Delayed Intervention|The control group will be offered the chance to participate in the 8-session course 1 year after enrollment into the trial.
3064084|NCT01004874|Experimental|Bevacizumab, XRT, Temozolomide, Topotecan|Patients are treated with standard radiation therapy and daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation. Following completion of radiation therapy, patients have a MRI and, if there is no evidence of disease progression, patients receive 12 cycles of Avastin, temozolomide, and topotecan. Beginning a minimum of 14 days after the last radiation treatment, the Avastin is dosed at 10 mg/kg every other week; temozolomide is given at 150 mg/m2 daily the first 5 days in combination with topotecan on days 2 through 6 at 1.5 mg/ m2 for patient not taking EIAEDs and 2.0 mg/ m2 for patients taking EIAEDs on days 2-6 of each 28-day.
3064085|NCT01004939||fondaparinux prescribed subjects|fondaparinux prescribed subjets
3064086|NCT01004991|Experimental|All patients|subjects will receive azacytidine dose dependent on dose-escalation schedule at time of enrollment - all will receive standard dose RCHOP
3064087|NCT01005251|Experimental|60 mg|PPI+lesogaberan (AZD3355) 60 mg bid
3064088|NCT01005251|Experimental|120 mg|PPI+lesogaberan (AZD3355) 120 mg bid
3064089|NCT01005251|Experimental|180 mg|PPI+lesogaberan (AZD3355) 180 mg bid
3064090|NCT01005251|Experimental|240 mg|PPI+lesogaberan (AZD3355) 240 mg bid
3064091|NCT01005251|Placebo Comparator|Placebo|PPI+ Placebo
3064092|NCT01005290|Experimental|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
3064093|NCT01005290|Active Comparator|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
3064094|NCT01005316||Cohort A: Non-Sensitized|"Cohort A will include participants who are alloantibody Luminex(TM) LABScreen. There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen. Non-sensitized recipients receive steroid-free maintenance immunosuppression:~Induction Therapy (anti-T cell antibody induction)~Tacrolimus (Prograf®)~Mycophenolate Mofetil- MMF (CellCept®)."
3320887|NCT02014558|Experimental|Gilteritinib 120 mg in Escalation Phase|Participants received a single dose of 120 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 120 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3064095|NCT01005316||Cohort B: Sensitized|"Cohort B will include participants who are alloantibody positive (Sensitized) as determined by Luminex LabScreen for Class I or Class II with specificities identified by single antigen testing.~There is no study mandated care or treatment. All care given is clinical site standard of care. All sites follow a similar standard of care regimen.~Sensitized recipients receive:~Induction Therapy (anti-T cell antibody induction)~Intraoperative plasma exchange/pheresis~Short-term post-operative plasmapheresis~Post-transplant course of intravenous immunoglobulin (IVIG) therapy~Maintenance corticosteroids (Prednisone)~Tacrolimus (Prograf®)~Mycophenolate Mofetil-MMF (CellCept®)."
3064096|NCT01005329|Experimental|Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel)|Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3064097|NCT01005355|Experimental|IMC-1121B|Participants receiving IMC-1121B intravenously
3064098|NCT01005407|Experimental|HEPLISAV and/or Placebo|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
3064099|NCT01005407|Active Comparator|Engerix-B(1)|1.0 mL Engerix-B
3064100|NCT01005459|Active Comparator|tetracaine 2mg|
3064101|NCT01005459|Active Comparator|Bupivacaine 2 mg|
3064102|NCT01005576|Experimental|Conditioning regimen|Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
3064103|NCT01005602|Experimental|Digoxin Dosing per Nomogram|Subjects will have their digoxin maintenance dose determined according to the nomogram we have developed.
3064104|NCT01005602|Other|Standard Digoxin Dosing|This arm represents historical control subjects in whom the dose of digoxin was determined at the physician's discretion using traditional dosing methods.
3064105|NCT01005680|Experimental|Pemetrexed plus Cisplatin|
3064106|NCT01005680|Active Comparator|Gemcitabine plus Cisplatin|
3064107|NCT01005706|Active Comparator|Tacrolimus Withdrawal Arm|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
3064108|NCT01005706|Active Comparator|Tacrolimus Minimization Arm|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
3064109|NCT01005719|Experimental|Zegerid|Participants receiving Zegerid (omeprazole/sodium bicarbonate) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
3064110|NCT01005719|Active Comparator|Prevacid®|Participants receiving Prevacid® (lansoprazole) in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants also took approximately 2 oz of water with their medication.
3064111|NCT01005719|No Intervention|No treatment|Participants receiving No treatment in Periods 1, 2 or 3. All participants were randomized to a 3-way crossover design and received Zegerid Capsules (20 mg omeprazole/ 1100 mg sodium bicarbonate), Prevacid Capsules (15 mg lansoprazole), or no treatment in a random order. All participants took approximately 2 oz of water once daily for 7 days.
3064112|NCT01005745|Experimental|TIL With High Dose IL-2|"Day -7 and -6: Cyclophosphamide 60 mg/kg/day I.V. in 250 ml NS over approximately 2 hours. Mesna 20 mg/kg with D5W or NS at 125 ml/hour infused intravenously over 24 hours.~Day -5 to Day -1: Fludarabine 25 mg/m^2 intravenous piggyback (IVPB0 daily over approximately 30 minutes for 5 days.~Day 0: T cell infusion in 250-1000 ml NS over approximately 15-60 minutes depending on volume to be infused.~Days 1-5: High dose IL-2, 720,000 IU/kg IV bolus (about 15 minutes) every 8-16 hours for up to 15 doses, beginning approximately 12-16 hours after T cell infusion."
3064113|NCT01005810|Active Comparator|N-Acetylcysteine|
3064114|NCT01005810|Placebo Comparator|Placebo|
3064115|NCT01005875|Experimental|Radiation followed by Sorafenib|Radiation therapy, stereotactic body radiation therapy followed by Sorafenib
3064116|NCT01005888|Experimental|C1INH-nf First, then Placebo|1,000 Units (U) of C1INH-nf administered intravenously (IV) every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by matching placebo (saline) administered IV every 3 to 4 days for 12 weeks.
3064117|NCT01005888|Experimental|Placebo First, then C1INH-nf|Matching placebo (saline) administered IV every 3 to 4 days (approximately twice weekly) for 12 weeks, followed by 1,000 U of C1INH-nf administered IV every 3 to 4 days for 12 weeks.
3064118|NCT01005901|Experimental|Glycopyrronium bromide|Glycopyrronium bromide 50µg delivered once daily via Single Dose Dry Powder Inhaler (SDDPI). At visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
3064119|NCT01005901|Placebo Comparator|Placebo|Placebo delivered once daily via SDDPI. At Visit 1 all patients were provided with a short acting β2-agonist (salbutamol/albuterol) which they were instructed to use throughout the study as rescue medication.
3064120|NCT01005966|Other|Run in|Placebo
3064121|NCT01005966|Experimental|Sodium Fluoride Toothpaste|Sodium fluoride toothpaste
3064122|NCT01005966|Active Comparator|Amine Fluoride Toothpaste|Amine Fluoride
3064123|NCT01005966|Other|675ppmf toothpaste|Dose response
3064124|NCT01005966|Active Comparator|Sodium monofluorophosphate/sodium fluoride Toothpaste|Sodium monofluorophosphate/sodium fluoride Toothpaste
3064125|NCT01005966|Placebo Comparator|0 ppmf toothpaste|
3064126|NCT01006122|Placebo Comparator|Placebo|
3064127|NCT01006122|Active Comparator|PF-03654746|At the end of the second arm of the study, the patient will have completed the study and have a 7-10 day follow-up visit.
3064128|NCT01006135||COPD patients|
3064129|NCT01006252|Experimental|Tasisulam-sodium|Individualized tasisulam-sodium dose was dependent on participant's height, weight, and gender. Dose was adjusted based on laboratory parameters. Treatment was administered intravenously on Day 1 of a 28-day cycle, until disease progression.
3064130|NCT01006252|Active Comparator|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m^2) administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
3064131|NCT01006265|Experimental|ACT-128800 Dose 1|ACT-128800 Dose 1
3064132|NCT01006265|Experimental|ACT-128800 Dose 2|ACT-128800 Dose 2
3064133|NCT01006265|Experimental|ACT-128800 Dose 3|ACT-128800 Dose 3
3064134|NCT01006265|Placebo Comparator|Placebo|Matching placebo
3064135|NCT01006291|Experimental|IDeg OD FF|
3064136|NCT01006291|Experimental|IDeg OD|
3064137|NCT01006291|Experimental|IGlar OD|
3064138|NCT01006356|Experimental|Hydromorphone hydrochloride (HCl) oral osmotic system (OROS)|Hydromorphone HCl OROS 8 milligram (mg) once daily for 2 weeks.
3064139|NCT01006369|Experimental|FOLFOX6 + Bevacizumab + Hydroxychloroquine|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
3064140|NCT01006369|Experimental|XELOX + Bevacizumab + Hydroxychloroquine|"Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days.~Drug: hydroxychloroquine hydroxychloroquine 200 mg po BID daily"
3064141|NCT01006538|Experimental|Arm A (treatment)|Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.
3064142|NCT01006538|Active Comparator|Arm B (control):|Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.
3064143|NCT01006590|Experimental|1|Saxagliptin 5 mg
3064144|NCT01006590|Active Comparator|2|Metformin 500 -1000 mg
3064145|NCT01006603|Experimental|1|Saxagliptin 5 mg
3064146|NCT01006603|Active Comparator|2|Glimepiride 1 - 6 mg
3064147|NCT01006616|Experimental|Navarixin 10 mg|Participants receive navarixin 10 mg, as one navarixin 10 mg capsule and two placebo capsules, administered orally once daily (QD) for up to 2 years
3064148|NCT01006616|Experimental|Navarixin 30 mg|Participants receive navarixin 30 mg, as one navarixin 30 mg capsule and two placebo capsules, administered orally QD for up to 2 years
3064149|NCT01006616|Experimental|Navarixin 50 mg|Participants receive navarixin 50 mg, as two navarixin 10 mg capsules and one navarixin 30 mg capsule, administered orally QD for up to 2 years
3064150|NCT01006616|Placebo Comparator|Placebo|Participants receive placebo to navarixin, as three placebo capsules, administered orally QD for up to 2 years
3064151|NCT01006629|Experimental|palivizumab|palivizumab 15 mg/kg intramuscularly every 30 days for 3 to 5 injections
3064152|NCT01006655|Placebo Comparator|placebo, adenosine challenge test|Controlled or partially controlled multiple trigger wheezing children received 4 weeks of placebo, preceded and succeeded by AMP challenge test,
3064153|NCT01006655|Active Comparator|Qvar, adenosine challenge test|Patients will receive 4 weeks of inhale QVAR (HFA beclomethasone) 100µg through a spacer device, twice a day
3064154|NCT01006707|Other|Ondansetron, then Placebo|Some participants received ondansetron pretreatment during the second session, and then placebo during the third session.
3064155|NCT01006707|Other|Placebo, then Ondansetron|Some participants received placebo pretreatment during the second session, and then ondansetron pretreatment during the third session.
3064156|NCT01006889|Experimental|Exenatide (twice daily)|Patients with T2DM well-controlled on an intensified insulin regimen for the previous 6 months by the will have their insulin aspart discontinued and replaced for exenatide twice daily while continuing the bedtime detemir insulin. Safety and efficacy parameters will be measured before and after 6 months of treatment.
3064157|NCT01006967|Active Comparator|ActiveStep|Subjects will use the ActiveStep treadmill as part of their physical therapy program for balance
3064158|NCT01006967|Active Comparator|Standard physical therapy|Subjects will receive a standard physical therapy program for gait and balance.
3064159|NCT01006980|Experimental|Vemurafenib|
3064160|NCT01006980|Active Comparator|Dacarbazine|
3064161|NCT01007032|Experimental|Cixutumumab|Participants receive IV cixutumumab every 2 or 3 weeks. A cycle equals 6 weeks, with radiological evaluation of tumor response after each cycle. After 1st cycle, pts with a complete response (CR), PR, or SD continue to receive cixutumumab cohort dose and schedule disease progression. 3 pts enroll in each cohort. Starting dose in Cohort 1 is 6 mg/kg every 2 weeks. Dose escalation from Cohort 1 to Cohort 2 (10 mg/kg every 2 weeks) occurs at least 3 pts in Cohort 1 completes 1 cycle of therapy. Enrollment into Cohort 3 (starting dose: 15 mg/kg administered every 3 weeks) will not proceed until at least 3 pts have completed one cycle of therapy in Cohort 2. Pts enroll in Cohort 4 once at least 3 pts have completed once cycle of therapy in Cohort 3; pts in Cohort 4 receive 20 mg/kg every 3 weeks.
3064162|NCT01007071|Experimental|Growth hormone|Subjects randomized to growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Dose adjustments based on serum insulin-like growth factor-1 (IGF-1) levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 standard deviation (SD) to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
3064163|NCT01007071|Placebo Comparator|Placebo|Subjects randomized to placebo for 16 weeks. As noted above, placebo subjects will be initiated on a daily subcutaneous injection, with dose changes based on changes in active drug subjects.
3064164|NCT01007110|Active Comparator|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA)
3064165|NCT01007110|Placebo Comparator|Placebo|soy/corn oil placebo
3064166|NCT01007123|Experimental|A3309 low dose|Administered once daily for the duration of the study
3064167|NCT01007123|Experimental|A3309 intermediate dose|Administered once daily for the duration of the study.
3064168|NCT01007123|Experimental|A3309 high dose|Administered once daily for the duration of the study
3064169|NCT01007123|Placebo Comparator|Placebo|Administered once daily for the duration of the study
3064170|NCT01007136|Experimental|tDCS and occupational therapy|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
3064171|NCT01007136|Sham Comparator|Sham and occupational therapy|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
3064172|NCT01007149|Experimental|Omalizumab|Participants received subcutaneous injections of omalizumab every 2 weeks or every 4 weeks; dosage dependent on IgE level and body weight.
3064173|NCT01007149|Placebo Comparator|Placebo|Participants received subcutaneous injections of placebo to omalizumab every 2 weeks or every 4 weeks.
3064174|NCT01007253|Other|FF/PL, PL/OLO, FF/OLO, PL/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO), and~placebo (PL) nasal spray and PL eye drops (PL/PL)."
3064175|NCT01007253|Other|PL/OLO, FF/OLO, PL/PL, FF/PL|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO),~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL), and~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL)."
3064176|NCT01007253|Other|FF/OLO, PL/PL, FF/PL, PL/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO),~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL), and~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO)."
3064177|NCT01007253|Other|PL/PL, FF/PL, PL/OLO, FF/OLO|"Each subject received a total of 4 weeks of treatment (1 week per treatment with 2 week washout period between treatments) in the following order:~placebo (PL) nasal spray and PL eye drops (PL/PL),~fluticasone furoate (FF) nasal spray and PL eye drops (FF/PL),~PL nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (PL/OLO), and~FF nasal spray and olopatadine (OLO) 0.2% ophthalmic solution (FF/OLO)."
3064178|NCT01007396|Other|new healthcare workers|doctors and nurses who were newly hired in 2008 at the Samsung Medical Center
3064179|NCT01007435|Experimental|(A) Tocilizumab 8 mg/kg + placebo to methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + placebo to methotrexate orally once a week for 104 weeks.
3064180|NCT01007435|Experimental|(B) Tocilizumab 8 mg/kg + methotrexate|Patients received tocilizumab 8 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
3064181|NCT01007435|Experimental|(C) Tocilizumab 4 mg/kg + methotrexate|Patients received tocilizumab 4 mg/kg iv every 4 weeks + methotrexate orally once a week for 104 weeks.
3064182|NCT01007435|Active Comparator|(D) Placebo to tocilizumab + methotrexate|Patients received placebo tocilizumab intravenously (iv) every 4 weeks + methotrexate orally once a week for 104 weeks.
3064183|NCT01007448|Experimental|Bexarotene 150 milligrams (mg)/square meter (m^2)/day|Participants will receive bexarotene 150 mg/m^2/day once daily for 24 weeks.
3064184|NCT01007448|Experimental|Bexarotene 300 mg/m^2/day|Participants will receive bexarotene 300 mg/m^2/day once daily for 24 weeks.
3064185|NCT01007526|Experimental|CCRT plus VIDL|CCRT followed by VIDL chemotherapy Concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation Patients who are planned to be treated with CCRT plus VIDL chemotherapy and/or autologous stem cell transplantation
3064186|NCT01007552|Experimental|Gemcitabine, Capecitabine and Bevacizumab|Estimate the toxicity of the regimen, and estimate the quality of life (QOL).
3064187|NCT01007591|Active Comparator|LEO 80190 ointment|
3064188|NCT01007591|Active Comparator|Hydrocortisone 10 mg/g ointment|
3064189|NCT01007643|Experimental|Wii Fit (TM) Interactive Video Game|Wii Fit (TM) Interactive Video Game
3064190|NCT01007643|Active Comparator|Traditional Home Exercise Program|Traditional Home Exercise Program
3064191|NCT01007656|Experimental|GD Antrodia camphorata|"GD Antrodia Camphorata is the extract from mycelium of the fungus Antrodia Camphorata which is an endemic species in Taiwan. According to the literatures, mycelium of Antrodia camphorata is beneficial to health. Moreover, the study product GD Antrodia Camphorata has been approved by Department of Health, Taiwan as a health supplement (approval number A00124)."
3064192|NCT01007812|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week, followed by Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week.
3064193|NCT01007812|Other|Comfilcon A / Lotrafilcon B|Comfilcon A silicone hydrogel, toric, soft contact lenses worn for one week, followed by Lotrafilcon B silicone hydrogel, toric, soft contact lenses worn for one week.
3064194|NCT01007838|Experimental|Chronic kidney disease progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
3064195|NCT01007838|Sham Comparator|Chronic kidney disease sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
3064196|NCT01007838|Experimental|Healthy controls progressive resistance training group|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
3064197|NCT01007838|Sham Comparator|Healthy controls sham exercise group|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
3064198|NCT01007916|Other|Lotrafilcon B / Habitual|Lotrafilcon B contact lenses worn first, with habitual contact lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
3064199|NCT01007916|Other|Habitual / Lotrafilcon B|Habitual contact lenses worn first, with lotrafilcon B lenses worn second. Both products worn bilaterally as often as is typical for habitual lenses, and in the same modality as is typical for habitual lenses, as prescribed by regular eye care practitioner, with extended wear not to exceed 6 nights.
3064200|NCT01007942|Experimental|Everolimus + vinorelbine + trastuzumab|Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
3064201|NCT01007942|Placebo Comparator|placebo + vinorelbine + trastuzumab|Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only
3064202|NCT01007994|Active Comparator|New Medication|A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.
3064203|NCT01007994|No Intervention|Control|Subjects in the control group will continue to take their medications as usual.
3064204|NCT01008059|Experimental|Alfentanil|Alfentanil (0.5-1 mg IV bolus) followed 3 hours later or simultaneously by 1-4 mg oral deuterium-labeled (d3) alfentanil on each study visit.
3064205|NCT01008150|Active Comparator|Arm 1: paclitaxel + trastuzumab then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Trastuzumab concurrently with paclitaxel weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Following paclitaxel/trastuzumab, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3064206|NCT01008150|Experimental|Arm 2: paclitaxel + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on Days 1, 8, and 15 of a 28-day cycle. Neratinib 240 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3064207|NCT01008150|Experimental|Arm 3: paclitaxel + trastuzumab + neratinib then A C|4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3064208|NCT01008150|Experimental|Arm 3 NR: paclitaxel+trastuzumab+neratinib|Non-randomized: 4 cycles of paclitaxel 80 mg/m2 on days 1, 8, and 15 of a 28 day cycle. Trastuzumab concurrently with paclitaxel, weekly for a total of 16 doses (4 mg/kg loading dose, then 2 mg/kg weekly). Neratinib 200 mg orally once daily beginning on Day 1 of paclitaxel and continuing through Day 28 of the final cycle of paclitaxel. Following paclitaxel/trastuzumab/neratinib therapy, standard AC every 21 days for 4 cycles. Following surgery, trastuzumab (8 mg/kg loading dose, then 6 mg/kg) every 3 weeks to complete 1 year of targeted therapy (either preoperative trastuzumab therapy or neratinib therapy)
3064209|NCT01008280|Experimental|Baclofen|baclofen 10 mg po tid
3064210|NCT01008280|Placebo Comparator|Placebo|placebo given tid
3064211|NCT01008319|Active Comparator|Traditional Administration|The traditional approach to ovulation induction with clomiphene citrate involves administration of 50mg/day for five days (starting on cycle day 3, 4, or 5). If ovulation does not occur then a progestin is prescribed to induce menses (which occurs within one week of stopping the progestin) and then a higher dose of medication is used in the next cycle.
3064212|NCT01008319|Experimental|Stair-Step Administration|The stair-step protocol the dose of clomiphene citrate would be increased without administering progestin and inducing a period. This would eliminate the days of progestin (10 days) and the waiting for the period (usually 3 to 7 days) and finally waiting to start clomiphene citrate on cycle day 3 at the earliest (3 more days) for a total of up to 20 days difference for the 100 mg dose of clomid. If they did not ovulate on 100mg, then the process repeats and another 20 days before they start 150mg. Therefore, the time to ovulation and pregnancy may be reduced, and hopefully pregnancy, by using the stair-step protocol. This method utilizes ultrasound monitoring for follicle development before increasing the dose of clomiphene citrate.
3064213|NCT01008410|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
3064214|NCT01008410|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
3064215|NCT01008423|Experimental|Budesonide|Participants who were diagnosed with active mild to moderate UP or UPS, will receive 2 milligrams (mg)/25 milliliter (mL) of budesonide foam, rectally twice daily for a period of 2 weeks followed by 2 mg/25 mL of budesonide foam, rectally once daily for a period of 4 weeks.
3064216|NCT01008423|Placebo Comparator|Placebo|Participants who were diagnosed with active mild to moderate UP or UPS will receive 25 mL of placebo matching to budesonide foam twice daily for a period of 2 weeks followed by once daily for a period of 4 weeks.
3064217|NCT01008449|Active Comparator|Absorbable Subcuticular Surgical Suture|Patients in this arm will receive absorbable subcuticular suture for wound closure of cesarean deliveries.
3064218|NCT01008449|Active Comparator|Surgical staples|Patients in this arm will receive surgical staples for wound closure.
3064219|NCT01008462|Experimental|Treatment (autologous HCT, donor HCT)|See Detailed Description
3064220|NCT01008475|Experimental|Safety part: EMD 525797 250 mg + Standard of Care (SoC)|EMD 525797 250 mg in combination with cetuximab and irinotecan
3064221|NCT01008475|Experimental|Safety part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
3064222|NCT01008475|Experimental|Safety part: EMD 525797 750 mg + SoC|EMD 525797 750 mg in combination with cetuximab and irinotecan
3064223|NCT01008475|Experimental|Safety part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg in combination with cetuximab and irinotecan
3064224|NCT01008475|Experimental|Randomized part: EMD 525797 500 mg + SoC|EMD 525797 500 mg in combination with cetuximab and irinotecan
3064225|NCT01008475|Experimental|Randomized Part: EMD 525797 1000 mg + SoC|EMD 525797 1000 mg (or dose as defined by safety monitoring committee (SMC)] in combination with cetuximab and irinotecan.
3064226|NCT01008475|Other|Randomized Part: SoC|Cetuximab and irinotecan
3064227|NCT01008553|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will continue for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
3064228|NCT01008553|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
3064229|NCT01008553|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
3064230|NCT01008605|Experimental|Caverject Impulse|representative users
3064231|NCT01008618|Experimental|Fentanyl (Titration period)|One-day adhesive transdermal patch containing fentanyl (JNS020QD) applied to chest, abdomen, upper arm and thigh and replaced every day, starting at the dose of 12.5 microgram per hour (mcg/hr) for at least first 2 days, which will be increased by 12.5 mcg/hr at one time based on the medical examination of number of rescue treatments and visual analog scale (VAS) score of the participants. The dose will be increased up to maximum of 50 mcg/hr. The treatment will be continued for 10-29 days and then the eligible participants from this group will be randomly assigned to either of the two groups in the double-blind period.
3064232|NCT01008618|Experimental|Fentanyl (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to fentanyl group, will be administered one-day adhesive transdermal patch containing fentanyl, applied to chest, abdomen, upper arm and thigh and replaced every day, the dose of which will be same as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will be continued for 12 weeks.
3064233|NCT01008618|Placebo Comparator|Placebo (Double-blind period)|Participants meeting the pre-defined criteria for transfer from titration period to double-blind period and randomly assigned to placebo group, will be administered one-day adhesive transdermal placebo patch indistinguishable from fentanyl in appearance, applied to chest, abdomen, upper arm and thigh and replaced every day. The dose of fentanyl (from titration period) will be gradually decreased to prevent withdrawal symptoms and the dose of the matching placebo will be gradually increased up to same dose as the final application dose in the titration period (in the range of 12.5 to 50 mcg/hr). The treatment will continue for 12 weeks.
3064234|NCT01008696|Experimental|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
3064235|NCT01008696|Active Comparator|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
3064236|NCT01008748|Experimental|Smoking Cessation Treatment|Nicotine replacement therapy (NRT), self-help materials, + brief in-person and telephone counseling, all conducted in Spanish. Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
3064237|NCT01008904|Experimental|Supportive care (magnesium oxide)|Patients receive magnesium oxide by mouth daily or twice daily for 4 weeks.
3064238|NCT01008943|Experimental|1|
3064239|NCT01008995|Experimental|001|placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16
3064240|NCT01008995|Experimental|002|placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16
3064241|NCT01009034||12 male HIV-positive patients|Male HIV-positive patients who have been receiving stable antiretroviral therapy that includes maraviroc for a minimum of three months.
3064242|NCT01009047|Experimental|Paliperidone extended-release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
3064243|NCT01009047|Active Comparator|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
3064244|NCT01009060|Experimental|GSK239512|Repeat dose.
3064245|NCT01009060|Placebo Comparator|Placebo|Repeat dose. Placebo to match GSK239512
3064246|NCT01009086|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 88. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
3064247|NCT01009086|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 88. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3064248|NCT01009086|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 88. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3064249|NCT01009099|Experimental|Arm 1|exercise training with breathing retraining
3064250|NCT01009099|Active Comparator|Arm 2|exercise training
3064251|NCT01009138|Experimental|Diabetes-Specific CBT (DS-CBT)|Cognitive Behavioral Intervention (Group) focusing on Diabetes-Specific Problems
3064252|NCT01009138|Active Comparator|Standard Diabetes Education|Standard Diabetes Education Lessons will be given to quantify the unspecific antidepressive Effects of Participation in Group Sessions with social Contact and Acquisition of Knowledge.
3064253|NCT01009203|Experimental|Temsirolimus and Erlotinib|Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
3064254|NCT01009281|Experimental|AIN457|
3320888|NCT02014558|Experimental|Gilteritinib 200 mg in Escalation Phase|Participants received a single dose of 200 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 200 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3064256|NCT01009333|Experimental|Low InterStim rate setting at 5.2 Hz|
3064257|NCT01009333|Experimental|Medium InterStim rate setting at 14 Hz|
3064258|NCT01009333|Experimental|High InterStim rate setting at 25 Hz|
3064259|NCT01009346|Experimental|RAD001|Daily RAD001 in combination with weekly cetuximab and cisplatin/ carboplatin on Day 1, 8 of each 28 day cycle.
3064260|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064261|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064262|NCT01009463|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064263|NCT01009463|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
3064264|NCT01009515|Experimental|Chemotherapy Combination|Chemotherapy Combination of paclitaxel, carboplatin, temozolomide: Carboplatin at an AUC of 5 on Day 1, paclitaxel at 175 mg/m2 on Day 1, and temozolomide at 125 mg/m2 Day 2-Day 6, on a 28 day cycle.
3064265|NCT01009554|Experimental|Potassium Oxylate|1.5% potassium oxalate sensitive mouthwash
3064266|NCT01009554|Active Comparator|Sodium Fluoride|Sodium Fluoride Dentifrice
3064267|NCT01009580|Experimental|IDegAsp BID|
3064268|NCT01009580|Experimental|BIAsp 30 BID|
3064269|NCT01009619|Experimental|Azithromycin|250 mg daily for 5 days, followed by 250 mg three times a week (Mon.-Wed.-Fri.) until the end of study
3064270|NCT01009619|Placebo Comparator|Placebo|PLacebo daily for 5 days, followed by placebo three times a week (Mon.-Wed.-Fri.) until end of study.
3064271|NCT01009645|Experimental|Fact Only|The educational message used will contain facts only.
3064272|NCT01009645|Experimental|Fact and Myth|The educational material seen by this arm will contain facts and myths only.
3064273|NCT01009645|Experimental|Fact, Myth, Why|The educational material seen by this arm will contain myths, facts, and refutations of the myths.
3064274|NCT01009645|Placebo Comparator|Control|This arm will receive fact/myth educational materials originally developed and used by the CDC.
3064275|NCT01009762|Placebo Comparator|Saline|Sterile saline for injection is used as placebo arm. It is administered i.m. in the same way as for the active vaccine, week 0, 2, 4, 8.
3064276|NCT01009762|Active Comparator|AFO-18 vaccine|the intervention is injection of the experimental therapeutic peptide vaccine (AFO-18) consisting of 18 peptides in CAF01 adjuvant intra muscularly (i.m.) week 0, 2, 4, 8
3064277|NCT01009814|Experimental|BMS-663068 600 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 600 milligram (mg) and Ritonavir (RTV) 100 mg every 12 hours (Q12H) from Day 1 to Day 8.
3064278|NCT01009814|Experimental|BMS-663068 1200 mg QHS + RTV 100 mg QHS|All participants received BMS-663068 1200 mg and RTV 100 mg every night (quaque hora somni [QHS]) from Day 1 to Day 8.
3064279|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg Q12H|All participants received BMS-663068 1200 mg and RTV 100 mg Q12H from Day 1 to Day 8.
3064280|NCT01009814|Experimental|BMS-663068 1200 mg Q12H + RTV 100 mg QAM|All participants received BMS-663068 1200 mg Q12H and RTV 100 mg every 24 hours in the morning (quaque ante meridiem [QAM]) from Day 1 to Day 8.
3064281|NCT01009814|Experimental|BMS-663068 1200 mg Q12H|All participants received BMS-663068 1200 mg Q12H from Day 1 to Day 8.
3064282|NCT01009840|Experimental|IV busulfan|Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.
3064283|NCT01009918|Experimental|Arm I lisinopril|Patients receive oral lisinopril once daily.
3064284|NCT01009918|Experimental|Arm II Coreg CR®|Patients receive oral Coreg CR® once daily.
3064285|NCT01009918|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily.
3064286|NCT01009983|Experimental|Arm 1|Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.
3064287|NCT01010009|Experimental|Resveratrol 250mg|
3064288|NCT01010009|Experimental|Resveratrol 500mg|
3064289|NCT01010009|Placebo Comparator|Placebo|
3064290|NCT01010061|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3064291|NCT01010061|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3064292|NCT01010061|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3064293|NCT01010126|Experimental|Treatment (temsirolimus, bevacizumab)|Patients receive temsirolimus IV on days 1, 8, 15, and 22, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3064294|NCT01010204|Experimental|Varenicline|We will be comparing Varenicline to placebo in a double-blind placebo controlled, randomized study.
3064295|NCT01010204|Placebo Comparator|Placebo|We will be using placebo in a randomized, controlled, and blinded trial to compare to varenicline in subjects with bipolar disorder.
3064296|NCT01010217|Experimental|Haploidentical related|Arm 1 - Stem Cell Transplantation (SCT), Melphalan 140 mg/m^2 , Thiotepa 5 mg/kg, Fludarabine 40 mg/m^2 + high-dose post-transplant cyclophosphamide 50 mg/kg/day
3064297|NCT01010217|Experimental|1 Antigen Mismatch Related or Unrelated|Arm 2 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide.
3064298|NCT01010217|Experimental|Matched Unrelated Donor (MUD)|Arm 3 - SCT, Melphalan, Thiotepa, Fludarabine + high-dose post-transplant cyclophosphamide
3064299|NCT01010230|Placebo Comparator|LMHF mechanical stimulation placebo device|The placebo device is identical in appearance and function to the active platform; except when activated, it emits the same sound as the active device but does not deliver the vibration.
3064300|NCT01010230|Active Comparator|LMHF mechanical stimulation|"Low magnitude, high frequency mechanical stimulation device (vibrating) platform"
3064301|NCT01010282|Active Comparator|Glycerin and Polysorbate 80 based artificial tear|Glycerin and Polysorbate 80 based artificial tear
3064302|NCT01010282|Experimental|Artificial Tears Formulation 1|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear
3064303|NCT01010282|Experimental|Artificial Tears Formulation 2|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
3064304|NCT01010399|Experimental|Boosted Lexiva with Lovaza|
3064305|NCT01010477|Experimental|Nicotine Nasal Spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. . Nasal spray will be used from the TQD through the end of Week 20.
3064306|NCT01010477|Placebo Comparator|Placebo nasal spray|Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Subjects will be instructed to use the nasal spray at a minimum of 8 doses each day and up to a maximum of 5 doses per hour and 40 doses in 24 hours starting on the TQD. Nasal spray will be used from the TQD through the end of Week 20.
3064307|NCT01010503|Experimental|Single Arm|
3064308|NCT01010555|Active Comparator|lotrafilcon B|Lotrafilcon B contact lens randomly assigned to one eye, with balafilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3064309|NCT01010555|Active Comparator|balafilcon A|Balafilcon A contact lens randomly assigned to one eye, with lotrafilcon B contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear senofilcon A contact lens randomly assigned to one eye and enfilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3064310|NCT01010555|Active Comparator|senofilcon A|Senofilcon A contact lens randomly assigned to one eye, with enfilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3064311|NCT01010555|Active Comparator|enfilcon A|Enfilcon A contact lens randomly assigned to one eye, with senofilcon A contact lens assigned to the fellow eye for contralateral wear. Both products to be worn on a daily wear basis for 4 weeks, after which participant will wear lotrafilcon B contact lens randomly assigned to one eye and balafilcon A contact lens in the fellow eye for an additional 4 weeks of daily wear.
3064312|NCT01010568|Experimental|Ofatumumab and Bendamustine|Ofatumumab and Bendamustine
3064313|NCT01010633|Experimental|Loteprednol Etabonate|Loteprednol etabonate
3064314|NCT01010633|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate
3064315|NCT01010750|Active Comparator|LDX + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
3064316|NCT01010750|Active Comparator|MAS-IR + LDX Placebo|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
3064317|NCT01010750|Placebo Comparator|Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
3064318|NCT01010763|Experimental|M2a Magnum|Total HIp Arthroplasty using with the M2a Magnum Large Metal Articulation is an ultra-high performance metal-on-metal articulation with a big ball (greater than or equal to 38mm) in acetabulums as small as 44mm.
3064319|NCT01010763|Active Comparator|M2a Taper|Total Hip Arthroplasty using with the M2a Taper Acetabular System consists of a titanium outer shell with cobalt chromium (Co-Cr-Mo) metallic liner, which articulates with with a cobalt chromium (Co-Cr-Mo) modular femoral head.
3064320|NCT01010776|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 milligram (mg) will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
3064321|NCT01010854|Experimental|VPA FEC100|Valproic Acid with FEC100
3064322|NCT01010867|Experimental|Lactobacillus plantarum|There is a single intervention arm in this study. Target accrual for the intervention is 30 subjects. Subjects receive supplementation with Lactobacillus plantarum strains 299 and 299v.
3064323|NCT01010906|Experimental|Mild Hepatic Insufficiency (HI)|Participants with mild hepatic insufficiency (HI) administered a single 300 mg oral tablet of vaniprevir
3064324|NCT01010906|Experimental|Healthy Control to Mild HI|Healthy, matched to mild HI, control participants administered a single 300 mg oral tablet of vaniprevir
3064325|NCT01010906|Experimental|Moderate HI|Participants with moderate HI administered a single 300 mg oral tablet of vaniprevir
3064326|NCT01010906|Experimental|Healthy Control to Moderate HI|Healthy, matched to moderate HI, control participants administered a single 300 mg oral tablet of vaniprevir
3064327|NCT01010906|Experimental|Severe HI|Participants with severe HI administered a single 200 mg oral tablet of vaniprevir
3064328|NCT01010906|Experimental|Healthy Control to Severe HI|Healthy, matched to severe HI, control participants administered a single 200 mg oral tablet of vaniprevir
3064329|NCT01010932|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
3064330|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 160 μg|160 μg once daily
3064331|NCT01010971|Experimental|Ciclesonide HFA Nasal Aerosol 80 μg|80 μg once daily
3064332|NCT01010971|Placebo Comparator|Placebo|Placebo
3064333|NCT01010984|Experimental|Transcatheter Arterial Chemoembolization|TACE using LC beads loaded with Doxorubicin
3064334|NCT01011049|Experimental|Group 1: Fluzone ID After Fluzone ID|Participants will receive Fluzone intradermal (ID) following Fluzone ID in Study FID31
3064335|NCT01011049|Experimental|Group 2: Fluzone IM After Fluzone ID|Participants will receive Fluzone intramuscular (IM) following Fluzone ID in Study FID31
3064336|NCT01011049|Experimental|Group 3: Fluzone IM After Fluzone IM|Participants will receive Fluzone intramuscular (IM) following Fluzone IM in Study FID31
3064337|NCT01011049|Experimental|Group 4: Fluzone ID After Fluzone IM|Participants will receive Fluzone intradermal (ID) following Fluzone intramuscular (IM) in Study FID31
3064338|NCT01011075|Experimental|Imatinib mesylate + Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses bracketing each paclitaxel infusion (days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
3064339|NCT01011153||All Dermatologists|
3064340|NCT01011179|Experimental|Internet-based JIA Self-Management Program|
3064341|NCT01011179|Active Comparator|Attention Control Group|
3064342|NCT01011218|Experimental|BBT-I + Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~Armodafinil 150 mg/day by mouth."
3064343|NCT01011218|Experimental|Behavioral placebo + Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~Armodafinil 150 mg/day by mouth."
3064344|NCT01011218|Sham Comparator|BBT-I without Armodafinil|"Two Brief Behavioral Therapy for Insomnia (BBT-I) sessions in person and additional brief BBT-I sessions over the phone.~No pharmaceutical intervention."
3064345|NCT01011218|Placebo Comparator|Behavioral placebo without Armodafinil|"Control behavioral intervention is a sleep hygiene handout completed by participant.~No pharmaceutical intervention."
3064346|NCT01011283|Active Comparator|1|
3064347|NCT01011283|Active Comparator|2|
3064348|NCT01011309|Experimental|LEISH-F2 + MPL-SE vaccine|Recombinant three antigen Leishmania polyprotein + MPL-SE adjuvant
3064349|NCT01011309|Active Comparator|Sodium stibogluconate (SSG)|20 mg/kg/day IV for 20 days
3064350|NCT01011335|Experimental|Active Vaccine|Monovalent rAT or Monovalent rLukS-PV or Bivalent rLukS-PV / rAT
3064351|NCT01011335|Placebo Comparator|Placebo with Alum|
3064352|NCT01011335|Placebo Comparator|Saline Placebo|
3064353|NCT01011387|Other|NPWT system|Negative pressure wound therapy
3064354|NCT01011413|Active Comparator|600 milligram (mg) Efavirenz|Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3064355|NCT01011413|Experimental|400mg Efavirenz|Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3064356|NCT01011439|Experimental|Milciclib Maleate (PHA-848125AC)|100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle
3064357|NCT01011465|Experimental|Oxytocin|One primary experimental manipulation is the receipt of intranasal oxytocin vs placebo spray prior to participation in a psychosocial stress protocol
3064358|NCT01011465|Placebo Comparator|Placebo|The comparison condition for receipt of oxytocin is receipt of a saline intranasal spray
3064359|NCT01011465|Experimental|Social Support|Participants bring a friend to the laboratory who sits with them while they engage in the stress protocol tasks
3064360|NCT01011465|Placebo Comparator|No Social Support|Individuals in this condition do not have a friend present while they are engaging in the laboratory protocol.
3064361|NCT01011465|Other|Female Gender|Effects of oxytocin and social support are examined among women versus men
3064362|NCT01011465|Other|Male Gender|Consider effects of oxytocin and social support in men versus women
3064363|NCT01011556|Active Comparator|20 mcg Subcutaneous Teriparatide|Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.
3064364|NCT01011556|Experimental|30 mcg Transdermal Teriparatide|Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3064365|NCT01011556|Experimental|50 mcg Transdermal Teriparatide|Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3064366|NCT01011556|Experimental|80 mcg Transdermal Teriparatide|Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.
3064367|NCT01011673|Active Comparator|Ketorolac|Ketorolac 30mg IVSS
3064368|NCT01011673|Active Comparator|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
3064369|NCT01011738||Cohort|
3064370|NCT01011816|Experimental|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc
3064371|NCT01011816|Placebo Comparator|Saline|One injection of up to 4 mL of saline solution into a single lumbar intervertebral disc
3064372|NCT01011829|Active Comparator|Varenicline|"Varenicline:~0.5 mg daily for days 1-3~0.5 mg twice daily for days 4-7~1 mg twice daily from day 8 until end of week 8."
3064373|NCT01011829|Placebo Comparator|Placebo|8 weeks of daily matching oral placebo in tablet form
3064374|NCT01011868|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose daily
3064375|NCT01011868|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose daily
3064376|NCT01011868|Placebo Comparator|placebo|Patients receive placebo to match BI 10773 daily
3064377|NCT01011894|Experimental|pts getting lenalidomide|Patients with intermediate or high-risk chronic lymphocytic leukemia (≥ 65 years old) will receive lenalidomide until disease progression at the 20mg dose level (recognizing that progression at this dose requires non-protocol alternate therapy) or unacceptable toxicity.
3064378|NCT01011907|Experimental|varenicline|Drug: varenicline (Chantix) 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
3064379|NCT01011907|Placebo Comparator|placebo|Drug: placebo for varenicline 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
3064380|NCT01011933|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Blood and archived tumor tissue samples are collected for biomarker studies.
3064381|NCT01011946|Experimental|Positron Emission Mammography|
3064382|NCT01012037|Experimental|linagliptin low dose|linagliptin low dose twice daily
3064383|NCT01012037|Placebo Comparator|placebo|placebo matching linagliptin
3064384|NCT01012037|Experimental|linagliptin medium dose|linagliptin medium dose once daily
3064385|NCT01012089|Experimental|Daptomycin|Pediatric patients on hemodialysis or peritoneal dialysis with suspected or confirmed infection and who were receiving standard of care antibiotics were also eligible to receive a single dose of daptomycin 5mg/kg IV. Serial blood draws were obtained to assess daptomycin pharmacokinetics
3064386|NCT01012167|Active Comparator|1: galantamine/placebo-oxytocin|Subjects randomized to galantamine will receive galantamine and placebo-oxytocin
3064387|NCT01012167|Active Comparator|2: oxytocin/placebo-galantamine|Subjects randomized to oxytocin will receive oxytocin and placebo-galantamine
3064388|NCT01012167|Placebo Comparator|3: placebo-galantamine /placebo-oxytocin|Subjects randomized to placebo will receive placebo-galantamine and placebo-oxytocin
3064389|NCT01012219|Experimental|Period 1|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
3064390|NCT01012219|Experimental|Period 2|In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
3064391|NCT01012219|Experimental|Period 3|
3064392|NCT01012245||patients with glaucoma and ocular hypertension|
3064393|NCT01012258|Experimental|Cetuximab|All eligible subjects will receive cetuximab treatment only during week 1 of the treatment course and concomitant cetuximab and boost radiotherapy (RT) during week two to week seven of the treatment course
3064394|NCT01012297|Experimental|Arm I Gem+Doce+Placebo|Patients receive a placebo IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim subcutaneously (SC) on days 9-15 or pegfilgrastim SC on day 9 or 10.
3064395|NCT01012297|Experimental|Arm II Gem+Doce+Bev|Patients receive bevacizumab IV over 30-90 minutes on day 1, gemcitabine hydrochloride IV over 90 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10.
3064396|NCT01012323|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 weeks (17 infusions) or 4 weeks (13 infusions) for 1 year.
3064397|NCT01012336|Experimental|Aprepitant|
3064398|NCT01012362|Experimental|Optimum Tolerated Dose Determination|"Patient receives assigned dose level:~Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2."
3064399|NCT01012362|Experimental|Optimum Tolerated Dose Confirmation|Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.
3064400|NCT01012388|Experimental|Radiesse|
3064401|NCT01012440|Experimental|Beast cancer subjects|Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods
3064402|NCT01012492|Experimental|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
3064403|NCT01012609|Experimental|pts with high-grade astrocytoma|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
3064404|NCT01012609|Experimental|pts with diffuse pontine tumor|This is a 2-group parallel (high-grade astrocytoma, diffuse pontine tumor), single stage study investigating cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan in pediatric and young adult patients. Optional exploratory components of the study include (1) correlation of tumor molecular markers with outcome, (2) CSF proteomics, and (3) assay of serum cytokine levels in patients who develop a cetuximab-associated rash.
3064405|NCT01012622|Experimental|OROS Methylphenidate Hydrochloride|
3064406|NCT01012661|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).
3064407|NCT01012661|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.
3064408|NCT01012674|Experimental|Dotarem and TOF MRA|Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.
3064409|NCT01012713|Experimental|Open-Label Treatment|All patients will receive treatment with Clobex Spray, Vectical Ointment, and Excimer Laser
3064410|NCT01012739|Experimental|Indacaterol 150μg-placebo-Indacaterol 60μg-Indacaterol 120μg|In treatment period 1, patients received indacaterol 150 μg via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received placebo to indacaterol via the Concept1 DPI; in treatment period 3, patients received indacaterol 60 μg via the Simoon DPI; and in treatment period 4, patients received indacaterol 120 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3064411|NCT01012739|Experimental|Indacaterol 60μg-Indacaterol 150μg-Indacaterol 120μg-placebo|In treatment period 1, patients received indacaterol 60 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 150 μg via the Concept1 DPI; in treatment period 3, patients received indacaterol 120 μg via the Simoon DPI; and in treatment period 4, patients received placebo to indacaterol via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3064412|NCT01012739|Experimental|Indacaterol 120μg-Indacaterol 60μg-placebo-Indacaterol 150μg|In treatment period 1, patients received indacaterol 120 μg via the Simoon dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 60 μg via the Simoon DPI; in treatment period 3, patients received placebo to indacaterol via the Concept1 DPI; and in treatment period 4, patients received indacaterol 150 μg via the Concept1 DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3064413|NCT01012739|Experimental|Placebo-Indacaterol 120μg- Indacaterol 150μg- Indacaterol 60μg|In treatment period 1, patients received placebo to indacaterol via the Concept1 dry-powder inhaler (DPI); in treatment period 2, patients received indacaterol 120 μg via the Simoon DPI; in treatment period 3, patients received indacaterol 150 μg via the Concept1 DPI; and in treatment period 4, patients received indacaterol 60 μg via the Simoon DPI. Patients received each treatment only once. There was a washout period of 14-17 days between treatments for patients undergoing pharmacokinetic (PK) assessments; for patients not undergoing PK assessments, the washout period was 7-10 days. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol was available for rescue use throughout the study.
3064414|NCT01012765|Experimental|Indacaterol - placebo - tiotropium|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064415|NCT01012765|Experimental|Placebo - Tiotropium - Indacaterol|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064416|NCT01012765|Experimental|Tiotropium - indacaterol - placebo|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064417|NCT01012765|Experimental|Placebo - indacaterol - tiotropium|In treatment period 1, patients received placebo to indacaterol once daily; in treatment period 2, patients received indacaterol 150µg once daily; in treatment period 3, patients received tiotropium 18µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064418|NCT01012765|Experimental|Indacaterol - tiotropium - placebo|In treatment period 1, patients received indacaterol 150µg once daily; in treatment period 2, patients received tiotropium 18µg once daily; in treatment period 3, patients received placebo to indacaterol once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064419|NCT01012765|Experimental|Tiotropium - placebo - indacaterol|In treatment period 1, patients received tiotropium 18µg once daily; in treatment period 2, patients received placebo to indacaterol once daily; in treatment period 3, patients received indacaterol 150µg once daily. Patients received indacaterol and placebo by single-dose dry powder inhaler (SDDPI); tiotropium was delivered via a proprietary inhalation device. There was a washout period of 13 days between each period. Use of fixed-dose combination of an anticholinergic plus a short-acting β2-agonist and use of long-acting β2-agonists were discontinued. Salbutamol rescue use was allowed during the treatment period as needed.
3064420|NCT01012921|Active Comparator|Bio-Gide® membrane|Bio-Gide® membrane This is a biodegradable bilayer membrane for bone and tissue regeneration. It has a natural collagen structure and is of porcine origin
3064421|NCT01012921|Experimental|MembraGel|MembraGel The Straumann membrane is a synthetic degradable barrier membrane
3064422|NCT01012947|Experimental|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
3064423|NCT01012947|Experimental|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
3064424|NCT01012947|Experimental|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
3064425|NCT01012947|Experimental|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
3064426|NCT01012947|Experimental|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
3064427|NCT01012973|Experimental|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
3064428|NCT01012973|Sham Comparator|Sham treatment|Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.
3064429|NCT01012999|Experimental|Intranasal sufentanil, pain relief|Intranasal sufentanil administered at a dose of 0.5 mcg/kg times one dose at beginning of thirty minute period
3064430|NCT01013194|Experimental|Treated patients|Cirrhotic patients treated with Human Fetal Liver Cell Transplantation.
3064431|NCT01013194|No Intervention|Control patients|Cirrhotic patients on Standard therapy.
3064432|NCT01013207|Experimental|Nexus (S9) CPAP device|"Fifty subjects with obstructive sleep apnea (OSA), established on CPAP therapy (≥ 6 months) were recruited into this study. These patients use their CPAP device every night while sleeping to treat their OSA.~Nexus (S9) is a new CPAP device with improved humidification system (heated tube and climate control), reduced noise, improved comfort of breathing and new user interface. During the study, patients will use this CPAP every night in place of their own CPAP for a period of 4 weeks. Compliance data from the Nexus will then be compared to the patient's usual CPAP pre trialling Nexus and post trialling Nexus."
3064433|NCT01013285|Experimental|bevacizumab, temozolomide, external beam radiation|
3064434|NCT01013350||Never Exposed to Cladribine|All participants who received placebo matched to cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826 , NCT00641537, NCT00938366 and NCT00725985).
3064435|NCT01013350||Exposed to Cladribine|All participants who received cladribine in previously conducted clinical trials (NCT Number: NCT00213135, NCT00436826, NCT00641537, NCT00938366 and NCT00725985).
3064436|NCT01013597|Experimental|LBH589|
3064437|NCT01013740|Experimental|Lapatinib + Vinorelbine|Lapatinib + Vinorelbine
3064438|NCT01013740|Active Comparator|Lapatinib + Capecitabine|Lapatinib + Capecitabine
3064439|NCT01013753|Experimental|Olodaterol (BI 1744) low|Low dose inhaled orally once daily from the Respimat inhaler
3064440|NCT01013753|Experimental|Olodaterol (BI 1744) very low|Very low dose inhaled orally once daily from the Respimat inhaler
3064441|NCT01013753|Experimental|Olodaterol (BI 1744) medium|Medium dose inhaled orally once daily from the Respimat inhaler
3064442|NCT01013753|Experimental|Olodaterol (BI 1744) high|High dose inhaled orally once daily from the Respimat inhaler
3064443|NCT01013753|Active Comparator|Formoterol 12 mcg|12mcg inhaled twice daily from the Aerolizer inhaler
3064444|NCT01013753|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler and/or Formoterol placebo inhaled twice daily from the Aerolizer inhaler
3064445|NCT01013792|Experimental|Non-adherent Wound Dressing|The non-adherent dressing is the same as the Tegaderm Matrix dressing, with potassium chloride, rubidium chloride, calcium chloride, zinc chloride, potassium citrate and citric acid removed. This dressing is a Class I medical device (21 CFR Sec. 878.4020 Occlusive wound dressing) that is exempt from premarket notification procedures.
3064446|NCT01013792|Active Comparator|Tegaderm Matrix Dressing with PHI|A commercial wound dressing to be used per manufacturer's instructions for use.
3064447|NCT01013844|Active Comparator|Solo Learning|Participant learning alone (without partner).
3064448|NCT01013844|Active Comparator|Dyadic Learning|Participant and partner learning together.
3064449|NCT01013870|Experimental|MTBI subjects randomized to drug|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the treatment arm of the phase II drug trial of atorvastatin. These subjects will receive a daily weight-based dose of atorvastatin 1mg/kg (up to 80 mg) for seven days and started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving a placebo.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
3320889|NCT02014558|Experimental|Gilteritinib 300 mg in Escalation Phase|Participants received a single dose of 300 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 300 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3064450|NCT01013870|Placebo Comparator|MTBI subjects randomized to placebo|"Of 200 MTBI subjects enrolled, 1:1 randomization will be used to assign half (i.e 100) to the placebo arm of the phase II drug trial of atorvastatin. These subjects will receive a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug.~NOTE: The 100 Orthopedic Injury subjects recruited for and participating in the Observational studies are not included in the Medication study portion of this protocol."
3064451|NCT01013883||systolic dysfunction|patients having left ventricular systolic dysfunction on echocardiography
3064452|NCT01013883||distolic heart failure|patients with clinical heart failure and preserved LV systolic dysfunction
3064453|NCT01013961|Active Comparator|Arm A (standard dose)|"Patients receive alemtuzumab subcutaneously (SC) on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and standard-dose rituximab 375 mg/m^2/week intravenously (IV) on days 8, 15, 22, and 29 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 and standard-dose rituximab IV on days 3, 10, 17, and 24. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
3064454|NCT01013961|Experimental|Arm B (low dose)|"Patients receive alemtuzumab SC on days 1-3, 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 and low-dose rituximab at 20 mg/m^2 IV on days 6, 8, 10, 13, 15, 17, 20, 22, 24, 27, 29, and 31 in cycle 1 (33-day cycle). In cycle 2 and subsequent cycles (28-day cycle), patients receive alemtuzumab SC and low-dose rituximab IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 3 cycles.~Alemtuzumab dose for cycle 1 week 1 requires a 'dose ramp' (3 mg day 1, 10 mg day2, and 30 mg day 3 of cycle 1) and then is 30 mg 3 times a week."
3064455|NCT01014013|Experimental|ertapenem sodium (MK0826)|ertapenem sodium
3064456|NCT01014013|Active Comparator|ceftriaxone sodium|ceftriaxone sodium
3064457|NCT01014091|Experimental|GSK2340272A F1 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
3064458|NCT01014091|Experimental|GSK2340272A F1 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 1 (F1) in the deltoid region of the arm, according to a 0-21 day schedule.
3064459|NCT01014091|Experimental|GSK2340272A F2 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
3064460|NCT01014091|Experimental|GSK2340272A F2 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 2 (F2) in the deltoid region of the arm, according to a 0-21 day schedule.
3064461|NCT01014091|Experimental|GSK2340272A F3 Y3-5 GROUP|Healthy male or female children, between 3 and 5 years of age (Y3-5) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
3064462|NCT01014091|Experimental|GSK2340272A F3 Y6-9 GROUP|Healthy male or female children, between 6 and 9 years of age (Y6-9) at the time of first study vaccination, who intramuscularly received 2 doses of GSK2340272A vaccine formulation 3 (F3) in the deltoid region of the arm, according to a 0-21 day schedule.
3064463|NCT01014143|Placebo Comparator|Fluoride toothpaste|Negative control
3064464|NCT01014143|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste
3064465|NCT01014143|Active Comparator|Chlorhexidine Oral Rinse|Positive Control mouthrinse
3064466|NCT01014169|No Intervention|Usual care|Mothers in the control group will receive the nursing discharge newborn information from the nurse practitioner [sometimes via a Spanish interpreter, if required] according to current standard of care, which includes verbal information and written handouts.
3064467|NCT01014169|Experimental|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of the discharge envelope using their language of preference when receiving the standard newborn information.
3064468|NCT01014208|Experimental|OFATUMUMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with ofatumumab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with ofatumumab. All subjects will receive the same ofatumumab regimen and dose.
3064469|NCT01014208|Active Comparator|RITUXIMAB + DHAP CHEMOTHERAPY REGIMEN|This study is a parallel arm study, with rituximab + DHAP. The Investigators are required to prospectively choose to treat all of their subjects with either DHAP chemotherapy regimens in combination with rituximab. All subjects will receive the same rituximab regimen and dose.
3064470|NCT01014351|Experimental|Paclitaxel/Carboplatin/Everolimus|Systemic Therapy using everolimus, paclitaxel and carboplatin given during a 21-day treatment cycle
3064471|NCT01014390|Experimental|WallFlex Biliary RX FC Stent System|The WallFlex Biliary RX Fully Covered Stent System is being evaluated for treatment of benign biliary strictures.
3064472|NCT01014403|Experimental|enoxaparin 30 mg SQ q12 hours|Enoxaparin started at 24 hours post-injury and continued until 96 hours post-injury.
3064473|NCT01014403|Placebo Comparator|placebo|vehicle administered sq q 12 hours
3064474|NCT01014442|Experimental|Mycophenolate Mofetil; Cystic Fibrosis|Participants with cystic fibrosis will receive mycophenolate mofetil 1.5 g, orally (PO), BID from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
3064475|NCT01014442|Experimental|Mycophenolate Mofetil; Other|Participants with COPD, emphysema, idiopathic pulmonary fibrosis, or A1AD will receive mycophenolate mofetil 1.5 g, PO, BID, from Days 2 through 30 post-transplantation, and 1 g, PO, BID from Days 31 through 90 post-transplantation.
3064476|NCT01014455|Experimental|CO reminder|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
3064477|NCT01014455|Placebo Comparator|no CO reminder|a brief intervention that recommends fasting but does not mention that CO will be checked
3064478|NCT01014533|Placebo Comparator|Placebo|After 3 nights in the UM sleep lab and randomization, this arm receives placebo for one week. They then return to the sleep lab for the same procedures.
3064479|NCT01014533|Active Comparator|Gabapentin|After spending 3 baseline nights in the UM sleep lab, alcohol dependent subjects are randomized. This arm receives gabapentin . On nights 1 and 2 of medication, the dose is 600 mg by mouth 30 min before bedtime. On nights 3-10, the dose is 1200 mg by mouth 30 min before bedtime. On nights 8-10 of medication, subjects return to the UM sleep lab and complete 3 sleep nights with the same procedures. On night 11, the dose is reduced to 600 mg by mouth 30 min before bedtime, and then stopped.
3064480|NCT01014585|Placebo Comparator|1|Placebo tablets administered orally twice daily
3064481|NCT01014585|Experimental|2|Milnacipran tablets administered orally twice daily
3064482|NCT01014624|Experimental|Prasugrel|Prasugrel 10mg administered for 7 days followed by a Washout Period up to 12 days.
3064483|NCT01014624|Active Comparator|Clopidogrel|Clopidogrel 75mg administered for 7 days followed by a 12 day Washout Period up to 12 days.
3064484|NCT01014689|Active Comparator|Adapalene 0.1% / BPO 2.5% gel|
3064485|NCT01014689|Placebo Comparator|Adapalene 0.1% / BPO 2.5% Vehicle Gel|
3064486|NCT01014728|Active Comparator|Intravenous anesthesia|Intravenous anesthesia with propofol for endoscopic sinus surgery
3064487|NCT01014728|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane for endoscopic sinus surgery
3064488|NCT01014741|Experimental|Ibutilide arm|
3064489|NCT01014741|Placebo Comparator|Placebo arm|
3064490|NCT01014871|Other|intra-individual comparison|
3064491|NCT01014910|Active Comparator|Continuous pulse oximetry monitoring|Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
3064492|NCT01014910|Active Comparator|Intermittent pulse oximetry monitoring|Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
3064493|NCT01014936|Experimental|MSC2156119J Regimen 1|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 30 mg to 400 mg (capsule formulation) once daily for 14 days, followed by 7 days with no treatment (21-day cycle) in Regimen 1.
3064494|NCT01014936|Experimental|MSC2156119J Regimen 2|Subjects will be administered with micronized or non-micronized MSC2156119J in dose ranging from 60 mg to 315 mg (capsule formulation) once daily 3 times per week for 3 weeks (21-day cycle) in Regimen 2.
3064495|NCT01014936|Experimental|MSC2156119J Regimen 3|Subjects will be administered with micronized MSC2156119J in dose ranging from 300 mg to 1400 mg (capsule or tablet formulation) once daily for 21 days (21-day cycle) in Regimen 3.
3064496|NCT01014975|Experimental|20 mg Plasmin (Human)|20 mg of Plasmin (Human)
3064497|NCT01014975|Experimental|40 mg Plasmin (Human)|40 mg of Plasmin (Human)
3064498|NCT01014975|Experimental|80 mg Plasmin (Human)|80 mg of Plasmin (Human)
3064499|NCT01014988|Other|Single Arm|A single arm open-label design has been selected to achieve the primary objective of providing regulatory authorities with safety data on IV zanamivir in an expedited manner. This study design also facilitates the provision of safety data on a real-time basis, if necessary.
3064500|NCT01015118|Experimental|BIBF 1120|patients to receive BIBF 1120 standard dose twice daily PO in combination with combination with carboplatin and paclitaxel
3064501|NCT01015118|Placebo Comparator|Placebo|patients to receive capsules identical to those containing BIBF 1120 in combination with combination with carboplatin and paclitaxel
3064502|NCT01015131|Experimental|All Participants|18F-FLT-PET imaging
3064503|NCT01015170|Experimental|Bupropion HCl|Up to 8 week of bupropion SR (150mg BID) + counseling.
3064504|NCT01015287|Experimental|Non pre-treatment|A placebo oral loading dose is given at the time of diagnosis and a 60 milligrams (mg) oral loading dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days.
3064505|NCT01015287|Experimental|Split Loading Dose|A 30 mg oral loading dose of prasugrel is given at diagnosis and a 30 mg oral dose of prasugrel is given at the time of PCI followed by 5 mg or 10 mg oral daily maintenance dose of prasugrel for 30 days
3064506|NCT01015326||Expert Interviews|Expert cohort consists of providers with expertise in administering epidermal growth factor receptor inhibitors (EGFRI) or treating patients with EGFRI-associated skin toxicities. Experts will be asked open-ended questions about symptoms and issues as they relate to HRQL in patients with EFGRI skin toxicities. Experts will then be presented with a pool of potential items and will be asked through interview and questionnaire to relate items according to how common and how important they are when occurring in patients with this condition.
3064507|NCT01015326||Patient Interviews|Patient cohort will consist of those treated with an epidermal growth factor receptor inhibitor (EGFRI) and referred to a specialized dermatology clinic for skin rash management. Patients will be asked open-ended questions about symptoms and issues as they relate to their HRQL to elicit personal experiences about how EGFRI skin toxicities and its treatment affects patients. Patients will be asked through interview and questionnaire to rate items according to how often they are experienced and how important they are to the patient.
3064508|NCT01015443|Experimental|Investigational Arm|Tecemotide (L-BLP25) + Single low dose cyclophosphamide + Best supportive care (BSC)
3064509|NCT01015443|Placebo Comparator|Control Arm|Saline + Placebo + Best supportive care (BSC)
3064510|NCT01015534|Experimental|Whole brain irradiation plus Temozolomide|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks, and a fixed dose of oral Temozolomide, 1h before each fraction of whole brain irradiation, 200 mg on Monday, Wednesday, Friday; 300 mg on Tuesday, and Thursday. Without adjuvant cycles of Temozolomide.
3064511|NCT01015534|Active Comparator|Whole brain irradiation|Whole brain irradiation at a dose of 30 Gy in 10 daily fractions over 2 weeks
3064512|NCT01015560|Experimental|treatment|MLN1202 8mg/kg IV Days 1, 15, 29 given as 1 6 week cycle
3064513|NCT01015586|Experimental|Lamotrigine|Add-on lamotrigine plus pre-existing mood stabilizing medication regimen. Active fixed-dose drug titration from 25-200 mg/day over first six weeks, 200 mg/day fixed-dose maintenance for second six weeks
3064514|NCT01015586|Placebo Comparator|Placebo|Add-on placebo plus pre-existing mood stabilization regimen for 12 weeks
3064515|NCT01015612|Experimental|Medtronic CoreValve® System Implantation|Patients with symptomatic severe aortic stenosis who have an elevated surgical risk
3064516|NCT01015638|Experimental|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
3064517|NCT01015638|Active Comparator|Clindamycin phosphate and BPO 2.5% gel|Once Daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel.
3064518|NCT01015677|Experimental|MK-6913 75 mg|MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and Stage 2)
3064519|NCT01015677|Active Comparator|17-β estradiol 1 mg|17β-estradiol 1 mg tablet and matching placebo for MK-6913 75 mg capsule once daily for 4 weeks (Stage 1 and Stage 2)
3064520|NCT01015677|Placebo Comparator|Placebo|Matching placebo for MK-6913 75 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 1 and State 2)
3064521|NCT01015677|Experimental|MK-6913 25 mg|MK-6913 25 mg capsule and matching placebo for 17β-estradiol 1 mg tablet once daily for 4 weeks (Stage 2)
3064522|NCT01015703|Experimental|CoVaccine HT|
3064523|NCT01015768|Experimental|Test eye|Uses ReNu Multiplus as multipurpose soaking solution
3064524|NCT01015768|Active Comparator|Control|A new lens (PureVision) is soaked for 2 hours in non-preserved saline
3064525|NCT01015781|Experimental|Arm 1|Progressive Tinnitus Management
3064526|NCT01015781|Other|Arm 2|Wait List Control
3064527|NCT01015807|Placebo Comparator|Placebo|Sterile Saline used for TAP block = Bupivacaine Placebo + Clonidine Placebo
3064528|NCT01015807|Active Comparator|TAP (Bupi)|2x20mL 0.375% Bupivacaine + 2x1mL of 0.9% NaCl = 150mg Bupivacaine + Clonidine Placebo
3064529|NCT01015807|Active Comparator|Clo-TAP (Bupi + Clon)|2x20mL 0.375% Bupivacaine + 2x1mL Clonidine = 150mg Bupivacaine + 150µg Clonidine
3064530|NCT01015820|Experimental|Cancer group|Participants in this group had pathologically confirmed pancreatic adenocarcinoma. They received an EGD with EUS. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
3064531|NCT01015820|Other|Control group|Participants in this group were without pancreatic adenocarcinoma. Participants in the control group received an EGD with EUS for the indication of abdominal pain. During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
3064534|NCT01015976|Experimental|Post bariatric surgery|Roux en Y bariatric surgery
3064535|NCT01015976|Other|Control|No surgery
3064536|NCT01016015|Experimental|Treatment (cixutumumab and temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3064537|NCT01016067|Experimental|INFUSE/MASTERGRAFT|Patients received INFUSE/MASTERGRAFT granules with rigid internal fixation.
3064538|NCT01016067|Active Comparator|Autograft bone|Patients received autograft bone with rigid internal fixation.
3064539|NCT01016106|Active Comparator|AA pts AD and IV|African American patients with a diagnosis of atopic dermatitis and ichthyosis vulgaris. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
3064540|NCT01016106|Active Comparator|AA patients (controls)|African American patients with no personal or family history of ichthyosis vulgaris or atopy. During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT
3064541|NCT01016262|Experimental|MAX-002|
3064542|NCT01016262|Placebo Comparator|Placebo|
3064543|NCT01016262|Active Comparator|Canasa®|
3064544|NCT01016483|Experimental|Safety Run-in Part: Regimen 1|Subjects will receive pimasertib capsule orally once daily (qd) doses of 15, 30, 45, 68, 90, and 120 milligram (mg) on Day 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15,16, 17, 18, 19, 22, 23, 24, 25, 26 and gemcitabine 1000 milligram per square meter (mg/m^2) intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks).
3064545|NCT01016483|Experimental|Safety Run-in Part: Regimen 2|Subjects will receive pimasertib capsule orally twice daily (bid) doses of 60 and 75 mg continuously for a 28-day cycle and gemcitabine 1000 mg/m^2 intravenous (IV) infusion for 30 minutes on Days 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (1 Cycle = 8 weeks) (bid - continuous regimen).
3064546|NCT01016483|Active Comparator|Phase II: Arm 1 (Gemcitabine + Placebo)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion on for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and placebo matched to pimasertib orally bid - continuous regimen.
3064547|NCT01016483|Experimental|Phase II: Arm 2 (Gemcitabine + Pimasertib)|Subjects will receive gemcitabine 1000 mg/m^2 IV infusion for 30 minutes on Day 1, 8, 15, 22, 29, 36, and 43 followed by a 1-week rest (Cycle 1) then on Days 1, 8, and 15 of a 28-day cycle and pimasertib capsule orally bid - continuous regimen.
3064548|NCT01016600|Experimental|Cohort 1|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 25 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3064549|NCT01016600|Experimental|Cohort 2|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 50 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3064550|NCT01016600|Experimental|Cohort 3|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3064551|NCT01016600|Experimental|Phase II|"Induction regimen (total 2 cycles)~Lenalidomide 50 mg PO daily days 1-28~Azacitidine 75 mg/m2 (dose determined in Phase I) mg/m2 IV days 1-5~Maintenance Regimen~Lenalidomide 10 mg PO daily days 1-28~Azacitidine 75 mg/m2 IV days 1-5"
3064552|NCT01016652|Other|etafilcon A multifocal / etafilcon A sphere|period 1: etafilcon A multifocal worn, period 2: etafilcon A sphere worn.
3064553|NCT01016652|Other|etafilcon A sphere / etafilcon A multifocal|period 1: etafilcon A sphere worn, period 2: etafilcon A multifocal worn.
3064554|NCT01016678|Other|Active, Active, Active, Placebo|One fifth of the 105 subjects will be randomized to this arm and treat their four migraines in this order. First three will be treated with Active Treximet and the last or 4th migraine will be treated with Placebo.
3064555|NCT01016678|Other|Active, Active, Placebo, Active|This is another of the five treatment arms. One fifth of the 105 subjects will be randomized to this group and will treat the first two migraines with Active drug, Treximet, and then the third migraine with placebo and the last (4th) migraine with Treximet.
3064556|NCT01016678|Other|Active, Placebo, Active, Active|Approximately one fifth of the 105 subjects will be randomized to this group and treat their first migraine with Active Treximet and the second migraines with Placebo. The final two migraines treated will be with Active study drug.
3064557|NCT01016678|Other|Placebo, Active, Active, Active|One fifth of the 105 subjects will be randomized to this treatment arm, where they will treat the first headache with placebo and the remaining three migraines will be treated with Active treximet.
3064558|NCT01016678|Other|Active, Active, Active, Active|One fifth of the subject will treat all their migraines with Active Treximet.
3064559|NCT01016691|Experimental|High Dose Drug Device/ bimatoprost 0.03%|drug device containing 65 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3064560|NCT01016691|Experimental|Low Dose Drug Device / bimatoprost 0.03%|drug device containing 45 micrograms of bimatoprost released over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3064561|NCT01016691|Other|Placebo Device / bimatoprost 0.03%|placebo drug device worn over 4 days (first period) bimatoprost 0.03% ophthalmic solution for one day (second period).
3064562|NCT01016769|Experimental|Temsirolimus + Weekly Paclitaxel + Carboplatin|"In Part 1 (Phase I) of the study, the primary endpoint is to establish the phase II recommended dose for the combination of temsirolimus + weekly paclitaxel + carboplatinPart 1 (Phase I) features a standard 3 + 3 phase I dose escalation design. Up to 3 dose levels are planned in the Phase I portion of the study.~In Part 2 (Phase II) of the study, the primary endpoint is to determine the objective response rate (CR or PR) after two cycles (approximately 6 weeks) of treatment with the combination of temsirolimus + weekly paclitaxel + carboplatin as palliative therapy for recurrent or metastatic HNSCC. A two-stage design will be employed."
3064563|NCT01016834|Other|Sumavel(R) DosePro(R)|Single arm study (Sumavel DosePro)
3064564|NCT01016873|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
3064565|NCT01016873|Sham Comparator|Sham 16 Gy IRay|Sham 16 Gy IRay + PRN Lucentis®
3064566|NCT01016873|Experimental|24 Gy IRay|24 Gy IRay + PRN Lucentis®
3064567|NCT01016873|Sham Comparator|Sham 24 Gy IRay|Sham 24 Gy IRay + PRN Lucentis®
3064568|NCT01016912|Experimental|Arm A (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3064569|NCT01016912|Experimental|Arm B (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3064570|NCT01016912|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2b, Ribavirin)|Treatment Naive
3064571|NCT01016912|Experimental|Arm D (BMS-790052, plus peginterferon alfa-2b, Ribavirin)|Non-Responder
3064572|NCT01016912|Experimental|Arm E (BMS-790052, plus Peginterferon alfa-2b, Ribavirin)|Non-Responder
3064573|NCT01016938||Group I|This is a pilot study and there is only one group.
3064574|NCT01016964|Sham Comparator|Sham Device|Sham device
3064575|NCT01016964|Active Comparator|LLT Device 2009 12 Beams|HairMax LaserComb 2009 model 12 beam
3064576|NCT01016977|Active Comparator|Duac & taz|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
3064577|NCT01016977|Active Comparator|Acanya & taz|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
3064578|NCT01017003|Experimental|1|0.6mg colchicine tablet
3064579|NCT01017003|Experimental|2|colchicine 0.6mg q12 hours for 10 days
3064580|NCT01017029|Active Comparator|Immediate introduction of everolimus|
3064581|NCT01017029|Experimental|Delayed introduction of everolimus|delayed introduction) + Cyclosporin + steroids
3064582|NCT01017042|Experimental|colchicine|colchicine 1.2mg by mouth initially then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
3064583|NCT01017120|Experimental|1|Tazarotene foam, 0.1%
3064584|NCT01017120|Placebo Comparator|2|Vehicle Foam
3064585|NCT01017146|Experimental|1|Tazarotene foam, 0.1%
3064586|NCT01017146|Placebo Comparator|2|Vehicle Foam
3064587|NCT01017237|Active Comparator|Dex plus midazolam|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg i.v.
3064588|NCT01017237|Active Comparator|Dex plus midazolam and ketamine|Dexmedetomidine loading dose of 0.4 mcg/kg followed by an infusion of 0.5 mcg/kg/hr plus midazolam 0.04 mg/kg and 0.25 mg/kg ketamine i.v.
3064589|NCT01017250|Experimental|Stereotactic Radiosurgery|Avastin and Radiosurgery
3064590|NCT01017497|Experimental|1mm margin|GTV expanded by 1 mm
3064591|NCT01017497|Experimental|3mm margin|GTV expanded by 3 mm
3064592|NCT01017536|Placebo Comparator|Placebo|Thirteen subjects received placebo vaccine that did not contain any AERAS-402.
3064593|NCT01017536|Experimental|Investigational Vaccine|Thirteen subjects received active vaccine 3 x 10^10 vp AERAS-402.
3064594|NCT01017549|Other|Treatment|This is a single arm study where all patients are treated with FDA cleared electronic brachytherapy treatment.
3064595|NCT01017575|Experimental|Arm A (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3064596|NCT01017575|Experimental|Arm B (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3064597|NCT01017575|Placebo Comparator|Arm C (Placebo, plus Peginterferon alfa-2a, Ribavirin)|Treatment Naive
3064598|NCT01017575|Experimental|Arm D (Daclatasvir, plus peginterferon alfa-2a, Ribavirin)|Non-Responder
3064599|NCT01017575|Experimental|Arm E (Daclatasvir, plus Peginterferon alfa-2a, Ribavirin)|Non-Responder
3064600|NCT01017601|Experimental|Arm I|Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
3064601|NCT01017601|Placebo Comparator|Arm II|Patients receive a single dose of placebo IV over 1 hour on day 1.
3064602|NCT01017653|Experimental|Panitumumab and irinotecan|
3064603|NCT01017731|Experimental|IMC-1121B|"Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period.~For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab [10 milligrams per kilogram (mg/kg)] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between."
3064604|NCT01017874|Experimental|Pemetrexed + Cisplatin + Gefitinib|
3064605|NCT01017874|Active Comparator|Gefitinib|
3064606|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 100/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064607|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 50mcg/25mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064608|NCT01017952|Experimental|FF/GW642444 Inhalation Powder 200/25 mcg QD|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3064609|NCT01017952|Experimental|GW642444 25mcg QD|Long Acting Beta Agonist(LABA)
3064610|NCT01018030|Experimental|FFNS 110 mcg QD|
3064611|NCT01018030|Experimental|FFNS 110 mcg BID|
3064612|NCT01018030|Placebo Comparator|Placebo Nasal Spray|
3064613|NCT01018056|Experimental|D-serine (glutamate agonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive D-serine for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3064614|NCT01018056|Experimental|Riluzole (glutamate antagonist)|24 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive riluzole for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3064615|NCT01018056|Placebo Comparator|Placebo|12 subjects age 8-17 years with moderate to severe TS (TTS > 22) will be enrolled in this treatment arm. They will receive placebo for 6-weeks of the study, during which time drug dose may gradually be increased as needed. At 6-weeks participants will taper off drug.
3064616|NCT01018095|Active Comparator|Single dose|Metronidazole 2 gm single dose
3064617|NCT01018095|Active Comparator|7 day dose|Metronidazole 500 mg dose x 7 days
3064618|NCT01018134|Experimental|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered once daily to affected area
3064619|NCT01018134|Experimental|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered twice daily to affected area
3064620|NCT01018134|Experimental|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered once daily to affected area
3064621|NCT01018134|Experimental|Desoximetasone 0.25% twice daily|Desoximetasone topical spray 0.25% administered twice daily to affected area
3064622|NCT01018134|Placebo Comparator|Vehicle once daily|Vehicle administered to affected areas once daily
3064623|NCT01018134|Placebo Comparator|Vehicle twice daily|Vehicle administered to affected areas twice daily
3064624|NCT01018186|Experimental|Fluticasone furoate/GW642444|
3064625|NCT01018186|Active Comparator|Fluticasone propionate|
3064626|NCT01018264|Experimental|solifenacin succinate (VESIcare)|
3064627|NCT01018264|Placebo Comparator|placebo|
3064628|NCT01018394|Active Comparator|nicotine lozenges|40 subjects will be assigned to receive nicotine lozenges for 8 weeks. They will use the nicotine lozenges ad lib, up to 8 lozenges per day.
3064629|NCT01018394|Active Comparator|tobacco free snuff|41 subjects will receive tobacco free snuff for 8 -12 weeks. The tobacco-free snuff will be used ad lib - as needed.
3064630|NCT01018420|Experimental|Colchicine|
3064631|NCT01018420|Active Comparator|Moxifloxacin|
3064632|NCT01018511|Placebo Comparator|Placebo|Participants received 3 tablets once a day for 12 weeks. Placebo tamsulosin hydrochloride oral controlled absorption system (OCAS) 0.4 mg tablet; Placebo fixed dose combination (FDC) tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3064633|NCT01018511|Active Comparator|TOCAS 0.4 mg|Participants received 3 tablets once a day for 12 weeks. Tamsulosin hydrochloride OCAS (TOCAS) 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3064634|NCT01018511|Experimental|FDC 0.4 mg/6 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3064635|NCT01018511|Experimental|FDC 0.4 mg/9 mg|Participants received 3 tablets once a day for 12 weeks. Placebo TOCAS 0.4 mg tablet; Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg tablet; FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg tablet
3064636|NCT01018680|Placebo Comparator|Placebo|
3064637|NCT01018680|Experimental|Duloxetine|
3064638|NCT01018732|Experimental|I: MenACWY-CRM vaccine|Subjects had been given one dose of Meningococcal ACWY (MenACWY) vaccine conjugated to CRM197 (cross-reactive material-mutant of diptheria toxin) 5 years ago. All subjects were given one dose of the Men ACWY in the present study.
3064639|NCT01018732|Experimental|II: Licensed Polysaccharide Meningococcal vaccine|Subjects had been given one dose of a licensed MenACWY polysaccharide meningococcal vaccine (Menomune) 5 years ago. All subjects were given one dose of Men ACWY vaccine in the present study.
3064640|NCT01018732|Experimental|III: Meningococcal Naive|Subjects were age matched with groups 1 and 2 (age inclusive: 16 years to 23 years) and enrolled at visit 1 and given one dose of Men ACWY vaccine during the present study.
3064641|NCT01018862|Active Comparator|MP03-36 (0.15% solution)|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3064642|NCT01018862|Active Comparator|MP03-33 (0.10% solution)|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3064643|NCT01018862|Placebo Comparator|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
3064644|NCT01018953|Experimental|BIM 23A760|This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).
3064645|NCT01018979|Experimental|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
3064646|NCT01018979|Experimental|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
3064647|NCT01018992|Placebo Comparator|Placebo|Adult women with DSM-IV defined PTSD will receive matching placebo for 6 weeks
3064648|NCT01018992|Experimental|GSK561679|Adult women with DSM-IV-defined PTSD will receive GSK561679 at a fixed dose of 350 mg/day for 6-weeks
3064649|NCT01019135|Active Comparator|Women-Only Cardiac Rehabilitation|The women-only CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format, wherein participants engage in on-site female-only group exercise sessions, as well as female-only group education sessions.
3064650|NCT01019135|Active Comparator|Co-ed Cardiac Rehabilitation|The traditional hospital-based co-ed CR programs include on-site group exercise training sessions 1-2 days/week. Participants are encouraged to walk at home on alternate days of the week. Education sessions are also given in a group format.
3064651|NCT01019135|Active Comparator|Home-Based Cardiac Rehabilitation|In the monitored home-based programs, patients attend an intake appointment where an exercise test is performed as the basis for exercise prescription. Patients are given written guidelines for aerobic conditioning based on their treadmill test. Patients are cautioned about symptoms, and taught how to check their heart rate during walking sessions. Patients are provided with reading materials regarding CVD, risk factors and lifestyle modification. These are discussed with an allied health professional from the home-based CR program by telephone during weekly scheduled telephone calls.
3064652|NCT01019252|Experimental|CBT for ADHD first, then follow-up|Participants received Cognitive Behavioral Therapy following randomization.
3064653|NCT01019252|No Intervention|Wait list first, then CBT for ADHD|Cross-over: Participants were assigned to a wait list after the initial assessment. They received Cognitive Behavioral Therapy after the 4 month assessment.
3064654|NCT01019317|Experimental|Cytarabine + Fludarabine|Fludarabine 15 mg/m^2 intravenous (IV) every 12 hours for 5 days; Cytarabine 0.5 grams/m^2 IV over 2 hours every 12 hours for 5 days.
3064655|NCT01019369|Experimental|Self Administration of DMPA|Self administration of subcutaneous depot medroxyprogesterone acetate
3064656|NCT01019369|Active Comparator|Clinic administration of DMPA|Clinic administration (routine care) of DMPA
3064657|NCT01019486|Experimental|Type 1 Diabetic Subjects|Regadenoson 400mcg slow IV bolus to identify assess myocardial blood flow (MBF). Stratified by coronary calcium score of below 100 or greater than score of 100 for low and high risk individuals respectively.
3064658|NCT01019486|Active Comparator|Nondiabetic Subjects|Regadenoson myocardial perfusion imaging (MPI) Intervention: Regadenoson (400mcg slow IV bolus) stress to assess myocardial blood flow (MBF) and MPI to identify occult coronary artery disease (CAD). These individuals serve as an active control with higher risk non-diabetic individuals with scores greater than 100.
3064659|NCT01019694|Experimental|Combivent Respimat 20/100 microgram(mcg)|patient to take 1 inhalation 4 times a day
3064660|NCT01019694|Active Comparator|Combivent CFC-MDI 36/206 microgram-mcg|patient to take 2 inhalations 4 times a day
3064661|NCT01019694|Active Comparator|Atrovent HFA 42 mcg + Albuterol HFA|patient to take 2 inhalations of each 4 times a day
3064662|NCT01019707|Placebo Comparator|Sugar pill|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
3064663|NCT01019707|Active Comparator|Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
3064664|NCT01019928|Experimental|First AZD1386, then washout, then placebo|
3064665|NCT01019928|Experimental|First placebo, then washout, then AZD1386|
3064666|NCT01020006|Active Comparator|Gemcitabine|Subjects receive Gemcitabine 1000 mg/m2 weekly intravenous infusion.
3064667|NCT01020006|Experimental|PCI-27483 + Gemcitabine|"Part A: Subjects received PCI-27483 0.8 mg/kg BID as initial dose and may be escalated to 1.2, and 1.5 mg/kg BID. At the same time, subjects received Gemcitabine 1000 mg/m2 weekly intravenous infusion.~Part B: Subjects received the PCI-27483 at 1.2 mg/kg BID and Gemcitabine 1000 mg/m2 weekly intravenous infusion."
3064668|NCT01020019|Experimental|Lofexidine and Dronabinol|Maintained at 1.8mg/day Lofex. and 60 mg/day of Dronabinol
3064669|NCT01020019|Placebo Comparator|Placebo|Lofex. matched placebo Dronabinol placebo
3064670|NCT01020123|Experimental|1|AZD1656
3064671|NCT01020123|Experimental|2|AZD1656
3064672|NCT01020123|Experimental|3|AZD1656
3064673|NCT01020123|Experimental|4|AZD1656
3064674|NCT01020123|Experimental|5|AZD1656
3064675|NCT01020123|Placebo Comparator|6|
3064676|NCT01020123|Active Comparator|7|Glipizide administered to 1 group of patients
3064677|NCT01020305|Experimental|Temsirolimus + Bicalutamide|"Temsirolimus 25 mg administered intravenously (IV) once weekly for 12 weeks~Casodex (bicalutamide) administered 50 mg/day orally (PO)"
3064678|NCT01020435|Active Comparator|Spinal Manipulation High Velocity|This non-rotary upper cervical procedure uses an impulse thrust with a controlled depth (high velocity). The participant's head is supported by a specially designed cushion and the doctor usually approaches the participant from in front of his or her head to contact soft tissue over the atlas transverse process, posterior to the lateral mass or occasionally on the C2 lamina or spinous process, with the pisiform process of one hand. The thrust is delivered by a contraction of the triceps muscles of both arms, which straightens the arms and applies the thrust to the participant.
3064679|NCT01020435|Placebo Comparator|Sham Spinal Manipulation|The sham assessment procedures will be similar to the active group. It has been developed and validated by Vernon et al.
3064680|NCT01020448|Experimental|Triptorelin (Decapeptyl®) 22.5 mg|
3064681|NCT01020474|Placebo Comparator|Placebo|
3064682|NCT01020474|Experimental|drug-pregabalin|
3064683|NCT01020487|Experimental|Part 1: Paricalcitol|Participants received a single 3 µg dose of paricalcitol capsules on Study Day 1.
3064684|NCT01020487|Placebo Comparator|Part 2: Placebo|Participants received placebo capsules three times a week (TIW) for 12 weeks during the double-blind treatment phase. From Weeks 12 to 24 participants received open-label paricalcitol at an initial dose of 1 µg three times a week. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target Kidney Disease Outcomes Quality Initiatives (KDOQI) target levels.
3064685|NCT01020487|Experimental|Part 2: Paricalcitol|Participants received paricalcitol three times a week for 12 weeks during the double-blind treatment period and during the open-label period (Weeks 12-24). The initial dose of paricalcitol was 1 µg TIW. Doses could be increased in 1 μg increments every 4 weeks based on chemistry evaluations to target KDOQI target levels.
3064686|NCT01020526|Experimental|Pregabalin|
3064687|NCT01020591|Active Comparator|Osteopathic evaluation|osteopathic evaluation of motion and tissue mobility
3064688|NCT01020591|Experimental|Osteopathic evaluation with treatment|osteopathic evaluation of motion and tissue mobility followed by osteopathic manual therapy release of the tight or restricted tissues
3064689|NCT01020773|Active Comparator|SBT group|In the SBT group, the patients underwent a 1 hr SBT with inspiratory PS of 7 cmH2O with other settings remaining constant (FiO2, PEEP, trigger sensitivity). The patients who tolerated the SBT underwent immediate extubation.
3064690|NCT01020773|No Intervention|no-SBT group|In no-SBT group, as soon as a patient met readiness criteria, he or she underwent extubation without SBT process.
3064691|NCT01020786|Experimental|Pemetrexed + Carboplatin|After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.
3064692|NCT01020799|Experimental|AZD7268|The AZD7268 15 mg BID arm consisted of 3 AZD7268 5 mg capsules dosed orally in the morning and evening. In addition, 2 placebo tablets to match encapsulated escitalopram tablets were dosed orally in the morning only.
3064693|NCT01020799|Placebo Comparator|Placebo|The placebo arm consisted of 3 placebo capsules to match AZD7268 capsules dosed orally in the morning and evening. In addition, 2 placebos to match encapsulated escitalopram tablets were dosed orally in the morning only.
3064694|NCT01020799|Active Comparator|Escitalopram|The escitalopram 20 mg QD arm consisted of 3 placebo to match AZD7268 capsules dosed orally in the morning and evening. In addition, during Week 1, one encapsulated 10-mg escitalopram tablet and 1 placebo to match encapsulated escitalopram tablet were dosed orally in the morning only. During Weeks 2 through 4, two encapsulated 10-mg escitalopram tablets were dosed orally in the morning only.
3064695|NCT01020812|Experimental|Stereotactic body radiotherapy (SBRT)|"SBRT will be delivered on Varian's linear accelerator with On-Board Imaging (OBI) capabilities. The tumor will be tracked with the ethiodol material from the TACE procedure, and respiratory gating will be used to minimize motion due to respiration. Treatment will be given in either 3 or 5 fractions . SBRT will take place after the treatment planning and within 12 weeks of the last TACE procedure.~Doses: 45 Gy at 15 Gy/fraction , 36 Gy at 12 Gy/fraction, 45 Gy at 9 Gy/fraction, 40 Gy at 8 Gy/fraction"
3064696|NCT01020838|Experimental|Florbetaben (BAY94-9172)|
3064697|NCT01020877|Experimental|1|Metronidazole Vaginal Gel
3064698|NCT01020877|Active Comparator|2|MetroGel-Vaginal®
3064699|NCT01020981||Group 1|Michigan State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
3064700|NCT01020981||Group 2|Indiana State Army National Guard soldiers who have returned from OEF/OIF deployments starting December 2008
3064701|NCT01021007|Placebo Comparator|A|control mouthrinse
3064702|NCT01021007|Experimental|B|new prototype mouthrinse
3064703|NCT01021020|Experimental|1|Colchicine (fasted)
3064704|NCT01021020|Experimental|2|Colchicine (fed)
3064705|NCT01021020|Active Comparator|3|Colchicine/Probenecid (fasted)
3064706|NCT01021111|Experimental|Activity Training with Feedback|Subject is tested prior to training and retested with feedback training designed to modify the mechanics of landing during jumping and running activities
3064707|NCT01021137||TBI & Blast|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure and a diagnosis of mild TBI
3064708|NCT01021137||Blast Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with history of blast exposure without TBI
3064709|NCT01021137||TBI Only|OEF/OIF Veterans complaining of dizziness and/or imbalance with a history of mild TBI and no blast exposure
3064710|NCT01021137||Healthy Controls|Age and gender matched control participants with no complaints of dizziness and/or imbalance or history of TBI or blast exposure
3064711|NCT01021137||Excluded|Participants who did not meet inclusion criteria, did not return to complete evaluation, and/or were excluded from data analysis.
3064712|NCT01021215|Experimental|Arm I: Zileuton|Zileuton 1200 mg twice orally twice a day on days 1-6.
3064713|NCT01021215|Experimental|Arm II: Zileuton and Celecoxib|Combined Zileuton 1200 mg twice daily plus Celecoxib 200 mg twice daily on days 1-6.
3064714|NCT01021293|Experimental|Poliorix Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Poliorix™ (IPV) vaccine at 2, 3 and 4 months of age, administered intramuscularly into the anterolateral side of the right thigh.
3064715|NCT01021293|Active Comparator|Control Group|Healthy male and female Chinese infants between, and including 60 and 90 days of age, who received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.
3064716|NCT01021306|Active Comparator|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner.
3064717|NCT01021306|Active Comparator|Dental Care & Self Care|Intraoral splints are removable orthopedic appliances fabricated of hard acrylic resin positioned between the remaining teeth of the patient. They are designed in theory to support the function of the TMJ and relieve associated pain. Stabilization splints are believed to function by stabilizing the intracapsular structure of the TMJ, reducing activity of masticatory muscles, distributing occlusal forces, and reducing bruxism (teeth grinding).
3064718|NCT01021306|Sham Comparator|Sham AMCT & Self Care|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except no thrust will be delivered. Self-care only participants successfully completing the 6 month assessment will be given the option for RIST or AMCT for one month.
3064719|NCT01021306|Placebo Comparator|Self-care only group|All patients will be offered the self-care checklist of homecare approaches at baseline. Self-care only participants successfully completing the 6 months assessment will be given the option for RIST or AMCT for one month.
3064720|NCT01021332|Experimental|Total Group|Participants who received at least one dose of open-label fixed dose combination (FDC) treatment
3064721|NCT01021423|Experimental|Lenalidomide|Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
3064722|NCT01021423|Experimental|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
3064723|NCT01021553|Placebo Comparator|placebo|placebo
3064724|NCT01021553|Active Comparator|50 mg|50 mg GSK557296
3064725|NCT01021553|Active Comparator|150 mg|150 mg GSK557296
3064726|NCT01021618|Active Comparator|Vasodilator-exercise stress|Four-minute infusion of dipyridamole (0.56 mg/kg) followed by symptom-limited exercise; injection of technetium-99m labeled radiopharmaceutical at peak hyperemia or peak exercise followed by SPECT myocardial perfusion imaging
3064727|NCT01021618|Experimental|Exercise-vasodilator stress|Symptom-limited exercise followed by a bolus intravenous injection of regadenoson (0.4 mg/5 mL) in patients failing to achieve a standard clinical endpoint; injection of technetium-99m labeled radiopharmaceutical 15 seconds after administration of regadenoson (or at peak exercise if regadenoson not administered) followed by SPECT myocardial perfusion imaging.
3064728|NCT01021683||Itraconazole|Participants who have been receiving itraconazole will be observed prospectively. Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
3064729|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg QD|Participants receive MK-2206 45 mg oral tablets once every other day (QOD) PLUS AZD6244 75 mg oral capsules once daily (QD) starting on Day 1 of each 28-day cycle.
3064730|NCT01021748|Experimental|MK-2206 45 mg QOD + AZD6244 75 mg BID|Participants receive MK-2206 45 mg oral tablets QOD PLUS AZD6244 75 mg oral capsules twice daily (BID) starting on Day 1 of each 28-day cycle.
3064731|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 50 mg BID|Participants receive MK-2206 90 mg oral tablets once weekly (QW) PLUS AZD6244 50 mg oral capsules BID starting on Day 1 of each 28-day cycle.
3064732|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3064733|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 75 mg BID|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 75 mg oral capsules BID starting on Day 1 of each 28-day cycle.
3064734|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3064735|NCT01021748|Experimental|MK-2206 90 mg QW + AZD6244 150 mg QD|Participants receive MK-2206 90 mg oral tablets QW PLUS AZD6244 150 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3064736|NCT01021748|Experimental|MK-2206 100 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 100 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3064737|NCT01021748|Experimental|MK-2206 135 mg QW + AZD6244 100 mg QD|Participants receive MK-2206 135 mg oral tablets QW PLUS AZD6244 100 mg oral capsules QD starting on Day 1 of each 28-day cycle.
3064738|NCT01021761|Active Comparator|Xibrom|Xibrom to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
3064739|NCT01021761|Active Comparator|Nevanac|Nevanac to be given 1 drop 2 times (BID) the day before surgery and 3 doses pre op the day of surgery prior to surgery
3064740|NCT01021761|Active Comparator|Acuvail|Acuvail to be given preoperatively. One drop 2 times (BID), 1 day pre op and day of surgery 3 doses prior to surgery.
3064741|NCT01021813|Experimental|Suvorexant|After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to <65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
3064742|NCT01021813|Placebo Comparator|Placebo|After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.
3320890|NCT02014558|Experimental|Gilteritinib 450 mg in Escalation Phase|Participants received a single dose of 450 mg gilteritinib orally on day -2 to evaluate pharmacokinetics of gilteritinib. Then starting on day 1 of cycle 1, participants received 450 mg gilteritinib orally once daily in 28-day cycles until disease progression or participant discontinuation in the escalation phase of the study.
3064743|NCT01021852|Experimental|MK-6096 2.5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for overnight polysomnography (PSG) recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive dose-matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3064744|NCT01021852|Experimental|Placebo/MK-6096 2.5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment for the remaining 11 days. During Treatment Period 2, participants receive MK-6096 2.5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3064745|NCT01021852|Experimental|MK-6096 5 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3064746|NCT01021852|Experimental|Placebo/MK-6096 5 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 5 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3064747|NCT01021852|Experimental|MK-6096 10 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3064748|NCT01021852|Experimental|Placebo/MK-6096 10 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 10 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3064749|NCT01021852|Experimental|MK-6096 20 mg/Placebo|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory on Days 1 and 29 for 2 overnight PSG recordings, on which days they receive MK-6096 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo to MK-6096 for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive placebo 30 minutes before bedtime.
3064750|NCT01021852|Experimental|Placebo/MK-6096 20 mg|Prior to Treatment Period 1, participants undergo a 3 week screening period and receive single-blind placebo for the last 2 weeks if screening criteria are met. During Treatment Period 1, participants receive matched placebo to MK-6096 daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29, on which days they receive placebo 30 minutes before bedtime. Treatment Period 1 is followed by a 2-week washout period during which the participant receives single-blind placebo for the first 3 days and no treatment the remaining 11 days. During Treatment Period 2, participants receive MK-6096 20 mg daily for 4 weeks at 5-10 minutes before bedtime and return to the sleep laboratory for 2 overnight PSG recordings on Days 1 and 29 (Study Days 44 and 72), on which days they receive MK-6096 30 minutes before bedtime.
3064751|NCT01021878|Experimental|icodextrin|glucose sparing alternative dialysis solution
3064752|NCT01021878|Active Comparator|dextrose|dianeal, Control group, standard treatment
3064753|NCT01021956|Experimental|WST11 (STAKEL)|Single doses of 2.5 mg/kg of STAKEL® in combination with transpupilar illumination of the macula at escalating doses from 12.5 to 75 Joules/cm².
3064754|NCT01022073||Globus Pallidus interna Group|Cohort of subjects who received DBS-GPi as part of the CSP 468 intervention trial, and still have their device working and in place.
3064755|NCT01022073||Subthalamic Nucleus Group|Cohort of subjects who received DBS-STN as part of the CSP 468 intervention trial, and still have their device working and in place.
3064756|NCT01022112|Experimental|TA-7284-Low|
3064757|NCT01022112|Experimental|TA-7284-Low-middle|
3064758|NCT01022112|Experimental|TA-7284-High-middle|
3064759|NCT01022112|Experimental|TA-7284-High|
3064760|NCT01022112|Placebo Comparator|Placebo|
3064761|NCT01022190|Experimental|Drug: Etoricoxib (Arcoxia, MSD), 90 mg.|Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.
3064762|NCT01022203|Experimental|Structured Approach Therapy|Couple-Based Intervention called Structured Approach Therapy provides skills training to couple so they can reduce PTSD.
3064763|NCT01022203|Active Comparator|PTSD Family Education|Couple-Based Education called PTSD Family Education teaches couple about PTSD symptoms, related problems, and treatment.
3064764|NCT01022242|Placebo Comparator|Placebo|Placebo is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
3064765|NCT01022242|Experimental|PXL01|PXL01 is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
3064766|NCT01022307||Group 1: no history of TBI|184 participants with no history of traumatic brain injury (TBI).
3064767|NCT01022307||Group 2: with a history of TBI|28 patients with a history of TBI. Most of these patients had suffered mild TBI.
3064768|NCT01022359|Active Comparator|Tesio Catheter|Patients randomised to receive the established catheter type in use at our centre [control]
3064769|NCT01022359|Active Comparator|LifeCath|Patients randomised to receive the LifeCath Twin catheter - the catheter type being compared to the standard line in use at our centre (Tesio)
3064770|NCT01022424|Experimental|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
3064771|NCT01022502|Active Comparator|refined indigo naturalis ointment|Refined indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
3064772|NCT01022502|Active Comparator|crude indigo naturalis ointment|Crude indigo naturalis ointment was applied topically to one of 2 bilaterally symmetrical psoriatic plaque lesions of the same patient for 8 weeks, starting on the date of enrollment in the study
3064773|NCT01022567|Active Comparator|Operative treatment|Regular open appendicectomy
3064774|NCT01022567|Active Comparator|Antibiotic treatment|Ertapenem 1 g i.v. x 1 three days
3064775|NCT01022580|Active Comparator|Infasurf surfactant (ONY, Inc.)|Infants already receiving inhaled nitric oxide will receive scheduled doses of late surfactant (Infasurf) on study days 0, 2, 4, 6 and 8.
3064776|NCT01022580|Sham Comparator|Sham (No Treatment)|"Infants already receiving inhaled nitric oxide will receive Sham (no treatment) doses on study days 0,2,4,6, and 8."
3064777|NCT01022762|Active Comparator|repaglinide|1 mg repaglinide twice daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 4 mg three times daily
3064778|NCT01022762|Active Comparator|gliclazide|80 mg gliclazide once daily (weeks 0-4), titrated (individually adjusted) to maintenance dose (weeks 4-16). Maximum dose is 160 mg twice daily
3064779|NCT01022853|Experimental|BIBF 1120 and BI 6727|Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
3064780|NCT01022996|Experimental|RAD001|"Patients with a history of classical Hodgkin lymphoma (ie, nodular sclerosing, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) whose disease had progressed after receiving high-dose chemotherapy with AHSCT (if eligible) and/or after therapy with a gemcitabine- or vinorelbine- or vinblastine-containing regimen, were enrolled into this study. All patients were assigned to a daily dose of everolimus 10 mg (two 5-mg tablets), selfadministered orally and continuously from Cycle 1 Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death, or discontinuation from the study for any other reason.~A treatment cycle consisted of 28 days."
3064781|NCT01023022||Medtronic CareLink® Network|"Patients with implanted Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices, who will be monitored by the Medtronic CareLink® System.~The System consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website."
3064782|NCT01023035|Experimental|Treated/Not Randomized|Participants received 4 weeks of PEG2b/RBV followed by 24 or 44 weeks of boceprevir plus PEG2b/RBV depending on Hepatitis C Virus RNA (HCV-RNA) levels. Participants continued with this treatment if their serum hemoglobin remained >10 g/dL throughout the 28- or 48-week treatment period.
3064783|NCT01023035|Experimental|Ribavirin Dose Reduction|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Ribavirin (RBV) Dose Reduction Arm received reduced doses of RBV for management of the anemia in combination with PEG2b and boceprevir therapies.
3064784|NCT01023035|Experimental|Erythropoietin Use|After the initiation of treatment with 4 weeks with PEG2b/RBV followed by 24 or 44 weeks of boceprevir, participants who became anemic (serum hemoglobin = ≤10 g/dL) within the 28- or 48-week treatment period and who were randomized to the Erythropoietin Use Arm received erythropoietin for management of the anemia in addition to PEG2b/RBV and boceprevir therapies.
3064785|NCT01023061|Experimental|Treatment (antihormone therapy and radiation therapy)|Patients receive abiraterone acetate and prednisone daily for 24 weeks. Patients also receive leuprolide acetate or goserelin in weeks 1 and 13. Patients undergo external beam radiotherapy starting in week 15 for 8.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3064786|NCT01023074|No Intervention|Non-MS Control|Non-MS control group
3064787|NCT01023074|Active Comparator|MS: Auditory Training|MS group receiving auditory training
3064788|NCT01023074|Placebo Comparator|MS: Control Activity|MS group not receiving auditory training, doing control activity
3064789|NCT01023178|Active Comparator|Vivelle-Dot|17Beta Estradiol - transdermal
3064790|NCT01023178|Active Comparator|Premarin|Conjugated estrogens
3064791|NCT01023178|Active Comparator|Estrace|17beta Estradiol
3064792|NCT01023217|Experimental|Adefovir plus Entecavir|Adefovir + Entecavir for 104 weeks
3064793|NCT01023217|Active Comparator|Adefovir plus Lamivudine|Adefovir + Lamivudine for 52 weeks, and thereafter, Adefovir + Entecavir for 52 more weeks
3064794|NCT01023256|Experimental|Group 1: MOR103, experimental|Biological: MOR103 0.3 mg/kg or placebo
3064795|NCT01023256|Experimental|Group 2: MOR103, experimental|Biological: MOR103 1.0 mg/kg or placebo
3064796|NCT01023256|Experimental|Group 3: MOR103, experimental|Biological: MOR103 1.5 mg/kg or placebo
3064797|NCT01023269|Other|ON / OFF|Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
3064798|NCT01023269|Other|OFF / ON|Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.
3064799|NCT01023308|Experimental|Panobinostat + Bortezomib + Dexamethasone|
3064800|NCT01023308|Placebo Comparator|Placebo + Bortezomib + Dexamethasone|
3064801|NCT01023477|Experimental|Chloroquine Standard Dose (500mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month standard dose chloroquine (500 mg/week).
3064802|NCT01023477|Experimental|Chloroquine Low Dose (250mg/week)|Patients with ER+ or ER- DCIS regardless of histologic grade will be randomly assigned to receive one month low dose chloroquine (250mg/week).
3064803|NCT01023516|Experimental|1|
3064804|NCT01023516|Placebo Comparator|2|
3064805|NCT01023568|Active Comparator|Macintosh blade|Intubation with Macintosh blade laryngoscope
3064806|NCT01023568|Active Comparator|Glidescope|Intubation with Glidescope laryngoscope
3064807|NCT01023568|Active Comparator|Truview PCD|Intubation with the Truview PCD laryngoscope
3064808|NCT01023581|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, twice daily and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3064809|NCT01023581|Experimental|Alogliptin 25 QD|Alogliptin 25 mg, tablets, orally, once daily (QD) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3064810|NCT01023581|Experimental|Alogliptin 12.5 BID|Alogliptin 12.5 mg, tablets, orally, twice daily (BID) and Metformin placebo-matching capsules, orally, twice daily for up to 26 weeks.
3064811|NCT01023581|Active Comparator|Metformin 500 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 500 mg capsules, orally, twice daily for up to 26 weeks.
3064812|NCT01023581|Active Comparator|Metformin 1000 BID|Alogliptin placebo-matching tablets, orally, twice daily and Metformin 1000 mg capsules, orally, twice daily for up to 26 weeks.
3064813|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 500 BID|Alogliptin 12.5mg, tablets, orally, twice daily and Metformin 500 mg, capsules, orally, twice daily for up to 26 weeks.
3064814|NCT01023581|Experimental|Alogliptin 12.5 BID + Metformin 1000 BID|Alogliptin 12.5 mg, tablets, orally, twice daily and Metformin 1000 mg, capsules, orally, twice daily for up to 26 weeks.
3064815|NCT01023659|Active Comparator|Bupropion + motivational emails|participants receive Zyban (300mg/day) plus weekly motivational emails for 12 weeks.
3064816|NCT01023659|Active Comparator|Varenicline + motivational emails|participants receive Champix (2mg/day) plus weekly motivational emails for 12 weeks.
3064817|NCT01023659|Active Comparator|Motivational emails|participants receive weekly motivational emails for 12 weeks.
3064818|NCT01023672|Other|Armodifinil|150-250 mg armodafinil by mouth daily
3064819|NCT01023711|Other|Inactivated H1N1 Vaccine|Subject will recieve 0.5 mL IM injection of Inactivated H1N1 vaccine
3064820|NCT01023724|Active Comparator|bromfenac 0.09%|bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
3064821|NCT01023724|Active Comparator|Acuvail|Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
3064822|NCT01023776|Other|live monovalent H1N1 vaccine|A/California/07/09 live monovalent H1N1 vaccine 0.2 given intranasally, 2 doses given 28 days apart
3064823|NCT01023789|Experimental|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation in the treatment of coronary artery disease
3064824|NCT01023815|Experimental|Group A -Once-a-day regimen|"Everolimus: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole daily dose of everolimus was taken in the morning, at the same time of the CsA and steroid dosing. At the Rand+1W visit, the everolimus dose was adjusted to reach and maintain everolimus blood levels between 5 and 8 ng/mL until end of Month 12.~Cyclosporine: in patients randomized to Group A before Amendment 1 approval, from the day following randomization, the whole cyclosporine daily dose was taken in the morning. The dose was then adjusted to maintain C2 levels between 350 and 700 ng/mL.~Prednisone: In patients randomized to Group A before Amendment 1 approval, the dose of prednisone was kept stable at 5 mg/day in the morning."
3064825|NCT01023815|Experimental|Group B - Steroid Withdrawal group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine:after randomization the cyclosporine dose was adjusted to maintain CsA C2 levels within 300-500 ng/mL until M12.~Prednisone: starting from Visit 5 (day 90 ± 28 days), oral prednisone was tapered until complete stop. It was recommended to taper prednisone by 1 mg/week until complete stop in 5 to 6 weeks."
3064826|NCT01023815|Active Comparator|Group C - Standard twice-a-day group|"Everolimus: after randomization the everolimus dose was adjusted, if necessary, in order to maintain a C0 within 6-10 ng/mL until M12.~Cyclosporine: after randomization the cyclosporine dose was gradually adjusted to reach and maintain C2 blood levels of 200-450 ng/mL between Month 6 and Month 12.~Prednisone: the dose of prednisone was kept stable at 5 mg/day in the morning."
3064827|NCT01023815|Experimental|Not Randomized Population (NRP)|"NRP defined in whom a renal transplantation was performed, received at least one dose of study drug (everolimus) but who did not qualify for randomization at Visit 5, Day 90. This group was addressed as not randomized patients (NRP) and described with respect to baseline characteristics, treatment and outcome variables."
3064828|NCT01023841|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
3064829|NCT01023841|Placebo Comparator|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
3064830|NCT01023958|Experimental|single arm|open label
3064831|NCT01024010|Experimental|Arm A (PCO, closed to accrual as of 8/23/2011)|Patients receive induction therapy comprising ofatumumab IV on day 1 (days 1-2 of course 1 only), pentostatin IV over 30 minutes on day 1, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3064832|NCT01024010|Experimental|Arm B (PCO with ofatumumab consolidation)|Patients receive induction therapy as in Arm A. Patients then receive consolidation therapy comprising ofatumumab IV on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3064833|NCT01024036|Experimental|Siltuximab+best supportive care (BSC)|Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
3064834|NCT01024036|Placebo Comparator|Placebo+BSC|Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.
3064835|NCT01024231|Experimental|Cohort 1: BMS-936558 (0.3 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 0.3 mg/kg solution, 60 minutes intravenous infusion every 3 (q3) weeks for 21 weeks in induction and every 12 (q12) weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3064836|NCT01024231|Experimental|Cohort 2: BMS-936558 (1 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
3064837|NCT01024231|Experimental|Cohort 3: BMS-936558 (3 mg/kg)+Ipilimumab (3 mg/kg)|"Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance~BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance"
3064838|NCT01024231|Experimental|Cohort 4: BMS-936558 (10 mg/kg)+Ipilimumab (3 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 3 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3064839|NCT01024231|Experimental|Cohort 5: BMS-936558 (10 mg/kg)+Ipilimumab (10 mg/kg)|"BMS-936558 (MDX1106-04) 10 mg/kg solution, 60 minutes intravenous infusion, q3 weeks for 21 weeks in induction and q12 weeks for 84 weeks in maintenance~Ipilimumab (BMS-734016) 10 mg/kg solution, 90 minutes intravenous infusion, q3 weeks for 9 weeks in induction and q12 weeks for 84 weeks in maintenance"
3064840|NCT01024231|Experimental|Cohort 6: BMS-936558 (1 mg/kg)|BMS-936558 (MDX1106-04) 1 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
3064841|NCT01024231|Experimental|Cohort 7: BMS-936558 (3 mg/kg)|BMS-936558 (MDX1106-04) 3 mg/kg solution, 60 minutes intravenous infusion, once q2 weeks for a total maximal duration of 96 weeks
3064842|NCT01024231|Experimental|Cohort 8: Nivolumab+Ipilimumab|"Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg solution intravenously q3 weeks, 4 doses for 12 weeks~Followed by Nivolumab 3 mg/kg solution alone intravenously q2 weeks, 48 doses for a maximum of 96 weeks"
3064843|NCT01024244|Placebo Comparator|0 milligrams (mg) Placebo|Participants received 2 placebo capsules by mouth (po), twice daily (BID), prior to morning and evening meals for 12 weeks.
3064844|NCT01024244|Experimental|100 mg LY2599506|Participants received 50-mg capsules of LY2599506 po BID (One 50 mg LY2599506 capsule + 1 matching placebo capsule), prior to morning and evening meals for 12 weeks.
3064845|NCT01024244|Experimental|200 mg LY2599506|Participants received two 50-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
3064846|NCT01024244|Experimental|400 mg LY2599506|Participants received two 100-mg capsules of LY2599506 po BID, prior to morning and evening meals for 12 weeks.
3064847|NCT01024244|Experimental|200 mg LY2599506 once daily|Participants received 200-mg of LY2599506 po once daily (QD) (Two 100 mg LY2599506 capsules prior to morning meal, 2 matching placebo capsules prior to evening meal for 12 weeks).
3064848|NCT01024296|Experimental|Gastric Bypass Surgery Patients|Surgical site closure using Port Close device
3064849|NCT01024309|Active Comparator|Mini-Posterior Approach|Mini-Posterior surgical approach for total hip arthroplasty
3064850|NCT01024309|Experimental|Direct Anterior Approach|Direct Anterior surgical approach for total hip arthroplasty
3064851|NCT01024335|Active Comparator|Naltrexone and placebo|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month while placebo will be taken daily for the first 5 weeks of treatment.
3064852|NCT01024335|Experimental|Naltrexone and dronabinol|A long-acting, injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month (the total of two injections, once at the end of hospitalization, and once at end of first month of outpatient treatment), while dronabinol (15 mg bid) will be taken daily for the first 5 weeks of treatment.
3064853|NCT01024387|Experimental|AMG 479|Patients receive AMG 479 at a dose of 18 mg/kg administered IV on day 1 (± 3 days) of every 3-week cycle. Treatment should continue until disease progression, unacceptable toxicity or withdrawal of consent.
3064854|NCT01024465|Experimental|ReShape Duo Balloon|Patients seeking weight loss with a starting BMI in the 30-40 range, received the ReShape Duo Balloon
3320891|NCT02014558|Experimental|Gilteritinib 20 mg in Expansion Phase|Participants received 20 mg gilteritinib orally once daily stating on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. Starting on day 16 of cycle 1, participants also received 200 mg voriconazole orally every 12 hours through day 1 of cycle 2.
3064855|NCT01024569|Experimental|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks. Topics include: Introduction to WRAP, Developing a Wellness Toolbox, Creating a Daily Maintenance Plan, Identifying Triggers, Identifying Early Warning Signs, Managing When Things Break Down, and Crisis Planning. Coursework is interactive, using lecture, question and answer, group discussion, and individual or group exercises. Each session includes a lecture on recovery topics such as self-esteem, changing negative thoughts to positive ones, peer support, and lifestyle issues.
3064856|NCT01024569|No Intervention|Comparison Wait-List Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend WRAP groups after their final research interview.
3064859|NCT01024686|Experimental|p52-p36- GAP Vaccine|"p52-/p56- GAP Vaccine: Administered by five bites from GAP-infected Anopheles mosquito.~p52-/p56- GAP Vaccine: Administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
3064860|NCT01024686|No Intervention|Infectivity Control|Active Control: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum
3064861|NCT01024686|Experimental|p52-p36- GAP Vaccine + Infectivity Challenge|"p52-/p36- GAP Vaccine: Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito.~Challenge: Administered by five bites from Anopheles mosquitoes infected with wild type NF54 strain Plasmodium falciparum."
3064862|NCT01024738|Placebo Comparator|Fluoride toothpaste|negative control toothpaste
3064863|NCT01024738|Active Comparator|Triclosan/Fluoride toothpaste|positive control toothpaste (Total toothpaste)
3064864|NCT01024738|Active Comparator|Chlorhexidine Oral Rinse|positive control oral rinse
3064865|NCT01024751|Experimental|Bausch & Lomb Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
3064866|NCT01024751|Active Comparator|Ciba's Multi-Purpose Solution|Multi-Purpose Solution to be used for disinfecting contact lenses.
3064867|NCT01024855|Experimental|RevitaLens OcuTec Multipurpose Solution (Investigational MPS)|
3064868|NCT01024855|Active Comparator|Opti-Free RepleniSH Multipurpose Solution (MPS, Control)|
3064869|NCT01024920|Experimental|Nintedanib (BIBF 1120)|Non-marketed substance: Twice daily oral doses of 200mg BIBF 1120 given continuously.
3064870|NCT01024920|Active Comparator|sunitinib|Marketed substance: Once a day oral doses of 50mg sunitinib given in repeated 6 week cycles: 4 weeks active, 2 weeks rest.
3064871|NCT01024946|Experimental|Pts getting everolimus|This is a multicenter, open label, phase II study of everolimus as a second or third line therapy for the treatment of advanced malignant pleural mesothelioma, which will also evaluate Merlin/NF2 loss as a biomarker to predict sensitivity to everolimus. Patients who have disease progression after one or two prior chemotherapy regimens will be eligible. In the first stage of this design, 19 patients will be accrued. If 6 or less patients among the first 19 patients show clinical benefit, then the study will be terminated and declared negative. If 7 or more patients show clinical benefit, than an additional 20 patients will be accrued to the second stage. At the end of the study, if 17 or more patients show clinical benefit out of a total of 39 patients enrolled, the regimen will be considered worthy of further investigation.
3064872|NCT01024959|Experimental|PCA3 Assay|
3064873|NCT01024972|Experimental|Dantrolene|Dantrolene 1.25mg/kg IV every 6 hours x 7 days
3064874|NCT01024972|Placebo Comparator|Placebo|Equiosmolar volume (5% Mannitol)
3064875|NCT01025037|Other|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement at the rotator cuff repair site
3064876|NCT01025076|Experimental|StomaphyX Group|"Primary Roux-en-Y gastric bypass with evidence of enlarged gastric pouch volume or enlarged stoma diameter of ≥ 20 mm via endoscopy or fluoroscopy.~Patients also demonstrate a weight regain of 15% of excess body weight loss."
3064877|NCT01025154|Experimental|Clofarabine, Cytarabine + Idarubicin|Induction Cycle: Clofarabine 20 mg/m^2 intravenous (IV) daily for 5 days; Idarubicin 10 mg/m^2 IV daily for 3 days; Cytarabine 1 g/m^2 IV daily for 5 days
3064878|NCT01025193|Experimental|Belimumab|Belimumab will be administered intravenously at a dose of 10mg/kg on days 0, 14, 28 and every 28 days for up to 52 weeks to normalize alloantibody levels in sensitized patients awaiting kidney transplantation. Subjects who are not able to undergo transplantation before the end of the treatment period will have final follow-up evaluation 8 weeks after the last dose of belimumab is administered.
3064879|NCT01025232|Active Comparator|4 Week Re-treatment|Subjects can receive re-treatment every 4 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Subjects will go no longer than 12 weeks without treatment.
3064880|NCT01025232|Active Comparator|6 Week Re-treatment|Subjects can receive re-treatment every 6 weeks if there is persistent or recurrent intraretinal, subretinal, or sub-RPE fluid on any OCT modality, or any evidence of hemorrhage on clinical evaluation. Every 6 weeks regimen will test potential longer duration of action of 2.0 mg ranibizumab. Subjects will go no longer than 12 weeks without treatment.
3064881|NCT01025284|Experimental|Part A LY2523355|8 milligrams per square meter (mg/m²) per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 5, 9 of each 21-day cycle, until disease progression or unacceptable toxicity.
3064882|NCT01025284|Experimental|Part B LY2523355|5 or 6 mg/m² per dose based on participant's body surface area, administered intravenously as a 1-hour infusion on Days 1, 2, 3 plus granulocyte colony-stimulating factor (G-CSF) support administered subcutaneously beginning on Day 4 of each 21-day cycle, until disease progression or unacceptable toxicity.
3064883|NCT01025336|Other|23vPS Naive|Group 1.1 13vPnC/13vPnC Group 1.2 13vPnC/23vPS Group 2 23vPS/13vPNC
3064884|NCT01025336|Other|Prior 23vPS>/= 5 years|Group 1 13vPnC/13vPnC Group 2 23vPS/13vPnC
3064885|NCT01025427|Experimental|Elite controller|Sixteen controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
3064886|NCT01025453|Experimental|Pts getting Temsirolimus and Sorafenib|We propose a phase II study to evaluate the efficacy of the combination sorafenib with temsirolimus in patients with thyroid cancer of follicular cell origin (e.g., papillary, follicular, Hurthle cell). A maximum of 36 subjects will be evaluated during the study. Restaging scans, with evaluation of response, will be done every 2 cycles (8 weeks of treatment). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 4 weeks, or at the discretion of the treating physician or patient.
3064887|NCT01025635|Experimental|Azelaic acid foam, 15% (BAY39-6251)|Participants received azelaic acid foam, 15% topically twice daily for 12 weeks
3064888|NCT01025635|Placebo Comparator|Vehicle foam|Participants received vehicle foam topically twice daily for 12 weeks
3064889|NCT01025752|Experimental|Arm 1|Ten session IVR-based cognitive behavior therapy intervention for chronic low back pain
3064890|NCT01025752|Active Comparator|Arm 2|Ten session face to face cognitive behavior therapy for chronic low back pain
3064891|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: placebo/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
3064892|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.1 mg/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: placebo/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
3064893|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.1 mg/ Period 2: placebo/ Period 3: 0.5/ Period 4: 1.0 mg/ Period 5: placebo.
3064894|NCT01025791|Experimental|Panel A, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 0.2 mg/ Period 3: 0.5 mg/ Period 4: 1.0 mg/ Period 5: 1.0 mg dose followed in 6 hours by a 0.8 mg dose.
3064895|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 1|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: placebo/ Period 4: 0.4 mg fed/ Period 5: na.
3064896|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 2|MK-8266 in Period 1: 0.4 mg/ Period 2: placebo/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
3064897|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 3|MK-8266 in Period 1: 0.4 mg/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 0.4 mg fed/ Period 5: na.
3064898|NCT01025791|Experimental|Panel B, Healthy Male Participants, Sequence 4|MK-8266 in Period 1: placebo/ Period 2: 1.2 mg/ Period 3: 1.2 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na.
3064899|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 1|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
3064900|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 2|Period 1: placebo/ Period 2 1.2 mg dose followed in 8 hours by a 1.0 mg dose/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
3064901|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 3|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2 placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
3064902|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 4|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: placebo/ Period 3: 1.0 mg dose followed in 6 hours by a 0.6 mg dose followed in 6 hours by a 0.6 mg dose/ Period 4: placebo/ Period 5: na
3064903|NCT01025791|Experimental|Panel C, Mild/Moderate Hypertension, Sequence 5|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: 1.0 mg dose followed in 6 hours by a 1.0 mg dose followed in 6 hours by a 0.6 mg dose/ Period 5: na
3064904|NCT01025791|Placebo Comparator|Panel C, Mild/Moderate Hypertension, Sequence 6|Period 1: 1.0 mg dose followed in 8 hours by a 0.8 mg dose/ Period 2: 1.2 mg dose followed in 8 hours by a 1.0 mg dose// Period 3: placebo/ Period 4: placebo/ Period 5: na
3064905|NCT01025817|Experimental|Everolimus (EVR) & low dose of tacrolimus|Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was < 3 ng/mL, or reduced if the trough level was > 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.
3064906|NCT01025817|Active Comparator|Mycophenolate mofetil & standard dose tacrolimus|Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
3064907|NCT01025830|Experimental|Generic|generic fixed dose combination of Stavudine, Lamivudine and Nevirapine (Triomune)
3064908|NCT01025830|Active Comparator|Brand|3 separate single pills of Zerit (Stavudine)Epivir (Lamivudine) Viramune (Nevirapine)
3064909|NCT01025843|Experimental|Pbo → 5 mg → Candesartan → 24 mg → 38 mg|Placebo in Period 1; 5 mg MK-5478 in Period 2; Candesartan in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064910|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Candesartan → Pbo|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Candesartan in Period 4; and Placebo in Period 5. There was a minimum 7 days washout between periods.
3064911|NCT01025843|Experimental|1 mg → Candesartan → Pbo → 24 mg → 38 mg|1 mg MK-5478 in Period 1; Candesartan in Period 2: Placebo in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064912|NCT01025843|Experimental|1 mg → 5 mg → 12 mg → Pbo → Candesartan|1 mg MK-5478 in Period 1; 5 mg MK-5478 in Period 2; 12 mg MK-5478 in Period 3; Placebo in Period 4; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
3064913|NCT01025843|Experimental|Pbo→ 8 mg→ 18 mg → 2 mg fed→Candesartan|Placebo in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Candesartan in Period 5. There was a minimum 7 days washout between periods.
3064914|NCT01025843|Experimental|2 mg→Pbo → Candesartan → Pbo fed→38 mg|2 mg MK-5478 in Period 1; Placebo in Period 2; Candesartan in Period 3; Placebo in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064915|NCT01025843|Experimental|2 mg→Candesartan→Pbo→Candesartan fed→38 mg|2 mg MK-5478 in Period 1; Candesartan in Period 2; Placebo in Period 3; Candesartan in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064916|NCT01025843|Experimental|2 mg → 8 mg → 18 mg → 2 mg fed → Pbo|2 mg MK-5478 in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and Placebo in Period 5. There was a minimum 7 days washout between periods.
3064917|NCT01025843|Experimental|Candesartan→8 mg→ 18 mg →2 mg fed→38 mg|Candesartan in Period 1; 8 mg MK-5478 in Period 2; 18 mg MK-5478 in Period 3; 2 mg MK-5478 in Period 4 with a high fat meal; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064918|NCT01025843|Experimental|Candesartan→Pbo → 12 mg → 24 mg→38 mg|Candesartan in Period 1; Placebo in Period 2; 12 mg MK-5478 in Period 3; 24 mg MK-5478 in Period 4; and 38 mg MK-5478 in Period 5. There was a minimum 7 days washout between periods.
3064919|NCT01026012|Experimental|Combined Protocol|patient with submaximal symptom limited maximal exercise testing will also be administered regadenoson pharmacological stress test.
3064920|NCT01026038|Experimental|1|1 dose (0.5 mL), IM of 13vPnC vaccine.
3064921|NCT01026103|Experimental|Tri Staple|This is a single arm study.
3064922|NCT01026142|Active Comparator|A: Capecitabine + Trastuzumab|
3064923|NCT01026142|Experimental|B: Capecitabine + Trastuzumab + Pertuzumab|
3064924|NCT01026181||LSG|Laparoscopic Sleeve Gastrectomy
3064925|NCT01026181||LRYGB|Laparoscopic Roux-en-Y Gastric Bypass
3064926|NCT01026181||LAGB|Laparoscopic Adjustable Gastric Banding
3064927|NCT01026194|Placebo Comparator|Placebo / Teneli + Pio|
3064928|NCT01026194|Experimental|Teneli / Teneli + pio|
3468800|NCT03892278|Experimental|Aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
3064932|NCT01026324|Experimental|Treatment (dinaciclib)|Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
3064933|NCT01026389|Active Comparator|Gadovist|Patient received contrast-enhanced MRA with Gadovist
3064934|NCT01026389|Experimental|Dotarem, interventional|Patients received contrast-enhanced MRA with Dotarem
3064935|NCT01026402|Experimental|AZD2014|AZD2014 dose escalation phase in Part A and expansion phase in Part B.
3064936|NCT01026454|Active Comparator|acyclovir|acyclovir 400 mg orally twice daily
3064937|NCT01026454|Active Comparator|valacyclovir|valacyclovir 1.5 g orally twice daily
3064938|NCT01026493|Experimental|Phase I: Dose Level 1|ABT-888 20 mg x 21 days plus temozolomide 60 mg x 21 days
3064939|NCT01026493|Experimental|Phase I: Dose Level 2a|ABT-888 40 mg x 21 days plus temozolomide 60 mg x 21 days
3064940|NCT01026493|Experimental|Phase I: Dose Level 2b|ABT-888 20 mg x 21 days plus temozolomide 75 mg x 21 days
3064941|NCT01026493|Experimental|Phase I: Dose Level 3|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3064942|NCT01026493|Experimental|Phase II: Arm 1/BEV-NAIVE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3064943|NCT01026493|Experimental|Phase II: Arm 2/BEV-NAIVE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
3064944|NCT01026493|Experimental|Phase II: Arm 1/BEV-FAILURE|ABT-888 40 mg x 21 days plus temozolomide 75 mg x 21 days
3064945|NCT01026493|Experimental|Phase II: Arm 2/BEV-FAILURE|ABT-888 40 mg x 5 days plus temozolomide 150 mg x 5 days
3064946|NCT01026623|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60-70 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3064947|NCT01026792|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. For complete responders, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or for 2 courses after complete response criteria are first met. For other patients, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3064948|NCT01026805||Hysteroscopic Morcellator|11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
3064949|NCT01026818|Experimental|Tadalafil daily [5 milligrams (mg)]|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3064950|NCT01026818|Experimental|Tadalafil on demand (20 mg)|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3064951|NCT01026818|Placebo Comparator|Placebo|After the treatment period and 6-week study Drug-Free Period, all participants can continue on study in an optional 5-mg tadalafil 3-month Open-Label Period.
3064952|NCT01026831|Experimental|Tafluprost|Preservative-free tafluprost
3064953|NCT01026831|Active Comparator|timolol maleate|Preservative-free timolol maleate
3064954|NCT01026844|Experimental|Erlotinib plus hydroxychloroquine|erltoinib 150mg per day plus HCQ in esclating doses of 400mg, 600mg, 800mg and 1000mg per day
3064955|NCT01026844|Experimental|Hydroxychloroqine|hydroxychloroquine given at escalating doses of 400mg, 600mg, 800mg and 1000mg per day
3064956|NCT01026909|Experimental|Injection|Patients in this arm receive one single dose of Triamcinolone hexacetonide injectable suspension (Aristopan), USP, 20mg/mL Parenteral. They will aso be enrolled in physical therapy.
3064957|NCT01026909|No Intervention|Control|Patients will be enrolled in physical therapy
3064958|NCT01026948||Propess and Monica AN24 care package|Women who are eligible and consent to recruitment will receive the Propess and Monica AN24 care package for outpatient induction of labour
3064959|NCT01026974|Experimental|4rMenB|Subjects received three primary doses of rMenB vaccine (at the age of 6-8 months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB vaccine at 40 months of age in the present study.
3064960|NCT01026974|Experimental|4rMenB+OMV NZ|Subjects received three primary doses of rMenB+OMV NZ vaccine (at the age of 6-8months; 2 months after and at 12 months) in parent study (NCT00433914) and one booster dose of rMenB+OMV NZ vaccine at 40 months of age in the present study.
3064961|NCT01026974|Experimental|Naive_4042|Vaccine-naive subjects who received two catch -up doses of rMenB+OMV NZ vaccine at 40 and 42 months of age in the present study.
3064962|NCT01026974|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of rMenB+OMV NZ vaccine at 60 and 62 months of age in the present study.
3064963|NCT01027000|Experimental|Treatment (Combination of chemotherapy and transplant)|See detailed description
3064964|NCT01027195|Placebo Comparator|Standard Bovie Electrocautery|Standard Bovie electrocautery [Valleylab, Boulder, Colorado] used on surgical site during primary total hip arthroplasty to deliver high frequency electrical current to seal tissues and blood vessels.
3064965|NCT01027195|Experimental|Bipolar Radiofrequency|Aquamantys 6.0 bipolar sealer [Salient Surgical Technologies, Portsmouth, New Hampshire] used on surgical site during primary total hip arthroplasty to deliver radiofrequency energy coupled with saline solution irrigation for hemostatic sealing (i.e. shrinking of collagen in the walls of tissue vessels) at lower temperatures (<100 degrees Celsius) than standard Bovie electrocautery.
3064966|NCT01027273|Experimental|Peer-Led Stroke Recurrence Prevention Education|The intervention group will participate in a 6-session course held over a 6-week period. The Prevent Return of Stroke Workshop, led by trained peer educators, aims to help participants control the risk factors for stroke, thereby preventing recurrence of strokes.
3064967|NCT01027273|Placebo Comparator|Usual Care (Delayed Intervention)|The control group will be offered the chance to take part in the 6-week session intervention after 12 months after enrollment into the trial.
3064968|NCT01027286|Experimental|Vitagel|
3064969|NCT01027286|No Intervention|Control|No Vitagel used.
3064970|NCT01027351|Experimental|5rMenB|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
3064971|NCT01027351|Experimental|5rMenB+OMV NZ|Subjects who had received four doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 2,4,6 and 12 months of age) in the parent study were administered a fifth dose of the same vaccine, at 40 months of age in the present study.
3064972|NCT01027351|Experimental|3rMenB|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine without OMV (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
3064973|NCT01027351|Experimental|3rMenB+OMV NZ|Subjects who had previously received one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine (at 12 months of age) were administered two doses of the same vaccine, at 40 and 42 months of age in the present study.
3064974|NCT01027351|Experimental|Naive_4042|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 40 and 42 months of age in the present study.
3064975|NCT01027351|Experimental|Naive_6062|Vaccine-naive subjects who received two catch-up doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 60 and 62 months of age in the present study.
3064976|NCT01027364|Experimental|Fixed Weekly Interval|"50 IU/kg rFIXFc via intravenous (IV) injection once every 7 days initially, then at a dose indicated by the participant's baseline pharmacokinetic (PK) assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial weekly dose of rFIXFc (50 IU/kg) were to be made based on baseline PK assessments, occurrence of spontaneous bleeding episodes, and the trough levels, which were to be monitored at Weeks 4, 16, 26, and 39.~Prior to the first dose of rFIXFc, participants in the Sequential PK subgroup were to receive a single dose of 50 IU/kg BeneFIX administered IV in the clinic, followed by PK sampling. A single dose of 50 IU/kg rFIXFc was administered following a 120-hour washout from BeneFIX, followed by PK sampling for a baseline PK profiling. At Week 26 (±1 week) subjects were to receive a single dose of 50 IU/kg rFIXFc for repeat PK profiling."
3064977|NCT01027364|Experimental|Individualized Interval|100 IU/kg rFIXFc via IV injection once every 10 days initially, then at an interval derived from the baseline PK assessment that ensured a target trough of 1% to 3% above baseline or higher, as clinically indicated. Adjustments to the initial 10-day interval were to be made based on baseline PK assessments and trough levels, which were monitored at Weeks 4, 16, 26, and 39.
3064978|NCT01027364|Experimental|On Demand|20 to 100 IU/kg rFIXFc via IV injection, or the dose indicated by the participant's baseline PK to target a plasma level of 20% to 100%, as needed for the treatment of mild to severe bleeding episodes
3320892|NCT02014558|Experimental|Gilteritinib 40 mg in Expansion Phase|Participants received 40 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
3064979|NCT01027364|Experimental|Surgery|The surgical period and dosing are dependent on the type of surgery the participant undergoes. Participants who started the study in one of the other treatment arms prior to surgery will return to the original treatment arm. Participants who joined the study in the Surgery arm will be assigned to one of the other treatment arms following post-operative rehabilitation.
3064980|NCT01027416|No Intervention|No Intervention|
3064981|NCT01027416|Active Comparator|Tamoxifen|Tamoxifen 20 mg orally 1x/day for 4 weeks
3064982|NCT01027468|Experimental|group 1|bevacizumab intravitreal injection
3064983|NCT01027559|Active Comparator|Depressed Group: CBT|Depressed participants randomized to receive Cognitive Behavioral Therapy (CBT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
3064984|NCT01027559|No Intervention|Healthy Control Group|Healthy controls will an fMRI scan session and their second fMRI scan session will occur approximately 12 weeks after.
3064985|NCT01027559|Active Comparator|Depressed Group: SRT|Depressed participants randomized to receive the antidepressant sertraline (SRT) for treatment. A fMRI scan session will occur immediately prior to starting treatment, and their second fMRI scan will occur immediately following the completion of 12 weeks of therapy.
3064986|NCT01027598|Experimental|Erlotinib + Pazopanib|"Erlotinib: 150 mg orally daily~Pazopanib: 600 mg orally daily"
3064987|NCT01027598|Placebo Comparator|Erlotinib + Placebo|"Erlotinib: 150 mg orally daily~Placebo: orally daily"
3064988|NCT01027650|Experimental|Stage 1 Cohort 1|AGN208397 intravitreal injection 75 ug on Day 1.
3064989|NCT01027650|Experimental|Stage 1 Cohort 2|AGN208397 intravitreal injection 300 ug on Day 1.
3064990|NCT01027650|Experimental|Stage 1 Cohort 3|AGN208397 intravitreal injection 600 ug on Day 1.
3064991|NCT01027650|Experimental|Stage 1 Cohort 4|AGN208397 intravitreal injection 900 ug on Day 1.
3064992|NCT01027650|Experimental|Stage 2 Arm 1|AGN208397 intravitreal injection 600 ug on Day 1.
3064993|NCT01027650|Experimental|Stage 2 Arm 2|AGN208397 intravitreal injection 450 ug on Day 1.
3064994|NCT01027650|Experimental|Stage 2 Arm 3|AGN208397 intravitreal injection 300 ug on Day 1.
3064995|NCT01027650|Active Comparator|Stage 2 Arm 4|Dexamethasone 700 ug intravitreal implant on Day 1.
3064996|NCT01027702|Experimental|Infusion of donor lymphocytes|Patients will receive an infusion of donor lymphocyte after T-cell depleted transplant.
3064997|NCT01027754|Experimental|Varenicline|Drug treatment in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
3064998|NCT01027754|Placebo Comparator|Placebo|Matched placebo capsules in combination with telephone quitline referral and brief individual counseling based on PHS guidelines at weeks 2, 4, 8, and 12
3064999|NCT01027780|Active Comparator|Mindfulness-Based Stress Reduction|Participation in the Mindfulness-Based Stress Reduction (MBSR) program following the initial assessment period, just prior to the start of the immunological measures.
3065000|NCT01027780|No Intervention|Wait-list control|Wait-list control participants were offered MBSR training after completion of their primary assessments periods.
3065001|NCT01027793|Active Comparator|Tretinoin|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
3065002|NCT01027793|Active Comparator|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center.
3065003|NCT01027806|Active Comparator|Montelukast|
3065004|NCT01027806|Placebo Comparator|Placebo|
3065005|NCT01027819|Active Comparator|Mobile bearing|Mobile bearing type between polyethylene insert and tibial component MB type will be randomly used in total knee arthroplasty
3065006|NCT01027819|Active Comparator|Fixed bearing|Fixed bearing type between polyethylene insert and tibial component FB type will be randomly used in total knee arthroplasty
3065007|NCT01027845|Experimental|10Pn Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of Synflorix (10Pn) vaccine, administered intramuscularly on alternating (left/right) sides of the anterolateral thigh and DPT KAKETSUKEN Syringe (DTPa) vaccine administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm. Both vaccines were administered at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
3065008|NCT01027845|Active Comparator|DTPa Group|"Healthy male or female subjects, between 90 and 118 days of age who received 3 doses of the DPT KAKETSUKEN Syringe (DTPa) vaccine, administered subcutaneously on alternating (left/right) sides of the distal one third of the upper arm at 3, 4, and 5 months of age, followed by a booster dose at 17-19 months of age."
3065009|NCT01027871|Experimental|LY2605541 Dosing Algorithm 1|Participants took both LY2605541 and their pre-study insulin for first several days
3065010|NCT01027871|Experimental|LY2605541 Dosing Algorithm 2|Participants took only LY2605541 with first dose doubled
3065011|NCT01027871|Active Comparator|Insulin glargine|
3065012|NCT01027884|Placebo Comparator|Placebo|Placebo 900 mg/day
3065013|NCT01027884|Experimental|Idebenone|Idebenone 900 mg/day
3065014|NCT01027897|Experimental|Doripenem group|Patients will receive doripenem for the treatment of their infection
3065015|NCT01027910|Experimental|PCI-24781 without mandated GCSF|PCI-24781 in combination with doxorubicin without mandated GCSF
3065016|NCT01027910|Experimental|PCI-24781 with mandated GCSF|PCI-24781 in combination with doxorubicin with mandated GCSF
3065017|NCT01027949|Experimental|Oral Treprostinil|Subjects from previous studies TDE-PH-202 (NCT01104870), TDE-PH-203 (NCT01477333), and TDE-PH-205 (NCT01588405), TDE-PH-301 (NCT00325442), TDE-PH-302 (NCT00325403), or TDE PH-308 (NCT00887978). Subjects were instructed to take the appropriate amount of 0.125, 0.25, 0.5, 1, and/or 2.5 mg tablets based upon their prescribed dose. Investigators were instructed to increase the dose of oral treprostinil in the absence of dose limiting drug-related AEs to ensure each subject received the optimal clinical dose throughout the study
3065018|NCT01028014|Active Comparator|Pseudoephedrine|Pseudoephedrine 120mg extended release tablets
3065019|NCT01028014|Active Comparator|Solifenacin|Solifenacin 5mg capsule
3065020|NCT01028014|Active Comparator|Tamsulosin|Tamsulosin 0.4mg capsule
3065021|NCT01028014|Active Comparator|Imipramine|Imipramine 25mg tablet
3065022|NCT01028014|Active Comparator|Cyclobenzaprine|Cyclobenzaprine 10mg tablet
3065023|NCT01028014|Placebo Comparator|Lactose capsules|Sham
3065024|NCT01028027|Experimental|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension
3065025|NCT01028027|Active Comparator|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension
3065026|NCT01028053|Experimental|Flutemetamol (18F) Injection|Flutemetamol (18F) Injection
3065027|NCT01028131|No Intervention|Control|Participants randomized by the computer into this condition will only view the 20-minute video clips of music and tv videos.
3065028|NCT01028131|Experimental|Computerized brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model (ask, advise, assess, assist & arrange) and Motivational Interviewing.
3065029|NCT01028131|Experimental|Contingency Management Alone|Participants randomized by the computer into this condition will view a 20-minute music and tv video clip after completing the brief assessment. The research assistant will then briefly describe the CM process, with some time to discuss questions regarding procedure to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
3065030|NCT01028131|Experimental|Combined Brief Intervention and CM|Combined intervention. Participants in this condition will receive both the brief intervention and the brief description of the CM process.
3065031|NCT01028222|Experimental|Nilotinib|400 mg twice daily
3065032|NCT01028222|Active Comparator|DTIC|850 mg/m2 IV every 3 weeks
3065033|NCT01028352|Other|Duloxetine|
3065034|NCT01028378|Experimental|Topography-guided LASIK|Topography-guided LASIK for Myopia or Hyperopia
3065035|NCT01028391|Experimental|Sitagliptin + Pioglitazone|
3065036|NCT01028391|Active Comparator|Pioglitazone + Placebo|
3065037|NCT01028560|Active Comparator|No immunotherapy, receive standard of care asthma treatment|This group consists of children who do not receive allergy immunotherapy. Both groups - the experimental as well as the control group receive otherwise standard of care asthma and allergy treatment
3065038|NCT01028560|Experimental|Allergen immunotherapy|This group receives initially weekly, later biweekly subcutaneous injections of a mixture of allergen extracts, tailored to the individual child's allergy sensitization profile. The maximum number of injections at each visit is 1-3 injections per child. In addition to allergy immunotherapy. this group receives standard of care asthma and allergy treatment
3065039|NCT01028651||Portopulmonary hypertension|
3065040|NCT01028677|Experimental|intranasal spray with oxytocin|Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
3065041|NCT01028677|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.
3065042|NCT01028820|Experimental|Open-Label, Flexible-Dose Aripiprazole|This is a single group assignment pharmacodynamics study in which all study participants are given an open-label, flexible dose of aripiprazole for up to 8 weeks.
3065043|NCT01028911|Experimental|PF-03654746|
3065044|NCT01028911|Placebo Comparator|Placebo|
3065045|NCT01028937|Experimental|Hyperopia|The NTK Optimal Keratoplasty System/Procedure is indicated for the temporary improvement of distance uncorrected visual acuity (in patient eyes that have manifest refraction, spherical equivalent equal to +1.0 to +2.5 Diopters, with less than or equal to 0.75 Diopters of refractive astigmatism (minus cylinder format) and with uncorrected distance visual acuity less than 20/40 but greater than or equal to 20/80. Patients must be at least 40 years of age with a documented stability of refraction for the prior 12 months, as demonstrated by a change of less than or equal to 0.5 Diopters in MRSE. The magnitude of D-UCVA improvement by Opti-K treatment may diminish over time, caused by some regression of effect in addition to natural progressive loss of accommodation and, for most patients, progressive hyperopic shift with increasing age.
3065046|NCT01029054|Experimental|carfilzomib, lenalidomide w/dexamethasone|"Phase I: carfilzomib will be taken with a combination of lenalidomide plus dexamethasone in a series of escalating dosages to determine the maximum tolerated dose level~Phase II: carfilzomib will be given at the MTD established in the Phase I portion of the study"
3065047|NCT01029262|Experimental|Arm #1 - Lenalidomide plus placebo|Lenalidomide 10 mg by mouth (PO) daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 60 mL/min for at least 168 days until disease progression, intolerable side effects or withdrawal of consent. Lenalidomide 5 mg PO daily plus 2 placebo capsules for participants with a creatinine clearance ≥ 40 and < 60 mL/min.
3065048|NCT01029262|Placebo Comparator|Arm #2 - placebo|Three placebo capsules once daily for at least 168 days until disease progression occurred, intolerable side effects or withdrawal of consent.
3065049|NCT01029340|Experimental|Arm 1: Recombinant Factor VIII (BAY81-8973) then Kogenate FS|Part A - Arm 1: Participants first received one single intravenous (IV) injection of BAY81-8973 50 IU/kg, then 1 single IV injection of Kogenate FS (BAY14-2222) 50 IU/kg with a wash-out period of at least 2-3 days in between
3065050|NCT01029340|Experimental|Arm 2: Kogenate FS then Recombinant Factor VIII (BAY81-8973)|Part A - Arm 2: Participants first received one single intravenous (IV) injection of Kogenate FS (BAY14-2222) 50 IU/kg, then 1 single IV injection of BAY81-8973 50 IU/kg with a wash-out period of at least 2-3 days in between
3065051|NCT01029340|Experimental|Arm 3: Recombinant Factor VIII by CS/EP then by CS/ADJ|Part B - Arm 3: Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months
3065052|NCT01029340|Experimental|Arm 4: Recombinant Factor VIII by CS/ADJ then by CS/EP|Part B - Arm 4:. Participants received IV injection of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay/Adjusted to Label Potency for 6 months and then crossed over to study drug measured by Chromogenic Substrate Assay Per European Pharmacopeia for 6 months
3065053|NCT01029340|Experimental|Arm 5: Recombinant Factor VIII by CS/EP|Part C - Arm 5: Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
3065054|NCT01029353|Active Comparator|Randomized Trial: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
3065055|NCT01029353|Active Comparator|Randomized Trial: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
3065056|NCT01029353|Active Comparator|Preference Cohort: Laparotomy|Under general anesthesia in the NICU or operating room, a laparotomy will be performed following standard procedures.
3065057|NCT01029353|Active Comparator|Preference Cohort: Peritoneal drain placement|Place a one-fourth inch Penrose drain in the lower abdomen with local anesthesia and sedation.
3065058|NCT01029366|Experimental|CART-19 CLL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
3065059|NCT01029366|Experimental|CART-19 ALL|CART-19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion days 0, 1, 2 and 11 in the absence of disease progression or unacceptable toxicity.Minimum/maximum total dose: 1.5x10^7 / 5x10^9 administered to patients with chronic Lymphocytic Leukemia (CLL) and Acute Lymphoblastic Leukemia (ALL).
3065060|NCT01029392|Experimental|Required Vitamin D|Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
3065061|NCT01029392|No Intervention|Normal Vitamin D|Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
3065062|NCT01029405|Active Comparator|1. AN2728 Ointment B|2%, administered twice daily
3065063|NCT01029405|Placebo Comparator|2. AN2728 Ointment B Vehicle|
3065064|NCT01029405|Active Comparator|3. AN2728 Ointment B|2%, administered once daily
3065065|NCT01029405|Active Comparator|4. AN2728 Ointment B|0.5%, administered twice daily
3065066|NCT01029405|Active Comparator|5. AN2728 Ointment B|0.5%, administered once daily
3065067|NCT01029535|Experimental|Juvederm® VOLUMA™|Juvederm® VOLUMA™ injected in both sides of face (up to 4 mL per side) at Investigator's discretion to achieve at least a 2-point improvement in the Mid-face Volume Deficit Scale. Participants who completed Week 8 of Phase 1 were eligible to participate in Phase 2 and could receive an additional optional treatment if applicable.
3065068|NCT01029587|Experimental|Eculizumab|Patients will receive eculizumab in conjunction with systemic anticoagulation before and after kidney transplant operation
3065069|NCT01029652|Experimental|Canakinumab 150 mg|"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive re-dose of study drug on demand upon occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after previous dose. Patients completing 12 weeks core study were allowed to continue treatment in another 12-week extension for any new gout flare on demand with same treatment as assigned in core study.~After completing the first extension, patients were offered to enter second extension study, whereby all patients were treated open-label on demand with canakinumab 150 mg sc upon new flare for 1 year for a total duration of 18 months following randomization in core study. Patients completing first 12 weeks extension study were allowed to continue to be treated in another single-arm, open-label 48 weeks extension when all patients from both treatment arms received canakinumab on demand"
3065070|NCT01029652|Active Comparator|Triamcinolone acetonide 40 mg|"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.~Patients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period Triamcinolone acetonide was not to be administered in the 48-week session."
3065071|NCT01029691|Experimental|Positive Airway Pressure (compliant)|This arm was women who used auto-titrating positive airway pressure (APAP) for at least 4 hours per night
3065072|NCT01029691|No Intervention|Standard care|
3065073|NCT01029691|Experimental|Positive Airway Pressure (non-compliant)|No one was assigned to this arm, but for results data quality purposes, women assigned to PAP who were explicitly non-compliant (used less than 4 hours per night), were analyzed separately from women who were compliant with the PAP assignment.
3065074|NCT01029704|Experimental|EGT0001442|
3065075|NCT01029704|Placebo Comparator|Placebo|
3065076|NCT01029730|Experimental|Bendamustine/Bortezomib/Rituximab|Treatment for all patients will be given in cycles of 28 days (4 weeks). All patients will receive treatment with bendamustine, bortezomib, and rituximab for a maximum of 6 cycles. Rituximab should be administered first.
3065077|NCT01029782|Active Comparator|IV cefazolin plus oral probenecid and placebo cephalexin|
3065078|NCT01029782|Active Comparator|Oral cephalexin and saline IV plus probenecid placebo|
3065079|NCT01029795|Experimental|LY2599506|Combinations of 50-milligram (mg) or 100-mg capsules of LY2599506 or matching placebo capsules (each dose contains at least 1 capsule of active drug). LY2599506 will be administered, based on predefined glycemic targets, in escalating doses from 100 mg/day up to 800 mg/day.
3065080|NCT01029795|Active Comparator|Glyburide|Combinations of 2.5-mg capsules of Glyburide or matching placebo capsules (each dose contains at least 1 capsule of active drug). Glyburide will be administered, based on predefined glycemic targets, in escalating doses from 5 mg/day up to 20 mg/day.
3065081|NCT01029886|Experimental|1|
3065082|NCT01029886|Active Comparator|2|
3065083|NCT01029912|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES) Electrical Stimulator
3065084|NCT01029912|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) Electrical Stimulator
3065085|NCT01029925|Experimental|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart.
3320893|NCT02014558|Experimental|Gilteritinib 80 mg in Expansion Phase|Participants received 80 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
3065086|NCT01030133|Active Comparator|Real TMS|Participants in the real Transcranial Magnetic Stimulation (TMS) group will receive real stimulation across all interventions; the operator role Real TMS and receiver role Real TMS. rTMS will be used to stimulate the left prefrontal cortex using two Neuronetics TMS machines with figure-8, iron core coils at 10Hz and at 110% of resting motor threshold [5 second trains following each trial (25 trials per visit)].
3065087|NCT01030133|Sham Comparator|Sham TMS|Participants in the sham Transcranial Magnetic Stimulation (TMS) group will receive sham stimulation across all interventions; the operator role Sham TMS and receiver role Sham TMS. Sham Stimulation involves 5 second trains of 10Hz rTMS in pairs alternating between real TMS and eSham TMS (randomly ordered). All sham treatment will be delivered with a specially designed, manufacture-provided sham TMS coil that looks and sounds identical to a real TMS coil but no magnetic current is transferred to the participant.
3065088|NCT01030133|Other|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
3065089|NCT01030289|Active Comparator|real tDCS First Visit|On the First Visit, A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
3065090|NCT01030289|Sham Comparator|sham tDCS First Visit|On the First Visit, For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3065091|NCT01030289|Active Comparator|real tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. A single 20-minute tDCS session will be conducted using 2.0mA current. Using the international 10-20 EEG system, the anode will be placed over F4, which corresponds to the right dorsolateral prefrontal cortex (DLPFC), and the cathode will be placed over F3, which corresponds to the left dorsolateral prefrontal cortex. Electrodes will be standard sponge electrodes soaked In a sterile solution of .9% sodium chloride insulated by a latex casing.
3065092|NCT01030289|Sham Comparator|sham tDCS Second Visit|Participant returns for the second visit 48-72 hours after completing the first visit. For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3065093|NCT01030341|Experimental|CGMS and insulin pump|Continuous glucose monitoring in conjunction with insulin pump
3065094|NCT01030406|Active Comparator|40/0mg taken first|8x oxycodone/niacin 5/0mg tablets
3065095|NCT01030406|Active Comparator|80/0mg taken first|8x oxycodone/niacin 10/0mg tablets
3065096|NCT01030406|Experimental|40/240mg taken first|8x oxycodone/niacin 5/30mg tablets
3065097|NCT01030406|Experimental|80/480mg taken first|8x oxycodone/niacin 10/60mg tablets
3065098|NCT01030406|Placebo Comparator|0/0mg taken first|Placebo
3065099|NCT01030458|Experimental|amlodipine plus valsartan|In the experimental group, Exforge will be used in two dosage steps, respectively, amlodipine 5 mg plus 160 mg valsartan and amlodipine 10 mg plus 160 mg valsartan.
3065100|NCT01030458|Active Comparator|hydrochlorothiazide plus bisoprolol|In the reference group, the Lodoz will be used in two dosage steps, respectively 6.25 mg hydrochlorothiazide plus 5 mg or 6.25 mg hydrochlorothiazide plus 10 mg bisoprolol
3065101|NCT01030523|Experimental|Short Implants|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
3065102|NCT01030523|Active Comparator|Long Implants|ASTRA TECH Implants System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
3065103|NCT01030536|Experimental|CAT-8015 20 microgram per kilogram (mcg/kg)|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3065104|NCT01030536|Experimental|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3065105|NCT01030536|Experimental|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3065106|NCT01030536|Experimental|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3065107|NCT01030536|Experimental|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle. Dose escalation is to be continued to the Maximum tolerated dose (MTD) or Optimal biologic dose (OBD). Subsequent dose levels with a 10 mcg/kg increase from the previous dose level are possible if an MTD or OBD is not reached by 60 mcg/kg.
3065108|NCT01030575|Experimental|Inositol low volume|10 mg/kg/day Intravenous inositol 5%
3065109|NCT01030575|Experimental|Inositol mid-level volume|40 mg/kg/day Intravenous inositol 5%
3065110|NCT01030575|Experimental|Inositol high volume|80 mg/kg/day Intravenous inositol 5%
3065111|NCT01030575|Placebo Comparator|Placebo|Glucose 5% given in volumes equal to that of the comparator drug
3065112|NCT01030653|Experimental|Voriconazole low dose first then high dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (200 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (300 mg Every 12 Hours x 7 Doses)
3320894|NCT02014558|Experimental|Gilteritinib 120 mg in Expansion Phase|Participants received 120 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study.
3065113|NCT01030653|Experimental|Voriconazole high dose first then low dose|Voriconazole administered by Mouth as a Loading Dose (400 mg x 2 Doses, Day 1) and as Maintenance Doses (300 mg Every 12 Hours x 7 Doses) followed by 7 day washout followed by Loading Dose (400 mg x 2 Doses, Day 1) and a Maintenance Doses (200 mg Every 12 Hours x 7 Doses)
3065114|NCT01030666|Experimental|doxycycline|"The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
3065115|NCT01030666|Placebo Comparator|placebo|"The patients of the control group will take placebo once a day for 7 days after regenerative therapy of an infrabony defect~modified/simplified papilla preservation flap; scaling~Prefgel/Emdogain~0.12% chlorhexidine gluconate solution~Ibuprofen 400 mg (if necessary)~1% chlorhexidine gluconate gel (if necessary)"
3065116|NCT01030718|Experimental|dasatinib (CML-CP)|CML - Chronic Phase
3065117|NCT01030718|Experimental|dasatinib (CML-AP/BP)|CML - Accelerated Phase and Blast Phase
3065118|NCT01030718|Experimental|dasatinib (Ph+ ALL)|Ph+ Acute Lymphoblastic Leukemia
3065119|NCT01030783|Experimental|tivozanib (AV-951)|
3065120|NCT01030783|Active Comparator|sorafenib|
3065121|NCT01030822|Experimental|Group A|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 9-18 months of age.
3065122|NCT01030822|Experimental|Group B|Subjects previously primed with pneumococcal vaccine GSK1024850A in the first year of life and receiving a booster dose of GSK1024850A at 15-18 months of age.
3065123|NCT01030822|Experimental|Group C|Unprimed subjects receiving a catch-up vaccination (2+1 schedule) in the second year of life.
3065124|NCT01030861|Active Comparator|teplizumab|Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
3065125|NCT01030861|Placebo Comparator|Placebo infusion|Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.
3065126|NCT01030874|No Intervention|Usual Rehabilitation Care|Usual rehab care
3065127|NCT01030874|Experimental|Experimental Treatment/Medication Review|Treatment for, and prevention of, orthostatic hypotension
3065128|NCT01030952|Experimental|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
3065129|NCT01030952|Active Comparator|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
3065130|NCT01030965|Experimental|GSK573719 125mcg|125mcg once-daily via novel dry powder inhaler
3065131|NCT01030965|Experimental|GSK573719 250mcg|250mcg once-daily via novel dry powder inhaler
3065132|NCT01030965|Experimental|GSK573719 500mcg|500mcg once-daily via novel dry powder inhaler
3065133|NCT01030965|Placebo Comparator|Placebo|once-daily via novel dry powder inhaler
3065134|NCT01031004|Experimental|narafilcon B|contact lens
3065135|NCT01031004|Active Comparator|etafilcon A|contact lens
3065136|NCT01031043|Experimental|Topical Bethanechol|patients will be given either 5 mg (first phase) or 10 mg (second phase) of bethanechol in 1 ml of solution containing an absorption enhancer. Administration will be performed by throat spray device
3065137|NCT01031069|Experimental|HIV+/Cervarix Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
3065138|NCT01031069|Active Comparator|HIV+/Gardasil Group|HIV seropositive female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
3065139|NCT01031069|Experimental|HIV-/Cervarix Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Cervarix vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
3065140|NCT01031069|Active Comparator|HIV-/Gardasil Group|HIV seronegative female subjects, between and including 15 and 25 years of age, who received 3 doses of Gardasil vaccine, administered intramuscularly in the deltoid muscle of the non-dominant arm, according to a three-dose schedule: at Day 0, Week 6, Month 6.
3065141|NCT01031095|Experimental|Low dose intracoronary heparin|Low dose intracoronary heparin: In this group elective coronary intervention was performed with low dose intracoronary Heparin
3065142|NCT01031095|Active Comparator|Standard treatment arm|Standard treatment arm: In this group elective coronary intervention performed with standard dose intravenous heparin
3065143|NCT01031134|Experimental|Shared Decision Making|1 in person session followed by 2 telephone calls 1 and 2 weeks later.
3065144|NCT01031134|Active Comparator|Usual Care|Physician Usual Care of depressed patients.
3065145|NCT01031381|Other|Rad001/Bevacizumab|Patients will receive RAD001 by mouth everyday and Bevacizumab IV every 14 days until clinical progression.
3065146|NCT01031420|Experimental|dose dense MVAC|standard doses of MVAC given every 14 days x 3.
3065147|NCT01031446|Experimental|Treatment|
3065148|NCT01031498|Active Comparator|Ondansetron: Standard of Care|Standard of care, Ondansetron 8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
3065149|NCT01031498|Experimental|Palonosetron Group 1 (5 Days)|Palonosetron once a day 0.25 mg IV injection for 5 days, given over 30 seconds, 30 minutes before chemotherapy treatment.
3065150|NCT01031498|Experimental|Palonosetron Group 2 (3 Days)|Palonosetron once a day 0.25 mg IV injection on Days 1, 3, and 5 of chemotherapy treatment, given over 30 seconds, 30 minutes before chemotherapy treatment.
3320895|NCT02014558|Experimental|Gilteritinib 200 mg in Expansion Phase|Participants received 200 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, certain participants also received 500 mg cephalexin as a single oral dose.
3065151|NCT01031537|Other|FSME-IMMUN 0.5mL Baxter|FSME-IMMUN 0.5mL Baxter is non-US licensed vaccine for tick-borne encephalitis virus. The FSME-IMMUN 0.5mL Baxter is available as 0.5mL in a pre-loaded vaccine syringe. All participants received active vaccine using a rapid immunization schedule, with vaccine administration on Days 0, 14, 161 and 245. Participants that tested seropositive for tick-borne encephalitis virus or subjects that developed positive viral neutralizer titers after the 3rd or 4th vaccine were given a booster of FSME-IMMUN 0.5mL Baxter vaccine at 3, 6 and 9 years after enrollment.
3065152|NCT01031680|Experimental|1|Dapagliflozin 10 mg tablet
3065153|NCT01031680|Placebo Comparator|2|Matching placebo tablet
3065154|NCT01031706|Experimental|Hypertonic saline|6% NaCl, 4 ml TID via eFlow
3065155|NCT01031706|Placebo Comparator|Placebo|0.12% x 4ml via eFlow nebulizer
3065156|NCT01031810|Other|tranylcypromine|patients will receive treatment with tranylcypromine
3065157|NCT01031836|Experimental|MEDI-545 1.0 mg/kg|Cohort 1
3065158|NCT01031836|Experimental|MEDI-545 3.0 mg/kg|Cohort 2
3065159|NCT01031836|Experimental|MEDI-545 10.0 mg/kg|Cohort 3
3065160|NCT01031836|Experimental|MEDI-545 100 mg|Cohort 4
3065161|NCT01031836|Experimental|MEDI-545 600 mg|Cohort 5
3065162|NCT01031836|Experimental|MEDI-545 1,200 mg|Cohort 6
3065163|NCT01031914|Experimental|Paced Breathing Sleep/Wake detection|All subjects enrolled will have oobstructive sleep apnea (OSA) and will be current Continuous Positive Airway Pressur (CPAP) users.
3065164|NCT01031953|Experimental|Fosaprepitant|
3065165|NCT01031979|Experimental|Yohimbime Group|Patients will take one 21.6 mg. dose of yohimbine one hour before first imaginal exposure in PE.
3065166|NCT01031979|Placebo Comparator|Placebo Group|Patients will take a placebo one hour before first imaginal exposure in PE.
3065167|NCT01032018|Active Comparator|Referred Care|Immediately after the initial post-ACS screening, the participant's physician will be notified in writing if the participant is depressed according to the BDI. Depending upon the physician's own evaluation of the participant, he or she may elect to defer depression treatment, initiate it, or to refer the patient to a mental health specialist.
3065168|NCT01032018|Experimental|Stepped Care|Stepped Care participants will be given a description of the choices available in this arm, including choosing antidepressant medication and/or telephone-based, Problem-Solving Therapy (PST). If the patient is randomized to Stepped Care, their physician will be informed that depression treatment is being provided by the trial. Patients will select their preferred treatment approach. Depression symptoms will be monitored to determine whether the patient is improving relative to his/her baseline score. Relapse monitoring and maintenance therapy will continue for the duration of the study.
3065169|NCT01032044|Active Comparator|Standard endoscopic evaluation|Standard high-definition white light endoscopy guided evaluation
3065170|NCT01032044|Experimental|pCLE-guided evaluation|Endoscopic evaluation of BE guided by probe-based Confocal Laser Endomicroscopy (pCLE guided evaluation)
3065171|NCT01032070|Experimental|Erlotinib|Erlotinib was administered orally at a dose of 85 mg/m^2 per day continuously until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
3065172|NCT01032070|Active Comparator|Etoposide|Etoposide 50 mg/m^2 per day was administered orally for 21 days followed by a 7-day rest period until either progression, death, patient request or investigator decision to discontinue study drug or intolerable toxicity.
3065173|NCT01032135|Active Comparator|1-MI-IOP Engaged|Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
3065174|NCT01032135|Experimental|2-MI-IOP Non-Engaged|Randomized to treatment as usual, and do not attend.
3065175|NCT01032135|Active Comparator|3-MI-PC Engaged|Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
3065176|NCT01032135|Experimental|4-MI-PC Non-engaged|Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
3065177|NCT01032174||Azithromycin SR|Acute Bacterial Maxillary Sinusitis
3065178|NCT01032174||Amoxiclav 1000 mg|Acute Bacterial Maxillary Sinusitis
3065179|NCT01032200|Experimental|Arm I - Armodafinil|Patients receive oral armodafinil once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
3065180|NCT01032200|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo once daily beginning no later than the fifth fraction of brain radiotherapy and continuing for 9-11 weeks in the absence of unacceptable toxicity.
3065181|NCT01032239|Active Comparator|ITB therapy|Intrathecal Baclofen therapy (Intrathecal baclofen + implantable pump)
3065182|NCT01032239|No Intervention|Best Medical Treatment (BMT)|Use one or a combination oral antispastic medication.
3065183|NCT01032265|Active Comparator|Web-based treatment|Web-based treatment with information (including life style), PFMT, elements of CBT and regular mail contact with an urotherapist
3065184|NCT01032265|Active Comparator|Pamphlet treatment|Information (including life style), and PFMT exercises.
3065185|NCT01032291|Experimental|lenalidomide plus cetuximab|Combination therapy of lenalidomide plus cetuximab
3065186|NCT01032291|Experimental|lenalidomide|Single agent therapy of lenalidomide
3065187|NCT01032330|No Intervention|Observation|Patients randomized to the observation group will receive no treatment (other than refractive correction).
3065188|NCT01032330|Active Comparator|Occlusion Therapy|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
3065189|NCT01032382|Active Comparator|Paromomycin Alone Treatment|
3065190|NCT01032382|Active Comparator|WR 279,396|
3065191|NCT01032538||Patients with knee osteoarthritis|Patients with knee osteoarthritis that are about to get an operation with oxford unicondylar knee
3065192|NCT01032603|Active Comparator|Bilateral lateral rectus recession|Bilateral lateral rectus recession surgery
3065193|NCT01032603|Active Comparator|Unilateral lateral rectus recession|Unilateral lateral rectus recession w/ medial rectus resection surgery
3065194|NCT01032629|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) on background standard of care for diabetes once daily for the duration of the study
3065195|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 100 mg|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily on background standard of care for diabetes once daily for the duration of the study
3065196|NCT01032629|Experimental|Canagliflozin (JNJ-28431754) 300 mg|Each patient will receive canagliflozin (JNJ-28431754) 300 mg once daily on background standard of care for diabetes once daily for the duration of the study
3065197|NCT01032694||Z-max treated group|Patients with Community-Acquired Pneumonia
3065198|NCT01032694||Amoxiclav treated group|Patients with Community-Acquired Pneumonia
3065199|NCT01032733|Experimental|Lifestyle Counseling|In the experimental condition, participants attended a group-based weight management session plus three supervised exercise sessions each week.
3065200|NCT01032733|Placebo Comparator|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss.
3065201|NCT01032759|Active Comparator|Memantine|
3065202|NCT01032759|Placebo Comparator|Placebo|Placebo
3065203|NCT01032837|Experimental|Oseltamivir standard dose 5 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
3065204|NCT01032837|Experimental|Oseltamivir standard dose 10 days|Adults and children 13 years and older received 75 mg oseltamivir and a placebo capsule twice daily for 10 days. Children aged 1 - 12 years received a weight-based dose (from 30 to 75 mg) oseltamivir suspension and placebo suspension orally twice daily for 10 days.
3065205|NCT01032837|Experimental|Oseltamivir high dose 5 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 5 days. Children aged 1 - 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 5 days. Participants received matching placebo for the second 5 days of treatment.
3065206|NCT01032837|Experimental|Oseltamivir high dose 10 days|Adults and children 13 years and older received 150 mg (2 x 75 mg) oseltamivir capsules twice daily for 10 days. Children aged 1- 12 years received a weight-based dose (from 60 to 150 mg) oseltamivir suspension orally twice daily for 10 days.
3065207|NCT01032850|Experimental|Arm 1: Sorafenib & Capecitabine|Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400mg) Capecitabine twice a day by mouth (850mg)
3065208|NCT01032889|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3065209|NCT01032889|Experimental|Deoxycholic acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3065210|NCT01032889|Experimental|Deoxycholic acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3065211|NCT01032915|Experimental|AIN457 300mg s.c weekly for 3 weeks|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
3065212|NCT01032915|Experimental|AIN457 300mg s.c at baseline and Week 2|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
3065213|NCT01032915|Experimental|AIN457 150mg s.c at baseline and Week 2|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
3065214|NCT01032915|Placebo Comparator|Placebo s.c weekly for 3 weeks|Placebo s.c weekly for 3 weeks then every 2 weeks
3065215|NCT01032928|Experimental|Respiratory Phase Training|Chronically dysphagic, medically stable patients at least 6 months post treatment for head and neck cancer with non-optimal respiratory-swallowing patterns participated in up to 8 sessions of respiratory phase training to learn an optimal respiratory - swallow phase pattern
3065216|NCT01032954|Active Comparator|"125 to 170 IU of 'Botulinum toxin' "|group with intervention of 125 to 170 IU of 'Botulinum toxin'
3065217|NCT01032954|Active Comparator|171 to 210 IU of 'Botulinum toxin'|Patients who have received 171 to 210 IU of 'Botulinum toxin'
3065218|NCT01032954|Active Comparator|211 to 250 IU of Botulinum toxin|Patients who have received 211 to 250 U of Botulinum toxi'
3065219|NCT01032993|Active Comparator|Coenzyme Q10|600 mg of CoQ10 taken as 300 mg (three 100 mg wafers) two times daily. Study wafers: ChewQ (Tishcon Corp, Westbury, NY) are chewable wafers each containing 100 mg of Coenzyme Q10 (ubidecarenone USP). All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
3065220|NCT01032993|Placebo Comparator|Placebo|Placebo was manufactured by the manufacturer of ChewQ, Tishcon Corp (Westbury, NY), included the same excipients, but no active CoQ10, and looked and tasted identical to active agent. All participants randomized continued use of simvastatin 20 mg started during the run-in phase of the study.
3065221|NCT01033019|Experimental|LDE225 0.75%|Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
3065222|NCT01033019|Placebo Comparator|Vehicle|Participants topically applied matching placebo cream twice daily for 6 weeks.
3065223|NCT01033032|Experimental|Amrubicin Phase I/II|Systemic therapy with amrubicin
3065224|NCT01033071|Experimental|Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD|
3065225|NCT01033071|Experimental|Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD|
3065226|NCT01033071|Active Comparator|Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD|
3065227|NCT01033136|Experimental|MCET-V|Multiple Channel Exposure Therapy -Veterans (MCET-V) is a 12-session cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks. It is an integrated treatment designed to target panic and PTSD symptoms simultaneously.
3065228|NCT01033136|Active Comparator|CPT|Cognitive Processing Therapy (CPT) is a 12-session cognitive-behavioral treatment for persons with PTSD. It is a gold-standard cognitive behavioral intervention designed to target PTSD symptoms.
3065229|NCT01033227|No Intervention|No drug|No study drug administered
3065230|NCT01033227|Experimental|Sodium nitrite injection, USP|Administration if sodium nitrite injection, USP
3065231|NCT01033240|Experimental|Safety Cohort 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (2 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
3065232|NCT01033240|Experimental|Safety Cohort 2 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (4 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
3065233|NCT01033240|Active Comparator|Safety Cohort 3 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib; CS-1008 (6 mg/kg per week) in combination with sorafenib (400 mg self-administered by mouth twice daily) over 4 weeks observation, and may continue treatment until progression.
3065234|NCT01033240|Experimental|Treatment Group 1 CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 1: CS-1008 (6 mg/kg [or as determined] loading, 2 mg/kg/week maintenance) + sorafenib twice daily (N=50)
3065235|NCT01033240|Experimental|Treatment Group 2 with CS-1008 and Sorafenib|Combination of CS-1008 and sorafenib. Treatment Group 2: CS-1008 (6 mg/kg [or as determined] loading, 6 mg/kg/week [or maximum tolerated dose {MTD}] maintenance) + sorafenib twice daily (N=50)
3065236|NCT01033240|Experimental|Treatment Group 3 with Sorafenib Alone|Sorafenib. Treatment Group 3: sorafenib twice daily (N=50)
3065237|NCT01033383|Placebo Comparator|3 placebo capsules|3 placebo capsules qd
3065238|NCT01033383|Experimental|1 cranberry capsule & 2 placebo capsules|1 active cranberry capsule and 2 placebo capsules qd
3065239|NCT01033383|Experimental|2 cranberry capsules & 1 placebo capsule|2 active cranberry capsules and 1 placebo capsules qd
3065240|NCT01033383|Experimental|3 cranberry capsules|3 active cranberry capsules qd
3065241|NCT01033422|Experimental|CF101 1mg|CF101 1mg orally q12 hours
3065242|NCT01033422|Placebo Comparator|Placebo|matching placebo orally q12 hours
3065243|NCT01033422|Experimental|CF101 2mg|CF101 2mg orally q12 hours
3065244|NCT01033448|Experimental|Single arm|
3065245|NCT01033487|Placebo Comparator|Placebo|
3065246|NCT01033487|Active Comparator|active comparator|
3065247|NCT01033487|Experimental|PF-03635659|
3065248|NCT01033565|Experimental|Natrol|Subjects receive Natrol (sustained release melatonin) 5mg tablet 30 minutes prior to bedtime for 10 to 14 days
3065249|NCT01033643|Experimental|MK-3614 0.25 mg (Panel A)|Participants received 0.25 mg of MK-3614 twice daily (BID) every 12 hours orally for 10 days.
3065250|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel B)|Participants received 0.50 mg of MK-3614 in the morning (AM) and 0.25 mg of MK-3614 in the evening (PM) 12 hours apart orally for 10 days.
3065251|NCT01033643|Experimental|MK-3614 0.50/0.25 mg (Panel C Repeat)|Participants were to receive 0.75 mg of MK-3614 BID every 12 hours orally for 10 Days. Per protocol amendment, the Panel B dose was repeated, and participants received instead 0.50 mg of MK-3614 in the AM, and 0.25 mg of MK-3614 in the PM, 12 hours apart orally for 10 days.
3065252|NCT01033643|Experimental|MK-3614 0.50 mg (Panel D)|Participants received 0.50 mg of MK-3614 three times a day (TID) orally every 8 hours on Day 1 followed by a wash out period for Days 2, 3 and 0.50 mg of MK-3614 every 12 hours orally for 10 days (Days 4-13).
3065253|NCT01033643|Experimental|MK-3614 0.50 mg (Panel E)|Participants were to receive orally 0.50 mg of MK-3614 BID every 12 hours on Day 1 followed by 3 doses (0.50/0.50/0.25 mg) of MK-3614 each 8 hours apart on Day 2; three doses of 0.50 mg of MK-3614 8 hours apart on Days 3,4; and 0.75 mg of MK-3614 BID every 12 hours on Days 5-14. No participants were enrolled in this group.
3065254|NCT01033643|Placebo Comparator|Placebo (All Panels)|Participants received a dose matched placebo orally according to randomization.
3065255|NCT01033734|Experimental|Single arm|
3065256|NCT01033747|Experimental|Deferasirox|Deferasirox group consists of all participants who were initially randomized to 10 and 20 mg/kg/day deferasirox orally daily in the main study and remained on the same treatment during the comparative prolongation study (NCT00379483) and at the beginning of the 5-year non-comparative study
3065257|NCT01033747|Experimental|Deferasirox Crossover|Deferasirox Crossover group consists of participants who were initially randomized to 40 mg/kg/day deferoxamine (DFO)subcutaneously in the main study and comparative prolongation study and crossed over to 5mg/kg/day to 30 mg/kg/day deferasirox orally daily at the beginning of the 5-year non-comparative extension study
3065258|NCT01033773|Other|Diabetes education and medication management|All enrolled patients received the intervention. There was no comparative arm. The analysis was done as pre and post.
3065259|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 mcg once daily
3065260|NCT01033825|Experimental|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily
3065261|NCT01033825|Placebo Comparator|HFA Nasal Aerosol placebo|HFA Nasal Aerosol Placebo once daily
3065262|NCT01033825|Experimental|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
3065263|NCT01033825|Placebo Comparator|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
3065264|NCT01033825|Active Comparator|Placebo HFA plus Dexamethasone 6 mcg|Placebo HFA plus Dexamethasone 6 mg once daily
3065265|NCT01033825|Active Comparator|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mg once daily
3065266|NCT01033851|Active Comparator|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
3065267|NCT01033851|Active Comparator|Stress Management Education|Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
3065268|NCT01033864|Experimental|MMF, Prednisone|Participants received mycophenolate mofetil (MMF) orally (PO) at a dose of 1 gram per day (g/day) twice daily (BID), and prednisone, PO, up to 5 milligrams per day (mg/day) for at least 1 month.
3065269|NCT01033864|Active Comparator|EC-MPS|Participants received mycophenolate sodium (EC-MPS), PO, at a dose of 720 mg/day BID, and prednisone PO up to 5 mg/day for at least 1 month.
3065270|NCT01033942|Experimental|FTC/TDF as PrEP|Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
3065271|NCT01033942|Placebo Comparator|Placebo Pill Control|Blinded administration of placebo pill; HIV behavioral intervention
3065272|NCT01033942|Active Comparator|No Pill Control|Subjects receive HIV behavioral intervention but no pill.
3065273|NCT01034111|Experimental|Sitagliptin|Sitagliptin as add-on therapy to a stable dose of metformin
3065274|NCT01034137|Experimental|Tocilizumab + Methotrexate|Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
3065275|NCT01034137|Active Comparator|Tocilizumab + Placebo Methotrexate|Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
3065276|NCT01034137|Active Comparator|Methotrexate + Placebo Tocilizumab|Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
3065277|NCT01034163|Experimental|Panobinostat (PAN)|Participants received 45 mg orally 3 times a week (TIW), every other week (QOW),
3065278|NCT01034163|Placebo Comparator|Placebo|Participants received matching placebo to PAN TIW, QOW.
3065279|NCT01034176|Active Comparator|Levofloxacin|Levofloxacin 500 mg every day (dose adjusted for renal function) for 30 days
3065280|NCT01034176|Placebo Comparator|placebo|placebo identical to levofloxacin drug daily for 30 days
3065281|NCT01034306|Experimental|CF101 1 mg|
3065282|NCT01034306|Placebo Comparator|Placebo|
3065283|NCT01034358|Experimental|Human Papillomavirus Vaccine|The Gardasil HPV vaccine was administered in 3 doses: baseline, 2 months, and 6 months.
3065284|NCT01034397|Experimental|1|
3065285|NCT01034397|Placebo Comparator|2|
3065286|NCT01034462|Experimental|1|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing.
3065287|NCT01034462|Placebo Comparator|2|Matching placebo capsules, oral administration, once daily dosing.
3065288|NCT01034527|Experimental|Neuromuscular Training|Combination of exercises and phases designed to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
3065289|NCT01034527|No Intervention|Speed Training|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
3065290|NCT01034540|Experimental|POM3|POM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment
3065291|NCT01034540|Placebo Comparator|Placebo|Placebo for the first six weeks of treatment. POM3 for the second six weeks of treatment
3065292|NCT01034553|Experimental|Arm I|Patients receive oral aurora A kinase inhibitor MLN8237 once daily on days 1-14 and bortezomib IV on days 1, 4, 8 and 11.
3065293|NCT01034579|Other|Rebif® Cohort|
3065294|NCT01034579|Other|Copaxone® Cohort|
3065295|NCT01034592|Experimental|Lenalidomide|Subjects will initially receive lenalidomide 2.5 mg, and may escalate up to 2.5 mg/wk up to 5 mg 3x/wk, depending toxicity and response.
3065296|NCT01034631|Active Comparator|Combination Arm A: Everolimus + BNC105P|Combination Arm A: Everolimus 10 mg, BNC105P MTD (from Phase 1 study) 21 day cycle
3065297|NCT01034631|Active Comparator|Sequential Arm B:Everolimus followed by BNC105P Monotherapy|"Sequential Arm B: Everolimus 10 mg, 21 day cycle~Patients to receive BNC105P monotherapy at 16 mg/m2 following progression or intolerable toxicity on everolimus therapy."
3065298|NCT01034657|Experimental|LBH589|During the core phase, all participants received oral LBH589 40 mg (30 mg after a protocol amendment) for 4 months. During the randomization phase, participants with hematological improvement of the erythropoetic system (HI-E) and participants with stable disease, who were randomized to single agent LBH589, continued on single agent LBH589 40mg/30mg for an additional 4 months.
3065299|NCT01034657|Experimental|LBH589 + Epoetin Alfa|During the randomized phase, participants randomized to LBH589 + Epoetin Alfa (ESA) received oral LBH589 40mg/30mg + ESA 30000 international units (IU)/week injected subcutaneously for 4 months.
3065300|NCT01034709||Symptomatic|Subjects with a confirmed CMV viremia by the site's CMV-LDT as well as CMV symptoms
3065301|NCT01034709||Asymptomatic|Subjects who must have been serologically positive for CMV IgG prior to transplantation and do not have any CMV symptoms
3065302|NCT01035047|No Intervention|Inpatient Care|This is the comparison arm. Patients are admitted to the hospital and undergo usual care.
3065303|NCT01035047|Experimental|CDU-CMR Protocol|Patients will be transferred to the clinical decision unit and undergo a stress cardiac MRI evaluation.
3065304|NCT01035060||Older Adult|Healthy Men and Women Over 70 Years of Age
3065305|NCT01035060||Young Adult|Healthy Men and Women Aged 18-30 Years
3065306|NCT01035099|Experimental|Titrated dose Letrozole|Patients who are randomized to the titrated dose of Letrozole, will start gonadotropins in the evening of day #2 of their menstrual cycle with injectable follicle stimulating hormone (FSH) and human menopausal gonadotropin (HMG). Oral Letrozole will be added to the stimulation in the following titrated regimen.
3065307|NCT01035099|Active Comparator|Fixed dose Letrozole|Patients who are randomized to fixed dose Letrozole will start Letrozole 5mg daily (orally) on the second day of their menstrual cycle and then gonadotropins on the fourth day of their menstrual cycle.
3065308|NCT01035138|Experimental|Drug: semagacestat|
3065309|NCT01035151|Active Comparator|Delayed Control|Women in the delayed control condition received culturally sensitive smoking cessation written materials at week 1, and mailed materials at week 6, 12, and 18. At the end of the study (i.e., after the 12 month data collection), participants were offered counseling, nicotine patches, and community health worker contacts.
3320896|NCT02014558|Experimental|Gilteritinib 300 mg in Expansion Phase|Participants received 300 mg gilteritinib orally once daily starting on day 1 of cycle 1 and continued in 28-day cycles until disease progression or participant discontinuation in the expansion phase of the study. On day -1 and day 15 of cycle 1, participants also received 2 mg midazolam as a single oral dose.
3320897|NCT02014571|Experimental|Cohort A|Eight subjects will be randomized to receive either 10 mg of GSK2878175 active treatment (4 HCV genotype 1a [GT1a] and 2 HCV genotype 1b [GT1b]) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3065310|NCT01035151|Experimental|Experimental|Women in neighborhoods randomized to the S2S received 24-week bundled multi-level intervention. Individual-led strategies were led by paid community health workers (CHWs). The CHWs provided 1:1 contact to reinforce social support, and enhanced self-efficacy with cessation attempts. A certified smoking cessation counselor led behavioral group sessions using the S2S handbook based on the PHS Guidelines. The weekly group sessions were initiated during the 1st week of the intervention, with a total of 6 group sessions over a 6-week period. Transdermal nicotine patches were offered to participants who set a quit date. Within the 24-week study period, the neighborhood tenant association, in partnership with study staff, implemented at least two neighborhood level anti-smoking activities
3065311|NCT01035229|Experimental|Everolimus + Best Supportice Care (BSC)|Patients were assigned to the Everolimus + BSC arm in a ratio of 2:1 over the Placebo arm. Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the investigational drug. In addition to taking Everolimus, all patients also received BSC as per normal local practice.
3065312|NCT01035229|Placebo Comparator|Placebo + Best Supportive Care|Placebo Everolimus was taken as a daily oral dose of 7.5 mg and was defined as the control drug. In addition to taking Placeb Everolimus, all patients also received BSC as per normal local practice.
3065313|NCT01035255|Experimental|LCZ696|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. LCZ696 200mg BID during double blind treatment period
3065314|NCT01035255|Active Comparator|Enalapril|single-blind active run-in period consisted of treatment with enalapril 10 mg bid, followed by LCZ696 100 mg bid, and then LCZ696 200 mg bid over a total duration of 5 to 10 weeks. Temporary down-titration from LCZ696 200 mg bid to LCZ696 100 mg bid was allowed provided the patient was up-titrated back to LCZ696 200 mg bid and tolerated this dose for at least two weeks before being eligible for randomization. Enalapril 10 mg BID during double blind treatment period
3065315|NCT01035333|Experimental|orlistat 60mg|Patients assigned to treatment group for up to 6 months of therapy.
3065316|NCT01035346|Experimental|A|
3065317|NCT01035346|Placebo Comparator|B|
3065318|NCT01035463|Experimental|Treatment (stem cell transplantation)|"PRE-CONDITIONING (patients with CD20+ NHL): Patients receive rituximab IV per standard of care.~PREPARATIVE REGIMEN: Patients receive carmustine IV on day -6, etoposide IV BID and cytarabine IV BID on days -5 through -2, and melphalan IV on day -1.~AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION: Patients undergo stem cell infusion on day 0.~MAINTENANCE THERAPY: Beginning approximately 100 days post-transplant, patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity."
3065319|NCT01035606|Experimental|Goal-oriented Attention Regulation Training|training in goal-directed attention regulation
3065320|NCT01035606|Active Comparator|Education|brain health education
3065321|NCT01035606|Experimental|Technology-assisted Goal-directed Self-Regulation Training|computer-assisted training in goal-directed attention regulation
3065322|NCT01035658|Experimental|Dose Level 1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (40mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3065323|NCT01035658|Experimental|Dose Level -1|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib (400mg) and liposomal doxorubicin (30mg) administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3065324|NCT01035658|Experimental|Dose Level 1 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (30mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3065325|NCT01035658|Experimental|Dose Level 2 Sequential|Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). In this schedule, liposomal doxorubicin (40mg) was given on day 1, and pazopanib (400mg) was given days 3 - 26 of each 28 day cycle. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
3065326|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F1 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 1 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3065327|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3065328|NCT01035749|Experimental|AREPANRIX-ADJUVANTED F2 3D GROUP|Subjects received 3 doses of Arepanrix ™ formulation 2 adjuvanted vaccine on Day 0, Day 21 and Day 182 (booster).
3065329|NCT01035749|Experimental|AREPANRIX-UNADJUVANTED F2 2D GROUP|Subjects received 2 doses of Arepanrix ™ unadjuvanted vaccine on Day 0 and Day 182 (booster) and one dose of saline placebo on Day 21.
3065330|NCT01035788|Experimental|Mindfulness-Based CBCT|Mindfulness Based Cognitive Behavioral Conjoint Therapy for PTSD
3065331|NCT01035788|Active Comparator|CBCT Communication Skills|CBCT for PTSD - Communication Skills
3065332|NCT01035905|Experimental|Nelfilcon A|Nelfilcon A contact lens
3065333|NCT01035905|Active Comparator|Narafilcon A|Narafilcon A contact lens
3065334|NCT01036009|No Intervention|Group I: Observation|Group I (observation): Patients with full donor chimerism and no evidence of MRD continue to undergo clinical monitoring for acute and chronic graft-vs-host disease and relapse until 3 years post-transplant. Patients undergo repeat chimerism testing at 12 and 24 months post-transplant.
3065335|NCT01036009|Experimental|Group II: Intervention|Group II (intervention): Patients undergo withdrawal of immunosuppression and receive donor lymphocyte infusions between days 60-365 post-transplant (or until full donor chimerism is achieved). Patients also undergo clinical monitoring and repeat chimerism testing as in group I.
3065336|NCT01036022|Experimental|Group 2|ASACOL 800mg t.i.d.
3065337|NCT01036022|Experimental|Group 1|GSK1399686 at 3-4 dose levels
3065338|NCT01036022|Experimental|Group 3|Placebo
3065339|NCT01036321|Active Comparator|Purified Isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler. 40 mg daily.
3065340|NCT01036321|Placebo Comparator|Methyl cellulose blend|Placebo.
3065341|NCT01036438|Placebo Comparator|Mepilex product|
3065342|NCT01036438|Active Comparator|Mepilex Ag|
3065343|NCT01036490|No Intervention|Control|Control group
3065344|NCT01036490|Experimental|Exercise|Exercise Group
3065345|NCT01036529|Experimental|Precision Spinal Cord Stimulator|Spinal Cord Stimulation
3065346|NCT01036529|Active Comparator|Back Surgery|Discectomy, laminotomy, laminectomy, foraminotomy, fusion with or without instrumentation
3065347|NCT01036594|Experimental|Ketoconazole + Hydrocortisone|"po = oral tid = 3 times per day qam = every morning qom = every evening bid = twice daily~1 cycle = 28 days~Ketoconazole: 200mg during first week of study (run-in phase), then 400mg po tid~Hydrocortisone 20mg po qam and 10mg po qpm: If participant has ≥ 30% Prostate-specific antigen (PSA) decline at 12 week evaluation, treatment continues until progressive disease (by RECIST criteria OR by Prostate Specific Antigen Working Group (PSAWG) criteria) is documented. After that, drug will be discontinued. If participant has < 30% PSA decline at 12 week evaluation, participant goes off study."
3065348|NCT01036594|Experimental|Ketoconazole + Dexamethasone|"Ketoconazole: 400mg po tid~Dexamethasone 0.5mg po bid: If ≥ 30% PSA decline (Prostate-specific antigen) at 12 week evaluation, administration starts when disease progression (by RECIST criteria OR by PSAWG criteria) is documented."
3065349|NCT01036724||Carto 3|Those subjects whose cases use the CARTO 3 EP Navigation System.
3065350|NCT01036724||NAVX|Those subjects whose cases use the NAVX(TM) EP Navigational System.
3065351|NCT01036802|Active Comparator|Warfarin|Patients on the active treatment arm will be anticoagulated using the vitamin K antagonist, warfarin
3065352|NCT01036802|Placebo Comparator|Placebo|matching active products
3065353|NCT01037088|Experimental|Mild dose cannabis|3.53% THC by weight
3065354|NCT01037088|Experimental|Low dose cannabis|1.29% THC by weight
3065355|NCT01037088|Placebo Comparator|Placebo cannabis|placebo marijuana
3065356|NCT01037114|Experimental|Twinrix Group|"Subjects who received 2 doses of Twinrix (lot A, B or C) in the primary study.~As lot to lot consistency was assessed during the primary study, the 3 groups (lot A, B or C) were pooled into the Twinrix Group for data analyses during the first long-term follow-up NCT00289718 and this long-term follow-up.~A challenge dose of the Havrix or Engerix-B vaccines can be administered in this study based on serology results at each time point."
3065357|NCT01037127|Experimental|Cohort A|Subjects who have had previous treatment with a BRAF inhibitor.
3065358|NCT01037127|Experimental|Cohort B|Subjects who have had previous chemotherapy or immunotherapy without a BRAF inhibitor.
3065359|NCT01037192|Experimental|Vanco once daily|Subject receives vancomycin 30 mg/kg dose
3065360|NCT01037192|Active Comparator|Vanco twice daily|Subject receives vancomycin 15 mg/kg twice daily
3065361|NCT01037218|Experimental|Udenafil 50 mg|50 mg Udenafil tablet plus 100 & 150 mg placebo tablets
3065362|NCT01037218|Experimental|Udenafil 100 mg|100 mg Udenafil tablet plus 50 & 150 mg placebo tablets
3065363|NCT01037218|Experimental|Udenafil 150mg|150 mg Udenafil tablet plus 50 & 100 mg placebo tablets
3065364|NCT01037218|Placebo Comparator|Placebo|50, 100 & 150 mg placebo tablets
3065365|NCT01037244|Placebo Comparator|Placebo|
3065366|NCT01037244|Experimental|Udenafil 50 mg|
3065367|NCT01037244|Experimental|Udenafil 100 mg|
3065368|NCT01037244|Experimental|Udenafil 150 mg|
3132348|NCT03419403|Experimental|Enhanced Steroids + Vasoconstrictor + Cold Compress|Enhanced steroid eye drops: 1 drop each eye, 6 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Ophthalmic Steroid Ointment; applied to each eye once daily before sleep, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. Cold compress was to be applied in increments no longer than 30 min (could be shorter if the patient is uncomfortable).
3132349|NCT03419533||2018 school leavers|South Australian school leavers in 2018 (year 12 in 2017)
3132350|NCT03419533||2019 school leavers|South Australian school leavers in 2019 (year 12 in 2018)
3132351|NCT03419598||All study participants|All virtual participants who received a virtual opening wedge high tibial osteotomy. The baseline information was the individual CT-based geometry of tibia.
3132352|NCT03419780|Active Comparator|Single-Unit Blood Transfusion Protocol|In this arm, patients receive a 1 unit pRBC transfusion with the plan for post-transfusion blood count at 4-6 hours post-transfusion and clinical reassessment.
3132353|NCT03419780|Active Comparator|Multiple-Unit Blood Transfusion Protocol|In this arm, patients receive 2 units of pRBCs, followed by 4-6 hour post-transfusion blood count and clinical reassessment.
3132354|NCT03419962||COPD patients|Chronic obstructive pulmonary disease
3132355|NCT03420300|Experimental|EBR/GZR|Elbasvir/grazoprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
3132356|NCT03420625|Active Comparator|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
3132357|NCT03420625|Active Comparator|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
3132358|NCT03420625|Active Comparator|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
3132359|NCT03420625|Active Comparator|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJO,TM, CefarCompex Mi-Theta 500 stimulator
3132360|NCT03421197|Experimental|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg once per day
3132361|NCT03421197|Experimental|PPC-06 400 mg BID|Tepilamide Fumarate 400 mg twice per day
3132362|NCT03421197|Experimental|PPC-06 600 mg BID|Tepilamide Fumarate 600 mg twice per day
3132363|NCT03421197|Placebo Comparator|Placebo BID|White placebo tablet to mimic Tepilamide Fumarate
3065369|NCT01037309|Experimental|PRO044, cohort 1|Subcutaneous injection of 0.5 mg/kg on day 1, 8, 15, 22 and 29.
3065370|NCT01037309|Experimental|PRO044, cohort 2|Subcutaneous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29.
3065371|NCT01037309|Experimental|PRO044, cohort 3|Subcutaneous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29.
3065372|NCT01037309|Experimental|PRO044, cohort 4|Subcutaneous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29.
3065373|NCT01037309|Experimental|PRO044, cohort 5|Subcutaneous injection of maximally 10 mg/kg on day 1, 8, 15, 22 and 29
3065374|NCT01037309|Experimental|PRO044, cohort 6|Subcutaneous injection of maximally 12 mg/kg on day 1, 8, 15, 22 and 29
3065375|NCT01037309|Experimental|PRO044, cohort 7|Intravenous injection of maximally 1.5 mg/kg on day 1, 8, 15, 22 and 29
3065376|NCT01037309|Experimental|PRO044, cohort 8|Intravenous injection of maximally 5 mg/kg on day 1, 8, 15, 22 and 29
3065377|NCT01037309|Experimental|PRO044, cohort 9|Intravenous injection of maximally 8 mg/kg on day 1, 8, 15, 22 and 29
3065378|NCT01037413|Experimental|EXC 001|
3065379|NCT01037413|Placebo Comparator|Placebo|
3065380|NCT01037452|Experimental|Combination product|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg tablet
3065381|NCT01037452|Active Comparator|PPI alone|Lansoprazole
3065382|NCT01037452|Active Comparator|Antacid alone|Calcium carbonate/magnesium hydroxide
3065383|NCT01037452|Placebo Comparator|Placebo|Placebo
3065384|NCT01037790|Experimental|Arm 1 - Metastatic breast cancer|"Metastatic breast cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
3065385|NCT01037790|Experimental|Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation|"Metastatic colorectal cancer that harbors the Kras or BRAF mutation~PD-0332991 Given orally, 125 mg QD on a 21-day"
3065386|NCT01037790|Experimental|Arm 3 - Advanced or metastatic esophageal and/or gastric cancer|"Advanced or metastatic esophageal and/or gastric cancer~PD-0332991 Given orally, 125 mg QD on a 21-day"
3065387|NCT01037790|Experimental|Arm 4 - Cisplatin-refractory, unresectable germ cell tumors|"Cisplatin-refractory, unresectable germ cell tumors~PD-0332991 Given orally, 125 mg QD on a 21-day"
3065388|NCT01037790|Experimental|Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations|"Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint.~PD-0332991 Given orally, 125 mg QD on a 21-day"
3065389|NCT01037881|Experimental|LEO 29102 0.03 mg/g cream|
3065390|NCT01037881|Experimental|LEO 29102 0.1 mg/g cream|
3065391|NCT01037881|Experimental|LEO 29102 0.3 mg/g cream|
3065392|NCT01037881|Experimental|LEO 29102 1.0 mg/g cream|
3065393|NCT01037881|Experimental|LEO 29102 2.5 mg/g cream|
3065394|NCT01037881|Placebo Comparator|LEO 29102 cream vehicle|
3065395|NCT01037881|Active Comparator|Elidel® cream (pimecrolimus) 10 mg/g|
3065396|NCT01037985|Experimental|EXC 001|
3065397|NCT01037985|Placebo Comparator|Placebo|
3065398|NCT01038128|Experimental|Memantine|Memantine, 10-40 mg daily
3065399|NCT01038297|Experimental|EXC 001|
3065400|NCT01038297|Placebo Comparator|Placebo|
3065401|NCT01038323|Experimental|CBT and milnacipran|Subjects randomized to this group will receive a combination of eight telephone sessions of Cognitive Behavior Therapy (CBT) and a 21-week regimen of milnacipran.
3065402|NCT01038323|Placebo Comparator|CBT and placebo|Subjects randomized to this arm will receive a series of eight telephone sessions of Cognitive Behavioral Therapy (CBT) along with a 21-week regimen of a placebo(sugar pill)medication.
3065403|NCT01038323|Active Comparator|Educational with milnacipran|Subjects randomized to this group will receive a series of eight educational phone calls regarding fibromyalgia along with a 21-week regimen of milnacipran.
3065404|NCT01038336|Experimental|Multimedia HLPP|Multimedia Hearing Loss Prevention Program (HLPP)
3065405|NCT01038336|Active Comparator|Hearing Conservation Brochure|Hearing Conservation Brochure (HCB)
3065406|NCT01038336|No Intervention|Standard-of-Care|Standard-of-Care (SoC)
3065407|NCT01038427|Experimental|Test|Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
3065408|NCT01038427|Active Comparator|Reference|Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray administered once daily at a dose of 200 mcg (4 actuations) for 14 days.
3065409|NCT01038427|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
3065410|NCT01038557|Active Comparator|Refrigerated RBCs 0-14 days old|Standard, refrigerated RBC units stored up to 14 days
3065411|NCT01038557|Active Comparator|Refrigerated RBCs 15-42 days old|Standard, refrigerated RBC units stored 15-42 days
3065412|NCT01038557|Experimental|Frozen RBCs|RBC units stored frozen at -80 degrees Celsius, then thawed and deglycerolized using the ACP 215.
3065413|NCT01038609|Placebo Comparator|Placebo|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3065414|NCT01038609|Active Comparator|Acetaminophen|1 dose of 1 placebo capsule (for morphine extended release) plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
3065415|NCT01038609|Active Comparator|Morphine Extended Release|1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release) plus 1 morphine extended release capsule, administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3065416|NCT01038609|Active Comparator|Morphine Extended Release / Acetaminophen|1 dose of 1 morphine extended release capsule plus 1 acetaminophen tablet, administered once every 12 hours, and 1 dose of 1 acetaminophen tablet, administered once every 6 hours (for a total of 8 doses).
3065417|NCT01038609|Experimental|Hydrocodone/Acetaminophen Extended Release|1 dose of 1 hydrocodone/acetaminophen extended release tablet plus 1 placebo capsule (for morphine extended release), administered once every 12 hours, and 1 dose of 1 placebo tablet (for hydrocodone/acetaminophen extended release), administered once every 6 hours (for a total of 8 doses).
3065418|NCT01038635|Experimental|5-Azacytidine + Lenalidomide|5-Azacytidine 75 mg/m^2 by vein daily x 5 days on days 1 to 5. Lenalidomide starting dose 10 mg orally daily x 5 days on days 6 to 10.
3065419|NCT01038687|Experimental|A3309 15 mg|Patients randomized to this arm received one oral tablet daily of 15 mg A3309 for a period of 14 consecutive days.
3065420|NCT01038687|Experimental|A3309 20 mg|Patients randomized to this arm received one oral tablet daily of 20 mg A3309 for a period of 14 consecutive days.
3065421|NCT01038687|Placebo Comparator|Placebo|Patients randomized to this arm received one oral tablet daily of a matching placebo for a period of 14 consecutive days.
3065422|NCT01038713|Experimental|Resectable; plastic stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a plastic biliary stent to relieve their biliary obstruction.
3065423|NCT01038713|Experimental|Resectable; uncovered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
3065424|NCT01038713|Experimental|Resectable; fully covered metal stent|Patients determined to have surgically resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
3065425|NCT01038713|Experimental|Unresectable; uncovered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive an uncovered metal biliary stent to relieve their biliary obstruction.
3065426|NCT01038713|Experimental|Unresectable; fully covered metal stent|Patients determined to have surgically non-resectable malignancy presenting with malignant biliary obstruction randomized to receive a fully-covered metal biliary stent to relieve their biliary obstruction.
3065427|NCT01038778|Experimental|Treatment (entinostat, aldesleukin)|"Patients receive entinostat PO every 2 weeks beginning on day -14 and high-dose aldesleukin IV every 8 hours on days 1-5 and 15-19. Cycles repeat every 84 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients with evidence of tumor shrinkage may receive up to 3 cycles of high-dose aldesleukin therapy. Patients with stable disease by RECIST version 1.0 criteria, but without evidence of tumor shrinkage after two cycles will receive only entinostat until disease progression is documented."
3065428|NCT01038856|Experimental|+JAK2V61F mutation|Patients with MPN diagnoses and polycythemia vera who also have a confirmed JAK2V617F mutation
3065429|NCT01038869|Experimental|Azelaic acid 15% (Finacea)|Open label pilot study, Topical gel to be appiled twice daily for 16 weeks
3065430|NCT01038921|Experimental|Melatonin|Melatonin 8mg one hour before bedtime for 10 weeks
3065431|NCT01038921|Placebo Comparator|Placebo|Placebo administered 1 hour before bedtime for 10 weeks
3065432|NCT01039207|Experimental|Treatment (rilotumumab)|Patients receive rilotumumab IV over 30-60 minutes on days 1 and 14. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Tumor tissue and blood samples may be collected periodically for further laboratory analysis.
3065433|NCT01039376|Experimental|ARM A: Ofatumumab|300 mg IV Week 1 followed by 1000 mg IV Week 2 1000 mg IV (a dose every 8 weeks for up to 2 years following the first 1000 mg dose)
3065434|NCT01039376|Other|ARM B: Observation and assessments as per Arm A|Disease status assessments to determine subject response or progression performed approximately every 8 weeks for up to 2 years for both arms according to IWCLL criteria
3065435|NCT01039428|Experimental|HS219|
3065436|NCT01039428|Placebo Comparator|Placebo|
3065437|NCT01039467|Active Comparator|Managed Ventricular Pacing|Managed Ventricular Pacing group: programmed on
3065438|NCT01039467|Active Comparator|Search AV+|Search AV+: programmed on
3065439|NCT01039519|Experimental|ganetespib 200 mg/m^2|Ganetespib (STA-9090) 200 mg/m^2 intravenous infusion once weekly for 3 consecutive weeks followed by one week dose free interval (3 weeks on and 1 week off represent a treatment cycle). Treatment continues until disease progression or unacceptable toxicity.
3065440|NCT01039584|Placebo Comparator|Placebo|vehicle of the test product; applied intravaginally once within 48 hours of randomization
3065441|NCT01039584|Experimental|Test Product|Butoconazole Nitrate Vaginal Cream; applied intravaginally once within 48 hours of randomization
3065442|NCT01039584|Active Comparator|Reference Product|Gynazole 1 Vaginal Cream; applied intravaginally once within 48 hours of randomization
3065443|NCT01039675|Experimental|GSK573719/GW642444|
3065444|NCT01039675|Placebo Comparator|Placebo|
3065445|NCT01039688|Experimental|5 mg BID CP-690,550|
3065446|NCT01039688|Experimental|10 mg BID CP-690,550|
3065447|NCT01039688|Active Comparator|methotrexate|
3065448|NCT01039792|Placebo Comparator|Placebo|Placebo
3065449|NCT01039792|Experimental|Active|Active Methyl B12
3065450|NCT01040052|Experimental|Study Group|
3065451|NCT01040130|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3065452|NCT01040130|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3065453|NCT01040130|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled once daily from the Respimat inhaler
3065454|NCT01040169|Placebo Comparator|Nupro C Prophylaxis paste|Fluoride Free
3065455|NCT01040169|Experimental|ProClude Prophylaxis paste|Arginine
3065456|NCT01040208|Experimental|flibanserin 50 mg to 100 mg qhs|Patient to receive one tablet of flibanserin 50 mg and one tablet of flibanserin placebo qhs for 14 days then will receive 2 flibanserin tablets of 50 mg qhs
3065457|NCT01040208|Experimental|flibanserin 100 mg qhs|Patient to receive 2 flibanserin tablets of 50 mg qhs
3065458|NCT01040208|Experimental|placebo 2 tablets qhs|Patient to receive 2 placebo tablets of 50 mg qhs
3065459|NCT01040260|Experimental|Contingency management|Use of tangible rewards for verified abstinence
3065460|NCT01040260|Active Comparator|Counseling plus nicotine patches|Counseling plus nicotine patches
3065461|NCT01040351|Experimental|1: Hydrosalpinx needle aspiration|After the retrieval of oocytes an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely .
3065462|NCT01040351|No Intervention|2. no aspiration|IVF-ET is done without prior aspiration of hydrosalpingeal fluid
3065463|NCT01040403|Experimental|olodaterol (BI 1744) low and placebo|low dose inhaled olodaterol orally once daily from the Respimat inhaler
3065464|NCT01040403|Experimental|olodaterol (BI 1744) low and low tio|low dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065465|NCT01040403|Experimental|olodaterol (BI 1744) low and medium tio|low dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065466|NCT01040403|Experimental|olodaterol (BI 1744) low and high tio|low dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065467|NCT01040403|Experimental|olodaterol (BI 1744) high and placebo|high dose inhaled olodaterol orally once daily from the Respimat inhaler
3065468|NCT01040403|Experimental|Olodaterol (BI 1744) high and low tio|high dose inhaled olodaterol and low dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065469|NCT01040403|Experimental|Olodaterol (BI 1744) high and medium tio|high dose inhaled olodaterol and medium dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065470|NCT01040403|Experimental|Olodaterol (BI 1744) high and high tio|high dose inhaled olodaterol and high dose inhaled tiotropium, both from the Respimat inhaler and once daily
3065473|NCT01040689|Placebo Comparator|Placebo|olodaterol placebo and/or Tiotropium placebo inhaled once daily
3065474|NCT01040689|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
3065475|NCT01040689|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
3065476|NCT01040689|Active Comparator|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
3065477|NCT01040728|Experimental|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
3065478|NCT01040728|Experimental|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
3065479|NCT01040728|Active Comparator|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
3065480|NCT01040728|Placebo Comparator|Placebo|Olodaterol placebo and/or Tiotropium placebo inhaled once daily
3065481|NCT01040780|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
3065482|NCT01040780|Active Comparator|Gefitinib|250 mg every 24 hours by mouth
3065483|NCT01040793|Experimental|Olodaterol (BI 1744) Low|Low dose inhaled orally once daily from the Respimat inhaler
3065484|NCT01040793|Experimental|Olodaterol (BI 1744) High|High dose inhaled orally once daily from the Respimat inhaler
3065485|NCT01040793|Placebo Comparator|Placebo|Olodaterol (BI 1744) placebo inhaled orally from the Respimat inhaler
3065486|NCT01040819|Experimental|Pioglitazone 15 mg|Patients will receive PIO 15 mg/d for two months. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
3065487|NCT01040819|Experimental|Pioglitazone 30 mg/d|Patients will receive PIO 15 mg/d for one month. Then, dose will be increased to 30 mg/d for an additional month. Serum and urine samples for 6-keto-PGF1a and 15-epi-lipoxin A4 will be taken at baseline, one month and 2 months.
3065488|NCT01040832|Experimental|Cetuximab plus EMD 1201081|
3065489|NCT01040832|Active Comparator|Cetuximab monotherapy|
3065490|NCT01040845|Experimental|Oral Contraceptive with Colchicine then Placebo|
3065491|NCT01040845|Placebo Comparator|Oral Contraceptive with Placebo then Colchicine|
3065492|NCT01040858|Experimental|Cognitive Strategies Training|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study). Cognitive Strategies training consisted of interactive didactic presentations, in-class discussions, and activities that introduced participants to a variety of cognitive strategies and external aids.
3065493|NCT01040858|Placebo Comparator|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
3065494|NCT01040871|Experimental|VR-CAP|VR-CAP arm received rituximab 375 mg/m2 IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, VELCADE 1.3 mg/m2 IV on Days 1, 4, 8, and 11, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.
3065495|NCT01040871|Active Comparator|R-CHOP|R-CHOP received rituximab 375 mg/m2IV on Day 1, cyclophosphamide 750 mg/m2 IV on Day 1, doxorubicin 50 mg/m2 IV on Day 1, vincristine 1.4 mg/m2 (maximum total of 2 mg) IV on Day 1, and prednisone 100 mg/m2 orally on Days 1 through 5 of each 21-day (3-week) cycle for up to 6 cycles.Prednisone
3065496|NCT01041209|Experimental|BPS|BPS guidance
3065497|NCT01041209|Active Comparator|Guideline|Enforced guidelines
3065498|NCT01041248|Experimental|Tocilizumab|Single arm open label study. In this arm patient will receive 8mg/kg of Tocilizumab q 2 weeks iv.
3065499|NCT01041274|Experimental|Citalopram|Participants will receive a daily dose of citalopram, with flexible dosing as determined by clinician, for 12 months.
3065500|NCT01041274|Placebo Comparator|Placebo|Participants will receive a daily dose of placebo for 12 months.
3065501|NCT01041287|Active Comparator|Nebivolol/ Metoprolol|"Subjects were randomized to nebivolol for 3 months. They crossed over to take 3 months of metoprolol succinate. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
3132364|NCT03421210|Other|Nicotine Replacement Therapy|Participants will receive nicotine replacement therapy for 10 weeks after quitting smoking.
3132365|NCT03421379|Experimental|Glucagon Nasal Powder|A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.
3065502|NCT01041287|Active Comparator|Metoprolol/Nebivolol|"Subjects were randomized to metoprolol succinate for 3 months. They crossed over to take 3 months of nebivolol. The initial 5 mg daily dose of nebivolol was titrated to 10 mg daily after 2 weeks if their BP remained >125/80, and subsequently titrated to 20 mg daily after another 2 weeks if the BP remained >125/80. Similarly, the initial 50 mg daily dose of metoprolol succinate was titrated to 100 mg daily after 2 weeks if BP remained >125/80, and further increased to 200 mg after 2 weeks if BP remained >125/80."
3065503|NCT01041404|Experimental|Trastuzumab, Fluoropyrimidine, Cisplatin|Participants received an initial loading dose of 8 milligrams per kilogram (mg/kg) trastuzumab i.v. on Day 1 of cycle, followed by 6 mg/kg i.v. every 3 weeks until disease progression; 800 mg/m2 fluorouracil i.v. on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
3065504|NCT01041404|Active Comparator|Fluoropyrimidine, Cisplatin|Participants received 800 milligrams per square meter (mg/m2) fluorouracil intravenous (i.v.) on Days 1 through 5 of cycle every 3 weeks for 6 cycles; 80 mg/m2 cisplatin i.v. on Day 1 of cycle every 3 weeks for 6 cycles; and 1000 mg/m2 capecitabine orally (p.o.) twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles.
3065505|NCT01041417|Experimental|GM-CSF|Subjects will receive GM-CSF 500μg (Sargramostim (Leukine), Sanofi Aventis) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
3065506|NCT01041417|Placebo Comparator|Placebo|Subjects will receive a saline injection (placebo) by a self-administered subcutaneous injection thrice weekly on Monday, Wednesday, and Friday for four weeks
3065507|NCT01041495|Experimental|cyclobenzaprine ER|
3065508|NCT01041495|Placebo Comparator|placebo|
3065509|NCT01041521|Experimental|Lovaza (omega three fatty acid)|"Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.~Other Names:~Lovaza was previously known as Omacor (omega-3-acid ethyl esters) capsules"
3065510|NCT01041521|No Intervention|sugar pill|"Dietary Supplement: sugar pill~2 capsules given twice daily Arms: sugar pill"
3065511|NCT01041573|Experimental|IC51 0.5 mL|Japanese Encephalitis Vaccine 6mcg im. at day 0 and day 28
3065512|NCT01041573|Experimental|IC51 0.25 mL|Japanese Encephalitis Vaccine 3mcg im. at day 0 and day 28
3065513|NCT01041573|Active Comparator|Havrix 720|Havrix®720 0.5 ml im. at day 0 and month 7
3065514|NCT01041573|Active Comparator|Prevnar|Prevnar 0.5 ml im. at day 0 and day 56 and month 7 or 0.5 ml im. at day 0, day 28 and day56 and month 7-13
3065515|NCT01041638|Experimental|Treatment (Ch14.18, GM-CSF, IL-2, isotretinoin)|Patients receive sargramostim SC or IV over 2 hours on days 0-13 of courses 1, 3, and 5; monoclonal antibody Ch14.18 IV over 10 hours on days 3-6 of courses 1, 3, and 5 and on days 7-10 of courses 2 and 4; and isotretinoin PO BID on days 11-24 of course 1, on days 14-27 of courses 2, 4, and 6, and on days 10-23 of courses 3 and 5. Patients also receive aldesleukin IV continuously on days 0-3 and on days 7-10 of courses 2 and 4. Treatment repeats every 24-32 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3065516|NCT01041781|Experimental|Arm I|Patients receive gemcitabine hydrochloride* IV on days 1 and 8 OR pemetrexed disodium* IV on day 1. Patients also receive carboplatin IV on day 1 and oral celecoxib twice daily on days 1-21.
3065517|NCT01041781|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* and carboplatin as in arm I. Patients also receive oral placebo twice daily on days 1-21.
3065518|NCT01041859|Experimental|Tapentadol Extended Release (ER)|
3065519|NCT01041859|Placebo Comparator|Placebo|
3065520|NCT01041976|Experimental|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
3065521|NCT01041976|Placebo Comparator|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
3065522|NCT01042093|Active Comparator|ROP/EPI/TOR/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
3065523|NCT01042093|Active Comparator|ROP/EPI/TOR|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Toradol 30mg/ml (1 ml)
3065524|NCT01042093|Active Comparator|ROP/EPI/CLO|Ropivacaine 5mg/ml (49.25 ml) Epinephrine 1 mg/ml (0.5 ml) Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
3065525|NCT01042093|Active Comparator|ROP/EPI|Ropivacaine 5mg/ml (49.25ml) Epinephrine 1 mg/ml (0.5 ml)
3065526|NCT01042145|Active Comparator|Prednisone|Prednisone, 2mg/kg for 3 days
3065527|NCT01042145|Active Comparator|Dexamethasone|Dexamethasone, 0.6mg/kg for one day, then placebo for 2 days
3065528|NCT01042158|Other|Tadalafil and ambrisentan upfront therapy|This will be a 36-week, single group, open label study assessing the effects of Tadalafil plus Ambrisentan combination therapy in patients with pulmonary arterial hypertension associated with the scleroderma spectrum of disease (PAH-SSD).
3065529|NCT01042236|Experimental|Arm 1|
3065530|NCT01042288|Experimental|Carboplatin/Pemetrexed/Panitumumab|Systemic Therapy
3065531|NCT01042366|Experimental|Vaccine co-cultured with melanoma cells|Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance
3065532|NCT01042366|Experimental|Vaccine pulsed with tumor cell lysates|Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance
3065533|NCT01042366|Experimental|Vaccine fused with tumor cells|Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance
3132366|NCT03421379|Active Comparator|Glucagon Hydrochloride Solution|A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)
3132367|NCT03421431|Experimental|EDP-305 Dose 1|Subjects will take 2 tablets once a day orally for 12 weeks
3065534|NCT01042392|Active Comparator|Ramipril|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Ramipril 5 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to Ramipril 10 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal): At visit 4, part of patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
3065535|NCT01042392|Experimental|Aliskiren|"In period I (washout and single-blind): from visit 1 to visit 2, 2 weeks placebo run-in.~In period II (double-blind treatment, randomized): Aliskiren 150 mg for 4 weeks (visit 2 - visit 3). At visit 3, medications had to be titrated to aliskiren 300 mg only if BP remained ≥ 140/90 mmHg. Double blind treatment had to be continued for another 4-week period until visit 4.~In period III (double-blind withdrawal ): At visit 4, part of the patients received the active treatment for 1 day. The study ended at visit 5 (48 hours later than visit 4)."
3065536|NCT01042392|Placebo Comparator|Placebo to Ramipril|In period III (double-blind withdrawal ): At visit 4, part of patients from Ramipril arm received placebo to Ramipril for 1 day. The study ended at visit 5 (48 hours later than visit 4).
3065537|NCT01042392|Placebo Comparator|Placebo to Aliskiren|In period III (double-blind withdrawal ): At visit 4, part of the patients from Aliskiren arm received placebo to Aliskiren for 1 day. The study ended at visit 5 (48 hours later than visit 4).
3065538|NCT01042496|Active Comparator|Bipolar Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC) before and after treatment with Lamotrigine.
3065539|NCT01042496|Active Comparator|Control Group|Subjects underwent proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
3065540|NCT01042509|Experimental|Alemtuzumab and rituximab|Patients with chronic GVHD after first-line therapy failure will receive Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25. THE STUDY HAVE ONLY ONE ARM.
3065541|NCT01042535|Experimental|Treatment (vaccine therapy, 1-methyl-d-tryptophan)|Participants receive adenovirus-p53 transduced dendritic cell (Ad.p53-DC) vaccine ID in weeks 1, 3, 5, and 10, and then every 3 weeks for 6 total doses. Participants also receive 1-methyl-d-tryptophan (indoximod) orally (PO) daily (QD) on days 1-21. Treatment with 1-methyl-d-tryptophan repeats every 28 days (patients with stable disease) for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3065542|NCT01042600|Active Comparator|Endotracheal intubation|Endotracheal tube insertion for surfactant administration, following morphine and atropine pre-medication
3065543|NCT01042600|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
3065544|NCT01042613|Other|Group A|Research participants are randomly assigned into group A (Accuvein AV300 assisted intravenous catheter insertion)
3065545|NCT01042613|Other|Group B|(standard technique of insertion of the intravenous cannula)
3065546|NCT01042678|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
3065547|NCT01042678|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
3065548|NCT01042678|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
3065549|NCT01042678|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
3065550|NCT01042678|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
3065551|NCT01042678|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
3065552|NCT01042795|Experimental|Continuous Daily Dosing of Sunitinib|
3065553|NCT01042938|Active Comparator|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
3065554|NCT01042938|Placebo Comparator|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks).
3065555|NCT01042977|Experimental|1|dapagliflozin 10 mg tablet
3065556|NCT01042977|Placebo Comparator|2|matching placebo tablet
3065557|NCT01043094|Experimental|Pitavastatin 4mg renal impaired|Subjects with severe renal impairment (glomerular filtration rate [GFR] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis
3065558|NCT01043094|Active Comparator|Pitavastatin 4mg healthy subjects|Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)
3065559|NCT01043133|Experimental|Intervention group|
3065560|NCT01043133|No Intervention|Control Group|
3065561|NCT01043146|Active Comparator|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
3065562|NCT01043146|Placebo Comparator|placebo|intravenous 0.9 % NaCl
3065563|NCT01043185|Experimental|A|AZD3355 30 mg
3065564|NCT01043185|Experimental|B|AZD3355 90 mg
3065565|NCT01043185|Experimental|C|AZD3355 120 mg
3065566|NCT01043185|Experimental|D|AZD3355 240 mg
3065567|NCT01043185|Placebo Comparator|E|Placebo
3065568|NCT01043393|Experimental|Psoriasis involving 10-15% BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of 10-15% of their body surface area.
3065569|NCT01043393|Experimental|Psoriasis involving >15% of BSA|Patients 18 years of age or older with a confirmed diagnosis of moderate to severe plaque psoriasis having involvement of >15% of their body surface area.
3065570|NCT01043432||Moderate/severe TBI and history of suicidal behavior Group 1|Moderate/severe TBI and history of suicidal behavior
3065571|NCT01043432||Moderate/Severe TBI and no history of suicidal behaviorGroup|Moderate/Severe TBI and no history of suicidal behavior
3065572|NCT01043432||No TBI and a history of suicidal behavior Group 3|No TBI and a history of suicidal behavior
3065573|NCT01043432||No TBI and no history of suicidal behavior Group 4|No TBI and no history of suicidal behavior
3065574|NCT01043523||Group 1|
3132368|NCT03421431|Experimental|EDP-305 Dose 2|Subjects will take 2 tablets once a day orally for 12 weeks
3132369|NCT03421431|Placebo Comparator|Placebo|Subjects will take 2 tablets once a day orally for 12 weeks
3065575|NCT01043562||Pediatric ICD pts|Inclusion criteria for study participants included: 1) weight ≤60 kg, 2) new or existing ICD system, and 3) clinically necessary assessment of the defibrillation efficacy of the ICD system. Transvenous systems utilized a high-voltage ICD coil with active-fixation lead attached to the right ventricular endocardial surface, whereas non-transvenous systems depended upon a high-voltage shocking coil placed within the pericardial, subcutaneous or pleural space. To be included in the post-shock pacing portion of the study, adequate sinus and AV node function had to be present at baseline. Exclusion criteria included 1) tenuous hemodynamic status felt to warrant abbreviation of the defibrillation efficacy testing or 2) inability to induce fibrillation during defibrillation threshold testing (DFT).
3065576|NCT01043640|Experimental|Transplant Patients|Includes patients who received allogeneic stem cell transplantation following treatment plan of Campath-1H, cyclophosphamide, cyclosporine A, mycophenolate mofetil, and busulfan.
3065577|NCT01043653||Maryland Assessment of Recovery in Serious Mental Illness|Individuals with serious mental illness treated in mental health outpatient programs
3065578|NCT01043705||CIED replacement with CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with a CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
3065579|NCT01043705||CIED replacement with ICD and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD and the TYRX Anti-bacterial envelope, with or without lead revision.
3065580|NCT01043705||CIED replacement with ICD or CRT and TYRX|(Prospective Arm) Patients who have undergone CIED replacement with an ICD or CRT and the TYRX Anti-bacterial envelope, with or without lead revision.
3065581|NCT01043705||CIED replacement w/ CRT & no TYRX|(Retrospective Case-Control Arm) Patients who have undergone CIED replacement with a CRT and no TYRX Anti-bacterial envelope, with or without lead revision/addition.
3065582|NCT01043705||CIED replacement w/ CRT & TYRX vs. Case Match Arm|Patients who have undergone CIED replacement with a CRT and TYRX Anti-bacterial envelope, with or without lead revision/addition. Cohort is TYRX Case, Matched to Retrospective Case-Control Arm)
3065583|NCT01043874|Experimental|Nilotinib|400 mg BID
3065584|NCT01043926|Experimental|Participants with Moderate Hepatic Insufficiency (Part I)|Participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3065585|NCT01043926|Experimental|Healthy Participants (Part I)|Healthy participants matched to participants with moderate hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3065586|NCT01043926|Experimental|Participants with Mild Hepatic Insufficiency (Part II)|Participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
3065587|NCT01043926|Experimental|Healthy Participants (Part II)|Healthy participants matched to participants with mild hepatic insufficiency will receive a single dose of 20 mg open-label suvorexant during Part II of the study (if conducted).
3065588|NCT01043939|Active Comparator|Purple Grape Juice First|After 4 week run-in period, drink 6 ounces of purple grape juice twice daily, then 4 week washout, week 12 drink 6 ounces of clear apple juice for 4 weeks twice daily
3065589|NCT01043939|Active Comparator|Apple Juice First|After 4 week run-in period, drink 6 ounces of clear apple juice twice daily, then 4 week washout, week 12 drink 6 ounces of purple grape juice for 4 weeks twice daily
3065590|NCT01044030|Experimental|Xylitol syrup|
3065591|NCT01044030|Placebo Comparator|Placebo|
3065592|NCT01044056|Active Comparator|Levonorgestrel/ethinylestradiol oral contraceptive pill|Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
3065593|NCT01044056|Active Comparator|Norelgestrominum and ethinylestradiol contraceptive patch|Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
3065594|NCT01044056|Active Comparator|Etonogestrel and ethinylestradiol contraceptive vaginal ring|Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
3065595|NCT01044212|Active Comparator|Docusate|Docusate is the standard of care regimen
3065596|NCT01044212|Experimental|Bowel medications|Docusate, Miralax, Metamucil wafers, Bisacodyl suppository
3065597|NCT01044264|Active Comparator|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Test product
3065598|NCT01044264|Active Comparator|DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Reference product
3065599|NCT01044264|Placebo Comparator|Placebo|
3065600|NCT01044290|Experimental|Outlook Intervention|"Subjects in the first group (Life Completion) completed a psychosocial intervention which consisted of meeting with the facilitator three times for 45-60 minutes each. In the first session, subjects were asked to discuss issues related to life review. In session two, participants spoke about issues of regret and forgiveness. In the final session, subjects focused on heritage and legacy."
3065601|NCT01044290|Active Comparator|Attention Control|"The subjects in the second group (attention control) met with a facilitator three times for 45 minutes and listened to a non-guided relaxation CD."
3065602|NCT01044290|No Intervention|Treatment as Usual|"Subjects in the third group (treatment as usual) were exposed to no intervention or attention control during the intervention window."
3065603|NCT01044303|Experimental|Myfortic Escalation|Participants EC-MPS dose was escalated to a minimum daily dose of 1440mg or equivalent, with the maximum dose never exceeding the manufacturer's recommendations.
3065604|NCT01044433|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.
3065605|NCT01044459|Experimental|Aclidinium Bromide 200 µg|aclidinium bromide, inhaled, 52 weeks of treatment
3065606|NCT01044459|Experimental|Aclidinium Bromide 400 µg|aclidinium bromide, inhaled, 52 weeks of treatment
3065607|NCT01044498|Experimental|Tocilizumab 8 mg/kg + Ortho-Novum® 1/35 (Group 1)|Patients with rheumatoid arthritis received Ortho-Novum® 1/35 daily on Days 1-21 of 3 consecutive 28-day cycles. On the first day of Cycle 2, patients received tocilizumab 8 mg/kg administered intravenously.
3065608|NCT01044498|Other|Ortho-Novum® 1/35 (Group 2)|Healthy volunteers received Ortho-Novum® 1/35 tablets daily on Days 1-21 of one 28-day cycle.
3065609|NCT01044537|Placebo Comparator|Placebo|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo.
3065610|NCT01044537|Experimental|PF-04937319|In each ascending-dose cohort, approximately 6 subjects will receive active treatment and 3 will receive placebo. There will be approximately 6 dosing levels of PF-04937319
3065611|NCT01044576||Multiple Sclerosis|Patients with relapsing-remitting or secondary progressive multiple sclerosis
3065612|NCT01044589|Experimental|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft
3065613|NCT01044589|Active Comparator|Overlapping Sphincter Repair|Control
3065614|NCT01044693|Placebo Comparator|Placebo capsule|Placebo capsule
3065615|NCT01044693|Experimental|Nebivolol 5 mg|Nebivolol 5 mg capsule
3065616|NCT01044693|Active Comparator|Metoprolol tartrate 50 mg|Metoprolol tartrate 50 mg single oral dose
3065617|NCT01044693|Active Comparator|Sildenafil 25 mg|Sildenafil 25 mg single oral dose
3065618|NCT01044706|Experimental|Bicalutamide 50 mg Tablet|Bicalutamide 50 mg Tablet
3065619|NCT01044706|Active Comparator|Casodex® 50 mg Tablet|Casodex® 50 mg Tablet
3065620|NCT01044732|Experimental|Group A - COLO, then TER|"Complete examination with standard colonoscope (COLO) followed by complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope"
3065621|NCT01044732|Active Comparator|Group B - TER, then COLO|"Complete examination with Third Eye Retroscope (TER) used in conjunction with standard colonoscope, followed by complete examination with standard colonoscope (COLO) alone"
3065622|NCT01044745|Experimental|Treatment (Rituximab and allogeneic HCT transplant)|"CONDITIONING REGIMEN: Patients receive one of the following conditioning regimens as per the transplant physician: cyclophosphamide and TBI; targeted busulfan and fludarabine; reduced-dose busulfan and fludarabine; or fludarabine and TBI.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive rituximab IV on days -6, 1, 8, and 15 and anti-thymocyte globulin IV over 6-8 hours on days -3 to -1. Patients also receive tacrolimus IV continuously and then PO beginning on day -1 and continuing until day 150 followed by a taper until day 180 and mycophenolate mofetil PO or IV twice daily on days -1 to 60.~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0."
3065623|NCT01044758|Experimental|aMCI_62.5mg drug first, then placebo|"Amnestic MCI:~62.5mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3065624|NCT01044758|Experimental|aMCI_Placebo first, then 62.5mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 62.5mg levetiracetam twice daily (two weeks)"
3065625|NCT01044758|Experimental|aMCI_125mg drug first, then placebo|"Amnestic MCI:~125mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3065626|NCT01044758|Experimental|aMCI_Placebo first, then 125mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 125mg levetiracetam twice daily (two weeks)"
3065627|NCT01044758|Experimental|aMCI_250mg drug first, then placebo|Amnestic MCI: 250mg levetiracetam twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)
3065628|NCT01044758|Experimental|aMCI_Placebo first, then 250mg drug|"Amnestic MCI:~Placebo capsule twice daily (two weeks), washout (4 weeks), and 250mg levetiracetam twice daily (two weeks)"
3065629|NCT01044758|Placebo Comparator|Control_Placebo first, then placebo|"Healthy control:~placebo capsule twice daily (two weeks), washout (4 weeks), and placebo capsule twice daily (two weeks)"
3065630|NCT01044771|Other|change from tenofovir to raltegravir|"Single arm study:~Tenofovir containing nucleoside backbone changed over to raltegravir in all patients"
3065631|NCT01044862|Active Comparator|Aromatase Inhibitors (AI)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
3065632|NCT01044862|Active Comparator|Clomiphene Citrate (CC)|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
3065633|NCT01044862|Active Comparator|Follicle Stimulating Hormone (FSH)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
3065634|NCT01044901||Subjects with Sickle Cell Disease (SCD)|38 clinically stable black patients with Sickle Cell Disease (SCD) (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis).
3065635|NCT01044901||Healthy Volunteers|13 healthy control subjects were frequency matched to patients with SCD on age, sex, and race.
3065636|NCT01044966|Experimental|ITV DepoCyt + Temozolomide|Patients will undergo an induction phase of intraventricular (ITV) DepoCyt, using the dosage determined from the Phase I portionPatients with stable disease (clinically and radiographically), not exhibiting systemic toxicity, will undergo a three month consolidation phase of ITV DepoCyt, for one month (Cycles 3-6). Patients without progression or toxicity will undergo maintenance therapy using ITV DepoCyt every four weeks (+/- 3 days) for a maximum of 8 months (cycles 7-14) or until recurrence or toxicity ensues. Oral metronomic Temozolomide dosing of 75 mg/m2 daily for 21 days followed by 7 days off will be given throughout the Induction, Consolidation, and Maintenance Phases of the ITV DepoCyt described above.
3065637|NCT01045031||Controls|"Controls were subsequently contacted via personal contact and three additional advertisements (two in an Austrian newspaper (Krone) and one in an Austrian bicyclist journal (Bicyclist Sports). The controls were matched according to age, sex and years of education"
3065638|NCT01045031||marathon athletes|Runners participating in the 2008 Wachau half marathon (21,2 km) and the Vienna City marathon (42,5 km) as well as bicyclists participating at the Corinthian marathon (180km). Inclusion criteria:1) participation in at least one of these 3 marathons in the preceding two years,2)still in continuous training during the recruitment phase (at least 2 hours/week), 3) aged over 60. Exclusion criteria:(a) present or past exposure to neurotoxic substances (b) if they did not speak German as their native language (c) diseases that markedly affect CNS functions (d) manifest cardiovascular disease, (e) chronic alcoholism (daily alcohol intake > 60 g or diagnosed history of alcoholism) and (f) unwillingness to give informed consent.
3065639|NCT01045057|Experimental|Puncture Set and Flexible Protector|Provox Vega Puncture Set is used to create the primary puncture and insert the prosthesis during total laryngectomy
3065640|NCT01045096|Experimental|Dexlansoprazole 15 mg QD|
3065641|NCT01045096|Experimental|Dexlansoprazole 30 mg QD|
3065642|NCT01045096|Experimental|Dexlansoprazole 60 mg QD|
3065643|NCT01045122|Other|Propofol|Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
3065644|NCT01045122|Other|Dexmedetomidine|Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
3065645|NCT01045135||first time delivery|Women giving birth to their first child
3065646|NCT01045161|Experimental|1|Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
3065647|NCT01045161|Experimental|2|Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
3065648|NCT01045161|Placebo Comparator|3|Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks
3065649|NCT01045174|Active Comparator|Breath-Actuated Nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer.
3065650|NCT01045174|Active Comparator|Conventional continuous-ouput nebulizer|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer
3065651|NCT01045187|Other|endometrial cancer|Patients are treated with electronic brachytherapy for an FDA cleared indication.
3065652|NCT01045265||Raltegravir treated men|Single group study of seminal plasma pharmacokinetics of raltegravir in men receiving chronic raltegravir therapy
3065653|NCT01045421|Experimental|MLN8237 (Alisertib)|MLN8237 administered as an enteric-coated tablet (ECT)
3065654|NCT01045447|Experimental|IDegAsp OD|
3065655|NCT01045447|Active Comparator|IGlar OD|
3065656|NCT01045460|Experimental|ASCT + MILs|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4.
3065657|NCT01045460|Experimental|ASCT + MILs + vaccine|Cyclophosphamide and filgrastim will be given to mobilize peripheral blood stem cells. Leukapheresis will be performed to collect peripheral blood from which activated marrow infiltrating lymphocytes will be produced. A melphalan conditioning regimen will be used prior to autologous stem cell transplant, and the MILs product will be administered on Days 3 and 4. The allogeneic myeloma vaccine will be administered on Days 21, 60, 180, and 300.
3065658|NCT01045499|Experimental|laparoscopic gastric banding|Adolescent patients who have undergone laparoscopic adjustable gastric banding. Weight, BMI, and co-morbidity data will be compared to patient's pre-operative values.
3065659|NCT01045551|Experimental|Apremilast 20 mg (twice per day)|All subjects will receive Apremilast 20mg taken orally twice per day.
3065660|NCT01045707|Experimental|IDegAsp OD|
3065661|NCT01045707|Experimental|IGlar OD|
3065662|NCT01045798|Experimental|Caspofungin|caspofungin acetate
3065663|NCT01045798|Placebo Comparator|Placebo|normal saline
3065664|NCT01045967|Experimental|Invesigational Test Product|Lansoprazole 30 mg delayed-release Capsules
3065665|NCT01045967|Active Comparator|Reference Listed Drug|Prevacid® 30 mg delayed-release Capsules
3065666|NCT01045993|Active Comparator|1|Heat device
3065667|NCT01045993|Sham Comparator|2|Placebo arm
3065668|NCT01045993|Active Comparator|3|Marketed analgesic
3065669|NCT01045993|Placebo Comparator|4|(Oral) Placebo comparator
3065670|NCT01046084|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
3065671|NCT01046084|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
3065672|NCT01046110|Experimental|IDeg OD|
3065673|NCT01046110|Experimental|DPP-IV inhibitor|
3065674|NCT01046136|Active Comparator|Mucinex|
3065675|NCT01046136|Placebo Comparator|placebo|
3065676|NCT01046253|Experimental|Investigational Test Product|Lansoprazole 30 mg Delayed-Release Capsule
3065677|NCT01046253|Active Comparator|Reference Listed Drug|Prevacid® 30 mg Delayed-Release Capsule
3065678|NCT01046396|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
3065679|NCT01046396|Active Comparator|Differin® Lotion 0.1%|Adapalene Lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
3065680|NCT01046565|Active Comparator|Differin® Cream 0.1%|Adapalene Cream 0.1% - apply once daily on one side of the face for 3 weeks
3065681|NCT01046565|Active Comparator|Differin® Lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face
3065682|NCT01046643|Active Comparator|Estrogen followed by Placebo|Estrogen treatment with Estradiol (E2) followed by Placebo.
3065683|NCT01046643|Active Comparator|Progesterone followed by Placebo|Progesterone (P10) treatment followed by Placebo.
3065684|NCT01046643|Active Comparator|Placebo followed by Estrogen|Placebo followed by Estrogen treatment with Estradiol (E2)
3065685|NCT01046643|Active Comparator|Placebo followed by Progesterone|Placebo followed by Progesterone (P10) treatment.
3065686|NCT01046669|Sham Comparator|Control|Standard medical care for septic shock
3065687|NCT01046669|Experimental|Treatment|Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
3065688|NCT01046682|Active Comparator|Salsalate|
3065689|NCT01046682|No Intervention|Usual care|
3132370|NCT03421730|Experimental|AB - VR647 5 breaths, then VR647 10 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3065690|NCT01046695|Active Comparator|TENS Unit|"This arm will be adding the use of the TENS unit for 48 hours in addition to standard care for their post operative pain control.~Patient's primary area of postoperative pain was determined by nursing personnel. Four electrodes were placed on or around the area of maximum pain. The TENS unit was turned on, 1 of 5 frequency patterns selected and the impulse turned up until the patient could feel the impulse. The location of the electrodes, the pattern, and/or the intensity of the TENS unit were adjusted until the patient achieved maximum comfort with the sensation."
3065691|NCT01046695|No Intervention|Control Arm|This arm will have standard care for their post operative pain control.
3065692|NCT01046877|Experimental|Tympanostomy Tube placement|Tympanostomy Tube Delivery System (TTDS) used for placement of tympanostomy tubes in patients indicated for such treatment for chronic Otitis Media with Effusion (OME) or recurrent Acute Otitis Media(AOM).
3065693|NCT01046903||1|
3065694|NCT01047007|Experimental|Part 1:MK-1775 65 mg BID|Participants received 65 mg of MK-1775 administered orally twice a day (BID) on Days 1-5 of a 21-day cycle.
3065695|NCT01047007|Experimental|Part 2 A1:MK-1775 20 mg BID+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally BID on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle.
3065696|NCT01047007|Experimental|Part 2 A2:MK-1775 20 mg QD+5-FU 1000 mg|Participants received 20 mg of MK-1775 administered orally once a day (QD) on Days 1-5 of a 21-day cycle and 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle.
3065697|NCT01047007|Experimental|Parts 2B +3:MK-1775+5-FU+CDDP|Participants were to receive 20 mg or 65 mg of MK-1775 administered either BID or QD on Days 1-5 of a 21-day cycle; 1000 mg/m^2/day of 5-FU administered as an IV infusion on Days 1-4 of a 21-day cycle; and 60 mg/m^2 to 100 mg/m^2 of CDDP administered as an IV infusion on Day 1.
3065698|NCT01047189|Experimental|1|Ziana gel (clindamycin phosphate 1.2% and tretinoin 0.025%) applied once daily for 12 weeks
3065699|NCT01047189|Active Comparator|2|Generic clindamycin 1% gel plus tretinoin 0.025% cream
3065700|NCT01047241|Experimental|Intranasal sufentanil/ketamine|Intranasal combination of sufentanil and ketamine. Dose of sufentanil 0.5 mcg/kg and ketamine 0.5 mg/kg, single dose.
3065701|NCT01047293|Experimental|All patients|All participants enrolled.
3065702|NCT01047306||No Treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIA to identify potential surrogate endpoints for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures.
3065704|NCT01047332|Active Comparator|Uncovered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (uncovered type).
3065705|NCT01047332|Experimental|Partially Covered Wallstent|Endoscopically-placed biliary self-expanding metal stent (SEMS) (partially covered type).
3065706|NCT01047345|Experimental|9vHPV Vaccine|Blinded 9vHPV vaccine (V503) 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study. Participants will not continue to the Extension Study.
3065707|NCT01047345|Placebo Comparator|Placebo|Blinded 0.5 mL intramuscular injection of saline placebo at Day 1, Month 2, and Month 6 of the Base Study. After completion of the Base Study, participants will be eligible to receive open-label 9vHPV 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Extension Study.
3065708|NCT01047358||ajuvant group|adjuvant setting after two to three years of tamoxifen
3065709|NCT01047358||palliative group|palliative setting after progression of disease with anti-estrogen therapy
3065710|NCT01047436|Experimental|ArTiMist (artemether sublingual spray)|
3065711|NCT01047436|Active Comparator|Intravenous Quinine|
3065712|NCT01047475|Active Comparator|MB-6+FOLFOX4|MB-6 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
3065713|NCT01047475|Placebo Comparator|Placebo+FOLFOX4|Placebo, 6 capsules tid be taken with meals plus FOLFOX4, will be given for 16 weeks
3065714|NCT01047527|Active Comparator|8 weeks transdermal nicotine|8 weeks of transdermal nicotine
3065715|NCT01047527|Active Comparator|24 weeks transdermal nicotine|24 weeks of transdermal nicotine
3065716|NCT01047527|Experimental|52 weeks transdermal nicotine|52 weeks of transdermal nicotine
3065717|NCT01047553|Experimental|1|Formoterol 9 μg/dose
3065718|NCT01047709|Experimental|positional therapy|Avoidance of supine positioning.
3065719|NCT01047709|No Intervention|Control|Position ad lib.
3065720|NCT01047839|Experimental|>=2 months to <3 years|IC51 0.25 ml, 2 i.m. vaccinations at Day 0 and 28
3065721|NCT01047839|Experimental|>=3 to <12 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
3065722|NCT01047839|Experimental|>=12 to <18 years|IC51, 0.5 ml, 2 i.m. vaccinations at Day 0 and 28
3065723|NCT01048099|Experimental|PRO Onc Assay and Treatment|Blood specimens tested for circulating tumor cells followed by systemic treatment based on assay results with either trastuzumab or pertuzumab
3065724|NCT01048242|Experimental|Ramelteon|Ramelteon 8 mg oral before bedtime
3065725|NCT01048242|Placebo Comparator|sugar pill|
3065726|NCT01048333|Experimental|Formoterol, then Salmeterol, then Placebo|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Placebo Diskus and Placebo Turbuhaler
3065727|NCT01048333|Experimental|Salmeterol, then Palcebo, then Formoterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Placebo Diskus and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
3065728|NCT01048333|Experimental|Placebo, then Formoterol, then Salmeterol|Placebo Diskus and Placebo Turbuhaler first,then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
3065729|NCT01048333|Experimental|Formoterol, then Placebo, then Salmeterol|Formoterol Turbuhaler 9 μg and Placebo Diskus first, then Placebo Diskus and Placebo Turbuhaler, then Salmeterol Diskus 50 μg and Placebo Turbuhaler
3065730|NCT01048333|Experimental|Salmeterol, then Formoterol, then Placebo|Salmeterol Diskus 50 μg and Placebo Turbuhaler first, then Formoterol Turbuhaler 9 μg and Placebo Diskus, then Placebo Diskus and Placebo Turbuhaler
3065731|NCT01048333|Experimental|Placebo, then Salmeterol, then Formoterol|Placebo Diskus and Placebo Turbuhaler first, then Salmeterol Diskus 50 μg and Placebo Turbuhaler, then Formoterol Turbuhaler 9 μg and Placebo Diskus
3065732|NCT01048424|Experimental|Paced respiration|Participants will be instructed to practice slow-paced respiration for 15 minutes a day using the RESPeRATE device, and will also be given a Urinary Incontinence pamphlet containing general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
3065733|NCT01048424|Placebo Comparator|Control|Participants will be given a Urinary Incontinence pamphlet including general information about urinary incontinence and behavioral strategies for managing incontinence symptoms.
3065734|NCT01048502|Experimental|Fenofibrate (Tricor) (145 mg/day)|Participants will be given 1 fenofibrate (Tricor) 145mg and 4 fish oil placebos - supplies of study drug will be provided to last 8 weeks.
3065735|NCT01048502|Placebo Comparator|Placebo|Participants will be given 5 placebo pills (4 fish oil placebo and 1 fenofibrate placebo) - supplies of study drug will be provided to last 8 weeks.
3065736|NCT01048502|Experimental|Lovaza (900 mg/day)|Participants will be given 1 Lovaza capsule, 3 Fish oil placebo capsules, and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
3065737|NCT01048502|Experimental|Lovaza (3,600 mg/day)|Participants will be given 4 Lovaza capsules and 1 Fenofibrate placebo - supplies of study drug will be provided to last 8 weeks.
3065738|NCT01048541|Active Comparator|SpeediCath catheter|Standard treatment
3065739|NCT01048541|Experimental|Test product|
3065740|NCT01048593|Experimental|Dose 1|114ug
3065741|NCT01048593|Experimental|Dose 2|513ug
3065742|NCT01048593|Experimental|Dose 3|684ug
3065743|NCT01048606|Active Comparator|Placeco + exercise|Placebo (no phytoestrogen): Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) Exercise (three 1h-sessions/week)
3065744|NCT01048606|Active Comparator|Phytoestrogens without exercise|Phytoestrogens (70mg/day of soy isoflavone) Without exercise (no structured exercise session)
3065745|NCT01048606|Experimental|Phytoestrogens + exercise|Phytoestrogens (70 mg/day soy isoflavone) Exercise (1h-sessions 3 times/week)
3065746|NCT01048606|No Intervention|Placebo without exercise|Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day) No exercise
3065747|NCT01048658|Active Comparator|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
3065748|NCT01048658|Placebo Comparator|No Sevoflurane|Subject receives standard of care drug regimens for anesthesia with this procedure.
3065749|NCT01048671||Antiretroviral combination therapy including raltegravir|Participants received ARV combination treatment including raltegravir. Treatment of participants was at the discretion of the investigator who provided standard care in a real life setting.
3065750|NCT01048697|Experimental|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
3065751|NCT01048788|Experimental|OPC|
3065752|NCT01048866|Experimental|flurbiprofen 8.75 mg lozenge|Participants were instructed to suck one study (flurbiprofen 8.75 mg) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another study medication lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use study medication lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
3065753|NCT01048866|Placebo Comparator|placebo lozenge|Participants were instructed to suck one study (placebo) lozenge and efficacy assessments were taken in the clinic. Upon discharge, participants were instructed to use another lozenge every 3-6 hours, up to a total of 5 study lozenges in 24 hours. Following efficacy assessments, participants were again instructed to use a lozenge every 3-6 hours, up to a total of 5 study lozenges per day (plus rescue medication if needed) for the remaining time in the 7 day study.
3065754|NCT01048879|Other|ECMO alone|Patients receiving oseltamivir and Extracorporeal Membrane Oxygenation (ECMO) therapy (patients were already receiving oseltamivir and ECMO due to an illness)- Procedure/Surgery: pharmacokinetic blood sampling
3065755|NCT01048879|Other|CVVHD Alone|"Patients receiving Continuous Venovenous Hemodialysis(CVVHD) and oseltamivir (Patients were already receiving oseltamivir and CVVHD as a result of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
3065756|NCT01048879|Other|CVVHD + ECMO|"Patient receiving oseltamivir and ECMO and CVVHD (patients were already receiving oseltamivir, ECMO, and CVVHD as part of an illness).~Procedure/Surgery: pharmacokinetic blood and dialysate sampling"
3065757|NCT01048905|Experimental|Treatment: L-glutamine|Patients will receive an 8-week course of oral L-glutamine 10 grams TID
3065758|NCT01048944|Active Comparator|Bupropion SR|150 mg bid bupropion SR
3065759|NCT01048944|Active Comparator|Nicotine Patch|21mg, 14mg, 7mg
3065760|NCT01048944|Placebo Comparator|Placebo Patch and Placebo Pill|Individuals were placed on both a placebo patch that were the same size as active patches given to the Nicotine Patch group and were also given placebo pills were the same size and identically packaged as the active pills (bupropion) given to the Bupropion SR group.
3065761|NCT01048944|No Intervention|Delayed-quit control|Smoke for 67 days while others have quit, then quit.
3065762|NCT01049009|Active Comparator|Nebivolol followed by Metoprolol XL|Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
3065763|NCT01049009|Active Comparator|Metoprolol XL followed by Nebivolol|Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
3320898|NCT02014571|Experimental|Cohort B|Eight subjects will be randomized to receive either 30 mg of GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3320899|NCT02014571|Experimental|Cohort C|Eight subjects will be randomized to receive either GSK2878175 active treatment (4 GT1a and 2 GT1b) or matching placebo (1 GT1a and 1 GT1b) daily for 2 days fasted.
3320900|NCT02014571|Experimental|Cohort D|Twenty subjects will be randomized to receive either 60 mg of GSK2878175 active treatment (6 GT2, 6 GT3, 3 GT4) or matching placebo (2 GT2, 2 GT3, 1 GT4).
3320901|NCT02014623|Active Comparator|Grass pollen sublingual immunotherapy tablet|A sublingual allergen immunotherapy tablet (Oralair) containing: 300 index of reactivity (IR) of 5 grass pollen allergen extracts:perennial ryegrass (Lolium perenne), meadow grass (Poa pratensis), timothy grass (Phleum pratense), cocksfoot (Dactylis glomerata) and sweet vernal grass (Anthoxanthum odoratum) in an open label fashion administered for 4 months prior to the pollen season.
3320902|NCT02014623|Other|Control|Standard medical therapy: oral antihistamines AND/OR nasal steroids AND/OR nasal antihistamines
3320903|NCT02014636|Experimental|Part 1|Part 1 is a dose escalation phase in which subjects will receive pazopanib orally and the MK 3475 intravenously. Subjects will be evaluated for a minimum of 8 weeks before the next dose level cohort is enrolled.
3320904|NCT02014636|Experimental|Part 2|"Part 2 is a randomized phase in which subjects will be enrolled in each treatment arm:~Pazopanib monotherapy Pazopanib+MK-3475 MK-3475 monotherapy"
3320905|NCT02014649|Experimental|20mg Laninamivir Octanoate|Dry Powder plus placebo
3065771|NCT01049217|Experimental|Active drug|
3065772|NCT01049217|Placebo Comparator|Control|
3065773|NCT01049243|Other|Fluocinonide Cream 0.1%|Fluocinonide Cream 0.1% open label
3065774|NCT01049308||Heart Failure|veteran population with documented heart failure
3065775|NCT01049334|Experimental|flurbiprofen 8.75 mg lozenge|Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
3065776|NCT01049334|Placebo Comparator|Placebo lozenge|Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
3065777|NCT01049360|Experimental|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
3065778|NCT01049360|Experimental|Aclidinium 400 μg / formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
3065779|NCT01049360|Experimental|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID)
3065780|NCT01049360|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily
3065781|NCT01049360|Placebo Comparator|Placebo|Placebo twice-daily
3065782|NCT01049373|Experimental|Lymphdiaral Basistropfen (HDC)|HDC (Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X), each 10 drops t.i.d. for 15 weeks.
3065783|NCT01049373|Placebo Comparator|Placebo Solution|10 drops t.i.d. for 15 weeks
3065784|NCT01049412|Experimental|LY2605541 First, Then Insulin Glargine|Participants received LY2605541 for 8 weeks, followed by insulin glargine for 8 weeks.
3065785|NCT01049412|Active Comparator|Insulin Glargine First, Then LY2605541|Participants received insulin glargine for 8 weeks, followed by LY2605541 for 8 weeks.
3065786|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3065787|NCT01049503|Active Comparator|Caries-active 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3065788|NCT01049503|Active Comparator|Caries-active 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-active children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3065789|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3065790|NCT01049503|Active Comparator|Caries-inactive 550 ppm F, pH 4.5|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3320906|NCT02014649|Experimental|40mg Laninamivir Octanoate|Dry Powder
3320907|NCT02014662|Other|Arm 1|Healthy subjects aged 18 to 35 years
3320908|NCT02014675||SD01 ICD lead|
3320909|NCT02014688||American Indian or Alaskan Native Descent|
3320910|NCT02014688||Black or African American Descent|
3320911|NCT02014688||Asian Descent|
3320912|NCT02014688||Hispanic Descent|
3320913|NCT02014701|Other|Echocardiogram|Patients presenting with NSTEMI who are scheduled to undergo elective cardiac catheterization and coronary angiography with primary PCI will be selected for participation in the study. The patients will undergo a clinically indicated resting non-contrast echocardiogram to assess LV function and regional wall motion. They will then undergo contrast echocardiography with bolus injection of Optison™ contrast to reassess LV ejection fraction, improve LV opacification and assess regional wall motion abnormalities. Finally, they will be given a continuous infusion of Optison™ and will have assessment of myocardial perfusion of each of the 17 myocardial segments using low mechanical index continuous imaging of the myocardium and blood pool.
3320914|NCT02014714|Active Comparator|Morphine|Intrathecal Morphine 0.1mg
3320915|NCT02014714|Active Comparator|Fentanyl|Intrathecal Fentanyl 40mcg
3320916|NCT02014727|Experimental|AMA1-DiCo + Alhydrogel|AMA1-DiCo: 50µg Alhydrogel® : 0.85 mg Al3+ per dose Route : Intramuscular Vaccination schedule : Do, W4, W26
3320917|NCT02014727|Experimental|AMA1-DiCo+ GLA-SE|"Group A2 (15) : European volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3065791|NCT01049503|Active Comparator|Caries-inactive 1100 ppm F, pH 7.0|This arm aims to assess the overall effect of the dentifrice pH and fluoride concentration in the caries control of caries-inactive children of a fluoridated area. One drop of the LD (liquid dentifrice) should be used 3 times/day for 12 months.
3065792|NCT01049581|Experimental|pediatric aquatic therapy|The children of the PAT group participated in a 1 hour/time, twice-per-week, 12-week, PAT program in addition to conventional rehabilitation programs
3065793|NCT01049581|No Intervention|conventional therapy|The children included in the control group continued with their original rehabilitation programs
3065794|NCT01049776|Experimental|Pazapanib (GW786034)|
3065795|NCT01049802|Experimental|Active rTMS|Experimental subjects will receive subthreshold or suprathreshold rTMS to contralesional hemisphere for up to 20 minutes at 1 Hz followed by task oriented arm and hand therapy to affected limb.
3065796|NCT01049802|Placebo Comparator|Sham rTMS|Subject will receive sham rTMS to contralesional hemisphere for up to 20 minutes followed by task-oriented arm and hand rehabilitation to affected limb
3065797|NCT01049919|Experimental|Concentrated bone marrow aspirate (cBMA)|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
3065798|NCT01049919|Sham Comparator|Placebo control (sham)|Placebo procedure (sham) consists of simulated bone marrow aspiration followed by simulated intramuscular injections into the affected limb
3065799|NCT01049945|Experimental|Arm I|Patients receive dexamethasone orally or IV on days 1, 8, 15, and 22; bendamustine hydrochloride IV over 30 minutes on days 1 and 2; and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3065800|NCT01049984|Experimental|Rasagiline 1 mg|Participants took a 1 mg rasagiline tablet orally each day for 18 weeks.
3065801|NCT01049984|Placebo Comparator|Placebo|Participants took a matching placebo tablet once daily for 18 weeks.
3065802|NCT01050062||Micombi® Combination Tablet AP|
3065803|NCT01050062||Micombi® Combination Tablet BP|
3065804|NCT01050153|Active Comparator|Control (standard of care)|Dalteparin sodium 5000IU subcutaneously daily
3065805|NCT01050153|Experimental|TEG-guided thromboprophylaxis|Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
3065806|NCT01050205|Active Comparator|Current Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Current intervention Arm in which case they will receive the intervention immediately."
3065807|NCT01050205|Active Comparator|Delayed Intervention|"Eligible participants will be asked to choose Group Lifestyle Balance Group (GLB-Group) or Group Lifestyle Balance DVD (GLB-DVD). Upon choosing, participants will be randomly assigned to Delayed Intervention Arm in which case they will receive delayed intervention at 6 months."
3065808|NCT01050231|Experimental|Robotic group (Type I)|Type I Robotic Therapy (Functional activities first) Participants in this group will participate in functional/task-oriented multi-joint training with the BONES robot first, followed by individual joint training with the BONES robot. A one-week break was provided between interventions.
3065809|NCT01050231|Active Comparator|Robotic group (Type II)|Type II Robotic Therapy (Individual joints first) Participants in this group will participate in individual joint training with the BONES robot first, followed by functional/task-oriented multi-joint training with the BONES robot. A one-week break was provided between interventions.
3065810|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 100 mg|Oseltamivir (TAMIFLU®) 100 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 75 mg oral oseltamivir twice daily to complete the 5 days of treatment. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
3065811|NCT01050257|Experimental|Oseltamivir (TAMIFLU®) 200 mg|Oseltamivir (TAMIFLU®) 200 mg intravenous (IV) infused over 2 hours, two times a day (every 12 hours) for 5 days. At the discretion of the investigator after 3 days of treatment (6 doses), participants could either continue IV treatment or switch to 150 mg oral oseltamivir twice daily for 5 days. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug (IV or oral) for up to 5 days.
3065812|NCT01050257|Experimental|Oseltamivir Open Label|Moderate/Severe renal impaired participants received open label oseltamivir IV or oseltamivir capsules at reduced doses for 5 days as per protocol. If necessary, after completing the 5 days of treatment, participants could receive additional treatment with study drug as per protocol.
3065813|NCT01050530|Experimental|OPC-41061|
3065814|NCT01050530|Placebo Comparator|Placebo|
3065815|NCT01050543|Experimental|Sugammadex|
3065816|NCT01050543|Active Comparator|Neostigmine|
3065817|NCT01050569|Active Comparator|VLNC Cigarette|Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
3065818|NCT01050569|Active Comparator|Nicotine Patch|21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
3065819|NCT01050569|Experimental|VLNC Cigarette plus Nicotine Patch|Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks
3065820|NCT01050582|Experimental|Risperidone|Risperidone as per local prescribing practices
3065821|NCT01050582|Experimental|Other atypical antipsychotic drugs|Other atypical antipsychotic drugs as per local prescribing practices
3065822|NCT01050634||Observational|
3065823|NCT01050647|Active Comparator|17-hydroxyprogesterone caproate|Weekly injections of 17-hydroxyprogesterone caproate until patient reached 34 completed weeks of gestation
3065824|NCT01050647|Placebo Comparator|Castor oil injections|Weekly injections of Caster Oil (placebo)
3065825|NCT01050660|Active Comparator|3 gm/kg/day intravenous lipid emulsion|
3065826|NCT01050660|Experimental|Intravenous Fat Emulsion-restricted|
3065827|NCT01050673|Active Comparator|VERSAJET|Excision with VERSAJET™ Hydrosurgery System
3065828|NCT01050673|Active Comparator|Conventional Therapy|Conventional operating room excision will consist of sharp instrumentation and electrocautery techniques, with the use of pulse lavage at the investigator's discretion. The type of sharp instrumentation, together with the brand of pulse lavage will be recorded.
3065829|NCT01050764|Experimental|T-reg Cell Infusion after Allogeneic Stem Cell Transplant|
3065830|NCT01050790|Experimental|Aza Len Lymphapheresis SCT ALI|Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.
3065831|NCT01050816|Experimental|Chondron implantation|ankle cartilage defect patients who had CHONDRON transplantation
3065832|NCT01050907|Experimental|Miltefosine|2.5 mg/kg/day for 28 days
3065833|NCT01050946|Other|Haploidentical/cord transplant|Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
3065834|NCT01050998|Experimental|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 milligram (mg) injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3065835|NCT01050998|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3065836|NCT01050998|Experimental|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3065837|NCT01050998|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3065838|NCT01050998|Placebo Comparator|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) orally or parenterally.
3065839|NCT01051063|Experimental|Partial Remission Group|Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
3065840|NCT01051063|Experimental|Complete Remission Group|Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
3065841|NCT01051310|Experimental|CoreValve|
3065842|NCT01051323||1|
3065843|NCT01051349|Experimental|BIIB019|Participants received BIIB019, 150 mg subcutaneous injection every 4 weeks up to Week 288.
3065844|NCT01051440|Placebo Comparator|Placebo|Subjects will receive placebo for lisdexamfetamine.
3065845|NCT01051440|Active Comparator|Lisdexamfetamine|Subjects will start with 20 mg per day of lisdexamfetamine and may increase to a maximum of 40 mg.
3065846|NCT01051466|Experimental|Duloxetine|
3065847|NCT01051466|No Intervention|Healthy Participants|
3065848|NCT01051518|Experimental|CoreValve|
3065849|NCT01051557|Experimental|Treatment (temsirolimus and perifosine)|"PHASE I: Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and perifosine PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive temsirolimus and perifosine as in phase I. Some patients may also undergo cytoreductive surgery."
3065850|NCT01051570|Experimental|Carboplatin, RAD 001 & Prednisone|"Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle~RAD 001: 5 mg Orally daily, starting from Day 2 continuously~Prednisone 5 mg Orally twice daily, continuously"
3065851|NCT01051596|Experimental|ABT-888 and temozolomide|Temozolomide Days 1-5 and ABT-888 Days 1-7 of each 28-day cycle
3065852|NCT01051661|Experimental|Arepanrix 2D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
3065853|NCT01051661|Experimental|Arepanrix 2D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the Arepanrix™ vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
3065854|NCT01051661|Experimental|Arepanrix 1D 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
3065855|NCT01051661|Experimental|Arepanrix 1D 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 1 dose (D) of the Arepanrix™ vaccine followed by 1 dose of saline placebo at a 21-day interval at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
3065856|NCT01051661|Experimental|GSK2340273A 6M-3Y Group|Subjects, male and female, aged 6 months (M) to 3 years (Y), received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified) or, for children <12 months of age, in the left anterolateral thigh. Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm) or, for, children <12 months of age, in the right anterolateral thigh.
3065857|NCT01051661|Experimental|GSK2340273A 3Y-10Y Group|Subjects, male and female, aged 3 years (Y) to 10 years, received 2 doses (D) of the GSK2340273A vaccine at a 21-day interval (Days 0 and 21). First doses were administered in the deltoid region of the non-dominant arm (or left arm if dominance is not yet identified). Second doses were administered at a 21-day interval in the deltoid region of the dominant arm (or right arm).
3065858|NCT01051739||Group 1|glaucoma
3065859|NCT01051739||Group 2|normal
3065860|NCT01051778|Experimental|enoxaparin 40 mg plus low dose aspirin|
3065861|NCT01051778|Active Comparator|Heparin calcium 5,000 U twice daily plus low dose aspirin|
3065862|NCT01051791|Experimental|Everolimus 10 mg daily|"The study of the efficacy of everolimus will proceed in two stages after the method of Simon1. In the first stage 15 patients will be accrued and treated. If 9 or fewer patients show clinical benefit the study will be terminated. If 10 or more patients show clinical benefit the study will proceed to the second stage, accruing an additional 26 patients. If the second stage is complete and a total of 29 or more patients show clinical benefit among the 41 patients treated, the treatment CBR for will be considered high enough to warrant further study. Conversely, if the evaluation of everolimus concludes at the first stage, or if 28 or fewer patients experience a clinical benefit after completing the second stage, the therapy will not be considered for further study.~1"
3065863|NCT01051817|Experimental|AIN457|
3065864|NCT01051817|Placebo Comparator|Placebo|
3065865|NCT01051856|Active Comparator|SEAMGUARD with bioabsorbable staple|In this arm pancreatic transection will be executed using an endoscopic linear stapling device. The individual staple depth can be chosen by the operating surgeon. Bioabsorbable Mesh sleeves specifically manufactured for the chosen staple depth and cartridge length will be placed over the stapler before firing.
3065866|NCT01051856|Active Comparator|TissueLink with radiofrequency ablation|After pancreatic transection, with any method chosen by the operating surgeon, the pancreatic remnant will be treated with TissueLink alone for an ablation depth (thickness) of approximately 7 mm using electrosurgical generator settings of 100 W and a saline drip rate of 1-2 drops per second.
3065867|NCT01051960|Experimental|ambrisentan|ambrisentan dosed at either 5mg or 10mg orally once per day
3065868|NCT01051986|Active Comparator|SVG group|"patients who underwent off-pump coronary artery bypass using saphenous vein composite grafting based on the left internal thoracic artery~use saphenous vein as a composite graft connected to the left internal thoracic artery"
3065869|NCT01051986|Active Comparator|RITA group|"patient who underwent off-pump coronary artery bypass using right internal thoracic artery composite grafting based on the left internal thoracic artery~use right internal thoracic artery as a composite graft connected to the left internal thoracic artery"
3065870|NCT01052012|Experimental|Active: SABER-Bupivacaine|SABER-Bupivacaine
3065871|NCT01052012|Active Comparator|Comparator: Bupivacaine HCl|Bupivacaine HCl
3065872|NCT01052012|Placebo Comparator|Placebo: SABER-Placebo|SABER-Placebo
3065873|NCT01052038|Placebo Comparator|Group 1 Placebo|Normal saline 100ml (placebo) administered as a intravenous infusion 30 minutes prior to surgery.
3065874|NCT01052038|Active Comparator|Group 2: Dexamethasone 0.05mg/kg|Dexamethasone 0.05 mg/kg administered in 100 ml of sterile saline solution prior to surgery
3065875|NCT01052038|Active Comparator|Group 3:Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to surgery.
3065876|NCT01052077|Experimental|Brexipiprazole + ADT|OPC-34712 Tablets, Oral, 1 - 3 mg OPC-34712 + ADT
3065877|NCT01052077|Placebo Comparator|Placebo + ADT|Placebo + ADT
3065878|NCT01052103|Experimental|LY2140023|
3065879|NCT01052103|Placebo Comparator|Placebo|
3065880|NCT01052116|Active Comparator|Soy Isoflavone|Oral isoflavone supplement (100 mg/day)
3065881|NCT01052116|Placebo Comparator|Placebo|Matching placebo
3065882|NCT01052207||Critically Ill Patients|Evaluation of Oxidative Stress, Glucocorticoid Receptor function, and Adrenal Insufficiency amongst critically ill pediatric patients. Serum, and when available endotracheal samples, will be obtained within 24 hours of admission and at 5 days provided patients are 1) still in the PICU and 2) blood draws and endotracheal aspirates are part of their standard of care. Endotracheal aspirates will be sent on day 14, 21, and 28 provided patients are intubated and require suctioning as part of their standard of care.
3065883|NCT01052207||Healthy Controls|Healthy controls will be evaluated and defined as those who do not have any chronic medical condition, are not on steroids (inhaled or oral), and have not received steroids or etomidate in the last month. Given the time and need for multiple lab draws low dose adrenocorticotropin (ACTH) testing will not be done in healthy patients, nor will tracheal aspirate samples be obtained.
3065884|NCT01052272|Active Comparator|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
3065885|NCT01052272|Active Comparator|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
3065886|NCT01052272|Active Comparator|Ramipril and Allopurinol|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily. It is anticipated that the starting dose of each drug will be initiated in hospital and that the second dose will be implemented prior to discharge from the hospital. The starting dose of Allopurinol is 300 mg daily.
3320918|NCT02014727|Experimental|AMA1-DiCo + GLA-SE|"Group B1 (18) : African volunteer : AMA1-DiCo + GLA-SE~AMA1-DiCo: 50µg~GLA-SE 2.5 µg GLA per dose~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3065887|NCT01052272|Active Comparator|Candesartan cilexetil and Allopurinol|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily. The starting dose of Allopurinol is 300 mg daily.
3065888|NCT01052428|Active Comparator|Toprol XL|beta 1 receptor blockade; generic name metoprolol succinate
3065889|NCT01052428|Placebo Comparator|Placebo|Pill that looks like Toprol XL but does not have the active ingredients
3065890|NCT01052480|Experimental|Plasma and Standard Care|Participants will receive plasma with high titer anti-influenza A or anti-influenza B antibodies (Anti-Influenza Immune Plasma) in addition to standard care.
3065891|NCT01052480|Active Comparator|Standard Care|Participants will receive standard care.
3065892|NCT01052493|Experimental|2mg PP 1420|PP 1420 single dose, subcutaneous
3065893|NCT01052493|Experimental|4mg PP 420|PP 1420 single dose, subcutaneous
3065894|NCT01052493|Experimental|8mg PP 1420|PP 1420 single dose, subcutaneous
3065895|NCT01052493|Placebo Comparator|Placebo|0.9% saline
3065896|NCT01052545|Experimental|Arm 1- Intervention: Audit-Feedback|Baseline surveillance for the clinical outcomes will begin in year 1 at the intervention site and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will occur during year 2 of the study at the intervention site. Feedback will be delivered to individual health care providers at the intervention site during year 2.Unit-level audit feedback will be delivered at the intervention site during years 2 and 3 of the study. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the intervention site in years 2 and 3 of the project.
3065897|NCT01052545|No Intervention|Arm 2- Control|At the control site, baseline surveillance for the clinical outcomes will begin in year 1 at the and continue for all 3 years of the project. Guideline distribution will begin in year 2 and continue throughout the project. Audit-feedback will not occur at the control site. Provider surveys of knowledge and attitudes concerning the ABU guidelines will be administered at the control site in year 3 of the project.
3065898|NCT01052662|Experimental|Memantine 30mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 30 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3065899|NCT01052662|Experimental|Memantine 15mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Memantine 5mg in the morning was started on week 2. The dose was titrated on a twice a day schedule until the target dose of 15 mg/day was achieved by week 4. The medication was discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3065900|NCT01052662|Placebo Comparator|Memantine 0mg/day + Buprenorphine|"Participants were inducted onto buprenorphine/naloxone sublingual tablets during the first week of study participation. The dose was titrated from bup/nal 8mg to bup/nal 16mg in three days where it will remain until the last day of week 8. The 7-day discontinuation of buprenorphine-naloxone on week 9 was 12mg, 10mg, 8mg, 6mg, 4mg, 2mg, 2mg and stopped.~Matching placebo capsule was started on week 2. The placebo capsules were given on a twice a day schedule until week 12 and then discontinued over a one-week period on week 13. Patients received a 7-day supply of their medication each week."
3065901|NCT01052701|Active Comparator|Ribavirin plus Abacavir|Ribavirin plus Abacavir Administration intervention
3065902|NCT01052701|Active Comparator|Ribavirin alone|Ribavirin alone administration
3065903|NCT01052714|No Intervention|Usual Care|Control group with time-matched study visits
3065904|NCT01052714|Active Comparator|Lifestyle Balance|Weight management group education and individual counseling
3065905|NCT01052714|Other|Usual Care then Lifestyle Balance|Participants originally randomized to Usual Care, allowed to change over to Lifestyle Balance at month 6 per their request.
3065906|NCT01052779|Experimental|Ferumoxytol|Participants received an IV injection of ferumoxytol (510 milligrams [mg], 17 milliliters [mL]) on Day 1 (Baseline). This was followed by a second injection of ferumoxytol (510 mg, 17 mL) 5±3 days later for a total cumulative dose of 1.02 grams (g).
3065907|NCT01052779|Active Comparator|Iron Sucrose|"Participants received iron sucrose based on hemodialysis status. Participants on hemodialysis received either slow IV injection or IV drip infusion of 100 mg of iron sucrose on Day 1 (Baseline) and at the following 9 consecutive hemodialysis sessions for a total cumulative dose of 1.0 g.~Participants not on dialysis received either slow IV injection or IV drip infusion of 200 mg of iron sucrose on Day 1 (Baseline) and at 4 subsequent visits on nonconsecutive days over a 14-day period for a total cumulative dose of 1.0 g."
3065908|NCT01052831|Active Comparator|Naltrexone|For the first four weeks of the study, participants were administered naltrexone at 50mg per day. Participants not in response at week 4 were increased to 100mg per day for the remaining four weeks of the study.
3065909|NCT01052831|Placebo Comparator|Placebo|Participants received the placebo treatment which looked identical to active study medication.
3065910|NCT01052844|Placebo Comparator|Control group|"Placebo:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
3065911|NCT01052844|Experimental|Gabapentin|"Gabapentin 300mg:~Five and four days before chemotherapy (day -5 and day -4): 1x daily~Three and two days before chemotherapy (day -3 and day -2): 2x daily~One day before to five days after chemotherapy ( day -1 to day 5): 3x daily"
3065912|NCT01052948||Cohort 1|All persons who newly start one of the dopamine agonists (DA) after start of eligibility period
3065913|NCT01052948||Cohort 2|All persons who started levodopa after start of eligibility period and had not been treated with dopamine agonists anytime prior.
3065914|NCT01052948||Cohort 3|All persons with newly diagnosed hyperprolactinemia who had not been treated with dopamine agonists anytime prior.
3065915|NCT01052948||Cohort 4|healthy controls from general population matched on age, gender, index date and general practitioner (GP) practice to persons exposed to dopamine agonists
3065916|NCT01053000|Experimental|Lt. Arm Tazorac/Rt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Left arm only and then receive ALA- PDT Treatment to both arms
3065917|NCT01053000|Experimental|Rt. Arm Tazorac/Lt. Arm No Pretreatment|Apply Tazorac 0.1% gel for 1 week to the Right arm only and then receive ALA- PDT Treatment to both arms
3065918|NCT01053013|Experimental|Macrobead Implantation|patients will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
3065919|NCT01053078|Experimental|Naltrexone|
3065920|NCT01053078|Placebo Comparator|Placebo|
3065921|NCT01053156|Placebo Comparator|Placebo pill|All patients will be on placebo for 3 months in this crossover study.
3065922|NCT01053156|Experimental|Minocycline|All patients will be on minocycline for 3 months in this crossover trial.
3065923|NCT01053247|Experimental|Test|Test product that contains the active pharmaceutical ingredient
3065924|NCT01053247|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
3065925|NCT01053247|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3065926|NCT01053312|Experimental|1 flutemetamol|
3065927|NCT01053429||observational cohort|
3065928|NCT01053507|Active Comparator|Treximet|In the 30-day Treatment Period, subjects randomized to Treximet will treat with 1 tablet Treximet (sumatriptan 85mg / naproxen sodium 500mg) per day x 30 days.
3065929|NCT01053507|Placebo Comparator|Placebo|In the 30-day Treatment Period, subjects randomized to placebo will treat with 1 tablet placebo x 30 days. Placebo matches Treximet.
3320919|NCT02014727|Placebo Comparator|Placebo|"Group B2 (18) : African volunteer : Placebo~Placebo : isotonic saline solution~Route : Intramuscular Vaccination schedule : Do, W4, W26"
3065932|NCT01053663|Experimental|1|
3065933|NCT01053741|Experimental|Seminal Fluid then Normosol|2.5 mL radiolabeled autologous seminal fluid administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled Normosol-R administered rectally X1.
3065934|NCT01053741|Experimental|Normosol then Seminal Fluid|2.5 mL radiolabeled Normosol-R administered rectally x1. Two week pause between interventions. Then 2.5 mL radiolabeled autologous seminal fluid administered rectally X1.
3065935|NCT01053819|Experimental|Etanercept|open label treatment(50 mg SQ)per Food and Drug Administration approval for 24 weeks
3065936|NCT01053897|Experimental|GBT009|
3065937|NCT01053897|Placebo Comparator|Placebo|
3065938|NCT01053962|Experimental|SP-304 0.3 mg|SP-304 0.3 mg tablet by mouth once daily for 14 consecutive days.
3065939|NCT01053962|Experimental|SP-304 1.0 mg|SP-304 1.0 mg tablet by mouth once daily for 14 consecutive days.
3065940|NCT01053962|Experimental|SP-304 3.0 mg|SP-304 3.0 mg tablet by mouth once daily for 14 consecutive days
3065941|NCT01053962|Experimental|SP-304 9.0 mg|SP-304 9.0 mg tablet by mouth once daily for 14 consecutive days.
3065942|NCT01053962|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 14 consecutive days
3065943|NCT01053988|Experimental|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3065944|NCT01053988|Experimental|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
3065945|NCT01053988|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
3065946|NCT01053988|Placebo Comparator|Placebo|Placebo
3065947|NCT01053988|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3065948|NCT01054079|Experimental|Treatment (cinacalcet hydrochloride)|Patients receive cinacalcet hydrochloride PO QD for 20 weeks in the absence of disease progression or unacceptable toxicity.
3065949|NCT01054144|Experimental|Response Adapted Therapy|Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.
3065950|NCT01054170|Experimental|AZD9668|
3065951|NCT01054170|Placebo Comparator|Placebo|
3065952|NCT01054183|Experimental|Intubation using GlideScope Ranger|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team A to use the GlideScope Ranger for all intubations on that day.
3065953|NCT01054183|Active Comparator|intubation using direct laryngoscopy|The study site has two critical care transport teams per shift and will, at shift change, assign intubation team B. Team B will do intubations using direct laryngoscopy only that day.
3065954|NCT01054209|No Intervention|A: standard care, no warming|Control arm. Full standard care. No mattress warming. May receive warmed fluids if standard practise for clinician
3065955|NCT01054209|Active Comparator|B: electric warming mattress|Warming with warming mattress
3065956|NCT01054222|Other|Fesoterodine 4 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
3065957|NCT01054222|Other|Fesoterodine 8 mg|Dose determined as per previous drug regime in A0221045 and investigator's evaluation.
3065958|NCT01054300|Experimental|Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg|Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
3065959|NCT01054300|Experimental|Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo|Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
3065960|NCT01054300|Experimental|Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg|Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
3065961|NCT01054300|Experimental|Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo|Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a >= 7 day washout period between Period 1 and Period 2.
3065962|NCT01054339|Experimental|Low dose|rAAV1-CB-hAAT at dosage level of 6 x 10e11 vg/kg
3065963|NCT01054339|Experimental|Middle dose|rAAV1-CB-hAAT at dosage level of 1.9 x 10e12 vg/kg
3065964|NCT01054339|Experimental|High dose|rAAV1-CB-hAAT at dosage level of 6 x 10e12 vg/kg
3065965|NCT01054404|Active Comparator|Furosemide|Furosemide 0.3 mg/kg
3065966|NCT01054404|Placebo Comparator|Placebo|Up to 5 mL saline
3065967|NCT01054443|Placebo Comparator|Placebo|Participants received placebo tablets orally once a day for 42 days.
3065968|NCT01054443|Experimental|Lusutrombopag 0.5 mg|Participants received 0.5 mg lusutrombopag orally once a day for 42 days.
3065969|NCT01054443|Experimental|Lusutrombopag 0.75 mg|Participants received 0.75 mg lusutrombopag orally once a day for 42 days.
3065970|NCT01054443|Experimental|Lusutrombopag 1.0 mg|Participants received 1.0 mg lusutrombopag orally once a day for 42 days.
3065971|NCT01054456|Experimental|All Participants: Palonosetron 0.25 mg/5 mL|Participants will receive palonosetron 0.25 milligram (mg) per (/) 5 milliliter (mL) intravenous injection 30 minutes prior to receiving a low emetogenic chemotherapy (LEC) agent on Day 1.
3065972|NCT01054560|Experimental|SOLITAIRE™ Device|The SOLITAIRE™ Device (investigational device) is the experimental arm
3065973|NCT01054560|Active Comparator|MERCI® Device|The MERCI® Device (control device) is commercially available.
3065974|NCT01054573|Experimental|Telaprevir + Standard Treatment|Telaprevir 750 mg orally (by mouth) every 8h for 12 weeks plus standard treatment. Standard treatment is 180 mcg subcutaneous (under the skin) injection pegylated interferon (Peg-IFN) alfa-2a and 1000-1200 mg twice daily ribavirin (RBV) for 48 weeks.
3065975|NCT01054586||HIV pts w/ HBV or HCV, w/ or w/o mild to moderate HI|Patients with HIV coinfected with HBV or HCV with or without mild to moderate HI who are enrolled in one of the participating HIV patient cohorts. These patients will be exposed to FPV/RTV or LPV/RTV.
3065976|NCT01054599|Experimental|Memantine|Subjects will randomly assigned to take either a placebo or memantine for 13 weeks. The assignment will be double-blind, neither the study members nor the subject will know if he/she is taking memantine or a placebo.
3065977|NCT01054599|Placebo Comparator|Sugar Pill|Subjects will be randomly assigned to take either memantine or a placebo. The study is double-blind, and neither the study members nor the subject will know if he/she is taking memantine or a placebo.
3065978|NCT01054625|Experimental|zalutumumab 4 mg/kg|zalutumumab 4 mg/kg iv single infusion week 1,3, 4 and 5
3065979|NCT01054625|Experimental|zalutumumab 8 mg/kg|zalutumumab 8 mg/kg iv single infusion week 1, 3, 4 and 5
3065980|NCT01054625|Experimental|zalutumumab 16 mg/kg|zalutumumab 16 mg/kg iv single infusion week 1, 3, 4 and 5
3065981|NCT01054703|Experimental|Ethmoid Sinus Spacer placement|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
3065982|NCT01054729|Experimental|Sofosbuvir 100 mg+PEG+RBV|Participants received sofosbuvir 100 mg (1 x 100 mg tablet) and placebo to match sofosbuvir (3 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3065983|NCT01054729|Experimental|Sofosbuvir 200 mg+PEG+RBV|Participants received sofosbuvir 200 mg (2 x 100 mg tablets) and placebo to match sofosbuvir (2 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3065984|NCT01054729|Experimental|Sofosbuvir 400 mg+PEG+RBV|Participants received sofosbuvir 400 mg (4 x 100 mg tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3065985|NCT01054729|Active Comparator|Placebo+PEG+RBV|Participants received placebo to match sofosbuvir (4 tablets) for 28 days (baseline to Day 28), plus PEG+RBV (baseline to Week 48)
3065986|NCT01054742||Standard of Care PegIntron Plus Ribavirin [Part 2]|Participants who had relapsed during Part 1 of the study, had detectable HCV-RNA on Day 1 of Part 2 of the study, and who were re-treated during Part 2 of the study with standard of care PegIntron plus ribavirin for 48 weeks.
3065987|NCT01054768|Experimental|alpha-lipoic acid and acetyl-L-carnitine|alpha-lipoic acid and acetyl-L-carnitine1400 mg tablet twice a day for 6 months.
3065988|NCT01054768|Placebo Comparator|Placebo|1400 mg placebo tablet twice a day for 6 months.
3065989|NCT01054820|Experimental|FLECTORA Patch (diclofenac epolamine topical patch) 1.3%|One patch applied every 12 hours
3065990|NCT01054846|Experimental|Helmet and helmet education|Each participant preschool child received a free bicycle Bell helmet, manufactured by Bell Sports Inc., Rantoul IL, USA. In addition, classroom bicycle helmet education was provided to all participant children and their caregivers, consisting of a video on rules of biking and the importance of proper helmet use and a classroom melon drop demonstration with and without a helmet to participants and their caregivers.
3065991|NCT01054846|Active Comparator|Helmet education|Each child did not receive a bicycle Bell helmet but the child and his/her caregiver was given bicycle helmet education package as above.
3065992|NCT01054885|Experimental|Fluticasone Furoate Inhalation Powder|Inhaled Corticosteroid (ICS)
3065993|NCT01054885|Experimental|FF Inhalation Pwdr|Inhaled Corticosteroid (ICS)
3065994|NCT01054885|Experimental|Fluticasone Furoate/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3065995|NCT01054885|Experimental|FF/GW642444 Inhalation Pwdr|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3065996|NCT01054885|Experimental|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
3065997|NCT01054885|Placebo Comparator|Placebo|Placebo
3065998|NCT01054911|Experimental|Sunitinib pill|Patients will receive six weeks of sunitinib and then subsequently continue for an additional 6 weeks if the evaluation at 6 weeks shows stable disease or objective response. Restaging CT scans will be performed again after 12 weeks of therapy to determine response in preparation for surgical resection anticipated to occur around week 14-16.
3065999|NCT01054976|Experimental|Galantamine|
3066000|NCT01055028|Experimental|Regimen A / Treatment 1|"Participants were to receive paclitaxel 200 mg/m² intravenously over 3 hours every 21 days followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
3066001|NCT01055028|Experimental|Regimen B / Treatment 2|"Patients were to receive paclitaxel 90 mg/m² weekly x 3 of a 28-day cycle followed by bevacizumab 15 mg/kg intravenously over (cycle 1: 90 min; cycle 2: 60 min; cycles 3 to 6: 30 min) every 21 days x 6 cycles.~Maintenance bevacizumab (MB), 15 mg/kg once every 21 days intravenously for a maximum of 8 cycles, was initiated after the completion of paclitaxel + bevacizumab combination."
3066002|NCT01055067|Experimental|Tivantinib (ARQ 197)|3 capsules of 120 mg each, administered twice a day (once in the morning and once in the evening - total daily dose of 720 mg) in continuous 4-week cycles
3066003|NCT01055132|Other|Etafilcon A toric contact lens/Nelfilcon A toric|Etafilcon A toric contact lens first, then nelfilcon A toric second
3066004|NCT01055132|Other|Nelfilcon A toric/ Etafilcon A toric|Nelfilcon A toric contact lens first, then etafilcon A toric toric second
3066005|NCT01055171|Active Comparator|Propranolol|Patients will receive Propranolol in this condition.
3066006|NCT01055171|Placebo Comparator|Placebo|Patient to receive placebo in this condition.
3066007|NCT01055184|Experimental|2009 H1N1 Vaccine|Participants will be stratified by age into two groups: those between 60 and 70 years old, and those older than 70 years of age. All participants will receive the 2009 H1N1 vaccine.
3066008|NCT01055197|Experimental|PCI|Prophylactic Cranial Irradiation (PCI)
3066009|NCT01055197|Experimental|PCI + Consolidation RT|Prophylactic Cranial Irradiation (PCI) plus consolidative radiation therapy (RT) to locoregional and residual metastatic disease
3066010|NCT01055223||Type 2 diabetes subjects|Type 2 diabetes subjects
3066011|NCT01055262|Experimental|Heatwrap 1|Experimental heatwrap device for the lower back
3066012|NCT01055314|Experimental|Group 1 (chemotherapy, radiation therapy, cixutumumab)|Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1-5, 7, 8, 11, 12, 15, 16, 20-24, 28, 29, 32, 33, 35, 38, 41-44, 47, 48, 50, and 51; irinotecan hydrochloride IV over 90 minutes on days 1-5 of weeks 1, 4, 20, 23, 47, and 50; ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 of weeks 9, 13, 17, 26, and 30; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 7, 11, 15, 28, and 32; cyclophosphamide IV over 30-60 minutes on day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41, and 44; dactinomycin IV over 1-5 minutes on day 1 of weeks 35, 38, 41, and 44; and cixutumumab IV over 1 hour on day 1 of weeks 1-51. Patients also undergo radiation therapy on days 1-5 of weeks 20-24.
3066013|NCT01055314|Experimental|Group 2 (chemotherapy, radiation therapy, temozolomide)|Patients receive vincristine sulfate, irinotecan hydrochloride, ifosfamide, etoposide, doxorubicin hydrochloride, cyclophosphamide, and dactinomycin and undergo radiation therapy as in group 1. Patients also receive temozolomide PO on days 1-5 of weeks 1, 4, 20, 23, 47, and 50.
3066014|NCT01055457|Experimental|Experimental Multi-Purpose Solution|contact lens care solution
3066015|NCT01055457|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
3066016|NCT01055496|Experimental|Arm 1 (R-CVP)|Subjects in arm 1 will be enrolled in dose escalation cohorts that will initially evaluate an escalating dose of cyclophosphamide in combination with set doses of inotuzumab ozogamicin, vincristine, prednisone, and rituximab.
3066017|NCT01055496|Experimental|Arm 2 (R-GDP)|Subjects in arm 2 will be enrolled in dose escalation cohorts that will initially evaluate escalating doses of gemcitabine and/or cisplatinum in combination with set doses of inotuzumab ozogamicin, dexamethasone, and rituximab.
3066018|NCT01055613|Experimental|Experimental multi-purpose solution|Multi-purpose contact lens care solution.
3066019|NCT01055613|Active Comparator|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution.
3066020|NCT01055639|Active Comparator|In-person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT). ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
3066021|NCT01055639|Experimental|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT). Sessions were delivered via videoconferencing system. ACT is a psychotherapy intervention comprised of meditation, goal-setting, and behavior change.
3066022|NCT01055704|Experimental|Methylnaltrexone|
3066023|NCT01055704|Experimental|Codeine|
3066024|NCT01055704|Experimental|Methylnaltrexone + codeine|
3066025|NCT01055704|Placebo Comparator|Placebo|
3066026|NCT01055769|Other|Group 1|Subjects will accept Linezolid OS 600 MG first, after 4 days wash-out, then will accept Linezolid tablet 600 MG.
3066027|NCT01055769|Other|Group 2|Subjects will accept Linezolid tablet 600 MG first, after 4 days wash-out, then will accept Linezolid OS 600 MG.
3066028|NCT01055782|Experimental|With endoguide|Colonoscopy completed with endoguide
3066029|NCT01055782|No Intervention|Without endoguide|Colonoscopy completed without endoguide
3066030|NCT01055834|Experimental|Eszopiclone 3 mg tablet|
3066031|NCT01055834|Experimental|Eszopiclone 1 mg tablet|
3066032|NCT01055886|Active Comparator|Nicotine Patch|Nicotine patch given pre-quit attempt at weeks 4 through 6
3066033|NCT01055886|Placebo Comparator|placebo patch|placebo patch given pre-quit from weeks 4 through 6
3066034|NCT01056016|No Intervention|Wait-list control|Wait-list control group
3066035|NCT01056016|Experimental|ADHD Collaborative Intervention|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a Diagnostic and Statistical Manual-IV (DSM-IV) based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales. The intervention lasts for 6 months.
3066036|NCT01056107|Experimental|ROSE-010 30 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 30 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3066037|NCT01056107|Experimental|ROSE-010 100 mcg|A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 100 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3066038|NCT01056107|Experimental|ROSE-010 300 mcg|A glucagon-like peptide-1 (GLP-1) analogue. A glucagon-like peptide-1 (GLP-1) analogue. Subjects received a ROSE-010 300 mcg subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3066039|NCT01056107|Placebo Comparator|Placebo|Subjects received a matching placebo subcutaneous injection daily for 3 consecutive days and on 1 day 2-10 days later.
3066040|NCT01056198|Active Comparator|Santyl|2 mm Santyl applied once daily
3066041|NCT01056198|Sham Comparator|Control|Daily gauze and optional sharp debridement
3066042|NCT01056263||Non-Interventional Study|Subjects participating in this observational study originally participated in study A4061012 [NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
3066043|NCT01056276|Experimental|Treatment|Bendamustine, Bortezomib,and Dexamethasone for 8 cycles or 2 cycles beyond a confirmed complete response, assessed by IMWG criteria. Patients with stable disease and no intolerable toxicity may continue maintenance therapy with Bortezomib and Dexamethasone until disease progression or intolerable toxicity.
3066044|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|
3066045|NCT01056289|Active Comparator|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|
3066046|NCT01056289|Placebo Comparator|Placebo|
3066047|NCT01056302||Group 1|15 patients who underwent surgical repair of mandibular fractures at San Francisco VA Medical Center
3066048|NCT01056328|Experimental|St. Jude Medical Cardiac Ablation System|
3066049|NCT01056328|Active Comparator|FDA approved Open Irrigated Radio Frequency Ablation System|
3066050|NCT01056341|Experimental|Propranolol oral solution|
3066051|NCT01056341|Placebo Comparator|Placebo|
3066052|NCT01056380|Active Comparator|Nitazoxanide|
3066053|NCT01056380|Placebo Comparator|Placebo|
3066054|NCT01056484|Experimental|Meditation|Mindfulness Based Relapse Prevention for Alcohol Dependence intervention + Standard of Care therapy
3066055|NCT01056484|Other|Wait-list control|Standard of Care therapy only
3066056|NCT01056510|Experimental|A|
3066057|NCT01056510|Experimental|B|
3066058|NCT01056523|Experimental|Ribavirin-Cytarabine arabinoside|Ribavirin will be given orally bid according to a dose escalation scheme daily for 28 days of a 28 day cycle Cytarabine arabinoside will be given 20 mg sc bid days 1 to 10 of a 28 day cycle
3066059|NCT01056536|Experimental|Structured intervention + free condoms|The subjects will receive a structured intervention on STI's and will be offered free condoms
3066060|NCT01056536|Active Comparator|Free condoms|Subjects will be offered free condoms at the end of the pre-travel consultation
3066061|NCT01056536|No Intervention|No intervention|The topic of STI's will not be actively discussed during the pretravel consultation
3066062|NCT01056601|Experimental|Pancreatic Cancer Patients|Pancreatic cancer patients who received treatment with bortezomib and panobinostat after progressing on gemcitabine.
3066063|NCT01056640|Experimental|Home Telemonitoring|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line. This device has video monitoring which allows a real time face to face interaction with the provider. This allows for an individualized home care plan based upon multiple concerns which have not been adequately studied.
3066064|NCT01056640|Active Comparator|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required. It also includes home health care, timely post-hospital outpatient visits, a nurse generated phone call progress report within one business day of hospital dismissal, and standard clinic phone triage during business hours. It also involves a 24 hour nurse triage line for questions. Patients will be informed of the general options currently available to patients including the above as well as options for care in extended hours and at Mayo Express care.
3066065|NCT01056653|Experimental|Group A Teal|Standard Dose - Two intervention home visits (at 4 and 6 months of age)
3066066|NCT01056653|Experimental|Group B Purple|High Dose - Four intervention home visits (at 4, 5, 6, and 7 months of age)
3066067|NCT01056653|Sham Comparator|Group C Yellow|Comparison Group - One home visit, information only (at 4 months of age)
3066068|NCT01056718|Other|Nebivolol treatment|10 week open label nebivolol treatment.
3066069|NCT01056822|Active Comparator|1|Mycophenolate mofetil
3066070|NCT01056822|Experimental|2|Miycophenolate sodium
3066071|NCT01056913|Other|NITI CAR27 (ColonRing)|
3066072|NCT01057017|Experimental|intervention|"Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression"
3066073|NCT01057121|Experimental|Lenalidomide|Patients receive lenalidomide PO once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3066074|NCT01057225|Experimental|Arm I|Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.
3066075|NCT01057251|Experimental|1|
3066076|NCT01057251|Placebo Comparator|2|
3066077|NCT01057277|Experimental|RAD001(Afinitor)|Radiation 47 days Cisplatin day 1,8,15,22,29,36,43 RAD001 Day 1 according to assigned group to day 47
3066078|NCT01057381|Active Comparator|Dexmedetomidine 0.75 mcg/kg|Intraoperative administration for analgesia.
3066079|NCT01057381|Active Comparator|Dexmedetomidine 1mcg/kg|Intra-operative administration of dexmedetomidine 1 mcg/kg for analgesia
3066080|NCT01057381|Active Comparator|Morphine 50 mcg/kg|Intra-operative administration of morphine 50 mcg/kg for analgesia
3066081|NCT01057381|Active Comparator|Morphine 100mcg/kg|Intra-operative administration of morphine 100mcg/kg for analgesia
3066082|NCT01057394|Active Comparator|Radiofrequency Ablation|PVI using RF ablation
3066083|NCT01057394|Experimental|Visually Guided Ablation|PVI using visually guided ablation with an endoscopic ablation system
3066084|NCT01057433|Experimental|Pitavastatin|Healthy adult subjects
3066085|NCT01057589|Experimental|Pemetrexed + Cisplatin + Cetuximab|"Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m^2) intravenous (IV) infusion and as a 250 mg/m^2 IV weekly dose thereafter.~As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter."
3066086|NCT01057693|Experimental|pregabalin (Lyrica)|
3066087|NCT01057693|Placebo Comparator|Placebo|
3066088|NCT01057810|Experimental|Ipilimumab|
3066089|NCT01057810|Placebo Comparator|Placebo|
3066090|NCT01057862|Experimental|Naltrexone|
3066091|NCT01057862|Placebo Comparator|Placebo|
3066092|NCT01057888|Experimental|Autodialer|Autodialer reminder/recall
3066093|NCT01057888|Experimental|Letters|Mailed reminder letters
3066094|NCT01057888|No Intervention|Controls|Controls
3066095|NCT01057901|Experimental|Flibanserin 100 mg|Flibanserin 100 mg administered at bedtime
3066096|NCT01057901|Placebo Comparator|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
3066097|NCT01058005|Experimental|Natalizumab|
3066098|NCT01058005|Active Comparator|Interferon Beta-1a|
3066099|NCT01058005|Active Comparator|Glatiramer Acetate|
3066100|NCT01058070|Experimental|Implantable Device|Subjects who meet eligibility criteria are implanted with the Magnetic Esophageal Sphincter device (MES)
3066101|NCT01058096|Experimental|Cariprazine|Cariprazine 3 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3066102|NCT01058096|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3066103|NCT01058239|Experimental|Rituximab plus Bortezomib|This is a single arm trial adding the new drug bortezomib to the standard drug rituximab
3066104|NCT01058265|Experimental|Integrative|Integrative Medical care is defined as a comprehensive medical evaluation that emphasizes wellness and healing of the whole person as major goals above and beyond suppression of a specific somatic disease. The patient is viewed as a whole person with mind and spirit as well as body and these dimensions are incorporated into diagnosis and treatment plans. An integrative medicine evaluation includes four aspects of health: physical, emotional, mental and spiritual health. Maximum improvement in health is achieved by addressing each aspect through an integrated treatment plan. The evaluation generally takes 90-120 minutes.
3066105|NCT01058265|Active Comparator|Standard|Standard general medical evaluation.
3066106|NCT01058304|Experimental|Group Physical Therapy for Knee OA|Group Physical Therapy for Knee OA
3066107|NCT01058304|Active Comparator|Individual Physical Therapy for Knee OA|Individual Physical Therapy for Knee OA
3066108|NCT01058356||IBD research group in KASID|KASID is Korean Association Study of Intestinal Disease. It has several research group suh as inflammatory bowel disease (IBD) research group.
3066109|NCT01058395|Experimental|800 mg loading then 200 mg Q12|Minocycline 800 mg. loading followed by 200 mg. Q 12 hours.
3066110|NCT01058395|Experimental|800 mg loading then 400 mg Q12|Minocycline 800 mg. loading followed by 400 mg. Q 12 hours.
3066111|NCT01058421|Experimental|Intensive physical therapy|four week intervention of daily intensive physical therapy
3066112|NCT01058421|Active Comparator|control group|
3066113|NCT01058655|Experimental|Phase I Cohort 1: Everolimus 5 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3066114|NCT01058655|Experimental|Phase I Cohort 2: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3066115|NCT01058655|Experimental|Phase I Cohort 3: Everolimus 10 mg + Tivozanib 1.5 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3066116|NCT01058655|Experimental|Phase II: Everolimus 10 mg + Tivozanib 1 mg|Patients received oral everolimus daily continuously and oral tivozanib daily for 3 of a 4 weeks cycle. Patients are treated until disease progression, unacceptable toxicity or withdrawal of consent.
3066117|NCT01058668|Experimental|Cariprazine (3-6 mg/day)|Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
3066118|NCT01058668|Experimental|Cariprazine (6-12 mg/day)|Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
3066119|NCT01058668|Placebo Comparator|Placebo|Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.
3066120|NCT01058707|Experimental|MLN0128 QD|MLN0128 2 mg, 4 mg, 6 mg or 7 mg, capsule, orally, once daily (QD) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 52.1 weeks).
3066121|NCT01058707|Experimental|MLN0128 QW|MLN0128 7 mg, 10 mg, 15 mg, 20 mg, 30 mg or 40 mg capsule, orally, once weekly (QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 139.4 weeks).
3066122|NCT01058707|Experimental|MLN0128 QDx3d QW|MLN0128 6 mg, 9 mg, 12 mg, 16 mg or 20 mg capsule, orally, once daily every 3 days a week (QDx3d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 129.4 weeks).
3066123|NCT01058707|Experimental|MLN0128 QDx5d QW|MLN0128 7 mg, 10 mg or 13 mg capsule, orally, once daily every 5 days a week (QDx5d QW) in 28-day cycle in the Dose Escalation Phase until Maximum Tolerated Dose (MTD) was established (Up to 161.9 weeks).
3066124|NCT01058707|Experimental|MLN0128 5 mg QD|MLN0128 5 mg, capsule, orally, QD in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 98.3 weeks).
3066125|NCT01058707|Experimental|MLN0128 30 mg QW|MLN0128 30 mg, capsule, orally QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 240 weeks).
3066126|NCT01058707|Experimental|MLN0128 40 mg QW|MLN0128 40 mg, capsule, orally, QW in 28-day cycle until disease progression or unacceptable toxicity in the Dose Expansion Phase (Up to 100.1 weeks).
3066127|NCT01058863|Experimental|Albuterol Spiromax® 90 mcg|A single dose of albuterol 90 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler. Placebo inhalers used to maintain the blind.
3066128|NCT01058863|Experimental|Albuterol Spiromax® 180 mcg|A single dose of albuterol 180 mcg delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
3066129|NCT01058863|Active Comparator|ProAir® HFA 90 mcg|A single dose of albuterol 90 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
3066130|NCT01058863|Active Comparator|ProAir® HFA 180 mcg|A single dose of albuterol 180 mcg delivered with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler (2 inhalations). Placebo inhalers used to maintain the blind.
3066131|NCT01058863|Placebo Comparator|Placebo Inhaler|Placebo delivered with Spiromax®, an inhalation-driven, multi-dose dry powder inhaler, and with ProAir®, a 'press-and-breathe', metered-dose, aerosol inhaler. Placebo inhalers used to maintain the blind.
3066132|NCT01058941|Experimental|Lipoic acid and Omega-3 fatty acids|Three 1-gram fish oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two lipoic acid (LA) capsules per day in the morning. Total daily dose of study drug: 675 mg DHA, 975 mg EPA, 600 mg LA.
3066133|NCT01058941|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 capsules in the morning and 1 capsule in the evening) plus two placebo LA capsules per day in the morning.
3066134|NCT01058993|Experimental|AMD3100 or plerixafor|SINGLE arm study with increasing doses of Plerixafor
3066135|NCT01059071|Experimental|DFMO and Etoposide|
3066136|NCT01059175|Experimental|CRT With Dual Site LV Pacing|Cardiac resynchronization therapy with the addition of a second LV lead. Positioning of a pacing lead in a cardiac vein should be considered first. An epicardial lead will be used if the implant of an endocardial lead is impossible or previously failed.
3066137|NCT01059175|Active Comparator|Standard CRT|Conventional cardiac resynchronization therapy. Patients in this arm will keep their CRT system unchanged.
3066138|NCT01059305|Experimental|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
3066139|NCT01059318|Experimental|Everolimus|"All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks.~The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks."
3066140|NCT01059344|Experimental|Mesalamin|4.8g Mesalamin (800mg tablet)
3066141|NCT01059344|Placebo Comparator|Placebo|4.8g Placebo to Mesalamin (800 mg tablet)
3066142|NCT01059357|Experimental|Transoral Robotic Surgery (TORS)|Transoral Robotic Surgery (TORS) using the Da Vinci Robotic Surgical System
3066143|NCT01059435|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of matching placebo administered by subcutaneous or intravenous injection.
3066144|NCT01059435|Experimental|Romosozumab|Participants were randomized to receive a single dose of romosozumab administered by subcutaneous or intravenous injection. The starting dose was 0.1 mg/kg, with sequential escalation up to 10 mg/kg.
3066145|NCT01059526||Patients naive to KALBITOR|HAE patients that have not been treated with KALBITOR (ecallantide) prior to enrollment in the study
3066146|NCT01059526||Patients non- naive to KALBITOR|HAE patients that have been treated with KALBITOR prior to enrollment in the study
3066147|NCT01059539|Experimental|Cariprazine 3-12 mg/day for 16 weeks|Participants received cariprazine 1.5 mg orally on Day 1 and cariprazine 3.0 mg orally on Days 2 and 3. Starting on Day 4, the dose could be increased in increments of 3 mg every 2 days up to a maximum dose of 12 mg, if the response was not adequate and there were no tolerability issues based on the judgment of the principal investigator.
3066148|NCT01059565|Experimental|AZLI|Participants were randomized to receive AZLI for up to 24 weeks and may have continued to receive AZLI during the open-label phase for up to an additional 24 weeks.
3066149|NCT01059565|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match AZLI for up to 24 weeks and may have switched to AZLI during the open-label phase for up to 24 weeks.
3066150|NCT01059617|Experimental|Flulaval/Arepanrix Group|subjects received Flulaval vaccine on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3066151|NCT01059617|Experimental|Flulaval/Unadjuvanted Arepanrix Group|subjects received Flulaval vaccine on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3066152|NCT01059617|Experimental|Placebo/Arepanrix Group|subjects received a saline placebo on Day 0 and Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3066153|NCT01059617|Experimental|Placebo/Unadjuvanted Arepanrix Group|subjects received a saline placebo on Day 0 and the unadjuvanted formulation of Arepanrix vaccine on Day 122 and Day 143. All vaccines were given intramuscularly, in the deltoid region of the non-dominant arm at Days 0 and 122 and of the dominant arm at Day 143.
3066154|NCT01059630|Active Comparator|Bendamustine Alone|Participants will receive bendamustine 120 milligrams per meter square (mg/m^2) Intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.
3066155|NCT01059630|Experimental|Obinutuzumab + Bendamustine|"Induction phase: Participants will receive bendamustine 90 mg/m^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants will also receive obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6.~Maintenance phase: Participants with complete response (CR), partial response (PR) or stable response (SD) then will receive obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurs first)."
3066156|NCT01059643|Experimental|LY2523355|
3066157|NCT01059682|Experimental|Dalcetrapib|
3066158|NCT01059682|Placebo Comparator|Placebo|
3066159|NCT01059760|Other|Fasting Day First|28±4 hours of water-only fasting followed by 28±4 hours fed
3066160|NCT01059760|Other|Fed Day First|28± 4 hours fed followed by 28± 4 hours of fasting
3066161|NCT01059773|Experimental|Immediate Methotrexate Cessation|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
3066162|NCT01059773|Active Comparator|Gradual Reduction of Methotrexate|Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.
3066163|NCT01059799|Experimental|IDeg OD|
3066164|NCT01059799|Active Comparator|IGlar OD|
3066165|NCT01059812|Experimental|IDegAsp BID|
3066166|NCT01059812|Active Comparator|BIAsp 30 BID|
3066167|NCT01059825|Placebo Comparator|Placebo|Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
3066168|NCT01059825|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3066169|NCT01059825|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3066170|NCT01059825|Experimental|Ertugliflozin 10 mg|Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
3066171|NCT01059825|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
3066172|NCT01059825|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days
3066173|NCT01059851|Experimental|Participants with Severe Renal Impairment (Part I)|"Participants with severe renal impairment will receive a~single dose of 20 mg open-label suvorexant during Part I of the~study."
3066174|NCT01059851|Experimental|Healthy Participants (Severe Impairment Controls) (Part I)|Healthy participants matched to participants with severe renal impairment will receive a single dose of 20 mg open-label suvorexant during Part I of the study.
3066175|NCT01059851|Experimental|Participants with Moderate Renal Impairment (Part II)|Participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3066176|NCT01059851|Experimental|Healthy Participants (Moderate Impairment Controls) (Part II)|Healthy participants matched to participants with moderate renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3066177|NCT01059851|Experimental|Participants with Mild Renal Impairment (Part II)|Participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3066178|NCT01059851|Experimental|Healthy Participants (Mild Impairment Controls) (Part II)|Healthy participants matched to participants with mild renal impairment will receive a single dose of 20 mg open-label suvorexant during Part II of the study.
3066179|NCT01059864|Experimental|Arm 1|
3066180|NCT01059864|Experimental|Arm 2|
3066181|NCT01059877|Active Comparator|1072nm Infrared Photobiomodulation|Received treatment for dementia with transcranial 1072nm infrared light stimulation.
3066182|NCT01059877|Placebo Comparator|Placebo|Placebo device simulated transcranial photobiomodulation
3066183|NCT01059903|Experimental|Rotigotine PR2.2.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 separated by a washout phase of at least 5 days
3066184|NCT01059903|Experimental|Rotigotine PR2.1.1 first|Rotigotine transdermal patch 4.5 mg/10 cm^2, reference drug product PR2.1.1 followed by Rotigotine transdermal patch 4.5 mg/10 cm^2, test drug product PR2.2.1 separated by a washout phase of at least 5 days
3066185|NCT01059929|Active Comparator|Dexmedetomidine|Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
3066186|NCT01059929|Active Comparator|Propofol|Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
3066187|NCT01059994|Placebo Comparator|placebo sildenafil young|Younger subjects (ages 20-35) were administered placebo sildenafil orally daily for 1 week.
3066188|NCT01059994|Experimental|sildenafil young|Younger subjects (ages 20 -35) were administered sildenafil daily (25 mg/day) orally for 1 week.
3066189|NCT01059994|Placebo Comparator|placebo sildenafil older|Older subjects (ages 60-80) were administered placebo sildenafil orally daily for 1 week.
3066190|NCT01059994|Experimental|sildenafil older|Older subjects (ages 60 - 80) were administered sildenafil daily (25 mg/day) orally for 1 week.
3066191|NCT01060007|Experimental|Neoadjuvant radiation followed by FOLFOX|"Radiation - 20 Gy in 5 fractions to regional nodes. 25 Gy in the same 5 fractions to macroscopic disease. This is given over 1 week.~FOLFOX Chemotherapy - after two weeks rest - oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV/2 hours followed sequentially by 5FU 400 mg/m2 IV push and 5FU 2400 mg/m2 over 46 hour CIVI. Repeat ever other week for a total of 4 courses (this equals 6 weeks).~If 5-FU is unavailable -- oral capecitabine can be given as 1000 mg/m2 BID on days 1-7 every 14 days."
3066192|NCT01060020|Experimental|Sildenafil 40mg or 80mg|A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (<50%) EF.
3066193|NCT01060059||exenatide|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide.
3066194|NCT01060059||basal insulin|The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin.
3066195|NCT01060072|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5% ophthalmic suspension
3066196|NCT01060072|Placebo Comparator|Vehicle|Vehicle of loteprednol etabonate ophthalmic suspension
3066197|NCT01060098||Rheumatoid arthritis|Participants with Rheumatoid arthritis
3066198|NCT01060098||Ankylosing spondylitis|Participants with Ankylosing spondylitis
3066199|NCT01060098||Psoriatic arthritis|Participants with Psoriatic arthritis
3066200|NCT01060111|Experimental|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
3320920|NCT02014753||CoCr-EES, 2-week OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 2-week after PCI.
3066201|NCT01060111|Experimental|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
3066202|NCT01060111|Experimental|Topiramate Slow and Propranolol Booster|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion. Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
3066203|NCT01060124|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl D-trans|
3066204|NCT01060150|Experimental|OROS Methylphenidate HCl|
3066205|NCT01060345|Experimental|Women with Ductal Carcinoma in Situ|Women who have been diagnosed with ductal carcinoma in situ (DCIS) and will be taking Polyphenon E
3066206|NCT01060384|Experimental|Phase 1/Phase II|All participants will receive the same dose of Ofatumumab. There will be three planned dose cohorts for the Lenalidomide in the Phase 1 portion of this trial. A maximum of 18 patients will be enrolled in to Phase 1. Three evaluable patients will be enrolled in to each of the dose cohorts with an additional 3 patients to be enrolled in the maximum tolerated dose (MTD). An additional 29 evaluable patients will be enrolled in to Phase II using the MTD for Lenalidomide that was determined in Phase 1.
3066207|NCT01060540|Experimental|CR+G|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus genetic testing for type 2 diabetes
3066208|NCT01060540|Active Comparator|CR+EYE|conventional risk counseling (lifetime risk, fasting plasma glucose, and family history) plus eye disease counseling
3066209|NCT01060553|Experimental|Arm 1|The treatment program consisted of 24 semi-individualized acupuncture treatments over 12 weeks. It combines front and back treatments to avoid point fatigue (tolerance due to frequent use). The front treat-ment uses 11 needles, bilateral at acupuncture points LR3, PC6, HT7, ST36, SP6, and one at Yintang; the back treatment uses 14 needles, bilateral at points GB20, and BL14, 15, 18, 20, 21, and 23. There are 15 other points from which the flexibly prescribed points could be chosen
3066210|NCT01060553|No Intervention|wait list control|subjects were put on a wait list control. due to small numbers completing in both groups, the data from the wait list who completed acupuncture are combined with the experimental treatment group for analysis.
3066211|NCT01060592|Experimental|Stoma Adjustment at Surgery|The first band adjustment will be made at surgery versus historical controls where the adjustment is not made for 3-4 weeks post-surgery. EndoFLIP device (FDA Device Listing Number : D091203)will be used to make the adjustment.
3066212|NCT01060592|No Intervention|Historic|Weight loss profile over time for 50 patients in the first 12 months after surgery as derived from historic control records. Band adjustments are made in a heuristic fashion during the year after surgery using the experience of surgeon alone
3066213|NCT01060670|Experimental|Dermal Replacement Device|Device: INTEGRA® Dermal Regeneration Template
3066214|NCT01060670|Active Comparator|Moist Wound Therapy|0.9% Saline gel
3066215|NCT01061008|Experimental|Handgrip exercise|Handgrip exercise - patients allocated to this intervention will carry out an eight week post operative progressive handgrip exercise training program
3066216|NCT01061008|Active Comparator|Treatment as usual|
3066217|NCT01061151|Active Comparator|Antepartum Arm A|Mothers received ZDV + sdNVP + TRV Tail
3066218|NCT01061151|Experimental|Antepartum Arm B|Mothers received Triple ARV (3TC-ZDV + LPV-RTV)
3066219|NCT01061151|Experimental|Antepartum Arm C|Mothers received Triple ARV (TRV + LPV-RTV)
3066220|NCT01061151|Other|Late Presenters|Registration to facilitate a structure to screen women and infants for randomization in the Postpartum Component.
3066221|NCT01061151|Experimental|Postpartum Arm A (Maternal Prophylaxis)|Mothers received prophylaxis [preferred regimen: TRV + LPV-RTV]. Infants received short-course NVP.
3066222|NCT01061151|Experimental|Postpartum Arm B (Infant Prophylaxis)|Infants received extended NVP.
3066223|NCT01061151|Experimental|Maternal Health Arm A (Continue triple ARVs)|Mothers continued receiving triple ARV regimen [preferred regimen: TRV + LPV-RTV].
3066224|NCT01061151|Active Comparator|Maternal Health Arm B (Discontinue triple ARVs)|Mothers discontinued triple ARV regimen.
3066225|NCT01061177|Experimental|Nilotinib|This was a single-arm study; therefore all participants received nilotinib (AMN107) 300 mg bid given as two 150 mg capsules twice daily.
3066226|NCT01061333|Experimental|Placebo|Placebo
3066227|NCT01061333|Experimental|Montelukast|Montelukast
3066228|NCT01061333|Experimental|Nedocromil|Nedocromil
3066229|NCT01061333|Experimental|Mometasone|Mometasone
3066230|NCT01061359||Non-Interventional Study|Chemotherapy containing Epirubicin
3066231|NCT01061385|Experimental|ReShape Intragastric Balloon|Patients receiving the ReShape Intragastric Balloon
3066232|NCT01061385|Other|Control Arm|Weight loss using behavior modification (diet and exercise counseling) alone
3066233|NCT01061476|Other|Single arm - Sleep apnea|"Participants with sleep apnea will be recruited for the study. Each participant will undergo 3 sleep studies to assess the effect of the Provent™ device. Participants will only use the device while they are in the sleep laboratory. They will not use the device at home between sleep studies .~Baseline sleep study (No device) - Assess the effects of no Provent™ on sleep apnea severity.~Treatment sleep study (Provent™ device used) - Assess the effects of Provent™ on sleep apnea severity~Physiology sleep study (Provent™ on/off) - Assess the physiological effects of the Provent™ device on breathing during sleep."
3066234|NCT01061528|Experimental|New Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
3066235|NCT01061528|Active Comparator|Standard Smoking Cessation Counseling|"One 60-minute individual session~Seven 2-hour group sessions~Two individual brief telephone contacts over an eight-week period.~Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue even after the treatment sessions have ended. Standard nicotine patch dosing will be used."
3066236|NCT01061567||Male and female patients with Parkinson's disease|
3066237|NCT01061606|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3066238|NCT01061671|Active Comparator|simvastatin|40 mgms of simvastatin daily
3066239|NCT01061671|Placebo Comparator|placebo|Matched placebo pill daily
3066240|NCT01061710||varenicline (Champix®)|Subjects who have been retreated with varenicline within 52 weeks and have been enrolled to varenicline protocol A3051109.
3066241|NCT01061723|Placebo Comparator|Placebo|Placebo (for sarilumab) weekly (qw) for 12 weeks.
3066242|NCT01061723|Experimental|Sarilumab 100 mg q2w|Sarilumab 100 mg Subcutaneous (SC) injection alternating with placebo every other week (q2w) for 12 weeks.
3066243|NCT01061723|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks.
3066244|NCT01061723|Experimental|Sarilumab 100 mg qw|Sarilumab 100 mg SC injection qw for 12 weeks.
3066245|NCT01061723|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks.
3066246|NCT01061723|Experimental|Sarilumab 150 mg qw|Sarilumab 150 mg SC injection qw for 12 weeks.
3066247|NCT01061736|Experimental|Part A: SAR 100 mg qw|Sarilumab 100 mg subcutaneous (SC) injection weekly (qw) on top of MTX for 12 weeks.
3066248|NCT01061736|Experimental|Part A: SAR 150 mg qw|Sarilumab 150 mg SC injection qw on top of MTX for 12 weeks.
3066249|NCT01061736|Experimental|Part A: SAR 100 mg q2w|Sarilumab 100 mg SC injection every other week (q2w) alternating with placebo on top of MTX for 12 weeks.
3066250|NCT01061736|Experimental|Part A: SAR 150 mg q2w|Sarilumab 150 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
3066251|NCT01061736|Experimental|Part A: SAR 200 mg q2w|Sarilumab 200 mg SC injection q2w alternating with placebo on top of MTX for 12 weeks.
3066252|NCT01061736|Placebo Comparator|Part A: Placebo qw|Placebo (for sarilumab) qw on top of MTX for 12 weeks.
3066253|NCT01061736|Experimental|Part B Cohort 1: Non-selected Doses|Sarilumab 100 mg qw, 150 mg qw or 100 mg q2w SC injections as in Part A on top of MTX up to dose selection. After dose selection, participants were not continued but were allowed to participate in the open-label, long-term, extension study SARIL-RA-EXTEND (LTS11210).
3066254|NCT01061736|Experimental|Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 150 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3066255|NCT01061736|Experimental|Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)|Sarilumab 200 mg SC injection q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3066256|NCT01061736|Experimental|Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2)|Placebo (for sarilumab) q2w on top of MTX for a maximum of 52 weeks. Participants with inadequate response from Week 16 could be rescued with open-label highest dose of sarilumab.
3066257|NCT01061775|Experimental|Exenatide|5mcg of exenatide will be given twice a day for 4 weeks and increased to 10 mcg twice a day for 20 weeks.
3066258|NCT01061866|Experimental|Thalidomide|Open-labeled preliminary trial
3066259|NCT01062009|No Intervention|Control group|No intervention
3066260|NCT01062009|Active Comparator|Low dose group|250 mcg/kg/day supplemental IV zinc sulfate divided every 8 hours for 7 days
3066261|NCT01062009|Active Comparator|Medium dose group|500 mcg/kg/day supplemental IV zinc sulfate q8 hours for 7 days
3066262|NCT01062009|Active Comparator|High dose group|750 mcg/kg/day supplemental IV zinc sulfate q8 hrs for 7 days
3066263|NCT01062061||VARIVAX|Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.
3066264|NCT01062074||Korean Participants Vaccinated with GARDASIL|Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
3066265|NCT01062113|Experimental|Celecoxib 400mg|
3066266|NCT01062113|Experimental|Celecoxib 200mg|
3066267|NCT01062113|Placebo Comparator|Placebo|
3066268|NCT01062165|Experimental|Capsofungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
3066269|NCT01062230|Experimental|All patients|All participants enrolled.
3066270|NCT01062256|Placebo Comparator|Placebo|Placebo
3066271|NCT01062256|Experimental|Guaifenesin|Guaifenesin
3066272|NCT01062256|Experimental|Buckwheat Honey|Buckwheat Honey
3066273|NCT01062269|Active Comparator|Cholestyramine 4 grams|
3066274|NCT01062269|Active Comparator|Cholestyramine 12 grams|
3066275|NCT01062269|Placebo Comparator|Tang|
3066276|NCT01062308|Experimental|Taping|The tri-pull method of taping was used.Taping was initiated by first applying three, two-inch wide and approximately ten-inch long, pieces of elastic adhesive tape strips. The first strip was applied from the mid-humerus deltoid tuberosity across the scapula. The second strip was applied from the deltoid tuberosity across the clavicle to the mid-clavicle, but before the supra-sternal notch. The third strip was placed from the deltoid tuberosity over the acromion process to the neck.
3066277|NCT01062308|Active Comparator|Sham Taping|This was done using the same tapes. Three strips of tapes were applied in same position without repositioning the joint. All other Physiotherapy measures like positioning, handling technique and range of motion exercises were equally done for both the groups.
3066278|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 2.5 mg/day|Radiation therapy (RT), concurrent temozolomide (TMZ), and concurrent RAD001 2.5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3066279|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 5 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 5 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3066280|NCT01062399|Experimental|Ph I: RT + TMZ + RAD001 10 mg/day|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3066281|NCT01062399|Active Comparator|Ph II: RT + TMZ|Radiation therapy and concurrent temozolomide followed by post-radiation temozolomide
3066282|NCT01062399|Experimental|Ph II: RT + TMZ + RAD001|Radiation therapy, concurrent temozolomide, and concurrent RAD001 10 mg/day followed by post-radiation temozolomide and post-radiation RAD001 10 mg/day.
3066285|NCT01062555|Active Comparator|Phase I Arm 1|CSA and MMF
3066286|NCT01062555|Active Comparator|Phase I Arm 2|FK and MMF
3066287|NCT01062555|Active Comparator|Phase II Arm 1|Low CNI and MMF
3066288|NCT01062555|Active Comparator|Phase II Arm 2|Rapa and MMF
3066289|NCT01062568|Experimental|Obese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
3066290|NCT01062568|Experimental|Nonobese group|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after ACTH, blood samples will be obtained for repeat hormone measurements.
3066291|NCT01062763|Experimental|addition of spironolactone|spironolactone is added to previous antihypertensive treatment
3066292|NCT01062763|Placebo Comparator|Placebo|Addition of placebo
3066293|NCT01062841|Active Comparator|Intervention: Targeted Infection Control|Nursing homes allocated to the Intervention Arm will implement a series of new infection control programs.
3066294|NCT01062841|No Intervention|Control|Nursing homes allocated to the control group will continue with their standard infection control procedures. No changes will be made to their practices.
3066295|NCT01062893|Placebo Comparator|0 mls saline injected|NO SALINE INJECTED
3066296|NCT01062893|Active Comparator|15 mls saline|15ML SALINE ADMINISTERED EPIDURALLY
3066297|NCT01062971|Active Comparator|A|IOP Dorzolamide-Timolol-Brimonidine group
3066298|NCT01062971|Active Comparator|B|IOP dorzolamide-timolol group
3066299|NCT01063036|Experimental|Entecavir + Tenofovir|
3066300|NCT01063049|Active Comparator|Nulytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
3066301|NCT01063049|Experimental|Gatorade/Miralax + Placebo|Gatorade 64 oz (1/2 gallon), Miralax 306 g and a placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and placebo at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
3066302|NCT01063049|Experimental|Gatorade/Miralax + Bisacodyl|Gatorade 64 oz (1/2 gallon), Miralax 306 g and Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy as follows: Miralax 51 g and Bisacodyl 10 mg at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
3066303|NCT01063062|Experimental|tocilizumab|Participants received an 8 mg/kg tocilizumab intravenous (IV) infusion once every 4 weeks for 24 weeks (6 infusions). Participants taking concomitant methotrexate (MTX) at Baseline remained on a stable dose as per standard of care at the Investigator's discretion.
3066304|NCT01063075|Experimental|Cetuximab and Carboplatin (D)|"Group D:~Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m ²) cetuximab administered intravenously (I.V) on week 1,day 1. Carboplatin area under the curve (AUC=5) administered I.V on week 1,day 1.~Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/ m ²/day administered starting on week 1, day 1.~After 1 cycle, participants may then receive cetuximab as determined by clinical exam or radiological imaging studies until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants were placed into Group D only."
3066305|NCT01063075|Experimental|Cetuximab and Carboplatin (C)|"Group C: Cycle 1 (4 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week 1, day 1.1000 mg/m ²/day 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks, combination therapy): Carboplatin (AUC=5) administered I.V on week1,day1.1000 mg/m ²/d 5-FU as a 96-hour C.I. starting on week1, day1. 250 mg/m ² cetuximab administered I.V on Week 1-3, day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3066306|NCT01063075|Experimental|Cetuximab and Carboplatin (B)|"Group B:~Cycle 1 (3 weeks, single-agent cetuximab):~400 mg/m² cetuximab administered I.V on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 2 and 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V weeks 1- 3,day 1.~After 6 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011,any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3132371|NCT03421730|Experimental|AC - VR647 5 breaths, then VR647 20 breaths|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3132372|NCT03421730|Experimental|AD - VR647 5 breaths, then Pulmicort|5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
3066307|NCT01063075|Experimental|Carboplatin and Cetuximab (A)|"Group A:~Cycle 1 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1.~400 mg/m ² cetuximab administered I.V on week 2, day 1. 250 mg/m ² cetuximab administered I.V on week 3, day 1.~Cycle 2 (3 weeks, combination therapy):~Carboplatin (AUC=5) administered I.V on week 1, day 1. 1000 mg/m ²/d 5-FU administered as a 96-hour C.I. starting on week 1, day 1. 250 mg/m ² cetuximab administered I.V on weeks 1- 3, day 1.~After 7 cycles, participants may then receive cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and carboplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into Group D arm only."
3066308|NCT01063153|Experimental|Concerta|Open-Label Concerta (Osmotic Release Methylphenidate)
3066309|NCT01063153|No Intervention|Control group|Healthy subjects without ADHD will be assessed using EEG.
3066310|NCT01063283|Active Comparator|Group A|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
3066311|NCT01063283|Active Comparator|Group B|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg once, followed three weeks later by Carboplatin+Pemetrexed+Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
3066312|NCT01063348|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine - 600mg tablets by mouth (dosing 1200mg - 3000mg qd)
3066313|NCT01063348|Placebo Comparator|Placebo|Matching placebo taken daily
3066314|NCT01063517|Experimental|1|Olaparib + paclitaxel
3066315|NCT01063517|Active Comparator|2|paclitaxel + placebo
3066316|NCT01063595|Experimental|Octaplas LG|Participants received 1200 mL of Octaplas LG intravenously once.
3066317|NCT01063595|Active Comparator|Octaplas SD|Participants received 1200 mL of Octaplas SD intravenously once.
3066318|NCT01063712|Other|Nit-Occlud PDA-R|Interventional, prospective clinical study, non randomized.
3066319|NCT01063764|Experimental|Levetiracetam|Open-label, single-arm
3066320|NCT01063829|Experimental|Dose regimen 1|60 mg AIC246, one tablet per day
3066321|NCT01063829|Experimental|Dose regimen 2|120 mg AIC246, one tablet per day
3066322|NCT01063829|Experimental|Dose regimen 3|240 mg AIC246, one tablet per day
3066323|NCT01063829|Other|Placebo|Placebo arm
3066324|NCT01063855|Experimental|Dapoxetine + PDE5I|Dapoxetine 30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
3066325|NCT01063855|Placebo Comparator|Placebo + PDE5I|Placebo tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks + a PDE5I (phosphodiesterase-5 inhibitor) prescribed prior to study entry for the treatment of erectile dysfunction.
3066326|NCT01063868|Experimental|001|Tapentadol extended release (ER) 100 150 200 250 mg twice daily for 52 weeks
3066327|NCT01063868|Active Comparator|002|Oxycodone controlled release (CR) 20 30 40 50 mg twice daily for 52 weeks
3066328|NCT01063881|Experimental|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity may be increased after 4 weeks to 60mg taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
3066329|NCT01063907|Experimental|Phase 1: Cohort 1|Cohort 1: KW 2478 130 mg/m^2 and Bortezomib 1.0 mg/m^2
3066330|NCT01063907|Experimental|Phase 1: Cohort 2|Cohort 2: KW 2478 130 mg/m^2 and Bortezomib 1.3 mg/m^2
3066331|NCT01063907|Experimental|Phase 1: Cohort 3|Cohort 3: KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
3066332|NCT01063907|Experimental|Phase 1: Cohort 4|Cohort 4: KW 2478 175 mg/m^2 and Bortezomib 1.3 mg/m^2
3066333|NCT01063907|Experimental|Phase 2|KW 2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2
3066334|NCT01063972|Experimental|Experimental 1|Experimental: 1 Centralized disease management
3066335|NCT01063972|Experimental|Experimental 2|Experimental: 2 Counseling alone
3066336|NCT01064076|Experimental|S-ICD System|This is a single arm study
3066337|NCT01064167|Experimental|Tranexamic Acid group|
3066338|NCT01064167|Placebo Comparator|Control group|
3066339|NCT01064284|Active Comparator|PLASMA DERIVED Factor VIII|Plasma-derived vWF/FVIII
3066340|NCT01064284|Active Comparator|rFVIII|Recombinant FVIII
3066341|NCT01064297||Women exposed to lamotrigine during pregnancy|
3066342|NCT01064310|Experimental|pazopanib followed by sunitinib|800mg pazopanib orally for 10 weeks followed by 50mg sunitinib orally for 10 weeks
3066343|NCT01064310|Experimental|sunitinib followed by pazopanib|50mg sunitinib orally for 10 weeks followed by 800mg pazopanib orally for 10 weeks
3066344|NCT01064323|Other|Intermittent leg compression|Intermittent leg compression daily for 3 hrs a day for 4 weeks
3066345|NCT01064362||Prophylaxis following major orthopedic surgery|Patients age 18 years and older in the PHARMO RLS database treated with either fondaparinux sodium or LMWH for thromboprophylaxis following hip fracture and/or hip/knee replacement surgery.
3066346|NCT01064401|Experimental|Daclizumab High Yield Process 150 mg SC|Daclizumab High Yield Process (DAC HYP) 150mg subcutaneous (SC) injection once every 4 weeks plus placebo to IFN β-1a intramuscular (IM) injection once weekly for 96 to 144 weeks
3066347|NCT01064401|Active Comparator|IFN β-1a 30 µg IM|Interferon beta-1a (IFN β-1a) 30 µg IM once weekly plus placebo to DAC HYP SC once every 4 weeks for 96 to 144 weeks
3066348|NCT01064414|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
3066349|NCT01064414|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
3066350|NCT01064414|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks.
3066351|NCT01064531||MIS Femoral Neck Stem|Subject will be randomized to either MIS or Synergy implant.
3066352|NCT01064531||Synergy Hip System|Subject will be randomized to either Synergy or MIS implant.
3320921|NCT02014753||CoCr-EES, 3-month OCT follow-up|Undergo primary PCI with cobalt-chromium everolimus-eluting stent (CoCr-EES) for AMI culprit lesion and perform OCT observation at 3-month after PCI.
3066353|NCT01064622|Active Comparator|Arm I (gemcitabine hydrochloride and placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and placebo PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of disease progression, patients are unblinded and may crossover to arm II.
3066354|NCT01064622|Experimental|Arm II (gemcitabine hydrochloride and vismodegib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3066355|NCT01064648|Experimental|Arm I (pemetrexed disodium, cisplatin, cediranib maleate))|Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive cediranib maleate alone PO QD in the absence of disease progression or unacceptable toxicity.
3066356|NCT01064648|Active Comparator|Arm II (pemetrexed disodium, cisplatin, placebo)|Patients receive pemetrexed disodium and cisplatin as in arm I and placebo PO QD on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive placebo alone PO QD in the absence of disease progression or unacceptable toxicity.
3066357|NCT01064687|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3066358|NCT01064687|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3066359|NCT01064687|Active Comparator|Exenatide|"Exenatide: 5 micrograms (mcg), subcutaneous (SC), twice daily for 4 weeks, followed by 10 mcg, SC, twice daily for 48 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3066360|NCT01064687|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC), once weekly for 26 weeks~LY2189265 (Dulaglutide): After 26 weeks, participants were randomized to receive either 0.75 milligrams (mg) or 1.5 mg, SC, once weekly for an additional 26 weeks (from week 26 through week 52).~Metformin: at least 1500 milligrams per day (mg/day), oral, for 52 weeks~Pioglitazone: at least 30 mg/day, oral, for 52 weeks"
3066361|NCT01064713|Experimental|Tesetaxel|Therapy initiated at a flat dose of 40 mg for subjects in Cohort A and at a flat dose of 50 mg for subjects in Cohort B. Tesetaxel administered orally once every 21 days until the subject meets a withdrawal criterion or initiates nonstudy therapy for melanoma. Duration of protocol therapy will not exceed 12 months.
3066362|NCT01064739|Experimental|Study Diet +/- fava beans|Participants underwent testing while on a methylxanthine-free diet providing 150 mEq sodium and 75 mEq potassium per day. The study involved a longitudinal design where the participants served as their own controls. Subjects consumed the standard fixed sodium diet on study day one. On study day two, participants ate 100 g of puréed fava beans and pods with study diet at breakfast (0800hr) and lunch (1200hr).
3066363|NCT01064817|Experimental|PRM-151|PRM-151 (recombinant human serum amyloid P, recombinant human pentraxin 2)
3066364|NCT01064817|Placebo Comparator|Placebo|Placebo
3066365|NCT01064830|Active Comparator|topical cyclosporine suspension|apply 2 drops to 2 target nails under occlusion daily for 20 weeks
3066366|NCT01064830|Placebo Comparator|vehicle|apply to target nails daily under occlusion daily for 20 weeks
3066367|NCT01064856|Experimental|Double-blind (DB) Adalimumab|Adalimumab 40 mg subcutaneous (SC) injection every other week (eow) up to Week 12 in double-blind period.
3066368|NCT01064856|Placebo Comparator|Double-blind Placebo|Placebo subcutaneous (SC) injection every other week (eow) up to Week 12 in the double-blind period.
3066369|NCT01064856|Experimental|Double-blind Adalimumab / Open-label Adalimumab|Adalimumab 40 mg SC injection eow up to Week 12 in double-blind period and from Week 12 to Week 156 in open-label period.
3066370|NCT01064856|Placebo Comparator|Double-blind Placebo / Open-label Adalimumab|Placebo SC injection every other week (eow) up to Week 12 in the double-blind period; adalimumab 40 mg subcutaneous injection eow from Week 12 to Week 156 in the open-label period.
3066371|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.005%|bimatoprost ophthalmic sterile solution 0.005%
3066372|NCT01064882|Experimental|bimatoprost ophthalmic solution 0.015%|bimatoprost ophthalmic sterile solution 0.015%
3066373|NCT01064882|Active Comparator|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03%
3066374|NCT01065350|Active Comparator|Propofol|As part of the induction, patients will be given 2 milligrams of propofol per kilogram (mg/kg) of body weight. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL.
3066375|NCT01065350|Experimental|Ketofol|"As part of the induction, patients will be given 20 mL syringe of an admixture called ketofol, which combines ketamine and propofol in one syringe. The dose is weight-based such that ketamine will represent 0.75 mg/kg of the dose and propofol, 1.5 mg/kg of the dose."
3066376|NCT01065428||Weaning failure|Weaning failure:(1) failed SBT; (2) reintubation and /or resumption of support following successful extubation; or (3) die 48h following extubation.
3066377|NCT01065428||Weaning successful|Weaning successful:extubation and the absence of ventilatory support 48 h following the extubation
3066382|NCT01065480|Active Comparator|Live Teleconference Supervision|Clinicians from participating substance abuse treatment programs receive live supervision by MI trainer via teleconference while in session with client.
3066383|NCT01065480|Active Comparator|Taped Review Supervision|Clinicians from participating substance treatment programs audio record session with client and receive supervision after the session by MI trainer.
3066384|NCT01065506|Active Comparator|Standard Care plus Wellness Program|
3066385|NCT01065506|Active Comparator|Standard Care plus Exercise Program|
3066386|NCT01065558|Experimental|Ecopipam 12.5 - 200 mg/day|Patients were administered ecopipam on an escalated dosing schedule over 11 days starting at 12.5 mg/day and increasing to the maximal tolerated dose or to 200 mg/day.
3066387|NCT01065571|Experimental|carrageenan-free diet with placebo|This is the experimental arm in which subjects will be on a no-carrageenan diet and receive placebo capsules. This will test whether the no carrageenan diet leads to longer relapse-free interval for patients with ulcerative colitis.
3066388|NCT01065571|Active Comparator|carrageenan-free diet w/ carrageenan|The carrageenan-free diet with carrageenan supplement will mimic the carrageenan normally consumed in the diet. The study will permit blinded comparison of carrageenan-free vs. carrageenan consumption.
3066389|NCT01065597|Experimental|Nonconvulsive electrotherapy|Open label single arm study of nonconvulsive electrotherapy
3066390|NCT01065714|Experimental|Hydrogel vehicle|Parallel designed study. Split body treatment
3066391|NCT01065714|Active Comparator|Eucerin Lotion|Parallel study design. Split body study.
3066392|NCT01065766||All participants|Korean participants with type 2 diabetes mellitus treated with sitagliptin/metformin
3066393|NCT01065779||FOSAMAX PLUS or FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg/2800 IU) or FOSAMAX PLUS D (70 mg/5600 IU).
3066394|NCT01065844|Experimental|Nelfinavir|1250 mg Nelfinavir twice daily Monday-Sunday
3066395|NCT01066000|Experimental|Mircera|
3066396|NCT01066026|Experimental|Metallic cannula|Nasolabial Fold with metallic cannula and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle. Hyaluronic acid injected with the new tool
3066397|NCT01066026|Active Comparator|Standard needle|Nasolabial Fold with standard needle and hyaluronic acid injected. hyaluronic acid with metallic cannula or standard needle.
3066398|NCT01066039|Experimental|Bisoprolol|
3066399|NCT01066052|Experimental|r-hGH|Participants (girls) will receive r-hGH as a subcutaneous injection administered by a parent in the evening. During Years 1-2, the dose of r-hGH received will depend on participants' baseline height standard deviation score (SDS) relative to the general population standard: participants with a height SDS of -2 standard deviation (SD) or lower will receive 0.05 milligrams per kilogram (mg/kg) per day r-hGH and those with a height SDS between -1 and -2 SD will receive 0.035 mg/kg per day r-hGH. After 2 years of treatment, all participants will receive a fixed dose of 0.05 mg/kg per day for a further 2 years.
3066400|NCT01066052|No Intervention|Historical Control|This arm will include matching (age and height) historical control participants (girls) with turner syndrome, who were born between 1961 and 1990 and were untreated.
3066401|NCT01066104|Placebo Comparator|Xolair placebo|Xolair placebo 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg) ). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
3066402|NCT01066104|Active Comparator|Xolair (omalizumab)|Xolair (omalizumab) 150-375 mg is administered subcutaneously (SC) every 2 or 4 weeks depending on the patient's baseline serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Doses of more than 150 mg are divided among more than one injection site to limit injections to not more than 150 mg per site.
3066403|NCT01066143|Experimental|Seroquel XR|
3066404|NCT01066156|Experimental|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
3066405|NCT01066364|Placebo Comparator|Placebo (sugar) pill|Six tablets per day (identical to colesevelam)
3066406|NCT01066364|Experimental|Colesevelam arm|3.75 grams per day
3066407|NCT01066520|Experimental|Traumeel S ointment|Traumeel S ointment 2 g, 3 times daily topical during 14 days
3066408|NCT01066520|Experimental|Traumeel S gel|Traumeel S gel 2 g, 3 times daily topical during 14 days
3066409|NCT01066520|Active Comparator|Diclofenac gel|Diclofenac gel 2 g, 3 times daily topical during 14 days
3066410|NCT01066546|Experimental|Dimebon|
3066411|NCT01066585|Experimental|0.5% Ivermectin Cream|
3066412|NCT01066585|Placebo Comparator|Vehicle control|
3066413|NCT01066624|Active Comparator|0.9% Sodium Chloride irrigation solution|Standard of care for prevention and management of oral mucositis (0.9% Sodium Chloride irrigation solution): Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study.
3066414|NCT01066624|Active Comparator|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion. After patients are done with the cryotherapy they will follow the standard of care for prevention and management of oral mucositis until the end of the study.
3066415|NCT01066624|Active Comparator|Calcium phosphate (Caphosol) mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
3066416|NCT01066780|Experimental|Group A: ClearVoice Medium|Chronic use of ClearVoice MEDIUM for two weeks followed by chronic use of ClearVoice HIGH for two weeks.
3066417|NCT01066780|Experimental|Group B: ClearVoice High|Chronic use of ClearVoice HIGH for two weeks followed by chronic use of ClearVoice MEDIUM for two weeks.
3066418|NCT01066793||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6
3066419|NCT01066819||Cohort|Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
3066420|NCT01066871|Experimental|Sprifermin (AS902330) 10 mcg|
3066421|NCT01066871|Experimental|Sprifermin (AS902330) 30 mcg|
3066422|NCT01066871|Experimental|Sprifermin (AS902330) 100 mcg|
3066423|NCT01066871|Placebo Comparator|Placebo|
3132373|NCT03421730|Experimental|BA - VR647 10 breaths, then VR647 5 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3066424|NCT01066897|Experimental|Pramipexole|Patients will receive 0.125 mg of pramipexole three times a day for the first week, 0.25 mg three times a day for the second week, and 0.5 mg three times a day for the third week. The dose will then be adjusted as needed by the treating physician (Dr. DeBattista), with a target range of 1.0 mg to 1.5 mg per day. Dose escalations will continue until 1) achievement of the primary endpoint (> 50% reduction from baseline on the HDRS scores; 2) intolerable side effects; or 3) completion of the 8-week study. Participants will be seen weekly the first four weeks and biweekly thereafter. Side effects, depression, and anhedonia will assessed at each visit.
3066425|NCT01066897|No Intervention|Healthy Controls|Non depressed, non-intervention comparison group
3066426|NCT01066923|Experimental|Daily ASA, Active cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, aspirin immediately post exercise
3066427|NCT01066923|Experimental|Daily ASA, Active cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, active cooling following exercise, placebo immediately post exercise
3066428|NCT01066923|Experimental|Daily ASA, Passive cool, Acute ASA|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, aspirin immediately post exercise
3066429|NCT01066923|Experimental|Daily ASA, Passive cool, Acute placebo|Two weeks of daily aspirin therapy prior to exercise, passive cooling following exercise, placebo immediately post exercise
3066430|NCT01066923|Experimental|Daily placebo, active cool, Acute ASA|Two weeks of daily placebo prior to exercise, active cooling following exercise, aspirin immediately post exercise
3066431|NCT01066923|Experimental|Daily placebo, active cool, Acute placebo|Two weeks of daily placebo prior to exercise, active cooling following exercise, placebo immediately post exercise
3066432|NCT01066923|Experimental|Daily placebo, Passive cool, Acute ASA|Two weeks of daily placebo prior to exercise, passive cooling following exercise, aspirin immediately post exercise
3066433|NCT01066923|Placebo Comparator|Daily placebo, Passive cool, Acute placebo|Two weeks of daily placebo prior to exercise, passive cooling following exercise, placebo immediately post exercise
3066434|NCT01067105|Experimental|ciclesonide|ciclesonide HFA 160 μg once daily
3066435|NCT01067144|Placebo Comparator|Control|Active placebo given pre-operatively, followed by inactive placebo for 10 doses post-operatively
3066436|NCT01067144|Experimental|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
3066437|NCT01067326|Active Comparator|Aliskiren|150 mg Aliskiren once daily for a period of 4 months.
3066438|NCT01067326|Placebo Comparator|Placebo|1 pill per day by mouth for 4 months.
3066439|NCT01067339|Experimental|Darapladib|Subjects randomized to this arm will receive a darapladib tablet, 160 mg, by mouth, once per day for 6 months.
3066440|NCT01067339|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a placebo tablet matching the study drug, once per day for 6 months.
3066441|NCT01067352|Experimental|Group A (A1)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive Saizen at the daily dose of 0.035 milligram (mg)/kilogram (kg) (Group A1) or no treatment (Group A2) for two years.
3066442|NCT01067352|No Intervention|Group A (A2)|Participants were allocated to Group A if were still third percentile for height (according to the Tanner reference table) at the age of 4-6 years. Group A would be then randomized to receive no treatment (Group A2) for two years.
3066443|NCT01067352|No Intervention|Group B|Participants were allocated to Group B being third percentile (thus showing a spontaneous catch-up growth).
3066444|NCT01067456|No Intervention|Dedicated CT arm|Subjects in this arm will continue to receive standard of care - that is the dedicated CT protocol to rule out either aortic dissection or acute coronary syndrome or pulmonary embolism.
3066445|NCT01067456|Experimental|Comprehensive Cardiothoracic CT arm|The intervention consisted in a change of the routine CT protocol (as in dedicated CT protocol) to a comprehensive cardiothoracic CT protocol which includes changes in contrast injection and coverage to enable evaluation of the presence of acute coronary syndrome/aortic dissection/pulmonary embolism in a single scan.
3066446|NCT01067469|Experimental|Standard Dose Bevacizumab|Bevacizumab 10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
3066447|NCT01067469|Experimental|Low Dose Bevacizumab + Lomustine|Bevacizumab 5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle. Lomustine starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
3066448|NCT01067508|Experimental|Fiji Water|Participants are asked to consume one liter of this silicon-rich water daily for three months.
3066449|NCT01067508|No Intervention|Aquafina Water|Participants are asked to drink one liter of this deionized water daily for three months.
3066452|NCT01067716|Experimental|Refractive Error|
3066453|NCT01067768|Experimental|Daily review|In the intervention group a nurse reviewed daily, by using a checklist designed for this study, the indications and pertinence of the catheter. If it was not indicated she asked the doctor to order the removal of the catheter, but the doctor would make the final decision.
3066454|NCT01067768|No Intervention|Routine care|In the control group, the attending team would remove the catheter as routine, without any suggestion by the research protocol.
3066455|NCT01067781|Experimental|1|Two vaccination regimen with an LT patch (no swabbing)
3066456|NCT01067781|Experimental|2|Two vaccination regimen with an LT patch (with swabbing)
3066457|NCT01067781|Placebo Comparator|3|Two vaccination regimen with a placebo patch (no swabbing)
3066458|NCT01067781|Placebo Comparator|4|Two vaccination regimen with a placebo patch (with swabbing)
3066459|NCT01067846|Experimental|DCS and Cognitive Behavioral Therapy|Subjects will receive 250 mg of Seromycin or D-cycloserine (DCS) prior to computerized cognitive behavioral therapy.
3066460|NCT01067846|Placebo Comparator|Placebo and Cognitive Behavioral Therapy|Subjects will receive a 250 mg identical looking placebo pill prior to computerized cognitive behavioral therapy.
3066461|NCT01067976|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced MRM, followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg bw [0.1 ml/kg bw] as an intravenous injection (i.v.) injection at a rate of 2 ml/sec. UMRM and CMRM image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective XRM was added and evaluated together with the UMRM images.
3066462|NCT01068158|Experimental|0.5% Ivermectin Cream|Up to 4 ounces of topical Ivermectin Cream applied to hair and scalp on day 1
3066463|NCT01068158|Placebo Comparator|Vehicle control|Up to 4 ounces of topical control applied to hair and scalp on day 1.
3066464|NCT01068262|Experimental|Panel A - Odanacatib|Panel A - Healthy male subjects receiving Odanacatib
3066465|NCT01068262|Placebo Comparator|Panel A - Placebo|Panel A - Healthy male subjects receiving placebo
3066466|NCT01068262|Experimental|Panel B - Odanacatib|Panel B - Healthy female subjects receiving Odanacatib
3066467|NCT01068262|Placebo Comparator|Panel B - Placebo|Panel B - Healthy female subjects receiving placebo
3066468|NCT01068418|Experimental|Vitamin D3|15000IU of vitamin D3 daily: open-label, single-arm
3066469|NCT01068509|Experimental|Non-randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs. The 6-8 injections contained ~ 60 × 10^6 dendritic cells. Following evaluation after the first dose, participants received additional injections as described for the randomized Cvac group below.
3066470|NCT01068509|Experimental|Randomized Cvac|Participants received 6-8 intradermal injections of Cvac at 4 sites along both upper arms and both thighs every 4 weeks for 24 weeks (7 doses at Weeks 8, 12, 16, 20, 24, 28, and 32), and then every 8 weeks for 24 weeks (3 doses at Weeks 40, 48, and 56). The 6-8 injections contained ~ 60 × 10^6 dendritic cells.
3066471|NCT01068509|No Intervention|Observational standard of care|Participants in this group did not receive any treatment during the study.
3066472|NCT01068548|No Intervention|Arm 1|pre-implementation of computer based intervention
3066473|NCT01068548|Experimental|Arm 2|post-implementation of computer based length of stay clinical reminder
3066474|NCT01068600|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg inhaled once daily in the morning via Concept1, a single dose dry powder inhaler (SDDPI), for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066475|NCT01068600|Placebo Comparator|Placebo|"Placebo to indacaterol inhaled once daily in the morning via Concept1, a SDDPI, for 12 weeks.~Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066476|NCT01068626|Active Comparator|Rosuvastatin|
3066477|NCT01068626|Placebo Comparator|Placebo for Rosuvastatin|
3066478|NCT01068652|Active Comparator|Detemir + Met|Individually adjusted insulin detemir (Detemir) was given subcutaneoulsy (s.c.) at bedtime in the thigh at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, individually adjusted insulin aspart was added to the insulin detemir treatment (up to three doses daily for maximum 36 weeks, injected s.c. [under the skin]) if treatment target of HbA1c below 7.0% was not reached.
3066479|NCT01068652|Active Comparator|BIAsp 30 + Met|Individually adjusted biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously (s.c.) in the abdomen at dinner at an initial dose of 0.1 U/kg once daily for 50 weeks in combination with 1000-2000 mg/day metformin (Met). Pending evaluation of HbA1c every 3 months, the dose was intensified up to 3 doses daily, injected s.c. (under the skin) if treatment target of HbA1c below 7.0% was not reached.
3066480|NCT01068665|Experimental|IDeg 200 U/mL OD|
3066481|NCT01068665|Active Comparator|IGlar OD|
3066482|NCT01068678|Experimental|IDeg 3 times weekly (3TW)|
3066483|NCT01068678|Active Comparator|IGlar OD|
3066484|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fasted state
3066485|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fasted state)|Single oral dose of a 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC) tablet administered in the fasted state
3066486|NCT01068717|Other|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Single oral doses of saxagliptin, 2.5 mg, and metformin, 500 mg, administered together as tablets in the fed state
3066487|NCT01068717|Other|Saxagliptin, 2.5 mg/Metformin, 500 mg FDC (fed state)|Single oral dose of saxagliptin, 2.5 mg/metformin, 500 mg, FDC tablet administered in the fed state
3066488|NCT01068730|Other|Treatment A|500 mg metformin (Diabex): Single oral dose of 500 mg metformin (Diabex) tablet administered in the fed condition
3066489|NCT01068730|Other|Treatment B|500 mg metformin (Glucophage™): Single oral dose of 500 mg metformin (Glucophage™) tablet administered in the fed condition
3066490|NCT01068730|Other|Treatment C|1000 mg metformin (Diabex): Single oral dose of 1000 mg metformin (Diabex) tablet administered in the fed condition
3066491|NCT01068730|Other|Treatment D|1000 mg metformin (Glucophage™): A Single oral dose of 1000 mg metformin (Glucophage™) tablet administered in the fed condition
3066492|NCT01068743|Other|Arm A (saxagliptin 2.5 mg + metformin 850 mg; Fasting)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fasted condition.
3066493|NCT01068743|Other|Arm B (saxagliptin 2.5 mg + metformin 850 mg FDC; Fasting)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin fixed dose combination (FDC) administered in the fasted condition.
3066494|NCT01068743|Other|Arm C (saxagliptin 2.5 mg + metformin 850 mg; Fed)|A single oral dose of 2.5-mg Onglyza tablet and 850-mg Glucophage (marketed by Merck Serono) tablet administered together in the fed condition.
3066495|NCT01068743|Other|Arm D (saxagliptin 2.5 mg + metformin 850 mg FDC; Fed)|A single oral dose of 2.5-mg saxagliptin/850-mg metformin FDC administered in the fed condition.
3066496|NCT01068769|Experimental|Regorafenib|Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle
3066497|NCT01068821|Active Comparator|Egg crate foam mattress|Patients will be placed on egg-crate foam mattress instead of a gel pad by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
3066498|NCT01068821|Active Comparator|Gel pad|Patients will be placed on gel pad instead of egg-crate foam mattress by randomization. All other positioning and measurements, including outcomes measures will be the same as for the the primary experimental intervention (gel pad).
3066499|NCT01068860|Experimental|Canakinumab 150 mg + Metformin|Eligible participants received a single subcutaneous injection Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
3066500|NCT01068860|Placebo Comparator|Placebo + Metformin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) monotherapy treatment at least 1000 mg/day for 3 months prior to screening
3066501|NCT01068860|Experimental|Canakinumab 150 mg + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3066502|NCT01068860|Placebo Comparator|Placebo + Metforimin + Sulfonylurea|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3066503|NCT01068860|Experimental|Canakinumab 150 mg + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg.Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3066504|NCT01068860|Placebo Comparator|Placebo + Met + Sulfonyl + Thiazolidinedione|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus and be on a stable dose of Metformin (Met) at least 1000 mg/day , and a Sulfonylurea (Sulfonyl), at least 1/2 the maximally labeled dose, and a Thiazolidinedione (Thiaz)at least 1/2 the maximally labeled dose combination therapy, for 3 months prior to screening.
3066505|NCT01068860|Experimental|Canakinumab 150 mg + Insulin|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
3066506|NCT01068860|Placebo Comparator|Placebo + Insulin|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had documented diagnosis of Type 2 Diabetes Mellitus for 3 months prior to screening and be on a stable dose of Insulin, 2 insulin injections per day for a total daily dose of less than 100 U with or without Metformin (Met)for 3 months prior to screening
3066507|NCT01068860|Experimental|Canakinumab 150 mg in patients with IGT|Eligible participants received a single subcutaneous injection of Canakinumab 150 mg. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
3066508|NCT01068860|Placebo Comparator|Placebo in patients with IGT|Eligible participants received a single subcutaneous injection of Placebo to Canakinumab. Patients must have had Impaired Glucose Tolerance (IGT) as defined by the World Health Organization (WHO) criteria confirmed at screening visit.
3066509|NCT01068873|Experimental|open label single arm|Drug: lopinavir/ritonavir plus maraviroc
3066510|NCT01068912|Experimental|1: Experimental|Low-dose favipiravir regimen: 1000 mg favipiravir twice a day (BID) x 1 day, and 400 mg favipiravir BID x 4 days
3066511|NCT01068912|Experimental|2: Experimental|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
3066512|NCT01068912|Placebo Comparator|Placebo|Placebo
3066513|NCT01068964|Experimental|0.03% Bimatoprost/0.5% Timolol in Same Bottle|Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
3066514|NCT01068964|Active Comparator|0.03% Bimatoprost and 0.5% Timolol in Separate Bottles|Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
3066515|NCT01069003|Placebo Comparator|Placebo Arm|Subjects are randomized to receive 18 months of placebo thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
3066516|NCT01069003|Active Comparator|Thienopyridine Therapy|Subjects are randomized to receive 18 months of active thienopyridine and aspirin (ASA). Eligible subjects are without death, myocardial ischemia, stroke, repeat coronary revascularization, major bleeding or stent thrombosis in the first 12 months prior to randomization.
3066517|NCT01069003|Other|Surveillance Arm|Non randomized subjects followed through 24 months
3066518|NCT01069172|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery group (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device. If necessary, ultrasound (U/S) phacoemulsification will also be applied to facilitate removal of the crystalline lens during cataract surgery.
3066519|NCT01069172|Active Comparator|CCC Surgery|For the continuous curvilinear capsulorhexis (CCC) group (CCC Surgery), subjects will receive the standard of care for CCC and U/S phacoemulsification surgery to facilitate removal of the crystalline lens during cataract surgery.
3066520|NCT01069185|Experimental|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
3066521|NCT01069185|Other|Routine endotracheal suctioning|Endotracheal suctioning every two hours
3066522|NCT01069289|Experimental|1|Symbicort Turbuhaler 160/4.5 microgram, 2 inhalations twice daily
3066523|NCT01069289|Active Comparator|2|Oxis Turbuhaler 4.5 microgram, 2 inhalations twice daily
3066524|NCT01069315|Experimental|Normal saline and High pressure|Irrigation with normal saline delivered at high pressure
3066525|NCT01069315|Experimental|Soap solution and High pressure|Irrigation with soap solution delivered at high pressure
3066526|NCT01069315|Experimental|Normal saline and Low pressure|Irrigation with saline solution delivered at low pressure
3066527|NCT01069315|Experimental|Soap solution and Low pressure|Irrigation with soap solution delivered at low pressure
3066528|NCT01069341|Other|Treatment|All subjects enrolled received treatment with identical dosage of Ranibizumab
3066529|NCT01069354|Experimental|Radiesse® Mixed with Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
3066530|NCT01069354|Active Comparator|Radiesse® without Lidocaine|Injectable Dermal Filler. The same participants received the experimental device and the active comparator device at the same time (left and right sides of face).
3066531|NCT01069419||Cimzia|All patients will be treated with Cimzia according to normal clinical practice for the prescribing physician and as defined by the SmPC
3066532|NCT01069484|Experimental|Postpartum pelvic floor muscle training|Beyond a customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the participants are given supervised pelvic floor muscle group training led by physiotherapists once a week. In addition, the participants train every day at home, with at least 3 sets of 8-12 contractions. Training period is 4 months.
3066533|NCT01069484|No Intervention|Control|Beyond the customary leaflet (received from the postnatal ward) and the thorough initial instruction on how to contract the PFM correctly, the control group participants received no further intervention. They were not discouraged from doing PFMT on their own.
3066534|NCT01069510|Placebo Comparator|Placebo|Patients will receive placebo
3066535|NCT01069510|Experimental|Spironolactone|Spironolactone 25 mg daily
3066536|NCT01069523|Placebo Comparator|Placebo|Patients will be started on 1 mg of guanfacine extended release matching placebo tablets at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
3066537|NCT01069523|Experimental|Guanfacine Extended Release|Patients will be started on 1 mg of guanfacine extended release at week 1. A physician blind to drug status will titrate the study medication in week 2-3 to a maximum of 4 mg (4 tablets).
3066538|NCT01069562|Active Comparator|MANUAL|In the manual group isoflurane was administered using Tech 7 vapouriser. The dial setting was controlled by the anesthesiologist to achieve and maintain a BIS of 50 during anesthesia.
3066539|NCT01069562|Experimental|IAADS group|In this group, liquid isoflurane was injected into the circuit using a syringe pump controlled by the IAADS system.The IAADS system has the algorithm to regulate the rate of infusion of isoflurane such that BIS is achieved and maintained at 50 during anesthesia.
3066540|NCT01069627|Experimental|1|
3066541|NCT01069705|Experimental|Tobramycin Inhalation Powder (TIPnew)|Participants received four capsules of 28 mg TIPnew (112 mg), inhaled twice a day (b.i.d.) in the morning and the evening given in a cycle of 28 days on treatment followed by 28 days off treatment for three consecutive cycles.
3066542|NCT01069900|Experimental|Moxifloxacin (Avelox, BAY12-8039)|Subjects randomized to the moxifloxacin arm of this study received intravenous moxifloxacin plus ertapenem placebo (0.9 % sodium chloride [NaCl solution]) for a minimum of 3 days and, if switched to oral treatment, PO moxifloxacin plus PO amoxicillin/clavulanate placebo. Total treatment duration is 5-14 days.
3066543|NCT01069900|Active Comparator|Comparator Ertapenem|Subjects randomized to the comparator arm of this study received intravenous ertapenem plus moxifloxacin placebo (0.9 % NaCl solution) for a minimum of 3 days and, if switched to oral treatment, amoxicillin/clavulanate as an oral suspension plus PO moxifloxacin placebo. Total treatment duration is 5-14 days.
3066544|NCT01069939|Experimental|Esomeprazole 20mg|Esomeprazole 20mg once daily oral
3066545|NCT01069939|Placebo Comparator|Placebo|Placebo once daily oral
3066546|NCT01070043|Experimental|Amlodipine 5mg/Valsartan 80 mg|During double-blind treatment period, patients randomized to combination therapy received daily one dosage (Amlodipine/Valsartan 5mg/80mg) with one single tablet size for 8 weeks.
3066547|NCT01070043|Active Comparator|Valsartan 160 mg|In double blinded treatment period, patients randomized to this arm received 160 mg Valsartan once daily for 8 weeks.
3066548|NCT01070043|Other|Run-In Valsartan 80 mg|During run-in period, oral valsartan 80 mg once daily for 4 weeks.
3066549|NCT01070095|Experimental|Electronic Asthma Action Plan System|Electronic Asthma Action Plan System (eAAPS)
3066550|NCT01070173||Short Stature|Poor linear growth
3066551|NCT01070173||Poor Weight Gain (Failure-To-Thrive)|Poor Weight Gain
3066552|NCT01070173||Isolated Gastrointestinal Symptoms|No growth symptoms
3066553|NCT01070303|Experimental|Adalimumab 40 mg every other week or every week|
3066554|NCT01070316|Experimental|Everolimus|Subjects will be administered study drug if they meet study criteria after 4 weeks of baseline phase. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily.
3066555|NCT01070329|Experimental|Duloxetine|
3066556|NCT01070329|Placebo Comparator|Placebo|
3066557|NCT01070381|Other|nelfilcon A / ocufilcon D|Nelfilcon A contact lenses worn first, with ocufilcon D contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3066558|NCT01070381|Other|ocufilcon D / nelfilcon A|Ocufilcon D contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3066559|NCT01070394|Experimental|LDX Treatment|Eligible participants received 12 weeks of open-label treatment. Those on treatment prior to baseline underwent a 7-day (for amphetamine or methylphenidate) or 28-day (for atomoxetine or other medications) washout period prior to initiating LDX treatment. The starting dose was 30mg/day, which could be titrated up by 20mg/day during visits 2-6 (for a maximum dose of 70mg/day). At discretion of investigator, the dose could be down-titrated by 20mg/day during visits 4-6. Once the dose was optimized (after visit 6), the dose was maintained for 8 weeks.
3066560|NCT01070550||Cohort|Participants chronically infected with the hepatitis C virus including Genotypes 1 to 6.
3066561|NCT01070693|Experimental|Prolene Hernia System device|Inguinal hernia repair either with a bilayer mesh (PHS)
3066562|NCT01070693|Experimental|Lichtenstein|Inguinal hernia repair with the Lichtenstein technique
3066563|NCT01070784|Experimental|1|
3066564|NCT01070784|Active Comparator|2|
3066565|NCT01070810|Placebo Comparator|1|50 ml D5W
3066566|NCT01070810|Experimental|2|200mg Thiamine in 50ml D5W
3066567|NCT01070888|Experimental|Budesonide/Formoterol first|This arm will receive blinded budesonide/formoterol and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide and dummy inhaler.
3066568|NCT01070888|Active Comparator|Budesonide first|This arm will receive blinded budesonide and dummy inhaler and will be asked to take 2 inhalations of each inhaler, twice daily. The second study period will be budesonide/formoterol and dummy inhaler.
3066569|NCT01070953||EZETROL® 10 mg|Participants with Hypercholesterolemia treated with EZETROL®
3066570|NCT01070966||VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/10 (ezetimibe 10 mg/simvastatin 10 mg tablets)
3066571|NCT01070966||VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/20 (ezetimibe 10 mg/simvastatin 20 mg tablets)
3066572|NCT01070966||VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/40 (ezetimibe 10 mg/simvastatin 40 mg tablets)
3066573|NCT01070966||VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)|Participants with Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH) treated with VYTORIN® 10/80 (ezetimibe 10 mg/simvastatin 80 mg tablets)
3066574|NCT01070979|Experimental|Estradiol acetate (E3A)|
3066575|NCT01070979|Active Comparator|Estradiol|
3066576|NCT01070979|Active Comparator|Conjugated equine estrogens (CEE):|
3066577|NCT01071044|Active Comparator|Lisdexamfetamine Dimesylate|Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
3066578|NCT01071044|Placebo Comparator|Sugar pill|"Matching Placebo 30, 50 or 70 mg"
3066579|NCT01071070|Active Comparator|Group 1|Initial dosing based on a formula of intact parathyroid hormone value/80 (where intact parathyroid hormone value is the baseline value in pg/mL).
3066580|NCT01071070|Active Comparator|Group 2|Dose determined by US paricalcitol injection package insert dosing instructions (starting dose at 0.04 microgram/kg)
3066581|NCT01071083|Active Comparator|natalizumab|
3066582|NCT01071083|Placebo Comparator|IV placebo|
3066583|NCT01071083|Active Comparator|interferon β-1a, glatiramer acetate, or methylprednisolone|
3066584|NCT01071096|Active Comparator|OnabotulinumtoxinA|Minimum dose of 155 international units (U) OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
3066585|NCT01071096|Placebo Comparator|Saline|155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas.
3066586|NCT01071200|Experimental|A|Subjects treated with r-hFSH and r-hLH (2:1 ratio of r-hFSH:r-hLH)
3066587|NCT01071200|Active Comparator|B|Subjects treated with r-hFSH alone
3066588|NCT01071252|Experimental|AIN457 1x25mg|
3066589|NCT01071252|Experimental|AIN457 3x25mg|
3066590|NCT01071252|Experimental|AIN457 3x75mg|
3066591|NCT01071252|Experimental|AIN457 3x150mg|
3066592|NCT01071252|Placebo Comparator|Placebo|
3066593|NCT01071278||Patients treated within a disease management program|Participant prescribed Tredaptive® for dyslipidemia and also participated in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
3066594|NCT01071278||Patients treated outside a disease management program|Participant prescribed Tredaptive® for dyslipidemia and did not participate in a disease management program for treatment of diabetes mellitus, coronary heart disease or both.
3066595|NCT01071317|Experimental|Comprehensive care|Reinforcement of diagnosis, education, medications, and referral
3066596|NCT01071317|Active Comparator|Typical care|Usual care
3066597|NCT01071356|Experimental|Intensive MI|9 hours of Motivational Interviewing + outpatient substance abuse treatment
3066598|NCT01071356|Active Comparator|Single session MI|1.5 hours of Motivational Interviewing + 8 hours of time equivalent nutrition classes +outpatient substance abuse treatment
3066599|NCT01071395|Experimental|Amantadine|Amantadine 100mg tab BID or TID for duration of study
3066600|NCT01071395|Placebo Comparator|Placebo|Placebo one tab BID or TID for duration of study
3066601|NCT01071512|Experimental|Tysabri|Natalizumab 300 mg IV every 4 weeks
3066602|NCT01071538|Experimental|Buprenorphine|Older adults with treatment resistant depression will receive buprenorphine up to 1.6 mg/day for 8 weeks. Discontinuation of the buprenorphine will occur during weeks 9-12.
3066603|NCT01071798||Main Analysis Set|Participants who received at least one cycle of rituximab
3066604|NCT01071915|Experimental|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenace of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
3066605|NCT01071954|Experimental|Romiplostim|Participants received romiplostim administered by subcutaneous injection once a week. The starting dose of romiplostim was 1 μg/kg; weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of between 50 x 10^9/L and 200 x 10^9/L.
3066606|NCT01072006||Control Group|Control group without traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD)
3066607|NCT01072006||PTSD Group|PTSD (not TBI)
3066608|NCT01072006||TBI Group|TBI (no PTSD)
3066609|NCT01072006||TBI+PTSD Group|Combined TBI history and PTSD
3066610|NCT01072032|Experimental|Low-Reward|Low-Reward Anklebot training Group: The low reward-feedback group receives the Anklebot training with only immediate feedback on target successes, without cumulative scores and with minimal social interaction with the research team.
3066611|NCT01072032|Active Comparator|High-Reward|High-Reward Anklebot training Group: The high-reward group receives cumulative scores and abundant social interaction and are eligible for prizes during each training session and at completion of the study
3066612|NCT01072136|Placebo Comparator|Placebo|Placebo.
3066613|NCT01072136|Experimental|Azithromycin/Cefixime|A single dose of cefixime 400 mg (1 tablet oral at 400 mg) and azithromycin 1 gram (2 tablets oral at 500 mg each).
3066614|NCT01072149|Experimental|50mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3066615|NCT01072149|Experimental|100mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3066616|NCT01072149|Experimental|200mcg Fluticasone Furoate (FF)/25mcg GW642444|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA)
3066617|NCT01072149|Placebo Comparator|placebo|placebo
3320922|NCT02014766|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
3066621|NCT01072188|Active Comparator|ProClude Prophylaxis paste-A|Arginine Bicarbonate prophylaxis paste
3066622|NCT01072188|Placebo Comparator|Nupro-M Prophylaxis paste -B|Control prophylaxis paste (Fluoride free - placebo)
3066623|NCT01072201|Experimental|Total toothpaste|Triclosan/copolymer/fluoride toothpaste
3066624|NCT01072201|Placebo Comparator|Ultrabrite toothpaste|Fluoride Toothpaste
3066625|NCT01072331|Experimental|MP-513 10 mg, once a day, for 4 weeks|
3066626|NCT01072331|Experimental|MP-513 20 mg, once a day, for 4 weeks|
3066627|NCT01072331|Placebo Comparator|Placebo of MP-513|
3066628|NCT01072344|Experimental|Chamomile Extract|Pharmaceutical grade oral chamomile extract.
3066629|NCT01072344|Placebo Comparator|Placebo|Pharmaceutical grade lactose monohydrate.
3066630|NCT01072357|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 milliliter (mL) (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3066631|NCT01072357|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% sodium chloride (NaCl). Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3066632|NCT01072396|Active Comparator|18 mcg tiotropium|Patient to receive 1 tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3066633|NCT01072396|Placebo Comparator|Placebo|Patient to receive 1 placebo inhalation powder capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
3066634|NCT01072396|No Intervention|Control|Age and gender matched control subjects to conduct incremental and constant work rate exercise tests for comparison to subjects with early stage COPD
3066635|NCT01072409|Other|Single Arm|Single arm design
3066636|NCT01072448|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3066637|NCT01072448|Placebo Comparator|Placebo to indacaterol|Patients inhaled placebo to indacaterol once daily in the morning between 8:00 AM and 11:00 AM via a single-dose dry-powder inhaler (SDDPI) for 12 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short-acting β2-agonist salbutamol/albuterol was available for rescue use throughout the study.
3066638|NCT01072500|Active Comparator|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
3066639|NCT01072500|Active Comparator|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
3066640|NCT01072539||Patients who have approved indications of Tygacil|"Approved indications of Tygacil~-complicated intraabdominal infection, complicated skin and skin structure infection, community-acquired bacterial pneumonia"
3066641|NCT01072617|Experimental|Safety of rTMS in schizophrenia patients|Participants will receive repetitive transcranial magnetic stimulation via MagPro x100 device to the vermis of cerebellum twice a day over 5 days
3066642|NCT01072630|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
3066643|NCT01072630|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
3066644|NCT01072630|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
3132374|NCT03421730|Experimental|BC - VR647 10 breaths, then VR647 20 breaths|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3066645|NCT01072643|Experimental|Dexmedetomidine|To study safety of DEX with regard to effect on PVR; There will be 3 study groups (n=8 per group). The groups will be based on DEX doses as follows- Group 1 - Bolus 1 mcg/kg followed by infusion 0.7 mcg/kg/hr Group 2 - Bolus 1.5 mcg/kg followed by infusion 1.05 mcg/kg/hr Group 3 - Bolus 2 mcg/kg followed by infusion 1.4 mcg/kg/hr
3066646|NCT01072656|Active Comparator|Treatment group|Active stimulation and programmed to the settings found to be optimal during the titration process.
3066647|NCT01072656|Sham Comparator|Control group|IPG is set to ON but the voltage is set to 0V.
3066648|NCT01072669|Active Comparator|ambrisentan|"drug arm~use of ambrisentan in limited scleroderma patients with raynaud's to evaluate digital microvascular flow"
3066649|NCT01072669|Placebo Comparator|sugar pill|those getting sugar pill to evaluate if the active drug improves digital microvascular flow in limited scleroderma patients
3066650|NCT01072773|Experimental|Bortez/Cyc/Dex|Bortezomib IV on days 1, 8, and 15, oral cyclophosphamide and oral dexamethasone once daily on days 1, 8, 15, and 22.
3066651|NCT01072877|Experimental|Polidocanol injectable foam 0.125%|Polidocanol injectable foam 0.125%
3066652|NCT01072877|Experimental|Polidocanol injectable foam 0.5%|Polidocanol injectable foam 0.5%
3066653|NCT01072877|Experimental|Polidocanol injectable foam 1.0%|Polidocanol injectable foam 1.0%
3066654|NCT01072877|Experimental|Polidocanol injectable foam 2.0%|Polidocanol injectable foam 2.0%
3066655|NCT01072877|Placebo Comparator|Vehicle|Injection of vehicle comparator
3066656|NCT01072929|Experimental|Armodafinil 150 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 150 mg/day. The 150 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment.
3066657|NCT01072929|Experimental|Armodafinil 200 mg/day|Participants started the study at a dose of 50mg/day of armodafinil and titrated up in the first week to 200 mg/day. The 200 mg/day dosage was continued for 7 more weeks for a total of 8 weeks of treatment. This treatment arm was discontinued via a protocol amendment.
3066658|NCT01072929|Placebo Comparator|Placebo|Participants were administered placebo and titrated to match the armodafinil treatment arms. Total treatment was 8 weeks.
3066659|NCT01073020|Active Comparator|Gastric Band vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) laparoscopic placement of an adjustable gastric band (LAGB) or 2) treatment with an intensive medical and weight management (IMWM) program.~LAGB will be placed using the pars flaccida technique. The Allergan laparoscopic band LAP BAND system will be utilized. LAGB ports will be placed in subcutaneous pockets in the right upper abdomen.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
3066660|NCT01073020|Active Comparator|RYGB vs Intensive Diabetes & Weight Management|"Patients will be randomized to receive either 1) Roux-en-Y gastric bypass (RYGB) surgery or 2) treatment with an intensive medical and weight management (IMWM) program.~RYGB will be performed using a 75 cm antecolic, ante-gastric Roux limb created with a 50 cm pancreaticobiliary limb. A 15-20 cc gastric pouch will be created lying along the lesser curve of the stomach, with division of the vagal trunks at the lower border of the pouch.~The IMWM group will participate in the Weight Achievement and Intensive Treatment (Why WAIT) program, which is a multidisciplinary program for weight control and intensive diabetes management designed by Joslin Diabetes Center. Key aspects include: 1) Intensive and interactive medication adjustments, 2) Structured modified dietary intervention, 3) Graded, balanced, and individualized exercise intervention, 4) Cognitive behavioral intervention and 5) Group education."
3066661|NCT01073163|Experimental|Bendamustine with Rituximab|Participants were administered bendamustine intravenous (IV) infusion at 90 mg/m^2 on Days 1 and 2 of each 28-day cycle, and rituximab IV infusion at 375 mg/m^2 on Day 1 of each 28-day cycle.
3066662|NCT01073267|Experimental|TSEBT|Total Skin Electron Beam Therapy (TSEBT) to dose of 12 Gy
3066663|NCT01073293|Experimental|Concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1
3066664|NCT01073293|Experimental|Non-concomitant Vaccination|V503 given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm on Day 1, Month 2, and Month 6, and Repevax™ given as a 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1
3066665|NCT01073449||Cardiac device|All patients implanted with a cardiac device, pacemaker(PM)or Implantable Cardioverter Defibrillator (ICD)
3066666|NCT01073462||Paricalcitol IV|Participants with chronic kidney disease stage 5 with secondary hyperparathyroidism and cardiac morbidity received intravenous (IV) paricalcitol (Zemplar) prescribed according to current practice with regards to dose, population and indication for up to 2 years.
3066667|NCT01073566|Experimental|Finesse|Finesse Insulin Delivery Patch
3066668|NCT01073566|Active Comparator|Usual injection device|Pen/Syringe
3066669|NCT01073605|Active Comparator|Genotonorm A|Continuous 0.7 IU/kg/week or 0.03 mg/kg/day
3066670|NCT01073605|Active Comparator|Genotonorm B|Continuous, 1.4 IU/kg/week or 0.06 mg/kg/day
3066671|NCT01073605|Active Comparator|Genotonorm C|Intermittent, 1.4 IU/kg/week or 0.06 mg/kg/day
3066672|NCT01073618||A.|Patients who are indicated for VFEND according to drug package insert.
3066673|NCT01073631||1|Patients who are indicated for use of voriconazole tablet.
3066674|NCT01073657|Experimental|Supported Education|Veterans received supported education services. A Veteran peer met weekly as needed with a subject for up to six months in a psycho-social rehabilitation service for meeting education goals. Goals included choosing a college, getting admitted or enrolled, and maintaining enrollment and completing classes.
3066675|NCT01073657|Active Comparator|General Peer Support|Matched attention was provided by a Veteran peer who met weekly with Veterans but who focused on help with any personal goal (eg, employment, housing) but not on education.
3066676|NCT01073865|Experimental|1|"Zoladex 10.8 mg (goserelin acetate) will be injected once every 12 weeks (± 7 days).~One oral tamoxifen 20 mg tablet also will be taken daily"
3066677|NCT01073865|Active Comparator|2|Zoladex 3.6 mg (goserelin acetate) will be injected once every 4 weeks (± 7 days). One oral tamoxifen 20 mg tablet will also be taken daily.
3066678|NCT01073930|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day, during the morning prior to the colonoscopy."
3066679|NCT01073930|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
3066680|NCT01073943|Experimental|PicoPrep|"Day Before method and consists of two separate doses: the first dose during the afternoon or early evening before the colonoscopy and the second dose 6 hours later during the evening before the colonoscopy."
3066681|NCT01073943|Active Comparator|HalfLytely|HalfLytely and Bisacodyl Tablets Bowel Prep Kit was used according to the approved labeled dosage and administration instructions. The two bisacodyl tablets were taken the day prior to the procedure and the HalfLytely was taken following the first bowel movement or 6 hours after the bisacodyl tablets.
3066682|NCT01074008|Experimental|ABT-450/r (50/100 mg) once daily (QD) + pegIFN/RBV|Participants received 50 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066683|NCT01074008|Experimental|ABT-450/r (100/100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066684|NCT01074008|Experimental|ABT-450/r (200/100 mg) once daily (QD) + pegIFN/RBV|Participants received 200 mg ABT-450 and 100 mg ritonavir (r) monotherapy once daily for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066685|NCT01074008|Experimental|ABT-072 (100 mg) once daily (QD) + pegIFN/RBV|Participants received 100 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066686|NCT01074008|Experimental|ABT-072 (300 mg) once daily (QD) + pegIFN/RBV|Participants received 300 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066687|NCT01074008|Experimental|ABT-072 (600 mg) once daily (QD) + pegIFN/RBV|Participants received 600 mg ABT-072 monotherapy once daily for 3 days followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066688|NCT01074008|Experimental|ABT-333 (400 mg) twice a day (BID) + pegIFN/RBV|Participants received 400 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066689|NCT01074008|Experimental|ABT-333 (800 mg) twice daily (BID) + pegIFN/RBV|Participants received 800 mg ABT-333 monotherapy twice a day for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066690|NCT01074008|Placebo Comparator|Placebo + pegIFN/RBV|Participants received matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level for 3 days, followed by the addition of pegylated interferon/ribavirin (pegIFN/RBV) for a total of 12 weeks of combination treatment, followed by 36 weeks of pegIFN/RBV alone. Pegylated interferon was dosed at 180 µg subcutaneously once a week and RBV was dosed 1000 or 1200 mg daily divided twice a day.
3066691|NCT01074034|Experimental|AV Therapy Assessment group|appropriate system performance of the atrial and ventricular tachyarrhythmia therapies in the ASSURE device
3066692|NCT01074047|Experimental|Azacitidine|Azacitidine daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
3066693|NCT01074047|Active Comparator|Conventional Care Regimen|Conventional Care Regimen
3066694|NCT01074099|Active Comparator|Control|CABG only
3066695|NCT01074099|Experimental|BMAC enhanced CABG|Injection of concentrated bone marrow nucleated cells (BMAC) as an adjunct to CABG surgery
3066696|NCT01074125|Experimental|1 g/day|1 g/day KRX-0502 (ferric citrate)
3066697|NCT01074125|Experimental|6 g/day|6 g/day KRX-0502 (ferric citrate)
3066698|NCT01074125|Experimental|8 g/day|8 g/day KRX-0502 (ferric citrate)
3066699|NCT01074164|Placebo Comparator|Control group|This group of subjects will serve as the control group and will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids.
3066700|NCT01074164|Experimental|Accu-patch pellet|This group of subjects will follow a standard-of-care treatment regimen for AD, including the use of moisturizers and topical corticosteroids. Additionally, they will use a titanium pellet (accu-patch pellet) to self-apply pressure at the LI11 acupuncture pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times weekly for 1 month.
3066701|NCT01074177|Experimental|BIBW 2992|BIBW 2992 Taken orally once a day
3066702|NCT01074216|Experimental|vitamin D, vitamin D3|This is a Phase II study involving Stage IV colorectal cancer patients with serum vitamin D deficiency, to determine the ability to correct vitamin D deficiency and to maintain serum vitamin D levels (25-hydroxy vitamin D) once achieved.
3066703|NCT01074229|Placebo Comparator|Placebo|sterile normal saline as placebo
3066704|NCT01074229|Active Comparator|Drug .5% Ropivacaine|Instillation of 20 cc of 0.5% ropivacaine
3066705|NCT01074229|Active Comparator|20 cc of 0.25% ropivacaine|Instillation of 20 cc of 0.25% ropivacaine
3066706|NCT01074242||Rotateq|Korean Infants vaccinated with Rotateq in usual practice. The Rotateq vaccination series consists of 3 ready-to-use liquid (oral) doses with the first dose to be administered at age 6-12 weeks and subsequent doses to be administered at 4 to 10-week intervals.
3066707|NCT01074255||Korean Participants Treated With EMEND (aprepitant)|Participants receiving EMEND on Treatment Days 1, 2, and 3 concomitantly with a corticosteroid and a 5-hydroxytryptamine 3 (5-HT3) antagonist.
3066708|NCT01074268|Experimental|IDeg OD|
3066709|NCT01074268|Active Comparator|IDet|
3066710|NCT01074307|Experimental|Low Dose Bisoprolol|
3066711|NCT01074307|Experimental|High Dose Bisoprolol|
3066712|NCT01074450|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
3066713|NCT01074450|Active Comparator|2|Mirapex® 0.25 mg Tablets
3066714|NCT01074463|Experimental|1|Pramipexole Dihydrochloride 0.25 mg Tablets
3066715|NCT01074463|Active Comparator|2|Mirapex® 0.25 mg Tablets
3066716|NCT01074554|Experimental|Antibiotic Regimen|"The Antibiotic Regimen consists of Levaquin 750 mg loading on day 1, then 500 mg po QD and Ethambutol 15-25 mg/kg for a maximum of 1200mg QD and Azithromycin 500mg on day 1, then 250 mg po QD and Rifampin 5-10 mg/kg for a maximum of 300mg po QD.~All four drugs are given concomitantly."
3066717|NCT01074554|Placebo Comparator|Placebo Regimen|The placebo regimen consists of Lactose tablets, one for each antibiotic with equivalent pills
3066718|NCT01074658||severe aortic valve stenosis|elderly patients with severe aortic valve stenosis requiring treatment
3066719|NCT01074931||Lopinavir/ritonavir group|This study is a non-interventional, observational study in which lopinavir/ritonavir is prescribed in the usual manner in accordance with the terms of China market authorization with regards to dose, population and indication. It is planned to enroll approximately 100 patients in total.
3066720|NCT01074944|Experimental|Twice Daily (BID) Dose Regimen|Patients will receive either 50 mg BID or 100 mg BID
3066721|NCT01074944|Experimental|Once Daily (QD) Dose Regimen|Patients will receive either 100 mg QD or 200 mg QD
3066722|NCT01075048|Experimental|Phase 2: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
3066723|NCT01075048|Placebo Comparator|Phase 2: Placebo, cetuximab, irinotecan|Placebo in combination with irinotecan and cetuximab
3066724|NCT01075048|Experimental|Phase 1: Tivantinib, cetuximab, irinotecan|Tivantinib in combination with irinotecan and cetuximab.
3066725|NCT01075074|Active Comparator|Ropivacaine 0.05%|Subject received a bilateral transversus abdominis plane block block using 15 cc of 0.5% ropivacaine on each side
3066726|NCT01075074|Placebo Comparator|Normal Saline|Subjects received a bilateral transversus abdominis plane block using 15 cc of sterile normal saline.
3066727|NCT01075074|Active Comparator|Ropivacaine 0.25%|Subjects received a bilateral transversus abdominis plane block using 15cc of 0.25% ropivacaine on each side
3066728|NCT01075087|Placebo Comparator|Placebo|(control group) will receive sterile normal saline in the block
3066729|NCT01075087|Active Comparator|Active comparator|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
3066730|NCT01075100|Experimental|Weekly Ixabepilone +carboplatin|Subjects will receive ixabepilone and carboplatin on Days 1 and 8 of each 21-day cycle.
3066731|NCT01075152|Experimental|Earlier HIV Therapy|HIV therapy initiated at 7-13 days of cryptococcal meningitis diagnosis. HIV therapy consisting of a nucleoside with lamivudine and efavirenz.
3066732|NCT01075152|Active Comparator|Deferred HIV Therapy|"HIV therapy initiated at 5 weeks after cryptococcal meningitis diagnosis (+/- 1 week).~HIV therapy consisting of a nucleoside with lamivudine and efavirenz."
3066733|NCT01075178||Palivizumab-treated subjects (CASES)|HSCHD infants, <2 yrs old at first dose of palivizumab
3066734|NCT01075178||Non-palivizumab-treated subjects (CONTROLS)|HSCHD infants, <2 yrs old that did not receive palivizumab
3066735|NCT01075191||HIV-infected participants|"HIV-infected participants taking lopinavir/ritonavir (Kaletra) and one other protease inhibitor.~Lopinavir/ritonavir (Kaletra) dosing and administration according to the Summary of Product Characteristics (three 133 mg/33 mg capsules twice daily or two 200 mg/50 mg tablets twice daily)."
3066736|NCT01075204||Clarithromycin modified release|Patients with upper or lower respiratory tract infection were administered clarithromycin modified release 500 mg once daily for 7 days and then followed for a further 3 days, per routine clinical practice.
3066737|NCT01075217|Experimental|Isovue 250 (iopamidol)|
3066738|NCT01075217|Active Comparator|Visipaque 270 (iodixanol)|
3066739|NCT01075243|Experimental|Paracetamol 1000mg|Paracetamol 1000mg
3066740|NCT01075243|Experimental|Paracetamol 650 mg|Paracetamol 650 mg
3066741|NCT01075243|Placebo Comparator|Placebo|Placebo
3066742|NCT01075256|Active Comparator|5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 5% sodium calcium phosphosilicate toothpaste.
3066743|NCT01075256|Active Comparator|7.5% calcium sodium phosphosilicate toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with 7.5% sodium calcium phosphosilicate toothpaste.
3066744|NCT01075256|Placebo Comparator|Placebo toothpaste|Participants to brush their teeth for two minutes, twice daily for 15 days with placebo toothpaste.
3066745|NCT01075282|Experimental|LY2189265 1.5 mg|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3066746|NCT01075282|Experimental|LY2189265 0.75 mg|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3066747|NCT01075282|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 78 weeks~Metformin: at least 1500 milligrams per day (mg/day), oral, for 78 weeks~Glimepiride: at least 4 mg/day, oral, for 78 weeks"
3066748|NCT01075321|Experimental|Arm I|Patients receive oral everolimus once daily and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3066749|NCT01075347|Active Comparator|Autologous serum use|Patients treated with additional 20% autoserum after diabetic vitrectomy or penetrating keratoplasty
3066750|NCT01075347|Placebo Comparator|Non-autologous serum use|Patients treated with traditional medication(0.1% betamethasone, 0.3% gentamicin and 0.4% tropicamide eye drops application 4 times daily) after diabetic vitrectomy or penetrating keratoplasty
3066751|NCT01075399|Experimental|[F 18]HX4|[F18]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.
3066752|NCT01075412|Experimental|Group 2|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 20 fractions of radiation therapy.
3066753|NCT01075412|Experimental|Group 1|Receives fourth [F18]Fluorothymidine (FLT) PET scan after 15 fractions of radiation therapy.
3066754|NCT01075516||Standard Follow Up|ICD patients followed through periodic in-hospital visits
3066755|NCT01075516||Remote Follow Up|ICD patients followed with remote transmitters (Merlin@Home) that periodically communicate correct system functioning
3066756|NCT01075646|Experimental|Ropivacaine|After a bolus administration of Ropivacaine a perfusion ot the same anesthetic is initiated through an elastomeric wound during 48 hours
3066757|NCT01075646|Placebo Comparator|saline solution|After a bolus administration of saline solution a perfusion ot saline solution is initiated through an elastomeric wound during 48 hours
3066758|NCT01075685|Experimental|Web-based alcohol programme|"Participants could log on to their account and access the programme whenever they wanted to.~They received automated email reminders inviting them to use follow-up tools, especially the diary in order to register their alcohol intake on the previous week:~4 weeks after starting the programme, so that they would take advantage of the monitoring stage in case they had not spontaneously done so.~2 weeks later for 6-week follow-up."
3066759|NCT01075685|Placebo Comparator|Minimum information|Participants could log on to their account and access the programme whenever they wanted to. At 6 week follow-up they received an automated email reminder inviting them to use the diary in order to register their alcohol intake on the previous week.
3066760|NCT01075763|Experimental|Treatment arm - Rebif®|Subjets in this arm received interferon beta-1a (Rebif® 22 mcg tiw)
3066761|NCT01075763|Placebo Comparator|Placebo arm|Subjects in this arm received placebo
3066762|NCT01075815|Experimental|rFSH + rhLH|Recombinant human luteinizing hormone (rhLH,Luveris®) injection 150 IU subcutaneously daily along with rFSH 300 IU subcutaneously daily from S1 to S4 and then rFSH dose can be adjusted depending on the ovarian response till r-hCG administration day.
3066763|NCT01075815|Active Comparator|rFSH|rFSH injection 300 IU subcutaneously daily from S1 to S4 and then dose can be adjusted depending on the ovarian response till r-hCG administration day.
3066764|NCT01075971|Experimental|Buprenorphine hydrochloride|
3066765|NCT01075984|Active Comparator|POS IV 200 mg single dose (Cohort 0)|POS 200 mg IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
3066766|NCT01075984|Placebo Comparator|Dextrose 5% in water (Cohort 0)|Placebo IV single dose infused over 1.5 hours on Day 1 followed 12 hours later by POS oral 400 mg, then by POS oral 400 mg BID on Days 2 through 6 and a single morning dose on Day 7 (Cohort 0)
3066767|NCT01075984|Experimental|POS IV 200 mg BID (Cohort 1)|POS 200 mg IV infused over 1.5 hours BID on Day 1, followed by POS 200 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 1)
3066768|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 2)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 14, then by POS 400 mg oral BID through Day 28 (Cohort 2). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
3066769|NCT01075984|Experimental|POS IV 300 mg BID (Cohort 3)|POS 300 mg IV infused over 1.5 hours BID on Day 1, followed by POS 300 mg IV once daily on Days 2 through 5, then by POS 200 mg oral TID or POS 400 mg oral BID through Day 28, or POS 200-300 mg IV once daily as required (Cohort 3). After Day 5, POS IV was administered continuously or intermittently, depending on oral tolerability.
3066770|NCT01076010|Experimental|Sorafenib crossover to tivozanib.|The subjects who failed sorafenib (had Response Evaluation Criteria in Solid Tumors [RECIST] - defined progressive disease) on the parent protocol AV-951-09-301 will be offered tivozanib hydrochloride on Protocol AV- 951-09-902.
3066771|NCT01076010|Experimental|First line tivozanib.|The subjects who were randomized to tivozanib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability in Protocol AV-951-09-301.
3066772|NCT01076010|Active Comparator|First line sorafenib.|The subjects who were randomized to sorafenib (continued from the parent Protocol AV-951-09-301) and demonstrated clinical benefit and acceptable tolerability were to be offered long-term access to sorafenib.
3066773|NCT01076036|Experimental|CorPath 200 System|Robotic-assisted PCI with the CorPath 200
3066774|NCT01076049|Active Comparator|Standard of Care (SoC)|For subjects randomized to the control group, the preferred irrigation solution was chosen by the site's emergency department physician(s).
3066775|NCT01076049|Active Comparator|Irrisept|For subjects randomized to the investigational group, Irrisept was used.
3066776|NCT01076075|Active Comparator|placebo/pioglitazone|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg; Phase B (Weeks 24-54): placebo to Sitagliptin 100 mg + pioglitazone 30 mg
3066777|NCT01076075|Experimental|Sitagliptin|Phase A (Weeks 0-24): Sitagliptin 100 mg; Phase B (Weeks 24-54): Sitagliptin 100 mg + placebo to pioglitazone
3066778|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 500 mg|Sitagliptin 50 mg and metformin 500 mg twice a day for 24 weeks.
3066779|NCT01076088|Experimental|Sitagliptin 50 mg + metformin 850 mg|Sitagliptin 50 mg and metformin 850 mg twice a day for 24 weeks.
3066780|NCT01076088|Active Comparator|Metformin 500 mg|Metformin 500 mg twice daily for 24 weeks.
3066781|NCT01076088|Active Comparator|Metformin 850 mg|Metformin 850 mg twice daily for 24 weeks.
3066782|NCT01076088|Experimental|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
3066783|NCT01076088|Placebo Comparator|Placebo|Matching placebo tablets for 24 weeks.
3066784|NCT01076153||Patients with respiratory tract infection|Thai patients with upper or lower respiratory tract infections on Klacid MR.
3066785|NCT01076166||Children with lower respiratory tract infection|Thai children with lower respiratory tract infections on Klacid Granules for Oral Suspension
3066786|NCT01076179||Human Immunodeficiency Virus (HIV)-Infected Participants|HIV-infected participants on Kaletra and INIs or NNRTIs or CCR5 antagonists
3066787|NCT01076192||Moderate-to-severe chronic plaque psoriasis|Participants with moderate-to-severe chronic plaque psoriasis treated with adalimumab in routine clinical practice
3066788|NCT01076205||Adalimumab|Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.
3066789|NCT01076231|Experimental|Arm I|"Patients undergo proton beam radiotherapy over 5.5-7.5 weeks. Patients receive concurrent chemotherapy comprising cisplatin IV on days 1, 8, 29, and 36 and etoposide IV on days 1-5 and days 29-33.Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 4-6 weeks after completion of chemoradiotherapy, patients may undergo surgical resection or additional chemoradiotherapy."
3066790|NCT01076244|Other|Minimally invasive lumbar decompression|
3066791|NCT01076270|Experimental|Filgrastim and plerixafor for PBSC mobilization|"Donors receive filgrastim subcutaneously (SC) and plerixafor SC on day -14 and undergo leukapheresis to collect peripheral blood stem cells (PBSC) on day -13. These cells are frozen to preserve them. Treatment modifications may apply according to sufficient collection of PBSC. Patients receive standard high-dose conditioning and undergo allogeneic PBSC transplantation on day 0 using the previously frozen cells.~After completion of study treatment, donors are followed up 1 day after the last stem cell donation."
3066792|NCT01076283|Active Comparator|Baclofen|Baclofen 10 mg three times a day (t.i.d.) for 8-10 days
3066793|NCT01076283|Placebo Comparator|Cyproheptadine|Cyproheptadine 2 mg t.i.d. for 8-10 days
3066794|NCT01076335|Experimental|Neoadjuvant Hormones + Docetaxel|Neoadjuvant Hormonal Therapy plus Docetaxel followed by Radical Prostatectomy
3066795|NCT01076400|Experimental|Part 1: MK-1775 + topotecan/cisplatin|Part 1: Dose escalation study. MK-1775 capsules will be administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3066796|NCT01076400|Experimental|Part 2: MK-1775 + topotecan/cisplatin|Part 2: MK-1775 capsules will be administered at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3066797|NCT01076400|Placebo Comparator|Part 2: Placebo to MK-1775 + topotecan/cisplatin|Part 2: Placebo to MK-1775 capsules will be administered twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3. Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
3066798|NCT01076452|Active Comparator|STN|Participants were randomized to receive deep brain stimulation on STN (Subthalamic Nucleus) target.
3066799|NCT01076452|Active Comparator|GPi|Participants were randomized to receive deep brain stimulation on GPi (Globus Pallidus) target.
3066800|NCT01076504|Experimental|Amrubicin/Carboplatin with Pegfilgrastim|Systemic therapy
3066801|NCT01076543|Experimental|Treatment (lenalidomide, temsirolimus)|Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.
3066802|NCT01076647|Experimental|IDeg 3TW|
3066803|NCT01076647|Active Comparator|IGlar OD|
3066804|NCT01076686||Bupivacaine and low dose SKY0402|
3066805|NCT01076686||Bupivacaine and high dose SKY0402|
3066806|NCT01076686||Bupivacaine|
3066807|NCT01076686||High dose SKY0402|
3066808|NCT01076959||Humira|The sponsor was required to include all patients diagnosed with rheumatoid arthritis and who were treated Humira in routine medical practice during the review period by the PMDA. The safety analysis set included all patients who met all eligibility criteria and received at least one dose of Humira. The full analysis set included all patients who were treated with Humira for at least 2 weeks and had complete DAS 28 assessments at baseline and at least one other time point.
3066809|NCT01076972||Lopinavir/ritonavir group|All patients in this non-interventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
3066810|NCT01076985||Lopinavir/ritonavir group|All pregnant women in this noninterventional, post-marketing observational study, who were prescribed lopinavir/ritonavir (Kaletra) in accordance with the local Prescribing Information for the treatment of HIV infection.
3066811|NCT01077024|Experimental|Smoking-cessation treatment + substance treatment as usual|
3066812|NCT01077024|No Intervention|Substance-treatment as usual|Treatment as usual is outpatient stimulant-dependence treatment as typically provided by the participating site.
3066813|NCT01077050|Other|SciBase III|Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.
3066814|NCT01077063|Active Comparator|paracentesis|cutting and draining procedure for malignant ascites
3066815|NCT01077063|Active Comparator|Pleurx catheter|a catheter drainage system the subject uses himself/herself.
3066816|NCT01077076|Experimental|Zegerid OTC Capsules|20 mg omeprazole and 1100 mg sodium bicarbonate
3066817|NCT01077076|Active Comparator|Prilosec OTC™ tablets containing 20 mg-equivalent omeprazole|20.6 mg omeprazole-magnesium complex.
3066818|NCT01077076|Placebo Comparator|Placebo|Inert substance
3066819|NCT01077128||Patients with psoriasis|All eligible patients with psoriasis treated with Adalimumab
3066820|NCT01077154|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once every 4 weeks for 6 months followed by placebo subcutaneous injections once every 3 months for 4.5 years.
3066821|NCT01077154|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneous injections once every 4 weeks for 6 months followed by denosumab 120 mg subcutaneous injections once every 3 months for 4.5 years.
3066822|NCT01077193|Other|Gastric Plication Surgery|
3066823|NCT01077258||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
3066824|NCT01077271||Premature infants 33 - 35 wGA prophylaxed with palivizumab|Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)
3066825|NCT01077284|Experimental|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
3066826|NCT01077284|Active Comparator|Allopurinol|Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
3066827|NCT01077284|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 6 months.
3066828|NCT01077310|Active Comparator|Intramuscular naltrexone|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
3066829|NCT01077310|Placebo Comparator|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail.
3066830|NCT01077323||Exenatide Initiators|
3066831|NCT01077323||Other Antidiabetic Drug Initiators|
3066832|NCT01077323||Non-Diabetes Cohort|
3066833|NCT01077362|Experimental|Placebo|Participants will receive subcutaneous (SC) injections of placebo at Weeks 0, 4, 16, and 20. At Week 24 participants will cross over to receive SC injections of ustekinumab 45 mg at Weeks 24 and 28 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 45 mg ustekinumab will be given at Weeks 16, 20, and 28 and every 12 weeks thereafter with the last dose at Week 40. For participants entering early escape, a SC placebo injection will be given at Week 24 to maintain the blind.
3066834|NCT01077362|Experimental|Ustekinumab 45 mg|Participants will receive SC injections of ustekinumab 45 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, SC injections of 90 mg ustekinumab will be given at Week 16 and every 12 weeks thereafter with the last dose at Week 40. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3066835|NCT01077362|Experimental|Ustekinumab 90 mg|Participants will receive SC injections of ustekinumab 90 mg at Weeks 0 and 4 and every 12 weeks thereafter with the last dose at Week 40. If early escape, the same dosage schedule will continue. Participants will receive SC injections of placebo at Weeks 20 and 24 to maintain the blind.
3066836|NCT01077375|Placebo Comparator|Placebo|Placebo tablets, twice a day, oral administration
3066837|NCT01077375|Experimental|Milnacipran|Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses.
3066838|NCT01077401|Experimental|Ranibizumab 0.5mg|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
3066839|NCT01077401|Experimental|Ranibizumab 2.0 mg|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
3066840|NCT01077518|Experimental|Ofatumumab and Bendamustine (Arm A)|Up to 8 cycles of bendamustine (90 mg/m2) on Days 1,2 every 21 days with12 doses of ofatumumab (1000 mg, Day 1 q21 days when with bendamustine and q28 days when given as monotherapy)
3066841|NCT01077518|Active Comparator|Bendamustine (Arm B)|Up to 8 cycles of bendamustine (120 mg/m2) on Days 1,2 every 21 days
3066842|NCT01077544|Experimental|Group 1|1 year to < 10 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
3066843|NCT01077544|Experimental|Group 2|>= 10 years to <18 years pediatric patients with newly diagnosed CP-Ph+ CML, or CP or AP-Ph+ CML resistant/intolerant to imatinib and/or dasatinib, or relapsed/refractory Ph+ ALL (acute lymphoblastic leukemia) treated at the proposed dose of 230 mg/m2 bid.
3066844|NCT01077596||New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006|All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription.
3066845|NCT01077622|Experimental|2000 mg dose|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
3066846|NCT01077713|Experimental|1|
3066847|NCT01077713|Experimental|2|
3066848|NCT01077739|Experimental|Avastin (bevacizumab) + standard of care|
3066849|NCT01077804||Varivax vaccinated children|Children who are members of Kaiser Permanente Medical Care Program (KPMCP) and who received a first dose of the varicella vaccine, Varivax, in 1995 between the ages of 12 and 23 months.
3066850|NCT01077817||Esophageal Cancer Cases|Participants with any United Kingdom General Practice Research Database (GPRD) Medical code for esophageal cancer (cases). Cases were confirmed and case onset dates determined by electronic algorithm (based on electronic medical record data) or by medical record review.
3066851|NCT01077817||Comparison Sample (Case-Cohort)|Participants who were matched to cases by age and membership in the GPRD on the case's onset date, and had not experienced any form of esophageal cancer or Paget's Disease and had not received oral or intravenous steroids or chemotherapy or radiotherapy, as indicated by GPRD codes.
3066852|NCT01077817||Non-treated Comparators|Participants who did not initiate treatment of osteoporosis with a study drug
3066853|NCT01077817||Alendronate|Participants initiating treatment for osteoporosis with alendronate
3066854|NCT01077817||Etidronate|Participants initiating treatment for osteoporosis with etidronate
3066855|NCT01077817||Ibandronate|Participants initiating treatment for osteoporosis with ibandronate
3066856|NCT01077817||Risedronate|Participants initiating treatment for osteoporosis with risedronate
3066857|NCT01077817||Raloxifene|Participants initiating treatment for osteoporosis with raloxifene
3066858|NCT01077830||Ezetimibe/Simvastatin 10/40 mg|Participants who received Ezetimibe/Simvastatin 10/40 mg in the base study
3066859|NCT01077830||Placebo|Participants who received placebo in the base study
3066860|NCT01077856||Pre-Vaccine|Registry, survey, and HPV status data from 2004-2006
3066861|NCT01077856||Post-Vaccine|Registry, survey, and HPV status data from 2011-2012
3066862|NCT01077921|Experimental|Propranolol|Drug arm
3066863|NCT01077921|Placebo Comparator|Sugar pill|Placebo arm
3066864|NCT01077960|Experimental|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
3066865|NCT01077973|Experimental|Treatment A|
3066866|NCT01077973|Active Comparator|Treatment B|
3066867|NCT01077973|Placebo Comparator|Treatment C|
3066868|NCT01078090||Rheumatoid arthritis|Participants with rheumatoid arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 5 years.
3066869|NCT01078116||Patients with Rheumatoid Arthritis|Eligible rheumatoid arthritis patients treated with adalimumab according to the approved Summary of Product Characteristics (SmPC) in European Union
3066870|NCT01078155||Participants with Active Rheumatoid Arthritis (RA)|Participants (women and men) with active early and long-standing RA according to American College of Rheumatology revised criteria from 1987 were prescribed adalimumab in the usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. The decision to prescribe or not to prescribe an anti-TNF was taken prior to a participant's enrollment in the study.
3066871|NCT01078168|Active Comparator|Acitretin|oral, 30 mg per day, day 1-28
3066872|NCT01078168|Placebo Comparator|Placebo|oral, day 1-28
3066873|NCT01078220||3-Dose Safety Population (Primary)|Females between ages 9 to 26 at receipt of the first dose of GARDASIL who are members of the participating MCOs and have completed the 3-dose regimen of GARDSIL vaccination with 12 months.
3066874|NCT01078220||Pregnancy Safety Population|Females who received at least one dose of GARDASIL during pregnancy.
3066875|NCT01078220||Autoimmune Safety Population|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
3066876|NCT01078220||Any Dose Safety Population (Secondary)|Females who have received at least one dose of GARDASIL and have been members in the same MCO for at least 12 months prior to receiving their first dose of GARDASIL.
3066877|NCT01078233||Raltegravir Cohort|Participants with HIV-1 infection who started raltegravir on or after 21 December 2007 (the authorization date in the European Union) and had at least 1 month prospective follow-up in the Raltegravir Cohort. Participants from the Historical Cohort and Concurrent Cohort were eligible for inclusion in the Raltegravir Cohort.
3066878|NCT01078233||Historical Cohort|Participants with HIV-1 infection who started a new antiretroviral drug as part of a combination antiretroviral therapy (cART) regimen on or after 1 January 2006 and before 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Historical Cohort.
3066879|NCT01078233||Concurrent Cohort|Participants with HIV-1 infection who started a new antiretroviral drug other than raltegravir as part of a cART regimen on or after 21 December 2007. Participants had no previous exposure to the new drug and had at least 1 month prospective follow-up in the Concurrent Cohort. Participants from the Historical Cohort were eligible for inclusion in the Concurrent Cohort.
3066880|NCT01078246||Raltegravir Cohort Only|Participants with HIV-1 infection who received raltegravir (RAL) on or after 12 October 2007 (the market authorization date in the United States) (Raltegravir Cohort). These participants contributed data to the Raltegravir Cohort only.
3066881|NCT01078246||Historical and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received RAL on or after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Historical and Raltegravir Cohorts only.
3066882|NCT01078246||Historical Cohort Only|Participants with HIV-1 infection who received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort). These participants contributed data to the Historical Cohort only.
3066883|NCT01078246||Historical and Concurrent Cohorts Only|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), and 2) received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Historical and Concurrent Cohorts only.
3066884|NCT01078246||Concurrent Cohort Only|Participants with HIV-1 infection who received therapy with a new non-RAL antiretroviral therapy after 12 October 2007 (Concurrent Cohort). These participants contributed data to the Concurrent Cohort only.
3066885|NCT01078246||Concurrent and Raltegravir Cohorts Only|Participants with HIV-1 infection who 1) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 2) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to the Concurrent and Raltegravir Cohorts only.
3066886|NCT01078246||Historical, Concurrent and Raltegravir Cohorts|Participants with HIV-1 infection who 1) received antiretroviral therapy (non-RAL) between 1 January 2005 and 11 October 2007 (Historical Cohort), 2) received therapy with a new non-RAL antiretroviral therapy on or after 12 October 2007 (Concurrent Cohort), and 3) received RAL after 12 October 2007 (Raltegravir Cohort). These participants contributed data to all three cohorts.
3066887|NCT01078298|Experimental|varenicline|
3066888|NCT01078298|Placebo Comparator|placebo|placebo
3066889|NCT01078363|Active Comparator|ramipril|ramipril, 5mg starting dose to maximum dose of 20mg daily dose for one year.
3066890|NCT01078363|Placebo Comparator|Placebo|Sugar pill manufactured to mimic ramipril 5mg starting dose , increasing to 20mg daily for one year.
3066891|NCT01078376|Experimental|Cohort 1: Healthy Adults (18 years to 45 years old)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
3066892|NCT01078376|Experimental|Cohort 1: Adolescents (≥12 to <17 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
3066893|NCT01078376|Experimental|Cohort 2: Children (≥6 to <12 years old)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
3066894|NCT01078376|Experimental|Cohort 3: Children (≥1 to <6 years old)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
3066895|NCT01078389|Experimental|Febuxostat 40 mg or 80 mg|Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.
3066896|NCT01078389|Placebo Comparator|Placebo|Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.
3066897|NCT01078402||Single patients group: RA, PsA and AS|Single patients group with: Active Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)
3066898|NCT01078441|Experimental|Treatment (combination chemotherapy)|Patients receive bortezomib 1.3 mg/m2 subcutaneously on days 1, 8, and 15; liposomal doxorubicin 30 mg/m2 intravenously (IV) over 1 hour on day 4; oral dexamethasone 20mg on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide 750 mg/m2 IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3066899|NCT01078454|Experimental|ARM A (Mel-Dex)|Patients receive melphalan 0.22 mg/kg orally (PO) and dexamethasone 40 mg PO on days 1-4 every 4 weeks. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
3066900|NCT01078454|Experimental|ARM B (B-Mel-Dex)|Patients receive melphalan 0.22 mg/kg PO and dexamethasone 40 mg PO on days 1-4 and bortezomib 1.3 mg/m^2 intravenously (IV) on days 1, 4, 8, and 11 every 4 weeks. Treatment repeats every 4 weeks for 2 cycles. Patients then receive melphalan PO and dexamethasone PO on days 1-4 and bortezomib IV on days 1, 8, 15, and 22 every 5 weeks. Treatment repeats every 5 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3066901|NCT01078545||Adv. PCa patients with LUTS treated with GnRH analogue|Patients with advanced prostate cancer and lower urinary tract symptoms treated with GnRH analogue Lucrin Depot 11.25 mg (Lucrin Depot 3.75mg - in Ukraine)
3066902|NCT01078558||Patients with rheumatic disease|Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
3066903|NCT01078571||RA patients in treatment with adalimumab (Humira)|RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks
3066904|NCT01078584||Hypertensive Participants|Hypertensive diabetics and non-diabetics, with or without isolated systemic hypertension and/or renal dysfunction, who were naïve to trandolapril or on trandolapril within past 30 days.
3066905|NCT01078623|Active Comparator|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
3066906|NCT01078623|Placebo Comparator|Placebo|Placebo twice daily
3066907|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
3066908|NCT01078623|Experimental|Aclidinium 200 μg / formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
3066909|NCT01078623|Experimental|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
3066910|NCT01078662|Experimental|1|olaparib 400mg BD
3066911|NCT01078675|Experimental|1|
3066912|NCT01078753|Experimental|Desmopressin|During treatment period I participants received 120 μg per day desmopressin oral lyophilisate tablet for 14 days. Participants for whom treatment was effective (a reduction of ≥ 75% from Baseline in the number of wet nights), and who showed no problems with tolerability, continued to receive the same treatment for a further 14 days in treatment period II. Participants for whom efficacy was inadequate (a reduction of <75% from Baseline in the number of wet nights), but who showed no tolerability problems, received an increased dose of desmopressin oral lyophilisate tablet 240 µg for 14 days in treatment period II.
3066913|NCT01078753|Placebo Comparator|Placebo|Participants received matching placebo tablets during treatment periods I and II according to the same efficacy criteria as participants in the Desmopressin treatment group.
3066914|NCT01078805||FORTEO (teriparatide)-treated|FORTEO-treated
3066915|NCT01078909|Experimental|300mg Fish Oil (EPA + DHA) Supplement|
3066916|NCT01078909|Experimental|600mg Fish Oil (EPA+DHA) Supplement|
3066917|NCT01078909|Experimental|900mg Fish Oil (EPA + DHA) Supplement|
3066918|NCT01078909|Experimental|1800mg Fish Oil (EPA + DHA) Supplement|
3066919|NCT01078909|Placebo Comparator|Placebo|
3066920|NCT01078922|Experimental|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
3066921|NCT01078974|Experimental|pomalidomide, dexamethasone, rituximab|"Drug: pomalidomide Taken orally once a day~Drug: dexamethasone Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15~Drug: rituximab Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15"
3066922|NCT01079130|Experimental|Indacaterol 18.75 µg|"Indacaterol 18.75 µg once daily in the morning via Concept1, a single-dose dry powder inhaler (SDDPI) and Placebo to Salmeterol in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066923|NCT01079130|Experimental|Indacaterol 37.5 µg|"Indacaterol 37.5 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066924|NCT01079130|Experimental|Indacaterol 75 µg|"Indacaterol 75 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066925|NCT01079130|Experimental|Indacaterol 150 µg|"Indacaterol 150 µg once daily in the morning via Concept1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3132375|NCT03421730|Experimental|BD - VR647 10 breaths, then Pulmicort|10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
3066926|NCT01079130|Active Comparator|Salmeterol|"Salmeterol 50 µg twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI) and Placebo to Indacaterol once daily in the morning via Concept1, a SDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066927|NCT01079130|Placebo Comparator|Placebo|"Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI and Placebo to Salmeterol in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.~Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. The short acting (beta) β2-agonist (SABA) albuterol was available for rescue use throughout the study."
3066928|NCT01079143|Experimental|Certican EMT+|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
3066929|NCT01079143|Experimental|Certican EMT-|Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®.
3066930|NCT01079143|Active Comparator|Neoral EMT+|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
3066931|NCT01079143|Active Comparator|Neoral EMT-|Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®.
3066932|NCT01079182||Ankylosing spondylitis|Participants with ankylosing spondylitis
3066933|NCT01079195||Single Patient group with Hypertension|Single Patient group with Hypertension
3066934|NCT01079234|Experimental|Flex + insulin aspart|
3066935|NCT01079234|Experimental|Fixed + insulin aspart|
3066936|NCT01079234|Active Comparator|IGlar + insulin aspart|
3066937|NCT01079299|Experimental|IPC plus standard compression|
3066938|NCT01079299|Active Comparator|Standard compression alone|
3066939|NCT01079390|Experimental|High dose acupuncture|six needle applied during acupuncture
3066940|NCT01079390|Experimental|Low dose acupuncture|two needles will be applied.
3066941|NCT01079390|Placebo Comparator|placebo acupuncture|sham acupuncture treatment will be applied
3066942|NCT01079663|Experimental|Chlorhexidine chip (Periochip®)|PerioChip®, consisting of 2.5 mg Chlorhexidine Gluconate PerioChips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
3066943|NCT01079663|Placebo Comparator|Placebo chip|Placebo Chip Placebo Chips were inserted only to target pockets whose pocket depth (PD) at Baseline visit (Week 0), Week 2, Week 4, Week 6, Week 8, Week 12 and Week 18 was ≥ 6 mm
3066944|NCT01079741|Experimental|Dose-escalation component|Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen and Montanide will be held constant.
3066945|NCT01079741|Active Comparator|Phase II is the randomized component.|The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B).
3066946|NCT01079806|Active Comparator|Entecavir|Participants received entecavir, 0.015 mg/kg up to 0.5 mg, once daily, for 96 to 144 weeks, depending on response
3066947|NCT01079806|Placebo Comparator|Placebo|Participants received placebo, 0 mg, once daily, for 48 to 96 weeks, depending on response
3066948|NCT01079832|Experimental|Arm I: CyberKnife Radiosurgery|Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.
3066949|NCT01079936|Experimental|Lenalidomide + High-Dose Melphalan|Lenalidomide beginning dose level 25 mg by mouth (PO) on Days -8 to -2. High-Dose Melphalan dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion. Stem cell infusion on Day 0.
3066950|NCT01079949|Experimental|r-hLH + r-hFSH|
3066951|NCT01079949|Active Comparator|r-hFSH|
3066952|NCT01079962|Experimental|Bisoprolol|
3066953|NCT01079962|Active Comparator|Atenolol|
3066954|NCT01079988|Experimental|Cyclosporin|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
3066955|NCT01079988|Experimental|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
3066956|NCT01079988|Experimental|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
3066957|NCT01079988|Experimental|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
3066958|NCT01079988|Experimental|Systemic corticosteroids/methotrexate|"Corticosteroid starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%.~Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks."
3066959|NCT01080118|Other|control group|Control group, taught with a standard Macintosh laryngoscope
3066960|NCT01080118|Experimental|Study group|Study group taught with the Airtraq video laryngoscope
3132376|NCT03421730|Experimental|CA - VR647 20 breaths, then VR647 5 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3132377|NCT03421730|Experimental|CB - VR647 20 breaths, then VR647 10 breaths|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3066961|NCT01080131|Experimental|Canakinumab 150 mg|"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to receive open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year, for a total duration of 18 months."
3066962|NCT01080131|Active Comparator|Triamcinolone acetonide 40 mg|"Participants received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Participants completing the 12 week core study could continue to be treated in a 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.~In the second extension study participants were to switch to open-label on demand treatment with canakinumab 150 mg sc upon new flare for 1 year. Triamcinolone acetonide was not to be administered in the second extension study."
3066963|NCT01080196|Experimental|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
3066964|NCT01080196|No Intervention|TRADITIONAL|"The TRAD group will perform their lower extremity resistance exercise for 15 minutes per session with isotonic weight machines and cuff weights as part of their multicomponent exercise fall reduction program (MCERFP). The progression of the 3 x/week, 12 week TRAD program will be determined as a relative function of their 1 repetition maximum (1RM) weight that can be lifted in a safe and successful manner. The 1RM will be measured before the 12 week training program and every 2 weeks thereafter. A target resistance workload (i.e., weight level) commensurate with 60-70% of the 1RM of the knee and hip extensors will be calculated bi-monthly and 3 sets of 15 repetitions of 3-4 different knee and hip exercises will be used over a 15 minute time period."
3066965|NCT01080209|Experimental|Brimo PS DDS® 400 μg (2 implants)|Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study.
3066966|NCT01080209|Experimental|Brimo PS DDS® 400 μg (1 implant)|Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study.
3066967|NCT01080209|Experimental|Brimo PS DDS® 200 μg (2 implants)|Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study.
3066968|NCT01080209|Experimental|Brimo PS DDS® 200 μg (1 implant)|Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study.
3066969|NCT01080209|Experimental|Brimo PS DDS® 100 μg (1 implant)|Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study.
3066970|NCT01080209|Experimental|Brimo PS DDS® 50 μg (1 implant)|Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study.
3066971|NCT01080209|Sham Comparator|Sham|Patients who received sham in a previous study.
3066972|NCT01080248|Experimental|Arm 1 (gemcitabine & pazopanib)|"Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle.~Pazopanib 800 mg PO daily of each 28 day cycle."
3066973|NCT01080261|Experimental|PROMUS Element|everolimus-eluting coronary stent
3066974|NCT01080300|Experimental|Gabapentin Extended Release|Active treatment
3066975|NCT01080300|Other|Placebo|Placebo
3066976|NCT01080326|Experimental|Endoscopic Translumenal Omental Patch|Patients with the clinical diagnosis of a perforated viscus who are scheduled to undergo surgical exploration will be recruited. The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix the Endoscopic Translumenal Omental Patch in place.
3066977|NCT01080391|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Treatment was administered in cycles repeated every 28 days. Lenalidomide 25 mg was administered orally on days 1 to 21 and dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22.
3066978|NCT01080391|Experimental|Carfilzomib, Lenalidomide, and Dexamethasone (CRd)|Treatment was administered in cycles every 28 days. Carfilzomib 20 mg/m² was administered intravenously (IV) on days 1 and 2 of cycle 1, escalating to 27 mg/m² on days 8, 9, 15, and 16 of cycle 1 and continuing on days 1, 2, 8, 9, 15, and 16 of cycle 2 through cycle 12 and then from cycle 13 through cycle 18, 27 mg/m² on days 1, 2, 15, and 16. Lenalidomide 25 mg was administered orally on days 1 to 21 from cycle 1 through cycle 18 and from cycle 19 and higher. Dexamethasone 40 mg was administered orally or IV on days 1, 8, 15, and 22 from cycle 1 through cycle 18 and from cycle 19 and higher.
3066979|NCT01080625|Experimental|phenylephrine|100 mcg of phenylephrine is administered at the time of reperfusion
3066980|NCT01080625|Experimental|epinephrine|10 mcg of epinephrine is administered iv at the time of reperfusion
3066981|NCT01080625|Placebo Comparator|control|10 ml of normal saline is administered at the time of reperfusion
3066982|NCT01080677|Placebo Comparator|Placebo|Participants will receive placebo to match caffeine/propranolol (single dose)
3066983|NCT01080677|Experimental|Low dose|Participants will receive caffeine/propranolol 400/40 mg combination tablet (single dose)
3066984|NCT01080677|Experimental|High dose|Participants will receive caffeine/propranolol 1000/40 mg combination tablet (single dose)
3066985|NCT01080716|Experimental|Part 1/Arm 1 of Study: WRSS1 vaccine|WRSS1 is a live attenuated S. sonnei vaccine candidate derived from the Mosely strain of S.sonnei
3066986|NCT01080716|Placebo Comparator|Part 1/Arm 2 of Study: Placebo vaccine|Placebo
3066987|NCT01080716|Experimental|Part 2/Arm 1 of Study: S. sonnei 53G|10 volunteers from Study Arm 1/Part 1 (WRSS1 vaccine) plus 4 alternates from Arm 1/Part 1 are given 53G S. sonnei
3066988|NCT01080716|Active Comparator|Part 2/Arm 2 of Study: S sonnei 53G|10 subjects (naïve controls) plus 4 alternates are give 53G S sonnei
3066989|NCT01080794|Active Comparator|Double rTMS|High frequency rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
3066990|NCT01080794|Active Comparator|M1 Active rTMS + DLPFC Sham rTMS|High frequency stimulation of the primary motor cortex (M1) and sham stimulation of the dorsolateral prefrontal cortex (DLPFC).
3066991|NCT01080794|Active Comparator|DLPFC Active rTMS + M1 Sham rTMS|High frequency stimulation of the dorsolateral prefrontal cortex (DLPFC) and sham stimulation of the primary motor cortex (M1).
3066992|NCT01080794|Sham Comparator|Double Sham rTMS|Sham rTMS stimulation of the bilateral primary motor cortex (M1) and left dorsolateral prefrontal cortex (DLPFC).
3066993|NCT01080807|Experimental|150 mg/day armodafinil|
3066994|NCT01080807|Placebo Comparator|Matching placebo|
3066995|NCT01080976||Primary Care Physicians|
3066996|NCT01080976||Diabetologists|
3066997|NCT01081041|Experimental|Safety Lead-In (cetuximab manufactured by ImClone)|"Cycle 1:~Week 1 - Cetuximab 400 milligrams per square meter (mg/m^2) on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3066998|NCT01081041|Experimental|Cetuximab manufactured by ImClone|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3066999|NCT01081041|Experimental|Cetuximab manufactured by Boehringer Ingelheim|"Cycle 1:~Week 1 - Cetuximab 400 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m^2 on Day 1; Cisplatin 100 mg/m^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m^2 on Days 1-4~Week 2 - Cetuximab 250 mg/m^2 on Day 1~Week 3 - Cetuximab 250 mg/m^2 on Day 1~After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met."
3067000|NCT01081132|Experimental|Extended-release Guanfacine HCl|
3067001|NCT01081132|Placebo Comparator|Placebo|
3067002|NCT01081145|Experimental|Extended-release Guanfacine HCl|
3067003|NCT01081145|Placebo Comparator|Placebo|
3067004|NCT01081249|Experimental|Placebo then Oxytocin|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
3067005|NCT01081249|Experimental|Oxytocin then placebo|Participant was randomized to receive placebo before the first psychotherapy session, and then received the active drug at the second visit.
3468801|NCT03892278|Experimental|Aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
3468802|NCT03892278|Active Comparator|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
3067010|NCT01081301|Experimental|Living with Hope Program|Receive Living with Hope Program
3067011|NCT01081626|Experimental|Group I: Chronic Low dose Protocol|Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
3067012|NCT01081626|Experimental|Group II: Low dose Protocol|Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
3067013|NCT01081665||Chronic Kidney Disease|All eligible patients treated with IV Paricalcitol (Zemplar)
3067014|NCT01081678|Placebo Comparator|Placebo|Participants received placebo to romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
3067015|NCT01081678|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
3067016|NCT01081678|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
3067017|NCT01081678|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection on day 1 and at weeks 2, 6, and 12.
3067018|NCT01081769|Experimental|Paliperidone Palmitate|paliperidone palmitate injection with 150 mg equivalent on Day 1 100 mg equivalent on Day 8 75 mg equivalent on Day 38 and flexible dosing with 25 50 75 100 or 150 mg equivalent once monthly thereafter
3067019|NCT01081769|Active Comparator|Oral Antipsychotics|oral antipsychotics daily treatment according to local label for maximally 24 months
3067020|NCT01081795|Experimental|Topiramate (JNS019) 50 mg|In titration period, topiramate 25 milligram (mg) tablet will be given once daily in evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily along with matching placebo tablet once daily in the evening orally from Day 15 to Day 21; then topiramate 25 mg tablet along with matching placebo tablet twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
3067021|NCT01081795|Experimental|Topiramate 100 mg|In titration period, topiramate 25 mg tablet will be given once daily in the evening orally for 7 days; then topiramate 25 mg tablet twice daily orally from Day 8 to Day 14; then topiramate 25 mg tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; then 2 topiramate 25 mg tablets twice daily orally from Day 22 to Day 28 and will be continued further for 18 weeks in the fixed dose period.
3067022|NCT01081795|Placebo Comparator|Placebo|In titration period, matching placebo tablet will be given once daily in evening orally for 7 days; followed by matching placebo tablet twice daily orally from Day 8 to Day 14; followed by matching placebo tablet twice daily (1 tablet in the morning and 2 tablets in the evening) orally from Day 15 to Day 21; followed by 2 matching placebo tablets twice orally from Day 22 to Day 28 and will becontinued further for 18 weeks in the fixed dose period.
3067023|NCT01081834|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
3067024|NCT01081834|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks (Main Study) or 26 weeks only (High Glycemic Substudy).
3067025|NCT01081834|Experimental|Placebo/Sitagliptin|In the Main Study, each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52.
3067026|NCT01081873||Advanced prostate cancer participants|Participants with advanced prostate cancer treated with Lucrin /Lucrin- Tri-depot (leuprolide) or any other treatment within local reimbursement guidelines.
3067027|NCT01081912|Active Comparator|Hydrocodone Bitartrate Capsules|Hydrocodone Bitartrate Controlled-Release Capsules
3067028|NCT01081912|Placebo Comparator|Placebo comparator|
3067029|NCT01081951|Experimental|1|200mg, 400mg BID - CAPSULES Olaparib paclitaxel iv and carboplatin iv
3067030|NCT01081951|Active Comparator|2|paclitaxel iv and carboplatin iv
3067031|NCT01082081|Experimental|Paracetamol 1000 mg|Paracetamol 1000 mg
3067032|NCT01082081|Experimental|Paracetamol 500 mg|Paracetamol 500 mg
3067033|NCT01082081|Placebo Comparator|Placebo|Placebo
3067034|NCT01082159|Other|lumbar decompression|Percutaneous lumbar decompression with mild® Device Kit.
3067035|NCT01082211|Experimental|Partial Breast Re-Irradiation|Partial Breast Re-Irradiation (PBrI) 3D-Conformal External Beam 1.5 Gy x 15 (BID) to 45 Gy Total
3067036|NCT01082328|Experimental|Kuvan®|
3067037|NCT01082367|Experimental|TOBI (tobramycin inhaled solution)/Placebo|Participants randomized to TOBI received the investigational treatment for 28 days twice daily (bi)d in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the open label (OL) phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received placebo for 28 days bid (second treatment cycle).
3067038|NCT01082367|Placebo Comparator|Placebo/TOBI|Participants randomized to placebo group received 0.9 % saline (NaCl) for 28 days bid in the first treatment cycle. At the end of first treatment cycle, participants who were positive for P. aeruginosa entered the OL phase of the study and received TOBI for 28 days bid. Participants who were negative for P. aeruginosa at the end of first treatment cycle and agreed to participate in the cross-over treatment period received TOBI for 28 days bid (second treatment cycle).
3067039|NCT01082380|Experimental|1|
3067040|NCT01082575||Major Surgery|Oxygen Monitoring
3067041|NCT01082588|Active Comparator|pravastatin|pravastatin 40mg, once a day, shortly after baseline for 12 consecutive weeks
3067042|NCT01082588|Placebo Comparator|Placebo|placebo, once a day, shortly after baseline for 12 consecutive weeks
3067043|NCT01082614|No Intervention|Standard fluid management|standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
3067044|NCT01082614|Experimental|Goal directed therapy|Intraoperative fluid management guided by stroke volume variation determined by arterial pressure pulse wave contour analysis
3067045|NCT01082640|Placebo Comparator|Placebo|Placebo-matching capsules, orally, twice daily for up to 12 months.
3067046|NCT01082640|Experimental|Febuxostat 30 mg BID|Febuxostat 30 mg, capsules, orally, twice daily (BID) for up to 12 months.
3067047|NCT01082640|Experimental|Febuxostat 40/80 mg QD|Participants initially received febuxostat 40 mg, capsules, once daily (QD) and one placebo-matching capsule QD and remained on this dose for up to 12 months if their serum urate (sUA) was <6.0 mg/dL at the Day 14 visit. Participants whose sUA was ≥6.0 mg/dL at the Day 14 visit received febuxostat 80 mg, capsule, QD, and one placebo-matching capsule QD at the Month 1 visit, and for the remainder of the study.
3067048|NCT01082874|Experimental|Active Clonidine and Active ASA|
3067049|NCT01082874|Experimental|Active Clonidine and Placebo ASA|
3067050|NCT01082874|Experimental|Placebo Clonidine and Active ASA|
3067051|NCT01082874|Placebo Comparator|Placebo Clonidine and Placebo ASA|
3067052|NCT01082939|Experimental|CFAR|CFAR: Cyclophosphamide 250 mg/m^2/day intravenous (IV) Days 3-5, Fludarabine 25 mg/m^2/day IV Days 3-5, Alemtuzumab 30 mg IV Days 1, 3 and 5 over 2-4 hours, repeated every four weeks for a total of 6 planned cycles, and Rituximab Cycle 1 (Week 1): 375 mg/m^2/day IV Day 2 over 4- 6 hours, Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV Day 2 over 4- 6 hours.
3067053|NCT01082952||Asthmatic patients|
3067054|NCT01082952||Non asthmatic patients|
3067055|NCT01082965|Experimental|Treatment|
3067056|NCT01082965|Placebo Comparator|Placebo|
3067057|NCT01083121||Adalimumab|Participants who were prescribed with adalimumab per approved prescribing information of adalimumab in Korea.
3067058|NCT01083160||Non responders to other anti-TNF|Patients with lack of efficacy to infliximab or etanercept treated with adalimumab according to the routine clinical practice of the participating centers. A 40 mg dose was administered every other week for 24 weeks.
3067059|NCT01083173||Participants with HIV-1 infection|Participants treated with Kaletra (lopinavir/ritonavir 200 mg/50 mg and 100 mg/25 mg) tablet
3067060|NCT01083186||Chronic Kidney Disease (CKD), Secondary Hyperpathyroidism|Participants with chronic kidney disease stage 3-5 with secondary hyperparathyroidism, who were prescribed oral paricalcitol according to the approved Summary of Product Characteristics (SmPC)
3067061|NCT01083199|Experimental|CONTINUUMTM|
3067062|NCT01083316|Experimental|Single Arm - Investigational|"Induction:~Bortezomib (Velcade) 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
3067063|NCT01083368|Experimental|Arm 1: Combination of temsirolimus and AVASTIN|Patients receive temsirolimus IV over 30-60 minutes once weekly and bevacizumab IV over 30-90 minutes once every two weeks . Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3067064|NCT01083485|Experimental|Tablets Oxycodone Naloxone (OXN)|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)
3067065|NCT01083485|Active Comparator|Oxycodone|Oxycodone PR 20mg or 10mg (twice a day) BID for 2.5 days (total 5 dosages)
3067066|NCT01083576|Active Comparator|Paromomycin Alone Treatment|Paromomycin Alone Cream (15% paromomycin topical cream): topical application to uncomplicated cutaneous leishmaniasis (CL) lesions once daily for 20 days
3067067|NCT01083576|Active Comparator|WR 279,396|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream): topical application to uncomplicated CL lesions once daily for 20 days
3067068|NCT01083602|Experimental|panobinostat + bortezomib & dexamethasone|panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma
3067069|NCT01083628|Experimental|Group CBT for Depression with MoodText'|Group cognitive behavioral therapy utilizing the BRIGHT manual for depression along with automated text messaging for mood monitoring and reminder of session content
3067070|NCT01083628|Active Comparator|Group CBT for Depression|Standard group cognitive behavioral therapy utilizing the BRIGHT manual for depression
3067071|NCT01083641|Experimental|Estrogen Therapy|Estrogen therapy
3067072|NCT01083654|Active Comparator|Standard Treatment Counseling|Standard Treatment (ST) will consist of 12 weeks of open-label varenicline and smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
3067073|NCT01083654|Experimental|Culturally-Tailored Treatment|The Culturally-Tailored Treatment will consist of 12 weeks of open-label varenicline and culturally-tailored (for American Indians) smoking cessation counseling consisting of four sessions: one in-person pre-quit counseling session during Study Visit 2, counseling during a phone call on the day after the quit day, and two additional in-person counseling sessions at Study Visits 3 and 4 (one week and three weeks after the quit day, respectively).
3067074|NCT01083667|Experimental|Pyrimethamine|Open label. Only one arm will receive the intervention.
3067075|NCT01083680||Participants with Crohn's Disease (CD)|Participants with Crohn's Disease treated with adalimumab (HUMIRA®) in routine clinical practice.
3067076|NCT01083693||Rheumatoid, Psoriatic Arthritis, Ankylosing Spondylitis|Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, patients with unsustainable clinical response to disease modifying antirheumatic drugs and or biological disease modifying antirheumatic drugs.
3067077|NCT01083706|Experimental|Treatment (chemotherapy)|Patients receive azacitidine SC or IV on days 1-7. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3067078|NCT01083732|Experimental|dabigatran etexilate|treatment with dabigatran oral solution as a single dose
3067079|NCT01083758|Other|LEO 80185 (Taclonex® Scalp topical suspension/ Xamiol® gel)|
3067080|NCT01083771|Experimental|Olive Oil|At least 3 tablespoons of olive oil each day
3067081|NCT01083810||therapy-naive|Patients who had not received prior antiretroviral drug therapy
3067082|NCT01083810||pre-treated|Patients that had previously received antiretroviral therapy, but are protease inhibitor naive
3067083|NCT01083810||non-B|Patients infected with non-B subtypes of HIV-1
3067084|NCT01083849||Paricalcitol|Participants with chronic kidney disease and a diagnosis of secondary hyperparathyroidism, received paricalcitol injection or capsules, on an on-label basis in an everyday setting. Participants were observed for 12 months.
3067085|NCT01083901|Experimental|Resistance training with Acetaminophen|Acetaminophen
3067086|NCT01083901|Experimental|Resistance Training with ibuprofen|Ibuprofen
3067087|NCT01083901|Placebo Comparator|placebo|Placebo
3067088|NCT01083979|Experimental|Liposomes|Intravesical instillation of Liposomes in sterile water totally 40 cc at four weekly treatments.
3067089|NCT01084005|Experimental|linagliptin|patients receive linagliptin 5 mg tablets once daily
3067090|NCT01084005|Placebo Comparator|placebo|patients receive placebo tablets matching linagliptin 5 mg once daily
3067091|NCT01084083|Experimental|Group 1|After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
3067092|NCT01084083|Experimental|Group 2|After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.
3132378|NCT03421730|Experimental|CD - VR647 20 breaths, then Pulmicort|20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System followed by 1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty
3067093|NCT01084135|Experimental|Rivastigmine- Liquid form|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
3067094|NCT01084135|Placebo Comparator|Liquid placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
3067095|NCT01084148|Experimental|V0034CR01B|cream
3067096|NCT01084148|Placebo Comparator|V0034 CR 01B vehicle|cream
3067097|NCT01084174|Experimental|Active SLIT/Placebo OIT|These subjects will receive peanut powder given orally and placebo extract given sublingually.
3067098|NCT01084174|Experimental|Active OIT/Placebo SLIT|These subjects will receive peanut extract given sublingually and placebo powder given orally.
3067099|NCT01084239|No Intervention|Standard of care|Subjects in this arm (50% of the total cohort) continued to receive standard non-invasive evaluation of acute chest pain symptoms in the emergency department - mostly comprising of, but not limited to - exercise treadmill test, stress test with imaging and stress echocardiography.
3067100|NCT01084239|Experimental|Cardiac CT|Subjects in this arm (50% of the total cohort) were randomized to receive a cardiac computed tomography scan as part of the initial evaluation of acute chest pain symptoms, upon presentation to the emergency department.
3067101|NCT01084252|Experimental|Phase 1:Isatuximab <=1 mg/kg Q2W|Participants with CD38+ hematological malignancies (HM), received Isatuximab at any one of the dose less than or equal to (<=) 1 milligram per kilogram (mg/kg) (i.e. either 0.0001 mg/kg or 0.001 mg/kg or 0.01 mg/kg or 0.03 mg/kg or 0.1 mg/kg or 0.3 mg/kg or 1 mg/kg) as intravenous (IV) infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal by participant, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067102|NCT01084252|Experimental|Phase 1: Isatuximab 3mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 3 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067103|NCT01084252|Experimental|Phase 1: Isatuximab 5 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 5 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067104|NCT01084252|Experimental|Phase1:Isatuximab (CD38+HM and Standard Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with standard risk multiple myeloma were included this arm and, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067105|NCT01084252|Experimental|Phase 1:Isatuximab (CD38 + HM and High Risk Multiple Myeloma)|Participants with CD38+ HM along with participants with high risk multiple myeloma, received Isatuximab 10 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067106|NCT01084252|Experimental|Phase 1: Isatuximab 10 mg/kg QW|Participants with CD38+ HM, received Isatuximab 10 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067107|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg Q2W|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion on Day 1 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067108|NCT01084252|Experimental|Phase 1: Isatuximab 20 mg/kg QW|Participants with CD38+ HM, received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1 and 8 of each 14-day treatment cycle until occurrence of unacceptable toxicity, disease progression, death, consent withdrawal, investigator's decision, and/or availability of study drug (maximum exposure: 120 weeks).
3067109|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 3 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 3 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable adverse event (AE), disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
3067110|NCT01084252|Experimental|Phase 2 Stage 1a: Isatuximab 10 mg/kg Q2W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion on Day 1 and Day 15 of each 28-day cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
3067111|NCT01084252|Experimental|Phase2 Stage1a:Isatuximab 10mg/kg Q2W; Then Q4W|Participants with multiple Myeloma received Isatuximab 10 mg/kg, as IV infusion Q2W, i.e. on Day 1 and Day 15 of Cycle 1 and 2 (each cycle 28 days), then every 4 week (Q4W), i.e. on Day 1 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 77 weeks).
3067112|NCT01084252|Experimental|Phase 2 Stage 1b: Isatuximab 20mg/kg QW and Then Q2W|Participants with multiple Myeloma received Isatuximab 20 mg/kg, as IV infusion QW, i.e. on Day 1, 8, 15 and 22 of Cycle 1 and 2 (each cycle 28 days), then Q2W, i.e. on Day 1 and Day 15 of each 28-days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination or lost to follow up (maximum exposure: 53 weeks).
3067113|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab Alone|Participants with relapsed or relapsed/refractory multiple myeloma (RRMM), received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision maximum exposure: 97 weeks).
3067114|NCT01084252|Experimental|Phase 2 Stage 2: Isatuximab + Dexamethasone|Participants with relapsed or RRMM, received Isatuximab 20 mg/kg, as IV infusion on Day 1, 8, 15 and Day 22 of Cycle 1 (28 days) and then on Day 1 and 15 of each subsequent 28-day cycles along with dexamethasone: tablet or as IV infusion (40 mg/day for less than [<] 75 years of age; 20 mg/day [greater than or equal to [>=] for 75 years of age) on Days 1, 8, 15 and 22 of each 28 days cycle until unacceptable AE, disease progression, poor compliance to the study protocol, study termination, lost to follow up or investigator's decision (maximum exposure: 97 weeks).
3067115|NCT01084278|Experimental|Healthy|Healthy participants with normal renal function (Creatinine Clearance [CrCl] ≥90 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3067116|NCT01084278|Experimental|Mild renal impairment|Participants with mild renal impairment (estimated Glomerular Filtration Rate [eGFR] 60 to 89 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3067117|NCT01084278|Experimental|Moderate renal impairment|Participants with moderate renal impairment (CrCl/eGFR 30 to 59 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3067118|NCT01084278|Experimental|Severe renal impairment|Participants with severe renal impairment (eGFR 15 to 29 mL/min) received one colchicine 0.6 mg tablet on study day 1.
3067119|NCT01084278|Experimental|End stage renal disease (ESRD)|Participants with end stage renal disease (ESRD) received one colchicine 0.6 mg tablet on study day 1 immediately following dialysis. After a 14-day washout, participants received one colchicine 0.6 mg tablet on Day 15 prior to dialysis.
3067120|NCT01084499|Experimental|Femara First, Then Peratra (Sequence 1)|Participants first receives a branded letrozole (reference - Femara), then a generic letrozole (test - Peratra). Each treatment period is separated by a 5-week washout period.
3067121|NCT01084499|Experimental|Peratra First, Then Femara (Sequence 2)|Participants first receives a generic letrozole (test - Peratra) , then a branded letrozole (reference - Femara). Each treatment period is separated by a 5-week washout period.
3067122|NCT01084538||End stage chronic kidney disease|Secondary hyperparathyroidism defined as intact PTH > 300 pg/mL
3067123|NCT01084551|Experimental|SPM 962 4.5|started at 2.25 mg/day to 4.5 mg/day for 13 weeks
3067124|NCT01084551|Experimental|SPM 962 6.75|started at 2.25 mg/day to 6.75 mg/day for 13 weeks
3067125|NCT01084551|Placebo Comparator|placebo|for 13 weeks
3067126|NCT01084603|Experimental|Oral Nicotine 1|One oral administration of 1 mg nicotine
3067127|NCT01084603|Experimental|Oral Nicotine 2|Two oral administrations of 1 mg nicotine
3067128|NCT01084603|Experimental|Oral Nicotine 4|Four oral administrations of 1 mg nicotine
3067129|NCT01084603|Active Comparator|NiQuitinTM Nicotine Lozenge 4 mg|One 4 mg marketed nicotine lozenge
3067130|NCT01084603|Active Comparator|Nicorette® Gum 4 mg|One marketed Nicorette® nicotine gum 4 mg chewed for 30 minutes
3067131|NCT01084655|Experimental|Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 200 milligram (mg), tablets, orally, twice daily (BID) starting from Day 1 along with docetaxel 75 milligram per square meter (mg/m^2), infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
3067132|NCT01084655|Experimental|Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Day 1 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets , orally, twice daily from Day 8 up to Day 21 of each treatment cycle. Cycle 1 of Phase 1 consisted of a 28-day treatment period and subsequent cycles consisted of 21-day treatment periods.
3067133|NCT01084655|Experimental|Phase 2: Orteronel 400 mg BID + Docetaxel + Prednisone|Orteronel (TAK-700) 400 mg, tablets, orally, twice daily starting from Cycle 1 Day 15 along with docetaxel 75 mg/m^2, infusion, intravenously over 1 hour on Day 1 and prednisone 5 mg, tablets, orally, twice daily from Day 1 up to Day 21 of each 21-day treatment cycle until disease progression or end of treatment (EOT).
3067134|NCT01084668||Adalimumab|Participants with moderate to severe chronic plaque psoriasis treated with adalimumab after biologic disease modifying anti-rheumatic drug (BDMARD) failure
3067135|NCT01084707|Experimental|Oral Nicotine 24-SA|2 Self-administrations of Experimental Nicotine once every hour
3067136|NCT01084707|Experimental|Oral Nicotine 24|2 administrations of Experimental Nicotine by study personnel once every hour
3067137|NCT01084707|Experimental|Oral Nicotine 48|2 administrations of Experimental Nicotine by study personnel once every 30 minutes
3067138|NCT01084707|Active Comparator|NiQuitin™ Lozenge 4 mg|1 NiQuitin™ lozenge, administered by study personnel once every hour
3067139|NCT01084707|Active Comparator|Nicorette® Gum 4 mg|1 piece Nicorette® gum, chewed for 30 minutes once every hour
3067140|NCT01084759|Experimental|Etoposide and Testosterone|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy).On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days.
3067141|NCT01084772|Other|VISIONAIRE Instrumentation|TKA with VISIONAIRE instrumentation
3067142|NCT01084772|Other|Standard Instrumentation|TKA with standard instrumentation
3067143|NCT01085006|Experimental|Tranexamic acid|
3067144|NCT01085006|Placebo Comparator|normal saline infusion|
3067145|NCT01085045|Experimental|Inhaled PT003 (Dose 1)|PT003 MDI Dose 1
3067146|NCT01085045|Experimental|Inhaled PT003 (Dose 2)|PT003 MDI Dose 2
3067147|NCT01085045|Experimental|Inhaled PT005 (Dose 1)|PT005 MDI Dose 1
3067148|NCT01085045|Experimental|Inhaled PT005 (Dose 2)|PT005 MDI Dose 2
3067149|NCT01085045|Placebo Comparator|Inhaled Placebo|Placebo MDI
3067150|NCT01085045|Active Comparator|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Tiotropium Bromide inhalation powder
3067151|NCT01085045|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
3067152|NCT01085045|Experimental|Inhaled PT001 (Dose 1)|PT001 MDI Dose 1
3067153|NCT01085136|Active Comparator|Investigator's choice of chemotherapy|Patients will be treated with investigator's choice of chemotherapy
3067154|NCT01085136|Experimental|BIBW 2992 and Paclitaxel|Patients will be treated with BIBW 2992daily with a medium dose and weekly administration of Paclitaxel at a dose of 80 mg/m2
3067155|NCT01085201|Experimental|Stage 1|12-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3067156|NCT01085201|Experimental|Stage 2|24-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3067157|NCT01085201|Experimental|Stage 3|24-hour infusion to adults with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AND CLOSED TO ACCRUAL.
3067158|NCT01085201|Experimental|Stage 4|24-hour infusion to children with SCD who are having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
3067159|NCT01085201|Experimental|Stage 2B|48-hour infusion to adults with SCD who are not having a pain crisis. THIS STAGE IS COMPLETE AFTER STUDYING 3 PATIENTS BY AGREEMENT FROM THE FDA, IRB, AND DSMB. THIS STAGE IS CLOSED TO ACCRUAL.
3067160|NCT01085214|Experimental|AZD6244 (Selumetinib) Treatment|Participants receive AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3067161|NCT01085318|Active Comparator|Arm 1 MS Patients|Rebif 44 tiw
3067162|NCT01085318|No Intervention|Arm 2 Healthy Control|
3067163|NCT01085331|Experimental|Part 1 or Safety Run-in Part: Pimasertib+FOLFIRI|
3067164|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Pimasertib+FOLFIRI|Planned, not performed
3067165|NCT01085331|Experimental|Part 2 or Phase 2 Randomized part: Placebo+FOLFIRI|Planned, not performed
3067166|NCT01085344|Experimental|Factor VIII|escalating dose Factor VIII
3067167|NCT01085357|Experimental|CyPass Micro-Stent + Cataract Surgery|Subjects receive the CyPass Micro-Stent at the conclusion of their cataract surgery
3067168|NCT01085357|Active Comparator|Cataract Surgery Only|Subjects do not receive the CyPass Micro-Stent at the conclusion of their cataract surgery
3067169|NCT01085500|Experimental|Simulation Curriculum|General surgery residents will undergo a simulation-based educational curriculum (Mastery Learning TEP Curriculum) on TEP hernia repair
3067170|NCT01085500|Other|Current Practice|General surgery residents will undergo current practice of learning how to perform the TEP repair in the operating room under direct supervision of the staff surgeon without any simulation pre-training.
3067171|NCT01085513|Active Comparator|Patients|Patients previously indicated for manometry
3067172|NCT01085513|Active Comparator|Healthy volunteers|Healthy volunteers
3067173|NCT01085591|Experimental|CB-183,315, 125 mg|125 milligrams (mg) CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
3067174|NCT01085591|Experimental|CB-183,315, 250 mg|250 mg CB 183,315 administered orally twice daily, alternating with twice daily oral administration of placebo tablets, for 10 days.
3067175|NCT01085591|Active Comparator|Vancomycin, 125 mg|125 mg vancomycin administered orally four times a day for 10 days.
3067176|NCT01085630|Experimental|Arm I|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3067177|NCT01085630|Active Comparator|Arm II|Patients undergo observation until disease progression.
3067178|NCT01085682|Active Comparator|Lifestyle counseling|
3067179|NCT01085682|Active Comparator|Standard care|
3067180|NCT01085734|Active Comparator|Group 1|Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema
3067181|NCT01085734|Active Comparator|Group 2|Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema
3067182|NCT01085760|Experimental|Vancomycin 125 mg orally 4 times a day|The patients will be randomized into four groups of ten patients: one group will receive low dose vancomycin, one group will receive high dose vancomycin, one group will receive low dose metronidazole and one group will receive high dose metronidazole.
3067183|NCT01085760|Experimental|Vancomycin 250 mg orally 4 times a day|
3067184|NCT01085760|Experimental|Metronidazole 250 mg orally 3 times a day|
3067185|NCT01085760|Experimental|Metronidazole 500 mg orally 3 times a day|
3067186|NCT01085786|Active Comparator|14-day sequential treatment|One in which the first component consists of a proton pump inhibitor and amoxicillin given for 7 days followed by the PPI, clarithromycin and metronidazole for 7 days.
3067187|NCT01085786|Experimental|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
3067188|NCT01085812|Experimental|2|40, 80 or 120 mg/day Levomilnacipran ER capsules, oral administration, once daily dosing.
3067189|NCT01085812|Placebo Comparator|1|Matching placebo capsules, oral administration, once daily dosing.
3067190|NCT01085825|Active Comparator|Manual Vacuum Aspiration|
3067191|NCT01085825|Active Comparator|Electric Vacuum Aspiration|
3067192|NCT01085903|Active Comparator|normal subjects|Normal subjects are persons without stroke who receive baseline, CPS, Post CPS and Follow up interventions.
3067193|NCT01085903|Active Comparator|stroke subjects|Stroke subjects are persons who have had a stroke affecting the right hemisphere and are subject to neglect or dysphagia who receive modafinil, placebo, baseline, CPS, Post CPS and Follow up interventions.
3067194|NCT01085968|Experimental|PD Subjects|PD subjects who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
3067195|NCT01085968|Active Comparator|Control Subjects|Age matched controls who undergo to PC-based neurorehabilitation intervention. This intervention will train research subjects to improve movement initiation in response to visual stimuli.
3067196|NCT01086033||Humira|Participants with rheumatoid arthritis treated with Humira (adalimumab) as prescribed by the rheumatologist in the setting of routine clinical care.
3067197|NCT01086150|Other|Healthy control patients|Subjects 18 to 70 years of age, non-diabetic with no nervous system disease. Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
3067198|NCT01086150|Other|Type I or Type II diabetes with painful diabetic neuropathy|18 to 70 years old with significantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at biaseline and end of study.
3067199|NCT01086150|Other|patients with non-painful diabetic peripheral neuropathy|18-70 years of age with Type I or Type II diabetes with non-painful or insignificantly painful diabetic neuropathy.Lidocaine 5% patch applied to both feet daily, Skin biopsies at baseline, 4 weeks, and end of study.
3067200|NCT01086215||Limb Ischemia|Patients presenting with limb ischemia for treatment
3067201|NCT01086215||Deep Vein Thrombosis|Patients presenting with deep vein thrombosis for treatment
3067202|NCT01086215||Hemodialysis Access|Patients presenting with thrombosed hemodialysis access for treatment
3067203|NCT01086215||Other Thrombotic Conditions|Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
3067204|NCT01086228||XIENCE V / PROMUS stent|Only the patients treated with the XIENCE V / PROMUS stent during the index procedure will be analyzed.
3067205|NCT01086358|Active Comparator|Triptan|Arm 1 subjects began with their prescribed triptan
3067206|NCT01086358|Active Comparator|Treximet 85Mg-500Mg Tablet|Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)
3067207|NCT01086384|Experimental|Fluticasone furoate/GW642444|
3067208|NCT01086384|Experimental|fluticasone furoate|
3067209|NCT01086410|Active Comparator|FF/444 Dose B|Fluticasone furoate/GW642444 Dose B inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3067210|NCT01086410|Active Comparator|FF/444 Dose A|Fluticasone furoate/GW642444 Dose A inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3067211|NCT01086410|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral placebo capsule each day on the last 7 days of the study
3067212|NCT01086410|Active Comparator|Prednisolone|Placebo inhalation powder once daily for 6 weeks' treatment + 1 oral prednisolone 10mg capsule each day on the last 7 days of the study
3067213|NCT01086423|Experimental|INFANRIX-IPV+HIB 1 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right thigh.
3067214|NCT01086423|Experimental|INFANRIX-IPV+HIB 2 GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-IPV+Hib vaccine at 3, 4 and 5 months of age, administered intramuscularly in the upper side of the right thigh.
3067215|NCT01086423|Active Comparator|INFANRIX-HIB+POLIORIX GROUP|Healthy male or female infants, between and including 60 and 90 days of age at the time of the first study visit, received 3 doses of Infanrix™-Hib vaccine co-administered with Poliorix™ vaccine at 2, 3 and 4 months of age, administered intramuscularly in the upper side of the right or left thigh, respectively.
3067216|NCT01086475|Experimental|D-cycloserine|Subjects randomized to D-cycloserine will be administered 50 mg 30 minutes prior to each of ten Social Skills Training Sessions
3067217|NCT01086475|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive placebo pill 30 minutes prior to each of ten Social Skills Training Sessions
3067218|NCT01086540|Experimental|Rituximab+PAH SOC|"Rituximab (1000 mg) will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
3067219|NCT01086540|Placebo Comparator|Placebo + PAH SOC|"Placebo will be administered as 2 intravenous infusions given 2 weeks apart.~Concurrent stable-dose Pulmonary Arterial Hypertension (PAH) medical therapy will be continued/managed as per standard of care (PAH SOC)."
3067220|NCT01086605|Experimental|Arm I|Patients receive pixantrone dimaleate IV over 1 hour on day 1. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3067221|NCT01086605|Experimental|Arm II|Patients receive pixantrone dimaleate IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3067222|NCT01086761|Experimental|MP0112 (0.04 mg)|Single 0.04 mg intravitreal injection of MP0112 in the study eye.
3067223|NCT01086761|Experimental|MP0112 (0.15 mg)|Single 0.15 mg intravitreal injection of MP0112 in the study eye.
3067224|NCT01086761|Experimental|MP0112 (0.4 mg)|Single 0.4 mg intravitreal injection of MP0112 in the study eye.
3067225|NCT01086761|Experimental|MP0112 (1.0 mg)|Single 1.0 mg intravitreal injection of MP0112 in the study eye.
3067226|NCT01086761|Experimental|MP0112 (2.0 mg)|Single 2.0 mg intravitreal injection of MP0112 in the study eye.
3067227|NCT01086761|Experimental|MP0112 (3.6 mg)|Single 3.6 mg intravitreal injection of MP0112 in the study eye.
3067228|NCT01086852|Experimental|FACTOR X|Human Coagulation Factor X
3067229|NCT01086969|Experimental|Study Group|Participants in three age cohorts - Children: 2 - 11 years of age; Adolescents: 12 - 17 years of age, and Adults: 18 - 55 years of age will be enrolled.
3067232|NCT01087489|Experimental|4% lidocaine|Eyes were anesthetized with 0.5% proparacaine and then with three cotton swabs soaked in 4% liquid lidocaine applied with moderate pressure to the site of the injection inferotemporally to the limbus. Each participant was assigned to have this prep during one of the consecutive study visits if unilateral or in one eye if patient requires bilateral injections given the same day
3067233|NCT01087489|Experimental|3.5% ophthalmic lidocaine gel|Eye was anesthetized with 0.5% proparacaine and then with 3.5% ophthalmic lidocaine gel applied to the surface of the eye. Each participant was randomly assigned to receive this preparation during one of two consecutive intravitreal injection (if unilateral disease) or in one eye if requiring bilateral injections given on the same day.
3067234|NCT01087502|Experimental|Linagliptin|52 weeks treatment
3067235|NCT01087502|Placebo Comparator|Placebo|First 12 weeks of treatment
3067236|NCT01087502|Active Comparator|Glimepiride|Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
3067237|NCT01087528|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3067238|NCT01087541|No Intervention|Control|Usual clinical health care
3067239|NCT01087541|Experimental|Intervention|Behavioural program of education for health professionals. Standardized program of 6 hours for health professionals ( doctors and nurses )
3067240|NCT01087723|Experimental|Bivalirudin|Given immediately upon enrollment as an intravenous (IV) bolus of 0.75 mg/kilogram (mg/kg), followed immediately by an infusion of 1.75 mg/kg/hour (mg/kg/h). This infusion was to be run continuously until completion of PCI, at which time the infusion was reduced to 0.25 mg/kg/h for at least 4 hours. An optional PCI-dose infusion of 1.75 mg/kg/h was also permitted for up to 4 hours at the discretion of the operator.
3067241|NCT01087723|Active Comparator|Standard of Care: Heparins with Optional GPI|"Standard-of-care anti-thrombotic therapy as outlined in the European Society of Cardiology Dosing Guidelines for Management of STE-ACS, not including bivalirudin: UFH (100 international units/kg [IU/kg] without GPI and 60 IU/kg with GPI). Any of the following approved GPIs were used either as a routine strategy or as a bail out: eptifibatide (two 180-micrograms/kilogram [μg/kg] IV boluses with a 10-minute [min] interval followed by an infusion of 2.0 μg/kg/min for 72-96 hours); tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18-24 hours); or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours [maximum dose of 10 μg/min]).~For this study, the control consisted of treatment with UFH or low molecular weight heparin (LMWH) with or without GPI and is referred to as heparins with optional GPI."
3067242|NCT01087736|Experimental|Topiramate|Participants will be randomly assigned to either the topiramate arm or placebo arm. Neither the participant nor the researchers will know which arm the participant is in. Participants in the topiramate arm will be ingesting daily doses of topiramate that will gradually increase to a maximum, and then taper off.
3067243|NCT01087736|Placebo Comparator|Placebo|The Drug Product Services Laboratory at UCSF will purchase and supply our lab with USP or NF grade topiramate study capsules and matching placebo capsules. Randomization will be done by a consulting biostatistician, who will be the only one to know which participants are assigned to placebo. Dosing will follow the same procedures as with topiramate in that arm of the study. If adverse events occur, there will be a procedure in place for unblinding only that participant.
3067244|NCT01087762|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
3067245|NCT01087762|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
3067246|NCT01087762|Placebo Comparator|Placebo|"Matching Placebo to CZP injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16.~After 24 weeks, all subjects were randomized to active treatment with CZP 200 mg Q2W or CZP 400 mg Q4W."
3067247|NCT01087762|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067248|NCT01087762|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067249|NCT01087762|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067250|NCT01087762|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067251|NCT01087775|Experimental|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
3067252|NCT01087788|Experimental|CZP 200 mg Q2W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.~At every visit, subjects received one injection of 200 mg CZP and one injection of Placebo to maintain the study blind."
3067253|NCT01087788|Experimental|CZP 400 mg Q4W|"Subjects received Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 8 onwards.~Subjects received 2 injections of Placebo every 4 weeks in between the 2 injections of 200 mg CZP to maintain the study blind."
3067254|NCT01087788|Placebo Comparator|Placebo|"Matching Placebo to Certolizumab Pegol (CZP) injections from Week 0 to Week 24. Placebo subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group and were re-randomized to either CZP 200 mg Q2W or CZP 400 mg Q4W arm on Week 16.~After 24 weeks, all subjects were re-randomized to active treatment with CZP 200 mg every two weeks (Q2W) or CZP 400 mg every four weeks (Q4W)."
3067255|NCT01087788|Other|Placebo to CZP 200 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 22 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3132379|NCT03421730|Experimental|DA - Pulmicort, then VR647 5 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 5 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3067256|NCT01087788|Other|Placebo to CZP 400 mg escape on Week 16|Matching Placebo to CZP injections from Week 0 to Week 16. Subjects who did not achieve certain predefined response criteria at both Weeks 14 and 16 left the Placebo group on Week 16 and were treated with three loading doses of CZP 400 mg sc on Weeks 16, 18 and 20, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 24 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067257|NCT01087788|Other|Placebo to CZP 200 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 30 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067258|NCT01087788|Other|Placebo to CZP 400 mg on Week 24|Matching Placebo to CZP injections from Week 0 to Week 24. Three loading doses of CZP 400 mg sc were given on Weeks 24, 26 and 28, followed by 400 mg CZP sc every 4 weeks (Q4W) from Week 32 onwards. Additionally, Placebo injections were administered as appropriate in order to maintain the study blind.
3067259|NCT01087801|Active Comparator|ChiRhoStim|Human Secretin for Injection
3067260|NCT01087801|Placebo Comparator|Placebo|Saline for Injection
3067261|NCT01087814|Active Comparator|efavirenz|
3067262|NCT01087814|Experimental|over-encapsulated efavirenz|
3067263|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
3067264|NCT01087905|Active Comparator|2 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks"
3067265|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3067266|NCT01087905|Active Comparator|2 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~2 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks~2 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3067267|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
3067268|NCT01087905|Active Comparator|6 Weeks of Nicotine Patch Only plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks"
3067269|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum, No CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3067270|NCT01087905|Active Comparator|6 Wks Nicotine Patch+Nic Gum plus CMAC|"Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling~6 Weeks of Nicotine patch dosed as follows:~If > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks~If < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks~6 Weeks of Nicotine gum dosed as follows:~If < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
3067271|NCT01087918|Experimental|First RAGT, then strength training|16 sessions of 45 minutes of robot-assisted gait training 4 times a week in first intervention period and 16 sessions of 45 minutes of strength training 4 times a week in second intervention period.
3067272|NCT01087918|Experimental|First strength training, then RAGT|16 sessions of 45 minutes of strength training 4 times a week in first intervention period and 16 sessions of 45 minutes of robot-assisted gait training 4 times a week in second intervention period.
3067273|NCT01087931|Active Comparator|Bupivacaine|This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site.
3067274|NCT01087931|Placebo Comparator|Saline|This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.
3067275|NCT01087944|Experimental|1|"Peginterferon via auto-injector device.~All participants will receive Peginterferon in a cross-over design."
3067276|NCT01087944|Active Comparator|2|"Peginterferon via pre-filled syringe.~All participants will receive Peginterferon in a cross-over design."
3067277|NCT01087957|Active Comparator|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
3067278|NCT01087957|Active Comparator|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
3067279|NCT01087970|Experimental|Triplet Combination Therapy|"Cycle 1:~Week 1 - Cetuximab 400 milligrams/square meter (mg/m²) on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin area under curve (AUC) 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Cycle 2-6:~Week 1 - Cetuximab 250 mg/m² on Day 1; Pemetrexed 500 mg/m² on Day 1; Carboplatin AUC 5 on Day 1 or Cisplatin 75 mg/m² on Day 1~Week 2 - Cetuximab 250 mg/m² on Day 1~Week 3 - Cetuximab 250 mg/m² on Day 1~Following Cycle 6, Cetuximab Monotherapy: 250 mg/m² intravenously weekly on Day 1"
3067280|NCT01087996|Experimental|Auto-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million autologous human mesenchymal stem cells.
3067281|NCT01087996|Experimental|Allo-hMSCs|Participants will receive an injection of 20 million, 100 million or 200 million allogeneic human mesenchymal stem cells.
3067282|NCT01088048|Experimental|Idelalisib + Rituximab|"Participants with chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (iNHL) will receive treatments as follows:~Cohort 1a: Idelalisib (IDELA) 100 mg orally twice daily (BID) on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 intravenously (IV) on Days 1, 8, 15 & 22, Cycles 1 & 2~Cohort 2a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 3e: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2~Cohort 4a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle, starting Cycle 2 Day 1 with the 5th dose of rituximab + rituximab 375 mg/m^2 IV on Days 1, 8, 15, & 22, Cycles 1 & 2"
3067283|NCT01088048|Experimental|Idelalisib + Rituximab + Bendamustine|"Participants with CLL, iNHL and mantle cell lymphoma (MCL) will receive treatments as follows:~Cohort 3a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle from Cycles 1 - 6~Cohort 5c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
3067284|NCT01088048|Experimental|Idelalisib + Bendamustine|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 1b: IDELA 100 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 2b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3f: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 3g: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bendamustine 70 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6~Cohort 4b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle starting Cycle 2, Day 3 (after the Cycle 2 bendamustine dosing) + bendamustine 90 mg/m^2 IV on Days 1 & 2 of each 28-day cycle, Cycles 1 - 6"
3067285|NCT01088048|Experimental|Idelalisib + Ofatumumab|"Participants with CLL will receive treatments as follows:~Cohort 3c: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + ofatumumab 12 doses (300 mg (Day 1 or Day 2, Dose 1), followed 1 week later by 1,000 mg weekly for 7 doses (Doses 2 - 8), followed 5 weeks later by 1,000 mg every 4 weeks for 4 doses (Doses 9 - 12))"
3067286|NCT01088048|Experimental|Idelalisib + Fludarabine|"Participants with CLL will receive treatments as follows:~Cohort 3d: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + fludarabine 40 mg/m^2 orally on Days 1 - 5 of each 28-day cycle, Cycles 1 - 6"
3067287|NCT01088048|Experimental|Idelalisib + Everolimus|"Participants with MCL will receive treatments as follows:~Cohort 5a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + everolimus 10 mg orally once daily on Days 1 - 28 of each 28-day cycle"
3067288|NCT01088048|Experimental|Idelalisib + Bortezomib|"Participants with MCL will receive treatments as follows:~Cohort 5b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 8 & 15 of each 28-day cycle"
3067289|NCT01088048|Experimental|Idelalisib + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6a: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
3067290|NCT01088048|Experimental|Idelalisib + Rituximab + Chlorambucil|"Participants with CLL will receive treatments as follows:~Cohort 6b: IDELA 150 mg orally BID on Days 1 - 28 of each 28-day cycle + rituximab 375 mg/m^2 IV on Day 1 of each 28-day cycle, Cycles 1 - 6 + chlorambucil 10 mg/m^2 orally once daily for 7 days every 28 days, Cycles 1 - 12"
3067291|NCT01088048|Experimental|Idelalisib + Rituximab + Lenalidomide|"Participants with CLL and iNHL will receive treatments as follows:~Cohort 7a: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 5 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7b: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 10 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles~Cohort 7c: IDELA 150 mg orally BID on Days 1 - 35 of Cycle 1 (35 days) & Days 1 - 28 of all subsequent 28-day cycles + rituximab 375 mg/m^2 IV on Days 1 & 8 of Cycle 1 & Day 1 of Cycles 2 - 6 + lenalidomide 20 mg orally once daily on Days 8 - 28 of Cycle 1 (35 days) & Days 1 - 21 of next five 28-day cycles"
3067292|NCT01088243|Experimental|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
3067293|NCT01088243|Placebo Comparator|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
3067294|NCT01088295|Experimental|Telmisartan|Telmisartan 40mg po daily for 24 weeks
3067295|NCT01088399||Somatropin replacement treatment|Adult participants with growth hormone deficiency receiving somatropin replacement treatment.
3067296|NCT01088399||No treatment|Adult participants with growth hormone deficiency receiving no somatropin replacement treatment.
3067297|NCT01088412||Treated|Participants treated with somatropin for improvement of growth
3067298|NCT01088412||Untreated|Untreated participants with presence or history of neoplastic disease evaluated for endocrine or growth disorder or with any SHOX deficiency related disorder
3067299|NCT01088438|Experimental|Contextualization workshop|A four-hour course on contextualization.
3067300|NCT01088438|No Intervention|Control|No intervention
3067301|NCT01088464|Experimental|Cohort 1|
3067302|NCT01088464|Experimental|Cohort 2|
3067303|NCT01088464|Experimental|Cohort 3|
3067304|NCT01088503||ADP receptor inhibitor treatment|Participants admitted for non ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) and treated with an ADP receptor inhibitor during the index hospitalization.
3067305|NCT01088529|Experimental|AA+LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) and 1,000 mg abiraterone acetate (AA) plus 5 mg of prednisone daily for 3 months prior to radical prostatectomy.
3067306|NCT01088529|Experimental|LHRHa|Participants received luteinizing hormone-releasing hormone analog (LHRHa) for a maximum of 4 months (monthly injection or injection every 3 months) prior to radical prostatectomy.
3067307|NCT01088672|Other|Acute Ischemic Stroke|Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
3067308|NCT01088711|Experimental|Healthy Omarigliptin|Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
3067309|NCT01088711|Placebo Comparator|Healthy Placebo|Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
3067310|NCT01088711|Experimental|T2D Omarigliptin|Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
3067311|NCT01088711|Placebo Comparator|T2D Placebo|Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).
3468803|NCT03892395|Active Comparator|Treatment group|"Supplementation for 2 years with one of the following treatments in capsule form:~Treatment group will receive: B vitamins + vitamin D, a daily capsule containing 200 µg/day folic acid, 10 µg/day vitamin B12, 10 mg/day vitamin B6 and 5 mg/day riboflavin, and 10 µg/day vitamin D combined"
3067313|NCT01088984|Experimental|Bendamustine|Bendamustine 90 or 120 mg/m^2 administered as an intravenous (IV) infusion over 60 minutes on Days 1 and 2 of each 21-day cycle (maximum of 12 total cycles), with delays up to 2 weeks for neutrophil and platelet count recovery, for up to a 35-day cycle.
3067314|NCT01088997|Experimental|High Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
3067315|NCT01088997|Experimental|Low Dose Milrinone|Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
3067316|NCT01089023|Experimental|1|
3067317|NCT01089062|Other|Treatment A, then Treatment B, then Treatment C|"The second dose in each treatment group (A,B,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
3067318|NCT01089062|Other|Treatment A, then Treatment C, then Treatment B|"The second dose in each treatment group (A,C,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
3067319|NCT01089062|Other|Treatment B, then Treatment A, then Treatment C|"The second dose in each treatment group (B,A,C) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 4."
3067320|NCT01089062|Other|Treatment B, then Treatment C, then Treatment A|"The second dose in each treatment group (B,C,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 2.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
3067321|NCT01089062|Other|Treatment C, then Treatment A, then Treatment B|"The second dose in each treatment group (C,A,B) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 3.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 4."
3067322|NCT01089062|Other|Treatment C, then Treatment B, then Treatment A|"The second dose in each treatment group (C,B,A) was given two hours from the time of the first dose. There were 7-11 days between each treatment visit.~Treatment C = inhaler placebo and IV placebo for first dose, inhaler placebo for second dose at Visit 2.~Treatment B = MAP0004 1.0mg and IV placebo for first dose, MAP0004 1.0mg for second dose at Visit 3.~Treatment A = inhaler placebo and IV DHE for first dose, inhaler placebo for second dose at Visit 4."
3132380|NCT03421730|Experimental|DB - Pulmicort, then VR647 10 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 10 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3067323|NCT01089127|Experimental|Indacaterol 18.75 μg|Patients inhaled indacaterol 18.75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067324|NCT01089127|Experimental|Indacaterol 37.5 μg|Patients inhaled indacaterol 37.5 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067325|NCT01089127|Experimental|Indacaterol 75 μg|Patients inhaled indacaterol 75 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067326|NCT01089127|Experimental|Indacaterol 150 μg|Patients inhaled indacaterol 150 μg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067327|NCT01089127|Active Comparator|Salmeterol 50 μg|Patients inhaled salmeterol 50 μg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067328|NCT01089127|Placebo Comparator|Placebo|Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.
3067329|NCT01089231|Placebo Comparator|Placebo - healthy subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
3067330|NCT01089231|Placebo Comparator|Placebo - hyperlipedemic subjects|Dietary Supplement: corn oil capsules (6 per day) about 3 months
3067331|NCT01089231|Experimental|Fish oil - hyperlipidemic subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
3067332|NCT01089231|Experimental|Fish oil - healthy subjects|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months.
3067333|NCT01089361|Placebo Comparator|Normal saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
3067334|NCT01089361|Experimental|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
3067335|NCT01089413||Cohort|
3067336|NCT01089504|Active Comparator|Phenobarbital|Phenobarbital, 4-5 mg/kg/day, for 4 months
3067337|NCT01089504|Placebo Comparator|Placebo|Placebo in a volume equivalent to active drug for 4 months
3067338|NCT01089517|Active Comparator|Lucentis|
3067339|NCT01089517|Experimental|E10030 low dose plus Lucentis|
3067340|NCT01089517|Experimental|E10030 high dose plus Lucentis|
3067341|NCT01089543|Experimental|Rabeprazole 10 mg|
3067342|NCT01089543|Experimental|Rabeprazole 20 mg|
3067343|NCT01089543|Experimental|Rabeprazole 40 mg|
3067344|NCT01089543|Placebo Comparator|Placebo|
3067345|NCT01089556|Experimental|Duloxetine|"Initial Treatment:~Duloxetine 30 milligram (mg) daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 90 mg (60 mg in the morning, 30 mg in the evening) daily for 1 week~Duloxetine 120 mg (60 mg twice daily) daily for 7 weeks"
3067346|NCT01089556|Experimental|Pregabalin+Duloxetine|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 300 mg (150 mg twice daily) daily for 8 weeks~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks"
3067347|NCT01089556|Experimental|Pregabalin|"Initial Treatment:~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks~Intensive Treatment:~Pregabalin 450 mg (300 mg in the morning, 150 mg in the evening) daily for 1 week~Pregabalin 600 mg (300 mg twice daily) daily for 7 weeks"
3067348|NCT01089556|Experimental|Duloxetine + Pregabalin|"Initial Treatment:~Duloxetine 30 mg daily for 1 week~Duloxetine 60 mg daily for 7 weeks~Intensive Treatment:~Duloxetine 60 mg daily for 8 weeks~Pregabalin 150 mg daily for 1 week~Pregabalin 300 mg (150 mg twice daily) daily for 7 weeks"
3067349|NCT01089569|Active Comparator|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
3067350|NCT01089569|Active Comparator|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
3067351|NCT01089569|Active Comparator|Exenatide + Insulin Glargine|"Exenatide: 5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study~+ Insulin Glargine: 0.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results"
3067352|NCT01089582||AD patients|
3067353|NCT01089595|Active Comparator|Nilotinib|Nilotinib 400 mg po bid
3067354|NCT01089595|Active Comparator|Nilotinib + Imatinib|Nilotinib 400 mg BID with Imatinib 400 mg daily
3067355|NCT01089608|Placebo Comparator|Unifluid|Eye drops in Single Dose Unit
3067356|NCT01089608|Experimental|Azithromycin|Eye drops Single dose unit
3067357|NCT01089647|Active Comparator|budesonide and montelukast|treatment arm
3067358|NCT01089647|Placebo Comparator|placebo|sugar pill, salt water nasal spray
3067359|NCT01089725|Placebo Comparator|Placebo|
3067360|NCT01089725|Experimental|2.5 mg tanezumab SC and placebo IV|
3067361|NCT01089725|Experimental|5 mg tanezumab SC and placebo IV|
3067362|NCT01089725|Experimental|10 mg tanezumab SC and placebo IV|
3067363|NCT01089725|Experimental|10 mg tanezumab IV|
3067364|NCT01089751|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
3067365|NCT01089751|Placebo Comparator|Placebo|Placebo once daily on an empty stomach for 14 weeks.
3067366|NCT01090011|Experimental|combination arm|patients to receive medium BIBW 2992 once daily plus biweekly cetuximab infusion at low, median and high dose level
3067367|NCT01090011|Experimental|sequential arm|patients to receive BIBW 2992 once daily, upon progression add biweekly cetuximab
3067368|NCT01090050|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Sumatriptan/Naproxen Sodium will treat daily with 1 tablet Sumatriptan 85mg / Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Sumatriptan/Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue.
3067369|NCT01090050|Active Comparator|Naproxen Sodium|In Treatment Period Month 1: Subjects randomized to Naproxen Sodium will treat daily with 1 tablet Naproxen Sodium 500mg per day x 30 days. Subjects will be provided with 30 tablets of Naproxen Sodium for rescue. In Treatment Period Months 2 and 3: Subjects randomized to Naproxen Sodium will be provided with 14 tablets of Naproxen Sodium to treat on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue.
3067370|NCT01090076|Experimental|Abound|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)
3067371|NCT01090076|Placebo Comparator|Placebo|Placebo comparator that contains none of the active ingredients
3067372|NCT01090102|Experimental|Mesalamine|
3067373|NCT01090102|Placebo Comparator|Placebo|
3067374|NCT01090180|Experimental|Arm 1: Dexamethasone|Dexamethasone (oral)
3067375|NCT01090180|Placebo Comparator|Arm 2: Placebo|Placebo (inactive)
3067376|NCT01090310|Experimental|AIN457 300mg every 2 weeks|AIN457 300 mg subcutaneous (s.c.) weekly for 3 weeks followed by AIN457 300 mg s.c. every 2 weeks
3067377|NCT01090310|Experimental|AIN457 300 mg every 4 weeks|AIN457 300 mg s.c. at baseline for Week 2 followed by AIN457 300 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
3067378|NCT01090310|Experimental|AIN457 150 mg every 4 weeks|AIN457 150 mg s.c. and placebo s.c. at Baseline and Week 2 followed by AIN457 150 mg s.c. monthly, alternating with placebo s.c. at Weeks 1 and 4 and then monthly
3067379|NCT01090310|Placebo Comparator|Placebo|Placebo s.c. every 2 weeks
3067380|NCT01090323|Experimental|ICL670|
3067381|NCT01090414|Experimental|Idelalisib|Participants will receive up to 350 mg of idelalisib twice daily until disease progression or unacceptable toxicity.
3067382|NCT01090427|Experimental|Ustekinumab Half-standard Dosage|Participants will receive ustekinumab at half the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
3067383|NCT01090427|Experimental|Ustekinumab Standard Dosage|Participants will receive ustekinumab at the standard dosage at Weeks 0, 4, 16, 28, and 40. In addition, all participants will receive a single SC dose of placebo at Week 12.
3067384|NCT01090427|Experimental|Placebo|Participants will receive matching placebo at Week 0 and 4, followed by ustekinumab at half-standard or standard dosage at Weeks 12, 16, 28, and 40.
3067385|NCT01090453|Experimental|GSK2202083A Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of GSK2202083A vaccine, co-administered with Prevenar 13® at 2, 4 and 12 months of age. The GSK2202083A and Prevenar 13® vaccines were administered intramuscularly into the right and left sides of the thigh, respectively. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
3067386|NCT01090453|Active Comparator|Infanrix hexa Group|Subjects aged between and including 8 and 12 weeks of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® and Menjugate® at 2, 4 and 12 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the right and upper left sides of the thigh, respectively and the Menjugate® vaccine was administered intramuscularly in the lower left thigh. An optional 2-dose vaccination with Rotarix™ was offered to the study participants at 2 and 4 months of age.
3067387|NCT01090479|No Intervention|Control|This group will perform an ordinary shower the night prior and the morning of their scheduled surgery date.
3067388|NCT01090479|Experimental|2% Chlorhexidine cloth|This group will use the 2% chlorhexidine wipes the night prior as well as the morning of their surgery date.
3067389|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 1)|
3067390|NCT01090492|Experimental|Secondary Raynaud 4 mg dose (period 2)|
3067391|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 1)|
3067392|NCT01090492|Experimental|Secondary Raynaud 20 mg dose (period 2)|
3067393|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 1)|
3067394|NCT01090492|Experimental|Primary Raynaud 4 mg dose (period 2)|
3067395|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 1)|
3067396|NCT01090492|Experimental|Primary Raynaud 20 mg dose (period 2)|
3067397|NCT01090739|Experimental|TOPAS|TOPAS Treatment for Fecal Incontinence
3067398|NCT01090752|Placebo Comparator|Pioglitazone|placebo-controlled, randomized, cross-over study
3067399|NCT01090752|Placebo Comparator|Metformine|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
3067400|NCT01090765|Experimental|TRC105 1 mg/kg every 2 weeks|Intravenous infusion at 1 mg/kg every 2 weeks
3067401|NCT01090765|Experimental|TRC105 3 mg/kg every 2 weeks|Intravenous infusion at 3 mg/kg every 2 weeks
3067402|NCT01090765|Experimental|TRC105 10 mg/kg every 2 weeks|Intravenous infusion at 10 mg/kg every 2 weeks
3067403|NCT01090765|Experimental|TRC105 10 mg/kg weekly|Intravenous infusion at 10 mg/kg weekly
3067404|NCT01090765|Experimental|TRC105 15 mg/kg every 2 weeks|Intravenous infusion at 15 mg/kg every 2 weeks
3067405|NCT01090765|Experimental|TRC105 20 mg/kg every 2 weeks|Intravenous infusion at 20 mg/kg every 2 weeks
3067406|NCT01090921|Experimental|Single-Arm|Bortezomib is administered at a dose of 1.6mg/m2 IV push over 3 to 5 seconds. Treatment is administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle. Dexamethasone is also administered at a dose of 40mg daily on day of and day after each dose of Bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone. The study duration for a given subject will be approximately 30 weeks.
3067407|NCT01090973|Experimental|Oral drug treatment|LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
3067408|NCT01091103|Experimental|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
3067409|NCT01091116|Experimental|Double dose MEN16132 0.125 mg|Intra-articular administration of two 0.125 mg doses of MEN16132 at 2-week interval.
3067410|NCT01091116|Experimental|Double dose MEN16132 0.25 mg|Intra-articular administration of two 0.25 mg doses of MEN16132 at 2-week interval.
3067411|NCT01091116|Experimental|Double dose MEN16132 0.5 mg|Intra-articular administration of two 0.5 mg doses of MEN16132 at 2-week interval.
3067412|NCT01091116|Experimental|Single dose MEN16132 0.5 mg|Intra-articular administration of one 0.5 mg dose of MEN16132 followed by one intra-articular injection of placebo at 2-week interval.
3067413|NCT01091116|Placebo Comparator|Placebo|Intra-articular administration of two doses of Placebo at 2-week interval.
3067414|NCT01091155|Experimental|ColonRing TM|
3067415|NCT01091168|Experimental|arm A: Vinflunine|Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m² on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.
3067416|NCT01091168|Active Comparator|arm B: Alkylating agent of physician choice|Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.
3067417|NCT01091246|Experimental|Q/LAIV (MEDI3250)|Q/LAIV (quadrivalent live attenuated influenza vaccine) (MEDI3250) was supplied in the Becton Dickinson Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 fluorescent focus units (FFU) of each of 4 temperature sensitive, cold-adapted, attenuated, 6:2 resassortant influenza strains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], B/Victoria [B/Malaysia/2506/2004], and B/Yamagata [B/Florida/4/2006]).
3067418|NCT01091246|Experimental|FluMist/B/Yamagata|FluMist/B/Yamagata (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza strains (A/H1N1 [South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Yamagata [B/Florida/4/2006])
3067419|NCT01091246|Experimental|FluMist/B/Victoria|FluMist/B/Victoria (trivalent live attenuated influenza vaccine) was supplied in the BD Accuspray device that delivers a 0.2 mL total volume intranasal dose divided into each nostril (ie, administered as 0.1 mL per nostril). Each 0.2 mL dose contained 10^7.0 ± 0.5 FFU of each of 3 temperature sensitive, cold-adapted, attenuated, 6:2 reassortant influenza stains (A/H1N1 [A/South Dakota/6/2007], A/H3N2 [A/Uruguay/716/2007], and B/Victoria [B/Malaysia/2506/2004]).
3067420|NCT01091259|Experimental|Irinotecan with Bevacizumab|Irinotecan is administered every 3 weeks at a dose of 175 mg/m^2, bevacizumab is administered at 15 mg/kg every 3 weeks. Irinotecan is administered before bevacizumab. Patients will continue on therapy until evidence of disease progression, or until development of adverse events that prevent further treatment, or if the patients wishes to discontinue therapy.
3067421|NCT01091363|Experimental|deep cultural arm|deep cultural therapy
3067422|NCT01091363|Active Comparator|standard arm|brief cessation counseling
3067423|NCT01091428|Experimental|Alisertib (Phase 1 - Ovarian cancer)|Participants with ovarian cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
3067424|NCT01091428|Experimental|Alisertib (Phase 1 - Breast cancer)|Participants with breast cancer received alisertib (MLN8237) 10, 20, 30 or 40 mg, orally, twice daily (BID) on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 or 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 1 (Up to 37 cycles).
3067425|NCT01091428|Experimental|Alisertib 40 mg BID+Paclitaxel 60 mg/m^2 (Phase 2)|Alisertib 40 mg, orally, BID on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel 60 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
3067426|NCT01091428|Experimental|Paclitaxel 80 mg/m^2 (Phase 2)|Paclitaxel 80 mg/m^2, intravenous infusion, weekly (Days 1, 8, 15) in 28-day cycles in Phase 2 (Up to 28 cycles).
3067427|NCT01091454|Experimental|Treatment (cisplatin and brostallicin)|Patients receive cisplatin IV over 2 hours on day 1 and brostallicin IV over 10 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3067428|NCT01091519||Toviaz(fesoterodine) plus educational materials|
3067429|NCT01091519||Toviaz(fesoterodine) alone|Toviaz(fesoterodine) without additional educational materials
3067430|NCT01091662|Experimental|eslicarbazepine acetate 1600 mg|Subjects randomized to 1600 mg QD of eslicarbazepine acetate will titrate from 600 mg QD(Day 0) to 1200 mg once a day(Week 2) to 1600 mg QD (Weeks 3-18) and may taper down from 1600 mg to 800 mg QD 3 days after the Week 18 visit.
3132381|NCT03421730|Experimental|DC - Pulmicort, then VR647 20 breaths|1 mg/2 mL Pulmicort Respules delivered by the conventional jet nebulizer nebulized to empty followed by 20 breaths of the VR647 Inhalation Suspension 1 mg/2 mL delivered by the VR647 Inhalation System
3067431|NCT01091662|Experimental|eslicarbazepine acetate 1200 mg|"Subjects randomized to 1200 mg QD eslicarbazepine acetate will titrate from 400 mg QD (Day0) to 800 mg QDweek2) to 1200 mg QD(weeks 3-18) and may taper down from 1200 mg to 600 mg QD 3 days after the Week 18 visit.~Subjects may continue in an open-label extension study with a starting dose of 1200 mg QD, or taper off their previous antiepileptic drugs during weeks 2-8."
3067432|NCT01091675|Experimental|etoricoxib|All the patients who fulfil the eligibility criteria will start a 4-week open label treatment period to evaluate the response to treatment with etoricoxib 90 mg.
3067433|NCT01091948|Active Comparator|Fiberoptic Intubation|Subjects will be intubated with the Fiberoptic laryngoscope.
3067434|NCT01091948|Active Comparator|GlideScope® Video Laryngoscope|Subjects will be intubated with the GlideScope® Video Laryngoscope.
3067435|NCT01091974|Experimental|1 - CBT-I + placebo|CBT-I and placebo
3067436|NCT01091974|Experimental|2 - CBT-I + Armodafinil|CBT-I + Armodafinil
3067437|NCT01091974|Placebo Comparator|3 - Placebo only|Placebo only
3067438|NCT01091974|Experimental|4 - Armodafinil only|Armodafinil only
3067439|NCT01092182|Experimental|Group A - Burkitt lymphoma Low Risk Arm|Burkitt lymphoma Low Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
3067440|NCT01092182|Experimental|Group B - Burkitt lymphoma High Risk Arm|Burkitt lymphoma High Risk Arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
3067441|NCT01092182|Experimental|Group C - DLBCL high risk arm|Diffuse large B-cell lymphoma (DLBCL) high risk arm Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
3067442|NCT01092195|Active Comparator|Cohort 1|Female subjects post stem cell transplant on no systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
3067443|NCT01092195|Active Comparator|Cohort 2|Female subjects post stem cell transplant with chronic GVHD requiring systemic immunosuppression. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
3067444|NCT01092195|Active Comparator|Cohort 3|Healthy normal female volunteers. Gardasil® will be administered using the FDA approved regimen of 3 separate 0.5ml intramuscular injections at 0, 2, and 6 months.
3067445|NCT01092338|Active Comparator|4000IU|Subjects in this arm take a daily dose of 4000IU of Vitamin D3
3067446|NCT01092338|Active Comparator|7000IU|Subjects in this arm of the study take a daily dose of 7000IU of Vitamin D3
3067447|NCT01092364|Experimental|Cell phone intervention|Behavioral lifestyle intervention for weight loss, delivered by cell phone.
3067448|NCT01092364|Experimental|Personal counseling intervention|Behavioral lifestyle intervention for weight loss, delivered by personal counseling.
3067449|NCT01092364|No Intervention|Advice only|Advice only control group.
3067450|NCT01092442||Retrospective Patients|Retrospective Patients: The patient group who had the CryoValve SG Pulmonary Human Heart Valve implanted prior to the February 2008 clearance of the valve.
3067451|NCT01092442||Prospective Patients|Prospective Patients: The patient group that had the CryoValve SG Pulmonary Human Heart Valve implanted after the February 2008 clearance of the valve.
3067452|NCT01092507|Experimental|JE-CV Group|Participants will receive one dose of Japanese encephalitis chimeric virus vaccine (JE-CV)
3067453|NCT01092507|Active Comparator|SA14-14-2 vaccine Group|Participants will receive one dose of Japanese encephalitis live vaccine, SA14-14-2 vaccine. (CD.JEVAX®)
3067454|NCT01092546|Experimental|Arm 1|
3067455|NCT01092559|Experimental|nitric oxide via GeNO Nitrosyl system|Nitric Oxide via GeNO Nitrosyl system
3067456|NCT01092637||Cooled|Child was allocated standard intensive care plus moderate whole body hypothermia treatment within 6 hours of birth
3067457|NCT01092637||Non-cooled|Child was allocated standard intensive care only within 6 hours of birth
3067458|NCT01092663|Active Comparator|Colesevelam HCl: 3 tablets, 2x/day|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
3067459|NCT01092663|Active Comparator|Colesevelam plus Sitagliptin|"Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.~Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks."
3067460|NCT01092676|Active Comparator|Regular Ibuprofen Dosing|Regular Ibuprofen Dosing throughout 4 days of study
3067461|NCT01092676|Active Comparator|PRN Ibuprofen dosing|As needed Ibuprofen dosing
3067462|NCT01092702|Other|Varenicline|Everyone on study will receive Varenicline daily for 12 weeks
3067463|NCT01092728|Active Comparator|Group 1: Completely Resectable|Dasatinib 100 mg daily for 7 days and then surgical resection on Day 8. Afterwards, Dasatinib 100 mg daily will be administered for a total of 12 months/12 cycles (1 cycle = 4 weeks of treatment).
3067464|NCT01092728|Active Comparator|Group 2: Unresectable|100 mg Dasatinib daily continued up to 12 months/12 cycles (1 cycle = 4 weeks of treatment).
3067465|NCT01092767|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|Valiant Thoracic Stent Graft with the Captivia Delivery System
3067466|NCT01092780|Experimental|MK-7288 10mg/Pbo/MK-7288 20mg/Modafinil|Participants received single doses of study drug in the following order: MK-7288 10 mg in Treatment Period 1, Placebo (Pbo) in Treatment Period 2, MK-7288 20 mg in Treatment Period 3 and Modafinil 200 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3067467|NCT01092780|Experimental|MK-7288 20mg/MK-7288 10mg/Modafinil/Pbo|Participants received single doses of study drug in the following order: MK-7288 20 mg in Treatment Period 1, MK-7288 10 mg in Treatment Period 2, Modafinil 200 mg in Treatment Period 3 and Placebo in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3067468|NCT01092780|Experimental|Modafinil/MK-7288 20mg/Pbo/MK-7288 10mg|Participants received single doses of study drug in the following order: Modafinil 200 mg in Treatment Period 1, MK-7288 20 mg in Treatment Period 2, Placebo in Treatment Period 3 and MK-7288 10 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3132382|NCT03421886|Experimental|Aerodentis system|30 patients will be systematically assigned to the treatment group (wearing Aerodentis Device).
3067469|NCT01092780|Experimental|Pbo/Modafinil/MK-7288 10 mg/MK-7288 20mg|Participants received single doses of study drug in the following order: Placebo in Treatment Period 1, Modafinil 200 mg in Treatment Period 2, MK-7288 10 mg in Treatment Period 3 and MK-7288 20 mg in Treatment Period 4. The first 3 treatment periods were followed by a 7-day washout period.
3067470|NCT01092832|Experimental|Active voriconazole|All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
3067471|NCT01092910|Experimental|Esteem Implant|Subjects are implanted with the Esteem Totally Implantable Hearing System
3067472|NCT01092923|Experimental|Air/Oxygen|Sevoflurane with Air/Oxygen Mix
3067473|NCT01092923|Experimental|sevoflurane in N2O/O2|
3067474|NCT01093014|Experimental|Arm 1: High-force muscle stimulation|High-force muscle stimulation
3067475|NCT01093014|Experimental|Arm 2: Low-force muscle stimulation|Low-force muscle stimulation
3067476|NCT01093014|Experimental|Arm 3: Sequential low-force and high-force muscle stimulation|Sequential low-force and high-force muscle stimulation
3067477|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
3067478|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
3067479|NCT01093183|Experimental|Treatment (lenalidomide and cyclophosphamide)|Patients receive lenalidomide PO QD on days 1-21 and cyclophosphamide PO QD on days 1-28. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response.
3067480|NCT01093222|Experimental|Treatment (sorafenib tosylate and erlotinib hydrochloride)|Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3067481|NCT01093417|Placebo Comparator|Placebo|Participants that have been randomized into this arm will receive placebo pills.
3067482|NCT01093417|Active Comparator|Vitamin D 4000 IU|Participants that have been randomized into this arm will receive Vitamin D 4000 IU (International Units) daily.
3067483|NCT01093469|Experimental|Aquaphor Healing Ointment|Aquaphor Healing Ointment three times daily to atopic dermatitis
3067484|NCT01093469|Active Comparator|Atopiclair Nonsteroidal Cream|Atopiclair Nonsteroidal Cream three times daily to atopic dermatitis
3067485|NCT01093469|Active Comparator|EpiCream Skin Barrier Emulsion|EpiCream Skin Barrier Emulsion three times daily to atopic dermatitis
3067486|NCT01093482||mechanically ventilated patients|"Patients who are admitted to the participating intensive care units and require invasive mechanical ventilation (endotracheal tube or tracheostomy) for more than 12 hours.~Patients who are admitted to the participating intensive care units and require non-invasive mechanical ventilation (Bilevel positive airway pressure (BIPAP) or continuous positive airway pressure (CPAP) with nasal or facial mask) for more than 1 hour."
3067487|NCT01093521|Experimental|100 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 100 mg/m2
3067488|NCT01093521|Experimental|200 mg/m2 dose|Five day continuous IV Gallium Nitrate (Ganite®) infusion at 200 mg/m2
3067489|NCT01093534|Placebo Comparator|Placebo|Participants received 2 placebo tablets once daily for 12 weeks.
3067490|NCT01093534|Experimental|Solifenacin 5 mg|Participants received one 5 mg solifenacin tablet and one placebo tablet, once daily for 12 weeks.
3067491|NCT01093534|Experimental|Solifenacin 10 mg|Participants received two 5 mg solifenacin tablets once daily for 12 weeks.
3067492|NCT01093573|Experimental|Dose Level 1|Aza at 75 mg/m2 D1-7 & Midostaurin 25 mg BID D 8-21
3067493|NCT01093573|Experimental|Dose Level 2|Aza at 75 mg/m2 D1-7 & Midostaurin 50 mg BID D 8-21
3067494|NCT01093573|Experimental|Dose Level 3|Azacitidine 75 mg/m2 IV D1-7 & Midostaurin 75 mg PO BID D 8-21
3067495|NCT01093586|Experimental|Arm I|PREPARATIVE REGIMEN: Patients receive oral busulfan on days -8 to -5, cyclophosphamide IV on days -4 to -3, and anti-thymocyte globulin or methylprednisolone IV on days -3 to -1. TRANSPLANTATION: Patients undergo a double-unit umbilical cord blood allogeneic stem cell transplantation on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -2, patients receive cyclosporine IV and taper beginning on day 100. Patients also receive mycophenolate mofetil IV or orally on days -3 to 45.
3067496|NCT01093599|Active Comparator|Quit Line Only|Control Participants will call the Wisconsin Tobacco Quit Line intervention including phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
3067497|NCT01093599|Active Comparator|Quit Line plus MTS|Participants in the study group will receive the Quit Line intervention (talk to a Quit Line Counselor, receive quit smoking materials and get 4 weeks of nicotine patches) and also receive 4 weeks of training in mindfulness meditation through the mindfulness for smokers intervention.
3067498|NCT01093625|Experimental|Narafilcon B Contact Lens|Investigational Silicone Hydrogel Contact Lens
3067499|NCT01093625|Active Comparator|Spectacles|
3067500|NCT01093651|Experimental|DPPIV inhibition|Four to six months of sitagliptin administration (100mg/d) to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
3067501|NCT01093651|Placebo Comparator|Placebo|Four to six months of placebo to people living with HIV-1 who have well-controlled immunologic (CD4+ T-cell count >350 cells/µL) and virologic (plasma HIV RNA <50 copies/mL) status.
3067502|NCT01093690|Experimental|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg orally four times a day on day 2-5
3067503|NCT01093690|Placebo Comparator|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
3067504|NCT01093755|Active Comparator|dexlansoprazole|Participants will be treated with dexlansoprazole 60-90 mg/day for 6 months
3067505|NCT01093755|Active Comparator|omeprazole|Participants will be treated with omeprazole 20mg/day for a minimum of 6 weeks. If symptomatic can increase dose by 20mg twice.
3132383|NCT03421886|Active Comparator|Invisalign clear aligner system|15 patients will be systematically assigned to the control group (wearing clear aligners).
3067506|NCT01093794|Experimental|1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 500 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin"
3067507|NCT01093794|Experimental|2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 850 mg metformin~Co-administration of 50 mg sitagliptin and 500mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet"
3067508|NCT01093794|Experimental|3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/850 mg FDC tablet~sitagliptin/metformin 50 mg/500 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500mg metformin"
3067509|NCT01093794|Experimental|4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC|"Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments:~sitagliptin/metformin 50 mg/850 mg FDC tablet~Co-administration of 50 mg sitagliptin and 500 mg metformin~Co-administration of 50 mg sitagliptin and 850 mg metformin~sitagliptin/metformin 50 mg/500 mg FDC tablet"
3067510|NCT01093885|Other|open label: medication Ambrisentan|"Open label study of Ambrisentan.~Ambrisentan will begin at 5mg daily for the first month.~Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week. Subjects will continue their present dose and schedule of disease modifying/antifibrotic medication for the duration of the study.~** Dose escalation was attempted however none of the patients were able to increase. Therefore all subjects remained on 5 mg daily throughout the study. 12 patients on mycophenolate mofetil, 2 on mycophenolic acid and one on methotrexate"
3067511|NCT01093976|Experimental|Dronabinol|Dronabinol (Marinol) - 2.5mg-15mg by mouth once a day for twelve-weeks
3067512|NCT01094106|Active Comparator|Ropivacaine 0,75%|Postoperative wound infusion 15 mg /h / 48h
3067513|NCT01094106|Placebo Comparator|NaCl 0,9%|Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h
3067514|NCT01094119|Active Comparator|Bair Hugger heated blanket|Patients will be warmed during surgery with the Bair Hugger heated blanket.
3067515|NCT01094119|Active Comparator|LMA PerfecTemp system|Patients will be warmed during surgery with the PerfecTemp heated pad .
3067516|NCT01094171|Experimental|Poliorix Group|Subjects received 3 primary doses of PoliorixTM and InfanrixTM vaccines at 3, 4.5 and 6 months of age. All vaccines were administered intramuscularly in the anterolateral side of the left thigh (Poliorix) and the right thigh (Infanrix).
3067517|NCT01094184|Experimental|Bevacizumab 10 mg/kg Q2W|Participants will receive bevacizumab at a dose of 10 milligrams per kilogram (mg/kg) every 2 weeks (Q2W) as intravenous infusion along with paclitaxel every week (Q1W) or docetaxel every 3 weeks (Q3W) as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
3067518|NCT01094184|Experimental|Bevacizumab 15 mg/kg Q3W|Participants will receive bevacizumab at a dose of 15 mg/kg Q3W as intravenous infusion along with paclitaxel Q1W or docetaxel Q3W as per discretion of the treating physician until disease progression, unacceptable toxicity or withdrawal of consent.
3067519|NCT01094288|Experimental|Alisertib + Docetaxel|"Alisertib in escalating dose (10-40 mg), enteric-coated tablets (ECT), orally, twice daily for 7 days followed by 14-day rest period in Cycle 1, 3 and onwards (21-day cycle) and orally twice daily from Day 3 to Day 7 followed by 14 day rest period in Cycle 2 along with docetaxel 60-75 mg/m^2, intravenous (IV) infusion on Day 1 of each cycle for maximum of 12 months, or until the occurrence of progressive disease (PD), unmanageable adverse events (AEs) or withdrawal of consent.~The starting alisertib dose is 10 mg, orally, twice daily (total 20 mg/day)."
3067520|NCT01094301|Experimental|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
3067521|NCT01094522|Experimental|Methadone|One half the Study patients will be randomized to receive a loading dose of IV methadone, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
3067522|NCT01094522|Active Comparator|Morphine|One half the Study patients will be randomized to receive a loading dose of IV morphine, followed by IV doses (given by the ICU nurse), on a PRN basis, for pain control for up to 24 hours during their postoperative course while they are intubated.
3067523|NCT01094548|Experimental|Tecemotide (L-BLP25) plus single low dose cyclophosphamide|
3067524|NCT01094548|Experimental|Tecemotide (L-BLP25) plus multiple low dose cyclophosphamide|
3067525|NCT01094574|Active Comparator|Alfentanil|Experimental inflammation, and tissue injury sites were created, an infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3067526|NCT01094574|Active Comparator|Propranolol|Experimental inflammation and tissue injury sites were created, an infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3067527|NCT01094574|Placebo Comparator|Placebo|Experimental inflammation and tissue injury sites were created, an infusion of normal saline was administered over 3 hours using a programmable infusion pump, and data were collected to measure inflammation, pain response, and cytokine levels locally.
3067528|NCT01094704|Experimental|Hypertonic Saline - 1 hour|sodium chloride (7%); mucociliary clearance measured 1 hour post dose
3067529|NCT01094704|Experimental|Hypertonic Saline - 4 hours|sodium chloride (7%); mucociliary clearance measured four hours post-dose.
3067530|NCT01094717|Experimental|acitretin and active excimer laser|patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions.
3067531|NCT01094717|Experimental|acitretin and sham excimer laser|Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of body psoriasis lesions.
3067532|NCT01094717|Experimental|tazarotene and active excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and excimer (active) laser to randomly assigned left or right side of body psoriasis lesions.
3067533|NCT01094717|Experimental|tazarotene and sham excimer laser|patients enrolled in this arm were treated with tazarotene 0.1% gel topical application daily and sham excimer laser to randomly assigned left or right side of body psoriasis lesions.
3067534|NCT01094730|Other|galyfilcon A prototype/marketed galyfilcon A|The galyfilcon A prototype lens worn daily for 12-16 days during the first period then the marketed galyfilcon A lens worn daily for 12-16 days during the second period.
3067535|NCT01094730|Other|marketed galyfilcon A/galyfilcon A prototype|The marketed galyfilcon A lens worn daily for 12-16 days during the first period then the galyfilcon A prototype lens worn daily for 12-16 days during the second period; during each period.
3067536|NCT01094743|Other|galyfilcon A prototype lens / lotrafilcon B lens|The galyfilcon A prototype lenses will be worn during the first period and lotrafilcon B lenses will be worn during the second period. Each period consists of daily lens wear for one week.
3067537|NCT01094743|Other|lotrafilcon B lens / galyfilcon A prototype lens|The lotrafilcon B lenses will be worn during the first period and galyfilcon A prototype lenses will be worn during the second period. Each period consists of daily lens wear for one week.
3067538|NCT01094782|Active Comparator|Healthy - True Acupuncture|Healthy volunteers with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7.This group received true acupuncture treatment (the needles punctured the skin).
3067539|NCT01094782|Sham Comparator|Healthy - Sham Acupuncture|Healthy with no neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
3067540|NCT01094782|No Intervention|Healthy - No Treatment|Healthy volunteers with no neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
3067541|NCT01094782|Active Comparator|Pain - True Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received true acupuncture treatment (the needles punctured the skin).
3067542|NCT01094782|Sham Comparator|Pain - Sham Acupuncture|Volunteers with radiating neck or back pain who attended 7 visits over 4 weeks and received 6 30 minute acupuncture treatment sessions during visits 2-7. This group received sham acupuncture treatment (the needles did not puncture the skin).
3067543|NCT01094782|No Intervention|Pain - No Treatment|Volunteers with radiating neck or back pain who attended 3 visits over 4 weeks and received no sham or true acupuncture treatment.
3067544|NCT01094808|Experimental|Pregabalin 75 mg|Subjects randomized to this arm received a single dose of pregabalin 75 mg orally
3067545|NCT01094808|Experimental|Pregabalin 200 mg|Subjects randomized to this arm received a single dose of pregabalin 200 mg orally
3067546|NCT01094808|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo medication orally
3067547|NCT01094886|Experimental|001|Rivaroxaban 10mg tablet daily receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
3067548|NCT01095003|Experimental|Vinflunine plus Capecitabine|"Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks."
3067549|NCT01095003|Active Comparator|Capecitabine single-agent|Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).
3067550|NCT01095094|Experimental|Arm I|Patients receive oral ritonavir and lopinavir twice daily in the absence of disease progression or unacceptable toxicity.
3067551|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 1|
3067552|NCT01095497|Experimental|IV CINRYZE First, Then SC CINRYZE Dose 2|
3067553|NCT01095510|Experimental|500 U CINRYZE (10-25 kg body weight)|Single IV dose of 500 U CINRYZE
3067554|NCT01095510|Experimental|1000 U CINRYZE (10-25 kg body weight)|Single IV dose of 1000 U CINRYZE
3067555|NCT01095510|Experimental|1000 U CINRYZE (>25 kg body weight)|Single IV dose of 1000 U CINRYZE
3067556|NCT01095510|Experimental|1500 U CINRYZE (>25 kg body weight)|Single IV dose of 1500 U CINRYZE
3067557|NCT01095653|Experimental|Group 1|
3067558|NCT01095653|Experimental|Group 2|
3067559|NCT01095653|Experimental|Group 3|
3067560|NCT01095666|Experimental|Group 1|
3067561|NCT01095666|Experimental|Group 2|
3067562|NCT01095666|Experimental|Group 3|
3067563|NCT01095757|Other|Plerixafor + Chemo and G-CSF|Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
3067564|NCT01095796|Experimental|Stribild|Stribild plus placebo to match Atripla
3067565|NCT01095796|Active Comparator|Atripla|Atripla plus placebo to match Stribild
3067566|NCT01095835|Experimental|PEG-IFN48|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks.
3067567|NCT01095835|Experimental|PEG-IFN96|Treatment with PEG-IFN in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by another 48 weeks of PEG-IFN treatment (total 96 weeks of treatment).
3067568|NCT01095835|Experimental|PEG-IFN+LAM96|Treatment with PEG-IFN and lamivudine in participants with HBeAg-negative chronic hepatitis B virus for 48 weeks followed by 48 weeks of only PEG-IFN treatment (total 96 weeks of treatment).
3067569|NCT01095887|Experimental|eculizumab|Eculizumab was given on Day 0, day 1, and weekly for the first four weeks after transplant.
3067570|NCT01095978||Acute upper respiratory tract diseases, bronchitis, pneumonia|
3067571|NCT01096017|Experimental|1|Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI ⇒salbutamol pMDI 200 μg +placebo Turbuhaler®
3067572|NCT01096017|Experimental|2|salbutamol pMDI 200 μg +placebo Turbuhaler® ⇒Terbutaline Turbuhaler® 0.4mg + pMDI placebo pMDI
3067573|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 1 Group|Subjects received 2 doses of influenza vaccine GSK2186877A formulation 1 at Day 0 and Day 21 and 1 dose of Fluarix vaccine at Month 6.
3067574|NCT01096056|Experimental|Influenza vaccine GSK2186877A formulation 2 Group|Subjects received 1 dose of influenza vaccine GSK2186877A formulation 2 at Day 0 and 1 dose of Fluarix vaccine at Month 6.
3067575|NCT01096160|Experimental|Panel A: MK-8266 BID, 1 mg/Placebo|MK-8266 1 mg (0.7 mg in the morning [AM] + 0.3 mg in the evening [PM]), or as matching placebo BID.
3067576|NCT01096160|Experimental|Panel B: MK-8266 BID, 1.8 mg/Placebo|MK-8266 1.8 mg (1 mg in the AM + 0.8 mg in the PM), or as matching placebo BID.
3067577|NCT01096160|Experimental|Panel C: MK-8266 TID, 1.8 mg/Placebo|MK-8266 TID, 1.8 mg (0.6 mg every 6 hours [q6hr]), or as matching placebo TID.
3067578|NCT01096160|Experimental|Panel D: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel D), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel D was completed prior to initiation of Panel E.
3067579|NCT01096160|Experimental|Panel E: MK-8266 TID, 2.4 mg/Placebo|MK-8266 TID (Panel E), 2.4 mg (0.8 mg q6hr), or as matching placebo TID. Panel E was initiated after completion of Panel D.
3067580|NCT01096186|Other|Open Label IPX066|Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
3067581|NCT01096290|Experimental|Lubiprostone 24mcg BID for 30 days|Active medication
3067582|NCT01096290|Placebo Comparator|Placebo|Placebo, matched, blinded
3067583|NCT01096316|Experimental|Intervention|"The intervention will integrate care between a depression care manager, consulting study team (psychiatry, psychology, OB-GYN researchers) and OB-GYN clinic providers. The 3-part intervention includes:~enhanced education of patients and providers~engagement of patients~depression care management with patient choice of initial antidepressant medication or Problem-Solving Treatment-Primary Care and behavioral activation."
3067584|NCT01096316|No Intervention|Usual Care|Patients randomized to Usual Care Arm will be informed of their diagnosis and encouraged to inform her OB-GYN provider about her depression diagnosis. Patients will be encouraged to proceed with care using any primary care or specialty services normally available to them inside/outside their OB-GYN clinic. All treatment decision for Usual Care Arm patients are left to the OB-GN provider.
3067585|NCT01096342|Experimental|Treatment|Patients receive dinaciclib IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3067586|NCT01096446|Experimental|Higher Infusion|Infants randomized into the experimental group will receive 2 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
3067587|NCT01096446|Other|Standard Infusion|Infants randomized into the control group will receive 0.5 gm/kg/day of Intravenous Fat Emulsions (IVFE) on their first day of total parenteral nutrition (TPN). The IVFE will be increased by 0.5 gm/kg/day daily until a goal reached of 3 gm/kg/day of IVFE in the TPN.
3067588|NCT01096550|Experimental|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
3067589|NCT01096550|Active Comparator|Outpatient|Buprenorphine patients receiving between 2 and 8 hours of outpatient counseling.
3067590|NCT01096589|Experimental|Arm 1 - 3M Coban 2|3M Coban 2 - 2 apps/wk
3067591|NCT01096589|Experimental|Arm 2 - 3M Coban 2|3M Coban 2 - 3 apps/wk
3067592|NCT01096589|Experimental|Arm 3 - 3M Coban 2|Arm 3 - 3M Coban 2 - 5 apps/wk
3067593|NCT01096589|Active Comparator|Arm 4 - Comprilan|Comprilan short-stretch bandage 5 apps/wk
3067594|NCT01096667|Placebo Comparator|Placebo|Placebo to ertugliflozin (resembling either 1 mg or 5 mg), placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days.
3067595|NCT01096667|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
3067596|NCT01096667|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, placebo to ertugliflozin (resembling 25 mg), and placebo to HCTZ once daily for 28 days
3067597|NCT01096667|Experimental|Ertugliflozin 25 mg|Ertugliflozin 25 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to HCTZ once daily for 28 days
3067598|NCT01096667|Active Comparator|HCTZ 12.5mg|HCTZ 12.5 mg, placebo to ertugliflozin (resembling either 1 mg or 5 mg), and placebo to ertugliflozin (resembling 25 mg) once daily for 28 days
3067599|NCT01096680|Experimental|SPD489 20 mg|
3067600|NCT01096680|Experimental|SPD489 50 mg|
3067601|NCT01096680|Experimental|SPD489 70 mg|
3067602|NCT01096680|Active Comparator|Armodafinil|
3067603|NCT01096680|Placebo Comparator|Placebo|
3067604|NCT01096771|Experimental|ClinOleic 20%|96 hour continuous infusion.
3067605|NCT01096771|Active Comparator|Intralipid 20%|96 hour continuous infusion.
3067606|NCT01096784|Active Comparator|rhIGF-I/rhIGFBP-3|Continuous IV Infusion
3067607|NCT01096784|No Intervention|Control|The comparator group will receive no treatment with rhIGF-1/rhIGFBP-3
3067608|NCT01096810|Experimental|TBL 12|TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression
3067609|NCT01096823|Experimental|Iyengar Yoga|
3067610|NCT01096823|No Intervention|Waitlist Control|
3067611|NCT01096849|Experimental|plazomicin (10 mg/kg)|Patients received two intravenous (IV) infusions daily for 5 consecutive days: 10 milligrams per kilogram (mg/kg) plazomicin followed by placebo.
3067612|NCT01096849|Experimental|plazomicin (15 mg/kg)|Patients received two IV infusions daily for 5 consecutive days: 15 mg/kg plazomicin followed by placebo.
3067613|NCT01096849|Active Comparator|levofloxacin|Patients received two IV infusions daily for 5 consecutive days: placebo followed by 750 milligrams (mg) levofloxacin.
3067614|NCT01096875|Active Comparator|Atorvastatin|Hydroxymethylglutaryl-CoA Reductase Inhibitors
3067615|NCT01096875|Placebo Comparator|Placebo|Atorvastatin like pill
3067616|NCT01096992|Experimental|Phase 1 20 mg/m^2|Bendamustine, Fludarabine + Rituximab
3067617|NCT01096992|Experimental|Phase 2|Bendamustine 30 mg/m^2 by vein (fixed), Days 1,2,3 + Fludarabine + Rituximab
3067618|NCT01096992|Experimental|Phase 1 30 mg/m^2|Bendamustine, Fludarabine + Rituximab
3067619|NCT01096992|Experimental|Phase 1 40 mg/m^2|Bendamustine, Fludarabine + Rituximab
3067620|NCT01096992|Experimental|Phase 1 50 mg/m^2|Bendamustine, Fludarabine + Rituximab
3067621|NCT01097005||Klaricid|Those with an exposure
3067622|NCT01097044|Experimental|Afamelanotide|Dose: 16 mg implant; release of 16 mg over 7 to 10 days Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
3067623|NCT01097044|Placebo Comparator|Placebo|Dose: 16 mg implant; Mode of administration: Subcutaneous implantation Frequency: Every 60 days (on Days 0, 60 and 120)
3067624|NCT01097057|Experimental|Treatment (rituximab, etoposide, carboplatin, ifosfamide)|Patients receive rituximab IV on day 1, etoposide IV on days 2-4, carboplatin IV on day 3, and ifosfamide IV on day 3 over 24 hours. Patients also receive G-CSF SC once daily beginning on day 6 and continuing until apheresis is completed and plerixafor SC once daily for up to 4 days beginning 24 hours after recovery from nadir and continuing until apheresis is completed. Patients may undergo up to 4 apheresis procedures until the optimal number of CD34+ cells are collected.
3067625|NCT01097304|Experimental|Treatment (ursodiol)|Patients receive ursodiol PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3067626|NCT01097330|Active Comparator|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia
3067627|NCT01097330|Active Comparator|Amiodarone|amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study.
3067628|NCT01097343|Active Comparator|75 mg clopidogrel|
3067629|NCT01097343|Active Comparator|150 mg clopidogrel|
3067630|NCT01097395|Active Comparator|Standard Weight-Based Ribavirin Dosing|1000 mg daily in patients weighing <75 kg and 1200 mg daily in patients weighing ≥ 75 kg
3067631|NCT01097395|Experimental|Concentration-Controlled Ribavirin Dosing|Dose adjusted based on first dose AUC0-12
3067632|NCT01097421||Patient with parkinsons disease|
3067633|NCT01097460|Experimental|MM-111 + Herceptin|MM-111 will be combined with Herceptin
3067634|NCT01097577|Experimental|pregabalin|Oral Pregabalin 75 mg capsule twice daily administered prior to PRK and continued for 5 days
3067635|NCT01097577|Placebo Comparator|Placebo|Oral placebo capsule (Lactose) twice daily administered prior to PRK and continued for 5 days
3067636|NCT01097616|Experimental|Suvorexant HD|Drug
3067637|NCT01097616|Experimental|Suvorexant LD|Drug
3067638|NCT01097616|Placebo Comparator|Placebo|Placebo Comparator
3067639|NCT01097629|Experimental|Suvorexant HD|Drug
3067640|NCT01097629|Experimental|Suvorexant LD|Drug
3067641|NCT01097629|Placebo Comparator|Placebo|Placebo Comparator
3067642|NCT01097642|Active Comparator|Ixabepilone|Brand name is Ixempra ®; it is an epothilone B analog used in combination with other chemotherapeutics against cancer.
3067643|NCT01097642|Experimental|Ixabepilone plus Cetuximab|Cetuximab, brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor and monoclonal antibody used with Ixabepilone against cancer.
3067644|NCT01097655||HIV-infected Participants|"HIV-infected participants starting with Kaletra tablets.~Participants included 3 subgroups:~antiretroviral therapy (ART) treatment-naïve participants starting with Kaletra tablets~participants receiving their first protease inhibitor (PI)-containing regimen (apart from Kaletra) pretreated with any non nucleoside reverse transcriptase inhibitor (NNRTI)-containing or nucleoside reverse transcriptase inhibitor (NRTI)-containing regimen~participants pretreated with a PI-containing regimen (apart from Kaletra)."
3067645|NCT01097668|Experimental|Intradermal injection|Injections will be given by the intradermal route
3067646|NCT01097668|Experimental|Subcutaneous injection|Injections will be given by the subcutaneous route
3067647|NCT01097694|Active Comparator|Imatinib mesylate|Group on active imatinib treatment
3067648|NCT01097694|Placebo Comparator|Placebo|Group on Placebo treatment
3067649|NCT01097707|Experimental|1mg LY500307|
3067650|NCT01097707|Experimental|3mg LY500307|
3067651|NCT01097707|Experimental|10mg LY500307|
3067652|NCT01097707|Experimental|25mg LY500307|
3067653|NCT01097707|Placebo Comparator|Placebo|
3067654|NCT01097785|Active Comparator|Simvastatin|40 mg Simvastatin 1 pill every day for 30 days
3067655|NCT01097785|Placebo Comparator|Placebo|Placebo cap 1 pill every day for 30 days
3067656|NCT01097863|Experimental|nelfilcon A, modified inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
3067657|NCT01097863|Experimental|nelfilcon A, no inversion indicator|Nelfilcon A investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for one week
3067658|NCT01097863|Active Comparator|nelfilcon A, inversion indicator|Nelfilcon A commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for one week.
3067659|NCT01097915||PROP taste sensitivity|"PROP Sensitive and non sensitive individuals are defined as Tasters and Non-tasters, respectively. Taster are further divided in Super-taster who perceived PROP as extremely bitter and Medium tasters who perceived PROP as moderately bitter."
3067660|NCT01098006|Other|Immune tolerant patients Group|Immune tolerant patients aged between and including 18 and 65 years of age at study start, having high levels of hepatitis B viruss (HBV) replication characterized by elevated HBV DNA levels and presence of hepatitis B envelope antigen (HBeAg), but normal alanine aminotransferase (ALT) levels with normal or mild histology findings.
3067661|NCT01098006|Other|HBeAg positive Group|HBeAg positive chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having elevated or fluctuating ALT levels, presence of HBeAg and variable HBV DNA on a high level, histology mainly with activee inflammation and varying degrees of liver fibbrosis.
3067662|NCT01098006|Other|Inactive carriers Group|Inactive carriers aged between and including 18 and 65 years of age at study start, having normal ALT levels, undetectable or low levels of serum HBV DNA; absence of HBeAg and presence of anti-HBe antibodies, histology with little or no inflammation and varying degrees of liver fibrosis.
3067663|NCT01098006|Other|HBeAg negative Group|HBeAg negative chronic Hepatitis B patients aged between and including 18 and 65 years of age at study start, having absence of HBeAg, presence of anti-HBe, elevated ALT and HBV DNA levels, histology with significant inflammatory changes, liver fibrosis and cirrhosis.
3067664|NCT01098032|Active Comparator|Systemic alone therapy group|Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
3067665|NCT01098032|Experimental|RenalGuard System group|Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow <300 ml/h.
3067666|NCT01098071|Experimental|mometasone furoate nasal spray|
3067667|NCT01098097||Peginterferon alpha and ribavirin|Peginterferon alpha and ribavirin will be administered at the discretion of the treating physician, in accordance per label according to local guidelines for all participating countries.
3067668|NCT01098110|Experimental|Asenapine 5 mg BID|Participants received a 5 mg asenapine fast dissolving tablet twice daily (BID) for 6 weeks.
3067669|NCT01098110|Experimental|Asenapine 10 mg BID|Participants received a 5 mg asenapine fast dissolving tablet BID on Day 1, then 10 mg asenapine fast dissolving tablet BID thereafter for a total of 6 weeks.
3067670|NCT01098110|Placebo Comparator|Placebo BID|Participants received matching placebo BID for 6 weeks.
3067671|NCT01098162||Vimpat®|Routine treatment in accordance with the local marketing authorization for Vimpat® added to one Baseline antiepileptic drug.
3067672|NCT01098240|Experimental|Active Treatment|CP-601,927
3067673|NCT01098240|Placebo Comparator|Placebo|Placebo
3067674|NCT01098253|Experimental|Adherence Intervention|Factors affecting adherence to oral hypoglycemic agents and antidepressants were addressed using a problem solving process.
3067675|NCT01098253|No Intervention|Usual Care|
3067676|NCT01098266|Experimental|A: NGR-hTNF + BIC|NGR-hTNF plus Best Investigator's Choice
3067677|NCT01098266|Placebo Comparator|B: Placebo+BIC|Placebo plus Best Investigator's Choice
3067678|NCT01098305|Active Comparator|Varenicline|
3067679|NCT01098305|Placebo Comparator|Placebo|
3067680|NCT01098318|Experimental|Rhodiola rosea|Herbal extract
3067681|NCT01098318|Active Comparator|Sertraline|Conventional anti-depressant
3067682|NCT01098318|Placebo Comparator|Sugar pill|Lactose monohydrate
3067683|NCT01098422|Experimental|Yttrium-90 Radioactive Resin Microspheres|Yttrium-90 Radioactive Resin Microspheres
3067684|NCT01098461|Active Comparator|albiglutide 15mg weekly|once weekly subcutaneous injection of albiglutide 15mg
3067685|NCT01098461|Active Comparator|albiglutide 30mg weekly|once weekly subcutaneous injection of albiglutide 30mg
3067686|NCT01098461|Active Comparator|albiglutide 30mg every other week|subcutaneous injection of 30mg albiglutide every other week
3067687|NCT01098461|Placebo Comparator|placebo|once weekly subcutaneous injection of placebo to match albiglutide
3067688|NCT01098474|Experimental|SB692342 2 dose Group|Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, on a 0, 1 month schedule after having completed their primary EPI regimen.
3067689|NCT01098474|Experimental|SB692342 1 dose Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, at Month 0, after having completed their primary EPI regimen.
3067690|NCT01098474|Active Comparator|Control Menjugate Group|Subjects received three doses of the control Menjugate™ vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, on a 0, 1, 7 months schedule. The first two doses were administered 1 month apart during the primary vaccination phase and the third dose was administered 6 months after the last primary vaccination dose.
3067691|NCT01098474|Experimental|SB692392 2 dose + Tritanrix + Prevnar + Polio Sabin Group|"Subjects received two doses of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, 1 month apart, concomintantly with the last two doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered instramuscularly in the right arm, on a 0, 1, 2 months schedule.~All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose."
3067692|NCT01098474|Experimental|SB692392 1 dose + Tritanrix + Prevnar + Polio Sabin Group|Subjects received one dose of SB692342 vaccine (0,5 mL), administered intramuscularly in the anterolateral region of the right thigh, concomitantly with the last dose of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered intramuscularly in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine, administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
3067693|NCT01098474|Active Comparator|Control Tritanrix + Prevnar + Polio Sabin Group|Subjects received three doses of the primary EPI regimen containing Tritanrix™ HepB+Hiberix™ vaccine, administered in the anterolateral region of the left thigh, Polio Sabin™ vaccine, administered orally, and Prevnar® vaccine administered intramuscularly in the right arm, on a 0, 1, 2 months schedule. All subjects received a booster dose of the Tritanrix™ HepB+Hiberix™, Polio Sabin™ and Prevnar® vaccines approximately 1 year after their last dose.
3067694|NCT01098487|Experimental|Open Label|Oral eltrombopag once daily, starting dose 50 mg (or 25 mg for subjects of East Asian ancestry).
3067695|NCT01098500||Cancer patients|Adults (age ≥18 years) with at least two ICD-9 codes for a particular cancer within a 6 month timeframe and at least one code for a TKI drug that occurs on or after the first cancer diagnosis code
3067696|NCT01098539|Active Comparator|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
3067697|NCT01098539|Active Comparator|sitagliptin|albiglutide matching placebo + sitagliptin
3067698|NCT01098578|Experimental|Floseal|Received 1 syringe of Floseal for treatment of posterior epistaxis.
3067699|NCT01098747|Experimental|Treatment A|
3067700|NCT01098747|Active Comparator|Treatment B|
3067701|NCT01098747|Active Comparator|Treatment C|
3067702|NCT01098747|Placebo Comparator|Treatment D|
3067703|NCT01098812|Active Comparator|Control IOL|Approved Intraocular control lens
3067704|NCT01098812|Experimental|Toric IOL|Investigational Toric IOL
3067705|NCT01098812|Experimental|Higher Cylinder Toric IOL|Investigational Toric IOLs with higher cylinder powers.
3067706|NCT01098851||Obstructive Sleep Apnea|Surgery patients at high risk for Obstructive Sleep Apnea
3067707|NCT01098851||Surgery Patients|Surgery patients at low risk for Obstructive Sleep Apnea
3067708|NCT01099111||Irritable Bowel Syndrome|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3067709|NCT01099111||Ulcerative Colitis|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3067710|NCT01099111||Crohn's Disease|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3067711|NCT01099111||Colo Rectal Cancer|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3067712|NCT01099111||Control: Normal Subjects|only one Colonoscopy with mucosal washing samples collection at the time of recruitment
3067713|NCT01099202|Experimental|Procrit|Starting dose 40,000 units subcutaneously once a week with chemotherapy.
3067714|NCT01099202|No Intervention|No Procrit|No intervention.
3067715|NCT01099215|Other|PVS-10200|Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.
3067716|NCT01099267||Lenalidomide|No intervention was given during this extension study which gathered survival information on participants of study NCT00065156 (Celgene study CC-5013-MDS-003). During the CC-5013-MDS-003 study, participants initially took a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle. The study was amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.
3067717|NCT01099358|Experimental|Cetuximab and Cisplatin (D)|"Cycle 1 (1 week, combination therapy):~400 milligrams per square meter (mg/m²) cetuximab administered (admin) intravenously (I.V) on week 1, day 1.~100 mg/m² cisplatin administered I.V on week 1, day 1. Optional 5- fluorouracil (FU) administered as a 96-hour continuous infusion (C.I.) of 1000 mg/m²/day (d) administered starting on week 1, day 1.~After 1 cycle, participants may continue treatment as determined by the physician until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3067718|NCT01099358|Experimental|Cetuximab and Cisplatin (C)|"Cycle 1 (4 weeks, combination therapy):~100 mg/m² Cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3 and 4, day 1.~Cycle 2-6 (3 weeks combination therapy):~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 1, 2, and 3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3067719|NCT01099358|Experimental|Cetuximab on Cisplatin (B)|"Cycle 1:~400 mg/m² cetuximab admin I.V on week 1, day 1. 250 mg/m² cetuximab admin I.V on week 2 and 3, day 1.~Cycle 2:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1- 4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~Cycle 3 + :~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on week 1-3, day 1.~After 6 cycles, participants may then receive weekly cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3067720|NCT01099358|Experimental|Cisplatin on Cetuximab (A)|"Cycle 1:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~400 mg/m² cetuximab admin I.V on week 2, day 1. 250 mg/m² cetuximab admin I.V on week 3, day 1.~Cycle 2 +:~100 mg/m² cisplatin admin I.V on week 1, day 1. 5- FU admin as a 96-hour C.I. of 1000 mg/m²/d admin starting on week 1, day 1-4.~250 mg/m² cetuximab admin I.V on weeks 1-3, day 1.~After 7 cycles, participants may then receive weekly Cetuximab monotherapy until progression of disease, unacceptable toxicity, or another withdrawal criterion is met.~Due to protocol amendment in September 2011, any newly enrolled participants were placed into cetuximab and cisplatin (C) arm only. After protocol amendment February 2014, any newly enrolled participants will be placed into cetuximab and cisplatin (D) arm only."
3067721|NCT01099397||PEAR Participants|All participants eligible for PEAR study. Each participant will be have fasting and oral glucose tolerance test data collected.
3067722|NCT01099449|Experimental|Arm I|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy comprising leucovorin calcium, fluorouracil, and oxaliplatin).
3067723|NCT01099449|Placebo Comparator|Arm II|Patients receive placebo IV over 30 minutes immediately before and after oxaliplatin administration (part of FOLFOX chemotherapy).
3067724|NCT01099449|Experimental|Arm III|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and placebo IV over 30 minutes immediately after oxaliplatin administration (part of FOLFOX chemotherapy).
3067725|NCT01099475|Experimental|Pringle manoeuvre 15 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 2 cycles of 15 minutes of hepatic inflow occlusion will be applied each followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
3067726|NCT01099475|Experimental|Pringle manoeuvre 30 minutes|When intermittent pedicle occlusion during parenchymal transection is necessary, 1 cycle of 30 minutes of hepatic inflow occlusion will be applied followed by 5 minutes of reperfusion. During inflow occlusion, the complete portal triad was clamped using a rubber sling.
3067727|NCT01099579|Experimental|Atazanavir powder, 150 mg/Ritonavir oral solution, 80 mg|Patients weighing 5 to <10 kg received atazanavir (ATV), 150-mg powder dosed in 50-mg packets, and ritonavir (RTV) oral solution, 80 mg. Stage 1: Initial dose was determined by patient's weight on the day of first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage. All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3067728|NCT01099579|Experimental|Atazanavir powder, 200 mg/Ritonavir oral solution, 80 mg|Patients weighing 10 to <15 kg received ATV powder, 200 mg, dosed in 50-mg sachet packets and RTV oral solution, 80 mg. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from the powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3067729|NCT01099579|Experimental|Atazanavir powder, 250 mg/Ritonavir oral solution, 80 mg|Patients weighing 15 to <25 kg received 250 mg of ATV powder dosed in 50-mg sachet packets, with 80 mg of RTV solution. Stage 1: Initial dose was determined by the patient's weight on the day of the first on-treatment study visit (Day 1). ATV dispersible powder was mixed with a small amount of food or beverage (water, milk, chocolate milk, liquid infant formula, applesauce, or yogurt). All of the mixture must have been consumed to obtain the full dose. The RTV oral solution was taken immediately before or after the ATV powder preparation. Stage 2: Patients who reached the age of 6 years or a weight of ≥25kg transitioned from powder to the capsule formulation of ATV. Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
3067730|NCT01099618|Active Comparator|Metformin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3067731|NCT01099618|Active Comparator|Sitagliptin|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg (n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3067732|NCT01099618|Placebo Comparator|Placebo|All newly diagnosed subjects with KPDM that are able to discontinue insulin after 12 weeks or less will be randomized in double-blind fashion to receive either metformin 1000 mg, sitagliptin 100mg or placebo once daily. Subjects that do not achieve remission will continue to receive insulin therapy and will discontinue the protocol. A total of 48 obese subjects with DKA (N=24) and obese subjects with hyperglycemia without ketoacidosis (n=24) will be equally randomized to receive metformin (MET) 1000 mg(n=16), sitagliptin (SIT) 100mg (n=16) or placebo (n=16).
3067733|NCT01099631|Experimental|Salmonella typhimurium 10 to the 5th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067734|NCT01099631|Experimental|Salmonella typhimurium 10 to the 6th -- Level 2|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067735|NCT01099631|Experimental|Salmonella typhimurium 10 to the 7th -- Level 3|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067736|NCT01099631|Experimental|Salmonella typhimurium 10 to the 8th - Level 4|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067737|NCT01099631|Experimental|Salmonella typhimurium 10 to the 9th - Level 5|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067738|NCT01099631|Experimental|Salmonella typhimurium 10 to the 10th - Level 1|Patients will receive (a minimum of 3 patients) escalating doses of Salmonella typhimurium to achieve a maximum tolerated dose (MTD).
3067739|NCT01099709|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
3067740|NCT01099709|Active Comparator|Original OxyContin® (OXY) 10 mg|Original OxyContin® (OXY) 10 mg x 1 dose
3067741|NCT01099761|Experimental|ACE-031 0.5 mg/kg q4wk|
3067742|NCT01099761|Experimental|ACE-031 1.0 mg/kg q2wk|
3067743|NCT01099761|Placebo Comparator|Placebo|
3067744|NCT01099774|Experimental|Bimatoprost 0.03% Formulation B Ophthalmic Solution|Bimatoprost 0.03% Formulation B Ophthalmic Solution
3067745|NCT01099774|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% Ophthalmic Solution
3067746|NCT01099917|Experimental|Maitake|This is a phase II trial examining hematopoietic response in MDS patients.
3067747|NCT01099969|Experimental|Glidescope with non-styletted Endotrol ETT|The patients in this arm will be intubated using a Glidescope videolaryngoscope with non-styletted Endotrol endotracheal tube (ETT).
3067748|NCT01099969|Active Comparator|Glidescope with styletted regular ETT|The patientsin this arm will be intubated using the glidescope videolaryngoscope and regular endotracheal tube (ETT) with gliderite stylet.
3067749|NCT01099969|Experimental|McGrath with non-styletted Endotrol ETT|The patients in this arm will be intubated using McGrath videolaryngoscope and non-styletted Endotrol endotracheal tube (ETT).
3067750|NCT01099969|Active Comparator|McGrath with with styletted regular ETT|The patients receiving this arm will be intubation using McGrath videolaryngoscope and regular endotracheal tube (ETT) with Gliderite stylet.
3067751|NCT01100034||1|pediatric patients with plaque psoriasis on etanercept
3067752|NCT01100073||Patients with Parkinson's disease|Early and advanced Parkinson's disease patients
3067753|NCT01100086|Experimental|Reformulated OXY 10 mg|Reformulated OXY 10 mg x 1 dose
3067754|NCT01100086|Active Comparator|Original OxyContin® (OXY)10 mg|Original OxyContin® (OXY)10 mg x 1 dose
3067755|NCT01100112|Experimental|Budesonide|Budesonide-MMX 9 mg tablet
3067756|NCT01100242|Experimental|Arm 1: VELCADE and Sorafenib|Patients will be given VELCADE® (bortezomib) 1mg/m2 intravenously on days 1,4,8 & 11 and sorafenib at a dosage of 200 mg orally twice per day. One full course is comprised of 21 days.
3067757|NCT01100255|Active Comparator|Group A|0.5mg/kg IV ketamine infusion over 40 minutes then IV saline infusion over 40 minutes
3067758|NCT01100255|Active Comparator|Group B|IV saline infusion over 40 minutes then 0.5mg/kg IV ketamine infusion over 40 minutes
3067759|NCT01100268|Experimental|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
3067760|NCT01100307|Experimental|pegaptanib sodium|
3067761|NCT01100307|Sham Comparator|sham injection|
3067762|NCT01100320|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
3067763|NCT01100320|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
3067764|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules crushed and mixed in solution and administered orally at each patient's stable dose, given either once daily or twice daily.
3067765|NCT01100437|Experimental|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA (morphine sulfate plus naltrexone hydrochloride ER) capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily
3067766|NCT01100502|Experimental|Brentuximab vedotin|brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
3067767|NCT01100502|Placebo Comparator|Placebo|placebo every 3 weeks by IV infusion
3067768|NCT01100528|Experimental|Arm I|Patients receive dacarbazine IV on days 1 and 29. Beginning 4 weeks after the second dose of dacarbazine, patients receive recombinant interferon alfa-2b subcutaneously 3 times a week for 24 weeks in the absence of disease progression or unacceptable toxicity.
3067769|NCT01100567|Placebo Comparator|Placebo platform|Randomized to stand on placebo platform for 10 minutes/day
3067770|NCT01100567|Active Comparator|Low-magnitude mechanical stimulation|Randomized to stand on LMMS platform 10 minutes/daily
3067771|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Juice|
3067772|NCT01100606|Experimental|EUR-1008 (APT-1008) in Apple Sauce|
3067773|NCT01100723|Experimental|Computer directed dosing decisions|This study will be an open-label, non-randomized, single arm design. Patients will have their mineral and bone disorders managed by the computer directed algorithm. The computer algorithm will make recommendations for dosing active vitamin D and cinacalcet. The doses of these medications recommended by the algorithm will then be prescribed to the subjects participating in the study unless overridden by the patients primary attending nephrology for other clinical or safety concerns. At any time in the study, subjects may be on neither, one, or both of these medication depending on their laboratory results and the output recommendations of the algorithm.
3067774|NCT01100762|Experimental|Single Group|10 subjects with Parkinson's Disease receiving tPCS during the first session, treadmill walk, 7-10 days later (second session, and combined tPCS and treadmill 7-10 days week later (third session)
3067775|NCT01100853|Active Comparator|Extended release VIVITROL injection 380 mg, 24 weeks|Efficacy of 24 week course of Extended Release VIVITROL 380 mg with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
3067776|NCT01100853|Placebo Comparator|VIVITROL placebo injection, 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
3067777|NCT01100931|Experimental|YM155 in Solid Tumors|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
3067778|NCT01100944|Experimental|Therapy in Thymic Malignancies|PXD101 (Belinostat) will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression. A conventional 3+3 dose escalation design was used with up to 3 additional patients added if one patient exhibited a dose limiting toxicity (DLT). Dose escalation was halted if at least 2 out of a maximum of 6 patients within a cohort exhibited a DLT.
3067779|NCT01101022|Active Comparator|SPD489|
3067780|NCT01101022|Placebo Comparator|Placebo|
3067781|NCT01101035|Experimental|Febuxostat|Febuxostat 40 mg (or 80 mg beginning on week 4 if serum uric acid level was ≥6.0 mg/dL), tablets, orally, once daily for up to approximately 82 months.
3067782|NCT01101035|Active Comparator|Allopurinol|Allopurinol 300 mg to 600 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with mildly impaired renal function or normal renal function (estimated creatinine clearance [eCLcr] ≥60 mL/min) or allopurinol 200 mg to 400 mg (increased in 100 mg increments each month until serum uric acid was <6.0 mg/dL), tablets, orally, once daily for up to approximately 83 months to participants with moderately impaired renal function (eCLcr ≥30 but <60 mL/min).
3067783|NCT01101061|Experimental|Romosozumab|Japanese women in cohorts 1, 2, and 4 will receive a single dose of 1, 3, or 5 mg/kg romosozumab. Non-Japanese women in cohort 3 will receive a single dose of 3 mg/kg romosozumab.
3067784|NCT01101061|Placebo Comparator|Placebo|Participants will receive a single dose of placebo.
3067785|NCT01101100|Experimental|AMG 827|AMG 827
3067786|NCT01101165|Experimental|Reformulated OXY 40 mg|Reformulated OXY 40 mg x 1 dose
3067787|NCT01101165|Active Comparator|Original OxyContin® (OXY) 40 mg|Original OxyContin® (OXY) 40 mg x 1 dose
3067788|NCT01101178|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
3067789|NCT01101178|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
3067790|NCT01101191|Experimental|Reformulated OXY 80 mg|Reformulated OXY 80 mg x 1 dose
3067791|NCT01101191|Active Comparator|Original OxyContin® (OXY) 80 mg|Original OxyContin® (OXY) 80 mg x 1 dose
3067792|NCT01101308|Experimental|Reformulated OXY 10 mg (Totowa)|Reformulated OXY 10 mg (Totowa) x 1 dose
3067793|NCT01101308|Active Comparator|Reformulated OXY 10 mg (Wilson)|Reformulated OXY 10 mg (Wilson) x 1 dose
3067794|NCT01101321|Experimental|Reformulated OXY 80 mg (Totowa)|Reformulated OXY 80 mg (Totowa) x 1 dose
3067795|NCT01101321|Active Comparator|Reformulated OXY 80 mg (Wilson)|Reformulated OXY 80 mg (Wilson) x 1 dose
3067796|NCT01101334|Experimental|CS-7017 plus erlotinib|
3067797|NCT01101334|Active Comparator|erlotinib|
3067798|NCT01101464|Experimental|Asenapine Sequence 1|
3067799|NCT01101464|Experimental|Asenapine Sequence 2|
3067800|NCT01101477|Active Comparator|Titration by target effect site concentration (Cet) 0.5μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3067801|NCT01101477|Active Comparator|Titration by Cet 0.2μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3067802|NCT01101477|Active Comparator|Titration by Cet 0.1μg/ml|The investigator will titrate the Cet to keep stable vital signs and sedative level during the flexible bronchoscopy. The criteria for titration is descried in the intervention.
3067803|NCT01101542||Cervarix Group|Subjects received 3 doses of the Cervarix vaccine. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0,1, 6 month vaccination schedule. According to the prescribing information, if flexibility in the vaccination schedule is necessary, the second dose can be administered between 1 month and 2.5 months after the first dose.
3067804|NCT01101750|Other|Liver and Kidney Transplant Patient Arm|Standard of Care Intervention: Participants on this arm receive Gardasil vaccine and have a history of liver or kidney transplant.
3067805|NCT01101841|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
3067806|NCT01101841|Placebo Comparator|Placebo capsules|Sugar pill
3067807|NCT01101867|Experimental|Aspart flexible dose|aspart dose determined based upon carbohydrate intake.
3067808|NCT01101867|Active Comparator|Aspart fixed dose|fixed meal dose of aspart (based upon weight or total daily insulin dose)
3067809|NCT01101880|Experimental|Treatment (chemotherapy and colony stimulating factor)|"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.~CONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.~Treatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity."
3067810|NCT01101958|Other|Chartis System-EBV Treatment|Subjects with heterogeneous emphysema, had their collateral ventilation status in the target treatment lobe assessed using the Chartis System (CV- or CV+) and underwent endobronchial lung volume reduction (ELVR) with endobronchial valves (EBV).
3067811|NCT01101971|Experimental|first year medical students|
3067812|NCT01101997|Experimental|Experimental: Abdomen Treatment Group|All subjects were treated on the abdomen with the CoolSculpting system.
3067813|NCT01102218|Experimental|erythropoietin plus pentoxifylline|
3067814|NCT01102218|Active Comparator|erythropoietin alone|
3067815|NCT01102231|Experimental|A|Chemoradiotherapy
3067816|NCT01102257|Experimental|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 esssential fatty acid i.e Omega-3 EFA supplement comprised of:~2000 mg EPA 1000 mg DHA"
3067817|NCT01102257|Placebo Comparator|Olive Oil|Gel Capsule
3067818|NCT01102270|Active Comparator|Eszopiclone|Eszopiclone 3mg prior to sleep (1 night)
3067819|NCT01102270|Placebo Comparator|Sugar Pill|Sugar Pill (placebo) prior to sleep (1 night)
3067820|NCT01102374|Experimental|High Dose Vitamin D|100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
3067821|NCT01102374|Active Comparator|Standard Dose Vitamin D|12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.
3067822|NCT01102413|Experimental|Monofer|Injections or infusions
3067823|NCT01102413|Active Comparator|Iron Sulphate|Oral intake
3067824|NCT01102426|Experimental|Plitidepsin+Dexamethasone|plitidepsin + dexamethasone combination
3067825|NCT01102426|Active Comparator|Dexamethasone|dexamethasone single agent
3067826|NCT01102491|Experimental|Ramosetron prophylaxis|ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery
3067827|NCT01102491|No Intervention|Control|no antiemetic prophylaxis
3067828|NCT01102738||Premature babies (<32 weeks)|All premature babies born at less than 32 completed weeks gestation who are admitted to an Imperial College NHS Healthcare Trust Neonatal Intensive Care Unit (St. Mary's Hospital or Queen Charlotte's & Chelsea Hospital), and whose parents/guardians have given their consent will be eligible to enter the study.
3067829|NCT01102764|Experimental|Arm 1: PE via telemedicine|PE via telemedicine
3067830|NCT01102764|Active Comparator|Arm 2: PE in person|PE in person
3067831|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
3067832|NCT01102777|Other|Internet-mediated Walking Program|"participants in the intervention arm are asked to participate in a walking program~automated internet-mediated walking program: intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress"
3067833|NCT01102803|Placebo Comparator|Sugar Pill|Participants will receive placebo augmented cognitive behavioral therapy
3067834|NCT01102803|Experimental|D-Cycloserine|Participants will receive D-Cycloserine augmented cognitive behavioral therapy
3067835|NCT01102894|Experimental|Low fiber and High Fiber|Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
3067836|NCT01102972|Experimental|ATV + ABC/3TC|Subjects will change to ATV 400mg administered as two 200mg capsules orally, once daily and to the fixed-dose combination tablet of ABC 600mg/3TC 300mg (EPZICOM) administered as one tablet orally, once daily for 48 weeks. The subject's pre-study RTV will be discontinued.
3067837|NCT01102972|Active Comparator|ATV + RTV + TDF/FTC|Subjects will continue their pre-study therapy, un-modified, of ATV 300mg administered as one capsule orally, once daily plus RTV 100mg administered orally, once daily plus fixed dose combination tablet tenofovir 300mg/emtricitabine 200mg administered as one tablet orally, once daily for 48 weeks.
3067838|NCT01103063|Experimental|AZCQ|Azithromycin/chloroquine
3067839|NCT01103063|Active Comparator|SP|sulfadoxine-pyrimethamine (Fansidar)
3067840|NCT01103141|Active Comparator|Micropuncture|
3067841|NCT01103141|Active Comparator|Standard|
3067842|NCT01103232|Experimental|Electrical Muscle Stimulation|Electrical muscle stimulation of the right wrist flexor muscles was applied
3067843|NCT01103232|Sham Comparator|Control|Transcutaneous electrical nerve stimulation was applied
3067844|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 300|"Hydrochlorothiazide (HCTZ) 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg (ALI 150) daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 300mg ((ALI 300) for 1 month"
3067845|NCT01103245|Active Comparator|HCTZ plus ALI 150 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25mg (SPL 25) daily for one month"
3067846|NCT01103245|Active Comparator|HCTZ plus SPL 25 then SPL 50|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg (SPL 25) daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 50 mg daily for one month"
3067847|NCT01103245|Active Comparator|HCTZ plus SPL 25 then ALI 150 and SPL 25|"HCTZ 12.5mg daily for 1 month~then HCTZ 12.5mg daily plus Spironolactone 25 mg daily for 1 month~then HCTZ 12.5mg daily plus Aliskiren 150 mg daily and Spironolactone 25 mg daily for one month"
3067848|NCT01103271|Experimental|Open-label Placebo Immediate Treatment|Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.
3067849|NCT01103271|Placebo Comparator|Open-label Placebo Waitlist Treatment|Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.
3067850|NCT01103284|Experimental|DiaPep277|Administration of 1 mg DiaPep277®, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
3067851|NCT01103284|Placebo Comparator|Placebo|Administration of placebo, subcutaneously (s.c.) in the upper arm at 0, 1, 3, 6, 9, 12, 15, 18, 21, and 24 months, for a total of 10 administrations.
3067852|NCT01103323|Experimental|Regorafenib (Stivarga, BAY73-4506)+BSC|Participants received Regorafenib 160 mg per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care(BSC).
3067853|NCT01103323|Placebo Comparator|Placebo+BSC|Participants received matching placebo tablets per oral once daily for 3 weeks on 1 week off of every 4 week cycle plus Best Supportive Care (BSC).
3067854|NCT01103362|Experimental|flibanserin 100mg|flibanserin 100mg po qd
3067855|NCT01103414|Experimental|Mitoglitazone 50 mg capsules|Mitoglitazone 50 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3067856|NCT01103414|Experimental|Mitoglitazone 100 mg capsules|Mitoglitazone 100 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3067857|NCT01103414|Experimental|Mitoglitazone 150 mg capsules|Mitoglitazone 150 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3067858|NCT01103414|Active Comparator|Pioglitazone 45 mg capsules|Pioglitazone 45 mg capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3067859|NCT01103414|Placebo Comparator|Matching placebo|Placebo capsules self administered once-daily each morning after an overnight fast and 30 minutes before the morning meal for 84 days.
3067860|NCT01103440|Other|Conventional Strategy|Patient receive 325 mg ASA orally and loading does of 600mg Clopidogrel at time of procedure
3067861|NCT01103440|Active Comparator|Aggressive Strategy|Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
3067862|NCT01103466|Active Comparator|New ostomy appliance (Atlas)|Atlas= new base plate. Due to company confidentiality the product is just called Atlas and this is not short for any other names
3067863|NCT01103466|Active Comparator|SenSura|Commercially available ostomy appliance
3067864|NCT01103466|Active Comparator|Conform 2|Commercially available ostomy appliance
3067865|NCT01103479|No Intervention|Control|Participants will complete interviewer-administered pre- and post-test
3067866|NCT01103479|Experimental|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer screening guidelines, communication skills, and health literacy training
3067867|NCT01103479|Experimental|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational digital video disc (DVD) on CRC and CRC screening
3067868|NCT01103492|Experimental|Ablation catheter|Procedure using the HALO90 Ablation catheter to heat a thin layer of rectal tissue using radiofrequency to reduce inflammation and bleeding in subjects with radiation proctitis.
3067869|NCT01103505|Other|ForeseeHome AMD Monitoring Device|Participants in the device monitoring arm will receive a packed device at home, with instructions to install and connect the device to a modem as well as instructions for daily use of the device in addition to standard care
3067870|NCT01103505|No Intervention|Standard care alone (control) arm|Standard care instruction per clinic routine for home vision monitoring to detect progression of AMD and routine eye exams
3067871|NCT01103713|Experimental|AZCQ|Azithromycin/Chloroquine
3067872|NCT01103778|Experimental|Velcade® therapy|Patients with greater than 1gm of proteinuria per day will receive Velcade®.
3067873|NCT01103934|Active Comparator|Fluticasone Propionate plus Vitamin D3|Subjects will be treated with fluticasone propionate and Vitamin D once daily for 2 weeks during allergy season
3067874|NCT01103934|Placebo Comparator|Fluticasone Propionate plus Placebo|Subjects will be treated with fluticasone propionate and placebo for Vitamin D once daily for 2 weeks during allergy season
3067875|NCT01103960|Experimental|Telmisartan80mg+Amlodipine5mg|combination therapy
3067876|NCT01103960|Active Comparator|amlodipine 5 mg|Monotherapy
3067877|NCT01103973|Placebo Comparator|Control (Spa Certificate)|For every three months in the study control subjects received $50 spa gift certificates.
3067878|NCT01103973|Experimental|Mind/Body Program|Ten week group mind/body program. Skills include relaxation training, cognitive strategies, and lifestyle modifications.
3067879|NCT01104025|Experimental|Induction Therapy|ATG, rabbit: intravenous, 5 mg/kg/dose, 5 consecutive days Dexamethasone: intravenous, 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days Etoposide: intravenous, 150 mg/m2 weekly, starting 7 days after first dose of Thymoglobulin Methotrexate and hydrocortisone: intrathecal to patients with central nervous system involvement, age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg, on day 7, 14, 21 and 42
3067880|NCT01104090|Experimental|C-MAC direct laryngoscopy, then C-MAC indirect laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and then using C-MAC with indirect laryngoscopy.
3067881|NCT01104090|Experimental|C-MAC indirect laryngoscopy, then C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with indirect laryngoscopy first and then using C_MAC with direct laryngoscopy.
3067882|NCT01104103|Experimental|BOA(R)|Nurse or paramedic uses the BOA(R)-Constricting IV Band to attempt placement of an upper extremity IV in an adult
3067883|NCT01104103|Active Comparator|Standard care|Nurse or paramedic uses standard IV starting technique in the upper extremity of adults
3067884|NCT01104155|Active Comparator|eribulin mesylate, 21 day cycle|
3067885|NCT01104155|Active Comparator|eribulin mesylate, 28 day cycle|
3067886|NCT01104207|Experimental|Arm 1|Half of the study participants will receive 2000 pulses of 1 Hz active rTMS daily on 10 consecutive work days.
3067887|NCT01104207|Sham Comparator|Arm 2|Half of the study participants will receive 2000 pulses of 1 Hz placebo rTMS daily on 10 consecutive work days.
3067888|NCT01104246|Experimental|Testosterone Transdermal Systems|Testosterone
3067889|NCT01104285||Standard care|Treatment of pleural effusion with diuresis
3067890|NCT01104285||Chest tube|Treatment of pleural effusion with diuresis and chest tube
3067891|NCT01104311|Experimental|Aggressive BP lowering|Lowering of systolic blood pressure between 110mmHg and 120mmHg during study period
3067892|NCT01104311|Active Comparator|Modest BP lowering|Lowering of systolic blood pressure between 130mmHg and 140mmHg
3067893|NCT01104376|Experimental|CYP2B6|"Healthy volunteers will receive Efavirenz and Vericonazole as follow:~In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered. In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
3067894|NCT01104402|No Intervention|Standard Care|Subjects will receive education about signs and symptoms indicative of worsening CF.
3067895|NCT01104402|Active Comparator|Home monitoring|Subjects will be randomized to monitor home spirometry and symptoms using a handheld device.
3067896|NCT01104415|Experimental|Telotristat etiprate - Core Phase|Following a 2-week Run-In Period, participants received telotristat etiprate capsules at a starting dose of 150 mg, orally three times daily (TID) for 14 days in the Core Phase. Dose escalations (250 mg, 350 mg, 500 mg) occurred serially every 14 days, up to a maximum dosage of telotristat etiprate 500 mg TID, as guided by specific clinical criteria for dose escalation. Upon completion of 12 weeks of treatment, participants were eligible to receive telotristat etiprate in the optional Open-label Extension Period.
3067897|NCT01104415|Experimental|Telotristat etiprate - Extension Period|Participants received telotristat etiprate at their highest tolerated dose (250 mg or 500 mg), orally, TID for 124 weeks in the Open-label Extension Period. If neither dose was tolerated participants were discontinued from the study and completed the 2-week Follow-up Visit.
3067898|NCT01104493|Experimental|1|Single dose of monovalent vaccine
3067899|NCT01104493|Placebo Comparator|2|Placebo
3067900|NCT01104545|Experimental|Panel A - Healthy|Healthy participants receive single oral dose of MK-3614 0.25 mg, 1.25 mg, 0.25 mg w/ food, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast except for Period 3. Period 3 dose was administered after the ingestion of a high-fat breakfast.
3067901|NCT01104545|Experimental|Panel B - Healthy|Healthy participants receive single oral dose of MK-3614 0.5 mg. 0.75 mg, 0.25 mg twice a day (b.i.d.), 0.25 mg three times a day (t.i.d), or matching placebo. There is at least a 7-day washout between the 4 dosing periods. All doses were administered after an 8-hour fast
3067902|NCT01104545|Experimental|Panel C - Hypertensive|Hypertensive participants receive single oral dose of MK-3614 0.75 mg. 0.5 mg. 0.75 mg, 0.75 mg or matching placebo. There is at least a 7-day washout between the 4 dosing period. All doses were administered after an 8-hour fast
3067903|NCT01104584|Experimental|Gadobutrol (Gadavist, BAY86-4875)|Patients first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection (i.v.) at a rate of 2 ml/sec. Unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
3067904|NCT01104636||Single group prospective treatment cohort (varenicline)|
3067905|NCT01104662|Experimental|Daptomycin, Bacteremia, Severe Renal Impairment|Cohort 1. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with Creatinine Clearance (CLcr) below 30 milliliters per minute (mL/min) and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 14 to 42 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 14 to 42 days based on disease resolution or Investigator discretion.
3067906|NCT01104662|Active Comparator|Vancomycin or SSP, Bacteremia, Severe Renal Impairment|Cohort 1. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by Methicillin-Susceptible Staphylococcus Aureus (MSSA) could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered intravenously (IV) until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3067907|NCT01104662|Experimental|Daptomycin, Bacteremia, Moderate Renal Impairment|Cohort 2. Daptomycin was given intravenously 6 milligrams per kilogram (mg/kg) per administration. For bacteremia participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 14 to 42 days based on disease resolution or Investigator discretion.
3067908|NCT01104662|Active Comparator|Vancomycin or SSP , Bacteremia, Moderate Renal Impairment|Cohort 2. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for bacteremia or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3067909|NCT01104662|Experimental|Daptomycin, cSSSI, Severe Renal Impairment|Cohort 3. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr below 30 mL/min and currently receiving hemodialysis, daptomycin was administered immediately following each hemodialysis session (3 per week) for 7 to 14 days based on disease resolution or Investigator discretion. For participants not receiving dialysis, daptomycin was administered every 48 hours for 7 to 14 days based on disease resolution or Investigator discretion.
3067910|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Severe Renal Impairment|Cohort 3. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3067911|NCT01104662|Experimental|Daptomycin, cSSSI, Moderate Renal Impairment|Cohort 4. Daptomycin was given intravenously 4 milligrams per kilogram (mg/kg) per administration. For cSSSI participants with CLcr values between 30 and 50 mL/min not receiving dialysis, daptomycin was administered every 24 hours for 7 to 14 days based on disease resolution or Investigator discretion.
3067912|NCT01104662|Active Comparator|Vancomycin or SSP , cSSSI, Moderate Renal Impairment|Cohort 4. Participants randomized to the comparator therapy group received vancomycin or penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin). Investigators were allowed to select an agent based on local availability and normal treatment practices. Participants randomized to comparator subsequently found to have an infection caused by MSSA could have switched from vancomycin to penicillinase-resistant penicillin (nafcillin, oxacillin, or cloxacillin) at the Investigator's discretion. All treatments were dosed per Investigator's discretion and were administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3067913|NCT01104701|Active Comparator|Group A|2 mg exenatide once weekly subcutaneous (SC). This arm is used as a reference arm in the study.
3067914|NCT01104701|Experimental|Group B|Low dose 5 mg exenatide once monthly suspension SC.
3067915|NCT01104701|Experimental|Group C|Medium dose 8 mg exenatide once monthly suspension SC.
3067916|NCT01104701|Experimental|Group D|High dose 11 mg exenatide once monthly suspension SC.
3067917|NCT01104766|Experimental|Cariprazine 3mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
3067918|NCT01104766|Experimental|Cariprazine 6mg|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
3067919|NCT01104766|Active Comparator|Aripiprazole 10mg|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
3067920|NCT01104766|Placebo Comparator|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
3067921|NCT01104779|Experimental|Cariprazine (3-6 mg/day)|Cariprazine once daily fixed-flexible low dose
3067922|NCT01104779|Experimental|Cariprazine (6-9 mg/day)|Cariprazine once daily fixed-flexible high dose
3067923|NCT01104779|Placebo Comparator|Placebo|Placebo
3067924|NCT01104792|Experimental|Cariprazine|Participants received cariprazine 3.0, 4.5, 6.0, or 9.0 mg orally once a day for 48 weeks.
3067925|NCT01104870|Active Comparator|Dose Group 1|UT-15C 0.25 mg twice daily
3067926|NCT01104870|Active Comparator|Dose Group 2|UT-15C 1.25 mg twice daily
3067927|NCT01104870|Active Comparator|Dose Group 3|UT-15C individual Maximum Tolerated Dose
3067928|NCT01105065|Experimental|Patients with RVD|Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.
3067929|NCT01105091|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
3067930|NCT01105091|Active Comparator|2|Flolan®
3067931|NCT01105117|Active Comparator|1|ACT-385781A (Actelion Epoprostenol)
3067932|NCT01105117|Active Comparator|2|Flolan®
3067933|NCT01105130|Placebo Comparator|Arm I - Placebo|Patients receive oral placebo twice daily (total of 6 capsules per day).
3067934|NCT01105130|Experimental|Arm II - low dose|Patients receive oral L-arginine and oral placebo twice daily (total of 3 capsules of each per day).
3067935|NCT01105130|Experimental|Arm III - high dose|Oral L-arginine twice daily = 6 capsules per day.
3067936|NCT01105247|Experimental|PCI-32765|
3067937|NCT01105312|Experimental|panobinostat (LBH589) and letrozole|Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks. There are two phases of the study. The first phase determines the maximum tolerated dose for LBH589 in combination with letrozole. The second phase is to assess and confirm the response rate and safety profile of LBH589 in combination with letrozole.
3067938|NCT01105377|Experimental|Treatment (entinostat, azacitidine)|Patients receive azacitidine subcutaneously on days 1-5 and 8-10 and oral entinostat on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3067939|NCT01105533|Experimental|Cohort 1|
3067940|NCT01105533|Experimental|Cohort 2|
3067941|NCT01105533|Experimental|Cohort 3|
3067942|NCT01105533|Experimental|Cohort 4|
3067943|NCT01105533|Experimental|Cohort 5|
3067944|NCT01105533|Experimental|Cohort 6|
3067945|NCT01105533|Experimental|Cohort 7|
3067946|NCT01105533|Experimental|Cohort 8|
3067947|NCT01105533|Experimental|Cohort 9|
3067948|NCT01105533|Experimental|Cohort 10|
3067949|NCT01105650|Experimental|Arm 1: CsA|Patients receiving Cyclosporine (CsA) and Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3067950|NCT01105650|Experimental|Arm 2: CsA plus Methylprednisolone (10mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer cells (NK) infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3067951|NCT01105650|Experimental|Arm 3: CsA plus Methylprednisolone (1 mg)|Patients receiving Cyclosporine (CsA), methylprednisolone and natural killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 6 doses given post NK cell infusion.
3067952|NCT01105650|Experimental|Arm 4: CsA minus Methylprednisolone|Patients receiving Cyclosporine (CsA), no methylprednisolone, eliminating IL-2 doses 4-6 and receiving Natural Killer (NK) cells infusion (created from donor lymphapheresis) after preparative regimen of Fludarabine and Cyclophosphamide. Interleukin-2 (IL-2) 6 million units 3 times a week x 3 doses given post NK cell infusion.
3067953|NCT01105702|Experimental|TBL/RT|"Cycle 1(One 42-day cycle)~Temozolomide 75 mg/m^2 orally (42 consecutive days), beginning the night prior to the first radiation treatment~Radiation within 3-5 weeks of surgery~Bevacizumab 10mg/kg, IV, starting 29 (+3) days post surgery and every 2 weeks~Treatment Cycles 2-7 (28 days per cycle)~Temozolomide at a dose of 150 mg/m^2 on Days 1-7~Bevacizumab 10 mg/kg on Day 8 and Day 22~Initiate Lithium carbonate treatment at 300 mg, orally, twice a day; dose increased every 7 days up to 600mg, orally, twice a day, to a serum lithium level of 0.8-1.2 mEq/L."
3067954|NCT01105754|No Intervention|Standard Care|Parents of children in the standard care group will complete the baseline assessment, but no asthma prompt will be created for either the caregiver or provider, and no information regarding the interview will be shared with the provider. After the baseline assessment, the office visit will proceed according to usual care.
3067955|NCT01105754|Experimental|Multifaceted Prompting Intervention|Multifaceted Prompting Intervention
3067956|NCT01105767|No Intervention|Group 1 Standard|Trainees received a preventive medicine briefing augmented with SSTI and MRSA SSTI prevention information and personal hygiene instructions. Trainees seeking medical care for an SSTI received standardized SSTI care (e.g., antimicrobial therapy, wound management, patient education) at the Troop Medical Clinic. High-touch common surfaces within the battalion areas were cleaned with standard Environmental Protection Agency-registered disinfectants.
3067957|NCT01105767|Active Comparator|Group 2 Enhanced Standard|Trainees received the components of the Standard group as well as supplemental training, education and hygiene. They were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit. Supplemental SSTI education for trainees and drill sergeants was also provided (e.g., pocket cards, posters). Drill sergeants received briefings on SSTI and skin inspection/minor wound care.
3067958|NCT01105767|Active Comparator|Group 3 Chlorhexidine|Trainees received the components of the Standard and Enhanced Standard groups and were offered chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) to use with a wash cloth after using their personal soap for the additional once-weekly shower. Trainees were provided with verbal and written/graphic instructions for use.
3067959|NCT01105936|Experimental|Paracetamol caplets|Two 665 mg sustained release paracetamol caplets administered orally with water.
3067960|NCT01105936|Placebo Comparator|Placebo caplets|Two placebo caplets administered orally with water.
3067961|NCT01105975|Experimental|30 milligram (mg) LY2484595 monotherapy|
3067962|NCT01105975|Experimental|100 mg LY2484595 monotherapy|
3067963|NCT01105975|Experimental|500 mg LY2484595 monotherapy|
3067964|NCT01105975|Placebo Comparator|Placebo|
3067965|NCT01105975|Active Comparator|20 mg Atorvastatin monotherapy|
3067966|NCT01105975|Experimental|100 mg LY2484595 + 20 mg Atorvastatin|
3067967|NCT01105975|Active Comparator|40 mg Simvastatin monotherapy|
3067968|NCT01105975|Experimental|100 mg LY2484595 + 40 mg Simvastatin|
3067969|NCT01105975|Active Comparator|10 mg Rosuvastatin monotherapy|
3067970|NCT01105975|Experimental|100 mg LY2484595 + 10 mg Rosuvastatin|
3067971|NCT01106014|Experimental|1|Selexipag is up-titrated from Day 1 to Week 12 to each patient's maximum tolerated dose in the range of 200-1600 µg twice a day (b.i.d.) in 200 µg steps starting with one 200 µg oral tablet on Day 1. From Day 2 onwards, a b.i.d. dose regimen with an interval of approximately 12 hours is followed. If this dose (selexipag 200 μg b.i.d.) is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg. Up-titration is followed by a stable maintenance treatment period from Week 12 onwards, up to Week 26, at the maximum tolerated dose
3067972|NCT01106014|Placebo Comparator|2|Matching placebo is administered orally with a dosing interval of approximately12 h. A (mock) up-titration scheme is followed
3067973|NCT01106027|Experimental|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery. Patients will be given 900 mg of eculizumab on Day 1 post-transplant. Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant.~At week 4, patients will be assessed for donor specific anti-donor human leukocyte antigen (HLA) antibody (DSA). Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly."
3067974|NCT01106040|Experimental|Lymphoseek, Lymphatic mapping, Injection|
3067975|NCT01106092|Experimental|GSK2036874A GROUP 1|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 1) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3067976|NCT01106092|Experimental|GSK2036874A GROUP 2|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 2) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3067977|NCT01106092|Experimental|GSK2036874A GROUP 3|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of GSK2036874A vaccine (Formulation 3) intramuscularly into the anterolateral region of the left thigh, at Day 0.
3067978|NCT01106092|Active Comparator|ZILBRIX/HIB/POLIORIX GROUP|Healthy male or female children between and including 12 and 24 months of age at the time of the booster vaccination, who were primed with a three-dose vaccination course of polio vaccine, additionally received 1 dose of Zilbrix/Hib™ and Poliorix™ vaccines at Day 0, administered intramuscularly into the anterolateral regions of the left and right thighs, respectively.
3067979|NCT01106157|Experimental|Anti-Thymocyte Globin plus pegylated GCSF|Subjects will receive an infusion of Anti-Thymocyte Globin (ATG) followed by 6 doses of pegylated GCSF every 2 weeks for 10 weeks.
3067980|NCT01106157|Placebo Comparator|Placebo|Saline infusion will be given on both Day 1 and Day 2 followed by placebo injection given in identical volumes in identical syringes in the identical subcutaneous manner
3067981|NCT01106248|Other|Eribulin Mesylate|
3067982|NCT01106287|Experimental|Treatment Sequence 1|Period 1: Placebo - Period 2: 80 mg - Period 3: 100 mg - Period 4: Placebo - Period 5: 140 mg
3067983|NCT01106287|Experimental|Treatment Sequence 2|Period 1: 60 mg - Period 2: 80 mg - Period 3: 100 mg - Period 4: 120 mg - Period 5: Placebo
3067984|NCT01106287|Experimental|Treatment Sequence 3|Period 1: 60 mg - Period 2: Placebo - Period 3: 100 mg - Period 4: 120 mg - Period 5: 140 mg
3067985|NCT01106287|Experimental|Treatment Sequence 4|Period 1: 60 mg - Period 2: 80 mg - Period 3: Placebo - Period 4: 120 mg - Period 5: 140 mg
3067986|NCT01106326|Experimental|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
3067987|NCT01106352|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) + docetaxel|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection. In the randomized phase IIa part of the protocol, the dose established in the dose-escalation part of the protocol (Phase I) will be used, i.e. 5 doses of 50 kBq/kg b.w. every 6 weeks in combination with the approved step-down dose of docetaxel (60 mg/m^2) administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone.
3067988|NCT01106352|Active Comparator|Docetaxel|Docetaxel (75 mg/m2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
3067989|NCT01106391|Experimental|AAA stent graft system|Abdominal aortic aneurysm stent graft system
3067990|NCT01106404|Other|6-week AdaptiveStim followed by 6-week manual programming|
3067991|NCT01106404|Other|6-week manual followed by 6-week AdaptiveStim programming|
3067992|NCT01106430|Experimental|Lisdexamfetamine Dimesylate|
3067993|NCT01106430|Active Comparator|Atomoxetine Hydrochloride|
3067994|NCT01106456|Experimental|All Nations Breath of Life (ANBL)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
3067995|NCT01106456|Experimental|Nontailored (NT)|"All participants in the proposed study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT) then randomized into either the culturally-tailored All Nations Breath of Life program (ANBL) or Nontailored program (NT)."
3067996|NCT01106586|Experimental|Stribild|
3067997|NCT01106586|Active Comparator|ATV/r + FTC/TDF|
3067998|NCT01106625|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3067999|NCT01106625|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3068000|NCT01106625|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
3068001|NCT01106651|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3068002|NCT01106651|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3068003|NCT01106651|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
3068004|NCT01106677|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3068005|NCT01106677|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3068006|NCT01106677|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin immediate release.
3068007|NCT01106677|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks and will then switch from placebo to 100 mg of sitagliptin once daily until Week 52. Placebo and sitagliptin will be given with protocol-specified doses of metformin immediate release.
3068008|NCT01106690|Other|Placebo/Sitagliptin|Each patient will receive matching placebo once daily for 26 weeks with stable doses of metformin and pioglitazone. At Week 26, patients will be switched from placebo to 100 mg of sitagliptin once daily with stable doses of metformin and pioglitazone until Week 52.
3068009|NCT01106690|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
3068010|NCT01106690|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with stable doses of metformin and pioglitazone.
3068011|NCT01106833|Active Comparator|calcineurin inhibitor|Sirolimus + calcineurin inhibitor + prednisone
3068012|NCT01106833|Experimental|Sirolimus and prednisone|Sirolimus + prednisone
3068013|NCT01106846|Placebo Comparator|Group A: Saline group|Group A: Saline group , infusion of saline intravenously
3068014|NCT01106846|Active Comparator|Group B: 1% Ketamine group|Group B: Infusion of ketamine 1% intravenously
3068015|NCT01106859|Active Comparator|zopiclone|Zopiclone is taken at bedtime 9 hours before driving. The middle-of-the-night medication is a placebo matching zolpidem tartrate sublingual tablet.
3068016|NCT01106859|Experimental|zolpidem 3 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 3 hours prior to driving.
3068017|NCT01106859|Experimental|zolpidem 4 hours prior|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is zolpidem tartrate sublingual tablet taken 4 hours prior to driving.
3068018|NCT01106859|Placebo Comparator|Placebo|A placebo matching zopiclone is taken at bedtime. The middle-of-the-night treatment is a placebo matching zolpidem tartrate sublingual tablet.
3068019|NCT01106898|Experimental|Treatment (chemotherapy with or without maintenance therapy)|"SYSTEMIC CHEMOTHERAPY: Patients receive cyclophosphamide IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY (Her-2 neu positive patients): Patients receive trastuzumab IV over 30 minutes on day 1. Treatment repeats every 14 days for 5 courses and then every 21 days for 14 courses in the absence of disease progression or unacceptable toxicity."
3068020|NCT01106950|Experimental|Treated Patients|Patients are treated with donor natural killer cells, fludarabine, cyclophosphamide, Denileukin diftitox, Donor lymphapheresis and IL-2.
3068021|NCT01106976||Group 1 Parkinson disease subjects|Subjects with Parkinson disease who previously participate in a motor and brain PET (brain positron emission tomography) imaging study who were invited for a longitudinal observational study.
3068022|NCT01107015|No Intervention|Group 1: Usual Care|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
3068023|NCT01107015|Active Comparator|Group 2: patient intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
3068024|NCT01107015|Active Comparator|Group 3: patient-physician intervention|Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
3068025|NCT01107015|Active Comparator|Group 4: data analyzed intervention|Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations
3068026|NCT01107197|Active Comparator|Isonitrogenous isocaloric formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula isonitrogenous isocaloric to the experimental one
3068027|NCT01107197|Experimental|Enriched nutrition formula|Patients were given standard diet plus 2 bottles of an hypercaloric oral formula enriched in arginine, zinc and antioxidant oligoelements
3068028|NCT01107353|Active Comparator|First Imipramine Pamoate, then Tofranil-PM|First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)
3068029|NCT01107353|Active Comparator|First Tofranil PM, then imipramine pamoate|First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)
3068030|NCT01107379||Balloon catheter device|Dilation of sinuses using Relieva Balloon Sinuplasty System
3068031|NCT01107392|Experimental|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
3068032|NCT01107392|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
3068033|NCT01107405|Active Comparator|Loteprednol etabonate base (QD)|Loteprednol etabonate ophthalmic base dosed once/day.
3068034|NCT01107405|Active Comparator|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base dosed two times/day
3068035|NCT01107405|Active Comparator|Loteprednol etabonate base (QID)|Loteprednol etabonate ophthalmic base dosed four times/day.
3068036|NCT01107405|Active Comparator|Loteprednol etabonate suspension (QID)|Loteprednol etabonate ophthalmic suspension dosed four times/day
3068037|NCT01107405|Placebo Comparator|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate, dosed either QD, BID, or QID
3068038|NCT01107418|Experimental|1|
3068039|NCT01107418|Experimental|2|
3068040|NCT01107418|Experimental|3|
3068041|NCT01107418|Experimental|4|
3068042|NCT01107444|Experimental|LY2181308 + Docetaxel|"LY2181308: 750 milligrams (mg), intravenous (IV), on Day -2 and Day -1 of a 2 day lead-in period; on Day 1, Day 6, and Day 14 for Cycle 1 (1 cycle = 21 days); and once weekly for Days 1 through 21 for Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.~Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV), on Day 1 of Cycle 1 (1 cycle = 21 days) and on Day 1 of Cycles 2 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met."
3068043|NCT01107444|Active Comparator|Docetaxel|Docetaxel: 75 milligrams/square meter (mg/m^2), intravenous (IV) on Day 1 of Cycles 1 through 6 (1 cycle = 21 days). After 6 cycles, it was possible to continue therapy until progression of disease, unacceptable toxicity, or another withdrawal criterion was met.
3068044|NCT01107457|Experimental|10 mg Ixekizumab|"Part A:~10 milligrams (mg) ixekizumab given subcutaneous (SC) on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3068045|NCT01107457|Experimental|25 mg Ixekizumab|"Part A:~25 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC (Q4W). Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3068046|NCT01107457|Experimental|75 mg Ixekizumab|"Part A:~75 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3068047|NCT01107457|Experimental|150 mg Ixekizumab|"Part A:~150 mg ixekizumab given SC on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional)~Administered 120 mg ixekizumab SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC Q4W through approximately week 344."
3068048|NCT01107457|Placebo Comparator|Placebo|"Part A:~Placebo given on weeks 0, 2, 4, 8, 12 and 16 for a total of six administrations.~Part B: (optional) 120 mg ixekizumab given SC Q4W. Subsequent to an amendment on May 2012, administration changed to 80 mg Q4W through Week 236.~Part C: (optional)~80 mg ixekizumab given SC Q4W through approximately week 344."
3068049|NCT01107457|Experimental|120 mg Ixekizumab|"Part B: (optional)~120 mg ixekizumab given SC every 4 weeks. Subsequent to an amendment on May 2012, administration changed to 80 mg every 4 weeks through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
3068050|NCT01107457|Experimental|80 mg Ixekizumab|"Part B: (optional)~Subsequent to an amendment on May 2012, administration changed to 80 mg ixekizumab Q4W through Week 236.~Part C: (optional) 80 mg ixekizumab given SC every 4 weeks through approximately week 344."
3068051|NCT01107535||Infants receiving Synagis (palivizumab) immunoprophylaxis|Infants born <= 32 weeks of gestation and are younger than 6 months of age, children with bronchopulmonary dysplasia who have received medical treatment in the last 6 months until the first year of life, and children 12 months or younger with hemodynamically significant acyanotic congenital heart disease (pulmonary hypertension or heart failure in treatment) prescribed Synagis (palivizumab) immunoprophylaxis according to the usual clinical practice.
3068052|NCT01107626|Experimental|Arm A (Induction then Maintenance with Bevacizumab)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm A receive bevacizumab IV over 30-90 minutes on day 1 of every cycle until progression or unacceptable toxicity."
3468804|NCT03892395|Placebo Comparator|Control group|"Supplementation for 2 years with one of the following treatments in capsule form:~Control group will receive: Vitamin D, a daily capsule containing 10 µg/day vitamin D"
3068053|NCT01107626|Experimental|Arm B (Induction then Maintenance with Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm B receive pemetrexed IV over 10 minutes on day 1 of every cycle until progression or unacceptable toxicity."
3068054|NCT01107626|Experimental|Arm C (Induction then Maintenance with Bevacizumab & Pemetrexed)|"Induction Therapy:~Patients receive paclitaxel IV over 3 hours, carboplatin IV over 15-30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Maintenance Therapy:~Patients achieving complete response, partial response or stable disease following induction therapy are randomized to 1 of 3 treatment arms. Patients in arm C receive bevacizumab as in arm A and pemetrexed as in arm B."
3068055|NCT01107665|Experimental|Pazopanib and Paclitaxel|Treatment on study will be administered in 4-week cycles. Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
3068056|NCT01107730|Active Comparator|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
3068057|NCT01107730|Active Comparator|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
3068058|NCT01107730|Active Comparator|Placebo|
3068059|NCT01107743||Amlodipine and Atorvastatin Combination Tablet|Subjects taking Amlodipine and Atorvastatin Combination Tablets
3068060|NCT01107834||Healthy Control|HIV-negative children born to healthy, HIV-negative women
3068061|NCT01107834||Exposed to HIV/HAART|HIV-negative children exposed to HIV and HAART in utero
3068062|NCT01107886|Experimental|Saxagliptin|
3068063|NCT01107886|Placebo Comparator|Placebo|Placebo
3068064|NCT01107899|Active Comparator|clopidogrel 600 mg|
3068065|NCT01107899|Active Comparator|prasugrel 60 mg|
3068066|NCT01107899|Experimental|prasugrel 30 mg|
3068067|NCT01107912|Experimental|5 milligrams (mg) prasugrel|
3068068|NCT01107912|Active Comparator|10 mg prasugrel|
3068069|NCT01107912|Active Comparator|75 mg clopidogrel|
3068070|NCT01107925|Experimental|5 mg prasugrel|
3068071|NCT01107925|Active Comparator|10 mg prasugrel|
3068072|NCT01107925|Active Comparator|75 mg clopidogrel|
3068073|NCT01107964|Active Comparator|Omega-3-acid ethyl esters|
3068074|NCT01107964|Placebo Comparator|Corn oil capsule|
3068075|NCT01108003|Experimental|Arm I|Patients receive oral broccoli sprout extract once daily on days 1-14 in the absence of disease progression or unacceptable toxicity.
3068076|NCT01108003|Placebo Comparator|Arm 2|Patients receive mango juice alone.
3068078|NCT01108068|Experimental|Lithium|patients with OPPG will be treated with lithium for 6 months
3068079|NCT01108068|No Intervention|Unaffected controls|Family members of patients with OPPG will have DXA and pQCT to compare to OPPG patients. These unaffected participants will not receive lithium.
3068080|NCT01108081|Experimental|Arm 1|Physical activity
3068081|NCT01108081|Experimental|Arm 2|Diet
3068082|NCT01108081|Active Comparator|Arm 3|Health education
3068083|NCT01108081|Experimental|Arm 4|Combined physical activity and diet
3068084|NCT01108094|Experimental|Cohort A - Itraconazole 400 mg|Oral itraconazole 400 mg as 200 mg twice daily, for 1 month, stratified by prior vismodegib history
3068085|NCT01108094|Experimental|Cohort B - Itraconazole 200 mg|Oral itraconazole 200 mg as 100 mg twice daily, for up to 3 months
3068086|NCT01108094|No Intervention|Untreated Control|Patients otherwise eligible but unwilling to take itraconazole were enrolled onto the control arm of the study and received no treatment
3068087|NCT01108185||Acute Respiratory Infections|Slovak patients with lower respiratory tract infection or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
3068088|NCT01108237|Other|TruMatch™ Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch™ Personalized Solutions
3068089|NCT01108237|Other|Historical Control|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional and CAS surgical techniques without TruMatch™ instrumentation.
3068090|NCT01108263|Active Comparator|Integra Flowable on wound bed|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
3068091|NCT01108263|Active Comparator|INTEGRA Flowable on wound & injected subcutaneously|INTEGRA™ Flowable is a wound Matrix made of bovine (cow) collagen. It provides a scaffold for cellular and capillary growth. Dosage is dependent on the size of the wound. It will be applied once.
3068092|NCT01108341|Experimental|Bendamustine and Ofatumumab|There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofatumumab administered at 1000 mg iv on day 1 of all additional cycles.
3068093|NCT01108406|Experimental|SoundBite Hearing System|"The objective of this study was to assess the long-term safety and quality of life impact of the SoundBite™ Hearing System.~Safety was measured in terms of dental, audiological and medical adverse events related to device or procedure.~Quality of Life was measured in terms of changes in Abbreviated Profile of Hearing Aid Benefit (APHAB) and as reported in a quality of life survey (SSD Questionnaire).~The duration of the study was 6 months with measures taken at Day 1, 3 months and 6 months."
3068094|NCT01108445|Active Comparator|RAD001|Subjects in this treatment arm will receive everolimus/RAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
3068095|NCT01108445|Active Comparator|Sunitinib|Subjects in this treatment arm will take sunitinib 50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
3068096|NCT01108458|Experimental|Pertuzumab plus Erlotinib Hydrochloride|"Pertuzumab 840 mg intravenous (IV) single loading dose followed by 420 mg IV every 3 weeks~Erlotinib hydrochloride 150 mg/day by mouth"
3068097|NCT01108510|Experimental|ATV+COBI+FTC/TDF|COBI + RTV placebo + ATV + FTC/TDF once daily
3068098|NCT01108510|Active Comparator|ATV+RTV+FTC/TDF|RTV + COBI placebo + ATV + FTC/TDF once daily
3068099|NCT01108718|Experimental|Participants: Tempur Pedic first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder who receive the Tempur-Pedic mattress first, then the Control Mattress.
3068100|NCT01108718|Placebo Comparator|Participants: Control Mattress first.|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic mattress.
3068101|NCT01108731|Active Comparator|Patients taking the drug Milnacipran|Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
3068102|NCT01108731|Placebo Comparator|Patients taking the placebo|Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.
3068103|NCT01108757|Experimental|Drug|
3068104|NCT01108757|Placebo Comparator|Placebo|
3068105|NCT01108796||Patients at cardiovascular risk|
3068106|NCT01108809||Patients with arterial hypertension|
3068107|NCT01108835|Active Comparator|comprehensive care programme|Comprehensive care involving multidisciplinary input.
3068108|NCT01108835|No Intervention|Control group|Control arm with usual care
3068112|NCT01109056|Experimental|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
3068113|NCT01109056|Placebo Comparator|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
3068114|NCT01109069|Experimental|PCI-32765|
3068115|NCT01109108||Children <2 years of age|Children <2 years of age with and without respiratory tract infection
3068116|NCT01109108||Children 2<5 years of age|Children 2<5 years of age with and without respiratory tract infection
3068117|NCT01109147|Active Comparator|aripiprazole|"Imagery: A fMRI session is conducted on schizophrenic patients under aripiprazole (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
3068118|NCT01109147|Active Comparator|risperidone|"Imagery: A fMRI session is conducted on schizophrenic patients under rsiperidone (medication taken and stabilized for at least six weeks before inclusion, no intervention on the medication is scheduled during the study).~Genetic: pharmacogenetic sampling. One sample was collected for each subject."
3068119|NCT01109147|Other|control|Imagery: A fMRI session is conducted on healthy volunteers. Genetic: pharmacogenetic sampling. One sample was collected for each subject.
3068120|NCT01109173|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
3068121|NCT01109173|Active Comparator|NEVANAC|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
3068122|NCT01109173|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Ophthalmic Suspension 0.3% Vehicle, one drop in affected eye once daily for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional dose was administered between 30-120 minutes prior to surgery.
3068123|NCT01109173|Placebo Comparator|NEVANAC Vehicle|Nepafenac 0.1% vehicle, one drop in affected eye three times daily, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery.
3068124|NCT01109316|Active Comparator|Insulin Lispro 2 Day|
3068125|NCT01109316|Experimental|Insulin Lispro 6 Day|
3068126|NCT01109316|Active Comparator|Insulin Aspart 6 Day|
3068127|NCT01109381|Experimental|Treatment with GT08|Initial phase - omeprazole, N-acetyl cysteine (NAC), lauric acid dose and duration titration from 1 up to 14 days of treatment. Secondary phase - 14 days treatment with omeprazole, NAC, lauric acid
3068128|NCT01109524|Experimental|Cetuximab + Cisplatin + Vinorelbine|
3068129|NCT01109576|Experimental|DSL workshop participants|Three to five Veterans with DSL.
3068130|NCT01109602|Experimental|Arm 1: Yoga Group|"Yoga Group, 8 week bi-weekly in-person yoga training focused on strength, flexibility, and balance~Yoga focused on strength, flexibility, and balance"
3068131|NCT01109602|Experimental|Arm 2: Yoga Group Plus|"Yoga Group Plus: 8 week, bi-weekly in-person yoga training focused on strength, flexibility, and balance paired with almost daily at home yoga focused on breathing and relaxation.~Yoga focused on strength, flexibility, and balance~Data for both yoga groups were combined for analyses as there were not any differences between these two groups."
3068132|NCT01109602|No Intervention|Arm 3: Wait list control group|wait-list control: will be assessed before and after 8 weeks. Will then be offered the 8 week yoga intervention.
3068133|NCT01109849|Active Comparator|weight recovery treatment- monitoring|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the monitoring arm , participants will continue on their ER stimulant 7 days a week and have their weight, height and BMI checked monthly.
3068134|NCT01109849|Active Comparator|behavior therapy|10 week basic parent training, advanced 8 week parent training course. monthly boosters, option for individual parent training sessions, school consultant assigned to each subject
3068135|NCT01109849|Experimental|ER stimulant|daily use of 12 hour extended release methylphenidate product
3068136|NCT01109849|Experimental|weight recovery treatment- caloric supplement|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the caloric supplement arm, participants will continue on their ER stimulant 7 days a week, have their weight, height and BMI checked monthly and be prescribed a 150 kcal caloric supplement to be consumed every evening.
3068137|NCT01109849|Experimental|weight recovery treatment- drug holiday|Subjects in either the behavior therapy arm or the medication arm will be assigned to one of 3 treatments if subject does not meet projected BMI goals. In the drug holiday arm, participants will only take their ER stimulant on school days a week and have their weight, height and BMI checked monthly.
3068138|NCT01109940|Experimental|AIN457|
3068139|NCT01109979|Active Comparator|Estradiol+MPA|
3068140|NCT01109979|Active Comparator|Estradiol+DRSP|
3068141|NCT01109992|Active Comparator|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
3068142|NCT01109992|Experimental|Exercise + Regadenoson (Lexercise)|Exercise plus Regadenoson (Lexercise) Rubidium-82 Positron Emission Tomography
3068143|NCT01110005|Active Comparator|D5 Lactated Ringer's solution (D5LR)|IV fluid containing glucose administered throughout labor at an average infusion rate of 125 ml/hr.
3068144|NCT01110005|Active Comparator|Lactated Ringer's solution (LR)|Non-glucose IV fluid administered throughout labor at an average infusion rate of 125 ml/hr.
3068145|NCT01110135|Experimental|Treatment (chemotherapy and colony-stimulating factor)|"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until > 5 x 10^6 CD34+/kg has been collected.~."
3068146|NCT01110187|Experimental|IV LCM (lacosamide)|Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
3068147|NCT01110187|Active Comparator|IV fPHT (fos-phenytoin)|Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin
3068148|NCT01110200|Active Comparator|ADVAIR DISKUS 250/50 mcg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
3068149|NCT01110200|Active Comparator|Serevent 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
3068150|NCT01110239|Experimental|remote limb preconditioning|Subjects with subarachnoid hemorrhage will undergo escalating times of limb ischemia to determine tolerability and safety. The leg will be made transiently ischemic with application of a blood pressure cuff for up to 3 cycles of 10 minutes.
3068151|NCT01110252|Active Comparator|pre-procedure|emphysema patients evaluated prior to the stem cells infusion
3068152|NCT01110252|Experimental|post-procedure|emphysema patients evaluated 30 days after the stem cells infusion
3068153|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F126)|ketoconazole 2% cream (formulation F126) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3068154|NCT01110330|Experimental|Ketoconazole 2% cream (formulation F012) (Nizoral)|ketoconazole 2% cream (formulation F012) (Nizoral) A topical white homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3068155|NCT01110330|Placebo Comparator|Placebo cream|Placebo cream A topical white homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet) once daily (at night or in the evenings) for a total of 4 weeks.
3068156|NCT01110382|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose)will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
3068157|NCT01110382|Experimental|Meropenem|Meropenem 20 mg/kg per dose (up to 1 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV meropenem only or IV meropenem followed by oral amoxicillin/clavulanate potassium). Total duration of treatment 5 to 14 days.
3068158|NCT01110395|Experimental|MR Spectroscopy Post-Heart Transplant|Patients post heart transplant getting heart biopsy
3068159|NCT01110408|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3068160|NCT01110408|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3068161|NCT01110421|Experimental|Doripenem|Doripenem 20 mg/kg per dose (up to 500 mg/dose) will be administered every 8 hours as 60-minutes IV (at least 3 days of IV doripenem only or IV doripenem followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3068162|NCT01110421|Experimental|Cefepime|Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
3068163|NCT01110434|Experimental|Topiramate|Topiramate (200 mg daily)
3068164|NCT01110434|Placebo Comparator|Sugar pill|
3068165|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068166|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068167|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068168|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068169|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068170|NCT01110499|Experimental|Part 1, AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye and bimatoprost ophthalmic solution 0.03% in the other eye once daily for 7 days.
3068171|NCT01110499|Experimental|Part 2, AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
3068172|NCT01110499|Active Comparator|Part 2, bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% in both eyes once daily for 4 weeks.
3068173|NCT01110681|Experimental|Solesta|"Open label. Solesta (Dextranomer in gel of stabilized non-animal hyaluronate) The study treatment consisted of 4 submucosal injections, 1 mL Solesta each, in the proximal part of the high pressure zone in the anal canal.~Re-treatment is allowed one month after initial treatment if the subject is still incontinent."
3068174|NCT01110707|Experimental|r-hFSH + r-hLH|
3068175|NCT01110707|Active Comparator|r-hFSH alone|
3068176|NCT01110876|Experimental|Phase I Group 1: Vorinostat + Erlotinib + Temozolomide|"Phase I 3-Drug Combination Vorinostat with Erlotinib + Temozolomide~Starting doses Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 125 mg/m^2 orally once daily on Days 1-7 and 15-21."
3068177|NCT01110876|Experimental|Phase I Group 2: Vorinostat + Erlotinib|"This Phase I arm to be activated only after completion of Part A of the Phase II trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
3068178|NCT01110876|Experimental|Phase II Part A 3-Drug Combination|"Vorinostat+Erlotinib+Temozolomide where drug dosing based on the MTD identified in the Phase I portion of the study.~Vorinostat 200 mg orally twice daily on Days 1-7 and 15-21 of every cycle; Erlotinib 200 mg orally once daily on Days 1-21; Temozolomide 100 mg/m^2 orally once daily on Days 1-7 and 15-21."
3068179|NCT01110876|Experimental|Phase II Part B 2-Drug Combination|"This Phase II Part B arm to be activated only after completion of Part A of the Phase I and II Part A trial of the 3-Drug combination. If part A of the Phase II trial shows lack of efficacy, trial will be terminated.~Vorinostat orally twice daily, Days 1-14; and Erlotinib orally once daily Days 1-21 of every cycle."
3068180|NCT01110915|Experimental|MRI group|Subjects randomized to the MRI group will undergo a one-hour MRI scan, including 16 individual sequences in the chest and head region, at 9-12 weeks post-implant.
3068181|NCT01110915|Active Comparator|Control group|Subjects randomized to the Control group will wait for one hour without having any MRI scan at 9-12 weeks post-implant.
3068183|NCT01111058|Experimental|Everolimus (RAD001)|Subjects will receive Everolimus 10 mg daily
3068184|NCT01111058|Experimental|Placebo|Subjects will receive double-blind placebo
3068185|NCT01111110|Experimental|Anti-static then Static for Albuterol|albuterol anti-static first then static chamber second.
3068186|NCT01111110|Experimental|Static then Anti-static for Albuterol|static then antistatic albuterol
3068187|NCT01111123|Active Comparator|1|Lac-Hydrin lotion twice daily everyday + Ultravate ointment twice daily on weekends only
3068188|NCT01111123|Placebo Comparator|2|Lac-Hydrin lotion twice daily everyday + placebo ointment twice daily on weekends only
3068189|NCT01111149|Placebo Comparator|Sugar Pill|Sugar pill will be given to patients as a comparison group to the active varenicline group. In the fist week, one placebo pill will be given per patient, followed by 2 pills per day for the remaining 12 weeks of the study.
3068190|NCT01111149|Experimental|Varenicline|Varenicline has not previously been examined for its efficacy and safety in subjects with schizophrenia. Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study. This is an experimental group to be compared against both placebo and bupropion HCl.
3068191|NCT01111149|Active Comparator|Bupropion HCl|Bupropion HCl is an established smoking cessation agent and will be used to compare its efficacy and safety against varenicline. Subjects in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study.
3068192|NCT01111162|Experimental|Vaccine|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
3068193|NCT01111240||Psoriatic Arthritis|Participants with Psoriatic Arthritis prescribed adalimumab in routine clinical practice were observed from the first dose for up to 24 months.
3068194|NCT01111292|Experimental|Arm I (inositol)|Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
3068195|NCT01111292|Placebo Comparator|Arm II (placebo)|Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.
3068196|NCT01111305|Active Comparator|Reslizumab + DEC|Reslizumab 1 mg/kg iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
3068197|NCT01111305|Placebo Comparator|Placebo + DEC|Placebo iv single dose followed by diethylcarbamazine 9 mg/kg/day po for 21 days
3068198|NCT01111318|Experimental|BI 10773|50 mg single dose
3068199|NCT01111331|Experimental|BI 10773 25 mg|1 tablet 25 mg BI 10773 qd for 5 days
3068200|NCT01111331|Experimental|BI 10773 25 mg + Warfarin 25 mg|1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose
3068201|NCT01111331|Active Comparator|Warfarin 25 mg|5 tablets 5 mg warfarin single dose
3068202|NCT01111370|Experimental|CGM|continuous glucose monitoring system
3068203|NCT01111461|Experimental|Lenvatinib 24 mg|Participants with advanced endometrial cancer and disease progression following platinum-based, first line chemotherapy.
3068204|NCT01111474|Active Comparator|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
3068205|NCT01111474|Active Comparator|Laser|3 Low intensity laser application (48 hour interval). The application of 1Joule/cm^2 was performed for eight seconds at three points along the dental neck, using the infrared wavelength (795nm)
3068206|NCT01111526|Experimental|LBH589, in Addition to Glucocorticoids|Phase I Dose Escalation, Followed by Phase II Treatment at Maximum Tolerated Dose (MTD) of LBH589, in Addition to Glucocorticoids.
3068207|NCT01111539|Experimental|Phase B: Single-blind Prospective Treatment Phase|Participants received initial dose of escitalopram 10 milligram (mg) blinded capsule (over-encapsulated tablet), orally, once daily, increased to 20 mg/day at the end of Week 1 based upon tolerability profile, for up to maximum of Week 8. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
3068208|NCT01111539|Experimental|Phase B+: Single-blind Phase B Responders|Participants with response (≥50% reduction in depressive symptom severity in Hamilton Depression Rating Scale {HAM-D17} Total Score; or a HAM-D17 Total Score of <14 at Week 8 or a Clinical Global Impression of Improvement {CGI-I} Score of <3 at the Week 6 or 8) at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B, for up to maximum of Week 14, in Phase B+.
3068209|NCT01111539|Experimental|Phase C: Aripiprazole/Escitalopram Combination|Participants with incomplete response (less than 50% reduction in depressive symptom severity between Baseline and Week 8 measured by the HAM-D17 Total Score and HAM-D17 Total Score of ≥14 at Week 8 and CGI-I Score of ≥3 at Week 6 and 8) at Week 8 received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily at Week 9. Participants were up titrated to aripiprazole target dose of 12 mg/day at Week 10 (if initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on initial 6 mg/day dose), and thereafter received same dose up to maximum of Week 14. No dose increases were allowed for aripiprazole after end of Week 12, however, doses might be decreased at any visit based upon tolerability. In combination with aripiprazole, participants received escitalopram (10 or 20 mg/day blinded capsules) taken during final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments allowed for escitalopram during Phase C.
3068210|NCT01111539|Experimental|Phase C: Escitalopram Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received escitalopram dose (10 or 20 mg/day blinded capsules) taken during the final week of Phase B for up to maximum Week 14, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
3068211|NCT01111539|Experimental|Phase C: Aripiprazole Monotherapy|Participants with incomplete response (less than a 50% reduction in depressive symptom severity between the Baseline and Week 8 as measured by the HAM-D17 Total Score and a HAM-D17 Total Score of ≥14 at Week 8 and a CGI-I Score of ≥3 at Week 6 and 8) at Week 8, received initial dose of aripiprazole 6 mg blinded capsule, orally, once daily for Week 9. Participants were up titrated to the aripiprazole target dose of 12 mg/day at Week 10 (if the initial 6 mg/day dose was tolerated) or down titrated to 3 mg/day (if significant tolerability issues arise on the initial 6 mg/day dose), and thereafter received the same dose for up to maximum of Week 14. No dose increases were allowed for aripiprazole after the end of Week 12, however, doses might be decreased at any visit based upon tolerability.
3068212|NCT01111552|Active Comparator|Phase B: Single-blind Prospective Treatment Phase|Escitalopram 10 mg capsule, orally, once daily increased to 20 mg/day at the end of Week 1 based upon tolerability profile, plus one matching placebo capsule, for 8 weeks. No dose reductions were allowed after Week 4 and no dose increments were allowed after Week 3. Participants with incomplete response at the end of the Phase B (Week 8) entered Phase C and the rest of the participants continued to Phase B+.
3068213|NCT01111552|Active Comparator|Phase B+: Single-blind Phase B Responders|Participants with response at the end of the Phase B (Week 8) continued treatment with the single-blind escitalopram monotherapy at the dose (10 or 20 mg/day) taken during the final week of Phase B plus one matching placebo capsule, for an additional 6 weeks, in Phase B+.
3068214|NCT01111552|Active Comparator|Phase C: Escitalopram Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received escitalopram monotherapy 10 or 20 mg capsule, orally, once daily, whichever dose was taken during the final week of Phase B plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram monotherapy during Phase C.
3068215|NCT01111552|Active Comparator|Phase C: Aripiprazole Monotherapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated. No dose increments were allowed after Week 12; however, doses may have been decreased at any week, based upon tolerability.
3068216|NCT01111552|Active Comparator|Phase C: Aripiprazole/Escitalopram Combination Therapy|Participants with incomplete response at Week 8 who were randomized to this arm group received aripiprazole 3, 6, or 12 mg capsule, orally, once daily in combination with the escitalopram 10 or 20 mg orally, once daily plus one matching placebo capsule for 6 weeks, in Phase C. No dose adjustments were allowed for escitalopram during Phase C. Participants were titrated to the aripiprazole target dose of 12 mg/day at Week 9 if the initial 6 mg/day dose was tolerated.
3068217|NCT01111604|Active Comparator|mFOLFOX-6|mFOLFOX-6
3068218|NCT01111604|Experimental|mFOLFOX-6 + Ramucirumab|mFOLFOX-6 + Ramucirumab
3068219|NCT01111604|Experimental|mFOLFOX-6 + Icrucumab|mFOLFOX-6 + Icrucumab
3068220|NCT01111825|Experimental|Temsirolimus plus Neratinib|This is an open-label, single arm, dose-escalation phase I-II study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and efficacy of this combination when given to patients with advanced breast carcinoma. Patients with trastuzumab-refractory HER2-amplified disease or triple negative disease will be enrolled in both phases of this clinical trial.
3068221|NCT01111838|Experimental|STA-9090|This is an open-label Phase 2 clinical study in patients with advanced colorectal cancer (CRC). Patients will be treated with 200mg/m2 of STA-9090 during a 1-hour intravenous infusion 1 time per week for three consecutive weeks followed by a 1 week dose-free interval. Patients tolerating STA-9090 will be permitted to continue treatment until disease progression.
3068222|NCT01111851|Experimental|Fosaprepitant 150 mg|Fosaprepitant 150 mg
3068223|NCT01111851|Experimental|Aprepitant 165 mg|Aprepitant 165 mg
3068224|NCT01111851|Experimental|Aprepitant 250 mg|Aprepitant 250 mg
3068225|NCT01112059|Placebo Comparator|Placebo|Patients given placebo twice a day for 8 days at beginning of inpatient CF exacerbation
3068226|NCT01112059|Active Comparator|doxycycline|Patients given doxycycline 100 mg tablet twice a day for 8 days at the beginning of inpatient CF exacerbation
3068227|NCT01112228||Obese patients|Obese patients for Bariatric surgery
3068228|NCT01112241|Experimental|albuterol-tiotropium|At visit 1, lung function measurements will be performed in triplicate before and 90 min after inhaling four separate doses of 100 μg of albuterol (Ventolin®) and soon after 18 μg of tiotropium bromide [Spiriva®] to ensure maximal or near-maximal bronchodilation. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber (Volumatic®) and tiotropium by a dry-powder device (Handihaler®).
3068229|NCT01112267|Experimental|Tramadol Hydrochloride (HCl)/acetaminophen|Participants will receive 1 tablet containing fixed dose of combination of tramadol hydrochloride (HCl) 75 milligram (mg) /acetaminophen Extended Release (ER) 650 mg orally once daily on Days 1 to 3, 1 tablet twice daily (tramadol HCl 150 mg/acetaminophen 1300 mg) on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
3068230|NCT01112267|Placebo Comparator|Placebo|Prticipants will receive 1 tablet matching placebo once daily orally on Days 1 to 3, 1 tablet twice daily on Days 4 to 7, then 1 or 2 tablets twice daily on Days 8 to 28.
3068231|NCT01112293|Experimental|Investigational drug infusion-for safety and effectiveness|Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment
3068232|NCT01112358|Experimental|r-FSH + r-hLH|Lutropin alfa (r-hLH) will be administered at a daily dose of 150 International Units (IU) from the presence of at least one follicle greater than (>) 14 millimeter (mm) to complete ovarian stimulation. Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 milligrams (mg) of recombinant Human Chorionic Gonadotropin (r-hCG) will be administered subcutaneously at 12 hours after the last injection of lutropin alfa and/or follitropin alfa and analogous GnRH antagonist.
3068233|NCT01112358|Active Comparator|r-FSH|Follitropin alfa (r-FSH) will be administered at an initial dose of 225-450 IU per day (according to standard center practice); the dose will then be adjusted to ovarian response as assessed by ovarian ultrasound and/or serum estradiol. Participants will also receive analogous GnRH antagonist and natural progesterone, as per standard center practice. To complete follicular maturation and trigger ovulation, a single dose of 250 mg of r-hCG will be administered subcutaneously at 12 hours after the last injection of follitropin alfa and analogous GnRH antagonist.
3068234|NCT01112514|Experimental|ICG Injection|These participants underwent a colonoscopy after having an ICG injection.
3068235|NCT01112579|Experimental|Treatment|
3068236|NCT01112579|Other|Control|
3068237|NCT01112670|Experimental|ABCB1 Group 1|ABCB1 CGC/CGC genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3068238|NCT01112670|Experimental|ABCB1 Group 2|ABCB1 CGC/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3068239|NCT01112670|Experimental|ABCB1 Group 3|ABCB1 TTT/TTT genetic make-up; sitagliptin 100 mg x 1 dose; atorvastatin 40 mg x 5 doses
3068240|NCT01112683|Experimental|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
3068241|NCT01112683|Placebo Comparator|Placebo|These are identically-looking pills to the ones in the Memantine Arm
3068242|NCT01112696|Other|Sensor|All subjects that wear sensors (all subjects)
3068243|NCT01112735|Experimental|ARTISS|ARTISS will be used as an adjuvant to standard of care.
3068244|NCT01112735|Other|Standard of care|Standard of care
3068245|NCT01112865|Other|Mark VII/Current pen|Subject will use Mark VII pen for 2 months followed by Current pen for 2 months
3068246|NCT01112865|Other|Current pen/Mark VII|Subject will use current Genotropin pen for 2 months followed by Mark VII pen for 2 months
3068247|NCT01112917|Experimental|VenaTech Convertible Vena Cava Filter|Implantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
3068248|NCT01112982|Other|Febuxostat Sub-Study|"To analyze the effect of urate-lowering therapy (specifically with febuxostat [Uloric]) on the synovial pannus in the index joint of a subgroup of patients. Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric) and who have a serum urate level of > or = to 9.0, will be treated with febuxostat (Uloric) and their serum urate level will be followed at months 1, 3, 6, and 9. Magnetic Resonance Imaging (with and without gadolinium) of the same index joint will be repeated at month 9 to assess for the presence and degree of synovial pannus. Because initiation of urate-lowering therapy can induce acute attacks of gout, these subjects will also be started on colchicine as a prophylactic (and remain on colchicine for 6 months)."
3068249|NCT01112982|Other|MRI of index joint|"To analyze synovial pannus in the Magnetic Resonance Imaging (with and without gadolinium) of the index joint on Subjects not currently on any urate-lowering therapy, or on a serum urate lowering drug other than febuxostat (Uloric)."
3068250|NCT01113008|Experimental|Remote postcondtioning|Patients assigned to remote ischemic postconditioning (randomized controlled trial)
3068251|NCT01113008|Placebo Comparator|Control group|
3068252|NCT01113385|Experimental|Galactose|Oral galactose will be given at a dose of 0.2gm/kg/dose twice a day (BID) to a maximum of 15 gm BID for a period of 16 weeks.
3068253|NCT01113398|Experimental|AMG 102 with Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg prior to AMG 102, which will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg. Subjects will receive infusions every 2 weeks.
3068254|NCT01113463|Experimental|TPI 287|TPI 287 Starting dose 160 mg/m^2 intravenous (IV) every 3 weeks
3068255|NCT01113502|Experimental|Phase 1 DL1|50 mg; Taken daily by mouth
3068256|NCT01113502|Experimental|Phase 1 DL 2|100 mg; Taken daily by mouth
3068257|NCT01113502|Experimental|Phase 1 DL3|200 mg; Taken daily by mouth
3068258|NCT01113502|Experimental|Phase 1 DL 4|300 mg; Taken daily by mouth
3068259|NCT01113502|Experimental|Phase 2|200 mg taken daily by mouth for 2 weeks; then 300 mg taken daily by mouth
3068260|NCT01113541|Experimental|Active treatment (switch to oral Ziprasidone)|
3068261|NCT01113580|Experimental|Adults|Healthy volunteers aged 18 to 59 years
3068262|NCT01113580|Experimental|Older Adults|Healthy volunteers aged 60 years or older
3068263|NCT01113632|Experimental|Ofatumumab 1000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 1000mg weekly for a total of 8 weeks
3068264|NCT01113632|Experimental|Ofatumumab 2000mg|Ofatumumab 300mg IV Day 1 followed by ofatumumab 2000mg weekly for a total of 8 weeks
3068265|NCT01113710||Neupro®|Routine treatment in accordance with the local marketing authorization for Neupro® in RLS
3068266|NCT01113723|Other|CMAC Device|CMAC Intubating device time to achieve successful tracheal intubation.
3068267|NCT01113723|Active Comparator|Fiberoptic bronchoscope|Fiberoptic bronchoscope Intubating device time to achieve successful tracheal intubation.
3068268|NCT01113749|Experimental|Decision support|Structured decision aid with prompting to share information in discussion with primary treating health care providers.
3068269|NCT01113749|No Intervention|Control|Usual care
3068270|NCT01113801|Placebo Comparator|Placebo|
3068271|NCT01113801|Experimental|2 mg LY2382770|
3068272|NCT01113801|Experimental|10 mg LY2382770|
3068273|NCT01113801|Experimental|50 mg LY2382770|
3068274|NCT01113879|Experimental|Aphasia therapy with an exercise adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Aerobic exercise: An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate."
3068275|NCT01113879|Placebo Comparator|Aphasia therapy with a stretching adjuvant|"Aphasia therapy for anomia: The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.~Stretching: Stretching will occur for 50 minutes a day, three days/week for 12 weeks."
3068276|NCT01113892|Active Comparator|EXXCEL Soft|A vascular graft comprised of extruded, expanded polytetrafluroethylene (ePTFE), indicated for use as a vascular prosthesis for replacement or bypass of diseased peripheral arteries (510(k) K962433).
3068277|NCT01113892|Experimental|FUSION Bioline|A synthetic vascular graft constructed of two layers. The inner layer is comprised of extruded, ePTFE. The outer layer is comprised of knit polyester textile. These two layers are fused together with a proprietary polycarbonate-urethane adhesive. The vascular graft also has a heparin coating on the graft's luminal surface. The Bioline coating is a bioactive surface coating consisting of a covalent Heparin Sodium coupled to immobilized recombinant human albumin.
3068278|NCT01113931|Experimental|Doxycycline Hyclate 200 mg tablet|Once daily
3068279|NCT01113931|Active Comparator|Vibramycin 100 mg capsule|Twice daily
3068280|NCT01113983|Experimental|TAVI - TF and TA approach|Transcatheter aortic valve implantation and transfemoral/ transapical approach
3068281|NCT01114139|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
3068282|NCT01114139|Placebo Comparator|Placebo|Participants received a total of 2 doses of IV saline (17 mL). The first IV dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose.
3068283|NCT01114204|Experimental|Ferumoxytol|Participants received a total of 2 doses of IV ferumoxytol 510 milligrams (mg) (17 milliliters [mL]). The first IV 510 mg dose was administered on Day 1 (Baseline) and second dose 2 to 8 (5±3) days after the first dose, for a total cumulative dose of 1.02 grams (g).
3068284|NCT01114204|Active Comparator|Iron Sucrose|Participants received an IV injection or infusion of iron sucrose 200 mg (10 mL) on Day 1 (Baseline) and on 4 other non-consecutive days over a 14-day period, for a total cumulative dose of 1.0 g. Participants receiving their first ever exposure to IV iron sucrose, received a test dose on Day 1 prior to receiving the remainder of the first dose, as prescribed in the package insert for some countries.
3068285|NCT01114217|Experimental|Ferumoxytol|Participants received ferumoxytol or placebo during AMAG-FER-IDA-301 [NCT01114139]. Participants enrolled in AMAG-FER-IDA-303, a 6-month Extension Study, were evaluated monthly and could receive treatment with ferumoxytol only if they met criteria defined as persistent or recurrent IDA, hemoglobin <11.0 grams per deciliter (g/dL) and transferrin saturation (TSAT) <20% at any evaluation visit, (except study termination visit). Participants who met criteria began a 5-week treatment period (TP) and received 2 doses of ferumoxytol 510 mg intravenously (IV). The first IV 510-mg dose was administered on TP Day 1 (Baseline); the second 2-8 (5±3) days after Dose 1. The first treatment course with ferumoxytol for participants who previously received placebo in AMAG-FER-IDA-301 was considered Course 1; Course 2 included participants who previously received ferumoxytol in AMAG-FER-IDA-301; subsequent treatment courses were serially numbered.
3068286|NCT01114334|Active Comparator|Guideline-based Medical Management|"Manual-based GBMM training will be provided to both intervention and control physicians. A note on the patient's chart will apprise the primary care provider that the patient screened positive for moderate or more severe depressive symptoms, and has agreed to participate in the study.~The evidence-based algorithm covers medical management of depression including indications for treatment, selection of initial therapy, starting dosages, dose escalation, switching or augmenting treatment, assessing efficacy, treatment goals and duration, a schedule of follow-up visits and referral indications"
3068287|NCT01114334|Experimental|Motivational Interview with GBMM|Motivational Interviewing for Depression combined with guideline-based medical management for depression
3068288|NCT01114360|Active Comparator|Melatonin|African-American subjects with mild to moderate essential hypertension will be given 8mg time release melatonin for 4 weeks. (either before or after placebo exposure).
3068289|NCT01114360|Placebo Comparator|Placebo|African-American subjects with mild to moderate essential hypertension will be given placebo for 4 weeks (either before or after exposure to melatonin)
3068290|NCT01114373|Active Comparator|Melatonin|Subjects with mild to moderate essential hypertension will be given 24mg time release melatonin for 4 weeks either before or after exposure to 4 week of placebo with no washout period.
3068291|NCT01114373|Placebo Comparator|Placebo|Subjects with mild to moderate essential hypertension will be given placebo for 4 weeks either before or after exposure to 4 weeks of 24mg daily dose of time release melatonin with no washout period.
3068292|NCT01114438|Experimental|Device|
3068293|NCT01114503|Experimental|Part A|Up to 4 cohorts of 5 patients receive dose rising treatments of otelixizumab
3068294|NCT01114503|Experimental|Part B - Otelixizumab|Parallel dosing group in Part B receive otelixizumab over 8 days at a dose decided upon results from Part A
3068295|NCT01114503|Active Comparator|Part B - Methylprednisolone|Parallel dosing group in Part B of weekly doses of methylprednisolone for 12 weeks
3068296|NCT01114516|No Intervention|control|emergent cerclage with no peri-operative antibiotics or indomethacin
3068297|NCT01114516|Experimental|indomethacin and antibiotics|perioperative antibiotics and indomethacin
3068298|NCT01114529|Experimental|Everolimus|Conversion from CNI to everolimus in combination with Myfortic and steroids
3068299|NCT01114529|Active Comparator|Calcineurin inhibitor, Prograf or Neoral|Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids
3068300|NCT01114555|Experimental|Bevacizumab, Irinotecan and Temozolomide|This is a phase II study of the combination of irinotecan, temozolomide and bevacizumab in patients with resistant NB.
3068301|NCT01114581|Active Comparator|Guaifenesin|Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets
3068302|NCT01114581|Placebo Comparator|Placebo|Given as 2 tablets
3068303|NCT01114620|Experimental|Arepanrix Group|Healthy Japanese male and female adults, 65 years of age or older, who received one dose of the study vaccine Arepanrix™, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
3068304|NCT01114646|Other|Cemented Hip Hemiarthroplasty|This arm received a hemiarthroplasty with a cemented femoral prosthesis (VerSys LD/Fx, Zimmer, Warsaw, IN).
3068305|NCT01114646|Experimental|Press-Fit Hip Hemiarthroplasty|This arm received a press-fit hemiarthroplasty (VerSys Beaded FullCoat, Zimmer, Warsaw, IN),
3068306|NCT01114672|Active Comparator|Ergocalciferol|
3068307|NCT01114672|Placebo Comparator|oral placebo|
3068308|NCT01114724|Experimental|Valiant Thoracic Stent Graft with the Captivia Delivery System|
3068309|NCT01114737|Experimental|Sapropterin dihydrochloride|
3068310|NCT01114737|Placebo Comparator|Tablet without active ingredient|
3068311|NCT01114828|Experimental|3.75 mg|Once-daily oral administration of OPC-41061
3068312|NCT01114828|Experimental|7.5 mg|Once-daily oral administration of OPC-41061
3068313|NCT01114880|Placebo Comparator|Placebo|Blinded placebo from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
3068314|NCT01114880|Experimental|Adalimumab|Blinded adalimumab from Week 0 to Week 10, open-label adalimumab from Week 12 to Week 24.
3068315|NCT01114893|Active Comparator|TRAVATAN|TRAVATAN 0.004% once daily
3068316|NCT01114893|Placebo Comparator|Travoprost Vehicle|Travoprost Vehicle
3068317|NCT01114893|Experimental|Travoprost Group A|Travoprost Group A
3068318|NCT01114893|Experimental|Travoprost Group B|Travoprost Group B
3068319|NCT01114893|Experimental|Travoprost Group C|Travoprost Group C
3068320|NCT01114945|Experimental|Video-Mac|Video-Mac device used during intubation procedure
3068321|NCT01114945|Experimental|GlideScope|GlideScope device used during intubation procedure
3068322|NCT01114945|Experimental|McGrath|McGrath device used during intubation procedure
3068323|NCT01114945|Active Comparator|Direct Macintosh Laryngoscopy|Direct Macintosh Laryngoscopy (DL) used during intubation procedure
3068324|NCT01114971|Active Comparator|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or Heart Rate (HR) > 80 bpm)"
3068325|NCT01114971|Experimental|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
3068326|NCT01114971|Experimental|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
3068327|NCT01114997|Active Comparator|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg Post- Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
3068328|NCT01114997|Active Comparator|Esmolol|Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Post-Induction: Infusion dose 7.5 - 15 mcg /kg/min
3068329|NCT01114997|Experimental|Lidocaine + Esmolol (Combo)|"Performed with the administration of both drugs.~Pre-induction:~Lidocaine Loading dose(1 mg/kg)+Esmolol Loading dose(750 mcg/Kg)~Post-induction:~Infusion rate: Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
3068330|NCT01115101|Experimental|Oxycodon|
3068331|NCT01115101|Active Comparator|Patient controlled analgesia (PCA) device with Pritramid|
3068332|NCT01115166||Cardiac surgery|Patients subjected to open cardiac surgery with the help of extracorporal circulation.
3068333|NCT01115231||Group 1 (Control)|Case control subjects without AMD diagnosis
3068334|NCT01115231||Group 2 (Age-related Macular Degeneration)|Case (i.e., within 5 years) subjects will be recruited. Cases are defined as subjects with diagnosed AMD.
3068335|NCT01115309|Other|XprESS Balloon Device|Sinus dilation
3068336|NCT01115452|Experimental|5% KNO3 solution|Participants to apply 5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
3068337|NCT01115452|Experimental|2.5% KNO3 solution|Participants to apply 2.5% potassium nitrate solution to a single sensitive tooth for two minutes, in each of the five day treatment period.
3068338|NCT01115452|Placebo Comparator|Sterile Water|Participants to apply sterile water to a single sensitive tooth for two minutes, in each of the five day treatment period.
3068339|NCT01115491|Experimental|A|
3068340|NCT01115517|Experimental|Bevacizumab|
3068341|NCT01115517|Active Comparator|Mitomycin C|
3068342|NCT01115556|Experimental|Lucentis 2.0 mg|Lucentis 2.0 mg
3068343|NCT01115556|Active Comparator|LUCENTIS 0.5 mg|
3068344|NCT01115569|Experimental|Hydrocodone Bitartrate|Open-label, all patients fulfilling the protocol Inclusion/Exclusion criteria will receive HC-CR in a flexible dosing regimen.
3068345|NCT01115582|Experimental|Cholic Acid Capsule|Manufactured cholic acid capsules
3068346|NCT01115660|Experimental|stroke education|Patients in this arm receive a telephone call by a medication coach who reviews their condition and importance of adherence to medication regimen.
3068347|NCT01115660|No Intervention|control arm|Subjects in this arm received instruction at hospital discharge and a 3-month follow-up call to collect study data.
3068348|NCT01115673|Experimental|ACE-1000|1000 mg Acetaminophen Caplet
3068349|NCT01115673|Active Comparator|ACE-650|650 mg Acetaminophen Caplet
3068350|NCT01115673|Placebo Comparator|ACE-0|0 mg Acetaminophen Caplet
3068351|NCT01115738|Placebo Comparator|Placebo and 60 milligram (mg) Prasugrel|Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3068352|NCT01115738|Experimental|600 mg Clopidogrel and 60 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3068353|NCT01115738|Experimental|600 mg Clopidogrel and 30 mg Prasugrel|600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
3068354|NCT01115803|Experimental|Arm A: LY2584702 + Erlotinib|Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
3068355|NCT01115803|Experimental|Arm B: LY2584702 + Everolimus|Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.
3068356|NCT01115855|Experimental|Eplerenone arm|Add on standard heart failure therapy
3068357|NCT01115855|Placebo Comparator|Placebo arm|Add on standard heart failure therapy
3068358|NCT01115933|Experimental|XIENCE PRIME SV EECSS|XIENCE PRIME SV EECSS: Small Vessel Everolimus Eluting Coronary Stent System
3068359|NCT01115998|Experimental|Power wheelchair|
3068360|NCT01115998|Other|Control group|
3068361|NCT01116024|Experimental|3f Enable Aortic Bioprosthesis Model 6000|Single arm study
3068362|NCT01116037|Other|ATS 3f Aortic Bioprosthesis|ATS 3f Aortic Bioprosthesis, Model 1000 (equine pericardial bioprosthesis)
3068363|NCT01116102|Experimental|24 ga catheter, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3068364|NCT01116102|Experimental|24 ga catheter, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3068365|NCT01116102|Experimental|24 ga catheter, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3068366|NCT01116102|Experimental|24 ga catheter, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 24 gauge plastic catheter; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3068367|NCT01116102|Experimental|25 ga needle, dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3068368|NCT01116102|Experimental|25 ga needle, no dose flush, single-step rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 250 mL/h for the first hour and 200 mL/hr for the remainder of the infusion.
3068369|NCT01116102|Experimental|25 ga needle, dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX and 3 mL Lactated Ringer's solution flush administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3068370|NCT01116102|Experimental|25 ga needle, no dose flush, up-titrated rate scheme|Single 150 U subcutaneous (SC) dose of HYLENEX (without a Lactated Ringer's solution flush) administered through 25 gauge metal butterfly needle; followed by SC infusion of 1000 mL Lactated Ringer's solution via large-volume infusion pump at 50 mL/h for the first 5 min, 100 mL/h for the next 5 min, 285 mL/h for the next 50 min and 200 mL/h for the remainder of the infusion.
3068371|NCT01116401|Experimental|GnRH Agonist Injection|We will be administering an injection of leuprolide acetate (a GnRH agonist) to all participants.
3068372|NCT01116427|Experimental|Abatacept|Receives abatacept during first course of treatment, switching to placebo during extension phase.
3068373|NCT01116427|Placebo Comparator|Placebo, followed by abatacept|Receives a placebo for first course of treatment, switching to abatacept in the extension phase.
3068374|NCT01116440|Experimental|BGS649 co-administered with Levora 28™|
3068375|NCT01116440|Placebo Comparator|Placebo co-administered with Levora 28™|
3068376|NCT01116466|Experimental|ActiGait|Receiving ActiGait - implantable drop foot stimulator
3068377|NCT01116544|Experimental|AMES therapy with EMG biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of EMG activity the subject is able to generate in the hand. This study will examine whether AMES therapy combined with EMG biofeedback can restore hand opening to plegic stroke subjects.
3068378|NCT01116544|Experimental|AMES therapy with Torque biofeedback|The AMES device provides a 30 minute treatment period of alternating passive flexion and then extension of the hand while vibrators vibrate the muscles of the hand. The subjects job is to attempt to assist the device in the movement. A computer screen will provide visual feedback of the amount of torque (force) the subject is able to generate in the hand during the movement. This study will examine whether AMES therapy combined with Torque biofeedback can restore hand opening to plegic stroke subjects.
3468805|NCT03892200|Experimental|Daily Mouth Care|The intervention being tested is a standardized educational and skill-building program for use in assisted living communities, which highlights that mouth care is infection control (e.g., can reduce pneumonia); includes techniques and products to clean and protect the teeth, tongue, gums, and dentures (e.g., the jiggle-sweep approach to remove plaque, use of an interdental brush instead of floss); provides strategies for care provision in special situations (e.g., broken teeth); and includes a toolkit of dementia-sensitive approaches for people who are resistant (e.g., refuse to open the mouth). It also includes information about potential dental emergencies and issues that merit assessment.
3068381|NCT01116661|Experimental|ALA for glioma (WHO G1-IV) subjects|Up to 300 patients with diagnosed glioma (WHO G1-IV) eligible for surgery will be entered into the trial and will be given 5-Aminolevulinic Acid (ALA) orally at a dose of 20mg/kg body weight preoperatively
3068382|NCT01116687|Experimental|Treatment (RO4929097)|See detailed description.
3068383|NCT01116739|Experimental|COHS administered fluoride varnish and oral health education|Paraprofessionals, called community oral health specialists (COHS), will be trained to administer fluoride varnish and oral health education to head start children quarterly for 2 years.
3068384|NCT01116739|Active Comparator|Usual care|Usual care will include regular dental services provided by the Indian Health Service.
3068385|NCT01116882|Active Comparator|SOS|Patients randomized to the SOS arm are transferred to tertiary hospitals for their PCI procedure.
3068386|NCT01116882|Experimental|Non-SOS|Patients in the non-SOS arm are randomized to stay at the community hospitals for their PCI procedure.
3068387|NCT01116895|Active Comparator|LEO 22811 0.5 mg|LEO 22811 0.5 mg: Oral solution
3068388|NCT01116895|Active Comparator|LEO 22811 1.5 mg|LEO 22811 1.5 mg: Oral solution
3068389|NCT01116895|Active Comparator|LEO 22811 3.0 mg|LEO 22811 3.0 mg: Oral solution
3068390|NCT01116895|Placebo Comparator|Placebo|Placebo: Oral solution
3068391|NCT01116921|Active Comparator|nCPAP Control Group|Infants in the Control Group were maintained continuously on nasal CPAP 6 cm H2O with no surfactant administered.
3068392|NCT01116921|Experimental|LMA Group|Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
3068393|NCT01116934||PLS patients|Eight PLS patients (one female) from 6 families.
3068394|NCT01116934||Healthy controls|Healthy donors had abstained from taking drugs for two weeks prior to the study. Due to wide spread use of oral contraceptives only male probands were chosen.
3068395|NCT01116986|Experimental|1, Patch, Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068396|NCT01116986|Experimental|2, Patch, Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068397|NCT01116986|Experimental|3, Patch, Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068398|NCT01116986|Experimental|4, Patch, Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068399|NCT01116986|Experimental|5, Patch, Gum, No Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068400|NCT01116986|Experimental|6, Patch, Gum, No Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068401|NCT01116986|Experimental|7, Patch, Gum, No Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068402|NCT01116986|Experimental|8, Patch, Gum, No Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068403|NCT01116986|Experimental|9, Patch, No Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068404|NCT01116986|Experimental|10, Patch, No Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068405|NCT01116986|Experimental|11, Patch, No Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068406|NCT01116986|Experimental|12, Patch, No Gum, Prequit, Int In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068407|NCT01116986|Experimental|13, Patch, No Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068408|NCT01116986|Experimental|14, Patch, No Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068409|NCT01116986|Experimental|15, Patch, No Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068410|NCT01116986|Experimental|16, Patch, No Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068411|NCT01116986|Experimental|17, No Patch, Gum, Prequit, Min In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068412|NCT01116986|Experimental|18, No Patch, Gum, Prequit, Min In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068413|NCT01116986|Experimental|19, No Patch, Gum, Prequit, Int In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068414|NCT01116986|Experimental|20, No Patch, Gum, Prequit, Int In-Person, Int Phone, 16Wk|How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt
3068415|NCT01116986|Experimental|21, No Patch, Gum, No Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068416|NCT01116986|Experimental|22, No Patch, Gum, No Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068417|NCT01116986|Experimental|23, No Patch, Gum, No Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068418|NCT01116986|Experimental|24, No Patch, Gum, No Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068419|NCT01116986|Experimental|25, No Patch, No Gum, Prequit, Min In-Person, Min Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3468806|NCT03892200|No Intervention|Standard Mouth Care|Assisted living communities will continue to provide standard mouth care to all residents. Assisted living staff will not receive training or supplies in the control condition.
3468807|NCT03892213|Other|Benznidazole and E1224|Benznidazole and E1224
3068420|NCT01116986|Experimental|26, No Patch, No Gum, Prequit, Min In-Person, Int Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068421|NCT01116986|Experimental|27, No Patch, No Gum, Prequit, Int In-Person, Min Phone, 16Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068422|NCT01116986|Experimental|28, No Patch, No Gum, Prequit, Int In-Person, Int Phone, 8Wk|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068423|NCT01116986|Experimental|29, No Patch, No Gum, No Prequit, Min In-Person, Min Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068424|NCT01116986|Experimental|30, No Patch, No Gum, No Prequit, Min In-Person, Int Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068425|NCT01116986|Experimental|31, No Patch, No Gum, No Prequit, Int In-Person, Min Phone, 8W|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Minimal Phone counseling during quit attempt, 8Wk Medication duration during quit attempt"
3068426|NCT01116986|Experimental|32, No Patch, No Gum, No Prequit, Int In-Person, Int Phone, 16|"This arm of the project will address the following question:~How effective is the following Intervention? No Prequit Nicotine Patch, No Prequit Nicotine Gum, No Counseling before quit attempt, Intensive In-person counseling during quit attempt, Intensive Phone counseling during quit attempt, 16Wk Medication duration during quit attempt"
3068427|NCT01117012|Experimental|VX-770|VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).
3068428|NCT01117051|Placebo Comparator|placebo|placebo
3068429|NCT01117051|Active Comparator|Resolor|prucalopride
3068430|NCT01117181|Experimental|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day) and psychosocial intervention
3068431|NCT01117181|Placebo Comparator|Placebo|matching placebo and psychosocial intervention
3068432|NCT01117311|Experimental|VNB off first, then VNB on|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB off first for the first intervention (Mixed Meal 2), then VNB on for the second intervention (Mixed Meal 3).
3068433|NCT01117311|Experimental|VNB on first, then VNB off|Subjects assigned to this reporting group had the vagal nerve blocker (VNB) on for the lead in period (Mixed Meal 1), then VNB on first for the first intervention (Mixed Meal 2), then VNB off for the second intervention (Mixed Meal 3).
3068434|NCT01117337|No Intervention|Mesh Non Fixation Group|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed by ant means
3068435|NCT01117350|Experimental|Insulin Glargine|"Insulin glargine administered once a day, in the morning or in the evening, at the most convenient time. The time of injection, once chosen was to remain unchanged during the whole duration of the study.~The starting dose was 0.2 Unit per kilogram of body weight or 10 Units. Patients were empowered to adjust their insulin doses, under strict investigator's supervision. Insulin titration (by 2 or 4 Units) was done every 3 days according to the median value of Fasting Plasma Glucose (FPG) of the last 3 days. The goal was to achieve 70 < FPG ≤ 100 mg/dL (3.9 < FPG ≤ 5.5 mmol/L). Minor deviations from the titration scheme could be allowed, based on Investigator's judgment and patient's situation."
3068436|NCT01117350|Active Comparator|Liraglutide|"Liraglutide administered once a day, in the morning or in the evening, at the most convenient time. The time of injection , once chosen was to remain unchanged during the whole duration of the study.~The dose was 0.6 mg/day during the first week, 1.2 mg/day during the second week and 1.8 mg/day until week 24. The dose might be decreased to 1.2 mg for safety reasons (e.g. gastro-intestinal tolerability), based on Investigator's judgment."
3068437|NCT01117428|Experimental|Sym004|
3068438|NCT01117454|Other|Flecainide then placebo|In this crossover study, half of the subjects will be randomized to flecainide plus standard therapy with beta-blockers first, then crossover to placebo plus standard therapy with beta-blockers.
3068439|NCT01117454|Other|Placebo then flecainide|In this crossover study, half of the subjects will be randomized to placebo plus standard therapy with beta-blockers first, then crossover to flecainide plus standard therapy with beta-blockers.
3068440|NCT01117480||Moderate-to-severe rheumatoid arthritis|Participants with moderate-to-severe rheumatoid arthritis treated with adalimumab in routine clinical practice
3068441|NCT01117623|Experimental|Arm 1|
3068442|NCT01117623|Experimental|Arm 2|
3068443|NCT01117623|Experimental|Arm 3|
3068444|NCT01117623|Experimental|Arm 4|
3068445|NCT01117623|Experimental|Arm 5|
3068446|NCT01117623|Experimental|Arm 6|
3068447|NCT01117623|Experimental|Arm 7|
3068448|NCT01117623|Experimental|Arm 8|
3068449|NCT01117727|Experimental|Pilot Testing|
3068450|NCT01117766|Active Comparator|Active drug|
3068451|NCT01117766|Placebo Comparator|Placebo|
3068452|NCT01117792|Experimental|S-ICD System|
3068453|NCT01117857|Experimental|Duloxetine|After a one-week placebo lead-in, all eligible subjects will receive Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg Duloxetine per day for 7 weeks.
3068454|NCT01117870|Placebo Comparator|Placebo|The needle will be continuously stimulated at a low voltage to give a sensation of PRF treatment.
3068455|NCT01117870|Experimental|Pulsed Radiofrequency|PRF will be applied for 120 seconds at 42 degrees celsius.
3068456|NCT01117948|Experimental|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
3068457|NCT01117948|Placebo Comparator|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
3068458|NCT01117987|Experimental|Core imatinib|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
3068459|NCT01117987|Experimental|Core placebo|Depending on the participants' randomized treatment in the core study, CQTI571A2301 (NCT00902174), and their completion status in the core study, participants received imatinib at 200 mg qd, 400 mg qd, or 200 mg qd with an increase to 400 mg qd after 2 weeks, if tolerated.
3068460|NCT01118052|Experimental|Treatment (EGEN-001)|Patients receive intraperitoneal EGEN-001 on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3068461|NCT01118091|Active Comparator|Arm 1-Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
3068462|NCT01118091|Experimental|Arm 2 - Adoptive cell therapy|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x10^8) and the administration of high-dose aldesleukin.
3068463|NCT01118117|Experimental|Misago™ Self-Expanding Stent System|
3068464|NCT01118143|Experimental|intervention group|Tailored oral health literacy instruction
3068465|NCT01118143|No Intervention|control group|Oral health instruction not tailored to oral health literacy level
3068466|NCT01118221|Experimental|Arm 1|enroll in pulmonary rehabilitation program
3068467|NCT01118221|No Intervention|Arm 2|no structured exercise
3068468|NCT01118273|Experimental|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|
3068469|NCT01118273|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
3068470|NCT01118273|Experimental|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|
3068471|NCT01118273|Active Comparator|Naproxen Sodium 220 mg (BAYH6689)|
3068472|NCT01118273|Active Comparator|DPH 50mg|
3068473|NCT01118273|Active Comparator|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|
3068474|NCT01118299|Experimental|Device|AMPLATZER Cardiac Plug
3068475|NCT01118299|Active Comparator|Optimal Medical Therapy (control)|Warfarin Dabigatran
3068476|NCT01118312|Active Comparator|Nasal Steroid|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
3068477|NCT01118312|Placebo Comparator|Placebo|Intranasal placebo, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day
3068478|NCT01118325|Experimental|AZD6140 45 mg bd|
3068479|NCT01118325|Experimental|AZD6140 90 mg bd|
3068480|NCT01118325|Active Comparator|Clopidogrel 75 mg od|
3068481|NCT01118338|Experimental|Redesigned Purevision Contact Lens|Redesigned Bausch & Lomb PureVision contact lens
3068482|NCT01118338|Active Comparator|PureVision Contact Lens|Bausch & Lomb PureVision contact lens
3068483|NCT01118351|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3068484|NCT01118377|Experimental|Capecitabine + radiation therapy|Participants received 9 weeks of capecitabine 650 mg/m^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
3068485|NCT01118455|Experimental|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
3068486|NCT01118455|Experimental|Anti-Epileptic Drug (AED)|This arm will supply a comparison between VNS and new AEDs which is necessary to determine an overall treatment regimen for the 30% to 40% of patients who fail to respond to 2 AEDs.
3068487|NCT01118520|Active Comparator|perindopril|ACE inhibitor blood pressure lowering agent
3068488|NCT01118520|Active Comparator|amlodipine|calcium channel blocker blood pressure lowering agent
3068489|NCT01118520|Placebo Comparator|placebo|inactive substance identical in appearance to the othe two comparators
3068490|NCT01118624|Experimental|Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin (Folotyn)|"Intravenous (IV) push administration over 3-5 minutes. Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
3068491|NCT01118663|Experimental|Acetadote without EDTA|Acetadote EF [Ethylenediaminetetraacetic Acid (EDTA) - Free]
3068492|NCT01118663|Active Comparator|Acetadote|Acetadote [Old formulation containing EDTA]
3068493|NCT01118715|Experimental|Compression glove|Patients in this group have a compression glove incorporated into their splint for 2 weeks post-op, and wear a glove underneath their cast for 3 weeks. The patient then wears the glove at night after cast removal.
3068494|NCT01118715|No Intervention|Control|Patients in this group undergo standard recovery procedures. This includes a splint worn for 2 weeks post-op, followed by a short arm cast worn for the next 3 weeks.
3068495|NCT01118728|Experimental|Sarilumab|Sarilumab 150 mg subcutaneous (SC) injection every week (or every other week in case of safety issue) for 260 weeks, or until commercially available, or until discontinuation of the project, whichever came first.
3068496|NCT01118780|Experimental|Duloxetine 30 milligrams (mg) -120 mg|
3068497|NCT01118780|Placebo Comparator|Placebo|
3068498|NCT01118845|Experimental|SyB L-0501|
3068499|NCT01118949|Experimental|Lacosamide|
3468808|NCT03892083|Active Comparator|Anodal tDCS (M1)|tDCS applied over primary motor cortex. Dose: 1mA, 20 minutes
3068500|NCT01118962|Experimental|Lacosamide|"Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949).~Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses."
3068501|NCT01118975|Experimental|Pilot Phase - Vornistat 200 to 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and escalating doses of vorinistat (200mg run-up, 300mg, and 400mg 4 days on 3 days off)
3068502|NCT01118975|Experimental|Phase II - Vorinistat 400mg + Lapatinib|lapatinib 1,250 mg continuous daily and vorinostat 400 mg 4 days on 3 days
3068503|NCT01118988|Experimental|Mentorship|"Subjects randomly assigned to this arm received the specified Mentorship Intervention"
3068504|NCT01118988|No Intervention|Control|Subjects randomly assigned to this control group receive treatment as usual (TAU).
3068505|NCT01118988|No Intervention|Mentors|"Subjects recruited to the Mentor arm of the study are UCLA Pediatric Pain Program patients between the ages of 14 and 18. These mentors are identified by the Principal Investigator as children who have not necessarily eliminated pain, but have learned how to cope with pain and maintain appropriate functioning in daily life. Mentors undergo an in depth training from doctoral level psychologists who are members of the research team. Mentors present pain coping information developed by the research team, provide support, and encourage mentees to attend pain management therapies. They are also monitored by doctoral level psychologists throughout the duration of the study to ensure safety and appropriate contact with mentees via telephone."
3068506|NCT01119001|Experimental|P300 Brain Computer Interface for people with ALS|
3068507|NCT01119040|Experimental|NOTES PEG Rescue|A new way of performing surgery is called Natural Orifice Translumenal Endoscopic Surgery, or NOTES, for short. NOTES may allow surgeons to perform abdominal surgery without any skin incisions. By using natural openings in the body, like the mouth, surgeons can enter the stomach with a tube instead of the traditional method of making an incision in the skin of the abdomen.
3068508|NCT01119105|Experimental|BC-3781 dose 100mg|
3068509|NCT01119105|Experimental|BC-3781 dose 150mg|
3068510|NCT01119105|Active Comparator|Vancomycin|
3068511|NCT01119118|Experimental|1|ZD4054 + multimodal PET/MRI imaging
3068512|NCT01119131|Active Comparator|Arm 1|Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
3068513|NCT01119131|Placebo Comparator|Arm 2|Will be on placebo and 1000mg of calcium.
3068514|NCT01119222|Active Comparator|Gabapentin 1200mg|
3068515|NCT01119222|Active Comparator|Diphenhydramine 50 mg|
3068516|NCT01119222|Active Comparator|Morphine 10 mg|
3068517|NCT01119222|Placebo Comparator|Placebo formulations|
3068518|NCT01119248||Children undergoing MRI|120 children ages of 6 months and 8 years for MRI and axillary temperature before MRI and after the MRI with MRI compatible device
3068519|NCT01119287|Experimental|Maxidex|Dexamethasone 0.1% ophthalmic suspension, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3068520|NCT01119287|Experimental|Patanol|Olopatadine hydrochloride 0.1% ophthalmic solution, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3068521|NCT01119287|Placebo Comparator|Tears Naturale II|Inactive ingredients, used as placebo, 2 drops in each eye, 2-5 minutes apart, twice a day, for 9 days [Visit 4 through Visit 6 morning only]
3068522|NCT01119443|Other|Treatment sequence A|V4: PPX ER 1.5mg x 1 fed, V5: PPX ER 0.375mg x 4 fed, V6:: PPX ER 1.5mg x 1 fasted, V5: PPX ER 0.375mg x 4 fasted
3068523|NCT01119443|Other|Treatment sequence B|V4: PPX ER 0.375mg x 4 fed, V5: PPX ER 1.5mg x 1 fed, V6:: PPX ER 0.375mg x 4 fasted, V5: PPX ER 1.5mg x 1 fasted
3068524|NCT01119456|Experimental|IMC-RON8|A monoclonal antibody to human macrophage-stimulating 1-receptor-8 (RON8).
3068525|NCT01119508|Experimental|Ipilimumab + Temozolomide|Induction: Ipilimumab 10 mg/kg IV over 90 minutes Day 1 + Temozolomide 200 mg/m2 PO on Days 1 - 4, every 3 weeks for 4 courses over 3 months.
3068526|NCT01119625|Experimental|Synflorix™ Commercial-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of commercial lot of Synflorix™ co-administered with Rotarix™ and Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
3068527|NCT01119625|Active Comparator|Synflorix™ Clinical-Commercial + Infanrix™-IPV/Hib Group|children primed with 3 doses of clinical lot of Synflorix™ + Rotarix™ co-administered with Infanrix™-hexa in the primary phase of the study (NCT00808444) and boosted with commercial lot of Synflorix™ co-administered with Infanrix™-IPV/Hib. The Synflorix™ vaccine (clinical and commercial lots) was administered intramuscularly in the right deltoid or anterolateral thigh and the Infanrix™-IPV/Hib vaccine was administered intramuscularly in the left deltoid or anterolateral thigh.
3068528|NCT01119703||Arm 1: Healthy, elderly participants|Healthy participants 65 years old and older.
3068529|NCT01119703||Arm 2: Healthy, young, participants|Healthy participants 25 to 40 years old.
3068530|NCT01119716||All Enrolled Participants|Participants with documented atrial fibrillation in the hospital setting for whom a cardioversion is one of the planned therapeutic options
3068531|NCT01119768|Active Comparator|Esomeprazole 8 weeks treatment|20 mg q.d. (quaque die) once a day dosing for 8 weeks
3068532|NCT01119768|Active Comparator|Esomeprazole 2 Weeks Treatment|20 mg q.d. (quaque die) once a day dosing for 2 weeks
3068533|NCT01119794|Experimental|ofatumumab and bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
3068534|NCT01119846|Experimental|Part A|Part A (Cohort 1) is a single-blind, randomized, placebo-controlled, 5-period crossover in which drug naïve T2DM subjects will receive escalating doses of GSK1292263 in each of 3 periods and placebo and open-label sitagliptin in the other 2 periods. The sequence will be randomized, but will maintain the low, medium and high dose order for GSK1292263.
3068535|NCT01119846|Experimental|Part B|Part B (Cohort 2) is a single-blind, randomized, 2-period study in which T2DM subjects will receive a single dose of GSK1292263, fasted or fed.
3468809|NCT03892083|Experimental|Anodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
3068536|NCT01119846|Experimental|Part C|Part C (Cohort 3, optional Cohort 4) is a single-blind, randomized, placebo-controlled, 5-arm study of 14 days of dosing with GSK1292263, placebo or open-label sitagliptin. An optional Cohort 4 may be enrolled to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1292263 when dosed in a BID regimen.
3068537|NCT01119859|Experimental|Tocilizumab 8 mg/kg|Patients received 6 infusions of tocilizumab 8 mg/kg intravenously every 4 weeks and 12 injections of placebo to adalimumab subcutaneously every 2 weeks.
3068538|NCT01119859|Active Comparator|Adalimumab 40 mg|Patients received 12 injections of adalimumab 40 mg subcutaneously every 2 weeks and 6 infusions of placebo to tocilizumab intravenously every 4 weeks.
3068539|NCT01119898|Experimental|PENNSAID Gel|Diclofenac sodium 2.0% w/w
3068540|NCT01119898|Placebo Comparator|Vehicle|The complete carrier containing ingredients at the same concentrations as experimental arm without diclofenac sodium
3068541|NCT01119937|Experimental|NVA237|50µg once daily
3068542|NCT01119937|Experimental|Tiotropium|18µg once daily
3068543|NCT01119950|Experimental|NVA237 12.5 µg q.d.|NVA237 12.5 µg once daily
3068544|NCT01119950|Experimental|NVA237 25.0 µg q.d.|NVA237 25.0 µg once daily
3068545|NCT01119950|Experimental|NVA237 12.5 µg b.i.d.|NVA237 12.5 µg twice daily
3068546|NCT01119950|Experimental|NVA237 50.0 µg q.d.|NVA237 50.0 µg once daily
3068547|NCT01119950|Experimental|NVA237 25.0 µg b.i.d.|NVA237 25.0 µg twice daily
3068548|NCT01119950|Experimental|NVA237 100.0 µg q.d.|NVA237 100.0 µg once daily
3068549|NCT01119950|Experimental|NVA237 50.0 µg b.i.d.|NVA237 50.0 µg twice daily
3068550|NCT01119950|Placebo Comparator|Placebo|Placebo to NVA237 once daily
3068551|NCT01119963|Active Comparator|17-alpha hydroxyprogesterone caproate, Makena®|250 mg of 17P, Makena® intramuscular (IM) weekly.
3068552|NCT01119963|Placebo Comparator|Placebo|Castor Oil (Placebo)intramuscular (IM) weekly
3068553|NCT01120028|Experimental|Alemtuzumab/Sirolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
3068554|NCT01120028|Experimental|Alemtuzumab/Tacrolimus|"Induction therapy allocation: Alemtuzumab (Campath-1H).~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
3068555|NCT01120028|Active Comparator|Basiliximab/Tacrolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Tacrolimus"
3068556|NCT01120028|Active Comparator|Basiliximab/Sirolimus|"Induction therapy allocation: Basiliximab.~Maintenance therapy allocation (at 6-months post-transplant): Sirolimus"
3068557|NCT01120067|Experimental|Intensive Treatment|Intensive 3 week treatment for pain and PTSD. This includes elements of Cognitive Processing Therapy and CBT for Chronic Pain
3068558|NCT01120067|Experimental|Treatment as Usual|Treatment as Usual. Participants are eligible for all treatment services as needed except for treatment of pain or PTSD
3068559|NCT01120093|Experimental|Aclidinium bromide 100 μg bid|Aclidininum bromide 100 μg twice daily by inhalation
3068560|NCT01120093|Experimental|Aclidininum bromide 200 μg bid|Aclidininum bromide 200 μg twice daily by inhalation
3068561|NCT01120093|Experimental|Aclidininum bromide 400 μg bid|Aclidininum bromide 400 μg twice daily by inhalation
3068562|NCT01120093|Placebo Comparator|Placebo|Placebo twice-daily by inhalation
3068563|NCT01120093|Active Comparator|Formoterol 12 μg bid|Formoterol 12 μg twice daily by inhalation
3068564|NCT01120184|Experimental|Trastuzumab + Taxane (docetaxel or paclitaxel)|
3068565|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab|
3068566|NCT01120184|Experimental|Trastuzumab emtansine + pertuzumab placebo|
3068567|NCT01120197|Experimental|Exercise group|"Exercise group with intervention~Subjects in the intervention group must participate in a training course consisted of 24 sessions over 3 months. The exercises include aerobic, stretching, balance and functional training, i.e. circuit exercises focus been on: the prevention of falls and fractures, improving balance and coordination, improving posture, and informing subjects about risk factors for falls and for osteoporosis and fractures. A 3-hour session of information and supervision will be hold for the intervention group by the same physiotherapist who leads the training sessions. The focus is on body awareness and ergonomic advice in specific, daily-life situations (e.g. lifting/carrying, resting positions)."
3068568|NCT01120197|Other|Control Group|"Control group with no intervention~Subjects in the control group are asked to maintain their current lifestyle. No restrictions are placed on their exercise activities. The control group is followed for the same duration as the intervention group."
3068569|NCT01120210|Experimental|Part 1 (Main Study)|3 consecutive 1-hour infusions of JNJ-39588146 5, 15, or 30 ng/kg/min or matching placebo
3068570|NCT01120210|Experimental|Part 2 (Extended Infusion Sub-Study)|1 18-hr infusion of JNJ-39588146 of the highest tolerated dose from Part 1 of the study or matching placebo
3068571|NCT01120223|Experimental|LEO 80185 gel once daily application|
3068572|NCT01120236|Experimental|Arm I (androgen deprivation and cixutumumab)|Patients receive androgen deprivation therapy comprising bicalutamide PO QD on days 1-28 and either goserelin acetate SC or leuprolide acetate IM every 1, 3, 4, 6, or 12 months. Patients also receive cixutumumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for 7 courses in the absence of disease progression or unacceptable toxicity.
3068573|NCT01120236|Active Comparator|Arm II (androgen deprivation therapy)|Patients receive androgen deprivation therapy comprising bicalutamide and either goserelin acetate or leuprolide acetate as in arm I.
3068574|NCT01120275|Experimental|Treatment (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3068575|NCT01120379||XV-LTF cohort|
3068576|NCT01120405|Experimental|Xenon|0.8-1.1 minimum alveolar concentration (MAC) Xenon in 30 % oxygen (Group A)
3068577|NCT01120405|Active Comparator|sevoflurane|0.8-1.1 Minimum Alveolar Concentration (MAC) Sevoflurane in 30 % oxygen (Group B)
3068578|NCT01120600|Experimental|Odanacatib 50 mg once weekly|Participants will receive one Odanacatib 50 mg tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
3068579|NCT01120600|Placebo Comparator|Placebo once weekly|Participants will receive one Placebo tablet once weekly. In addition, they will receive a weekly dose 5600 IU of open-label Vitamin D3 as well as a sufficient supply of open-label calcium carbonate so that their total daily calcium intake from both dietary and supplemental sources is approximately 1200 mg.
3068580|NCT01120626|Active Comparator|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
3068581|NCT01120626|Placebo Comparator|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
3068582|NCT01120639|Experimental|Stereotactic Radiosurgery (25 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
3068583|NCT01120639|Experimental|Stereotactic Radiosurgery (30 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
3068584|NCT01120639|Experimental|Stereotactic Radiosurgery (35 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
3068585|NCT01120639|Experimental|Stereotactic Radiosurgery (40 Gray x 5 fractions)+Temozolomide|Hypofractionated stereotactic radiosurgery with concurrent temozolomide, stratified by Planning Target Volume (PTV) < 60 cm³ vs 60 to 150 cm³.
3068586|NCT01120691|Experimental|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3068587|NCT01120691|Active Comparator|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3068588|NCT01120691|Active Comparator|open-label tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
3068589|NCT01120704|Experimental|1, 26Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068590|NCT01120704|Experimental|2, 26Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068591|NCT01120704|Experimental|3, 26Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068592|NCT01120704|Experimental|4, 26Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068593|NCT01120704|Experimental|5, 26Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068594|NCT01120704|Experimental|6, 26Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068595|NCT01120704|Experimental|7, 26Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068596|NCT01120704|Experimental|8, 26Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068597|NCT01120704|Experimental|9, 26Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068598|NCT01120704|Experimental|10, 26Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068599|NCT01120704|Experimental|11, 26Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068600|NCT01120704|Experimental|12, 26Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3468810|NCT03892083|Experimental|Cathodal Cerebellar tDCS|tDCS applied over the cerebellum. Dose: 1mA, 20 minutes
3068601|NCT01120704|Experimental|13, 26Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068602|NCT01120704|Experimental|14, 26Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068603|NCT01120704|Experimental|15, 26Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068604|NCT01120704|Experimental|16, 26Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~26Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068605|NCT01120704|Experimental|17, 8Wks, Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068606|NCT01120704|Experimental|18, 8Wks, Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068607|NCT01120704|Experimental|19, 8Wks, Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068608|NCT01120704|Experimental|20, 8Wks, Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068609|NCT01120704|Experimental|21, 8Wks, Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068610|NCT01120704|Experimental|22, 8Wks, Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068611|NCT01120704|Experimental|23, 8Wks, Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068612|NCT01120704|Experimental|24, 8Wks, Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068613|NCT01120704|Experimental|25, 8Wks, No Counseling, CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068614|NCT01120704|Experimental|26, 8Wks, No Counseling, CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068615|NCT01120704|Experimental|27, 8Wks, No Counseling, CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068616|NCT01120704|Experimental|28, 8Wks, No Counseling, CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068617|NCT01120704|Experimental|29, 8Wks, No Counseling, No CAM, AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068618|NCT01120704|Experimental|30, 8Wks, No Counseling, No CAM, AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3468811|NCT03892083|Sham Comparator|Sham tDCS|tDCS applied over the cerebellum Dose: 1mA, 20 minutes (30s ON)
3468812|NCT03892291||Civilian mTBI|Civilians with persistent symptoms from mTBI
3468813|NCT03892291||Civilian Control|Civilian healthy controls
3068619|NCT01120704|Experimental|31, 8Wks, No Counseling, No CAM, No AutoCalls, Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device + Feedback"
3068620|NCT01120704|Experimental|32, 8Wks, No Counseling, No CAM, No AutoCalls, No Feedback|"This arm of the project will address the following question:~How effective is the following intervention?:~8Wks Medication duration during quit attempt, No Maintenance Counseling, No Cognitive Adherence Intervention, No Automated Medication Adherence Calls, Electronic Medication Monitoring Device but No Feedback"
3068621|NCT01120717|Experimental|QVA149|110µg/50µg capsule for oral inhalation, once daily, delivered by a single dose dry powder inhaler (SDDPI)
3068622|NCT01120717|Placebo Comparator|Placebo|Placebo to match QVA149, capsules for inhalation once daily, delivered by an SDDPI
3068623|NCT01120756|Experimental|Goal-oriented attentional self-regulation training|Goal-oriented attentional self-regulation training (GOALS).
3068624|NCT01120756|Active Comparator|Brain Health Education|Brain Health Education (EDU)
3068625|NCT01120782|Active Comparator|etafilcon A toric new lens/etafilcon A toric lens|The lens worn first is a new etafilcon A toric contact lens and the lens worn second is a marketed etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
3068626|NCT01120782|Active Comparator|etafilcon A toric lens/etafilcon A toric new lens|The lens worn first is a marketed etafilcon A toric contact lens and the lens worn second is a new etafilcon A toric contact lens. Each lens worn for a maximum of 15 minutes bilaterally.
3068627|NCT01120808|Experimental|All Participants|Participants were registered competitors in RacingThePlanet 6 stage 7 day 155mile (250km) ultramarathon.
3068628|NCT01120834|Experimental|all subjects|
3068629|NCT01120899|Experimental|Minocycline|
3068630|NCT01120990|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
3068631|NCT01121146|Active Comparator|Crosslinked Marathon polyethylene|
3068632|NCT01121146|Active Comparator|Standard Enduron polyethylene|
3068633|NCT01121172||obese|obese subjects according to International Obesity Task Force criteria
3068634|NCT01121172||lean|
3068635|NCT01121185|Experimental|MBL-HCV1|
3068636|NCT01121185|Placebo Comparator|0.9% sodium chloride|
3068637|NCT01121211|Active Comparator|Testosterone|Testosterone x 24 weeks
3068638|NCT01121211|Placebo Comparator|Placebo|Placebo x 24 weeks
3068639|NCT01121224|Active Comparator|BMS Group|Patients who receive a bare metal stent in the saphenous vein graft target lesion(s).
3068640|NCT01121224|Experimental|DES Group|Patients who receive a drug-eluting stent in the saphenous vein graft target lesion(s).
3068641|NCT01121250|Experimental|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
3068642|NCT01121250|Active Comparator|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
3068643|NCT01121250|No Intervention|Usual Care|Participants do not receive any services.
3068644|NCT01121263||Angiogram Review Group|All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
3068645|NCT01121263||Therapeutic Intervention Group|"Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR~Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents"
3068646|NCT01121393|Experimental|Arm A BIBW 2992|Patients receive a tablet of BIBW 2992 daily until progression or unacceptable toxicity
3068647|NCT01121393|Active Comparator|Arm B Chemotherapy|Patients receive Gemcitabine and Cisplatin, maximum is 6 courses
3068648|NCT01121406|Experimental|BI 6727|Patients receive BI 6727 infusion every 3 weeks
3068649|NCT01121406|Active Comparator|Cytotoxic|At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin
3068650|NCT01121484|Experimental|desvenlafaxine succinate sustained-release|
3068651|NCT01121484|Placebo Comparator|Placebo|
3068652|NCT01121536|Experimental|Armodafinil 150-200 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. At the discretion of the investigator, the dosage of armodafinil may be increased to 200 mg/day on day 6 or thereafter, and reduced to 150mg/day if the higher dose is not well tolerated. Treatment was administered for six months.
3068653|NCT01121549||Aromasin|All patients included in the study
3068654|NCT01121562|Experimental|Sunitinib arm|
3068655|NCT01121575|Experimental|Arm 1|PF-02341066 AND PF-00299804: Patients will be treated with combined cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
3068656|NCT01121575|Experimental|Arm 2|PF-00299804 FOLLOWED BY COMBINED PF-02341066 AND PF-00299804: Patients will be treated with single agent panHER inhibitor (PF-00299804) until disease progression and then with the maximum tolerated combined dose of cMET inhibitor (PF-02341066) and panHER inhibitor (PF-00299804).
3068657|NCT01121666|Active Comparator|Gonal-f® (Follitropin alfa)|
3068658|NCT01121666|Experimental|AFOLIA-150 (Follitropin alfa)|
3068659|NCT01121757|Experimental|Azacitidine followed by Lenalidomide|"Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.~Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1."
3468814|NCT03892291||Active Duty Control|Active duty service member healthy controls
3068660|NCT01121757|Experimental|Lenalidomide followed by Azacitidine|"Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.~Azacitidine 75 mg/m2 subcutaneously (SC) or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a."
3068661|NCT01121900|Experimental|Trazodone HCl OAD|OAD: Once A Day
3068662|NCT01121900|Active Comparator|Trazodone HCl (Apotex Corp.)|
3068663|NCT01121913|Experimental|Trazodone Contramid® OAD (test product 1)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
3068664|NCT01121913|Experimental|Trazodone Contramid® OAD(test product 2)|Test product 1 and Test product 2 are two different prototype formulations of Trazodone Contramid® OAD (once a day)
3068665|NCT01121913|Active Comparator|Triticco®|
3068666|NCT01121913|Active Comparator|Desyrel®|
3068667|NCT01121926|Experimental|Trazodone HCl OAD|OAD: Once A Day
3068668|NCT01121926|Active Comparator|Trazodone HCl (Apotex Corp.)|
3068669|NCT01121939|Experimental|1|combination of bevacizumab, pertuzumab, and sandostatin for patients with advanced neuroendocrine cancers
3068670|NCT01122030|Experimental|Cohort 1|In this cohort 9 participants received one 0.1 mg naldemedine tablet and 3 participants received matching placebo administered on Day 15 under fasted conditions.
3068671|NCT01122030|Experimental|Cohort 2|In this cohort 9 participants received a single dose of 0.3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3068672|NCT01122030|Experimental|Cohort 3|In this cohort 9 participants received a single dose of 1 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3068673|NCT01122030|Experimental|Cohort 4|In this cohort 9 participants received a single dose of 3 mg naldemedine tablets and 3 participants received matching placebo tablets administered on Day 15 under fasted conditions.
3068674|NCT01122030|Experimental|Cohort 5|In this cohort 9 participants received a single dose of 0.03 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
3068675|NCT01122030|Experimental|Cohort 6|In this cohort 9 participants received a single dose of 0.01 mg naldemedine oral solution and 3 participants received matching placebo oral solution administered on Day 15 under fasted conditions.
3068676|NCT01122108|Active Comparator|Cholestyramine 12 grams|Cholestyramine 12 grams
3068677|NCT01122108|Active Comparator|Colesevelam HCl|Colesevelam HCl, 4 grams
3068678|NCT01122160|Placebo Comparator|placebo|Placebo with berries (blackberries + strawberries)
3068679|NCT01122160|Experimental|omeprazole|Prilosec (omeprazole) 20.6 mg tablet with berries (blackberries + strawberries)
3068680|NCT01122173|Experimental|Robotic catheter manipulation, Ablation|To evaluate the safety and effectiveness of the family of Artisan guide catheters when used to remotely introduce and position commercially available cardiac RF ablation catheters to treat subjects with paroxysmal atrial fibrillation.
3068681|NCT01122238|Experimental|1, Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068682|NCT01122238|Experimental|2, Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068683|NCT01122238|Experimental|3, Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068684|NCT01122238|Experimental|4, Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068685|NCT01122238|Experimental|5, Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068686|NCT01122238|Experimental|6, Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068687|NCT01122238|Experimental|7, Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068688|NCT01122238|Experimental|8, Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068689|NCT01122238|Experimental|9, No Nicotine Patch, Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068690|NCT01122238|Experimental|10, No Nicotine Patch, Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068691|NCT01122238|Experimental|11, No Nicotine Patch, Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068692|NCT01122238|Experimental|12, No Nicotine Patch, Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068693|NCT01122238|Experimental|13, No Nicotine Patch, No Nicotine Gum, Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068694|NCT01122238|Experimental|14, No Nicotine Patch, No Nicotine Gum, Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068695|NCT01122238|Experimental|15, No Nicotine Patch, No Nicotine Gum, No Reduction, MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and Motivational Interviewing (MI)"
3068696|NCT01122238|Experimental|16, No Nicotine Patch, No Nicotine Gum, No Reduction, No MI|"This arm of the project will address the following question:~How effective is the following intervention? No Nicotine Patch, No Nicotine Gum, No Smoking Reduction Counseling, and No Motivational Interviewing (MI)"
3068697|NCT01122264|Experimental|Tadalafil on demand|10 milligrams (mg) or 20 mg on demand
3068698|NCT01122264|Experimental|Tadalafil once a day|5 mg or 2.5 mg once a day
3068699|NCT01122264|Active Comparator|Sildenafil Citrate|50 mg, 100 mg, or 25 mg on demand
3068700|NCT01122316|Experimental|Metformin|
3068701|NCT01122394|Experimental|Tailored Intervention (TI)|Tailored intervention based on the transtheoretical model
3068702|NCT01122394|Placebo Comparator|Attention Placebo (AP)|Attention Placebo
3068703|NCT01122446|Placebo Comparator|Placebo comparator|Two doses of placebo day 1 and 30
3068704|NCT01122446|Active Comparator|Alum-GAD (Diamyd)|20 microgram Diamyd day 1 and 30
3068705|NCT01122576|Experimental|Crystalens AO|Eligible subjects to undergo small incision cataract surgery and were implanted with the Crystalens AO bilaterally.
3068706|NCT01122576|Active Comparator|ReSTOR|Eligible subjects to undergo small incision cataract surgery and were implanted with the ReSTOR IOL bilaterally.
3068707|NCT01122576|Active Comparator|Tecnis Multifocal IOL|Eligible subjects to undergo small incision cataract surgery and were implanted with the Tecnis Multifocal IOL bilaterally.
3068708|NCT01122680|Experimental|Treatment A|patients inhale 2 puffs (dose of 1.25 mcg) once daily in the evening via Respimat inhaler
3068709|NCT01122680|Experimental|Treatment C|patients inhale 2 puffs (dose of 5 mcg) once daily in the evening via Respimat inhaler
3068710|NCT01122680|Placebo Comparator|Placebo|patients inhale 2 puffs of placebo matching tiotropium once daily in the evening via Respimat inhaler
3068711|NCT01122680|Experimental|Treatment B|patients inhale 2 puffs (dose of 2.5 mcg) once daily in the evening via Respimat inhaler
3068712|NCT01122849|Experimental|Prototype Nasal Dilator|Prototype Nasal Dilator
3068713|NCT01122849|Active Comparator|Marketed Nasal Strip|Marketed Nasal Strip
3068714|NCT01122849|Placebo Comparator|Placebo Nasal Strip|Placebo
3068715|NCT01122862|Active Comparator|0.12% Chlorhexidine Mouthrinse|Commercially available 0.12% Chlorhexidine mouthrinse
3068716|NCT01122862|Active Comparator|Cosmetic mouthrinse|Commercially available cosmetic mouthrinse
3068717|NCT01122862|Placebo Comparator|Sterile Water|Sterile Water
3068718|NCT01122901|Experimental|Group A (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, 15-17, and 22-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3068719|NCT01122901|Experimental|Group B (gamma-secretase inhibitor RO4929097, surgery)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days -6 to -1. Patients undergo surgical resection on day 0. Within 30 days after surgical resection, patients receive gamma-secretase inhibitor RO4929097 as in group A.
3068720|NCT01122927|Experimental|Phase 1 and Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3068721|NCT01123070|Experimental|TL011|TL011 infusions
3068722|NCT01123070|Active Comparator|MabThera|MabThera infusions
3068723|NCT01123083|Experimental|otelixizumab|otelixizumab
3068724|NCT01123083|Placebo Comparator|placebo|placebo
3068725|NCT01123148|Other|Tilt testing|
3068726|NCT01123161|Active Comparator|Group1: IV t-PA and normothermia|IV tpa and normothermia
3068727|NCT01123161|Active Comparator|Group 2 : IV t-PA and hypothermia and anti-shivering treatment|IV tpa and hypothermia and anti-shivering treatment
3068728|NCT01123200|Other|Brain Computer Interface In-Home Use|
3068729|NCT01123356|Experimental|Oratumumab and Lenalidomide|"Single arm, non randomized study~Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.~Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.~Treatment to be administered for up to 6 cycles"
3068730|NCT01123382|Experimental|IM Electrical Stimulation (IM ES)|The IM ES Group will receive electrical stimulation treatment for three weeks (6 hrs daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
3068731|NCT01123382|Active Comparator|Usual Care (UC)|The Usual Care Group will receive outpatient therapy for four weeks, coupled with prescribed daily home exercises.
3068732|NCT01123395|Experimental|Colcrys® (colchicine USP) 0.6 mg intact tablet|One Colcrys® (colchicine USP) 0.6 mg intact tablet taken by mouth
3068733|NCT01123395|Experimental|Colcrys® 0.6 mg tab in apple juice|One Colcrys® 0.6 mg tablet crushed and dissolved in apple juice
3068734|NCT01123512|Experimental|Kiva VCF Treatment System|
3068735|NCT01123512|Active Comparator|Balloon Kyphoplasty|
3068736|NCT01123642||Group 1|Operation Enduring Freedom and Operation Iraqi Freedom Veterans
3068737|NCT01123655|Experimental|Arm 1|"The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate.~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
3068738|NCT01123655|Experimental|Arm 2|"The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2).~Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate."
3468815|NCT03892291||Active Duty mTBI|Active duty service members with persistent symptoms from mTBI who are referred for physical therapy due to their symptoms
3068739|NCT01123655|Experimental|Arm 3|"Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously.~Intervention: Drug treatment will be stopped or interrupted if indicated."
3068740|NCT01123889|Active Comparator|control|corticosteroid injection into subacromial space
3068741|NCT01123889|Experimental|experimental|patients will receive an injection of platelet rich plasma into the subacromial space
3068742|NCT01123928|Experimental|Counseling|Subjects will be asked to watch a 5-10 min video and participate in a 10-15 min pre-operative counseling session with a trained nurse. Subjects will also participate in a 5 min post-operative counseling session.
3068743|NCT01123928|No Intervention|Non-counseling|
3068744|NCT01123941|Experimental|NVGH Vi-CRM197 conjugate vaccine|
3068745|NCT01123941|Active Comparator|Vi-polysaccharide vaccine|
3068746|NCT01123980|Experimental|BIAsp 30|0.1-0.2 U/kg (starting dose) administered once daily (OD) immediately before dinner in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
3068747|NCT01123980|Active Comparator|Insulin glargine|0.1-0.2U/kg (starting dose) administered once daily (OD) at bedtime in combination with at least 1500 mg (Chinese patients) or 500 mg (Japanese patients) total daily dose of metformin and at least 4 mg glimepiride
3068748|NCT01124006|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3068749|NCT01124006|Placebo Comparator|Water for injection|Sterile water for injection
3068750|NCT01124045|Experimental|DUREZOL|Difluprednate ophthalmic emulsion, 0.05%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
3068751|NCT01124045|Active Comparator|PRED FORTE|Prednisolone acetate ophthalmic suspension, 1.0%, 1 drop in the study eye at the end of surgery (Day 0) and 4 times a day beginning on the day after surgery (Day 1) for 14 days, followed by a tapering period of 14 days, dependent upon the Investigator's determination of adequate response to treatment
3068752|NCT01124097|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
3068753|NCT01124097|Experimental|Eslicarbazepine acetate 1200 mg QD|
3068754|NCT01124097|Experimental|Eslicarbazepine acetate 1600 mg QD|
3068755|NCT01124097|Placebo Comparator|Placebo|
3068756|NCT01124149|Experimental|MMX mesalamine/ mesalazine|
3068757|NCT01124162|Experimental|Generic Test Product|Losartan 100mg Tablets
3068758|NCT01124162|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
3068759|NCT01124175|Experimental|Generic Test Product|Losartan 100 mg Tablets
3068760|NCT01124175|Active Comparator|Reference Listed Drug|Cozaar® 100 mg Tablets
3068761|NCT01124188|Experimental|Study Intervention Arm|Higher-dose venlafaxine and Problem Solving Therapy for Depression and Pain (PST-DP)
3068762|NCT01124188|Active Comparator|Active Control|Higher-dose venlafaxine and supportive management (SM)
3068763|NCT01124292|Experimental|Able-bodied subject with piercing|Able-bodied subjects who already have tongue piercing.
3068764|NCT01124292|Experimental|Able-bodied subject without piercing|Able-bodied subjects who willing to receive a tongue piercing for this study.
3068765|NCT01124292|Experimental|Subjects with spinal cord injury|Persons with mobility limitations requiring power wheel chair, able to move tongue, able to follow simple commands, and have some experience with computers. All participants willingly received a mid-line tongue piercing.
3068766|NCT01124305|Active Comparator|Traditional Instrumentation|Control group: Cases performed with traditional surgical instruments
3068767|NCT01124305|Experimental|Customized Patient Instrumentation|Experimental group: Cases performed with custom instruments specifically made for each patient using pre-op CT scans.
3068768|NCT01124370|Experimental|Treatment|All enrolled subjects will undergo attempted system implantation and therapeutic assessment. Subjects' baseline assessment values will serve as control parameters for the therapy evaluation.
3068769|NCT01124422|Experimental|fluticasone propionate/salmeterol DISKUS 250/50 + tiotropium|This is the active DISKUS (that is, containing fluticasone propionate/salmeterol combination) + open-label tiotropium
3068770|NCT01124422|Placebo Comparator|placebo DISKUS + tiotropium|This is the DISKUS and excipient minus the active ingredient (which is fluticasone propionate/salmeterol combination) + open-label tiotropium
3068771|NCT01124448|Experimental|Lactobacillus salivarius PS2|Women with mastitis (n=25) receiving Lactobacillus salivarius PS2 (9.5 log per day, 21 days)
3068772|NCT01124448|Active Comparator|Lactobacillus salivarius PS2B|Lactating women without mastitis (n=15)
3068773|NCT01124604|Experimental|Tapentadol Hydrochloride|
3068774|NCT01124604|Placebo Comparator|Placebo|
3068775|NCT01124617|Experimental|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
3068776|NCT01124617|Placebo Comparator|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
3068777|NCT01124643|Experimental|Replagal 0.2 mg/kg EOW|Intravenous, 0.2mg/kg EOW
3068778|NCT01124734|Experimental|Course 1 Cycle 1 and Cycle 2|"Course 1 Cycle 1: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals.~Course 1 Cycle 2: Participants will be given high-dose Interleukin-2 (HD IL-2) 600,000 IU/kg, up to 14 doses at 8 hour intervals. On the day after discharge, patients will be given oral temozolomide at 75 mg/m2 daily for 21 days."
3068779|NCT01124786|Experimental|CO-1.01|
3068780|NCT01124786|Active Comparator|gemcitabine|
3068781|NCT01124838|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by every other week (eow) dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 to 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
3068782|NCT01124838|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses eow starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper until Week 19.
3068783|NCT01124864|Experimental|EGFR mutant patients|Patients with EGFR activating mutation tumors (Note: These patients must have progressed on one prior EGFR TKI containing regimen unless they have documented T790M activating mutation). Patients received AUY922 at 70 mg/m^2 weekly infusions.
3068784|NCT01124864|Experimental|Kras mutant patients|Patients with KRAS mutant tumors. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3068785|NCT01124864|Experimental|EGFR and Kras wild type patients|Patients exhibiting both mutations were stratified to the KRAS mutation stratum. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3068786|NCT01124864|Experimental|Patients with EML4-ALK translocation|Patients with NSCLC who have tumors with an inversion in the short arm of chromosome 2 that results in the fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the ALK gene leading to the production of an EML4-ALK fusion tyrosine kinase. ALK is a transmembrane protein, which has a kinase domain and is not usually expressed in the lung. EML4 mediate ligand-independent dimerization, and therefore constitutive activity of the ALK tyrosine kinase domain. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3068787|NCT01124864|Experimental|Modified EGFR mutant patients|The modified EGFR stratum was defined as patients less heavily pretreated who had received one or two lines of prior therapy, with a documented response to a EGFR tyrosine kinase inhibitor (TKI) (complete response (CR), partial response (PR) or stable disease (SD) for ≥ 6 months), unless the patient had de novo resistance to EGFR TKI. Patients received AUY922 at 70 mg/m^2 weekly infusions.
3068788|NCT01124916|Active Comparator|Laparoscopic Abdominal Sacrocolpopexy (LASC)|Women assigned to this cohort will receive standard laparoscopic abdominal sacrocolpopexy (LASC)
3068789|NCT01124916|Experimental|Robotic Assisted Laparoscopic (RASC)|Women assigned to this cohort will receive robotic assisted laparoscopic abdominal sacrocolpopexy (RASC)
3068790|NCT01124955|Active Comparator|Intervention Group|Patients receive 5 sessions of real acupuncture. The technique of acupuncture used in this study is Yamamoto New Scalp Acupuncture called YNSA.
3068791|NCT01124955|Placebo Comparator|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
3068792|NCT01125046|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3068793|NCT01125098||PRO-CT group: Experimental|COPD patients in the PRO-CT group will continue or discontinue antibiotic therapy depending on PRO-CT values.
3068794|NCT01125098||Standard group: No intervention|COPD patients in the Standard group will continue antibiotic therapy for 10 days according to guidelines recommended treatment plan in case of COPD exacerbations.
3068795|NCT01125163|Active Comparator|multivitamin with iron|daily oral multivitamin providing 2mg/kg of iron
3068796|NCT01125163|Placebo Comparator|multivitamin without iron|daily oral multivitamin without iron
3068797|NCT01125176|Experimental|All subjects|In Cycle -1, even numbered patients will receive oral lenalidomide daily on days 1-14 and then no treatment on days 15-28. In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by no treatment on days 15-28. Starting with cycle 1, all patients will alternate daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28. Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every 6th cycle thereafter (cycles 7, 13, 19, etc.)
3068798|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg)|
3068799|NCT01125189|Experimental|Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg)|
3068800|NCT01125189|Placebo Comparator|Placebo plus peg-interferon alfa-2a and ribavirin|
3068801|NCT01125202|Experimental|SCT-based behavioral intervention|Intervention participants continue to receive routine dialysis care, as well as a 16 week dietary counseling intervention based on Social Cognitive Theory. Dietary counseling is paired with Personal Digital Assistant-based dietary self-monitoring.
3068802|NCT01125202|Active Comparator|Attention control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
3068803|NCT01125293|Experimental|Phase I Stage A Level 1|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3068804|NCT01125293|Experimental|Phase I Stage A Level 2|"Combination of everolimus & rituximab for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3068805|NCT01125293|Experimental|Phase I Stage B Level 1|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 5 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle (1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3468816|NCT03892317|Other|Medication adherence interventions|Pharmacist led medication adherence interventions which will be tailored to individual patient need
3068806|NCT01125293|Experimental|Phase I Stage B Level 2|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3068807|NCT01125293|Experimental|Phase I Dose Expansion|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~(1 cycle = 28 days)~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3068808|NCT01125293|Experimental|Phase II|"Combination of everolimus & rituximab with bortezomib for 6 cycles:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~Rituximab 375 mg/Kg: Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only~Bortezomib 1.6 mg/m^2: Given intravenously on days 1, 8 and 15 of every cycle~Maintenance:~Everolimus 10 mg: Taken orally on a daily basis x 28 days~(1 cycle = 28 days)~Participants are treated on everolimus maintenance until progression, unacceptable toxicity or withdrawal for other reasons."
3068809|NCT01125358|Experimental|10 milligrams (mg) LY2140023|
3068810|NCT01125358|Experimental|80 mg LY2140023|
3068811|NCT01125358|Experimental|160 mg LY2140023|
3068812|NCT01125358|Placebo Comparator|Placebo|
3068813|NCT01125514|Experimental|Furosemide 60 mg|Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.
3068814|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 150 mg|Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.
3068815|NCT01125514|Experimental|Furosemide 60 mg + Aliskiren 300 mg|Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.
3068816|NCT01125566|Active Comparator|Arm B: trastuzumab with vinorelbine|patients receive weekly intravenous infusion of trastuzumab and vinorelbine
3068817|NCT01125566|Experimental|Arm A: BIBW 2992 with vinorelbine|patients receive BIBW 2992 tablets once daily combined with weekly intravenous infusion of vinorelbine
3068818|NCT01125605||Adults > 12 years|adult patients and patients older than 12 years
3068819|NCT01125605||Children 6-12 years|children between 6 and 12 years
3068820|NCT01125605||Children 1-6 years|children between 1 and 6 years
3068821|NCT01125722|Active Comparator|Investigator Placement Group|
3068822|NCT01125722|Active Comparator|Subject Placement Group|
3068823|NCT01125748|Experimental|Omalizumab|Participants received omalizumab subcutaneously at the same dose and dosing interval as administered prior to enrollment in this study. The dose of omalizumab was either a minimum of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a minimum of 0.016 mg/kg/IgE (IU/mL) every 4 weeks for 48 weeks.
3068824|NCT01125748|Placebo Comparator|Placebo|Participants received placebo subcutaneously at the same dosing interval as omalizumab was administered prior to enrollment in this study.
3068825|NCT01125774|Experimental|Telcagepant|Telcagepant 140 mg was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
3068826|NCT01125774|Placebo Comparator|Placebo|Placebo was administered once daily at bedtime for 7 consecutive days each month, beginning at the onset of menses, for up to 6 months. Dosing could begin up to 3 days prior to menses onset if prodromal symptoms reliably predicted onset of menses.
3068827|NCT01125800|Experimental|LDE225 233mg/m2 daily dose|Pediatric dose.
3068828|NCT01125800|Experimental|LDE225 372mg/m2 daily dose|Pediatric dose.
3068829|NCT01125800|Experimental|LDE225 425 mg/m2 daily dose|Pediatric dose.
3068830|NCT01125800|Experimental|LDE225 680 mg/m2 daily dose|Pediatric dose.
3068831|NCT01125800|Experimental|LDE225 800 mg/m2 daily dose|Adult dose
3068832|NCT01125813|Experimental|human cl-rhFVIII|
3068833|NCT01125917|Experimental|BTDS|Buprenorphine transdermal patch
3068834|NCT01125930|Placebo Comparator|Vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
3068835|NCT01125930|Active Comparator|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
3068836|NCT01126060|Active Comparator|Fibrin sealant|usage of fibrin sealant after surgery
3068837|NCT01126060|No Intervention|Control|No usage of fibrin sealant
3068838|NCT01126099|Experimental|Prazosin|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
3068839|NCT01126099|Placebo Comparator|Placebo|In the double blind phase (12 weeks), study participants will take either prazosin for placebo. For the open label phase (12 weeks), all study participants will take prazosin.
3068840|NCT01126268|Experimental|Retapamulin ointment 1%|
3068841|NCT01126359|Placebo Comparator|Lidocaine then Placebo-Saline|
3068842|NCT01126359|Active Comparator|Placebo-Saline then Lidocaine|
3068843|NCT01126424|Experimental|Solifenacin|Participants received 21 days of treatment with 5 mg solifenacin, in tablet form once a day.
3068844|NCT01126424|Active Comparator|Oxybutynin|Participants received 21 days of treatment with 10 mg oxybutynin (1 x 5 mg twice daily) in capsule form.
3068845|NCT01126424|Placebo Comparator|Placebo|Participants received 21 days of treatment with placebo.
3068846|NCT01126437|Experimental|tiotropium 2.5 mcg and placebo|Patients receive one of the active tiotropium arms daily
3068847|NCT01126437|Active Comparator|tiotropium 18 mcg and placebo|Patients receive one of the active tiotropium arms daily
3068848|NCT01126437|Experimental|tiotropium 5 mcg and placebo|Patients receive one of the active tiotropium arms daily
3068849|NCT01126541|Experimental|A|1000 mg IV rituximab
3068850|NCT01126541|Experimental|B|2 x 1000 mg IV rituximab
3068851|NCT01126580|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
3068852|NCT01126580|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneously (SC), once weekly for 52 weeks~Placebo: 1 tablet per day, orally, for Week 1; 2 tablets per day, orally, for Week 2; 3 tablets per day, orally, for Week 3; 4 or at least 3 tablets, orally, for Weeks 4 through Week 52"
3068853|NCT01126580|Active Comparator|Metformin|"Metformin: 500 milligrams per day (mg/day), orally, for Week 1; 1000 mg/day, orally, for Week 2; 1500 mg/day, orally, for Week 3; 2000 or at least 1500 mg/day, orally, for Weeks 4 through Week 52~Placebo: subcutaneously (SC), once weekly for 52 weeks"
3068854|NCT01126593|Placebo Comparator|Placebo group|The placebo group will receive the same subacromial infusion catheter as the study group.However, the reservoir will be filled with 200cc of 0.9% normal saline.
3068855|NCT01126593|No Intervention|Control group|The control group patients will receive no continuous infusion catheter.
3068856|NCT01126593|Experimental|Study Group|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The infusion rate will be 4cc per hour.
3068857|NCT01126619||Anti-TNF|Participants with moderate to severe psoriasis who were prescribed an Anti Tumor Necrosis Factor (anti-TNF) agent prior to enrollment according to national approved indications and reimbursement guidelines.
3068858|NCT01126671|Active Comparator|Low Dose Vitamin D|Subjects are randomized to take 200 IU vitamin D3 daily in this arm.
3068859|NCT01126671|Active Comparator|High Dose Vitamin D|Subjects are randomized to take 1000 IU vitamin D3 daily in this arm.
3068860|NCT01126723|Experimental|Tai Chi group|
3068861|NCT01126723|Active Comparator|Educational Control group|
3068862|NCT01127061|Experimental|Exercise Training|Participants in the exercise group will undergo 4 months of training, 4-7 days per week with a minimum of 20 minutes per day. The protocol will be custom designed in consultation with an exercise physiologist based on data from the initial cardiopulmonary stress test. Exercise regimen will begin at a low level of intensity then increase in duration and training intensity to a goal of 60 minutes a day and 70% of the heart rate reserve during the 1st month of the study protocol with maintenance of the program thereafter. There is no need to come to a participating site for actually doing the exercise regimen. No strength training or burst activity will be prescribed and all activities will fall well within the recommended national guidelines for recreational exercise.
3068863|NCT01127061|No Intervention|Usual Activity|Participants in this group are not restricted in their activities. They simply are not guided in their physical activities by the study team. At the end of the 4 month study period, they will also receive an individualized exercise prescription for personal use.
3068864|NCT01127087|Experimental|RYGB CaOx Stone Formers|"Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB).~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
3068865|NCT01127087|Experimental|Idiopathic Hyperoxaluria CaOx Stone Formers|"Subjects with idiopathic hyperoxaluria.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
3068866|NCT01127139||Czech patients with essential hypertension|Czech hypertensive patients (women and men) with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg who can be treated with fixed-combination Tarka®.
3068867|NCT01127165|Experimental|Zonisamide Low Dose Group|
3068868|NCT01127165|Experimental|Zonisamide High Dose group|
3068871|NCT01127321|Placebo Comparator|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
3068872|NCT01127321|Experimental|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
3068873|NCT01127321|Experimental|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
3068874|NCT01127321|Experimental|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
3068875|NCT01127321|Experimental|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
3068876|NCT01127373|Experimental|radiation therapy via multi-beam IMRT|This is a single-arm feasibility study of multi-beam IMRT with daily set-up verification in the treatment of women with node-positive breast cancer who will receive radiation to the breast/chest wall and regional lymph nodes, including the internal mammary lymph nodes.
3068877|NCT01127438|Active Comparator|fospropofol disodium Subgroup 1 Lower Dose|
3068878|NCT01127438|Active Comparator|: fospropofol disodium Subgroup 1 Approved Dose|
3068879|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Lower Dose|
3068880|NCT01127438|Active Comparator|fospropofol disodium Subgroup 2 Approved Dose|
3068881|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Lower Dose|
3068882|NCT01127438|Active Comparator|fospropofol disodium Subgroup 3 Approved Dose|
3068883|NCT01127581|Experimental|MVI 200|MVI 200 mcg vaginal insert
3068884|NCT01127581|Active Comparator|Dinoprostone Vaginal Insert (DVI)|10 mg Dinoprostone vaginal insert
3068885|NCT01127607|Experimental|stimulant medication|blinded lisdexamfetamine at the optimal dose for the individual participant as previously determined during the med optimization portion of the study
3068886|NCT01127607|Placebo Comparator|placebo pill|placebo medication identical in appearance to active med
3068887|NCT01127633|Experimental|Solanezumab|
3068888|NCT01127633|Placebo Comparator|Placebo|
3068889|NCT01127646|Experimental|Atomoxetine|Participants received 25-80 milligrams (mg) of atomoxetine orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 25-80 mg of atomoxetine orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 25-80 mg of atomoxetine orally, once daily for 1-5 days.
3068890|NCT01127646|Active Comparator|Osmotic-release oral system methylphenidate|Participants received 18-54 mg of osmotic-release oral system (OROS) methylphenidate orally, once daily during the run-in period for up to 7 days. The run-in period was followed by the 4-week on/off period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 4 weeks, except for the off-days, where participants received 1 or 2 oral once daily placebo doses per week, with 6 nonconsecutive, double-blinded placebo doses in total over the 4-week on/off period. The on/off period was followed by a run-out period in which participants received 18-54 mg of OROS methylphenidate orally, once daily for 1-5 days.
3068891|NCT01127659|Active Comparator|diabetes with HH-active|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
3068892|NCT01127659|No Intervention|diabetes with normal testosterone|Eugonadal subjects with diabetes. They will not be treated
3068893|NCT01127659|Active Comparator|obese with HH-active|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
3068894|NCT01127659|No Intervention|obese with normal testosterone|Eugonadal non-diabetic obese subjects. They will not be treated
3068895|NCT01127659|Placebo Comparator|Diabetes with HH-placebo|Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
3068896|NCT01127659|Placebo Comparator|Obese with HH-placebo|Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.
3068897|NCT01127737|Placebo Comparator|Control|
3068898|NCT01127737|Active Comparator|Intervention|Educational intervention consisting of a mnemonic and a workbook used by kidney transplant recipients (KTRs) to assist with early detection of SCCs.
3068899|NCT01127763|Experimental|RAD001+carboplatin|Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.
3068900|NCT01127893|Experimental|Tanezumab 10 mg|
3068901|NCT01127893|Experimental|Tanezumab 5 mg|
3068902|NCT01127893|Experimental|Tanezumab 2.5 mg|
3068903|NCT01128049|Active Comparator|Normal Patient Population|Non-Dry Eye patient population (intervention remains the same across all arms)
3068904|NCT01128049|Active Comparator|MGD Patient Population|Meibomium Gland Dysfunction population(intervention remains the same across all arms)
3068905|NCT01128049|Active Comparator|ADDE Population|Aqueous Deficient Dry Eye population(intervention remains the same across all arms)
3068906|NCT01128153|Experimental|Saxagliptin 5 mg once daily|
3068907|NCT01128153|Placebo Comparator|Placebo once daily|
3068908|NCT01128179|Experimental|Lanthanum carbonate|
3068909|NCT01128179|Placebo Comparator|Placebo|
3068910|NCT01128192|Experimental|Pasireotide 600 µg sc bid|n=19. Pasireotide 600 µg sc bid
3068911|NCT01128192|Experimental|Pasireotide 900 µg sc bid|n=19. Pasireotide 900 µg sc bid
3068912|NCT01128192|Experimental|Pasireotide 1200 µg sc bid|n=7. Due to increased severity of gastro-intestinal side effects, this arm was discontinued. These participants were only included in the safety analysis.
3068913|NCT01128244|Experimental|Vitamin B6 Effects in OC Users|"All subjects will be given an infusion of labeled serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.~The results from analysis of vitamin B6 and these amino acids in blood will provide us with specific measurements of the rates of two aspects of metabolism (Primary Outcomes 1 and 2) and specific measurements of vitamin B6 nutritional status (Primary Outcomes 3 and 4)."
3068914|NCT01128270|Experimental|1A: Chloral Hydrate and DCA: Env|Subjects consume Chloral Hydrate 1.5ug/kg by mouth for 5 nights. On the 6th day they consume DCA 2.5ug/kg by mouth and have blood samples drawn. (Period 1)
3068915|NCT01128270|Experimental|1B: Chloral Hydrate Env dose|Drug Study Subjects are admitted to the clinical research unit and receive 1.5 ug/kg (environmental dose) of Chloral Hydrate for 5 nights. Pharmacokinetics are done on days 1 and day 5. (Period 2)
3068916|NCT01128270|Experimental|2A: Chloral Hydrate and DCA therapeutic|Drug Study Subjects are admitted to the clinical research center and receive a clinical dose of Chloral Hydrate for 5 nights (25mg/kg). On day 6 they are given a clinical dose (25mg/kg)of Dichloroacetate. (Period 3)
3068917|NCT01128270|Experimental|2B: Chloral Hydrate Therapeutic|Subjects are given 25 mg/kg of Chloral Hydrate for five nights. Pharmacokinetics are done on days 1 and 5. (Period 4)
3068918|NCT01128296|Experimental|Hydroxychloroquine + Gemcitabine (HcGc)|Hydroxychloroquine orally twice daily in combination with gemcitabine for 31 days prior to surgical resection
3068919|NCT01128361|Experimental|Aerobic Exercise|
3068920|NCT01128361|Active Comparator|Stretching|
3068921|NCT01128387|Experimental|Dose Level -1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 60mg/m2 cisplatin, 750mg/m2 5FU (Fluorouracil)
3068922|NCT01128387|Experimental|Dose Level 1|Panitumumab/Cisplatin/Fluorouracil and Radiation therapy 1.5mg/kg Panitumumab, 80mg/m2 cisplatin, 1000mg/m2 5FU (Fluorouracil)
3068923|NCT01128400||rs1761667- AA genotype|subjects carrying the CD36 genotype rs1761667, i.e. a Single Nucleotide Polymorphism that significantly reduces CD36 level and has a minor allele frequency of 38-48%.
3068924|NCT01128400||rs1761667-GG genotype|subjects who are homozygous of CD36 genotype rs1761667-G allele.
3068925|NCT01128400||rs1761667-AG genotype|Heterozygous of CD36 gene rs1761667-A genotype.
3468817|NCT03892148|Active Comparator|Standard|Use of loop diuretics and thiazide diuretics leaves to the discretion of the responsible physician
3068926|NCT01128413|Experimental|Fluid Optimization (FO)|"Cheetah NICOM® (non-invasive cardiac output monitoring) Passive Leg Raise Testing (PLRT) that demonstrates a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) will receive a 500ml normal saline bolus. NICOM® PLRT with SVI or CI <15% will receive a saline lock. If bolused, NICOM® PLRT will be performed within 10 minutes after the bolus with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements. If saline locked, NICOM® PLRT will be performed every 30 minutes with the decision to re-bolus or saline lock according to repeated NICOM® PLRT measurements.~Additionally, USCOM®, IVC Ultrasound collapsibility, CURVES Questionnaire, and repeat lactate measurements will be performed."
3068927|NCT01128413|Active Comparator|Routine Care (RC)|Patients randomized to receive routine ED care will receive IV fluid administration per the treating clinicians discretion. The Cheetah NICOM®PLRT, USCOM®, IVC Ultrasound collapsibility, and CURVES Questionnaire will be performed and repeat lactate measurements will only be revealed to the routine care arm if they are used as part of the provider's routine care.
3068928|NCT01128426||1|
3068929|NCT01128543|Active Comparator|lapatinib 1250mg|Patients will receive 1250mg lapatinib once a day for 24 weeks.
3068930|NCT01128543|Active Comparator|Vinorelbine 25mg/sqm|Patients will receive vinorelbine 25mg/sqm IV Day 1 and Day 8, every 3 week for 24 weeks.
3068931|NCT01128569|Placebo Comparator|Placebo|Placebo Inhaler
3068932|NCT01128569|Active Comparator|inhaled corticosteroid(ICS)/long acting bronchodilator (LABA)|ICS/LABA inhaler
3068933|NCT01128569|Active Comparator|ICS|ICS inhaler
3068934|NCT01128595|Active Comparator|ICS|
3068935|NCT01128595|Active Comparator|ICS/LABA|
3068936|NCT01128595|Active Comparator|LABA|
3068937|NCT01128595|Placebo Comparator|Placebo|
3068938|NCT01128621|Other|Part A|Part A is open label, in T2DM subjects on established metformin monotherapy. Subjects will receive a single dose of GSK1292263 with food. This will permit a comparison of GSK1292263 exposures in this cohort with those observed in study GPR111598 in which T2DM subjects were drug naïve or washed off prior anti-diabetic medications.
3068939|NCT01128621|Placebo Comparator|Part B - PLA|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3068940|NCT01128621|Active Comparator|Part B - Active|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3068941|NCT01128621|Active Comparator|Part B - Sitagliptin|Part B is a single-blind, randomized, placebo-controlled, 4-arm cohort of 48 subjects dosed for 14 days with one of two doses of GSK1292263 BID, placebo BID or open-label sitagliptin 50mg BID. It is being conducted to assess safety, tolerability, PK and PD of GSK1292263 and open-label sitagliptin after 14-days of dosing in T2DM subjects already taking metformin monotherapy.
3068942|NCT01128738|Active Comparator|GSK1358820|Onabotulinum toxin type A
3068943|NCT01128738|Placebo Comparator|Placebo|Placebo
3068944|NCT01128829|Experimental|water-sucralose|"Subjects in this group drank water 10 min before drinking a glucose load on their first oral glucose tolerance test (OGTT) and drank sucralose 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
3068945|NCT01128829|Experimental|sucralose-water|"Subjects in this group drank sucralose 10 min before drinking a glucose load on their first OGTT and drank water 10 min before drinking a glucose load on their second OGTT. The two OGTT were separated on average by 1 week (i.e. washout was approximately 1 week)."
3068946|NCT01128842|Experimental|Neratinib + Capecitabine|Neratinib + Capecitabine
3068947|NCT01128894|Experimental|albiglutide|weekly albiglutide subcutaneous injection
3068948|NCT01128894|Active Comparator|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
3068949|NCT01128946|Experimental|Fluoride Toothpaste 1|Fluoride toothpaste containing sodium fluoride (NaF)
3068950|NCT01128946|Experimental|Fluoride Toothpaste 2|Fluoride toothpaste containing stannous fluoride (SnF) and NaF.
3068951|NCT01128946|Experimental|Fluoride Toothpaste 3|Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.
3068952|NCT01128946|Active Comparator|Reference Dentifrice|Low fluoride toothpaste containing NaF
3068953|NCT01128959|Experimental|Intravenous Carbamazepine (IV CBZ)|
3068954|NCT01128972|Experimental|Test Dentifrice + Test Mouth Rinse (MR)|Test fluoride dentifrice and test fluoride MR
3068955|NCT01128972|Experimental|Test Dentifrice + Sterile Water Rinse|Test fluoride dentifrice and sterile water rinse
3068956|NCT01128972|Experimental|Placebo Dentifrice + Test MR|Placebo dentifrice and test fluoride rinse
3068957|NCT01128972|Active Comparator|Reference Dentifrice + Sterile Water Rinse|Marketed fluoride dentifrice with sterile water rinse
3068958|NCT01128972|Placebo Comparator|Placebo Dentifrice + Sterile Water Rinse|Placebo dentifrice and sterile water rinse
3068959|NCT01129011|Experimental|PN400|Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily
3068960|NCT01129011|Active Comparator|Naproxen|Naproxen 500 mg dosed twice daily
3068961|NCT01129024|Experimental|Lusutrombopag|Participants received lusutrombopag 0.5 mg administered orally once a day for up to 3 years or until study termination. The dose was adjusted based on platelet counts. If a subject's platelet count remained < 50,000/μL, the dose could have been increased by 0.25 mg up to a maximum dose of 2.0 mg.
3068962|NCT01129102|Experimental|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
3068963|NCT01129102|Active Comparator|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
3068964|NCT01129102|Placebo Comparator|Placebo|Placebo for NPC-01
3068965|NCT01129115|Active Comparator|Nonexercise control group|
3068966|NCT01129115|Experimental|Aerobic Exercise Group 1|
3068967|NCT01129115|Experimental|Aerobic Exercise Group 2|
3068968|NCT01129115|Experimental|Aerobic Exercise Group 3|
3068969|NCT01129128|Active Comparator|Echinacea preparation 1|Commercially available Echinacea purpurea product
3068970|NCT01129128|Active Comparator|Echinacea preparation 2|Commercially available Echinacea purpurea product
3068971|NCT01129128|Placebo Comparator|Placebo|Inert liquid that is similar in appearance and taste to the active Echinacea products
3068972|NCT01129141|Experimental|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
3068973|NCT01129141|Other|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
3068974|NCT01129206|Experimental|Arm I|Patients receive pralatrexate IV over 3-5 minutes and docetaxel IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3068975|NCT01129245|No Intervention|Control cycle|Control menstrual cycle
3068976|NCT01129245|Experimental|Pre-LH surge celecoxib administration|Pre-LH surge dosing of celecoxib
3068977|NCT01129245|Experimental|Post-LH surge celecoxib administration|Post-LH surge dosing of celecoxib
3068978|NCT01129284|Experimental|Acthar gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
3068979|NCT01129336|Experimental|Patients without bone metastases|Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.
3068980|NCT01129336|Experimental|Patients with bone metastases|Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)
3068981|NCT01129440|Active Comparator|Fluoride Varnish|Topical fluoride varnish (FV) applications every 6 months
3068982|NCT01129440|Experimental|FV + Glass Ionomer Sealants|Topical fluoride varnish (FV) applications every 6 months, and fluoride-releasing glass ionomer sealants (GIS) placed on primary molars at baseline and annually, as needed
3068983|NCT01129531|Experimental|AGN-214868 3.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 3.25 μg per treatment.
3068984|NCT01129531|Experimental|AGN-214868 16.25 μg|AGN-214868 injected into areas of postherpetic neuralgia pain for a total dose of 16.25 μg per treatment.
3068985|NCT01129531|Placebo Comparator|Placebo|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
3068986|NCT01129557|Active Comparator|Tekturna|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months
3068987|NCT01129557|Active Comparator|Diovan|Diovan (Valsartan), an angiotensin receptor blocker (ARB) 320 mg by mouth once daily for 9 months
3068988|NCT01129557|Active Comparator|Tekturna & Diovan|Tekturna (Aliskiren), a direct renin inhibitor (DRI) 150 mg by mouth once daily & Diovan (Valsartan), an angiotensin receptor (ARB) 160 mg by mouth once daily for 9 months
3068989|NCT01129583|Experimental|Botulinum Toxin|100 U injected into biceps, 100 U into brachialis
3068990|NCT01129583|Placebo Comparator|Saline|100 U injected into biceps, 100 U into brachialis
3068991|NCT01129609||Participants with Successful Secondary Endovascular Treatment|
3068992|NCT01129622|Experimental|Letrozole, Breast enhancement, Safety|Single arm of healthy postmenopausal women who received baseline diagnostic MRI will receive letrozole of 12.5 mg/day orally for three successive days. A second post treatment breast MRI is done right after receiving the three days of letrozole treatment and within one month after the first MRI .
3068993|NCT01129765||Parents of congested children|Parents of children less than six years of age with nasal congestion for which nasal suctioning and salt water irrigation is traditionally recommended.
3068994|NCT01129778|Experimental|Received Zegerid (Ome-NaBic)|Administered Ome-NaBic 40 mg orally 1 h before breakfast and bedtime
3068995|NCT01129804|Experimental|Network Support|Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
3068996|NCT01129804|Active Comparator|Packaged Cognitive-Behavioral Treatment|The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.
3068997|NCT01129882|Experimental|Aripiprazole IM depot|Active treatment of monthly doses of aripiprazole IM depot (300 mg or 400 mg)
3068998|NCT01129921|Active Comparator|Decompression with mild® Device Kit|Fluoroscopically guided percutaneous lumbar decompression using the Vertos mild® Device Kit for bone and tissue removal to decompress the targeted stenosed level(s).
3068999|NCT01129921|Sham Comparator|Sham lumbar decompression|Sham procedure of fluoroscopically guided percutaneous placement of mild® Device Kit instrumentation with no removal of bone or tissue.
3069000|NCT01129960|Experimental|Eslicarbazepine acetate 800 mg once daily (QD)|
3069001|NCT01129960|Experimental|Eslicarbazepine acetate 1200 mg QD|
3069002|NCT01129960|Experimental|Eslicarbazepine acetate 1600 mg QD|
3069003|NCT01129960|Placebo Comparator|Placebo|
3069004|NCT01130051|Experimental|Colcrys® 0.6 mg intact tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
3069005|NCT01130051|Experimental|Colcrys® 0.6 mg tablet on applesauce|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
3069006|NCT01130103|Experimental|Paroxetine|Paroxetine and Prolonged Exposure Therapy
3069007|NCT01130103|Placebo Comparator|Placebo pill|Placebo pill plus Prolonged Exposure Therapy
3468818|NCT03892148|Experimental|Protocol|use of loop diuretics and thiazide diuretics according to the CARRESS-HF protocol developed by the Heart Failure Network
3069008|NCT01130168|Experimental|Placebo/ISMN ER/Amlodipine (Sequence 1)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
3069009|NCT01130168|Experimental|ISMN ER/Amlodipine/Placebo (Sequence 2)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3069010|NCT01130168|Experimental|Amlodipine/Placebo/ISMN ER (Sequence 3)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3069011|NCT01130168|Experimental|ISMN ER/Placebo/Amlodipine (Sequence 4)|Participants received a ISMN ER 30 mg capsule orally for 4 weeks during Period 1, followed by a dose-matched Placebo capsule orally for 4 weeks during Period 2, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 3, with a 2-week washout between each period.
3069012|NCT01130168|Experimental|Placebo/Amlodipine/ISMN ER (Sequence 5)|Participants received a dose-matched Placebo capsule orally for 4 weeks during Period 1, followed by Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 2, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 3, with a 2-week washout between each period.
3069013|NCT01130168|Experimental|Amlodipine/ISMN ER/Placebo (Sequence 6)|Participants received Amlodipine 10 mg (two 5 mg capsules) orally for 4 weeks during Period 1, followed by a ISMN ER 30 mg capsule orally for 4 weeks during Period 2, followed by a dose-matched Placebo capsule for 4 weeks during Period, with a 2-week washout between each period.
3069014|NCT01130272|Experimental|Eluxadoline 5 mg|Eluxadoline 5 mg tablets, orally, twice daily for up to 12 weeks.
3069015|NCT01130272|Experimental|Eluxadoline 25 mg|Eluxadoline 25 mg tablets, orally, twice daily for up to 12 weeks. .
3069016|NCT01130272|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 12 weeks.
3069017|NCT01130272|Experimental|Eluxadoline 200 mg|Eluxadoline 200 mg tablets, orally, twice daily for up to 12 weeks.
3069018|NCT01130272|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 12 weeks.
3069019|NCT01130337|Experimental|1|
3069020|NCT01130493|Other|IPX066-CLE-OLE|Dose conversion from CLE to IPX066, IPX066 (Part 1 Period 1), Open-label IPX066, CLE (Part 1 Period 2), OLE (Part 2)
3069021|NCT01130493|Other|CLE-IPX066-OLE|Dose conversion from CLE to IPX066, CLE (Part 1 Period 1), Open-label IPX066, IPX066 (Part 1 Period 2), OLE (Part 2)
3069022|NCT01130532|Active Comparator|2.5 milligram (mg) titrated to 5 mg Tadalafil|2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
3069023|NCT01130532|Active Comparator|5 mg Tadalafil|5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
3069024|NCT01130532|Placebo Comparator|Placebo|for 12 weeks
3069025|NCT01130597|Experimental|patiromer|spironolactone + patiromer
3069026|NCT01130740|No Intervention|Arm 1|usual care
3069027|NCT01130740|Experimental|Arm 2|Osteoarthritis Intervention - Primary care providers receive patient-specific osteoarthritis information and treatment recommendations approximately one week prior to the patient's first post-enrollment routine appointment with PCP; patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
3069028|NCT01130844|Experimental|MMX Mesalamine (30mg/kg)|
3069029|NCT01130844|Experimental|MMX Mesalamine (60 mg/kg)|
3069030|NCT01130844|Experimental|MMX Mesalamine (100 mg/kg)|
3069031|NCT01130883||Respiratory Infections|Czech patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid®SR treatment 6 weeks prior to the next Klacid®SR dose or in intervals: 7-week - 3- month, 4- month - 12- month, 13- month - 24- month prior to the next Klacid®SR dose (next Klacid®SR dose = dose administered within this PMOS).
3069032|NCT01130896||MRI and Cardiac Devices|Clinically indicated MRI (all types) in patients with implanted pacemakers and ICD
3069033|NCT01130974|Experimental|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
3069034|NCT01130974|Active Comparator|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
3069035|NCT01131052|Active Comparator|BASAL PLUS|Diabetic subjects receive insulin glargine once daily plus corrective doses of insulin glulisine before meals and bedtime as needed
3069036|NCT01131052|Active Comparator|sliding scale regular insulin (SSRI)|Diabetic subjects receive sliding scale regular insulin (SSRI) before meals and at bedtime as needed
3069037|NCT01131065|Experimental|Hepatitis B immune globulin|Treatment group (newly liver transplanted subjects due to HBV induced liver disease)
3069038|NCT01131078|Experimental|Bevacizumab + Irinotecan + Capecitabine (1000 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle. Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks. Capecitabine was administered orally at a dose of 1000 mg/m^2 twice daily (Day 2 to 15). Cycle length was 3 weeks consisting of 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
3069039|NCT01131078|Experimental|Bevacizumab + Capecitabine (1250 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle in combination with capecitabine administered orally at 1250 mg/m^2 twice daily (Day 1 to 14). Cycle length was 3 weeks with 2 weeks of capecitabine treatment followed by 1 week without treatment up to 6 cycles. After 6 cycles, participants with objective response or SD were treated with bevacizumab alone until unacceptable toxicity, PD, or participant withdrawal.
3468819|NCT03892304||Adult women with Cystic Fibrosis|Cohort of 164 women diagnosed with Cystic Fibrosis (CF) who were patients at the Cystic Fibrosis Adult Referral Centre in Lyon, France in 2017 (compared to 155 in 2014). Women attending the CF adult centre in 2017 were asked to complete a written questionnaire.
3069040|NCT01131078|Experimental|Bevacizumab + Capecitabine (650 mg/m^2)|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 Week cycle in combination with capecitabine administered orally at 650 mg/m^2 twice daily (Day 1 to 21). Cycle length was 3 weeks with 3 weeks of capecitabine treatment without interruptions. Participants received the same regimen until unacceptable toxicity, PD, or participant withdrawal.
3069041|NCT01131104||Cohort 1|Participants with NAION who have used PDE5 inhibitors
3069042|NCT01131130|Experimental|Investigational contact lens|Bausch & Lomb
3069043|NCT01131130|Active Comparator|Acuvue Oasys Contact Lens|Johnson & Johnson Lens
3069044|NCT01131130|Active Comparator|Air Optix Aqua|Ciba Vision
3069045|NCT01131182|Experimental|Sitagliptin|Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
3069046|NCT01131182|Active Comparator|Sulfonylurea|Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
3069047|NCT01131260|Experimental|Open Group|• Fetal STAN monitor electrode inserted and data available to caregivers
3069048|NCT01131260|Other|Masked Group|•Fetal STAN monitor electrode inserted, but data masked to the caregivers
3069049|NCT01131299|Active Comparator|Alpha cyclodextrin first then placebo|Randomized subjects will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks. After the one week washout, the subjects will receive 2 tablets orally of placebo (three times a day for 12-14 weeks).
3069050|NCT01131299|Placebo Comparator|Placebo first then Alpha cyclodextrin|Participants will receive 2 tablets orally of placebo (three times a day for 12-14 weeks). The subjects will have a one-week washout. After the washout, the participants will receive alpha cyclodextrin 2g orally three times a day for 12-14 weeks.
3069051|NCT01131312|Experimental|Cytology|Referred to colposcopy if cytology is high grade
3069052|NCT01131312|Experimental|Human Papillomavirus (HPV)|Referred to colposcopy if cytology is high grade or HPV +
3069053|NCT01131312|Experimental|Colposcopy|All refer to colposcopy
3069054|NCT01131325|Experimental|Nilotinib|
3069055|NCT01131351|Experimental|Delamanid 250 mg BID+ OBR|Participants received delamanid five 50 milligrams (mg) (250 mg) tablets, twice a day (BID), along with at least 2 additional anti-TB medications per optimized background regimen (OBR) for up to 28 weeks.
3069056|NCT01131351|Experimental|Delamanid 300 mg BID+ OBR|Participants received delamanid six 50 mg (300 mg) tablets, BID, along with at least 2 additional anti-TB medications per OBR for up to 28 weeks.
3069057|NCT01131494|Experimental|Swallowing exercises|
3069058|NCT01131507|Experimental|EUR-1008 (APT-1008)|
3069059|NCT01131520|Experimental|Computerized Brief Intervention|Computerized one-session brief intervention for drug use
3069060|NCT01131520|Active Comparator|Counselor delivered brief intervention|This is a brief intervention focused on drug use delivered by a behavioral health counselor and based on motivational interviewing
3069061|NCT01131585|Experimental|Active laser photocoagulation and ranibizumab|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Ranibizumab intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
3069062|NCT01131585|Active Comparator|Active laser photocoagulation and sham injection|"Active laser treatment applied at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.~Sham intravitreal injection given at baseline, at 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment."
3069063|NCT01131676|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3069064|NCT01131676|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3069065|NCT01131676|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3069066|NCT01132118|Other|Placebo then HCQ|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
3069067|NCT01132118|Other|HCQ then Placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive hydroxychloroquine for 8 weeks and then crossover to a placebo for 8 weeks. Study staff will be blinded to which order they are taking the hydroxychloroquine and placebo in.
3069068|NCT01132144|Experimental|Endometrial injury group|Endometrial biopsy was performed once with a pipelle de Cornier® in the month before initiating controlled ovarian stimulation.
3069069|NCT01132144|Sham Comparator|Control group|Introduction of the speculum and wiping of the cervix with gaze for 30 seconds.
3069070|NCT01132313|Experimental|2|4 weeks of high dose TID BI 207127 and QD BI 201335 in combination with RBV, Part 1
3069071|NCT01132313|Experimental|1|4 weeks of low dose three times per day (TID) BI 207127 and once daily (QD) BI 201335 in combination with RBV, Part 1
3069072|NCT01132313|Experimental|3|16 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3069073|NCT01132313|Experimental|4|28 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3069074|NCT01132313|Experimental|5|40 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3069075|NCT01132313|Experimental|6|28 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 2
3069076|NCT01132313|Experimental|7|28 weeks of TID BI 207127 and QD BI 201335 without RBV, Part 2
3069077|NCT01132313|Experimental|8|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3069078|NCT01132313|Experimental|9|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3069079|NCT01132313|Experimental|10|24 weeks of TID BI 207127 and QD BI 201335 in combination with RBV, Part 3
3069080|NCT01132313|Experimental|11|16 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
3069081|NCT01132313|Experimental|12|24 weeks of BID BI 207127 and QD BI 201335 in combination with RBV, Part 4
3069082|NCT01132326|Experimental|Droxidopa|Open-Label Droxidopa
3069083|NCT01132378|Active Comparator|Mini-midvastus approach|Mini Midvastus approach with skin incision less than 13 cm long and vastus medialis obliquus dissection not more than 3 cm from the patellar margin was used to perform total knee arthroplasty in 40 patients.
3069084|NCT01132378|Active Comparator|Medial Parapatellar Approach|Mini Medial Parapatellar approach with skin incision less than 13 cm. The extension into quadriceps tendon did not exceed 3 cm.Mini medial parapatellar approach was used to perform total knee arthroplasty.
3069085|NCT01132482|Experimental|Sildenafil|Subjects will receive escalating doses of sildenafil
3069086|NCT01132482|Placebo Comparator|Placebo|During the placebo arm, subjects receiving placebo will have sham dose escalation to maintain blinding.
3069087|NCT01132495|Other|Cohort A: PCI plus OMT|PCI plus optimal medical treatment
3069088|NCT01132495|Other|Cohort A: OMT alone|Optimal medical treatment alone
3069089|NCT01132495|Other|Cohort B|FFR > 0.80; treatment according to local practice
3069090|NCT01132508||Treatment|
3069091|NCT01132547|Experimental|Arm I cyproheptadine hydrochloride|Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
3069092|NCT01132547|Placebo Comparator|Arm II placebo|Patients receive an oral placebo twice daily for 8 weeks.
3069093|NCT01132612|Experimental|Fixed-time interval regimen|Secukinumab 150 mg subcutaneous (sc) administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter
3069094|NCT01132612|Experimental|Treatment at start of relapse regimen|Placebo administered at Week 1 (baseline) of the extension study and every 12 weeks thereafter. If relapse, then switch to secukinumab 150 mg sc administered every 4 weeks
3069095|NCT01132612|Experimental|Open-label|Secukinumab 150 mg sc administered every 4 weeks
3069096|NCT01132651|Experimental|Chillow cooling pillow|This group of subjects will follow their current eczema regimen with the addition of using the cooling pillow at night to sleep on.
3069097|NCT01132651|Placebo Comparator|Standard of care (regular pillow at night)|This group of subjects will serve as the control group following a their current eczema care regimen, including sleeping on their normal pillow.
3069098|NCT01132664|Experimental|HER2+ metastatic breast cancer|Patients with HER2-overexpressing metastatic breast cancer, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
3069099|NCT01132664|Experimental|HER2+ metastatic breast cancer with BM|Patients with HER2-overexpressing metastatic breast cancer and brain metastases, with or without PIK3 signaling pathway alteration, who have previously failed trastuzumab
3069100|NCT01132690|Experimental|30 units/kg|
3069101|NCT01132690|Experimental|60 units/kg|
3069102|NCT01132755|Experimental|Patients who require diagnostic laparoscopy|Diagnostic peritoneal lavage will be performed at the time of laparoscopy utilizing a Veress needle/Seldinger technique to insert a peritoneal dialysis catheter. This is not a new technique. The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon.
3069103|NCT01132807|Experimental|Treatment (chemotherapy and F-18 PET/CT)|See Detailed Description
3069104|NCT01132820|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3069105|NCT01132846|Active Comparator|Low dose Dopamine|"Drug: Dopamine~Participants will be randomized to receive low dose dopamine or placebo during first 72 hours of participation in the study"
3069106|NCT01132846|Placebo Comparator|Placebo|Drug: Placebo Participants will receive placebo in place of low dose dopamine or low dose nesiritide depending on randomization.
3069107|NCT01132846|Active Comparator|Low Dose Nesiritide|Participants could be randomized to receive low dose nesiritide or placebo during the first 72 hours in the trial.
3069108|NCT01133158|Experimental|R-BMD|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone Induction: 6 Rituximab, Bendamustine, Mitoxantrone, Dexamethasone cycles Maintenance: Rituximab every 3 months for 2 years
3069109|NCT01133171|Experimental|Dashboard Plus Nurse|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling plus a computerized dashboard intervention.
3069110|NCT01133171|Experimental|Nurse Alone|Patients randomized to this intervention arm were seen twice over six months by a research nurse to collect data on risk factors and received counseling.
3069111|NCT01133171|No Intervention|Control|Patients randomized to this group were followed retrospectively to collect data on their primary care visits and laboratory results and past medical history over the 12 month study period. They had no contact with study personnel and did not receive any type of intervention.
3069112|NCT01133275|Experimental|Lenalidomide and Prednisone Therapy|All participants received lenalidomide and prednisone therapy for 6 cycles (24 weeks). Each cycle is 28 days (4 weeks).
3069113|NCT01133379|Experimental|PO-019|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride (12027-019)
3069114|NCT01133379|Experimental|PO-020|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride (12027-020)
3069115|NCT01133379|Sham Comparator|PO-021|Vehicle Control Mouthrinse (without potassium oxalate and without fluoride) (12027-021)
3069116|NCT01133392|Experimental|Insulin Lispro A|20 units (U) subcutaneously (SC)
3069117|NCT01133392|Active Comparator|Insulin lispro B|20 units (U) subcutaneously (SC)
3069118|NCT01133405|Experimental|LY2886721 Part 1: Cohort A/B|Single (7 milligram (mg), 15 mg, 25 mg, 35 mg) doses of LY2886721 administered orally in up to three of three study periods
3069119|NCT01133405|Placebo Comparator|Placebo Part 1: Cohort A/B|Single dose in up to 1 period
3069120|NCT01133405|Experimental|LY2886721 Part 2: Cohort C|Single 10 mg dose of LY2886721, dose determined by Part 1
3069121|NCT01133405|Experimental|LY2886721 Part 2: Cohort D|Single 35 mg dose of LY2886721, dose determined by Part 1
3069122|NCT01133405|Placebo Comparator|Placebo Part 2: Cohort C/D|Single dose
3069123|NCT01133418|Experimental|Cognitive Training|Computerized Progressive Attention Training
3069124|NCT01133418|Sham Comparator|Non-progressive cognitive training|Children in the control condition will participate in the same tasks as children in the Intervention arm. They will experience the same number of blocks and trials of training as the intervention group. Further, their training will be conducted by the same set of trainers and for the same amount of time as the intervention group. However, children in the control group will remain at the lowest level for each CT task throughout training irrespective of performance.
3069125|NCT01133522|Experimental|Evolocumab|Participants received one of 5 dose levels of evolocumab administered as multiple subcutaneous doses.
3069126|NCT01133522|Placebo Comparator|Placebo|Participants received matching placebo dose regimens by subcutaneous injection.
3069127|NCT01133626|Placebo Comparator|Placebo|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
3069128|NCT01133626|Experimental|BDP HFA 320 µg/day|Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
3069129|NCT01133626|Active Comparator|Prednisone|Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.
3069130|NCT01133665|Experimental|Sub Group 1|All Subjects Enrolled in the Trial
3069131|NCT01133678|Experimental|Everolimus|Everolimus 5 mg PO Daily for 2 21-day cycles
3069132|NCT01133678|Experimental|Placebo|Placebo 5 mg PO Daily for 2 21-day cycles
3069133|NCT01133704|Active Comparator|sipuleucel-T (APC8015)|
3069134|NCT01133704|Placebo Comparator|Placebo|
3069135|NCT01133756|Experimental|Lenvatinib plus carboplatin + gemcitabine|Phase IB and Phase II
3069136|NCT01133756|Active Comparator|Carboplatin + gemcitabine|Phase II
3069137|NCT01133821|Placebo Comparator|Placebo|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus placebo (sugar pill). This condition will be called IPSRT-PLA.
3069138|NCT01133821|Experimental|IPSRT plus quetiapine|Subjects will receive 20 weeks of an experimental psychotherapy called interpersonal and social rhythm therapy (IPSRT) plus the FDA approved medication quetiapine (Seroquel). This condition will be called IPSRT-QUE.
3069139|NCT01133847|Experimental|Intensive Reading Instruction|Specialized phonologically-based reading instruction provided by well-trained tutors either individually (one-on-one) or to groups of two students for 45 minutes, four days per week, for 16 weeks. The instructional approach includes an individualized combination of published programs targeting word reading and decoding; reading fluency; and reading comprehension.
3069140|NCT01133847|Experimental|ADHD Intervention|Carefully-managed medication and behavioral parent training. Medication treatment begins with a four-week titration period, beginning with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions provided by a psychologist addressing ADHD and its treatment, principals of behavior modification, and evidence-supported practices for managing behavior.
3069141|NCT01133847|Experimental|Combined ADHD and Reading Instruction|"All interventions described in Reading Instruction and ADHD treatment arms:~Phonologically-based reading instruction provided for 45 minutes, four days per week, for 16 weeks. Carefully-managed medication and behavioral parent training. Medication treatment begins with a trial of methylphenidate. If benefit is insufficient or side effects are intolerable, the physician may initiate a trial of mixed salt amphetamine, followed by either Atomoxetine or Guanfacine. When the optimum medication and dosage is determined the child returns for monthly medication maintenance visits until the end of the 16-week intervention period. Parent training consists of nine group sessions on parenting a child with ADHD."
3069142|NCT01133860|Experimental|eltrombopag|
3069143|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 1b)|Participants received 16 mg, 20 mg or 22 mg lenvatinib once daily in combination with dacarbazine
3069144|NCT01133977|Experimental|Lenvatinib + Dacarbazine (Phase 2)|Participants received lenvatinib per the maximum tolerated dose (MTD) as determined in the Phase Ib of the study in combination with dacarbazine
3069145|NCT01133977|Active Comparator|Dacarbazine (Phase 2)|Participants received dacarbazine
3069146|NCT01134016|Experimental|Antroquinonol|"6 dose levels, Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~A maximum of 36 patients were planned based on a criteria of a maximum of 6 patients per cohort: 1 to 6 patients were planned for each dose group in the accelerated phase; 3 to 6 patients for each dose group in the standard phase .~The method of dose escalation in the accelerated titration phase continued to the next higher dose level until a patient experienced MT or a DLT. Standard titration phase start with 3+3 patients. Dose escalation proceeded sequentially between cohorts."
3069147|NCT01134042|Experimental|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
3069148|NCT01134042|Active Comparator|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks
3069149|NCT01134042|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 24 weeks
3069150|NCT01134055|Experimental|investigational arm 1|5 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
3069151|NCT01134055|Experimental|investigational arm 2|5 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
3069152|NCT01134055|Experimental|investigational arm 3|10 mg/mL pazopanib eye drops BID with allowance for as-needed ranibizumab injection
3069153|NCT01134055|Experimental|investigational arm 4|10 mg/mL pazopanib eye drops TID with allowance for as-needed ranibizumab injection
3069154|NCT01134055|Experimental|investigational arm 5|10 mg/mL pazopanib eye drops QID with allowance for as-needed ranibizumab injection
3069155|NCT01134055|Placebo Comparator|placebo control arm|Placebo eye drops QID with allowance for as-needed ranibizumab injection
3069156|NCT01134055|Active Comparator|active open-label control arm|Ranibizumab intravitreal injection every 4 weeks
3069157|NCT01134081|Experimental|CelTx™|Living bilayered cell therapy product
3069158|NCT01134081|Active Comparator|Free Gingival Grafts|Harvested tissue from palate
3069159|NCT01134107|Experimental|Insulin Lispro 6 Day (6D)|
3069160|NCT01134107|Active Comparator|Insulin Aspart 6 Day (6D)|
3069161|NCT01134198|Active Comparator|Mifepristone|Mifepristone 600mg
3069162|NCT01134198|Placebo Comparator|placebo|Placebo
3069163|NCT01134263|Experimental|CYD Dengue Vaccine Phase III Lot 1|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
3069164|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 2|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
3069165|NCT01134263|Experimental|CYD Dengue vaccine - Phase III Lot 3|Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
3069166|NCT01134263|Experimental|CYD Dengue vaccine - Phase II Lot|Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
3069167|NCT01134263|Placebo Comparator|Placebo|Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
3069168|NCT01134276|Active Comparator|PTBD|biliary drainage : PTBD procedure for obstructive jaundice in patients with periampullary cancer
3069169|NCT01134276|Active Comparator|ERBD|biliary drainage : ERBD/ENBD procedure for obstructive jaundice in patients with periampullary cancer
3069170|NCT01134315||Paricalcitol|Pediatric participants who received paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). Paricalcitol was prescribed by each physician under the usual and customary practice of that physician.
3069171|NCT01134315||Calcitriol|Pediatric participants who received calcitriol to treat secondary hyperparathyroidism (SHPT). Calcitriol was prescribed by each physician under the usual and customary practice of that physician.
3069172|NCT01134328|Experimental|AC-150 Combo|
3069173|NCT01134328|Active Comparator|AC-150A 0.1%|
3069174|NCT01134328|Active Comparator|AC-150B 0.005%|
3069175|NCT01134328|Other|Vehicle|
3069176|NCT01134393|Experimental|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of blood pressure goal
3069177|NCT01134510|Experimental|C1 esterase inhibitor|10 subjects will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
3069178|NCT01134510|Placebo Comparator|Placebo|10 subjects placebo [normal saline] in addition to standard of care immunosuppressive therapy.
3069179|NCT01134549|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous injection.
3069180|NCT01134549|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide intravenous injection; the starting dose was 0.5 mg.
3069181|NCT01134562|Placebo Comparator|Placebo|Participants received a single dose of placebo intravenous (IV) injection after hemodialysis.
3069182|NCT01134562|Experimental|Etelcalcetide|Participants received a single dose of etelcalcetide by intravenous (IV) injection after hemodialysis.
3069183|NCT01134575|Experimental|Period 1: CMC-544 (Inotuzumab Ozogamycin) 1.3mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
3069184|NCT01134575|Experimental|Period 3: Weekly CMC-544 (Inotuzumab Ozogamycin)|CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
3069185|NCT01134575|Experimental|Period 2: CMC-544 (Inotuzumab Ozogamycin) 1.8mg/m^2|First patients > 16 years and < 16 years receive CMC-544 (Inotuzumab Ozogamycin) at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle. With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
3069186|NCT01134614|Experimental|Arm A (ipilimumab and sargramostim)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy comprising ipilimumab IV over 90 minutes on day 1 and sargramostim SC once daily on days 1-14. Treatment with ipilimumab repeats every 12 weeks and treatment with sargramostim repeats every 21 days. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and patients with responsive or stable disease then continue maintenance therapy until disease progression or unacceptable toxicity.
3069187|NCT01134614|Active Comparator|Arm B (ipilimumab)|Patients receive induction therapy comprising ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles. After 12 weeks of induction treatment, anti-tumor response is assessed and patients then receive maintenance therapy of ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 12 weeks. After 12 weeks of maintenance therapy, anti-tumor response is reassessed and cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity
3069188|NCT01134627|Experimental|Minocycline group|
3069189|NCT01134627|Placebo Comparator|Placebo Group|
3069190|NCT01134705|Experimental|BDP HFA 320 µg/day|During the 6-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily.
3069191|NCT01134705|Placebo Comparator|Placebo|During the 6-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily.
3069192|NCT01134731|Experimental|paliperidone|dose escalation , levels 1-5 daily dosing ranged from 1-5mg
3069193|NCT01134731|Active Comparator|lithium|dose escalation, level 1-5 daily dosing 300-1500mg
3069194|NCT01134731|Placebo Comparator|placebo|1-5 placebo capsules
3069195|NCT01134783|Experimental|Intervention Group|The CHOICES intervention included a 1-credit, academic college course focusing on healthy weight behaviors and participation in a social networking and social support website
3069196|NCT01134783|No Intervention|Control Group|Control group (serving as a comparison group)
3069197|NCT01134887|Experimental|Arm 1: Intervention-Veterans|"Veterans enrolled in the Intervention-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. Just prior to their next scheduled visit an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Educational Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management."
3069198|NCT01134887|Active Comparator|Arm 2: Control-Veterans|"Veterans enrolled in the Control-Veterans arm received a copy of the NIA guide for Talking with Your Doctor [Informational Guide for Patients]. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
3069199|NCT01134887|Experimental|Arm 3: Intervention-Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians [Monograph for Physicians]. The Four Habits provided practical evidence-based advice for improving patient-physician communication. Second, physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients [Video-Assisted Coaching], but before seeing them for follow-ups. The main goal of this meeting was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management."
3069200|NCT01134887|Active Comparator|Arm 4: Control-Physicians|"Primary care providers randomly assigned to the Control-Physicians arm of the study did not receive coaching or additional resources, and conducted their primary care practice as usual [Control]."
3069201|NCT01134900|Experimental|Dashboard|Patients appear on dashboard and are eligible for pharmacy intervention in addition to existing clinical decision support interventions.
3069202|NCT01134900|No Intervention|Control|Patients do not appear on dashboard for pharmacy intervention, but only receive existing clinical decision support interventions.
3069203|NCT01134939||HIV-infected women and men|
3069204|NCT01134952|Experimental|Mycophenolate to sirolimus switch|Liver transplant recipients with Hepatitis C virus switched from mycophenolate mofetil (MMF) to sirolimus (SRL) for 3 months and then switched back to MMF
3069205|NCT01135017|Experimental|Dronedarone|Dronedarone 400 mg twice a day for 12 weeks
3069206|NCT01135017|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day for 12 weeks
3069207|NCT01135069|Active Comparator|Generic|treatment of acne for 12 weeks
3069208|NCT01135069|Active Comparator|Brand|Treatment of acne for 12 weeks
3069209|NCT01135069|Placebo Comparator|Placebo|Treatment if acne for 12 weeks as placebo
3069210|NCT01135095|Experimental|low-dose imaging|low dose versus standard dose imaging
3069211|NCT01135134|Experimental|Mometasone furoate nasal spray (MFNS) (50 μg spray device)|"The dose will be as follows:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
3069212|NCT01135134|Placebo Comparator|MF placebo nasal spray|"Administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
3069213|NCT01135186|Other|Sapropterin|open label study of sapropterin dihydrochloride
3069214|NCT01135329|Experimental|Transplant|Reduced-intensity transplant with a fludarabine- and busulfan-based preparative regimen. GVHD prophylaxis with cyclophosphamide, tacrolimus, and mycophenolate mofetil.
3069215|NCT01135368|Experimental|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months."
3069216|NCT01135381|Experimental|CHF patients, IVR-Enhanced Care|Patients with congestive heart failure (CHF) who receive the interactive voice response (IVR) intervention.
3069217|NCT01135381|Experimental|COPD patients, IVR-Enhanced Care|Patients with chronic obstructive pulmonary disease (COPD) who receive the interactive voice response (IVR) intervention.
3069218|NCT01135381|No Intervention|CHF patients, Usual Discharge Care|Patients with congestive heart failure (CHF) who receive usual discharge care (no intervention).
3069219|NCT01135381|No Intervention|COPD patients, Usual Discharge Care|Patients with chronic obstructive pulmonary disease (COPD) who receive usual discharge care (no intervention).
3069220|NCT01135394|Experimental|Pioglitazone (Actos)|Participants will have metabolism studies to consist of outpatient X-ray and MR measurements of bone density and body composition, metabolic testing (intravenous glucose tolerance test), and muscle and adipose tissue biopsies. Blood will also be drawn for genetic testing and for microarray studies of leukocytes. Upon completion of the above studies, the participant will begin pioglitazone therapy. Every 4 weeks throughout the drug intervention, glycemic control, lipoprotein profile, and weight will be monitored. After 12 weeks of pioglitazone therapy, the X-ray and MR measurements of body composition, the biopsies, microarray studies for leukocytes and the metabolic tests will be repeated.
3069221|NCT01135420|Active Comparator|Usual Care|Psychiatry inpatient usual care
3069222|NCT01135420|Experimental|Telephone Monitoring|Patients in the TM condition will receive an in-person session while in treatment, followed by monitoring over the telephone for three months after discharge. The intervention will incorporate motivational interviewing to monitor patients' substance use, facilitate entry into outpatient treatment, and encourage 12-step self-help group participation.
3069223|NCT01135498|Experimental|1|
3069224|NCT01135511|Experimental|Treatment 1|
3069225|NCT01135511|Experimental|Treatment 2|
3069226|NCT01135511|Experimental|Treatment 3|
3069227|NCT01135511|Placebo Comparator|Treatment 4|
3069228|NCT01135511|Active Comparator|Treatment 5|
3069229|NCT01135524|Experimental|BTDS|Buprenorphine transdermal patch
3069230|NCT01135537|Experimental|Thymoglobulin|Thymoglobulin 7.5 mg/kg/course prior to HSCT
3069231|NCT01135914|Experimental|Combination Therapy|Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
3069232|NCT01135914|Experimental|Ranibizumab Monotherapy|Participants received ranibizumab intravitreal injection therapy only
3069233|NCT01135914|Active Comparator|Laser Monotherapy|Participants received Laser photocoagulation therapy only
3069234|NCT01135992|Experimental|IGlar/IDeg|
3069235|NCT01135992|Experimental|IDeg 3TW|
3069236|NCT01136174|Experimental|BIBF 1120 50 mg|Low dose for cohort 1
3069237|NCT01136174|Experimental|BIBF 1120 100 mg|Middle dose for cohort 2
3069238|NCT01136174|Experimental|BIBF 1120 150 mg|High dose for cohort 3
3069239|NCT01136174|Placebo Comparator|Placebo|Placebo for cohort 1,2,3
3069240|NCT01136226|Other|Eligard (TM)|Eligard (TM) administered 22.5mg
3069241|NCT01136291|Other|physical exercise|exercise on obese and overweight pregnant women, routine prenatal care and nutritional counseling
3069242|NCT01136291|No Intervention|no exercise|Routine prenatal care and nutritional counseling. No exercise
3069243|NCT01136356|Experimental|Morphine, then Buprenorphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day). Participants then underwent an 18-day period of spontaneous opioid withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
3069244|NCT01136356|Experimental|Buprenorphine, then Morphine|Healthy, out of treatment opioid-dependent residential volunteers (N=7) were randomized to receive buprenorphine (32 mg/day i.m.) administered in four divided doses each day for 9 days (8 mg of buprenorphine four times per day). Participants then underwent an 18-day period of spontaneous withdrawal, during which four double blind i.m. placebo injections were administered daily. After the period of spontaneous withdrawal, participants received morphine (120 mg/day i.m.) administered in four divided doses each day for 9 days (30 mg of morphine four times per day) followed by a second 18-day period of spontaneous withdrawal identical to the withdrawal period described above.
3069245|NCT01136382|Experimental|1|Budesonide pMDI 160 ug bid (80 ug x 2 inhalations bid)
3069246|NCT01136382|Placebo Comparator|2|Placebo pMDI 2 inhalations bid
3069247|NCT01136408|Experimental|Dabigatran etexilate 220 mg daily|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
3069248|NCT01136408|Experimental|Dabigatran etexilate 300 mg daily|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
3069249|NCT01136408|Active Comparator|Warfarin|Dose-adjusted warfarin based on target INR values
3069250|NCT01136655|Experimental|BUD 160/FM 2.25|2.25 μg formoterol (as 80/2.25 μg Symbicort pMDI × 1 inhalation) + 40 μg budesonide HFA pMDI × 2 inhalations
3069251|NCT01136655|Experimental|BUD 160/FM 4.5|placebo HFA pMDI × 1 inhalation + 4.5 μg formoterol (as 80/2.25 μg Symbicort pMDI × 2 inhalations)
3069252|NCT01136655|Experimental|BUD 160/FM 9.0|placebo HFA pMDI × 1 inhalation + 9 μg formoterol (as 80/4.5 μg Symbicort pMDI × 2 inhalations)
3069253|NCT01136655|Placebo Comparator|BUD 160|placebo HFA pMDI × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
3069254|NCT01136655|Active Comparator|BUD 160/Foradil 12.0|Foradil Aerolizer 12 μg × 1 inhalation + 80 μg budesonide HFA pMDI × 2 inhalations
3069255|NCT01136733|Experimental|Lenvatinib|
3069256|NCT01136733|Experimental|Lenvatinib plus Everolimus|
3069257|NCT01136733|Active Comparator|Everolimus|
3069258|NCT01136746|Active Comparator|Sliding scale regular insulin|
3069259|NCT01136746|Experimental|Basal-bolus therapy|
3069260|NCT01136772|Experimental|Paliperidone palmitate|Intramuscular injections of paliperidone palmitate 39-234 mg every month
3069261|NCT01136772|Active Comparator|Haloperidol decanoate|Intramuscular injections of haloperidol decanoate 25-200 mg every month
3069262|NCT01136785|Active Comparator|Active CPAP therapy|7 days of treatment in the laboratory with active CPAP therapy.
3069263|NCT01136785|Sham Comparator|Sham CPAP therapy|7 days of sham CPAP therapy in the laboratory.
3069264|NCT01136798|Placebo Comparator|Usual T2 DM med regimen|Subjects will continue on Type 2 DM therapy but will add placebo injected subcutaneously twice daily to their regimen for a total of 6 weeks.
3069265|NCT01136798|Experimental|Usual T2 DM med regimen plus Exenatide|Subjects will continue on Type 2 DM therapy but will add injectable exenatide to their regimen There will be twice daily treatment with subcutaneous injections of 5 µg of Exenatide for 2 weeks followed by 4 weeks of treatment with twice daily subcutaneous injections of 10 µg of Exenatide.
3069266|NCT01136876|Active Comparator|Iopamidol|Non-ionic low-osmolar iodinated contrast media
3069267|NCT01136876|Active Comparator|Iodixanol|Non-ionic iso-osmolar iodinated contrast media comparator
3069268|NCT01136915|Active Comparator|IOPAMIDOL injection 370|
3069269|NCT01136915|Active Comparator|Iodixanol 320|
3069270|NCT01136954|Experimental|1|
3320923|NCT02014766|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.375% ropivacaine is injected.
3320924|NCT02014779|Experimental|eChange web-based relapse prevention|A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
3069273|NCT01137006|Experimental|IMC-20D7S (1A-4A Cohorts)|Escalating doses up to 30 milligrams per kilogram (mg/kg) administered intravenously (i.v.) every 2 weeks; includes Cohorts 1A, 2A, 3A, and 4A.
3069274|NCT01137006|Experimental|IMC-20D7S (1B-3B Cohorts)|Escalating doses up to 30 mg/kg administered i.v. every 3 weeks; includes Cohorts 1B, 2B, and 3B.
3069275|NCT01137032|Experimental|Pandel Cream 0.1%|Pandel Cream 0.1%
3069276|NCT01137071|Experimental|Monoclonal antibody hu3S193|Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.
3069277|NCT01137110|Other|Brief LEV|Administration of three days of levetiracetam twice daily after SAH
3069278|NCT01137110|Other|Extended LEV|Administration of levetiracetam twice daily after SAH
3069279|NCT01137292||Active Treatment|Patients who are eligible for voriconazole treatment according to their physician decision.
3069280|NCT01137370||Patients with TB|
3069281|NCT01137370||People without TB|
3069282|NCT01137396|Experimental|Modafinil|
3069283|NCT01137396|Placebo Comparator|Placebo|
3069284|NCT01137435|Experimental|Study Group|
3069285|NCT01137474|Experimental|Dapagliflozin, 10 mg|Oral tablets administered as 10 mg once daily for up to 12 weeks
3069286|NCT01137474|Placebo Comparator|Placebo-matching dapagliflozin|Oral tablets administered once daily in the morning
3069287|NCT01137474|Experimental|Dapagliflozin, 2. 5 mg|Oral tablets administered as 2.5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
3069288|NCT01137474|Experimental|Dapagliflozin, 5 mg|Oral tablets administered as 5 mg once daily for up to 12 weeks (Arm discontinued as of Protocol Amendment 8)
3069289|NCT01137539|Experimental|Gynecare TVT-SECUR system|All patients enrolled into the study will receive the TVT-SECUR system to treat stress urinary incontinence
3069290|NCT01137578|Other|Cohort A: US, MRI with contrast, MRI without contrast|Subjects with a central venous catheter (CVC) in place and asymptomatic for a CVC-related DVT to have an Ultrasound (US), Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3069291|NCT01137578|Other|Cohort B: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place either symptomatic for a CVC-related DVT or having an incidental diagnosis of CVC-related DVT by radiographic imaging performed for other clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3069292|NCT01137578|Other|Cohort C: US, MRI with contrast, MRI without contrast|Subjects with a CVC in place having an MRI for clinical reasons to have an Ultrasound, Magnetic Resonance Imaging (MRI) with contrast and MRI without contrast performed.
3069293|NCT01137604|Experimental|Cohort 1|"Cohort 1 assessed participants with recurrent Grade 4 malignant glioma (ie, glioblastoma [GBM]) who were bevacizumab-naive. Participants were planned to be accrued in Cohort 1 and randomized in a 1:1 ratio to receive lenvatinib (experimental) or bevacizumab (active comparator).~Cohort 1 - Bevacizumab~Cohort 1 - Lenvatinib"
3069294|NCT01137604|Experimental|Cohort 2|Cohort 2 assessed participants with recurrent Grade 3 malignant glioma who were bevacizumab-naive. Participants in Cohort 2 were planned to be treated with lenvatinib.
3069295|NCT01137604|Experimental|Cohort 3|Cohort 3 assessed participants with recurrent GBM who had disease progression following prior bevacizumab treatment. Participants in Cohort 3 were planned to be treated with lenvatinib.
3069296|NCT01137682|Experimental|Pasireotide LAR 40 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
3069297|NCT01137682|Experimental|Pasireotide LAR 60 mg|Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution)
3069298|NCT01137682|Active Comparator|Control arm (octreotide or lanreotide)|"If a patient is randomized to the open label arm the investigator will either:~be instructed to contact a Novartis delegate to initiate shipment of either octreotide LAR 30 mg or lanreotide ATG 120 mg from a Novartis or designee depot to the site, or~continue to dispense either octreotide LAR 30 mg or lanreotide ATG 120 mg available at the institution to the patient if permitted by local regulations."
3069301|NCT01137786|Active Comparator|IOPAMIDOL 370|
3069302|NCT01137786|Active Comparator|IODIXANOL 320|
3069303|NCT01137812|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
3069304|NCT01137812|Active Comparator|Sitagliptin 100 mg|Each patient will receive 100 mg of sitagliptin once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
3069305|NCT01137890|Experimental|Zonisamide|Participants administered blind capsules containing either placebo or zonisamide.
3069306|NCT01137890|Placebo Comparator|Placebo|Participants administered only placebo capsules containing lactose.
3069307|NCT01138007|Experimental|323U66 SR 150 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening throughout the treatment phase.
3069308|NCT01138007|Experimental|323U66 SR 300 mg cohort|323U66 SR 150 mg tablet is orally administered once in the morning and 323U66 SR 150 mg placebo tablet is orally administered once in the evening during the first week of the treatment phase. At the second week, 323U66 SR 300mg cohort is up-titrated to a daily dose of 323U66 SR 300 mg, administered as 323U66 SR 150 mg tablet twice daily in the morning and in the evening, and the same daily dose is maintained to administer until the end of the treatment phase.
3069309|NCT01138007|Placebo Comparator|Placebo cohort|323U66 SR placebo tablet is orally administered twice daily throughout the treatment phase.
3069310|NCT01138046|Experimental|Lap+weekly Pacli|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
3069311|NCT01138098|Experimental|Infanrix-hexa/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-hexa vaccine in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
3069312|NCT01138098|Active Comparator|Infanrix-IPV+Hib/Engerix-B Group|Subjects aged 11-12 year old received 3 doses of Infanrix-IPV+Hib and Engerix-B vaccines in the primary study (217744/031 (NCT01457495)) and a challenge dose of Engerix-B vaccine in this study. Engerix-B was administered as a single dose intramuscularly into the deltoid region of the non-dominant arm.
3069313|NCT01138111|Experimental|Arm 1|
3069314|NCT01138124||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993.
3069315|NCT01138150|Active Comparator|Treximet|"Fourteen participants randomized to receive Treximet (sumatriptan & naproxen) during an acute migraine attack. Blood drawn for immune & inflammatory markers (adipocytokines,cytokines, sex hormones) at different time points - on presentation with moderate to severe migraine pain; then 30 minutes, 1 hour and 2 hours after administration of study drug (Treximet).~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of Treximet if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
3069316|NCT01138150|Placebo Comparator|Sugar Pill|"Fourteen participants randomized to receive placebo during an acute migraine attack. Blood is drawn for immune & inflammatory markers (adipocytokines,cytokines), sex hormones at different time points - on presentation with moderate to severe migraine pain, then 30 minutes, 1 hour and 2 hours after administration of placebo.~Participants will be offered a traditional headache rescue medicine at 2 hours after administration of placebo if participant still reports moderate to severe pain and desires further treatment. Rescue medicine may include the following: prochlorperazine 10 mg IV preceded by diphenhydramine 25 mg IV/PO or metoclopramide 10 mg IV preceded by diphenhydramine 25 mg IV/PO or Toradol 30 mg IV to be determined by the physician."
3069317|NCT01138475|Active Comparator|Paricalcitol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules,cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3069318|NCT01138475|Active Comparator|cholecalciferol|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3069319|NCT01138475|Placebo Comparator|placebo|This is a randomized, double-blind, double-dummy, placebo-controlled trial investigating the effects of paricalcitol capsules, cholecalciferol capsules, and matching placebo on PTH level at 6 weeks in patients with sHPT after RYGB. The pool of patients in the Beaumont Bariatric Surgery program will be sufficient to enroll approximately 75 subjects (25 per treatment group).
3069320|NCT01138501|Experimental|rFVIII|
3069321|NCT01138514|Active Comparator|Clindamycin 1%/Benzoyl Peroxide 5%|
3069322|NCT01138514|Active Comparator|Reference Product|
3069323|NCT01138514|Placebo Comparator|Vehicle|
3069324|NCT01138657|Experimental|Adalimumab|Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
3069325|NCT01138657|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
3069326|NCT01138735|Active Comparator|adapalene/benzoyl peroxide|Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks
3069327|NCT01138735|Placebo Comparator|Topical Gel Vehicle|Topical Gel Vehicle applied topically once daily for 12 weeks
3069328|NCT01138826|Active Comparator|treatment A - reference w/ water|
3069329|NCT01138826|Experimental|Treatment B - ODT (test) w/ water|
3069330|NCT01138826|Experimental|Treatment C - ODT (test) w/o water|
3069331|NCT01138917|Experimental|all participants|All participants will receive both ReCell and split-thickness skin graft
3069332|NCT01138969|Active Comparator|Esomeprazole plus clopidogrel group|esomeprazole (20 mg qd) plus clopidogrel (75 mg qd) for 6 months
3069333|NCT01138969|No Intervention|Clopidogrel group|clopidogrel 75 mg qd for 6 months
3069334|NCT01138995|Active Comparator|Ankle-foot orthosis (AFO) Control Group|"The Control Group will walk with the a usual ankle-foot orthosis (AFO) for 30 weeks."
3069335|NCT01138995|Experimental|Ness L300 Treatment Group|The Original Treatment Group will walk with the Ness L300 for 30 weeks.
3069336|NCT01139008|Active Comparator|metronidazole 1% gel|
3069337|NCT01139008|Active Comparator|azelaic acid 15% gel|
3069338|NCT01139021|Experimental|B246_12_M12|Subjects assessed one year post administration of rMenB+OMV NZ and MMRV at 12th month after primary vaccination at 2nd ,4th and 6th months of age.
3069339|NCT01139021|Experimental|B246_12M13|Subjects assessed one year post administration of rMenB+OMV NZ at 12th month and MMRV at 13th month after primary vaccination at 2nd ,4th and 6th months of age.
3069340|NCT01139021|Experimental|B13_15_27|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at 13th and 15th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 27 months of age.
3069341|NCT01139021|Experimental|B12_14_26|Subjects assessed at 12 months after two catch-up doses of rMenB+OMV NZ administered to children at either 12th and 14th months of age and MMRV at 12th month; at 1 month and 6 months post booster dose administered at 26 months of age.
3069342|NCT01139021|Experimental|B_24_26|Subjects assessed at 1 month and 6 months post two catch-up doses of rMenB+OMV NZ administered to naive children at 24 and 26 months of age.
3069343|NCT01139021|Experimental|B12M13|Subject was randomized in group B13_15_27 but treated as group B12_M13.
3069344|NCT01139047|Active Comparator|metronidazole 1% gel|
3069345|NCT01139047|Active Comparator|azelaic acid 15% gel|
3069346|NCT01139164|Experimental|Single Arm, non-randomized study|
3069347|NCT01139190|Experimental|PL3100|
3069348|NCT01139190|Active Comparator|Naproxen|
3069349|NCT01139411|Experimental|Behavioral Weight Control with Enhanced Parent Involvement|This treatment arm included periodic dyadic sessions with adolescents and their parents, focusing on weight-related communication combined with standard behavioral weight control.
3069350|NCT01139411|Placebo Comparator|Behavioral Weight Control with Minimal Parent Involvement|This treatment arm included standard behavioral weight control delivered to the adolescent with minimal parent involvement.
3069351|NCT01139450|Experimental|Test|Test product that contains the active pharmaceutical ingredient
3069352|NCT01139450|Active Comparator|Reference|Reference product that contains the active pharmaceutical ingredient
3069353|NCT01139450|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3069354|NCT01139515|Experimental|Treatment A|1 X 20 mg eletriptan
3069355|NCT01139515|Experimental|Treatment B|1 X 40 mg eletriptan
3069356|NCT01139515|Experimental|Treatment C|2 X 40 mg eletriptan
3069357|NCT01139515|Experimental|Treatment D|1 X 40 mg tablet given 2 hr after initial 1 X 40 mg tablet dose
3069358|NCT01139580|Experimental|Calcipotriene Foam|Calcipotriene Foam 0.005%,
3069359|NCT01139580|Placebo Comparator|Vehicle Foam|Vehicle Foam
3069360|NCT01139658||All comers|
3069361|NCT01139762|Experimental|Tadalafil|
3069362|NCT01139762|Placebo Comparator|Placebo|
3069363|NCT01139775|Experimental|Phase 1: LY2603618 130 to 275 mg|"Cycle 1-2 (21-day cycle):~Day 1: pemetrexed 500 milligrams per meter square (mg/m^2) + cisplatin 75 mg/m^2~Day 2: LY2603618 at 130-275 milligrams (mg)~After 2 cycles, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3069364|NCT01139775|Experimental|Phase 2: Pemetrexed + Cisplatin + LY2603618|"Cycles 1-4 (21-day cycle):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~Day 2: LY2603618 dose from phase 1 portion of trial~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Experimental Arm (every 21 days):~Before 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~Day 2: LY2603618 dose determined from phase 1~After 25 Oct 2012:~Day 1: pemetrexed 500 mg/m^2~If, as of 25 Oct 2012, participant was in maintenance therapy and randomized to the experimental arm, the participant is eligible to continue with pemetrexed (Day 1)/LY2603618 (Day 2) therapy if the investigator deems it is in the best interest of the participant and the participant consents."
3069365|NCT01139775|Active Comparator|Phase 2: Pemetrexed + Cisplatin|"Cycle 1-4 (21-day cycle):~Day 1: pemetrexed 500 mg/m^2 + cisplatin 75 mg/m^2~After 4 cycles, participants may continue on maintenance therapy until disease progression, unacceptable toxicity, or other withdrawal criterion is met.~Maintenance Therapy Comparator Arm: Phase 2 (every 21 days):~Day 1: pemetrexed 500 mg/m^2"
3069366|NCT01139801|Active Comparator|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
3069367|NCT01139801|Experimental|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
3069368|NCT01139814|Experimental|Catheter Robot|device
3069369|NCT01139879|Experimental|P400 support surface|All patients will receive the P400 mattress
3069370|NCT01140048||All Enrolled Participants|All participants who completed Protocol 272 and were enrolled in Protocol 374
3069371|NCT01140061|Experimental|Panel A - MK-0873 5.1 mg|In Part I, healthy participants received skin patches containing nothing (plain patch), placebo, and various potencies of MK-0873 cream (0.05%, 0.5%, or 2%; yielding a dose of 5.1 mg of MK- 0873) once daily for 21 days.
3069372|NCT01140061|Placebo Comparator|Panel A - Placebo|In Part I, healthy participants received skin patches containing nothing (plain patch) or placebo once daily for 10 days.
3069373|NCT01140061|Experimental|Panel B - MK-0873 25 mg|In Part II, healthy participants received skin application of 0.5% MK-0873 cream (yielding a dose of 25 mg of MK- 0873) twice daily for 10 days.
3069374|NCT01140061|Placebo Comparator|Panel B - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
3069375|NCT01140061|Experimental|Panel C - MK-0873 100 mg|In Part II, healthy participants received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) once daily for 10 days.
3069376|NCT01140061|Placebo Comparator|Panel C - Placebo|In Part II, healthy participants received skin application of placebo cream once daily for 10 days.
3069377|NCT01140061|Experimental|Panel D - MK-0873 200 mg|In Part II, healthy participants received skin application of 2% MK-0873 (yielding a dose of 100 mg of MK-0873) twice daily for 10 days.
3069378|NCT01140061|Placebo Comparator|Panel D - Placebo|In Part II, healthy participants received skin application of placebo cream twice daily for 10 days.
3069379|NCT01140061|Experimental|Panel E and Extension - MK-0873 200 mg|In Part III, participants with mild psoriasis received skin application of 2% MK-0873 cream (yielding a dose of 100 mg of MK-0873) twice daily for up to 28 days.
3069380|NCT01140061|Placebo Comparator|Panel E and Extension - Placebo|In Part III, participants with mild psoriasis received skin application of placebo cream twice daily for up to 28 days.
3069381|NCT01140191|Experimental|WR 279,396|All subjects in this one-arm study will receive topical WR 279,396
3069382|NCT01140295|Active Comparator|1, Miralax|Miralax colonoscopy preparation
3069383|NCT01140295|Active Comparator|2, senna|Senna colonoscopy preparation
3069384|NCT01140347|Experimental|Ramucirumab DP and BSC|
3069385|NCT01140347|Placebo Comparator|Placebo and BSC|
3069386|NCT01140360|Experimental|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
3320925|NCT02014779|Active Comparator|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy
3320926|NCT02014792||Chronic kidney disease, stage 5|Patients with stage 5 chronic kidney disease who have recently commenced haemodialysis treatment (within 6-10 weeks of starting treatment)
3069389|NCT01140477|Experimental|Crystalens toric IOL|Toric Accommodating Lens Crystalens toric silicone multi-piece accommodating IOL (Models AT-50T/AT-52T)
3069390|NCT01140477|Active Comparator|Crystalens IOL|Accommodating Lens Crystalens silicone multi-piece accommodating IOL (Models AT-50SE/AT-52SE)
3069391|NCT01140503|Experimental|apremilast|apremilast 20mg bid
3069392|NCT01140568|Experimental|nilotinib|Patients will take nilotinib twice daily at the standard dose of 400mg taken by mouth twice a day until disease progression or development of unacceptable side effects.
3069393|NCT01140646|Experimental|Arm I|The first week of the study is a baseline week where data are being collected but study agent is not being taken. Patients then receive oral s-adenosyl-L-methionine, 400 mg, once daily on days 8-14 and twice daily on days 15-49 in the absence of unacceptable toxicity.
3069394|NCT01140815|Active Comparator|Total|The Smith and Nephew Total Knee System
3069395|NCT01140815|Experimental|Deuce|The Journey Deuce Bicompartmental Knee System
3069397|NCT01140880|Experimental|Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Increasingly valuable incentives will be provided for urine samples that lack metabolites of stimulant drugs.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
3069398|NCT01140880|Sham Comparator|Yoked Contingency Management|"Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for stimulant metabolites. Incentives will be provided to participants independent of stimulant drug use and determined in the same rate and timing as a randomly selected participant in the active CM condition.~Participants reporting recent (i.e., < 48 hours) exposure to HIV viral inoculum will have the opportunity to initiate Truvada (1 pill daily for 28 days)."
3069399|NCT01140906|Placebo Comparator|Placebo|
3069400|NCT01140906|Experimental|Vortioxetine: 15 mg|
3069401|NCT01140906|Experimental|Vortioxetine: 20 mg|
3069402|NCT01140906|Other|Duloxetine: 60 mg|Active Reference
3069403|NCT01141049|Active Comparator|Gabapentin|Gabapentin will be titrated over a 7-day period to the dose target or the maximum tolerated dose. The maximum dose will be 1200mg TID. Participants must be able to tolerate and comply with at least 400 mg daily.
3069404|NCT01141049|Placebo Comparator|Placebo|Placebo capsules will be administered TID.
3069405|NCT01141075|Experimental|Ataluren|"Cycle 1: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 5 mg/kg (morning), 5 mg/kg (midday), and 10 mg/kg (evening); there will then be an interval of 21 up to 42 days without treatment.~Cycle 2: Ataluren treatment will be taken 3 times per day with meals for 28 days at doses of 10 mg/kg (morning), 10 mg/kg (midday), and 20 mg/kg (evening); there will then be an interval of 14 days without treatment."
3069406|NCT01141205|Experimental|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
3069407|NCT01141205|Placebo Comparator|Saline|Saline
3069408|NCT01141283|Experimental|BTDS|Buprenorphine transdermal patch
3069409|NCT01141374|No Intervention|control group without treatment|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3069410|NCT01141374|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
3069411|NCT01141374|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
3069412|NCT01141478|Active Comparator|Proton Beam Radiotherapy plus Sorafenib|A combination of radiation therapy (proton) to kill tumor cells as well as Sorafenib which is a study drug administered to patients to stop tumor growth.
3069413|NCT01141478|Active Comparator|Sorafenib|Sorafenib is an oral pill taken daily to inhibit tumor growth at the cellular level.
3069414|NCT01141491|Experimental|Arm A|Vaccine plus OPT-821
3069415|NCT01141491|Active Comparator|Arm B - OPT-821 immunologic adjuvant|Patients will be given 10 injections of OPT-821 alone as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
3069416|NCT01141569|Experimental|Treatment (RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3069417|NCT01141595|Experimental|Kuvan®|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
3069418|NCT01141608|Experimental|Vigorous Intensity High Dose Exercise|Usual Care Augmented with Vigorous Intensity High Dose Exercise
3069419|NCT01141608|Experimental|Health Education Intervention|Health Education Intervention
3069420|NCT01141647|Experimental|24-Month Supported Employment|Evidence-Based Supported Employment Vocational Rehabilitation or Other Vocational Services
3069421|NCT01141660|Experimental|Endotracheal Tube|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
3069422|NCT01141660|Experimental|Laryngeal Mask Airway|Children undergoing adenotonsillectomy are randomized to endotracheal tube or laryngeal mask airway.
3069423|NCT01141712|Other|Autologous transplant|Patients will receive BCNU 300 mg/m^2 Day -6, Etoposide 100 mg/m^2 BID Days -5 to -2, Cytarabine 100 mg/m^2 BID Days -5 to -2, and Melphalan 140 mg/m^2 Day -1 followed by autologous HCT.
3320927|NCT02014805|Experimental|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
3320928|NCT02014805|No Intervention|observation|no treatment after radical resection for thymoma
3320929|NCT02014818|Experimental|3 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 3 months after the index procedure.
3069424|NCT01141725|Experimental|Treatment (combination chemotherapy)|Patients receive bendamustine hydrochloride IV on days 1-5 and idarubicin IV on days 1 and 2. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3069425|NCT01141907|Experimental|Heart Failure Self Care Support|The goal of the Heart Failure Self Care Support Intervention (Navigator Program), delivered by a nurse and community health navigator team over 3 months post discharge from the index hospitalization, was to improve care transitions by providing patients with tools and support that promote knowledge and skills for HF self care as they transition from hospital to home. The multifaceted Navigator Intervention included the following intervention components: HF home automated telemonitoring support, medication and symptom self management, patient-centered record, HF care follow up, and activation of key supporter.
3069426|NCT01141907|Active Comparator|Usual Heart Failure Care|Usual care for HF patients included the following: 1) Referral to HF clinic if the patient has no usual source of HF outpatient care, 2) HF patient education by HF care coordinator (advanced practice nurse), and 3) HF self care guide. All participants were treated by their usual source of HF care in the usual manner.
3069427|NCT01142089|Placebo Comparator|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours)
3069428|NCT01142089|Experimental|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
3069429|NCT01142115|Experimental|Monza|nonCE marked intermittent catheter
3069430|NCT01142115|Active Comparator|control|SpeediCath coated catheter
3069431|NCT01142193|Experimental|USL255|
3069432|NCT01142193|Placebo Comparator|Placebo|
3069433|NCT01142232|Experimental|Melphalan with lenalidomide|Melphalan will be given on Day -2 and Day -1. Lenalidomide will be given from Day -7 to Day +2.
3069434|NCT01142297|Other|dental implant|standard SLA surface and chemically modified surface
3069435|NCT01142310|Active Comparator|Lamotrigine|Dose titration: begin at Baseline at 25mg PO QD for two weeks. Increase to 50mg PO QD at Week 2 for two weeks. Increase to 100mg PO QD at Week 4. Increase to 150mg PO QD at Week 5. Increase to 200mg PO QD at Week 6. Increase to 250mg PO QD at Week 7. Increase to 300mg PO QD at Week 8. Increase to 350mg PO QD at Week 9. Increase to 400mg PO QD at Week 10. Stay at 400mg PO QD from Week 10 to Week 48.
3069436|NCT01142310|Placebo Comparator|Placebo|Placebo administered the same as the Lamotrigine just described.
3069437|NCT01142323|Experimental|Fenofibrate|fenofibrate 160 mg po daily
3069438|NCT01142336|Experimental|Simvastatin|Simvastatin 40mg qHS for 1 year
3069439|NCT01142336|Placebo Comparator|Placebo|Placebo 1 tablet qHS for 1 year
3069440|NCT01142388|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3069441|NCT01142388|Experimental|Arm II (cixutumumab, paclitaxel)|Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
3069442|NCT01142466|Experimental|Rebif (3x44 mcg) Group|
3069443|NCT01142466|No Intervention|No treatment Group|
3069444|NCT01142596|Experimental|Asenapine 5 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg BID at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
3069445|NCT01142596|Experimental|Asenapine 10 mg BID|Participants continue in the same arm they were on in core trial P06124 (except placebo arm starts 5 mg bid at Week 2) and will be re-randomized after Week 6 to asenapine 5 mg BID or asenapine 10 mg BID, administered open-label for 46 weeks. Open label dose can be adjusted using dose options of 5 and 10 mg BID for efficacy and tolerability
3069446|NCT01142661|Experimental|Eribulin mesylate|
3069447|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate, 2.5 mg|Participants received abatacept, 125 mg subcutaneously, plus methotrexate, 2.5 mg orally as tablets, once weekly, during the 12-month Treatment Period
3069448|NCT01142726|Active Comparator|Methotrexate, 2.5 mg, plus abatacept placebo|Participants received methotrexate, 2.5 mg, orally as tablets, plus abatacept placebo subcutaneously, once weekly during the 12-month Treatment Period
3069449|NCT01142726|Active Comparator|Abatacept, 125 mg, plus methotrexate placebo|Participants received abatacept, 125 mg subcutaneously, plus methotrexate placebo tablets orally, once weekly during the 12-month Treatment Period
3069450|NCT01142791|Other|ExAblate treatment|
3069451|NCT01142908|Experimental|Arm 1|The pharmacist CVD intervention group - clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
3069452|NCT01142908|No Intervention|Arm 2|The education control group - these participants will receive educational material about CVD reduction.
3069453|NCT01142947|Other|beclomethasone dipropionate (BD)|Patients who meet eligibility criteria will be treated with 6 weeks of beclomethasone dipropionate to assess change in pulmonary function and asthma control. These change will be used as phenotypes in a genetic association study. There is no placebo group.
3069454|NCT01143038|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection during the 12-month treatment period. The starting dose was 1 μg/kg with weekly dose increases continued in increments of 1 μg/kg/week to a maximum dose of 10 μg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
3069455|NCT01143051|Active Comparator|Treatment C|Active comparator arm utilizing marketed Primatene Mist with CFC propellant at the labeled dose.
3069456|NCT01143051|Experimental|Treatment 1|T1 is HFA propelled epinephrine inhalation aerosol 125 mcg/inhalation
3069457|NCT01143051|Experimental|Treatment 2|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation
3069458|NCT01143077|Experimental|Lurasidone Open-Label Arm A|
3069459|NCT01143077|Experimental|Lurasidone Open-Label Arm B|
3069460|NCT01143077|Experimental|Lurasidone Open-Label Arm C|
3069461|NCT01143090|Experimental|Open Label|Subjects will continue on treatment with the same dose of lurasidone flexible dosing - 40 mg to 12 mg once daily taken orallay at endpoint of the D1050289 ( NCT01143077) core study.
3069462|NCT01143142|Experimental|Tailoring|Individuals assigned to the experimental group will receive a two-page brochure tailored based on their responses to the survey.
3069463|NCT01143142|Active Comparator|Untailored information|Individuals assigned to the control group will receive the CDC vaccine information sheet that is standardly provided.
3069464|NCT01143181|Experimental|Brincidofovir|Subjects received either a weight-based or a fixed-dose of oral brincidofovir (BCV) once weekly or twice weekly for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer.
3069465|NCT01143207|Experimental|Medroxyprogesterone acetate|Single injection of Medroxyprogesterone acetate (hormonal contraceptive)
3069466|NCT01143259|Placebo Comparator|300 mg Polyethylene|
3069467|NCT01143259|Active Comparator|Alvimopan|
3069468|NCT01143272|Active Comparator|Saccharomyces boulardii|Participants received Saccharomyces boulardii 250 mg capsules twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
3069469|NCT01143272|Placebo Comparator|Microcristallin cellulose|Participants received matching placebo twice per day within 24 hours of initiating antibiotic treatment and continued treatment for 7 days after antibiotic discontinuation
3069470|NCT01143324||MAST™ procedure|
3069471|NCT01143337|Experimental|1|dose1
3069472|NCT01143337|Placebo Comparator|2|Placebo
3069473|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 5 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).
3069474|NCT01143389|Active Comparator|Riboflavin 0.1% eyedrops every 2 minutes|The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).
3069475|NCT01143402|Experimental|Arm I (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are unable to be treated with temozolomide may be treated with dacarbazine IV every 3 weeks (with approval from the Principal Investigator). Patients who experience disease progression may crossover to arm II.
3069476|NCT01143402|Experimental|Arm II (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3069477|NCT01143610|Experimental|Newly forming bone|Miller class I or II deep recessions treated by the newly forming bone technique.
3069478|NCT01143610|Active Comparator|Subepithelial connective tissue graft|Miller class I or II deep recessions treated by subepithelial connective tissue graft.
3069479|NCT01143636|Sham Comparator|Active tDCS - pelvic pain patients|ACTIVE tDCS: Subjects will receive a total of 10 consecutive sessions of active tDCS over a two-week period (administered Monday - Friday). During each session, the anode electrode will be placed over the primary motor cortex of the predominantly painful side.
3069480|NCT01143636|Experimental|Sham tDCS - pelvic pain patients|SHAM tDCS: Subjects will receive a total of 10 consecutive sessions of sham tDCS over a two-week period (administered Mon-Fri). During each session, the anode will be placed over the primary motor cortex of the predominantly painful side.
3069481|NCT01143636|Experimental|Active tDCS - healthy|The healthy controls will undergo one day of treatment with active tDCS. All participants will receive both active and sham stimulation in a randomized order.
3069482|NCT01143636|Experimental|Sham tDCS - healthy|The healthy controls will undergo one day of treatment with sham tDCS. All participants will receive both active and sham stimulation in a randomized order.
3069483|NCT01143649|Experimental|active tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday).
3069484|NCT01143649|Experimental|active tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT)
3069485|NCT01143649|Experimental|tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one session of treatment with active tACS (in which the order in which they receive either sham or active transcranial alternating current stimulation (tACS) stimulation will be randomized).
3069486|NCT01143649|Sham Comparator|sham tDCS + CIMT - stroke patients|Participants will receive 5 sessions of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT - 10 consecutive sessions Monday- Friday). For the sham session, tDCS is turned off after 30seconds.
3069487|NCT01143649|Sham Comparator|sham tDCS + CIMT - Healthy|Participants will receive one session of tDCS over the primary motor cortex (M1). We will use the following stimulation parameters: intensity of 1mA and for the first 40 minutes of constraint induced movement therapy (CIMT). The sham stimulation consists of 30 seconds of stimulation at the beginning of the 40 min of treatment.
3069488|NCT01143649|Sham Comparator|sham tACS - Healthy Subjects|The investigators will have 40 healthy subjects who will undergo one day of treatment with sham tACS. All participants received active and sham stimulation in a randomized order.
3069489|NCT01143688|Active Comparator|albuterol inhaler|albuterol
3069490|NCT01143688|Placebo Comparator|placebo inhaler|placebo
3069491|NCT01143688|Placebo Comparator|placebo acupuncture|placebo
3069492|NCT01143701|Experimental|ADHD Collaborative Intervention|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the American Academy of Pediatrics consensus recommendation for evidence-based ADHD care.
3069493|NCT01143701|No Intervention|Typical ADHD care|Physicians in this group will provide typical ADHD care.
3069494|NCT01143714|Active Comparator|A|
3069495|NCT01143714|Placebo Comparator|B|
3069496|NCT01143727|Active Comparator|A|Santyl
3069497|NCT01143727|Active Comparator|B|Tegaderm Hydrogel
3069498|NCT01143766|Active Comparator|Standard sedation|Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.
3069499|NCT01143766|Active Comparator|Gapabentin|Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.
3069500|NCT01143792|Experimental|CRA + HIV prevention|
3069501|NCT01143792|Active Comparator|Case Management + HIV prevention|
3069502|NCT01143792|Active Comparator|MET + HIV prevention|
3069503|NCT01143818||AndroGel (testosterone gel )1%|AndroGel is topical testosterone gel 1% (1 sachet of 5 g contains 50 mg of testosterone), 1 daily dose.
3069504|NCT01143870|Other|Hemoglobin A1C|Diabetes control related to patients using standard hemoglobin A1C
3069505|NCT01143870|Experimental|Face|Face expressing emotion used to depict diabetes control
3069506|NCT01143870|Experimental|Letter grade|Letter grade used to express diabetes control
3069507|NCT01143883|Experimental|Silverlon Dressing|The Silverlon(Cura Surgical, Geneva, IL) dressing is applied to the surgical wound postoperatively. This dressing is coated with silver nylon.
3069508|NCT01143883|Active Comparator|Standard of Care Dressing|The standard plain gauze is used to dress the wound postoperatively
3069509|NCT01143896|Experimental|Arm 1: Depression Collaborative Care|Depression collaborative care: includes a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
3069510|NCT01143896|No Intervention|Arm 2: Usual Care|Usual care will include depression screening with the same PHQ-9 screener used for Arm 1. The depression collaborative care team will not be a part of the usual care condition.
3069511|NCT01144026|Experimental|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
3069512|NCT01144026|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
3069513|NCT01144052|Active Comparator|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
3069514|NCT01144052|Experimental|Interferon-beta-1b|250 mcg (8 MIU) subcutaneous injections every other day
3069515|NCT01144143|Experimental|Infliximab|
3069516|NCT01144143|Placebo Comparator|Salt Water|
3069517|NCT01144143|Active Comparator|Methylprednisolone acetate|
3069518|NCT01144182|No Intervention|Current Best Practice (CBP)|CBP received no intervention and only current best practices for inpatient HF care.
3069519|NCT01144182|Active Comparator|Quality improvement program (QIP)|Comprehensive quality improvement program (QIP) intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
3069520|NCT01144286|Placebo Comparator|placebo|placebo pessary, single dose
3069521|NCT01144286|Experimental|Arasertaconazole nitrate 150 mg|Arasertaconazole nitrate 150 mg pessary, single dose
3069522|NCT01144286|Experimental|arasertaconazole nitrate 300 mg|Arasertaconazole nitrate 300 mg pessary, single dose
3069523|NCT01144286|Experimental|arasertaconazole 600 mg|Arasertaconazole nitrate 600 mg pessary, single dose
3069524|NCT01144299|Experimental|Fluarix Adult Group|Subjects aged 18 to 60 years received one dose of Fluarix™.
3069525|NCT01144299|Experimental|Fluarix Elderly Group|Subjects aged > 60 years received one dose of Fluarix™.
3069526|NCT01144338|Experimental|Exenatide Once Weekly|
3069527|NCT01144338|Placebo Comparator|Placebo|
3069528|NCT01144364|Experimental|1|
3069529|NCT01144377|Experimental|180 mg LY2541546 Q4W + Placebo|"LY2541546: 180 milligrams (mg) administered subcutaneously every 4 weeks (Q4W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
3069530|NCT01144377|Experimental|180 mg LY2541546 Q2W|LY2541546: 180 milligrams (mg) administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3069531|NCT01144377|Experimental|270 mg LY2541546 Q2W|LY2541546: 270 milligrams (mg) LY2541546 administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3069532|NCT01144377|Experimental|270 mg LY2541546 Q12W + Placebo|"LY2541546: 270 milligrams (mg) administered subcutaneously every 12 weeks (Q12W) for 52 weeks.~Placebo: administered subcutaneously every alternate 2 weeks from the LY2541546 dose for 52 weeks."
3069533|NCT01144377|Placebo Comparator|Placebo Comparator Q2W|Placebo: administered subcutaneously every 2 weeks (Q2W) for 52 weeks.
3069534|NCT01144403|Experimental|Rituximab|Rituximab, 375 milligram per meter square (mg/m^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
3069535|NCT01144416|Experimental|Single injection of 150 µg SCH 900962 (MK-8962)|Participants received a single injection of 150 ug SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections with placebo-recFSH from Stimulation Days 1-7
3069536|NCT01144416|Active Comparator|Daily 300 IU recFSH|Participants received a single injection of placebo SCH 900962 (MK-8962) on Stimulation Day 1 and 7 injections of recFSH from Stimulation Days 1-7
3069537|NCT01144442|Experimental|HIPC Treatment|
3069538|NCT01144455|Active Comparator|Gemcitabine|Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle
3069539|NCT01144455|Experimental|240 mg/m2 TH-302 + Gemcitabine|"TH-302: 240 mg/m2 administered IV over 30 minutes Day 1, 8, and 15 of each 28-day cycle~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
3069540|NCT01144455|Experimental|340 mg/m2 TH-302 + Gemcitabine|"TH-302: 340 mg/m2 of TH-302 be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.~Gemcitabine: 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle"
3069541|NCT01144494|Active Comparator|Intraocular pressure lowering drug|Eyedrops for lowering intraocular pressure
3069542|NCT01144494|Placebo Comparator|Artificial Tears|Lubricated eye drops
3069543|NCT01144598||Turkish patients with rheumatoid arthritis|
3069544|NCT01144624|Experimental|1|"AZD9773 250 units/kg (1 infusion) + 50 units/kg (9 infusions) (Dose Cohort 1):~AZD9773 500 units/kg (1 infusion) + 100 units/kg (9 infusions) (Dose Cohort 2)"
3069545|NCT01144624|Placebo Comparator|2|
3069546|NCT01144637|Experimental|Group 1|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #1
3069547|NCT01144637|Experimental|Group 2|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #2
3069548|NCT01144637|Experimental|Group 3|Two vaccinations four weeks apart (at Day 0 and Day 28) with IMVAMUNE® Lot #3
3069549|NCT01144637|Placebo Comparator|Group 4|Two vaccinations four weeks apart (at Day 0 and Day 28) with 0.5 ml Placebo, Tris-buffered saline (TBS)
3069550|NCT01144663|Experimental|Nimenrix 3 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 3 primary doses of Nimenrix™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 3, 4 and 12 months of age.
3069551|NCT01144663|Experimental|Nimenrix 2 Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Nimenrix™ vaccine at 2 and 4 months of age, followed by a booster dose of Nimenrix™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
3069552|NCT01144663|Active Comparator|Menjugate Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of Menjugate® vaccine at 2 and 4 months of age, followed by a booster dose of Menjugate® vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
3069553|NCT01144663|Active Comparator|NeisVac-C Group|Healthy male or female subjects aged between and including, 6 and 12 weeks of age, intramuscularly received 2 primary doses of NeisVac-C™ vaccine at 2 and 4 months of age, followed by a booster dose of NeisVac-C™ vaccine at 12 months of age. Subjects were also administered intramuscular injections of Infanrix™ hexa and Synflorix™ vaccines at 2, 4 and 12 months of age.
3069554|NCT01144715|Experimental|Hand Mentor Therapy|Use of the Hand Mentor (TM) Stroke Therapy Device at home for 8 weeks
3069555|NCT01144715|Active Comparator|Control|Self administered home therapy program
3069556|NCT01144949|Active Comparator|silodsosin|
3069557|NCT01144949|Placebo Comparator|placebo|
3069558|NCT01145001|Active Comparator|Active Nicotine Patch and Contingency Management|Subjects in this group will receive Contingency Management and active nicotine patch
3069559|NCT01145001|Active Comparator|Nicotine Patch with no Contingency Management|Subjects in this group will receive active nicotine patch without contingency management for abstinence
3069560|NCT01145001|Placebo Comparator|Placebo patch and Contingency Management|Subjects in this group will receive a placebo transdermal patch and contingency management
3069561|NCT01145001|Placebo Comparator|Placebo Patch and no Contingency Management|Subjects in this group will receive a placebo patch and will not receive contingency management
3069562|NCT01145053||Treatment|
3069563|NCT01145066|Experimental|borage and echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7 g/day GLA
3069564|NCT01145066|Active Comparator|fish oil|Croda 18:12 fish oil
3069565|NCT01145066|Placebo Comparator|corn oil|
3069566|NCT01145183|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
3069567|NCT01145183|Placebo Comparator|Placebo|Matched placebo daily dosing.
3069568|NCT01145209|Experimental|FO Arm (fludarabine and ofatumumab)|For patients with non-high risk FISH changes
3069569|NCT01145209|Experimental|FCO Arm (fludarabine, cyclophosphamide, and ofatumumab)|For patients with high risk FISH changes
3069570|NCT01145222|Experimental|A. Remimazolam (CNS 7056)|"Initial 8 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
3069571|NCT01145222|Experimental|B. Remimazolam (CNS 7056)|"Initial 7 mg iv for sedation induction, and 2 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
3069572|NCT01145222|Experimental|C. Remimazolam (CNS 7056)|"Initial 5 mg iv for sedation induction, and 3 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses."
3069573|NCT01145222|Active Comparator|D. Midazolam|"Initial 2.5 mg iv for sedation induction, and 1 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: up to 100 μg (at the discretion of the investigator) and 25 μg top-up doses"
3069574|NCT01145352||Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis during registered period (2.5 year).
3069575|NCT01145391|No Intervention|Control|Patients receive usual care.
3069576|NCT01145391|Active Comparator|Intervention|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
3069577|NCT01145417|Experimental|Pregabalin (Lyrica)|
3069578|NCT01145482|Experimental|insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
3069579|NCT01145482|Placebo Comparator|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
3320930|NCT02014818|Experimental|1 month OCT follow-up, CoCr-EES|Elective PCI can be performed with the use of an EES. PCI in another vessel or follow-up angiography is expected to be performed 1 months after the index procedure.
3320931|NCT02014831|Active Comparator|TIP|"Reference arm; Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment)"
3069580|NCT01145508|Experimental|Arm A (vaccine therapy and chemotherapy)|Patients receive rilimogene-galvacirepvec SC on day 1 of course 1 and fowlpox-PSA-TRICOM vaccine SC on days 15, 29, 43, and 57 of course 1. Beginning on day 85 (day 1 of course 2), patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment with docetaxel and prednisone repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3069581|NCT01145508|Active Comparator|Arm B (docetaxel, prednisone)|Patients receive docetaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3069582|NCT01145547|Active Comparator|low glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a low Glycemic Index.
3069583|NCT01145547|Active Comparator|high glycemic index effect on post-prandial peak|Seven adult subjects with type 1 diabetes participated in two experiments, each consisting of two meals each. In one experiment, both meals had a high Glycemic Index.
3069584|NCT01145560|Experimental|1|AZD9773 250/50 units/kg
3069585|NCT01145560|Experimental|2|AZD9773 500/100 units/kg
3069586|NCT01145560|Placebo Comparator|3|
3069587|NCT01145625|Experimental|5% MTF|5% Minoxidil Topical Foam
3069588|NCT01145625|Active Comparator|2% MTS|2% Minoxidil Topical Solution
3069589|NCT01145638|Experimental|iron isomaltoside 1000|Iron isomaltoside intravenously as bolus or infusion
3069590|NCT01145638|Active Comparator|iron sulphate|oral iron sulphate twice a day
3069591|NCT01145755|Experimental|AZD2066|
3069592|NCT01145755|Placebo Comparator|Placebo|
3069593|NCT01145755|Active Comparator|Duloxetine|Duloxetine
3069594|NCT01145833|Active Comparator|Immediate treatment group|The immediate treatment group begins the 5-month treatment immediately after baseline assessment.
3069595|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group serves as the control group. This group starts treatment 5 months after the baseline assessment. No intervention is involved during this 5-month waiting period. After 5 months, the delayed group is assessed for the second time and then begins the 5-month treatment.
3069596|NCT01145885|Experimental|BI 6727|BI 6727 cycles in every 21 days
3069597|NCT01145898||Glaucoma patients|Patients with Glaucoma
3069598|NCT01146054|Experimental|SBRT and Gemzar|Before stereotactic Body Radiotherapy (SBRT) 3-5 gold fiducials are placed by endoscopic ultrasound or CT guidance. A simulation FDG-PET/CT (Fludeoxyglucose (18F) - Positron emission tomography/Computerized tomography) scan will be used for treatment planning purposes (standard free-breathing CT and respiratory-correlated 4-D (4 dimensional) pancreatic protocol CT). Patients are treated by either respiratory gated (Trilogy, Elekta, Novalis) or by respiratory tracking (CyberKnife). SBRT is delivered in 5 fractions of 6.6 Gy by LINAC-based or CyberKnife based radiotherapy over a five-day period. Gemcitabine, cycles should resume/start up to 4 weeks following SBRT on a 3-week on, 1-week off schedule. Initial follow up is at 4, 6, 9 and 12 months and then for years 2-5 is every 3-6 months.
3069599|NCT01146275|Other|Participants in the Pilot study 31GB0601|"This is an additional safety follow up 7-years post treatment, for subjects enrolled in a pilot study using a previous formulation of Macrolane for breast augmentation.~Radiological breast examinations - MRI of breast, mammography and ultrasound of breast"
3069600|NCT01146288|Experimental|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
3069601|NCT01146288|Experimental|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.
3069602|NCT01146379|Experimental|Low Movement Dose, 3200 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3069603|NCT01146379|Experimental|Medium Movement Dose, 6400 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3069604|NCT01146379|Experimental|High Movement Dose, 9600 total reps|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3069605|NCT01146379|Experimental|Individual Maximum High Movement Dose|he experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
3069606|NCT01146418|Experimental|Corifollitropin alfa 150 μg|Participants in Base Study P06029 received a single injection of 150 ug corifollitropin alfa on Stimulation Day 1 and daily injections of placebo-recFSH from Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
3069607|NCT01146418|Active Comparator|recFSH 300 IU|Participants in the reference group in Base Study P06029 received a single injection of placebo for corifollitropin alfa on Stimulation Day 1 and daily injections of 300 IU recFSH on Stimulation Days 1 through 7. No medication or investigational product was administered in Follow-Up Study P06031.
3069608|NCT01146457|Placebo Comparator|Placebo|
3069609|NCT01146457|Active Comparator|Morphine 25|
3069610|NCT01146457|Active Comparator|Morphine 50|
3069611|NCT01146457|Active Comparator|Morphine 75|
3069612|NCT01146457|Active Comparator|Morphine 100|
3069613|NCT01146496|Active Comparator|Storage container|Ultraviolet light resistant plastic in-ground pesticide storage container
3069614|NCT01146496|No Intervention|Control|
3069615|NCT01146561|Experimental|Tanezumab 20 mg|
3069616|NCT01146561|Placebo Comparator|Placebo|
3069617|NCT01146600|Experimental|Random Group A|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
3069618|NCT01146600|Experimental|Random Group B|Subjects will be randomized to group A or group B. The order of presentation of placebo and clarithromycin will be opposite in these two groups, but investigators and subjects will remain blinded to group allocation and order of treatment presentation within the groups.
3069619|NCT01146613|Active Comparator|Varenicline|Varenicline Tartrate
3069620|NCT01146613|Placebo Comparator|Sugar Pill|
3069621|NCT01146665|Experimental|Computer-based PAF|Standard medical care followed by computer-based personalized assessment feedback (PAF).
3069622|NCT01146665|Sham Comparator|Computer-based sham|Standard medical care followed by a computer-based sham.
3069623|NCT01146704|Active Comparator|Standard Diet|Standard protein diet group as control based on 0.5 gram protein per pound of lean body mass with same calories: 15% protein and 55% carbohydrate.
3069624|NCT01146704|Active Comparator|High Protein Diet|High protein diet group based on 1 gram of protein per pound of lean body mass: 30% protein and 40% carbohydrate.
3069625|NCT01146782|Experimental|Treatment|Treatment with the Attune Sleep Apnea System
3069626|NCT01146795|Experimental|Carboplatin, Paclitaxel, and Bevacizumab|"Three 21 day cycles of carboplatin, paclitaxel, and bevacizumab.~After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill all criteria to be considered eligible for surgical exploration: 1) ≥50% reduction in pretreatment cancer antigen 125 (CA-125) and 2) No medical contraindications to surgery.~After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
3069627|NCT01146808|Experimental|ADV plus hepatitis B vaccination|Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
3069628|NCT01146834|Experimental|Arm A: VELCADE, CYCLOPHOSPHAMIDE, & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
3069629|NCT01146834|Experimental|Arm B: VELCADE & G-CSF|VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Day 12 start pheresis collection
3069630|NCT01146834|Experimental|Arm C: CYCLOPHOSPHAMIDE & G-CSF|High-dose cyclophosphamide at 2.0 g/m2 on day 1. G-CSF is given for ten (+/- two) consecutive days starting on day 2 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
3069631|NCT01146834|Experimental|Arm D: PLERIXAFOR & G-CSF|G-CSF is given for ten (+/- two) consecutive days starting on day 1 at a dose of 10 micrograms/kg/day. Plerixafor is given on day 4, approximately 11 hours prior to stem cell collection attempt on Day 5. Both G-CSF and plerixafor are continued daily until collection is complete. Pheresis will commence for everyone on Day 5 regardless of ANC status.
3069632|NCT01146834|Experimental|Arm E: PLERIXAFOR, VELCADE, & G-CSF|"Bortezomib at 1.3 mg/m2 IVP on days 1, 4, 8 and 11. G-CSF is given for ten (+/- wo) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day.~Plerixafor is given on day 12, approximately 11 hours prior to stem cell collection attempt and is continued daily until collection is complete. Pheresis will commence for everyone on Day 13 regardless of ANC status."
3069633|NCT01146860|Experimental|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
3069634|NCT01146860|Placebo Comparator|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration: 15 days
3069635|NCT01146873|Active Comparator|Group 1: Lopinavir/ritonavir (LPV/r)|Participants are assigned to remain on their current LPV/r-based antiretroviral regimen. Ritonavir-boosted lopinavir syrup was given twice per day at 230 mg/m^2 per dose. Children able to swallow tablets were given 1 tablet twice per day (200 mg lopinavir/50 mg ritonavir) if body surface area was less than 0.9m^2 or 2 tablets twice per day if body surface area was 0.9m^2 or higher.
3069636|NCT01146873|Experimental|Group 2: Efavirenz (EFV)|Participants are assigned to switch to an EFV-based antiretroviral regimen. Efavirenz was prescribed once daily in the evening at 200 mg for weights of 10 kg to 13.9 kg (22-30 lb) and 300mg for weights of 14 kg to 24.9 kg (31-55 lb). Efavirenz was available in 50-mg and 200-mg capsules. If children were unable to swallow capsules, caregivers were shown how to open the capsules and dissolve the contents in water.
3069637|NCT01146873|Active Comparator|Group D: Stavudine (D4T)|Children are assigned to remain on their current antiretroviral regimen, which includes D4T. D4T was given at 1 mg/kg twice daily
3069638|NCT01146873|Experimental|Group A: Abacavir (ABC)|Children stop taking D4T and switch to ABC. ABC was given at 8 mg/kg twice daily.
3069639|NCT01146912|Experimental|Text message vaccine reminders|Receipt of text message vaccine reminders
3069640|NCT01146912|Active Comparator|automated phone call from clinic|Receipt of automated phone call from clinic
3069641|NCT01146951|Experimental|Rufinamide (E2080)|
3069642|NCT01146951|Placebo Comparator|Placebo|
3069643|NCT01147055|Experimental|1|There should be at least 14-day washout period between treatment A and B.
3069644|NCT01147068|Experimental|PanBlok 135µg No Adjuvant|135µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
3069645|NCT01147068|Experimental|PanBlok 45µg No Adjuvant|45µg recombinant hemagglutinin, no adjuvant; Two 0.5 mL IM injections 21 days apart
3069646|NCT01147068|Experimental|PanBlok 45µg and GLA 1.0µg, SE 2%|45µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3069647|NCT01147068|Experimental|PanBlok 15µg and GLA 1.0µg, SE 2%|15µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3069648|NCT01147068|Experimental|PanBlok 7.5µg and GLA 1.0µg, SE 2%|7.5µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3069649|NCT01147068|Experimental|PanBlok 3.8µg and GLA 1.0µg, SE 2%|3.8µg recombinant hemagglutinin and Glucopyranosyl Lipid A 1.0µg in a 2% oil-in-water stable emulsion; Two 0.5 mL IM injections 21 days apart
3069650|NCT01147068|Placebo Comparator|Placebo|0.9% Sodium Chloride; Two 0.5 mL IM injections 21 days apart
3069651|NCT01147107|Experimental|Raltegravir based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
3069652|NCT01147107|Active Comparator|Efavirenz based therapy|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
3069653|NCT01147172|Experimental|Elevess|Gel implant (dermal filler) composed of hyaluronan produced by Streptococcus equi (bacterial fermentation) that is cross-linked and suspended in phosphate buffered saline with 0.3% lidocaine HCl and 0.1% sodium metabisulfite
3069654|NCT01147250|Placebo Comparator|Placebo|Placebo matched to lixisenatide once daily (QD) up to end of treatment.
3069655|NCT01147250|Experimental|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to end of treatment.
3069656|NCT01147302|Experimental|C1 Esterase Inhibitor (Human)|Subjects were to receive C1 esterase inhibitor intravenously at a rate of approximately 1 mL per minute as tolerated. Subjects were to receive a total of 7 doses over a 2-week period: an initial IV infusion of 5000 U (not to exceed 100 U/kg) on Day 1, followed by 2500 U (not to exceed 50 U/kg) IV on Days 3, 5, 7, 9, 11, and 13
3069657|NCT01147302|Placebo Comparator|Normal Saline|placebo infused as above
3069658|NCT01147341|Placebo Comparator|placebo|Placebo (0.9% sodium chloride) given as 2 subcutaneous (sc) injections at weeks 0, 2, and 4, followed y 1 sc injection given an weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
3069659|NCT01147341|Active Comparator|active treatment with Cimzia|400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 0, 2, and 4, followed by 1 sc injection at weeks 6, 8, and 10. At week 12 subjects entered the open label phase. Subjects received 400 mg of Cimzia (CZP) given as two 200 mg subcutaneous (sc) injections at weeks 12,14 and 16, followed by 1 sc injection at weeks 18, 20, and 22.
3069660|NCT01147380|Experimental|Small dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells( mainly NK cells) is between 10 and 100 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate. Patient of this arm receive small dose of liver NK cell inoculation as described.
3069661|NCT01147380|Experimental|Large dose|From the donor liver perfusate, mononuclear cell will be extracted and cultured. Then, the cells will be stimulated with IL-2. The number of inoculation cells(mainly NK cells) is between 100 and 1000 million cells. The cells will be given to the liver transplant recipient who had the same donor for liver and liver perfusate.Patient of this arm receive large dose of liver NK cell inoculation as described.
3069662|NCT01147406|Experimental|Active|N6022
3069663|NCT01147406|Placebo Comparator|Placebo|Placebo
3069664|NCT01147458|Experimental|PF-04191834 followed by placebo|PF-04191834 600 mg BID dose followed by matched placebo plus naproxen placebo.
3069665|NCT01147458|Experimental|Placebo followed by PF-04191834|Placebo followed by 600 mg BID dose of PF-04191834 plus naproxen placebo.
3069666|NCT01147458|Experimental|PF-04191834+Naproxen followed by Naproxen|PF-04191834 600 mg BID + Naproxen 500 mg BID followed by Naproxen 500 mg BID plus PF-04191834 placebo
3069667|NCT01147458|Experimental|Naproxen followed by PF-04191834+Naproxen|Naproxen 500 mg BID followed by PF-04191834 600 mg BID + Naproxen 500 mg BID
3069668|NCT01147471|Active Comparator|Operative rib fixation|"Randomized subjects will be operated upon within 72 hours of ventilation (early fixation) to stabilize the stove-in segment. Where all fractured ribs are accessible and the number of fractured ribs is few, stabilization of all fractured ribs would be the goal. However, where fractured ribs are in areas difficult to access, enough ribs, based on surgeon judgment, would be fixed to stabilize the stove-in segment. Post-operatively, the patients would receive the standard of care, similar to what is outlined for the non-operative arm.~Operative fixation will be accomplished utilizing the MatrixRIB Fixation System (Synthes CMF, West Chester, PA, USA) according to the device's instructions for use. Sites will obtain the product based on their medical center's normal purchasing practices."
3069669|NCT01147471|No Intervention|Non-operative arm|"Randomized subjects to receive standard of care therapy for blunt thoracic trauma (as per each participating institution's own protocols):~a. Ventilatory support b.Timing of extubation (removal from ventilator): c.Analgesia: institution should provide adequate analgesia utilizing available resources including oral, parenteral, epidural, local nerve blocks etc., d.Chest physical therapy, e.Postural drainage, f.Incentive spirometry - after extubation."
3069670|NCT01147497|Experimental|misoprostol|Misoprostol 400mcg taken buccally 2 hours prior to IUD insertion visit
3069671|NCT01147497|Placebo Comparator|placebo|Pill that is identical to the study drug in appearance, taste, and smell, taken buccally 2 hours prior to IUD insertion visit
3069672|NCT01147601|Active Comparator|Topical 0.5% Timolol|Half of the enrolled subjects (intervention group) will receive topical 0.5% Timolol.
3069673|NCT01147601|Placebo Comparator|Placebo|Aqueous placebo, 2-3 drops to cover the hemangioma, twice daily
3069674|NCT01147627|Active Comparator|Exenatide|
3069675|NCT01147627|Active Comparator|Premixed insulin analog|
3069676|NCT01147627|Active Comparator|pioglitazone|
3069677|NCT01147640|Experimental|CXA 101/tazobactam and metronidazole|
3069678|NCT01147640|Active Comparator|meropenem with matching saline placebo|
3069679|NCT01147653|Active Comparator|Autologous UCB Reinfusion First,Then Placebo|Subjects receive their autologous umbilical cord blood cells at Baseline, than placebo at Year 1.
3069680|NCT01147653|Placebo Comparator|Placebo First, Then Autologous UCB Reinfusion|Subjects receive placebo at Baseline, then autologous umbilical cord blood cell reinfusion at Year 1.
3069681|NCT01147744|Experimental|GSK2190915 10mg and placebo|GSK2190915 10mg (1 x 10mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3069682|NCT01147744|Experimental|GSK2190915 30mg and placebo|GSK2190915 30mg (1 x 30mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3069683|NCT01147744|Experimental|GSK2190915 100mg QD and placebo|GSK2190915 100mg (1 x 100mg, 1 x placebo tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3069684|NCT01147744|Experimental|GSK2190915 300mg QD and placebo|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning and placebo caspule once daily in the evening and inhaled placebo twice daily via ACCUHALER/DISKUS
3069685|NCT01147744|Active Comparator|Fluticasone propionate 100mcg and placebo|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS and two placebo tablets in the morning and one placebo capsule in the evening
3069686|NCT01147744|Active Comparator|Montelukast 10mg and placebo|Montelukast 10mg (1 x 10mg capsule) once daily in the evening and two placebo tablets in the morning and inhaled placebo twice daily via ACCUHALER/DISKUS
3069687|NCT01147744|Placebo Comparator|Placebo Comparator|Two GSK2190915 placebo tablets once daily in the morning, montelukast placebo capsule once daily in the evening and fluticasone propionate placebo twice daily via ACCUHALER/DISKUS
3069688|NCT01147809|Active Comparator|Eltrombopag|Drug: eltrombopag olamine thrombopoietin receptor agonist
3069689|NCT01147809|Placebo Comparator|Placebo|Other: Placebo Placebo tablets with no active pharmaceutical ingredient
3468820|NCT03892005||MOTIVATION HIP Total Hip System|All study subjects have undergone routine preoperative clinical evaluations prior to their THA, and implanted MOTIVATION HIPTM Total Hip System in accordance to indications and intended use, and appropriate surgical technique(s) will be invited to participate in the study at their first year of postoperative follow up visit, and sign ICF.
3069692|NCT01147848|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/vilanterol inhalation powder once daily + placebo inhalation powder twice daily for 24 weeks
3069693|NCT01147848|Active Comparator|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol inhalation powder twice daily + placebo inhalation powder once daily for 24 weeks
3069694|NCT01147874|No Intervention|psoriatic arthritis (PsA) questionnaire|
3069695|NCT01147900|Experimental|Boostrix-REF Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3069696|NCT01147900|Experimental|Boostrix-US Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3069697|NCT01147900|Experimental|Boostrix-INV Group|Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3069698|NCT01147926|Placebo Comparator|Placebo|Placebo
3069699|NCT01147926|Active Comparator|Prucalopride|1 milligram (mg) or 2 mg
3069700|NCT01148017|Experimental|ACWY - 4|Subjects who had previously received 4 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their first year of life are administered one booster dose of the same vaccine at 60 months of age.
3069701|NCT01148017|Experimental|ACWY - 2|Subjects who had previously received 1 or 2 doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in the parent study during their second year of life, are administered one booster dose of the same vaccine at 60 months of age.
3069702|NCT01148017|Other|Naïve - 40|Control subjects, age-matched with the intervention groups subjects (40 months of age), to receive 1 optional dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3069703|NCT01148017|Active Comparator|Naïve - 60|Control subjects, age-matched with the intervention groups subjects (60 months of age), are administered one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3069704|NCT01148225|Other|Adalimumab|Participants received open label (OL) adalimumab 40 mg by subcutaneous (SC) injection every other week (eow) until the final visit.
3069705|NCT01148420|Experimental|DMPA & MPA|150 mg intramuscularly received DMPA and two 10 mg tablets of MPA every 8 hours for 3 days
3069706|NCT01148459|Experimental|Group A|Infants enrolled to this group will receive 3 doses of the experimental vaccine.
3069707|NCT01148459|Active Comparator|Group B|Infants enrolled to this group will receive 3 doses of the rabies comparator vaccine.
3069708|NCT01148511|Experimental|Treat and Extend|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
3069709|NCT01148511|Active Comparator|Treat and Observe|Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
3069710|NCT01148524|Other|rMenB06|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 6 months) and placebo (at 1 and 2 months) in V72P10 study had a blood draw.
3069711|NCT01148524|Other|rMenB0|Subjects who had received 1 dose of rMenB+OMV-NZ (at 0 month) and 3 doses of placebo (at 1, 2 and 6 months) in V72P10 study had a blood draw.
3069712|NCT01148524|Other|rMenB016|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 6 months) and 1 dose of placebo (at 2 months) in V72P10 study had a blood draw.
3069713|NCT01148524|Other|rMenB01|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 1 month) and placebo (at 2 and 6 months) in V72P10 study had a blood draw.
3069714|NCT01148524|Other|rMenB026|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 2 and 6 months) and 1 dose of placebo (at 1 month) in V72P10 study had a blood draw.
3069715|NCT01148524|Other|rMenB02|Subjects who had received 2 doses each of rMenB+OMV-NZ (at 0 and 2 months) and placebo (at 1 and 6 months) in V72P10 study had a blood draw.
3069716|NCT01148524|Other|rMenB012|Subjects who had received 3 doses of rMenB+OMV-NZ (at 0, 1 and 2 months) and 1 dose of placebo (at 6 months) in V72P10 study had a blood draw.
3069717|NCT01148524|Other|rMenB6|Subjects who had received 1 dose of rMenB+OMV-NZ (at 6 months) and 3 doses of placebo (at 0, 1 and 2 months) in V72P10 study had a blood draw.
3069718|NCT01148524|Other|Naive|An additional study group of naïve subjects that served as a baseline comparator for assessing antibody persistence in the vaccine groups and had blood draw for serological analyses at the time of enrollment.
3069719|NCT01148537|Experimental|BTDS|Buprenorphine transdermal patches 5, 10, 20, and 2 * 20 mcg/h.
3069720|NCT01148537|Placebo Comparator|Placebo TDS|Matching placebo transdermal patches 5, 10, 20 and 2 * 20.
3069721|NCT01148537|Active Comparator|Moxifloxacin|Moxifloxacin hydrochloride 400 mg tablets
3069722|NCT01148563|No Intervention|Standard Care|The Standard Care group will continue regular LSU HCSD disease management care for heart failure patients with no additional intervention.
3069723|NCT01148563|Active Comparator|Tele-health Monitoring Group|The tele-monitoring intervention group will have the continual standard care from their physician plus the tele-health monitoring. The tele-health monitor will collect the following data: weight, blood pressure, pulse oximetry, pulse rate, & patient responses to disease-specific questions regarding changes in state of health for 6 months.
3069724|NCT01148693|Active Comparator|gentamicin|adding 10mg gentamicin to every 10 ml of contrast media
3069725|NCT01148693|Placebo Comparator|Placebo|Identical placebo
3069726|NCT01148745|Other|ferumoxytol|FDA approved drug
3069727|NCT01148771|Experimental|Ertapenem 1 gram intravenous (IV) 5 minute bolus|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 5 minute IV bolus.
3069728|NCT01148771|Active Comparator|Ertapenem 1 gram IV 30 minute infusion|Participants received ertapenem 1 gram every 24 hours for 3 doses with each dose infused as a 30 minute infusion (i.e., the standard dose).
3069729|NCT01148810|Placebo Comparator|Placebo|
3069730|NCT01148810|Experimental|BAF312|
3069731|NCT01148836|Experimental|Coenzyme Q 10 and Pulmonary Hypertension|PAH subjects to take Co-Q daily for three months
3069732|NCT01148836|Experimental|Coenzyme Q 10 and Normal Controls|Normal controls to take Co-Q daily for three months
3069733|NCT01148862|Other|Group A|Group A will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature activated
3069734|NCT01148862|Other|Group B|Group B will wear the MiniMed Paradigm® X54 System with the Low Glucose Suspend (LGS) feature deactivated
3069735|NCT01148940||White women with Hb AA|White pregnant and postpartum women with Hb AA
3069736|NCT01148940||Black women with Hb AA|Black pregnant and postpartum women with HbAA
3069737|NCT01148940||Black women with Sickle Trait|Black pregnant and postpartum women with HbAS
3069738|NCT01148979|Experimental|Adjunct Lisdexamfetamine (Vyvanse)|Participants receive Lisdexamfetamine Dimesylate 20-50 mg capsule each morning for 4 weeks. After a washout period of 2 weeks, they receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) capsule) each morning for 4 weeks.
3069739|NCT01148979|Placebo Comparator|Adjunct Placebo|Participants receive Placebo capsule (matching Lisdexamfetamine Dimesylate (Vyvanse) 20-50 mg capsule) each morning for 4 weeks. After a washout period of 2 weeks, they receive Lisdexamfetamine Dimesylate capsule each morning for 4 weeks.
3069740|NCT01149057|Experimental|Single Arm|
3069741|NCT01149096|Active Comparator|Arm I (conventional bone marrow harvest)|Donors undergo conventional (i.e., unstimulated) bone marrow harvest on day 0.
3069742|NCT01149096|Experimental|Arm II (filgrastim, bone marrow harvest)|Donors receive filgrastim subcutaneously on days -4 through 0. Donors then undergo bone marrow harvest on day 0.
3069743|NCT01149148|Active Comparator|Intervention INVOS Cerebral Oximetry Monitoring|Intervention will be initiated if rSO2 drops > 20% from baseline or rSO2 declines below 50%.
3069744|NCT01149148|Active Comparator|Standard of Care|Blinded cerebral oximetry monitoring with no intervention in surgical procedures and anesthesia without deviation from standard of care.
3069745|NCT01149343|Experimental|GSK2302025A Cohort 1|Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3069746|NCT01149343|Experimental|GSK2302025A Cohort 2|Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3069747|NCT01149343|Experimental|GSK2302025A Cohort 3|Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
3069748|NCT01149343|Experimental|GSK2302025A Cohort 4|In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
3069749|NCT01149369|Active Comparator|Aprepitant|Aprepitant 125 mg per day
3069750|NCT01149369|Placebo Comparator|Aprepitant-placebo|Placebo aprepitant 125mg per day
3069751|NCT01149421|Experimental|1.5 milligram (mg) LY2189265|LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)
3069752|NCT01149421|Experimental|0.75 milligram (mg) LY2189265|LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)
3069753|NCT01149421|Placebo Comparator|Placebo|Placebo: subcutaneous (SC), once weekly (QW)
3069754|NCT01149434|Experimental|Pharmacokinetic Arm|Patients going on Pharmacokinetic arm will receive JI-101 & Everolimus (4 patients only)
3069755|NCT01149434|Experimental|Pharmacodynamic arm|Patients going on the Pharmacodynamic study will receive JI-101 only.
3069756|NCT01149460|Experimental|Valacyclovir|Test 1000 mg Tablet
3069757|NCT01149460|Active Comparator|Valtrex|Reference Listed Valacyclovir 1000 mg Tablet
3069758|NCT01149473|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
3069759|NCT01149473|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
3069760|NCT01149486|Experimental|Generic Test Product|Losartan potassium/Hydrochlorothiazide 100/25 mg Tablets
3069761|NCT01149486|Active Comparator|Reference Listed Drug|Hyzaar® 100/25 mg Tablets
3069762|NCT01149512||LAGB patients in Weight Wise Program|All patients seen within the Weight Wise program and selected for surgical management, who have undergone LAGB will be included in this analysis.
3069763|NCT01149538|Experimental|Choline Bitartrate|Choline Bitartrate supplementation
3069764|NCT01149538|Placebo Comparator|Placebo|Placebo for choline bitartrate supplementation
3069765|NCT01149616|Active Comparator|Intervention|Dexamethasone 8mg iv x 1
3069766|NCT01149616|Placebo Comparator|Placebo|placebo
3069767|NCT01149655|Experimental|Phase 1|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3069768|NCT01149655|Experimental|Phase 2|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
3069769|NCT01149655|Placebo Comparator|Phase 3|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo
3069770|NCT01149681|Experimental|Arm one|
3069771|NCT01149733|Experimental|Tamsulosin|0.4 mg Capsule
3069772|NCT01149733|Active Comparator|Flomax®|0.4 mg Capsule
3069773|NCT01149759|Experimental|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks.
3069774|NCT01149772|Experimental|ACCESS|Medically ill patients received six-sessions of cognitive behavioral therapy tailored to their unique needs. Patients received 2 core modules and 3 elective modules. Elective modules focused on physical health, cognitive restructuring, behavioral activation, and relaxation. The six session was a wrap up that everyone received. Patients also had the option to receive 2 follow-up booster sessions to aid in maintenance of skills learned.
3069775|NCT01149772|No Intervention|Enhanced Usual Care|Patients in this arm received feedback about their physical and emotional health functioning and were still able to receive usual primary care services.
3069776|NCT01149785|Experimental|1|There should be at least 14-day washout period between treatment A and B.
3069777|NCT01149863|Experimental|Plerixafor 17 hours prior to apheresis|Dosing of plerixafor will occur at 3PM (1500 hours).
3069778|NCT01149876|Experimental|Nu Skin Product|
3069779|NCT01149876|Experimental|Nu Skin product with galvanic spa system|
3069780|NCT01149876|Active Comparator|Tretinoin cream 0.05|
3069781|NCT01149876|Placebo Comparator|over the counter moisturizer|
3069782|NCT01150045|Active Comparator|Arm A - FOLFOX and placebo (12 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
3069783|NCT01150045|Experimental|Arm B - FOLFOX and celecoxib (12 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
3069784|NCT01150045|Active Comparator|Arm C - FOLFOX and placebo (6 treatments)|Patients receive FOLFOX every 2 weeks plus placebo every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
3069785|NCT01150045|Experimental|Arm D - FOLFOX and celecoxib (6 treatments)|Patients receive FOLFOX every 2 weeks plus celecoxib every day for 6 treatments (12 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive celecoxib alone every day for 3 years total.
3069786|NCT01150097|Experimental|Everolimus + reduced tacrolimus|Participants were maintained on whole blood trough levels of 3 - 8 ng/mL everolimus and 3 - 5 ng/mL tacrolimus.
3069787|NCT01150097|Experimental|Tacrolimus elimination|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL everolimus.
3468821|NCT03892343||Transplant recipients|Patients undergoing live donor kidney transplant.
3069788|NCT01150097|Active Comparator|Tacrolimus control|Participants were maintained on a whole blood trough level of 6 - 10 ng/mL tacrolimus.
3069789|NCT01150123|Experimental|5 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (5 µg) without any adjuvant
3069790|NCT01150123|Experimental|20 µg_No Adj|Subjects received either 1 or 2 doses of active vaccine (20 µg) without any adjuvant.
3069791|NCT01150123|Experimental|5 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
3069792|NCT01150123|Experimental|20 µg_Alum|Subjects received either 1 or 2 doses of active vaccine (5 µg) with Alum adjuvant.
3069793|NCT01150123|Experimental|5 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 4.87 mg of MF59
3069794|NCT01150123|Experimental|20 µg_MF59-H|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 4.87 mg of MF59
3069795|NCT01150123|Experimental|5 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (5 µg) adjuvanted with 9.75 mg of MF59
3069796|NCT01150123|Experimental|20 µg_MF59-F|Subjects received either 1 or 2 doses of active vaccine (20 µg) adjuvanted with 9.75 mg of MF59
3069797|NCT01150123|Placebo Comparator|Placebo|Subjects received 2 injections of placebo administered 1 month apart
3069798|NCT01150357|Experimental|Low Dose Aliskiren|Participants received body-weight stratified dose of aliskiren capsules (6.25/12.5/25 mg) once daily. Participants whose body weight ≥ 20 kilogram (kg) to less than < 50 kg received 6.25 mg; ≥50 kg and < 80 kg received 12.5 mg and ≥ 80 kg and ≤ 150 kg received 25 mg of aliskiren.
3069799|NCT01150357|Experimental|Mid dose|Participants received body-weight stratified dose of aliskiren capsules (37.5/75/150 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 37.5 mg; ≥50 kg and < 80 kg received 75 mg and ≥ 80 kg and ≤ 150 kg received 150 mg of aliskiren.
3069800|NCT01150357|Experimental|High dose|Participants received body-weight stratified dose of aliskiren capsules (150/300/600 mg) once daily. Participants whose body weight ≥ 20 kg to < 50 kg received 150 mg; ≥50 kg and < 80 kg received 300 mg and ≥ 80 kg and ≤ 150 kg received 600 mg of aliskiren.
3069801|NCT01150461|Experimental|losartan|Losartan 50 mg b.i.d.
3069802|NCT01150461|Placebo Comparator|placebo|Placebo b.i.d.
3069803|NCT01150474|Experimental|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
3069804|NCT01150474|Placebo Comparator|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
3069805|NCT01150500|Experimental|Drug Eluting Stent|Up to two lesions in two separate target vessels may be treated under this protocol. The lesions should be amenable to treatment with at least one 2.25 mm stent, a second lesion could be treated with any stent from 2.25 to 3.5 mm.
3069806|NCT01150760||Alvimopan Users|
3069807|NCT01150760||Matched controls|
3069808|NCT01150838|Experimental|Propofol administration|"For each of the 6 groups, propofol 2 mg/kg will be administered to first subject. The propofol dose will move separately for each of the 6 groups, and be increased by 0.3 mg/kg for the next subject if intubation score is not excellent and decreased by 0.3 mg/kg if intubation score is excellent. This dosing scheme will be continued until there are 6 crossovers as described above."
3069809|NCT01150903||PDE5 inhibitor prescription|
3069810|NCT01150903||Age-matched Control|
3069811|NCT01150981|Experimental|Rosiglitazone|One 8mg capsule daily for 6 weeks.
3069812|NCT01150981|Placebo Comparator|Placebo|One capsule daily for 6 weeks.
3069813|NCT01151020|Experimental|Arm 1|Zenith® TX2® Low Profile TAA Endovascular Graft (Thoracic Aortic Aneurysm)
3069814|NCT01151046|Experimental|MM-121 (SAR256212) + exemestane|
3069815|NCT01151046|Placebo Comparator|Placebo + exemestane|
3069816|NCT01151085||Voriconazole|Subjects who are treated with voriconazole
3069817|NCT01151098|Experimental|BTDS 5, 10 or 20|Buprenorphine transdermal patch
3069818|NCT01151137|Experimental|Dronedarone|Dronedarone 400 mg twice a day until the CSED
3069819|NCT01151137|Placebo Comparator|placebo|Placebo (for Dronedarone) twice a day until the CSED
3069820|NCT01151189|Placebo Comparator|Placebo|The placebo is a licensed product manufactured by Allermed, Inc. and is used for evaluation of delayed-type of hypersensitivity reactions in adults.
3069821|NCT01151189|Experimental|MVA85A/AERAS-485|MVA85A/AERAS-485 is a recombinant modified vaccinia virus Ankara expressing the M. tuberculosis antigen, Ag85A. Dosage of the study vaccine to be administered will be 1x10^8 pfu.
3069822|NCT01151215|Experimental|1|AZD8931 40mg (bd) plus anastrozole 1mg (od)
3069823|NCT01151215|Experimental|2|AZD8931 20mg (bd) plus anastrozole 1mg (od)
3069824|NCT01151215|Placebo Comparator|3|Placebo (bd) plus anastrozole 1mg (od)
3069825|NCT01151280|Experimental|WallFlex Biliary Fully Covered Stent|All eligible patients entered into the study will be treated with a WallFlex Biliary Fully Covered Stent
3069826|NCT01151345|Experimental|diltiazem|
3069827|NCT01151371|Experimental|narafilcon B daily disposable 4 weeks|narafilcon B soft contact lenses worn daily on a daily disposable/replacement schedule, for 4 weeks
3069828|NCT01151371|Active Comparator|nelfilcon A daily disponsable 1 week|nelfilcon A soft contact lenses worn daily on a daily disposable/replacement schedule, for 1 week
3069829|NCT01151371|Active Comparator|lotrafilcon B daily wear, monthly replacement, 4-weeks|lotrafilcon B soft contact lenses worn daily on a 1-month replacement schedule, for 4 weeks
3069830|NCT01151410|Experimental|Aliskiren|Patients will receive one of the following doses based on the their weight: Low weight (≥20 to <50 kg) patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg Mid weight (≥50 to <80 kg) patients: Starting dose 75 mg with optional titration to 150 and then 300 mg High weight (≥80 to ≤150 kg) patients: Starting dose 150 mg with optional titration to 300 and then 600 mg
3069831|NCT01151410|Active Comparator|Enalapril|Patients will receive one of the following doses based on their weight: Low weight (≥20 to <50 kg) patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg Mid weight (≥50 to <80 kg) patients: Starting dose 5 mg with optional titration to 10 and then 20 mg High weight (≥80 to ≤150 kg) patients: Starting dose 10 mg with optional titration to 20 and then 40 mg
3069832|NCT01151423|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
3069833|NCT01151423|Placebo Comparator|Placebo|Placebo once daily
3069834|NCT01151436|Experimental|hyaluronic acid|
3069835|NCT01151449|Experimental|Treatment (gamma-secretase/Notch signalling pathway inhibitor)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3069836|NCT01151540|Experimental|Rufinamide|Ralfinamide was administered orally twice daily after breakfast and dinner. Participants on placebo in Study 304 were titrated over to rufinamide within 2 weeks during the Conversion Period. As a general rule, the dose of rufinamide at the end of the Conversion Period was maintained throughout the Maintenance Period.
3069837|NCT01151579|Active Comparator|Levalbuterol 0.63|Patients received an initial dose of levalbuterol 0.63 mg alternating with albuterol 2.5 mg.
3069838|NCT01151579|Active Comparator|Levalbuterol 1.25|Patients received an initial dose of levalbuterol 1.25 mg alternating with albuterol 2.5 mg.
3069839|NCT01151618|Experimental|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
3069840|NCT01151761|Experimental|SBRT, Chemo and Liver Transplantation|The patients received Stereotactic Body Radiotherapy and Chemotherapy followed by a liver transplantation. The chemo could be any combination of the following: Gemcitabine, Cisplatin, Carboplatin, Capecitabine and 5FU
3069841|NCT01151813|Active Comparator|Varenicline|Varenicline, oral administration for 1 week
3069842|NCT01151813|Placebo Comparator|Placebo|Placebo, oral administration for 1 week
3069843|NCT01151852|Experimental|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
3069844|NCT01151852|Placebo Comparator|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
3069845|NCT01152021|Active Comparator|Dexmedetomidine Group|Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
3069846|NCT01152021|Active Comparator|Propofol Group|Propofol bolus at an initial dose of 1 mg/kg over 1 minute then up to two additional 1 mg/kg boluses may be administered (total 3 mg/kg) - each over a one (1) minute interval, waiting 30 seconds after completion of each bolus to reassess sedation level. Once a minimum Ramsey Sedation Score 4 is achieved, an infusion at 125 mcg/kg/min is initiated. It may be titrated to 300 mcg/kg/min. If there is movement or awakening the patient may be rebolused with no more than 2 doses of Propofol at 1 mg/kg over 1 minute, in the same dosing manner as described above, waiting 30 seconds between doses. If adequate sedation is not achieved, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg.
3069847|NCT01152112|Experimental|Treatment, Office Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in an office setting
3069848|NCT01152112|Experimental|Treatment, Hospital Setting, myomectomy|Myomectomy for uterine polyps and/or fibroids occurring in a hospital setting
3069849|NCT01152190|Experimental|5 milligrams (mg) Tadalafil|
3069850|NCT01152190|Placebo Comparator|Placebo|
3069851|NCT01152294|No Intervention|Control|Group not receiving the decision aid (DVD and booklet)
3069852|NCT01152294|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
3069853|NCT01152307|Experimental|Decision Aid|Group receiving the decision aid (DVD/booklet)
3069854|NCT01152307|No Intervention|Control|Group not receiving the decision aid (DVD/booklet)
3069855|NCT01152359|Experimental|Arm 1|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
3069856|NCT01152359|Active Comparator|Arm 2|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
3069857|NCT01152385|Experimental|high|AZD1656 titration 40 - 80 - 140 - 200 mg (daily dose)
3069858|NCT01152385|Experimental|Middle|AZD1656 titration 20 - 40 - 80 - 140 mg (daily dose)
3069859|NCT01152385|Experimental|low|AZD1656 titration 10 - 20 - 40 - 80 mg (daily dose)
3069860|NCT01152385|Placebo Comparator|4|
3069861|NCT01152437|Experimental|BIBW 2992|Patients receive BIBW 2992 tablets once daily
3069862|NCT01152437|Active Comparator|Cetuximab|Patients receive cetuximab intravenously once a week, every week
3069863|NCT01152450|Experimental|Tiotropium daily dose q.d.|two actuations delivered via Respimat® inhaler
3069864|NCT01152450|Experimental|Tiotropium half daily dose b.i.d.|two actuations delivered via Respimat® inhaler
3069865|NCT01152450|Placebo Comparator|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
3069866|NCT01152515|No Intervention|Control|stopping of propofol and remifentanil infusion
3069867|NCT01152515|Active Comparator|Remifentanil|stopping of propofol and maintenance of remifentanil infusion
3069868|NCT01152554|Experimental|SSRI/Serotonin/SNRI + TC-5214 1-4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214 1-4 mg BID
3069869|NCT01152554|Placebo Comparator|SSRI/Serotonin/SNRI + placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + placebo BID
3069870|NCT01152580|Placebo Comparator|Sugar pill|
3069871|NCT01152580|Active Comparator|melatonin|
3069872|NCT01152697|Experimental|Patient Noncompliance|There was only one arm for this study.
3069873|NCT01152788|Active Comparator|rIL-21|
3069874|NCT01152788|Active Comparator|Dacarbazine|
3069875|NCT01152814|Experimental|Arm 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3069876|NCT01152996|Experimental|Vortioxetine|Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.
3069877|NCT01153009|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 9 weeks.
3069878|NCT01153009|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
3069879|NCT01153009|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 20 mg, encapsulated tablets, orally, once daily for 7 weeks, then placebo-matching capsules, orally, once daily for one week.
3069880|NCT01153009|Active Comparator|Duloxetine 60 mg|Duloxetine 30 mg capsules, orally, once daily for one week then duloxetine 60 mg, capsules, orally, once daily for 7 weeks, then duloxetine 30 mg capsules, once daily, for one week.
3069881|NCT01153269||HIV-infected patients with hepatitis co-infection|HIV-infected patients with co-infections of Hepatitis B or Hepatitis C
3069882|NCT01153321|Experimental|1|Oral treatment
3069883|NCT01153321|Placebo Comparator|2|Oral treatment
3069884|NCT01153347|Experimental|SSRI/Serotonin/SNRI+ TC-5214 0.5 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.5 mg BID
3069885|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 2 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 2 mg BID
3069886|NCT01153347|Experimental|SSRI/Serotonin/SNRI + TC-5214 4 mg|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
3069887|NCT01153347|Placebo Comparator|SSRI/Serotonin/SNRI + Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3069888|NCT01153425|Active Comparator|Teriparatide (Forteo)|20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months.
3069889|NCT01153425|Active Comparator|Zoledronic Acid (Reclast)|5 mg of zoledronic Acid will be administered intravenously at baseline and 12 months and an MRI at 3T ('Virtual Bone Biopsy) will be performed at 0 and 12 months.
3069890|NCT01153503|Active Comparator|Ketorolac 30 mg, IV + TAP block|"Ketorolac 30 mg, IV + Bilateral ultrasound-guided TAP blocks at the end of the surgery~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3069891|NCT01153503|Active Comparator|TAP block|"Intraoperative (at the end of surgery): Bilateral ultrasound-guided TAP block at the end of the surgery~First 24-h Postoperative: IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3069892|NCT01153503|No Intervention|Ketorolac 30 mg|"Intraoperative (at the end of surgery): Ketorolac 30 mg, IV at the end of the surgery.~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h +IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
3069893|NCT01153581|Experimental|Ganirelix acetate|Subjects were given 250 μg in 0.5ml normal saline for 16 days. (Organon, Roseland, NJ, USA)
3069894|NCT01153581|Experimental|17β-Oestradiol, E2|The same women added 17β-Oestradiol, E2; 0.2 mg day-1 patch (Vivelle; CIBA Pharmaceuticals, Summit, NJ) for days 4-16.
3069895|NCT01153581|Experimental|Progesterone|The same women added progesterone (P4, 200 mg day-1 Prometrium, oral, Solvay Pharmaceuticals, Marietta, GA, USA) on days 13-16.
3069896|NCT01153620|Placebo Comparator|Ringer's Solution|
3069897|NCT01153620|Active Comparator|Lavasept 0.04%|
3069898|NCT01153633|Active Comparator|Prontosan Wound Solution and Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
3069899|NCT01153633|Placebo Comparator|Normal Saline and Placebo Gel|Cleansing the wound bed, a sterile gauze dressing impregnated with the Prontosan® or saline solution, removed after 15 minutes; wound will be sparingly covered with Prontosan® Wound Gel or inactive gel. Secondary dressing to be a semi occlusive dressing. Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day)
3069900|NCT01153672|Experimental|Treatment (enzyme inhibitor therapy, AI sensitization therapy)|Patients receive vorinostat PO QD for 2 weeks followed by AI therapy comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3069901|NCT01153685|Experimental|Fluviral A Group|Subjects aged between 18 and 60 years who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
3069902|NCT01153685|Experimental|Fluviral B Group|Subjects over 60 years of age who received one dose of Fluviral vaccine at Day 0, administered intramuscularly in the deltoid region of the non-dominant arm.
3069903|NCT01153698||patients after hip or knee replacement|
3069904|NCT01153711|Experimental|BI 1744 10 mcg|solution for oral inhalation
3069905|NCT01153711|Experimental|Ketoconazole 400 mg|tablet
3069906|NCT01153724|Experimental|Olodaterol|
3069907|NCT01153724|Experimental|Olodaterol + Fluconazole|
3069908|NCT01153763|Other|All patients|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
3069909|NCT01153815|Placebo Comparator|placebo|Sodium chloride
3069910|NCT01153815|Experimental|GSK1358820(Botulinum Toxin Type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
3069911|NCT01153841|Experimental|Synflorix Group|Subjects receiving Synflorix™(GSK 1024850A) co-administered along with Infanrix hexa™.
3069912|NCT01153841|Active Comparator|Control Group|Subjects receiving Infanrix hexa™ vaccine alone.
3069913|NCT01153893|Experimental|Synflorix/Infanrix primed Group|Subjects previously primed with the Synflorix™ vaccine in the primary study 110521 (NCT00678301) received a booster dose of the Synflorix™ vaccine co-administered with a booster dose of the Infanrix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
3069914|NCT01153893|Experimental|Synflorix/Infanrix unprimed Group|Unprimed subjects from the primary study 110521 (NCT00678301), not previously vaccinated with any pneumococcal vaccine, received a 2-dose catch-up vaccination of Synflorix™ vaccine at 15-21 and 17-23 months of age and a booster dose of Infanrix™ vaccine co-administered with the first dose of Synflorix™ vaccine at 15-21 months of age. Synflorix™ vaccine was administered intramuscularly in the right thigh or deltoid muscle of the arm. Infanrix™ vaccine was administered intramuscularly in the left thigh or deltoid muscle of the arm.
3069915|NCT01153958|Experimental|Colposeptine (A)|
3069916|NCT01153958|Active Comparator|Metronidazole (B)|
3069917|NCT01153971|Experimental|1|
3069918|NCT01153984|Experimental|Erlotinib|Participants will receive 150 milligrams (mg) erlotinib orally daily until disease progression, unacceptable toxicity, withdrawal due to any reason or death.
3069919|NCT01154010|Active Comparator|Active Device|"ActiPatch, a device that emits a low frequency energy called pulsed electromagnetic field (PEMF), will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids."
3069920|NCT01154010|Placebo Comparator|Placebo Device|Patients wear the PEMF placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
3069921|NCT01154036|Experimental|Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg|Co-administration of EZ 10 mg tablet + Atorva 10 mg tablet; once daily for 6 weeks
3069922|NCT01154036|Active Comparator|Phase I: Atorvastatin 20 mg|Atorvastatin 20 mg tablet once daily for 6 weeks
3069923|NCT01154036|Active Comparator|Phase I: Rosuvastatin 10 mg|Rosuvastatin 10 mg tablet once daily for 6 weeks
3069924|NCT01154036|Experimental|Phase II: EZ 10mg+Atorva 10mg|Participants who had previously received EZ 10 mg + Atorva 10 mg in Phase I and continued on EZ 10 mg + Atorva 10 mg once daily for 6 weeks during Phase II regardless of whether or not LDL-C goals were achieved in Phase I
3069925|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [A]|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched to EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
3069926|NCT01154036|Active Comparator|Phase II: Atorva 40mg|Participants who had previously received Atorva 20 mg in Phase I and did not reach LDL-C goal and were switched Atorva 40 mg once daily for 6 weeks in Phase II
3069927|NCT01154036|Experimental|Phase II: EZ 10mg + Atorva 20mg [R]|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and received EZ 10 mg + Atorva 20 mg once daily for 6 weeks in Phase II
3069928|NCT01154036|Active Comparator|Phase II: Rosuvastatin 20mg|Participants who had previously received Rosuvastatin 10 mg in Phase I and did not reach LDL-C goal and were switched to Rosuvastatin 20 mg once daily for 6 weeks in Phase
3069929|NCT01154088|Experimental|Group A|
3069930|NCT01154088|Experimental|Group B|
3069931|NCT01154088|Active Comparator|Group C|
3069932|NCT01154101|Active Comparator|Cohort 2 - 500mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 2 will commence after Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 2 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
3069933|NCT01154101|Active Comparator|Cohort 3 - 1000mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 3 will commence after Cohort 2 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee.~Cohort 3 will be administered four SRT2104 capsules at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff."
3069934|NCT01154101|Active Comparator|Cohort 1 - 250mg SRT2104/placebo dose group|"10 subjects will be randomized 4:1 (SRT2104: placebo) in each of 3 treatment arms (250mg, 500mg, or 1000mg).~Cohort 1 will be administered at approximately the same time every day, approximately 15 minutes following the consumption of food. Subjects must wait at least 1 hour after dosing before consuming additional calories. Dietary recommendations for the meal that precedes dosing will be provided to the study subjects by the clinical site staff.~Dosing for Cohort 2 will not commence until Cohort 1 has completed 28 consecutive days of dosing, followed by the completion of a safety review by an Independent Safety Review Committee."
3069935|NCT01154127|Experimental|NVA237 followed by Placebo|"Period 1: 50 μg NVA237 via NEOHALER inhaler device for 21 days~Period 2: Matching placebo via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
3320932|NCT02014831|Experimental|Cetuximab + TIP|"Experimental arm: Patients will be treated with 6 cycles of Paclitaxel + Ifosfamide + Cisplatin (TIP treatment) and weekly infusion of Cetuximab."
3069936|NCT01154127|Experimental|Placebo followed by NVA237|"Period 1: Matching placebo of NVA237 via NEOHALER inhaler device for 21 days~Period 2: 50 μg NVA237 via NEOHALER inhaler device for 21 days~The washout period ran for 14 to 28 days between treatment periods. Daily inhaled corticosteroid treatment (if applicable) was allowed to remain stable throughout the study.~Salbutamol (albuterol) was used as rescue medication throughout the study."
3069937|NCT01154140|Experimental|A|
3069938|NCT01154140|Active Comparator|B|
3069939|NCT01154153|Placebo Comparator|Placebo|"placebo during the screening phase and~placebo during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
3069940|NCT01154153|Experimental|TAA-AQ|"placebo during the screening phase and~TAA-AQ (Nasacort AQ) during the treatment phase.~All children had the option to take rescue medication, (Claritin®) as needed to relieve symptoms of AR."
3069941|NCT01154166|Experimental|ReQuip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
3069942|NCT01154166|Placebo Comparator|Placebo|Placebo
3069943|NCT01154192|Experimental|PCOS group|Intervention: Each subject in the PCOS group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
3069944|NCT01154192|Experimental|Normal group|Intervention: Each subject in the Normal group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
3069945|NCT01154192|Experimental|Oligomenorrhea group|Intervention: Each subject in the Oligomenorrhea group will receive dexamethasone 1 mg orally in the evening and return the next morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will the have blood drawn at -0.5, 0, 0.5, and 24 hours after hCG injection for steroid hormone measurements.
3069946|NCT01154218|Experimental|1|"All subjects will receive four treatments in one of the indicated orders:~A-B-C-D, B-D-A-C, C-A-D-B, D-C-B-A"
3069947|NCT01154231||Nonacog Alfa (Genetical Recombination)|
3069948|NCT01154283|Active Comparator|Bi-level, standard, NIPPV|Standard NIPPV with both an inspiratory and expiratory positive airway pressure.
3069949|NCT01154283|Experimental|IPAP-only, NIPPV|NIPPV with only inspiratory positive airway pressure, no expiratory positive airway pressure
3069950|NCT01154296|Experimental|Rapid HIV Testing w/ Counseling (Group 1)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.
3069951|NCT01154296|No Intervention|Rapid HIV Testing & Information Only (Group 2)|Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.
3069952|NCT01154322|Experimental|Pediatric mask|
3069953|NCT01154335|Experimental|Dose Level 1|"combination of OSI-906 and everolimus~OSI-906: 50 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
3069954|NCT01154335|Experimental|Dose Level 2|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 10mg Daily, cycle-28 days"
3069955|NCT01154335|Experimental|Dose Level 2a|"combination of OSI-906 and everolimus~OSI-906: 100 mg Twice a Day, cycle-28 days~Everolimus: 5mg Daily, cycle-28 days"
3069956|NCT01154452|Experimental|Arm I (gamma-secretase inhibitor RO4929097)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
3069957|NCT01154452|Experimental|Arm II (vismodegib and gamma-secretase inhibitor RO4929097)|Patients receive vismodegib PO and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21.
3069958|NCT01154634|Experimental|First 5 mg, then placebo, then 16 mg, then 40 mg|period 1: AZD2516 5 mg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD2516 16 mg, period 6: washout, period 7: AZD2516 40 mg.
3069959|NCT01154634|Experimental|First 40 mg, then 16 mg, then placebo, then 5 mg|period 1: AZD2516 40 mg, period 2: washout, period 3: AZD2516 16 mg, period 4: washout, period 5: placebo, period 6: washout, period 7: AZD2516 5 mg.
3069960|NCT01154634|Experimental|First 16 mg, then 5 mg, then 40 mg, then placebo|period 1: AZD2516 16 mg, period 2: washout, period 3: AZD2516 5 mg, period 4: washout, period 5: AZD2516 40 mg, period 6: washout, period 7: placebo.
3069961|NCT01154634|Experimental|First placebo, then 40 mg, then 5 mg, then 16 mg|period 1: placebo, period 2: washout, period 3: AZD2516 40 mg, period 4: washout, period 5: AZD2516 5 mg, period 6: washout, period 7: AZD2516 16 mg
3069962|NCT01154673|Experimental|Intensive HAART|"Patients in this arm will receive the following HAART regimen:~Raltegravir 400 mg BID + Maraviroc 150mg BID + emtricitabine 200mg /tenofovir 300mg QD + lopinavir 400 mg/ritonavir 100mg BID for 96 weeks"
3069963|NCT01154673|Placebo Comparator|Placebo Arm|Placebo (in place of raltegravir and maraviroc) will be added to standard HAART (Emtricitabine 200mg /tenofovir 300mg QD + Lopinavir 400 mg/ritonavir 100mg BID) for 48 weeks and then offered open label Raltegravir and Maraviroc after 48 weeks
3069964|NCT01154699|Experimental|Usual Care first, then Bilevel PAP|"Subjects will begin the study by continuing their usual care for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period. After a Washout Period of an additional 4 weeks of usual care, they will then start Bilevel PAP therapy for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests."
3069965|NCT01154699|Experimental|Bilevel PAP first, then Usual Care|"Subjects will begin the study by starting on Bilevel PAP for 4 weeks. Just before and after the Bilevel PAP they will complete questionnaires and breathing tests. After a 4 week Washout Period of usual care, they will start a Usual Care period for 4 weeks. They will complete questionnaires and breathing tests at the start and end of this 4 week period."
3069966|NCT01154751|Other|Device SUPERA Stent|SUPERA Interwoven Self-Expanding Nitinol Stent System
3069967|NCT01154816|Experimental|Arm I (neuroblastoma- measurable)|Patients with measurable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069968|NCT01154816|Experimental|Arm II (Neuroblastoma- MIBG evaluable)|Patients MIBG evaluable neuroblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069969|NCT01154816|Experimental|Arm III (rhabdomyosarcoma)|Patients with rhabdomyosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069970|NCT01154816|Experimental|Arm IV (osteosarcoma)|Patients with osteosarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069971|NCT01154816|Experimental|Arm V (Ewing sarcoma/peripheral PNET)|Patients with Ewing sarcoma/peripheral PNET receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069972|NCT01154816|Experimental|Arm VI (non-RMS soft tissue sarcoma)|Patients with non-RMS soft tissue sarcoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069973|NCT01154816|Experimental|Arm VII (hepatoblastoma)|Patients hepatoblastoma receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069974|NCT01154816|Experimental|Arm VIII (malignant germ cell tumor)|Patients with malignant germ cell tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069975|NCT01154816|Experimental|Arm IX (Wilms tumor)|Patients with Wilms tumor receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069976|NCT01154816|Experimental|Arm X (acute lymphoblastic leukemia)|Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069977|NCT01154816|Experimental|Arm XI (acute myelogenous leukemia)|Patients acute myelogenous leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069978|NCT01154816|Experimental|Arm XII (rhabdoid malignancy)|Patients with rhabdoid malignancy receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3069979|NCT01154985|Placebo Comparator|Placebo|3x placebo capsules TID
3069980|NCT01154985|Experimental|EPA-E 1800 mg/day|2x EPA-E 300 mg capsules + 1placebo capsule TID
3069981|NCT01154985|Experimental|EPA-E 2700 mg/day|3x EPA-E 300 mg capsules TID
3069982|NCT01155011|Experimental|MIPARC intervention|"Eleven Continuing Care Retirement Communities were randomized to either the MIPARC intervention or an attention-control condition. The intervention focused on increasing light to moderate PA.~The MIPARC study intervenes on four levels: individual (pedometer self monitoring, educational materials and monthly counseling calls, support), interpersonal (monthly group educational sessions and peer mentoring), environment (walking signage prompts, tailored environmental resources, step counts)and policies (review of on-site activity opportunities and walkability, recommendations for policy change and peer led advocacy)to increase the activity levels of residents.~For the first 3 months, intervention participants will engage in either a group educational session, phone counseling call, or a peer led session, on a rotating basis."
3069983|NCT01155011|Active Comparator|Health Education Control|The control group received an active health education intervention. The education curriculum will involve both lectures and mailed materials. The lectures were delivered to match the MIPARC intervention schedule. Sessions included information on general health and healthy aging. Physical activity was not discussed in these sessions but participants received information on the benefits of PA. Control participants also received health check phone calls to match the individual attention paid to participants in the MIPARC intervention sites.
3069984|NCT01155024|Other|Traditional Socket First, then DM Socket|Initial fitting of a traditional diagnostic prosthetic socket in first intervention period and initial fitting of a direct manufactured prosthetic socket in the second intervention period
3069985|NCT01155024|Other|DM Socket First, then Traditional Socket|Initial fitting of a direct manufactured prosthetic socket in first intervention period and initial fitting of a traditional diagnostic prosthetic socket in the second intervention period
3069986|NCT01155050|Active Comparator|Tele-health Home Monitoring|Participants will use the tele-health monitoring equipment to measure daily weight.
3069987|NCT01155050|No Intervention|Self-Directed Group|Participants will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss.
3069988|NCT01155050|Active Comparator|TrestleTree Telephone Coaching|Participants will speak to Trestletree health coaches for 15 to 60 minutes each session. During these sessions, the coaches will identify the participant's stage of change and intervene accordingly. The telephone calls will be centered on weight loss.
3069989|NCT01155050|Active Comparator|Home monitoring + telephone coach|System to track stage of change in weight loss.
3069990|NCT01155063||Main Group|Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer Who Are Disease-Free After 2-3 Years Of Initial Adjuvant Tamoxifen Therapy
3069991|NCT01155141|Experimental|No arms|There are no arms to this study. All patients receive drug (H.P. Acthar Gel)
3069992|NCT01155154|Active Comparator|clindamycin|clindamycin 300 mg (two 150 mg capsules) every 6 hours for 7 days
3069993|NCT01155154|Active Comparator|cepahlexin|
3069994|NCT01155154|Placebo Comparator|Placebo|
3069995|NCT01155167|Placebo Comparator|Placebo|
3069996|NCT01155167|Experimental|Topical dilator|
3069997|NCT01155180|Experimental|Leptin|We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
3069998|NCT01155180|Placebo Comparator|Placebo|We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
3069999|NCT01155193||Palivizumab|Participants were prescribed palivizumab (Synagis®) prophylaxis according to the German summary of product characteristics (SPC) for Synagis® to prevent serious disease due to RSV infection during the RSV season.
3320933|NCT02014844|Experimental|aldoxorubicin|Subjects will receive either 250 mg/m2 or 350 mg/m2 aldoxorubicin IV.
3070000|NCT01155219|Experimental|Geltim LP®|Geltim LP® 1 mg/g (0.1 % timolol maleate, without preservative) packaged in single-dose containers (unidoses); one drop in the conjunctival sac of each eye in the morning (84 days).
3070001|NCT01155219|Active Comparator|Xalatan®|Xalatan® (Latanaprost) aqueous eye drop (one drop in the conjunctival sac of each eye in the evening during 84 days.
3070002|NCT01155284|Experimental|Sitagliptin and Lansoprazole|Sitagliptin 50mg co-administered with Lansoprazole 30mg. Subjects age 11-17 years at Visit 2 will take 1 capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 capsules of each once daily
3070003|NCT01155284|Placebo Comparator|Placebo|Sitagliptin Placebo and Lansoprazole placebo capsules will be administered. Subjects age 11-17 years at Visit 2 will take 1 placebo capsule of each once daily Subjects age 18-45 years at Visit 2 will take 2 placebo capsules of each once daily
3070004|NCT01155323|Active Comparator|etafilcon A/omafilcon A|etafilcon A contact lenses will be worn during the first week and omafilcon A contact lenses will be worn during the second. Lenses were replaced daily
3070005|NCT01155323|Active Comparator|omafilcon A/etafilcon A|omafilcon A contact lenses will be worn during the first week and etafilcon A contact lenses will be worn during the second. Lenses were replaced daily.
3070006|NCT01155336|Experimental|Lovaza®|Lovaza® is a prescription grade EPA+DHA fish oil supplement. Four capsules (each containing 1 gram of fish oil) were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
3070007|NCT01155336|Placebo Comparator|Corn Oil|The placebo contained 1 gram of corn oil in each capsule. Four capsules were taken within hours after the PCI, daily for the duration of hospitalization, and daily for 1 week until a post-discharge follow-up appointment.
3070008|NCT01155466|Experimental|Preladenant 2 mg|Preladenant 2 mg tablet + placebo to rasagiline capsule in AM and preladenant 2 mg tablet in PM for 12 weeks
3070009|NCT01155466|Experimental|Preladenant 5 mg|Preladenant 5 mg tablet + placebo to rasagiline capsule in AM and preladenant 5 mg tablet in PM for 12 weeks
3070010|NCT01155466|Experimental|Preladenant 10 mg|Preladenant 10 mg tablet + placebo to rasagiline capsule in AM and preladenant 10 mg tablet in PM for 12 weeks
3070011|NCT01155466|Placebo Comparator|Placebo|Placebo to preladenant tablet + placebo to rasagiline capsule in AM and placebo to preladenant tablet in PM for 12 weeks
3070012|NCT01155466|Active Comparator|Rasagiline 1 mg|Rasagiline 1 mg capsule + placebo to preladenant tablet in AM and placebo to preladenant tablet in PM for 12 weeks
3070013|NCT01155479|Experimental|Preladenant 2 mg|Preladenant 2 mg oral tablet and placebo for rasagiline taken in the morning (AM) followed by preladenant 2 mg oral tablet taken in the evening (PM) for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3070014|NCT01155479|Experimental|Preladenant 5 mg|Preladenant 5 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 5 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3070015|NCT01155479|Experimental|Preladenant 10 mg|Preladenant 10 mg oral tablet and placebo for rasagiline taken in the AM followed by preladenant 10 mg taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3070016|NCT01155479|Placebo Comparator|Placebo|Placebo for preladenant and placebo for rasagiline taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1); preladenant 5 mg was taken twice daily for 26 weeks (Part 2).
3070017|NCT01155479|Active Comparator|Rasagiline|Rasagiline 1 mg oral capsule and placebo for preladenant taken in the AM followed by placebo for preladenant taken in the PM for 26 weeks (Part 1) and then for another 26 weeks (Part 2).
3070018|NCT01155531|Experimental|Telenzepine - Group A|Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine
3070019|NCT01155531|Experimental|Sertraline plus Telenzepine - Group B|Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3070020|NCT01155531|Experimental|Sertraline plus Telenzepine - Group C|Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3070021|NCT01155531|Experimental|Sertraline plus Telenzepine - Group D|Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine
3070022|NCT01155570||Humira|Humira 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 80 mg.
3070023|NCT01155583|Experimental|Arm A - Azacitidine/Lenalidomide/Dexamethasone|"Dose Level (DL) 1 - Azacitidine 30mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 40mg/m2 1x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 3 - Azacitidine 30mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 4 - Azacitidine 40mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 5 - Azacitidine 50mg/m2 2x week + Lenalidomide 25mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR > 60 ml/min) receive azacitidine subcutaneously 1 or 2x per weekly and oral Dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
3070024|NCT01155583|Experimental|Arm B - Chronic Kidney Disease (CDK) Cohort|"DL (-1) - Azacitidine 30mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 1 - Azacitidine 40mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~DL 2 - Azacitidine 50mg/m2 2x week + Lenalidomide 10mg d1-21 every 28d + Dexamethasone 40mg once a week~Patients (with GFR 30-59 ml/min Chronic Kidney Disease (CKD)) receive azacitidine subcutaneously 1 or 2x per weekly and oral dexamethasone 1x weekly starting on day 1. Patients receive oral lenalidomide 1x daily on days 1-21. Treatment repeats every 28 days for 6 courses. Patients then continue to receive lenalidomide as maintenance therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
3070025|NCT01155661|Experimental|LY2216684 (edivoxetine) + SSRI|
3070026|NCT01155726|Active Comparator|Nelfilcon A, Masked, Unmasked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3070027|NCT01155726|Active Comparator|Nelfilcon A, Masked, Partially Masked|Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3070028|NCT01155726|Active Comparator|Etafilcon A, Masked, Unmasked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3070029|NCT01155726|Active Comparator|Etafilcon A, Masked, Partially Masked|Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.
3070030|NCT01155778|Experimental|10 mg rhHNS|10 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
3070031|NCT01155778|Experimental|45 mg rhHNS|45 mg monthly via an IDDD (every 28 [±7 days]) for a total of 6 months
3070032|NCT01155778|Experimental|90 mg rhHNS|Given IDDD as a 45 mg dose every 14 [±2 days] for a monthly total of 90 mg for 6 months
3070033|NCT01155830||Infants with CHD|Infants with Congenital Diaphragmatic Hernia (CHD)
3070034|NCT01155830||Infants with sepsis|Infants who are culture positive for sepsis and require vasopressor support
3070035|NCT01155830||Infants treated with ECMO|Infants suffering cardiopulmonary failure significant enough to require heart/lung bypass treatment with extracorporeal membrane oxygenation (ECMO)
3070036|NCT01155869|Experimental|XR-NTX|Depot naltrexone (Vivitrol) 380 mg. IM monthly
3070037|NCT01155869|Active Comparator|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
3070038|NCT01155999|Experimental|T1225|
3070039|NCT01155999|Active Comparator|Tobramycin|
3070040|NCT01156012|Experimental|T2345|One drop of T2345
3070041|NCT01156012|Active Comparator|Prostaglandin|One drop
3070042|NCT01156051|Experimental|Guanfacine Extended-Release Tablets|Guanfacine Extended-Release Tablets 1mg, 2mg, 3mg, and 4mg
3070043|NCT01156051|Placebo Comparator|Placebo comparator|Placebo control
3070044|NCT01156116|Active Comparator|Continuous positive airway pressure|2 weeks of continuous positive airway pressure (CPAP) treatment which includes wearing the CPAP mask for 8 hours each night
3070045|NCT01156116|Placebo Comparator|Placebo|2 weeks of oral administration of a placebo tablet 30min before bedtime
3070046|NCT01156142|Experimental|Arm I|Patients receive doxepin hydrochloride oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm II on day 2.
3070047|NCT01156142|Placebo Comparator|Arm II|Patients receive placebo oral rinse (swish, gargle, and spit) over 1 minute on day 1. Patients may crossover to arm I on day 2.
3070048|NCT01156311|Experimental|Glatiramer acetate (GA) and dimethyl fumarate|Participants taking a stable dose of GA for at least 12 months prior to the study remain on that dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
3070049|NCT01156311|Experimental|Interferon beta (IFNβ) and dimethyl fumarate|Participants taking a stable dose of one of the IFNβ products for at least 12 months prior to the study remain on that product and dose throughout the study. Dimethyl fumarate is administered at 120 mg three times a day (TID) on Days 1-7, and 240 mg TID on Day 8 until the end of treatment (approximately 6 months).
3070050|NCT01156363|Experimental|Single Arm|
3070051|NCT01156376|Experimental|PO-019|Formula 12027-019 Mouthwash
3070052|NCT01156376|Experimental|PO-020|Formula 12027-020 Mouthwash
3070053|NCT01156376|Active Comparator|PO-116-A|Cool Mint Listerine
3070054|NCT01156480|Experimental|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via intravenous (IV) route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. Subjects in placebo group will receive equal volume of placebo on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
3070055|NCT01156480|Placebo Comparator|Placebo|Subjects in placebo group will receive equal volume of placebo (as compared to hydrocortisone arm) on the same dosing schedule. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
3070056|NCT01156532||Adalimumab Treatment in Participants with Psoriasis|Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.
3070057|NCT01156571|Experimental|cangrelor|"Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours.~Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered."
3070058|NCT01156571|Active Comparator|clopidogrel|"Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion.~During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm."
3070059|NCT01156597|Active Comparator|Pioglitazone Group|This is a baseline versus treatment study comparing subjects on pioglitazone to a matched group of subjects treated with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level
3070060|NCT01156597|No Intervention|Comparator Group|This group of subjects will be maintained on standard treatment with either metformin or sulfonylurea with the intent of controlling blood sugar to a comparable level as group treated with pioglitazone.
3070061|NCT01156675|Experimental|FLEXUS™ Interspinous Spacer|
3070062|NCT01156675|Active Comparator|XSTOP® Interspinous Spacer|
3320934|NCT02014857||Periodonatlly healthy smokers|Gingival crevicular fluid sampling
3320935|NCT02014857||Periodontally healhty non-smokers|Gingival crevicular fluid sampling
3070063|NCT01156701||Cohort1: Prophylaxis with untreated index|"Individuals are eligible to be included in the prophylaxis with untreated index cohort if they are at least 5 years old and have at least 6 months of continuous enrollment, and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family identifier code has had a medical visit (outpatient, inpatient or emergency room (ER) visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3070064|NCT01156701||Cohort2: Prophylaxis with treated index|"Individuals are eligible to be included in the prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034), and~Have no diagnosis of influenza (ICD-9 487.xx) on the day of Relenza dispensing or in the 3 preceding days, and~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) in the 3 days preceding or the day of the Relenza dispensing with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3070065|NCT01156701||Cohort3: No prophylaxis with untreated index|"Individuals are eligible to be included in the no prophylaxis with untreated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza (HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has not received any antiviral therapy (oseltamivir (Tamiflu), rimantadine, amantadine, and zanamivir (Relenza)) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza."
3070066|NCT01156701||Cohort4: No prophylaxis with treated index|"Individuals are eligible to be included in the no prophylaxis with treated index cohort if they are at least 5 years old, have 6 months continuous enrollment and~Have not received a dispensing of Relenza(HICL=020398 or HCPCS = G9018 or G9034) within 3 days following the date on which~A household member (index case) with the same family ID variable has had a medical visit (outpatient, inpatient or ER visit) with a diagnosis of influenza (ICD-9 487.xx), and~The household member (index case) has received zanamivir (Relenza) on the day of or the day after the index case's medical visit associated with a diagnosis of influenza"
3070067|NCT01156714|Other|Arm 1: Treadmill Training|Treadmill training with aerobic exercise
3070068|NCT01156714|Other|Arm 2: Memory Training|Memory training with computerized memory program
3070069|NCT01156714|Other|Arm 3: Treadmill and Memory Training|Combination of treadmill training and computerized memory program
3070070|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 100mg QD (AM)|FP 100mcg BID plus GSK2190915 100mg QD (AM)
3070071|NCT01156792|Experimental|FP 100mcg BID plus GSK2190915 300mg QD (AM)|FP 100mcg BID plus GSK2190915 300mg QD (AM)
3070072|NCT01156792|Active Comparator|FP 100mcg BID plus montelukast 10mg QD (PM)|FP 100mcg BID plus montelukast 10mg QD (PM)
3070073|NCT01156792|Active Comparator|FP 100mcg BID plus placebo BID|FP 100mcg BID plus placebo BID
3070074|NCT01156792|Active Comparator|FP/SAL 100/50mcg BID plus placebo BID|FP/SAL 100/50mcg BID plus placebo BID
3070075|NCT01156805|Experimental|Educational intervention, Control|Experimental, intervention group has received specific educational training to improve food habits and physical activity during the period of the study.
3070076|NCT01156805|No Intervention|Educational program|No intervention has been made.
3070077|NCT01156844|Experimental|Indacaterol 37.5 µg (twice a day)|"Indacaterol 37.5 µg twice a day (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3070078|NCT01156844|Experimental|Indacaterol 75 µg (once a day)|"Indacaterol 75 µg once a day (qd) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and Placebo to Indacaterol inhaled once daily via Concept1 in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3070079|NCT01156844|Experimental|Indacaterol 150 µg (every other day)|"Indacaterol 150 µg every other day (qod) inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for a total of 16 days. Indacaterol 150 µg inhaled via Concept1, a SDDPI, in the morning and Placebo to Indacaterol inhaled via Concept1 in the evening on odd days; and Placebo to Indacaterol inhaled via Concept1 in the morning and in the evening on even days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3070080|NCT01156844|Placebo Comparator|Placebo|"Placebo to Indacaterol twice daily (bid) inhaled via Concept1, a single dose dry powder inhaler (SDDPI), in the morning and in the evening for 16 days.~All patients had to receive daily treatment with inhaled corticosteroid up to the maximum dose per day in a stable regimen for at least 4-weeks prior to screening and remain stable through out the study. The short acting (beta) β2-agonist (SABA) salbutamol/albuterol was available for rescue use throughout the study."
3070081|NCT01156987|Experimental|Healthy Volunteers|Five healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.
3070082|NCT01156987|Experimental|Breast Cancer Patients|40 breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.
3070083|NCT01157065|Experimental|AL-78898A|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
3070084|NCT01157065|Active Comparator|Lucentis|Single 50-µL (microliter) intravitreal injection with 12 weeks follow-up
3070085|NCT01157078|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
3070086|NCT01157078|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3070087|NCT01157117|Experimental|Omalizumab/milk OIT|Participants receive blinded omalizumab injections every 2 to 4 weeks through Month 16 and unblinded omalizumab injections thereafter until the Month 28 desensitization oral food challenge (OFC). Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk OFC and discontinue omalizumab injections. If they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
3070088|NCT01157117|Placebo Comparator|Placebo for omalizumab/milk OIT|Participants receive blinded placebo for omalizumab injections every 2 to 4 weeks through Month 16; after unblinding the injections are discontinued. Participants ingest milk powder daily starting at Month 4 with a dose of 0.07 mg milk protein and escalate for 22 to 40 weeks until reaching the maintenance dose of 3.84 g milk protein (minimum required maintenance dose is 520 mg milk protein). At Month 28, participants complete a 10g milk oral food challenge (OFC); if they fail the OFC they permanently discontinue ingestion of the milk powder; if they pass the OFC they continue ingestion of the maintenance dose of milk powder through Month 30 and then discontinue it.
3070089|NCT01157117|No Intervention|Untreated control|Participants did not receive any study intervention but provided regular blood draws at specific study time points to allow mechanistic comparisons with the participants in the other two groups who did receive study intervention.
3070090|NCT01157169|Experimental|Investigational Test Product|Buprenorphine 8 mg Sublingual Tablets
3070091|NCT01157169|Active Comparator|Reference Listed Drug|Subutex® 8 mg Sublingual Tablets
3070092|NCT01157182|Experimental|Investigational Test Product|Estradiol/Norethindrone acetate 1/0.5 mg Tablets
3070093|NCT01157182|Active Comparator|Reference Listed Drug|Activella® 1/0.5 mg Tablets
3070094|NCT01157234|Active Comparator|Nebivolol|Nebivolol starting dose of 5 mg orally once daily, titrated to a maximum total daily dose of 40 mg daily to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
3070095|NCT01157234|Active Comparator|Metoprolol|Metoprolol starting dose of 25mg orally once twice daily, titrated to a maximum total daily dose of 400 mg to achieve a target blood pressure of <140/90 and continued until month-12 of the study.
3070096|NCT01157351|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months
3070097|NCT01157351|Active Comparator|002|aripiprazole flexible dosing as prescribed by the study doctor for 15 months
3070098|NCT01157351|Active Comparator|003|haloperidole flexible dosing as prescribed by the study doctor for 15 months
3070099|NCT01157351|Active Comparator|004|olanzapine flexible dosing as prescribed by the study doctor for 15 months
3070100|NCT01157351|Active Comparator|005|paliperidone flexible dosing as prescribed by the study doctor for 15 months
3070101|NCT01157351|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 15 months
3070102|NCT01157351|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 15 months
3070103|NCT01157351|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 15 months
3070104|NCT01157364|Other|bimatoprost 20 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 20 µg generation 2 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070105|NCT01157364|Other|bimatoprost 15 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070106|NCT01157364|Other|bimatoprost 10 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070107|NCT01157364|Other|bimatoprost 6 µg generation 2, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable). One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070108|NCT01157364|Other|bimatoprost 15 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070109|NCT01157364|Other|bimatoprost 10 µg generation 1, bimatoprost 0.03%|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1. One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
3070110|NCT01157377|Experimental|AGN-214868 total dose 500 ng|AGN-214868 injected into the bladder for total dose of 500 ng on Day 1.
3070111|NCT01157377|Experimental|AGN-214868 total dose 1000 ng|AGN-214868 injected into the bladder for total dose of 1000 ng on Day 1.
3070112|NCT01157377|Experimental|AGN-214868 total dose 2000 ng|AGN-214868 injected into the bladder for total dose of 2000 ng on Day 1.
3070113|NCT01157377|Experimental|AGN-214868 total dose 6000 ng|AGN-214868 injected into the bladder for total dose of 6000 ng on Day 1.
3070114|NCT01157377|Experimental|AGN-214868 total dose 18000 ng|AGN-214868 injected into the bladder for total dose of 18000 ng on Day 1.
3070115|NCT01157377|Experimental|AGN-214868 total dose 60000 ng|AGN-214868 injected into the bladder for total dose of 60000 ng on Day 1.
3070116|NCT01157377|Placebo Comparator|Placebo to AGN-214868|Placebo to AGN-214868 injected into the bladder on Day 1.
3070117|NCT01157416|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
3070118|NCT01157416|Placebo Comparator|Placebo plus CBT|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
3070119|NCT01157429|Active Comparator|D-cycloserine plus CBT|Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.
3070120|NCT01157429|Placebo Comparator|Placebo pill|Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.
3070121|NCT01157676|Active Comparator|Open cystectomy|Open cystectomy performed using an incision made just above or at the level of umbilicus to the pubic symphysis.
3070122|NCT01157676|Active Comparator|Robotic assisted radical cystectomy|Robotic assisted Radical Cystectomy (RARC) is accomplished by a robot assisted laparoscopic approach.
3070123|NCT01157845|Experimental|Laboratory assay|
3070124|NCT01157897|Experimental|Cohort 1: 15 μg VMP001|15ug VMP001 per vaccination on days -1 or 0, 28, and 84. P. vivax sporozoite challenge on day 98.
3070125|NCT01157897|Experimental|Cohort 2: 30 μg VMP001|30ug VMP001 per vaccination on days 14, 42, and 84. P. vivax sporozoite challenge on day 98.
3070126|NCT01157897|Experimental|Cohort 3: 60 μg VMP001|60ug VMP001 per vaccination on days 28, 56, and 84. P. vivax sporozoite challenge on day 98.
3070127|NCT01157897|Other|Control|No Vaccinations given for controls. P. vivax sporozoite challenge on day 98.
3070128|NCT01158118|Experimental|Arm 1 - Donor|"Days 1-5: Mobilization with 5 mcg/kg/day GM-CSF (first 4 donors were mobilized with 10 mcg/kg GM-CSF then changed to 5 mcg/kg for remaining donors)~Day 5: Mobilization with 320 mcg/kg plerixafor IV~Day 5: Leukopheresis~If PBSC collected are not adequate, then donor will be mobilized with GM-CSF and plerixafor IV on day 6 and have leukopheresis collection on day 6."
3070129|NCT01158118|No Intervention|Arm 2 - Recipient|"Conditioning Regimens~fludarabine and busulfan +/- thymoglobulin~fractionated total body irradiation and cyclophosphamide~busulfan and cyclophosphamide~single dose total body irradiation and cyclophosphamide~Day -2 = GvHD prophylaxis~Day 0 or +1 = PBSC transplant~Day +7 until neutrophil engraftment = G-CSF 5 ug/kg/day"
3070130|NCT01158157|Other|Vaccination|This study was a single arm study. All eligible subjects received ACAM2000.
3070131|NCT01158222|Experimental|Arm I|Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3070132|NCT01158261||Vascular Surgery Subjects Treated with EVICEL|
3070133|NCT01158378|Active Comparator|DuraSeal Dural Sealant System|
3070134|NCT01158378|Experimental|Adherus Dural Sealant System|
3070135|NCT01158404|Experimental|LY900009|"Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
3070136|NCT01158521|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
3070137|NCT01158534|Experimental|Arm I|Patients receive oral celecoxib twice daily and recombinant interferon alpha-2b subcutaneously, once daily, 5 times a week. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3070138|NCT01158573||Healthy non-asthmatic obese adults|Healthy non-asthmatic obese adults
3070139|NCT01158573||Healthy non-asthmatic non-obese adults|Healthy non-asthmatic non-obese adults
3070140|NCT01158573||Asthmatic obese adults|Asthmatic obese adults
3070141|NCT01158573||Asthmatic non-obese adults|Asthmatic non-obese adults
3070142|NCT01158651|Experimental|RAD001 (Everolimus) Active Therapy|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
3070143|NCT01158703|Active Comparator|clopidogrel|aspirin and clopidogrel
3070144|NCT01158703|Placebo Comparator|sugar pill|aspirin and placebo
3070145|NCT01158716|Active Comparator|Remote Ischemic Preconditioning|
3070146|NCT01158716|No Intervention|Control|
3070147|NCT01158820|Placebo Comparator|Placebo|midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
3070148|NCT01158820|Active Comparator|dexmedetomidine and ketamine|dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand
3070149|NCT01158885|Experimental|Single Arm|"A maximum of two courses of the following regimen will be administered.~Clofarabine: 20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.~Cytarabine intravenous: 1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.~Methotrexate: to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age.~Intrathecal (IT) cytarabine: is optional for acute myelogenous leukemia (AML) patients."
3070150|NCT01158924|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3070151|NCT01158950|Experimental|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
3070152|NCT01158950|Placebo Comparator|Placebo|Drug: Placebo for tolcapone administered at study visit
3070153|NCT01158976|Experimental|DHA supplementation|
3070154|NCT01158976|Placebo Comparator|Soybean Oil|
3070155|NCT01159015|Experimental|KetoNaph|KetoNaph Ophthalmic Solution
3070156|NCT01159015|Placebo Comparator|Vehicle|Vehicle of KetoNaph Ophthalmic Solution
3070157|NCT01159054|Experimental|This study has only one arm.|Blood sample and scan results to be compared before and after intervention in each subject.
3070158|NCT01159067|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
3070159|NCT01159171|Experimental|1|
3070160|NCT01159262|Experimental|Dexmedetomidine 0.05 mcg/kg|Dexmedetomidine loading dose 0.05 mcg/kg; maintenance infusion: 0.05 mcg/kg/hr.
3070161|NCT01159262|Experimental|Dexmedetomidine 0.1 mcg/kg|Dexmedetomidine loading dose: 0.1 mcg/kg; maintenance infusion 0.1 mcg/kg/hr.
3070162|NCT01159262|Experimental|Dexmedetomidine 0.2 mcg/kg|Dexmedetomidine loading dose 0.2 mcg/kg; maintenance infusion 0.2 mcg/kg/hr.
3070163|NCT01159431|Experimental|Active|
3070164|NCT01159431|Other|Control|
3070165|NCT01159535|Active Comparator|MBRP|The Mindfulness Based Relapse Prevention (MBRP) intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include mindfulness practices targeting craving, Negative affect, and reactivity, as well as discussion about how to implement practice into high-risk situations and in daily life.
3070166|NCT01159535|Active Comparator|Relapse Prevention (RP)|The RP intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants). Individual sessions will be team-taught by two therapists and will include discussions of personal high-risk situations, coping skills assessment, and exercises to evaluate expectancies, self-efficacy, and craving.
3070167|NCT01159535|Active Comparator|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
3070168|NCT01159574|Experimental|all patients|"ClaPd therapy:~Dexamethasone (40mg ) will be given on days 1, 8, 15, 22 of a 28-day cycle. Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle.~Pomalidomide will be given 4mg daily for days 1-21 of each 28 day cycle. Dosing will be in the morning at approximately the same time each day."
3070169|NCT01159600|Experimental|BI 10773 Arm 2|BI 10773 once daily high dose
3070170|NCT01159600|Placebo Comparator|Placebo|Placebo matching BI 10773
3070171|NCT01159600|Experimental|BI 10773 open-label|BI 10773 once daily high dose open label
3070172|NCT01159600|Experimental|BI 10773 Arm 1|BI 10773 once daily low dose
3070173|NCT01159665|Experimental|PPV 5-30 minutes after injection|Primary Pars Plana Vitrectomy 5 to 30 minutes after 125µg of ocriplasmin intravitreal injection
3070174|NCT01159665|Experimental|PPV 31-60 minutes after injection|Primary Pars Plana Vitrectomy 31 to 60 minutes after 125µg of ocriplasmin intravitreal injection
3070175|NCT01159665|Experimental|PPV 2-4 hours after injection|Primary Pars Plana Vitrectomy 2 to 4 hours after 125µg of ocriplasmin intravitreal injection
3070176|NCT01159665|Experimental|PPV 24 hours (+2 hours) after injection|Primary Pars Plana Vitrectomy 24 hours (+2 hours)after 125µg of ocriplasmin intravitreal injection
3070177|NCT01159665|Experimental|PPV 7 days (+1 day) after injection|Primary Pars Plana Vitrectomy 7 days (+1 day)after 125µg of ocriplasmin intravitreal injection
3070178|NCT01159665|No Intervention|PPV without injection|Control Arm, no ocriplasmin intravitreal injection
3070179|NCT01159691||Neupro|Routine treatment as per approved label in Europe/ in accordance with the terms of the local marketing authorization for Neupro® transdermal patch.
3070180|NCT01159743||Efavirenz|HIV-infected patients on initial antiretroviral therapy for at least two years with efavirenz (Sustiva®; EFV) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
3070181|NCT01159743||Lopinavir / Ritonavir|HIV-infected patients on initial antiretroviral therapy for at least two years with lopinavir/ritonavir (Kaletra®; LPV/r) with a combination of tenofovir (TDF) plus emtricitabine (FTC) or lamivudine (3TC).
3070182|NCT01159769|Experimental|Olopatadine 0.2%|1 drop self-administered in each eye once daily in the morning for 7 days
3070183|NCT01159912|Experimental|Fluticasone Furoate OD and Placebo BID|Fluticasone furoate inhalation powder once daily and placebo inhalation powder twice daily for 24 weeks
3070184|NCT01159912|Active Comparator|Fluticasone Propionate BID and Placebo OD|Fluticasone propionate inhalation powder twice daily and placebo inhalation powder once daily for 24 weeks
3070185|NCT01159912|Placebo Comparator|Placebo only BID|Placebo inhalation powder twice daily for 24 weeks
3070186|NCT01159938|Experimental|T2DM, albuminuria but normal kidney function|
3070187|NCT01159938|No Intervention|Healthy participants|
3070188|NCT01159938|Experimental|T2DM, normal urinary albumin excretion rate (UAER)|
3070189|NCT01160198|Experimental|ferrous bisglycinate chelate 1 OD|ferrous bisglycinate chelate 1 tablet daily
3070190|NCT01160198|Active Comparator|ferrous ascorbate|ferrous ascorbate, 1 tablet daily
3070191|NCT01160198|Experimental|ferrous bisglycinate chelate 2 OD|ferrous bisglycinate chelate 2 tablets daily
3070192|NCT01160211|Experimental|Lapatinib plus trastuzumab plus aromatase inhibitor|Experimental
3070193|NCT01160211|Active Comparator|trastuzmab plus aromatase inhibitor|Active Comparator
3070194|NCT01160211|Active Comparator|lapatinib plus aromatase inhibitor|Active Comparator
3070195|NCT01160237|Experimental|Group A|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
3070196|NCT01160237|Experimental|Group B|Subjects previously vaccinated with a vaccine against the pandemic H1N1 strain
3070197|NCT01160237|Active Comparator|Group C|Subjects not previously vaccinated with a vaccine against the pandemic H1N1 strain
3070198|NCT01160289|Experimental|1 milligram (mg) LY2452473 + 5 mg tadalafil|
3070199|NCT01160289|Experimental|5 mg LY2452473 + 5 mg tadalafil|
3070200|NCT01160289|Experimental|5 mg LY2452473 + placebo|
3070201|NCT01160289|Active Comparator|10 mg tadalafil + placebo|
3070202|NCT01160289|Active Comparator|5 mg tadalafil + placebo|
3070203|NCT01160354|Experimental|Plerixafor 240 mcg/kg + Clofarabine|"Plerixafor 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before hour IV administration of Clofarabine fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).~Phase II: Plerixafor at the highest dose tolerated in Phase I.~Plerixafor was dose-escalated in a 3+3 design, starting at 240 mcg/kg, and proceeding to dose levels of 320 mcg/kg, and 400 mcg/kg."
3070204|NCT01160380|Experimental|Armodafinil|The patients receive armodafinil for all 56 days of the study.
3070205|NCT01160380|Placebo Comparator|Placebo-First|These patients receive a placebo for the first 28 days of the study. They are then crossed over and receive armodafinil for the final 28 days of the study (days 29-56).
3070206|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Melanoma|"Patients with metastatic melanoma Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
3070207|NCT01160445|Experimental|HD IL-2 + Zanolimumab - Renal Cell|"Patients with metastatic renal cancer Zanolimumab 14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.~Aldesleukin (IL-2) 720,000 IU/kg every 8 hours for a maximum of 15 doses."
3070208|NCT01160458|Experimental|IMC-A12 Monotherapy in Patients|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
3070209|NCT01160484|Experimental|DVD-R single arm|"Dose schematic of Dexamethasone + Bortezomib + Pegylated Liposomal Doxorubicin + Lenalidomide (DVD-R) Therapy:~Dexamethasone*- 40 mg IV Bortezomib**- 1.0 mg/m2 IV Push Pegylated Liposomal Doxorubicin*- 4.0 mg/m2 IV Lenalidomide***- 10 mg PO~Per 28 Day Cycle~Intravenous infusion (IV) Days 1, 4, 8 and 11 ** Intravenous push (IVP) Days 1, 4, 8 and 11 *** Per Orem (PO) Days 1-14"
3070210|NCT01160614|Experimental|ORF Tablets|ORF Tablets
3070211|NCT01160640|Placebo Comparator|Ceftriaxone/Doxycycline/Placebo Oral Cap|ceftrixone 250mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus placebo oral capsule PO bid x 14 days
3070212|NCT01160640|Active Comparator|Ceftriaxone, Doxycycline, Metronidazole|ceftriaxone 250 mg IM single dose plus doxycycline 100 mg PO bid x 14 days plus metronidazole 500 mg PO bid x 14 days
3070213|NCT01160744|Experimental|IMC-1121B + Pemetrexed + Carboplatin (AUC 6) or Cisplatin|IMC-1121B + Pemetrexed + Carboplatin [Area Under the Concentration Time Curve 6 (AUC 6)] or Cisplatin
3070214|NCT01160744|Active Comparator|Pemetrexed + Carboplatin (AUC 6) or Cisplatin|Pemetrexed + Carboplatin (AUC 6) or Cisplatin
3070215|NCT01160744|Experimental|IMC-1121B + Gemcitabine + Carboplatin (AUC 5) or Cisplatin|IMC-1121B + Gemcitabine + Carboplatin [Area Under the Concentration Time Curve 5 (AUC 5)] or Cisplatin
3070216|NCT01160744|Active Comparator|Gemcitabine + Carboplatin (AUC 5) or Cisplatin|Gemcitabine + Carboplatin (AUC 5) or Cisplatin
3070217|NCT01160770|Experimental|Clobazam|
3070218|NCT01160822|Experimental|Part A: Canakinumab|In this ascending dose part, participants received a single intra-articular injection of canakinumab. The beginning dose was 150 mg, escalating to the 300 mg dose and then to 600 mg.
3070219|NCT01160822|Placebo Comparator|Part A: Placebo|Participants received a single intra-articular injection of canakinumab-matching placebo.
3070220|NCT01160822|Experimental|Part B: Canakinumab|Participants received a single intra-articular injection of canakinumab on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
3070221|NCT01160822|Placebo Comparator|Part B: Placebo|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen matching placebo tablets orally twice daily for 12 weeks.
3070222|NCT01160822|Active Comparator|Part B: Naproxen|Participants received a single intra-articular injection of canakinumab matching placebo on Day 1 and naproxen 500mg tablets orally twice daily for 12 weeks.
3070223|NCT01160848|Other|Part 1|Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application
3070224|NCT01160848|Other|Part 2|For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)
3070225|NCT01161043|Experimental|Sensor|All subjects that wear sensors (all subjects)
3070226|NCT01161121|Experimental|Adenosine then Regadenoson|Adenosine infusion will be compared to Regadenoson for efficacy and safety/side effects. Arterial blood pressure, coronary pressure, heart rate, oxygen saturation and coronary flow, FFR, and coronary flow velocity will be assessed. Safety will be assessed by monitoring for any side effects such as chest pain, headache, flushing, nausea, or arrhythmias. Adenosine infusion will be administered at 140 mcg/kg for 2 minutes and once mean coronary flow velocity returns to within 15% of pre-dose value, Regadenoson IV bolus 0.4 mg/5 ml will be administered followed by a 5 cc normal saline flush.
3070227|NCT01161160|Experimental|AREPANRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3070228|NCT01161160|Experimental|PANDEMRIX 1/2 GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 half (1/2) pediatric dose of Pandemrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3070229|NCT01161160|Experimental|AREPANRIX GROUP|Healthy male or female children aged 3 to less than (<) 10 years at the time of study vaccination, who received 1 pediatric dose of Arepanrix™ vaccine at Day 0, administered intramuscularly in the deltoid of the non-dominant arm.
3070230|NCT01161173||Erlotinib|Participants received erlotinib (Tarceva) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics. The recommended daily dose of erlotinib is 150 mg orally once daily.
3070231|NCT01161225|Experimental|peer-led asthma self-managment program|
3070232|NCT01161225|Active Comparator|Adult-led asthma self-management program|
3070233|NCT01161329|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
3070234|NCT01161329|Experimental|Intervention group|Exercising two times/week according to the High-Intensity Functional Exercise Program (HIFE) in groups of 5-7 patients in combination with motivational discussions.
3070235|NCT01161407|Placebo Comparator|Placebo|Placebo control for calcium carbonate, given in same capsule form as the calcium carbonate, 3 times per day with meals.
3070236|NCT01161407|Active Comparator|Calcium Carbonate (Phosphate Binder)|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium.
3070237|NCT01161420|Experimental|Inspire Therapy|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
3070238|NCT01161446|Experimental|Home Testing|
3070239|NCT01161446|No Intervention|Standard Testing|
3070240|NCT01161472|Experimental|4mg fesoterodine|
3070241|NCT01161472|Experimental|fesoterodine 8mg|
3070242|NCT01161472|Active Comparator|1mg alprazolam|
3070243|NCT01161472|Placebo Comparator|Placebo|
3070244|NCT01161498|Active Comparator|Radiation/Cisplatin|Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period.
3070245|NCT01161498|Experimental|Talimogene Laherparepvec + Radiation/Cisplatin|The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming units (PFU)/mL, administered into all injectable affected nodes on Day 0. Subsequent doses were up to 8 mL total volume (up to 4 mL per lesion) at 10⁸ PFU/mL on Days 21, 42, and 63. Participants also received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42 and radiation administered concurrently in 35 fractions over a 7-week period.
3070246|NCT01161524|Experimental|Perampenal (Core Study)|Participants received perampanel 2 mg per day and up-titrated weekly in 2-mg increments to a target dose range of 8 to 12 mg per day.
3070247|NCT01161524|Placebo Comparator|Placebo (Core Study)|Participants received matching placebo tablets once a day (6 tablets of placebo).
3070248|NCT01161524|Experimental|Perampanel (Extension Phase)|During the Extension Phase, participants previously assigned to perampanel arm (Core Study) continued taking study medication at the dose achieved at the end of the Core Study once daily. Participants previously assigned to a placebo arm (Core Study) started perampanel dose at 2 mg/day and up-titrated weekly in 2-mg increments up to a maximum dose of 12 mg/day.
3070249|NCT01161537|Experimental|VX-770|"Part A: Subjects received placebo tablets matched to VX-770 150 milligram (mg) orally twice daily from Day 1 to 14 (Placebo run-in period), followed by VX-770 150 mg tablets orally twice daily from Day 15 to 42 (VX-770 treatment period), and then placebo tablets matched to VX-770 150 mg orally twice daily from Day 43 to 57 (Placebo washout period) during Part A of the study.~Part B: Subjects received VX-770 150 mg tablets orally twice daily for 48 weeks during Part B of the study. Part B included subjects from Part A and newly enrolled subjects."
3070250|NCT01161563|Active Comparator|Leuprolide acetate|Polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) injected subcutaneously in upper or mid-abdominal area. Injection occurred either 6 months before or 6 months after injection of triptorelin pamoate suspension (Trelstar 22.5 mg) intramuscularly in the buttock.
3070251|NCT01161563|Active Comparator|Triptorelin pamoate|Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock. Injection occurred either 6 months before or 6 months after injection of polymeric matrix formulation of leuprolide acetate (Eligard 45 mg) subcutaneously in upper or mid-abdominal area.
3070252|NCT01161628|Experimental|Rituxan|All patients receive Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
3070253|NCT01161771||Patients with cataract and corneal astigmatism|Patients with cataract(s) and corneal astigmatism who received surgical treatment (cataract extraction and limbal-relaxing incisions)
3070254|NCT01161862|Experimental|Bi-hormonal with meal-priming bolus|The first meal-priming bolus was solely based on weight (0.05 U/kg), after which meal-priming boluses were automatically adapted by the control system online targeting 75% of the anticipated insulin needed in the first four hours after the start of the meal
3070255|NCT01161862|Experimental|Bi-hormonal without meal-priming bolus|The insulin controller was entirely reactive to CGMG; there were no meal priming boluses and no meal announcements
3070256|NCT01162005|Experimental|Tacrolimus|Tacrobell
3070257|NCT01162096|Experimental|Transplantation|
3070258|NCT01162122|Experimental|aTIV|Subjects received one dose of MF59-adjuvanted trivalent subunit influenza vaccine (aTIV) from one of three consecutive lots (Lot 1, Lot 2 or Lot 3).
3070259|NCT01162122|Experimental|Licensed TIV|Subjects received one dose of non-adjuvanted trivalent subunit influenza vaccine (TIV).
3070260|NCT01162135|Experimental|Open Label Pilot Study|
3070261|NCT01162239|Experimental|Extended Brief Contact|Following standard brief treatment, participants have monthly meetings with medical staff.
3070262|NCT01162239|Experimental|Extended Health Education|Following standard treatment, participants receive monthly counseling with content based on a health education model.
3070263|NCT01162239|Experimental|Extended Relapse Prevention plus varenicline|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model plus access to ongoing medication treatment with varenicline.
3070264|NCT01162239|Experimental|Extended Relapse Prevention|Following standard treatment, participants receive monthly counseling with content based on a relapse prevention model.
3070265|NCT01162317|Active Comparator|Arm 1: sham acupuncture|sham acupuncture
3070266|NCT01162317|Experimental|Arm 2: acupuncture|acupuncture
3070267|NCT01162343||Older Emergency Department Patients|Patients who were 65 years or older from the emergency department were enrolled.
3070268|NCT01162421|Experimental|Early Adalimumab|Participants in the Early Adalimumab arm will receive adalimumab and methotrexate at Baseline and every other week for study duration.
3070269|NCT01162421|Active Comparator|Standard of Care|Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
3070270|NCT01162473|Active Comparator|Delayed Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing delayed desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 16 and continue thru Week 50. Total active participation will last 51 weeks.
3070271|NCT01162473|Active Comparator|Immediate Sensitivity|All subjects will undergo a food challenge (week 2). Subjects undergoing immediate desensitization via milk oral immunotherapy with milk protein powder will begin build-up of desensitization during Week 3 and continue thru Week 35. Total active participation will last 38 weeks.
3070272|NCT01162486|Active Comparator|Rifampin control|Rifampin + midazolam
3070273|NCT01162486|Experimental|RPT 1|RPT Cohort 1 - 5 mg/kg
3070274|NCT01162486|Experimental|RPT 2|RPT Cohort 2 - 10 mg/kg
3070275|NCT01162486|Experimental|RPT 3|RPT Cohort 3 - 15 mg/kg
3070276|NCT01162486|Experimental|RPT 4|RPT Cohort 4 - 20 mg/kg
3070277|NCT01162486|Experimental|RPT 5|RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed
3070278|NCT01162499|Experimental|Exendin-(9-39) first, then Vehicle|"After an overnight fast, an intravenous (IV) infusion of Exendin-(9-39) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1). The Exendin-(9-39) dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects.~The next day, all procedures will be repeated except subjects will receive an IV infusion of normal saline (vehicle) over 6 hours."
3070279|NCT01162499|Active Comparator|Vehicle first, then Exendin-(9-39)|"After an overnight fast, an intravenous (IV) infusion of normal saline (vehicle) will be started 1 hour prior to the meal challenge and continued for 5 hours. After the first hour of the infusion, subjects will undergo a mixed meal tolerance test in which Pediasure (10cc/kg) will be consumed by mouth or gastrostomy/nasogastric tube over a period of 15 minutes (for infants under 12 months, Pediasure will be replaced by the infant's formula). Blood samples will be drawn at different time points during the infusion to measure blood glucose, plasma insulin, glucagon and plasma glucagon-like-peptide-1 (GLP-1).~The next day, all procedures will be repeated except subjects will receive an IV infusion of Exendin-(9-39) which will be started 1 hour prior to the meal challenge and continue for 5 hours. The dose for the first 3 subjects will be 300pmol/kg/min and, if tolerated, the dose will be increased to 500pmol/kg/min for subsequent subjects."
3070280|NCT01162551|Experimental|Sirolimus and Methotrexate|"Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days"
3070281|NCT01162733|Active Comparator|Study Drug 1|Vancomycin 15mg/kg
3070282|NCT01162733|Active Comparator|Study Drug 2|Vancomycin 30mg/kg
3070283|NCT01162863|Active Comparator|Lubiprostone 8 mcg BID|
3070284|NCT01162863|Active Comparator|Lubiprostone 24 mcg QD|
3070285|NCT01162863|Placebo Comparator|Placebo|
3070286|NCT01163032|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
3070287|NCT01163032|Placebo Comparator|placebo|Placebo capsules, PO daily for 6 months
3070288|NCT01163097|Experimental|Palifermin 40 µg/kg and heparin IV infusion|Treatment A: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections and continuous heparin IV infusion
3070289|NCT01163097|Experimental|Palifermin 40 µg/kg|Treatment B: palifermin 40 µg/kg/day for three consecutive days as IV bolus injections
3070290|NCT01163097|No Intervention|Control group without any treatment|Treatment C: control group without any treatment administered.
3070291|NCT01163149|Experimental|Cohort 1|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (2.1 mg/kg/week total)
3070292|NCT01163149|Experimental|Cohort 2|Cohort 2: Daily SC injections of 0.5 mg/kg asfotase alfa (3.5 mg/kg/week total)
3070293|NCT01163149|No Intervention|Concurrent Control|Following completion of the Week 24 visit, all patients (including those randomized to the concurrent control cohort) may be eligible to participate in an open-label extension treatment period. In this extension period, all patients will be treated with daily SC injections of 0.5 mg/kg/day asfotase alfa (a total of 3.5 mg/kg/week) for approximately 24 weeks, then subjects will receive 1 mg/kg/day 6 days/week for an additional 48 weeks or until regulatory approval of the drug.
3070294|NCT01163162|Experimental|Paricalcitol|After baseline measurements are complete, pt will receive 2 mcg Paricalcitol (Zemplar) for 7 consecutive days. After this, Kidney function will again be measured. The pt will then be washed off the paricalcitol for 7 days then kidney function will be measured for the last time.
3070295|NCT01163214|Experimental|Nerve Block|Preoperative femoral block with indwelling femoral catheter and a single shot sciatic block.
3070296|NCT01163214|Active Comparator|Periarticular Injection|Injection combination prior to skin closure.
3070297|NCT01163253|Experimental|Active Treatment|"The study is anticipated to continue for up to at least 2 years post First Market Approval (FMA) in a global, major market.~All subjects will receive 10 mg BID of CP-690,550 for first 3 months of trial. Study has the option for variable dosing with 5 mg or 10 mg BID after first 3-months of treatment based on PI discretion"
3070298|NCT01163266|Placebo Comparator|Placebo|Placebo-matching capsules, orally, once daily for up to 8 weeks.
3070299|NCT01163266|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3070300|NCT01163266|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
3070301|NCT01163279|Experimental|Cognitive Training|
3070302|NCT01163279|Active Comparator|Psychosocial Education|
3070303|NCT01163292||Adalimumab|Participants who continued adalimumab treatment after completion of Study NCT00870467 (M06-859)
3070304|NCT01163292||Non-Adalimumab|Participants who discontinued adalimumab treatment after completion of Study NCT00870467(M06-859)
3070305|NCT01163318||Adalimumab 40 mg/0.8 mL syringe for subcutaneous injection|Participants with rheumatoid arthritis who received adalimumab, per approved label
3070306|NCT01163461|Experimental|Immediate Treatment|individuals will receive 60 hours of speech therapy
3070307|NCT01163461|Experimental|Delayed Treatment|individuals will receive 60 hours of speech therapy after 6 week delay period
3070308|NCT01163474|Experimental|Arm 1 - All study participants|Evaluate video clinic visit prior to Face-to-Face usual care visit
3070309|NCT01163604|Experimental|Argatroban group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive continuous infusions of argatroban for 2 days before and 3 days after stenting, with accompanied aspirin and clopidogrel treatment.
3070310|NCT01163604|Experimental|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
3070311|NCT01163617|Experimental|Current/Physiolis Syringe|Self-injection using current syringe at Week 0 (Visit 1), self-injection using Physiolis syringe at Week 2 (Visit 2) (Phase A)
3070312|NCT01163617|Experimental|Physiolis/Current Syringe|Self-injection using Physiolis syringe at Week 0 (Visit 1), self-injection using current syringe at Week 2 (Visit 2) (Phase A)
3070313|NCT01163617|Experimental|Current/Physiolis Autoinjector|Self-injection using current autoinjector at Week 0 (Visit 1), self-injection using Physiolis autoinjector at Week 2 (Visit 2) (Phase A)
3070314|NCT01163617|Experimental|Physiolis/Current Autoinjector|Self-injection using Physiolis autoinjector at Week 0 (Visit 1), self-injection using current autoinjector at Week 2 (Visit 2) (Phase A)
3070315|NCT01163617|Experimental|Physiolis Autoinjector at 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at storage temperature (2° to 8°C) (Phase B)
3070316|NCT01163617|Experimental|Current Autoinjector 2° to 8°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at storage temperature (2° to 8°C) (Phase B)
3070317|NCT01163617|Experimental|Physiolis Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using Physiolis autoinjector at room temperature (20° to 27°C) (Phase B)
3070318|NCT01163617|Experimental|Current Autoinjector 20° to 27°C|Injection performed by health care provider at Week 4 (Visit 3) using current autoinjector at room temperature (20° to 27°C) (Phase B)
3070319|NCT01163643|Experimental|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension
3070320|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension
3070321|NCT01163643|Placebo Comparator|Vehicle|Vehicle twice daily (BID)
3070322|NCT01163643|Experimental|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension
3070323|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension in the morning|2% BOL-303242-X ophthalmic suspension in the morning (AM) and vehicle in the afternoon (PM)
3070324|NCT01163643|Experimental|2% BOL-303242-X ophthalmic suspension PM|Vehicle in the AM and 2% BOL-303242-X ophthalmic suspension in the PM.
3070325|NCT01163656|Active Comparator|Direct Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Miller Laryngoscope.
3070326|NCT01163656|Active Comparator|Glidescope Cobalt Video Laryngoscopy|Laryngoscopy will be performed with the randomized device, which will be the Glidescope Cobalt Video Laryngoscope.
3070327|NCT01163721|Experimental|Ranolazine|Participants were randomized to receive ranolazine for 12 weeks.
3070328|NCT01163721|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match ranolazine for 12 weeks.
3070329|NCT01163747|Active Comparator|Methotrexate|Participants continued to receive their standard dose of methotrexate up to Week 8. From Week 8 participants also received 8 mg/kg tocilizumab intravenously every 4 weeks until Week 20. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
3070330|NCT01163747|Experimental|Tocilizumab + Methotrexate|Participants received 8 mg/kg tocilizumab intravenously at Baseline (Day 1) and every 4 weeks up to Week 20, in addition to their standard dose of methotrexate. At Week 3 participants received both pneumococcal and tetanus toxoid vaccinations.
3070331|NCT01163760|Other|etafilcon A / ocufilcon D|etafilcon A contact lens worn first daily disposable , ocufilcon D contact lens worn second daily disposable
3070332|NCT01163760|Other|oculfilcon D / etafilcon A|ocufilcon D contact lens worn first, etafilcon A contact lens worn second
3070333|NCT01163760|Other|ocufilcon D / ocufilcon D|ocufilcon D contact lens worn first and second
3070334|NCT01163760|Other|etafilcon A / etafilcon A|etafilcon A contact lens worn first and second
3070335|NCT01163786|Experimental|Bortezomib|Patients will Receive 2 4week cycles of Bortezomib. Each cycle will consist of weekly bortezomib with a 2 week interval between cycles.
3070336|NCT01163851|Experimental|PF-04950615 (RN316)|
3070337|NCT01163916||Patients with RA, PsA and AS|Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) prescribed adalimumab as part of Routine Clinical Care in Russia.
3070338|NCT01163955|Other|Sitting in a chair|Sitting in a chair with back support and feet flat on the ground
3070339|NCT01163955|Other|Sitting on the Floor|Sitting on the floor without back support, crossed leg style
3070340|NCT01164007|Experimental|Dacarbazine + Bevacizumab|Participants with unresectable/metastatic melanoma not previously treated with chemotherapy for metastatic disease will receive dacarbazine and bevacizumab until disease progression, unacceptable toxicity, participant withdrawal, or physician decision to discontinue.
3070341|NCT01164098|Active Comparator|Rituximab|Participants will receive Rituximab post within 24 of Kidney Transplant
3070342|NCT01164098|No Intervention|No rituximab|Participants will not receive Rituximab within 24 hours of Kidney Transplant
3070343|NCT01164137|Experimental|Medication Reconciliation Intervention|Participants receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
3070344|NCT01164137|No Intervention|Medication Reconciliation Non-Interven.|Participants not receiving a pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at identifying and correcting medication discrepancies.
3070345|NCT01164228|Experimental|Arm A (Sunitinib + Gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 22, and 29 and oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
3070346|NCT01164228|Experimental|Arm B (Sunitinib)|Patients receive oral sunitinib malate once daily on days 1-14 and 22-35. Each cycle was 42 days (6 weeks) and was to be repeated for a total of one year.
3320936|NCT02014870|Experimental|Cohort 1|1:1000 dilution of neat virus
3070347|NCT01164475|Experimental|Fixed Dose Plerixafor|10 microgram per kilogram (mcg/kg) granulocyte-colony stimulating factor (G-CSF) subcutaneous (SC) injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by 20 milligram (mg) plerixafor SC injection (fixed dose) in evening of Day 4 (10 to 11 hours prior to first apheresis), and then 10 mcg/kg G-CSF SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of cluster of differentiation 34 (CD34+) stem cells (greater than or equal to [>=] 5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
3070348|NCT01164475|Active Comparator|Weight-Based Plerixafor|G-CSF 10 mcg/kg SC injection once daily in morning from Day 1 through Day 4 (G-CSF mobilization period), followed by plerixafor 0.24 milligram per kilogram (mg/kg) SC injection (weight-based dose) in evening of Day 4 (10 to 11 hours before first apheresis), and then G-CSF 10 mcg/kg SC injection in morning of Day 5 (1 hour prior to first apheresis). Apheresis process and treatment with plerixafor (10 to 11 hours prior to apheresis) and G-CSF (1 hour prior to apheresis) was continued until the target number of CD34+ stem cells (>=5*10^6 cells/kg) was collected or until a maximum 4 apheresis sessions occurred.
3070349|NCT01164501|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3070350|NCT01164501|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3070351|NCT01164501|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3070352|NCT01164579|Experimental|Tofacitinib (CP 690,550) 10 mg BID plus MTX|
3070353|NCT01164579|Experimental|Tofacitinib (CP-690,550) 10 mg BID, tablet plus placebo MTX|
3070354|NCT01164579|Active Comparator|Placebo tofacitinib (CP-690,55) plus MTX 10 mg/wk to 20 mg/wk|
3070355|NCT01164644|Active Comparator|Arnica Montana|The subject will take twelve pills by mouth three times a day over four days.
3070356|NCT01164644|Placebo Comparator|Placebo|The subject will take twelve pills by mouth three times a day over four days.
3070357|NCT01164722|Experimental|Arm I: Infrared coagulator treatment|Infrared photocoagulation therapy. The infrared coagulator (IRC) contact tip is placed in direct contact with lesion under high-resolution anoscopy (HRA) guidance. Patients then undergo IRC ablation for 1.5 second pulses. IRC ablation is reapplied until the level of submucosal vessels are reached.
3070358|NCT01164722|Active Comparator|Arm II: Expectant management|Patients receive standard of care and undergo clinical observation. After 12 months, patients may receive IRC ablation to all anal intraepithelial neoplasia lesions despite of their size.
3070359|NCT01164865|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose disinfecting solution used with study contact lenses on a daily basis for 2 weeks.
3070360|NCT01164865|Active Comparator|Clear Care|Clear Care contact lens care system used with study contact lenses on a daily basis for 2 weeks.
3070361|NCT01164891|Experimental|Single Arm|
3070362|NCT01164956|Experimental|M-P, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070363|NCT01164956|Experimental|P-M, P-M, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070364|NCT01164956|Experimental|P-M, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070365|NCT01164956|Experimental|M-P, M-P, M-P|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070366|NCT01164956|Experimental|M-P, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070367|NCT01164956|Experimental|M-P, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070368|NCT01164956|Experimental|P-M, P-M, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070369|NCT01164956|Experimental|P-M, M-P, P-M|Participants were randomized to receive 3 treatment pairs of placebo (P) then methylphenidate (M) or M then P. Each M or P was given daily for 3 days and therefore treatment duration was 18 days over 3 treatment pairs. M or P was administered orally at a starting dose of 0.3 mg/kg/dose. For participants > 40 kg, the maximum of dose in the first treatment pair was 12.5 mg per dose. Dose escalation to maximum 0.5 mg/kg/dose was permitted.
3070370|NCT01165021|Experimental|Pemetrexed + Cisplatin|
3070371|NCT01165047|Experimental|Nitric Oxide|80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM
3070372|NCT01165112|Experimental|Treatment (chemotherapy and monoclonal antibody therapy)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60 minutes on days 1-3, and carboplatin IV over 60 minutes on day 1. Patients with CD20+ T-cell lymphoma disease also receive rituximab IV on day 2 or 3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3070373|NCT01165138|Experimental|Fluticasone furoate/Vilanterol (GW642444)|Fluticasone furoate/Vilanterol inhalation powder once daily for 12 weeks
3070374|NCT01165138|Experimental|Fluticasone Furoate|Fluticasone furoate inhalation powder once daily for 12 weeks
3070375|NCT01165138|Placebo Comparator|Placebo|Placebo inhalation powder once daily for 12 weeks
3070376|NCT01165177|Experimental|GSK1437173A group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
3070377|NCT01165177|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
3070378|NCT01165203|Experimental|GSK1437173A Group|Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
3070379|NCT01165203|Placebo Comparator|Placebo Group|Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.
3070380|NCT01165216|Experimental|Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
3070381|NCT01165216|Experimental|Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin|Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
3070382|NCT01165229|Experimental|Zoster vaccine group|Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
3070383|NCT01165229|Placebo Comparator|Placebo group|Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
3070384|NCT01165242|Experimental|Group A|Subjects were vaccinated with vaccine GSK134612 Lot A
3070385|NCT01165242|Experimental|Group B|Subjects were vaccinated with vaccine GSK134612 Lot B
3070386|NCT01165242|Active Comparator|Group C|Subjects were vaccinated with Menactra®
3070387|NCT01165281|Experimental|001|R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
3070388|NCT01165281|Active Comparator|002|Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.
3070389|NCT01165307|Active Comparator|Medical Therapy|Subjects will be prescribed monthly packets of Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills. Subjects who are unable to tolerate oral contraceptive pills or are unwilling to take oral contraceptive pills will be prescribed naproxen sodium pills. The latter will be administered as follows; 500mg with onset of menses, then 250mg three times daily for the duration of the menses (or maximum of five days).
3070390|NCT01165307|Active Comparator|Radiofrequency Endometrial Ablation|Subjects will undergo NovaSure® radiofrequency endometrial ablation within 4 weeks of randomization. The procedure will occur at any time during the menstrual cycle, without endometrial pre-treatment. Endometrial thinning will be carried out using suction curettage in 50% of the cases included in the ablation group. Random assignment for this treatment will be included in the overall randomization plan.
3070391|NCT01165320|Experimental|Participants with Esophageal Candidiasis|Candida infection is strongly suspected based on clinical symptoms and the participant's clinical course, white moss (plaque) is observed on the esophageal mucosa, and therapy via intravenous infusion is judged to be suitable for the present episode of esophageal candidiasis. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 7 and 28 days, respectively.
3070392|NCT01165320|Experimental|Participants with Invasive Candidiasis|Candida infection is strongly suspected based on the presence of refractory fever not responding to an antibiotic agent, or clinical symptoms at the site of disease, or the participant's clinical course. In addition, at least 1 of the following criteria must be met: 1) Candida infection is strongly suspected based on radiographic imaging findings and positive serological test for fungus, 2) yeast is observed by direct microscopy or histopathological test of tissue biopsied from the site of disease, or 3) Candida species are observed by culture test of specimens sampled from the site of disease. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 56 days, respectively.
3070393|NCT01165320|Experimental|Participants with Aspergillosis|Aspergillus infection is strongly suspected based on clinical symptoms and the participant's clinical course, and characteristic radiographic imaging findings are observed. In addition, at least 1 of the following criteria must be met: 1) risk factors predisposing to an Aspergillus infection, 2) positive serological test for Aspergillus, 3) acute-branching mold with separated hyphae are observed by direct microscopy or histopathological test, or 4) Aspergillus species are observed by culture test. MK-0991 therapy as a single loading dose of 70 mg/m^2 intravenously on Day 1 (maximum not to exceed 70 mg), followed by 50 mg/m^2 as a single once-daily dose on all subsequent days (maximum of 70 mg daily). The minimum and maximum treatment duration was 14 and 84 days, respectively.
3070394|NCT01165424|Experimental|MFNS 50 μg device|"MFNS 50 μg spray device. The dose will be as follows:~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
3070395|NCT01165541|Active Comparator|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine XR 50-400mg
3070396|NCT01165541|Experimental|Quetiapine XR and Mirtazapine|Quetiapine XR 50-400mg + Mirtazapine 7.5-45mg
3070397|NCT01165554|Experimental|[18F] Flutemetamol|
3070398|NCT01165684|Experimental|Step-wise|
3070399|NCT01165684|Active Comparator|Basal-bolus|
3320937|NCT02014870|Experimental|Cohort 2|1:100 dilution of neat virus
3070400|NCT01165775||Threatened pre term labor patients|Patients receiving betamethasone to minimize the complications of prematurity will monitor blood glucose levels using the Dexcom Seven Plus Continuous Glucose Monitoring System.
3070401|NCT01165840|Experimental|Dapsone|Dapsone 100 mg PO x 1 dose
3070402|NCT01165983|Placebo Comparator|Placebo|
3070403|NCT01165983|Experimental|Aliskiren|
3070404|NCT01165996|Experimental|Arm I: decitabine|INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts &lt; 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
3070405|NCT01166126|Experimental|Treatment (temsirolimus and selumetinib)|"Treatment Phase: This period begins with the first intravenous (through the vein) infusion of TEMSIROLIMUS and the first AZD6244 administration by mouth (visit 2, Week 1) and will continue until Week 8 (Visit 4).~As many as 38 patients will receive the same dosage of TEMSIROLIMUS injected in the veins once a week for 8 weeks, and the AZD6244 will be given as capsules by mouth twice a day for 8 weeks. That is one cycle. The TEMSIROLIMUS and AZD6244 will be given to participants as an outpatient, unless admission to the hospital was needed for treatment of related side effects or underlying disease. The subsequent cycles of TEMSIROLIMUS and AZD6244 will be given every 8 weeks. The TEMSIROLIMUS will be injected in a vein over 30 minutes.~The continuation phase begins with visits at weeks 12 in patients who receive at least two cycles of treatments."
3070406|NCT01166139|Experimental|Nilotinib 400 mg twice daily|
3070407|NCT01166230||Patients with Ta/T1, randomized to white light cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
3070408|NCT01166230||Patients with Ta/T1 randomized to Hexvix cystoscopy|Patients with non-invasive papillary bladder cancer (Ta/T1), enrolled in the previously completed pivotal phase III study PC B305/04 who were followed for recurrence.
3070409|NCT01166282|Placebo Comparator|Double-blind Placebo EOW|Placebo for adalimumab every other week (eow) for 12 weeks.
3070410|NCT01166282|Experimental|Double-blind Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for 12 weeks.
3070411|NCT01166282|Experimental|Open-label Adalimumab EOW|Adalimumab (body surface area dosing 24 mg/m^2 up to a maximum of 40 mg) every other week (eow) for up to 192 weeks.
3070412|NCT01166347|Experimental|HeartWare® VAS|Implant of HeartWare® Ventricular Assist System
3070413|NCT01166347|Active Comparator|Control LVAD|Implant of FDA-approved LVADs approved for destination therapy
3070414|NCT01166373|Experimental|Enrollment video arm|Arm of subjects that will be shown a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
3070415|NCT01166373|No Intervention|No video intervention arm|This group of subjects will not view a standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process.
3070416|NCT01166373|Experimental|ULS|Uterosacral Ligament Suspension was one of the randomized surgical treatments in the OPTIMAL study
3070417|NCT01166373|Experimental|SSLF|Sacrospinous Ligament Fixation was one of the randomized surgical treatments in the OPTIMAL study.
3070418|NCT01166373|Experimental|PMT|Perioperative Behavioral Therapy/Pelvic Muscle Training was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
3070419|NCT01166373|Other|Usual Care|No Perioperative Behavioral Therapy/Pelvic Muscle Training (i.e., usual care) was one of the randomized non-surgical (behavioral) interventions in the OPTIMAL study.
3070420|NCT01166386|Experimental|First steps treatment intervention|"A brief 10-session manualized acute neurobehavioral intervention program will be individually implemented with randomly assigned treatment participants. Session components include injury-related education, enhancement of self-awareness of deficits from the TBI, coping and cognitive skills training, and supported practice. The acronym FANCI refers to the name of the program which is First Steps Acute Neurobehavioral and Cognitive Intervention."
3070421|NCT01166386|Placebo Comparator|standard rehabilitation care|The controls will spend 10 one-half hours with a therapist viewing videos they choose from a menu, some of which have to do with brain injury. The therapist will interact naturally with the controls and occasionally relate the movie or film to brain injury rehabilitation.
3070422|NCT01166438|Experimental|Botox A|A single intradetrusor injection of 100U botulinum toxin A (Botox A®) plus daily oral placebo tablets
3070423|NCT01166438|Active Comparator|Standardized Anticholinergic Regimen|A standardized 3-step anticholinergic regimen of daily oral solifenacin 5mg, solifenacin 10mg, and/or trospium chloride XR 60mg, as well as a single intradetrusor injection of saline (placebo). All subjects will begin on solifenacin 5 mg for 2 mo. If a subject's symptoms are not adequately controlled at 2 mo, she will be escalated to solifenacin 10mg, and similarly at 4 mo to trospium XR 60mg. If a subject's symptoms are adequately controlled on solifenacin 5 mg, she may continue that study medication for the entirety of the study (6 mo). Additionally, if a subject is dose-escalated to solifenacin 10mg at study mo 2 or 4, and her symptoms are adequately controlled, she may continue the solifenacin 10mg dose for the remainder of the study.
3070424|NCT01166568|Experimental|Implantation-Non Randomized|Subjects are not participants in the randomized sub-study. PresView Scleral Implants surgical placed in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
3070425|NCT01166568|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. PresView Scleral Implants surgical placed in the eye(s)Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
3070426|NCT01166568|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have PresView Scleral Implants surgically placed in the eye(s) and become part of the overall study experimental group.
3070427|NCT01166646|Experimental|Halobetasol Proprionate Lotion 0.05%|Subjects randomized to receive lotion
3070428|NCT01166646|Active Comparator|Halobetasol Proprionate Cream 0.05%|Subjects randomized to receive cream
3070429|NCT01166659|Experimental|CyPass Micro-Stent|Subjects receive the CyPass Micro-Stent
3070430|NCT01166750|Experimental|CD-ROM-treatment|
3070431|NCT01166750|Active Comparator|Wait-list Control Group|
3070432|NCT01166763|Experimental|high dose vitamin D3 (10,000 IU weekly)|Group/Cohort Label vitamin D3
3070433|NCT01166945|Placebo Comparator|Short Course|Short course (5 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination and placebo for next 9 days.
3070434|NCT01166945|Active Comparator|Long Course|Long course (14 days) of antimicrobial therapy Amoxicillin-Potassium Clavulanate Combination given orally for 14 days.
3070435|NCT01166958|Active Comparator|Daily teriparatide (Forteo)|
3070436|NCT01166958|Active Comparator|Monthly cycles of teriparatide followed by raloxifene|
3070437|NCT01166971|Experimental|ReSTOR +3|Bilateral Implantation of ReSTOR +3 Intraocular lenses after cataract extraction
3070438|NCT01166971|Active Comparator|Tecnis MF|Bilateral Implantation of Tecnis Multifocal Intraocular lenses after cataract extraction
3070439|NCT01166984|Experimental|AB103 7.5 µg/kg|AB103 7.5 µg/kg administered as a single IV infusion
3070440|NCT01166984|Experimental|AB103 37.5 µg/kg|AB103 37.5 µg/kg administered as a single IV infusion
3070441|NCT01166984|Experimental|AB103 150 µg/kg|AB103 150 µg/kg administered as a single IV infusion
3070442|NCT01166984|Experimental|AB103 450 µg/kg|AB103 450 µg/kg administered as a single IV infusion
3070443|NCT01166984|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride) administered as a single IV infusion
3070444|NCT01166997|Experimental|Ultrasound accelerated thrombolysis|Patients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose <20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
3070445|NCT01166997|Active Comparator|Intravenous unfractionated heparin|Patients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
3070446|NCT01167023|Experimental|7.5 mg Prasugrel|Participants were to receive 7.5 milligrams (mg) of prasugrel orally, once daily if they weighed ≥60 kilograms (kg) and if pharmacodynamic (PD) measures indicated that the 5-mg prasugrel dose did not produce a steady-state PD response equivalent to inhibition of platelet activation (IPA) ≥25%. Because these criteria were not met, no participants received 7.5 mg of prasugrel.
3070447|NCT01167023|Placebo Comparator|Placebo|
3070448|NCT01167023|Experimental|5 mg Prasugrel|
3070449|NCT01167140|Experimental|Cryo-Touch II|
3070450|NCT01167153|Experimental|Valsartan/amlodipine|Valsartan/amlodipine 80/5 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
3070451|NCT01167153|Active Comparator|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg, one tablet once daily at 8:00 a.m. everyday for 12 weeks.
3070452|NCT01167179|No Intervention|comparison group|Usual care Participants in the comparison group receive the usual care which consists of a 5 year medical routine control schedule based on the national guidelines, and - if appropriate - involvement of the dietician and the speech language therapist.During years one to five the routine control appointments are planned at a minimum of every 2, 3, 4, 6 and 12 months respectively. Most patients who undergo a total laryngectomy have additional contact with an oncology nurse during their 6-8 weekly medical control visits at the outpatient clinic for approximately the first year of follow-up. All other head and neck cancer patients have no structured follow-up contact with an oncology nurse.
3070453|NCT01167179|Experimental|nurse-led consultation|"Interventional care Year 1 follow-up: 2-monthly medical control visit + 30 minute nursing consultation, to a minimum of 6 in year 1. No restrictions with regard to cancer stage, site or treatment modality.~Intervention consist of standardised nursing consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. Goals: helping patients (and their partners) cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship."
3070454|NCT01167192|Experimental|Neoadjuvant Cisplatin or Carboplatin AUC 6 & Radiation|"Cisplatin 75 mg/m^2 IV every 21 days for 4 cycles or Carboplatin AUC 6 IV every 21 days for 4 cycles.~Radiation beginning cycle 2 day 1 daily for 5-6 weeks 45-50 Gy.~Recommended mastectomy~Recommended adjuvant chemotherapy~-doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 for 14 days for 4 cycles followed by paclitaxel 175 mg/m2 for 14 days for 4 cycles)"
3070455|NCT01167257|Experimental|Experimental arm|"Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL in Liposome 80 mg/40 mL) in single intravesical instillation~Liposome encapsulated botulinum toxin A'"
3070456|NCT01167257|Placebo Comparator|Control arm|"Normal saline 50 mL in single intravesical instillation~Normal saline instillation'"
3070457|NCT01167426|Active Comparator|20 mg/0.5 mL Glatiramer Acetate|Participants received once daily subcutaneous administration of 20 mg glatiramer acetate as 20 mg/1.0 mL utilizing autoject 2 for glass syringe for two weeks (Period 1), followed by 20 mg/0.5 mL utilizing the autoject 2 device for four weeks (Period 2).
3070458|NCT01167452|Experimental|Sulfamethoxazole/trimethoprim|2 DS tablets of sulfamehtoxazole/trimethoprim (1600 mg/320 mg)
3070459|NCT01167504||Saliva Sample Collection|Saliva collection
3070460|NCT01167569|Active Comparator|A-Ascorbic Acid (Vitamin C)|Ascorbic Acid (Vitamin C) 10mg/kg x 2 in the operating room followed by Ascorbic Acid (Vitamin C) 5mg/kg every 4 hours x 48 hours.
3070461|NCT01167569|Placebo Comparator|B-5% Dextrose Water or Normal Saline|5% Dextrose Water or Normal Saline (placebo) x 2 in the operating room followed by 5 % Dextrose Water or NS (placebo) every 4 hours X 48 hours.
3070462|NCT01167582|Experimental|Liberal Transfusion Strategy|Patients randomly allocated to the liberal transfusion strategy receive one unit of packed red cells following randomization and receive enough blood to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days. Any transfusion following the initial unit of packed red cells must be preceded by blood test documenting a hemoglobin concentration below 10 g/dL.
3320938|NCT02014870|Experimental|Cohort 3|1:10 dilution of neat virus
3320939|NCT02014883|Experimental|GLUT1 DS|
3320940|NCT02014896||Ischemic Stroke|"Ischemic stroke subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
3070463|NCT01167582|Experimental|Restrictive transfusion strategy|"Receive a transfusion if they develop symptoms related to anemia. Transfusion is also permitted, but not required, in the absence of symptoms only if the hemoglobin concentration falls below 8 g/dL. Blood is administered one unit at a time and the presence of symptoms is reassessed. Only enough blood is given to relieve symptoms. If the transfusion is given because the hemoglobin concentration falls below 8 g/dL, then only enough blood is given to increase the hemoglobin concentration above 8 g/dL.~Symptoms of anemia that will be indications for transfusion are: 1) Definite angina requiring treatment with sublingual nitroglycerin or equivalent therapy. 2) Unexplained tachycardia or hypotension."
3070464|NCT01167595|Experimental|PEP uP Protocol|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
3070465|NCT01167595|No Intervention|Standard Feeding Protocol|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
3070466|NCT01167608||People with Parkinson's disease|Individuals diagnosed with Parkinson's disease
3070467|NCT01167634|No Intervention|1|
3070468|NCT01167634|Experimental|2|Deposit contract with a 1:1 match
3070469|NCT01167634|Experimental|3|Deposit contract with a 2:1 match
3070470|NCT01167634|Experimental|Experimental 4|Deposit contract with no match
3070471|NCT01167712|Experimental|Arm I (adjuvant chemotherapy suboptimally debulked)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
3070472|NCT01167712|Experimental|Arm II (neoadjuvant chemotherapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.
3070473|NCT01167829|Experimental|Acyline and oral testosterone|
3070474|NCT01167881|Experimental|BI 10773 dose plus metformin|Patients receive one BI10773 tablet and one placebo Glimepiride capsule once daily
3070475|NCT01167881|Active Comparator|Glimepiride 1-4 mg plus metformin|Patients receive one glimepiride capsule and one placebo tablet Bi 10773 once daily.
3070476|NCT01167907|Experimental|0.2% ropivacaine|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
3070477|NCT01167907|Placebo Comparator|Saline|Patients with evidence of sciatic and saphenous nerve block will be randomized to receive a postoperative continuous infusion of either saline (control) or 0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement.
3070478|NCT01168024|Experimental|CINCOR™ System Treatment|Use of the CINCOR™ System and CCS-1 device during the pericutanous coronary intervention (PCI) procedure plus Standard of Care peri-procedural hydration for the prevention of contrast induced nephropathy (CIN).
3070479|NCT01168024|Other|Standard of Care|The control group will receive a peri and post-procedural hydration rate.
3468822|NCT03892343||Non-transplanted|Patients on the deceased donor waiting list without prospect of a live donor transplant.
3070481|NCT01168232|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3070482|NCT01168349||Cohort|
3070483|NCT01168401|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus Bivalent GI.1 and GII.4 VLP Vaccine, adjuvanted with 50 microgram (mcg) MPL and 500 mcg Al(OH)3, IM, on Days 0 and 28.
3070484|NCT01168401|Placebo Comparator|Saline|
3070485|NCT01168596|Placebo Comparator|sugar pill|Placebo tablet, 1 per day, duration is approximately 12 weeks.
3070486|NCT01168596|Active Comparator|rasagiline|Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
3070487|NCT01168674|Placebo Comparator|Sugar pill|Patients are randomized to a sugar pill (placebo), added to their current medications.
3070488|NCT01168674|Active Comparator|Ziprasidone|Patients are randomized to ziprasidone, added to their current medications.
3070489|NCT01168687|Experimental|Group A|Twenty moderate to heavy social alcohol users will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
3070490|NCT01168687|Experimental|Group B|Twenty moderate to heavy social alcohol users will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days.
3070491|NCT01168726|Experimental|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
3070492|NCT01168726|Experimental|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
3070493|NCT01168726|Active Comparator|Alcohol Education|Educational information about harms associated with heavy drinking.
3070494|NCT01168856||Cohort|
3070495|NCT01168908|Experimental|Revatio (sildenafil)|This arm will receive Revatio (sildenafil) for 12 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
3070496|NCT01168908|Other|Placebo|This arm will receive placebo (sugar pill) for 6 months and Revatio (sildenafil) for 6 months. During the first 6 months, the subject and investigator will be blinded to treatment. The second 6 months, will be open label treatment with Revatio.
3070497|NCT01168934|Experimental|1|Each subject will receive single oral and IV doses of crizotinib separated by at least 14 days.
3070498|NCT01168973|Experimental|Ramucirumab + Docetaxel|
3070499|NCT01168973|Placebo Comparator|Placebo + Docetaxel|
3070500|NCT01168986|Active Comparator|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
3468823|NCT03892135||Physicians|3 paediatricians and 3 rheumatologists
3468824|NCT03892135||Parents|Parents
3468825|NCT03892135||Children|Children
3468826|NCT03892252||before surgery|no intervention(s)
3468827|NCT03892252||after surgery|no intervention(s)
3468828|NCT03892252||Normal colonoscopy|People who were diagnosed by colonoscopy without colorectal cancer.
3070501|NCT01168986|Active Comparator|Exercise|Participants perform an exercise to strengthen the deep neck flexors
3070502|NCT01168986|No Intervention|No intervention|Participants receive/perform no intervention
3070503|NCT01168999|Active Comparator|spinal manipulation|a spinal manipulation known to be effective in the treatment of low back pain for some individuals
3070504|NCT01168999|Placebo Comparator|sham spinal manipulation|a sham spinal manipulation intended to mimic the studied spinal manipulation
3070505|NCT01168999|No Intervention|natural history|No intervention is provided to participants in this arm of the study
3070506|NCT01168999|Placebo Comparator|Enhanced sham spinal manipulation|"a sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
3070507|NCT01169038|Active Comparator|Antibiotics|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
3070508|NCT01169064|Active Comparator|Silver-containing surgical dressing|Self adhesive 4 x 10 dressing impregnated with nanocrystalline silver
3070509|NCT01169064|Active Comparator|Cloth adhesive dressing|Soft cloth adhesive wound dressing
3070510|NCT01169103|Experimental|recombinant human growth hormone|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
3070511|NCT01169103|Placebo Comparator|Placebo|Forty subjects will be randomized to receive either recombinant human growth hormone or placebo.
3070512|NCT01169259|Active Comparator|Vitamin D + fish oil|
3070513|NCT01169259|Active Comparator|Vitamin D + fish oil placebo|
3070514|NCT01169259|Active Comparator|Vitamin D placebo + fish oil|
3070515|NCT01169259|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3070516|NCT01169311|Experimental|HEEA Stapler|hemorrhoidopexy using Covidien EEA Hemorrhoid and Prolapse Stapling Set
3070517|NCT01169337|Experimental|Arm A (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3070518|NCT01169337|Active Comparator|Arm B (observation)|Patients undergo observation until progression to symptomatic myeloma.
3070519|NCT01169350|Experimental|Diagnostic (18F FDG and 18F FMISO PET/CT)|Patients undergo 18F FDG and 18F FMISO PET/CT scans before starting neoadjuvant chemotherapy (without or without radiotherapy) and after completion of 4 courses of neoadjuvant therapy.
3070520|NCT01169467|Active Comparator|Standard-of-Care plus Precedex|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment.
3070521|NCT01169467|Placebo Comparator|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
3070522|NCT01169493|Experimental|VVI-40 to RV DDD-40 to Bi-V DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
3070523|NCT01169493|Experimental|VVI-40 to Bi-V DDD-40 to RV DDD-40|Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
3070524|NCT01169493|Experimental|Bi-V DDD-40 to VVI-40 to RV DDD-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
3070525|NCT01169493|Experimental|Bi-V DDD-40 to RV DDD-40 to VVI-40|Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
3070526|NCT01169493|Experimental|RV DDD-40 to VVI-40 to Bi-V DDD-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
3070527|NCT01169493|Experimental|RV DDD-40 to Bi-V DDD-40 to VVI-40|Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
3070528|NCT01169519|Active Comparator|Sildenafil|Pharmacokinetic and hemodynamic evaluation following sildenafil administration
3070529|NCT01169532|Experimental|Treatment (ridaforolimus and vorinostat)|Patients receive ridaforolimus PO once daily on days 1-5 and vorinostat PO twice daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3070530|NCT01169558|Experimental|Bevacizumab|Bevacizumab will be administered in combination with fluoropyrimidine-based chemotherapy as first line treatment in participants with metastatic cancer of the colon or rectum until disease progression or study completion.
3070531|NCT01169636|Experimental|Panobinostat MTD + ICE|Phase 1: Escalating Panobinostat dose with routine ICE Chemotherapy
3070532|NCT01169636|Experimental|ICE Chemotherapy|Phase 2: Routine ICE Chemotherapy (Ifosfamide, Carboplatin, + Etoposide)
3070533|NCT01169636|Experimental|Panobinostat + ICE|Phase 2: Panobinostat with ICE Chemotherapy
3070534|NCT01169649|Experimental|islet cell carcinomas and carcinoid tumors|This is an open label phase II study of MK-2206 administered to patients with metastatic neuroendocrine tumors.
3070535|NCT01169675|Experimental|BIBW 2992 low dose|patient receives low dose tablet BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070536|NCT01169675|Experimental|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070537|NCT01169675|Experimental|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070538|NCT01169675|Experimental|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070539|NCT01169675|Experimental|BIBW 2992 medium dose 6 day|patient receives medium BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070540|NCT01169675|Experimental|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 plus pemetrexed 500mg/m^2 on day 1 of 21 day cycle
3070541|NCT01169701|Active Comparator|Tacrolimus|Participants continued with the same tacrolimus+Mycophenolic acid (MPA) (Myfortic® or Cell-Cept®) doses that were taken before study initiation (tacrolimus levels 4-7 ng/ml).
3070542|NCT01169701|Experimental|Everolimus|Participants received an initial dose (day 1) of Everolimus (EVL) 2mg at night and tacrolimus (if taking Prograf®, a full dose of Prograf® in the morning and a 50% dose of Prograf® at night; if taking Advagraf®, a 75% dose in the morning. On days 2 and 3, participants took EVL 2 mg twice daily (bid) without tacrolimus. On days 4 and 5, the EVL dose was adjusted and levels maintained between 5-8 ng/mL. Participants also continued with their MPA doses that were taken prior to study initiation.
3070543|NCT01169779|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD up to Week 24.
3070544|NCT01169779|Placebo Comparator|Placebo|1-step initiation regimen of volume matching placebo: 10 mcg QD for 2 weeks, followed by 20 mcg QD up to Week 24.
3070545|NCT01169844|Experimental|AIN457/AIN457 3 mg/kg.|Participants who were treated with secukinumab 2x10 mg/kg during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
3070546|NCT01169844|Placebo Comparator|Placebo/AIN457 3 mg/kg.|Participants who were treated with placebo during the core study were treated with secukinumab at 3mg/kg infused intravenously every 4 weeks during the extension study, over a total period of 52 weeks.
3070547|NCT01169987||Participants Treated with Adalimumab|Participants with chronic plaque psoriasis in whom adalimumab (Humira) treatment is initiated. All medications will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
3070548|NCT01170039|Active Comparator|Lubiprostone|
3070549|NCT01170039|Placebo Comparator|Placebo|
3070550|NCT01170065|Experimental|BIBF 1120 low qd|Low dose BIBF 1120 once daily
3070551|NCT01170065|Experimental|BIBF 1120 low bid|Low dose BIBF 1120 twice daily
3070552|NCT01170065|Experimental|BIBF 1120 medium bid|Intermediate dose BIBF 1120 twice daily
3070553|NCT01170065|Experimental|BIBF 1120 high bid|High dose BIBF 1120 twice daily
3070554|NCT01170091||Pramipexole|
3070555|NCT01170117|Placebo Comparator|Placebo|Control group receiving placebo
3070556|NCT01170117|Experimental|Olanzapine|Group receiving olanzapine
3070557|NCT01170208|Other|Group I|Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.
3070558|NCT01170208|Other|Group II|Type 2 diabetes treated with basal-bolustherapy and insulin dose software.
3070559|NCT01170208|Other|Group III|Type 2 diabetes treated with biphasic insulin and insulin dose software.
3070560|NCT01170221|Experimental|TR-701 FA|TR0-701 FA 200 mg tablets once a day for six days followed by 4 days of placebo
3070561|NCT01170221|Active Comparator|Linezolid|Linezolid 600 mg tablets oral twice a day for 10 days
3070562|NCT01170247|Experimental|Intranasal Ketamine|
3070563|NCT01170247|Active Comparator|Intramuscular Ketamine|
3070564|NCT01170273|Placebo Comparator|Placebo Arm|placebo capsule
3070565|NCT01170273|Experimental|Cholecalciferol 4000 IU|cholecalciferol 4000 IU daily
3070566|NCT01170364|Experimental|Sibutramine|Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.
3070567|NCT01170364|Experimental|Placebo|Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.
3070568|NCT01170390|Other|All participants|A low dose oral contraceptive given cyclically (21 days of active pills/cycle with a 7 day hormonal-free interval) for 2 cycles (56 days).
3070569|NCT01170390|Active Comparator|Aviane and Portia|A low dose oral contraceptive given cyclically (30mcg EE component, 21 days of active pills/cycle with a 7 day hormonal-free interval) for two cycles
3070570|NCT01170390|Active Comparator|Aviane & Aviane|A very-low dose oral contraceptive given continuously for 56 days (20mcg EE component, 28 days of active pills/cycle with no hormone free interval)
3070571|NCT01170533|Active Comparator|Omeprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
3070572|NCT01170533|Active Comparator|Pantoprazole|prospective, open-label, two-sequence, three-period, randomized crossover study
3070573|NCT01170546|Experimental|KLCIR|plate-loaded kneeling leg curl with internal rotation
3070574|NCT01170546|Experimental|SP (Squat Press)|plate-loaded squat press
3070575|NCT01170546|Experimental|KLC (Kneeling Leg Curl)|plate-loaded kneeling leg curl
3070576|NCT01170598|Experimental|Exercise|
3070577|NCT01170663|Experimental|Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel|Ramucirumab (IMC-1211B) DP and Paclitaxel
3070578|NCT01170663|Placebo Comparator|Placebo and Paclitaxel|Placebo and Paclitaxel
3070579|NCT01170715|Experimental|Experimental Group|Enbrel (etanercept): started with self-injection of 50 mg subcutaneous twice weekly for 12 weeks, followed by self-injection of 50 mg subcutaneous weekly for 40 weeks.
3070580|NCT01170754|Experimental|PEG-3350 and Gatorade|255 miralax with 64 oz gatorade.
3070581|NCT01170754|Active Comparator|Golytely 4 Liters|Golytely 4 Liters
3070582|NCT01170884|Active Comparator|Combigan® + Lumigan®|COMBIGAN® (fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution) adjunctive to LUMIGAN® (bimatoprost 0.03% ophthalmic solution)
3070583|NCT01170884|Active Comparator|Lumigan®|LUMIGAN® (bimatoprost 0.03% ophthalmic solution) plus Gen Teal® Mild (hypromellose 0.2% eye drops) used for masking purposes
3070584|NCT01170949|Experimental|Miltefosine|
3070585|NCT01170949|Placebo Comparator|Placebo|
3070586|NCT01170962|Experimental|Arm 1: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
3070587|NCT01170962|Experimental|Arm 2: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior null responders)
3070588|NCT01170962|Experimental|Arm 3: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
3070589|NCT01170962|Experimental|Arm 4: BMS-790052 plus peginterferon alfa-2a and ribavirin|(prior partial responders)
3070590|NCT01170962|Experimental|Arm 5: Placebo plus peginterferon alfa-2a and ribavirin|(prior partial responders only)
3070591|NCT01171118|Experimental|Sedation & Physostigmine & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3070592|NCT01171118|Placebo Comparator|Sedation & Placebo & Room Air|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3070593|NCT01171118|Experimental|Sedation & Physostigmine & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3070594|NCT01171118|Placebo Comparator|Sedation & Placebo & Oxygen|We are attempting to demonstrate a decrease in the frequency and severity of sedation-induced respiratory arrhythmias (central and obstructive apneas) with pharmacological pre-treatment in this pilot project and then eventually to understand the mechanisms behind this decrease. The efficacy and mechanisms of these treatments, while evaluated during sleep in OSA patients, have not been systematically studied during sedation in either normal subjects or OSA patients. The agent to be assessed in this study is physostigmine versus placebo.We are interested in the effect of breathing oxygen vs. room air on the regulation of respiratory control during moderate sedation.
3070595|NCT01171183|Placebo Comparator|Placebo|
3070596|NCT01171183|Active Comparator|Carvedilol controlled release|controlled release carvedilol (Coreg CR) at 80 mg/day in once daily dosing
3070597|NCT01171521|Experimental|DermaClose Group|DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.
3070598|NCT01171612||Coronary Stent|Patients with coronary Bare Metal Stent (BMS) or Drug Eluting Stent (DES) undergoing noncardiac surgery
3070599|NCT01171625|Other|CEP Aortic Bioprothesis, model 3300TFX|
3070600|NCT01171677|Experimental|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
3070601|NCT01171677|No Intervention|Treatment as Usual|
3070602|NCT01171690|Experimental|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
3070603|NCT01171794|Active Comparator|ibuprofen|600mg ibu TID
3070604|NCT01171794|Placebo Comparator|placebo|visually identical
3070605|NCT01171820|Active Comparator|TAXUS® Liberté™|
3070606|NCT01171820|Active Comparator|XIENCE V® EECSS|
3468829|NCT03892096||Metastatic Lung Cancer, Colorectal Cancer or Breast Cancer|A total of 750 subjects with lung cancer, CRC and breast cancer will be consecutively enrolled. It is expected that 250 subjects will be lung cancer patients, 250 mCRC patients and 250 breast cancer patients.
3468830|NCT03892044|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO BID on days 1-28 and nivolumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3468831|NCT03891979|Experimental|Pembrolizumab + Antibiotics|Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.
3468832|NCT03892187|Experimental|Intervention Group|Participants are prescribed a walking prescription based on their baseline daily step count. During the interim between the day of consultation until the day of surgery, a study staff member will make weekly calls to each participant. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
3070611|NCT01171924|Experimental|Arm A: 5 days/week schedule|
3070612|NCT01171924|Experimental|Arm B: 3 days/week schedule|
3132384|NCT03422159|Experimental|Treatment Arm|Based on published clinical data, vitamin C pharmacokinetic modeling, the package insert as well as the preliminary study by Marik et al, Vitamin C will be administered as an intravenous dose of 6gm per day divided in 4 equal doses. This dosage is reported to be devoid of any complications or side effects. Hydrocortisone will be dosed according to the consensus guidelines of the American College of Critical Care Medicine. Thiamine will be administered according to current recommendations in a dose of 200mg q 12 hourly. This will be continued for 4 days, or less if discharged from the ICU prior.
3468833|NCT03892187|No Intervention|Control Group|Participants receive usual care prior to surgery. Participants will also log all of their physical activities including the date, activity type, and number of minutes.
3070613|NCT01171963|Experimental|Rotarix Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Rotarix™ vaccine, liquid formulation, at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccines were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Rotarix™ vaccine. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Rotarix™ and OPV vaccines were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
3070614|NCT01171963|Placebo Comparator|Placebo Group|Subjects aged between and including 6 and 16 weeks at the time of first vaccination received 2 doses of Placebo at Day 0 and at Month 1. As part of the routine childhood vaccination according to the Expanded Program of Immunization (EPI) recommendations in China, subjects in this group also received 3 doses of Infanrix™ vaccine and 3 doses of the oral poliovirus vaccine manufactured by the Institute of Medical Biology of the Chinese Academy of Medical Sciences (OPV). The Infanrix™ and the OPV vaccine were administered independently of (Sub-cohort 1) or concomitantly with (Sub-cohort 2) the Placebo. When administered concomitantly, subjects received the 3 doses of Infanrix™ vaccine at Months 1, 2 and 3, and the 3 doses of the OPV vaccine at Day 0, Month 1 and Month 2. The Placebo and the OPV vaccine were administered orally; the Infanrix™ vaccine was administered intramuscularly in the left anterolateral thigh.
3070615|NCT01171976|Experimental|TE Ranibizumab 0.5 mg and Laser|On Day 1, all patients received an intravitreal injection with 0.5 mg ranibizumab and subsequently entered Phase A which comprised of monthly injections. Laser therapy was applied at Day 1. It could then be re-administered according to ETDRS criteria at any visit with 0.5 mg ranibizumab treatment if deemed necessary by the Treating Investigator with a minimal treatment interval between laser treatments of 3 months. Laser therapy was administered ≥ 30 minutes prior to the ranibizumab injection.
3070616|NCT01171976|Experimental|TE Ranibizumab 0.5 mg alone|Patients received ranibizumab intravitreal injection therapy only.
3070617|NCT01171976|Active Comparator|PRN Ranibizumab 0.5 mg|Patients received ranibizumab intravitreal injection therapy as needed according to signs and symptoms of disease.
3070618|NCT01171989|Experimental|GSK2202083A + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of GSK2202083A and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of GSK2202083A vaccine at Day 0 and of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3070619|NCT01171989|Active Comparator|INFANRIX HEXA/MENJUGATE GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and 2 doses of Menjugate® vaccine in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with Menjugate® vaccine at Day 0. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3070620|NCT01171989|Active Comparator|INFANRIX HEXA/NEISVAC-C + SYNFLORIX GROUP|Healthy male and female subjects between, and including, 12 to 18 months of age at the time of booster vaccination, who were primed with 3 doses of Infanrix hexa™ vaccine and Synflorix™ vaccines in the primary study DTPa-HBV-IPV=HIB-MenC-TT-002 (112157), additionally received a booster dose of Infanrix hexa™ vaccine co-administered with NeisVac-C® vaccine at Day 0 and 1 dose of Synflorix™ vaccine at Month 1. Both vaccines were administered intramuscularly in the anterolateral side of the thigh.
3070621|NCT01172067|Experimental|Quickopt Group|the QuickOpt Group patients will be optimized by QuickOpt(IEGM);
3070622|NCT01172067|Active Comparator|Echocardiography group|the Echo Group patients will be optimized by Echo.
3070623|NCT01172145|Placebo Comparator|Cholinesterase inhibitor only|
3070624|NCT01172145|Experimental|Cholinesterase Plus Modafinil|
3070625|NCT01172184||Severe mitral regurgitation|Patients with severe mitral regurgitation are admitted for pre-operation cardiac catheterization and are willing to participate in this study.
3070626|NCT01172197|Active Comparator|Ropivacaine|Local anaesthetic bolus and infusion
3070627|NCT01172197|Active Comparator|Levobupivacaine|Local anaesthetic bolus and infusion
3070628|NCT01172275|Experimental|N-Acetylcysteine|N-Acetylcysteine effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
3070629|NCT01172275|Placebo Comparator|Placebo|Placebo effervescent tablets. 1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
3070630|NCT01172288|Experimental|N-Acetylcysteine|NAC was titrated up to a maximum dose of 2400 mg over the course of 2 weeks. Subjects were assigned 600 mg twice a day for weeks 1-2, and then were assigned 1200 mg twice a day for the remainder of the 12 week study.
3070631|NCT01172288|Placebo Comparator|Placebo|Placebo: Subjects were assigned to take two capsules twice a day for weeks 1-2, and then were assigned 4 capsules twice a day for the remainder of the 12 week study.
3070632|NCT01172353|Experimental|sodium bicarbonate|hydration with sodium bicarbonate
3070633|NCT01172353|Active Comparator|saline|hydration with saline 1ml/Kg/h for 6 hours
3070634|NCT01172418|Active Comparator|Thymoglobulin and Daclizumab|Group I: Our standard steroid avoidance protocol, i.e., 3 daily doses of 1 mg/kg of Thymoglobulin®, the first to be infused at surgery, accompanied by 2 doses of anti-CD25 humanized monoclonal antibody, the first also to be given at surgery, and the second 2 weeks later. (controls)
3070635|NCT01172418|Experimental|Thymoglobulin and Alemtuzumab|Group II: A new steroid avoidance protocol in which 1 dose of 1 mg/kg of Thymoglobulin® is to be infused at surgery followed by 1 dose of alemtuzumab (Campath-1H) at 0.3 mg/kg within 24 hours. No further antibody therapy will be used.
3070636|NCT01172522|Experimental|Fexofenadine left; placebo right|"Topical treatment active versus placebo.~Double blind randomized placebo controlled split face intrasubject comparison."
3070637|NCT01172522|Experimental|Fexofenadine right; placebo left|Split face double blind
3070638|NCT01172535|Experimental|Lopinavir/ritonavir|Participants will receive lopinavir/ritonavir in addition to two nucleoside reverse transcriptase inhibitors (NRTIs) chosen by their doctors.
3070639|NCT01172600|Active Comparator|Entonox|Patients will receive inhaled Entonox along with the interventional block they are scheduled.
3070640|NCT01172600|Placebo Comparator|Oxygen|Patients will receive inhaled oxygen along with the interventional block they are scheduled.
3070641|NCT01172639|Other|CoBRA classic high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Sulfasalazine 2g tablet by mouth, daily for 40 weeks~Prednisone tablet by mouth, weekly step down scheme 60 - 40 - 25 - 20 - 15 - 10 mg daily for 6 weeks, followed by 7.5mg daily till week 28, then further tapered down to stop at week 32"
3070642|NCT01172639|Other|CoBRA slim high risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
3070643|NCT01172639|Other|CoBRA avant-garde high risk group|"Methotrexate 15mg tablet by mouth, weekly for 40 weeks (continued for entire trial if randomized to Methotrexate monotherapy at week 40)~Leflunomide 10mg tablet by mouth, daily for 40 weeks (continued for entire trial if randomized to Leflunomide monotherapy at week 40)~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
3070644|NCT01172639|Other|CoBRA slim low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~Prednisone tablet by mouth, weekly step down scheme 30 - 20 - 12.5 - 10 - 7.5 mg daily for 5 weeks, followed by 5mg daily till week 28, then further tapered down to stop at week 32"
3070645|NCT01172639|Other|Tight Step Up low risk group|"Methotrexate 15mg tablet by mouth, weekly for entire trial~No oral steroids allowed during the first year of the trial"
3070646|NCT01172808|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3070647|NCT01172808|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3070648|NCT01172808|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
3070649|NCT01172808|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
3070650|NCT01172821|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3070651|NCT01172821|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler (+ inhalation of placebo HFA MDI twice daily)
3070652|NCT01172821|Active Comparator|50 mcg salmeterol|Twice daily, delivered with HFA MDI (+ inhalation of placebo Respimat® inhaler once daily)
3070653|NCT01172821|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler + twice daily delivered with HFA MDI
3070654|NCT01172847|Active Comparator|A|
3070655|NCT01172847|Active Comparator|B|
3070656|NCT01172847|Experimental|C|
3070657|NCT01172873|Active Comparator|DCS + Exposure and Response Prevention|Participants in this arm receive 10 twice-weekly 60-minute sessions of Exposure and Response Prevention (E/RP) therapy and 50mg of D-Cycloserine immediately after each therapy session. D-Cycloserine is only administered on days in which therapy sessions are held.
3070658|NCT01172873|Active Comparator|E/RP alone (no DCS administration)|Participants in this arm received twice-weekly 60 minute sessions of E/RP alone for a total of 10 sessions.
3070659|NCT01172938|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3070660|NCT01172938|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3070661|NCT01172938|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3070662|NCT01172938|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3070663|NCT01173016|Experimental|Laronidase After Transplantation|Patients with Mucopolysaccharidosis type IH (MPS I, Hurler syndrome) treated with a prior allogeneic transplant >2 years previously and treated with Laronidase weekly for 2 years after transplant.
3070664|NCT01173029||Resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was not achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure >/=130 mmHg or mean 24hr diastolic pressure >/=80mmHg) by non-investigation specialized hypertensive unit care, in spite of appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
3070665|NCT01173029||Pseudo-resistant Arterial Hypertension|Subjects with systemic arterial hypertension in whom arterial pressure control was achieved (24hr ambulatory pressure monitoring: mean 24hr systolic pressure <130 mmHg and mean 24hr diastolic pressure <80mmHg) by non-investigation specialized hypertensive unit care, with appropriate drug treatment regimen with three or more anti-hypertensive drugs including a diuretic. Anti-hypertensive drug treatment was non-investigational and was prescribed at discretion of the physician who performed primary evaluation.
3070666|NCT01173055|Experimental|Milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
3070667|NCT01173055|Experimental|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
3070668|NCT01173120|Experimental|Abatacept Combination Product (ACP)|Participants from the long-term period of study NCT00559585 who enrolled in the ACP substudy switched to administration of subcutaneous (SC) abatacept via the ACP for the duration of the substudy. Abatacept was administered SC using the ACP by the participant or caregiver on Substudy Day 1 and at weekly intervals thereafter. The ACP was a pre-filled liquid product device delivering 125 mg abatacept/device (125 mg/mL).
3070669|NCT01173159|Experimental|Omegaven|Subjects will receive Omegaven at a dose of up to 1 g/kg body weight/day until they no longer require Total Parenteral Nutrition or until their conjugated/direct bilirubin has normalized and their enteral lipid intake is sufficient to discontinue intravenous lipids.
3070670|NCT01173211|Experimental|Arm 1: Fluarix®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluarix®.
3070671|NCT01173211|Experimental|Arm 3: Fluzone®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Fluzone®.
3070672|NCT01173211|Experimental|Arm 2: Agriflu®|60 pregnant women and 20 non-pregnant women to receive a single intramuscular 0.5 mL dose of Agriflu®.
3070673|NCT01173471|Experimental|1) AZD4017|Europe: 200 mg AZD4017
3070674|NCT01173471|Placebo Comparator|2) Placebo|Europe: placebo
3070675|NCT01173471|Experimental|3) AZD4017|USA: 800 mg AZD4017
3070676|NCT01173471|Placebo Comparator|4) Placebo|USA: placebo
3070677|NCT01173523|Experimental|Cohort A: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort A participants had relapsed > 60 days following initial chemotherapy completion.
3070678|NCT01173523|Experimental|Cohort B: STA-9090|Once weekly IV dosing of STA-9090 200mg/m2 was given weeks 1, 2, and 3 of a 4-week cycle. Participants received treatment until evidence of progressive disease or unacceptable toxicity. Participants were stratified at baseline into 2 distinct prognostic groups. Cohort B participants had not responded or had relapsed </= 60 days from the completion of initial chemotherapy.
3070679|NCT01173601|Experimental|12 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 12-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3070680|NCT01173601|Experimental|18 milligrams (mg) LY2216684 + SSRI|"LY2216684: 12 milligrams (mg), administered orally, once daily (QD) for 1 week, followed by 18 mg, administered orally, once daily for 7 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the LY2216684 18-mg treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early entered a 2-week Discontinuation (DC) Phase. Participants were randomly assigned to either abrupt DC or tapered DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3070681|NCT01173601|Placebo Comparator|Placebo + SSRI|"Placebo: Tablet equivalent to LY2216684, administered orally, once daily (QD) for 11 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase and after randomization criteria were met, participants were randomized to the placebo treatment arm (AT Phase).~Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase. Participants who had received placebo were assigned to the abrupt DC over the 2-week DC Phase. Participants maintained their SSRI treatment during the DC Phase."
3070682|NCT01173653|Placebo Comparator|Standard EM Smoking Cessation Info|Patients discharged from ER receive pamphlet re: smoking cessation
3070683|NCT01173653|Active Comparator|Patients contact 1-800-QUIT-NOW before leaving ED|Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
3070684|NCT01173679|Other|dasatinib, rituximab, fludarabine|Single-arm, open-label
3070685|NCT01173692|Placebo Comparator|Placebo|Twice Daily Orally
3070686|NCT01173692|Experimental|Minocycline|100 mg Twice Daily Orally
3070687|NCT01173718|Experimental|GORE® ACUSEAL Vascular Graft|
3070688|NCT01173848|Active Comparator|Vitamin D2|Patients randomized to take vitamin D2
3070689|NCT01173848|Active Comparator|Vitamin D3|Patient's randomized to take Vitamin D3
3070690|NCT01173874|Experimental|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
3070691|NCT01173874|No Intervention|Cognitive activity control group|This is a non-specific mental activity control condition, conducted two times per week for a total of 30 sessions.
3070692|NCT01174004|Experimental|1|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
3070693|NCT01174004|Placebo Comparator|2|placebo, tablet, once daily by mouth for 6 weeks
3070694|NCT01174030|Experimental|CD07805/47 Gel 0.5% QD|
3070695|NCT01174030|Experimental|CD07805/47 Gel 0.18% QD|
3070696|NCT01174030|Experimental|CD07805/47 Gel 0.18% BID|
3070697|NCT01174030|Placebo Comparator|Vehicle Gel QD|
3070698|NCT01174030|Placebo Comparator|Vehicle Gel BID|
3070699|NCT01174043|Experimental|Erlotinib|
3070700|NCT01174082|Experimental|KLH Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
3070701|NCT01174082|Experimental|KLH-id Vaccine (Patient)|After DLI on same day, patients receive vaccine according to donor randomization (the same type of vaccine that their donors received).
3070702|NCT01174082|Experimental|KLH Vaccine (Donor)|Donor Group 1: (non-specific vaccination) vaccinated with KLH only vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
3070703|NCT01174082|Experimental|Vaccine KLH-id (Donor)|Donor Group 2: (myeloma specific vaccination) vaccinated with KLH-id vaccine 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collections.
3070704|NCT01174160|Experimental|vernakalant HCl|vernakalant hydrochloride
3070705|NCT01174160|Placebo Comparator|placebo|placebo
3070706|NCT01174173|Experimental|Ranolazine|1000 mg PO BID
3070707|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin elevated|Spondylitis patients with elevated levels of fecal calprotectin. Patients are treated with adalimumab
3070708|NCT01174186|Active Comparator|Spondyloarthritis and calprotectin normal|Spondylitis patients with normal levels of fecal calprotectin. Patients are treated with adalimumab.
3070709|NCT01174238|Experimental|Arm A|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. In addition patients enrolled in Arm A will also have FLT-PET scans.
3070710|NCT01174238|Experimental|Arm B|Patients enrolled in Arm A and Arm B will receive the same treatment with study drugs axitinib, carboplatin, and paclitaxel. Patients enrolled in Arm A and Arm B will have tumor imaging assessments: PET-CT, CT Scan, and/or MRI. Patients enrolled in Arm B will not have FLT-PET scans.
3070711|NCT01174264|Experimental|Arm I (vismodegib on empty stomach)|Patients receive a single dose of vismodegib PO on an empty stomach. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
3070712|NCT01174264|Experimental|Arm II (vismodegib after high fat meal)|Patients receive a single dose of vismodegib PO after eating a high fat meal. Beginning 7 days later, patients receive vismodegib PO on an empty stomach daily on days 1-28.
3070713|NCT01174264|Experimental|Arm III (vismodegib after low fat meal)|Patients receive a single dose of vismodegib PO after eating a low fat meal. Beginning 7 days later, patients receive vismodegib PO after eating a meal daily on days 1-28.
3070714|NCT01174342||Pregnant women|Healthy pregnant women
3070715|NCT01174446|Experimental|BAX 326|Recombinant factor IX (rFIX)
3070716|NCT01174446|Active Comparator|BeneFIX|Recombinant Factor IX (rFIX)
3070717|NCT01174459||Patient with Restless Legs Syndrome|
3070718|NCT01174550|Active Comparator|Functional diagnostic tests|Stress Echocardiogram Nuclear Stress Test Exercise Electrocardiogram
3070719|NCT01174550|Active Comparator|Anatomic diagnostic test|Coronary Angiography
3468834|NCT03892187|No Intervention|Observation Group|Participants who are not frail will receive usual care prior to surgery and charts will be reviewed for outcomes following surgery.
3070721|NCT01174576|Experimental|caffeinated coffee|200 mL caffeinated coffee with 3 mg caffeine per kg body weight
3070722|NCT01174576|Experimental|decaffeinated coffee|200 mL decaffeinated coffee, same amount as caffeinated coffee
3070723|NCT01174576|Experimental|Water|200 mL, control intervention
3070724|NCT01174784|Experimental|Treatment|The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
3070725|NCT01174823|Experimental|Bepotastine Besilate Ophthalmic Solution|
3070726|NCT01174823|Placebo Comparator|Placebo|
3070727|NCT01175005||Fever and a central venous catheter|
3070728|NCT01175018|Experimental|Anakinra|Anakinra 100 mg injectable subcutaneously daily
3070729|NCT01175018|Placebo Comparator|Placebo|0.67 ml of sodium chloride (NaCl) 0.9% solution
3070730|NCT01175031|Experimental|REMstar Auto with A-Flex|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be measured with REMstar Auto with A-Flex.
3070731|NCT01175031|Other|Manually Scored Polysomnography (PSG)|Manipulation of positive airway pressure (PAP) will occur throughout the night to induce breaking events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced, and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night. Events will be Manually Scored Polysomnography (PSG).
3070732|NCT01175083|Experimental|Tritanrix-HepB/Hib+Polio Sabin <6S Group|Children below (<) 6 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
3070733|NCT01175083|Active Comparator|Tritanrix-HepB/Hib+Polio Sabin <6NS Group|Healthy children, below (<) 6 months of age at time of enrolment, who received a 3-dose primary vaccination at Study Months 0, 1 and 2 with Synflorix vaccine co-administered with Tritanrix-HepB/Hib and Polio Sabin vaccines, followed by a booster vaccination at Study Month 8.
3070734|NCT01175083|Experimental|Synflorix 7-11S Group|Children between 7-11 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
3070735|NCT01175083|Active Comparator|Synflorix 7-11NS Group|Healthy children between 7-11 months of age at time of enrolment, who received a 2-dose primary vaccination at Study Months 0 and 1 with Synflorix vaccine, followed by a booster vaccination at Study Month 3.
3070736|NCT01175083|Experimental|Synflorix 12-23S Group|Children between 12-23 months of age at time of enrolment, diagnosed with sickle cell disease (S), who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
3070737|NCT01175083|Active Comparator|Synflorix 12-23NS Group|Healthy children between 12-23 months of age at time of enrolment, who received a 2-dose vaccination with Synflorix vaccine, at Study Months 0 and 2.
3070738|NCT01175135|Experimental|PF-02545920 5 mg|
3070739|NCT01175135|Experimental|PF-02545920 15 mg|
3070740|NCT01175135|Placebo Comparator|Placebo|
3070741|NCT01175135|Active Comparator|Risperidone 3 mg|
3070742|NCT01175148|Experimental|Recipient - Atorvastatin to prevent GVHD|Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning. Patients will receive atorvastatin until +180 days or development of grade 2 GVHD. This is the experimental arm for outcome measures.
3070743|NCT01175148|Other|Donor - Atorvastatin conditioning for donors|Sibling donors will start taking Atorvastatin calcium (Lipitor) orally at 40mg once daily between 14-28 days before the anticipated first day of apheresis or bone marrow harvest.
3070744|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of SC of IGSC, 10% only (safety follow-up)
3070745|NCT01175213|Experimental|SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety|Efficacy and safety of subcutaneous (SC) administration of Immune Globulin Subcutaneous Solution (IGSC), 10% after SC administration of recombinant human hyaluronidase (rHuPH20) followed by Safety of intravenous (IV) administration of IGSC, 10% only (safety follow-up)
3070746|NCT01175213|Experimental|IV treatment with IGSC, 10% only|Partial efficacy (trough levels of immunoglobulin G [IgG] only) and safety of intravenous (IV) administration of IGSC, 10% only. This was for participants enrolled in the study who had anti-rHuPH20 andibody titer from study160603
3070747|NCT01175226|Experimental|BTA798|
3070748|NCT01175226|Placebo Comparator|Placebo|
3070749|NCT01175317|Experimental|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
3070750|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
3070751|NCT01175343|Experimental|Treatment (RO4929097)|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for correlative studies. Ascitic fluid may also be collected."
3070752|NCT01175356|Experimental|Treatment (131I-MIBG, chemotherapy)|See Detailed Description.
3070753|NCT01175369|No Intervention|Usual Care|Usual asthma care
3070754|NCT01175369|Experimental|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
3070755|NCT01175382|Active Comparator|Behavioral Treatment alone|Behavioral treatment is implemented in 4 clinic visits over a period of 6 weeks, followed by 6 weeks of combined behavioral + drug therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and daily bladder diaries, supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
3070756|NCT01175382|Active Comparator|Drug Therapy (Tolterodine + tamsulosin)|Drug therapy for 6 weeks implemented in a clinic visit with telephone follow-up at 3 weeks, followed by 6 weeks of combined drug + behavioral therapy. Participants in the drug group will receive an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
3070757|NCT01175382|Experimental|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
3070758|NCT01175395|Experimental|IBI-20089/Lucentis|Alternate treatment of either 6.9 mg IBI-20089/Lucentis or 13.8 mg IBI-20089/Lucentis
3070759|NCT01175434|Experimental|School-Based Medication Group|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse will begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
3070760|NCT01175434|No Intervention|Usual Care Group|Children in the Usual Care group will not receive preventive medications delivered at school. These children will continue to receive all of their asthma care from their parents and primary care physicians.
3070761|NCT01175473|Experimental|Lixisenatide|1-step initiation regimen of lixisenatide: 10 microgram (mcg) once daily (QD) for 2 weeks, followed by 20 mcg QD for up to Week 4.
3070762|NCT01175473|Active Comparator|Liraglutide|2-step initiation regimen of liraglutide: 0.6 milligram (mg) QD subcutaneously for 1 week, followed by 1.2 mg QD for 1 week, then 1.8 mg QD up to Week 4.
3070763|NCT01175590|Experimental|Besivance|besifloxacin ophthalmic suspension 0.6%
3070764|NCT01175590|Placebo Comparator|Vehicle|Vehicle of Besivance
3070765|NCT01175668|Experimental|NMS/Clonidine|
3070766|NCT01175668|Active Comparator|NMS/Phenobarbital|
3070767|NCT01175707|Experimental|Daptomycin|500 milligrams (mg) daptomycin, administered intravenously (IV) for 7 to 10 days accordingly to the package insert or according to institutional practice, if warranted
3070768|NCT01175707|Active Comparator|Vancomycin|Vancomycin monotherapy is administered according to prescribing physician's order with duration of treatment modified, if warranted, according to Investigator site's standard practice, and End of Treatment (EOT) is dependent on this. Dose adjustments of vancomycin will be suggested by the pharmacist and approved by prescribing or following physician
3070769|NCT01175798|No Intervention|No treatment (standard of care)|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
3070770|NCT01175798|Experimental|Vitamin D repletion|Patients will be randomized in a 3:2 ratio to oral Vitamin D treatment, or standard of care (no repletion).
3070771|NCT01175811|Experimental|Premixed Insulin|Twice daily (before breakfast and lunch) insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension [LM50]) and once daily (before dinner) insulin lispro mix 25 (25% insulin lispro, 75% insulin lispro protamine suspension [LM25])
3070772|NCT01175811|Active Comparator|Basal-Bolus|Once daily (bedtime) insulin glargine and three pre-meal insulin lispro
3070773|NCT01175824|Experimental|Insulin lispro low mixture (LM)|Two daily injections (breakfast and dinner) of insulin lispro mix 75/25
3070774|NCT01175824|Active Comparator|Insulin glargine+insulin lispro|Once-daily (bedtime) basal insulin glargine and once-daily (before the main meal with the highest average 2-hour postprandial blood glucose concentration) prandial insulin lispro
3070775|NCT01175850|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
3070776|NCT01175850|Active Comparator|Standard PTA|Standard Percutaneous Transluminal Angioplasty (PTA) Balloon: Balloon Angioplasty
3070777|NCT01175902|Active Comparator|Arm 1|Latanoprost first, then Dorzolamide/Timolol Patients first on Latanoprost eyedrops once a day, then on Dorzolamide/Timolol twice a day
3070778|NCT01175902|Active Comparator|Arm 2|Dorzolamide/Timolol first, then Latanoprost Patients first on Dorzolamide/Timolol eyedrops twice a day, then on Latanoprost eyedrops once a day
3070779|NCT01175980|Experimental|Treatment (vorinostat)|Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3070780|NCT01176032|Experimental|Aliskiren|"Aliskiren 150 mg od for 2 weeks and up-titration to aliskiren 300 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
3070781|NCT01176032|Active Comparator|Lostaran|"Losartan 50 mg od for 2 weeks and up-titration to losartan 100 mg od for 34 weeks. In addition to the study medication, amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks of treatment at the maximum doses of study medication. At week 18 the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.~HCTZ 12.5mg was prescribed at week 26 if the required values (<140/90 mmHg) had not been reached."
3070782|NCT01176058|Active Comparator|open label|
3070783|NCT01176240|Experimental|Droxidopa|droxidopa active drug
3070784|NCT01176240|Placebo Comparator|Placebo|Placebo matched control
3070785|NCT01176266|Experimental|Asfotase alfa|A total of 6 mg/kg/week of asfotase alfa administered by SC injection (either 1 mg/kg asfotase alfa 6 times per week, or 2 mg/kg asfotase alfa 3 times per week)
3070786|NCT01176292|Other|Rotating Platform High-Flex Cruciate Substituting TKA|
3070787|NCT01176292|Other|Rotating Platform Cruciate Substituting TKA|
3070788|NCT01176435|Active Comparator|0.76 mg/kg L-DOPA|Solution taken orally three times a day.
3070789|NCT01176435|Active Comparator|0.51 mg/kg L-DOPA|Solution taken orally three times a day.
3070790|NCT01176435|Placebo Comparator|Placebo|Solution taken orally three times a day.
3070791|NCT01176448|Experimental|Fractionated laser|This Arm is the section of scar that will be treated with Fractionated Laser
3070792|NCT01176448|Active Comparator|Dermabrasion|Dermabrasion is the gold standard for scar resurfacing and will be used as the control against which Fractionated Laser is compared.
3070793|NCT01176565|Active Comparator|Standard SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the standard BP reduction group will be to reduce and maintain SBP < 180 mmHg for 24 hours from randomization. 160 mmHg is the target SBP for this arm.~For the standard group, SBP below the assigned treatment range is not artificially elevated to stay within the range if lower SBP occurs with nicardipine turned off (no fluid bolus given unless SBP falls below 110 mmHg with nicardipine off and there is risk for hypotension). Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
3070794|NCT01176565|Active Comparator|Intensive SBP Reduction Arm|"Intravenous nicardipine hydrochloride will be used as necessary (pro re nata or PRN) as the primary agent in lowering SBP.~The goal for the intensive BP reduction group will be to reduce and maintain SBP < 140 mmHg for 24 hours from randomization. 125 mmHg is the target SBP for this arm.~For the intensive group, SBP falling below 110 mmHg (lower limit of the assigned treatment range) with nicardipine off is treated with normal saline fluid bolus to prevent or remedy hypotension. Euvolemic fluid maintenance is encouraged for all patients according to their medical needs, which may differ."
3070795|NCT01176591|Experimental|Placebo Session 1, Aprepitant Session 2|Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.
3070796|NCT01176591|Placebo Comparator|Placebo Session 1, Placebo Session 2|Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.
3070797|NCT01176617|No Intervention|Conventional Monitoring Strategy|Subjects will be monitored for 12 months using the conventional strategy which includes wearing a monitor over 3 separate 30-day periods over the first year post-ablation and daily pulse checks.
3070798|NCT01176617|Other|Reveal XT|Subjects will be monitored using the conventional monitoring strategy for the first 6 months post-ablation. During the next 6 months, subjects will be monitored using the data from the Reveal device, transmitted from home every 30 days.
3070799|NCT01176773|Experimental|Juvéderm® Ultra Lip Injectable Gel|
3070800|NCT01176877|Other|keloid scar|Those with a diagnosis of keloid scar.
3070801|NCT01176916|Experimental|A|
3070802|NCT01176955|Experimental|Internet survey|Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.
3070803|NCT01176955|Placebo Comparator|Control|Subjects will receive standard-of-care treatment with the study medication, without internet surveys.
3070804|NCT01176968|Experimental|Eplerenone plus standard of care|
3070805|NCT01176968|Placebo Comparator|Placebo plus standard of care|Matching placebo for eplerenone 25mg film coated tablets.
3070806|NCT01176981|Experimental|HDMTX|This is a single arm study. All subjects enrolled in the study will be in this arm.
3070807|NCT01177007|Experimental|TheraSphere|
3070808|NCT01177059|Other|Anti-HIV-1 Ribozyme (OZ1) transduced cells|OZ1 transduced cells Long term follow up of previously infused OZ1 transduced cells
3070809|NCT01177098|Experimental|bimatoprost/timolol formulation A|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
3070810|NCT01177098|Active Comparator|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
3070811|NCT01177137|Experimental|TRT|TRT includes treatment with a conventional sound generator (SG) and directive counseling (DC)
3070812|NCT01177137|Other|Partial TRT|Partial TRT includes treatment with a placebo sound generator (placebo SG) and directive counseling (DC).
3070813|NCT01177137|Other|Standard of Care (SC)|The standard of care arm includes care as typically delivered in US military medical centers
3070814|NCT01177189|Other|Arm 1|Young healthy men and women aged 18-30
3070815|NCT01177189|Other|Arm 2|Older healthy men and women aged >70.
3070816|NCT01177228|Placebo Comparator|Placebo|Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
3070817|NCT01177228|Experimental|Vedolizumab 2 mg/kg|Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3070818|NCT01177228|Experimental|Vedolizumab 6 mg/kg|Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3070819|NCT01177228|Experimental|Vedolizumab 10 mg/kg|Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
3070820|NCT01177293|Active Comparator|treatment A - reference w/ water|
3070821|NCT01177293|Experimental|Treatment B - ODT (test) w/o water|
3070822|NCT01177384|Experimental|Sitagliptin|Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily [t.i.d.])
3070823|NCT01177384|Placebo Comparator|Placebo|Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)
3070824|NCT01177410|Placebo Comparator|Placebo|
3070825|NCT01177410|Experimental|Mesalamine Granules 750 mg|
3070826|NCT01177410|Experimental|Mesalamine Granules 1500 mg|
3070827|NCT01177553|Active Comparator|Surgery Group|"Patients randomized to surgery will have hospital arrangements (laboratory tests and anesthesia assessment) finalized for a surgery the next day. Patients will sign the informed consent form.~Patients undergoing surgery will be admitted to Tampa General Hospital and will complete usual hospital admission procedures."
3070828|NCT01177553|Active Comparator|Expectant Management Group|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
3070829|NCT01177709|Experimental|Metformin|
3070830|NCT01177722|Experimental|Group 1: DTaP-IPV-Hep B-PRP-T (Lot A)|
3070831|NCT01177722|Experimental|Group 2: DTaP-IPV-Hep B-PRP-T (Lot B)|
3070832|NCT01177722|Experimental|Group 3: DTaP-IPV-Hep B-PRP-T (Lot C)|
3070833|NCT01177722|Active Comparator|Group 4: Active Control|
3070834|NCT01177735|Experimental|Pomalidomide|
3070835|NCT01177787|Active Comparator|zeltiq|Cryolipolysis had been done for 1 hour on ipsilateral thigh fat through Zeltiq machine.
3070836|NCT01177787|Sham Comparator|electrical stimulation|Lipolysis had been done for 30 minutes on controlateral thigh fat through amplitude modulated frequency.
3070837|NCT01177800|Experimental|Infliximab|5 milligram per kilogram (mg/kg) infusion (a fluid or a medicine delivered into a vein by way of a needle) of infliximab administered intravenously (into a vein) at Week 0, 2 and 6 followed by maintenance regimen of 5 mg/kg infliximab at Week 14 and 22. Placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial infusion), matched to infliximab will be given at Week 10, 12 and 16. Total duration of treatment will be 26 weeks.
3070838|NCT01177800|Experimental|Placebo|Placebo infusion, matched to infliximab will be given intravenously at Week 0, 2 and 6. At Week 10, 12 and 16, participants will receive 5 mg/kg infliximab intravenously. Placebo infusion will be again given at Week 14 and 22. Total duration of treatment will be 26 weeks.
3070839|NCT01177813|Experimental|BI 10773 low dose|Patients receive BI 10773 low dose tablets once daily
3070840|NCT01177813|Experimental|BI 10773 high dose|Patients receive BI 10773 high dose tablets once daily
3070841|NCT01177813|Placebo Comparator|Placebo|Patients receive tablets identical to those containing BI 10773 low dose and high dose and to Sitagliptin
3070842|NCT01177813|Active Comparator|Sitagliptin 100 mg|Patients receive Sitagliptin 100 mg tablets once daily
3070843|NCT01177813|Experimental|BI 10773 high dose open label|Patients receive BI 10773 high dose tablets open label once daily
3070844|NCT01177943|Experimental|Atomoxetine Oral Solution|
3070845|NCT01177943|Active Comparator|Atomoxetine Capsule Formulation|
3070846|NCT01177956|Experimental|Cetuximab + Cisplatin + 5-Fluorouracil (5-FU)|
3070847|NCT01177969|Experimental|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
3070848|NCT01177969|Placebo Comparator|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
3070849|NCT01178073|Active Comparator|Combination ambrisentan + tadalafil|ambrisentan + tadalafil
3070850|NCT01178073|Active Comparator|Monotherapy ambrisentan|ambrisentan
3070851|NCT01178073|Active Comparator|Monotherapy tadalafil|tadalafil
3070852|NCT01178086||Participants With CLL|Participants with CLL who are being treated with intravenous (IV) rituximab in combination with chemotherapy, will be observed for 24 months including 6-month treatment period.
3070853|NCT01178099|Experimental|Prasugrel|Participants received a single 10 milligram (mg) dose on Day 1 (single dose [SD]), followed by either 5 mg/day (for participants<60 kilograms [kg]) or 7.5 mg/day (for participants≥60 kg) for an additional 11 days (multiple dose [MD]).
3070854|NCT01178125|Experimental|DR-102|desogestrel/ethinyl estradiol 0.15/0.02 mg for 21 days then ethinyl estradiol 0.01 mg for 7 days
3070855|NCT01178138|Other|Prazosin effects on methamphetamine|Randomized placebo controlled trial of prazosin effects on methamphetamine
3070856|NCT01178216|Experimental|Rituxan|All study patients will receive Rituxan 1g on day 15 from start of desensitization and either 3M or 6M post transplant depending on the presence of DSA.
3070857|NCT01178268|Active Comparator|XIENCE V EECSS|Patients who will receive this stent.
3070858|NCT01178268|Active Comparator|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
3070859|NCT01178281|Experimental|Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit (defined as a reduction from Baseline of ≥ 50% in RBC-transfusion frequency during the prior 84-day interval) could continue to receive pomalidomide until loss of RBC-transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
3070860|NCT01178281|Placebo Comparator|Placebo|"Participants received placebo taken by mouth once daily for at least 168 days unless there were unacceptable side effects or disease progression.~Participants who were RBC-transfusion independent or experienced clinical benefit could continue to receive placebo until loss of RBC- transfusion independence response or clinical benefit, or other criteria for treatment discontinuation applied."
3070861|NCT01178281|Experimental|China Extension: Pomalidomide 0.5 mg|"Participants received pomalidomide 0.5 mg/day by mouth for at least 168 days unless there were unacceptable side effects, disease progression, or they received a RBC-transfusion.~Participants who experienced anemia response could continue treatment until the response was lost or other criteria for treatment discontinuation applied."
3070862|NCT01178294|Experimental|OBI-1|Initial dose: 200 U/kg - additional doses at the discretion of the investigator based on FVIII activity level and clinical assessment of response to treatment (upper limit: 400 U/kg every 2 hours)
3070863|NCT01178385|Experimental|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
3070864|NCT01178385|Active Comparator|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3070865|NCT01178411|Experimental|Tivantinib (Monotherapy or Combination Therapy)|Tivantinib 360 mg will be administered twice daily, orally, with meals, as a monotherapy or in combination with other drug therapies.
3070866|NCT01178528|Experimental|Ivabradine|7.5 mg bd
3070867|NCT01178528|Active Comparator|Carvedilol|up to 25 mg bd
3070868|NCT01178528|Experimental|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
3070869|NCT01178671|Experimental|Sertraline and Mirtazapine|Flexible dose of both medications for up to 24 weeks
3070870|NCT01178671|Active Comparator|Sertraline and Sugar pill|Sertraline and Sugar pill for up to 24 weeks
3070871|NCT01178762|Experimental|Observation|
3070872|NCT01178814|Experimental|Revlimid|Revlimid (Lenalidomide) capsule taken orally once a day
3070873|NCT01178827|Experimental|Sanctura XR®|Sanctura XR® (trospium chloride), 60mg once daily for 10 days
3070874|NCT01178827|Active Comparator|Oxybutynin IR|Oxybutynin IR (oxybutynin immediate release), 5 mg three times daily for 2 days
3070875|NCT01178827|Placebo Comparator|Oxybutynin IR placebo|Oxybutynin IR placebo three times daily for 2 days
3070876|NCT01178853|Experimental|Pitavastatin/Rosuvastatin|
3070877|NCT01178853|Experimental|Rosuvastatin/Pitavastatin|
3070878|NCT01178944|Experimental|Treatment (pralatrexate, oxaliplatin)|Patients receive pralatrexate IV over 3-5 minutes and oxaliplatin IV over 2 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Oxaliplatin will be discontinued after 12 courses.
3070879|NCT01179048|Experimental|Liraglutide|
3070880|NCT01179048|Placebo Comparator|Placebo|
3070881|NCT01179113|Placebo Comparator|Placebo|Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively
3070882|NCT01179113|Active Comparator|Esmolol|Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively
3070883|NCT01179191|Experimental|morphine sulfate and naltrexone hydrochloride (EMBEDA)|
3070884|NCT01179217|Experimental|L-glutamine|Patients will be randomized to receive investigational product, L-Glutamine.
3070885|NCT01179217|Placebo Comparator|100% maltodextrin|Patients will be randomized to receive Placebo.
3070886|NCT01179334|Experimental|Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT|Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
3070887|NCT01179334|Placebo Comparator|Placebo|Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks. Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
3070888|NCT01179347|Experimental|tiotropium|2 inhalations once daily delivered with Respimat® inhaler
3070889|NCT01179347|Placebo Comparator|placebo|2 inhalations once daily delivered with Respimat® inhaler
3070890|NCT01179490|Experimental|SyB L-0501 + prednisolone|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.
3070891|NCT01179516|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 8 weeks.
3070892|NCT01179516|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
3070893|NCT01179516|Experimental|Vortioxetine 15 mg|Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week, then vortioxetine 15 mg, encapsulated tablets, orally, once daily for up to 7 weeks.
3070894|NCT01179568|Active Comparator|CGT with Citalopram|Targeted psychotherapy for complicated grief will be combined with SSRI medication.
3070895|NCT01179568|Active Comparator|Citalopram|Citalopram is an Selective Serotonin Reuptake Inhibitor (SSRI) medication. It will be combined with grief-focused clinical management.
3070896|NCT01179568|Placebo Comparator|Placebo (Sugar pill)|Inactive medication. It will be combined with grief-focused clinical management.
3070897|NCT01179568|Active Comparator|CGT with Placebo|The targeted psychotherapy for complicated grief will be combined with inactive medication.
3070898|NCT01179672|Experimental|Duloxetine|
3070899|NCT01179672|Placebo Comparator|Placebo|
3070900|NCT01179919|Experimental|Oseltamivir Dosed Group|Oseltamivir 75 mg by mouth every 12 hours for 9 doses
3070901|NCT01179984|Experimental|PTA and study stent|Bard® LifeStent® Vascular Stent System
3070902|NCT01180036|Active Comparator|Rituximab Treatment Arm|Patients randomized to the RTX arm will receive 1000 mg IV on Days 1 and 15. Patients who achieve complete remission at 6 months will not be retreated. A second course of RTX 1000 mg IV will be administered at study month 6 for individuals who have not achieved a complete remission, but have achieved a minimum of >25% reduction in Time 0 proteinuria. Dosing at study month 6 will be independent of cluster of differentiation (CD) 19+ B cell count.
3070903|NCT01180036|Active Comparator|Cyclosporine Treatment Arm|Patients randomized to the Cyclosporine arm will be started at a dose of CsA = 3.5 mg/kg/day p.o. divided into 2 equal doses given at 12 hour intervals. Target trough CsA blood levels are 125 to 175 ng/ml. Patients will have their doses adjusted according to their blood levels of CSA as monitored every 2 weeks until the target trough level is reached. If a complete remission is achieved by 6 months, CSA will be tapered and discontinued over a three-month period. If after 6 months there has not been a reduction in proteinuria of at least 25% of baseline values, the drug will also be discontinued. If there has been a >25% reduction in baseline proteinuria (but not complete remission) the CSA will be continued for an additional 6 months.
3070904|NCT01180049|Active Comparator|temsirolimus (Torisel) 175mg weekly x 3, then 75mg weekly|
3070905|NCT01180049|Active Comparator|temsirolimus (Torisel) 75mg weekly|
3070906|NCT01180127|Active Comparator|exercise, dietary intervention|aerobic training and flavanol containing food product for 12 weeks
3070907|NCT01180127|Active Comparator|no exercise, dietary intervention|wait list control plus flavanol containing food product for 12 weeks
3070908|NCT01180127|Active Comparator|exercise, food product lacking flavanol|aerobic training plus food product without flavanol for 12 weeks
3070909|NCT01180127|Placebo Comparator|wait list control food additive without flavanol|wait list control plus food product without flavanol for 12 weeks
3070910|NCT01180244|Active Comparator|Active treatment|Subjects in this group will receive the noninvasive cortical stimulation signal from the treatment device
3070911|NCT01180244|Placebo Comparator|Placebo group|Subjects in this group will be provided the same experience as those in the active treatment arm, but will not receive the noninvasive cortical stimulation signal from the treatment device
3070912|NCT01180296|Experimental|Progesterone Group|Oral Micronized Progesterone
3070913|NCT01180296|Placebo Comparator|Placebo|Identical Placebo Tablet
3070914|NCT01180400|Experimental|TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1-4 mg BID
3070915|NCT01180400|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3070916|NCT01180478|Other|Narrow Band Imaging|Narrow Band Imaging (NBI)
3070917|NCT01180478|Other|White Light Trans Urethral Resection|White Light Trans Urethral Resection
3070918|NCT01180647|Active Comparator|Extended-release naltrexone (XR-NTX)|A single 380mg IM depot injection of XR-NTX in the week prior to release from jail. A second 380mg IM injection is offered to persons in the XR-NTX arm post-release and 4 weeks after the initial injection.
3070919|NCT01180647|Placebo Comparator|Motivational Enhancement Counseling Only|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
3070920|NCT01180660|Active Comparator|Lidocaine|Lidocaine infusion
3070921|NCT01180660|Placebo Comparator|Placebo|Placebo Normal Saline Infusion
3070922|NCT01180777|Other|etafilcon A (A)/etafilcon A (B)/etafilcon A (C)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
3070923|NCT01180777|Other|etafilcon A (A)/etafilcon A (C)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
3070924|NCT01180777|Other|etafilcon A (C)/etafilcon A (A)/etafilcon A (B)|Printed etafilcon A Lens with PVP (A) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (B) worn the last. Each period consisted of approximately one week of daily lens wear.
3070925|NCT01180777|Other|etafilcon A (B)/etafilcon A (C)/etafilcon A (A)|Printed etafilcon A Lens with PVP (B) worn first, then printed etafilcon A Lens with PVP (C) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
3070926|NCT01180777|Other|etafilcon A (C)/etafilcon A (B)/etafilcon A (A)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (B) worn second, then printed etafilcon A Lens with PVP (A) worn the last. Each period consisted of approximately one week of daily lens wear.
3070927|NCT01180777|Other|etafilcon A (B)/etafilcon A (A)/etafilcon A (C)|Printed etafilcon A Lens with PVP (C) worn first, then printed etafilcon A Lens with PVP (A) worn second, then printed etafilcon A Lens with PVP (C) worn the last. Each period consisted of approximately one week of daily lens wear.
3070928|NCT01180790|Experimental|Segment 1: 200 mg ACH-0141625|200 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a and ribavirin for 48 weeks
3070929|NCT01180790|Experimental|Segment 1: 400 mg ACH-0141625|400 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3070930|NCT01180790|Experimental|Segment 1: 800 mg ACH-0141625|800 mg ACH-0141625 for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3070931|NCT01180790|Placebo Comparator|Segment 1: Placebo|Placebo for 28 days plus Peg-IFN alpha-2a plus ribavirin for 48 weeks
3070932|NCT01180790|Experimental|Segment 2: 200 mg ACH-0141625|200 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3070933|NCT01180790|Experimental|Segment 2 : 400 mg ACH-0141625|400 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3070934|NCT01180790|Experimental|Segment 2 : 800 mg ACH-0141625|800 mg ACH-0141625 for 12 weeks plus Peg-IFN and ribavirin for up to a total of 24 or 48 weeks
3070935|NCT01180894|Active Comparator|Iron sucrose|100 mg IV TIW
3070936|NCT01180894|Placebo Comparator|Placebo|Pacebo - Normal Saline
3070937|NCT01180985|Other|galyfilcon A prototype/comfilcon A|The galyfilcon A prototype lenses are worn during first period and comfilcon A lenses worn during second period. Each period consists of daily lens wear for one week.
3070938|NCT01180985|Other|comfilcon A/galyfilcon A prototype|The comfilcon A lenses are worn during first period and galyfilcon A prototype lenses worn during second period. Each period consists of daily lens wear for one week.
3070939|NCT01180998|Other|Spherical contact lens users|Habitual spherical contact lens (non-toric lens) users tried one of two toric lenses in a daily wear modality.
3070940|NCT01180998|Other|Contact lens drop-outs|Habitual spectacle users (for vision correction) who have failed contact lens fit and wear, tried one of two toric lenses in a daily wear modality.
3070941|NCT01180998|Other|Habitual Correction with Spectacles (Neophytes)|Habitual spectacle lens wearers (for vision correction) who have never used or been fitted with contact lenses tried one of two toric lenses in a daily wear modality.
3070942|NCT01181011|Experimental|amlodipine/telmisartan/combination|all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
3070943|NCT01181050|Experimental|4.0 mg/kg|Subjects received a single dose of 4 mg/kg NNC0142-0002
3070944|NCT01181050|Placebo Comparator|Placebo|Subjects received a single dose of placebo
3070945|NCT01181076|Experimental|Individualized Nutrition|
3070946|NCT01181076|No Intervention|Control group|The patients in the control group will be nourished after established routine, first by the oral route, later by the PN route. Naso-jejunal tube will not be inserted and enteral nutrition will not be given.
3070947|NCT01181102|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
3070948|NCT01181102|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg (=2000IU) 0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
3070949|NCT01181128|Experimental|Individualized (Tailored) Prophylaxis|"On rFVIIIFc Day 0, all participants underwent pharmacokinetic (PK) analysis with 50 IU/kg rFVIIIFc to estimate their PK parameters and guide the appropriate dose or interval of dosing. A subset of participants (Sequential PK subgroup) also had PK analyses performed with a single dose of 50 IU/kg Advate (Advate Day 0) within 8 weeks prior to rFVIIIFc Day 0. A >= 96 hour washout was performed before the PK dose of Advate or rFVIIIFc was administered. Repeat PK profiling with a single dose of 50 IU/kg rFVIIIFc was conducted at Week 14 or after 12 to 24 weeks of prophylaxis with rFVIIIFc.~After PK assessments, all participants started twice weekly treatment with 25 IU/kg of rFVIIIFc via intravenous (IV) injection on Day 1 and 50 IU/kg on Day 4, followed by individualized dose and interval modification within the range of 25 to 65 IU/kg every 3 to 5 days, as determined by rFVIIIFc PK analysis, to maintain a trough level of 1% to 3% (or higher, as clinically indicated) FVIII activity."
3070950|NCT01181128|Experimental|Weekly Prophylaxis|65 IU/kg of rFVIIIFc via IV injection every 7 days
3070951|NCT01181128|Experimental|Episodic (On-Demand) Dosing|10 to 50 IU/kg rFVIIIFc via IV injection, as required to treat a bleeding episode
3070952|NCT01181141|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery
3070953|NCT01181141|Active Comparator|Enoxaparin sodium|Enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
3070954|NCT01181167|Experimental|DU-176b|DU-176b oral tablets, 30 mg., taken once daily for 2 weeks, initiated within 6 to 24 hours after surgery.
3070955|NCT01181167|Active Comparator|enoxaparin sodium|enoxaparin sodium 20mg(=2000IU)/0.2ml twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery.
3070956|NCT01181258|Experimental|Patients Receiving NK Cell Infusion|Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
3070957|NCT01181271|Experimental|Autologous then Allogeneic transplant|"All patients will receive conditioning with busulfan, etoposide, and cyclophosphamide (with mesna) and then will undergo autologous (auto) peripheral blood stem cell transplantation.~Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative allogeneic (allo) transplant. If eligible to proceed, allogenic transplantation will take place no earlier than 40 days and no later than 180 days after autologous stem cell transplantation.~Conditioning for the allogeneic transplant will consist of fludarabine and busulfan. Participants will receive tacrolimus and sirolimus as prophylaxis against graft versus host disease (GVHD)."
3070958|NCT01181323|Experimental|Group 1: LAIV|0.2 ml of Live attenuated influenza vaccine (LAIV), Flumist® given intranasally (IN) and 0.5 ml of placebo given intramuscularly (IM) injection administered to 120 maternal subjects.
3070959|NCT01181323|Experimental|Group 2: TIV|0.5 ml of Inactivated Trivalent Influenza Vaccine (TIV), Fluzone® given intramuscularly (IM) and 0.2 ml of placebo given intranasally (IN) administered to 120 maternal subjects.
3070960|NCT01181349||P07535 study participants with a TOF ratio <0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio <0.9 at PACU arrival.
3070961|NCT01181349||P07535 study participants with a TOF ratio ≥0.9|Participants enrolled in the P07535 study who are included in the primary outcome measurement, which is defined as the incidence of postoperative residual neuromuscular blockade, who had a TOF ratio ≥0.9 at PACU arrival.
3070962|NCT01181479|Experimental|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel. Type of intervention is drug.
3070963|NCT01181479|Active Comparator|Lessina crossover to AG200-15|Lessina containing ethinyl estradiol and levonorgestrel for 6 cycles followed by AG200-15 for 6 cycles. Type of intervention is drug.
3070964|NCT01181492||*1/*1|Grouped by CYP3A4*1G polymorphism, wild-type homozygote
3070965|NCT01181492||*1/*1G|Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote
3070966|NCT01181492||*1G/*1G|Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote
3070967|NCT01181531|Active Comparator|Traditional Vitamin D Therapy|
3070968|NCT01181531|Experimental|Cinacalcet|
3070969|NCT01181596||Arm 1: observational ultrasound|Collection of image data with the ultrasound probe.
3070970|NCT01181609|Experimental|1|
3070971|NCT01181674|Experimental|Group 1 (short)|
3070972|NCT01181674|Experimental|Group 2 (long)|
3070973|NCT01181674|Other|Standard care|
3070974|NCT01181726|Experimental|Investigational Test Product|Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
3070975|NCT01181726|Active Comparator|Reference Listed Drug|Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
3070976|NCT01181778||All Qualified Participants|All healthy women who consulted their physician for information on contraceptive choices and were eligible for primary and secondary outcome measure analysis, based on the physician's assessment
3070977|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fed)|Participants will start therapy with a single dose of boceprevir tablets, orally, in fed condition, and then 4 days later will take a single dose of boceprevir capsules, orally, in fed condition.
3070978|NCT01181804|Experimental|Boceprevir Capsules then tablets (fed)|Participants will start therapy with a single dose of boceprevir capsules, orally, in fed condition, and then 4 days later will take a single dose of boceprevir tablets, orally, in fed condition.
3070979|NCT01181804|Experimental|Boceprevir Tablets then Capsules (fasted)|Participants will start therapy with a single dose of boceprevir tablets, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir capsules, orally, following an overnight fast.
3070980|NCT01181804|Experimental|Boceprevir Capsules then Tablets (fasted)|Participants on this study arm will start therapy with a single dose of boceprevir capsules, orally, following an overnight fast, and then 4 days later will take a single dose of boceprevir tablets, orally, following an overnight fast.
3070981|NCT01181895|Experimental|Vilanterol|Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
3070982|NCT01181895|Active Comparator|Salmeterol|Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
3070983|NCT01181895|Placebo Comparator|Placebo|Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
3070984|NCT01181947||patients undergoing TEVAR|Those with a thoracic aortic aneurysm/dissection
3070985|NCT01181986|Experimental|Exenatide SC (Sub-study 1)|Study groups will be individuals with recent onset (<3 years) or established (>5 years) T2D. The plan is to achieve 40 complete studies of subcutaneous injection of exenatide BID (Byetta®, 5 or 10 µg) or identically looking Placebo SC for 10 days, separated by 14-day washout period. On the next day after each treatment phase, a single dose of the assigned medication will be injected just before a fat-enriched breakfast meal. A lunch meal of similar caloric and nutrient content will be administered 4 hours following the breakfast meal. Endothelial function will be measured just prior to the injection and every 2 hours during 8-hour post-breakfast period.
3070986|NCT01181986|Experimental|Exenatide IV (Sub-study 2)|Study group will be individuals with recent onset (<1 year) T2D on diet and impaired glucose tolerance. The plan is to achieve 35 complete studies. The intervention will include 3 randomly ordered visits with intravenous infusion of exenatide in the presence (v1) or absence (v2) of GLP-1 receptor inhibitor exendin-9, and a control test with Placebo IV without exendin-9 (v3). Endothelial function will be measured at baseline and 2 hours later during the final 15 minutes of the infusion cocktails. Study participants will remain fasting during the test visit (3 hours total).
3070987|NCT01182103||Major depressive patients|
3070988|NCT01182103||Healthy subjects|
3070989|NCT01182181|Experimental|Investigational Test Product|Anastrozole Tablets, 1 mg
3070990|NCT01182181|Active Comparator|Reference Listed Drug|Arimidex® Tablets, 1 mg
3070991|NCT01182194|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
3070992|NCT01182194|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
3070993|NCT01182207|Experimental|Investigational Test Product|Drospirenone/Ethinyl Estradiol Tablets, 3 mg/0.02 mg
3070994|NCT01182207|Active Comparator|Reference Listed Drug|YAZ® Tablets, 3 mg/0.02 mg
3070995|NCT01182285|Experimental|A - Phase I Radioiodine-Resistant|Drug: Valproic Acid Week 1 - 10 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening
3070996|NCT01182285|Active Comparator|B1 - Phase 2 Schedule 1|Drug: Valproic Acid Week 11 - 17 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Drug: Cytomel (25 micrograms) Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Liothyronine Sodium (Cytomel) for 4 weeks (25 micrograms twice a day)
3070997|NCT01182285|Active Comparator|B2 - Phase 2 Schedule 2|Drug: Valproic Acid Week 11 - 52 (Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening Weeks 17-52: Patients who show a response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or have a decreased thyroglobulin level from Day 1 of the treatment (registered as a partial response to the treatment) will continue on valproic acid at their current dose for a total of 52 weeks.
3070998|NCT01182298||Hepatitis C|latino participants with Hepatitis C
3070999|NCT01182337|Experimental|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
3071000|NCT01182337|Placebo Comparator|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
3071001|NCT01182350|Experimental|radiation + bevacizumab|"Cohort 1: MGMT-/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles"
3071002|NCT01182350|Experimental|radiation + bevacizumab + erlotinib|"Cohort 2: MGMT-/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
3071003|NCT01182350|Experimental|radiation + bevacizumab + temozolomide|"Cohort 3. MGMT+/EGFR-~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Temozolomide: Administered orally at 90 mg/m2/day continuously during radiation therapy, held through the interim period and then 200 mg/m2/day for 5 days for up to 10 maintenance cycles"
3071004|NCT01182350|Experimental|radiation + bevacizumab + erlotinib + temozolomide|"Cohort 4. MGMT+/EGFR+~Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days).~Radiation therapy: Given in 180 cGy fractions to a total dose of 59.4 + 1.8 Gy/-5.4 Gy for approximately 7 weeks beginning 7-21 days after biopsy~Bevacizumab: Administered intravenously at 10 mg/kg beginning no sooner than 21 days from biopsy and every 14 days concurrent with radiation therapy, through the interim period and for up to 10 maintenance cycles~Erlotinib: Administered orally at 85 mg/m2 daily continuously during radiation therapy, through the interim period and for up to 10 maintenance cycles"
3071005|NCT01182376|Placebo Comparator|Placebo|Half of the patients will be assigned placebo.
3071006|NCT01182376|Experimental|Multaq® (dronedarone)|Half of the patients will be prescribed dronedarone.
3071007|NCT01182415|Experimental|High-dose chemotherapy with autologous stem cell transplant|
3071008|NCT01182428|Experimental|XIENCE V® / XIENCE PRIME™|
3071009|NCT01182428|Active Comparator|CYPHER SELECT|
3071010|NCT01182441|Experimental|WATCHMAN|Subjects assigned to receive the WATCHMAN device.
3071011|NCT01182441|Active Comparator|Warfarin|Subjects assigned to warfarin therapy.
3071012|NCT01182493|Experimental|Insulin Pump Treatment|Patients will get an insulin pump
3071013|NCT01182493|No Intervention|Insulin treatment with MDI|patients treated with Multiple Daily Injections (MDI); basal/bolus therapy with rapid- and long-acting analogs with at least 3 injections per day
3071014|NCT01182675|Experimental|T-cell Graft Permissive SCID|"Patients with SCID with:~i. NK- phenotype; ii. NK+ phenotype with 10/10 HLA-matched relative or unrelated donor; or iii. NK+ phenotype with maternal engraftment by STR analysis and undergoing haplocompatible HSCT from maternal donor Intervention: Transplant Conditioning with Mobilization Only"
3071015|NCT01182675|Experimental|T-cell Graft Resistant SCID|Patients with SCID with NK+ phenotype with HLA-mismatched donor Intervention: Transplant Conditioning with Mobilization and Alemtuzumab
3071016|NCT01182727|Experimental|salsalate|Salsalate will be administered in two divided doses of 2grams in the morning and 2 grams in the evening. Salsalate will be administered for 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until a tolerated dose or a minimum dose of 2 grams per day is reached.
3071017|NCT01182805|Other|Single arm study.|
3071018|NCT01182844|No Intervention|Control|Usual care
3071019|NCT01182844|Experimental|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
3071020|NCT01183013|Active Comparator|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily
3071021|NCT01183013|Active Comparator|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily
3071022|NCT01183013|Active Comparator|Pioglitazone 45 mg|Pioglitazone Capsules 45 mg once daily
3071023|NCT01183013|Active Comparator|Linagliptin 5mg|Linagliptin 5mg Tablets once daily
3071024|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 15 mg|Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily
3071025|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 30 mg|Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily
3071026|NCT01183013|Experimental|Linagliptin 5mg / Pioglitazone 45 mg|Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily
3071027|NCT01183065|Experimental|pralatrexate and vitamin supplementation|This will be an open-label, single arm, Simon optimal two-stage design phase II study.
3071028|NCT01183104|Experimental|Sitagliptin|
3071029|NCT01183104|Active Comparator|Glimepiride|
3071030|NCT01183143|Experimental|GONAL-f®|
3071031|NCT01183169|Experimental|Treatment A: ALV 600 mg QD|Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks
3071032|NCT01183169|Experimental|Treatment B: ALV 800 mg QD|Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks
3071033|NCT01183169|Experimental|Treatment C1: ALV Placebo - 600 mg QD|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.
3071034|NCT01183169|Experimental|Treatment C2: ALV Placebo - 400 mg BID|ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.
3071035|NCT01183169|Experimental|Treatment D: ALV 400 mg BID|Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks
3071036|NCT01183234|Experimental|SPD544 (Equasym XL)|
3071037|NCT01183234|Experimental|Methylphenidate hydrochloride (Metadate CD )|
3071038|NCT01183260|Experimental|Trabecular Metal Revision Cup|Patients randomized to this arm will receive a trabecular metal revision component which does not have a titanium inner surface and requires a cemented highly crosslinked polyethylene liner.
3071039|NCT01183260|Active Comparator|Trabecular Metal Modular Cup|Patients randomized to this arm will receive a trabecular metal modular component which has a titanium inner surface and requires a non-cemented highly crosslinked polyethylene liner.
3071040|NCT01183312|Experimental|Placebo, then Flumazenil|Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil
3071041|NCT01183312|Experimental|Flumazenil, then Placebo|Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo.
3071042|NCT01183390|Experimental|Investigational Test Product|Anastrozole 1 mg Tablets
3071043|NCT01183390|Active Comparator|Reference Listed Drug|Arimidex® 1 mg Tablets
3071044|NCT01183481|Experimental|Aprepitant and Granisetron|Patients will be given a single dose of Granisetron 2 mg orally and Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the Palliative radiation therapy.
3071045|NCT01183533|Experimental|off label rt-PA used|off label rt-PA used on all subject enrolled within 3 hours of waking with stroke symptoms at the standard of care dose.
3071046|NCT01183546||Wheelchair Users with Spinal Cord Injury|wheelchair users with spinal cord injury
3071047|NCT01183559|Other|Vandetanib|Vandetanib 100 mg (6 patients) or 200 mg (3 patients) orally daily during the conventional 3D-guided conformal radiation therapy plus chemotherapy with carboplatin (AUC 5) on days 1 and 29, paclitaxel 50 mg/m2 i.v. weekly on days 1, 8, 15, 22, 29; and continuous infusion of 5-fluorouracil at 225 mg/m2 for 96 hours Monday-Friday during the radiation.
3071048|NCT01183650|Experimental|Tadalafil|5 mg, administered orally, daily for 10 days
3071049|NCT01183689|No Intervention|Control Group|"Self-Guided Behavior Changes. This group will be used to determine average rate of weight gain over 3 years with little intervention. Participants randomized to this group will receive one face-to-face session that will provide general education of self-weighing and information about both the small and large changes approach. Participants will also be provided with quarterly newsletters describing study events and very limited information on health eating."
3071050|NCT01183689|Experimental|Small behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate small changes (e.g., modify diet by approximately 100 kcal, decrease portion sizes or change types of food, increase activity by 2000 steps/day).
3071051|NCT01183689|Experimental|Large behavior changes|Participants randomized to this group will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate large changes (e.g., modify diet to 1200-1500 or 1500-1800 kcal/day with < 30% fat, increase exercise to 250 minutes/week of moderate intensity activity).
3071052|NCT01183728|Experimental|MSV autologous transplantation|Bone marrow collected from patient will be used for mesenchymal stem cells isolation and expansion under GMP conditions at IBGM-Valladolid (MSV). Autologous MSV implanted in knee by articular injection
3071053|NCT01183780|Experimental|FOLFIRI + Ramucirumab|
3071054|NCT01183780|Placebo Comparator|FOLFIRI + Placebo|
3071055|NCT01183858|Experimental|Erlotinib 150 mg|Erlotinib 150 mg single daily oral dose until disease progression.
3071056|NCT01183858|Experimental|Erlotinib 300 mg|Erlotinib 300 mg single daily oral dose until disease progression.
3071057|NCT01183923|Experimental|Broccoli Sprouts, then Alfalfa Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by alfalfa sprouts after washout.
3071058|NCT01183923|Experimental|Alfalfa Sprouts, then Broccoli Sprouts|Alfalfa Sprout sandwich/wrap will be eaten daily for 7 consecutive days followed by broccoli sprouts after washout.
3071059|NCT01183975||Patients treated with SAGB by solicited teams|Patients treated with SAGB by solicited teams. No selection criteria at cohort inclusion applied to the 500 (+50) first patients treated in order to ensure consecutive and exhaustive recruitment in the concerned centers over the inclusion period.
3071060|NCT01184014|Experimental|Experimental group|a study-specific steroid (NPH) dosing algorithm plus standard recommended care. The intervention is Neutral Protamine Hagedorn (NPH) insulin plus complete insulin orders (CIO).
3071061|NCT01184014|Active Comparator|Control group|the standard recommended care (Methodist Hospital Complete Insulin Orders)
3071062|NCT01184053|Experimental|Trisenox treatment|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
3071063|NCT01184079|Experimental|12 months|Administration of 3rd dose at 12 months quadrivalent human papillomavirus vaccine
3071064|NCT01184079|Active Comparator|6 month|Administration of 3rd dose at 6 months quadrivalent human papillomavirus vaccine
3071065|NCT01184118|No Intervention|FP Discontinued|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
3071066|NCT01184118|Active Comparator|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
3071067|NCT01184326|Experimental|Dose Level 0: Everolimus 5mg + Pazopanib 600 mg|Everolimus 5mg + Pazopanib 600 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
3071068|NCT01184326|Experimental|Dose Level -1: Everolimus 5mg + Pazopanib 400 mg|Everolimus 5mg + Pazopanib 400 mg once daily for 28 days each cycle Participants were treated until disease progression, unacceptable toxicity or patient withdrawal.
3071069|NCT01184326|Experimental|All Phase I Dose Expansion Participants|All phase I dose expansion participants received Everolimus 5mg and Pazopanib at the maximum tolerated dose established in the dose finding part of the study.
3071070|NCT01184326|Experimental|All Phase I Participants|All phase I participants received Everolimus 5mg and Pazopanib according to the established dose escalation schedule or the maximum tolerated dose established in the dose finding part of the study.
3071071|NCT01184417|Active Comparator|Phenobarbital group|10 mg/kg IV phenobarbital in 100 ml saline
3071072|NCT01184417|Placebo Comparator|Placebo group|100 ml saline
3071073|NCT01184508|Experimental|LY2300559|
3071074|NCT01184508|Placebo Comparator|Placebo|
3071075|NCT01184755|Experimental|Resperate device used for 8 weeks|Participants to use Resperate device to guide breathing for 8 weeks. After the primary 8-week trial, this group is divided into two subgroups to examine 16-week data: one subgroup that stops using the device after 8 weeks, and one asked to continue to use the device for the full 16 weeks.
3071076|NCT01184755|Active Comparator|Relaxation control device|Participants use modified device to pace breathing in the 13/minute range for daily practice for 8 weeks and no device thereafter
3071077|NCT01184755|No Intervention|Usual Care|Participants continue their usual medication and other management for their hypertension. All participants (including UC) are given a home BP monitor and asked to take their BP in morning and evening 3 days/week.
3071078|NCT01184846|Experimental|IgPro10|10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.
3071079|NCT01184859|Experimental|Desmopressin 10µg|Study period 1: single dose of desmopressin 10µg. Study period 2: daily doses of desmopressin 10µg taken before bedtime for 28 days.
3071080|NCT01184859|Experimental|Desmopressin 25µg|Study period 1: single dose of desmopressin 25µg. Study period 2: daily doses of desmopressin 25µg taken before bedtime for 28 days.
3071081|NCT01184859|Experimental|Desmopressin 50µg|Study period 1: single dose of desmopressin 50µg. Study period 2: daily doses of desmopressin 50µg taken before bedtime for 28 days.
3071082|NCT01184859|Experimental|Desmopressin 100µg|Study period 1: single dose of desmopressin 100µg. Study period 2: daily doses of desmopressin 100µg taken before bedtime for 28 days.
3071083|NCT01184859|Placebo Comparator|Placebo|Study period 1: single dose of placebo. Study period 2: daily doses of placebo taken before bedtime for 28 days.
3071084|NCT01184872|Experimental|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
3071085|NCT01184872|Active Comparator|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
3071086|NCT01184885|Experimental|Hyper-CVAD and Sirolimus|Hyper-CVAD and Sirolimus
3071087|NCT01184898|Experimental|Sirolimus and MEC|Sirolimus and MEC (Mitoxantrone, Etoposide, and Cytarabine)
3071088|NCT01184989|Other|Dabigatran etexilate|open label, once daily dose approved by EMEA and Health Canada
3071089|NCT01185028|Experimental|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
3071090|NCT01185080|Experimental|1. AZD8848|20 μg AZD8848 three times weekly
3071091|NCT01185080|Placebo Comparator|2. Placebo|Placebo three times weekly
3071092|NCT01185080|Experimental|3. AZD8848 and placebo|60 μg AZD8848 once weekly and placebo twice weekly
3071093|NCT01185171|Experimental|ZD1839 500mg by mouth (po) daily|Single arm, two-stage, phase II trial of induction therapy with carboplatin and paclitaxel, followed by ZD1839, 5-FU, hydroxyurea, and hyperfractionated radiotherapy, followed by adjuvant ZD1839 alone.
3071094|NCT01185249|Experimental|Body weight taken in a standing position|Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
3071095|NCT01185288|Experimental|Adalimumab + Low Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
3071096|NCT01185288|Active Comparator|Adalimumab + High Dose Methotrexate|Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
3071097|NCT01185301|Active Comparator|ADA + 2.5 mg MTX|2.5 mg methotrexate (MTX) oral capsule weekly with 40 mg adalimumab (ADA) subcutaneous (SC) injection every other week (EOW) for 26 weeks
3071098|NCT01185301|Active Comparator|ADA + 5 mg MTX|5 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
3071099|NCT01185301|Active Comparator|ADA + 10 mg MTX|10 mg MTX oral capsule weekly with 40 mg ADA SC injection EOW for 26 weeks
3071100|NCT01185301|Active Comparator|ADA + 20 mg MTX|MTX oral capsule dose escalation from 10 mg to 20 mg in 2.5 mg increments every other week (10 mg x 2 weeks, 12.5 mg x 2 weeks, 15 mg x 2 weeks, 17.5 mg x 2 weeks), then 20 mg for 18 weeks with 40 mg ADA SC injection EOW for 26 weeks
3071101|NCT01185340|Experimental|LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the LY2216684 treatment arm.~For the first 2 weeks of the AT Phase, participants received a starting dose of 12 mg QD. Then, based on efficacy and tolerability, the dose could be increased to 18 mg QD over the next 6 weeks. Participants who had their dose increased to 18 mg QD could have had their dose decreased to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3071102|NCT01185340|Placebo Comparator|Placebo + SSRI|"Placebo: Administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (administered orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to the placebo treatment arm.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3071103|NCT01185353|Experimental|1 mg LY3009104 once daily|Administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071104|NCT01185353|Experimental|2 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071105|NCT01185353|Experimental|4 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071106|NCT01185353|Experimental|8 mg LY3009104 once daily|Administered orally once daily for 24 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071107|NCT01185353|Placebo Comparator|Placebo once daily|Placebo administered orally once daily for initial 12 weeks followed by randomization to either 4 mg LY3009104 once daily or 2 mg LY3009104 twice daily for an additional 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071108|NCT01185353|Experimental|2 mg LY3009104 twice daily|(Not utilized in Part A) After 12 weeks treatment with 1 mg LY3009104 once daily or Placebo once daily in Part A, administered orally twice daily for 12 weeks. After 24 weeks of treatment participants will be eligible to participate in an open-label extension period (Part C). Part C: 4 mg or 8 mg administered orally once daily for 52 additional weeks. After 76 weeks of treatment participants will be eligible to participate in an additional open-label extension period (Part D). Part D: 4 mg administered orally once daily for 52 additional weeks.
3071109|NCT01185366|Experimental|Everolimus Group 1|Everolimus 10 mg by mouth once a day.
3071110|NCT01185366|Active Comparator|Sunitinib Group 2|Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.
3071111|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Cohort A|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by fluorescence in situ hybridization (FISH) (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
3071112|NCT01185509|Experimental|Trastuzumab and Vinorelbine - Main Cohort|Cycle 1: Patients received trastuzumab 8 mg/kg intravenously (IV) on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Cycles 2+: Patients received trastuzumab 6 mg/kg IV on day 1 and vinorelbine 25 mg/kg IV on days 1, 8 and 15 of each 21 day cycle Patients were treated until disease progression or unacceptable toxicity. Eligibility required patients to have HER2 amplification by FISH (mean ratio > 2.0). The CTC tests of the first 11 patients were done at DFCI. The study team then decided to proceed with a different CTC test performed outside of DFCI. Because the method of CTC isolation was different from that performed by DFCI, the first 11 patients were placed into a separate cohort (Cohort A) and the remaining 20 patients represented the main cohort.
3071113|NCT01185522||Tocilizumab|Eligible participants receiving tocilizumab according to summary of product characteristics in a real life setting will be observed for 4 months
3071114|NCT01185548|Experimental|Tasisulam and Tolbutamide|"Three study periods and continued access to tasisulam every 28 days (except Period 1 which was tolbutamide only and lasted 4 days) until disease progression:~Period 1: 500 milligram (mg) tolbutamide administered on Day 1.~Period 2: 500 mg of tolbutamide and individualized tasisulam dose [based on area under the curve albumin-corrected threshold (AUCalb)]. The AUCalb is a surrogate marker for unbound tasisulam, and this dosing approach represents the maximum level of unbound tasisulam which may be achieved clinically, administered on Day 1.~Period 3: Individualized tasisulam dose (based on AUCalb) administered on Day 1 and 500 mg tolbutamide administered on Day 4."
3071115|NCT01185561|No Intervention|Usual medical care|Participants assigned to this arm represent the control group and will receive usual medical care only.
3071116|NCT01185561|Experimental|Psychoeducational intervention|Participants assigned to this arm represent the experimental group and will receive group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes
3071117|NCT01185600|Active Comparator|Transfusion with washed RBC|Subject assigned to this arm will be transfused with washed RBC
3071118|NCT01185600|Active Comparator|Transfusion with unwashed RBC|Subjects assigned to this arm will be transfused with unwashed RBC
3071119|NCT01185639|Experimental|SBRT for metastatic NSCLC|SBRT for lung lesions, liver lesions, adrenal lesions, spinal lesions
3071120|NCT01185704|Experimental|Day 1 protocol|
3071121|NCT01185704|Experimental|Day 7 protocol|
3071122|NCT01185782|Experimental|SJ-0021 group|
3071123|NCT01185782|Active Comparator|Purified pituitary gonadotropin group|
3071124|NCT01185821|Experimental|BAF312 10 mg/2 mg|10 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3071125|NCT01185821|Experimental|BAF312 2 mg/2 mg|2 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3071126|NCT01185821|Experimental|BAF312 1.25 mg/2 mg|1.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3071127|NCT01185821|Experimental|BAF312 .5 mg/2 mg|.5 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3071128|NCT01185821|Experimental|BAF312 .25 mg/2 mg|.25 mg dose in Double Blind Phase and 2 mg in Open Label Phase
3071129|NCT01185964|Experimental|Phase 1b: Olaratumab + doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
3071130|NCT01185964|Experimental|Phase 2: Olaratumab and doxorubicin|"All cycles are 21 days.~Cycles 1-8: Olaratumab 15 mg/kg on days 1+8, and doxorubicin 75 mg/m2 on day 1~All subsequent cycles until progression: Olaratumab 15 mg/kg on days 1+8"
3071131|NCT01185964|Active Comparator|Phase 2: Doxorubicin: Optional Olaratumab After Progression|"All cycles are 21 days.~Cycles 1-8: doxorubicin 75 mg/m2 on day 1 until disease progression.~At disease progression: optional Olaratumab 15 mg/kg on days 1+8 until further progression."
3071132|NCT01186250|Active Comparator|Pioglitazone|Pioglitazone
3071133|NCT01186250|Placebo Comparator|Placebo|Placebo
3071134|NCT01186328|Experimental|Single Arm|Patients will receive 2 doses of EZN-3042 (and intrathecal cytarabine, conditionally) prior to initiating systemic therapy with vincristine, doxorubicin, prednisone and PEG-asparaginase. Patients with CNS 1 or 2 will also receive intrathecal methotrexate, and patients with CNS 3 will also receive triple intrathecal therapy (methotrexate, hydrocortisone, and cytarabine).
3071135|NCT01186406|Experimental|Gliadel, Radiation Therapy, Avastin, Temodar|Single arm study where patients with newly diagnosed Grade IV malignant glioma will receive Gliadel at the time of resection, followed by radiation therapy (XRT), Avastin, and Temodar for approximately 6 1/2 weeks, followed by Avastin and Temodar post-radiation
3071136|NCT01186419|Experimental|SPD602 (16mg)|
3071137|NCT01186419|Experimental|SPD602 (32mg)|
3071138|NCT01186458|Experimental|Fludarabine, Velcade and Rituximab|Fludarabine, Velcade and Rituximab
3071139|NCT01186562|Active Comparator|Sitagliptin|
3071140|NCT01186562|Placebo Comparator|Placebo|
3071141|NCT01186692|Experimental|Melody TPV Implant|Melody® Transcatheter Pulmonary Valve implanted into a dysfunctional RVOT Conduit.
3071142|NCT01186705|Experimental|MK-2206|This will be a single-arm, phase II study of the AKT inhibitor MK-2206 in patients with KRAS-wild-type, PIK3CA-mutated, colorectal cancer whose tumors have progressed through standard chemotherapy regimens.
3071143|NCT01186744|Experimental|Active Treatment (10 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
3071144|NCT01186744|Experimental|Active Treatment (10 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
3071145|NCT01186744|Experimental|Active Treatment (5 mg) BID / Placebo BID|Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
3071146|NCT01186744|Experimental|Active Treatment (5 mg) BID|Continuous active treatment (CP-690,550) for 56 weeks
3071147|NCT01186770|Experimental|MNTX 150 mg|Participants will receive methylnaltrexone (MNTX) 150 milligrams (mg) (1 tablet of MNTX 150 mg and 2 matching placebo tablets) orally once daily (QD) for 28 days (4 weeks), then MNTX tablets at a dose as needed (PRN) for remaining 56 days (8 weeks).
3071148|NCT01186770|Experimental|MNTX 300 mg|Participants will receive MNTX 300 mg (2 tablets of MNTX 150 mg each and 1 matching placebo tablet) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
3071149|NCT01186770|Experimental|MNTX 450 mg|Participants will receive MNTX 450 mg (3 tablets of MNTX 150 mg each) orally QD for 28 days (4 weeks), then MNTX tablets at a dose PRN for remaining 56 days (8 weeks).
3071150|NCT01186770|Placebo Comparator|Placebo|Participants will receive 3 tablets of placebo matched to MNTX orally QD for 84 days (12 weeks).
3071151|NCT01186796|Experimental|Fulvestrant|
3071152|NCT01186809|Experimental|Cytokine Induced Killer|Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
3071155|NCT01186939|Experimental|Azacitidine|Azacitidine (study drug) plus best supportive care.
3071156|NCT01186978|Other|Single arm|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve CR and have a negative post-chemotherapy PET scan following 4 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
3071157|NCT01187004||Acute Lung Injury (ALI)|patients who might develop acute lung injury (ALI) after cardiac surgery with cardiopulmonary by pass
3071158|NCT01187017|Experimental|Fludarabine/Cyclophosphamide in Participants with Severe Aplastic Anemia|Participants with Severe Aplastic Anemia will receive Fludarabine at 125 mg/m squared plus Cyclophosphamide at 60 mg/kg (Flu/Cy).
3071159|NCT01187043|Experimental|ARM 1|1 mg Proellex
3071160|NCT01187043|Experimental|ARM 2|3 mg Proellex
3071161|NCT01187043|Experimental|ARM 3|6 mg Proellex
3071162|NCT01187043|Experimental|ARM 4|9 mg Proellex
3071163|NCT01187043|Experimental|ARM 5|12 mg proellex
3071164|NCT01187095|Experimental|counselling|Does couples in IVF treatment benefit from emotional disclosure
3071165|NCT01187095|Active Comparator|Control|Neutral writing exercise
3071166|NCT01187329|Experimental|hyperinsulinemic normoglycemic clamp (HNC)|Patients will be randomized to receive treatment with HNC during cardiac surgery.
3071167|NCT01187329|Placebo Comparator|standard glucose management|Patients will be randomized to receive treatment with standard glucose management during cardiac surgery.
3071168|NCT01187355|Experimental|Alcon MPDS|MPDS used for 30 days as specified in protocol for contact lens care.
3071169|NCT01187355|Active Comparator|renu fresh MPS|MPS used for 30 days as indicated for contact lens care.
3071170|NCT01187381||Participants with Breast Cancer|Participants with early or metastatic HER2-positive breast cancer who were receiving treatment with trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines, will be observed. Dosing and treatment duration of the trastuzumab will be at the discretion of the treating physician.
3071171|NCT01187407|Experimental|12 or 18 mg flexible dose LY2216684 + SSRI|"LY2216684: flexible dose of 12 or 18 milligrams (mg), administered orally, once daily (QD) for 8 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)~Prior to entering the Adjunctive Treatment (AT) Phase, participants completed a 3-week Confirmation (CF) Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to a 12 or 18 mg flexible dose of LY2216684.~During the AT Phase, participants first received 6 mg LY2216684 QD for 3 days, followed by 12 mg QD for the next 11 days. Then, based on efficacy and tolerability, dosage could be increased to 18 mg QD over the next 6 weeks. Participants on 18 mg QD could have had their dose decreased back to 12 mg QD. Participants who completed the AT Phase or discontinued early had the option to enter the Discontinuation (DC) Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3071172|NCT01187407|Experimental|6 mg fixed dose LY2216684 + SSRI|"LY2216684: fixed dose of 6 mg, administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to 6 mg fixed dose of LY2216684.~During the AT Phase, participants received a 6 mg fixed dose of LY2216684 adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3071173|NCT01187407|Placebo Comparator|Placebo + SSRI|"Placebo: administered orally, QD for 8 weeks, adjunctive to an SSRI~Prior to entering the AT Phase, participants completed a 3-week CF Phase where they received placebo (orally, QD) adjunctive to their SSRI. After the CF Phase, and after randomization criteria were met, participants were randomized to placebo.~During the AT Phase, participants received placebo (administered orally, QD) adjunctive to their SSRI for 8 weeks. Participants who completed the AT Phase or discontinued early had the option to enter the DC Phase.~During the 1-week abrupt DC Phase, participants maintained their SSRI treatment."
3071174|NCT01187433|Experimental|Dengue Vaccine Group|Participants will receive Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus vaccine
3071175|NCT01187433|Placebo Comparator|Control Group|Participants will receive a placebo, NaCl 0.9%.
3071176|NCT01187446|Experimental|TSEBT & Vorinostat|"Total skin electron beam therapy (TSEBT) will be performed per institution guidelines.~Vorinostat will be administered at a dose of 400 mg/day, starting one day prior to the initiation of TSEBT. During TSEBT, vorinostat should be taken in the morning and preferably prior to TSEBT."
3071177|NCT01187446|Active Comparator|TSEBT only|"Total skin electron beam therapy (TSEBT) will be administered according to the Stanford 6-field technique or equivalent technique per institutional standards. Patients will receive a planned total skin dose of 12 grey (Gy) fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks. Supplements will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions (1-2 Gy fractions to a total dose of 12 Gy). Discrete tumors may receive additional boost treatment not to exceed 12 Gy."
3071178|NCT01187498|Experimental|Behavioral Training|Behavioral training using delayed voiding, urge suppression techniques, and pelvic floor muscle training
3071179|NCT01187498|Active Comparator|Drug Therapy|Oxybutynin chloride, extended-release, individually-titrated, 5-30 mg
3071180|NCT01187511|Active Comparator|GSK561679|GSK561679 was given orally, once a day in the evening, for 21 days, at a dose of 350mg, administered as four tablets consisting of 3 x 100mg tablets plus 1 x 50mg tablet.
3071181|NCT01187511|Placebo Comparator|Placebo|Placebo was given orally, once a day in the evening, for 21 days, in the form of four tablets that matched those of GSK561679
3071182|NCT01187771|Active Comparator|Laparoscopic Gastric Banding|
3071183|NCT01187771|Active Comparator|Continuous Positive Airway Pressure|
3071184|NCT01187901|Active Comparator|Erlotinib and Sulindac|Erlotinib 75 mg per day in combination with sulindac 150 mg twice daily for 6 months.
3071185|NCT01187901|Placebo Comparator|Placebo A and Placebo B|Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months
3071186|NCT01187914||Open Irrigation|Those individuals who had an ablation using open irrigation cooled-tip RF ablation.
3071187|NCT01187953|Experimental|LCP-Tacro|The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
3071188|NCT01187953|Experimental|Prograf (tacrolimus)|Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Doses will be adjusted according to whole blood tacrolimus trough levels. In the initial post-transplant period, plasma trough levels will be measured at 24 and 48 hours. Study drugs will be adjusted to maintain the whole blood pre-dose (trough) concentration of tacrolimus in the target range of 6 - 11 ng/mL for the first 30 days, then 4 - 11 ng/mL for the remainder of the study.
3071189|NCT01188109|Experimental|Gemcitabine / Cisplatin|Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.
3071190|NCT01188226|Experimental|Nano Hybrid Composite Denture teeth|Denture teeth are made of nano hybrid composite material
3071191|NCT01188343|Experimental|Group 1|Participants will receive the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0 and Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 42
3071192|NCT01188343|Experimental|Group 2|Participants will receive Measles, mumps, and rubella live attenuated virus vaccine (MMR) on Day 0, and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 42.
3071193|NCT01188343|Experimental|Group 3|Participants will receive the Measles, mumps, and rubella live attenuated virus vaccine (MMR) and the Japanese encephalitis chimeric virus vaccine (JE-CV) on Day 0
3071194|NCT01188369|Experimental|levosimendan|infusion 0,1ug/kg/min for duration of ca. 4 hours prior to operation and until the end of operation
3071195|NCT01188369|Placebo Comparator|Placebo|Identical placebo
3071196|NCT01188421|Active Comparator|buprenorphine|Sublingual buprenorphine/naloxone tablets (or placebo)
3071197|NCT01188421|Active Comparator|clonidine|Oral clonidine tablets (or placebo)
3071198|NCT01188421|Experimental|tramadol ER|Oral tramadol tablets (or placebo)
3071199|NCT01188447|Experimental|Eligible low-risk trauma patients|Paramedics will use the Canadian C-Spine Rule to evaluate low-risk trauma patients meeting the study inclusion criteria in order to determine the need for spinal immobilization for transport to the hospital.
3071200|NCT01188460|Placebo Comparator|Control Group|Receive one weekly telephone follow-up call per week to monitor sleep progress, complete 7 weeks of sleep diaries only (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), complete questionnaires at three study timepoints
3071201|NCT01188460|Experimental|Experimental Group|Receive one weekly telephone call to monitor sleep progress, complete 7 weeks of sleep diaries (sleep diary measures Total Sleep Time in hours, Time to Fall Asleep in minutes, Number of Nocturnal Awakenings, Sleep Efficiency as a percentage, and Sleep Quality as units on a scale), implement one chapter per week of self-help manual for insomnia over 7 weeks at home, complete questionnaires at three study timepoints
3071202|NCT01188499|Experimental|Carboplatin/Paclitaxel + Birinapant|Carboplatin (AUC 6/Paclitaxel (175 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3071203|NCT01188499|Experimental|Irinotecan + Birinapant|Irinotecan (350 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3071204|NCT01188499|Experimental|Docetaxel + Birinapant|Docetaxel (75 mg/m2/IV) once every 3 (q3) weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 1 week off for each cycle (3 weeks per cycle).
3071205|NCT01188499|Experimental|Gemcitabine + Birinapant|Gemcitabine (1000 mg/m2/IV) once weekly (7 days +/- 2 days) for 3 consecutive weeks followed by 1 week off + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 week off for each cycle (4 weeks per cycle).
3071206|NCT01188499|Experimental|Liposomal Doxorubicin + Birinapant|Liposomal doxorubicin (40 mg/m2/IV) every 4 weeks + birinapant (TL32711) once weekly (7 days +/- 2 days) for 2 consecutive weeks followed by 2 weeks off for each cycle (4 weeks per cycle).
3071207|NCT01188538|Experimental|Epiduo gel|"Dose or Concentration:Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
3071208|NCT01188538|Active Comparator|BPO gel|"Dose or Concentration:Adapalene 0% / Benzoyl Peroxide 2.5% Gel.~Mode and Frequency of Administration:Topical to the face, once daily application in the evening.~Duration of Treatment:12 weeks"
3071209|NCT01188551|Experimental|dexmedetomidine w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of dexmedetomidine 1mcg/kg given intranasally in OR.
3071210|NCT01188551|Active Comparator|fentanyl w/ midazolam|Midazolam 0.5 mg/kg given orally pre-op and 1 dose of fentanyl 2mcg/kg given intranasally in OR.
3071211|NCT01188551|Experimental|dexmedetomidine w/o midazolam|1 dose of dexmedetomidine 1mcg/kg given intranasally in OR without any pre-medication.
3071212|NCT01188551|Active Comparator|fentanyl w/o midazolam|1 dose of fentanyl 2mcg/kg given intranasally in the OR without any pre-medication.
3071213|NCT01188564|Experimental|rhC1INH|
3071214|NCT01188564|Placebo Comparator|Placebo (Saline)|
3071215|NCT01188577|Experimental|Epinephrine Inhalation Aerosol, HFA|Experimental treatment of 10 inhalations of 125 mcg epinephrine base propelled by HFA 134a
3071216|NCT01188577|Active Comparator|Epinephrine Inhalation Aerosol, CFC|Epinephrine Inhalation Aerosol, CFC propelled, 220 mcg/inhalation , 10 inhalations
3071217|NCT01188603|Experimental|flibanserin|flibanserin 100 mg dose every evening
3071218|NCT01188655||Treatment Group Enbrel|
3071219|NCT01188668|Experimental|Aripiprazole + Desvenlafaxine SR|
3071220|NCT01188681|Experimental|Phase 1: 15 mg/kg TRU-016 + Bendamustine|TRU-016 (15 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
3071221|NCT01188681|Experimental|Phase 1: 20 mg/kg TRU-016 + Bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 6 patients
3071222|NCT01188681|Experimental|Phase 2: TRU-016 and bendamustine|TRU-016 (20 mg/kg) and bendamustine (70 mg/m2), n = 32 patients
3071223|NCT01188681|Active Comparator|Phase 2: Bendamustine|Bendamustine (70 mg/m2), n = 33 patients
3071224|NCT01188694|Experimental|Psychotherapy plus Methylene Blue, USP|
3071225|NCT01188694|Placebo Comparator|Psychotherapy Plus Placebo|
3071226|NCT01188694|Other|Delayed Psychotherapy|
3071227|NCT01188772|Experimental|Sofosbuvir 200 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 200 mg (2 x 100 mg tablets)+placebo to match sofosbuvir (2 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3071228|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3071229|NCT01188772|Active Comparator|Placebo (Genotype 1)|Participants with genotype 1 HCV infection were randomized to receive placebo to match sofosbuvir (4 tablets)+PEG+RBV for 12 weeks followed by PEG+RBV for up to an additional 36 weeks.
3071230|NCT01188772|Experimental|Sofosbuvir 400 mg (Genotype 2/3)|Participants with genotype 2 or 3 HCV infection received sofosbuvir 400 mg (4 x 100 mg tablets)+PEG+RBV for 12 weeks.
3071231|NCT01188811|Experimental|Arm 1: lipoic acid|28 subjects receive oral lipoic acid 1200mg daily
3071232|NCT01188811|Placebo Comparator|Arm 2: placebo|28 subjects receive placebo daily
3071233|NCT01188876|Experimental|Carboplatin/Pralatrexate|
3071234|NCT01188928|Experimental|LEO 80185|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) topical suspension
3071235|NCT01188928|Active Comparator|Betamethasone|Betamethasone 0.5 mg/g (as dipropionate) in the topical suspension vehicle
3071236|NCT01188928|Active Comparator|Calcipotriol|Calcipotriol 50 mcg/g in the topical suspension vehicle
3071237|NCT01188928|Placebo Comparator|Topical suspension vehicle|The topical suspension vehicle alone
3071238|NCT01188967|Experimental|GSK598809|Active medication
3071239|NCT01188967|Placebo Comparator|Placebo|Placebo
3071240|NCT01189032|Experimental|High concentration|
3071241|NCT01189032|Experimental|Low concentration|
3071242|NCT01189032|Placebo Comparator|Placebo|
3071243|NCT01189110|Active Comparator|Arm 1|Stimulation of auriculotherapy points on both ears with functioning Stim Flex 400A TENS unit once a week for 5 weeks.
3071244|NCT01189110|Placebo Comparator|Arm 2|Stimulation of auriculotherapy points on both ears with disabled Stim Flex 400A TENS unit once a week for 5 weeks.
3071245|NCT01189123|Active Comparator|Standard dose influenza vaccine|Fluzone (Sanofi Pasteur)
3071246|NCT01189123|Active Comparator|High Dose Vaccine|High Dose Fluzone by sanofi pasteur
3071247|NCT01189136|Sham Comparator|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
3071248|NCT01189136|Experimental|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
3071249|NCT01189201|Experimental|BI 10773/linagliptin FDC SID|medium single dose ofBI 10773/linagliptin FDC (Formulation A1)
3071250|NCT01189201|Experimental|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
3071251|NCT01189201|Experimental|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
3071252|NCT01189201|Experimental|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
3071253|NCT01189240|Experimental|Phase I Dose Finding|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3071254|NCT01189240|Experimental|Phase II Stage I|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15.Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3071255|NCT01189240|Experimental|Phase II Stage II Arm 1|"Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3071256|NCT01189240|Active Comparator|Phase II Stage II Arm 2|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Other: laboratory biomarker analysis: correlative studies.~Phase 2 - not implemented due to drug supply from company"
3071257|NCT01189240|Experimental|Phase I Dose Finding - Level 1 5mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 5mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3071258|NCT01189240|Experimental|Phase I Dose Finding - Level 2 10mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 10mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3071259|NCT01189240|Experimental|Phase I Dose Finding - Level 3 20mg|Patients receive oral gamma-secretase/Notch signalling pathway inhibitor RO49290977 20mg on days 1-3, 8-10, 15-17, and 22-24, and bevacizumab IV over 30-90 minutes on days 1 and 15. Other: pharmacological study: correlative studies; laboratory biomarker analysis: correlative studies.
3071260|NCT01189266|Experimental|Arm 1 Phase I Vorinostat 180 mg/m^2|Patients in phase I received vorinostat at 180 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3071261|NCT01189266|Experimental|Arm 2 Phase 1 Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3071262|NCT01189266|Experimental|Arm 3 Phase II Evaluation Vorinostat 230 mg/m^2|Patients received a higher dose of vorinostat at 230 mg/m^2/day PO on Monday through Friday weekly for the duration of radiation therapy (6-7 weeks). Patients underwent 3D conformal or intensity-modulated radiation therapy 5 days per week for 6 weeks. After completing concurrent vorinostat and radiation therapy, patients then received maintenance therapy comprising of vorinostat at 230 mg/m^2/ day PO on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3071263|NCT01189279|Experimental|Part 1: bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
3071264|NCT01189279|Experimental|Part 1: bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
3071265|NCT01189279|Experimental|Part 2: bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
3071266|NCT01189292|Active Comparator|Dexamethasone injection|Administration of 8mg(2ml) intravenous Dexamethasone (Mephameson®)
3071267|NCT01189292|Placebo Comparator|Placebo (NaCl 0.9%)|
3071268|NCT01189370|Experimental|Intra-Patient Dose Escalation: Sorafenib|All patients will receive a starting dose of sorafenib 400 mg by mouth twice daily. At four weeks, all patients who have not experienced Grade 3 or 4 toxicity will undergo dose escalation using a treatment schedule of days 1-5 days of each week. Doses will continue to be escalated every 4 weeks depending on tolerability and tumor response.
3071269|NCT01189409|Experimental|PEG then Senna|PEG in stepped bowel protocol
3071270|NCT01189409|Experimental|Senna then PEG|Stepped bowel protocol with Senna then PEG
3071271|NCT01189461|Experimental|pegaptanib sodium arm|all patients will receive pegaptanib sodium
3071272|NCT01189487|Experimental|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium 12g/day (3 g four times a day) IV
3071273|NCT01189500|Experimental|Tamoxifen and Desvenlafaxine SR|
3071274|NCT01189604|Placebo Comparator|Arm1 - Placebo|
3071275|NCT01189604|Active Comparator|Arm 2 - ICI35,868 (propofol)|
3071276|NCT01189604|Active Comparator|Arm 3 - ICI35,868 (propofol)|
3071277|NCT01189604|Active Comparator|Arm 4 - ICI35,868 (propofol)|
3071278|NCT01189604|Active Comparator|Arm 5 - ICI35,868 (propofol)|
3071279|NCT01189604|Active Comparator|Arm 6 - ICI35,868 (propofol)|
3071280|NCT01189604|Active Comparator|Arm 7 - ICI35,868 (propofol)|
3071281|NCT01189617|Experimental|Formula PD-F-7619|At least twice per week for one week, massage about a dime-sized amount of the PD-F-7619 personal lubricant product to the application site as directed.
3071282|NCT01189747|Experimental|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1.
3071283|NCT01189747|Placebo Comparator|placebo (normal saline)|normal saline injected into bilateral Crow's Feet Line areas on Day 1.
3071284|NCT01189760|Experimental|onabotulinumtoxinA 44U|44 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3071285|NCT01189760|Other|onabotulinumtoxinA 24U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo (normal saline) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3071286|NCT01189760|Placebo Comparator|placebo (normal saline)|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients received two treatments 4 months apart.
3071287|NCT01189812|Placebo Comparator|sugar pill|
3071288|NCT01189812|Active Comparator|Lithium|
3071289|NCT01189890|Experimental|Sitagliptin|Sitagliptin phosphate 100 mg or 50 mg once daily (QD)
3071290|NCT01189890|Active Comparator|Glimepiride|Glimepiride 1-6 mg QD
3071291|NCT01190007|Experimental|Caduet|
3071292|NCT01190020|Active Comparator|Lubiprostone|24mcg BID for 4 weeks, oral medication
3071293|NCT01190020|Placebo Comparator|Placebo|24mcg BID for 4 weeks (placebo), oral medication
3071294|NCT01190085|Active Comparator|Ghrelin (1 microg/kg)|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3071295|NCT01190085|Active Comparator|Ghrelin (3 microg/kg)|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3071296|NCT01190085|Placebo Comparator|Saline Solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
3071297|NCT01190098|Experimental|Lacosamide|
3071298|NCT01190098|Placebo Comparator|Sugar pill|
3071299|NCT01190124||CohortHIV|Adult multiple-experienced HIV infected patients who needed to change their antiretroviral therapy and initiated raltegravir + optimized background therapy under the Early Access Program.
3071300|NCT01190150|Experimental|0.65 g / 1.3 g tranexamic acid|Participants received a single dose of 0.65 g tranexamic acid on Day 1 and a single dose of 1.3 g tranexamic acid on Day 8.
3071301|NCT01190150|Experimental|1.3 g / 0.65 g tranexamic acid|Participants received a single dose of 1.3 g tranexamic acid on Day 1 and a single dose of 0.65 g tranexamic acid on Day 8.
3071302|NCT01190176|Experimental|HPV-062 study subjects Group|HPV-015 (NCT00294047) study subjects who had normal cervical cytology, but tested positive for oncogenic HPV infection at their concluding HPV-015 (NCT00294047) study visit or were pregnant, so that no cervical sample could be collected at their concluding HPV-015 (NCT00294047) study visit.
3071303|NCT01190189|Experimental|Cervarix Group|Healthy female subjects who received control vaccine in the primary study HPV-015 (NCT00294047), were administered three doses of Cervarix vaccine intramuscularly, according to a 0,1,6-month schedule.
3320941|NCT02014896||TIA (Transient Ischemic Attack)|"TIA subjects presenting within 24 hours from symptom onset will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department (if available) or hospital; 24 hours +/- 6 hours from symptom onset (if available) and 48 hours+/- 6 hours from symptom onset (if available).~Biomarker blood draw"
3320942|NCT02014896||Non-Ischemic TNE|"Non-Ischemic Transient Neurological Event (TNE) subjects will have serial PAX Gene Blood RNA tubes drawn within 18 hours of onset of symptoms upon arrival to the Emergency Department or hospital.~Biomarker blood draw"
3320943|NCT02014896||Control|"Control group subjects will have PAX Gene Blood RNA tubes drawn within 8 hours of arrival to the Emergency Department or hospital. Control group matched with ischemic stroke and TIA subjects for age, race, gender, smoking history with at least one of the following vascular risk factors: diabetes, hypertension, atrial fibrillation, hyperlipidemia.~Biomarker blood draw"
3320944|NCT02014909|Experimental|KTN3379|KTN3379
3071308|NCT01190215|Experimental|Fluarix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 dose of Fluarix vaccine. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
3071309|NCT01190215|Active Comparator|Havrix Group|Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
3071310|NCT01190228|Experimental|Group 1: JE-CV Vaccine Booster|Participants previously vaccinated with JE-CV vaccine will receive a booster dose of JE-CV vaccine on Day 0.
3071311|NCT01190228|Experimental|Group 2: JE-CV Vaccine First Dose|JE-CV vaccine naïve participants will receive a single dose of JE-CV vaccine on Day 0.
3071312|NCT01190228|Active Comparator|Group 3: Varicella Vaccine|JE-CV vaccine naïve participants will receive one dose of Varicella vaccine on Day 0.
3071313|NCT01190254|Experimental|Asenapine 2.5 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID for 8 weeks.
3071314|NCT01190254|Experimental|Asenapine 5.0 mg BID|Participants receive active asenapine 2.5 mg tablets sublingually BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive active asenapine 5.0 mg tablets sublingually BID for the remainder of the 8-week treatment period.
3071315|NCT01190254|Placebo Comparator|Placebo|Participants receive placebo asenapine tablets sublingually BID for 8 weeks.
3071316|NCT01190267|Experimental|Asenapine|All enrolled participants receive open-label asenapine 2.5 mg twice daily (BID) on Day 1-3, which is increased to 5.0 mg BID on Day 4 (dose can be increased earlier at the investigator's discretion). Asenapine dosing is flexible for the remainder of the 26-week open-label drug administration period, and can be adjusted to either 2.5 mg or 5.0 mg BID at the investigator's discretion, based on tolerability and/or symptomatology.
3071317|NCT01190410|Experimental|Certolizumab pegol: high-dose group|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
3071318|NCT01190410|Experimental|Certolizumab pegol: low-dose group (weight adjusted)|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
3071319|NCT01190436|Experimental|Bisoprolol|
3071320|NCT01190449|Experimental|Arm I|Patients receive high-dose ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
3071321|NCT01190449|Experimental|Arm II|Patients receive a lower dose of ofatumumab IV over 2-8 hours on days 1, 8, 15, and 22 and then once monthly in months 3-9.
3071322|NCT01190475|Experimental|BGS649 high dose|1 BGS649 1.0mg capsule with three 0.1 mg placebo capsules.
3071323|NCT01190475|Experimental|BGS649 low dose|1 BGS649 1.0 mg placebo capsule and 3 BGS649 0.1 mg capsules
3071324|NCT01190475|Placebo Comparator|Placebo to BGS649|1 matching placebo 1.0mg matching and three matching 0.1 mg placebo capsules
3071325|NCT01190514|Experimental|Bioequivalence and Food effect|
3071326|NCT01190527|Other|FDG-PET|All subjects will have the same course of treatment, the study treatment.
3071327|NCT01190813|Active Comparator|Levodopa/Carbidopa|Levodopa 0.76 mg/kg with Carbidopa 0.17 mg/kg tid
3071328|NCT01190813|Placebo Comparator|Placebo|Oral placebo tid
3071329|NCT01190839|Experimental|Infliximab|Infliximab Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
3071330|NCT01190839|Placebo Comparator|Placebo|Placebo Type=equal unit=mg number=5 form=intravenous infusion route=intravenous use once every 8 weeks
3071331|NCT01190865|Other|HP802-247|Assessment Duration = 8 days Assessment Duration = 15 days Assessment Duration = 22 days Assessment Duration = 29 days Assessment Duration = 31 days Assessment Duration = 43 days Assessment Duration = 50 days Assessment Duration = 57 days
3071332|NCT01190878|Experimental|ISV-303 BID|
3071333|NCT01190878|Experimental|ISV-303 QD|
3071334|NCT01190878|Active Comparator|Xibrom BID|
3071335|NCT01190878|Placebo Comparator|DuraSite Vehicle BID|
3320945|NCT02014909|Experimental|Part II, Arm A|Combination of KTN3379 and cetuximab
3320946|NCT02014909|Experimental|Part II, Arm B|Combination of KTN3379 and erlotinib
3320947|NCT02014909|Experimental|Part II, Arm C|Combination of KTN3379 and vemurafenib
3320948|NCT02014909|Experimental|Part II, Arm D|Combination of KTN3379 and trastuzumab
3320949|NCT02014922|No Intervention|Control|Participants randomized to the control group will be allowed to continue using their habitual artificial tears, and / or additional habitual concurrent dry eye treatments.
3071336|NCT01190891|Active Comparator|Manual Physical Therapy|The orthopaedic manual physical therapy (OMPT) intervention approach used in this study will be based on an impairment model. The physical therapist providing the intervention will address the impairments found in the shoulder joints to include the acromioclavicular joint, glenohumeral joint, and scapular-thoracic joints, and cervical/thoracic spine. Patients will receive procedures tailored to their specific impairments. Procedures will include mobilizations and manipulations of the joint and soft-tissues.
3071337|NCT01190891|Active Comparator|Corticosteroid Injection (Subacromial)|Location: Subacromial space; Syringe: 10mL; Needle: 25 gauge, 1.5 inch; Anesthetic: 6 mL of 1% lidocaine or marcaine; Corticosteroid: 1.0 mL Triamcinolone Acetonide (Kenalog), 40 mg/mL
3071338|NCT01190930|Experimental|Arm A (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3071339|NCT01190930|Experimental|Arm B (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on days 1, 29, and 57; dexamethasone PO BID on days 1-5, 29-33, and 57-61; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3071340|NCT01190930|Experimental|Arm B-LLy (4-week cycle maintenance)|See Detailed Description.
3071341|NCT01190930|Experimental|Arm C (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3071342|NCT01190930|Experimental|Arm D (risk-adapted chemotherapy)|Patients receive vincristine sulfate IV on day 1; dexamethasone PO BID on days 1-5; higher-dose methotrexate PO on days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78; mercaptopurine PO on days 1-84; and IT methotrexate on day 1.
3071343|NCT01190930|Experimental|Arm LR-C (risk-adapted chemotherapy)|Patients receive consolidation, interim maintenance I, delayed intensification, interim maintenance II, and maintenance therapy. See detailed description.
3071344|NCT01190930|Experimental|Arm LR-M (risk-adapted chemotherapy)|Patients receive consolidation and maintenance therapy. See detailed description.
3071345|NCT01190930|Experimental|Arm SR DS (12-week cycle maintenance)|See Detailed Description
3071346|NCT01191008||Latan-timolol maleate fixed comb ophthalmic solution|
3071347|NCT01191086|Experimental|Open-label USL255|Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day
3071348|NCT01191190|Experimental|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered.~Each patient may receive 3 cycles of treatment in the absence of progressive disease or significant toxicity."
3071349|NCT01191255|Active Comparator|Active Control|PhosLo (calcium acetate) Renvela (sevelamer carbonate)
3071350|NCT01191255|Placebo Comparator|Placebo|Placebo
3071351|NCT01191255|Experimental|KRX-0502 (Ferric Citrate)|ferric citrate
3071352|NCT01191268|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3071353|NCT01191268|Experimental|0.75 mg LY2189265|"LY2189265 (Dulaglutide): 0.75 milligrams (mg), subcutaneous (SC), once weekly for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3071354|NCT01191268|Active Comparator|Insulin Glargine|"Insulin Glargine: dose titration based on blood glucose measures, subcutaneous (SC), once daily for 52 weeks~Insulin Lispro: dose titration based on blood glucose measures, subcutaneous (SC), thrice daily (after each meal) for 52 weeks"
3071355|NCT01191320|Placebo Comparator|Placebo|Placebo
3071356|NCT01191320|Experimental|Androxal 12.5 mg|12.5 mg/day
3071357|NCT01191320|Experimental|Androxal 25 mg|25 mg/day
3071358|NCT01191333|Experimental|Active rTMS|Those receiving experimental treatment will receive 20 to 30 sessions of rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
3071359|NCT01191333|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 to 30 sessions of sham rTMS in blocks of 5 sessions. The treatment will be delivered by trained medical personnel.
3071360|NCT01191398|Placebo Comparator|Placebo and Ketamine|Normal Saline 0.9% will act as a placebo. Two ml of normal saline 0.9% will be administered intravenously 30 minutes prior to the administration of the ketamine.
3071361|NCT01191398|Active Comparator|Atropine and Ketamine|Atropine will be administered as a single dose of 0.01 mg/kg, with a minimum of dosage of 0.1 mg and a maximum dosage of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
3071362|NCT01191398|Active Comparator|Glycopyrrolate and Ketamine|Glycopyrrolate will be administered as a single dose of 0.01 mg/kg, with no minimum dosage and a maximum dose of 0.4 mg, intravenously 30 minutes before the administration of the ketamine.
3071363|NCT01191411|Active Comparator|Mailed invitations for FIT test kits|"Fecal Immunochemical Tests (FIT) kits from Polymedco Incorporated are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer using a Polymedco home FIT kit. Mailed invitation to complete a free one sample home FIT kit. Automated and live phone call reminders to promote screening completion, plus usual medical care.~Patients with abnormal FIT results are navigated to complete a diagnostic colonoscopy."
3071364|NCT01191411|Active Comparator|Mailed invitations for a colonoscopy|"Invitation to schedule a colonoscopy are mailed to patients' homes for free colorectal cancer screening.~Intervention: Screening for colorectal cancer with colonoscopy. Mailed invitation to complete one free colonoscopy. Automated and live phone reminders to promote screening completion, plus usual medical care.~Patients with abnormal polyps or adenomas will follow standard clinical protocol after their procedure."
3071365|NCT01191411|Active Comparator|Visit Based Care|"No invitation to complete colorectal cancer screening.~Intervention: Usual medical care. Patients will continue to see their regular physician, and follow their physician's regular standard of care."
3071366|NCT01191476|Active Comparator|Sevoflurane|Subjects received sevoflurane, a inhalational (volatile) anesthetic, which was administered for induction and maintenance of general anesthesia. Inhalational induction was induced via vital capacity induction at 8% and maintained at 0.8-1.5 minimum alveolar concentration (MAC).
3071367|NCT01191476|Active Comparator|Propofol|Subjects received propofol, an intravenous (IV) anesthetic, which was administered for induction and maintenance of general anesthesia.
3071368|NCT01191476|Active Comparator|Propofol Induction and Sevoflurane Maintenance|Subjects received a bolus dose of propofol of 1.5 mg/kg administered for IV induction followed by sevoflurane at 0.8-1.5 MAC for maintenance anesthesia.
3071369|NCT01191541|Active Comparator|DNR+Ara-c(Ara-C group)|patients in this group were treated with DNR+Ara-C in consolidation
3071370|NCT01191541|Experimental|DNR(No Ara-C group)|patients in this group were treated with DNR alone in consolidation
3071371|NCT01191723|Other|Treatment A, then Treatment B, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3071372|NCT01191723|Other|Treatment A, then Treatment C, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3071373|NCT01191723|Other|Treatment B, then Treatment A, then Treatment C|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3071374|NCT01191723|Other|Treatment B, then Treatment C, then Treatment A|"There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
3071375|NCT01191723|Other|Treatment C, then Treatment A, then Treatment B|"There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing."
3071376|NCT01191723|Other|Treatment C, then Treatment B, then Treatment A|"There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing."
3071377|NCT01191736|Experimental|No training, assessed within 60 mins|Subjects receive no training
3071378|NCT01191736|Experimental|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
3071379|NCT01191736|Experimental|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
3071380|NCT01191736|Experimental|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
3071381|NCT01191736|Experimental|Ultra-brief video; assessed at 2 months|
3071382|NCT01191736|Experimental|Brief video; assessed 2 months later|
3071383|NCT01191736|Experimental|Brief video + hands-on; ass'd 2 ms later|
3071384|NCT01191749|Experimental|Alemtuzumab|Alemtuzumab 10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
3071385|NCT01191762|Active Comparator|sevelamer carbonate|2400 mg (3 pills) with each meal
3071386|NCT01191762|Placebo Comparator|placebo control|3 placebo tablets with each meal; tablets are identical to sevelamer carbonate 800 mg tablets.
3071387|NCT01191788|Experimental|Group CBT|Clients received up to 16 sessions of group CBT for depression
3071388|NCT01191788|Active Comparator|Comparison|Treatment as Usual comparison condition
3071389|NCT01191801|Experimental|Group A: vosaroxin + cytarabine|vosaroxin (short IV infusion within 10 minutes) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
3071390|NCT01191801|Placebo Comparator|Group B: placebo + cytarabine|placebo (short IV infusion within 10 minutes and volume matched to vosaroxin) on days 1 and 4: cytarabine on days 1 through 5; a maximum of 2 cycles of Induction and 2 cycles for Consolidation
3071391|NCT01191827||risperidone|
3071392|NCT01191827||clozapine|Patients with schizophrenia treated with clozapine
3071393|NCT01191840|Experimental|Algorithm-determined therapy|
3071394|NCT01191840|Active Comparator|Standard of Care|
3071395|NCT01191944|Experimental|pramipexole Extended release|subjects will receive 0.375mg once a day to 4.5mg once a day depending on investigator's judgement
3071396|NCT01191944|Active Comparator|pramipexole Immediate release|subjects will receive 0.125mg three times a day to 1.0mg three times a day depending on investigator's judgement
3071397|NCT01192022|Active Comparator|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3071398|NCT01192022|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3071399|NCT01192100|Experimental|Breakfast Skipping|Breakfast skipping serves as the baseline/control arm since the participants habitually skip breakfast (i.e., skip breakfast at least 5 times/week). Thus, during the week prior to and including the testing day, the participants will continue to skip breakfast each morning.
3071400|NCT01192100|Experimental|Normal Protein Breakfast Meals|For 7 days, the participants will consume normal protein breakfast meals each morning. These meals will consist of cereal-based foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 15% protein (13 g of dietary protein), 65% CHO, and 20% fat.
3071401|NCT01192100|Experimental|Protein-rich Breakfast Meals|For 7 days, the participants will consume protein-rich breakfast meals each morning. These meals will consist of home-cooked foods and will be 350 kcal, which is approximately 18% of daily energy intake for overweight and obese adolescents ages 9-18 y. The macronutrient composition of these meals will contain 40% protein (35 g of protein), 40% CHO, and 20% fat.
3071402|NCT01192126|Experimental|Bausch & Lomb new daily disposable|New daily disposable contact lenses
3071403|NCT01192126|Active Comparator|Johnson & Johnson Acuvue Moist|Contact lenses
3071404|NCT01192139|Experimental|5 mg saxagliptin + a single 500 mg metformin XR tablet|
3071405|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fed)|under fed state
3071406|NCT01192139|Experimental|FDC tablet (5 mg saxagliptin + 500 mg metformin XR) (Fasting)|under fasted state
3071407|NCT01192152|Experimental|5 mg saxagliptin + 2 Glucophage XR 500 mg tablet|
3071408|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (single dose)|under fed state, single dose
3071409|NCT01192152|Experimental|FDC tablet (5 mg saxa + 1000 mg metformin XR) (4 days)|under fed state, 4 days
3071410|NCT01192178|Active Comparator|FLOVENT™ DISKUS™ 100 mcg|FLOVENT™ DISKUS™ 100 mcg is an inhaled corticosteroid indicated in the US for maintenance treatment of asthma as prophylactic therapy in patients 4 years and older.
3071411|NCT01192178|Experimental|ADVAIR™ DISKUS™ 100/50 mcg|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a corticosteroid and a long acting beta2 adrenergic agonist indicated for; maintenance treatment of asthma in patients 4 years of age and older.
3071412|NCT01192191|Experimental|Fluticasone Furoate/GW642444 100/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
3071413|NCT01192191|Experimental|Fluticasone Furoate/GW642444 200/25mcg|Combination inhaled corticosteroid and long-acting beta2-agonist
3071414|NCT01192204|Active Comparator|10% FBR containing bioadhesive gel|Drug consisting of 10% FBR containing bioadhesive gel. Participants instructed to apply 0.5 gm of 10% FBR containing bioadhesive gel four times a day to lesional site
3071415|NCT01192204|Placebo Comparator|Placebo Gel|Color/consistency matched placebo (no black raspberry) gel
3071416|NCT01192282||Genital Warts|All female patients with Genital Warts presenting to Groote Schuur Hospital
3071417|NCT01192295|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride (HCl) controlled-release (CR)
3071418|NCT01192399|Experimental|Eculizumab|Eculizumab intravenous infusions every week x 4 doses, then 900 mg 1 week later for 1 dose, then 900 mg every 2 weeks for 4 doses
3071419|NCT01192412|Active Comparator|'Less tight' control.|The diastolic blood pressure (dBP) treatment goal is 100 mmHg.
3071420|NCT01192412|Active Comparator|'Tight' control.|The diastolic blood pressure (dBP) treatment goal is 85 mmHg.
3071421|NCT01192516|Experimental|Arm 1|Tailored activity pacing
3071422|NCT01192516|Experimental|Arm 2|General activity pacing and symptom management (Occupational therapy)
3071423|NCT01192516|No Intervention|Arm 3|Usual care group
3071424|NCT01192542|Other|galyfilcon A prototype lens/enfilcon A lens|galyfilcon A prototype contact lens worn daily for 6-8 days first then enfilcon A contact lens worn daily for 6-8 days second.
3071425|NCT01192542|Other|enfilcon A lens/galyfilcon A prototype lens|enfilcon A contact lens worn daily for 6-8 days first then galyfilcon A prototype contact lens worn daily for 6-8 days second.
3071426|NCT01192698|Experimental|IV interferon|IV interferon oral ribavirin
3071427|NCT01192698|No Intervention|Standard of care|standard of care
3071428|NCT01192776|Active Comparator|33.5°C for 72 hours|Target Temp: 33.5°C Duration: 72 hrs
3071429|NCT01192776|Experimental|33.5°C for 120 hours|Target Temp: 33.5°C Duration: 120 hrs
3071430|NCT01192776|Experimental|32.0°C for 72 hours|Target Temp: 32.0°C Duration: 72 hrs
3071431|NCT01192776|Experimental|32.0°C for 120 hours|Target Temp: 32.0°C Duration:120 hrs
3071432|NCT01192815|Experimental|Arm I|Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3071433|NCT01192828|Experimental|Taurine|Treatment with Taurine
3071434|NCT01193010|Active Comparator|Control|Surgery without computer-assisted planning.
3071435|NCT01193010|Experimental|Computer-Assisted Surgical Planning|
3071436|NCT01193049|Experimental|Prednisone, then Placebo|Prednisone in the first crossover treatment period and placebo in the second crossover treatment period
3071437|NCT01193049|Experimental|Placebo, then Prednisone|Placebo in the first crossover treatment period and prednisone in the second crossover treatment period
3071438|NCT01193101|Experimental|LCZ696 100 mg|LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
3071439|NCT01193101|Experimental|LCZ696 200 mg|LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.
3071440|NCT01193101|Experimental|LCZ696 400 mg|LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.
3071441|NCT01193101|Placebo Comparator|Placebo|Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.
3071442|NCT01193114|Experimental|Ecologically-Based Behavioral Treatment|Ecologically-Based Treatment was provided over a period of 6 months. The treatment integrated independent housing, case management services and substance abuse counseling. Specifically, the mothers were housed in an apartment of their choice and received three months of utility and rental assistance of up to $600 per month.
3071443|NCT01193114|Active Comparator|Treatment as Usual|The Mothers were offered services provided through the family shelter.
3071444|NCT01193127|Experimental|OMS302 Solution|OMS302 Solution
3071445|NCT01193127|Experimental|OMS302 Mydriatic Solution|OMS302 Mydriatic Solution
3071446|NCT01193127|Experimental|OMS302 Anti-inflammatory Solution|OMS302 Anti-inflammatory Solution
3071447|NCT01193127|Placebo Comparator|Balanced Salt Solution (BSS) Solution|Balanced Salt Solution (BSS) Solution
3071448|NCT01193153|Experimental|001|paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months
3071449|NCT01193153|Placebo Comparator|002|Placebo monthly by i.m. injection for 15 months
3071450|NCT01193218|Experimental|BI 10773 low dose QD|BI 10773 tablets low dose once a day
3071451|NCT01193218|Experimental|BI 10773 mid-low dose QD|BI 10773 tablets mid-low dose once a day
3071452|NCT01193218|Experimental|BI 10773 mid-high dose QD|BI 10773 tablets mid-high dose once a day
3071453|NCT01193218|Experimental|BI 10773 high dose QD|BI 10773 tablets high dose once a day
3071454|NCT01193218|Placebo Comparator|Placebo|Placebo tablets once a day
3071455|NCT01193244|Experimental|Orteronel + prednisone|
3071456|NCT01193244|Placebo Comparator|Placebo + prednisone|
3071457|NCT01193257|Experimental|Orteronel + prednisone|
3071458|NCT01193257|Placebo Comparator|Placebo + prednisone|
3071459|NCT01193283|Experimental|SAA hematologic response|Treatment-naive severe aplastic anemia patients will receive a low dose of cyclophosphamide (120mg/kg) and low dose cyclosporine ( target therapeutic level of 100-200 micrograms per liter). Cyclophosphamide will be given once daily for 4 doses. Cyclosporine will be started after cyclophosphamide completion, cyclosporine will be given twice daily. The dosing will be modified to attain the therapeutic level.
3071460|NCT01193335|Active Comparator|Group 1: Preterm infants|Infant born at < 37 weeks of gestation.
3071461|NCT01193335|Active Comparator|Group 2: Term infants|Infants born at ≥ 37 weeks of gestation
3071462|NCT01193348|Experimental|Eculizumab|
3071463|NCT01193517|Experimental|Phase I|Dose Escalation of Azacitidine + CAPOX (Capecitabine, Oxaliplatin)
3071464|NCT01193517|Experimental|Phase II|MTD of Azacitidine + CAPOX
3071465|NCT01193582|Experimental|Group 1|
3071466|NCT01193582|Experimental|Group 2|
3071467|NCT01193582|Experimental|Group 3|
3071468|NCT01193582|Experimental|Group 4|
3071469|NCT01193608|Experimental|0.5 mg/kg AAB-003|
3071470|NCT01193608|Experimental|1 mg/kg AAB-003|
3071471|NCT01193608|Experimental|2 mg/kg AAB-003|
3071472|NCT01193608|Experimental|4 mg/kg AAB-003|
3071473|NCT01193608|Experimental|8 mg/kg AAB-003|
3071474|NCT01193608|Placebo Comparator|Placebo|
3071475|NCT01193660|Experimental|Umbilical Cord Blood & Erythropoietin & Rehabilitation|Allogenic umbilical cord blood infusion, erythropoietin injection & active rehabilitation
3071476|NCT01193660|Active Comparator|Erythropoietin & Rehabilitation|Erythropoietin injection, active rehabilitation
3071477|NCT01193660|Placebo Comparator|Only Rehabilitation|Active rehabilitation
3071478|NCT01193686|Experimental|Peer Visitation Training (Peer Mentor)|Veteran Peer Visitors participated in a 2-day training program and then provide at 1-5 visits to at least 2 recipients.
3071479|NCT01193686|Experimental|Peer Visitation|Veterans who received at least one visit from a Veteran Peer Visitor.
3468835|NCT03892057|Experimental|Internet-based Positive Psychological Intervention|The investigator's culturally-tailored internet-based Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
3071482|NCT01193868|Experimental|RO4929097|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Blood and tumor tissue samples are collected for pharmacogenetic, pharmacodynamic, and biomarker studies by IHC, FISH, and TUNEL assay."
3071483|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 12.5 mcg|1 dose of 0.5 mL containing 12.5 mcg of Vi-CRM
3071484|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 5 mcg|1 dose of 0.5 mL containing 5 mcg of Vi-CRM
3071485|NCT01193907|Experimental|NVGH Vi-CRM197 conjugate vaccine 1.25 mcg|1 dose of 0.5 mL containing 1.25 mcg of Vi-CRM
3071486|NCT01193907|Active Comparator|Typherix|1 dose of 0.5 mL containing 25 mcg of Vi-polysaccharide
3071487|NCT01193920|Experimental|1: GBS Trivalent Vaccine with aluminium - 20/20/20 μg|Non-pregnant women who received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
3071488|NCT01193920|Placebo Comparator|2: Placebo - Sterile saline|Non-Pregnant Women who received two injection of saline solution.
3071489|NCT01193920|Experimental|3: GBS Trivalent Vaccine - 0.5/0.5/0.5 µg|Pregnant women who received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3071490|NCT01193920|Experimental|4: GBS Trivalent Vaccine - 2.5/2.5/2.5 µg|Pregnant Women who received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3071491|NCT01193920|Experimental|5: GBS Trivalent Vaccine - 5/5/5 µg|Pregnant women who received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
3071492|NCT01193920|Placebo Comparator|6: Placebo - Sterile saline|Pregnant Women who received one injection of saline solution.
3071493|NCT01194089|Active Comparator|Nasal Nicotine Spray|3 mg of nasal nicotine will be administered postoperatively.
3071494|NCT01194089|Placebo Comparator|Nasal Normal Saline Spray|1 ml of nasal normal saline spray will be administered postoperatively.
3071495|NCT01194154|Experimental|Mircera|
3071496|NCT01194154|Placebo Comparator|Placebo|
3071497|NCT01194219|Active Comparator|Apremilast|Subjects initially randomized to apremilast 30 mg twice a day, and who demonstrate a PASI 75 response at Week 32 will be randomized (1 to 1) to either continue to receive apremilast 30 mg ) BID or to receive placebo (until effect is lost). At the time effect is lost, subjects will be treated with apremilast 30 mg twice a day for the duration of their participation in the study.
3071498|NCT01194219|Placebo Comparator|Placebo|Subjects initially randomized to placebo, are assigned to apremilast 30 mg twice a day beginning at Week 16 for the duration of the subject's participation in the study.
3071499|NCT01194219|Active Comparator|Apremilast 30 mg|Apremilast 30 mg by mouth (PO) twice a day (BID). Participants initially randomized to apremilast 30 mg BID, and who were able to demonstrate a Psoriasis Area Severity Index (PASI) -75 response at week 32 were randomized (1 to 1) to either apremilast 30 mg BID or oral placebo (until effect is lost). At relapse/loss of response to therapy prior to Week 52 (the time at which 75% improvement in PASI score compared to baseline was lost) or at Week 52, participants were re-treated with apremilast 30 mg BID for the duration of their participation in the study. Non-responders or partial responders (PASI response <75) received additional topical therapies or phototherapy beginning at Week 32.
3071500|NCT01194245|Experimental|Lispro-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3071501|NCT01194245|Experimental|Aspart-PH20 / Insulin Lispro|"All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3071502|NCT01194258|Experimental|Lispro-PH20/Insulin lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually.~Next, participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (combined: Lispro-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3071503|NCT01194258|Experimental|Aspart-PH20/Insulin Lispro|"All enrolled participants underwent a titration period of 4 to 6 weeks in which they received 100 U/mL insulin glulisine, injected SC, pre-meals, with doses titrated to each participant individually.~Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle.~Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 µg/mL rHuPH20 (combined: Aspart-PH20), injected SC, pre-meals, with doses titrated to each participant individually.~Insulin lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually.~Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine."
3071504|NCT01194271|Experimental|Neoadjuvant Ipilimumab|Leuprolide Acetate 22.5 mg administered as a single intramuscular 3 month depot + Ipilimumab 10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy + Radical Prostatectomy Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
3071505|NCT01194297|Experimental|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
3071506|NCT01194297|Active Comparator|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
3071507|NCT01194414|Experimental|Tocilizumab SC|"Participants received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab intravenous (IV) infusion every 4 weeks for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3071508|NCT01194414|Experimental|Tocilizumab IV|"Participants received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly for a total of 24 weeks in the double-blind period. Participants continued to receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3071509|NCT01194414|Experimental|Tocilizumab SC Then Tocilizumab IV|"Participants who received tocilizumab 162 mg subcutaneous (SC) injection weekly plus placebo to tocilizumab IV infusion every 4 weeks for 24 weeks in double blind treatment period switched to tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose continued throughout the study."
3071510|NCT01194414|Experimental|Tocilizumab IV Then Tocilizumab SC|"Participants who received tocilizumab 8 mg/kg infusion (IV) every 4 weeks plus placebo to tocilizumab SC injection weekly in double blind treatment period switched to tocilizumab 162 mg SC injection weekly for a total of 72 weeks in open label extension period.~Non-biologic disease-modifying anti-rheumatic drugs (DMARDs) at a stable dose will be continued throughout the study."
3071511|NCT01194440|Experimental|Arm I - IV Zoledronic Acid Prophylaxis|Patients receive zoledronic acid IV at months 1 and 6. Beginning 14 days after first zoledronic acid infusion, patients receive oral letrozole once daily for 12 months in the absence of disease progression or unacceptable toxicity.
3071512|NCT01194453|Experimental|Group A|
3071513|NCT01194453|Active Comparator|Group B|
3071514|NCT01194466|Active Comparator|Active TENS|Active high frequency TENS will be use for Active TENS.
3071515|NCT01194466|Experimental|Placebo (low intensity) TENS|Placebo TENS will be applied for one arm of the study
3071516|NCT01194466|Sham Comparator|No Treatment|TENS unit in place but not turned on
3071517|NCT01194479|Active Comparator|Type 1 Diabetics|The active group were participants with type 1 diabetes.
3071518|NCT01194479|Other|Healthy Volunteers|The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.
3071519|NCT01194531|No Intervention|CONTROL arm|Subjects assigned to this arm of the study will receive no PGS testing.
3071520|NCT01194531|Other|TEST arm|Subjects assigned to this arm of the study will receive PGS testing.
3071521|NCT01194570|Experimental|Placebo|Participants with primary progressive multiple sclerosis (PPMS) received placebo matched to ocrelizumab at a schedule interval of 24 weeks up to at least 120 weeks.
3071522|NCT01194570|Placebo Comparator|Ocrelizumab 600 mg|Participants with PPMS received ocrelizumab as two IV infusions of 300 mg separated by 14 days at a scheduled interval of every 24 weeks up to at least 120 weeks.
3071523|NCT01194674|Experimental|Microplasmin|
3071524|NCT01194804|Experimental|Eculizumab|Treatment with eculizumab for patients with PNH who have successfully completed the C07-001 protocol
3071525|NCT01194830|Active Comparator|Linagliptin|1 Tablet PO QD
3071526|NCT01194830|Placebo Comparator|Placebo|1 Tablet PO QD
3071527|NCT01194869|Experimental|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
3071528|NCT01194973|Experimental|Eculizumab|
3071529|NCT01194999|Experimental|Pubovaginal sling procedure|Patients undergoing pubovaginal slings for stress urinary incontinence.
3071530|NCT01195025|Other|A.acetatedRingers, B.colloid & C.colloid+acetatedRingers|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by 150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
3071531|NCT01195025|Other|A.colloid, B.colloid+acetatedRinger & C.acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
3071532|NCT01195025|Other|A.acetatedRingers, B.acetatedRingers+colloid & C.colloid|"First intervention: A. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B.Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples."
3071533|NCT01195025|Other|A.colloid, B.acetatedRingers & C.colloid+acetatedRingers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout >7 days~Second intervention: B. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected.~Washout > 7 Days~Third intervention: C. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples."
3071534|NCT01195025|Other|A.colloid+acetatedRingers, B.colloid & C.acetated Ringers|"First intervention: A. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed 90 minutes later by acetated Ringers 20 ml/kg bodyweight during 30 minutes. thereafter the subjects stayed for Another 285 minutes of equilibration and blood samples.~Washout >7 days~Second intervention: B. Voluven 6 % (starch solution) 10 ml/kg bodyweight during 30 minutes followed by 390 minutes of equilibration and blood samples.~Washout > 7 Days~Third intervention: C. acetated Ringers 20 ml/kg bodyweight during 30 minutes followed by150 minutes of equilibration, when blood samples were collected."
3071535|NCT01195090|Active Comparator|sitagliptin|add sitagliptin100mg/d to pre-study OADs
3071536|NCT01195090|Active Comparator|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
3071537|NCT01195103|Experimental|10 mg/kg Lusedra|10 mg/kg Lusedra initial bolus.
3071538|NCT01195103|Active Comparator|6.5 mg/kg Lusedra|6.5 mg/kg Lusedra initial bolus.
3071539|NCT01195103|Active Comparator|Placebo + Midazolam|Placebo initial bolus with dose of midazolam based on patient's weight
3071540|NCT01195116|Active Comparator|Dexmedetomidine|Dexmedetomidine is a FDA-approved medication that is a highly selective, short acting, alpha-2 adrenoreceptor agonist. To date, its safety and efficacy is well studied and established.It produces sedative, anxiolytic, and analgesic effects when used while patients undergo procedures and surgical operations.Interstitial Cystitis, as a chronic visceral pain syndrome, has the potential to have a neuropathic component for which an alpha-2 adrenergic agonist may be more effective than other classes, including opioids or NSAIDs.
3071541|NCT01195116|Placebo Comparator|Normal Saline|
3071542|NCT01195272|Experimental|Single Arm|
3071543|NCT01195363|Active Comparator|quetiapine SR|quetiapine SR, 200-600mg, po, qd
3071544|NCT01195363|Placebo Comparator|quetiapine sr Placebo|quetiapine SR placebo, 200-600mg, po qd
3071545|NCT01195415|Experimental|Treatment (vismodegib, gemcitabine hydrochloride)|Patients receive vismodegib PO QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 (beginning in course 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3071546|NCT01195467|Experimental|All Subjects Truvada/Raltegravir|All Subjects will receive the same intervention, Truvada/Raltegravir
3071547|NCT01195545|Experimental|Veritas Mesh in Hernia Repair|Subjects undergoing laparoscopic paraesophageal hiatal hernia repair using a bovine pericardium mesh (BP) (Veritas® Collagen Matrix, Synovis ®, St. Paul MN) as a reinforcing material during repair.
3071548|NCT01195584||BMI < 25|Body Mass Index (WHO) established by WHO. BMI < 25 has been defined as 'normal weight'.
3071549|NCT01195584||25 >= BMI < 30|Body Mass Index (WHO) established by WHO. BMI >= 25 and < 30 has been defined as 'overweight'.
3071550|NCT01195584||BMI >= 30|Body Mass Index (WHO) established by WHO. BMI > 30 has been defined as 'obese'.
3071551|NCT01195597|Experimental|E-Cigarette 7.2 mg nicotine|Well characterized group of 40 regular smokers not intending to quit experimenting the E-Cigarette with 7.2 mg nicotine cartridges.
3071552|NCT01195623|Active Comparator|varicose vein surgery with preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination and has then the extra information available from a preoperative duplex examination to plan surgery more in detail
3071553|NCT01195623|No Intervention|varicose vein surgery no preop duplex|The surgeon has planned surgery for varicose veins from a clinical examination only
3071554|NCT01195636|Experimental|XPF-002|
3071555|NCT01195636|Placebo Comparator|Placebo|
3071556|NCT01195662|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablets
3071557|NCT01195662|Placebo Comparator|Placebo matching Dapagliflozin|Placebo tablets matching dapagliflozin tablets
3071558|NCT01195675|Experimental|BI 10773|single oral (high and low) dose per subject
3071559|NCT01195675|Placebo Comparator|Placebo|2 single oral doses per subject
3071560|NCT01195675|Active Comparator|Moxifloxacin|single oral dose per subject
3071561|NCT01195701||Anorgasmia (cases)|Women with difficulty or inability to reach sexual climax will be the cases in this study.
3071562|NCT01195701||Normal orgasmic function|Women who report that they usually or always achieve sexual climax will be the controls in this study.
3071563|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
3071564|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
3071565|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
3071566|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
3071567|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation A3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
3071568|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation A3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
3071569|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B1 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
3071570|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B1 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
3071571|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B2 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
3071572|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B2 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
3071573|NCT01195779|Experimental|GSK2584786A vaccine 1 dose of Formulation B3 Group|Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
3071574|NCT01195779|Experimental|GSK2584786A vaccine 2 doses of Formulation B3 Group|Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
3071575|NCT01195779|Experimental|GSK2321138A vaccine Group|Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
3071576|NCT01195779|Active Comparator|Fluarix Group|Subjects received 2 doses of Fluarix Vaccine.
3071577|NCT01195831|Experimental|Xamiol® gel|Calcipotriol (as hydrate) 50mcg/g plus betamethasone 0.5mg/g (dipropionate)
3071578|NCT01195831|Active Comparator|Calcipotriol scalp solution|Calcipotriol (as hydrate) 50 mcg/ml
3071579|NCT01195844||Brazilian Children With Rotavirus Gastroenteritis|Brazilian children under 5 years of age who have diarrhea attributed to rotavirus located in 4 hospitals from 4 different Brazilian regions
3071580|NCT01195883|Active Comparator|Crystalloid|Lactated Ringers solution will be used for fluid replacement.
3071581|NCT01195883|Active Comparator|Colloid|Low-molecular weight colloid HES 130/0.4 (Voluven) will be used for fluid replacement
3071582|NCT01195922|Experimental|Sirolimus|Subjects will be treated with sirolimus 21 days
3071583|NCT01195948|Experimental|B27PD 1 mg|Participants randomly assigned to the B27PD 1 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3071584|NCT01195948|Experimental|B27PD 4 mg|Participants randomly assigned to the B27PD 4 mg arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3071585|NCT01195948|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm were instructed to take the capsule orally three times per week (i.e., Monday, Wednesday and Friday) in the morning, at least four hours after the last meal and at least 30 minutes before the next meal for 24 weeks.
3071586|NCT01196026|Experimental|Fluarix 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3071587|NCT01196026|Experimental|Fluarix 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3071588|NCT01196026|Experimental|Fluarix 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine, will receive one or two doses of Fluarix vaccine
3071589|NCT01196026|Active Comparator|Havrix Junior 6-11 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3071590|NCT01196026|Active Comparator|Havrix Junior 12-35 months Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3071591|NCT01196026|Active Comparator|Havrix Junior 3-9 years Group|Subjects previously vaccinated with Pandemrix vaccine will receive two doses of Havrix Junior vaccine
3071592|NCT01196052|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg was administered intravenously on Day 1 of each 3-week treatment cycle up to a maximum of 17 cycles.
3071593|NCT01196078|Experimental|1|
3071594|NCT01196078|Active Comparator|2|
3071595|NCT01196091|Experimental|LY2127399 every 2 weeks|Administered SC
3071596|NCT01196091|Experimental|LY2127399 every 4 wks|During the Treatment Period, for blinding purposes, patients will alternate injections of LY2127399 and injections of placebo every 2 weeks.
3071597|NCT01196091|Placebo Comparator|Placebo|Administered SC
3071598|NCT01196104|Experimental|Technosphere® Insulin Inhalation Powder (TI)|Insulin Glargine and Technosphere® Insulin Inhalation Powder
3071599|NCT01196104|Active Comparator|Comparator|Insulin Glargine and Insulin Aspart
3071600|NCT01196117|Placebo Comparator|14 days of Placebo therapy, then CPAP|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
3071601|NCT01196117|Active Comparator|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
3071602|NCT01196377|Active Comparator|Nebulized albuterol 10mg/hr continuous|Active control arm, 10mg/hr continuous.
3071603|NCT01196377|Experimental|10mg/hr pulsed|Experimental 10mg/hr pulsed albuterol regimen.
3071604|NCT01196377|Experimental|25mg/hr continuous|Experimental 25mg/hr continuous albuterol.
3071605|NCT01196377|Experimental|25mg/hr pulsed|Experimental 25mg/hr pulsed albuterol
3468836|NCT03892057|No Intervention|Attention Control Group|Participants will complete computerized surveys to document the frequency of positive and negative emotions experienced in daily life. The attention control group will be given the option to access our positive psychological intervention and associated content via the web at the conclusion of the 12-week data collection phase.
3468837|NCT03892070|Experimental|HMB GROUP|HMB Supplementation with 1.5 g of HMB taken twice daily. Supplementation will be provided for 12 weeks
3071608|NCT01196416|Experimental|Treatment (RO4929097, cisplatin, vinblastine, temozolomide)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-21, cisplatin IV over 30 minutes and vinblastine IV over 30 minutes on days 1-3, and temozolomide PO QD on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without progressive disease continue to receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temozolomide as above in the absence of disease progression or unacceptable toxicity.
3071609|NCT01196429|Experimental|Treatment (paclitaxel, carboplatin, temsirolimus, docetaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV on days 1 and 8. Treatment repeats every 3 weeks for 6 courses. Patients then receive consolidation therapy comprising temsirolimus IV on days 1, 8, and 15. Treatment repeats every 3 weeks for 11 courses in the absence of disease progression or unacceptable toxicity.~NOTE: * For circumstances in which docetaxel should be substituted for paclitaxel, docetaxel is given IV over 1 hour."
3071610|NCT01196442|Experimental|Arm I electric stimulation pain therapy|Patients undergo electric stimulation pain therapy comprising MC5-A Calmare therapy over 30 minutes once daily for 10 days.
3071611|NCT01196533|Experimental|Non Invasive Monitoring|Intervention: Device: Non invasive peripheral blood monitoring
3071612|NCT01196741|Active Comparator|Saracatinib plus weekly paclitaxel|
3071613|NCT01196741|Placebo Comparator|Placebo plus weekly paclitaxel|
3071614|NCT01196793||febrile children, age 3 m to 5 y|
3071615|NCT01196819|Active Comparator|Xience V|Implantation of Xience V drug eluting stent
3071616|NCT01196819|Experimental|Firehawk|Implantation of Firehawk drug eluting stent
3071617|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (150 mg)|
3071618|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (150 mg)|
3071619|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (150 mg)|
3071620|NCT01196871|Experimental|Agalsidase Beta (0.5 mg/kg)-Migalastat (450 mg)|
3071621|NCT01196871|Experimental|Agalsidase Beta (1.0 mg/kg)-Migalastat (450 mg)|
3071622|NCT01196871|Experimental|Agalsidase Alfa (0.2 mg/kg)-Migalastat (450 mg)|
3071623|NCT01196923|Experimental|HeartLight Ablation|
3071624|NCT01196936|Experimental|Arm I (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
3071625|NCT01196936|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 24 months in the absence of disease progression or unacceptable toxicity.
3071626|NCT01196975|Experimental|GSK2282512A 1 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071627|NCT01196975|Experimental|GSK2282512A 2 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071628|NCT01196975|Experimental|GSK2282512A 3 Group|Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3468838|NCT03892070|Placebo Comparator|PLACEBO GROUP|Mannitol 1.5 g twice daily. Supplementation will be provided for 12 weeks
3468839|NCT03892161|Experimental|Standard dose DRV/r|Standard dose DRV/r 800/100mg without Rifampicin
3071629|NCT01196975|Active Comparator|Victoria Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071630|NCT01196975|Active Comparator|Yamagata Strain FluLaval Group|Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071631|NCT01196988|Experimental|GSK2321138A 1 Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3071632|NCT01196988|Active Comparator|Fluarix Group|Subjects aged 3-17 years received if primed, 1 dose of Fluarix at Day 0 and if unprimed, 2 doses of Fluarix at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3071633|NCT01196988|Active Comparator|GSK2604409A Group|Subjects aged 3-17 years received if primed, 1 dose of GSK2604409A at Day 0 and if unprimed, 2 doses of GSK2604409A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3071634|NCT01196988|Experimental|GSK2321138A 2 Group|Subjects aged 6-35 months received if primed, 1 dose of GSK2321138A at Day 0 and if unprimed, 2 doses of GSK2321138A at Day 0 and Day 28. The vaccine was administered intramuscularly into the deltoid for subjects aged 12 months or above or into the anterolateral region of the thigh for subjects below 12 month of age. The vaccine was administered in the non-dominant side of the body at Day 0 and in the opposite side at Day 28.
3071635|NCT01197300|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
3071636|NCT01197326||Group 1|Patients who triggered MET/RRT calls prior to the use of the MP5 EWS patient monitor.
3071637|NCT01197326||Group 2|Patients who triggered MET/RRT calls after the use of the MP5 EWS patient monitor.
3071638|NCT01197378|Experimental|Cysteamine Bitartrate|Cysteamine bitartrate delayed-release capsules were administered twice daily for up to 96 months.
3071639|NCT01197417|Experimental|Magnesium group|Intravenous Magnesium Sulfate
3071640|NCT01197417|Placebo Comparator|Placebo group|Normal Saline placebo
3071641|NCT01197456||Exposed/chemotherapy|Breast cancer patients who will undergo chemotherapy
3071642|NCT01197456||Unexposed|Breast cancer patients who will not undergo chemotherapy
3071643|NCT01197495|Experimental|Treatment|Juvederm(R) Ultra XC Injectable Gel
3071644|NCT01197495|Experimental|Control|No treatment for 3 months followed by Juvederm(R) Ultra XC Injectable Gel at Month 3.
3071645|NCT01197508|Experimental|0.1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 0.1 mg BID
3071646|NCT01197508|Experimental|1 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 1 mg BID
3071647|NCT01197508|Experimental|4 mg BID TC-5214|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + TC-5214, 4 mg BID
3071648|NCT01197508|Placebo Comparator|Placebo|Selective serotonin reuptake inhibitor (SSRI)/Serotonin/norepinephrine reuptake inhibitor (SNRI) + Placebo BID
3071649|NCT01197521|Experimental|Dosing Regimen A|Oral Treatment
3071650|NCT01197521|Experimental|Dosing Regimen B|Oral Treatment
3071651|NCT01197521|Placebo Comparator|Dosing Regimen C|Oral Treatment
3071652|NCT01197534|Experimental|Dosing Regimen A|Oral Treatment
3071653|NCT01197534|Experimental|Dosing Regimen B|Oral Treatment
3071654|NCT01197534|Placebo Comparator|Dosing Regimen C|Oral Treatment
3071655|NCT01197547|Other|Genesys HTA|Genesys HTA Endometrial Ablation
3071656|NCT01197560|Experimental|Lenalidomide|Lenalidomide 25 mg capsules by mouth on days 1-21 of each 28 day cycle. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
3071657|NCT01197560|Active Comparator|Investigators Choice|"One of the following:~Gemcitabine, Oxaliplatin, Rituximab, or Etoposide"
3071658|NCT01197573|Active Comparator|Standard DCD liver transplant|Standard method of liver transplant utilizing a DCD organ
3071659|NCT01197573|Active Comparator|rTPA Treatment Liver Transplant|Ex-vivo treatment of liver donated after cardiac death (DCD) with rTPA
3071660|NCT01197573|Active Comparator|Standard DCD kidney transplant|Standard method of kidney transplant utilizing a DCD organ
3071661|NCT01197573|Active Comparator|rTPA Treatment Kidney Transplant|Ex-vivo treatment of kidney donated after cardiac death (DCD) with rTPA
3071662|NCT01197612|Other|Single Arm; nostrils as experimental and comparator|each subject serves as their own control with one nostril being treated with pulmicort and one not
3071663|NCT01197755|Experimental|Dosing Regimen A|Oral Treatment
3071664|NCT01197755|Experimental|Dosing Regimen B|Oral Treatment
3071665|NCT01197755|Placebo Comparator|Dosing Regimen C|Oral Treatment
3071666|NCT01197794|Experimental|AZD1981 10 mg|AZD1981 10 mg
3071667|NCT01197794|Experimental|AZD1981 40 mg|AZD1981 40 mg
3071668|NCT01197794|Experimental|AZD1981 100 mg|AZD1981 100 mg
3071669|NCT01197794|Experimental|AZD1981 400 mg|AZD1981 400 mg
3071670|NCT01197794|Experimental|AZD1981 80 mg|AZD1981 80 mg
3071671|NCT01197794|Experimental|AZD1981 200 mg|AZD1981 200 mg
3071672|NCT01197794|Placebo Comparator|Placebo|
3071673|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable microfoam 0.125%|Endovenous ablation followed by an injection of polidocanol injectable microfoam 0.125% to target vein
3071674|NCT01197833|Experimental|Endovenous ablation+polidocanol injectable micrfoam, 1.0%|Endovenous ablation followed by injection of polidocanol injectable microfoam, 1.0% to the target vein
3071675|NCT01197833|Active Comparator|endovenous ablation+vehicle (placebo)|endovenous ablation followed by injection of vehicle (placebo) to target vein
3071676|NCT01197898|Experimental|Collagenase Santyl|Ointment applied once daily
3071677|NCT01197898|Placebo Comparator|Vehicle Base|Applied once daily
3071678|NCT01197911|Experimental|Mild impairment|
3071679|NCT01197911|Experimental|Moderate impairment|
3071680|NCT01197911|Experimental|Normal HF|
3071681|NCT01198002|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 100 weeks. Participants receive a 240 mg loading dose when initiating treatment. During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Weeks 16 and 52, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3071682|NCT01198002|Experimental|90 mg LY2127399|"Given Q2W for 100 weeks. Participants receive a 180 mg loading dose when initiating treatment.~At Weeks 16 and 52, responders will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q4W for the rest of the 100-week treatment period.~At Week 16, NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3071683|NCT01198002|Placebo Comparator|Placebo|"Given Q2W for 52 weeks. At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 52 weeks.~At Week 52, responders are randomized to receive 1 of the 2 doses of LY2127399, with loading dose of 240 mg or 180 mg of LY2127399, followed by 120 mg of LY2127399 Q4W or 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period.~At Week 16, NR will receive a loading dose of 180 mg of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 100-week treatment period."
3071684|NCT01198028|Experimental|Treatment (erlotinib)|Participants receive erlotinib PO QD in the absence of disease progression or unacceptable toxicity.
3071685|NCT01198132|Experimental|Cholecalciferol|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 3 times a week.
3071686|NCT01198132|Placebo Comparator|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks along with subcutaneous injection of Rebif 3 times weekly.
3071687|NCT01198145|Experimental|Arm I: Sulfasalazine|Patients receive oral sulfasalazine twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
3071688|NCT01198145|Placebo Comparator|Arm II: Placebo|Patients receive oral placebo twice daily during radiotherapy and for 4 weeks after completion of radiotherapy.
3071689|NCT01198158|Active Comparator|Arm I (everolimus)|Patients receive everolimus PO QD on days 1-28.
3071690|NCT01198158|Experimental|Arm II (everolimus with bevacizumab)|Patients receive everolimus PO QD on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15.
3071691|NCT01198275|Active Comparator|n-3 PUFAs|
3071692|NCT01198275|Placebo Comparator|placebo|
3071693|NCT01198327|Experimental|Ranibizumab as needed|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart; with optional peripheral laser to areas of non-perfusion.
3071694|NCT01198366|Placebo Comparator|Dose Finding Gr 1 placebo x 2|Subjects received two doses (x2) of placebo (sterile buffer) on study days 0 and 28.
3071695|NCT01198366|Experimental|Dose Finding Gr 2 AERAS-402 (1.5 x 10^10 vp) x2|Subjects received two doses (x2) of AERAS-402 (1.5 x 10^10 vp) on study days 0 and 28.
3071696|NCT01198366|Experimental|Dose Finding Gr 3 AERAS-402 (3.0 x 10^10 vp) x 2|Subjects received two doses (x2) of AERAS-402 (3.0 x 10^10 vp) on study days 0 and 28.
3071697|NCT01198366|Experimental|Dose Finding Gr 4 AERAS-402 (1.0 x 10^11 vp) x 2|Subjects received two doses (x2) of AERAS-402 (1.0 x 10^11 vp) on study days 0 and 28.
3071698|NCT01198366|Experimental|Expanded Safety Phase Gr 5 AERAS-402 (1.0 X 10^11 vp) x 3|Subjects received 3 doses (x3) of AERAS-402 (1.0 X 10^11 vp) on days 0, 28 and 280.
3071699|NCT01198366|Placebo Comparator|Expanded Safety Phase Gr 5 Placebo x3|Subjects received 3 doses (x3) of placebo (sterile buffer) on days 0, 28 and 280.
3071700|NCT01198470|Experimental|TRIUMPH® Artificial Disc|Treatment of degenerative disc disease with the TRIUMPH Lumbar Artificial Disc. This is a non-randomized pilot study with only one arm (no control).
3071701|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - doxycycline|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
3071702|NCT01198509|Active Comparator|Rheumatoid Arthritis (RA) - vancomycin|Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
3071703|NCT01198509|No Intervention|RA, PsA, healthy|"Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.~Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.~Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients."
3071704|NCT01198574|Experimental|Iron group|
3071705|NCT01198574|Experimental|Vitamin A group|Vitamin A group
3071706|NCT01198574|Experimental|Iron and Vitamin A group|Iron and Vitamin A group
3071707|NCT01198574|Experimental|Placebo group|Placebo group with folic acid
3071708|NCT01198587|Experimental|Outpatient Zinc Sulfate|Zinc Sulfate
3071709|NCT01198587|Experimental|Inpatient Zinc Sulfate|Zinc Sulfate
3071710|NCT01198587|Placebo Comparator|Outpatient Placebo|Placebo oral capsule
3071711|NCT01198587|Placebo Comparator|Inpatient Placebo|Placebo oral capsule
3071712|NCT01198600|Other|Phase 1: Habitual no Replacement, then Habitual Replacement|Contact lenses per participant's habitual prescription worn for 30 days with no replacement, followed by contact lenses per habitual prescription worn for 30 days with a replacement pair dispensed at Day 28.
3468840|NCT03892161|Experimental|Standard DRV/r with Rifampicin|Rifampicin 600mg QD will be added and darunavir/ritonavir steady state pharmacokinetic analysis will be performed.
3071713|NCT01198600|Other|Phase 1: Habitual Replacement, then Habitual no Replacement|Contact lenses per participant's habitual prescription worn for 30 days with replacement pair dispensed at Day 28, followed by contact lenses per habitual prescription worn for 30 days with no replacement.
3071714|NCT01198600|Other|Phase 2: Lotrafilcon B Replacement|Contact lenses worn for 56 days with replacement pair dispensed at Day 28.
3071715|NCT01198600|Other|Phase 3: Lotrafilcon B Replacement Replacement|Contact lenses worn for 43 days with replacement pair dispensed at Day 1 and Day 28.
3071716|NCT01198691|Placebo Comparator|Control Group|This group will receive the standard metallic staples to close their incision.
3071717|NCT01198691|Experimental|Case Group|This group will receive the Insorb absorbable staples to close their incision.
3071718|NCT01198756|Experimental|GSK2282512A 1 Group|Subjects, 3 to 17 years old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071719|NCT01198756|Active Comparator|Victoria strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ VB vaccine containing the Victoria lineage B flu strain at Day 0 or 2 doses of Fluarix™ VB vaccine at Day 0 and Day 28. The Fluarix™ VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071720|NCT01198756|Active Comparator|Yamagata strain Fluarix Group|Subjects, 3 to 17 years old, received 1 dose of Fluarix™ YB vaccine containing the Yamagata lineage B flu strain at Day 0 or 2 doses of Fluarix™ YB vaccine at Day 0 and Day 28. The Fluarix™ YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3071721|NCT01198756|Experimental|GSK2282512A 2 Group|Subjects, 6 to 35 months old, received 1 dose of GSK2282512A vaccine at Day 0 or 2 doses of GSK2282512A vaccine at Day 0 and Day 28. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm for subjects ≥12 months of age and into the antero-lateral region of the left thigh for infants <12 months of age.
3071722|NCT01198769|Experimental|Rotarix Group|subjects received 2 oral doses of Rotarix™ vaccine at 2 and 4 months of age.
3071723|NCT01198795|Experimental|1|Flexible-dose 10mg-20mg once-daily oral (10mg tablets) dose of escitalopram
3071724|NCT01198873|Experimental|Dronedarone|Dronedarone 400 mg twice a day
3071725|NCT01198873|Placebo Comparator|Placebo|Placebo (for Dronedarone) twice a day
3071726|NCT01198977|Active Comparator|Brief telephone-based counseling|Telephone based counseling and instructional video
3071727|NCT01198977|Placebo Comparator|Education Counseling|Mailed Physical Activity information and instructional video only
3071728|NCT01199016||1|
3071729|NCT01199042|Other|BiPAP autoSV Advanced Device|Positive airway pressure device
3071730|NCT01199055|Experimental|CS-7017+Carboplatin/Paclitaxel|"Drug: CS-7017 from 0.25 mg twice a day (BID) to 0.50 mg BID for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Carboplatin IV, Area under the curve (AUC) of 6 mg/mL*min, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)~Drug: Paclitaxel IV, 200mg/m^2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)"
3071731|NCT01199068|Experimental|CS-7017+Erlotinib|Drug: CS-7017 from 0.25 mg to 0.50 mg twice a daily Drug: Erlotinib 150 mg once daily
3071732|NCT01199146|Experimental|Abiraterone acetate|
3071733|NCT01199198|Experimental|Tolvaptan Group|Tolvaptan Group: Starting dose 15 mg by mouth once a day for 14 days.
3071734|NCT01199198|Placebo Comparator|Placebo Group|Placebo Group: Placebo by mouth once a day for 14 days.
3071735|NCT01199237|Active Comparator|Sevoflurane|Patients receive sevoflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
3071736|NCT01199237|Active Comparator|Desflurane|Patients receive Desflurane, rocuronium with neostigmine + glycopyrrolate reversal (70 and 14 ug/kg)
3071737|NCT01199263|Experimental|Arm I (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3071738|NCT01199263|Experimental|Arm II (paclitaxel and wild-type reovirus)|Patients receive paclitaxel as in arm I and wild-type reovirus IV over 1 hour on days 1-5.
3071739|NCT01199289|Placebo Comparator|Placebo|Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
3071740|NCT01199289|Experimental|AMG 827 140 mg|Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
3071741|NCT01199289|Experimental|AMG 827 210 mg|Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
3071742|NCT01199289|Experimental|AMG 827 280 mg|Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
3071743|NCT01199380|Active Comparator|Standard Treatment (ST)|Participants will receive a standard, group smoking cessation treatment equated for contact time, based on the most recent clinical practice guideline for treating tobacco. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will complete between group exercises and will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events. Participants will also receive 8 weeks of the transdermal nicotine patch.
3071744|NCT01199380|Experimental|Behavioral Activation for Smoking|Behavioral Activation Treatment for Smoking (BATS) includes standard smoking cessation strategies and identifying life areas, values, and daily activities to help manage mood. Participants will complete between group exercises and will also monitor and plan daily activities in line with their values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Participants will also receive 8 weeks of the transdermal nicotine patch.
3071745|NCT01199471||Chinese Patients Requiring Surgery with Anesthesia|Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).
3321410|NCT02018614||testretest relaibility|Data from a sample of 50 patients will be used to explore the test-retest reliability of the scale administered by the same trained clinician, on two occasions four hours apart, without any treatment in between. The ALGOPLUS® scores obtained from the patients at a time t will be compared with their (t + 4 hours) scores to assess test-retest reliability
3071746|NCT01199575|Experimental|Revlimid + Rituximab|"A: Lenalidomide starting at a low dose 2.5 or 5 mg, 21 days/cycle escalated based on patient tolerability. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles (3-7). Each patient may receive up to 7 cycles of treatment with the combination lenalidomide/rituximab if no progressive disease or significant toxicity. Patients with residual disease can elect to receive 6 additional cycles of single agent Revlimid as consolidation.~Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity."
3071747|NCT01199601|Experimental|Concentrated postpartum counseling|Women randomized to receiving concentrated postpartum counseling from the retrained provider.
3071748|NCT01199601|No Intervention|Routine postpartum counseling|Women receiving intra-partum testing and post-partum counseling from existing cadres of hospital providers at standard of care.
3071749|NCT01199705|Experimental|IgPro20|
3071750|NCT01199731|Experimental|GSK2248761 100mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
3071751|NCT01199731|Experimental|GSK2248761 200mg OAD|In combination with darunavir/ritonavir BID and raltegravir BID
3071752|NCT01199731|Active Comparator|Etravirine|In combination with darunavir/ritonavir BID and raltegravir BID
3071753|NCT01199744||Influenza virus infection patients exposed to zanamivir|Safety of Influenza virus infection patients exposed to zanamivir
3071754|NCT01199822|Experimental|Olaratumab|
3071755|NCT01199848|Placebo Comparator|Placebo|Pbo
3071756|NCT01199848|Experimental|10G STRB powder|Dose 1
3071757|NCT01199848|Experimental|20G STRB powder|Dose 2
3071758|NCT01199848|Experimental|40G STRB powder|Dose 3
3071759|NCT01199848|Placebo Comparator|PlacebonoFiber|Placebo without fiber
3071760|NCT01199861|Experimental|Fingolimod|Participants received Fingolimod 0.5 mg capsules orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
3071761|NCT01199861|Placebo Comparator|Placebo|Participants received placebo tablets orally once daily for 12 weeks. At Week 6 of study treatment participants received a seasonal influenza vaccination and a tetanus booster vaccination.
3071762|NCT01199926|Experimental|Vitamin D|Participants in this arm consumed a 4000 IU vitamin D supplement daily for 12 weeks while participating in a resistance exercise training program.
3071763|NCT01199926|Placebo Comparator|Placebo|Participants in this arm consumed a placebo (microcrystalline cellulose) daily for 12 weeks while participating in a resistance exercise training program.
3071764|NCT01199939|Experimental|ETR + DRV/rtv|Darunavir 800mg once daily orally for 48 weeks,Etravirine 400mg once daily orally for 48 weeks,Ritonavir 100mg once daily orally for 48 weeks
3071765|NCT01199952|No Intervention|Control|The control group will not receive a counseling phone call one month after enrollment.
3071766|NCT01199952|Experimental|Intervention|Intervention arm receives a counseling phone call 3 to 4 weeks after enrollment. The call is from a health educator intended to assist with contraception.
3071767|NCT01199965|Other|IV DHE then MAP0004|Smokers and non-smokers received Intravenous Dihydroergotamine Mesylate (IV DHE) at Visit 2 followed by MAP0004 7-11 days later at Visit 3.
3071768|NCT01199965|Other|MAP0004 then IV DHE|Smokers and non-smokers received MAP0004 at Visit 2 followed by Intravenous Dihydroergotamine Mesylate (IV DHE) 7-11 days later at Visit 3.
3071769|NCT01200030|Experimental|electrical stimulation with exercises|The TENS + TRTT group received TENS simultaneously with the TRTT at home under the instruction of a physical therapist.
3071770|NCT01200030|Placebo Comparator|placebo stimulation with exercises|The TENS + TRTT group received placebo-simultaneously with the TRTT at home under the instruction of a physical therapist.
3071771|NCT01200030|No Intervention|Control|Subjects in this group did not receive any active training. Home safety advice and health education including diet control and blood pressure monitoring were given to the subjects during the home-visit and telephone follow-up.
3071772|NCT01200069|Placebo Comparator|Sugar water|500 milliliters of intravenous ringers lactate administered over 30 minutes prior to ECT for treatments 1,2 and 3
3071773|NCT01200069|Active Comparator|Ibuprofen|300mg/8milliliters of intravenous ibuprofen/caldolor over 30 min in 500mL of ringers lactate to be administered prior to ECT for treatments # 1, 2 and 3
3071774|NCT01200160||Lipid abnormalities|Niacin
3071775|NCT01200238|Experimental|STA-9090: Cohort A|"Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
3071776|NCT01200238|Experimental|STA-9090: Cohort B|"Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal."
3071777|NCT01200290|Experimental|LY2127399|
3071778|NCT01200329|Experimental|Gemcitabine + Busulfan + Melphalan|Gemcitabine 2775 mg/m2 by vein over about 3 hours on days -8 and -3. Busulfan 32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient. AUC 4,000 by vein over about 3 hours on days -8 to -5. Melphalan 60 mg/m2 by vein over about 30 minutes on days -3 and -2. Palifermin 60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2. Infusion of stem cells on Day 0.
3071779|NCT01200342|Experimental|Genasense + Paclitaxel + Carboplatin|Genasense 900 mg intravenous (IV) on a fixed-dose as a 1-hour infusion on Days 1, 3, and 5 of a 21 day cycle; Paclitaxel 175 mg/m^2 IV over 3 hours Day 3 after Genasense; Carboplatin dose in mg (target area under the concentration [AUC)]=6) administered over 30 minutes IV Piggyback (IVPB) on Day 3 after Paclitaxel.
3071780|NCT01200355|Experimental|micafungin|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
3071781|NCT01200355|Experimental|posaconazole|This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).
3071782|NCT01200368|Experimental|1|Experimental
3071783|NCT01200368|Active Comparator|2|Active comparator
3071784|NCT01200368|Active Comparator|3|Active comparator
3071785|NCT01200394|Experimental|PF-00489791|
3071786|NCT01200394|Placebo Comparator|Placebo|
3071787|NCT01200407||Filipino Hypertensive patients|Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec
3071788|NCT01200433|Active Comparator|propofol|Subjects will be sedated with propofol.
3071789|NCT01200433|Active Comparator|dexmedetomidine|Subjects will be sedated with dexmedetomidine.
3071790|NCT01200485|Experimental|Rasburicase Alone|Rasburicase by vein on Day 1 (0.15 mg/kg or a flat dose of 3 mg) as a single dose, plus as needed dosing (until day 5), during cycle 1 (21 day cycle).
3071791|NCT01200485|Experimental|Arm A (Rasburicase)|Participants randomized to Rasburicase (0.15 mg/kg) by vein on day 1 plus as needed dosing (until day 5) during Cycle 2.
3071792|NCT01200485|Experimental|Arm B (Allopurinol)|Participants randomized to Allopurinol (300 mg/day) by vein each day on Days 1-5 of Cycle 2.
3071793|NCT01200498|Experimental|SB939|SB939 starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
3071794|NCT01200511|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3071795|NCT01200524|Experimental|AZD2423, 20mg|
3071796|NCT01200524|Experimental|AZD2423, 150 mg|
3071797|NCT01200524|Placebo Comparator|Placebo|Tablet to match the 20 mg and 50 mg AZD2423 active tablet
3071798|NCT01200589|Experimental|Arm A: Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
3071799|NCT01200589|Active Comparator|Arm B: Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
3071800|NCT01200758|Active Comparator|Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP)|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
3071801|NCT01200758|Experimental|Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP)|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
3071802|NCT01200797|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3071803|NCT01200810|Placebo Comparator|Arm I|"Patients receive oral placebo once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
3071804|NCT01200810|Experimental|Arm II|"Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Treatment repeats every 21 days for 18 courses in the absence of PSA progression.~COMBINATION PHASE: All patients then receive oral bicalutamide once daily on days 1-21 and oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for 12 months in the absence of disease progression or unacceptable toxicity."
3320950|NCT02014922|Experimental|Treatment|"Participants in the study treatment group will receive all four products:~TheraTears® Lubricant Eye Drop (15mL) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® preservative-free single-use containers (32-pack, 0.6mL each) - Dosage: Ophthalmic, 1 or 2 drops, prn~TheraTears® Nutrition (90 pack) - Dosage: Oral, 3 capsules QD~TheraTears® TheraLid® Eyelid Cleanser (48mL) - Dosage: Ophthalmic, 1 or 2 application OU, QD"
3321411|NCT02018614||statistical test|For a sample of at least 50 patients, two physicians trained for the use of ALGOPLUS, will assess pain independently. A statistical test will be used to compare the results for the inter-rater reliability
3321412|NCT02018666|Experimental|spontaneous NAVA mode|
3071808|NCT01200992|Experimental|EN3348|8 mg mixed with sterile water for injection for a total volume of 50mL
3071809|NCT01200992|Active Comparator|Mitomycin C|40 mg powder will be reconstituted with sterile water for injection to a total volume of 40 mL
3071810|NCT01201057|Experimental|0.5% SPL7013 Gel|
3071811|NCT01201057|Experimental|1.0% SPL7013 Gel|
3071812|NCT01201057|Experimental|3.0% SPL7013 Gel|
3071813|NCT01201057|Placebo Comparator|Placebo Gel|
3071814|NCT01201265|Experimental|Overall Participants|Participants received a combination therapy of bevacizumab with gemcitabine plus carboplatin.
3071815|NCT01201317|Experimental|AZD2423, 150 mg|Tablets, 150 mg once daily in the morning.
3071816|NCT01201317|Experimental|AZD2423, 20 mg|Tablets, 20 mg once daily in the morning.
3071817|NCT01201317|Placebo Comparator|Placebo|Tablets, placebo, once daily in the morning.
3071818|NCT01201356|Experimental|Fingolimod 0.5 mg/day|Open-label fingolimod 0.5 mg, taken orally once daily
3071819|NCT01201486||Pregnant women|Pregnant females in the 2nd trimester.
3071820|NCT01201629|Sham Comparator|t DC stimulation|Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
3071821|NCT01201629|Experimental|tDC stimulation|Actual DC stimulation
3071822|NCT01201759|Experimental|Placebo to Salsalate 2gr BID|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.
3071823|NCT01201759|Experimental|Salsalate 2gr BID to placebo|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days.
3071824|NCT01201772|Active Comparator|Prasugrel 60mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3071825|NCT01201772|Active Comparator|Prasugrel 30mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3071826|NCT01201772|No Intervention|Prasugrel 10mg|Patients will be randomized to: 10mg, 30mg, or 60mg dose of prasugrel
3071827|NCT01201785|Experimental|Aspirin dose range|
3071828|NCT01201798|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop in study eye, 4 times a day for 14 days, followed by a 14-day tapering period
3071829|NCT01201798|Active Comparator|Pred Forte|Prednisolone acetate 1.0% ophthalmic suspension, 1 drop in study eye, 8 times a day for 14 days, followed by a 14-day tapering period
3071830|NCT01201811|Experimental|Single-Arm|Azacitidine 75 mg/m^2/day Subcutaneous for 7 days Day every 28 days for up to 6 cycles
3071831|NCT01201850|Experimental|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses.
3071832|NCT01201863|Experimental|Low T Intervention - Androgel Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Androgel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
3071833|NCT01201863|Placebo Comparator|Low T Intervention - Placebo Treatment|Men with TBI meeting study criteria with Low Testosterone levels were randomly assigned to the Placebo gel treatment group. They underwent hormonal assays, FIM ratings and NIH Toolbox testing at baseline and every other week for 12 weeks during inpatient rehabilitation hospitalization.
3071834|NCT01201863|No Intervention|Normal T|A subset of men with TBI meeting study criteria with normal T at screening were assessed at all data collection time points to provide a control group. Thirty-eight men obtained normal T levels at screening of which 24 were followed.
3071835|NCT01201915|Experimental|Cohort 1: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
3071836|NCT01201915|Experimental|Cohort 2: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 12 weeks.
3071837|NCT01201915|Experimental|Cohort 3: Vismodegib 150 mg|Participants received vismodegib 150 mg orally daily for 8 weeks, followed by 4 weeks with no treatment, followed by a second 8-week vismodegib treatment period.
3071838|NCT01201967|Experimental|Collaborative care|Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
3071839|NCT01201967|Placebo Comparator|Usual care|Patient's physicians are informed of diagnosis of depression/anxiety disorder
3071840|NCT01202071|Experimental|Rabeprazole sodium Tablets, 5 mg|
3071841|NCT01202071|Experimental|Rabeprazole sodium Tablets, 10 mg|
3071842|NCT01202071|Experimental|Rabeprazole sodium Tablets, 20 mg|
3071843|NCT01202071|Experimental|Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)|
3071844|NCT01202162|Active Comparator|Desflurane|Administration of Desflurane
3071845|NCT01202162|Active Comparator|Sevoflurane|Administration of Sevoflurane
3071846|NCT01202175|Experimental|Nebivolol|
3071847|NCT01202175|Placebo Comparator|Sugar pill|
3071848|NCT01202188|Experimental|indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3071849|NCT01202188|Active Comparator|glycopyrronium (NVA237)|NVA237 50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3071850|NCT01202188|Active Comparator|indacaterol (QAB149)|QAB149 150 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3071851|NCT01202188|Active Comparator|tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3071852|NCT01202188|Placebo Comparator|Placebo|Matching placebo capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDDPI) for 26 weeks. Participants remained on a stable dose of inhaled corticosteroid (ICS) and salbutamol/albuterol was available for use as rescue medication throughout the study.
3071853|NCT01202227|Experimental|Pregabalin|Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
3071854|NCT01202253||Anidulafungin|
3071855|NCT01202279|Active Comparator|Mucinex D|Mucinex D (1200 mg guaifenesin and 120 mg pseudoephedrine HCl) extended release bilayer tablet twice a day (bid) with a full glass of water for 7 days
3071856|NCT01202279|Placebo Comparator|Placebo|Placebo given bid with a full glass of water for 7 days
3071857|NCT01202409|Experimental|Panitumumab|Starting Dose of Panitumumab: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
3071858|NCT01202565||Adalimumab|Participants with moderate to severe plaque psoriasis received adalimumab (Humira®) therapy according to the local product label and prescription/reimbursement guidelines.
3071859|NCT01202578|Experimental|tympanostomy tube|performance and safety of tympanostomy tube delivery system
3071860|NCT01202591|Experimental|AZD4547 + exemestane|Safety run-in: AZD4547 plus exemestane
3071861|NCT01202591|Experimental|AZD4547 + fulvestrant|A Randomised phase IIa: AZD4547 plus fulvestrant
3071862|NCT01202591|Placebo Comparator|Placebo + fulvestrant|Randomised phase IIa: Matching placebo plus fulvestrant
3071863|NCT01202643|Experimental|G-CSF|G-CSF 300 units administered by trans-cervical infusion one time on day of hCG trigger for Ovulation
3071864|NCT01202643|Placebo Comparator|Saline|Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
3071865|NCT01202656|Experimental|G-CSF then Saline|G-CSF (Granulocyte colony stimulating factor)
3071866|NCT01202656|Placebo Comparator|Saline then G-CSF|Normal Saline
3071867|NCT01202721|Experimental|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg.
3071868|NCT01202721|Experimental|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg
3071869|NCT01202747|Experimental|LipiFlow Treatment|Treatment with LipiFlow device
3321413|NCT02018666|Active Comparator|Inspiratory pressure support (IPS)|
3071870|NCT01202760|Experimental|120 mg LY2127399|"LY2127399: 120 milligrams (mg), subcutaneous (SC) injection, every 4 weeks for 24 weeks. Participants received a 240-mg (2 SC injections of 120 mg each) loading dose of LY2127399 when initiating treatment.~During the Treatment Period, for blinding purposes, participants alternated injections of LY2127399 and injections of Placebo every 2 weeks.~After 16 weeks, non-responders received 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3071871|NCT01202760|Experimental|90 mg LY2127399|"LY2127399: 90 milligrams (mg), subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a 180-mg (2 SC injections of 90 mg each) loading dose of LY2127399 when initiating treatment.~After 16 weeks, non-responders continued to receive 90 mg of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3071872|NCT01202760|Placebo Comparator|Placebo|"Placebo: subcutaneous (SC) injection, every 2 weeks for 24 weeks. Participants received a loading dose of 2 SC injections of Placebo when initiating treatment.~After 16 weeks, non-responders received 90 milligrams (mg) of LY2127399 every 2 weeks for the rest of the 24-week Treatment Period."
3071873|NCT01202773|Experimental|120 milligrams (mg) LY2127399|"Given every 4 weeks (Q4W) for 24 weeks. Participants receive a 240-mg loading dose when initiating treatment.~During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks (Q2W).~At Week 16, responders will receive 1 injection of 120 mg of LY2127399 and 1 injection of placebo, followed by 120 mg of LY2127399 Q4W for the rest of the 24-week treatment period.~At Week 16, non-responders (NR) will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3071874|NCT01202773|Experimental|90 mg LY2127399|"Given Q2W for 24 weeks. Participants receive a 180-mg loading dose when initiating treatment.~At Week 16, both responders and NR will receive 1 injection of 90 mg of LY2127399 and 1 injection of placebo, followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3071875|NCT01202773|Placebo Comparator|Placebo|"Given Q2W for 24 weeks. Participants receive 2 injections of placebo when initiating treatment.~At Week 16, responders will receive 2 injections of placebo, followed by 1 injection of placebo Q2W for the rest of the 24-week treatment period.~At Week 16, NR will receive a 180-mg loading dose of LY2127399 (2 injections of 90 mg), followed by 90 mg of LY2127399 Q2W for the rest of the 24-week treatment period."
3071876|NCT01202877|Experimental|5-azacytidine + PKC412|5-azacytidine 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle. PKC412 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
3071877|NCT01202903|Experimental|Omalizumab|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 mL vial that was designed to deliver 150 mg of omalizumab for subcutaneous administration upon reconstitution with 1.4 mL sterile water for injection. The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
3071878|NCT01202903|Placebo Comparator|Placebo|The placebo was the same mixture of inactive excipients, in quality and quantity, as those used for the drug product. The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
3071879|NCT01202955|Active Comparator|Tolcapone|Tolcapone
3071880|NCT01202955|Placebo Comparator|Placebo|Placebo
3071881|NCT01202994|Experimental|Flute|Flutemetamol PET scan.
3071882|NCT01203046|Active Comparator|GROUP A: 7 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery.
3071883|NCT01203046|Experimental|GROUP B - 3 DAYS ANTIBIOTIC THERAPY|Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.
3071884|NCT01203072|Experimental|DU-176b 5 mg|
3071885|NCT01203072|Experimental|DU-176b 15 mg|
3071886|NCT01203072|Experimental|DU-176b 30 mg|
3071887|NCT01203072|Experimental|DU-176b 60 mg|
3071888|NCT01203072|Placebo Comparator|Placebo|
3071889|NCT01203098|Experimental|DU-176b 30mg once daily|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
3071890|NCT01203098|Active Comparator|Enoxaparin sodium twice daily|Enoxaparin sodium 20mg (=2000IU) / 0.2mL twice daily, subcutaneous injection for 2 weeks, initiated within 24 to 36 hours after surgery
3071891|NCT01203098|Experimental|DU-176b 15mg once daily|DU-176b 15mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery
3071892|NCT01203189|Active Comparator|Shampoo Group|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
3071893|NCT01203189|Active Comparator|Foam group|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
3071894|NCT01203189|Active Comparator|Cross Over Group|apply ketoconazole 2% foam to scalp twice daily for four weeks. Subjects in the Shampoo group will be able to cross over into the Foam group if the TDSS score does not improve by 60% at the end of the four week treatment period using shampoo.
3071895|NCT01203319|Experimental|60mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 60mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3071896|NCT01203319|Experimental|30mcg/1.0ml recombinant hepatitis B vaccine|600 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3071897|NCT01203319|Placebo Comparator|10mcg/1.0ml recombinant hepatitis B vaccine|300 participants aged 16 and older who failed to respond to routine administration of 10mcg recombinant hepatitis B vaccines to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
3071898|NCT01203644|Active Comparator|Bupivacaine HCl|(e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3071899|NCT01203644|Active Comparator|SKY0402|Low dose, low-mid dose, mid-dose, and high dose
3071900|NCT01203774|Active Comparator|Pen-administered vs syringe-admnistered Glargine|SoloSTAR pen-administered Glargine insulin then syringe-administered Glargine insulin
3071901|NCT01203774|Active Comparator|Syringe-administered vs pen-administered Glargine|Syringe-administered Glargine insulin and then pen-administered Glargine insulin
3071902|NCT01203787|Active Comparator|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24
3071903|NCT01203787|Experimental|Sorafenib Ramp-Up Regimen|200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
3071904|NCT01203826|Experimental|asfotase alfa|asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection
3071905|NCT01203852|Experimental|Metoprolol + Chlorthalidone|Study participants in this group had their current hypertension treatment withdrawn, baseline labs drawn and hypertension documented. Participants were initiated on metoprolol tartrate 50 mg twice daily for two weeks, followed by dose titration to 100 mg twice daily for six additional weeks if blood pressure (BP) > 120/70 mmHg. BP measures were again recorded. Participants entered a washout where metoprolol was titrated, then discontinued, and the patient's hypertension was re-established. After another set of identical baseline labs, study participants were initiated on chlorthalidone 25 mg four days per week (Monday, Wednesday, Thursday, Saturday) 15 mg daily for two weeks, followed by 25 mg daily for an additional six weeks.
3071906|NCT01203878|Experimental|Imiquimod & photodynamic therapy|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by one session of photodynamic therapy of the entire face with aminolevulinic acid and blue light
3071907|NCT01203878|Active Comparator|Imiquimod|Imiquimod 3.75% applied to the entire face daily for 2 2-week cycles separated by a 2-week no treatment period, followed by observation
3071908|NCT01203917|Other|1|gefitinib 250mg tablet
3071909|NCT01203930|Experimental|Idelalisib|This arm consists of 2 cohorts. Participants in Cohort 1 will receive idelalisib for up to twelve 28-day cycles (or development of unacceptable toxicity) plus rituximab (8 doses through the end of Cycle 2). Upon completion of twelve 28-cycles, participants are eligible to remain on idelalisib in a continuation protocol. Participants in Cohort 2 will receive idelalisib until disease progression or development of unacceptable toxicity.
3071910|NCT01203956|Experimental|SmartFlex|Use Continuous Airway Pressure device with SmartFlex engaged
3071911|NCT01203956|Active Comparator|Standard|Use Continuous Airway Pressure device without SmartFlex engaged
3071912|NCT01204203|Experimental|Zometa|Zometa (zoledronic acid) will be administered by infusion on Day 1 of a 3-week cycle followed by tumor assessment from CT and/or PET scans every 2 cycles. This will continue until progression of disease and/or intolerable toxicity.
3071913|NCT01204255|Experimental|Arm I|Patients apply lorazepam, diphenhydramine hydrochloride, and haloperidol gel topically over 2 minutes.
3071914|NCT01204294|Experimental|Bigu+Lina|biguanide plus linagliptin
3071915|NCT01204294|Experimental|Glin+Lina|glinide plus linagliptin
3071916|NCT01204294|Experimental|Glit+Lina|glitazone plus linagliptin
3071917|NCT01204294|Experimental|SU+Lina|sulfonylurea plus linagliptin
3071918|NCT01204294|Experimental|A-GI+Lina|alpha-glucosidase inhibitor plus linagliptin
3071919|NCT01204294|Active Comparator|SU+Met|sulfonylurea plus metformin
3071920|NCT01204294|Active Comparator|A-GI+Met|alpha-glucosidase inhibitor plus metformin
3071921|NCT01204398|Experimental|eligible hypertension patient|Patients will be given placebo for 2 weeks for wash-out, then qualified patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
3071922|NCT01204658|Experimental|10PP-LD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with low doses (LD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD) co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
3071923|NCT01204658|Experimental|10PP-HD/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of the GSK 2189242A (or 10PP) vaccine combined with high doses (HD) of pneumococcal pneumolysin toxoid proteins (dPly) and pneumococcal histidine protein D (PhtD), co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of the 10PP and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for the 10PP vaccine and on the right side for Infanrix hexa™.
3071924|NCT01204658|Active Comparator|Synflorix/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Synflorix™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Synflorix™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Synflorix™ and on the right side for Infanrix hexa™.
3071925|NCT01204658|Active Comparator|Prevnar 13/Infanrix hexa Group|This group consisted in infants aged 6-14 weeks at primary vaccination who received a 3-dose primary vaccination of Prevnar 13™ vaccine, co-administered with the Infanrix hexa™ vaccine at Study Months 0, 1 and 2. Subjects also received a booster dose of each of these vaccines, administered at Study Month 10. The 3 primary doses of Prevnar 13™ and Infanrix hexa™ vaccines were administered intramuscularly (IM) in the thigh, on the right and left side, respectively. Booster doses were administered IM into the deltoid or thigh if the deltoid muscle size was not adequate, on the left side for Prevnar 13™ and on the right side for Infanrix hexa™.
3071926|NCT01204671|Experimental|GSK2321138A Lot 1 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3071927|NCT01204671|Experimental|GSK2321138A Lot 2 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3071928|NCT01204671|Experimental|GSK2321138A Lot 3 Group|Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3071929|NCT01204671|Active Comparator|Fluarix Group|Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3071930|NCT01204671|Active Comparator|GSK2604409A Group|Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
3071931|NCT01204697|Experimental|A|
3071932|NCT01204697|Experimental|B|
3071933|NCT01204710|Experimental|Olaratumab + Mitoxantrone|1 cycle = 3 weeks (21 days)
3071934|NCT01204710|Active Comparator|Mitoxantrone: Optional Olaratumab Monotherapy|"1 cycle = 3 weeks (21 days)~Participants who experience progressive disease (PD) have the option to receive olaratumab monotherapy treatment."
3071935|NCT01204736||Group 1|Subjects with posterior deltoid-to-triceps tendon transfers
3071936|NCT01204736||Group 2|Subjects with biceps-to-triceps tendon transfers
3071937|NCT01204736||Group 3|Subjects with cervical SCI who have not had tendon transfers
3071938|NCT01204736||Group 4|Unimpaired control subjects
3071939|NCT01204775|Experimental|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
3071940|NCT01204775|Placebo Comparator|Placebo|Placebo matching saxagliptin tablet
3071941|NCT01204853|Experimental|Sitaxentan treatment|
3071942|NCT01204905|Experimental|Open Label ART|Patients received raltegravir 400 mg PO BID and maraviroc 300 mg PO BID in combination for 48 weeks.
3071943|NCT01204918|Experimental|Riluzole addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 8 weeks
3071944|NCT01204918|Placebo Comparator|Placebo addition to standard SSRI antidepressant|Placebo will be added to ongoing SSRI or SNRI antidepressant treatment for 8 weeks
3071945|NCT01204918|Experimental|Riluzole/Placebo addition to SSRI antidepressant|Riluzole 100mg added to ongoing SSRI or SNRI antidepressant for 4 weeks and placebo will added to ongoing SSRI or SNRI antidepressant treatment for 4 weeks
3071946|NCT01205035|No Intervention|Observation|Observation; No treatment given
3071947|NCT01205035|Experimental|Intravitreal ranibizumab 2.0mg|Initial dose 2.0mg switched to 1.0mg at near conclusion of study.
3071948|NCT01205126|Experimental|OROS Hydromorphone hydrochloride (HCl)|OROS Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
3071949|NCT01205126|Active Comparator|Oxycodone HCl Controlled release (CR)|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titrationphase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
3071950|NCT01205152|Experimental|asfotase alfa|An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week
3071951|NCT01205165|Experimental|Adefovir Dipivoxil 10mg|All enrolled subject were enrolled to adefovir dipivoxil 10mg arm.
3071952|NCT01205230|Experimental|Pazonib+ketoconazole|Administration of oral pazopanib 400mg (2 200-mg tablets) once-daily each morning for at least 7 consecutive doses during Period 1. Then administration of oral ketoconazole 400 mg (2 - 200 mg tablets) followed immediately by pazopanib 400 mg (2 -200 mg tablets) once-daily each morning for a total of 5 consecutive doses during Period 2.
3071953|NCT01205230|Experimental|Pazonib+esomeprazole|Subjects will receive orally administered pazopanib 800mg (4 - 200mg tablets) once-daily each morning for at least 7 consecutive doses in Period 1. In the evening on the last day of Period 1, subjects will take their initial dose of esomeprazole 40 mg (1 - 40 mg capsule) approximately 3 hours after the evening meal. Subjects will continue to receive pazopanib (each morning) and esomeprazole each evening once-daily for a total of 5 consecutive doses.
3071954|NCT01205269|Experimental|First 50 mcg, then 200 mcg, then placebo|period 1: AZD8683 50 mcg, period 2: washout, period 3: AZD8683 200 mcg, period 4:washout, period5: placebo
3071955|NCT01205269|Experimental|First 50 mcg, then placebo, then 200 mcg|period 1: AZD8683 50 mcg, period 2: washout, period 3: placebo, period 4: washout, period5:AZD8683 200 mcg
3071956|NCT01205269|Experimental|First 200 mcg, then placebo, then 50 mcg|period 1: AZD8683 200 mcg, period 2: washout, period 3: placebo, period 4: washout, period 5: AZD8683 50 mcg
3071957|NCT01205269|Experimental|First 200 mcg, then 50 mcg, then placebo|period 1: AZD8683 200 mcg, period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period 5: placebo
3071958|NCT01205269|Experimental|First placebo, then 200 mcg, then 50 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 200 mcg, period 4: washout, period5: AZD8683 50 mcg
3071959|NCT01205269|Experimental|First placebo, then 50 mcg, then 200 mcg|period 1: placebo , period 2: washout, period 3: AZD8683 50 mcg, period 4: washout, period5: AZD8683 200 mcg
3071960|NCT01205399||AlloMax Surgical Graft Group|
3071961|NCT01205438|Experimental|LY2127399 every 2 weeks|
3071962|NCT01205438|Experimental|LY2127399 every 4 weeks|During the Treatment Period, for blinding purposes, participants will alternate injections of LY2127399 and injections of placebo every 2 weeks.
3071963|NCT01205438|Placebo Comparator|Placebo|
3071964|NCT01205451|Experimental|BTX-A|Botulinum toxin type A
3071965|NCT01205503|Other|Cycle 1 Saline; Cycle 2 Mesna|Saline infused over 15 minutes administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
3468841|NCT03892161|Experimental|Boosed ritonavir 200mg|Rifampicin 600mg QD continued with ritonavir 200mg dose doubled QD and darunavir remains 800mg QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
3071966|NCT01205503|Other|Cycle 1 Mesna; Cycle 2 Saline|Mesna administered (infused over 15 minutes, 360 mg/m2) prior to and 3 hours post doxorubicin infusion with following Cyclophosphamide 6 hours post doxorubicin during 1st cycle, then Saline administered prior to and 3 hours post doxorubicin infusion (over 15 minutes) with following Cyclophosphamide 6 hours post doxorubicin during 2nd cycle
3071967|NCT01205529|Other|AF with ST changes on ECG|Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will harbor cardiac sodium channel gene variants.
3071968|NCT01205568|Experimental|Patients with Resistant Pulmonary Artery Stenosis|Vessels with resistant PA stenosis were identified during catheterization and eligible vessels were randomized to Cutting Balloon or High Pressure Balloon Dilation
3071969|NCT01205581|Active Comparator|Leukemia-HD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3071970|NCT01205581|Active Comparator|Leukemia-SD|Subjects with a diagnosis of leukemia will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3071971|NCT01205581|Active Comparator|Solid Tumor-HD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3071972|NCT01205581|Active Comparator|Solid Tumor-SD|Subjects with a diagnosis of solid tumor will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3071973|NCT01205581|Active Comparator|HIV-HD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone High Dose Vaccine and evaluated for development of immune responses.
3071974|NCT01205581|Active Comparator|HIV-SD|Subjects with a diagnosis of human immunodeficiency virus (HIV) will be vaccinated twice with Fluzone Standard Dose Vaccine and evaluated for development of immune responses.
3071975|NCT01205646|Experimental|Zometa & PET Scans|Zoledronate therapy & PET scan ;2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility, Bone scan (within 4 weeks prior to registration), bone turnover markers, and PSA will be obtained pretherapy. After that, Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration.
3071976|NCT01205685|Experimental|OSI-906 + Erlotinib + Letrozole + Goserelin|"OSI-906 in a pill form, by mouth, twice a day (12 hours a part)~Erlotinib in a pill form, by mouth, once a day~Letrozole in a pill form, by mouth, once a day~Goserelin, by injection once per month for women who are pre-menopausal"
3071977|NCT01205776|Active Comparator|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
3071978|NCT01205776|Active Comparator|Coronary Artery Bypass Graft|Those patients receiving CABG
3071979|NCT01205828|Experimental|Temozolomide and ABT-888 in HCC patients|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days
3071980|NCT01206062|Experimental|Intensive Control of SBP|"Participants randomized into the Intensive BP arm will have a goal of SBP <120 mm Hg. 2-drug therapy initiated in most Intensive participants; age ≥75 years and SBP 130-139 mm Hg on 0-1 drug; may begin with 1 drug, but add second at 1 month if SBP ≥130 mm Hg; drugs added and/or titrated at each visit (monthly) to achieve SBP <120 mm Hg; at periodic milepost visits: addition of another drug required if not at goal."
3071981|NCT01206062|Active Comparator|Standard Control of SBP|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mm Hg @ 1 visit; ≥140 mm Hg @ 2 consecutive visits; Down-titration if SBP <130 mm Hg @ 1 visit; <135 mm Hg @ 2 consecutive visits
3071982|NCT01206140|Experimental|Arm I (selumetinib and temsirolimus)|Patients receive selumetinib PO twice daily on days 1-28 and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22.
3071983|NCT01206140|Experimental|Arm II (selumetinib)|Patients receive selumetinib as in arm I. Patients who experience disease progression may cross over to arm I.
3071984|NCT01206166|Experimental|Enteral Nutrition + Parenteral Nutrition|Enteral nutrition with the addition of parenteral supplementation (Olimel 5.7%E/N9E).
3071985|NCT01206166|No Intervention|Enteral Nutrition Only|Enteral nutrition only - no intervention
3071986|NCT01206322|Experimental|Insulin vs. placebo|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
3071987|NCT01206322|Other|Healthy vs. Diabetic|Comparisons of acute effects of intranasal insulin or placebo (saline) on cerebral blood flow and cognition in healthy controls and type 2 diabetes.
3071988|NCT01206387|Experimental|active product|Desoximetasone Spray 0.25%
3071989|NCT01206387|Placebo Comparator|placebo comparator|vehicle
3071990|NCT01206452|Experimental|Ablation plus prednisone|Participants undergo ablation procedure and receive predinisone at protocol determined times.
3071991|NCT01206452|Placebo Comparator|Ablation plus placebo|Participants undergo ablation procedure and receive placebo at protocol determined times.
3071992|NCT01206465|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pralatrexate IV over 5 minutes on day 1 and fluorouracil IV continuously over 48 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3071993|NCT01206478|Experimental|Amitriptyline plus Megestrol|Amitriptyline once daily at bedtime plus megestrol starting at visit 2
3071994|NCT01206478|Active Comparator|Placebo plus Megestrol|Matching placebo once daily at bedtime plus megestrol starting at visit 2
3071995|NCT01206517|Experimental|Cohort 1|Participants 10 or 11 years of age
3071996|NCT01206517|Experimental|Cohort 2|Participants 10 or 11 years of age
3071997|NCT01206517|Experimental|Cohort 3a-d|"Cohort 3a: Participants 10 or 11 years of age~Cohort 3b: Participants 12 or 13 years of age~Cohort 3c: Participants 14 or 15 years of age~Cohort 3d: Participants 16 or 17 years of age"
3071998|NCT01206582|Active Comparator|Hemin|Panhematin®, Ovation Pharmaceuticals, Deerfield, Illinois (IL). Hemin was diluted in 25% albumin to obtain a concentration of 2.4 mg/mL and administered at a dose of 1.25 mL/Kg and at a rate of 60 mL/hour. 10 iv infusions for 8 weeks
3071999|NCT01206582|Placebo Comparator|Albumin|10 iv infusions for 8 weeks
3072000|NCT01206595|Active Comparator|SKY0402|Low-dose (175 mg), low-mid dose( 225 mg), and mid-dose (350 mg)
3072001|NCT01206595|Active Comparator|Bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3072002|NCT01206608|Active Comparator|Low-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3072003|NCT01206608|Active Comparator|Mid-dose SKY0402 + bupivacaine HCl|Marcaine with epinephrine 1:200,000 is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402
3072004|NCT01206660|Experimental|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
3072005|NCT01206660|Placebo Comparator|placebo|Placebo administered to affected area twice a day for 28 days
3072006|NCT01206738|Experimental|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
3072007|NCT01206738|Experimental|Alternative intervention|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
3072008|NCT01206738|Active Comparator|General information|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
3072009|NCT01206764|Experimental|RAD001|
3072010|NCT01206777|Experimental|Rituximab|
3072011|NCT01206816|Experimental|two experimental arms|patients receive increasing doses of BI 6727 in combination with increasing doses of BIBW 2992
3072012|NCT01207219|Experimental|Yoga therapy|Hatha yoga including breathing control (10 minutes), body posture(40-45minutes), and relaxation (5 minutes).
3072013|NCT01207219|Experimental|Aerobic exercise|Aerobic exercise includes walking on the treadmill for 15-20 minutes and stationary cycling for 25-30 minutes.
3072014|NCT01207219|No Intervention|Waitlist group|Patients in waiting list will be treated as usual and acted as control group.
3072015|NCT01207388|Experimental|Blinatumomab|Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
3072016|NCT01207401|Experimental|Paracervical Block|
3072017|NCT01207401|No Intervention|No Paracervical Block|
3072018|NCT01207414|Experimental|iloperidone gradual switch|"Participants taking risperidone, olanzapine or aripiprazole gradually decreased the dose they were taking: 50% of original dose on Day 1, 25% of original dose after the first week and the total discontinuation of the drug after the second week.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
3072019|NCT01207414|Experimental|iloperidone immediate switch|"Participants taking risperidone, olanzapine or aripiprazole discontinued the drug immediately.~On Day 1 participants began taking iloperidone orally twice a day (bid) in the morning and in the evening beginning at a dose of 1 mg and increasing to 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg bid on consecutive days over a 7-day period to achieve a total dose of 12-24 mg/day for 12 weeks."
3072020|NCT01207427|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally twice daily (BID) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
3072021|NCT01207427|Experimental|ADL5945 0.1 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.1-milligrams (mg) ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
3072022|NCT01207427|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally BID for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-mg ADL5945 capsule orally BID for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally BID for 1 week.
3072023|NCT01207440|Experimental|Cohort A: CP-CML R-I|CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072024|NCT01207440|Experimental|Cohort B: CP-CML with T315I Mutation|CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072025|NCT01207440|Experimental|Cohort C: Accelerated Phase (AP)-CML R-I|AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072026|NCT01207440|Experimental|Cohort D: AP-CML with T315I Mutation|AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072027|NCT01207440|Experimental|Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I|BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072028|NCT01207440|Experimental|Cohort F: BP-CML or Ph+ ALL with T315I Mutation|BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3468842|NCT03892161|Experimental|Double dose DRV/r 1600/200mg QD|Rifampicin 600mg QD and DTG QD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
3072029|NCT01207440|Experimental|Unassigned to Cohorts A-F|Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
3072030|NCT01207453|Other|Milnacipran then placebo|This arm of the study will contain half the study population after randomization. The participants in this arm will receive milnacipran for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to a placebo for 6 weeks.
3072031|NCT01207453|Other|Placebo then milnacipran|"This arm of the study will contain half the study population after randomization. The participants in this arm will receive placebo for 6 weeks. They will undergo a one-week taper and a two week washout period and then crossover to milnacipran for 6 weeks."
3072032|NCT01207466|Other|Nelfilcon A invest'l / nelfilconA comm'l|Nelfilcon A investigational toric contact lenses worn first, with nelfilcon A commercial toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
3072033|NCT01207466|Other|Nelfilcon A comm'l / nelfilconA invest'l|Nelfilcon A commercial toric contact lenses worn first, with nelfilcon A investigational toric contact lenses worn second. Each product worn bilaterally on a daily disposable basis for one week.
3072034|NCT01207492|Experimental|Nilotinib|Nilotinib 200 mg taken as 400 mg twice daily, continuously
3072035|NCT01207570|Experimental|Endermotherapy|The subjects in the experimental group will receive a single session (5 minutes) of endermotherapy) applied to the gastrocnemius/soleus muscle group in the more affected side. The treatment will b e carried out by a qualified physiotherapist.
3072036|NCT01207570|Active Comparator|Passive stretching|The subjects in this group will receive a single session of passive stretching of the gastrocnemius/soleus muscle for 5 minutes.
3072037|NCT01207583||healthy children after vaccination|healthy children after vaccination
3072038|NCT01207596|Active Comparator|Hydromorphone|
3072039|NCT01207648||Retrospective Cohort|Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events were observed in this retrospective cohort study. In this study, medical records of participants evaluated between 1997 to 2009 were reviewed. The observation period started with the first medical record available on site till last medical record available on site or the end of the observation period (31 December 2009), whichever occurred first.
3072040|NCT01207687|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 6 weeks for up to 48 weeks in the absence of disease progression or unacceptable toxicity.
3072041|NCT01207752|Experimental|Systane Balance|Artificial tear emulsion
3072042|NCT01207752|Active Comparator|Optive Lubricant Eye Drops|Artificial tear
3072043|NCT01207765|Experimental|Zevalin|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging on study day +1. 90Y Zevalin will be administered seven to nine days after 111In Zevalin administration. The dose of 90Y Zevalin will be 0.4 mCi/kg, capped at a maximum dose of 32 mCi.
3072044|NCT01207908|Experimental|IGF-1|IGF-1 plus standard steroid treatment
3072045|NCT01207908|No Intervention|Standard steroid treatment alone|Standard daily steroid treatment for DMD
3072046|NCT01207934|Placebo Comparator|placebo|saline placebo for fourteen days
3072047|NCT01207934|Experimental|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
3072048|NCT01207934|Experimental|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
3072049|NCT01208038|Experimental|Testosterone|Testosterone transdermal patch 300micrograms, twice weekly for 12 weeks
3072050|NCT01208051|Experimental|Arm A (cediranib maleate)|Patients receive cediranib maleate 30 mg PO QD on days 1-28. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3072051|NCT01208051|Experimental|Arm B (cediranib maleate plus lenalidomide thru April 10, 2015)|Patients receive cediranib maleate 30 mg PO and lenalidomide 15 mg PO on days 1-21. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. NOTE: As of April 10, 2015, patients assigned to this arm are discontinued lenalidomide and continued on cediranib alone.
3072052|NCT01208103|Experimental|Treatment (oxaliplatin, bevacizumab, capecitabine)|Participants receive oxaliplatin via CVC over 2 hours and bevacizumab IV over 30-90 minutes on day 1. Participants also receive capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3072053|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and Part 2 of the study.
3072054|NCT01208181|Experimental|Etoricoxib 60 mg/Etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg tablets administered orally once daily for 6 weeks in Part 1 and etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 2 of the study.
3072055|NCT01208181|Experimental|Etoricoxib 90 mg|The etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
3072056|NCT01208181|Placebo Comparator|Placebo|The placebo treatment sequence will receive matching placebo to etoricoxib tablets administered orally once daily for 6 weeks in Part 1 and will not participate in Part 2 of the study.
3072057|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 60 mg|The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II
3072058|NCT01208207|Experimental|etoricoxib 60 mg/etoricoxib 90 mg|The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II
3072059|NCT01208207|Experimental|etoricoxib 90 mg/etoricoxib 90 mg|The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II
3072060|NCT01208207|Active Comparator|naproxen 1000 mg/naproxen 1000 mg|The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II
3072061|NCT01208220|Active Comparator|Negative pressure wound therapy|NPWT changed TIW
3072062|NCT01208220|Experimental|NPWT plus Collagenase Ointment|Collagenase applied TIW with NPWT
3072063|NCT01208233|Experimental|1 mg PF-03049423|
3072064|NCT01208233|Experimental|3 mg of PF-03049423|
3072065|NCT01208233|Experimental|6 mg of PF-03049423|
3072066|NCT01208233|Placebo Comparator|Placebo|
3072067|NCT01208324|Active Comparator|Estrogen patch|Vivelle Dot® 0.10 - 0.15 mg/day for 8 weeks
3072068|NCT01208324|Active Comparator|Amino Acids|L-Isoleucine (4.2 g), L-Leucine (6.6 g), L-Lysine (4.8 g), L-Methionine (1.5 g), L-Phenylalanine (6.6 g), L-Threonine (3.0 g), L-Valine (4.8 g)
3072069|NCT01208324|Placebo Comparator|Placebo Patch|Placebo
3072070|NCT01208324|Placebo Comparator|Placebo pills|31.5 g of lactose or microcellulose
3072071|NCT01208337|Other|Alemtuzumab induction|Intestine transplant recipients who receive induction with alemtuzumab prior to transplantation.
3072072|NCT01208402|Active Comparator|oral long acting beta blocker|oral administration of long acting beta blocker as standard of care on the day of surgery
3072073|NCT01208402|Experimental|Esmolol infusion|given 30 minutes prior to induction up to 12 hours post-op
3072074|NCT01208415|Experimental|Device Implant|
3072075|NCT01208870|Experimental|Variety Group|Traditional family based weight control treatment program with components to reduce variety of high energy dense foods incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
3072076|NCT01208870|Experimental|Nutrition Education Control|Traditional family based weight control treatment program, without components from habituation theory incorporated into the treatment. Families meet weekly for 12 weeks, then by-weekly for 1 month and 1 monthly session for a total of 15 behavioral intervention sessions.
3072077|NCT01208922|Experimental|Group A|Rifamycin SV-MMX® 200 mg tablets
3072078|NCT01208922|Active Comparator|Group B|Ciprofloxacin 500 mg capsules
3072079|NCT01208961|Active Comparator|Epanova-Lovaza-Epanova-Lovaza|
3072080|NCT01208961|Active Comparator|Lovaza-Epanova-Lovaza-Epanova|
3072081|NCT01209078|Experimental|Regimen 1|GSK1322322 1500mg and Placebo Linezolid given twice a day (BID) for 10 days
3072082|NCT01209078|Active Comparator|Regimen 2|Linezolid 600mg and placebo GSK1322322 given BID for 10 days
3072083|NCT01209143|Experimental|Vismodegib + rosiglitazone|Participants received rosiglitazone 4 mg orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
3072084|NCT01209143|Experimental|Vismodegib + oral contraceptive|Participants received the oral contraceptive norethindrone 1 mg/ethinyl estradiol 35 µg (Ortho-Novum 1/35®) orally on Days 1 and 8 of the study. Participants also received vismodegib 150 mg orally once a day beginning on Day 2 until one of the following occurred; disease progression, intolerable toxicity, most probably attributable to vismodegib, or patient withdrawal of consent.
3072085|NCT01209195|Experimental|MM-121 + Paclitaxel|Escalating doses of MM-121 given IV QW in combination with paclitaxel at standard dose of 80 mg/m2 IV QW
3072086|NCT01209234|Active Comparator|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
3072087|NCT01209234|Active Comparator|Education Arm|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home. In addition, educational material on hygiene practices to prevent MRSA infection will be provided.
3072088|NCT01209260|Experimental|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
3072089|NCT01209260|Active Comparator|Mechanical needle|Mechanical (Brockenbrough) needle for transseptal access
3072090|NCT01209286|Experimental|Blinatumomab 15 μg|Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
3072091|NCT01209286|Experimental|Blinatumomab 5/15 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
3072092|NCT01209286|Experimental|Blinatumomab 5/15/30 μg|Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.
3072093|NCT01209325|Experimental|Vaccination|Gardasil (quadrivalent HPV types 6, 11, 16, 18) vaccination at weeks 0, 8, 24.
3072094|NCT01209442|Experimental|RT with Temozolomide and Bevacizumab|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily TMZ at 75 mg/m2 qd concurrent with IMRT (including weekends and holidays). Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Day 1 and the 1st Fx of IMRT must start on the same day. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab therapy, patients will have a brain MRI and if there is no evidence of disease progression, patients will receive 6 cycles of Bevacizumab and TMZ. Beginning a minimum of 28 days after the last radiation treatment the bevacizumab will be dosed at 10 mg/kg on day 1 and day 15 of each cycle. TMZ will be given at 150-200 mg/m2 qd on days 1-5 of each cycle. Each cycle is 28 days.
3072095|NCT01209598|Experimental|Palbociclib 200mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
3072096|NCT01209598|Experimental|Palbociclib 125mg|This is a phase II study of Palbociclib in patients with advanced / metastatic liposarcoma. A one-stage design is used to determine whether patients treated with Palbociclib achieved a PFS rate of ≥ 40% at 12 weeks.
3072097|NCT01209689|Experimental|Tocilizumab 4 mg/kg|Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
3072098|NCT01209689|Experimental|Tocilizumab 8 mg/kg|Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
3072099|NCT01209689|Placebo Comparator|Placebo|Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.
3072100|NCT01209702|Placebo Comparator|Part 1: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
3072101|NCT01209702|Experimental|Part 1: Tocilizumab|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 12. Following the Week 12 visit, participants who completed Part 1 of the study received open-label 8 mg/kg tocilizumab through Week 208.
3072102|NCT01209702|Placebo Comparator|Part 2: Placebo|Participants received intravenous infusions of placebo once every 4 weeks until Week 24. Participants who did not attain an ASsessment in Ankylosing Spondylitis-20 (ASAS20) response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3072103|NCT01209702|Experimental|Part 2: Tocilizumab 4 mg/kg|Participants received intravenous infusions of 4 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3072104|NCT01209702|Experimental|Part 2: Tocilizumab 8 mg/kg|Participants received intravenous infusions of 8 mg/kg tocilizumab once every 4 weeks until Week 24. Participants who did not attain an ASAS20 response at Week 16 were, at the investigator's discretion, eligible to receive open-label escape therapy consisting of 8 mg/kg tocilizumab. After Week 24, participants were to receive open-label treatment with 8 mg/kg tocilizumab every 4 weeks until Week 104. At the completion of Week 104, all Part 2 participants were to receive tocilizumab 8 mg/kg in the common open-label extension phase, however the study was terminated prior to any participants reaching this stage.
3468843|NCT03892161|Experimental|Double dose DRV/r 800/100mg BD|Rifampicin 600mg QD and DTG BD continued. Double dose DRV/r QD. The darunavir/ritonavir steady state pharmacokinetic analysis will be performed and compared.
3468844|NCT03892174|No Intervention|Treatment protocol without adsorption|
3468845|NCT03892174|Active Comparator|Treatment protocol with adsorption|
3072108|NCT01209780|Experimental|TIV (3-8 years)|Non-Naive subjects received one dose and naive subjects received two doses, administered 4 weeks apart, of investigational trivalent influenza vaccine (TIV)
3072109|NCT01209780|Active Comparator|Control TIV (3-8 years)|Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to <4 years and subjects aged 4 to 8 years received different control TIV.
3072110|NCT01209780|Experimental|TIV ( 9-17 years)|All subjects received one dose of investigational TIV. The subjects in this cohort were included only for safety analysis.
3072111|NCT01209780|Active Comparator|Control TIV ( (9-17 years)|All subjects received one dose of the control vaccine. The subjects from this cohort were included only for safety analysis.
3072112|NCT01209832|Experimental|Drug Interaction arm|
3072113|NCT01209949|Other|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|
3072114|NCT01210001|Experimental|BI 10773 low dose|BI 10773 tablets once daily
3072115|NCT01210001|Experimental|BI 10773 high dose|BI 10773 tablets once daily
3072116|NCT01210001|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3072117|NCT01210079|Experimental|Gabapentin|
3072118|NCT01210079|Placebo Comparator|Placebo|
3072119|NCT01210118|Experimental|High intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
3072120|NCT01210118|Other|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
3072121|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Long Agonist Protocol|
3072122|NCT01210144|Experimental|Gonal-f® + Ovitrelle® + Multi-dose Antagonist Protocol|
3072123|NCT01210170|Experimental|mometasone 400 mcg - 30 min|randomly assigned intervention
3072124|NCT01210170|Experimental|mometasone 400 mcg simultaneous|randomly assigned intervention
3072125|NCT01210170|Placebo Comparator|placebo- 30 min|randomly assigned intervention
3072126|NCT01210170|Placebo Comparator|placebo simultaneous|randomly assigned intervention
3072127|NCT01210170|Experimental|mometasone 400 mcg - 60 min|randomly assigned intervention
3072128|NCT01210170|Placebo Comparator|placebo- 60 min|randomly assigned intervention
3072129|NCT01210170|Experimental|mometasone 200 mcg - 30 min|randomly assigned intervention
3072130|NCT01210170|Experimental|mometasone 200 mcg - 60 min|randomly assigned intervention
3072131|NCT01210170|Experimental|mometasone 200 mcg simultaneous|randomly assigned intervention
3072132|NCT01210222|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072133|NCT01210352|Experimental|CII Drug|Open Label
3072134|NCT01210443|Experimental|Sitaxentan treatment|
3072135|NCT01210495|Experimental|A|Participants in this group received axitinib + best supportive care. Participants with Child-Pugh Class A disease (score 5 or 6) were enrolled into the randomized portion at a starting axitinib dose of 5 mg BID orally. Participants with Child-Pugh Class B disease (score 7) were to begin enrollment into the randomized portion of the study following determination of the recommended axitinib starting dose in the non-randomized portion. Study treatment was administered in cycles of 4 weeks in duration
3072136|NCT01210495|Placebo Comparator|B|Participants in this group received placebo + best supportive care. Treatment was administered in cycles of 4 weeks in duration. The starting dose of placebo for participants with Child Pugh Class A disease (score 5 or 6) was chosen as 5 mg BID. Participants with Child-Pugh Class B, score 7 received placebo that was determined from the non-randomized portion of the study until the recommended starting dose was determined, participants with Child-Pugh Class B, score 7, were not permitted to enter the randomized portion of the study
3072137|NCT01210560|Experimental|20 mg MR|
3072138|NCT01210560|Experimental|40 mg MR|
3072139|NCT01210560|Experimental|60 mg MR|
3072140|NCT01210560|Experimental|120 mg MR|
3072141|NCT01210560|Experimental|120 mg IR|
3072142|NCT01210651|Experimental|Hatha Yoga Practice Group|Participants in this group practiced 90-minute sessions of hatha yoga exercises twice weekly for a total of 8 weeks.
3072143|NCT01210651|Active Comparator|Attention Control Education Group|Participants in this group attended 90-minute educational seminars on yoga history twice weekly for a total of 8 weeks.
3072144|NCT01210664|Experimental|Polyclonal Regulatory T Cells|Patients with Type 1 Diabetes Mellitus will have their regulatory T cells (Tregs) isolated by researchers and receive Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells by infusion
3072145|NCT01210690||Patients, 1 - 11 months old, prescribed Keppra® oral solution|Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol.
3072146|NCT01210716|Experimental|AMICUS Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
3072147|NCT01210716|Active Comparator|Spectra Therapeutic plasma exchange, TPE|Patients are randomized to either TPE on AMICUS or Spectra.
3072148|NCT01210807|Experimental|Multifocal Intraocular Lens|ZMB00 multifocal intraocular lens
3072149|NCT01210807|Active Comparator|Monofocal Intraocular Lens|ZCB00 monofocal intraocular lens
3072150|NCT01210820|Experimental|Natural Astigmatism|Subjects with refractive astigmatism and no prior history of ophthalmic surgery. May include subjects with cataracts.
3072151|NCT01210820|Experimental|Post cataract with residual astigmatism|Subjects who have had cataract removal surgery but have residual astigmatism.
3072152|NCT01211106|Experimental|Arm 1: Integrated Conditions|Motivational enhancement therapy for addiction is combined with Prolonged exposure therapy for PTSD from the beginning of treatment. Both are delivered by the same provider throughout treatment.
3072153|NCT01211106|Experimental|Arm 2 Sequential therapy|Motivational enhancement therapy for addiction is delivered in the first 4 weeks and only after the addiction is addressed is the Prolonged exposure therapy for PTSD started.
3072154|NCT01211145|Placebo Comparator|1|Placebo
3072155|NCT01211145|Experimental|2|ZOMIG 0.5 mg
3072156|NCT01211145|Experimental|3|ZOMIG 2.5 mg
3072157|NCT01211145|Experimental|4|ZOMIG 5.0 mg
3072158|NCT01211184|Placebo Comparator|Fasting|patients undergo surgery in the fasting state
3072159|NCT01211184|Active Comparator|Water administration|Patients undergo hip surgery after receiving 800 ml water by mouth the morning 2 hours before surgery
3072160|NCT01211184|Active Comparator|carbohydrate drink|Patients undergo hip surgery after receiving 800 ml carbohydrate drink by mouth
3072161|NCT01211197|Experimental|A|3 treatments will be investigated in randomized order
3072162|NCT01211197|Experimental|B|3 treatments will be investigated in randomized order
3072163|NCT01211197|Experimental|C|3 treatments will be investigated in randomized order
3072164|NCT01211262|Experimental|IMCgp100 weekly dosing regimen|Weekly intravenous (IV) infusions of IMCgp100 over treatment cycles of 8 weeks each.
3072165|NCT01211262|Experimental|IMCgp100 daily dosing regimen|Daily IV infusions of IMCgp100 administered on days 1 to 4 and days 22 to 25 of a six-week treatment cycle.
3072166|NCT01211288|Active Comparator|HIV negative group|This group contains participants consented to receive implants and identified as negative for HIV
3072167|NCT01211288|Experimental|HIV positive group|This group contains participants consented to receive implants and identified as positive for HIV
3072168|NCT01211340|No Intervention|Usual Care|Usual hospice care- there is no intervention in this arm
3072169|NCT01211340|Experimental|ACTIVE|Behavioral intervention using web conferencing
3072170|NCT01211483|Experimental|Part A: U3-1287 (high dose) + Erlotinib|U3-1287 (high dose) intravenously (IV) every three weeks (Q3W) + Erlotinib 150 mg/day orally (PO) until cancer gets worse, side effects become unacceptable or participant withdraws consent
3072171|NCT01211483|Experimental|Part B: U3-1287 (low dose) + Erlotinib|U3-1287 (low dose) IV Q3W + Erlotinib 150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
3072172|NCT01211483|Placebo Comparator|Part B: Placebo + Erlotinib|Placebo matching U3-1287 IV Q3W + Erlotinib150 mg/day PO until cancer gets worse, side effects become unacceptable or participant withdraws consent
3072173|NCT01211522|Experimental|Haloperidol|Haloperidol
3072174|NCT01211522|Experimental|Ziprasidone|Ziprasidone
3072175|NCT01211522|Placebo Comparator|Placebo|Placebo
3072176|NCT01211535|Experimental|OPTI-FREE RepleniSH|OPTI-FREE RepleniSH multipurpose solution used with study contact lenses on a daily wear basis for 14 days
3072177|NCT01211535|Active Comparator|ReNu Biotrue|ReNu Biotrue multipurpose solution used with study contact lenses on a daily wear basis for 14 days
3072178|NCT01211600|Active Comparator|Staples|Interrupted Ethicon Staples
3072179|NCT01211600|Active Comparator|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
3072180|NCT01211613|Experimental|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
3072181|NCT01211613|Experimental|Mechanical Manipulation|Doctor of chiropractic will apply a mechanically-assisted thrust to the lumbar spine of research participants using the Activator IV Instrument.
3468846|NCT03891966|Active Comparator|Splint|
3468847|NCT03891966|Active Comparator|Soft Dressing|
3072182|NCT01211613|Active Comparator|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
3072183|NCT01211665|Experimental|Pulsed IVMP|Intravenous methylprednisolone (IVMP) 1 g/day administered the first 3 days of each weekly cycle, and repeated for 3 additional cycles (totaling 4 cycles). If necessary, 2 additional weekly cycles of 1 g IVMP daily for 3 days can be administered at the discretion of the investigator.
3072184|NCT01211665|Experimental|IVMP with oral prednisolone taper|Intravenous methylprednisolone (IVMP) 1g/day for 6 days followed by an oral taper of prednisolone over 2 months (suggested dosages starting at 80 mg and tapering to 5 mg). If necessary, additional cycles of 1 g IVMP daily for 3 to 5 days can be administered at any time.
3072185|NCT01211730|Active Comparator|140 Group|Insulin treatment to target blood glucose at 140 mg/dl
3072186|NCT01211730|Active Comparator|180 Group|Insulin treatment to target blood glucose at 180 mg/dl
3072187|NCT01211769|Experimental|PUFAs|Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;
3072188|NCT01211769|Active Comparator|Naltrexone|Naltrexone chlorhydrate 50 mg
3072189|NCT01211769|Placebo Comparator|Placebo|"Naltrexone Placebo: pill with 50mg of talcum powder, identical to the pill of naltrexone;~Polyunsaturated fatty acids Placebo (PUFAs Placebo): yellow liquid paraffin identical to the pills of borage seed and fish oil."
3072190|NCT01211769|Other|Naltrexone + PUFAs|"Polyunsaturated fatty acids (PUFAs): borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram; along with 1 gram of fish oil - rich in omega 3 PUFA;~Naltrexone chlorhydrate 50 mg"
3072191|NCT01211873|Experimental|Dotarem (gadoterate meglumine )|Dotarem and Magnevist were randomised as 2:1 ratio for adult patients.
3072192|NCT01211873|Active Comparator|Magnevist (gadopentetate dimeglumine)|Dotarem and Magnevist were randomised as 2:1 ratio
3072193|NCT01211873|Experimental|Dotarem 2 (gadoterate meglumine )|Pediatric patients were assigned to Dotarem group only.
3072194|NCT01212094|Experimental|Rituximab|Patients received 25mg of rituximab into the CSF and 200mg of rituximab intravenously at Month 0, followed by additional 200mg of rituximab intravenously at Month 0.5 and another 25mg of rituximab into CSF at months 1.5 and 12.
3072195|NCT01212094|Placebo Comparator|Placebo|Patients received normal saline into the CSF and intravenously at Month 0, followed by additional normal saline intravenously at Month 0.5 and another dose of normal saline into CSF at months 1.5 and 12.
3072196|NCT01212094|No Intervention|Baseline|Patients in their first year baseline prior to study drug phase
3072197|NCT01212107|Experimental|Part A: 2 mg FGF Receptor QD|"Part A: Dose escalation~2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072198|NCT01212107|Experimental|Part A: 4 mg FGF Receptor QD|"Part A: Dose escalation~4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072199|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD|"Part A: Dose escalation~10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
3072200|NCT01212107|Experimental|Part A: 10 mg FGF Receptor QD + Phosphate Binders|"Part A: Dose escalation~10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072201|NCT01212107|Experimental|Part A: 8 mg FGF Receptor BID|"Part A: Dose escalation~8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072202|NCT01212107|Experimental|Part A: 10 mg FGF Receptor BID|"Part A: Dose escalation~10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072203|NCT01212107|Experimental|Part A: 14 mg FGF Receptor BID|"Part A: Dose escalation~14 FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072204|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID|"Part A: Dose escalation~18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072205|NCT01212107|Experimental|Part A: 24 mg FGF Receptor BID|"Part A: Dose escalation~24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
3072206|NCT01212107|Experimental|Part A: 18 mg FGF Receptor BID Extension|"Part A: Dose escalation~18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072207|NCT01212107|Experimental|Part A: 16 mg FGF Receptor BID|"Part A: Dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072208|NCT01212107|Experimental|Part B: 16 mg FGF Receptor BID|"Part B: Dose determined by part a dose escalation~16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle.~If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
3072209|NCT01212159|No Intervention|No self monitoring device|Standard or usual care of high LDL including lab lipid profiles after treatment with statin therapy. No device or telemedicine education will be provided
3072210|NCT01212159|Experimental|Self Monitoring Lipid Analyzer|Self measured blood lipids using a home lipidometer, and telephone reporting of data to the clinical center.
3072211|NCT01212172|Active Comparator|Soprano/SHR|Alma Soprano/SHR 810 nm Diode Laser
3072212|NCT01212172|Active Comparator|LightSheer|LightSheer Duet 810 nm diode laser
3072213|NCT01212185|Placebo Comparator|intranasal spray without oxytocin|Twice daily intranasal spray without oxytocin.
3072214|NCT01212185|Experimental|intranasal oxytocin spray|Twice daily intranasal oxytocin spray
3072215|NCT01212302|Experimental|aspirin, clopidogrel|If the treatment with aspirin and/or clopidogrel is insufficient (platelet function testing) the dose was increased or the drug was changed (clopidogrel to ticlopidine or prasugrel)
3072216|NCT01212445|Experimental|PEG + E, 13.125 g|Single sachet of PEG+E (13.125 g) dissolved in 125 mL of non-carbonated water ingested orally with entire volume taken at one time
3072217|NCT01212445|Experimental|PEG + E, 26.25 g|Two sachets of PEG+E (26.25 g) dissolved in 250 mL of non-carbonated water ingested orally with entire volume taken at one time
3072218|NCT01212445|Experimental|PEG + E, 39.375 g|Three sachets of PEG+E (39.375 g) dissolved in 375 mL of non-carbonated water ingested orally with entire volume taken at one time
3072219|NCT01212471|Experimental|Bromfenac Ophthalmic Solution A|Bromfenac ophthalmic solution A
3072220|NCT01212471|Experimental|Bromfenac Ophthalmic Solution B|Bromfenac ophthalmic solution B
3072221|NCT01212471|Placebo Comparator|Placebo Comparator|Placebo Comparator
3072222|NCT01212484|Experimental|Placebo (first), Carbidopa (second)|Crossover design Placebo first followed by carbidopa
3072223|NCT01212484|Experimental|Carbidopa (first), Placebo (second)|Crossover design carbidopa first followed by placebo
3072224|NCT01212588|Experimental|Mifepristone|Mifepristone 600mg once daily x 7 days
3072225|NCT01212588|Placebo Comparator|Placebo|Matching placebo tablets one daily
3072226|NCT01212627|Experimental|Ridaforolimus|Ridaforolimus: 20mg Daily, 5 days each week, on a 28 day cycle until progression
3072227|NCT01212744|Experimental|rAvPAL-PEG|rAvPAL-PEG in varying doses
3072228|NCT01212757|Experimental|Apremilast 20mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3072229|NCT01212757|Experimental|Apremilast 30mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3072230|NCT01212757|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3072231|NCT01212757|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3072232|NCT01212770|Experimental|Apremilast 20 mg|20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase
3072233|NCT01212770|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice a day for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice a day for up to 4.5 years in the active treatment / long-term safety phase orally twice daily
3072234|NCT01212770|Placebo Comparator|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 20 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 20 mg Apremilast twice daily at Week 16
3072235|NCT01212770|Placebo Comparator|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast tablets administered twice daily for 24 weeks during the placebo-controlled phase followed by 30 mg Apremilast tablets administered twice daily for up to 4.5 years in the active treatment / long-term safety phase. Subjects who do not have at least 20% improvement in their swollen and tender joint counts at Week 16 will escape to 30 mg Apremilast twice daily at Week 16.
3072236|NCT01212874|Active Comparator|Nitroglycerin|nitroglycerin titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
3072237|NCT01212874|Active Comparator|Esmolol|esmolol titrated to control hypertension between anesthesia induction and initiation of cardiopulmonary bypass
3072238|NCT01212900|Experimental|Imaging|Lipid targets assigned according to the severity of atherosclerotic plaque measured as wall volume in the common and internal carotid arteries by MRI
3072239|NCT01212900|Active Comparator|Standard|Standardized statin therapy based on NCEP ATP IIIR guidelines, including clinical risk factors and blood lipid levels.
3072240|NCT01212952|Experimental|Arm I|Patients receive oral pomalidomide on days 1-21; bortezomib IV on days 1, 8, 15, 22; and oral dexamethasone on days 1, 8, 15, 22. Treatment repeats every 28 days for 8 courses. Patients then receive maintenance therapy comprising oral pomalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072241|NCT01212991|Experimental|Enzalutamide|
3072242|NCT01212991|Placebo Comparator|Placebo|
3072243|NCT01213043|Active Comparator|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 60 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
3072244|NCT01213043|Experimental|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks. Subjects were infused with 120 mg/kg Prolastin-C by means of one of two possible treatment sequences: 1) 60 mg/kg weekly infusion of Prolastin-C for 8 weeks followed by 120 mg/kg Prolastin-C for 8 weeks, or 2) 120 mg/kg Prolastin-C for 8 weeks followed by 60 mg/kg weekly infusion of Prolastin-C for 8 weeks (total of 16 weeks).
3072245|NCT01213082|Experimental|24GyE + anti-VEGF|
3072246|NCT01213082|Experimental|16GyE + anti-VEGF|
3072247|NCT01213082|Sham Comparator|Sham Irradiation + anti-VEGF|
3072248|NCT01213173|Active Comparator|1|
3072249|NCT01213173|Experimental|2|
3072250|NCT01213199|Experimental|Differin 0.3%|"Differin® 0.3% Gel~Adapalene 0.3%~Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks."
3072251|NCT01213251|Experimental|Single Site Pacing|
3072252|NCT01213251|Experimental|Dual Site Pacing|
3072253|NCT01213251|No Intervention|Control|
3072254|NCT01213264||Spontaneous NMB reversal|Participants whose reversal from NMB is spontaneous (no reversal agent used)
3072255|NCT01213264||NMB reversal with sugammadex|Participants who are administered sugammadex for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
3072256|NCT01213264||NMB reversal with other agents|Participants who are administered any other agent (other than sugammadex) for NMB reversal in accordance with routine anesthesiology practice, and labeling guidelines
3072257|NCT01213316||Overall Participants|HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 96 weeks (Initial Cohort), 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.
3072258|NCT01213316||Aging Participants|"HIV-1 infected participants received raltegravir 400 mg tablet orally twice daily for 144 weeks (Prolonged Cohort) or 48 weeks (Amendment Cohort) in combination with other antiretroviral drugs under conditions representative of standard of clinical practice for HIV-1 patients in Germany.~Includes newly enrolled participants ≥ 50 years of age (Amendment Cohort), plus participants from the Initial Cohort who were ≥ 50 years of age at time of recruitment and who completed 48 weeks of treatment (Prolonged Cohort)."
3072259|NCT01213472|Experimental|NY-ESO 1 Group|Patients with non-operable and progressing metastatic cutaneous melanoma, received up to 24 doses of GSK2241658A Cancer Immunotherapeutic, provided that at each tumor evaluation time point, the clinical criteria to continue the treatment were met, including patients having a clinical response.
3072260|NCT01213524|Active Comparator|Active nicotine replacement (NRT) + denicotinized cigarettes|42 mg nicotine replacement plus sensorimotor replacement
3072261|NCT01213524|Active Comparator|Placebo NRT + denicotinized cigarettes|inactive transdermal patches plus sensorimotor replacement
3072262|NCT01213524|Active Comparator|Active NRT + no cigarettes|42 mg nicotine replacement with no sensorimotor replacement
3072263|NCT01213524|Placebo Comparator|Placebo NRT + No cigarettes|Double placebo: No nicotine or sensorimotor replacement
3072264|NCT01213524|Active Comparator|usual brand smoking|positive control: usual brand smoking
3072265|NCT01213576|Active Comparator|albendazole 400mg and ivermectin 200mcg/kg|Annual treatment
3072266|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg/kg|Annual treatment
3072267|NCT01213576|Active Comparator|Albendazole 400mg and ivermectin 200mcg/kg|albendazole 400mg and ivermectin 200mcg/kg given twice a year
3072268|NCT01213576|Active Comparator|Albendazole 800mg and ivermectin 400mcg /kg bi-annually|Albendazole 800mg and ivermectin 400mcg/kg given twice a year
3072269|NCT01213589||Descending thoracic aortic dissection|Patients diagnosed with a descending thoracic aortic dissection and who are amenable to stent-graft operation. The patient had an indication for treatment by either endovascular stent graft implantation for either an acute, sub-acute or chronic Type B dissection.
3072270|NCT01213706|Experimental|Whole Body Periodic Acceleration (WBPA)|All subjects will be performing this procedure. WBPA in spinal axis (pGz) will be administered with a platform that resembles a bed. The platform moves in a repetitive head-to-foot direction at 140 times a minute, producing 0.22 g.
3072271|NCT01213706|Experimental|Sham WBPA|"Sham WBPA :~All subjects will be performing this procedure before the WBPA. The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge."
3072272|NCT01213823||Cases|Potential cases were defined as patients with a diagnosis of severe hepatic injury identified in the acute-care inpatient cohort using ICD-9 codes associated with the case definition of severe liver injury. Case status was validated by a Consultant Gastroenterologist blinded to study drug exposure via medical record review using an apriori algorithm. Only validated cases were included in the analysis (N=69)
3072273|NCT01213823||Controls|Controls were defined as patients without a diagnosis of severe hepatic injury (i.e. with no ICD-9 codes associated with the case definition of severe liver injury) selected at random from the same acute-care inpatient cohort as cases (N=467)
3072274|NCT01213836|Active Comparator|First Seroquel XR then Seroquel IR|Patients randomised to Seroquel XR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel IR for 10-16 days
3072275|NCT01213836|Active Comparator|First Seroquel IR then Seroquel XR|Patients randomised to Seroquel IR will have treatment for 10-16 days and after that cross-over to treatment with Seroquel XR for 10-16 days
3072276|NCT01213940|Other|baratric surgery|surgery vs.weight loss program 6 months prior to bariatric surgery
3072277|NCT01213940|Other|pre-bariatric weight loss program|weight loss program prior to bariatric surgery
3072278|NCT01213966|Experimental|800 mg OZ439 po single dose|800 mg OZ439 po single dose
3072279|NCT01213966|Experimental|400 mg OZ439 p.o. single dose|400 mg OZ439 p.o. single dose
3072280|NCT01213966|Experimental|200mg OZ439 p.o. single dose|200mg OZ439 p.o. single dose
3072281|NCT01213966|Experimental|1200 mg OZ439 po single dose|1200 mg OZ439 po single dose
3072282|NCT01214044|Experimental|Study Drug|Subjects will have a total of 12 visits to Oregon Clinical & Translational Research Institute at Oregon Health & Science University over the 14-16 weeks of study. Subjects will first undergo an initial screening visit to determine eligibility. Subjects who meet criteria and agree to participate will then stop taking their current antidepressant medication (if applicable), during which time the study doctor and staff will conduct weekly mood assessments to ensure safety. Subjects will then have a study initiation/materials visit followed by 9 visits during treatment with placebo or escitalopram. A final post-study follow-up safety visit will be scheduled at the end of treatment.
3072283|NCT01214057|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia (TIVA) with propofol and remifentanyl
3072284|NCT01214057|Active Comparator|Inhaled Anesthesia|Inhaled anesthesia with sevoflurane and remifentanyl.
3072285|NCT01214083|Experimental|Arm 1|N-acetylcysteine + high-dose naltrexone (150 mg)
3072286|NCT01214083|Experimental|Arm 2|High-dose naltrexone (150 mg) alone
3072287|NCT01214083|Active Comparator|Arm 3|Low-dose naltrexone (50 mg) alone
3072288|NCT01214109|Experimental|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
3072289|NCT01214109|Active Comparator|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
3072290|NCT01214161|Experimental|lidocaine gel|This group will be those randomized to receiving the intervention with 2% lidocaine gel.
3072291|NCT01214161|Placebo Comparator|placebo gel (surgilube)|This group will be randomized to having the intervention with the placebo surgilube gel.
3072292|NCT01214174|Experimental|Dose 1|513ug
3072293|NCT01214174|Experimental|Dose 2|776ug
3072294|NCT01214174|Experimental|Dose 3|1046ug
3072295|NCT01214187|Experimental|carbon monoxide inhalation|The primary intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
3072296|NCT01214187|Placebo Comparator|Oxygen 21%|
3072297|NCT01214200|Experimental|High Intensity Non Invasive Pos.Pressure|The High Intensity Non-invasive Pos.Pressure trial is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation (HINPPV) for 90 days. Participants will receive HINPPV via bilevel positive airway pressure (BiPAP Synchrony) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O (centimeters of water); or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
3072298|NCT01214239|Experimental|Linagliptin|once a day
3072299|NCT01214239|Placebo Comparator|Placebo|once a day
3072300|NCT01214252||Permacol Patients|Patients who have undergone surgical repair of their abdominal wall defect with Permacol Surgical Implants with at least 12 months follow up.
3072301|NCT01214317|Active Comparator|mitoxantrone and plasmapheresis|Monthly Plasmapheresis (plasma exchange machine: Haemonetics, model TCS2, USA) 25 ml/kg for 5 cycles, with replacement of 0.9% saline and 5% human serum albumin followed by monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) at the end of each Plasmapheresis course for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
3072302|NCT01214317|No Intervention|mitoxantrone|Monthly IV infusion of 12 mg/m2 mitoxantrone (EBEWE Pharma, Amsterdam, The Netherlands) for three successive months. Then, treatment is continued by adding two more 6 mg/m2 doses of mitoxantrone in 3-month intervals.
3072303|NCT01214330|Experimental|Patient-Collected Cervical Pap Smear|women will receive a self Papanicolaou Smear test (SoloPap) in addition to their physician-collected Papanicolaou Smear
3072304|NCT01214356|Placebo Comparator|Lower Dose Vitamin D|Vitamin D3 supplementation of 400 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
3072305|NCT01214356|Active Comparator|Higher Dose Vitamin D|Vitamin D3 supplementation of 4000 IU/D or 4000 IU/D with combined calcium carbonate supplementation of 1000 mg/day
3072306|NCT01214421|Experimental|Tolvaptan|Participants received a daily split-dose of tolvaptan titrated to the maximally tolerated dose, starting daily tolvaptan dose of 45 milligrams (mg) in the morning [AM]/15 mg in the evening [PM] titrated to 60 mg [AM]/30 mg [PM], then 90 mg [AM]/30 mg [PM] based on tolerability were given orally twice daily until the last participant originating from prior studies (either 156-04-251 or 156-04-250, 156-06-260, 156-09-284, 156-09-285, and 156-09-290) who was eligible for efficacy analysis completed the Month 24.
3072307|NCT01214434|Experimental|Promiseb Topical Cream|
3072308|NCT01214434|Sham Comparator|Bland emollient|
3072309|NCT01214603|Experimental|LY2090314|"Cohort 1: 40 milligrams (mg) LY2090314 administered on Days 1, 8, and 15 of a 28-day cycle for at least two (2) 28-day cycles. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met.~Due to a protocol amendment on September 2010, the study added 2 additional treatment schedules/cohorts. Cohort 2: 40 mg dose given on Days 1, 5, and 9 of a 21-day cycle. Cohort 3: 40 mg dose given on Days 1, 5, 9, and 12 of a 21-day cycle. Participants experiencing clinical benefit may continue treatment until after the discontinuation criteria are met."
3072310|NCT01214616|Experimental|afatinib and vinorelbine IV|patient to receive 20mg or 40mg of po daily afatinib in combination with vinorelbine IV
3072311|NCT01214629|Experimental|LY2523355|
3072312|NCT01214629|Experimental|LY2523355 + pegfilgrastim|
3072313|NCT01214642|Experimental|LY2523355 Days 1, 5, 9|LY2523355 administered intravenously on Days 1, 5 and 9, starting dose is 2 milligrams per meter squared (mg/m^2) for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3072314|NCT01214642|Experimental|LY2523355 Days 1, 8|LY2523355 administered intravenously on Days 1 and 8, starting dose is 8 mg/m^2 for 2 planned 21-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3072315|NCT01214642|Experimental|LY2523355 Days 1, 5 + pegfilgrastim|LY2523355 administered intravenously on Days 1 and 5, starting dose is 8 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 6 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3072316|NCT01214642|Experimental|LY2523355 Days 1, 4 + pegfilgrastim|LY2523355 administered on Days 1 and 4, starting dose is 12 mg/m^2 for 2 planned 21-day cycles and 6 mg pegfilgrastim administered subcutaneously on Day 5 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion are met.
3072317|NCT01214655|Experimental|LY2523355 on Days 1, 2, and 3|Starting dose was 2 milligrams per meter squared (mg/m^2) administered by a 1-hour intravenous (IV) infusion on Days 1, 2, and 3 of every 21-day Cycle.
3072318|NCT01214655|Experimental|LY2523355 on Days 1, 5, and 9|Starting dose was 8 milligrams per meter squared (mg/m^2) administered by a 1-hour IV infusion over 1 hour on Days 1, 5, and 9 of every 21-day Cycle.
3072319|NCT01214668|Experimental|LY573636 + Liposomal Doxorubicin|
3072320|NCT01214720|Experimental|1|
3072321|NCT01214759|Other|Truvada and Raltegravir|Single arm
3072322|NCT01214811|Other|Mepilex Border Ag|Non comparative study with one active arm - Mepilex Border Ag
3072323|NCT01214837|Experimental|MenACWY3|Subjects received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
3072324|NCT01214837|Experimental|MenACWY4|All the subjects received a 3-dose primary series at 2, 4 and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
3072325|NCT01214837|Placebo Comparator|Routine Vaccines|Subjects received routine vaccines only, including PCV-13, at 2, 4 and 6 months of age and a toddler dose at 12 months of age.
3072326|NCT01214850|Experimental|rMenB+OMV|Subjects (18-24 years) received two injections of rMenB+OMV NZ vaccine, one month apart
3072327|NCT01214850|Experimental|MenACWY|Subjects (18-24 years) received one injection of MenACWY-CRM vaccine followed by one injection of placebo, one month apart
3072328|NCT01214850|Active Comparator|Control|Subjects (18-24 years) received two injections of a control vaccine (Japanese Encephalitis), one month apart
3072329|NCT01214915|Experimental|Anagrelide Hydrochloride|
3072330|NCT01214980|Experimental|MIST Therapy in conjunction with SOC|Low-frequency, non-contact ultrasound administered in conjunction with standard of care treatment
3072331|NCT01214980|Active Comparator|Control arm|Standard of care treatment
3072332|NCT01215032|Experimental|Metformin|This is the only arm of this phase 2 open label study
3072333|NCT01215097|Experimental|Linagliptin|once a day
3072334|NCT01215097|Placebo Comparator|placebo|once a day
3072335|NCT01215110|Experimental|TMC207 700/500/400|TMC207- 700 mg Day 1; 500 mg Day 2; 400 mg Days 3-14
3072336|NCT01215110|Experimental|TMC207 500/400/300|TMC207- 500 mg Day 1; 400 mg Day 2 and 300 mg Days 3-14.
3072337|NCT01215110|Experimental|TMC207 400/300/200|TMC207- 400 mg Day 1; 300 mg Day 2 and 200 mg Days 3-14
3072338|NCT01215110|Experimental|TMC207 200/100|TMC207- 200 mg Day 1 and 100 mg Days 2-14
3072339|NCT01215110|Active Comparator|Rifafour e-275 mg|Rifafour e-275 mg
3072340|NCT01215123||Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
3072341|NCT01215175|Active Comparator|Prevnar™ - Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
3072342|NCT01215175|Experimental|V114 Adjuvanted -Toddler Cohort|Healthy toddler (12-15 months of age) participants who had completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
3072343|NCT01215175|Experimental|V114 Nonadjuvanted-Toddler Cohort|Healthy toddlers (12-15 months of age) participants who completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of non-adjuvanted V114 on Day 1.
3072344|NCT01215175|Active Comparator|Prevnar™- Toddler Cohort|Healthy toddlers (12-15 months of age) participants who had previously completed a documented full 3-dose infant series of Prevnar™ received a single 0.5 mL intramuscular injection of Prevnar™ on Day 1.
3072345|NCT01215175|Experimental|V114 Adjuvanted -Adult Cohort|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
3072346|NCT01215188|Experimental|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
3072347|NCT01215188|Experimental|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age.
3072348|NCT01215188|Active Comparator|Prevnar 13®|Four IM doses at 0.5 mL of Prevnar 13® at 2, 4, 6, and 12 to 15 months of age.
3072349|NCT01215227|Experimental|Preladenant 2 mg|Participants who received preladenant 2 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 2 mg in this extension study. Participants will receive preladenant 2 mg taken orally twice daily (BID): one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3072350|NCT01215227|Experimental|Preladenant 5 mg|Participants who received preladenant 5 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3072351|NCT01215227|Experimental|Preladenant 5 mg (on placebo in parent study)|Participants who received placebo to preladenant tablet in parent study NCT01155466 or NCT01227265 will receive preladenant 5 mg in this extension study. Participants will receive preladenant 5 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3072352|NCT01215227|Experimental|Preladenant 10 mg|Participants who received preladenant 10 mg in parent study NCT01155466 or NCT01227265 will continue to receive preladenant 10 mg in this extension study. Participants will receive preladenant 10 mg taken orally BID: one tablet plus placebo capsule to rasagiline in the morning, and one tablet in the evening, for 40 weeks.
3072353|NCT01215227|Active Comparator|Rasagiline 1 mg|Participants who received rasagiline 1 mg in parent study NCT01155466 or NCT01227265 will continue to receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
3072354|NCT01215227|Active Comparator|Rasagiline 1 mg (on placebo in parent study)|Participants who received placebo to rasagiline capsule in parent study NCT01155466 or NCT01227265 will receive rasagiline 1 mg in this extension study. Participants will receive rasagiline 1 mg capsule once a day: one capsule plus placebo tablet to preladenant in the morning, and one placebo tablet to preladenant in the evening, for 40 weeks.
3072355|NCT01215240|Experimental|Prophylactic peritoneal dialysis|Prophylactic peritoneal dialysis
3072356|NCT01215240|No Intervention|Standard care without PDC|
3468848|NCT03891693|Experimental|Passeo-18 Lux and SUPERA® stent|Target lesion will be treated with Passeo-18 Lux Drug Eluting Balloon and SUPERA® stent during angioplasty
3072357|NCT01215253|Active Comparator|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
3072358|NCT01215253|Placebo Comparator|Placebo|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at end of first week. For patients on anti-arrhythmic therapy at the time of randomization, their ECG will be checked at end of first week on 500 mg dose and again at end of second week on 1000 mg dose. For patients with CrCl <60ml/min prior to randomization, their CrCl will be checked again at 2 weeks and study drug discontinued if <30ml/min. For patients with CrCl <60ml/min at 2 weeks, their CrCl will be checked again at 4 weeks and study drug discontinued if <30ml/min.
3072359|NCT01215279|Experimental|AZD2423|AZD2423 Oral Treatment for 28 days
3072360|NCT01215279|Placebo Comparator|Placebo|Oral treatment for 28 days
3072361|NCT01215292|Placebo Comparator|Acyline & T Gel & Placebo Ketoconazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel (T gel) 5 gm daily Days 1-10, + placebo tab PO 1x daily, Day 3-10
3072362|NCT01215292|Experimental|Acyline & T Gel & Ketoconazole 400|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Days 1-10, + ketoconazole 400mg PO 1x daily, Days 3-10
3072363|NCT01215292|Experimental|Acyline & T gel & Ketoconazole 800|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + ketoconazole 800mg PO 1x daily, Days 3-10
3072364|NCT01215292|Experimental|Acyline & T gel & Dutasteride|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + dutasteride 2.5 mg PO 1x daily, Days 3-10
3072365|NCT01215292|Experimental|Group 5: anastrazole|Acyline 300 mcg/kg on Day 1 + 1% testosterone gel 5 gm daily Day 1-10, + anastrazole 1 mg PO 1x daily, Days 3-10
3072366|NCT01215318|Experimental|Modified vaginal tampons|Patients using modified vaginal tampons during FDG PET/CT
3072367|NCT01215318|Placebo Comparator|Unmodified vaginal tampons|Patients using unmodified vaginal tampons during FDG PET/CT
3072368|NCT01215344|Experimental|VRD|VELCADE, Lenalidomide, Dexamethasone
3072369|NCT01215344|Experimental|VDD|VELCADE, liposomal doxorubicin, dexamethasone
3072370|NCT01215357|Experimental|Ecopipam|Ecopipam is a selective antagonist of one the classes of dopamine receptor.
3072371|NCT01215422||children intubated with Glidescope|children intubated with Glidescope
3072372|NCT01215422||children intubated with DCI|children intubated with DCI
3072373|NCT01215435|Experimental|Pre-breakfast BIAsp 30|
3072374|NCT01215435|Experimental|Pre-dinner BIAsp 30|
3072375|NCT01215513|Experimental|Degarelix|
3072376|NCT01215643|Experimental|ALV 1000 mg|Alisporivir (ALV) 600 mg twice daily (BID) for 1 week, followed by ALV 1000 mg once daily (QD) during Weeks 2 to 24.
3072377|NCT01215643|Experimental|ALV 600 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 600 mg QD with ribavirin (RBV) during Weeks 2 to 24.
3072378|NCT01215643|Experimental|ALV 800 mg+RBV|Alisporivir (ALV) 600 mg BID with RBV for 1 week, followed by ALV 800 mg QD with RBV during Weeks 2 to 24.
3072379|NCT01215643|Experimental|ALV 600 mg+PEG|Alisporivir (ALV) 600 mg BID with Peginterferon alfa-2a (PEG) for 1 week, followed by ALV 600 mg QD with PEG once weekly during Weeks 2 to 24.
3072380|NCT01215643|Active Comparator|PEG+RBV|Peginterferon alfa-2a (PEG) and RBV during Weeks 1 to 24.
3072381|NCT01215695|Active Comparator|Control|Patients will be randomly assigned to having their ETT placed with use of a pre-formed stylet provided by the manufacturer of the GVL (control group)
3072382|NCT01215695|Experimental|Intervention|Patients will be randomly assigned to either having their ETT placed with use of flexible, disposable tracheoscope (aScope, Ambu, Denmark) (intervention group).
3072383|NCT01215721|Experimental|Vesicare|Vesicare 5mg daily for 90 days was prescribed for men presenting with post-Robotic Assisted Radical Prostatectomy (RARP) severe incontinence.
3072384|NCT01215734|Active Comparator|High-Dose Trivalent Inactivated Influenza Vaccine|Forty adult hematopoetic stem cell transplant recipients at least 6 months post transplant will receive high dose trivalent influenza vaccine
3072385|NCT01215734|Active Comparator|Standard dose Trivalent Inactivated Flu Vaccine|Twenty Adult stem cell transplant recipients at least 6 months post transplant will receive standard dose trivalent influenza vaccine.
3072386|NCT01215786|Other|AGN-207281 ophthalmic solution|AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14
3072387|NCT01215786|Active Comparator|Timolol ophthalmic solution 0.5%|timolol ophthalmic solution 0.5%
3072388|NCT01215786|Placebo Comparator|Placebo|AGN-207281 vehicle ophthalmic solution (Placebo)
3072389|NCT01215851|Experimental|TMC207|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide placebo administered once daily
3072390|NCT01215851|Experimental|TMC207 and pyrazinamide|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day
3072391|NCT01215851|Experimental|PA-824 and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin placebo (matched to moxifloxacin tablets) administered once daily
3072392|NCT01215851|Experimental|PA-824 and moxifloxacin and pyrazinamide|PA-824 administered once daily as 200mg tablets and pyrazinamide administered once daily in 500mg tablets dosed by weight as follows: < or = 55kg received 2 tablets/day; >55kg to 75kg received 3 tablets/day; >75kg received 4 tablets/day and moxifloxacin administered once daily as 400mg tablets
3468849|NCT03891784|Experimental|Treatment (abemaciclib)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072393|NCT01215851|Active Comparator|Rifafour e-275 mg|Rifafour e-275 administered once daily with each tablet containing 150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, and 275mg ethambutol and dose by weight as follows: 30kg-37kg received 2 tablets/day; 38kg-54kg received 3 tablets/days; 55kg-70kg received 4 tablets/day; > or = 71kg received 5 tablets/day
3072394|NCT01215851|Experimental|TMC207 and PA-824|TMC207 administered once daily as 100mg tablet for total daily dose of 700 mg on Day 1; 500mg on Day 2; 400mg on Days 3-14 plus PA-824 administered once daily as 200mg tablets
3072395|NCT01215916|Experimental|Experimental: Pemetrexed followed by LY573636|Pemetrexed on Day 1 followed by LY573636 on Day 4
3072396|NCT01215916|Experimental|Experimental: LY573636 followed by Pemetrexed|LY573636 on Day 1, pemetrexed on Day 4
3072397|NCT01215916|Experimental|Experimental: LY573636 and Pemetrexed on Day 1|LY573636 and Pemetrexed on Day 1
3072398|NCT01215929|Active Comparator|Dextroamphetamine|
3072399|NCT01215929|Placebo Comparator|Placebo|
3072400|NCT01215942|Experimental|120 milligrams (mg) of LY2127399|"Given every 4 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 240 mg loading dose when initiating treatment.~Or~Given every 4 weeks for 168 weeks for those participants from Study BCDM."
3072401|NCT01215942|Experimental|90 mg LY2127399|"Given every 2 weeks for 240 weeks for those participants from Study BCDO or Study BCDV. Participants who had been receiving placebo immediately prior to enrollment will receive a 180 mg loading dose when initiating treatment.~Or~Given every 2 weeks for 168 weeks for those participants from Study BCDM."
3072402|NCT01215955|Experimental|3 Day Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the past three days.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
3072403|NCT01215955|Experimental|Daily Algorithm|"Basal insulin glargine plus mealtime bolus insulin lispro titrated based on blood glucose readings from the previous day.~(Sites were assigned to Study A and Study B according to an allocation plan that was pre-specified before initiation of Study A and Study B)"
3072404|NCT01215968|Placebo Comparator|Placebo|"Each participant will receive placebo on Week 1. Participants randomized to placebo will receive once-weekly doses of placebo on Weeks 2 to 5.~Placebo will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
3072405|NCT01215968|Experimental|LY2189265|"Participants randomized to LY2189265 will receive once-weekly doses of LY2189265 on Weeks 2 to 5.~1.5 milligram (mg) LY2189265 will be administered by single subcutaneous injection into the skin of the abdominal wall.~Participants regularly taking metformin will continue their normal dosing regimen throughout the study."
3072406|NCT01215981|Active Comparator|Participants Receiving 1 Dose of Vaccine|"Control group participants (healthy volunteers):~Age 18 to 50 years~No history of previous allergic reaction to influenza vaccine, known egg allergy or Guillan-Barre Syndrome~No flu vaccine in previous 4 months~and/or HSCT recipients who are greater than 60 days post transplant."
3072407|NCT01215981|Active Comparator|Participants Receiving 2 Doses of Vaccine|Hematopoietic stem cell transplant (HSCT) recipients who are greater than 60 days post transplant.
3072408|NCT01216072|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period .
3072409|NCT01216072|Active Comparator|Multiple Sclerosis Disease Modifying Treatments (MS DMTs)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months. An open-label extension of up to 3 months of treatment with fingolimod was to be available for patients in the DMT arm who successfully completed all study visits.
3072410|NCT01216163|Experimental|Treatment A|
3072411|NCT01216163|Active Comparator|Treatment B|
3072412|NCT01216163|Placebo Comparator|Treatment C|
3072413|NCT01216176|Experimental|Phase 1 - Cohort A|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression for treatment of metastatic breast cancer
3072414|NCT01216176|Active Comparator|Phase 2 - Cohort B [Anastrozole + AZD0530]|Dual treatment with 1 mg anastrozole orally once daily together with AZD0530 (saracatinib) 175 mg orally once daily, or as specified per protocol, until disease progression or 4-6 months of treatment completed.
3072415|NCT01216176|Placebo Comparator|Phase 2 - Cohort B [Anastrozole + Placebo]|Dual treatment with 1 mg anastrozole orally once daily together with Placebo orally once daily, or as specified per protocol, until disease progression or4-6 months of treatment completed.
3072416|NCT01216189||Preoperative radiotherapy|Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
3072417|NCT01216189||No preoperative radiotherapy|Women with rectal cancer treated with surgery alone (no RT).
3072418|NCT01216202||Preoperative RT|Men with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
3072419|NCT01216202||No preoperative RT|Men with rectal cancer or prostate cancer treated with surgery alone (no RT).
3072420|NCT01216241|Active Comparator|Daptomycin|Daptomycin intravenous 8mg/kg once per day 5-10 days.
3072421|NCT01216241|Placebo Comparator|Saline Placebo|Saline solution
3072422|NCT01216319|Experimental|Nipple Reconstruction Cylinder|
3072423|NCT01216332|Experimental|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
3072424|NCT01216332|Active Comparator|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
3072425|NCT01216397|Experimental|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
3072426|NCT01216397|Experimental|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
3072427|NCT01216410|Active Comparator|Metoclopramide|Prophylaxis with metoclopramide and phenylephrine infusion.
3072428|NCT01216410|Placebo Comparator|Phenylephrine infusion|Prophylactic phenylephrine infusion and placebo antiemetics
3072429|NCT01216410|Active Comparator|Combination Group|Metoclopramide and Ondansetron prophylaxis with phenylephrine infusion
3072430|NCT01216683|Experimental|Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab)|"Arm A (induction): Patients receive rituximab intravenously (IV) on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm D (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
3072431|NCT01216683|Experimental|Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab)|"Arm B (induction): Patients receive rituximab IV on day 1; bortezomib IV on days 1, 4, 8, and 11; and bendamustine hydrochloride IV over 1 hour on days 1 and 4. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm E (continuation): Beginning 4 weeks after the completion of induction therapy, patients who have stable disease or better at time of post-induction restaging receive rituximab as in arm D."
3072432|NCT01216683|Experimental|Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab)|"Arm C (induction): Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Arm F (continuation): Immediately after completing induction therapy, patients who have stable disease or better at time of post-induction restaging receive oral lenalidomide on days 1-21. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of induction therapy, these patients receive rituximab IV on day 1. Treatment repeats every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
3072433|NCT01216735|Active Comparator|smokers, Fluticasone first, then Placebo|The current smokers will be given a 3-week treatment course of inhaled fluticasone (220 ug fluticasone twice a day administered as a MDI) . The subjects and the investigators will be blinded to the random choice of inhaler.
3072434|NCT01216735|Placebo Comparator|smokers Placebo first, then Fluticasone|The current smokers will be given a 3-week treatment course of inhaled placebo MDI. The subjects and the investigators will be blinded to the random choice of inhaler.
3072435|NCT01216735|No Intervention|health non-smokers|The healthy non-smokers will have only visit 1 and no intervention.
3072436|NCT01216748|Experimental|health life-time non smokers|health lifetime non-smokers will be challenged with 4 respiratory maneuvers:quiet breathing, hypocapnic hyperventilation, hypercapnic hyperventilation, and eucapnic hyperventilation
3072437|NCT01216761|Active Comparator|CHG then PI then IT|"Skin antisepsis prior to any peripheral blood culture collection on Floor A was performed with CHG for 3 months, followed by PI for 3 months, followed by IT for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT"
3072438|NCT01216761|Active Comparator|IT then CHG then PI|"Skin antisepsis prior to any peripheral blood culture collection on Floor B was performed with iodine tincture for 3 months, followed by Chlorhexidine gluconate for 3 months, followed by povidone iodine for 3 months. Each 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI"
3072439|NCT01216761|Active Comparator|PI then IT then CHG|"Skin antisepsis prior to any peripheral blood culture collection on Floor C was performed with povidone iodine for 3 months, followed by iodine tincture for 3 months, followed by chlorhexidine gluconate for 3 months. Each 3 3 month intervention period was separated by a one month wash out period where data regarding blood culture contamination was not collected.~10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS) -- PI~Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS) -- IT~2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS) -- CHG"
3072440|NCT01216943|Experimental|Triple Combination Therapy|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
3072441|NCT01217073|Experimental|Omarigliptin 0.25 mg (Base)|Omarigliptin 0.25 mg administered once weekly for 12 weeks (Base)
3072442|NCT01217073|Experimental|Omarigliptin 1 mg (Base)|Omarigliptin 1 mg administered once weekly for 12 weeks (Base)
3072443|NCT01217073|Experimental|Omarigliptin 3 mg (Base)|Omarigliptin 3 mg administered once weekly for 12 weeks (Base)
3072444|NCT01217073|Experimental|Omarigliptin 10 mg (Base)|Omarigliptin 10 mg administered once weekly for 12 weeks (Base)
3072445|NCT01217073|Experimental|Omarigliptin 25 mg (Base)|Omarigliptin 25 mg administered once weekly for 12 weeks (Base)
3072446|NCT01217073|Placebo Comparator|Placebo (Base)|Matching placebo to omarigliptin administered once weekly for 12 weeks (Base)
3072447|NCT01217073|Experimental|Pooled omarigliptin (Extension)|Participants who received omarigliptin during the base study, received omarigliptin 25 mg once weekly and placebo to metformin once daily for 66 weeks (Extension).
3072448|NCT01217073|Active Comparator|Placebo/Metformin|Participants who received matching placebo to omarigliptin during the base period, received pioglitazone administered once daily and matching placebo to omarigliptin once weekly for 66 weeks (extension period). Note: A protocol amendment removed pioglitazone during the extension period. Participants discontinued pioglitazone and switched to blinded metformin. Participants who were previously rescued with open-label metformin during the base period continued in the extension period on open-label metformin.
3072449|NCT01217112|Active Comparator|GWP42004 and placebo|Contains GWP42004 5 mg and placebo (excipients only)
3072450|NCT01217112|Active Comparator|1:1 GWP42003 : GWP42004|Contains 5 mg each of GWP42003 and GWP42004
3072451|NCT01217112|Active Comparator|20:1 GWP42003 : GWP42004|Contains 100 mg GWP42003 and 5 mg GWP42004
3072452|NCT01217112|Placebo Comparator|Placebo|Contains excipients only
3072453|NCT01217112|Active Comparator|GWP42003 and placebo|Contains 100 mg GWP42003 and placebo (excipients only)
3072454|NCT01217190|Experimental|Ondansetron ODFS then Zofran ODT|Single dose of Ondansetron Orally Dissolving Film Strip 8 mg followed by single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg with 7 days washout between the 2 periods
3072455|NCT01217190|Experimental|Zofran ODT then Ondansetron ODFS|Single dose of Zofran ODT® Orally Disintegrating Tablet containing Ondansetron 8 mg followed by single dose of Ondansetron Orally Dissolving Film Strip 8 mg with 7 days washout between the 2 periods
3072456|NCT01217229|Experimental|PLX3397|
3072457|NCT01217307|Experimental|Metformin|metformin 500mg twice daily during 4 months
3072458|NCT01217307|Placebo Comparator|Placebo|Placebo twice daily during 4 months
3072459|NCT01217385|Experimental|DOSI Pre-Surgery|Participants undergo approximately four assessments of breast health using the DOSI technology during treatment and prior to surgery for breast cancer.
3072460|NCT01217411|Active Comparator|Arm I (WBRT or SRS)|Patients with >= 4 brain lesions undergo WBRT as in phase I and patients with =< 3 brain lesions undergo SRS as in phase I.
3072461|NCT01217411|Experimental|Arm II (WBRT or SRS and RO4929097)|Patients with >= 4 brain lesions receive RO4929097 and undergo WBRT as in phase I and patients with =< 3 brain lesions receive RO4929097 and undergo SRS as in phase I.
3072462|NCT01217437|Experimental|Arm I (temozolomide, irinotecan hydrochloride)|Patients receive temozolomide PO and irinotecan hydrochloride IV over 90 minutes on days 1-5.
3072463|NCT01217437|Experimental|Arm II (temozolomide, irinotecan hydrochloride, bevacizumab)|Patients receive temozolomide PO and irinotecan hydrochloride IV as in arm I and bevacizumab IV over 30-90 minutes on days 1 and 15.
3072464|NCT01217463|Active Comparator|Trafermin 0.01% spray|
3072465|NCT01217463|Placebo Comparator|Matching placebo spray|
3072466|NCT01217476|Active Comparator|Trafermin 0.01% spray|
3072467|NCT01217476|Placebo Comparator|Matching placebo spray|
3072468|NCT01217515|Experimental|Diltiazem hydrochloride 4% cream|2.5 cm Diltiazem hydrochloride 4% cream applied peri-anally three times daily for eight weeks.
3072469|NCT01217515|Experimental|Diltiazem hydrochloride 2% cream|2.5 cm of Diltiazem hydrochloride 2% cream applied peri-anally three times daily for eight weeks.
3072470|NCT01217515|Placebo Comparator|Placebo cream|2.5 cm placebo cream applied peri-anally three times daily for eight weeks.
3072471|NCT01217606|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
3072472|NCT01217606|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
3072473|NCT01217749|Experimental|Group 1|In Group 1, PCI-32765 420 mg PO was administered daily for 1 cycle (28 days) before the start of ofatumumab IV dosing
3072474|NCT01217749|Experimental|Group 2|In Group 2, PCI-32765 420 mg PO daily was initiated concomitantly with ofatumumab IV (PCI-32765 initiated on Day 2 of Cycle 1)
3072475|NCT01217749|Experimental|Group 3|In Group 3, two cycles of ofatumumab IV were administered prior to the start of PCI-32765 420 mg PO daily
3072476|NCT01217801|Experimental|Ondansetron (ODFS)|single dose of Ondansetron Orally Dissolving Filmstrip 8 mg
3072477|NCT01217801|Active Comparator|Zofran (ODT)|Single dose of Zofran (Ondansetron) ODT Orally Disintegrating Tablets 8 mg
3072478|NCT01217814|Placebo Comparator|Placebo|Placebo 2 mL to match sarilumab once a week (qw) and 0.5 mL to match golimumab every 4 weeks (q4w) on top of MTX (15-25 mg) qw for 12 weeks.
3072479|NCT01217814|Active Comparator|Golimumab 50 mg|Golimumab 50 mg q4w and placebo (matched to sarilumab) qw on top of MTX (15-25 mg) qw for 12 weeks.
3072480|NCT01217814|Experimental|Sarilumab 150 mg|Sarilumab 150 mg qw and placebo (matched to golimumab) q4w on top of MTX (15-25 mg) qw for 12 weeks.
3072481|NCT01217827|Experimental|Clinical Reminder|Reminder of potential candidacy for an implantable cardioverter defibrillator. The reminder is placed in the medical record with copy to the primary provider and any cardiologist managing the patient.
3072482|NCT01217827|No Intervention|Control|This group does not receive an intervention.
3072483|NCT01217840|Experimental|vitamin D|"Subjects were assigned to receive two observed doses of vitamin D2 (150,000 IU ergocalciferol, Barr Laboratories and Winthrop (Sanofi-Aventis)), given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments.~Intervention: Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks"
3072484|NCT01217840|Placebo Comparator|Placebo|Subjects were assigned to receive two observed doses of placebo, given at baseline and 12 weeks. Capsules were packaged by the hospital's clinical trial pharmacist and were administered by study staff blinded to group assignments. Height, weight, and BMI were obtained at baseline, 12 weeks and 24 weeks
3072485|NCT01217892|Experimental|1|Dapagliflozin 2.5 mg twice-daily plus open-label metformin
3072486|NCT01217892|Experimental|2|Dapagliflozin 5.0 mg twice-daily plus open-label metformin
3072487|NCT01217892|Experimental|3|Dapagliflozin 10 mg once-daily plus open-label metformin
3072488|NCT01217892|Placebo Comparator|4|Placebo plus open-label metformin
3072489|NCT01217944|Experimental|Ranibizumab driven by disease activity|Participants received active ranibizumab on day 1. Thereafter they received ranibizumab treatment based on disease activity criteria
3072490|NCT01217944|Experimental|Ranibizumab driven by stabilization criteria|Participants received ranibizumab on day 1 and month 1. Thereafter they received ranibizumab based on stabilization criteria for visual acuity
3072491|NCT01217944|Active Comparator|Verteporfin PDT|Participants received active vPDT on day 1. From month 3 onwards participants could receive ranibizumab, vPDT or a combination of the two if needed.
3072492|NCT01217957|Experimental|Phase 1: Ixazomib 1.68 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 1.68 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3072493|NCT01217957|Experimental|Phase 1: Ixazomib 2.23 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.23 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.23 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3072494|NCT01217957|Experimental|Phase 1: Ixazomib 2.97 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 2.97 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 2.97 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3072495|NCT01217957|Experimental|Phase 1: Ixazomib 3.95 mg/m^2 + Lenalidomide + Dexamethasone|In phase 1, ixazomib 3.95 mg/m^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 3.95 mg/m^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3072496|NCT01217957|Experimental|Phase 2: Ixazomib 4.0 mg + Lenalidomide + Dexamethasone|In phase 2, ixazomib 4.0 mg fixed dose, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 4.0 mg fixed dose, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.
3072497|NCT01218009|Experimental|Albuterol Spiromax|Albuterol multi-dose dry powder inhaler (Spiromax) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they take albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
3072498|NCT01218009|Placebo Comparator|Placebo Spiromax|Placebo delivered using a multi-dose dry powder inhaler (Spiromax) as 2 inhalations four times a day for the 12 week double-blind period. Participants then continue into the 40 week open-label period in which they administer albuterol multi-dose dry powder inhaler (Spiromax) inhalations of 90 mcg /inhalation as required (PRN).
3072499|NCT01218048|Experimental|Neo-Adjuvant Cetuximab|"Neo-Adjuvant Cetuximab + Surgery + Post-Surgical Radiation + Cisplatin (or Carboplatin)~NOTE: Based the results of surgery if the treating physician feels patient is not a candidate for chemotherapy, radiation can be given alone or with cetuximab."
3072500|NCT01218087|Experimental|Cranial cup device and Moldable positioner device|The cranial cup for 12/24 hours and the moldable positioner device was used for positioning infants the remainder of the 24 hours
3072501|NCT01218087|Active Comparator|Moldable positioner device|Moldable positioner device was used for positioning infants for 24/24 hours
3072502|NCT01218100|Experimental|1|Combination group - starting dose level nebivolol 5mg and lisinopril 10mg
3072503|NCT01218100|Active Comparator|2|Nebivolol monotherapy group - starting dose level nebivolol 5mg
3072504|NCT01218100|Active Comparator|3|Lisinopril monotherapy group - starting dose level lisinopril 10mg
3072505|NCT01218100|Placebo Comparator|4|Placebo group - starting dose is placebo
3072506|NCT01218113|Experimental|3D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of the HIV Vaccine 732462 at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
3072507|NCT01218113|Experimental|2D_HIV Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 2 doses of the HIV Vaccine 732462 at Weeks 0 and 4 and one dose of placebo (saline solution) at Week 28, administered intramuscularly in the deltoid of the non-dominant arm.
3072508|NCT01218113|Placebo Comparator|Control Group|HIV-1 infected male and female subjects, between and including 18 to 55 years of age at the time of first vaccination, who received 3 doses of placebo (saline solution) at Weeks 0, 4 and 28, administered intramuscularly in the deltoid of the non-dominant arm.
3072509|NCT01218126|Experimental|losmapimod 2.5 mg|losmapimod 2.5 mg
3072510|NCT01218126|Placebo Comparator|placebo|
3072511|NCT01218126|Experimental|losmapimod 7.5 mg|losmapimod 7.5 mg
3072512|NCT01218126|Experimental|losmapimod 15 mg|losmapimod 15 mg
3072513|NCT01218204|Other|Part A Run-in|Subjects on stable 40mg atorvastatin > 4 weeks may raise their dose to 80mg for 2 weeks in order to qualify for Part A.
3072514|NCT01218204|Experimental|Part A Co-Dosing 800mg GSK1292263|Dosing for 14 days
3072515|NCT01218204|Other|Part B Washout|Washout for 4 weeks
3072516|NCT01218204|Active Comparator|Part B Run-in 10mg atorvastatin|Dosing for 4 weeks
3072517|NCT01218204|Active Comparator|Part B Run-in 80mg atorvastatin|Dosing for 4 weeks
3072518|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 100mg GSK1292263|Dosing for 14 days
3072519|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 300mg GSK1292263|Dosing for 14 days
3072520|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
3072521|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + 10mg ezetimibe|Dosing for 14 days
3072522|NCT01218204|Experimental|Part B Dosing 100mg GSK1292263|Dosing for 14 days
3072523|NCT01218204|Experimental|Part B Dosing 300mg GSK1292263|Dosing for 14 days
3072524|NCT01218204|Experimental|Part B Dosing 800mg GSK1292263|Dosing for 14 days
3072525|NCT01218204|Experimental|Part B Dosing Placebo GSK1292263|Dosing for 14 days
3072526|NCT01218204|Experimental|Part B Co-Dosing 80mg atorvastatin + 800mg GSK1292263|Dosing for 14 days
3072527|NCT01218204|Experimental|Part B Co-dosing 80mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
3072528|NCT01218204|Experimental|Part B Co-Dosing 10mg atorvastatin + Placebo (GSK1292263)|Dosing for 14 days
3072529|NCT01218243|Experimental|acupoint|Needle at bilateral BL33 60-80 mm with a 45°angle.A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd)is put on with Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. There are 5 sessions in the first two weeks and 3 sessions in the last two weeks, 30 min/session.
3072530|NCT01218243|Sham Comparator|non-acupoint|Take the place 2 cun far from BL33 on the outside horizontally as the non-point. Needle on the non-point for 60-80mm with a 45°angle. A feeling of soreness and distension will be felt .Needle with a 100-125mm long needle without lifting, thrusting or rotating.Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.
3072531|NCT01218308|Experimental|FluLaval® Quadrivalent Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of FluLaval® Quadrivalent vaccine at Day 0 and, if unprimed, 2 doses of FluLaval® Quadrivalent vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3072532|NCT01218308|Active Comparator|Havrix Group|Subjects between 3 and 8 years of age at the time of first vaccination received, if primed, 1 dose of Havrix™ vaccine at Day 0 and, if unprimed, 2 doses of Havrix™ vaccine at Days 0 and 28. The vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
3072533|NCT01218399|Active Comparator|Budesonide|"Combination of budesonide and formoterol. Medications are given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Symbicort study arm."
3072534|NCT01218399|Placebo Comparator|Placebo Comparator: Budesonide|"Control of budesonide alone. Medication was given according to the package insert and manufacturer's instructions.~Participants that develop a viral upper respiratory illness which induces an asthma exacerbation.within the specified period following enrollment, are randomly assigned 1:1 to either study arm. 5 participants were randomly assigned to the Budesonide study arm."
3072535|NCT01218438|Experimental|Study Epochs 1-4|"Epoch 1 (13 weeks): Pharmacokinetic (PK) assessment at 2nd to last infusion (in all participants ≥12 years of age). Participants will be treated intravenously once every 3 or 4 weeks at same monthly equivalent dose as prior to the study.~Epoch 2 (12-16 weeks): PK assessment (in first 15 participants ≥12 years of age) at 9th infusion to determine adjusted dose for Epoch 3 and individually adapted dose for Epoch 4. Participants will be treated subcutaneously every 7 days at a dose of IGSC, 20% that is 145% of the weekly equivalent of the IV dose in Epoch 1.~Epoch 3 (12 weeks): Participants will be treated subcutaneously every 7 days using the adjusted dose determined in Epoch 2. The individually adapted dose for use in Epoch 4 will also be determined.~Epoch 4 (40 weeks): Participants will be treated subcutaneously once every week at the individually adapted dose determined in Epoch 3. PK assessment at 17th infusion."
3072536|NCT01218477|Experimental|Dasatinib, 100/140 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
3072537|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 50 mg QD|Participants received dasatinib, 100/140 mg once daily (QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase) plus BMS-833923, 50 mg, QD
3072538|NCT01218477|Experimental|Dasatinib, 100/140 mg QD + BMS-833923, 100 mg BID/QD|Participants received BMS-833923, 100 mg twice daily (BID) for 7 days then once daily (QD) + dasatinib, 100/140 mg QD, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
3072539|NCT01218477|Experimental|Dasatinib, 100 /140 mg QD+ BMS-833923, 200 mg BID/QD|Participants received BMS-833923, 200 mg twice daily (BID) for 7 days then 200 mg once daily (QD) plus dasatinib, 100 /140 mg QD), depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
3072540|NCT01218516|Active Comparator|Farletuzumab plus Chemotherapy|During Combination Therapy, farletuzumab will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6, cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive farletuzumab as monotherapy until disease progression.
3072541|NCT01218516|Placebo Comparator|Placebo plus Chemotherapy|During Combination Therapy, placebo will be given with a protocol-approved platinum doublet (either carboplatin/paclitaxel, carboplatin/pemetrexed, or cisplatin/pemetrexed) for at least 4, but not more than 6 cycles. Participants who experience clinical benefit from the Combination Therapy will enter the Monotherapy Phase and receive placebo as monotherapy until disease progression.
3072542|NCT01218542|Experimental|Volumetric modulated arc therapy|Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.
3072543|NCT01218594|Experimental|Endostatin combine CCRT|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
3072544|NCT01218646|Experimental|Group 1: Investigational Quadrivalent Influenza Vaccine|Participants will receive a dose of Investigational Quadrivalent Inactivated Influenza Vaccine
3072545|NCT01218646|Experimental|Group 2: Investigational Trivalent Influenza Vaccine|Participants will receive a dose of Investigational Trivalent Inactivated Influenza Vaccine
3072546|NCT01218646|Active Comparator|Group 3: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
3072547|NCT01218646|Active Comparator|Group 4: Licensed 2010-2011 Trivalent Influenza Vaccine|Participants will receive a dose of Licensed 2010-2011 Trivalent Inactivated Influenza Vaccine
3072548|NCT01218659|Experimental|Migalastat|Participants received 150 mg migalastat orally QOD during the 18-month randomized treatment period and the optional 12-month OLE period. Participants received an inactive reminder capsule on alternate days during both treatment periods.
3072549|NCT01218659|Active Comparator|ERT|Participants received ERT (either agalsidase alfa or agalsidase beta) as prescribed by the participant's treating physician and administered in accordance with the approved prescribing information during the 18-month randomized treatment period. Participants were required to be given >80% of the currently labeled dose and regimen during the 18-month randomized treatment period. During the optional 12-month OLE period, participants received 150 mg migalastat orally QOD. Participants received an inactive reminder capsule on alternate days during the OLE.
3072550|NCT01218672|Experimental|GreenLight XPS|Photoselective vaporization of the prostate using GreenLight XPS laser system.
3072551|NCT01218672|Active Comparator|Transurethral Resection of the Prostate|Monopolar and bipolar Transuretheral resection of the prostate (TURP)
3072552|NCT01218802|Active Comparator|Rosuvastatin|Participants will take Rosuvastatin 10 mg. daily for 96 weeks
3072553|NCT01218802|Placebo Comparator|Sugar Pill placebo|Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.
3072554|NCT01218867|Experimental|Cohort 1 (1x10(6) cells (high dose IL-2)|Patients will receive (1x10(6) cells plus high dose aldesleukin
3072555|NCT01218867|Experimental|Cohort 2 (3x10(6) cells (high dose IL-2)|Patients will receive (3x10(6) cells plus high dose aldesleukin
3072556|NCT01218867|Experimental|Cohort 3 (1x10(7) cells (high dose IL-2)|Patients will receive (1x10(7) cells plus high dose aldesleukin
3072557|NCT01218867|Experimental|Cohort 4 (3x10(7) cells (high dose IL-2)|Patients will receive (3x10(7) cells plus high dose aldesleukin
3072558|NCT01218867|Experimental|Cohort 5 (1x10(8) cells (high dose IL-2)|Patients will receive (1x10(8) cells plus high dose aldesleukin
3072559|NCT01218867|Experimental|Cohort 6 (3x10(8) cells (high dose IL-2)|Patients will receive (3x10(8) cells plus high dose aldesleukin
3072560|NCT01218867|Experimental|Cohort 7 (1x10(9) cells (high dose IL-2)|Patients will receive (1x10(9) cells plus high dose aldesleukin
3072561|NCT01218867|Experimental|Cohort 8 (1x10(9) cells (low dose IL-2)|Patients will receive (1x10(9) cells plus low dose aldesleukin
3072562|NCT01218867|Experimental|Cohort 9 (3x10(9) cells (low dose IL-2)|Patients will receive (3x10(9) cells plus low dose aldesleukin
3072563|NCT01218867|Experimental|Cohort10(1x10(10) cells (low dose IL-2)|Patients will receive (1x10(10) cells plus low dose aldesleukin
3072564|NCT01218867|Experimental|Cohort11(3x10(10) cells (low dose IL-2)|Patients will receive (3x10(10) cells plus low dose aldesleukin
3072565|NCT01218958|Experimental|Medisorb naltrexone 190 mg|
3072566|NCT01218958|Experimental|Medisorb naltrexone 380 mg|
3072567|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 190 mg|
3072568|NCT01218958|Placebo Comparator|Placebo for Medisorb naltrexone 380 mg|
3072569|NCT01218971|Experimental|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.
3072570|NCT01218971|Experimental|Medisorb naltrexone 190 mg|IM injection administered once every 4 weeks for up to 48 weeks.
3072571|NCT01218984|Experimental|Medisorb naltrexone 75 mg|
3072572|NCT01218984|Experimental|Medisorb naltrexone 150 mg|
3072573|NCT01218984|Experimental|Medisorb naltrexone 300 mg|
3072574|NCT01218997|Experimental|Medisorb naltrexone 380 mg (VIVITROL)|
3072575|NCT01218997|Active Comparator|Oral naltrexone 50 mg|
3072576|NCT01219738|Experimental|budesonide 360ug|asthmatic subject received different doses of inhaled budesonide in random other
3072577|NCT01219738|Experimental|budesonide 720ug|asthmatic subject received different doses of inhaled budesonide in random other
3072578|NCT01219738|Experimental|budesonide 1440ug|asthmatic subject received different doses of inhaled budesonide in random other
3072579|NCT01219738|Placebo Comparator|placebo|asthmatic subject received inhaled placebo
3072580|NCT01219738|Experimental|Budesonide720ug 4 times|asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.
3072581|NCT01219777|Experimental|Carboplatin|AUC 5.0 or 6.0
3072582|NCT01219777|Experimental|Bevacizumab|15 mg/kg
3072583|NCT01219777|Experimental|Paclitaxel|60-80 mg/m2
3072584|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 60µg|
3072585|NCT01219855|Experimental|Cohort 1: CTAP101 Capsules 90µg|
3072586|NCT01219855|Placebo Comparator|Cohort 1: Sugar Capsule|
3072587|NCT01219855|Experimental|Cohort 2: CTAP101 Capsules 30µg|
3072588|NCT01219855|Placebo Comparator|Cohort 2: Sugar Capsule|
3072589|NCT01219881|Active Comparator|Desflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Desflurane.
3072590|NCT01219881|Active Comparator|Sevoflurane|Comparing the effect on recovery time in patients undergoing urological cytoscope surgery under general anesthesia with a laryngeal mask airway (LMA) using Sevoflurane.
3072591|NCT01219933|Experimental|1|
3072592|NCT01219959|Active Comparator|Non-glucose Sparing|Dianeal only
3072593|NCT01219959|Experimental|Glucose Sparing|Dianeal, Extraneal, Nutrineal
3072594|NCT01219985|Experimental|Investigation arm|"standard and respiratory-gated PET acquisitions  for patients included in the trial."
3072595|NCT01220024|Experimental|2, 5x5cm bupivacaine collagen sponges|collagen sponges
3072596|NCT01220024|Placebo Comparator|2, Placebo collagen sponges|Placebo collagen sponges
3072597|NCT01220128|Experimental|Cohort A-GSK2302024A Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
3072598|NCT01220128|Placebo Comparator|Cohort A-Placebo Group|This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
3072599|NCT01220128|Experimental|Cohort B-GSK2302024A Group|This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3072600|NCT01220128|Placebo Comparator|Cohort B-Placebo Group|This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3072601|NCT01220128|Experimental|Cohort C-GSK2302024A Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3072602|NCT01220128|Placebo Comparator|Cohort C-Placebo Group|This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3072603|NCT01220128|Experimental|Cohort D-GSK2302024A-D14 Group|This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
3072604|NCT01220167|Experimental|Sequence ABC|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
3072605|NCT01220167|Experimental|Sequence BCA|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment B (Ondansetron 8 mg ODFS with water), Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
3072606|NCT01220167|Experimental|Sequence CAB|Six subjects received a single dose of each of the 3 study treatments in the following order: Test Treatment C (Zofran ODT® containing ondansetron 8 mg without water), Test Treatment A (Ondansetron 8 mg ODFS without water), Test Treatment B (Ondansetron 8 mg ODFS with water). Each dose was administered following a 10-hour fast with a 3-day washout period between doses.
3072607|NCT01220180||Epilepsy|
3072608|NCT01220180||Neuropathic Pain|
3072609|NCT01220180||Fibromyalgia|
3072610|NCT01220297|Experimental|Carmustine Etoposide Cyclophosphamide|Carmustine + Etoposide + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
3072611|NCT01220297|Experimental|FTBI + Cyclophosphamide|FTBI + Cyclophosphamide followed by Sirolimus and Mycophenolate mofetil (MMF) as prophylaxis.
3072612|NCT01220401|Experimental|ERRT-M|Exposure, Relaxation, and Rescripting Therapy for military populations. 4 sessions.
3072613|NCT01220414|Active Comparator|Men|
3072614|NCT01220414|Active Comparator|Women|
3072615|NCT01220466|Experimental|Refractive Error|
3072616|NCT01220557|Experimental|PRIMAS group|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
3072617|NCT01220557|Active Comparator|Control group|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
3072618|NCT01220609|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3072619|NCT01220687|Placebo Comparator|Placebo 20ppm|Nitrogen at 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
3072620|NCT01220687|Experimental|Inhaled Nitric Oxide (iNO) 20 ppm|Inhaled Nitric Oxide 20 ppm at the beginning of study start with gradual taper at 10 minutes of the study and completely off by 17 minutes of the study
3072621|NCT01220726|Active Comparator|Botox|200U onabotulinumtoxinA (botox)
3072622|NCT01220726|Placebo Comparator|Placebo|200U Saline
3072623|NCT01220739|Sham Comparator|IV tPA + Sham Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by sham transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
3072624|NCT01220739|Active Comparator|IV tPA +Transcranial Laser Therapy|Subjects in this treatment arm will receive IV tPA within 3 hours of stroke symptom onset followed by transcranial laser therapy no sooner than 12 hours after tPA and no greater than 24 hours from stroke onset.
3072625|NCT01220856|Experimental|Reparixin|"Reparixin + Immunosuppression~Reparixin was administered at a dose of 2.772 mg/kg body weight/hour for 7 days (168 hours) at each transplant. It was administered as a continuous IV infusion into a (high-flow) central vein. Investigational Product infusion was to begin approximately 12 hours (range between 6 to 16 hours) before each pancreatic islet infusion was started. The Investigator identified the time to start study drug administration.~Reparixin was given to all patients of this arm using the same dosing solution (reparixin 11.00 mg/mL), but the pump rate was adjusted to provide an infusion rate of approximately 0.25 mL/kg/hour.~For immunosoppression regimen see the other arm description."
3072626|NCT01220856|No Intervention|No experimental intervention|Immunosuppression only. Induction: First islet infusion: anti-thymocyte globulin (ATG), administered IV (central vein) at the dose of 1.5 mg/kg on Day -1, 0, 1, and 2 of islet infusion. The first ATG injection was preceded by a bolus IV injection of 500 mg methylprednisolone. Induction for the second islet infusion was to be administered per center practice. Maintenance: Mycophenolate mofetil (MMF), administered orally at the dose of 1 g twice a day, starting on Day -1 of the first islet infusion; Tacrolimus, administered orally starting on Day -1 of the first islet infusion at a dose of 0.087 mg/kg twice a day. Thereafter, dosing was to be targeted to blood trough levels of 8 to 10 ng/mL. Administration continued up to Month 3 after the first transplant. Rapamycin was to replace tacrolimus from Month 3 after the first transplant. It was to be administered orally at the starting dose of 0.1 mg/kg once a day, then targeted to a blood trough level of 10 to 12 ng/mL.
3072627|NCT01220869|Experimental|Degarelix|
3072628|NCT01220973|Experimental|Atorvastatin and Celecoxib|
3072629|NCT01220999|Experimental|Cohort 1|Subjects received an initial loading dose of 111^In-CS-1008 (0.2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
3072630|NCT01220999|Experimental|Cohort 2|Subjects received an initial loading dose of 111^In-CS-1008 (1 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
3072631|NCT01220999|Experimental|Cohort 3|Subjects received an initial loading dose of 111^In-CS-1008 (2 mg/kg) on Day 1, CS-1008 (6 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
3072632|NCT01220999|Experimental|Cohort 4|Subjects received an initial loading dose of 111^In-CS-1008 (4 mg/kg) on Day 1, CS-1008 (4 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
3072633|NCT01220999|Experimental|Cohort 5|Subjects received an initial loading dose of 111^In-CS-1008 (6 mg/kg) on Day 1, CS-1008 (2 mg/kg) on Day 8, and subsequent weekly doses of CS-1008 (2 mg/kg) on Days 15, 22, 29, 36, and 43; the Day 36 dose was also radiolabeled with 111^In. Additional 4-week cycles of weekly CS-1008 (2 mg/kg) were permitted for subjects benefiting from treatment.
3072634|NCT01221090|Experimental|Personal Digital Assistant|Individuals in this arm were taught to use a diabetes self-care software, Diabetes Pilot™ (Digital Altitudes, Arlington Heights, IL), developed for PalmOS® (Palm, Sunnyvale, CA) which was loaded on to compatible PDAs, the Tungsten™ E2 handheld device. The Diabetes Pilot allowed participants to monitor their blood glucose, blood pressure, medication usage, physical activity, and dietary intake by tracking these measures in an electronic diary.
3072635|NCT01221090|Active Comparator|CDSMP|6-week, classroom-based program for diabetes self-management. The CDSMP, developed by Stanford University, equipped participants with the education and skill sets needed to take a more proactive approach in managing their chronic condition(s) and related symptoms.
3072636|NCT01221090|Active Comparator|PDA/CDSMP|Combined intervention
3072637|NCT01221090|No Intervention|Control|Usual Care
3072638|NCT01221181|Experimental|Eculizumab|Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitides vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment.
3072639|NCT01221194|Active Comparator|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
3072640|NCT01221194|Active Comparator|PFC Stockings|The stocking therapy group will be given PFC shear reducing stockings to wear.
3072641|NCT01221207|Active Comparator|Device - Total Contact Cast (TCC)|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
3072642|NCT01221207|Active Comparator|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
3072643|NCT01221207|Active Comparator|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
3072644|NCT01221233|Experimental|NMES AND Stabilization Exercises|Neuromuscular Electrical Stimulation and Lumbar Stabilization Exercises
3072645|NCT01221233|Active Comparator|Moist Heat AND Stabilization Exercises|Moist Heat and Lumbar Stabilization Exercises
3072646|NCT01221272|Experimental|Ranolazine/Placebo|Participants received ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
3072647|NCT01221272|Experimental|Placebo/Ranolazine|Participants received placebo to match ranolazine from Day 1 through Day 15 (± 2 days) of Period 1, followed by an exercise SPECT MPI study, then received ranolazine from Day 1 through Day 15 (± 2 days) of Period 2, followed by an exercise SPECT MPI study.
3072648|NCT01221285|Experimental|German cockroach allergenic extract|Participants will receive weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
3072649|NCT01221298|Experimental|ABT-450/r and ABT-072, plus ribavirin (RBV)|ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.
3072650|NCT01221311|Experimental|Fully Covered Metallic Stent|Among patients randomized to the covered, self-expandable metallic stent (cSEMS) group, the endoscopist will deploy a cSEMS of sufficient length to traverse the papilla. Dilation will not be performed unless the cSEMS deployment catheter cannot be advanced over a guidewire beyond the stricture. A biliary sphincterotomy may be performed at the discretion of the treating endoscopist.
3072651|NCT01221311|Active Comparator|Plastic Stent|Patients randomized to the plastic stent (PS) group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and multiple (as many as technically feasible) PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing endoscopic retrograde cholangiopancreatography (ERCP), until the stricture has been obliterated using clinical and fluoroscopic criteria (details below).
3072652|NCT01221350|Experimental|Lipoic acid|Lipoic acid 600 mg oral dose (two 300 mg capsules) once daily in the morning during 60 days
3072653|NCT01221350|Placebo Comparator|Placebo|Placebo (two placebo capsules) orally once daily in the morning during 60 days
3072654|NCT01221363|Active Comparator|Lifestyle counselling|Theory based individually tailored lifestyle counselling aimed at reduction of sitting time during leisure time and at work. Four individual sessions over a six months period.
3072655|NCT01221363|No Intervention|Control group|No intervention control group
3072656|NCT01221441|Experimental|TissueGene-C|TissueGene-C at 3 x 10e7 cells per injection (intraarticular)
3072657|NCT01221441|Placebo Comparator|Placebo Control|Normal Saline injection
3072658|NCT01221597|Experimental|AA4500|collagenase clostridium histolyticum
3072659|NCT01221597|Placebo Comparator|Placebo|placebo
3072660|NCT01221623|Experimental|AA4500|collagenase clostridium histolyticum
3072661|NCT01221623|Placebo Comparator|Placebo|Placebo
3072662|NCT01221727|Other|Midazolam|All 27 subjects will receive midazolam.
3072663|NCT01221727|Active Comparator|Denosumab|Eighteen (18) subjects will receive denosumab.
3072664|NCT01221753|Experimental|TPF Induction Chemotherapy followed by Chemoradiotherapy|Patients received 3 cycles (21 days each) of TPF induction chemotherapy: docetaxel 75 mg/m2 IV day 1; cisplatin 100 mg/m2 IV day 1 (carboplatin substitute permitted); 5-FU 1000 mg/m2/day IV pump continuous days 1-4. Concurrent chemoradiotherapy followed 4-6 weeks after day 1 of cycle 3 TPF induction: cetuximab 400 mg/m2 IV loading dose 1 week prior and 250 mg/m2 IV weekly (panitumumab substitute permitted); carboplatin AUC 1.5 (Calvert formula) IV weekly; Intensity modulated radiation therapy (IMRT)-response based dosing for 6-7 weeks.
3072665|NCT01221857|Experimental|NiCord|
3072666|NCT01221948|Experimental|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
3072667|NCT01222078|Experimental|otelixizumab|otelixizumab
3072668|NCT01222091|Active Comparator|Propranolol, Then Placebo|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
3072669|NCT01222091|Placebo Comparator|Placebo, Then Propranolol|Propranolol, a beta blocker, or placebo to match, will be given to test whether or not it could modulate the expression of remifentanil-induced postinfusion hyperalgesia (RPH) during two pain test including: mechanically evoked pain to map the size of the hyperalgesic skin region caused by electrical stimulation and heat pain.
3072670|NCT01222104||Angio-Seal|Angio-Seal attempted and/or deployed
3072671|NCT01222104||Not deployed|Other method of closure
3072672|NCT01222117|Experimental|Plasmin Open-label Treatment Group A|Open-label 150 mg Plasmin administered without initial proximal pulse; 5-hour infusion using 10 mL/hour infusion rate.
3072673|NCT01222117|Experimental|Plasmin Open-label Treatment Group B|Open-label 150 mg Plasmin administered with initial proximal pulse; 5-hour infusion using 15 mL/hour infusion rate
3072674|NCT01222117|Experimental|Plasmin Open-label Treatment Group C|Open-label 150 mg Plasmin administered with proximal pulse; 5 hour infusion using 30 mL/hour infusion rate.
3072675|NCT01222117|Experimental|Plasmin Open-label Treatment Group D|Open-label 150 mg Plasmin administered with proximal pulse; 2-hour infusion using 35 mL/hour infusion rate
3072676|NCT01222117|Active Comparator|Plasminogen Activator Blinded Group E|PA administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice
3072677|NCT01222117|Placebo Comparator|PA Placebo Blinded Treatment Arm F|PA placebo (normal saline for injection) administered for five hours at a dose and volume according to the Investigator's clinical judgement/standard practice for PA administration
3072678|NCT01222117|Experimental|Plasmin Open-label Treatment Group G|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 60 mL/hour infusion rate
3072679|NCT01222117|Experimental|Plasmin Open-label Treatment Group H|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 75 mL/hour infusion rate
3072680|NCT01222117|Experimental|Plasmin Open-label Treatment Group I|Open-label 150 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
3072681|NCT01222117|Experimental|Plasmin Open-label Treatment Group J|Open-label 150 mg Plasmin administered without pulsing; 2-hour infusion using 35 mL/hour infusion rate with balloon occlusion catheter
3072682|NCT01222117|Experimental|Plasmin Open-label Treatment Group M|Open-label 250 mg Plasmin administered without pulsing; 5-hour infusion using 30 mL/hour infusion rate with balloon occlusion catheter
3072683|NCT01222195|Experimental|Lenalidomide + Darbepoetin alfa|Lenalidomide 10 mg/day orally days 1-21 and Darbepoetin alfa 200 mcg subcutaneously every 2 weeks of 28 day cycle
3072684|NCT01222234|Experimental|Group 1: Cholecalciferol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
3072685|NCT01222234|Experimental|Group 2: Calcitriol - CKD|Patients in this group have low vitamin D levels and Chronic Kidney Disease (CKD). They will be administered calcitriol 0.25mcg daily for 8 weeks.
3072686|NCT01222234|Experimental|Group 3: Cholecalciferol - non-CKD|Patients in this arm have low vitamin D levels and normal kidney function. They will be administered cholecalciferol 50,000 IU twice weekly for 8 weeks.
3072687|NCT01222247|Active Comparator|Betamethasone|A course of two 2mL intramuscular (IM) injections containing 3 mg of betamethasone, 24 hours apart
3072688|NCT01222247|Placebo Comparator|Placebo|A similar course of an identical appearing placebo: two 2 mL IM injections of placebo, 24 hours apart
3072689|NCT01222260|Experimental|Treatment Arm|Subjects with AL will receive Bendamustine and Dexamethasone
3072690|NCT01222273|Other|Open label|open label Vitamin D
3072691|NCT01222286|Experimental|IPH2101 0.2 mg/kg|0.2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
3072692|NCT01222286|Experimental|IPH2101 2 mg/kg|2 mg/Kg every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
3072693|NCT01222299|Experimental|Arm 1 - Low Dose|bepotastine besilate nasal product - low dose
3072694|NCT01222299|Experimental|Arm 2 - Medium Dose|bepotastine besilate nasal product - medium dose
3072695|NCT01222299|Experimental|Arm 3 - High Dose|bepotastine besilate nasal product - high dose
3072696|NCT01222299|Placebo Comparator|Arm 4 - Placebo|placebo comparator nasal product
3072697|NCT01222390|Experimental|Contour Profile Tissue Exander|Patients undergoing breast reconstruction using a Contour Profile Tissue Expander (CPX3).
3072698|NCT01222403|Experimental|Fluad|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
3072699|NCT01222403|Experimental|Vantaflu_aTIV|Subjects aged >65 years received one dose of investigational MF59-adjuvanted trivalent influenza vaccine (aTIV).
3072700|NCT01222416|Experimental|fluorodeoxyglucose PET/CT (FDG-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
3072701|NCT01222416|Experimental|fluorodeoxythymidine PET/CT (FLT-PET/CT)|A PET/CT scan prior to the initiation of therapy, and then two additional scans following the initiation of therapy. Each patient will have up to three scans in a 6 month time frame.
3072702|NCT01222494|Placebo Comparator|Antipsychotic Treated Educational Cntrl|Antipsychotic treated participants randomized to this arm will receive diet and exercise education at monthly intervals with a study clinician or coordinator.
3072703|NCT01222494|Experimental|Antipsychotic Treated Weekly BWL|Antipsychotic treated participants randomized to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
3072704|NCT01222494|Active Comparator|Non-antipsychotic Treated Weekly BWL|Participants assigned to this arm will engage in an evidence-based, 16 week manualized behavioral weight loss intervention that includes weekly meetings and phone check-ins with a trained study therapist.
3072705|NCT01222507||Brain Speed Test|60 subjects who complete 60 Second Brain Game and Brain Speed Test
3072706|NCT01222520|Experimental|Telmisartan and amlodipine FDC|once a daily
3072707|NCT01222520|Active Comparator|Telmisartan monotherapy|once a daily
3072708|NCT01222533|Experimental|Tiotropium low|Tiotropium inhalation solution low dose
3072709|NCT01222533|Experimental|Tiotropium medium|Tiotropium inhalation solution medium dose
3072710|NCT01222533|Experimental|Tiotropium high|Tiotropium inhalation solution high dose
3072711|NCT01222533|Active Comparator|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
3072712|NCT01222533|Placebo Comparator|Tiotropium placebo|Placebo inhalation solution
3072713|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 1)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 54 Gy; Stereotactic Boost to Primary: 10 Gy; Total Dose to Primary: 64 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3072714|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 2)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 50 Gy; Stereotactic Boost to Primary: 15 Gy; Total Dose to Primary: 65 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3072715|NCT01222572|Experimental|Stereotactic Boost to Chemoradiotherapy (Dose Level 3)|"Chemotherapy: Etoposide 50 mg/m2, d1-5, 29-33 and Cisplatin 50 mg/m2, d1, 8, 29, 36; Conventional RT Dose to Primary: 46 Gy; Stereotactic Boost to Primary: 20 Gy; Total Dose to Primary: 66 Gy~- Patients were to start radiation to the primary tumor site and to the lymph nodes and chemotherapy in the same week. The treatment was identical to standard chemotherapy and radiation treatment until the 5th week. During the fifth week, patents would undergo another radiation mapping session to prepare for the stereotactic boost. After that, the radiation treatments to the lymph nodes would continue but the radiation treatment to the primary cancer site would stop until the last week (week 7). During week 7, participants would receive 2 doses of stereotactic radiotherapy to the site of the primary tumor instead of the lower doses of radiotherapy that they were treated with up to that point."
3072716|NCT01222585|Experimental|Treatment|Intravenous metronidazole loading dose 15 mg/kg followed by 7.5 mg/kg every 12-24 hours
3072717|NCT01222689|Experimental|Treatment (erlotinib hydrochloride, selumetinib)|Patients receive selumetinib PO QD and erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3072718|NCT01222715|Experimental|Arm I (vinorelbine tartrate, cyclophosphamide, bevacizumab)|Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8 and cyclophosphamide IV over 30-60 minutes on day 1. Patients also receive bevacizumab IV over 30-90 minutes on day 1.
3072719|NCT01222715|Experimental|Arm II (vinorelbine tartrate, cyclophosphamide, temsirolimus)|Patients receive vinorelbine tartrate and cyclophosphamide as in arm I. Patients also receive temsirolimus IV over 30-60 minutes on days 1, 8, and 15.
3072720|NCT01222767|Experimental|Arm 1|
3072721|NCT01222832|Experimental|Bacitracin|Nasopore sponge soaked in Bacitracin, no oral antibiotics
3072722|NCT01222832|No Intervention|Saline|Nasopore sponge soaked in saline, routine oral antibiotics
3072723|NCT01222884|Active Comparator|Iron isomaltoside 1000|Iron isomaltoside 1000 (Monofer)administered as 500 mg intravenous single bolus injections OR administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
3072724|NCT01222884|Active Comparator|Iron sucrose|Iron sucrose administered as 500 mg fractionated (100mg+200mg+200mg) intravenous bolus injection
3072725|NCT01223027|Experimental|Dovitinib + best supportive care (BSC)|Patients randomized to the dovitinib treatment arm received 500 mg of dovitinib orally on 5 days on/2 days off dosing schedule.
3072726|NCT01223027|Active Comparator|Sorafenib + BSC|Patients in the sorafenib control arm received400 mg of sorafenib (2 x 200 mg tablets) orally taken twice daily.
3072727|NCT01223183|Active Comparator|isotonic saline then hypertonic saline|Subjects inhaled nebulized isotonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized 7% hypertonic saline on study day 2.
3072728|NCT01223183|Active Comparator|hypertonic saline then isotonic saline|Subjects inhaled nebulized 7% hypertonic saline on study day 1, and then after a 5-24 day washout period, subjects inhaled nebulized isotonic saline on study day 2.
3072729|NCT01223196|Placebo Comparator|Placebo|One arm of the study subjects will be treated with Placebo only, once a day, for 6 months
3072730|NCT01223196|Active Comparator|Pioglitazone|One arm of the study subjects will be treated with Pioglitazone, 15mg, once a day, for 6 months
3072731|NCT01223235|Experimental|bevacizumab & polyvalent vaccine-KLH conjugate + OPT-821|This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
3072732|NCT01223352|Experimental|Bosentan 2 mg/Kg t.i.d.|2 mg/kg bosentan administered three times a day (morning, afternoon, evening) for a planned duration of 24 weeks
3072733|NCT01223352|Experimental|Bosentan 2 mg/Kg b.i.d.|2 mg/kg bosentan administered twice daily (morning and evening) for a planned duration of 24 weeks
3072734|NCT01223365|Experimental|Hydrocodone ER|Participants were titrated (or re-titrated for roll-over participants) at escalating dosages of extended-release hydrocodone tablets at dosages of 15, 30, 45, 60, or 90 mg orally every 12 hours until deemed successful for managing their pain during the open-label titration period. Once a successful dose was identified, participants entered the 52 week open-label treatment period in which hydrocodone ER was administered at the successful dose (15, 30, 45, 60, or 90 mg) every 12 hours.
3072735|NCT01223378|Experimental|BOL-303259-X|ophthalmic solution
3072736|NCT01223378|Active Comparator|Latanoprost|ophthalmic solution
3072737|NCT01223404|Experimental|Placebo, Nicotine, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
3072738|NCT01223404|Experimental|Nicotine, Placebo, Mecamylamine|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (mecamylamine), a placebo patch and a mecamylamine capsule is administered."
3072739|NCT01223404|Experimental|Placebo, Mecamylamine, Nicotine|"Participants undergo 3 test sessions:~In the first session (placebo), a placebo patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
3072740|NCT01223404|Experimental|Nicotine, Mecamylamine, Placebo|"Participants undergo 3 test sessions:~In the first session (nicotine), a nicotine patch and a placebo capsule is administered.~In the second session (mecamylamine), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
3072741|NCT01223404|Experimental|Mecamylamine, Placebo, Nicotine|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (placebo), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (nicotine), a nicotine patch and a placebo capsule is administered."
3072742|NCT01223404|Experimental|Mecamylamine, Nicotine, Placebo|"Participants undergo 3 test sessions:~In the first session (mecamylamine), a placebo patch and a mecamylamine capsule is administered.~In the second session (nicotine), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.~In the third session (placebo), a placebo patch and a placebo capsule is administered."
3072743|NCT01223469|Experimental|Atrial Fibrillation|
3072744|NCT01223469|Experimental|Right-sided Supraventricular Tachycardia|
3072745|NCT01223703|Active Comparator|n-3 PUFAs|
3072746|NCT01223703|Placebo Comparator|Placebo|
3072747|NCT01223937|Experimental|Desmopressin 25 μg|Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
3072748|NCT01223937|Placebo Comparator|Placebo|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
3072749|NCT01223963||Macrolane|Women that have had breast enhancement with Macrolane Volume Restoration Factor.
3072750|NCT01224015|Other|onabotulinumtoxinA 24U|24 units (U) onabotulinumtoxinA (botulinum toxin Type A) total dose and placebo injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3072751|NCT01224015|Placebo Comparator|placebo (normal saline)|Normal Saline (placebo) injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3072752|NCT01224015|Experimental|onabotulinumtoxinA 44U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
3072753|NCT01224145|Experimental|Drug: Bupivacaine Collagen Sponge|bupivacaine collagen sponges
3072754|NCT01224158|Experimental|PR-009577 Toothbrush|Experimental Power Toothbrush
3072755|NCT01224158|Active Comparator|PR-000172 Toothbrush|Flat trimmed Manual Toothbrush
3072756|NCT01224171|Placebo Comparator|Placebo|Participants received placebo intravenous infusion at Weeks 0, 2 and 6.
3072757|NCT01224171|Experimental|Vedolizumab|Participants received 300 mg intravenous vedolizumab at Weeks 0, 2, and 6.
3072758|NCT01224210|Other|Ambrisentan (24 Weeks), Extension (4 Weeks)|Open Label Ambrisentan
3072759|NCT01224236|Experimental|iron supplementation|2 mg/kg/day of elemental iron as a multivitamin with iron solution
3072760|NCT01224236|Sham Comparator|control|multivitamin solution without iron
3072761|NCT01224431|Experimental|Buffered lidocaine J-tip|Needleless injection of buffered lidocaine prior to lumbar puncture versus placebo (Normal saline)
3072762|NCT01224431|Placebo Comparator|Normal saline J-tip|Needleless injection of normal saline (placebo) prior to lumbar puncture versus use of buffered lidocaine
3072763|NCT01224444||All adenomatous polyps|Standard polypectomy snare of adenomatous polyps (included serrated adenomas) from ≤5mm to ≤20mm.
3072764|NCT01224626||Zyvox (linezolid)|Patients who have been treated with Zyvox (linezolid).
3072765|NCT01224639|Experimental|Group 1: Low Dose; SC|TDV-1: 8 x 10^3 Plaque Forming Units (PFU), TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
3072766|NCT01224639|Experimental|Group 2: Low Dose; ID|TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, TDV-4: 2 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
3072767|NCT01224639|Experimental|Group 3: High Dose; SC|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered subcutaneously on Days 0 and 90. Dose volume is 0.5 mL.
3072768|NCT01224639|Experimental|Group 4: High Dose; ID|TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, TDV-4: 3 x 10^5 PFU or placebo administered intradermally on Days 0 and 90. Dose volume is 0.1 mL.
3072769|NCT01224639|Placebo Comparator|Placebo (SC)|Phosphate buffered saline administered subcutaneously in a volume of 0.5 mL.
3072770|NCT01224639|Placebo Comparator|Placebo (ID)|Phosphate buffered saline administered intradermally in a dose volume of 0.1 mL.
3072771|NCT01224678|Placebo Comparator|Placebo|Patients receive oral placebo once daily for 12 months.
3072772|NCT01224678|Experimental|Vitamin D|Patients receive oral vitamin D (2000 IU) once daily for 12 months.
3072773|NCT01224782||Chronic Kidney Disease, Secondary Hyperparathyroidism|All eligible participants with chronic kidney disease stage 3 and 4 and secondary hyperparathyroidism treated with Zemplar (paricalcitol) capsules according to the local marketing authorization
3072774|NCT01224821|Experimental|Tositumomab and Iodine I-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
3072775|NCT01224925|Active Comparator|Capping over carious exposure with Dycal|Total caries removal. In case of pulp exposure Direct Pulp capping with (Dycal®, Dentsply DeTrey GmbH, Konstanz, Germany)
3072776|NCT01224925|Experimental|Capping over carious exposure with WMTA|Total caries removal. In case of pulp exposure Direct Pulp capping with Mineral Trioxide Aggregate White ProRoot® (WMTA) (DENTSPLY, Tulsa Dental, Tulsa, OK, USA)
3072777|NCT01225029|No Intervention|Standard Fluids|Term neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
3072778|NCT01225029|Experimental|Restricted Fluids|Term neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
3072779|NCT01225055|Experimental|Teriparatide|Teriparatide alone with sham vibration
3072780|NCT01225055|Experimental|Vibration|Vibration alone with placebo-teriparatide
3072781|NCT01225055|Experimental|Teriparatide and vibration|Teriparatide with vibration applied in conjuction
3072782|NCT01225068|Experimental|Milnacipran|milnacipran 50 mg bid; can be increased to 100 mg bid
3072783|NCT01225068|Placebo Comparator|Placebo|Placebo
3072784|NCT01225146|Active Comparator|Treatment Experienced (Cohort 1|"Previously treated with 6 or more intravitreal ranibizumab with persistent edema followed in RAVE 1 (FVF3348s).~Cohort 1 patients will receive 1 dose of ranibizumab 2.0 mg, followed by PRN based on pre-defined retreatment criteria"
3072785|NCT01225146|Active Comparator|Treatment Naive (Cohort 2)|Treatment naïve. Cohort 2 patients will receive 6 doses of ranibizumab 2.0 mg, followed by PRN based on pre-defined re-treatment criteria.
3072786|NCT01225159|Experimental|Tight glycaemic control (TGC)|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
3072787|NCT01225159|Placebo Comparator|Conventional glycaemic control (Control)|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
3072788|NCT01225172|Experimental|BMS-754807|
3072789|NCT01225172|Experimental|BMS-754807 + letrozole|
3072790|NCT01225211|Placebo Comparator|Cohort 1: Placebo|Participants homozygous (HO) for the F508del-CF transmembrane conductance regulator gene (CFTR) mutation received lumacaftor matched placebo once daily (qd) (Day 1 through Day 14), followed by lumacaftor matched placebo qd in combination with ivacaftor matched placebo every 12 hours (q12h) (Day 15 through Day 21).
3072791|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 150 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 milligram (mg) of lumacaftor (LUM) qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 150 mg of ivacaftor (IVA) q12h (Day 15 through Day 21).
3072792|NCT01225211|Experimental|Cohort 1: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 14), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 15 through Day 21).
3072793|NCT01225211|Placebo Comparator|Cohort 2 and 3: Placebo (HO and HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo qd (Day 1 through Day 28), followed by lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 29 through Day 56).
3072794|NCT01225211|Experimental|Cohort 2: LUM 200 mg qd/LUM 200 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 200 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 200 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3072795|NCT01225211|Experimental|Cohort 2: LUM 400 mg qd/LUM 400 mg qd+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 400 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3072796|NCT01225211|Experimental|Cohort 2: LUM 600 mg qd/LUM 600 mg qd+IVA 250 mg q12h (HO&HE)|Participants homozygous or heterozygous for the F508del-CFTR mutation received 600 mg of lumacaftor alone qd (Day 1 through Day 28), followed by 600 mg of lumacaftor qd in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3072797|NCT01225211|Experimental|Cohort 3: LUM 400 mg q12h/LUM 400 mg q12h+IVA 250 mg q12h (HO)|Participants homozygous for the F508del-CFTR mutation received 400 mg of lumacaftor alone q12h (Day 1 through Day 28), followed by 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 29 through Day 56).
3072798|NCT01225211|Placebo Comparator|Cohort 4: Placebo|Participants heterozygous for the F508del-CFTR mutation received lumacaftor matched placebo in combination with ivacaftor matched placebo q12h (Day 1 through Day 56).
3072799|NCT01225211|Experimental|Cohort 4: LUM 400 mg q12h+IVA 250 mg q12h|Participants heterozygous for the F508del-CFTR mutation received 400 mg of lumacaftor q12h in combination with 250 mg of ivacaftor q12h (Day 1 through Day 56).
3072800|NCT01225250|Experimental|Polydioxanone (PDS) plates|15 subjects will be randomized to receive a caudal septal extension graft using a PDS plated cartilagenous graft
3072801|NCT01225250|Other|Non-plated cartilagenous graft|15 subjects will be randomized to receive a cartilagenous caudal septal extension fgraft
3072802|NCT01225263|Experimental|Simvastatin and vitamin D|Participants in this arm will receive simvastatin + vitamin D.
3072803|NCT01225263|Placebo Comparator|"Placebo Sugar Pill"|"Participants in this arm will take placebo pills, which look like the simvastatin and vitamin D. A placebo pill has no active medication in it, and is like taking a sugar pill."
3072804|NCT01225289|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with MS confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
3072805|NCT01225289|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo per day
3468850|NCT03892018|Active Comparator|Fed/ Fasted Treatment Sequence|"Subjects will be assigned a fed/fasted sequence.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose."
3072808|NCT01225354|Experimental|Calcium hydroxylapatite|Subject will be treated at baseline and, if needed, at 2 weeks.
3072809|NCT01225549|Experimental|1|AZD5423 75ug
3072810|NCT01225549|Experimental|2|AZD5423 300ug
3072811|NCT01225549|Active Comparator|3|Budesonide 200 microgram
3072812|NCT01225549|Placebo Comparator|4|Placebo
3072813|NCT01225562|Experimental|1|Oral Treatment
3072814|NCT01225562|Experimental|2|Oral Treatment
3072815|NCT01225562|Placebo Comparator|3|Oral Treatment
3072816|NCT01225731|Experimental|Part 1: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, subcutaneously (SC) at Weeks 0 and 4
3072817|NCT01225731|Experimental|Part 1: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, at Weeks 0 and 4
3072818|NCT01225731|Experimental|Part 1: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, at Weeks 0 and 4
3072819|NCT01225731|Experimental|Part 1: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, at Weeks 0 and 4
3072820|NCT01225731|Placebo Comparator|Part 1: Placebo|Participants receive placebo, SC, at Weeks 0 and 4
3072821|NCT01225731|Experimental|Part 2: Tildrakizumab 5 mg|Participants receive tildrakizumab 5 mg, SC, every 12 weeks for up to 36 weeks
3072822|NCT01225731|Experimental|Part 2: Tildrakizumab 25 mg|Participants receive tildrakizumab 25 mg, SC, every 12 weeks for up to 36 weeks
3072823|NCT01225731|Experimental|Part 2: Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg, SC, every 12 weeks for up to 36 weeks
3072824|NCT01225731|Experimental|Part 2: Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg, SC, every 12 weeks for up to 36 weeks
3072825|NCT01225731|No Intervention|Part 3: Tildrakizumab 5 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3072826|NCT01225731|No Intervention|Part 3: Tildrakizumab 25 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3072827|NCT01225731|No Intervention|Part 3: Tildrakizumab 100 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3072828|NCT01225731|No Intervention|Part 3: Tildrakizumab 200 mg Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3072829|NCT01225731|No Intervention|Part 3: Placebo Follow-up|Participants are followed for up to 20 weeks after the last dose of study drug.
3072830|NCT01225822|Experimental|BIBR 1048 50 mg bis in die(b.i.d)|BIBR 1048 50 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus one placebo matching enoxaparin 0 mg once a day for the treatment period
3072831|NCT01225822|Experimental|BIBR 1048 150 mg b.i.d|BIBR 1048 150 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3072832|NCT01225822|Experimental|BIBR 1048 225 mg b.i.d|BIBR 1048 225 mg b.i.d twice a day plus two capsules of placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3072833|NCT01225822|Experimental|BIBR 1048 300 mg quaque die(q.d)|BIBR 1048 150 mg q.d once a day plus placebo matching BIBR 1048 0 mg twice a day plus placebo matching enoxaparin 0 mg once a day for the treatment period
3072834|NCT01225822|Active Comparator|Enoxaparin 40 mg subcutaneous(s.c)|placebo matching BIBR 1048 0 mg twice a day plus enoxaparin 40 mg s.c once a day for the treatment period
3072835|NCT01225835|Experimental|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
3072836|NCT01225835|Active Comparator|Follitrophin Alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
3072837|NCT01225887|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072838|NCT01225926|Experimental|Toric T3 - T9|AcrySof IQ Toric IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
3072839|NCT01225926|Active Comparator|IQ SN60WF|AcrySof IQ IOL surgically implanted in the capsular bag of the eye following cataract removal. Both eyes were implanted, with the second eye implanted at least 1 week after and within 1 month of the first eye.
3072840|NCT01225952|Experimental|Crystalens AO|Bausch & Lomb silicone multi-piece accommodating IOL is a modified plate haptic lens
3072841|NCT01225952|Active Comparator|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
3072842|NCT01225952|Active Comparator|AMO Tecnis Multifocal|A foldable hydrophobic acrylic IOL,(Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL
3072843|NCT01225991|Experimental|Milnacipran, active drug, open-label|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day, or to their maximum tolerated dose in the course of the first week. The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day). Final efficacy assessments will be made at the termination visit, and the study medication will be tapered down following 12 weeks of drug treatment.
3072844|NCT01226043|Experimental|Lantus (insulin glargine) vial & syringe|10 mL vial, 1000 U per vial for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
3072845|NCT01226043|Experimental|Lantus (insulin glargine) SoloSTAR pen|3 mL SoloSTAR pre-filled disposable insulin delivery device (pen), 300 U per device for subcutaneous administration once a day. Starting dose will be 0.2 Unit per kilogram of body weight.
3072846|NCT01226095||Osteoarthritic patients|Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
3072847|NCT01226121|Active Comparator|Day 1 manipulation|Finger manipulation one day following Clostridial collagenase injectable
3072848|NCT01226121|Active Comparator|Day 2 manipulation|Finger manipulation two days following Clostridial collagenase injectable
3072849|NCT01226121|Active Comparator|Day 4 manipulation|Finger manipulation four days following Clostridial collagenase injectable
3072850|NCT01226420|Experimental|Alefacept|Alefacept iv
3072851|NCT01226459|Experimental|Minoxidil Foam|5% Minoxidil Topical Foam
3072852|NCT01226459|Placebo Comparator|Vehicle Foam|Vehicle Topical Foam
3072853|NCT01226472|Experimental|KW-0761|
3072854|NCT01226485|Experimental|Taladegib|"Part A Cohort 1: 50 milligram (mg) taladegib administered orally QD on a 28-day cycle.~Part A Cohort 2: 100 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 3: 200 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 4: 400 mg taladegib administered orally QD on a 28-day cycle.~Part A Cohort 5: 600 mg taladegib administered orally QD on a 28-day cycle.~Part C: 400 mg taladegib administered orally QD. Participants with advanced solid tumors.~Part D: 400 mg taladegib administered orally QD. Participants with advanced basal cell carcinoma (BCC)."
3072855|NCT01226511|Experimental|Duloxetine|30-120 mg flexible dosing once daily for 10 weeks. At the end of the 10 week blinded treatment period, participants may participate in an 18 week extension
3072856|NCT01226511|Placebo Comparator|Placebo|Administered once daily for 10 weeks. At the end of the 10 week blinded treatment period, placebo participants receive duloxetine in the 18 week extension
3072857|NCT01226706|Placebo Comparator|Placebos|Placebo injected into the detrusor at Day 1,
3072858|NCT01226706|Experimental|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
3072859|NCT01226719|Experimental|FOLFOXIRI+panitumumab regimen|"All patients will receive the FOLFOXIRI/panitumumab regimen, with drugs administered in the following order:~Panitumumab~Oxaliplatin~Irinotecan~Leucovorin~5-Fluorouracil"
3072860|NCT01226732|Experimental|Dose Level 1|Hsp90 Inhibitor AUY922: 22mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3072861|NCT01226732|Experimental|Dose Level 2|Hsp90 Inhibitor AUY922: 28mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3072862|NCT01226732|Experimental|Dose Level 3|Hsp90 Inhibitor AUY922: 40mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3072863|NCT01226732|Experimental|Dose Level 4|Hsp90 Inhibitor AUY922: 55mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3072864|NCT01226732|Experimental|Dose Level 5|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1000mg/m2 PO BID d 1-14 of 21-day cycles
3072865|NCT01226732|Experimental|Dose Level 6|Hsp90 Inhibitor AUY922: 70mg/m2 IV days 1, 8, and 15 of 21-day cycles Capecitabine: 1250mg/m2 PO BID d 1-14 of 21-day cycles
3072866|NCT01226745|Experimental|ONO-4641 0.15 milligram (mg) - 0.15 mg|
3072867|NCT01226745|Experimental|ONO-4641 0.10 mg - 0.10 mg|
3072868|NCT01226745|Experimental|ONO-4641 0.05 mg - 0.05 mg|
3072869|NCT01226745|Experimental|Placebo - ONO4641 0.15 mg|
3072870|NCT01226745|Experimental|Placebo - ONO4641 0.10 mg|
3072871|NCT01226745|Experimental|Placebo - ONO4641 0.05 mg|
3072872|NCT01226914|Placebo Comparator|Placebo|For subjects in the placebo group, saline was drawn into the applicator and aerosolized in a similar fashion; it was allowed to remain in the wound during closure.
3072873|NCT01226914|Experimental|Evicel|For subjects in the treatment group, Evicel was applied in the usual manner by study personnel, with 5mL of each component drawn into a two-barrel syringe device and aerosolized using a pedal-controlled inert gas supply.
3072874|NCT01226979|Experimental|HDRBT (High Dose Rectal Brachytherapy)|Radiation: High-dose endorectal brachytherapy The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer. A daily dose of 6.5 Gy over four consecutive days
3072875|NCT01227005|Active Comparator|Whole Blood|Whole Blood plus pooled platelets
3072876|NCT01227005|Active Comparator|Component Therapy|Red blood cells, plasma, platelets
3072877|NCT01227018|Experimental|STA-9090|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3072878|NCT01227044|Active Comparator|NTX + MM/MC|Naltrexone + Medical Management/Medication Coaching
3072879|NCT01227044|Placebo Comparator|Placebo + MM/MC|Placebo plus Medical Management/Medication Coaching
3072880|NCT01227057|Experimental|Arm 1: Cognitive Rehabilitation|Cognitive rehabilitation and exposure therapy for hoarding
3072881|NCT01227057|Active Comparator|Arm 2: Case Management|Case management
3072882|NCT01227252|Experimental|LY2886721|
3072883|NCT01227252|Placebo Comparator|Placebo|
3072884|NCT01227265|Experimental|Preladenant 2 mg|Participants received 2 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
3072885|NCT01227265|Experimental|Preladenant 5 mg|Participants received 5 mg as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extension trial or return for a follow-up visit two (2) weeks later.
3072886|NCT01227265|Placebo Comparator|Placebo|Participants received preladenant-matching placebo as a single oral dose twice daily for 12 weeks. Participants could then enroll in an extention trial or return for a follow-up visit two (2) weeks later.
3072887|NCT01227278|Placebo Comparator|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
3072888|NCT01227278|Experimental|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
3072889|NCT01227382|Other|ERCP with Cholangiopancreatoscopy|The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.
3072890|NCT01227395||Azithromycin|Patients taking Azithromycin.
3072891|NCT01227421|Active Comparator|Nitazoxanide, Placebo|300 mg nitazoxanide tablet and 1 placebo tablet twice daily for 5 days
3072892|NCT01227421|Active Comparator|Nitazoxanide, Nitazoxanide|Two 300 mg nitazoxanide tablets(600mg) twice daily for 5 days
3072893|NCT01227421|Placebo Comparator|Placebo|2 placebo tablets twice daily for 5 days
3072894|NCT01227434|Experimental|Surgical Group|PD 0332991 125 mg daily for 7 days prior to an indicated, intended surgical resection as clinical care for progression, and then resume drug at the same dose after recovery from surgery on a repeating schedule of 21 consecutive days of drug followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
3072895|NCT01227434|Experimental|Non-surgical group|Patients not in need of surgery treated with PD 0332991 125 mg daily for 21 consecutive days followed by a 7 day break off therapy (cycle length is 28 days). Treatment will be repeated every 28 days, and in the absence of disease progression patients may receive treatment for 12 cycles. At that time patients will be given the option to continue on study past 12 cycles, up to a maximum of 24 cycles.
3072896|NCT01227512|Experimental|Tolvaptan 15-60mg|Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.
3072897|NCT01227512|Active Comparator|Fluid Restriction|Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.
3072898|NCT01227551|Experimental|Intratumoral injection|Each patient will receive 4 separate Coxsackievirus A21 (CVA21) administrations in the first 8 days on trial (Days 1, 3, 5 and 8), followed by a fifth dose 2 weeks later (Day 22) and further administrations at 3 weekly intervals (Days 43, 64, 85, 106 and 127, up to a maximum of 10 sets of injections) until confirmed disease progression or development of excessive toxicity. Subjects with stable disease or better at Day 127 were eligible to receive up 9 more sets of CVA21 administrations under an extension protocol (VLA-008).
3072899|NCT01227564|Experimental|ACC-001 3 μg/ QS-21 50 μg|
3072900|NCT01227564|Experimental|ACC-001 10 μg/ QS-21 50 μg|
3072901|NCT01227564|Placebo Comparator|Placebo- Phosphate buffered saline (PBS)|
3072902|NCT01227577|Experimental|Nilotinib|Participants received 300 mg twice daily (b.i.d.). Dose increases to 400 b.i.d. were permitted, per Investigator's discretion.
3072903|NCT01227616|Experimental|Ferumoxytol|Intravenous (IV) iron
3072904|NCT01227616|Active Comparator|IV Iron Sucrose|Intravenous (IV) iron
3072905|NCT01227629|Experimental|dabigatran 50 mg twice daily (bid)|Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).
3072906|NCT01227629|Experimental|dabigatran 50 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.
3072907|NCT01227629|Experimental|dabigatran 50 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3072908|NCT01227629|Experimental|dabigatran 150 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
3072909|NCT01227629|Experimental|dabigatran 150 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3072910|NCT01227629|Experimental|dabigatran 150 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3072911|NCT01227629|Experimental|dabigatran 300 mg bid|Dabigatran: one capsule in the morning and 1 capsule in the evening
3072912|NCT01227629|Experimental|dabigatran 300 mg bid + 81 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3072913|NCT01227629|Experimental|dabigatran 300 mg bid + 325 mg ASA qd|Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning
3072914|NCT01227629|Active Comparator|warfarin|once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0
3072915|NCT01227655|Experimental|BIA 9-1067 25 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 25 mg once daily (QD).
3072916|NCT01227655|Experimental|BIA 9-1067 50 mg once daily (QD).|BIA 9-1067, OPC, Opicapone 50 mg once daily (QD).
3072917|NCT01227655|Placebo Comparator|Placebo|PLC, Placebo
3072918|NCT01227668|Experimental|Aripiprazole|
3072919|NCT01227668|Placebo Comparator|Placebo|
3072920|NCT01227681|Experimental|high dose G-CSF|high dose group: 3.3ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
3072921|NCT01227681|Active Comparator|low dose G-CSF|low dose group: 1.65ug/kg/day for consecutive 5 days of each 60 day cycle (6 cycles)
3072922|NCT01227681|Placebo Comparator|placebo|Sodium Chloride (NaCl) 0.9 %
3072923|NCT01227707|Experimental|Single Arm|
3072924|NCT01227785||INCEPTA ICD and CRT-D|ICD and CRT-D indicated patients were included in the study. Overall patient population, CRT-D or ICD populations, and patients experiencing or not experiencing a protocol-defined heart failure event were included (dependent on outcomes measured).
3072925|NCT01227824|Experimental|GSK1349572 (N=~394)|GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily
3072926|NCT01227824|Active Comparator|raltegravir (N=~394)|raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily
3072927|NCT01227889|Experimental|GSK2118436|Subjects in this arm will receive GSK2118436 150 mg twice daily.
3072928|NCT01227889|Active Comparator|Dacarbazine (DTIC)|Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks
3072929|NCT01227889|Experimental|Crossover|Subjects who initially receive DTIC will be allowed to receive GSK2118436 after initial progression.
3072930|NCT01227902|Experimental|Retigabine IR|Open Label flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
3072931|NCT01227928|Experimental|pazopanib|experimental medication
3072932|NCT01227928|Placebo Comparator|placebo|placebo comparator
3072933|NCT01227954|Other|WBRT with Hippocampal Avoidance|Whole brain radiotherapy (WBRT) with hippocampal avoidance using intensity-modulated radiation therapy (IMRT)
3072934|NCT01227967|Experimental|Combination Therapy|Amantadine, Ribavirin, Oseltamivir
3072935|NCT01227967|Active Comparator|Oseltamivir monotherapy|Oseltamivir
3072936|NCT01227980|Active Comparator|Pexacerfont|Pexacerfont was given orally as a loading dose of 300 mg/day for 1 week, followed by 100mg/day for 16-20 days
3072937|NCT01227980|Placebo Comparator|Placebo|Oral placebo was given during the 1-week loading dose phase, and during the next 16-20 days
3072938|NCT01227993|Experimental|Finasteride|Participants are treated with 5 mg oral finasteride daily when they have clinically significant subretinal fluid accumulation, defined as any subretinal fluid in the macula with a volume of at least 0.1 microliter and causing visual change such as reduced acuity, metamorphopsia, or microperimetry deficits.
3072939|NCT01228019||All participants|Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)
3072940|NCT01228071|Experimental|40 mg daily dose of testosterone gel 2%|testosterone gel 2%
3072941|NCT01228084|Experimental|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
3072942|NCT01228149|Active Comparator|Diamox/DexaEDO|Patients receive Diamox (oral acetazolamide) starting 28 days Prior to trabeculectomy. 7 days preoperatively DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally. Patient will undergo trabeculectomy.
3072943|NCT01228149|Experimental|Cosopt S|Patients receive Cosopt S (dorzolamide/timolol) eye drops starting 28 days before trabeculectomy.
3072944|NCT01228175|Active Comparator|Varenicline|Varenicline
3072945|NCT01228175|Placebo Comparator|Microcrystal Cellulose|Microcrystal cellulose placebo
3072946|NCT01228318|Experimental|Zoledronic acid|Subjects in this arm will receive 5 milligram (mg) per 100 milliliter (mL) solution of zoledronic acid infused intravenously over 15-30 minutes under the supervision of study personnel.
3072947|NCT01228318|Placebo Comparator|Placebo|Subjects in the placebo arm will receive placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution administered iv over 15-30 minutes under the supervision of study personnel.
3072948|NCT01228435|Experimental|ALK-inhibitor naive|No prior exposure to ALK-inhibitor
3072949|NCT01228435|Experimental|ALK-inhibitor pre-treated|Prior exposure to ALK inhibitor
3072950|NCT01228591|Other|Acuvue Advance Plus/ Acuvue Advance|Acuvue Advance Plus contact lenses worn first period and Acuvue Advance contact lenses worn second.
3072951|NCT01228591|Other|Acuvue Advance/Acuvue Advance Plus|Acuvue Advance contact lenses worn first period and Acuvue Advance Plus contact lenses worn second.
3072952|NCT01228734|Experimental|Cetuximab + FOLFOX-4|Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
3072953|NCT01228734|Active Comparator|FOLFOX-4|Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
3072954|NCT01228747|Placebo Comparator|Placebo|Matching placebo for 28 weeks
3072955|NCT01228747|Experimental|Levetiracetam|Levetiracetam treatment with flexible dosing of 1000 mg/day or 2000 mg/day or 3000 mg/day for 28 weeks
3072956|NCT01228903|Placebo Comparator|Control|Patients who are randomized to this group will received placebo tablets. Placebo tables do not contain an active ingredient. This group will be used as a baseline group to compare the effects of lowering uric acid on vascular function.
3072957|NCT01228903|Active Comparator|Allopurinol|Patients who are randomized to this group will receive allopurinol tablets. Allopurinol is a medicine that lowers uric acid levels. The effects of lowering uric acid on vascular function outcomes will be assessed and compared to the control group.
3072958|NCT01228929|Experimental|Normal|Subjects with no clinical diagnosis or symptoms of dry eye.
3072959|NCT01228929|Experimental|Aqueous Deficiency Dry Eye (ADDE)|Subjects with low tear volume measured by Schirmer's test less than 10 mm.
3072960|NCT01228929|Experimental|Meibomian Gland Dysfunction (MGD)|Subjects having mild to moderate Meibomian Gland Dysfunction by slit lamp evaluation.
3072961|NCT01228968||Volunteers|Volunteers will have a range of body mass index from 19 - 45 kilogram per square meter. In order to fit in the magnetic resonance scanner subjects must weigh less than 300 pounds.
3072962|NCT01229111|Experimental|Treatment (cediranib maleate and modified FOLFOX)|Patients receive cediranib maleate PO QD on days 1-14 and modified FOLFOX6 comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1.
3072963|NCT01229150|Active Comparator|KRAS Mut 2|KRAS Mutant patients randomized to combination therapy arm
3072964|NCT01229150|Active Comparator|KRAS Mut 1|KRAS Mutant patients randomized to monotherapy arm
3072965|NCT01229150|Active Comparator|WT KRAS 1|Wild-Type KRAS patients randomized to monotherapy arm
3072966|NCT01229150|Active Comparator|WT KRAS 2|Wild-Type KRAS patients randomized to combination therapy arm
3072967|NCT01229176|Experimental|Vi-CRM, Adults|Adults (18 to 45 years) receiving 1 dose of NVGH Vi-CRM197 vaccine
3072968|NCT01229176|Active Comparator|Vi-PS, Adults|Adults (18 to 45 years) receiving 1 dose of licensed Vi Polysaccharide vaccine
3072969|NCT01229176|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3072970|NCT01229176|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
3072971|NCT01229176|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3072972|NCT01229176|Active Comparator|PNC13, Older infants|Older Infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
3072973|NCT01229176|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
3072974|NCT01229176|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
3072975|NCT01229228|Experimental|Naproxen Test (lower dose)|200-mg
3072976|NCT01229228|Experimental|Naproxen Test (upper dose)|400-mg (2 x 200-mg)
3072977|NCT01229228|Active Comparator|Naprosyn 250 mg|
3072978|NCT01229228|Active Comparator|Naprosyn 500 mg|
3072979|NCT01229228|Placebo Comparator|Placebo|
3072980|NCT01229254|Experimental|Amiodarone|Participants on betrixaban 30 mg and concomitant baseline amiodarone
3072981|NCT01229254|Experimental|Betrixaban 60 mg|Participants with lower weights
3072982|NCT01229254|Experimental|Betrixaban 90 mg|Participants with higher weights
3072983|NCT01229267|Experimental|V212 Consistency Lot 1|Participants randomized to receive V212 consistency Lot 1 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3072984|NCT01229267|Experimental|V212 Consistency Lot 2|Participants randomized to receive V212 consistency Lot 2 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3072985|NCT01229267|Experimental|V212 Consistency Lot 3|Participants randomized to receive V212 consistency Lot 3 given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3072986|NCT01229267|Experimental|V212 High Antigen Lot|Participants randomized to receive V212 High Antigen Lot given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3072987|NCT01229267|Placebo Comparator|Placebo|Participants randomized to receive matching placebo given as a 0.5 mL subcutaneous injection at 30 days before and 30, 60, and 90 days after auto-HCT.
3072988|NCT01229371|Active Comparator|Subjects ≥18 to ≤60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group A will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3072989|NCT01229371|Active Comparator|Subjects >60 Years - CSL HA Antigen|Inflexal V influenza vaccine (CSL HA Antigen) 2010 Group B will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011 containing per 0.5 mL i.m. dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3072990|NCT01229371|Experimental|Subjects ≥18 to ≤60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group C will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3072991|NCT01229371|Experimental|Subjects >60 Years - AdImmune HA Antigen|Inflexal V influenza vaccine (AdImmune HA Antigen) 2010/2011 Group D will be vaccinated with Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 containing per 0.5 mL i.m.dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
3072992|NCT01229397|Active Comparator|Inflexal V 0.25 mL x 2|
3072993|NCT01229397|Experimental|Inflexal V 0.5 mL x 1|
3072994|NCT01229410|Experimental|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
3072995|NCT01229410|Experimental|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
3072996|NCT01229423|Experimental|LATISSE®|bimatoprost 0.03% (LATISSE®)
3072997|NCT01229436|Experimental|Xiapex Injection|
3072998|NCT01229449|Experimental|Ibuprofen/acetaminophen (lower dose)|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
3072999|NCT01229449|Experimental|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
3073000|NCT01229449|Active Comparator|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
3073001|NCT01229449|Active Comparator|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
3073002|NCT01229449|Placebo Comparator|Placebo|Two placebo tablets
3073003|NCT01229462|Other|Combigan®|One drop of brimonidine tartrate/timolol combination ophthalmic solution (Combigan®) and one drop of brimonidine tartrate/timolol fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
3073004|NCT01229462|Active Comparator|Alphagan® and Timolol Concurrent|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) and one drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
3073005|NCT01229527|Experimental|Remifentanil RS1|
3073006|NCT01229527|Experimental|Remifentanil RS2|
3073007|NCT01229527|Active Comparator|Meperidine|
3073008|NCT01229722|Active Comparator|Beeper|Patients randomized to the control arm (Beeper) will receive the standard of care at each clinic visit. The subjects will bring their HIV medications every 3 weeks (MEMS measure, pill count) and questioned on their adherence to antiretroviral therapy (ART) in the past 7 days. They will not receive any text messages addressing their adherence to ART between each study visit. Their providers will not be receiving any adherence reports but will be asked to assess their adherence at at the start of the trial (Time 1 or T1) and at subsequent clinic visit scheduled according to a frequency defined by standard of care.
3073009|NCT01229722|Experimental|Cell Phone|Participants will receive a text message reminder via ARemind at scheduled intervals, with varying frequency. They will also be subject to a remote adherence assessment, over text messages, interactive voice response (IVR), or a remote pill count with assistance over the phone from a counselor. Those who demonstrate lower adherence rates may receive a call from a counselor.
3073010|NCT01229735|Experimental|Levetiracetam|250 mg and 500 mg levetiracetam tablet; titration from 1000 mg/day (500 mg bid) to 3000 mg/day (1500 mg bid) levetiracetam with treatment duration up to 52 weeks
3073011|NCT01229735|Active Comparator|Topiramate|25 mg and 100 mg topiramate tablet; titration from 100 mg/day (50 mg bid) to 400 mg/day (200 mg bid) topiramate with treatment duration up to 52 weeks
3073012|NCT01229891|Placebo Comparator|Plain yogurt drink|daily intake of two bottle (250 mL) plain yogurt drink
3073013|NCT01229891|Experimental|vitamin D-fortified yogurt drink|daily intake of two bottle yogurt drink fortified with 500 IU vitamin D/250 mL
3073014|NCT01229891|Experimental|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 mL
3073015|NCT01229943|Experimental|Arm I (octreotide acetate and everolimus)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28 and octreotide acetate 20 mg IM on day 1.
3073016|NCT01229943|Experimental|Arm II (octreotide acetate, everolimus, and bevacizumab)|Patients receive 28-day cycles until progression or unacceptable toxicity consisting of: everolimus 10 mg PO QD on days 1-28, octreotide acetate 20 mg IM on day 1 and bevacizumab 10 mg/kg IV on days 1 and 15.
3073017|NCT01230021|Experimental|recombinant factor XIII|
3073018|NCT01230060|Experimental|enVista|enVista One-Piece Hydrophobic Acrylic Intraocular Lens
3073019|NCT01230125|Experimental|Mapracorat|Ophthalmic suspension 3%
3073020|NCT01230125|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
3073021|NCT01230177||Etanercept (genetical recombination)|Among the patients with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy), the patients who will have changed regimen from 10 mg twice a week administration to 25 mg once a week administration.
3073022|NCT01230424|Experimental|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
3073023|NCT01230424|Placebo Comparator|Sodium Chloride|0.9% Sodium chloride injection as Placebo will be given into the study knee once every 12 weeks for a total of 8 injections.
3073024|NCT01230502|Active Comparator|Group 3: Donor Specific Regulation (DSR) -, standard of care|Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
3073025|NCT01230502|Active Comparator|Group 2 Donor Specific Regulation (DSR) +; standard of care|Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
3073026|NCT01230502|Experimental|Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy|"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy:~Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive"
3073027|NCT01230554|Experimental|Prism I|Bausch & Lomb daily disposable cosmetic tint contact lens
3073028|NCT01230593|Active Comparator|Hot Compress|"Hot Compress"
3073029|NCT01230593|Active Comparator|Tobrex|"Hot Compress, Tobrex Drops, Tobrex Ointment"
3073030|NCT01230593|Active Comparator|Tobradex|"Hot Compress, Tobradex Drops, Tobradex Ointment"
3073031|NCT01230710|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once a day for 48 weeks.
3073032|NCT01230749|Experimental|JNJ-41443532 250 mg|Participants will receive JNJ-41443532 250 mg in morning and evening for 28 days.
3073033|NCT01230749|Experimental|JNJ-41443532 1000 mg|Participants will receive JNJ-41443532 1000 mg (4 X 250 mg) in morning and evening for 28 days.
3073034|NCT01230749|Active Comparator|Pioglitazone|Participants will receive pioglitazone 30 mg in morning for 28 days.
3073035|NCT01230749|Placebo Comparator|Placebo|Participants will receive matching placebo for JNJ-41443532 and pioglitazone for 28 days.
3073036|NCT01230801|Experimental|BMN 701|IV infusion
3073037|NCT01230814|Experimental|Arm 1|Intravaginal metronidazole 750 mg plus miconazole 200 mg (co-formulated suppositories) nightly for 5 consecutive nights each month; 117 Subjects.
3073038|NCT01230814|Placebo Comparator|Arm 2|Placebo suppositories nightly for five consecutive nights each month; 117 Subjects.
3073039|NCT01230827|Experimental|CNTO 148 (Golimumab)|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response at Week 16 and who are randomly allocated to golimumab, will receive 30 mg per square meter every 4 weeks through Week 48. Patients will continue to receive golimumab 30 mg per square meter after Week 48 in a long-term extension until Week 248. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
3073040|NCT01230827|Placebo Comparator|Placebo|All patients will receive golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 12. Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive placebo every 4 weeks through Week 48. However, patients receiving placebo and who will have lack/loss of clinical response will be eligible to receive golimumab 30 mg per square meter every 4 weeks through Week 48. At Week 48, patients do not have a clinical response will begin to receive golimumab 30 mg per square meter in a long-term extension until Week 248 and patients who have a clinical response will be discontinued from the study. All patients will receive their fixed dose of commercial methotrexate throughout the study duration.
3073041|NCT01230892|Active Comparator|Nebivolol|
3073042|NCT01230892|Active Comparator|Atenolol|
3073043|NCT01230931|Experimental|Vitagel and Standard of Care|This group of patients will receive the vitagel topical surgical hemostat spray intra-operatively, along with all the other standards of care.
3073044|NCT01230931|Active Comparator|Standard of Care|This group of patients will receive the standard of care for hemostasis in acetabular surgery (electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing). They will not receive the vitagel product.
3073045|NCT01231230|Experimental|fluticasone/salmeterol|participants were treated fluticasone/salmeterol,
3073046|NCT01231230|Experimental|salmeterol|participants were treated with salmeterol
3073047|NCT01231230|Experimental|fluticasone|participants were treated with fluticasone
3073048|NCT01231230|Placebo Comparator|placebo inhalation|participants were treated with placebo
3073049|NCT01231321|Experimental|adalimumab|Adalimumab / pre-filled syringe 40 mg/0.8 ml
3073050|NCT01231334|Active Comparator|Aczone® Gel 5% plus Differin® 0.3% Gel|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
3073051|NCT01231334|Active Comparator|Duac® Topical Gel plus Differin® 0.3% Gel|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.
3073052|NCT01231373|Experimental|polidocanol injectable foam, 0.125%|
3073053|NCT01231373|Experimental|polidocanol injectable foam, 0.5%|
3073054|NCT01231373|Experimental|polidocanol injectable foam, 1.0%|
3073055|NCT01231373|Placebo Comparator|Vehicle|
3073056|NCT01231399|Experimental|Arm I|Patients receive fluorouracil IV continuously over 46 hours, leucovorin calcium IV over 2 hours, and oxaliplatin IV over 2 hours on day 1. Patients also receive oral everolimus once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3073057|NCT01231412|Active Comparator|Arm I (MMF and CSP)|Patients receive FLU IV over 30 minutes on days -4 to -2. Patients also receive CSP PO BID on days -3 to 96 with taper to day 150 and MMF PO TID daily on days 0-29 and then BID on days 30-150 with taper to day 180. Patients undergo allogeneic PBSCT on day 0 following the TBI.
3073058|NCT01231412|Experimental|Arm II (MMF, CSP, and Sirolimus)|Patients receive FLU and CSP as in Arm I and sirolimus PO QD on days -3 to 150 with taper to day 180. Patients also receive MMF PO TID on days 0-29 and then BID on days 30-40. MMF will then be discontinued without taper unless GVHD or disease relapse/progression occurs. Patients undergo allogeneic PBSCT on day 0 following the TBI.
3073059|NCT01231412|Experimental|Arm 0 (CSP and Sirolimus)|Patients receive CSP orally (PO) twice daily (BID) on days -3 to 96 with taper to day 150 and and sirolimus PO once daily (QD) on days -3 to 150 with taper to day 180. Arm removed as of 14-Sep-2011
3073060|NCT01231464|Placebo Comparator|placebo|vehicle placebo nasal spray
3073061|NCT01231464|Experimental|FFNS|fluticasone furoate nasal spray
3073062|NCT01231503|Experimental|RTS,S Neo-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 14 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073063|NCT01231503|Experimental|RTS,S Neo-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) when ≤ 7 days of age and at 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanri xHepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073064|NCT01231503|Experimental|RTS,S 6-10-14 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 14 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073065|NCT01231503|Experimental|RTS,S 6-10-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073066|NCT01231503|Experimental|Engerix-B Neo/RTS,S 6-10-26 Group|Subjects received one dose of Engerix-B (HBV) when ≤ 7 days of age followed by 3 doses of RTS,S/AS01E (GSK257049) at 6, 10 and 26 weeks of age In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E and HBV vaccines were administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073067|NCT01231503|Experimental|RTS,S 10-14-26 Group|Subjects received 3 doses of RTS,S/AS01E (GSK257049) at 10, 14 and 26 weeks of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073068|NCT01231503|Experimental|RTS,S 14-26-9M Group|Subjects received 3 doses of RTS,S/AS01E (or GSK257049) at 14 and 26 weeks of age and at 9 months of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when below ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The RTS,S/AS01E vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073069|NCT01231503|Active Comparator|Engerix-B Neo Group|Subjects in this group received one dose of Engerix-B (HBV) ≤ 7 days of age. In addition, all subjects received a 3-doses course of Tritanrix HepB/Hib (DTPwHepB/Hib), administered at 6, 10 and 14 weeks of age, one dose of Bacille Calmette Guerin tuberculosis vaccine (BCG), administered when below ≤ 7 days of age, 4 doses of Polio Sabin (OPV), administered when ≤ 7 days of age and at 6, 10 and 14 weeks of age, and one dose of Rouvax (Measles), administered at 9 months of age. The HBV vaccine was administered intramuscularly (IM) in the left antero-lateral thigh. The DTPwHepB/Hib and Measles vaccines were administered IM in the right antero-lateral thigh and the OPV vaccine orally. The BCG vaccine was administered via intradermal route in the shoulder.
3073070|NCT01231516|Experimental|GSK1349572 + Raltegravir Placebo|Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
3073071|NCT01231516|Active Comparator|Raltegravir + GSK1349572 Placebo|Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
3073072|NCT01231555|Experimental|GSK2248761 100 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3073073|NCT01231555|Experimental|GSK2248761 200 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3073074|NCT01231555|Active Comparator|Efavirenz 600 mg once daily|In combination with either abacavir/lamivudine FDC qd or tenofovir/emtricitabine FDC qd
3073075|NCT01231581|Experimental|GSK1120212 plus Gemcitabine|GSK1120212 administered orally plus gemcitabine IV
3073076|NCT01231581|Active Comparator|Placebo plus Gemcitabine|Placebo administered orally plus gemcitabine IV
3073077|NCT01231607|Active Comparator|1mg Finasteride|1mg finasteride active plus dutasteride placebo, by mouth once daily
3073078|NCT01231607|Active Comparator|0.02mg Dutasteride|0.02mg dutasteride active plus finasteride placebo, by mouth once daily
3073079|NCT01231607|Active Comparator|0.1mg Dutasteride|0.1mg dutasteride active plus finasteride placebo, by mouth once daily
3073080|NCT01231607|Active Comparator|0.5mg Dutasteride|0.5mg dutasteride active plus finasteride placebo, by mouth once daily
3073081|NCT01231607|Placebo Comparator|Placebo|1mg finasteride placebo plus dutasteride placebo, by mouth once daily
3073082|NCT01231620|Experimental|Intravenous (IV) Zanamivir 300mg Twice Daily|300mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
3073083|NCT01231620|Experimental|Intravenous (IV) Zanamivir 600mg Twice Daily|600mg of IV zanamivir infusion twice daily plus oral oseltamivir placebo twice daily
3073084|NCT01231620|Active Comparator|Oral Oseltamivir 75mg Twice Daily|75mg oral oseltamivir twice daily plus intravenous placebo zanamivir twice daily
3073085|NCT01231633|Experimental|Group 1|Subjects randomized to this arm will receive one initial treatment with Ozurdex then treated with Avastin if needed.
3073086|NCT01231633|Active Comparator|Group 2|Subjects randomized to this arm will receive one initial treatment with Avastin then treated with Avastin if needed.
3073087|NCT01231646||Lamotrigine|No intervention
3073088|NCT01231646||Valproate|No intervention
3073089|NCT01231659|Experimental|Everolimus + Letrozole|All patients received 2 tablets (5 mg each) of Everolimus (a total of 10 mg) + 1 tablet of Letrozole (2.5 mg) daily until disease progression or as described in the protocol.
3073090|NCT01231841|Experimental|rATG + Cyclosporine|Patients receive anti-thymocyte globulin IV daily over 4-24 hours on days 1-5. Beginning on day 6, patients receive oral cyclosporine twice daily for 6 months followed by a taper. Treatment continues in the absence of disease progression or unacceptable toxicity
3073091|NCT01231906|Experimental|Arm A (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9."
3073092|NCT01231906|Experimental|Arm B (combination chemotherapy, topotecan hydrochloride)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.~CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19."
3073093|NCT01231984|Experimental|4 mm vs. 8 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 8mm x 31G Pen Needle for 12 weeks (Period 1), then switched to the alternate pen needle (PN) for another 12 weeks (Period 2). Order of PN use was randomly determined.
3073094|NCT01231984|Experimental|4 mm vs. 12.7 mm|Subjects randomized to this study arm first used either the 4 mm x 32G Pen Needle or the 12.7mm x 29G Pen Needle (PN) for 12 weeks (Period 1), then switched to the alternate PN for another 12 weeks (Period 2). Order of PN use was randomly determined.
3073095|NCT01232127|Other|Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI|The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3073096|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3073097|NCT01232127|Other|Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)|FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.
3073098|NCT01232205|Active Comparator|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
3073099|NCT01232205|Placebo Comparator|Control|
3073100|NCT01232283|Experimental|Apremilast|Participants were initially randomized 2:1 and received apremilast 30 mg twice a day (BID). Participants maintained dosing through Week 32. At Week 32, responders, those with a Psoriasis Area Severity Index response -≥75 (PASI-75) and partial responders (≥PASI-50) were re-randomized 1:1 to apremilast 30 mg BID or matching placebo (treatment withdrawal). Participants could resume apremilast 30 mg BID at the time of loss of 50% of improvement in PASI score response which was observed at Week 32 compared to baseline), and no later than Week 52. At Week 52, the non-responders (<PASI-50) had the option of adding topical therapies and/or phototherapy to their treatment regimen. Those re-randomized to apremilast 30 mg BID continued dosing through Week 52. At Week 52, participants continued treatment with apremilast 30 mg BID.
3073101|NCT01232283|Placebo Comparator|Placebo|Participants will be initially randomized to placebo, identically matching during Weeks 0-16. At Week 16, Placebo participants will be switched to receive apremilast 30 mg BID. All participants will maintain Apremilast dosing through Week 32. At Week 32, participants originally randomized to placebo at baseline (Week 0) and are considered non-responders i( < PASI-50) will have the option of adding topical therapies and/or phototherapy to their Apremilast treatment regimen. At Week 52, all participants will continue treatment with apremilast 30 mg BID. Participants will be followed and evaluated for safety and efficacy for up to an additional 4 years (years 2 through 5).
3073102|NCT01232296|Experimental|TKI258|capsule
3073103|NCT01232296|Experimental|Sorafenib|tablet
3073104|NCT01232452|Experimental|Pemetrexed + Cisplatin + Cixutumumab|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 plus cixutumumab 20 mg/kg given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 plus cixutumumab 20 mg/kg given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3073105|NCT01232452|Active Comparator|Pemetrexed + Cisplatin|"Induction Treatment: Pemetrexed 500 mg/m^2 plus cisplatin 75 mg/m^2 given intravenously (IV) on Day 1 of a 21 day cycle for up to 4 cycles. Two additional cycles of cisplatin may be given (6 cycles total) for patients with significant tumor size reduction, after sponsor approval.~Maintenance Therapy: Pemetrexed 500 mg/m^2 given IV every 21 days until progression of disease, unacceptable toxicity, or another withdrawal criterion is met."
3073106|NCT01232465||IVF|those individuals undergoing conventional IVF to inseminate their retrieved eggs
3073107|NCT01232465||ICSI|those individuals whose eggs were fertilized via intracytoplasmic sperm injection (ICSI)
3073108|NCT01232491|Active Comparator|Control|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects did not receive dietary consultation except for basic dietary advice at baseline. Insulin doses were individually adjusted.
3073109|NCT01232491|Experimental|Dietician|Insulin detemir (Levemir®) 100 U/mL, was injected subcutaneously once daily with the evening meal or at bedtime as add-on to subject's pre-trial treatment of metformin for 26 weeks. Subjects received dietary consultation according to local standard during 3 face-to-face meetings and 3 phone contacts. Insulin doses were individually adjusted.
3073110|NCT01232504|Experimental|rhGM-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
3073111|NCT01232504|Active Comparator|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
3073112|NCT01232504|Active Comparator|rhG-CSF group|subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
3073113|NCT01232556|Experimental|1|Inotuzumab ozogamicin+rituximab
3073114|NCT01232556|Active Comparator|2|Investigator's choice of (1) rituximab+gemcitabine, or (2) rituximab+bendamustine
3073115|NCT01232569|Experimental|Tocilizumab 162 mg sc|Patients will receive tocilizumab 162 mg subcutaneously (sc) every 2 weeks for 24 weeks.
3073116|NCT01232569|Placebo Comparator|Placebo sc|Patients will receive placebo subcutaneously (sc) every 2 weeks for 24 weeks.
3073117|NCT01232738|Experimental|rasagiline|Treated for 12 months with rasagiline 2mg orally, once daily.
3073118|NCT01232790|Experimental|Group A: Intervention/Placebo|Group A first receives the commercially available sustained release form of N-acetylcysteine, then the matching placebo capsules both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
3073119|NCT01232790|Placebo Comparator|Group B: Placebo/Intervention|Group B first receives the placebo and then receives a commercially available sustained release form of N-Acetylcysteine. In each arm, the capsules are both administered at 1200mg twice a day for 3 full days, along with 1200mg once on the evening prior to and once on the morning following the 3 days (8 total doses over 5 days).
3073120|NCT01232829|Experimental|Treatment (RO4929097)|"Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.~Patients may undergo tumor biopsy at baseline and on days 16 or 17 of course one for biomarker and other correlative studies. Blood samples may also collected at baseline and periodically during study for pharmacokinetic and angiogenesis marker studies."
3073121|NCT01232868|Other|Age 25-40|Trivalent Influenza vaccine given to age 25-40
3073122|NCT01232868|Other|Age ≥65|Trivalent Influenza vaccine given to age≥65
3073123|NCT01232894|Experimental|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
3073124|NCT01232894|Active Comparator|Long-acting beta2-agonist|Participants' current long-acting beta2-agonist (LABA) bronchodilator therapy
3073125|NCT01232920|Active Comparator|Methotrexate|
3073126|NCT01232920|Active Comparator|Mycophenolate mofetil|
3073127|NCT01232946|Experimental|Iiraglutide|Type 2 diabetic subjects will be assigned to 3 months of treatment with 1.8mg liraglutide administered once daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3073128|NCT01232946|Experimental|insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with insulin detemir administered twice daily in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3073129|NCT01232946|Experimental|Liraglutide plus insulin detemir|Type 2 diabetic subjects will be assigned to 3 months of treatment with a combination of liraglutide and insulin detemir in addition to background metformin 2000mg/day. PET measurements of myocardial glucose uptake will take place at the end of treatment.
3073130|NCT01233050|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
3073131|NCT01233050|Active Comparator|Iodine Povacrylex/74% Isopropyl Alcohol|Preoperative Skin Antisepsis Preparation
3073132|NCT01233076|Other|Nelfilcon A / Narafilcon B|Nelfilcon A worn first, with narafilcon B worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
3073133|NCT01233076|Other|Narafilcon B / Nelfilcon A|Narafilcon B worn first, with nelfilcon A worn second. Each product worn bilaterally in a daily wear, daily disposable basis for one week.
3073134|NCT01233232|Placebo Comparator|1|Placebo dose
3073135|NCT01233232|Experimental|2|Treatment arm AZD5069 50mg
3073136|NCT01233232|Experimental|3|Treatment arm AZD5069 80mg
3073137|NCT01233258|Experimental|Arm 1: rFVIII on demand first CS/EP then CS/ADJ|Participants received on-demand treatment with recombinant factor VIII (rFVIII, BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months, followed by cross-over to study drug assayed by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months.
3073138|NCT01233258|Experimental|Arm 2: rFVIII on demand first CS/ADJ then CS/EP|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/ADJ for 6 months, followed by cross-over to study drug assayed by CS/EP for 6 months.
3073139|NCT01233258|Experimental|Arm 3: rFVIII prophylaxis low-dose first CS/EP then CS/ADJ|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII(BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
3073140|NCT01233258|Experimental|Arm 4: rFVIII prophylaxis low-dose first CS/ADJ then CS/EP|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
3073141|NCT01233258|Experimental|Arm 5: rFVIII prophylaxis high-dose first CS/EP then CS/ADJ|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) measured by CS/ EP for 6 months then crossed over to study drug measured by CS/ADJ for 6 months.
3073142|NCT01233258|Experimental|Arm 6: rFVIII prophylaxis high-dose first CS/ADJ then CS/EP|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII(BAY81-8973) measured by CS/ADJ for 6 months then crossed over to study drug measured by CS/ EP for 6 months.
3073143|NCT01233284|Experimental|tiotropium low dose once daily|once daily, delivered by the Respimat® inhaler
3073144|NCT01233284|Experimental|tiotropium medium dose once daily|once daily, delivered by the Respimat® inhaler
3073145|NCT01233284|Experimental|tiotropium high dose once daily|once daily, delivered by the Respimat® inhaler
3073146|NCT01233284|Placebo Comparator|Placebo once daily|once daily, delivered by the Respimat® inhaler
3073147|NCT01233518|Other|Single arm study|Patients will receive cCTA, ICA, FFR, and cFFR per protocol.
3073148|NCT01233609|Active Comparator|Valproic Acid|Subjects who receive valproic acid
3073149|NCT01233609|Placebo Comparator|Placebo|Subjects who receive placebo
3073150|NCT01233687|Experimental|AMG 102 and erlotinib|Combination of AMG 102 and erlotinib
3073151|NCT01233726|Experimental|T-DIET PLUS DIABET IR|Patients of this group will receive T-Diet plus Diabet IR as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3073152|NCT01233726|Active Comparator|ISOSOURCE PROTEIN FIBRE|Patients of this group will receive ISOSOURCE PROTEIN FIBRE (Nestlé Nutrition) as unique nutritional support throughout the day receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3073153|NCT01233726|Active Comparator|GLUCERNA SELECT|Patients of this group will receive GLUCERNA SELECT (Abbott Laboratories) as unique nutritional support throughout the day, receiving 25 kcal / kg • day (from the first 48 hours after checking tolerance) via gastric or transpyloric
3073154|NCT01233817|Experimental|Spinal muscular atrophy|Children and adolescents with diagnosis of SMA type II or III. The intervention group (the only arm/group in this pilot study) receives a home-based, supervised, 12-week progressive strength-training program.
3073155|NCT01233869|Experimental|Cohort A|
3073156|NCT01233869|Experimental|Cohort B|
3073157|NCT01233869|Placebo Comparator|Cohort C|
3073158|NCT01233921|Experimental|Arm I (palifermin)|Patients receive palifermin IV on days 1-3 in the absence of unacceptable toxicity.
3073159|NCT01233921|Active Comparator|Arm II (no palifermin)|Patients do not receive palifermin.
3073160|NCT01233999|Placebo Comparator|Botox|single-drug dosage comparison cross-over study
3073161|NCT01234207|Active Comparator|Randomized Order of Interventions 1|Randomized to first wear standard, non-free-form, non-customized PAL spectacles, then second, crossover to wear individually customized free-form surfaced PAL spectacles
3073162|NCT01234207|Active Comparator|Randomized Order of Interventions 2|Randomized to first wear individually customized free-form surfaced PAL spectacles, then second, crossover to wear standard, non-free-form, non-customized PAL spectacles
3073163|NCT01234337|Experimental|Sorafenib (Nexavar, BAY43-9006) + Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
3073164|NCT01234337|Placebo Comparator|Placebo + Capecitabine|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
3073165|NCT01234350||FIRMAGON|
3073166|NCT01234350||GnRH Agonist|
3073167|NCT01234402|Experimental|Ramucirumab DP + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
3073168|NCT01234402|Experimental|Icrucumab + Capecitabine|Cycles repeat until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant.
3073169|NCT01234402|Active Comparator|Capecitabine*|"Crossover Study:~* At the discretion of the investigator, participants will be eligible to receive either ramucirumab DP or Icrucumab (IMC-18F1) in combination with capecitabine, after radiographic disease progression while on capecitabine. The investigator will decide which investigational product will be given.~Cycles repeat every 21 days until disease progression, the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the participant."
3073170|NCT01234467|Experimental|Bendamustine, Rituximab|This is a single arm intervention where patients will receive bendamustine at a dose of 120 mg/m^2 infused over 60 minutes in days 1 and 2 of each 21 day cycle along with rituximab 375 mg/m^2 after bendamustine on day 1 of each cycle. Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 3 at baseline were allowed to receive bendamustine at a dose of 90 mg/m^2 daily with a dose increase to 120 mg/m^2 daily if their ECOG improved.
3073171|NCT01234480|Experimental|Participants with Cervical Disease|Participants positive for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
3073172|NCT01234480|Experimental|Participants without Cervical Disease|Participants negative for Cervical Disease (CIN2 or higher) as determined by adjudicated histology from biopsy/ECC.
3073173|NCT01234649|Experimental|Metformin XR plus liraglutide|Metformin XR plus Liraglutide Metformin extended release (XR) 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid- 84 weeks (end study) Liraglutide - start .6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated
3073174|NCT01234649|Active Comparator|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -84 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
3073175|NCT01234675|Experimental|milnacipran|Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo
3073176|NCT01234675|Placebo Comparator|placebo|Drug: placebo 45-day placebo treatment before or after crossover to milnacipran
3073177|NCT01234714||Major liver resection|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonant Imaging (MRI) and underwent major liver resection (>=3 segments).
3073178|NCT01234766|Experimental|Single Arm|Subjects will receive bendamustine and rituximab, followed by 90-yttrium (Y) Ibritumomab Tiuxetan
3073179|NCT01234831|Other|Active Screening|Patients randomized to active screening will have two nasal swabs collected daily for 3 days, for both nucleic acid amplification and culture (CHROMagar)assays.
3073180|NCT01234831|Other|Passive Screening|Patients randomized to passive screening will not actively be identified for testing but may be tested using culture-based algorithm by care team.
3073181|NCT01234870|Experimental|Ischemic heart disease patients|Patients with suspected ischemic heart disease prospectively recruited for first pass myocardial perfusion MRI. All subject to receive Gadolinium infusion of 0.075 mmol/kg at rate of 4 ml/sec. Adenosine administered at a rate of 0.14 mg/kg/min for a duration of 4 minutes to induce stress.
3073182|NCT01234883|Experimental|multiple electrolyte solution|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
3073183|NCT01234883|Active Comparator|saline|Subjects were randomized to receive either multiple electrolyte solution or saline. These solutions were administered IV at 10-20 mL/kg until the subject appeared clinically rehydrated as assessed by the clinician. The selected dose for these solutions is considered standard of care when treating clinical dehydration in children and is consistent with product labeling.
3073184|NCT01234922|Experimental|Arm I|Patients receive oral benazepril hydrochloride once daily on days 1-7.
3073185|NCT01234922|Experimental|Arm II|Patients receive oral lisinopril once daily on days 1-7.
3073186|NCT01234922|Experimental|Arm III|Patients receive oral ramipril twice daily on days 1-7.
3073187|NCT01234922|Experimental|Arm IV|Patients receive oral losartan potassium once daily on days 1-7.
3073188|NCT01235195|Active Comparator|Sertraline 50 mg capsules|
3073189|NCT01235195|Active Comparator|Sertraline 50 mg tablet|
3073190|NCT01235234|Experimental|CF101 0.1 mg|
3073191|NCT01235234|Experimental|CF101 1 mg|
3073192|NCT01235234|Placebo Comparator|Placebo|
3073193|NCT01235338|Experimental|LDX (SPD489) + Venlafaxine XR (Effexor XR)|
3073194|NCT01235338|Experimental|Venlafaxine XR + LDX|
3073195|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 carriers|Clopidogrel for CYP2C19*2 gene carriers
3073196|NCT01235351|Active Comparator|Clopidogrel - for CYP2C19*2 non-carriers|Clopidogrel for CYP2C19*2 gene NON-carriers
3073197|NCT01235377|Active Comparator|Favor Chlorthalidone|Providers randomized to Favor Chlorthalidone will have agreed to prescribe chlorthalidone for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
3073198|NCT01235377|Active Comparator|Favor Hydrochlorothiazide|Providers randomized to Favor Hydrochlorothiazide will have agreed to prescribe hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. This cluster designation applies only for patients for whom there is equipoise; providers are expected to deviate if medically indicated for individual patients
3073199|NCT01235403|Experimental|Lacosamide|Flexible dosing between 200mg/day and 400mg/day
3073200|NCT01235442|Experimental|etanercept and clobetasol|Etanercept 50 mg twice weekly x 12 weeks + clobetasol propionate foam (weeks 11 and 12) then Etanercept 50 mg once weekly x 12 weeks + clobetasol propionate foam (weeks 23 and 24)
3073201|NCT01235442|Experimental|etanercept|Etanercept 50 mg twice weekly x 12 weeks then Etanercept 50 mg once weekly x 12 weeks
3073202|NCT01235507|Experimental|Single Arm|
3073203|NCT01235546|Placebo Comparator|Placebo and standard of care|250 cc normal saline
3073204|NCT01235546|Experimental|Azithromycin and Standard of care|500 mg Azithromycin in 250 cc normal saline
3073205|NCT01235598|Other|Placebo followed by Certolizumab Pegol (CZP)|Placebo, saline solution for sc injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
3073206|NCT01235598|Experimental|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) 400 mg for subcutaneous injection at Weeks 0, 2 and 4 followed by 200 mg 2-weekly from Week 6 to Week 40
3073207|NCT01235689|Experimental|Tight Control Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI), high sensitivity C-reactive protein (hs-CRP), fecal calprotectin, and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine. Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified tight control criteria: At Key Visit 1 the success criteria were CDAI < 150, hs-CRP, < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone use. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria were CDAI < 150, hs-CRP < 5 mg/L, fecal calprotectin < 250 μg/g, and absence of prednisone during the preceding week."
3073208|NCT01235689|Active Comparator|Clinically Driven Management|"Participants randomized to receive management of disease activity using criteria based on Crohn's Disease Activity Index (CDAI) and corticosteroid use.~Participants received customized therapy that could include prednisone, adalimumab, and azathioprine.~Participants who randomized at Week 9 meeting success criteria started with no therapy; participants who randomized prior to Week 9 or who randomized at Week 9 but did not meet the success criteria began treatment with adalimumab.~Therapy was escalated according to pre-specified failure criteria using less stringent criteria:~At Key Visit 1 the criteria for management of disease activity were a CDAI decrease ≥ 70 (CR-70) compared to Baseline or CDAI < 200 at 1 week prior to the visit. At Key Visits 3, 4, and 5 (every 12 weeks after Key visit 1), the criteria for a change in treatment were a CDAI decrease of ≥ 100 (CR-100) compared to Baseline or CDAI < 200, and absence of prednisone during the preceding week."
3073209|NCT01235715|Active Comparator|Evicel|Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical. It has been shown to stop bleeding in 2 minutes or less. Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue. It is a bioresorbable and biocompatible agent.
3073210|NCT01235715|No Intervention|no evicel|Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
3073211|NCT01235728|Experimental|Treatment Sequence 1|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
3073212|NCT01235728|Experimental|Treatment Sequence 2|Participants were randomized to received MK-0873 on lower lesion A and vehicle on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
3073213|NCT01235728|Experimental|Treatment Sequence 3|Participants were randomized to receive MK-0873 on upper lesion A and vehicle on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
3073214|NCT01235728|Experimental|Treatment Sequence 4|Participants were randomized to receive MK-0873 on lower lesion A and vehicle on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
3073215|NCT01235728|Experimental|Treatment Sequence 5|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and MK-0873 on lower lesion C and calcitriol on lower lesion D.
3073216|NCT01235728|Experimental|Treatment Sequence 6|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and MK-0873 on upper lesion C and calcitriol on upper lesion D.
3073217|NCT01235728|Experimental|Treatment Sequence 7|Participants were randomized to receive vehicle on upper lesion A and MK-0873 on upper lesion B, and calcitriol on lower lesion C and MK-0873 on lower lesion D.
3073218|NCT01235728|Experimental|Treatment Sequence 8|Participants were randomized to receive vehicle on lower lesion A and MK-0873 on lower lesion B, and calcitriol on upper lesion C and MK-0873 on upper lesion D.
3073219|NCT01235741|Experimental|Group A|Pramlintide+Metreleptin
3073220|NCT01235741|Placebo Comparator|Group B|Placebo
3073221|NCT01235793|Experimental|DRBEAT Regimen|
3073222|NCT01235897|Experimental|Maximum tolerated dose|
3073223|NCT01235910|Other|1|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
3073224|NCT01235923|Active Comparator|three times weekly Epo|Epo 400 units/kg three times weekly given subcutaneously for 4 weeks
3073225|NCT01235923|Active Comparator|weekly Epo|1,200 units/kg given once a week subcutaneously for 4 weeks
3073226|NCT01235949|Experimental|Group IIBU|Immediate ibuprofen group: subjects receiving immediate ibuprofen treatment after each primary vaccine dose
3073227|NCT01235949|Active Comparator|Group DIBU|Delayed ibuprofen group: subjects receiving delayed ibuprofen treatment after each primary vaccine dose
3073228|NCT01235949|Active Comparator|Group NIBU|No ibuprofen group: subjects receiving no prophylactic ibuprofen treatment after each primary vaccine dose
3073229|NCT01235949|Experimental|Group IPARA|Immediate paracetamol group: subjects receiving immediate paracetamol treatment after each primary vaccine dose
3073230|NCT01235949|Experimental|Group DPARA|Delayed paracetamol group: subjects receiving delayed paracetamol treatment after each primary vaccine dose
3073231|NCT01235949|Active Comparator|Group NPARA|No paracetamol group: subjects receiving no prophylactic paracetamol treatment after each primary vaccine dose
3073232|NCT01235949|Experimental|Group IIBU-IIBU|1/3 of the subjects from the primary IIBU group receiving immediate ibuprofen treatment after booster vaccination
3073233|NCT01235949|Experimental|Group IIBU-DIBU|1/3 of the subjects from the primary IIBU group receiving delayed ibuprofen treatment after booster vaccination
3073234|NCT01235949|Experimental|Group IIBU-NIBU|1/3 of the subjects from the primary IIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3073235|NCT01235949|Experimental|Group DIBU-IIBU|1/3 of the subjects from the primary DIBU group receiving immediate ibuprofen treatment after booster vaccination
3073236|NCT01235949|Experimental|Group DIBU-DIBU|1/3 of the subjects from the primary DIBU group receiving delayed ibuprofen treatment after booster vaccination
3073237|NCT01235949|Experimental|Group DIBU-NIBU|1/3 of the subjects from the primary DIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3073238|NCT01235949|Experimental|Group NIBU-IIBU|1/3 of the subjects from the primary NIBU group receiving immediate ibuprofen treatment after booster vaccination
3073239|NCT01235949|Experimental|Group NIBU-DIBU|1/3 of the subjects from the primary NIBU group receiving delayed ibuprofen treatment after booster vaccination
3073240|NCT01235949|Active Comparator|Group NIBU-NIBU|1/3 of the subjects from the primary NIBU group receiving no prophylactic ibuprofen treatment after booster vaccination
3073241|NCT01235949|Experimental|Group IPARA-NPARA|subjects from the primary IPARA group receiving no paracetamol treatment after booster vaccination
3073242|NCT01235949|Experimental|Group DPARA-IPARA|subjects from the primary DPARA group receiving immediate paracetamol treatment after booster vaccination
3073243|NCT01235949|Experimental|Group NPARA-IPARA|subjects from the primary NPARA group receiving immediate paracetamol treatment after booster vaccination
3320951|NCT02014935|Experimental|Low intensity laser|"So that this research recrutarou 30 subjects with spastic hemiparesis sequel, post stroke who have gone through three phases, with three evaluations. If this conformation is necessary, therefore, it is a search for intergroup analysis, and the values found in Phase I were faced with the values found in Phases II and III.~The phases comprise:~Phase I (1st Cycle): Individuals treated with LLLT not only performed the evaluation of muscle activity, torque and lactic acid level.~Phase II (2nd Cycle): Individuals undergoing the application of LLLT, with the same off, and assessment of muscle activity, torque and lactic acid level.~Phase III (3rd Cycle): Individuals undergoing the application of LILT and evaluation of muscle activity, torque and lactic acid level."
3320952|NCT02014948|Experimental|Exercises|This group will consist of 20 individuals, 10 with lumbar disc herniation and 10 with chronic low back pain who underwent treatment with exerxises.
3073246|NCT01235975|Experimental|Group A|
3073247|NCT01235975|Active Comparator|Group B|
3073248|NCT01236001||Vimpat® treatment|Patients who started VIMPAT® treatment before enrollment and patients who started VIMPAT® on/after enrollment.
3073249|NCT01236053||UK GPRD 1993-2008|The study cohort from which cases and controls are drawn is all subjects in the United Kingdom (UK) General Practice Research Database (GPRD) 1993-2008. Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date.
3073250|NCT01236105|Experimental|6 mg LY2624803 Alone Morning Dosing|Participants received 6 milligrams (mg) LY2624803 alone orally (po) at approximately 0800 hours following an overnight fast.
3073251|NCT01236105|Experimental|6 mg LY2624803 Morning Dosing + Activated Charcoal|Participants received 6 mg LY2624803 po at approximately 0800 hours following an overnight fast, followed 1 hour later by a single po dose of 1 gram per kilogram (g/kg) body weight of activated charcoal, mixed with caffeine-free diet cola.
3073252|NCT01236105|Experimental|6 mg LY2624803 Alone Evening Dosing|Participants received 6 mg LY2624803 alone po at approximately 2200 hours following a 4-hour fast.
3073253|NCT01236118|Experimental|30 milligrams (mg) LY2439821|Participants will start receiving LY2439821 30 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
3073254|NCT01236118|Experimental|80 mg LY2439821|Participants will start receiving LY2439821 80 mg once every week for the first 3 doses and then once every 2 weeks until week 44. Investigators or its designees will increase the LY2439821 dose to 160 mg at any visit once the safety of LY2439821 180 mg is confirmed by the Data Review Meeting in Study I1F-JE-RHAL (NCT01253265).
3073255|NCT01236118|Experimental|160 mg LY2439821|Participants will start receiving LY2439821 160 mg once every 2 weeks for the first 3 doses and then once every 4 weeks until Week 44.
3073256|NCT01236170||Group 1|Veterans with spinal cord injury or amputated limbs who use a wheelchair as their primary source of mobility
3073257|NCT01236196|Experimental|Arm 1 - Telephone CBT|telephone cognitive behavior therapy for pain management
3073258|NCT01236196|Active Comparator|Arm 2 - telephone education|telephone pain education
3073259|NCT01236300|Experimental|Cellvizio system|
3073260|NCT01236326|Active Comparator|LESS-DN|
3073261|NCT01236326|Active Comparator|Conventional LDN|
3073262|NCT01236339|Experimental|TIPS|TIPS with GORE® VIATORR® TIPS Endoprosthesis
3073263|NCT01236339|Active Comparator|LVP|"Large Volume Paracentesis~*A subject may be crossed-over from large volume paracentesis to TIPS with GORE® VIATORR® TIPS Endoprosthesis if the subject has completed their six month study visit and has met the criteria for cross-over (LVP failure)."
3073264|NCT01236352|Experimental|Phase 1 (Cohort 1): BMS-911543 (5 mg)|BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
3073265|NCT01236352|Experimental|Phase 1 (Cohort 2): BMS-911543 (10 mg)|BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
3073266|NCT01236352|Experimental|Phase 1 (Cohort 3): BMS-911543 (20 mg)|BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
3073267|NCT01236352|Experimental|Phase 1 (Cohort 4): BMS-911543 (40 mg)|BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
3073268|NCT01236352|Experimental|Phase 1 (Cohort 5): BMS-911543 (80 mg)|BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
3073269|NCT01236352|Experimental|Phase 1 (Cohort 6): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
3073270|NCT01236352|Experimental|Phase 1 (Cohort 7): BMS-911543 (160 mg)|BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
3073271|NCT01236352|Experimental|Phase 1 (Cohort 8): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
3073272|NCT01236352|Experimental|Phase 1 (Cohort 9): BMS-911543 (240 mg)|BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
3073273|NCT01236352|Experimental|Phase 1 (Cohort 10): BMS-911543 (320 mg)|BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
3073274|NCT01236352|Experimental|Phase 2 (Cohort 11): BMS-911543 (120 mg)|BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
3073275|NCT01236352|Experimental|Phase 2 (Cohort 12): BMS-911543 (200 mg)|BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
3073276|NCT01236365|Experimental|Atorvastatin|
3073277|NCT01236365|Placebo Comparator|Placebo|
3073278|NCT01236378|Experimental|sirolimus|Subjects must be taking sirolimus (1 mg tablet formulation) with or without concomitant medications, unless specifically excluded below, for prophylaxis of renal rejection.
3073279|NCT01236391|Experimental|Participants received PCI-32765 560 mg daily|Participants were enrolled and received 560 mg/day dose, stratified into 2 groups based on prior bortezomib exposure.
3073280|NCT01236521|Experimental|Arm 1: Pharmacological (MED)|Subjects in the Pharmacological (MED) arm will receive at least 8 contacts with the nurse care managers (NCM) over the trial period. Participants will have an initial visit at baseline to assess their current and past treatments for chronic lower back pain, pain intensity, and pain-related limitations. Patients' opioids will be adjusted and/or co-analgesics (or adjuvants) will be initiated. During follow-up calls, patients' pain severity, response to treatment, adherence, adverse effects, and desire to change current treatment will be assessed. Follow-up NCM telephone contacts will occur at 2 and 4 weeks after baseline, and months 2, 3, 4, 6, and 9 months. On average, these calls last between 10 to 20 minutes. Detailed logs will be kept of the timing and content of patient contacts.
3073281|NCT01236521|Experimental|Arm 2: Behavioral treatment (CBT)|Veterans randomized to behavioral treatment arm (CBT) will receive a series of 8 pain self-management/coping skills training sessions delivered by one of three primary-care based clinical psychologists. Since optimal application of non-pharmacological interventions for pain involves tailoring to patient needs, participants will be introduced to a menu of self-management and coping skills rather than receive a prescribed program. Delivery of the behavioral intervention will employ a flexible approach that is easily adapted to individual preferences and perceived need for learning specific pain coping skills. Tailoring will include the selection of relevant content and skills and assessment of readiness to change behaviors.
3073282|NCT01236534|Active Comparator|Lubiprostone|
3073283|NCT01236534|Placebo Comparator|Sugar pill|
3073284|NCT01236547|Experimental|Arm I (paclitaxel, pazopanib hydrochloride, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and pazopanib hydrochloride PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
3073285|NCT01236547|Active Comparator|Arm II (paclitaxel, placebo, IMRT)|Patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD for 2-3 weeks. Patients then receive concurrent paclitaxel IV over 1 hour once weekly and placebo PO QD for 6-7 weeks (or until radiation treatment is completed) and IMRT 5 days per week for 6.5 weeks (total of 66 Gy in 33 fractions). Beginning 25-31 days after the completion of IMRT, patients receive paclitaxel IV over 1 hour once weekly and placebo PO QD. Treatment repeats every 3 weeks for 4 cycles (for patients with no measurable disease) or continues in the absence of disease progression or unacceptable toxicity (for patients with measurable disease).
3073286|NCT01236560|Experimental|Arm I (vorinostat, Phase II Arm A)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at the maximum-tolerated dose determined in the feasibility study. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073287|NCT01236560|Experimental|Arm II (temozolomide, Phase II Arm B)|Patients undergo RT as in the feasibility arm and receive temozolomide PO once daily for 42 days by day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073288|NCT01236560|Experimental|Arm III (Bevacizumab, Phase II Arm)|Patients undergo RT as in the feasibility arm and receive bevacizumab IV over 30-90 minutes on days 22 and 36. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073289|NCT01236560|Experimental|Arm IV (temozolomide, Phase 3 Arm B)|Patients undergo RT as in the Arm II and receive temozolomide PO once daily for 42 days beginning on day 5 of RT. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073290|NCT01236560|Experimental|Arm V (vorinostat/bevacizumab, Phase 3, Chemoradiotherapy)|Patients receive treatment as in phase II, arm I or phase II, arm III, whichever was established as superior in phase II. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073291|NCT01236560|Experimental|Feasibility (vorinostat)|Patients undergo RT 5 days a week for 6 weeks and receive vorinostat at 230 mg/m2/day. In the event of 2 or more DLTs, participants will de-escalate to vorinostat at 180 mg/m2/day. Patients receive Maintenance therapy of bevacizumab 10mg/kg/dose every 2 weeks and temozolomide 200 mg/m2/dose Days 1-5, for up to twelve cycles in the absence of progressive disease and unacceptable toxicities.
3073292|NCT01236573|Experimental|Group 1 - CD8 + TIL expressing IL-12 1x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of interleukin-12 (IL-12) gene-transduced tumor infiltrating lymphocytes (TIL).
3073293|NCT01236573|Experimental|Group 2 - CD8 + TIL expressing IL-12 3x10^6|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073294|NCT01236573|Experimental|Group 3 - CD8 + TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073295|NCT01236573|Experimental|Group 4- CD8+TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073296|NCT01236573|Experimental|Group 5 - Bulk TIL expressing IL-12 1x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073297|NCT01236573|Experimental|Group 6 - Bulk TIL expressing IL-12 3x10^7|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073298|NCT01236573|Experimental|Group 7- Bulk TIL expressing IL-12 1x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073299|NCT01236573|Experimental|Group 8 - Bulk TIL expressing IL-12 3x10^8|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073300|NCT01236573|Experimental|Group 9 - Bulk TIL expressing IL-12 1x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073301|NCT01236573|Experimental|Group 10- Bulk TIL expressing IL12 3x10^9|Phase 1. Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073302|NCT01236573|Experimental|Group 11 - Bulk TIL expressing MTD 1x10^9 (Phase 2)|Maximum tolerated dose (MTD). Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous infusion of IL-12 gene-transduced TIL.
3073303|NCT01236742|Experimental|single-vision glasses and ortho-k lenses|Children who are currently wearing ortho-k lenses at night for correction of refractive errors will be switched to wear single-vision glasses for the first 7 months and then switched back to ortho-k lenses for the next 7 months
3073304|NCT01236742|Active Comparator|ortho-k lenses|Children who are currently wearing ortho-k lenses at night for the correction of refractive errors will continue with the current treatment and serve as the first control group
3073305|NCT01236742|Other|single-vision glasses|Children who are currently wearing single-vision spectacles in the daytime for correcting their refractive errors will continue with the current treatment and serve as the second control group
3073306|NCT01236755|Experimental|ortho-k lenses|Children were switched to wear ortho-k lenses for 7 months after wearing single-vision glasses for 7 months
3073307|NCT01236768|Experimental|AG200-15|Thin transdermal contraceptive delivery system (TCDS) that gives systemic exposure of levonorgestrel (LNG) and ethinyl estradiol (EE)
3073308|NCT01236768|Active Comparator|Levora|oral contraceptive containing 150mcg of LNG and 30mcg of EE
3073309|NCT01237041|Experimental|Niacin First|Subjects receive niacin 500mg hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive placebo hourly for 4 hours on day 2 at (7:30am, 8:30am, 9:30am, and 10:30am).
3073310|NCT01237041|Experimental|Placebo First|Subjects receive placebo hourly for 4 hours on day 1 (at 7:30am, 8:30am, 9:30am, and 10:30am) then cross over to receive niacin hourly for 4 hours on day 2 (at 7:30am, 8:30am, 9:30am, and 10:30am).
3073311|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 250mg|Subjects received Niacin 250 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
3073312|NCT01237041|Experimental|Dose-Establishing Study 1 Niacin 500mg|Subjects received Niacin 500 mg every 2 hours for 3 doses (at 6am, 8am, and 10am).
3073313|NCT01237041|Experimental|Dose-Establishing Study 2 Niacin 500mg|Subjects received Niacin 500 mg hourly for 4 doses (administered at 7:30am, 8:30am, 9:30am, and 10:30am).
3073314|NCT01237054|Experimental|Imaging in MGUS, SMM, and MM|Participants will have three imaging studies on separate days: a standard positron emission tomography/computed tomography scan (18-FDG PET/CT), a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT), and magnetic resonance imaging (DCE-MRI).
3073315|NCT01237080|Experimental|Fastrach|50 persons beeing intubated using the Fastrach.
3073316|NCT01237080|Experimental|GlideScope|50 persons beeing intubated using the GlideScope.
3073317|NCT01237197|Experimental|Exenatide, then Open-Label Exenatide|Exenatide 5 micrograms (mcg): administered with injection twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study (5 months)
3073318|NCT01237197|Placebo Comparator|Placebo, then Open Label Exenatide|Placebo injection twice a day for three months; Exenatide open label 5mcg twice a day for one month and up-titrated to 10mcg twice a day for remaining two months of study.
3073319|NCT01237223|Placebo Comparator|Placebo|In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study. In single blind run-in (4 weeks) and double blind treatment period (8 weeks), patients were received matching placebo of aliskiren/amlodipine 150/5 mg tablet, aliskiren/amlodipine 150/2.5 mg tablet, aliskiren 150 mg tablet and two amlodipine 2.5 mg capsules once daily.
3073320|NCT01237223|Active Comparator|Aliskiren 150 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Aliskiren 150 mg tablet once daily (o.d)+ placebo of two amlodipine 2.5 mg capsule o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
3073321|NCT01237223|Active Comparator|Amlodipine 2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received Amlodipine 2.5 mg capsule once daily (o.d)+ placebo of amlodipine 2.5 mg capsule o.d., Aliskiren 150 mg o.d., aliskiren/amlodipine 150/5 mg tablet o.d , aliskiren/amlodipine 150/2.5 mg tablet o.d for 8 weeks of double blind period."
3073322|NCT01237223|Active Comparator|Amlodipine 5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received amlodipine 5 mg (two amlodipine 2.5 mg capsules o.d.)+ placebo of aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. , aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
3073323|NCT01237223|Experimental|Aliskiren/amlodipine 150/2.5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/2.5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/5 mg tablet o.d. for 8 weeks of double blind period."
3073324|NCT01237223|Experimental|Aliskiren/amlodipine 150/5 mg|"In order to adequately blind the study, patients were required to take a total of 3 tablets and 2 capsules of study medication throughout the study.~Patients received aliskiren/amlodipine 150/5 mg tablet o.d. + placebo of two amlodipine 2.5 mg capsules o.d., aliskiren 150 mg tablet o.d., aliskiren/amlodipine 150/2.5 mg tablet o.d. for 8 weeks of double blind period."
3073325|NCT01237301|Experimental|CGM Group|Wear an unblinded CGM for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use real time continuous glucose monitoring (rt CGM).
3073326|NCT01237301|Active Comparator|SMBG Group|Use SMBG 4 to 7 times a day for 16 weeks. Subjects continued previously started medication regiments for their diabetes. Subjects in this arm were randomized to use structured self monitoring blood glucose (stSMBG) and periodic, blinded continuous glucose monitoring (CGM).
3073327|NCT01237327|Active Comparator|1|
3073328|NCT01237327|Experimental|2|
3073329|NCT01237340|Experimental|Saizen®|
3073330|NCT01237353|Experimental|betaine hydrochloride and rabeprazole|
3073331|NCT01237587|Experimental|Duloxetine|"Blinded treatment period: 30mg or 60mg once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
3073332|NCT01237587|Placebo Comparator|Placebo|"Blinded treatment period:Placebo once daily for 13 weeks~Open label extension: 30mg or 60mg Duloxetine once daily for 26 weeks~Taper period: 30mg Duloxetine or placebo once daily for 1 week."
3073333|NCT01237678|Experimental|IMGN901 with carboplatin and etoposide|Patients will receive IMGN901 along with carboplatin and etoposide for up to 6 cycles and then be able to continue on IMGN901 alone until no further benefit or toxicity.
3073334|NCT01237678|Active Comparator|Carboplatin and Etoposide|Patients will receive Carboplatin and etoposide for up to 6 cycles.
3073335|NCT01237821|Active Comparator|BenzaClin|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
3073336|NCT01237821|Active Comparator|effaclar|Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with > or equal to 15 inflammatory lesions, > or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or tanning beds throughout the study, . Exclusion- Participants who have another skin condition that will interfere with lesion counting or assessments
3073337|NCT01237899|Experimental|1 mg LY2623091|Daily by mouth for 7 days.
3073338|NCT01237899|Experimental|10 mg LY2623091|Daily by mouth for 7 days.
3073339|NCT01237899|Experimental|25 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of 100 mg based on safety and tolerability data. The 25 mg LY2623091 was administered daily by mouth for 7 days.
3073340|NCT01237899|Experimental|0.3 mg LY2623091|The anticipated dose of LY2623091 was revised down from the original proposed dose level of up to 200 mg. The 0.3 mg LY2623091 was determined based on an interim analysis after the third dose level and was administered daily by mouth for 7 days.
3073341|NCT01237899|Placebo Comparator|Placebo|Daily by mouth for 7 days.
3073342|NCT01237899|Active Comparator|50 mg Eplerenone|Daily by mouth for 7 days.
3073343|NCT01237951|Experimental|GemBuMel|"Gemcitabine 1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.~Busulfan 32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan area under curve (AUC) 4,000 by vein on Days -8 to -5 as an outpatient or inpatient.~Melphalan 60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.~Palifermin 60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~Palifermin 60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient.~Dexamethasone 8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.~Stem Cell Transplant: On Day 0, stem cells returned to body by vein over 30-60 minutes."
3073344|NCT01238120|Active Comparator|Placebo and Home-Based Exercise|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
3073345|NCT01238120|Active Comparator|Ibuprofen 200mg BID, Home-Based Exercise|200mg ibuprofen (taken twice a day at least 8 hours apart) and a progressive walking and resistance band exercise program called Exercise for Cancer Patient (EXCAP) for a period of 6 weeks.
3073346|NCT01238120|Placebo Comparator|Placebo|200mg placebo (taken twice a day at least 8 hours apart) for a period of 6 weeks.
3073347|NCT01238120|Active Comparator|Ibuprofen 200 mg BID|200mg ibuprofen (taken twice a day at least 8 hours apart) for a period of 6 weeks.
3073348|NCT01238172|Experimental|Arm A - MEAL Program Intervention|Patients will receive dietary education and telephone counseling sessions over 24 months.
3073349|NCT01238172|Experimental|Arm B - Prostate Cancer Foundation Booklet|Patients receive information about diet, nutrition, exercise and cancer. Patients also receive regularly scheduled newsletters.
3468851|NCT03892018|Active Comparator|Fasted/ Fed Treatment Sequence|"Subjects will be assigned a fasted/fed sequence.~Fasted Sequence- subjects will fast overnight and continue fasting until 4 hours post paclitaxel dose.~Fed sequence- subjects will fast overnight and continue fasting until they consume a standardized test meal at a predetermined time after paclitaxel administration."
3073351|NCT01238341||Pancreatobiliary disease|Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease.
3073352|NCT01238471|Experimental|Propranolol|Oral propranolol for premature infants allocated to this arm by randomization
3073353|NCT01238471|Placebo Comparator|Oral sucrose 5%|Placebo: Oral sucrose 5% for premature infants allocated to control arm by randomization
3468852|NCT03891667|Experimental|8 Week Disulfiram|Patients in this group receive disulfiram for 8 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg for week 3, and 500 mg daily for week 4 to week 8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
3073354|NCT01238536|Experimental|Epidural Steroid injection|"Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.~Intervention: Epidural steroid with local anesthetic injection~2cc of .25 - 1% lidocaine and glucocorticoid (Kenalog 40-120 mg, depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg)"
3073355|NCT01238536|Active Comparator|Epidural local anesthetic injection|Intervention: Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
3073356|NCT01238549||Spinal Cord Injury|Participants with SCI
3073357|NCT01238575|Experimental|Extended-release guanfacine|
3073358|NCT01238575|Placebo Comparator|Inactive placebo|
3073359|NCT01238588|Other|Sevelamer Carbonate (Renvela)|Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.
3073360|NCT01238640|Experimental|Code STD|"An experimental 2 mg nicotine product coded STD"
3073361|NCT01238640|Experimental|Code STE|"An experimental 2 mg nicotine product coded STE"
3073362|NCT01238640|Active Comparator|Nicorette Microtab|A comparative 2 mg marketed nicotine product called Nicorette Microtab
3073363|NCT01238822|Placebo Comparator|Placebo|
3073364|NCT01238822|Active Comparator|Low Dose Methylphenidate|Low dose: 18 mg methylphenidate
3073365|NCT01238822|Active Comparator|Medium Dose Methylphenidate|Medium Dosage: 36 mg if more than 50 kg and 27 mg if less than 50 kg
3073366|NCT01238822|Active Comparator|High Dose Methylphenidate|54 mg if more than 50 kg and 36 mg if less than 50 kg
3073367|NCT01238835|Experimental|TAVR-TA|Transcatheter valve replacement with transapical access
3073368|NCT01238848|Experimental|Hypertonic|Nebulized hypertonic saline (sodium chloride 3%) + albuterol
3073369|NCT01238848|Active Comparator|Normal|Normal saline (sodium chloride 0.9%) + albuterol
3073370|NCT01238861|Placebo Comparator|Eosinophilic phenotype (EOS+) Placebo|EOS+ (defined as ELEN Index [proprietary mathematical algorithm to predict sputum eosinophil's greater than or equal to 2 percent] positive and/or FeNO [fraction of exhaled nitric oxide] greater than or equal to [>=] 50 parts per billion [ppb]) participants received matching placebo injections subcutaneous injection every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073371|NCT01238861|Experimental|EOS+ Benralizumab (2 mg)|EOS+ participants received single benralizumab 2 milligram (mg) injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073372|NCT01238861|Experimental|EOS+ Benralizumab (20 mg)|EOS+ participants received single benralizumab 20 mg injection subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073373|NCT01238861|Experimental|EOS+ Benralizumab (100 mg)|EOS+ participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073374|NCT01238861|Placebo Comparator|Non-eosinophil phenotype (EOS-) Placebo|EOS- (defined as ELEN Index negative and FeNO <50 ppb) participants received matching placebo subcutaneous every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073375|NCT01238861|Experimental|EOS- Benralizumab (100 mg)|EOS- participants received benralizumab 50 mg as two injections subcutaneously every 4 weeks for first 3 doses and then every 8 weeks for next 4 doses up to Week 40.
3073376|NCT01238900||benign biliary strictures|All patients who have a medical indication for an ERCP to place a stent in their benign biliary strictures
3073377|NCT01238991|Experimental|ACC-001 (3 micrograms) + QS-21|Active vaccine dose of 3 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3073378|NCT01238991|Experimental|ACC-001 (10 micrograms) + QS-21|Active vaccine dose of 10 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3073379|NCT01238991|Experimental|ACC-001 (30 micrograms) + QS-21|Active vaccine dose of 30 micrograms +adjuvant, IM injection, at Day 1, month 6, 12 and 18
3073380|NCT01239043|Experimental|Menomune® vaccine group|Participants received Menomune® vaccine in MTA29 (NCT00874549)
3073381|NCT01239043|Experimental|Menactra® vaccine group|Participants received Menactra® vaccine in trial MTA29 (NCT00874549)
3073382|NCT01239056||Pancreatic Pseudocysts|All adult patients who have a clinical indication to undergo an endoscopic drainage of a pancreatic pseudocyst.
3073383|NCT01239121|Experimental|HIE-Enhanced Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
3073384|NCT01239121|Active Comparator|Optimal Medication Reconciliation without HIE|Optimal Medication Reconciliation without Health Information Exchange (HIE) for Veterans admitted to James J Peters VA hospital units 6B, 7B, 7C, and 8B (each unit crossing over between intervention and control every 3-4 months)
3073385|NCT01239121|Other|Pilot HIE-Enhanced Outpatient Medication Reconciliation|Health Information Exchange (HIE)-Enhanced Medication Reconciliation for Veterans seen as outpatients in Geriatrics Primary care clinic
3073386|NCT01239160|Experimental|Advanced PCD|The use of an advanced PCD device to reduce and maintain limb volume
3073387|NCT01239160|Active Comparator|Simple PCD|The use of the Simple PCD is to reduce and maintain limb volume
3073388|NCT01239316|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3073389|NCT01239342|Experimental|Arm I (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who are progression free after 1 year may receive a 12 week study drug supply of Akt inhibitor MK2206.
3073390|NCT01239342|Experimental|Arm II (everolimus)|Patients receive everolimus PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3073391|NCT01239355|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive oral Akt inhibitor MK2206 on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3320953|NCT02014961|Active Comparator|Mutation Carriers|Whole-exome sequencing (WES) Dermal biopsy Gastro-intestinal questionnaire
3320954|NCT02014961|Placebo Comparator|Non-Mutation Carriers|Whole-exome sequencing (WES) Gastro-intestinal questionnaire
3073394|NCT01239381|Experimental|SBRT-Proton|Stereotactic body radiotherapy by proton radiation
3073395|NCT01239394|Other|ofatumumab|single-arm, open-label, interventional
3073396|NCT01239472|No Intervention|tacrolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone.
3073397|NCT01239472|Active Comparator|everolimus|Kidney transplant patients with living or deceased donors using tacrolimus, mycophenolate sodium and prednisone, and converted for everolimus, mycophenolate sodium, and prednisone 90 days after renal transplantation.
3073398|NCT01239511|Placebo Comparator|Placebo group|placebo capsule 2# t.i.d./day
3073399|NCT01239511|Experimental|Treatment Group A|150 mg STA-2, 2 capsules t.i.d., after meal (900 mg STA-2 total dose per day)
3073400|NCT01239511|Experimental|Treatment Group B|300 mg STA-2, 2 capsules t.i.d., after meal (1800 mg STA-2 total dose per day)
3073401|NCT01239511|Experimental|Treatment Group C|450 mg STA-2, 2 capsules t.i.d., after meal (2700 mg STA-2 total dose per day)
3073402|NCT01239732|Experimental|Bevacizumab + Paclitaxel + Carboplatin|Participants will receive bevacizumab 15 mg/kg IV on Day 1 every 3 weeks from Cycle 1 to Cycle 36 (initially concurrent with chemotherapy, then continued as a single agent following the completion of chemotherapy), or until protocol defined disease progression or until unacceptable toxicity (whichever occurred first). Participants will receive paclitaxel 175 mg/m^2 IV on Day 1 every 3 weeks or 80 mg/m^2 IV every week and carboplatin (AUC 5-6) IV on Day 1 every 3 weeks for a minimum of 4 and maximum of 8 cycles (including up to 4 pre-surgical cycles), or until protocol defined disease progression, or unacceptable toxicity (whichever occurred first).
3073403|NCT01239745||1|
3073404|NCT01239797|Active Comparator|Lenalidomide + Dexamethasone|
3073405|NCT01239797|Experimental|Lenalidomide + Dexamethasone +Elotuzumab|
3073406|NCT01239992|Experimental|Niacin/ Laropiprant|
3073407|NCT01240122|Active Comparator|Biotrue MPS|
3073408|NCT01240122|Experimental|Investigational MPS|
3073409|NCT01240135|Other|FID 114576A / renu fresh|FID 114675A used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after which renu fresh used for contact lens care for an additional 14 days.
3073410|NCT01240135|Other|renu fresh / FID 114675A|Renu fresh used for contact lens care per protocol-specified instructions for 14 days, followed by a minimum 1-day washout period, after FID 114675A used for contact lens care for an additional 14 days.
3073411|NCT01240200|Active Comparator|Vial & Syringe (Period 1) / Pen (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine vial and syringe in Period 1 and Insulin glargine SoloSTAR pen in Period 2.
3073412|NCT01240200|Experimental|Pen (Period 1) / Vial & Syringe (Period 2)|Crossover phase: patients randomized to the sequence: Insulin glargine SoloSTAR® pen in Period 1 and Insulin glargine vial and syringe in Period 2.
3073413|NCT01240356|Experimental|Phase I: Healthy Volunteers|Subjects without history of Central Nervous System Disease will receive 2-hours of hands-free 2-megahertz (MHz) transcranial Doppler ultrasound insonation continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
3073414|NCT01240356|Experimental|Phase II: 0-3 hour Patients|Ischemic stroke patients who present between 0-3 hours will receive 2-hours of hands-free 2-MHz transcranial Doppler ultrasound Continuously to the intracranial vessels.
3073415|NCT01240382|Experimental|3% DE-089|
3073416|NCT01240382|Active Comparator|0.1% HA|
3073417|NCT01240551|Active Comparator|Mets via NaF-18 PET/CT|Patients with known bone metastases (i.e. mets).
3073418|NCT01240551|Active Comparator|No-Mets via NaF-18 PET/CT|Patients with no clinical evidence of bone metastases
3073419|NCT01240590|Experimental|Ph I Level -1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 8 mg/m(2) Crolibulin
3073420|NCT01240590|Active Comparator|Ph I Level 1: Cisplatin + Crolibulin|75mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
3073421|NCT01240590|Active Comparator|Ph I Level 2: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 13 mg/m(2) Crolibulin
3073422|NCT01240590|Active Comparator|Ph II Level 3: Cisplatin + Crolibulin|100mg/m(2) Cisplatin + 20 mg/m(2) Crolibulin
3073423|NCT01240590|Active Comparator|Ph II Level 4: Cisplatin|100mg/m(2) Cisplatin
3073424|NCT01240746|Active Comparator|Group 1: Licensed 2010-2011 TIV|Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.
3073425|NCT01240746|Experimental|Group 2: Investigational TIV|Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain
3073426|NCT01240746|Experimental|Group 3: Investigational QIV|Participants will receive the investigational Quadrivalent Influenza Vaccine
3073427|NCT01240785|Active Comparator|Metformin|Metformin 500 mg 1-2 tablets twice daily according to plasma glucose values
3073428|NCT01240785|Active Comparator|insulin|NPH insulin once or twice daily and/or insulin lispro or aspart according to preprandial and postprandial glucose values
3073429|NCT01240811|No Intervention|Control-No IUD|Healthy volunteers not at risk of pregnancy and not using any hormonal contraception.
3073430|NCT01240811|Experimental|Levonorgestrel IUS|Healthy volunteers seeking contraception with IUD. Randomized to LNG IUS.
3073431|NCT01240811|Experimental|Copper T380A IUD|Healthy volunteers seeking contraception with IUD. Randomized to Copper T380A IUD.
3073432|NCT01240863|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
3073433|NCT01240863|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
3073434|NCT01240902|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
3073435|NCT01240902|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
3073436|NCT01240902|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3073437|NCT01240902|Active Comparator|High Risk: SAVR|High Risk Surgical Patients: Surgical Aortic Valve Replacement (SAVR)
3073438|NCT01240915|Experimental|Cohort 1|The first 9 subjects will be recruited into Cohort 1 and will receive either placebo (n=3) or MultiStem low dose (n=6) as an intravenous infusion on Day 1. The first five patients enrolled constitute a subgroup of Cohort 1 and these patients will receive multiple doses, once every day for 7 days for 3 doses (Day 1 and Weeks 1 & 2).
3073439|NCT01240915|Experimental|Cohort 2|This group will receive either placebo (n=3) or MultiStem high dose (n=6) as an intravenous infusion on Day 1. The subjects then receive the opposite dose of study medication at Week 8.
3073440|NCT01240915|Experimental|Cohort 3|These subjects (total n=88 evaluable patients) will receive either Placebo or MultiStem (1:1 randomization) as an intravenous infusion on Day 1. In addition all subjects in Cohort 3 will receive a single infusion of either MultiStem or Placebo at Week 8, depending on their randomization schedule. A total of ~22 patients will receive an additional infusion of MultiStem, ~44 patients will receive the alternative blinded therapy to that which they received for Day 1 infusion, and ~22 patients will receive an additional infusion of placebo.
3073441|NCT01241240|Experimental|Triple Combination Therapy|Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
3073442|NCT01241240|Active Comparator|Combigan®|Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
3073443|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 10mg|
3073444|NCT01241292|Experimental|BMS-901608 (Elotuzumab) 20mg|
3073445|NCT01241318|Experimental|Chlorhexidine cord care|Mothers located in health facility catchment areas assigned to this arm will apply Chlorhexidine gluconate (4%) to their infants daily until three days after the cord completely separates. Bottles of chlorhexidine is provided to women during antenatal care.
3073446|NCT01241318|Active Comparator|Dry cord care|Mothers in health facility catchment areas assigned to this arm will use dry cord care - keeping their babies' umbilical stumps clean and dry - as per normal routine standard of care and in accordance with Zambia Ministry of Health policy.
3073447|NCT01241344|Active Comparator|Brincidofovir|"Adult subjects: 200mg BCV administered as 50mg tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: 4mg/kg BCV (not to exceed a total single dose of 200mg) administered using a 10 mg/mL liquid formulation taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
3073448|NCT01241344|Placebo Comparator|Placebo|"Adult subjects: Matching placebo tablets taken orally either once weekly (QW; 4 tablets) or twice weekly (BIW; 2 tablets).~Pediatric subjects: Matching liquid placebo taken orally either QW (as 4 mg/kg) or BIW (as 2 mg/kg)."
3073449|NCT01241435|Experimental|LY2216684|LY2216684: A single dose of 18 milligrams (mg) administered orally in participants with normal hepatic function, mild hepatic impairment (Child-Pugh A), moderate hepatic impairment (Child-Pugh B), or severe hepatic impairment (Child-Pugh C)
3073450|NCT01241448|Placebo Comparator|Placebo|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3073451|NCT01241448|Experimental|2.5 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3073452|NCT01241448|Experimental|10 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3073453|NCT01241448|Experimental|20 mg LY2409021|Taken orally once daily for 24 weeks. Participants who entered the study on stable metformin therapy were to continue at the dose prescribed by their physician.
3073454|NCT01241461|Experimental|LY2584702|
3073455|NCT01241513|Experimental|N-acetyl-L-Cysteine|N-Acetyl-L-Cysteine
3073456|NCT01241513|Placebo Comparator|Placebo|placebo
3073457|NCT01241539|Experimental|Dabigatran etexilate 110 mg|Capsule, oral
3073458|NCT01241539|Experimental|Dabigatran etexilate 75 mg|Capsule, oral
3073459|NCT01241539|Experimental|Dabigatran etexilate 150 mg|Capsule, oral
3073460|NCT01241552|Experimental|MK-3415 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-3415 + Standard of Care for CDI
3073461|NCT01241552|Experimental|MK-6072 + SOC|Single IV infusion of 10 mg/kg MK-6072 + Standard of Care for CDI
3073462|NCT01241552|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + Standard of Care for CDI
3073463|NCT01241552|Placebo Comparator|Placebo + SOC|Normal saline infusion (0.9% sodium chloride) + Standard of Care for CDI
3073464|NCT01241565|Experimental|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|Single arm study, all patients will receive the study device.
3073465|NCT01241591|Experimental|CP 690,550 5 mg BID+Placebo BIW|
3073466|NCT01241591|Experimental|CP 690,550 10 mg BID+Placebo BIW|
3073467|NCT01241591|Active Comparator|Placebo BID+Etanercept 50 mg BIW|
3073468|NCT01241591|Placebo Comparator|Placebo BID+Placebo BIW|
3073469|NCT01241604|Active Comparator|Respironics BiPAP S/T|Control Arm using Respironics BiPAP S/T
3073470|NCT01241604|Active Comparator|Respironics BiPAP Auto SV3|Treatment arm using Respironics BiPAP Auto SV3
3073471|NCT01241760|Experimental|001 T(q8h) / PR|Telaprevir (T) 750 mg (2 oral tablets) every 8 hours for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
3073472|NCT01241760|Experimental|002 T(b.i.d.) / PR|Telaprevir (T) 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks, in combination with pegylated interferon (P) and ribavirin (R)
3073473|NCT01241903|Experimental|Crestor|
3073474|NCT01241903|Placebo Comparator|sugar pill|
3073475|NCT01241916|Experimental|Static-progressive splint|
3073476|NCT01241916|Experimental|Dynamic Splint|
3073477|NCT01242085|Active Comparator|control group|control group will have standard instrumentation of their knee replacement
3073478|NCT01242085|Experimental|trumatch group|the trumatch patient will have custom instruments made from preop CT scans
3073479|NCT01242111|Experimental|BMN 110|
3073480|NCT01242176|Experimental|BI 10773 Final Formulation|one single film-coated tablet in the morning
3073481|NCT01242176|Experimental|BI 10773 XX Trial Formulation 2|one single dose tablet in the morning
3073482|NCT01242241|Other|Non-obese|Non-obese children categorized as those with a body mass index(BMI)between 25-84th percentile
3073483|NCT01242241|Active Comparator|Obese children|Obese children are categorized as those with a body mass index >95th percentile
3073484|NCT01242371|Active Comparator|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
3073485|NCT01242371|Placebo Comparator|Identical-appearing Placebo|Identical appearing placebo 1 tablet by mouth daily for 14 weeks after 2 week placebo run-in
3073486|NCT01242514|Experimental|A|Oral treatment
3073487|NCT01242514|Experimental|B|Oral treatment
3073488|NCT01242514|Experimental|C|Oral treatment
3073489|NCT01242527|Placebo Comparator|placebo|
3073490|NCT01242527|Experimental|Epanova 2 g|
3073491|NCT01242527|Experimental|Epanova 3 g|
3073492|NCT01242527|Experimental|Epanova 4 g|
3073493|NCT01242644|Experimental|pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour;
3073494|NCT01242644|Active Comparator|saline pain pump , injectable medication|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
3073495|NCT01242644|Active Comparator|injectable medication only|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected and no pain pump.
3073496|NCT01242748|Experimental|Degarelix 240 mg/480 mg|
3073497|NCT01242748|Active Comparator|Goserelin acetate|
3073498|NCT01242813|Experimental|Canakinumab|This was an open-label, single treatment arm, multicenter study of monthly canakinumab 150 mg (2 mg/kg for patient ≤ 40 kg) subcutaneous injections in patients with active recurrent or chronic TRAPS.
3073499|NCT01243112|Experimental|Lidocaine w/ Epi|0.2ml 1% Lidocaine with Epinephrine (1:100,000)
3073500|NCT01243112|Experimental|Bupivacaine with epi|0.2 ml 0.25% Bupivacaine with epinephrine (1:200,000)
3073501|NCT01243112|Experimental|Low dose Lido and Bupi w/ Epi|0.2ml 0.5% Lidocaine + 0.125% Bupivacaine with Epinephrine (1:150,000)
3073502|NCT01243112|Experimental|High Dose Lido and Bupi with epi|0.2ml 1% Lidocaine + 0.25% Bupivacaine with Epinephrine (1:150,000)
3073503|NCT01243151|Placebo Comparator|A|
3073504|NCT01243151|Experimental|B|
3073505|NCT01243151|Experimental|C|
3073506|NCT01243151|Experimental|D|
3073507|NCT01243151|Experimental|E|
3073508|NCT01243177|Experimental|Lacosamide|
3073509|NCT01243177|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|
3073510|NCT01243242|Experimental|METADOXINE|Eligible subjects will be randomly assigned to receive MG01CI (1,400 mg)
3073511|NCT01243242|Placebo Comparator|Placebo|Eligible subjects will be randomly assigned to receive Placebo (1,400 mg)
3073512|NCT01243268||Patients with essential hypertension|
3073513|NCT01243294|Active Comparator|SenSura|"CE marked and launched (The letters CE do not represent any specific words, though may have initially stood for Communauté Européenne (European Community) or Conformité Européenne (European Conformity). By affixing the CE marking to a product, the manufacturer declares that it meets EU safety and health and environmental requirements."
3073514|NCT01243294|Active Comparator|New ostomy appliance (SS)|SS = New ostomy appliance. Due to company confidentiality the product is just called SS and this is not short for any other names.
3073515|NCT01243320|Experimental|10ppm Oral Silver|Oral Dose of 10ppm
3073516|NCT01243320|Experimental|32ppm Oral Silver|Oral Dose of 32ppm
3073517|NCT01243333|Experimental|Diagnostic (multi-tracer PET scans)|Patients undergo Positron Emission Tomography (PET) scans with [F-18]fluorodeoxyglucose and [F-18]fluorothymidine at baseline and within 7 days of completion of 1 or 2 (if the course is less than 3 weeks) therapeutic agent courses.
3073518|NCT01243411|Experimental|AA4500|collagenase clostridium histolyticum
3073519|NCT01243424|Experimental|linagliptin|patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
3073520|NCT01243424|Active Comparator|glimepiride 1-4 mg QD|patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)
3073521|NCT01243450|Active Comparator|Active generic|Treatment of acne for 12 weeks with generic tretinoin
3073522|NCT01243450|Placebo Comparator|Placebo|Treatment of acne for 12 weeks with Placebo
3073523|NCT01243450|Active Comparator|Brand|Treatment of acne over 12 weeks with tretinoin Brand
3073524|NCT01243567|Active Comparator|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
3073525|NCT01243567|Active Comparator|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
3073526|NCT01243580|Active Comparator|Ortho-Cyclen®|Ortho-Cyclen® is a comparator drug intervention
3073527|NCT01243580|Experimental|AG200-15|AG200-15 is an investigational transdermal contraceptive delivery system that is a drug intervention
3073528|NCT01243593|Experimental|Treatment Group|
3073529|NCT01243593|Active Comparator|Control Group|
3073530|NCT01243619|Experimental|FLT PET|This is a single arm trial, in which all patients receive three FDG-PET scans and three FLT-PET scans, before, during and after pre-operative chemoradiation for esophageal cancer.
3073531|NCT01243671|Experimental|Adalimumab|Adalimumab 160 mg at Week 0, 80 mg at Week 2 and 40 mg every other week (eow) starting at Week 4 to Week 50, subcutaneous injection. After Week 52, participants could continue the treatment with 40 mg eow until the day before approval of adalimumab for intestinal Behçet's disease in Japan.
3073532|NCT01243762|Experimental|Dalotuzumab 7.5 mg/kg + MK-0752 1800 mg|Participants in Part 1 of the study receive dalotuzumab 7.5 mg/kg intravenously (IV) weekly + MK-0752 1800 mg orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073533|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-0752 1800 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-0752 1800 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073534|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 90 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK-2206 90 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073535|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 135 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 135 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073536|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 150 mg|Participants in Parts 1 and 2 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 150 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073537|NCT01243762|Experimental|Dalotuzumab 10 mg/kg + MK-2206 200 mg|Participants in Part 1 of the study receive dalotuzumab 10 mg/kg IV weekly + MK- 2206 200 mg PO weekly in 28-day cycles for a maximum of 6 months of study therapy.
3073538|NCT01243762|Experimental|Dalotuzumab + Ridaforolimus|Participants in Part 2 of the study receive dalotuzumab 10 mg/kg IV weekly + ridaforolimus 20 mg PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy.
3073539|NCT01243775|Experimental|Belotaxel plus Belloxa|Belotaxel 60 mg/m2 3 weekly (day 1) Belloxa 70 mg/m2 3 weekly (day 2)
3073540|NCT01243944|Experimental|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg once a day (QD) to 25 mg BID based on safety and efficacy
3073541|NCT01243944|Other|Best Available Therapy|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
3073542|NCT01243957|Experimental|LY2216684 + fluoxetine|"LY2216684: 18 milligrams (mg) oral (po) once daily (QD) on Days 1, 2, and 3 and Days 25-27~Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)"
3073543|NCT01244035|Experimental|Part I - Sequence ABC|Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
3073544|NCT01244035|Experimental|Part I - Sequence ACB|Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
3073545|NCT01244035|Experimental|Part I - Sequence BCA|Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
3073546|NCT01244035|Experimental|Part I - Sequence BAC|Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
3073547|NCT01244035|Experimental|Part I - Sequence CAB|Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
3073548|NCT01244035|Experimental|Part I - Sequence CBA|Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
3073549|NCT01244035|Experimental|Part II - Sequence DEF|Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
3073550|NCT01244035|Experimental|Part II - Sequence DFE|Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
3073551|NCT01244035|Experimental|Part II - Sequence EFD|Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
3073552|NCT01244035|Experimental|Part II - Sequence EDF|Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
3073553|NCT01244035|Experimental|Part II - Sequence FDE|Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
3073554|NCT01244035|Experimental|Part II -Sequence FED|Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3
3073555|NCT01244061|Experimental|Varenicline|
3073556|NCT01244061|Placebo Comparator|Placebo|
3073557|NCT01244126|Active Comparator|IM morphine|0.1 mg/kg morphine IM
3073558|NCT01244126|Active Comparator|IV morphine|0.1 mg/kg morphine IV
3073559|NCT01244126|Active Comparator|fentanyl IN|Intranasal fentanyl 2 mcg/kg IN
3073560|NCT01244191|Experimental|Tivantinib and erlotinib|Tivantinib 720 mg daily (360 mg twice a day) in combination with 150 mg of erlotinib, given once a day
3073561|NCT01244191|Active Comparator|Placebo and erlotinib|Tivantinib placebo given twice a day in combination with 150 mg of erlotinib, given once a day
3073562|NCT01244243|Experimental|Active therapy|All subjects receive the same active robotic therapy, there is no placebo arm, as a key goal of this study is to define predictors of response to active treatment.
3073563|NCT01244425|Experimental|FS VH S/D 500 s-apr|Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), not to exceed 20mL per participant. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
3073564|NCT01244425|Active Comparator|Manual compression - Control|A dry surgical gauze swab will be used to apply by hand an even light pressure onto the oozing resection surface of the liver. Hemostasis will be assessed at 4, 6, 8 and 10 minutes after application of the study treatment.
3073565|NCT01244451|Experimental|Bendofa|Bendamustine + Ofatumumab
3073566|NCT01244477|Experimental|CPT-C|Participants in group CPT-C
3073567|NCT01244477|No Intervention|Treatment-as-Usual|Participants randomly assigned to the Waitlist Control Group (who will participate in CPT-C after 12 weeks).
3073568|NCT01244490|Experimental|Extended-release Guanfacine Hydrochloride|
3073569|NCT01244490|Other|Atomoxetine Hydrochloride|Active Reference
3073570|NCT01244490|Placebo Comparator|Placebo|
3073571|NCT01244503|Experimental|Sodium Octanoate Breath Test|Only subjects with metabolic syndrome and suspected non alcoholic fatty liver disease will undergo breath test. They must not have any other liver disease.
3073572|NCT01244516|Other|galyfilcon A|Subjects that were randomized to receive the galyfilcon A lens with a base curve of 8.30 throughout the entire course of the study.
3073573|NCT01244516|Other|lotrafilcon B|Subjects that were randomized to wear lotrafilcon B lens throughout the course of the study.
3073574|NCT01244516|Other|comfilcon A|Subjects that were randomized to wear comfilcon A lens throughout the course of the study.
3073575|NCT01244529|Other|galy A Plus/ galy A / seno A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
3073576|NCT01244529|Other|galy A Plus / seno A / galy A|"Pair 1: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3073577|NCT01244529|Other|galy A / galy A Plus / seno A|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8)."
3073578|NCT01244529|Other|galy A / seno A / galy A Plus|"Pair 1: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 2: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3073579|NCT01244529|Other|seno A / galy A / glay A Plus|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3073580|NCT01244529|Other|seno A / galy A Plus / galy A|"Pair 1: seno A- subjects were randomized to receive different base curves for each eye (BC: 8.4 or 8.8).~Pair 2: galy A Plus-subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7).~Pair 3: galy A -subjects were randomized to receive different base curves for each eye (BC: 8.3 or 8.7)."
3073581|NCT01244633|Experimental|Ecopipam|Active treatment
3073582|NCT01244711|Experimental|Quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
3073583|NCT01244724|Experimental|Lexapro|escitalopram 10 mg or 20 mg/d
3073584|NCT01244815|Experimental|Asenapine 2.5 mg twice daily (BID)|Participants receive asenapine 2.5 mg BID for 21 days.
3073585|NCT01244815|Experimental|Asenapine 5.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. Participants receive asenapine 5.0 mg BID for the remainder of the 21-day treatment period.
3073586|NCT01244815|Experimental|Asenapine 10.0 mg BID|Participants receive asenapine 2.5 mg BID through Day 3. On Day 4 participants receive asenapine 2.5 mg in the morning and 5.0 mg in the evening. On Day 5 and 6 participants receive asenapine 5.0 mg BID. On Day 7 participants receive asenapine 5.0 mg in the morning and 10.0 mg in the evening. Participants receive asenapine 10.0 mg BID for the remainder of the 21-day treatment period.
3073587|NCT01244815|Placebo Comparator|Placebo|Participants receive placebo BID for 21 days.
3073588|NCT01244828|Experimental|Asenapine|Asenapine 5 mg twice daily (BID) for the first week of treatment, then either 5 mg or 10 mg BID.
3073589|NCT01244893|Other|Acuvue Advance Plus prePQ/Acuvue Advance Plus postPQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification will be worn first and Acuvue AdvancePlus silicone hydrogel contact lens manufactured after process qualification will be worn second.
3073590|NCT01244893|Other|Acuvue Advance Plus postPQ/Acuvue Advance Plus prePQ|Acuvue Advance Plus silicone hydrogel contact lens manufactured prior to process qualification worn first and Acuvue Advance Plus silicone hydrogel contact lens manufactured after process qualification worn second.
3073591|NCT01244906|Experimental|Reduced Intensity Allogeneic Stem Cell Transplantation|All patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
3073592|NCT01244984|Experimental|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
3073593|NCT01244984|Experimental|Fluticasone Furoate|Inhaled corticosteroid
3073594|NCT01245049|Experimental|BOOSTRIX POLIO GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
3073595|NCT01245049|Active Comparator|REPEVAX GROUP|Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Repevax™ vaccine co-administered with Priorix™ vaccine at Day 0. Repevax™ vaccine was administered intramuscularly in the deltoid muscle of the arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arn or as an intramuscular injection into the deltoid muscle of the right arm.
3073596|NCT01245062|Experimental|GSK1120212|MEK inhibitor
3073597|NCT01245062|Active Comparator|Chemotherapy|Investigator Choice of DTIC or paclitaxel
3073598|NCT01245062|Experimental|Crossover|MEK inhibitor after documented progression on Chemotherapy Arm
3073599|NCT01245101|Experimental|Raltegravir and then Observation|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
3073600|NCT01245101|Active Comparator|Observation and then Raltegravir|The total duration of the study will be 40 weeks. This will include Part 1 (16 weeks) followed by Part 2 (8 weeks) followed by the crossover to Part 2 (16 weeks). During Part 1 participants in Group A will receive open-label raltegravir in addition to their established antiretroviral regimen while Group B participants will continue taking their established antiretroviral regimen for 16 weeks. After completion of Part 1, both groups will enter Part 2 that will consist of a washout period of 8 weeks during which both groups will only take their established antiretroviral regimen without raltegravir. This will be followed by Part 3 during which the two study groups will undergo a crossover with respect to the treatment assignment during Part 1 so that Group A will continue to receive their established antiretroviral regimen while Group B will receive open-label raltegravir in addition to their established antiretroviral regimen for 16 weeks.
3073601|NCT01245140|Active Comparator|Active|to receive study drug (alitretinoin, 20 patients)
3073602|NCT01245140|Placebo Comparator|Placebo|to receive placebo (dummy drug, 10 patients)
3073603|NCT01245270|Experimental|Bilberry capsule first, then control cap|"Volunteers will be given a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract) followed by a 14 day washout period then a single control placebo capsule.~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
3073604|NCT01245270|Experimental|Control capsule first, then bilberry cap|"Volunteers will be given a single control placebo capsule followed by a 14 day washout period the a single capsule of 0.47 grams of mirtoselect (a concentrated bilberry extract)~First Intervention (1 day), Washout (14 days), Second Intervention (1 day)"
3073605|NCT01245283|Active Comparator|Wait-list Non-exercise Control (CON)|Subjects will continue to participate in their normal activities and clinical care during the four month study period if assigned to this group.
3073606|NCT01245283|Active Comparator|Concentric Focused RX (CRX)|Training protocol for 1 set of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
3073607|NCT01245283|Active Comparator|Eccentric Focused RX (ERX)|"The Human Dynamics Laboratory features prototype equipment that increases resistance loads during the eccentric phase of the contraction while assistance is provided by the machine during the concentric phase. One set of each exercise - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press."
3073608|NCT01245374|Experimental|Nordiflex Norditropin®|Individually adjusted dose administered with Norditropin NordiFlex® for 6 weeks. Dosage depended on age, weight, etiologies and according to the summary of product characteristics (SPC)
3073609|NCT01245387||Macugen|
3073610|NCT01245413|Active Comparator|SenSura Adhesive (device)|Sensura is a commercially available adhesive, that is designed to collect output from a stoma.
3073611|NCT01245413|Experimental|Athena adhesive|Athena = new test adhesive. The Athena baseplate is intended for collecting output from a stoma.
3073612|NCT01245439|Experimental|1|
3073613|NCT01245595|Active Comparator|Aminophylline|Patients to receive aminophylline 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
3073614|NCT01245595|Placebo Comparator|Placebo|Normal Saline Placebo
3073615|NCT01245647|Placebo Comparator|Sugar Pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
3073616|NCT01245647|Active Comparator|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
3073617|NCT01245673|Experimental|Prevnar, T Cells, Lenalidomide, MAGE A-3|All patients will receive a priming immunization with a MAGE-A3/GM-CSF vaccine with adjuvant Hiltonol® (Poly-ICLC) along with the pneumococcal conjugate vaccine/PCV control vaccine about 10 days before a steady-state mononuclear cell apheresis. Patients will then undergo hematopoietic stem cell mobilization. All patients will receive high-dose melphalan followed by hematopoietic stem cells on day 0. On day +2, patients will receive anti-CD3/anti-CD28-costimulated autologous T cells. At days 14, 42, and 90, patients will receive MAGEA3/GM-CSF (+Hiltonol® Poly-ICLC) and PCV booster immunizations followed by restaging studies and immune assessments at day +100. At day 100, after immunizations and restaging, patients will start Revlamid® (Lenalidomide) maintenance therapy followed by 2 additional MAGE-A3 and PCV immunizations at days 120 and 150.
3073618|NCT01245699|No Intervention|Before RTAVF and post-event debriefing|Before scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
3073619|NCT01245699|Active Comparator|After RTAVF and post-event debriefing|After scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing
3073620|NCT01245738||Participants|Participants admitted to participating tertiary cardiac care centers who experienced a first coronary event.
3073621|NCT01245751|Experimental|Group 1: Booster Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who received Zoster Vaccine, Live approximately 10 years prior in the Shingles Prevention Study V211-004 NCT00007501)
3073622|NCT01245751|Experimental|Group 2: First Dose Participants ≥70 years of age|Herpes zoster history-negative participants ≥70 years of age who have never received Zoster Vaccine, Live and are matched to Group 1 participants by age
3073623|NCT01245751|Experimental|Group 3: First Dose Participants ≥60 and <70 years of age|Herpes zoster history-negative participants ≥60 and <70 years of age who have never received Zoster Vaccine, Live
3073624|NCT01245751|Experimental|Group 4: First Dose Participants ≥50 and <60 years of age|Herpes zoster history-negative participants ≥50 and <60 years of age who have never received Zoster Vaccine, Live
3073625|NCT01245764|Experimental|GARDASIL™ 9 to 12 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3073626|NCT01245764|Experimental|GARDASIL™ 13 to 15 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3073627|NCT01245764|Experimental|GARDASIL™ 16 to 26 Years Old|GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. Participants will not continue to study Phase B.
3320955|NCT02014961|Other|Spouse|Whole-exome sequencing (WES) 12-Lead ECG
3073628|NCT01245764|Placebo Comparator|Placebo 9 to 12 Years Old|Placebo to GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase A. After database lock and unblinding for study Phase A, participants will have the option to receive GARDASIL™ 0.5 mL injection at the Day 1, Month 2, and Month 6 visits in study Phase B.
3073629|NCT01245972|No Intervention|Control|No treatment administered
3073630|NCT01245972|Experimental|PDL Setting 1|PDL Setting 1: 15 J/cm2, 3ms pulse length, no dynamic cooling, 7mm spot size, 10% overlap between the pulses, 2 passes
3073631|NCT01245972|Experimental|PDL Setting 2|PDL Setting 2: 7.5 J/cm2, 3ms pulse length, no dynamic cooling, 10mm spot size, 10% overlap between the pulses, 2 stacked pulses
3073632|NCT01246050|Experimental|Arm 1: Received HF Training|Providers will receive 3 days of HF training, receive access to clinical pharmacist medication titration serviced and receive performance feedback
3073633|NCT01246050|Active Comparator|Arm 2: No HF Training|CBOC Providers in the same CBOC who did not received HF Training, access to clinical pharmacist services or performance feedback
3073634|NCT01246063|Experimental|Phase I - Part 1 Dose Level 0 (Carfilzomib 20/27 mg/m^2)|Dose Level 0: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (27 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (27 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (27 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
3073635|NCT01246063|Experimental|Phase I - Part 1 Dose Level 1 (Carfilzomib 20/36 mg/m^2)|"Dose Level 1: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (36 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (36 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (36 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.~Dose Level 1: Carfilzomib IV (1 dose level above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (1 dose level above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (1 dose level above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.~Dose Level 2: Carfilzomib IV (2 dose levels above MTD) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (2 dose levels above MTD) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (2 dose levels above MTD) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib."
3073636|NCT01246063|Experimental|Phase I - Part 1 Dose Level 2 (Carfilzomib 20/45 mg/m^2)|Dose Level 2: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (45 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
3073637|NCT01246063|Experimental|Phase I - Part 1 Dose Level 3 (Carfilzomib 20/56 mg/^2)|Dose Level 3: Carfilzomib IV (20 mg/m^2) D1&D2 of C1 and carfilzomib IV (56 mg/m^2)D8, D9, D15, D16 of C1. Carfilzomib IV (56 mg/m^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (56 mg/m^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m^2)D8 C1-6.
3073638|NCT01246063|Experimental|Phase I -Part 2 Cohort 0 (Carfilzomib 56 mg/m^2+Dexamethasone)|Cohort 0: Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
3073639|NCT01246063|Experimental|Phase 2 (Carfilzomib 56 mg/m^2+ Dexamethasone)|Carfilzomib IV (56 mg/^2 - Phase 1 Part 1) D1, D2, D8, D9, D15, D16 C1-6. Carfilzomib IV (56 mg/m^2 - Phase 1 Part 1) D1, D8, D15, D22 C7 and subsequent cycles. PLD IV (30 mg/m^2 - Phase 1 Part 1) D8 of each cycle. Dexamethasone 20 mg IV or PO same schedule as carfilzomib.
3073640|NCT01246076|Experimental|Lenalidomide|"Lenalidomide 50 mg/day for two 28 day cycles.~Patients who have bone marrow aplasia as defined by a cellularity of <10% will be observed till counts recover. If patients do not progress following 2 cycles of HD lenalidomide, they will receive low dose lenalidomide 10 mg daily for 12 cycles."
3073641|NCT01246206|Experimental|Tacrolimus and Thymoglobulin|Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis
3073642|NCT01246258||Test group|Standard tests of balance function
3073643|NCT01246349|Experimental|Motivational Interviewing Group|For the Motivational Interviewing (MI) treatment group, a clinical psychology doctoral student trained in Motivational Interviewing administered six individual motivational interviewing treatment sessions, each 30 minutes in length.
3073644|NCT01246349|Active Comparator|Control Group|The comparison group received six social skills training sessions instead of Motivational Interviewing (MI).
3073645|NCT01246401|Active Comparator|Extended-Release Naltrexone|Participants will receive intramuscular (IM) injections of Naltrexone once monthly for 6 months, the first injection being prior release
3073646|NCT01246401|Placebo Comparator|Placebo|Participants will receive IM injections of Placebo once monthly for 6 months, the first injection being prior release
3073647|NCT01246466|Experimental|AtriCure Bipolar System combined with a catheter ablation|procedure using the AtriCure Bipolar System plus a catheter ablation
3073648|NCT01246479|Other|No treatment|subjects will be followed up on immunity (analysis of blood samples) and safety
3073649|NCT01246583|Experimental|Treatment Group A|
3073650|NCT01246583|Placebo Comparator|Treatment Group B|
3073651|NCT01246583|Experimental|Treatment Group C|
3073652|NCT01246583|Placebo Comparator|Treatment Group D|
3073653|NCT01246713|Placebo Comparator|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
3073654|NCT01246713|Active Comparator|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.
3073655|NCT01246791|Experimental|NPC-01|Single oral administration of NPC-01
3073656|NCT01246895||Experimental|Microfracture with BST-CarGel
3073657|NCT01246895||Control|Microfracture without BST-CarGel
3073658|NCT01246960|Experimental|Ramucirumab|"Oxaliplatin 85 milligrams per square meter (mg/m^2) given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-Fluorouracil (5-FU) 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Ramucirumab 8 milligrams per kilogram (mg/kg) given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3320956|NCT02014974||Public Hospitals|Patients presenting and treated in public trauma centers in India.
3320957|NCT02014974||Private Hospitals|Patients presenting and treated in private trauma centers in India.
3073659|NCT01246960|Placebo Comparator|Placebo|"Oxaliplatin 85 mg/m^2 given on Day 1 of a 2-week cycle~Leucovorin 400 mg/m^2 given on Day 1 of a 2-week cycle~5-FU 400 mg/m^2 bolus given on Day 1 of a 2-week cycle~5-FU 2400 mg/m^2 continuously given over 46-48 hours on Day 1 of a 2-week cycle~Placebo given on Day 1 of a 2-week cycle~Participants will receive study treatment every 2 weeks until disease progression, unacceptable toxicity, or another withdrawal criterion is met"
3073660|NCT01246973|Experimental|curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
3073661|NCT01246973|Placebo Comparator|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
3073662|NCT01246986|Experimental|Part A Cohort 1-160 milligram (mg) LY2157299|"Per the protocol, following an interim analysis, the decision was taken to no longer randomize participants to the 160 mg LY2157299 arm. As of May 25,2012, all newly enrolled participants will receive 300 mg LY2157299.~80 mg LY2157299 given orally twice daily (BID) for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073663|NCT01246986|Experimental|Part A Cohort 2 - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073664|NCT01246986|Experimental|Part B - 300 mg LY2157299|"150 mg LY2157299 given orally BID for 14 days followed by 14 days off (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073665|NCT01246986|Experimental|Part C Cohort 1 - 160 mg LY2157299 + 800 mg Sorafenib|"80 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073666|NCT01246986|Experimental|Part C Cohort 2 - 300 mg LY2157299 + 800 mg Sorafenib|"150 mg LY2157299 given orally BID on Days 1 to 14 in combination with 400 mg Sorafenib BID on days 1 to 28 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073667|NCT01246986|Experimental|Part D Cohort 1 - 160 mg LY2157299 + 8 mg/kg Ramucirumab|"80 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kilogram (kg) intravenous (IV) on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073668|NCT01246986|Experimental|Part D Cohort 2 - 300 mg LY2157299 + 8 mg/kg Ramucirumab|"150 mg LY2157299 given orally BID on days 1 to 14 in combination with ramucirumab 8 mg/kg IV on days 1 and 15 (28-day cycle).~Participants will continue to receive until disease progression, unacceptable toxicity, or another withdrawal criterion is met."
3073669|NCT01246999|Active Comparator|Live Attenuated Influenza vaccine|LAIV 0.2 ml will be given intranasally followed by LAIV 0.2 mg given intranasally 28 days later
3073670|NCT01246999|Active Comparator|Trivalent Influenza Vaccine 2010-2011|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 8 years intramuscularly followed by a second dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly 28 days later
3073671|NCT01246999|Active Comparator|TIV followed by LAIV|TIV will be given in a dose of .25mg 2 years to 36 months of age or .5 ml ages 37 months to 9 years intramuscularly followed by LAIV given in a dose of .2 ml intranasally 28 days later
3073672|NCT01246999|Active Comparator|LAIV followed by TIV|LAIV will be given in a dose of .2 ml intranasally followed by a dose of TIV given in a dose of .25 ml 2 years to 36 months or .5 ml 37 months to 9 years intramuscularly 28 days later
3073673|NCT01247064|Experimental|Nebulized 3% Saline|
3073674|NCT01247064|Placebo Comparator|Nebulized 0.9% Normal Saline|
3073675|NCT01247090|Active Comparator|Group 1: Vasopressin - Very Low Dose|0.15 mU per kg per minute
3073676|NCT01247090|Active Comparator|Group 2: Vasopressin - Low Dose|0.30 mU per kg per minute
3073677|NCT01247090|Placebo Comparator|Group 3: Placebo|No Dose
3073678|NCT01247220|Experimental|Peripheral Laser + Ranibizumab|Angiography-directed peripheral laser + ranibizumab
3073679|NCT01247220|Active Comparator|Ranibizumab|Ranibizumab
3073680|NCT01247272|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
3073681|NCT01247272|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
3073682|NCT01247285|Experimental|Investigational Test Product|90 mg Fluoxetine Hydrochloride Capsules (Teva)
3073683|NCT01247285|Active Comparator|Reference Listed Drug|90 mg PROZAC WEEKLY® Capsules (Eli Lilly)
3073684|NCT01247298|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive stereotactic body radiation therapy (SBRT) which is 3 radiation treatments at 15 Gy, for a total of 45 Gy. Patients will be given Trans-Arterial Chemoembolization (TACE), prior to enrollment. (TACE is not performed as part of this clinical study, even though it is part of the inclusion criteria.)
3073685|NCT01247324|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
3073686|NCT01247324|Experimental|Ocrelizumab|Ocrelizumab 600 mg intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
3073687|NCT01247350|Experimental|2 mg LY3009104 (Cohort 1)|2mg administered once on day 1 (single dose)
3073688|NCT01247350|Experimental|5 mg LY3009104 (Cohort 2)|5mg administered once on day 1 (single dose)
3073689|NCT01247350|Experimental|10 mg LY3009104 (Cohort 3)|10 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3073690|NCT01247350|Experimental|14 mg LY3009104 (Cohort 4 )|14 mg administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3073691|NCT01247350|Placebo Comparator|Placebo|administered on day 1 (single dose) and following a 7 day washout period, administered once daily for 10 days (multiple dose)
3073692|NCT01247363|Experimental|LY2608204|Oral capsules of LY2608204 given once daily at a starting dose of 160 milligram (mg), which may be titrated in 3 dose escalations to 240 mg, 320 mg and 400 mg, with a 7-day treatment duration at each dose level for up to 28 days total treatment.
3073693|NCT01247428|Experimental|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
3073694|NCT01247571|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3073695|NCT01247675|Experimental|ACP-001, 0.02 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.02 mg hGH/kg/week for 4 weeks
3073696|NCT01247675|Experimental|ACP-001, 0.04 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.04 mg hGH/kg/week for 4 weeks
3073697|NCT01247675|Experimental|ACP-001, 0.08 mg hGH/kg/wk|Once weekly subcutaneous injection of ACP-001 equivalent to 0.08 mg hGH/kg/week for 4 weeks
3073698|NCT01247675|Active Comparator|Omnitrope, 0.04 mg hGH/kg/wk|Once daily subcutaneous injection of human Growth Hormone (Omnitrope) equivalent to 0.04 mg hGH/kg/week for 4 weeks
3073699|NCT01247922|Experimental|Erlotinib|Participants who received erlotinib in a continuous oral dose of 85 mg/m^2 per day until dose modification, interruption or study discontinuation occurred.
3073700|NCT01247974|Experimental|CorMatrix ECM for Pericardial Closure|Pericardial closure with CorMatrix ECM
3073701|NCT01247974|No Intervention|Control|No Pericardial Closure
3073702|NCT01248065|Placebo Comparator|Ciclesonide + placebo|
3073703|NCT01248065|Experimental|Ciclesonide + Vitamin D|
3073704|NCT01248104|Active Comparator|Tranexamic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The TXA group re- ceived a bolus of 10 mg / kg over 15 minutes fol- lowed by an infusion of 1 mg/kg/hr.
3073705|NCT01248104|Active Comparator|Aminocaproic Acid|The research pharmacist used computer randomization to assign patients to receive either TXA or EACA. The EACA group received a bolus of 100 mg / kg given over 15 minutes shortly after induction of anesthesia followed by an infusion of 10 mg/kg/hr.
3073706|NCT01248221|Experimental|Healthy subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
3073707|NCT01248221|Experimental|Dyspeptic subjects|The subject will consume the test meal containing [13C]-Spirulina platensis and 99mTc sulfur colloid, after which gastric emptying will be assessed simultaneously by scintigraphy and breath tests. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
3073708|NCT01248364|Experimental|BI 10773 Arm|BI 10773 high dose once daily
3073709|NCT01248416|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg or Letrozole 2.5mg daily orally for 2 to 3 years
3073710|NCT01248416|Active Comparator|Growth Hormone|Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
3073711|NCT01248416|Active Comparator|Aromatase Inhibitor and Growth Hormone|Anastrozole 1mg or Letrozole 2.5mg orally daily for 2 to 3 years and Somatropin 0.3mg/kg/week divided daily subcutaneously for 2 to 3 years
3073712|NCT01248455|Experimental|anti-KIR in Smoldering Multiple Myeloma Patients|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
3073713|NCT01248468|Experimental|Aspirin, acetaminophen and caffeine|AAC: 2 tablets, each containing acetaminophen 250 mg, aspiring 250 mg, caffeine 65 mg and 1 placebo tablet matching sumatriptan 100 mg tablets
3073714|NCT01248468|Active Comparator|Sumatriptan (100 mg)|1 tablet containing sumatriptan 100 mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
3073715|NCT01248468|Placebo Comparator|Placebo|1 placebo tablet matching sumatriptan 100mg and 2 placebo tablets matching acetaminophen 250 mg, aspirin 250 mg and caffeine 65 mg tablets
3073716|NCT01248585|Active Comparator|Dexamethasone|2 x 4 mg dexamethasone tablets taken once daily for 5 days
3073717|NCT01248585|Placebo Comparator|Placebo|2 placebo tablets taken once daily for 5 days
3073718|NCT01248715|Experimental|Oseltamirvir|These patients will receive early oseltamivir plus current, standard empiric antibacterial therapy.
3073719|NCT01248715|No Intervention|Standard of care|These patients will be treated with the current, standard care, including currently recommended antibiotics or antiviral therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP and ACIP antiviral use guidelines for hospitalized patients with confirmed of suspect influenza, per clinician discretion. In addition these patients with have a NP swab collected for influenza PCR testing and clinical information will be extracted from the medical record.
3073720|NCT01248728|Active Comparator|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea high-EPA (HP) (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2.
3073721|NCT01248728|Placebo Comparator|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2.
3073722|NCT01248741|Experimental|HDR prostate brachytherapy|An array of 17 gauge steel needles, 20 cm in length, is inserted under Ultrasound (US) guidance into the prostate and advanced to the base of the prostate. A template is used to maintain spacing and parallelism and the needles are individually locked into the template once positioned. A continuously acquired set of US images is obtained for treatment planning purposes. Each needle is connected to a Varisource afterloader and treatment is delivered using a 10 Curie Iridium-192 source. The needles are then removed.
3073723|NCT01248780|Experimental|Golimumab + methotrexate (MTX)|Participants will receive golimumab 50 mg as subcutaneous (SC) (under the skin) injections administered every 4 weeks for up to 48 weeks. In addition, participants will receive a stable dose of MTX.
3073724|NCT01248780|Experimental|Placebo + methotrexate (MTX)|Participants will be administered Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48. In addition, participants will receive a stable dose of MTX.
3073725|NCT01248793|Experimental|Placebo|
3073726|NCT01248793|Experimental|Golimumab|
3073727|NCT01248884|Experimental|GSK217744 Group 1|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation A vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3073728|NCT01248884|Experimental|GSK217744 Group 2|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of GSK217744 formulation B vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The GSK217744 and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3073729|NCT01248884|Active Comparator|Infanrix hexa Group|Subjects aged between and including 60 and 90 days of age at the time of first vaccination received 3 doses of Infanrix hexa™ vaccine, co-administered with Prevenar 13® at 2, 3 and 4 months of age. The Infanrix hexa™ and Prevenar 13® vaccines were administered intramuscularly into the left and right sides of the thigh, respectively.
3073730|NCT01248936|Experimental|Overall Trial|Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor
3073731|NCT01248949|Experimental|MEDI3617 SINGLE AGENT TOTAL|Participants will receive MEDI3617 via intravenous (IV) infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
3073732|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q3W ESCALATION|Participants will receive MEDI3617 with bevacizumab via IV infusion every 3 weeks (Q3W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 21 days.
3073733|NCT01248949|Experimental|MEDI3617 + BEVACIZUMAB Q2W TOTAL|Participants will receive MEDI3617 with bevacizumab via IV infusion every 2 weeks (Q2W) in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons. Each cycle consists of 28 days.
3073734|NCT01248949|Experimental|MEDI3617 + PACLITAXEL TOTAL|Participants will receive MEDI3617 on Days 1 and 15 with paclitaxel on Days 1, 8, and 15 via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons. Each cycle consists of 28 days.
3073735|NCT01248949|Experimental|MEDI3617 + CARBOPLATIN/PACLITAXEL TOTAL|Participants will receive MEDI3617 with carboplatin and paclitaxel on Day 1 via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons. Each cycle consists of 21 days.
3073736|NCT01248962|Experimental|Standard 30-minute infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatin containing chemotherapy regimen.
3073737|NCT01248962|Experimental|extended 3-hour infusion|This is a non-blinded randomized study comparing standard 30-minute infusion carboplatin to extended 3-hour infusion carboplatin in women with recurrent, ovary, fallopian tube, and primary peritoneal cancer who will be treated with a carboplatincontaining chemotherapy regimen.
3073738|NCT01249027||Observational|Single arm prospective, observational, single-arm, open-label, multicenter, postapproval registry study using XIENCE V® Everolimus Eluting Coronary Stent System (EECSS).
3073739|NCT01249092|Experimental|Pentoxifylline 400 mg TID|This study is an open label pilot with only one arm.
3073740|NCT01249118|Experimental|Part 1: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 milligrams (mg) IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
3073741|NCT01249118|Experimental|Part 2: GDC-0973 IV Infusion First, Then GDC-0973 Capsules|Participants will receive single dose of GDC-0973 2 mg IV infusion in first intervention period followed by single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in second intervention period. The washout period between each period will be a minimum of 10 days.
3073742|NCT01249118|Experimental|Part 2: GDC-0973 Capsules First, Then GDC-0973 IV Infusion|Participants will receive single dose of GDC-0973 20 mg oral capsules (four 5-mg capsules) in first intervention period followed by single dose of GDC-0973 2 mg IV infusion in second intervention period. The washout period between each period will be a minimum of 10 days.
3073743|NCT01249131|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliter (mL) room temperature water after at least an 8-hour fast, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard Food and Drug Administration (FDA) high-fat meal, in third intervention period. The washout period between each period will be a minimum of 10 days.
3073744|NCT01249131|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib administered will be orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3320958|NCT02014987|Experimental|Running training programmes|"Runners with a high body mass index are going to follow a training programme of 3 kilometres per week compared to a training programme of 6 kilometres per week.~The amount of running will be increased with 10 % per week."
3073745|NCT01249131|Experimental|Treatment B first, then Treatment A, followed by Treatment C|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in third intervention period.
3073746|NCT01249131|Experimental|Treatment B first, then Treatment C, followed by Treatment A|Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in first intervention period. Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3073747|NCT01249131|Experimental|Treatment C first, then Treatment A, followed by Treatment B|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3073748|NCT01249131|Experimental|Treatment C first, then Treatment B, followed by Treatment A|Treatment C: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water within 30 minutes of eating a standard FDA high-fat meal, in first intervention period. Treatment B: Four 5-mg capsules of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in second intervention period. Treatment A: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast, in third intervention period.
3073749|NCT01249261|Placebo Comparator|Placebo/Risedronate|Placebo years 1-5, Risedronate 5mg/day years 6 & 7, no drug year 8
3073750|NCT01249261|Active Comparator|Risedronate|Risedronate 5mg years 1-7, no drug year 8
3073751|NCT01249274|Placebo Comparator|Placebo|Matched placebo pills to be taken twice daily
3073752|NCT01249274|Experimental|Progesterone|100 mgs progesterone twice daily
3073753|NCT01249365|Experimental|HPV vaccine|Healthy female subjects aged 26 years and above, who received control vaccine in the primary study NCT00294047, were administrated 3 intramuscular injections of Cervarix vaccine into the deltoid of the non-dominant arm, according to a 0, 1, 6-month schedule in the current study.
3073754|NCT01249404|Experimental|Dysport® 1000 U, IM|1000 U, I.M. (in the muscle), on day 1 (single treatment cycle)
3073755|NCT01249404|Experimental|Dysport® 1500 U, IM|1500 U, I.M., on day 1 (single treatment cycle)
3073756|NCT01249404|Placebo Comparator|Placebo|I.M., on day 1 (single treatment cycle)
3073757|NCT01249417|Experimental|Dysport 10 U/Kg|10 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
3073758|NCT01249417|Experimental|Dysport 15 U/Kg|15 U/Kg per lower limb. Either one or both lower limbs can be treated. Total volume injected, 2ml per leg.
3073759|NCT01249417|Placebo Comparator|Placebo|Total volume to be injected per lower limb - 2ml. Either one or both lower limbs can be treated.
3073760|NCT01249625|Active Comparator|N95 Respirator|The investigators are comparing specific N95 respirator against specific medical masks.
3073761|NCT01249625|Active Comparator|Medical/surgical mask|The investigators are comparing medical/surgical masks against the N95 respirator.
3073762|NCT01249651|Other|1|One arm: esomeprazole 40 mg
3073763|NCT01249664|Experimental|Arm 1|
3073764|NCT01249664|Sham Comparator|Arm 2|
3073765|NCT01249833|Active Comparator|Oseltamivir|Added to standard of care for influenza
3073766|NCT01249833|No Intervention|Standard of care alone|Standard of care for influenza
3073767|NCT01249872|Active Comparator|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group A patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline. Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
3073768|NCT01249872|Active Comparator|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Group B patients receive an epidural bolus dose of 1mg of morphine intra-operatively (45 min before the estimated end of the surgery). Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3073769|NCT01249872|Active Comparator|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Group C patients receive an epidural bolus dose 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, patients receive PCEA of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3073770|NCT01249872|Active Comparator|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group D patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline, epidurally. Postoperatively,patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3073771|NCT01249872|Active Comparator|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Group E patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 1mg of morphine.Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3073772|NCT01249872|Active Comparator|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Group F patients receive intra-operatively (45 min before the estimated end of the surgery) an epidural bolus dose of 2 mg of morphine. Postoperatively, patients receive PCEA of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h
3073773|NCT01250002|Active Comparator|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
3073774|NCT01250002|Placebo Comparator|Placebo|Placebo will receive the same volume of saline infusion.
3073775|NCT01250054|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B multifocal contact lenses worn first, with comfilcon A multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
3073776|NCT01250054|Other|Comfilcon A /Lotrafilcon B|Comfilcon A multifocal contact lenses worn first, with lotrafilcon B multifocal contact lenses worn second. Each product worn bilaterally on a daily wear basis for one week.
3073777|NCT01250119|Experimental|Single Arm|
3073778|NCT01250145|Experimental|LY333334 + placebo|"Part A:~Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, for 22 days~Part B:~Induction phase: Both a placebo and an 80 microgram active patch will be applied to the same arm for at least 6 hours daily, test arms will be alternated daily, 4 times a week for 3 weeks~Rest phase: 2 weeks with no patch application~Challenge phase: 80 microgram active patch given once for at least 6 hours"
3073779|NCT01250171|Experimental|Secukinumab 10 mg/kg|Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period.
3073780|NCT01250171|Experimental|Canakinumab 10 mg/kg|Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period.
3073781|NCT01250171|Placebo Comparator|Placebo|Patients received a single placebo infusion intravenously over a 2 hour period.
3073782|NCT01250184|Active Comparator|Physical Therapy|Twelve sessions, 3 per week.
3073783|NCT01250184|Active Comparator|Lidocaine injection|Blocking the myofascial trigger point (MTP) with lidocaine injection, unique dose.
3073784|NCT01250184|Experimental|Lidocaine injection + physical therapy|Blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program, twelve sessions, 3 per week.
3073785|NCT01250210|Experimental|AG200-15|Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.
3073786|NCT01250210|Experimental|AG200|Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.
3073787|NCT01250210|Experimental|AG200LE|Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.
3073788|NCT01250379|Active Comparator|1|
3073789|NCT01250379|Experimental|2|
3073790|NCT01250418|Active Comparator|Ketamine Group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
3073791|NCT01250418|No Intervention|No ketamine|No ketamine added to anesthesia regimen
3073792|NCT01250509|Experimental|CALMM|Participants receiving the 'Craving and Lifestyle Management through Mindfulness' intervention, i.e. program that combines stress reduction with mindful eating practices.
3073793|NCT01250509|No Intervention|Waitlist Control|Participants were waitlisted for the intervention during the experimental phase.
3073794|NCT01250717|Experimental|Docetaxel Followed by Radical Prostatectomy|Docetaxel,Dexamethasone,Estramustine,Zoladex,Casodex,Prostatectomy
3073795|NCT01250730|Experimental|1.0|This study will consist of three cohorts: PF-02341066 150 mg treatment group (n = 6), PF-02341066 250 mg treatment group (n = 6) and PF-02341066 400 mg treatment group (n = 6).
3073796|NCT01250756|Experimental|1|Experimental
3073797|NCT01250756|Experimental|2|Active comparator
3073798|NCT01250769|Active Comparator|Manual Toothbrush 1|Manual Toothbrush used for 1 minute twice a day
3073799|NCT01250769|Active Comparator|Manual Toothbrush 2|Manual Toothbrush used for 2 minutes twice a day
3073800|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 1|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used once a day
3073801|NCT01250769|Experimental|Manual Toothbrush + Interproximal Cleaning 2|Manual Toothbrush used twice a day for 2 minutes plus Interproximal Cleaning Device used twice a day
3073802|NCT01250834|Experimental|LY2189265 + Atorvastatin|"Period 1: Participants received a single 40-milligram (mg) oral dose of atorvastatin on Day 1, followed by a 7- to 10-day washout period between Period 1 and Period 2.~Period 2: Participants received a single 1.5-mg subcutaneous dose of LY2189265 on Day 1, followed by a single 40-mg oral dose of atorvastatin on Day 3."
3073803|NCT01250873|Experimental|LY2216684/sertraline/LY2216684 + sertraline|"Period 1: LY2216684 18 milligram (mg) oral (po) dose on Days 1-3.~Period 2: Sertraline 50 mg po dose on Day 4 followed by sertraline 100 mg po dose on Days 5-10.~Period 3: LY2216684 18 mg po dose + sertraline 100 mg po dose on Days 11-13."
3073804|NCT01250899|No Intervention|Vitamin D Sufficient|HIV-infected men and women with HIV-1 viral load <200 copies/mL on stable ART and 25(OH)D level ≥30ng/mL receive no intervention.
3073805|NCT01250899|Experimental|Vitamin D Insufficient|HIV-infected men and women with HIV-1 viral load <200 copies /mL on stable ART and 25(OH)D level <30ng/mL receive 50,000 IU twice weekly for 5 weeks followed by 2000 IU daily to complete 12 weeks.
3073806|NCT01250912|Experimental|Imaging Tracer|No arms, the Radio tracer will be used in all subjects imaging tests.
3073807|NCT01250925|Active Comparator|OPTI-FREE® RepleniSH®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3073808|NCT01250925|Active Comparator|Clear Care®|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3073809|NCT01250925|Active Comparator|ReNu MultiPlus® MultiPurpose Solution|33 participants will be assigned to use this lens care regimen during the six-week assessment period
3073810|NCT01250977|Placebo Comparator|Placebo|Participants are instructed to take one placebo pill every night before going to bed with a glass of water for 28 days.
3073811|NCT01250977|Experimental|Donepezil|Participants are instructed to take one 5mg pill (donepezil HCL [Aricept®]) every night before going to bed with a glass of water for 28 days.
3073812|NCT01250990|Active Comparator|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
3073813|NCT01250990|Placebo Comparator|Placebo|Placebo tablet with 50 mg niacin for the first 4 weeks to maintain blinding of the study team and subjects, changed to pure placebo after that.
3073814|NCT01251042|Experimental|Sangvia and retransfusion|
3073815|NCT01251042|Sham Comparator|Sangvia and no retransfusion|
3073816|NCT01251146|Experimental|Bisoprolol|
3073817|NCT01251146|Active Comparator|Atenolol|
3073818|NCT01251276|Experimental|Modified Process Hepatitis B Vaccine in Base Study|Participants who received 3 doses of Modified Process Hepatitis B Vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
3073819|NCT01251276|Experimental|ENGERIX-B™ Vaccine in Base Study|Participants who received 3 doses of ENGERIX-B™ vaccine in the Base Study were eligible to receive a single challenge dose of Modified Process Hepatitis B Vaccine on Day 1 of the Challenge Dose Study
3073820|NCT01251315|Placebo Comparator|Placebo low dose|Placebo for low dose group given as a single dose.
3073821|NCT01251315|Active Comparator|N Acetyl cysteine, 600mg (low dose)|N-Acetyl Cysteine (NAC)600 mg (low dose) given as a single dose.
3073822|NCT01251315|Active Comparator|Proimmune 200(FT061452)|Proimmune 200(FT061452) low dose group 3000 mg given as a single dose.
3073823|NCT01251315|Placebo Comparator|Placebo high dose|Placebo given to high dose group given as a single dose.
3073824|NCT01251315|Active Comparator|N Acetyly cysteine, 1200mg (high dose)|N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
3073825|NCT01251315|Active Comparator|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
3073826|NCT01251354|Experimental|BN83495|
3073827|NCT01251367|Experimental|Dysport®|Dysport® is injected into lower limbs across 4 cycles of treatment, a minimum of 12 weeks between 2 injections. Doses vary from 1000 U to 1500 U.
3073828|NCT01251380|Experimental|Dysport|Dysport was injected into either one or both lower limbs in up to 4 cycles of treatment, a minimum of 12 weeks apart and up to a maximum of 40 weeks apart. Doses varied from 5 Units (U)/Kg to 20 U/kg for one leg, or from 10 U/Kg to 30 U/kg for two legs, with a maximum dose of no more than 30 U/Kg overall, or 1000 U, whichever was reached first.
3073829|NCT01251393|Experimental|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
3073830|NCT01251393|Placebo Comparator|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
3073831|NCT01251536|Other|Arm B - standard dose of cetuximab|Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab 250 mg/m2 weekly. No comparison between arms was planned.
3073832|NCT01251536|Experimental|Arm A - dose escalation of cetuximab|Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly.
3073833|NCT01251575|Experimental|Treatment (fludarabine, transplant, immunosuppression)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2. Patients also undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation.~IMMUNOSUPPRESSION: Patients receive sirolimus PO QD on days -3 to 180 with taper to day 365; cyclosporine PO BID on days -3 to 150 with taper to day 180; and mycophenolate mofetil PO TID on days 0-30 and then BID to day 100 with taper to day 150."
3073834|NCT01251588||MACI|autologous cultured chondrocytes on porcine collagen membrane implant received in previous MACI00206 study
3073835|NCT01251588||Microfracture|Microfracture treatment received in previous MACI00206 study
3073836|NCT01251614|Experimental|Adalimumab 0.4 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.4 mg/kg (up to a maximum of 20 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.4 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.4 mg/kg eow.
3073837|NCT01251614|Experimental|Adalimumab 0.8 mg/kg|In Period A participants received a single subcutaneous loading dose of adalimumab 0.8 mg/kg (up to a maximum of 40 mg) at Week 0 followed by every other week dosing beginning at Week 1. To maintain the blind, participants also received weekly dosing of methotrexate placebo tablets. Participants who were non-responders in Period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
3073838|NCT01251614|Active Comparator|Methotrexate|Participants received 0.1 mg/kg methotrexate at Baseline (Week 0), and up to 0.4 mg/kg weekly (maximum dose of 25 mg/week) in Period A. Participants also received adalimumab placebo as a single subcutaneous loading dose at Week 0, followed by every other week (eow) dosing from Week 1. Participants who were non-responders in period A entered Period D directly and received open-label adalimumab at 0.8 mg/kg eow for up to 52 weeks. Participants who responded in Period A entered the Treatment Withdrawal Phase (Period B) for up to 36 weeks. Participants who experienced a loss of disease control in Period B entered the Re-treatment Phase (Period C) and received blinded adalimumab 0.8 mg/kg eow for 16 weeks. Participants who completed Period B with no loss of disease control entered Period D and were observed off study medication for up to 52 weeks. Participants who completed Period C entered Period D for an additional 52 weeks of treatment with blinded adalimumab 0.8 mg/kg eow.
3073839|NCT01251653||Afatinib and docetaxel|
3073840|NCT01251653||Afatinib and gemcitabine|
3073841|NCT01251744|Experimental|CMV Mothers' Group|Pregnant subjects with confirmed primary CMV infection.
3073842|NCT01251744|Experimental|CMV Newborns' Group|Offsprings of the CMV Mothers' Group, also tested for CMV infection, comprising infants that were live born.
3073843|NCT01251757|No Intervention|Usual Care (UC)|Participants in this arm received their usual care with no restrictions.
3073844|NCT01251757|Active Comparator|Interactive Voice Recognition (IVR)|automated phone calls
3073845|NCT01251757|Active Comparator|Enhanced IVR (IVR+)|automated phone calls & Educational mailings and follow-up for nonadherence
3073846|NCT01251770|Experimental|half saline|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
3073847|NCT01251770|Active Comparator|third saline|Subjects in this arm will receive 0.3% NaCl/dextrose 5% intravenous (IV) maintenance fluids.
3073848|NCT01251861|Active Comparator|Arm A (observation and bicalutamide)|Patients undergo observation on weeks 1-12. Patients then receive bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
3073849|NCT01251861|Experimental|Arm B (Akt inhibitor MK2206 and bicalutamide)|Patients receive Akt inhibitor MK2206 PO once per week on weeks 1-44 and bicalutamide PO QD on weeks 13-44. Patients with a PSA decline of >= 50% may continue on Akt inhibitor MK2206 and bicalutamide until week 72 in the absence of disease progression or unacceptable toxicity.
3073850|NCT01251887|Experimental|Diet A: Low omega-3 (n-3) + High linoleic acid (LA)|Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks
3073851|NCT01251887|Experimental|Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks
3073852|NCT01251887|Experimental|Diet C: High omega-3 (n-3) + Low linoleic acid (LA)|Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks
3073853|NCT01251965|Experimental|Ruxolitinib 50 mg BID|Phase I - Starting dose of Ruxolitinib 50 mg by mouth twice a day for 28 day cycle.
3073854|NCT01251965|Experimental|Ruxolitinib 100 mg BID|Phase I dose of Ruxolitinib 100 mg by mouth twice a day for 28 day cycle.
3073855|NCT01251965|Experimental|Ruxolitinib 200 mg BID|Phase I dose of Ruxolitinib 200 mg by mouth twice a day for 28 day cycle.
3073856|NCT01251978|Active Comparator|High dose Ranibizumab|6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.
3073857|NCT01251978|Active Comparator|Standard Dose Ranibizumab|6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.
3073858|NCT01252095|Experimental|PG545|
3073859|NCT01252134|Other|Synergi, then Biotrue, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073860|NCT01252134|Other|Synergi, then OTE, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073861|NCT01252134|Other|Biotrue, then OTE, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073862|NCT01252134|Other|Biotrue, then Synergi, then OTE|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073863|NCT01252134|Other|OTE, then Biotrue, then Synergi|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073864|NCT01252134|Other|OTE, then Synergi, then Biotrue|Three lens care systems randomly assigned. Contact lenses were pre-soaked overnight prior to insertion, then worn for 8 hours, with a minimum two-day washout between each wear period.
3073865|NCT01252186|Experimental|91-day Levonorgestrel Oral Contraceptive|Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy in each 91-day cycle for a total of two 91-day cycles.
3073866|NCT01252186|Active Comparator|28-day Levonorgestrel Oral Contraceptive|Participants received 21 days of active combination tablets containing 150 µg LNG/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
3073867|NCT01252186|Active Comparator|28-day Desogestrel Oral Contraceptive|Participants received 21 days of active combination tablets (containing 150 µg desogestrel (DSG)/30 µg EE, followed by no treatment for 7 days in each 28-day cycle for a total of six 28-day cycles.
3073868|NCT01252238|Placebo Comparator|Valsartan and Aliskiren|Valsartan 150 mg and Aliskiren (150 mg followed by force titration to 300 mg)
3073869|NCT01252238|Experimental|Aliskiren|
3073870|NCT01252238|Placebo Comparator|Placebo Group|Only taking Amlodipine
3073871|NCT01252251|Experimental|RAD001 and pasireotide LAR|This study will be an open-label, single-arm, phase II study of RAD001 and pasireotide LAR.
3073872|NCT01252277|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
3073873|NCT01252290|Experimental|Lovaza™|Lovaza™ (two 1 gram capsules twice daily) for six months
3073874|NCT01252355|Experimental|Teriflunomide 7 mg + IFN-beta|Teriflunomide 7 milligram (mg) once a day concomitantly with IFN-beta therapy.
3073875|NCT01252355|Experimental|Teriflunomide 14 mg + IFN-beta|Teriflunomide 14 mg once a day concomitantly with IFN-beta therapy.
3073876|NCT01252355|Placebo Comparator|Placebo + IFN-beta|Placebo (for teriflunomide) once a day concomitantly with IFN-beta therapy.
3073877|NCT01252563||Amlodipine 10mg Tablet|Subjects taking Amlodipine 10mg Tablet.
3073878|NCT01252667|Experimental|Part 1 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073879|NCT01252667|Experimental|Part 1 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073880|NCT01252667|Experimental|Part 1 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073881|NCT01252667|Experimental|Part 2 - Dose 1 (30 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 30 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073882|NCT01252667|Experimental|Part 2 - Dose 2 (40 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 40 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073883|NCT01252667|Experimental|Part 2 - Dose 3 (50 mg/m^2 Clofarabine)|"CONDITIONING REGIMEN: Patients receive 50 mg/m^2 clofarabine IV over 2 hours on days -6 to -2. Patients also undergo TBI on day 0.~IMMUNOSUPPRESSION: Patients with related donors receive cyclosporine PO every 12 hours on days -3 to 56 with taper to day 180 and mycophenolate mofetil PO every 12 hours on days 0 to 28. Patients with unrelated donors receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 180 and mycophenolate mofetil PO every 8 hours on days 0 to 40 with taper to day 96.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~Allogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Clofarabine: Given IV~Cyclosporine: Given PO~Laboratory Biomarker Analysis: Correlative studies~Mycophenolate Mofetil: Given PO~Peripheral Blood Stem Cell Transplantation: Undergo allogeneic hematopoietic PBSCT~Pharmacological Study: Optional correlative studies~Total-Body Irradiation: Undergo TBI"
3073884|NCT01252732|Experimental|Single-Dose IV Oritavancin Diphosphate|
3073885|NCT01252732|Active Comparator|IV Vancomycin|
3073886|NCT01252745|Experimental|10.0 mg of TBS-1, 4.0% T.I.D.|TBS-1 syringes pre-filled with 125 μL 4.0% gel to deliver 5.0 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 30 mg/day)
3073887|NCT01252745|Experimental|13.5 mg of TBS-1, 4.5% B.I.D|TBS-1 syringes pre-filled with 150 μL 4.5% gel to deliver 6.75 mg of Testosterone per nostril (intra-nasal) given b.i.d. at 2100 and 0700 hours. (total dose 27.0 mg/day)
3073888|NCT01252745|Experimental|11.25 mg of TBS-1, 4.5% T.I.D|TBS-1 syringes pre-filled with 125 μL 4.5% gel to deliver 5.625 mg of Testosterone per nostril (intra-nasal) given t.i.d. at 2100, 0700, and 1300 hours. (total dose 33.75 mg/day)
3073889|NCT01252810|Experimental|GE 145 320mg I/ml injection|
3073890|NCT01252810|Active Comparator|Iopamidol 370mg I/ml injection|
3073891|NCT01252940|Experimental|FTC/RPV/TDF|Participants will switch from their existing treatment regimen to the emtricitabine (FTC)/rilpivirine (RPV)/tenofovir disoproxil fumarate (TDF) single-tablet regimen (STR) at the beginning of the study.
3073892|NCT01252940|Experimental|SBR/Delayed Switch|Participants will stay on baseline regimen (SBR; their existing treatment regimen of PI+RTV plus 2 NRTIs) at the beginning of the study through Week 24, and may switch to the FTC/RPV/TDF STR (Delayed Switch) at the Week 24 visit.
3073893|NCT01252953|Experimental|Anacetrapib|
3073894|NCT01252953|Placebo Comparator|Placebo anacetrapib|
3073895|NCT01252966|Experimental|Cognitive Training|Participants in this arm received computerized cognitive training in addition to nicotine patch and smoking cessation counseling.
3073896|NCT01252966|Placebo Comparator|Control Training|Participants in this arm received computerized control training in addition to nicotine patch and smoking cessation counseling
3073897|NCT01253018|Experimental|Robot Therapy|12 weeks of robotic therapy
3073898|NCT01253018|Active Comparator|Transition to Task Training|12 weeks of task specific practice combined with robotic therapy
3073899|NCT01253044|Experimental|Acceptance and Commitment Therapy|12 weeks of individually delivered Acceptance and Commitment Therapy
3073900|NCT01253044|Active Comparator|Present Centered Therapy|12 weeks of individually delivered Present Centered Therapy
3073901|NCT01253070|Experimental|Treatment (daunorubicin, cytarabine, sorafenib tosylate)|"INDUCTION THERAPY: Daunorubicin hydrochloride 60 mg/m^2/day by IV push or short IV on days 1-3, cytarabine 100 mg/m^2/day by continuous IV on days 1-7, and sorafenib tosylate orally every 12 hours on days 1-7.~CONSOLIDATION THERAPY - Every 28 days for 2 cycles: Cytarabine 2 g/m^2/day by IV on days 1-5 and sorafenib tosylate 400 mg orally every 12 hours on days 1-28.~MAINTENANCE - Every 28 days for up to 12 cycles: Sorafenib tosylate 400 mg orally every 12 hours on days 1-28."
3073902|NCT01253135|Placebo Comparator|Control|White Petrolatum
3073903|NCT01253135|Other|Test article|Vehicle (fibrinogen)
3073904|NCT01253148|Experimental|Arterial Injection of 90-Y Microspheres|Intrahepatic Arterial Injection of 90-Y Glass Microspheres as First-Line Treatment For Cholangiocarcinoma
3073905|NCT01253174|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 film-coated SHT470FA tablet (Yasmin with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
3073906|NCT01253174|Experimental|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532A tablet (with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3073907|NCT01253174|Active Comparator|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SHT04532C, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3073908|NCT01253187|Experimental|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|single oral administration of 1 film-coated SHT00186D tablet (YAZ), containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)
3073909|NCT01253187|Experimental|EE 0.02mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE20/DRSP/L-5-MTHF Ca)|single oral administration of 1 film-coated SHT04532B tablet, containing 0.020 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3073910|NCT01253187|Experimental|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated SHT04532C tablet, containing 0.451 mg Metafolin (L-5-methyltetrahydrofolate calcium [MTHF-Ca])
3073911|NCT01253200|Experimental|Blazer® Open-Irrigated Ablation Catheter|Patients treated with the Blazer® Open-Irrigated Ablation Catheter
3073912|NCT01253200|Active Comparator|Control Catheter|Patients treated with an open-irrigated radiofrequency ablation catheter that has received FDA market approval for the treatment of type 1 atrial flutter( Biosense Webster ThermoCool® ablation catheters (NaviStar™, EZ Steer, or SF) or St. Jude Medical ablation catheters (Therapy™ Cool Path™ or Safire BLU™),
3073913|NCT01253226|Experimental|30 milligrams (mg) Tabalumab|30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)
3073914|NCT01253226|Experimental|60 mg Tabalumab|60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
3073915|NCT01253226|Experimental|120 mg Tabalumab|120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)
3073916|NCT01253226|Placebo Comparator|Placebo Q4W|Q4W for 20 weeks
3073917|NCT01253226|Experimental|120 mg once every 2 weeks (Q2W) Tabalumab|Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)
3073918|NCT01253226|Placebo Comparator|Placebo Q2W|Q2W for 20 weeks
3073919|NCT01253265|Experimental|30 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3073920|NCT01253265|Experimental|80 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3073921|NCT01253265|Experimental|180 mg LY2439821|Administered subcutaneously at Week 0, 1, 2, 4, 6, 8 and 10
3073922|NCT01253265|Placebo Comparator|Placebo|Placebo is administered subcutaneously in the same manner as active drug in each dose group
3073923|NCT01253265|Experimental|120 mg LY2439821|Administered subcutaneously at 240 mg as a single loading dose followed by 120 mg every week
3073924|NCT01253291|Experimental|30mg/120 mg LY2127399|Participants in the 30 milligrams (mg) every 4 weeks arm of the lead-in study will receive 30 mg every 4 weeks until the safety of the 120 mg every 4 weeks dose is confirmed in the lead-in study.
3073925|NCT01253291|Experimental|120 mg LY2127399|Participants in the 60 mg every 4 weeks, 120 mg every 4 weeks and 120 mg every 2 weeks arms of the lead-in study will receive 120 mg every 4 weeks as these participants will enroll in this study after the safety of the 120 mg every 4 weeks dose in the lead-in study is confirmed.
3073926|NCT01253304|Experimental|Normal hepatic function|LY2189265: A single, subcutaneous (SC) 1.5-milligram (mg) injection on Day 1 in participants with normal hepatic function
3073927|NCT01253304|Experimental|Mild hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with mild hepatic impairment (Child-Pugh A)
3073928|NCT01253304|Experimental|Moderate hepatic impairment|LY2189265: A single, SC 1.5-mg injection on Day 1 in participants with moderate hepatic impairment (Child-Pugh B)
3073929|NCT01253304|Experimental|Severe hepatic impairment|LY2189265: A single, SC-1.5 mg injection on Day 1 in participants with severe hepatic impairment (Child-Pugh C)
3073930|NCT01253317|Experimental|rhIGF-1|Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the OLE.
3073931|NCT01253343||inpatient high aggression|
3073932|NCT01253343||inpatient low aggression|
3073933|NCT01253369|Experimental|Pazopanib|Pazopanib was given at a dose of 800 mg orally once per day for 28 day cycles (+/- 3 days). Patients received treatment as long as they were receiving clinical benefit.
3073934|NCT01253408|Experimental|Dronabinol 2.5 mg bid|Dronabinol 2.5 mg will be taken orally with water twice per day for two days.
3073935|NCT01253408|Experimental|Dronabinol 5 mg bid|Dronabinol 5 mg will be taken orally with water twice per day for two days.
3073936|NCT01253408|Placebo Comparator|Placebo|Placebo will be taken orally with water twice per day for two days.
3073937|NCT01253421|Active Comparator|MDD-amisulpride|Subjects experiencing a current episode of major depression who are randomized to receive amisulpride
3073938|NCT01253421|Placebo Comparator|MDD-placebo|Subjects experiencing a current episode of major depression who are randomized to receive placebo
3073939|NCT01253421|Active Comparator|HC-amisulpride|Subjects having no history of mental disorder (healthy controls, HC) who are randomized to receive amisulpride
3073940|NCT01253421|Placebo Comparator|HC-placebo|Subjects having no history of mental disorder who are randomized to receive placebo
3073941|NCT01253447|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 200 mg orally once a week for each 28 day treatment cycle
3073942|NCT01253460|Experimental|Cyclophosphamide, Rituximab + Sapacitabine|After Sapacitabine 350 mg orally Days 1-3, Cyclophosphamide 250 mg/m2 IV 2 hours, followed by Rituximab 375 mg/m2 IV Day 3, Course 1, and 500 mg/m2 Day 1, subsequent courses.
3073943|NCT01253525|Experimental|Ramucirumab (IMC-1121B ) and Pacitaxel|Each treatment cycle is 4 weeks (28 days)
3073944|NCT01253564|Experimental|Single Arm|
3073945|NCT01253577|Active Comparator|Drug Coated|Sinus stent coated with steroid
3073946|NCT01253577|Placebo Comparator|Non coated|Sinus stent without drug coating
3073947|NCT01253642|Experimental|Treatment (antiangiogenesis, chemosensitizer, chemotherapy)|Patients receive phenelzine sulfate PO QD on days -7 to -4, and then BID on days -3 to 21. Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for at least 12 weeks in the absence of disease progression or unacceptable toxicity.
3073948|NCT01253811|Experimental|rFXIII 35 IU/kg|
3073949|NCT01253824|Experimental|NPC-01|1mg norethisterone and 0.02mg ethinyl estradiol
3073950|NCT01253824|Active Comparator|IKH-01|1mg norethisterone and 0.35mg ethinyl estradiol
3073951|NCT01253902|Active Comparator|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
3073952|NCT01253902|Active Comparator|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
3073953|NCT01253902|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
3073954|NCT01253980|Active Comparator|Amoxicillin|Amoxicillin
3073955|NCT01253980|Placebo Comparator|Placebo suspension|Placebo
3073956|NCT01254019|Experimental|GSK2402968|6mg/kg
3073957|NCT01254019|Experimental|Placebo|dose-matched
3073958|NCT01254045|Experimental|placebo, oxytocin 24IU, oxytocin 48IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073959|NCT01254045|Experimental|oxytocin 24IU, placebo, oxytocin 48IU|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073960|NCT01254045|Experimental|oxytocin 48IU, oxytocin 24IU, placebo|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073961|NCT01254045|Experimental|oxytocin 24IU, oxytocin 48IU, placebo|intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073962|NCT01254045|Experimental|oxytocin 48IU, placebo, oxytocin 24IU|intranasal oxytocin (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal placebo (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles ; intranasal oxytocin (24 international units) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073963|NCT01254045|Experimental|placebo, oxytocin 48IU, oxytocin 24IU|intranasal placebo (48 international units; 4IU per puff) once at baseline, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (48 international units; 4IU per puff) once at time 2, 6 puffs (3 puffs per nostril) from each of 2 bottles; intranasal oxytocin (24 international units; 4IU per puff) and intranasal placebo (24 international units; 4IU per puff) once at time 3, 6 puffs (3 puffs per nostril) from each of 2 bottles
3073964|NCT01254188|Experimental|Nilotinib|300 mg BID
3073965|NCT01254214|Experimental|tMBSR|telephone-adapted Mindfulness Based Stress Reduction (tMBSR) is an 8-week program of training in mindfulness meditation consisting of two in-person group meetings and 6 conference calls, led by a trained meditation teacher.
3073966|NCT01254214|Active Comparator|Support Group|The Support Group is a group intervention led by a trained facilitator and designed to match the intervention for time, attention and social support
3073967|NCT01254227|Experimental|Deferasirox|Deferoxamine combination followed by Deferasirox monotherapy
3073968|NCT01254292|Experimental|LCS12 (Skyla, BAY86-5028)|Participants received LCS12 (low dose levonorgestrel [LNG] intrauterine delivery system [IUS]) with an initial in vitro release rate of 12 μg LNG per day for 18 months with optional extension to 36 months
3073969|NCT01254292|Active Comparator|EE30/DRSP (Yasmin, BAY86-5131)|Participants received combined oral contraceptive (COC) tablet Yasmin containing 30 μg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP) for 18 months/19 cycles
3073970|NCT01254305|Experimental|1|40 -120 mg/day Levomilnacipran ER capsules, oral administration
3073971|NCT01254305|Active Comparator|2|Randomized to treatment with 1 of 4 Selective Serotonin Reuptake Inhibitors (SSRIs) - Paroxetine, Sertraline, Citalopram or Fluoxetine Oral administration, once daily dosing
3073972|NCT01254305|Placebo Comparator|3|Matching placebo capsules, oral administration
3073973|NCT01254318||Participants at high risk for IFI|Participants will be considered high risk if they are undergoing high dose chemotherapy for leukemia. This includes, but is not limited to participants with acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. Participants are also considered to be at high risk for IFI if they have undergone allogeneic hematopoietic stem-cell transplantation.
3073974|NCT01254331|Experimental|Single arm|
3073975|NCT01254344|Experimental|Ertapenem sodium 1 g|Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
3073976|NCT01254344|Active Comparator|Ceftriaxone sodium 2 g|Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
3073977|NCT01254396|Active Comparator|Sildenafil ODT tablet 50 mg, Fasted|Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.
3073978|NCT01254396|Experimental|Sildenafil ODT tablet 50 mg, Fed|Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.
3073979|NCT01254409|Experimental|PRM-151|PRM-151 administered at escalating doses of 1, 5, and 10 mg/kg by 30 minute intravenous (IV) infusion days 1, 3, 5, 8 and 15.
3073980|NCT01254409|Placebo Comparator|Placebo|0.9% saline administered by 30 minute IV infusion Days 1, 3, 5, 8, and 15.
3073981|NCT01254422|Experimental|CYD Dengue vaccine group|Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.
3073982|NCT01254422|Placebo Comparator|Placebo Group|Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.
3073983|NCT01254552|Experimental|Dotarem and Xenetix 350|
3073984|NCT01254565|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous injection at the end of each hemodialysis session three times a week (TIW). The starting dose level was 5 mg; dose escalation was to proceed to 10 and 20 mg pending safety review of the prior cohort.
3073985|NCT01254565|Placebo Comparator|Placebo|Participants received placebo administered by intravenous injection at the end of each hemodialysis session three times a week (TIW).
3073986|NCT01254604|Experimental|Tafluprost|One drop of preservative-free vehicle (contains no active drug) per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for four weeks. Morning dose with vehicle only allows blinding to match twice daily dosing of comparator arm.
3073987|NCT01254604|Active Comparator|Timolol|One drop of preservative-free timolol maleate (0.05%) per eye twice daily (morning and evening) for four weeks.
3073988|NCT01254630|Experimental|V212-STM|Participants with STM receiving chemotherapy randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3073989|NCT01254630|Experimental|V212-HM|Participants with HM randomized to receive V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3073990|NCT01254630|Placebo Comparator|Placebo-STM|Participants with STM receiving chemotherapy randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3073991|NCT01254630|Placebo Comparator|Placebo-HM|Participants with HM randomized to receive placebo to V212 vaccine given as a 4-dose regimen administered ~30 days apart.
3073992|NCT01254643|Experimental|All Enrolled|9-valent human papillomavirus (9vHPV) L1 VLP vaccine (V503), 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6.
3073993|NCT01254656|Experimental|LRV 500mg|
3073994|NCT01254656|Experimental|LRV 750mg +TVD|
3073995|NCT01254656|Active Comparator|EFV|
3073996|NCT01254656|Experimental|LRV 750mg+ DRV/r + OBT|
3073997|NCT01254656|Experimental|LRV 1000mg +DRV/r + OBT|
3073998|NCT01254656|Active Comparator|ETR|
3073999|NCT01254669|No Intervention|control, standard of care|Mothers assigned to the Control Group received the low-literacy, standard-practice, HPV-vaccine information sheet
3074000|NCT01254669|Experimental|BNI-brief Negotiated Interview|The BNI intervention addressed mothers' beliefs, values, and concerns about HPV prevention and takes their priorities for health and well-being into account.
3074001|NCT01254721|Experimental|1|Seroquel XR tablet
3074002|NCT01254721|Active Comparator|2|Seroquel XR + lithium
3074003|NCT01254747|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3074004|NCT01254747|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3074005|NCT01254747|Active Comparator|Nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3074006|NCT01254747|Active Comparator|Narafilcon A|Narafilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for four weeks.
3074007|NCT01254760|Other|Investigational multifocal / Commercial multifocal|Investigational multifocal contact lenses worn first, with commercial multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
3074008|NCT01254760|Other|Commercial multifocal / Investigational multifocal|Commercial multifocal contact lenses worn first, with investigational multifocal contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 5 days.
3074009|NCT01254851|Active Comparator|goal-augmented post-operative care.|Patients in this group will be given a goal number of steps to take on each post-operative day.
3074010|NCT01254851|No Intervention|Usual care|routine post-operative ambulation
3074011|NCT01254877|Placebo Comparator|Placebo Ondansetron - sugar pill|Placebo is an oral preparation made to appear and taste like the active drug preparation.
3074012|NCT01254877|Experimental|low dose ondansetron (0.2 mg bid)|
3074013|NCT01254877|Experimental|moderate dose ondansetron (0.8 mg bid)|
3074014|NCT01254890|Experimental|Azacitidine + Sorafenib|Azacitidine (AZA) 75 mg/m^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days; Sorafenib 200 mg orally twice a day.
3074015|NCT01255137|Experimental|Adrenal Cortex Neoplasms|Aggressive cancer that starts in the adrenal gland located at the top of the kidneys.
3074016|NCT01255163|Experimental|Exendin-4|Exenatide 5 mcg or 10 mcg SC twice daily
3074017|NCT01255163|Placebo Comparator|Placebo|Placebo SC twice daily
3074018|NCT01255306||NO IOP|Patients without raised IOP
3074019|NCT01255306||RAISED IOP|Patients with raised IOP
3074020|NCT01255423|Experimental|Diclofenac sodium topical gel 1%|
3074021|NCT01255423|Placebo Comparator|Placebo|
3074022|NCT01255436|Experimental|SMS text reminders|Participants in this arm will receive SMS text messages on top of the usual care they receive from their physicians.
3074023|NCT01255436|Other|Usual Care|Participants in this arm will receive the usual care they receive from their physicians.
3074024|NCT01255449|Experimental|albuterol|Twenty-six consecutive patients undergoing allogeneic HSCT for hematological malignancies were studied. All patients were in stable clinical conditions at the time of study. All patients received a myeloablative conditioning regimen either including or not including total body irradiation. Spirometry, lung volumes, FOT and lung CT scan were obtained before the start of conditioning treatment and, approximately, two months after HSCT. On each study day, all the above measurements were taken before and 30 min after inhaling four consecutive albuterol doses, of 100 mcg each, through a valved-holding chamber. DLco was measured only after bronchodilator inhalation.
3074025|NCT01255592|Experimental|1|Treatment arm AZD5069
3074026|NCT01255592|Placebo Comparator|2|Placebo dose.
3074027|NCT01255631|Sham Comparator|Sham PEMF device|
3074028|NCT01255631|Active Comparator|PEMF Device|
3074029|NCT01255670|Active Comparator|penicillin and metronidazole|After incision and drainage 100 randomized patients receive penicillin and metronidazole as treatment of peritonsillar abscess
3074030|NCT01255670|Placebo Comparator|penicillin and placebo|After incision and drainage 100 randomized patients receive penicillin and placebo as treatment of peritonsillar abscess
3074031|NCT01255722|Experimental|Iobitridol|Patients were IV injected with a single dose of iobitridol before a coronary CT angiography
3074032|NCT01255722|Active Comparator|Iopromide|Patients were IV injected with a single dose of iopromide before a coronary CT angiography
3074033|NCT01255722|Active Comparator|Iomeprol|Patients were IV injected with a single dose of iomeprol before a coronary CT angiography
3074034|NCT01255761|Other|RAPID3 to assess response to Cimzia|"RAPID3 is a subject-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a patient measure tool, a tool based on patient-report outcomes (RAPID3); using a total score of 30 points"
3074035|NCT01255761|Other|CDAI to assess response to Cimzia|"CDAI is an investigator-based assessment tool used to assess subject's response to Cimzia.~Subjects will be randomized to a clinical measures tool, a tool based on Investigator measures without the need for a lab value (CDAI)"
3074036|NCT01255787|Experimental|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 10 weeks.
3074037|NCT01255787|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
3074038|NCT01255787|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for 8 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily for 2 weeks.
3074039|NCT01255787|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, followed by vortioxetine 20 mg, tablets, orally, once daily for 7 weeks, followed by vortioxetine placebo-matching tablets, orally, once daily, for 2 weeks.
3074040|NCT01255865||A1 - up to 1 month|Age group 0 up to 1 month
3074041|NCT01255865||A2 - 1 to 3 months|Age group from 1 month to 3 months
3074042|NCT01255865||A3 - 3 months to 1 year|Age group from 3 months to 1 year
3074043|NCT01255865||B - 1 year to 5 years|Age group from older than 1y and younger than 5 years
3074044|NCT01255865||C - 5 years to 12 years|Age group from older than 5y and younger than 12 years
3074045|NCT01255865||D - 12 years to 21 years|Age group from older than 12 years and younger than 21 years
3074046|NCT01255865||E - 21 years and older|Age group older than 21 years
3074047|NCT01255904|Experimental|Arm 1|Oral Chloral and intranasal placebo
3074048|NCT01255904|Experimental|Arm 2|oral placebo and intranasal dexmedetomidine
3074049|NCT01256008|Placebo Comparator|stage 1 Clinical Management|The group will receive clinical management treatment only each session.
3074050|NCT01256008|Experimental|stage1 CBT|The experimental group will receive CBT
3074051|NCT01256008|No Intervention|stage1 Control group|Participants with breast cancer in the control group received standard medical care, but don't receive any other interventions.
3074052|NCT01256034|Active Comparator|Group A|preoperative immunonutrition
3074053|NCT01256034|No Intervention|Group B|ordinary diet
3074054|NCT01256060|Experimental|Intanasal Oxytocin|A modified dose finding method will be used to determine safety among four dose levels for Intranasal Oxytocin. Half the dose (0.2 IU/kg /dose) is the minimum dose and two intermediate doses will also be evaluated (0.26 and 0.33 IU/kg / dose) Dose-finding escalations will be done in groups of three patients.Three patients will be studied at the first dose level. If none of these patients experience dose limiting toxicity, the dose will be escalated. If one experiences dose limiting toxicity, up to three more will be accrued at the same level. If none of these experience dose limiting toxicity, the dose will be escalated. If one or more of these experience dose-limiting toxicity, entry at that dose level will be stopped. Up to three more patients will be treated at the next lower dose. If zero out of these experience dose limiting toxicity, an additional three patients will be treated at that dose.
3074055|NCT01256086|Experimental|24 µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
3074056|NCT01256086|Experimental|12µg Formoterol Novolizer|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
3074057|NCT01256086|Active Comparator|24 µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
3074058|NCT01256086|Active Comparator|12µg Formoterol Aerolizer|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
3074059|NCT01256164|Experimental|Fibrocaps + Gelfoam|After identification of a Target Bleeding Site (TBS), topical Fibrocaps should be applied using the Fibrospray device for general surgeries; and either the Fibrospray device or direct application for spinal and vascular surgeries, followed by application of Gelfoam and manual pressure with sterile gauze.
3320959|NCT02015000|Experimental|pterygium recurrence|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
3074060|NCT01256164|Active Comparator|Gelfoam|Treatment is Gelfoam followed by manual pressure with sterile gauze. If hemostasis is not achieved within 10 minutes of the Start Time,the subject should be considered a treatment failure and the surgeon should implement additional hemostatic measures.
3074061|NCT01256177|Experimental|1|
3074062|NCT01256177|Placebo Comparator|2|
3074063|NCT01256190|Experimental|Fibrocaps + Gelatin sponge|Topical Fibrocaps powder followed by application of gelatin sponge
3074064|NCT01256190|Active Comparator|Gelatin Sponge|approved device for surgical bleeding
3074065|NCT01256294|Experimental|Sequence 1 - Branded Tacrolimus / Generic Tacrolimus|In Period 1 (Days 1-14) participants received branded tacrolimus (Prograf) orally twice a day and in Period 2 (Days 15 - 28) participants received generic tacrolimus (Sandoz) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
3074066|NCT01256294|Active Comparator|Sequence 2 - Generic Tacrolimus / Branded Tacrolimus|In Period 1 (Days 1 - 14) participants received generic tacrolimus (Sandoz) orally twice a day and in Period 2 (Days 15 - 28) participants received branded tacrolimus (Prograf) orally twice a day. Participants received the same stable dosage of tacrolimus they had been taking prior to enrollment (on a milligram for milligram basis).
3074067|NCT01256385|Experimental|Arm A (cetuximab and temsirolimus)|Patients receive temsirolimus IV over 30-60 minutes and cetuximab IV over 1-2 hours once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3074068|NCT01256385|Experimental|Arm B (temsirolimus)|Patients receive temsirolimus as in Arm A. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over to Arm A.
3074069|NCT01256398|Experimental|Treatment (chemotherapy, transplant)|See Detailed Description
3074070|NCT01256411|Experimental|LCZ696|
3074071|NCT01256424|Experimental|HAL 5% with illumination|HAL PDT 5%
3074072|NCT01256424|Experimental|HAL 1% with illumination|HAL PDT 1%
3074073|NCT01256424|Experimental|HAL 0.2% with illumination|HAL PDT 0.2%
3074074|NCT01256424|Placebo Comparator|Placebo ointment without illumination|Placebo without illumination
3074075|NCT01256450|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3074076|NCT01256450|Placebo Comparator|BEMA Placebo|placebo buccal soluble film
3074077|NCT01256476|Experimental|pitavastatin 4 mg once daily (QD)|
3074078|NCT01256476|Active Comparator|pravastatin 40 mg once daily (QD)|
3074079|NCT01256502|Other|Implanted Participants|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
3074080|NCT01256567|Experimental|ramucirumab and docetaxel combination|
3074081|NCT01256593||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
3074082|NCT01256658|Experimental|Intervention|Participants received COA566 treatment for asymptomatic carriage of P. falciparum and for symptomatic malaria episodes.
3074083|NCT01256658|Experimental|Control|Participants received COA566 treatment for symptomatic malaria episodes only.
3074084|NCT01256671|Experimental|DHEA|0.5% DHEA (intravaginal)
3074085|NCT01256684|Placebo Comparator|Placebo|
3074086|NCT01256684|Experimental|0.25% DHEA|
3074087|NCT01256684|Experimental|0.5% DHEA|
3074088|NCT01256788|Experimental|Viscosupplementation|Hyaluronic acid injection
3074089|NCT01256788|Placebo Comparator|Saline injection|
3074090|NCT01256840||Calorie Restricting Group|
3074091|NCT01256840||Normal-eating controls|
3074092|NCT01256840||Obese comparison group|
3074093|NCT01256879|Experimental|CimTest-A|200mg cimetidine (as 2 capsules)
3074094|NCT01256879|Experimental|CimTest-B|200mg cimetidine (as 2 capsules)
3074095|NCT01256879|Active Comparator|Sorbitol-free cimetidine solution|200mg cimetidine (as oral liquid)
3074096|NCT01256879|Experimental|Commercial cimetidine solution|200mg cimetidine (as oral liquid)
3074097|NCT01256944||Control|The normal reproductive-aged women
3074098|NCT01256944||PCOS|"Women who met the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria:~Oligo- or anovulation~Clinical and/or biochemical signs of hyperandrogenism~Polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing's syndrome)"
3074099|NCT01256983|Experimental|Bright Light Therapy|Bright Light Therapy with 10000 lux beginning at day 21 until day 42
3074100|NCT01256983|Other|Wait-list intervention|Wait-list design Intervention. Bright Light Therapy with 10000 lux beginning at day 63 until day 84, when the 9 study weeks were over.
3074101|NCT01257087|Experimental|Intensive glycaemic control|Intensive glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
3074102|NCT01257087|Active Comparator|Conservative glycaemic control|Conservative glycaemic control All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
3074103|NCT01257204|Active Comparator|Control|Placebo + Pegylated interferon alfa-2a + Ribavirin
3074104|NCT01257204|Experimental|12 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
3074105|NCT01257204|Experimental|16 Week Cohort|Daclatasvir + Pegylated interferon alfa-2a + Ribavirin
3074106|NCT01257217|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1 or AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT, lens assignment and model determined by preoperative keratometric astigmatism, bilateral implantation
3074107|NCT01257217|Active Comparator|Acri.LISA|Acri.LISA® 366D IOL or Acri.LISA® 466TD Toric IOL, lens assignment determined by preoperative keratometric astigmatism, bilateral implantation
3074108|NCT01257230|Placebo Comparator|placebo|once daily, delivered with Respimat inhaler
3074109|NCT01257230|Experimental|tiotropium low dose|once daily, delivered with Respimat inhaler
3074110|NCT01257230|Experimental|tiotropium high dose|once daily, delivered with Respimat inhaler
3074111|NCT01257347|Other|Concealment (control)|Clinicians in the control arm will not receive any electronically-monitored medication adherence information (collected via MedSignals pillbox) at the 1-month visit and will be expected to manage hypertension according to their usual care.
3074112|NCT01257347|Experimental|Disclosure (intervention)|"Disclosure of adherence report to clinician:~At clinic visits with patients with uncontrolled hypertension, clinicians in the intervention arm were provided with a quantitative summary of their patients' electronic adherence to antihypertensive medications (collected via MedSignals pillbox)."
3074113|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) IM.|
3074114|NCT01257425|Other|Triptorelin Pamoate (Pamorelin® LA 11.25 mg) SC.|
3074115|NCT01257438|Experimental|Fluency Plus Endovascular Stent Graft|Fluency Plus Endovascular Stent Graft
3074116|NCT01257438|Active Comparator|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty only
3074117|NCT01257503|Experimental|Homeopathic cold remedy|5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
3074118|NCT01257503|Placebo Comparator|placebo|5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
3074119|NCT01257542|Experimental|Active|
3074120|NCT01257542|Placebo Comparator|Placebo|
3074121|NCT01257568|Other|Rejuvenate Modular Hip System|Rejuvenate Modular Hip
3074122|NCT01257581|Experimental|Creatine 30gm|"Creatine will be taken as a powder mixed into food or liquid twice a day. Volunteers in this arm will take a total of 30gm of creatine per day for 38 weeks. Volunteers will also take placebo capsules twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Creatine is a nutritional supplement and is not approved by the U.S. Food and Drug Administration (FDA) for treating ALS."
3074123|NCT01257581|Experimental|Tamoxifen 40mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 40mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
3074124|NCT01257581|Experimental|Tamoxifen 80mg|"Tamoxifen will be taken as capsules twice a day. Volunteers in this arm will take a total of 80mg of tamoxifen per day for 38 weeks. Volunteers will also take placebo powder twice a day for 38 weeks.~This is a blinded study, so neither participants nor study staff will know which treatment a volunteer is receiving.~Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for breast cancer treatment but is not approved for treating ALS."
3074125|NCT01257698|Active Comparator|Dorzolamide-timolol topical drops|
3074126|NCT01257698|No Intervention|Standard of care|
3074127|NCT01257737|Experimental|HPN-100|Participants continued HPN-100 treatment after completion of HPN-100-005SE, HPN-100-007, or HPN-100-012SE.
3074128|NCT01257750|Experimental|Pazopanib|This is a single site, open label, safety and efficacy study of pazopanib (5mg/ml) where all 20 patients with corneal neovascularization in a single arm will receive pazopanib in one eye.
3074129|NCT01257802|Active Comparator|LUPRON|Monthly depot leuprolide acetate 3.75 mg injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
3074130|NCT01257802|Placebo Comparator|Placebo|Monthly placebo injection during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses.
3074131|NCT01257880||Control (absence of PFO)|Persons who have migraine aura and no evidence of PFO, based on transcranial Doppler evaluation.
3074132|NCT01257880||Large PFO|Persons who have migraine aura and large PFO, as assessed by transcranial Doppler evaluation.
3074133|NCT01258049|Experimental|ArTiMist|
3074134|NCT01258049|Active Comparator|Quinine|
3074135|NCT01258075|Experimental|Colesevelam|High-dose colesevelam suspended in a drink for oral administration once daily with dinner
3074136|NCT01258075|Experimental|Placebo proxy|Low-dose colesevelam suspended in a drink for oral administration once daily with dinner
3074137|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (24 Weeks)|Participants received peginterferon alfa-2a (PEG-IFNα-2a) 180 mcg once weekly + Ribavirin 800 mg daily for 24 weeks (W).
3074138|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (24 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 24 W.
3074139|NCT01258101|Experimental|Peginterferon/Ribavirin 800 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 800 mg daily for 16 W.
3074140|NCT01258101|Experimental|Peginterferon/Ribavirin 400 mg (16 Weeks)|Participants received PEG-IFNα-2a 180 mcg once weekly + Ribavirin 400 mg daily for 16 W.
3074141|NCT01258153|Experimental|Nepadutant Low Dose|
3074142|NCT01258153|Experimental|Nepadutant High Dose|
3074143|NCT01258153|Placebo Comparator|Placebo|
3074144|NCT01258348|Experimental|LY573636 +sunitinib|
3074145|NCT01258374||Single arm with dual therapy|Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD
3074146|NCT01258387|Placebo Comparator|GGF2|Seven dosing cohorts: 2 patients randomized to receive 1 GGF2, 1 placebo; if no drug-related dose-limiting toxicities in GGF2-treated patient, other 4 patients in cohort will be randomized (3:1) and dosed
3074147|NCT01258504||CYP2C9 wild type|"CYP2C9 wild type =extensive metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
3074148|NCT01258504||CYP2C9 mutant|"CYP2C9 *2/*2 or 2*/*3 or *3/*3 = poor metaboliser~Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19~Administration of St. Johns Wort: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
3074149|NCT01258582|Experimental|Oral HIV testing|
3074150|NCT01258582|Active Comparator|Fingerstick HIV testing|
3074151|NCT01258595|Experimental|High-Dose Trivalent Inactivated Influenza Vaccine|
3074152|NCT01258595|Active Comparator|Trivalent Inactivated Influenza Vaccine|
3074153|NCT01258608|Experimental|Sorafenib plus mapatumumab|Mapatumumab 30 milligrams (mg)/kilogram (kg) intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
3074154|NCT01258608|Placebo Comparator|Sorafenib plus Placebo|Placebo intravenously on Day 1 of each cycle (i.e. every 21 days) plus sorafenib 400 mg orally twice daily continuously in each cycle until radiologic disease progression or unacceptable toxicity
3074155|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
3074156|NCT01258660|Experimental|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
3074157|NCT01258738|Active Comparator|etanercept|In Period 1 : Subjects will receive via a prefilled syringe an active dose equivalent to 1.0ml of Etanercept solution once weekly SC once weekly. Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
3074158|NCT01258738|Placebo Comparator|PLACEBO|In Period 1: Subjects will receive in a prefilled syringe with a PLACEBO dose equivalent to 1.0 ml of placebo solution once weekly SC Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
3074159|NCT01258790|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, in the form of Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using a Sham TMS coil.
3074160|NCT01258790|Experimental|Active Repetitive Transcranial Magnetic Stimulation|Eight sessions of Repetitive Transcranial Magnetic Stimulation, Continuous Theta Burst Stimulation, was delivered over the Supplementary Motor Area over 2 days using an Active Magstim Figure-8 TMS coil.
3074161|NCT01258803|Experimental|Sequence 1|Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI
3074162|NCT01258803|Experimental|Sequence 2|Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI with spacer
3074163|NCT01258803|Experimental|Sequence 3|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: Placebo MDI with spacer; Treatment Period 4: MF/F MDI with spacer
3074164|NCT01258803|Experimental|Sequence 4|Treatment Period 1: Placebo MDI without spacer; Treatment Period 2: MF/F MDI with spacer; Treatment Period 3: F DPI; Treatment Period 4: MF/F MDI without spacer
3074165|NCT01258803|Experimental|Sequence 5|Treatment Period 1: MF/F MDI without spacer; Treatment Period 2: F DPI; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI without spacer
3074166|NCT01258803|Experimental|Sequence 6|Treatment Period 1: MF/F MDI with spacer; Treatment Period 2: Placebo MDI without spacer; Treatment Period 3: MF/F MDI without spacer; Treatment Period 4: F DPI
3074167|NCT01258855|Experimental|Arm I (ziv-aflibercept and aldesleukin)|Patients receive ziv-aflibercept IV over at least 1 hour in weeks 1, 3, 5, and 7 (and in week 9 of course 1 only) and high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3 (and in weeks 3 and 5 of course 1 only). Treatment repeats every 8 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising ziv-aflibercept IV on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3074168|NCT01258855|Experimental|Arm II (aldesleukin)|Patients receive high-dose aldesleukin IV over 15 minutes every 8 hours for 5 days in weeks 1 and 3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3074169|NCT01258985|Active Comparator|Tai Chi|12 weeks of Tai Chi classes
3074170|NCT01258985|Active Comparator|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of Supervised Home Exercise
3074171|NCT01258998|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3074172|NCT01259011|No Intervention|control|Written information on advance directives and the patient's right to have an advance directive is provided to every patient on the first day of dialysis treatment by a social worker at the clinic. A social worker documents whether the patient has an advance directive, a surrogate decision maker, and/or a Do-Not-Resuscitate (DNR) Order on a Comprehensive Interdisciplinary Assessment form. The social worker encourages patients to complete an advance directive and addresses their questions about life-sustaining treatment options. If completed, the advance directive is placed in the medical record.
3074173|NCT01259011|Experimental|SPIRIT intervention|The SPIRIT intervention is a two-session, 1½ hour-long, structured intervention that is composed of six steps (assessing representations, identifying and exploring gaps and concerns, creating conditions for conceptual change, introducing replacement information, summarizing, and setting goals and planning), presented to both patient and surrogate by a trained nurse interventionist in a face-to-face interview format based on the representational approach.
3074174|NCT01259063|Experimental|Pts who failed or relapsed after intravesical BCG|Phase I: Everolimus will be administered as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be administered at the dose determined in Phase .Everolimus will be continued for 12 months in the patients who achieve a CR or a Partial Response. Patients demonstrating a CR (by cystoscopy and cytology) or a Partial Response at their Cycle 12 cystoscopy will be observed with serial cystoscopies every 3 months.
3074175|NCT01259089|Experimental|Arm I|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour once weekly and oral erlotinib hydrochloride once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3074176|NCT01259102|Experimental|No Rest|BTDS 10 with no application site rest period prior to application of second BTDS
3074177|NCT01259102|Experimental|7-Day Rest|BTDS 10 with 7-day rest period prior to application of second BTDS
3074178|NCT01259102|Experimental|14-Day Rest|BTDS 10 with 14-day rest period prior to application of second BTDS
3074179|NCT01259102|Experimental|21-Day Rest|BTDS 10 with 21-day rest period prior to application of second BTDS
3074180|NCT01259102|Experimental|28-Day Rest|BTDS 10 with 28-day rest period prior to application of second BTDS
3074181|NCT01259115|Experimental|Sequence A|BTDS 10 with ketoconazole 200 mg tablets twice daily in period 1 and BTDS 10 with ketoconazole placebo tablets twice daily in period 2.
3074182|NCT01259115|Experimental|Sequence B|BTDS 10 with ketoconazole placebo tablets twice daily in period 1 and BTDS 10 with ketoconazole 200 mg twice daily in period 2.
3074183|NCT01259128|Experimental|SER120 500 ng/day|SER120 Level 1 (500 ng/day)
3074184|NCT01259128|Experimental|SER120 750 ng/day|SER120 Level 2 (750 ng/day)
3074185|NCT01259245|Experimental|Tai chi + PRP|Tai chi elements in incorporated into the exercise component of standard pulmonary rehabilitation program. The exercise content was totally identical to the PRP group except 15 minutes of Tai Chi exercises was substituted to 15 minutes of relaxation exercise. The 5 forms of Sun Style of Tai Chi were taught.
3074186|NCT01259245|Active Comparator|PRP|PRP is a formal pulmonary rehabilitation program consisted of physical training including warm up and cool down exercise and aerobic exercises in addition to breathing control exercises, safety precautions for physical training, Thera-Band strengthening exercises and overview of COPD management.
3074187|NCT01259297|Experimental|Aliskiren + Amlodipine|"In run-in period (4-5 weeks) , patients on thiazide background therapy and approximately 50% of patients on neither CCB nor thiazide background therapy received Amlodipine 5 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + Amlodipine 5 mg once daily during the double blind period."
3074188|NCT01259297|Experimental|Aliskiren + Hydrochlorothiazide (HCTZ)|"In run-in period (4-5 weeks) , patients on CCB background therapy and approximately 50% of patients on neither thiazide nor CCB background therapy: received Hydrochlorothiazide 12.5/25 mg and Aliskiren 150/300 mg daily in a titrated manner as per protocol.~In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~Patients randomized to this arm received Aliskiren 300 mg + HCTZ 25 mg once daily."
3074189|NCT01259297|Experimental|Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for Amlodipine 5 mg"
3074190|NCT01259297|Experimental|Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received Aliskiren 300 mg + Placebo for HCTZ 25 mg once daily"
3074191|NCT01259297|Experimental|Amlodipine + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received Amlodipine 5 mg + placebo for Aliskiren 300 mg once daily"
3074192|NCT01259297|Experimental|HCTZ + Placebo for Aliskiren|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received HCTZ 25 mg + placebo for Aliskiren 300 mg once daily"
3074193|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for Amlodipine|"In double blind period, all patients who successfully completed run-in with Amlodipine plus Aliskiren were randomized equally to the 4 arms of the Amlodipine add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for Amlodipine 5 mg once daily"
3074194|NCT01259297|Placebo Comparator|Placebo for Aliskiren + Placebo for HCTZ|"In double blind period, all patients who successfully completed run-in with HCTZ plus Aliskiren were randomized equally to the 4 arms of the HCTZ add-on stratum.~In double blind period, randomized patients to this arm received placebo for Aliskiren 300 mg + placebo for HCTZ 25 mg once daily"
3074195|NCT01259375|Experimental|All patients|All participants who received Amrubicin.
3074196|NCT01259388|Experimental|Lithium|"Lithium-treatment phase~Lithium Carbonate: Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time."
3074197|NCT01259388|No Intervention|Observation|During observation subjects continue on their standard of care disease modifying agent (or no agent at all if judged not appropriate by the treating physician).
3074198|NCT01259401|Experimental|SIP group|The Sleep Intervention Program group received a sleep education program based on behavioral principles, delivered in 4 individual sessions carried out within the Adult Day Health Care program.
3074199|NCT01259401|Active Comparator|Control group|The Control group received basic sleep education, delivered in 4 individual sessions carried out within the Adult Day Health Care
3074200|NCT01259427|Experimental|Arm 1: Ending Self Stigma|Ending Self Stigma (ESS): Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
3320961|NCT02015091|Experimental|1, 4, 5, 6, 7|Vaccination schedules with 3 to 4 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3320962|NCT02015091|Experimental|2|Vaccination schedules 4 IM vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3074201|NCT01259427|Active Comparator|Arm 2: Health and Wellness Group|Health and Wellness Group: The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
3074202|NCT01259440|Active Comparator|Video Teleconferencing Care|Video teleconferencing care
3074203|NCT01259440|Placebo Comparator|Usual Care|Usual Care
3074204|NCT01259466|Experimental|Cognitive Behavioral + Nicotine Patch|Cognitive Behavioral Therapy + Nicotine Replacement Patch
3074205|NCT01259466|Active Comparator|Health Education + Nicotine Patch|Health Education + Nicotine Replacement Patch
3074206|NCT01259492|Experimental|Ritalin LA 40 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2, continued in same dose till week 9. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3074207|NCT01259492|Experimental|Ritalin LA 60 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14.In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3074208|NCT01259492|Experimental|Ritalin LA 80 mg|In period 1 patients were given Ritalin LA 20 mg and up titrated to 40 mg at week 2 and to 60 mg at week 3 and to 80 mg at week 4. Period 2- The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 60 mg. Optimal dose was defined as the dose at which the investigator considered an optimal balance between control of symptoms and side effects was maintained for a period of at least one week prior to Week 14. In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3074209|NCT01259492|Placebo Comparator|Placebo|Period 1- Placebo controlled Period 2 - The dose of study medication was re-titrated for all patients (including those in the Placebo arm during Period 1) starting at 20 mg/day Ritalin LA and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose (40, 60 or 80 mg). In period 3, patients were re- randomized to either their optimal dose of medication (40, 60, or 80 mg/day) or Placebo from beginning of week 15 to end of week 40.
3074210|NCT01259596|Active Comparator|Cognitive behavioral therapy|Cognitive-behavioral therapy consists of psychoeducation, relaxation techniques, cognitive therapy, problem-solving, thought stopping, behavioral activation, exposure, coping with pain, sleep, and relapse prevention
3074211|NCT01259596|Active Comparator|Nondirective supportive therapy|Nondirective supportive therapy consists of providing a warm and accepting environment in which a person can reflect on their experiences, thoughts, and feelings
3074212|NCT01259713|Experimental|Liposomal amphotericin B|Liposomal amphotericin B 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
3074213|NCT01259713|Placebo Comparator|Placebo|Placebo to match liposomal amphotericin B twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
3074214|NCT01259726|Placebo Comparator|Placebo|
3074215|NCT01259726|Experimental|VP20621 Low Dose and Placebo|
3074216|NCT01259726|Experimental|VP20621 High Dose and Placebo|
3074217|NCT01259726|Experimental|VP20621 High Dose|
3074218|NCT01259856|Experimental|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
3074219|NCT01259856|Active Comparator|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
3074220|NCT01259869|Experimental|PX-866|
3074221|NCT01260142|Experimental|Arm 1|
3074222|NCT01260142|Experimental|Arm 2|
3074223|NCT01260142|Experimental|Arm 3|
3074224|NCT01260181|Experimental|Erlotinib|Participants will receive erlotinib 150 millgrams (mg) orally daily until disease progression.
3074225|NCT01260194|Experimental|1|
3074226|NCT01260272|Active Comparator|Alternative Snack Group|This group will receive 100 calorie alternative snack packs to consume three times a day with meals. Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables
3074227|NCT01260272|Experimental|Raisin Group|This group will receive raisins to consume three times a day with meals
3074228|NCT01260311||Patients prescribed with Fesoterodine|Patients diagnosed with Over-active bladder and prescribed with fesoterodine.
3074229|NCT01260324||NAION cases|From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
3074230|NCT01260324||Controls|From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
3074231|NCT01260350|Experimental|Group 1: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive (TN) participants with genotype (GT) 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074232|NCT01260350|Experimental|Group 2: SOF+RBV 12 wk+PEG 4 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 4 weeks.
3074233|NCT01260350|Experimental|Group 3: SOF+RBV 12 wk+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks plus PEG 180 µg once weekly for 8 weeks.
3074234|NCT01260350|Experimental|Group 4: SOF+RBV+PEG 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily+weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 12 weeks.
3074235|NCT01260350|Experimental|Group 5: SOF 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily for 12 weeks.
3074236|NCT01260350|Experimental|Group 6: SOF+RBV+PEG 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus PEG 180 µg once weekly for 8 weeks.
3074237|NCT01260350|Experimental|Group 7: SOF+RBV 12 wk: GT 1, TE|Treatment-experienced (TE) participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074238|NCT01260350|Experimental|Group 8: SOF+RBV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074239|NCT01260350|Experimental|Group 9: SOF+RBV 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074240|NCT01260350|Experimental|Group 10: SOF+RBV 8 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 8 weeks.
3074241|NCT01260350|Experimental|Group 11: SOF+RBV 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive SOF 400 mg once daily plus split-dose RBV (800 mg in a divided daily dose) for 12 weeks.
3074242|NCT01260350|Experimental|Group 12: SOF+RBV+LDV 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
3074243|NCT01260350|Experimental|Group 13: SOF+RBV+LDV 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus LDV 90 mg once daily for 12 weeks.
3074244|NCT01260350|Experimental|Group 14: SOF+RBV+GS-9669 12 wk: GT 1, TE|Treatment-experienced participants with genotype 1 HCV infection who did not respond to prior treatment will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
3074245|NCT01260350|Experimental|Group 15: SOF+RBV+GS-9669 12 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive SOF 400 mg once daily plus weight-based RBV (1000-1200 in a divided daily dose) plus GS-9669 500 mg once daily for 12 weeks.
3074246|NCT01260350|Experimental|Group 16: LDV/SOF FDC 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection and Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3074247|NCT01260350|Experimental|Group 17: LDV/SOF FDC+RBV 12 wk: GT 1, fibrosis|Treatment-experienced participants with genotype 1 HCV infection with Stage F4 fibrosis who did not respond to prior treatment will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074248|NCT01260350|Experimental|Group 18: LDV/SOF FDC 12 wk: GT 2 or 3, TN|Treatment-naive participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3074249|NCT01260350|Experimental|Group 19: LDV/SOF FDC 12 wk: GT 2 or 3, TE|Treatment-experienced participants with genotype 2 or 3 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily for 12 weeks.
3074250|NCT01260350|Experimental|Group 20: LDV/SOF FDC+RBV 12 wk: GT 1, hemophiliac|Hemophiliac participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 12 weeks.
3074251|NCT01260350|Experimental|Group 21: LDV/SOF FDC+RBV 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection will receive LDV 90 mg/SOF 400 mg FDC once daily plus weight-based RBV (1000-1200 in a divided daily dose) for 6 weeks.
3074252|NCT01260350|Experimental|Group 22: LDV/SOF FDC 6 wk: GT 1, TN|Treatment-naive participants with genotype 1 HCV infection were randomized to receive LDV 90 mg/SOF 400 mg FDC once daily for 6 weeks.
3074253|NCT01260454|Experimental|Qutenza patch|All participants actively treated with Qutenza
3074254|NCT01260467|Experimental|memantine arm|
3074255|NCT01260493|No Intervention|Conventional care, controlgroup|conventional care, control group
3074256|NCT01260493|Experimental|integrated health care chain|integrated health care chain. Geriatric assessment at emergency department (ED), case manager with multiprofessional team in the community, support for informal caregivers
3074257|NCT01260584|Experimental|Prasugrel|Prasugrel 10 mg film-coated tablet daily dose × 10 days. To maintain blinding, placebo film-coated tablets matching clopidogrel in appearance will be given daily × 10 days to subjects in the prasugrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
3074258|NCT01260584|Active Comparator|Clopidogrel|Clopidogrel 75 mg film-coated tablet daily dose x 10 days To maintain blinding, placebo film-coated tablets matching prasugrel in appearance will be given daily × 10 days to subjects in the clopidogrel treatment group. In addition, aspirin 81 mg to 325 mg daily will be taken.
3074259|NCT01260649|Experimental|ketamine|ketamine (0.5 mg/kg) followed by anesthetic agent titrated to sedation and succinylcholine titrated to muscle relaxation Right unilateral ECT at 5-6x seizure threshold three times a week
3074260|NCT01260649|Placebo Comparator|placebo|"IV saline, followed by anesthestic agent titrated to sedation and succinylcholine titrated to muscle relaxation.~Right unilateral ECT at 5-6x seizure threshold three times a week"
3074261|NCT01260662|Active Comparator|Propofol|Deep sedation using propofol
3074262|NCT01260662|Experimental|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
3074263|NCT01260662|Experimental|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 0.1 cc/kg as initial bolus, followed by 1/2 that dose every 3 minutes as need for sedation
3074264|NCT01260688|Experimental|Arm I|Patients receive oral cediranib maleate once daily and oral dasatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074265|NCT01260688|Experimental|Arm II|Patients receive cediranib maleate as in arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074266|NCT01260701|Experimental|Treatment (CLOSED TO ACCRUAL 05/01/13)|Patients receive Akt inhibitor MK2206 PO every other day on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074267|NCT01260883|Experimental|ketorolac 1 mg/kg|ketorolac 1 mg/kg iv given by 10 min infusion
3074268|NCT01260883|Active Comparator|ketorolac 0.5 mg/kg|ketorolac 0.5 mg/kg iv given by 10 min infusion
3074269|NCT01260883|Sham Comparator|placebo|placebo group received D5W 10 min infusion
3074270|NCT01260896|Experimental|Investigational Test Product|150 mg Venlafaxine Hydrochloride Extended-Release Capsules
3074271|NCT01260896|Active Comparator|Reference Listed Drug|150 mg Effexor® XR Extended-Release Capsules
3074272|NCT01260922|Experimental|Investigational Test Product|Donepezil Hydrochloride 10 mg Orally Disintegrating Tablets
3074273|NCT01260922|Active Comparator|Reference Listed Drug|Aricept® 10 mg Orally Disintegrating Tablets
3074274|NCT01260948|Experimental|Investigational Test Product|Donepezil Hydrochloride Orally Disintegrating Tablets, 10 mg
3074275|NCT01260948|Active Comparator|Reference Listed Drug|Aricept® Orally Disintegrating Tablets, 10 mg
3074276|NCT01261000|Experimental|Pegvisomant|
3074277|NCT01261052|Active Comparator|FMPD/APD intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the first 13 hours, the original artificial pancreas algorithm FMPD, will be used to control the subject's blood glucose. After 13 hours, the adaptive component or APD will be used to control the subject's blood glucose for the remaining 20 hours.
3074278|NCT01261052|Active Comparator|APD only intervention|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 33 hours. For the entire study, the adaptive component or APD will be used to control the subject's blood glucose.
3074279|NCT01261247|Experimental|Arm I|Patients receive oral panobinostat 3 times weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3074280|NCT01261325|Placebo Comparator|Placebo|Matching placebo tablets administered twice daily
3074281|NCT01261325|Experimental|Brivaracetam 100 mg/ day|Brivaracetam 50 mg/ day administered twice daily.
3074282|NCT01261325|Experimental|Brivaracetam 200 mg/ day|Brivaracetam 100 mg/ day administered twice daily
3074283|NCT01261338|Experimental|olestra|Non-absorbable fat administered in the form of 24 potato crisps per day (12 each with mid-day and evening meal) providing approximately 15g/day of olestra.
3074284|NCT01261338|Placebo Comparator|Vegetable oil|Absorbable fat administered in the form of 12 potato crisps per day (6 each with mid-day and evening meal) in order to match the caloric intake provided by the crisps with Olestra.
3074285|NCT01261390|Placebo Comparator|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide ~30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breath Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
3074286|NCT01261390|Sham Comparator|Sham PAP (Sham)|"In addition to receiving CMT, participants in this treatment arm will receive a sham-CPAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active PAP arms.~The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up~1-month follow up~3-month follow up~6-month follow up~9-month follow up (will not occur if on a 6-month follow-up protocol)~It is estimated that each in-person follow-up adherence visit with the PAP specialist would last ~30 minutes."
3074287|NCT01261390|Active Comparator|Active PAP with RT Support (Active-Beh)|"In addition to receiving CMT, participants will receive active-PAP. The treatment visit schedule is outlined below.~PAP Initial Set-Up~1-week follow up (FU)~1-month FU~3-month FU~6-month FU~9-month FU (12-month follow-up protocol only)~All visits will take place with a PAP specialist. All follow-up visits will be anchored to the initial PAP set-up visit. At these visits, using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. Each follow-up visit with the PAP specialist will last 30 minutes."
3132385|NCT03422159|Placebo Comparator|Placebo Arm|"Vitamin C placebo will consist of an identical bag of 100mL normal saline (but with no vitamin C) and will be labeled Vitamin C or Placebo. Placebo will be infused over 30 minutes as per the infusion instructions of the active vitamin and protected from light with a brown bag. Hydrocortisone placebo will be provided as an identical 3mL syringe as 1mL of normal saline.The thiamine placebo will be placed in a 50mL bag of Normal Saline labeled Thiamine 200mg or Placebo and run over 30 minutes (100mL/hr) Placebo patients will receive a matching 50mL bag of Normal Saline. All of these will be given for up to 4 days, or less if discharged from the ICU prior."
3074288|NCT01261390|Active Comparator|Active PAP with Behavioral Modification (Active+Beh)|"In addition to receiving CMT and active-PAP, participants will have behavioral intervention sessions to promote PAP adherence. The treatment visit schedule is outlined below:~Visits with Behavioral Interventionist (in addition to active-PAP treatment visits):~PAP Initial Set-Up (in-person, 1-hr)~1-week follow-up (FU) (in-person, 1-hr)~1-month FU~2-month FU~3-month FU~5-month FU~8-month FU (12-month follow-up protocol only)~All follow-up visits will be anchored to the initial PAP set-up visit. PAP treatment visits will occur as outlined in the active-PAP arm.~All behavioral intervention visits will be 30-min phone calls, unless otherwise noted. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training."
3074289|NCT01261559|No Intervention|Standard CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) but without the Chrysalis device.
3074290|NCT01261559|Experimental|Chrysalis CT|Women assigned to undergo CT using the standard dose reduction methods (including bismuth shielding and tube current modulation) plus application of the Chrysalis device for breast displacement.
3074291|NCT01261611|Experimental|Dysport NG|"500U (1mL) administered as intramuscular injection on day 1 of treatment cycle 1 and 2.~250U (0.5mL), 500U (1mL) or 750U (1.5mL) administered as intramuscular injection on day 1 of treatment cycle 3.~250U (0.5mL), 500U (1mL), 750U (1.5mL) or 1000U (2mL) administered as intramuscular injection on day 1 of treatment cycle 4 and 5."
3074292|NCT01261611|Active Comparator|Dysport|500U (1mL) injected as intramuscular injection on day 1 of treatment cycle 1.
3074293|NCT01261611|Placebo Comparator|Placebo|1mL administered as, intramuscular injection on day 1 of treatment cycle 1.
3074294|NCT01261624|Experimental|Givinostat 1.0 mg/kg daily|
3074295|NCT01261624|Experimental|Givinostat 1.5 mg/kg daily|
3074296|NCT01261780|Sham Comparator|Sham device|Sham therapy device to area of painful chemotherapy induced peripheral neuropathy (CIPN) for 45 minutes daily x 10 days
3074297|NCT01261780|Active Comparator|MC-5A treatment|MC-5A therapy to the area of painful CIPN for 45 minutes daily for a total of 10 days.
3074298|NCT01261793|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
3074299|NCT01261793|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12 week treatment cycles
3074300|NCT01261793|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
3074301|NCT01261819|Experimental|transurethral laparoscope|These patients had cystoscopy performed with the transurethral laparoscope.
3074302|NCT01261819|Active Comparator|Traditional cystoscopy|"These patients had cystoscopy performed with the traditional cystoscope, which is considered to be the gold standard."
3074303|NCT01261975|Experimental|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial microincision
3074304|NCT01261975|Active Comparator|Coaxial Small Incision Cataract Surgery|2.75 mm standard incision
3074305|NCT01262027|Experimental|Dovitinib|A complete treatment cycle defined as 28 days or 4 weeks (+/- 2 days). Patients receive a single daily oral dose of 500 mg of dovitinib for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule).
3074306|NCT01262092|Active Comparator|Gabapentin|Buprenorphine will be given along with 2 capsules of gabapentin in the morning and 2 take-home capsules of gabapentin for night.
3074307|NCT01262092|Placebo Comparator|Placebo|Buprenorphine will be given, with 2 capsules of placebo in the morning and 2 take-home capsules of placebo in the evening
3074308|NCT01262105|No Intervention|No device|
3074309|NCT01262105|Experimental|Device deployed|
3074310|NCT01262118|Experimental|CP-690,550 (tasocitinib) 10 mg twice daily (BID)|
3074311|NCT01262118|No Intervention|Healthy Volunteers|No intervention
3074312|NCT01262131|Active Comparator|Resonator Protocol A|
3074313|NCT01262131|Active Comparator|Resonator Protocol B|Application of magnetic fields using the Resonator device Protocol B
3074314|NCT01262131|Placebo Comparator|Inactive Resonator|
3074315|NCT01262287|Experimental|dutasteride|dutasteride (1 mg oral daily dose) for 8-week treatment period
3074316|NCT01262287|Placebo Comparator|Placebo|placebo daily for 8-week treatment period
3074317|NCT01262352|Experimental|Treatment Sequence 1|Ivacaftor administered in Treatment Period 1 and placebo administered in Treatment Period 2.
3074318|NCT01262352|Experimental|Treatment Sequence 2|Placebo administered in Treatment Period 1 and ivacaftor administered in Treatment Sequence 2.
3074319|NCT01262365|Placebo Comparator|Placebo (Weekly infusion)|Placebo infusions delivered weekly for a total of 4 weeks over four 12-week treatment cycles
3074320|NCT01262365|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
3074321|NCT01262365|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles
3074322|NCT01262456|Experimental|Desmopressin 50 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 50 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3074323|NCT01262456|Experimental|Desmopressin 75 μg Double-Blind / 100 μg Open-Label|Participants took 1 orally disintegrating tablet of desmopressin 75 μg every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3074324|NCT01262456|Placebo Comparator|Placebo Double-Blind / Desmopressin 100 μg Open-Label|Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour prior to bedtime for the entire duration of the 3-month double-blind treatment period. Participants completing the double-blind period were switched to desmopressin 100 μg for the 1-month open-label extension period.
3074325|NCT01262547|Experimental|Dermabrasion-Micrografting|Dermabrasion-Micrografting
3074326|NCT01262547|Active Comparator|Dermabrasion alone|Dermabrasion alone
3074327|NCT01262547|No Intervention|Control|Control
3074328|NCT01262560|Active Comparator|Supportive Care|Standard supportive care
3074329|NCT01262560|Experimental|Liquid Manuka Honey|Manuka honey in liquid form
3074330|NCT01262560|Experimental|Lozenge Manuka Honey|Manuka honey in lozenge form
3074331|NCT01262573|Experimental|Barbed|Vaginal cuff closure with barbed suture
3074332|NCT01262573|Active Comparator|Smooth|Vaginal cuff closure with smooth suture
3074333|NCT01262599|Sham Comparator|Sham PEMF Device|Patients will receive inactive device
3074334|NCT01262599|Active Comparator|PEMF Device|Patients will receive Ivivi Torino II PEMF Device
3074335|NCT01262638|Experimental|ETC-1002 120 mg (Group 1)|Subjects with hypercholesterolemia and normal triglycerides
3074336|NCT01262638|Experimental|ETC-1002 80 mg (Group 2)|Subjects with hypercholesterolemia and normal triglycerides
3074337|NCT01262638|Experimental|ETC-1002 40 mg (Group 3)|Subjects with hypercholesterolemia and normal triglycerides
3074338|NCT01262638|Experimental|Placebo (Group 4)|Subjects with hypercholesterolemia and normal triglycerides
3074339|NCT01262638|Experimental|ETC-1002 120 mg (Group 5)|Subjects with hypercholesterolemia and elevated triglycerides
3074340|NCT01262638|Experimental|ETC-1002 80 mg (Group 6)|Subjects with hypercholesterolemia and elevated triglycerides
3074341|NCT01262638|Experimental|ETC-1002 40 mg (Group 7)|Subjects with hypercholesterolemia and elevated triglycerides
3074342|NCT01262638|Experimental|Placebo (Group 8)|Subjects with hypercholesterolemia and elevated triglycerides
3074343|NCT01262651|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3074344|NCT01262651|Placebo Comparator|Placebo (GA-0034)|Placebo Comparator: Placebo (GA-0034) Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol: propylene glycol (50:50)
3074345|NCT01262677|Experimental|pregabalin CR 330 mg|
3074346|NCT01262677|Experimental|pregabalin CR 165 mg|
3074347|NCT01262677|Placebo Comparator|Placebo|
3074348|NCT01262755||African Americans|Consists of 450 African Americans living in the zip code surrounding Temple Hospital between the ages of 18 and 80.
3074349|NCT01262820|Experimental|Single Intervention|Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
3074350|NCT01262846|Active Comparator|Fluzone SD|Fluzone® Standard dose
3074351|NCT01262846|Experimental|Fluzone® High dose|Fluzone® High dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
3074352|NCT01262872|Experimental|10PP-HD 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation at Day 0. The 10PP vaccine was administered intramuscularly in the non-dominant deltoid.
3074353|NCT01262872|Active Comparator|Prevnar13 1d Group|This group consisted in children aged 2-4 years at vaccination enrolled as part of the Cohort 1/Step 1 of the study who received a single dose of Prevnar 13™ at Day 0. Prevnar 13™ was administered intramuscularly in the non-dominant deltoid.
3074354|NCT01262872|Experimental|10PP-LD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its low-dose (LD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, LD formulation, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074355|NCT01262872|Experimental|10PP-HD 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of the GSK 2189242A (or 10PP) vaccine in its high-dose (HD) formulation and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the 10PP vaccine, HD formulation, co-administered with the Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074356|NCT01262872|Active Comparator|Synflorix 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Synflorix™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of the Synflorix™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074357|NCT01262872|Active Comparator|Prevnar13 3+0d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received 3 doses of Prevnar 13™ and EPI vaccines according to a 3+0 Schedule. That is, subjects received 3 doses of Prevnar 13™, co-administered with Tritanrix™-HepB/Hib and Polio Sabin™ at 2-3-4 months of age (Day 0, Month 1 and Month 2), followed by one dose of each of the M-Vac™, Stamaril™ and Polio Sabin™ vaccines administered at approximately 9 months of age. Prevnar 13™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074358|NCT01262872|Experimental|10PP-HD 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received the GSK 2189242A (or 10PP) vaccine, in its high-dose (HD) formulation, and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the 10PP vaccine, HD formulation co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of the same formulation co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age.. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. The 10PP vaccine was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074359|NCT01262872|Active Comparator|Synflorix 2+1d Group|This group consisted in infants aged 8-10 weeks at first vaccination enrolled as part the Cohort 2/Step 2 of the study who received Synflorix™ and EPI vaccines according to a 2+1 Schedule. That is, subjects received 2 doses of the Synflorix™ co-administered with Tritanrix™-Hep B/Hib and Polio Sabin™ at 2-4 months of age (at Day 0 and Month 2), followed by a third dose of Synflorix™ co-administered with M-Vac™, Stamaril™ and Polio Sabin™ at approximately 9 months of age. The 2nd doses of Tritanrix™-Hep B/Hib and Polio Sabin™ in EPI vaccines were administered without any pneumococcal vaccine at 3 months of age. Synflorix™ was administered intramuscularly into the right thigh; Tritanrix™-HepB/Hib, M-Vac™ and Stamaril™ were administered intramuscularly into the left thigh; Polio Sabin™ was administered orally.
3074360|NCT01262898|Experimental|GSK962040 (10 mg)|GSK962040 10 mg
3074361|NCT01262898|Experimental|GSK962040 (50 mg)|GSK962040 50 mg
3074362|NCT01262898|Experimental|GSK962040 (125 mg)|GSK962040 125 mg
3074363|NCT01262898|Experimental|Placebo|Placebo
3074364|NCT01262976|Experimental|HIV(+)-HA/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074365|NCT01262976|Placebo Comparator|HIV(+)-HA/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were on Highly Active Anti-Retroviral Therapy (HAART) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074366|NCT01262976|Experimental|HIV(+)-TN/GSK692342|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074367|NCT01262976|Placebo Comparator|HIV(+)-TN/Placebo|HIV-infected subjects between and including 18 to 59 years of age, who were HAART-treatment naive (TN) at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074368|NCT01262976|Experimental|HIV(-)/GSK692342|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of GSK692342 vaccine (TB) at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074369|NCT01262976|Placebo Comparator|HIV(-)/Placebo|Subjects between and including 18 to 59 years of age, who were HIV-negative at the time of study enrolment, received two doses of saline solution at Day 0 and Day 30, intramuscularly into the arm's deltoid region.
3074370|NCT01262989|Active Comparator|tamsulosin Reference|Reference drug administration followed by Test drug administration
3074371|NCT01262989|Active Comparator|tamsulosin Test|Test drug administration followed by Reference drug administration
3074372|NCT01263015|Experimental|Dolutegravir (N=~394):|Dolutegravir 50mg once daily + abacavir/lamivudine as the fixed-dose combination once daily + Atripla placebo once daily
3074373|NCT01263015|Active Comparator|Atripla (N=~394):|Atripla once daily + Dolutegravir placebo once daily + abacavir/lamivudine as the fixed-dose combination placebo once daily
3074374|NCT01263054|Experimental|TransDiscal System|Kimberly-Clark TransDiscal System in addition to standard medical management
3074375|NCT01263054|Other|Medical Management|Standard medical management
3074376|NCT01263093|Experimental|Clopidogrel First, Then LY2216684 + Clopidogrel|"Period 1: a single 300-milligram (mg) dose of clopidogrel administered orally on Day 1 (Treatment 1).~Period 2: an 18-mg dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
3074377|NCT01263093|Experimental|LY2216684 + Clopidogrel First, Then Clopidogrel|"Period 1: an 18-milligram (mg) dose of LY2216684 administered orally, once daily (QD) on Days 1 through 3, plus a single 300-mg dose of clopidogrel administered orally on Day 3 (Treatment 2).~Period 2: a single 300-mg dose of clopidogrel administered orally on Day 1 (Treatment 1).~There was a washout period of at least 14 days between the last dose of study drug in Period 1 and the first dose in Period 2."
3074378|NCT01263106|Experimental|Theophylline, LY2216684 + Theophylline|Period 1: single 200-milligram (mg) theophylline oral dose on Day 1; Washout period of at least 7 days; Period 2: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3
3074379|NCT01263106|Experimental|LY2216684 + Theophylline, Theophylline|Period 1: 18 mg LY2216684 orally, once daily on Days 1-5 with single 200-mg theophylline oral dose coadministered on Day 3; Washout period of at least 7 days; Period 2: single 200-mg theophylline oral dose on Day 1
3074380|NCT01263119|Experimental|Warfarin, LY2216684 + Warfarin|Period 1: Single 10-milligram (mg) warfarin oral dose on Day 1; Washout Period of at least 14 days; Period 2: 18-mg LY2216684 oral dose, once daily on Days 1 to 12, with single 10-mg warfarin oral dose coadministered on Day 3.
3074381|NCT01263132|Experimental|F0434|
3074382|NCT01263132|Active Comparator|Gabapentin|
3074383|NCT01263197|Experimental|LY2216684, albuterol, LY2216684+albuterol|LY2216684 as an 18 milligram (mg) oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
3074384|NCT01263197|Experimental|albuterol, LY2216684+albuterol, LY2216684|Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
3074385|NCT01263197|Experimental|LY2216684+albuterol, LY2216684, albuterol|LY2216684 as an 18 mg oral dose on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for albuterol on days 1, 3 and 5 in second intervention period, Placebo for LY2216684 on days 1-5 and albuterol as a 2 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
3074386|NCT01263197|Experimental|LY2216684, propranolol, LY2216684+propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in first intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
3074387|NCT01263197|Experimental|propranolol, LY2216684+propranolol, LY2216684|Placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the second intervention period, and LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in third intervention period. There is a minimum 7 day washout between each intervention period.
3074388|NCT01263197|Experimental|LY2216684+propranolol, LY2216684, propranolol|LY2216684 as an 18 mg oral dose on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the first intervention period, LY2216684 as an 18 mg oral dose on days 1-5 and placebo for propranolol on days 1, 3 and 5 in second intervention period, placebo for LY2216684 on days 1-5 and propranolol as a 40 mg oral dose on days 1, 3 and 5 in the third intervention period. There is a minimum 7 day washout between each intervention period.
3074389|NCT01263223|Experimental|LY2216684, placebo, LY or placebo|"Period 1: 18 milligrams (mg) LY2216684 administered orally once daily on Days 1-4~Period 2: placebo administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
3074390|NCT01263223|Experimental|Placebo, LY2216684, placebo or LY|"Period 1: placebo administered orally once daily on Days 1-4~Period 2: 18 mg LY2216684 administered orally once daily on Days 1-4~Period 3: 36 mg LY2216684 or placebo administered orally daily on Days 1-4"
3074391|NCT01263301|Active Comparator|carotid duplex for hemolytic patients wtih SSS|assigned intervention:carotid duplex
3074392|NCT01263301|Active Comparator|carotid duplex for nonhemolytic patients with SSS|
3074393|NCT01263314|Experimental|Panel A MK-8266 0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
3074394|NCT01263314|Experimental|Panel A MK-8266 0.6 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
3074395|NCT01263314|Experimental|Panel A MK-8266 0.7/0.3 mg (Elderly Males with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
3074396|NCT01263314|Placebo Comparator|Panel A Placebo to MK-8266 (Elderly Males with Mild/Mod. HTN)|Placebo to MK-8266 single dose
3074397|NCT01263314|Experimental|Panel B MK-8266 0.3 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.3 mg
3074398|NCT01263314|Experimental|Panel B MK-8266 0.6 mg (Elderly Females with Mild/Mod. HTN)|MK-8266 single dose 0.6 mg
3074399|NCT01263314|Experimental|Panel B MK-8266 0.7/0.3 mg (Elderly Fem. with Mild/Mod. HTN)|MK-8266 single dose 0.7 mg and then 0.3 mg after 10 hours
3074400|NCT01263314|Placebo Comparator|Panel B Placebo to MK-8266 (Elderly Fem. with Mild/Mod. HTN)|Placebo to MK-8266 single dose
3074401|NCT01263444|Experimental|Azarga|Brinzolamide 1% / timolol 0.5% Fixed Combination administered as 1 drop in study eye(s) twice a day (8:00 AM and 8:00 PM) for 12 weeks, at a 5 minute interval from the habitual prostaglandin monotherapy.
3074402|NCT01263470|Placebo Comparator|Placebo|
3074403|NCT01263470|Experimental|Alogliptin 6.25 mg QD|
3074404|NCT01263470|Experimental|Alogliptin 12.5 mg QD|
3074405|NCT01263470|Experimental|Alogliptin 25 mg QD|
3074406|NCT01263470|Experimental|Alogliptin 50 mg QD|
3074407|NCT01263470|Active Comparator|Voglibose 0.2 mg TID|
3074408|NCT01263483|Active Comparator|Voglibose 0.2 mg TID|
3074409|NCT01263483|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
3074410|NCT01263483|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
3074411|NCT01263496|Experimental|Alogliptin 6.25 mg QD|
3074412|NCT01263496|Experimental|Alogliptin 12.5 mg QD|
3074413|NCT01263496|Experimental|Alogliptin 25 mg QD|
3074414|NCT01263496|Experimental|Alogliptin 50 mg QD|
3074415|NCT01263496|Active Comparator|Voglibose 0.2-mg TID|
3074416|NCT01263509|Experimental|Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID|
3074417|NCT01263509|Experimental|Alogliptin 25 mg QD and Voglibose 0.2 mg TID|
3074418|NCT01263561|Active Comparator|trabeculectomy|trabeculectomy filtering surgery
3074419|NCT01263561|Experimental|ExPRESS|ExPRESS miniature glaucoma drainage device
3074420|NCT01263639|Experimental|Intervention Group, biosketch card|The investigators aim to improve the patient-physician relationship and improve patient satisfaction by providing a biosketch card of the attending orthopaedic trauma surgeon to the patient. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies.
3074421|NCT01263639|Active Comparator|Control group, standard care|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The control group will receive the usual/standard care as provided to all orthopaedic trauma admission patients without receiving a biosketch card."
3074422|NCT01263665|Experimental|25cm Gore VIABAHN|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
3074423|NCT01263691|Active Comparator|BioThrax|BioThrax, 0.5 mL AVA per dose
3074424|NCT01263691|Experimental|AV7909 Formulation 1|0.5 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
3074425|NCT01263691|Experimental|AV7909 Formulation 2|0.5 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
3074426|NCT01263691|Experimental|AV7909 Formulation 3|0.25 mL AVA + 0.5 mg CPG 7909 per 0.5 mL dose
3074427|NCT01263691|Experimental|AV7909 Formulation 4|0.25 mL AVA + 0.25 mg CPG 7909 per 0.5 mL dose
3074428|NCT01263691|Placebo Comparator|Control|Saline control
3074429|NCT01263704|Experimental|Rituximab plus Fludarabine and Cyclophosphamide|Elderly participants with chronic lymphocytic leukemia (CLL) will receive combination treatment with low-dose fludarabine and cyclophosphamide combined with standard-dose of rituximab for 6 months. Treatment is followed by a follow up period of 36 months.
3074430|NCT01263717|Experimental|Tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given subcutaneously x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
3074431|NCT01263717|Placebo Comparator|Placebo (inactive injection)|Placebo 2mg daily given subcutaneously for the first 6 months of the study, followed by 6 months of tesamorelin (growth hormone releasing hormone) 2mg daily during an open label phase
3074432|NCT01263782|Experimental|Carboplatin + Pemetrexed|"The chemotherapy will be Carboplatin (AUC 6) and Pemetrexed (500 mg/m2) every 3 weeks for 4 cycles.~Then maintenance Pemetrexed (500 mg/m2 every 3 weeks) will be administered until disease progression or excessive toxicity.~If patients are randomized into one of the arms with a biologic therapy, patients will take the chemotherapy prescribed above, but will also receive the biologic therapy during the same time period."
3074433|NCT01263782|Experimental|Chemo (Carbo/Peme) + Bevacizumab|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle. Bevacizumab 15 mg/kg by vein on day 1 of each 21 day cycle.
3074434|NCT01263782|Experimental|Chemo (Carbo/Peme)|Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.
3074435|NCT01263782|Experimental|Chemo (Carbo/Peme) + Cixutumumab|"Carboplatin AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles. Pemetrexed 500 mg/m2 by vein on day 1 of each 21 day cycle.~Cixutumumab 20 mg/kg by vein on day 1 of each 21 day cycle."
3074436|NCT01263873|Active Comparator|Mallinckrodt (ETT)|Artifical Airway Device
3074437|NCT01263873|Experimental|Parker Flex Tip (ETT)|Artifical Airway Device
3074438|NCT01263925|Experimental|Alprostadil|Alprostadil (Prostaglandin E1) intravenous and matching Placebo to Pentoxifylline oral
3074439|NCT01263925|Active Comparator|Pentoxifylline|Pentoxifylline oral and matching Placebo to Alprostadil (Prostaglandin E1) intravenous
3074440|NCT01263938|Other|Atorvastatin|
3074441|NCT01264016|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use an investigational blood glucose monitoring system.
3074442|NCT01264081|Experimental|Lapatinib|Lapatinib will be administered as an oral dose of 500 mg twice daily in the morning and evening one hour before or after meals.
3074443|NCT01264380|Experimental|1|
3074444|NCT01264380|Experimental|2|
3074445|NCT01264380|Experimental|C|
3074446|NCT01264419|Experimental|Silk Road Embolic Protection System|Eligible subjects who are to receive a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
3074447|NCT01264601|Experimental|Single Dose|This arm will receive TIV as 2 doses, the first of which will be normal saline administered at approximately 10% of the total age appropriate dose volume, followed 30 minutes later by the full age appropriate dose. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
3074448|NCT01264601|Experimental|Graded Challenge|Subjects in this arm will receive TIV by standard 10%/90% 2-step graded challenge split of the age appropriate dose, separated by 30 minutes. For children receiving a 0.25ml dose, a 20%/80% split will be used for ease of administration in drawing up the dose.
3074449|NCT01264614|Experimental|Early stage dementia|Individuals with early stage dementia who attended a Adult Day Care Program at least twice a week. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
3074450|NCT01264614|Active Comparator|Normative older adults|Normative older adults with no known neurological condition. Participants engaged in a strengthening exercise program three to five times per week for 10 weeks.
3074451|NCT01264705|Experimental|Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 1: Participants were administered Bavituximab:0.3 mg/kg weekly Sorafenib: 400mg PO twice daily
3074452|NCT01264705|Experimental|Bavituximab: 1.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 2: Participants were administered Bavituximab:1.0 mg/kg weekly Sorafenib: 400mg PO twice daily
3074453|NCT01264705|Experimental|Bavituximab: 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily|Cohort 3: Participants were administered Bavituximab:3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
3074454|NCT01264718|No Intervention|Control|After randomization to the control group, minority low-income parents of uninsured, Medicaid/CHIP-eligible children received only traditional Medicaid/Children's Health Insurance Program (CHIP) outreach and enrollment.
3074455|NCT01264718|Experimental|Parent Mentors|After randomization to the Parent Mentor group, minority low-income parents of uninsured Medicaid/CHIP-eligible children received face-to-face instruction and guidance from Parent Mentors on obtaining and keeping Medicaid/CHIP for their child; getting a doctor, dentist, and pharmacist; and addressing social determinants of health.
3074456|NCT01264770|Experimental|Dosing Group A|Oral treatment and subcutaneous injection
3074457|NCT01264770|Experimental|Dosing Group B|Oral treatment and subcutaneous injection
3074458|NCT01264770|Experimental|Dosing Group C|Oral treatment and subcutaneous injection
3074459|NCT01264770|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection
3074460|NCT01264770|Placebo Comparator|Dosing Group E|Oral treatment and subcutaneous injection
3074461|NCT01264887|Experimental|Tapentadol Prolonged Release|Participants allocated to this treatment arm can be flexibly dosed between 100 to 250 mg tapentadol twice daily (50 and 100 mg tablets to be dispensed).
3074462|NCT01264939|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
3074463|NCT01264939|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
3074464|NCT01265056|Placebo Comparator|Sugar Pill|Placebo
3074465|NCT01265056|Experimental|Gabapentin|Gabapentin
3074466|NCT01265394|Experimental|(18F) Flutemetamol|
3074467|NCT01265420|Experimental|Injectable clostridial collagenase|Patients with thumb 1st web contracture secondary to Dupuytren's disease will be treated with 0.58mg of collagenase
3074468|NCT01265446|Experimental|Lidocaine 8mg +CPC 2mg|one single dose
3074469|NCT01265446|Active Comparator|Lidocaine 1mg + CPC 2mg|one single dose
3074470|NCT01265459|Experimental|Durolane 3ml|Durolane 3 ml is an Intraarticular hyaluronic acid
3074471|NCT01265459|Experimental|Durolane 4.5|Durolane 4.5 is an Intraarticular hyaluronic acid
3074472|NCT01265459|Experimental|Durolane 6 ml|Durolane 6 ml is an Intraarticular hyaluronic acid
3074473|NCT01265498|Active Comparator|Obeticholic acid|obeticholic acid
3074474|NCT01265498|Placebo Comparator|Placebo|Placebo
3074475|NCT01265511|Placebo Comparator|Placebo|Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
3074476|NCT01265511|Active Comparator|SCY-635 600 mg|SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
3074477|NCT01265524|Active Comparator|CLP|Investigational drug: 15 g CLP per day given as capsules
3074478|NCT01265524|Placebo Comparator|Placebo|Placebo, capsules
3074479|NCT01265537|Experimental|Low target tacrolimus (Advagraf)|"This group will receive rabbit anti-thymocyte globulin (rATG) induction (3 -4 doses of 1.5 mg/kg during the first post transplant week) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and low-target Advagraf."
3074480|NCT01265537|Active Comparator|Standard target tacrolimus (Advagraf)|"This group will receive basiliximab induction (40 mg total) with IV solumedrol, MPA (Mycophenolate Mofetil or Mycophenolate Sodium), and standard target Advagraf."
3074481|NCT01265550|Other|Medical Treatment Group|Omeprazole or Omeprazole + baclofen or Omeprazole + desipramine
3074482|NCT01265550|Other|Surgical Treatment Group|Laparoscopic nissen fundoplications
3074483|NCT01265550|Other|Placebo Medical Treatment Group|Omeprazole + placebo
3074484|NCT01265563|Placebo Comparator|NAC placebo and Silibin placebo|Drug: N-acetylcysteine placebo and Drug: Silibin placebo
3074485|NCT01265563|Experimental|NAC active and Silibin placebo|Drug: N-acetylcysteine and Drug: Silibin placebo
3074486|NCT01265563|Experimental|NAC placebo and Silibin active|Drug: N-acetylcysteine placebo and Drug: Silibin active
3074487|NCT01265563|Experimental|NAC active and Silibin active|Drug: N-acetylcysteine active and Drug: Silibin active
3074488|NCT01265563|Experimental|NAC active and High-dose Silibin active|Drug: N-acetylcysteine active and Drug: Silibin higher dose active
3074489|NCT01265615|Active Comparator|Paricalcitol treatment|6-8 μg daily per os (orally) without special diet
3074490|NCT01265615|Active Comparator|Calcitriol treatment|2-4 μg daily orally under with dietary restrictions of vitamin D
3074491|NCT01265615|Active Comparator|Cholecalciferol|alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day
3074492|NCT01265615|Other|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
3074493|NCT01265667|Experimental|CF101 2 mg|CF101 2mg oral tablets
3074494|NCT01265667|Placebo Comparator|Placebo|Placebo oral tablets
3074495|NCT01265719||Latanoprost-treatment group|
3074496|NCT01265719||Non-topical prostaglandin analogue treatment group|
3074497|NCT01265784|Experimental|TP-434, 1.5 mg/kg q24h|TP-434 was administered intravenously (IV) at a dose of 1.5 milligrams per kilogram of body weight (mg/kg) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3074498|NCT01265784|Experimental|TP-434, 1.0 mg/kg q12h|TP-434 was administered IV at a dose of 1.0 mg/kg every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). TP-434 treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3074499|NCT01265784|Active Comparator|Ertapenem, 1 g q24h|Ertapenem was administered IV at a dose of 1 gram (g) q24h for a minimum of 4 days and a maximum of 14 days (7 days for participants in India). Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3074500|NCT01265797|Active Comparator|Cranial Electrostimulator|wears active cranial electrostimulation device for 20 minutes daily for 28 days
3074501|NCT01265797|Sham Comparator|Sham device|wears sham device for 20 minutes daily for 28 days
3074502|NCT01265823|Experimental|Adalimumab|
3074503|NCT01265875|Other|human secretin|intravenous secretin administration in escalating doses three times daily for three days. After each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
3074504|NCT01265953|Experimental|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of sulforaphane (SFN) daily, 2 capsules (1 capsule B.I.D.) daily
3074505|NCT01265953|Placebo Comparator|Placebo capsules|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
3074506|NCT01265966||Moderate Sedation|Children undergoing moderate sedation for procedures.
3074507|NCT01265966||Deep Sedation|Children undergoing deep sedation for procedures.
3074508|NCT01265992||Paricalcitol capsules|Patients with secondary hyperparathyroidism associated with Stage 3 - 5 CKD and not yet on dialysis and prescribed paricalcitol capsules in accordance with the terms of the marketing authorization in Sweden.
3074509|NCT01266018|Experimental|Cohort 1: Sensitive Disease|"Cohort 1 comprised subjects with sensitive disease, defined as subjects who were treated with 1 previous line of chemotherapy and maintained an appropriate response for 90 days or more. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
3074510|NCT01266018|Experimental|Cohort 2: Refractory Disease|"Cohort 2 comprised subjects with refractory disease, defined as subjects who either (a) were treated with 1 previous line of chemotherapy and either had no response or progressed < 90 days after completing treatment or (b) required third-line therapy, i.e., had completed 2 previous lines of chemotherapy, regardless of response. Subjects received 4 administrations of ADI-PEG 20 (320 IU/m^2) followed by 1 week of follow-up in each treatment cycle."
3320963|NCT02015091|Experimental|3|Vaccination schedules 5 IV vaccinations per subject. Evaluation of protection against controlled human malaria infection (CHMI) is included.
3320964|NCT02015091|No Intervention|8|Participation in controlled human malari infection (CHMI) without prior vaccinations to serve as controls.
3074513|NCT01266070|Experimental|Dovitinib|500 mg/day on a 5 day on, 2 day off schedule
3074514|NCT01266122|No Intervention|HIV/STI voluntary counseling and testing|Participants enrolled in the control arm will receive study assessments only.
3074515|NCT01266122|Experimental|Behavioral intervention|Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.
3074516|NCT01266148|Experimental|Everolimus|Participants started immunosuppressive regimen consisting of low dose CsA, everolimus, MMF and CS. After week 11, the participants regimen consisted of everolimus, MMF and CS.
3074517|NCT01266148|Experimental|Control|Participants received an immunosuppressive regimen consisting of CsA, MMF and CS throughout the study.
3074518|NCT01266161|Experimental|Ibuprofen 600 mg extended release|
3074519|NCT01266161|Placebo Comparator|Placebo|
3074520|NCT01266265||Tyvaso|The Tyvaso group will consist of patients receiving Tyvaso and may be receiving another FDA approved PAH therapy as part of routine care.
3074521|NCT01266265||Control|The control group will consist of patients with no previous Tyvaso exposure and not taking Tyvaso at the time of the Baseline visit, but receiving any other FDA approved PAH therapy as part of routine care.
3074522|NCT01266291|Other|Treatment with Sabril (vigabatrin)|This is a single arm study. All subjects who are eligible for treatment will begin taking vigabatrin (Sabril) during the third month of the study. Treatment will be in accordance with the FDA-approved prescribing information: upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
3074523|NCT01266317|Experimental|Combined PEX, Rituximab and Steroids|"Standard Steroid Treatment: One gm of methylprednisolone I.V., on day 0, followed by 40 mg/day I.V. on days 1-4, and days 6-12 (or the P.O. prednisone equivalent). Methylprednisolone 100 mg I.V. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone I.V. (or P.O. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the principle investigator.~Plasma exchange (PEX) will consist of 1.5x estimated plasma volume exchanges for 3 successive days (0, 1,2) and then, after a one day interval to enable equilibration of autoantibodies sequestered in tissues, two more daily treatments on days 4 and 5.~Rituximab: One gm I.V. will be administered on day 5 (after completion of the last PEX) and day 13."
3074524|NCT01266447|Experimental|Treatment (veliparib, topotecan hydrochloride, filgrastim)|Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3074525|NCT01266460|Experimental|Treatment (ADXS11-001)|Patients receive live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001 IV over 30 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074526|NCT01266590|Experimental|LY2216684 + digoxin|Two oral 0.5-milligrams (mg) (two 0.25-mg tablets) doses of digoxin separated by 12 hours on Day 1, followed by once daily 0.25-mg (single 0.25-mg tablet) dose of digoxin on Days 2-14. Daily oral 18-mg (two 9-mg tablets) doses of LY2216684 on Days 8-14.
3074527|NCT01266603|Experimental|HDIL-2 + recMAGE-A3 + AS15|HDIL-2 720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle. recMAGE-A3 300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
3074528|NCT01266642|Experimental|Arm I (HF-WBI)|Patients undergo HF-WBI comprising external beam RT 5 days a week for approximately 3 weeks.
3074529|NCT01266642|Active Comparator|Arm II (CF-WBI)|Patients undergo CF-WBI comprising external beam RT 5 days a week for approximately 5 weeks.
3074530|NCT01266850|Active Comparator|Group 1, RotaTeq® x 3|2, 4 and 6 months of age: RotaTeq®
3074531|NCT01266850|Experimental|Group 5, Rotarix®, RotaTeq® x2|2 months of age: Rotarix®; 4 and 6 months of age: RotaTeq®
3074532|NCT01266850|Active Comparator|Group 4, Rotarix® x 2|2 and 4 months of age: Rotarix®
3074533|NCT01266850|Experimental|Group 2, RotaTeq®, Rotarix® x 2|2 months of age: RotaTeq®; 4 and 6 months of age: Rotarix®
3074534|NCT01266850|Experimental|Group 3, RotaTeq® x 2, Rotarix®|2 and 4 months of age: RotaTeq®; 6 months of age: Rotarix®
3074535|NCT01266876|Placebo Comparator|Placebo|Placebo SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3074536|NCT01266876|Experimental|Alirocumab 150 mg Q4W|Alirocumab 150 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3074537|NCT01266876|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3074538|NCT01266876|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg SC injection Q4W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3074539|NCT01266876|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W added to stable statin regimen with or without concomitant ezetimibe for 12 weeks.
3074540|NCT01266902|Experimental|Rilpivirine|Rilpivirine 25 mg once daily
3074541|NCT01266967|Experimental|Single Arm|Single arm with 2 cohorts; Cohort A no previous brain therapy and Cohort B previous brain therapy
3074542|NCT01266993|Experimental|Nimenrix Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Nimenrix vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Nimenrix vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
3074543|NCT01266993|Experimental|Menjugate Group|Healthy male or female subjects aged 2 through 10 years old, who were primed with one dose of Menjugate vaccine during the primary 111414 study (NCT00674583), additionally received one booster dose of Menjugate vaccine in the current study, at Month 68, administered intramuscularly in the deltoid region of the non-dominant arm.
3074544|NCT01267019|Experimental|Arm 1: vivo augmentation|social cognitive training with in vivo augmentation
3074545|NCT01267019|Active Comparator|Arm 2: social cognitive|social cognitive training
3074546|NCT01267019|Active Comparator|Arm 3: non-social skills|non-social skills training
3074547|NCT01267045|Experimental|Arm 1|Participants in this arm undergo the mindfulness training intervention through taking part in a Mindfulness-Based Stress Reduction course
3074548|NCT01267045|No Intervention|Arm 2|Treatment as usual for Gulf War Syndrome symptoms (medications, psychotherapy, etc.)
3074549|NCT01267136|Experimental|Capital® with Codeine Suspension|
3074550|NCT01267136|Active Comparator|Tramadol suspension|
3074551|NCT01267175|Experimental|X54 pump|All subjects transferred from current pump to X54
3074552|NCT01267201|Experimental|POS formulation #1|
3074553|NCT01267201|Experimental|POS formulation #2|
3074554|NCT01267201|Active Comparator|commercial tablet|
3074555|NCT01267227|Active Comparator|High Dose|Pterostilbene 125 mg twice daily
3074556|NCT01267227|Active Comparator|Low Dose|Pterostilbene 50 mg twice daily
3074557|NCT01267227|Active Comparator|Low Dose Combination|Pterostilbene 50 mg/Grape Extract 100 mg twice daily
3074558|NCT01267227|Placebo Comparator|Placebo|Matching placebo twice daily
3074559|NCT01267240|Experimental|Arm I (capecitabine, vorinostat)|Patients receive capecitabine PO BID and vorinostat PO daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3074560|NCT01267253|Experimental|Treatment (brivanib alaninate)|Patients receive brivanib alaninate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074561|NCT01267266|Experimental|Arm I (saracatinib)|Patients receive oral saracatinib once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3074562|NCT01267266|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Upon progression, patients may crossover to arm I.
3074563|NCT01267279|Placebo Comparator|Placebo|
3074564|NCT01267279|Experimental|Zoledronic Acid|
3074565|NCT01267292|Experimental|Buspirone plus Methylphenidate|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
3074566|NCT01267292|Placebo Comparator|Placebo for Buspirone plus Methylphenidate|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; no Methylphenidate or Methylphenidate placebo] [week 2: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday; Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
3074567|NCT01267422|Experimental|rAAV2-ND4|injection
3074568|NCT01267656|Experimental|Lubricating and Rewetting Drops|Lubricating and Rewetting Drops, after one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week.
3074569|NCT01267656|Active Comparator|AMO Blink Contacts Lubricant Eye Drops|AMO Blink Contacts Lubricant Eye Drops, After one week of using the first rewetting drops, the subjects will return for an exam and crossover to the second rewetting drops for one week
3074570|NCT01267864|Active Comparator|Metoclopramide|Metoclopramide 10mg IVSS
3074571|NCT01267864|Active Comparator|Ketorolac|Ketorolac 30mg IV
3074572|NCT01267864|Active Comparator|Valproate|1gm IV
3074573|NCT01267929|Experimental|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months. The mirror neurons stimulation based VCD program that contained four volumes. The first volume includes activities activities for improving balance in sitting position. The second volume includes activities of sitting to standing. The third volume includes activities for improving balance in standing position. The last one includes activities of sideway walking. The running time of each volume is 30 minutes. The children had been practicing for two weeks per volume. Their parents were trained for practicing their children by VCD program at home and were asked to complete daily record of children's activities. The children were scheduled to meet a pediatric physical therapist once a week to monitor possible side effects.
3074574|NCT01267929|Active Comparator|The conventional physical therapy|The children receive manual physical therapy regularly at the hospital once a week for first two months and twice a month for last four months. The conventional physical therapy technique in this study derive from the manual technique including the Bobath concept, stretching exercise and functional training for 30-45 minutes at a time.
3074575|NCT01267955|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074576|NCT01267994|Experimental|Single Arm-Open Label|Single Arm-Open Label use of Anakinra
3074577|NCT01268046|Experimental|Young postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
3074578|NCT01268046|Experimental|Older postmenopausal women - estrogen|transdermal estrogen patch OR estradiol oral capsule for 1 month
3074579|NCT01268046|Placebo Comparator|Young postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
3074580|NCT01268046|Placebo Comparator|Older postmenopausal women - placebo|transdermal placebo patch for 1 month or placebo oral capsule for 1 month
3074581|NCT01268059|Active Comparator|Carboplatin/Paclitaxel|Carboplatin/paclitaxel regimen (carboplatin area under the plasma concentration-time curve [AUC] of 6 milligram per milliliter into minute [mg/mL*min], and paclitaxel 200 milligram per square meter [mg/m^2]) administered as an intravenous (IV) infusion once every 21 days on Day 1, for a total of 6 doses (cycles) until unacceptable toxicity, disease progression, or other reasons for participant withdrawal. Subjects were enrolled from North America/European Union (EU) and Japan regions.
3074582|NCT01268059|Experimental|Carboplatin/Paclitaxel + MEDI-575|Carboplatin/paclitaxel regimen (carboplatin AUC = 6 mg/mL*min, and paclitaxel 200 mg/m^2) followed by MEDI-575 at a dose of 25 milligram per kilogram (mg/kg) administered as an IV infusion once every 21 days on Day 1 for a total of 6 cycles until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for participant withdrawal. MEDI-575 alone continued in those participants who achieved stable disease or better at the completion of carboplatin/paclitaxel therapy and did not demonstrate toxicity to MEDI-575. Subjects were enrolled from North America/European Union (EU) and Japan regions.
3074583|NCT01268098|Experimental|25 µg dose|25 µg
3074584|NCT01268098|Experimental|50 µg dose|50 µg
3074585|NCT01268111|Experimental|Vitamin D|ERgocalcifoerol 50,000 units q weekly for 8 weeks
3074586|NCT01268111|Placebo Comparator|Placebo|
3074587|NCT01268150|Experimental|Experimental|
3074588|NCT01268189|Experimental|Burn wound patients with donor sites|Oxygen diffusing dressing applied to wound vs standard of care dressing (Xeroform) applied to wound (patient serves as own control as s/he receives 1 dressing on 1 donor site and the other on a 2nd donor site)
3074589|NCT01268267|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using an investigational blood glucose monitoring system (development name Ninja 2).
3074590|NCT01268293|Experimental|1|
3074591|NCT01268306|Experimental|B+L Biotrue MPS and B+L PureVision|Successful contact lens wearers switched to B&L BioTrue MPS while wearing B+L PureVision lenses
3074592|NCT01268488|Experimental|Intended Users of the System|Untrained subjects with diabetes obtained capillary fingerstick, palm, and forearm blood and performed Blood Glucose (BG) tests using a Ninja 2 investigational blood glucose meter and the Contour® sensor. This BG monitoring system will not proceed to marketed product.
3074593|NCT01268501|Experimental|Lotrafilcon B multifocal|Lotrafilcon B multifocal contact lenses worn bilaterally for 3 weeks on a daily wear basis
3074594|NCT01268527|Experimental|Cohort 1|Three concentrations of E6201 topical gel (0.03%, 0.1%, and 0.2%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. The 3 concentrations of E6201 gel were dosed first in Cohort 1 to establish the safety and tolerability prior to dosing in Cohort 2.
3074595|NCT01268527|Experimental|Cohort 2|Three concentrations of E6201 topical gel (0.005%, 0.01%, and 0.05%) and active comparator, calcipotriene cream (0.005%), were applied once daily for 12 days to specific test fields determined at Baseline. Cohort 2 participants were not dosed until all participants in Cohort 1 completed treatment and safety data were collected and evaluated.
3074596|NCT01268553|Experimental|Active treatment|This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.
3074597|NCT01268566|Experimental|MEDI-575, 25 mg/kg|MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.
3074598|NCT01268644|Experimental|active open label Leptin|Active open label Leptin for type 1 Diabetes
3074599|NCT01268683|Experimental|Glyburide for Injection|This arm is administered a glyburide bolus followed by continuous infusion of glyburide for 72 hours
3074600|NCT01268891|Placebo Comparator|Placebo|
3074601|NCT01268891|Experimental|Azilect®|
3074602|NCT01268943|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3074603|NCT01268943|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3074604|NCT01268943|Experimental|1400mg|capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3074605|NCT01268943|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3074606|NCT01269047|Experimental|Pramlintide + Insulin Group|These kids will get Pramlintide (Symlin) along with insulin before breakfast and supper.
3074607|NCT01269047|Experimental|Exenatide + Insulin Group|This group will get Exenatide(Byetta) along with insulin before breakfast and supper.
3074608|NCT01269047|Active Comparator|Insulin monotherapy|This group will be on their regular insulin therapy.
3074609|NCT01269125|Active Comparator|Endometriosis, leuprolide, IVF|Women with stage II endometriosis received GnRH-a (leuprolide) prior to an IVF attempt.
3074610|NCT01269125|Active Comparator|Endometriosis, IVF|Women with mild endometriosis who underwent an IVF attempt without prior administration of GnRH-a.
3074611|NCT01269125|Active Comparator|Tubal infertility, IVF|Women with tubal infertility underwent an IVF attempt.
3074612|NCT01269346|Experimental|1|
3074613|NCT01269372|Other|PillCam Colon 2 and Standard Colonoscopy|All subjects received Capsule Endoscopy (CE) using the PillCam Colon 2 followed by a standard colonoscopy.
3074614|NCT01269385|Experimental|Arm I|Patients receive PGG beta-glucan IV over 2-4 hours on days 1, 5, 10, 17, 24, and 31; alemtuzumab subcutaneously on days 3, 4, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33; and rituximab IV on days 10, 17, 24, and 31. Treatment continues in the absence of disease progression or unacceptable toxicity.
3074615|NCT01269736|Experimental|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
3074616|NCT01269736|No Intervention|Control|Usual in-service education for nurses
3074617|NCT01269801|Active Comparator|Botox Cosmetic|onabotulinumtoxinA for injection
3074618|NCT01269801|Active Comparator|JUVÉDERM|JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC Injectable Gel
3074619|NCT01269918|Active Comparator|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
3074620|NCT01269918|Active Comparator|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
3074621|NCT01270126|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
3074622|NCT01270126|No Intervention|Sham stimulation (placebo condition)|A clicking sound was presented and the same electrode montage set-up was used during rtACS- and placebo-stimulation, except that placebo patients received no current (stimulator turned off)
3074623|NCT01270139|Experimental|Nano group|60 patients in Nano group were treated with transplantation of nanoparticles (NP), particularly with a bioengineered patch that was grown with allogenous stem cells pre-cultivated in the medium with NP. After the admission, patients were examined with QCA, and allocated to the trial. The implantation of the patch onto the artery was undergone by the minimally invasive cardiac surgery (MICS CABG) with fixation of the graft to the epicardial myocardium. MICS CABG implies a beating-heart multi-vessel heart surgery performed through several small incisions under direct vision through an anterolateral mini-thoracotomy in the 4th-6th intercostal spaces. The patients can expect high quality of life resuming all everyday activities within a few weeks of their operation. NP were activated with NIR laser at 7 days after the intervention. Patients were treated with bolus of bivalirudin on the day of NP detonation.
3074624|NCT01270139|Active Comparator|Ferro group|60 patients in Ferro group were managed with transplantation of iron-bearing nanoparticles (NP), particularly with intracoronary infusion of allogenous stem cells or CD68 targeted micro-bubbles pre-cultivated in the medium with iron-bearing NP. Cells and/ or micro-bubbles were infused with QCA- and IVUS-guidance to the target coronary artery via micro-catheter on the day of admission. The destruction of CD68 targeted micro-bubbles was obtained by using a Sonos 5500 machine with an S3 transducer operating in ultraharmonic mode (transmit, 1.3MHz/ receive, 3.6 MHz) with a mechanical index of 1.5 and a depth of 4 cm. The AXIOM Artis dBC (Siemens) magnetic navigation system was used for precise delivery of NP to the atheroma through two permanent computer-controlled external magnets generating a navigational magnetic field of 0.08 Tesla in any direction. NP were detonated with NIR laser under the protection of anti-platelet therapy.
3074625|NCT01270139|Other|Stenting control|In case of control group (stenting control), XIENCE V stent was implanted to 60 patients. Patients with a single de novo native coronary stenosis of less than 12 mm lesion length, more than 50% stenosis and reference diameter of 3.0 mm as assessed by online QCA were stented by a single stent of 3.0 x 18 mm. The procedure of implantation had to be performed according to common interventional practices including the administration of intracoronary nitroglycerine 0.2 mg of glycerol trinitrate or isosorbide dinitrate and intra-arterial heparin (50-100 U/kg body weight). Predilation with a conventional balloon catheter was recommended before DES deployment according to the manufacturer's recommendation. The protocol recommended the study stent should cover 2 mm of non-diseased tissue on either side of the target lesion. Postdilatation was allowed with a balloon that was shorter than was the study device.
3074626|NCT01270256|Active Comparator|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
3074627|NCT01270256|Placebo Comparator|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
3074628|NCT01270321|Experimental|Arm A (Everolimus alone)|CURRENTLY CLOSED TO ACCRUAL--Everolimus alone followed by Everolimus + Pasireotide at the time of progression
3074629|NCT01270321|Experimental|Arm B (Pasireotide alone)|CURRENTLY CLOSED TO ACCRUAL--Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
3074630|NCT01270321|Experimental|Arm C (Everolimus + Pasireotide)|CURRENTLY CLOSED TO ACCRUAL
3074631|NCT01270464|Placebo Comparator|Placebo|Placebo administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
3074632|NCT01270464|Experimental|Reslizumab - 0.3 mg/kg|0.3 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses
3074633|NCT01270464|Experimental|Reslizumab - 3.0 mg/kg|3.0 mg/kg, administered intravenously (iv) once every 4 weeks, for a total of 4 doses.
3074634|NCT01270503|Experimental|Menactra® Group 1|Participants aged 2 to 11 on enrollment
3074635|NCT01270503|Experimental|Menactra® Group 2|Participants aged 12 to 17 on enrollment
3074636|NCT01270503|Experimental|Menactra® Group 3|Participants aged 18 to 55 on enrollment
3074637|NCT01270516|Placebo Comparator|Control, to be given saline solution|Intervention: This group will be given saline (30 ml every 12 hours) for 10 days
3074638|NCT01270516|Experimental|EPA, eicosapentaenoic acid|This group will be given 1000 mg EPA every 12 hours for 10 days
3074639|NCT01270516|Experimental|HMB, hydroxymethylbutyrate|This arm will be given HMB (1500 mg) every 12 hours for 10 days.
3074640|NCT01270516|Experimental|EPA and HMB|Intervention: This group will be given EPA (1000 mg every 12 hours given via the GI tract) and HMB (1500 mg every 12 hours given via the GI tract) for 10 days.
3074641|NCT01270529|Experimental|CKD Stages 1-4|
3074642|NCT01270529|Experimental|ESRD on Dialysis|
3074643|NCT01270529|Experimental|Kidney Transplant recipients|
3074644|NCT01270542|Experimental|Avastin Injection Group (AIG)|Subjects in this group will get single 0.05 mL intravitreal injection of bevacizumab 1.25 mg 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
3074645|NCT01270542|Sham Comparator|Sham Injection Group (SIG)|Subjects in this group will get a sham injection 3-7 days prior to surgery for tractional retinal detachment secondary to Proliferative Diabetic Retinopathy.
3074646|NCT01270555|Experimental|Bupropion|
3074647|NCT01270620|Active Comparator|Propofol|Patients will receive propofol as general anesthetics.
3074648|NCT01270620|Active Comparator|Desflurane|Patients will receive desflurane as general anesthetics.
3074649|NCT01270659|Experimental|Low-FBT|Subject will receive FBT and placebo at a low dose
3074650|NCT01270659|Experimental|High-FBT|Subject will receive the high dose regimen of FBT and a high dose placebo
3074651|NCT01270659|Active Comparator|Low control|"Subject will receive active oxycodone/APAP 5/325 mg and lansoprazole solutab for the fentanyl placebo"
3074652|NCT01270659|Active Comparator|High control|"Subject will receive the higher dose of the active comparator, #2 oxycodone/APAP 5/325mg, and lansoprazole solutab for the fentanyl placebo"
3074653|NCT01270711||Cabergoline users|cohort of patients, who are treated with cabergoline during the study period ( from January 1st, 2006 to July 1st 2012)
3074654|NCT01270802|Active Comparator|Tenofovir/emtricitabine/efavirenz|Tenofovir/emtricitabine/efavirenz
3074655|NCT01270802|Experimental|Tenofovir/emtricitabine plus raltegravir|Tenofovir/emtricitabine/efavirenz is switched to tenofovir/emtricitabine plus raltegravir
3074656|NCT01270828|Experimental|Pregablain CR tablet 82.5 to 660mg|
3074657|NCT01270828|Placebo Comparator|Placebo|
3074658|NCT01270841|Placebo Comparator|Placebo|Placebo
3074659|NCT01270841|Active Comparator|Testim (topical testosterone)|Testim (topical testosterone)
3074660|NCT01270841|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
3074661|NCT01270841|Experimental|Androxal 25 mg|Androxal 25 mg/day
3074662|NCT01270867|Active Comparator|Merci Retriever|Merci Retriever is the predicate product that received FDA clearance in 2004. Merci Retriever a first generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke.
3074663|NCT01270867|Experimental|Trevo Stentriever|Trevo Retriever is a second generation mechanical thrombectomy device intended to remove clot and restore blood flow in a neurovascular vessel in the setting of acute ischemic stroke. The Trevo Retriever is a type of stent, specifically design to allow for clot integration into the device. The clot in the retriever is then removed and blood flow is restored.
3074664|NCT01270880|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour once weekly in weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3074665|NCT01270958|Experimental|TREATMENT|50 adult patients with Perennial Allergic Rhinities treated with Avamys.
3074666|NCT01270971|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
3074667|NCT01270971|Placebo Comparator|Solution Vehicle|Solution Vehicle
3074668|NCT01271010|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants received rituximab 375 milligrams per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle; fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle and cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle. Treatment duration was 6 cycles, 28 days each.
3074669|NCT01271036|Experimental|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
3074670|NCT01271244|Active Comparator|PTSD Depression Group|Escitalopram 10-20 mg/day
3074671|NCT01271244|Active Comparator|Major Depression Group|Escitalopram 10-20 mg/day
3074672|NCT01271413|Experimental|Adaptive cognitively stimulating activities|
3074673|NCT01271413|Active Comparator|Non-adaptive cognitively stimulating activities|
3074674|NCT01271452|Active Comparator|Vistabel®|botulinum toxin type A (Vistabel®)
3074675|NCT01271452|Active Comparator|Bocouture®|botulinum toxin type A (Bocouture®)
3074676|NCT01271504|Active Comparator|Phase Ib: Cohort 1,2, and 3|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
3074677|NCT01271504|Active Comparator|Phase II: Arm 1; E7050 + Sorafenib|Phase II: Arm 1; E7050 + 400 mg Sorafenib Arm 2; 400 mg Sorafenib
3074678|NCT01271543|Active Comparator|MacIntosh group|
3074679|NCT01271543|Experimental|Shikani optical stylet|
3074680|NCT01271686|Experimental|0.01% bimatoprost|bimatoprost 0.01% one time per day at bedtime for 4 weeks.
3074681|NCT01271712|Experimental|Regorafenib (Stivarga, BAY73-4506)|Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
3074682|NCT01271712|Placebo Comparator|Placebo|Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks
3074683|NCT01271725|Experimental|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
3074684|NCT01271725|Experimental|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
3074685|NCT01271725|Experimental|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
3074686|NCT01271803|Experimental|DES (Cohort 1): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 milligrams (mg) cobimetinib once daily (QD) on Days 1-14, followed by 14 days off on Days 15-28 (14/14 dosing schedule) and oral 720 mg vemurafenib twice daily (BID) on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074687|NCT01271803|Experimental|DES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-21, followed by 7 days off on Days 22-28 (21/7 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074688|NCT01271803|Experimental|DES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074689|NCT01271803|Experimental|DES (Cohort 1C): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on Days 1-28 (28/0 dosing schedule) and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074690|NCT01271803|Experimental|DES (Cohort 1D): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 28/0 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074691|NCT01271803|Experimental|DES (Cohort 2): 80 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074692|NCT01271803|Experimental|DES (Cohort 2A): 100 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 100 mg cobimetinib QD on 14/14 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074693|NCT01271803|Experimental|DES (Cohort 3): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074694|NCT01271803|Experimental|DES (Cohort 4): 80 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 80 mg cobimetinib QD on 14/14 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074695|NCT01271803|Experimental|Cobimetinib Monotherapy (100 mg or 60 mg)|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule, or oral 100 mg cobimetinib QD on 14/14 dosing schedule of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074696|NCT01271803|Experimental|CES (Cohort 1A): 60 mg Cobimetinib + 720 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 720 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074697|NCT01271803|Experimental|CES (Cohort 1B): 60 mg Cobimetinib + 960 mg Vemurafenib|Participants will receive oral 60 mg cobimetinib QD on 21/7 dosing schedule and oral 960 mg vemurafenib BID on Days 1-28 of every cycle (1 Cycle=28 Days), until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
3074698|NCT01271855|Placebo Comparator|Glycerin suppository|Women assigned to this arm receive a glycerin suppository (placebo) every 8 hours after delivery during the first 24 hours postpartum
3074699|NCT01271855|Experimental|Belladonna and opioid suppository|Women assigned to this arm receive a belladonna and opioid (B&O) suppository every 8 hours after delivery during the first 24 hours postpartum
3074700|NCT01271868|Experimental|IB1001|
3074701|NCT01271907|Experimental|Cohort 0|Drosophila generated CTL + SQ IL-2 Drug: 1 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) (CTL-05), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
3074702|NCT01271907|Experimental|Cohort 1|2 Experimental Lymphodepleting regimen +Cells+Low dose IL-2 Drug: 2 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL), aldesleukin Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
3074703|NCT01271907|Experimental|Cohort 2|1 Experimental Lymphodepleting regimen +Cells Drug: 3 fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ peripheral blood lymphocytes (PBL) Fludarabine 25 mg/m^2 x 5 days Cyclophosphamide 60 mg/kg intravenous (IV) x2 days, Up to 1x10e10 CTL-05 cells
3074704|NCT01271933|Experimental|Pregabalin|
3074705|NCT01271933|Placebo Comparator|Placebo|
3074706|NCT01271946|Other|Diagnostic Procedure|
3074707|NCT01272011|Experimental|Phase 1 Arm (Pilot)|Individuals were exposed to intermittent hypoxia and locomotor training to establish our interventions (set up lab, train personnel, develop study protocols/interventions, etc)
3074708|NCT01272011|Experimental|Phase 2 Arm (LTF)|Individuals were exposed to 10 days of intermittent hypoxia to determine the effect of this intervention on ventilatory long-term facilitation, as measured by minute ventilation
3074709|NCT01272011|Other|Phase 3 Arm (Ventilatory Loading)|Individuals were exposed to 10 days of intermittent hypoxia to determine changes in ventilatory loading.
3074710|NCT01272076||Dry AMD and geographic atrophy|Patients diagnosed with dry AMD and geographic atrophy
3074711|NCT01272180|Experimental|ABCWY+OMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus Outer Membrane Vesicles (OMV) administered two months apart."
3074712|NCT01272180|Experimental|ABCWY+qOMV|"Subjects in this group received two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of Outer Membrane Vesicles (qOMV) administered two months apart."
3074713|NCT01272180|Active Comparator|rMenB+OMV|"Subjects in this group received two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine,administered two months apart."
3074714|NCT01272180|Active Comparator|MenACWY|"Subjects in this group received a dose of placebo followed by one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine administered two months later."
3074715|NCT01272193|Experimental|IDegAsp OD|
3074716|NCT01272193|Active Comparator|IGlar OD|
3074717|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)|
3074718|NCT01272219|Experimental|Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)|
3074719|NCT01272219|Placebo Comparator|Liraglutide Placebo, no Pre-diabetes|
3074720|NCT01272219|Experimental|Liraglutide 3.0mg, Pre-diabetes|
3074721|NCT01272219|Placebo Comparator|Liraglutide Placebo, Pre-diabetes|
3074722|NCT01272232|Experimental|Lira 3.0 mg|
3074723|NCT01272232|Experimental|Lira 1.8 mg|
3074724|NCT01272232|Experimental|Placebo|
3074725|NCT01272245|Experimental|Omacetaxine and Cytarabine|Omacetaxine 1.25 mg/m2 SQ every 12 hours x 3 days + Cytarabine 20 mg SQ x 7 days of 4-7 week cycle.
3074726|NCT01272284|Other|Altis® SIS|Subjects enrolled with Altis® SIS
3074727|NCT01272388|Active Comparator|Tadalafil|
3074728|NCT01272388|Placebo Comparator|Placebo|
3074729|NCT01272583|Other|Sequence A (sitagliptin→placebo)|Cross-over, both arms reveived the same intervention in different order.
3074730|NCT01272583|Other|Sequence B (placebo→sitagliptin)|Cross-over, both arms reveived the same intervention in different order.
3074731|NCT01272635|Experimental|Azythromycin (APRIL) and Prednisolone (OCELOT)|
3074732|NCT01272635|Experimental|Azythromycin (APRIL) and Placebo (OCELOT)|
3074733|NCT01272635|Experimental|Placebo (APRIL) and Prednisolone (OCELOT)|
3074734|NCT01272635|Placebo Comparator|Placebo (APRIL) and Placebo (OCELOT)|
3074735|NCT01272661|Active Comparator|Enhanced Curriculum|New Enhanced Breastfeeding Curriculum with 11 brief modules
3074736|NCT01272661|Active Comparator|Enhanced Curriculum+Breastfeeding Doula|"Enhanced Curriculum + mother selects a support person to learn about breastfeeding with her and support her postpartum (breastfeeding doula)"
3074737|NCT01272661|Active Comparator|Enhanced Curriculum +Father Support|Enhanced Curriculum+ mother provides father-friendly information about breastfeeding to her partner plus an invitation to an educational group for fathers
3074738|NCT01272804|Experimental|PF-04937319|
3074739|NCT01272804|Placebo Comparator|Placebo|
3074740|NCT01272830|Experimental|oral Apatone®B|An amalgam of Vitamins C & K3
3074741|NCT01272830|Placebo Comparator|Placebo|Oral capsule of similar appearance and taste without Apatone®B
3074742|NCT01272869|Active Comparator|Sensura|SenSura is the reference product and the product is already commercially available
3074743|NCT01272869|Experimental|Morfeus|The test product is the product with the proposed new filter (Morfeus)
3074744|NCT01272882|Experimental|Adults with ARDS or ALI|Adults with PaO2/FiO2 ratio less than 300. Consented patients will be placed on EIT monitor. The only intervention is the addition of Electrical Impedance Tomography monitoring using the Chest belt with 16 electrodes connected to the EIT device. No changes to standard patient care will occur other than collecting EIT monitor data.
3074745|NCT01272908|Experimental|Single arm|
3074746|NCT01272921|Active Comparator|Bupivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
3074747|NCT01272921|Active Comparator|Ropivacaine|Varying does to determine duration of analgesia following a sciatic nerve block
3074748|NCT01272934|Placebo Comparator|Placebo|
3074749|NCT01272934|Experimental|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%
3074750|NCT01272947|Experimental|Diclofenac sodium topical gel 1%|
3074751|NCT01272947|Placebo Comparator|placebo|
3074752|NCT01272960|Active Comparator|Interval Insertion|Will receive Mirena at 4-8 weeks post-partum after vaginal delivery.
3074753|NCT01272960|Experimental|Post-Placental Mirena Insertion|Will receive Mirena insertion within 10 minutes of delivery of placenta
3074754|NCT01272999||1|Otitis media cases
3074755|NCT01273038|Active Comparator|SenSura|The reference product is the CE marked and launched SenSura product which is commercially available
3074756|NCT01273038|Experimental|Morfeus|The test product is the product with the proposed new Morfeus filter
3074757|NCT01273155|Active Comparator|Normal Function-Belinostat 1000 mg/m(2)|Normal Liver Function was defined as bilirubin ≤Upper Limit of Normal (ULN) and aspartate aminotransferase (AST) ≤ ULN.
3074758|NCT01273155|Experimental|Mild Dysfunction-Belinostat 750 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
3074759|NCT01273155|Experimental|Mild Dysfunction-Belinostat 1000 mg/m(2)|Mild Liver Dysfunction was defined as bilirubin >Upper Limit of Normal (ULN) but ≤1.5 x ULN and/or aspartate aminotransferase (AST) > ULN.
3074760|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 500 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
3074761|NCT01273155|Experimental|Moderate Dysfunction-Belinostat 750 mg/m(2)|Moderate Liver Dysfunction was defined as bilirubin >1.5 to ≤ 3 x ULN and any aspartate aminotransferase (AST).
3074762|NCT01273155|Experimental|Severe Dysfunction-Belinostat 250 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
3074763|NCT01273155|Experimental|Severe Dysfunction-Belinostat 350 mg/m(2)|Severe Liver Dysfunction was defined as bilirubin >3 but ≤ 10 x ULN and any aspartate aminotransferase (AST).
3074764|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 5x10e9|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
3074765|NCT01273181|Experimental|Ph I:Anti-MAGE A3/12 TCR PBL 3x10e10|"Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase I: The study will begin by evaluating the safety of two ranges of cells, 5x10^9-3x10^10, and greater than 3x10^10-1x10^11 in a standard phase I dose escalation fashion using a 3+3 design."
3074766|NCT01273181|Experimental|Ph II:Anti-MAGE TCR PBL MTD+HD IL-2|"Phase II:Anti-MAGE A3/12 TCR PBL MTD + HD IL-2, Melanoma, RCC~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
3074767|NCT01273181|Experimental|Ph II:Anti-MAGE A3/12 TCR PBL MTD|"Phase II: Anti-MAGE A3/12 TCR PBL MTD + HD-IL2 Other Cancer~Cyclophosphamide : 60 mg/kg/day x 2 days intravenous (IV)~Aldesleukin : 720,000 IU/kg every 8 hours for a maximum of 15 doses~PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes :~Fludarabine : 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.~Note for phase II:patients will be entered into two cohorts based on histology:cohort 1 will include patients with metastatic melanoma or renal cell cancer; cohort 2 will include patients with other types of metastatic cancer."
3074768|NCT01273207|Experimental|Inhaled Cyclosporine in HSCT Participants|Hemopoietic Stem Cell transplant (HSCT) subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) at maximum tolerated dose not exceeding 300 mg administered three times per week
3074769|NCT01273519||RA, PsA, AS|Participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) prescribed Humira (adalimumab) in the usual manner and in accordance with the terms of the local marketing authorization with regards to dose, population and indication.
3074770|NCT01273597||End-stage kidney disease with secondary hyperparathyroidism|Participants with chronic kidney disease (CKD) stage 5 receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (SHPT)
3074771|NCT01273623|Experimental|Patients with PAD|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention who have moderate to severe obstructive intraluminal calcium
3074772|NCT01273766|Experimental|Arm I|Patients receive oral deferasirox once daily for up to 6 months or until blood counts recover in the absence of disease progression or unacceptable toxicity.
3074773|NCT01273766|No Intervention|control arm|blood tested on healthy patients
3074774|NCT01273766|No Intervention|correlative|treated off study with or without oral deferasirox (patient choice) but lab draws to gather lab analysis
3074775|NCT01273805|Experimental|Hydroxychloroquine 400 mg b.i.d.|Patients received 400 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
3074776|NCT01273805|Experimental|Hydroxychloroquine 600 mg b.i.d.|Patients received 600 mg hydroxychloroquine orally twice per day. Cycle duration was 4 weeks. Patients remained on treatment indefinitely without the occurrence of disease progression, unacceptable adverse events, patient withdrawal, or discontinuation per MD decision.
3074777|NCT01273818|Active Comparator|gentamicin|80 mg gentamicin topical application intraoperatively
3074778|NCT01273818|Active Comparator|Cefazolin|Application of 1000 mg cefazolin intra venously 1 hour before surgery
3074779|NCT01273818|Active Comparator|gentamicin and cefazolin|1000 mg cefazolin application 1 hour before surgery and topical 80 mg gentamicin intraoperatively
3074780|NCT01273857|Sham Comparator|Control|Subjects will undergo standard staged-procedures without cell infusion
3074781|NCT01273857|Experimental|Cell infusion|Subjects will receive transcoronary infusion of autologous cardiosphere-derived cells 1 month after staged shunt procedure
3074782|NCT01273883|Experimental|Magnesium first, then placebo|Magnesium 532 mg daily for 25 days followed by 2 weeks of washout followed by 25 days of placebo.
3074783|NCT01273883|Placebo Comparator|Placebo first, then magnesium|Placebo daily for 25 days followed by 2 weeks of washout followed by magnesium 532 mg daily for 25 days.
3074784|NCT01273896|Experimental|STA-9090|This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.
3074785|NCT01274182|Experimental|GP2013|
3074786|NCT01274182|Active Comparator|MabThera|
3074787|NCT01274182|Active Comparator|Rituxan|
3074788|NCT01274338|Experimental|Arm A (HIP)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (closed accrual as of 4/4/14) (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3074789|NCT01274338|Experimental|Arm B (HDI)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3074790|NCT01274338|Experimental|Arm C (LIP)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (adult accrual has completed to Arms A, B, and C as of 8/15/2014)
3074791|NCT01274338|Experimental|Arm D (HIP; Pediatric)|Patients receive induction high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance high-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
3074792|NCT01274338|Experimental|Arm E (HDI; Pediatric)|Patients receive high-dose recombinant interferon alpha-2b IV on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance high-dose recombinant interferon alpha-2b SC on days 1, 3, and 5. Treatment repeats every week for 48 weeks in the absence of disease progression or unacceptable toxicity. (ages 12-17)
3074793|NCT01274338|Experimental|Arm F (LIP; Pediatric)|Patients receive induction low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity. Beginning on week 24, patients receive maintenance low-dose ipilimumab IV over 90 minutes on day 1. Treatment repeats every 12 weeks for a maximum of 4 courses in the absence of disease progression or unacceptable toxicity. (ages 12-17)
3074794|NCT01274351|Experimental|Nilotinib|administered orally at a dose of 300 mg twice daily for 24 months
3074795|NCT01274520|Experimental|Experimental: Hypothermic Machine Perfusion Group|The Medtronic Portable Bypass System (PBS®) with Model 550 Bioconsole and the BioCal® blood temperature control module will be used for machine perfusion of liver grafts. These products are commercially available and used in clinical practice for cardiopulmonary bypass and extracorporeal membrane oxygenation. The Medtronic system utilizes an atraumatic centrifugal pump that can deliver the flow rates approximating portal venous flow in human livers, and it has modules for online membrane oxygenation, and electronic flow measurement.
3132386|NCT03422172|Experimental|Subjects receiving CAB|Eligible subjects will receive oral doses of CAB 30 milligrams (mg) tablets once daily for 4 weeks followed by IM injectable suspension of CAB LA 600 mg at Week 5, Week 9, Week 17, Week 25 and Week 33. There will be an approximately 1-week washout period between the last oral dose and the first injection of CAB at Week 5.
3074796|NCT01274520|No Intervention|Matched control group|The proposed study is a matched cohort design. Subjects will be matched with 24 historical control patients who received similar cold stored ECD grafts. Subjects will be matched on known covariates including donor age, donation after cardiac death, steatosis, both warm and cold ischemia times, recipient age, MELD score and disease etiology. Additional analyses will be performed on historical control blood and/or tissue samples previously collected and stored in the study's sample repository.
3074797|NCT01274585|Sham Comparator|No active treatment|
3074798|NCT01274585|Experimental|stimulation/treatment|
3074801|NCT01274637|Experimental|low molecular weight heparin|Prophylactic-dose (5000 IU/0.2ml)low molecular weight heparin (LMWH), administered subcutaneously once daily in pre-filled glass syringes for 10 days (+/- 3 days) for a total of 10 (+/-3) study drug injections.
3074802|NCT01274637|No Intervention|Control Group|No treatment control group.
3074803|NCT01274715|Experimental|Behavioral Health Coaching arm|This is a single-arm, pilot study of a health behavior coaching intervention to consist of 12 sessions of coaching over a 3 month period. There is no control arm for this pilot study.
3074804|NCT01274897|Experimental|MenACWY-CRM|Subjects received one dose of MenACWY-CRM conjugate vaccine.
3074805|NCT01274897|Placebo Comparator|Placebo|Subjects received the saline placebo.
3074806|NCT01275053|Experimental|Leptin|
3074807|NCT01275066|Placebo Comparator|Placebo|
3074808|NCT01275066|Experimental|BMN 110 Weekly|
3074809|NCT01275066|Experimental|BMN 110 Every Other Week|
3074810|NCT01275092|Experimental|CorPath robotic-assisted PCI|CorPath 200 robotic-assisted PCI
3074811|NCT01275131|Active Comparator|Stage 1: Insulin aspart first, then insulin aspart-rHuPH20|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
3074812|NCT01275131|Active Comparator|Stage 1: Insulin aspart-rHuPH20 first, then insulin aspart|"Participants first received 0.15 units per kilogram (U/kg) insulin aspart and 5 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) (insulin aspart-rHuPH20) coadministered as a continuous subcutaneous insulin infusion (CSII), for 4 days (Days 1-4; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2 and 4.~After a 5- to 14-day washout period, participants received 0.15 U/kg insulin aspart alone as a CSII, for 4 days (Days 5-8; Period 2), including during a 6-hr euglycemic clamp on Days 6 and 8."
3074813|NCT01275131|Active Comparator|Stage 3: Insulin aspart first, then insulin aspart + rHuPH20|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6-hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a sham injection was administered 2.5 hr prior to the 6-hr euglycemic clamp.~After a 5- to 14-day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the 6-hr euglycemic clamp."
3074814|NCT01275131|Active Comparator|Stage 3: Insulin aspart + rHuPH20 first, then insulin aspart|"Participants first received 0.12 units per kilogram (U/kg) insulin aspart administered as a continuous subcutaneous insulin infusion (CSII), for 5 days (Days 1-5; Period 1), including during a 6- hour (hr) euglycemic clamp on Days 2, 3, and 5. On Day 2 only, a 1.0-milliliter (mL) subcutaneous (SC) injection of 1.25 micrograms per milliliter (μg/mL) recombinant human hyaluronidase PH20 (rHuPH20) was administered 2.5 hr prior to the euglycemic clamp .~After a 5- to 14- day washout period, participants received 0.12 U/kg insulin aspart administered as a CSII, for 5 days (Days 6-10; Period 2), including during a 6-hr euglycemic clamp on Days 7, 8, and 10. On Day 7 only, a sham injection was administered 2.5 hr prior to the 6-hour euglycemic clamp."
3074815|NCT01275144|Experimental|LY2216684+lorazepam, placebo+lorazepam|Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
3074816|NCT01275144|Experimental|Placebo+Lorazepam, LY2216684+Lorazepam|Oral doses of placebo on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 1. Oral 18 mg doses of LY2216684 on days 1-6 with a single oral 1 mg dose of lorazepam on day 3 in treatment period 2. There is a washout period of at least 7 days between dosing periods.
3074817|NCT01275170|Experimental|Panel A Mild Renal Impairment|Participants with an eGFR of >50 to <80 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
3074818|NCT01275170|Experimental|Panel B Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel A and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
3074819|NCT01275170|Experimental|Panel C Moderate Renal Impairment|Participants with an eGFR of 30 to 50 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
3074820|NCT01275170|Experimental|Panel D Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel C and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1.
3074821|NCT01275170|Experimental|Panel E Severe Renal Impairment|Participants with an eGFR <30 mL/min/1.73 m^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
3074822|NCT01275170|Experimental|Panel F Healthy Participants|A subset of healthy control participants were matched specifically to participants in Panel E and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
3132387|NCT03422250|Experimental|Arm 1|Alzheimer's disease (AD): anodal tDCS of the default mode network (DMN)
3074823|NCT01275170|Experimental|Panel G End Stage Renal Disease with Hemodialysis (ESRD/HD)|Participants with ESRD/HD receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV postdialysis (Part 1, Period 1) and predialysis (Part 1, Period 2). In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg predialysis (Part 2, Period 1) and postdialysis (Part 2, Period 2).
3074824|NCT01275170|Experimental|Panel H Healthy Volunteers|A subset of healthy control participants were matched specifically to participants in Panel G and receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
3074825|NCT01275196|Experimental|Nilotinib|
3074826|NCT01275196|Active Comparator|Imatinib|
3074827|NCT01275222|Experimental|Phase l: RAD001 20mg/week|RAD001 20 mg was given once a week.
3074828|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 600mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
3074829|NCT01275222|Experimental|Phase l: RAD001 5mg/day + Glivec 600mg/day|RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
3074830|NCT01275222|Experimental|Phase l: RAD001 2.5mg/day + Glivec 800mg/day|RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
3074831|NCT01275222|Experimental|Phase ll - Stratum l (first-line resistant/refractory): RAD001 2.5mg/day + Glivec 600mg/day|All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
3074832|NCT01275222|Experimental|Phase ll - Stratum ll: (post second-line therapy): RAD001 2.5mg/day + Glivec 600mg/day|All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
3074833|NCT01275300|Placebo Comparator|Placebo phase I|Subjects were given 5 days of placebo. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of placebo. Urine was collected sequentially for analysis. The same subjects came back for cross-over study and were assigned to Aspirin group. There was a 2-week washout period between each treatment.
3074834|NCT01275300|Active Comparator|Aspirin phase I|Subjects were given 5 days of 81 mg aspirin. On day 5, they were given a single dose of niacin (600 mg) administered 30 minutes after the last dose of aspirin or placebo. Urine was collected sequentially for analysis.
3074835|NCT01275300|Active Comparator|Aspirin phase II|In phase II study, subjects were given 5 days of 81 mg aspirin. On day 6, they were given a single dose of niacin (600 mg) administered 24 hours after the last dose of aspirin. Urine was collected sequentially for analysis
3074836|NCT01275313|Experimental|Custom-Fitted Lightweight Wheelchair & Cushion|Receive a new custom-fitted lightweight wheelchair, skin protection cushion and wheelchair skills training
3074837|NCT01275313|Other|Cushion Only|Receive a skin protection cushion and wheelchair training, but remain in facility-issued wheelchair
3074838|NCT01275339|Active Comparator|Tadalafil in Diabetic Cohort|
3074839|NCT01275339|Placebo Comparator|Placebo in Diabetic Cohort|
3074840|NCT01275339|Active Comparator|Tadalafil in Non-Diabetic Cohort|
3074841|NCT01275339|Placebo Comparator|Placebo in Non-Diabetic Cohort|
3074842|NCT01275365|No Intervention|Placebo/Low Protein|Placebo injections weekly; 0.8 g/kg/day protein
3074843|NCT01275365|No Intervention|Placebo/High Protein|Placebo injections weekly; 1.3 g/kg/day protein
3074844|NCT01275365|Other|Testosterone/Low Protein|Testosterone enanthate 100 mg intramuscularly weekly; 0.8 g/kg/day protein
3074845|NCT01275365|Other|Testosterone/High Protein|Testosterone enanthate 100 mg intramuscularly weekly; 1.3 g/kg/day protein
3074846|NCT01275430|Experimental|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
3074847|NCT01275430|Active Comparator|"Blind Placement"|"PICCs will be placed blindly, without the use of any tip location/positioning device."
3074848|NCT01275586|Experimental|Tasigna|Following enrollment each subject will initially receive the drug Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated. Subjects will have his/her dose increased as tolerated dose during the first three months of therapy. The maximum targeted dose is 400mg twice daily.
3074849|NCT01275625|Experimental|Treatment|Single arm study of combivir and maraviroc for 48 weeks
3074850|NCT01275664|Experimental|Treatment (granisetron, dexamethasone, aprepitant)|Patients apply one patch of granisetron transdermal system to the upper outer arm on day 0 (at least 24 hours before intraperitoneal [IP] platinum therapy). Patients then receive dexamethasone PO on days 1-4, aprepitant IV over 15 minutes on day 1 (30 minutes before IP platinum therapy), and aprepitant PO on days 2-3.
3468853|NCT03891667|Active Comparator|4 Week Disulfiram|Patients in this group receive disulfiram for 4 weeks followed by placebo capsules for 4 weeks. The dosing schedule is fixed-flexible, starting at 250 mg every other day at week 1, 250 mg daily for week 2, 250 mg alternating with 500 mg during week 3, and 500 mg daily during week 4. Placebo capsules are given during weeks 5-8. Dose increases are based on clinical judgment guided by patient tolerance, response, body weight, and side effects.
3468854|NCT03891927|Experimental|olive group|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO ( high polypheol Extra virgin olive oil)
3074853|NCT01275755|Placebo Comparator|Placebo|Each participant received 1 placebo capsule orally every day (QD) during the Run-in Placebo Period (1 week), the Double-blind Treatment Period (4 weeks), and the Run-out Placebo Period (1 week).
3132388|NCT03422250|Experimental|Arm 2|Alzheimer's disease (AD): cathodal tDCS of the salience network (SN)
3468855|NCT03891927|No Intervention|non olive group|No intervention
3468856|NCT03891615|Experimental|Niraparib + Osimertinib|"Niraparib will be administered orally once daily~Osimertinib will be administered by mouth once daily"
3468857|NCT03891758|Experimental|BK1310|
3468858|NCT03891758|Active Comparator|ActHIB® and Tetrabik|
3074854|NCT01275755|Experimental|ADL5945 0.25 mg|During the Run-in Placebo Period, each participant received 1 placebo capsule orally QD for 1 week. Then during the Double-blind Treatment Period, each participant received one 0.25-milligrams (mg) ADL5945 capsule orally QD for 4 weeks. Then during the Run-out Placebo Period, each participant received 1 placebo capsule orally QD for 1 week.
3074855|NCT01275833|Experimental|Device programming modifies AV timing|DDD-40-BiV
3074856|NCT01275833|No Intervention|Device programming allows intrinsic AV timing.|VVI-40-RV
3074857|NCT01276041|Experimental|pertuzumab in combination with trastuzumab and paclitaxel|This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.
3074858|NCT01276106|Experimental|AC-201, 25mg|25mg BID for 24 weeks
3074859|NCT01276106|Experimental|AC-201, 50mg|50mg BID for 24 weeks
3074860|NCT01276106|Experimental|AC-201, 75mg|75mg BID for 24 weeks
3074861|NCT01276106|Placebo Comparator|Placebo|Placebo BID for 24 weeks
3074862|NCT01276171|Active Comparator|Ultrasound|Participants will place arterial line using ultrasound technique
3074863|NCT01276171|Active Comparator|Doppler|Participants will place arterial line using doppler technique
3074864|NCT01276171|Active Comparator|Palpation|Participants will place arterial line using palpation technique
3074865|NCT01276184|No Intervention|Usual Care|Participants follow the usual practices for scheduling their follow up visit(s) for vaccination at the clinic. Participants will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate).
3074866|NCT01276184|Experimental|SMS Text Message|Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their scheduled appointment(s) (phone call, letter, etc, as appropriate). Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit.
3074867|NCT01276197|Experimental|Arm 1: Story-Telling DVD|Participant will receive a DVD with informational and story-telling components
3074868|NCT01276197|Active Comparator|Arm 2: Non-Storytelling DVD|Participant will receive an informational DVD
3074869|NCT01276223|Experimental|Durezol|Difluprednate 0.05% ophthalmic emulsion, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week to allow for tapering of the steroid exposure.
3074870|NCT01276223|Placebo Comparator|Vehicle|Difluprednate vehicle, 1 drop to the study eye 2 times a day for 4 weeks, followed by 1 drop to the study eye once daily for 1 week.
3074871|NCT01276236|Experimental|Treatment Arm (Maraviroc)|The subjects in this arm will receive Maraviroc as treatment, while continuing their current antiretroviral medication regimen.
3074872|NCT01276288|Active Comparator|Reference 1|administration of BI 10773 once daily for 5 days (20 patients)
3074873|NCT01276288|Active Comparator|Reference 2|administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)
3074874|NCT01276288|Active Comparator|Reference 3|administration of torasemide (TOR) once daily for 4 days (10 patients)
3074875|NCT01276288|Experimental|Test 1|administration of BI 10773 + HTC once daily for 5 days (10 patients)
3074876|NCT01276288|Experimental|Test 2|administration of BI 10773 + TOR once daily for 5 days (10 patients)
3074877|NCT01276301|Experimental|Reference|single dose BI 10773
3074878|NCT01276301|Active Comparator|Test|single dose BI 10773 + single dose verapamil
3074879|NCT01276314|Experimental|anti- TNF-a treatment|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Etanercept administration:~The experimental group received the first dose of Etanercept (25 mg) i.v., followed by two doses per week and maintain 2 to 3 weeks"
3074880|NCT01276314|Active Comparator|control group|"Meet the conditions of inclusion and exclusion, seek the consent of the patient, and fill out the ICF~Fill out the case report form~Blood test and physiological assessment, and do TNF-alpha serum concentration and peripheral blood mononuclear spherical cDNA expression analysis~Drug administration:~The control group of drug delivery: systemic intravenous steroid therapy, the dose is equivalent to prednisolone 1-1.5 mg / kg / day, according to the treatment of 3-4 days gradually decreased dose."
3074881|NCT01276327|Experimental|1 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
3074882|NCT01276327|Experimental|2 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
3074883|NCT01276327|Experimental|3 Linagliptin/Pioglitazone (Test)|Fixed-Dose-Combination-Tablet, oral administration with 240 mL water
3074884|NCT01276327|Experimental|4 Linagliptin + Pioglitazone (Ref)|Tablets, oral administration with 240 mL water for each treatment
3074885|NCT01276353|Experimental|1|
3074886|NCT01276353|Active Comparator|2|
3074887|NCT01276379|Experimental|FOLFIRI (m) or FOLFOX-6 (m) + cetuximab|FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.
3074888|NCT01276457|Experimental|Upper everolimus blood target + very low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
3074889|NCT01276457|Active Comparator|Standard everolimus blood target + low dose cyclosporine|Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.
3074890|NCT01276509|Placebo Comparator|Placebo-SC Injection|Placebo delivered SC, 3 doses separated by 4 weeks.
3074891|NCT01276509|Experimental|Drug Dose level 1- SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks.
3074892|NCT01276509|Experimental|Drug Dose level 2-SC injection|Drug dose level 2 delievered SC, 3 doses separated by 4 weeks.
3074893|NCT01276509|Experimental|Drug Dose level 3- SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks.
3074894|NCT01276535|Experimental|Erchonia MLS + Erchonia THL|"The Erchonia® MLS contains 5 independent diodes: 4 each emitting 17 milliwatt (mW) 635 nanometers (nm) of red laser light and the fifth diode emitting 17 mW, 405 nm of blue laser light.~The Erchonia THL is a single diode pulsed laser that emits 4.9 milliwatts (mW) of red 635 nanometer (nm) light."
3074895|NCT01276639|Experimental|Active Treatment 10 mg BID|
3074896|NCT01276639|Experimental|ActiveTreatment 5 mg BID|
3074897|NCT01276639|Placebo Comparator|Placebo Treatment|
3074898|NCT01276652|Active Comparator|Environmental modification|Subjects assigned to this group receive the environmental modification intervention for 48 hours beginning the morning after enrollment.
3074899|NCT01276652|No Intervention|Usual care (randomized)|"Usual care is provided for the first 48 hours. Subsequently, in the initial protocol, subjects received 48 hours of the environmental modification intervention so long as they remained in the ICU during this time. The opportunity to receive the Delayed intervention was later removed from the protocol."
3074900|NCT01276652|No Intervention|Usual care (observational)|Usual care was provided.
3074901|NCT01276756|Active Comparator|Standard of care|Group A: comprises 50 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3074902|NCT01276756|Experimental|Triple therapy|Group B: comprises 50 treatment-naive chronic HCV patients who will receive oral Nitazoxanide 500 mg twice daily for 4 weeks (lead-in phase) followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3074903|NCT01276821|Placebo Comparator|Standard Treatment|L-Epinephrine and Normal Saline (0.9%)
3074904|NCT01276821|Active Comparator|Study Treatment|L-Epinephrine and Hypertonic Saline (3%)
3074905|NCT01276847|Experimental|Ustekinumab|
3074906|NCT01276847|Active Comparator|Etanercept|
3074907|NCT01276847|No Intervention|No treatment|
3074908|NCT01276860|Other|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
3074909|NCT01277042|Experimental|Cervarix Group|Subjects received a 3-dose vaccination course of the Cervarix™ vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3074910|NCT01277042|Active Comparator|Engerix Group|Subjects received a 3-dose vaccination course of the Engerix™-B vaccine administered intramuscularly in the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
3074911|NCT01277081|Active Comparator|Paracetamol hot drink|Hot drink containing paracetamol
3074912|NCT01277081|Active Comparator|Paracetamol tablets|Paracetamol tablets
3074913|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg).|Control Nerve Block. IV Dexamethasone (4 mg).
3074914|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
3074915|NCT01277159|Experimental|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorp|Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
3074916|NCT01277159|Experimental|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (|Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
3074917|NCT01277159|Experimental|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine|Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
3074918|NCT01277211|Experimental|ENG-EE (NuvaRing)|Participants were to complete 13 cycles of etonogestrel (ENG) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day ring-free period. Participants used one ring per cycle. Each ring contained 11.7 mg ENG and 2.7 mg EE, and released on average 120 mcg/day of ENG and 15 mcg/day of EE.
3074919|NCT01277211|Active Comparator|DRSP-EE|Participants were to complete 13 cycles of drospirenone (DRSP) and ethinylestradiol (EE) use. Each cycle was 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received a total of 21 tablets of DRSP-EE per cycle. Each tablet contained 3 mg DRSP and 30 μg EE.
3074920|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.
3074921|NCT01277302|Experimental|Ranibizumab 0.5 mg PRN - randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.
3074922|NCT01277302|Experimental|Ranibizumab 0.5 mg monthly - non-randomized subjects|Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.
3074923|NCT01277341|Experimental|2% Twice a day|Bepotastine Besilate Nasal Spray 2% Twice a day
3074924|NCT01277341|Experimental|3% Twice a day|Bepotastine Besilate Nasal Spray 3% Twice a day
3074925|NCT01277341|Experimental|4% Twice a day|Bepotastine Besilate Nasal Spray 4% Twice a day
3074926|NCT01277341|Placebo Comparator|Placebo|Placebo nasal spray
3074927|NCT01277354|Active Comparator|Cognitive Processing Therapy|Participants are seen weekly for six weeks for therapy. At visits 2, 4, and 6 they also complete ratings.
3074928|NCT01277354|Placebo Comparator|Waitlist|Participants come in at the end of weeks 2, 4, and 6 to complete ratings but do not receive therapy.
3074929|NCT01277510|Placebo Comparator|Placebo|Participants received standard of care and placebo once daily for 30 weeks during the double-blind phase. During the open-label phase, participants received cinacalcet with standard of care for an additional 30 weeks. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks up to Week 54 to a maximum dose of 4.2 mg/kg.
3074930|NCT01277510|Experimental|Cinacalcet|Participants received standard of care and cinacalcet once daily for 30 weeks during the double-blind phase. The starting dose of cinacalcet was ≤ 0.20 mg/kg based on dry weight, and could be titrated up according to plasma iPTH and serum calcium levels every 4 weeks until Week 24 to a maximum dose of 4.2 mg/kg. During the open-label phase participants continued to receive cinacalcet with standard of care for an additional 30 weeks.
3074931|NCT01277523|Experimental|A|
3074932|NCT01277523|Experimental|B|
3074933|NCT01277523|Placebo Comparator|C|
3074934|NCT01277549||Non-mobilized donors|In this arm the collection efficiency of mononuclear cells from non-mobilized donors will be studied.
3074935|NCT01277549||G-CSF mobilized donors|In this arm the collection efficiency of CD34+ cells will be studied.
3074936|NCT01277601|Experimental|TDF+Peg-IFN 48 Weeks|TDF plus Peg-IFN for 48 weeks
3074937|NCT01277601|Experimental|TDF 48 Weeks + Peg-IFN 16 Weeks|TDF plus Peg-IFN for 16 weeks, followed by TDF alone for an additional 32 weeks
3074938|NCT01277601|Active Comparator|TDF 120 Weeks|TDF monotherapy for 120 weeks
3074939|NCT01277601|Active Comparator|Peg-IFN 48 Weeks|Peg-IFN monotherapy for 48 weeks
3074940|NCT01277666|Placebo Comparator|Placebo|orally administered
3074941|NCT01277666|Experimental|GSK1605786A 500mg once daily|orally administered
3074942|NCT01277666|Experimental|GSK1605786A 500mg twice daily|orally administered
3074943|NCT01277718|Experimental|Treatment A first, then Treatment B, followed by Treatment C|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 milliliters (mL) room temperature water after at least an 8-hour fast. Treatment B in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized Food and Drug Administration (FDA) high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. There will be a 13-day washout between cobimetinib doses of each period.
3074944|NCT01277718|Experimental|Treatment A first, then Treatment C, followed by Treatment B|Treatment A in Period 1: One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast. Treatment C in Period 2: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of the treatment period, 20 mg rabeprazole will be administered in fasted state. Approximately 30 minutes later, participants will be provided a standardized FDA high-fat meal, and approximately 30 minutes after starting meal, one 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water. Treatment B in Period 3: 20 mg oral rabeprazole will be administered once daily for 4 days starting on Day -4. On Day 1 of treatment period, 20 mg rabeprazole will be administered in fasted state followed by one 20-mg tablet of cobimetinib administration orally with 240 mL room temperature water after at least an 8-hour fast. There will be a 13-day washout between cobimetinib doses of each period.
3074945|NCT01277744|Experimental|HIPEC + Cisplatin|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions. Cisplatin 100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the Cisplatin.
3074946|NCT01277757|Experimental|Treatment (Akt inhibitor MK-2206)|Akt Inhibitor MK-2206 mg orally once a week on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3074947|NCT01277783|Experimental|Endocardial Left Ventricular pacing|All patients will undergo the intervention, and are followed at 1, 3, 6, and 12 months (minimum) and biannually thereafter until 1 year after enrollment of the last patient.
3074948|NCT01277822|Experimental|Losartan/amlodipine Treatment Arm|One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
3074949|NCT01277822|Active Comparator|Amlodipine Treatment Arm|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
3074950|NCT01277861|Active Comparator|FENTANYL|FENTANYL
3074951|NCT01277861|Placebo Comparator|SALINE|SALINE
3074952|NCT01277887|Active Comparator|Cognitive-Behavioral Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
3074953|NCT01277887|Placebo Comparator|Smoking Cessation Counseling|The intervention consists of 8 sessions provided over 10 weeks. Counseling commences 4 weeks before quitting smoking. Participants will also receive the nicotine patch for 6 weeks starting on the day of quit date.
3074954|NCT01278030|No Intervention|Control group|Patients will be implanted according to the standard of care with the LV lead in the traditional LV lead position.
3074955|NCT01278030|Experimental|3D echo-guided LV lead placement group|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on Real-Time 3-Dimensional Echocardiography (RT3DE) will be available to the physician at the time of implant. This location will be used as the target for optimal LV lead placement.
3132389|NCT03422250|Experimental|Arm 3|Behavioral-variant frontotemporal dementia (bvFTD): anodal tDCS of the salience network (SN)
3132390|NCT03422250|Experimental|Arm 4|Behavioral-variant frontotemporal dementia (bvFTD): cathodal tDCS of the default mode network (DMN)
3074956|NCT01278160|Experimental|BIAsp 30 (2:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 2/3 and 1/3 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
3074957|NCT01278160|Experimental|BIAsp 30 (1:1)|After discontinuation of previous treatment of once daily biphasic insulin aspart 30 (BIAsp 30) or insulin glargine combined with metformin and glimepiride in trial BIAsp-3756, subjects were adminstered BIAsp 30 twice daily with initial dosage split regimen of 1/2 and 1/2 total daily dose before breakfast and before dinner, respectively combined with metformin administered orally with meals
3074958|NCT01278173|Other|Sabril|
3074959|NCT01278303|Other|Treatment of Aortic Wall Injury|Repair of aortic wall injury with covered CP Stents
3074960|NCT01278342|Active Comparator|Sandostatin LAR high dose Alone|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with controlled GH and IGF-I after 3 months of Sandostatin LAR monotherapy continued to receive Sandostatin LAR 40 mg i.m. every 28 days for an additional 4 months.
3074961|NCT01278342|Experimental|Sandostatin LAR high dose + Pegvisomat|All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR40 mg every 28 days in combination with weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for a further 4 months
3074962|NCT01278342|Experimental|Sandostatin LAR high dose + Cabergoline|"All patients were treated with Sandostatin LAR 40 mg i.m. every 28 days for 3 months. Following biochemical assessment, patients with uncontrolled GH and or IGF-I received Sandostatin LAR 40 mg every 28 days in combination with weekly cabergoline for a further 4 months, with cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
3074963|NCT01278394|Experimental|Group 1|AN2690 Solution, 5.0%
3074964|NCT01278407|Placebo Comparator|Placebo - Confirmatory Phase|Participants received donepezil matched placebo tablets orally, once daily for 12 weeks in the confirmatory phase.
3074965|NCT01278407|Experimental|Donepezil 5 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 10 weeks in the confirmatory phase.
3074966|NCT01278407|Experimental|Donepezil 10 mg - Confirmatory Phase|Participants received donepezil tablets orally, once daily for 12 weeks. Treatment began with 3 mg for 2 weeks, and then the dose was increased to 5 mg for 4 weeks. Thereafter, the dose was increased to 10 mg for 6 weeks in the confirmatory phase.
3074967|NCT01278407|Experimental|Placebo to Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil matched placebo up to Week 12 in the Confirmatory Phase, continued placebo until Week 16 (at the beginning of the Extension Phase). Participants received 3 mg of donepezil, and the dose was then increased to 5 mg at Week 18 and to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
3074968|NCT01278407|Experimental|Donepezil (5 +10 mg) - Extension Phase|Participants previously receiving donepezil (5 mg or 10 mg) up to Week 12 in the Confirmatory Phase, maintained allocated treatment and dosages until Week 24. In the 5 mg group of the Confirmatory Phase, the dose was increased to 10 mg at Week 24. After Week 24, dose reduction to 5 mg was allowed if continuation at 10 mg caused any safety concerns.
3074969|NCT01278485||Sulphonylurea (SU) Monotherapy or SU + Metformin|Participants with Type 2 diabetes that have been treated with SU monotherapy for at least 6 months by a cardiologist, nephrologist, or family practice doctor.
3074970|NCT01278615|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity
3074971|NCT01278745|Experimental|Rituximab|Rituximab induction/conventional immunosuppression
3074972|NCT01278745|Placebo Comparator|Rituximab Placebo|Rituximab Placebo / conventional immunosuppression
3074973|NCT01278797|Active Comparator|Telmisartan/Amlodipine Fixed Dose|Telmisartan/Amlodipine medium fixed dose combination tablet once daily.
3074974|NCT01278797|Active Comparator|Amlodipine Monocomponent|Amlodipine Monocomponent 10mg tablet once daily
3074975|NCT01278862|Experimental|DVS veneer|veneer made by CAD/CAM method
3074976|NCT01278862|Active Comparator|Conventional veneer|Veneer made by laboratory technician
3074977|NCT01278927|Active Comparator|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief (10 minute) personalized introduction to the home-based exercise intervention. On Day 30 post hematopoietic cell transplantation (HCT), participants will meet briefly with the same interventionist when possible. To minimize contamination across intervention conditions, participants randomized to Exercise will be provided with only general advice regarding stress management (i.e., to continue using any techniques they currently use to manage stress). The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant.
3074978|NCT01278927|Active Comparator|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief standardized introduction to the self-administered intervention. On Day 30 post HCT, the interventionist will meet with the participant to answer any questions about the intervention, encourage the continued use of stress management techniques as recommended, and monitor for any adverse reactions to use of the techniques. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
3074979|NCT01278927|Active Comparator|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions. On Day 30 post HCT, the same interventionist will meet with the participant briefly to answer any questions about the interventions, encourage the continued use of the interventions as recommended, and monitor for any adverse reactions. The interventionist will meet with the patient again in person or by phone at approximately 60 days post transplant. Whenever possible, the interventionist meeting with the patient at 30 and 60 days should be the same interventionist who previously met with the patient.
3074980|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive a digital video disc (DVD). The interventionist will briefly discuss the topics of the DVD and elicit questions. To minimize contamination across intervention conditions, participants randomized to the control group will be provided with only general advice about exercise and stress management during treatment (i.e., to maintain any usual patterns of exercise to the extent possible and to continue using any techniques they currently use to manage stress).
3074981|NCT01278953|Experimental|TactiCath|Catheter ablation to treat paroxysmal AF using the TactiCath catheter with contact force capability
3074982|NCT01278953|Active Comparator|Control|Catheter ablation to treat paroxysmal AF using a catheter with no contact force sensing capability
3074983|NCT01279044|Active Comparator|1|HIV testing with adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)
3074984|NCT01279044|Placebo Comparator|2|HIV testing with information only
3074985|NCT01279057|Experimental|Test|Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
3074986|NCT01279057|Active Comparator|Reference|Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray administered once daily at a dose of 110 mcg (4 actuations) for 14 days.
3074987|NCT01279057|Placebo Comparator|Placebo|Placebo nasal spray administered once daily for 14 days.
3074988|NCT01279070|Experimental|REPYFLEC cognitive remediation training|REPYFLEC cognitive remediation as a Problem solving and Cognitive flexibility group training.
3074989|NCT01279070|Active Comparator|Leisure group|"Leisure group is a stimulating activity focused on socialization through group dynamics, board games, coffee and talk."
3074990|NCT01279109|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building healthy lifestyle skills and reciprocal social ties between the intervention group members
3074991|NCT01279109|Active Comparator|Home visit|Home visits focused on preventable infant injuries
3074992|NCT01279187|Experimental|Teriparatide|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
3074993|NCT01279187|Placebo Comparator|Control|demeclocycline HCl (150 mg, four times per day for 3d) followed by a 12 day intermission then 3 more days of demeclocycline HCl (150 mg, four times per day). One day after the last demeclocycline dosage, subjects will be instructed to self-administer teriparatide (or placebo) for 7 weeks. Twenty-five days after the last demeclocycline dosage, subjects will begin their second set of tetracycline labels:(250 mg, four times per day) for three days, followed by 12 days off, and then repeat another 3 days of tetracycline HCl (250 mg, four times per day). On day of the last teriparatide (or placebo) injection, subjects will present for bone core removal and dental implant placement.
3074994|NCT01279200|Active Comparator|Urinary LH Kits|Patients randomized to this arm will monitor ovulation with home-based urinary LH kits (Ovulation Predictor Kits, OPK's).
3074995|NCT01279200|Active Comparator|Midcycle ultrasound + hCG injection|Patients randomized to this arm will undergo ovulation monitoring with midcycle ultrasound and receive hCG injection if evidence of a mature size follicle.
3074996|NCT01279265|Active Comparator|Nutramigen Lipil with Enflora|Formula with probiotics (Lactobaccillus Rhamnosus GG)
3074997|NCT01279265|Placebo Comparator|Nutramigen A+|Hypoallergenic formula without probiotics (Lactobaccillus Rhamnosus GG)
3074998|NCT01279317|Experimental|vinegar co-ingestion|25 ml vinegar is added to glucose containing beverage
3074999|NCT01279317|Placebo Comparator|Placebo co-ingestion|25 ml vinegar is substituted by 25 ml water
3075000|NCT01279343|Experimental|Foley Bulb plus Misoprostol|
3075001|NCT01279343|No Intervention|Misoprostol|
3075002|NCT01279447|Sham Comparator|Placebo|A sham infrapatellar block performed under US guidance with normal saline
3075003|NCT01279447|Experimental|Infrapatellar nerve block|An infrapatellar nerve block performed under US guidance with 0.25% bupivacaine
3075004|NCT01279564|Experimental|ETview|ETview TVT endotracheal tube
3075005|NCT01279564|Sham Comparator|Control|Endotracheal tube
3075006|NCT01279681|Active Comparator|Arm A [fluoropyrimidine + bevacizumab (BEV)]|Patients receive either 5FU/LV or Capecitabine, plus BEV. 5FU/LV + BEV is comprised of 5FU IV over 46-48 hours, LV calcium IV over 2 hours, and BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Capecitabine + BEV is comprised of capecitabine PO BID on days 1-14 and BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3075007|NCT01279681|Experimental|Arm B [fluoropyrimidine/oxaliplatin (OXAL) + BEV]|Patients receive either mFOLFOX7 plus BEV, or Capecitabine + OXAL (XELOX) plus BEV. mFOLFOX7 + BEV is comprised of OXAL IV over 2 hours, LV calcium IV over 2 hours, and 5FU IV over 46-48 hours on day 1. Patients also receive BEV IV over 10-90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. XELOX + BEV is comprised of OXAL IV over 2 hours on day 1 and capecitabine PO BID on days 1-14. Patients also receive BEV IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3075008|NCT01279850||Pregabalin (Lyrica) capsule|"Patients administered Pregabalin capsule."
3075009|NCT01279954|Experimental|open-label abatacept first, then 5 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 5 mg/kg abatacept (18 months)
3075010|NCT01279954|Experimental|open-label abatacept first, then 10 mg/kg abatacept|10 mg/kg abatacept (6 months). Then 10 mg/kg abatacept (18 months)
3075011|NCT01280058|Experimental|Arm I (wild-type reovirus, carboplatin, paclitaxel)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and wild-type reovirus IV over 60 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3075012|NCT01280058|Experimental|Arm II (carboplatin, paclitaxel)|Patients receive paclitaxel and carboplatin as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
3075013|NCT01280110|Active Comparator|Preserved (BAK 0.006%) lubricating drop|One group will receive preserved lubricating drops 4 times a day for 1 month.
3075014|NCT01280110|Active Comparator|Preservative-free lubricating drops|The second group will receive preservative-free lubricating drops 4 times a day for 1 month.
3075015|NCT01280123|Experimental|15 mg pioglitazone|15 mg pioglitazone
3075016|NCT01280123|Experimental|45 mg pioglitazone|45 mg pioglitazone
3075017|NCT01280123|Placebo Comparator|Matching Placebo|Placebo
3075018|NCT01280201|Experimental|Pazopanib|
3075019|NCT01280266|Experimental|Amlodipine-Udenafil (AU) arm|Amlodipine 10mg PO QD for 4 weeks, washout period, then Udenafil 100mg PO QD for 4 weeks
3075020|NCT01280266|Experimental|Udenafil-Amlodipine (UA) arm|Udenafil 100mg PO QD for 4 weeks, washout period, then Amlodipine 10mg PO QD for 4 weeks
3075021|NCT01280357|Active Comparator|Monitor Philips 50XM (K954351)|CTG Fetal Monitor If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
3075022|NCT01280357|Experimental|Monica AN24 (K101801)|EHG Fetal Monitor
3075023|NCT01280409|Placebo Comparator|Placebo|Compounded placebo
3075024|NCT01280409|Experimental|Metformin|Compounded metformin as the intervention
3075025|NCT01280552|Experimental|ICT-107|Autologous dendritic cells pulsed with immunogenic peptides from tumor antigens
3075026|NCT01280552|Placebo Comparator|Control|Autologous dendritic cells that have not been pulsed with antigens
3075027|NCT01280591|Experimental|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|
3075028|NCT01280591|Experimental|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|
3075029|NCT01280591|Active Comparator|Naproxen sodium 440 mg (BAYH6689)|
3075030|NCT01280591|Active Comparator|DPH 50 mg|
3075031|NCT01280604|Experimental|Intervention 'Fenofibrate 54mg'|Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
3075032|NCT01280604|No Intervention|Control 'Fenofibrate 160mg'|Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).
3075033|NCT01280617|Experimental|Thymoglobulin 1.25mg/kg dose|The safety and efficacy of low dose Thymoglobulin (1.25mg/kg) as an induction agent in renal transplant subjects.
3075034|NCT01280617|Experimental|Thymoglobulin 0.75mg/kg dose|The safety and efficacy of low dose Thymoglobulin (0.75mg/kg) as an induction agent in renal transplant subjects.
3075035|NCT01280656||Conventional Interferon Plus Ribavirin|Eligible participants who will receive conventional interferon plus ribavirin for Chronic Hepatitis C (CHC) according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3075036|NCT01280656||Peginterferon Alfa-2a Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2a plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3075037|NCT01280656||Peginterferon Alfa-2b Plus Ribavirin|Eligible participants who will receive peginterferon alfa-2b plus ribavirin for CHC according to the standard of care and aligned with the local prescription instructions will be observed during treatment period (48 weeks) and follow up period (24 weeks).
3075038|NCT01280695|Placebo Comparator|Placebo|Placebo capsule once daily
3075039|NCT01280695|Experimental|MSDC-0602 100 mg|MSDC-0602 capsule 100 mg once daily
3075040|NCT01280695|Experimental|MSDC-0602 250 mg|MSDC-0602 capsule 250 mg once daily
3075041|NCT01280695|Experimental|MSDC-0602 500 mg|MSDC-0602 capsule 500 mg once daily
3075042|NCT01280695|Active Comparator|Pioglitazone 45 mg|Pioglitazone capsule 45 mg once daily
3075043|NCT01280721|Experimental|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
3075044|NCT01280812|Experimental|PA intervention and Maintenance plus|3-month physical activity intervention and 6-month maintenance intervention-Plus program
3075045|NCT01280812|Experimental|PA intervention and Maintenance regular|3-month physical activity intervention and 6-month maintenance - Regular program
3075046|NCT01280812|Active Comparator|Pedometer|Non-intervention group
3075047|NCT01280903|Experimental|STAR Intervention|Staying Active with Arthritis Intervention
3075048|NCT01280903|Placebo Comparator|Attention-Control|Senior Health Information Intervention
3075049|NCT01280942|No Intervention|Control|Patients admitted to 4 GHWs designated as controls. Nurses will not be notified when patients on these GHWs satisfy the EWS algorithm. They will also not wear the wireless sensor devices.
3075050|NCT01280942|Experimental|Nurse notification of EWS alert|Patients admitted to 4 GHWs designated as intervention wards at BJH. Nurses will be notified when patients on these wards satisfy the EWS algorithm. Some patients will be asked to wear the wireless remote sensors.
3075051|NCT01280955|Experimental|Transplant Recipients|Transplant recipients from matched sibling donors and dual cord donors. Subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
3075052|NCT01280968|Experimental|NIC002 Vaccine in Aluminum hydroxide|4 subcutaneous vaccinations were performed over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 100 μg of NIC002 and 0.46 mg aluminum hydroxide.
3075053|NCT01280968|Placebo Comparator|Placebo Vaccine - Aluminum hydroxide|4 placebo injections were administered subcutaneously over the course of 3 months, with 4 weeks between each vaccination. The administered volume of 0.65 mL of sterile water contained 0.46 mg aluminum hydroxide.
3075054|NCT01280981|Experimental|Tranexamic acid|Two 650 mg tablets orally 3 times per day with liquids for up to 5 days (not to exceed 3 doses in 1 day or 15 doses during the menstrual period).
3075055|NCT01281007|Experimental|Famciclovir 125 mg|1 tablet every 12 hours for 5 days
3075056|NCT01281007|Active Comparator|Aciclovir 200 mg|1 tablet every 4 hours (excluding nocturnal dose) for 5 days
3075057|NCT01281189|Experimental|Dexpramipexole|
3075058|NCT01281189|Placebo Comparator|Placebo|
3075059|NCT01281202|Active Comparator|CPP-109 Vigabatrin Tablets|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received 3 CPP-109 Vigabatrin 500 mg Tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Individual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
3075060|NCT01281202|Placebo Comparator|Placebo|"Subjects were evaluated for their compliance with protocol inclusion/exclusion criteria during a -2 to -4 week Screening/Baseline Phase~During treatment, subjects received Vigabatrin matching placebo tablets, bid, for 9 weeks~Subjects were provided with on-site, supervised, standardized, manualized Indivdiual Drug Counseling 1x per week for 9 weeks and the first 4 weeks for the follow-up phase (weeks 10-13)"
3075061|NCT01281306|Experimental|VAL + AHU 400 mg|Participants were started with AHU377 100 mg + valsartan 160 mg every day (qd) for 1 week, then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for another week, and then were uptitrated to AHU377 400 mg + valsartan 320 mg for the remaining 6 weeks.
3075062|NCT01281306|Experimental|VAL + AHU 200 mg|Participants were started with AHU377 100 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 200 mg + valsartan 320 mg qd for the remaining 7 weeks.
3075063|NCT01281306|Experimental|VAL + AHU 100 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 100 mg + valsartan 320 mg for the remaining 7 weeks.
3075064|NCT01281306|Experimental|VAL + AHU 50 mg|Participants were started with AHU377 50 mg + valsartan 160 mg qd for 1 week and then were uptitrated to AHU377 50 mg + valartan 320 mg qd for the remaining 7 weeks.
3075065|NCT01281306|Experimental|VAL 320 mg|Participants were started with valsartan 160 mg qd for 1 week and then were uptitrated to valsartan 320 mg qd for the remaining 7 weeks.
3075066|NCT01281306|Experimental|LCZ 400 mg|Participants were started with LCZ696 200 mg qd for 1 week and then were uptitrated to LCZ696 400 mg qd for the remaining 7 weeks.
3075067|NCT01281306|Experimental|Placebo|Participants received matching placebo to LCZ696, AHU377 and valsartan for 8 weeks.
3075068|NCT01281475|Experimental|Levodopa|Levodopa is prescribed as a combination of levodopa/carbidopa (4:1) to reduce the peripheral side effects. The dosage used was 15 mg/kg/day in 3 divided doses.
3075069|NCT01281475|Placebo Comparator|Placebo|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa, so it is not expected to have any effect.
3075070|NCT01281501|Active Comparator|Conventional|Oral antacid, 20 mg of intravenous hyoscine butylbromide, normal saline
3075071|NCT01281501|Experimental|Pantoprazole|Oral antacid, 20 mg of intravenous hyoscine butylbromide, 80 mg of intravenous pantoprazole
3075074|NCT01281839|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
3075075|NCT01281839|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
3075076|NCT01281865|Experimental|Treatment (everolimus and imatinib mesylate)|Patients receive everolimus PO once daily and imatinib mesylate PO once daily on days 1-28. Course repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and tumor tissue sample collection at baseline and periodically during study for correlative biomarker and protein expression studies.
3075077|NCT01281917|Experimental|Velcade plus Temsirolimus|"Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)~Treat for up to 6 cycles, cycles are 35 days long."
3075078|NCT01281956|Experimental|Placebo Then PRX|Subjects are administered Placebo x3 months followed by PRX (selective 5HT1A agonist) x3 months
3075079|NCT01281956|Experimental|PRX Then Placebo|Subjects are administered PRX (selective 5HT1A agonist) x3 months followed by Placebo x3 months
3075080|NCT01281969|Experimental|Group A|Drug: Gamunex Intravenous Immunoglobulin 2.0 gm/kg total, IV (in the vein), over 2 days
3075081|NCT01281969|Placebo Comparator|Group B|Drug: Placebo Normal saline, IV (in the vein), over 2 day
3075082|NCT01282086||Adults requiring anesthesia for surgery|Adult patients requiring general anesthesia for surgery
3075083|NCT01282138|Experimental|Patanol|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
3075084|NCT01282138|Placebo Comparator|Tears Naturale II|One drop twice daily in each eye for five days prior to allergen provocation testing, followed by an additional drop in each eye approximately 15 minutes prior to start of testing.
3075085|NCT01282164|Experimental|Study patients|patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).
3075086|NCT01282164|Active Comparator|Control|"The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.~Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT)."
3075087|NCT01282203||Adults requiring anesthesia for surgery|This post-marketing observational study will be conducted in a prospective, multi-centre format. It is a non-interventional, observational study in which Sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. Sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. No additional procedures (other than standard of care) shall be applied to the patients. Each patient will be observed from the start of anesthesia through anesthesia end. Markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). Additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with Sevorane as a single anesthetic will be assessed.
3075088|NCT01282229|Active Comparator|LANAP Quadrant|Treated with LANAP
3075089|NCT01282229|No Intervention|Modified Widman Flap|Quadrant treated with Modified Widman Flap surgery
3075090|NCT01282229|No Intervention|Scaling and Root Planing|Quadrant treated with scaling and root planing alone
3075091|NCT01282229|No Intervention|Coronal Debridement|Quadrant treated with coronal debridement
3075092|NCT01282242|Experimental|IV rt-PA|open-label
3075093|NCT01282294||ETN PROtect|There is only 1 cohort in this case series
3075094|NCT01282372||Participants with moderate to severe rheumatic disease|Participants with moderate to severe rheumatic disease (RA, PsA, or AS), who received adalimumab in accordance with approved label
3075095|NCT01282424|Experimental|Idelalisib|Treatment with idelalisib will be continued until tumor progression or development of unacceptable toxicity.
3075096|NCT01282463|Active Comparator|Docetaxel|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3075097|NCT01282463|Experimental|Docetaxel + Ramucirumab DP|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3075098|NCT01282463|Experimental|Docetaxel + Icrucumab|Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.
3075099|NCT01282476|Experimental|Panobinostat/Rituximab|single-arm, open-label; Panobinostat with Rituximab: Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
3075100|NCT01282710||Pregnant, In Labor|
3075101|NCT01282723||Pregnant, In Labor|
3075102|NCT01282801|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules
3075103|NCT01282801|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
3075104|NCT01282814|Experimental|Investigational Test Product|Venlafaxine Hydrochloride 150 mg Extended-Release Capsules.
3075105|NCT01282814|Active Comparator|Reference Listed Drug|Effexor® XR 150 mg Extended-Release Capsules
3075106|NCT01282866|Experimental|HS treatment|Treatment with HS handpiece
3075107|NCT01283009|Placebo Comparator|Arm 1: Inactive substance|Inactive substance
3075108|NCT01283009|Active Comparator|Arm 2: Methylprednisolone|Methylprednisolone
3075109|NCT01283022|Experimental|MVI 200|MVI 200 mcg vaginal insert
3075110|NCT01283035|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 will be taken PO once a week for four weeks (one cycle). Treatment will continue for as long as a subject is benefiting from the study drug.
3075111|NCT01283139|Experimental|Sifalimumab 200 milligram (mg)|Sifalimumab 200 milligram (mg) will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3075112|NCT01283139|Experimental|Sifalimumab 600 mg|Sifalimumab 600 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3075113|NCT01283139|Experimental|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg will be administered intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3075114|NCT01283139|Placebo Comparator|Placebo|Placebo matching to sifalimumab will be administered intravenously at a fixed dose every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
3075115|NCT01283152|Active Comparator|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|
3075116|NCT01283152|Other|Lactulose|Per standard of care
3075117|NCT01283282|Active Comparator|Clopidogrel/Placebo|Subjects were randomized to clopidogrel 75 mg daily for 6 weeks. Then immediately transitioned to a placebo daily for 6 weeks.
3075118|NCT01283282|Active Comparator|Placebo/Clopidogrel|Subjects were randomized to a placebo daily for 6 weeks. Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
3075119|NCT01283321|Experimental|Group A: RiaSTAP|Human fibrinogen concentrate
3075120|NCT01283321|Active Comparator|Group B: apheresis platelets|single apheresis unit
3075121|NCT01283334|Experimental|A|Treatment arm with carboplatin, cetuximab and RAD001
3075122|NCT01283386|Experimental|FCR-lite|Rituximab, fludarabine, and cyclophosphamide
3075123|NCT01283386|Active Comparator|LR Therapy|Rituximab and chlorambucile
3075124|NCT01283464|Active Comparator|Retinol|Retinol 1.0% cream
3075125|NCT01283464|Active Comparator|Tretinoin|Tretinoin 0.02% cream
3075126|NCT01283516|Experimental|LDK378 750 mg: Arm 1A and Arm 1B|NSCLC patients previously treated with an ALK inhibitor
3075127|NCT01283516|Experimental|LDK378 750 mg: Arm 2|NSCLC patients not previously treated with an ALK inhibitor
3075128|NCT01283516|Experimental|LDK378 750 mg: Arm 3|Patients with other tumors that are ALK positive other than NSCLC
3075129|NCT01283542|Experimental|Pasireotide LAR|All patients will receive pasireotide LAR (long acting release) 60 mg every 28 ± 3 days for 24 weeks
3075130|NCT01283555|Experimental|User-Filled Applicator|
3075131|NCT01283555|Other|Prefilled applicator|
3075132|NCT01283581|Experimental|Delafloxacin|300 mg IV (intravenous) every 12 hours for 5-14 days
3075133|NCT01283581|Active Comparator|Vancomycin|15 mg/kg, up to 1250 mg, IV every 12 hours for 5-14 dyas
3075134|NCT01283581|Active Comparator|Linezolid|600 mg IV every 12 hours for 5-14 days
3075135|NCT01283971|Experimental|Tocilizumab + Methotrexate|Tocilizumab 8 mg/kg intravenous (IV) every 4 weeks + Placebo to adalimumab subcutaneous (SC) every 2 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
3075136|NCT01283971|Active Comparator|Adalimumab + Methotrexate|Adalimumab 40 mg SC every 2 weeks + Placebo to tocilizumab IV every 4 weeks for 24 weeks. All participants received methotrexate 10-25 mg and folate at least 5 mg/kg weekly.
3075137|NCT01284062|Experimental|Arm 1|200 mg PF-05230917, Anrukinzumab active dose level
3075138|NCT01284062|Experimental|Arm 2|400 mg PF-05230917, Anrukinzumab active dose level
3075139|NCT01284062|Experimental|Arm 3|600 mg PF-05230917, Anrukinzumab active dose level
3075140|NCT01284062|Placebo Comparator|Arm 4|Matching placebo - administered at matching dose level 200 mg, 400 mg or 600 mg.
3075141|NCT01284114|Active Comparator|Aliskiren|
3075142|NCT01284127||Deferiprone|All patients must have MRI evidence of superficial siderosis and be treated with deferiprone according to standard of care guidelines.
3075143|NCT01284140|Experimental|Sleep promotion protocol|Behavioral: 48 hours of sleep and circadian rhythm promotion including timed light exposure.
3075144|NCT01284140|Active Comparator|Usual care|Behavioral: 48 hours of usual care.
3075145|NCT01284244|Experimental|Uresta|
3075146|NCT01284244|Sham Comparator|Silastic vaginal ring|
3075147|NCT01284296|Experimental|Digital block|
3075148|NCT01284335|Experimental|Gemcitabine plus LY573636|
3075149|NCT01284335|Experimental|Docetaxel plus LY573636|
3075150|NCT01284335|Experimental|Temozolomide plus LY573636|
3075151|NCT01284335|Experimental|Cisplatin plus LY573636|
3075152|NCT01284335|Experimental|Erlotinib plus LY573636|
3075153|NCT01284361|Experimental|30 cm Intermittent Catheter|Intervention was the test of a 30 cm catheter compared to standard commercial 40 cm catheter in a cross-over design.
3075154|NCT01284361|Active Comparator|40 cm Intermittent Catheter|Active comparator 40 cm commercial catheter was compared to experimental 30 cm catheter in a cross-over design.
3075155|NCT01284426||Chronic urticaria|Chronic urticaria, Natural history
3075156|NCT01284517|Experimental|Lurasidone 20-120 mg flexible dose|
3075157|NCT01284517|Placebo Comparator|Placebo|
3075158|NCT01284621|Experimental|BI 10773|1 tablet per days for 5 days, oral administration with 240 mL water for each treatment
3075159|NCT01284621|Other|Ramipril|1 tablet on day 1 and 2 tablets per day on day 2-5, oral administration with 240 mL water for each treatment
3075160|NCT01284621|Other|BI 10773 + Ramipril|1 tablet BI 10773 and 1 tablet on day 1 and 2 tablets ramipril per day on day 2-5, oral administration with 240 mL water for each treatment
3075161|NCT01284634|Experimental|GWP42003 200 milligrams (mg)/day Dose|Participants self-administered one x 100 mg GWP42003 capsule twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3075162|NCT01284634|Experimental|GWP42003 400 mg/day Dose|Participants self-administered two x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3075163|NCT01284634|Experimental|GWP42003 800 mg/day Dose|Participants self-administered four x 100 mg GWP42003 capsules twice daily for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]).
3075164|NCT01284634|Experimental|Placebo|Participants self-administered one, two or four placebo capsules twice daily, for 8 weeks (the first dose was 30 minutes before breakfast [fasted] and the second was 30 minutes before the evening meal [typically 12 hours apart]). Each capsule exactly matched the GWP42003 capsules in terms of appearance, size, smell and taste.
3075165|NCT01284959|Experimental|risperidone|Drug: risperidone 3mg, PO two times Groups: risperidone
3075166|NCT01284959|Placebo Comparator|placebo|drug: lactose, PO 3 times group: placebo
3075167|NCT01284959|Experimental|paliperidone ER|drug : Paliperidone ER 6mg PO, two times group: paliperidone ER
3075168|NCT01285024|No Intervention|Control|No Vitagel used during total hip arthroplasty
3075169|NCT01285024|Experimental|Vitagel|Vitagel applied just prior to closure during total hip arthroplasty
3075170|NCT01285050|Other|pre post ART|HCV and HIV viral load pre and post antiretroviral therapy (ART). ART is the intervention and the comparison is the HIV and HCV viral load reductions as determined by RT-PCR after administration of interferon alfa in each instance (before and after ART)
3075171|NCT01285076||All Enrolled Participants|Adults with Type 2 DM ≥30 years of age who have been treated with SU monotherapy or SU + MF combination therapy for at least 6 months by a cardiologist, nephrologist, neurologist, or family practice doctor.
3075172|NCT01285310|Experimental|Apremilast 30 mg|
3075173|NCT01285310|Experimental|Apremilast 20 mg|
3075174|NCT01285310|Placebo Comparator|Placebo|
3075175|NCT01285323|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3075176|NCT01285323|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3075177|NCT01285349|Experimental|Couple-based HIV prevention|7-session couple-based HIV/STI risk reduction intervention (CSTI)
3075178|NCT01285349|Active Comparator|Individual HIV/STI Prevention|7-session individual HIV/STI intervention comparison condition (ISTI) provided to the index participant alone, which is identical in content to the CSTI.
3075179|NCT01285349|Placebo Comparator|Couple Wellness Promotion|7-session couple-based stress reduction intervention (CSR) that serves as an attentional control condition.
3075180|NCT01285401|Experimental|VigantOL® oil|VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
3075181|NCT01285401|Placebo Comparator|Placebo|Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L
3075182|NCT01285401|Experimental|Rebif|Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L
3075183|NCT01285427||DNA loci (SeCore vs. SSP UniTray platforms)|
3075184|NCT01285492|Experimental|QVA149|QVA149 110/50 μg once a day (o.d)
3075185|NCT01285492|Active Comparator|Tiotropium|tiotropium 18 μg o.d.
3075186|NCT01285518|Experimental|Treatment|
3075187|NCT01285518|Placebo Comparator|Placebo|0.9% w/v sodium chloride injection, USP
3075188|NCT01285609|Experimental|Ipilimumab + Paclitaxel and Carboplatin|"Ipilimumab + Active Chemo Backbone~Ipilimumab: IV solution, intravenous (IV), 10 mg/kg, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
3075189|NCT01285609|Placebo Comparator|Placebo + Paclitaxel and Carboplatin|"Placebo + Active Chemo Backbone~Placebo: IV solution, IV, 0.9% sodium chloride or 5% dextrose, 90 minute infusion, Once every 3 weeks for 4 doses and then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)~Paclitaxel: IV solution, IV, 175 mg/m², 3 hour infusion, Once every 3 weeks for 6 doses~Carboplatin: IV solution, IV, Area Under the Curve (AUC) = 6, 30 minute infusion, Once every 3 weeks for 6 doses"
3075190|NCT01285635|Active Comparator|Docetaxel Alone|
3075191|NCT01285635|Experimental|Pulse Dose AT-101 Arm|
3075192|NCT01285635|Experimental|Metronomic AT-101 Arm|
3075193|NCT01285713|Experimental|5% Dextrose (D5) in Normal Saline (NS)|10cc/kg D5NS, followed by 30cc/kg NS
3075194|NCT01285713|Active Comparator|Normal Saline (NS)|10cc/kg NS, followed by 30cc/kg NS
3075195|NCT01285791||patients undergoing laparoscopic adjustable gastric banding|morbid obese patients undergoing laparoscopic adjustable gastric banding will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased.
3075196|NCT01285791||patients undergoing laparoscopic sleeve gastrectomy|morbid obese patients undergoing laparoscopic sleeve gastrectomy will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
3075197|NCT01285791||patients undergoing laparoscopic gastric bypass|morbid obese patients undergoing laparoscopic gastric bypass will be evaluated by ultrasound before surgery and one year after surgery to determine the amount of visceral fat layer decreased
3075198|NCT01285843|Active Comparator|Quadra Group|
3075199|NCT01285843|Active Comparator|AMIStem Group|
3075200|NCT01285908|No Intervention|Baseline|Baseline values measured at various tilt angles, so that each participant may serve as their own control.
3075201|NCT01285908|Placebo Comparator|Saline infusion|Subjects received a saline IV infusion as a placebo, while measurements were taken at various tilt angles.
3075202|NCT01285908|Active Comparator|Norepinephrine Infusion|Subjects were given an norepinephrine infusion at various tilt angles, while measurements were taken.
3075205|NCT01285960|Experimental|ExAblate treatment UF V2|ExAblate MRgFUS Treatment
3075206|NCT01286012|Active Comparator|SFP in liquid bicarbonate|
3075207|NCT01286012|Placebo Comparator|Placebo: Conventional Liquid Bicarbonate|Control concentrate lacking SFP does not contain SFP (total iron = 0)
3075208|NCT01286077|Experimental|bortezomib|bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles
3075209|NCT01286077|No Intervention|Non-treated control|no treatment, observation only
3075210|NCT01286129|Active Comparator|Allergic asthmatic|Subjects with allergic asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
3075211|NCT01286129|Active Comparator|Allergic rhinitic without asthma|Subjects with allergic rhinitis without asthma will undergo nasal allergen provocations with either house dust mite or cat pelt.
3075212|NCT01286168|Experimental|Antisepsis Side|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days. The drainage bulb will be irrigated with 10ml of 0.125% sodium hypochlorite (Dakin's solution) twice a day.
3075213|NCT01286168|Other|Control Side|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
3075214|NCT01286207|Experimental|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
3075215|NCT01286207|Experimental|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
3075216|NCT01286207|Active Comparator|Standard Care|Standard care at onset of migraine attack
3075217|NCT01286259|Experimental|Intervention Arm|
3075218|NCT01286311|Experimental|Direct-to-patient tailored cardiovascular risk message system|Eligible patients cared for by physicians randomized to the active intervention group will be mailed a tailored cardiovascular risk message.
3075219|NCT01286311|No Intervention|Control|
3075220|NCT01286324|Experimental|Chamomile High Grade Extract|Each capsule contains 90 mg dry extract of chamomile flowering tops [6:1 (v/v) extraction solvent (ethanol 70%/30% water): flowering tops] standardized up to 2.5 mg of (-)-α-bisabolol and ≥ 2.5 mg of apigenin per tablet
3075221|NCT01286324|Placebo Comparator|Placebo Tablet|Contained lactose
3075222|NCT01286402|Experimental|Bupropion SR (sustained release)|Group receiving bupropion SR medication
3075223|NCT01286402|Placebo Comparator|Placebo|
3075224|NCT01286441|Placebo Comparator|Placebo|Placebo for East Indian Sandalwood Oil ointment administered topically twice daily
3075225|NCT01286441|Active Comparator|10% EISO|East Indian Sandalwood Oil ointment, 10% (w/w), applied topically twice daily
3075226|NCT01286441|Active Comparator|20% EISO|East Indian Sandalwood Oil ointment, 20% (w/w), applied topically twice daily
3075227|NCT01286441|Active Comparator|30% EISO|East Indian Sandalwood Oil ointment, 30% (w/w), applied topically twice daily
3075228|NCT01286454|Experimental|A|4 mg fesoterodine IR beads in capsule under fasting condition
3075229|NCT01286454|Experimental|B|4 mg fesoterodine 10% coated ER beads in capsule under fasting condition
3075230|NCT01286454|Experimental|C|4 mg fesoterodine 15% coated ER beads in capsule under fasting condition.
3075231|NCT01286454|Experimental|D|4 mg fesoterodine 20% coated ER beads in capsule under fasting condition.
3075232|NCT01286454|Experimental|E|4 mg fesoterodine ER tablets under fasting condition.
3075233|NCT01286454|Experimental|F|4 mg fesoterodine TBD % coated ER beads in capsule under fed condition.
3132391|NCT03423082|Experimental|18F fluciclovine PET scan|Subjects with recently biopsy-proven malignancy of the cervix or uterus undergo an 18F fluciclovine PET scan on a hybrid PET/MRI scanner after they have completed a standard-of-care F-18 FDG PET/CT study.
3132392|NCT03423173|Placebo Comparator|Placebo|TDV placebo matching injection, subcutaneously (SC) once on Day 1, and Day 90.
3132393|NCT03423173|Experimental|TDV Lot 1|Participants were administered TDV lot 1, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
3132394|NCT03423173|Experimental|TDV Lot 2|Participants were administered TDV lot 2, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection, once on Day 1, and Day 90.
3075234|NCT01286480|Experimental|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
3075235|NCT01286480|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies. Time-pressured clinic visits limit the opportunity to discuss many of the topics noted above.
3075236|NCT01286493|Experimental|Rabies vaccines on day 0 and 3|Cell culture Rabies vaccines on day 0 and 3
3075237|NCT01286558|Experimental|80mg telmisartan and 5mg amlodipine FDC|once daily
3075238|NCT01286558|Active Comparator|40mg telmisartan and 5mg amlodipine FDC|once daily
3075239|NCT01286740|Experimental|FTC/RPV/TDF|Participants switched from their existing treatment regimen of EFV/FTC/TDF to the FTC/RPV/TDF STR.
3075240|NCT01286753|Experimental|Tyrosine Kinase Inhibitor (TKI) Naive|Vemurafenib in participants naive to any prior systemic TKI therapy.
3075241|NCT01286753|Experimental|TKI Experienced|Vemurafenib in participants previously treated with TKI therapy active against vascular endothelial growth factor receptor 2 (VEGFR).
3075242|NCT01286779|Experimental|BAX 326|
3075243|NCT01286805|Experimental|Lumbar Plexus Blockade + CSE|The study group will receive a lumbar plexus blockade with 30 mL of 0.25% bupivacaine with 1:200,000 epinephrine, followed by a combined spinal-epidural.
3075244|NCT01286805|Placebo Comparator|Control Group|The control group will receive only a combined spinal-epidural.
3075245|NCT01286818|Experimental|FOLFIRI plus Ramucirumab (IMC-1121B)|
3075246|NCT01286870|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
3075247|NCT01286987|Experimental|Talazoparib|
3075248|NCT01287013|Other|Cone Beam CT|Procedure performed with Xperguide cone-beam Computed Tomography (CT) navigation
3075249|NCT01287013|Other|Conventional CT|Procedure performed with Conventional Computed Tomography (CT) image guidance
3075250|NCT01287039|Placebo Comparator|Placebo|Placebo administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3075251|NCT01287039|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for a total of 13 doses.
3075252|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - AM dosing|FF(100mcg)/Vilanterol(25mcg) in the morning (approx 09.00) for 14 days (± 2 days).; placebo in evening (approx 21.00) for 14 days (± 2 days).
3075253|NCT01287065|Experimental|FF(100mcg)/Vilanterol(25mcg) - PM dosing|Placebo in morning (approx 09.00) for 14 days (± 2 days); FF(100mcg)/Vilanterol(25mcg) in evening (approx 21.00) for 14 days (± 2 days).
3075254|NCT01287065|Placebo Comparator|Placebo|Placebo given in morning (approx 09.00) and in evening (approx (21.00) for 14 days (± 2 days).
3075255|NCT01287078|Experimental|Inhaled Cyclosporine in Lung Transplant and HSCT Recipients|Subjects with Bronchiolitis Obliterans Syndrome (BOS) received cyclosporine inhalation solution (CIS) 150 mg, three times weekly during weeks 1-5. Dose escalated to 300 mg three times weekly from weeks 6-8. Study drug administration ended at week 19.
3075256|NCT01287104|Experimental|Pre-Bone Marrow Transplant (BMT) Prep Regimen|Pre-bone marrow transplant (BMT) Prep Regimen with Stem Cell and natural killer (NK) Cell Infusions coupled with Induction therapy
3075257|NCT01287117|Placebo Comparator|Placebo|Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
3075258|NCT01287117|Experimental|Omalizumab 75 mg|Participants received omalizumab 75 mg subcutaneously every 4 weeks during the 24 week treatment period.
3075259|NCT01287117|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 24 week treatment period.
3075260|NCT01287117|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
3075261|NCT01287195|Experimental|Oral OKT3|Participants with ulcerative colitis will receive Oral OKT3 given with Omeprazole once daily for 30 days.
3075262|NCT01287208|Active Comparator|Unblinded activity monitor|Subjects wear the activity device and can see the data on the device and on a website where the data is uploaded.
3075263|NCT01287208|Placebo Comparator|Blinded activity monitor|Subjects wear a blinded activity device and cannot see the activity on the device and cannot log on to the website where the data gets uploaded.
3075264|NCT01287221|Active Comparator|Rifampicin|Subjects randomized to this arm will receive 300 mg Rifampicin two times a day for 12 months.
3075265|NCT01287221|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo capsules twice daily for 12 months. The capsules will contain riboflavin (vitamin B2).
3075266|NCT01287364|Experimental|ciclesonide HFA followed by mometasone|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily in first intervention period, followed by a 7-14 day washout period, after which the second intervention of mometasone nasal inhalation 200 μg once daily will be administered.
3075267|NCT01287364|Active Comparator|mometasone followed by ciclesonide HFA|mometasone nasal inhalation 200 μg once daily in first intervention period followed by a 7-14 day washout period after which the second intervention of ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily will be administered
3075268|NCT01287377|Experimental|Pre-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients will be encouraged to start using these patches PRIOR to their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
3075269|NCT01287377|Active Comparator|Post-Patch and Telephone Counseling|"Nicotine patches (2 weeks' worth) are mailed directly to the subject. Clients are encouraged to start using their patches ON their quit date.~Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls."
3075270|NCT01287377|Active Comparator|Telephone Counseling and no patches sent|Counseling includes a comprehensive pre-quit session (to include motivation, planning, discussion of nicotine patch use, and setting of a quit date) and up to 4 proactive follow-up calls.
3075271|NCT01287403|Placebo Comparator|Refined wheat flour|A negative control flour to serve as a reference.
3075272|NCT01287403|Active Comparator|Esterase wholegrain wheat flour|Wholegrain wheat flour treated with esterases to release phenolics (positive control for phenolic acids)
3075273|NCT01287403|Experimental|Wholegrain wheat flour|Flour with unknown response
3075274|NCT01287403|Experimental|Liquid whole grain wheat flour|Test flour with unknown response.
3075275|NCT01287403|Experimental|Wholegrain barley flour|Test flour with unknown response.
3075276|NCT01287403|Experimental|Liquid wholegrain barley flour|Test flour with unknown response.
3075277|NCT01287416|Experimental|Applied Suicide Intervention Skills Training (ASIST)|"ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The training is designed for anyone (especially those in a position of trust), from professionals and volunteers to members of the community. Participants range from those in caring roles to people concerned about family members or friends. The theory is that suicide can be pre¬vented with the help of prepared caregivers. ASIST is designed to help all caregivers become more willing, ready and able to help persons at risk. Just as CPR skills make physical first aid possible, training in suicide intervention develops the skills used in suicide first aid."
3075278|NCT01287416|Active Comparator|Resilience Retreat|The two days will be divided into cultural activities, sharing circles, small group discussions, story telling and dance. Two First Nations community leaders will be identified to lead each of the two retreats.
3075279|NCT01287520|Experimental|LY2090314/pemetrexed/carboplatin|"Part A, Cycle 1 (28 days): Intravenous doses of LY2090314 starting at 10 milligram (mg) were given on Day 1 followed by 10 mg LY2090314, 500 milligram per square meter (mg/m^2) pemetrexed (intravenous dose), and 5 or 6 area under the concentration-time curve (AUC) intravenous dose of carboplatin on Day 8.~Part A, Cycle 2 (21 days): Pemetrexed and carboplatin given on Day 1 at the same dose administered in Cycle 1.~Part A, Cycle 3 (21 days) and beyond: LY2090314, Pemetrexed and carboplatin were given on Day 1 at the same dose administered in Cycle 1. LY2090314 doses were escalated until the maximum tolerated dose (MTD) was reached.~Part B: Dose determined in Part A was administered. Participants were allowed to continue the combination treatment if they were receiving therapeutic benefit until they fulfilled one of the criteria for discontinuation."
3075280|NCT01287611|Active Comparator|Purse string closure technique|Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
3075281|NCT01287611|Active Comparator|Continuously locked closure technique|Eighty four patients were allocated to the control group. Due to expanded Kerr incisions 3 patients in control group did not receive their allocated intervention. In addition, 16 patients in the control group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 65 study group.
3320965|NCT02015117|Experimental|Cohort A (trametinib, whole-brain radiation therapy)|Patients receive trametinib PO QD for 4 weeks. Beginning in week 2, patients undergo whole brain radiation therapy five days a week for 3 weeks. Treatment continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
3320966|NCT02015117|Experimental|Cohort B (trametinib, surgery)|Patients receive trametinib PO QD on days 1-14 followed by surgical resection of the tumor.
3075284|NCT01287754|Experimental|Single Arm|
3075285|NCT01287832|Active Comparator|High dose vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
3075286|NCT01287832|Experimental|High-dose daptomycin|Daptomycin dosed at 8 mg/kg/daily (every 48 hours in end-stage renal disease)
3075287|NCT01287897|Placebo Comparator|Placebo- SC injection|
3075288|NCT01287897|Experimental|Drug Dose level 1 - SC injection|
3075289|NCT01287897|Experimental|Drug Dose level 2 - SC injection|
3075290|NCT01288027|Experimental|Alglucosidase Alfa|
3075291|NCT01288053|Experimental|Allogeneic Stem Cell Therapy|Allogeneic Stem Cell Therapy will be performed after conditioning
3075292|NCT01288079|Experimental|1|TC-5214, 1 mg BID
3075293|NCT01288079|Experimental|2|TC-5214, 4 mg BID
3075294|NCT01288079|Active Comparator|3|Duloxetine 60 mg Q Day
3075295|NCT01288079|Placebo Comparator|4|Placebo
3075296|NCT01288209|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3075297|NCT01288209|Experimental|TMC435 100 mg 24 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin ( PR) for 24 weeks (Wks). Treatment will be stopped at Week 24 if participants achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3320967|NCT02015130|Experimental|individual treatment|Individualized treatment
3320968|NCT02015130|No Intervention|control group|treatment according to current national guidelines
3320969|NCT02015143||Bipolar Disorder|
3320970|NCT02015143||Unipolar Disorder|
3075298|NCT01288287||Week 12 Disease Activity Score (DAS) Responders|Patients achieving a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
3075299|NCT01288287||Week 12 Disease Activity Score (DAS) Non-Responders|Patients who fail to achieve a reduction from Baseline in a Disease Activity Score 28-joint count (Erythrocyte Sedimentation Rate) [DAS28(ESR)] score of greater than 1.2 points at Week 12
3075300|NCT01288430|Experimental|DS-2248|"Study Part 1: DS-2248 oral capsule(s) of increasing strength in a dose escalation study in subjects with advanced solid tumors, administered once daily in 21-day cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression is observed.~Study Part 2: DS-2248 oral capsule(s) dose of 4.5 mg/m^2, in subjects with non-small cell lung cancer who have developed acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors or whose tumors carry an ALK translocation and are resistant to ALK inhibitor therapy, administered once daily in 21 day-cycles, with no interruption between cycles if no unacceptable treatment-related toxicity or tumor progression are observed."
3075301|NCT01288443|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
3075302|NCT01288443|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3075303|NCT01288443|Experimental|Alirocumab 100 mg Q2W|Alirocumab 100 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3075304|NCT01288443|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3075305|NCT01288443|Experimental|Alirocumab 200 mg Q4W|Alirocumab 200 mg every 4 weeks (Q4W) and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
3075306|NCT01288443|Experimental|Alirocumab 300 mg Q4W|Alirocumab 300 mg Q4W and alternating placebo Q2W for 12-weeks in combination with atorvastatin stable dose.
3075307|NCT01288469|Placebo Comparator|Placebo + Atorvastatin 80 mg|Placebo (for alirocumab) subcutaneous (SC) administration every 2 weeks (Q2W) in combination with atorvastatin 80 mg orally once daily for 8 weeks.
3075308|NCT01288469|Experimental|Alirocumab + Atorvastatin 10 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 10 mg orally once daily for 8 weeks.
3075309|NCT01288469|Experimental|Alirocumab + Atorvastatin 80 mg|Alirocumab 150 mg SC administration Q2W in combination with atorvastatin 80 mg orally once daily for 8 weeks.
3075310|NCT01288521|Experimental|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Participants first received tacrolimus in combination with with ketoconazole. After a 1-2 week washout they received tacrolimus alone.
3075311|NCT01288521|Experimental|Tacrolimus alone, Then Tacrolimus + Ketoconazole|The participants first received tacrolimus alone. After a 1-2 week washout period they received tacrolimus in combination with ketoconazole.
3075312|NCT01288534|Experimental|Radiation Treatment|
3075313|NCT01288612|Active Comparator|Sedated Endoscopy|Sedated esophagogastroduodenoscopy with biopsy
3075314|NCT01288612|Active Comparator|Transnasal Endoscopy at Hospital Unit|Unsedated transnasal endoscopy at hospital unit.
3075315|NCT01288612|Active Comparator|Transnasal Endoscopy at Mobile Unit|Unsedated transnasal endoscopy in mobile research van
3075316|NCT01288729|Experimental|Group 1 - Steel Cathetar, then Teflon|Participants will alternate between wearing the Sure-T Steel Infusion Set Catheter for 7 days, then the Quick-Set Teflon for 7 days.They will wear each set twice starting with the Sure-T Steel Infusion Set.
3075317|NCT01288729|Experimental|Group 2 - Teflon Cathetar, the Steel|Participants will alternate between wearing the Quick-Set Teflon catheter for 7 days, then the Quick-Set Teflon for 7 days. They will wear each set twice starting with the Quick-Set Teflon set.
3075318|NCT01288781|Experimental|Acetazolamide|Arm 1: ACETAZOLAMIDE (250mg) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
3075319|NCT01288781|Placebo Comparator|Placebo|Placebo (LACTOSE MONOHYDRATE) will be given to subjects at fifteen, twenty and thirty two hours post hypoxic exposure (3777m).
3075320|NCT01288807|Experimental|Treatment|Titrated Milnacipram doses
3075321|NCT01288833|Experimental|Close focus HD NBI Colonoscopy System|Use of close focus to make optical diagnosis
3075322|NCT01288833|No Intervention|Current HD NBI Colonoscopy System|Use of standard focus for optical diagnosis
3075323|NCT01288859|Experimental|encapsulated curcumin|
3075324|NCT01288859|Experimental|encapsulated curcumin + PQG|PQG means Piperine, Quercetin and Genistein
3075325|NCT01288859|Active Comparator|free cocoa polyphenol|
3075326|NCT01288859|Placebo Comparator|control|
3075327|NCT01288859|Experimental|encapsulated cocoa polyphenols|
3075328|NCT01288859|Active Comparator|free curcumin|Subjects will consume bread added with free curcumin
3075329|NCT01288911|Experimental|Enzalutamide|Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
3075330|NCT01288911|Active Comparator|Bicalutamide|Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.
3075331|NCT01288937|Experimental|Milnacipran|Patients will receive Milnacipran
3075332|NCT01288937|Placebo Comparator|Placebo|Patients will receive Placebo
3075333|NCT01288976||MitraClip Therapy|Patients treated with the MitraClip System.
3075334|NCT01288976||Medical Management|Patients with MR managed non-surgically based on standard hospital clinical practice.
3075335|NCT01288976||Mitral Valve Surgery|Patients with MR managed surgically (repair or replacement) based on standard hospital clinical practice.
3075336|NCT01288989|Experimental|IMC-3C5|Participants receiving IMC-3C5 intravenously
3075337|NCT01289015|Experimental|NAFT-600 ( naftin 2 % gel)|
3075338|NCT01289015|Placebo Comparator|Placebo|
3075339|NCT01289028|Experimental|Nilotinib|nilotinib 400 mg twice daily (bid).
3075340|NCT01289041|Experimental|All Patients|
3075341|NCT01289067|Other|Satraplatin, Single Arm|
3075342|NCT01289080|Active Comparator|Group 1|subjects with normal renal function
3075343|NCT01289080|Active Comparator|Group 2|severely renally impaired subjects
3320971|NCT02015156|Experimental|PF-05280014|
3075344|NCT01289119|Placebo Comparator|Placebo|Participants received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3075345|NCT01289119|Experimental|Alogliptin Monotherapy|Participants received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
3075346|NCT01289119|Other|Metformin|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3075347|NCT01289119|Experimental|Metformin + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of metformin (≥1000 mg/day) and also received alogliptin 25 mg tablets, orally, once daily for up to 16 weeks.
3075348|NCT01289119|Other|Pioglitazone|Participants continued to receive their stable dose of pioglitazone with or without metformin, and also received alogliptin placebo-matching tablets, orally once daily for up to 16 weeks.
3075349|NCT01289119|Experimental|Pioglitazone + Alogliptin Add-on Therapy|Participants continued to receive their stable dose of pioglitazone with or without metformin and also received alogliptin, 25 mg tablets orally once daily for up to 16 weeks.
3075350|NCT01289210|Other|VTX-2337 plus radiation|
3075351|NCT01289275|Experimental|Telephone Counseling|Up to 5 proactive counseling sessions
3075352|NCT01289275|Experimental|Nicotine Patches|8 weeks of nicotine patches
3075353|NCT01289275|Experimental|Telephone Counseling + Patches|5 proactive sessions, 8 weeks patches
3075354|NCT01289275|Active Comparator|Brief hospital counseling|brief in hospital counseling, no proactive sessions or patches
3075355|NCT01289353|Experimental|ChemoRT|Concurrent Carboplatin and Radiotherapy
3075356|NCT01289392|Active Comparator|Continuous Positive Airway Pressure (CPAP)|CPAP is the gold standard treatment
3075357|NCT01289392|Active Comparator|Oral Appliance|Alternative treatment for obstructive sleep apnea patients
3075358|NCT01289392|Active Comparator|Physical Exercise|Aerobic and resistance physical exercises
3075359|NCT01289418||Health care workers in Québec|Health care workers from CHUQ hospitals
3075360|NCT01289418||Health care workers in Toronto|Health care workers from the Mount Sinai Hospital
3075361|NCT01289418||Health care workers in Halifax|Health care workers from the Queen Elizabeth Hospital
3075362|NCT01289431|Experimental|Mapracorat|
3075363|NCT01289431|Placebo Comparator|Mapracorat Vehicle|
3075364|NCT01289457|Experimental|Clofarabine + Idarubicin + Cytarabine|Phase I: Clofarabine Starting dose 15 mg/m2 by vein for 5 days (days 1-5) + Idarubicin 10 mg/m2 by vein on day 1-3 + Cytarabine 1 g/m2 by vein on day 1-5.
3075365|NCT01289457|Experimental|Group 1 CIA|Phase II, Group 1 CIA (Clofarabine + Idarubicin + Cytarabine): Clofarabine Maximum Tolerated Dose (MTD) based on Phase I by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
3075366|NCT01289457|Experimental|Group 2 FLAI|Phase II, Group 2 FLAI (Fludarabine + Idarubicin + Cytarabine): Fludarabine 30 mg/m2 by vein on days 1-5; Idarubicin 10 mg/m2 by vein on days 1-3; Cytarabine 1 g/m2 by vein on days 1-5.
3075367|NCT01289522|Experimental|cetuximab|Patients receive four cycles of chemotherapy comprising cetuximab IV plus docetaxel IV over 1 hour and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. After completion of the fourth cycle of chemotherapy, patients receive a maintenance therapy with cetuximab every 2 weeks. Treatment will be continued until disease progression or unacceptable toxicities according
3075368|NCT01289548|No Intervention|control|patients (both donors and recipients) had a deflated cuff placed on the left lower limb for 30 min
3075369|NCT01289548|Experimental|donor|Donors receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; recipients only have a deflated blood pressure cuff around their leg for 30 minutes.
3075370|NCT01289548|Experimental|recipient|recipients receive remote ischaemic preconditioning after anaesthesia induction and before surgery started; donors only have a deflated blood pressure cuff around their leg for 30 minutes.
3075371|NCT01289574|Placebo Comparator|Vehicle control cream|
3075372|NCT01289574|Experimental|0.025% ASC-J9 cream|
3075373|NCT01289574|Experimental|0.1% ASC-J9 cream|
3075374|NCT01289639|Placebo Comparator|Placebo|matching placebo 1 po qd
3075375|NCT01289639|Experimental|Fenofibrate|micronized fenofibrate 200 mg 1 po qd
3075376|NCT01289639|Experimental|Pioglitazone|pioglitazone 30 mg po qd
3075377|NCT01289665|Experimental|Lubricating Gel|
3075378|NCT01289665|Active Comparator|Water|
3075379|NCT01289678|Experimental|interleukin-2|interleukin-2 therapy during lymphocyte recovery
3075380|NCT01289782|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
3075381|NCT01289782|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks
3075382|NCT01289821|Experimental|Regorafenib + oxaliplatin/folinic acid/5-FU (mFOLFOX6)|On Day 1, participants received 85 mg/m^2 oxaliplatin as a 2-hour intravenous (IV) infusion and folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2-hour IV infusion. Once the initial infusion was completed, participants received 5-FU 400 mg/m^2 IV bolus injection immediately followed by a 5-FU 2400 mg/m^2 IV infusion for 46 hours. The next cycle of mFOLFOX6 was administered on Day 15 to 17. Participants received Regorafenib (Stivarga, BAY73-4506) 160 mg orally (po) once daily (qd) on Days 4 to 10 and Days 18 to 24. One cycle comprised 28 days.
3075383|NCT01289847|Experimental|Gammaplex|
3075384|NCT01289912|Experimental|RAD001|RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis.
3075385|NCT01289912|Placebo Comparator|Placebo|Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10.
3075386|NCT01289990|Experimental|BI 10773 low (drug naive)|BI 10773 tablets once daily
3075387|NCT01289990|Experimental|BI 10773 high (drug naive)|BI 10773 tablets once daily
3075388|NCT01289990|Placebo Comparator|Placebo (drug naive)|Placebo tablets matching BI 10773 / Sitagliptin once daily
3075389|NCT01289990|Active Comparator|Sitagliptin 100mg (drug naive)|Sitagliptin once daily
3075390|NCT01289990|Experimental|BI 10773 low (pioglitazone)|BI 10773 tablets once daily
3075391|NCT01289990|Experimental|BI 10773 high (pioglitazone)|BI 10773 tablets once daily
3075392|NCT01289990|Placebo Comparator|Placebo (pioglitazone)|Placebo tablets matching BI 10773 once daily
3075393|NCT01289990|Experimental|BI 10773 low (metformin)|BI 10773 tablets once daily
3075394|NCT01289990|Experimental|BI 10773 high (metformin)|BI 10773 tablets once daily
3075395|NCT01289990|Placebo Comparator|Placebo (metformin)|Placebo tablets matching BI 10773 once daily
3075396|NCT01289990|Experimental|BI 10773 low (metformin+sulfonylurea)|BI 10773 tablets once daily
3075397|NCT01289990|Experimental|BI 10773 high (metformin+sulfonylurea)|BI 10773 tablets once daily
3075398|NCT01289990|Placebo Comparator|Placebo (metformin+sulfonylurea)|Placebo tablets matching BI 10773
3075399|NCT01290029|Experimental|Cinacalcet|Participants received a single, oral dose of 0.25 mg/kg cinacalcet.
3075400|NCT01290068|Experimental|ReSTOR +3|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, bilateral implantation
3075401|NCT01290068|Experimental|ReSTOR +3 Toric|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative corneal astigmatism, bilateral implantation, or implanted in 1 eye with AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL in the other eye
3075402|NCT01290068|Active Comparator|Monofocal|Monofocal IOL, bilateral implantation
3075403|NCT01290094|Experimental|Single Arm|
3075404|NCT01290224|Experimental|Supportive Care|See Detailed Description
3075405|NCT01290237|Experimental|Vancomycin loading dose|Intervention: administer intravenous vancomycin 30 mg/kg/dose once, followed 8 hours later by 20 mg/kg/dose every 8 hours
3075406|NCT01290237|Active Comparator|Control|No intervention. Administer intravenous vancomycin 20 mg/kg/dose every 8 hours as per hospital guideline.
3075407|NCT01290263|Experimental|Amgen 386|Cohort A will assess recurrent Glioblastoma Multiforme (GBM) patients who receive AMG 386 monotherapy at 30mg/kg every week. As of August 1, 2013, Cohort A was closed to new accrual following early interim analysis of first 10 participants enrolled on study. None of these patients had achieved stable disease or response at their initial evaluation after 1-2 months of study therapy. Therefore, study investigators and sponsor agreed that the level of single-agent anti-tumor activity associated with AMG386 for recurrent glioblastoma patients is most likely insufficient to satisfy the stopping rule for low efficacy outlined in Section 14.5 for Cohort A.
3075408|NCT01290263|Experimental|Amgen 386 and Bevacizumab|Cohort B will assess recurrent Glioblastoma Multiforme(GBM) patients who receive AMG 386 plus bevacizumab. Because the maximum tolerated dose of this combination therapy has not yet been established, a 3x3 Phase I study was used to determine the maximum tolerated dose. As of June 6, 2014, the MTD was determined to be AMG386 30 mg/kg administered intravenously every week(dose level +1) in combination with bevacizumab at 10mg/kg administered intravenously every other week. As of July 25, 2014 the Cohort B, Phase II portion of the study was opened to accrual.
3075409|NCT01290315|Experimental|Ferric Carboxymaltose (FCM)|Intravenous iron
3075410|NCT01290315|Active Comparator|Iron Sucrose / Iron Dextran|Intravenous iron
3075411|NCT01290341|Experimental|NAFT-600 ( naftin 2 % gel)|Topical; applied once daily for two weeks
3075412|NCT01290341|Placebo Comparator|Placebo|Topical; applied once daily for two weeks.
3075413|NCT01290445||Exposed|Infants exposed in utero to varenicline
3075414|NCT01290445||Unexposed|infants exposed in utero to cigarette smoke from maternal smoking
3075415|NCT01290445||Reference|infants not exposed in utero to either varenicline or cigarette smoke from maternal smoking
3075416|NCT01290484|Experimental|Open Label|Sildenafil oral tablet three times daily
3075417|NCT01290523|Experimental|Yttrium-90 liver radioembolization|Patients who receive liver-directed therapy with Yttrium-90 glass microspheres (TheraSphere)
3075418|NCT01290536|Experimental|Yttrium-90 liver radioembolization|
3075419|NCT01290601|Experimental|Cohort 1 Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
3075420|NCT01290601|Active Comparator|Cohort 1-Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
3075421|NCT01290601|Experimental|Cohort 2 Tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
3075422|NCT01290601|Active Comparator|Cohort 2 Chloroquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
3075423|NCT01290614|Experimental|Pharmacist intervention|
3075424|NCT01290614|Active Comparator|Control - usual care|Patients assigned to control will continue to receive care from their VA provider.
3075425|NCT01290627||Knee Prosthesis LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
3075426|NCT01290627||Knee Prosthesis Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
3075427|NCT01290627||Control|Subjects with normal knees
3075428|NCT01290640||TC3 TKA|Subjects implanted with a DePuy fixed-bearing Total Condylar III (TC3) TKA
3075429|NCT01290640||PFC RP TC3 TKA|Subjects implanted with a DePuy PFC Rotating Platform TC3 TKA
3075430|NCT01290666||GORE® BIO-A® Fistula Plug|All patients in study receive the GORE® BIO-A® Fistula Plug.
3075431|NCT01290679|Experimental|TMC435|TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 24 or 48 weeks
3075432|NCT01290679|Placebo Comparator|Placebo|Placebo 150 mg capsule once daily for 12 weeks in addition peginterferon alfa-2a (Pegasys) or peginterferon alfa-2b (PegIntron) (PegIFN alpha-2a/b) and ribavirin (Copegus or Rebetol) for 48 weeks
3132395|NCT03423173|Experimental|TDV Lot 3|Participants were administered TDV lot 3, 0.5 ml (each TDV 0.5 mL dose contained TDV-1, TDV-2, TDV-3, and TDV-4), SC injection once on Day 1, and Day 90.
3132396|NCT03423186|Experimental|Dose group 1|SOBI003 dose 3 mg/kg once weekly for 24 weeks
3075433|NCT01290731|Experimental|TMC435 100 mg 12 Wks + PR24/48|Participants will receive TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24 (PR 24). Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels less than (<) 1.2 log10 IU/mL detectable or undetectable of at Week 4, and undetectable HCV RNA levels at Week 12. All other participants will continue PR until Week 48 (PR 48).
3075434|NCT01290757|Experimental|Dabigatran etexilate 150 mg (T)|Capsugel (T), oral administration
3075435|NCT01290757|Experimental|Dabigatran etexilate 150 mg (R)|Qualicaps (R), oral administration
3075436|NCT01290796|Other|Ajust Adjustable Single-Incision Sling|Urinary incontinence sling
3075437|NCT01290874|Experimental|Tiotropium|Tiotropium bromide will be evaluated as a treatment for asthma.
3075438|NCT01290874|Active Comparator|Salmeterol or Formoterol|Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.
3075439|NCT01290887|Experimental|Reslizumab 3.0 mg/kg|Reslizumab 3.0 mg/kg administered intravenously once every 4 weeks ( +-7 days) for up to 24 months.
3075440|NCT01290913|Experimental|omalizumab, oral desensitization|Patients receive omalizumab along with oral peanut desensitization.
3075441|NCT01290952|Experimental|Off-pump bypass surgery|Off-pump coronary artery bypass graft (OPCAB) using mandatory a stabilization device and advisable, but not mandatory, a heart positioner
3075442|NCT01290952|Active Comparator|On-pump bypass surgery|coronary artery bypass graft with cardiopulmonary bypass (CPB/CAB)
3075443|NCT01290978|Active Comparator|ChloraPrep|Applied ChloraPrep on the application site per manufacturer's instruction
3075444|NCT01290978|Active Comparator|DuraPrep|Apply DuraPrep to the application site per manufacturer's instruction
3075445|NCT01291017|Experimental|PD0332991|PD0332991 125 mg PO days 1 - 21
3075446|NCT01291056|Active Comparator|Clomphine|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
3075447|NCT01291056|Placebo Comparator|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
3075448|NCT01291108|Experimental|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1.
3075449|NCT01291108|Experimental|AGN-210669 + bimatoprost|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% applied as 1 drop of each treatment in both eyes every evening during Month 2.
3075450|NCT01291108|Experimental|AGN-210669 + bimatoprost vehicle|AGN-210669 0.05% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
3075451|NCT01291108|Active Comparator|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1.
3075452|NCT01291108|Experimental|bimatoprost + AGN-210669|bimatoprost ophthalmic solution 0.03% + AGN-210669 0.05% applied as 1 drop of each treatment in both eyes every evening during Month 2.
3075453|NCT01291108|Other|bimatoprost + bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% + bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop of each treatment in both eyes every evening during Month 2.
3075454|NCT01291160|Experimental|Epiflo Treatment|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. The Treatment Arm includes subjects with DFU who will receive EPIFLO in addition to standard wound care therapy during the Treatment Period.
3075455|NCT01291160|Sham Comparator|Sham Device|The cohort will comprise of 2 populations: the Treatment Arm of up to 90 subjects; and the Control Arm of up to 90 subjects, in order to collect 120 invaluable subjects. Control Arm includes subjects with Diabetic Foot Ulcers who will receive sham units of EPIFLO along with standard wound care therapy during the treatment Period.
3075456|NCT01291173|Experimental|SPD489 30 mg|
3075457|NCT01291173|Experimental|SPD489 50 mg|
3075458|NCT01291173|Experimental|SPD489 70 mg|
3075459|NCT01291173|Placebo Comparator|Placebo|
3075460|NCT01291225|Other|Playground|"The playground arm of the study will consist of playground audits and KAP surveys about playground safety in both Chillicothe and Circleville, Ohio.~The intervention is Playground Safety Renovations and Development."
3075461|NCT01291225|Other|Farms|The Farm Arm will consist of farm audits with safety checklists and KAP surveys about farm safety. The intervention is a Safety Educational Campaign.
3075462|NCT01291277|Active Comparator|Ligation: 1-week interval|Endoscopic variceal ligation performed at 1-week intervals
3075463|NCT01291277|Active Comparator|Ligation 2-week interval|Endoscopic variceal ligation performed at 2-week intervals
3075464|NCT01291498|Other|HIFU Treatment|High Intensity Focused Ultrasound. This is not a comparative study
3075465|NCT01291784|Experimental|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
3075466|NCT01292005|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
3075467|NCT01292005|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
3075468|NCT01292057|Active Comparator|Aripiprazole|Medication
3075469|NCT01292057|Placebo Comparator|Sugar pill|
3075470|NCT01292135|Experimental|PCI-32765 plus fludarabine/cyclophosphamide/rituximab (FCR)|
3075471|NCT01292135|Experimental|PCI-32765 plus bendamustine/rituximab (BR)|
3075472|NCT01292187|Experimental|Oral calcitonin at dinner-or bedtime|Intervention: Oral calcitonin at dinnertime or oral calcitonin at bedtime. Postmenopausal subjects with osteopenia were treated for one year (also with vitamin D and calcium supplements) to determine if oral calcitonin tablets would prevent the loss of bone mineral density compared with placebo. Randomization to active or placebo was done 2:1. After randomization, further randomization was done to divide each arm into two groups, one in which dosing was at dinnertime and the other in which dosing was at bedtime to determine if food affected efficacy or safety.
3075473|NCT01292187|Experimental|Oral placebo at dinner- or bedtime|Intervention: oral placebo at dinnertime or oral placebo at bedtime
3132397|NCT03423186|Experimental|Dose group 2|SOBI003 dose 10 mg/kg once weekly for 24 weeks
3075474|NCT01292226|Experimental|Mycophenolate Mofetil Monotherapy|Participants received an initial dose of mycophenolate mofetil (MMF), 1 gram (g), orally (PO), twice per day (BID), within 5 days of transplant for 24 weeks. Participants also received concurrent antibody induction, cyclosporine, and corticosteroids as needed according to center's practice.
3075475|NCT01292239|Experimental|TMC435 100 mg 12 Wks + PR 24/48|Participants received TMC435 100 mg once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment was stopped at Week 24 for participants who achieved HCV RNA < 1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable HCV RNA at Week 12. All other participants continued PR until Week 48.
3075476|NCT01292239|Experimental|PBO 12 Wks + PR 48|Participants received placebo (PBO) once daily with PegIFNα-2a and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
3075477|NCT01292252|Experimental|Treatment|Forteo, Terapeptide 20 ug subcutaneous injection
3075478|NCT01292252|Placebo Comparator|Control|Saline placebo
3075479|NCT01292304|Experimental|Tolvaptan|Tolvaptan 15 mg tablet once daily for 7 days followed by Tolvaptan 30 mg (two 15 mg tablets) once daily according to efficacy and tolerability
3075480|NCT01292447|Placebo Comparator|Control Group|Will receive placement of inert glycerin gel on ectocervix and in cervical canal prior to IUD placement.
3075481|NCT01292447|Experimental|Study Group|Will receive placement of 2% lidocaine gel on ectocervix and in cervical canal prior to IUD placement.
3075482|NCT01292473|Experimental|Placebo|Placebo subcutaneously (sc) every 4 weeks
3075483|NCT01292473|Experimental|Omalizumab 75 mg|Omalizumab 75 mg sc every 4 weeks
3075484|NCT01292473|Experimental|Omalizumab 150 mg|Omalizumab 150 mg sc every 4 weeks
3075485|NCT01292473|Experimental|Omalizumab 300 mg|Omalizumab 300 mg sc every 4 weeks.
3075486|NCT01292486|Experimental|Patients with multiple myeloma|Multiple myeloma patients who receive autologous stem-cell transplants, collected using the Spectra Optia Apheresis System, following myeloablative therapy. The study is limited to subjects who are expected demonstrate normal neutrophil recovery.
3075487|NCT01292538|Experimental|Erchonia GLS 532nm|532nm green laser light therapy.
3075488|NCT01292538|Sham Comparator|Placebo laser|Sham light output with no therapeutic benefit
3075489|NCT01292603|Experimental|1|
3075490|NCT01292603|Experimental|2|
3075491|NCT01292603|Experimental|3|
3075492|NCT01292629|Experimental|Investigational intraocular lens|iSert 251 intraocular lens
3075493|NCT01292642|Experimental|Treatment|Cognitive behavioral therapy (CBT) plus transdermal patch nicotine replacement therapy (NRT) to treat co-occurring nicotine and cannabis dependence during a 10-week study.
3075494|NCT01292746|Experimental|Erchonia ML Scanner (MLS)|Erchonia MLS employs four diodes emitting 10 milliwatts (mW) 635 nanometer (nm) red laser light
3075495|NCT01292798|Experimental|0.5mg and 2.0mgRanibizumab|Three consecutive intravitreal ranibizumab 0.5mg injections followed by three consecutive intravitreal ranibizumab 2.0mg injections if specific criteria is met.
3075496|NCT01292837|Experimental|Levetiracetam|Twice daily (morning and evening) orally
3075497|NCT01292876|Other|Extracellular Matrix|Implantation of Extracellular Matrix
3075498|NCT01292928|Experimental|Stent|Stent implantation into SFA/PPA
3075499|NCT01293006|Experimental|Suvorexant first, then placebo|"During Period 1, participants <65 years of age were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening and participants ≥65 years of age were administered a 30-mg oral dose of~suvorexant once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening."
3075500|NCT01293006|Experimental|Placebo first, then suvorexant|"During Period 1, participants <65 years of age received one placebo tablet matching suvorexant, orally, once daily for 4 consecutive days in the evening and participants ≥65 years of age received one placebo tablet matching~suvorexant, orally, once daily for 4 consecutive days in the evening. A washout period of at least 7 days followed Period 1. During Period 2, participants were administered a 40-mg oral dose of suvorexant once daily for 4 consecutive days in the evening."
3075501|NCT01293032|Experimental|Group 1 (RS < 11)|"Patients with a Recurrence Score (RS) less than 11 (RS <11) are assigned to Group 1, neoadjuvant hormonal therapy either tamoxifen (pre-menopausal women) or an aromatase inhibitor (post-menopausal women) for 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
3075502|NCT01293032|Experimental|Group 2 Arm 1 (RS 11-25)|"Patients with an intermediate RS (11-25) assigned to Group 2. Randomized to Arm 1, neoadjuvant hormonal therapy as in Group 1.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/ Oncotype DX Gene Expression Profiling System~Hormonal therapy:~Tamoxifen Citrate (pre-menopausal women) OR~Aromatase Inhibition Therapy (post-menopausal women)"
3075503|NCT01293032|Experimental|Group 2 Arm 2 (RS 11-25)|"Patients with an intermediate RS(11-25) assigned to Group 2. Randomized to Arm 2, neoadjuvant chemotherapy 6-8 courses of anthracycline/taxane based regimen over 4-6 months in the absence of disease progression or unacceptable toxicity.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
3075504|NCT01293032|Experimental|Group 3 (RS > 25)|"Patients with a high RS (> 25) assigned to Group 3, neoadjuvant chemotherapy as in Group 2 Arm 2.~Treatment:~Neoadjuvant therapy~Therapeutic conventional surgery~Laboratory biomarker analysis/Correlative studies~Gene Expression Analysis/Oncotype DX Gene Expression Profiling System~Systemic chemotherapy"
3075505|NCT01293084|Experimental|7% saline|5 mL of 7% saline was inhaled once over a 20 minute period.
3075506|NCT01293084|Placebo Comparator|0.12% saline|5mL 0.12% saline inhaled once during 20 minutes
3075507|NCT01293240|Experimental|Lotrafilcon B|
3075508|NCT01293396|Active Comparator|Biphasic Insulin Aspart 30|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
3075509|NCT01293396|Active Comparator|Biphasic Insulin Aspart 70|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
3075510|NCT01293396|Active Comparator|Insulin Aspart|35% of their usual total daily insulin dose before the standardized breakfast and 25% prior to lunch
3075511|NCT01293539|Other|Intraocular Retinoblastoma Patients|Single group assignment of patients with intraocular retinoblastoma, unilateral or bilateral.
3075512|NCT01293682|Experimental|Calcitriol|Calcitriol 45mcg/week
3075513|NCT01293695|Active Comparator|Hypnosis|Receives 5 weeks of hypnotic relaxation therapy
3075514|NCT01293695|Placebo Comparator|Structured Attention|Meets with therapist for five weekly sessions, but receives no hypnotic relaxation therapy
3075515|NCT01293825|Experimental|Medication Adherence Bipolar Disorder|There was only one group in this study. All participants received the study drug Ziprasidone.
3075516|NCT01293968|Experimental|5cc Ibuprofen100mg,10 cc Diphenhydramine25mg,10 cc AlMgS550mg|
3075517|NCT01293968|Active Comparator|100 cc Diphenhydramine, 25 mg and 100 cc AlMgS 550 mg|
3075518|NCT01294098|No Intervention|PCA only|this group will only get a pain control anesthesia pump to use for post-operative pain
3075519|NCT01294098|Experimental|PCA and femoral nerve block|this group will be receiving a femoral nerve block during surgery and have a PCA post-operatively
3075520|NCT01294098|Experimental|PCA + hematoma block|patient will receive hematoma block during surgery
3075521|NCT01294150|Active Comparator|UroLift System|The treatment group subjects underwent the UroLift system procedure. The subject was blinded to his randomization into control or treatment group. Unblinding will occurred at 3 months post procedure after the assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to retreat with the UroLift system if he met the retreatment inclusion and exclusion criteria. Subjects that went on to UL retreatment within the first 12 months started their follow-up schedule over and were considered treatment failures. All UL subjects will be followed a minimum of 5 years.
3075522|NCT01294150|Sham Comparator|Cystoscopy|The control group subjects underwent a cystoscopy procedure. The subject was blinded to his randomization into the control or treatment group. Unblinding will occurred at 3 months post procedure, after follow-up assessments were completed. Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
3075523|NCT01294150|Active Comparator|Crossover|Between 3 and 12 month follow-up assessments, a subject was allowed to crossover and undergo a UL procedure if he met crossover inclusion and exclusion criteria. Subjects crossing over will then be followed for 5 years post-treatment. The subject can also be treated by other approved therapies, or receive no treatment at all, which would require participation through 12 months.
3075524|NCT01294163|Experimental|Xenon|
3075525|NCT01294163|Active Comparator|Sevoflurane|
3075526|NCT01294163|Active Comparator|Total intravenous anaesthesia|
3075527|NCT01294241|Experimental|Oleogel-S10|The eligible wound (half) was topically treated with Oleogel-S10 and covered with a non-adhesive wound dressing (Mepilex®) on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
3075528|NCT01294241|Other|Non-adhesive wound dressing|Mepilex® soft silicone faced polyurethane foam dressing was used as non-active comparator. The eligible wound (half) was covered with Mepilex® as control on Day 0. Wound dressings were changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
3075529|NCT01294267|Other|Circulatory Support System|Percutaneous use of left ventricular assist device, Impella 2.5 Circulatory Support System to facilitate mapping and ablation of ongoing VT by maintaining near-normal hemodynamics, reducing myocardial workload and preservice organ perfusion.
3075530|NCT01294306|Experimental|Treatment (Akt inhibitor MK2206, erlotinib hydrochloride)|Patients receive Akt inhibitor MK2206 PO QOD of a 28-day course, and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3075531|NCT01294319|Experimental|Sedentary young adults, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
3075532|NCT01294319|Experimental|Endurance-trained young athletes, SMCP|Spironolactone, Then Mifepristone, Then Combined, Then Placebo (SMCP), Then Dexamethasone
3075533|NCT01294319|Experimental|Sedentary young adults, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
3075534|NCT01294319|Experimental|Endurance-trained young athletes, MSPC|Mifepristone, Then Spironolactone, Then Placebo, Then Combined (MSPC), Then Dexamethasone
3075535|NCT01294319|Experimental|Sedentary young adults, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
3075536|NCT01294319|Experimental|Endurance-trained young athletes, CPSM|Combined, Then Placebo, Then Spironolactone, Then Mifepristone (CPSM), Then Dexamethasone
3075537|NCT01294319|Experimental|Sedentary young adults,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
3075538|NCT01294319|Experimental|Endurance-trained young athletes,PCMS|Placebo, Then Combined, Then Mifepristone, Then Spironolactone (PCMS), Then Dexamethasone
3075539|NCT01294358|Experimental|Gemcitabine Dose Escalation|gemcitabine dose escalation
3075540|NCT01294371||Leuprorelin|"Patients with genital endometriosis received leuprorelin (Lucrin Depot®) in accordance with the respective marketing authorization/manufacturer's directions. All participants received leuprorelin for up to 6 months intramuscularly at a dose of 3.75 mg once a month. If intramuscular administration was not possible, leuprorelin was injected subcutaneously at a dose of 3.75 mg once a month. The first injection was to be carried out on the 3rd day of a menstrual period.~Accepted options for add-back therapy included: monophasic combined low-dose products for hormonal replacement therapy; combined oral contraceptives; and, if use of hormones was not possible, phytoestrogens with calcium products."
3075541|NCT01294384|Experimental|New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
3075542|NCT01294384|Experimental|New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
3320972|NCT02015156|Active Comparator|Trastuzumab-US|
3075543|NCT01294384|Active Comparator|Refresh Tears®|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
3075544|NCT01294397|Experimental|Etanercept + Denosumab|Participants received etanercept 50 mg subcutaneously once weekly for 25 weeks. On study day 8, participants were administered a single 60 mg subcutaneous injection of denosumab.
3075545|NCT01294423|Experimental|1|Dapagliflozin 5 mg
3075546|NCT01294423|Experimental|2|Dapagliflozin 10 mg
3075547|NCT01294423|Placebo Comparator|3|
3075548|NCT01294436|Experimental|Open label treatment|
3075549|NCT01294449||MADIT-CRT ICD|
3075550|NCT01294449||MADIT-CRT CRT-D|
3075551|NCT01294462|Experimental|1|Ticagrelor (AZD6140)
3075552|NCT01294462|Active Comparator|2|Clopidogrel
3075553|NCT01294514||Healthy Volunteers|Healthy volunteers ASA Class 1
3075554|NCT01294553||rosiglitazone/metformin group|Korean subjects who are administered rosiglitazone/metformin according to the prescription information
3075555|NCT01294579|Experimental|ofatumumab and bendamustine|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase and 1000 mg IV every 2 months for 2 years.~Bendamustine 90 mg/m2 was given on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)"
3075556|NCT01294592|Active Comparator|Dutasteride plus tamsulosin|Dutasteride plus tamsulosin arm + lifestyle advice
3075557|NCT01294592|Experimental|Watchful waiting with escalation to tamsulosin|Watchful waiting with escalation to tamsulosin
3075558|NCT01294644|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075559|NCT01294644|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075560|NCT01294644|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075561|NCT01294683|Experimental|Sequence 1: MK-0524B 2g/40g→MK-0524A 2g + Simvastatin 40 mg|After a 2-week placebo run-in, participants received extended release (ER) niacin/laropiprant (N/LRPT) 1 g/20 mg combination tablet (MK-0524B) once daily for 4 weeks, then ERN/LRPT/Simvastatin (SIM) 2 g/40 mg combination tablet once daily for 8 weeks. Participants then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks.
3075562|NCT01294683|Experimental|Sequence 2: MK-0524A 2g + Simvastatin 40 mg→ MK-0524B 2g/40g|After a 2-week placebo run-in, participants received ERN/LRPT 1 g (MK-0524A) co-administered with SIM 20 mg once daily for 4 weeks then received ERN/LRPT 2 g (MK-0524A) co-administered with SIM 40 mg once daily for 8 weeks. Participants then received ERN/LRPT/SIM 2 g/40 mg combination tablets (MK-0524B) once daily for 8 weeks.
3075563|NCT01294696||All Enrolled Participants|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
3075564|NCT01294709|Experimental|Telcagepant/ Placebo|Participants receive single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 1 and single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
3075565|NCT01294709|Experimental|Placebo/Telcagepant|Participants receive single oral dose of two capsules or tablets of placebo for telcagepant (or three capsules of placebo for telcagepant) in Period 1 and a single oral dose of 600 mg (two 300 mg capsules or two bioequivalent 280 mg tablets) or 900 mg telcagepant (three 300 mg capsules) in Period 2 of the crossover. Each treatment period is separated by a washout of 96-240 hours.
3075566|NCT01294748|Experimental|MiStent DES|The MiStent SES is a sirolimus-eluting absorbable polymer stent for coronary artery revascularization.
3075567|NCT01294748|Active Comparator|Endeavor DES|The Endeavor DES is an everolimus-eluting durable polymer stent for coronary artery revascularization.
3075568|NCT01294787|Experimental|indacaterol and glycopyrronium bromide (QVA149)|QVA149 delivered once daily via single-dose dry powder inhaler.
3075569|NCT01294787|Placebo Comparator|placebo|Placebo, delivered once daily via single-dose dry powder inhaler.
3075570|NCT01294787|Active Comparator|tiotropium|Tiotropium delivered once daily via HandiHaler® device.
3075571|NCT01294800|Experimental|Preladenant 2 mg|Participants will receive preladenant 2 mg taken orally twice daily (BID), one tablet in the morning and one tablet in the evening, for 12 weeks.
3075572|NCT01294800|Experimental|Preladenant 5 mg|Participants will receive preladenant 5 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3075573|NCT01294800|Experimental|Preladenant 10 mg|Participants will receive preladenant 10 mg taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3075574|NCT01294800|Placebo Comparator|Placebo|Participants will receive a placebo to preladenant tablet taken orally BID, one tablet in the morning and one tablet in the evening, for 12 weeks.
3075575|NCT01294917|Experimental|Investigational MPS|AMO Investigational MPS.
3075576|NCT01294917|Active Comparator|Clear Care|Peroxide-based lens care regimen.
3075577|NCT01294917|Active Comparator|Opti-Free RepleniSH|Multi-purpose disinfecting solution (Alcon).
3075578|NCT01295034|Placebo Comparator|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
3075579|NCT01295034|Experimental|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
3075580|NCT01295112|Sham Comparator|Group 1|Active bevacizumab (Avastin®) and Sham Ozurdex®
3075581|NCT01295112|Active Comparator|Group 2|Active bevacizumab (Avastin®) and Active Ozurdex®
3075582|NCT01295216|Experimental|Intervention|Pre-hypertensive subjects who receive mHealth support for 12 months
3075583|NCT01295216|No Intervention|Control|Individuals who receive the usual primary health care
3075584|NCT01295281|Experimental|LoFric POBE 2.0 - PVC|First period (7 days) use of LoFric POBE 2.0 followed by second period (7 days) use of LoFric PVC
3075585|NCT01295281|Experimental|LoFric PVC - POBE 2.0|First period (7 days) use of LoFric PVC followed by second period (7 days) use of LoFric POBE 2.0.
3075586|NCT01295320|Experimental|GSK1437173A Group|Subjects who received 2 doses of HZ vaccine in the intermediate dose study group in study 108494 (NCT00434577). No treatment was given in this current study (NCT01295320).
3075587|NCT01295515|Experimental|Interferon treatment|Interferon treatment The intervention is administration of Pegylated Interferon Alpha 2b (PEGINTRON) weekly for four weeks
3075588|NCT01295580|Active Comparator|ARTZ sodium hyaluronate|The comparator product, ARTZ, is manufactured by Seikagaku Corporation, Japan. Subjects randomized to the ARTZ group were administered five weekly intra-articular injections (2.5 ml, NASHA 25 mg). ARTZ is a sterile, viscoelastic nonpyrogenic solution of purified, high molecular weight (620,000-1,170,000 daltons) sodium hyaluronate having a pH of 6.8-7.8. The sodium hyaluronate is extracted from chicken combs.
3075589|NCT01295580|Active Comparator|DUROLANE hyaluronic acid|The investigational product was provided in pre-filled syringes containing stabilized non-animal hyaluronic acid (20 mg/mL). Only one injection was given for those subjects randomized to the DUROLANE group, followed by 4 sham injections. DUROLANE is free from products of animal origin and is manufactured by Q-Med AB Corporation.The sham injection procedure was same as the active injection, except that they were subcutaneous and an empty syringe was used.
3075590|NCT01295671|Active Comparator|Sugar-Sweetened Beverages|Provision of beverages: Sugar-sweetened beverages
3075591|NCT01295671|Experimental|Artificially-sweetened Beverages|Provision of beverages: Artificially-sweetened beverages
3075592|NCT01295671|Experimental|Unsweetened Beverages|Provision of beverages: Unsweetened beverages
3075593|NCT01295710|Active Comparator|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
3075594|NCT01295710|Placebo Comparator|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
3075595|NCT01295814|Experimental|adalimumab|Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
3075596|NCT01295814|Placebo Comparator|Inactive drug|Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
3075597|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 1 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 1 mg/kg pembrolizumab intravenous (IV) infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 1 mg/kg every 2 weeks (Q2W) starting with Cycle 2.
3075598|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 3 mg/kg Q2W (Part A)|During Cycle 1 participants received a dose of 3 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 3 mg/kg Q2W starting with Cycle 2.
3075599|NCT01295827|Experimental|Solid Tumors: Pembrolizumab 10 mg/kg Q2W (Parts A+A1)|During Cycle 1 participants received a dose of 10 mg/kg pembrolizumab IV infusion over 30 minutes on Day 1 of a 28-day cycle for evaluation of dose-limiting toxicities and pharmacokinetics. Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W starting with Cycle 2.
3075600|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 1 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.005 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg every 3 weeks (Q3W) starting with Cycle 2.
3075601|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 2 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.02 mg/kg to 0.3 mg/kg to 2.0 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 2 mg/kg Q3W starting with Cycle 2.
3075602|NCT01295827|Experimental|Solid Tumors: Pembrolizumab Titration Cohort 3 Q3W (Part A2)|During Cycle 1 participants received pembrolizumab dose titration from 0.06 mg/kg to 1.0 mg/kg to 10 mg/kg on Days 1, 8, and 22, administered as an IV infusion over 30 minutes. Participants received 10 mg/kg Q3W starting with Cycle 2.
3075603|NCT01295827|Experimental|MEL: Pembrolizumab 2 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q2W. After Amendment 3, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075604|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q3W (Parts B+D)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 7, participants received dosing Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075605|NCT01295827|Experimental|MEL: Pembrolizumab 10 mg/kg Q2W (Part B)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075606|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part F)|Participants received pembrolizumab IV at a dose of 2 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075607|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Parts C+F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q3W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075608|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q2W (Part F)|Participants received pembrolizumab IV at a dose of 10 mg/kg Q2W. After Amendment 10, all remaining and ongoing participants were treated with a 200 mg fixed dose of pembrolizumab IV Q3W based on analysis of safety and efficacy data.
3075609|NCT01295827|Experimental|NSCLC: Pembrolizumab 2 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 2 mg/kg Q3W. No participants were enrolled in this arm.
3075610|NCT01295827|Experimental|NSCLC: Pembrolizumab 5 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 5 mg/kg Q3W. No participants were enrolled in this arm.
3320973|NCT02015169|Experimental|XELOX+lapatinib|"D1 Oxaliplatin130mg/m2 + D5W 500ml MIV over 2hrs~D1-D14 Capecitabine 850mg/m2 p.o bid~D1 ~ Lapatinib 1250 mg qd dailiy"
3075611|NCT01295827|Experimental|NSCLC: Pembrolizumab 10 mg/kg Q3W (Part E-Not Enrolled)|Participants were to receive pembrolizumab IV at a dose of 10 mg/kg Q3W. No participants were enrolled in this arm.
3075612|NCT01295840|No Intervention|CRT therapy|Cardiac Resynchronization Therapy Defibrillator (CRT-D)
3075613|NCT01295879|Experimental|Ergocalciferol|Subjects will take Ergocalciferol (vitamin D), 50,000 IU's orally per week for 8 weeks
3075614|NCT01295905|Experimental|delefilcon A|Investigational contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
3075615|NCT01295905|Active Comparator|narafilcon B|Commercially marketed contact lenses worn in both eyes on a daily wear, daily disposable basis for 3 months.
3075616|NCT01296035|Experimental|Panitumumab and Gemcitabine|Panitumumab and Gemcitabine
3075617|NCT01296152|Experimental|Depo-medroxyprogesterone acetate (DMPA)|At study entry/ Day 0, subjects will receive depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
3075618|NCT01296191|Active Comparator|VIGAMOX|Subjects undergoing cataract surgery, randomized to the VIGAMOX group Generic name is moxifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
3075619|NCT01296191|Active Comparator|Besivance|Subjects scheduled for cataract surgery, randomized to the Besivance group Generic name is besifloxacin eye drops, drops to be used 1 drop 4 times daily for 3 days prior to surgery and 1 drop on day of surgery.
3075620|NCT01296347|No Intervention|Saline|Patients will receive a placebo infusion of 0.9% sodium chloride, which will start 10 minutes prior to the start of the operation and continue for 96 hours.
3075621|NCT01296347|Experimental|ketamine|Patients will receive intravenous ketamine, starting 10 minutes prior to surgery and will continue for 96 hours
3075622|NCT01296360|Active Comparator|>14 months to <2 years|IXIARO 0.25 ml i.m. (milliliter, intramuscular)
3075623|NCT01296360|Active Comparator|>3 years - <18 years|IXIARO 0.5 ml i.m (milliliter, intramuscular)
3075624|NCT01296412|Experimental|Sitagliptin +/- glimepiride|Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
3075625|NCT01296412|Active Comparator|Liraglutide|Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin >=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
3075626|NCT01296542|Active Comparator|VIGAMOX|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
3075627|NCT01296542|Active Comparator|Besivance|Subjects will self administer drops 4 times daily for 3 days and one drop prior to sample collection
3075628|NCT01296568|Experimental|LY2603618|"Single 250 milligram (mg) intravenous dose of LY2603618 containing carbon-14-labeled LY2603618 ([^14C]LY2603618).~After the completion of a minimum 7-day washout period, participants may receive additional doses of LY2603618 in combination as follows:~Gemcitabine 1000 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 with 230 mg LY2603618 being administered on Days 2, 9 and 16 of a 28-day cycle OR~Pemetrexed 500 mg/m^2 on Day 1 and 275 mg LY2603618 on Day 2 of a 21-day cycle~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
3075629|NCT01296646|Active Comparator|Arm 1|Sweet Liker, High Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
3075630|NCT01296646|Active Comparator|Arm 2|Sweet Liker - Low Craver Half of this group will be on naltrexone the other half will be on placebo. All subjects will receive Brenda Therapy Sessions
3075631|NCT01296646|Active Comparator|Arm 3|Sweet Disliker - High Craver. Half of this group will be on naltrexone the other half will be on Placebo. All subjects will receive Brenda Therapy Sessions
3075632|NCT01296646|Active Comparator|Arm 4|Sweet Disliker - Low Craver; half of this group will be on naltrexone the other half on placebo. All subjects will receive Brenda Therapy Sessions
3075633|NCT01296672|Experimental|Finasteride|Finasteride 5mg tablets every day by mouth for 3 months
3075634|NCT01296672|Placebo Comparator|Placebo|Placebo 5mg tablet every day by mouth for 3 months
3075635|NCT01296698|Placebo Comparator|Placebo|0 mg Oral NRT, up to 4 times per hour for 12 weeks
3075636|NCT01296698|Experimental|Nicotine|1 mg Oral NRT, up to 4 times per hour for 12 weeks
3075637|NCT01296763|Experimental|Irinotecan, Cisplatin, Olaparib, then add Mitomycin-C|A 3+3 dose escalation design will be used starting with dose 1. The maximally tolerated dose is defined as the highest dose for which at most 1 out of 6 patients experiences a DLT. We will use 3 patients per dose cohort. If 0 of 3 patients have a DLT (see section 5a) then the escalation will be continued at the next dose level. If 1 of 3 patients have a DLT then three more patients will be enrolled at this dose. If 1 of 6 patients has a DLT then the dose escalation will continue. If 2 or more of the first 3 patients, or >2 of 6 patients treated have a DLT at the dose level, we will reduce the dose to the previous dose level of Olaparib for the phase 2 and then test Mitomycin C (phase 1 dose 5). If DLTs are observed at our dose 1 regimen, we will reduce the duration of Olaparib from day 1 and day 8 to just day 1 (dose level -1) and we will not test Mitomycin C in the trial.
3075638|NCT01296815|No Intervention|HAART|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
3075639|NCT01296815|Experimental|HAART+ Bevacizumab injection|Patients received antiretroviral treatment according to the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Patients received 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) in the target lesion every 2 weeks. Bevacizumab was injected using an insulin syringe in a submucosal plane. The volume injected was based on the size of the target lesion; the dose was 0.2 mL (5 mg) per cm2.
3075640|NCT01296841|No Intervention|Standard encounter|"Standard in-house clinical visit between patient and physician."
3075641|NCT01296841|Experimental|Telemedicine Encounter|Remote clinical appointment between patient and physician.
3075642|NCT01296932|Experimental|Patients with relapsed CLL|Patients with relapsed CLL after at least two prior treatment regimens will receive BI 836826.
3075643|NCT01297062|Experimental|Exenatide|
3075644|NCT01297062|Placebo Comparator|Placebo|
3075645|NCT01297062|Active Comparator|Moxifloxacin|
3075646|NCT01297244|Experimental|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
3075647|NCT01297270|Active Comparator|PegIFN/RBV|48 weeks
3075648|NCT01297270|Experimental|BI 201335 for 24 weeks|BI 201 335 QD dosing in combination with IFN/RBV
3075649|NCT01297270|Experimental|BI201335 for 12 weeks|BI 201335 QD doing in combination with PEFG IFN/RBV
3075650|NCT01297270|Placebo Comparator|Placebo|
3075651|NCT01297283|Experimental|Leadless ECG first|Measurement of pacing thresholds are done first with the support of a leadless ECG provided by the implanted device
3075652|NCT01297283|Active Comparator|Programmer ECG first|Measurements of pacing thresholds are done first with the support of the programmer ECG
3075653|NCT01297309|Experimental|NPSP558|titration of 25, 50, 75 or 100 μg
3075654|NCT01297322|Active Comparator|Manual compression|Using manual compression to reach hemostasis
3075655|NCT01297322|Experimental|VASCADE™ Vascular Closure System|The Cardiva VASCADETM Vascular Closure System (VCS) is indicated for the percutaneous closure of common femoral artery access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular catheterization procedures utilizing 6 Fr or 7 Fr procedural sheaths.
3075656|NCT01297335|Experimental|Intrathecal Clonidine|Subject will receive one time Clonidine injection via lower lumber interspace. Clonidine (Duraclon), 100 μg/ml, 1.5 ml will be diluted to 2 ml with preservative free saline, and total of 150 μg will be delivered. Supine and sitting blood pressures and heart rate will be measured at 10 minute intervals until 60 minutes after clonidine administration, then at 15 minutes for next 3 hours.
3075657|NCT01297348||Lybrel®|Current users of 90 ug levonorgestrel / 20 ug ethinyl estradiol - cases and controls (i.e., women diagnosed with new venus thromboembolism [VTE] and women not diagnosed with VTE).
3075658|NCT01297348||Other OCs containing 20μg of ethinyl estradiol|Current users of oral contraceptives containing 20μg of ethinyl estradiol - cases and controls (i.e. women diagnosed with new VTE and women not diagnosed with VTE)
3075659|NCT01297465|Active Comparator|Gonal-f® Plus Pergoveris®|
3075660|NCT01297465|Experimental|Pergoveris®|
3075661|NCT01297491|Experimental|Squamous BKM120 100mg qd|Diagnosed patients with non-small cell lung cancer (NSCLC) that progressed after one prior, platinum-based chemotherapy line for metastatic disease.
3075662|NCT01297491|Experimental|Non-Squamous BKM120 100mg qd|Diagnosed patients with non-squamous NSCLC that progressed after one or two prior antineoplastic therapy lines for metastatic disease.
3075663|NCT01297504||Palivizumab|Infants at risk for respiratory syncytial virus infection received palivizumab prescribed in accordance with the terms of the local marketing authorization.
3075664|NCT01297517|Experimental|Brinzolamide/Brimonidine|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, one drop instilled in each eye three times a day for 3 months
3075665|NCT01297517|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, one drop instilled in each eye three times a day for 3 months
3075666|NCT01297517|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, one drop instilled in each eye three times a day for 3 months
3075667|NCT01297595|Experimental|crizotinib|
3075668|NCT01297920|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 3 times a day for 3 months
3075669|NCT01297920|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each eye 3 times a day for 3 months
3075670|NCT01297920|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each eye 3 times a day for 3 months
3075671|NCT01297959|Experimental|E-101 Solution 300 GU/mL|Participants will receive E-101 Solution at porcine myeloperoxidase (pMPO) concentration of 300 guaiacol units per milliliter (GU/mL) applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
3075672|NCT01297959|Placebo Comparator|Placebo (Saline solution)|Participants will receive placebo (saline solution) matched to E-101 Solution applied topically twice to surgical wound site. The first topical application will occur just after incision to the level of the rectus fascia or linea alba without penetration through the peritoneum and the second topical application will occur just after closure of the rectus fascia or linea alba but prior to closure of the incisional wound.
3075673|NCT01297985|Experimental|BRIDGES Intervention|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a 10-week course to an 8-week course, meeting for 2 1/2 hours once a week.
3075674|NCT01297985|No Intervention|Comparison Wait-list Group|Participants assigned to the comparison group were in a delayed treatment condition in which they continued in public services as usual, but were offered the chance to attend the BRIDGES program after their final research interview.
3075675|NCT01298063|Experimental|Afatinib Group A, B (2), D|healthy subjects, mild and moderate liver impaired subjects to receive one single dose treatment containing the highest dose afatinib
3075676|NCT01298063|Experimental|Afatinib Group B (3), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the medium dose of afatinib
3075677|NCT01298063|Experimental|Afatinib Group B (1), D|healthy subjects, moderate liver impaired subjects to receive one single dose treatment containing the low dose of afatinib
3075678|NCT01298128|Experimental|NuvaRing|NuvaRing for IVF pre-treatment
3075679|NCT01298128|Active Comparator|Combined oral contraceptive pill|OCP for IVF pre-treatment
3075680|NCT01298141|Experimental|Replagal®|All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.
3075681|NCT01298167|Active Comparator|Cyanoacrylate Superior/Inferior|This arm contains data from only the Cyanoacrylate used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast Absorbing Gut suture.
3075682|NCT01298167|Active Comparator|Fast Absorbing Gut Suture Superior/Inferior|This arm contains data from only the Fast Absorbing Gut Suture used on superior ½ of wounds & inferior ½ of wounds in randomized patients to determine the impact of Cyanoacrylate tissue glue versus Fast absorbing gut suture.
3075683|NCT01298193|Experimental|Aprepitant|"Observational phase (first cycle):~Day 0 (Dexamethasone 8mg) Day 1 (5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2,Tropisetron: 5 mg, Dexamethasone 24 mg) + Chemotherapy (Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 ).~Days 2 and 3 (Dexamethasone 16 mg).~If not complete response:~Efficacy phase (second cycle):~Day 0 (Dexamethasone 8mg) Day 1 (Aprepitant: 125 mg,5-HT3 antagonist, Ondansetron: 8 mg x2, Granisetron: 1mg x2, Tropisetron: 5 mg, Dexamethasone 12 mg)+ Chemotherapy: Docetaxel 75mg/m2 and Cyclophosphamide 600mg/m2 .~Days 2 and 3 (Aprepitant: 1 capsule of 80 mg daily, Dexamethasone 8 mg)."
3075684|NCT01298219|Experimental|Lubiprostone|24 mcg capsules twice daily (BID)
3075685|NCT01298219|Placebo Comparator|Placebo|0 mcg capsules twice daily (BID)
3075686|NCT01298323|Active Comparator|Vandetanib Control|Control - treatment 300mg vandetanib opel label
3075687|NCT01298323|Experimental|Experimental|Experimental - treatment 300mg vandetanib opel label
3075688|NCT01298362||AIs as first line therapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as first line therapy for 12 months.
3075689|NCT01298362||AIs after chemotherapy|Patients in postmenopausal status, with ER-positive early breast cancer, treated with an AI as maintenance therapy for 12 months after initial treatment with anthracycline- and/or taxane-based chemotherapy (chemotherapy treatment duration: 1-6 months).
3075690|NCT01298492|Experimental|Open-Label Treatment|Subjects eligible for this study will have completed the 12 week double blind induction period in study A7281006 and will be stratified by responders or non responders based on change in CDAI in that study, without unblinding treatment assignment from study A7281006. Additionally, subjects who have completed study A7281008
3075691|NCT01298518|Experimental|PF-04620110|
3075692|NCT01298518|Placebo Comparator|placebo|
3075693|NCT01298531|Active Comparator|etanercept|Group A: etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
3075694|NCT01298531|Placebo Comparator|etanercept-placebo|Group B: placebo subcutaneous (SC) injections once weekly for (how many) weeks follwed by etanercept 50 mg SC injections once weekly.
3075695|NCT01298544|Other|All subjects|
3075696|NCT01298570|Active Comparator|Regorafenib + FOLFIRI|regorafenib 160 mg + FOLFIRI
3075697|NCT01298570|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
3075698|NCT01298596|Experimental|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
3075699|NCT01298596|Experimental|Loop Electrosurgical Excision Procedure|Loop Electrosurgical Excision Procedure (LEEP) uses a low-voltage electrified wire loop to cut out diseased part of cervix
3075700|NCT01298648||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
3075701|NCT01298661|Other|Healthy Young Subjects|Subjects apparently healthy, with age of 18 to 27 years old.
3075702|NCT01298661|Other|Healthy Elderly subjects|Subjects apparently healthy, with age of 60 to 75 years old.
3075703|NCT01298661|Other|COPD Patients|Patients with clinical and spirometric diagnosis of COPD
3075704|NCT01298700|Experimental|Bimatoprost 0.01% Ophthalmic Solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
3075705|NCT01298700|Active Comparator|Bimatoprost 0.03% Ophthalmic Solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
3075706|NCT01298752|Experimental|Mapracorat|Mapracorat ophthalmic suspension
3075707|NCT01298752|Placebo Comparator|Vehicle|Vehicle of mapracorat ophthalmic suspension
3075708|NCT01298765|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3075709|NCT01298778|Placebo Comparator|Standard of care|Spinal consists of duramorph 150 mcg combined with fentanyl and bupivacaine in conjunction with placebo capsules 2 PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
3075710|NCT01298778|Active Comparator|Acetaminophen and increased dose of Duramorph|Spinal consists of duramorph 300 mcg combined with fentanyl and bupivacaine in conjunction with Acetaminophen 1 Gm PO q 6 hrs x 4 doses in first 24 hrs postop. Ibuprofen given as standard of care.
3075711|NCT01298999|Experimental|YF476|YF476 (gastrin-receptor antagonist)
3075712|NCT01298999|Placebo Comparator|Placebo|Placebo pill (identical in appearance to YF476 pills)
3075713|NCT01299025|No Intervention|Control|Participants allocated as controls receive no treatment. They may be physically active as usual.
3075714|NCT01299025|Experimental|Training with Nintendo Wii Fit|Training 6 weeks with Nintendo Wii Fit, 30 minutes 2 times per week
3075715|NCT01299038|Active Comparator|Group 1|Rosuvastatin 20mg taken orally once a day for 4 weeks
3075716|NCT01299038|Active Comparator|Group 2|Rosuvastatin 40mg taken orally once a day for 4 weeks
3075717|NCT01299077||Lumbar disc degenerative disease|Triple therapy (MBL+ MYO+ NSAIDs) which prescribed by doctors (Drs) based on disease condition
3075718|NCT01299090|Experimental|Treatment Group|All subjects enrolled were in the treatment group.
3075719|NCT01299103|Active Comparator|Single Treatment|Treatment of facial wrinkle with one treatment only
3075720|NCT01299103|Active Comparator|Double Treatment|Treatment of facial wrinkle with two treatments
3075721|NCT01299103|Active Comparator|Triple treatment|Treatment of facial wrinkle with three treatments
3075722|NCT01299116|Other|Preference SARC|Participants received one of a variety of oral contraceptives or DMPA
3075723|NCT01299116|Experimental|Randomized LARC|"Participants receive one of the following interventions:~Implanon® or Nexplanon®; ParaGard®; Mirena®"
3075724|NCT01299116|Active Comparator|Randomized SARC|Participants received one of a variety of oral contraceptives or DMPA
3320974|NCT02015182||Blood sample for bupivicaine pharmacokinetics|Children undergoing TAP block will have blood sampled for bupivacaine pharmacokinetics
3075725|NCT01299272|Experimental|LY2216684 + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization continued their current dose of LY2216684 for another 24 weeks. Participants who completed this period or discontinued early were randomized to abrupt (placebo for 2 weeks) or tapered (12 mg LY2216684 for 4 days, 6 mg LY2216684 for 4 days, then placebo for 6 days) discontinuation of LY2216684."
3075726|NCT01299272|Placebo Comparator|Placebo + SSRI|"Acute Open-label (OL) Period: Participants received a starting dose of 12 milligrams (mg) LY2216684, administered orally, once daily for at least 2 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI). Then, based on efficacy and tolerability, the dose could be increased to 18 mg (and decreased back to 12 mg) over the next 6 weeks.~Stabilization OL Period: Participants meeting remission criteria continued on the same dose of LY2216684 for an additional 12 weeks. Participants who discontinued early during either OL Period were discontinued abruptly from LY2216684.~Double-blind (DB) Randomized Withdrawal Period: At 20 weeks, participants meeting criteria for randomization were tapered from their LY2216684 dose to placebo following the regimen of 12 mg for 7 days, 6 mg for 7 days, and placebo for the remaining 22 weeks. Participants who completed this period or discontinued early continued to receive placebo for an additional 2 weeks"
3075727|NCT01299285|Experimental|LY3009104|Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
3075728|NCT01299376|Experimental|L50/H12.5/A5→L50/H12.5/A5|One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
3075729|NCT01299376|Active Comparator|L50/H12.5→L50/H12.5/A5|One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension
3075730|NCT01299389|Experimental|Paliperidone palmitate|
3075731|NCT01299389|Placebo Comparator|Placebo|
3075732|NCT01299454|Active Comparator|Normal|
3075733|NCT01299454|Active Comparator|Mild|
3075734|NCT01299454|Active Comparator|Moderate|
3075735|NCT01299454|Active Comparator|Severe|
3075736|NCT01299480|Experimental|Group 1|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
3075737|NCT01299480|Experimental|Group 2|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
3075738|NCT01299480|Experimental|Group 3|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
3075739|NCT01299480|Experimental|Group 4|rLP2086 at visits 1 and 3, saline at visits 2 and 5
3075740|NCT01299480|Experimental|Group 5|rLP2086 at visits 3 and 5, saline at visits 1 and 2
3075741|NCT01299571||Dutasteride|Patients administrated dutasteride at the site
3075742|NCT01299584||Remifentanil|Patients administrated remifentanil at the site
3075743|NCT01299610|Experimental|GW870086 2.0% &amp; 0.2%|GW870086 2.0%, GW870086 0.2% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3075744|NCT01299610|Experimental|GW870086 2.0% & FP 0.05%|GW870086 2.0%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3075745|NCT01299610|Experimental|GW870086 0.2% & FP 0.05%|GW870086 0.2%, FP 0.05% &amp; Placebo each applied to a separate specific lesion for 21±2 days.
3075746|NCT01299727|Experimental|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3075747|NCT01299727|Experimental|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3075748|NCT01299727|Experimental|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
3075749|NCT01299766|Experimental|Behavior Activation|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
3075750|NCT01299766|Placebo Comparator|Supportive Therapy (ST)|ST is a person-centered treatment in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
3075751|NCT01299805|Experimental|Vortioxetine|Vortioxetine 20 mg, encapsulated tablet, orally, once daily for up to 14 days.
3075752|NCT01299805|Placebo Comparator|Placebo|Vortioxetine placebo-matching capsules, orally, once daily for up to 14 days.
3075753|NCT01299896|Active Comparator|Usual Care|Participants will continue to receive all the care currently offered in the VAPHS, including medications for smoking cessation and use of the in-person or telephone counseling options for quit smoking classes. For veterans with a co-pay, incurred fees with be reimbursed.
3075754|NCT01299896|Active Comparator|Coordinated Care|A CTQ Coordinator will coordinate the delivery of smoking related care.
3075755|NCT01299909|Active Comparator|Mindfulness Training for Smokers|MTS participants will receive 8 classes of training in mindfulness meditation, access to the MTS website, and 2 weeks of nicotine patches.
3075756|NCT01299909|Active Comparator|Integrated Training for Smokers|ITS participants will receive 8 classes of training in smoking cessation strategies, access to the Freedom From Smoking online program, and 2 weeks of nicotine patches.
3075757|NCT01299909|Other|Quitline|Quitline participants will consist of participants who elect not to participate in the high-intensity treatments (Mindfulness Training for Smokers; Integrated Training for Smokers. This Quitline group is a Non-Randomized, Treatment as Usual group.
3075758|NCT01299961|Experimental|Subcutaneous Abatacept|All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.
3075759|NCT01300052|Experimental|AN2728 ointment, 2%|AN2728 ointment, 2%
3075760|NCT01300052|Placebo Comparator|Ointment Vehicle|Ointment Vehicle
3075761|NCT01300065|Experimental|Experimental- Soflens|Bausch & Lomb experimental soflens daily disposable contact lens packaged in an investigational storage solution.
3075762|NCT01300065|Active Comparator|Marketed - Soflens|Bausch & Lomb daily disposable marketed soflens contact lens packaged with: 0.5% poloxamine in buffered saline solution.
3075763|NCT01300234|Experimental|A (TDF tablets)|Tenofovir disoproxil fumarate (TDF) tablets
3075764|NCT01300234|Active Comparator|B (ADV tablets)|Adefovir dipivoxil (ADV) tablets
3075765|NCT01300247|Experimental|Obinutuzumab + Fludarabine + Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6), fludarabine (25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6), and cyclophosphamide (250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6).
3075766|NCT01300247|Experimental|Obinutuzumab + Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab (1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6) and bendamustine (90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6).
3075767|NCT01300260|Experimental|LY2189265 then Placebo|"LY2189265 (Dulaglutide) then Placebo: A single 1.5 milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 in Period 1, followed by a single SC injection of Placebo on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
3075768|NCT01300260|Experimental|Placebo then LY2189265|"Placebo then LY2189265 (Dulaglutide): A single subcutaneous injection of Placebo on Day 1 in Period 1, followed by a single 1.5 milligrams (mg) subcutaneous injection of LY2189265 on Day 1 in Period 2.~On Day 3 of each period, participants underwent a 6-hour insulin infusion, followed by an intravenous (IV) dextrose bolus (0.3 gram/kilogram [g/kg] over approximately 2 minutes). Three hours later, participants were administered a second IV dextrose bolus of 25 g of 50% dextrose or a suitably adjusted dose according to glycemic status (20 g of 50% dextrose for participants with 3-hour glucose between 5.2 and 10 millimole/liter [mmol/L] or 15 g of 50% dextrose for participants with 3-hour glucose >10 mmol/L), followed by a 20% dextrose at the set infusion rate of 600 milliliter/hour [mL/h] for 35 minutes. Fifteen minutes after the start of the 20% dextrose infusion, an IV 1-mg glucagon bolus was administered.~There was a washout period of at least 28 days between Periods 1 and 2."
3075769|NCT01300286|Experimental|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
3075770|NCT01300338|Experimental|Blood pressure with telemetry|Home blood pressure monitor with telemetry
3075771|NCT01300338|Active Comparator|Blood pressure without telemetry|Home blood pressure self monitor without telemetry.
3075772|NCT01300351|Experimental|Fulvestrant 500mg|Fulvestrant 500mg (2 syringes of Fulvestrant 250mg), Fulvestrant 500 mg i.m. every 28 (+/- 3) days plus an additional 500 mg on day 14 (+/-3) of first month only
3075773|NCT01300351|Active Comparator|Fulvestrant 250mg|Fulvestrant 250mg (1 syringe of fulvestrant 250mg + 1 syringe matching placebo), Fulvestrant 250 mg and matching placebo i.m. every 28 (+/- 3) days plus an additional 2 placebo syringes on day 14 (+/-3) of first month only
3075774|NCT01300455|Experimental|Suvorexant (40 mg)|In Period 1, suvorexant (40 mg tablets) administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. Period 2 consists of placebo administered once daily for 4 consecutive days in the evening.
3075775|NCT01300455|Placebo Comparator|Placebo|In Period 1, placebo administered orally once daily for 4 consecutive days in the evening. Period 1 is followed by a washout period of a minimum of 5 days. In Period 2, suvorexant (40 mg tablets) administered once daily for 4 consecutive days in the evening.
3075776|NCT01300546|Active Comparator|Sumatriptan/Naproxen Sodium|In Treatment Period, subjects randomized to Sumatriptan/Naproxen Sodium will be provided with 14 tablets of Sumatriptan/Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Sumatriptan/Naproxen Sodium per month for rescue of persistent or recurring headache.
3075777|NCT01300546|Active Comparator|Naproxen Sodium|In Treatment Period, subjects randomized to Naproxen Sodium 500mg will be provided with 14 tablets of Naproxen Sodium to treat migraine within 1 hour of onset on 14 or fewer days per month. Subjects will be provided with 14 tablets of Naproxen Sodium per month for rescue of persistent or recurring headache.
3075778|NCT01300559|Experimental|Treatment Group|Tissuelink device plus Unipolar electrocautery will be used in this arm of the study.
3075779|NCT01300559|No Intervention|No treatment|Unipolar electrocautery without Tissuelink device will be used in this arm of the study.
3075780|NCT01300572|Experimental|Y-90-BC8 & Allogeneic Transplant|"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180."
3075781|NCT01300624|Experimental|Verb Network Strengthening Treatment|Verb Network Strengthening Treatment (VNeST) tasks involve the retrieval of nouns related to a target verb. For example, for the verb measure, participants would come up with people who measure and what they measure (e.g., carpenter/lumber, chef/sugar). They would then answer questions related to why, where, and when these things might occur (e.g., for carpenter/measure, they might say to get the right length of board, (why) at a construction site, (where) and when building a house (where). Cues and assistance are provided to the participants when they are unable to complete any given task. As the participants improve, cues are reduced.
3075782|NCT01300650|Experimental|Anakinra|
3075783|NCT01300728|Experimental|intravenous immunoglobulin (IVIG)|IVIG (NewGam 10%)at 0.4 g/kg
3075784|NCT01300728|Placebo Comparator|Saline solution|0.9% saline solution
3075785|NCT01300741|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with galyfilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
3075786|NCT01300741|Active Comparator|Galyfilcon A|Galyfilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW modality).
3075787|NCT01300767|Experimental|Lotrafilcon B|Lotrafilcon B commercially marketed contact lens randomly assigned to one eye, with balafilcon A commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
3075788|NCT01300767|Active Comparator|Balafilcon A|Balafilcon A commercially marketed contact lens randomly assigned to one eye, with lotrafilcon B commercially marketed contact lens in the fellow eye for contralateral wear. Lenses were worn for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks in a daily wear (DW) modality.
3075789|NCT01300819|Placebo Comparator|Placebo|
3075790|NCT01300819|Experimental|Rotigotine|
3075791|NCT01300923|Active Comparator|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
3075792|NCT01300923|No Intervention|Autism Spectrum Disorder|This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
3075793|NCT01300949|Active Comparator|Glaucoma|154 glaucoma, ocular hypertension and glaucoma suspect patients will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
3075794|NCT01300949|Active Comparator|Controls|125 patients with no eye diseases will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart. This included patients with refractive errors (needing glasses) and nuclear sclerosis (cataract).
3075795|NCT01300949|Active Comparator|Age-Related Macular Degeneration (ARMD)|35 retina patients with age-related macular degeneration (ARMD) will have contrast sensitivity measured by Spaeth/Richman Contrast Sensitivity Test (SPARCS) and Pelli-Robson Contrast Sensitivity Chart.
3075796|NCT01301001|Placebo Comparator|Placebo oral capsule|Placebo capsule daily in first intervention period and Gabapentin capsule 3000 mg daily in in second intervention (after washout period)
3075797|NCT01301001|Active Comparator|Gabapentin|Gabapentin capsule 3000 mg daily in first intervention period and Placebo capsule in second intervention (after washout period)
3075798|NCT01301027|Active Comparator|Pioglitazone|15 mg/day pioglitazone for 2 weeks, then 30 mg/day for remaining 24 weeks
3075799|NCT01301027|Placebo Comparator|Placebo|1 placebo pill a day matching the pioglitazone treatment for 26 weeks
3075800|NCT01301066|Experimental|Pitavastatin 4 mg QD|
3075801|NCT01301066|Active Comparator|Pravastatin 40 mg QD|
3075802|NCT01301079|Active Comparator|Ketamine|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), remifentanil (1 μg/kg), and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group ketamine received remifentanil (0.4 μg/kg/min) and ketamine (5 μg/kg/min).~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
3075803|NCT01301079|Placebo Comparator|Saline|"A cardioscope, a capnograph, a pulse oximeter, and a noninvasive blood pressure meter were used to monitor the patients. Propofol (2-4 mg/kg), 1 μg/kg remifentanil, and atracurium (0.5 mg/kg) were administered for intubation. Atracurium was titrated to maintain muscle relaxation. Anesthesia was maintained with remifentanil, 0.8% isoflurane, and 50% oxygen without nitrous oxide. Infusion of the solutions was continued until skin closure.~The patients in group saline received remifentanil (0.4 μg/kg/min) and saline solution.~Remifentanil was administered as necessary until skin closure. Neostigmine was used for antagonizing the neuromuscular block."
3075804|NCT01301092|Experimental|Part A: LY2189265 intravenous|Single intravenous (IV) dose, starting at 0.1 milligrams (mg) of LY2189265. Dose may be increased to 0.2 mg or decreased to 0.05 mg for subsequent patients, dependent on safety assessments of the first 3 patients.
3075805|NCT01301092|Experimental|Part B: LY2189265 subcutaneous, intravenous|Patients are randomized to 2 sequences of 2 treatments. Single 1.5 mg subcutaneous (SC) dose of LY2189265 in Period 1; single intravenous (IV) dose of LY2189265 (determined by Part A IV arm data) in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
3075806|NCT01301092|Experimental|Part C: LY2189265 subcutaneous, intramuscular|Patients are randomized to 2 sequences of 2 treatments. Single 0.75 mg subcutaneous (SC) dose of LY2189265 in Period 1; single 0.75 mg intramuscular (IM) of LY2189265 in Period 2 or vice versa. There is a washout period of at least 4 weeks between dosing periods.
3075807|NCT01301183|Experimental|Rh IGF-1 + Transdermal estradiol|RhIGF-1 with transdermal 17-beta estradiol
3075808|NCT01301183|Placebo Comparator|Placebo + Transdermal estradiol|Placebo and transdermal 17-beta estradiol
3075809|NCT01301274|Active Comparator|Hypotonic|Subjects in this arm will receive 0.45% NaCl/5% dextrose intravenous maintenance fluids.
3075810|NCT01301274|Experimental|Isotonic|Subjects in this arm will receive 0.9% NaCl/5% dextrose intravenous maintenance fluids.
3075811|NCT01301391|Experimental|Milciclib|Milciclib Maleate capsules
3075812|NCT01301456|Placebo Comparator|Treatment Arm 1 (Stage 1A)|
3075813|NCT01301456|Experimental|Treatment Arm 2 (Stage 1A)|
3075814|NCT01301456|Experimental|Treatment Arm 3 (Stage 1A)|
3075815|NCT01301456|Experimental|Treatment Arm 4 (Stage 1A)|
3075816|NCT01301456|Placebo Comparator|Treatment Arm 5 (Stage 1B)|
3075817|NCT01301456|Experimental|Treatment Arm 6 (Stage 1B)|
3075818|NCT01301456|Experimental|Treatment Arm 7 (Stage 1B)|
3075819|NCT01301456|Experimental|Treatment Arm 8 (Stage 1B)|
3075820|NCT01301456|Placebo Comparator|Treatment Arm 9 (Stage 2)|
3075821|NCT01301456|Experimental|Treatment Arm 10 (Stage 2)|
3075822|NCT01301456|Experimental|Treatment Arm 11 (Stage 2)|
3075823|NCT01301456|Experimental|Treatment Arm 12 (Stage 2)|
3075824|NCT01301456|Experimental|Treatment Arm 13 (Stage 2)|
3075825|NCT01301508|Experimental|AN2898 ointment, 1%, vs. ointment vehicle|"AN2898 ointment applied twice daily for 6 weeks to one target lesion, and AN2898 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
3075826|NCT01301508|Experimental|AN2728 ointment, 2%, vs. ointment vehicle|"AN2728 ointment applied twice daily for 6 weeks to one target lesion, and AN2728 ointment vehicle applied twice daily for 6 weeks to a second target lesion.~Treatments will be randomly assigned to target lesions A and B."
3075827|NCT01301625||MitraClip Implant|Eligible patients undergoing a MitraClip procedure in Australia and New Zealand
3075828|NCT01301729|Experimental|Trastuzumab|Participants with metastatic breast cancer received a loading dose of 4 milligrams per kilograms (mg/kg) of trastuzumab intravenously (IV) followed by 2 mg/kg of trastuzumab IV once a week along with docetaxel 100 milligrams per meter square (mg/m^2), every 3 weeks or paclitaxel 90 mg/m^2 once a week until progression of disease, occurrence of intolerable toxicity, the participant discontinues the study or dies.
3075829|NCT01301742|Active Comparator|BI 10773|Subject to receive one single dose BI 10773
3075830|NCT01301742|Experimental|BI 10773 plus gemfibrozil|Subject to receive one single dose BI 10773 plus 600 mg gemfibrozil bid for 5 days
3075831|NCT01301833|Experimental|teneligliptin|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained )
3075832|NCT01301833|Experimental|teneligliptin and glinide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus glinide
3075833|NCT01301833|Experimental|teneligliptin and biguanide|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus biguanide
3075834|NCT01301833|Experimental|teneligliptin and alpha-glucosidase inhibitor|teneligliptin (20 mg once daily, titrated to 40 mg if no adequate efficacy is obtained ) plus alpha-glucosidase inhibitor
3075835|NCT01301950|Active Comparator|TruMatch® Personalized Solutions|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using TruMatch® Personalized Solutions (Custom Patient Instrumentation)
3075836|NCT01301950|Active Comparator|Conventional Total Knee Replacement|Cruciate Retaining and Posterior Stabilized Fixed-Bearing or Rotating Platform Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments
3075837|NCT01302041|Experimental|Enzalutamide|Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.
3075838|NCT01302054|Experimental|Fesoterodine|
3075839|NCT01302054|Placebo Comparator|Placebo|
3075840|NCT01302067|Experimental|Fesoterodine 8mg|
3075841|NCT01302067|Experimental|Fesoterodine 4mg|
3075842|NCT01302067|Placebo Comparator|Placebo|
3075843|NCT01302080||Sertraline-treated|enrolled subjects beginning treatment for one of the study qualifying disorders with sertraline
3075844|NCT01302080||psychotherapy only|enrolled subjects beginning treatment for one of the study qualifying disorders with psychotherapy
3075845|NCT01302119|Experimental|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%
3075846|NCT01302119|Placebo Comparator|Solution Vehicle|Solution Vehicle
3075847|NCT01302366|Experimental|Sea cucumber extract|TBL12 is administered orally at a dose of 2 units (of 20 mL each) twice a day, in 4-week cycles, until disease progression or there is sign of disease progression.
3075848|NCT01302379|Active Comparator|Metformin + lifestyle intervention|
3075849|NCT01302379|Active Comparator|Placebo + lifestyle intervention|
3075850|NCT01302379|Active Comparator|Metformin + standard dietary guidelines|
3075851|NCT01302379|Placebo Comparator|Placebo + standard dietary guidelines|
3075852|NCT01302392|Active Comparator|Best Supportive Care|
3075853|NCT01302392|Experimental|Carfilzomib|
3075854|NCT01302418||Symptomatic|Individuals with signs and symptoms of an acute respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
3075855|NCT01302483|Experimental|Kovacaine Nasal Spray|3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
3075856|NCT01302483|Active Comparator|Lidocaine Injection|.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
3075857|NCT01302548|Experimental|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
3075858|NCT01302548|Active Comparator|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
3075859|NCT01302691|Experimental|L50/H12.5/A5|Participants receive 1 tablet, containing 50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
3075860|NCT01302691|Active Comparator|L50 + A5|Participants receive tablet, containing 50 mg losartan potassium (L50), and tablet containing 5 mg amlodipine besylate (A5), orally, once daily, for 8 weeks.
3075861|NCT01302743|Active Comparator|Metformin|oral extended-release Metformin 1000 mg once a day for 90 days
3075862|NCT01302743|Experimental|Cinnamon Bark|Cinnamon Bark 1000 mg once a day for 90 days
3075863|NCT01302743|Experimental|Cinnulin PF|Cinnulin PF 500 mg once a day for 90 days
3075864|NCT01302808|Experimental|Cohort 1 (Erlotinib plus Romidepsin (8 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
3075865|NCT01302808|Experimental|Cohort 2 (Erlotinib plus Romidepsin (10 mg/m^2))|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
3075866|NCT01302808|Experimental|Cohort 3 (Erlotinib plus Romidepsin (10 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 10 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
3075867|NCT01302808|Experimental|Cohort 4 (Erlotinib plus Romidepsin (8 mg/m^2)) + Antiemetic prophylaxis|Erlotinib 150 mg orally daily plus romidepsin IV days 8 mg/m^2 with antiemetic prophylaxis administered as a 4-h intravenous infusion on days 1, 8, and 15 of a 28-day cycle.
3075868|NCT01302834|Active Comparator|IMRT + Cisplatin|Intensity-modulated radiotherapy (IMRT) with concurrent cisplatin
3075869|NCT01302834|Active Comparator|IMRT + Cetuximab|Intensity-modulated radiotherapy (IMRT) with concurrent cetuximab
3075870|NCT01302860|Experimental|Canakinumab|Canakinumab s.c. injection (2 mg/kg) was administered every 8 weeks.
3075871|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)+HCTZ/Ram+Ali/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
3075872|NCT01302899|Experimental|Ramipril (Ram) +HCTZ/Ram+Aliskiren (Ali)/Ram+Ali + HCTZ/Ram|"Period 1(Day 1 to end of week 6): 1 tablet ramipril 10 mg once daily (o.d.) + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule Hydrochlorothiazide (HCTZ) 25 mg o.d.~Period 2 (Weeks 7 to 12): 1 tablet ramipril 10 mg o.d.+ 1 tablet aliskiren 150 mg in 1st week of period; thereafter, 2 tablets aliskiren 150mg o.d.+ 1 capsule placebo to HCTZ 25 mg o.d.~Period 3 (Weeks 13 to 18): 1 tablet ramipril 10 mg o.d. + 2 tablets aliskiren 150mg o.d. + 1 capsule HCTZ 25 mg o.d.~Period 4 (Weeks 19 to 26): 1 tablet ramipril 10 mg o.d. + 2 tablets placebo to aliskiren 150mg o.d. + 1 capsule placebo to HCTZ 25 mg o.d."
3075873|NCT01302938|Experimental|Tolterodine ER|
3075874|NCT01302938|Placebo Comparator|Placebo|
3075875|NCT01302964|Experimental|Mirtazapine|The starting dose for subjects is 7.5 mg daily. The maximum daily dose will be 45 mg.
3075876|NCT01302964|Placebo Comparator|Placebo|Subjects randomized to placebo arm will receive capsules identical in size and appearance to those subjects receiving study drug. Placebo capsules contain inactive ingredients.
3075877|NCT01303068|Experimental|CF patients, 13C urea breath test kit|CF patients with Pseudomonas infection tested with 13C urea breath test
3075878|NCT01303068|Active Comparator|Healthy controls, 13C urea breath test kit|Healthy subjects using 13C urea breath test kit
3075879|NCT01303159|Experimental|Radiofrequency probe (ENDOHPB)|"Intervention:~The EndoHPB is an endoscopic bipolar catheter designed to ablate tissue in malignant tumors within luminal structures, such as the biliary tree or pancreatic ducts. EndoHPB can be deployed via an ERCP or Percutaneous Transhepatic Cholangiographic (PTC) route. By using radiofrequency (RF) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may delay tumour growth and the time before the stent lumen becomes blocked. Thereby, allowing increased periods between the need for intervention and further stent deployment"
3075880|NCT01303172|Active Comparator|Gemcitabine chemotherapy|Patients in the control arm will receive normal standard of care - up to 12 cycles of Gemcitabine. Dosing of Gemcitabine is as per the normal prescribing information for pancreatic cancer.
3075881|NCT01303172|Experimental|IMM-101 in addition to gemcitabine|"Patients in the experimental arm will receive IMM-101 in addition to the current standard of care, namely chemotherapy (Gemcitabine). The treatment regimen with IMM-101 will be every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~For patients in the active group, chemotherapy (Gemcitabine) will begin at least 14 days after first dose of IMM-101.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Patients who complete the Main Study and who provide informed consent are eligible to participate in a long term treatment Sub-Study (IMM-101-002A)"
3075882|NCT01303224|Experimental|Ibodutant low dose|Oral tablet, to be given once daily in fasting conditions.
3075883|NCT01303224|Experimental|Ibodutant intermediate dose|Oral tablet, to be given once daily in fasting conditions.
3075884|NCT01303224|Experimental|Ibodutant high dose|Oral tablet, to be given once daily in fasting conditions.
3075885|NCT01303224|Placebo Comparator|Placebo|Oral tablet, to be given once daily in fasting conditions.
3075886|NCT01303380|Experimental|Canakinumab|
3075887|NCT01303406|Placebo Comparator|Placebo|"Following the body weight, patients will be allocated to one of the following regimen:~Placebo Patients < 45 kg - 3 tablets 3 times a day with meals~Placebo Patients > 45 kg - 5 tablets 3 times a day with meals"
3075888|NCT01303406|Experimental|idebenone|"Following the body weight, patients will be allocated to one of the following regimen:~Idebenone Patients < 45 kg - 3 tablets 3 times a day with meals~Idebenone Patients > 45 kg - 5 tablets 3 times a day with meals"
3075889|NCT01303419|Experimental|CE-BMRI|Subject will undergo bilateral CE-BMRI as per usual clinical practice within 30 days after the new breast cancer diagnosis. Subject will then undergo bilateral DE-CEDM examination within 8 weeks after the CE-BMRI exam.
3075890|NCT01303445|Active Comparator|Treatment A|Aggrenox alone
3075891|NCT01303445|Experimental|Treatment B|Aggrenox and omeprazole
3075892|NCT01303445|Active Comparator|Treatment C|Omeprazole alone
3075893|NCT01303445|Experimental|Treatment D|Aggrenox and omeprazole
3075894|NCT01303510|Experimental|Group A|Adults from 18 to 60 years old inclusive
3075895|NCT01303510|Experimental|Group B|Elderly subjects aged over 60 years
3075896|NCT01303627|Active Comparator|ultiva,remifentanil,opioid,analgesic|Remifentanil:1.5ng/ml remifentanil infusion maintained at the end of the surgery
3075897|NCT01303627|No Intervention|control|Control:Remifentanil stopped at the end of the surgery
3075898|NCT01303744|Experimental|CHF 5074 1x|oral tablet, multidose
3075899|NCT01303744|Experimental|CHF 5074 2x|oral tablet, multidose
3075900|NCT01303744|Experimental|CHF 5074 3x|oral tablet, multidose
3075901|NCT01303744|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3075902|NCT01303835|Experimental|Naltrexone|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
3075903|NCT01303835|Placebo Comparator|Placebo|Randomized patients received placebo to be taken every night before bed.
3075904|NCT01303861|Active Comparator|varenicline|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline.
3075905|NCT01303861|Active Comparator|Nicotine Patches only|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches(assessed at Session P2). They will continue to receive only nicotine patches.
3075906|NCT01303861|Active Comparator|Nicotine Patches with Nicotine Inhaler|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will continue to receive nicotine patches and will receive a nicotine inhaler to use as needed after their quit date.
3075907|NCT01303861|Active Comparator|varenicline with bupropion|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation nicotine patches (assessed at Session P2). They will receive varenicline in combination with bupropion.
3075908|NCT01303939|Other|Glaucoma Patients|Patients who were outliers from two previous studies: Assessment of Ability Related to Vision (AARV) or Assessment of Disability Related to Vision (ADREV) with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
3075909|NCT01303939|Other|Control Patients|Age, gender and race matched (to each glaucoma patient) group of healthy individuals with no ocular diseases with mini mental status exam score of 25 or higher underwent magnetic resonance imaging (MRI) of the brain to look at structures and volume.
3075910|NCT01303965|Experimental|Open Label, Single Arm|Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
3075911|NCT01304082|Placebo Comparator|normal saline|
3075912|NCT01304082|Active Comparator|lidocaine|
3075913|NCT01304082|Experimental|alkalinized lidocaine|
3075914|NCT01304147|Experimental|Ketamine|Subjects randomized to this arm will receive the active study medication, intranasal ketamine.
3075915|NCT01304147|Placebo Comparator|Placebo|Subjects randomized to this arm will receive intranasal saline.
3075916|NCT01304238||lepirudin|lepirudin treated subjects
3075917|NCT01304238||danaparoid|danaparoid treated subjects
3075918|NCT01304238||argatroban|argatroban treated subjects
3075919|NCT01304238||fondaparinux|fondaparinux treated subjects
3075920|NCT01304277|Experimental|Replagal® (0.2 mg/kg, IV, EOW)|"Screening period of approximately 14 days during which all patients received 1 infusion of 0.2 mg/kg Replagal RB (Week 0)~Treatment period of 14 weeks during which all patients received 7 infusions of 0.2 mg/kg Replagal AF"
3075922|NCT01304329|Experimental|treatment A, reference|1 tablet BI 10773, oral administration with 240 ml water
3075923|NCT01304329|Experimental|treatment B, reference|1 tablet simvastatin, oral administration with 240 ml water
3075924|NCT01304329|Experimental|treatment C, test|1 tablet BI 10773 + 1 tablet simvastatin, oral administration with 240 ml water
3075925|NCT01304407|Other|RTS Subjects, Calcium Isotope|Subjects consume breakfast and 180 ml of calcium-fortified orange juice to which 20 mg of 46Ca stable isotope was added. Immediately after breakfast, subjects receive 5 mg of 42Ca intravenously.
3075926|NCT01304498|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3075927|NCT01304498|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3075928|NCT01304589|Experimental|Milnacipran|This was an 18-week, open-label, flexible-dose exploratory trial where eligible patients were treated with 200 mg/day of milnacipran (or the maximum tolerated dose) for a total of 12 weeks. The study design involved 3 phases: screening and baseline assessment, dose escalation and stable-dose phase. All women received 12 weeks of stable dose treatment after a 6-week dose-escalation period for a total of 18 weeks of drug exposure.
3075929|NCT01304641||Atorvastatin Initiators|
3075930|NCT01304641||Simvastatin Initiators|
3075931|NCT01304693|Experimental|ESBA1008|ESBA1008 solution, single intravitreal injection
3075932|NCT01304693|Active Comparator|LUCENTIS|Ranibizumab 0.5 mg, single intravitreal injection
3075933|NCT01304706|Experimental|Fluocinolone Acetonide|
3075934|NCT01304940||PTSD group|Individuals in this group meet criteria for PTSD as defined by DSM-IV
3075935|NCT01304940||trauma control group|individuals in this group do not meet criteria for any Axis I diagnosis as defined by DSM-IV
3075936|NCT01305044|Experimental|Tai Chi Chih|The Tai Chi Chih classes were 60 minutes sessions, held three times a week, over twelve weeks. The classes were led by an instructor who was certified and licensed in the Tai Chi Chih form.
3075937|NCT01305044|Active Comparator|Health Education Classes|Health Education classes were 60 minute sessions that occurred three times a week, over twelve weeks. These classes were taught by specialists in the class topic and focused on topics related to aging (e.g., sleep quality, nutrition, pain, etc.).
3075938|NCT01305200|Placebo Comparator|Arm I (placebo)|Patients rinse and gargle with placebo over 1 minute QID beginning the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
3075939|NCT01305200|Experimental|Arm II (supersaturated calcium phosphate rinse)|Patients rinse and gargle with supersaturated calcium phosphate rinse over 1 minute QID beginning on the first day (about day -7) of the conditioning regimen. Treatment continues until day 20 post-transplantation.
3075940|NCT01305213|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3075941|NCT01305213|Experimental|Arm II (bevacizumab, fosbretabulin tromethamine)|Patients receive bevacizumab IV over 30-90 minutes and fosbretabulin tromethamine IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3075942|NCT01305239||Postmenopausal ER+ patients treated by Aromasin.|
3075943|NCT01305252|Active Comparator|tadalafil alone|tadalafil 40mg QD(Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated).
3075944|NCT01305252|Active Comparator|tadalafil and treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths.Each breath provides approximately 6 mcg of treprostinil.Tadalafil 20 mg QD PO increasing to 40 mg QD as tolerated.
3075945|NCT01305265|Active Comparator|intervention|Endotracheal tube will be adjusted to 22-26 cm H20 pressure immediately post intubation using a cuff manometer
3075946|NCT01305265|No Intervention|control|endotracheal tube cuff will be inflated using standard technique
3075947|NCT01305356|Experimental|Augment® Injectable Bone Graft|Standard rigid fixation + Augment® Injectable Bone Graft (beta-TCP/bovine collagen matrix + rhPDGF-BB)
3075948|NCT01305356|Active Comparator|Autologous bone graft|Standard Rigid Fixation + Autologous bone graft
3075949|NCT01305408|Placebo Comparator|Placebo|Participants began taking placebo to match armodafinil and following the same titration procedure. Treatment was administered for a total of 8 weeks.
3075950|NCT01305408|Experimental|Armodafinil 150 mg/day|Participants began taking armodafinil at a dosage of 50 mg/day; the dosage was increased by 50 mg/day on days 2 and 4, up to a dosage of 150 mg/day. Treatment was administered for a total of 8 weeks.
3075951|NCT01305473||Sepramesh Group|
3075952|NCT01305564|Experimental|Denali inferior vena cava filter|All subjects enrolled will receive the Denali vena cava filter.
3075953|NCT01305577|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075954|NCT01305577|Experimental|Deoxycholic Acid Injection 1 mg/cm²|Participants received deoxycholic acid 1 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075955|NCT01305577|Experimental|Deoxycholic Acid Injection 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 4 treatments.
3075956|NCT01305655|Experimental|Glucarpidase arm|In the NOPHO ALL-2008 protocol patients with delayed methotrexate elimination (DME) in high-dose methotrexate treatments should be given Glucarpidase (50 ie/kg) with-in 60 hours from start of the methotrexate treatment.
3075957|NCT01305772|Experimental|Surgery|Patients who underwent surgery after research PET/CT scans and subsequent radiation therapy with panitumumab administration
3075958|NCT01305772|Active Comparator|Radiation Therapy|Patients who underwent radiation therapy only, in conjunction with panitumumab therapy.
3075959|NCT01305811|Experimental|Bi-weekly acupuncture treatment|Bi-weekly acupuncture treatment
3075960|NCT01305811|Active Comparator|Wait list|Wait list for 2 months followed by weekly acupuncture for 4 months
3075961|NCT01305941|Experimental|Everolimus +Vinorelbine + trastuzumab|daily everolimus plus weekly (Days 1, 8, and 15) vinorelbine and trastuzumab
3075962|NCT01306032|Experimental|Triple-negative Breast Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3075963|NCT01306032|Experimental|Triple-negative Breast Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3075964|NCT01306032|Experimental|BRCA-positive Ovarian Cancer: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3075965|NCT01306032|Experimental|BRCA- positive Ovarian Cancer: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3075966|NCT01306032|Experimental|Non-Hodgkin's: ABT-888 + Cyclophosphamide|Oral cyclophosphamide 50mg by mouth (PO) for 21 days and oral ABT-888 60mg by mouth (PO) on a continuous schedule.
3075967|NCT01306032|Experimental|Non-Hodgkin's: Cyclophosphamide Alone|Oral cyclophosphamide 50mg by mouth (PO) for 21 days. Participants in the cyclophosphamide alone arm crossed over to the ABT-888 plus cyclophosphamide arm at time of disease progression.
3075968|NCT01306058|Experimental|Sorafenib & TRC105 in Hepatocellular CA|CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day
3075969|NCT01306162|Experimental|A: Dabigatran alone (Reference)|Capsule, oral administration with 240 mL water
3075970|NCT01306162|Experimental|B: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3075971|NCT01306162|Experimental|C: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3075972|NCT01306162|Experimental|D: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3075973|NCT01306162|Experimental|E: Dabigatran plus Dronedarone (Test)|Capsule and Tablets, oral administration with 240 mL water
3075974|NCT01306175|Experimental|Digoxin alone (Reference)|Tablet, oral administration with 240 mL water
3075975|NCT01306175|Experimental|Digoxin plus BI 10773 (Test)|Tablets, oral administration with 240 mL water
3075976|NCT01306201||In-patient Volunteers|In-patients from the hospital who choose to participate in the study
3075977|NCT01306214|Experimental|BI 10773 low dose|BI 10773 low dose once daily
3075978|NCT01306214|Experimental|BI 10773 high dose|BI 10733 high dose once daily
3075979|NCT01306214|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3075980|NCT01306253|Experimental|Elderly|Elderly subjects aged over 60 years
3075981|NCT01306253|Experimental|Adults|Adults from 18 to 60 years old inclusive
3075982|NCT01306292|Experimental|SonoVue|Ultrasound contrast agent under development
3075983|NCT01306292|Placebo Comparator|Placebo|normal saline 0.9% for injection used as the comparator
3075984|NCT01306305|Experimental|Elderly|Elderly subjects aged over 60 years
3075985|NCT01306305|Experimental|Adults|Adults from 18 to 60 years old inclusive
3075986|NCT01306331|Active Comparator|Conceptrol|100 mg (4% concentration) of nonoxynol-9 in 2.5 mL volume of gel
3075987|NCT01306331|Experimental|Amphora|Citric acid USP, potassium bitartrate USP, and L-lactic acid USP
3075988|NCT01306617|Experimental|ABT-450/r (250/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (250/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
3075989|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in treatment-naïve|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID for 12 weeks in treatment-naïve participants.
3075990|NCT01306617|Experimental|ABT-450/r (150/100 mg) and ABT-333 plus RBV in non-responders|ABT-450/r (150/100 mg) once daily (QD) and ABT-333 (400 mg) twice daily (BID) plus weight-based ribavirin (RBV) divided BID in previous non-responders to pegylated interferon (pegIFN) and RBV.
3075991|NCT01306643|Experimental|Idelalisib|
3075992|NCT01306656|Experimental|Group 1|10,000 IU Vitamin D3 plus a multivitamin with 400 IU vitamin D
3075993|NCT01306656|Placebo Comparator|Group 2|Placebo plus a multivitamin with 400 IU vitamin D
3075994|NCT01306877|Experimental|EEA Hemorrhoid and Prolapse Stapling Set|
3075995|NCT01306877|Active Comparator|Endosurgery Proximate PPH03 Stapling Set|
3075996|NCT01306890||sipuleucel-T|
3075997|NCT01306942|Experimental|Dasatinib + trastuzumab + paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg once daily (QD) (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
3075998|NCT01306968|No Intervention|Standard TBI Care|Routine post-concussive symptoms (PCS) care as practiced within Departments of Defense (DoD)
3075999|NCT01306968|Experimental|HBO2 Group|Routine PCS care supplemented with hyperbaric oxygen (HBO2) at the dose of 1.5 ATA for 60 minutes administered over 40 sessions given daily Monday through Friday
3076000|NCT01306968|Sham Comparator|Sham Group|Routine PCS care supplemented with an otherwise identical sham hyperbaric air exposure at 1.2 atmospheres absolute (ATA)
3076001|NCT01306968|No Intervention|PTSD With no History of TBI|Subjects who have been diagnosed with PTSD but have no diagnosed or suspected brain injuries. This group does not receive HBO2.
3076002|NCT01307007|Experimental|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
3076003|NCT01307007|Active Comparator|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
3076004|NCT01307020|Placebo Comparator|Placebo|
3076005|NCT01307020|Active Comparator|Ibuprofen|
3076006|NCT01307020|Active Comparator|TRAM.HCl high dose|
3076007|NCT01307020|Active Comparator|TRAM.HCl low dose|
3076008|NCT01307020|Active Comparator|DKP-TRIS high dose|
3076009|NCT01307020|Active Comparator|DKP-TRIS low dose|
3076010|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl low dose|
3076011|NCT01307020|Experimental|DKP-TRIS low dose - TRAM.HCl high dose|
3076012|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl low dose|
3076013|NCT01307020|Experimental|DKP-TRIS high dose - TRAM.HCl high dose|
3076014|NCT01307033|Active Comparator|MK-954H (L50/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 50 mg (L50) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will then receive open label MK-0954A (L100/H12.5) orally, once daily for 44 weeks (extension)
3076015|NCT01307033|Experimental|MK-0954A (L100/H12.5)|One combination tablet daily, orally, for 8 weeks. Each tablet contains Losartan 100 mg (L100) and 12.5 mg of hydrochlorothiazide (H12.5). Participants will continue to receive MK-0954A orally, once daily for 44 week extension
3076016|NCT01307046|Experimental|MK-0954A|Participants administered MK-0954A, Placebo for Losartan 50 mg , and Placebo for Losartan 100 mg orally, once daily for 8 weeks.
3076017|NCT01307046|Active Comparator|Losartan|Participants administered Losartan 100 mg, Placebo for MK-0954A, and Placebo for Losartan 50 mg orally, once daily for 8 weeks.
3076018|NCT01307098|Experimental|Sebelipase alfa 0.35 mg/kg|Cohort 1: Participants were administered once weekly (qw) infusions of 0.35 mg/kg sebelipase alfa.
3076019|NCT01307098|Experimental|Sebelipase alfa 1 mg/kg|Cohort 2: Participants were administered qw infusions of 1 mg/kg sebelipase alfa.
3076020|NCT01307098|Experimental|Sebelipase alfa 3 mg/kg|Cohort 3: Participants were administered qw infusions of 3 mg/kg sebelipase alfa.
3076021|NCT01307111|Experimental|Misoprostol|Misoprostol 400 micrograms inserted buccally or vaginally, per the participants desire.
3076022|NCT01307111|Placebo Comparator|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
3076023|NCT01307267|Experimental|Portion A|PF-05082566 single agent in patients with advanced cancer
3076024|NCT01307267|Experimental|Portion B|PF-05082566 in combination with rituximab in patients with Non-Hodgkin's Lymphoma
3076025|NCT01307319|Experimental|BDP HFA 80 mcg/day|Participants/parents administer 40 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
3076026|NCT01307319|Experimental|BDP HFA 160 mcg/day|Participants/parents administer 80 mcg of beclomethasone dipropionate hydrofluoroalkane (BDP HFA) (one spray per nostril) once daily for 15 days.
3076027|NCT01307319|Placebo Comparator|Placebo nasal aerosol once daily|Participants/parents administer placebo (a spray with no medication in each nostril) once daily for 15 days.
3076028|NCT01307397|Experimental|Vemurafenib|Participants will receive vemurafenib at a dose of 960 milligrams (mg) twice daily (bid) until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
3076029|NCT01307423|Experimental|Apremilast 20mg|Apremilast 20mg twice daily, orally
3076030|NCT01307423|Experimental|Apremilast 30mg|Apremilast 30mg twice daily, orally
3076031|NCT01307423|Placebo Comparator|Placebo + 20mg Apremilast|Placebo + 20mg Apremilast tablets administered twice daily
3076032|NCT01307423|Placebo Comparator|Placebo + 30mg Apremilast|Placebo + 30mg Apremilast tablets administered twice daily
3076033|NCT01307449|Experimental|Older Group on PREVNAR|Participants between the ages of 60-89 received PREVNAR
3076034|NCT01307449|Experimental|Younger Group on PREVNAR|Participants between the ages of 25-40 years received PREVNAR
3076035|NCT01307449|Experimental|Older Group on PNEUMOVAX|Participants between the ages of 60-89 received PNEUMOVAX
3076036|NCT01307449|Experimental|Younger Group on PNEUMOVAX|Participants between the ages of 25-40 years received PNEUMOVAX
3076037|NCT01307462|Experimental|Treatment (BOS therapy)|Patients receive fluticasone propionate inhaled PO BID, azithromycin PO 3 days a week, and montelukast sodium PO QD. Treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
3076038|NCT01307501|Other|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. No more than 3 tumors in 1 lung can be treated in a single session, and no more than 5 total lung tumors (across both lungs) can be treated during the study.
3076039|NCT01307579|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over one hour QD beginning within 24-72 hours following the last dose of chemotherapy for each course. and continuing until ANC > 100-500/uL following the nadir or the next chemotherapy course begins.
3076040|NCT01307579|Active Comparator|Arm II (fluconazole)|Patients receive fluconazole IV over 1-2 hours or PO QD beginning within 24-72 hours following the last dose of chemotherapy for each course.
3076041|NCT01307618|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising recombinant MAGE-3.1 antigen, MART-1 antigen, gp100 antigen, and NA17-A2 peptide emulsified with Montanide ISA-51 ID or SC on days 1, 22, and 50.
3076042|NCT01307618|Experimental|Arm II (vaccine therapy, IL-12)|Patients receive vaccination as in arm I with an admixture of IL-12 ID or SC on days 1, 22, and 50.
3076043|NCT01307631|Experimental|Treatment (Akt inhibitor MK2206|Patients receive Akt inhibitor MK2206 PO once weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3076044|NCT01307748|Experimental|stress reducing aroma|aroma with reported stress reducing effects
3076045|NCT01307748|Placebo Comparator|Placebo aroma 1|
3076046|NCT01307748|Placebo Comparator|Placebo aroma 2|
3076047|NCT01307787|Experimental|fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component.
3076048|NCT01307787|No Intervention|waiting list control group|The waiting-list control group was allowed to enter the FIT program for rehabilitation after the study period.
3076049|NCT01307891|Experimental|Abraxane + Tigatuzumab|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8, and 15 at 28-day intervals and tigatuzumab to be administered as a 10 mg/kg loading dose followed by 5 mg/kg for the first cycle and then every other week on Days 1 and 15 for subsequent cycles. Patients will be evaluated for response every 8 weeks. Patients with disease progression will be taken off the study.
3076050|NCT01307891|Experimental|Abraxane alone|Patients will receive Abraxane at 100 mg/m2 weekly X 3 doses on Days 1, 8, and 15 at 28-day intervals. Patients will have the option to crossover to the combination arm based upon the pre-clinical data.
3076051|NCT01307930|Experimental|Anidulafungin|Six volunteers will have a body mass index (BMI) less than 25 kg/m2, 6 will have a BMI 25-40 kg/m2, and 6 will have a BMI greater than 40 kg/m2.
3076052|NCT01307956|Experimental|Treatment (panitumumab, chemotherapy, radiation)|Patients receive panitumumab IV over 1 hour on day 1. Patients also receive oxaliplatin IV and leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1 (FOLFOX chemotherapy). Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Within 24 hours of the start of chemotherapy, patients undergo radiation therapy 5 days a week for 5.5 weeks. Patients then undergo surgery within 6-8 weeks after completion of radiation therapy. Patients with residual disease receive 4 additional courses of FOLFOX chemotherapy on days 1, 15, 29, and 42.
3076053|NCT01308008|Experimental|Functional exercise- home physical activity|On-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with telephonic behavioral support
3076054|NCT01308008|Active Comparator|Flex and tone- home health education|Initial on-site flex and toning program continued on follow-up along with health education
3076055|NCT01308060|Experimental|Botulinum Toxin type A|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
3076056|NCT01308060|Placebo Comparator|Placebo|During part A, efficacy and safety parameters will be assessed for Azzalure vs. placebo
3076057|NCT01308294|Experimental|2 vaccine injections in 1 limb|9 patients initially planned: patients received peptides with IMP321/LAG-3Ig and Montanide in 2 injections sites at 5 cm distance from each other 2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
3076058|NCT01308294|Experimental|2 vaccine injections in distinct limbs|Groupe2: 2 vaccine injections in different limb should include 9 patients that were initially planned: patients received the same vaccine in 2 syringes injected each in a distinct limb (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)
3076059|NCT01308294|Experimental|"2 vaccine injections in distinct limbs"|Groupe3: 2 vaccine injections in distinct limb should include 9 patients that were initially planned; due to premature trial termination, no patients could be enrolled. Patients of this group should have received the same vaccine but without the MHC class II peptide (MAGE-A3)
3076060|NCT01308424|Experimental|BTL TML HSV|
3076061|NCT01308424|Placebo Comparator|Matching Placebo|
3076062|NCT01308450||Single Arm, Non ADHD Control Group|Single site, single visit study. Subjects will be administered Standard Rating Scales (Defined) and the Quotient ADHD System Test (Adolescent and Adult Version). Subject's assessed to be Non-ADHD will be eligible to have their Quotient tests added to the Quotient Adolescent and Adult Normative Database.
3076063|NCT01308476||SMS group|
3076064|NCT01308476||control group|
3076065|NCT01308567|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.
3076066|NCT01308567|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
3076067|NCT01308567|Active Comparator|Docetaxel 75 mg/m^2|Docetaxel (TXT) 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.
3076068|NCT01308580|Experimental|Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
3076069|NCT01308580|Experimental|Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.
3076070|NCT01308619|Active Comparator|Oracea®|Doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules
3076071|NCT01308619|Active Comparator|placebo|placebo
3076072|NCT01308736|Active Comparator|varenicline|
3076073|NCT01308736|Placebo Comparator|placebo pill|
3076074|NCT01308749|Placebo Comparator|Placebo|Intervention: Drug: placebo
3076075|NCT01308749|Active Comparator|Oxytocin|Intervention: Drug: Syntocinon® Nasal Spray
3076076|NCT01308762|Experimental|IMM-101|"Patients received an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28. Doses used were:~'Heat killed whole cell M. obuense (IMM-101) 0.1 mg', 'Heat killed whole cell M. obuense (IMM-101) 0.5 mg', or 'Heat killed whole cell M. obuense (IMM-101) 1.0 mg'"
3076077|NCT01308788||aqueous suppressant|aqueous suppressant treated
3076078|NCT01308788||aqueous outflow|aqueous outflow treated
3076079|NCT01308814|Placebo Comparator|Placebo|Placebo patches for 12 months and placebo pills for 12 days every 2 months.
3076080|NCT01308814|Experimental|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months and oral micronized progesterone (200 mg/day) for 12 days every two months.
3076081|NCT01308840|Experimental|Panitumumab|Panitumumab 6mg/kg on days 1 and 15 of every cycle (28 days); Gemcitabine 1000mg/m2 on days 1 and 15 of every cycle (28 days); Oxaliplatin 85mg/m2 on days 1 and 15 of every cycle (28 days)
3076082|NCT01308853|Other|Macrolane|Open label
3076083|NCT01308918||GlideScope DLT intubation|Patients having a thoracic surgery (non cardiac) via either thoracoscopy or thoracostomy. Patients were all 18 years old or over, and have read, understood and signed an informed consent at the preoperative evaluation or on surgery morning.
3076084|NCT01309100|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens.
3076085|NCT01309100|Active Comparator|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens.
3076086|NCT01309100|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens.
3076087|NCT01309165|Experimental|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10 one-hour sessions intervention format. Participants randomized to the CO-OP group will continue to receive usual out-patient services, such as physiotherapy or speech-language therapy, but will receive CO-OP instead of usual occupational therapy.
3076088|NCT01309165|Active Comparator|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
3076089|NCT01309204|Experimental|Brinz/Brim|Vehicle, 1 drop instilled in each eye, followed by Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
3076090|NCT01309204|Active Comparator|Brinz+Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye, followed by Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye. A 10-minute waiting period separated the instillations. Study drugs were instilled twice a day for 6 months.
3076091|NCT01309243|Experimental|FTC/RPV/TDF|
3076092|NCT01309243|Experimental|EFV/FTC/TDF|
3076093|NCT01309269||Cohort|
3076094|NCT01309282||Rituximab|Sero-positive [Rheumatoid Factor (RF) and/or anti-Cyclic Citrullinated Peptide (CCP+)] rheumatoid arthritis (RA) patients, who had initiated therapy with Rituximab (MabThera) following lack of response or intolerance to a single tumour necrosis factor (TNF)-inhibitor will be included in this arm
3076095|NCT01309308|Experimental|The membranes swept group|This group will have a sweeping of the membranes after the 38th of gestation at hospital, in order to reduce the latency period until labor. Sweeping of the membranes is done by the insertion of examiners finger between the decidua and fetal membranes and by the circular movement of the finger, the membranes are detached from the decidua.
3076096|NCT01309308|Sham Comparator|No sweeping group|This group will not have sweeping of the membranes, will only have vaginal ultrasound
3076097|NCT01309360|Active Comparator|group A : 40ml Prilocaine 1%|40 outpatients : 40ml Prilocaine 1% were administered for axillary plexus block
3076098|NCT01309360|Active Comparator|group B : 30ml Prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
3076099|NCT01309360|Active Comparator|group C : 20ml Prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
3076100|NCT01309386|Experimental|Tapentadol ER|Tapentadol extended-release (ER) (JNS024ER) oral tablets 100 to 400 milligram (mg) daily for 8 weeks (maximum dose could be up to 500 mg daily), as per Investigator's discretion.
3076101|NCT01309386|Active Comparator|Morphine SR|Morphine sustained-release (SR) oral tablets 30 to 120 mg daily for 8 weeks (maximum dose could be up to 140 mg daily), as per Investigator's discretion.
3076102|NCT01309451|Active Comparator|Bevacizumab alone|
3076103|NCT01309451|Active Comparator|Combined group|Bevacizumab plus Ozurdex
3076104|NCT01309646|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™-IPV+Hib at 2, 4 and 6 months of age, 3 doses of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™-IPV+Hib was administered intramuscularly in the right thigh, the Synflorix™ vaccine was administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
3076105|NCT01309646|Active Comparator|Infanrix IPV Group|Subjects aged between, and including, 42 and 69 days at the time of first vaccination received 3 doses of Infanrix™ IPV and Hiberix™ co-administered at separate injection sites at 2, 4 and 6 months of age, 3 dose of Synflorix™ at 6 weeks, 3.5 and 5.5 months of age and 2 doses of Rotarix™ at 6 weeks and 3.5 months of age. The Infanrix™ IPV was administered intramuscularly in the right thigh, the Synflorix™ and Hiberix™ vaccines were administered intramuscularly in the left thigh and the Rotarix™ vaccine was administered orally.
3076106|NCT01309659|Experimental|Immediate Intervention Group|Subjects randomized to the immediate treatment group will be scheduled to begin treatment with IV iron infusion immediately (or within 2 business days). They will receive 200mg IV iron sucrose a week for 5 weeks followed by 19 weeks of follow up.
3076107|NCT01309659|Experimental|Wait List Control|Subjects randomized to the wait list control group will have an observation visit at week 6 and week 12. After that they will begin treatment with IV iron infusion. They will receive 200mg IV iron sucrose a week for 5 weeks followed by 7 weeks of follow up
3076108|NCT01309737|Experimental|Active Treatment 10 mg BID|
3076109|NCT01309737|Experimental|Active Treatment 5 mg BID|
3076110|NCT01309737|Placebo Comparator|Placebo Treatment|
3076111|NCT01309802|No Intervention|placebo|no intervention
3076112|NCT01309802|Active Comparator|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
3076113|NCT01309828|Experimental|Azilsartan Medoxomil + Chlorthalidone|United States and Europe: Azilsartan medoxomil 20 mg plus chlorthalidone 12.5 mg fixed dose combination tablets, titrated up to azilsartan medoxomil 40 mg plus chlorthalidone 25 mg orally, once daily for up to 52 weeks.
3076114|NCT01309828|Active Comparator|Olmesartan Medoxomil + Hydrochlorothiazide|United States: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 40 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks. Europe: Olmesartan medoxomil 20 mg plus hydrochlorothiazide 12.5 mg fixed dose combination tablets, titrated up to olmesartan medoxomil 20 mg plus hydrochlorothiazide 25 mg orally, once daily for up to 52 weeks.
3076115|NCT01309841|Experimental|1|Oral treatment
3076116|NCT01309841|Experimental|2|Oral treatment
3076117|NCT01309841|Placebo Comparator|3|Oral treatment
3076118|NCT01309867|Experimental|Investigational Toric Lens|Bausch + Lomb investigational toric contact lenses
3076119|NCT01309867|Active Comparator|PureVision Toric Lens|Currently marketed Bausch + Lomb PureVision toric contact lenses
3076120|NCT01309880|Active Comparator|Air Optix Aqua|Ciba Vision daily wear contact lens
3076121|NCT01309880|Experimental|Test Lens|Investigational silicone hydrogel contact lens
3076122|NCT01309893|Experimental|Investigational Lens|Bausch & Lomb investigational silicone hydrogel contact lens for 1 week; then issued Air Optix Aqua Lens for 1 week.
3076123|NCT01309893|Active Comparator|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens for 1 week; then issued Investigational Lens for 1 week.
3076124|NCT01309906|Experimental|Investigational lens|Bausch & Lomb investigational silicone hydrogel lens
3076125|NCT01309906|Active Comparator|Air Optix Aqua lens|Ciba Vision Air Optix Aqua contact lens
3076126|NCT01309919|Active Comparator|IUD Arm|Subjects who receive an IUD within 48 hours of delivery (vaginal or cesarean birth)
3076127|NCT01309919|Other|Diary Arm|Subjects who will not have an IUD placed postpartum; they may use another form of contraception, or no form at all
3076128|NCT01309997|Experimental|Arm I (enzyme inhibitor)|Patients receive imatinib mesylate PO QD for 6 months in the absence of progression of sclerosis or unacceptable toxicity.
3076129|NCT01309997|Experimental|Arm II (monoclonal antibody)|Patients receive rituximab IV on days 1, 8, 15, and 22. A second treatment cycle is repeated at 3 months for a total of 8 doses of rituximab in the absence of progression of sclerosis or unacceptable toxicity.
3076130|NCT01310036|Experimental|Erlotinib|Erlotinib 150 mg daily
3076131|NCT01310075|Experimental|Alloderm Mesh|Alloderm Mesh - 6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
3076132|NCT01310075|Experimental|Surgimend Mesh|Surgimend Mesh - 10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
3076133|NCT01310075|No Intervention|Control (no mesh)|
3076134|NCT01310127|Experimental|Bromday|Patients receiving Bromday self-administered one drop of bromfenac 0.09% daily as a topical ophthalmic drop three days prior to cataract surgery, on the day of cataract surgery and 21 days post operatively.
3076135|NCT01310127|Active Comparator|Nevanac|Patients in this arm self-administered nepafenac topical ophthalmic drops three times daily beginning 3 days prior to cataract surgery, on the day of surgery and for 21 days postoperatively in addition to usual cataract procedure.
3076136|NCT01310179|Experimental|Ad/PNP and fludarabine monophosphate|Ad/PNP will be injected three times into the tumor over 2 days followed by three daily intravenous infusions of F-araAMP (fludarabine monophosphate). Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
3076137|NCT01310231|Active Comparator|Metformin|Metformin plus standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
3076138|NCT01310231|Placebo Comparator|Placebo|Placebo and standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
3076139|NCT01310400|Experimental|Inflexal 0.5 mL|
3076140|NCT01310400|Experimental|Inflexal 0.25 mL|
3076141|NCT01310400|Experimental|Agrippal 0.25 mL|
3076142|NCT01310413|Experimental|Influenza A (H5N1) adjuvanted 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076143|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076144|NCT01310413|Experimental|Influenza A (H5N1) Virus monovalent vaccine 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A vaccine or GSK Biologicals' monovalent A/Indonesia/5/2005 (H5N1) vaccine adjuvanted) at Days 0 and 21. Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076145|NCT01310413|Placebo Comparator|Placebo 6-<36M Group|Subjects aged at enrolment between 3 and 36 months, 36 months excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly. For children aged up to 12 months, 12 months excluded (< 12 months), Dose 1 was administered in the left anterolateral thigh and Dose 2 in the right anterolateral thigh. For children older than (>=) 12 months, Dose 1 was administered in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076146|NCT01310413|Placebo Comparator|Placebo 3-<9Y Group|Subjects aged at enrolment between 3 and 9 years, 9 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076147|NCT01310413|Placebo Comparator|Placebo 9-<18Y Group|Subjects aged at enrolment between 9 and 18 years, 18 years excluded, received 2 doses of saline placebo at Days 0 and 21. The saline placebo was administered intramuscularly, Dose 1 in the deltoid region of the non-dominant arm (or left arm if dominance was not yet identified) and Dose 2 in the deltoid region of the dominant arm (or right arm).
3076148|NCT01310413|Experimental|Placebo/Influenza A (H5N1) adjuvanted Group|Subjects in this group were those who were administered the saline placebo solution in the Blinded Phase of the study (either in the Placebo 6-<36M, Placebo 3-<9Y or Placebo 9-<18Y Group). These were subjects aged at enrolment between 6 months and 18 years, 18 years excluded, who had received 2 doses of saline placebo at Days 0 and 21 in the Blinded Phase of the study, as per described in the descriptions of the Placebo 6-<36M, Placebo 3-<9Y and Placebo 9-<18Y groups. After consenting to participating to the Unblinded Phase of the study, these subjects received in addition 2 doses of Influenza A (H5N1) Virus monovalent vaccine at Days 385 (Day U0) and Day 385 + 21 days (Day U21). Influenza A (H5N1) Virus monovalent vaccine was administered intramuscularly. Dose 1 of was administered in the deltoid region of the non-dominant arm and Dose 2 in the deltoid region of the dominant arm.
3076149|NCT01310582|Active Comparator|Desflurane|During the surgery the subjects were given Desflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
3076150|NCT01310582|Active Comparator|Sevoflurane|During the surgery the subjects were given Sevoflurane, general anesthesia, that will keep the patient asleep during the surgery. The dosage form was inhalation gas, dosage equivalent to 1 MAC, frequency was once and the duration was throughout the surgery (30-45 minutes).
3076151|NCT01310699|Experimental|High Definition NBI Colonoscopy|Use of high definition narrow band imaging colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
3076152|NCT01310699|Placebo Comparator|High Definition White Light Colonoscopy|Use of high definition white light colonoscopy during examination for polyp detection. The same intervention is used on both arms: the Olympus Colonoscope CFHQ190AL, a technically improved colonoscope with close focus high definition narrow band imaging.
3076153|NCT01310777|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
3076154|NCT01310777|Active Comparator|Brinz|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in each eye 2 times a day for 6 months
3076155|NCT01310777|Active Comparator|Brim|Brimonidine tartrate 0.2% ophthalmic solution, 1 drop instilled in each eye 2 times a day for 6 months
3076156|NCT01310855|Active Comparator|Cediranib & Gefitinib|Cediranib maleate 30mg od orally and gefitinib 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
3076157|NCT01310855|Placebo Comparator|Cediranbib & placebo|Cediranib maleate 30mg od orally and placebo 500mg od orally. Each cycle of treatment lasts 6 weeks. Treatment will continue until confirmation of progression, patient decision or the development of unacceptable toxicity (if there is radiological progression only treatment can continue if the investigator has the opinion that the patient is receiving benefit.
3076158|NCT01310868|Experimental|5-ALA and Gliadel wafers|This is a single arm feasibility study to evaluate the safety and tolerability of combining 2 technologies (5-ALA and Gliadel wafers) in the surgical management of patients with GBM.
3076159|NCT01311024||Sibling vaccinated with PCV GSK1024850A|"Older sibling of a child vaccinated with Pneumococcal conjugate vaccine GSK1024850A in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
3076160|NCT01311024||Control-vaccinated sibling|"Older sibling of a child vaccinated with control vaccine (hepatitis B vaccine or hepatitis A vaccine) in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)~NOTE: the primary analysis cohort include siblings of the PCV-vaccinated according to infant schedules (excluding siblings of catch-up vaccinated children)"
3076161|NCT01311102|Experimental|2% Lidocaine liquid|1.33cc of 2% liquid lidocaine infused in endo cervix and endometrium
3076162|NCT01311102|Placebo Comparator|Normal Saline|1.33cc of normal saline infused in endo cervix and endometrium
3076163|NCT01311362||CYP2C19 wild type|"CYP2C19 wild type =extensive metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
3076164|NCT01311362||CYP2C19 mutant|"CYP2C19 *2/*2 or *2/*3 or *3/*3 = poor metaboliser~Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of St. Johns wort: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
3076165|NCT01311505|Active Comparator|A|Test
3076166|NCT01311505|Active Comparator|B|Reference
3076167|NCT01311557|Experimental|Adacel Vaccine Group 1|Participants enrolled at 10 to < 11 years of age
3076168|NCT01311557|Experimental|Adacel Vaccine Group 2|Participants enrolled at 11 to < 12 years of age
3076169|NCT01311648|Experimental|PTPs 0-12 years|Previously treated patients (PTPs) aged below 12 years received BAY81-8973 25-50 IU/kg at least 2x/week for 6 months and at least 50 exposure days (EDs) in main study - Part A. Participants having reached at least 50 EDs in main study - Part A were offered participation in an open label extension study (optional). Participants who transitioned from main study - Part A to the extension study received BAY81-8973, 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part A and extension study).
3076170|NCT01311648|Experimental|PUPs/MTPs 0-<6 years|Previously untreated patients (PUPs) or minimally treated patients (MTPs, patients who had no more than 3 exposure days (EDs) with any FVIII product) received BAY81-8973 15-50 IU/kg at least 1x/week for at least 50 EDs or until inhibitor development in main study - Part B. Participants having reached at least 50 EDs in main study - Part B were offered participation in an open label extension study and received BAY81-8973 25-50 IU/kg at least 2x/week for at least 100 cumulative EDs (main study - Part B and extension study); participants who developed an inhibitor in main study - Part B were offered participation in open label extension study and received Immune Tolerance Induction (ITI) treatment with BAY81-8973 until successful eradication of the inhibitor, or until failure, for approximately 18 months.
3076171|NCT01311661|Experimental|Olodaterol medium daily dose|Olodaterol medium daily dose given either as once daily or split into two low doses daily or placebo only in randomised sequence of three cross-over treatment phases
3076172|NCT01311661|Experimental|Olodaterol high daily dose|Olodaterol high daily dose given either as once daily or split into two medium doses daily or placebo only in randomised sequence of three cross-over treatment phases
3076173|NCT01311674|Active Comparator|Schedule 1- Standard dose primary vaccination series|Schedule 1 subjects received 20 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
3076174|NCT01311674|Experimental|Schedule 2 - High dose primary vaccination series|Schedule 1 subjects received 40 µg/1.0 mL of Engerix-B® on Day 0, Day 30, Day 60, Day 180 with booster of 20 µg/1.0 mL of Engerix-B® every 120 days (4 months) (after Day 180 vaccination)
3076175|NCT01311687|Experimental|Pomalidomide + Low-Dose Dexamethasone|Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
3076176|NCT01311687|Active Comparator|High-Dose Dexamethasone|Participants received 40 mg dexamethasone (or 20 mg for participants > 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.
3076177|NCT01311895|Experimental|H2O|2 mg IV hydromorphone administered over 2-3 minutes as initial dose
3076178|NCT01311895|Experimental|1+1|"1 mg IV hydromorphone followed by an additional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the following question: Do you want more pain medication?"
3076179|NCT01312038|Experimental|simethicone|125 mg tablet
3076180|NCT01312038|Placebo Comparator|placebo|chewable calcium tablet
3076181|NCT01312129|Experimental|Sulfasalazine|Sulfasalazine 1500 mg
3076182|NCT01312129|Placebo Comparator|Placebo|Placebo capsule x 3 doses 12 hours apart
3076183|NCT01312181|Active Comparator|HealthCall +Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
3076184|NCT01312181|Active Comparator|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
3076185|NCT01312181|Placebo Comparator|HIV/AIDS health education - DVD control|HIV/AIDS health education - DVD control. The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
3076186|NCT01312233|Active Comparator|Medical Care|Conventional medical care alone
3076187|NCT01312233|Active Comparator|Dual Care|Unlinked co-occurrence of conventional medical care and chiropractic care
3076188|NCT01312233|Active Comparator|Shared Care|Co-management of medical care and chiropractic care
3076189|NCT01312272|Placebo Comparator|Inactive nasal spray|A placebo nasal spray will be prepared to be otherwise identical to the active treatment nasal spray except lacking oxytocin. The ingredients in the inactive nasal spray are mannitol, glycerin, and preserved water.
3076190|NCT01312272|Experimental|Intranasal Oxytocin|Oxytocin nasal spray (40 units/ml) will be administered in a single intranasal dose of 40 IU. Its formula is: oxytocin 1 unit/mg mannitol trituration 0.2Gm + glycerin USP 0.1ml + preserved water 5ml.
3076191|NCT01312389|Experimental|Phase 2: Arm A|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions.
3076192|NCT01312389|Experimental|Phase 2: Arm B|10 patients will receive vaccine (OC-L, an autologous vaccine comprised of autologous oxidized tumor cell lysate, admixed with Montanide ISA 51 VG) injected by intradermal/subcutaneous injection in both groin regions, administered in combination with intravenous Ampligen.
3076193|NCT01312389|Experimental|Phase 1|3 patients will be enrolled receiving the vaccine (tumor lysate/Montanide) plus Ampligen using a 3+3 approach. If no DLTs in the first three subjects, we will move to phase II; if one 1/3 subject develops DLTs, we will enroll 3 additional subjects; if 2/6 subjects develop DLTs, we will discontinue the study. Following completion of run---in phase I (3 or 6 subjects), we will transition to Phase 2.
3076194|NCT01312467|Experimental|Prevention (metformin hydrochloride)|Patients receive metformin hydrochloride PO QD during week 1 and then BID during weeks 2-12. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.
3076195|NCT01312519|Active Comparator|Manual bone marrow sampling device|Hollow needle with a t-shaped handle manually pushed into the bone for the purpose of bone marrow aspiration and core biopsy collection. Manual Bone Marrow Sampling Device.
3076196|NCT01312519|Active Comparator|OnControl Bone Marrow System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest. OnControl Bone Marrow Biopsy and Aspiration System.
3076197|NCT01312675|Experimental|Group A|S.A.F.E.BT plus Standard of Care therapy
3076198|NCT01312675|No Intervention|Group B|Standard of Care therapy alone
3076199|NCT01312766|Experimental|hMG-IBSA|New hMG preparation.
3076200|NCT01312766|Active Comparator|Menopur|
3076201|NCT01312779|Other|All subjects receive implant|Subjects serve as own control
3076202|NCT01312805|Active Comparator|CHICA Control|This arm received CHICA without the asthma module
3076203|NCT01312805|Experimental|CHICA Asthma Module|This arm received the CHICA asthma module
3076204|NCT01312818|Experimental|Chemotherapy|Bortezomib IV Vorinostat PO Dexamethasone PO Intrathecal Methotrexate Imatinib Mesylate PO (for Ph+ ALL patients only)
3076205|NCT01312844|Experimental|Scopolamine|Patients receiving IV scopolamine at ECT treatment
3076206|NCT01312844|Placebo Comparator|Placebo|Patients receiving IV placebo at ECT treatment
3076207|NCT01312909|Experimental|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
3076208|NCT01312909|Experimental|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
3076209|NCT01312909|Placebo Comparator|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
3076210|NCT01312948|Experimental|Prototype mask|
3076211|NCT01312961|Placebo Comparator|Placebo (for Dupilumab)|Placebo (for Dupilumab) subcutaneous (SC) injection once weekly (qw) for 12 weeks added to background therapy of inhaled corticosteroids/long-acting beta2-adrenergic agonist (ICS/LABA) (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
3076212|NCT01312961|Experimental|Dupilumab 300 mg qw|Dupilumab 300 mg SC injection qw for 12 weeks added to background therapy of ICS/LABA (Fluticasone/Salmeterol combination therapy at stable dose for 4 weeks followed by Fluticasone monotherapy, dose progressively decreased and discontinued at Week 9). Albuterol or Levalbuterol was given as rescue medication.
3076213|NCT01313039|Experimental|AZD6244|
3076214|NCT01313078|Experimental|Pegaspargase in women with cancer|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
3076215|NCT01313117|Experimental|Alpha lipoic acid|Oral administration three times daily (morning, mid-day, night)
3076216|NCT01313182|Active Comparator|3M Skin and Nasal Antiseptic|Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
3076217|NCT01313182|Active Comparator|Bactroban Nasal|Mupirocin calcium ointment, 2%
3076218|NCT01313208|Placebo Comparator|Placebo|"Participants received placebo subcutaneous injections once a week for 12 weeks and then open-label etanercept 50 mg subcutaneous injection once weekly for the next 12 weeks.~All participants continued their disease modifying anti-rheumatic drug (DMARD) treatment throughout the 24-week study period."
3076219|NCT01313208|Experimental|Etanercept|"Participants received etanercept 50 mg subcutaneous injection once weekly for 12 weeks and then open-label etanercept 50 mg subcutaneous injection for the next 12 weeks.~All participants continued their DMARD treatment throughout the 24-week study period."
3076220|NCT01313221|Active Comparator|Etanercept 50 mg BIW|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept twice weekly for 12 weeks.
3076221|NCT01313221|Experimental|Etanercept 50 mg QW + Topical|Following 12 weeks of etanercept 50 mg twice weekly, participants were randomized to 50 mg etanercept once weekly plus as needed topical agents.
3076222|NCT01313286|Experimental|LY2608204 Reference, LY2608204 Test|Single oral 80 mg dose of LY2608204 reference formulation in period 1; single oral 80 mg dose of LY2608204 test formulation in period 2. There is a washout period of at least 14 days between dosing periods.
3076223|NCT01313286|Experimental|LY2608204 Test, LY2608204 Reference|Single oral 80 mg dose of LY2608204 test formulation in period 1; single oral 80 mg dose of LY2608204 reference formulation in period 2. There is a washout period of at least 14 days between dosing periods.
3076224|NCT01313299|Experimental|Dysport 500 U|
3076225|NCT01313299|Experimental|Dysport 1000 U|
3076226|NCT01313299|Placebo Comparator|Placebo|
3076227|NCT01313312|Experimental|Total Dysport®|A total of 254 subjects in the open label study received between 1 and 5 intramuscular (i.m) injections of Dysport® according to their individual needs, for a period of up to 12 months. All subjects were administered an appropriate dosage of Dysport® (1000 Units [U] or 500 U) on Day 1 of treatment Cycle 1. At each study visit from Week 12 onwards, subjects were assessed to determine whether a subsequent treatment cycle was required and treatment cycles were administered at intervals of a minimum of 12 weeks apart depending on the subject's safety and efficacy response. From Cycle 2 onwards, a total dose of 1500 U could be administered in subjects requiring treatment with Dysport® in their shoulder and other upper limb muscles. Subjects who showed improvement in their upper limb during the first two treatment cycles were able to receive concomitant injections of Dysport® 500 U into at least one calf muscle, from Cycle 3 onwards as long as the total dose did not exceed 1500 U.
3076228|NCT01313494|Experimental|Roflumilast|Roflumilast 500 μg, tablet, oral, once daily for up to 24 weeks.
3076229|NCT01313494|Placebo Comparator|Placebo|Placebo to roflumilast, tablet, oral, once daily for up to 24 weeks.
3076230|NCT01313507|Experimental|NewGam|Participants received NewGam 200-800 mg/kg intravenously every 3 or 4 weeks for 3 months (5 or 4 total infusions, respectively).
3076231|NCT01313520|Experimental|Infliximab|3 mg/kg of Infliximab intravenous infusion
3076232|NCT01313520|Placebo Comparator|Placebo|saline via intravenous infusion
3076233|NCT01313559|Active Comparator|Cohort A (pasireotide)|Patients receive pasireotide IM once every 4 weeks
3076234|NCT01313559|Experimental|Cohort B (pasireotide and everolimus)|Patients receive pasireotide as in cohort A and everolimus PO QD
3076235|NCT01313624|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3076236|NCT01313624|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3076237|NCT01313637|Experimental|GSK573719/GW642444|125/25mcg
3076238|NCT01313637|Experimental|GSK573719|125mcg
3076239|NCT01313637|Experimental|GW642444|25mcg
3076240|NCT01313637|Placebo Comparator|Placebo|Placebo
3076241|NCT01313650|Experimental|GSK573719/GW642444|62.5/25mcg
3076242|NCT01313650|Experimental|GSK573719|62.5mcg
3076243|NCT01313650|Experimental|GW642444|25mcg
3076244|NCT01313650|Placebo Comparator|Placebo|Placebo
3076245|NCT01313663|Experimental|Pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
3076246|NCT01313663|Active Comparator|Pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
3076247|NCT01313676|Experimental|fluticasone furoate/vilanterol|Combination of both products in one inhaler
3076248|NCT01313676|Experimental|fluticasone furoate|comparator of individual component
3076249|NCT01313676|Experimental|vilanterol|comparator of individual component
3076250|NCT01313676|Placebo Comparator|placebo|once daily via inhaler
3076253|NCT01313728|Experimental|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
3076254|NCT01313728|Active Comparator|Tretinoin Gel Alone|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks - all subjects participate in both arms in a split-face model
3076255|NCT01313767|Experimental|Meditoxin®|Botulinum toxin type A
3076256|NCT01313767|Active Comparator|Botox®|Botulinum Toxin type A
3076257|NCT01313780|Experimental|'Oxycodone/Naloxone'|Trade name is Targin(fixed combination drug).
3076258|NCT01313780|Active Comparator|Oxycodone|Trade name is Oxycontin(single compound).
3076259|NCT01313858||Participants with Rheumatoid Arthritis|Simponi®-naïve participants with rheumatoid arthritis given Simponi® 50 mg once a month as a subcutaneous injection. Combination use with methotrexate was recommended.
3076260|NCT01313858||Participants with Psoriatic Arthritis|Simponi®-naïve participants with psoriatic arthritis given Simponi® 50 mg once a month as a subcutaneous injection.
3076261|NCT01313858||Participants with Ankylosing Spondylitis|Simponi®-naïve participants with ankylosing spondylitis given Simponi® 50 mg once a month as a subcutaneous injection.
3076262|NCT01313884|Experimental|Combination Therapy|"Regimen A alternating with Regimen B every 21 days~Regimen A:~Cytoxan 1200mg/m2~Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~Irinotecan 50 mg/m2/day x 5 days~Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free"
3076263|NCT01313897|Experimental|Velcade for Anti-MM therapy|Day(s) -9,-6,-2 3 doses of Bortezomib at 1.0 mg/m2, i.v.
3076264|NCT01313910|Experimental|ImmunoLin®|8-week treatment course
3076265|NCT01313936|Experimental|15 mCi/kg of 131I-MIBG|The first cohort for safety will be 3-6 patients treated with vincristine and irinotecan and 15 mCi/kg of 131I-MIBG.
3076266|NCT01313936|Experimental|18 mCi/kg of 131I-MIBG|The second cohort will be 3-6 patients at the same doses of vincristine and irinotecan and 18 mCi/kg of 131I-MIBG.
3076267|NCT01314001|Placebo Comparator|Placebo (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076268|NCT01314001|Active Comparator|Varenicline (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076269|NCT01314001|Active Comparator|Transdermal Nicotine (Slow Metabolizers)|"Subjects in this arm are those identified as slow metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076270|NCT01314001|Placebo Comparator|Placebo (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076271|NCT01314001|Active Comparator|Varenicline (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take active varenicline pills daily for twelve weeks & wear a placebo patch daily for eleven weeks.~When taking the active varenicline, subjects will follow the same treatment regimen per the manufacturer.~The placebo patch will look identical to the active transdermal nicotine patches; however, they do not contain actual nicotine. Subjects will follow the same regimen as those in the active transdermal nicotine arm.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076272|NCT01314001|Active Comparator|Transdermal Nicotine (Normal Metabolizers)|"Subjects in this arm are those identified as normal metabolizers of nicotine (based on their NMR) and will take placebo pills daily for twelve weeks & will wear an active transdermal nicotine patch daily for eleven weeks.~The placebo pill will look identical to the active varenicline tablets; however, they will not contain any active medication. Subjects will follow the same drug regimen as those in the active varenicline arm.~When wearing the active transdermal nicotine, subjects will follow the same treatment regimen per the manufacturer.~All subjects in this arm will receive smoking cessation counseling during their sessions."
3076273|NCT01314014|Experimental|Imexon|Subjects will be treated on Days 1-5 of 21-day treatment cycles for up to one year. Following pre-treatment with anti-emetics Amplimexon will be given by intravenous infusion over 60 minutes.
3076274|NCT01314105|Experimental|BIBF 1120 L+ Carboplatin + PLD|BIBF 1120 (100 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3076275|NCT01314105|Experimental|BIBF 1120 M + Carboplatin + PLD|BIBF 1120 (150 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3076276|NCT01314105|Experimental|BIBF 1120 H + Carboplatin + PLD|BIBF 1120 (200 mg twice daily (BID)) + Carboplatin (Area Under the Curve (AUC) 5 mg/mL*min) + PLD (30 mg/m2)
3076278|NCT01314261|Experimental|ABT-267 (5 mg) once daily + pegIFN/RBV|Participants were given 5 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3076279|NCT01314261|Experimental|ABT-267 (50 mg) once daily + pegIFN/RBV|Participants were given 50 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3076280|NCT01314261|Experimental|ABT-267 (200 mg) once daily + pegIFN/RBV|Participants were given 200 mg ABT-267 once daily in combination with pegylated interferon/ribavirin (pegIFN/RBV) for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3076281|NCT01314261|Placebo Comparator|Placebo + pegIFN/RBV|Participants were given matching placebo to ABT-267 once daily in combination with pegIFN/RBV for 12 weeks, followed by 36 weeks of pegIFN/RBV treatment alone. Pegylated interferon was dosed 180 µg subcutaneously once a week. Ribavirin was dosed 1000 or 1200 mg daily divided twice a day.
3076282|NCT01314313|Experimental|PIIA - SAPIEN XT|PIIA is operable group
3076283|NCT01314313|Active Comparator|Control: SAVR|SAVR (surgical aortic valve replacement) is the control arm
3076284|NCT01314417|Experimental|Methotrexate|400 μg/100 μL injection
3076285|NCT01314443|Experimental|Placebo + Smoking Cessation|Individuals will quit smoking without use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
3076286|NCT01314443|Experimental|Supplement + Smoking Cessation|Individuals will quit smoking without the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
3076287|NCT01314443|Experimental|Placebo + Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a placebo for 7 days
3076288|NCT01314443|Experimental|Supplement+Nicotine Replacement Therapy|Individuals will quit smoking with the use of nicotine replacement therapy (NRT) and ingest a gamma-tocopherol supplement for 7 days
3076289|NCT01314716|Experimental|AZLI-AZLI|Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3076290|NCT01314716|Placebo Comparator|Placebo-AZLI|Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.
3076291|NCT01314742|Experimental|Biotene OralBalance® gel Arm|Biotene OralBalance® gel contains antibacterial active ingredients: lactoperoxidase, lysozyme and lactoferrin. These enzymes occur naturally in the human milk and colostrum and have mimicking properties of the human saliva activity in vivo.
3076292|NCT01314742|Placebo Comparator|Sterile Water Arm|Sterile Water moisten cotton tipped applicator
3076293|NCT01314872|Placebo Comparator|Part 1: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine extended release (ER) capsule, taken orally each morning, for 8 weeks.
3076294|NCT01314872|Experimental|Part 1: vibegron 3 mg|Participants received one vibegron 3 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3076295|NCT01314872|Experimental|Part 1: vibegron 15 mg|Participants received one vibegron 15 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3076296|NCT01314872|Experimental|Part 1: vibegron 50 mg|Participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3076297|NCT01314872|Experimental|Part 1: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 8 weeks.
3076298|NCT01314872|Active Comparator|Part 1: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 8 weeks.
3076299|NCT01314872|Experimental|Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg|Participants received one vibegron 50 mg tablet and one placebo matching vibegron tablet, taken orally each morning, for 8 weeks. They also received one tolterodine ER 4 mg capsule for the first 4 weeks and one placebo matching tolterodine ER capsule for the second 4 weeks, both taken orally each morning.
3076300|NCT01314872|Placebo Comparator|Part 2: placebo|Participants received two placebo matching vibegron tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
3076301|NCT01314872|Experimental|Part 2: vibegron 100 mg|Participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 4 weeks.
3076302|NCT01314872|Active Comparator|Part 2: tolterodine ER 4 mg|Participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 4 weeks.
3076303|NCT01314872|Experimental|Part 2: vibegron 100 mg + tolterodine ER 4 mg|Participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 4 weeks.
3076304|NCT01314872|Experimental|Extension Study: vibegron 50 mg|Participants in Base Study/Part 1 who received vibegron 50 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 3 mg received vibegron 50 mg in the Extension Study. Also, participants in Base Study/Part 1 who received vibegron 50 mg + tolterodine ER for 4 weeks, followed by vibegron 50 mg alone for 4 weeks, remained on vibegron 50 mg in the Extension Study. In the extension, participants received one vibegron 50 mg tablet, one placebo matching vibegron tablet, and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
3076305|NCT01314872|Experimental|Extension Study: vibegron 100 mg|Participants in Base Study/Part 1 or Part 2 who received vibegron 100 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received vibegron 15 mg received vibegron 100 mg in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one placebo matching tolterodine ER capsule, taken orally each morning, for 52 weeks.
3076306|NCT01314872|Experimental|Extension Study: tolterodine ER 4 mg|Participants in Base Study/Part 1 or Part 2 who received tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 1 who received placebo also received tolterodine ER 4 mg in the Extension Study. In the extension, participants received one tolterodine ER 4 mg capsule and two placebo matching vibegron tablets, taken orally each morning, for 52 weeks.
3076307|NCT01314872|Experimental|Extension Study: vibegron 100 mg + tolterodine ER 4 mg|Participants in Base Study/Part 1 who received vibegron 100 mg + tolterodine ER 4 mg continued their treatment in the Extension Study. In addition, participants in Base Study/Part 2 who received placebo were assigned to the vibegron 100 mg + tolterodine ER 4 mg arm in the Extension Study. In the extension, participants received two vibegron 50 mg tablets and one tolterodine ER 4 mg capsule, taken orally each morning, for 52 weeks.
3076308|NCT01314911|Experimental|Oseltamivir|
3076309|NCT01314911|Placebo Comparator|Placebo|
3076310|NCT01314963|Experimental|Intraoperative handheld Gamma Camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC)
3076311|NCT01314963|Active Comparator|Gamma probes (GP)|Standard of care intraoperative gamma probes (GP) currently in use.
3076312|NCT01315002|Active Comparator|Nicotine Patch|Transdermal nicotine patch
3076313|NCT01315002|Placebo Comparator|Placebo patch|Placebo patch
3076314|NCT01315028|Experimental|Psychological Therapy|Cognitive Interpersonal Therapy (CIT) was a psychological therapy which emphasised assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive-behavioural and interpersonal strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
3076315|NCT01315028|Active Comparator|Treatment As Usual|All participants continued to receive their usual care from their local community mental health team and other psychological therapies were not withheld during the conduct of the trial.
3076316|NCT01315132|Experimental|Allogeneic Transplantation|Matched Sibling Allogeneic Transplantation
3076317|NCT01315145|Active Comparator|Percutaneous Lumbar Decompression|Patients receiving percutaneous decompression using the mild® Device Kit.
3076318|NCT01315145|Active Comparator|Lumbar Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
3076319|NCT01315158|Active Comparator|Propofol+Benzo/Opioids|"If the patient is randomized into this arm the recommended Versed and Fentanyl doses are standardized:~Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
3076320|NCT01315158|Active Comparator|Propofol Alone|"The patients randomized into the sedation with propofol alone are able to cross over if they are unable to be successfully sedated under propofol alone. The the recommended doses before considering crossover are standardized:~Induction Dose: 2-2.5 mg/kg~Maintenance Dose: 0.1-0.2 mg/kg/min"
3076321|NCT01315236|Experimental|LAI 590 mg QD|LAI 590 mg QD
3076322|NCT01315236|Placebo Comparator|Placebo|placebo QD
3076323|NCT01315249|Experimental|QVA149|Participants received indacaterol and glycopyrronium (QVA149) and placebo to fluticasone/salmeterol.
3076324|NCT01315249|Active Comparator|fluticasone/salmeterol|Participants received fluticasone/salmeterol and placebo to indacaterol and glycopyrronium (QVA149).
3320975|NCT02015208|Experimental|Ruxolitinib|Ruxolitinib will be administered over a 28-day cycle, which will be repeated 6 more times in the absence of intolerable toxicity, disease progression, patient withdrawal of consent, or investigator decision to end therapy. The dose and schedule have been adapted from the product monograph for myelofibrosis. The starting dose will be 20 mg orally twice a day with normal .platelet and absolute neutrophil counts and no hepatic and renal impairment.
3320976|NCT02015247|Other|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
3320977|NCT02015260|Placebo Comparator|placebo|placebo 0% nitrite cream and placebo 0% citric acid cream
3076328|NCT01315574|Active Comparator|Latanoprost (Xalatan)|7 Patients were randomized to receive BAK-containing Xalatan for treatment of their glaucoma.
3076329|NCT01315574|Active Comparator|Travoprost (Travatan Z)|7 Patients were randomized to receive BAK-free Travatan Z for treatment of their glaucoma.
3076330|NCT01315665|Experimental|Healthy volunteers|100 grams of raw broccoli sprouts once daily for 5 consecutive days
3076331|NCT01315665|Experimental|Subjects with cystic fibrosis|100 grams of raw broccoli sprouts once daily for 5 consecutive days
3076332|NCT01315678|Experimental|Arikayce™|Arikayce™ is liposomal amikacin for inhalation
3076333|NCT01315678|Active Comparator|TOBI®|TOBI® is tobramycin inhalation solution
3076334|NCT01315847|Experimental|Healthy Participants (Part I)|Baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 megabecquerel [MBq]) was performed in healthy participants; this PET data served as the baseline for both Period 1 and 2 of Part I. Subsequently in study Part I, Period 1 the healthy participants received a single 1120 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~3 hours post telcagepant dose. In Part I, Period 2 the healthy participants received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part I Period 1 and 2 was to be at least 1 week.
3076335|NCT01315847|Experimental|Participants with Migraine (Part III)|In study Part III, Period 1 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine during a migraine attack (ictal phase). Later in Part III, Period 1 the participants with an ongoing migraine attack (ictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. In Part III, Period 2 baseline PET imaging of the brain using [11C]MK-4232 tracer (~300 MBq) was performed in participants with migraine, however, without a migraine attack ongoing (interictal phase). Later in Part III, Period 2 participants with migraine without a migraine attack ongoing (interictal phase) received a single 140 mg dose of telcagepant followed by PET imaging of brain with [11C]MK-4232 tracer (~300 MBq) beginning ~2 hours post telcagepant dose. Interval between Part III Period 1 and 2 was to be at least 1 week.
3076336|NCT01316042|Placebo Comparator|sugar pill|2 pills per day for 12 months
3076337|NCT01316042|Active Comparator|Metformin|2 212.5mg pill/day for 12 months
3076338|NCT01316055|Active Comparator|Healthy: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in healthy volunteers
3076339|NCT01316055|Active Comparator|Mild renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with mild renal impairment
3076340|NCT01316055|Active Comparator|Moderate renal: Dalfampridine-ER 7.5 mg|Dalfampridine-ER 7.5 mg single and steady-state dosing in volunteers with moderate renal impairment
3076341|NCT01316211|Active Comparator|coflex™|Implantation of coflex™ device in assigned patients
3076342|NCT01316211|Active Comparator|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant.
3076343|NCT01316224||Moderate or severe plaque psoriasis|Participants with moderate or severe plaque psoriasis treated with adalimumab
3076344|NCT01316263|Experimental|PDGFRα mutation negative|Participants with GIST with genotypes that do not have a PDGFRα mutation given 20 milligrams per kilogram (mg/kg) Olaratumab intravenously (IV) every 14 days.
3076345|NCT01316263|Experimental|PDGFRα mutation positive|Participants with GIST with genotypes that have a PDGFRα mutation given 20 mg/kg Olaratumab IV every 14 days.
3076346|NCT01316276|Experimental|LAI|590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).
3076347|NCT01316302|Experimental|Pristiq|Flexible dose, 50-100mg QD
3076348|NCT01316302|Placebo Comparator|Placebo|Matching placebo
3076349|NCT01316315|Experimental|Active|N6022 - 5 mg
3076350|NCT01316315|Placebo Comparator|Placebo|Placebo
3076351|NCT01316341|Experimental|BI10773 low dose Per Os(p.o.)|patient to receive a tablet containing low dose BI10773 Per Os(p.o.) plus one placebo
3076352|NCT01316341|Placebo Comparator|Placebo|patient to receive two placebos
3320978|NCT02015260|Active Comparator|Topical NO Dose A|3% sodium nitrite + 4.5% citric acid twice daily
3320979|NCT02015260|Active Comparator|Topical NO Dose B|6% sodium nitrite + 9% citric acid once daily
3320980|NCT02015260|Active Comparator|Topical NO Dose C|6% sodium nitrite + 9% citric acid twice daily
3320981|NCT02015273||Growth Disorders|
3076353|NCT01316341|Experimental|BI10773 high dose Per Os(p.o.)|patient to receive a tablet containing high dose BI10773 Per Os(p.o.) plus one placebo
3076354|NCT01316380|Experimental|tiotropium 5 mcg|once daily delivered via Respimat inhaler
3076355|NCT01316380|Experimental|tiotropium 2.5 mcg|once daily delivered via Respimat inhaler
3076356|NCT01316380|Placebo Comparator|placebo|once daily delivered via Respimat inhaler
3076357|NCT01316419||Patients with essential hypertension|
3076358|NCT01316510|Active Comparator|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge (whichever happens first)
3076359|NCT01316510|Placebo Comparator|Placebo|A dilute formulation of the elemental formula Nutramigen (diluted to look like the probiotic arm).
3076360|NCT01316575|Experimental|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
3076361|NCT01316575|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
3076362|NCT01316614|Experimental|With Stylet & Without Stylet|There will only be one arm in this study. This arm will undergo EUS-guided FNA with the use of a stylet for half of their FNA passes and without a stylet for the other half. Patients will be exposed to an equal number of passes with and without a stylet. Each pass will be individually assessed by a skilled cytopathologist who is blinded to the technique used. We will compare the adequacy of both techniques to determine whether or not a stylet leads to a higher diagnostic accuracy rate in patients with solid lesions.
3076363|NCT01316692|Experimental|MLN8237|Patients receive oral Aurora A kinase inhibitor MLN8237 every 12 hours on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3076364|NCT01316770|Placebo Comparator|Placebo Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with saline (placebo). { UPDATE: drug(generic) was administered at what time pt, dose of drug, route administration, frequency}
3076365|NCT01316770|Experimental|Dexamethasone Parotid Irrigation|Within-Subject, Double-Blind, Placebo-Controlled Study. This parotid gland is irrigated with dexamethasone {UPDATE: drug (generic) was administered at what time pt, dose of drug, route administration, frequency}
3076366|NCT01316887|Experimental|GSK573719/GW642444|125/25 mcg once-daily
3076367|NCT01316887|Experimental|GSK573719|125 mcg once-daily
3076368|NCT01316887|Placebo Comparator|Placebo|inactive
3076369|NCT01316900|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
3076370|NCT01316900|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
3076371|NCT01316900|Experimental|GW642444|25 mcg once-daily
3076372|NCT01316900|Active Comparator|tiotropium bromide|18 mcg once-daily
3076373|NCT01316913|Experimental|GSK573719/GW642444 125/25|125/25 mcg once-daily
3076374|NCT01316913|Experimental|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
3076375|NCT01316913|Experimental|GSK573719|125 mcg once-daily
3076376|NCT01316913|Active Comparator|tiotropium bromide|18 mcg once-daily
3076377|NCT01316926|Active Comparator|Paxil CR Reference|Reference drug administration followed by test drug administration
3076378|NCT01316926|Active Comparator|Paxil CR Test|Test drug administration followed by Reference drug administration
3076379|NCT01316939|Placebo Comparator|Placebo|Placebo
3076380|NCT01316939|Experimental|GSK1605786A once daily|500 milligrams once daily
3076381|NCT01316939|Experimental|GSK1605786A twice daily|500 milligrams twice daily
3076382|NCT01317004|Experimental|Fingolimod|Patients randomized in this arm received Fingolimod 0.5 mg/day oral capsule for 6 months core period.
3076383|NCT01317004|Active Comparator|Multiple Sclerosis Disease Modifying Treatment (MS DMT)|Patients randomized in this arm received selected Standard MS DMT such as Interferon beta-1b or Interferon beta-1a or Glatiramer acetate for 6 months.
3076384|NCT01317030||Contact Lens Wear|Senofilcon A Lenses, using Sensitive Eyes Saline Solution and/or Biotrue Multipurpose Solution
3076385|NCT01317030||Non-Contact Lens Wear|
3076386|NCT01317095|Active Comparator|Wire closure is the intervention|Patients will have their sternum closed using stainless steel wires.
3076387|NCT01317095|Active Comparator|Rigid fixation|Patients will have their sternum closed by rigid fixation using Starnalock plates.
3076388|NCT01317160|No Intervention|Routine care: Plaster Cast Treatment|Two weeks of postoperative conventional lower limb plaster cast immobilization in 30 degrees of plantarflexion
3076389|NCT01317160|Experimental|Intermittent pneumatic compression (IPC)|Two weeks of calf IPC by Aircast® VenaFlow® Elite System during immobilization in an orthosis Aicast® XP Walker.
3076390|NCT01317199|Experimental|Phase 1: Dose-escalation of Muscadine Plus Grape Skin Extract|Muscadine Plus Grape Skin Extract (MPX): Phase I Dose-escalation starts at 500mg daily for 1 cycle (28 days), then increased to 1000mg for 2nd cycle, then increased to 2000mg daily for 3rd cycle, then increased to 3000mg daily for 4th cycle, then increased to maximum dose of 4000mg daily for final cycle. Pills given by mouth once daily for 28 days per cycle.
3076391|NCT01317199|Placebo Comparator|Phase 2: Placebo control|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
3076392|NCT01317199|Experimental|Phase 2: Low-dose MPX|Randomly-assigned participants receive low-dose (500mg) MPX
3076393|NCT01317199|Experimental|Phase 2: High-dose MPX|Randomly-assigned participants receive high-dose (4000mg) MPX
3076394|NCT01317277|Experimental|Personalized Reminder Texting (iTAB) + Psychoeducation|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications.
3076395|NCT01317277|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV medications. They will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
3076396|NCT01317472|Experimental|Dexlansoprazole|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
3320982|NCT02015286||Growth Disorders|
3076397|NCT01317472|Placebo Comparator|Sugar pill|Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
3076398|NCT01317550|Experimental|Armodafinil + Placebo|Armodafinil orally 150 mg/day + Placebo capsules for 10 weeks
3076399|NCT01317550|Experimental|Minocycline + Placebo|Minocycline orally 100 mg twice/day + Placebo capsules for 10 weeks
3076400|NCT01317550|Experimental|Armodafinil + Minocycline|Armodafinil orally 150 mg/day for 10 weeks + Minocycline orally 100 mg twice/day for 10 weeks
3076401|NCT01317550|Placebo Comparator|Placebos|Placebo Capsules orally once/day for 10 weeks
3076402|NCT01317615|Experimental|RAD001 plus paclitaxel/carboplatin|Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.
3076403|NCT01317641|Experimental|ODM-201 Phase I|
3076404|NCT01317641|Experimental|ODM-201 Phase II Dose 1|
3076405|NCT01317641|Experimental|ODM-201 Phase II Dose 2|
3076406|NCT01317641|Experimental|ODM-201 Phase II Dose 3|
3076407|NCT01317667|Experimental|Group 1|RVEc vaccine 20 μg/dose x 3 doses
3076408|NCT01317667|Experimental|Group 2|RVEc vaccine 50 μg/dose x 3 doses
3076409|NCT01317667|Experimental|Group 3|RVEc vaccine 100 μg/dose x 1 dose
3076410|NCT01317797|Experimental|Namilumab 150 mg|Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
3076411|NCT01317797|Experimental|Namilumab 300 mg|Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
3076412|NCT01317797|Placebo Comparator|Placebo|Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.
3076413|NCT01317901|Experimental|TRU-016+bendamustine+rituximab|Two dose levels (10 and 20 mg/kg) of TRU 016 combined with rituximab 375 mg/m2 and bendamustine 90 mg/m2 were evaluated during up to 6 cycles (28 days each). TRU-016 was administered by intravenous (IV) infusion on Days 1 and 15 of each cycle. Rituximab was administered by IV infusion on Day 2 of each cycle. Bendamustine was administered by IV infusion on Days 1 and 2 of each cycle. Subjects received study treatment for up to 6 cycles.
3076414|NCT01317940|Experimental|Group A (Newly Diagnosed Subjects)|
3076415|NCT01317940|No Intervention|Standard of Care Group A|
3076416|NCT01317940|Experimental|Group B (Early Survivors)|
3076417|NCT01317940|No Intervention|Observation Only - Group B|
3076418|NCT01317940|No Intervention|Group C (Siblings of Group A)|
3076419|NCT01318018||Magnetic Seizure Therapy Group|Patients receiving magnetic seizure therapy for depression
3076420|NCT01318018||Electroconvulsive Therapy Group|Patients receiving electroconvulsive therapy for depression
3076421|NCT01318070|Experimental|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30mg QD|
3076422|NCT01318070|Experimental|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
3076423|NCT01318070|Active Comparator|Pioglitazone (15mg or 30mg ) QD|
3076424|NCT01318083|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride QD or BID|
3076425|NCT01318083|Active Comparator|Alogliptin 25 mg QD and Glimepiride QD or BID|
3076426|NCT01318083|Active Comparator|Glimepiride 1, 2, 3 or 4 mg QD or BID|
3076427|NCT01318109|Active Comparator|Alogliptin 12.5 mg QD and metformin 500mg BID or 750mg TID|
3076428|NCT01318109|Active Comparator|Alogliptin 25mg QD and metformin 500mg BID or 750mg TID|
3076429|NCT01318109|Active Comparator|Metformin 500mg BID or 750mg TID|
3076430|NCT01318122|Active Comparator|Alogliptin 12.5 mg QD and Pioglitazone 15 or 30 mg QD|
3076431|NCT01318122|Active Comparator|Alogliptin 25 mg QD and Pioglitazone 15 or 30 mg QD|
3076432|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Glimepiride 1- 6 mg QD or BID|
3076433|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Glimepiride 1 - 6 mg QD or BID|
3076434|NCT01318135|Active Comparator|Alogliptin 12.5 mg QD and Metformin 500 mg BID or 750 mg TID|
3076435|NCT01318135|Active Comparator|Alogliptin 25 mg QD and Metformin 500 mg BID or 750 mg TID|
3076436|NCT01318278|Active Comparator|Dopamine treatment|Dopamine treatment beginning at 5 mcg/kg/min and titrated by 5 mcg/kg/min to effect up to maximum of 20 mcg/kg/min
3076437|NCT01318278|Active Comparator|Vasopressin treatment|Arginine Vasopressin treatment beginning at 0.01 units/kg/hr and titrated up by 0.01 units/kg/hr to effect up to a maximum of 0.04 units/kg/hr
3076438|NCT01318278|No Intervention|Comparison Arm|Infants who did not require vasopressor support for hypotension during the first 24 hours of life
3076439|NCT01318356|Experimental|Cognitive behavioral therapy|
3076440|NCT01318356|Experimental|Doxycycline|
3076441|NCT01318356|Placebo Comparator|Placebo|
3076442|NCT01318382|Experimental|TOF-Watch SX®|Participants who have undergone elective open or laparoscopic abdominal surgery, received general anesthesia, received at least one dose of non-depolarizing neuromuscular blocker and had the extent of their recovery from NMB monitored by a TOF-Watch SX®.
3076443|NCT01318408|Experimental|Levetiracetam|Levetiracetam was titrated over 4 weeks, with initial dosing of 250 mg bis in die (BID). Dosing was flexible and was based on the prescribing physician's discretion.
3076444|NCT01318499|Experimental|Nepafenac 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3076445|NCT01318499|Active Comparator|Nepafenac 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3076446|NCT01318499|Placebo Comparator|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
3076447|NCT01318512||Chronic Kidney Disease|Participants with CKD, not undergoing haemodialysis in clinical practice setting and started treatment with methoxy polyethylene glycol-epoetin beta (MIRCERA) subcutaneously (SC) as per summary of product characteristics (SPC) due to decreased levels of haemoglobin.
3320983|NCT02015299|Experimental|Linagliptin|Linagliptin 5 mg/day + lifestyle advise
3076448|NCT01318538|Experimental|Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
3076449|NCT01318538|Active Comparator|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
3076450|NCT01318577|Experimental|Investigational Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses.
3076451|NCT01318577|Active Comparator|Clear Care Solution|Hydrogen peroxide system for cleaning, protein removal, disinfecting and storing of contact lenses
3076452|NCT01318694|Experimental|Treatment Arm A|"Alisporivir (ALV) 600 mg twice daily (BID) with Peginterferon alfa-2a (PEG) and ribavirin (RBV) for 1 week, followed by an additional 23 or 47 weeks according to response-guided treatment duration (RGT):~Participants with a viral load below the level of detection (< LOD) at Week 4 stop study treatment after 24 weeks~Participants with a viral load ≥ LOD at Week 4 complete 48 weeks of study treatment"
3076453|NCT01318694|Experimental|Treatment Arm B|Alisporivir (ALV) 400 mg twice daily (BID) with PEG and RBV for 24 or 48 weeks according to response-guided treatment duration (RGT)
3076454|NCT01318694|Experimental|Treatment Arm C|Alisporivir (ALV) 600 mg BID with PEG and RBV for 1 week, followed by 600 mg once daily (QD) for 47 weeks
3076455|NCT01318694|Active Comparator|Treatment Arm D|ALV Placebo with PEG and RBV for 48 weeks
3076456|NCT01318733|Experimental|CD07805/47 Gel 0.5%|
3076457|NCT01318811|Active Comparator|Dilute heparin|Arm A will receive dilute heparin delivered as an intravenous infusion proximal to the dialysis filter.
3076458|NCT01318811|Active Comparator|Standard concentrated heparin|Arm B will receive standard concentrated heparin and will be delivered as an intravenous infusion proximal to the dialysis filter.
3076459|NCT01318876||BC Children's and Women's Hospital, Vancouver.|
3076460|NCT01318876||University of British Columbia, Vancouver.|
3076461|NCT01318876||Health care workers in Halifax|
3076462|NCT01318876||Health care workers from CHUQ hospitals|
3076463|NCT01318876||Health care workers from Toronto|
3076464|NCT01318876||Centre hospitalier et universitaire de Sherbrooke|
3076465|NCT01318876||The Ottawa General Hospital, Ottawa|
3076466|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
3076467|NCT01318902|Experimental|Dose Escalation Cohort: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsule, orally, once weekly on Days 1, 8 and 15 during each 28-day treatment cycle for 3 cycles. If there was no hematologic response, dexamethasone 40 mg, tablet, orally was added once on Days 1 to 4 of every cycle, beginning in Cycle 4 for 3 additional cycles. If there was no hematologic response the participant was discontinued. Participants with hematologic response continued treatment up to maximum 12 cycles.
3076468|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were not treated with any other proteasome inhibitor (PI). Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
3076469|NCT01318902|Experimental|Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)|Ixazomib 4.0 mg, capsule, orally, on Days 1, 8 and 15 during a 28-day treatment cycle until PD or unacceptable toxicity, for participants with relapsed or refractory amyloidosis and who were previously treated with any other PI. Duration of treatment was up to 12 months unless the investigator and sponsor determined the participant would benefit from therapy beyond 12 months.
3076470|NCT01318915|Experimental|Induction (Rituximab and ATG)|Study participants will undergo induction with rituximab and ATG and an initial maintenance therapy with tacrolimus, mycophenolate mofetil (MMF) and sirolimus. MMF will be discontinued on day 12. Participants will be evaluated for eligibility for tacrolimus withdrawal which must be initiated between weeks 26 and 38. Tacrolimus withdrawal must be completed in no fewer than 4 weeks and no more than 8 weeks. Then after at least 26 weeks on sirolimus monotherapy, participants will be evaluated for eligibility for sirolimus withdrawal which must be initiated between weeks 56 and 88. Sirolimus withdrawal must be completed in no fewer than 12 weeks and no more than 26 weeks.
3076471|NCT01318967|Placebo Comparator|PAH|PAH measure of renal blood flow is first performed on subjects prior to administration of furosemide
3076472|NCT01318967|Active Comparator|MRI after furosemide|After the PAH measurement is complete, subjects receive 20 mg furosemide and undergo BOLD MRI to estimate renal blood flow
3076474|NCT01319045|Experimental|Iloprost|Participants will be administered iloprost at 5 mcg/dose x 6 doses daily for 3 months.
3076475|NCT01319110|Experimental|CoenzymeQ10|Patients will receive CoenzymeQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
3076476|NCT01319110|Placebo Comparator|Placebo|Patients will receive 20 ml chocolate Ensure (as a placebo) three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). Placebo will be given through pre-existing NG or OG tube.
3076477|NCT01319318||Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
3076478|NCT01319383|Experimental|Open Label, Translational Research|Vorinostat will be administered to all eligible participants in each step of each phase (period) of the study
3076479|NCT01319422|Experimental|Pomalidomide 2 mg/d on 28 days/28 day cycle|
3076480|NCT01319422|Experimental|Pomalidomide 4 mg/d on 21 days/28 day cycle|
3076481|NCT01319500||Yasmin|"Users of the drospirenone/ethinylestradiol (DRSP/EE) containing OC Yasmin"
3076482|NCT01319500||Other OCs|"Users of OCs except Yasmin (Other OCs)"
3076483|NCT01319539|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days -9 and -2, and undergo segmental resection or total mastectomy (therapeutic conventional surgery) on day 0. Patient samples will be processed for pharmacological study and laboratory biomarker analysis.
3076484|NCT01319552|Other|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
3076485|NCT01319552|Experimental|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
3076486|NCT01319617|Experimental|SENSIMED Triggerfish|
3076487|NCT01319721|Active Comparator|Group LCAG|After extensive excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft for repairing the conjunctival defect.
3076488|NCT01319721|Active Comparator|Group AMG|After excision of recurrent pterygium, intraoperative 0.2 mg/ml MMC (0.02%) for 3 minutes will be applied topically onto the exposed surgical area and then an amniotic membrane graft for repairing the conjunctival defect.
3076489|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation A (Formulation A)|Parallel-Group Phase (PGP): cyclosporine ophthalmic emulsion Formulation A
3076490|NCT01319773|Experimental|cyclosporine ophthalmic emulsion Formulation B (Formulation B)|PGP: cyclosporine ophthalmic emulsion Formulation B
3076491|NCT01319773|Other|Formulation A and cyclosporine ophthalmic emulsion 0.05%|Paired-Eye Phase (PEP): cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion 0.05%
3076492|NCT01319773|Other|Formulation B and cyclosporine ophthalmic emulsion 0.05%|PEP: cyclosporine ophthalmic emulsion Formulation B and cyclosporine ophthalmic emulsion 0.05%
3076493|NCT01319773|Experimental|Formulation A and Formulation B|PEP: cyclosporine ophthalmic emulsion Formulation A and cyclosporine ophthalmic emulsion Formulation B
3076494|NCT01319799||Surgical aortic valve replacement|Single observational study. Count of microembolic signals during open heart surgery and measurement of properative vs postoperative levels of markers in cerebrospinal fluid of neuronal damge.
3076495|NCT01319812|Experimental|Astron Stent Group|"Participants indicated for stenting in iliac atherosclerotic lesions.~Intervention: Device: Astron Stents"
3076496|NCT01319812|Experimental|Pulsar Stent Group|"Participants indicated for stenting in superficial femoral or proximal popliteal atherosclerotic lesions.~Intervention: Device: Pulsar Stents"
3076497|NCT01319851|Experimental|Alefacept|Pediatric subjects with non-malignant diseases (NMD) will receive pre-conditioning with alefacept 0.5 mg/kg/dose i.v. with the first dose split on days -40 and -39 and the remaining doses given on days -33, -26, -19, and -12 (e.g. weekly for 5 doses).
3076498|NCT01319877||First Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a first line therapy.
3076499|NCT01319877||Second Line Treatment|Participants received bevacizumab in combination with 5-FU based chemotherapy as a second line therapy.
3076500|NCT01319929|Experimental|LY2828360 then Placebo|80 milligrams (mg) of LY2828360 daily by mouth for 4 weeks: placebo daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
3076501|NCT01319929|Experimental|Placebo then LY2828360|Placebo daily by mouth for 4 weeks: LY2828360 daily by mouth for 4 weeks. There is a washout period of 3 weeks between treatments.
3076502|NCT01319994|Experimental|Metformin|Metformin 850mg TDS (12 weeks)
3076503|NCT01319994|Placebo Comparator|Placebo|Placebo 850mg TDS (12 weeks)
3076504|NCT01320033|Experimental|CD2475/101 40 mg|Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.
3076505|NCT01320033|Active Comparator|Doxycycline 100 mg|Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.
3076506|NCT01320033|Placebo Comparator|Placebo|Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.
3076507|NCT01320072||Aspirin-sensitive asthmatics|asthma patients with aspirin allergy
3076508|NCT01320072||aspirin-tolerant asthmatics|asthma patients without aspirin allergy
3076509|NCT01320085|Experimental|BRAFV600 mutant, 45mg bid MEK162|BRAFV600 mutant, 45mg bid MEK162
3076510|NCT01320085|Experimental|NRAS mutant, 45mg bid MEK162|NRAS mutant, 45mg bid MEK162
3076511|NCT01320085|Experimental|BRAFV600 mutant, 60mg bid MEK162|BRAFV600 mutant, 60mg bid MEK162
3076512|NCT01320137|Other|Allergy Group|Subjects with ages ranging from 18-45 years and inclusive, presenting symptomatic allergy to birch pollen.
3076513|NCT01320137|Other|Control Group|Subjects with ages ranging from 18-45 years and inclusive, with no known allergies.
3076514|NCT01320150||PPP and Non-PPP|Study Subjects with PPP and without PPP at followup
3076515|NCT01320202|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
3076516|NCT01320202|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
3076517|NCT01320293|Experimental|Adalimumab 40mg|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA] Dose administered every other week for 6 months
3076518|NCT01320553|Experimental|SPARC1102 I|1334H 0.15% eye drops will be administered in both eyes at 3 occasions
3076519|NCT01320553|Experimental|SPARC1102 II|1334H 0.3% eye drops (solution) will be administered in both eyes at 3 occasions
3076520|NCT01320553|Experimental|SPARC1102 III|1334H 0.45% eye drops (solution)will be administered in both eyes at 3 occasions
3076521|NCT01320553|Placebo Comparator|Vehicle|Placebo eye drops (solution)will be administered in both eyes at 3 occasions
3076522|NCT01320722|Experimental|Vitamin D|Vitamin D ergocalciferol 50,000 unit soft gel capsule once per week for 8 weeks.
3076523|NCT01320722|Experimental|Probenecid|Probenecid 500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total).
3076524|NCT01320722|Experimental|Allopurinol|Allopurinol 300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total).
3076525|NCT01320722|Placebo Comparator|Placebo- Vitamin D|Placebo soft gel once per week for 8 weeks.
3076526|NCT01320722|Placebo Comparator|Placebo- Uric Acid|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total).
3076527|NCT01320735||Advanced PCa|Participants with advanced PCa
3076528|NCT01320826||Physician colonoscopists|"All primary care physicians (family physicians and general internists) who perform colonoscopies were approached to voluntarily participate in the APC-Endo study.~All patients having a colonoscopy done by an APC-Endo study physician endoscopist were approached at the time of their endoscopy to consent to the post procedure telephone survey."
3076529|NCT01320943|Experimental|Stop TDF|Participants randomized to this arm will stop TDF therapy at baseline.
3076530|NCT01320943|Active Comparator|Continue TDF|Participants randomized to this arm will continue TDF therapy.
3076531|NCT01321073|Experimental|DelIVery for Pulmonary Arterial Hypertension Single Arm|All subjects were enrolled for implantation of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection.
3076532|NCT01321151|Placebo Comparator|Sugar Pill|Placebo control
3076533|NCT01321151|Experimental|Resveratrol|Intervention
3076534|NCT01321177|Experimental|Integrated Treatment|Integrated program of treatments and services delivered by a coordinated team of providers.
3076535|NCT01321177|Active Comparator|Community Care|Standard mental health treatments and services offered at the local agency.
3076536|NCT01321437|Experimental|Axitinib|Patients receive axitinib PO BID on days 1-28. Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery within 14-21 days after completion of treatment. Beginning 28-56 days after surgery, patients receive axitinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
3076537|NCT01321541|Experimental|Pixantrone + Rituximab|Pixantrone and Rituximab
3076538|NCT01321541|Active Comparator|Gemcitabine + Rituximab|Gemcitabine and Rituximab
3076539|NCT01321554|Experimental|Lenvatinib (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
3076540|NCT01321554|Placebo Comparator|Placebo (Randomization Phase)|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
3076541|NCT01321554|Experimental|Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
3076542|NCT01321554|Experimental|Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)|Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
3076543|NCT01321606|Experimental|Arm 1: Probiotic|subjects will be given a capsule formulation of a 1x10^10 colony-forming units of probiotic L. rhamnosus HN001 to be taken once a day, for 4 weeks
3076544|NCT01321606|Placebo Comparator|Arm 2: Placebo|Placebo identical to the active product will be given
3076545|NCT01321710|Active Comparator|Dietary information & standard care|"Mothers in this arm receive dietary information aimed at reducing postpartum sleep disturbance.~Infants in this arm receive no intervention beyond standard immunization care."
3076546|NCT01321710|Experimental|Sleep hygiene & standard care|"Mothers in this arm receive a sleep hygiene intervention aimed at improving their postpartum sleep.~Infants in this arm receive standard immunization care."
3076547|NCT01321710|Experimental|Sleep hygiene & acetaminophen|"Mothers in this arm receive a sleep hygiene intervention aimed at improving postpartum sleep.~Infants in this arm receive an acetaminophen intervention (12.5mg per kg infant weight, 1 dose 30 minutes prior to immunization and q4-6h thereafter, for a total of 5 doses) to minimize sleep disturbance following immunization."
3076548|NCT01321723|Experimental|PTH analog tablet|PTH(1-31) 5 mg tablet, once daily
3076549|NCT01321723|Placebo Comparator|Placebo|Placebo matching tablet, once daily
3076550|NCT01321723|Active Comparator|Forsteo|Forsteo (teriparatide) 20 mcg SC Injection, once daily
3076551|NCT01321749|Experimental|RIPC+stroke secondary prevension|"Procedure/Surgery: Remote Ischemic Preconditioning (RIPC) The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.~Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)"
3076552|NCT01321749|No Intervention|stroke secondary prevention|Procedure:stroke secondary prevention(Such as Antiplatelet therapy, Cholesterol-lowering therapymaintain blood pressure and blood sugar normal)
3076553|NCT01321879|Experimental|Telavancin|10 or 7.5 mg/kg intravenous daily
3076554|NCT01322009|Experimental|Drug|Probenecid and N-acetyl cysteine will be administered at standard doses for the first 4 days after TBI.
3076555|NCT01322009|Placebo Comparator|Placebo|Placebos will be prepared for the two experimental drugs and administered at identical time periods.
3076556|NCT01322022|Experimental|Parent Training|Behavioral Intervention
3076557|NCT01322022|Active Comparator|Parent Education|5 Sessions of individual parent education
3076558|NCT01322048|Experimental|Adrenergic Blockade|Propranolol and Clonidine
3076559|NCT01322048|Placebo Comparator|Placebo|Placebo
3076560|NCT01322347|Active Comparator|Soluble Ferric Pyrophosphate (SFP) in dialysate|11 micrograms (µg) of iron / deciliter (dL) of dialysate.
3076561|NCT01322347|Placebo Comparator|Standard Dialysate|0 micrograms (µg) of iron / deciliter (dL) of dialysate.
3076562|NCT01322360|Other|Morphine Sulfate|oral solution (10 mg/5 mL or 20 mg/5 mL) or tablets (15 mg or 30 mg)given based on based on the current pediatric prescribing guidelines
3076563|NCT01322386|Experimental|Oral Vancomycin|Vancocin
3076564|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF"
3076565|NCT01322490|Experimental|PROSTVAC-V/F-TRICOM + GM-CSF placebo|"PROSTVAC-V-TRICOM~PROSTVAC-F-TRICOM~GM-CSF placebo"
3076566|NCT01322490|Placebo Comparator|Placebo Control|PROSTVAC V/F Placebo + GM-CSF Placebo
3076567|NCT01322594|Experimental|MEDI2338 10 MG|MEDI2338 (10 mg) administered as a single, fixed intravenous (IV) dose over a minimum of 60 minutes using an infusion pump
3076568|NCT01322594|Experimental|MEDI2338 30 MG|MEDI2338 (30 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3076569|NCT01322594|Experimental|MEDI2338 100 MG|MEDI2338 (100 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3076570|NCT01322594|Experimental|MEDI2338 300 MG|MEDI2338 (300 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3076571|NCT01322594|Experimental|MEDI2338 1000 MG|MEDI2338 (1000 mg) administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3076572|NCT01322594|Placebo Comparator|Placebo|Placebo administered as a single, fixed IV dose over a minimum of 60 minutes using an infusion pump
3076573|NCT01322607|Other|Arm 1: High-Intensity Program|High-intensity treadmill-based exercise
3076574|NCT01322607|Other|Arm 2: Low-Intensity Program|Low-intensity lifestyle intervention (group exercise)
3076575|NCT01322633||Pantoprazole|Patients who received treatment with pantoprazole tablets for at least 240 days within a 12-month period from 2000 through 2003.
3076576|NCT01322633||Other proton pump inhibitors|Patients who received treatment with any other proton pump inhibitor for at least 240 days within a 12-month period from 1996 through 2003.
3076577|NCT01322815|Experimental|Chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40 yeast units (YU) GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
3076578|NCT01322815|Experimental|GI-4000 and bevacizumab|maintenance with GI-4000 and bevacizumab for patients who have completed first-line chemotherapy
3076579|NCT01322841|Active Comparator|CHICA Diagnosis Module|This arm had the CHICA screening module turned on
3076580|NCT01322841|Placebo Comparator|CHICA Placebo|This arm had CHICA but no additional module
3076581|NCT01322945||Endonasal surgery|Single cohort of patients undergoing endonasal surgery
3076582|NCT01323010|Experimental|Albuterol - Experimental|Albuterol dosages during the first hour include 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
3076583|NCT01323010|Active Comparator|Albuterol - Control|Albuterol dosages during the first hour include either 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg).
3076584|NCT01323140|Experimental|TMTS treatment|Following a lead-in dose-proportionality phase (Days 1-2) and a site-to-site bioavailability phase (Days 2-9), subjects were dosed for efficacy analysis beginning on Day 9 at dose level B (a single 48 cm2 testosterone matrix transdermal system). Based on pharmacokinetic (PK) analysis of blood samples drawn on Day 16, on Day 22 subjects could be dose-titrated up to dose level C (one 28 cm2 plus one 48 cm2 TMTS), down to dose level A (one 28 cm2 TMTS), or remain at dose level B. Subjects at all dose levels were pooled for primary efficacy analysis on Days 29/30.
3076585|NCT01323153|Experimental|Dalcetrapib|
3076586|NCT01323153|Placebo Comparator|Placebo|
3076587|NCT01323192|Experimental|JNS001|
3076588|NCT01323192|Placebo Comparator|Placebo|
3076589|NCT01323270|Experimental|rLP2086|rLP2086 and Repevax
3076590|NCT01323270|Placebo Comparator|Saline and Repevax|Saline and Repevax
3076591|NCT01323387|Other|Treatment|Interbody fusions with Anterior Plating
3076592|NCT01323478|Experimental|Vortioxetine|
3076593|NCT01323517|Experimental|Ipilimumab, Melphalan and Dactinomycin|This is a single-institution phase II trial with a primary outcome of progression free survival (PFS).
3076594|NCT01323530|Experimental|Dose-escalation Phase (Phase 1b)|Participants with advanced and/or metastatic tumors will receive eribulin mesylate as a 2 to 5 min Intravenous (IV) bolus or infusion in two different schedules (Schedule 1 [1.2, 1.6, 2.0 mg/m2], given on Day 1 only, and Schedule 2 [0.7, 1.1, 1.7 mg/m^2], given on Days 1 and 8) and oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles) in both schedules. If maximum tolerated dose (MTD) is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m^2 bid on Days 1-14 (21-day cycles) depending on the Dose limiting toxicities (DLTs) observed and/or pharmacokinetic (PK) data when available. Based on the data and safety monitoring board review of dose escalation phase data (DLTs that will be observed in first cycle), Dose-Confirmation Phase (Phase 2) will may get initiated.
3076595|NCT01323530|Experimental|Dose-confirmation Phase (Phase 2)|Participants with advanced and/or metastatic tumors will receive Eribulin mesylate at the MTD for the selected schedule of dose escalation phase based on safety/PK data.
3076596|NCT01323582|Active Comparator|erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
3076597|NCT01323582|Experimental|Azithromycin|The dose of Azithromycin was determined based on our dose response curve obtained on 10 healthy subjects who were given three different doses of Azithromycin, 50 mg, 100 mg and 133 mg and underwent breath testing to determine the gastric emptying half-time. These doses were determined based on a maximum safe dosage per day of Azithromycin of 400 mg given the medication would then be administered three times daily before meals. The appearance of the medication (azithromycin) and administration period was then identical to that of Erythromycin, i.e. 5ml elixir administered orally three times a day half an hour prior to meals. The total daily dosage of Azithromycin was determined after obtaining the dose- response analysis.
3076598|NCT01323595|Experimental|Celecoxib|Celecoxib will be given for 6 days after surgery
3076599|NCT01323595|Placebo Comparator|Sugar pill|Sugar pill for 6 days after surgery.
3076600|NCT01323621|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3076601|NCT01323621|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3076602|NCT01323634|Experimental|Fluticasone Furoate / GW642444 (vilanterol)|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3076603|NCT01323634|Active Comparator|Fluticasone Propionate / salmeterol|Inhaled Corticosteroid (ICS)/ Long acting Beta Agonist (LABA)
3076604|NCT01323647|Experimental|Group A|Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
3076605|NCT01323647|Active Comparator|Group B|Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.
3076606|NCT01323660|Experimental|GSK573719/GW642444 125/25|125mcg/25mcg nDPI
3076607|NCT01323660|Experimental|GSK573719/GW642444 62.5/25|62.5mcg/25mcg nDPI
3076608|NCT01323660|Experimental|GSK573719/ 125|125mcg nDPI
3076609|NCT01323660|Experimental|GSK573719 62.5|62.5mcg nDPI
3076610|NCT01323660|Experimental|GW642444 25|25mcg nDPI
3076611|NCT01323660|Placebo Comparator|Placebo|Plb nDPI
3076612|NCT01323673|Active Comparator|Clobetasol Propionate 0.05%|
3076613|NCT01323673|Placebo Comparator|Vehicle|
3076614|NCT01323777|Experimental|ReSTOR +3.0|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3076615|NCT01323790|Experimental|1|Oral treatment
3076616|NCT01323790|Experimental|2|Oral treatment
3076617|NCT01323790|Placebo Comparator|3|Oral treatment
3076618|NCT01323855|Experimental|Part 1: Severe Renal Impairment|Participants with severe CRI, defined as creatinine clearance of <30 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3076619|NCT01323855|Experimental|Part 2: Moderate Renal Impairment|Participants with moderate CRI defined as creatinine clearance of ≥30 and <50 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3076620|NCT01323855|Experimental|Part 2: Mild Renal Impairment|Participants with mild CRI, defined as creatinine clearance of ≥50 and ≤80 mL/min/1.73m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3076621|NCT01323855|Experimental|Part 1: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3076622|NCT01323855|Experimental|Part 2: Normal Renal Function|Participants with normal renal function, defined as creatinine clearance of >80 mL/min/1.73 m^2, were treated with a single tablet of 5 mg preladenant, administered orally
3076623|NCT01323920|Experimental|Velcade/Tac/MTX|"Drug: Bortezomib. Other Names: Velcade. Bortezomib 1.3 mg/m^2 IV~Drug: Tacrolimus. Tacrolimus 0.05 mg/kg PO bid~Drug: Methotrexate. Methotrexate 15 mg/m^2 IV"
3076624|NCT01323946|Experimental|GSK1562902A 6 to 12 M Group|Subjects between 6 and 12 months of age (6 to 12 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
3076625|NCT01323946|Experimental|GSK1562902A 12 to 24 M Group|Subjects between 12 and 24 months of age (12 to 24 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
3076626|NCT01323946|Experimental|GSK1562902A 24 to 36 M Group|Subjects between 24 and 36 months of age (24 to 36 M), who received 2 primary doses of A/Indonesia/05/2005 GSK1562902A vaccine on Days 0 and 21 and 1 booster dose of the A/turkey/Turkey/1/2005 GSK1562902A vaccine on Day 182.
3076627|NCT01323959|Experimental|BOOSTRIX POLIO GROUP|Healthy subjects who had received one booster dose Boostrix™ Polio vaccine in the NCT01277705 study received one additional booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3076628|NCT01323959|Experimental|BOOSTRIX+POLIORIX GROUP|Healthy subjects who had received one booster dose of the co-administered Boostrix™ and Poliorix™ vaccines in the NCT01277705 study received one booster dose Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3076629|NCT01323959|Experimental|REVAXIS GROUP|Healthy subjects who had received one booster dose of Revaxis® vaccine in the NCT01277705 study received one booster dose of Boostrix™ Polio vaccine in this study, administered as an intramuscular injection into the deltoid region of the left arm.
3076630|NCT01323972|Experimental|GSK 257049-Lot 1 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine from the commercial scale lot 1 (formulation 1 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3076631|NCT01323972|Experimental|GSK 257049-Lot 2 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 2 (formulation 2 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3076632|NCT01323972|Experimental|GSK 257049-Lot 3 Group|Healthy male or female children aged 5 to 17 months received 3 doses of the GSK 257049 vaccine, from the commercial scale lot 3 (formulation 3 of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3076633|NCT01323972|Experimental|GSK 257049-Pilot Group|Healthy male or female children aged 5 to 17 received 3 doses of the GSK 257049 vaccine from the pilot scale (pilot formulation of the GSK 257049 vaccine) administered intramuscularly (IM) in the deltoid of the left arm, at Day 0, at Month 1 and at Month 2.
3076634|NCT01323998||5ARI monotherapy|Patients with BPH receiving 5ARI monotherapy
3076635|NCT01323998||AB monotherapy|Patients with BPH receiving AB monotherapy
3076636|NCT01323998||Early combination (5ARI + AB) therapy|Patients receiving early initiation of combination therapy with a 5ARI plus AB. Early initiation defined as starting 5ARI therapy within 30 days of initiating AB therapy
3076637|NCT01323998||Delayed combination (5ARI + AB) therapy|Patients receiving delayed initiation of combination therapy with a 5ARI plus AB. Delayed initiation defined as starting 5ARI therapy more than 30 days but less than 6 months after initiating AB therapy
3076638|NCT01324024|Experimental|Lisdexamfetamine, then placebo|Participants first received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks followed by a 2-week washout, then they received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks.
3076639|NCT01324024|Experimental|Placebo, then Lisdexamfetamine|Participants first received Placebo tablets (matching Lisdexamfetamine tablets) each day for 4 weeks followed by a 2-week washout, then they received titrated doses of Lisdexamfetamine 20 to 60 mg/d each day for 4 weeks.
3076640|NCT01324102|Active Comparator|1. Yoga therapy|The intervention is an 8 week Yoga therapy class adapted to the specific needs of the veteran. The class meets two times per weeks for 90 minutes. A series of poses are instructed, with adaptations used as provided by a physical therapist.
3076641|NCT01324102|No Intervention|2. Wait list|The comparative intervention is an 8 week wait list control group for which there is no intervention provided within the study protocol.
3076642|NCT01324128|Experimental|PA21 (2.5 g tablet)|
3076643|NCT01324128|Active Comparator|Sevelamer carbonate|
3076644|NCT01324128|Other|PA21-1 (1.25 g tablet)|
3076645|NCT01324141|Experimental|1/Chemo + Radiation|Chemo + Radiation
3076646|NCT01324232|Placebo Comparator|Placebo|
3076647|NCT01324232|Experimental|AVP-923-45|
3076648|NCT01324232|Experimental|AVP-923-30|
3076649|NCT01324232|Experimental|AVP-923-20|
3076650|NCT01324271|Experimental|Tympanostomy tube placement|placement of tympanostomy tube under local anesthesia in office/clinic setting
3076651|NCT01324310|Experimental|Romidepsin and ketoconazole|"Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Ketoconazole 400 mg oral once daily on Days 4-8"
3076652|NCT01324323|Experimental|Romidepsin and rifampin|"Romidepsin 14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.~Rifampin 600 mg oral once daily on Days 4-8"
3076653|NCT01324349|Experimental|Veriset Hemostatic Patch|Veriset Hemostatic Patch
3076654|NCT01324349|Active Comparator|Fibrin Sealant (TachoSil®)|Fibrin Sealant (TachoSil®)
3076655|NCT01324388|Experimental|LY2189265 + Lisinopril|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
3076656|NCT01324388|Placebo Comparator|Placebo + Lisinopril|"Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study.~Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study."
3076657|NCT01324388|Experimental|LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study)."
3076658|NCT01324388|Experimental|Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)|"LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study.~Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study.~There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study)."
3076659|NCT01324401|No Intervention|Control|The subjects randomized to the observational control group will have follow-up visits every 6 months. Each visit will involve a medical history and physical examination. These subjects are then offered to cross-over to active treatment.
3076660|NCT01324401|Experimental|Peanut OIT|The subjects randomized to the active treatment group will receive defatted peanut flour per protocol.
3076661|NCT01324440|Experimental|V710 without MAA|
3076662|NCT01324440|Active Comparator|V710 with MAA|
3076663|NCT01324453|Experimental|Post conditioning + PCI|
3076664|NCT01324453|Active Comparator|Standard PCI|
3076665|NCT01324518|Experimental|Low dose of ORM-12741|
3076666|NCT01324518|Experimental|High dose of ORM-12741|
3076667|NCT01324518|Placebo Comparator|Placebo|
3076668|NCT01324570|Experimental|Overall BTDS|Buprenorphine transdermal system
3076669|NCT01324622|Active Comparator|Laminectomy|Control
3076670|NCT01324622|Active Comparator|Laminoplasty|Treatment group
3076671|NCT01324687||Control|Group without access to telemedicine in the home for acute care issues.
3076672|NCT01324687||Telemedicine care|Cohort with access to telemedicine in the home for acute care issues.
3076673|NCT01324700|Active Comparator|High severity group: Escitalopram|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into escitalopram group.
3076674|NCT01324700|Active Comparator|Low severity group: Escitalopram|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into escitalopram group.
3076675|NCT01324700|Placebo Comparator|High severity group: Placebo|Participants with Baseline score of 20 or above on the 17-item Hamilton Rating Scale for Depression (HRSD) AND 3 or more courses of oral corticosteroids in the past 12 months were stratified into high severity group. Then these participants were further stratified into placebo group.
3076676|NCT01324700|Placebo Comparator|Low severity group: Placebo|Participants with Baseline HRSD score of less than 20 AND fewer than 3 courses of oral corticosteroids in the past 12 months were stratified into low severity group. Then these participants were further stratified into placebo group.
3076677|NCT01324830|Experimental|arm A|14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
3076678|NCT01324830|Experimental|arm B|5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
3076679|NCT01324882|Experimental|Study Arm|This is the group who will have a colonoscopy with the Olympus Technically Improved Colonoscope.
3076680|NCT01324882|Active Comparator|Control|This is the group who will have a colonoscopy with the traditional colonoscope Olympus CF-H180.
3320984|NCT02015299|Placebo Comparator|Placebo|Matching placebo + lifestyle advise
3076681|NCT01324947|Experimental|Pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
3076682|NCT01324999|Experimental|Sarcoid Associated Pulm. Hypertension|Single-arm open-label proof of concept study of tadalafil in patients with sarcoidosis associated pulmonary hypertension.
3076683|NCT01325181|Active Comparator|Low-fluence PDT with Verteporfin|Half the regular laser fluence PDT(Visudyne®; Novartis); a total light energy of 25J/cm2, a light dose rate of 300mW/cm2. If subretinal fluid was sustained after primary treatment, rescue treatment(ranibizumab injection) was considered
3076684|NCT01325181|Active Comparator|Ranibizumab|Consecutive Intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months. If subretinal fluid was sustained after primary treatment, rescue treatment(low-fluence photodynamic therapy) was considered
3076685|NCT01325207|Experimental|intravenous trastuzumab infusions|A Phase I single dose study (H0407g) of intravenous trastuzumab infusions ranging from 10-500 mg resulted in dose-dependent pharmacokinetics (PK) with serum clearance of trastuzumab decreasing with an increasing dose at doses <250 mg. PK modeling of trastuzumab concentration-time data from 7 patients that were administered doses of 250 mg and 500 mg had in a mean halflife of 5.8 days (range 1-32 days).
3076686|NCT01325311|Experimental|Arm I (cholecalciferol, genistein)|Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
3076687|NCT01325311|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
3076688|NCT01325337|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076689|NCT01325337|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076690|NCT01325337|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076691|NCT01325337|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076692|NCT01325337|Active Comparator|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
3076693|NCT01325350|Experimental|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076694|NCT01325350|Experimental|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076695|NCT01325350|Experimental|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076696|NCT01325350|Placebo Comparator|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
3076697|NCT01325350|Active Comparator|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
3076698|NCT01325428|Experimental|Afatinib once daily (OD)|Patients receive afatinib monotherapy once daily until progression of their disease
3076699|NCT01325493|Placebo Comparator|Normal Saline|Normal Saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
3076700|NCT01325493|Active Comparator|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
3076701|NCT01325532|Experimental|Active CES|"Active CES: The FW-100 Cranial Stimulator headset was placed on the scalp over the two dorsolateral prefrontal cortex areas. The power knob was turned to maximum setting. The waveform contains a 15000Hz square wave carrier from 0-4 mAmp. The first 15Hz modulating signal provides 50msec of on and 16.7msec of off time (total 66.7msec, 50% duty cycle). A second 500Hz modulating signal changes the on time series of 15000Hz pulses (750 pulses/50msec) into 25 smaller bursts of 15 pulses of the 15000Hz carrier signal, for 375 pulses in 50msec. The consecutive positive burst and off time is followed by an opposite negative burst and off time, balancing the current component to zero. Output voltage ranges from 0-40V, positive and negative. CES automatically shut off after 20 mins."
3076702|NCT01325532|Sham Comparator|Sham CES|Shame CES: The sham devices were modified to not deliver current to the headset. The current from the active device departs from the posts at the top of the device into the headsets, creating a loop when the headset is worn by the subject with the wet electrode sponges. This loop is eliminated in the sham devices by wrapping wire around the posts, thus containing the loop within the device, with no electricity leaving the headsets. This approach allows the loop to be maintained, and therefore all of the device's green and yellow amperage lights still light up, protecting the blind.
3076703|NCT01325584|Experimental|Omegaven (compassionate use)|This is a compassionate use study. All participants will receive intravenous Omegaven (10% fish oil emulsion) with parenteral nutrition for 4 weeks.
3076704|NCT01325623|Other|Model 106 VNS Therapy System|Model 106 VNS Therapy System includes a new Seizure Detection Algorithm (SDA) and corresponding Automatic Magnet Mode (AMM) feature.
3076705|NCT01325701|Experimental|PCI-32765: 560 mg|Treatment Group 1: Subjects received 560 mg of ibrutinib once daily, on a continuous basis.
3076706|NCT01325701|Experimental|PCI-32765: 840 mg|Treatment Group 2: Subjects received 840 mg of ibrutinib once daily, on a continuous basis.
3076707|NCT01325714|Experimental|Arm 1: PAVeD Intervention|In the experimental arm, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
3076708|NCT01325714|Active Comparator|Arm 2: Enhanced Usual Care|In the comparison arm, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
3076709|NCT01325792||GORE® BIO-A® Tissue Reinforcement|Single-staged open complex ventral incisional repair of primary or recurrent anterior abdominal wall hernia.
3076710|NCT01325870|Experimental|ACD-CPR +ITD|Active Compression Decompression CPR with the ResQPRO device and ResQPOD ITD device.
3076711|NCT01325870|Experimental|S-CPR + ITPR|
3076712|NCT01325870|Active Comparator|S-CPR|
3076713|NCT01326026|Experimental|IDeg Simple|
3076714|NCT01326026|Experimental|IDeg Step wise|
3076715|NCT01326481|Experimental|Single|All patients received TRC105 + capecitabine
3076716|NCT01326533|Experimental|hydroxychloroquine|Thirteen weeks of daily hydroxychloroquine following FSIGTT testing
3076717|NCT01326533|Placebo Comparator|Placebo|Thirteen weeks of daily placebo following FSIGTT testing
3076718|NCT01326546|Experimental|Therapeutic HBV vaccine+Entecavir|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
3076719|NCT01326546|Placebo Comparator|placebo+Entecavir|Placebo comparator: Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 and Oral intake entecavir 0.5mg per day.
3076720|NCT01326702|Experimental|Treatment (veliparib, bendamustine hydrochloride, rituximab)|"Patients receive veliparib PO BID on days 1-7 and bendamustine hydrochloride IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Once the maximum-tolerated dose is determined, a cohort of patients receives veliparib and bendamustine hydrochloride as above and rituximab IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3076721|NCT01326728||Allogeneic Stem Cell Transplant|Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells)
3076722|NCT01326780|Experimental|1.2% Facial Cream|1.2% JNJ 10229570-AAA
3076723|NCT01326780|Experimental|2.4% Facial Cream|2.4% JNJ 10229570-AAA
3076724|NCT01326780|Experimental|3.6% Facial Cream|3.6% JNJ 10229570-AAA
3076725|NCT01326780|Placebo Comparator|0% Facial Cream|Vehicle control
3076726|NCT01326910|Experimental|19306-127|Experimental Topical cream applied twice daily (or as needed)
3076727|NCT01326910|Other|19306-137|Marketed Topical cream applied twice daily (or as needed)
3076728|NCT01326962|Experimental|Single Arm|
3076729|NCT01327053|Experimental|LDE225 200 mg|The study was double blinded and enrolled at least 50 evaluable patients in the 200 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 200 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
3076730|NCT01327053|Experimental|LDE225 800 mg|The study was double blinded and enrolled at least 100 evaluable patients in the 800 mg LDE225 arm. The efficacy and safety of LDE225 was analyzed separately in each group. Patients who met all the inclusion and none of the exclusion criteria were treated with 800 mg LDE225 daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawal of consent.
3076731|NCT01327157|Placebo Comparator|Visual Analog Scale (VAS)|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final~VAS and dental cleaning at the first query.~VAS at the last query. In the second period (91-180 days) that participants have been moved from the Placebo group (VAS) to the Experimental group(Occlusal Adjustment)."
3076732|NCT01327157|Experimental|Occlusal adjustment|In all consultations, was performed VAS and occlusal adjustment. Three sessions of intervention are doing. The Gnathostatic models were performed in the first and last query. To reach a terminal axis of rotation of the jaw the patient to perform the act of swallowing for 3 times, and after palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth and started the adjustment following the rules of Guichet with a cylindrical drill with a thin cut.. The rules to guide the occlusal adjustment selective grinding were in this sequence: Occlusal adjustment to the centric relation: with sliding towards anterior; with sliding towards the medium line; with sliding opposite to the medium line; No sliding.
3076733|NCT01327274|Experimental|Treatment Arm|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the interventional treatment arm by having outpatient surgery and the Magnetic MIni-Mover Magnimplant procedure is performed during which the magnetic implant is surgically placed. After 2 years of treatment with the implanted magnet and brace treatment, the Magnetic Mini-Mover Magnimplant will be explanted. After surgery and recovery, all subjects will be fitted for an orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25).
3076734|NCT01327300|Active Comparator|Mesalamine|This group received the drug Mesalamine for 12 weeks then a wash out for 3 weeks prior to crossing over to the placebo arm.
3076735|NCT01327300|Placebo Comparator|Placebo|This group will receive the Placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
3076736|NCT01327313|Experimental|EMD525797 250 milligram (mg)|
3076737|NCT01327313|Experimental|EMD525797 500 mg|
3076738|NCT01327313|Experimental|EMD525797 1000 mg|
3076739|NCT01327313|Experimental|EMD525797 1500 mg|
3076740|NCT01327339||Subjects eligible for REQUIP prescription|Male and female subjects who were considered appropriate to be prescribed REQUIP according to the prescribing information will be included in this study.
3076741|NCT01327482|Experimental|All|All patients were part of the intervention arm, as this was a pharmacokinetic study. All women took Raltegravir 400mg orally, twice daily for 3 weeks.
3076742|NCT01327495|Placebo Comparator|Arm 1: Placebo|Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
3076743|NCT01327495|Active Comparator|Arm 2:1.25g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
3076744|NCT01327495|Active Comparator|Arm 3: 2.5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
3076745|NCT01327495|Active Comparator|Arm 4: 5g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
3076746|NCT01327495|Active Comparator|Arm 5: 10g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
3076747|NCT01327495|Active Comparator|Arm 6: 15g Testosterone|Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
3076748|NCT01327508|Experimental|TRIGEN SURESHOT Distal Targeting|TRIGEN SURESHOT Distal Targeting Instrumentation is utilized to find screw holes.
3076749|NCT01327508|Active Comparator|Standard Nailing Instrumentation.|Free-hand technique utilizes x-rays to find screw holes
3076750|NCT01327547|Experimental|1.0|
3076751|NCT01327547|Placebo Comparator|2|
3076752|NCT01327573|Experimental|Eculizumab|"eculizumab will be given in addition to standard immunosuppression regimen (oral tacrolimus or equivalent, MMF [mycophenolate mofetil~], prednisone)"
3076753|NCT01327573|No Intervention|no additional therapy|patients in this arm will receive standard immunosuppression regimen (oral tacrolimus or equivalent, MMF, prednisone only, no additional therapy
3076754|NCT01327599|Experimental|DUOTRAV®|Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks
3076755|NCT01327612|Experimental|Conatumumab Monotherapy|Participants will continue to receive conatumumab every 2 weeks (Q2W) or every 3 weeks (Q3W) at the same dose and regimen as at the conclusion of the parent study.
3076756|NCT01327612|Experimental|Conatumumab + Ganitumab|Participants will receive conatumumab and ganitumab by intravenous infusion at the same dose and regimen as at the conclusion of the parent study.
3076757|NCT01327612|Experimental|Ganitumab Monotherapy|Participants will continue to receive ganitumab Q3W or every 4 weeks (Q4W) at the same dose and regimen as at the conclusion of the parent study.
3076758|NCT01327612|Experimental|Conatumumab + mFOLFOX6 ± Bevacizumab|Participants will continue to receive conatumumab by intravenous infusion in addition to modified FOLFOX6 chemotherapy with or without bevacizumab.
3076759|NCT01327651|Active Comparator|Daily dosing|Participants will receive oral FTC/TDF daily.
3076760|NCT01327651|Experimental|Time-driven dosing|Participants will receive oral FTC/TDF twice weekly with a post-exposure dose.
3076761|NCT01327651|Experimental|Event-driven dosing|Participants will receive oral FTC/TDF before and after a potential exposure to HIV infection.
3076762|NCT01327677|Active Comparator|Pro re nata (PRN) fentanyl|A nurse can give the patient up to 3 doses of fentanyl intravenously (through a vein) each hour whenever a patient indicates that he or she is in pain.
3076763|NCT01327677|Active Comparator|Intravenous Patient-controlled Analgesia (IVPCA) fentanyl|Fentanyl will be given with a Patient Controlled Analgesia (PCA) pump.
3076764|NCT01327703|Experimental|Panzytrat® 25,000|
3076765|NCT01327703|Active Comparator|Kreon® 25,000|
3076766|NCT01327846|Experimental|Canakinumab Dose 50 mg|"Pivotal Phase:~Blinded Canakinumab 50 mg quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
3076767|NCT01327846|Experimental|Canakinumab Dose 150 mg|"Pivotal Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
3076768|NCT01327846|Experimental|Canakinumab Dose 300 mg|"Pivotal Phase:~Blinded Canakinumab 300 mg quarterly subcutaneous (with one additional dose at week 2) + standard of care therapy.~Extension phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
3076769|NCT01327846|Placebo Comparator|Placebo|"Pivotal Phase:~Blinded matching placebo quarterly subcutaneous + standard of care therapy.~Extension Phase:~Switched to open-label Canakinumab 150 mg quarterly subcutaneous + standard of care therapy"
3076770|NCT01327885|Experimental|Arm A|
3076771|NCT01327885|Active Comparator|Arm B|
3076772|NCT01327963|Experimental|Transoral Incisionless Fundoplication|"Intervention: Transoral Incisionless Fundoplication 2.0 technique iteration (TIF 2.0).~With patient in general anesthesia. The EsophyX (brand name) device is introduced through the mouth, over a standard endoscope, into the stomach. Multiple gastro-esophageal plications are performed, apposing the fundus to the distal part of the esophagus and repositioning the GastroEsophageal Junction (GEJ) below the diaphragm, into the abdomen. Multiple prolene fasteners are used to secure and keep in place the plications."
3076773|NCT01327976|Active Comparator|vBloc (Active Device)|The treatment group will receive a functional device that will deliver charge to the vagus nerve during the study period
3076774|NCT01327976|Sham Comparator|Sham (Non-active Device)|The control group will receive a functional, but non-active device that will deliver no charge to the vagus nerve during the study period
3076775|NCT01327989||Solitaire™ FR device|Eligible subjects treated with the Solitaire™ FR device.
3076776|NCT01328002|Experimental|Milnacipran|oral administration, twice daily dosing
3076777|NCT01328002|Placebo Comparator|Placebo|oral administration, twice daily dosing
3076778|NCT01328041|Experimental|dolutegravir|dolutegravir plus background antiretroviral therapy optimised at Day 8
3076779|NCT01328054|Experimental|lapatinib/placebo|This is a crossover study where subjects will receive placebo that mimics lapatinib for 2 days and lapatinib for 2 days. Subjects will not know when they are receiving placebo vs. lapatinib.
3076780|NCT01328080|Experimental|Targeted UV-B (Left)|Targeted UV-B on left side of the scalp.
3076781|NCT01328080|Experimental|Targeted UV-B (Right)|Targeted UV-B on right side of the scalp.
3076782|NCT01328158||Lopinavir/Ritonavir|Participants with HIV infection who were receiving Lopinavir/Ritonavir or who started Lopinavir/Ritonavir therapy during the registration period were evaluated
3076783|NCT01328184|Experimental|Reference|multiple doses of Microgynon
3076784|NCT01328184|Active Comparator|Test|multiple doses of Microgynon + BI 10773
3076785|NCT01328249|Experimental|Doxorubicin and cyclophosphamide followed by eribulin mesylate|
3076786|NCT01328366||Participants with severe psoriasis|The participants had severe disease as defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and had not responded to standard systemic therapies.
3076787|NCT01328379|Active Comparator|Dalfampridine-ER 5mg|5mg, twice daily
3076788|NCT01328379|Active Comparator|Dalfampridine-ER 10mg|10mg, twice daily
3076789|NCT01328379|Placebo Comparator|Placebo|placebo, twice daily
3076790|NCT01328405|Experimental|Air-Q LMA|Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
3076791|NCT01328405|Experimental|Proseal LMA|LMA-Proseal TM (LMA North America, San Diego, Ca.)
3076792|NCT01328431|No Intervention|Standard Care|Subjects receive a brochure for the state's Smokers' Quitline only.
3076793|NCT01328431|Experimental|SBIRT+NRT|Subjects receive a 6 week course of NRT, a motivational Brief Negotiated Interview, and a facilitated referral to the state's Smokers' Quitline.
3076794|NCT01328444|Experimental|GSK 573719 + GW642444 125/25|125mcg/25mcg nDPI
3076795|NCT01328444|Experimental|GSK 573719 +GW642444 62.5/25|62.5mcg/25mcg nDPI
3076796|NCT01328444|Experimental|GSK 573719 125|125mcg nDPI
3076797|NCT01328444|Experimental|GSK 573719 62.5|62.5 mcg nDPI
3076798|NCT01328444|Experimental|GW 642444 25|25mcg nDPI
3076799|NCT01328444|Placebo Comparator|Plb|Plb nDPI
3076800|NCT01328496|Other|Research Arm|"Participant with high-risk hematologic malignancies undergoing Hematopoietic Cell Transplantation, who do not have a suitable Human Leukocyte Antigen -matched related/sibling donor, Matched Unrelated Donor or Killer immunoglobulin receptors ligand mismatched haploidentical donor identified, will receive a single UCB unit.~Intervention: Preparative Regimen"
3076801|NCT01328496|Other|Observation Arm|"Patients requiring two UCB units will be eligible for UCBT01 on the observational arm.~Intervention: Preparative Regimen"
3076802|NCT01328535|Experimental|Treatment (individualized chemotherapy)|Patients with an established biorhythm receive TMZ PO on recommended day for 5 days. Treatment repeats every 21-42 days until disease progression or unacceptable toxicity. Patients without an established biorhythm receive TMZ PO on days 1-5. Courses repeat every 28 days until disease progression or unacceptable toxicity.
3076803|NCT01328548||Nursing Home Elderly Cases|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.
3076804|NCT01328548||Nursing Home Elderly Controls|Non-ambulatory nursing home residents >= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.
3076805|NCT01328548||Community dwelling seniors|Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.
3076806|NCT01328574|Experimental|Single Arm - TRC105 in Urothelial Carcinoma|TRC105 15 mg/kg/dose every two weeks
3076808|NCT01328717|Experimental|Intended Users of the System|Subjects with diabetes used Contour Link Investigational Blood Glucose Monitoring System
3076809|NCT01328743|No Intervention|Treatment as usual|Treatment as usual in an HIV primary care setting. Participants receive assessment of alcohol use but not counseling or advice regarding drinking.
3076810|NCT01328743|Experimental|Brief Alcohol Intervention|Participants receive 3 face-to-face sessions of counseling on alcohol use and 2 follow-up phone calls
3076811|NCT01328756|Experimental|Lisdexamfetamine Dimesylate|
3076812|NCT01328769|Active Comparator|Febuxostat|Investigational
3076813|NCT01328769|Placebo Comparator|Placebo|Placebo
3076814|NCT01328782|Active Comparator|The group receiving oral pain medicine|This group will receive Oxycodone with Acetaminophen orally
3076815|NCT01328782|Active Comparator|The group receiving bupivacaine and oral pain medicine|This group will receive an intra-articular shot during surgery and will then be sent to the recovery room to receive pain medication as needed.
3076816|NCT01328782|Active Comparator|The group receiving ropivacaine and oral pain medicine|This group will receive an intra-articular shot of ropivacaine during surgery and will be sent to the recovery room to receive pain medicine as needed.
3076817|NCT01328873|Experimental|Laboratory testing|All patients will receive the lab testing on bronchoscopy specimens
3076818|NCT01328951|Experimental|Early Erlotinib|Participants will receive blinded erlotinib as 150 mg PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
3076819|NCT01328951|Placebo Comparator|Late Erlotinib|Participants will receive blinded placebo tablets PO once daily in the maintenance setting until disease progression, death, or unacceptable toxicity. Those who demonstrate disease progression may be unblinded to receive second-line erlotinib as 150 mg PO once daily until disease progression, death, or unacceptable toxicity. Participants may be observed during a final SFU period after discontinuation from study treatment.
3076820|NCT01328964||Children Ages 4-11 with asthma|Children ages 4 to 11 with a diagnosis of asthma receiving a prescription for an asthma therapy
3076821|NCT01329029|Active Comparator|Roflumilast|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
3076822|NCT01329029|Placebo Comparator|Placebo|concomitant medication: fixed combination of long-acting β2-agonist and inhaled glucocorticosteroid
3076823|NCT01329185|Placebo Comparator|Placebo|Eligible consenting kidney transplant donors who are randomized to receive placebo will be given 1 placebo in morning and 1 in evening for 14 days prior to transplant date
3076824|NCT01329185|Experimental|Valganciclovir|Eligible consenting kidney transplant donors who are randomized to the experimental arm of the study will receive 450mg of Valganciclovir twice a day for 14 days prior to the transplant date
3076825|NCT01329198|Active Comparator|Delayed Activation - Deep Brain Stimulation (DBS)|"Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
3320985|NCT02015312|Experimental|Epigallocatechin-3-gallate (EGCG)|EGCG 400 mg/d p.o. for 3 months; 800 mg/d p.o. for 3 months, 1200 mg/d p.o. for 6 months
3320986|NCT02015312|Placebo Comparator|Placebo|"capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
3076826|NCT01329198|Active Comparator|Immediate Activation - Deep Brain Stimulation (DBS)|"Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency & severity, while limiting potential stimulation-induced side-effects.~There will be a one month post-operative period during which stimulation is not turned on.~One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.~By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.~Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
3076827|NCT01329263|Experimental|Nonmenthol|Participants switch from menthol to non-menthol cigarettes.
3076828|NCT01329263|No Intervention|Menthol|Participants smoke own brand of menthol cigarettes.
3076829|NCT01329328|No Intervention|CONTROL|NO VIBRATION EXERCISE
3076830|NCT01329328|Experimental|VIBRATION EXERCISE|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIOS, MILAN, ITALY
3076831|NCT01329328|Experimental|VIBRATION EXERCISE PLUS RADIOFREQUENCY ADMINISTRATION|WHOLE-BODY VIBRATION EXERCISE ON A VIBRATION DEVICE (BIOPLATE RF, BIO, MILAN, ITALY PLUS LOCAL ADMINISTRATION OF RADIOFREQUENCY
3076832|NCT01329380||Adalimumab|Participants with ankylosing spondylitis (AS) receiving treatment with adalimumab (Humira) as prescribed by their physician.
3076833|NCT01329419||adefovir dipivoxil|Patients administrated adefovir at the site
3076834|NCT01329562|Active Comparator|Treximet|"Subjects randomized to Group A will be provided with 1 tablet of Treximet to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
3076835|NCT01329562|Placebo Comparator|Placebo|"Subjects randomized to Group B will be provided with 1 tablet of placebo to be taken at onset of menstrual migraine headache pain.~All subjects will be provided with 1 tablet of Treximet for treatment of persistent or recurring headache between 2 and 24 hours following treatment with study medication at headache onset."
3076836|NCT01329679|Experimental|Energy Drink|Energy drink, 2 oz twice daily for 7 days
3076837|NCT01329679|Placebo Comparator|Placebo|Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days
3076838|NCT01329848||discomfort symptoms|level of discomfort symptoms while performing near work
3076839|NCT01329900|Experimental|Ofatumumab + Stem Cell Collection|Ofatumumab 1000 mg by vein on Day 1 and 2000 mg by vein on Day 8. Ifosfamide 3.33 gm/m2 by vein on Days 2, 3, and 4 continuously. Etoposide 150 mg/m2 by vein over 2 hours every 12 hours for 6 doses. Mesna 2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts). Mesna 2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide). After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose. G-CSF 6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis. Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
3076840|NCT01329939|Experimental|Obese atopic asthmatics, montelukast|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
3076841|NCT01329939|Placebo Comparator|Lean atopic asthmatics, placebo|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
3076842|NCT01329939|Active Comparator|Lean atopic asthmatics, montelukast|Normal weight (BMI less than 85%ile or above for children and < 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive montelukast in a double blinded fashion.
3076843|NCT01329939|Placebo Comparator|Obese atopic asthmatics, Placebo|Obese/overweight (BMI 85%ile or above for children and > 25 for adults) mild to moderate persistent asthmatics age 7 and above, with environmental allergies who were on daily inhaled corticosteroid treatment and not on montelukast, were randomized to receive placebo in a double blinded fashion.
3076844|NCT01329978|Experimental|SOF+PEG+RBV 12 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks.
3076845|NCT01329978|Experimental|SOF+PEG+RBV 24 weeks|Participants were randomized to receive sofosbuvir+PEG+RBV for 24 weeks.
3076846|NCT01329978|Experimental|SOF+PEG+RBV 12 week/Rerandomization Group|Participants were randomized to receive sofosbuvir+PEG+RBV for 12 weeks, then were rerandomized to receive sofosbuvir only or sofosbuvir+RBV for 12 additional weeks.
3076847|NCT01330017|Experimental|PE 10 mg|
3076848|NCT01330017|Experimental|PE 20 mg|
3076849|NCT01330017|Experimental|PE 30 mg|
3076850|NCT01330017|Experimental|PE 40 mg|
3076851|NCT01330017|Placebo Comparator|Placebo|
3076852|NCT01330030|Experimental|Drug Selegiline|6 mg selegiline patch (transdermal) worn for 24 hours for 8 weeks
3076853|NCT01330030|Placebo Comparator|Matching placebo|matching placebo worn 24 hours for 8 weeks
3076854|NCT01330043|Active Comparator|Non-extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks"
3076855|NCT01330043|Experimental|Extended treatment|"26 weeks of CBT~10 weeks of combination bupropion plus nicotine patch~Additional 16 weeks of bupropion plus nicotine patch if increased craving or depression scores or varenicline if smoking at 10 weeks~24 additional weeks of CBT"
3076856|NCT01330108|Experimental|Ambrisentan|patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
3076857|NCT01330134|Experimental|lidocaine onto skin prior to lidocaine subcutaneous injection|1-2ml of 1% lidocaine dripped onto the surface of the skin immediately prior to subcutaneous injection of 1% lidocaine.
3076858|NCT01330134|Active Comparator|lidocaine subcutaneous injection alone|1% lidocaine subcutaneous injection alone by standard approach
3320987|NCT02015325|No Intervention|Control|Control schools were included if they did not have any ongoing water and sanitation hygiene initiative.
3076859|NCT01330290||Neupro® Treatment|Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
3076860|NCT01330303|Active Comparator|tamsulosin - Reference|Reference drug administration followed by Test drug administration
3076861|NCT01330303|Active Comparator|tamsulosin - Test|Test drug administration followed by Reference drug administration
3076862|NCT01330316|Experimental|BI 201335 for 24 weeks|BI 201335 once daily dose for 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
3076863|NCT01330355|Experimental|Besivance|Besifloxacin 0.6% ophthalmic suspension
3076864|NCT01330355|Active Comparator|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution
3076865|NCT01330381|Experimental|prucalopride|drug
3076866|NCT01330381|Placebo Comparator|Placebo|
3076867|NCT01330381|Active Comparator|PEG 4000|4-20g administered as an oral solution once daily
3076868|NCT01330394|Sham Comparator|sham-tDCS control|simulate control for transcranial Direct Current Stimulation
3076869|NCT01330394|Active Comparator|active tDCS|active transcranial Direct Current Stimulation
3076870|NCT01330420|Experimental|Relaxation Response Resiliency Program for Depression|"The Relaxation Response Resiliency Program for Depression (3RP-D) is a low-cost, easily replicable, 6-session, 1.5 hour, mind body intervention.~The 3RP-D was designed to promote resiliency by reducing the harmful effects of stress through the elicitation of the relaxation response, and through skill training to enhance positive attitudes and beliefs, nutrition, exercise, recuperative sleep, social support, and coping. Specific interventions include: cognitive behavioral therapy (CBT), enhancing social support (SS), cultivating positive attitudes and beliefs (CPE), and promoting Healthy Lifestyle Habits(HL). The 3RP-D program has been manualized for use by group facilitators and health center patients."
3076871|NCT01330433|No Intervention|No CoSeal Surgical Spray|A patient randomized to the No CoSeal Surgical Spray group will not have CoSeal Surgical Spray applied at the end of their first staged procedure.
3076872|NCT01330433|Experimental|CoSeal Spray Group|CoSeal Spray will be applied at the end of the first staged procedure in patients randomized to the experimental group.
3076873|NCT01330459|Active Comparator|Hydrocodone/acetaminophen|"Subject will receive hydrocodone/acetaminophen 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
3076874|NCT01330459|Placebo Comparator|Placebo|"Subject will receive placebo 45-90 minutes prior to abortion procedure.~Subject will also recieve ibuprofen, lorazepam, and lidocaine 45-90 minutes prior to abortion procedure."
3076875|NCT01330628|Experimental|Laser atherectomy and PTA|laser, then balloon angioplasty
3076876|NCT01330628|Active Comparator|Balloon angioplasty|
3076877|NCT01330914||Gastric Bypass Surgery Patients|Obese men and women undergoing gastric bypass surgery
3076878|NCT01330953|Placebo Comparator|Placebo|Single intravenous placebo dose.
3076879|NCT01330953|Experimental|30 mg LY2928057 (Cohort 1)|Day 1: single 30-milligram (mg) LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 30-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 30-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 30 mg LY2928057.
3076880|NCT01330953|Experimental|100 mg LY2928057 (Cohort 2)|Day 1: single 100-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 100-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 100-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 100 mg LY2928057.
3076881|NCT01330953|Experimental|300 mg LY2928057 (Cohort 3)|Day 1: single 300-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 300-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 300-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 300 mg LY2928057.
3076882|NCT01330953|Experimental|1000 mg LY2928057 (Cohort 4)|Day 1: single 1000-mg LY2928057 intravenous dose; Days 2 and 3: observation period; Days 4 and 5: single 1000-mg LY2928057 intravenous dose followed by 24-hour observation period; Days 6 and 7: single 1000-mg LY2928057 intravenous dose; Days 8-85: participant follow-up for minimum of 12 weeks to assess the safety, immunogenicity, and pharmacokinetic profile of 1000 mg LY2928057.
3076883|NCT01330966|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
3076884|NCT01331005|Placebo Comparator|Placebo|Placebo will be given three times per day for one year
3076885|NCT01331005|Active Comparator|nepafenac 0.1% drops|Nepafenac drops will be given three times per day for one year
3076886|NCT01331083|Experimental|PX-866|
3076887|NCT01331109|Experimental|Milnacipran|oral administration, twice daily dosing
3076888|NCT01331161|Experimental|Older group|Participants between the ages of 60-79
3076889|NCT01331161|Experimental|Younger group|Participants between the ages of 25-40
3076890|NCT01331213|Active Comparator|Pregabalin|Subjects randomized to this arm received a single dose of pregabalin 200mg orally.
3076891|NCT01331213|Placebo Comparator|Placebo|Subjects randomized to this arm received a single dose of placebo orally.
3076892|NCT01331239|Experimental|Part l: Core cohort|Participants took an ascending dose of LCI699 (osilodrostat) from 2mg bid or 5 mg bid, up to 30 mg bid and participated in Part I of this study. 4 patients in this cohort moved to Part II of the study
3076893|NCT01331239|Experimental|Part II Core: Expansion cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Expansion of this study. These patients were all newly enrolled into the phase II part of the study
3076894|NCT01331239|Experimental|Part II Core: Follow-up cohort|Participants took an ascending dose from 2mg bid or 5 mg bid, up to 30 mg bid and participated in the Part II Core Follow-up of this study. These patients were patients who transferred from Part I Core phase of the study
3076895|NCT01331291|Experimental|Arm A|Patients who are surgical candidates. Participants are given oral bosutinib, 400mg daily, for 7-9 days prior to resection. After at least 10 days elapsed post-operatively, bosutinib dosing was resumed.
3076896|NCT01331291|Experimental|Arm B|Patients that are not surgical candidates. Participants are given oral bosutinib, 400 mg daily in 28 day cycles until disease progression, intolerability or withdrawal of consent.
3076897|NCT01331304|Other|Li + APT|Study participants will take lithium in addition to any other medications recommended by the study physician.
3076898|NCT01331304|Other|QTP + APT|Study participants will take quetiapine in addition to any other medications recommended by the study physician.
3076899|NCT01331408|Experimental|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks
3076900|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
3076901|NCT01331681|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
3076902|NCT01331681|Active Comparator|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
3076903|NCT01331694||COPD|copd patients 65 years and older
3076904|NCT01331824|Experimental|Amrubicin|35 mg/m2/day intravenously
3076905|NCT01331837|Active Comparator|Etanercept|
3076906|NCT01331837|Experimental|Tocilizumab|
3076907|NCT01332019|Experimental|peginterferon beta-1a Q4W|125 µg peginterferon beta-1a administered by subcutaneous (SC) injection every 4 weeks (Q4W) for at least 2 years and up to 4 years.
3076908|NCT01332019|Experimental|peginterferon beta-1a Q2W|125 μg peginterferon beta-1a administered by SC injection every 2 weeks (Q2W) for at least 2 years and up to 4 years.
3076909|NCT01332071|Active Comparator|Avandamet test product|Test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 miligrams (mg) + 1000 mg in Period 1, followed by a 7-day washout period during which no medication was administered, followed by reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 mg + 500 mg in Period 2
3076910|NCT01332071|Active Comparator|Avandamet reference product|Reference product: Avandamet (Rosiglitazone Maleate + Metformin) 2 miligrams (mg) + 500 mg in Period 1; followed by a 7-day washout period during which no medication was administered; followed by test product: Avandamet (Rosiglitazone Maleate + Metformin) 4 mg + 1000 mg in Period 2
3076911|NCT01332123|Experimental|Alignment perturbations|The following modifications will be applied to the prostheses: increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
3076912|NCT01332149|Experimental|300 mg/day pregabalin (Lyrica)|Patient take pregabalin capsule twice a day
3076913|NCT01332149|Placebo Comparator|Placebo|
3076914|NCT01332188|Experimental|AC-170 0.05%|
3076915|NCT01332188|Experimental|AC-170 0.1%|
3076916|NCT01332188|Experimental|AC-170 0.24%|
3076917|NCT01332188|Placebo Comparator|AC-170 0%|
3076918|NCT01332227|Experimental|Atazanavir/Ritonavir + Raltegravir|Atazanavir + Ritonavir (heat-stable) + Raltegravir
3076919|NCT01332227|Other|Atazanavir/Ritonavir + Tenofovir/Emtricitabine|"Reference~Atazanavir + Ritonavir (heat-stable) + Tenofovir/Emtricitabine"
3076920|NCT01332253|Experimental|Intravenous Ibuprofen|
3076921|NCT01332253|Placebo Comparator|Normal Saline|
3076922|NCT01332292|Active Comparator|COHORT 1 RANDOMISATION A|(8-11 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Day 2-13 = home dosing
3076923|NCT01332292|Placebo Comparator|COHORT 1 RANDOMISATION B|(8-11 years old) Repeat dose session: matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3076924|NCT01332292|Active Comparator|COHORT 2 RANDOMISATION A|(5-7 years old) Repeat dose session: Fluticasone furoate 100µg; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3076925|NCT01332292|Placebo Comparator|COHORT 2 RANDOMISATION B|(5-7 years old) Repeat dose session: Matching placebo; Day 1 and Day 14 = in house dosing; Days 2-13 = home dosing
3076926|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 600 mg|GEn (XP13512/GSK1838262) 600 mg
3076927|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1200 mg|GEn (XP13512/GSK1838262) 1200 mg
3076928|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 1800 mg|GEn (XP13512/GSK1838262) 1800 mg
3076929|NCT01332305|Experimental|GEn (XP13512/GSK1838262) 2400 mg|GEn (XP13512/GSK1838262) 2400 mg
3076930|NCT01332305|Placebo Comparator|Placebo|Placebo
3076931|NCT01332318|Placebo Comparator|Placebo|XP13512 Placebo + Diphenhydramine Placebo
3076932|NCT01332318|Experimental|XP13512 1200 mg|XP13512 1200 mg/day + Diphenhydramine Placebo
3076933|NCT01332318|Experimental|XP13512 1800 mg|XP13512 1800 mg/day + Diphenhydramine Placebo
3076934|NCT01332318|Active Comparator|Placebo + Diphenhydramine|XP13512 Placebo + 50 mg Diphenhydramine
3076935|NCT01332331|Experimental|Low Dose Ambrisentan|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
3076936|NCT01332331|Experimental|High Dose Ambrisentan|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
3076937|NCT01332357||Fluticasone propionate/salmeterol combination ED MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the ED physician
3076938|NCT01332357||Fluticasone propionate/salmeterol combination OP MD|Asthma subjects discharged from an institution after treatment for severe asthma exacerbation that receive fluticasone propionate/salmeterol combination from the OP physician
3076939|NCT01332435||Early 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
3076940|NCT01332435||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (more than 30 days but less than 6 months after initiation of AB)
3076941|NCT01332461||COPD Patients|Patients over the age of 40 with a COPD-related hospital or ER visit
3076942|NCT01332487||Early initiation of 5ARI therapy|Patients starting 5ARI therapy within 30 days of initiating AB therapy
3076943|NCT01332487||Delayed initiation of 5ARI therapy|Patients starting 5ARI therapy more than 30 days but less than 6 months from the initiation of AB therapy
3076944|NCT01332500||adult migraineurs with/without aura|Adult migraine patients >18-65 years who have initiated treatment for migraine with Treximet ™ or other orally administered triptan.
3076945|NCT01332578|Experimental|Test Product|Paracetamol, phenylephrine and ascorbic acid to be administered in 150 milliliters (mL) of hot water.
3076946|NCT01332578|Active Comparator|Paracetamol tablet|Two paracetamol 500 mg tablets to be administered with 150 mL of hot water.
3076947|NCT01332630|Experimental|TPI 287|TPI 287 administered at 160 mg/m2 by vein on Day 1 and repeated every three weeks. Day 1 of each subsequent cycle is equivalent of day 22 of the previous cycle; pre TPI 287: Dexamethasone 6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, Dexamethasone 10 mgby vein may be given 30-60 minutes prior to treatment with TPI 287, Benadryl 12.5-25 mg IV push over 30-60 minutes, and Ranitidine 1mg/kg IV over 30-60 minutes.
3076948|NCT01332721|Experimental|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
3076949|NCT01332851|Experimental|Promoting First Relationships (PFR)|"PFR is a strengths-based 10 week in-home parenting intervention based on attachment theory. Each week has a theme for discussion, an activity, and time for joining - checking in with the parent, listening to their concerns and establishing a positive, supportive relationship. The sessions include handouts which focus on the content area covered that day and applying a topic to their relationship with their child. The provider also videotapes playtime between parent and child. On alternate weeks, the provider watches the video with the parent, reflecting on both the parent's and the child's needs. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent identify her own feelings and needs around parenting."
3076950|NCT01332851|Active Comparator|Resource & Referral|This condition consists of 1) Resource and Referral assistance provided over the phone, and 2) Local Services Resource Packet. The participant receives a phone call from a Resource and Referral Specialist to conduct a needs assessment to identify the particular needs or concerns of the family (such as housing needs, mental health, tangible goods). If a need is identified, the Referral and Referral Specialist will provide the family with local information regarding the stated need. The R&R provider makes two follow-up check in calls with the families. In addition, families can call the Research and Referral Specialist if additional needs arise. The resource packet includes information organized by type of need or resource. These packets are updated regularly as services change over time.
3468859|NCT03891810|Experimental|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
3468860|NCT03891810|No Intervention|Control|This group was a wait list control group who received the treatment following the intervention period.
3076953|NCT01332981||Cohort|
3076954|NCT01332994|Experimental|1|
3076955|NCT01332994|Experimental|2|
3076956|NCT01333033|Experimental|Arm I (FOLFOX regimen)|Patients receive modified FOLFOX-6 therapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-5. Treatment repeats every 14 days for 3 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreased by >= 35%) receive 3 additional courses of FOLFOX-6 therapy and undergo concurrent RT (3D-conformal or intensity-modulated) once daily, 5 days a week, for approximately 6 weeks. Patients without responsive disease (tumor metabolic activity did not decrease by 35%) cross over to Arm II during RT.
3076957|NCT01333033|Experimental|Arm II (carboplatin + paclitaxel + radiation)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 2 courses. Patients then undergo PET/CT scan. Patients with responsive disease (tumor metabolic activity decreases >= 35%) continue to receive carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly for 5 weeks and undergo RT (3D-conformal or intensity-modulated) once a day, 5 days a week, for approximately 6 weeks. Patients without responsive disease (metabolic activity did not decrease by 35%) cross over to Arm I during RT
3076958|NCT01333059|Experimental|Experimental Group|"In this arm Fentanyl and Midazolam was replaced with placebo (normal saline) during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the placebo drug (normal saline). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the placebo drug (normal saline), was started. The switch Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol"
3132398|NCT03423238|Active Comparator|Rehab Only|Patients will be randomized to Rehab only using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation, which includes meeting with dietitian, exercise, health education, and exercise compliance.
3468861|NCT03891797|Experimental|Cognitive Processing Therapy|12 sessions of group-based Cognitive Processing Therapy administered 1x/week for 90 minutes each session.
3468862|NCT03891797|No Intervention|Control|No treatment/treatment as usual. Participants will complete questionnaires at three time points with no intervention.
3468863|NCT03891940||Patient receiving Anterior Cervical Spine Surgery|"Patients who fulfill the criteria of anterior cervical spine surgery under general anesthesia~Aged from 20-80 years old"
3076959|NCT01333059|Active Comparator|Control Group|"In this arm, midazolam and fentanyl were administered during cycling.~At cycling time for midazolam, the continuous infusion of midazolam was stopped by the bedside nurse. The nurse started a pump containing a syringe labeled Study Drug M which contained the control drug (midazolam). The switch to Study Drug M occurred twice daily at 0800 and 2000 for a period of 3 hours each. At cycling time for fentanyl, the continuous infusion of fentanyl was stopped by the bedside nurse. The pump containing a syringe labeled Study Drug F, which contained the control drug (fentanyl), was started. The switch to Study Drug F occurred twice daily at 1400 and 0200 for a period of 3 hours each.~Dosing was done per standard of care and not prescribed per protocol."
3076960|NCT01333072|Active Comparator|Risperidone|Atypical antipsychotic
3076961|NCT01333072|Active Comparator|Aripiprazole|Atypical antipsychotic
3076962|NCT01333098|Experimental|mifepristone|1 week mifepristone or placebo (followed by 3 weeks open label mifepristone)
3076963|NCT01333111|Experimental|Prophylaxis, high dose (trial duration 52 weeks)|
3076964|NCT01333111|Experimental|Prophylaxis, low dose (trial duration 52 weeks)|
3076965|NCT01333111|Experimental|On-demand (trial duration 28 weeks)|
3076966|NCT01333189|Experimental|RELOAD: Weight-bearing biofeedback exercise|RELOAD participants participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games. These biofeedback training sessions were provided in addition to the standard of care rehabilitation that the CONTROL group received. Total dose of exercise across groups was matched.
3076967|NCT01333189|Active Comparator|CONTROL: Standard of care exercise|CONTROL participants were provided two weeks of home rehabilitation (6 visits) by a physical therapist. Patients then progressed to outpatient rehabilitation, consisting of 4 weeks of treatment for a total of 6 weeks of standard of care rehabilitation. Total dose of exercise across groups was matched.
3076968|NCT01333397|Experimental|Dysport RU 20 U|
3076969|NCT01333397|Experimental|Dysport RU 50 U|
3076970|NCT01333397|Experimental|Dysport RU 75 U|
3076971|NCT01333397|Active Comparator|Dysport (Azzalure) 50 U|
3076972|NCT01333397|Placebo Comparator|Placebo|
3076973|NCT01333436|Experimental|Diabetic participants|Diabetic participants with normal to moderately high LDL-C
3076974|NCT01333436|Experimental|Nondiabetic participants|Non-diabetic participants with normal to moderately high LDL-C
3076975|NCT01333475|Experimental|TAC1:MK-2206 & AZD6244 in Pts with Colorectal Ca|Cycle = 28 days:MK-2206:90 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 75 mg PO QD (every day) MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
3076976|NCT01333475|Experimental|TAC1A:MK-2206 & AZD6244 in Pts with Colorectal Ca|"Cycle = 28 days:MK-2206:135 mg PO days 1, 8, 15, and 22 AZD6244 Hydrogen sulfate: 100 mg PO QD~MK-2206 + AZD6244: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression."
3076977|NCT01333488|No Intervention|Conventional Therapy|
3076978|NCT01333488|Experimental|Hypothermia|Subjects will have their core body temperatures lowered to 34C.
3076979|NCT01333488|Experimental|Hypothermia plus supplemental magnesium sulfate infusion|
3076980|NCT01333501|Experimental|Fingolimod|0.5 mg in capsules for oral administration once daily
3076981|NCT01333501|Active Comparator|Interferon beta 1b|250 μg injected s.c. every other day
3076982|NCT01333527|Experimental|Group A (early ROM)|Group A (early ROM) will use the sling for comfort only
3076983|NCT01333527|Active Comparator|Group B (usual care)|Group B (usual care) will be immobilized in a sling for 6 weeks.
3076984|NCT01333592|Experimental|KAD-1229|
3076985|NCT01333722|Placebo Comparator|Placebo|placebo, 1 oral tablet every 12 hours
3076986|NCT01333722|Experimental|Hydrocodone/Acetaminophen Extended Release|hydrocodone/acetaminophen extended release, 1 oral tablet every 12 hours
3076987|NCT01333813|Experimental|Engerix-B Kinder Group|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 7-8 years of age.
3076988|NCT01333865|Experimental|Memantine (Namenda) Treatment|
3076989|NCT01333943|Experimental|Experimental|Saphenous (Adductor Canal) Nerve Block
3076990|NCT01333943|Active Comparator|Control|Femoral Nerve Block
3076991|NCT01333956|Placebo Comparator|Control|Patients will receive 0mg of pregabalin
3076992|NCT01333956|Experimental|50mg Arm|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of post-operative day (POD)14 and one capsule at bedtime POD15, POD16.
3076993|NCT01333956|Experimental|100mg Arm|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
3076994|NCT01333956|Experimental|150mg Arm|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
3076995|NCT01334086|Experimental|Aprepitant|
3076996|NCT01334125|Experimental|Metformin|Metformin 1000 mg once daily by mouth for 9 months
3076997|NCT01334125|Placebo Comparator|Placebo|2 capsules once daily by mouth for 9 months
3076998|NCT01334216|Active Comparator|CHICA Smoking Cessation Module|This arm had the CHICA smoking cessation module turned on
3076999|NCT01334216|Placebo Comparator|CHICA Placebo|This arm had CHICA without the smoking cessation module
3077000|NCT01334229|Experimental|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
3077001|NCT01334229|Placebo Comparator|Placebo|Placebo for 6 weeks
3468864|NCT03891472|Experimental|Arm 1|
3077002|NCT01334515|Experimental|Disease measured by standard radiographic criteria|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
3077003|NCT01334515|Experimental|Disease evaluable only by I-MIBG or BM histology|Treatment (hu14.18-Interleukin 2(IL2) fusion protein and isotretinoin). Patients receive sargramostim (SC [preferred]) or IV over 2 hours on days 1-2 and 8-14, hu14.18-IL2 fusion protein IV over 4 hours on days 4-6, and isotretinoin PO twice daily on days 11-24. Treatment repeats every 28 days for 4-10 courses in the absence of disease progression or unacceptable toxicity. Patients in stratum-1 who achieve stable disease (SD) after course 4 are removed from protocol therapy. Patients in stratum-2 who achieve SD after course 4 receive 2 additional courses of study treatment. Patients may undergo blood and bone marrow sample collection periodically for correlative studies.
3077004|NCT01334554|Experimental|Sildenafil|Sildenafil 20 mg three times a day
3077005|NCT01334554|Placebo Comparator|Placebo|placebo
3077006|NCT01334710|Experimental|Sorafenib and OSI-906|This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients.
3077007|NCT01334723||Acute Urinary Retention|This subset of the Integrated Health Care Information Solutions (ICHIS) benign prostate hyperplasia (BPH) study population was used to assess acute urinary retention as a clinical outcome.
3077008|NCT01334723||Prostate Surgery|This subset of the ICHIS BPH study population was used to assess surgery as a clinical outcome.
3077009|NCT01334827|Other|Formulations|high volume gel; low volume gel; vaginal film
3077010|NCT01334918|Experimental|Single Photon Emission Computed Tomography (SPECT)|"Resting SPECT imaging was performed prior to regadenoson stress SPECT~imaging. Imaging was conducted with one of two radiotracers (99mTc sestamibi or tetrofosmin). Regadenoson 0.4 mg was administered prior to stress SPECT as a single bolus injection."
3077011|NCT01334918|Experimental|Multidetector Computed Tomography (MDCT)|Multidetector Computed Tomography (MDCT), composed of CCTA and regadenoson CTP. Regadenoson stress CTP was performed prior to rest CCTA/CTP imaging. Regadenoson 0.4 mg was administered prior to stress CTP as a single bolus injection. The rest CCTA/CTP was performed at least 30 minutes after completion of the stress CTP, after resolution of any symptoms brought on by the regadenoson infusion and after the participant's heart rate had returned to baseline.
3077012|NCT01334944|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 5-10 minute Treatment Period.
3077013|NCT01334957|Experimental|Intravenous ibuprofen|Intravenous ibuprofen (800 mg intravenous ibuprofen administered intravenously over 5-10 minutes) will be administered as a single dose during the 10 minute Treatment Period.
3077014|NCT01335009|Experimental|MORAb-004, 2 mg/kg|Biologic (monoclonal antibody)
3077015|NCT01335009|Experimental|MORAb-004, 4 mg/kg|Biologic (monoclonal antibody)
3077016|NCT01335061|Other|BeneFIX|
3077017|NCT01335191|Experimental|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0 and Week 3.
3077018|NCT01335191|Placebo Comparator|Placebo|Two subcutaneous injections of placebo at Day 0 and Week 3.
3077019|NCT01335204|Experimental|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle. Bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
3077020|NCT01335230||10 HIV mono-infected subjects|10 subjects infected with HIV only
3077021|NCT01335230||10 HCV mono-infected subjects|10 subjects infected with HCV only
3077022|NCT01335230||10 HIV/HCV co-infected subjects|10 subjects infected with both HIV and HCV
3077023|NCT01335230||10 control subjects|10 subjects without HIV, HCV, or both
3077024|NCT01335308|Active Comparator|Standard Care with Education Materials|Measure height and weight only. usual care
3077025|NCT01335308|Experimental|Moderate Dose Motivational Interviewing|MI delivered by PCP, 4 sessions
3077026|NCT01335308|Experimental|Higher Dose Motivational Interviewing|MI delivered by PCP, 4 sessions plus MI delivered by RD, 6 sessions
3077027|NCT01335399|Active Comparator|Lenalidomide + Dexamethasone|
3077028|NCT01335399|Experimental|Lenalidomide + Dexamethasone + Elotuzumab|
3077029|NCT01335464|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
3077030|NCT01335464|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
3077031|NCT01335477|Placebo Comparator|placebo|patient receives capsules identical to those containing active drug
3077032|NCT01335477|Experimental|BIBF 1120|patient receives capsules containing BIBF 1120 twice a day
3077033|NCT01335542|Active Comparator|Epidural Pathway (PCEA+FNB)|
3077034|NCT01335542|Active Comparator|Peri-Articular Injection|
3077035|NCT01335581|Experimental|Laser treatment|Laser treatment added to microdermabrasion and topical lightening agent regimen
3077036|NCT01335620|Other|Tenofovir/Emtricitabine and Raltegravir|"Single arm study~tenofovir/emtricitabine 245/200 mg once daily and raltegravir 400 mg twice daily"
3320988|NCT02015325|Experimental|Planet Water Program Intervention|School were included that were receiving the Planet Water Foundation's Program (PWP) providing a school-based program focusing on three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. Children will have access to safe water in the schools provided through the use of an AquaTower, and a 4 week educational program.
3320989|NCT02015338||Typically Developing Children|Children with typical development (e.g. no presence of neurological disorders or diagnoses)
3320990|NCT02015338||Children with Hemiparesis|Children diagnosed with Hemiparesis
3320991|NCT02015351|Experimental|Anti-VEGF and Immunosuppression|"Bevacizumab: Dosage 1.25mg/0.05ml; Frequency monthly injections; Duration at least 3 months.~Immunosuppression: cyclosporine and/or azathioprine"
3320992|NCT02015364|Experimental|Controlled early mobilization|The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 to 8
3320993|NCT02015364|No Intervention|Immobilization|The control group: In line with the current treatment regimen the patients must keep the boot on at all times and they are not allowed to move the ankle.
3320994|NCT02015377|Experimental|High Sugar/Low Fiber (HSLF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
3320995|NCT02015377|Experimental|Low Sugar/High Fiber (LSHF) meals|Comparing the impact of High sugar/Low fiber (HSLF) meal versus Low Sugar/High Fiber meals (LSHF) on insulin and glucose profiles, gut hormones (ghrelin, amylin, leptin) free fatty acids, cortisol, mood (MOOD), meaning of physical activity (MEANPA), and physical activity engagement (PA) in overweight African American and Hispanic youth
3320996|NCT02015403|Experimental|Standard Care + NAC (N-ACETYLCYSTEINE) infusion|
3320997|NCT02015403|Active Comparator|Standard Care|
3077045|NCT01335698|Experimental|Stage 1: Atazanavir + Ritonavir|Participants received atazanavir powder orally (dosed by weight: 5 to <10 kg=150 mg, 5 to <10 kg=200 mg, 10 to <15 kg=200 mg, 15 to <25 kg=250 mg, 25 to <35 kg=300 mg) once daily for 24 to 48 weeks or a weight ≥35 kg. Participants also received ritonavir once daily for 24 to 48 weeks or weight ≥35 kg in the form of 80-mg/mL solution, orally (dosed by weight 5 to <25 kg=80 mg, 25 to <35 kg=100 mg); 100-mg capsule, orally (dosed by weight 25 to <35 kg=100 mg); or 100-mg tablet, orally (dosed by weight 25 to <35 kg=100 mg)
3077046|NCT01335724|Experimental|Diclofenac diethylamine 1.16% gel|
3077047|NCT01335724|Placebo Comparator|placebo gel|
3077048|NCT01335750|Experimental|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
3077049|NCT01335750|Experimental|Multipurpose Solution #2|OptiFree Replenish Multipurpose Solution
3077050|NCT01335750|Experimental|Multipurpose Solution #3|Ciba ClearCare Multipurpose Solution
3077051|NCT01335750|Active Comparator|Multipurpose Solution #4|Saline Solution
3077052|NCT01335789|Active Comparator|Oxytocin|intranasal administration
3077053|NCT01335789|Placebo Comparator|saline|intranasal administration
3077054|NCT01335867|Experimental|Vigabatrin|Vigabatrin titrated to 3 grams daily for 8 weeks
3077055|NCT01335867|Placebo Comparator|Placebo|Identical placebo daily for three weeks
3077056|NCT01335932|Experimental|IV Ganciclovir|5mg/kg IV twice daily for 5 days, then followed by either IV ganciclovir or oral valganciclovir once daily until hospital discharge
3077057|NCT01335932|Placebo Comparator|Placebo|normal saline IV twice daily for 5 days, then followed by either IV normal saline or oral placebo once daily until hospital discharge
3077058|NCT01335971|Active Comparator|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
3077059|NCT01335971|Active Comparator|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
3077060|NCT01335971|Placebo Comparator|Placebo|Microcrystalline cellulose
3077061|NCT01336023|Experimental|IDeg|
3077062|NCT01336023|Experimental|IDegLira|
3077063|NCT01336023|Experimental|Lira|
3077064|NCT01336140|Experimental|Aminophylline|75 mg of intravenous aminophylline.
3077065|NCT01336140|Placebo Comparator|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
3077066|NCT01336205|Experimental|1|Oral Treatment
3077067|NCT01336205|Active Comparator|2|Oral treatment
3077068|NCT01336296|Active Comparator|Myfortic preload|Initiation of mycophenolic acid (Myfortic) 2 weeks prior to transplantation (with Simulect induction at time of transplant)
3077069|NCT01336296|Active Comparator|Myfortic standard|mycophenolic acid (Myfortic) at time of transplant with Thymoglobulin induction
3077070|NCT01336413|Active Comparator|Arm 1|Pregnenolone
3077071|NCT01336413|Placebo Comparator|Arm 2|Placebo
3077072|NCT01336569|Experimental|DuoTrav|Travoprost 0.004%/timolol maleate 0.5% fixed combination, one drop to the study eye nightly for up to 6 weeks
3077073|NCT01336608|Experimental|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
3320998|NCT02015416|Experimental|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
3320999|NCT02015429|Active Comparator|Control|Pasta meal with added fractions or control with no fractions Pasta meal with no pea fractions
3321000|NCT02015429|Experimental|10 g protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein added to pasta meal
3321001|NCT02015429|Experimental|7 g yellow pea fibre|Pasta meal with added fractions or control with no fractions 7 g net yellow pea fibre added to pasta meal
3321002|NCT02015429|Experimental|Yellow pea fibre & protein|Pasta meal with added fractions or control with no fractions 10 g net yellow pea protein plus 7 g net yellow pea fibre added to pasta meal
3321003|NCT02015455|Experimental|Intervention Arm|Epidemiologic benchmarks included in lumbar imaging reports
3321004|NCT02015455|No Intervention|Usual Care Arm|Clinics with typical lumbar imaging reports (no epidemiologic benchmarks included)
3321005|NCT02015468|Experimental|Early mobilization|
3321006|NCT02015468|Experimental|Late mobilization|
3321007|NCT02015494|Experimental|4 mcg VAX2012Q|4 mcg VAX2012Q
3321008|NCT02015494|Experimental|8 mcg VAX2012Q|8 mcg VAX2012Q
3321009|NCT02015494|Experimental|14 mcg VAX2012Q|14 mcg VAX2012Q
3321010|NCT02015494|Experimental|18 mcg VAX2012Q|18 mcg VAX2012Q
3321011|NCT02015494|Experimental|12 mcg VAX2012Q|12 mcg VAX2012Q
3321012|NCT02015494|Experimental|8 mcg VAX2012Q repeated|8 mcg VAX2012Q
3321013|NCT02015494|Experimental|12 mcg VAX2012Q repeated|12 mcg VAX2012Q
3321014|NCT02015507|Active Comparator|Cohort 1|participants in Cohort 1 will be administered ivacaftor alone followed by ivacaftor with concomitant ciprofloxacin.
3321015|NCT02015507|Experimental|Cohort 2|Participants in Cohort 2 will be administered VX-661 in combination with ivacaftor followed by VX-661 in combination with ivacaftor and concomitant ciprofloxacin
3077074|NCT01336608|Experimental|vilanterol|Inhaled long acting beta-agonist
3077075|NCT01336608|Placebo Comparator|placebo|Placebo
3321016|NCT02015533|Experimental|CR8020|
3077077|NCT01336634|Experimental|Cohort A|Subjects will receive dabrafenib 150mg BID and will continue on treatment until disease progression, death, or unacceptable adverse event. Subjects receiving and adequately tolerating dabrafenib as a single agent and who continue to meet the inclusion and exclusion criteria will have the option to switch to dabrafenib (150 mg BID) and trametinib (2 mg once daily) combination treatment within 4 weeks of radiologic disease progression with prior approval from a GSK medical monitor
3077078|NCT01336634|Experimental|Cohort B|Subjects enrolled in Cohort B will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event.
3077079|NCT01336634|Experimental|Cohort C|Subjects enrolled in Cohort C will receive dabrafenib 150 mg BID in combination with trametinib 2 mg once daily and will continue on treatment until disease progression, death, or unacceptable adverse event
3077080|NCT01336647|Experimental|Group A|Group A Low-Dose Ha44 Gel 0.37% w/w topically administered to head and scalp.Single application for 10 minutes.
3077081|NCT01336647|Experimental|Group B|Group B High-Dose Ha44 Gel 0.74% w/w. Topically administered to hair and scalp. Single application for 10 minutes of duration.
3077082|NCT01336647|Placebo Comparator|Group C|Group C Placebo/ vehicle Ha44 Gel. Topically administered to hair and scalp.Single application for 10 minutes of duration.
3077083|NCT01336712|Experimental|Myeloablative Haploidentical Transplant|Haplo transplant
3077084|NCT01336738|Placebo Comparator|Placebo|Matching placebo for PF-04991532 and Sitagliptin
3077085|NCT01336738|Experimental|150 mg PF-04991532|
3077086|NCT01336738|Experimental|450 mg PF-04991532|
3077087|NCT01336738|Experimental|750 mg PF-04991532|
3077088|NCT01336738|Active Comparator|Sitagliptin 100 mg|
3077089|NCT01336764|Experimental|Active|individual coping self-statements and stimulus guided paced breathing.
3077090|NCT01336764|Sham Comparator|Control|Coping self statements and breathing retraining will be replaced with undirected passive behaviors such as listening to music.
3077091|NCT01336803|Experimental|Feraheme|Intravenous injection of Feraheme, 5 mg Fe/kg
3077092|NCT01336894|Active Comparator|Arm I (SR+Brachytherapy)|Patients undergo sublobar resection comprising either a wedge resection or anatomical segmentectomy with or without intraoperative brachytherapy comprising an iodine I 125 implant at the resection margin.
3077093|NCT01336894|Experimental|Arm II (SBRT)|Patients undergo 3 fractions of stereotactic body radiation therapy at 2-8 days apart.
3077094|NCT01336933|Experimental|Treatment|"A Treatment: Cyclophosphamide,Etoposide, Vincristine and Prednisone (CEOP) B Treatment: Pralatrexate (P)~A cycles (CEOP) of the treatment regimen are 14 days, followed by  B cycles (P) which are 21 days, followed by 7 days of rest for a total of 42 days per course, unless criteria are met for stopping or holding treatment or to a maximum of 6 courses.~Patients with Complete Response (CR) or Partial Response (PR), per investigators discretion, may then undergo hematopoietic stem cell collection and administration of standard preparative regimen followed by hematopoietic stem cell transplantation."
3077095|NCT01336959|Experimental|Open Label - BCT197 Part A|10mg single dose of BCT197
3077096|NCT01336959|Experimental|BCT197 Part B|Single dose of 50mg BCT197
3077097|NCT01336959|Placebo Comparator|BCT 197 Placebo Part B|Single dose of matching placebo to 50mg BCT197
3077098|NCT01336972|Experimental|Group A - eGFR > 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3077099|NCT01336972|Experimental|Group B - eGFR 30 to 60 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3077100|NCT01336972|Experimental|Group C - eGFR < 30 ml/min/1.73m^2|Participants received tolvaptan for the first 3 weeks of the 6 week study. Participants were up-titrated on a weekly basis from tolvaptan 45/15 mg to 60/30 mg to 90/30 mg oral split-dose (AM and PM [8 hours later]) to the maximally tolerated dose.
3077101|NCT01337050|Experimental|A|PF-03446962
3077102|NCT01337076|Other|cochlear implant|
3077103|NCT01337089|Experimental|Non-comparative, open-label Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray, in the morning and evening, up to a maximum of 10 sprays per day for 6 months. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3077104|NCT01337115|Active Comparator|Continuous femoral nerve block (CFNB)|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
3077105|NCT01337115|Experimental|Single shot SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h
3077106|NCT01337167|Experimental|V419|V419 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; PedvaxHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
3077107|NCT01337167|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, and 6 months of age; Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age; Daptacel™ 0.5 mL IM at 15 months of age; ActHIB™ 0.5 mL IM at 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age.
3321017|NCT02015533|Placebo Comparator|Placebo|
3077108|NCT01337297|Placebo Comparator|sham-tDCS|the electrodes are positioned in the same manner as the active-tDCS, activated for 20 s (time to climb ramp of the current until reach the current intensity used in the experiment), enough to produce the sensation of itch, and turned off until the end of the session.
3077109|NCT01337297|Experimental|active-tDCS|low-intensity transcranial Direct Current Stimulation (tDCS)applied over the dorsolateral prefrontal cortex
3077110|NCT01337336||COPD patients with comorbid depression/anxiety|Patients aged 40 and over with COPD and comorbid depression/anxiety. Managed care enrolees (aged >40 years) having newly initiated drug therapy with FSC or AC during the identification period (01/01/2004 to 06/30/2008) to treat COPD with a medical or pharmacy claim for depression before and 60 days post index date were the target population. The first fill date of FSC or AC was the index date.
3077111|NCT01337596|Experimental|Single dose 1 milligram (mg) LY2951742|Administered single subcutaneous injection
3077112|NCT01337596|Experimental|Single dose 5 mg LY2951742|Administered single subcutaneous injection
3077113|NCT01337596|Experimental|Single dose 25 mg LY2951742|Administered single subcutaneous injection
3077114|NCT01337596|Experimental|Single dose 75 mg LY2951742|Administered single subcutaneous injection
3077115|NCT01337596|Experimental|Single dose 200 mg LY2951742|Administered single subcutaneous injection
3077116|NCT01337596|Experimental|Single dose 600 mg LY2951742|Administered single subcutaneous injection
3077117|NCT01337596|Placebo Comparator|Single dose placebo|Administered single subcutaneous injection
3077118|NCT01337596|Placebo Comparator|Multiple dose placebo|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
3077119|NCT01337596|Experimental|150 mg LY2951742|Administered subcutaneously every 2 weeks for 6 weeks (4 doses)
3077120|NCT01337635|Active Comparator|Standard dose vitamin D|Treatment with cholecalciferol 400 IU daily at home.
3077121|NCT01337635|Active Comparator|High dose vitamin D|Treatment with ergocalciferol 300,000 IU (6 capsules of 50,000 IU) as a single oral dose observed in clinic.
3077122|NCT01337674|Experimental|Panel A: MK-4618 + Met → PBO + Met|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
3077123|NCT01337674|Experimental|Panel A: PBO + Met → MK-4618 + Met|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of metoprolol (Met) for the duration of the study. A 2-week washout period follows Period 1.
3077124|NCT01337674|Experimental|Panel B: MK-4618 + Amlo → PBO + Amlo|Once daily oral dose of MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 1 followed by once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
3077125|NCT01337674|Experimental|Panel B: PBO + Amlo → MK-4618 + Amlo|Once daily oral dose of placebo (two tablets) on Days 1 through 7 in Period 1 followed by MK-4618 (two 50-mg tablets) on Days 1 through 7 in Period 2. Participants receive previously prescribed daily dose of amlodipine (Amlo) for the duration of the study. A 2-week washout period follows Period 1.
3077126|NCT01337687|Experimental|Oxytocin|
3077127|NCT01337687|Placebo Comparator|Placebo|
3077128|NCT01337700|Experimental|Milnacipran|
3077129|NCT01337700|Placebo Comparator|Placebo|
3077130|NCT01337739|Placebo Comparator|Placebo Comparator|Continuous infusion of placebo during operative procedure
3077131|NCT01337739|Active Comparator|Active Comparator|Administration of Dexmedetomidine
3077132|NCT01337960|Experimental|Arm 1|Seated robot training group. Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
3077133|NCT01337960|Experimental|Arm 2|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
3077134|NCT01337960|Active Comparator|Arm 3|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
3077135|NCT01337973|Experimental|Arm 1: MI-CBT|MI-CBT (six sessions during acute treatment phase integrating motivational interviewing and cognitive behavioral approaches)
3077136|NCT01337973|Experimental|Arm 2: MI-CBT+CC|MI-CBT+CC (acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention)
3077137|NCT01337973|Active Comparator|Arm 3: E-TAU|E-TAU (enhanced treatment as usual - includes brief session and provision of resources)
3077138|NCT01337986|Active Comparator|Group B: Dalfampridine First|Dalfampridine/Placebo: Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
3077139|NCT01337986|Active Comparator|Group A: Dalfampridine Second|Placebo/Dalfampridine: Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks
3077140|NCT01338012|Experimental|sipuleucel-T|Men with metastatic castrate resistant prostate cancer previously treated with sipuleucel-T in the androgen dependent setting in the Dendreon P-11 study. Subjects received one infusion of sipuleucel-T every two weeks for for a total of three infusions.
3077141|NCT01338025|Active Comparator|Arm A, non-suppressive HAART regimen|"In Step 1, subjects were randomized to continue their non-suppressive HAART regimen.~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
3077142|NCT01338025|Active Comparator|Arm B, 3TC or FTC monotherapy|"In step 1, subjects were randomized to receive 3TC or FTC (the choice of 3TC or FTC was left to the provider).~In Step 2, subjects either began a new HAART regimen, continued randomized treatment, or discontinued therapy while remaining on follow-up, as decided by their provider."
3077143|NCT01338298|Active Comparator|Aripiprazole|
3077144|NCT01338298|Placebo Comparator|Placebo|
3077145|NCT01338415|Experimental|bosentan 2mg/kg b.i.d.|Patients who received 2 mg/kg bosentan twcie daily (b.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
3077146|NCT01338415|Experimental|bosentan 2mg/kg t.i.d.|Patients who received 2 mg/kg bosentan 3 times a day (t.i.d.) during the FUTURE 3 core study and continued with the same dose regimen during the extension study
3077147|NCT01338493||lumbar spinal arthroplasty + Maverick™|Patients requiring total disc replacement
3077148|NCT01338506|Experimental|COPE Therapy|Combined prolonged exposure therapy for PTSD with cognitive behavioral therapy for substance use disorder.
3077149|NCT01338506|Active Comparator|Treatment as usual|CBT for substance use disorder.
3077150|NCT01338610|Experimental|ESBA105|ESBA105 ophthalmic solution, 1 drop in each eye 3 times per day for 4 weeks
3077151|NCT01338610|Placebo Comparator|Vehicle|ESBA105 vehicle, 1 drop in each eye 3 times per day for 4 weeks
3077152|NCT01338636|Other|Exercise-induced PAH|Open-label ambrisentan
3077153|NCT01338649|Active Comparator|Bright White|Exposure to bright white light treatment.
3077154|NCT01338649|Placebo Comparator|Dim red light|Exposure to dim red light treatment.
3077155|NCT01338792|Experimental|Treatment (chemotherapy and enzyme inhibitor)|Patients receive oxaliplatin IV over 2 hours and pemetrexed disodium IV on day 1. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3077156|NCT01338818|Experimental|Ritalin LA|All participants started with Ritalin LA 20 mg/day and increased at weekly intervals in increments of 20 mg/day until reaching the patient's optimal dose 40, 60 or 80 mg/day).
3077157|NCT01338857|Experimental|Sorafenib (Nexavar)|Sorafenib will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
3077158|NCT01338870|Placebo Comparator|Placebo|Placebo for PF-04991532 and sitagliptin
3077159|NCT01338870|Experimental|25 mg PF-04991532|
3077160|NCT01338870|Experimental|75 mg PF-04991532|
3077161|NCT01338870|Experimental|150 mg PF-04991532|
3077162|NCT01338870|Experimental|300 mg PF-04991532|
3077163|NCT01338870|Active Comparator|Sitagliptin 100 mg|
3077164|NCT01338987|Active Comparator|Arm1 First Transplt/males/leuprolide/+/-FLT Imaging|"Males randomized to leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
3077165|NCT01338987|Active Comparator|Arm2 First Transplt/males/No Leuprolide/+/- FLT Imaging|"Males not receiving leuprolide for first transplant~[18F]fluorothymidine (FLT) imaging"
3077166|NCT01338987|Experimental|Arm3 First Transplt/females/leuprolide+/- FLT Imaging|"Females receiving leuprolide for first transplant.~[18F]fluorothymidine (FLT) imaging"
3077167|NCT01338987|Experimental|Arm4-Second Transplt/leuprolide and FLT Imaging|Second transplant with leuprolide and [18F]fluorothymidine (FLT) imaging
3077168|NCT01338987|No Intervention|Healthy Volunteer - Arm 5|Healthy Volunteer
3077169|NCT01339000|Experimental|Arm A -Sequence 1 Immunizations|Receive vaccine of Sequence 1 first, then vaccines of Sequence 2, 7 weeks later, after receiving interleukin-7 (IL-7)
3077170|NCT01339000|Experimental|Arm B - Sequence 2 Immunizations|Receive vaccines of Sequence 2 first then vaccines of Sequence1, 7 weeks later, after receiving IL-7
3077171|NCT01339013|Active Comparator|AnaConDa|
3077172|NCT01339052|Experimental|Cohort 1: Surgical subjects|"Subjects scheduled for surgery~BKM120: 100 mg once daily, orally, for 8-12 days prior to surgery~Surgery: Surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
3077173|NCT01339052|Experimental|Cohort 2: Non-surgical subjects|"Subjects not candidates for surgery~BKM120: 100 mg once daily, orally, for 28-day cycles~Patients continued treatment until disease progression or unacceptable toxicity."
3077174|NCT01339091|Experimental|Dalbavancin|
3077175|NCT01339091|Active Comparator|Vancomycin with possible switch to oral linezolid|
3077176|NCT01339247|Active Comparator|Paxil CR Reference|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 1, followed by Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 2
3077177|NCT01339247|Active Comparator|Paxil CR Test|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada, in Period 1, followed by Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico, in Period 2
3077178|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-cycle 1|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
3077179|NCT01339260|Active Comparator|Palonosetron+dexamethasone-cycle 1|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
3077180|NCT01339260|Experimental|Netupitant and Palonosetron+dexamethasone-multicycle extension|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule with oral dexamethasone (12 mg), both given on Day 1, prior to each scheduled chemotherapy cycle
3077181|NCT01339260|Active Comparator|Palonosetron+dexamethasone-multicycle extension|Oral palonosetron 0.50 mg (Aloxi) with oral dexamethasone (20 mg) both given on Day 1, prior to each scheduled chemotherapy cycle
3077182|NCT01339273|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
3077183|NCT01339273|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
3077184|NCT01339299|Experimental|recombinant luteinizing hormone|150 IU r-LH, recombinant luteinising hormone, from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14)
3077185|NCT01339299|Active Comparator|recombinant human chorionic gonadotrofin|25 IU of r-hCG from treatment day 1 (stimulation day 1) until day of r-hCG administration (normally treatment day 10 to 14 )
3077186|NCT01339390|Experimental|Arm 1: MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE! program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
3077187|NCT01339390|Active Comparator|Arm 2: MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the primary care provider (PCP) to determine if the person would benefit from a weight loss program, and to refer them to MOVE! if they and the patient agree that it would be beneficial. The MOVE! program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
3077188|NCT01339403||HIV infected|No study specific intervention, non-interventional trial
3077189|NCT01339403||HIV-uninfected|No study specific intervention, non-interventional trial
3077190|NCT01339416||HIV infected cohort|HIV infected patients in the HIV cohorts at the three participating hospitals
3077191|NCT01339429|Experimental|simplified Negative Pressure Wound Therapy|The simplified Negative Pressure device will be placed on subjects selected from the hospital ward and meeting the eligibility criteria.
3077192|NCT01339559|Experimental|Brivaracetam|Brivaracetam with a maximum of 200 mg/day
3077193|NCT01339832||Cohort|
3077194|NCT01339858|Experimental|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 600 mg of NAC. Dosing will begin at 600 mg/d and titrated up over 5 weeks until a maximum dose of 3600 mg/d is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose.
3077195|NCT01339858|Placebo Comparator|Sugar Pill|matched placebo
3077196|NCT01339897|Active Comparator|5 mg/N6022|Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.
3077197|NCT01339897|Placebo Comparator|Placebo|Injectable formulation normal saline
3077198|NCT01339897|Active Comparator|10mg/N6022|Injectable formulation, given at doses of 10 mg given QD each day over 7 days.
3077199|NCT01339897|Active Comparator|20mg/N6022|Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.
3077200|NCT01339910|Experimental|Reduced Intensity Conditioning (RIC)|One of two different regimens in RIC will be administered; fludarabine and busulfan, or fludarabine and melphalan.
3077201|NCT01339910|Active Comparator|Myeloablative Conditioning Regimen (MAC)|One of three different regimens in MAC will be administered; busulfan and fludarabine, busulfan and cyclophosphamide, or cyclophosphamide and total body irradiation.
3077202|NCT01339923|Experimental|B_2h3h5_11|Subjects, approximately 2.5 months of age, received 3 dose primary vaccination of rMenB+OMV NZ at 2.5, 3.5, 5 months of age, followed by a booster dose at 11 months of age.
3077203|NCT01339923|Experimental|B_3h5_11|Subjects, approximately 3.5 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 3.5 and 5 months of age, followed by a booster dose at 11 months of age.
3077204|NCT01339923|Experimental|B_68_11|Subjects, approximately 6 months of age, received 2 dose primary vaccination of rMenB+OMV NZ at 6 and 8 months of age, followed by a booster dose at 11 months of age.
3077205|NCT01339923|Experimental|B_02_2_5|Subjects, 2-5 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
3077206|NCT01339923|Experimental|B_02_6_10|Subjects, 6-10 years of age received 2 catch-up doses of rMenB+OMV NZ, each at 0 and 2 months. Blood draw at 0 and 3 months since study start.
3077207|NCT01339923|Experimental|BC_35_12|Subjects, 3 months of age received rMenB+OMV NZ + MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone dose at 7 months of age.
3077208|NCT01339923|Experimental|C_35_12|Subjects, 3 months of age received MenC-CRM and Synflorix concomitantly at 3, 5 and 12 months of age and an additional dose of Synflorix alone at 7 months of age and rMenB+OMV NZ alone at 13 and 15 months of age.
3077209|NCT01339936|Experimental|Investigational eye drop|Formulation 1: Carboxymethylcellulose sodium, glycerin and polysorbate 80 based eye drops formulated for the relief of ocular surface irritation and symptoms of dryness
3077210|NCT01340014|Other|AZARGA/COSOPT|1 drop AZARGA instilled in each eye twice a day for 7 days, followed by 1 drop COSOPT instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
3077211|NCT01340014|Other|COSOPT/AZARGA|1 drop COSOPT instilled in each eye twice a day for 7 days, followed by 1 drop AZARGA instilled in each eye twice a day for 7 days. A 48-hour washout period separated the two treatment periods.
3077212|NCT01340027|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once a day for 12 weeks
3077213|NCT01340027|Active Comparator|Mirabegron 25 mg|Participants received mirabegron 25 mg tablets orally once a day for 12 weeks
3077214|NCT01340027|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg tablets orally once a day for 12 weeks
3077215|NCT01340027|Active Comparator|Solifenacin 2.5 mg|Participants received solifenacin 2.5 mg tablets orally once a day for 12 weeks
3077216|NCT01340027|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg tablets orally once a day for 12 weeks
3077217|NCT01340027|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 10 mg tablets orally once a day for 12 weeks
3077218|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 25 mg|Participants received solifenacin 2.5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3077219|NCT01340027|Experimental|Solifenacin 2.5 mg and Mirabegron 50 mg|Participants received solifenacin 2.5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3077220|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 25 mg|Participants received solifenacin 5 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3077221|NCT01340027|Experimental|Solifenacin 5 mg and Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3077222|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 25 mg|Participants received solifenacin 10 mg and mirabegron 25 mg tablets orally once a day for 12 weeks
3077223|NCT01340027|Experimental|Solifenacin 10 mg and Mirabegron 50 mg|Participants received solifenacin 10 mg and mirabegron 50 mg tablets orally once a day for 12 weeks
3077224|NCT01340053|Placebo Comparator|Placebo|Capsule that is identical in size and color to other treatments
3077225|NCT01340053|Experimental|Low Dose|10 mg capsule of tenapanor
3077226|NCT01340053|Experimental|Mid Dose|30 mg capsule of tenapanor
3077227|NCT01340053|Experimental|High Dose|100 mg capsule of tenapanor
3077228|NCT01340066|Experimental|UISH001|
3077229|NCT01340066|Placebo Comparator|Matching placebo|
3077230|NCT01340144||PFC Sigma PS TKA|one group received primary TKA using the PFC Sigma PS TKA
3077231|NCT01340144||PFC Sigma HP PS TKA|One group received primary TKA using the PFC Sigma HP PS TKA.
3077232|NCT01340196|Experimental|sequence 1|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through day 22 (morning dose on day 22 only)
3077233|NCT01340209|Experimental|Tiotropium Respimat (low dose)|Tiotropium low dose once daily delivered with Respimat inhaler
3077234|NCT01340209|Experimental|Tiotropium Respimat (high dose)|Tiotropium high dose once daily delivered with Respimat inhaler
3077235|NCT01340209|Placebo Comparator|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
3077236|NCT01340300|Active Comparator|Exercise training|Exercise training with exercise physiologist
3077237|NCT01340300|Active Comparator|Exercise training with metformin|Exercise training with exercise physiologist with oral metformin
3077238|NCT01340300|Active Comparator|Metformin|Metformin
3077239|NCT01340300|Active Comparator|Control|Educational information
3077240|NCT01340482|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)
3077241|NCT01340495|Experimental|Proton Radiation|Radiation therapy with proton beam
3077242|NCT01340586|Experimental|Group A: Apixaban|
3077243|NCT01340586|Experimental|Group B: Apixaban|
3077244|NCT01340625|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/35 mcg Chewable Tablets (Teva)
3077245|NCT01340625|Active Comparator|Reference Listed Drug|Ovcon® 35 Fe 0.4 mg/35 mcg Chewable Tablets (Warner Chilcott)
3077246|NCT01340651|Experimental|Ruxolitinib 25 mg SR/10, 15, or 20 mg IR|Participants began administration with 25 mg ruxolitinib sustained release (SR) once daily (QD). After 8 weeks, if there was inadequate efficacy, the dose level could be titrated to 50 mg SR QD or 25 mg SR every other day (QOD) alternating with 50 mg SR QOD. At Week 16, participants transitioned to ruxolitinib 10, 15, or 20 mg immediate release (IR) orally twice daily. Participants who continued to demonstrate benefit in the opinion of the investigator could remain on ruxolitinib IR until the last participant completed Week 36 or the commercial availability of ruxolitinib IR, whichever was earlier; the dose received was based on platelet counts at the time of transition.
3077247|NCT01340664|Experimental|Canagliflozin 50 mg bid|Each patient will receive 50 mg canagliflozin twice daily for 18 weeks.
3077248|NCT01340664|Experimental|Canagliflozin 150 mg bid|Each patient will receive 150 mg canagliflozin twice daily for 18 weeks
3077249|NCT01340664|Placebo Comparator|Placebo|Each patient will receive matching placebo twice daily for 18 weeks
3077250|NCT01340768|Experimental|Sitagliptin|Sitagliptin 100mg taken orally once daily with or without metformin
3077251|NCT01340768|Active Comparator|Sulfonylurea Therapy|Usual sulfonylurea therapy with or without metformin
3077252|NCT01340794|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3077253|NCT01340872|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
3077254|NCT01340872|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
3077255|NCT01340898|Experimental|Nimenrix 3+1 Group|Subjects, male and female, received 4 doses of Nimenrix™ vaccine (3 doses at 2, 4 and 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
3077256|NCT01340898|Experimental|Nimenrix 1+1 Group|Subjects, male and female, received 2 doses of Nimenrix™ vaccine (1 dose at 6 months of age followed by a booster dose at 15-18 months of age) and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
3077257|NCT01340898|Experimental|Nimenrix Control Group|Subjects, male and female, received 1 dose of Nimenrix™ at 15-18 months of age and 4 doses of Synflorix™ and Infanrix-IPV/Hiberix™ vaccines (at 2, 4, 6 and 15-18 months of age). All vaccines were administered intramuscularly (IM) in the anterolateral region of the thigh.
3077258|NCT01340937|Experimental|V419 Lot A|V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3077259|NCT01340937|Experimental|V419 Lot B|V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3077260|NCT01340937|Experimental|V419 Lot C|V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
3077261|NCT01340937|Active Comparator|Control|Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age
3077262|NCT01340976|Experimental|LY2787106 Dose Escalation|Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.
3077263|NCT01340976|Experimental|10 mg/kg LY2787106|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
3077264|NCT01340976|Experimental|10 mg/kg LY2787106+Iron|Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.
3077265|NCT01341067||Basal insulin, approved oral medications|
3077266|NCT01341301|Experimental|Allogeneic HSCT|"CONDITIONING: Patients undergo Total Body Irradiation (TBI) twice daily (BID) on days -10 to -7. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients receive DLI on day -6 and undergo cluster of differentiation 34 (CD34+) selected allogeneic HSCT on day 0~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO on days -1 with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID or PO on days -1 to 28."
3077267|NCT01341444|Experimental|Prevena Incision Management System|Negative Pressure Therapy Device
3077268|NCT01341444|Placebo Comparator|Standard of Care for Surgical Incisions|Sterile gauze and a non-penetrable barrier
3077269|NCT01341457|Experimental|LY2603618 + Gemcitabine|"Gemcitabine 1000 milligrams per meter squared (mg/m^2) administered intravenously on days 1, 8 and 15 of at least one 28-day cycle. 170 or 230 mg LY2603618 administered intravenously on days 2, 9 and 16 of at least one 28-day cycle.~Participants experiencing benefit may continue on the combination therapy until discontinuation criteria are met."
3077270|NCT01341470|Experimental|Single IV dose LY2495655|Single 70 milligram (mg) dose LY2495655 administered intravenously (IV)
3077271|NCT01341470|Experimental|Multiple SC dose 17.5 mg LY2495655|17.5 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
3077272|NCT01341470|Experimental|Multiple SC dose 140 mg LY2495655|140 mg of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
3077273|NCT01341470|Experimental|Multiple SC dose 420 mg LY2495655|420 mg dose of LY2495655 administered subcutaneously (SC) every 2 weeks for 8 weeks (total 5 doses)
3077274|NCT01341470|Placebo Comparator|Single IV dose placebo|Single Placebo dose administered intravenously (IV)
3077275|NCT01341470|Placebo Comparator|Multiple SC dose placebo|Placebo dose administered subcutaneously (SC) every 2 weeks for 8 weeks (total of 5 doses)
3077276|NCT01341600|Experimental|Clopidogrel in poor metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 poor metabolizers (PM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3077277|NCT01341600|Experimental|Clopidogrel in intermediate metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 intermediate metabolizers (IM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3077278|NCT01341600|Experimental|Clopidogrel in extensive metabolizers|"Healthy subjects who have been genotyped for CYP2C19*2 and received clopidogrel as part of a prior study (PAPI) will be recruited. We will select 6 extensive metabolizers (EM) to clopidogrel 75 mg from participants who previously received 75 mg clopidogrel as part of another NIH sponsored clinical trial entitled, Pharmacogenetics of Anti-platelet Intervention (PAPI) Study (NCT 00799396). Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days."
3077279|NCT01341600|Experimental|Omeprazole/Clopidogrel in PM|PM participants who have completed Arm 1 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3077280|NCT01341600|Experimental|Omeprazole/Clopidogrel in IM|IM participants who have completed Arm 2 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3077281|NCT01341600|Experimental|Omeprazole/Clopidogrel in EM|EM participants who have completed Arm 3 will have the option to participate. After a washout of at least one week, these participants will given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
3077282|NCT01341639|Experimental|PR5I|V419 + RotaTeq + Prevenar 13 + ProQuad
3077283|NCT01341639|Active Comparator|INFANRIX™ hexa|INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad
3077284|NCT01341652|Experimental|pTVG-HP vaccine with GM-CSF|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
3077285|NCT01341652|Active Comparator|GM-CSF alone|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
3077286|NCT01341730|Active Comparator|Atorvastatin 20 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg group is to take atorvastatin 20 mg and take follow up PET CT in 3 months"
3077287|NCT01341730|Experimental|Atorvastatin 20 mg + Pioglitazone 30 mg|"After the subject take PET CT, he or she is randomized to either  Atorvastatin 20 mg group or  Atorvastatin 20 mg+ Pioglitazone 30 mg. The  Atorvastatin 20 mg + Pioglitazone 30 mg group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months"
3077288|NCT01341782|Experimental|Paricalcitol|Participants received paricalcitol at an initial dose of 2 µg, and maxacalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 1 µg based on protocol-specified criteria up to a maximum of 7 µg.
3077289|NCT01341782|Active Comparator|Maxacalcitol|Participants received maxacalcitol at an initial dose of 5 µg (iPTH < 500 pg/mL at Screening) or 10 µg (iPTH ≥ 500 pg/mL at Screening), and paricalcitol placebo administered 3 times per week at each hemodialysis via intravenous catheter for 12 weeks. After 2 weeks the dose could be adjusted ± 2.5 µg based on protocol-specified criteria up to a maximum of 20 µg.
3077290|NCT01341912|Experimental|Human-cl rhFVIII|Recombinant FVIII derived from a human cell line.
3077291|NCT01341977|Experimental|Alcon MPDS|Alcon Multi-Purpose Disinfecting Solution (MPDS)
3077292|NCT01341977|Active Comparator|ReNu Fresh Multi-Purpose Solution|ReNu Fresh Multi-Purpose Solution
3077293|NCT01341990|Experimental|FID 114675A|Multi-purpose disinfecting solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
3077294|NCT01341990|Active Comparator|ReNu MultiPlus|Multi-purpose solution used per protocol-specified instructions for cleaning, rinsing, disinfecting/storing, and reinserting study contact lenses
3077295|NCT01342029|Experimental|Ranolazine|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
3077296|NCT01342029|Placebo Comparator|Placebo|147 subjects, with projected 9-10% dropout and anticipated 134 completed subjects will undergo baseline testing and then be randomized into a clinical cross-over trial of stepped dosing of ranolazine or placebo 500-1,000 mg po bid for 2 weeks with exit testing followed by cross-over to the alternate ranolazine or placebo and repeat exit testing.
3077297|NCT01342081|Experimental|1|DE-111 ophthalmic solution
3077298|NCT01342081|Active Comparator|2|Tafluprost ophthalmic solution 0.0015%
3077299|NCT01342081|Active Comparator|3|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
3077300|NCT01342094|Experimental|DE-111 ophthalmic solution|DE-111 ophthalmic solution (one drop at a time, once daily) and Placebo ophthalmic solution (one drop at a time, BID) in both eyes.
3077301|NCT01342094|Active Comparator|Timolol ophthalmic solution 0.5%|Timolol ophthalmic solution 0.5% (one drop at a time, BID) and Placebo ophthalmic solution (one drop at a time, once daily) in both eyes.
3077302|NCT01342107|Experimental|FID 114675A|Contact lens soaked overnight in an investigational multi-purpose disinfecting solution randomly assigned to one eye, with contact lens removed directly from the blister pack assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
3077303|NCT01342107|Active Comparator|Blister Pack|Contact lens removed directly from the blister pack randomly assigned to one eye, with contact lens soaked overnight in an investigational multi-purpose disinfecting solution assigned to the fellow eye for contralateral wear. Both products worn for one day, 16 hours.
3077304|NCT01342172|Experimental|Lenalidomide|capsules for oral administration
3077305|NCT01342211|Placebo Comparator|Treatment A|
3077306|NCT01342211|Experimental|Treatment B|
3077307|NCT01342211|Experimental|Treatment C|
3077308|NCT01342211|Experimental|Treatment D|
3077309|NCT01342211|Experimental|Treatment E|
3077310|NCT01342341|Experimental|Parafon Forte first, then Placebo|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (1st intervention; 14 days), followed by a washout (7 days), and then followed by placebo (2nd intervention; 14 days).
3077311|NCT01342341|Placebo Comparator|Placebo first, then Parafon Forte|Experimental: Forty moderate to heavy social alcohol users (women=10-25 drinks/week, men=14-30 drinks/week) will receive placebo (1st intervention; 14days) followed by a washout (7 days), and then followed by either 250 or 500 mg of chlorzoxazone BID (500 or 1000 mg/day) x 7 days followed by 500 or 1000 mg of chlorzoxazone BID (1000 or 2000 mg/day) x 7 days (2nd intervention; 14 days).
3077312|NCT01342367|Experimental|Oral Androgen Therapy|Subjects will receive two oral hormonal drugs (bicalutamide with dutasteride or bicalutamide with finasteride)
3077313|NCT01342445|Experimental|lisdexamfetamine dimesylate|All participants will be assessed across five conditions (baseline, placebo, 30-mg, 50-mg, & 70-mg) in a double-blind, crossover design
3077314|NCT01342458|Experimental|Intervention Group|Daily use of the intervention Flexible footwear (Moleca®) for 6 months, for at least 42 hours/week (approximately 6 hours/day, 7 days/week). The Moleca® shoe (Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a low-cost women's double canvas, flexible, flat, walking shoe without heels, with a 5-mm anti-slip rubber sole and a 3-mm flat insole of ethylene vinyl acetate that provides only protection but no correction. The mean weight of the shoe is 0.172±0.019 kg (range 0.091 to 0.182 kg), depending on size. This minimalist footwear is commonly worn by the elderly of all social classes and its average cost is US$ 6.25.
3077315|NCT01342458|No Intervention|Control Group|During the intervention period, patients from the Control Group (CG) were instructed not to wear Flexible footwear (Moleca®) or other similar minimalist footwear. During everyday activities, the CG group was only permitted to wear a standard, neutral tennis shoe. At the end of the intervention period, all CG participants also received one pair of Moleca® shoes at no cost.
3077316|NCT01342471|Active Comparator|30-min walk|"Instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Participants were permitted to exercise in one long bout (30 min) or divide the exercise into multiple bouts as long as the bout length was 10 min or greater."
3077317|NCT01342471|Experimental|TV commercial stepping|"Instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Rather than exercising continuously for at least 10-minute bouts, participants performed multiple (~9 or 10), short (~3-5 min) bouts, conveniently incorporated into their daily TV viewing time."
3077318|NCT01342484|Experimental|linagliptin low dose|linagliptin low dose for children once daily
3077319|NCT01342484|Experimental|linagliptin high dose|linagliptin high dose for children once daily
3077320|NCT01342484|Placebo Comparator|placebo|matching placebo for each linagliptin dose once daily
3077321|NCT01342510|Experimental|Lidocaine|Lidocaine 50 mg in a 10 cc syringe
3077322|NCT01342510|Experimental|Magnesium|Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe
3077323|NCT01342510|Experimental|Lidocaine/Magnesium|Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe
3077324|NCT01342510|Placebo Comparator|Control|0.9% saline in a 10 cc syringe
3077325|NCT01342523|Experimental|No CIS/No loz/No Email/Lite Website/Brief Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, No nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
3077326|NCT01342523|Experimental|CIS/No loz/No email/Lite Website/Brief booklet|"This arm of the project will address the following question:~Does the following treatment provide efficacy relative to others:~CIS calls, no NRT lozenge, no motivational email, Lite website, Brief mailed booklet"
3077327|NCT01342523|Experimental|no CIS/Loz/No email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services achieve effectiveness compared to others:~No CIS phone counseling, NRT lozenge, no motivational email, lite website, brief mailed booklet"
3077328|NCT01342523|Experimental|No CIS/no loz/email/lite website/brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence:~No CIS counseling calls, no NRT lozenge, motivational emails, lite website, brief mailed booklet."
3077329|NCT01342523|Experimental|No CIS/No loz/No email/Full website/Brief booklet|"This arm of the project will address the following question:~Does this combination of services lead to greater abstinence?~No CIS counseling, no NRT lozenge, no motivational email, full website, brief mailed booklet"
3077330|NCT01342523|Experimental|No CIS/No loz/No email/lite website/full booklet|"This arm seeks to answer the question:~Does this combination of services achieve efficacy compared to others:~No CIS counseling, no NRT lozenge, no motivational email, lite website, full mailed booklet"
3077331|NCT01342523|Experimental|CIS/Loz/No email/Lite website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, brief mailed booklet"
3077332|NCT01342523|Experimental|CIS/No loz/Emails/Lite Website/Brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3077333|NCT01342523|Experimental|CIS/No loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3077334|NCT01342523|Experimental|CIS/No loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, No nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3077335|NCT01342523|Experimental|No CIS/Loz/emails/Lite Website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3077336|NCT01342523|Experimental|No CIS/Loz/No emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3077337|NCT01342523|Experimental|No CIS/Loz/No emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3077338|NCT01342523|Experimental|no CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
3077339|NCT01342523|Experimental|no CIS/no loz/emails/lite web/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
3077340|NCT01342523|Experimental|no CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
3077341|NCT01342523|Experimental|CIS/loz/emails/lite website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, brief mailed booklet"
3077342|NCT01342523|Experimental|CIS/loz/no email/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, brief mailed booklet"
3077343|NCT01342523|Experimental|CIS/loz/no email/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, lite website, full mailed booklet"
3077344|NCT01342523|Experimental|CIS/no loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, brief mailed booklet"
3077345|NCT01342523|Experimental|CIS/no loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, lite website, full mailed booklet"
3077346|NCT01342523|Experimental|CIS/no loz/no email/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, No motivational emails, full website, full mailed booklet"
3077347|NCT01342523|Experimental|No CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
3077348|NCT01342523|Experimental|No CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
3077349|NCT01342523|Experimental|No CIS/loz/no emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
3077350|NCT01342523|Experimental|no CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
3077351|NCT01342523|Experimental|CIS/loz/emails/full website/brief booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, brief mailed booklet"
3077352|NCT01342523|Experimental|CIS/loz/emails/lite website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, lite website, full mailed booklet"
3077353|NCT01342523|Experimental|No CIS/loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~No CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
3077354|NCT01342523|Experimental|CIS/no loz/emails/full website/full booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, no nicotine lozenge, motivational emails, full website, full mailed booklet"
3077355|NCT01342523|Experimental|CIS/Loz/no Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, No motivational emails, full website, full mailed booklet"
3077356|NCT01342523|Experimental|CIS/Loz/Emails/Full Website/Full Booklet|"This arm of the project will address the following question:~How effective is the following intervention?~CIS calls, nicotine lozenge, motivational emails, full website, full mailed booklet"
3077357|NCT01342549|Active Comparator|Arm 1|sodium valproate
3077358|NCT01342549|Active Comparator|Arm 2|naltrexone
3077359|NCT01342640|Experimental|Single Arm|
3077360|NCT01342666|Experimental|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
3077361|NCT01342666|Placebo Comparator|Cucumber consumption|Daily consumption of 300g of cucumber.
3077362|NCT01342757|Experimental|Arm I|"Patients receive vorinostat once daily on days -7 to -1 (course 1 only) and days 8-14 and 22-28 and temozolomide on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients undergo magnetic resonance spectroscopic imaging at baseline and at approximately 1 and 8 weeks on treatment. Patients also undergo a survey administration of Inventory of Depression Symptomatology Self-Reported (IDS-SR) assessment at baseline and periodically during study."
3077363|NCT01342770|Experimental|Treatment (pioglitazone hydrochloride)|Patients receive pioglitazone hydrochloride PO QD for 14-42 days. Patients then undergo surgery.
3077364|NCT01342796|Experimental|Arm 1|
3077365|NCT01342796|Active Comparator|Arm 2|
3077366|NCT01342887|Experimental|Treatment (immunosuppression, enzyme inhibitor, and chemo)|Patients receive cyclosporine IV continuously on days 5-9. Patients also receive pravastatin sodium PO every 6 hours on days 1-10, etoposide IV continuously on days 5-9, and mitoxantrone hydrochloride IV continuously on days 5-9. Treatment repeats for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR/CRi may receive 2 additional courses in the absence of disease progression or unacceptable toxicity.
3077367|NCT01342913|Experimental|Fluticasone Furoate/Vilanterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA)
3077368|NCT01342913|Active Comparator|Fluticasone Propionate/Salmeterol|Inhaled Corticosteroid (ICS)/Long Acting Beta Agonist (LABA
3077369|NCT01342926|Experimental|GSK933776 3 mg/kg|3 mg/kg administration of GSK933776 via intravenous infusion
3077370|NCT01342926|Experimental|GSK933776 6 mg/kg|6 mg/kg administration of GSK933776 via intravenous infusion
3077371|NCT01342926|Placebo Comparator|Placebo|Placebo via intravenous infusion
3077372|NCT01342926|Experimental|GSK933776 15 mg/kg|15 mg/kg administration of GSK933776 via intravenous infusion
3077373|NCT01342965|Experimental|Erlotinib|Participants received erlotinib 150 mg orally once daily until progressive disease or unacceptable toxicity.
3077374|NCT01342965|Active Comparator|Chemotherapy|Participants received gemcitabine 1250 mg/m^2 intravenously (IV) on Days 1 and 8 and cisplatin 75 mg/m^2 IV on Day 1 of every 3 week cycle until disease progression, unacceptable toxicity, or a total of 4 cycles, whichever came first.
3077375|NCT01343004|Placebo Comparator|Placebo|Placebo identical in appearance to BA058 study drug
3077376|NCT01343004|Experimental|BA058 80 mcg (abaloparatide)|
3077377|NCT01343004|Active Comparator|teriparatide|Blinded until after randomization, then open-label
3077378|NCT01343043|Experimental|Cohort 1 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
3077379|NCT01343043|Experimental|Cohort 2 treated with NY-ESO-1 T Cells|Low NY-ESO-1 expression and the use of cyclophosphamide plus fludarabine as the lymphodepleting chemotherapy.
3077380|NCT01343043|Experimental|Cohort 3 treated with NY-ESO-1 T Cells|High NYESO-1 expression and the use of cyclophosphamide only for lymphodepletion rather than fludarabine as the lymphodepleting chemotherapy.
3077381|NCT01343043|Experimental|Cohort 4 treated with NY-ESO-1 T Cells|High NY-ESO-1 expression and the use of reduced dose cyclophosphamide plus fludarabine regimen as the lymphodepleting chemotherapy.
3077382|NCT01343056|Active Comparator|Office Staff follow up education|"A designee in the office staff shall be assigned to follow up with the patient for for behavioral goal setting attainment. The office staff will call patients monthly to monitor goal attainment. It will be suggested that they phone the participant monthly but researchers will observe how and if they provide follow up.~The intervention is the follow up goal attainment and office staff have been trained on elements of goal attainment."
3077383|NCT01343056|Active Comparator|Peer follow up education|"A person with diabetes trained as a peer shall meet the participant at their 6 week follow up visit and then call the participant monthly to monitor behavioral goal attainment.The intervention is the follow up goal attainment and peers have been trained on elements of goal attainment."
3077384|NCT01343056|Active Comparator|Usual Care|ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
3077385|NCT01343056|Active Comparator|Educator support follow up|A diabetes educator will provide follow up support and make monthly call to the patient to ascertain behavioral goal setting attainment. The diabetes educator uses behavioral goal setting as an education intervention. The educator calls patient to determine goal attainment. That is the intervention.
3077386|NCT01343082|Experimental|1|DE-111 ophthalmic solution
3077387|NCT01343095|No Intervention|Usual Care|Usual Care between 10pm-6am
3077388|NCT01343095|Active Comparator|Earplugs|Application of foam earplugs from 10pm-6am nightly for seven nights or until ICU discharge.
3077389|NCT01343095|Active Comparator|Earplugs and Headphones|Foam Earplugs and Noise canceling headphones applied from 10pm-6am nightly for 7 nights or until ICU discharge.
3077390|NCT01343160|Other|GORE VIABIL® Biliary Endoprosthesis|Placement of GORE VIABIL® Biliary Endoprosthesis to establish duct patency
3077391|NCT01343251||HeRO Graft|patients who are evaluated and receive a HeRO Graft implant for hemodialysis
3077392|NCT01343251||Control|control group of non-HeRO patients who are evaluated but do not receive a HeRO Graft for any reason
3077393|NCT01343277|Experimental|Trabectedin|
3077394|NCT01343277|Active Comparator|Dacarbazine|
3077395|NCT01343368|Experimental|Interventional - Received Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-HCT and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days for patients who undergo myeloablative allogeneic or autologous hematopoietic cell transplantation.
3077396|NCT01343368|Active Comparator|Observational Arm|Women undergoing reduced intensity allogeneic HCT will be observed. Progestin contraceptives, Norethindrone acetate, and any other hormone methods can be used according to the prescription guidelines except for GnRH agonists to suppress menses.
3077397|NCT01343407|Experimental|MK-1029 60 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
3077398|NCT01343407|Experimental|MK-1029 500 mg|Part 2 - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
3077399|NCT01343407|Placebo Comparator|Placebo|Part II - Participants will receive 5 days of double-blind, once-daily MK-1029 60 mg followed by a 21-day washout in Period 2, 3, or 4 in a crossover design
3077400|NCT01343485|No Intervention|Control, standard care for HPV vaccine|Study participants in control sites will receive standard care for HPV vaccine administration and follow-up per PPFA protocol
3077401|NCT01343485|Experimental|Intervention, computer reminder system|Study participants in the intervention sites will receive standard care for HPV vaccine administration per PPFA protocol, reminder messages for subsequent vaccination appointments, and real-time determination of financial assistance for HPV vaccine.
3077402|NCT01343667|Other|GFRS EPD|Carotid artery stenting with Gore Flow Reversal System embolic protection device
3077403|NCT01343667|Other|GEF EPD|Carotid artery stenting with Gore Embolic Filter embolic protection device
3077404|NCT01343693||Anterior cervical discectomy and fusion|Any subject with DDD, tumor, deformity ot trauma to the cervical spine in which the investigator determines the subject will require an ACDF using the MaxAn Plate.
3077405|NCT01343823|Active Comparator|ecallantide 10mg|Administered as one 3 mL SC injection containing 10 mg ecallantide and one 3 mL SC injection of matching placebo.
3077406|NCT01343823|Placebo Comparator|placebo|Administered as two SC 3 mL injections
3077407|NCT01343823|Active Comparator|ecallantide 60mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
3077408|NCT01343823|Active Comparator|ecallantide 30mg|Administered as one 3 mL SC injection containing 30 mg ecallantide and one 3 mL SC injection of matching placebo.
3077409|NCT01343888|Active Comparator|PegIFN/RBV|PegIFN/RBV for 48 weeks
3077410|NCT01343888|Experimental|BI 201335 for 12 or 24 weeks|BI 201335 once daily low dose for 12 or 24 weeks in combination with PegIFN/RBV for 24 or 48 weeks
3077411|NCT01343888|Active Comparator|Placebo and PegIFN/RBV|Placebo (oral) once daily plus PegIFN/RBV (subcutaneous injection/oral) for 24 weeks, followed by PegIFN/RBV alone up to Week 48.
3077412|NCT01343901||Bevacizumab|Participants with metastatic colorectal cancer (mCRC) with exclusively liver or liver and lung metastases, who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases will be observed.
3077413|NCT01344057|Other|Sub unit, Inactivated, MF59C.1 Adjuvanted Influenza Vaccine|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3077414|NCT01344161|Placebo Comparator|Lactose|
3077415|NCT01344161|Experimental|Vitamin D|
3077416|NCT01344356|Other|Benign Tumors|Benign head and neck tumors will be treated with SBRT
3077417|NCT01344356|Other|Malignant Tumors|Malignant Head and Neck Tumors will be treated with SBRT.
3077418|NCT01344369|Experimental|Investigational Test Product|Norethindrone/Ethinyl Estradiol 0.4 mg/0.035 mg Chewable Tablets (Teva)
3077419|NCT01344369|Active Comparator|Reference Listed Drug|FEMCON® Fe 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott)
3077420|NCT01344447|Experimental|Arm 1|
3077421|NCT01344460|Experimental|Arm 1|
3077422|NCT01344538|Experimental|Ginger Root Extract|
3077423|NCT01344538|Placebo Comparator|Lactose Capsule|
3077424|NCT01344616|No Intervention|usual clinical care|usual clinical care with no intervention
3077425|NCT01344616|Experimental|lifestyle counseling|computer-based clinical support to patient
3077426|NCT01344629|Experimental|Telmisartan80mg/Amlodipin5mg FDC|single-dose, four-period replicated crossover design
3077427|NCT01344629|Experimental|Telmisartan80mgtab + Amlodipin5mg tab|single-dose, four-period replicated crossover design
3077428|NCT01344759|Active Comparator|Propofol|
3077429|NCT01344759|Active Comparator|Dexmedetomidine|
3077430|NCT01344824|Other|Single Arm Trial|Bevacizumab, Carboplatin, and Pemetrexed disodium, with option for second line erlotinib hydrochloride
3077431|NCT01344876|Experimental|OPB-51602|OPB-51602 1, 2, 4 and 6 mg/day oral once daily (QD) in a 4 week cycle
3077432|NCT01345019|Active Comparator|Zoledronic acid|Zoledronic acid 4 mg intravenously plus placebo to denosumab subcutaniously (SC) once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
3077433|NCT01345019|Experimental|Denosumab|Denosumab 120 mg subcutaniously (SC) plus placebo to zoledronic acid intravenously once every 4 weeks (Q4W) in the double-blind treatment period (Since denosumab was determined to have a positive benefit:risk profile in the primary analysis of the study, per protocol, participants who were still undergoing Q4W scheduled assessments were offered open-label denosumab 120 mg SC Q4W for up to 2 years)
3077434|NCT01345058|Experimental|Lacosamide + Low-Dose Levetiracetam|Participants received lacosamide 50 mg twice a day for one week followed by 100 mg twice daily added to low dose levetiracetam ≤1500 mg/day (polytherapy) for 6 months in patients with breakthrough seizures on low-dose levetiracetam.
3077435|NCT01345058|Other|Control Group (High-Dose Levetiracetam)|Historical chart review of patients whose dose of levetiracetam was raised to high dose levetiracetam >1500 mg/day (monotherapy) after a breakthrough seizure. No intervention was administered in the study.
3077436|NCT01345123|Experimental|Decision Aid with Health Coaching|
3077437|NCT01345123|Experimental|Decision Aid only|
3077438|NCT01345123|No Intervention|No condition specific support|
3077439|NCT01345162|Other|ketorolac|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then Ketorolac postoperative 10mg 1cp x 3/die, from the day of surgery for 4 days after surgery.
3077440|NCT01345162|Other|acetaminophene+tramadol|Patients will be given intraoperative analgesia with Ketorolac and tramadol before the the end of surgery, then postoperative Patrol (acetaminophene 325mg+tramadol 37,5mg) 1cp x 3/die for 4 days after surgery.
3077441|NCT01345188|Active Comparator|Ranolazine|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
3077442|NCT01345188|Placebo Comparator|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
3321018|NCT02015559|Experimental|Arm I (mucoadhesive oral wound rinse)|Patients receive mucoadhesive oral wound rinse PO as a gentle swish for 30-60 seconds 3-6 times daily beginning on day 1 of everolimus therapy and continuing for up to 6 months in the absence of unacceptable toxicity.
3321019|NCT02015559|No Intervention|Arm II (no intervention)|Patients receive no intervention.
3321020|NCT02015572|Experimental|Occupational intervention|Early coordinated occupational intervention. Supervision in physically activities by a physiotherapist.
3132399|NCT03423238|Experimental|Rehab+Weight Loss (WL)|Patients will be randomized to Rehab+WL using a randomization scheme with blocking stratified by sex and obesity severity (BMI<30 vs. BMI≥30 kg/m2). All participants will undergo standard exercise-based cardiac rehabilitation in addition to a weight-loss intervention, which includes meeting with dietitian, exercise, health education, and exercise compliance, calorie-restricted diet, behavioral modification, and weight-loss compliance.
3132400|NCT03423641||Direct Acting Antivirals|Patients who receive a direct acting antiviral enter the DAA cohort at the time of initiation of the drug.
3132401|NCT03423641||Comparison|The exposure time of patients who have not received a direct acting antiviral (patients can change from the comparison to the DAA group once they receive the medication)
3321021|NCT02015572|Active Comparator|Usual care|Intervention from the patient's general physician.
3321022|NCT02015585|Experimental|Interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
3321023|NCT02015585|Experimental|Relining complete denture base|Patients will be submitted to a procedure of relining their old dentures 30 days before the replacement of the complete dentures.
3321024|NCT02015585|Active Comparator|Only Rehabilitation|Patients will be treated with a complete denture without any kind of previous intervention
3321025|NCT02015598|Experimental|Carbocysteine|Carbocysteine , tablet ,250mg per one tablet , patients oral intake with 500mg .tid.(1500mg/day)
3321026|NCT02015598|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure(CPAP),auto-CPAP(USA,Philips), patients use Nasal CPAP overnight.
3321027|NCT02015611|Placebo Comparator|Placebo|Matched bottle/pill placebo
3321028|NCT02015611|Experimental|Vitamin D|2,000 IU Vitamin D3 per day
3321029|NCT02015650|Active Comparator|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
3321030|NCT02015650|Active Comparator|Mitomycin-C / 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
3321031|NCT02015689|Experimental|Benefits to Child|CDC VIS + message emphasizing benefits of MMR vaccine to child
3321032|NCT02015689|Active Comparator|CDC VIS|CDC Vaccine Information Statement (VIS)
3321033|NCT02015689|Experimental|Benefits to Society|CDC VIS + message emphasizing benefits of MMR vaccine to society
3321034|NCT02015689|Experimental|Benefits to Child and Society|CDC VIS + message emphasizing benefits of MMR vaccine to both child and to society
3321035|NCT02015702|Experimental|One-on-one physician training|One-on-one physician training Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
3321036|NCT02015702|Active Comparator|Usual training|Usual training. This group will get the usual specified training for learning to use our electronic health record. Both groups received 12 hours of EPIC classroom training, exposure to the EPIC e-learning modules, user acceptability testing classes, and unlimited time on the EPIC 'playground', a site to practice on virtual patients. All had 90 days of elbow support with an EPIC-training non-physician technician, who were visible and available on all inpatient wards, as well as access to a physician-only support line available at all hours.
3321037|NCT02015715|Experimental|RO6864018|Asian participants will receive a single oral dose of RO6864018 capsule on Day 1. The first dose escalation cohort will receive a single 400 mg oral dose. Dose will be escalated in subsequent cohorts (up to Cohort 4) up to a maximum of 1600 mg, based on safety, pharmacokinetic, and pharmacodynamic data available from lower dose cohorts. The Cohort 5 will include Caucasian participants who will receive a single 1200 mg (or the highest dose well-tolerated by Asian participants, if lower than 1200 mg) oral dose of RO6864018 capsules on Day 1.
3321038|NCT02015715|Placebo Comparator|Placebo|Participants will receive a single oral dose of placebo matching to RO6864018.
3321039|NCT02015728|Experimental|Regimen B|"Depending on tumor biology testing, subjects assigned to Regimen B will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Everolimus 3 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3321040|NCT02015728|Experimental|Regimen C|"Depending on tumor biology testing, subjects assigned to Regimen C will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Erlotinib 85 mg/m2/dose daily PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3321041|NCT02015728|Experimental|Regimen D|"Depending on tumor biology testing, subjects assigned to Regimen D will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Dasatinib 60 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3321042|NCT02015728|Experimental|Regimen A|"Depending on tumor biology testing, subjects assigned to Regimen A will receive:~Temozolomide 150 mg/m2/dose daily PO on days 1-5, Etoposide 50 mg/m2/dose daily PO on days 1-12, and Sorafenib 150 mg/m2/dose BID PO on days 1-28. Cycles will be repeated every 28 days for up to 12 cycles."
3321043|NCT02015741||Aged patients|EEG monitoring with Bispectral Index and NeuroSENSE
3321044|NCT02015767||Roflumilast|Participants prescribed roflumilast (Daxas®) according to local guidelines and marketing authorization.
3321045|NCT02015780|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, once daily, and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam placebo-matching tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
3321046|NCT02015780|Experimental|Fasiglifam|Fasiglifam 50 mg tablets, once daily and stable antihyperglycemic therapy for up to 16 weeks. Then Fasiglifam 50 mg tablets, once daily and antihyperglycemic therapy, adjusted as necessary per the Investigator's discretion, for up to 36 weeks.
3321047|NCT02015806|Experimental|All meds but depression, 1x daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
3321048|NCT02015806|Experimental|All meds but depression, 1x daily use, Take-N-Slide|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
3321049|NCT02015806|Experimental|All meds but depression, 1x daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
3321050|NCT02015806|No Intervention|All meds but depression, 1x daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
3321051|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
3321052|NCT02015806|Experimental|All meds but depression, ≥1 med >1 daily use, pillbox|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
3321053|NCT02015806|No Intervention|All meds but depression, ≥1 med >1 daily use, control|Individuals who are taking 1-3 cardiovascular or other non-depression chronic disease medications and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
3321054|NCT02015806|Experimental|Only depression meds, 1x daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a RxTimerCap.
3321055|NCT02015806|Experimental|Only depression meds, 1x daily use, Take-N-Slide|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a Take-N-Slide.
3321056|NCT02015806|Experimental|Only depression meds, 1x daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to receive a standard pillbox.
3321057|NCT02015806|No Intervention|Only depression meds, 1x daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, whose medications are all intended for once daily use, and who are randomized to continue with usual care.
3077454|NCT01345253|Experimental|Belimumab|10mg/kg
3077455|NCT01345253|Placebo Comparator|Placebo|placebo
3077456|NCT01345292|Experimental|12027-027|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
3077457|NCT01345292|Active Comparator|310158077046|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
3077458|NCT01345292|Placebo Comparator|037000003212|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
3077459|NCT01345318|Experimental|Open-label Treatment|
3077460|NCT01345513||Solid Tumor Cancer|
3077461|NCT01345591|Experimental|Fat Grafting|Twenty (20) subjects who have had severe facial trauma, 18 years of age and older enrolled to clinical trial will receive Fat grafting intervention procedure
3077462|NCT01345630|Experimental|Maraviroc|Maraviroc 150 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for emtricitabine/tenofovir once daily.
3077463|NCT01345630|Active Comparator|Emtricitabine/tenofovir|Emtricitabine/tenofovir 200/300 mg once daily plus darunavir/ritonavir 800/100 mg once daily plus placebo for maraviroc once daily.
3077464|NCT01345669|Experimental|Afatinib (BIBW 2992)|Once daily
3077465|NCT01345669|Placebo Comparator|Placebo|Once daily
3077466|NCT01345682|Experimental|Afatinib (BIBW 2992)|Once daily
3077467|NCT01345682|Active Comparator|Methotrexate|Weekly
3077468|NCT01345721|Experimental|MenACWY (2 primary + 1 booster dose)|Subjects who had previously received two primary doses of MenACWY-CRM vaccine (at 6-8 months and 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
3077469|NCT01345721|Experimental|MenACWY (1 primary + 1 booster dose)|Subjects who had previously received one primary dose of MenACWY-CRM vaccine (at 12 months of age) in parent study, were administered one booster dose of the same vaccine in this extension study.
3077470|NCT01345721|Experimental|MenC (1 primary dose)+MenACWY (1 booster dose)|Subjects who had previously received one primary dose of the comparator MenC vaccine (at 12 months of age) in parent study, were administered one booster dose MenACWY-CRM vaccine in this extension study.
3077471|NCT01345786|Experimental|Commercial NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
3077472|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 1|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch A), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from Site 1."
3077473|NCT01345786|Experimental|Commercial NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
3077474|NCT01345786|Active Comparator|Phase 3 NOMAC-E2, Part 2|"Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program (Batch B), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from Site 2."
3077475|NCT01345929|Experimental|CXA-201 as treatment for cUTI|CXA-201 IV infusion (1500mg q8) for 7 days
3077476|NCT01345929|Active Comparator|Levofloxacin as treatment for cUTI|Levofloxacin IV infusion (750mg qd) for 7 days
3077477|NCT01346059|Placebo Comparator|Saline|The saline arm will receive normal saline through the catheter as a placebo.
3077478|NCT01346059|Experimental|Vancomycin|The vancomycin arm will receive vancomycin solution through the catheter.
3077479|NCT01346072|Other|Tolvaptan|Single arm study
3077480|NCT01346085|Experimental|CNI-free single-group|
3077481|NCT01346176|Experimental|Positive default|Patients in this arm will receive AD forms where specific life-extending interventions will be provided unless patients specifically opt-out from such selections
3077482|NCT01346176|Experimental|Negative default|Patients in this arm will receive AD forms where specific life-extending interventions will not be provided unless patients specifically opt-into such selections
3077483|NCT01346176|Experimental|Forced Choice|Patients in this arm will receive AD forms in which they must actively choose whether to receive each intervention.
3077484|NCT01346189|Active Comparator|Physician Incentives|"(with adherence feedback)~Quarterly payments to physician combined based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL with daily patient statin adherence information made available."
3077485|NCT01346189|Active Comparator|Patient Incentives|"(with adherence feedback)~Quarterly payments to patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL."
3321058|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, RxTimerCap|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a RxTimerCap.
3321059|NCT02015806|Experimental|Only depression meds, ≥1 med >1 daily use, pillbox|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to receive a standard pillbox.
3077486|NCT01346189|Active Comparator|Physician and Patient Combined Incentives|"(with adherence feedback)~Quarterly payments shared evenly by physician and patient based on patient achieving an LDL reduction of at least 10 mg/dl relative to baseline LDL or the last quarter's target LDL. Physicians will receive daily information about patients' statin adherence."
3077487|NCT01346189|No Intervention|Usual Care|
3077488|NCT01346267|Experimental|Arm I- Real Acupressure bands|Patients wear Sea-Band acupressure wristbands on each wrist beginning approximately 30 minutes prior to the first cisplatin-containing chemotherapy course and continually for 24 hours after the last chemotherapy dose (acute phase), and for a maximum of 7 days or until the next chemotherapy course starts (delayed phase). Patients are allowed to take bands off intermittently (up to 4 times a day, for no more than 15 minutes each time) to relieve pressure or to bathe. Patients also receive standard of care anti-emetic prophylaxis comprising granisetron, ondansetron, or dexamethasone during chemotherapy according to institutional or physician preference.
3077489|NCT01346267|Sham Comparator|Arm II- Placebo Acupressure Bands|Patients wear placebo wristbands on each wrist and receive standard of care anti-emetic prophylaxis during chemotherapy as patients in arm I.
3077490|NCT01346293|Experimental|Study Group 1|Participants will receive concomitantly a dose of DTap-IPV, a dose of M-M-R®II, and a dose of VARIVAX® vaccine on Day 0
3077491|NCT01346293|Experimental|Study Group 2|Participants will receive concomitantly a dose of DAPTACEL®, a dose of IPOL®, a dose of M-M-R®II, and a dose of VARIVAX® vaccines on Day 0
3077492|NCT01346293|Experimental|Study Group 3|Participants will receive concomitantly a dose of DTap-IPV with or without a dose of M-M-R®II and a dose of VARIVAX® on Day 0
3077493|NCT01346293|Experimental|Study Group 4|Participants will receive concomitantly a dose of DAPTACEL® vaccine, a dose of IPOL® vaccine with or without a dose of M-M-R®II and a dose of VARIVAX® vaccines on Day 0
3077494|NCT01346371|Placebo Comparator|Refresh Tears® eye drops|Must add drops twice a day every day during trial enrollment.
3077495|NCT01346371|Experimental|Bepreve® 1.5% solution|Must add drops twice a day every day while enrolled in trial.
3077496|NCT01346397||cyclosporine group|cyclosporine group - after alemtuzumab induction cyclosporine was administered
3077497|NCT01346397||tacrolimus group|tacrolimus group - after alemtuzumab induction tacrolimus was administered
3077498|NCT01346410|Experimental|A|Stereotactic Radiation to Pancreas
3077499|NCT01346475|Active Comparator|valacyclovir|
3077500|NCT01346475|Experimental|high dose valacyclovir|
3077501|NCT01346488||Adalimumab|Participants with RA treated with adalimumab who are either engaged in paid work for more than 35 hours per week (paid workers) or those who are either engaged in paid work for less than 35 hours per week or who perform basic activities of daily life other than paid work (home workers).
3077502|NCT01346501||Adalimumab|"Participants with Rheumatoid Arthritis (RA) who continued adalimumab treatment after completion of study M06-859, participated in the observational period of studies P12-069 and P12-707.~Other name for adalimumab is Humira."
3077503|NCT01346501||Non-adalimumab|Patients who discontinued adalimumab treatment after completion of the study M06-859.
3077504|NCT01346514|Experimental|Arm 1: Addiction/Housing Case Management(AHCM)|The AHCM condition provided individual case management, delivered at the VA and in the community, designed to assist homeless Veterans with SUD issues who may be unable to take advantage of housing opportunities available in the VA due to difficulty navigating multiple services and maintaining stability with respect to SUD and co-occurring mental health conditions.
3077505|NCT01346514|Active Comparator|Arm 2: Housing Support Group(HSG)|The HSG condition involved a weekly drop-in housing support group.
3077506|NCT01346540|Experimental|BIBF 1120|VEGF inhibitor
3077507|NCT01346540|Placebo Comparator|Placebo|BIBF 1120 placebo
3077508|NCT01346592|Active Comparator|aTIV (6 to <72 months)|Subjects received an investigational MF59-adjuvanted trivalent influenza vaccine (aTIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3077509|NCT01346592|Active Comparator|Comparator TIV (6 to <72 months)|Subjects received a licensed comparator trivalent split influenza vaccine (comparator TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3077510|NCT01346592|Active Comparator|TIV (6 to <72 months)|Subjects received an investigational trivalent split influenza vaccine (TIV), subjects aged between 6 to <36 months received two doses of 0.25 mL each, while subjects aged ≥36 months received two doses of 0.5 mL each, at Days 1 & 29
3077511|NCT01346683|Experimental|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
3077512|NCT01346696|Experimental|OsseoSpeed™ TX implants|OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.
3077513|NCT01346774|Experimental|Cranberry powder capsules|"TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food."
3077514|NCT01346774|Placebo Comparator|Placebo capsules|Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
3077515|NCT01346839|Experimental|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
3132402|NCT03424044|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in dual hormone mode and XeriSol glucagon to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
3077516|NCT01346839|No Intervention|Usual Care Control|"The usual care at MEDVAMC consists of providers using an advanced EHR and its notification system (the View Alert system) that immediately alerts providers about clinically significant events. The system relies primarily on computerized notification (alerts) displayed prominently through a View Alert window that is displayed in the EHR every time a provider signs on or switches between patient records. The system does not require providers to read alerts, and providers do have an option of ignoring the View Alert window to bypass it. At SWHS there is a navigation program for patients who have received a cancer diagnosis by tissue biopsy. However, currently there is no routine tracking of patients if they do not show for their scheduled appointments and tests at SWHS."
3077517|NCT01346852||Pediatric participants|Pediatric participants (age 4 to 17) with a diagnosis of asthma
3077518|NCT01346852||Adult participants|Adult participants (age 18 and older) with a diagnosis of asthma
3077519|NCT01346969|Active Comparator|Group 1|
3077520|NCT01346969|Placebo Comparator|Group 2|
3077521|NCT01346969|Placebo Comparator|Group 3|
3077522|NCT01346969|Placebo Comparator|Group 4|
3077523|NCT01347008|Active Comparator|Sildenafil citrate|Oral Sildenafil citrate, 50mg, b.i.d.
3077524|NCT01347008|Placebo Comparator|Sugar pill|Placebo pill (identical to Sildenafil citrate 50mg), b.i.d.
3077525|NCT01347034|Active Comparator|External Beam Radiation Therapy (RT)|Arm A - University of Florida - External Beam Radiation Therapy (RT) - As outlined in Intervention Description
3077526|NCT01347034|Experimental|External Beam RT + DC Injection|Arm B - Moffitt Cancer Center - External Beam RT + Autologous Dendritic Cells (DC) Injection - As outlined in Intervention Description
3077527|NCT01347060||Medicare-eligible subjects with asthma|Asthma subjects at least 65 years of age enrolled in a large Medicare managed care health plan.
3077528|NCT01347073|Experimental|HPN-100|Switch over from sodium phenylbutyrate to open label HPN-100 oral liquid over 10 days then open label, long term treatment for 12 months
3077529|NCT01347086|Experimental|BI 207127 NA (low dose)|Single dose of BI 207127 NA
3077530|NCT01347086|Placebo Comparator|Matching placebo (low dose)|Single dose of matching placebo
3077531|NCT01347086|Experimental|BI 207127 NA (medium dose)|Single dose of BI 207127 NA
3077532|NCT01347086|Placebo Comparator|Matching placebo (medium dose)|Single dose of matching placebo
3077533|NCT01347086|Experimental|BI 207127 NA (high dose)|Single dose of BI 207127 NA
3077534|NCT01347086|Placebo Comparator|Matching placebo (high dose)|Single dose of matching placebo
3077535|NCT01347112|Active Comparator|Varenicline|varenicline 1.0 mg twice daily for 12 weeks
3077536|NCT01347112|Placebo Comparator|Sugar Pil|Varenicline look alike sugar pill twice daily for 12 weeks
3077537|NCT01347255|Experimental|LEO 90100 cutaneous spray ointment|LEO 90100 cutaneous spray, ointment, is a new product containing calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate).
3077538|NCT01347255|Active Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle w. Betamethasone|Vehicle cutaneous spray, ointment, with betamethasone 0.5 mg/g (as dipropionate)
3077539|NCT01347255|Placebo Comparator|LEO 90100 Cutaneous Spray, Ointment, Vehicle|LEO 90100 vehicle served as a negative control for the two cutaneous spray ointments with active ingredients.
3077540|NCT01347255|Active Comparator|Daivobet® Ointment|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
3077541|NCT01347307|Other|SBRT for Benign Extradural Spine Tumors|Benign extradural spine tumors such as chordomas, meningiomas, schwannomas, neurofibromas, paragangliomas, and arteriovenous malformations (AVMs).
3077542|NCT01347307|Other|SBRT for Vertebral/Paraspinal Metastases|Vertebral and/or paraspinal metastases, with or without prior surgery and/or fractionated radiotherapy
3077543|NCT01347333|Other|liver metastases|Oligometastases (1-3) with aggregate tumor diameter < 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes
3077544|NCT01347333|Other|Primary Liver Tumors|Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma
3077545|NCT01347541|Experimental|Stepped care|Combination of behavioral therapy and drug therapy
3077546|NCT01347541|Active Comparator|Standard care provided to injured trauma survivors|
3077547|NCT01347554|Active Comparator|Xience V stent group|Xience V (Everolimus eluting stent) insertion in patients with acute myocardial infarction
3077548|NCT01347554|Active Comparator|Endeavor resolute group|Endeavor resolute (Zotarolimus eluting stent) insertion in patients with acute myocardial infarction
3077549|NCT01347580|Experimental|Ticagrelor|Loading dose of Ticagrelor (180 mg) followed by matching placebo. After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
3077550|NCT01347580|Experimental|Placebo|Placebo followed by a loading dose of Ticagrelor (180 mg). After the loading dose the patient will receive Ticagrelor (90 mg bid) for 30 days.
3077551|NCT01347710|Experimental|Flurpiridaz F18|Open-label study of a single dose of Flurpiridaz F18 injection for PET MPI compared to a single dose of 99mTc sestamibi or tetrofosmin for SPECT MPI in patients with suspected or known coronary artery disease referred for coronary catheterization
3077552|NCT01347762|Experimental|Nabilone|nabilone titrated to 2 mg daily
3077553|NCT01347762|Placebo Comparator|Placebo|Placebo
3077554|NCT01347788|Experimental|Cohort 1|Dose level 0: cabozantinib 40 mg daily
3077555|NCT01347788|Experimental|Cohort 2|Dose level -1: cabozantinib 20 mg daily
3077556|NCT01347788|Experimental|Expansion cohort|Dose level 0: cabozantinib 40 mg daily
3077557|NCT01347866|Experimental|Arm D: PF-05212384 + PD-0325901|
3077558|NCT01347866|Experimental|Arm C: PF-05212384 + irinotecan|
3077559|NCT01347879|Experimental|Visonac cream with PDT|active treatment with light dose of 37 Joule/cm2
3077560|NCT01347879|Placebo Comparator|Vehicle cream with PDT|Placebo treatment, Light dose 37 Joule/cm2
3077561|NCT01347931|Experimental|NIOV System|Noninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
3077562|NCT01347931|Active Comparator|Standard Oxygen Therapy|Supplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
3077563|NCT01348087|Experimental|AFQ056 100 mg (Bid)|All patients initiated treatment with AFQ056 at a starting dose of 25 milligram (mg) twice daily. The dose was titrated from 25mg bid to 50mg bid, 75mg bid and 100mg bid at weekly intervals. Dose adjustments (up- and down titrations) were permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose not to exceed 100mg bid.
3077564|NCT01348100|Experimental|Iloperidone 50 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 50 mg in a depot intramuscular (IM) injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
3077565|NCT01348100|Experimental|Iloperidone 125 mg crystalline formulation - Phase A|Participants received a crystalline formulation of iloperidone 125 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 7 days to stable doses of 12 to 24 mg daily.
3077566|NCT01348100|Experimental|Iloperidone 250 mg crystalline formulation - Phase B|Participants received a crystalline formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3077567|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase B|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 1 time. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3077568|NCT01348100|Experimental|Iloperidone 250 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 250 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3077569|NCT01348100|Experimental|Iloperidone 500 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 500 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3077570|NCT01348100|Experimental|Iloperidone 625 mg microparticle formulation - Phase C|Participants received a microparticle formulation of iloperidone 625 mg in a depot IM injection 2 times 28 days apart. Prior to receiving IM iloperidone, participants were gradually titrated up with oral iloperidone for at least 10 to 14 days to stable doses of 12 to 24 mg daily.
3077571|NCT01348139|Experimental|1|AZD3199 800 µg inhaled via single inhaler device (SID), single dose
3077572|NCT01348139|Experimental|2|AZD3199 880 µg inhaled via SID, single dose
3077573|NCT01348139|Experimental|3|AZD3199 1400 µg inhaled via SID, single dose
3077574|NCT01348139|Experimental|4|AZD3199 300 µg inhaled via Turbuhaler inhaler, single dose
3077575|NCT01348139|Experimental|5|AZD3199 1200 µg inhaled via Turbuhaler inhaler, single dose
3077576|NCT01348139|Placebo Comparator|6|Placebo inhaled via Turbuhaler inhaler and SID, single dose
3077577|NCT01348165|Experimental|BI 137882 Dose 1|Powder for oral solution
3077578|NCT01348165|Experimental|BI 137882 Dose 2|Powder for oral solution
3077579|NCT01348165|Experimental|BI 137882 Dose 3|Powder for oral solution
3077580|NCT01348165|Experimental|BI 137882 Dose 4|Powder for oral solution
3077581|NCT01348165|Experimental|BI 137882 Dose 5|Powder for oral solution
3077582|NCT01348165|Experimental|BI 137882 Dose 6|Powder for oral solution
3077583|NCT01348165|Experimental|BI 137882 Dose 7|Powder for oral solution
3077584|NCT01348165|Experimental|BI 137882 Dose 8|Powder for oral solution
3077585|NCT01348165|Experimental|BI 137882 Dose 9|Powder for oral solution
3077586|NCT01348165|Placebo Comparator|Placebo|Powder for oral solution
3077587|NCT01348347|Experimental|Volasertib|Patient to receive low, middle and high doses of Volasertib IV
3077588|NCT01348425|Experimental|Longer Stents|
3077589|NCT01348425|Experimental|Shorter Stents|
3077590|NCT01348490|Experimental|Ruxolitinib 5 mg|Participants began administration with 5 mg ruxolitinib twice daily (BID) orally. Beginning at the Week 4 visit, doses of ruxolitinib could be increased in 5 mg once a day (QD) increments every 4 weeks every 4 weeks not to exceed a dose of 25 mg BID.
3077591|NCT01348542|Active Comparator|Trazodone|
3077592|NCT01348542|Active Comparator|Cognitive Behavioral Therapy|
3077593|NCT01348607|Experimental|Arm I - methylphenidate hydrochloride|Patients receive oral methylphenidate extended-release once daily for 7-42 days in the absence of unacceptable toxicity.
3077594|NCT01348607|Experimental|Arm II -modafinil|Patients receive oral modafinil once daily for 7-42 days in the absence of unacceptable toxicity.
3077595|NCT01348607|Placebo Comparator|Arm III placebo|Patients receive oral placebo once daily for 7-42 days in the absence of unacceptable toxicity.
3077596|NCT01348698||Adrenal Gland Neoplasm|To collect adrenal tumor tissue biopsy samples in order to study and evaluate new methods that may help identify cancerous or precancerous cells. Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor.
3077597|NCT01348763|Experimental|Truvada, Darunavir/r and Maraviroc|Participants will be taking Truvada, Darunavir/r before entering the study. On day 1 they will add maraviroc then on day 11 they will stop the Truvada
3077598|NCT01348776|Experimental|Hair2Go (Mē)|Subjects treated with Hair2Go (Mē) Device
3077599|NCT01348789|Experimental|Hair2Go (Mē)|Treatment with Hair2Go (Mē)device
3077600|NCT01348828|Other|Single Arm|All patients meet study criteria receives a single use Ventana Fenestrated System, which requires administration of intravascular contrast. Catheter advancement is performed under fluoroscopic guidance and Ventana Fenestrated System is placed.
3077601|NCT01348854|Experimental|Natural Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct naturally occurring corneal astigmatism in eyes with no prior history of ophthalmic surgery. May include eyes with cataracts.
3077602|NCT01348854|Experimental|Post Cataract with Residual Astigmatism|Use of the iFS Femtosecond Laser System to make arcuate incisions to correct residual astigmatism in eyes that have undergone cataract extraction. May also include eyes with residual astigmatism following implantation of a phakic intraocular lens implanted.
3077603|NCT01349036|Experimental|PLX3397-Cohort 1|10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
3077604|NCT01349036|Experimental|PLX3397-Cohort 2|30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
3077605|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397 (RP2D)|Subjects will be dosed at the recommended Phase 2 dose (RP2D)
3077606|NCT01349049|Experimental|oral dose of 800 mg/day of PLX3397|Level 0
3077607|NCT01349049|Experimental|oral dose of 1000 mg/day PLX3397|Level 1
3077608|NCT01349049|Experimental|oral dose of 1200 mg/day PLX3397|Level 2
3077609|NCT01349049|Experimental|oral dose of 1400 mg/day PLX3397|Level 3
3077610|NCT01349049|Experimental|oral dose of 2000 mg/day PLX3397|Level 4
3077611|NCT01349049|Experimental|oral dose of 3000 mg/day PLX3397|Level 5
3077612|NCT01349049|Experimental|oral dose of 4000 mg/day PLX3397|Level 6
3077613|NCT01349049|Experimental|oral dose of 5000 mg/day PLX3397|Level 7
3077614|NCT01349114|Active Comparator|aliskiren 300 mg once daily for 12 weeks|aliskiren 300 mg daily
3077615|NCT01349114|Placebo Comparator|Sugar pill/ placebo|Patients were double-blind placebo-controlled randomized to either aliskiren 300 mg once daily or sugar pill/ placebo
3077616|NCT01349140|Experimental|Nerve Block|The dominant side (left or right) will be randomized to one of two treatment groups: the higher or lower concentration of the local anesthetic EXPAREL. The non-dominant contralateral side will receive the other possible treatment. The volume of each and every single-injection femoral nerve block will be 30 mL (standard for femoral nerve blocks is 30-40 mL).3 Since volume will remain constant, we will vary the dose of EXPAREL by varying concentration (volume x concentration = dose). Of note, EXPAREL may be mixed with normal saline to vary the concentration. Randomization will be based on computer-generated codes. Randomization will be in blocks of two, and stratified by sex.
3077617|NCT01349192|Experimental|Treatment|Subjects are treated with two oral antibiotics, topical antibiotics, and are instructed to use environmental decontamination techniques.
3077618|NCT01349192|No Intervention|Observational|Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
3077619|NCT01349231|Experimental|Ketamine|Ketamine will be given at a dose of 0.5mg/kg over 40 minutes. This dose is identical to that used in previous anti-depressant studies of ketamine.
3077620|NCT01349465|Other|Group 1: TMC 435 - Patients With SVR at LPVPS|Patients with sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
3077621|NCT01349465|Other|Group 2: TMC 435 - Patients With No SVR at LPVPS|Patients with no sustained virologic response (SVR) who completed last post-therapy follow-up visit of the previous study (LPVPS) [Phase IIb or Phase III] in which they received a TMC435-containing regimen for the treatment of HCV infection.
3077622|NCT01349491|Experimental|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated.
3077623|NCT01349491|Placebo Comparator|Placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion.
3077624|NCT01349569|Experimental|Myeloma Vaccine, Prevnar, & Lenalidomide|Lenalidomide will be continued on the same dose as was being administered prior to the study. The allogeneic myeloma vaccine and Prevnar-13 vaccine will be given on four days over the course of the study.
3077625|NCT01349660|Experimental|BKM120/Bevacizumab|"Phase I:~BKM 120 orally (PO) once daily (dose is 60mg or 80mg). Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks~Phase II:~BKM 120 orally (PO) once daily - dose is optimal dose determined in Phase I. Bevacizumab: 10mg/kg intravenous (IV) every 2 weeks"
3077626|NCT01349673|Experimental|Budesonide Foam|Participants administered topical rectal budesonide foam at 2 mg/25 mL BID (morning and 12 hours later) for 2 weeks followed by 2 mg/25 mL QD (in the evenings) for 4 weeks for up to 8 cycles. After Cycle 1, participants needed to qualify to be able to participate in subsequent cycles. Participants underwent a 48-hour study drug washout period between each cycle.
3077627|NCT01349790|Experimental|NewGam|Each participant received 1 g/kg NewGam intravenously on 2 consecutive days.
3077628|NCT01349803|Experimental|PT005 MDI|PT005 MDI
3077629|NCT01349803|Experimental|PT001 MDI|PT001 MDI
3077630|NCT01349803|Experimental|PT003 MDI|PT003 MDI
3077631|NCT01349803|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
3077632|NCT01349816|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
3077633|NCT01349816|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
3077634|NCT01349816|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
3077635|NCT01349816|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
3077636|NCT01349816|Experimental|PT001|PT001 MDI
3077637|NCT01349816|Experimental|PT005|PT005 MDI
3077638|NCT01349829|Experimental|HAVpur|
3077639|NCT01349829|Active Comparator|Havrix|
3077640|NCT01349907|Experimental|Asenapine/Asenapine|Participants treated with asenapine in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg twice per day (BID), then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
3077641|NCT01349907|Experimental|Placebo/Asenapine|Participants treated with placebo in base trial P06107, were first treated with open-label flavored asenapine 2.5 mg BID, then up-titrated to 5 mg BID at day 4, then up-titrated to 10 mg BID at Day 7. After Day 7, flexible dosing of asenapine was continued for up to 50 weeks.
3077642|NCT01349920||Infliximab 5 mg/kg|Infliximab treatment and endoscopy.
3077643|NCT01349933|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive 200 mg Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3132403|NCT03424044|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
3468865|NCT03891823|Experimental|MitraClip|"Study of MitraClip in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
3077645|NCT01349972|Experimental|Arm I (alvocidib, cytarabine, mitoxantrone hydrochloride)|Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Patients who achieve complete or partial response to the first course (completion of all doses) may receive a second course of treatment or high-dose cytarabine after 21-63 days following blood count recovery, and/or undergo allogeneic bone marrow transplant.
3077646|NCT01349972|Active Comparator|Arm II (cytarabine, daunorubicin hydrochloride)|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients who have residual disease on day 14 may receive additional cytarabine for 5 days and daunorubicin hydrochloride for 2 days.
3077647|NCT01350102|Active Comparator|Bacitracin wound care dressing alone|Bacitracin wound care dressing alone
3077648|NCT01350102|Active Comparator|Bacitracin with Vit C|Bacitracin wound care dressing with Vitamin C supplementation
3077649|NCT01350102|Active Comparator|AmeriGel® wound care dressing alone|AmeriGel® wound care dressing alone
3077650|NCT01350102|Active Comparator|AmeriGel® with Vit C|AmeriGel® wound care dressing with Vitamin C supplementation
3077651|NCT01350115|Active Comparator|LDE225|Participants received 400 mg once daily.
3077652|NCT01350115|Placebo Comparator|Placebo|Participants received matching placebo.
3077653|NCT01350128|Experimental|PT001 MDI (Dose 1)|PT001 MDI
3077654|NCT01350128|Experimental|PT001 MDI (Dose 2)|PT001 MDI
3077655|NCT01350128|Experimental|PT001 MDI (Dose 3)|PT001 MDI
3077656|NCT01350128|Experimental|PT001 MDI (Dose 4)|PT001 MDI
3077657|NCT01350128|Active Comparator|Ipratropium Bromide HFA Inhalation Aerosol|Ipratropium Bromide HFA Inhalation Aerosol
3077658|NCT01350128|Placebo Comparator|Placebo MDI|PT001 Placebo MDI
3077659|NCT01350141|Placebo Comparator|Treatment A|
3077660|NCT01350141|Experimental|Treatment B|
3077661|NCT01350141|Experimental|Treatment C|
3077662|NCT01350245|Experimental|TJU 2 Step Regimen|All patients treated on this trial will have hematological malignancies that are in remission at the time of the transplant. Their diseases would be expected to relapse with standard therapy alone.
3077663|NCT01350271|Placebo Comparator|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
3077664|NCT01350271|Active Comparator|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
3077665|NCT01350271|Experimental|Mebendazole polymorph C 500 mg|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
3077666|NCT01350336|Experimental|Alair|Alair system
3077667|NCT01350388|Active Comparator|Febuxostat|80 mg/day of febuxostat for 24 weeks
3077668|NCT01350388|Placebo Comparator|Placebo|1 placebo tablet per day for 24 weeks
3077669|NCT01350401|Experimental|NY-ESO-1/LAGE-1 and HLA-A*02 Positive Subjects|
3077670|NCT01350414||Alair Group|Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)
3077671|NCT01350453|Experimental|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
3077672|NCT01350453|Active Comparator|Standard Care|Participants received their usual care which included home exercises
3077673|NCT01350479||MRSA colonized|Residents with history of MRSA in the past year
3077674|NCT01350479||Not MRSA colonized|Residents without history of MRSA in the past year
3077675|NCT01350492|Experimental|Arm 1|Resistance exercise training
3077676|NCT01350492|No Intervention|Arm 2|Waitlist Control
3077677|NCT01350505|Experimental|All subjects|13 minutes of light at night (2 hours after bedtime)
3077678|NCT01350544|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 6-month follow-up assessment.
3077679|NCT01350544|Experimental|treatment advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with AIDS Project Los Angeles' (APLA) social service programs, as necessary.
3077680|NCT01350804|Experimental|AIN457 10mg/kg - 75 mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
3077681|NCT01350804|Experimental|AIN457 10mg/kg - 150 mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
3077682|NCT01350804|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24.
3077683|NCT01350804|Active Comparator|Abatacept|Participants received abatacept (from 500 to 1000 mg i.v. based on weight). Participants who did not respond to abatacept at Week 16 were re-randomized 1:1 to AIN457 75mg or 150mg at week 24 (after an 8 week washout period).
3077684|NCT01350934|Experimental|Fosamax Plus|Participants received alendronate 70 mg plus vitamin D3 5600 IU in a combination tablet (FOSAMAX PLUS D) once weekly for 6 months (base study), and then once weekly for another 6 months (extension study).
3077685|NCT01350934|Active Comparator|Calcitriol|Participants received calcitriol 0.25 μg once daily orally for 6 months (base study), and then once daily orally for another 6 months (extension study).
3077686|NCT01350947|Experimental|All patients|All participants enrolled.
3077687|NCT01350973|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 12 weeks.
3077688|NCT01350973|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 12 weeks.
3077689|NCT01350973|Experimental|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 12 weeks.
3077690|NCT01350999|Experimental|TAK-085 2 g|TAK-085 2 g, orally, once daily for up to 52 weeks.
3077691|NCT01350999|Experimental|TAK-085 4 g|TAK-085 2 g, orally, twice daily for up to 52 weeks.
3077692|NCT01350999|Active Comparator|EPA-E 1.8 g|Eicosapentaenoic acid-ethyl (EPA-E) capsule 0.6 g, orally, three-times daily for up to 52 weeks.
3077693|NCT01351025|Experimental|Arm A: atorvastatin / placebo|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated atorvastatin at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at the week 4 visit. At week 20, atorvastatin was stopped for a 4-week washout period.~At week 24, placebo was started for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the placebo dose was doubled at week 28. At week 44, the placebo was stopped to allow for another 4-week washout period."
3077694|NCT01351025|Experimental|Arm B: placebo / atorvastatin|"At study entry (week 0), participants continued the entry boosted PI-based antiretroviral regimen (not provided by the study) and initiated placebo for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, the dose of placebo was doubled at the week 4 visit. At week 20, the placebo was stopped for a 4-week washout period.~At week 24, atorvastatin was started at a daily dose of 10 mg for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, the dose of atorvastatin was increased to 20 mg daily at week 28. At week 44, atorvastatin was stopped to allow for another 4-week washout period."
3077695|NCT01351064|Experimental|CHICA ADHD Module|This arm received The CHICA ADHD Module
3077696|NCT01351064|No Intervention|CHICA ADHD Control|This arm received CHICA without the ADHD module
3077697|NCT01351077|Experimental|CHICA DevScreen Module|This arm will get the CHICA Developmental Screening Module
3077698|NCT01351077|No Intervention|CHICA DevScreen Control|This arm will get CHICA without the developmental screening module
3077699|NCT01351090|Experimental|Ketorolac tromethamine (5%)|
3077700|NCT01351090|Experimental|Ketorolac tromethamine (15%)|
3077701|NCT01351090|Placebo Comparator|Placebo|
3077702|NCT01351337|Other|intraoperative functional monitoring|intraoperative functional monitoring
3077703|NCT01351350|Experimental|MLN0128P 30 mg QW|MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077704|NCT01351350|Experimental|MLN0128P 40 mg QW|MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077705|NCT01351350|Experimental|MLN0128P 6 mg QD×3d QW|MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077706|NCT01351350|Experimental|MLN0128P 7 mg QD×3d QW|MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077707|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077708|NCT01351350|Experimental|MLN0128P 9 mg QD×3d QW|MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077709|NCT01351350|Experimental|MLN0128P 10 mg QD×3d QW|MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077710|NCT01351350|Experimental|MLN0128P 7 mg QD×5d QW|MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.
3077711|NCT01351350|Experimental|MLN0128P 8 mg QD×3d QW HER2-|MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
3077712|NCT01351350|Experimental|MLN0128PH 8 mg QD×3d QW HER2+|MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.
3077713|NCT01351376|Placebo Comparator|Placebo|CDT + inactive LLL
3077714|NCT01351376|Active Comparator|LLL combined with CDT|CDT + active LLL
3077715|NCT01351415|Experimental|Bevacizumab + Standard of Care|Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
3077716|NCT01351415|Active Comparator|Standard of Care|Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).
3077717|NCT01351480|Other|abatacept|open label use of abatacept for 12 months
3077718|NCT01351623|Experimental|Carfilzomib|A single arm, open-label, single institution phase 2 clinical trial is planned.
3077719|NCT01351740|Experimental|Switch|switch to unboosted atazanavir 400mg daily with the same nucleoside (NRTI) backbone
3077720|NCT01351740|Active Comparator|Continuation|continue on current regimen of atazanavir/ritonavir 300mg/100mg with the same nucleoside (NRTI) backbone
3077721|NCT01351753|Active Comparator|Metformin|
3077722|NCT01351753|Experimental|Metformin + Orlistat|
3077723|NCT01351753|Experimental|Metformin + Topiramate|
3077724|NCT01351753|Experimental|Topiramate|
3077725|NCT01351753|Experimental|Metformin + Topiramate + Orlistat|
3077726|NCT01351753|Placebo Comparator|Placebo|
3077727|NCT01351766|Experimental|Behavioral Activation for Smoking|"Eight 60-minute group sessions over an eight-week period. Eight weeks of transdermal nicotine patch, which will begin at the time of quitting smoking and will continue after treatment sessions have ended.~Transdermal Nicotine: Participants will use 8 weeks of the nicotine patch at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level."
3077728|NCT01351805|Experimental|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3077729|NCT01351805|Experimental|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
3077730|NCT01351805|Placebo Comparator|placebo|Subjects will receive placebo pill.
3077731|NCT01351805|Experimental|Vitamin D and Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3077732|NCT01352117|Active Comparator|Arm A: ART alone or with delayed ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks. Arm A participants who experienced KS progression on ART alone could receive ET in addition to EFV/FTC/TDF in Step 2 of the study.
3077733|NCT01352117|Experimental|Arm B: ART with immediate ET|Participants were prescribed ART (co-formulated efavirenz/emtricitabine/tenofovir disoproxil fumarate, EFV/FTC/TDF) for 96 weeks with immediate ET for up to 16 weeks.
3077734|NCT01352182|Experimental|Pioglitazone hydrochloride|Pioglitazone hydrochloride treatment group
3077735|NCT01352182|No Intervention|Normal standard care|Normal standard care control group
3077736|NCT01352221|Experimental|ST10|ST10 (Ferric Maltol) 30mg capsules, taken orally twice a day
3077737|NCT01352221|Placebo Comparator|Placebo|Matching placebo capsules for ST10 (Ferric Maltol), taken orally twice a day
3077738|NCT01352286|Experimental|Autologous Genetically modified T cells|Patients with advanced myeloma and who are candidates for autologous stem cell transplants, or syngeneic stem cell transplants (SSCT), will be eligible. Prior to full screening on this study, patients will undergo prescreening to evaluate HLA-A type and presence of NY-ESO-1c259T/LAGE antigen. Patients will undergo a steady-state mononuclear cell apheresis for T cell collection, with an optional second collection. Once mononuclear cells have been collected, patients (or donors in the case of SSCT) will then undergo hematopoietic stem cell mobilization. Patients will receive a dose >0.1-1 x 10¹º anti-CD3/anti-CD28-costimulated autologous T cells which have been genetically modified to express high affinity NY-ESO-1c259 TCRs.
3077739|NCT01352442|Experimental|AcuFocus Corneal Inlay|The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.
3077740|NCT01352468|Experimental|Multifaceted Cognitive Training|Cognitive Training with 4 different tasks each of which gets progressively more difficult as children obtain proficiency.
3077741|NCT01352468|Sham Comparator|Sham Cognitive Training|Cognitive Training with 4 different tasks which does not get progressively more difficult throughout training
3077742|NCT01352507|Experimental|Tadalafil then Sildenafil|"20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED)."
3077743|NCT01352507|Active Comparator|Sildenafil then Tadalafil|"100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments.~At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED."
3077744|NCT01352546|Experimental|BOTOX|intravaginal Botox injections and progressive dilation under anesthesia to cure vaginismus.
3077745|NCT01352585||JAK2 Positive Participants|
3077746|NCT01352585||JAK2 Negative Participants|
3077747|NCT01352598|Other|Stereotactic Body Radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
3077748|NCT01352637|Placebo Comparator|Placebo + Prolonged Imaginal Exposure|Drug: Placebo (sugar pill) + Prolonged Imaginal Exposure (PE) PTSD treatment
3077749|NCT01352637|Placebo Comparator|Placebo + VR exposure|Drug: Placebo (sugar pill) + Virtual Reality Exposure (VR) PTSD treatment
3077750|NCT01352637|Active Comparator|DCS + Prolonged Imaginal Exposure|Drug: 50mg DCS (D-Cycloserine ) + Prolonged Imaginal Exposure (PE) PTSD treatment
3077751|NCT01352637|Active Comparator|DCS+VR exposure|Drug: 50mg DCS (D-Cycloserine ) + Virtual Reality Exposure (VR) PTSD treatment
3077752|NCT01352715|Experimental|Arm A: LPV/r plus RAL|Participants were administered LPV/r plus RAL orally twice daily throughout follow-up.
3077753|NCT01352715|Experimental|Arm B: LPV/r plus best available NRTIs|"Participants were administered LPV/r orally twice daily, plus NRTI options provided by the study, to include the best available NRTIs (listed below) throughout follow-up-~FTC/TDF orally twice daily~ABC/3TC/ZDV orally twice daily~ABC/3TC orally once daily~3TC/ZDV orally twice daily~ABC 300mg orally twice daily or 600 mg once daily~3TC orally twice daily~ZDV orally twice daily"
3077754|NCT01352741|Experimental|Tapentadol Prolonged Release|Tapentadol Prolonged Release (100 - 500 mg per day) Oral administration twice daily
3077755|NCT01352741|Active Comparator|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release (100 - 300 mg per day) with Pregabalin (150 - 300 mg per day) Both administered orally twice a day.
3077756|NCT01352793|Experimental|rLP2086 vaccine|rLP2086 vaccine
3077757|NCT01352793|Other|control|The control treatment will be HAVRIX vaccine at month 0 and 6 and a normal saline injection at month 2.
3077758|NCT01352845|Experimental|rLP2086|
3077759|NCT01352845|Placebo Comparator|Control|Steril normal saline solution
3077760|NCT01353079|Experimental|Short Ragweed Pollen Allergenic Extract|
3077761|NCT01353079|Placebo Comparator|Glycero-COCAs|
3077762|NCT01353144|No Intervention|esomeprazole|esomeprazole (40 mg/day) for 8 weeks
3077763|NCT01353144|Active Comparator|esomeprazole plus aspirin|esomeprazole (40 mg/day) plus aspirin (100 mg/day) for 8 weeks
3077764|NCT01353196||stenosis|carotid stenosis
3077765|NCT01353196||no stenosis|no stenosis
3077766|NCT01353222|Experimental|DN24-02|Subjects received infusion of DN24-02, at 2-week intervals, for a total of 3 infusions.
3077767|NCT01353222|Other|Standard of Care|Subjects randomized to the control arm were treated per standard of care, which in this patient population is generally observation, as there is currently no evidence that treatment with non-cisplatin containing chemotherapy is beneficial in the adjuvant setting for this patient population.
3077768|NCT01353274||Patients with hypertension|
3077769|NCT01353495|Experimental|APM Graft (BIOTAPE XMTM|graft applied to wound q 3 weeks for 12 weeks
3077770|NCT01353495|Active Comparator|standard wound care|Wound debridement and gels and foams applied to wound weekly for 12 weeks.
3077771|NCT01353508|Experimental|LCZ696 to Valsartan - Heart Failure (HF) cohort|Participants in this arm received Valsartan 160 mg twice daily (bid) during open-label run-in, LCZ696 200 mg bid double blind treatment during period 1, Valsartan 160 mg bid during wash-out, and Valsartan 160 mg bid double blind treatment during period 2.
3077772|NCT01353508|Experimental|Valsartan to LCZ696 - HF Cohort|Participants in this arm received Valsartan 160 mg twice daily bid during open-label run-in, Valsartan 160 mg bid during period 1, Valsartan 160 mg bid during wash-out, and LCZ696 200 mg bid double blind treatment during period 2.
3077773|NCT01353508|Experimental|LCZ696 to Valsartan - Hypertension (HTN) cohort|Participants in this arm received Valsartan 320 mg once daily (qd) during open-label run-in, LCZ696 400 mg qd double blind treatment during period 1, Valsartan 320 mg qd during wash-out, and Valsartan 320 mg qd double blind treatment during period 2.
3077774|NCT01353508|Experimental|Valsartan to LCZ696 - HTN cohort|Participants in this arm received Valsartan 320 mg qd during open-label run-in, Valsartan 320 mg qd during period 1, Valsartan 320 mg qd during wash-out, and LCZ696 400 qd bid double blind treatment during period 2.
3077775|NCT01353586|Experimental|nMARQ™ System|The nMARQ™ System (Circular and Crescent Mapping and Ablation Catheters as well as the Multi-Channel Radiofrequency Generator) as part of the Multi-Electrode Irrigated Pulmonary Vein (PV) Isolation System will serve as a treatment method for subjects undergoing radiofrequency catheter ablation for drug refractory, symptomatic Paroxysmal Atrial Fibrillation (PAF). The study later included a Subpopulation Neurological Assessments (SNA) substudy which is a prospective, non-randomized, controlled, acute assessment to compare subjects treated with the nMARQ™ System against control subjects treated with the NAVISTAR® THERMOCOOL® Irrigated Tip Catheter.
3077776|NCT01353664|Experimental|Romidepsin|This study is an open-label, single-arm study. The study is divided into the Screening Period, Treatment Period, and Follow-up Period.
3077777|NCT01353703|Experimental|INFANRIX HEXA 6-10-14 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
3077778|NCT01353703|Active Comparator|INFANRIX HEXA 2-4-6 GROUP|Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
3077779|NCT01353859|Experimental|Single Arm|
3077780|NCT01353898|Experimental|MK-1972 50 mg once daily (Part I)|Ten capsules containing a total daily dose of 50 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3077781|NCT01353898|Experimental|MK-1972 200 mg once daily (Part I)|Ten capsules containing a total daily dose of 200 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3077782|NCT01353898|Experimental|MK-1972 800 mg once daily (Part I)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, once per day for 10 days (Part I)
3077783|NCT01353898|Experimental|MK-1972 25 mg twice daily (Part I)|Ten capsules containing a total daily dose of 25 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
3077784|NCT01353898|Experimental|MK-1972 100 mg twice daily (Part I)|Ten capsules containing a total daily dose of 100 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part I)
3077785|NCT01353898|Placebo Comparator|Placebo twice daily (Part I)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part I)
3077786|NCT01353898|Experimental|MK-1972 800 mg twice daily (Part II)|Ten capsules containing a total daily dose of 800 mg MK-1972 or placebo were taken orally, twice per day for 10 days (Part II)
3077787|NCT01353898|Placebo Comparator|Placebo twice daily (Part II)|Ten capsules containing placebo were taken orally, twice per day for 10 days (Part II)
3077788|NCT01353911|Experimental|Grazoprevir 100 mg|TN non-cirrhotic (NC) participants receive Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3077789|NCT01353911|Experimental|Grazoprevir 200 mg|TN NC participants receive Grazoprevir 200 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3077790|NCT01353911|Experimental|Grazoprevir 400 mg|TN NC participants receive Grazoprevir 400 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3077791|NCT01353911|Experimental|Grazoprevir 800 mg|TN NC participants receive Grazoprevir 800 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3077792|NCT01353911|Active Comparator|Boceprevir 800 mg|TN NC participants start a 4 week lead-in with Peg-IFN + RBV, then receive Boceprevir 800 mg + Peg-IFN + RBV for 24 weeks followed by 0 or 20 weeks of Peg-IFN + RBV, based on response guided therapy.
3077793|NCT01353911|Experimental|Grazoprevir 400 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 400 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
3077794|NCT01353911|Experimental|Grazoprevir 800 mg/100 mg|As the result of an interim analysis, TN NC participants assigned to the 800 mg grazoprevir group were unblinded and transitioned to 100 mg grazoprevir once daily + Peg-IFN + RBV and will remain in the study.
3077795|NCT01353911|Experimental|OL Grazoprevir 100 mg|TN cirrhotic participants receive open-label Grazoprevir 100 mg + Peg-IFN + RBV for 12 weeks followed by 12 or 36 weeks of Peg-IFN + RBV, based on response guided therapy.
3077796|NCT01353963||1|
3077797|NCT01353976|Experimental|Econazole Nitrate Foam 1%|Study medication
3077798|NCT01353976|Placebo Comparator|Vehicle Foam|Placebo medication
3077799|NCT01354015|Experimental|Use of messaging system|Use of DRMS
3077800|NCT01354015|No Intervention|Usual Care|Usual Care
3077801|NCT01354028|Experimental|Massage therapy|Massage therapy for 10 minutes during quiet alert state following 9 AM feeding. Actigraph in place to measure sleep for 3 hours.
3077802|NCT01354028|No Intervention|No massage therapy|This was a crossover trial with two arms. On one day, infants received massage therapy for 10 minutes. On the other day, infants were monitored as usual with the Actigraph to measure sleep efficiency, but received no massage therapy. This was the control or no intervention arm.
3077803|NCT01354106|Experimental|3M Kind Removal Silicone Tape|"investigational medical Silicone tape, 1 x 1.5 sample, applied on time, worn for 24 hours."
3077804|NCT01354106|Other|3M Micropore Medical Tape|"Commercially available Medical Paper Tape, 1 x 1.5 sample, applied on time, worn for 24 hours. Study Control."
3077805|NCT01354132|Active Comparator|n-acetyl-cysteine|N-Acetyl cysteine effervescent tablets in water 2 in am and 1 in pm for 28 weeks
3077806|NCT01354132|Placebo Comparator|Placebo|matching effervescent tablets in water 2 in am and 1 in pm
3077807|NCT01354145|Experimental|Chondroitin sulfate (Condrosan)|CHONDROITIN SULPHATE Group: 1200 mg (three capsules of 400 mg each) taken once a day in the morning
3077808|NCT01354145|Active Comparator|Celecoxib|CELECOXIB Group: 200 mg (one capsule of 200 mg CELECOXIB + two placebo capsules) taken in the morning
3077809|NCT01354197||All ICU admission patients|All ICU admission to surgical intensive care unit at cohort time
3077810|NCT01354223|Experimental|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
3077811|NCT01354223|Active Comparator|ocufilcon B contact lens|Randomized to ocufilcon B contact lens worn in a daily wear, daily disposable mode
3077812|NCT01354314|Experimental|Fluconazole|Fluconazole 100 mg every 12 hours orally per day; placebo in place of paroxetine
3077813|NCT01354314|Experimental|Paroxetine|Paroxetine 20 mg orally once per day; placebo in place of fluconazole
3077814|NCT01354314|Experimental|Paroxetine and Fluconazole|Fluconazole 100 mg every 12 hours orally per day and paroxetine 20 mg every evening orally per day
3077815|NCT01354314|Placebo Comparator|Placebo|Placebo in place of both fluconazole and paroxetine
3077816|NCT01354353|Active Comparator|Aripiprazole|Part A: Continue current prescribed dosing regimen -- Study Day 1 to discharge (Study Day 21). Part B: Continue current prescribed dosing regimen (≤ 30 milligrams [mg]/day ) -- Study Day 1 to discharge (Study Day 23, 25 or 28 based on adaptive design)
3077817|NCT01354353|Experimental|Part A: 160 mg LY2140023|Administered orally, twice daily (BID) for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3077818|NCT01354353|Experimental|Part A: 240 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3077819|NCT01354353|Experimental|Part A: 320 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3077820|NCT01354353|Experimental|Part A: 400 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3077821|NCT01354353|Experimental|Part A: 480 mg LY2140023|Administered orally BID for 6 days (Study Days 10-15) and as a single morning dose on the 7th day (Study Day 16)
3077822|NCT01354353|Experimental|Part B: LY2140023|If doses up to or equal to 400 mg BID are not tolerated, Part B of the study may be started. The dose of LY2140023 will be titrated in the same participant from highest dose that was tolerated in Part A, with the intention to reach a dose of 480 mg LY2140023.
3077823|NCT01354431|Experimental|Arm 1: nivolumab - 0.3 mg/kg|
3077824|NCT01354431|Experimental|Arm 2: nivolumab - 2.0 mg/kg|
3077825|NCT01354431|Experimental|Arm 3: nivolumab - 10.0 mg/kg|
3077826|NCT01354444|Active Comparator|Carvedilol|Carvedilol is a is a beta-blocker. Beta-blockers are generally used to reduce the workload on the heart and help it to beat more regularly.
3077827|NCT01354444|Placebo Comparator|Placebo|Non active substance
3077828|NCT01354496|Experimental|Cohort 1 - LY2409021 reference form|A 20 milligram (mg) LY2409021 dose, reference form administered orally in the fasted state
3077829|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fed|Single 20 mg LY2409021 test form with medium particle size administered orally immediately after ingestion of a standardized high-fat meal
3077830|NCT01354496|Experimental|Cohort 1 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
3077831|NCT01354496|Experimental|Cohort 2 - LY2409021 low test form fasted|Single 20 mg LY2409021 test form with low particle size administered orally in the fasted state
3077832|NCT01354496|Experimental|Cohort 2 - LY2409021 medium test form fasted|Single 20 mg LY2409021 test form with medium particle size administered orally in the fasted state
3077833|NCT01354496|Experimental|Cohort 2 - LY2409021 high test form fasted|Single 20 mg LY2409021 test form with high particle size administered orally in the fasted state
3077834|NCT01354652|Experimental|entecavir|"Oral 0.5mg/day until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
3077835|NCT01354652|Active Comparator|lamivudine|"Oral 100mg/day lamivudine until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18.~Participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
3077836|NCT01354652|No Intervention|no NRTI group|hepatitis C virus associated LC patients for the calculation of lactic acidosis incidence
3077837|NCT01354691|Experimental|ladostigil hemitartrate|Ladostigil capsules 80 mg
3077838|NCT01354691|Placebo Comparator|Placebo|Placebo capsules
3077839|NCT01354938||Acute Exacerbation of Chronic Bronchitis (AECB)|Participants with a diagnosis of chronic bronchitis and signs and symptoms of an acute exacerbation who were prescribed Klaricid XL (500 mg of modified release clarithromycin) at a dose of one tablet once a day or two tablets once a day based on physician's decision of severity of symptoms per routine clinical care.
3077840|NCT01354964|Experimental|Vitamin D|Participants received weekly oral vitamin D drops using a weight-based calculated dosage for up to six months.
3077841|NCT01354964|Placebo Comparator|Placebo|Participants received weekly oral placebo drops (similar in taste and appearance to vitamin D) for up to six months.
3077842|NCT01354990||Participants treated with sitagliptin|
3077843|NCT01355068|Active Comparator|Treatment A|Epanutin Infatabs 50 mg (sourced from Germany), 1 x 50 mg (REFERENCE)
3077844|NCT01355068|Experimental|Treatment B|Dilantin Infatabs 50 mg (sourced from Australia), 1 x 50 mg (TEST)
3077845|NCT01355081|Experimental|Vortioxetine 5 mg|Vortioxetine 5 mg, tablets, orally, once daily for up to 8 weeks.
3077846|NCT01355081|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, tablets, orally, once daily for up to 8 weeks.
3077847|NCT01355081|Placebo Comparator|Placebo|Vortioxetine placebo-matching tablets, orally, once daily for up to 8 weeks.
3077848|NCT01355159|Experimental|Folic Acid 4 mg|Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
3077849|NCT01355159|Placebo Comparator|Placebo|Women will be randomised in a 1:1 ratio to folic acid 4.0 mg or placebo
3077850|NCT01355224|No Intervention|No risk feedback|No obesity risk information given (control)
3077851|NCT01355224|Experimental|Genetic risk feedback|Only personal genetic risk information provided
3077852|NCT01355224|Experimental|Lifestyle risk feedback|Only personal lifestyle risk information provided
3077853|NCT01355224|Experimental|Both genetic or lifestyle risk feedback|Personal genetic and lifestyle information provided
3077854|NCT01355289|Placebo Comparator|Placebo (Core Study)|Placebo, will be administered orally, once daily for up to 21 days.
3077855|NCT01355289|Active Comparator|Avatrombopag 10 mg (Core Study)|Avatrombopag 10 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3077856|NCT01355289|Active Comparator|Avatrombopag 20 mg (Core Study)|Avatrombopag 20 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3077857|NCT01355289|Active Comparator|Avatrombopag 30 mg (Core Study)|Avatrombopag 30 mg, will be administered orally, once daily, preferably with food for up to 21 days.
3077858|NCT01355289|Experimental|Avatrombopag (Open-Label Extension)|Avatrombopag will be initiated at a dose of 20 mg, once daily in the open-label extension (OLE) period. The avatrombopag dose will be titrated up or down in accordance with the participant's individual response, within the range of a minimum of 5 mg and a maximum of 50 mg for up to 48 weeks.
3077859|NCT01355302|Experimental|Phase Ib: Cohort 1 and 2 and 3|"Phase Ib: Cohort 1; 200 mg E7050 + 80 mg/m2 cisplatin + 1000 mg/m2 capecitabine~Cohort 2; 300 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine Cohort 3; 400 mg E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine"
3077860|NCT01355302|Active Comparator|Phase II: Arm 1; E7050 + cisplatin+ capecitabine|Phase II: Arm 1; MTD E7050 + 80 mg/m2 cisplatin + 2000 mg/m2 capecitabine
3077861|NCT01355419||obstructive sleep apnea, CPAP|moderate to severe obstructive sleep apnea requiring CPAP therapy
3077862|NCT01355458|Experimental|CD07805/47 gel|
3077863|NCT01355458|Placebo Comparator|Placebo|
3077864|NCT01355471|Experimental|CD07805/47 gel|
3077865|NCT01355471|Placebo Comparator|Placebo|
3077866|NCT01355484|Experimental|GTx-024|subject will receive GTx-024 treatment for the duration of the trial
3077867|NCT01355484|Placebo Comparator|Placebo|subject will receive placebo for the duration of the trial
3077868|NCT01355497|Experimental|GTx-024 3mg once daily|subjects will be randomized to receive GTx-024 3mg sofgel capsule once daily for the duration of the trial
3077869|NCT01355497|Placebo Comparator|placebo|subjects will be randomized to receive matching placebo once daily for the duration of the trial
3077870|NCT01355523|Active Comparator|Melatonin|6 mg oral melatonin daily
3077871|NCT01355523|Placebo Comparator|Placebo|6 mg oral placebo daily
3077872|NCT01355575|Experimental|Rifaximin for 6-weeks followed by 6-week observation period|All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.
3077873|NCT01355588|Experimental|Ketorolac Tromethamine|
3077874|NCT01355588|Experimental|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|
3077875|NCT01355588|Experimental|Ketorolac Tromethamine with 5% Lidocaine HCl|
3077876|NCT01355588|Experimental|Ketorolac Tromethamine with 6% Lidocaine HCl|
3077877|NCT01355627|Experimental|TachoSil®|
3077878|NCT01355627|Active Comparator|Current practice group|
3077879|NCT01355679|Experimental|Guided therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3077880|NCT01355705|Experimental|Amrubicin + Lenalidomide + Dexamethasone|"Amrubicin will be given intravenously on Day 1 of each 3-week cycle beginning with 40 mg/m2, for a maximum of 4 cycles.~Concurrent therapeutic medications:~Lenalidomide: 10 or 15 mg daily by mouth, Days 1 to 14~Dexamethasone: 40 mg weekly by mouth (Days 1, 8, and 15)~Other drugs:~Aspirin: 81 or 325 mg daily oral~Pegfilgrastim subcutaneous on Day 2"
3077881|NCT01355796|Experimental|Aerosolized Hypertonic xyltiol|Aerosolized xylitol (5 ml) twice daily for 14 days
3077882|NCT01355796|Active Comparator|Hypertonic saline|Aerosolized 7% hypertonic saline (4 ml) twice daily for 14 days
3077883|NCT01355978|Experimental|Noninvasive Open Ventilation System|Portable noninvasive open ventilator & nasal interface.
3077884|NCT01356147|Sham Comparator|Sham placebo|No therapy will be given to placebo arm. Respiratory therapist will shield infant from view and nebulize saline solution into incubator rather than into ventilator circuit.
3077885|NCT01356147|Active Comparator|Dornase alfa|Dornase alfa 2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
3077886|NCT01356277|Experimental|Multi-component Intervention|"Multi-component Intervention consisting of:~Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient~text message, email, or visual cue dose reminders"
3077887|NCT01356277|No Intervention|Attention control|Control group study visits were conducted at the same intervals as intervention visits and consisted of the Coach engaging in active listening and providing non-specific support only. Adherence was NOT discussed with control participants.
3077888|NCT01356407|Experimental|PICOPREP|"Split Dose method and consists of two separate doses: the first dose during the evening before the colonoscopy and the second dose the next day before the colonoscopy."
3077889|NCT01356407|Active Comparator|PEG-ELS|PEG-ELS was used according to the approved labeled dosage and administration instructions. Only received one dose of 2 boxes (6 packets), administrated on the day of colonoscopy examination.
3077890|NCT01356498|Experimental|q2 RCT|Pegloticase every 2 wk arm of Randomized Controlled Trial(RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
3077891|NCT01356498|Experimental|q4 RCT|Pegloticase every 4 wk arm of Randomized Controlled Trial (RCT), continued to receive pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in Open Label Extention (OLE) study
3077892|NCT01356498|Experimental|Placebo in RCT|Placebo arm in Randomized Controlled Trial (RCT), received pegloticase every 2 weeks (q2 wk) or every 4 weeks (q4 wk) in OLE
3077893|NCT01356589||Cohort|
3077894|NCT01356602|Experimental|Canakinumab, pre-filled syringes (PFS)|Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.
3077895|NCT01356602|Active Comparator|Canakinumab, lyophilizate (LYO)|The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized powder and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.
3077896|NCT01356602|Active Comparator|Triamcinolone Acetonide|The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.
3077897|NCT01356628|Experimental|PD-0332991|PD-0332991 in the Treatment in Patients with Advanced Hepatocellular Carcinoma
3077898|NCT01356940|Active Comparator|dalfampridine ER 10mg bid-placebo|4 week administration of dalfampridine ER 10mg bid followed by 2 week washout and 4 weeks of placebo control
3077899|NCT01356940|Placebo Comparator|placebo-dalfampridine ER 10mg bid|placebo tablet administered bid for four weeks followed by 2 week washout and 4 weeks of dalfampridine ER 10mg bid
3077900|NCT01356966|Experimental|Tetrahydrobiopterin + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive Tetrahydrobiopterin (6R-BH4) 200 mg twice daily and folic acid 1 mg daily
3077901|NCT01356966|Placebo Comparator|Placebo + Folate|Male subjects with hypertension and chronic kidney disease stage 2 or 3 will receive 2 placebo pills twice daily and folic acid 1 mg daily
3077902|NCT01357135||Metformin + Sitagliptin|Participants taking metformin + sitagliptin (Januvia®/Xelevia®) as prescribed in routine clinical practice.
3077903|NCT01357135||Metformin + Sulfonylurea|Participants taking metformin + sulfonylurea as prescribed in routine clinical practice. The sulfonylurea could include: gliclazide, glibenclamide, or glimepiride.
3077904|NCT01357135||Sitagliptin +/- Other Antihyperglycemic Medication|Participants taking sitagliptin +/- other antihyperglycemic medication (other than metformin) as prescribed in routine clinical practice. These other antihyperglycemic medications could include: insulin, glinides, sulfonylurea, glitazone, an alpha-glucosidase inhibitor, or combinations thereof.
3077905|NCT01357148||Participants treated with sitagliptin phosphate/metformin HCl|
3077906|NCT01357161|Experimental|Part 1: MK-1775 225 mg + paclitaxel +carboplatin|During the open-label run-in, participants receive 225 mg MK-1775 twice daily (BID) starting on Day 1 of Cycle 1 (cycle=21 days) for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (area under the curve [AUC] 5).
3077907|NCT01357161|Experimental|Part 2: MK-1775 225 mg + paclitaxel +carboplatin|During Part 2, participants receive 225 mg MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive MK-1775 in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
3077908|NCT01357161|Placebo Comparator|Part 2: Placebo + paclitaxel +carboplatin|During Part 2, participants receive matched placebo to MK-1775 BID starting on Day 1 of each 21 day cycle for a total of 5 doses. Participants receive placebo in combination with paclitaxel (175 mg/m2) and carboplatin (AUC 5).
3077909|NCT01357239|Experimental|25 mg bid|
3077910|NCT01357239|Experimental|50 mg bid|
3077911|NCT01357239|Experimental|100 mg bid|
3077912|NCT01357239|Placebo Comparator|Placebo|
3077913|NCT01357356|Experimental|SER120 (750 ng/day)|SER120 (750 ng/day)
3077914|NCT01357356|Experimental|SER120 (1000 ng/day)|SER120 (1000 ng/day)
3077915|NCT01357356|Experimental|SER120 (1500 ng/day)|SER120 (1500 ng/day)
3077916|NCT01357356|Placebo Comparator|Placebo|Placebo
3077917|NCT01357512|Experimental|MRI done|Subjects with MRI prior prostate biopsies
3077918|NCT01357512|No Intervention|no MRI|No MRI before prostate biopsies
3077919|NCT01357525|Other|Stereotactic Body Radiotherapy|
3077920|NCT01357551|Experimental|Maintenance intervention|Participants receive a theoretically-informed maintenance intervention for 42 weeks, followed by 14 weeks of no intervention contact to examine sustainability. The maintenance intervention involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
3077921|NCT01357551|No Intervention|Usual care|Participants receive usual care for 56 weeks
3077922|NCT01357564|Experimental|Tailored Activity Program|Occupational therapists assess the person's home environment, preserved capabilities, daily routines, interests and the caregiver's readiness and ability to use activities. Activities are developed that reflect the Veteran's previous or current interests and are modified to match their preserved capabilities without taxing the most impaired areas of cognition (e.g., memory, new learning). TAP-VA provides caregivers with the knowledge and skills to use activities. The overall goal is to provide predictability, familiarity, and structure in the daily life of the Veteran and establish a level of environmental stimulation appropriate to that person's abilities.
3077923|NCT01357564|Active Comparator|Attention Control|Caregivers in this group receive bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers are provided important information about dementia and strategies for disease management. Each telephone contact begins with a brief overview of the specific purpose of the session, followed by a description of the key facts about the session topic, and concludes with a question and answer period. The attention control group intervention is delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
3077924|NCT01357577|Experimental|Arm 1: TAU + CBT|The experimental group will receive treatment as usual (TAU) plus cognitive behavioral therapy (CBT).
3077925|NCT01357577|No Intervention|Arm 2: TAU|"The no intervention group will receive treatment as usual (TAU)."
3077926|NCT01357616|Experimental|AZARGA|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension, 1 drop in the affected eye(s) dosed twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
3077927|NCT01357616|Active Comparator|AZOPT + Timolol|Brinzolamide 1% ophthalmic suspension, 1 drop instilled in the affected eye(s), followed by Timolol 0.5% ophthalmic solution, 1 drop instilled in the affected eye(s). Approximately 10 minutes separated the 2 instillations. The study drugs were instilled twice daily (9AM and 9PM) for 8 weeks. Both eyes were dosed unless there was a potential safety issue to the patient in the opinion of the Investigator.
3077928|NCT01357655|Active Comparator|Arm 1: Dasatinib|
3077929|NCT01357655|Experimental|Arm2: Dasatinib + BMS-833923|Dasatinib for 1 year followed by dasatinib plus BMS-833923 for 2 years followed by dasatinib alone for approximately 2 years; depending on response
3077930|NCT01357720|Experimental|Quinvaxem|
3077931|NCT01357720|Active Comparator|Tritanrix Hib/HepB + Quinvaxem|
3077932|NCT01357850|Experimental|GSK716155 (3.75mg)|GSK716155 (3.75mg)
3077933|NCT01357850|Experimental|GSK716155 (15mg)|GSK716155 (15mg)
3077934|NCT01357850|Experimental|GSK716155 (30mg)|GSK716155 (30mg)
3077935|NCT01357850|Placebo Comparator|GSK716155-matched placebo|GSK716155-matcued placebo
3077936|NCT01357889|Active Comparator|process 2 albiglutide|albiglutide 30mg from process 2 drug substance
3077937|NCT01357889|Active Comparator|process 3 albiglutide|albiglutide 30mg from process 3 drug substance
3077938|NCT01357915|Experimental|GSK149203A S- Group|Male subjects who received 3 doses of GSK Biologicals' candidate GSK149203A vaccine according to a 0-1-6 month schedule in the primary study 108890 (NCT00435396).
3077939|NCT01357915|Other|GSK149203A S+ Group|Male subjects who were assessed as being naturally infected with Cytomegalovirus (CMV) at the screening visit of the primary study 108890 (NCT00435396).
3077940|NCT01357980|Experimental|Dysport 750 U (15 injection sites)|
3077941|NCT01357980|Placebo Comparator|Placebo (15 injection sites)|
3077942|NCT01357980|Experimental|Dysport 750 U (30 injection sites)|
3077943|NCT01357980|Placebo Comparator|Placebo (30 injection sites)|
3077944|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 75 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3077945|NCT01358175|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3077946|NCT01358175|Placebo Comparator|Placebo|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3077947|NCT01358266|Active Comparator|Ophthalmic solution low dose|
3077948|NCT01358266|Active Comparator|Ophthalmic solution medium dose|
3077949|NCT01358266|Active Comparator|Ophthalmic solution high dose|
3077950|NCT01358331|Experimental|MK-8353 100 mg twice daily (BID)|100 mg capsules administered orally twice daily for 28 days for each cycle
3077951|NCT01358331|Experimental|MK-8353 200 mg BID|200 mg capsules administered orally twice daily for 28 days for each cycle
3077952|NCT01358331|Experimental|MK-6353 300 mg BID|300 mg capsules administered orally twice daily for 28 days for each cycle
3077953|NCT01358331|Experimental|MK-8353 350 mg BID|350 mg capsules administered orally twice daily for 28 days for each cycle
3077954|NCT01358331|Experimental|MK-8353 400 mg BID|400 mg capsules administered orally twice daily for 28 days for each cycle
3077955|NCT01358331|Experimental|MK-8353 800 mg BID|800 mg capsules administered orally twice daily for 28 days for each cycle
3077956|NCT01358357|Experimental|Lurasidone 20-80 mg flexible dose|
3077957|NCT01358357|Placebo Comparator|Placebo|
3077958|NCT01358526|Experimental|OXN|Oxycodone/Naloxone Controlled-release Tablets (OXN)
3077959|NCT01358526|Placebo Comparator|Placebo|Placebo tablets to match OXN
3077960|NCT01358578|Experimental|AIN457 150mg|AIN457 150mg
3077961|NCT01358578|Experimental|AIN457 300mg|AIN457 300mg
3077962|NCT01358578|Placebo Comparator|Placebo|Placebo
3077963|NCT01358578|Active Comparator|Etanercept|Etanercept
3077964|NCT01358578|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase
3077965|NCT01358578|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase
3077966|NCT01358708|Experimental|LACTEOL® 340 mg|
3077967|NCT01358708|Placebo Comparator|PLACEBO|
3077968|NCT01358721|Experimental|Arm 1: BMS-936558|
3077969|NCT01358721|Experimental|Arm 2: BMS-936558|
3077970|NCT01358721|Experimental|Arm 3: BMS-936558|
3077971|NCT01358721|Experimental|Arm 4: BMS-936558|(treatment naive)
3077972|NCT01358734|Experimental|Lenalidomide in combination with azacitidine|Repeated cycles of azacitidine 75 mg/m^2/day subcutaneous (SC) on Days 1-7 and lenalidomide 50 mg/day by mouth (PO) on Days 8-28 followed by a 14-day break plus best supportive care
3077973|NCT01358734|Experimental|Lenalidomide - single agent|Lenalidomide 50 mg PO daily for 28 days for the first 2 cycles and lenalidomide 25 mg daily for 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg daily PO plus best supportive care
3077974|NCT01358734|Experimental|Azacitidine-single agent|Repeated cycles of azacitidine 75mg/m^2/day subcutaneous on Days 1-7 followed by a 21-day break plus best supportive care
3077975|NCT01358760|Placebo Comparator|Placebo|
3077976|NCT01358760|Experimental|0.25% DHEA|
3077977|NCT01358760|Experimental|0.5% DHEA|
3077978|NCT01358825|Experimental|Infanrix hexa Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix hexa™ (DTPa-HBV-IPV/Hib) administered intramuscularly in study NCT00307034.
3077979|NCT01358825|Experimental|Infanrix-IPV/Hib Group|Subjects aged 5 years previously vaccinated at 3, 5 and 11 months of age with 3 doses of Infanrix-IPV/Hib™ (DTPa-IPV/Hib) administered intramuscularly in study NCT00307034.
3077980|NCT01358864|Active Comparator|Placebo/PegIFN/RBV|patient to receive two capsules identical to those containing BI201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
3077981|NCT01358864|Experimental|BI201335 12 weeks|patient to receive two capsules containing BI 201335 once a day for 12 weeks and PegIFN/RBV for 48 weeks
3077982|NCT01358864|Experimental|BI201335 24 weeks|patient to receive two capsules containing BI 201335 once a day for 24 weeks and PegIFN/RBV for 48 weeks
3077983|NCT01358877|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab (840 mg loading dose, then 420 mg) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg) intravenously (IV) every 3 weeks (Q3W) for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 mg/m^2 + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 once weekly (QW); 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin area under the curve (AUC) 6 (up to 900 mg).
3077984|NCT01358877|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo matching to pertuzumab IV Q3W and trastuzumab (8 milligrams per kilogram [mg/kg] loading dose, then 6 mg/kg) IV Q3W for 1 year (maximum 18 cycles) in combination with 1 of the following IV chemotherapy regimen (anthracycline-based or nonanthracycline-based) per Investigator's choice: 1) 3-4 cycles (Q3W) of 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) + epirubicin 90-120 mg/m^2 or doxorubicin 50 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W (100 mg/m^2 for 3 cycles, 75 mg/m^2 in first cycle and 100 mg/m^2 in subsequent cycles, or 75 mg/m^2 for 4 cycles) or 12 cycles of paclitaxel 80 mg/m^2 QW; 2) 4 cycles (Q3W) of doxorubicin 60 mg/m^2 or epirubicin 90-120 mg/m^2 + cyclophosphamide 500-600 mg/m^2 followed by either 3-4 cycles of docetaxel Q3W or 12 cycles of paclitaxel QW (as described in Option 1); 3) 6 cycles (Q3W) of docetaxel 75 mg/m^2 + carboplatin AUC 6 (up to 900 milligrams [mg]).
3077985|NCT01358968|Experimental|LY2603618|"Single 50 milligrams (mg) oral dose of desipramine on day 1 of study period 1. Single 275 mg intravenous infusion over one hour of LY2603618 followed by single 50 mg oral dose of desipramine on day 1 of study period 2. Participants may then receive additional doses of LY2603618 in combination as follows: 1000 milligrams per square meter (mg/m²) intravenous administration over 30 minutes of gemcitabine on days 1, 8 and 15 and 230 mg intravenous dose of LY2603618 on days 2, 9 and 16 of 28-day cycles OR 500 mg/m² intravenous administration over 10 minutes of pemetrexed on day 1 and 275 mg intravenous dose of LY2603618 on day 2 of 21-day cycles.~Participants will be allowed to continue to receive the combination therapy until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression."
3077986|NCT01358981|Experimental|LY2881835|"One cohort of healthy participants will receive single oral doses of LY2881835 in up to 3 of the 4 periods in Part A (dose escalation: 0.5 milligram (mg), 1.5 mg, subsequent doses determined based on review of safety, tolerability, glycaemic response and available pharmacokinetic (PK) data from the first 2 dose levels). One cohort of participants with Type 2 Diabetes Mellitus (T2DM) will receive single oral doses of LY2881835 in up to 2 of the 3 periods in Part B (dose escalation: starting dose based on review of safety, tolerability, glycaemic response and available PK data from Part A).~There is a washout period of at least 5 days between periods (doses)."
3077987|NCT01358981|Placebo Comparator|placebo|"One cohort of healthy participants will receive a single oral dose of placebo in 1 of the 4 periods in Part A. Another cohort of participants with T2DM will receive a single oral dose of placebo in 1 of the 3 periods in Part B.~There is a washout period of at least 5 days between periods (doses)."
3077988|NCT01359007|Experimental|FOLFIRINOX|Combination of drugs (Irinotecan, Oxaliplatin, Leucovorin, and 5-Fluorouracil (5-FU)) known as FOLFIRINOX every 2 weeks for 4 treatments. At the end of 4 cycles, patients will be re-evaluated for resectability by CT scan within 28 days of the last dose of chemo. If found amendable to surgery, patient will proceed with resection, and type of resection (R0 or R1) will be recorded.
3077989|NCT01359046|Experimental|silver SPC|Subjects randomized to receive silver-impregnated SPC.
3077990|NCT01359046|Active Comparator|standard SPC|subjects randomized to receive standard SPC.
3077991|NCT01359150|Experimental|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects).|CP-690,550 will be administered for 4 weeks, vaccines will be administered at week 4. CP-690,550 will then continue for another 5 weeks at which point the immune response will be evaluated.
3077992|NCT01359150|Placebo Comparator|Treatment Group 2:Placebo CP-690,550 (100 subjects).|Placebo will be administered for 4 weeks, vaccines will be administered at week 4. Placebo will then continue for another 5 weeks at which point the immune response will be evaluated.
3077993|NCT01359371||Peer telephone cessation counseling|The cohort is 131 veteran smokers who received the standard-of-care Tobacco Tactics intervention while in the hospital follow up volunteer peer telephone cessation counseling
3077994|NCT01359410|Active Comparator|Stapled transection with mesh reinforcement|Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)
3077995|NCT01359410|No Intervention|Stapled transection without mesh reinforcement|
3077996|NCT01359449|Experimental|Menactra® Vaccine Group|Meningococcal vaccine naive participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate vaccine (Menactra®) at 12 months of age and at 18 months of age concomitantly with routine vaccines administered as per provincial schedule
3077997|NCT01359449|Active Comparator|Menjugate® Vaccine Group|Meningococcal vaccine naive participants will receive MenC vaccine (Menjugate) given concomitantly at 12 months of age with routine vaccines administered as per provincial schedule.
3077998|NCT01359592|Active Comparator|PET Negative: R-CHOP|R-CHOP x 3 Cycles
3077999|NCT01359592|Experimental|PET Positive: IFRT +Zevalin|Standard IFRT+ Zevalin IV per ABW
3078000|NCT01359644|Experimental|Treatment A: PSI-7977 + Daclatasvir|Genotype 1a or 1b
3078001|NCT01359644|Experimental|Treatment B: PSI-7977 + Daclatasvir|Genotype 2 or 3
3078002|NCT01359644|Experimental|Treatment C: PSI-7977 + Daclatasvir|Genotype 1a or 1b
3078003|NCT01359644|Experimental|Treatment D: PSI-7977 + Daclatasvir|Genotype 2 or 3
3078004|NCT01359644|Experimental|Treatment E: PSI-7977 + Daclatasvir + Ribavirin|Genotype 1a or 1b
3078005|NCT01359644|Experimental|Treatment F: PSI-7977 + Daclatasvir+ Ribavirin|Genotype 2 or 3
3078006|NCT01359644|Experimental|Treatment G: PSI-7977 + Daclatasvir|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
3078007|NCT01359644|Experimental|Treatment H: PSI-7977 + BMS-790052 + Ribavirin|"Hepatitis C virus genotype 1, treatment-naive patients~Genotype 1a or 1b"
3078008|NCT01359644|Experimental|Treatment I: PSI-7977 + Daclatasvir|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
3078009|NCT01359644|Experimental|Treatment J: PSI-7977 + Daclatasvir + Ribavirin|"Patients who experienced telaprevir/boceprevir treatment failure~Genotype 1a or 1b"
3078010|NCT01359735|Active Comparator|HP802-247|allogeneic, growth arrested keratinocytes and fibroblasts: final concentration of 5.0 M cells/mL with a ratio of 1:9 keratinocytes:fibroblasts, applied weekly
3078011|NCT01359735|Active Comparator|Bacitracin Ointment|bacitracin antibiotic ointment
3078012|NCT01359748|Other|Wrist Size <= 14.25 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3078013|NCT01359748|Other|Wrist Size >=14.26 <16.50 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3078014|NCT01359748|Other|Wrist size >=16.5 <17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3078015|NCT01359748|Other|Wrist Size >=17.75 Cm|"Blood pressure measured using the reference sphygmomanometer.~Blood pressure measured using the Sphygmomanometer under test."
3078016|NCT01359904|Active Comparator|high dialysate bath|additive is put in the dialysate to increase the concentration of glucose to 10mmol/l
3078017|NCT01359904|No Intervention|Standard dialysate glucose concentration|Standard 5.5 mmol/L dialysate glucose concentration.
3078018|NCT01359943|Experimental|secukinumab 10 mg/kg i.v. loading|secukinumab 10mg/kg i.v. loading at Weeks 0, 2 and 4, and placebo s.c. at weeks 0, 1, 2, 3 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
3078019|NCT01359943|Experimental|secukinumab 150 mg s.c. loading|secukinumab 150mg s.c. loading at Weeks 0, 1, 2, 3 and 4, and placebo i.v. at weeks 0, 2 and 4, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 8
3078020|NCT01359943|Placebo Comparator|placebo|placebo at Weeks 0, 1, 2, 3, 4, 8 & 12, followed by secukinumab 150mg s.c. every 4 weeks starting at Week 16
3078021|NCT01359956|Experimental|A1|combination chemotherapy without interferon
3078022|NCT01359956|Experimental|A2|combination chemotherapy with interferon
3078023|NCT01359956|Active Comparator|B1|single agent dacarbazine without interferon
3078024|NCT01359956|Experimental|B2|single agent dacarbazine plus interferon
3078025|NCT01360021|Active Comparator|1 Symbicort/inhaler|Symbicort BA MDI 2x160/4.5 μg twice daily
3078026|NCT01360021|Active Comparator|Symbicort/inhaler|Symbicort AC pDMI 2x160/4.5 μg twice daily
3078027|NCT01360021|Active Comparator|Budesonide/inhaler|Budesonide AC pMDI 2x160 μg twice daily
3078028|NCT01360229|Sham Comparator|Randomized Subjects receive a sham acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
3078029|NCT01360229|Active Comparator|Randomized Subjects receive real acupuncture.|Subjects will be randomized in a 1:1 ratio to receive either real or sham acupuncture.
3078030|NCT01360398|Other|Cohort|COPD male and female patients between 40 and 85 years of age, recruited among the patients of the Southampton General Hospital and referring practices.
3078031|NCT01360450|Experimental|Treatment|Interventions: Infants will receive intravenous or oral clonidine(Duraclon) for the treatment of pain and sedation: Duration: (Clonidine HCL) 1 mcg/kg/dose q4 either iv or po.
3078032|NCT01360450|Placebo Comparator|Control|Intervention: Infants will receive place (saline) (if receiving it IV) or orally (sterile water) if receiving it orally
3078033|NCT01360554|Experimental|A|Blinded active PF-00299804 + blinded placebo comparator (erlotinib)
3078034|NCT01360554|Active Comparator|B|Blinded active comparator (erlotinib) + blinded placebo PF-00299804
3078035|NCT01360632|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
3078036|NCT01360632|Placebo Comparator|Phase A|Drug: Placebo + ADT
3078037|NCT01360645|Experimental|Phase B|"Drug: OPC-34712 + ADT~Drug: Placebo + ADT"
3078038|NCT01360645|Placebo Comparator|Phase A|Intervention: Drug: Placebo + ADT
3078039|NCT01360762|Experimental|Pentamidine Secondary Prophylaxis (PSP)|"Patients with co-infection of human immunodeficiency virus (HIV)and visceral leishmaniosis (VL), having being treated for VL, are allocated to pentamidine secondary prophylaxis, to prevent VL relapses. The treatment period is of 12 months, plus an extended treatment period of 0 to 6 months depending on the immunosuppression status, plus 12 months follow-up after the extended treatment period."
3078040|NCT01360840|Placebo Comparator|Placebo + Standard of care (SoC)|
3078041|NCT01360840|Experimental|EMD 525797 750 mg + SoC|
3078042|NCT01360840|Experimental|EMD 525797 1500 mg + SoC|
3078043|NCT01360866|Experimental|OPC-34712 (Brexpiprazole) and Escitalopram|OPC-34712: Oral tablet; 0.5 to 3 mg/day Escitalopram: Oral tablet; 10 or 20 mg/day
3078044|NCT01360866|Experimental|OPC-34712 and Fluoxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Fluoxetine: Oral capsules; 20 or 40 mg/day
3078045|NCT01360866|Experimental|OPC-34712 and Paroxetine CR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Paroxetine CR: Oral controlled-release tablets; 37.5 or 50 mg/day
3078046|NCT01360866|Experimental|OPC-34712 and Sertraline|OPC-34712: Oral tablet; 0.5 to 3 mg/day Sertraline: Oral tablets; 100, 150, or 200 mg/day
3078047|NCT01360866|Experimental|OPC-34712 and Duloxetine|OPC-34712: Oral tablet; 0.5 to 3 mg/day Duloxetine: Oral delayed-release capsules; 40 or 60 mg/day
3078048|NCT01360866|Experimental|OPC-34712 and Venlafaxine XR|OPC-34712: Oral tablet; 0.5 to 3 mg/day Venlafaxine XR: Oral extended-release capsules; 75, 150, or 225 mg/day
3078049|NCT01360996|Experimental|3 mg DRSP/20 μg EE--normal weight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~Normal weight -BMI 18-24.9 kg/ m2"
3078050|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Overweight|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 25-29.9 kg/ m2"
3078051|NCT01360996|Experimental|3 mg DRSP/20 μg EE- Grade 1 obese|"Folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive~BMI 30-34.9 kg/ m2"
3078052|NCT01361009||pramipexole group|It's a open-label, non-intervention,observation post marketing surveillance to observe the safety and efficacy of pramipexole in real world.
3078053|NCT01361048|Active Comparator|oral metronidazole|control arm
3078054|NCT01361048|Experimental|neo penotran forte|neo penotran forte vaginal suppository twice a day for 7 days
3078055|NCT01361048|Experimental|neo penotran forte once a day|neo penotran forte vaginal suppository once a day for 7 days
3078056|NCT01361113|Other|Single Arm Neoadjuvant Pazopanib|Pazopanib 800 mg PO once daily for 8 weeks
3078057|NCT01361126|Experimental|On-demand|The routine prophylactic therapy interval is targeted at every 7 days.
3078058|NCT01361126|Experimental|Prophylactic|On-demand subjects will receive rIX-FP only for the treatment of a bleeding episode.
3078059|NCT01361178|No Intervention|Transplant patients who do not receive SQ IVIG|Patients participating in the observational arm of the study who do not need to receive IgG replacement.
3078060|NCT01361178|Active Comparator|Transplant patients who receive SQ IVIG|Patients participating in the observational arm of the study who are randomized to receive a dosage of SQ IVIG due to low IgG level.
3078061|NCT01361217|Experimental|Fluoxetine DDI|Only arm in the study. Successive Control (Study Days 1 and 3) and fluoxetine multiple-dose treatment (Study Days 16 and 18) Sessions.
3078062|NCT01361308|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate)
3078063|NCT01361308|Placebo Comparator|Placebo Capsules|Placebo Capsules
3078064|NCT01361464|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib orally twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3078065|NCT01361568|Experimental|CR845|Peripheral kappa opioid receptor agonist
3078066|NCT01361568|Placebo Comparator|Placebo|Matched Placebo
3078067|NCT01361594|Active Comparator|Intensive insulin treatment|Intensive insulin treatment (BG target: 100-140 mg/dL)
3078068|NCT01361594|Active Comparator|Conventional insulin treatment|Conventional insulin treatment (BG target: 141-180 mg/dl)
3078069|NCT01361607|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligram [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3078070|NCT01361607|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
3078071|NCT01361620|Other|Aspirin|All subjects took 7-10 days of 81 mg aspirin
3078072|NCT01361633|Experimental|Medication|250 mg d-cycloserine
3078073|NCT01361633|Placebo Comparator|Sugar Pill|
3078074|NCT01361711|Experimental|Treatment (monoclonal antibody therapy)|Patients receive alemtuzumab SC three times a week in weeks 1-18 and ofatumumab IV over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and 17.
3078075|NCT01361854|Experimental|polysomnography for suspicion of SDB|adults, suspects of suffering from sleep disordered-breathing, who must undergo a diagnostic polysomnography
3078076|NCT01361867|Other|Robot-induced perturbations|The subject walks on a treadmill with his/her legs strapped to a robotic system (Lokomat by Hocoma AG) that generates mechanical perturbations aimed to modify the subject's walking pattern.
3078077|NCT01361919|Experimental|Feedback During CPR Training and Testing|"A feedback defibrillator (ZOLL R series) will be used at teaching, immediate testing and 12 week (retention) testing. A simulation manikin with an attached accelerometer pad on its sternum will be used to collect CPR performance data. Subjects will be told to perform compressions on top of the accelerometer pad and will be taught to use and follow the audio and visual feedback to optimize their CPR performance. After training, the raw data collected by the accelerometer will be used as a demonstration and training tool, to correct the subjects' performance by visually demonstrating the difference between ideal and suboptimal CPR performance. Testing will be carried out with the use of a feedback defibrillator."
3078078|NCT01361919|Active Comparator|Feedback during CPR Training Not Testing|"A feedback defibrillator will be used for teaching, with a standard no feedback defibrillator used at immediate and 12 week (retention) testing to assess if the techniques the students' learned during training are transferable to devices without feedback. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest."
3321060|NCT02015806|No Intervention|Only depression meds, ≥1 med >1 daily use, control|Individuals who are taking only antidepressants and who are suboptimally adherent to these therapies, who have at least one medication that is intended for use more than once daily, and who are randomized to continue with usual care.
3078079|NCT01361919|Placebo Comparator|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
3078080|NCT01362049|Active Comparator|'Eligible' Subject Group - STAB|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
3078081|NCT01362049|Active Comparator|'Ineligible' Subject Group - STAB|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
3078082|NCT01362049|Active Comparator|'Eligible' Subject Group - MSI|"Subjects between the ages of 21-55 years with low back pain >12 months who are eligible for Treatment-Based Classification (TBC) stabilization exercises based on current criteria:~straight leg raise > 90 degrees~aberrant trunk movement with trunk forward flexion~positive prone instability test AND/OR~passive lumbar mobility testing that is judged to be hypermobile at any level."
3078083|NCT01362049|Active Comparator|'Ineligible' Subject Group -MSI|Subjects between the ages of 21-55 years with low back pain >12 months who are not eligible for the TBC-based stabilization exercises based on current criteria
3078084|NCT01362062||RA Cohort|Participants with active RA who had an inadequate clinical response to current non-biologic disease modifying anti-rheumatoid drug (DMARD) and/or anti-tumor necrosis factor (anti-TNF) therapy being treated with tocilizumab according to the routine clinical practice and in line with prescribing information will be observed for a total duration of 12 months.
3078085|NCT01362127|Active Comparator|Radiochemotherapy|Arm I: Radiochemotherapy + Surgery
3078086|NCT01362127|Active Comparator|Chemotherapy|Arm II: Chemotherapy + surgery
3078087|NCT01362140|Experimental|Darbepoetin alfa|Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
3078088|NCT01362140|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
3078089|NCT01362192|Other|532 nm KTP Laser Treatment|
3078090|NCT01362205|Experimental|Dexmedetomidine|Dexmedetomidine titrated to achieve predefined goals on selected components of the MINDS score using the minimum amount of medication possible. Blinded study medication will be started at a rate determined by the MINDS score. The maximum infusion rate is 1.4 μg/kg per hour. Uncontrolled SAWS/D symptoms, will be treated with open label lorazepam according to the MINDS score algorithm. Persistent SAWS/D symptoms despite maximum infusion rate of study medication treatment limiting symptoms while receiving higher infusion rates of study medication, ancillary therapies will be administered according to the MINDS score algorithm, at the discretion of the treating physician.
3078091|NCT01362205|Placebo Comparator|Placebo|Blinded placebo study drug administration in equal volume per hour as active study medication arm.
3078092|NCT01362244|Experimental|Treatment Periods 1-8|Part A comprises eight outpatient visits (Visits 1 - 8). For six of these visits, subjects will receive a dose of either 750 mg mepolizumab or placebo. Dosing occurs in four week intervals. Assessment for entry into Part B will take place at the last visit in Part A (Visit 8). Subjects not eligible for Part B will have study exit procedures performed and be discontinued.
3078093|NCT01362244|Other|Run In period|10-14 day run in period to assess the patients suitability for entry into Part A of the trial.
3078094|NCT01362244|No Intervention|Treatment periods 9-13|Subjects eligible for Part B will attend the clinic for up to 5 more outpatient visits (Visits 9 - 13) for assessments. Visits occur every four weeks. There is no dosing in Part B. At the point when each subject meets Study Exit criteria, study exit procedures will be performed and the subject will exit the study.
3078095|NCT01362270|Experimental|Verum Acupuncture|Subjects will receive acupuncture using real acupuncture needles.
3078096|NCT01362270|Sham Comparator|Sham acupuncture|Subjects will receive sham acupuncture therapy using the Streitberger needle at the same points and on the same schedule as patients in the treatment group. Streitberger needles are blunt tipped and retract into themselves rather than penetrating the skin.
3078097|NCT01362296|Experimental|GSK1120212|Oral once daily
3078098|NCT01362296|Active Comparator|docetaxel|IV once every 3 weeks
3078099|NCT01362322|Experimental|BOOSTRIX NEW GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
3078100|NCT01362322|Active Comparator|BOOSTRIX PREV GROUP|Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.
3078101|NCT01362348|Experimental|pazopanib eye drops|pazopanib topical ocular administration
3078102|NCT01362439|Experimental|Paliperidone ER|
3078103|NCT01362491|Experimental|Treatment A|
3078104|NCT01362491|Active Comparator|Treatment B|
3078105|NCT01362491|Placebo Comparator|Treatment C|
3078106|NCT01362517|Experimental|Quinvaxem|
3078107|NCT01362530|Experimental|Aprepitant Regimen|"Cycle 1:~Participants 12 to 17 years of age, Day 1: aprepitant 125 mg capsule orally (PO) + ondansetron, Days 2 to 3: aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: aprepitant powder for suspension (PFS), 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: aprepitant PFS, 2.0 mg/kg (up to 80 mg).~Optional Cycles 2-6:~Open-label aprepitant administered in the same manner as in Cycle 1."
3321061|NCT02015832||Percutaneous Coronary Intervention|All patients (single arm study) will be receiving the SYNERGY™ Everolimus eluting stent (EES)
3321062|NCT02015845|Experimental|Accuvein|Use of Accuvein to facilitate placement of peripheral intravenous catheters in obese patients
3078108|NCT01362530|Placebo Comparator|Control Regimen|Cycle 1: Participants 12 to 17 years of age, Day 1: matching placebo for aprepitant 125 mg capsule oral (PO) + ondansetron Days 2 to 3: matching placebo for aprepitant 80 mg capsule PO. Participants 6 months to <12 years of age, Day 1: matching placebo PFS: 3.0 mg/kg (up to 125 mg) + ondansetron, Days 2 to 3: matching placebo PFS: 2.0 mg/kg (up to 80 mg). Optional Cycles 2-6: Open-label aprepitant administered in the same manner as in Cycle 1.
3078109|NCT01362608|Experimental|Canakinumab and placebo matching to triamcinolone acetonide|ACZ885H
3078110|NCT01362608|Active Comparator|Triamcinolone acetonide 40 mg|ACZ885H
3078111|NCT01362686|Experimental|Donepezil|See intervention note.
3078112|NCT01362686|Experimental|Galantamine|See intervention note.
3078113|NCT01362686|Experimental|Rivastigmine|See intervention note.
3078114|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg days 10, 12, and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
3078115|NCT01362790|Experimental|Mesothelioma Pilot Phase Regimen B|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle Regimen B: Cycle 1: 4 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1 (dsFv)PE38 Regimen B: Cycle 1: 35mcg/kg days 18, 20, and 22. Cycles 2-4: (Days 6, 8, and 10), for a maximum of six treatment cycles."
3078116|NCT01362790|Experimental|Phase 2 Peritoneal Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5 and 9 of 38 day cycle Cycles 2-6: 4 mg/m^2 on day 1 and 5 of 25 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen B: Cycle 1: 35 mcg/kg or 25 mcg/kg days 18, 20 and 22. Cycles 2-4: Days 6, 8, and 10, for a maximum of six treatment cycles."
3078117|NCT01362790|Experimental|Phase 2 Pleural Mesothelioma Pilot Expansion Phase|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
3078118|NCT01362790|Experimental|Mesothelioma Positive Ca Dose De-escalation Pilot Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
3078119|NCT01362790|Experimental|Phase 2 Pancreatic Adenocarcinoma Pilot Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
3078120|NCT01362790|Experimental|Phase 2 Lung Adenocarcinoma Pilot Expansion Phase Regimen A|"Drug: Pentostatin Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle~Other Names:~• Nipent Drug: Cyclophosphamide Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle~Other Names:~• Cytoxan Drug: SS1(dsFv)PE38 Regimen A: Cycle 1: 35 mcg/kg or 25 mcg/kg days 10, 12 and 14. Cycles 2-4: Days 2, 4, and 6, for a maximum of six treatment cycles."
3078121|NCT01362894|Other|nelfilcon A / etafilcon A|Nelfilcon A lenses worn first, with etafilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3078122|NCT01362894|Other|etafilcon A / nelfilcon A|Etafilcon A lenses worn first, with nelfilcon A lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3078123|NCT01362907|Other|Delefilcon A / etafilcon A|Delefilcon A contact lenses worn first, with etafilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3078124|NCT01362907|Other|Etafilcon A / delefilcon A|Etafilcon A contact lenses worn first, with delefilcon A contact lenses worn second. Both products worn bilaterally on a daily wear, daily disposable basis for one week each.
3078125|NCT01362946|Experimental|Reward-Emphasized treatment|This treatment consisted of behavior therapy modified to match the unique learning styles of children with CPCU. This was accomplished by emphasizing rewards and de-emphasizing punishments. This treatment was administered using a summer treatment program.
3078126|NCT01362946|Active Comparator|Standard treatment|This treatment consisted of standard behavior therapy, in which reward and punishment components were used in a balanced manner, as is typically done in outpatient settings. This treatment was administered using a summer treatment program.
3078127|NCT01362959|Experimental|Nicotine patch|
3078128|NCT01362959|Placebo Comparator|Control patch|The control product is a look-alike patch compared to the test product, containing no nicotine or other active substances.
3078129|NCT01363011|Experimental|E/C/F/TDF (Cohort 1)|"Participants who have not received prior antiretroviral (ARV) treatment and who are virologically unsuppressed at baseline will initiate treatment with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) single-tablet regimen (STR) for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of E/C/F/TDF was received in the applicable country."
3321063|NCT02015845|Active Comparator|Routine technique|Routine technique used to insert a peripheral intravenous catheters in obese patients.
3321064|NCT02015858||Epidural analgesia|Postoperative patients with epidural analgesia
3078130|NCT01363011|Experimental|COBI+PI+2 NRTI (Cohort 2)|"Participants who have received prior ARV treatment and who are virologically suppressed at baseline will continue their treatment regimen, switching the regimen's pharmacoenhancer component from ritonavir to cobicistat (COBI), and continuing their existing protease inhibitor (PI; either atazanavir (ATV) or darunavir (DRV)) plus 2 nucleoside reverse transcriptase inhibitor (NRTI) regimen for up to 96 weeks.~Following Week 96, participants continued their treatment until all participants discontinued from the study or commercial approval of cobicistat was received in the applicable country."
3078131|NCT01363050|Experimental|Ketorolac tromethamine|
3078132|NCT01363076|Experimental|Ketorolac Tromethamine (15 mg)|Ketorolac Tromethamine - single dose (15 mg) administered intranasally (IN) for subjects weighing <50 kg.
3078133|NCT01363076|Experimental|Ketorolac Tromethamine (30 mg)|Ketorolac Tromethamine - single dose (30 mg) administered intranasally (IN) for subjects weighing ≥50 kg.
3078134|NCT01363128|Experimental|Treatment (hyper-CVAD, ofatumumab)|"COURSES 1, 3, 5, 7: Patients receive hyper-CVAD comprising cyclophosphamide IV over 3 hours every 12 hours on days 1-3; doxorubicin hydrochloride IV over 24 hours on day 4; vincristine sulfate IV over 15 minutes on days 4 and 11; and dexamethasone IV over 30 minutes or PO QD on days 1-4 and 11-14. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 11 of courses 1 and 3.~COURSES 2, 4, 6, 8: Patients receive high-dose methotrexate IV over 2 hours and then over 22 hours on day 1 and cytarabine IV over 2 hours every 12 hours on days 2-3. Patients also receive ofatumumab IV over 4-6 hours on days 1 and 8 of courses 2 and 4.~Treatment repeats every 21-28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive maintenance therapy for an additional 30 months."
3078135|NCT01363258|Experimental|Care-resistant mouth care (MOUTh)|These nursing home residents with dementia receive mouth care from study personnel who use strategies to reduce care-resistant behavior (Managing Oral Hygiene Using Threat Reduction or MOUTh) while providing evidence-based mouth care.
3078136|NCT01363258|Active Comparator|Evidence Base Mouth Care|Nursing home residents with dementia received mouth care from study personnel who were trained in evidence-based mouth care only.
3078137|NCT01363297|Experimental|Inotuzumab Ozogamicin|
3078138|NCT01363349|Experimental|CYP-1020|Dose titration 15-35mg/day for 6 months
3078139|NCT01363349|Active Comparator|Risperidone|Dose titration 2-6mg/day for 6 months
3078140|NCT01363388|Placebo Comparator|Placebo|
3078141|NCT01363388|Experimental|CCX168|Active study medication
3078142|NCT01363401|Experimental|Test group|Treatment group with HYNR-CS inj.
3078143|NCT01363401|Experimental|Control group|No treatment with HYNR-CS inj.
3078144|NCT01363440|Active Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants received macular laser treatment at baseline and as-needed at visits at which laser re-treatment criteria were met, but no more frequently than every 12 weeks.
3078145|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks.
3078146|NCT01363440|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q8|Participants received 2mg Intravitreal aflibercept injection (IAI) every 4 weeks for 5 visits followed by injections every 8 weeks.
3078147|NCT01363479|Experimental|Oral palonosteron plus dexamethasone|Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3078148|NCT01363479|Active Comparator|I.V. palonosetron plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3078149|NCT01363492|Experimental|Replagal 0.2 mg/kg every other week (EOW)|
3078150|NCT01363661|Experimental|Molsidomine|Coruno (molsidomine 16 mg tablet; per os; once daily)
3078151|NCT01363661|Placebo Comparator|Placebo|Placebo (16 mg tablet; once a day)
3078152|NCT01363700|Experimental|1|
3078153|NCT01363700|Placebo Comparator|2|
3078154|NCT01363700|Active Comparator|3|
3078155|NCT01363713|Experimental|1|
3078156|NCT01363765|Experimental|Xpert MTB/Rif|Sputum specimens arriving during intervention period will be submitted to this technology, a real-time automated polymerase chain reaction test
3078157|NCT01363765|Active Comparator|Sputum smear|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining
3078158|NCT01363843|Experimental|treatment|"Induction therapy - Modified FOLFOX6 - Oxaliplatin 85 mg/m2 + Leucovorin 400 mg/m2 IV, followed by 5-FU 400 mg/m2 IV, followed 5-FU 2400 mg/m2 IV by continuous infusion over 46 hours - Repeat q14 days x 8 cycles~Concurrent Chemoradiation~50.4 Gy Radiation in 28 fractions (45 Gy IMRT, 5.4 Gy 3D conformal boost)~Surgery"
3078159|NCT01363908|Experimental|SPD602 (26 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks
3078160|NCT01363908|Experimental|SPD602 (36 mg/kg)|Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.
3078161|NCT01363908|Experimental|SPD602 (16 mg/kg)|A single dose given in the initial pharmacokinetic phase.
3078162|NCT01363986|Experimental|Trastuzumab Monotherapy|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.), followed by weekly doses of 2 mg/kg i.v. for up to 18 weeks.
3078163|NCT01363999|Experimental|A|RO5317116/F01 bilayer tablet
3078164|NCT01363999|Experimental|B|RO5317116/F03 bilayer tablet
3078165|NCT01363999|Experimental|C|RO5317116/F04 active-coated tablet
3078166|NCT01363999|Experimental|D|RO4607381/F49 tablet
3078167|NCT01364090|Active Comparator|Standard Treatment Duration (24 weeks)|Subjects with detectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 24 and follow-up for an additional 24 weeks following treatment completion (48 weeks in total).
3078168|NCT01364090|Experimental|Shortened Treatment Duration (12 Weeks)|Subjects with undetectable HCV RNA after four weeks of therapy will continue on PEG-IFN and ribavirin until week 12 and follow-up for an additional 24 weeks following treatment completion (36 weeks in total).
3078169|NCT01364207|Experimental|Caffeinated Coffee 1st Visit, Decaffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of caffeinated coffee on their first visit and 8 oz cup of decaffeinated coffee on their second visit.
3078170|NCT01364207|Experimental|Decaffeinated Coffee 1st Visit, Caffeinated Coffee 2nd Visit|Participants will be given an 8 oz cup of decaffeinated coffee on their first visit and 8 oz cup of caffeinated coffee on their second visit.
3078171|NCT01364233|Other|MotifMesh|Condensed polytetrafluoroethylene (cPTFE, MotifMESH) mesh
3078172|NCT01364259|Placebo Comparator|Placebo|Placebo and SRS
3078173|NCT01364259|Experimental|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
3078174|NCT01364298|Experimental|Gabapentin/B-complex|
3078175|NCT01364298|Active Comparator|Pregabalin|
3078176|NCT01364389|Experimental|ACZ885|On day 1, patients received a single intravenous dose of ACZ885 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of ACZ885 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
3078177|NCT01364389|Experimental|AIN457|On day 1, patients received a single intravenous dose of AIN457 3mg/kg along with a placebo intravenous infusion in a double dummy manner to maintain the blind. On day 15, partial and complete responders continued in the open label phase of this treatment arm where they were eligible to receive one re-dose of AIN457 upon confirmed disease flare. Non-responders started a 20 mg dose cycle of prednisone or prednisolone followed by standard steroid tapering.
3078178|NCT01364389|Other|Prednisone|On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
3078179|NCT01364428|Experimental|IDeg 200 U/mL|
3078180|NCT01364428|Experimental|IDeg 100 U/mL|
3078181|NCT01364467|Placebo Comparator|Placebo|Placebo is provided by the sponsor and is identical in composition to the treatment only lacking active drug.
3078182|NCT01364467|Active Comparator|Guaifenesin|
3078183|NCT01364558|Experimental|Diazepam Nasal Spray Suspension|Diazepam Nasal Suspension - 10 mg
3078184|NCT01364558|Experimental|Diazepam Nasal Spray Solution|Diazepam Nasal Spray Solution - 10 mg
3078185|NCT01364558|Active Comparator|Diazepam injection|Diazepam injection IV - 5 mg
3078186|NCT01364584|Experimental|Exenatide|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of exenatide for 2.5 months
3078187|NCT01364584|Placebo Comparator|Placebo|Pre-dosed inject-able pen (an automatic device which injects under the skin) 10 mcg twice a day of placebo for 2.5 months
3078188|NCT01364623|Experimental|Low dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)
3078189|NCT01364623|Experimental|Medium dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)
3078190|NCT01364623|Experimental|High dose TBS-2 single dose|TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)
3078191|NCT01364623|Experimental|Medium dose TBS-2 multiple doses|TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)
3078192|NCT01364649|Experimental|Vortioxetine|Vortioxetine 10 mg, tablets, orally, once daily for 1 week, then dose adjustment to a maximum 20 mg, tablets, orally, once daily for up to 7 weeks. At week 8, vortioxetine placebo-matching capsules, orally, once daily for 1 week only.
3078193|NCT01364649|Active Comparator|Escitalopram|Escitalopram 10 mg, tablets, orally, once daily for 1 week, then escitalopram dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks. At week 8, escitalopram 10 mg, capsules, capsules, orally, once daily for 1 week only.
3078194|NCT01364727|Experimental|Amrubicin|Amrubicin 35mg/m2 IV days 1-3 every 3 weeks
3078195|NCT01364740|Experimental|PMP-300E, In-Lab PSG|PMP-300E, A 7-channel (nasal pressure, effort, snoring, SpO2, pulse rate, body position and movement) Level 3 portable monitor (11.2 x 3.3 x 5.5cm, 80g, Pacific Medico Co., LTD) to measure sleep-related breathing will be tested against conventional gold-standard In-Lab Polysomnography (sleep study)
3078196|NCT01364870|Active Comparator|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
3078197|NCT01364870|Placebo Comparator|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
3078198|NCT01364870|No Intervention|Standard Care|"Subjects randomized to Standard Care will be given no TENS unit."
3078199|NCT01364896||Inflammatory bowel disease, Immunosuppressive agent|Men and women 18 years + with a histological diagnosis of IBD (ulcerative colitis or Crohn's disease) who are undergoing a colonoscopy prior to starting a non-corticosteroid immunosuppressive agent
3078200|NCT01364922|Experimental|Open-label Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 2 tablets twice daily
3078201|NCT01364922|Experimental|Double-blind Hydrocodone/Acetaminophen Extended Release|Hydrocodone/acetaminophen extended release, 1 tablet twice daily
3078202|NCT01364922|Placebo Comparator|Double-blind Placebo|Placebo, 1 tablet twice daily
3078203|NCT01365039|Experimental|Test lens|Test contact lens will be worn on a daily disposable wear basis.
3078204|NCT01365039|Active Comparator|SofLens lens|The currently marketed Bausch + Lomb SofLens daily disposable contact lens. Worn on a daily disposable wear basis.
3078205|NCT01365052|Experimental|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|
3078206|NCT01365052|Placebo Comparator|Placebo|
3078207|NCT01365091|Experimental|Arm 1: Treatments A,B/B,A|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC) in the fasted state (Treatment A), followed by a washout period of at least 7 days. Then, participants received single oral doses of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg, tablets together in the fasted state (Treatment B). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5-mg and metformin XR, 500-mg tablets together in the fasted state (Treatment B), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fasted state (Treatment A)."
3078208|NCT01365091|Experimental|Arm 2: Treatments C,D/D,C|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg fixed-dose combination (FDC), in the fed state (Treatment C), followed by a washout period of at least 7 days. Then, participants received a single oral dose of saxagliptin, 5-mg, and metformin extended-release (XR), 500-mg tablets together in the fed state (Treatment D). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metforminXR, 500-mg tablets together in the fed state (Treatment D), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 500 mg FDC, in the fed state (Treatment C)."
3078209|NCT01365091|Experimental|Arm 3: Treatments E, F/F,E|"Period 1: Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fasted state (Treatment E), followed by a washout period of at least 7 days. Participants received single oral doses of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fasted state (Treatment F). Followed by a washout period of at least 4 days.~Period 2: Participants received single oral doses of saxagliptin, 5- mg and metformin XR, 1000-mg tablets together in the fasted state (Treatment F), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fasted state (Treatment E)."
3078210|NCT01365091|Experimental|Arm 4: Treatments G,H/H,G|"Period 1: Participants received a single oral dose of saxagliptin , 5 mg/metformin, 1000 mg fixed-dose combination (FDC), in the fed state (Treatment G), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5-mg and metformin extended-release (XR), 1000-mg tablets together in the fed state (Treatment H). Followed by a washout period of at least 4 days.~Period 2: Participants received a single oral dose of saxagliptin, 5-mg and metformin XR, 1000-mg tablets together in the fed state (Treatment H), followed by a washout period of at least 7 days. Participants received a single oral dose of saxagliptin, 5 mg/metformin, 1000 mg FDC, in the fed state (Treatment G)."
3078211|NCT01365130|Experimental|real drug|patients will receive Jevtana 25mg/m2, IV every 21 days until disease progression or unacceptable toxicity
3078212|NCT01365273|No Intervention|Bridal Veil together with staples|Standard of care. Bridal Veil is fixed over the graft with staples.
3078213|NCT01365273|Active Comparator|Mepitel One|Device, dressing
3078214|NCT01365455|Experimental|AIN457 150 mg|AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
3078215|NCT01365455|Experimental|AIN457 300 mg|AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week
3078216|NCT01365455|Placebo Comparator|placebo|placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3078217|NCT01365455|Experimental|AIN457 150mg from Placebo|Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3078218|NCT01365455|Experimental|AIN457 300mg from Placebo|Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.
3078219|NCT01365468|Experimental|Everolimus (RAD001)|enrolled patients received everolimus (RAD001) in an open label manner. Recommended starting dose of everolimus depend on body surface area, starting from 2.5 mg once daily to 7.5 mg once daily.
3078220|NCT01365481|Experimental|valsartan|Valsartan starting dose: ≥18 kg to <35 kg is 40 mg, ≥35 kg to <80 kg is 80 mg, ≥80 kg to ≤160 kg is 160 mg for 1 week then Valsartan maintenance dose: ≥18 kg to <35 kg is 80 mg, ≥35 kg to <80 kg is 160 mg, ≥80 kg to ≤160 kg is 320 mg after Week 8 if the Mean Sitting Systolic Blood Pressure (MSSBP) and/or Mean Sitting Diastolic Blood Pressure (MSDBP) was higher than 95th percentile for age, gender and height under the maintenance valsartan dose then add amlodipine and/or Hydrochlorothiazide (HCTZ). The valsartan +antihypertensive group includes patients who received background antihypertensive medication or received antihypertensive medication including amlodipine or HCTZ during the study.
3078221|NCT01365494|Active Comparator|Group A-Zagreb|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered intramuscularly (IM) according to the 2-1-1 (Zagreb) schedule (i.e., 2 doses of vaccine administered on day 0 and 1 dose of vaccine each administered on day 7 and day 21)
3078222|NCT01365494|Active Comparator|Group B-Essen|Purified Chick Embryo Cell Inactivated Rabies Vaccine, administered IM according to the 1-1-1-1-1 (Essen) schedule (i.e., 1 dose of vaccine administered on day 0, 3, 7, 14, and 28)
3078223|NCT01365507|Experimental|IDegAsp Simple|
3078224|NCT01365507|Experimental|IDegAsp Step wise|
3078225|NCT01365546|Experimental|human VWF/FVIII concentrate|
3078226|NCT01365585||Sildenafil ≥20mg three times daily|Subjects receiving sildenafil ≥20mg three times daily for the treatment of PAH
3078227|NCT01365611|Experimental|Ketorolac tromethamine|
3078228|NCT01365624|Experimental|Ketorolac tromethamine|
3078229|NCT01365650|Experimental|Ketorolac Tromethamine|
3078230|NCT01365650|Experimental|Oxymetazoline Hydrochloride|
3078231|NCT01365650|Experimental|Fluticasone Propionate|
3078232|NCT01365793|Experimental|Rapid rehydration using 0.45% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.45% saline will be used as the replacement fluid for this arm.
3078233|NCT01365793|Experimental|Rapid rehydration using 0.9% saline replacement fluid|This arm will involve more rapid intravenous fluid treatment which will include a second 10cc/Kg bolus of 0.9% saline and assume a 10% fluid deficit. 0.9% saline will be used as the replacement fluid.
3078234|NCT01365793|Experimental|Slower rehydration using 0.45% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fluid bolus) with 0.45% saline used as the replacement fluid.
3078235|NCT01365793|Experimental|Slower rehydration using 0.9% saline intravenous fluid|This arm will involve slower rehydration (assumed 5% fluid deficit and no additional fuid bolus) with 0.9% saline used as the replacement fluid.
3078236|NCT01365819|Placebo Comparator|Sugar pill|Placebo
3078237|NCT01365819|Experimental|Varenicline|Varenicline (Chantix (R))
3078238|NCT01365845|Active Comparator|1|Conventional photon plan
3078239|NCT01365845|Experimental|2|3D-Proton/Conventional plan or 3D-proton only
3078240|NCT01365910|Experimental|Treatment (enzyme inhibitor)|Patients receive linifanib PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3078241|NCT01366092|Experimental|Interleukin-2|Each study participant will receive daily subcutaneous IL-2 (1 x 106 IU/m2/day) for self-administration for 12 weeks, followed by a 4-week hiatus. IL-2 will be typically administered on an outpatient basis. After completing the 16 week study (12 weeks of IL-2 study treatment and a mandatory 4 weeks off-IL-2), patients experiencing clinical benefit (complete or partial response; as well as minor response not meeting NIH criteria for partial response) with an acceptable toxicity profile will be permitted to continue extended-duration treatment indefinitely at the discretion of the treating physician.
3078242|NCT01366196|Placebo Comparator|Control Group (C)|Patients in the control group will receive a placebo tablet with a sip of water one hour prior to surgery and a placebo tablet twice a day for a total of two weeks.
3078243|NCT01366196|Experimental|Pregabalin Group (P)|Patients in the treatment group will receive 150 mg of pregabalin with a sip of water one hour prior to surgery, and then 150 mg daily (75 mg BID) for a total of two weeks.
3078244|NCT01366209|Active Comparator|Active Arm|
3078245|NCT01366209|Placebo Comparator|Placebo Arm|
3078246|NCT01366443||women pregnant|Healthy pregnant women between 15 or greater weeks gestation reporting with signs or symptoms of rupture of membranes.
3078247|NCT01366495|Experimental|On-site Rapid HIV Testing|On-site rapid testing conducted by research staff co-located for the purposes of this study at the probation/parole office.
3078248|NCT01366495|No Intervention|Off-site Referral for HIV Testing|Off-site referral for rapid HIV testing at a community health center or HIV testing clinic
3078249|NCT01366495|Experimental|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
3078250|NCT01366495|No Intervention|Treatment as Usual|Passive referral to HIV community treatment provider.
3078251|NCT01366521|Experimental|Mepolizumab 250 mg subcutaneous (SC)|250 mg subcutaneous (SC)
3078252|NCT01366521|Experimental|Mepolizumab 125 mg subcutaneous (SC)|125 mg subcutaneous (SC)
3078253|NCT01366521|Experimental|Mepolizumab 12.5 mg subcutaneous (SC)|12.5 mg subcutaneous (SC)
3078254|NCT01366521|Experimental|Mepolizimab 75 mg intravenously (I.V.)|75 mg intravenously (I.V.)
3078255|NCT01366534|Experimental|Ad35.CS.01 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered one dose of Ad35.CS.01 vaccine at Month 0, and 2 doses of GSK257049 at Months 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
3078256|NCT01366534|Experimental|GSK257049 Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were administered 3 doses of GSK257049 vaccine at Months 0, 1 and 2 intramuscularly in the deltoid of the non-dominant arm. The duration of the study was approximately 11 months for vaccinated subjects.
3078257|NCT01366534|Experimental|Control Group|Healthy male or non-pregnant female subjects, aged 18 to 50 years, were volunteers who did not receive any immunization but were subjected to the sporozoite challenge. The duration of the study was approximately 8 months for infectivity control subjects.
3078258|NCT01366638|Experimental|Treatment-Naive: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks), followed by PR until Week 24 or Week 48. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3078259|NCT01366638|Experimental|Prior Relapser: TMC435 100 mg 12 Wks+PR 24/48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 24. Treatment will be stopped at Week 24 in participants who achieve plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels <1.2 log10 IU/mL detectable or undetectable at Week 4, and undetectable plasma HCV RNA levels at Week 12. All other participants will continue PR until Week 48.
3078260|NCT01366638|Experimental|Prior Non-Responder: TMC435 100 mg 12 Wks+PR 48|Participants will receive TMC435 100 mg once daily with PegIFNa-2b and ribavirin (PR) for 12 weeks (Wks) followed by PR until Week 48.
3078261|NCT01366846|Experimental|Peanut avoidance after continuous peanut consumption|These participants were the peanut consumption group of the ITN032AD (LEAP) study
3321065|NCT02015858||Oral analgesics|Postoperative patients with oral analgesics
3078262|NCT01366846|Experimental|Continued peanut avoidance|These participants were the peanut avoidance group of the ITN032AD (LEAP) study
3078263|NCT01366885|Experimental|Intervention during pregnancy|5000 IU Vitamin D3 to be given to the mother during pregnancy. 7000 IU Vitamin D3 to be given during breast feeding if breast feeding. If not breastfeeding, infant to be given 400 IU Vitamin D3 during first year of age, then increased to 1000 IU D3 until completion of research trial.
3078264|NCT01366976|Placebo Comparator|Placebo|
3078265|NCT01366976|Active Comparator|Acetaminophen|Acetaminophen will ge given as 1g every 6 hours for 4 doses over a 24 hours study period
3078266|NCT01367080|Experimental|A Group|"1st administration - DWETR10~2nd administration - DWETR25"
3078267|NCT01367080|Experimental|B Group|"1st administration - DWETR25~2nd administration - DWETR10"
3078268|NCT01367119|Active Comparator|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic prior to electroconvulsive therapy (ECT).
3078269|NCT01367119|Active Comparator|Methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic prior to electroconvulsive therapy.
3078270|NCT01367158|Experimental|3ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
3078271|NCT01367158|Experimental|2ABCWY|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
3078272|NCT01367158|Experimental|3ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of the same in current study
3078273|NCT01367158|Experimental|2ABx2CWY|two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus one dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine in previous study and one dose of Tdap in current study
3078274|NCT01367158|Experimental|3ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of the same in current study
3078275|NCT01367158|Experimental|2ABCWY+OMV|Two doses Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus outer membrane vesicles (OMV) in previous study and one dose of Tdap in current study
3078276|NCT01367158|Experimental|3ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of the same in current study
3078277|NCT01367158|Experimental|2ABCWYqOMV|Two doses of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus one quarter dose of outer membrane vesicles (qOMV) in previous study and one dose of Tdap in current study
3078278|NCT01367158|Active Comparator|3B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of the same in current study
3078279|NCT01367158|Active Comparator|2B|Two doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine in previous study and one dose of Tdap in current study
3078280|NCT01367158|Active Comparator|1ACWY|One dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine followed by one dose of placebo and one dose of Tdap in current study
3078281|NCT01367236|Active Comparator|standard care|"treatment with:~atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily* * as the fixed dose combination Truvada™"
3078282|NCT01367236|Active Comparator|Novel therapeutic approach|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily**~abacavir 600 mg daily**~maraviroc 150 mg once daily ** as the fixed dose combination Kivexa ™"
3078283|NCT01367249|Experimental|Bromfenac Ophthalmic Solution|Bromfenac ophthalmic solution 0.07% one drop into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
3078284|NCT01367249|Placebo Comparator|Placebo|One drop of placebo into study eye, once daily (QD) starting the day before cataract surgery and continued for 14 days post surgery for a total of 16 days.
3078285|NCT01367262|Experimental|Radiolabeled LY2886721|Single 25 milligram (mg) oral dose containing 80 microCuries of radiolabeled LY2886721
3078286|NCT01367275|Experimental|Brivanib + Irinotecan|Brivanib 800 mg orally daily Days 1-14, and Irinotecan intravenously 180 mg/m^2 on Day 1.
3078287|NCT01367444|Experimental|SAR422459 (Dose 1)|Starting dose of SAR422459 given through subretinal injection
3078288|NCT01367444|Experimental|SAR422459 (Dose 2)|Escalating dose of SAR422459 given through subretinal injection
3078289|NCT01367444|Experimental|SAR422459 (Dose 3)|Maximum tolerated dose (MTD) of SAR422459 given through subretinal injection
3078290|NCT01367457||Patients that received treatment with Temsirolimus|Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
3078291|NCT01367665|Experimental|Vismodegib - Locally Advanced|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
3078292|NCT01367665|Experimental|Vismodegib - Metastatic|Participants received vismodegib 150 mg orally once a day until one of the following occurs: Disease progression, intolerable toxicity most probably attributable to vismodegib, consent withdrawal, death, study termination by the Sponsor, or other reason deemed by the Investigator. vismodegib: 150 mg once daily until disease progression or unacceptable toxicity
3078293|NCT01367704|Active Comparator|Control School|Control schools (where the coaches do not receive the Coaching Boys into Men (CBIM) training until following academic year 'wait list control')
3078294|NCT01367704|Experimental|Intervention School|Intervention schools (where coaches receive the CBIM training at start of sports season)
3321066|NCT02015871|Experimental|Degarelix|
3078295|NCT01367834|Experimental|Growth Hormone|Subjects in the somatotropin (growth hormone, GH) arm will receive GH injections from 12-24 months of life.
3078296|NCT01367834|No Intervention|Control|Subjects will receive no GH or placebo.
3078297|NCT01367847|Active Comparator|Helping the Noncompliant Child (HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
3078298|NCT01367847|Experimental|Technology-Enhanced HNC (TE-HNC)|Standard HNC (see HNC Arm/Title) Program plus Technology-Enhancement (smartphones, which are being used for mid-week video calls to check-in re: skill-building, videotaping of family practice of skills at home, daily surveys re: skills practice & child behavior, reminders re: practice & sessions.
3078299|NCT01367860|Active Comparator|OMicro|This group will be formed by randomization, which gets out surgery to open microdiscectomy
3078300|NCT01367860|Experimental|SJet|This group will be formed by randomization, and receive the discectomy procedure addressed by the technique of Percutaneous Diskectomy SpineJet
3078301|NCT01367886|Other|Fesoterodine|Females with overactive bladder symptoms will be given Fesoterodine 4 mg. daily for six weeks.
3078302|NCT01368042||Chronic Kidney Disease, Secondary Hyperpathyroidism|All eligible participants treated with paricalcitol iv according to the approved Summary of Product Characteristics (SmPC)
3078303|NCT01368081|Experimental|BI 10773 low dose|BI 10773 low dose tablet once daily
3078304|NCT01368081|Experimental|BI 10773 high dose|BI 10773 high dose tablet once daily
3078305|NCT01368081|Active Comparator|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
3078306|NCT01368185||All Participants|Participants with hypertension who had been treated with MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg) for at least three months
3078307|NCT01368211|Active Comparator|Mirasol first, then Reference|This study arm will receive first a 2-4-day-old Mirasol-treated platelets transfusion and then a reference 2-4-day-old untreated platelets transfusion (Mirasol-Reference sequence).
3078308|NCT01368211|Active Comparator|Reference first, then Mirasol|This study arm will receive first a reference 2-4-day-old untreated platelets transfusion and then a 2-4-day-old Mirasol-treated platelets transfusion (Reference-Mirasol sequence).
3078309|NCT01368263|Experimental|Group 1 (Ki67 <10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Neoadjuvant treatment repeats every 28 days for a total of 16-18 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Recommendations for postsurgical treatment will be based on PEPI score and physician discretion.
3078310|NCT01368263|Experimental|Group 2 (Ki67 >= 10%, E2 <= 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant chemotherapy in the absence of disease progression or unacceptable toxicity. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
3078311|NCT01368263|Experimental|Group 3 (E2 > 15 pg/ml)|Patients receive 1 cycle (28 days) of endocrine therapy consisting of goserelin acetate SC on day 1 and letrozole or anastrozole PO QD. Patients receive standard neoadjuvant therapy at the discretion of the physician. Patients then undergo the appropriate standard surgical procedure to remove the cancer. Postsurgical treatment at physician discretion.
3078312|NCT01368276|Active Comparator|GM-CSF|Granulocyte macrophage colony-stimulating factor (GM-CSF) was administered at a dose of 125 μg/m²/day subcutaneously for 14 consecutive days followed by 14 days of rest, in 28-day treatment cycles for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
3078313|NCT01368276|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered at a concentration of 10⁸ plaque forming units (PFU)/mL injected into 1 or more skin or subcutaneous tumors on Days 1 and 15 of each 28-day cycle for up to 12 months or until a complete response, occurrence of an unacceptable toxicity, death or another criterion for withdrawal from treatment was met. Participants who demonstrated a partial response after being on treatment for 12 months could continue to be treated until disease progression or another treatment discontinuation criterion was met.
3078314|NCT01368406|Experimental|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
3078315|NCT01368406|No Intervention|treatment as usual|patients were on regular visits on psychiatrist
3078316|NCT01368432|Placebo Comparator|Placebo|Daily for 12 weeks
3078317|NCT01368432|Experimental|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks
3078318|NCT01368497|Experimental|Entecavir and peginterferon|Entecavir for 8 weeks followed by 40 weeks of both entecavir and peginterferon
3078319|NCT01368536|Experimental|Valturna|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule placebo for 4 weeks.
3078320|NCT01368536|Active Comparator|Valturna + Amlodipine|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 5 mg amlodipine for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 10 mg amlodipine for 4 weeks.
3078321|NCT01368536|Active Comparator|Valturna + chlorthalidone|At double-blind randomization, all patients received 1 tablet Valturna 150/160 mg + 1 tablet Placebo Valturna+ 1 capsule placebo for 2 weeks. From Week 2, patients received 1 tablet Valturna 150/160 mg, + 1 tablet Valturna 150/160 mg + 1 capsule 15 mg chlorthalidone for 6 weeks. From Week 8, patients received 1 tablet Valturna 150/160 mg + 1 tablet Valturna 150/160 mg + 1 capsule 25 mg chlorthalidonefor 4 weeks.
3078322|NCT01368562|Experimental|Methylnaltrexone|Participants will receive single dose of MNTX 0.15 milligrams per kilogram (mg/kg) subcutaneously (SC). Subsequent dosing could be adjusted upward (to a maximum of 0.3 mg/kg) to achieve a desired clinical response or decreased to improve tolerability.
3078323|NCT01368614|Experimental|AVAPS-AE|AVAPS-AE Mode of ventilation
3078324|NCT01368614|Active Comparator|Respironics OmniLab Advanced BiPAP S mode|OmniLab Advanced BiPAP S Mode of ventilation
3078325|NCT01368614|Active Comparator|Respironics OmniLab Advanced CPAP mode|OmniLab Advanced CPAP Mode of ventilation
3078326|NCT01368653|Active Comparator|Standard treatment|In this arm, smokers receive a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help them quit smoking
3078327|NCT01368653|Experimental|Standard treatment+practice quitting|In this arm, participants receive standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling.
3078328|NCT01368653|Experimental|Very low nicotine cigarettes|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this group. Those assigned to this group will receive a 6-week supply of cigarettes that contain tobacco with very low levels of nicotine (in regular or menthol flavors) to smoke instead of regular cigarettes containing nicotine. This treatment is designed to help people stop smoking after slipping (returning to smoking) during an attempt to stop smoking
3078329|NCT01368653|No Intervention|Advice and encouragement only|In this condition, smokers from both the Standard treatment and the Standard treatment+practice quitting arms who have smoked in the last 7-days at a 4-week post-target-smoking-cessation-date follow-up interview may be randomly assigned to this condition. Those in this arm will receive advice and encouragement to try to stop smoking again after they have slipped (returned to smoking) during a stop smoking attempt.
3078330|NCT01368809|Active Comparator|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
3078331|NCT01368809|Placebo Comparator|Saline Solution|Saline Solution 2 ml at induction, 1-2 ml boluses as needed
3078332|NCT01368835|Experimental|Ulthera treatment|
3078333|NCT01368874|Active Comparator|Group A|Ulthera® System treatment of the submental and submandibular regions at two treatment depths, and the lower neck region at one treatment depth.
3078334|NCT01368874|Active Comparator|Group B|Ulthera® System treatment of skin above the jawline, as well as the submental, submandibular and lower neck regions.
3078335|NCT01368874|Active Comparator|Group C|Ulthera® System treatment of the submental, submandibular, and the lower neck regions at two treatment depths.
3078336|NCT01368900|Experimental|Ulthera System Treatment|Ulthera treatment to the upper face.
3078337|NCT01368965|Experimental|Ulthera® System treatment|
3078338|NCT01369030||Deplin®|Subjects with depression who have been prescribed Deplin® daily.
3078339|NCT01369069|Experimental|IV insulin drip with target glucose 80 mg/dL - 130 mg/dL|The intervention arm will have a targeted glucose concentration of 80-130 mg/dL. IV insulin drip will be titrated to keep glucose concentration in this range.
3078340|NCT01369069|Active Comparator|Sub Q insulin to keep glucose less than 180 mg/dL|This standard care arm will get sub q insulin sliding scale to keep glucose concentration less than 180 mg/dL
3078341|NCT01369108|Experimental|Flowable composite|Flowable composite
3078342|NCT01369108|Active Comparator|Conventional composite|Highly filled conventional composite restorative
3078343|NCT01369199|Experimental|Peginterferon and entecavir|A combination of 8 weeks of entecavir followed by 40 weeks of both entecavir and peginterferon.
3078344|NCT01369225|Experimental|0.5 mg/kg AAB-003|
3078345|NCT01369225|Experimental|1 mg/kg AAB-003|
3078346|NCT01369225|Experimental|2 mg/kg AAB-003|
3078347|NCT01369225|Experimental|4 mg/kg AAB-003|
3078348|NCT01369225|Experimental|8 mg/kg AAB-003|
3078349|NCT01369329|Placebo Comparator|001|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
3078350|NCT01369329|Experimental|002|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
3078351|NCT01369329|Experimental|003|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
3078352|NCT01369342|Placebo Comparator|Placebo IV|Group 1: Placebo Form=solution for injection route=intravenous use in a single dose.
3078353|NCT01369342|Experimental|Ustekinumab 130 milligram (mg)|Group 2 ustekinumab 130 mg Type=exact unit=mg number=130 form=solution for injection route= intravenous use in a single dose.
3078354|NCT01369342|Experimental|Ustekinumab approximately (~) 6 milligram per kilogram (mg/kg)|Group 3: ustekinumab approximately 6 mg/kg Type=range unit=mg/kg number=6 form=solution for injection route= intravenous use in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg) 390 mg (weight > 55 kg and <= 85 kg) and 520 mg (weight > 85 kg).
3078355|NCT01369355|Placebo Comparator|001|Participants who were responders to Intravenous (IV) infusion of ustekinumab induction will be randomized to receive a single dose of placebo subcutaneously (SC) every 4 weeks (q4w).
3078356|NCT01369355|Experimental|002|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 milligram (mg) SC every 12 weeks (q12w).
3078357|NCT01369355|Experimental|003|Participants who were responders to IV ustekinumab induction will be randomized to receive a single dose of ustekinumab 90 mg SC every 8 weeks (q8w).
3078358|NCT01369355|Experimental|004|Participants who were nonresponders to IV ustekinumab induction will receive a single dose of ustekinumab 90 mg SC and one placebo IV at week 0, if then respond will continue to receive one ustekinumab 90 mg SC q8w.
3078359|NCT01369355|Experimental|005|Participants who were nonresponders to IV placebo induction will receive a single dose of ustekinumab 130 mg IV and one placebo SC at week 0, if then respond will continue to receive one ustekinumab 90 mg SC at week 8 then q12w.
3078360|NCT01369355|Placebo Comparator|006|Participants who were responders to IV placebo induction will receive one dose of placebo SC q4w.
3078361|NCT01369433|Experimental|tivozanib renal cell carcinoma (RCC)|Subjects who participated in a Phase 2 monotherapy study in RCC and showed tolerability and clinical benefit will be allowed access to tivozanib (AV-951).
3078362|NCT01369433|Experimental|tivozanib + temsirolimus|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + temsirolimus combination.
3078363|NCT01369433|Experimental|tivozanib + paclitaxel|Subjects who participated in a Phase 1b study and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951) + paclitaxel combination.
3078364|NCT01369433|Experimental|tivozanib solid tumors - QTC|Subjects who participated in a Phase 1 and showed tolerability and clinical benefit will be allowed continued access to the tivozanib (AV-951).
3078365|NCT01369433|Experimental|tivozanib + capecitabine|After Ph 1b study tolerable to Tivo + Xeloda®
3078366|NCT01369433|Experimental|tivozanib Advanced RCC|After biomarker study tolerable to Tivo
3078367|NCT01369485|Active Comparator|Active Treatment group|VERV™ System
3078368|NCT01369485|Sham Comparator|Sham Treatment Group|Sham version of (VERV™ System)
3078369|NCT01369498|Experimental|Simtuzumab 200 mg|Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
3078370|NCT01369498|Experimental|Simtuzumab 700 mg|Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
3078371|NCT01369498|Experimental|Simtuzumab 200 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
3078372|NCT01369498|Experimental|Simtuzumab 700 mg+Ruxolitinib|In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.
3078373|NCT01369511|Placebo Comparator|Placebo|Administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3078374|NCT01369511|Experimental|35 mg LY2495655|LY2495655: 35 milligrams (mg) administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3078375|NCT01369511|Experimental|105 mg LY2495655|LY2495655: 105 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3078376|NCT01369511|Experimental|315 mg LY2495655|LY2495655: 315 mg administered subcutaneously every 4 weeks for 12 weeks (administered 4 times)
3078377|NCT01369615|Experimental|Oxycodone HCl controlled-release|Oxycodone hydrochloride controlled-release tablets
3078378|NCT01369680|Experimental|Ketamine 0.25 mg/kg/dose|The first three subjects were administered 0.25 mg/kg/dose oral ketamine.
3078379|NCT01369680|Experimental|Ketamine 0.5 mg/kg/dose|The second group of three subjects were administered 0.5 mg/kg/dose oral ketamine.
3078380|NCT01369680|Experimental|Ketamine 1 mg/kg/dose|The third group of three subjects were administered 1 mg/kg/dose oral ketamine.
3078381|NCT01369680|Experimental|Ketamine 1.5 mg/kg/dose|The fourth group of three subjects were administered 1.5 mg/kg/dose oral ketamine.
3078382|NCT01369706|Other|Hand-held metal detector|Exposure to two hand-held metal detectors
3078383|NCT01369732|Placebo Comparator|Saline group|We administrate the saline single bolus (5ml, intravenously) 30 min before the commencement of ischemia.
3078384|NCT01369732|Experimental|erythropoietin group|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
3078385|NCT01369745|Active Comparator|Prednisolone|Prednisolone 2.7 mg daily for 12 weeks
3078386|NCT01369745|Active Comparator|dipyridamole|Dipyridamole 360 mg daily for 12 weeks
3078387|NCT01369745|Active Comparator|prednisone|Prednisone 5 mg daily for 12 weeks
3078388|NCT01369745|Experimental|Z102 (2.7/360)|Prednisolone 2.7 mg plus dipyridamole 360 mg daily for 12 weeks
3078389|NCT01369745|Placebo Comparator|placebo|Placebo daily for 12 weeks
3078390|NCT01369758|Experimental|Intrauterine pathology, myomectomy|Subjects with intrauterine fibroids and/or polyps will undergo intrauterine pathology removal using the MyoSure Tissue Removal System; myomectomy procedure.
3078391|NCT01369784||refractory/relapsed LDCBG|patients with refractory/relapsed diffuse large B-cell lymphoma
3078392|NCT01369849|Experimental|Treatment (Akt inhibitor MK2206, bendamustine, rituximab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22 (days 1, 8, 15, 22, and 29 of course 1); rituximab IV on day 1 (day 8 of course 1); and bendamustine hydrochloride IV over 30-60 minutes on days 1-2 (days 8-9 of course 1). Treatment repeats every 28 days (35 days for course 1 and 84 days for course 6) for 6 courses in the absence of disease progression or unacceptable toxicity.
3078393|NCT01369875|Experimental|Standard Young TIL|"Tumor Infiltrating Lymphocytes : intravenous (IV) over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
3078394|NCT01369875|Experimental|ECCE Young TIL|"Tumor Infiltrating Lymphocytes : IV over 30 minutes on day 0~Aldesleukin : 720,000 IU/kg IV over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)~Fludarabine : 25 mg/m2/day IVPB daily over 30 minutes for 5 days (days -5 to -1)~Cyclophosphamide : 60 mg/kg/day X 2 days IV over 1 hour on days -7 and -6"
3078395|NCT01369888|Experimental|IL-15 following Young TIL (0.25 mcg)|0.25 mcg/kg/day x 10
3078396|NCT01369888|Experimental|IL-15 following Young TIL (0.50 mcg)|0.50 mcg/kg/day x 10
3078397|NCT01369888|Experimental|IL-15 Following Young TIL (1 mcg)|1 mcg/kg/day x 10
3078398|NCT01369888|Experimental|IL-15 Following Young TIL (2 mcg)|2 mcg/kg/day x 10
3078399|NCT01370005|Experimental|BI 10773 low dose|BI 10773 low dose once daily
3078400|NCT01370005|Experimental|BI 10773 high dose|BI 10773 high dose once daily
3078401|NCT01370005|Placebo Comparator|Placebo|Placebo tablets matching BI 10773
3078402|NCT01370018|Experimental|alpha-1 proteinase inhibitor in HIV|HIV-1 infected individuals treated with Alpha-1 proteinase inhibitor
3078403|NCT01370083|Experimental|Stroke: TPPT|Adults with dysphagia post stroke (within 4-16 weeks of onset) who have radiographically confirmed difficulties with thin liquid bolus control. Individuals will complete 24 sessions of tongue-pressure-profile training over 8-12 weeks.
3078404|NCT01370083|Active Comparator|Stroke: TPSAT Control|Individuals with dysphagia (within 4-16 weeks post stroke) who demonstrate difficulties with thin liquid control on videofluoroscopy. Individuals will complete 24 sessions of tongue-pressure strength-and-accuracy training over 8-12 weeks.
3078405|NCT01370174|Active Comparator|Induced Step Training (IST)|The IST group will receive waist-pulls in both the left and right lateral directions by a motorized pulling system to produce stepping.
3078406|NCT01370174|Active Comparator|Hip Strength Training (HST)|The HST group will have muscle strength training, to include hip abduction (AB) and adduction (AD) resistance exercises.
3078407|NCT01370174|Active Comparator|Combined Induced Step and Hip Strength Training|This training group consists of combined induced step training (IST) and hip AB-AD strength training (HST).
3078408|NCT01370174|Placebo Comparator|Standard Flexibility and Relaxation (SFR)|The SFR group will perform a flexibility and relaxation program involving minimal-intensity exercises.
3078409|NCT01370213|Experimental|CD34 Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and filgrastim mobilized CD34+ selected peripheral blood stem cell graft from the same donor.
3078410|NCT01370213|Experimental|TCRα/β Schema - High-Risk Acute Myeloid Disease|Patients with high risk acute myeloid disease treated with preparative regimen including Fludara, Cytoxan and total body irradiation followed by haploidentical donor NK cells, Interleukin-2, rabbit anti-thymocyte globulin, and same donor TCR α/β-depleted cells infusion.
3078411|NCT01370265|Active Comparator|Regadenoson, then Adenosine|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the first intervention period. Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the second intervention period (after washout period). Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered.
3078412|NCT01370265|Active Comparator|Adenosine, then Regadenoson|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes in the first intervention period. Three minutes after the start of adenosine infusion, N-13 ammonia (10-20 mCi) was administered. After a washout period, Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush and N-13 ammonia (10-20 MCi) injection and an additional saline flush in the second intervention period.
3078413|NCT01370317|Experimental|MK-1029|
3078414|NCT01370317|Placebo Comparator|Placebo|
3078415|NCT01370356|Active Comparator|Varenicline Tartrate|
3078416|NCT01370356|Placebo Comparator|Placebo|
3078417|NCT01370369|Experimental|Single Testosterone Dose (Inner Thigh)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the inner thigh followed by a seven day washout period.
3078418|NCT01370369|Experimental|Single Testosterone Dose (Abdomen)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the abdomen followed by a seven day washout period.
3078419|NCT01370369|Experimental|Single Testosterone Dose (shoulder/upper arm)|Subjects received a single application of 2.50 mL (two strokes) of the testosterone gel 2% applied to the shoulder/upper arm.
3078420|NCT01370369|Experimental|Testosterone 1.25|Subjects received testosterone gel 2% at dose of 1.25 mL (one stroke) applied once daily for 10 consecutive days to the shoulder/upper arm.
3078421|NCT01370369|Experimental|Testosterone 2.50|Subjects received testosterone gel 2% at dose of 2.50 mL (two strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
3078422|NCT01370369|Experimental|Testosterone 3.75|Subjects received testosterone gel 2% at dose of 3.75 mL (three strokes) applied once daily for 10 consecutive days to the shoulder/upper arm.
3078423|NCT01370408|Experimental|Palonosetron|"All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation~Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO"
3078424|NCT01370460|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total knee arthroplasty.
3078425|NCT01370460|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
3078426|NCT01370499|Experimental|LY2216684 + SSRI|"LY2216684: 12 milligrams (mg) or 18 mg, administered orally, once daily for 52 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI).~During the open-label phase, all participants started at the 12 mg dose and could have the dose increased to 18 mg after the first week of treatment. During the first 12 weeks, participants were allowed (at scheduled or unscheduled visits) to decrease their dose to 12 mg based on response. After a decrease in dose to 12 mg, participants could have had an increase back up to 18 mg at any scheduled visit based on response and tolerability. After 12 weeks of treatment, participants maintained a stable dose.~Open-label treatment was followed by a 1-week abrupt discontinuation phase. Participants who either completed study visits through Week 52 or discontinued early from the study for any reason returned 1 week later for follow-up visit. Participants did not receive LY2216684 but continued their SSRI treatment at a stable dose."
3078427|NCT01370525|Experimental|Esomeprazole 20 mg|
3078428|NCT01370525|Placebo Comparator|Placebo|
3078429|NCT01370538|Experimental|Esomeprazole 20 mg|
3078430|NCT01370538|Placebo Comparator|Placebo|
3078431|NCT01370564|Other|Daily diuretic adjustment|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
3078432|NCT01370590|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 20 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
3078433|NCT01370590|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/20 mg, placebo to ezetimibe, and placebo to atorvastatin.
3078434|NCT01370603|Active Comparator|Ezetimibe and atorvastatin|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including 10 mg ezetimibe, 40 mg atorvastatin, and placebo to ezetimibe/atorvastatin.
3078435|NCT01370603|Experimental|Ezetimibe/atorvastatin combination|Medication will be administered in a double dummy fashion as 3 tablets orally on a daily basis, including ezetimibe/atorvastatin 10 mg/40 mg, placebo to ezetimibe, and placebo to atorvastatin.
3078436|NCT01370616|Experimental|Ertapenem sodium|Participants received 1.0 g intravenous (IV) ertapenem sodium as a single daily dose at Hour 0 infused over a 30-minute interval , and IV piperacillin/tazobactam-matching placebo at Hours 8 and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
3078437|NCT01370616|Active Comparator|Piperacillin/tazobactam sodium|Participants received 4.5 g IV piperacillin/tazobactam at Hours 0, 8, and 16 infused over a 30-minute interval, for 5 to 28 days. Participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
3078438|NCT01370629||All participants|Participants treated with vernakalant IV in acute care and inpatient hospital settings
3078439|NCT01370642|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) and then 12 weeks of placebo to vaniprevir along with 24 weeks of treatment with peg-IFN and RBV.
3078440|NCT01370642|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV.
3078441|NCT01370642|Active Comparator|Control Arm|Participants on this arm receive 24 weeks of treatment with placebo to vaniprevir along with 48 weeks of treatment with peg-IFN and RBV.
3078442|NCT01370655|Experimental|MK-7145 6 mg (Treatment A)|MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally) and placebo to HCTZ (two 12.5-mg capsules) then three x 1-mg MK-7145 capsules 4 hours later, daily for 4 weeks.
3078443|NCT01370655|Experimental|MK-7145 3 mg (Treatment B)|MK-7145 3 mg (one 2mg MK-7145 and one MK-7145 placebo capsule) then one 1-mg MK-7145 capsule and two MK-7145 placebo capsules 4 hours later and placebo to HCTZ (2 capsules once daily) daily for 4 weeks.
3078444|NCT01370655|Active Comparator|Hydrochlorothiazide 25 mg (Treatment C)|HCTZ 25 mg (two 12.5-mg capsules) and placebo to MK-7145 (one 3-mg capsule) then placebo for MK-7145 (one 3-mg capsule) 4 hours later daily for 4 weeks.
3078445|NCT01370655|Placebo Comparator|Placebo (Treatment D)|Placebo to MK-7145 (2 x 3-mg capsules) and placebo to HCTZ 25 mg (2 capsules) then placebo to MK-7145 (2 x 3-mg capsules) 4 hours later daily for 4 weeks
3078446|NCT01370694|Experimental|MK-8808 Combination Therapy|Participants received MK-8808 375 mg/m^2 intravenously (IV) + cyclophosphamide 750 mg/m^2 IV + vincristine 1.4 mg/m^2 IV (maximum dose of 2 mg IV) on Day 1 each cycle, plus prednisolone 40 mg/m^2, orally on Days 1 to 5 of each cycle for a maximum of 8 cycles. Participants receiving clinical benefit could remain on MK-8808 375 mg/m^2 IV starting 8 weeks after last dose of combination therapy, every 2 months for up to 2 years.
3078447|NCT01370733|Experimental|Active sTMS|Treatment with the NEST-1 Device
3078448|NCT01370733|Sham Comparator|Sham|Treatment with a sham (inactive) device, identical in sound and appearance to the NEST-1 Device
3078449|NCT01370837|Experimental|Healthy controls|
3078450|NCT01370837|Experimental|Diabetes|Patients with diabetes mellitus without polyneuropathy.
3078451|NCT01370837|Experimental|Polyneuropathy|Patients with diabetes and polyneuropathy.
3078452|NCT01370863|Experimental|SPD557|
3078453|NCT01370863|Placebo Comparator|Placebo|
3078454|NCT01371006|Experimental|BI201335 low dose Efavirenz|low dose Efavirenz
3078455|NCT01371006|Experimental|BI201335 high dose Efavirenz|normal dose Efavirenz
3078456|NCT01371032|Active Comparator|Video-Miller laryngoscope|using the screen (Video laryngoscopy group)
3078457|NCT01371032|Active Comparator|Direct laryngoscopy|without use the screen (Direct laryngoscopy group)
3078458|NCT01371110|Active Comparator|Ketamine|Study participants will receive a one-time intravenous infusion of 0.5 mg/kg racemic ketamine hydrochloride
3078459|NCT01371110|Sham Comparator|Midazolam|Study participants will receive a one-time intravenous infusion of 0.045 mg/kg midazolam
3321067|NCT02015884||All patients admitted to the ophthalmologic emergency unit.|
3321068|NCT02015897|Active Comparator|Physical TherapyB|Group B
3078462|NCT01371539|Other|Lotrafilcon B / Comfilcon A|Lotrafilcon B contact lenses worn first, with comfilcon A contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
3078463|NCT01371539|Other|Comfilcon A / Lotrafilcon B|Comfilcon A contact lenses worn first, with lotrafilcon B contact lenses worn second. Both products worn bilaterally on a daily wear basis for one week each.
3078464|NCT01371552|Experimental|delefilcon A|Part 1: Delefilcon A contact lenses, followed by filcon II 3 contact lenses and narafilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3078465|NCT01371552|Active Comparator|filcon II 3|Part 1: Filcon II 3 contact lenses, followed by narafilcon A contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3078466|NCT01371552|Active Comparator|narafilcon A|Part 1: Narafilcon A contact lenses, followed by filcon II 3 contact lenses and delefilcon A contact lenses (in randomized order). Each product worn for three consecutive days, with a minimum 1-day washout between each product. At the conclusion of this wear cycle, the delefilcon A contact lenses were worn in Part 2 for one additional week. All products worn bilaterally in a daily wear, daily disposable modality.
3078467|NCT01371565|Experimental|mifepristone|
3078468|NCT01371643|Active Comparator|Medical treatment by Octreotide LAR|Medical therapy with Octreotide LAR 30 mg/month for 3 months preceding surgery
3078469|NCT01371643|Active Comparator|Surgical debulking followed by Octreotide LAR|Surgical debulking of pituitary tumor followed by Octreotide LAR if not surgically cured
3321069|NCT02015897|Placebo Comparator|Physical TherapyA|Group A
3078470|NCT01371656|Experimental|Arm I (levofloxacin)|Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover.
3078471|NCT01371656|No Intervention|Arm II (standard of care)|Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
3078472|NCT01371708|Experimental|Desvenlafaxine Succinate Sustained-Release|
3078473|NCT01371721|Experimental|Desvenlafaxine Succinate Sustained-Release|
3078474|NCT01371734|Experimental|Experimental Arm 1 - high dose|
3078475|NCT01371734|Experimental|Experimental Arm 2 - low dose|
3078476|NCT01371734|Placebo Comparator|Placebo Arm|
3078477|NCT01371747|Experimental|Stratum 1: 8.4 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L (milliequivalent)
3078478|NCT01371747|Experimental|Stratum 1: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
3078479|NCT01371747|Experimental|Stratum 1: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.0 to 5.5 mEq/L
3078480|NCT01371747|Experimental|Stratum 2: 16.8 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3078481|NCT01371747|Experimental|Stratum 2: 25.2 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3078482|NCT01371747|Experimental|Stratum 2: 33.6 g/d patiromer|Participants with baseline serum potassium > 5.5 to < 6.0 mEq/L
3078483|NCT01371786|Experimental|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister followed by a washout period of 120 hours and a radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
3078484|NCT01371786|Active Comparator|mometasone|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle followed by a washout period of 120 hours and a radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
3078485|NCT01371825|Experimental|Open-Label Sebelipase Alfa|Participants received intravenous (IV) infusions of sebelipase alfa during the open-label treatment. Participants initially received 0.35 milligrams (mg)/kilogram (kg) qw and escalated to 1 mg/kg qw after demonstrating acceptable safety and tolerability during at least 2 infusions. One participant initiated treatment under a Temporary Use Authorization prior to enrollment, wherein the participant's dose was gradually escalated from 0.2 to 1 mg/kg over 4 weeks; the participant started the study at this dose. Participants on treatment for 96 weeks and on stable qw dosing for 24 weeks could be switched to an every other week (qow) dosing schedule. In the event of protocol-defined disease progression at any time during treatment, a participant could receive a dose increase from 1 to 3 mg/kg qw and, if necessary, a dose increase to 5 mg/kg qw with Safety Committee approval. Participants dosed qow who met dose-escalation criteria were reverted to qw dosing or escalated to 1 or 3 mg/kg qow.
3078486|NCT01371838|Experimental|Ceftaroline|
3078487|NCT01371838|Active Comparator|Ceftriaxone plus placebo|
3078488|NCT01371851|Experimental|Doxazosin|Doxazosin extended release will be administered initially at 4 mg/day. On day 8 the dose is increased to 8 mg/day and the participant is maintained on the study until the end of the trial.
3078489|NCT01371851|Placebo Comparator|Placebo|Participants will be maintained on placebo (cellulose) throughout the trial.
3078490|NCT01371877|Experimental|Vitamin D3 4000 IU|"Subjects will be randomized 1:1 to high dose vitamin D defined as 4000 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 4000 IU daily."
3078491|NCT01371877|Active Comparator|Vitamin D3 600 IU|"Subjects will be randomized 1:1 to low dose vitamin D as defined as 600 IU per day for 3 months.~Subjects will be given Vitamin D3 supplementation at 600 IU daily"
3078492|NCT01371981|Experimental|Arm A|See Detailed Description
3078493|NCT01371981|Experimental|Arm B|See Detailed Description
3078494|NCT01371981|Experimental|Arm C (Cohort 1)|See Detailed Description
3078495|NCT01371981|Experimental|Arm C (Cohort 2)|See Detailed Description.
3078496|NCT01371981|Experimental|Arm C (Cohort 3)|See Detailed Description. Different dose.
3078497|NCT01371981|Experimental|Arm D|See Detailed Description. May reassigned to Arm C.
3078498|NCT01371994|Experimental|Solifenacin succinate|Participants received 5 mg solifenacin succinate tablets once a day for 12 weeks. At week 4, based on efficacy and safety and in agreement with the investigator, the dose might be increased to 10 mg (2 tablets of 5 mg) once daily.
3078499|NCT01371994|Placebo Comparator|Placebo|Participants received matching placebo tablets once a day for 12 weeks.
3078500|NCT01372085|Experimental|Part A: 25 mg RF|A single 25 mg dose of LY2584702 RF
3078501|NCT01372085|Placebo Comparator|Part A: Placebo|Placebo taken orally
3078502|NCT01372085|Experimental|Part B: Sequence 1|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by placebo in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3078503|NCT01372085|Experimental|Part B: Sequence 2|Placebo during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3078504|NCT01372085|Experimental|Part B: Sequence 3|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by a single dose of 50 mg TF in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3078505|NCT01372085|Experimental|Part B: Sequence 4|A single 10 mg dose of LY2584702 TF during the first intervention period, followed by a single dose of 50 mg RF in the second intervention period, followed by placebo in the third intervention period, followed by either an open-label single dose of 50 mg TF after a high fat breakfast (Period 4a) OR placebo or escalated dose of TF in the fasted state (Period 4b). There will be a washout period of at least 3 days between periods.
3078506|NCT01372150|Experimental|DVS SR|
3078507|NCT01372150|Other|Fluoxetine|Active control for assay sensitivity
3078508|NCT01372150|Experimental|Placebo|
3078509|NCT01372202|Active Comparator|Arm A|Paclitaxel with Cisplatin along with Radiotherapy and followed by Esophagectomy
3078510|NCT01372202|Active Comparator|Arm B|Cisplatin or Oxaliplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
3078511|NCT01372202|Active Comparator|Arm C|Cisplatin with 5-Fluorouracil along with Radiotherapy and followed by Esophagectomy
3078512|NCT01372254|Active Comparator|Standard smoking cessation|Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
3078513|NCT01372254|Experimental|BA for substance abusing smokers|The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
3078514|NCT01372384|Experimental|Single Arm|
3078515|NCT01372410|Active Comparator|Tiotropium|18 mcg, inhaled long acting muscarinic antagonist
3078516|NCT01372410|Experimental|GSK573719|inhaled medication
3078517|NCT01372410|Placebo Comparator|Placebo|inactive/excipients only
3078518|NCT01372462|Experimental|NIOV - Room air|Subjects exercise using the NIOV device powered by compressed air (room air, 21% O2).
3078519|NCT01372462|Experimental|NIOV - Oxygen|Subjects exercise using the NIOV device powered by compressed medical oxygen (100% O2).
3078520|NCT01372462|Active Comparator|Nasal Cannula Oxygen|Subjects exercise using a standard nasal cannula using medical oxygen (100% O2).
3078521|NCT01372462|No Intervention|No treatment|Control arm. Subjects exercise without using supplemental oxygen or NIOV.
3078522|NCT01372501|Experimental|Experimental: Device|All patients will be implanted with the Endobarrier Liner device
3078523|NCT01372605|Experimental|Collaborative depression care|Measurement-Based Care: Decision support from paraprofessional to HIV medical provider around initiating and monitoring antidepressant treatment.
3078524|NCT01372605|Other|Enhanced usual care|Usual care. Enhanced through pre-study training of providers, provision of psychiatric diagnostic information at enrollment to HIV provider, and availability of best-practices guidelines for reference in clinic.
3078525|NCT01372748|Active Comparator|Standard CPR|American Heart Association (AHA)recommended cardiopulmonary resuscitation (CPR) of 30 compressions with brief pause for 2 ventilations
3078526|NCT01372748|Experimental|Continuous chest compressions|Continuous compression CPR
3078527|NCT01372774|Active Comparator|Arm I - WBRT|Patients undergo whole brain radiotherapy (WBRT) once a day, 5 days a week, for approximately 3 weeks. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
3078528|NCT01372774|Experimental|Arm II - SRS|Patients undergo stereotactic radiosurgery (SRS) using a gamma knife or a linear accelerator procedure. Patient observation/follow up occurs at week 12 and months 6, 9, 12, 16 and 24 post registration/randomization. Event monitoring occurs every 6 months until 5 years post registration/randomization.
3078529|NCT01372813|Other|Clear Cell Renal Carcinoma|Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
3078530|NCT01372995|Experimental|Enteral vitamin D3 50,000 IU|An arm where subjects receive 50,000 IU of Vitamin D for 5 days.
3078531|NCT01372995|Experimental|Enteral Vitamin D3 100,000 IU|Arm where subjects receive 100,000 IU of Vitamin D for 5 days
3078532|NCT01372995|Placebo Comparator|Inactive Substance|Arm where patients receive inactive substance for 5 days.
3078533|NCT01373164|Experimental|Phase 1b: 80 mg Galunisertib + Gemcitabine|"Cohort 1: 40 mg Galunisertib was administered orally twice daily (BID) for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3078534|NCT01373164|Experimental|Phase 1b: 160 mg Galunisertib + Gemcitabine|"Cohort 2: 80 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3078535|NCT01373164|Experimental|Phase 1b: 300 mg Galunisertib + Gemcitabine|"Cohort 3: 150 mg Galunisertib was administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3078536|NCT01373164|Experimental|Phase 2: Recommended dose of Galunisertib + Gemcitabine|"Galunisertib recommended dose (300 mg) determined from phase 1, administered orally twice daily for 14 days followed by 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3078537|NCT01373164|Experimental|Phase 2: Placebo + Gemcitabine|"Placebo administered orally twice daily for 14 days followed 14 days of rest (28 day cycle).~Gemcitabine at a dose of 1000 mg/m^2 was administered intravenously once per week for 7 weeks followed by 1 week of rest and then once per week for 3 weeks of every 4 weeks."
3078538|NCT01373229|Experimental|Lenalidomide + Plerixafor+ Rituximab|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
3078539|NCT01373242|Experimental|Peanut ( liquid peanut extract) SLIT|All subjects will receive peanut SLIT upon enrollment for at least the first 48 months. After the desensitization DBPCFC after at least 48 months of treatment, subjects will be randomized off treatment from 1 to 17 weeks. Subjects will then undergo another DBPCFC.
3078540|NCT01373281|Experimental|Dengue Vaccine Group|Participants were to receive CYD dengue vaccine at 0, 6, and 12 months.
3078541|NCT01373281|Placebo Comparator|Control Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
3078542|NCT01373294|Experimental|A: Combination Arm|"Bacille Calmette-Guerrin (BCG) and lenalidomide.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer. This group received BCG + lenalidomide)"
3078543|NCT01373294|Active Comparator|B: Control Arm|"Bacille Calmette-Guerrin (BCG) only.~Participants were assigned to receive BCG or BCG and lenalidomide based on their cancer.~This group was not eligible to receive the combination of BCG + lenalidomide."
3078544|NCT01373346|Experimental|Long limb Roux-en Y reconstruction|Long limb Roux-en Y reconstruction means that the length of Roux limb and biliopancreatic limb are longer than conventional reconstruction method after gastrectomy.
3078545|NCT01373450|Experimental|OXM → Lg-0.6 → Pbo → Lg-1.2|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first, Liraglutide 0.6 mg in the second, Placebo in the third, and Liraglutide 1.2 mg in the fourth period
3078546|NCT01373450|Experimental|Lg-0.6 → Pbo → OXM → Pbo|Participants received Liraglutide 0.6 mg in the first, Placebo in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Placebo in the fourth period
3078547|NCT01373450|Experimental|Pbo → OXM → Lg-0.6 → Pbo|Participants received Placebo in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
3078548|NCT01373450|Experimental|Lg-0.6 → OXM → Pbo → Lg-1.2|Participants received Liraglutide 0.6 mg in the first, Oxyntomodulin 3.0 pmol/kg/min in the second, Placebo in the third and Liraglutide 1.2 mg in the fourth period
3078549|NCT01373450|Experimental|OXM → Pbo → Lg-0.6 → Pbo|Participants received Oxyntomodulin 3.0 pmol/kg/min in the first; Placebo in the second, Liraglutide 0.6 mg in the third, and Placebo in the fourth period
3078550|NCT01373450|Experimental|Pbo → Lg-0.6 → OXM → Lg-1.2|Participants received Placebo in the first, Liraglutide 0.6 mg in the second, Oxyntomodulin 3.0 pmol/kg/min in the third, and Liraglutide 1.2 mg in the fourth period
3078551|NCT01373489|No Intervention|Usual Care|The usual care group received the current standards of care at the study clinics.
3078552|NCT01373489|Experimental|Technology Assisted Case Management|The TACM group used the FORA 2-in-1 Telehealth system for diabetes management intervention to link a case manager to patients with poorly controlled type 2 diabetes in real time.
3078553|NCT01373580|Experimental|Raindrop|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
3078554|NCT01373671|Other|Mammography exam|Siemens DBT scan
3078555|NCT01373918|Experimental|low dose intravenous fat emulsion|Subjects in this arm will receive approximately 1 g/kg/d IV of intravenous soybean oil (Intralipid).
3078556|NCT01373918|Active Comparator|standard dose intravenous fat emulsion|Subjects in this arm will receive approximately 3 g/kg/d IV of intravenous soybean oil (Intralipid).
3078557|NCT01373931|Experimental|OC + LY2216684 First, Then OC + Placebo|28-day lead-in period of Ortho Cyclen (OC; 28-day packet), followed by randomization to OC administered orally once daily for 28 days + 18 milligrams (mg) of LY2216684 administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days.
3078558|NCT01373931|Experimental|OC + Placebo First, Then OC + LY2216684|28-day lead-in period of OC (28-day packet), followed by randomization to OC administered orally once daily for 28 days + placebo administered concomitantly orally once daily for 21 days, followed by OC administered orally once daily for 28 days + 18 mg of LY2216684 administered concomitantly orally once daily for 21 days.
3078559|NCT01374087|Experimental|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
3078560|NCT01374087|Active Comparator|Brachytherapy|Brachytherapy: Low or high dose rate.
3078561|NCT01374178|Experimental|LY2963016|A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
3078562|NCT01374178|Active Comparator|Lantus|A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
3078563|NCT01374217|Experimental|Tadalafil|Subject will take tadalafil in combination with with Lenalidomide and dexamethasone (Rd) or Clarithromycin/Lenalidomide/ dexamethasone (BiRd)
3078564|NCT01374269|Experimental|Excercise|One group will be assigned to protocolized back pain exercise, three times a week for 4 weeks. This program is carried out by physiotherapists from participating institutions who wish to participate in research and who will be given a training which will standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. Treatment, type of exercises, exercise tolerance and adverse reactions will be registered
3078565|NCT01374269|Active Comparator|NSAID|Naproxen 500 mg per day by 10 days or Celecoxib 200 mg per day by 10 days and Acetaminophen 1,5 a 2 g as rescue
3078566|NCT01374425|Experimental|Bevacizumab + mFOLFOX6|Participants will receive bevacizumab plus mFOLFOX6 by intravenous (IV) infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to oxaliplatin, with bevacizumab continued in 3-week cycles.
3078567|NCT01374425|Experimental|Bevacizumab + FOLFIRI|Participants will receive bevacizumab plus FOLFIRI by IV infusion on Day 1 of each 2-week cycle until disease progression or unacceptable toxicity. Participants may be transitioned to oral capecitabine in the event of unacceptable toxicity to irinotecan, with bevacizumab continued in 3-week cycles.
3078568|NCT01374438|Experimental|MSDC-0160 capsules|MSDC tablets contained in #00 capsules
3078569|NCT01374438|Placebo Comparator|Placebo capsules|Placebo tablets contained in #00 capsules
3078570|NCT01374451|Experimental|Paseriotide LAR + Everolimus|everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
3078571|NCT01374451|Experimental|Everolimus|everolimus 10 mg once daily po alone
3078572|NCT01374490|Experimental|Crofelemer|
3078573|NCT01374516|Experimental|CYD Dengue Vaccine Group|Participants were to receive 3 doses of CYD dengue vaccine; one each at 0, 6, and 12 months.
3078574|NCT01374516|Placebo Comparator|Placebo Group|Participants were to receive a placebo vaccine at 0, 6, and 12 months.
3078575|NCT01374568|Active Comparator|sitagliptin|Sitagliptin
3078576|NCT01374568|Placebo Comparator|Placebo|Placebo
3078577|NCT01374802|Experimental|BI 201335|capsule for oral administration
3078578|NCT01374802|Experimental|Darunavir 400 mg|tablet for oral administration
3078579|NCT01374802|Experimental|Ritonavir 100 mg|tablet for oral administration
3078580|NCT01374906|Experimental|10 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
3078581|NCT01374906|Experimental|30 mg LAR dose|Randomization was stratified based on Screening mUFC to ensure balanced distribution of disease severity in the two dose arms.
3078582|NCT01374919|Other|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
3078583|NCT01374971|Other|Certolizumab Pegol (CZP)|Certolizumab Pegol (CZP) liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks with arthroscopic synovial tissue biopsy pre- and post-treatment.
3078584|NCT01375010|Placebo Comparator|Group A|Placebo vitamin D3 capsule daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 1000 IU.
3078585|NCT01375010|Experimental|Group B|2000 IU vitamin D3 daily plus vitamin supplements that contains 1000 IU vitamin D3 and 1000 mg calcium carbonate daily. Total daily vitamin D3 dose = 3000 IU.
3078586|NCT01375049|Experimental|Aztreonam for Inhalation Solution (AZLI)|Participants will receive one 28-day course of AZLI, then will be followed for a 24-week period (through Day 196).
3078587|NCT01375075|Experimental|30 milligrams (mg) LY2484595|Administered orally once daily for 12 weeks
3078588|NCT01375075|Experimental|100 mg LY2484595|Administered orally once daily for 12 weeks
3078589|NCT01375075|Experimental|500 mg LY2484595|Administered orally once daily for 12 weeks
3078590|NCT01375075|Placebo Comparator|Placebo|Administered orally once daily for 12 weeks
3078591|NCT01375075|Active Comparator|10 mg Atorvastatin|Administered orally once daily for 12 weeks
3078592|NCT01375075|Experimental|100 mg LY2484595 + 10 mg Atorvastatin|Administered orally once daily for 12 weeks
3078593|NCT01375127||Subjects from Study A3921009|
3078594|NCT01375127||Subjects from Study A3921030|
3078595|NCT01375140|Experimental|Ruxolitinib + Lenalidomide|Ruxolitinib 15 mg orally twice daily continuously + Lenalidomide orally 5 mg/day on days 1-21, followed by 7 days of no therapy (28-day cycle). Prednisone will be added for patients who have not responded after 3 cycles of therapy. Prednisone 30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued.
3078596|NCT01375205|Active Comparator|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
3078597|NCT01375205|Experimental|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
3078598|NCT01375374|Experimental|Lacosamide|commercial 50 mg (pinkish) and 100 mg (yellow) tablets
3078599|NCT01375491|Experimental|Doxycycline|Participants with DM2 receiving doxycycline 100mg BID
3078600|NCT01375491|Placebo Comparator|Placebo|Pills prepared identical to doxycycline.
3078601|NCT01375569|Experimental|TRC105 in Liver Cancer|TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
3078602|NCT01375608|Other|decitabine|active treatment
3078603|NCT01375660|Placebo Comparator|Arm 1|Placebo: One capsule weekly
3078604|NCT01375660|Experimental|Arm 2|50K vitamin D2: One capsule weekly
3078605|NCT01375673|Experimental|Exercise|Exercise: Walking Strength Training Bicycling
3078606|NCT01375673|No Intervention|Usual Care|Usual Care
3078607|NCT01375751|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 4 weeks for 12 weeks.
3078608|NCT01375751|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078609|NCT01375751|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078610|NCT01375764|Active Comparator|Ezetimibe|Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
3078611|NCT01375764|Experimental|Evolocumab + Ezetimibe|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.
3078612|NCT01375764|Experimental|Evolocumab 280 mg|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078613|NCT01375764|Experimental|Evolocumab 350 mg|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078614|NCT01375764|Experimental|Evolocumab 420 mg|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078615|NCT01375777|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3078616|NCT01375777|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3078617|NCT01375777|Active Comparator|Ezetimibe|Participants received 10 mg ezetimibe orally once a day for 12 weeks.
3078618|NCT01375777|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078619|NCT01375777|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078620|NCT01375777|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078621|NCT01375777|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078622|NCT01375777|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078623|NCT01375777|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078624|NCT01375946|Experimental|AG200-15 location|The subject will wear AG200-15 for 7 days and be exposed to one of 5 external conditions (normal, treadmill, cold water, whirlpool, dry sauna).
3468866|NCT03891823|Active Comparator|Medical Therapy|"Study of medical therapy in symptomatic heart failure patients with moderate (2+, 2-3+) functional mitral regurgitation and left ventricular dysfunction.~Subjects will be followed for 24 months and there will be one formal interim analysis for futility after approximately 50% of subjects have completed their 24-month follow-up."
3468867|NCT03891914|Experimental|Symptomatic Multiple Myeloma on first-line treatment|
3078627|NCT01376037|Placebo Comparator|inactive placebo laser device|The inactive placebo laser device looks identical to the active laser device, but does not emit any therapeutic light output.
3078628|NCT01376037|Active Comparator|Erchonia ML Scanner (MLS)|The Erchonia ML Scanner (MLS) is a low level laser light therapy device comprising 4 independent rotating diodes, each emitting 17mW 635nm of red laser light. The diodes are mounted in scanner devices positioned 120 degrees apart from each other, tilted at a 30 degree angle. The Erchonia® MLS is activated for 20 minutes per arm during which time the 4 rotating diodes create a spiraling circle pattern that is totally random and independent from the others. These patterns overlap each other to guarantee total coverage within the target area. The total laser energy the test subject is exposed to per treated arm is approximately 3.94 joules per square centimeter. Six procedures are administered evenly across 2 weeks.
3078629|NCT01376050|Active Comparator|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 milliWatts (mW) 635 nanometer (nm) light emitting diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center, and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
3078630|NCT01376050|Placebo Comparator|Placebo Laser|Placebo Laser has the same appearance and application as the Erchonia MLS but does not emit an therapeutic output.
3078631|NCT01376089|Other|Arm 1-Iodixanol|
3078632|NCT01376089|Active Comparator|Arm 2-Iopamidol|
3078633|NCT01376167|Experimental|Tafenoquine 50mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 50mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3078634|NCT01376167|Experimental|Tafenoquine 100mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 100mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3078635|NCT01376167|Experimental|Tafenoquine 300mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3078636|NCT01376167|Experimental|Tafenoquine 600mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 600mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3078637|NCT01376167|Active Comparator|Primaquine 15mg|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15.
3078638|NCT01376167|Placebo Comparator|Chloroquine only|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered.
3078639|NCT01376167|Experimental|Tafenoquine 300mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 300mg Tafenoquine will be administered on either Day 1 or Day2 depending on when eligibility is confirmed.
3078640|NCT01376167|Active Comparator|Primaquine 15mg (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered. 15mg Primaquine once daily Days 2-15
3078641|NCT01376167|Placebo Comparator|Chloroquine only (Part 2)|On Day 1 and Day 2 600mg Chloroquine will be administered, on Day 3 300mg Chloroquine will be administered
3078642|NCT01376245|Experimental|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
3078643|NCT01376245|Placebo Comparator|placebo|matching placebo
3078644|NCT01376297|Experimental|Netupitant and Palonosetron plus dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3078645|NCT01376297|Active Comparator|Aprepitant and Palonosetron plus dexamethasone|Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.
3078646|NCT01376310|Experimental|Cohort A|Subjects on GSK1120212 Monotherapy who have been treated less than 24 weeks in their parent study.
3078647|NCT01376310|Experimental|Cohort B|Subjects on GSK monotherapy who have been treated for 24 weeks or greater in their parent study. Also, subjects entering this study from any GSK1120212 combo trial.
3321070|NCT02015923|Experimental|colonic resection|Arm A (experimental): surgery (complete tumoral resection; R0) followed by chemotherapy, regimen according to each center.
3321071|NCT02015923|Active Comparator|Chemotherapy|Arm B (control): chemotherapy alone, regimen according to each center
3321073|NCT02015949|Active Comparator|Methylphenidate|2 weeks of 0.3mg/kg twice daily of methylphenidate to the nearest 5mg
3321074|NCT02015949|Placebo Comparator|Sugar pill|2 weeks of twice daily placebo
3321075|NCT02015962|Experimental|Intravenous potassium|Patients in this arm will be administered intravenous potassium if they develop hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. In the IVPR group, potassium will be given according to the hospital protocol through a central line. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 1 hour after replacement in the IVPR group.
3078658|NCT01376349|Experimental|Arm I low dose DHEA|Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone [DHEA]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3078659|NCT01376349|Experimental|Arm II high dose DHEA|Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3078660|NCT01376349|Placebo Comparator|Arm III placebo|Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.
3078661|NCT01376362|Experimental|Interferon gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
3078662|NCT01376388|Experimental|GSK573719/GW642444|125/25mcg
3078663|NCT01376557|Experimental|Treatment A|
3078664|NCT01376557|Experimental|Treatment B|
3078665|NCT01376557|Experimental|Treatment C|
3078666|NCT01376557|Experimental|Treatment D|
3078667|NCT01376557|Placebo Comparator|Placebo|
3078668|NCT01376700|Experimental|ADVATE - Prophylactic Regimen|Weekly infusions of ADVATE. Study visits (physical examination, lab tests including FVIII inhibitor tests) every week during the first 10 exposure days (EDs), every 5 weeks during the next 10 EDs and every 10 weeks thereafter.
3078669|NCT01376804|Experimental|Valganciclovir|Participants received a once daily oral dose (solution or tablets) of valganciclovir starting within 10 days of kidney transplant for up to 200 days post-transplant. Dose (in milligrams) was calculated using the algorithm [7 * Body Surface Area * Creatinine Clearance].
3078670|NCT01376908|Experimental|Kuvan® + Phe-restricted diet|Subjects will be treated with Kuvan® tablets once daily along with Phe-restricted diet therapy.
3078671|NCT01376908|Other|Phe-restricted diet alone|Subjects will follow a Phe-restricted diet alone.
3078672|NCT01377012|Experimental|AIN457 10mg/kg-75mg|Participants received AIN457 i.v. (10 mg/kg) at Baseline (BSL), Weeks 2 and 4 then AIN457 75 mg s.c. at Week 8 and injected every 4 weeks
3078673|NCT01377012|Experimental|AIN457 10mg/kg-150mg|Participants received AIN457 i.v. (10 mg/kg) at BSL, Weeks 2 and 4 then AIN457 150 mg s.c. at Week 8 and injected every 4 weeks
3078674|NCT01377012|Placebo Comparator|Placebo|Participants received matching placebo to AIN457 until week 16 or week 24 based on responder status (>= 20% reduction in tender and swollen joint count). Non-responders were switched to active treatment at week 16. Responders were switched to active treatment at week 24
3078675|NCT01377194|Experimental|1|40mg Levomilnacipran ER
3078676|NCT01377194|Experimental|2|80mg of Levomilnacipran ER
3078677|NCT01377194|Placebo Comparator|3|Placebo
3078678|NCT01377233|Experimental|Zicronapine open-label lead-in 10 mg daily|
3078679|NCT01377233|Experimental|Zicronapine 10 mg daily|
3078680|NCT01377233|Experimental|Zicronapine 20 mg once weekly|
3078681|NCT01377233|Experimental|Zicronapine 30 mg once weekly|
3078682|NCT01377233|Experimental|Zicronapine 45 mg once weekly|
3078683|NCT01377389|Experimental|Ipilimumab + ADT|Ipilimumab 10 mg/kg intravenous (IV) Weeks 5, 9, 13, and 17 plus Androgen Depravation Therapy (ADT) of either Leuprolide 7.5 mg intramuscular (IM) , Goserelin 3.6 mg subcutaneous (SQ) or Degarelix 80 mg SQ once a month for 8 months beginning Week 1.
3078684|NCT01377402||Chest pain|Men and women admitted with chest pain and suspected acute coronary syndrome (ACS).
3078685|NCT01377467|Experimental|Denosumab|60 mg denosumab s.c. at baseline and after 6 months
3078686|NCT01377467|No Intervention|Control|No treatment
3078687|NCT01377480|Experimental|Posaconazole|Posaconazole (POS) 400 mg (10 mL) oral suspension twice daily for 60 days
3078688|NCT01377480|Placebo Comparator|Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days
3078689|NCT01377480|Experimental|Posaconazole + Benznidazole|Posaconazole 400 mg (10 mL) oral suspension twice daily for 60 days and benznidazole (BNZ) 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
3078690|NCT01377480|Active Comparator|Benznidazole + Placebo|Posaconazole placebo (10 mL) oral suspension twice daily for 60 days and benznidazole 100 mg oral tablet twice daily (200-mg daily dose) for 60 days
3078691|NCT01377584|Experimental|Patients in the Couple-oriented intervention|Patients randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with their partner and participate in an individual telephone follow-up session.
3078692|NCT01377584|Other|Patients in Usual Care|Patients will not attend any intervention sessions.
3078693|NCT01377584|Experimental|Patients in the Patient-oriented intervention|Patients randomly assigned to the patient-oriented (PT) group will attend two face to face sessions and participate in a telephone follow-up session.
3078694|NCT01377584|Experimental|Partners in the Couple-oriented intervention|Partners randomly assigned to the couple-oriented (CO) group will attend two face to face sessions with the patient and participate in an individual telephone follow-up session.
3078695|NCT01377584|Other|Partners in Usual Care|Partners will not attend any intervention sessions.
3078696|NCT01377584|Experimental|Partners in the Patient-oriented intervention|Partners randomly assigned to the patient-oriented (PT) group will not attend any intervention sessions.
3078697|NCT01377623|Placebo Comparator|Placebo group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
3078698|NCT01377623|Experimental|Dexmedetomidine group|Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
3468868|NCT03891524|Experimental|Group A: JNJ-70033093 25 mg + Placebo BID|Participants will receive JNJ-70033093 25 milligram (mg) (1*25 mg capsule) and 1 placebo capsule twice daily (BID), orally for 10 to 14 postoperative days.
3078699|NCT01377636|Experimental|Isoproterenol, BIS, forearm test|30 consecutive patients scheduled for EP studies under general anesthesia will participate in the study. Patients with neuromuscular disease precluding the use of succinylcholine will be excluded. The only other exclusions will be patient or cardiologist refusal. No attempts will be made to alter concurrent patient medication.
3078700|NCT01377844|Experimental|EGT0001442|EGT0001442 capsule, 20 mg, daily, 96 weeks
3078701|NCT01377844|Placebo Comparator|Placebo|Placebo
3078702|NCT01377922|Placebo Comparator|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
3078703|NCT01377922|Experimental|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
3078704|NCT01377987|Experimental|Acetazolamide|
3078705|NCT01377987|Placebo Comparator|Sugar pill|
3078706|NCT01378104|Experimental|80% dosage group of peginterferon alfa 2a|This group patients will treated the same full dose (180ug/week) of peginterferon alfa 2a during the first 12 weeks and then reduce the 75% dose (135ug/week) of peginterferon alfa 2a during remnant 36 weeks. At a result, these patients treated with 80% dosage of originally prescribed peginterferon alfa-2a for standard 48 weeks of treatment.
3078707|NCT01378104|Active Comparator|100% dosage group of peginterferon alfa 2a|These group patients would be treated with standard dose 180 ug/week for 48 weeks.
3078708|NCT01378117|Experimental|Sitagliptin + SSI prn|Sitagliptin once daily plus supplemental doses of lispro if needed using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with GFR 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
3078709|NCT01378117|Experimental|Sitagliptin and glargine+ SSI|Sitagliptin 50-100 mg per oral once a day and SubCutaneous (SQ) glargine insulin once daily + correctional doses of lispro if needed for elevated blood glucose using sliding scale insulin (SSI). 100 mg/day (at any time of day) for patients with glomerular filtration rate (GFR) 50-100 ml/min and 50 mg/day for patients with GFR 30-50 ml/min
3078710|NCT01378117|Active Comparator|Glargine and Lispro + SSI|Glargine once daily and lispro before meals supplemental insulin lispro as needed for elevated blood glucose using sliding scale insulin (SSI)
3078711|NCT01378195|Experimental|CBT-based|CBT-based program (Cognitive Behavioral Therapy) with video, workbook, and website
3078712|NCT01378195|Active Comparator|Educational/Resources Materials|Educational/Resources Materials: video, workbook, and website.
3078713|NCT01378221||Group 1|cardiac surgery patients age 65 years and less
3078714|NCT01378221||Group 2|cardiac surgery patients aged 75 years and over
3078715|NCT01378273|Placebo Comparator|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
3078716|NCT01378273|Experimental|Epo 1000 U/kg followed by 400 U/kg|Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.
3078717|NCT01378299|Experimental|Arm 1: Testosterone Cypionate|All patients who qualify for the study will receive testosterone cypionate
3078718|NCT01378325|Experimental|Phenylephrine|PHenylephrine infusion started at 0.75 microgram per kg per mL started at spinal injection till delivery
3078719|NCT01378325|Placebo Comparator|Saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
3078720|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 12.5 mg|
3078721|NCT01378377|Experimental|Pimasertib 45 mg+Temsirolimus 25 mg|
3078722|NCT01378377|Experimental|Pimasertib 75 mg+Temsirolimus 25 mg|
3078723|NCT01378416|Experimental|1|
3078724|NCT01378429|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
3078725|NCT01378429|Placebo Comparator|Placebo|
3078726|NCT01378520|Experimental|ketoconazole|600 mg ketoconazole
3078727|NCT01378520|Placebo Comparator|inert powder|inert powder in capsule
3078728|NCT01378858|Experimental|Varenicline treatment as usual (TAU)|Subjects in the TAU arm will self administer varenicline for 12 weeks.
3078729|NCT01378858|Experimental|Varenicline directly observed therapy|Subjects in the directly observed therapy (DOT) arm will receive varenicline directly administered by methadone clinic nurses 4-6 times per week at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
3078730|NCT01378962|Experimental|Single Arm|
3078731|NCT01378975|Experimental|Cohort 1: Previously Untreated Participants|Participants who had not received previous treatment for brain metastases [i.e., had never received brain stereotactic radiotherapy (SRT), whole-brain radiotherapy (WBRT), surgery, or any other treatment for their brain metastases] received Vemurafenib 960 milligram (mg) tablet orally, twice daily (BID) from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
3078732|NCT01378975|Experimental|Cohort 2: Previously treated Participants|Participants who were previously treated with brain SRT, WBRT, or surgery for their brain metastases and have progressed following this treatment, received Vemurafenib 960 milligram (mg) tablet orally, BID from Day 1 until development of progressive disease within the brain or outside of the brain (whichever occurred first), unacceptable toxicity, consent withdrawal, protocol violation endangering participant's safety, death, reasons deemed by the investigator, or study termination by the Sponsor.
3078733|NCT01378988|Experimental|Dose level 1|Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion
3078734|NCT01378988|Experimental|Dose level 2|Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion
3078735|NCT01379183|Active Comparator|Erythromycin|Erythromycin 200 mg i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
3078736|NCT01379183|Placebo Comparator|Placebo|Matching placebo i.v. suspension, Barium Sulfate Solution, and Magnetic Resonance Imaging
3078737|NCT01379222|Experimental|ENGAGE PAS De Novo Subjects|The Endurant Stent Graft System Bifurcated device is administered to patients diagnosed with an abdominal aortic or aortoiliac aneurysm who are considered candidates for endovascular repair, per the FDA approved Instructions For Use (IFU).
3078738|NCT01379508|Experimental|telbivudine|telbivudine 600 mg tablet orally (p.o.) once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with tenofovir 300 mg tablets p.o. once daily for the remaining weeks of treatment. The investigator was to initiate tenofovir add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive telbivudine monotherapy
3078739|NCT01379508|Active Comparator|tenofovir|tenofovir 300 mg tablets p.o. once daily for up to 156 weeks. Patients with HBV DNA ≥ 300 copies/mL at Week 24 were to initiate add-on therapy with telbivudine 600 mg tablet p.o. once daily for the remaining weeks of treatment. The investigator was to initiate telbivudine add-on therapy within 2 weeks of central laboratory confirmation. Patients with HBV DNA < 300 copies/mL at Week 24 were to continue to receive tenofovir monotherapy
3078740|NCT01379521|Experimental|everolimus + TACE|everolimus 7.5mg/day by mouth + transcatheter arterial chemoembolization (TACE)
3078741|NCT01379521|Placebo Comparator|placebo + TACE|Placebo by mouth + transcatheter arterial chemoembolization (TACE)
3078742|NCT01379534|Experimental|TKI258|1 treatment arm (single agent TKI258), with patients classified into 2 groups based on their FGFR2 mutation status
3078743|NCT01379573|Experimental|Pregnant women with previous child with cardiac neonatal lupus|400 mg/day Hydroxychloroquine
3078744|NCT01379625|Active Comparator|Medium Chain Triglyceride (MCT)|Subjects randomized to consume 20% of energy from MCT
3078745|NCT01379625|Experimental|Triheptanoin|Subject randomized to consume 20% of energy from triheptanoin.
3078746|NCT01379651|Experimental|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of food antigen
3078747|NCT01379651|No Intervention|control|controls were kept on an egg-free diet for 6 months
3078748|NCT01379664|Experimental|Isoflurane|Isoflurane is to be administered to patients in this arm during surgery
3078749|NCT01379664|Experimental|Sevoflurane|Sevoflurane is to be administered to patients in this arm during surgery
3078750|NCT01379703||Single patients group|Single HIV-1 infected patients group
3078751|NCT01379768|Active Comparator|Lotrafilcon A|Lotrafilcon A contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon A contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
3078752|NCT01379768|Active Comparator|Lotrafilcon B|Lotrafilcon B contact lenses worn on a daily wear basis for 1 week, followed by 8 hours overnight wear in a replacement pair. After a 12-hour washout period, a new pair of lotrafilcon B contact lenses were dispensed for 4 weeks of daily wear, followed by 8 hours overnight wear.
3078753|NCT01379768|No Intervention|No lens wear|No contact lens wear for the duration of the study. One 8-hour sleep at 1 week, followed by an 8-hour sleep 4 weeks later.
3078754|NCT01379781|Experimental|Behavioral Intervention for PPD|Behavioral Intervention for PPD delivered over 3 in-person sessions.
3078755|NCT01379781|No Intervention|Treatment As Usual|Referred to Treatment in the Community.
3078756|NCT01379924|Experimental|Young Parents Program plus Parenting/Life Skills modules|In addition to receiving standard medical and social services for young parents and their children, patient takes part in 5 one on one modules during the first year of child's life aimed at educational attainment, budgeting, child development, safety in the home and substance abuse.
3078757|NCT01379924|Active Comparator|Young Parents Program usual care|Patients receive regular standard of care without modules.
3078758|NCT01379937|Experimental|GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1, a booster vaccination dose of Influenza vaccine GSK1562902A Formulation 2 and 1 dose of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3078759|NCT01379937|Experimental|GSK1562902A Formulation 1 - Havrix / Havrix Jr Group|Subjects in this group received 2 primary vaccination doses of Influenza vaccine GSK1562902A Formulation 1 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3078760|NCT01379937|Active Comparator|GSK1562902A Formulation 2 - Havrix / Havrix Jr Group|Subjects in this group received 1 dose of Influenza vaccine GSK1562902A Formulation 2 and 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3078761|NCT01379937|Active Comparator|Havrix / Havrix Jr Group|Subjects in this group received 2 doses of Havrix™ or Havrix™ Junior vaccine, administered intramuscularly in the deltoid region.
3078762|NCT01379963||Cohort|
3078763|NCT01380080|Experimental|Arm A: Empiric|Study treatment for Arm A participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral treatment as soon as possible following randomization and within no more than 3 days following randomization plus a 4-drug anti-tuberculosis treatment (ATT) regimen (defined as rifampin/isoniazid/ethambutol/pyrazinamide) as soon as possible following randomization and within no more than 7 days following initiation of antiretroviral therapy. After 2 months (or 8 weeks), the 4-drug ATT will be followed with 4 months (or 16 weeks) of 2-drug ATT (defined as rifampin/isoniazid). All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only
3078764|NCT01380080|Experimental|Arm B: IPT|Study treatment for Arm B participants is the strategy of initiating study-provided or other FDA-approved or tentatively approved antiretroviral therapy as soon as possible following randomization and within no more than 3 days following randomization and of initiating anti-TB treatment (ATT) only when indicated according to local standard practice and at the discretion of the site investigator. All participants will be followed through week 96. Drug provision by or through the study will be through week 48 only. Pyridoxine is provided by the sites to all participants while they are receiving isoniazid (INH).
3078765|NCT01380093|Placebo Comparator|Placebo|
3078766|NCT01380093|Active Comparator|MS Contin (morphine sulfate, controlled release)|
3078767|NCT01380093|Experimental|EMBEDA (morphine sulfate / naltrexone hydrochloride)|
3078768|NCT01380106|Active Comparator|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
3078769|NCT01380106|Active Comparator|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15mg once daily for days 1-21 out of a 28 cycle
3078770|NCT01380145|Experimental|recMAGE-A3 Protein + AS15 Adjuvant|Subjects received a total of 8 pre- and post-auto-SCT immunizations with recMAGE-A3 + AS15.
3078771|NCT01380184|Experimental|Ridaforolimus 40 mg|In Part 1 (Days 1-19), participants received ridaforolimus (MK-8669) 40 mg via oral enteric-coated tablet on Day 1; followed by no study treatment on Days 2-7; followed by two weekly sequences (Days 8-19) consisting of 5 consecutive days of ridaforolimus 40 mg and 2 consecutive days off study treatment. Following Part 1, participants underwent at least a 2-day study treatment washout prior to starting Part 2. In Part 2, participants received a weekly treatment regimen consisting of 5 consecutive days (Days 1-5) of ridaforolimus 40 mg via oral enteric-coated tablet and 2 consecutive days (Days 6-7) off study treatment. This weekly treatment regimen was repeated every subsequent week for the remainder of participation in Part 2.
3078772|NCT01380197|Active Comparator|Randomizing particiipants to Morphine|Randomizing participants to Morphine or Nubain for treatment of Sickle Cell Pain Crisis
3078773|NCT01380197|Active Comparator|Randomization to Nubain|Randomization toNubain or Morphine for the management of Pain Crisis in Sickle Cell patients
3078774|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 420 microliters daily
3078775|NCT01380327|Placebo Comparator|Placebo|Placebo administered sublingually not to exceed the maximally tolerated dose of either 1.) 420 microliters daily (placebo - low dose randomization) or 2.) 840 microliters twice daily (placebo - high dose randomization)
3078776|NCT01380327|Experimental|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Glycerinated German cockroach (Blatella germanica) allergen extract administered sublingually with a maximally tolerated dose of 840 microliters taken twice daily
3078777|NCT01380366|Other|Patients consent to rHGH study|Patients consent to be given growth hormone (rHGH) for their short bowel syndrome.
3078778|NCT01380379|Experimental|Life skills and self-defense training|Women will participate in a therapeutic group which covers education, skills, and empowerment activities.
3078779|NCT01380535|Experimental|ECP Methoxsalen + Standard of Care|Participants receive methoxsalen administered via ECP in addition to standard of care
3078780|NCT01380535|Active Comparator|Standard of Care|Participants receive standard of care only
3078781|NCT01380639|Experimental|Rehabilitation with vibration training|
3078782|NCT01380639|No Intervention|Rehabilitation without vibration training|
3078783|NCT01380691|Experimental|LY, Alc, Pl-Match Alc, Then Pl-Match LY, Alc, Pl-Match Alc|"Period 1: 18 milligrams (mg) LY2216684 (LY) administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic (Alc) beverage (with an alcohol dose of 0.6 grams per kilograms [g/kg] for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching (Pl-Match) alcoholic beverage, taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
3078784|NCT01380691|Experimental|Pl-Match LY, Alc, Pl-Match Alc, Then LY, Alc, Pl-Match Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time. On Day 8, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
3078785|NCT01380691|Experimental|LY, Pl-Match Alc, Alc, Then Pl-Match LY, Pl-Match Alc, Alc|"Period 1: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
3078786|NCT01380691|Experimental|Pl-Match LY, Pl-Match Alc, Alc, Then LY, Pl-Match Alc, Alc|"Period 1: Placebo-matching LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~Period 2: 18 mg LY2216684 administered orally, once daily for 8 days. On Day 6, participants were administered 2 cups of a placebo-matching alcoholic beverage, taken orally, one time. On Day 8, participants were administered 2 cups of an alcoholic beverage (with an alcohol dose of 0.6 g/kg for women and 0.7 g/kg for men), taken orally, one time.~There was a 7-day washout period between Periods 1 and 2."
3078787|NCT01380730|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3078788|NCT01380730|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3078789|NCT01380730|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078790|NCT01380730|Experimental|Evolocumab 105 mg Q2W|Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078791|NCT01380730|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3078792|NCT01380730|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078793|NCT01380730|Experimental|Evolocumab 350 mg Q4W|Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078794|NCT01380730|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3078795|NCT01380743|Experimental|Cohort 1, Duvoglustat 50 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 50 milligram (mg) oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3078796|NCT01380743|Experimental|Cohort 2, Duvoglustat 100 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 100 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3078797|NCT01380743|Experimental|Cohort 3, Duvoglustat 250 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 250 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3078798|NCT01380743|Experimental|Cohort 4, Duvoglustat 600 mg + rhGAA|"During Period 1, participants received a single intravenous infusion of rhGAA. During Period 2, each participant received a single 600 mg oral dose of duvoglustat 1 hour prior to initiation of a single rhGAA infusion.~Participants were on a stable regimen and dose of rhGAA for at least 3 months before screening."
3078799|NCT01380769|Experimental|CRLX101|
3078800|NCT01380769|Other|Best supportive care|
3078801|NCT01380782|Experimental|Bevacizumab Naive|Bevacizumab naive subjects
3078802|NCT01380782|Experimental|Prior Bevacizumab|Patients previously treated with bevacizumab
3078803|NCT01380834|Active Comparator|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
3078804|NCT01380834|Placebo Comparator|Placebo group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
3078805|NCT01380899||PD Parkinson´s Disrease|We are studying the presence of alpha-synuclein in the epidermis and dermis besides the end nerve terminal. We have several reports until now, and we are following the study because we wish to convince the academic and scientific society over the utility of this study to be close to the molecular diagnosis of this kind of disease.
3078806|NCT01380899||AP Atypical Parkinsonism|with neurodegenerative disease (proteinopathies) and secondary AP.
3078807|NCT01380899||Control group|Subjects without neurodegenerative disease and apparently good health status with an age that matches the problems groups
3078808|NCT01380990|Experimental|Gene Therapy|Infusion of autologous EFS-ADA LV CD34+ cells
3078809|NCT01380990|Other|Historical Control Group|Historical data from ADA-SCID patients who were treated with Hematopoietic Stem Cell Transplantation (HSCT)
3078810|NCT01381016|Other|Group 1 - Normal Weight|"Group 1: Normal weight (BMI 18-25 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
3078811|NCT01381016|Experimental|Group 2 - Obese|"Group 2: Obese (BMI >30 kg/m2)~Subjects were instructed to apply 0.1 mg/d transdermal estrogen (Estradiol) for one month. Pituitary response was assessed to determine how estradiol administration altered pituitary sensitivity to Gonadotropin-releasing hormone - GnRH. Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary."
3078812|NCT01381068|Experimental|Monitored Arm|The end tidal CO2 sensor is placed in the respiratory circuit and the monitor is visible to the resuscitation team. The resuscitation team is instructed to adjust ventilation to keep EtCO2 levels between 40-55.
3078813|NCT01381068|Placebo Comparator|Control Arm|The end tidal CO2 sensor is placed in th respiratory circuit. The monitor is covered so the resuscitation team can not see the display. The resuscitation team is instructed to provide ventilation according to clinical judgment.
3078814|NCT01381120|Experimental|VESIcare + Narcotic Painkiller|VESIcare: Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
3078815|NCT01381120|Active Comparator|Narcotic Painkiller|Oxycodone and acetaminophen combination treatment: Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
3078816|NCT01381172|Experimental|Treatment|The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.
3078817|NCT01381172|Other|Control|The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.
3078818|NCT01381406||COPD patients|Patients who are at least 40 years of age and diagnosed with COPD using ICD-9 codes of 491.xx, 492.xx, and 496.xx in an administrative claims database.
3078819|NCT01381471||COPD|Patients with a diagnosis code of COPD
3078820|NCT01381549|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
3078821|NCT01381549|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
3078822|NCT01381549|Active Comparator|imipenem-cilastatin|500 mg imipenem monohydrate and 500 mg cilastatin sodium; q6h administered via IV infusion, plus saline placebo
3078823|NCT01381562|Experimental|GSK2251052 750mg|q12h administered via IV infusion, plus saline placebo
3078824|NCT01381562|Experimental|GSK2251052 1500mg|q12h administered via IV infusion, plus saline placebo
3078825|NCT01381562|Active Comparator|Meropenem 1G|q8h administered via IV infusion, plus saline placebo
3078826|NCT01381575|Experimental|Cervarix 1 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3078827|NCT01381575|Active Comparator|Cervarix 2 Group|Female subjects aged 15 to 25 years at the time of the first vaccination, who received 3 doses of the Cervarix vaccine at Day 0, at Month 1 and at Month 6, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3078828|NCT01381575|Experimental|Cervarix 3 Group|Female subjects aged 9 to 14 years at the time of the first vaccination, who received 2 doses of the Cervarix vaccine at Day 0 and at Month 12, respectively. The vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm.
3078829|NCT01381679||All participants|Participants in whom LDL-C target levels have not been achieved and for whom ezetimibe therapy has been chosen.
3078830|NCT01381692|Active Comparator|Arm I (rituximab, bortezomib, dexamethasone)|Patients receive rituximab IV over 30-60 minutes on days 1, 8, 15, and 22 (of courses 1 and 4 only) and bortezomib IV or SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3078831|NCT01381692|Experimental|Arm II (temsirolimus, rituximab, bortezomib, dexamethasone)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and rituximab, bortezomib, and dexamethasone as in arm I. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3078832|NCT01381718|Experimental|Arm I|Participants receive modafinil orally (PO) once daily (QD) on days 1-42.
3078833|NCT01381718|Placebo Comparator|Arm II|Participants receive placebo PO QD on days 1-42.
3078834|NCT01381861|Experimental|Carotuximab (TRC105) alone|Single arm, open label Carotuximab (TRC105) alone therapy dosed at 10 mg/kg administered intravenously over 1 to 4 hours on days 1, 8, 15 and 22 of each 28 day cycle
3078835|NCT01381874|Experimental|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate + Prednisone or Prednisolone Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use. All drugs are taken once daily.
3078836|NCT01381874|Experimental|Abiraterone acetate + Prednisone/Prednisolone + Exemestane|Abiraterone acetate + Prednisone/Prednisolone + Exemestane Abiraterone acetate type=equal unit=mg number=250 form=tablet route=oral use 4 tablets Prednisone or Prednisolone type=equal unit=mg number=5 form=tablet route=oral use Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
3078837|NCT01381874|Experimental|Exemestane|Exemestane Exemestane type=equal unit=mg number=25 form=tablet route=oral use. All drugs are taken once daily.
3078838|NCT01381900|Experimental|Canagliflozin 100mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3078839|NCT01381900|Experimental|Canagliflozin 300mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3078840|NCT01381900|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks with protocol-specified doses of metformin alone or metformin plus sulphonylurea.
3078841|NCT01381926|Experimental|Exenatide then Placebo|"Study participants in phase1 will receive the study drug, exenatide, at a dose of 5mg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the dose of exenatide will be increased to 10mg subcutaneously twice daily before meals for one month. During the third month of the study, no study medication will be given and this will serve as a wash out period prior to the second phase of the study (placebo). During the fourth and fifth months, study participants will get placebo alternatives to exenatide 5mg and exenatide 10mg, respectively, subcutaneously twice daily before meals."
3078842|NCT01381926|Active Comparator|Placebo then Exenatide|"Study participants in phase1 will receive the saline placebo, at a dose of 5mcg subcutaneously twice daily 30 minutes before meals for one month. During the second month of the study, the saline placebo will be increased to 10mcg subcutaneously twice daily before meals for one month. During the third month of the study, no treatment will be given and this will serve as a wash out period prior to the second phase of the study. During the fourth month study participants will receive Exenatide 5mcg twice daily with meals. During the fifth month, study participants will receive exenatide 10mcg, subcutaneously twice daily before meals."
3078843|NCT01381952|Experimental|Reduced radiation dose (ClarityIQ)|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology
3078844|NCT01381952|Active Comparator|Normal radiation dose (AlluraXper)|Normal dose DSA with conventional X-ray technology.
3078845|NCT01382108||Normal participants|
3078846|NCT01382108||Meibomian Gland Dysfunction|
3078847|NCT01382186||Purposive Sampling|Purposive sampling was used to identify a sample of 33 Veterans who have been Personally Authenticated for the SM feature on MHV. Participants were recruited from each site (Tampa, Boston). Women were purposively recruited to ensure females were represented in data findings.
3078848|NCT01382186||Random Sampling|Random sampling was used to conduct a quantitative survey with 819 veterans to explore their experiences using secure messaging.
3078849|NCT01382212|Experimental|Paricalcitol|Open-label paricalcitol (maximum dose of 16 µg), 3 times weekly (no more frequently than every other day) for 12 weeks.
3078850|NCT01382225|Experimental|Sodium Hyaluronate|Sodium Hyaluronate Ophthalmic Solution, 0.18%, 1-2 drops instilled in each eye 3-6 times a day for 14 days
3078851|NCT01382225|Placebo Comparator|Vehicle|Inactive ingredients, 1-2 drops instilled in each eye 3-6 times a day for 14 days
3078852|NCT01382251||Patient|Patients undergoing ambulatory surgery
3078853|NCT01382251||Caregiver|Spouse, family members, or friends identified as the patient's primary source of support in the community.
3078854|NCT01382303|Active Comparator|Pentoxifylline|Pentoxifylline 400mg three times a day
3078855|NCT01382303|Placebo Comparator|Placebo|placebo tablet
3078856|NCT01382446|Active Comparator|Standard Oral Care Regimen|Current oral care protocol includes the use of 1.5% H2O2-coated swabs every four hours, toothbrushing with toothpaste every 12 hours, and use of continuous subglottic suction apparatus.
3078857|NCT01382446|Experimental|Chlorhexidine Oral Care Regimen|This study will compare our current oral care practice with the use of Chlorhexidine Gluconate 0.12% (Peridex, 3M Corporation) Twice daily in addition to regularly scheduled oral care as a means to decrease the incidence of VAP utilizing evidence-based strategies.
3078858|NCT01382602|Experimental|AMDC-USR|Subjects received 1 or 2 treatments of 150 million AMDC-USR delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded. Subjects were followed for 2 years after initial AMDC-USR treatment.
3078859|NCT01382602|Placebo Comparator|Placebo|Subjects received 1 or 2 treatments of placebo delivered via transurethral intrasphincteric injection. After completing 12 months follow-up subjects were unblinded and could elect to receive open-label AMDC-USR treatment. Subjects that received unblinded AMDC-USR treatment were followed for 2 years after initial placebo treatment.
3078860|NCT01382719|Placebo Comparator|Placebo|Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.
3078861|NCT01382719|Experimental|bremelanotide arm 1|Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3078862|NCT01382719|Experimental|bremelanotide arm 2|Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3078863|NCT01382719|Experimental|bremelanotide arm 3|High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
3078864|NCT01382901|Experimental|Intravenous (IV) Iron|
3078865|NCT01382901|Placebo Comparator|Placebo|
3078866|NCT01382940|Experimental|Rituximab|Rituximab intravenous (IV) infusions were administered over a 4.25-hour period on Day 1, and over a 2-hour period on Day 15 (first course) and on Days 168 and 182 (second course). All participants continued to receive methotrexate as prescribed by their treating physician. Premedication included methylprednisolone, an antihistamine and acetaminophen.
3078867|NCT01383005||Kaletra (LPV/r) QD as First Kaletra Treatment|HIV-infected participants treated with lopinavir/ritonavir once daily (LPV/r QD) from ≥3 months to <2 years who had not been treated with any of the following: LPV/r twice daily (BID), a protease inhibitor, or a ritonavir-boosted protease inhibitor.
3078868|NCT01383005||Kaletra (LPV/r) QD from Kaletra BID|HIV-infected participants treated with LPV/r from ≥3 months to <2 years who had initiated on LPV/r BID and at any time within this period (but at least 3 months before inclusion in the study) had changed dosing from BID to QD.
3078869|NCT01383018||AMS penile prosthesis receipients|Men for whom an AMS penile prosthesis is recommended
3078870|NCT01383096|Active Comparator|Cohort 1 - Treatment A: OZ439 800mg PIB, fed|OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.
3078871|NCT01383096|Experimental|Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.
3078872|NCT01383096|Experimental|Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.
3078873|NCT01383096|Experimental|Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted|Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.
3078874|NCT01383096|Experimental|Cohort 1 - Treatement B: OZ439 800mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
3078875|NCT01383096|Experimental|Cohort 1 - Treatment C:OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
3078876|NCT01383096|Experimental|Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted|Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.
3078877|NCT01383096|Experimental|Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.
3078878|NCT01383096|Experimental|Cohort 2 - Treatement F: OZ439 800 mg PIB fasted|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.
3078879|NCT01383096|Experimental|Cohort 2 - Treatement G: OZ439 800mg PIB with milk|OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.
3078880|NCT01383096|Experimental|Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk|OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.
3078881|NCT01383161|Active Comparator|Curcumin|Theracurmin (180mg/day)
3078882|NCT01383161|Placebo Comparator|Placebo|Sugar Pill
3078883|NCT01383174|Experimental|Peer Support Program|Nuevo Amanecer is the peer support program. Participants receive the peer support program as soon as possible after randomization.
3078884|NCT01383174|No Intervention|Wait-list Control|Waits six months, and at the end of the six months is offered the option of participating in the peer support program.
3078885|NCT01383200|Active Comparator|Tetracaine R/Lidocaine L|Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
3078886|NCT01383200|Active Comparator|Tetracaine L/Lidocaine R|Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.
3078887|NCT01383213|Experimental|CPAP (group A)|group A will be treated with CPAP using a helmet, initial PEEP of 10 cmH20 and an FiO2 set in order to maintain SpO2 ≥92%
3078888|NCT01383213|Active Comparator|oxygen therapy (group B)|group B (standard treatment) will be treated with oxygen therapy by Venturi mask with an FiO2 set in order to maintain SpO2 ≥92%.
3078889|NCT01383317|Active Comparator|RIPC|A tourniquet on the thigh will be inflated to 300 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
3078890|NCT01383317|Sham Comparator|Sham RIPC|A tourniquet on the thigh will be inflated to 15 mmHg for 5 minutes then deflated for 5 minutes. This will be repeated three times
3078891|NCT01383356|Experimental|Linagliptin/Metformin medium dosecombo|patient to receive a single medium dose combination tablet containing Linagliptin and Metformin once daily
3078892|NCT01383356|Active Comparator|Linagliptin plus Metformin medium dose|patient to receive two individual tablets: Linagliptin and Metformin (medium dose)
3078893|NCT01383421||Participants With RA Receiving Adalimumab|"Participants with RA who were prescribed adalimumab based on current clinical practice criteria (regardless of participation in the study), with the first dose corresponding to the Enrollment/Baseline visit.~All participants were offered to participate in the PSP while treated with ADA for their RA."
3078894|NCT01383486|Experimental|Naproxen Sodium ER (BAYH6689) or Advil IR|Eligible subjects were provided with 24 Advil immediate-release (IR) caplets containing 200 mg Ibuprofen and Naproxen Sodium extended release (ER) tablets containing 660 mg Naproxen Sodium. Upon a single incidence of pain, subjects were instructed to review both packages and choose one product to use. Subject were not offered any additional instructions for use beyond what is on the packages.
3078895|NCT01383499|Experimental|Treatment A|patients inhale 2 puffs (low dose) once daily in the evening via Respimat inhaler
3078896|NCT01383499|Experimental|Treatment B|patients inhale 2 puffs (medium dose) once daily in the evening via Respimat inhaler
3078897|NCT01383499|Experimental|Treatment C|patients inhale 2 puffs (high dose) once daily in the evening via Respimat inhaler
3078898|NCT01383499|Placebo Comparator|Treatment D|patients inhale 2 puffs of placebo inhalation solution matching tiotropium once daily in the evening via Respimat inhaler
3078899|NCT01383616|Active Comparator|Unipedicular kyphoplasty|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
3078900|NCT01383616|Active Comparator|Bipedicular Kyphoplasty group|Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.
3078901|NCT01383707|Experimental|Bevacizumab + mFOLFOX-6|Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
3078902|NCT01383720|Experimental|Lotus Valve System|Patients enrolled in the study to receive treatment with the Lotus Valve System for symptomatic aortic valve stenosis
3078903|NCT01383759|Experimental|Bortezomib/Dexamethasone (BD) , STC & Maintenance BD|This is a pilot study to gain information and estimate the toxicity/tolerability of 1-3 cycles of BD, followed by HDM/ASCT, and maintenance therapy with BD in patients with MIDD associated with multiple myeloma and AL amyloidosis.
3078904|NCT01383928|Experimental|Phase 1: Ixazomib 3 mg or 3.7 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 1. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
3078905|NCT01383928|Experimental|Phase 2: Ixazomib 3 mg|Ixazomib (MLN9708), orally, twice-weekly in combination with lenalidomide orally and dexamethasone orally as prescribed, in 21-day treatment cycles for up to 16 cycles in the absence of disease progression or unacceptable toxicity as induction therapy during Phase 2. Participants with stable or responding disease continued receiving ixazomib (MLN9708) orally, twice weekly in 21-day treatment cycles as maintenance therapy until progressive disease or unacceptable toxicity.
3078906|NCT01383954|Other|Diclofenac gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
3078907|NCT01383993|Experimental|1.0|Immunocompromised children aged 2 to <15 and 12 to <15 years weighing <50 kg who are at high risk for systemic fungal infection.
3078908|NCT01383993|Experimental|2.0|Immunocompromised children aged 12 to <15 years weighing more than 50 kg who are at high risk for systemic fungal infection.
3078909|NCT01384019|Experimental|DP-TA|distal protection and thrombus aspiration during primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI)
3078910|NCT01384019|Placebo Comparator|c-PCI|conventional PCI without DP-TA during primary percutaneous coronary intervention for ST-elevation myocardial infarction
3078911|NCT01384292|Experimental|1 (part A and B)|Oral treatment
3078912|NCT01384292|Experimental|2 (part A and B)|Oral treatment
3078913|NCT01384292|Placebo Comparator|3 (part A only)|Oral treatment
3078914|NCT01384539|Experimental|Cholecalciferol|Cholecalciferol 4000 IU capsule by mouth daily x 1 month then 2000 IU capsule by mouth daily x 5 months
3078915|NCT01384539|Experimental|Calcitriol|Calcitriol 0.25 mcg capsule by mouth daily x 1 month then 0.5 mcg capsule by mouth daily x 5 months
3078916|NCT01384591|Experimental|Losartan and placebo N-acetylcysteine|losartan (25mg/dose) and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
3078917|NCT01384591|Placebo Comparator|Placebo losartan and placebo N-acetylcysteine|Placebo losartan and placebo N-acetylcysteine (NAC) 3 total doses: 1 dose on day 1, 2 doses on day 2.
3078918|NCT01384591|Experimental|N-acetylcysteine and placebo losartan|N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
3078919|NCT01384734|Experimental|Arm A: BMS-663068 (400mg) + Raltegravir + Tenofovir|Treatment Group 1
3078920|NCT01384734|Experimental|Arm B: BMS-663068 (800 mg) + Raltegravir + Tenofovir|Treatment Group 2
3078921|NCT01384734|Experimental|Arm C: BMS-663068 (600 mg) + Raltegravir + Tenofovir|Treatment Group 3
3078922|NCT01384734|Experimental|Arm D: BMS-663068 (1200 mg) + Raltegravir + Tenofovir|Treatment Group 4
3078923|NCT01384734|Active Comparator|Arm E: Atazanavir + Ritonavir + Raltegravir + Tenofovir|Treatment Group 1 (reference arm)
3078924|NCT01384760|Active Comparator|Lifestyle modification program|"At the 1st session, the dietitian carried out a complete behavioral assessment, with emphasis on patient's current eating and lifestyle patterns, specific eating-related behaviors, knowledge of risks associated with current eating patterns, and concerns and feelings about specific lifestyle changes. In the subsequent follow up visit, the dietitian reviewed the 7-day food diaries to ensure nutritional adequacy and treatment compliance, and also offered recommendations for controlling caloric intake.~Patients were encouraged to see an exercise instructor who designed an individualized suitable exercise regime with cardiovascular and resistance exercises for the patients to perform at home. Subjects were encouraged to perform 30-minute aerobic exercise 2-3 times a week."
3078925|NCT01384760|Placebo Comparator|Simple lifestyle advice|Subjects in control group received simple lifestyle advice from a clinician at baseline and month 6. This was a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects were encouraged to perform regular 30-minute exercise 2 to 3 times per week. This was to resemble routine clinical practice.
3078926|NCT01384877|Experimental|Lidocaine|Lidocaine
3078927|NCT01384877|Placebo Comparator|Placebo (D5W)|Placebo first as compared with lidocaine first
3078928|NCT01385098|Experimental|Vitamin D3 and Calcium|Dietary supplement of vitamin D3 and calcium
3078929|NCT01385137|Experimental|Arm I|Patients receive oral omega-3-fatty acid twice daily (BID) or three times daily (TID) for 24 weeks in the absence of disease progression or unacceptable toxicity.
3078930|NCT01385137|Placebo Comparator|Arm II|Patients receive oral placebo BID or TID for 24 weeks in the absence of disease progression or unacceptable toxicity.
3078931|NCT01385176|Experimental|Therapy|"Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period.~The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant.~Titration during the randomization phase with delivery of highest tolerable by patient stimulation current.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
3078932|NCT01385176|Sham Comparator|Control|"Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation.~Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current."
3078933|NCT01385189|Experimental|Cohort 1|10 μg Na-GST-1/Alhydrogel vs. 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3078934|NCT01385189|Experimental|Cohort 2|30 μg Na-GST-1/Alhydrogel vs. 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3078935|NCT01385189|Experimental|Cohort 3|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3078936|NCT01385189|Experimental|Cohort 4|100 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)
3078937|NCT01385189|Experimental|Cohort 5|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)
3078938|NCT01385202|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
3078939|NCT01385293|Experimental|Study arm|BKM120 at 100mg orally daily
3078940|NCT01385306|Experimental|AlphaCore System|non-invasive vagus nerve stimulation (nVNS) using the AlphaCore System
3078941|NCT01385371|Experimental|SCH 697243|
3078942|NCT01385371|Placebo Comparator|Placebo|
3078943|NCT01385566|Active Comparator|Full Dose Subcutaneous|Participants will receive a full dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Nine participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1.
3078944|NCT01385566|Experimental|1/3 Dose Subcutaneous|Participants will receive a 1/3 dose of ZOSTAVAX™ administered subcutaneously on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3078945|NCT01385566|Experimental|Full Dose Intradermal|Participants will receive a full dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3078946|NCT01385566|Experimental|1/3 Dose Intradermal|Participants will receive a 1/3 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3078947|NCT01385566|Experimental|1/10 Dose Intradermal|Participants will receive a 1/10 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3078948|NCT01385566|Experimental|1/27 Dose Intradermal|Participants will receive a 1/27 dose of ZOSTAVAX™ administered intradermally on Day 1 of the study. Six participants in this group will also receive saline placebo intradermally in the alternate limb on Day 1. Participants will have the option to receive a full subcutaneous dose of ZOSTAVAX™ after completion of the study.
3078949|NCT01385579|No Intervention|usual care|Patients assigned to the usual care arm may be referred for colorectal cancer screening by their providers per usual health center protocol and practice. They receive no additional outreach by the preventive care care manager.
3078950|NCT01385579|Experimental|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit
3078951|NCT01385644|Experimental|1*10^6 MSC / kg|Placental MSC
3078952|NCT01385644|Experimental|2*10^6 MSC / kg|Placental MSC
3078953|NCT01385696|Experimental|group A|Genuair first, HandiHaler second
3078954|NCT01385696|Experimental|group B|HandiHaler first, Genuair second
3078955|NCT01385748|Active Comparator|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablets, once de day, every day up to 8 weeks
3078956|NCT01385748|Active Comparator|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
3078957|NCT01385748|Placebo Comparator|Placebo Lauriad®|Placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
3078958|NCT01385995|Active Comparator|Continuous Positive Airway Pressure (CPAP)|
3078959|NCT01385995|Sham Comparator|Sham-Continuous Positive Airway Pressure (CPAP)|
3078960|NCT01386008|Other|enfilcon A + senofilcon A|Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
3078961|NCT01386125|Experimental|Mometasone Furoate Nasal Spray (MFNS)|Participants receive mometasone furoate nasal spray (MFNS) 200 mcg twice daily (BID) for 16 weeks
3078962|NCT01386125|Placebo Comparator|Placebo|Participants receive matching placebo nasal spray BID for 16 weeks
3078963|NCT01386385|Experimental|Arm I (RT, veliparib, carboplatin, paclitaxel)|Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase I induction and consolidation therapy.
3078964|NCT01386385|Active Comparator|Arm II (3D-CRT, placebo, carboplatin, paclitaxel)|Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days 1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and paclitaxel as in Phase I.
3078965|NCT01386528|Experimental|Patients enrolled in trial|New patients will be included as well as transferred patients from Paradigm™ 2 or Paradigm™ 4 trial
3078966|NCT01386554|Experimental|80 U Acthar|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) two times per week
3078967|NCT01386554|Placebo Comparator|1.0 mL Placebo|Placebo (1.0 mL) two times per week
3078968|NCT01386554|Experimental|40 U Acthar|Acthar (Repository Corticotropin Injection) 40 U (1.0 mL) two times per week
3078969|NCT01386606|Experimental|Androxal 6.25 mg|Androxal 6.25 mg/day
3078970|NCT01386606|Experimental|Androxal 12.5 mg|Androxal 12.5 mg/day
3078971|NCT01386606|Experimental|Androxal 25 mg|Androxal 25 mg/day
3078972|NCT01386606|Active Comparator|AndroGel|AndroGel 5G topical testosterone
3078973|NCT01386632|Active Comparator|DCA (dichloroacetate) Treatment|DCA orally 12.5mg/kg or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
3078974|NCT01386632|Placebo Comparator|Placebo|Placebo orally or per G-tube BID for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60 minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
3078975|NCT01386645|Active Comparator|Low GI diet|low glycemic index diet
3078976|NCT01386645|Placebo Comparator|High GI diet placebo|high glycemic index diet plus placebo
3078977|NCT01386645|Active Comparator|High GI diet NAC|high glycemic index diet plus N-acetylcysteine
3468869|NCT03891524|Experimental|Group B: JNJ-70033093 50 mg BID|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
3078980|NCT01386788||Smoke Inhalation patients|Closed space fire, Soot deposits, Altered mental status Blood specimen before intravenous antidote treatment (cyanide measurement) Known delay between end of smoke exposure and blood sampling
3078981|NCT01386944||Neupro® Treatment|Routine treatment (1,2,3 mg/24 h) as per approved label in the European Union (EU).
3078982|NCT01386970|Active Comparator|HIV-negative|This group was used to compare intracellular ZDV- and 3TC-triphosphate concentrations to the HIV-infected group and in men versus women.
3078983|NCT01386970|Active Comparator|HIV-infected|This group was started on ZDV-3TC based therapy. Intracellular ZDV- and 3TC-triphosphate concentrations were compared in men versus women and the HIV-negative group.
3078984|NCT01386983||Early 5ARI Initiation|Patients with EP receiving either 5ARI monotherapy or combination therapy (AB + 5ARI) with early initiation of 5ARI (within 30 days of initiation of AB)
3078985|NCT01386983||Late 5ARI Initiation|Patients with EP receiving combination therapy (AB + 5ARI) with late initiation of 5ARI (within 31 to 180 days after initiation of AB)
3078986|NCT01387022|Experimental|Tenofovir, lamivudine and efavirenz|
3078987|NCT01387022|Active Comparator|Zidovudine, lamivudine and efavirenz|
3078988|NCT01387074||botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
3078989|NCT01387139|Active Comparator|Ketamine Alone|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
3078990|NCT01387139|Experimental|Ketamine Co-Administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
3078991|NCT01387178||COPD patients - risk analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. Patient records for the risk analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 3 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and June 30, 2008).
3078992|NCT01387178||COPD patients - cost analysis population|Patient-records from patients aged 40 and older with at least 2 medical claims with a diagnosis of COPD, at least on diagnosis in the 12 months prior to the index date and at least one diagnosis in the post-index date observation period, and at least one prescription claim for either FSC 250 µg/50µg or TIO. The cost analysis population is a subset of the risk analysis population. Patient records for the cost analysis population will be required to have continuous medical and pharmacy health plan enrollment for at least 12 months before and at least 12 months after the index date. The index date will be defined as the date of the first prescription claim for FSC or TIO (between January 1, 2004 and September 30, 2007).
3078993|NCT01387230|Experimental|GSK573719|active drug
3078994|NCT01387230|Placebo Comparator|Placebo|no active drug
3078995|NCT01387269|Experimental|100 mg QD|Anamorelin HCL 100 mg will be administered daily
3078996|NCT01387269|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3078997|NCT01387282|Active Comparator|100 mg QD|Investigational: Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.
3078998|NCT01387282|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3078999|NCT01387347|Active Comparator|Thymosin Beta 4|RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
3079000|NCT01387347|Placebo Comparator|Placebo|The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.
3079001|NCT01387464|Experimental|ISV-303|
3079002|NCT01387464|Active Comparator|Bromday™|
3079003|NCT01387516|Experimental|Motivational Intervention|Motivational Interviewing (MI) will be a 60-90 minutes individual session.The focus is on establishing rapport and building motivation. The counselor explores youth's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancy, and perceptions of self-efficacy. A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
3079004|NCT01387516|Active Comparator|Relaxation Intervention|The Relaxation Therapy intervention is a 60-90 minute individual session. The session encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and as a whole is really a meditation protocol.
3079005|NCT01387516|Experimental|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy (CBT) Intervention is administered during two 90 minute group sessions. The focus is on the interrelationship between thoughts, feelings, and behaviors. It is used to address specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
3079006|NCT01387516|Active Comparator|Self-Help Programming|"Self Help intervention is administered during two 90 minute group sessions. The intervention modules are based on the principles of Nicotine Anonymous (NicA), to provide those who use nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. Elements incorporated in this intervention include the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
3079007|NCT01387542|Experimental|Paliperidone Extended Release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
3079008|NCT01387581||Without MelaFind|Study dermatologists will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
3079009|NCT01387581||With MelaFind|Study dermatologists will review clinical exam information, 3 high quality digital images, and MelaFind result for each lesion
3079010|NCT01387581||Experts Without MelaFind|PSL Experts, prospectively identified and recruited by the PI after the general recruitment is completed. They will review clinical exam information and 3 high quality digital images for each lesion without MelaFind result.
3079011|NCT01387594|Experimental|Cohort 1|Interventions prior to treatment. Control arm
3079012|NCT01387594|Experimental|Cohort 2|Interventions prior to and after 3 monthly injections
3079013|NCT01387607|Experimental|Pregabalin|
3079014|NCT01387607|Placebo Comparator|Placebo|Matched placebo
3079015|NCT01387672|Active Comparator|Nitrol|Nitroglycerin Ointment 2% USP
3079016|NCT01387672|Active Comparator|Nitro-Dur|Nitroglycerin Extended Release Patch 160mg
3079017|NCT01387672|Active Comparator|Nitrostat 1|Nitroglycerin 0.3mg Sublingual Tablet
3079018|NCT01387672|Active Comparator|Nitrostat 2|Nitroglycerin 0.6mg Sublingual Tablet
3079019|NCT01387672|Active Comparator|ISMO|Isosorbide Mononitrate 20mg Oral Tablet
3079020|NCT01387672|Placebo Comparator|Placebo|Placebo Ointment
3079021|NCT01387737|Experimental|TA-7284-Low|
3079022|NCT01387737|Experimental|TA-7284-High|
3079023|NCT01387789||Scheduled to start adalimumab therapy|Patients diagnosed with rheumatoid arthritis for at least 3 months that previously had not received prior anti-TNF agents.
3079024|NCT01387815||Topical/Traditional Systemic Agent|Participants who initiated treatment with a new topical agent that was not used before or already being treated with topical agent and not responding, thereby requiring a change of treatment type, frequency, or dose and all participants who initiated treatment with a new systemic agent that was not used before alone or in combination with topical agents.
3079025|NCT01387815||Adalimumab|Participants treated with adalimumab alone or in combination with topical agents.
3079026|NCT01387932|Experimental|HepaSphere/QuadraSphere TACE|HepaSphere/QuadraSphere TACE
3079027|NCT01387932|Active Comparator|Conventional TACE|Conventional TACE
3079028|NCT01388166||Patients with COPD|
3079029|NCT01388335|Experimental|warfarin + enzastaurin|"On Day 1 of Period 1, a single 5-milligram (mg) oral dose of warfarin will be given, followed by at least a 7-day washout.~Period 2: 500 mg enzastaurin administered orally once daily for at least 19 consecutive days and 5 mg warfarin administered as a single oral dose on Day 15.~Safety Extension: Participants are allowed to continue receiving enzastaurin alone until disease progression or other discontinuation criteria are met."
3079030|NCT01388361|Experimental|IDeg (non-randomised)|
3079031|NCT01388361|Experimental|IDeg + IAsp|
3079032|NCT01388361|Experimental|IDeg + liraglutide|
3079033|NCT01388478|Experimental|R(+)pramipexole|Each study participant will be given the active study drug, R-pramipexole. There is no placebo arm.
3468870|NCT03891524|Experimental|Group C: JNJ-70033093 100 mg + Placebo BID|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) and 1 placebo capsule BID orally for 10 to 14 postoperative days.
3468871|NCT03891524|Experimental|Group D: JNJ-70033093 200 mg BID|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID orally for 10 to 14 postoperative days.
3079036|NCT01388530|Experimental|trigeminal nerve stimulation|Open label treatment with trigeminal nerve stimulation in an 8-week trial.
3079037|NCT01388543|Active Comparator|CYP3A5 Expressors|A pre-screening genetic test determines CYP3A5 expressor status
3079038|NCT01388543|Active Comparator|CYP3A5 Non-expressors|A pre-screening genetic test determines CYP3A5 non-expressor status
3079039|NCT01388647|Experimental|Eribulin, carboplatin, and trastuzumab|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle. Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle. Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
3079040|NCT01388777|Experimental|Cryoablation|Cryoablation therapy followed by re-imaging then complete surgical resection.
3079041|NCT01388790|Experimental|Cetuximab plus cisplatin plus S-1|
3079042|NCT01388816|Placebo Comparator|Placebo capsule|
3079043|NCT01388816|Experimental|DRL-17822 50 mg|
3079044|NCT01388816|Experimental|DRL-17822 150 mg|
3079045|NCT01388816|Experimental|DRL-17822 300 mg|
3079046|NCT01388907|Experimental|Prevadh film|Patient randomized in this arm have been treated with Prevadh film applied on the uterine surgical sites, at the end of the myomectomy surgery to prevent post-surgey adhesion formation.
3079047|NCT01388907|Active Comparator|Ringer solution|Patients randomized in the Ringer solution group have been treated with Ringer lactate solution directly applied to the uterine surgical sites at the end of the myomectomy surgery.
3079048|NCT01388946|Active Comparator|Ropivacaine 0.75|Continuous infusion of ropivacaine 7.5 mg/ml, 2 ml/h for 24 hours
3079049|NCT01388946|Placebo Comparator|Normal saline|Continuous infusion of normal saline 2 ml/h for 24 hours
3079050|NCT01388985|Active Comparator|Standard vaccination schedule|One injection will be given on three different days (day 0, day 7 and day 21 or 28)
3079051|NCT01388985|Experimental|Accelerated vaccination schedule|Two injections will be given on the same day (day 0 and day 7): one on each forearm.
3079052|NCT01389076|Experimental|Treatment arm|Low dose methotrexate and Bexxar
3079053|NCT01389102|Placebo Comparator|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3079054|NCT01389102|Placebo Comparator|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3079055|NCT01389102|Placebo Comparator|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
3079056|NCT01389102|Active Comparator|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3079057|NCT01389102|Active Comparator|Estradiol transdermal two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
3079058|NCT01389102|Active Comparator|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
3079059|NCT01389128|Active Comparator|Control Group|Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
3079060|NCT01389128|Experimental|Intervention Group|Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: pelvic mobility , lumbosacral massage and warm shower.
3079061|NCT01389232|Experimental|SeriScaffold® Surgical Scaffold|Participants with breast reconstruction surgery implanted with SERI® Surgical Scaffold.
3079062|NCT01389245|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
3079063|NCT01389258|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
3079064|NCT01389284|Experimental|Naproxen Sodium ER (BAYH6689)|1 naproxen sodium extended release (ER) 660 mg tablet and 1 naproxen sodium immediate release (IR) 220 mg placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
3079065|NCT01389284|Active Comparator|Naproxen Sodium IR (Aleve, BAYH6689)|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg tablet initially followed by 1 naproxen sodium IR 220 mg tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg tablet eight hours at hour 16 (± 15 min)
3079066|NCT01389284|Placebo Comparator|Placebo|1 naproxen sodium ER 660 mg matching placebo tablet and 1 naproxen sodium IR 220 mg matching placebo tablet initially followed by 1 naproxen sodium IR 220 mg matching placebo tablet at hour 8 (± 15 min), and 1 naproxen sodium IR 220 mg matching placebo tablet at hour 16 (± 15 min)
3079067|NCT01389323|Experimental|Arm 1: Daclatasvir + Peg-Interferon Alfa-2a + Ribavirin|
3079068|NCT01389596|Placebo Comparator|Placebo|
3079069|NCT01389596|Experimental|Pregabalin Level 1 (max 150 mg/day)|
3079070|NCT01389596|Experimental|Pregabalin Level 2 (max 600 mg day)|
3079071|NCT01389752|Experimental|LY2216684 without Charcoal, then with Charcoal|Period 1: Single 18-mg (milligram) (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg (gram/kilogram) of Activated Charcoal. Periods will be separated by a minimum of 7 days.
3079072|NCT01389752|Experimental|LY2216684 with Charcoal, then without Charcoal|Period 1: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered with single oral dose of 1 g/kg of Activated Charcoal. Period 2: Single 18-mg (two 9-mg tablets) oral dose of LY2216684 administered without Activated Charcoal. Periods will be separated by a minimum of 7 days.
3079073|NCT01389765|Experimental|LY2216684 administered in fasted then fed state|Period 1: Single 18-mg (milligram) oral dose of LY2216684 administered in fasted state. Period 2: Single 18-mg oral dose of LY2216684 administered in fed state. Periods will be separated by a minimum of 7 days.
3079074|NCT01389765|Experimental|LY2216684 administered in fed then fasted state|Period 1: Single 18-mg oral dose of LY2216684 administered in fed state. Period 2: Single 18-mg oral dose of LY2216684 administered in fasted state. Periods will be separated by a minimum of 7 days.
3079075|NCT01389856|Experimental|1|Bosentan
3079076|NCT01389856|Placebo Comparator|2|Matching placebo
3079077|NCT01389882|Experimental|ventilator assist|
3079078|NCT01389973|Experimental|Open-label: ustekinumab 90 mg|
3079079|NCT01389973|Experimental|Double-blind: ustekinumab 45 mg|
3079080|NCT01389973|Experimental|Double-blind: ustekinumab 90 mg|
3079081|NCT01389973|Experimental|Double-blind: ustekinumb 180 mg|
3079082|NCT01389973|Placebo Comparator|Double-blind: placebo|
3079083|NCT01390038|Experimental|Simpliciti™ Shoulder System|The Simpliciti™ Shoulder System is intended for Total Shoulder Arthroplasty of the shoulder.
3079084|NCT01390064|Experimental|Initial Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms
3079085|NCT01390064|Active Comparator|Escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms
3079086|NCT01390064|Active Comparator|De-escalation Cohort|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 100 micrograms
3079087|NCT01390077|Experimental|Nitisinone|all subjects will receive open-label nitisinone
3079088|NCT01390220|Experimental|USL261|intranasal midazolam 5mg
3079089|NCT01390220|Experimental|Placebo|Intranasal placebo
3079090|NCT01390233|Active Comparator|Urinary Balloon Catheter Only|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. The catheter will be deflated and removed after 6 hours. If spontaneously expelled from the uterus, time of expulsion will be noted. Six hours after insertion of catheter, a digital exam will be performed and Bishop score recorded. If no active labor at time of catheter removal or expulsion, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
3079091|NCT01390233|Active Comparator|Prepadil Only|Prepidil Only : Prepidil gel will be inserted into the vaginal fornix according to manufacturer's direction. No oxytocin or other intervention will commence until 6 hours after insertion of gel. Six hours after insertion of gel, digital exam will be performed and Bishop score recorded. If no active labor 6 hours after the administration of gel, standardized protocol of oxytocin will commence. Labor management will be at the discretion of the physician.
3079092|NCT01390233|Experimental|Combined Urinary Catheter & Prepidil Gel|A urinary balloon catheter will be placed through the cervix into the lower uterine segment and the bulb inflated with 40ml of saline. The catheter will be taped to the patient's thigh and placed under traction using a liter bag of saline. Prepidil gel will be inserted through the catheter into the lower uterine segment, in a dose equivalent to manufacturer's recommendation. No oxytocin or other intervention will commence until 6 hours after insertion of the catheter and administration of prepidil gel (even if catheter is spontaneously expelled). After 6 hours, digital exam will be performed and Bishop score recorded. If no active labor, standardized protocol of oxytocin will commence.
3079093|NCT01390246|Active Comparator|Bupropion SR + cessation counseling|"Bupropion SR and smoking cessation counseling Subjects received Bupropion SR 150 mg tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (bupropion SR 150 mg orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose Bupropion SR 150 mg tablet orally BID for a total medication treatment of 12 full weeks.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
3079094|NCT01390246|Placebo Comparator|Placebo + cessation counseling|"Placebo and smoking cessation counseling Subjects received matching Bupropion SR placebo tablet orally twice daily (BID) for 12 weeks. Subjects were instructed to begin using study medication (matched placebo tablets orally for 3 days, then BID for 4 days) on study visit day 1, which was approximately 1 week prior to their quit date. Thereafter, they were continued to dose matching Bupropion SR placebo tablet orally BID for a total medication treatment of 12 full weeks of therapy.~Smoking cessation counseling included 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the trained study nurse."
3079095|NCT01390259|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
3079096|NCT01390259|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
3079097|NCT01390272|Experimental|Titration Intervention|"The intervention arm includes three levels of resource intensity targeted to improve patients' systolic blood pressure (SBP) [top number of blood pressure measurement].~Medium/level 1 resource intensity: a registered nurse (RN) will provide monthly tailored behavioral support telephone calls + home BP monitoring.~High/level 2 resource intensity: a pharmacist will provide monthly tailored behavioral support telephone calls + home BP monitoring + pharmacist-directed medication management.~Booster (low) resource intensity: a licensed practical nurse (LPN) will provide non-tailored behavioral support telephone calls every two months to patients whose SBP comes under control."
3079098|NCT01390272|Active Comparator|LPN Control|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months (identical to booster (low) resource intensity component of the titrated intervention). The control arm will utilize the same procedures as the booster level for intervention patients for whom SBP comes under control.
3079099|NCT01390298||Observational|Adult patients scheduled for elective unicompartmental or total knee replacement surgery or total hip replacement will be consented to participate
3079100|NCT01390389|Experimental|CoQ10|"Subjects who meet DSM-IV diagnostic criteria for Bipolar Disorder, Current Episode Depressed are assigned to this arm and administered the Coenzyme Q10 intervention. CoQ10 dosing guidelines:~Visit 1 (Baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of Baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
3079101|NCT01390389|No Intervention|Control|Subjects without a known psychiatric disorder and/or unstable medical illness are assigned to the control group. The control subjects are not given CoQ10.
3079102|NCT01390402|Experimental|NK Infusion + Chemotherapy|Fludarabine 40 mg/m2 intravenous (IV) daily for 4 days, immediately followed by Busulfan 130 mg/ m2 IV every 24 hours and NK cell infusion IV.
3079103|NCT01390415||Losartan 50 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 50 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
3079104|NCT01390415||Losartan 100 mg|Adults with Type II diabetes mellitus with hypertension and microalbuminuria who received losartan 100 mg for at least 6 months during the period between 1 June 2007 and 31 December 2008.
3079105|NCT01390428|Experimental|Part 1-Mild Hepatic Impairment (HI)|Participants with mild hepatic impairment will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
3079106|NCT01390428|Experimental|Part 1-Healthy Matched to Mild HI|Healthy participants will receive 200 mg of Grazoprevir once a day for 10 consecutive days during Part 1 of the study.
3079107|NCT01390428|Experimental|Part 2-Moderate HI|Participants with moderate hepatic impairment will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
3079108|NCT01390428|Experimental|Part 2-Healthy Matched to Moderate HI|Healthy participants will receive 100 mg of Grazoprevir once a day for 10 consecutive days during Part 2 of the study.
3079109|NCT01390428|Experimental|Part 3-Severe HI|Participants with severe hepatic impairment will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
3079110|NCT01390428|Experimental|Part 3-Healthy Matched to Severe HI|Healthy participants will receive 50 mg of Grazoprevir once a day for 10 consecutive days during Part 3 of the study.
3079111|NCT01390441|Experimental|Part A: MK-8808 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MK-8808 (500 mg/m^2) administered intravenously (IV) on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open-label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, subcutaneously (SC), or intramuscularly (IM) for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3079112|NCT01390441|Active Comparator|Part A: MabThera® 500 mg/m^2 / Extension A: MK-8808 1000 mg|"During the Treatment Period, participants receive one course of MabThera® (500 mg/m^2) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~During the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3079113|NCT01390441|Experimental|Part B: MK-8808 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MK-8808 (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) adminstered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3079114|NCT01390441|Active Comparator|Part B: MabThera® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of MabThera® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3079115|NCT01390441|Experimental|Part B: Rituxan® 1000 mg / Extension B: MK-8808 1000 mg|"In the Treatment Period, participants receive one course of Rituxan® (1000 mg) administered IV on Day 1 and Day 15 (with a second optional course of treatment at Weeks 26 and 28). Participants are followed up to Week 52 in the Treatment Period.~In the Extension Period, participants receive open label MK-8808 (1000 mg) administered IV at Week 54 and Week 56 (with a second optional course at Weeks 80 and 82). Participants are followed up to Week 106 in the Extension Period.~Methotrexate 12.5 to 25 mg/week is administered either orally, SC, or IM for the duration of the trial. A 10 mg dose may be administered if a greater dose is not tolerated."
3079116|NCT01390584|Experimental|ABVD + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are negative, patients receive the following treatment.~ABVD + INRT: Patients receive doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine as in induction chemotherapy. Treatment repeats every 28 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients undergo involved-node radiotherapy (INRT) 5 days a week for approximately 3½ weeks."
3079117|NCT01390584|Experimental|ABVD + BEACOPP + INRT|"Induction ABVD chemotherapy: Patients receive doxorubicin hydrochloride IV, bleomycin sulfate IV, vinblastine IV over 3-5 minutes, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 2 courses.~PET-CT scan: Then patients undergo fludeoxyglucose F 18 (18 FDG) positron emission tomography (PET)/computed tomography (CT). If results are positive, patients receive the following treatment.~BEACOPP + INRT: Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 60 minutes on day 1, etoposide IV over 60 minutes on days 1-3, procarbazine hydrochloride orally (PO) on days 1-7, prednisone PO on days 1-14, and bleomycin sulfate IV and vincristine sulfate IV on day 8. Treatment repeats every 21 days for 4 courses. Within 3-6 weeks after completion of chemotherapy, patients who achieve complete response with a negative 18FDG-PET/CT scan undergo INRT 5 days a week for approximately 3½ weeks."
3079118|NCT01390649|Experimental|IgPro10|
3079119|NCT01390779|Experimental|SENSIMED Triggerfish|All subjects enrolled in the trial were housed in a sleep laboratory for 24 hours, during which they underwent SENSIMED Triggerfish recording on one randomly selected eye.
3079120|NCT01390818|Experimental|MSC1936369B and SAR245409 once daily|
3079121|NCT01390818|Experimental|MSC1936369B and SAR245409 twice daily|
3079122|NCT01390844|Experimental|Boceprevir|PEG + RBV for 4 weeks followed by BOC + PEG + RBV for 32 weeks. At the Treatment Week 36 visit, participants with undetectable HCV-RNA at Treatment Weeks 8 and 12 will proceed to 36 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 8 and undetectable HCV-RNA at Treatment Week 12 will continue on BOC + PEG + RBV until Treatment Week 36, receive placebo + PEG + RBV until Treatment Week 48, and then proceed to 24 weeks of post-treatment follow-up. Participants with any HCV-RNA result at Treatment Week 8 and detectable HCV-RNA at Treatment Week 12 will discontinue treatment and proceed to 24 weeks of post-treatment follow-up.
3079123|NCT01390844|Active Comparator|Control|PEG + RBV for 4 weeks followed by BOC placebo + PEG + RBV for 44 weeks. Participants with undetectable HCV-RNA at Treatment Week 12 and at subsequent assays will continue on placebo + PEG + RBV through Treatment Week 48 and proceed to 24 weeks of post-treatment follow-up. Participants with detectable HCV-RNA at Treatment Week 12 may roll over to Cross-Over BOC treatment beginning with Treatment Week 14.
3079124|NCT01390857||Pediatric patients prescribed valaciclovir|Pediatric patients with chickenpox prescribed valaciclovir during study period.
3079125|NCT01390870||Patient Survey|Men from the United States aged 50 years or older who initiated medication for EP within the past 12 months.
3079126|NCT01390909||Medicaid patients with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in anti-epileptic drug (AED) therapy occurring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or emergency department (ED) visits within the 365 days
3079127|NCT01390909||Medicaid patients with well-controlled epilepsy|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
3079128|NCT01390909||Medicaid patients with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
3079129|NCT01390909||Patients in a private health plan with uncontrolled epilepsy|Database records for patients with 2 or more consecutive changes in AED therapy occuring at least 30 days apart and followed by 1 or more epilepsy-related inpatient or ED visits within 365 days
3079130|NCT01390909||Patients in a private health plan with well-controlled epileps|Database records for patients with an epilepsy diagnosis but no AED change and no epilepsy-related inpatient or ED visits
3079131|NCT01390909||Patients in a private health plan with intermediate epilepsy|Database records for patients who are not classified as uncontrolled or well-controlled
3079132|NCT01390948|Experimental|Bevacizumab + TMZ Young Patient Cohort (YPC)|Participants aged greater than or equal to (>/=) 6 months and less than (<) 3 years will receive 10 milligrams per kilogram (mg/kg) Bevacizumab every 2 weeks and 150 to 200 milligrams per meter squared (mg/m^2) of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
3079133|NCT01390948|Experimental|Main Cohort: Chemoradiation + Bevacizumab + TMZ|Participants will receive a total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle. Bevacizumab will be given concomitantly at a dose of 10 mg/kg every 2 weeks throughout the entire treatment period.
3079134|NCT01390948|Active Comparator|Main Cohort: Chemoradiation + TMZ|Participants will receive a total dose of 54 Gy units delivered in 30 daily fractions of 1.8 Gy over 6 weeks with 75 mg/m^2 TMZ daily for up to 49 days followed by a treatment break of approximately 4 weeks. The treatment break will be followed by an adjuvant treatment phase where participants will receive 150 to 200 mg/m^2 of TMZ daily on Days 1-5 of each cycle. TMZ will be given at a dose of 150 mg/m^2 on Days 1-5 of cycle 1 and then escalated to 200 mg/m^2 on days 1-5 from cycle 2 onwards depending on the tolerance during the 1st cycle.
3079135|NCT01391000|Experimental|Laser CO2|
3079136|NCT01391000|Active Comparator|TENS|
3079137|NCT01391013|Experimental|Monotherapy|Monotherapy: darunavir/ritonavir (DRV/r) will be administered for 48 weeks.
3079138|NCT01391013|Experimental|Combination therapy|DRV/r along with 2 nucleoside reverse transcriptase inhibitors (NRTIs) will be administered for 48 weeks and whenever possible, participants should take these medications at the same time. Switch of NRTIs will be allowed in the event of suspected toxicity/intolerance, providing this change can be linked to a documented adverse event (AE)/serious AE.
3079139|NCT01391130|Experimental|LY2510924 + Sunitinib|LY2510924: 20 milligram administered subcutaneously once daily, given every day of the 6 week cycle. Sunitinib: 50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3079140|NCT01391130|Active Comparator|Sunitinib|50 milligram administered orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment. Treatment cycles will continue until disease progression, unacceptable toxicity, or another withdrawal criterion is met.
3079141|NCT01391273|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
3079142|NCT01391273|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
3079143|NCT01391286|Experimental|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
3079144|NCT01391286|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
3079145|NCT01391299|Active Comparator|botulinum toxin Type A (40 Units)|Botulinum toxin Type A 40 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
3079146|NCT01391299|Active Comparator|botulinum toxin Type A (30 Units)|Botulinum toxin Type A 30 Units (total dose) injected into bilateral forehead and frown line areas on Day 1.
3079147|NCT01391299|Placebo Comparator|placebo (Normal saline)|Placebo (Normal saline) injected into bilateral forehead and frown line areas on Day 1.
3079148|NCT01391312|Active Comparator|botulinum toxin Type A|Botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
3079149|NCT01391312|Placebo Comparator|placebo (Normal Saline)|Normal Saline (placebo) injected into the glabellar region on Day 0.
3079150|NCT01391325|Other|Allopurinol|Treatment.
3079151|NCT01391364|Experimental|SofLens in investigational solution|Bausch + Lomb SofLens daily disposable contact lens packaged in an investigational storage solution.
3079152|NCT01391364|Active Comparator|SofLens in currently marketed solution|SofLens daily disposable contact lens packaged in currently marketed storage solution.
3079153|NCT01391468|Placebo Comparator|Placebo|cornstarch
3079154|NCT01391468|Experimental|Probiotics|probiotics
3079155|NCT01391507|Placebo Comparator|Placebo|
3079156|NCT01391507|Experimental|20 mg COR-1|
3079157|NCT01391507|Experimental|80 mg COR-1|
3079158|NCT01391507|Experimental|160 mg COR-1|
3079159|NCT01391546|Experimental|ZOSTAVAX intramuscular (IM) route|Single dose of 0.65 mL via IM injection
3079160|NCT01391546|Active Comparator|ZOSTAVAX subcutaneous (SC) route|Single dose of 0.65 mL via SC injection
3079161|NCT01391559|Experimental|arformoterol|beta-2 agonist bronchodilator
3079162|NCT01391559|Active Comparator|salmeterol|beta-2 agonist bronchodilator
3079163|NCT01391611|Experimental|Pazopanib arm|
3079164|NCT01391663|Experimental|Alogliptin 12.5 mg QD|
3079165|NCT01391663|Experimental|Alogliptin 25 mg QD|
3079166|NCT01391663|Experimental|Alogliptin 50 mg QD|
3079167|NCT01391793|Active Comparator|Adjuvant dexamethasone|
3079168|NCT01391793|Placebo Comparator|Placebo|
3079169|NCT01391819|Other|Study cohort|Children age 5 to 13 years at the time of enrollment, selected from schools in Fortaleza.
3079170|NCT01391832|Sham Comparator|Sham rTMS|Sham Treatment Intervention: Device: Repetitive Transcranial Magnet Stimulation (sham treatment)
3079171|NCT01391832|Active Comparator|active rTMS|"Active Repetitive Transcranial Magnet Stimulation treatment~Intervention: Device: Active rTMS of dorsolateral pre-frontal cortex"
3079172|NCT01391858|Active Comparator|pregabalin|pregabalin (lyrica)
3079173|NCT01391858|Placebo Comparator|placebo|placebo
3079174|NCT01392053|No Intervention|Control group|Control Group (CG) that will receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group
3079175|NCT01392053|Experimental|Massage Group|Massage Group (GM):receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation
3079176|NCT01392183|Experimental|Pazopanib|Pazopanib 800 mg by mouth daily. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
3079177|NCT01392183|Experimental|Temsirolimus|Temsirolimus 25 mg by vein infused over 30-60 minutes weekly. Benadryl 25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus. Quality of Life Assessment - Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
3079178|NCT01392300|Experimental|DB IncobotulinumtoxinA (Xeomin) (400 U)|IncobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
3079179|NCT01392300|Placebo Comparator|DB Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) (400 Units): Main period, one injection session - double-blind (DB), randomized treatment assignment
3079180|NCT01392326|Experimental|Group 1|Secukinumab (75mg)
3079181|NCT01392326|Experimental|Group 2|Secukinumab (150 mg)
3079182|NCT01392326|Placebo Comparator|Group 3|
3079183|NCT01392378|Experimental|Group 1|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of paracetamol on the day of each vaccination.
3079184|NCT01392378|Experimental|Group 2|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 2 doses of ibuprofen on the day of each vaccination.the first dose.
3079185|NCT01392378|Experimental|Group 3|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of paracetamol on the day of each vaccination.
3079186|NCT01392378|Experimental|Group 4|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. They will also receive 3 doses of ibuprofen on the day of each vaccination.
3079187|NCT01392378|Experimental|Group 5|Subjects will receive 13-valent pneumococcal vaccine and INFANRIX hexa at 2, 3, 4 and 12 months of age. This group does not receive any antipyretic medication as part of the study.
3079188|NCT01392443|Experimental|Ruxolitinib|Ruxolitinib was taken twice daily, unless instructed. Starting dose 15 mg BID for patients with baseline platelet count of 100,000/μL to 200,000/μL (inclusive) or 20 mg BID for those with baseline platelet count >200,000/μL (approximately 12 hours apart: morning and night), increased or decreased per standardized dosing paradigm.
3079189|NCT01392469|Experimental|Imatinib + Bosentan + Sildenafil|Participants received treatment with bosentan 125 milligrams (mg) twice daily and sildenafil thrice daily for 8 days in treatment period 1. Participants were on the same sildenafil dose level (20, 40, 50 or 60 mg) they had been at study entry which was well tolerated in conjunction with bosentan. Following treatment period 1, the participants received concomitant treatment of oral imatinib 200 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 2. Following treatment period 2, the participants received concomitant treatment of oral imatinib 400 mg daily, bosentan 125 mg twice daily and sildenafil thrice daily for 14 days in treatment period 3.
3079190|NCT01392495|Experimental|QTI571|Participants received 200 mg or 400 mg every day (qd) based on their highest tolerated dose in CQTI571A2102 (NCT01392469).
3079191|NCT01392547|Experimental|rFVIIa|
3079192|NCT01392547|Experimental|vatreptocog alfa|
3079193|NCT01392560|Experimental|BI 10773|Oral once daily
3079194|NCT01392573|Experimental|IDegLira + metformin|IDegLira was injected subcutaneously once daily for 26 weeks.
3079195|NCT01392573|Experimental|IDeg + metformin|IDeg was injected subcutaneously once daily for 26 weeks.
3079196|NCT01392625|Active Comparator|Autologous hMSCs|Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
3079197|NCT01392625|Active Comparator|Allogeneic hMSCs|Group 2 (18 patients) Eighteen (18) patients will be treated with allogeneic hMSCs (Allo-hMSCs): 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs.
3079198|NCT01392677|Experimental|Dapagliflozin 10 mg tablet|
3079199|NCT01392677|Placebo Comparator|matching placebo tablet|
3079200|NCT01392703|Other|Dasatinib, 100 mg as tablets + water|Treatment A. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3079201|NCT01392703|Other|Dasatinib, 100 mg as liquid + water|Treatment B. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3079202|NCT01392703|Other|Dasatinib, 100 mg as tablets in orange juice + water|Treatment C. Participants were randomized to and received treatment in 1 of 6 sequences (ABC, ACB, BCA, BAC, CAB, or CBA), administered over 3 1-day treatment periods (Days 1, 5, and 9), with treatment changing to next in the sequence at start of each new period. A 3-day washout period followed treatment periods 1 and 2.
3079203|NCT01392742||Cohort|
3079204|NCT01392859|Experimental|Initial Treatment: Levocetirizine(LCT)|Group 1 will begin with active Levocetirizine(LCT) 0.5 mg/ml oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and placebo will be provided for 5-8 days.
3079205|NCT01392859|Experimental|Initial Treatment: Placebo|Group 2 will begin with placebo oral solution for 5-8 days. This arm will then undergo a 3-7 day washout period at which point crossover will occur and active Levocetirizine(LCT) 0.5 mg/ml will be provided for 5-8 days.
3079206|NCT01392963|Experimental|Botox, Then Placebo|At baseline visit (week 0) participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications. After a 3 month evaluation period, participants received a placebo injection (matching botulinum toxin) to glabella region at study visit 4 (week 12).
3079207|NCT01392963|Experimental|Placebo, Then Botox|At baseline visit (week 0) participants received a placebo injection (matching botulinum toxin) to glabella region. After a 3 month evaluation period, participants received an injection of clostridium botulinum toxin type A neurotoxin complex (Allergan; total injection of 29-40 U) in the glabella region according to standard protocols of cosmetic botulinum toxin applications at study visit 4 (week 12).
3079208|NCT01392989|Experimental|Allogeneic Cytokine-induced Killer Cells (CIK)|Target dose of ≥ 5 x 10e6 CD34+ cells/kg of recipient body weight plus an additional 2 x10e9 mononuclear cells.
3079209|NCT01393106|Experimental|Idelalisib|Participants will receive up to 300 mg of idelalisib twice daily.
3079210|NCT01393132|Experimental|Thymosin Beta 4 eye drops|It is a preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, six times daily for 28 days
3079211|NCT01393132|Placebo Comparator|Vehicle Control|It is composed of the same excipients as RGN-259 but does not contain Tβ4 for direct instillation into each eye, six times daily for 28 days.
3079212|NCT01393158|Experimental|20 mg BID|Patients dosed with 20 mg orally of Apremilast BID for 3 months.
3079213|NCT01393158|Experimental|30 mg BID|Patients dosed with 30 mg orally of Apremilast BID for 6 months.
3079214|NCT01393301|Experimental|Behavioral Intervention Arm|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
3079215|NCT01393301|Other|Control Arm|Enhanced Treatment as Usual (ETAU); enhanced standard smoking cessation treatment and nicotine replacement therapy (NRT).
3079216|NCT01393392|Experimental|Intensive, tailored intervention|Participants in the intensive intervention condition will receive eight individual counseling sessions, with a smoking cessation counselor, over three months. Each session will last approximately 45 minutes and occur in the methadone clinic. Participant treatment needs will be assessed during the first session and the intervention will be tailored to the participants' needs. Prior to quitting participants will receive nicotine replacement patches and lozenges and instructions on how to use them.
3079217|NCT01393392|Active Comparator|Control Intervention|Participants randomized to the control intervention will receive a referral to the NJ Quitline (a telephone smoking cessation counseling service). Participants will receive a brochure and information about the referral. Study staff will contact the NJ Quitline for control participants, and a counselor from the Quitline will call control participants.
3079218|NCT01393405|Active Comparator|Methotrexate|25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
3079219|NCT01393405|Placebo Comparator|Placebo|Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
3079220|NCT01393444|Experimental|Direct Brain Interface Users|"All participants enrolled in the study will undergo Implantation of ECoG sensors on the brain surface to record neural activity. There is no control group. There are no other arms."
3079221|NCT01393457|Active Comparator|ldopa + ropinirole low dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 2 mg/d
3079222|NCT01393457|Active Comparator|ldopa + ropinirole high dose|levodopa/carbidopa 800/200 mg/d plus ropinirole 4 mg/d
3079223|NCT01393457|Active Comparator|ldopa|levodopa/carbidopa 800/200 mg/d
3079224|NCT01393457|Placebo Comparator|placebo|Placebo
3079225|NCT01393600|Experimental|NBI-98854 12.5 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 1: Placebo once daily dose for Days 1-14 and 12.5 mg NBI-98854 once daily dose for Days 15-28.~Sequence 2: 12.5 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
3079226|NCT01393600|Experimental|NBI-98854 50 mg|"During the Cross-Over Study, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence 3: Placebo once daily dose for Days 1-14 and 50 mg NBI-98854 once daily dose for Days 15-28.~Sequence 4: 50 mg NBI-98854 once daily dose for Days 1-14 and placebo once daily dose for Days 15-28."
3079227|NCT01393613|Experimental|Dose 3 OPC 34712|Higher dose, tablet, once daily, for six weeks
3079228|NCT01393613|Experimental|Dose 2 OPC 34712|Middle dose, tablet, once daily, for six weeks
3079229|NCT01393613|Experimental|Dose 1 OPC 34712|Lower dose, tablet, once daily, for six weeks
3079230|NCT01393613|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
3079231|NCT01393626|Placebo Comparator|Placebo BID|
3079232|NCT01393626|Experimental|5mg BID|
3079233|NCT01393626|Experimental|10mg BID|
3079234|NCT01393704|Active Comparator|High Volume Dilute Vasopressin|20 units Vasopressin diluted in 400 mL of Saline, inject 200 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
3079235|NCT01393704|Active Comparator|Low volume dilute vasopressin|20 units Vasopressin diluted in 60 mL of Normal Saline, inject 30 mL total of the dilute Vasopressin solution in subserosal location overlying fibroid (total 10 units Vasopressin used).
3079236|NCT01393717|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses. Patients in the new cohort receive regular study dose of brentuximab vedotin for courses 1 and 2. Patients not achieving CR after 2 courses receive higher-dose brentuximab vedotin IV over 60 minutes on day 1 for 2 additional courses.
3079237|NCT01393730|Experimental|Abiraterone+prednisone+dutasteride|Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression
3079238|NCT01393743|Experimental|Perampanel|Participants received 6 tablets (initially 1 tablet of 2-mg perampanel plus 5 tablets of perampanel matched placebo) and up-titrated weekly in 2-mg increments to a target dose range of 8 mg per day maintaining the blind with administration of 6 tablets per day of either perampanel/placebo.
3079239|NCT01393743|Placebo Comparator|Placebo|Participants received 6 tablets of perampanel matched placebo, once a day.
3079240|NCT01393821|Experimental|Arm I (lotion)|Patients apply menadione topical lotion BID for 28 days.
3079241|NCT01393821|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo lotion BID for 28 days.
3079242|NCT01393899|Placebo Comparator|Placebo BID|
3079243|NCT01393899|Experimental|5mg BID|
3079244|NCT01393899|Experimental|10mg BID|
3079245|NCT01393964|Experimental|Arm 1: Lenalidomide + Dexamethasone +Elotuzumab|Severe Renal Impairment
3079246|NCT01393964|Experimental|Arm 2: Lenalidomide + Dexamethasone +Elotuzumab|End-stage renal disease
3079247|NCT01393964|Experimental|Arm 3: Lenalidomide + Dexamethasone +Elotuzumab|Normal renal function
3079248|NCT01393990|Experimental|LY2228820|"The study had 4 parts, dose-escalation (Part A), 2 dose-confirmation (Parts B and C), and a tumor-specific expansion for metastatic breast cancer (Part D).~Part A: Participants received escalating doses of 10, 20, 40, 65, 90, 120, 160, 200, 300, 420 and 560 milligrams (mg) of LY2228820 every 12 hours on Days 1 through 14 of a 28-day cycle.~Part B: Participants received 420 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle. Participants received midazolam orally 2 days before the first dose and again after the morning dose of study drug on Day 8 during the first cycle of treatment.~Part C: Participants received 300 mg of LY2228820 every 12 hours Days 1 through 14 of a 28-day cycle.~Part D: Participants received 200 mg and 300 mg of LY2228820 in combination with tamoxifen."
3079249|NCT01394003|Experimental|LY2584702|"Oral dose escalation starting at 25 milligrams (mg), daily for 28 day cycles in Part A; oral dose escalation starting at 50 mg, twice daily for 28 day cycles in Part B; oral dose with schedule determined by Parts A and B will be administered in Part C (dose confirmation).~Part A: Participants received 25 mg, 50 mg, 100 mg and 200 mg once daily (QD) and 300 mg twice daily (BID) of LY2584702 capsule, for a 28-day cycle during Part A of the study until the criteria for maximum tolerated dose (MTD) were met.~Part B: Participants received 50 mg, 75 mg and 100 mg LY2584702 orally as a capsule, twice daily (BID) for a 28-day cycle during Part B of the study until the criteria for maximum tolerated dose (MTD) were met."
3079250|NCT01394081|Experimental|Enhanced Engagement and Enrollment (EEE)|Enhanced Engagement and Enrollment (EEE) consists of the outreach worker (interventionalist) engaging the participant in education (about VA resources and medical care), navigating the patient through the VA eligibility, enrollment, and scheduling processes, and using motivational interview to focus on ambivalence about attending a VA appointment.
3079251|NCT01394081|Active Comparator|Administrative Outreach (AO)|Administrative Outreach (AO) consists of the outreach worker giving the participants an application package to VA enrollment or phone number for the scheduling clerk. This intervention does not involve education, patient navigation (guidance through VA eligibility, enrollment, and scheduling processes) or motivational interviews (interviews focused on ambivalence about attending a VA appointment).
3079252|NCT01394159|Active Comparator|22G ProCore biopsy needle|Using the 22G ProCore needle for sampling pancreatic mass lesions, the tissue obtained will be compared to the standard FNA needle.
3079253|NCT01394159|Active Comparator|22G standard FNA needle|Using the 22G standard fine needle aspiration needle (FNA) for sampling pancreatic mass lesions, the tissue obtained will be compared to the 22 G ProCore needle.
3079254|NCT01394185|Active Comparator|Low Dose Dronabinol, High Dose Dronabinol, and placebo|Participants were administered dronabinol (0 mg/day, 120mg/day and 240mg/day) for 12 days each in a random order
3079255|NCT01394250|Experimental|Buzzy|If randomized to Buzzy®, the nurse will demonstrate the cold pack and the device just prior to the IV cannulation procedure. The device will be applied with a Velcro strap 5 centimeters proximal to the site of IV cannulation; it will remain in place until the IV cannula is inserted and secured. All nurses that work during the study hours will be trained on the device prior to beginning the study. Training includes direct one-one training with the device including return demonstration.
3079256|NCT01394250|Active Comparator|Topical Lidocaine 4% Cream|If randomized to topical lidocaine cream, subjects will have the cream placed on two or more potential IV sites as soon as possible after the consent procedure is complete. These subjects will undergo IV placement no less than 30 minutes after the cream is applied.
3079257|NCT01394276||Tocilizumab|Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed. Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
3079258|NCT01394510|Experimental|N-acetylcysteine dose study|Subjects will take N-acetylcysteine (NAC) 600 mg twice daily for 2 weeks, then 1200 mg twice daily for an additional 2 weeks. Study procedures will be performed at baseline, after 2 weeks and after 4 weeks.
3079259|NCT01394523|Active Comparator|Caudal epidural|The caudal epidural block will be delivered with 1.5ml/kg of 0.25% Bupivacaine up to a maximum of 30 mL.
3079260|NCT01394523|Active Comparator|Rectus sheath|The rectus sheath block will be performed with 0.1ml/kg of 0.25% Bupivacaine on each side at the T9-T10 distribution under ultrasound guidance.
3079261|NCT01394523|Active Comparator|Local|The surgeon will inject either 0.5% Bupivicaine 0.5ml/kg or 0.25% Bupivicaine 1ml/kg at the surgeon's discretion.
3079262|NCT01394614||Narcoleptics exposed to A/H1N1 vaccine|Adjuvanted (ASO3) A/H1N1 pandemic vaccine
3079263|NCT01394614||Narcoleptics unexposed to A/H1N1 vaccine|Narcoleptic subjects who were unexposed (non-vaccinated or vaccinated after onset) to adjuvanted (ASO3) A/H1N1 pandemic vaccine.
3079264|NCT01394627|Experimental|Eplerenone|hypoglycemia (50 mg/dl) with pretreatment with two doses of eplerenone (100 mg of eplerenone per dose)
3079265|NCT01394627|Placebo Comparator|placebo|hypoglycemia of 50 mg/dl plus placebo
3079266|NCT01394692|Active Comparator|intraoperative MRI|tumor resection with intraoperative MRI-guidance
3079267|NCT01394692|Active Comparator|conventional group|standard microsurgical tumor resection
3079268|NCT01394705|No Intervention|Standard of Care|standard of care (office provider exercise counseling)
3079269|NCT01394705|Experimental|Intervention|The intervention group received a personalized exercise prescription (using the FITT principles) and wore an accelerometer up to 7days/week (most waking hours) and logged their activity by regularly (3 times a week) uploading the device for a period of 3 months, use of the internet was supervised by a parent or guardian. Their activity was monitored via the online BodyMedia site on a regular basis by study personnel and feedback was provided at least once a week through email and/or phone calls
3079270|NCT01394718|Placebo Comparator|Saline Placebo|Control subjects will receive saline as placebo at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
3079271|NCT01394718|Experimental|Intravenous Acetaminophen|Subjects will receive the first dose of intravenous (IV) acetaminophen (at 15 mg/kg, with maximum doses based on patient age and weight) at the time of skin closure intra-operatively and will continue to receive IV acetaminophen for 42 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
3079272|NCT01394939|Experimental|Single Agent_ Cohort 1|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: Recombinant Vaccinia Granulocyte-Macrophage Colony-Stimulating Factor (RAC VAC GM-CSF) Cohort 1: JX-594 3 x 10^8 plaque forming unit (pfu), Days 1, 8,15, 22, and 29"
3079273|NCT01394939|Experimental|Single Agent_Cohort 2|"JX-594 administered intravenously weekly for 5 weeks followed by up to 3 additional intravenous infusion boosts.~JX-594: RAC VAC GM-CSF Cohort 2: JX-594 1 x 10^9 pfu, Days 1, 8,15, 22, and 29"
3079274|NCT01394939|Experimental|Combination_Cohort 3|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF Irinotecan: 180 mg/m2 IV every 2 weeks. JX-594 3 x 10^8 pfu Day 1,8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
3079275|NCT01394939|Experimental|Combination_Cohort 4|"JX-594 administered intravenously weekly for 5 weeks followed by up to three additional intravenous infusion boosts in combination with Irinotecan administered every 14 days beginning at Day 9.~JX-594: RAC VAC GM-CSF JX-594 1 x 10^9 pfu Day1, 8, 15, 22, 29 + irinotecan 180 mg/m2 biweekly starts on Day 9."
3079276|NCT01394952|Experimental|1.5 mg Dulaglutide|Administered once weekly, subcutaneously
3079277|NCT01394952|Placebo Comparator|Placebo|Administered once weekly, subcutaneously
3079278|NCT01394978|Other|Control|No treatment.
3079279|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant with standard surgical closure|Standard surgical closure (suturing or stapling of visible air leaks incurred during resection of lung parenchyma) plus Progel Pleural Air Leak Sealant.
3079280|NCT01394978|Experimental|ProGEL Pleural Air Leak Sealant without standard surgical closure|Progel Pleural Air Leak Sealant without standard surgical closure (without suturing or stapling of visible air leaks incurred during resection of lung parenchyma).
3079281|NCT01394991|Experimental|001|Epoetin alfa 450 IU/kg once a week (QW) 450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
3079282|NCT01394991|Experimental|002|Epoetin alfa 150 IU/kg 3 times a week (TIW) 150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
3079283|NCT01395017|Active Comparator|Group 1|One arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus dasatinib 100 mg by mouth once daily (QD).
3079284|NCT01395017|Placebo Comparator|Group 2|The other arm will receive standard of care treatment (ie, GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle) plus matched placebo by mouth once daily (QD).
3079285|NCT01395030|Experimental|18F-fluoromethylcholine PET/CT|Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
3079286|NCT01395043|Other|TAP-catheter|Each patient receives bilateral TAP-catheters preoperatively.
3079287|NCT01395277|Experimental|High Flavanol first then Low Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with high flavanol content and 2) before and 2 hours following consumption of a beverage with low flavanol content."
3079288|NCT01395277|Experimental|Low Flavanol first then High Flavanol|"The measurements will be made on all study participants on two separate occasions; 1) before and 2 hours following consumption of a beverage with low flavanol content and 2) before and 2 hours following consumption of a beverage with high flavanol content."
3079289|NCT01395316|Experimental|Alemtuzumab|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
3079290|NCT01395329|Active Comparator|Nebivolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Nebivolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of nebivolol.
3079291|NCT01395329|Active Comparator|Metoprolol|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of Metoprolol. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of Metoprolol.
3079292|NCT01395329|Placebo Comparator|Placebo|Systolic and Diastolic blood pressure will be measured before and after randomization to12 weeks of placebo. Forearm blood flow will be measured in response to 100 nmol/min of BQ-123, BQ-123+BQ788 (50 mol/min), Acetylcholine (4.0, 8.0, 16.0 ug/100 mL tissue/min), Sodium Nitroprusside (1.0, 2.0, 4.0 ug/100 mL tissue/min) and BQ-123+BQ-788+Acetylcholine (same doses as above) will be measured before and after the 12 weeks of placebo.
3079293|NCT01395368||Brain Speed Test|Brain Speed Test
3079294|NCT01395394|Experimental|BH4 Non-Responders|Participants in this group have PKU and were deemed unresponsive to the drug. They will attend their first study visit, and proceed through the meal challenge without BH4. They will then take BH4 for 2 weeks. The second meal challenge will be performed with the participant's final dose of BH4.
3079295|NCT01395394|Experimental|Healthy Controls|Participants in this group match an enrolled PKU participant in terms of age, gender, and body mass index class. They will participate in a single study visit and will not be given BH4.
3079296|NCT01395394|Experimental|BH4 Responders|Participants in this group will use their already prescribed BH4 with the meal challenge and be assessed at a single study visit. They will take their prescribed BH4 with the meal.
3079297|NCT01395524|Experimental|NKTR-118 12.5mg|
3079298|NCT01395524|Experimental|NKTR-118 25mg|
3079299|NCT01395524|Placebo Comparator|Placebo|
3079300|NCT01395537|Experimental|Lapatinib With Carboplatin and Paclitaxel|
3079301|NCT01395758|Experimental|tivantinib (ARQ 197) plus erlotinib arm|"Eligible subjects will be randomly assigned to receive erlotinib plus tivantinib (ARQ 197).~Treatment will be open-label and continue until progression of disease, unacceptable toxicity, or another discontinuation criterion is met."
3079302|NCT01395758|Active Comparator|Chemotherapy arm|Investigator's choice of single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered in 3-week cycles according to the approved label until disease progression or unacceptable toxicity. Subjects who discontinued chemotherapy can be switched to the crossover arm (tivantinib plus erlotinib) and continue treatment until disease progression or unacceptable toxicity.
3079303|NCT01395784|Placebo Comparator|Placebo Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Placebo (PCB).
3079304|NCT01395784|Experimental|PIO 15 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 15 mg.
3079305|NCT01395784|Experimental|PIO 45 Maintenance Period|Participants will complete the various outcome measures following a 2-3 week maintenance period on Pioglitazone (PIO) 45 mg.
3079306|NCT01395797|Placebo Comparator|Placebo - Heroin|Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.
3079307|NCT01395797|Experimental|PIO low dose - Heroin|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.
3079308|NCT01395797|Experimental|PIO high dose - Heroin|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.
3079309|NCT01395797|Placebo Comparator|Placebo - Nicotine|Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.
3079310|NCT01395797|Experimental|PIO Low Dose - Nicotine|Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine
3079311|NCT01395797|Experimental|PIO High Dose - Nicotine|Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine
3079312|NCT01395810|Experimental|Prophylaxis, high dose (once weekly)|
3079313|NCT01395810|Experimental|Prophylaxis, low dose (once weekly)|
3079314|NCT01395810|Experimental|On-demand|
3079315|NCT01395810|Experimental|Prophylaxis, high dose (every second week)|
3079316|NCT01395823|Other|ergocalciferol supplementation|
3079317|NCT01395823|Placebo Comparator|placebo|
3079318|NCT01395888|Experimental|Relovair|Inhaled long-acting bronchodilator and corticosteroid combination
3079319|NCT01395888|Active Comparator|Tiotropium|Inhaled long-acting anticholinergic
3079320|NCT01395901|Experimental|Palonosetron and placebo to Ondansetron|Intervention: Drug: Palonosetron
3079321|NCT01395901|Active Comparator|Ondansetron and placebo to Palonosetron|Intervention: Drug: Comparator: Ondansetron
3079322|NCT01395914|Experimental|100 mg QD|100 mg yellow coated, oval tablet; oral administration once daily
3079323|NCT01395914|Placebo Comparator|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once daily
3079324|NCT01395966|Active Comparator|DF289|Ear drops
3079325|NCT01395966|Active Comparator|DF277|Ear drops
3079326|NCT01395966|Experimental|DF289 plus DF277|Ear drops
3079327|NCT01396005|Experimental|Methadone + boceprevir|Participants receive standard methadone maintenance therapy (20-150 mg tablets, liquid, or disket, orally, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7)
3079328|NCT01396005|Experimental|Buprenorphine/naloxone + boceprevir|Participants receive standard buprenorphine/naloxone maintenance therapy (8/2-24/6 mg, tablets, sublingual, once per day) on Days 1 through 8 + boceprevir (800 mg [4 x 200 mg capsules], orally, every 8 hours) on Days 2 through 7
3079329|NCT01396044|Experimental|Electronic checklist|Electronic checklist
3079330|NCT01396044|Experimental|Verbal prompting|Verbal prompting with written checklist
3079331|NCT01396057|Experimental|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally
3079332|NCT01396057|Sham Comparator|Dexamethasone|Intravitreal implant as per commercial label (700 μg Dexamethasone; long acting release (LAR) over 6 months
3079333|NCT01396070|Experimental|Brentuximab vedotin|Novel antibody-drug conjugate, 1.8 mg/kg intravenously every 3 weeks
3079334|NCT01396083|Experimental|Ranibizumab|
3079335|NCT01396083|Active Comparator|Standard of Care|
3079336|NCT01396148|Experimental|Children with GIST|children ages 6yrs-<18yrs
3079337|NCT01396148|Experimental|Young adults with GIST|young adults ages 18yrs-<21 yrs
3079338|NCT01396161|Experimental|30 mg PF-05175157 or Placebo QD|
3079339|NCT01396161|Experimental|100 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
3079340|NCT01396161|Experimental|200 mg PF-05175157 or Placebo QD|Planned dose might be modified based on emerging safety and PK data.
3079341|NCT01396161|Experimental|100 mg PF-05175157 or Placebo BID|Planned dose might be modified based on emerging safety and PK data.
3079342|NCT01396161|Experimental|xxx mg PF-05175157|Dose will be determined based on results obtained from Arms 1 to 4.
3079343|NCT01396187|Experimental|Treatment|
3079344|NCT01396187|Placebo Comparator|Placebo|
3079345|NCT01396226|Experimental|1|A single dose of AZD2927 administered as an iv infusion
3079346|NCT01396226|Placebo Comparator|2|A single dose of placebo administered as an iv infusion
3079347|NCT01396239|Experimental|AVI-4658 (Eteplirsen)|"50 mg/kg eteplirsen for 28 weeks~30 mg/kg eteplirsen for 28 weeks"
3079348|NCT01396239|Placebo Comparator|Placebo / Delayed Treatment|"3a. Placebo 50 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 50 mg/kg of eteplirsen for 4 weeks.~3b. Placebo 30 mg/kg phosphate buffered saline solution identical in appearance to eteplirsen for 24 weeks followed by 30 mg/kg of eteplirsen for 4 weeks."
3079349|NCT01396265|Experimental|Afatinib alone (Reference)|Tablet, Oral administration with 240 mL of water
3079350|NCT01396265|Experimental|Rifampicin + Afatinib (Test)|Tablet, Oral administration with 240 mL of water
3079351|NCT01396317|Experimental|Tocilizumab|This is a single-arm study. All subjects will receive the active study treatment for 12 months, and will then be evaluated for 3 months of long-term follow-up.
3079352|NCT01396382|Experimental|68Ga-DOTATATE PET|Patients will receive a 68Ga-DOTATATE PET scans
3079353|NCT01396395|Experimental|Standard treatment plus nicorandil|The subjects will receive nicorandil 5 milligram (mg ) tablet orally three times daily for a period of 12 weeks along with one of the standard antianginal therapies (such as aspirin, beta-blockers, lipid lowering statins and angiotensin-converting enzyme inhibitors [(ACEIs] as permitted by disease condition /as per standard local practices/prescribed per discretion of investigators).
3079354|NCT01396395|Other|Standard treatment|
3079355|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] High Dose|Higher Dose, tablet, once daily, for six weeks
3079356|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Middle Dose|Middle Dose, tablet, once daily, for six weeks
3079357|NCT01396421|Experimental|OPC-34712 [Brexpiprazole] Low Dose|Lower Dose, tablet, once daily, for six weeks
3079358|NCT01396421|Placebo Comparator|Placebo|Placebo, once daily, for six weeks
3079359|NCT01396434||Prevenar 13 patients|
3079360|NCT01396447|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks.
3079361|NCT01396447|Experimental|Cariprazine 0.75 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2 and cariprazine 0.75 mg orally once a day starting on Day 3 for the remainder of the 8 week treatment period.
3079362|NCT01396447|Experimental|Cariprazine 1.5 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, and cariprazine 1.5 mg orally once a day starting on Day 8 for the remainder of the 8 week treatment period.
3079363|NCT01396447|Experimental|Cariprazine 3.0 mg|Participants received cariprazine 0.5 mg orally once on Days 1-2, cariprazine 0.75 mg orally once on Days 3-4, cariprazine 1.0 mg orally once on Days 5-7, cariprazine 1.5 mg orally on Days 8-14, and cariprazine 3.0 mg orally once a day starting on Day 15 for the remainder of the 8 week treatment period.
3079364|NCT01396486|Active Comparator|Omega-3/Placebo|Combination Omega-3 and Placebo treatment.
3079365|NCT01396486|Active Comparator|Placebo/Inositol|Combination Placebo and Inositol treatment.
3079366|NCT01396486|Active Comparator|Omega-3/Inositol|Combination Omega-3 and Inositol treatment.
3079367|NCT01396512|Experimental|IMOJEV™ Vaccine Group|Participants will receive a single dose of the Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV™) on Day 0.
3079368|NCT01396512|Active Comparator|CD.JEVAX ™ Vaccine Group|Participants will receive a single dose of the Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine), CD.JEVAX™ on Day 0
3079369|NCT01396525|Experimental|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|
3079370|NCT01396551|Experimental|Transponder implantation|Implantation of anchored Beacon transponder in the lung
3079371|NCT01396837|Experimental|RedDress Wound Care System (RD1)|RD1 is a biologic autologous wound care product which is comprised of the patient whole blood and produced in the point of care using the RD1 kit
3079372|NCT01397071|Active Comparator|Ground Beef Patty with Avocado|Test burgers with fresh avocado added just prior to consumption
3079373|NCT01397071|Active Comparator|Ground Beef Patty without Avocado|Test burgers
3079374|NCT01397084|Other|esomeprazole 20 mg|esomeprazole 20 mg
3079375|NCT01397253|No Intervention|(Usual) MedTrak system of PCP notification|MedTrak, the information system used by the University of Pittsburgh Medical Center (UPMC), currently notifies PCPs when patients are admitted and discharged from the hospital.
3079376|NCT01397253|Experimental|Automated communication tools|An enhanced version of MedTrak (the present system of PCP notification). Electronic medical record links will be developed and used to allow automated communication with the PCP.
3079377|NCT01397409|Experimental|Stage 1: AGN-150998 4.2 mg|Stage 1: AGN-150998 4.2.mg given as a single intravitreal injection.
3079378|NCT01397409|Experimental|Stage 1: AGN-150998 3.0 mg|Stage 1: AGN-150998 3.0 mg given as a single intravitreal injection.
3079379|NCT01397409|Experimental|Stage 1: AGN-150998 2.0 mg|Stage 1: AGN-150998 2.0 mg given as a single intravitreal injection.
3079380|NCT01397409|Experimental|Stage 1: AGN-150998 1.0 mg|Stage 1: AGN-150998 1.0 mg given as a single intravitreal injection.
3079381|NCT01397409|Experimental|Stage 2: AGN-150998 4.2 mg|Stage 2: AGN-150998 4,2 mg (highest tolerated dose from Stage 1) given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3079382|NCT01397409|Experimental|Stage 2: AGN-150998 3.0 mg|Stage 2: AGN-150998 3.0 mg (one dose below highest tolerated dose) from Stage 1 given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3079383|NCT01397409|Active Comparator|Stage 2: ranibizumab 0.5 mg|Stage 2: ranibizumab 0.5 mg given as a single intravitreal injection at baseline. A second intravitreal injection will be given by week 16.
3079384|NCT01397409|Experimental|Stage 3: AGN-150998 2.0 mg|Stage 3: AGN-150998 2.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
3079385|NCT01397409|Experimental|Stage 3: AGN-150998 1.0 mg|Stage 3: AGN-150998 1.0 mg given as intravitreal injections at Baseline, Weeks 4 and 8, followed by sham injections at Weeks 12 and 16.
3079386|NCT01397409|Active Comparator|Stage 3: ranibizumab 0.5 mg|Stage 3: ranibizumab 0.5 mg given as intravitreal injections every 4 weeks for 16 weeks.
3079387|NCT01397422|Placebo Comparator|Treatment A|
3079388|NCT01397422|Active Comparator|Treatment B|Low dose ADS-5102 (amantadine extended release)
3079389|NCT01397422|Active Comparator|Treatment C|A mid-dose ADS-5102 (amantadine extended release)
3079390|NCT01397422|Active Comparator|Treatment D|High dose ADS-5102 (amantadine extended release)
3079391|NCT01397448|Experimental|E3810 5 mg|
3079392|NCT01397448|Experimental|E3810 10 mg|
3079393|NCT01397448|Active Comparator|Teprenone 150 mg|
3079394|NCT01397461|Experimental|ozenoxacin 1% cream|1% cream
3079395|NCT01397461|Placebo Comparator|ozenoxacin placebo|cream
3079396|NCT01397461|Active Comparator|retapamulin 1% ointment|1% ointment
3079397|NCT01397591|Experimental|Ofatumumab with Bortezomib|Ofatumumab was given intravenously on cycle 1 day 1 at a dose of 300mg, followed by a cycle 1 day 8 dose of 1000mg. During cycles 2 through cycle 6, Ofatumumab was given at a dose of 1000mg on day 1 of each cycle, with no dosing on any other day of the cycle. Bortezomib was given intravenously at a dose of 1.6mg/m2 on days 1, 8, and 15 of each cycle, following the Ofatumumab infusion, if given.
3079398|NCT01397617|Experimental|NobelActive Internal|NobelActive Internal implant
3079399|NCT01397617|Experimental|NobelActive External|NobelActive External implant
3079400|NCT01397617|Active Comparator|NobelReplace Tapered Groovy|NobelReplace Tapered Groovy implant
3079401|NCT01397656|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations followed by cross-over to CPR with Continuous Compressions
3079402|NCT01397656|Active Comparator|CPR with Continuous Compressions|Continuous Chest Compressions without ventilation followed by CPR 30:2 (30 chest compressions to 2 ventilations)
3079403|NCT01397747||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, who are at average risk of developing colorectal cancer.
3079404|NCT01397786|Experimental|OPC-34712|
3079405|NCT01397825|Experimental|Safety Lead-in|Alisertib 50 mg, enteric coated tablets (ECT), orally, twice daily (BID), on Days 1 to 7 followed by a 14-day rest period in 21-day cycles plus rituximab 375 mg/m^2, intravenous (IV), infusion on Day 1 of each 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3079406|NCT01397825|Experimental|Dose Escalation, Alisertib 30 mg|Alisertib 30 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1, plus vincristine 1.4 mg/m^2 (max 2 mg), IV, on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3079407|NCT01397825|Experimental|Dose Escalation, Alisertib 40 mg|Alisertib 40 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3468872|NCT03891524|Experimental|Group E: JNJ-70033093 25 mg Once Daily + Placebo|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) once daily and 1 placebo capsule in the morning and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
3079408|NCT01397825|Experimental|Dose Escalation, Alisertib 50 mg|Alisertib 50 mg, ECT, orally, BID, on Days 1 to 7 followed by a 14-day rest period plus rituximab 375 mg/m^2, IV, infusion on Day 1 plus vincristine 1.4 mg/m^2, IV (max 2mg), on Days 1 and 8 in a 21-day cycle for up to 8 cycles. Following 8 cycles of treatment (or early discontinuation of rituximab and/ or vincristine) all participants with documented disease response or stabilization may continue with alisertib single-agent therapy for up to 2 years.
3079409|NCT01397825|Experimental|Phase 2: Alisertib|Phase 2: Alisertib (MLN8237) at the Recommended Phase 2 Dose, ECT orally twice/day on Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV on Days 1 & 8 in a 21 Day cycle for up to 8 cycles was planned but not conducted.
3079410|NCT01397851|Experimental|Treatment: Insecticide-treated net|Smallholder farmers in the treatment group are informed that they won a raffle, and receive a free insecticide-treated net
3079411|NCT01397851|No Intervention|Control|Smallholder farmers in the control group are informed that they had a chance to win an insecticide-treated mosquito net in a raffle, but did not end up winning
3079412|NCT01397890|Other|1|Add-on treatment
3079413|NCT01397890|Other|2|Add-on treatment
3079414|NCT01398059|Experimental|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
3079415|NCT01398059|Experimental|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
3079416|NCT01398059|Experimental|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
3079417|NCT01398176|Experimental|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
3079418|NCT01398176|Experimental|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
3079419|NCT01398280|Experimental|Aminocaproic Acid (ACA)|Subjects will treat their facial skin twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
3079420|NCT01398280|Placebo Comparator|Vehicle cream|Subjects will apply vehicle twice daily for up to 12 weeks with 5-6 visits and 2 telephone visits. Investigator and subject will be blinded. Tape strip samples will be collected from facial skin at each visit to assess Kallikrein 5 (KLK5) activity.
3079421|NCT01398358|No Intervention|Usual Head Start Exposure|Children will attend their usual Head Start classroom and receive the usual educational interventions provided in that classroom.
3079422|NCT01398358|Experimental|Parents of Preschoolers Series (POPS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention.
3079423|NCT01398358|Experimental|POPS + Incredible Years Series (IYS)|Children attend Head Start preschool. Within the classroom, they receive a series of lessons about nutrition and obesity prevention delivered by an Extension Educator in collaboration with the classroom teacher. Parents are invited to attend a series of classes about nutrition and obesity prevention. In the classroom, children also receive a series of lessons about emotional and behavioral self-regulation delivered by a trained mental health specialist. The parents also are invited to classes about child behavioral and emotional self-regulation delivered by a mental health specialist.
3079424|NCT01398410|Experimental|Rabeprazole 5 mg|
3079425|NCT01398410|Experimental|Rabeprazole 10 mg|
3079426|NCT01398475|Experimental|LY3009104 Reference Formulation|8 milligrams (mg) LY3009104 (two 4-mg phosphate salt capsules), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3079427|NCT01398475|Experimental|LY3009104 Test Formulation 1|8 mg LY3009104 (one 8-mg smaller particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3079428|NCT01398475|Experimental|LY3009104 Test Formulation 2|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally in the fasted state, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3079429|NCT01398475|Experimental|LY3009104 Test Formulation 2 + Meal|8 mg LY3009104 (one 8-mg larger particle free base tablet), administered orally with high-fat/high calorie meal, once only. There will be a washout period of 5 to 7 days between doses of study drug.
3079430|NCT01398514|Experimental|Active medication|Escitalopram 10mg/day
3079431|NCT01398514|Placebo Comparator|Placebo|Matched pill placebo
3079432|NCT01398566|Experimental|SuperBetter Play|members of this group will play SuperBetter for 6 weeks (averaging 10 min per day of play for 6 week period)
3079433|NCT01398787|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear
3079434|NCT01398787|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear
3079435|NCT01398943|Experimental|COPD Patients|"Patients with COPD~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
3468873|NCT03891524|Experimental|Group F: JNJ-70033093 200 mg Once Daily + Placebo|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
3079436|NCT01398943|Experimental|Controls|"Healthy age- and sex- matched controls~AOC protocol: Brachial artery flow-mediated dilation, direct assessment of oxidative stress via EPR spectroscopy (O2-) and biomarkers of oxidative stress (8-isoprostane, LH, SOD) will be assessed at baseline and 2 hours following ingestion of a single oral antioxidant cocktail (1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid.) Antioxidant Cocktail: 1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid~BH4 protocol: Brachial artery flow-mediated dilation (FMD), markers of inflammation, and markers of oxidative stress will be assessed at baseline and following an increase in nitric oxide bioavailability after administering a single dose = 5 mg/kg of Tetrahydrobiopterin (BH4)"
3079437|NCT01398956|Experimental|Levetiracetam|Twice daily (morning and evening) orally
3079438|NCT01398982|Placebo Comparator|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
3079439|NCT01398982|Experimental|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
3079440|NCT01399008|Experimental|Arhalofenate 400 mg|Arhalofenate 400 mg plus allopurinol 300 mg
3079441|NCT01399008|Experimental|Arhalofenate 600 mg|Arhalofenate 600 mg plus allopurinol 300 mg
3079442|NCT01399008|Active Comparator|Allopurinol|Placebo plus Allopurinol 300 mg
3079443|NCT01399047|Active Comparator|Mycophenolate Mofetil|
3079444|NCT01399047|Placebo Comparator|Placebo liquid|
3079445|NCT01399099|Experimental|All Study Participants|Half of the abdomnioplasty incision was treated with the embrace device. Half of the abdomnioplasty incision was treated according to the investigator's standard of care. Participant served as his own control.
3079446|NCT01399125|Experimental|Rivastigmine patch|Once-daily target patch size 10 cm²
3079447|NCT01399125|Active Comparator|Rivastigmine capsules|Twice-daily target dose of 6 mg oral capsule
3079448|NCT01399190||Bevacizumab|Participants will receive bevacizumab in combination with capecitabine and oxaliplatin.
3079449|NCT01399229||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
3079450|NCT01399229||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
3079451|NCT01399229||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
3079452|NCT01399268|Experimental|Steroid|Hydrocortisone 100 mg IV Q 8hrs x3
3079453|NCT01399268|Placebo Comparator|Control|Saline IV Q8hr x3
3079454|NCT01399372|Active Comparator|Chemotherapy|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.
3079455|NCT01399372|Experimental|Chemotherapy + Low-Dose WBRT|Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.
3079456|NCT01399593|Experimental|Eculizumab|Patients were to receive eculizumab 1200 mg prior to allograft transplantation (Day 0, starting approximately one hour prior to kidney allograft reperfusion), eculizumab 900 mg (Days 1, 7, 14, 21, and 28), and eculizumab 1200 mg (Weeks 5, 7 and 9). All doses of eculizumab were administered intravenously: the median infusion time was 39 minutes.
3079457|NCT01399593|No Intervention|Standard of Care|Patients received standard of care (SOC) prophylactic therapy for acute AMR according to the SOC choice at each participating investigative site, which could have included any combination of plasmapheresis (PP) and intravenous immunoglobulin (IVIg). Patients randomized to SOC who were diagnosed with AMR could have received eculizumab for the treatment of AMR after initially receiving PP and/or IVIg.
3079458|NCT01399619|Experimental|BI201335 12W|patient to receive two capsules of BI 201335 once a day for 12 weeks and pegIFN/RBV for 24 or 48 weeks
3079459|NCT01399619|Experimental|BI 201335 24W|patient to receive two capsules of BI 201335 once a day for 24 weeks and PegIFN/RBV for 24 or 48 weeks
3079460|NCT01399619|Experimental|BI 201335 24 W|patient to receive one capsule of BI 201335 once a day for 24 weeks and pegIFN/RBV for 24 or 48 weeks
3079461|NCT01399697|Experimental|A|
3079462|NCT01399697|Active Comparator|B|
3079463|NCT01399723|Experimental|Amoxicillin 45mg/kg 12 hourly|
3079464|NCT01399723|Active Comparator|Benzyl Penicillin 50,000IU/kg 6 hourly|
3079465|NCT01399736|Active Comparator|FFR-guided revascularisation strategy|In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of >0.80 will not be treated.
3079466|NCT01399736|Placebo Comparator|randomised to guidelines group|In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
3079467|NCT01399788|Active Comparator|1.0|Test Myrin P Forte Contains 150mg Rifampicin, 75mg Isoniazid, 275mg Ethambutol, 400mg Pyrazinamide
3079468|NCT01399788|Active Comparator|2.0|Reference Single drug reference preparations contain Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
3079469|NCT01399827|Active Comparator|Omega-3 Fatty Acids|1060 mg EPA Omega-3 Fatty Acids
3079470|NCT01399827|Placebo Comparator|Placebo|
3079471|NCT01399866|Placebo Comparator|Placebo|50 mg capsule,single dose, twice, one week apart, by mouth
3079472|NCT01399866|Active Comparator|D-cycloserine|50 mg capsule,single dose, twice, one week apart, by mouth
3079473|NCT01399905|Experimental|High carbidopa followed by low carbidopa|450 mg of carbidopa per day for four weeks followed by 75 mg of carbidopa per day for four weeks
3079474|NCT01399905|Experimental|Low carbidopa followed by high carbidopa|75 mg of carbidopa per day for four weeks followed by 450 mg of carbidopa per day
3079475|NCT01400113|Experimental|Asenapine|This group received 10mg asenapine sl x 1 dose
3079476|NCT01400113|Placebo Comparator|Placebo|This group received placebo sl x 1 dose
3079477|NCT01400139|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
3079478|NCT01400243|Placebo Comparator|Placebo Patch|Placebo patch for 15-day quit period
3079479|NCT01400243|Active Comparator|Nicotine Patch|7 mg Habitrol nicotine patch-15 day quit period
3079480|NCT01400412|Experimental|MVC Arm: DRV/r + MVC + FTC + TDF placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Maraviroc 150 mg PO QD + Emtricitabine 200 mg PO QD + Placebo for Tenofovir disoproxil fumarate PO QD
3079481|NCT01400412|Experimental|TDF Arm: DRV/r + TDF + FTC + MVC placebo|Darunavir 800 mg PO QD + Ritonavir 100 mg PO QD + Emtricitabine 200 mg PO QD + Tenofovir disoproxil fumarate 300 mg PO QD + Placebo for Maraviroc PO QD
3079482|NCT01400425|Experimental|Subjects with Progressive Cognitive Decline|Subjects who have previously or are currently being evaluated for progressive cognitive decline. Enrolling physicians must have a confidence of less than 85% in their initial diagnosis of the subject's progressive cognitive decline and that there was at least a 15% chance that the subject's progressive cognitive decline was due to Alzheimer's disease. All subjects who did not complete the study withdrew before receiving a florbetapir F 18 injection and PET scan.
3079483|NCT01400451|Experimental|Ipilimumab + Vemurafenib|
3079484|NCT01400477|Experimental|DMXB-A-SR|Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR), 3-2, 4 dimethoxybenzylidene anabaseine sustained release (GTS-21)
3079485|NCT01400477|Placebo Comparator|Arm #2: Placebo Comparator|Inert capsule to resemble active drug.
3079486|NCT01400503|Experimental|Siltuximab|Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.
3079487|NCT01400516|Experimental|Teriparatide|The participants who are in treatment arm received teriparatide 20 μg, subcutaneous injection, 1 injection per day, with a biologic for 12 months. A second year of teriparatide was offered to all interested participants. All participants received daily 1000 milligrams (mg) of calcium citrate, 800 IU of vitamin D and a Tumor Necrosis Factor (TNF) antagonist.
3079488|NCT01400516|Other|Control Arm|The participants randomized to the control arm had the same testing as those in the treatment arm and were offered teriparatide, if determined to be effective in healing bone erosions, after the first 12 months. All participants received daily 1000 mg of calcium citrate, 800 IU of vitamin D and a TNF antagonist.
3079489|NCT01400698|Experimental|Saizen® (Continuous or intermittent treatment)|
3079490|NCT01400698|Experimental|Saizen® (Observed and then continuous or no treatment)|
3079491|NCT01400698|Other|Observation only|
3079492|NCT01400815|Experimental|X-22 Smoking Cessation Product|The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
3079493|NCT01400815|Active Comparator|Active Control Cigarette|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette."
3079494|NCT01400841|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
3079495|NCT01400880||Pregnant|In Labor
3079496|NCT01400893|Experimental|CRRT + SCD|Patients with a diagnosis of AKI requires CRRT will be randomized
3079497|NCT01400893|No Intervention|CRRT alone|Patients with a diagnosis of AKI requires CRRT will be randomized
3079498|NCT01400906|Placebo Comparator|3 periods cross-over study|Each subject will receive each intervention BID during a 7 days period. The treatment periods are separated by 14 days washout. The sequence in which the interventions are administered are at random and double blind.
3079499|NCT01400919|Experimental|Protégé™ EverFlex™ and GPS™ Self-Expanding Stent Systems|The objective of the study is to confirm the safety and effectiveness of the Protégé EverFlex and Protégé GPS Self-Expanding Stent Systems in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
3079500|NCT01400932|Experimental|GI148512 (Benzoyl Peroxide 3% Gel)|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime. Comparison of 2 arms (GI148512 vs vehicle)
3079501|NCT01400932|Placebo Comparator|vehicle gel|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
3079502|NCT01400958|Active Comparator|A: Nuvigil®|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent External Beam Radiation Therapy (EBRT) and Temozolomide (TMZ), there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
3468874|NCT03891524|Experimental|Group G: JNJ-70033093 50 mg once daily + Placebo|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules in the morning) once daily and 2 placebo capsules in the evening, orally for 10 to 14 postoperative days.
3468875|NCT03891524|Active Comparator|Group I: Enoxaparin 40 mg Once Daily|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
3079503|NCT01400958|Placebo Comparator|B: Placebo|Study evaluation times correspond to standard follow-up evaluations for newly diagnosed malignant glioma patients. After 6 weeks of concurrent EBRT and TMZ, there is typically a 4 week treatment break prior to the start of the 6 monthly cycles of TMZ. No further placebo or Nuvigil® will be given after the 6 week treatment regimen. Thus, study evaluations will occur at baseline (Week 0), immediately after completion of EBRT, TMZ, and Nuvigil® or placebo (Week 7), at the end of the 4 week washout period (Week 10), after the first 2 cycles of TMZ (Week 18), and after the 6th cycle of TMZ (Week 34).
3079504|NCT01400971||MOSAIc Participants|Participants enrolled in Multinational Observational Study Assessing Insulin use (MOSAIc) who had complete treatment data during the study.
3079505|NCT01401010|Active Comparator|Doripenem 500 mg|pharmacokinetics/pharmacodynamics
3079506|NCT01401010|Active Comparator|Doripenem 1000 mg|pharmacokinetics/pharmacodynamics
3079507|NCT01401023|Experimental|Clostridium difficile Patient|Open non-comparative trial
3079508|NCT01401062|Experimental|Arm 1 (Fresolimumab 1 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 1 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
3079509|NCT01401062|Experimental|Arm 2 (Fresolimumab 10 mg/kg)|Fresolimumab is administered intravenously (i.v.) at a dose of 10 mg/kg on day 1 of weeks 0, 3, 6, 9 & 12 and radiation administered at 7.5 Gy/fraction in 3 fractions during weeks 1 (to lesion 1) and 7 (to lesion 2).
3079510|NCT01401101|Experimental|PTSD Care Management (PCM)|PCM has six intervention components: 1) patient education, 2) patient screening and written feedback of screening information to primary care clinicians, 3) clinician education on practice guidelines , 4) structured feedback between primary care and mental health clinicians, 5) continuity of patient care, and 6) a resource guide detailing available community services where the FQHC has established reciprocal referrals. All of the intervention components will be implemented through the CM, except for the clinician education component, which will combine onsite and online continuing medical education (CME)-accredited sessions.
3079511|NCT01401101|Placebo Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition consists of only the clinician education and patient screening without written feedback.
3079512|NCT01401153|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water available on both days.
3079513|NCT01401153|Experimental|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water available on both days.
3079514|NCT01401166|Experimental|Cohort 1: SC (SID) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via single-use injection device (SID), and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
3079515|NCT01401166|Experimental|Cohort 1: IV then SC (SID) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via SID. In the continuation period, participants will receive IV Herceptin for up to 10 remaining cycles. Administration will be performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period will be offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP.
3079516|NCT01401166|Experimental|Cohort 2: SC (Vial) then IV Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin will be administered via handheld syringe using the vial formulation, and during Cycles 5 to 8, IV Herceptin will be given. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
3079517|NCT01401166|Experimental|Cohort 2: IV then SC (Vial) Herceptin|Participants will receive Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin will be given, and during Cycles 5 to 8, SC Herceptin will be administered via handheld syringe using the vial formulation. In the continuation period, participants will receive SC Herceptin via handheld syringe using the vial formulation for up to 10 remaining cycles. Administration will be performed by HCP throughout the study.
3079518|NCT01401257|Experimental|PXT3003 Low dose|Oral Liquid formulation, 1/100, bid, 12 months
3079519|NCT01401257|Experimental|PXT3003 Intermediate dose|Oral Liquid formulation, 1/50, bid, 12 months
3079520|NCT01401257|Experimental|PXT3003 High dose|Oral Liquid formulation, 1/10, bid, 12 months
3079521|NCT01401257|Placebo Comparator|Placebo|Oral Liquid formulation, bid, 12 months
3079522|NCT01401283|Active Comparator|Study group|intraoperative guidance of hemodynamics by measures of cardiac index and pulse pressure variation, measurement of cardiac output and pulse pressure variation, hemodynamic optimization according to cardiac index and pulse pressure variation
3079523|NCT01401283|No Intervention|Control group|hemodynamic management according to institutional clinical standards
3079524|NCT01401322|Experimental|Lenalidomide 50 mg/day x 28 days|Lenalidomide 50 mg daily for 28 consecutive days every 42 days (+/-7 days). Treatment to continue until evidence of disease progression or development of unexpected toxicities not reversed by dose reductions and/or interruptions.
3079525|NCT01401361|Experimental|Treatment Arm|Atrial Flutter RF Ablation treatment with the Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement.
3079526|NCT01401452||Participants with psoriasis and at least one co-morbid disease|Participants with moderate to severe plaque psoriasis with at least one co-morbid disease and/or symptom such as hypertension, psoriatic arthritis confirmed by a rheumatologist or other appropriate specialist, obesity, diabetes, metabolic syndrome or depression
3079527|NCT01401465|Experimental|Ciclesonide Nasal Aerosol|74 mcg ciclesonide nasal aerosol once daily
3079528|NCT01401465|Active Comparator|Mometasone Nasal Spray|200 mcg mometasone aqueous nasal spray once daily
3079529|NCT01401478||Stage 5 Chronic Kidney Disease|Planned for Zemplar administration due to secondary hyperparathyroidism
3079530|NCT01401517|Placebo Comparator|Placebo|Microcrystalline cellulose NF at 60 mg/capsule, BID
3079531|NCT01401517|Experimental|40 mg Sodium Nitrite|40 mg dose, BID
3079532|NCT01401517|Experimental|80 mg Sodium Nitrite|80 mg dose, BID
3079533|NCT01401530|Experimental|E7777|
3079534|NCT01401543|Active Comparator|5 mg LY2452473 + 5 mg Tadalafil|5-mg LY2452473 oral capsule and 5-mg tadalafil oral tablet, administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.
3079535|NCT01401543|Experimental|LY900010 (particle size #1)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a smaller particle size (d90 = 10 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
3079536|NCT01401543|Experimental|LY900010 (particle size #2)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with an intermediate particle size (d90 = 25 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
3079537|NCT01401543|Experimental|LY900010 (particle size #3)|"Single combination tablet containing 5 mg tadalafil and 5 mg LY2452473 with a larger particle size (d90 = 40 microns), administered orally, once only. There will be a washout period of at least 7 days between doses of study drug.~d90 is a measurement of the distribution of particle widths such that 90% of the particles have a diameter less than the specified value."
3079538|NCT01401582|No Intervention|care as usual|care as usual, no intervention, just observation of natural change/ trajectories over time
3079539|NCT01401582|Experimental|Implementation of Dementia Care Manager|"Subjects in this arm will be provided with a specialised Dementia Care Manager to be included in a subsidiary support system"
3079540|NCT01401595|Experimental|Night Eaters|Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
3079541|NCT01401595|No Intervention|Control Subjects|"At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls."
3079542|NCT01401647|Active Comparator|Amiodarone|Intravenous (IV) or intraosseous (IO) administration of amiodarone if VF/pulseless VT reoccurs after initial defibrillation.
3079543|NCT01401647|Active Comparator|Lidocaine|IV or IO administration of lidocaine if VF/pulseless VT reoccurs after initial defibrillation.
3079544|NCT01401647|Placebo Comparator|Normal saline|IV or IO administration of normal saline if VF/pulseless VT reoccurs after initial defibrillation.
3079545|NCT01401699|Experimental|Optical Frequency Domain imaging System|Optical Frequency Domain Imaging (OFDI) balloon based imaging
3079546|NCT01401842|Experimental|Strengthening Exercise|Lumbar ext. high intensity progressive resistance exercise
3079547|NCT01401842|Active Comparator|Stabilization Exercise|Low intensity core stabilization exercise
3079548|NCT01401907|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
3079549|NCT01401907|No Intervention|Standard of Care|Subjects receives standard of care
3079550|NCT01401959|Experimental|Cohort A: Triple-negative breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
3079551|NCT01401959|Experimental|Cohort B: ER/PR+ /HER2- breast cancer|Eribulin 1.4 mg/m^2 intravenously (IV)
3079552|NCT01401959|Experimental|Cohort C: HER2+ breast cancer|"Eribulin 1.4 mg/m^2 intravenously (IV)~Trastuzumab 6mg/kg intravenously (IV)"
3079553|NCT01402011|Experimental|25% dextrose in shoulder entheses|25% dextrose and .1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
3079554|NCT01402011|Active Comparator|.1% lidocaine in shoulder entheses|.1% lidocaine injected in the shoulder entheses (ligament and tendon insertions on the periosteum).
3079555|NCT01402011|Placebo Comparator|.1% lidocaine subcu. above shouldr enth.|.1% lidocaine injected subcutaneously above the shoulder entheses (ligament and tendon insertions on the periosteum).
3079556|NCT01402050|Active Comparator|FOLEY BALLOON|Comparing foley balloon to cervidil for decreased time from the start of the induction process to delivery
3079557|NCT01402050|Active Comparator|CERVIDIL|
3079558|NCT01402063|Experimental|radiation plus PPX(CT2103|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ intravenous PPX every week x 6 weeks for a total of 6 treatments"
3079559|NCT01402063|Active Comparator|radiation + Temozolomide|"Radiation therapy, Monday through Friday, for 6 weeks for a total of 30 treatments~+ Daily oral temozolomide(TMZ) (7 days) x 6 wks for a total of 42 days"
3079560|NCT01402102|Experimental|Aged garlic powder|
3079561|NCT01402102|Placebo Comparator|Placebo|
3079562|NCT01402115|Experimental|Polycan|Polycan 150mg for 12 weeks
3079563|NCT01402115|Placebo Comparator|Placebo|Placebo 15mg for 12 weeks
3079564|NCT01402128|Experimental|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
3079565|NCT01402128|Placebo Comparator|Placebo|Placebo for 12 weeks
3079566|NCT01402141|Experimental|Chungkookjang|
3079567|NCT01402141|Placebo Comparator|Placebo|
3468876|NCT03891420|Experimental|Galidesivir|Galidesivir IV infusion
3468877|NCT03891420|Placebo Comparator|Placebo|Placebo IV infusion
3079568|NCT01402284|Experimental|Carfilzomib, Lenalidomide, Dexamethasone|Patients will receive 8 cycles of induction combination therapy of carfilzomib, lenalidomide, and dexamethasone (CRd). Patients achieving stable disease or better after 8 cycles of CRd will receive lenalidomide extended dosing (phase I) for 12 cycles. After 12 cycles, patients will have the option to continue extended dosing (phase II) for one additional year
3079569|NCT01402375|Experimental|Hydrocodone (first trial)|Hydrocodone 5mg / Acetaminophen 500mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3079570|NCT01402375|Active Comparator|Codeine (first trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3079571|NCT01402375|Experimental|Oxycodone (for second trial)|Oxycodone 5mg / Acetaminophen 325mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3079572|NCT01402375|Active Comparator|Codeine (for second trial)|Codeine 30mg / Acetaminophen 300mg. Patients instructed to take 1 dose every 4 hrs as needed for pain.
3079573|NCT01402375|Experimental|Oxycodone (third trial)|Oxycodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
3079574|NCT01402375|Active Comparator|Hydrocodone (third trial)|Hydrocodone 5mg / Acetaminophen 325 mg. Patients instructed to take 1 dose every 4 hours as needed for pain.
3079575|NCT01402427|Active Comparator|Verapamil|
3079576|NCT01402427|Placebo Comparator|Placebo|
3079577|NCT01402492|Experimental|BUP4+XR-NTX|4mg buprenorphine plus naltrexone for 8 weeks of treatment
3079578|NCT01402492|Experimental|BUP16+XR-NTX|16mg buprenorphine plus naltrexone for 8 weeks of treatment
3079579|NCT01402492|Active Comparator|PLB+XR-NTX|naltrexone for 8 weeks of treatment
3079580|NCT01402544|Other|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg Intravitreal Injection, monthly, open-label, for the duration of 1 year
3079581|NCT01402570|Experimental|Glutathione supplement|All subjects will be taking a glutathione supplement.Glutathione is a naturally occuring antioxidant and a nonessential amino acid.
3079582|NCT01402700|Experimental|Visi-Pro™ Balloon Expandable Stent System|The objective of the study is to confirm the safety and effectiveness of the Visi-Pro stent in the treatment of stenotic, restenotic or occluded lesions in the common and external iliac artery.
3079583|NCT01402817|Experimental|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
3079584|NCT01402869|Experimental|Prilocaine|30 subjects will receive 5mg/kg of 4% prilocaine plain local anesthetic for restorative dental treatment under general anesthesia
3079585|NCT01402869|Experimental|Lidocaine|30 subjects will receive 2.5mg/kg of 2% lidocaine with 1:100,000 epinephrine local anesthetic for restorative dental treatment under general anesthesia
3079586|NCT01402869|No Intervention|No local anesthetic|30 subjects will not receive local anesthetic for dental treatment under general anesthesia-Negative control
3079587|NCT01402908|Experimental|PI-88|Arm 1
3079588|NCT01402908|Placebo Comparator|Placebo|Arm 2
3079589|NCT01402947|Experimental|Ciprofloxacin + MMX placebo|
3079590|NCT01402947|Experimental|MMX Mesalazine/mesalamine + Ciprofloxacin|
3079591|NCT01402986|Placebo Comparator|Placebo, Q2W - Cohort 1|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
3079592|NCT01402986|Experimental|Tralokinumab 300 mg, Q2W - Cohort 1|Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
3079593|NCT01402986|Placebo Comparator|Placebo, Q2/4W - Cohort 2|Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
3079594|NCT01402986|Experimental|Tralokinumab 300 mg, Q2/4W - Cohort 2|Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.
3079595|NCT01403051|Experimental|Arm A: EFV/FTC/TDF plus vitamin D3 and calcium carbonate|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), calcium carbonate and vitamin D3 4000 IU.
3079596|NCT01403051|Experimental|Arm B: EFV/FTC/TDF plus vitamin D placebo and calcium placebo|Participants were administered FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), a placebo for calcium carbonate, and a placebo for vitamin D3.
3079597|NCT01403064|Experimental|Open Label ALD518|
3079598|NCT01403064|Experimental|ALD518 Dose 1|
3079599|NCT01403064|Experimental|ALD518 Dose 2|
3079600|NCT01403064|Placebo Comparator|Placebo|
3079601|NCT01403090|Experimental|Angel Catheter|
3079602|NCT01403116|Experimental|Oral testosterone undecanoate (TU)|"Treatment Period 1: 100 mg capsules, BID, with food~Treatment Period 2: One of the following dosages:~100 mg BID~150 mg BID~100 mg BID~100 mg and 150 mg BID~150 mg capsules BID~Safety Follow-up Phase:~Initial dose: ~84 doses Maintenance dose-Titrated dose: ~96 doses Safety follow-up at maintenance dose: ~540 doses"
3079603|NCT01403116|Active Comparator|topical testosterone gel|"Treatment Period 1: 5 g of 1% transdermal T-gel applied QD~Treatment Period 2:~2.5 g of 1% transdermal T-gel applied QD~5 g of 1% transdermal T-gel applied QD~7.5 g of 1% transdermal T-gel applied QD~10 g of 1% transdermal T-gel applied QD~Safety Follow-up Phase:~Initial dose: ~42 doses Maintenance dose-Titrated dose: ~48 doses Safety follow-up at maintenance dose: ~270 doses"
3079604|NCT01403246|Experimental|Lenalidomide with Chlorambucil|
3079605|NCT01403376|Experimental|Teriflunomide 7 mg|Influenza vaccine in participants treated with teriflunomide 7 mg for at least 6 months
3079606|NCT01403376|Experimental|Teriflunomide 14 mg|Influenza vaccine in participants treated with teriflunomide 14 mg for at least 6 months
3079607|NCT01403376|Active Comparator|IFN-β-1|Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months
3079608|NCT01403441|Experimental|Radiosurgical Neuromodulation|Bilateral Radiosurgical Neuromodulation using the Cyberknife
3079609|NCT01403584|Experimental|AutoVPAP with addition of AutoEPAP|This arm will receive conventional device modified to enable algorithm for automatically applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
3079610|NCT01403584|Active Comparator|AutoVPAP without addition of AutoEPAP|This arm will receive conventionally applied Expiratory Positive Airway Pressure. Patients randomised to this group will then receive the other treatment the following night.
3079611|NCT01403610|Experimental|Cohort 1|Subjects received TH-302 single dose at 575 mg/m2 or placebo administered preoperative in a 2:1 randomization and were then administered 240 mg/m2 of TH-302 post-operative.
3079612|NCT01403610|Experimental|Cohort 2|Surgical subjects will receive TH-302 at 340 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
3079613|NCT01403610|Experimental|Cohort 3|Surgical or Non-Surgical subjects will receive TH-302 at 480 mg/m2 every 2 weeks (4 week cycles) starting after surgery from Cycle 1, Day 1 until disease progression.
3079614|NCT01403610|Experimental|Cohort 4|Non-surgical subjects will receive a dose up to 670 mg/m2 of TH-302
3079615|NCT01403805|Experimental|Oral care and vaccines|Oral care and pneumococcal plus influenza vaccines
3079616|NCT01403805|Active Comparator|Vaccine|Influenza vaccine only
3468878|NCT03891433|Active Comparator|Carbapenems group|Meropenem (1g intravenously every 8 hours or adjusted to renal function) or Ertapenem (1g intravenously every 24 hours or adjusted to renal function) by 10 days.
3079618|NCT01403987|Active Comparator|Control Arm|Control group will receive standard teaching by the Residency Program regarding management of ascites and performance of paracentesis.
3079619|NCT01403987|Experimental|Intermediate Education Arm|In addition to the teaching provided by the residency program, the intermediate education group will receive a dedicated lecture by a gastroenterology fellow designed to teach consensus guidelines and their rationale in management of ascites. They will also receive a pocket card noting specific indications for paracentesis, and a brief summary of guidelines.
3079620|NCT01403987|Experimental|"Intensive Education Arm (Pager Arm)"|This group will receive the residency teaching, the specialist lecture, the pocket card, and have access to a pager carried by a gastroenterology fellow for personal assistance in performing paracentesis.
3079621|NCT01404039|Experimental|Motor Learning (ML) sighted|"In this arm, subject will perform motor Learning with visual feedback - ML sighted.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
3079622|NCT01404039|Experimental|Motor Learning (ML) blind|"In this arm, subject will perform motor Learning without visual feedback - ML blind.~There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session."
3079623|NCT01404039|Placebo Comparator|Motor Learning (ML) control group|In this arm, subject will perform simple hand movements - control group. There will be an anticipated total of 15 subjects in this experimental arm. This arm will be conducted as a cross-over design. The subjects will undergo the three interventions listed (motor learning with visual feedback, motor learning without visual feedback, and control group) in a counterbalanced randomized order. There will be at least 24 hours between each experimental session.
3079624|NCT01404039|Experimental|Somatosensory Learning (SL sighted)|"In this arm, subject will perform sensory Learning with visual feedback - SL sighted.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3079625|NCT01404039|Experimental|Somatosensory Learning (SL blind)|"In this arm, subject will perform sensory Learning without visual feedback - SL blind.~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3079626|NCT01404039|Experimental|Somatosensory Activation (S activation)|"In this arm, subject will receive simple sensory stimulation over their left index finger - Sactivation.~There will be an anticipated total of 10 subjects in this experimental arm.This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3079627|NCT01404039|Placebo Comparator|Somatosensory Learning (SL) control group|"In this arm,the subjects will not receive any somatosensory input (SL control group).~There will be an anticipated total of 10 subjects in this experimental arm. This experimental arm will be conducted in a parallel design with 4 groups (SL sighted, SL blind, Sactivation, SL control)."
3079628|NCT01404039|Experimental|Observational Task (OT) - real|In this arm, the subjects will perform an observational task - observation of hand movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3079629|NCT01404039|Placebo Comparator|Observational Task (OT) - control group|In this arm, the subjects will perform a controlled observational task - observation of geometric shapes. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3079630|NCT01404039|Experimental|Mental Imagery (MI) - real|In this arm, the subjects will perform mental imagery - mental imagery of finger movements. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3079631|NCT01404039|Placebo Comparator|Mental Imagery (MI) - control group|In this arm, the subjects will perform a controlled task - simple mental calculation. This experimental arm will be conducted in a parallel design. There will be 15 subjects per intervention.
3079632|NCT01404039|Experimental|transcranial direct current stimulation - tDCS real|tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. 15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session.
3468879|NCT03891433|Active Comparator|Piperacillin/tazobactam.|Piperacillin / Tazobactam (4.5gr intravenously every 6 hours or adjusted to renal function) by 10 days.
3079633|NCT01404039|Placebo Comparator|transcranial direct current stimulation - tDCS sham|"tDCS will be applied over the motor cortex for 20minutes at an intensity of 2mA. The stimulation will be stopped after 30seconds.~15 subjects will be enrolled. The subjects will undergo two interventions, real and sham in a counterbalanced randomized order. There will be at least 3 days between each experimental session."
3079634|NCT01404078|Active Comparator|SD Polycap without potassium|Single dose polycap without pottasium
3079635|NCT01404078|Experimental|DD Polycap plus potassium|Double Dose polycap with potassium
3079636|NCT01404208|Active Comparator|D-Cycloserine|
3079637|NCT01404208|Placebo Comparator|Sugar Pill|
3079638|NCT01404234|Experimental|Open-label AZLI|Participants received three 28-day courses of AZLI, each followed by 28 days off-treatment.
3079639|NCT01404260|Experimental|Gemcitabine +Carboplatin +Gefitinib|Arm A: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles, Gefitinib 250mg/d every cycle d15-25, and Gefitinib 250mg/d from d15 of last cycle until disease progression
3079640|NCT01404260|Active Comparator|Gemcitabine +Carboplatin|Arm B: Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum4 cycles, observation until disease progression
3321076|NCT02015962|Experimental|Enteral potassium (ERP)|Once included in the study, patients in this arm will be given oral potassium if they develop an episode of hypokalemia. As per CICU protocol 1-ml blood sample from already placed art-line or central venous line is sent for analysis of serum potassium concentration in all the immediate post operative patients. As per a previously established protocol and bioavailability data, repeat serum potassium will be sent 2 hours after replacement in the EPR group. Replacement and serum level monitoring will be done till the episode of hypokalemia is resolved
3079643|NCT01404325|Experimental|Quadruple low level IS regimen|quadruple immunosuppressive (IS) regimen consisting of everolimus, CNI, MPA and steroids
3079644|NCT01404325|Experimental|Centre specific triple IS regimen|centre specific CNI-based triple drug immunosuppression (IS)
3079645|NCT01404429|Active Comparator|Methotrexate 7.5 mg per week|
3079646|NCT01404429|Experimental|Methotrexate 15 mg per week|
3079647|NCT01404559|Active Comparator|Prosthetic foot 1 (Ossur Variflex)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 1 (Ossur Variflex).
3079648|NCT01404559|Active Comparator|Prosthetic foot 2 (Ossur Ceterus)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 2 (Ossur Ceterus).
3079649|NCT01404559|Active Comparator|Prosthetic foot 3 (Endolite Elite Blade)|This arm included unilateral transtibial amputees who who were assessed while using prosthetic foot 3 (Endolite Elite Blade).
3079650|NCT01404559|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3079651|NCT01404572|Active Comparator|Atazanavir + 10% aspartame|
3079652|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame|
3079653|NCT01404572|Active Comparator|Atazanavir + 4.2% aspartame and sucralose|
3079654|NCT01404611|Active Comparator|DF289|Ear drops
3079655|NCT01404611|Active Comparator|DF277|Ear drops
3079656|NCT01404611|Experimental|DF289 plus DF277|Ear drops
3079657|NCT01404650|Experimental|AUY922|
3079658|NCT01404923|Experimental|meteospasmyl|
3079659|NCT01404923|Active Comparator|standard of care|
3079660|NCT01404936|Experimental|Interferon-2A + Chemotherapy|Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)
3079661|NCT01404949|Experimental|Tretinoin and Arsenic Trioxide|This is a multicenter, phase II trial to study the efficacy of combined tretinoin and ATO in the treatment of newly diagnosed APL in an effort to reduce or eliminate the amount of standard chemotherapy required for long-term remission.
3079662|NCT01404988|Experimental|Telephone-Delivered BI|Comprehensive behavioral intervention (BI) - Participants will receive the BI that is based on the transtheoretical model, which targets stage of change, decisional balance and self-efficacy, while also assessing and counseling regarding the barriers and facilitators of HF care, and to improve self-regulatory care such as self-monitoring, self-evaluation, feedback and reinforcement.
3079663|NCT01404988|Experimental|Telephone-Delivered BEI|Behavioral & Environmental Intervention (BEI) - Participants in this arm will receive the BI but will also receive environmental tailoring. Environmental Tailoring consists of Built Environment Tailoring (BET) where the intervention will incorporate aspects from the patients' environment, such as accessibility of health food stores or recreational facilities. Environmental Tailoring also consists of Human Environment Tailoring (HET) which incorporates patients' social support. Caregivers will be enrolled for patients in this arm of the study and they will also receive health education.
3079664|NCT01404988|Placebo Comparator|Telephone-Delivered API|Attention Placebo Intervention (API) - patients will receive non-tailored counseling on general health topics.
3079665|NCT01405027|Other|Group A - HCEE|Group A - CLDF Hepatology Centers of Educational Expertise (HCEE) are hepatologists experienced in educating health professionals about current developments in the management of chronic liver disease and with clinical trial experience using an HCV protease inhibitor. HCEE investigators provided patient education and management skills training during four (4) educational interventions to Community Site investigators.
3079666|NCT01405027|Other|Group B - Community Sites|Group B - community physicians treating HCV but without clinical trial experience with an HCV protease inhibitor received patient education and management skills training from Hepatology Centers of Educational Expertise (HCEEs) during four (4) educational interventions.
3079667|NCT01405053|Active Comparator|Rufinamide|
3079668|NCT01405053|Active Comparator|Any other approved AED|
3079669|NCT01405196|Other|10 mg of PF-04236921|
3079670|NCT01405196|Other|50 mg of PF-04236921|
3079671|NCT01405196|Other|200 mg of PF-04236921|
3079672|NCT01405196|Other|Placebo|
3079673|NCT01405313|Experimental|Modified ASV|Modified ASV Enhanced ASV algorithm which includes auto-adjusting expiratory pressure.
3079674|NCT01405313|Active Comparator|Conventional ASV|Conventional ASV This is the current (predicate) ASV algorithm.
3079675|NCT01405456|Experimental|Eplerenone and Lifestyle|First 6 months: eplerenone 50mg daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: same (eplerenone open label during second 6 months)
3079676|NCT01405456|Placebo Comparator|Placebo and Lifestyle|First 6 months: placebo pill daily along with lifestyle modification (counseling regarding lifestyle and diet, as well as following healthy activity guidelines) Second 6 months: eplerenone (open label) 50mg daily along with continued lifestyle modification
3079677|NCT01405469|Experimental|Peroral Endoscopic Myotomy|Patients with achalasia who are designed to either get balloon dilatation or have botulinum toxin injection, or to have surgical intervention (Heller myotomy)for treatment
3079678|NCT01405508|Experimental|Placebo tablets / Brivaracetam bolus|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive Placebo tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3079679|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV bolus|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by BRV bolus for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake bid for the fourth week"
3079680|NCT01405508|Experimental|Placebo tablets / Brivaracetam infusion|"Subjects will receive Placebo (PBO) tablets for one week followed by Brivaracetam (BRV) intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3079681|NCT01405508|Experimental|Brivaracetam (BRV) tablets / BRV infusion|"Subjects will receive Brivaracetam (BRV) tablets for one week followed by Brivaracetam intravenous infusion for 4.5 days.~Down-Titration:~If subject discontinues the study during the Run-In Period, then the subject will receive the treatment that he/she was assigned during Run-In~If subject discontinues during the Evaluation Period or after Day 12, the subject will receive BRV tablets during Down-Titration:~Tablets will be provided for 4 weeks; 75 mg / intake BID for the first week, 50 mg / intake BID for the second week, 25 mg / intake BID for the third week, 10 mg / intake BID for the fourth week"
3079682|NCT01405560|Experimental|Vaniprevir 24 Week Arm|Participants receive 24 weeks of vaniprevir (300 mg twice daily) with concomitant peg-IFN and RBV treatment
3079683|NCT01405742|Experimental|Arm A|"The intervention for Arm A is 40 IU/kg recombinant factor VIII (rFVIII) by once-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given thrice-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds."
3079684|NCT01405742|Experimental|Arm B|"The intervention for Arm B is 40 IU/kg recombinant factor VIII (rFVIII) by thrice-weekly intravenous injection for 26 weeks.~Cross-over will occur at 26 weeks after a 72 hour washout period, after which 40 IU/kg recombinant factor VIII (rFVIII) will be given once-weekly by intravenous injection until week 52, with up to two rescue doses per week for bleeds"
3079685|NCT01405768|Active Comparator|Lidocaine Arm|Women in this arm will receive plain lidocaine with epinephrine injected into their cervix prior to the LEEP procedure.
3079686|NCT01405768|Experimental|Buffered Lidocaine|Women in this arm will receive sodium bicarbonate buffered lidocaine mixed with epinephrine injected into their cervix prior to the LEEP procedure.
3079687|NCT01405794|Experimental|32ppm Oral Silver|14 Days Active Silver Solution
3079688|NCT01405794|Placebo Comparator|Sterile Water|No Silver Nanoparticles
3079689|NCT01405820|Active Comparator|Natalizumab 300 mg Intravenous (IV) Every 4 Weeks|Natalizumab 300 mg IV every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079690|NCT01405820|Experimental|Natalizumab 300 mg Subcutaneous (SC) Every 4 Weeks|Natalizumab 300 mg SC every 4 weeks for 60 weeks. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079691|NCT01405820|Experimental|Natalizumab 300 mg IV Every 12 Weeks|Natalizumab 300 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079692|NCT01405820|Experimental|Natalizumab 300 mg SC Every 12 Weeks|Natalizumab 300 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079693|NCT01405820|Experimental|Natalizumab 150 mg IV Every 12 Weeks|Natalizumab 150 mg IV every 12 weeks for 60 weeks with matching IV placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079694|NCT01405820|Experimental|Natalizumab 150 mg SC Every 12 Weeks|Natalizumab 150 mg SC every 12 weeks for 60 weeks with matching SC placebo administered during the intervening 4-week periods. Open-label natalizumab treatment 300 mg IV at Weeks 60, 64, and 68.
3079695|NCT01405898|Experimental|Beetroot Juice|
3079696|NCT01405898|Placebo Comparator|Nitrate-free beetroot juice|
3079697|NCT01405911|Placebo Comparator|Placebo|Participants will take one tablet of placebo for sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
3079698|NCT01405911|Experimental|Sitagliptin 25 mg|Participants will take one tablet of sitagliptin 25 mg and one tablet of placebo for sitagliptin 50 mg orally once daily for 8 weeks.
3079699|NCT01405911|Experimental|Sitagliptin 50 mg|Participants will take one tablet of sitagliptin 50 mg and one tablet of placebo for sitagliptin 25 mg orally once daily for 8 weeks.
3079700|NCT01405924|Experimental|Fosaprepitant 150 mg|Women with breast cancer receiving anthracycline-cyclophosphamide (AC)-like chemotherapy and women with gynecological cancer receiving carboplatin-paclitaxel (CT) chemotherapy receive fosaprepitant 150 mg administered intravenously (IV) on Day 1 of Cycle 2 of chemotherapy
3079701|NCT01405937|Experimental|Vaniprevir 12 Week Arm|Participants on this arm receive 12 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
3079702|NCT01405937|Experimental|Vaniprevir 24 Week Arm|Participants on this arm receive 24 weeks of vaniprevir (300 mg twice daily) along with 24 weeks of treatment with peg-IFN and RBV
3079703|NCT01405950|Experimental|Dose Level 1|
3079704|NCT01405950|Experimental|Dose Level 2|
3079705|NCT01405950|Experimental|Dose Level 3|
3079706|NCT01405950|Experimental|Dose Level 4|
3079707|NCT01406015|Active Comparator|Spironolactone|
3079708|NCT01406015|Placebo Comparator|Placebo|
3079709|NCT01406223|Active Comparator|varenicline|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline, smokers in this group will also receive placebo bupropion and placebo patches.
3079710|NCT01406223|Active Comparator|NRT (nicotine patches only)|21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
3079711|NCT01406223|Active Comparator|varenicline + bupropion|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) occurring at one week before the target quit date, smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus bupropion at a dose of 150mg once per day. Subsequently, the dose of varenicline will be 1 mg twice per day and the dose of bupropion will be 150 mg twice per day, and will remain at that dose for the remainder of the 12 weeks. During the time they receive varenicline and bupropion, smokers in this group will also receive placebo patches.
3079712|NCT01406223|Placebo Comparator|Post-quit NRT|Nicotine patches at 21 mg/24 h for 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. After the 1st week, smokers in this group will also receive placebo bupropion and placebo varenicline.
3079713|NCT01406444|Active Comparator|rhIGF-1 followed by Risedronate|Sequential therapy with rhIGF-1 (started at a dose of 30 mcg/kg subcutaneous BID and titrated) for 6 months followed by 6 months of risedronate 35mg PO once weekly
3079714|NCT01406444|Active Comparator|Risedronate|Risedronate 35mg PO once weekly for 12 months
3079715|NCT01406444|Placebo Comparator|Placebo|Placebo for 12 months
3079716|NCT01406574|Experimental|OPB-31121 p1|Phase1 step
3079717|NCT01406574|Experimental|OPB-31121 p2|Phase2 step
3079718|NCT01406652|Active Comparator|One-stage bursectomy|Bursectomy with debridement and primary closure of the wound during one surgical intervention
3079719|NCT01406652|Experimental|Two-stage bursectomy|Bursectomy with debridement and left open. Wound closure in a second step and in a second surgery.
3079720|NCT01406717|Experimental|SPIL1033|
3079721|NCT01406717|Placebo Comparator|Placebo|
3079722|NCT01406795|Experimental|Venous Stent Arm|The study is a single treatment arm study and the venous stent will be placed in all eligible participants.
3079723|NCT01406873|Active Comparator|Mexiletine|20 subjects will be randomized (assigned) to receive Mexiletine. Mexiletine is available on the market for the treatment of cardiac arrhythmias, but it is not currently approved for the treatment of myotonia or myotonic dystrophy.
3079724|NCT01406873|Placebo Comparator|Sugar pill|20 subjects will be randomized (assigned) to receive placebo (sugar pill). This control group is necessary to definitely establish the antimyotonic efficacy and safety of mexiletine.
3079725|NCT01406938|Experimental|AIN457150 mg- Induction period Only(IPO)|secukinumab 150 mg (1 injection per dose) and placebo to secukinumab 150 mg (1 injection per dose). Induction period only (IPO)
3079726|NCT01406938|Experimental|AIN457 300 mg - IPO|secukinumab- 2 x 150mg injections per dose
3079727|NCT01406938|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO (placebo) secukinumab injection
3079728|NCT01406938|Experimental|AIN457 300 mg FI|2 s.c. secukinumab 150 mg injections
3079729|NCT01406938|Experimental|AIN457 150 mg- Start of relapse (SoR)|1 s.c. secukinumab 150 mg injection + 1 s.c. PBO secukinumab injection
3079730|NCT01406938|Experimental|AIN457 300 mg- SoR|2 s.c. secukinumab 150 mg injections
3079731|NCT01406990||Aspirin 81 mg|Women with CAD taking 81 mg aspirin.
3079732|NCT01407068|Experimental|AA4500|AA4500 collagenase clostridium histolyticum
3079733|NCT01407094|Active Comparator|Sertraline|SSRI monotherapy
3079734|NCT01407094|Placebo Comparator|Placebo|Placebo control
3079735|NCT01407094|Active Comparator|Bupropion|BupropionXL
3079736|NCT01407107|Experimental|Nitroglycerin|Dose escalation trial of Nitroglycerin
3079737|NCT01407276|Experimental|Part 1: Mild Renal Impairment (Panel A)|
3079738|NCT01407276|Experimental|Part 1: Control to Match Panel A (Panel B)|
3079739|NCT01407276|Experimental|Part 1: Moderate Renal Impairment (Panel C)|
3079740|NCT01407276|Experimental|Part 1: Control to Match Panel C (Panel D)|
3079741|NCT01407276|Experimental|Part 1: Severe Renal Impairment (Panel E)|
3079742|NCT01407276|Experimental|Part 1: Control to Match Panel E (Panel F)|
3079743|NCT01407276|Experimental|Part 2: End-stage Renal Disease needing hemodialysis (Panel G)|
3079744|NCT01407276|Experimental|Part 2: Control to Match Panel G (Panel H)|
3079745|NCT01407354|Experimental|Lokomat Training|Lokomat robotic assisted treadmill training Lokomat Treadmill Training
3079746|NCT01407354|Active Comparator|Aquatic Therapy|Aquatic exercise therapy
3321077|NCT02015988|Experimental|Simvastatin and Fenofibrate|Simvastatin 40 mg once daily and fenofibrate 145 mg once daily orally for 52 weeks (1 year)
3321078|NCT02015988|Active Comparator|Simvastatin|Simvastatin 40 mg once daily orally for 52 weeks (1 year)
3079747|NCT01407367||Phase I and Phase II|"Phase I (First 100 participants):~Medical alert bracelet/necklace, Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs~Phase II (Next 250 participants):~Medical event diary, Medical event ascertainment, Repeated measurement of renal function and other electrolytes, Review for CKD-PSIs"
3079748|NCT01407523|Experimental|Levetiracetam|Twice daily intravenous (IV) infusion of Levetiracetam solution equivalent (mg-for-mg) to oral dose of Levetiracetam.
3079749|NCT01407575|Experimental|Buprenorphine|0.2 to 1.6mg of buprenorphine sublingual over the course of 8 weeks
3079750|NCT01407575|Placebo Comparator|Placebo|matching placebo- sublingual- over the course of 8 weeks
3079751|NCT01407926||Nurse-Led Mental Health Promotion Group|Interprofessional nurse-led strategy involving regular home visits over 6 months by an RN and PSW. The RN will conduct a comprehensive health assessment and screen clients for risk factors for depression and other chronic conditions, implement health promotion strategies to address this risk factors and enhance health, review their medications, conduct in-home exercise , refer clients to other health services
3079752|NCT01407952|Other|HydroCoil Embolic System|Aneurysm treatment using the HydroCoil Embolization System (21 CFR 882.5950)
3079753|NCT01407952|Other|Control|Aneurysm treatment using bare platinum coil(s)
3079754|NCT01408030|Placebo Comparator|Placebo spray|sterile saline
3079755|NCT01408030|Active Comparator|Bevacizumab spray|bevacizumab 1%
3079756|NCT01408030|Active Comparator|Estriol spray|Estriol 0.1%
3079757|NCT01408030|Active Comparator|Tranexamic acid spray|tranexamic acid 10%
3079758|NCT01408043|Experimental|Treatment (stem cell supermobilization)|Patients receive etoposide IV over 4 hours on day 0, filgrastim SC QD beginning day 1, and plerixafor SC 15-18 hours prior to apheresis. Patients unable to achieve target collection of >= 8 x 10^6 CD34+ cells/kg receive another dose of plerixafor followed by apheresis. Following the second apheresis, patients achieving =< 2 x 10^6 CD34+ cells/kg may continue filgrastim with plerixafor and continue collection according to the attending physician.
3079759|NCT01408147|Active Comparator|Treatment Group|This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
3079760|NCT01408147|No Intervention|Standard WIC care|The control group will received Standard Care as provided through WIC.
3079761|NCT01408277|Active Comparator|Santyl|2mm Santyl applied once daily.
3079762|NCT01408277|Active Comparator|Control|Standard Care
3079763|NCT01408303|Placebo Comparator|Olive Oil|olive oil: 4 g/day + prescription statin
3079764|NCT01408303|Experimental|Epanova, 2 g|omega-3-carboxylic acids, 2g/day + prescription statin
3079765|NCT01408303|Experimental|Epanova, 4 g|omega-3-carboxylic acids, 4g/day + prescription statin
3079766|NCT01408329|Sham Comparator|Control|Sham altitude changes - The CVAC device consists of a small pod-like chamber attached to a computer system that controls a strong pump that can draw air rapidly out of the chamber to increase the simulated altitude. The sham-treated group (SH) was exposed to regular, slowly-fluctuating pressures that reached a maximum altitude of 607 m for all 30 sessions. Sham sessions mimicked the noises and initial pressure-change sensations created in the active sessions, thus giving naıve subjects the impression that they were experiencing altitude treatment. All subjects were blind to their elevation throughout the intervention.
3079767|NCT01408329|Experimental|Hypoxic intervention|Cyclic Hypobaric Hypoxia (CHH) subjects were given 40 min sessions inside the CVAC device per day (two 20 min sessions sequentially per day), 3 days a week for 10 weeks, for a total of 30 sessions or 20 hours. After familiarization sessions, pre-programmed sessions were administered, progressing from Tier 1 to 5. Subjects rotated through three pre-programmed sessions per Tier and each session varied the pattern and rate of hypoxic fluctuations, so that subjects would experience a constantly changing stimulus at each elevation. Five weeks were allotted to progress from Tier 1 (3048 m) to Tier 4 (5486 m). At Tier 5 (6096 m), there was an additional 5 weeks of exposure.
3079768|NCT01408459|Active Comparator|Tomato product|Motivational telephone counseling weekly
3079769|NCT01408459|Placebo Comparator|Control|No Motivation telephone Counseling
3079770|NCT01408485|Experimental|Treatment Arm|Radio-frequency cardiac ablation for treatment of isthmus-dependant atrial flutter using the Therapy™ Cool Flex™ Irrigated Ablation System
3079771|NCT01408537|Experimental|JEVAC|JEVAC 0.5 mL/ dose subcutaneously injected on upper thigh at D0, 1-4wk, and 1 year
3079772|NCT01408563|Experimental|Fludarabine/Melphalan/TBI|All patients receive same therapy
3079773|NCT01408576|Experimental|Epratuzumab 600 mg per week|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over sixteen 12-week treatment cycles
3079774|NCT01408576|Experimental|Epratuzumab 1200 mg every other week|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over sixteen 12 week treatment cycles
3079775|NCT01408628|Experimental|Internet Insulin Education|"Single arm study; intervention represented by subjects' participation in 4 synchronous (live) interactive Internet classes."
3079776|NCT01408706|Active Comparator|Miller enema air tip|The Miller enema air tip rectal balloon is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy.
3079777|NCT01408706|Active Comparator|Radiadyne Immobilizer|The Radiadyne Immobilizer Treatment Device is inserted into the rectum prior to radiation simulation and also prior to each radiation treatment to immobilize prostate gland and displace rectal tissue during radiation therapy
3079778|NCT01408719|Experimental|5g LMW beta glucan|5 gram low molecular weight barley beta-glucan diet for 35 days
3079779|NCT01408719|Experimental|3g HMW beta glucan|3 gram high molecular weight barley beta-glucan diet for 35 days
3079780|NCT01408719|Experimental|3g LMW beta glucan|3 grams of low molecular weight beta-glucan diet for 35 days
3079781|NCT01408719|Placebo Comparator|Control|control diet containing negligible amount of beta glucan
3079782|NCT01408732|Experimental|Standard Treatment then Sclerotherapy Intervention|"The standard treatment group will continue their pre-study standard treatment methods to treat epistaxis on the first 6 weeks of the study, followed by intervention with sclerotherapy on the second 6 weeks of the study, plus any additionally needed standard treatments for breakthrough epistaxis. Wash out period 2 weeks"
3079783|NCT01408732|Experimental|Sclerotherapy Intervention then Standard Treatment'|This group will receive, on the first 6 weeks of the study, sclerotherapy with STS to any visible lesions in the nose at the outset, followed by any needed standard treatments for breakthrough epistaxis. On the second 6 weeks of the study this group will continue with standard treatments that they had been receiving for epistaxis prior to the study. Wash out period of two weeks
3079784|NCT01408862||controls|Healthy volunteers will be asked to donor a 10-80 ml blood through a venous puncture
3079785|NCT01408888|Experimental|LY2189265, Sitagliptin + LY2189265|A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
3079786|NCT01408888|Experimental|Sitagliptin + LY2189265, LY2189265|100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
3079787|NCT01408901|Experimental|A: GM-CSF + supervised treadmill exercise therapy|
3079788|NCT01408901|Active Comparator|B: GM-CSF + attention control group|
3079789|NCT01408901|Active Comparator|C: placebo + supervised exercise therapy|
3079790|NCT01408901|Placebo Comparator|D: placebo + attention control group|
3079791|NCT01408914|No Intervention|RIF 600|
3079792|NCT01408914|Experimental|RIF 900|
3079793|NCT01408914|Experimental|RIF 1200|
3079794|NCT01408992|Experimental|FMHT|All community people will be interviewed with Thai Five Minute Hearing Test questionnaire and will be tested with an audiometry.
3079795|NCT01409096|Active Comparator|Pregnenolone|This arm will be given 50mg Pregnenolone twice per day for 2 weeks, then 150mg Pregnenolone twice per day for 2 weeks, then 250mg Pregnenolone twice per day for 8 weeks.
3079796|NCT01409096|Placebo Comparator|Placebo|The arm will be given placebo that matches the Pregnenolone at the same frequency as the Pregnenolone for 12 weeks.
3079797|NCT01409213||All Enrolled Participants|
3079798|NCT01409239|Active Comparator|Subcutaneous Insulin|
3079799|NCT01409239|Experimental|Intravenous insulin|
3079800|NCT01409382|Active Comparator|Lifestyle counseling|Daily brisk walking plus a carbohydrate-restricted diet
3079801|NCT01409382|No Intervention|Standard follow-up|Prenatal care will proceed according to the routine.
3079802|NCT01409434|Other|Follow-Up Arm|All patients are recruited for inclusion in the Follow-Up Arm, which is the sole arm of the study. The Follow-Up Arm includes a one time study visit in which study interventions are performed. The Follow-Up Arm involves patients from the parent study who were enrolled in the follow-up study. The intervention in the Follow-Up Arm is the Oral Glucose Tolerance Test.
3079803|NCT01409564|Experimental|Cilostazol|Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.
3079804|NCT01409564|Placebo Comparator|Placebo|Placebo group means dementia patients group receiving donepezil with placebo.
3079805|NCT01409707|Experimental|Healthy lifestyles sessions|Healthy lifestyles sessions is a structured 9-12 session intervention that provides education about a variety of health-related topics. Each therapy session was 50-60 minutes long. Sessions included the provision of information, discussing participants' understanding of information, and answering questions about the information provided.
3079806|NCT01409707|Experimental|Trauma-focused exposure therapy|Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
3079807|NCT01409707|Experimental|Motivational enhancement + trauma-focused exposure therapy|A one session, 90 min. trauma-focused motivational enhancement therapy session was provided prior to starting the trauma-focused exposure therapy. Trauma focused exposure therapy is a well-described cognitive-behavioral therapy that utilizes imaginal and in vivo exposure techniques to reduce the symptoms of posttraumatic stress disorder. In addition to imaginal and iv vivo exposure techniques, in the current study patients were provided psychoeducation about posttraumatic stress disorder, a rationale for trauma focused exposure therapy, and were taught breathing retraining as a method to manage arousal associated with posttraumatic stress disorder. Nine to 12 50-60 minutes sessions were provided.
3079808|NCT01409811|Experimental|Treatment (zoledronic acid)|"Patients receive a single dose of zoledronic acid 4 mg IV over 15 minutes on day 1. Patients then undergo planned definitive surgery (lumpectomy or mastectomy) on day 10-23. Tissue and blood samples from the initial biopsy and definitive surgery are collected to measure changes in biomarkers of tumor growth and metastasis, immunologic function, and the expression of genes important to breast cancer progression and metastasis.~zoledronic acid: Given IV~laboratory biomarker analysis: Correlative studies~therapeutic conventional surgery: Undergo definitive lumpectomy or mastectomy"
3079809|NCT01409837|Placebo Comparator|Sugar pill|Started with Placebo until the crossover.
3079810|NCT01409837|Experimental|Lisinopril|Started with Lisinopril until the crossover
3079811|NCT01409915|Experimental|Sagramostim (Leukine)|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
3079812|NCT01409915|Placebo Comparator|Control Group|Saline -- placebo comparator. Given as a subcutaneous injection.
3132404|NCT03424044|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo a 76 hour study with 9 hours inpatient and 67 hours outpatient using the closed-loop artificial pancreas controller in predictive low glucose suspend mode. The system will run through the closed-loop system but will utilize the patient's optimized basal rates, correction factors and carb ratios as they would normally run on their own insulin pump. But the mode will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
3079813|NCT01409928|Experimental|Lap-Band|Placement of the LAP-BAND® system will be performed laparoscopically under general anesthesia, using the pars flaccida technique. The device will be placed by surgeons from the University of Texas Southwestern Medical Center Obesity Management Program at Children's Medical Center Dallas. Surgeons will be fully trained in the placement of the LAP-BAND® device, in accordance with FDA approval of the device for the placement in adults. As is current practice in adults undergoing the procedure, incidentally discovered hiatal hernias are repaired at the time of band placement, to reduce the incidence of post-operative reflux. Children receive prophylactic antibiotics, and are observed overnight after surgery. Patients are generally discharged from the hospital the next day. The band will initially be left empty at the end of the placement procedure.
3079814|NCT01409993|Experimental|sildenafil Aim 1|sildenafil 25 mg p.o. tid
3079815|NCT01409993|Placebo Comparator|placebo Aim 1|matching placebo p.o. tid
3079816|NCT01409993|Experimental|sildenafil Aim 2|sildenafil 25 mg p.o. tid
3079817|NCT01409993|Placebo Comparator|placebo Aim 2|matching placebo p.o. tid
3079818|NCT01410058||Nevirapine|HIV positive patients on nevirapine containing regimen, taking Moringa oleifera leaf powder
3079819|NCT01410058||Efavirenz|HIV positive patients on efavirenz containing regimen, taking Moringa oleifera
3079820|NCT01410084|Experimental|Vitamin D3|100,000 IU vitamin D3 once monthly
3079821|NCT01410084|Placebo Comparator|Vitamin E|400 IU vitamin E once monthly
3079822|NCT01410097|Experimental|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
3079823|NCT01410097|Placebo Comparator|Diabetes Support and Education (DSE)|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
3079824|NCT01410110|Experimental|Cognitive Training + Work Therapy|"Cognitive Training using auditory and visual Positscience software 5 hours/per week for 13 weeks.~Work Therapy for 15 hours per week at half minimum wage doing entry level duties at medical center job sites, supervised by regular medical center staff."
3079825|NCT01410110|Active Comparator|Work Therapy Only|Same work therapy but for 20 hours per week.
3079826|NCT01410227|Experimental|PK 80 Arm (minimum of 22 subjects with severe VWD)|PK assessment (80 IU/kg rVWF) + 12-month treatment period
3079827|NCT01410227|Experimental|PK 50 Arm (14 subjects with type 3 VWD)|Two single-blinded PK assessments (50 IU/kg rVWF + rFVIII/placebo) + 12-month treatment period
3079828|NCT01410227|Experimental|PK 50 Only Arm (minimum of 7 subjects with type 3 VWD)|PK assessment (50 IU/kg rVWF) only, no treatment of bleeding episodes
3079829|NCT01410227|Experimental|Treatment Only (up to 7 subjects independent of VWD subtype)|Treatment of bleeding episodes for a total of 12 months
3079830|NCT01410240|Active Comparator|Standard of Care (SoC)|SoC: conventional hemostatic techniques such as cautery and manual compression
3079831|NCT01410240|Experimental|FLOSEAL + Standard of Care (SoC)|"FLOSEAL: consists of bovine-derived gelatin granules and a human plasma-derived thrombin component.~SoC: conventional hemostatic techniques such as cautery and manual compression"
3079832|NCT01410344|Other|Allogeneic Transplant|One regimen from either reduced-intensity conditioning (RIC) (Fludarabine and Busulfan; or Fludarabine and Melphalan) or myeloablative conditioning (MAC) (Busulfan and Fludarabine; or Cyclophosphamide and Total Body Irradiation) will be administered prior to allogeneic hematopoietic cell transplantation (HCT).
3079833|NCT01410357|Experimental|Targeted Training in Illness Management (TTIM)|Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
3079834|NCT01410357|No Intervention|Treatment As Usual (TAU)|Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.
3079835|NCT01410409|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
3079836|NCT01410409|Active Comparator|MEDIC + TKR|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months after a total knee replacement.
3079837|NCT01410409|Active Comparator|Observational Cohort|If the patient can be included, but doesn't want to participate in the randomization, the patient is offered to enter into a prospective observational cohort with the same endpoints and the same follow-up as in the randomized study. The participant can then, in consultation with his/her physician, choose whether they would like MEDIC-treatment or TKR in combination with MEDIC-treatment.
3079838|NCT01410448|Active Comparator|Immediate Everolimus (IE)|Everolimus was started within 48 hours after graft reperfusion at a starting dose of 0.75 mg twice daily in combination with low-dose cyclosporine and steroids for 3 months.
3079839|NCT01410448|Experimental|Delayed Everolimus|The standard dose of mycophenolate sodium was administered within 48 hours after graft reperfusion in combination with a full dose of cyclosporine and steroids. After28 +/- 4 days of treatment, mycophenolate sodium was discontinued and everolimus was introduced at a starting dose of 0.75 mg twice daily for 3 months.
3079840|NCT01410474|Experimental|2-18 years|
3079841|NCT01410552|Other|ICD or CRT-D with PARAD+|only 1 arm is the study: all patients implanted with ICD or CRT-D with PARAD+ enabled, no comparator
3079842|NCT01410565|Active Comparator|Apaziquone|
3079843|NCT01410565|Placebo Comparator|Placebo|Placebo
3079844|NCT01410604|Experimental|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
3079845|NCT01410604|Placebo Comparator|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
3079846|NCT01410773|Experimental|Intended Users of the System|Untrained subjects with diabetes (at least 70% of subjects will be insulin users) use an investigational blood glucose monitoring system (Ninja 2) to self-test capillary blood obtained from fingerstick and palm.
3079847|NCT01410812|Experimental|Suggested Tying|Receive same treatments as control group, but instead of receiving cash they receive 4 iTunes audio novels for their own iPods. Further, they are prompted to try to listen to those novels only when exercising at the gym in order to increase their attendance.
3132405|NCT03424187|Experimental|whole chickpea|a test meal containing 26g available carbohydrates from chickpea (full structure)
3079848|NCT01410812|Experimental|Forced Tying|Receives same treatment as the control group. However, in addition to receiving the cash, they also receive 4 iTunes audio novels for a loaned iPod that they will only have access to at the gym. They are told they may only listen to these novels only when at the gym in order to increase their attendance.
3079849|NCT01410812|Experimental|Control|Control group of participants who do not receive any intervention but are weighed at the beginning and end of a 10 week period and receive weekly emails asking them about their exercise. They also receive the equivalent cash value of 4 iTunes audio novels
3079850|NCT01410890|Experimental|Alglucosidase alfa|Participants received intravenous (IV) infusion of Alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight on Day 1. Infusion was administered at an initial rate of approximately 1 milligram per kilogram per hour (mg/kg/hr) with allowed rate increased of 2 mg/kg/hr every 30 minutes, if there were no signs of infusion-associated reactions (IARs), until a maximum rate of approximately 7 mg/kg/hr was reached.
3079851|NCT01411085|Experimental|Risperidone + Desipramine|All participants will be treated with risperidone (or a risperidone-like agent including: risperidone long-acting, paliperdione, and paliperidone palmitate) at the time treatment with desipramine is initiated. The target dose of oral risperidone is 4mg though variations are allowed. The target dose of desipramine is 100mg.
3079852|NCT01411137|Experimental|IPX066|Subjects were to receive individualized IPX066 doses orally in an open-label manner using four dosage strengths.
3079853|NCT01411215||RA, AS|Rheumatoid arthritis patients Ankylosing spondylitis patients
3079854|NCT01411228|Experimental|60 Units/kg|
3079855|NCT01411228|Experimental|30 Units/kg|
3079856|NCT01411241|Experimental|CYD Dengue Vaccine Group 1|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a measles, mumps, rubella (MMR) vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), a booster dose of Pentaxim vaccine was administered concomitantly with the second injection of CYD dengue vaccine at Month 6 (15 to 18 months of age), placebo at Month 7 (16 to 19 months of age) to maintain the blind, and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
3079857|NCT01411241|Experimental|CYD Dengue Vaccine Group 2|Participants received the first injection of CYD dengue vaccine at Month 0 (9 to 12 months of age), a MMR vaccine and pneumococcal conjugate vaccine at Month 1 (10 to 13 months of age), the Pentaxim vaccine was administered concomitantly with placebo at Month 6 (15 to 18 months of age) to maintain the blind, a second injection of CYD dengue vaccine at Month 7 (16 to 19 months of age), and the third injection of CYD dengue vaccine at Month 12 (21 to 24 months).
3079858|NCT01411267|Experimental|ALL AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
3079859|NCT01411267|Experimental|AML AC220 @ 25mg/m2/day (Dose Level 1)|The starting dose is Dose Level 1 at 25 mg/m2/day. Dose escalation will proceed from level 1 to 2 to 3, and so on, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
3079860|NCT01411267|Experimental|ALL AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age.
3079861|NCT01411267|Experimental|ALL AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
3079862|NCT01411267|Experimental|ALL AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
3079863|NCT01411267|Experimental|ALL AC220 @ 130 mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
3079864|NCT01411267|Experimental|AML AC220 @ 40mg/m2/day (Dose Level 2)|Dose escalation will proceed from level 1 to level 2 for AC220 at 40mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age.
3079865|NCT01411267|Experimental|AML AC220 @ 60mg/m2/day (Dose Level 3)|Dose escalation will proceed from level 2 to 3 for AC220 at 60mg/m2/day, assuming the maximum tolerated dose is not exceeded. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 3 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
3079866|NCT01411267|Experimental|AML AC220 @ 90mg/m2/day (Dose Level 4)|If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
3132406|NCT03424187|Experimental|flour chickpea|a test meal containing 26g available carbohydrates from flour chickpea (destroyed structure)
3132407|NCT03424187|Experimental|intact cell chickpea|a test meal containing 26g available carbohydrates from intact cell chickpea flour (full structure)
3079867|NCT01411267|Experimental|AML AC220 @ 130mg/m2/day (Dose Level 5)|If the study dose of 90 mg/m2/day at Dose Level 4 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 5 at 130 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT cytarabine will be given to patients with AML on Day 0, dose assigned by age. Dose Level 5 is the highest dose for this study.
3079868|NCT01411319|Experimental|LEAD Radiation Therapy|Participants in this group will receive the LEAD Radiation Therapy on Day 1 followed by 38 daily standard IMRT beginning Day 2.
3079869|NCT01411332|Active Comparator|Arm I: SIMRT|'Participants in this group will receive the Standard Fractionated Intensity Modulated Radiotherapy (SIMRT) consisting 40 fractions over 8 weeks.
3079870|NCT01411332|Active Comparator|Arm II: HTIMRT|Participants in this group will receive the Hypofractionated Targeted Intensity Modulated Radiotherapy (HTIMRT) consisting of 38 fractions over 7.5 weeks.
3079871|NCT01411488|Experimental|Fecal Management System- Company 1|80 adult patients to be randomly assigned to receive a fecal management system by Bard Medical
3079872|NCT01411488|Active Comparator|Fecal Management System- Company 2|80 adult patients to be randomly assigned to receive a fecal management system by ConvaTec
3079873|NCT01411501|Experimental|Acupuncture at ST25 and BL25|the points formula of back-shu point combination with front-mu point.
3079874|NCT01411501|Experimental|Acupuncture at LI11 and ST37|the points formula of He-points
3079875|NCT01411501|Experimental|Acupuncture at ST25, BL25, LI11 and ST37|the formula of He-point,back-shu point and front-mu point
3079876|NCT01411501|Active Comparator|medicine|oral use of mosapride citrate
3079877|NCT01411527||Cross- sectional cohort|Schools were randomly selected and 6203 children (50.0 % girls) were invited to participate. 1864 (1097 girls and 767 boys) (age 5.6-20.0 years) were included, resulting in an overall participation-rate of 30%. Blood samples were drawn, and a thorough clinical examination was performed in all participating children
3079878|NCT01411527||Longitudinal cohort|"209 healthy Danish children (108 girls), were examined and blood samples were drawn every 6 months. In july 2011, the mean (range) number of examinations per child was 7 (2-10).~116 (63 boys and 53 girls) continued from the cross sectional study to the longitudinal study. Thus, the total number of participants in The COPENHAGEN Puberty Study was 2020 children."
3079879|NCT01411592|Active Comparator|Multilink|RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system [A/B primer and Multilink-Automix] with Metal/Zirconia primer)
3079880|NCT01411592|Active Comparator|Panavia 21 TC|RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
3079881|NCT01411696||All Participants|Patients who received at least 2 injections of OZURDEX® (dexamethasone intravitreal implant) to treat Macular Edema.
3079882|NCT01411774|Active Comparator|Cognitive-behavioral therapy plus pill placebo|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with pill placebo taken 1 hour before the session.
3079883|NCT01411774|Experimental|Cognitive-behavioral Therapy plus d-cycloserine|This study arm involves the subject receiving 10 sessions of cognitive behavioral therapy with d-cycloserine taken 1 hour before the session.
3079884|NCT01411839|Experimental|Cognitive-Behavioral Therapy (CBT-AD)|This arm type is a cognitive-behavioral therapy program intervention for issues of medication adherence and depression. The intervention is a therapy program intervention involves 10-weekly or biweekly sessions, with 2 booster session, and focused on psychoeducation, behavioral activation, cognitive restructuring, and problem-solving. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms.
3079885|NCT01411839|No Intervention|Control-Standard Care|Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter was sent to their medical provider indicating that mild symptoms of depression were detected and that they were enrolled in this intervention, but no details were provided regarding their assignment to one of two conditions/arms. The participants in the control arm are followed and matched to a participant in the intervention arm.
3079886|NCT01411852|Experimental|0.9% Sodium Chloride 250 mL bolus|0.9% Sodium Chloride 250 mL bolus - A large bore IV will be placed and a 250cc bag of normal saline (NS) will be hung. If IV placement is difficult, NS can be given through an intraosseous line. Using small bags versus large bags will physically limit the amount of fluid given to patients in the experimental group. The requirement to change the smaller bags of fluid and recheck the pulse or blood pressure will limit the amount of fluid given. The procedure will continue until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
3079887|NCT01411852|Active Comparator|0.9% Sodium Chloride 2000 mL bolus|0.9% Sodium Chloride 2000 mL bolus - The treatment of the control group will be consistent with traditional Prehospital Trauma Life Support and Advanced Trauma Life Support guidelines which recommend early aggressive fluid resuscitation. An intravenous line (IV) will be placed and a 1000cc bag of normal saline will be hung. If IV placement is difficult, fluid can be given through an intraosseous line. This procedure will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first. Hemorrhage control will be defined as ligation of a bleeding vessel, packing of a solid organ, removal of a solid organ, and angiographic embolization of a bleeding vessel.
3079888|NCT01411891|No Intervention|Control|Patients assigned to this study group will not have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
3079889|NCT01411891|Experimental|Chlorhexidine impregnated patch.|Patients assigned to this study group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
3079890|NCT01411917|Experimental|TAP block group|Patients in this group will have a preoperative, ultrasound guided injection of 30ml of 0.375% bupivacaine into the muscle plane between the transversus abdominis muscle and internal oblique muscles.
3079891|NCT01411917|Placebo Comparator|Placebo|Patients in this group will have an ultrasound guided subcutaneous injection of 30 ml of sterile preservative free saline.
3079892|NCT01411995|Experimental|2% Lidocaine gel|Women randomized to the Lidocaine arm will receive a total of 3-5cc of 2% gel at the tenaculum site and within the endocervical canal
3079893|NCT01411995|Placebo Comparator|Water based lubricant|Women randomized to the placebo arm will receive a total of 3-5cc of water based lubricant at the tenaculum site and within the the endocervical canal
3079894|NCT01412021||Humira|Participants with juvenile idiopathic arthritis who received Humira (adalimumab).
3079895|NCT01412060|Experimental|Cariprazine - Open-label Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 6 weeks; the dose could be modified during this time. The cariprazine dose was fixed at 3, 6, or 9 mg for the last 14 weeks of this 20 week Open-label Phase.
3079896|NCT01412060|Experimental|Placebo - Double-blind Treatment Phase|Participants received placebo orally once a day for 26 to 72 weeks.
3079897|NCT01412060|Experimental|Cariprazine - Double-blind Treatment Phase|Participants received 3, 6, or 9 mg cariprazine orally once a day for 26 to 72 weeks
3079898|NCT01412086||All Participants|Healthy volunteers. No treatment (intervention) was received.
3079899|NCT01412151|Other|Creatine monohydrate|single arm long-term open label follow-up
3079900|NCT01412164|Experimental|Firehawk|Using Firehawk biodegradable polymer rapamycin-eluting stent for CAD
3079901|NCT01412229|Experimental|Treatment|"nab-paclitaxel 100mg/m2~Carboplatin area under curve (AUC)2 (IV)~Cetuximab 400mg/m2 week 1 then 250mg/m2 for six weeks"
3079902|NCT01412281|Experimental|Group A - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
3079903|NCT01412281|Active Comparator|Group B - Young adults|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
3079904|NCT01412281|Experimental|Group C - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (AdImmune HA Antigen) 2011/2012
3079905|NCT01412281|Active Comparator|Group D - Elderly|1 x 0.5 mL i.m. virosomal influenza vaccine (CSL HA Antigen) 2011/2012
3079906|NCT01412333|Active Comparator|Interferon beta-1a 44 mcg SC|Interferon beta-1a 44 mcg SC injections three times per week (with placebo infusions matching ocrelizumab infusions every 24 weeks).
3079907|NCT01412333|Experimental|Ocrelizumab|Ocrelizumab 600 mg or matching placebo intravenous (IV) as 300 mg infusions on Days 1 and 15 for the first dose and as a single infusion of 600 mg for all subsequent infusions every 24 weeks, with placebo injections matching interferon beta-1a SC three times per week.
3079908|NCT01412372|Experimental|Placebo|This arm will include those who are randomized to the placebo
3079909|NCT01412372|Experimental|Mesalamine|This arm is for subjects randomized to the study drug, Mesalamine
3079910|NCT01412424|Experimental|Octreotide capsules|Participants received octreotide capsules orally twice a day for up to 13 months. Dosing started at 40 mg per day (20 in the morning + 20 in the evening) and increased to 60 mg per day (40 in the morning + 20 in the evening) or 80 mg per day (40 in the morning + 40 in the evening) if there was inadequate IGF-1 suppression.
3079911|NCT01412541|Experimental|Moxy Drug Coated Balloon|Paclitaxel coated balloon catheter
3079912|NCT01412541|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
3079913|NCT01412554||Longitudinal Insulin Sensitivity|The participants were examined using the hyperinsulinaemic isoglycaemic glucose clamp technique which is the gold standard to assess insulin sensitivity.
3079914|NCT01412710|Experimental|4000 IU group|This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.
3079915|NCT01412710|Experimental|6000 IU group|This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.
3079916|NCT01412801|Experimental|HIVneg|HIV-antibody negative maternal subjects at 24 to 35 weeks gestation received one dose of Group B streptococcus vaccine.
3079917|NCT01412801|Experimental|HIVposCD4HIGH|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count >350 cells/µL received one dose of Group B streptococcus vaccine.
3079918|NCT01412801|Experimental|HIVposCD4LOW|HIV-antibody positive maternal subjects at 24 to 35 weeks gestation with CD4+ count ≤350 cells/µL but > 50 cells/µL received one dose of Group B streptococcus vaccine
3079919|NCT01412866|Experimental|EDSS with CO monitor|Web-based electronic decision support system (EDSS) with carbon monoxide (CO) monitor and health-checklist
3079920|NCT01412866|Active Comparator|EDSS without CO monitor|Web-based electronic decision support system (EDSS) with health-checklist only
3079921|NCT01412879|Experimental|Arm I|Course 1 and 3: Patients receive induction therapy comprising rituximab IV on day 1; cyclophosphamide IV over 3 hours every 12 hours on days 2-4; doxorubicin hydrochloride IV over 72 hours on days 5-7; vincristine sulfate IV on days 5 and 12; and dexamethasone IV or orally (PO) once daily (QD) on days 2-5 and 12-15. Patients with responsive disease after course 1 proceed to course 2. Course 2 and 4: Patients receive rituximab IV on day 1; methotrexate IV over 2-22 hours on day 2; cytarabine IV over 2 hours every 12 hours on days 3-4; and leucovorin calcium PO or IV on days 3-6. Patients then undergo stem cell collection after completion of course 2. Patients undergo stem cell collection after completion of course 2.
3079922|NCT01412879|Experimental|Arm II|Course 1-6: Patients receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-4 weeks later, patients with responsive disease receive 2 additional courses of treatment. Beginning within 8 weeks, patients receive rituximab IV and cyclophosphamide IV over 1 hour on day 1. Patients then undergo stem cell collection about 26 days later.
3079923|NCT01412918|Experimental|Tinnitus|"Individual with tinnitus. Intervention: inhibitor device demonstration.~The Inhibitor™ Tinnitus Masking Device is a new tinnitus treatment device recently available in the United States for use of temporary relief of tinnitus. The device emits an ultra high frequency sound for 60 seconds via bone conduction when applied to the mastoid. Patients reporting tinnitus will be provided the opportunity to demonstrate the device to observe any changes in their tinnitus. The device may be demonstrated up to 5 times. The investigators will be recording the the degree and duration of change in tinnitus perception following treatment with the Inhibitor™ Tinnitus Masking Device."
3079924|NCT01412918|No Intervention|No tinnitus|Individuals without tinnitus will also be masked with the device.
3079925|NCT01412944|Experimental|AIN457 subcutaneous (s.c.)|During the intravenous (I.V.) period, participants received two 150 mg s.c. injections of AIN457 at randomization and week 4, and AIN457 placebo I.V. at randomization, week 2 and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
3079926|NCT01412944|Experimental|AIN457 I.V.|During the I.V. period, participants received AIN457 10mg/kg I.V. at randomization, week 2 and week 4, and AIN457 placebo s.c. at randomization and week 4. During the maintenance period, participants received 300 mg s.c. of open-label AIN457.
3079927|NCT01412957|Experimental|Panitumumab + BSC|Participants received panitumumab administered intravenously 6 mg/kg every 14 days plus BSC until disease progression, withdrawal of consent, death, or intolerance of study drug.
3079928|NCT01412957|Other|BSC Alone|Participants received best supportive care until disease progression, withdrawal of consent, or death.
3079929|NCT01412983|Experimental|Bausch & Lomb Test Lens|Bausch + Lomb investigational soft contact lens
3079930|NCT01412983|Active Comparator|Ciba Vision soft contact lens|Ciba Vision Air Optix Aqua soft contact lens
3079931|NCT01413087|Experimental|8 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 8 mg of BC-819
3079932|NCT01413087|Experimental|12 mg BC-819 and Gemcitabine|gemcitabine dose of 1000mg/m2 + 12 mg of BC-819
3079933|NCT01413178|Experimental|Busulfan + Melphalan|Busulfan test dose (32 mg/m^2) on day -9 then 130 mg/m^2 intravenous (IV) Days -7, -6, -5, and -4 + Melphalan 70 mg/m2 IV on Days -2 and -1. Stem Cell Transplant (SCT) Day 0.
3079934|NCT01413178|Experimental|Melphalan|High-dose Melphalan 200 mg/m2/day IV over 30 minutes on day -2. SCT Day 0.
3079935|NCT01413191|Experimental|CixutumumabTreatment|Cixutumumab 10 mg/kg intravenous (IV) over 1 hour on days 1 and 15 for 4 week courses.
3079936|NCT01413204|Experimental|TA-7284 Low|
3079937|NCT01413204|Experimental|TA-7284 High|
3079938|NCT01413204|Placebo Comparator|Placebo|
3079939|NCT01413360|Experimental|HD Vitamin C|High dose vitamin C
3079940|NCT01413503|Experimental|131I-MIBG|Patients received 131I-MIBG 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) diluted in 25 ml of normal saline. Patients were infused intravenously through a patient's peripheral or central line over 120 minutes
3079941|NCT01413516|Placebo Comparator|Placebo Control|Smoking cessation counseling with placebo comparator
3079942|NCT01413516|Active Comparator|Experimental: Varenicline|Smoking cessation counseling with varenicline
3079943|NCT01413542|Placebo Comparator|Placebo then sitagliptin (DPP4 inhibition) group 1|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to bradykinin and substance P are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3079944|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then placebo group 1|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to substance P and bradykinin are studied after administration of sitagliptin (DPP4 inhibition) or placebo
3079945|NCT01413542|Placebo Comparator|Placebo then sitagliptin group 2|The effect of vehicle and enalaprilat (ACE inhibition) on the forearm blood flow and t-PA responses to glucagon-like peptide-1 and brain natriuretic pepdie are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3079946|NCT01413542|Placebo Comparator|Sitagliptin (DPP4 inhibition) then comparator group 2|The effect of vehicle and enalaprilat on the forearm blood flow and t-PA responses to glucagon-like peptide and brain natriuretic peptide are studied after administration of placebo or sitagliptin (DPP4 inhibition).
3079947|NCT01413750|Experimental|Arm I (paclitaxel, carboplatin, vorinostat)|Patients receive paclitaxel IV over 3 hours, and carboplatin IV over 30 minutes on day 0. Patients also receive vorinostat PO once daily on days -2 to 2.
3079948|NCT01413750|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|Patients receive paclitaxel and carboplatin as in arm I. Patients also receive placebo PO once daily on days -2 to 2.
3079949|NCT01413958|Experimental|Phenylephrine|
3079950|NCT01413958|Placebo Comparator|Placebo|
3079951|NCT01414010|Active Comparator|Prebiotic|
3079952|NCT01414010|Active Comparator|Probiotic|
3079953|NCT01414010|Active Comparator|Antibiotic|
3079954|NCT01414010|No Intervention|Control|Control group, no intervention given.
3079955|NCT01414036|Active Comparator|Enhanced Traditional Care control|This arm will receive a low literacy smoking cessation educational brochure, a list of hospital and community resources for smoking cessation, in addition to usual care.
3079956|NCT01414036|Experimental|Patient Navigation|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of hospital and community resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
3079957|NCT01414075|Experimental|Arm A + E (Participants on HD): Roxadustat Only, No Iron|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally 3 times weekly (TIW) for 12 weeks.
3079958|NCT01414075|Experimental|Arm B (Participants on HD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
3079959|NCT01414075|Experimental|Arm C (Participants on HD): IV Iron (Ferric Gluconate Complex in Sucrose or Equivalent) 60 mg|Participants on HD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with approximately 60 mg IV iron (ferric gluconate complex in sucrose injection [for example, Ferrlecit®] or equivalent) once a week for 12 weeks.
3079960|NCT01414075|Experimental|Arm D (Participants on PD): PO Iron (Ferrous Fumarate or Ferrous Gluconate) Between 50 and 195 mg|Participants on PD will receive roxadustat capsules at the applicable dose (up to a maximum roxadustat dose of 140, 200, and 300 mg) based on weight and Hb level, administered orally TIW with iron (ferrous fumarate or ferrous gluconate) PO at doses containing elemental iron between 50 and 195 mg daily (depending on the type of iron formulation available in their countries) for 12 weeks.
3132408|NCT03424239|Experimental|Drug: Zoledronic Acid, Calcium+Vitamin D|Subjects will receive a single intravenous infusion of zoledronic acid (5 mg). Supplemental calcium citrate + vitamin D (500mg+500IU) and vitamin D3 (1000 IU) will be dispensed throughout the study to fit individual needs.
3132409|NCT03424265|Experimental|9g of EAA mixture supplement|Twice a day for 12 consecutive weeks.
3079961|NCT01414114|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) administered by intravenous bolus injection at the end of each hemodialysis session for 12 weeks. The starting dose was 5 mg and may have been titrated every 4 weeks based on the preceding serum parathyroid hormone (PTH) and corrected calcium (cCa) levels to a maximum dose of 20 mg per hemodialysis session in order to achieve the targeted PTH range while maintaining serum calcium within an acceptable range.
3079962|NCT01414153|Experimental|Monotherapy|4.0 mg iSONEP followed by sham injection; given monthly intravitreously for 4 months
3079963|NCT01414153|Experimental|0.5 mg iSONEP & Lucentis/Avastin/Eylea|0.5 mg iSONEP and 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
3079964|NCT01414153|Experimental|4.0 mg iSONEP & Lucentis/Avastin/Eylea|4.0 mg iSONEP followed by 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea; given monthly intravitreously for 4 months
3079965|NCT01414153|Active Comparator|Lucentis or Avastin or Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea followed by a sham injection; given monthly intravitreously for 4 months
3079966|NCT01414192||Ezetimibe monotherapy without prior treatment|Enrolled participants who had no prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
3079967|NCT01414192||Ezetimibe monotherpay with prior treatment|Enrolled participants with prior lipid-lowering therapy and were currently receiving Ezetimibe alone (Ezetrol®).
3079968|NCT01414192||Ezetimibe plus statin|Enrolled participants who were being coadministered ezetimide (Ezetrol®) and another prescription statin.
3079969|NCT01414192||Ezetimibe/simvastatin|Enrolled participants who were receiving ezetimibe and simavastatin fixed dose combination tablet (Inegy®).
3079970|NCT01414205|Experimental|Obinutuzumab 1000 mg|Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
3079971|NCT01414205|Experimental|Obinutuzumab 2000 mg|Participants received a 2000 mg IV infusion, on days 1 (split dose 100 mg Day 1, 900 mg Day 2 and 1000 mg Day 3), 8 and 15 of cycle 1 and day 1 of cycles 2 -8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
3079972|NCT01414244|Active Comparator|Glutamine supplementation|Glutamine
3079973|NCT01414244|Placebo Comparator|Placebo|Whey protein powder
3079974|NCT01414257||Methotrexate (MTX)|Patients who receive the MTX Preparation at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis.
3079975|NCT01414413|Experimental|Home assessment and initiation of ART|"Participants with a positive home-based HIV test result will receive a home visit from a study nurse who will complete the following on the first home visit:~Confirmatory fingerprick HIV testing~TB symptom screening~ART eligibility assessment (Word Health Organization clinical staging, sampling of blood for measurement of CD4 count and treatment education)~At a second home visit (within 5 days), participants who are ART eligible (as defined in National ART guidelines) will be initiated onto ART (using National Treatment Programme ART regimens).~Following home initiation of ART, participants in the intervention arm will receive detailed counselling from the study nurse about the need to attend their first 2-week follow-up appointment at the primary health care clinic that serves their household's residence. They will receive a referral slip detailing the date, time and place of their appointment."
3079976|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor. HIV care, including ART, will be started from the primary care clinic.
3079977|NCT01414426|Experimental|Arm I (chemoprevention)|Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3079978|NCT01414426|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
3079979|NCT01414634|Experimental|ETIMS 1x10^3|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^3 cells.
3079980|NCT01414634|Experimental|ETIMS 1x10^5|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^5 cells.
3079981|NCT01414634|Experimental|ETIMS 1x10^7|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^7 cells.
3079982|NCT01414634|Experimental|ETIMS 1x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^8 cells.
3079983|NCT01414634|Experimental|ETIMS 5x10^8|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 5x10^8 cells.
3079984|NCT01414634|Experimental|ETIMS 1x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 1x10^9 cells.
3079985|NCT01414634|Experimental|ETIMS 2.5x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 2.5x10^9 cells.
3079986|NCT01414634|Experimental|ETIMS 3x10^9|The drug product consists of autologous peripheral blood mononuclear cells that have been chemically coupled with seven myelin peptides and resuspended in autologous plasma. This patient receives 3x10^9 cells.
3079987|NCT01414738|Experimental|Radiation|Whole-Brain Radiotherapy
3079988|NCT01414855|Experimental|obinutuzumab + CHOP|Participants received 1000 mg obinutuzumab intravenously on Day 1 of each 21-day cycle for 8 cycles; during Cycle 1 administration also on Days 8 and 15. Participants also received standard CHOP therapy (cyclophosphamide, doxorubicin, vincristine and prednisone) for 6 cycles.
3132410|NCT03424265|Experimental|9g of placebo (whey protein)|Twice a day for 12 consecutive weeks.
3079989|NCT01415232|Experimental|Ultrasound measurement|Ultrasound using the Sonosite S-Nerve® US system (SonoSite, Bothell,WA) to measure depth to epidural space in morbidly obese parturients.
3079990|NCT01415349|Experimental|SSP-002358 alone|
3079991|NCT01415349|Experimental|SSP-002358 + omeprazole|SSP-002358 + omeprazole
3079992|NCT01415401|Experimental|AZARGA|Brinzolamide 1% / timolol 0.5% maleate fixed combination, 1 drop self-administered in study eye(s) twice daily for 8 weeks (8AM and 8PM)
3079993|NCT01415427|Experimental|BMN 110 Weekly|BMN 110 Weekly: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
3079994|NCT01415427|Experimental|BMN 110 Every Other Week|BMN 110 Every Other Week: In Part 1, patients will receive an intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and will receive infusions of placebo on alternating weeks.
3079995|NCT01415440|Experimental|Psychostimulant|30-70 mg capsule of Lisdexamfetamine once daily for 12 weeks
3079996|NCT01415440|Placebo Comparator|Placebo|30-70 mg capsule of placebo (sugar pill) once daily for 12 weeks
3079997|NCT01415453|Experimental|Retinitis Pigmentosa|Subject will have retinitis pigmentosa and will be legally blind in one or both eyes
3079998|NCT01415518|Other|1|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
3079999|NCT01415518|Other|2|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
3080000|NCT01415531|Experimental|1|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
3080001|NCT01415531|Placebo Comparator|2|Dose-matched placebo
3080002|NCT01415583|Placebo Comparator|Saline|Placebo is described in chart
3080003|NCT01415583|Experimental|Dexamethasone|Dexamethasone is described in chart
3080004|NCT01415908|Active Comparator|Control Group|
3080005|NCT01415908|Experimental|Investigational Group|
3080006|NCT01415921|Experimental|Pyridostigmine Bromide|Forced titration protocol 15-60 mg every 8 hours as tolerated
3080007|NCT01415921|Placebo Comparator|Placebo|Matching placebo forced titration 15-60 mg as tolerated
3080008|NCT01415934|No Intervention|Continue Statins|Participant will continue on statins as per usual
3080009|NCT01415934|Experimental|Discontinue statins|Participant will stop taking their statin drugs
3080010|NCT01415960|Experimental|Leuprolide acetate 22.5 mg depot|Leuprolide acetate 22.5 mg depot administered twice, 3 months apart
3080011|NCT01416025|Experimental|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
3080012|NCT01416025|No Intervention|Standard dosing|Standard doses of voriconazole will be used
3080013|NCT01416129|Active Comparator|Active Comparator: Prosthetic socket standard of care|
3080014|NCT01416129|Active Comparator|Active Comparator: Prosthetic brimless socket|
3080015|NCT01416142|Active Comparator|Spectacles|The subject's habitual spectacles (updated or confirmed as correct within the last 2 years)
3080016|NCT01416142|Experimental|PureVision2 HD contact lenses|Currently marketed Bausch + Lomb PureVision2 HD contact lenses
3080017|NCT01416155|Experimental|natalizumab|300 mg intravenous (IV) infusions of natalizumab every 4 weeks until product is approved in Japan or development is discontinued in Japan, whichever comes first.
3080018|NCT01416181|Experimental|natalizumab|In Part 1 participants were randomized to receive 300 mg of natalizumab intravenously (IV) every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
3080019|NCT01416181|Experimental|Placebo|In Part 1 participants were randomized to receive placebo IV every 4 weeks for 96 weeks. In Part 2 participants transitioned to receive open-label natalizumab 300 mg IV every 4 weeks for at least 96 weeks.
3080020|NCT01416194||Bazedoxifene|
3080021|NCT01416194||Primary Comparator|
3080022|NCT01416194||Secondary Comparator|
3080023|NCT01416389|Experimental|LY2523355 + pegfilgrastim or filgrastim|LY2523355: Five milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Pegfilgrastim or Filgrastim: Dosage is determined by standard of care and is administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
3080024|NCT01416389|Active Comparator|ixabepilone|Forty milligrams per meter squared per day (mg/m^2/day) (dosage determined by calculating participant's body surface area) administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles. If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.
3080025|NCT01416441|Experimental|Aripiprazole|Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
3080026|NCT01416571|Experimental|Influenza A (H5N1) Group|Healthy subjects aged between 18 and 64 years at the time of vaccination received two doses of the Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted, at Day 0 and Day 21. The vaccine was administered intramuscularly in the deltoid region of the arm.
3080027|NCT01416584|No Intervention|Usual Care Control|Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
3080028|NCT01416584|Experimental|Methadone Contingency Group|Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
3132411|NCT03424681|Experimental|Modafinil|Modafinil 300 mg by mouth each day
3132412|NCT03424681|Placebo Comparator|Placebo|Identical looking capsule/number of capsules by mouth each day without active medication
3080029|NCT01416584|Experimental|Methadone & Abstinence Contingency|Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).
3080030|NCT01416610||All Participants|Participants with chronic hepatitis C, Genotype 2, 3, 1 or 4, undergoing an opioid maintenance therapy
3080031|NCT01416636|Active Comparator|Treprostinil sodium low dose - Arm I|"Arm I (low dose):~Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
3080032|NCT01416636|Experimental|Treprostinil sodium high dose - Arm II|"Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks.~Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3.~This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump."
3080033|NCT01416805|Experimental|Computerized Cognitive Behavioral Therapy|
3080034|NCT01416805|Active Comparator|Treatment as Usual|
3080035|NCT01417000|Experimental|Cy/GVAX + CRS-207|200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.
3080036|NCT01417000|Experimental|Cy/GVAX|200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16; GVAX (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1, 4, 7, 10, 13, 16.
3080037|NCT01417026|Active Comparator|Intranasal Oxytocin|"Intranasal oxytocin (Trade name: Syntocinon)~Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril).~Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
3080038|NCT01417026|Placebo Comparator|Intranasal Placebo|"Intranasal placebo~The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal~Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril).~Placebo will be imported from Victoria Pharmacy Zurich- Switzerland."
3080039|NCT01417078|Experimental|Diazepam Nasal Spray|
3080040|NCT01417104|Active Comparator|Aliskiren|Aliskiren will be administered for 2 weeks at 150mg/day oral pill, followed by 34 weeks oral therapy with 300mg/day
3080041|NCT01417104|Placebo Comparator|Placebo|Placebo (sugar pill) built to mimic both the 150mg Aliskiren tablet ( administered for the first 2 weeks) and the 300mg Aliskiren tablet ( administered for the rest of treatment period)
3080042|NCT01417156|Experimental|All patients|
3080043|NCT01417195|Experimental|Menopur and Bravelle combination|The initial daily dose consisted of 225 IU of gonadotropins, mixed in the same syringe and administered by subcutaneous (SC) injection for 5 days. The initial daily dose, based on the Investigator's judgment, consisted of either 150 IU of Menopur and 75 IU of Bravelle or 150 IU of Bravelle and 75 IU of Menopur. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and was always to include at least 75 IU of Menopur and 75 IU of Bravelle. Treatment could not continue beyond day 20.
3080044|NCT01417195|Active Comparator|Menopur alone|The initial daily dose consisted of 225 IU of Menopur administered by subcutaneous (SC) injection for 5 days. Dosing adjustments were allowed as of day 6. Dose could vary between 150-450 IU daily and treatment could not continue beyond day 20.
3080045|NCT01417234||SNaP® Wound Care System|
3080046|NCT01417455||Rheumatoid Arthritis|Active Rheumatoid Arthritis patients
3080047|NCT01417455||Ankylosing Spondylitis|Active Ankylosing Spondylitis
3080048|NCT01417455||Controls|Healthy donors age and sex matched to the patients
3080049|NCT01417481|Active Comparator|Glycine|Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.
3080050|NCT01417481|Placebo Comparator|Placebo|Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.
3080051|NCT01417741|No Intervention|Standard Therapy Only|Patients will not receive acupuncture. Standard anti-emetic therapy will be given.
3080052|NCT01417741|Experimental|Acupuncture Plus Standard Therapy|Bilateral P6 acupuncture applied after anesthesia induction and removed at the termination of the surgery. Patients will also receive standard anti-emetic therapy.
3080053|NCT01417780|Active Comparator|AB103 0.25 mg/kg|
3080054|NCT01417780|Active Comparator|AB103 0.5 mg/kg|
3080055|NCT01417780|Placebo Comparator|Placebo|Normal saline (0.9% sodium chloride)
3080056|NCT01417936|Experimental|Sym004|
3080057|NCT01418001|Experimental|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|This will be a multicenter single arm phase IB/II trial to evaluate the clinical safety and efficacy of gemcitabine/docetaxel and pazopanib in the neoadjuvant treatment of soft tissue sarcoma.
3080058|NCT01418209|Active Comparator|Low-dose 17-ß-estradiol with progesterone taper|
3080059|NCT01418209|Active Comparator|Venlafaxine XR|
3080060|NCT01418209|Placebo Comparator|Placebo|
3080061|NCT01418339|Experimental|Aripiprazole|Aripiprazole was administered orally once a week (QW) for 8 weeks in a double-blind manner. Participants randomized to aripiprazole received aripiprazole tablets at a starting dose of 52.5 milligrams (mg) QW on Day 0. At Week 1, according to the investigator's discretion based on efficacy and tolerability, the dose of aripiprazole could remain at 52.5 mg QW or could be increased to 77.5 mg QW. The dose could be increased to 110 mg QW as early as Week 2. For the remainder of the study (up to Week 8), the dose was to be adjusted up and down among these three dose levels, as determined by the investigator.
3080062|NCT01418339|Placebo Comparator|Placebo|Participants randomized to placebo received aripiprazole-matching placebo, tablet, orally, QW for 8 weeks in a double-blind manner.
3080063|NCT01418352|Placebo Comparator|Matching Placebo|Participants received aripiprazole matching placebo, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
3080064|NCT01418352|Experimental|Aripiprazole 52.5 mg|Participants received aripiprazole 52.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
3080065|NCT01418352|Experimental|Aripiprazole 77.5 mg|Participants received aripiprazole 77.5 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
3080066|NCT01418352|Experimental|Aripiprazole 110 mg|Participants received aripiprazole 110 mg, tablets, orally, once weekly for 8 weeks in the Double-blind Treatment Period.
3080067|NCT01418365|Experimental|Metronidazole + MMX placebo|
3080068|NCT01418365|Experimental|Metronidazole + MMX Mesalazine/mesalamine|
3080069|NCT01418378|Active Comparator|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
3080070|NCT01418378|Active Comparator|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
3080071|NCT01418482|Experimental|Mepilex Border Ag|Mepilex Border Ag, a silver dressing will be used
3080072|NCT01418703|Experimental|Closed Loop Control (CLC)|"The CLC used a computer to make recommendations for their insulin treatment. This study arm was designed to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged hyperglycemic episodes (i.e. control to range). This system was designed to both:~monitor the meal boluses of the patient and correct it in case of observed/predicted under insulinization (avoidance of prolonged hyperglycemia), based on a coarse and subjective knowledge of the meal amount, a precise understanding of the subject's day to day insulin treatment, continuous glucose monitoring, and past insulin injections;~predict and avoid hypoglycemic events, based on continuous glucose reading and past insulin injection."
3080073|NCT01418703|Placebo Comparator|Open Loop|The subject were in charge of their insulin treatment.
3080074|NCT01418937|Experimental|HPV Group|
3080075|NCT01419015|Experimental|TAVI-TF Approach|Transcatheter aortic valve implantation and transfemoral approach. SAPIEN XT NovaFlex delivery system will be used.
3080076|NCT01419028||Patients with perinatal and/or infantile onset HPP|Patients with a confirmed diagnosis of perinatal or infantile onset hypophosphatasia (HPP)
3080077|NCT01419080||Peripheral Arterial Disease (PAD) patients|Patients with new onset or exacerbation of peripheral artery (PA) symptoms.
3080078|NCT01419171|Experimental|OMEGA™ Monorail Coronary Stent System|
3080079|NCT01419184|Experimental|Daptomycin|4 milligrams per kilogram (mg/kg) daptomycin administered intravenously (IV) once a day until end of antibiotic therapy for complicated skin and skin structure infections (cSSSI) or until hospital discharge, whichever occurred first. Investigators treated participants according to their usual decision-making and discretion.
3080080|NCT01419184|Active Comparator|Vancomycin|Vancomycin was reconstituted per the manufacturer's instructions and was dosed per investigator's discretion and was administered IV until end of antibiotic therapy for cSSSI or until hospital discharge, whichever occured first. Investigators treated participants according to their usual decision-making and discretion
3080081|NCT01419197|Experimental|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg intravenously every 3 weeks until disease progression (as assessed by the investigator) or unmanageable toxicity.
3080082|NCT01419197|Active Comparator|Treatment of physician's choice|Treatment of physician's choice until disease progression (as assessed by the investigator) or unmanageable toxicity. The treatments included single-agent chemotherapy, single-agent or dual-agent hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
3080083|NCT01419236|Experimental|Testosterone Solution 2% 60 milligrams (mg)|Testosterone Solution 2% 60 mg applied topically once daily with possible 1-time titration to 30 milligrams per day (mg/day) or 90 mg/day for 16 weeks
3080084|NCT01419236|Placebo Comparator|Placebo|Placebo solution applied topically once daily for 16 weeks
3080085|NCT01419249|Other|Retrospective cohort|
3080086|NCT01419275|Experimental|Moyamoya|Approximately 60 Moyamoya patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3080087|NCT01419275|Experimental|Acute stroke|Approximately 60 acute stroke patients will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3080088|NCT01419275|Experimental|Healthy participants|Approximately 30 healthy participants will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3080089|NCT01419275|Experimental|Diagnosis unspecified|Approximately 60 participants with diagnosis unspecified will be enrolled, and will receive arterial spin label MRI with Xenon contrast agent to assess collateral blood flow.
3080090|NCT01419314|Experimental|Splinting application|Participants will be asked to wear a pair of LE night splints for the duration of the study (6 weeks) at night/during sleep only.
3080091|NCT01419314|Placebo Comparator|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study.
3080092|NCT01419535|Experimental|Mifepristone, then Placebo|Participants first received Mifepristone 50mg tablet every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days.
3080093|NCT01419535|Experimental|Placebo, then Mifepristone|Participants first received Placebo tablet (matching mifepristone 50 mg) every six hours for nine days. After a washout period of no fewer than 6 but no more than 8 weeks, they then received Mifepristone 50 mg tablet every six hours for nine days.
3080094|NCT01419626|No Intervention|Negative Control|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste.
3468880|NCT03891602||Clinicians|Primary care clinicians (general internists, family physicians, nurse practitioners, physician assistants) who treat lung cancer screening eligible patients
3080095|NCT01419626|Sham Comparator|Device with Water|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
3080096|NCT01419626|Experimental|Device with Mouthrinse|Subjects will be instructed to follow their usual oral hygiene habits with the provided toothbrush and toothpaste, and to use their assigned product once a day for a period of 4 weeks.
3080097|NCT01419639|Experimental|RAD001|RAD001 taken orally continuously until disease progression or unacceptable toxicity, dosed according to age
3080098|NCT01419665|Experimental|GP2013|Type: Biological/Vaccine
3080099|NCT01419665|Active Comparator|rituximab|Type: Biological/Vaccine
3080100|NCT01419717|Experimental|Denosumab|Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
3080101|NCT01419769|Experimental|AXIOS Stent and Delivery System|
3080102|NCT01419795|Experimental|Arm I (lenalidomide, rituximab)|Patients who have relapsed/progressed within 180 days post-transplant (Cohort 1), beyond day 180 post-transplant (Cohort 2), or within 6 months but were not started within 3 months of relapse, receive lenalidomide PO QD on days 1-28 (patients with CLL/SLL/PLL) or days 1-21 (patients with NHL). Patients in Cohorts 1 and 2 also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and then every two months for courses 3, 5, 7, 9, and 11.
3080103|NCT01419795|Active Comparator|Arm II (lenalidomide)|Patients who have relapsed/progressed at any time point post-transplant and who have contraindications, prior severe hypersensitivity reaction to rituximab infusion, to receive rituximab or have CD20 negative disease (Cohort 3) receive lenalidomide as in Arm I.
3080104|NCT01419977|Placebo Comparator|Placebo|Normal saline solution
3080105|NCT01419977|Experimental|Dalteparin|5000 unites subcutaneously, Other Name: Fragmin
3080106|NCT01420016|Active Comparator|Prioritized Clinical Decision Support|The Prioritized Clinical Decision Support (CDS) intervention is a protocol driven CDS system linked within the EMR that identifies patients with high cardiovascular risk and provides tailored, prioritized decision support to the provider and patient at the point of care. The CDS was printed at intervention sites. It i) compiled most recent lab data (A1c, SBP, and LDL), BMI, smoking status, and aspirin use, (ii) calculated a 10-year risk for stroke or heart attack, (iii) prioritized clinical domains based on the absolute risk reduction for each component, (iv) compiled information related to renal and liver function, creatine kinase level, and previous diagnoses (CHF, CVD, DM), and (v) provided recommendations for intensification of therapy for A1c, SBP and/or LDL if not at goal.
3080107|NCT01420016|No Intervention|Usual Care|Providers in the usual care arm did not have access to the prioritized clinical decision support tool.
3080108|NCT01420068||All patients|All patients previously treated with study medication in the CSPP100A2365 and CSPP100A2365E1 studies.
3080109|NCT01420081|Experimental|B|PI3K Basal, IV Compound
3080110|NCT01420081|Experimental|C|PI3K Activated, Oral Compound
3080111|NCT01420081|Experimental|F|Japanese lead in cohort, IV compound
3080112|NCT01420146|Experimental|Zr89-trastuzumab PET/CT|Zr89-trastuzumab PET/CT single arm
3080113|NCT01420289|Experimental|HPIPC|High Pressure Intermittent Pneumatic compression (HPIPC)to be performed for 45 minutes twice daily
3080114|NCT01420289|Active Comparator|Excercise|Walking on a graded treadmill for 45 minutes once daily
3080115|NCT01420536|Experimental|Canine Guidance|"Complete dentures adjusted with mutually protected articulation in which the vertical and horizontal overlap of the canine teeth disengage the posterior teeth in the excursive movements of the mandible (The Glossary of Prosthodontic Terms. J. Prosthet. Dent., 94(1): 10-92)"
3080116|NCT01420536|Sham Comparator|Bilateral Balanced Occlusion|Complete dentures as conventionally adjusted: anterior and posterior teeth presented bilateral contact in excentric positions
3080117|NCT01420549|Experimental|Rosuvastatin + Ezetimibe|Participants received Rosuvastatin 10 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Rosuvastatin 20 mg+ Ezetimibe 10mg tablet orally once daily for more 4 weeks.
3080118|NCT01420549|Active Comparator|Simvastatin + Ezetimibe|Participants received Simvastatin 20 mg+ Ezetimibe 10 mg tablet orally once daily for 5 weeks and after a LDL evaluation if it level was <100 mg/dL the dose was maintained for more 4 weeks. However, if the LDL-C levels was ≥100 mg/dL, the dose was adjusted to Simvastatin 40 mg + Ezetimibe 10mg tablet orally once daily for more 4 weeks.
3080119|NCT01420627|Experimental|Adagen/EZN-2279|Patients started on Adagen and crossed over to experimental EZN-2279 treatment after at least a 3 week Lead-in Period on Adagen
3080120|NCT01420653|Experimental|Maxigesic 325|Acetaminophen 325mg + ibuprofen 97.5mg per tablet, two tablets every 6 hours, orally
3080121|NCT01420653|Active Comparator|Acetaminophen|Acetaminophen 325mg per tablet (standard dose acetaminophen), two tablets every 6 hours, orally
3080122|NCT01420653|Active Comparator|Ibuprofen|Ibuprofen 97.5mg per tablet (i.e. low dose ibuprofen), two tablets every 6 hours, orally
3080123|NCT01420653|Placebo Comparator|Placebo|Placebo tablets, every 6 hours, orally
3080124|NCT01420679|Experimental|Pralatrexate|Patients randomized to the Pralatrexate Arm will receive pralatrexate injection and Vitamins B12 and Folic Acid until a criterion for pralatrexate injection treatment discontinuation is met.
3080125|NCT01420679|No Intervention|Observation|Patients randomized to the Observation Arm will receive Vitamins B12 and Folic Acid and remain under observation until a criterion for observation discontinuation is met.
3080126|NCT01420848|Active Comparator|Auriculotherapy Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Two points were chosen to treat stress and anxiety (Shenmen and Brainstem)."
3080127|NCT01420848|Placebo Comparator|Placebo Group|Auriculotherapy by sham, at the fist and outer ear points. These points aren't indicated for stress and anxiety.
3080128|NCT01420848|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3321079|NCT02016001|Experimental|toothpaste 1|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
3080129|NCT01420926|Experimental|Arm A (decitabine)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-10. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3080130|NCT01420926|Experimental|Arm B (decitabine and bortezomib)|"REMISSION INDUCTION THERAPY: Patients receive 20 mg/m^2 decitabine IV over 1 hour QD on days 2-11 and 1.3 mg/m^2 bortezomib SC on days 1, 4, 8, and 11. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving CR or CRi proceed to continuation therapy. Patients achieving CR or CRi proceed to maintenance therapy.~CONTINUATION THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive 1.3 mg/m^2 bortezomib SC on day 1 and 20 mg/m^2 decitabine IV over 1 hour QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3080131|NCT01421017|Experimental|IMQ+RT|"This arm has been closed as of 6/4/2014.~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3080132|NCT01421017|Experimental|CTX/IMQ/RT|"Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3080133|NCT01421017|Experimental|CTX/RT|"For patients with only non-skin metastatic sites~First cycle (Cycle 1):~Week -1 (day -7): cyclophosphamide 200mg/m2 IV as single infusion~Weeks 1-2: RT given to one site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)~Week 9: response assessment~Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator."
3080134|NCT01421134|Experimental|Lurasidone|Lurasidone 20, 40 or 60 mg
3080135|NCT01421134|Placebo Comparator|Placebo|Placebo
3080136|NCT01421147|Experimental|LY2963016 + Insulin Lispro|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
3080137|NCT01421147|Active Comparator|Lantus + Insulin Lispro|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily at the same timing (daytime or evening/bedtime) as participant's prestudy basal insulin injection schedule in combination with premeal insulin lispro. Insulin lispro titrated based on blood glucose readings, administered subcutaneously, three times a day for 52 weeks.
3080138|NCT01421186|Experimental|Phase 1 dose escalation|"Part A: MOR03087 dose escalation; biweekly treatment~Part B: MOR03087 dose escalation; weekly treatment~Part C: MOR03087 dose escalation (weekly treatment) + dexamethasone~Part D: MOR03087 weekly treatment in combination with pomalidomide + dexamethasone~Part E: MOR03087 weekly treatment in combination with lenalidomide + dexamethasone~For all parts, patients will be treated until disease progression (PD) or until a maximum of 3 years after first treatment."
3080139|NCT01421186|Experimental|Phase 2a confirmatory cohorts|"Confirmatory cohorts of MOR03087 monotherapy (plus or minus dexamethasone), in combination with pomalidomide plus dexamethasone, and in combination with lenalidomide plus dexamethasone.~Following completion of Parts A, B, and C (dose escalation of MOR03087 biweekly and weekly schedules), the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen will be confirmed in a minimum of 6 subjects.~Following completion of Parts D (dose escalation of MOR03087 in combination with pomalidomide + dexamethasone) and E (dose escalation of MOR03087 in combination with lenalidomide + dexamethasone), the MTD and/or recommended dose in each part will be confirmed in a minimum of 6 subjects.~For all parts, patients will be treated until PD or until a maximum of 3 years after first treatment."
3080140|NCT01421225|Active Comparator|Standard Insulin Pump Therapy first, then Closed Loop|Standard therapy day 1, Closed-Loop therapy day 2.
3080141|NCT01421225|Active Comparator|Closed Loop first, then Standard Insulin Pump Therapy|Closed-loop therapy day 1, standard therapy day 2.
3080142|NCT01421277||Participants Enrolled in Protocol Version (V)1.1|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V1.1 of this study.
3080143|NCT01421277||Participants Enrolled in Protocol V2|Participants with physician-diagnosed migraine with or without aura who are treatment-naive to triptans, who received their first prescription for a triptan and took at least one dose within 6 months prior to being included in Protocol V2 of this study.
3080144|NCT01421303||AS patients who are working and treated with Enbrel|
3080145|NCT01421342|Active Comparator|Switching: Bupropion-SR|Switching: Bupropion-SR
3080146|NCT01421342|Active Comparator|Augmenting: Antidepressant + Bupropion-SR|Augmenting: Antidepressant + Bupropion-SR
3080147|NCT01421342|Active Comparator|Augmenting: Antidepressant + Aripiprazole|Augmenting: Antidepressant + Aripiprazole
3080148|NCT01421355|Experimental|Atazanavir 300 mg BID|Atazanavir 300 mg BID for 4 days.
3321080|NCT02016001|Experimental|toothpaste 2|toothpaste 2 will be the intervention with 1000 ppm of fluoride, which will be used by control group. They will brush the teeth twice daily for 2 minutes
3080149|NCT01421459|Experimental|LY2963016 + OAMs|LY2963016 titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 oral antihyperglycemic medications (OAMs) [alpha glucosidase inhibitors (AGI), dipeptidyl peptidases intravenous (DPP-IV), meglitinide (MEG), metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD)] administered per standard of care for 24 weeks
3080150|NCT01421459|Active Comparator|Lantus + OAMs|Lantus titrated based on blood glucose readings, administered subcutaneously, once daily in combination with at least 2 OAMs (AGI, DPP-IV, MEG, MET, SU, and TZD) administered per standard of care for 24 weeks
3080151|NCT01421472|Experimental|MM-121 (SAR256212) + paclitaxel|2 week run-in of MM-121 followed by MM-121 + dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
3080152|NCT01421472|Active Comparator|Paclitaxel only|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
3080153|NCT01421498|Experimental|5.0% Lifitegrast|Lifitegrast
3080154|NCT01421498|Placebo Comparator|Placebo|Placebo
3080155|NCT01421511|Experimental|TR-701 FA|• TR-701 FA IV followed by TR-701 FA tablets
3080156|NCT01421511|Active Comparator|Linezolid|• Linezolid IV followed by Linezolid Tablets
3080157|NCT01421589|Experimental|Growth Hormone|
3080158|NCT01421641|Active Comparator|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle.
3080159|NCT01421641|Active Comparator|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip (this amount of lidocaine will be measured out prior to procedure)
3080160|NCT01421654|Experimental|Fixed Mode + Acclimate|S9 Elite flow generator with Acclimate feature activated.
3080161|NCT01421654|Active Comparator|Fixed Mode only|S9 Elite Flow Generator with Fixed Mode only
3080162|NCT01421667|Experimental|Brentuximab vedotin+rituximab|
3080163|NCT01421667|Experimental|Brentuximab vedotin|
3080164|NCT01421719|Experimental|botulinum toxin treatment|botulinum toxin treatment Injection of Botox into urinary bladder for neurogenic symptoms.
3080165|NCT01422070||Patients admitted to the Study Units|Consecutive adult patients consecutively admitted to the Study Units during one month (either from 7th November to 4th December 2010, or from 16th January to 12th February 2012)
3080166|NCT01422135|Experimental|Abdomen, Buttock, Upper Torso|"Patch was placed on abdomen, buttock then the upper torso excluding breast.~Intervention: AG200-15 patch"
3080167|NCT01422135|Experimental|Abdomen, Upper Torso, Buttock|"Patch was placed on abdomen, upper torso excluding breast then the buttock.~Intervention: AG200-15 patch"
3080168|NCT01422135|Experimental|Buttock, Abdomen, Upper Torso|"Patch was placed on the buttock, abdomen, then the upper torso excluding breast.~Intervention: AG200-15 patch"
3080169|NCT01422135|Experimental|Buttock, Upper Torso, Abdomen,|"Patch was placed on the buttock, upper torso excluding breast then the abdomen~Intervention: AG200-15 patch"
3080170|NCT01422135|Experimental|Upper Torso, Abdomen, Buttock|"Patch was placed on the upper torso excluding breast, abdomen then buttock.~Intervention: AG200-15 patch"
3080171|NCT01422135|Experimental|Upper Torso, Buttock, Abdomen|"Patch was place on the upper torso excluding breast, buttock, then abdomen.~Intervention: AG200-15 patch"
3080172|NCT01422161|Experimental|Botulinum Toxin commonly known as BOTOX®|Some subjects will receive BOTOX® injections. Subject will not be informed of what injection they received.
3080173|NCT01422161|Placebo Comparator|Placebo|Some subject will receive a safe Placebo injection. Subjects will not be informed of what injection they have received.
3080174|NCT01422187|Experimental|Taliglucerase alfa 30 units/kg|Subjects randomized to receive 30 units/kg
3080175|NCT01422187|Experimental|Taliglucerase alfa 60 units/kg|Subjects randomized to 60 units/kg
3080176|NCT01422200|Experimental|Subcutaneous|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via subcutaneous route once
3080177|NCT01422200|Active Comparator|Intramuscular|0.5 mL of Fluzone (2011-2012 Northern Hemisphere formulation) influenza vaccine administered via intramuscular route once
3080178|NCT01422213|Placebo Comparator|Placebo|
3080179|NCT01422213|Experimental|Vortioxetine 10 mg|
3080180|NCT01422213|Experimental|Vortioxetine 20 mg|
3080181|NCT01422226|Experimental|Experimental active comparator|"Drug: Misoprostol~Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion"
3080182|NCT01422226|Placebo Comparator|Placebo comparator|"Other: Placebo~Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion"
3080183|NCT01422239|Experimental|Tailored behavioral counseling|"The focus of the first three sessions for participants receiving the tailored treatment will be their three most highly endorsed perceived risks of quitting. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. The last 5 counseling sessions will be based on perceived risks of quitting."
3080184|NCT01422239|Active Comparator|Standard behavioral counseling|"The focus of the first three sessions for participants receiving the standard treatment will be the benefits of quitting smoking. All participants will receive information about preparing for quit day in the second session and coping with withdrawal symptoms in the third session using the Mayo Clinic's Smoke Free and Living It manual. All participants will receive identical counseling sessions during week 4-8 based on material from the Mayo Clinic manual."
3080185|NCT01422304|Experimental|Sugammadex|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive sugammadex and placebo to neostigmine, and participants assigned to planned spontaneous recovery will receive sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
3321081|NCT02016014|Experimental|Intervention group|Lifestyle counseling in physical activity and alimentation and add for three months a smartphopne with a app (EVIDENT) to improve alimentation and physical activity
3321082|NCT02016014|Active Comparator|Lifestyle counseling|Lifestyle counseling in physical activity and alimentation
3321083|NCT02016027|Experimental|Carica folia Arm|
3080186|NCT01422304|Experimental|Usual Care|Prior to randomization, participants will be assigned to planned active reversal or planned spontaneous recovery by the anesthesiologist according to the recovery method the anesthesiologist would have chosen if the participant were not in the study. In this treatment arm, participants assigned to planned active reversal will receive neostigmine and placebo to sugammadex, and participants assigned to planned spontaneous recovery will receive placebo to sugammadex. Study drug will be administered after the last dose of rocuronium or vecuronium and after wound closure.
3080187|NCT01422369|Experimental|All Subjects|pitavastatin 4 mg
3080188|NCT01422382|Experimental|All Subjects|There was 1 treatment period, with each subject receiving a once-daily dose of pitavastatin 4 mg on Days 1 through 5 and on Days 11 through 15 and a once-daily dose of diltiazem 240 mg on Days 6 through 15
3080189|NCT01422408|Experimental|Supportive care (fluocinonide cream)|Patients apply topical fluocinonide cream BID in weeks 1-2 and QD in weeks 3-4.
3080190|NCT01422434|Active Comparator|LEO 90105 ointment|LEO 90105 ointment applied once daily for 4 weeks.
3080191|NCT01422434|Active Comparator|Dovonex® ointment|Applied twice daily for 4 weeks.
3080192|NCT01422434|Active Comparator|Rinderon® - DP ointment|Applied once daily for 4 weeks
3080193|NCT01422538|Active Comparator|Group A|Subjects will receive Ulthera® System alone.
3080194|NCT01422538|Active Comparator|Group B|Sculptra® only
3080195|NCT01422538|Active Comparator|Group C|Sculptra® treatment followed by Ultherapy™ treatment
3080196|NCT01422720|Experimental|Eslicarbazepine Acetate tablets (800 mg)|
3080197|NCT01422824||Cohort|
3080198|NCT01422876|Experimental|BI 10773/linagliptin FDC (high dose)|Patients receive BI 10773/linagliptin FDC (high dose) once daily
3080199|NCT01422876|Experimental|BI 10773/linagliptin FDC (low dose)|Patients receive BI 10773/linagliptin FDC (low dose) once daily
3080200|NCT01422876|Active Comparator|BI 10773 (high dose)|Patients receive BI 10773 (high dose) once daily
3080201|NCT01422876|Active Comparator|BI 10773 (low dose)|Patients receive BI 10773 (low dose) once daily
3080202|NCT01422876|Active Comparator|Linagliptin|Patients receive linagliptin once daily
3080203|NCT01422889||ION Registry|The ION Registry population was designed to collect real world safety and clinical outcomes data. There were 1120 subjects were enrolled, however 9 subjects did not receive a study stent therefore 1111 subjects were eligible for follow up.
3080204|NCT01422915|Experimental|colestipol treatment|2 grams morning and bedtime for 180 days
3080205|NCT01423084|Experimental|MenB Lot 1|MenB vaccine Lot 1: 2 doses administered 1 month apart
3080206|NCT01423084|Active Comparator|MenB Lot 2|MenB vaccine Lot 2: 2 doses administered 1 month apart
3080207|NCT01423162|Experimental|Drink with Vit C then drink without Vit C|Fortified oat drink with vitamin C on day 1 followed by fortified oat drink without vitamin C on day 2
3080208|NCT01423162|Experimental|Drink without Vit C then drink with Vit C|Fortified oat drink without vitamin C on day 1 followed by fortified oat drink with vitamin C on day 2
3080209|NCT01423253|Experimental|Lurasidone 20, 40, 60 mg|Lurasidone 20, 40, or 60 mg/day flexibly dosed
3080210|NCT01423604|Experimental|Capecitabine and ruxolitinib|
3080211|NCT01423604|Placebo Comparator|Capecitabine and placebo|
3080212|NCT01423617|Active Comparator|Zenoctil|
3080213|NCT01423617|Placebo Comparator|Placebo|
3080214|NCT01423760|Experimental|Tecemotide (L-BLP25)|
3080215|NCT01423760|Other|Observational|
3080216|NCT01423773|Other|Lotrafilcon A test/lotrafilcon A control|Lotrafilcon A test contact lens worn first, with lotrafilcon A control contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
3080217|NCT01423773|Other|Lotrafilcon A control/lotrafilcon A test|Lotrafilcon A control contact lens worn first, with lotrafilcon A test contact lens worn second. Each product worn bilaterally for two days as follows: 20 minutes on Day 1 and 10 hours on Day 2.
3080218|NCT01423812|Experimental|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily to Darunavir 800mg plus Ritonavir 100mg once-daily
3080219|NCT01423812|Active Comparator|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
3080220|NCT01423916|Active Comparator|Arm 1 (OPC-34712, placebo)|Arm 1 will be administered 4 mg OPC-34712 once daily (QD) for 11 days and OPC-34712 placebo for 1 day.
3080221|NCT01423916|Active Comparator|Arm 2 (OPC-34712, placebo)|Arm 2 will be administered 12 mg OPC-34712 QD for 11 days and OPC-34712 placebo for 1 day.
3080222|NCT01423916|Active Comparator|Arm 3 (moxifloxacin, placebo)|Arm 3 will be administered 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for 1 day and OPC-34712 placebo QD for 11 days.
3080223|NCT01423916|Active Comparator|Arm 4 (moxifloxacin, placebo)|Arm 4 will be administered OPC-34712 placebo QD for 11 days and 400 mg moxifloxacin (positive control) plus OPC-34712 placebo for one day.
3080224|NCT01424033|Experimental|N-Acetylcysteine|This is an open label trial, all patient will be entered into one treatment arm.
3080225|NCT01424072|No Intervention|Control Group|Control Group didn't receive any treatment and was evaluated at the same time and the same way of interventions group
3080226|NCT01424072|Experimental|Auriculotherapy by needles|The investigators used 3 points, Shenmen, Kidney, and Brain Stem with semi-permanent needles of 1.8 mm, 1 time per week for 8 sessions.
3080227|NCT01424072|Experimental|Auriculotherapy by seeds|The investigators used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.
3080228|NCT01424189|Experimental|ReSTOR Toric IOL|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, model determined by preoperative keratometric astigmatism, bilateral implantation
3080229|NCT01424189|Active Comparator|ReSTOR IOL|AcrySof® ReSTOR® Multifocal IOL Model SA60D3, bilateral implantation
3080230|NCT01424215|Experimental|ICG injection with Spyscope imaging|Indocyanine Green (ICG)
3080231|NCT01424215|No Intervention|Standard Critical View Technique|50 patients will be randomized to the no treatment arm. These patients will not get ICG injection but rather will have the standard technique for laparoscopic cholecystectomy performed including the critical view technique to expose the important structures prior to clipping and division.
3080232|NCT01424228|Placebo Comparator|Placebo|Placebo 2 mg tablet once daily before breakfast
3080233|NCT01424228|Active Comparator|prucalopride|Prucalopride 2 mg once daily before breakfast
3080234|NCT01424293|Experimental|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
3080235|NCT01424306|Experimental|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days.
3080236|NCT01424306|Experimental|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days.
3080237|NCT01424306|Experimental|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days.
3080238|NCT01424397|Experimental|SB-705498|Experimental
3080239|NCT01424397|Active Comparator|Fluticasone Propionate|Active Comparator
3080240|NCT01424397|Placebo Comparator|Placebo|Placebo Comparator
3080241|NCT01424397|Experimental|SB-705498+FP|Experimental
3080242|NCT01424501|Experimental|Group A|Subjects from TB-treated cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3080243|NCT01424501|Placebo Comparator|Group B|Subjects from TB-treated cohort will receive 2 doses of physiological Saline.
3080244|NCT01424501|Experimental|Group C|Subjects from TB-treatment cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3080245|NCT01424501|Placebo Comparator|Group D|Subjects from TB-treatment cohort will receive 2 doses of physiological Saline.
3080246|NCT01424501|Experimental|Group E|Subjects from TB-naive cohort will receive 2 doses of GSK's investigational vaccine GSK 692342.
3080247|NCT01424501|Placebo Comparator|Group F|Subjects from TB-naive cohort will receive 2 doses of physiological Saline.
3080248|NCT01424514|Experimental|SB-705498|
3080249|NCT01424514|Placebo Comparator|Placebo|
3080250|NCT01424566|Experimental|Nabiximols|Nabiximols was self-administered by participants as a 100 microliter (μL) oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 2 or 7 weeks. Nabiximols oromucosal spray contained delta-9-tetrahydrocannabinol (THC) (27 milligrams [mg]/milliliter [mL]):cannabidiol (CBD) (25 mg/mL), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%)flavoring. Each 100 μL actuation delivered 2.7 mg THC and 2.5 mg CBD.
3080251|NCT01424566|Placebo Comparator|Placebo (GA-0034)|Placebo was self-administered by participants as a 100 μL oromucosal spray in the morning and evening, up to a maximum of 10 sprays per day for 5 weeks. Placebo oromucosal spray contained ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorings.
3080252|NCT01424644|Placebo Comparator|Placebo + Tdap + HPV|This group will receive Tdap, HPV and placebo concomitantly for the first vaccination. The second and third doses of HPV vaccine will be administered to all subjects 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
3080253|NCT01424644|Experimental|MenACWY-CRM + Tdap + HPV|This group will receive Tdap, HPV and MenACWY-CRM concomitantly. The second and third doses of HPV vaccine will be administered to this group 2 and 6 months after the first dose. All subjects will have serum samples collected at Visit 1 (baseline), Visit 2 (31 days) and Visit 5 (7 months after visit 1) for serology testing.
3080254|NCT01424670|Experimental|Delamanid + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive 100 mg delamanid orally BID (morning and evening) + OBR for 2 months, followed by 200 mg delamanid QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
3080255|NCT01424670|Placebo Comparator|Placebo + OBR|"In the first period of this study, known as the 6-month Intensive Period, participants were randomized to receive placebo orally BID (morning and evening) + OBR for 2 months followed by placebo QD (every morning) + OBR for 4 months.~Following the 6-month Intensive Period, participants entered the second period of the study, known as the Continuation Period, wherein OBR was administered alone for 12 to 18 months.~OBR given throughout the study was administered as per WHO guidelines and national treatment norms."
3080256|NCT01424722|Experimental|ST Monitoring Feature|ST segment continous monitoring feature enabled and programmed ON
3080257|NCT01424813|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
3080258|NCT01424813|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
3080259|NCT01424930|Experimental|Abiraterone+prednisone (low-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
3080260|NCT01424930|Experimental|Abiraterone+prednisone (high-fat meal)|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
3080261|NCT01424943|Experimental|Stepping Stones Triple P|10-15 sessions of Level 4 Standard Stepping Stones Triple P delivered in family homes
3080262|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
3321084|NCT02016040|Active Comparator|HIFU hemi-ablation|Focal Therapy Using High Intensity Focused Ultrasound (Ablatherm)
3080264|NCT01425190|Experimental|Cohort 1: Children 17 to ≥13 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such pudding or applesauce. The first 4 participants were treated with a 11.4 mg/kg dose of boceprevir powder. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3321085|NCT02016053||cirrhosis with baseline renal function|500 patients of cirrhosis with normal baseline renal function will be enrolled.
3321086|NCT02016053||Cirrhosis with Acute Kidney Injury (AKI).|Cirrhotics patients who present with AKI (Acute Kidney Injury) will be enrolled.
3080265|NCT01425190|Experimental|Cohort 2: Children <13 to ≥7 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 1. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3080266|NCT01425190|Experimental|Cohort 3: Children <7 to ≥3 years|Participants were administered a single dose of boceprevir powder mixed in a suitable vehicle such as pudding or applesauce. The first 4 participants were treated with boceprevir at a dose contingent on the PK and safety results in Cohort 2. The dose/weight ratio may be adjusted for the next 12 participants based on the evaluation of the PK, safety, and tolerability data from the first 4 participants.
3080267|NCT01425203|Experimental|RGT BOC + PR|Participants received PR for 4 weeks before addition of BOC. Participants then received response guided therapy (RGT) with BOC + PR for up to 32 weeks followed by PBO + PR for up to 20 weeks.
3080268|NCT01425203|Placebo Comparator|PBO + PR (Control)|Participants received PR for 4 weeks before addition of BOC-matched PBO. Participants then received BOC + PR for up to 44 weeks.
3080269|NCT01425203|Experimental|Crossover Arm|Participants randomized to the PBO + PR Control arm who failed the futility rule at treatment week (TW) 12 or 24 were rolled over to the Crossover arm and received BOC + PR.
3080270|NCT01425229||Bosentan|Haplotypes of CYP2C9 and OATP1B1 characterisation of CYP2C9 (CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910)) and OATP1B1 (SLCO1B1*15 (rs2306283, rs4149056))
3080271|NCT01425268|Experimental|AeroForm Tissue Expansion|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
3080272|NCT01425268|Active Comparator|Saline Tissue Expansion|Saline Tissue Expansion inflated by needle injections of saline
3080273|NCT01425281|Active Comparator|XIENCE™|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
3080274|NCT01425281|Experimental|ABSORB BVS™|Experimental: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
3080275|NCT01425307|No Intervention|Standard Therapy|Standard Therapy of monthly transfusions
3080276|NCT01425307|Experimental|Treatment Arm|Hydroxyurea will be provided as capsules or liquid
3080277|NCT01425359|Placebo Comparator|Placebo|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment Period: Placebo to match ranolazine (Day 1: 1 tablet in the evening; Days 2-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 8 weeks."
3080278|NCT01425359|Experimental|Ranolazine|"Qualifying phase: Participants will enter a 2-week washout period if needing to discontinue antianginal drugs (except beta-blockers) followed by placebo to match ranolazine (1 tablet twice daily) during a 4-week run-in period. Participants with at least 85% adherence to documentation requirements (angina frequency and sublingual nitroglycerin use) over the last 21 days of the placebo run-in period will be randomized to the treatment period.~Treatment period: Ranolazine tablets (Day 1: 1 × 500 tablet in the evening; Days 2-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 8 weeks."
3080279|NCT01425463|Experimental|Ferrous (II) Glycine Sulphate Complex|Ferrous (II) Glycine Sulphate Complex treatment with 567.7 mg three times a day (t.i.d.) for 12 weeks plus Placebo to Polyferose.
3080280|NCT01425463|Active Comparator|Polyferose|Polyferose treatment with 150 mg twice daily (b.i.d) for 12 weeks plus Placebo to Ferrous (II) Glycine Sulphate Complex.
3080281|NCT01425528|Experimental|Kuvan Cohort 1|This cohort will be enrolled first. Analysis will be done to determine the optimum dosing of Kuvan to normalize BH4 levels in the Cerebral Spinal Fluid. This cohort will begin at a dose of 20mg/kg/day.
3080282|NCT01425528|Experimental|Kuvan Cohort 2|Participants in cohort 2 will be enrolled after the analysis of cohort 1 data has taken place. Dosing for cohort 2 will be based on results obtained in cohort 1, but will plan on starting at 30 mg/kg/day.
3080283|NCT01425632|Experimental|TAU-284 Low|
3080284|NCT01425632|Experimental|TAU-284 High|
3080285|NCT01425632|Placebo Comparator|Placebo|
3080286|NCT01425723|Experimental|On-Demand|The individual dose of rFIXFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor IX peak (recovery) levels.
3080287|NCT01425723|Experimental|Prophylaxis|Weekly prophylaxis, individualized prophylaxis or personalized prophylaxis available.
3080288|NCT01425749|Experimental|Arm A|Intramuscular injections of recMAGE-A3 + AS15 ASCI.
3080289|NCT01425749|Experimental|Arm B|Intradermal/Subcutaneous injections of recMAGE-A3 + AS15 ASCI. Requires an injection site biopsy at Day 8 and Day 50.
3080290|NCT01425801|Experimental|LAS100977 0.625 μg|Single-dose LAS100977 0.625 μg, during double-blind treatment period
3080291|NCT01425801|Experimental|LAS100977 1.25 μg|Single-dose LAS100977 1.25 μg, during double-blind treatment period
3080292|NCT01425801|Experimental|LAS100977 2.5 μg|Single-dose LAS100977 2.5 μg, during double-blind treatment period
3080293|NCT01425801|Active Comparator|Salbutamol|Single-dose salbutamol 400 μg, during double-blind treatment period
3080294|NCT01425801|Placebo Comparator|Placebo|Placebo to LAS100977, and placebo to salbutamol
3080295|NCT01425801|Experimental|LAS100977 0.313 μg|Single-dose LAS100977 0.313 μg, during double-blind treatment period
3080296|NCT01425814|Experimental|Arm #2|Single dose, double blind treatment period
3080297|NCT01425814|Experimental|Arm #3|Single dose, double blind treatment period
3080298|NCT01425814|Experimental|Arm #4|Single dose, double blind treatment period
3080299|NCT01425814|Active Comparator|Arm #5|Single dose, double blind treatment period
3080300|NCT01425814|Placebo Comparator|Arm #6|Single dose, double blind treatment period
3080301|NCT01425814|Experimental|Arm #1|Single dose, double blind treatment period
3080302|NCT01425853|Experimental|Chondroitin/Glucosamine (Droglican)|"Active ingredients: Chondroitin sulfate, 200 mg and Glucosamine hydrochloride 250 mg.~Pharmacotherapeutic group: Other specific antirheumatic agents. Anatomical Therapeutic Chemical Classification System (ATC) code: M01CX."
3321087|NCT02016066|Experimental|CR6261|
3080303|NCT01425853|Active Comparator|Celecoxib|Active ingredient: Celecoxib, 200 mg. Pharmacotherapeutic group: Coxibs. ATC code: M01AH.
3080304|NCT01425879|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3080305|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 via nebulizer (eFlow®)
3080306|NCT01426009|Active Comparator|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium bromide via (Spiriva® Handihaler®)
3080307|NCT01426009|Active Comparator|Ipratropium bromide Inhalation Solution|Ipratropium bromide Inhalation Solution via Handihaler® DPI
3080308|NCT01426009|Placebo Comparator|Placebo EP-101|Placebo
3080309|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 via nebulizer (eFlow®)
3080310|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 via nebulizer (eFlow®)
3080311|NCT01426009|Experimental|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 via nebulizer (eFlow®)
3080312|NCT01426191||xinzhijun|1.5-3.0g,iv,bid or tid for 5-12 days
3080313|NCT01426217|No Intervention|Control|Control arm using standard of care operating room procedures and equipment
3080314|NCT01426217|Experimental|Problem Solving Innovations (PSI) Experimental|Implementation of the passive bundle including HubScrub and DocIt
3080315|NCT01426230||Open Label|"Cohort by age-~- Patients >70 Yrs old"
3080316|NCT01426230||Open label|"Cohort by age-~- Patients < 70 Yrs old"
3080317|NCT01426269|Placebo Comparator|Placebo|Subjects will receive placebo during phase 2 (week 12 - week 52)
3080318|NCT01426269|Other|Doxycycline and Metronidazole|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)
3080319|NCT01426269|Active Comparator|Doxycycline|Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)
3080320|NCT01426347|Placebo Comparator|placebo group|"RA Patients with vitamin D deficiency will be randomized to placebo and active intervention arms.~Patients in the placebo arm will receive I placebo pill per week for 16 weeks. After completing this arm, they will cross-over to the active treatment arm."
3080321|NCT01426347|Active Comparator|Ergocalciferol|Patients with vitamin D deficiency will be randomized to either active or placebo group. In the active group, patients will receive ergocalciferol 50,000 IU per week for 16 weeks.
3080322|NCT01426360|Experimental|strontium chloride/potassium nitrate dentifrice|
3080323|NCT01426360|Placebo Comparator|control dentifrice|
3080324|NCT01426373|Experimental|Deoxycholic Acid 2 mg/cm²|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3080325|NCT01426386|Experimental|5.2 µg|
3080326|NCT01426386|Experimental|6.9 µg|
3080327|NCT01426386|Experimental|8.6 µg|
3080328|NCT01426386|Experimental|10.3 µg|
3080329|NCT01426386|Experimental|12.1 µg|
3080330|NCT01426386|Active Comparator|11 µg FbM (150 IU)|
3080331|NCT01426412|Experimental|LY3015014 intravenously (IV)|A single dose of LY3015014 up to 10.0 milligrams per kilogram (mg/kg) administered IV
3080332|NCT01426412|Experimental|LY3015014 IV Japanese|Single dose of LY3015014 10.0 mg/kg administered IV to Japanese participants. Added per protocol amendment effective October, 2012.
3080333|NCT01426412|Placebo Comparator|Placebo IV|Administered IV once only
3080334|NCT01426412|Experimental|LY3015014 subcutaneously (SC)|A single dose of LY3015014 up to 3.0 mg/kg administered SC
3080335|NCT01426412|Experimental|LY3015014 SC + Statin|A single dose of LY3015014 up to 3 mg/kg administered SC in addition to participant's dose of statin
3080336|NCT01426412|Placebo Comparator|Placebo SC|Administered SC once only
3080337|NCT01426425|Experimental|Cryoablation|Subjects diagnosed with atrioventricular nodal reentrant tachycardia and treated by cryoablation with Freezor Xtra.
3080338|NCT01426438|Experimental|Arm A: Extended-release niacin with aspirin|
3080339|NCT01426438|Experimental|Arm B: Fenofibrate|
3080340|NCT01426581|Experimental|Educational Intervention A|Intervention: Teach to Goal
3080341|NCT01426581|Experimental|Educational Intervention B:|Brief Intervention
3080342|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 1|Subcutaneous injection of 1000 Units of CINRYZE with 20,000 Units of rHuPH20 twice weekly for two weeks
3080343|NCT01426763|Experimental|SC CINRYZE with rHuPH20 Dose Level 2|Subcutaneous injection of 2000 Units of CINRYZE with 40,000 Units of rHuPH20 twice weekly for two weeks
3080344|NCT01426789|Experimental|Secukinumab|10 mg/kg intravenous (I.V.)
3080345|NCT01426789|Placebo Comparator|Placebo|Placebo I.V.
3080346|NCT01426828|Other|Arm A|"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of KLH only vaccine."
3080347|NCT01426828|Other|Arm B|Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)
3080348|NCT01426854|Active Comparator|Nepafenac|Nepafenac Ophthalmic Suspension, 0.1%, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
3080349|NCT01426854|Placebo Comparator|Placebo|Nepafenac Vehicle, 1 drop to the operative eye, 3 times a day, beginning 1 day preoperatively and continuing through the day of surgery and for 14 days postoperatively. An additional dose was administered prior to surgery.
3080350|NCT01426867|Experimental|Brinz/Brim|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled in each affected eye 3 times a day for 7 days
3080351|NCT01426867|Active Comparator|Brinzolamide|Brinzolamide ophthalmic suspension, 1%, 1 drop instilled in each affected eye 3 times a day for 7 days
3080352|NCT01426867|Active Comparator|Brimonidine|Brimonidine tartrate ophthalmic solution, 0.2%, 1 drop instilled in each affected eye 3 times a day for 7 days
3080353|NCT01426958|Active Comparator|treatment A|1 tablet afatinib single dose
3080354|NCT01426958|Experimental|treatment B|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
3080355|NCT01426958|Experimental|treatment C|2 x 2 tablets ritonavir for 3 days + 1 tablet afatinib on the second treatment day
3080356|NCT01427296|Active Comparator|OsmoPrep Tablets|
3080357|NCT01427296|Active Comparator|HalfLytely and Bisacodyl Tablet|
3080358|NCT01427309|Experimental|High Dose Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of High Dose Trivalent Inactivated Influenza Vaccine
3080359|NCT01427309|Active Comparator|Trivalent Inactivated Influenza Vaccine|Participants will receive an injection of the Trivalent Inactivated Influenza vaccine
3080360|NCT01427504|Experimental|Sequence 1a|Sequence 1,2,3: boceprevir only, then etravirine only, then both boceprevir and etravirine.
3080361|NCT01427504|Experimental|Sequence 1b|Sequence 1,3,2: boceprevir only, then both boceprevir and etravirine, then etravirine only.
3080362|NCT01427504|Experimental|Sequence 2a|Sequence 2,1,3: etravirine only, then boceprevir only, then both boceprevir and etravirine.
3080363|NCT01427504|Experimental|Sequence 2b|Sequence 2,3,1: etravirine only, then both boceprevir and etravirine, then boceprevir only.
3080364|NCT01427504|Experimental|Sequence 3a|Sequence 3,1,2: both boceprevir and etravirine, then boceprevir only, then etravirine only.
3080365|NCT01427504|Experimental|Sequence 3b|Sequence 3,2,1: Both boceprevir and etravirine, then etravirine only, then boceprevir only.
3080366|NCT01427517|Experimental|NAC in PD|single intravenous administration of N-acetylcysteine in PD patients
3080367|NCT01427517|Experimental|NAC in GD|single intravenous administration of N-acetylcysteine in GD patients
3080368|NCT01427517|Experimental|NAC in controls|single intravenous administration of N-acetylcysteine in control subjects
3080369|NCT01427595|Experimental|Metformin, progesterone , estrace|12 weeks Metformin oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (2X) oral estrace, 0.5-1 mg once a day for seven days (2X)
3080370|NCT01427608|Active Comparator|Sertraline + Olanzapine|Randomized to continue with sertraline and olanzapine under double-blind conditions.
3080371|NCT01427608|Placebo Comparator|Sertraline + Placebo|Randomized to continue with sertraline and substitute placebo for olanzapine under double-blind conditions.
3080372|NCT01427738|Experimental|Arm A: Topical GV solution|Topical GV 0.00165% solution (5 mL swish and gargle for 1 minute and expectorate [spit] 2 times per day [BID]) for 14 days
3080373|NCT01427738|Active Comparator|Arm B: Nystatin oral suspension|Nystatin oral suspension (5 mL of 100,000 units/mL swish for 1 minute and swallow 4 times per day [QID]) for 14 days
3080374|NCT01427751|Active Comparator|Ozurdex®|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
3080375|NCT01427751|Active Comparator|Lucentis®|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
3080376|NCT01427803|Experimental|Arm 1|
3080377|NCT01427881|Experimental|Treatment (TBI, PBSCT, and cyclophosphamide GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive TBI BID on days -4 or -3 to -1. Some patients also receive fludarabine IV daily on days -5 to -2 and busulfan IV over 3 hours QD or over 2 hours every 6 hours on days -5 to -2. Patients may also undergo CNS prophylaxis, testicular irradiation, and/or involved field irradiation as per standard practice.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0 per standard practice.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours on days 3-4. Patients also receive cyclosporine IV every 12 hours or every 8 hours beginning on day 5 with taper on days 56-126."
3080378|NCT01427907|Experimental|Phoslyra - Calcium Acetate Oral Solution|The investigational compound is calcium acetate oral solution (COS) or Phoslyra. It is a pale, light greenish-yellow clear liquid with a characteristic black cherry odor and flavor for oral ingestion. Each 5 mL of COS contains 667 mg calcium acetate equal to 169 mg of elemental calcium. Each subject will follow their usual prescription.COS will be taken either prior to or during meals and snacks.
3080379|NCT01427907|Active Comparator|Sevelamer Carbonate|Sevelamer carbonate is an anion exchange resin that binds phosphate in the gastrointestinal tract and is a buffered form of sevelamer hydrochloride developed for the treatment of hyperphosphatemia in End-Stage Renal Disease (ESRD) patients. Each film-coated tablet of sevelamer carbonate (trade name Renvela™) contains 800 mg of sevelamer carbonate on an anhydrous basis. Subjects will receive sevelamer tablets according to their prescription.
3080380|NCT01427920|Experimental|Subject-driven titration BIAsp 30 (BID) + metformin|The subjects performed the titration of BIAsp 30 dose.
3080381|NCT01427920|Active Comparator|Investigator-driven titration BIAsp 30 (BID) + metformin|The investigator performed the titration of BIAsp 30 dose.
3080382|NCT01427933|Experimental|Ramucirumab and Eribulin|"Ramucirumab 10 milligrams/kilogram (mg/kg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle~Eribulin 1.4 milligrams/square meter (mg/m²) administered by IV bolus on Day 1 and Day 8 of each 3-week cycle"
3080383|NCT01427933|Active Comparator|Eribulin Monotherapy|Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle
3080384|NCT01427972|Experimental|0.2 milligrams (mg) LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3080385|NCT01427972|Experimental|1.5 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3080386|NCT01427972|Experimental|10 mg LY2623091|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3080387|NCT01427972|Active Comparator|50 mg Eplerenone|Daily by mouth for 21 days. Days 1-20 administered in the fed state. Day 21 administered in the fasted state. Minimum wash-out period of 28 days between dosing in treatment periods
3080388|NCT01428024|Experimental|Restylane Lip Volume|Submucosal injections with Restylane Lip Volume. Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
3080389|NCT01428024|Experimental|Restylane Lip Refresh|Submucosal injections with Restylane Lip Refresh. Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 2 and 12.
3321088|NCT02016066|Placebo Comparator|Placebo|
3080390|NCT01428063|Experimental|Daclatasvir + Asunaprevir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule or 200-mg tablet, by mouth twice daily + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
3080391|NCT01428063|Experimental|Daclatasvir + PegIFNα-2a + Ribavirin|Patients received daclatasvir, (two 30-mg tablets or one 60-mg tablet, by mouth once daily) + pegIFNα-2a, 180-μg solution, subcutaneously weekly + ribavirin, weight-based dosing (<75 kg=1000 mg once daily; >=75 kg=1200 mg once daily) for 24 weeks
3080392|NCT01428063|Experimental|Daclatasvir + Asunaprevir|Patients received daclatasvir, 60-mg tablet, by mouth once daily + asunaprevir, 100-mg capsule, by mouth twice daily for 24 weeks
3080393|NCT01428076|Experimental|High Dose Polidocanol Endovenous Microfoam|
3080394|NCT01428076|Experimental|Medium Dose Polidocanol Endovenous Microfoam|
3080395|NCT01428115||Patients with severe active Crohn's disease|Patients with severe active Crohn's disease for whom adalimumab was prescribed in the usual manner in accordance with the terms of the local marketing authorization.
3080396|NCT01428128|Experimental|Arsenic Trioxide|
3080397|NCT01428193|Experimental|Flutamide, estrace, progesterone|"For flutamide, subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day for approximately 3 weeks.~Subjects will be given oral estrace, 0.5-1 mg once a day for 7 days following the first overnight study admission.~Subjects will be given oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days following the first overnight study admission."
3080398|NCT01428219|Experimental|Cabozantinib (XL184)|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
3080399|NCT01428245|Experimental|Progesterone, estrace|"oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days"
3080400|NCT01428258|Experimental|GMP Diet/GMP Medical Foods|The experimental intervention is the GMP diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the GMP diet as the first arm, and half of the subjects (n=15) were randomized to receive the GMP diet as the second arm.
3080401|NCT01428258|Active Comparator|AA Diet/AA Medical Foods|The experimental intervention is the AA diet followed at home for 3-wk. In this randomized crossover study, half of subjects (n=15) were randomized to receive the AA diet as the first arm, and half of the subjects (n=15) were randomized to receive the AA diet as the second arm.
3080402|NCT01428336|Active Comparator|Patients|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
3080403|NCT01428336|Active Comparator|Volunteers|Subjects will undergo three ACTH stimulation test using a dose of 1 ug cotrosyn, 25 ug cortrosyn, 250ug cortrosyn and one Insulin tolerance test
3080404|NCT01428453|Experimental|250mg rilapladib|Experimental drug
3080405|NCT01428453|Placebo Comparator|placebo|Placebo comparator
3080406|NCT01428583|Experimental|oxycodone HCl and naltrexone HCl extended-release capsules|
3080407|NCT01428661|Experimental|tasimelteon|
3080408|NCT01428661|Placebo Comparator|placebo|
3080409|NCT01428713|Active Comparator|Group A-Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
3080410|NCT01428713|Active Comparator|Group B-Combined oral contraceptive pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
3080411|NCT01428882|Active Comparator|Midazolam balanced propofol sedation|2 mg midazolam in 2 ml saline midazolam followed by continuous propofol iv infusion
3080412|NCT01428882|Placebo Comparator|Single-agent propofol sedation|2 ml saline followed by continuous propofol iv infusion
3080413|NCT01429051|Experimental|Intranasal Fentanyl Spray (INFS)|All participants were step-wise titrated to an effective dose of 50, 100, 200 or 400 μg INFS in the Titration Phase (I). Participants titrated to 200 or 400 μg INFS in the Titration Phase were randomized to an 8-spray sequence in the Efficacy Phase (II); 6 BTP episodes were treated with 400 μg INFS and 2 BTP episodes with placebo in a random sequence. Participants entered the Tolerability Phase (III) either directly from the Titration Phase (with an effective dose of 50 or 100 μg) or from the Efficacy Phase (400 μg) and continued with this specific dose, unless adjustment was needed, for a total treatment time of 12 weeks.
3080414|NCT01429064|Experimental|ODM-201|
3080415|NCT01429077|Active Comparator|Levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
3080416|NCT01429077|Placebo Comparator|Inactive pill|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
3080417|NCT01429259|Experimental|Meropenem 3 hour prolonged infusion|All 30 participants will receive meropenem as a 3 hour infusion.
3080418|NCT01429272|Placebo Comparator|Placebo & Placebo|Placebo for minocycline & placebo for aspirin
3080419|NCT01429272|Active Comparator|minocycline & aspirin|Minocycline 100mg PO BID for 6 weeks & Aspirin 81 mg PO BID for 6 weeks
3080420|NCT01429285|Experimental|Hydromorphone|Hydromorphone protocol
3080421|NCT01429285|Active Comparator|Usual care|Usual care
3080422|NCT01429298|Experimental|Hydromorphone|2 mg of IV dilaudid will be administered over 2-3 minutes as initial dose.
3080423|NCT01429298|Active Comparator|Usual care|The attending physician administers whatever IV opioid he/she deems appropriate in whatever dose he/she chooses for initial dosing
3080424|NCT01429350|Active Comparator|IV rtPA|IV infusion of rtPA at 0.9mg/kg to a maximum of 90mg
3080425|NCT01429350|Experimental|IV rtPA and IA Penumbra System|Dual IV rtPA therapy (0.9mg/kg to a maximum of 90mg) and IA adjunctive treatment with the Penumbra System
3080426|NCT01429441|Experimental|Ocriplasmin|
3080427|NCT01429441|Sham Comparator|Sham injection|
3080428|NCT01429454|Placebo Comparator|Soybean-Corn Blend Capsule|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them.
3080429|NCT01429454|Experimental|Omega 3 long chain fatty acid|The Omega-3 Fatty Acid compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
3080430|NCT01429532||Group I|1.8-mm-incision-size phacoemulsification system
3080431|NCT01429532||Group II|2.2-mm-incision-size phacoemulsification system
3080432|NCT01429532||Group III|3.0-mm-incision-size phacoemulsification system
3080433|NCT01429584|Active Comparator|0.25% bupivacaine|interscalene nerve block with 0.25% bupivacaine
3080434|NCT01429584|Active Comparator|0.125% bupivacaine|interscalene nerve block with 0.125% bupivacaine
3080435|NCT01429623|Experimental|ladostigil hemitartrate|10mg ladostigil base
3080436|NCT01429623|Placebo Comparator|Placebo Control|drug product excipients
3080437|NCT01429792|Experimental|Single Arm|
3080438|NCT01429987|Experimental|plecanatide 0.3 mg|Subjects receive plecanatide 0.3 mg for 12 consecutive weeks
3080439|NCT01429987|Experimental|plecanatide 1.0 mg|Subjects receive plecanatide 1.0 mg for 12 consecutive weeks
3080440|NCT01429987|Experimental|plecanatide 3.0 mg|Subjects receive plecanatide 3.0 mg for 12 consecutive weeks
3080441|NCT01429987|Placebo Comparator|Placebo|Subjects receive placebo for 12 consecutive weeks
3080442|NCT01430091|Active Comparator|Prasugrel clinical formulation|A single 5-milligram (mg) prasugrel tablet administered orally by swallowing it whole on 1 occasion.
3080443|NCT01430091|Experimental|Prasugrel (ODT) - on tongue|A single 5-mg prasugrel orally disintegrating tablet (ODT) administered orally by placing it on top of the tongue and keeping it there until it disintegrates.
3080444|NCT01430091|Experimental|Prasugrel (ODT) - apple juice|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue followed by drinking approximately 180 milliliters (ml) apple juice within 1 minute after the tablet finishes disintegration.
3080445|NCT01430091|Experimental|Prasugrel (ODT) - chewed|A single 5-mg prasugrel ODT administered orally by placing it on top of the tongue, but then chewed and swallowed rather than waiting for it to disintegrate.
3080446|NCT01430091|Experimental|Prasugrel (ODT) - under tongue|A single 5-mg prasugrel ODT administered orally by placing it under (rather than on top of) the tongue and keeping it there until it disintegrates.
3080447|NCT01430104|Experimental|Teriparatide + Aspara-CA + Alfarol|Aspara-CA 600 milligrams (mg) and Alfarol 1.0 microgram (µg) administered orally once daily throughout the study. Teriparatide 20 µg administered subcutaneously once daily for 28 days during the Treatment Period.
3080448|NCT01430130|Experimental|All Study Participants|Half of the revised incision was treated with the embrace device. Half of the revised incision was treated according to the Investigator's standard of care. Participant served as his/her own control.
3080449|NCT01430169|Experimental|AA4500|"collagenase clostridium histolyticum (AA4500) contains purified collagenase AA4500 (clostridium histolyticum) consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.~2 injections of AA4500 0.58 mg were administered 24 hours apart."
3080450|NCT01430182|Experimental|Methadone 0.2 mg/kg|0.2 mg/kg methadone by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
3080451|NCT01430182|Active Comparator|Morphine 0.2 mg/kg|0.2 mg/kg morphine by actual body weight, administered over ten minutes, initiated after induction of anesthesia and endotracheal intubation complete.
3080452|NCT01430299|Other|Demineralized Bone Matrix|a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space
3080453|NCT01430299|Other|rh-BMP2|A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2
3080454|NCT01430325|Sham Comparator|Sea Level Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Sea Level Equivalent 1.2 atm abs (2.6 psig) breathing regular air 20-chamber excursion"
3080455|NCT01430325|Experimental|Sea Level Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Sea Level Equivalent 1.5 atm abs (6.2 psig) breathing 100% oxygen 20-minute chamber excursion"
3080456|NCT01430325|Sham Comparator|Altitude Equivalent 1.2 atm abs (air)|"Sham Chamber Session~Altitude Equivalent 1.2 atm abs (5.1 psig) breathing regular air 20-minute chamber excursion"
3080457|NCT01430325|Experimental|Altitude Equivalent 1.5 atm abs (O2)|"Hyperbaric Oxygen (1.5 atm abs)~Altitude Equivalent 1.5 atm abs (9.6 psig) breathing 100% oxygen 20-minute chamber excursion"
3080458|NCT01430403|Experimental|Omalizumab|Participants receive active omalizumab (Xolair®) injections and a placebo Flovent® Diskus® (fluticasone) inhaler. Each participant will receive omalizumab (Xolair®) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. In addition, all participants receive standardized specialist asthma care.
3080459|NCT01430403|Experimental|Inhaled Corticosteroid Boost Therapy (ICS)|Participants in this group, the Inhaled Corticosteroid (ICS) boost arm, receive active ICS and placebo omalizumab (Xolair®) injections. Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone will be used. In addition, all participants receive standardized specialist asthma care.
3080460|NCT01430403|Placebo Comparator|Placebo|The placebo group receive placebo omalizumab (Xolair®) injections and placebo Flovent® Diskus® (fluticasone) inhaler. In addition, all participants receive standardized specialist asthma care.
3080461|NCT01430442|Experimental|Treatment A: Rimegepant, 10 mg|Participants received a single dose (one capsule) of rimegepant 10 milligram (mg) orally and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3321089|NCT02016079|Experimental|Omega-3|a fruit drink containing omega-3
3321090|NCT02016079|Placebo Comparator|Fruit drink|the same fruit drink given in the experimental arm, but not containing omega-3
3080462|NCT01430442|Experimental|Treatment B: Rimegepant, 25 mg|Participants received a single dose (one capsule) of rimegepant 25 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3080463|NCT01430442|Experimental|Treatment C: Rimegepant, 75 mg|Participants received a single dose (one capsule) of rimegepant 75 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3080464|NCT01430442|Experimental|Treatment D: Rimegepant, 150 mg|Participants received a single dose (one capsule) of rimegepant 150 mg orally; and three rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3080465|NCT01430442|Experimental|Treatment E: Rimegepant, 300 mg|Participants received a single dose (two 150 mg capsules) of rimegepant 300 mg orally; and two rimegepant placebo-matching capsules, orally, anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3080466|NCT01430442|Experimental|Treatment F: Rimegepant, 600 mg|Participants received a single dose (four capsules of 150 mg each) of rimegepant 600 mg orally; anytime within 45 days of randomization, once they experienced a migraine headache of moderate to severe intensity.
3080467|NCT01430442|Placebo Comparator|Treatment P: Rimegepant Placebo-Matching Capsules|Participants received a single dose (4 capsules) of rimegepant placebo-matching capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
3080468|NCT01430442|Active Comparator|Treatment G: Sumatriptan 100 mg|Participants received a single dose (one capsule) of rimegepant-matching sumatriptan 100 mg orally and three rimegepant matching placebo capsules orally, anytime within 45 days of randomization once they experienced a migraine headache of moderate to severe intensity.
3080469|NCT01430455|Experimental|Tranylcypromine|Active, open-label tranylcypromine treatment
3080470|NCT01430468|Experimental|Glenoid Positioning System|For the patients randomized to the GPS group, the surgeon will be given the GPS patient specific instrumentation and a model of the glenoid surface showing the exact placement and fit of the GPS alignment instruments.
3080471|NCT01430468|No Intervention|Standard Group|Each surgeon will use their standard methods of pre-operative planning using the pre-operative x-rays and CT scan.
3080472|NCT01430559|Other|Meloxicam|
3080473|NCT01430559|Placebo Comparator|Placebo|2 Placebo capsules once a day for 12 weeks
3080474|NCT01430585|Experimental|A|
3080475|NCT01430585|Experimental|B|
3080476|NCT01430585|Active Comparator|C|
3080477|NCT01430611|Experimental|Sanofi Pasteur Meningococcal A+C Polysaccharide Vaccine|
3080478|NCT01430611|Active Comparator|Lanzhou Institute Meningococcal A+C Polysaccharide Vaccine|
3080479|NCT01430624|Experimental|PPRS video|Prevention of post sexual assault stress
3080480|NCT01430624|Active Comparator|PIRI video|Pleasant imagery and relaxation instruction
3080481|NCT01430624|No Intervention|Standard care|Treatment as usual
3080482|NCT01430741|Other|Implementation as Usual Case Management|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar"
3080483|NCT01430741|Other|Implementation as Usual Veterans|"Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition):MISSION-Vet has been developed to target mental health, substance abuse and related issues faced by homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources.~Implementation as Usual (IU) - standard training on the MISSION model via a 1.5 hour webinar. Staff then deliver MISSION to Veterans."
3080484|NCT01430741|Experimental|Getting to Outcomes Case Management|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform.
3080485|NCT01430741|Experimental|Getting to Outcomes Veterans|Getting To Outcomes (GTO) is used to strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. In GTO, staff receive ongoing technical assistance using the GTO implementation platform, that guides staff while delivering MISSION to Veterans.
3080486|NCT01430754|Experimental|tasimelteon|20 mg tasimelteon capsules
3080487|NCT01430754|Placebo Comparator|Placebo|Placebo capsules
3080488|NCT01430819|Experimental|Fluzone® Vaccine Group|Participants will receive the Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation
3080489|NCT01430819|Active Comparator|Fluzone® High-Dose Vaccine Group|Participants will receive the Influenza Virus Vaccine, Fluzone® High-Dose 2011-2012 Formulation.
3080490|NCT01431014|Active Comparator|"Dexamethasonelow-dose"|5mg
3080491|NCT01431014|Experimental|"Dexamethasonehigh-dose"|15mg
3080492|NCT01431079|Experimental|Health belief model based education|This experimental arm will provide an educational intervention designed to modify constructs of health belief model regarding HPV vaccine acceptability.
3080493|NCT01431079|Active Comparator|Knowledge-based education|This comparison arm will provide education based on knowledge regarding HPV vaccine acceptability.
3080494|NCT01431105|Experimental|Atorvasatin|Atorvastatin dose titration to maximum tolerated dose
3080495|NCT01431131|Active Comparator|Intrasocket graft|Positive control
3080496|NCT01431131|Experimental|Intrasocket plus facial overlay graft|Intrasocket cancellous allograft plus a facial overlay bovine xenograft
3080497|NCT01431144|Active Comparator|Connective tissue autograft|A connective tissue autograft harvested from the palate was grafted onto the facial of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
3080498|NCT01431144|Experimental|connective tissue allograft|An acellular dermal matrix allograft was grafted on the facial surface of a simultaneously placed dental implant and soft tissue thickness was measured at baseline and Time 4.
3080499|NCT01431170|Experimental|Besivance Treatment Group|Besivance™ ophthalmic suspension, 0.6%
3080500|NCT01431170|Active Comparator|Polytrim Treatment Group|Polytrim ophthalmic solution
3080501|NCT01431209|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3080502|NCT01431274|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
3080503|NCT01431274|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
3080504|NCT01431274|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
3080505|NCT01431274|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
3080506|NCT01431274|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
3080507|NCT01431287|Experimental|tiotropium+olodaterol high dose FDC|Once daily 2 puffs solution for inhalation Respimat
3080508|NCT01431287|Experimental|tiotropium+olodaterol low dose FDC|Once daily 2 puffs solution for inhalation Respimat
3080509|NCT01431287|Active Comparator|olodaterol|Once daily 2 puffs solution for inhalation Respimat
3080510|NCT01431287|Active Comparator|tiotropium low dose|Once daily 2 puffs solution for inhalation Respimat
3080511|NCT01431287|Active Comparator|tiotropium high dose|Once daily 2 puffs solution for inhalation Respimat
3080512|NCT01431300|Active Comparator|0.03 mmol/kg|FDA-approved dose for lower extremity arterial imaging
3080513|NCT01431300|Experimental|0.02 mmol/kg|
3080514|NCT01431300|Experimental|0.01 mmol/kg|
3080515|NCT01431313|Experimental|Inhaled Nitrite|Sodium Nitrite Inhalation Solution (AIR001) 45mg dosage with one subsequent escalation dosage of 90mg based on tolerability.
3080516|NCT01431339|Active Comparator|Vancomycin with possible switch to oral linezolid|
3080517|NCT01431339|Experimental|Dalbavancin|
3080518|NCT01431391|Experimental|Arm 1: Sipuleucel-T followed by ADT|Arm 1: Subjects received one infusion of sipuleucel-T every two weeks for a total of three infusions. Two weeks after the third sipuleucel-T infusion, subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg). An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT.
3080519|NCT01431391|Experimental|Arm 2: ADT followed by sipuleucel-T|Arm 2: Subjects started ADT with 45 mg leuprolide acetate depot injection (Eligard® 45 mg) 12 weeks before infusion 1 of sipuleucel-T. An additional leuprolide acetate injection was administered at 6 months after the first injection for a total of 2 injections and 12 months of ADT. Twelve weeks after the initial leuprolide 45 mg depot injection, subjects began one infusion of sipuleucel-T every two weeks for a total of three infusions.
3080520|NCT01431508|Experimental|Losartan 50 mg / HCTZ 12.5 mg|Participants with mild to moderate essential hypertension who will receive Losartan 50 mg / HCTZ 12.5 mg once-a-day for 12 weeks.
3080521|NCT01431521|Experimental|MK-4074|Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks.
3080522|NCT01431521|Placebo Comparator|Placebo for MK-4074|Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks.
3080523|NCT01431521|Experimental|Pioglitazone|Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks.
3080524|NCT01431521|Placebo Comparator|Placebo for pioglitazone|Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks.
3080525|NCT01431534|Experimental|Ridaforolimus 22 mg/m^2|Participants receive 22 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
3080526|NCT01431534|Experimental|Ridaforolimus 28 mg/m^2|Participants receive 28 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
3080527|NCT01431534|Experimental|Ridaforolimus 33 mg/m^2|Participants receive 33 mg/m^2 of ridaforolimus administered orally for 5 consecutive days each week (2 days rest) in consecutive 28-day cycles for up to six months. Eligible participants can receive additional treatment in an extension phase of the study.
3080528|NCT01431573|Experimental|Wake Therapy + light box +/- lithium|"Bipolar patients must take lithium; others do not take lithium~all patients are hospitalized for a week during which they do not sleep on alternating nights~for six weeks, including the week in the hospital all patients sit in front of bright lights at specified times and for specified durations"
3080529|NCT01431638|Experimental|Canakinumab 150mg|Canakinumab 150mg in prefilled syringe subcutaneously
3080530|NCT01431716|Experimental|EFI/ACT-385781A|EFI/ACT-385781 administered by continuous intravenous infusion via a central venous catheter using an ambulatory infusion pump
3080531|NCT01431755|Other|Restylane SubQ|
3080532|NCT01431755|Other|Restylane SubQ Lidocaine|
3080533|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-600mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 600 mg daily.
3080534|NCT01431794|Active Comparator|Phase II-Arm A:Gem,nab-paclitaxel,LDE225|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
3080535|NCT01431794|Active Comparator|Phase II-Arm B:Gem,nab-paclitaxel|Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days.
3080536|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-400mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 400 mg daily.
3080537|NCT01431794|Experimental|Phase I-Gem,nab-paclitaxel,LDE225-800mg|Four cycles of Gemcitabine (gem) 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2 on days 1, 8, and 15 every 28 days cycle in combination with escalating doses of oral LDE225 (Sonidegib), 800 mg daily.
3321091|NCT02016092||Patients with Parkinson's disease|
3321092|NCT02016092||Healthy Controls|
3468881|NCT03891602||Smokers/Former Smokers|Current smoker or former smoker who has quit within the past 15 years
3080538|NCT01431846|No Intervention|Discharge Patient|Eight patients who were being discharged from Denver VA Medical Center for cardiac care to their primary care providers were recruited at the time of discharge and completed an interview two weeks following their discharge. Patients were asked to describe their transition to home and identify barriers and facilitators of this process, their understanding of their medical condition, new medications prescribed, timeliness of follow-up visit with their PCP and knowledge of signs/symptoms in which they should seek medical attention.
3080539|NCT01431846|No Intervention|Providers|Three providers who refer patients to the Denver VA Medical Center for cardiac care were interviewed to identify barriers and facilitators from their perspective of following-up with patients after their hospitalization at Denver VAMC. Additionally, the same information was asked of providers who participated in two focus groups in the Grand Junction VA.
3080540|NCT01431846|Experimental|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
3080541|NCT01431950|Experimental|FF 100mcg once daily|Inhaled corticosteroid (ICS)
3080542|NCT01431950|Experimental|FF 200mcg once daily|Inhaled corticosteroid
3080543|NCT01431963|Experimental|Lamotrigine|No comparison.
3080544|NCT01431976|Experimental|Lamotrigine|No comparison
3080545|NCT01431989|Active Comparator|Test formulation|Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.
3080546|NCT01431989|Active Comparator|Reference formulation|Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2
3080547|NCT01432015|Active Comparator|Fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Oral Placebo given on days 1-3
3080548|NCT01432015|Active Comparator|Aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. 100 cc of IV placebo administered on day 1
3080549|NCT01432145|Experimental|6MP/MTX|6-Mercaptopurine 55mg/m2 per day, and methotrexate 15mg/m2 per week
3080550|NCT01432171|Experimental|Arm I (lacosamide)|Participants receive lacosamide PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
3080551|NCT01432171|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO BID for up to 1 year. Treatment continues in the absence of disease progression or unacceptable toxicity.
3080552|NCT01432236|Experimental|Pregabalin|Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)
3080553|NCT01432236|Placebo Comparator|Placebo|Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)
3080554|NCT01432262|Experimental|Group 1|=> 65 years of age
3080555|NCT01432262|Experimental|Group 2|50 to 64 years of age
3080556|NCT01432275|Experimental|ADC, Then Comparator, Then ADC With Calculator|Subject used the ADC blood glucose meter for 7 days with the insulin calculator not activated, followed by a comparator blood glucose meter for 7 days. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
3080557|NCT01432275|Experimental|Comparator, Then ADC, Then ADC With Calculator|Subject used a comparator blood glucose meter for 7 days, followed by the ADC blood glucose meter for 7 days, with the insulin calculator not activated. For the last 10 days the subject used the ADC blood glucose meter with insulin calculator active.
3080558|NCT01432327|Placebo Comparator|Control group|This group receives no kind of feedback during the intervention period. The participants wear the SenseWear Armband for 4 weeks and results of the intervention are discussed after the 4 week intervention period.
3080559|NCT01432327|Experimental|Step Group|This group receives feedback about the daily amount of steps by means of a pedometer.
3080560|NCT01432327|Experimental|Display Group|Participants receive real time feedback on their energy expenditure, minutes of physical activity and step count by means of the SenseWear Display
3080561|NCT01432327|Experimental|Coaching Group|Participants receive real-time feedback on their energy expenditure, step count and minutes of physical activity by means of the SenseWear Display and weekly meet with a Personal Coach to discuss their progress
3080562|NCT01432366||Rheumatoid arthritis patients treated with SC anti-TNF|
3080563|NCT01432379||botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
3080564|NCT01432405|Experimental|Pioglitazone and exenatide|Exenatide 10 micrograms injected subcutaneously twice daily plus pioglitazone 45 mg daily orally for 12 months.
3080565|NCT01432405|Experimental|Pioglitazone|Pioglitazone 45 mg daily orally for 12 months
3080566|NCT01432444|Experimental|OPC-14597|Aripiprazole IM depot injection 300 mg or 400 mg.
3080567|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 50 mg/day|
3080568|NCT01432457|Experimental|desvenlafaxine succinate sustained-release 100 mg/day|
3080569|NCT01432457|Placebo Comparator|Placebo|
3080570|NCT01432535|Active Comparator|Healthy Participants|Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3080571|NCT01432535|Experimental|Participants with Moderate Renal Impairment|Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3080572|NCT01432535|Experimental|Participants with Severe Renal Impairment|Participants with severe renal impairment defined as having a creatinine clearance test value of <30 mL/min/1.73 m^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.
3080573|NCT01432561|Experimental|Cysteamine bitartrate|Cysteamine bitartrate, 500mg once a day, three days.
3080574|NCT01432574|Experimental|Gardasil Vaccine|Vaccine Administration: A total of 3 injections (shots) at 3 separate visits.
3080575|NCT01432600|Experimental|A: Dose Escalation of Cyclophosphamide|"Phase I: Pomalidomide, high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg by mouth (PO) days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Dose Escalation of Cyclophosphamide, orallly (PO) days 1, 8, 15 as follows:~Level 1: 300 mg; Level 2: 400 mg; Level 3: 500 mg.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3080576|NCT01432600|Active Comparator|B: Pomalidomide and Dexamethasone|"Randomized Phase II - Pomalidomide high dose dexamethasone:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3080577|NCT01432600|Active Comparator|C: Pomalidomide/Dexamethasone/Cyclophosphamide|"Randomized Phase II - Pomalidomide high dose dexamethasone and oral cyclophosphamide:~Pomalidomide 4 mg PO days 1-21 of a 28 days cycle.~Dexamethasone 40* mg PO days 1- 4, 15-18 of a 28 days cycle for the first 4 cycles and subsequently 40 mg PO Days 1,8,15, 22. *Participants who were >75 years of age or those who were known to be intolerant to 40 mg weekly dexamethasone received 20 mg dexamethasone on the same schedule.~Cyclophosphamide 400 mg PO days 1, 8, 15.~Aspirin 81 mg PO daily (unless the participants had contraindications or were receiving other form of anticoagulation for other indications)."
3080578|NCT01432600|Other|D: Crossover|Crossover from Arm B to Arm D. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician, in which case oral weekly Cyclophosphamide (400 mg orally on days 1, 8, and 15) was added to their tolerated dose of pomalidomide and dexamethasone.
3080579|NCT01432626|Experimental|Stress Induced Cardiomyopathy Patients|Patients presenting with stress induced cardiomyopathy, after meeting the Mayo criteria (normal coronary anatomy, EKG changes/Enzyme abnormalities, wall motion abnormalities consistent with stress induced cardiomyopathy and no evidence of pheochromocytoma) and signing informed consent, will receive an I123-mIBG scan to determine the sympathetic function of the heart during the acute presentation and after functional recovery.
3080580|NCT01432730|Experimental|Gefapixant 600 mg>Placebo|Gefapixant, 600 mg, twice daily (BID), taken orally for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, taken orally for 2 weeks.
3080581|NCT01432730|Experimental|Placebo>Gefapixant 600 mg|Placebo to gefapixant BID, taken orally for 2 weeks followed by a 2-week washout period and then gefapixant, 600 mg, BID, taken orally for 2 weeks.
3080582|NCT01432756|No Intervention|Wait-list control|Participants in the wait-list control group will not receive the intervention until after the 3-month follow-up assessment.
3080583|NCT01432756|Experimental|Let's Talk Worskite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
3080584|NCT01432886|Experimental|1|
3080585|NCT01432938|Experimental|Warfarin first, then Dulaglutide + Warfarin|A single, 10-milligram (mg) dose of warfarin administered orally on Day 1 (Treatment 1). There was a washout period of at least 24 days between treatment periods. Then a single, 1.5-mg dose of dulaglutide administered subcutaneously on Day 1, followed by a single, 10-mg dose of warfarin administered orally on Day 3 (Treatment 2).
3080586|NCT01432938|Experimental|Dulaglutide + Warfarin first, then Warfarin|A single, 1.5-mg subcutaneous dose of dulaglutide on Day 1, followed by a single, 10-mg oral dose of warfarin on Day 3 (Treatment 2). There was a washout period of at least 24 days between treatment periods. Then a single, 10-mg oral dose of warfarin on Day 1 (Treatment 1).
3080587|NCT01432951|Experimental|Enzastaurin|"Enzastaurin 500 mg, four 125-mg tablets administered orally once daily for 14 days. Dosing is held for 3 days, and resumes on Day 18. Participants may continue receiving optional enzastaurin for an additional 2 to 4 weeks.~Safety Extension: Participants had the option to continue receiving enzastaurin until disease progression or discontinuation criteria are met, as per the investigator's assessment."
3080588|NCT01433016|Experimental|Octanaote Breath Test|A Octanoate breath test will be performed on this single arm population
3080589|NCT01433042|Experimental|capsule endoscopy|
3080590|NCT01433055|Active Comparator|Minocycline|
3080591|NCT01433055|Placebo Comparator|Sugar Pill|
3080592|NCT01433081|Active Comparator|Magnesium sulfate infusion|Administration of magnesium suflate
3080593|NCT01433081|Placebo Comparator|Placebo|.9 normal saline infusion
3080594|NCT01433107|Experimental|Terbinafine|Drug
3080595|NCT01433107|Placebo Comparator|Placebo|Drug
3080596|NCT01433159|Experimental|HP011-101|
3080597|NCT01433159|Active Comparator|Various|Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
3080598|NCT01433172|Experimental|Phase I Vaccinations|Participants enrolled in the Phase I trial will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note for the phase I portion: the use of steroid medication is to be avoided for 4 weeks prior to the initiation of vaccine therapy and during the vaccine treatment period.
3080599|NCT01433172|Active Comparator|Phase II Arm A Vaccinations|Arm A participants will receive GM.CD40L cells vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
3080600|NCT01433172|Active Comparator|Phase II Arm B Vaccinations|Arm B participants will receive GM.CD40L.CCL21 vaccinations on 3 occasions, at 2 week intervals. Note on either Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period.
3080601|NCT01433250|Experimental|AIN 457 Core|(10mg/kg i.v.). AIN 457 core study /AIN 457 Extension
3080602|NCT01433250|Experimental|AIN457 Placebo Core|(10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension
3080603|NCT01433263|Experimental|30mg/kg BYM338|
3080604|NCT01433263|Placebo Comparator|Placebo / late 30mg/kg BYM338|
3080605|NCT01433354|Experimental|AFQ056 Treatment|All patients will initiate treatment with AFQ056 at a starting dose of 25 mg b.i.d. The dose will be titrated from 25 mg b.i.d to 50 mg b.i.d., 75 mg b.i.d. and 100 mg b.i.d. at weekly intervals. Dose adjustments (up- and down-titrations) will be permitted as needed to manage any tolerability issues and to ensure that patients reach their highest tolerated dose, not to exceed 100 mg b.i.d.
3080606|NCT01433549|Other|Lotrafilcon B / Senofilcon A|Lotrafilcon B worn first, with senofilcon A worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
3080607|NCT01433549|Other|Senofilcon A / Lotrafilcon B|Senofilcon A worn first, with lotrafilcon B worn second, as randomized. Each product was worn bilaterally in 2-hour intervals, separated by lens-free (recovery) intervals of either 0, 30, 60, or 80 minutes, over the course of a 12-hour day, for a total of 4 cycles (days).
3080608|NCT01433731|Placebo Comparator|placebo for SHAPE (SHP-141)|placebo for SHAPE (SHHP-141) topical gelled solution
3080609|NCT01433731|Experimental|SHAPE (SHP-141) 0.1%BID|SHAPE (SHP-141) topical gelled solution at 0.1% concentration twice weekly
3080610|NCT01433731|Experimental|SHAPE (SHP-141) 0.5% BID|SHAPE (SHP-141) topical gelled solution at 0.5% concentration twice weekly
3080611|NCT01433731|Experimental|SHAPE (SHP-141) 1.0% BID|SHAPE (SHP-141) topical gelled solution at 1.0% concentration twice weekly
3080612|NCT01433913|Experimental|Arm I (metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 4-12 weeks.
3080613|NCT01433913|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-12 weeks.
3080614|NCT01433978|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
3080615|NCT01433978|Active Comparator|Eltrombopag (Core Study)|Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.
3080616|NCT01433978|Experimental|Avatrombopag (Open-label Extension)|Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.
3080617|NCT01433991|Experimental|Phase 1B|Participants with unresectable advanced or metastatic solid tumors will receive E7050 in combination with lenvatinib to identify a Maximum Tolerated Dose. Dose escalation will begin at low doses of both E7050 and lenvatinib, and then gradually increase in future cohorts until a recommended combination dose is identified. A dose of E7050 and lenvatinib to be used in combination in Phase 2 will be recommended (RP2 dose). Participants will continue on treatment until disease progression, development of unacceptable toxicity, or withdrawal of consent.
3080618|NCT01433991|Experimental|Phase 2 Cohort 1 Arm A:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive E7050 and lenvatinib at the RP2 dose.
3080619|NCT01433991|Experimental|Phase 2 Cohort 1 Arm B:|Participants with recurrent glioblastoma (bevacizumab-naïve) will receive single agent lenvatinib 24 mg/day (1*4 mg capsule + 2*10 mg capsule) and at time of progression, E7050 add-on therapy at the RP2 dose (in combination with lenvatinib at dose of either the RP2 dose or the most recent dose of single agent lenvatinib, whichever is the lowest).
3080620|NCT01433991|Experimental|Phase 2 Cohort 2 Arm C:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive E7050 and lenvatinib at the RP2 dose.
3080621|NCT01433991|Experimental|Phase 2 Cohort 2 Arm D:|Participants with unresectable Stage III or Stage IV melanoma and disease progression after prior systemic treatment will receive single agent E7050 400 mg/day.
3080622|NCT01434030|Other|Behavioral Observer|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
3080623|NCT01434121|Active Comparator|High Dose Ascorbic Acid|Subject receives a high dose of infused Vitamin C
3080624|NCT01434121|Active Comparator|Low Dose Ascorbic Acid|Subject receives a low dose of infused Vitamin C
3080625|NCT01434121|Placebo Comparator|Placebo|Subject receives an infusion of saline
3080626|NCT01434186|Experimental|Arm 1: Saxagliptin +Metformin XR/IR|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight) Metformin XR/IR 1000 mg-2000 mg
3080627|NCT01434186|Placebo Comparator|Arm 2: Placebo +Metformin XR/IR|Placebo matching saxagliptin 0 mg Metformin XR/IR 1000 mg - 2000 mg
3080628|NCT01434290|Experimental|5 Fractions|36.25 Gy IMRT in 5 fractions over two and a half weeks
3080629|NCT01434290|Experimental|12 Fractions|51.6 Gy IMRT in 12 fractions over two and a half weeks
3080630|NCT01434342|Experimental|Arm I - Quitline|"Participants receive a letter from their physician advising them to quit smoking, and undergo a 15-30-minute smoking-cessation counseling session by a trained research staff.~The participants are educated and motivated about the importance of quitting smoking, and cancer-specific quitting issues. They will be called by Quitline in 2-3 days and receive a fact sheet about benefits of SC for cancer patients.~Participants receive 8 weeks of nicotine replacement patches and up to 5 proactive telephone calls over a 12-week period.~Participants also learn behavioral tips and coping skills."
3080631|NCT01434342|No Intervention|Arm II - Usual Care|"Participants receive a letter from their physician advising them to quit smoking, the importance of quitting smoking for cancer patients, and a copy of the National Cancer Institute's Clearing the Air smoking cessation booklet. Participants also receive standard of care from their oncology and other treatment providers which may or may not include nicotine replacement therapy."
3080632|NCT01434472|Experimental|Treatment (radiolabeled antibody, TBI, allogeneic PBSCT)|Beginning 24-48 hours prior to therapy infusion, patients receive rituximab IV over 4-6 hours and then receive a therapy-dose of high-dose yttrium Y 90 ibritumomab tiuxetan IV over 30 minutes on day -14 prior to transplant. Patients also receive fludarabine phosphate IV on days -4 to -2 and undergo TBI followed by allogeneic PBSCT on day 0. Patients also receive cyclosporine PO BID on days -3 to 56 with taper to day 180 (related donor) or -3 to 100 with taper over 11 weeks (unrelated donor) and mycophenolate mofetil PO BID on days 0-27 (related donor) or PO TID on days 0-40 with taper to day 96 (unrelated donor).
3080633|NCT01434641|Other|low-dose stress MPI SPECT|Patients will receive a low-dose stress/high-dose rest protocol. Subject results are compared to archived patients undergoing a standard protocol./
3080634|NCT01434654||Non Neuro-HAART (low CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
3080635|NCT01434654||Neuro-HAART (high CNS penetrance)|Participants will be assessed based on their current Highly Active Antiretroviral Treatment (HAART). A scoring system is utilised to determine if their current treatment has high Central Nervous System (CNS) penetrance or low CNS penetrance. This will determine which study cohort they are allocated to. No treatment adjustments or changes will be made, they will remain on their usual HAART regimen.
3080636|NCT01434667|Active Comparator|APOE Genotype Non-Disclosure|Subjects will receive Alzheimer's disease risk disclosure. This assessment is based on age and MCI status alone.
3080637|NCT01434667|Experimental|APOE Genotype Disclosure|Subjects will receive both APOE genotype and Alzheimer's disease risk disclosure. The assessment is based on age, MCI status, and genotype.
3080638|NCT01434680|Experimental|MenC-CRM LIQ (Liquid Formulation)|Subjects received 1 injection of MenC-CRM vaccine,liquid formulation.
3080639|NCT01434680|Experimental|MenC-CRM ROS (Rosia)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy
3080640|NCT01434680|Active Comparator|MenC-CRM EMV (Emeryville)|Subjects received 1 injection of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA
3080641|NCT01434693|Experimental|TSO 500|
3080642|NCT01434693|Experimental|TSO 2500|
3080643|NCT01434693|Experimental|TSO 7500|
3080644|NCT01434693|Placebo Comparator|Placebo|single dose
3080645|NCT01434810|Experimental|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
3080646|NCT01434810|Active Comparator|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
3080647|NCT01434823|Experimental|Intervention - nocturnal coverage|Nocturnal coverage from intensivists will be randomized by week. The weeks that have intensivists in the MICU during the 7pm to 7am shift are the intervention weeks.
3080648|NCT01434823|No Intervention|Control - standard of care|The weeks that are not randomized, the intervention arm will retain the current standard of care in the HUP MICU: attending intensivist availability by phone (home call).
3080649|NCT01435018|Experimental|ET+ART|Etoposide (ET) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
3080650|NCT01435018|Experimental|BV+ART|Bleomycin and Vincristine (BV) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
3080651|NCT01435018|Active Comparator|PTX+ART|Paclitaxel (PTX) plus co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)
3080652|NCT01435031|Other|CTO Treatment|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
3080653|NCT01435122|Experimental|Axitinib Administration|"The investigational drug used in this study is axitinib, and is available as tablets.~You will take the tablet orally with food. Doses should be taken around 12 hours apart continuously, without scheduled breaks. If you vomit anytime after taking a dose do not take another tablet to make up the dose but instead continue taking your next dose as planned.~Any missed dose may be taken late (up to 3 hours before the next scheduled dose); otherwise it should be skipped. If doses are missed or vomited, please keep track of this and report at your next visit."
3080654|NCT01435174|Experimental|Ranolazine|End-stage renal disease patients receiving a single-dose of ranolazine and a concomitant hemodialysis session.
3080655|NCT01435265|Active Comparator|Normal Nurse Education|Subjects receive normal nurse education materials provided by their physician.
3080656|NCT01435265|Experimental|Additional Nurse Education-|Subjects will receive additional nurse education beyond the normal education materials provided by their physician
3080657|NCT01435304|Experimental|Hemobag®|Hemobag® method of returning residual CPB blood (study group)
3080658|NCT01435304|No Intervention|cell saver|Standard method of returning the residual pump volume to the patient as washed, centrifuged cells (control group)
3080659|NCT01435356|Active Comparator|recMage-A3 + AS15 ASCI|MAGE-A3 positive patients treated with recMAGE-A3 + AS15 ASCI
3080660|NCT01435356|Placebo Comparator|Placebo|MAGE-A3 positive patients treated with placebo
3080661|NCT01435382|Experimental|Group A|
3080662|NCT01435382|Experimental|Group B|
3080663|NCT01435382|Experimental|Group C|
3080664|NCT01435382|Experimental|Group D|
3080665|NCT01435460|Experimental|Alrex|Ophthalmic formulation containing the active ingredient loteprednol etabonate, 0.2%
3080666|NCT01435460|Active Comparator|Patanol|Ophthalmic solution containing olopatadine, 0.1%
3080667|NCT01435512|Experimental|Group|PTSD-Focused Cognitive Behavioral Therapy for Partner Violence
3080668|NCT01435512|No Intervention|Waitlist|Control group - no intervention
3080669|NCT01435577|Experimental|Tapentadol intravenous|Tapentadol will be given by intravenous infusion. Tapentadol will be administered every 4 hours. Ibuprofen 600 mg orally may be given as rescue medication for pain not controlled by Tapentadol alone.
3080670|NCT01435577|Placebo Comparator|Matching placebo intravenous|Placebo (0.9% sodium chloride and water for injection). Ibuprofen 600 mg orally may be given as rescue medication for pain.
3080671|NCT01435603|Active Comparator|Standard Lifestyle Advice|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant).
3080672|NCT01435603|Experimental|Advice Plus Lifestyle Intervention|Primary care-based identification of pre-diabetes and/or type 2 diabetes with standard clinical education (offered by participant's usual primary care providers) and brief lifestyle advice (delivered by a study Research Assistant) Plus access to an intensive group-based lifestyle intervention offered in a community setting.
3080673|NCT01435616|Experimental|LY2605541|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC), once daily in combination with at least 2 pre-study oral antihyperglycemic medications (OAMs) prescribed by the personal physician, for 52 or 78 weeks
3080674|NCT01435616|Active Comparator|Glargine|Glargine titrated based on blood glucose readings, administered SC, once daily in combination with at least 2 pre-study OAMs prescribed by the personal physician, for 52 or 78 weeks
3080675|NCT01435655|Experimental|open|tafamidis
3080676|NCT01435759|Experimental|Antidepressant + SPD489 10 mg|
3080677|NCT01435759|Experimental|Antidepressant + SPD489 30 mg|
3080678|NCT01435759|Experimental|Antidepressant + SPD489 50 mg|
3080679|NCT01435759|Experimental|Antidepressant + SPD489 70 mg|
3080680|NCT01435759|Placebo Comparator|Antidepressant + Placebo|
3080681|NCT01435772|Experimental|BMN 701 20mg/kg|BMN 701 20mg/kg IV every other week
3080682|NCT01435772|Experimental|BMN 701 10mg/kg|BMN 701 10mg/kg IV every other week
3080683|NCT01435772|Experimental|BMN 701 5mg/kg|BMN 701 5mg/kg IV every other week
3080684|NCT01435798|Placebo Comparator|0% MTD Dex|0% MTD Dextromethorphan
3080685|NCT01435798|Experimental|25% MTD Dex|25% MTD Dextromethorphan
3080686|NCT01435798|Experimental|50% MTD Dex|50% MTD Dextromethorphan
3080687|NCT01435798|Experimental|100% MTD Dex|100% MTD Dextromethorphan
3080688|NCT01435824|Active Comparator|Water as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml water and orally administered in a fasting state.
3080689|NCT01435824|Experimental|Human milk as a vehicle of amoxicillin|Amoxicillin 500 mg was dissolved in 10 ml human milk and orally administered in a fasting state.
3080690|NCT01435928|Experimental|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
3080691|NCT01435928|Placebo Comparator|Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
3080692|NCT01436006||CT scan|patient with cancer
3080693|NCT01436045|Experimental|Insulin glulisine|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
3080694|NCT01436045|Placebo Comparator|Saline|A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
3080695|NCT01436071|Experimental|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
3080696|NCT01436071|Placebo Comparator|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
3080697|NCT01436110|Experimental|Fluticasone furoate 50 mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
3080698|NCT01436110|Active Comparator|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ ACCUHALER
3080699|NCT01436110|Placebo Comparator|Placebo|Inhalation Powder via Novel Dry Powder Inhaler and DISKUS/ ACCUHALER
3080700|NCT01436149|Experimental|Antidepressant + SPD489|
3080701|NCT01436149|Placebo Comparator|Antidepressant + Placebo|
3080702|NCT01436162|Experimental|Antidepressant + SPD489|
3080703|NCT01436162|Placebo Comparator|Antidepressant + Placebo|
3080704|NCT01436175|Experimental|SPD489 + Antidepressant|
3080705|NCT01436201|Experimental|Digoxin + Dulaglutide|"Digoxin: Two 0.5-milligram (mg) doses, oral, 12 hours apart on Day 1 (1 mg total on Day 1); 0.25 mg, oral, once daily on Day 2 to Day 17.~Dulaglutide (LY2189265): 1.5 mg, subcutaneous injection, once on Day 8 and once on Day 15."
3080706|NCT01436253||Croatian participants with hyperlipidemia|Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
3080707|NCT01436266|Active Comparator|Misoprostol|400 mcg buccally 2 hours prior to procedure
3080708|NCT01436266|Placebo Comparator|Placebo (Folic acid)|Two 1-mg tablets buccally 2 hours prior to procedure
3080709|NCT01436279|Experimental|Mifepristone + misoprostol|Mifepristone 200 mg PO given 20-24 hours prior to procedure, misoprostol 400 mcg given 2 hours prior to procedure
3080710|NCT01436279|Active Comparator|Osmotic dilators|Placed 20-24 hours prior to procedure
3080711|NCT01436305|Active Comparator|Tac maintenance|"Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)"
3468882|NCT03891628|Experimental|Modified ABC|Modified Attachment and Biobehavioral Catch-Up (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
3080712|NCT01436305|Experimental|Belatacept maintenance|"Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)"
3080713|NCT01436305|Experimental|Basiliximab induction/Short-term Tac|"Short term = 3 months~Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).~Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)"
3080714|NCT01436357|Experimental|Arm A (Stage I and II)|Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose at day 0 followed by 1 dose of MVA-NSmut intramuscularly 56 days later at the dosage 1.8 x10^8 plaque forming units (pfu): 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
3080715|NCT01436357|Placebo Comparator|Arm B (Stage I and II)|Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56: 34 (+/-2) subjects Stage I, then 191 (+/-2) subjects at Stage II.
3080716|NCT01436370|Experimental|Group 1 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
3080717|NCT01436370|Experimental|Group 2|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
3080718|NCT01436370|Experimental|Group 2 Controls|40 (up to 50) adults, healthy gender and age-matched controls, given a single 60 mcg intramuscular dose of Sanofi Pasteur Fluzone® High Dose.
3080719|NCT01436370|Experimental|Group 1|40 (up to 50) adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy, given a single 15 mcg intramuscular dose of Sanofi Pasteur Fluzone®
3080720|NCT01436396|Experimental|CYD Dengue Vaccine Group|Participants received the Stamaril® and the CYD dengue vaccine (Injection 1) at enrolment (Month [M] 0) at age 12 to 13 months; measles, mumps and rubella vaccine, pneumococcal conjugated vaccine, hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); diphtheria, tetanus, acellular pertussis, inactivated polio and Haemophilus influenza type b (DTaP-IPV/Hib) vaccine at M7 (age 19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
3080721|NCT01436396|Experimental|Placebo Group|Participants received the Stamaril® vaccine and placebo matched to CYD vaccine (Injection 1) at enrolment (M0) (age 12 to 13 months); measles, mumps, and rubella vaccine, pneumococcal conjugate vaccine and hepatitis A vaccine at M1 (age 13 to 14 months); CYD dengue vaccine (Injection 2) at M6 (age 18 to 19 months); DTaP IPV/Hib vaccine at M7 (age19 to 20 months); and CYD dengue vaccine (Injection 3) at M12 (age 24 to 25 months); and hepatitis A vaccine at M13 (age 25 to 26 months).
3080722|NCT01436435|Experimental|Jetstream Atherectomy System|Patients with symptomatic peripheral vascular disease undergoing percutaneous intervention including Atherectomy utilizing the Jetstream Atherectomy System with or without adjunctive therapy.
3080723|NCT01436500|Experimental|5 mg ifetroban, Type 1|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3080724|NCT01436500|Placebo Comparator|Placebo, Type 1|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.
3080725|NCT01436500|Experimental|5 mg ifetroban, Type 2|60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3080726|NCT01436500|Experimental|15 mg ifetroban, Type 1|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3080727|NCT01436500|Experimental|15 mg ifetroban, Type 2|60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3080728|NCT01436500|Experimental|50 mg ifetroban, Type 1|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
3080729|NCT01436500|Experimental|50 mg ifetroban, Type 2|60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3080730|NCT01436500|Experimental|150 mg ifetroban, Type 2|60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
3080731|NCT01436500|Placebo Comparator|Placebo, Type 2|60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.
3080732|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 2*5 mg, then 1*10 mg|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
3080733|NCT01436526|Experimental|Rivaroxaban (Xarelto, BAY59-7939) first 1*10 mg, then 2*5 mg|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
3080734|NCT01436643|Experimental|Fluoxetine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Fluoxetine, supplied in blistered packs containing 20 tablets; starting dose 20 mg; final dose 40 mg
3080735|NCT01436643|Experimental|Venlafaxine and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Venlafaxine, supplied in blistered packs containing 14 capsules; starting dose 75 mg; final dose 150 mg
3080736|NCT01436643|Experimental|Citalopram and Fingolimod|Fingolimod 0.5 mg per capsule(hard gelatin capsules) was taken p.o. once daily. Citalopram, supplied in blistered packs containing 20 tablets; starting dose 20 mg, final dose 40 mg
3080737|NCT01436799|Experimental|Desflurane|anaesthesia was induced with thiopental sodium 2 mg kg-1, alfentanil 10 μg kg-1 and rocuronium 0.6 mg kg-1. Anesthetic maintenance by desflurane
3080738|NCT01436799|Active Comparator|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1, alfentanil 10 μg kg-1, and rocuronium 0.6 mg kg-1. A commercially available target controlled infusion (TCI) pump (Orchestra®, Fresenius Vial, France) was used and the pharmacokinetic set used to calculate target effect-site concentrations for propofol was Schnider and colleagues' model
3080739|NCT01437098|Experimental|MDT-2111 CoreValve TAVI|Transcatheter Aortic Valve Implantation (TAVI) with MDT-2111 CoreValve system. Access sites for the implant include: Iliofemoral, Subclavian and Direct Aortic.
3080740|NCT01437111|Experimental|Fosamax Plus|Calcium supplement (elemental calcium and/or calcium carbonate) without vitamin D will also be supplied to participants
3080741|NCT01437124||Ceramic on metal THA|Those who have received a ceramic on metal total hip replacement
3080742|NCT01437267|Experimental|Vi-CRM, Older infants|Older Infants (9 to 12 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3080743|NCT01437267|Active Comparator|PNC13, Older infants|Older infants (9 to 12 months) receiving 2 doses of Pneumococcal conjugate vaccine
3080744|NCT01437267|Experimental|Vi-CRM, Infants|Infants (6 to 8 weeks) receiving 3 doses of NVGH Vi-CRM197 vaccine
3080745|NCT01437267|Active Comparator|PNC13, Infants|Infants (6 to 8 weeks) receiving 3 doses of Pneumococcal conjugate vaccine
3080746|NCT01437267|Experimental|Vi-CRM, Children|Children (24 to 59 months) receiving 2 doses of NVGH Vi-CRM197 vaccine
3080747|NCT01437267|Active Comparator|Vi-PS, Children|Children (24 to 59 months) receiving 1 dose of licensed Vi Polysaccharide vaccine and 1 dose of Pneumococcal conjugate vaccine
3080748|NCT01437319|Active Comparator|lotrafilcon A, comfilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to comfilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
3080749|NCT01437319|Active Comparator|lotrafilcon A, balafilcon A|All subjects are assigned to lotrafilcon A during a run-in (Phase 1) and then randomized to one of two lenses. This arm is assigned to balafilcon A at phase 2. Subjects classified as a Neophyte wore etafilcon A for 2-weeks before entering the run-in period in Phase I.
3080750|NCT01437397|Experimental|1|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/12μg
3080751|NCT01437397|Experimental|2|Aclidinium/formoterol Fixed Dose Combination (FDC) 400/6μg
3080752|NCT01437397|Active Comparator|3|Aclidinium monotherapy 400 μg
3080753|NCT01437397|Active Comparator|4|Formoterol monotherapy 12 μg
3080754|NCT01437397|Placebo Comparator|5|Placebo
3080755|NCT01437423|Experimental|TETRAXIM™ vaccine|Participants will receive a primary or booster dose of TETRAXIM™
3080756|NCT01437449|Experimental|Cisplatin + Docetaxel + Cetuximab|Patients will be treated weekly with cisplatin, docetaxel, and cetuximab.
3080757|NCT01437488|Experimental|Cabazitaxel|Cabazitaxel following platinum-based chemotherapy
3080758|NCT01437501|Experimental|Broccoli Sprout Extract Beverage|
3080759|NCT01437501|Placebo Comparator|Placebo beverage|
3080760|NCT01437540|Experimental|1|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
3080761|NCT01437540|Active Comparator|2|Inhaled formoterol fumarate 12 μg, twice per day
3080762|NCT01437605|Active Comparator|A: recMAGE-A3 + AS15|ASCI injections without Poly IC:LC
3080763|NCT01437605|Active Comparator|B: recMAGE-A3 + AS15 + Poly IC:LC|ASCI injections with Poly IC:LC
3080764|NCT01437852|Experimental|StrataGraft skin tissue|"All subjects enrolled in this study will receive StrataGraft tissue. Will randomly assign treatment regimens to the two comparable study treatment sites pre-identified as A or B. A sealed randomization envelope will be supplied to the clinical site along with the shipment of clinical tissue. Neither the surgeon nor scrubbed operating room personnel will be informed of the randomization until completion of surgical excision. The treatment sites A or B will be randomized to receive either StrataGraft skin tissue or autograft using a 1:1 ratio.~Two comparable areas of healthy skin will be pre-identified by the clinical staff as donor sites A or B. The randomization assignment will be identical as that above for the treatment sites. For example, if treatment site A is randomized to receive an autograft, donor site A will be designated the donor site for autografting"
3080765|NCT01437878|Experimental|iloprost|single dose inhalation using the power disc-6 with I-neb Adaptive Aerosol Delivery (AAD) system
3080766|NCT01437878|Placebo Comparator|placebo|matching placebo using the power disc-6 with I-neb AAD system
3080767|NCT01437943|Active Comparator|Aliskiren|Aliskiren 150 mg daily for 180 days
3080768|NCT01437943|Placebo Comparator|Placebo|Placebo identical to Aliskiren drug daily for 180 days
3080769|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 250/50 ug|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
3080770|NCT01437995|Active Comparator|Fluticasone/Salmeterol Diskus 100/50 ug|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
3080771|NCT01437995|Active Comparator|Fluticasone Diskus alone 250 ug|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
3080772|NCT01438008|Experimental|Sucrose 24% po|"24% sucrose solution. The Children's Hospital of Eastern Ontario (CHOE) pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum dose of 1 mL of a 24% sucrose solution"
3080773|NCT01438008|Placebo Comparator|Placebo po|"The CHEO pharmacy department will provide a syringe labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (contents almost identical in color, consistency and odor to the sucrose solution) in identical packagings"
3080774|NCT01438060|Experimental|Aripiprazole (BMS-337039)|Double blind Acute Phase (Week 1 to Week 10), Open label Extension Phase (Week 11 to Week 140)
3080775|NCT01438060|Placebo Comparator|Placebo|Double blind Acute Phase (Week 1 to Week 10)
3080776|NCT01438151|Experimental|Remicade|Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
3080777|NCT01438177|Experimental|Velcade+Cyclophosphamide+Chloroquine|"VELCADE given by intravenous push at 1.3 mg/m^2 on days 1, 4, 8, 11, 22, 25, 29 and 32.~Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35.~Chloroquine given at 500 mg orally daily on days 1-14 and 22-35.~Each cycle is 42 days in length."
3080778|NCT01438229|Experimental|renal artery ablation|Catheter-based RF ablation in renal artery
3080779|NCT01438294|Active Comparator|Aerobic exercise|The aerobic training will be done on the treadmill with heart monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.
3080780|NCT01438294|Experimental|Video game|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( reflex ridge- Adventure).
3080781|NCT01438307|Experimental|Schedule A|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
3080782|NCT01438307|Experimental|Schedule B|"Subjects with advanced non-small cell lung cancer who have been previously treated will be given a specific regimen of the novel taxane, Cabazitaxel-XRP6258, different from Schedule A.~Subjects with asymptomatic brain metastases will be eligible for the study and a subset analysis will take place to help determine what, if any, effect Cabazitaxel-XRP6258 has on brain metastases."
3080783|NCT01438411|Other|Cholic Acid|Active drug
3080784|NCT01438424|Experimental|Entecavir, 1.0 mg, with or without lamivudine|
3080785|NCT01438476|Experimental|IV Pain Management|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
3080786|NCT01438476|Experimental|Epidural Pain Management|Thoracic epidurals placed preoperatively in either holding area or in operating room. Hourly post surgery rating level of pain on a scale of 0-10. Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
3080787|NCT01438489|Experimental|Anifrolumab (MEDI-546) 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
3080788|NCT01438489|Experimental|Anifrolumab (MEDI-546) 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
3080789|NCT01438489|Placebo Comparator|Matching Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
3080790|NCT01438541|Experimental|Window|WindowTM is a protective layer that may reduce the shear and friction on the skin and may help to prevent skin breakdown. Window TM provides instant tack adhesion that minimizes the requirement of extra pressure in order to fixate well. The product does not leave residues and the adhesion level does not increase over time.
3080791|NCT01438710|Experimental|LCP-Tacro|LCP Tacro tables for once daily oral administration
3080792|NCT01438710|Experimental|Prograf|Tacrolimus capsules for twice daily oral administration
3080793|NCT01438814|Experimental|linagliptin + metformin|patients to receive linagliptin +metformin QD
3080794|NCT01438814|Active Comparator|metformin|patients to receive metformin BID
3080795|NCT01438840|Active Comparator|Avatrombopag (Core Study)|Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.
3080796|NCT01438840|Placebo Comparator|Placebo (Core Study)|Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.
3080797|NCT01438840|Experimental|Avatrombopag (Open-Label Extension)|Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.
3080798|NCT01438957|Placebo Comparator|Placebo|Dexmedetomidine 0 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0 mcg/kg/hr Maintenance dose
3080799|NCT01438957|Experimental|Dexmedetomidine 0.067 mcg/kg|Dexmedetomidine 0.4 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3080800|NCT01438957|Experimental|Dexmedetomidine 0.25 mcg/kg|Dexmedetomidine 1.5 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3080801|NCT01438957|Experimental|Dexmedetomidine 0.5 mcg/kg|Dexmedetomidine 3 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3080802|NCT01438957|Experimental|Dexmedetomidine 1.0 mcg/kg|Dexmedetomidine 6 mcg/kg/hr 10 min Initial dose + Dexmedetomidine 0.2 - 0.7 mcg/kg/hr Maintenance dose
3080803|NCT01438996|Experimental|NVGH Vi-CRM/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of NVGH Vi-CRM197 5.0 mcg in H01_04TP study
3080804|NCT01438996|Experimental|Vi-PS/NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in adults who received 1 dose of Vi-polysaccharide (PS) in H01_04TP study
3080805|NCT01438996|Experimental|NVGH Vi-CRM|One 0.5 mL dose of NVGH Vi-CRM197 5.0 mcg in naive adults
3080806|NCT01439009|Experimental|Tolvaptan|15 mg
3080807|NCT01439009|Placebo Comparator|Placebo|Placebo
3080808|NCT01439035|Experimental|MGH OFDI imaging|OFDI imaging
3080809|NCT01439074|Active Comparator|Mepilex Ag|Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
3080810|NCT01439074|Active Comparator|Silver Sulphadiazine Ag cream|SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.
3080811|NCT01439087|Experimental|OFDI imaging|OFDI imaging
3080812|NCT01439126|Active Comparator|Subjects on KAPVAY™ (clonidine hydrochloride)|Subjects in the KAPVAY™ arm receive their optimal dose of KAPVAY™ for the 26-week randomized-withdrawal period (Period 3)
3080813|NCT01439126|Placebo Comparator|Subjects on Placebo|Subjects in placebo arm tapered off optimal dose of KAPVAY™ (ie, Period 2 Maintenance Dose) at weekly intervals in decrements of 0.1 mg/day until reaching dose of 0 mg/day; subjects then receive only placebo for the rest of the study
3080814|NCT01439165|Experimental|Adacel® Vaccine Group|Participants randomized to receive a repeat dose of Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine (Adacel®)
3080815|NCT01439165|Active Comparator|Td Adsorbed Vaccine Group|Participants randomized to receive Subjects randomized to receive a Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine.
3080816|NCT01439204|Active Comparator|Abatacept (BMS-188667) manufactured at Lonza, NH facility|
3080817|NCT01439204|Experimental|Abatacept (BMS-188667) manufactured at Devens, MA facility|
3080818|NCT01439282|Experimental|Eribulin + Capecitabine|
3080819|NCT01439360|Experimental|D-QIV|Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
3080820|NCT01439360|Active Comparator|Control|In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).
3080821|NCT01439373|Experimental|GSK2336805|Study Part 1
3080822|NCT01439373|Placebo Comparator|Placebo|Study Part 1
3080823|NCT01439373|Experimental|GSK2336805 + pegylated interferon alfa-2a + ribavrin|Study Part 2
3080824|NCT01439373|Active Comparator|Placebo + pegylated interferon alfa-2a + ribavirin|Study Part 2
3080825|NCT01439555|Experimental|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
3080826|NCT01439568|Experimental|LY2510924 + Carboplatin + Etoposide|"LY2510924: 20 milligram (mg) administered once daily as a subcutaneous(SC) injection on days 1 to 7 of the 21 day cycle; repeat every 21 days for 6 cycles. Carboplatin: 5 milligram/millimeter/per minute (mg/mL/min) area under the curve (AUC) administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered intravenously on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
3080827|NCT01439568|Active Comparator|Carboplatin + Etoposide|"Carboplatin: 5 mg/mL/min area under the curve administered intravenously on day 1 of the 21 day cycle; repeat every 21 days for 6 cycles.~Etoposide: 100 milligram square meter (mg/m^2) administered on days 1 to 3 of the 21 day cycle; repeat every 21 days for 6 cycles."
3080828|NCT01439581|Experimental|Patients on mapping systems|
3080829|NCT01439581|Active Comparator|Patients not on mapping systems|
3080830|NCT01439594|Experimental|MGH OFDI Imaging|OFDI imaging
3080831|NCT01439620|Experimental|OFDI imaging|Subject will swallow an OFDI capsule and images will be obtained using MGH Optical Frequency Domain Imaging (OFDI) imaging system.
3080832|NCT01439633|Experimental|MGH OFDI marking and imaging|OFDI imaging
3080833|NCT01439672|Experimental|Insulin Sensitivity|Single arm. Each subject will consume a mixed meal beverage along with insulin administration in order to calculate insulin sensitivity.
3080834|NCT01439711|Experimental|letrozole + MRI + surgery|Patients receive letrozole (2.5 mg) one tablet each day after confirmation that the MRI is acceptable. There is a 3 and 6 month disease evaluation by MRI of both breasts. If the DCIS has grown, the patient will have surgery to remove it and will continue to take letrozole until the day before surgery. It is expected that decisions regarding any adjuvant treatment will be made individually based on best practice guidelines, using informed and shared decision making between the patient and provider.
3080835|NCT01439724|Placebo Comparator|Placebo|Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
3080836|NCT01439724|Experimental|Low Level Laser Therapy|The investigators used a Low Level Laser Therapy, diode laser (DMC, São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
3080837|NCT01439815|Placebo Comparator|Placebo Nasal Spray|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
3080838|NCT01439815|Active Comparator|Fluticasone Propionate|Two sprays in each nostril daily starting the day in office on Day 0 for up to a 17 day period until Day 16.
3080839|NCT01439854|Placebo Comparator|Placebo|this arm is control
3080840|NCT01439854|Experimental|Dapagliflozin|Interventional arm
3080841|NCT01439867|Experimental|Cinacalcet|"Prior to the partial clinical hold, the starting dose was 0.25 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 4.2 mg/kg) based on plasma intact parathyroid hormone (iPTH), corrected serum calcium levels obtained monthly, and adverse signs and symptoms.~After the partial clinical hold the starting dose was 0.20 mg/kg (based on dry weight) and was titrated upwards (maximum allowed daily dose of 2.5 or 60 mg, whichever was lower) based on plasma iPTH, corrected serum calcium levels obtained monthly, weekly monitoring of ionized calcium levels, and adverse signs and symptoms.~All participants also received standard of care, which may have included vitamin D sterols."
3080842|NCT01439880|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product [all-IP] period.
3080843|NCT01439880|Experimental|Evolocumab + SOC|Participants received evolocumab 420 mg once a month plus standard of care for the first year of the study (SOC-controlled period). At week 52 participants continued treatment with evolocumab 420 mg QM for another 4 years during the all-IP period.
3080844|NCT01439945|Experimental|Arm I|Patients receive a low-dose of magnesium oxide orally (PO) daily (QD).
3080845|NCT01439945|Experimental|Arm II|Patients receive a high-dose of magnesium oxide PO QD.
3080846|NCT01439945|Placebo Comparator|Arm III|Patients receive a low-dose of placebo PO QD.
3080847|NCT01439945|Placebo Comparator|Arm IV|Patients receive a high-dose of placebo PO QD.
3080848|NCT01439971|Experimental|1|
3080849|NCT01439971|Experimental|2|
3080850|NCT01439971|Experimental|3|
3080851|NCT01439971|Experimental|4|
3080852|NCT01439971|Experimental|5|
3080853|NCT01440049||Eplerenone|
3080854|NCT01440101|Experimental|Double-blind Natalizumab 300 mg|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
3080855|NCT01440101|Placebo Comparator|Double-blind Placebo|IV infusions of placebo over 60 minutes every 4 weeks for 20 weeks
3080856|NCT01440101|Experimental|Open-label Natalizumab|300 mg IV infusions of natalizumab over 60 minutes every 4 weeks for 20 weeks
3468883|NCT03891628|Active Comparator|Modified DEF|Modified Developmental Education for Families (14 session in-home intervention with parents and infants present) and Safe Environment for Every Kid (1 to 2 in-home resource visits)
3080857|NCT01440283|Experimental|Treatment|"Patients with high-risk abdominal neuroblastoma who receive any high-risk neuroblastoma treatment regimen will be eligible to enroll prior to surgical resection of the primary tumor. Following implantation of fiducial markers within the tumor bed and autologous hematopoietic rescue, patients will begin the planning process for abdominal irradiation.~Interventions: Intensity Modulated Radiation Therapy (IMRT)"
3080858|NCT01440322|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lenses with color worn in both eyes on a daily wear, monthly replacement basis for 3 months
3080859|NCT01440322|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear, monthly replacement basis for 3 months
3080860|NCT01440374|Experimental|Part 1, Open Label|100 mg daily (50 mg for subjects of East Asian heritage), intrasubject dose escalations to a maximum dose 300 mg (150 mg for subjects of East Asian heritage) are allowed.
3080861|NCT01440374|Experimental|Part 2, eltrombopag arm|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
3080862|NCT01440374|Experimental|Part 2, placebo arm|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
3080863|NCT01440374|Experimental|part 3 extension|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
3080864|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Adult Group|Subjects 18-60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3080865|NCT01440387|Experimental|FLULAVAL QUADRIVALENT Elderly Group|Subjects above 60 years of age received 1 dose of FLULAVAL® QUADRIVALENT vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3080866|NCT01440543|Experimental|Water/CO2|water immersion during colonoscope insertion and CO2 insufflation during colonoscope withdrawal
3080867|NCT01440543|Experimental|Water/Air|Water immersion during colonoscope insertion and air insufflation during colonoscope withdrawal
3080868|NCT01440543|Experimental|CO2/CO2|CO2 insufflation during both colonoscope insertion and withdrawal
3080869|NCT01440543|No Intervention|Air/Air|room air insufflation during both colonoscope insertion and withdrawal
3080870|NCT01440569|Experimental|COBI-boosted DRV|Participants will receive DRV+COBI+2 investigator-selected NRTIs for 48 weeks, and may continue their regimen in the open-label rollover phase.
3080871|NCT01440634|Other|supervised exercise|It consists of six months of supervised, intermittent track walking to near maximal leg pain or discomfort three days per week. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month.
3080872|NCT01440634|No Intervention|Standard of Care|Patients will be observed during the time of the study, no intervention will be applied. Patients are allowed to do their regular activity at home.
3080873|NCT01440647|Experimental|NIPPV|Extubation to NIPPV (nasal intermittent positive pressure ventilation)
3080874|NCT01440647|Active Comparator|CPAP|After extubation this arm was placed on CPAP (continuous positive airway pressure) and was not offered NIPPV in the first month on life
3080875|NCT01440764|Experimental|F(40), then Saline, then IV.F|"On Test Day 1, participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
3080876|NCT01440764|Experimental|IV.F, then F(40), then Saline|"On Test Day 1, participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 4ml by inhalation for 5-10 minutes."
3080877|NCT01440764|Experimental|Saline, then F(40), then IV.F|"On Test Day 1, participants received Aerosol Saline 4ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 3), participants received Aerosol Furosemide 40mg in 4ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Furosemide 15 mg diluted in 10 ml of saline by intravenous delivery for 5 minutes."
3080878|NCT01440764|Experimental|F(80), then Saline, then Saline|"On Test Day 1, participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
3080879|NCT01440764|Experimental|Saline, then F(80), then Saline|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes."
3080880|NCT01440764|Experimental|Saline, then Saline, then F(80)|"On Test Day 1, participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 2 (at least 24 hours after Test Day 1), participants received Aerosol Saline 8ml by inhalation for 5-10 minutes.~On Test Day 3 (at least 24 hours after Test Day 2), participants received Aerosol Furosemide 80mg in 8ml saline by inhalation for 5-10 minutes."
3080881|NCT01440803|Active Comparator|Teriparatide (Forteo)|Daily injection of Teriparatide for treatment of idiopathic osteoporosis
3080882|NCT01440803|Placebo Comparator|Placebo saline injection|Daily injection of saline placebo for 6 months, followed by 24 months of teriparatide treatment for idiopathic osteoporosis.
3080883|NCT01440816|Experimental|Cohort A: Tavo-EP|Patients in Cohort A received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, after which they proceeded to definitive treatment (surgery and/or radiation therapy) which started between 2 and 4 weeks after the first injection.
3080884|NCT01440816|Experimental|Cohort B: Tavo-EP|Patients in Cohort B received up to 4 cycles (3 daily treatments on Days 1, 5, and 8, per cycle) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation, with 12 planned weeks between each cycle, lasting up to 12 months.
3080885|NCT01440881|Active Comparator|Nesiritide|infuses at 0.01 MCG (micrograms)/KG (kilograms)/min (minute) for 48 hours
3080886|NCT01440881|Placebo Comparator|Placebo|infuses at 0.01MCG/KG/min for 48 hours
3080887|NCT01440920|Experimental|Cohort 1|0.3 mg
3080888|NCT01440920|Experimental|Cohort 2|1 mg
3080889|NCT01440920|Experimental|Cohort 3|3 mg
3080890|NCT01440946|Experimental|rFIXFc Prophylaxis|"At Baseline and at Day 1, participants receive a single intravenous (IV) injection of prestudy FIX and rFIXFc, respectively, over 10 (±5) minutes at a dose of 50 IU/kg. Immediately after the last PK sampling, the first prophylactic dose of approximately 50 to 60 IU/kg will be administered in clinic as an IV injection.~Dose could be increased or decreased in increments of 10 IU/kg; increases to a maximum of 100 IU/kg and frequency of administration to a maximum of twice weekly, were allowed as indicated."
3080891|NCT01440959|Experimental|TKI258|
3080892|NCT01440972|Active Comparator|Exercise without PBFR|
3080893|NCT01440972|Experimental|exercise with PBFR|
3080894|NCT01441037|Experimental|Danazol|Single arm in which danazol is administered orally at 800 mg daily for 2 years.
3080895|NCT01441063|Experimental|Tocilizumab|Tocilizumab 8 mg/kg on Day 1 of a 14 day cycle a maximum of 6 cycles. If indicated, zidovudine (AZT) and valganciclovir (VGC) will be administered concurrently with tocilizumab, with day 1 of the cycle being the day tocilizumab is administered.
3080896|NCT01441076|Experimental|Anakinra|Treatment with Anakinra 100mg subcutaneous daily with option to escalate dose up to 300mg subcutaneous daily
3080897|NCT01441102|Experimental|Dextromethorphan hydrobromide|
3080898|NCT01441180|Experimental|Phase 1|Participants (N =10) will receive GS-7977 QD in combination with RBV for a total of 24 weeks. The study team will perform an interim evaluation of data and safety at the end of 12 weeks of treatment.
3080899|NCT01441180|Active Comparator|Phase 2 Arm A|(N =25) 24 weeks of GS-7977 QD in combination with weight based RBV (1000 mg for participants weighing <75 kg and 1200 mg for participants weighing ≥75kg)
3080900|NCT01441180|Active Comparator|Phase 2 Arm B|(N = 25): 24 weeks of GS-7977 QD with low dose RBV (600mg).
3080901|NCT01441245|Experimental|Continuous furosemide infusion|The group that received the continuous infusion of furosemide (cIV), consisted of 30 patients;
3080902|NCT01441245|Experimental|Intermittent furosemide infusion|The group that received the bolus infusion of furosemide (iIV), consisted of 27 patients
3080903|NCT01441401||Gabapentin|Peadiatric subjects taking Gabapen Tablets and syrup.
3080904|NCT01441414|Experimental|ARM A|PF-04856884 in combination with AG-013736
3080905|NCT01441414|Active Comparator|ARM B|AG-013736 alone
3080906|NCT01441440|Experimental|venlafaxine ER 75 mg/day (fixed dose)|
3080907|NCT01441440|Experimental|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|
3080908|NCT01441440|Placebo Comparator|Placebo|
3080909|NCT01441466||Group without isolation|Patients in this arm are nursed together (in the same room) independent of viral agent.
3080910|NCT01441466||group with isolation|Patients in this arm are nursed separately until the test result of the PCR (polymerase chain reaction) for viral agents is known (within 24-48 hrs). RS-positive patients are nursed separately (separate room) from RS-negative patients
3080911|NCT01441492|Experimental|No Drains|Patients who will not receive intraperitoneal drainage following pancreas resection.
3080912|NCT01441492|Experimental|Drains|Patients who will receive drains, the standard of care treatment, following pancreas resection.
3080913|NCT01441570|Active Comparator|Nebivolol|
3080914|NCT01441570|Active Comparator|Metoprolol Succinate|
3080915|NCT01441596|Experimental|arm A: Afatinib monotherapy|Afatinib monotherapy: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
3080916|NCT01441596|Experimental|arm B: Afatinib in combination with vino|Afatinib 40 mg per day, continuous treatment, in combination with vinorelbine Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course.
3080917|NCT01441596|Active Comparator|arm C: investigator's choice of treatmen|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
3080918|NCT01441635|Experimental|Cohort 4 Elagolix 400 mg QD|Participants received elagolix 400 mg once a day (QD) for 3 months.
3080919|NCT01441635|Experimental|Cohort 4 Elagolix 100 mg BID|Participants received elagolix 100 mg twice a day (BID) for 3 months.
3080920|NCT01441635|Placebo Comparator|Cohort 4 Placebo|Participants received placebo to elagolix BID for 3 months.
3080921|NCT01441635|Experimental|Cohort 1 Elagolix 200 mg BID|Participants received elagolix 200 mg twice a day for 3 months.
3080922|NCT01441635|Placebo Comparator|Cohort 1 Placebo|Participants received placebo to elagolix twice a day for 3 months.
3080923|NCT01441635|Placebo Comparator|Cohort 3 Elagolix 200 mg BID + LD E2/NETA|Participants received elagolix 200 mg twice a day plus continuous low-dose (LD) estradiol (E2) 0.5 mg/norethindrone acetate 0.1 mg (NETA) once a day for 3 months.
3080924|NCT01441635|Experimental|Cohort 5 Elagolix 600 mg QD|Participants received elagolix 600 mg once a day for 3 months.
3080925|NCT01441635|Experimental|Cohort 2 Elagolix 300 mg BID|Participants received elagolix 300 mg twice a day for 3 months.
3080926|NCT01441635|Experimental|Cohort 2 Placebo|Participants received placebo to elagolix BID for 3 months.
3080927|NCT01441635|Experimental|Cohort 6 Elagolix 300 mg BID + CEP|Participants received elagolix 300 mg twice a day plus cyclical estrogen/progesterone (CEP, consisting of estradiol 1 mg a day and progesterone 200 mg on days 17 to 28 of each 30-day treatment cycle) for 3 months.
3080928|NCT01441765|Active Comparator|CT-011|CT-011 3 mg/kg for 4 cycles of 6 weeks
3080929|NCT01441765|Active Comparator|CT-011 with DC/RCC fusion vaccine|CT-011 with DC/RCC fusion vaccine for subjects undergoing nephrectomy, resection of tumor tissue, or aspiration of malignant effusion
3080930|NCT01441843|Active Comparator|Lorazepam|Lorazepam 4mg/4ml
3080931|NCT01441843|Placebo Comparator|NaCl 0.9%|NaCl 0.9% 4ml
3080932|NCT01441882|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD during course 1 and if tolerated, BID in subsequent courses. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3080933|NCT01441960|Experimental|Succinylcholine first, then Rocuronium|Cross-over randomized controlled, assessor blinded clinical trial.
3080934|NCT01441960|Experimental|Rocuronium first, then succinylcholine|Cross-over randomized controlled, assessor blinded clinical trial.
3080935|NCT01441973|Experimental|Elotuzumab, 20 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1: Days 1 and 8. Cycle 2 and beyond: Day 1 only.
3080936|NCT01441973|Experimental|Elotuzumab, 10 mg/kg|Intravenous solution administered in 28-day cycles. Cycle 1 and 2: Days 1, 8, 15, and 22. Cycle 3 and beyond: Days 1 and 15.
3080937|NCT01442038|Experimental|Ranolazine|
3080938|NCT01442038|Placebo Comparator|Placebo|
3080939|NCT01442064|Experimental|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.
3080940|NCT01442103|Experimental|Device, dressing|Normlgel Ag is an opaque, amorphous hydrogel containing a high water content, water soluble polymer chains and an antimicrobial silver compound.
3080941|NCT01442129|Experimental|MPC Intramyocardial injection|Intramyocardial injections of 25 million Mesenchymal Precursor Cells (MPCs)
3080942|NCT01442129|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
3080943|NCT01442155||Capecitabine + Oxaliplatin|Participants with stage lll colon cancer, who were starting adjuvant chemotherapy with capecitabine in combination with oxaliplatin according to standard of care.
3080944|NCT01442181|Active Comparator|Minimally Invasive Surgery|Thumb sized incisions are made on each sides of the chest wall where instruments are placed in the chest to perform the surgery.
3080945|NCT01442181|Active Comparator|Medical Therapy|Patients are treated with rhythm and rate control medications.
3080946|NCT01442376|Experimental|Palonosetron 10 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
3080947|NCT01442376|Experimental|Palonosetron 20 mcg/kg|"Palonosetron and placebo to Ondansetron~Intervention:~Drug: Palonosetron"
3080948|NCT01442376|Active Comparator|Ondansetron|"Ondansetron and placebo to Palonosetron~Drug:~Comparator: Ondansetron"
3080949|NCT01442493|Experimental|Patient-Centered Methadone Treatment|Patient-Centered Methadone Treatment alters the rules and staff roles in methadone treatment as usual in an attempt to increase treatment retention and improve patient outcomes.
3080950|NCT01442493|Active Comparator|Methadone Treatment as Usual|Methadone treatment provided as usual in the U.S.
3080951|NCT01442675|Experimental|Meningococcal vaccine Group|Participants must have received Menactra vaccine 4 to 6 years prior to enrollment
3080952|NCT01442688|Experimental|Amoxicillin + MMX placebo|
3080953|NCT01442688|Experimental|Amoxicillin + MMX mesalazine/mesalamine|
3080954|NCT01442714|Experimental|Azacitidine plus Lenalidomide|Patients will receive a single dose of azacitidine 75 mg/m² SC or IV on days 1 to 7, followed by lenalidomide 50 mg PO daily on days 8 to 28 of a 42-day cycle.
3080955|NCT01442844|Active Comparator|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
3080956|NCT01442844|No Intervention|No intervention|No intervention will be performed. Subject will receive dressings that are standard of care.
3080957|NCT01443026|Experimental|Lycopene|Lycopene 30 mg/day
3080958|NCT01443026|Placebo Comparator|Placebo|Placebo
3080959|NCT01443078|Experimental|pemetrexed plus cisplatin, vinorelbine and docetaxel|This is a phase 2 clinical trial for patients with clinical Stage IB-III resectable and operable non-small cell lung cancer, evaluating whether the switch to an alternative, non-platinum neoadjuvant chemotherapy is safe and effective in patients who do not respond to neoadjuvant platinum-based chemotherapy. Those who fail to respond to platinum-based chemotherapy will be switched to the alternative neoadjuvant chemotherapy vinorelbine 45 mg/m2 and docetaxel 45 mg/m2 on day 1 followed by pegylated filgrastim on day 2, repeated every 2 weeks for 4 doses, followed by repeat FDG PET and CT scan.
3080960|NCT01443130|Experimental|Chloroquine IPT|300 subjects to receive a therapeutic dose of chloroquine (1,500 mg given over 3 days, 2 tablets on Day 0, 2 tablets on Day 1, 1 tablet on Day 2) will be administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
3080961|NCT01443130|Experimental|Chloroquine Prophylaxis|300 subjects to receive a loading dose of chloroquine (base) 600 mg (2 tablets) at first administration followed by 300 mg of chloroquine base (1 tablet) every week.
3080962|NCT01443130|Active Comparator|SP IPT|300 subjects to receive a therapeutic dose of sulfadoxine-pyrimethamine (SP), (1500 mg sulfadoxine and 75 mg pyrimethamine (3 tablets)) administered twice during pregnancy at 20-28 weeks and at 28-34 weeks.
3080963|NCT01443364|Experimental|Certolizumab pegol|
3080964|NCT01443403|Placebo Comparator|Placebo|Participants received placebo orally once daily for 28 days.
3080965|NCT01443403|Experimental|Naldemedine 0.1 mg|Participants received 0.1 mg naldemedine orally once daily for 28 days.
3080966|NCT01443403|Experimental|Naldemedine 0.2 mg|Participants received 0.2 mg naldemedine orally once daily for 28 days.
3080967|NCT01443403|Experimental|Naldemedine 0.4 mg|Participants received 0.4 mg naldemedine orally once daily for 28 days.
3080968|NCT01443442|Active Comparator|Bepreve|1.5% bepotastine besilate, drops, twice per day, for two weeks
3080969|NCT01443442|Active Comparator|Alrex|treatment with 0.2 % loteprednol etabonate, drops, four times per day
3080970|NCT01443494|Experimental|NE group|Adjust NE dose to titrate MAP to usual level regardless of fluid responsiveness when after EGDT.
3080971|NCT01443546|Active Comparator|hCG|standard dose of hCG for ovulation trigger
3080972|NCT01443546|Active Comparator|Lupron Trigger|Leuprolide acetate 2 mg ovulation trigger
3080973|NCT01443546|Experimental|Dual Trigger|Lupron and hCG combined ovulation trigger
3080974|NCT01443845|Experimental|1|Roflumilast
3080975|NCT01443845|Placebo Comparator|2|Placebo
3080976|NCT01443858|Active Comparator|Placebo + Nicotine Patch|Subjects in this group will take placebo meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Placebo meclizine will be administered in two doses each day.
3080977|NCT01443858|Experimental|25mg Meclizine + Nicotine Patch|Subjects in this group will take 25mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
3080978|NCT01443858|Experimental|50mg Meclizine + Nicotine Patch|Subjects in this group will take 50mg of meclizine daily for the three weeks prior to their quit date. Subjects will also apply a 21mg/24h nicotine patch daily starting in the second week of pre-quit treatment. Meclizine will be administered in two doses each day.
3080979|NCT01444027|No Intervention|Attention Control|"This group receives standard care with the attention of social support/ friendly interactions and serves as an attention control group."
3080980|NCT01444027|Experimental|Intervention Group 1 (Face to Face)|This group receives Problem Solving Therapy in face to face visits.
3080981|NCT01444027|Experimental|Intervention Group 2 (Video)|This group receives Problem Solving Therapy via video.
3080982|NCT01444092|Experimental|Entocort|Study Medication
3080983|NCT01444287|Placebo Comparator|Spectacles No Lenses|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3080984|NCT01444287|Experimental|narafilcon B|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3080985|NCT01444287|Active Comparator|polymacon|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3080986|NCT01444287|Active Comparator|lotrafilcon A|Assigned in random order during one of four 8 hour sessions on four separate days, in one of 24 possible order combinations.
3080987|NCT01444300|Experimental|Dalfampridine|
3080988|NCT01444300|Placebo Comparator|Placebo|
3080989|NCT01444378|Experimental|Absolute Pro® and Pro LL® Peripheral Stent Systems|
3080990|NCT01444391|Experimental|Tympanostomy Tube Placement|
3080991|NCT01444417|Experimental|Romiplostim|Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L.
3080992|NCT01444417|Placebo Comparator|Placebo|Participants received weekly subcutaneous placebo for 24 weeks.
3080993|NCT01444430|Experimental|1|Symbicort
3080994|NCT01444430|Active Comparator|2|budesonide
3080995|NCT01444456||Cohort 1: Darbepoetin alfa|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) to treat symptomatic anemia according to routine institutional practice.
3080996|NCT01444456||Cohort 2: Any ESA|Participants receiving systemic chemotherapy for solid tumors who also received darbepoetin alfa (Aranesp®) or another erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia according to routine institutional practice.
3080997|NCT01444651|Active Comparator|Tadalafil|20 mg Tadalafil tablet taken by mouth once a day for 3 months
3080998|NCT01444651|Placebo Comparator|Placebo|Placebo tablet taken by mouth once a day for 3 months
3080999|NCT01444716|Experimental|Treatment (ofatumumab)|Participants receive ofatumumab IV over 4 hours once a week for 4 weeks, then monthly thereafter. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
3081000|NCT01444742|Experimental|Clofarabine + Cytarabine|"Induction:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 5 days (days 1-5) Cytarabine 20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~Clofarabine 10 mg/m2 1-2 hours by vein daily for 3 days (days 1-3) Cytarabine 20 mg subcutaneously twice daily for 5 days (days 1-5)"
3081001|NCT01444781|Experimental|Study Group 1|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of DTaP-IPV-Hep B-PRP~T vaccine + one dose of Prevenar™
3081002|NCT01444781|Active Comparator|Study Group 2|Participants previously primed with DTaP-IPV-Hep B-PRP~T, will receive one dose of Infanrix hexa™ vaccine + one dose of Prevenar™
3081003|NCT01444781|Experimental|Study Group 3|Participants previously primed with Infanrix hexa™ will receive one dose of DTaP-IPV-Hep B-PRP~T + one dose of Prevenar™.
3081004|NCT01444898|Experimental|Exenatide|All subjects enrolled in this study will be given Exenatide for 6 months. Exenatide: The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
3081005|NCT01444911|Experimental|Vaginal Renewal Program|
3081006|NCT01444911|Active Comparator|Standard of care|This will consist of still vaginal dilator and/or lubricant.
3081007|NCT01444924|Experimental|Bupivicaine|TAP block with bupivicaine/epinephrine placed prior to surgery.
3081008|NCT01444924|Placebo Comparator|Placebo|TAP block with placebo placed prior to surgery
3081009|NCT01445028|Experimental|Primary, high-risk retinal detachment|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
3081010|NCT01445028|Experimental|Recurrent RD associated with PVR|Oral isotretinoin on recurrent retinal detachment associated with Proliferative vitreoretinopathy
3081011|NCT01445080|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3081012|NCT01445171|Other|Study Valve|Subjects act as own control
3081013|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) once daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be once daily in the evening/bedtime.
3081014|NCT01445301|Experimental|GSK2585823(CLDM 1%-BPO 3% gel) twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
3081015|NCT01445301|Active Comparator|CLDM 1% gel twice daily|Subjects will apply in a quantity sufficient to cover the entire face (including the forehead, nose, cheeks, and chin). Also, the dose regimen will be twice daily in the morning and evening/bedtime.
3081016|NCT01445535|Experimental|siplizumab + EPOCH (combo chemo) + rituximab|siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
3081017|NCT01445548|Experimental|Sirolimus|"Participants initially received a 20 μL (440 μg) intravitreal injection sirolimus in the study eye at baseline and every two months thereafter unless contraindicated.~As of September 2012, sirolimus intravitreal injections were no longer administered to participants."
3081018|NCT01445613|Other|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
3081019|NCT01445626||All participants|Patients who received at least two OZURDEX® (dexamethasone intravitreal implant) injections.
3081020|NCT01445652|Experimental|nelfilcon A|Nelfilcon A contact lenses worn in both eyes on a daily disposable basis a minimum of five days per week, eight hours per day, for six months
3081021|NCT01445652|Active Comparator|Spectacles|Spectacles per current prescription worn a minimum of five days per week, eight hours per day, for six months
3081022|NCT01445678|Experimental|CXA-201 and Metronidazole as treatment for cIAI|
3081023|NCT01445678|Active Comparator|Meropenem as treatment for cIAI|
3081024|NCT01445730|Experimental|After fructose feeding|After 3 month fructose diet 75 g/day
3081025|NCT01445769|Experimental|Ruxolitinib|Participants initially received ruxolitinib 10 mg twice a day (bid) for 24 weeks. Dose increases of 5 mg bid were possible at Weeks 12 and 18 up to a maximum dose of 20 mg bid.
3081026|NCT01445821|Active Comparator|Cyclophosphamide rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. Peripheral blood stem cells (PBSC) will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
3081027|NCT01445821|Experimental|Cyclophosphamide rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 mg/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
3081028|NCT01445847|Active Comparator|Lidocaine|Lidocaine 1% was prepared in 10 mL syringe= 10 mg/mL, dosage was 1mg/kg, one bolus or 10 mL/kg, with range of 2mg could be added or missed. The maximum dose is 100 mg for patients with weight of more than 100
3081029|NCT01445847|Placebo Comparator|Placebo|Normal saline was prepared in 10 mL syringe, dosage was 1 mL/10 kg.
3081030|NCT01445873||PAH patients receiving Sitaxentan|
3081031|NCT01445886|Experimental|Indigo Naturalis Extract in Oil|A 5-ml eye drop bottles contain indigo naturalis powder mixed with olive oil, and the concentration was 200 ug indirubin per ml. Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
3081032|NCT01445886|Active Comparator|Calcipotriol solution|Calcipotriol solution (Daivonex® scalp solution, calcipotriol 50 ug/ml) was purchased from LEO Pharmaceutical Products, Ltd. (Ballerupt, Denmark) and also distributed into 5-ml eye drop bottles for this trial.Each subject was asked to apply one to two drops (0.05 ml per drop) of the solution twice daily onto the nail folds, plus the hyponychium, of affected nails. The maximum period of treatment was 24 weeks or until there was complete clearing of their nail psoriasis.
3081033|NCT01445951|Experimental|Technosphere® Insulin with MedTone C Inhaler|Subjects will receive TI with the MedToneC inhaler and remain on the basal insulin they were taking prior to study entry
3081034|NCT01445951|Active Comparator|Aspart Group|Subjects will receive insulin aspart and remain on the basal insulin they were taking prior to study entry
3081035|NCT01445951|Experimental|Technosphere ® Insulin-Gen2 Group|Subject will receive Technosphere Insulin with Gen2 Inhaler and remain on the basal insulin they were taking prior to study entry
3081036|NCT01446003|Experimental|MK-8457-Placebo Sequence|Participants received MK-8457 100 mg twice daily (BID) for 10 days followed by Placebo for 10 days. Each treatment was separated by a 10-day washout.
3081037|NCT01446003|Experimental|Placebo-MK-8457 Sequence|Participants received Placebo for 10 days followed by MK-8457 100 mg BID for 10 days. Each treatment was separated by a 10-day washout.
3081038|NCT01446042|Experimental|TBS-1 - b.i.d.|5.5 mg per nostril of 4.5% TBS-1 BID
3081039|NCT01446042|Experimental|TBS-1 - t.i.d.|5.5 mg per nostril of 4.5% TBS-1 TID
3081040|NCT01446159|Experimental|MEDI-573 10 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort A of the study will receive intravenous infusion of MEDI-573 10 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3081041|NCT01446159|Experimental|MEDI-573 30 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort B of the study will receive intravenous infusion of MEDI-573 30 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3081042|NCT01446159|Experimental|MEDI-573 45 mg/kg + AI|Participants who will be enrolled in Phase 1b Cohort C and Phase 2 Arm 1 of the study will receive intravenous infusion of MEDI-573 45 mg/kg on Day 1 of each 21-day cycle and AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3468884|NCT03891732||MRI pathway|Plain biparametric MRI prostate applied to men with elevated PSA, on top of standard screening pathway using PSA and Prostate Health Index
3081043|NCT01446159|Experimental|Aromatase Inhibitor|Participants who will be enrolled in Phase 2 Arm 2 of the study will receive oral AI of the investigator's choice (letrozole, anastrozole, or exemestane) orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
3081044|NCT01446237|Experimental|Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%|open label - no comparator; only Acne system - benzoyl peroxide 2.5%, Salicylic Acid 0.5%
3081045|NCT01446289|Experimental|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine.
3081046|NCT01446289|Placebo Comparator|Placebo|Pregnant women who received one injection of saline solution.
3081047|NCT01446419|Experimental|Intracept Treatment|
3081048|NCT01446419|Sham Comparator|Sham Treatment|
3081049|NCT01446666||HCC high-risk group|"Patients with liver cirrhosis with the 1-year risk of HCC of 5% or higher~; High Risk Index (>=2.33)~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive)."
3081050|NCT01446705||No Exchange|Patients in this arm will represent Veterans seen at the Indianapolis VA Medical Center (VAMC) for whom information exchange has not been activated.
3081051|NCT01446705||Enrolled in Exchange|"Patients in this arm will represent Veterans seen at the Indianapolis VAMC for whom information exchange has been activated by the patient choosing to opt-in."
3081052|NCT01446809|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
3081053|NCT01446809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
3081054|NCT01446874|Experimental|Pre-operative brushing (Pilot Portion)|-Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution
3081055|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Esophageal Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
3081056|NCT01446874|Experimental|Pre-operative & Post-Operative Brushing (Lung Resection)|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution~The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
3081057|NCT01446913|Active Comparator|Standard Intervention group|This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.
3081058|NCT01446913|Active Comparator|Enhanced CPAP intervention|This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.
3081059|NCT01446913|No Intervention|Usual Care|This group usual care after TIA/stroke and a sleep study at the end of the study.
3081060|NCT01446965|Experimental|Wearable defibrillator|subjects in the Device Group will receive a LifeVest® wearable cardioverter-defibrillator (manufacturer: ZOLL Medical Corporation) plus guideline-directed medical therapy for post-myocardial infarction patients
3081061|NCT01446965|No Intervention|Conventional treatment|subjects in the Control Group will only receive guideline-directed medical therapy for post-myocardial infarction patients
3081062|NCT01447017|Experimental|DPK-060 2% ear drops|DPK-060 2% ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
3081063|NCT01447017|Placebo Comparator|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops, 0.3 mL/pipette, 3 times daily for 7 or 10 days (as applicable).
3081064|NCT01447121|Experimental|Intended Users of the System|Untrained subjects with diabetes use an investigational blood glucose monitoring system (Tatsu/Tradewind Investigational BG Monitoring System) to self-test capillary blood obtained from fingerstick.
3081065|NCT01447225|Experimental|MM-121 plus Gemcitabine|escalating doses of MM-121 and gemcitabine on Day 1 and Day 8 of every 3 week cycle
3081066|NCT01447225|Experimental|MM-121 plus Carboplatin|carboplatin at AUC 6 with escalating doses of MM-121 on Day 1 of every 3 week cycle
3081067|NCT01447225|Experimental|MM-121 plus Pemetrexed|pemetrexed at 500 mg/m2 with escalating doses of MM-121 on Day 1 of every 3 week cycle
3081068|NCT01447225|Experimental|MM-121 plus Cabazitaxel|escalating doses of MM-121 and cabazitaxel on Day 1 of every 3 week cycle
3081069|NCT01447407|Active Comparator|NDV-3 vaccine with alum IM|300 ug Als3 and 0.5 mg Al as alum in PBS per dose, one dose administered IM
3081070|NCT01447407|Active Comparator|NDV-3 vaccine without alum IM|300 ug Als3 in PBS per dose, one dose administered IM
3081071|NCT01447407|Placebo Comparator|Placebo IM|0.5 mg Al as alum in PBS per dose, one dose administered IM
3081072|NCT01447407|Active Comparator|NDV-3 vaccine without alum ID|30 ug Als3 in PBS per dose, one dose administered ID
3081073|NCT01447420|Experimental|Peginterferon Alfa-2a Plus Ribavirin|
3081074|NCT01447433|Experimental|Calcium+D|Calcium supplements provide 600mg of calcium and 125IU vitamin D per day. A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
3081075|NCT01447433|Placebo Comparator|Control|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
3081076|NCT01447446||Dual Therapy: Peg-IFN Alfa-2a + Ribavirin|Participants with chronic hepatitis C (CHC) receiving dual therapy (pegylated interferon alfa-2a [peg-IFN Alfa-2a] along with ribavirin according to standard of care and in line with local labeling) were followed up for the duration of their treatment and for up to 24 weeks after therapy.
3081077|NCT01447446||Dual Therapy: Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving dual therapy (pegylated interferon alfa-2b [peg-IFN Alfa-2b] along with ribavirin according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3081078|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3468885|NCT03891732||Standard screening pathway|Intervention: Using blood tests PSA and Prostate Health Index to screen men at risk of prostate cancer
3081079|NCT01447446||Triple Therapy: Boceprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and boceprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3081080|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2a + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2a along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3081081|NCT01447446||Triple Therapy: Telaprevir + Peg-IFN Alfa-2b + Ribavirin|Participants with CHC receiving triple therapy (peg-IFN Alfa-2b along with ribavirin and telaprevir according to standard of care and in line with local labeling) were followed for the duration of their treatment and for up to 24 weeks after therapy.
3081082|NCT01447511|Other|CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3081083|NCT01447511|Other|CYP2C9*1B/*1B Haplotype|Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
3081084|NCT01447511|Other|CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3081085|NCT01447511|Other|CYP2C9*2/*3 Genotype|Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3081086|NCT01447511|Other|CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
3081087|NCT01447576|Experimental|OPC-34712 + ADT|Experimental: OPC-34712, Oral Tablets, 0.25 - 3 mg; Antidepressant drug treatment
3081088|NCT01447706|Active Comparator|Paclitaxel|Standard dosing paclitaxel: 80 mg/m2 QW intravenously)
3081089|NCT01447706|Experimental|MM-121 (SAR256212) + Paclitaxel|administered intravenously at 40 mg/kg loading dose on Cycle 1, Week 1 followed by 20 mg/kg QW for all subsequent doses
3081090|NCT01447849|Active Comparator|Lubiprostone 24 mcg Twice a day|Both controls and patients with chronic constipation will receive 1 week of therapy with lubiprostone and one week of placebo.
3081091|NCT01447849|Placebo Comparator|Placebo|Both controls and patients with chronic constipation will receive placebo pills twice daily for one week in cross over design
3081092|NCT01447888|Experimental|150% Oral Morphine Equivalent (OME)|Perioperative goal-directed opioid dosing at 150% of patient baseline oral morphine equivalent (OME) for opioid-tolerant patients
3081093|NCT01447888|Active Comparator|Control|Standard perioperative dosing, which does not currently account for patients' baseline opiate use.
3081094|NCT01447914|Experimental|ARQ 197 Treatment (Tivantinib)|Oral Tivantinib 360 mg twice daily continuously for each day (days 1-28) of every 4-week treatment cycle (taken as three tablets of 120 mg each). Courses continue every 28 days in the absence of disease progression or unacceptable toxicity.
3081095|NCT01447927|Experimental|Arm I|Patients receive extended-release metformin hydrochloride PO QD on week 1, and BID on weeks 2-12 (QAM QPM on week 3) in the absence of unacceptable toxicity or disease progression.
3081096|NCT01447927|Placebo Comparator|Arm II|Patients receive extended-release placebo PO QD on week 1and BID on weeks 2-12 (QAM and QPM on week 3) in the absence of unacceptable toxicity or disease progression.
3081097|NCT01448044|Experimental|BMS-790052 + PegIFNα-2a + Ribavirin|"BMS-790052 60 mg Tablets, Oral, once daily for 24 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 24 or 48 weeks depending on response~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 24 or 48 weeks depending on response"
3081098|NCT01448044|Placebo Comparator|Placebo matching BMS-790052 + PegIFNα-2a + Ribavirin|"Placebo matching BMS-790052 0 mg Tablets, Oral, once daily for 48 weeks~PegIFNα-2a 180 μg Subcutaneous Injection, once weekly for 48 weeks~Ribavirin 400 mg (2 tablets for participants < 75 kg) or 600 mg (3 tablets for participants ≥ 75 kg) in the morning and 600 mg (3 tablets) in the evening, Oral for 48 weeks"
3081099|NCT01448057|Experimental|Combination Product|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
3081100|NCT01448057|Active Comparator|Paracetamol tablets|Paracetamol (500 mg) tablets
3081101|NCT01448213|Active Comparator|Fluorometholone 0.1% Solution|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
3081102|NCT01448213|Active Comparator|Prednisolone acetate 1% Solution|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
3081103|NCT01448356|Experimental|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity"
3081104|NCT01448421|Experimental|Keystone Heart Embolic Deflection Device|Protected Transcatheter Aortic Valve Replacement
3081105|NCT01448447|Experimental|Sole method|patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS
3081106|NCT01448447|Experimental|Boost|patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS
3081107|NCT01448486|No Intervention|Standard of Care HAART|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART).
3081108|NCT01448486|Experimental|Raltegravir|Participants randomised to this arm will remain on their standard of care Highly Active Antiretroviral Therapy (HAART) with the addition of Raltegravir 400 mg twice daily (BID).
3081109|NCT01448525|Active Comparator|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
3081110|NCT01448525|Placebo Comparator|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
3081111|NCT01448616|No Intervention|Run-in Phase|Women will first participate in a run-in phase with twice daily swabbing.
3081112|NCT01448616|Experimental|Study Drug Phase: TDF|Participants will take tenofovir disoproxil fumarate (TDF) tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3081113|NCT01448616|Experimental|Study Drug Phase: Vaginal TFV Gel|Participants will take oral placebo tablets and apply a tenofovir 1% (TFV) vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3081114|NCT01448616|Placebo Comparator|Study Drug Phase: Double Placebo|Participants will take oral placebo tablets and apply a placebo vaginal gel. Participants will begin treatment and swab the genital region twice daily for 5 more weeks. Study drugs will be administered once daily.
3081115|NCT01448707|Experimental|Darunavir monotherapy|Darunavir (DRV) + ritonavir (rtv): 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal. Following the primary efficacy analysis after Week 48, patients who entered the study with a nadir CD4+ count of <200 cells/μL will also receive 2 N[t]RTIs (ie, triple therapy) as soon as possible
3081116|NCT01448707|Active Comparator|Triple therapy containing darunavir|Darunavir (DRV) + ritonavir (rtv) + 2 N[t]RTIs: 2 tablets DRV 400 mg should be taken together with 1 tablet rtv 100 mg within 30 minutes after a meal in combination with 2 N[t]RTIs (an investigator-selected dual combination of either abacavir (ABC), lamivudine (3TC), zidovudine (AZT), tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)
3081117|NCT01448824|Experimental|Part 1 (Cohort A): 100 mg, 1800 mg LY2484595, Placebo|"Period 1: Participants will receive either 100 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive either 1800 mg LY2484595 tablets or placebo tablets QD by mouth on Days 1 through 14 of Period 2."
3081118|NCT01448824|Experimental|Part 1 (Cohort B): 300 mg LY2484595, Placebo|Participants will receive either 300 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
3081119|NCT01448824|Experimental|Part 1 (Cohort C): 600 mg LY2484595, Placebo|Participants will receive either 600 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
3081120|NCT01448824|Experimental|Part 1 (Cohort D): 1200 mg LY2484595, Placebo|Participants will receive either 1200 milligrams (mg) LY2484595 tablets or placebo tablets once daily (QD) by mouth on Days 1 through 14.
3081121|NCT01448824|Experimental|Part 2 (Cohort E): 100 mg LY2484595 ± 400 mg Ketoconazole|"Period 1: Participants will receive 100 milligrams (mg) LY2484595 tablet by mouth on Day 1 of Period 1.~Washout period lasting ≥14 days.~Period 2: Participants will receive 400 mg ketoconazole tablets once daily (QD) by mouth on Days 1 through 14 of Period 2. Participants will receive 100 mg LY2484595 tablet by mouth on Day 5 of Period 2."
3081122|NCT01448850|Placebo Comparator|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
3081123|NCT01448850|Experimental|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 milligram (mg) as intravenous (IV) infusion on Day 1 followed by 300 mg injection subcutaneously (SC) every 4 weeks up to Week 53.
3081124|NCT01449006|No Intervention|Standard of care HAART regimen|Participants randomised to this arm of the trial will remain on their usual prescribed HAART regimen.
3081125|NCT01449006|Experimental|Maraviroc|Participants randomised to this arm will remain on their usual prescribed HAART regimen, with the addition of Maraviroc. Maraviroc will be prescribed according to the Product Information Sheet, with consideration given to background therapy.
3081126|NCT01449240||No treatment|Approximately 5 adults (equal to or not less than 18yrs old) and 5 children (equal to or not over 18yrs old)
3081127|NCT01449266|Other|Dotarem®-injected patients|Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
3081128|NCT01449279|Experimental|Ipilimumab Treatment + Radiation Therapy|Ipilimumab (BMS-734016, MDX010, MDX-CTLA4, Yervoy) will be administered as standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments. Palliative radiation therapy to 1 to 2 sites of disease will start within 5 days of the first ipilimumab dose. Subjects will have follow up visits 2 to 4 weeks after the last ipilimumab dose and then every 3 months (±2 weeks) thereafter until progression of disease.
3081129|NCT01449305|Experimental|Nanoone Woman Underwear|"Nanoone negative ion of textiles, which is health material specifically designed for human body, in short distance and long time to produce negative ion, the human body really needed, it can neutralize free radical in the human body."
3081130|NCT01449370|Experimental|Arm A|TAK-117 administered once a day orally
3081131|NCT01449370|Experimental|Arm B|TAK-117 administered orally intermittently, once every other day (Monday, Wednesday, and Friday) each week
3081132|NCT01449370|Experimental|Arm C|TAK-117 administered orally intermittently, once a day for 3 consecutive days (Monday, Tuesday, and Wednesday) each week
3081133|NCT01449461|Experimental|Brigatinib 30 mg QD/60 mg QD|Brigatinib 30 mg/60 mg, tablets, orally, once daily (QD) in each cycle of 28 days (Approximately up to 7.3 years).
3081134|NCT01449461|Experimental|Brigatinib 90 mg QD|Brigatinib 90 mg, tablets, orally, QD in each cycle of 28 days (Approximately up to 7.3 years).
3081135|NCT01449461|Experimental|Brigatinib 120 mg QD/60 mg BID|Brigatinib 120 mg, once daily or 60 mg, twice daily (BID), tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
3081136|NCT01449461|Experimental|Brigatinib 90 mg QD-180 mg QD|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in cycle 2 and onward cycles of 28 days.
3081137|NCT01449461|Experimental|Brigatinib 180 mg QD/90 mg BID|Brigatinib 180 mg, once daily or 90 mg, BID, tablets, orally in each cycle of 28 days (Approximately up to 7.3 years).
3081138|NCT01449461|Experimental|Brigatinib 240 mg QD/120 mg BID/300 mg QD|Brigatinib 240 mg, QD or 120 mg, BID or 300 mg once daily, tablets, orally, in each cycle of 28 days (Approximately up to 7.3 years).
3081139|NCT01449513|Active Comparator|PEP005 Gel 0.05%|active ingredient of PEP005: Ingenol mebutate
3081140|NCT01449513|Placebo Comparator|Placebo Gel|Vehicle of PEP005 Gel
3081141|NCT01449526|Experimental|B&L Investigational Contact Lens|The Bausch + Lomb investigational silicone hydrogel contact lens
3081142|NCT01449526|Active Comparator|B&L PureVision Contact Lens|The Bausch + Lomb PureVision silicone hydrogel contact lens
3081143|NCT01449630|Experimental|LY3031207|Participants received escalating doses of 5 mg (milligrams), 25 mg, 75 mg, 225 mg, 450 mg and 900 mg of LY3031207 capsule orally.
3081144|NCT01449630|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to two occasions separated by at least a 3 week wash-out period between each dose.
3081145|NCT01449630|Active Comparator|Celecoxib|Single 400mg dose of celecoxib administered orally on one occasion.
3081146|NCT01449682|Active Comparator|Ozurdex PRN|0.7 mg intravitreal DEX implant at Visit 1 then PRN for duration of trial (48 weeks) if evidence of fluid on OCT
3081147|NCT01449682|Active Comparator|Ozurdex Q16 weeks|0.7 mg intravitreal DEX implant at Visit 1 then Q16 weeks
3081148|NCT01449708|No Intervention|Balanced Anesthesia|Patients will receive balanced general anesthesia including volatile anesthetics and narcotics. This reflects our current clinical practice.
3081149|NCT01449708|Active Comparator|NoNarc TIVA|Patients will receive narcotic free total intravenous anesthesia with Propofol, dexmedetomidine and ketamine
3081150|NCT01449721|No Intervention|Control|Standard medical care by the primary treatment team.
3081151|NCT01449721|Experimental|Interventional arm|Protocolized empiric resuscitation delivering weight-based intravenous fluid resuscitation targeting lactate normalization
3081152|NCT01449747|Active Comparator|study group|sitagliptin hypo-response patients
3081153|NCT01449747|Sham Comparator|control group|sitagliptin response patients
3081154|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 1 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3081155|NCT01449812|Experimental|INFANRIX+HIB/POLIORIX 2 GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix-IPV/Hib™ vaccine at 3, 4 and 5 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3081156|NCT01449812|Active Comparator|CONTROL GROUP|Healthy male or female children between, and including, 18 and 24 months of age at the time of booster vaccination, who were primed with 3 doses of the Infanrix+Hib™ and of Poliorix™ vaccines at 2, 3 and 4 months of age in the DTPA-IPV-056 (112584) primary study, additionally received 1 dose of Poliorix™ and of Infanrix+Hib™ vaccines, administered intramuscularly into the upper sides of the left and right thighs, respectively.
3081157|NCT01449864|Experimental|Proton RT|Subjects receive proton radiation
3081158|NCT01449929|Experimental|dolutegravir 50mg once daily (OAD)|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
3081159|NCT01449929|Active Comparator|darunavir 800mg OAD in combination with ritonavir 100mg OAD|in combination with either abacavir/lamivudine fixed dose combination tablet OAD or tenofovir disoproxil fumarate/emtricitabline fixed dose combination tablet OAD
3081160|NCT01449955|Placebo Comparator|Placebo (e.g., sugar pill)|15 mg Placebo will be administered once, in pill form.
3081161|NCT01449955|Active Comparator|Rapamycin|15 mg of Rapamycin will be administered once, in pill form.
3081162|NCT01450007|Experimental|Dexamethasone block|Blockade with 25 ml ropivacaine 0.5% mixed with 8 mg dexamethasone (0.8 ml), and 5 ml intravenous normal saline
3081163|NCT01450007|Active Comparator|Dexamethasone IV|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and intravenous 8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml
3081164|NCT01450007|Placebo Comparator|Placebo|Blockade with 25 ml ropivacaine 0.5% mixed with 0.8 ml normal saline, and 5 ml intravenous normal saline
3081165|NCT01450098|Experimental|Cohort A: Fixed Sequence of Meal Conditions|LY2484595 (evacetrapib): 200 milligrams (mg) of LY2484595 administered orally, one time only, as an SDSD-PG tablet given with no food. There was a washout of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with low-fat breakfast. There was another washout period of at least 14 days before crossing over and receiving a 200 mg of LY2484595 administered orally, one time only, as a SDSD-PG tablet given with high-fat breakfast.
3081166|NCT01450098|Experimental|Cohort B: Comparison of Randomized Treatments|LY2484595 (evacetrapib): 100 mg of LY2484595 administered orally as an RF tablet given with a low-fat breakfast. There was a washout period of at least 14 days before crossing over and receiving 100 mg of LY2484595 administered orally as a SDSD-PG tablet given with a low-fat breakfast. There was another washout of at least 14 days before crossing over and receiving 300 mg of LY2484595 as a SDSD-PG tablet given with a low-fat breakfast.
3081167|NCT01450137|Experimental|Tocilizumab|Tocilizumab 8mg/kg every 4 weeks until week 52.
3081168|NCT01450137|Placebo Comparator|Placebo|Placebo every 4 weeks until week 52.
3081169|NCT01450189|Active Comparator|Standard Counseling Arm|The SC arm consists of a single session of standard HIV prevention messages during HIV post-test counseling. The counseling will be comparable to that given to persons with established HIV infection with supplemental information regarding the acute stage of their infection.
3081170|NCT01450189|Active Comparator|Behavioral Intervention Arm only|Behavior- BI: Information-Motivation-Behavioral Skills Model the Information-Motivation-Behavioral Skills (IMB) Model. The 5 sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
3081171|NCT01450189|Active Comparator|Behavioral Intervention plus ARV|The BIA arm consists of the behavioral intervention plus antiretroviral drugs (ARVs) with raltegravir (400 mg twice daily) and fixed dose combination (FDC) emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) (200/300 mg daily) orally for 12 weeks.
3081172|NCT01450306|Experimental|D-cycloserine plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus 50 mg oral d-cycloserine administered 1 hr prior to exposure therapy session
3081173|NCT01450306|Placebo Comparator|Placebo plus exposure therapy|Single session (up to 3 hr) of in vivo exposure therapy plus oral placebo capsule administered 1 hr prior to exposure therapy session
3081174|NCT01450319|Experimental|Cetuximab|
3081175|NCT01450397|Other|XIAFLEX|XIAFlEX
3081176|NCT01450540|Active Comparator|Group 1|REMStar auto A-Flex
3081177|NCT01450540|Experimental|Group 2|modified REMstar Auto A-Flex with AGPAP
3081178|NCT01450631|Active Comparator|Standard Dressing|Standard-of-care includes coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™) consistent with the national standard for dressing Cesarean section incisions.
3081179|NCT01450631|Experimental|Prevena™ (PIMS)|PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period.
3081180|NCT01450683|Experimental|Itraconazole|600 mg/day oral (PO)
3081181|NCT01450696|Active Comparator|Capecitabine + Cisplatin + Herceptin (6 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 mg/kg q3w as a standard of care from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
3081182|NCT01450696|Experimental|Capecitabine + Cisplatin + Herceptin (10 mg/kg)|Participants will receive Herceptin at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 10 mg/kg q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason (cycle length = 21 days). Participants will also receive cisplatin 80 mg/m^2 intravenously q3w plus capecitabine 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 treatment cycles (Cycles 1 to 6).
3081183|NCT01450761|Experimental|Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Ipilimumab: IV solution, Intravenous (IV), 10 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
3081184|NCT01450761|Placebo Comparator|Placebo matching Ipilimumab+Etoposide+Cisplatin/Carboplatin|"Placebo matching Ipilimumab: IV solution, IV, 0 mg/kg, Once every 3 weeks for 4 doses, then every 12 weeks, Until progression of disease or unacceptable toxicity, or until the maximum treatment period of 3 years is reached~Etoposide: IV solution, IV, 100 mg/m2, Days 1-3 every 3 weeks, 4 cycles~Cisplatin: IV solution, IV, 75 mg/m2, Once every 3 weeks, 4 doses~Carboplatin: IV Solution, IV, Area Under the Curve (AUC) 5, Once every 3 weeks, 4 doses"
3081185|NCT01450787||diabetics|diabetics
3081186|NCT01450787||non diabetics|non diabetics
3081187|NCT01450800|Active Comparator|Nitrofurantoin|Nitrofurantoin 100mg by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
3081188|NCT01450800|Placebo Comparator|Placebo|Placebo drug 1 tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
3081189|NCT01450813|Sham Comparator|Group 1|Saline 0.06 ml/kg
3081190|NCT01450813|Active Comparator|Group 2|Rocuronium 0.2 mg/kg
3081191|NCT01450813|Active Comparator|Group 3|Rocuronium 0.4 mg/kg
3081192|NCT01450813|Active Comparator|Group 4|Rocuronium 0.6 mg/kg
3081193|NCT01450826|Active Comparator|aprepitant+ondansetron|On day 1, patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide). Additionally, On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
3081194|NCT01450826|Active Comparator|ondansetron|On days 1-5, patients receive a single dose of Ondansetron 30 minutes before the receiving their prescribed dose of 5-day oral temozolomide.
3081195|NCT01450943|Active Comparator|Standard of care|debridement, irrigation , PRIMARY dressing Adaptic and Iodosorb, SECONDARY dressing gauze and tape
3081196|NCT01450943|Experimental|Dermagraft|debridement, irrigation , PRIMARY dressing Dermagraft and Adaptic, SECONDARY dressing gauze and tape
3081197|NCT01450943|Experimental|Oasis|debridement, irrigation , PRIMARY dressing Oasis and Adaptic, SECONDARY dressing gauze and tape
3081198|NCT01451164|Experimental|High dose|
3081199|NCT01451164|Experimental|Mid dose|
3081200|NCT01451164|Experimental|Low dose|
3081201|NCT01451164|Placebo Comparator|Placebo|
3081202|NCT01451203|Placebo Comparator|PBO + MTX|Participants who received placebo subcutaneously every two weeks (Q2W) at Weeks 0, 2, and 4; followed by placebo subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
3081203|NCT01451203|Experimental|CZP + MTX|Participants who certolizumab pegol (CZP) subcutaneously at a loading dose of CZP 400 mg every 2 weeks (Q2W) at Weeks 0, 2, and 4; followed by a dose of CZP 200 mg subcutaneously Q2W from Week 6 to Week 50 and an oral dose of MTX administered from Week 0 onwards
3081204|NCT01451385|Experimental|COV795|Participants receive 2 tablets of COV795 every 12 hours for up to 35 days
3081205|NCT01451398|Experimental|TI inhalation powder|Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs
3081206|NCT01451398|Placebo Comparator|Technosphere powder|Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs
3081207|NCT01451411|Experimental|Conivaptan hydrochloride|
3081208|NCT01451411|Placebo Comparator|Placebo|
3321093|NCT02016118||Ialuril|Intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
3081209|NCT01451424|Experimental|Proellex 12 mg PK group|Subjects receiving 12 mg Proellex administered vaginally, and completing a PK arm consisting of 1 x 24 hr PK of Proellex, 14 days of daily Proellex trough measurements, and 1 x 24 hr PK of Proellex after 14 days of daily dosing. 12 mg PK subjects will continue with the protocol as written after the first 2 week period and will be treated for a total of 16 weeks.
3081210|NCT01451424|Experimental|Proellex 12 mg per protocol|Subjects receiving 12 mg Proellex daily, vaginally for 12 weeks
3081211|NCT01451424|Experimental|Proellex 6 mg per protocol|Subjects receiving 6 mg Proellex daily, vaginally for 12 weeks
3081212|NCT01451424|Experimental|Proellex 3 mg per protocol|Subjects will receive 3 mg Proellex daily, vaginally for 12 weeks.
3081213|NCT01451424|Experimental|24 mg Proellex|24 mg vaginal Proellex daily for 16 weeks
3081214|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 30 mg QD|Participants received MK-8242 30 mg once daily (QD) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3081215|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 60 mg QD|Participants received MK-8242 60 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3081216|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg QD|Participants received MK-8242 120 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3081217|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg QD|Participants received MK-8242 250 mg QD monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles in Part 1 Arm A.
3081218|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 120 mg BID|Participants received MK-8242 120 mg twice daily (BID) monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 120 mg was administered QD in the morning) in Part 1 Arm A.
3081219|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 170 mg BID|Participants received MK-8242 170 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 170 mg was administered QD in the morning) in Part 1 Arm A.
3081220|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 210 mg BID|Participants received MK-8242 210 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 210 mg was administered QD in the morning) in Part 1 Arm A.
3081221|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 250 mg BID|Participants received MK-8242 250 mg BID monotherapy on Days 1-7 and Days 15-21 of a 28-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 250 mg was administered QD in the morning) in Part 1 Arm A.
3081222|NCT01451437|Experimental|Pt 1 Arm A: MK-8242 300 mg BID|Participants received MK-8242 300 mg BID monotherapy on Days 1-7 of a 21-day cycle up to a maximum of 12 cycles (except Cycle 1 Day 7 on which MK-8242 300 mg was administered QD in the morning) in Part 1 Arm A.
3081223|NCT01451541|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37mcg once daily
3081224|NCT01451541|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg once daily
3081225|NCT01451541|Placebo Comparator|Placebo|
3081226|NCT01451554|Active Comparator|Portion Control Intervention|Individuals will be given a portion control plate and dietary counseling
3081227|NCT01451554|Placebo Comparator|Usual Care|Provided with self-help booklets on diet and exercise.
3081228|NCT01451606|Placebo Comparator|Placebo pill|A pill that looks like the active drug, but does not contain any active ingredients.
3081229|NCT01451606|Active Comparator|Duloxetine|The drug, Duloxetine, is marketed under the trade name Cymbalta. It is a serotonergic and noradrenergic reuptake inhibitor (SNRI).
3081230|NCT01451632|Experimental|Part 1: MM-121 + cetuximab|increasing doses of weekly MM-121 + weekly cetuximab
3081231|NCT01451632|Experimental|Part 2: MM-121 + cetuximab + irinotecan|increasing doses of irinotecan + the Recommended Phase 2 Dose/Maximum Tolerated Dose (RP2D/MTD) of MM121 + cetuximab as determined in Part 1
3081232|NCT01451645|Other|placebo|daily placebo dosing for 16 weeks with background allopurinol therapy
3081233|NCT01451645|Active Comparator|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks with background allopurinol therapy
3081234|NCT01451749|Experimental|Shenwu Capsule|"Shenwu Capsule:1 capsule contains 451 mg of Shenwu extracts. 5 capsules/time, 3 times/day for 6 months.~Placebo: Placebo identical to donepezil tablets,1 placebo tablet/time, 1 time/day for 6 months."
3081235|NCT01451749|Active Comparator|Donepezil|"Donepezil: 1 tablet contains 5 mg of donepezil, 1 tablet/time, 1time/day for 6 months.~Placebo: Placebo identical to shenwu capsules,5 placebo capsules/time,3 times/day for 6 months"
3081236|NCT01451762|Placebo Comparator|Placebo|.9 normal saline IV
3081237|NCT01451762|Active Comparator|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
3081238|NCT01451762|Active Comparator|50 mg diphenhydramine IV|50 mg diphenhydramine IV administered before surgery
3081239|NCT01451775|Experimental|Treatment A|high dose of empagliflozin after overnight fasting for at least 10 h
3081240|NCT01451775|Experimental|Treatment B|high dose of empagliflozin after a standardised high fat breakfast
3081241|NCT01451775|Experimental|Treatment C|low dose empagliflozin after overnight fasting for at least 10 h
3081242|NCT01451814|Experimental|Positive psychotherapy|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
3081243|NCT01451814|Active Comparator|Standard treatment|6 sessions of individual behavioral smoking cessation counseling with 8 weeks of transdermal nicotine patch. Inlcudes relaxation training to match time in the experimental condition
3081244|NCT01451827|Experimental|Tolvaptan MR 50 mg|Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.
3081245|NCT01451827|Experimental|Tolvaptan MR 80 mg|Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
3081246|NCT01451827|Experimental|Tolvaptan IR 60/30 mg|Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.
3081247|NCT01451827|Placebo Comparator|Placebo|Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.
3081248|NCT01451931|Experimental|Point-of-care Ultrasound|Patient with suspected urolithiasis will receive ultrasonography performed in the emergency department. Perform ultrasonography in the ED (physician).
3081249|NCT01451931|Experimental|Radiology Ultrasound|Patient with suspected urolithiasis will receive diagnostic ultrasonography in the radiology department. Diagnostic ultrasound completed in the radiology department at time 0.
3081250|NCT01451931|Experimental|Radiology CT|Patient with suspected urolithiasis will receive computed tomography in the radiology department. Computed tomography of abdomen completed in the radiology department at time 0.
3081251|NCT01451983||ASD with PTEN|Individuals with autism spectrum disorder who are also found to have a PTEN mutation.
3081252|NCT01451983||ASD no PTEN macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation with a large head circumference.
3081253|NCT01451983||ASD no PTEN no macrocephaly|Individuals with autism spectrum disorder who do not have a PTEN mutation without a large head circumference.
3081254|NCT01451983||Siblings|Siblings of individuals with autism spectrum disorders.
3081255|NCT01451996|Other|Claritin ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Claritin.
3081256|NCT01451996|Other|Zyrtec ads|Subject will be given 10mg Claritin tablet and then watch a movie that includes commercials for Zyrtec.
3081257|NCT01452126|Experimental|Ropivacaine|Sequential allocation of ropivacaine concentration depending on the success or failure of surgical anesthesia of the previous patient
3081258|NCT01452152|Experimental|Genotype-directed, clopidogrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 extensive and ultrarapid metabolizers will receive clopidogrel.
3081259|NCT01452152|Experimental|Genotype-directed, prasugrel|Participants randomized to the G-D group will have CYP2C19 genotype analysis performed. CYP2C19 intermediate and poor metabolizers will receive prasugrel.
3081260|NCT01452152|No Intervention|Standard of Care|Participants randomized to the SOC group will not have CYP2C19 genotype analysis performed. They will receive dual anti-platelet therapy guided by the judgment of their treating physician according to standard medical practice irrespective of genotype.
3081261|NCT01452191|Active Comparator|Injury Prevention Briefing and facilitation|Children's Centres will be given an Injury Prevention Briefing which offers guidance on best evidence on reducing fire related injuries in the home, and facilitation by the research team to support implementation of the IPB
3081262|NCT01452191|Active Comparator|Injury Prevention Briefing only|Children's Centres will be given an Injury Prevention Briefing (IPB) , which offers guidance on best evidence on reducing fire related injuries in the home.
3081263|NCT01452191|No Intervention|Usual Care|
3081264|NCT01452269|Experimental|Immediate intervention group|This arm will receive the intervention immediately following baseline data collection.
3081265|NCT01452269|Experimental|Delayed intervention group|This arm will receive the intervention one year following the immediate intervention group.
3081266|NCT01452347|Experimental|Dabigatran etexilate|Patient dose dependent on screening CrCl levels and TT
3081267|NCT01452347|Active Comparator|warfarin|warfarin doses to maintain INR levels
3081268|NCT01452412|Experimental|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
3081269|NCT01452412|Placebo Comparator|Placebo|placebo dosage/frequency equivalent to sodium bicarbonate
3081270|NCT01452425|Experimental|Tourniquet|Inflation of a tourniquet
3081271|NCT01452529|Experimental|Hydrocodone bitartrate|Hydrocodone bitartrate (HYD) once daily (q24h) tablets
3081272|NCT01452529|Placebo Comparator|Placebo|Placebo to match hydrocodone bitartrate once daily tablets
3081273|NCT01452789|Experimental|sublingual buprenorphine|This is the group that received active sublingual buprenorphine and placebo for oral morphine
3081274|NCT01452789|Active Comparator|oral morphine|This is the group that received active oral morphine and placebo for sublingual buprenorphine
3081275|NCT01452919|Experimental|LY2140023/LY2140023|"Open label phase: 40 milligram (mg) LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time. Current dose level at randomization will remain constant through the double blind phase.~Double blind phase: 40 mg or 80 mg LY2140023 administered orally; given twice daily for up to 3 weeks."
3081276|NCT01452919|Placebo Comparator|LY2140023/Placebo|"Open label phase: 40 mg LY2140023 administered orally; given twice daily for up to 4 weeks. At the discretion of the investigator, dose may be adjusted one time to 80 mg. 80 mg dose may be adjusted back to 40 mg one time.~Double blind phase: placebo administered orally; given twice daily for up to 3 weeks."
3081277|NCT01453023|Active Comparator|Fluticasone Furoate|One of two study treatments subjects will receive. Given to allow comparison of FF exposure in combination versus as mono therapy.
3081278|NCT01453023|Experimental|Fluticasone Furoate/Vilanterol|One of two study treatments subjects will receive. FF/VI combined is being tested and compared to fluticasone furoate.
3081279|NCT01453036|Active Comparator|Conventional AOC group|The investigators do not perform mutation test in the conventional group apply amoxicillin 1 g, bid , rabeprazole 20 mg bid, clarithromycin 500 mg bid during 1weeks
3081280|NCT01453036|Active Comparator|Mutation test group|Mutation test group is composed of two groups, clarithromycin group and metronidazole group Clarithromycin subgroup ; no point mutation at 23S rRNA apply clarithromycin 500 mg bid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week Metronidazole subgroup ; point mutation at 23S rRNA apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
3081281|NCT01453036|Active Comparator|Conventional AOM group|The investigators do not perform mutation test in the conventional group apply metronidazole 500 mg tid, amoxicillin 1 g bid, rabeprazole 20 mg bid during 1 week
3081282|NCT01453049|Experimental|fix dose of rosiglitazone/glimepiride|4mg/1mg, 4mg/2mg, 4mg/4mg
3081283|NCT01453049|Active Comparator|glimepiride|1mg, 2mg, 4mg
3081284|NCT01453075|Experimental|Arm 1: valacyclovir|Assigned patients will take 1.5 mg po valacyclovir twice daily
3081285|NCT01453075|Placebo Comparator|Arm 2: placebo|Assigned patients will receiving matching placebo twice daily
3081286|NCT01453153|Active Comparator|Gemcitabine|Gemcitabine + Placebo
3081287|NCT01453153|Experimental|PEGPH20|PEGPH20+Gemcitabine
3081288|NCT01453166|Experimental|Group 1|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
3081289|NCT01453166|Experimental|Group 2|Group B received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
3081290|NCT01453166|Experimental|Group 3|Group C received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
3081291|NCT01453205|Active Comparator|Rituximab+ ICE/DHAP|Participants will receive Rituximab in combination with ifosfamide + carboplatin + etoposide (ICE) or dexamethasone + cisplatin + cytarabine (DHAP) for 3 cycles (21-day cycles) and will followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). Rituximab (375 mg/m^2) will be administered intravenous (IV) on 2 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of rituximab, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of rituximab, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3081292|NCT01453205|Experimental|MEDI-551 2 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (2 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (2 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3081293|NCT01453205|Experimental|MEDI-551 4 mg/kg + ICE/DHAP|Participants will receive MEDI-551 (4 mg/kg) in combination with ICE or DHAP for 3 cycles (21-day cycles) and will be followed until end of the study (36 months after the date of randomization for last participant, or date the sponsor stops the trial, whichever occurs first). MEDI-551 (4 mg/kg) will be administered IV on 7 days before the start of Cycle 1 and on Day 1 of each cycle. After completion of MEDI-551, IV infusion of ICE as: ifosfamide 5 g/ m^2 continuously for 24 hours with mesna on Day 2; carboplatin AUC=5 mg/mL x min (800 mg maximum) on Day 2; etoposide 100 mg/ m^2 on Days 1, 2, and 3 in 21-day cycles. After completion of MEDI-551, IV infusion of DHAP as: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m^2 continuously for 24 hours on Day 1; cytarabine 2 g/m^2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
3081294|NCT01453296|Active Comparator|COHORT 1 (RANDOMISATION AB or BA)|"8-11 years old; Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
3081295|NCT01453296|Active Comparator|COHORT 2 (RANDOMISATION AB or BA)|"5-7 years old. Subjects will be assigned to receive GW642444 25μg or matching placebo (in a 1:1 ratio) in an AB or BA (A= GW64244, B= Placebo) sequence.~Following randomisation (AB or BA) subjects will receive a single dose treatment, followed by 7 day washout period. This will then be followed by a repeat dose session of the same treatment (Day 8 and Day 14 in house, Days 9-13 at home).~Each subject will then complete the same sequence for the alternative treatment in the second session. There will be a washout period of at least 7 days between the treatment periods."
3081296|NCT01453348|Active Comparator|Group 1|This group will receive Inactivated hepatitis A and recombinant hepatitis B or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' alone on the different visits.
3081297|NCT01453348|Active Comparator|Group 2|This group will receive Inactivated hepatitis A vaccine and recombinant hepatitis B Vaccine or 'Combined inactivated hepatitis A & recombinant hepatitis B vaccine' concomitantly with MenACWY-CRM.
3081298|NCT01453348|Active Comparator|Group 3|This group will receive only MenACWY-CRM.
3081299|NCT01453361|Experimental|Vigil™ Vaccine|Autologous Vigil™ vaccine will be supplied by Gradalis, Inc. Patients will receive 1 x 10e7 cells via intradermal injection one day each month for a minimum maximum of 12 doses as long as subject is clinically stable.
3081300|NCT01453374|Experimental|VIVITROL|380 mg IM injection
3081301|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 1)|
3081302|NCT01453387|Experimental|Part 1 - MSC2015103B (Schedule 2)|
3081303|NCT01453413|Other|People with type 2 diabetes|People with type 2 diabetes who were in attendance at a diabetes conference were asked for their perceived Blood Glucose (BG) value. Then, after staff measured BG on a Blood Glucose meter, subjects were informed of their BG value.
3081304|NCT01453439|Experimental|Cognitive Behavioral Therapy|Group receiving Cognitive-Behavioral Therapy
3081305|NCT01453439|Active Comparator|Supportive Psychotherapy|Group receiving Supportive Psychotherapy
3081306|NCT01453569|Experimental|sodium oligo-mannurarate 900mg|
3081307|NCT01453569|Experimental|sodium oligo-mannurarate 600mg|
3081308|NCT01453569|Placebo Comparator|Placebo|
3081309|NCT01453595|Experimental|BEZ235|"This is a single-institution, open label, single-arm Phase 1b/2 trial of BEZ235 in patients with advanced RCC. The study will be conducted in two phases:~Phase 1b: dose-escalation will be performed to determine the maximally tolerated dose (MTD) of twice daily BEZ235 to use in Phase 2 (RP2 dose).~Phase 2: subjects with clear cell who have experienced disease progression on prior first or second-line mTOR targeted therapy will be treated on the MTD of twice daily BEZ235."
3081310|NCT01453725|Experimental|Golimumab→Golimumab|In Part 1, participants receive golimumab 50 mg, administered subcutaneously (SC) every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 48 weeks treatment with golimumab.)
3081311|NCT01453725|Placebo Comparator|Placebo→Golimumab|In Part 1, participants receive placebo, administered SC every 4 weeks for up to 12 weeks (16 weeks of treatment). In Part 2, participants receive golimumab 50 mg, administered SC every 4 weeks for up to 28 weeks (32 weeks of treatment). (Combined total of up to 32 weeks treatment with golimumab.)
3081312|NCT01453855|Experimental|Travoprost 0.003%|Travoprost ophthalmic solution, 0.003%, one drop instilled in each eye, once daily, for three months
3081313|NCT01453855|Active Comparator|TRAVATAN|Travoprost ophthalmic solution, 0.004%, one drop instilled in each eye, once daily, for three months
3081314|NCT01453894|Experimental|Reminder and Outreach Intervention|Participants randomized to this arm will receive the Reminder and Outreach intervention.
3081315|NCT01453894|No Intervention|Usual Care Control Group|Patients assigned to this arm will receive usual care.
3081316|NCT01453946|Other|Entocort|Study Medication
3081317|NCT01453998|Experimental|GSK217744 Group 1|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation A vaccine in the primary study and a booster dose of either GSK217744 formulation A vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3081318|NCT01453998|Experimental|GSK217744 Group 2|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the GSK217744 formulation B vaccine in the primary study and a booster dose of either GSK217744 formulation B vaccine (for subjects vaccinated before Protocol Amendment 2) or Infanrix hexa vaccine (for subjects vaccinated after Protocol Amendment 2) in this study, coadministered with a booster dose of Prevenar 13. The Infanrix hexa/GSK217744 and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3081319|NCT01453998|Active Comparator|Infanrix hexa Group|Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
3081320|NCT01454063|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3081321|NCT01454063|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3081322|NCT01454076|Experimental|Arm 1: Ixazomib 2.5 mg + Ketoconazole 400 mg|Ixazomib 2.5 milligram (mg), capsule B, orally, once on Day 1 and 15 along with ketoconazole 400 mg, tablets, orally, once daily from Day 12 to 25 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3081323|NCT01454076|Experimental|Arm 2: Ixazomib 4 mg Capsule A or B|Ixazomib 4 mg, capsule A, orally, once on Day 1 followed by ixazomib 4 mg, capsule B once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, once on Day 1 followed by ixazomib 4 mg, capsule A once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3081324|NCT01454076|Experimental|Arm 3: Ixazomib 4 mg Fasted or Fed|Ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fed state, once on Day 15 of Cycle 1 (28-day treatment cycle) or ixazomib 4 mg, capsule B, orally, under fed state, once on Day 1 followed by ixazomib 4 mg, capsule B, orally, under fasted state, once on Day 15 of Cycle 1 (28-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3081325|NCT01454076|Experimental|Arm 4: Ixazomib 4 mg + Rifampin 600 mg|Ixazomib, 4 mg, capsule B, orally, once on Day 8 along with rifampin 600 mg, capsule, orally, once daily from Day 1 to 14 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3081326|NCT01454076|Experimental|Arm 5: Ixazomib 2.5 mg + Clarithromycin 500 mg|Ixazomib, 2.5 mg, capsule B, orally, once on Day 6 along with clarithromycin, 500 mg, tablet, orally, twice daily from Day 1 to 16 of Cycle 1 (21-day treatment cycle). After Cycle 1, participants will receive ixazomib 4 mg, capsule B, orally, once daily on Days 1, 8 and 15 of each cycle (28-day treatment cycle) up to a maximum of 12 cycles, until disease progression or unacceptable toxicity.
3081327|NCT01454102|Experimental|Arm A: Nivolumab + Gemcitabine + Cisplatin|"Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
3468886|NCT03891654|Experimental|Dynamic Contrast Enhanced Computed Tomography|DCE-CT, also known as perfusion CT, is a functional imaging modality that uses repeated computed tomography imaging after injection of an iodine based contrast agent.
3081328|NCT01454102|Experimental|Arm B: Nivolumab + Pemetrexed + Cisplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles"
3081329|NCT01454102|Experimental|Arm C: Nivolumab + Paclitaxel + Carboplatin|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles"
3081330|NCT01454102|Experimental|Arm D: Nivolumab + Bevacizumab maintenance|"Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity"
3081331|NCT01454102|Experimental|Arm E: Nivolumab + Erlotinib|"Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity"
3081332|NCT01454102|Experimental|Arm F: Nivolumab|Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
3081333|NCT01454102|Experimental|Arm G: Nivolumab + Ipilimumab|"In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity"
3081334|NCT01454102|Experimental|Arm H: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3081335|NCT01454102|Experimental|Arm I: Nivolumab + Ipilimumab|"In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3081336|NCT01454102|Experimental|Arm J: Nivolumab + Ipilimumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3081337|NCT01454102|Experimental|Arm K: Nivolumab|"In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks"
3081338|NCT01454102|Experimental|Arm L: Nivolumab|"In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks"
3081339|NCT01454102|Experimental|Arm M: Nivolumab|"NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks"
3081340|NCT01454102|Experimental|Arm N: Nivolumab + Ipilimumab|"In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity"
3081341|NCT01454102|Experimental|Arm O: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3081342|NCT01454102|Experimental|Arm P: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3081343|NCT01454102|Experimental|Arm Q: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3081344|NCT01454102|Experimental|Arm R: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3081345|NCT01454102|Experimental|Arm S: Nivolumab + Ipilimumab|"Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity"
3081346|NCT01454284|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered subcutaneously (SC) once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
3081347|NCT01454284|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered SC once daily at bedtime for 52 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered SC at meal times for 52 weeks.
3081348|NCT01454362|Experimental|Electronic cigarette|We analysed 15 brands of the most popular E-Cs in the UK, EU and US for nicotine levels in the mist. Vapours were generated from cartridges of various nicotine content using a standard single-port linear smoking machine with a puff volume of 70 ml, 1 puff every 7 sec., and a puff duration of 1.8 sec (based on averaged puffing conditions from 10 E-C users found during preliminary studies). Nicotine was absorbed in two sequential washing bottles with methanol and internal standards and analysed with gas chromatography. One brand was selected for this study as it consistently delivers about 1mg of nicotine with 20 puffs.
3321094|NCT02016118||Standard of care|Antimicrobial prophylaxis (continuous or postcoital), as described in the Guidelines on Urological Infections of the European Association of Urology or Immunoactive prophylaxis or Prophylaxis with probiotics or Prophylaxis with cranberry, or combination of these.
3081349|NCT01454362|Active Comparator|Nicotine Inhalator|The inhalator consists of a nicotine cartridge which is placed into a plastic mouthpiece. One cartridge contains 10mg of nicotine of which 4mg of nicotine can be extracted. Nicotine is delivered mainly through the oral cavity, throat, and upper respiratory tract with a minor fraction reaching the lungs. A single cartridge can be used for one 20-minute period of continuous puffing or periodic use of up to 400 puffs per cartridge.
3081350|NCT01454401|Other|Weekly LeucoPatch treatment|Weekly treatment of diabetic foot ulcers with LeucoPatch
3081351|NCT01454414|Experimental|Permethrin Impregnated Uniforms|Uniforms (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin.
3081352|NCT01454414|No Intervention|Placebo|Uniforms sent to Insect Shield, washed and refolded (no permethrin applied).
3081353|NCT01454505|Experimental|Stage B/AL-53817|Stage B: AL-53817 nasal spray solution, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
3081354|NCT01454505|Placebo Comparator|Stage B/Vehicle|Stage B: Vehicle nasal spray, 1 spray to each nostril twice a day for 4 days. On Day 5, 1 spray to each nostril 60 minutes before entering the EEC.
3081355|NCT01454531|Experimental|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
3081356|NCT01454570|Experimental|Powered Exoskeleton|persons with SCI trained to use a powered exoskeleton to ambulate overground
3081357|NCT01454583||Aliskiren|Patients getting Aliskiren at baseline
3081358|NCT01454583||ACE-I/ARB|Patients getting ACE-I (angiotensin-converting enzyme inhibitors) or ARB (angiotensin-receptor blockers) at baseline, but not Aliskiren
3081359|NCT01454583||No RAS-inhibition|Patients getting no drugs at baseline that inhibit the renin-angiotensin-aldosterone-system (RAAS)
3081360|NCT01454596|Experimental|1/Phase I Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of epidermal growth factor receptor (EGFRv)III Chimeric antigen receptor (CAR) transduced peripheral blood lymphocytes (PBL) + aldesleukin
3081361|NCT01454596|Experimental|2/Phase II Arm|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + maximum tolerated dose (MTD) of anti-EGFRvIII CAR transduced PBL established in Phase I + aldesleukin
3081362|NCT01454726|Experimental|experimental group|receiving both Diaoshi Jifa therapy and the Western medical treatment.
3081363|NCT01454726|Other|control group|receiving the Western medical treatment alone.
3081364|NCT01454739|Experimental|On-Demand|The individual dose of rFVIIIFc to treat bleeding episodes will be based on participant's clinical condition, type and severity of the bleeding event, and if indicated, Factor VIII (FVIII) levels.
3081365|NCT01454739|Experimental|Prophylaxis|Tailored prophylaxis, Weekly prophylaxis or Personalized prophylaxis available.
3081366|NCT01454778|Experimental|Paclitaxel|
3081367|NCT01454791|Experimental|Diclofenac Sodium Topical Gel first then Placebo|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
3081368|NCT01454791|Placebo Comparator|Placebo first then Diclofenac Sodium Topical Gel|1:1 randomization to either of two treatment phases of 2 weeks duration (active-placebo or placebo-active).
3081369|NCT01454830|Experimental|Tailored|Tailored, or individualized, intervention addressing patient education, skills training, and cognitive perceptions
3081370|NCT01454830|Active Comparator|Usual care|The comparison group, usual care, includes the standard of care delivered to all newly-diagnosed OSA persons proceeding to CPAP treatment
3081371|NCT01454934|Experimental|Arm A|
3081372|NCT01454934|Active Comparator|Arm B|
3081373|NCT01454947|Experimental|SA, AJ, PC|Participants are given all 3 interventions.
3081374|NCT01454947|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
3081375|NCT01454947|Experimental|SA, PC|Participants receive the Suggested Alternative and Peer Comparison interventions, but not the Accountable Justification intervention.
3081376|NCT01454947|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternative intervention.
3081377|NCT01454947|Experimental|Peer Comparison (PC)|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
3081378|NCT01454947|Experimental|Suggested Alternatives (SA)|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
3081379|NCT01454947|Experimental|Accountable Justification (AJ)|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
3081380|NCT01454947|No Intervention|Education Control|Participants do not receive any of the 3 interventions.
3081381|NCT01455012|Experimental|Rotigotine|Rotigotine, optimal dose (minimum dose 1 mg/24 h, maximum dose 3 mg/24 h)
3081382|NCT01455012|Placebo Comparator|Placebo|Placebo
3081383|NCT01455064||Type 1 or 2 diabetes, MDI or pump|
3081384|NCT01455181|Experimental|NPSP558|
3081385|NCT01455194|Active Comparator|CIC 160|Two puffs of 40 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 160 mcg)
3081386|NCT01455194|Active Comparator|CIC 320|Two puffs of 80 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 320 mcg)
3081387|NCT01455194|Active Comparator|CIC 640|Two puffs of 160 mcg ciclesonide inhaled in the morning and the evening (corresponding to a total daily dose of 640 mcg)
3081388|NCT01455415|Experimental|1: Pregabalin|
3081389|NCT01455415|Placebo Comparator|2: Placebo|
3081390|NCT01455428|Experimental|Lyrica (pregabalin)|
3081391|NCT01455428|Placebo Comparator|Placebo|
3081392|NCT01455519|Placebo Comparator|Sugar pill|Subjects may receive a pill with no medicine.
3081393|NCT01455519|Active Comparator|Hydromorphone ER|Subjects received study drug: Hydromorphone ER
3081394|NCT01456000|Experimental|EAS-AC (HeartLight)|Treatment with the EAS-AC.
3081395|NCT01456000|Active Comparator|Control Arm Ablation|Treatment with standard ablation.
3468887|NCT03891576|Experimental|Niraparib 200 mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg
3081396|NCT01456039|Experimental|Romidepsin|Patients will receive romidepsin intravenously for 4 hours on Days 1, 8, and 15 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, severe adverse events, or consent withdrawal.
3081397|NCT01456052|Experimental|Low Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally once daily (QD).
3081398|NCT01456052|Experimental|High Dose Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally three times daily (TID).
3081399|NCT01456052|Placebo Comparator|Placebo|Matching placebo administered orally.
3081400|NCT01456130|Experimental|Alogliptin|Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
3081401|NCT01456143|Experimental|HRME with proflavine|High Resolution Microendoscopy (HRME) imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer. 0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa. HRME is used to capture images of suspicious areas sprayed with proflavine hemisulfate.
3081402|NCT01456169|Active Comparator|Azilsartan medoxomil 40 mg|Azilsartan medoxomil 40 mg and placebo to chlorthalidone combination tablets, orally, once daily for up to 8 weeks.
3081403|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/12.5 mg|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
3081404|NCT01456169|Experimental|Azilsartan medoxomil + chlorthalidone 40/25 mg|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
3081405|NCT01456195|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, once daily for up to 24 weeks.
3081406|NCT01456195|Experimental|Fasiglifam 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for up to 24 weeks.
3081407|NCT01456195|Experimental|Fasiglifam 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for up to 24 weeks.
3081408|NCT01456221|Experimental|omega 3 and an hypocaloric diet|Participants will receive a supplement containing omega 3: Docosahexaenoic acid (DHA) and EPA fatty acids together with an hypocaloric diet.
3081409|NCT01456221|Placebo Comparator|Placebo|Participants will receive a supplement containing sunflower oil with an hypocaloric diet.
3081410|NCT01456299|Placebo Comparator|Control|The control group, which received an infusion of normal saline.
3081411|NCT01456299|Active Comparator|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
3081412|NCT01456299|Active Comparator|Remifentanil 2|"Remifentanil 2: The R2 group, which received a target effect-site remifentanil concentration of 2 ng/ml."
3081413|NCT01456494|Experimental|Teach-to-Goal|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
3081414|NCT01456494|Experimental|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
3081415|NCT01456780|Active Comparator|Zylet|Subject randomized to this arm will be treated with Zylet (Loteprednol/tobramycin), twice a day, for 4 weeks. Zylet is a combination of loteprednol and tobramycin. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation. Tobramycin is an antibiotic.
3081416|NCT01456780|Active Comparator|Lotemax|Subject randomized to this arm will be treated with Lotemax, twice a day, for 4 weeks. Lotemax is also known as loteprednol. Loteprednol is in a class of drugs called corticosteroids. Loteprednol inhibits processes in the body that cause inflammation.
3081417|NCT01456780|Placebo Comparator|B+L Advanced Eye Relief Lubricant Drop|Subject randomized to this arm will be treated with B+L Advanced Eye Relief Lubricant Eye Drops (Artificial Tears), twice a day, for 4 weeks.
3081418|NCT01456897|Experimental|OPC-34712|
3081419|NCT01456936|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
3081420|NCT01456936|Active Comparator|varenicline|
3081421|NCT01456936|Active Comparator|bupropion|
3081422|NCT01456936|Active Comparator|Nicotine Replacement Therapy Patch|
3081423|NCT01456949|Other|Single Arm|Cryoablation
3081424|NCT01456962||Raltegravir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with raltegravir (RAL)
3081425|NCT01456962||Atazanavir group|HIV-1-infected women on a regimen of tenofovir (TDF) and emtricitabine (FTC) with ritonavir (RIT)-boosted atazanavir (ATZ)
3081426|NCT01457014|Active Comparator|servo ventilation auto mode|Inspiratory and expiratory pressures automatically determined by the servo ventilation device.
3081427|NCT01457014|Active Comparator|Continuous positive airway pressure|Airway pressure delivered at a constant pressure level.
3081428|NCT01457014|Active Comparator|servo ventilation manual|Inspiratory and expiratory pressures automatically determined by the servo ventilation device with mandatory minimal inspiratory minus expiratory pressure difference.
3081429|NCT01457118|Experimental|NKTR-102|
3081430|NCT01457196|Other|Sequencing Arm|
3081431|NCT01457339|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3081432|NCT01457339|Placebo Comparator|Placebo|
3081433|NCT01457352|Experimental|SPARC0921|
3081434|NCT01457352|Placebo Comparator|Placebo0921|
3081435|NCT01457417|Experimental|75 milligram (mg) DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3081436|NCT01457417|Experimental|150 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3081437|NCT01457417|Experimental|300 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3081438|NCT01457417|Experimental|600 mg DKN-01 Part A|"DKN-01: DKN-01 was administered intravenously (IV) once a week over a minimum of 30 minutes and up to a maximum of 2 hours for dose levels of 75 mg, 150 mg and 300 mg. At the 600 mg dose level, DKN-01 was administered by IV on days 1 and 15 of each cycle.~PART A - Dose Escalation: Study group of 3 participants were treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation occurred sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching the maximum tolerated dose (MTD) were met or the highest planned dose study group was completed. Cycle 1 defined the dose limiting toxicity (DLT) period that governs dose escalation. The dose escalation method was guided by the incidence of DLTs during the first cycle."
3081439|NCT01457417|Experimental|300 mg DKN-01 Part B|Dose Confirmation: Once the MTD had been established or the highest planned dose level completed, 300 mg of DKN-01 was administered as IV on days 1 and 15 of every 28 day cycle.
3081440|NCT01457430|Experimental|Icatibant|Open-label study
3081441|NCT01457521|Active Comparator|Therapeutic|Ibuprofen
3081442|NCT01457521|Active Comparator|Prophylactic|Ibuprofen
3081443|NCT01457573|Experimental|One (single arm)|All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg (1 tab) and Solifenacin (Vesicare) 5 mg (1 tab) orally at the same time.
3081444|NCT01457703|Active Comparator|BMI ≥30 kg/m2|"Group 2:~BMI ≥30 kg/m2~History of regular menstrual cycles every 25-40 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
3081445|NCT01457703|Experimental|BMI 18-25 kg/m2|"BMI 18-25 kg/m2~History of regular menstrual cycles every 25-35 days~Gonadorelin-GnRH (Lutrepulse), GnRH antagonists - Cetrorelix (Cetrotide), Recombinant LH (Luveris) were administered in Aim 1. GnRH or gonadorelin (Lutrepulse) and Letrozole were administered in Aim 2."
3081446|NCT01457846|Experimental|AZD4547|AZD4547 taken orally in tablet formation, 80mg b.d., in a 2 week on, 1 week off schedule
3081447|NCT01457846|Active Comparator|Paclitaxel|Paclitaxel - 80mg/m² as a 1 hour infusion given weekly on days 1, 8 and 15 of a 28 day cycle (up to the maximum number of cycles per local practice)
3081448|NCT01457885|Experimental|CloBu4 regimen|After pre-conditioning with CloBu4 (Clofarabine/Busulfan x 4), subjects will receive a peripheral blood stem cell transplant
3081449|NCT01457924|Experimental|Cohort 1|Placebo and one dose of Ofatumumab 3mg over 24 weeks
3081450|NCT01457924|Experimental|Cohort 2|Two doses of Ofatumumab 3mg over 24 weeks
3081451|NCT01457924|Experimental|Cohort 3.1|Two doses of Ofatumumab 30mg over 24 weeks
3081452|NCT01457924|Experimental|Cohort 3.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 30mg over 24 weeks
3081453|NCT01457924|Experimental|Cohort 4.1|Two doses of Ofatumumab 60mg over 24 weeks
3081454|NCT01457924|Experimental|Cohort 4.2|Conditioning dose of Ofatumumab 3mg at randomization, two doses of Ofatumumab 60mg over 24 weeks
3081455|NCT01457924|Experimental|Cohort 5.1|Six doses of Ofatumumab 60mg over 24 weeks
3081456|NCT01457924|Experimental|Cohort 5.2|Conditioning dose of Ofatumumab 3mg at randomization, six doses of Ofatumumab 60mg over 24 weeks
3081457|NCT01457950|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind phase
3081458|NCT01457950|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind phase
3081459|NCT01457950|Experimental|Arm 3|open-label phase follows the double-blind phase, denosumab 60mg subcutaneous injection, single dose at the start of the 6-month open-label phase
3081460|NCT01458106|Experimental|All participants|"PK subgroup: After a Washout Period of ≥72 hours, at the Baseline Visit (28±7 days prior to Day 1), participants receive a single IV injection of prestudy FVIII over 5 (±2) minutes at a dose of 50 IU/kg, rounded up to the nearest 250 IU increment, for a PK assessment. Following a second Washout Period of ≥72 hours, participants receive a single IV injection of rFVIIIFc over 5 (±2) minutes at a dose of 50 IU/kg for PK assessment. The first prophylactic dose of rFVIIIFc is administered at a starting dose of 25 IU/kg IV injection on Day 1 and 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated.~Non-PK subgroup: On Day 1, a first prophylactic dose of rFVIIIFc of 25 IU/kg IV injection is given, followed by a dose of 50 IU/kg on Day 4. Dose increases to a maximum of 80 IU/kg, and frequency of administration to a minimum interval of once every 2 days, are allowed as indicated."
3081461|NCT01458119|Experimental|Migalastat|Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
3081462|NCT01458132||Subjects who experienced seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and experienced seizure
3081463|NCT01458132||Subjects who did not experience seizure|Subjects who were previously randomized in the Phase 2b studies SGN113399 or SGN113404 and did not experience seizure
3081464|NCT01458171|Experimental|IgPro20|
3081465|NCT01458210|Experimental|Ortho-Cyclen (OC) Alone (Period 1); OC+Dulaglutide (Period 2)|"Ortho-Cyclen (OC) (0.25 milligram [mg] norelgestromin [NGMN] + 0.035 mg ethinyl estradiol [EE] [active tablets] for 21 days + non-active tablets for 7 days): A 28-day course of OC consists of 0.25 mg NGMN and 0.035 mg EE (active tablets), administered orally, once per day for 21 days, then non-active tablets, administered orally, once per day for 7 days. Participants received the first 28-day course (Lead-in) followed by 2 subsequent 28-day courses (Periods 1 and 2, respectively). Following the Lead-in period, the Period 1 sample was taken during the first 28-day course and the Period 2 sample was taken during the second 28-day course.~Dulaglutide: A single, 1.5-mg subcutaneous injection on Day 19 of Period 2."
3081466|NCT01458249|Experimental|eribulin mesylate 1.4 mg/m^2|
3081467|NCT01458275|Active Comparator|ciclesonide nasal aerosol 37mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
3081468|NCT01458275|Active Comparator|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
3081469|NCT01458275|Placebo Comparator|Placebo|
3081470|NCT01458288|Experimental|TG-0054 (3.14 mg/kg)|TG-0054 (3.14 mg/kg)
3081471|NCT01458327|Experimental|3,4-methylenedoxymethamphetamine (MDMA)-assisted therapy|125 mg and 62.5 mg MDMA and therapy
3081472|NCT01458366|Experimental|Bendamustine 70mg/m^2|Level 1: Bendamustine 70mg/m^2 Ofatumumab, Carboplatin, and Etoposide
3081473|NCT01458366|Experimental|Bendamustine 50mg/m^2|Level -1: Bendamustine 50mg/m^2 Ofatumumab, Carboplatin, and Etoposide
3081474|NCT01458366|Experimental|Bendamustine 90mg/m^2|Level 2: Bendamustine 90mg/m^2 Ofatumumab, Carboplatin, and Etoposide
3081475|NCT01458366|Experimental|Bendamustine 120mg/m^2|Level 3: Bendamustine 120mg/m^2 Ofatumumab, Carboplatin, and Etoposide
3081476|NCT01458366|Experimental|Phase II MTD|Phase II: Bendamustine at MTD from Phase I, Ofatumumab, Carboplatin, and Etoposide
3081477|NCT01458392|Experimental|Dalantercept|dalantercept
3081478|NCT01458418|Experimental|Montelukast 10 mg/day|Subjects will receive two 5mg tablets of Montelukast/day.
3081479|NCT01458418|Experimental|Montelukast 5mg/day|Subjects will receive one 5mg tablet of montelukast and 1 placebo tablet per day.
3081480|NCT01458418|Placebo Comparator|placebo|Subjects will receive two placebo tablets per day.
3081481|NCT01458522|Active Comparator|fPHT 20mg|fPHT treatment arm, a bolus of 20 mg PE/kg will be administered at a rate of no greater than 75 mg PE/minute. If a further bolus is required, 5 mg PE/kg will be administered. The daily maintenance dose for fPHT will be 5 mg PE/kg divided into 2 doses.
3081482|NCT01458522|Experimental|LCM 400mg|LCM treatment arm, a bolus of 400 mg will be administered over 30 minutes. If a further bolus is required, 200 mg will be administered. Regardless of whether the subject received a rebolus, he or she will begin receiving a maintenance dose 12 hours after the initial dose. The daily maintenance dose will be the same as the total bolus (400 mg or 600 mg) divided into 2 doses.
3081483|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided twice daily (BID) in treatment-naïve participants with HCV genotype 1 infection.
3081484|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 2 infection.
3081485|NCT01458535|Experimental|ABT-450/r and ABT-267 plus RBV in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD plus weight-based ribavirin (RBV) divided BID in treatment-naïve participants with HCV genotype 3 infection.
3081486|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 1 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 1 infection.
3081487|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 2 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 2 infection.
3081488|NCT01458535|Experimental|ABT-450/r and ABT-267 in genotype 3 participants|ABT-450/r (200/100 mg) once daily (QD) and ABT-267 (25 mg) QD in treatment-naïve participants with HCV genotype 3 infection.
3081489|NCT01458561|Experimental|BioFoam Surgical Matrix|Control of bleeding using BioFoam Surgical Matrix as a surgical adjunct
3081490|NCT01458561|Active Comparator|Gelfoam Plus|Control of bleeding using Gelfoam Plus as a surgical adjunct
3081491|NCT01458574|Placebo Comparator|Placebo Comparator|
3081492|NCT01458574|Experimental|CP-690,550 5 mg Arm|
3081493|NCT01458574|Experimental|CP-690,550 10 mg Arm|
3081494|NCT01458587|Experimental|ALA|
3081495|NCT01458587|Placebo Comparator|Vehicle|
3081496|NCT01458639|Experimental|Technegas|Technegas V SPECT imaging with Technetium-99m (Tc-99m) labeled carbon particles; approximately 1.1 milliCuries of Technegas, compared with the results of Xenon-133 ventilation scan
3081497|NCT01458639|Active Comparator|Xenon-133|Xenon-133 ventilation Planar imaging compared with the results of the Technegas scan.
3081498|NCT01458951|Experimental|tofacitinib 10 mg BID|
3081499|NCT01458951|Placebo Comparator|Placebo BID|
3081500|NCT01458990|Experimental|PPI inititation|Adding 40mg omeprazole QD for 14 days
3081501|NCT01458990|Active Comparator|PPI withdrawal|The intervention here is systematically withdrawing chronic PPI for 14 days
3081502|NCT01459016|Experimental|Imaging Biomarkers|
3081503|NCT01459068|No Intervention|Waitlist-Control|Eligible study subjects were assigned to the waitlist-control arm on a rolling admissions basis. The waitlist-controls waited for a period equivalent to the duration of the intervention and then were re-interviewed.
3081504|NCT01459068|Experimental|Common Elements Treatment Approach|Eligible study subjects randomized into the CETA intervention were offered ten weeks of counseling sessions, consisting of nine elements designed to treat symptoms of common mental health disorders including depression, PTS, and anxiety and to provide skills to deal with life stressors.
3081505|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
3468888|NCT03891576|Active Comparator|Niraparib 300 mg|Niraparib will be administered every day as oral at a fixed dose of 300 mg
3081506|NCT01459588|Experimental|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3081507|NCT01459588|Active Comparator|Carboxymethylcellulose Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3081508|NCT01459588|Active Comparator|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
3081509|NCT01459614|Experimental|GTX-C|"Each cycle is 21 days (2 weeks Tx + 1 week off). Xeloda given days 1-14, Gemcitabine, Taxotere, and Cisplatin given days 4 and 11.~For expansion cohort, each cycle is 28 days (2 weeks of Tx + 2 weeks off)"
3081510|NCT01459653||Only 1 group|Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
3081511|NCT01459705|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
3081512|NCT01459705|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
3081513|NCT01459705|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
3081514|NCT01459718|Experimental|Deferasirox / Deferasirox + Deferoxamine (DFO)|During Phase A, the induction treatment at entry, participants received Deferasirox -DFO combination. During Phase B, when participants transitioned to less intensive chelation therapy, participants received Deferasirox monotherapy.
3081515|NCT01459783|Active Comparator|Dementia care management in person|The dementia care management protocol will be delivered via face-to-face interactions in participants' homes or in mutually convenient locations between a trained care manager and the care recipient/informal family caregiver dyad, supplemented by telephone.
3081516|NCT01459783|Active Comparator|Dementia care management telephone only|The dementia care management protocol will be delivered via telephonic meetings only. Assessment, education, counseling, and social support procedures as well as referral and follow-ups will follow the same procedural content as stipulated for the face-to-face intervention, however, contact will not be planned in person.
3081517|NCT01459796|Experimental|Placebo|Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 51.
3081518|NCT01459796|Experimental|Rilonacept 80 mg|Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 51.
3081519|NCT01459913|Experimental|Telaprevir 12 Week (Wk)+Peg-IFN-alfa-2a,RBV 12 Wk (Randomized)|Telaprevir 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 12 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met rapid viral response (RVR, undetectable Hepatitis C Virus [HCV] Ribonucleic Acid [RNA] at Week 4) criteria, were randomized in this group, as planned, and did not receive any further treatment.
3081520|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects who completed initial 12 week of telaprevir and Peg-IFN/RBV and met RVR criteria, were randomized in this group, as planned.
3081521|NCT01459913|Experimental|Telaprevir 12 Wk+Peg-IFN-alfa-2a,RBV 24 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 24 weeks. Only subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, and had extended rapid viral response (eRVR, undetectable HCV RNA at Weeks 4 and 12), were included in this group, as planned.
3081522|NCT01459913|Experimental|Telaprevir 12 Wk +Peg-IFN-alfa-2a,RBV 48 Wk (Non Randomized)|Telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Only subjects with no RVR or no RVR assessment, and subjects with RVR who permanently discontinued telaprevir, Peg-IFN-alfa-2a, or RBV treatment before Week 12, who did not have eRVR or eRVR assessment, were included in this group, as planned.
3081524|NCT01460225|Experimental|Treatment|24 micrograms of lubiprostone twice daily for one week.
3081525|NCT01460290|Experimental|Asenapine|12-weeks of open-label asenapine treatment
3081526|NCT01460303|Experimental|OPTION-vf patient controlled catheter|"Patients who fail postop bladder challenge and are randomized to OPTION-vf arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
3081527|NCT01460303|Active Comparator|Transurethral catheter w/leg bag|"Patients who fail postop bladder challenge and are randomized to indwelling catheter with leg bag arm will be instructed in the use and care of this catheter, discharged home with it in place and given an appointment between 5-10 days postop for a bladder challenge."
3081528|NCT01460342|Placebo Comparator|Placebo|Following the 4-week placebo lead-in period, this arm will consist of a 12-week placebo treatment period involving 2 x 2.5-milligram (mg) tadalafil placebo tablets taken orally once daily.
3081529|NCT01460342|Experimental|Tadalafil|Following the 4-week placebo lead-in period, this arm will consist of a 12-week treatment period involving 2 x 2.5-mg tadalafil tablets taken orally once daily.
3081530|NCT01460368|Experimental|Part A: LY2409021|Participants will receive 2 standard meals; one alone without LY2409021, and one along with a single dose of 300 milligrams (mg) LY2409021 administered orally. Participants enrolled in Part A will not be allowed to participate in Part B.
3081531|NCT01460368|Experimental|Part B: LY2409021|300 milligrams (mg) LY2409021 administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
3081532|NCT01460368|Placebo Comparator|Part B: Placebo|Administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
3081533|NCT01460368|Active Comparator|Part B: Moxifloxacin|400 milligrams (mg) Moxifloxacin administered orally as a single dose on Day 1 of the relevant treatment period. The treatment and washout period was a total of 15 days in length.
3081534|NCT01460381|Experimental|LY2216684 + Quinidine (CYP2C19 poor metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 poor metabolizer (PM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 was administered on Day 1.~Period 2 (Days 8-15): 300 mg quinidine sulfate controlled release was administered orally, once daily on Days 8-15. Additionally, a single, oral dose of 18 mg LY2216684 was administered on Day 11."
3081535|NCT01460381|Experimental|LY2216684 (CYP2C19 extensive metabolizers)|"Participants were predicted to have a cytochrome P450 (CYP)2C19 extensive metabolizer (EM) phenotype, as determined by genotyping analysis.~Period 1 (Days 1-7): a single, oral dose of 18 milligrams (mg) LY2216684 administered on Day 1.~Period 2 (Days 8-15): EM participants did not participate in this period."
3081536|NCT01460407|Experimental|LY2216684 + Clarithromycin|Participants will receive a single 18-mg oral dose of LY2216684 on Days 1 and 10. Clarithromycin (500 mg) will be administered twice a day (BID) on Days 6 through 13.
3081537|NCT01460446|Experimental|Aviva Expert blood glucose meter|Participants used the Accu-Chek® Aviva Expert blood glucose meter with an integrated bolus advisor to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
3081538|NCT01460446|Active Comparator|Aviva Nano blood glucose meter|Participants used the Accu-Chek® Aviva Nano blood glucose meter and manual bolus calculation to determine the dose of insulin for each injection in their 24 week multiple daily injection therapy.
3081539|NCT01460628|Experimental|Armodafinil|Armodafinil is the drug being tested.
3081540|NCT01460719|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3081541|NCT01460732|Other|All patients|All eligible patients in the study consist a single group and the same intervention is assigned to all of them.
3081542|NCT01460875|Experimental|Treatment (interferon therapy)|Patients receive recombinant interferon alfa-2b SC thrice weekly. Treatment continues for 11 months in the absence of disease progression or unacceptable toxicity.
3081543|NCT01460901|Experimental|GD2 CAR modified Tri-virus CTL infusion|A single infusion of 2x10e6 cells per meter squared was performed 30 to 120 days following allogeneic stem cell transplant.
3081544|NCT01460927|Other|TriActive+ RF|Healthy male or female subjects 30-60 years of age, having at least two facial sub-areas (left peri-orbital, right peri-orbital or peri-oral) with visible lines/wrinkles and elastosis, which correlate to a score of 2-6 on the Fitzpatrick Classification of Wrinkling and Degree of Elastosis.
3081545|NCT01460940|Experimental|Lenalidomide and Panobinostat|In the phase I trial, three patients will be enrolled at each dose level, starting at dose level 1 using a standard 3 + 3 dose escalation phase I design.
3081546|NCT01461005|Experimental|Dynamic Stabilization System|Dynamic Stabilization System (DSS) System
3081547|NCT01461044||Cohort|
3081548|NCT01461057|Experimental|Pertuzumab 840/420 mg|Participants received pertuzumab as an intravenous (IV) infusion at a loading dose of 840 milligrams (mg) for cycle 1 and a dose of 420 mg every three weeks (Q3W) for cycles 2-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 milligram per meter squared (mg/m^2) was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 milligram per kilogram (mg/kg) Q3W for subsequent cycles.
3081549|NCT01461057|Experimental|Pertuzumab 840/840 mg|Participants received 840 mg as an IV infusion Q3W for cycles 1-6. Participants in both arms received trastuzumab, cisplatin, and capecitabine. Capecitabine 1000 mg/m^2 was administered orally twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle. Cisplatin 80 mg/m^2 was administered as an IV infusion on Day 1 of each cycle. Trastuzumab was administered as an IV infusion at a loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg Q3W for subsequent cycles.
3081550|NCT01461096|Experimental|Quadrivalent HPV Vaccine|Participants were prescribed the quadrivalent HPV vaccine at baseline and Weeks 8 and 24.
3081551|NCT01461096|Placebo Comparator|Placebo Vaccine|Participants were prescribed the placebo vaccine at baseline and Weeks 8 and 24.
3081552|NCT01461369|Experimental|Diclofenac Capsules 35 mg bid|
3081553|NCT01461369|Experimental|Diclofenac Capsules 35 mg tid|
3081554|NCT01461369|Placebo Comparator|Placebo Capsule|
3081555|NCT01461473|Active Comparator|Positive Airway Pressure|Participants randomized to standard clinical Positive Airway Pressure (PAP) treatment for Obstructive Sleep Apnea (OSA).
3081556|NCT01461473|Active Comparator|Oral Appliance|Subjects randomized to standard Oral Appliance (OA) treatment for Obstructive Sleep Apnea (OSA).
3081557|NCT01461499|Active Comparator|Direct renin inhibitor|
3081558|NCT01461499|Active Comparator|Angiotensin receptor blockers|
3081559|NCT01461538|Experimental|Brentuximab vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
3081560|NCT01461538|Experimental|Brentuximab vedotin 2.4 mg/kg|Brentuximab vedotin 2.4 mg/kg every 3 weeks by IV infusion
3081561|NCT01461538|Experimental|Brentuximab vedotin 1.2 mg/kg|Brentuximab vedotin 1.2 mg/kg weekly, 3 out of 4 weeks, by IV infusion
3081562|NCT01461551|Experimental|Sevoflurane|
3081563|NCT01461551|Experimental|Propofol|
3081564|NCT01461551|Experimental|Combine of sevoflurane and propofol|
3081565|NCT01461655|Placebo Comparator|Topical retinoid - Placebo|
3081566|NCT01461655|Active Comparator|Topical retinoid-NSAID|
3081567|NCT01461668|Experimental|Retapamulin|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
3081568|NCT01461668|Placebo Comparator|Placebo|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
3081569|NCT01461707|Experimental|Mobile app plus activity monitor group|Participants in the group will receive the mobile phone-based physical activity program and an activity monitor
3081570|NCT01461707|Active Comparator|Activity monitor group|Participants in the group will receive an activity monitor
3081571|NCT01461733|Experimental|amiodarone|standard dose amiodarone
3081572|NCT01461733|Placebo Comparator|placebo|
3081573|NCT01461811|Experimental|DAILIES® AquaComfort Plus® Toric|Nelfilcon A toric contact lenses (with comfort additives) worn in both eyes on a daily wear, daily disposable basis for three months
3081574|NCT01461811|Active Comparator|Focus® DAILIES® Toric|Nelfilcon A toric contact lenses worn in both eyes on a daily wear, daily disposable basis for three months
3081575|NCT01461824|Active Comparator|150 mg DMPA|Depot medroxyprogesterone acetate (DMPA) 150 mg every 12 weeks IM
3081576|NCT01461824|Experimental|104mg DMPA|Depot medroxyprogesterone acetate (DMPA) 104 mg every 12 weeks IM
3081577|NCT01461824|Experimental|75mg DMPA|Depot medroxyprogesterone acetate (DMPA) 75 mg every 12 weeks IM
3081578|NCT01461863|Active Comparator|protein calorie supplement|250 gm daily of specially designed porridge plus standard multivitamin
3081579|NCT01461863|Placebo Comparator|Multivitamin|Standard multivitamin control
3081580|NCT01461928|Other|Maintenance II Period Observation Only|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); no treatment in Maintenance II period until disease progression or end of study, whichever occurs first.
3081581|NCT01461928|Experimental|Maintenance II Period Rituximab|Participants will receive standard chemotherapy regimen in combination with 375 mg/m^2 rituximab IV in Cycle 1 (3-4 week-cycles), followed by 1400 mg rituximab SC every 3-4 weeks for 8 cycles (induction period); 1400 mg rituximab SC every 8 weeks for 24 months (Maintenance I period); 1400 mg rituximab SC every 8 weeks until disease progression or end of study, whichever occurs first (Maintenance II period).
3081582|NCT01461980|Active Comparator|MCV4 + Tdap+ rLP2086|Group 1 - MCV4 + Tdap + rLP2086
3081583|NCT01461980|Active Comparator|MCV4 + Tdap + saline|Group 2, MCV4 + Tdap+ saline
3081584|NCT01461980|Placebo Comparator|Saline + saline + rLP2086|Group 3- rLP2086 + saline
3081585|NCT01461993|Active Comparator|Group 1|rLP2086 + Gardasil
3081586|NCT01461993|Placebo Comparator|Group 2|rLP2086 and saline
3081587|NCT01461993|Active Comparator|Group 3|Saline + Gardasil
3081588|NCT01462045|Experimental|Exercise Group|Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
3081589|NCT01462045|No Intervention|Control Group|Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
3081590|NCT01462045|No Intervention|Base Group|Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.
3081591|NCT01462084|Experimental|Adaptive Servo-Ventilation (ASV) then BiLevel PAP|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual. ASV adjusts to the breathing events the individual is experiencing and provides enough PAP to resolve the breathing event. This is a crossover study, so all patients enter both treatment groups.
3081592|NCT01462084|Experimental|Bi-Level PAP then Adaptive Servo-Ventilation (ASV)|Bi-level pressure delivers two pressures, IPAP and EPAP. Both pressures are fixed and do not adjust based on the individuals breathing events. This is a crossover study, so all patients enter both treatment groups.
3081593|NCT01462110|Experimental|0.15% ethyl lauroyl arginate HCl-containing mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 0.15% ethyl lauroyl arginate HCl-containing mouthrinse (19415-154-1) for 30 seconds - repeat twice daily for four weeks.
3081594|NCT01462110|Sham Comparator|5% hydroalcohol mouthrinse|Brush teeth as usual, followed immediately by rinsing with 20 mL of assigned 5% hydroalcohol mouthrinse (W002194-0221P) for 30 seconds - repeat twice daily for four weeks.
3081595|NCT01462162||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab (RoActemra) according to the indications of the summary of product characteristics of the product and the standard clinical practice of each participating center will be followed-up for 6 months.
3081596|NCT01462227|Experimental|Naltrexone (higher dose)|Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
3468889|NCT03891576|Other|Niraparib 200mg/300mg|Niraparib will be administered every day as oral at a fixed dose of 200 mg or 300 mg
3081597|NCT01462227|Experimental|Naltrexone (lower dose)|Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
3081598|NCT01462253|Experimental|Clofarabine, Cyclophosphamide|"Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.~Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
3081599|NCT01462266|Experimental|Sitagliptin|Sitagliptin 100 mg once daily
3081600|NCT01462266|Placebo Comparator|Placebo|Placebo to sitagliptin once daily
3081601|NCT01462279|Experimental|Thiamine|Open label - 200mg IV
3081602|NCT01462292|Experimental|GSK2402968 3 mg/kg/week|3 mg/kg/week of investigational product
3081603|NCT01462292|Experimental|GSK2402968 6 mg/kg/week|6 mg/kg/week of investigational Product
3081604|NCT01462292|Experimental|Placebo to match GSK2402968 3 mg/kg/week|Placebo
3081605|NCT01462292|Experimental|Placebo to match GSK2402968 6 mg/kg/week|Placebo
3081606|NCT01462305|Experimental|goLITE|light therapy using 467nm LED source, within 30 minutes of waking in the morning every day for 6 weeks
3081607|NCT01462305|Active Comparator|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
3081608|NCT01462318|Experimental|DAC HYP|"DAC HYP 150 mg by a subcutaneous (SC) injection using the pre-filled syringe (PFS) every 4 weeks for 24 weeks followed by a 20-week washout period. After completion of the washout period, participants may resume monthly DAC HYP 150 mg using the PFS for up to 3 additional years.~Participants in the TP-DI sub-study will receive probe-drug cocktail administration at Weeks 43 and 53. The probe-drug cocktail consists of oral midazolam 5 mg, caffeine 200 mg, S-warfarin 10 mg, vitamin K 10 mg, omeprazole 40 mg, and dextromethorphan 30 mg. The oral vitamin K is used to counteract warfarin's anticoagula nt effect prophylactically."
3081609|NCT01462344|Experimental|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
3081610|NCT01462344|Experimental|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
3081611|NCT01462344|Active Comparator|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
3081612|NCT01462344|Active Comparator|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
3081613|NCT01462357|Experimental|Cervarix 2 dose Group|Subjects who received 2 doses of Cervarix vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3081614|NCT01462357|Experimental|Gardasil 2 dose Group|Subjects who received 2 doses of Gardasil vaccine at Day 0 and Month 6 and 1 dose of placebo at Month 2. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3081615|NCT01462357|Experimental|Gardasil 3 dose Group|Subjects who received 3 doses of Gardasil vaccine at Day 0 and at Months 2 and 6. The vaccines were administered intramuscularly, in the deltoid muscle of the non-dominant upper arm.
3081616|NCT01462370|Experimental|Etoricoxib+placebo ibuprofen then placebo etorcoxib+ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
3081617|NCT01462370|Experimental|Ibuprofen+placebo etoricoxib then etoricoxib+placebo ibuprofen|Participants will receive one tablet (active or placebo etoricoxib) and 3 capsules (active or placebo ibuprofen) as their first dose of study medication in Cycle 1 and Cycle 2. They can also take 3 capsules (active or placebo ibuprofen) up to 3 times more per day in Cycle 1 and Cycle 2.
3081618|NCT01462435|Experimental|Diclofenac Test (lower dose)|
3081619|NCT01462435|Experimental|Diclofenac Test (upper dose)|
3081620|NCT01462435|Active Comparator|Celecoxib|
3081621|NCT01462435|Placebo Comparator|Placebo|
3081622|NCT01462565|Experimental|All subjects|Subjects enter the study already taking current marketed FLOLAN (epoprostenol sodium) and continue for 4 weeks (run-in). At baseline, they will be swopped to the new thermo stable formulation of epoprostenol sodium for 4 weeks (or longer if they continue in the extension phase of the study).
3081623|NCT01462695|Experimental|Treatment (sunitinib)|Patients receive sunitinib malate orally (PO) once daily (QD) on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3081624|NCT01462773|Experimental|Treatment (enzyme inhibitor, interferon therapy)|Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15, and 22 and recombinant interferon alfa-2b SC on days 1, 3, and 5 (days 1 and 3 only in week 4 course 1) of weeks 1-4. Treatment repeats every 5 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.
3081625|NCT01462812|Active Comparator|Sumatriptan|
3081626|NCT01462812|Placebo Comparator|Matching placebo|
3081627|NCT01462877|Other|Fenofibrate arm|
3081628|NCT01462929|Experimental|Aclidinium bromide|Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
3081629|NCT01462929|Active Comparator|Tiotropium|Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
3081630|NCT01462929|Placebo Comparator|Placebo|Placebo comparator administered during 6 weeks of treatment
3081631|NCT01462942|Experimental|Aclidinium/Formoterol 400/6 μg|24 week, double blind treatment period
3081632|NCT01462942|Experimental|Aclidinium/Formoterol 400/12 μg|24 week, double blind treatment period
3081633|NCT01462942|Experimental|Aclidinium monotherapy 400 μg|24 week, double blind treatment period
3081634|NCT01462942|Active Comparator|Formoterol monotherapy 12 μg|24 week, double blind treatment period
3081635|NCT01462942|Placebo Comparator|Placebo|24 week, double blind treatment period
3081636|NCT01463007|Experimental|Radiation|AccuBoost APBI- 34.0 Gy in 10fx
3081637|NCT01463007|Experimental|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
3081638|NCT01463033|Active Comparator|Levetiracetam|66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy will receive levetiracetam 55 mg/kg/day in a b.i.d. schedule. Treatment will commence within 8 hours of the acute head injury and will last for 30 days. In addition, subjects will receive phenytoin for 1 week following head injury as standard clinical care.
3081639|NCT01463033|No Intervention|No Intervention Control|60 subjects with acute head injury with a high risk for developing post-traumatic epilepsy enrolled 8-24 hours after injury will not receive levetiracetam. Subjects will receive phenytoin for 1 week following head injury as standard clinical care.
3081640|NCT01463098|Experimental|Part A: E2006 1.0 mg|
3081641|NCT01463098|Experimental|Part A: E2006 2.5 mg|
3081642|NCT01463098|Experimental|Part A: E2006 5.0 mg|
3081643|NCT01463098|Experimental|Part A: E2006 10.0 mg|
3081644|NCT01463098|Experimental|Part A: E2006 25.0 mg|
3081645|NCT01463098|Experimental|Part A: E2006 50.0 mg|
3081646|NCT01463098|Experimental|Part A: E2006 100 mg|
3081647|NCT01463098|Experimental|Part A: E2006 200 mg|
3081648|NCT01463098|Experimental|Part B: Zolpidem 10 mg|
3081649|NCT01463098|Experimental|Part B: E2006 Matched Placebo or Zolpidem Matched Placebo|
3081650|NCT01463098|Experimental|Part A: E2006 Matched Placebo|
3081651|NCT01463098|Experimental|Part B: E2006 2.5 mg|
3081652|NCT01463098|Experimental|Part B: E2006 10 mg|
3081653|NCT01463098|Experimental|Part B: E2006 25 mg|
3081654|NCT01463111|Other|Mood stabilizer|Participants diagnosed with Bipolar Disorder will receive standard of care open-label treatment with a mood stabilizer for six weeks.
3081655|NCT01463202|Active Comparator|DMPA postpartum|Depot medroxyprogesterone acetate postpartum
3081656|NCT01463202|Active Comparator|DMPA at 4-6 weeks after delivery|Depot medroxyprogesterone acetate at 4-6 weeks after delivery
3081657|NCT01463267|Active Comparator|Device 2 passive|Device 2 will NOT remind patients to take medications
3081658|NCT01463267|Active Comparator|Device 2 active|Device 2 will remind patients to take medications
3081659|NCT01463267|Active Comparator|Device 1 active|Device 1 will remind patients to take their medications
3081660|NCT01463267|Placebo Comparator|Device 1 Passive|Device 1 will NOT remind patients to take medications.
3081661|NCT01463306|Experimental|Open|Pregabalin open label flexible dose
3081662|NCT01463358|Other|DDI30|Control group based only on backup pacing with lower rate 30 ppm
3081663|NCT01463358|Active Comparator|DDD60|Treatment arm based on full pacing support (60 Lower Rate)
3081664|NCT01463384|Active Comparator|Minocycline|Subjects will be administered 50mg minocycline twice daily.
3081665|NCT01463527|Experimental|Open Capnography|
3081666|NCT01463527|Placebo Comparator|Capnography Blind|
3081667|NCT01463631|Experimental|LY3007113|Study has a dose escalation phase (Part A) and dose confirmation phase (Part B). Participants in the dose escalation phase will receive 1 of 6 doses of LY3007113 administered orally every 12 hours for at least one cycle. Participants in the dose confirmation phase will receive the maximum tolerated dose from the dose escalation phase administered orally every 12 hours for at least 1 cycle. Three days prior to the start of the first cycle, participants will receive 1 dose at their assigned level to allow for the collection of single dose pharmacokinetics. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
3081668|NCT01463683|Experimental|V232-2XP SC|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
3081669|NCT01463683|Active Comparator|V232-1XP SC|1XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL subcutaneous injection on Day 1, Month 1, and Month 6
3081670|NCT01463683|Experimental|V232-2XP IM|2XP HEPTAVAX™-II vaccine 10 mcg in 0.5 mL intramuscular injection on Day 1, Month 1, and Month 6
3081671|NCT01463696|Experimental|MK-8242 60 mg BID|In Cycle 1, participants received MK-8242 60 mg administered orally (PO) twice a day (BID) on Days 1-6 and PO once daily (QD) in the morning on Day 7 of the 21-day cycle to accommodate pharmacokinetic (PK) sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 60 mg PO BID on Days 1-7 of each 21-day cycle.
3081672|NCT01463696|Experimental|MK-8242 120 mg BID|In Cycle 1, participants received MK-8242 120 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 120 mg PO BID on Days 1-7 of each 21-day cycle.
3081673|NCT01463696|Experimental|MK-8242 170 mg BID|In Cycle 1, participants received MK-8242 170 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 170 mg PO BID on Days 1-7 of each 21-day cycle.
3081674|NCT01463696|Experimental|MK-8242 250 mg BID|In Cycle 1, participants received MK-8242 250 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 250 mg PO BID on Days 1-7 of each 21-day cycle.
3081675|NCT01463696|Experimental|MK-8242 300 mg BID|In Cycle 1, participants received MK-8242 300 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 300 mg PO BID on Days 1-7 of each 21-day cycle.
3081676|NCT01463696|Experimental|MK-8242 350 mg BID|In Cycle 1, participants received MK-8242 350 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 350 mg PO BID on Days 1-7 of each 21-day cycle.
3081677|NCT01463696|Experimental|MK-8242 400 mg BID|In Cycle 1, participants received MK-8242 400 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 400 mg PO BID on Days 1-7 of each 21-day cycle.
3081678|NCT01463696|Experimental|MK-8242 500 mg BID|In Cycle 1, participants received MK-8242 500 mg administered PO BID on Days 1-6 and PO QD in the morning on Day 7 of the 21-day cycle to accommodate PK sampling. In Cycle 2 and subsequent cycles, participants received MK-8242 500 mg PO BID on Days 1-7 of each 21-day cycle.
3081679|NCT01463878|Experimental|Glycerna|Diabetic specific formula. The volume /rate of glycerna will be determined by the dietician according to standard formula.
3081680|NCT01463878|Active Comparator|Control - Jevity|The control arm of the study. Patients to receive Jevity. The volume /rate of Jevity will be determined by the dietician according to standard formula.
3081681|NCT01463982|Experimental|Oratecan and Capecitabine|"Oratecan(HM30181AK + Irinotecan HCl) and Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
3081682|NCT01464021||Adalimumab|Chinese adult participants with a diagnosis of rheumatoid arthritis (RA) (any disease duration) who meet the requirements per the local label for treatment with adalimumab. Participants must be naïve to adalimumab at the Baseline visit.
3081683|NCT01464190|Experimental|PA21|
3081684|NCT01464190|Active Comparator|Sevelamer carbonate|
3081685|NCT01464229|Experimental|Iloperidone addition to SSRI antidepressant|
3081686|NCT01464229|Placebo Comparator|Placebo addition to standard SSRI antidepressant|
3081687|NCT01464255|Experimental|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3081688|NCT01464255|Active Comparator|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3081689|NCT01464307|Experimental|IncobotulinumtoxinA (Xeomin) 400 Units|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3081690|NCT01464307|Placebo Comparator|Placebo Comparator Arm|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
3081691|NCT01464333||Humira|Participants who were prescribed Humira per approved prescribing information of Humira in Japan.
3081692|NCT01464346|Experimental|Enlite sensor, Abdomen/Abdomen|Subjects wearing 2 Enlite sensors in Abdomen
3081693|NCT01464346|Experimental|Enlite sensor, Abdomen/Buttock|Subjects wearing 2 Enlite sensors in Abdomen/Buttock
3081694|NCT01464346|Experimental|Enlite sensor, Buttock/Buttock|Subjects wearing 2 Enlite sensors in Buttock/Buttock
3081695|NCT01464359|Experimental|Patients with Acute Myelogenous Leukemia|Patients with chemotherapy refractory Acute Myelogenous Leukemia (AML) after a double T-cell depleted (TCD) umbilical cord blood (UCB) transplantation where the smaller unit is activated overnight in interleukin-2 (IL-2). IL-2 will be given three times weekly for 6 doses beginning on days+3 and days +60 to expand UCB-derived natural killer (NK) cells in vivo.
3081696|NCT01464424|Other|TRAVATAN, then LUMIGAN|Travoprost 0.004% ophthalmic solution (TRAVATAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by bimatoprost 0.01% ophthalmic solution (LUMIGAN), same dose, same duration, as randomized, for a total duration of 12 weeks
3081697|NCT01464424|Other|LUMIGAN, then TRAVATAN|Bimatoprost 0.01% ophthalmic solution (LUMIGAN), 1 drop to the study eye once daily every evening at 8:00 pm for 6 weeks, followed by travoprost 0.004% ophthalmic solution (TRAVATAN), same dose, same duration, as randomized, for a total duration of 12 weeks
3081698|NCT01464619|Experimental|Delayed Intervention|Those assigned to the delayed intervention arm will receive enhanced mental health referrals, monthly follow-up phone calls, and will be assigned to the parenting intervention 3-4 months after enrollment.
3081699|NCT01464619|Experimental|Intervention|Caregivers assigned to the intervention arm will be assigned to the Incredible Years parenting intervention immediately after enrollment. They will also receive enhanced mental health referrals and monthly follow-up phone calls.
3081700|NCT01464697|Experimental|oral micronized progesterone|Oral micronized progesterone is Prometrium 300 mg at bedtime daily
3081701|NCT01464697|Placebo Comparator|Placebo Comparator|Placebo
3081702|NCT01464775|Experimental|Narrow Band Imaging (NBI)|Women will be randomized to white light/NBI versus white light/white light laparoscopy
3081703|NCT01464775|Active Comparator|Standard White Light Laparoscopy|Women will be randomized to white light/NBI versus white light/white light laparoscopy
3081704|NCT01464788|Experimental|Low dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
3081705|NCT01464788|Experimental|High dose Argatroban + rt-PA (alteplase)|"100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours~and~rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour"
3081706|NCT01464788|Active Comparator|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
3081707|NCT01464827|Experimental|Group A|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 8 weeks.
3081708|NCT01464827|Experimental|Group B|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3081709|NCT01464827|Experimental|Group C|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3081710|NCT01464827|Experimental|Group D|Treatment-naïve participants received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3081711|NCT01464827|Experimental|Group E|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ABT-333 400 mg twice daily for 12 weeks.
3081712|NCT01464827|Experimental|Group F|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily for 12 weeks.
3081713|NCT01464827|Experimental|Group G|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3081714|NCT01464827|Experimental|Group H|Treatment-naïve participants received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3081715|NCT01464827|Experimental|Group I|Treatment-naïve participants received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3081716|NCT01464827|Experimental|Group J|Participants who were null-responders to previous HCV treatment received ABT-450 200 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3081717|NCT01464827|Experimental|Group K|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3081718|NCT01464827|Experimental|Group L|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 12 weeks.
3081719|NCT01464827|Experimental|Group M|Participants who were null-responders to previous HCV treatment received ABT-450 100 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3081720|NCT01464827|Experimental|Group N|Participants who were null-responders to previous HCV treatment received ABT-450 150 mg and ritonavir 100 mg once daily, ABT-267 25 mg once daily, ABT-333 400 mg twice daily, and ribavirin dosed by weight, twice daily, for 24 weeks.
3081721|NCT01464840||15 minutes|500 mg of intravenous azithromycin will be administered 15 minutes prior to incision.
3081722|NCT01464840||30 minutes|500 mg of intravenous azithromycin will be administered 30 minutes prior to incision.
3081723|NCT01464840||60 minutes|500 mg of intravenous azithromycin will be administered 60 minutes prior to incision.
3081724|NCT01464879|Experimental|Testosterone 2.50 mL (hand)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by hand, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
3081725|NCT01464879|Experimental|Testosterone 1.25 mL (applicator)|Subjects in this arm self-applied one stroke (1.25 mL) of testosterone gel by applicator to the shoulder/upper arm every day for seven days.
3081726|NCT01464879|Experimental|Testosterone 2.50 mL (applicator)|Subjects in this arm self-applied two strokes (2.50 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm every day for seven days.
3081727|NCT01464879|Experimental|Testosterone 3.75 mL (applicator)|Subjects in this arm self-applied three strokes (3.75 mL) of testosterone gel by applicator, one stroke to the shoulder/upper arm and a second stroke to the contralateral shoulder/upper arm and a third stroke to the first shoulder/upper arm, every day for seven days.
3081728|NCT01464931|Experimental|Denosumab|Participants received two 120 mg doses of denosumab administered subcutaneously on Day 1 and Day 29.
3081729|NCT01464996|Experimental|Adhesive OptiBond XTR|Adhesive OptiBond XTR will include composite restorations placed using the dental adhesive OptiBond XTR.
3081730|NCT01464996|Active Comparator|Adhesive OptiBond FL|Adhesive OptiBond FL will include composite restorations placed using the dental adhesive OptiBond FL.
3081731|NCT01465022|Active Comparator|Study Arm A|Study Arm A is one of two interventions (Combined estrogen-progestin pill)
3081732|NCT01465022|Active Comparator|Study Arm B|Study Arm B is one of two interventions (Progestin-only pill)
3081733|NCT01465048|Experimental|Plasmodium falciparum sporozoites 2sites|2,500 sporozoites intradermally
3081734|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1 site|2,500 sporozoites intramuscularly
3081735|NCT01465048|Experimental|Plasmodium falciparum sporozoites 1site|25,000 sporozoites intramuscularly
3081736|NCT01465178|Active Comparator|2000 IU vitamin D3|Cholecalciferol 2,000 IU capsules
3081737|NCT01465178|Placebo Comparator|Placebo|Non-matching placebo, gelatin filled capsules
3081738|NCT01465191|Experimental|50 micrograms (mcg) spinal morphine|Subjects will receive 50 mcg morphine in their spinal anesthetic for cesarean section
3081739|NCT01465191|Experimental|100 micrograms spinal morphine|Subjects will receive 100 mcg morphine in their spinal anesthetic for cesarean section
3081740|NCT01465191|Experimental|150 micrograms spinal morphine|Subjects will receive 150 mcg morphine in their spinal anesthetic for cesarean section
3081741|NCT01465334|Experimental|Treatment Naive|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
3081742|NCT01465334|Experimental|Relapsed/Refractory|"Participants were assigned to 1 of 2 groups based on prior treatment status. Both groups received the same therapy as follows (cycle duration=28 days):~Induction Part A: Ofatumumab + HDMP 2-4 cycles~Ofatumumab: cycle 1 - 300 mg intravenously (IV) Day 1 then 1000 mg IV Days 8, 15, 22; cycles 2-4 - 1000 mg IV Days 1, 8, 15, 22~High-Dose Methylprednisolone (HDMP): 1000 mg/m2 IV Days 1-3~Participants with nodal complete response at cycle 2 re-staging then discontinued Part A therapy.~Induction Part B: Ofatumumab + Alemtuzumab 1-6 cycles~Ofatumumab: 1000 mg IV Day 1~Alemtuzumab: 30 mg subcutaneously Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26~Participants with at least stable disease could continue continue to Part C or, if eligible, proceed to allogeneic stem cell transplant (SCT) off study.~Maintenance Part C: Ofatumumab + Alemtuzumab up to 26 cycles~Ofatumumab: 1000 mg IV Day 1 every other cycle~Alemtuzumab: 30 mg subcutaneously Days 14, 28"
3081743|NCT01465347|Experimental|TSC 0.25 mg/kg for 9 or 18 doses|This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.
3081744|NCT01465386|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive bortezomib SC on days 1, 8, 15 and 22. Treatment repeats every 35 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3081745|NCT01465412|Experimental|Mild Hepatic Impaired (HI) Part 1|Participants with mild chronic liver disease enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
3081746|NCT01465412|Active Comparator|Healthy to Match Mild HI Part 1|Healthy volunteers with normal hepatic function matched to participants with mild chronic liver disease by race, age, BMI, and gender, enrolled in Part 1 received one 5-mg preladenant tablet, orally, on Day 1.
3081747|NCT01465412|Experimental|Moderate HI Part 2|Participants with moderate chronic liver disease enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
3081748|NCT01465412|Active Comparator|Healthy to Match Moderate HI Part 2|Healthy volunteers with normal hepatic function matched to participants with moderate chronic liver disease by race, age, BMI, and gender, enrolled in Part 2 received one 5-mg preladenant tablet, orally, on Day 1.
3081749|NCT01465464|Experimental|Orantinib|
3081750|NCT01465464|Placebo Comparator|Placebo|
3081751|NCT01465659|Experimental|Temozolomide 100 mg/m2 and Pazopanib 400 mg|Temozolomide 100 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3081752|NCT01465659|Experimental|Temozolomide 75 mg/m2 and Pazopanib 400 mg|Temozolomide 75 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3081753|NCT01465659|Experimental|Temozolomide 150 mg/m2 and Pazopanib 400 mg|Temozolomide 150 mg/m2 on days 1-7 and 15-21 , Pazopanib 400 mg on days 1-28
3081754|NCT01465763|Experimental|tofacitinib 10 mg BID|
3081755|NCT01465763|Placebo Comparator|Placebo|
3081756|NCT01465802|Experimental|Cohort I|Arm A: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline placebo orally BID for 4 weeks Arm B: Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Doxycycline 100 mg orally BID for 4 weeks
3081757|NCT01465802|Experimental|Cohort II|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
3081758|NCT01465802|Experimental|Cohort III|Cohort III is an interrupted dosing schedule of dacomitinib in the first cycle only
3081759|NCT01465841|Experimental|Embolization with the PC 400 coils|
3081760|NCT01465958|Active Comparator|Intravenous GAMUNEX-C|
3081761|NCT01465958|Experimental|Subcutaneous GAMUNEX-C|
3081762|NCT01465997|Experimental|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
3081763|NCT01465997|Active Comparator|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum of 3.5 Years)
3081764|NCT01466062|Experimental|Palivizumab|15 mg/kg at 30-day intervals; at least 4 intramuscular injections up to a maximum of 7 intramuscular injections as appropriate for prophylaxis of severe respiratory syncytial virus (RSV) during the RSV season.
3081765|NCT01466075|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the Apollo Evolution Investigational BG Monitoring System.
3081766|NCT01466127|Placebo Comparator|Placebo|Matched nasal spray placebo.
3081767|NCT01466127|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
3081768|NCT01466153|Active Comparator|Rituximab + Bendamustine|Rituximab was administered by IV infusion as 375 mg/m^2 on Day 2 of Cycle 1 and then 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of rituximab in each cycle.
3081769|NCT01466153|Experimental|MEDI-551 2 mg/kg + Bendamustine|MEDI-551 2 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
3081770|NCT01466153|Experimental|MEDI-551 4 mg/kg + Bendamustine|MEDI-551 4 mg/kg was administered by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycle. Bendamustine was also administered by IV infusion on Day 1 and Day 2 of every cycle (total 6 cycles). Bendamustine was administered before the administration of MEDI-551 in each cycle.
3081771|NCT01466166||Pegloticase|Participants received pegloticase 8 mg by intravenous (IV) infusion every 2 weeks for up to 1 year, as prescribed by their treating physician.
3081772|NCT01466179|Experimental|Blinatumomab|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
3081773|NCT01466192|Experimental|MP-424|
3081774|NCT01466270|Experimental|Arm I|Patients receive donepezil hydrochloride PO QD.
3081775|NCT01466270|Placebo Comparator|Arm II|Patients receive placebo PO QD.
3081776|NCT01466348|Experimental|Paracetamol and Caffeine|Paracetamol and caffeine
3081777|NCT01466348|Active Comparator|Paracetamol|Paracetamol
3081778|NCT01466361|Active Comparator|Lower dose Nicotine|lower dose nicotine lozenge
3081779|NCT01466361|Active Comparator|Higher dose Nicotine|higher dose Nicotine lozenge
3081780|NCT01466361|Placebo Comparator|Placebo|Placebo
3081781|NCT01466387|Active Comparator|TF+YF|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide and yellow fever vaccine.
3081782|NCT01466387|Active Comparator|TF + YF + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received one dose of typhoid Vi polysaccharide, yellow fever and meningococcal ACWY conjugate vaccine.
3081783|NCT01466387|Active Comparator|JE + Rabies|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies vaccine.
3081784|NCT01466387|Active Comparator|JE + Rab + MenACWY-CRM197|Subjects ≥18 years to ≤60 years of age who received two doses of Japanese encephalitis and three doses of Rabies and one dose of meningococcal ACWY conjugate vaccine.
3081785|NCT01466387|Active Comparator|Rabies|Subjects ≥18 years to ≤60 years of age who received three doses of Rabies vaccine.
3081786|NCT01466387|Active Comparator|MenACWY-CRM197 (Combined)|Subjects ≥18 years to ≤60 years of age who received one dose of meningococcal ACWY conjugate vaccine.
3081787|NCT01466491|Placebo Comparator|4-site injection|The superior technique of Phase 1 will be compared to a 4-site technique (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
3081788|NCT01466491|Active Comparator|2-site Injection|The superior technique of Phase 1 will be compared to a 2-site technique (2 mL injected at the tenaculum site, 18 mL equally distributed between 4 and 8 o'clock) in a randomized fashion (both techniques will have no wait prior to dilation unless wait was superior in Phase 1).
3081789|NCT01466491|Placebo Comparator|4-Site PCB followed by 3-minute wait|Women will be randomized to receive a 4-site PCB followed by a 3-minute wait (PCB 20/4/3) prior to dilation
3081790|NCT01466491|Active Comparator|4-site PCB followed by no wait|Women will be randomized to receive a 4-site PCB followed by no wait (PCB 20/4/0).
3081791|NCT01466595|Experimental|Arm A: Treatment with rifaximin|Participants were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
3081792|NCT01466595|No Intervention|Arm B: No study treatment|No study treatment for 4 weeks
3081793|NCT01466660|Experimental|afatinib|afatinib once daily.
3081794|NCT01466660|Active Comparator|gefitinib|gefitinib once daily
3081795|NCT01466673|Experimental|Ethinyl estradiol/Norgestimate (EE/NGM)|
3081796|NCT01466673|Active Comparator|Ethinyl estradiol/Desogestrel (EE/DSG)|
3081797|NCT01466751|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3081798|NCT01466751|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3081799|NCT01466764|Active Comparator|Anakinra|Two subcutaneous injections of anakinra (IL-1ra) were given, the first one hour prior to surgery and the second 24 hours after surgery.
3081800|NCT01466764|Placebo Comparator|Saline injection|Two subcutaneous injections of normal saline (same volume as the anakinra group injection) were given, the first one hour prior to surgery and the second 24 hours after surgery.
3081801|NCT01466790|Experimental|Arm 1|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977(GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 24 weeks and followed by a 24-week follow-up phase.
3081802|NCT01466790|Experimental|Arm 2|15 patients wiil receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 24 weeks of and followed by a 24-week follow-up phase.
3081803|NCT01466790|Experimental|Arm 3|30 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) with ribavirin (1000-1200 mg/day) for 12 weeks and followed by a 36-week follow-up phase.
3081804|NCT01466790|Experimental|Arm 4|15 patients will receive TMC435 (150 mg once a day) plus PSI-7977 (GS7977) (400 mg once a day) for 12 weeks and followed by a 36-week follow-up phase.
3081805|NCT01466881|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
3081806|NCT01466972|Experimental|Pazopanib in combination with a NSAI|Non-randomized, open label
3081807|NCT01466985|Experimental|Panel A: Doravirine 25 mg or Placebo|Participants will receive oral doses of doravirine 25 mg or placebo once daily for 7 days.
3081808|NCT01466985|Experimental|Panel B: Doravirine 200 mg or Placebo|Panel B (doravirine 200 mg or placebo once daily for 7 days) will initiate upon satisfactory review of safety and tolerability from Panel A, and all safety, tolerability and pharmacokinetic data from the study MK-1439-001.
3081809|NCT01466985|Experimental|Panel C: Doravirine or Placebo|Panel C is optional. If conducted, the dose will be confirmed after review of data from prior panels.
3081810|NCT01467037||Rotavirus-negative|Patients with a negative result for rotavirus via enzyme immunoassay (EIA). No intervention done.
3081811|NCT01467037||Rotavirus-positive|Patients with a positive result for rotavirus via enzyme immunoassay (EIA). Rotavirus-positives were confirmed via real-time reverse-transcriptase polymerase chain reactions (RT-PCR). RT-PCR results were used in the event of discordant EIA results. Rotavirus genotyping was performed. No intervention done.
3081812|NCT01467063|Active Comparator|Glutamine|
3081813|NCT01467063|Placebo Comparator|Placebo|
3081814|NCT01467076|Active Comparator|Inhaled PGE1 (150 ng/kg/min)|150 ng/kg/min Inhaled PGE1
3081815|NCT01467076|Placebo Comparator|Aerosolized Normal Saline|Eligible infants will be randomly assigned to either IPGE1 [150ng/kg/min], IPGE1 [300ng/kg/min] or control group. Infants in the control group will receive the same volume of aerosolized saline and oxygen from the respirator.
3081816|NCT01467076|Active Comparator|Inhaled PGE1 (300 ng/kg/min)|300 ng/kg/min of Inhaled PGE1
3081817|NCT01467427|Experimental|NNC-0156-000-0009|
3081818|NCT01467466|Active Comparator|Saline & oral placebo|IV isotonic saline and oral placebo drug capsule
3081819|NCT01467466|Active Comparator|Saline & oral N-acetylcysteine|IV isotonic saline and oral N-acetylcysteine drug capsule
3081820|NCT01467466|Active Comparator|Bicarbonate & oral placebo|IV isotonic bicarbonate and oral placebo drug capsule
3081821|NCT01467466|Active Comparator|Bicarbonate & oral N-acetylcysteine|IV isotonic bicarbonate and oral N-acetylcysteine drug capsule
3081822|NCT01467479|Experimental|T/PR + HAART Regimen (ATV/r-Based)|Participants who were receiving atazanavir/ritonavir (ATV/r) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3321095|NCT02016131||none endoleak events|Patients who have no further endoleaks related adverse events including aneurysm enlargement and rupture or persistent endoleaks.
3081823|NCT01467479|Experimental|T/PR + HAART Regimen (EFV-Based)|Participants who were receiving efavirenz (EFV) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet three times a day for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3081824|NCT01467479|Experimental|T/PR + HAART Regimen (RAL-Based)|Participants who were receiving raltegravir (RAL) based highly active antiretroviral therapy (HAART) at baseline, received Telaprevir (T)1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 800 milligram per day (mg/day) for 24 or 48 weeks, depending on individual response to telaprevir treatment. Participants continued their HAART, as per standard practice and investigator discretion.
3081825|NCT01467492|Experimental|Black|Telaprevir 750 milligram (mg) tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 microgram per week (mcg/week) subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 milligram per day (mg/day) (for participants weighing <75 kilograms [kg]) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
3081826|NCT01467492|Experimental|Non-Black|Telaprevir 750 mg tablet 3 times per day for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day (for participants weighing <75 kg) or 1200 mg/day (for participants weighing >=75 kg) for 24 or 48 weeks.
3081827|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Tacrolimus)|Participants who were receiving tacrolimus (TAC) based immunosuppressant regimen at baseline, received telaprevir (T) 1125 milligram (mg) tablet twice daily for 12 weeks in combination with pegylated interferon alfa 2a (P) (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (R) (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (>=) 75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
3081828|NCT01467505|Experimental|T/PR + Immunosuppressant Regimen (Cyclosporine)|Participants who were receiving cyclosporine (CsA) based immunosuppressant regimen at baseline, received telaprevir 1125 mg tablet twice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing >=75 kg, for 48 weeks. Participants continued their immunosuppressant regimen, as per standard practice and investigator discretion.
3081829|NCT01467557||1-Day ACUVUE TruEye contact lens users|1-Day ACUVUE TruEye contact lens users
3081830|NCT01467557||1-Day ACUVUE MOIST contact lens users|1-Day ACUVUE MOIST contact lens users
3081831|NCT01467570|Experimental|Hipp ORS Apple 200|oral rehydration solution Hipp ORS 200 Apple
3081832|NCT01467570|Active Comparator|ESPGHAN ORS|ESPGHAN oral rehydration solution
3081833|NCT01467583|Experimental|Renal failure on intermittent dialysis|These are patients with renal failure, on intermittent hemodialysis (IHD), receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3081834|NCT01467583|Experimental|Renal failure-renal replacement therapy|These are patients with renal failure, either acute or chronic, on continuous renal replacement therapy (CRRT) receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3081835|NCT01467583|Experimental|Renal failure, not on dialysis|These are patients with acute kidney injury not yet on dialysis, receiving fondaparinux 2.5 mg subcutaneously every 48 hours
3081836|NCT01467661|Experimental|SPD422 (anagrelide hydrochloride)|
3081837|NCT01467700|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual (SL) [dissolved under the tongue], once daily (QD), every night at bedtime for up to 8 weeks.
3081838|NCT01467700|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3081839|NCT01467700|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3081840|NCT01467700|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual, once daily, every night at bedtime for up to 8 weeks.
3081841|NCT01467713|Placebo Comparator|Placebo|Ramelteon SL placebo-matching, tablets, sublingual (SL) [dissolved under the tongue], once daily, every night at bedtime for up to 9 months.
3081842|NCT01467713|Experimental|Ramelteon SL 0.1 mg|Ramelteon SL 0.1 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3081843|NCT01467713|Experimental|Ramelteon SL 0.4 mg|Ramelteon SL 0.4 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3081844|NCT01467713|Experimental|Ramelteon SL 0.8 mg|Ramelteon SL 0.8 mg, tablets, sublingual, once daily, every night at bedtime for up to 9 months.
3081845|NCT01467882|Experimental|Triptorelin|Triptorelin 22.5 mg, intramuscular (IM), at Day 1 and Day 169
3081846|NCT01467934||Trivalent inactivated influenza vaccine|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1
3081847|NCT01467934||TIV and PCV13 together|Trivalent inactivated influenza vaccine (TIV) 0.25 ml IM x 1; 13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
3081848|NCT01467934||13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine (PCV13) 0.5 mL IM x1
3081849|NCT01467947|Experimental|Berinert|
3081850|NCT01467960||Group I|Healthy Subjects aged 20-40
3081851|NCT01467960||Group II|Healthy Subjects aged 40-65
3081852|NCT01467960||Group III|Healthy Subjects aged more than 65
3081853|NCT01467960||Group A|Patients at Stage I, H&Y classification
3081854|NCT01467960||Group B|Patients at Stage II, H&Y classification
3081855|NCT01467960||Group C|Patients at Stage more than III, H&Y classification
3081856|NCT01467999|Experimental|Guanfacine|Guanfacine, 4mg given once daily
3081857|NCT01468012|Experimental|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily dosing of levodopa carbidopa and entacapone (LCE)
3081858|NCT01468012|Placebo Comparator|Placebo|placebo
3081859|NCT01468077|Experimental|Tocilizumab, Normal Administration|Tocilizumab 8 mg/kg infusion of 60 minutes duration every 4 weeks for 6 infusions (up to 24 weeks)
3081860|NCT01468077|Experimental|Tocilizumab, Fast Administration|Tocilizumab 8 mg/kg infusion of 31 minutes duration every 4 weeks for 6 infusions (up to 24 weeks). The first infusion was 1 hour. If an infusion reaction occurred during any treatment, 1 hour infusions were used for all subsequent infusions
3081861|NCT01468181|Experimental|LY2189265 + Sulfonylureas (SU)|"LY2189265: 0.75 milligrams (mg) administered subcutaneously (SC), once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of SU monotherapy throughout the study."
3081862|NCT01468181|Experimental|LY2189265 + Biguanides (BG)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of BG monotherapy throughout the study."
3081863|NCT01468181|Experimental|LY2189265 + alpha-glucosidase inhibitor (a-GI)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of a-GI monotherapy throughout the study."
3081864|NCT01468181|Experimental|LY2189265 + Thiazolidinedione (TZD)|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of TZD monotherapy throughout the study."
3081865|NCT01468181|Experimental|LY2189265 + Glinides|"LY2189265: 0.75 mg administered SC, once weekly for 52 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of glinides monotherapy throughout the study."
3081866|NCT01468207|Placebo Comparator|Placebo|Placebo for 12 weeks.
3081867|NCT01468207|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
3081868|NCT01468207|Experimental|Placebo/Adalimumab Every Week (EW)|Participants randomized to receive placebo in Period 1 received adalimumab 160 mg at Week 12, 80 mg at Week 14, and 40 mg ew from Week 16 to Week 35 in Period 2 (up to 24 weeks).
3081869|NCT01468207|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3081870|NCT01468207|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive adalimumab 40 mg eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
3081871|NCT01468207|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3081872|NCT01468233|Placebo Comparator|Placebo|Placebo for 12 weeks.
3081873|NCT01468233|Experimental|Adalimumab Every Week (EW)|Adalimumab ew for 12 weeks (160 mg at Week 0; 80 mg at Week 2; and 40 mg ew from Week 4 to Week 12).
3081874|NCT01468233|Placebo Comparator|Placebo/Placebo|Participants randomized to receive placebo in Period 1 received placebo every week from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3081875|NCT01468233|Experimental|Adalimumab Every Week (EW)/Placebo|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive placebo ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3081876|NCT01468233|Experimental|Adalimumab Every Week (EW)/ Adalimumab Every Other Week (EOW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab eow from Week 12 to Week 35 in Period 2; placebo injections were administered eow from Week 13 to Week 35 (up to 24 weeks).
3081877|NCT01468233|Experimental|Adalimumab Every Week (EW)/Adalimumab Every Week (EW)|Participants randomized to receive adalimumab ew in Period 1 were re-randomized to receive 40 mg adalimumab ew from Week 12 to Week 35 in Period 2 (up to 24 weeks).
3081878|NCT01468311|Experimental|Yttrium-90-labeled Daclizumab + Chemotherapy|Yttrium-90-labeled Daclizumab + BCNU, etoposide, cytarabine and melphalan (BEAM) + Auto stem cell transplant (ASCT)
3081879|NCT01468337|Experimental|Interferon gamma-1b|"Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. A single dropperette contains 1 mL of topical interferon gamma-1b (Actimmune®) at a concentration of 200 µg/mL, which is equivalent to 28 drops. Each drop provides a dose of 7 µg of investigational product.~All participants will receive interferon gamma-1b for two weeks. Doses of interferon gamma-1b eye drops will be escalated among participants during this initial 2-week period; however, additional doses will be dispensed to participants if needed at Week 4 or after the initial 8-week study period. Participants eligible for additional doses after 8 weeks will be administered the maximum dose of 4 drops 4 times daily for a total daily dose of 112 μg."
3081880|NCT01468350|Placebo Comparator|(PART A) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive a single witnessed dose of (A) dalfampridine-ER 10 mg, and a single witnessed dose of (B) placebo, two days apart
3081881|NCT01468350|Placebo Comparator|(PART A) BA: placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive a single witnessed dose of (B) placebo, and a single witnessed dose of (A) dalfampridine-ER 10 mg, two days apart
3081882|NCT01468350|Placebo Comparator|(PART B) AB: dalfampridine-ER 10mg then placebo|Each subject randomized to the AB arm will receive multiple doses of (A) dalfampridine-ER 10mg and multiple doses of (B) placebo
3081883|NCT01468350|Placebo Comparator|(PART B) BA: Placebo then dalfampridine-ER 10mg|Each subject randomized to the BA arm will receive multiple doses of (B) placebo, and multiple doses of (A) dalfampridine-ER 10mg
3081884|NCT01468454|Experimental|(18F-DOPA) PET/CT imaging|Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion
3081885|NCT01468532|Experimental|Treatment (chemotherapy, receptor agonist)|Patients receive pasireotide IM, 40 mg on day 1, docetaxel 75mg/m2 IV over 1 hour, and prednisone 5mg PO BID continuously. Courses with docetaxel repeat every 21 days and courses with pasireotide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3081886|NCT01468558|Other|All subjects|Subjects received MAP0004 on Day 1 of Visit 2, Ketoconazole on Days 3 through 6 of Visit 2, and MAP0004 again on Day 6 of Visit 2. Subjects then returned for Visit 3, 7-11 days from the end of Visit 2. At Visit 3 subjects received 1.0 mg IV DHE (Intravenous Dihydroergotamine Mesylate).
3081887|NCT01468584|Experimental|MP-424|
3081888|NCT01468597||One group|Emergency surgery
3081889|NCT01468675|Experimental|Intervention|The intervention is completion of a validated, web-based risk assessment used to assess personalized risk and generate a risk report
3081890|NCT01468675|No Intervention|Control|Usual Care
3081891|NCT01468818|Experimental|Immunotherapy for Metastatic Melanoma|Patients will receive non-myeloablative lymphodepleting preparative regimen cons
3081892|NCT01468844|Experimental|Minocycline|Participants injected with bevacizumab for three months followed by PRN dosing and 100mg minocycline twice daily for 24 months
3081893|NCT01468844|Placebo Comparator|Placebo|Participants injected with bevacizumab for three months followed by PRN dosing and placebo twice daily for 24 months
3081894|NCT01468896|Experimental|Treatment (cetuximab and recombinant interleukin-12)|Patients receive cetuximab IV over 1-2 hours on day 1 and recombinant interleukin-12 SC on days 2 and 5 beginning in course 2. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving clinical response or stable disease may continue with therapy until disease progression.
3081895|NCT01468909|Placebo Comparator|Arm I (paclitaxel and placebo)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and placebo PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3081896|NCT01468909|Experimental|Arm II (paclitaxel and pazopanib hydrochloride)|Patients receive paclitaxel as in arm I and pazopanib hydrochloride PO daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3081897|NCT01468974|Other|ESPRIT BVS|Subjects receiving the ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries.
3081898|NCT01468987|Active Comparator|Insulin Glargine + Insulin Lispro|"Participant-specific dose of Insulin Glargine will be administered subcutaneously (SC) once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial (pre-meal) and supplemental doses for 26 weeks."
3081899|NCT01468987|Experimental|LY2605541 + Insulin Lispro|"Participant-specific dose of LY2605541 will be administered SC once daily at bedtime for 26 weeks.~Participant-specific dose of Insulin Lispro will be administered SC for preprandial and supplemental doses for 26 weeks."
3081900|NCT01469000|Experimental|250 mg Gefitinib/500 mg Pemetrexed|250 milligrams (mg) Gefitinib taken orally once daily (QD) and 500 milligrams per square meter (mg/m²) Pemetrexed taken intravenously (IV) once every 3 weeks concurrently with Gefitinib taken orally QD.
3081901|NCT01469000|Active Comparator|250 mg Gefitinib|250 milligrams (mg) Gefitinib taken orally QD
3081902|NCT01469013|Placebo Comparator|Placebo|"2 placebo capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
3081903|NCT01469013|Experimental|1-mg Baricitinib (LY3009104)|"1 x 1-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
3081904|NCT01469013|Experimental|2-mg Baricitinib (LY3009104)|"2 x 1-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this treatment arm will be randomized in a 1:1 ratio to either the 4-mg baricitinib or 8-mg baricitinib arms. Participants rerandomized to 8-mg baricitinib arm at Week 12 will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.~The dosage form changed from capsule in treatment period (up to Week 12) to tablet in extension period (Week 13 to 64) per protocol amendment (b)."
3081905|NCT01469013|Experimental|4-mg Baricitinib (LY3009104)|1 x 4-mg baricitinib capsule + 1 identical placebo capsule, both administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form.
3081906|NCT01469013|Experimental|8-mg Baricitinib (LY3009104)|2 x 4-mg baricitinib capsules administered orally once daily for 12 weeks. Participants who complete this 12-week period will remain on this treatment regimen in tablet form. Participants taking 8-mg baricitinib tablet form will switch to 4-mg baricitinib once a day after the approval of protocol amendment (d) and will receive that switched dose until Week 64.
3081907|NCT01469039|Experimental|ALKS 9072|
3081908|NCT01469039|Placebo Comparator|Placebo|
3081909|NCT01469052|Experimental|Cohort 1|
3081910|NCT01469052|Experimental|Cohort 2|
3081911|NCT01469052|Experimental|Cohort 3|
3081912|NCT01469052|Experimental|Cohort 4|
3081913|NCT01469052|Experimental|Cohort 5|
3081914|NCT01469052|Experimental|Cohort 6|
3081915|NCT01469065|Experimental|PF-04991532|PF-04991532 experimental study medication
3081916|NCT01469065|Placebo Comparator|Placebo|PF-04991532 Matching Placebo
3081917|NCT01469182|Experimental|SCH 39641 12 Amb a 1-U|12 Units short ragweed (Ambrosia artemisiifolia) Major Allergen 1 (Amb a 1-U) extract in an AIT, sublingual, once daily.
3081918|NCT01469182|Placebo Comparator|Placebo|Matching placebo tablet, sublingual, once daily.
3081919|NCT01469221|Experimental|Apaziquone|Apaziquone (4 mg in 40 mL)
3081920|NCT01469221|Placebo Comparator|Placebo|Matching placebo (40 mL)
3081921|NCT01469234|Experimental|loratadine|Participants will receive one dose of loratadine following randomization at 120 minutes of exposure during visit 4.
3081922|NCT01469234|Experimental|fexofenadine|Participants will receive one dose of fexofenadine following randomization at 120 minutes of exposure during visit 4.
3081923|NCT01469234|Placebo Comparator|placebo|Participants will receive one dose of placebo following randomization at 120 minutes of exposure during visit 4.
3081924|NCT01469364|Experimental|Aztreonam Lysine for Inhalation (AZLI)|Patients to received Aztreonam Lysine(AZLI)
3081925|NCT01469377|Placebo Comparator|Placebo|Participants received placebo orally once a day for 8 weeks. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3081926|NCT01469377|Experimental|Cariprazine 1-2 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2 and 1.0 mg on Days 3-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 1.0 or 1.5 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 1.0, 1.5, or 2.0 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3081927|NCT01469377|Experimental|Cariprazine 2-4.5 mg|Participants received cariprazine orally once a day for 8 weeks. Participants received cariprazine 0.5 mg on Days 1 and 2, 1.0 mg on Day 3, 1.5 mg on Day 4, and 2.0 mg on Days 5-7. At the investigator's discretion dose levels could be increased during Week 2. Dose levels allowed during Week 2 were 2.0 or 3.0 mg. A second dose increase was allowed starting at Week 3. Dose levels allowed during Week 3 and the remainder of the treatment period were 2.0, 3.0, or 4.5 mg. Each participant continued to take the same dose of antidepressant therapy (bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, or vilazodone) the participant was receiving prior to entering this study throughout treatment.
3081928|NCT01469546|Experimental|Axitinib (AG-013736)|A prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma who have received no more than two prior lines of systemic therapy for recurrent or metastatic head and neck cancer.
3081929|NCT01469585|Active Comparator|Sub-antimicrobial doxycycline|Women will take sub-antimicrobial doxycyline in addition to the continuous oral contraceptive pill.
3081930|NCT01469585|No Intervention|Continuous Oral Contraceptive Pill|Women will take only the continuous oral contraceptive.
3081931|NCT01469637|Experimental|Sulfamethoxazole + MMX placebo|
3081932|NCT01469637|Experimental|Sulfamethoxazole + MMX Mesalazine/mesalamine|
3081933|NCT01469715|Experimental|GBP-CGM|All participants will wear one active GBP-CGM and one inactive GBP-CGM
3081934|NCT01469767|Experimental|Fluocinonide cream|Subjects will apply fluocinonide cream 0.1% twice daily for 5 days.
3081935|NCT01469819|Experimental|Lubiprostone|Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.
3081936|NCT01470001|Active Comparator|solifenacin|patients in this arm will receive drug
3081937|NCT01470001|Placebo Comparator|placebo|patients is this arm will receive placebo
3081938|NCT01470027|Active Comparator|N-acetylcysteine 1800mg|N-acetylcysteine 1800mg/day for 30 days
3081939|NCT01470027|Active Comparator|N-acetylcysteine 3600mg|N-acetylcysteine 3600mg daily for 30 days
3081940|NCT01470027|Placebo Comparator|Placebo|Placebo effervescent tablets daily for 30 days
3081941|NCT01470118|Active Comparator|LASTACAFT® (alcaftadine 0.25%)|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
3081942|NCT01470118|Active Comparator|Pataday™ (olopatadine 0.2%)|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
3081943|NCT01470118|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of placebo instilled in each eye at Day 0 and Day 14.
3081944|NCT01470144|Experimental|Treatment|Single arm, open-label
3081945|NCT01470170|Experimental|Group1|Alfentanil 2.5μg/kg before propofol
3081946|NCT01470170|Experimental|Group2|Alfentanil 5μg/kg before propofol
3081947|NCT01470170|Experimental|Group 3|Alfentanil 2.5μg/kg two minutes before propofol
3081948|NCT01470170|Experimental|Group 4|Alfentanil 5μg/kg two minutes before propofol
3081949|NCT01470170|Placebo Comparator|Group 5 Control|propofol alone
3081950|NCT01470196|Experimental|Treatment Arm|Carfilzomib, dexamethasone, rituximab
3081951|NCT01470248|Experimental|Arsenic Trioxide Treatment|This is a single arm study. All patients will be treated with the investigational agent, Arsenic Trioxide, according to the dose and schedule indicated in the protocol.
3081953|NCT01470417|Active Comparator|Chemotherapy|Individuals with low risk disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
3081954|NCT01470417|Active Comparator|Chemotherapy and ChemoRadiotherapy|Individuals with high-risk disease or borderline resectable disease will receive nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
3081955|NCT01470469|Active Comparator|SPD503|
3081956|NCT01470469|Placebo Comparator|Placebo|
3081957|NCT01470599|Experimental|5mg BID|
3081958|NCT01470599|Experimental|10mg BID|
3081959|NCT01470612|Experimental|CP-690,550 5 mg BID|5 mg BID
3081960|NCT01470612|Experimental|CP-690,550 10 mg BID|10 mg BID
3081961|NCT01470651|Experimental|Armodafinil|Active medication
3081962|NCT01470651|Placebo Comparator|Sugar pill|Inactive pill, matched to look like active medication
3081963|NCT01470781|Experimental|Cognitive Remediation|This arm will receive computer-based cognitive remediation treatment 3 times per week for 24 weeks, for a total of 70 hours of treatment
3081964|NCT01470781|Placebo Comparator|Computer Control|Group will receive 70 hours of computer time playing pre-selected computer games administered in a similar format as the Cognitive Remediation condition
3081965|NCT01470859|Active Comparator|pramipexole|0.375mg-4.5mg/day, flexible dosage according to an optimal improvement of movement dysfunction in PD patients
3081966|NCT01470859|Active Comparator|Levodopa|Sinemet CR CR， Controlled Release
3081967|NCT01470989|Experimental|canakinumab|canakinumab 150 mg s.c.
3081968|NCT01471015|Active Comparator|High dose Darbepoetin alfa|10 mcg/kg/dose Darbe x2 doses, with the first dose within 12 hours of delivery and the second dose at 7 days
3081969|NCT01471015|Active Comparator|Low dose Darbepoetin alfa|2 mcg/kg/dose Darbe x2, with the first dose given within 12 hours of delivery and the second dose given at 7 days old.
3081970|NCT01471015|Placebo Comparator|Placebo|Placebo given x2 doses, with the first given within 12 hours of delivery and the second given at 7 days old
3081971|NCT01471028|Experimental|ELAD Treatment|This group will receive treatment with ELAD plus standard of care treatment.
3081972|NCT01471028|Other|Standard of care (Control)|This group will receive standard of care treatment as defined in the protocol.
3081973|NCT01471041|Experimental|Venous Window Needle Guide|Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula
3081974|NCT01471054|Experimental|Ozurdex|Patients will be followed at 1 week after Ozurdex insertion (0.7 mg) and then at 1,2, 3,4, 5, and 6 months. Following the 6-month visit, patients will be seen every 2 months. At each visit patients will be checked for side effects of treatment, measurement of best-corrected visual acuity (BCVA), complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Each eye in the Ozurdex group can have a maximum total of three Ozurdex insertions at minimum of 4-month intervals in the first year after enrolling into the study.
3081975|NCT01471054|Active Comparator|Bevacizumab|Patients will be followed at 1 week after the initial bevacizumab injection and then at 1,2, 3,4, 5, and 6 months after implant. Following the 6-month visit, the patients will be examined every 4-8 weeks depending on the status of their macular edema. At each visit patients will be checked for side effects of treatment, measurement of BCVA, complete eye examination, fundus photography, and optical coherence tomography. Fluorescein angiography will be repeated at 6 and 12 months. Eyes in the Bevacizumab group can have a maximum total of twelve (12) bevacizumab injections at minimum of 4-week intervals in the first year after enrolling into the study.
3081976|NCT01471093|Experimental|Solution|A single dose of OPC-12759 Ophthalmic solution for two-day treatment
3081977|NCT01471093|Active Comparator|Suspension|A single dose of OPC-12759 Ophthalmic suspension for two-day treatment
3081978|NCT01471171|Experimental|Aclidinium bromide|3-week treatment periods
3081979|NCT01471171|Experimental|Placebo|3-week treatment periods
3081980|NCT01471197|Experimental|Arm 1: Ipilimumab|
3081981|NCT01471197|Active Comparator|Arm 2: Pemetrexed|
3081982|NCT01471340|Experimental|Mometasone Furoate/Formoterol MDI BID|MF/F MDI BID (pooled MF/F MDI 200/10 mcg BID and MF/F MDI 400/10 mcg BID treatments)
3081983|NCT01471340|Active Comparator|Mometasone Furoate MDI BID|MF MDI BID (pooled from MF MDI 200 mcg BID and MF MDI 400 mcg BID treatments)
3081984|NCT01471353|Experimental|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study.
3081985|NCT01471379|Experimental|Group A (50mg - 100mg)|Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
3081986|NCT01471379|Active Comparator|Group B (50mg x12)|Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
3081987|NCT01471379|Placebo Comparator|Group C (Placebo - 50mg)|Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II
3081988|NCT01471457|Experimental|Trimo-San group|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
3081989|NCT01471457|No Intervention|Control group|Pessary wearers are informed on standard care of pessary, which includes topical estrogen application if they are using. Pessary wearers do not use Trimo-San gel
3081990|NCT01471522|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization plus optimal medical therapy.
3081991|NCT01471522|Active Comparator|Conservative Strategy|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with acute coronary syndrome, ischemic heart failure, resuscitated cardiac arrest or refractory symptoms.
3081992|NCT01471574|Experimental|Daclatsvir + Ribavirin + PEG-Interferon alfa-2a|
3081993|NCT01471626|Experimental|telematic attended polysomnography|
3081994|NCT01471639|Experimental|Intranasal ketorolac (Sprix)|FDA approved drug used in single arm study
3081995|NCT01471691|Experimental|intravitreal ranibizumab 0.5mg|
3081996|NCT01471691|Experimental|intravitreal ranibizumab 1.0mg|
3081997|NCT01471782|Experimental|Blinatumomab|Blinatumomab was administered as a continuous intravenous (cIV) infusion at a constant daily flow rate over 4 weeks followed by a treatment-free interval of 2 weeks. Doses ranged between 5 and 30 µg/m²/day. Each participant received up to five cycles of treatment.
3081998|NCT01472185|Placebo Comparator|Placebo|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Placebo to match ranolazine (Days 1-7: 1 tablet twice daily; 2 tablets twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
3081999|NCT01472185|Experimental|Ranolazine|"Qualifying Period: Placebo to match ranolazine (1 tablet twice daily) for 14 days.~Treatment Period: Ranolazine tablets (Days 1-7: 1 × 500 mg twice daily; 2 × 500 mg twice daily thereafter) for up to 24 weeks.~Participants were required to maintain their diet and exercise regimen."
3082000|NCT01472289|Experimental|BMMNC treated group|Autologous bone marrow mononuclear cell concentrate (BMMNCs) prepared using the Res-Q 60 technology (a point of care system) to be injected intramuscularly into multiple sites in the ischemic muscle tissue of the affected limb at 0.5 cc/injection for a total of 15-20 cc.
3082001|NCT01472341||All Participants|Participants receiving routine care under a diabetologist.
3082002|NCT01472380|Active Comparator|Efavirenz 600mg alone|efavirenz 600mg by mouth taken on Day 1
3082003|NCT01472380|Active Comparator|Efavirenz co-administered with fenofibric acid|co-administered oral doses of efavirenz 600 mg and fenofibric acid 105 mg taken on Day 31
3321096|NCT02016131||Endoleak events|Patients who undergo endoleaks related adverse events or persistent endoleaks during follow up.
3321097|NCT02016157|Experimental|Moxifloxacin, Chronic periodontitis|50 micrograms Moxifloxacin
3082004|NCT01472432|Placebo Comparator|Placebo|In the placebo group, the dose of other concomitant hypoglycemic medication was changed to obtain a similar profile of metabolic parameters. All patients had diabetes and at least one full-thickness wound below the ankle for >3 months. All patients were examined weekly for the first 4 weeks (day 28) then every other week until day 120 or ulcer closure by any means. At each visit, tracings of the wound margins were made for computer planimetry to document changes in wound size, and photographs were taken for a visual record. All patients followed the regular treatment at the multidisciplinary diabetes foot clinic, included treatment of infection, debridement, off-loading, and metabolic control according to high international standards and standard good medical practice.
3082005|NCT01472432|Experimental|Vildagliptin|The experimental arm followed the same treatment of placebo group, but received also vildagliptin 50 mg per os b.i.d. for 4 months
3082006|NCT01472445|Experimental|Non-obese (Body Mass Index ≤ 25)|Non-obese participants receive Vitamin D at 400 or 10,000 IU/day
3082007|NCT01472445|Experimental|Obese (Body Mass Index > 25)|Obese participants receive Vitamin D at 400 or 10,000 IU/day
3082008|NCT01472549|Active Comparator|Iodine-alcohol|8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health)
3082009|NCT01472549|Experimental|Chlorhexidine-alcohol|2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health)
3082010|NCT01472562|Experimental|all patients|"Induction Phase (week 1 - 48):~Lenalidomide will be given at 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance Phase (week 49 - progression of disease):~Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle.~Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
3082011|NCT01472718|Active Comparator|standard primary coronary intervention|
3082012|NCT01472718|Experimental|coronary thrombectomy|
3082013|NCT01472757|Placebo Comparator|Placebo|
3082014|NCT01472757|Active Comparator|Dose 1|
3082015|NCT01472757|Active Comparator|Dose 2|
3082016|NCT01472757|Active Comparator|Dose 3|
3082017|NCT01472822|Experimental|Omija extract.|
3082018|NCT01472822|Placebo Comparator|Placebo|
3082019|NCT01472835|Experimental|Sedation|Pt will receive sedation with their procedure
3082020|NCT01472835|No Intervention|Control|Patient will not receive sedation during procedure
3082021|NCT01472874|Experimental|Once a day Trientine|Patients receive once a day trientine
3082022|NCT01472939|Active Comparator|SSP-002358 (0.1 mg) + Proton Pump Inhibitor (PPI)|
3082023|NCT01472939|Active Comparator|SSP-002358 (0.5 mg) + PPI|
3082024|NCT01472939|Active Comparator|SSP-002358 (2.0 mg) + PPI|
3082025|NCT01472939|Placebo Comparator|Placebo + PPI|
3082026|NCT01472965|Active Comparator|Treatment|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with 70% ethanol catheter lock therapy.
3082027|NCT01472965|Placebo Comparator|Control|Eligible patients with CLABSI will be enrolled within 96 hours of collection of positive blood culture and randomized to blinded treatment with heparin-saline placebo catheter lock therapy.
3082028|NCT01473160|Experimental|delefilcon A|Delefilcon A randomly assigned to one eye, with narafilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
3082029|NCT01473160|Active Comparator|narafilcon A|Narafilcon A randomly assigned to one eye, with delefilcon A assigned to the fellow eye for contralateral wear. Both products will be worn for one day for 16 hours (+/- 1 hour).
3082030|NCT01473355|Experimental|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) in lengths of 11-15 mm
3082031|NCT01473368|Active Comparator|prebiotic (Saccharomyces boulardii)|500 mg, 2 times daily for 14 days
3082032|NCT01473368|Active Comparator|antibiotic (Amoxicillin Clavulanate)|875/125 mg 2 times daily at least 1 hour before meals for 7 days
3082033|NCT01473368|Active Comparator|combination (prebiotic and antibiotic)|Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).
3082034|NCT01473368|No Intervention|control|
3082035|NCT01473381|Placebo Comparator|Placebo|Participants received 2 placebo to vilazodone tablets, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study.
3082036|NCT01473381|Experimental|Vilazodone 20 mg/day|Participants received 1 vilazodone tablet, 1 placebo to vilazodone tablet, and 1 placebo to citalopram capsule orally once daily for the 11 weeks of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20 mg/day during Weeks 2 to 10, and vilazodone 10 mg/day during Week 11.
3082037|NCT01473381|Experimental|Vilazodone 40 mg/day|Participants received 1 placebo to vilazodone tablet, 1 vilazodone tablet, and 1 placebo to citalopram capsule orally once daily during Weeks 1 and 2 of the study. Participants received 2 vilazodone tablets and 1 placebo to citalopram capsule orally once daily during Weeks 3 -10 of the study. Participants received vilazodone 10 mg/day during Week 1, vilazodone 20/day mg during Week 2, and vilazodone 40 mg/day during Weeks 3 to 10. During Week 11, participants received vilazodone 20 mg/day for 4 days and 10 mg/day for 3 days.
3082038|NCT01473381|Active Comparator|Citalopram 40 mg/day|Participants received 2 placebo vilazodone tablets, and 1 citalopram capsule once daily for the 11 weeks of the study. Participants received citalopram 20 mg/day during Weeks 1 and 2, citalopram 40 mg/day during Weeks 3 to 10, and citalopram 20 mg/day during Week 11.
3082039|NCT01473394|Placebo Comparator|Dose-matched placebo|Participants received dose-matched placebo orally once daily for 9 weeks.
3082040|NCT01473394|Experimental|Vilazodone|Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.
3082041|NCT01473407|Experimental|Epoetin Hospira|Epoetin Hospira
3082042|NCT01473407|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
3082043|NCT01473420|Experimental|Epoetin Hospira|Epoetin Hospira
3082044|NCT01473420|Active Comparator|Epogen (Amgen)|Epogen (Amgen)
3082045|NCT01473524|Experimental|DB OCA 5-10 mg|OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.
3082046|NCT01473524|Experimental|DB OCA 10 mg|OCA 10 mg for 12 months during the DB phase.
3082047|NCT01473524|Placebo Comparator|DB Placebo|Matching placebo for 12 months during the DB phase.
3082048|NCT01473524|Experimental|LTSE OCA|After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.
3082049|NCT01473563|Experimental|Pemetrexed|500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
3082050|NCT01473589|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
3082051|NCT01473589|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
3082052|NCT01473602|Placebo Comparator|Placebo|Administered once daily by subcutaneous (SC) injection for 6 months
3082053|NCT01473602|Experimental|Teriparatide|20 microgram (µg) administered once daily by SC injection for 6 months
3082054|NCT01473745|Active Comparator|modified alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The modified alar cinch suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
3082055|NCT01473745|Placebo Comparator|conventional alar base cinch suture|Before closure of the maxillary wound, an alar base cinch suture was performed with 3-O Nylon. The conventional alar base cinch suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
3082056|NCT01473758|Active Comparator|Roflumilast|added on to standard therapy for acute COPD exacerbations
3082057|NCT01473758|Placebo Comparator|Placebo|added on to standard therapy for acute COPD exacerbations
3082058|NCT01473836|Experimental|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) in combination with ceftriaxone sodium
3082059|NCT01473940|Experimental|Treatment (monoclonal antibody, chemotherapy)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes in weeks 1, 4, 7, and 10 and gemcitabine hydrochloride IV over 30 minutes in weeks 1-7 and 9-11.~MAINTENANCE: Beginning in week 22, patients receive ipilimumab IV over 90 minutes once every 12 weeks and gemcitabine hydrochloride IV over 30 minutes once weekly for 3 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Treatment modifications may apply according to response."
3082060|NCT01473953|Experimental|Cohort 1a: Lira-depot 2.25 mg|
3082061|NCT01473953|Experimental|Cohort 2a: Lira-depot 6.75 mg|
3082062|NCT01473953|Experimental|Cohort 3a: Lira-depot 15 mg|
3082063|NCT01473953|Experimental|Cohort 4a: Lira-depot 30 mg|
3082064|NCT01473953|Placebo Comparator|Placebo|
3082065|NCT01473992|Active Comparator|Prosthetic knee 1 (Otto Bock C-Leg)|This arm included unilateral transfemoral amputees who were assessed while using their preferred knee at study start(C-Leg). The Otto Bock C-Leg is a microprocessor knee using 2 sensors (1 for kinetics and 1 for kinematics).
3082066|NCT01473992|Active Comparator|Prosthetic knee 2 (Otto Bock Genium)|This arm included unilateral transfemoral amputees who were assessed while using the experimental/study knee, the Genium. The Otto Bock Genium is a microprocessor knee using multiple sensors that hypothetically increase mobility functions (e.g. walking backwards, intuitive stance)
3082067|NCT01473992|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3082068|NCT01474018|No Intervention|Metformin + Insulin|5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
3082069|NCT01474018|Experimental|QR-Bromocriptine +metformin+insulin|study drug add-on the usual therapy
3082070|NCT01474109|Active Comparator|macitentan 3mg|macitentan 3mg tablet once daily
3082071|NCT01474109|Active Comparator|macitentan 10mg|macitentan 10mg tablet once daily
3082072|NCT01474109|Placebo Comparator|placebo|matching placebo once daily
3082073|NCT01474122|Active Comparator|Macitentan 3 mg|Oral macitentan 3 mg, once daily
3082074|NCT01474122|Active Comparator|Macitentan 10 mg|Oral macitentan 10 mg, once daily
3082075|NCT01474122|Placebo Comparator|Placebo|Oral placebo, once daily
3082076|NCT01474200|Experimental|Aquapheresis (AQ) - isolated veno-venous ultrafiltration|Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
3082077|NCT01474200|Active Comparator|IV Loop Diuretics (LD)|Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment
3082078|NCT01474213|Active Comparator|dexmedetomidine|a loading dose (1.5mcg/kg) infused over10 min followed by a continuous infusion of 0.7 μg/kg/h
3082079|NCT01474213|Active Comparator|remifentanil|The initial target was 3.0 ng/ml and the TCI was adjusted by 0.5 ng/ml after the target concentration at the effect site had equilibrated with the plasma concentration, until the desired level of sedation was acheived.
3082080|NCT01474239|Experimental|Calibration Arm|
3082081|NCT01474239|Experimental|Investigational Arm|
3082082|NCT01474291||Tocilizumab|Tocilizumab administered as monotherapy or in combination with other standard of care therapy according to prescribing information and normal clinical practice.
3082083|NCT01474317|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
3321098|NCT02016196|Experimental|rifaximin|6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
3082084|NCT01474434|Experimental|Pradigastat (LCQ908) followed by placebo|Pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by pradigastat 20 mg (2 x 10-mg tablets) daily for two days followed by a 30-day washout period in between followed by 5-day placebo treatment
3082085|NCT01474434|Experimental|Placebo followed by pradigastat (LCQ908)|Placebo (5-day treatment period) followed by a 30-day washout period followed by pradigastat 80 mg (4 x 20-mg tablets) loading dose daily for three days followed by p20 mg (2 x 10-mg tablets) daily for two days
3082086|NCT01474486|Experimental|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
3082087|NCT01474512|Experimental|80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W)|Administered as two 80-mg subcutaneous (SC) injections at Week 0, then one 80-mg SC injection per Dosing Regimen 1 [every 2 weeks (Q2W)] up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 [every 4 weeks (Q4W)] or Dosing Regimen 3 [every 12 weeks Q12W)].
3082088|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 2 (Q4W)|Administered as two 80-mg SC injections at Week 0, then one 80-mg SC injection per Dosing Regimen 2 (Q4W) up to and including Week 10. At Week 12, arm is re-randomized to placebo, Dosing Regimen 2 (Q4W) or Dosing Regimen 3 (Q12W).
3082089|NCT01474512|Experimental|80 mg Ixekizumab Dosing Regimen 3 (Q12W)|Dosing Regimen 3 (Q12W) is not used until Week 12. At Week 12, participants who were re-randomized to this arm were administered one 80-mg SC injection Q12W.
3082090|NCT01474512|Placebo Comparator|Placebo|Administered as 2 SC injections at Week 0, then 1 SC injection per Dosing Regimen 1 (Q2W) up to and including Week 10. At Week 12, arm is re-randomized to placebo or Dosing Regimen 2 (Q4W).
3082091|NCT01474538|Active Comparator|Insulin Lispro, then Insulin Aspart|Insulin lispro [100 units/milliliter (U/mL)] administered by continuous subcutaneous insulin infusion (CSII) pump for 16 weeks in Treatment Period 1, followed by insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
3082092|NCT01474538|Active Comparator|Insulin Aspart, then Insulin Lispro|Insulin aspart (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 1, followed by insulin lispro (100 U/mL) administered by CSII pump for 16 weeks in Treatment Period 2.
3082093|NCT01474551|Experimental|vemurafenib|This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.
3082094|NCT01474590|Experimental|Epiduo/Tactuo + doxycycline 200mg|
3082095|NCT01474590|Active Comparator|Isotretinoin + vehicle gel|
3082096|NCT01474681|Experimental|HSC835|HSC835 infusion
3082097|NCT01474746|Placebo Comparator|Placebo|This arm will undergo identical treatment and assessments as the experimental group, with the exception of the active agent, sertraline. This group will be placed on a placebo.
3082098|NCT01474746|Experimental|Active|This arm will undergo identical treatment and assessments as the placebo group. This group will receive the active agent, sertraline.
3082099|NCT01474772|Experimental|Pregabain|
3082100|NCT01474772|Placebo Comparator|Placebo|
3082101|NCT01474863|Active Comparator|Low Dose Citrulline|Low Dose Citrulline
3082102|NCT01474863|Placebo Comparator|Placebo|Placebo IV infusion
3082103|NCT01474863|Active Comparator|High Dose Citrulline|High Dose Citrulline
3082104|NCT01474876||Ankylosing Spondylitis|Participants with a diagnosis of ankylosing spondylitis
3082105|NCT01474876||Psoriatic Arthritis|Participants with a diagnosis of psoriatic arthritis
3082106|NCT01474915|Active Comparator|Aprepitant|"Aprepitant is given orally, along with an oral or PO placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy 40mg Aprepitant PO + IV placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
3082107|NCT01474915|Active Comparator|Ondansetron|"Ondansetron is given via IV, along with an oral or IV placebo depending on their group assignment for uniformity. Each patient will receive three drugs in their respective triple prophylactic medication (25mg promethazine, 10mg dexamethasone, and either 4mg ondansetron or 40mg aprepitant) plus an IV or oral placebo prior to induction of anesthesia.~Triple therapy~4mg Ondansetron IV + PO placebo, 25mg Promethazine IV and 10mg dexamethasone IV"
3082108|NCT01474993|Placebo Comparator|Placebo|inactive placebo.
3082109|NCT01474993|Experimental|Interventional|sulforaphane-rich Broccoli Sprout Extract.
3082110|NCT01475071|Experimental|Metvix and daylight|
3082111|NCT01475071|Active Comparator|Metvix and lamp|
3082112|NCT01475097|Active Comparator|Active Arm|
3082113|NCT01475097|Active Comparator|Comparator Arm|
3082114|NCT01475136|Experimental|LY2140023|A single oral dose of 80 milligrams (mg) LY2140023 administered on Day 1.
3082115|NCT01475162|Experimental|Tocilizumab|"Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response."
3082116|NCT01475175|Experimental|CRT pacing at rest and during exercise|Rest and sub-maximal exercise
3082117|NCT01475214|Active Comparator|potassium bicarbonate low dose|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
3082118|NCT01475214|Active Comparator|potassium bicarbonate higher dose|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
3082119|NCT01475214|Placebo Comparator|placebo|microcrystalline cellulose
3082120|NCT01475253|Experimental|Lidocaine Releasing Intravesical System|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
3082121|NCT01475253|Placebo Comparator|LiRIS containing inactive substance only|LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
3082122|NCT01475253|Sham Comparator|Cystoscopy Procedure|No intervention. Cystoscopy procedure is performed on study Day 0 and study Day 14 to mimick active and placebo study arms without insertion of Investigational Product into the bladder.
3082123|NCT01475305|Placebo Comparator|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
3082124|NCT01475305|Experimental|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
3082125|NCT01475331|Active Comparator|Control Group|Cyst will be lavaged for 3-5 minutes with Ethanol (alcohol 80%). Following lavage with Ethanol (alcohol 80%), The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
3082126|NCT01475331|Experimental|Study Group|Cyst will be lavaged for 3-5 minutes with Normal Saline .. Following lavage with Normal Saline, The cyst will be infused with an admixture of chemotherapy drugs (Paclitaxel/ Gemcitabine) 3mg/ml paclitaxel and 19mg/ml gemcitabine.
3082127|NCT01475370|Experimental|OCV-501|
3082128|NCT01475461|Placebo Comparator|Placebo|
3082129|NCT01475461|Experimental|PF-04937319 - Dose 1|
3082130|NCT01475461|Experimental|PF-04937319 - Dose 2|
3082131|NCT01475461|Experimental|PF-04937319 - Dose 3|
3082132|NCT01475461|Experimental|PF-04937319 - Dose 4|
3082133|NCT01475461|Active Comparator|Sitagliptin|
3082134|NCT01475487|Active Comparator|Cricothyrotomy using Digital Palpation|Group-1 will perform Cricothyrotomy using conventional digital palpation technique
3082135|NCT01475487|Experimental|Ultrasound guided cricothyrotomy group|Group-2 Ultrasound guided cricothyrotomy
3082136|NCT01475513|Active Comparator|African-American women|African-American women
3082137|NCT01475513|Active Comparator|Caucasian women|Caucasian women
3082138|NCT01475643|Experimental|Loteprednol etabonate|Loteprednol etabonate 0.5%
3082139|NCT01475643|Active Comparator|Prednisolones acetate|Prednisolone acetate 1.0%
3082140|NCT01475721|Experimental|ADVAIR 100/50mcg|experimental drug
3082141|NCT01475721|Experimental|ADVAIR 250/50mcg|experimental drug
3082142|NCT01475721|Experimental|ADVAIR 500/50mcg|experimental drug
3082143|NCT01475721|Active Comparator|FLOVENT 100mcg|active comparator
3082144|NCT01475721|Active Comparator|FLOVENT 250mcg|active comparator
3082145|NCT01475721|Active Comparator|FLOVENT 500mcg|active comparator
3082146|NCT01475734|Active Comparator|albiglutide|single dose of albiglutide
3082147|NCT01475734|Placebo Comparator|placebo|single dose of placebo
3082148|NCT01475825|Experimental|Regimen A: Mipomersen|Subcutaneous injection of mipomersen 200 mg once weekly
3082149|NCT01475825|Placebo Comparator|Regimen A: Placebo|Placebo matching subcutaneous injection once weekly.
3082150|NCT01475825|Experimental|Regimen B: Mipomersen|Subcutaneous injection of mipomersen 70 mg thrice weekly.
3082151|NCT01475825|Placebo Comparator|Regimen B: Placebo|Placebo matching subcutaneous injection thrice weekly.
3082152|NCT01475838|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
3082153|NCT01475838|Active Comparator|PI+RTV+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of a PI boosted with RTV plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
3082154|NCT01475851|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet is administered orally once daily
3082155|NCT01475955|Experimental|Broad Area ALA 1-hour incubation|Broad Area ALA 1-hour incubation
3082156|NCT01475955|Experimental|Broad Area ALA 2-hour incubation|Broad Area ALA 2-hour incubation
3082157|NCT01475955|Experimental|Broad Area ALA 3-hour incubation|Broad Area ALA 3-hour incubation
3082158|NCT01475955|Experimental|Spot ALA 2-hour incubation|Spot ALA 2-hour incubation
3082159|NCT01475955|Placebo Comparator|Vehicle PDT|VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
3082160|NCT01476202|Experimental|Nicotine mouth strip|single dose
3082161|NCT01476202|Active Comparator|nicotine lozenge|single dose
3082162|NCT01476202|Active Comparator|nicotine gum|single dose
3082163|NCT01476267|Experimental|Single Arm|
3082164|NCT01476345|Experimental|LY2963016|A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
3082165|NCT01476345|Experimental|Lantus|A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
3082166|NCT01476449|Active Comparator|Monthly Ranibizumab|Patients randomized to the Monthly Ranibizumab arm of the study will be administered intravitreal injections each month for their diabetic macular edema for the duration of the study.
3082167|NCT01476449|Experimental|Treat and Extend Ranibizumab|"Patients randomized to this arm of the study will receive intravitreal injections of ranibizumab until their maculae are anatomically dry, at which point the evaluation and injection interval will be extended."
3082168|NCT01476475|Experimental|Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
3082169|NCT01476475|Active Comparator|Insulin glargine|Insulin glargine QD for 24 weeks. Dose individually adjusted.
3082170|NCT01476644|Other|Glaucoma Patients|Moderate glaucoma patients with a minimum 2-year diagnosis of primary open-angle glaucoma, chronic primary angle-closure glaucoma or pseudoexfoliation glaucoma were included to complete annual visits over a 4 year period. Each visit included (1) Clinical evaluation: a slit lamp examination, fundoscopy, intraocular pressure measurement, visual field examination, spectral domain optical coherence tomography, Pelli-Robson Contrast Sensitivity test and the Spaeth-Richman Contrast Sensitivity test; (2) a performance based measures: the Compressed Assessment of Ability Related to Vision; and (3) Subjective measures of vision-related quality of life (VRQoL) (the National Eye Institute Visual Functioning Questionnaire 25 and the Modified Glaucoma Symptom Scale).
3082171|NCT01476696|Experimental|Part A: Prasugrel Single Dose|Prasugrel 0.03 milligrams per kilogram (mg/kg) to 0.60 mg/kg dosage to be titrated up or down based on desired platelet inhibition, administered orally [oral-disintegrating tablet (ODT)], single dose given up to 3 occasions, at different strengths, with up to 18 days between doses.
3082172|NCT01476696|Experimental|Part B: Prasugrel Once-Daily Dose|Daily prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 30% administered orally, once daily for 10-18 days and then followed by prasugrel dose (mg/kg) that is expected to achieve mean platelet activation inhibition of 50% administered orally, once daily for 10-18 days, for a total of 20-36 days.
3082173|NCT01476722|Experimental|OPTI-FREE PureMoist|OPTI-FREE PureMoist multipurpose disinfecting solution used with study contact lenses on a daily wear basis for 30 days
3082174|NCT01476748|Active Comparator|Ethicon Xcel Trocars|Ethicon Xcel trocars will be used in this arm with Laprostop device
3082175|NCT01476748|Active Comparator|Covidien Veraport Trocars|Covidien Veraport Trocars will be used in this arm with the Laprostop device
3082176|NCT01476748|Active Comparator|Storz Reusable Trocars|Storz Reusable Trocars will be used in this arm with the Laprostop device
3082177|NCT01477320|Active Comparator|Pantoprazole 40mg IV daily and tube feed|
3082178|NCT01477320|Placebo Comparator|Placebo and tube feed.|
3082179|NCT01477333|Experimental|UT-15C SR BID|Initiated at 0.125 mg twice daily (BID), titrated as clinically indicated.
3082180|NCT01477450|Active Comparator|1 L/min ; 16 mL|Cylinder oxygen delivery (1 L/min) followed by pulse-dose oxygen by concentrator (16 mL)
3082181|NCT01477450|Active Comparator|2 L/min ; 32 mL|Cylinder oxygen delivery (2 L/min) followed by pulse-dose oxygen by concentrator (32 mL)
3082182|NCT01477450|Active Comparator|3 L/min ; 48 mL|Cylinder oxygen delivery (3 L/min) followed by pulse-dose oxygen by concentrator (48 mL)
3082183|NCT01477463|Experimental|Arm A: Vitamin D|4,000 IU oral vitamin D3
3082184|NCT01477463|Experimental|Arm B: Placebo + Vitamin D|Placebo + 4000 IU oral Vitamin D3
3082185|NCT01477567|Experimental|0.3 mg LY3009385|LY3009385: 0.3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082186|NCT01477567|Experimental|1 mg LY3009385|LY3009385: 1 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082187|NCT01477567|Experimental|3 mg LY3009385|LY3009385: 3 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082188|NCT01477567|Experimental|9 mg LY3009385|LY3009385: 9 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082189|NCT01477567|Experimental|22 mg LY3009385|LY3009385: 22 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082190|NCT01477567|Experimental|54 mg LY3009385|LY3009385: 54 milligrams (mg), subcutaneous (SC) injection, single dose on Day 1
3082191|NCT01477567|Placebo Comparator|Placebo|Placebo: saline, subcutaneous (SC) injection, single dose on Day 1
3082192|NCT01477710|Active Comparator|Hold Mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
3082193|NCT01477710|Active Comparator|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
3082194|NCT01477710|Active Comparator|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
3082195|NCT01477749|Experimental|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
3082196|NCT01477762|Active Comparator|PTSD Negative|Participants who do not have PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
3082197|NCT01477762|Experimental|PTSD Positive|Participants with PTSD will receive placebo and dexamethasone in random order for the duration of two consecutive study visits separated by at least one month.
3082198|NCT01477853|Experimental|Sitagliptin/Sitagliptin + Atorvastatin|In Phase A, participants received sitagliptin 100 mg plus matching placebo to atorvastatin daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
3082199|NCT01477853|Active Comparator|Atorvastatin/Atorvastatin + Glimepiride|In Phase A, participants received atorvastatin 80 mg plus matching placebo to sitagliptin daily for 16 weeks. Participants continuing to Phase B received atorvastatin 80 mg plus matching placebo to sitagliptin plus glimepiride daily for an additional 38 weeks.
3082200|NCT01477853|Experimental|Sitagliptin + Atorvastatin/Sitagliptin + Atorvastatin|In Phase A, participants sitagliptin 100 mg plus atorvastatin 80 mg daily for 16 weeks. Participants continuing to Phase B received sitagliptin 100 mg plus atorvastatin 80 mg plus matching placebo to glimepiride daily for an additional 38 weeks.
3082201|NCT01477892|Experimental|low dose remifentanil|continuous infusion of remifentanil 0.1mcg/kg/min
3082202|NCT01477892|Active Comparator|high dose remifentanil|continuous infusion of remifentanil 0.25mcg/kg/min
3082203|NCT01478009|Experimental|KRG Extract|
3082204|NCT01478009|Placebo Comparator|Placebo|
3082205|NCT01478048|Experimental|Arm A: Elotuzumab + Bortezomib + Dexamethasone|On days of Elotuzumab infusion: Dexamethasone (8mg IV + 8mg Oral) will be administered other days Dexamethasone 20 mg Oral will be administered
3082206|NCT01478048|Active Comparator|Arm B: Bortezomib + Dexamethasone|
3082207|NCT01478087|Other|Mysorba(single-arm)|
3082208|NCT01478256|Active Comparator|Besifloxocin|Use of topical besifloxocin to treat acute blepharitis
3082209|NCT01478256|Active Comparator|Erythromycin|Topical Erythromycin ointment for treatment of acute blepharitis
3082210|NCT01478321|Experimental|Treatment (radiation, chemotherapy, monoclonal antibody)|"CONCURRENT THERAPY: Patients undergo hypofractionated radiation therapy 5 days a week beginning on day 0. Patients also receive temozolomide PO QD and bevacizumab IV over 30-90 minutes once every 2 weeks beginning on days -3 to 0. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.~ADJUVANT THERAPY: Beginning 2 weeks after completion of radiation therapy, patients receive temozolomide PO QD for 6 weeks and bevacizumab IV over 30-90 minutes once every 2 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity."
3082211|NCT01478347|Experimental|rMenB+OMV NZ|Healthy adults (≥18 to ≤65 years), at high risk for meningococcal B disease due to routine occupational exposure to N. Meningitidis cultures (e.g. lab workers), were administered two injections of Recombinant meningococcal B (rMenB) + Outer Membrane Vesicle (OMV NZ) vaccine, 2 months apart, in part I of the study, were enrolled for optional blood draws and safety follow-up in part II of the study.
3082212|NCT01478360|Experimental|AIN457|AIN457 10 mg/kg
3082213|NCT01478360|Placebo Comparator|Placebo|Placebo intravenous injection
3082214|NCT01478373|Experimental|Dovitinib (TKI258)|Patients will receive Dovitinib (TKI258) on an outpatient basis at the dose of 500 mg qd for 5 days followed by 2 days off, every week for cycle of 4 weeks (28d) until disease progression, unacceptable toxicity, or consent withdrawal.
3082215|NCT01478581|Experimental|Cohort 1|PCI-32765 420 mg per day
3082216|NCT01478581|Experimental|Cohort 2|PCI-32765 560 mg per day, 40 mg dexamethasone (oral) once per week
3082217|NCT01478581|Experimental|Cohort 3|PCI-32765 840 mg per day
3082218|NCT01478581|Experimental|Cohort 4|PCI-32765 840 mg per day, 40 mg dexamethasone (oral) once per week
3082219|NCT01478594|Experimental|Tivozanib + mFOLFOX6|Participants received 1.5 mg of tivozanib orally once daily beginning on Day 1 of each cycle for 21 days followed by 7 days off treatment. Participants also received modified FOLFOX6 (mFOLFOX6) chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
3082220|NCT01478594|Active Comparator|Bevacizumab + mFOLFOX6|Participants received a dose of 5 mg/kg bevacizumab via intravenous infusion every 2 weeks on Days 1 and 15 of each cycle. Participants also received mFOLFOX6 chemotherapy every 2 weeks on Days 1 and 15 of each cycle.
3082221|NCT01478620|Experimental|Canephron® N|
3082222|NCT01478828|Experimental|Lovastatin|After informed consent and central pathology review of the core prostate biopsy, eligible patients who decide to undergo prostatectomy at Johns Hopkins will be scheduled to receive po lovastatin following a four times a day schedule, at the starting dose of 20 mg/kg/day. Following an initial period of monitoring for safety at this entry dose level of one month, we will then accrue patients to dose de-escalation (to 1, and 10 mg/kg/day) cohorts.
3082223|NCT01478854|Experimental|Neural Progenitor Cell Sparing Radiation with Temozolomide|All subjects are treated with neural progenitor cell sparing radiation to 60 Gy in 2 Gy per day, 30 fractions Concurrent and adjuvant temozolomide chemotherapy
3082224|NCT01478958|Active Comparator|high saturated fat diet|
3082225|NCT01478958|Experimental|high monounsaturated fat diet|
3082226|NCT01478958|Experimental|high n-6 polyunsaturated fat diet|
3082227|NCT01478971|Experimental|peginesatide injection|In the first 6 months participants received standard of care treatment with epoetin (the Standard of Care Period [SCP]), followed by a 1-week erythropoiesis-stimulating agent (ESA)-Free Period, followed by peginesatide injection for 6 months (the Peginesatide Treatment Period [PTP]).
3082228|NCT01479127|Experimental|Levodopa-carbidopa intestinal gel|"Following a 28-day Run-in Period where participants are switched from prior anti-PD medications to monotherapy with an oral 100 mg levodopa/10 mg carbidopa tablet (optimized every 3rd hour during waking hours), participants receive ABT-SLV187 (levodopa-carbidopa intestinal gel), administered over 16 hours a day with an infusion pump directly into the proximal jejunum by an NJ tube, for 3 weeks.~The individually-adjusted infusion dose (composed of the morning dose, the continuous maintenance dose, and the extra dose) is optimized by the Investigator for each participant during the study based on the participant's symptoms."
3082229|NCT01479270|Active Comparator|TAP Block|20mL of 0.25% Ropivacaine with Epinephrine 1:200,000 is injected into bilateral transversus abdominal planes under ultrasound guidance.
3082230|NCT01479270|No Intervention|No Block|Patients randomized to this arm have band aids applied to sites on lateral abdomen without injection.
3082231|NCT01479348|Experimental|1/Intravenous (IV) Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
3082232|NCT01479348|Experimental|2/Oral Tetrahydrouridine (THU)|[F-18]-5-fluoro-2'-deoxycytidine plus Tetrahydrouridine
3082233|NCT01479374|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop to each eye, 3 nonconsecutive days
3082234|NCT01479374|Placebo Comparator|Vehicle|AL-4943A vehicle, 1 drop to each eye, 3 nonconsecutive days
3082235|NCT01479374|Active Comparator|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop to each eye, 3 nonconsecutive days
3082236|NCT01479426|Experimental|EFLA400(960mg)|
3082237|NCT01479426|Placebo Comparator|Placebo(960mg)|
3082238|NCT01479439|Experimental|Sickle cell disease|The purpose of this research study is to see if losartan can help reduce or reverse damage done to the kidneys of children and adults with Sickle Cell Anemia (SCA) and Sickle Beta-zero (HbSβ0) Thalassemia.
3082239|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part A)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
3082240|NCT01479465|Experimental|FOLFIRI + SIM 200 mg (Part B)|Participants will receive SIM 200 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
3082241|NCT01479465|Experimental|FOLFIRI + SIM 700 mg (Part B)|Participants will receive SIM 700 mg via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
3082242|NCT01479465|Experimental|FOLFIRI + Placebo (Part B)|Participants will receive placebo to match SIM via intravenous infusion followed by FOLFIRI via intravenous infusion on Days 1 and 15 of each 28-day treatment cycle until disease progression or unacceptable toxicity.
3082243|NCT01479478|Active Comparator|Probiotic dietary supplement|Probiotic dietary supplement one capsule once per day until delivery.
3082244|NCT01479478|Placebo Comparator|Placebo|Placebo capsule, one daily until delivery.
3082245|NCT01479517|Experimental|Kovacaine Mist 0.1 mL x 4 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
3082246|NCT01479517|Experimental|Kovacaine Mist 0.2 mL x 2 sprays|Total dose: 12 mg tetracaine/0.2 mg oxymetazoline
3082247|NCT01479517|Experimental|Kovacaine Mist, 0.2 mL x 1 spray|Total dose: 6 mg tetracaine/0.1 mg oxymetazoline
3082248|NCT01479530|Placebo Comparator|Placebo|
3082249|NCT01479530|Experimental|Azilect®|
3082250|NCT01479543|Experimental|Group A|Volunteers received Probiotic CNCM I-4034.
3082251|NCT01479543|Experimental|Group B|Volunteers receive Probiotic CNCM I-4035.
3082252|NCT01479543|Experimental|Group C|Volunteers are given Probiotic CNCM I-4036.
3082253|NCT01479543|Experimental|Group D|Volunteers receive Probiotics CNCM I-4035 and CNCM I-4036.
3082254|NCT01479543|Placebo Comparator|Group E|Volunteers receive a Placebo.
3082255|NCT01479595|Experimental|QBX258|Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total.
3082256|NCT01479595|Placebo Comparator|Placebo|Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.
3082257|NCT01479621|Experimental|Fp MDPI 12.5 mcg|"Fluticasone propionate (Fp) 12.5 mcg per dose twice a day (for a total daily dose of 25 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3082258|NCT01479621|Experimental|Fp MDPI 25 mcg|"Fluticasone propionate (Fp) 25 mcg per dose twice a day (for a total daily dose of 50 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3082259|NCT01479621|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3082260|NCT01479621|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3082261|NCT01479621|Experimental|Placebo MDPI|Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
3082262|NCT01479621|Experimental|Flovent Diskus 100mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3082263|NCT01479725|Experimental|Ulcerative IC|HBOT for ulcerative IC
3082264|NCT01479725|Experimental|Non-Ulcerative IC|HBOT for non-ulcerative IC
3082265|NCT01479764|Experimental|Sugammadex|Participants receive sugammadex, 2 or 4 mg/kg, depending on level of neuromuscular recovery
3082266|NCT01479764|Active Comparator|Neostigmine/glycopyrrolate|Participants receive neostigmine/glycopyrrolate per usual practice
3082267|NCT01479777|Experimental|FES Stepping|For the next 8 weeks, we will ask you to come to the ICSCI twice (2) time per week during which you will perform FES Stepping.
3082268|NCT01479868|Experimental|TMC435 + pegylated interferon alpha-2a + ribavirin|Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.
3082269|NCT01479985|Experimental|CDM Tool|participants will be randomized to completing the CDM tool
3082270|NCT01479985|No Intervention|Control|Participants will fill out a computer survey similar to CDM tool without the decisive factors and computer print out
3082271|NCT01480076|Experimental|(BIIB041) Fampridine|All participants take 10 mg fampridine twice daily for the first 4 weeks. If deemed a treatment responder, a participant continues 10 mg fampridine twice daily for 44 weeks. Treatment non-responders can continue without treatment by completing quality of life questionnaires.
3082272|NCT01480089|Placebo Comparator|Atomized Intraperitoneal Saline (AIS)|Participants randomized to this arm will be given atomized intraperitoneal saline(AIS).
3082273|NCT01480089|Active Comparator|Intraperitoneal Ropivacaine(AIR)|Participants randomized to this arm will receive atomized intraperitoneal ropivacaine (AIR).
3321099|NCT02016196|Placebo Comparator|placebo|6 caps placebo morning and night, 15 days before and 6 months after TIPS
3082276|NCT01480219||Any Voriconazole|
3082277|NCT01480219||No Voriconazole|
3082278|NCT01480232|Experimental|EVP-6124 + NicoDerm (Active)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
3082279|NCT01480232|Active Comparator|Placebo + NicoDerm (Active)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NicoDerm patch (Active) daily for first 6 weeks (42 days)
3082280|NCT01480232|Experimental|EVP-6124 + NRT Patch (Placebo)|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
3082281|NCT01480232|Placebo Comparator|Placebo + NRT Patch (Placebo)|One placebo capsule ingested orally daily for 12 weeks (84 days) and one NRT patch (Placebo) daily for first 6 weeks (42 days)
3082282|NCT01480258|Experimental|PR5I|"Infant series: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: PR5I 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
3082283|NCT01480258|Active Comparator|INFANRIX™ hexa|"Infant series: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 2 and 4 months of age, and rotavirus vaccine (either Rotarix™ 1.5 mL oral dose at 2 and 4 months of age [subset 1] or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age [subset 2]).~Toddler dose: INFANRIX™ hexa 0.5 mL injection + Prevenar 13™ 0.5 mL injection administered at 11 to 12 months of age."
3082284|NCT01480284|Experimental|GSK548470 300 mg|GSK548470 300 mg tablet and ETV placebo capsule are administered once daily
3082285|NCT01480284|Active Comparator|ETV 0.5 mg|ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily
3082286|NCT01480297|Experimental|Salsalate|All subjects will take Salsalate, 3 grams daily (as 3 divided doses of 1 gram with breakfast, lunch and dinner).
3082287|NCT01480596|Experimental|Belimumab|10mg/kg
3082288|NCT01480596|Placebo Comparator|Placebo|placebo IV infusion
3082289|NCT01480674||Trastuzumab|Eligible participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic or locally advanced breast cancer, who were treated with trastuzumab as a first-line therapy and were progression-free for at least 3 years after treatment initiation, were included and were followed for one year.
3082290|NCT01480843|Experimental|Glargine|We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
3082291|NCT01481116|Experimental|TAK-875 25 mg QD|
3082292|NCT01481116|Experimental|TAK-875 50 mg QD|
3082293|NCT01481116|Active Comparator|Glimepiride 1-2 mg QD|
3082294|NCT01481129|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3082295|NCT01481324||Functioning Pressure Sensor Group|This group will have a functioning pressure sensor placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
3082296|NCT01481324||Non-Functioning Pressure Sensor Group|This group will have a non-functioning pressure sensor (a placebo) placed on the foot ankle orthosis. The group will be blinded as to whether or not the sensor is functioning.
3082297|NCT01481324||No Sensor Group|This group will not have a pressure sensor placed on the foot ankle orthosis.
3082298|NCT01481545|Experimental|preoperative chemoradiotherapy|Preoperative radiation therapy and combination chemotherapy plus bevacizumab
3082299|NCT01481558|Sham Comparator|Sham tDCS|sham-tDCS application every 2 days for 2 weeks (total of 6 applications)
3082300|NCT01481558|Experimental|Transcranial direct current stimulation|tDCS application every 2 days for 2 weeks (total of 6 applications)
3082301|NCT01481740|Experimental|Phenylephrine bolus|
3082302|NCT01481740|Experimental|Phenylephrine infusion|
3082303|NCT01481779|Experimental|LY2605541 + Insulin Lispro|LY2605541 titrated based on blood glucose readings, administered by subcutaneous (SC) injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
3082304|NCT01481779|Active Comparator|Glargine + Insulin Lispro|Glargine dose titrated based on blood glucose readings, administered by SC injection via pen device once daily at bedtime for 78 weeks in combination with Insulin Lispro. Insulin Lispro dose titrated based on blood glucose readings, administered by SC injection via pen device at meal times for 78 weeks.
3082305|NCT01481896||Metal-on-Metal Total Hip Arthroplasties|Consecutive series of patients who had metal-on-metal primary total hip arthroplasty performed with DePuy Pinnacle cups, Ultamet metal liners and 36-mm cobalt-chromium alloy femoral heads.
3082306|NCT01481935|Experimental|Enhanced Cleaning|Rooms in the Enhanced Cleaning arm will receive cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
3082307|NCT01481935|Sham Comparator|Sham Enhanced Cleaning|Rooms in the Sham Enhanced Cleaning arm will receive a sham cleaning of frequently contaminated surfaces by a study researcher in addition to standard room cleaning by hospital housekeeping staff.
3082308|NCT01482065|Experimental|CPAP|"Patients with moderate to severe apnea will be randomized to CPAP or deferred CPAP. Those in the CPAP group will be sent home with an autoset CPAP device, which they will be instructed to utilize for 4 months. The CPAP device will be set in the auto mode so that it will automatically adjust the pressure at night to eliminate upper airway obstruction during sleep.~Criteria for OSA severity are specifically designed to target patients with nocturnal hypoxemia, which is hypothesized to contribute to NAFLD progression. According to the guidelines of the American Academy of Sleep Medicine, apnea will be defined as cessation of airflow for ≥ 10 sec. and hypopnea will be defined as decreased airflow for ≥ 10 sec. leading to oxyhemoglobin desaturation ≥ 4%. Mild, moderate and severe OSA will be diagnosed by an Apnea-Hypopnea Index (AHI) of 5-14.9, 15-29.9, and ≥ 30 events/hr, respectively."
3082309|NCT01482091|Placebo Comparator|Intranasal Saline|
3082310|NCT01482091|Experimental|Intranasal Fentnayl|
3082311|NCT01482169|Active Comparator|Adenoscan|Subjects will have the FFR Measurement with IV Adenoscan®
3082312|NCT01482169|Experimental|Regadenoson|Subjects will have the FFR Measurement with IV Regadenoson
3468890|NCT03891589|Experimental|Optimized CF with Taburia|The intervention groups consisted of promotion of optimized complementary feeding with home fortification (taburia) one sachet per week
3468891|NCT03891589|Experimental|Optimized CF only|The intervention groups consisted of promotion of optimized complementary feeding without home fortification (taburia)
3082315|NCT01482221|Experimental|1|
3082316|NCT01482221|Experimental|2|
3082317|NCT01482221|Placebo Comparator|3|
3082318|NCT01482312|Active Comparator|Lotrafilcon A / Comfilcon A / Glasses|Lotrafilcon A contact lenses worn first, followed by comfilcon A contact lenses, followed by habitual glasses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3082319|NCT01482312|Active Comparator|comfilcon A / glasses / lotrafilcon A|Comfilcon A contact lenses worn first, followed by glasses, followed by lotrafilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3082320|NCT01482312|Active Comparator|glasses / lotrafilcon A / comfilcon A|Glasses worn first, followed by lotrafilcon A contact lenses, followed by comfilcon A contact lenses. Each product worn for 90 minutes in a controlled, low-humidity environment (LHE) chamber. Each period separated by a washout of approximately 7 days.
3321100|NCT02016209|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
3321101|NCT02016222|Experimental|Tears sampling|
3082321|NCT01482351|Experimental|MCI/OSA/CPAP Adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was equal to or greater than 4 hours per night over one year. CPAP adherence Intervention was provided by research staff.
3082322|NCT01482351|Experimental|MCI/OSA/CPAP Non-adherent|Device: Continuous Positive Airway Pressure (CPAP). This arm included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use in this arm was less than 4 hours per night or CPAP use was withdrew for any reason over one year. Attention control intervention was provided by staff.
3082323|NCT01482429|Experimental|Protocol-directed|Discontinuation of ventilation was based in multidisciplinary protocol.
3082324|NCT01482429|No Intervention|Usual care|Discontinuation of ventilation was left entirely to the discretion of the physicians.
3082325|NCT01482715|Experimental|Part 1 (Phase 1)|Rucaparib 40, 80, 160, 300, 500 mg QD and 240, 360, 480, 600, 840 mg BID, for continuous 21-day cycles. Patients in Part 1 were initially treated in a Dose-escalation Evaluation Period (Cycle 1) and could then continue to receive treatment in an optional Treatment-extension Period (Cycle 2 and beyond).
3082326|NCT01482715|Experimental|Part 2A (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
3082327|NCT01482715|Experimental|Part 2B (Phase 2)|Rucaparib 600 mg BID for 21-day cycles.
3082328|NCT01482715|Experimental|Part 3 (Phase 2)|Rucaparib 600 mg BID for 21-day cycles. Patients also received a single administration of 600 mg rucaparib on both Day -7 and Day 1 for assessing the effect of food on PK.
3082329|NCT01482767|Experimental|HCV Treatment-Naive (Group A)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV). Among non-cirrhotics, the Week 8 HCV RNA was used to determine total duration of therapy. Those who had undetectable HCV RNA at Week 8 completed therapy at Week 28. Those with detectable HCV RNA at Week 8 received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
3082330|NCT01482767|Experimental|HCV Treatment-Experienced (Group B)|Participants were prescribed a lead-in with PEG-IFN and RBV for 4 weeks. After the lead-in, BOC was added. Cirrhotic participants received 44 weeks of triple therapy (BOC+PEG-IFN+RBV), and non-cirrhotics received 32 weeks of triple therapy followed by 12 additional weeks of PEG-IFN+RBV.
3082331|NCT01482819|Other|Sequence 1|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Spectacles~Galyfilcon A Plus~Polymacon~Galyfilcon A"
3082332|NCT01482819|Other|Sequence 2|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Galyfilcon A~Lotrafilcon A~Polymacon~Spectacles"
3082333|NCT01482819|Other|Sequence 3|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Polymacon~Galyfilcon A Plus~Spectacles~Lotrafilcon A"
3082334|NCT01482819|Other|Sequence 4|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Lotrafilcon A~Polymacon~Galyfilcon A Plus~Galyfilcon A"
3082335|NCT01482819|Other|Sequence 5|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Galyfilcon A~Spectacles~Galyfilcon A Plus~Lotrafilcon A"
3082336|NCT01482819|Other|Sequence 6|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A~Galyfilcon A Plus~Polymacon~Lotrafilcon A~Spectacles"
3082337|NCT01482819|Other|Sequence 7|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Polymacon~Spectacles~Galyfilcon A~Lotrafilcon A~Galyfilcon A Plus"
3082338|NCT01482819|Other|Sequence 8|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Galyfilcon A Plus~Lotrafilcon A~Galyfilcon A~Spectacles~Polymacon"
3082339|NCT01482819|Other|Sequence 9|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Lotrafilcon A~Galyfilcon A Plus~Spectacles~Galyfilcon A~Polymacon"
3082340|NCT01482819|Other|Sequence 10|"Five separate sessions of bilateral lens wear of 8 to 12 hours; each session separated by a minimum of 24 hours. This sequence is as follows:~Spectacles~Polymacon~Lotrafilcon A~Galyfilcon A~Galyfilcon A Plus"
3082341|NCT01482884|Experimental|1|tralokinumab (CAT-354) sc injection
3082342|NCT01482884|Placebo Comparator|2|placebo sc injection
3082343|NCT01482910|Experimental|Aflibercept injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg intravitreal aflibercept injection (IAI) every 4 weeks for the first 12 weeks, followed by additional 2.0 mg IAI every 8 weeks until week 48. Additionally, sham photodynamic therapy (PDT) treatments was administered as needed.
3082344|NCT01482910|Active Comparator|PDT treatments|Participants received PDT as needed. Additionally, sham IAI injections was administered until week 28. Thereafter, participants received active IAI treatment until week 48.
3082345|NCT01482962|Experimental|Alisertib|Alisertib 50 mg, enteric-coated tablet formulation, orally, twice daily for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle (Up to 148 Weeks).
3082346|NCT01482962|Active Comparator|Pralatrexate, or Romidepsin, or Gemcitabine|Pralatrexate 30 mg/m^2, intravenous (IV) push over 3 to 5 minutes, once weekly, for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles were repeated every 7-weeks provided the participant continued to benefit from and tolerate the therapy (Up to 115 Weeks), or Gemcitabine 1,000 mg/m^2 over 30 minutes, intravenously, on Days 1, 8, and 15 of a 28-day cycle until the absence of disease progression or unacceptable toxicity (Up to 32 Weeks), or Romidepsin 14 mg/m^2, intravenously over a 4-hour period, on Days 1, 8, and 15 of a 28-cycle. Cycles were repeated every 28 days provided the patient continued to benefit from and tolerate the therapy (Up to 30 Weeks).
3082347|NCT01483118|Active Comparator|Cinnamon Extract Arm|PCOS patients receiving abstract of cinnamon
3082348|NCT01483118|Placebo Comparator|Placebo Arm|PCOS patients receiving placebo capsules
3082349|NCT01483144|Experimental|Eflornithine plus Sulindac|Eflornithine 750 mg and Sulindac 150 mg
3082350|NCT01483144|Active Comparator|Eflornithine plus Sulindac Placebo|Eflornithine 750 mg and Placebo
3082351|NCT01483144|Active Comparator|Sulindac plus Eflornithine Placebo|Sulindac 150 mg and Placebo
3082352|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 1: OPC-108459|To safely meet each of the following Cmax targets: 1.0-10.0 µg/mL. There will be 9 cohorts in all: 1.0, 1.6, 2.4, 3.6, 5.4, 7.0, 8.0, 9.0, and 10.0.
3082353|NCT01483183|Placebo Comparator|Persistent or Paroxysmal AF Part 1: Placebo|
3082354|NCT01483183|Experimental|Persistent or Paroxysmal AF Part 2: OPC-108459|Single dose to safely meet target concentration from Part 1, if subject fails to convert to sinus rhythm within 10 minutes, second dose will be administered to achieve 25% increase when compared to first infusion
3082355|NCT01483183|Placebo Comparator|Placebo Part 2|
3082356|NCT01483352|Experimental|Single Arm|Participants were implanted with Accu-Chek DiaPort with Infusion Set connected to an Accu-Chek Insulin Pump to perform continuous intraperitoneal insulin delivery.
3082357|NCT01483378|Other|Subjects who received the vaccine|Patients in this arm were eligible for the herpes zoster vaccine and chose to receive it.
3082358|NCT01483378|No Intervention|Subjects who declined the vaccine|
3082359|NCT01483560|Experimental|Metformin|Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
3082360|NCT01483560|Placebo Comparator|Placebo|
3082361|NCT01483599|Experimental|CNTO 1959 (5 mg)|CNTO 1959 5 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3082362|NCT01483599|Experimental|CNTO 1959 (15 mg)|CNTO 1959 15 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
3082363|NCT01483599|Experimental|CNTO 1959 (50 mg)|CNTO 1959 50 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3082364|NCT01483599|Experimental|CNTO 1959 (100 mg)|CNTO 1959 100 mg at weeks 0, 8, and 16, then every 8 weeks through Week 40
3082365|NCT01483599|Experimental|CNTO 1959 (200 mg)|CNTO 1959 200 mg at weeks 0, 4, and 16, then every 12 weeks through Week 40
3082366|NCT01483599|Active Comparator|Adalimumab (approved psoriasis dosing)|Adalimumab 80 mg at week 0 followed by 40 mg at week 1 and every second week through Week 39 (i.e., Weeks 3, 5, 7, etc.)
3082367|NCT01483599|Placebo Comparator|Placebo to CNTO 1959 (100 mg)|Placebo at weeks 0, 4, and 8; then crossover to CNTO 1959 100 mg at Week 16, then every 8 weeks through Week 40
3082368|NCT01483625|Experimental|tiotropium 18mcg|active
3082369|NCT01483625|Placebo Comparator|Placebo|placebo
3082370|NCT01483651|Experimental|Low, Medium and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
3082371|NCT01483651|Experimental|Low, High and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at lowest level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
3082372|NCT01483651|Experimental|Medium, Low and High insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at highest level with glucagon administration."
3082373|NCT01483651|Experimental|Medium, High and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at medium level with glucagon administration.~Second study is regular insulin infused at highest level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
3082374|NCT01483651|Experimental|High, Low and Medium insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at lowest level with glucagon adminstration.~Third study is regular insulin infused at medium level with glucagon administration."
3082375|NCT01483651|Experimental|High, Medium and Low insulin infusion|"All study subjects in this arm were randomized as follows:~First study is regular insulin infused at highest level with glucagon administration.~Second study is regular insulin infused at medium level with glucagon adminstration.~Third study is regular insulin infused at lowest level with glucagon administration."
3082376|NCT01483690|Experimental|Initial Dose Level|"Decitabine 15 mg/m2/day given IV over 1 hour on days 1 through 7 and days 15 through 21.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 3 through 10 and days 17 through 24"
3082377|NCT01483690|Experimental|Modified Dose Level|"Decitabine 10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.~Vorinostat: 180 mg/m2/day (Max dose=400 mg daily) given orally on days 2 through 7 and days 16 through 21"
3082378|NCT01483807|Experimental|SPT-B then SPT-R|Participants first received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
3082379|NCT01483807|Experimental|SPT-R then SPT-B|Participants first received Sound Production Treatment - Random (SPT-R) for 20 treatment sessions spanning approximately 7 weeks. After a washout period of 2 weeks, they then received Sound Production Treatment - Blocked (SPT-B) for 20 treatment sessions. Follow-up measures were conducted at 2, 6, and 10 weeks following the end of all treatment.
3082380|NCT01483820|Experimental|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
3082381|NCT01483924|Experimental|10 mg Apo805K1, or placebo|
3082382|NCT01483924|Experimental|30 mg Apo805K1, or placebo|
3082383|NCT01483924|Experimental|60 mg Apo805K1, or placebo|
3082384|NCT01483924|Experimental|100 mg Apo805K1, or placebo|
3321102|NCT02016248|Experimental|Low Risk Cohort|"The low risk cohort will receive:~Stereotactic Ablative Body Radiotherapy as Monotherapy on the CyberKnife System"
3468892|NCT03891589|Experimental|Taburia|The intervention groups consisted of provision taburia home fortification three sachet per week
3082385|NCT01483937|Active Comparator|Usual care physical therapy only|Subjects will receive usual care physical therapy intervention provided by vestibular and balance specialists. Usual care physical therapy, in general, includes but is not limited to static and dynamic balance activities with or without head movements on firm floor or compliant surfaces.
3082386|NCT01483937|Experimental|Usual care physical therapy plus SEMD|"Subjects will receive usual care physical therapy intervention provided by vestibular balance specialists while using the Sensory Enrichment Multimodal Device (SEMD). SEMD protocols use visual, vibrotactile, and auditory cueing referenced to subject's Center of Gravity (COG) and/or Sum of Pressure (SOP) data collected from a force platform upon which the subject is placed. Static and dynamic balance activities with or without head movement are preformed while watching a computer screen; paced with an auditory metronome; and cued by touch vibration via coin tactors imbedded in a belt worn around the waist matching the COG/SOP data display."
3082387|NCT01483963|Experimental|AA4500 0.29 mg/1 mL|Up to three injections
3082388|NCT01483963|Experimental|AA4500 0.58 mg/2 mL|Up to three injections
3082389|NCT01483963|Experimental|AA4500 0.58 mg/1 mL|Up to three injections
3082390|NCT01483963|Experimental|AA4500 0.58 mg/0.5 mL|Up to three injections
3082391|NCT01483963|Other|Shoulder exercises|Home shoulder exercises for 64 days
3082392|NCT01484028|Other|EALE/1DM|etafilcon A with PVP for light eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3082393|NCT01484028|Other|1DM/EALE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for light eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3082394|NCT01484028|Other|EADE/1DM|etafilcon A with PVP for dark eyes worn during the first period of 7-9 days then etafilcon A control lens worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3082395|NCT01484028|Other|1DM/EADE|etafilcon A control lens worn during the first period of 7-9 days then etafilcon A with PVP for dark eyes worn during the second period of 7-9 days, with a 1-3 days of wash-out time between the 2 periods.
3082396|NCT01484041|Experimental|Dovitinib plus aromatase inhibitors|Dovitinib with aromatase inhibitor
3082397|NCT01484054|Other|EAPVPDE/EADE|etafilcon A with embedded print and PVP lens for dark eyes worn daily during the first period of 7-9 days, then etafilcon A control lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
3082398|NCT01484054|Other|EADE/EAPVPDE|etafilcon A control lens worn daily during the first period of 7-9 days, then etafilcon A with embedded print and PVP for dark eyes lens worn daily during the second period of 7-9 days, with 1-3 days of wash-out time between the 2 periods.
3082399|NCT01484132|Experimental|Composite|
3082400|NCT01484197|Experimental|75 µg Indacaterol (LB) + Placebo (PoS)|75 µg indacaterol maleate lactose blend (LB) + placebo to indacterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
3082401|NCT01484197|Experimental|75 µg Indacaterol (PoS) + Placebo (LB)|75 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3082402|NCT01484197|Experimental|37.5 µg Indacaterol (PoS) + Placebo (LB)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3082403|NCT01484197|Experimental|Placebo (LB) and Placebo (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) + placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
3082404|NCT01484275|Experimental|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
3082405|NCT01484275|Placebo Comparator|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
3082406|NCT01484288|Experimental|Device group|Barostim Neo system
3082407|NCT01484340|Experimental|Counseling only|Participants in this arm will receive advice to quit smoking and self-help materials from the study interventionist in a standardized fashion (intensive anti-smoking counseling).
3082408|NCT01484340|Experimental|Nicotine Replacement Therapy +counseling|Participants in this arm will receive the nicotine patch in addition to the intensive anti-smoking counseling. Participants will receive instruction on proper use of the nicotine patch (i.e., placement, use of one patch a day, importance of not smoking while using the patch, and tapering of patches).
3082409|NCT01484431|Experimental|Tadalafil|"Light Weight <25 kg Period 1: 2 milligram (mg) or 4 mg tadalafil administered once daily (QD) in oral suspension formulation for 5 weeks then 8 mg,10 mg,15 mg or 20 mg tadalafil was administered QD in oral suspension formulation for 5 weeks.~Middle Weight: 25 kg to <40 kg Period 1: 5 mg tadalafil tablet administered QD for 5 weeks then 10 mg, 15 mg or 20 mg tablet tadalafil administered QD for 5 weeks.~Heavy: ≥40 kg Period 1: 10 mg tadalafil tablet administered QD for 5 weeks then 20 mg or 40 mg tablet tadalafil administered QD for 5 weeks."
3082410|NCT01484496|Placebo Comparator|Placebo plus standard therapy|Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
3082411|NCT01484496|Experimental|Belimumab 200 mg SC plus standard therapy|Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
3082412|NCT01484561|Active Comparator|Sequence 1|
3082413|NCT01484561|Placebo Comparator|Sequence 2|
3082414|NCT01484626|Experimental|Bendamustine|Bendamustine is combined with standard chemotherapy.
3082415|NCT01484652|Experimental|COV795|
3082416|NCT01484652|Placebo Comparator|Placebo|
3468893|NCT03891589|No Intervention|Control|No intervention but gave a standard education from primary health center
3082417|NCT01484834|Experimental|Exercise and Education|Company A received intervention of exercise in the workplace, posters with tips on health and quality of life computer software. The interventions with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
3082418|NCT01484834|Active Comparator|Exercise|The intervention with physical exercise in the workplace, were performed in the morning shift and had duration of three months with 15 minutes each and were applied three times per week every other day. In order to keep the workers motivated and participating in the exercise in the workplace, the sessions were very varied, using broomstick, latex tubes, exercises in pairs, massage, sitting exercises and relaxation on mats.
3082419|NCT01484834|Active Comparator|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
3082420|NCT01484834|Placebo Comparator|Control Company|No intervention
3082421|NCT01484873|Experimental|Exenatide|All patients received exenatide 10mcg BID x 50 weeks
3082422|NCT01484912|Experimental|STA-2|"STA-2 250 mg capsule, each containing 100 mg green tea polyphenols.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
3082423|NCT01484912|Placebo Comparator|Placebo|"Placebo capsule, containing non-active ingredients.~Two capsules t.i.d. (three times daily) for 6 weeks, to be administered in a non-fasting state."
3082424|NCT01484938|Experimental|OPTI-FREE|OPTI-FREE PureMoist multi-purpose contact lens solution used for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses, per protocol-specified regimen
3082425|NCT01484951|Experimental|AZARGA|Brinzolamide 1% and timolol 0.5% fixed combination eye drops, one drop administered to the study eye(s) twice daily (8:00 am and 8:00 pm) for up to 8 weeks.
3082426|NCT01484977|Experimental|Lacosamide|Lacosamide will be added to levetiracetam while withdrawing the sodium channel blocking antiepileptic drug (AED)
3082427|NCT01485055|Experimental|Infliximab and Basiliximab|"Other Names:~Simulect Remicade Monoclonal antibody~Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
3082428|NCT01485094|Placebo Comparator|Matching placebo|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3082429|NCT01485094|Experimental|GRT6010|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3082430|NCT01485094|Active Comparator|Pregabalin|Oral administration. Pain not sufficiently controlled may be treated with acetaminophen.
3082431|NCT01485120|Other|Blood Pressure monitoring|Blood Pressure (BP) monitoring using invasive arterial insertion as a standard reference, and an investigational, non-invasive blood pressure (NIBP) monitoring cuff. Data obtained from the cuff used the SuperSTAT NIBP algorithm and the Classic NIBP algorithm for output.
3082432|NCT01485172|Experimental|ropinirole|ropinirole 2, 4, 8, 12, or 24 mg/day
3082433|NCT01485172|Placebo Comparator|placebo|placebo comparator 2, 4, 8, 12, or 24 mg/day
3082434|NCT01485354|Experimental|Armeo Spring training|Subjects will participate in upper extremity rehabilitation using the Armeo Spring system for a period of 6 weeks. The intervention will consist of 18 training sessions (60 minute sessions, 3 times a week).
3082435|NCT01485380|Experimental|Active study arm|Subjects recruited into this study will be required to undergo two magnetic resonance imaging- positron emission tomography (MRI-PET) scans of the brain in addition to high density electroencephalogram (EEG) acquisition. The first scan will be a baseline scan while the second scan will be performed while dexmedetomidine is being infused.
3082436|NCT01485393|Experimental|Healthy Control Subjects: Zolpidem, Then Dexmedetomidine|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Zolpidem induced-sleep and then a night of Dexmedetomidine induced-sleep.
3082437|NCT01485393|Experimental|Healthy Control Subjects: Dexmedetomidine, Then Zolpidem|This arm will enroll healthy control subjects, who will receive a regular nights sleep followed by a night of Dexmedetomidine induced-sleep and then a night of Zolpidem induced-sleep.
3082438|NCT01485536|Experimental|AUY922|AUY922 starting dose 70 mg/m2 intravenous on Days 1, 8, 15, and 22 of 28 day cycle.
3082439|NCT01485588|Experimental|hI-con1™ 60µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
3082440|NCT01485588|Experimental|hI-con1™ 150µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
3082441|NCT01485588|Experimental|hI-con1™ 300µl|Phase 1- This is a dose escalation study (60µl, 150µl, or 300 µl) given at baseline and then the subject is followed up to week 24.
3082442|NCT01485614|Experimental|Sitagliptin|Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
3082443|NCT01485614|Placebo Comparator|Placebo/Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
3082444|NCT01485614|Active Comparator|Metformin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will continue to receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
3082445|NCT01485614|Placebo Comparator|Placebo/Sitagliptin|Participants will receive 1 tablet of placebo matching sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 0-20. Participants will receive 1 tablet of sitagliptin 100 mg prior to the morning meal and 2 tablets of placebo matching metformin 500 mg prior to both the morning and evening meals during Weeks 20-54.
3082446|NCT01485627|Experimental|Intervention|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
3082447|NCT01485627|No Intervention|Control|Patients will receive usual care
3082448|NCT01485640|Experimental|Lurasidone|Lurasidone flexibly dosed
3082449|NCT01485770|Experimental|Placebo, Then ADX-N05|Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
3082450|NCT01485770|Placebo Comparator|ADX-N05, Then Placebo|Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).
3082451|NCT01485796|Experimental|Epoch 1 and Epoch 2|In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.
3082452|NCT01485887|Experimental|Venlafaxine ER|
3082453|NCT01485991|Experimental|TMC435/PR|
3082454|NCT01485991|Active Comparator|TVR/PR|
3082455|NCT01486043|Experimental|Metformin and insulin therapy|Up to 30-40 patients will be in the prospectively recruited treatment group, which will receive both metformin and insulin therapy for transient hyperglycemia
3082456|NCT01486199|Experimental|CF pediatric|In the pediatric arm 10 CF subjects ages 6-14 will perform absorptive clearance scans at baseline and at t=2 years.
3082457|NCT01486199|Experimental|Controls adult|In the adult control arm 10 healthy adult subjects will perform a single absorptive clearance scan.
3082458|NCT01486238|Experimental|IVMac q6 Arm|Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6week intervals beginning on Day 0 and ending at Week 18. Macugen® injection will be administered as described in the package insert.
3082459|NCT01486238|Experimental|IVMac q4 Arm|Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Macugen® injection will be administered as described in the package insert.
3082460|NCT01486264|Active Comparator|Xeomin® Short Flex|short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
3082461|NCT01486264|Active Comparator|Xeomin® Long Flex|long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
3082462|NCT01486316|Other|Control arm|Subjects in the Control arm will be observed between implant and month 12. During this time, the standard device diagnostic suite will be used as it would normally, in the office using the programmer, or by data transmission from the patient's home (or another remote location). At month 12 through study close (month 18), study doctors for the all subjects will have access to the risk status.
3082463|NCT01486316|Experimental|Risk Status Guided|Study doctors will have access to the experimental IDENTIFY-HF Risk Status for subjects in the Guided arm between months 6 and 18. At all times during the study, study doctors will also be able to use the standard device diagnostics in the office using the programmer, or by data transmission from the patient's home (or another remote location).
3082464|NCT01486446|Experimental|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
3082465|NCT01486446|Placebo Comparator|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
3082466|NCT01486615|Placebo Comparator|Melatonin|Premedication with 3 mg melatonin (Meloset) tablet orally 1-2 hour prior to anesthesia
3082467|NCT01486615|Placebo Comparator|melatonin and alprazolam premedication|Premedication with 3 mg melatonin and 0.5 mg alprazolam (Stresnil) tablet orally 1-2 hrs prior to anesthesia
3082468|NCT01486615|Placebo Comparator|alprazolam premedication|Premedication with 0.5 mg alprazolam (Alprax) tablet orally 1-2 hr prior to anesthesia
3082469|NCT01486615|Active Comparator|placebo premedication|Premedication with a similar looking placebo tablet orally 1-2 hr prior to anesthesia
3082470|NCT01486758|Active Comparator|Azithromycin|Oral azithromycin
3082471|NCT01486758|Placebo Comparator|Placebo|Oral Placebo
3082472|NCT01486784|Experimental|Phase 1 DL1|26mg/m2/dose IV once per week x 3 weeks of 4 week cycle
3082473|NCT01486784|Experimental|Phase 1 DL-1|17mg/m2 IV/dose once per week x 3 weeks of 4 week cycle
3082474|NCT01486784|Experimental|Phase 1 DL-1a|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
3082475|NCT01486784|Experimental|Phase 1 DL-1b|17mg/m2/dose IV three times per week x 3 weeks of 4 week cycle
3082476|NCT01486784|Experimental|Phase 1 DL-1c|22mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
3082477|NCT01486784|Experimental|Phase 1 DL-1d|17mg/m2/dose IV twice per week x 3 weeks of 4 week cycle
3082478|NCT01486810|Experimental|Lisdexamfetamine and medication management|Patients will be titrated to the tolerated dose of Lisdexamfetamine over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks. All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
3082479|NCT01486927|Experimental|Recombinant Factor VIII (rFVIII)|
3082480|NCT01486966|Experimental|Insulin detemir / IAsp|
3082481|NCT01486966|Active Comparator|insulin NPH|
3082482|NCT01487161|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
3082483|NCT01487161|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection Extended-Release Formulation
3082484|NCT01487161|Experimental|FX006 60 mg|Single 3mL intra-articular (IA) injection Extended-Release Formulation
3082485|NCT01487161|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-Release Triamcinolone Acetonide
3082486|NCT01487200|Experimental|FX006 10mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
3082487|NCT01487200|Experimental|FX006 40mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
3082488|NCT01487200|Experimental|FX006 60 mg|Single 3 mL intra-articular (IA) injection Extended-release formulation
3082489|NCT01487200|Active Comparator|TCA IR (40 mg)|Single 1 mL intra-articular (IA) injection Immediate-release formulation
3082490|NCT01487265|Experimental|BKM120 and Erlotinib|"Cycle 1: BKM120 80 mg PO daily; Erlotinib 100mg PO daily~Cycles 2 and beyond: BKM120 100 mg PO daily; Erlotinib 100mg PO daily"
3082491|NCT01487525|Placebo Comparator|PBFR-|double leg press without application of partial blood flow restriction to the upper leg
3082492|NCT01487525|Experimental|PBFR+|double leg press with application of partial blood flow restriction to the upper leg
3082493|NCT01487577|Experimental|Mycophenolate mofetil|Pharmacokinetics-based targeting of mycophenolate mofetil
3082494|NCT01487668|No Intervention|Arm 1 - Usual Care|Usual care will include standard mental health and medical care available in the VA clinics but with no active management by the LGCC health specialist.
3082495|NCT01487668|Experimental|Arm 2 - Life Goals Collaborative Care|
3082496|NCT01487863|Experimental|Concurrent Arm|Subjects received sipuleucel-T concurrent with abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone treatment started the next day after the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
3082497|NCT01487863|Experimental|Sequential Arm|Subjects received sipuleucel-T therapy followed by abiraterone acetate plus prednisone. Abiraterone acetate plus prednisone started at week 10 from the start of the first infusion of sipuleucel-T and continued for 26 weeks or until disease progression, unacceptable toxicity, or death, occurred.
3082498|NCT01487954|Experimental|Arm I: alkaline water|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
3082499|NCT01487954|Active Comparator|Arm II: distilled water|Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy
3082500|NCT01488019|Experimental|Perforomist, nebulization, COPD|Active
3082501|NCT01488019|Placebo Comparator|Perforomist-Placebo|Placebo
3082502|NCT01488071|Experimental|Vortioxetine 10 mg or 20 mg|
3082503|NCT01488071|Active Comparator|Agomelatine 25 mg or 50 mg|
3082504|NCT01488097|Experimental|Open-Label Sebelipase Alfa|Participants were administered sebelipase alfa once weekly (qw) as an intravenous (IV) infusion at the same dose received in Study LAL-CL01 (0.35, 1, or 3 milligrams per kilogram [mg/kg]) for 4 weeks. After the initial 4 qw doses, participants transitioned to dosing every other week (qow) at either 1 mg/kg (participants who initiated treatment at 0.35 or 1 mg/kg qw) or 3 mg/kg (participants who initiated dosing at 3 mg/kg qw). Subsequent modifications to the dose and dosing frequency were permitted for individual participants based on observed safety, tolerability, and clinical response to treatment. Participants could continue to receive treatment with sebelipase alfa for up to 5 years.
3082505|NCT01488188|Active Comparator|Influenza vaccine-Nasal|Nasal administration
3082506|NCT01488188|Active Comparator|Influenza vaccine -Sublingual|Sublingual administration
3082507|NCT01488279|Active Comparator|Dexamethasone 2.5mg and Sitagliptin100mg|Participants received Dexamethasone 2.5 mg plus Sitagliptin 100 mg daily for 8 days
3082508|NCT01488279|Placebo Comparator|Dexamethasone 2.5mg and placebo tablet|Participants received Dexamethasone 2.5 mg plus Sitagliptin-matched placebo tablet daily for 8 days.
3082509|NCT01488318|Experimental|CETUXIMAB AND DASATINIB|"Cetuximab on a standard weekly schedule (see Section 6.2). Group 1 (subjects more than 2 weeks post last dose of Cetuximab): Loading dose of 400 mg/m2 on cycle 1, day 1 then 250 mg/m2 IV weekly.~Group 2 (subjects last Cetuximab treatment within 2 weeks): Cycle 1 will start at a dose of 250 mg/m2 Dasatinib 150 mg once daily without interruption. On the FIRST cycle (1 cycle is 3 weeks) dasatinib will start 3 days after the cetuximab loading dose (i.e. cycle 1, day 4) to avoid headache as shown on the previous phase I trial.~Treatment will continue until progression."
3082510|NCT01488370|Active Comparator|Glidescope|A device for endotracheal intubation.
3082511|NCT01488370|Active Comparator|Storz|A device for endotracheal intubation.
3082512|NCT01488370|Active Comparator|Standard Laryngoscope|A device for endotracheal intubation
3082513|NCT01488409|Experimental|Acipimox|Treatment with the study drug Acipimox
3082514|NCT01488409|Placebo Comparator|Placebo|Treatment with Placebo control.
3082515|NCT01488448|Experimental|Nebulized Hypertonic Saline|4mL nebulized 3% sodium chloride every 4 hours until discharge
3082516|NCT01488448|Placebo Comparator|Nebulized Normal Saline|4 mL nebulized 0.9% sodium chloride every 4 hours until discharge
3082517|NCT01488487|Experimental|Everolimus + pasireotide|Oral Everolimus 7.5 mg administered daily for 28 days per cycle, plus pasireotide Long Acting Release (LAR) 60 mg administered by intramuscular injection once per 28 day cycle on day 1.
3082518|NCT01488578||Tolterodine tartrate.|Subjects taking Tolterodine tartrate.
3082519|NCT01488708|Experimental|LY 2127399 Q2W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at week 0, followed by 1 SC injection of 120 mg LY2127399 every 2 weeks (Q2W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at Week 0, followed by 1 SC injection of 120 mg LY2127399 Q2W for 216 weeks.
3082520|NCT01488708|Experimental|LY2127399 Q4W|If participant received LY2127399 in core study: 1 subcutaneous (SC) injection of 120 mg LY2127399 and 1 SC injection of placebo at Week 0, followed by 1 SC injection of 120 mg LY2127399 every 4 weeks (Q4W) for 216 weeks. If participant received placebo in core study: 2 SC injections of 120 mg LY2127399 at week 0, followed by 1 SC injection of 120 mg LY2127399 Q4W for 216 weeks.
3082521|NCT01488877|Experimental|PF03882845|
3082522|NCT01488877|Active Comparator|Spironolactone|25 mg once daily
3082523|NCT01488877|Placebo Comparator|Placebo|Placebo once daily
3082524|NCT01488890|Experimental|CYD Dengue vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine; one each at 0, 6 and 12 months.
3082525|NCT01488890|Experimental|CYD Dengue vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months.
3082526|NCT01488890|Experimental|CYD Dengue and Yellow Fever vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine; one each at 0, 2 and 6 months, and single dose of YF vaccine at Day 0.
3082527|NCT01488890|Active Comparator|Yellow Fever vaccine: Group 4|Participants received single dose of YF vaccine at Day 0.
3082528|NCT01488994|Experimental|BAX326 < 6 years of age|
3082529|NCT01488994|Experimental|BAX326 6 to <12 years of age|
3082530|NCT01489020|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3082531|NCT01489020|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3082532|NCT01489020|Experimental|group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3082533|NCT01489020|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3082534|NCT01489020|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 doses of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3082535|NCT01489020|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3082536|NCT01489111|Experimental|Surgery|
3082537|NCT01489189|Experimental|Anti-VEGF+Deferred PRP|Anti-VEGF= Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
3082538|NCT01489189|Active Comparator|Prompt PRP|PRP= Panretinal Photocoagulation. PRP alone.
3082539|NCT01489254|Experimental|GTR|Drug
3082540|NCT01489254|Active Comparator|Copaxone®|Drug
3082541|NCT01489254|Placebo Comparator|Placebo|Drug
3082542|NCT01489358|Experimental|Group 1|Group 1 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 10 mcg.
3082543|NCT01489358|Experimental|Group 2|Group 2 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 20 mcg.
3082544|NCT01489358|Experimental|Group 3|Group 3 will receive three IM injections of VRC-CHKVLP059-00-VP (at weeks 0,4, and 20) at a dose of 40 mcg.
3082545|NCT01489527|Active Comparator|Gardasil Vaccine Administration|Gardasil Vaccine Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
3082546|NCT01489527|Placebo Comparator|Placebo Administration|Placebo Administration. Family Health International (FHI) statisticians randomly assigned each participant an allocation number and then subsequently assigned a unique vial identification number for the vial of vaccine the participant should receive at each visit. A single participant could not be assigned more than 1 allocation number.
3082547|NCT01489579|Active Comparator|BST counseling group|The patients in the Brief, structured, telephone tobacco cessation, BST, counseling group, will receive tobacco cessation counseling, intervention, by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources.
3082548|NCT01489579|Placebo Comparator|Usual care group|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
3082549|NCT01489670||Lumigan® 0.01%|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
3082550|NCT01489826|Experimental|Dexanabinol 2 mg/kg|Dexanabinol 2 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082551|NCT01489826|Experimental|Dexanabinol 3 mg/kg|Dexanabinol 3 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082552|NCT01489826|Experimental|Dexanabinol 6 mg/kg|Dexanabinol 6 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082553|NCT01489826|Experimental|Dexanabinol 12 mg/kg|Dexanabinol 12 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082554|NCT01489826|Experimental|Dexanabinol 15 mg/kg|Dexanabinol 15 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082555|NCT01489826|Experimental|Dexanabinol 22 mg/kg|Dexanabinol 22 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082556|NCT01489826|Experimental|Dexanabinol 30 mg/kg|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082557|NCT01489826|Experimental|Dexanabinol 36 mg/kg|Dexanabinol 36 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082558|NCT01489826|Experimental|Dexanabinol Expansion Phase|Dexanabinol 30 mg/kg formulated in cremophor/ethanol, administered once weekly intravenously (i.v.)
3082559|NCT01489891|Active Comparator|Lidocaine group|Blinded spraying 50 mg of pharyngeal topical lidocaine 180 seconds before sedated esophagogastroduodenoscopy (EGD)
3082560|NCT01489891|Placebo Comparator|Placebo|Excipients without lidocaine. The flavour taste is the same of active comparator ensuring the masking.
3082561|NCT01489956|Experimental|Immucothel alone (Part A)|100 µg Immucothel subcutaneously (SQ) on Day 0 and Day 9.
3082562|NCT01489956|Experimental|Immucothel+Montanide (Part A)|If an immune response was not observed in at least nine out of the first 10 participants after receiving Immucothel alone, 10 additional healthy subjects would be recruited and immunized with Immucothel (SQ) plus Montanide (SQ) on Day 0 and Day 9.
3082563|NCT01489956|Experimental|Immucothel alone or Immucothel+Montanide (Part B)|"Dependent on the results for Part A.~Briefly: Ten new, healthy participants were to be fed 50 mg of native keyhole limpet hemocyanin (KLH), a protein extracted from a mollusk (a sea animal), on Days 0 through 4 and Days 10 through 14, for a total dose of 500 mg. The participants were then immunized using the strategy that produced an immune response in at least nine out of 10 participants in Part A (Immucothel alone or Immucothel plus Montanide) on Days 26 and 35."
3082564|NCT01489969|Active Comparator|20 mg|Neu-P11 dose of 20 mg
3082565|NCT01489969|Active Comparator|50 mg|Neu-P11 dose of 50 mg
3082566|NCT01489969|Placebo Comparator|placebo|matching placebo
3082567|NCT01490060|Experimental|Single Dose Day 1|Arm 1, Single Dose: Fosaprepitant 150 mg intravenous (IV) Day 1 of Cycle 1 or Day 1 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
3082568|NCT01490060|Experimental|Two Doses Day 1 + Day 4|Arm 2, Two Doses: Fosaprepitant 150 mg IV Day 1 + Day 4 of Cycle 1 or Day 1 + Day 4 of Cycle 2. Participants randomized to Group 1 (Fosaprepitant Cycle 1 + No Fosaprepitant Cycle 2); or Group 2 (No Fosaprepitant Cycle 1 and Fosaprepitant Cycle 2). Dexamethasone intravenously (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5) and 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy. Doxorubicin 25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
3082569|NCT01490073|Active Comparator|Active nitroglycerin ointment|
3082570|NCT01490073|Placebo Comparator|Placebo ointment|
3082571|NCT01490086|Experimental|15mg RP5063 daily|
3082572|NCT01490086|Experimental|30mg RP5063 daily|
3082573|NCT01490086|Experimental|50mg RP5063 daily|
3082574|NCT01490086|Placebo Comparator|Placebo|
3082575|NCT01490086|Active Comparator|aripiprazole|aripiprazole 15 mg daily
3082576|NCT01490125|Experimental|QVA149 + placebo to tiotropium|Participants received QVA149 plus placebo to tiotropium during 1 of 3 treatment periods, once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3082577|NCT01490125|Active Comparator|Tiotropium + placebo to QVA149|Participants received tiotropium 18 μg plus placebo to QVA149 during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3082578|NCT01490125|Placebo Comparator|Placebo|Participants received placebo to QVA149 plus placebo to tiotropium during 1 of 3 treatment periods once a day for 6 weeks. Participants were provided with a salbutamol/albuterol inhaler to use as rescue medication.
3082579|NCT01490151|Experimental|TTR controller|The intervention will consist of using the TTR controller (Medtronic) for post-prandial glucose control following high and low glycemic meals
3082580|NCT01490190|Experimental|NuvaRing|
3082581|NCT01490294|Experimental|Gadobutrol 0.01 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.01 mmol/kg body weight (BW) (0.01mL/kg) for stress magnetic resonance imaging (MRI) via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.01 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3082582|NCT01490294|Experimental|Gadobutrol 0.025 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.025 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.025 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3082583|NCT01490294|Experimental|Gadobutrol 0.05 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.05 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.05 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3082584|NCT01490294|Experimental|Gadobutrol 0.1 mmol/kg BW (Gadavist, BAY86-4875)|Participants received 1 i.v. bolus injections of Gadobutrol 0.1 mmol/kg BW (0.01mL/kg) for stress MRI via a power injector at a rate of 3 mL/s. The second i.v. bolus injection of Gadobutrol 0.1 mmol/kg BW was given after a 10-15 minutes wash-out period of the stressor for the rest MRI.
3082585|NCT01490359|Experimental|HIV/STD risk-reduction|Men Making a Difference HIV/STD Risk Reduction Intervention was designed to reduce sexual risk behaviors that increase risk of HIV and other sexually transmitted diseases.
3082586|NCT01490359|Active Comparator|Health Promotion Control|Health Promotion Intervention was designed to increase physical activity, healthful diet, and other behaviors to reduce risk of noncommunicable diseases, including diabetes, hypertension, and cancers.
3082587|NCT01490450|Placebo Comparator|PBO: Placebo matching BMS-945429|
3082588|NCT01490450|Experimental|BMS-945429 (25mg)|
3082589|NCT01490450|Experimental|BMS-945429 (100mg)|
3082590|NCT01490450|Experimental|BMS-945429 (200mg)|
3082591|NCT01490580|Experimental|Atropine + Propofol|
3082592|NCT01490580|Active Comparator|Atropine + atracurium + sufentanil|
3082593|NCT01490632|Placebo Comparator|Placebo|Part A: Placebo administered orally (PO) once daily (QD) for 12 weeks. Part B: Placebo participants stayed on placebo or re-randomized to baricitinib 8 milligram (mg) or 10 mg PO QD for 12 weeks. Part C: Baricitinib participants re-randomized to 4 mg or placebo PO QD for 16 weeks. Part D: Retreated with Part B efficacious dose.
3082594|NCT01490632|Experimental|Baricitinib 2 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3082595|NCT01490632|Experimental|Baricitinib 4 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3082596|NCT01490632|Experimental|Baricitinib 8 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or re-randomized to increased dose PO QD for 12 weeks. Part C: Participants re-randomized to half dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3082597|NCT01490632|Experimental|Baricitinib 10 mg|Part A: Baricitinib administered PO QD for initial 12 weeks. Part B: Depending on participant's response, participant was maintained on current dose, or discontinued from the study for 12 weeks. Part C: Participants re-randomized to 4mg dose or placebo PO QD for 16 weeks. Part D: Participants retreated with Part B efficacious dose for 52 weeks.
3082598|NCT01490697|Experimental|Mifepristone plus d-Cycloserine (DCS)|DCS 100 mg capsule orally followed by mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
3082599|NCT01490697|Placebo Comparator|Placebo plus Placebo|Placebo-matching DCS 100 mg capsule orally followed by placebo-matching mifepristone1800 mg tablet orally 4 hours later and 90 minutes prior to traumatic memory retrieval via the traumatic event script preparation procedure, all on Day 7.
3082600|NCT01490723|Experimental|Yttrium-90 Ibritumomab + Chemo|Day -22 and -14, Rituximab 250 mg/m2 preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively. Day -22, -21 to -16, Imaging, repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Day -14, (90Y) ibritumomab tiuxetan administration. Day -5, -4 and -3, Fludarabine and Bendamustine following Stem Cell Transplant (SCT) and CT. Fludarabine 30 mg/m2 intravenously followed by Bendamustine 130 mg/m2 intravenously. All patients receive Graft Versus Host Disease (GvHD) prophylaxis, infections disease prophylaxis, growth factors, blood and platelet transfusion and other supportive treatment.
3082601|NCT01490788|Experimental|Treatment A|1 x TNX-102 2.4 mg gelcap under fasting conditions
3082602|NCT01490788|Experimental|Treatment B|1 x cyclobenzaprine 5 mg immediate release (IR) tablet under fasting conditions
3082603|NCT01490788|Active Comparator|Treatment C|1 x TNX-102 2.4 mg gelcap under fed conditions
3082604|NCT01490814|Active Comparator|Cryoballoon ablation|
3082605|NCT01490814|Active Comparator|Radiofrequency ablation|
3082606|NCT01490840|Experimental|E-training|Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
3082607|NCT01490840|Experimental|Waiting|Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
3082608|NCT01490866|Experimental|FOLFOX/bevacizumab and Axitinib|"Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC. (FOLFOX is a combination of 5-Fluorouracil, Leucovorin and Oxaliplatin.)~All patients will receive FOLFOX/bevacizumab for four 28-day cycles (a total of 16 weeks). After 4 cycles, maintenance axitinib will be started."
3082609|NCT01490892|Experimental|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
3082610|NCT01490918|Placebo Comparator|Acarbose placebo, Metformin, Sitagliptin|The Acarbose placebo should be changed into real Acarbose from the 16th week.
3082611|NCT01490918|Experimental|Sitagliptin, Metformin, Acarbose|Metformin, Sitagliptin, Acarbose group
3082612|NCT01490918|Other|Metformin placebo, Sitagliptin, Acarbose|The Metformin placebo should be changed into real Metformin from the 16th week.
3082613|NCT01490931|Experimental|Ketorolac nasal spray 31.5 mg|Recommended dose according to package insert in 18 - 64 year olds for moderate to moderately severe pain.
3082614|NCT01491022|Experimental|Ampyra|Ampyra 10 mg po BID for 4 weeks followed by placebo 4 weeks
3082615|NCT01491022|Sham Comparator|Placebo|placebo 4 weeks followed by Ampyra 10 mg po BID
3082616|NCT01491035|Experimental|Cohort CC1, 6 children|
3082617|NCT01491035|Experimental|Cohort CC2, 6 children|
3082618|NCT01491035|Experimental|Cohort CC3, 6 children|
3082619|NCT01491035|Experimental|Cohort CC4, 6 children|
3082620|NCT01491035|Experimental|Cohort AC1, 6 adolescents|
3082621|NCT01491035|Experimental|Cohort AC2, 6 adolescents|
3082622|NCT01491035|Experimental|Cohort AC3, 6 adolescents|
3082623|NCT01491035|Experimental|Cohort AC4, 6 adolescents|
3082624|NCT01491113|Experimental|Group A: Normal renal function|"Subjects who have normal renal function (CLcr >80 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose"
3082625|NCT01491113|Experimental|Group B: Mild renal impairment|"Patients who have mild renal impairment (50<CLcr <80 mL/min/1.73 m^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose"
3082626|NCT01491113|Experimental|Group C: Moderate renal impairment|"Patients who have moderate renal impairment (30<CLcr < 50 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose"
3082627|NCT01491113|Experimental|Group D: Severe renal impairment|"Patients who have severe renal impairment (CLcr <30 mL/min/1.73 m^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose~Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose"
3082628|NCT01491113|Experimental|Group E: End-stage renal disease|"Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3.~The 4-h Hemodialysis are scheduled as follows:~Dialysis: 44 h to 48 h after the first dose (Day 3)~Dialysis: 92 h to 96 h after the first dose (Day 5)~Dialysis: 140 h after the first dose (Day 7)~Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10.~Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44*, 44.25*, 44.5*, 45*, 46*, 47*, 48*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing.~49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis.~*Inflow blood, outflow blood, and dialysate fluid will be collected."
3082629|NCT01491178||Patients with NVAF|
3082630|NCT01491490|Active Comparator|GWP42003 : GWP42004 (40:1)|
3082631|NCT01491490|Placebo Comparator|Placebo|
3082632|NCT01491607|Experimental|BioThrax (0.5 mL, on days 0, 14, and 28)|
3082633|NCT01491633|Experimental|Dasatinib|Dasatinib 140 mg by mouth each day
3082634|NCT01491672|Experimental|RAD001|Participants, received RAD001 10 mg orally once daily.
3082635|NCT01491737|Experimental|Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy|"Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
3082636|NCT01491737|Active Comparator|Arm B: Trastuzumab + AI +/- Chemotherapy|"Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.~Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion."
3082637|NCT01491802|Experimental|LAMA alone, then LAMA/LABA combination|Participants will first receive an inhaled long-acting muscarinic antagonist (LAMA) once daily for 4 weeks. After a 2 week washout period, they will then receive the fixed-dose combination product [LAMA plus long-acting beta2-agonist (LABA)] once daily for 4 weeks.
3082638|NCT01491802|Experimental|LABA/LAMA combination, then LAMA alone|Participants will first receive a long-acting muscarinic antagonist (LAMA) plus long-acting beta2-agonist (LABA) combination product once daily for 4 weeks. After a 2 week washout period, they will then receive the LAMA single product once daily for 4 weeks.
3082639|NCT01491841|Experimental|Phase 1: Pixantrone, 55mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 55mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
3082640|NCT01491841|Experimental|Phase 1: Pixantrone, 85mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 85mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
3082641|NCT01491841|Experimental|Phase 1: Pixantrone, 115mg/m^2|Bendamustine, 120mg/m2; administered first on Day 1 of each cycle. Rituximab, 375mg/m2; administered second on Day 1 of each cycle. Pixantrone, 115mg/m2; to be administered last, 4-6 hours after bendamustine, on Day 1 of each cycle Pegfilgrastim, 6mg; administered on Day 2 of each cycle
3082642|NCT01491854|Other|Monitoring of long-term safety|Long-term safety follow-up after the end of treatment with Omnitrope (single arm)
3082643|NCT01491893|Experimental|Dose Level 1 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082644|NCT01491893|Experimental|Dose Level 2 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convention-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082645|NCT01491893|Experimental|Dose Level 3 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082646|NCT01491893|Experimental|Dose Level 4 (dose escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082647|NCT01491893|Experimental|Dose Level 5 (dose escalation)|Participants received a single intratumoral infusion of 1.0 x 10^10 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082648|NCT01491893|Experimental|Dose Level 4 (dose de-escalation)|Participants received a single intratumoral infusion of 3.3 x 10^9 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082649|NCT01491893|Experimental|Dose Level 2 (dose expansion)|Participants received a single intratumoral infusion of 3.3 x 10^8 TCID50 of PVSRIPO, via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082650|NCT01491893|Experimental|Dose Level -1 (dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082651|NCT01491893|Experimental|Dose Level -2 (dose expansion)|Participants received a single intratumoral infusion of 1.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082652|NCT01491893|Experimental|Dose Level -1 (selected dose expansion)|Participants received a single intratumoral infusion of 5.0 x 10^7 TCID50 Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO), via convection-enhanced delivery to the brain tumor, with 4 weeks of monitoring for toxicities after infusion.
3082653|NCT01491919|Experimental|Low Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.1 mg/kg/day
3082654|NCT01491919|Experimental|Medium Dose: Lisinopril|Participants will receive study medication for 14±3 days at a dose 0.2 mg/kg/day
3082655|NCT01491919|Experimental|High Dose: Lisinopril|Participants will initially receive study medication at 0.2 mg/kg/day for 5±2 days. If blood tests exclude drug-related toxicity, then the lisinopril dose will be increased to 0.4 mg/kg/day and participants will continue to complete the 14±3 day Treatment Period.
3082656|NCT01491945|Experimental|Ventana Fenestrated Stent Graft System|Ventana Fenestrated Stent Graft System
3082657|NCT01491958|Experimental|Donor|Related donors will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines. Peripheral blood stem cells will not be manipulated or T-depleted prior to administration.
3082658|NCT01491958|Experimental|Patient|Patients will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first. Standard post transplant care will be administered.
3082659|NCT01491984|Experimental|Laryngoscopy order: 1) MAC, 2) Levitan|Levitan FPS Intubation
3082660|NCT01491984|Experimental|Laryngoscopy order: 1) Levitan, 2) MAC|Macintosh Intubation
3082661|NCT01492088|Experimental|Brentuximab vedotin: Phase 1|Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity. Dose was escalated up to 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) depending upon the dose limiting toxicity (DLT).
3082662|NCT01492088|Experimental|Brentuximab vedotin: Phase 2|Brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there is evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.
3082663|NCT01492101|Experimental|NKTR-102|
3082664|NCT01492101|Active Comparator|Physician's Treatment of Choice|
3082665|NCT01492309|Active Comparator|Active Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive active 1 Hz right-sided dorsolateral prefrontal cortex (DLPFC) TMS.
3082666|NCT01492309|Sham Comparator|Sham Transcranial Magnetic Stimulation|38 pregnant women with MDD will be randomized to receive sham transcranial magnetic stimulation.
3082667|NCT01492400|Experimental|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
3082668|NCT01492400|Active Comparator|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
3082669|NCT01492426|Experimental|Daclatasvir + Peginterferon alfa-2a + Ribavirin|
3082670|NCT01492426|Experimental|Telaprevir + Peginterferon alfa-2a + Ribavirin|
3321103|NCT02016248|Experimental|High Risk Cohort|"The high risk cohort will receive:~28 treatments of external beam radiation therapy followed by Stereotactic Ablative Body Radiotherapy as a Boost on the CyberKnife System and hormonal therapy as indicated."
3082671|NCT01492439|Experimental|Cognitive Remediation and Supported Education|Participants in this group will receive cognitive remediation training in addition to supported education. Cognitive remediation has two components: computer-based cognitive exercise sessions held on a twice weekly basis for 10 weeks as well as 10 weekly group discussion sessions (approximately 60 minutes in duration).
3082672|NCT01492439|Active Comparator|Supported Education Only|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness (see http://www.georgebrown.ca/marketing/FTCal/access/C702.aspx for a full description). Participants in this arm will receive all services and supports provided by this program. However, they will not receive the additional cognitive remediation training provided to those randomized to the experimental arm of the study.
3082673|NCT01492582|Experimental|Prevention (vaccine therapy)|Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18, for patients enrolled on or before 3/1/16) or nonavalent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, and 58, for patients enrolled after 3/1/16) recombinant vaccine intramuscularly on day 1, at 8-12 weeks, and at 24-32 weeks.
3082674|NCT01492673|Experimental|Cyclophosphamide, Topotecan, and Bevacizumab (CTB)|This is a multi-center, open label phase II study evaluating the safety and efficacy of the novel combination of agents consisting of bevacizumab, cyclophosphamide, and topotecan.
3082675|NCT01492686|Experimental|Arm 1|
3082676|NCT01492686|Placebo Comparator|Arm 2|
3082677|NCT01493024|Placebo Comparator|Placebo|Placebo (silicified microcrystalline cellulose) randomized to mimic escalating doses of experimental drug administered three times daily (TID) with meals.
3082678|NCT01493024|Experimental|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated, microporous zirconium silicate, an oral sorbent) administered 3 times daily (tid) with meals.
3082679|NCT01493089|Experimental|Zegerid|Treatment of heartburn with Zegerid
3082680|NCT01493089|Active Comparator|Losec|Treatment of heartburn with Losec
3082681|NCT01493167|Other|limb casting/splinting|Patient age 0-90 years. Patient treatment requires extremity immobilization
3082682|NCT01493180|Experimental|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
3082683|NCT01493180|Active Comparator|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution
3082684|NCT01493284|Experimental|Transfemoral Access|Transfemoral Access for transcatheter aortic valve implant
3082685|NCT01493414|Experimental|INC424|5 - 25 mg twice a day (BID)
3082686|NCT01493427|Experimental|TRAVATAN® BAK-free|Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
3082687|NCT01493531|Experimental|lesinurad 200 mg + allopurinol|
3082688|NCT01493531|Experimental|lesinurad 400 mg + allopurinol|
3082689|NCT01493531|Placebo Comparator|Placebo + allopurinol|
3082690|NCT01493557|Other|Pradaxa (dabigaran etexilate)|Patients with non valvular atrial fibrillation for whom Pradaxa is indicated in accordance with the current local label, not previously treated with Pradaxa, will be provided 3 months of treatment for the prevention of stroke and systemic embolism. Patients who report gastrointestinal symptoms (GIS) will be randomized to one of two management strategies, and data documenting the intensity and duration of the GIS will be collected.
3082691|NCT01493557|Active Comparator|Pradaxa and pantoprazole|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
3082692|NCT01493557|Active Comparator|Pradaxa, 30 minutes after a meal|Patients that develop gastrointestinal symptoms (GIS) will be randomized 1:1 to either pantoprazole 40 mg q.a.m., p.o., or taking Pradaxa (dabigatran etexilate) within 30 minutes after a meal
3082693|NCT01493596|Other|CPP-115 Dose 1|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082694|NCT01493596|Other|CPP-115 Dose 2|2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082695|NCT01493596|Other|CPP-115 Dose 3|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082696|NCT01493596|Other|CPP-115 Dose 4|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082697|NCT01493596|Other|CPP-115 Dose 5|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082698|NCT01493596|Other|CPP-115 Dose 6|Each dose cohort will consist of 8 subjects with 6 subjects randomized to receive CPP-115 and 2 subjects to receive matching placebo. Progression to the next higher dose level will be contingent upon demonstration of a satisfactory assessment of the data from the previous dose.
3082699|NCT01493687|Experimental|CD5024|CD5024 1% Cream
3082700|NCT01493687|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
3082701|NCT01493778|Experimental|turoctocog alfa|
3082702|NCT01493947|Experimental|Ivermectin 1% cream|
3082703|NCT01493947|Active Comparator|Metronidazole 0.75% cream|
3082704|NCT01493960|Experimental|Cobitolimod|2 doses 4 weeks apart
3082705|NCT01493960|Placebo Comparator|Placebo|2 doses 4 weeks apart
3082706|NCT01494038|Experimental|Arm A (Immediate INH Treatment)|Women in Arm A received immediate, or antepartum-initiated, INH treatment. Women received INH at study entry through Week 28, then switched to placebo for INH treatment through Week 40 postpartum.
3082707|NCT01494038|Experimental|Arm B (Deferred INH Treatment)|Women in Arm B received deferred, or postpartum-initiated, INH treatment. Women received placebo for INH at study entry through Week 12 postpartum, then switched to INH through Week 40 postpartum.
3082708|NCT01494051|Active Comparator|High carbohydrate diet|Diet composition of 10% long-chain fatty acids, 20% medium-chain triglycerides, 12% protein and 68% carbohydrate is the current standard of care in long-chain fatty acid oxidation disorders.
3082709|NCT01494051|Experimental|High protein diet|Diet composition of 10% long-chain fatty acids, 20% medium chain triglycerides, 25% protein and 45% carbohydrate is the comparison diet. Fat content is the same between treatments; only the carbohydrate to protein ratio varies.
3082710|NCT01494298||T2DM|African-American men with type 2 diabetes who are not taking cholesterol-lowering medications.
3082711|NCT01494298||Control|African-American men without type 2 diabetes who are not taking cholesterol-lowering medications.
3082712|NCT01494350|Experimental|WR 279,396 topical cream|120 subjects will be enrolled to this open label study to receive WR 279,396 topical cream
3082713|NCT01494467|Experimental|CD5024|CD5024 1% Cream
3082714|NCT01494467|Placebo Comparator|CD5024 Vehicle|CD5024 Vehicle Cream
3082715|NCT01494506|Experimental|MM-398|MM-398 120 mg/m2 Q3W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 120 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 100 mg/ m2 of irinotecan free base.
3082716|NCT01494506|Active Comparator|5 Fluorouracil and Leucovorin IV|5 Fluorouracil and Leucovorin IV
3082717|NCT01494506|Experimental|MM-398, 5-FU and Leucovorin|MM-398 80 mg/m2, 5-FU and Leucovorin Q2W IV. Note: The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m2 dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/ m2 of irinotecan free base.
3082718|NCT01494532|Experimental|ropinirole|active treatment 4, 8, 12, 16, or 24mg/day
3082719|NCT01494532|Placebo Comparator|placebo|placebo comparator 4, 8, 12, 16, or 24mg/day
3082720|NCT01494545|Experimental|Delefilcon A|Delefilcon A contact lenses worn in both eyes on a daily wear, daily disposable basis for two weeks. A new pair was inserted each day.
3082721|NCT01494584|Experimental|ezogabine/retigabine|ezogabine dose escalation
3082722|NCT01494610|Experimental|SERETIDE Rotacaps|Fluticasone propionate (250 micrograms [ug])/Salmeterol (50 ug) combination delivered in a capsule-based inhaler
3082723|NCT01494610|Active Comparator|SERETIDE Diskus|Fluticasone propionate (250 ug)/Salmeterol (50 ug) combination delivered in a multi-dose dry powder inhaler
3082724|NCT01494610|Placebo Comparator|Placebo Rotacaps|Placebo delivered in a capsule-based inhaler
3082725|NCT01494610|Placebo Comparator|Placebo Diskus|Placebo delivered in a multi-dose dry powder inhaler
3082726|NCT01494649|Active Comparator|Toothpaste containing 0.454% stannous fluoride|USA marketed toothpaste [test]
3082727|NCT01494649|Other|Toothpaste containing 0.76% sodium monofluorophosphate|USA marketed toothpaste [negative control]
3082728|NCT01494753|Active Comparator|Prostaglandin|One drop.
3082729|NCT01494753|Experimental|T2345|One drop
3082730|NCT01494818|Experimental|CLEAR CARE/AOSEPT Plus|Hydrogen peroxide-based contact lens care system used per manufacturer's instructions
3082731|NCT01494818|Active Comparator|ReNu MultiPlus|PHMB-containing contact lens solution used per manufacturer's instructions
3082732|NCT01494922|Experimental|Open Label|
3082733|NCT01494987|Experimental|Ranolazine+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive ranolazine 500 mg twice daily plus glimepiride 4 mg once daily on Days 1 through 7, followed by ranolazine 1000 mg twice daily plus glimepiride 4 mg once daily from Day 8 (or by Day 16 if not well tolerated) through Week 24.~Participants will be required to maintain their diet and exercise regimen."
3082734|NCT01494987|Placebo Comparator|Placebo+glimepiride|"Glimepiride stabilization period (up to 8 weeks): participants not on stable glimepiride will receive glimepiride 2 mg once daily, and if tolerated the dose will be increased on Day 8 (+ 2 days) to 4 mg once daily.~Qualifying period: participants will receive placebo to match ranolazine twice daily in addition to glimepiride for 14 days (+ 2 days) and if ≥ 80% compliant and meeting eligibility criteria will continue to the treatment period.~Treatment period: participants will be randomized to receive placebo to match ranolazine plus glimepiride 4 mg once daily for 24 weeks.~Participants will be required to maintain their diet and exercise regimen."
3082735|NCT01495000|Experimental|Arm 1|denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
3082736|NCT01495000|Placebo Comparator|Arm 2|placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
3082737|NCT01495221|Other|Intravitreal aflibercept|All eligible patients will receive intravitreal aflibercept injection (2.0mg) every 4 weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every 8 weeks (2 months) through Week 24. Patients can be dosed as frequently as 2 mg every 4 weeks (monthly) upon investigator discretion.
3082738|NCT01495481|Experimental|Adenosine and Dexmedetomidine|Patients will receive adenosine and then dexmedetomidine for the termination of SVT
3082739|NCT01495572|Experimental|High Dose (HD) Aldesleukin|Pts receiving high dose aldesleukin: Cyclophosphamide 60 mg/kg intravenous (IV) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus melanoma antigen recognized by T cells (MART)-127-35 reactive CD8+ peripheral blood lymphocytes (PBL) up to 3x10^11 IV over 20-30 minutes on day 0, plus aldesleukin 720,000 IU/kg IV over 15 minutes, every 8 hrs for up to 5 days.
3082740|NCT01495572|Experimental|Peripheral Blood Lymphocytes (PBL)|Cyclophosphamide 60 mg/kg intravenous (IV ) for days -7 and -6, Fludarabine 25 mg/m^2 IV for days -5 to -1, plus MART-127-35 reactive CD8+ PBL up to 3x10^11 IV over 20-30 minutes on day 0
3082741|NCT01495585|Placebo Comparator|Placebo|Placebo control
3082742|NCT01495585|Experimental|Group 1|lonafarnib 100mg
3082743|NCT01495585|Experimental|Group 2|lonafarnib 200mg
3082744|NCT01495689|Active Comparator|Usual Care|Usual care for smoking cessation will be delivered to the control arm which comprises of strong physician advice, brief counseling from the clinic nurse +/- a prescription for smoking cessation aid if requested and willing
3082745|NCT01495689|Experimental|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
3082746|NCT01495702|Experimental|Stribild|Participants will switch from their baseline treatment regimen to Stribild for up to 96 weeks, and may continue to receive Stribild in the extension phase.
3082747|NCT01495702|Active Comparator|NNRTI+FTC/TDF|Participants will stay on their baseline treatment regimen antiretroviral regimen consisting of an NNRTI plus FTC/TDF for up to 96 weeks, and may switch to Stribild in the extension phase.
3082748|NCT01495793|Experimental|Rotigotine|In the Titration Period a subject received the first dose of rotigotine then the dose was increased weekly by a dose step over 4 weeks.
3082749|NCT01495819|Active Comparator|Nicotine|subjects will be randomly assigned to one of the five doses of nicotine (0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg). At the beginning of each experimental session, subjects will first sample the assigned nicotine dose and placebo (saline) condition that are randomly labeled as A or B. which may be nicotine or saline. This procedure will allow subjects to sample the nicotine and saline that will be available during that session. In addition, subjective and physiological responses to the sample nicotine dose and saline will be assessed.
3082750|NCT01495819|Placebo Comparator|Saline|Subjects will have sample A and B, one being nicotine and one being saline. The doses will be blinded from PI, subject and staff. The subject must choose A or B for the next ten choices.
3082751|NCT01495858|Experimental|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|
3082752|NCT01495858|Active Comparator|Naproxen Sodium 440 mg (BAYH6689)|
3082753|NCT01495858|Active Comparator|DPH 50 mg|
3082754|NCT01495923|Experimental|Epidural steroids|Injection of steroids into the epidural space
3082755|NCT01495923|Active Comparator|Gabapentin|Titration of gabapentin to effect
3082756|NCT01495975|No Intervention|Usual Care|Usual care for diabetes in the 1 month after discharge.
3082757|NCT01495975|Experimental|Diabetes Transitions Tool Kit|Remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), in the 1 month after discharge.
3082758|NCT01496066|Experimental|LAL|LAL implanted
3082759|NCT01496066|Active Comparator|Monofocal control|Monofocal control IOL implanted
3082760|NCT01496131|Active Comparator|Standard therapy|Radiation therapy in combination with androgen deprivation therapy (ADT).
3082761|NCT01496131|Experimental|Standard therapy plus tecemotide (L-BLP25)|Standard therapy (radiation therapy in combination with ADT) plus tecemotide (L-BLP25).
3082762|NCT01496157|Experimental|Patients with Primary Prostate Cancer|Patients will be imaged with 18F-DCFBC
3082763|NCT01496183|Placebo Comparator|Placebo|
3082764|NCT01496183|Experimental|Olanzapine|
3082765|NCT01496248|Experimental|Korean Red Ginseng|Extract of Korean red ginseng was administrated to subjects through capsule form.
3082766|NCT01496274|Experimental|Prophylaxis|"Routine weekly prophylaxis and episodic treatment for bleeding episodes. An individualized dosing interval may be tested in sub-group subjects during the 2nd part of the trial.~Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention."
3082767|NCT01496274|Experimental|On-demand|Episodic treatment for bleeding episodes during the first 6 months then switch to routine weekly prophylaxis for a further 6 months Subjects may participate in a surgical 'sub-study' in which rIX-FP may be administered prior to, during and after surgical intervention.
3082768|NCT01496287|Experimental|Tube placement group|
3082769|NCT01496313|Active Comparator|300mg vandetanib|
3082770|NCT01496313|Active Comparator|150mg vandetanib|
3082771|NCT01496352|Experimental|DFA-02|Progressive cohorts of 10 subjects (8 active, 2 placebo) receiving 10, 20 , 30 or 40 mL of DFA-02 or matching placebo.
3082772|NCT01496352|Placebo Comparator|DFA-02 placebo|
3082773|NCT01496365|Experimental|DS-5565 5mg nighttime|DS-5565 5 mg/day (one 5 mg tablet at bedtime)
3082774|NCT01496365|Experimental|DS-5565 10 mg at bedtime|DS-5565 10 mg/day (one 10 mg tablet at bedtime)
3082775|NCT01496365|Experimental|DS-5565 15 mg at bedtime|DS-5565 15 mg/day (one 5 mg tablet plus one 10 mg tablet at bedtime)
3082776|NCT01496365|Experimental|DS-5565 20 mg total per day|DS-5565 20 mg/day (one 10 mg tablet in the morning and one 10 mg tablet at bedtime)
3082777|NCT01496365|Experimental|DS-5565 30 mg total per day|DS-5565 30 mg/day (one 5 mg tablet plus one 10 mg tablet in the morning and one 5 mg tablet plus one 10 mg tablet at bedtime)
3082778|NCT01496365|Active Comparator|Pregabalin 300 mg total per day|Pregabalin 300 mg/day (two 150 mg capsules, in the morning and at bedtime)
3082779|NCT01496430|Placebo Comparator|Placebo QD|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.
3082780|NCT01496430|Experimental|Azilsartan Medoxomil 40 mg QD|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.
3082781|NCT01496430|Experimental|Azilsartan Medoxomil 80 mg QD|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.
3082782|NCT01496456|Placebo Comparator|Preventative measures|Caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
3082783|NCT01496456|Active Comparator|Lesion infiltration|Resin infiltration of caries lesion in addition to caries management by preventative measures of oral hygiene instruction, diet counseling and fluoride supplementation
3082784|NCT01496469|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks.
3082785|NCT01496469|Placebo Comparator|Placebo QD|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
3082786|NCT01496612|Experimental|Study Phase|
3082787|NCT01496612|Placebo Comparator|Alternate Study Phase|
3082788|NCT01496807|Experimental|Yervoy with Sylatron|Participants are given Yervoy induction every 3 weeks for four doses, for 12 weeks, and all participants simultaneously receive Sylatron induction weekly, followed by Sylatron maintenance alone for up to 144 additional weeks (total 156 weeks = 3 years).
3082789|NCT01496846|Active Comparator|IANB Articaine|IANB Articaine: Inferior alveolar nerve block (IANB) anesthesia with articaine local anesthetic.
3082790|NCT01496846|Active Comparator|SUP Articaine|SUP Articaine: Supplemental buccal anesthesia (SUP) with articaine local anesthetic after unsuccessful IANB.
3082791|NCT01496846|Active Comparator|SUP Lidocaine|SUP Lidocaine: Supplemental buccal anesthesia (SUP) with lidocaine local anesthetic after unsuccessful IANB.
3082792|NCT01496885||Nonhemorrhagic Ischemic Stroke|Subjects obtained within 24 to 48 hours of a nonhemorrhagic ischemic stroke
3082793|NCT01497067|Experimental|CACHET|ACRYSOF CACHET Phakic Lens (L-series) previously implanted
3082794|NCT01497197|Experimental|Gonal-f®+Luveris®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 1 until required recombinant human chorionic gonadotropin (r-hCG) level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
3082795|NCT01497197|Experimental|Gonal-f® Followed by Luveris®|GONAL-f® 300 IU per day as subcutaneous injection using liquid pen from stimulation Day 1-5 followed by Luveris® 150 IU per day lyophilized powder for subcutaneous injection from stimulation Day 6 until required r-hCG level is met. The dose will be adjusted from stimulation Day 6 (increased or decreased) based upon the subject's ovarian response and according to the center's standard practice.
3082796|NCT01497262|Experimental|Fingolimod|Open-label fingolimod 0.5 mg, taken orally once daily for 4 months
3082797|NCT01497275|Experimental|Zevalin + Velcade|"Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi."
3082798|NCT01497366|Experimental|Sofosbuvir+RBV|Participants were randomized to receive sofosbuvir+RBV for 12 weeks.
3082799|NCT01497366|Active Comparator|PEG+RBV|Participants were randomized to receive PEG+RBV for 24 weeks.
3082800|NCT01497496|Experimental|Immunotherapy|Combination regimen consisting of high dose methylprednisolone combined with ofatumumab, followed by consolidative therapy with lenalidomide in combination with ofatumumab.
3082801|NCT01497613|Active Comparator|PRISM B: Notebook Condition|Telephone check-in calls and a notebook containing similar categories of information as the features on the PRISM C computer system such as a resource guide; games; classroom and information, calendar.
3082802|NCT01497613|Experimental|PRISM C: Computer Condition|A computer-based system designed to support socialization and access to resources; knowledge and prospective memory. The system is placed in the homes of those randomized to the condition for 12 months.
3082803|NCT01497665|Experimental|GRN1005 alone|GRN1005 alone
3082804|NCT01497756|Experimental|CAPP application|Patients in whom device is used
3082805|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 2)|
3082806|NCT01497808|Experimental|Ipilimumab and Radiotherapy (8 Gy x 3)|
3082807|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 2)|
3082808|NCT01497808|Experimental|Ipilimumab and Radiotherapy (6 Gy x 3)|
3082809|NCT01497860|Experimental|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
3082810|NCT01497899|Experimental|E/C/F/TAF|E/C/F/TAF plus E/C/F/TDF placebo for at least 48 weeks
3082811|NCT01497899|Active Comparator|E/C/F/TDF|E/C/F/TDF plus E/C/F/TAF placebo for at least 48 weeks
3082812|NCT01497899|Experimental|E/C/F/TAF Open-Label|"Following study unblinding, participants from the E/C/F/TAF and E/C/F/TDF arms may have the option to receive E/C/F/TAF during an open-label extension phase.~Also, participants who are actively participating in a Gilead-sponsored study of cobicistat-boosted darunavir plus nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) who have reached the protocol-defined secondary endpoint (Week 48) and remain virologically suppressed are eligible to participate and receive E/C/F/TAF in this open-label extension phase."
3082813|NCT01497938|Experimental|Low Glucose Suspend feature (LGS)|According to randomization, Low Glucose Suspend (LGS) will be turned ON in the treatment arm of the study
3082814|NCT01497938|Experimental|Control Arm|The Low Glucose Suspend feature will not be available to subjects in the control arm
3082815|NCT01498068|Experimental|Treatment-naïve|Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
3082816|NCT01498068|Experimental|Treatment-experienced|Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
3082817|NCT01498120|Experimental|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)"
3082818|NCT01498185|Experimental|Arm 1: Dapagliflozin (1 mg)|
3082819|NCT01498185|Experimental|Arm 2: Dapagliflozin (2.5 mg)|
3082820|NCT01498185|Experimental|Arm 3: Dapagliflozin (5 mg)|
3082821|NCT01498185|Experimental|Arm 4: Dapagliflozin (10 mg)|
3082822|NCT01498185|Experimental|Arm 5: Placebo matching Dapagliflozin|
3082823|NCT01498289|Experimental|Arm I|FOLFOX regimen: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3082824|NCT01498289|Experimental|Arm II|Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3082825|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 100 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3082826|NCT01498419|Experimental|Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg)|Drug Sensitive Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3082827|NCT01498419|Active Comparator|Drug Sensitive: Rifafour|Drug Sensitive Participants: Rifafour was administered orally once daily for 8 weeks according to weight: 30 kg to 37 kg: two tablets; 38 kg to 54 kg: three tablets; 55 kg to 70 kg: four tablets; ≥71 kg: five tablets
3082828|NCT01498419|Experimental|Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg)|Multi Drug-Resistant Participants: One moxifloxacin (M) 400 mg tablet plus one Pretomanid (PA-824) 200 mg tablet plus three pyrazinamide 500 mg tablets taken once daily for 8 weeks
3082829|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 10 mg/m2|Less Intensive, Schedule A1 Dasatinib 100 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082830|NCT01498445|Experimental|Phase I - Dasatinib 100 mg + Decitabine 20 mg/m2|More Intensive, Schedule A2: Dasatinib 100 mg daily by mouth ; Decitabine ose 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082831|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth ; Decitabine 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082832|NCT01498445|Experimental|Phase I - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib 140 mg daily by mouth ; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082833|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 10 mg/m2|Less Intensive, Schedule B1 Dasatinib 140 mg daily by mouth; Decitabine e 10 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082834|NCT01498445|Experimental|Phase II - Dasatinib 140 mg + Decitabine 20 mg/m2|More Intensive, Schedule B2 Dasatinib140 mg daily by mouth; Decitabine 20 mg/m^2 by vein over 1 hour daily for 10 days; 28 day cycle.
3082835|NCT01498458|Experimental|pazopanib plus capecitabine|
3082836|NCT01498549|Active Comparator|Atomoxetine|Atomoxetine compared to the sugar pill
3082837|NCT01498549|Placebo Comparator|Sugar Pill|Sugar pill compared to atomoxetine
3082838|NCT01498575|Experimental|Teen Driving Plan|Access to web-based driving intervention
3082839|NCT01498575|No Intervention|Usual practice|Use of typical supervised practice driving resources
3082840|NCT01498588|Experimental|Eribulin+Doxorubicin+Cyclophosphamide|"Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide~Eribulin Day 1 and Day 8 of a 21 day cycle x 4 cycles:~Day 1: Eribulin 1.4mg/m² IV~Day 8: Eribulin 1.4mg/m² IV~Dose-dense doxorubicin and cyclophosphamide every 14 days x 4 cycles:~Day 1: Doxorubicin 60mg/m² IV~Day 1: Cyclophosphamide 600mg/m² IV~Day 2: Pegfilgrastim support 6mg sc at least 24 hours after chemotherapy at the discretion of the investigator."
3082841|NCT01498601|Experimental|Oral care treatment group|All subjects in the prospective intervention group will receive the same enhanced oral care protocol
3082842|NCT01498601|No Intervention|Retrospective study group|For comparison purposes, a retrospective chart review of matched in-patient population will reveal pneumonia rates in the same population who did not receive the enhanced oral care protocol.
3082843|NCT01498640|Experimental|XIAFLEX/XIAPEX MP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the metacarpophalangeal (MP) joint cord
3082844|NCT01498640|Experimental|XIAFLEX/XIAPEX PIP Joint|Up to 3 injections of collagenase clostridium histolyticum 0.58 mg in the proximal interphalangeal (PIP) joint cord
3082845|NCT01498653|Experimental|FF/VI 200/25mcg once daily|ICS/LABA
3082846|NCT01498653|Active Comparator|Fluticasone propionate 500mcg twice daily|ICS
3082847|NCT01498679|Active Comparator|fluticasone furoate/vilanterol trifenatate|Inhaled corticosteroid (ICS)/Long-acting beta2-agonist (LABA) combination
3082848|NCT01498679|Placebo Comparator|Placebo|placebo comparator
3082849|NCT01498692|Experimental|PROMUS Element|Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent
3082850|NCT01498744|Experimental|5 days postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
3082851|NCT01498744|Experimental|1 day postoperative antibiotic|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
3082852|NCT01498822|Experimental|Levetiracetam|Levetiracetam twice a day treatment group
3082853|NCT01498822|Active Comparator|Oxcarbazepine|Oxcarbazepine twice a day treatment group
3082854|NCT01498887|Experimental|Naive or de novo participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
3082855|NCT01498887|Experimental|Previously treated with first-line DMTs participants|Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.
3082856|NCT01498952|Experimental|Phase 1b Cohort A|Participants will receive MEDI-573 10 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
3082857|NCT01498952|Experimental|Phase 1b Cohort B|Participants will receive MEDI-573 45 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
3321104|NCT02016261|Experimental|Remitted Depression Outpatients|Adults 18-65 years old, males and females with the diagnosis of recurrent depressive disorder and who had at least two severe depressive episodes (with or without psychotic symptoms) of the disorder and who currently in remission
3082858|NCT01498952|Experimental|Phase 1b Cohort C|Participants will receive MEDI-573 30 mg/kg intravenous infusion on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
3082859|NCT01498952|Experimental|Phase 2 Arm 1|Participants will receive recommended dose of MEDI-573 from Phase 1b IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
3082860|NCT01498952|Active Comparator|Phase 2 Arm 2|Participants will receive sorafenib 400 mg orally twice daily until unacceptable toxicity, documentation of disease progression, initiation of alternative anticancer treatment, or withdrawal for other reasons.
3082861|NCT01498978|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression then receive maintenance ipilimumab IV once every 3 months for 4 additional doses.
3082862|NCT01499043|Experimental|PLX3397|Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
3082863|NCT01499082|Experimental|HOE901-U300|
3082864|NCT01499082|Active Comparator|Lantus|
3082865|NCT01499095|Experimental|HOE901-U300|
3082866|NCT01499095|Active Comparator|Lantus|
3082867|NCT01499134|Experimental|nebivolol|nebivolol 1 to 4 capsules daily
3082868|NCT01499134|Active Comparator|metoprolol succinate|metoprolol 1 to 4 capsules daily
3082869|NCT01499147|Active Comparator|Arm 1|All patients below age 55 should receive fludarabine/busulfan and ATG in case of unrelated or mismatched donor.
3082870|NCT01499147|Active Comparator|Arm 2|All patients above age 55 or below age 65 should receive fludarabine/ melphalan and ATG.
3082871|NCT01499160|Experimental|HER2-positive or negative|Lapatinib 1,500 mg/day + letrozole 2.5 mg/day until progression followed by everolimus 5 mg/day + letrozole 2.5 mg/day + lapatinib 1,250 mg/day.
3082872|NCT01499173|Experimental|Stroke preparedness intervention|Youth and adults from predominately African American churches in Flint will be enrolled to undergo a faith-based, scientific theory-driven, peer-led behavioral intervention utilizing a pre-post test design.
3082873|NCT01499199|Experimental|Dolutegravir 50mg Once Daily|All subjects will receive 50mg dolutegravir once daily in combination with background antiretroviral therapy consisting of one abacavir/lamivudine fixed dose combination tablet once daily
3082874|NCT01499277|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
3082875|NCT01499277|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
3082876|NCT01499290|Experimental|CAZ-AVI + Metronidazole|IV treatment
3082877|NCT01499290|Active Comparator|Meropenem|IV treatment
3082878|NCT01499303|Experimental|Fostamatinib 200|200mg fostamatinib bid n=60
3082879|NCT01499355|Placebo Comparator|Placebo|Placebo intravenous (IV) infusion on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48, plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF)
3082880|NCT01499355|Experimental|BIIB023 3 mg/kg|BIIB023 3 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3082881|NCT01499355|Experimental|BIIB023 20 mg/kg|BIIB023 20 mg/kg IV on Day 1, Week 2, Week 4, Week 8, and every 4 weeks thereafter through Week 48 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3082882|NCT01499368|Experimental|Lafutidine|Lafutidine 20mg/day
3082883|NCT01499368|Active Comparator|Famotidine|Famotidine 40mg/day
3082884|NCT01499368|Other|Omeprazole|Omeprazole 20mg/day
3082885|NCT01499498|Experimental|Sildenafil and Boceprevir|Healthy volunteers
3082886|NCT01499511||ASCOT participants amlodipine|It is follow up group from the ASCOT study, after treatment with amlodipine for 5.5 years. No treatment only follow up.
3082887|NCT01499511||ASCOT participants atenolol|It is follow up group from the ASCOT study, after treatment with atenolol for 5.5 years. No treatment only follow up.
3082888|NCT01499576|Experimental|Acetic acid spraying|
3082889|NCT01499654|Experimental|Half-dose radiotracer administration|For this study, researchers would like to administer half of the radiotracer, obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
3082890|NCT01499667|Experimental|8-week washout + Fingolimod (FTY720)|8-week washout (8 weeks no treatment) followed by 24 weeks of treatment with fingolimod 0.5mg once a day
3082891|NCT01499667|Experimental|12-week washout + Fingolimod (FTY720)|12-week washout (8 weeks no treatment and 4 weeks placebo) followed by 20 weeks of treatment with fingolimod 0.5mg once a day
3082892|NCT01499667|Experimental|16-week washout + Fingolimod (FTY720)|16-week washout (8 weeks no treatment and 8 weeks placebo) followed by 16 weeks of treatment with fingolimod 0.5mg once a day
3321105|NCT02016274|Experimental|sequential treatment|paclitaxel/cisplatin treatment and radiotherapy
3321106|NCT02016287|Experimental|sequential treatment|paclitaxel treatment and radiotherapy
3321107|NCT02016313|Experimental|Immediate therapy|Physiotherapy protocol
3321108|NCT02016313|Placebo Comparator|waiting list|Physiotherapy protocol
3082893|NCT01499810|Experimental|Renal denervation|All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.
3082894|NCT01499849|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV) + dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3082895|NCT01499849|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3082896|NCT01499862|Experimental|Tibion Arm|Arm of the study in which enrolled post-stroke subjects undergo rehabilitative therapy with the Tibion Bionic Leg.
3082897|NCT01499940|Experimental|Vitamin D3 2000 IU/day|Vitamin D3 2000 IU/day on day of 1st cycle of oxaliplatin; continue as long as patient treated with oxaliplatin and remains on study
3082898|NCT01500031|Experimental|OffRoad Re-entry catheter|Participants treated with OffRoad Re-entry Catheter System
3082899|NCT01500057|Active Comparator|Greenlight XPS Laser|Greenlight XPS Laser of the prostate
3082900|NCT01500057|Active Comparator|BiVAP Saline Vaporization|BiVAP Saline Vaporization of the prostate
3082901|NCT01500083|Experimental|Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with CLL will receive bendamustine at a dose of 100 mg/m2 on Days 1 and 2 in treatment cycles of 28 days for up to six cycles.
3082902|NCT01500083|Experimental|Patients with Indolent Non-Hodgkin's Lymphoma (iNHL)|Patients with iNHL will receive bendamustine at a dose of 120 mg/m2 on Days 1 and 2 in treatment cycles of 21 or 28 days for up to eight cycles.
3082903|NCT01500096|Active Comparator|American ginseng 1000 mg/day|4-week of American ginseng 1000 mg/day every morning
3082904|NCT01500096|Placebo Comparator|Placebo for American ginseng 1000 mg/day|4-week of placebo for American ginseng 1000 mg/day every morning
3082905|NCT01500096|Active Comparator|American ginseng 3000 mg/day|4-week of American ginseng 3000 mg/day every morning
3082906|NCT01500096|Placebo Comparator|Placebo for American ginseng 3000 mg/day|4-week of placebo for American ginseng 3000 mg/day every morning
3082907|NCT01500135|Experimental|TachoSil®|TachoSil® absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3082908|NCT01500135|Active Comparator|Surgicel® Original|Surgicel® Original absorbable patches, applied topically, once, intraoperatively to stop bleeding. The patches were lightly compressed against the suture line for 3 minutes. The number of patches used was determined by the surgeon based on the size of the wound. If bleeding did not stop after 5 minutes treatment was repeated.
3082909|NCT01500187|Active Comparator|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
3082910|NCT01500187|Experimental|3M Vanish Varnish|5% sodium fluoride varnish
3082911|NCT01500200|Experimental|ALKS 5461|
3082912|NCT01500200|Placebo Comparator|Placebo|
3082913|NCT01500213|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3082914|NCT01500213|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (10 mcg/kg IV)+ dexamethasone (20 mg PO) Days 2-4: Dexamethasone (8 mg PO) will be administered orally BID.
3082915|NCT01500226|Placebo Comparator|Placebo + Granisetron + Dexamethasone|Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
3082916|NCT01500226|Experimental|Rolapitant|Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.
3082917|NCT01500252|Experimental|Patellar Resurfacing|These subjects received a Profix TKR including an all polyethylene patellar implant.
3082918|NCT01500252|Active Comparator|Patellar Retention|This group received a Profix TKR, but retained their native patella
3082919|NCT01500278|Active Comparator|Certolizumab Pegol + Methotrexate (CZP + MTX)|
3082920|NCT01500278|Active Comparator|Adalimumab + Methotrexate (ADA + MTX)|
3082921|NCT01500278|Active Comparator|CZP + MTX followed by ADA + MTX|Those subjects who received Certolizumab Pegol (400 mg at Weeks 0, 2, 4 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) at Baseline and are Non-Responders at Week 12, switch to Adalimumab (40 mg) + Methotrexate (ADA + MTX) after Week 12.
3082922|NCT01500278|Active Comparator|ADA + MTX followed by CZP + MTX|Those subjects who received Adalimumab (40 mg + Placebo at Weeks 0, 2, 4 followed by 40 mg ADA every two weeks) + Methotrexate (ADA+ MTX) at Baseline and are Non-Responders at Week 12, switch to Certolizumab Pegol (400 mg at Weeks 12, 14, 16 followed by 200 mg every two weeks) + Methotrexate (CZP+ MTX) after Week 12.
3082923|NCT01500317|Active Comparator|Tapentadol|75 mg tapentadol tid
3082924|NCT01500317|Active Comparator|Oxycodone|5 mg oxycodone tid
3082925|NCT01500317|Placebo Comparator|Placebo|Placebo tid
3082926|NCT01500382|Experimental|Vibegron 100 mg + tolterodine ER 4 mg → placebo|During Treatment Period 1, participants will receive 7 days of once-daily vibegron 100 mg and tolterodine extended-release (ER) 4 mg. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER.
3082927|NCT01500382|Experimental|Placebo → vibegron 100 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 100 mg and placebo to match tolterodine ER.
3321109|NCT02016326|Experimental|HD Colon|High Definition White Light modality will be used by the endoscopist for the entire procedure.
3321110|NCT02016326|Experimental|I-Scan 1|I-scan 1 modality will be used by the endoscopist for the entire procedure.
3321111|NCT02016326|Experimental|I-Scan 2|I-Scan 2 modality will be used by the endoscopist through out the procedure.
3082928|NCT01500382|Active Comparator|Placebo → tolterodine ER 4 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily tolterodine 4 mg and placebo to match vibegron.
3082929|NCT01500382|Experimental|Placebo → vibegron 50 mg|During Treatment Period 1, participants will receive 7 days of once-daily placebo to match vibegron and placebo to match tolterodine ER. Participants will then complete a 2-week single-blind double-dummy placebo washout period prior to Treatment Period 2. During Treatment Period 2, participants will receive 7 days of once-daily vibegron 50 mg and placebo to match tolterodine ER.
3082930|NCT01500434|Experimental|PROMUS Element|Patients who received the PROMUS™ Element Everolimus-Eluting Coronary Stent
3082931|NCT01500525||asthmatic children|children diagnosed by a specialist as asthmatic patients
3082932|NCT01500525||non-asthmatic children|children who are healthy and who do not have respiratory syndrom
3082933|NCT01500629|Experimental|C-1266-7|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-7. After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-6 (placebo).
3082934|NCT01500629|Experimental|Placebo|In a crossover design with subjects randomized to treatment sequence, each subject will receive 200 uL of device Intervention C-1266-6 (placebo). After a washout period of approximately 14 days, subjects will receive 200 uL of device Intervention C-1266-7.
3082935|NCT01500694|Experimental|Extended-release Guanfacine HCl|
3082936|NCT01500720|Experimental|Cabazitaxel|
3082937|NCT01500720|Active Comparator|Topotecan|
3082940|NCT01500746|Experimental|Lavage arm|This group will serve as the experimental arm. They will undergo twice daily pulse lavage of their wounds for 4 days. In between the lavage treatments, their wounds will be dressed with moist gauze.
3082941|NCT01500746|Active Comparator|Moist dressings|This group will serve as the control group. They will undergo twice daily dressing changes with moist gauze dressings for a total of 4 days (8 dressing changes). Bacterial counts and gene expression analysis will be performed prior to the first dressing change and after the last dressing change.
3082942|NCT01501110|Active Comparator|n-acetylcysteine|intra-venous infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours.
3082943|NCT01501110|No Intervention|no intervention|No intervention
3082944|NCT01501162|Placebo Comparator|alcohol, hepatitis, Placebo|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
3082945|NCT01501162|Active Comparator|hepatitis, alcohol, probiotics|We explored the therapeutic effects of probiotics in patients with alcoholic hepatitis
3082946|NCT01501929|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he/she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subjects will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3082947|NCT01501929|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. If necessary, 2 weeks after drug withdrawal, subject will be started on HCTZ if BP > 140/90 mmHg and will continue HCTZ for a 2-week period, after which the subject will be transitioned to metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3082948|NCT01501955|Active Comparator|Stanmore|25 patients will have the Stanmore prosthesis
3082949|NCT01501955|Experimental|Metaphyseal Hip Prosthesis|25 patients will have the Metaphyseal Hip Prosthesis (MHP) prosthesis
3082950|NCT01502033|Experimental|Transcranial Magnetic Stimulation|Open-label course of 30 daily treatments with repetitive transcranial magnetic stimulation (rTMS) at 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
3082951|NCT01502072|Experimental|Inhaled Ribavirin|Group 1: Inhaled form of Ribavirin 60 milligrams/milliliter 3 times/day for 3 hours for up to 10 days.
3082952|NCT01502072|Experimental|Oral Ribavirin|Group 2: Ribavirin Capsules 20 mg/kg orally 3 times/day for up to 10 days.
3082953|NCT01502072|No Intervention|No Ribavirin|Group 3: No Ribavirin treatment.
3082954|NCT01502228|Experimental|62Cu-ETS PET assessment|CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
3082955|NCT01502293|Experimental|Main Study: tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 3-month intervals until disease progression or unacceptable toxicity for up to 5 cycles.
3082956|NCT01502293|Experimental|Addendum: Regimen A tavo-EP|Patients received one cycle (3 daily treatments on Days 1, 8, and 15) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 9 cycles.
3082957|NCT01502293|Experimental|Addendum: Regimen B tavo EP|Patients received one cycle (3 daily treatments on Days 1, 5, and 8) of intra-tumoral injection(s) of tavo at a fixed dose of 0.5 mg/mL (up to 4 tumor sites) followed immediately by in vivo electroporation. Treatment could be repeated at 6-week intervals until disease progression or unacceptable toxicity for up to 2 cycles.
3082958|NCT01502306|Experimental|Telephone counseling|One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling begins immediately after intake, if the client is available for a 30-minute session or by appointment at the clients' convenience. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls. The follow-up calls (about 10 minutes) will be scheduled as follows: a reminder call if the quit date is more than one week out for the initial counseling, on the quit date, 4-7 days after the quit date, and 10-14 days after the quit date.
3082959|NCT01502306|Experimental|Phone counseling & nicotine patches|"One-on-one, proactive telephone counseling to quit smoking; The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients the day after the screening intake. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day."
3082960|NCT01502306|Experimental|Phone counseling, NRT and incentives|"One-on-one, proactive telephone counseling to quit smoking; The counseling addresses behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. Counseling includes a comprehensive pre-quit session (to include motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four proactive follow-up calls.~Nicotine patches (four weeks' worth) are sent directly to clients. Dosage is 21 mg if smoking 11 or more per day, 14 mg if smoking 6-10 per day and 7mg if smoking <6 per day.~Gift cards (to one of 4 major chains) are $20 for the first counseling session and $10 for each additional one (up to five sessions total)."
3082961|NCT01502332|Experimental|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways.
3082962|NCT01502332|Active Comparator|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways.
3082963|NCT01502371|Experimental|MF MDI 50 mcg BID|Participants receive MF MDI 25 mcg x 2 inhalations (50 mcg total dose) BID PLUS Placebo dry powder inhaler (DPI) x 1 inhalation once daily (QD) in the evening for 12 weeks.
3082964|NCT01502371|Experimental|MF MDI 100 mcg BID|Participants receive MF MDI 50 mcg x 2 inhalations (100 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3082965|NCT01502371|Experimental|MF MDI 200 mcg BID|Participants receive MF MDI 100 mcg x 2 inhalations (200 mcg total dose) BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3082966|NCT01502371|Active Comparator|MF DPI 100 mcg QD|Participants receive Placebo MDI x 2 inhalations BID PLUS MF DPI x 1 inhalation QD in the evening for 12 weeks.
3082967|NCT01502371|Placebo Comparator|Placebo|Participants receive Placebo MDI x 2 inhalations BID PLUS Placebo DPI x 1 inhalation QD in the evening for 12 weeks.
3082968|NCT01502410|Experimental|Group 1 Relapsed/Refractory Rhabdomyosarcoma|"Patients with relapsed or refractory rhabdomyosarcoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3082969|NCT01502410|Experimental|Group 2 Relapsed/Refractory Wilms tumor|"Patients with relapsed or refractory Wilms tumor receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3082970|NCT01502410|Experimental|Group 3 Relapsed/Refractory hepatocellular carcinoma|"Patients with relapsed or refractory hepatocellular carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3082971|NCT01502410|Experimental|Group 4 Papillary thyroid carcinoma|"Patients with relapsed or refractory papillary thyroid carcinoma receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~sorafenib tosylate: Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28~pharmacological study: Optional correlative studies~laboratory biomarker analysis: Optional correlative studies"
3082972|NCT01502423|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
3082973|NCT01502423|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
3082974|NCT01502631|Active Comparator|SUN13837|
3082975|NCT01502631|Placebo Comparator|Placebo|
3082976|NCT01502644|Active Comparator|Low Negative Affect (NA)|Participants with low NA (HADS score ≤5 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3082977|NCT01502644|Active Comparator|Moderate NA|Participants with moderate NA (HADS score ≥6 to ≤8 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3082978|NCT01502644|Active Comparator|High NA|Participants with high NA (HADS score ≥9 on each subscale) received placebo or active opioid drug (immediate-release morphine 15 to 30 mg or oxycodone 5 to 10 mg) up to three times a day as needed for 1 week each in random order, followed by morphine or oxycodone titrated to a maximum allowable daily dose in morphine equivalents of 30 mg for short-acting medication and 60 mg for long-acting medication, respectively, three times a day for up to 20 weeks, followed by morphine or oxycodone tapering (individualized opioid dose was decreased by approximately 25% each week) for 4 weeks.
3082979|NCT01502709|Experimental|Caloric Vestibular Neurostimulation|Subjects received caloric vestibular neurostimulation
3082980|NCT01502709|Placebo Comparator|Placebo Arm|Subjects received placebo
3082981|NCT01502761|Experimental|Regional Intra-arterial Magnesium 0.75g|Regional Intra-arterial magnesium only 0.75 mg Magnesium Sulfate (50% Total Dose): 5 patients
3082982|NCT01502761|Experimental|Regional Intra-arterial magnesium 1.5g|Regional Intra-arterial magnesium Sulfate Only 1.5g (100% TD): 5 patients
3082983|NCT01502761|Experimental|Regional/ Distal (75/25%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (75% TD regional- 1.125g / 25% distal-0.375g): 5 patients
3082984|NCT01502761|Experimental|Regional/ Distal (50/50%) Magnesium 1.5g|Regional/ Distal intra-arterial magnesium (50% TD regional- 0.75g/ 50% distal-0.75g): 5 patients
3082985|NCT01502787|Active Comparator|Initial treatment with metoprolol|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3082986|NCT01502787|Active Comparator|Initial treatment with nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. There will be a 2-week washout period. Following washout, the subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3082987|NCT01502813|Experimental|Citicoline, Creatine, and Omega-3 Arm|Each participant will be given a supplement log at the end of visit 1. They will be asked to complete the log during the 28 days to indicate that the daily dose of supplements were taken according to instructions. The study coordinator will check the log on the second and third visits as well as count the remaining supplement pills. If participants do not comply with the daily supplement schedule, then the PI will determine if the participant should be withdrawn from the study.
3082988|NCT01502956|Active Comparator|InterStim® device|The FSLP InterStim® device is to be done within 3 months of enrolling/consenting. The 1st stage is lead placement into the S3 foramen with best response to stimulation. The 4 electrodes will be tested and set to an amplitude that achieves comfortable stimulation in the vaginal, perineal, or rectal sensation. If =/>50% improvement, participant will then have the 2nd stage IPG implantation, 8-18 days after last FSLP. If there is a technical problem with lead on 1st FSLP, then the participant can have a 2nd FSLP and may go on to have IPG implantation with lead replacement. The 2nd FSLP must be initiated no longer than 1 month since the initiation of the 1st FSLP. If the participant is a non-responder and there is no technical problem, then the lead is removed.
3082989|NCT01502956|Active Comparator|Botox® injection|Total of 200 units of Botox A will be dissolved into 10mL of saline and injected into the bladder within 3 months of enrolling/consenting. Participants determined to have a clinical response at the 1 month visit (post 1st injection) may receive additional injections between 6-24 months.
3082990|NCT01503021|Other|SFP/Placebo|Soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks, then 1 week washout, then standard liquid bicarbonate concentrate without SFP x 2 weeks
3082991|NCT01503021|Other|Placebo/SFP|Standard liquid bicarbonate concentrate without SFP x 2 weeks, then 1 week washout, then soluble ferric pyrophosphate (SFP) 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate x 2 weeks.
3082992|NCT01503164|Active Comparator|Positive pressure therapy (PAP)|Positive airway pressure(PAP) therapy is the standard of care for patients with obstructive sleep apnea. During sleep, a mask is worn over the nose and connected to the PAP machine.
3082993|NCT01503164|Sham Comparator|Lifestyle counseling|
3082994|NCT01503229|Experimental|Treatment (abiraterone acetate and prednisone)|Patients receive abiraterone acetate orally once daily and prednisone orally twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3082995|NCT01503333|No Intervention|Control|The control condition will complete data collection activities and receive their usual school offerings.
3082996|NCT01503333|Experimental|Physical activity intervention|Receiving Physical activity intervention which includes individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
3082997|NCT01503515|Experimental|Arm I (caspofungin acetate)|Patients receive caspofungin acetate IV over 1 hour once daily (QD) beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
3082998|NCT01503515|Active Comparator|Arm II (fluconazole or voriconazole)|Patients receive fluconazole IV over 1-2 hours QD or PO QD; or voriconazole IV over 1-2 hours QD or PO BID beginning within 24 hours of allogeneic HSCT (day -1 or 0) and continuing until day 42 in the absence of invasive fungal infections or disease progression.
3082999|NCT01503749|No Intervention|Control|Three patients with liver cirrhosis of this arm will not receive any intervention regarding to peripheral blood mononucleated cells.
3083000|NCT01503749|Active Comparator|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm.
3083001|NCT01503749|Experimental|Infusion of the mobilized monocyte cells|"G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells~. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance."
3083002|NCT01504204|Experimental|Medication with sample and demonstration|Subjects will receive a sample tube of the Adapalene + benzoyl peroxide samples with demonstration of how to use it at the first visit.
3083003|NCT01504204|Active Comparator|Medication without samples|Subjects will receive the Adapalene + benzoyl peroxide from standard tube without a sample or demonstration of proper use of the medication.
3083004|NCT01504412|Experimental|DS-5565 Low Dose|DS-5565 10mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3083005|NCT01504412|Experimental|DS-5565 Middle Dose|DS-5565 20mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3083006|NCT01504412|Experimental|DS-5565 High Dose|DS-5565 30mg/day, administered in 2 doses. Treatment period: 1 week titration and 6 weeks of fixed dose.
3083007|NCT01504412|Placebo Comparator|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day.
3083008|NCT01504412|Active Comparator|Pregabalin|Pregabalin capsules 300mg/day administered in 2 doses
3083011|NCT01504477|Experimental|Combination of Panitumumab and Bortezomib|IV panitumumab and bortezomib
3083012|NCT01504672|Experimental|Medication review|
3083013|NCT01504672|No Intervention|Usual care|
3083014|NCT01504711|Experimental|Treatment (nausea and vomiting prophylaxis)|Receive fosaprepitant dimeglumine IV 30 mins. prior to FOLFIRINOX chemotherapy.
3083015|NCT01504841|Experimental|Cohort I: Treatment experienced, 2 to 6 years of age|Children in this arm were at least 2 but younger than 6 years of age; they received the study drug etravirine (ETR) together with an optimized background regimen (OBR) consisting of one active boosted protease inhibitor (PI) and at least one other active antiretroviral (ARV) drug.
3083016|NCT01504841|Experimental|Cohort II: Treatment experienced, 1 to 2 years of age|Children in this arm were at least 1 but younger than 2 years of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
3083017|NCT01504841|Experimental|Cohort III: Treatment experienced, 2 months to 1 year of age|Children in this arm were at least 2 months but younger than 1 year of age; they received ETR together with an OBR consisting of one active boosted PI and at least one other active ARV drug.
3083018|NCT01504854|Experimental|Resveratrol|Subjects will take 500 mg by mouth once daily increasing at 13 week intervals to a maximum of 1 gram by mouth twice daily with or without food.
3083019|NCT01504854|Placebo Comparator|Placebo|Subjects will receive a matching placebo to be taken with or without food.
3083020|NCT01504867|Experimental|Aspirin|This arm received a 325mg loading dose of aspirin on study day one, followed by 81mg of aspirin on days 2-7.
3083021|NCT01504867|Placebo Comparator|Placebo|This group received matching lactose powder filled capsules on days 1-7.
3083022|NCT01504958|Active Comparator|Active rTMS with real cognitive training|High frequency rTMS stimulation to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
3083023|NCT01504958|Sham Comparator|Sham rTMS with real cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent active cognitive training.
3083024|NCT01504958|Sham Comparator|Sham rTMS with sham cognitive training|High frequency sham rTMS to the left and right parietal cortex (somatosensory association cortex), left and right DLPFC (dorsolateral prefrontal cortex), and left superior temporal gyrus (Broca's area) paired with concurrent sham cognitive training.
3083025|NCT01504971||Gastroesophageal reflux disease (GERD)|
3083026|NCT01504997|Experimental|Robot assisted distal gastrectomy|patients who received robot assisted distal gastrectomy
3083027|NCT01505010|Other|Control group|Standard antihypertensive drug treatment
3083028|NCT01505010|Experimental|Intervention group|Renal denervation plus standard antihypertensive drug treatment
3083029|NCT01505062|Experimental|SAR421869 (Cohort 1)|Starting dose of SAR421869 given through one subretinal injection.
3083030|NCT01505062|Experimental|SAR421869 (Cohort 2)|Escalating dose of SAR421869 given through one subretinal injection.
3083031|NCT01505062|Experimental|SAR421869 (Cohort 3)|Escalating dose of SAR421869 given through one subretinal injection.
3083032|NCT01505062|Experimental|SAR421869 (Cohort 4)|Maximum tolerated dose (MTD) of SAR421869 given through one subretinal injection.
3083033|NCT01505062|Experimental|SAR421869 (Cohort 5)|MTD of SAR421869 given through one subretinal injection.
3083034|NCT01505114|Experimental|Arm 1|MVC 300 mg plus FTC placebo and TDF placebo orally once daily
3083035|NCT01505114|Experimental|Arm 2|MVC 300 mg plus FTC 200 mg and TDF placebo orally once daily
3083036|NCT01505114|Experimental|Arm 3|MVC 300 mg plus FTC placebo and TDF 300 mg orally once daily
3083037|NCT01505114|Experimental|Arm 4|MVC placebo plus FTC 200 mg and TDF 300 mg orally once daily
3083038|NCT01505166|Experimental|Vigil™|Patients will receive 1 x 10^7 cells (Group A) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses (vaccine) starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
3083039|NCT01505166|Placebo Comparator|Placebo|Patients will receive placebo (Group B) via intradermal injection for a minimum of 4 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days.
3083040|NCT01505166|Experimental|Vigil™ Vaccine (6 patient run-in)|Six patients will be enrolled into the Part 1 of the study to receive intradermal autologous Vigil™ cancer vaccine (1.0 x 10e7 cells/injection; maximum of 12 vaccinations).
3083041|NCT01505179|Active Comparator|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
3083042|NCT01505179|Placebo Comparator|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
3083043|NCT01505374|Experimental|Study Technique Left Leg, Control Technique Right Leg|
3083044|NCT01505374|Experimental|Study Technique Right Leg, Control Technique Left Leg|
3083045|NCT01505387|Placebo Comparator|Placebo|Identical to Litramine 2 tablets 3 times daily (oral consumption, after meal)
3083046|NCT01505387|Experimental|Litramine|Fibre complex of plant origin n tablet form 2 tablets 3 times daily (oral consumption, after meal)
3083047|NCT01505465|Experimental|Study: Melatonin|
3083048|NCT01505465|Placebo Comparator|Control: Placebo|
3083049|NCT01505491|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
3083050|NCT01505491|Active Comparator|adalimumab - US|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
3083051|NCT01505491|Active Comparator|adalimumab - EU|Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab
3083052|NCT01505530|Experimental|300 mg LY2495655 + chemotherapy|300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
3083053|NCT01505530|Experimental|100 mg LY2495655 + chemotherapy|100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
3083054|NCT01505530|Placebo Comparator|Placebo + chemotherapy|Placebo in combination with standard of care chemotherapy (investigator's choice)
3083055|NCT01505608|Active Comparator|Arm A- Temozolomide and Irinotecan|"Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.~Patients who show progression on the I+TMZ arm may crossover to the I+TMZ+TPI 287 arm at anytime during cycles 1 to 6. If there is evidence of progression after completion of the I+TMZ arm (after completion of cycle 6) then the patient will have been considered to have completed therapy and is not eligible for the crossover."
3083056|NCT01505608|Experimental|Arm B- Temozolomide/Irinotecan + TPI 287|"Cycle 1 to 6: Irinotecan and Temozolomide in combination with TPI 287~Intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.~Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle.~Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle."
3083057|NCT01505634|Experimental|Relebactam 250 mg with imipenem/cilastatin|Relebactam 250 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
3083058|NCT01505634|Experimental|Relebactam 125 mg with imipenem/cilastatin|Relebactam 125 mg IV co-administered with 500 mg of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
3083059|NCT01505634|Placebo Comparator|Relebactam placebo with imipenem/cilastatin|Matching placebo for relebactam (0.9% normal saline) IV co-administered with 500 mg dose of imipenem/cilastatin once every 6 hours for a minimum of 96 hours. After 96 hours of IV treatment, participants may be switched to 500 mg ciprofloxacin (as optional oral therapy following minimum duration of IV study drug), administered orally, twice daily for the remainder of the study. Antibiotic therapy (IV and oral combined) should not exceed 14 days.
3083060|NCT01505647|Experimental|ZOSTAVAX™ (AMP)|ZOSTAVAX™ manufactured with an alternative process
3083061|NCT01505647|Active Comparator|ZOSTAVAX™|ZOSTAVAX™ manufactured with the current process
3083062|NCT01505673|Active Comparator|Liraglutide|
3083063|NCT01505673|Placebo Comparator|Saline injection|
3083064|NCT01505764|Experimental|Arm 1 (Anamorelin HCl)|Anamorelin HCl
3083065|NCT01505764|Placebo Comparator|Arm 2 (Placebo)|Placebo
3083066|NCT01505868|Experimental|Arm I (cabazitaxel)|Patients receive cabazitaxel IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3083067|NCT01505868|Experimental|Arm II (cabazitaxel and carboplatin)|Patients receive cabazitaxel IV over 60-90 minutes and carboplatin IV over 60-90 minutes on day 1. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3083068|NCT01505881|Experimental|Dabigatran etexilate|Patient dose determined by dose allocated in 1160.113 and CrCl levels
3083069|NCT01505881|Active Comparator|warfarin|warfarin doses to maintain INR levels
3083070|NCT01505933|Active Comparator|dexmedetomidine|
3083071|NCT01505933|Active Comparator|propofol|
3083072|NCT01506193|Active Comparator|Group A|Subjects in this arm will receive MMRV vaccine at Visit 1 (Day 0) and MenC vaccine at Visit 2 (Days 35-49).
3083073|NCT01506193|Experimental|Group B|Subjects will receive MMRV vaccine and MenC vaccine at Visit 1 (Day 0).
3083074|NCT01506193|Active Comparator|Group C|Subjects will receive Men C vaccine at Visit 1 (Day 0) and MMRV vaccine at Visit 2 (Day 35-49).
3083075|NCT01506271|Experimental|Relebactam 250 mg with imipenem/cilastatin|Participants randomized to receive relebactam 250 mg will be administered 250 mg doses of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
3083076|NCT01506271|Experimental|Relebactam 125 mg with imipenem/cilastatin|Participants randomized to receive relebactam 125 mg will be administered 125 mg doses of relebactam IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
3083077|NCT01506271|Placebo Comparator|Placebo to relebactam with imipenem/cilastatin|Participants randomized to receive placebo for relebactam will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
3083078|NCT01506323|Experimental|Mantram Repetition Program (MRP)|"A portable meditation-based Mantram Repetition Program (MRP) will be delivered individually in 8-weekly 1 hour sessions to teach a set of strategies for training attention to manage symptoms. For this study, the program targets symptoms of posttraumatic stress disorder (PTSD) in Veterans who have experienced military-related trauma."
3083079|NCT01506323|Active Comparator|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) is a form of individually-delivered 8-weekly, 1 hour sessions that are problem-oriented to improve current coping. For this study, it served as an attention control arm for the non-specific effects of individual therapist interaction.
3083080|NCT01506362|Experimental|A synthetic oligonucleotide for treatment of IBD.|BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
3083081|NCT01506453|Active Comparator|Gabapentin|Active treatment arm.
3083082|NCT01506453|Placebo Comparator|Placebo|Placebo arm.
3083083|NCT01506479|Sham Comparator|Control Group|Wait listed to moderate or vigorous exercise after 6 months of no exercise.
3083084|NCT01506479|Experimental|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
3083085|NCT01506479|Experimental|Moderate Exercise|Endurance exercise at 60-65% HR max, 4x/wk for 6 months.
3083086|NCT01506596|Experimental|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
3083087|NCT01506609|Experimental|Veliparib with Temozolomide|Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m^2 QD Days 1 through 5 in each 28-day cycle.
3083088|NCT01506609|Placebo Comparator|Placebo with Carboplatin and Paclitaxel|Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
3083089|NCT01506609|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m^2 administered on Day 3 of each 21-day cycle.
3083090|NCT01506726|Experimental|Active drug - oral salsalate|Subjects randomized to active drug arm will receive 750mg of salsalate (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 1500mg (2 pills) twice a day (if the 750mg dose was tolerated) for a further 5 months. Total treatment time is 6 months.
3083091|NCT01506726|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive a matching placebo pill (one pill) twice a day (am and pm) for one month. After one month the dose will be increased to 2 matching placebo pills twice a day (if the one pill dose was tolerated) for a further 5 months. Total treatment time is 6 months.
3083092|NCT01506882|Experimental|Levetiracetam 1000 mg/day to 2000 mg/day group|"Subjects in the LEV 1000 mg/day to 2000 mg/day group receive the initial dose of LEV 1000 mg/day for the 1- week Stabilization Period and enter the Evaluation Period. Unless a seizure occurs during the Evaluation Period, the subjects will continue LEV 1000 mg/day for 26 weeks. If a seizure occurs during the Evaluation Period, the dose will be increased to 2000 mg/day and a restart of stabilization on LEV 2000 mg/day for 1 week is required prior to restarting the 26-weeks Evaluation Period on LEV 2000 mg/day.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
3083093|NCT01506882|Experimental|Levetiracetam 3000 mg/day group|"Unless a seizure occurs, the subjects in this arm will continue LEV 3000 mg/day for 26 weeks. Subjects in the LEV 3000 mg/day group undergo a 4-week Up-Titration Period prior to the 1-week Stabilization Period.~They receive 1000 mg/day for 2 weeks and 2000 mg/day for 2 weeks during the Up-Titration Period and LEV 3000 mg/day for 1 week during the Stabilization Period.~The LEV dose could be decreased as a fallback option at the investigator's discretion, if the subject did not tolerate the LEV dosage, as evidenced by the development of an AE. The fallback option was permitted to be performed once for subjects on LEV 2000 mg/day at any time during the restarted Stabilization Period (SP), restarted Evaluation Period (EP), or Maintenance Period (MP), as well as for subjects on LEV 3000 mg/day at any time during the SP, EP, or MP."
3083094|NCT01506908|Active Comparator|Nicotine Polacrilex mint mini lozenge|
3083095|NCT01506908|Placebo Comparator|placebo|mint mini lozenge with no active
3083096|NCT01506947|Experimental|Paricalcitol|"Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL.~Participants may have also received routine darbepoetin alfa to treat anemia."
3083097|NCT01506960|Experimental|Coronary stenting with OCT, NIRS/IVUS|All subjects will have Near Infrared Spectroscopy/Intravascular Ultrasound Imaging performed.
3083098|NCT01507051|Experimental|Warfarin followed by Rivaroxaban (Xarelto, BAY59-7939)|Days -6 and -5: 10 mg warfarin once daily or lower depending on international normalized ratio (INR); Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 20 mg rivaroxaban once daily; Day 5: 10 mg vitamin K once daily
3083099|NCT01507051|Placebo Comparator|Warfarin followed by Placebo|Days -6 and -5: 10 mg warfarin once daily or lower depending on INR; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin once daily depending on INR; Days 0 to 3: 1 tablet matching placebo once daily; Day 5: 10 mg vitamin K once daily
3083100|NCT01507051|Active Comparator|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
3083101|NCT01507090||Normal Children|Otherwise healthy children 2 months to 16 years of age.
3083102|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)+CPA|
3083103|NCT01507103|Experimental|Chemoradiotherapy+tecemotide (L-BLP25)|
3083104|NCT01507103|Active Comparator|Chemoradiotherapy|
3083105|NCT01507155|Experimental|Patient-Reported Measures|Patients age 18 and older with a diagnosis of Major Depressive Disorder or Generalized Anxiety disorder who received genetic testing using the Genecept Assay and completed patient scales.
3083106|NCT01507155|Experimental|Clinician-Reported Outcomes|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
3083107|NCT01507181|Experimental|Ketamine|single dose IV ketamine, .5mg/kg
3083108|NCT01507181|Placebo Comparator|Midazolam|single dose IV midazolam, .45mg/kg
3083109|NCT01507220|Active Comparator|Morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
3083110|NCT01507220|Experimental|EXPAREL|EXPAREL (bupivacaine liposome extended-release injectable suspension)
3083111|NCT01507246|Active Comparator|IV morphine sulfate|Standard of Care (SOC), dosage variable, administered intravenously via PCA pump postsurgically, as need.
3083112|NCT01507246|Experimental|EXPAREL (bupivacaine liposome injectable suspension)|EXPAREL(R), dosage 266 mg, diluted with 0.9% saline to a total volume of 40 cc.
3083113|NCT01507298||Capsule endoscopy|
3083114|NCT01507298||24 hour oesophageal pH study|
3083115|NCT01507350||Obesity Surgery|Patients having gastric band, sleeve gastrectomy, and gastric bypass will have blood and urine tests, and 51 Cr-EDTA clearance to assess renal function. These are taken before and after the surgery at 6 weeks , 6 months and 12 months.
3083116|NCT01507493||mutant alleles|grouped by SCN9A mutant alleles including 3312T, 1719R, 1150W.
3083117|NCT01507493||wild-type alleles|grouped by SCN9A wild-type alleles including 3312G, 1719C, 1150R.
3083118|NCT01507662|Experimental|BMD Result Letter and Brochure|Patients who receive the intervention - BMD result letter with brochure.
3083119|NCT01507662|No Intervention|Control|Those who received usual care
3083120|NCT01507688|Experimental|Arm 1 SSM Intervention|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
3083121|NCT01507688|No Intervention|Arm 2 Usual Care|Usual care
3083122|NCT01507779|Experimental|Influenza vaccine|Received 0.50 mL of inactivated monovalent influenza vaccine (IVACFLU), administered intramuscularly, on days 0 and 21
3083123|NCT01507779|Placebo Comparator|Placebo|Received placebo, administered intramuscularly, on days 0 and 21
3083124|NCT01507831|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 78 weeks.
3083125|NCT01507831|Experimental|Alirocumab|Alirocumab 150 mg Q2W added to stable LMT for 78 weeks.
3083126|NCT01507896|Experimental|BAX326 in Surgery|BAX 326 (recombinant factor IX) in Surgery
3083127|NCT01507987||Patients with SJM leads implanted|Patient has at least one market released Riata, Riata ST, QuickSite/QuickFlex, or Durata lead implanted
3083128|NCT01508013|Experimental|Appearance-Focused Website Intervention|This is a Internet-based appearance-focused prevention intervention based on the Behavioral Alternatives Model.
3083129|NCT01508013|Active Comparator|Control Website|Control participants viewed an Internet site designed to provide drug and alcohol education for teens.
3083130|NCT01508052|Active Comparator|sequential compression device|Apply sequential compression device during the thyroidectomy
3083131|NCT01508052|Experimental|elastic stockings|Apply elastic stockings during the thyroidectomy
3083132|NCT01508117|Experimental|Axitinib + Radiation Therapy|Axitinib 5mg twice daily for 28 days followed by concurrent axitinib plus hypofractionated radiation therapy (45 Gy in 15 fractions) followed by maintenance axitinib 5mg twice daily until progression or unacceptable toxicity
3083133|NCT01508130||Cohort|
3083134|NCT01508169|Experimental|Foot orthosis|Forty-seven women in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas(UNICAMP) who met the inclusion criteria for this study (being female with osteoporosis and aged 60 or above) were assigned, at random, to wear ethyl-vinyl-acetate insoles with medial arch supports and metatarsal pads over a four-week period. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
3083135|NCT01508169|No Intervention|Control Group|Forty-seven elderly women with osteoporosis (in treatment in the outpatient clinic of the Rheumatology Division of State University of Campinas- UNICAMP) were assigned, at random, to enter the control group with no foot intervention. Balance, using the Berg Balance Scale (BBS) and the Timed Up and Go (TUG) indexes; pain, using a numeric pain scale (NPS); and disability of the feet, using the Manchester Foot Pain and Disability Index (MFPDI), were assessed at baseline and after four weeks.
3083136|NCT01508325|Experimental|Bisoprolol|
3083137|NCT01508325|Active Comparator|Metoprolol|
3083138|NCT01508455|Experimental|Dexmedetomidine|Dexmedetomidine Load 0.2 mcg/kg over 10 or 20 min Dexmedetomidine Maintenance 0.2 mcg/kg/hr (at least 6 and up to 24 hours)
3083139|NCT01508650|Active Comparator|No intervention|Usual care control group
3083140|NCT01508650|Active Comparator|Active Comparator|Multi domain rehabilitation intervention
3083141|NCT01508676|Active Comparator|Pennsaid Phase I|Pennsaid (20-40 drops; 2-4 times daily) Upon completion of the first phase, subjects in each arm will be crossed over (i.e., from placebo to Pennsaid and vise versa). Pennsaid or placebo lotion will be packed in a container with identical appearance before being dispensed to study subjects.
3083142|NCT01508676|Placebo Comparator|Placebo Phase I|Study subject will topically apply placebo lotion (20-40 drops) 2-4 times daily to the painful area for the next two weeks. The dose titration will be based on the size of painful area (approximately 10 drops for every 4 square inches). Subjects will be asked to fill in a daily pain diary and report any side effects to the research center. A phone number and a beeper number will be provided to subjects.
3083143|NCT01508702|Experimental|lesinurad 400 mg|
3083144|NCT01508702|Placebo Comparator|placebo|
3083145|NCT01508832|Active Comparator|Lidocaine|Lidocaine 1% Digital Nerve Block (2 cc)
3083146|NCT01508832|Active Comparator|Bupivacaine|Bupivacaine 0.25% Digital Block (2 cc)
3083147|NCT01508910|Experimental|Treatment Arm|Targeted intramyocardial delivery of 1 x 10^5 Auto-CD34+ cells after granulocyte-colony stimulating factor (G-CSF) mobilization and apheresis
3083148|NCT01508910|Placebo Comparator|Active Control Arm|Targeted intramyocardial delivery of placebo after G-CSF mobilization and apheresis
3083149|NCT01508910|Other|Unblinded Standard of Care (SOC) Arm|No study-related procedures will be performed.
3083150|NCT01508936|Placebo Comparator|Placebo|Placebo intravenous injection every 4 weeks for a total of 4 doses.
3083151|NCT01508936|Experimental|Reslizumab 3.0 mg/kg|Reslizumab intravenous injection at a dosage of 3.0 mg/kg every 4 weeks for a total of 4 doses.
3083152|NCT01509040|Active Comparator|Control|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3083153|NCT01509040|Experimental|Low Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/h, ultrafiltration 45 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3083154|NCT01509040|Experimental|High Volume Hemofiltration|Initiate standard post-resuscitative care including a triple lumen catheter to monitor central venous pressure, core temperature maintenance between 32C and 34C if unconscious. Hemofiltration x 48 hours via 11.5F double lumen venous catheter, blood flow 250 mL/kg/h, ultrafiltration 90 mL/kg/h. Fluids, 500-mL bolus of intravenous crystalloid given every 30 minutes to achieve a central venous pressure of 8 to 12 mm Hg; inotropes, vasopressors if mean arterial pressure is less than 65 mm Hg; vasodilators, if mean arterial pressure is 90 mm Hg or above to maintain hemodynamics.
3083155|NCT01509079|Experimental|Vitamin D3 4000 IU|
3083156|NCT01509079|Active Comparator|Vitamin D3 600 IU|
3083157|NCT01509105||Group1|
3083158|NCT01509183|Active Comparator|Intervention Group|Intervention group (IG) participants received access to and feedback from the Propeller Health System (formerly Asthmapolis System).
3083159|NCT01509183|No Intervention|Control Group|Control group (CG) participants were outfitted with sensors from the Propeller Health System, but did not receive feedback.
3083160|NCT01509404|Active Comparator|Valcyte|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
3083161|NCT01509404|Active Comparator|Valcyte then Cytogam|valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam 100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant for prophylaxis against CMV infection
3083162|NCT01509547|Experimental|varenicline|Participants >55 kg will take varenicline 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take varenicline 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
3083163|NCT01509547|Placebo Comparator|placebo|Participants >55 kg will take placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily for 11 weeks. Participants ≤55 kg will take placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily for 11 weeks.
3083164|NCT01509586|Experimental|PREP (Potentially Reduced Exposure Product) Group|
3083165|NCT01509586|No Intervention|cigarette group|
3083166|NCT01509612|Active Comparator|Additive homeopathy in cancer patients|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive additive classical homeopathy with homeopathic globules
3083167|NCT01509612|Placebo Comparator|Additive homeopathic placebo globules|Lung cancer patients receiving conventional chemo- and/or radiation therapy receive homeopathic placebo globules
3083168|NCT01509612|No Intervention|No intervention|No intervention
3083169|NCT01509638|Active Comparator|Group 1 Standard of Care|IV Morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump
3083170|NCT01509638|Active Comparator|Group 2 EXPAREL|bupivacaine liposome injectable suspension.
3083171|NCT01509664|Experimental|Discount intervention|Receives 50% discount intervention on selected fruits and vegetables at participating supermarket.
3083172|NCT01509664|No Intervention|Control|Received no discount at the participating supermarket.
3083173|NCT01509677|Active Comparator|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
3083174|NCT01509677|Placebo Comparator|Placebo|tablet, once daily, oral administration in the morning after breakfast
3083175|NCT01509807|Active Comparator|Group 1|IV morphine sulfate (or Sponsor-approved equivalent), Standard of Care (SOC)
3083176|NCT01509807|Experimental|Group 2|EXPAREL (bupivacaine liposome injectable suspension)
3083177|NCT01509846|Experimental|Cohort 1|Received one oral dose of 2.6±0.8 x 10^8 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
3083178|NCT01509846|Experimental|Cohort 2|Received three oral doses of 2.6±0.8 x 10^9 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
3083179|NCT01509846|Experimental|Cohort 3|Received three oral doses of 2.6±0.8 x 10^10 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
3083180|NCT01509846|Experimental|Cohort 4|Received three oral doses of 2.6±0.8 x 10^11 vp/mL Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)
3083181|NCT01509846|Placebo Comparator|Placebo|Received oral dose of placebo concurrent with Cohort 1 (one dose), 2, 3, or 4 (3 doses).
3083182|NCT01509872|Experimental|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behaviour Therapy (Cohen, Mannarino, Deblinger, 2006; Smith and Saunders, 2005) is a child-friendly, manualised psychological intervention for children who experience nightmares, flashbacks, anxiety, anger, social isolation, poor concentration or self-blame after experiencing or witnessing a violent and terrifying life event (e.g. rape, murder, abduction etc). This intervention was culturally modified for use with war-affected children.
3083183|NCT01509872|Active Comparator|A Child Friendly Space|A Child Friendly Space is a psychosocial intervention combining creative (e.g. art), imaginative (e.g. drama), physical (e.g. football), communicative (e.g. group discussions) and manipulative activities (e.g. story telling). It aids children's natural development by providing a safe place for children to learn, express themselves, grow and develop, supported by trained animators and peer educators.
3083184|NCT01509950|Active Comparator|Staples|Use of staples for skin closure at cesarean section
3083185|NCT01509950|Active Comparator|Prolene non-absorbable sutures|Use of Prolene non-absorbable sutures for skin closure at cesarean section
3083186|NCT01509950|Active Comparator|Absorbable sutures|Use of absorbable sutures for skin closure at cesarean section; monocryl or vicryl.
3083187|NCT01510028|Experimental|Cohort 1 (10 mg)|6 patients treated with HGT-1110 10 mg EOW by IT injection
3083188|NCT01510028|Experimental|Cohort 2 (30 mg)|6 patients treated with HGT-1110 30 mg EOW by IT injection
3083189|NCT01510028|Experimental|Cohort 3 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
3083190|NCT01510028|Experimental|Cohort 4 (100 mg)|6 patients treated with HGT-1110 100 mg EOW by IT injection
3083191|NCT01510145|Experimental|TRAVATAN® BAK-free|Travoprost 0.004% BAK-free, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks.
3083192|NCT01510158|Experimental|lesinurad 200 mg + allopurinol|
3083193|NCT01510158|Experimental|lesinurad 400 mg + allopurinol|
3083194|NCT01510158|Placebo Comparator|Placebo + allopurinol|
3083195|NCT01510327|Experimental|PROMUS Element|Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.
3083196|NCT01510379|Active Comparator|Reletex|Reletex plus scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
3083197|NCT01510379|Other|Control|Scheduled IV ondansetron 4 mg q 6 hours for a total of 4 doses. Breakthrough nausea will be treated using IV promethazine 25 mg q 6 hours prn during the hospital stay and in elixir at the same dose and frequency after discharge.
3083198|NCT01510457|Placebo Comparator|Sugar Pill|BID placebo
3083199|NCT01510457|Experimental|Milnacipran|Uptitration from 10mg to 50mg BID Milnacipran
3083200|NCT01510652|Active Comparator|Quad Group|Patients in the Quad group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
3083201|NCT01510652|Active Comparator|BiP Group|Patients in the BiP Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
3083202|NCT01510704|Placebo Comparator|Placebo|
3083203|NCT01510704|Experimental|Low dose APD421|1mg dose level
3083204|NCT01510704|Experimental|Mid Dose APD421|5mg dose level
3083205|NCT01510704|Experimental|High Dose APD421|20mg dose level
3083206|NCT01510717|Experimental|Multifocal IOL|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3083207|NCT01510717|Active Comparator|Monofocal IOL|AcrySof® IQ Monofocal IOL Model SN60WF, bilateral implantation
3083208|NCT01510769|Experimental|lesinurad 400 mg + febuxostat 80 mg|
3083209|NCT01510769|Experimental|lesinurad 200 mg + febuxostat 80 mg|
3083210|NCT01510769|Placebo Comparator|placebo + febuxostat 80 mg|
3083211|NCT01510834|Experimental|All STR2IVE Participants|All participants who met study criteria, consented and were enrolled, were asked to complete online assessments at three timepoints(baseline, 1-month, and 3-months) and complete 2 or more behavioral programs each month. Behavioral programs and assessments were provided online via the Multibehavioral, Computerized Tailored Intervention STR2IVE.
3083212|NCT01510912|Experimental|Diclofenac Capsules 35 mg bid or tid|
3083213|NCT01511016|Experimental|human recombinant leptin (metreleptin)|Each subject received 0.02 mg leptin / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg leptin / kg for two more months.
3083214|NCT01511016|Placebo Comparator|Placebo injection|Each subject received placebo at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by a dose of 0.04 mg / kg for two more months.
3083215|NCT01511055|Experimental|Folate-FITC|
3083216|NCT01511068|Experimental|Inhaled Leukine (rhGM-CSF)|Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor
3083217|NCT01511107|Active Comparator|Amoxicillin-Clavulanate, 10 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 10 days
3083218|NCT01511107|Other|Amoxicillin-Clavulanate, 5 days|amoxicillin-clavulanate, 90/6.4 mg/kg/day, 2 divided doses, 5 days plus placebo, 2 divided doses, 5 days
3083219|NCT01511250|Experimental|Part I: TDV 21 to 45 Years (yrs)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3083220|NCT01511250|Placebo Comparator|Part I: Placebo 21 to 45 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3083221|NCT01511250|Experimental|Part I: TDV 12 to 20 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3083222|NCT01511250|Placebo Comparator|Part I: Placebo 12 to 20 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3083223|NCT01511250|Experimental|Part I: TDV 6 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3083224|NCT01511250|Placebo Comparator|Part I: Placebo 6 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3083225|NCT01511250|Experimental|Part I: TDV 1.5 to 5 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3083226|NCT01511250|Placebo Comparator|Part I: Placebo 1.5 to 5 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3083227|NCT01511250|Experimental|Part II: TDV 1.5 to 11 yrs|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
3083228|NCT01511250|Placebo Comparator|Part II: Placebo 1.5 to 11 yrs|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3083229|NCT01511315|Experimental|Ustekinumab|
3083230|NCT01511419|Experimental|LAIV H7N3|"Test drug/agent: Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine (LAIV H7N3) grown in embryonated chicken eggs.~Name of active ingredient(s): Live-attenuated A/17/mallard/Netherlands/00/95 influenza vaccine.~Dose: ≥7.5 log egg infectious dose (EID) 50/0.5 ml dose; 0.25 ml/nare.~Route of administration: Intranasal aerosol.~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28."
3083231|NCT01511419|Placebo Comparator|Placebo|"Reference drug: Placebo; saline inoculated in embryonated chicken eggs and subsequently prepared in the same way as test vaccine.~Dose: 0.5 ml; 0.25 ml/nare~Route of administration: Intranasal aerosol~Duration of treatment: Two doses were delivered, one on Day 0 and one on Day 28"
3083232|NCT01511445|Active Comparator|ACDF with PEEK interbody cage|Anterior cervical discectomy and fusion (ACDF) with an interbody spacer made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is to be filled with local autologous bone harvested during the decompression phase of the procedure.
3083233|NCT01511445|Experimental|ACDF with Valeo CSC Ceramic Cage|ACDF with the Valeo CSC cage, a silicon nitride ceramic interbody cage. The center area of the cage is filled with porous silicon nitride. No autologous bone is used; the cage is soaked in patient blood.
3083234|NCT01511536|Experimental|Phase 1: Cabazitaxel 20 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3083235|NCT01511536|Experimental|Phase 1: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3083236|NCT01511536|Experimental|Phase 2: Cabazitaxel 25 mg/m^2 + Abiraterone 1000 mg|Cabazitaxel at maximum tolerated dose (MTD) as determined in phase 1 part (25 mg/m^2) IV infusion on Day 1 of each 21-day cycle in combination with abiraterone acetate 1000 mg orally once daily and prednisone 5 mg orally twice daily until disease progression, unacceptable toxicity or consent withdrawal.
3083237|NCT01511640|Experimental|Pregabalin 1|Dose 1
3083238|NCT01511640|Placebo Comparator|Placebo 1|Placebo 1
3083239|NCT01511640|Experimental|Pregabalin 2|Dose 2
3083240|NCT01511640|Placebo Comparator|Placebo 2|Placebo 2
3083241|NCT01511809|Experimental|Atazanavir/ritonavir monotherapy|Patients will simplify therapy to ATV/RTV 300mg/100mg OD as monotherapy
3083242|NCT01511809|No Intervention|Atazanavir/ritonavir triple therapy|Patients will continue the same regimen ATV/RTV 300mg/100mg OD plus 2 NRTIs as backbone
3083243|NCT01511939|Other|Pennsaid, warfarin|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of warfarin for at least 2 months
3083244|NCT01511939|Other|Pennsaid, dabigatran|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of dabigatran for at least 2 months
3083245|NCT01511939|Other|Pennsaid, aspirin and/or clopidogrel|Pennsaid 1.5%, 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period in a subject who has been taking a stable dose of aspirin and/or clopidogrel for at least 2 months
3083246|NCT01511978|Active Comparator|Continuous 3,4-DAP|Subjects continued taking their usual individualized regimen of 3,4-DAP base, 30 to 100 mg daily divided into at least 3 doses.
3083247|NCT01511978|Placebo Comparator|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual individualized regimen of 3,4-DAP base (30 to 100 mg daily divided into at least 3 doses) to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
3083248|NCT01512108|Experimental|Liraglutide + an OAD therapy|
3083249|NCT01512108|Active Comparator|Two OADs combination therapy|
3083250|NCT01512160|Experimental|PF-04531083 2000 mg|
3083251|NCT01512160|Experimental|PF-04531083 1000 mg|
3083252|NCT01512160|Active Comparator|Ibuprofen 400 mg|
3083253|NCT01512160|Placebo Comparator|Placebo|
3083254|NCT01512225|Experimental|Domperidone for days 1 to 28|Domperidone maleate tablets 10 mg orally three times daily from days 1 to 28
3083255|NCT01512225|Placebo Comparator|Placebo for days 1 to 14 and domperidone for day 15-28|Identical placebo tablets 10 mg orally three times daily from days 1 to 14 followed by Domperidone maleate tablets 10 mg orally three times daily from days 15 to 28
3083256|NCT01512251|Other|No Previous Treatment|150 mg oral dabrafenib twice a day until disease progression, death, or unacceptable adverse events.
3083257|NCT01512264|Experimental|rTMS|3 weeks of nerTMS
3083258|NCT01512264|Sham Comparator|1 week of Sham Treatment + 2 weeks of nerTMS|1 week of Sham Treatment + 2 weeks of nerTMS
3083259|NCT01512264|Sham Comparator|2 weeks of Sham Treatment +1 week of nerTMS|2 weeks of Sham Treatment +1 week of nerTMS
3083260|NCT01512264|Placebo Comparator|Control Group|3 weeks of Sham Treatment
3083261|NCT01512368|Experimental|Supervised exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks to participants.
3083262|NCT01512446|Active Comparator|Alendronate|
3083263|NCT01512446|Placebo Comparator|Placebo|
3083264|NCT01512667|Experimental|Severe Renal Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with severe renal insufficiency.
3083265|NCT01512667|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
3083266|NCT01512693|Experimental|Moderate Hepatic Insufficiency Group|Single-dose administration of odanacatib 50 mg to participants with moderate hepatic insufficiency.
3083267|NCT01512693|Experimental|Healthy Matched Control Group|Single-dose administration of odanacatib 50 mg to healthy matched control participants.
3083268|NCT01512745|Experimental|apatinib|
3083269|NCT01512745|Placebo Comparator|placebo|
3083270|NCT01512758|Experimental|Alisertib 30 mg|Alisertib 30 mg enteric-coated tablets (ECT), orally, twice a day (BID) for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 16 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
3083271|NCT01512758|Experimental|Alisertib 40 mg|Alisertib 40 mg ECT, orally, BID for 7 days, followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable alisertib-related toxicities (up to 7 cycles). Cycles could be extended to 28-day cycles (with additional 7-day rest period) if all alisertib-related toxicities (except alopecia) were not resolved to less than Grade 2.
3083272|NCT01512797|Active Comparator|Sitagliptin phosphate|100 mg/day sitagliptin phosphate (Januvia) PO once a day for 4-5 weeks
3083273|NCT01512797|Placebo Comparator|Placebo|1 Placebo pill / day PO once a day for 4-5 weeks
3083274|NCT01512849|Experimental|TA-7284 Low|
3083275|NCT01512849|Experimental|TA-7284 High|
3083276|NCT01512979|Experimental|linagliptin|patients receive linagliptin tablet once daily
3083277|NCT01512979|Experimental|linagliptin plus metformin|patients receive linagliptin tablet once daily and metformin tablets twice daily
3083278|NCT01513122|Active Comparator|Arm 1. Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3N(t)RTI
3083279|NCT01513122|Active Comparator|Arm 2. Lopinavir /ritonavir + raltegravir|
3083280|NCT01513148|Experimental|Superluminous Light Diode Irradiation|Application of super luminous diodes light irradiation over the superficial radial nerve
3083281|NCT01513148|Placebo Comparator|Sham Superluminous Light Diode Irradiation|Sham Superluminous Light Diode Irradiation over the Superficial Radial Nerve for the same time period as the intervention group
3083282|NCT01513239|Experimental|MK-6072 + SOC|Single intravenous (IV) infusion of 10 mg/kg MK-6072 + Standard of Care (SOC) for CDI
3083283|NCT01513239|Experimental|MK-3415A + SOC|Single IV infusion of 10 mg/kg MK-3415A + SOC for CDI
3083284|NCT01513239|Placebo Comparator|Placebo + SOC|Normal saline IV infusion (0.9% sodium chloride) + SOC for CDI
3083285|NCT01513291|Experimental|MK-6096|Participants were randomized to receive double-blind MK-6096, two 5 mg tablets (10 mg dose), orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period were randomized 1:1 to receive double-blind MK-6096 or placebo once daily in the 2-week Run-out Period.
3083286|NCT01513291|Placebo Comparator|Placebo|Participants were randomized to receive double-blind placebo, two tablets, orally, once daily for 12 weeks in the Treatment Period. Those who completed the Treatment Period continued to receive double-blind placebo once daily in the 2-week Run-out Period.
3083287|NCT01513317|Experimental|Siltuximab|15 mg/kg of siltuximab administered as a 1-hour infusion every 4 weeks + best supportive care (BSC)
3083288|NCT01513317|Experimental|Placebo|Placebo administered as a 1-hour infusion every 4 weeks + BSC
3083289|NCT01513330|Experimental|First Standard Care, then SenSura Mio|Subjects first test Standard Care (Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima) and after cross-over SenSura Mio
3083290|NCT01513330|Experimental|First SenSura Mio, then Standard Care|Subjects first test SenSura Mio and after cross-over Standard Care(Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima)
3083291|NCT01513447|Active Comparator|Sterile Water Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
3083292|NCT01513447|Placebo Comparator|Normal Saline Injection|"In the sitting position, study subjects will receive a total of 0.4 mL of study drug via four intracutaneous injections: bilateral injections at the posterior superior iliac spine and bilateral injections at 1 cm medial and 1-2 cm inferior to the first point."
3083293|NCT01513460|Experimental|NVA237 + Fluticasone/Salmeterol (Flu/Sal)|NVA237 50 µg once daily (NVA237 + Tiotropium placebo + Flu/Sal). NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI) o.d. plus Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3083294|NCT01513460|Active Comparator|Tiotropium + Flu/Sal|Tiotropium 18µg once daily (NVA237 placebo + Tiotropium + Flu/Sal). Tiotropium 18 μg o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3083295|NCT01513460|Placebo Comparator|Flu/Sal|Placebo (NVA237 placebo + Tiotropium placebo + Flu/Sal). Placebo to tiotropium o.d. delivered via a proprietary inhalation device plus Placebo to NVA237 o.d. delivered via single-dose dry-powder inhaler (SDDPI) plus Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device. In addition, at Visit 1, all participants were provided with a short acting β2-agonist (salbutamol) which they were instructed to use throughout the study as rescue medication.
3083296|NCT01513473|Experimental|Insulin Degludec + Insulin Aspart|
3083297|NCT01513473|Experimental|Insulin Detemir +Insulin Aspart|
3083298|NCT01513538||TherapyGuide|Patients implanted with a dual chamber pacemaker featuring the TherapyGuide function
3083299|NCT01513551|Experimental|V114|Healthy adult participants received a single 0.5 mL intramuscular injection of aluminum adjuvanted V114 on Day 1.
3083300|NCT01513551|Active Comparator|PNEUMOVAX® 23|Healthy adult participants received a single 0.5 mL intramuscular injection of PNEUMOVAX® 23 on Day 1.
3083301|NCT01513551|Active Comparator|PREVNAR 13®|Healthy adult participants received a single 0.5 mL intramuscular injection of PREVNAR 13® on Day 1.
3083302|NCT01513590|Experimental|IDegAsp BID|
3083303|NCT01513590|Active Comparator|BIAsp 30 BID|
3083304|NCT01513759|Experimental|EkoSonic® Endovascular System|Participants will receive a total of 24 milligrams (mg) of recombinant t-PA infusion, at an infusion rate of 1 milligrams/hour (mg/hr) per device (2 mg/hour for bilateral PE) delivered through the EkoSonic® Endovascular System. This regimen allows for a recombinant t-PA infusion time of 24 hours for one catheter and 12 hours for two catheters, respectively.
3083305|NCT01513902|Experimental|Cohort 1|Ages 12 to less than 18
3083306|NCT01513902|Experimental|Cohort 2|Ages 6 to less than 12
3083307|NCT01513902|Experimental|Corhort 3|Ages 2 to less than 6
3083308|NCT01513967|Experimental|Part A, SAD Treatment 1|RPh201 single dose (SAD Low Dose )
3083309|NCT01513967|Placebo Comparator|Part A, SAD Placebo 1|Placebo single dose (SAD Low Dose )
3083310|NCT01513967|Experimental|Part A, SAD Treatment 2|RPh201 single dose (SAD Mid Dose )
3083311|NCT01513967|Placebo Comparator|Part A, SAD Placebo 2|Placebo single dose (SAD Mid Dose )
3083312|NCT01513967|Experimental|Part A, SAD Treatment 3|RPh201 single dose (SAD High Dose )
3083313|NCT01513967|Placebo Comparator|Part A, SAD Placebo 3|Placebo single dose (SAD High Dose )
3083314|NCT01513967|Experimental|Part B, MAD Treatment 1|RPh201 multiple dose (MAD Low Dose )
3083315|NCT01513967|Placebo Comparator|Part B, MAD Placebo 1|Placebo multiple dose (MAD Low Dose )
3083316|NCT01513967|Experimental|Part B, MAD Treatment 2|RPh201 multiple dose (MAD Mid Dose )
3083317|NCT01513967|Placebo Comparator|Part B, MAD Placebo 2|Placebo multiple dose (MAD Mid Dose )
3083318|NCT01513967|Experimental|Part B, MAD Treatment 3|RPh201 multiple dose (MAD High Dose )
3083319|NCT01513967|Placebo Comparator|Part B, MAD Placebo 3|Placebo multiple dose (MAD High Dose )
3083320|NCT01514136|Experimental|One arm|The arm consists of two periods: in period one, products are tested in the order A, B, C, D, and in period two, products are tested in the order A*, B*, C*, D*.
3083321|NCT01514149|Experimental|Arm 1 - Weekly CJC-1134-PC|
3083322|NCT01514149|Experimental|Arm 2 - Weekly CJC-1134-PC|
3083323|NCT01514149|Experimental|Arm 3 - Weekly CJC-1134-PC|
3083324|NCT01514149|Experimental|Arm 4 - Weekly CJC-1134-PC|
3083325|NCT01514149|Placebo Comparator|Arm 5 - Weekly Placebo|
3083326|NCT01514162|Experimental|Trifecta Valve Group|Subjects implanted with a Trifecta valve.
3083327|NCT01514201|Experimental|Treatment (veliparib, temozolomide, 3D-CRT, IMRT)|"DOSE-ESCALATION: Patients receive veliparib PO BID 5 days a week for 6-7 weeks. Patients also undergo concurrent 3D-CRT or IMRT QD 5 days a week for 6-7 weeks.~MAINTENANCE THERAPY: Beginning 3-4 weeks later, patients receive veliparib PO BID on days 1-5 and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 10 courses in the absence of disease progression or unacceptable toxicity."
3083328|NCT01514240|Experimental|D9421-C|D9421-C 9 mg once daily
3083329|NCT01514240|Active Comparator|Mesalazine|Mesalazine 1 g three times a day
3083330|NCT01514279|Experimental|HealthyCHANGE|Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
3083331|NCT01514279|Experimental|SystemCHANGE|Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines
3083332|NCT01514279|No Intervention|Tools4CHANGE|In contrast to the behavioral arms, youths with their parent(s)/guardian randomized to this group will have one 60-minute face-to-face meeting at initiation of the study with a dietitian who is also trained in recommendations for exercise and sedentary behavior.
3083333|NCT01514292|Experimental|Real Time Continuous Glucose Monitoring System|7 day use of real time continuous glucose monitoring system
3083334|NCT01514318||Revelation|Subjects who received the Revelation Hip Stem prior to 2002 and have agreed to come into the office for a single visit.
3083335|NCT01514357|Other|Nesiritide (BNP)|Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.
3083336|NCT01514357|Placebo Comparator|Placebo|Subjects will receive SQ placebo bid for seven consecutive days.
3083337|NCT01514370|Experimental|IFN beta 1a 44 mcg TIW + curcumin (BCM95)|
3083338|NCT01514370|Placebo Comparator|IFN beta 1a 44 mcg TIW + placebo|
3083339|NCT01514383|Experimental|Surgical Adhesive|The surgical adhesive (cyanoacrylate) will be used once to close the topical skin surgical incision created during surgical procedures.
3083340|NCT01514396|Experimental|Surgical Glue|Surgiseal
3083341|NCT01514422|Experimental|Minocycline|All subjects will be given minocycline over 8 weeks
3083342|NCT01514448|Experimental|Everolimus|Everolimus 10 mg orally once daily until disease progression, occurrence of intolerable toxicity, start of another anticancer treatment or withdrawn consent.
3083343|NCT01514461|Experimental|LCQ908 20 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 10 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3083344|NCT01514461|Experimental|LCQ908 40 mg|"In period II (0-12 weeks) double-blind treatment: one LCQ908 40 mg active tablet + one LCQ908 placebo matching to 20mg tablet, once daily. No dose titration allowed.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 20 mg active tablet + one LCQ908 placebo matching to 40 mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3083345|NCT01514461|Placebo Comparator|Placebo|"In period II (0-12 weeks) double-blind treatment: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet, once daily.~In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 placebo matching to 40mg tablet + one LCQ908 placebo matching to 20mg tablet + one LCQ908 placebo matching to 10mg tablets, once daily.~A low fat diet will be followed and recorded in patient diary."
3083346|NCT01514513|Experimental|Licefreee Spray|
3083347|NCT01514513|Active Comparator|Nix Creme Rinse, 1% Permethrin|
3083348|NCT01514630|Experimental|Creatine monohydrate|14 female depressed methamphetamine users received 5 grams of creatine monohydrate daily for eight weeks.
3083349|NCT01514682|Placebo Comparator|Placebo|Placebo pills to be assigned using a permuted randomization system
3083350|NCT01514682|Experimental|Anti-inflammatory Combination Therapy|Salsalate, statin and omega-3-fatty acid combination therapy
3083351|NCT01514734|Experimental|AZARGA|Brinzolamide/timolol maleate fixed combination, one drop self-administered in study eye(s) twice a day for 8 weeks
3083352|NCT01514760|Experimental|Mobile-based Asthma Action Plan|The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts.
3083353|NCT01514786|No Intervention|Control|Same information is presented in the control website as is found in the intervention website, but no interactive component: preferences and risk assessment.
3083354|NCT01514786|Active Comparator|Intervention with Colorectal Website|Intervention website includes an interactive component including preferences and risk assessment.
3083355|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With Inactivating B-RAF Mutation)|Participants with nonsmall-cell lung cancer (NSCLC) and an inactivating B-RAF mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
3083356|NCT01514864|Experimental|Dasatinib, 140 mg (NSCLC With DDR2 Mutation)|Participants with NSCLC and a discoidin domain receptor 2 (DDR2) mutation received dasatinib, 140 mg, once daily as a tablet until unacceptable toxicity or disease progression occurred
3083357|NCT01515046|Experimental|Gemcitabine with escalating IV ascorbate|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off.~Ascorbate (vitamin C) given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbate / infusion for two infusions. Doses are then escalated in 25 gram increments until therapeutic window is achieved (350 mg/dL or above). Dose is then held at that level for the full cycle."
3083358|NCT01515072|No Intervention|No Remote Ischemic Preconditioning|The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
3083359|NCT01515072|Experimental|Remote Ischemic Preconditioning|The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes.
3083360|NCT01515176|Experimental|Treatment (ofatumumab, dinaciclib)|Patients receive ofatumumab IV over 4-6 hours on days 1, 8, 15, and 22 of courses 1-2, and on day 1 of courses 4-7. Beginning on course 2, patients also receive dinaciclib IV over 2 hours on days 2, 8, and 15 of course 2, and on days 1, 8, and 15 of courses 3-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
3083361|NCT01515189|Experimental|Arm 1: Ipilimumab (3 mg/kg)|Ipilimumab 3 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
3083362|NCT01515189|Experimental|Arm 2: Ipilimumab (10 mg/kg)|Ipilimumab 10 mg/kg solution intravenously once every 3 weeks for 4 doses; option for Re-induction, until disease progression or unacceptable toxicity
3083363|NCT01515306|Experimental|Part A: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: paclitaxel administered on Day 1 of 2-week cycle.~Cycle 2: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.~Cycle 3 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of each 4-week cycle."
3083364|NCT01515306|Experimental|Part B: ramucirumab (IMC-1121B) and paclitaxel|"Cycle 1: ramucirumab (IMC-1121B) administered as monotherapy on Day 1 of 3-week cycle.~Cycle 2 and beyond: ramucirumab (IMC-1121B) administered on Day 1 and Day 15, paclitaxel administered on Day 1, Day 8 and Day 15 of 4-week cycle.~*After Cycle 1 (mandatory pharmacokinetic phase) is completed, participants may continue to receive ramucirumab (IMC-1121B) monotherapy or combination therapy with paclitaxel as described in Part A."
3083365|NCT01515319|Experimental|2mg Y242 (Part A)|Y242 single dose, subcutaneous
3083366|NCT01515319|Experimental|7.5mg Y242 (Part A)|Y242 single dose, subcutaneous
3083367|NCT01515319|Experimental|15mg Y242 (Part A)|Y242 single dose, subcutaneous
3083368|NCT01515319|Experimental|30mg Y242 (Part A)|Y242 single dose, subcutaneous
3083369|NCT01515319|Experimental|60mg Y242 (Part A)|Y242 single dose, subcutaneous
3083370|NCT01515319|Experimental|90mg Y242 (Part A)|Y242 single dose, subcutaneous
3083371|NCT01515319|Placebo Comparator|Placebo - Part A|0.9% saline
3083372|NCT01515319|Experimental|60mg Y242 (Part B1)|Y242 single subcutaneous dose, administered once a week for 5 weeks
3083373|NCT01515319|Experimental|90mg Y242 (Part B2-B4)|Y242 single subcutaneous dose, administered once a week for 5 weeks
3083374|NCT01515319|Placebo Comparator|Placebo - Part B|0.9% saline
3083375|NCT01515345|Active Comparator|standard therapy|standard dual antiplatelet therapy after PCI for all patient populations (stable CVD and ACS)
3083376|NCT01515345|Experimental|individualized therapy|dual antiplatelet therapy modified according to clopidogrel on-treatment platelet reactivity measured by Multiplate Analyzer
3083377|NCT01515410|Experimental|DM-1992|DM-1992, a gastric-retentive extended-release tablet containing 72.5mg carbidopa (CD) and 230mg levodopa (LD)
3083378|NCT01515410|Active Comparator|Sinemet IR|An Immediate-release (IR) tablet containing 25mg carbidopa (CD) and 100mg levodopa (LD)
3083379|NCT01515423|Experimental|Paliperidone palmitate 3-month (PP3M)|A formulation of paliperidone palmitate with a 3-month injection interval
3083380|NCT01515423|Active Comparator|Paliperidone palmitate 1-month (PP1M)|A formulation of paliperidone palmitate with a 1-month injection interval
3083381|NCT01515475|Active Comparator|Glasses|Glasses are prescribed at enrollment and worn per protocol throughout the duration of the study.
3083382|NCT01515475|Placebo Comparator|Observation|Glasses will not be prescribed unless the patient has confirmation of one or more deterioration criteria as described in the protocol.
3083383|NCT01515488|Experimental|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
3083384|NCT01515488|Experimental|Nurse-initiated triage|Nurse-initiated triage for obtaining medical history and presenting problem(s)
3083385|NCT01515540|Active Comparator|lidocaine|5% lidoderm patch
3083386|NCT01515540|Placebo Comparator|control|placebo patch
3083387|NCT01515566|Experimental|Fentanyl|Fentanyl subcutaneously (SQ) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before walk test, and 6 minute walk test (6MWT) at baseline and 15 minutes after Fentanyl. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
3083388|NCT01515566|Active Comparator|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test, and 6 minute walk test at baseline and 15 minutes after Placebo. Two (2) Questionnaires completed at baseline taking about 10 minutes to complete, and one completed after study visit taking about 5 minutes to complete.
3083389|NCT01515657|Experimental|PL2200 Aspirin Capsules|Investigational drug arm; crossover design
3083390|NCT01515657|Active Comparator|Immediate-Release Aspirin Tablets|Active comparator; crossover design
3083391|NCT01515657|Active Comparator|Enteric-coated aspirin caplets|Active comparator; crossover design
3083392|NCT01515696|Active Comparator|Gastrografin|infants receive 3ml/kg Gastrografin + 6ml/kg sterile water
3083393|NCT01515696|Placebo Comparator|Sterile water|infants receive 9ml/kg sterile water
3083394|NCT01515748|Other|Surgery + Adjuvant Chemotherapy (SC)|Participants underwent surgery within 2 weeks after randomization followed by adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 milligrams per square meter (mg/m^2) administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after End-of-Treatment (EOT) until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
3083395|NCT01515748|Experimental|Neoadjuvant Chemotherapy +Surgery +Adjuvant chemotherapy (CSC)|Participants received neo-adjuvant chemotherapy with Docetaxel 50 mg/m^2 intravenously (IV) for greater than or equal to (>=)1 hour (hr) on Day 1 of each treatment cycle plus Oxaliplatin 100 mg/m^2 IV for >=2 hr on Day 1 of each treatment cycle plus S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily from Day 1 to 14, of each treatment cycle followed by surgery approximately 1-3 weeks after completion of neo-adjuvant chemotherapy and adjuvant chemotherapy with S-1 [(Gimeracil) + Oxo (Oteracil)] 40 mg/m^2 administered orally twice daily, from Day 1 to 28 of each cycle for 1 year, and were followed-up after EOT until disease progression or death or study cut-off date, whichever comes first (maximum duration: up to 8 years).
3083396|NCT01515865|Experimental|Midodrine HCl|
3083397|NCT01515865|Placebo Comparator|Placebo|
3083398|NCT01515891|Experimental|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
3083399|NCT01515943|Active Comparator|Computer-based therapy (CBT)|The CBT group will be assigned active home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3083400|NCT01515943|Active Comparator|Near target push-up (NTP)|The NTP group will be assigned placebo home-based computer vergence/accommodative therapy (5 minutes/day) plus near target push-ups (15 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3083401|NCT01515943|Placebo Comparator|Placebo|The placebo group will be assigned placebo home-based computer vergence/accommodative therapy (15 minutes/day) plus placebo yoked prism flipper therapy (5 minutes/day) for a total of 20/minutes per day, 5 days per week for the 12-week treatment phase.
3083402|NCT01515956|Experimental|BMN 110 Weekly|
3083403|NCT01515995|Experimental|Magnesium sulfate group|15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
3083404|NCT01515995|Active Comparator|Normal Saline group|15 mg albuterol in 22 ml of normal saline solution via nebulizer over one hour
3083405|NCT01516008|Experimental|Tapentadol IR 50 mg|
3083406|NCT01516008|Experimental|Tapentadol IR 75 mg|
3083407|NCT01516008|Placebo Comparator|Placebo|
3083408|NCT01516268|Active Comparator|Sufentanyl group|IN case group we add 1cc sufentanyl to 20 cc bupivacain in TAP block
3083409|NCT01516268|Placebo Comparator|Control group|In control group we add 1cc salin to 20cc bupivacain in TAP block
3083410|NCT01516424|Experimental|Blonanserin|Antipsychotics
3083411|NCT01516424|Active Comparator|Risperidone|Antipsychotics
3083412|NCT01516437|Experimental|HNS Group|Healthy non-smokers aged between 45-75 years
3083413|NCT01516437|Experimental|HS Group|Healthy smokers aged between 45-75 years
3083414|NCT01516437|Experimental|FeCOPD Group|COPD subjects with ≥ two exacerbations within 365 days prior to the screening visit (frequent exacerbators), aged between 45-75 years
3083415|NCT01516437|Experimental|NFeCOPD Group|COPD patients with one exacerbation within 365 days prior to the screening visit (non-frequent exacerbators), aged between 45-75 years
3083416|NCT01516632|Experimental|SMS USA|The 6-week smoking cessation intervention
3083417|NCT01516632|No Intervention|Attention matched control|Messages aimed at improving one's sleep and increasing one's fitness, along with general messages about the most well known health dangers of smoking. Messages sent on the same schedule as the intervention group.
3083418|NCT01516684|Experimental|Arm I (EMLA)|Patients receive topical EMLA cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
3083419|NCT01516684|Active Comparator|Arm II (placebo)|Patients receive topical placebo cream 60 minutes to 4 hours prior to the LP followed by standard sedation with fentanyl citrate and propofol.
3083420|NCT01516736|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
3083421|NCT01516736|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
3083422|NCT01516749|Experimental|Anakinra|All patients in this arm will receive the investigation drug anakinra once daily subcutaneously.
3083423|NCT01516879|Experimental|Evolocumab|Participants received evolocumab 420 mg subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
3083424|NCT01516879|Placebo Comparator|Placebo|Participants received placebo subcutaneously once a month for 52 weeks in addition to background lipid-lowering therapy.
3083425|NCT01516892|Experimental|BOTOX®|Participants received 155 U of onabotulinumtoxinA (BOTOX®) approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
3083426|NCT01516957|Experimental|AMG 827 140|140 mg AMG 827
3083427|NCT01516957|Placebo Comparator|Placebo SC|Placebo
3083428|NCT01516957|Experimental|AMG 827 280|280 mg AMG 827
3083429|NCT01516957|Experimental|AMG 827 210|AMG 827 SC 210 mg
3083430|NCT01516970|Experimental|DRV/r with 2 NRTIs|DRV/r 800/100 mg q.d. with 2 NRTIs: darunavir (800 mg) in combination with low-dose ritonavir (100 mg) administered once a day for at least 28 days and a maximum of 30 days along with 2 nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTIs).
3083431|NCT01516970|Active Comparator|Comparator standard of care HIV PEP|Comparator standard of care HIV PEP (as per German-Austrian Guidelines): Administration of the standard of care HIV PEP (postexposure prophylaxis) consisting of 2 NRTIs plus third partner.
3083432|NCT01517074|Experimental|Sirolimus|Participants will receive a15 μL (660 μg) subconjunctival injection of sirolimus in the study eye at baseline if a single quadrant or two adjacent quadrants are involved. If greater than two quadrants are involved (i.e., 3 or 4 quadrant involvement) or two non-adjacent quadrants are involved, two 15 μL (660 μg) injections will be given in two quadrants 180 degrees apart (total dose of 30 μL or 1,320 μg). Participants that still demonstrate active inflammation (incomplete or no response to initial injection) or experience a flare-up (as defined by a ≥1-step increase in scleral inflammation) after the initial injection will be eligible for a re-injection in the study eye at or after Week 4 (not to exceed a dose of 1,320 μg per eye within an eight-week period).
3083433|NCT01517178|Active Comparator|Standard Care base plate|Standard care are the participants own product and can have several manufacture and brand names
3083434|NCT01517178|Experimental|New ostomy base plate (SS)|SS = New ostomy base plate. Due to company confidentiality the product is called SS and this is not short for any name
3083435|NCT01517282|Experimental|MOR103 0.5 mg/kg|6 doses of MOR103 0.5 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3083436|NCT01517282|Experimental|MOR103 1.0 mg/kg|6 doses of MOR103 1.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3083437|NCT01517282|Experimental|MOR103 2.0 mg/kg|6 doses of MOR103 2.0 mg/kg administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3083438|NCT01517282|Placebo Comparator|Placebo|6 doses of placebo administered on Days 1 (Baseline), 15 (Visit 2), 29 (Visit 3), 43 (Visit 4), 57 (Visit 5), and 71 (Visit 6).
3083439|NCT01517295|Experimental|Group 1|Blood will be drawn at 0, 1, 3, and 5 hours after taking one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 3.
3083440|NCT01517295|Experimental|Group 2|Blood will be drawn at 0, 2, 4, and 6 hours after one dose of hydrocodone/APAP. Urine will be taken at hour 0 and 4.
3083441|NCT01517373|Placebo Comparator|Placebo|Placebo to match PF-04937319 and glimepiride
3083442|NCT01517373|Experimental|PF-04937319 10 mg|
3083443|NCT01517373|Experimental|PF-04937319 50 mg|
3083444|NCT01517373|Experimental|PF-04937319 100 mg|
3083445|NCT01517373|Active Comparator|Glimepiride|
3083446|NCT01517412|Experimental|Lixisenatide Main Meal|"Lixisenatide 10 mcg once daily (QD) within 1 hour before main meal of the day for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
3083447|NCT01517412|Active Comparator|Lixisenatide Breakfast|"Lixisenatide 10 mcg QD within 1 hour before breakfast for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24."
3083448|NCT01517529||10 Hepatitis C infected subjects|10 chronically HCV-infected patients who fail the standard peg-IFN and Ribavirin therapy (NR) and are therefore eligible for combined treatment with Protease Inhibitor therapy.
3083450|NCT01517750|Experimental|APAP with humidification|ICON Auto CPAP™ with Thermosmart heated tube
3083451|NCT01517750|Active Comparator|APAP without humidification|ICON Auto CPAP™ without Thermosmart heated tube
3083452|NCT01517867|Experimental|Intervention Chicago Parent Program arm|The Chicago Parent Program is a 12-session group-based parenting skills training program
3083453|NCT01517867|Active Comparator|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually tailored treatment for parents and children with behavior problems
3083454|NCT01517893|Experimental|Intervention arm|Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
3083455|NCT01517893|Placebo Comparator|Placebo Arm|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
3083456|NCT01517984|Experimental|Tacrolimus (CNI) Withdrawal|"Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal."
3083457|NCT01517984|Active Comparator|Standard Immunosuppressive Therapy|"Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.~Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur."
3083458|NCT01518153|Experimental|Low Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
3083459|NCT01518153|Experimental|High Dose Donor T-Cells|Fludarabine 40 mg/m^2 by vein on Day -6 to -3. Melphalan 140 mg/m^2 by vein on Day -2. Alemtuzumab 50 mg by vein on Day -1. Reduced intensity stem cell transplant on Day 0. High Dose Donor T-Cells Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64. Tacrolimus 0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35. Methotrexate 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
3083460|NCT01518192|Active Comparator|1Doxycycline|
3083461|NCT01518192|Active Comparator|2 Cefuroxime axetil|
3083462|NCT01518244|Experimental|AZARGA®|Brinzolamide/timolol maleate fixed combination, 1 drop self-administered in study eye(s) twice a day for 8 weeks
3083463|NCT01518257|Experimental|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
3083464|NCT01518257|Placebo Comparator|Placebo|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
3083465|NCT01518270||Healthy Females|Healthy Females
3083466|NCT01518309|Experimental|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
3083467|NCT01518322||FeNO|All subjects will have their Fractional Exhaled Nitric Oxide (FeNO) measured with the NIOX MINO® device according to instructions for NO measurements.
3083468|NCT01518374|Experimental|Florbetapir-PET Scans|
3083469|NCT01518530|Experimental|Passive Mobilization Cervical Spine|Patients with chronic neck pain according to the International Association of the Study of Pain criteria of the following types: facet joint disorder, post-whiplash injury, myofascial pain syndrome.
3083470|NCT01518699|Experimental|HA44 Abametapir Lotion|Study drug plus positive-control placebo.
3083471|NCT01518699|Placebo Comparator|Placebo|Placebo plus positive-control placebo.
3083472|NCT01518699|Active Comparator|Moxifloxacin|Placebo plus positive control
3083473|NCT01518868|Experimental|Investigational contact lens|multifocal high add soft contact lens
3083474|NCT01518868|Active Comparator|PureVision contact lens|Multi-focal contact lens
3083475|NCT01518946|Active Comparator|Midodrine HCl|
3083476|NCT01518946|Placebo Comparator|Placebo|
3083477|NCT01518972|Experimental|Prazosin|Prazosin medication
3083478|NCT01518972|Placebo Comparator|Placebo|Placebo medication
3083479|NCT01519063|Experimental|Naltrexone and memantine|Treatment with Naltrexone and memantine first
3083480|NCT01519063|Placebo Comparator|Naltrexone and Placebo|Treatment with naltrexone and placebo first
3083481|NCT01519089|Experimental|CP-690,550 10 mg BID|
3083482|NCT01519089|Experimental|CP690,550 5 mg BID|
3083483|NCT01519167|Experimental|Dexmedetomidine|
3083484|NCT01519206|Experimental|Ultherapy treatment|Ulthera System Treatment
3083485|NCT01519245|Experimental|Trial Drug|Solution containing 2 grams tranexamic acid + normal saline
3083486|NCT01519245|Placebo Comparator|Placebo|Normal saline
3083487|NCT01519271|Placebo Comparator|Placebo Patch|
3083488|NCT01519271|Active Comparator|Exelon Patch (rivastigmine transdermal system)|
3083489|NCT01519284|Placebo Comparator|Group 1|Placebo at all the dosing times
3083490|NCT01519284|Experimental|Group 2|"Day 1 to 7:~BIA 9-1067 5 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 5 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
3083491|NCT01519284|Experimental|Group 3|"Day 1 to 7:~BIA 9-1067 15 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 15 mg: 7 AM dose Placebo+ levodopa/carbidopa 100/25 mg: 8 AM dose"
3083492|NCT01519284|Experimental|Group 4|"Day 1 to 7:~BIA 9-1067 30 mg: 7 AM dose Placebo: 8 AM; 4 PM; 12 PM dose~Day 8:~BIA 9-1067 30 mg: 7 AM dose Placebo + levodopa/carbidopa 100/25 mg: 8 AM dose"
3083493|NCT01519284|Experimental|Group 5|"Day 1 to 7:~Placebo: 7 AM dose; Entacapone 200 mg: 8 AM; 4 PM; 12 PM dose~Day 8:~Placebo: 7 AM dose Entacapone 200 mg + levodopa/carbidopa 100/25 mg: 8 AM dose"
3083494|NCT01519323|Experimental|Vemurafenib|Participants received vemurafenib into two separate cohorts with different starting doses based on greater than or equal to (>=)45 kilogram (kg) and other weighing less than (<)45 kg. The starting dose for participants (>=45 kg) was 720 milligram (mg) of vemurafenib by mouth twice daily (BID) and the next dose level for participants in this cohort was 960 mg by mouth BID. The starting dose level for participants weighing <45 kg was to be 480 mg of vemurafenib by mouth BID, but no participants were enrolled into this cohort.
3083495|NCT01519414|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3083496|NCT01519414|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
3083497|NCT01519427|Experimental|Treatment (selumetinib and Akt inhibitor MK2206)|Patients receive selumetinib PO BID on days 1-21 and Akt inhibitor MK2206 PO once weekly.
3083498|NCT01519453|Experimental|Home Based Asthma Education|Families will receive 4 home based and 3 phone based asthma education sessions with a community asthma outreach worker
3083499|NCT01519453|No Intervention|Control|There is no control arm specific intervention
3083500|NCT01519466|Other|Intervention|Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
3083501|NCT01519466|Other|Control|Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
3083502|NCT01519518|Active Comparator|Unfractionated heparin|70 units/kg body weight intravenous
3083503|NCT01519518|Active Comparator|bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
3083504|NCT01519570|Experimental|An informational packet regarding shingles and the HZV|
3083505|NCT01519570|No Intervention|Standard medical care from their primary care physician|
3083506|NCT01519635|Active Comparator|Aliskiren|Aliskiren 150 to 300 mg once a Week for 8 weeks
3083507|NCT01519635|Active Comparator|Hydrochlorothiazide|HCTZ 12.5 - 25 mg/d once a day for 8 weeks
3083508|NCT01519648||Acute leukemia patients|Patients with de novo or relapsed acute myeloid and lymphoid leukemia
3083509|NCT01519648||Allo- or auto- transplant recipients|
3083510|NCT01519661|Experimental|Tobramycin Inhalation Powder (TIP)|Eligible patients were assigned to four capsules of TIP at 28mg dosage strength, inhaled b.i.d. in the morning and in the evening via the T-326 inhaler, for 28 days (on treatment), followed by 28 days of no study treatment (off treatment). Each treatment therefore consisted of 112mg tobramycin (4 capsules of 28mg each) with the total daily dose = 224mg tobramycin (112mg b.i.d.). These 56 days represented 1 cycle of therapy.
3083511|NCT01519674|Active Comparator|BIAsp 30 BID + sitagliptin + metformin|
3083512|NCT01519674|Active Comparator|BIAsp 30 BID + metformin|
3083513|NCT01519674|Active Comparator|BIAsp 30 OD + sitagliptin + metformin|
3083514|NCT01519700|Experimental|EP2006|Eligible patients will be teated with EP2006
3083515|NCT01519700|Active Comparator|Filgrastim|Eligible patients will be teated with Filgrastim
3083516|NCT01519713|Experimental|Adults Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3083517|NCT01519713|Experimental|Adolescents Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3083518|NCT01519713|Experimental|Children Study Group|Participants will receive a single dose of Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate vaccine.
3083519|NCT01519765|Experimental|Buccal misoprostol+placebo vaginal pill|
3083520|NCT01519765|Active Comparator|Vaginal Misoprostol+placebo buccal pill|
3083521|NCT01519778|Experimental|TR-701 FA|
3083522|NCT01519791|Experimental|Certolizumab Pegol + Methotrexate|
3083523|NCT01519791|Placebo Comparator|Placebo + Methotrexate|
3083524|NCT01519817|Experimental|Yeast-Brachyury vaccine|Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
3083525|NCT01519869|Experimental|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
3083526|NCT01519882|Placebo Comparator|Placebo|Placebo Transdermal Patches
3083527|NCT01519882|Experimental|Rotigotine|Rotigotine Transdermal Patches
3083528|NCT01519921|Experimental|PEG-IFN alfa-2a (Treatment naïve)|Eligible treatment naïve participants received peginterferon alfa-2a (PEGASYS) 180 micrograms (mcg) subcutaneously (SC) once weekly for 48 weeks, followed by 24 weeks of treatment-free follow-up.
3083529|NCT01519921|Experimental|PEG-IFN alfa-2a (YMDD mutant)|Eligible tyrosine-methionine-aspartate-aspartate (YMDD) mutant participants received PEGASYS 180 mcg SC once weekly for 48 weeks, followed by 24 weeks of treatment-free follow- up. Participants received lamivudine concomitantly for the initial 12 weeks.
3083530|NCT01519934||Ulthera-treated subjects|All enrolled subjects will have received an Ulthera treatment prior to enrollment.
3083531|NCT01519947|Active Comparator|Pre-dialysis, sea level|Participants received 50-250 mcg SC according to local label.
3083532|NCT01519947|Active Comparator|Dialysis, sea level|Participants received 50-250 mcg SC according to local label.
3083533|NCT01519947|Experimental|Pre-dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
3083534|NCT01519947|Experimental|Dialysis, >1800 meters|Participants received 50-250 mcg SC according to local label.
3083535|NCT01519960|Experimental|A Pegasys|
3083536|NCT01519960|No Intervention|B Untreated Control|
3083537|NCT01519960|Experimental|C Fibrosis non-randomized|
3083538|NCT01519960|Experimental|Switch|
3083539|NCT01520207|Placebo Comparator|Placebo group: (0.9% normal saline)|0.9% saline will be administered (IV) during the hemodialysis session at 1.25mL/kg/hour (max 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
3083540|NCT01520207|Active Comparator|Intervention: intravenous mannitol (20%)|Mannitol will be administered (IV) during the hemodialysis session at a maximum rate of 0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session). Administration will be discontinued 30 minutes before the end of the hemodialysis session.
3083541|NCT01520324|Experimental|Patients with UC undergoing colonoscopy|
3083542|NCT01520363|Active Comparator|Study drug-dextromethorphan (DM)|MECP2 mutation positive subjects randomized to receive DM
3083543|NCT01520363|Placebo Comparator|Placebo group|MECP2 positive subjects randomized to the placebo compound
3083544|NCT01520402|Experimental|Warfarin|Healthy subjects age 18-74 with no medical indication for warfarin therapy, who are free of medications and co-morbid medical conditions with the potential to interfere with warfarin metabolism, and who are willing to follow a fixed vitamin K diet (men 120 micrograms/day, women 90 micrograms/day) are included.
3083545|NCT01520454|Placebo Comparator|Placebo|IV saline with heparin, oral water
3083546|NCT01520454|Experimental|High dose fat solution|Intralipid at high dose, with heparin and PO water
3083547|NCT01520454|Experimental|Low dose fat solution|Low dose IV Intralipid with heparin and PO water
3083548|NCT01520454|Experimental|Oral fat|Oral fat load with IV saline
3083549|NCT01520506|Experimental|Rapid Renal Denervation|
3083550|NCT01520519|Experimental|Rituximab + PCI-32765|Rituximab (375 mg/m2) given intravenously (IV) on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6. PCI-32765 started on Day 2 of cycle 1 at a dose of 420 mg (3 * 140-mg capsules) orally daily and will be continued daily.
3083551|NCT01520532|Other|Ablation|
3083552|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 1|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the lowest of these three doses (dose 1) is 3×10^5 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3083553|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 2|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the middle dose of these three doses (dose 2) is 1×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3083554|NCT01520558|Experimental|CNDO-109-AANK Cells Dose 3|In stage 1, patients will receive one of three doses of CNDO-109-AANK cells, and the highest dose of these three doses (dose 3) is 3×10^6 cells/kg recipient body weight. In stage 2, the MTD will have been determined and all patients will receive either Dose 1, Dose 2 or Dose 3.
3083555|NCT01520688|Experimental|1 Treatment Sequence, FPQ|Period 2 Flovent Diskus Period 4 Pulmicort Flexhaler Period 6 QVAR
3083556|NCT01520688|Experimental|2 Treatment Sequence, FQP|Period 2 Flovent Diskus Period 4 QVAR Period 6 Pulmicort
3083557|NCT01520688|Experimental|3 Treatment Sequence, PFQ|Period 2 Pulmicort Period 4 Flovent Period 6 QVAR
3083558|NCT01520688|Experimental|4-Treatment Sequence, PQF|Period 2 Pulmicort Period 4 QVAR Period 6 Flovent
3083559|NCT01520688|Experimental|5 Treatment Sequence, QFP|Period 2 QVAR Period 4 Flovent Period 6 Pulmicort
3083560|NCT01520688|Experimental|6 Treatment Sequence, QPF|Period 2 QVAR Period 4 Pulmicort Period 6 Flovent
3083561|NCT01520727|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (Opicapone, OPC) - 10 mg
3083562|NCT01520727|Experimental|BIA 9-1067 25 mg|BIA 9-1067 (Opicapone, OPC) - 25 mg
3083563|NCT01520727|Experimental|BIA 9-1067 50 mg|BIA 9-1067 (Opicapone, OPC) - 50 mg
3083564|NCT01520727|Experimental|BIA 9-1067 100 mg|BIA 9-1067 (Opicapone, OPC) - 100 mg
3083565|NCT01520727|Experimental|BIA 9-1067 200 mg|BIA 9-1067 (Opicapone, OPC) - 200 mg
3083566|NCT01520727|Experimental|BIA 9-1067 400 mg|BIA 9-1067 (Opicapone, OPC) - 400 mg
3083567|NCT01520727|Experimental|BIA 9-1067 800 mg|BIA 9-1067 (Opicapone, OPC) - 800 mg
3083568|NCT01520727|Experimental|BIA 9-1067 1200 mg|BIA 9-1067 (Opicapone, OPC) - 1200 mg
3083569|NCT01520727|Placebo Comparator|Placebo|Placebo (PLC): single-dose
3083570|NCT01520870|Experimental|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end. Patients at first recurrence will be enrolled onto 1 of 2 cohorts that will be recruited and analysed independently. Cohort A will include patients who have EGFRvIII mutations. Cohort B will include patients who have EGFR gene amplification but no EGFRvIII mutations.
3083571|NCT01520909|Experimental|Eltrombopag plus standard of care|Part 1, double-blind treatment group
3083572|NCT01520909|Placebo Comparator|Placebo plus standard of care|Part 1, double-blind treatment group
3083573|NCT01520909|Experimental|Eltrombopag plus standard of care (Part 2 open-label)|Part 2, open-label
3083574|NCT01520922|Experimental|Ofatumumab plus bendamustine|In this single arm, Phase II study, each patient who is willing to participate and is found eligible according to the inclusion and exclusion criteria will enter the treatment phase. Eligible subjects will be allocated to receive the following study treatments depending upon their previous CLL treatment status: Subjects with Untreated CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (90 mg/m2, Days 1 and 2; every 28 Days). Subjects with Relapsed CLL: Up to 6 monthly intravenous infusions of Ofatumumab (Cycle 1: 300 mg Day 1 and 1000 mg Day 8; subsequent Cycles: 1000 mg at Day 1 every 28 days) in combination with up to 6 Cycles of intravenous infusions of bendamustine (70 mg/m2, Days 1 and 2; every 28 Days).
3083575|NCT01520987|Experimental|Caucasian 5 mg OPC|OPC, opicapone, BIA 9-1067
3083576|NCT01520987|Experimental|Caucasian 25 mg OPC|OPC, opicapone, BIA 9-1067
3083577|NCT01520987|Experimental|Caucasian 50 mg OPC|OPC, opicapone, BIA 9-1067
3083578|NCT01520987|Placebo Comparator|Caucasian Placebo|Placebo, PLC
3083579|NCT01520987|Experimental|Japanese 5 mg OPC|OPC, opicapone, BIA 9-1067
3083580|NCT01520987|Experimental|Japanese 25 mg OPC|OPC, opicapone, BIA 9-1067
3083581|NCT01520987|Experimental|Japanese 50 mg OPC|OPC, opicapone, BIA 9-1067
3083582|NCT01520987|Placebo Comparator|Japanese Placebo|Placebo, PLC
3083583|NCT01521026|Experimental|Cognitive Training|Cognitive training group
3083584|NCT01521026|No Intervention|Standard Pharmacotherapy|
3083585|NCT01521117|Experimental|Donepezil, Then Placebo|Donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6. After a washout period of 4 weeks, placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.
3083586|NCT01521117|Experimental|Placebo, Then Donepezil|"Placebo 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6.~After a washout period of 4 weeks, donepezil 5 mg a day for weeks 1 - 3, if tolerated increased to 10 mg a day for weeks 4 - 6."
3083587|NCT01521260|Placebo Comparator|Placebo group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
3083588|NCT01521260|Active Comparator|Chlorhexidine group|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
3083589|NCT01521364|Other|0mg, 250mg, and 500mg claritromycin|"Patients receive 300mg linezolid twice a day during entire study. After one week, 250mg claritromycin once daily is added for a duration of two weeks.~After another two weeks, 250mg claritromycin is replaced by 500mg claritromycin once daily for another two weeks.~After this, there is a wash-out period of one week during which no claritromycine is administered."
3083590|NCT01521494|Experimental|PA21 750 mg/day|
3083591|NCT01521494|Experimental|PA21 1500 mg/day|
3083592|NCT01521494|Experimental|PA21 2250 mg/day|
3083593|NCT01521494|Experimental|PA21 3000 mg/day|
3083594|NCT01521494|Placebo Comparator|Placebo|
3083595|NCT01521507|Experimental|LipiFlow System|Treatment with LipiFlow System at randomization in Stage 1 of study
3083596|NCT01521507|Active Comparator|Warm Compress and Lid Hygiene|Control group receiving warm compress therapy and lid hygiene at randomization in Stage 1 of study and crossover LipiFlow System treatment in Stage 2 of study
3083597|NCT01521546|Active Comparator|eplerenone|active study drug
3083598|NCT01521546|Placebo Comparator|sugar pill|placebo
3083599|NCT01521559|Sham Comparator|Macular Laser Photocoagulation Treatment (Control)|Participants will receive macular laser treatment at Baseline and then according to laser re-treatment criteria up to week 24. Participants will receive treatment with Intravitreal Aflibercept Injection (IAI) starting at week 24 if they met rescue criteria. Treatment with IAI once initiated was 3 initial monthly doses followed by Q8 week dosing.
3083600|NCT01521559|Experimental|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) 2Q4|Participants will receive 2 milligrams (mg) Intravitreal Aflibercept Injection (IAI) every 4 weeks (2Q4) through week 24 followed by injections every 8 weeks (2Q8) through week 48. Participants in this group may receive laser rescue at week 36.
3083601|NCT01521780|Experimental|Imaging|Magnetic resonance imaging (MRI) of HCC tumor.
3083602|NCT01521780|Experimental|Pathology|Pathology samples from surgical resection of HCC tumor and adjacent liver.
3083603|NCT01521780|Experimental|Imaging/Pathology|MRI of HCC tumor, followed by pathology samples from surgical resection of HCC tumor and adjacent liver.
3083604|NCT01521845|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
3083605|NCT01521845|No Intervention|control|This group is without omega 3 : just receives standard treatment
3083606|NCT01521871|Experimental|Tissue glue wound closure|Skin wound closure by tissue glue
3083607|NCT01521871|Active Comparator|Conventional suture + dressing|Skin wound closure by conventional suture + dressing
3083608|NCT01521884||RA Patients treated with SC anti-TNF|
3083609|NCT01521897||7-valent vaccine injection|Infants starting to receive Prevenar at the age of more than 2 and less than 7 months
3083610|NCT01521923|Experimental|CZP 200 mg Q2W + Methotrexate|
3083611|NCT01521923|Experimental|CZP 200 mg Q4W + Methotrexate|
3083612|NCT01521923|Placebo Comparator|Placebo + Methotrexate|
3083613|NCT01521949|Experimental|Acai Juice|2 ounces of Acai Juice Product by mouth twice daily.
3083614|NCT01522131|Other|Bioresorbable membrane will be used as the control|Bioresorbable membrane alone (control)
3083615|NCT01522131|Experimental|laser with bioresorabable membrane (test)|
3083616|NCT01522235|Active Comparator|IVIg group|Double blinded IVIg and single blinded IVIg
3083617|NCT01522235|Other|Placebo Group|Double blinded Placebo and single blinded IVIg
3083618|NCT01522248|Active Comparator|Cohort 1|receives vaccine in morning. Blood drawn at 3, 7, 24, and 48 hours and 14 days after vaccination.
3083619|NCT01522248|Active Comparator|Cohort 2|receives vaccine in evening, Blood drawn 16, 40 hours and 14 days after vaccination.
3083620|NCT01522339|Experimental|Safety of a Customized NICU MRI System|Device: GE OPTIMA MR430s with HDX/GE Electronics
3083621|NCT01522391|Placebo Comparator|Placebo for DPK-060 ointment|
3083622|NCT01522391|Experimental|DPK-060 1% ointment|
3083623|NCT01522404|Experimental|Atomoxetine / Inactive Compound|Participants in this arm received atomoxetine, starting with 10 mg po daily and increasing weekly by increments to a maximum of 100 mg po daily or the maximum tolerated dose for up to weeks 29 and are then crossed over to Inactive compound group
3083624|NCT01522404|Placebo Comparator|Inactive compound / Atomoxetine|Subjects in this arm received a matching placebo that have inactive compound for up to weeks 29 and then are crossed over to receive active treatment of Atomoxetine
3083625|NCT01522417|Experimental|Short Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
3083626|NCT01522417|Active Comparator|Eptifibatide (Integrilin)|"Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.~Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
3083627|NCT01522417|Experimental|Long Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion for 12 to 18 hours post PCI.~Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines)."
3083628|NCT01522443|Experimental|Cabozantinib|"Subjects randomized to the cabozantinib arm will also receive placebo mitoxantrone injections (color-matched with methylene blue) and placebo prednisone capsules.~There will be a maximum of 10 infusions for mitoxantrone placebo."
3083629|NCT01522443|Active Comparator|Mitoxantrone/prednisone|"Subjects randomized to the mitoxantrone + prednisone arm will also receive placebo cabozantinib tablets.~There will be a maximum of 10 infusions for mitoxantrone."
3083630|NCT01522456|Active Comparator|Epiduo Gel|Adapalene 0.1% and benzoyl peroxide 2.5% gel
3083631|NCT01522456|Active Comparator|Retin-A Micro Microsphere 0.1%|Tretinoin gel, 0.1%
3083632|NCT01522651|Placebo Comparator|Placebo|Ranolazine placebo plus dronedarone placebo for 12 weeks.
3083633|NCT01522651|Experimental|Ranolazine 750 mg|Ranolazine 750 mg plus dronedarone placebo for 12 weeks.
3083634|NCT01522651|Experimental|Dronedarone 225 mg|Ranolazine placebo plus dronedarone 225 mg for 12 weeks.
3083635|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 225 mg|Ranolazine 750 mg plus dronedarone 225 mg for 12 weeks.
3083636|NCT01522651|Experimental|Ranolazine 750 mg + Dronedarone 150 mg|Ranolazine 750 mg plus dronedarone 150 mg for 12 weeks.
3083637|NCT01522703|Experimental|Broccoli Sprouts|Broccoli Sprout sandwich/wrap will be eaten daily for 3 consecutive days
3083638|NCT01522703|Placebo Comparator|Alfalfa Sprouts|Alfalfa Sprouts will be eaten daily in a sandwich form for 3 consecutive days
3083639|NCT01522755||Patients implanted with the CapsureFix MRI pacing lead|Patients implanted with the CapsureFix MRI pacing lead model 5086
3083640|NCT01522924|Experimental|Counseling practice sessions|Dental students will be administered the first questionnaire before receiving a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients, and debriefing session.
3083641|NCT01522924|No Intervention|Lecture only|Students will receive the first questionnaire before the lecture and the second questionnaire after the lecture
3083642|NCT01522937|Experimental|Liver cancer patients|The aim of this study is to determine the safety and effectiveness of individualized Stereotactic Body Radiation Therapy (SBRT) in patients who either (1) have had previous liver treatments, and/or (2) have primary hepatocellular carcinoma (HCC).
3083643|NCT01522950|Active Comparator|Nebivolol|5 mg, continue for 1 month; dose titration to 10 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
3083644|NCT01522950|Active Comparator|Atenolol|25 mg, continue for 1 month; dose titration to 50 mg, continue for 8 months. Dose may be returned to initiation levels if side effects occur.
3083645|NCT01522950|Placebo Comparator|Placebo|"Continue for 1 month; dose titration to high dose placebo, continue for 8 months. Dose may be returned to initiation levels if side effects occur."
3083646|NCT01522963|Experimental|Nicotine Lozenge Immediately Prior to Stress task|Subjects will receive the nicotine lozenge immediately prior to the stress task at one laboratory session and after the stress task at the other laboratory session
3083647|NCT01522963|Experimental|Nicotine lozenge 10 Minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and immediately prior to the stress task at the other laboratory session
3083648|NCT01522963|Experimental|Nicotine lozenge 20 minutes prior to Stress task|Subjects will receive the nicotine lozenge after the stress task during one laboratory session and 10 minutes prior to the stress task at the other laboratory session
3083649|NCT01522963|Experimental|Nicotine Lozenge 30 minutes prior to stress taks|Subjects will receive the nicotine lozenge 10 minutes prior to the stress task during one laboratory session and after the stress task at the other laboratory session
3083650|NCT01523275|Experimental|Mitomycin-C|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
3083651|NCT01523275|Placebo Comparator|Saline|Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.
3083652|NCT01523301|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3083653|NCT01523301|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3083654|NCT01523366|Experimental|Ticagrelor|
3083655|NCT01523366|Active Comparator|Clopidogrel|
3083656|NCT01523392|Experimental|Ticagrelor|
3083657|NCT01523392|Active Comparator|Clopidogrel|
3083658|NCT01523457|Experimental|MPC modified FOLFIRINOX|Patients with metastatic pancreatic cancer (MPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
3083659|NCT01523457|Experimental|LAPC modified FOLFIRINOX|Patients with locally advanced pancreatic cancer (LAPC) were treated with modified FOLFIRINOX every 2 weeks as follows: oxaliplatin 85 mg m 2 infused over 120 min, immediately followed by folinic acid 400 mg m 2 infused over 120 min with the addition, after 30 min, of irinotecan 135 mg m 2 infused over 90 min, followed by 5FU 300 mg m 2 IV bolus, followed by 2400 mg m 2 continuous infusion for 46 h (25% reduction in bolus 5FU and irinotecan doses). All patients received pegylated filgrastim with each cycle on day 3 or 4 in the absence of severe leukocytosis. All patients routinely received palonosetron, aprepitant and dexamethasone for emesis prophylaxis.
3083660|NCT01523496|Active Comparator|HIV + Young Adults|All will be HIV+ and receiving randomized dose of vitamin D control dose (low dose) or supplementation dose (vitamin D medium dose or vitamin D high dose)
3083661|NCT01523496|Active Comparator|HIV - Controls|HIV negative controls will be receiving randomized Vitamin D doses: control vitamin D dose (low dose) or vitamin D supplementation dose (vitamin D medium dose or vitamin D high dose)
3083662|NCT01523587|Experimental|Afatinib|Patients receive afatinib tablets once daily
3083663|NCT01523587|Active Comparator|Erlotinib|Patients receive erlotinib tablets once daily
3083664|NCT01523613|Active Comparator|ROCK - Single Restorations|ChemFil Rock glassionomer restoration
3083665|NCT01523613|Active Comparator|Fuji IX GP - Single Restorations|Fuji IX GP Extra glassionomer restoration
3083666|NCT01523613|Active Comparator|Rock AND Fuji - Paired Restorations|"ChemFil Rock glassionomer restoration AND Fuji IX GP Extra glassionomer restoration.~While this is not truly a separate arm for outcome analysis, this arm represents those individuals who had paired restorations, one of each: 1 ChemFil Rock restoration and 1 Fuji IX GP restoration."
3083667|NCT01523704|Experimental|Home Monitoring(HM)|Patients assigned to HM Group(HM follow-up ONLY) will have Home Monitoring programmed ON. They will be seen in the office for device interrogations at the 3-month follow-up, and at 27 month follow-up. In the meanwhile the device status will be evaluated using HM only for the 9, 15 and 21 month scheduled follow-up. Patients will visit the hospital for device interrogation on 27 month final follow-up.
3083668|NCT01523704|Active Comparator|Control|Patients assigned to Control Group (HM + Conventional In-office follow-up - Control group) will have HM programmed ON. In addition to HM, these patients will visit the hospital for device interrogation at 3, 9, 15, 21 and 27 month follow-ups.
3083669|NCT01523743|Experimental|Compact catheter|Compact intermittent catheter
3083670|NCT01523743|Active Comparator|Standard Care|Standard Care: Coated intermittent catheter normally used by subject
3083671|NCT01523756|Experimental|test product 1 first|"own product (baseline) - test product 1 - test product 2~test product 1 = New ostomy base plate. Due to company confidentiality the product is just called test product 1"
3083672|NCT01523756|Experimental|test product 2 first|"own product (baseline) - test product 2 - test product 1~test product 2 = New ostomy base plate. Due to company confidentiality the product is just called test product 2"
3083673|NCT01523782|Experimental|GRASPA 50 IU/kg|Each patient will receive GRASPA 50 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase.
3083674|NCT01523782|Experimental|GRASPA 100 IU/kg|Each patient will receive GRASPA 100 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
3083675|NCT01523782|Experimental|GRASPA 150 IU/kg|Each patient will receive GRASPA 150 IU/kg at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
3083676|NCT01523808|Experimental|GRASPA 25|
3083677|NCT01523808|Experimental|GRASPA 50|
3083678|NCT01523808|Experimental|GRASPA 100|
3083679|NCT01523808|Experimental|GRASPA 150|
3083680|NCT01523821|Other|Cohort 1 (30 mg/kg)|Alpha 1 anti-trypsin (AAT) will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 30mg/kg (maintenance dose) every other day (QOD) on days 3, 5, 7, 9, 11, 13 & 15.
3083681|NCT01523821|Other|Cohort 2 (60 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg (loading dose) on day 1 followed by 60 mg/kg (maintenance dose) QOD on days 3, 5, 7, 9, 11, 13 & 15.
3083682|NCT01523821|Other|Cohort 3 (90 mg/kg)|AAT will be administered intravenously at a dose of 90 mg/kg on days 1, 3, 5, 7, 9, 11, 13 & 15.
3083683|NCT01523834|Experimental|Panobinosat|"The treatment is divided in three phases: induction phase (course 1 to 6), consolidation phase (courses 7 to 12), maintenance phase (from course 13 until the end of therapy for any reason). The duration of a treatment course will be 28 days. The first dose of panobinostat in course 1 defines day 1 of the treatment cycle, and each cycle thereafter will begin 28 days later.~Treatment:~Panobinostat should be taken p.o. at the dose of 40 mg/day three-times every week (QW) (e.g., on Monday, Wednesday, and Friday or Tuesday, Thursday, and Saturday), as part of a 4 week (28 days) treatment cycle."
3083684|NCT01523886|Active Comparator|Deep neuromuscular blockade|
3083685|NCT01523886|Placebo Comparator|Moderate neuromuscular blockade|
3083686|NCT01523899|Experimental|Xpert MRSA/SA SSTI|use of the Xpert MRSA/SSTI diagnostic assay
3083687|NCT01523899|Active Comparator|Standard culture|performance of standard bacterial culture of abscess material
3083688|NCT01523964|Other|DMD subject ages 3-7 inclusive|Young DMD Testing with EIM
3083689|NCT01523964|Other|DMD subject ages 8-12 inclusive|Older DMD Testing with EIM
3083690|NCT01523964|Other|Healthy Control ages 3-7 inclusive|Young Healthy Testing with EIM
3083691|NCT01523964|Other|Healthy Control ages 8-12 inclusive|Older Healthy Testing with EIM
3083692|NCT01524133|Active Comparator|Sertraline + enhanced medication management (SERT/EMM)|24 weeks of sertraline + enhanced medication management
3083693|NCT01524133|Active Comparator|Prolonged Exposure + sertraline (PE/SERT)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
3083694|NCT01524133|Active Comparator|Prolonged Exposure + placebo (PE/PLB)|Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
3083695|NCT01524198|Placebo Comparator|Normal Saline|Subjects who are receiving normal saline (NS) in addition to Albuterol 2.5 mg if < 20 kg or 5 mg if >= 20 kg body weight and ipratropium bromide (IB) 250 mcg; 3 nebulizations back to back
3083696|NCT01524198|Active Comparator|Budesonide|Subjects with acute asthma exacerbation who receive Budesonide 500 mcg, in addition to Albuterol 2.5 mg if < 20 kg body weight or 5 mg if >= 20 kg body weight and Ipratropium Bromine (IB) 250 mcg; 3 nebulization doses back to back
3083697|NCT01524224|Experimental|LY2495655|"Administered intravenously (IV) every 2 weeks (14 days) for four (4) 14 day cycles. Participants receiving clinical benefit may continue to receive treatment until one or more of the discontinuation criteria are met.~Starting dose in Part 1 (dose escalation) will be 2 mg. The dose will be subsequently increased to 7 mg, 21 mg, 70 mg, 210 mg, and 700 mg. The dose administered in Part 2 (dose confirmation) will be determined from Part 1."
3083698|NCT01524289|Experimental|Anacetrapib|Participants were administered one tablet of 100 mg anacetrapib orally once daily with a meal for 52 weeks during the treatment period.
3083699|NCT01524289|Placebo Comparator|Placebo|Participants were administered one matching placebo tablet orally once daily with a meal for 52 weeks during the treatment period.
3083700|NCT01524302|Active Comparator|Levofloxacin|Pharmacodynamics
3083701|NCT01524302|Active Comparator|Ceftaroline|Pharmacodynamics
3083702|NCT01524627|Placebo Comparator|Control Group|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
3083703|NCT01524627|Active Comparator|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
3083704|NCT01524679|Experimental|Treatment group|pegylated interferon alfa-2a (Pegasys®) 180 μg once weekly for 48 weeks added to an ongoing nucleos(t)ide based treatment in patients with chronic HBeAg-negative hepatitis B
3083705|NCT01524679|No Intervention|Control group|ongoing nucleos(t)ide based treatment alone
3083706|NCT01524692|Experimental|Single ARM Dovitinib treatment|Single ARM Dovitinib treatment
3083707|NCT01524770|Active Comparator|Manual syringe|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by manual syringe in one of two study periods separated by a 28-day minimum washout period.
3083708|NCT01524770|Experimental|Auto-injector|Dulaglutide: Single dose of 1.5 milligrams (mg) dulaglutide administered subcutaneously (SC) by auto-injector in one of two study periods separated by a minimum 28-day washout period
3083709|NCT01524783|Experimental|Everolimus + BSC|Participants received everolimus 10 mg once daily plus best supportive care (BSC) throughout the study
3083710|NCT01524783|Placebo Comparator|Placebo + BSC|Participants received matching placebo once daily plus best supportive care (BSC) during the blinded period. Participants were allowed to crossover to treatment with everolimus 10mg once daily plus BSC during the open-label period.
3083711|NCT01524796||Patients with peripheral neuropathic pain treated with Lyrica|
3083712|NCT01524887|Experimental|IGIV, 10% at high dose (0.4 g/kg)|
3083713|NCT01524887|Experimental|IGIV, 10% at low dose (0.2 g/kg)|
3083714|NCT01524887|Placebo Comparator|Placebo control|
3083715|NCT01524900||nevirapine extended release|
3083716|NCT01524913|Experimental|Hyaluronic acid|
3083717|NCT01524913|Active Comparator|Corticosteroid|
3083718|NCT01524913|Placebo Comparator|Saline|
3083719|NCT01524978|Experimental|Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - vemurafenib|Participants with NSCLC will be treated with vemurafenib monotherapy.
3083720|NCT01524978|Experimental|Cohort 2: Ovarian Cancer - vemurafenib|Participants with ovarian cancer will be treated with vemurafenib monotherapy.
3083721|NCT01524978|Experimental|Cohort 3a: Colorectal Cancer - vemurafenib|Participants with colorectal cancer will be treated with vemurafenib monotherapy.
3083722|NCT01524978|Experimental|Cohort 3b: Colorectal Cancer - vemurafenib + cetuximab|Participants with colorectal cancer will be treated with vemurafenib and cetuximab combination therapy.
3083723|NCT01524978|Experimental|Cohort 4: Cholangiocarcinoma - vemurafenib|Participants with cholangiocarcinoma will be treated with vemurafenib monotherapy.
3083724|NCT01524978|Experimental|Cohort 6: Multiple Myeloma - vemurafenib|Participants with multiple myeloma will be treated with vemurafenib monotherapy.
3083725|NCT01524978|Experimental|Cohort 7: Other Solid Tumors - vemurafenib|Participants with Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), anaplastic thyroid cancer, advanced stage astrocytoma, early stage astrocytoma and other BRAF V600-positive tumors will be treated with vemurafenib monotherapy. Subcohorts will be analyzed separately if 7 or more participants are enrolled for each indication.
3083726|NCT01524991|Experimental|Treatment|Gemcitabine 1000 mg/m2 Days 1 & 8 Cisplatin 70 mg/m2 Day 1 Ipilimumab 10 mg/kg Day 1 (start cycle 3)
3083727|NCT01525082|Experimental|Bevacizumab + Capecitabine + Temozolomide|Cycles repeat every 28 days until disease progression, unacceptable toxicity, or withdrawal.
3083728|NCT01525173|Active Comparator|ALPHAGAN® P and LUMIGAN®|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
3083729|NCT01525173|Active Comparator|LUMIGAN® Alone|1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
3083730|NCT01525225|Experimental|Metformin + Saxagliptin + Saxagliptin/Metformin XR FDC|
3083731|NCT01525238|Experimental|Dapagliflozin 2.5 mg|
3083732|NCT01525238|Experimental|Dapagliflozin 5 mg|
3083733|NCT01525238|Experimental|Dapagliflozin 10 mg|
3083734|NCT01525329|Experimental|Solid Organ Transplant with AKs|Patients who have undergone kidney or liver transplant within 2 years and have at least 4 premalignant skin lesions on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
3083735|NCT01525329|Active Comparator|Actinic Keratoses|Patients with at least 4 actinic keratoses on the face, ears, scalp, forearms and/or dorsal hands. Patients will serve as their own control, and one side of the body will be randomized to either 5-FU plus PDT, and the other will receive PDT alone.
3083736|NCT01525407|Experimental|Supportive care (donor statin treatment)|Donors receive atorvastatin calcium PO beginning on day -14 and continuing until the last day of stem cell collection.
3083737|NCT01525420|Experimental|ACT|ACT: This is the experimental arm of the study. This included 5 weekly sessions of ACT therapy via telephone.
3083738|NCT01525420|Active Comparator|CBT|CBT: This is the control arm of the study. This included 5 weekly sessions of CBT therapy via telephone.
3083739|NCT01525550|Experimental|sunitinib|
3083740|NCT01525563||Subjects with irregular Menstrual cycle|Adult subjects with irregular menstrual cycle and can be treated with Duphaston as per locally approved label can be enrolled.
3083741|NCT01525589|Experimental|PM01183|
3083742|NCT01525602|Experimental|Part 1|"Open-label, sequential PLX3397 single-agent dose escalation in combination with paclitaxel in approximately 30 patients with advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
3083743|NCT01525602|Experimental|Part 2|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients in advanced solid tumors. Enrollment completed.~(Closed to recruitment)"
3083744|NCT01525602|Experimental|Part 3|"Extension cohort at the RP2D of single-agent PLX3397 in combination with paclitaxel in approximately 30 patients with advanced, metastatic, or non-resectable, platinum-resistant or -refractory epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.~(Closed to recruitment)"
3083745|NCT01525615|Experimental|tiotropium+olodaterol low dose|once daily 2 puffs, fixed dose combination (FDC) solution for inhalation Respimat
3083746|NCT01525615|Experimental|tiotropium+olodaterol high dose|once daily 2 puffs, FDC solution for inhalation Respimat
3083747|NCT01525615|Placebo Comparator|placebo|once daily 2 puffs, solution for inhalation Respimat
3083748|NCT01525628|Experimental|Group A|Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
3083749|NCT01525628|Experimental|Group B|Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
3083750|NCT01525628|Experimental|Group C|Effect of Dual oral DAAs on tenofovir
3083751|NCT01525628|Experimental|Group D|Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
3083752|NCT01525628|Experimental|Group E|Effect of BI 201335 and BI 207127 on raltegravir
3083753|NCT01525641||Patient with Parkinson's Disease|
3083754|NCT01525667|Experimental|150M PLX-PAD|Single course, multiple IM injections
3083755|NCT01525667|Experimental|300M PLX-PAD|Single course, multiple IM injections
3083756|NCT01525667|Placebo Comparator|Placebo|Single course, multiple IM injections
3083757|NCT01525849|Active Comparator|Balloon Sinus Dilation|XprESS Multi-Sinus Dilation Balloon, FinESS Sinus Treatment
3083758|NCT01525849|Active Comparator|Functional Endoscopic Sinus Surgery|Traditional endoscopic sinus surgery (maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy) using cutting, grasping, and microdebrider tools.
3083759|NCT01525862|Experimental|Balloon sinus dilation|Balloon dilation of the maxillary sinus using a transnasal approach.
3083760|NCT01525875|Active Comparator|Magnesium oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
3083761|NCT01525875|Placebo Comparator|Placebo|Part 1: 1000 mg (one 500 mg capsule two times daily) of placebo.
3083762|NCT01526057|Experimental|A - PF-05280586|
3083763|NCT01526057|Active Comparator|B - Rituximab EU|
3083764|NCT01526057|Active Comparator|C- Rituximab-US|
3083765|NCT01526148|Active Comparator|Lithium|
3083766|NCT01526148|Active Comparator|Quetiapine|
3083767|NCT01526213|Other|Sequence 1: Water, GFJ, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083768|NCT01526213|Other|Sequence 2: Water, FC-free GFJ, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083769|NCT01526213|Other|Sequence 3: GFJ, FC-free GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083770|NCT01526213|Other|Sequence 4: GFJ, Water, FC-free GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083771|NCT01526213|Other|Sequence 5: FC-free GFJ, GFJ, Water|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083772|NCT01526213|Other|Sequence 6: FC-free GFJ, Water, GFJ|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice (GFJ), or furanocoumarin (FC)-free grapefruit juice.
3083773|NCT01526343|Experimental|Reveal XT|
3083774|NCT01526356|Placebo Comparator|Placebo|Cream only
3083775|NCT01526356|Active Comparator|0.1 % Rapamycin|0.1% Rapamycin cream
3083776|NCT01526356|Active Comparator|1% Rapamycin|1% Rapamycin cream
3083777|NCT01526538|Experimental|50 mg d-cycloserine|active drug condition
3083778|NCT01526538|Placebo Comparator|Sugar pill|Inactive placebo
3083779|NCT01526551|Experimental|Intervention Schools|High school students attending Wayne County and Monticello Ind. schools will be given opportunity to receive HPV Vaccine and HPV-related Health Education and Reduction of barriers to being vaccinated.
3083780|NCT01526577|Experimental|LC23-1306|experimental drug
3083781|NCT01526577|Placebo Comparator|placebo|LC23-1306 placebo
3083782|NCT01526577|Active Comparator|Ticagrelor|active comparator
3083783|NCT01526629||ICD patients with remote follow-up|Patients implanted with a fully automatic ICD and remotely followed-up.
3083784|NCT01526733|Sham Comparator|Insulin (Aspart or Lispro)-Sham|"In Phase I or Phase II of the study, participants received 0.15 units per kilogram (U/kg) insulin (either insulin aspart or insulin lispro) as a continuous subcutaneous insulin infusion (CSII) for 16 days, with sham injections administered prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16.~Each Phase was separated by a washout period of 5 to 21 days."
3083785|NCT01526733|Experimental|Insulin (Aspart or Lispro)-rHuPH20|"In Phase I or Phase II of the study, participants received 0.15 U/kg insulin (either insulin aspart or insulin lispro) as a CSII for 16 days. Prior to outpatient euglycemic clamps on Days 1 and 4 and prior to outpatient meal test procedures on Days 7, 10, 13, and 16, participants received a 1 mL (150 U) injection of recombinant human hyaluronidase (rHuPH20).~Each Phase was separated by a washout period of 5 to 21 days."
3083786|NCT01526785|Experimental|Alglucosidase alfa|Alglucosidase alfa (4000 L scale) intravenous (IV) infusion administered for 52 weeks as per physician's routine practice.
3083787|NCT01526889|Experimental|LFG316 -Intravitreal Injection|
3083788|NCT01526889|Active Comparator|Conventional Therapy|
3083789|NCT01526902|Active Comparator|omafilcon A / PC 1-D MF|"omafilcon A (PC 1-D MF) / lotrafilcon B (AIR OPTIX MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
3083790|NCT01526902|Active Comparator|lotrafilcon B / Air Optix MF|"lotrafilcon B (AIR OPTIX MF) / omafilcon A (PC 1-D MF)~Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses."
3083791|NCT01526928|Experimental|Rociletinib <900 mg BID FB formulation|Rociletinib free base (FB) dose <900 mg twice a day (BID)
3083792|NCT01526928|Experimental|Rociletinib 900 mg BID FB formulation|Rociletinib free base (FB) dose 900 mg twice a day (BID)
3083793|NCT01526928|Experimental|Rociletinib 500 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 500 mg twice a day (BID)
3083794|NCT01526928|Experimental|Rociletinib 625 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 625 mg twice a day (BID)
3083795|NCT01526928|Experimental|Rociletinib 750 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 750 mg twice a day (BID)
3083796|NCT01526928|Experimental|Rociletinib 1000 mg BID HBr formulation|Rociletinib hydrobromide (HBr) dose 1000 mg twice a day (BID)
3083797|NCT01527006|Experimental|perampanel|Age Cohort 1 ( greater than or equal to 7 to less than 12 years of age at time of consent/assent) and age Cohort 2 ( greater than or equal to 2 to less than 7 years of age).
3083798|NCT01527045|Experimental|Prevention (donor statin treatment)|See Detailed Description
3083799|NCT01527110|Experimental|Intravenous (IV) zanamivir 600mg twice daily|600mg of IV zanamivir infusion twice daily
3083800|NCT01527149|Experimental|Treatment (monoclonal antibody and combination chemotherapy)|"COURSES 1, 3, and 5 (O-HyperCVAD): Patients receive ofatumumab IV on day 1, cyclophosphamide IV over 2 hours every 12 hours for 6 doses on days 3-5, doxorubicin hydrochloride IV continuously over 72 hours on days 6-8, vincristine sulfate IV on days 6 and 13, and dexamethasone IV or PO on days 3-6 and 13-16.~COURSES 2, 4, and 6 (O-HD-MA): Patients receive ofatumumab IV on day 1, methotrexate IV continuously over 24 hours on day 3, and cytarabine IV over 2 hours every 12 hours on days 4-5.~All courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Eligible patients then undergo standard HDC-ASCT."
3083801|NCT01527162|Experimental|SAFO worn|Child wears their prescribed SAFO for 14 days
3083802|NCT01527162|No Intervention|SAFO not worn|Child does not wear the prescribed SAFO for 14 days
3083803|NCT01527357|Experimental|Fibrocaps + Gelatin Sponge|Single application of Fibrocaps plus gelatin sponge.
3083804|NCT01527357|Active Comparator|Gelatin Sponge|Single application of gelatin sponge alone.
3083805|NCT01527370|Experimental|Zoster Vaccine Live|
3083806|NCT01527383|Experimental|V212|Participants receive V212 as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3083807|NCT01527383|Placebo Comparator|Placebo|Participants receive placebo as a 0.5 mL subcutaneous injection in a four-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
3083808|NCT01527487|Experimental|Eribulin+Cyclophosphamide (ErC)|"Eribulin (Er): 1.4mg/m2 IV (Days 1 and 8) given short (≤1.5 minutes) IV infusion, per institutional standard~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
3083809|NCT01527487|Experimental|Docetaxel+Cyclophosphamide (TC)|"Docetaxel (T): 75 mg/m2 IV (Day 1), given by 1-hour IV infusion~Cyclophosphamide (C): 600 mg/m2 IV (Day 1), given by IV infusion, per institutional standard"
3083810|NCT01527500|Experimental|LFG316 higher dose|LFG316 10 mg/100 μL
3083811|NCT01527500|Sham Comparator|Sham|Sham injection
3083812|NCT01527500|Experimental|LFG316 lower dose|LFG316 5 mg/ 50 μL
3083813|NCT01527513|Experimental|Eslicarbazepine acetate (BIA 2-093)|
3083814|NCT01527513|Placebo Comparator|Placebo|
3083815|NCT01527682|Other|Latanoprost, Dorzolamide|According to intraocular (IOP) assessment, the eye will receive Latanoprost, Dorzolamide or both.
3083816|NCT01528033|Experimental|Vacuum Assisted Closure®|Negative pressure wound therapy
3083817|NCT01528033|Active Comparator|Standard conventional wound therapy|According to institutional clinical standards
3083818|NCT01528072|Experimental|Dynesys System|All patients will receive the Dynesys System and all patients will be compared to historical literature control. Dynesys Spinal System will be used for all subjects.
3083819|NCT01528124|Placebo Comparator|Placebo|0.9% sodium chloride given as a single subcutaneous injection
3083820|NCT01528124|Experimental|LY3025876|Single escalating doses of LY3025876 given as subcutaneous injections
3083821|NCT01528150||Accent MRI System|Accent MRI system will be implanted = Accent MRI Pacemaker + Tendril MRI Leads
3083822|NCT01528215|Experimental|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
3083823|NCT01528215|Active Comparator|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
3083824|NCT01528228|Active Comparator|Structured TENS Therapy|This group will be given an active TENS unit to use.
3083825|NCT01528228|Sham Comparator|Sham TENS Therapy|This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
3083826|NCT01528254|Active Comparator|Vilda 50mg bid + metformin|Metformin + vildagliptin
3083827|NCT01528254|Experimental|Placebo + metformin|Metformin + Placebo of vildagliptin
3083828|NCT01528319|Experimental|MG-1|Arthroscopic Bankart repair is applied for glenohumeral instability using MG-1
3083829|NCT01528332|Experimental|Pain Relief Patch|Pain Relief Patch: Light wavelength 453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm², 30 minutes
3083830|NCT01528332|Active Comparator|Control PRP device|Control PRP device: Light wavelength 531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm², light on for 5 seconds, device worn for 30 minutes
3083831|NCT01528345|Experimental|Fulvestrant + Dovitinib active|Fulvestrant in combination with the study drug Dovitinib.
3083832|NCT01528345|Placebo Comparator|Fulvestrant + Dovitinib placebo|Fulvestrant in combination with a placebo matching Dovitinib.
3083833|NCT01528592|Experimental|On / Off medication|Subjects undergo MRI scanning in the medication off state and 1 hour after receiving medications.
3083834|NCT01528605|Placebo Comparator|Placebo|starch in hard shell gelatine capsules
3083835|NCT01528605|Experimental|Low lutein|low lutein group
3083836|NCT01528605|Experimental|High lutein|high lutein group
3083837|NCT01528605|Experimental|Low lutein zeaxanthin|lutein plus zeaxanthin group
3083838|NCT01528605|Experimental|High zeaxanthin|zeaxanthin group
3083839|NCT01528605|Experimental|high lutein zeaxanthin|Zeaxanthin plus lutein group
3083840|NCT01528709|Experimental|High-dose statin therapy|Atorvastatin 80 mg daily
3083841|NCT01528709|Active Comparator|Moderate-dose statin therapy|Atorvastatin 10 mg daily
3083842|NCT01528735|Experimental|BI 207127 NA, BI 201335 NA(high dose), R|Patients receive BI 207127 NA,BI 201335 NA(high dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
3083843|NCT01528735|Experimental|BI 207127 NA,BI 201335 NA(low dose),RBV|Patients receive BI 207127 NA,BI 201335 NA(low dose) and RBV for 8 wks followed by BI 201335 NA,PegIFN/RBV for 24 wks
3083844|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
3083845|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
3083846|NCT01528787|Experimental|AR-13324 Ophthalmic Solution 0.04%|1 drop to study eye once daily
3083847|NCT01528787|Placebo Comparator|AR-13324 Ophthalmic Solution Vehicle|1 drop to study eye once daily
3083848|NCT01528878|Experimental|Good liver function.|Patients with good liver function as defined by no more than Child-Pugh Class A.
3083849|NCT01528878|Experimental|Compromised liver function.|Patients with compromised liver function as defined by patients with Child-Pugh Class B.
3083850|NCT01528891|Active Comparator|Dexmedetomidine|Dexmedetomidine
3083851|NCT01528891|Placebo Comparator|placebo|Normal saline
3083852|NCT01528969|Experimental|Xylitol|A half of the subjects will be randomly allocated into xylitol group.
3083853|NCT01528969|Active Comparator|Sorbitol|About 40 randomly allocated subjects will chew sorbitol chewing gum (1,5, g/pellet) three times a day
3083854|NCT01529034|Experimental|USL261|Intranasal midazolam 5 mg
3083855|NCT01529060|Active Comparator|Phenylbutyrate|Study Drug
3083856|NCT01529060|Placebo Comparator|Inactive Powder|Placebo powder
3083857|NCT01529112|Experimental|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in each 28-day treatment cycle plus Best Supportive Care (BSC)
3083858|NCT01529112|Placebo Comparator|Lenvatinib matched placebo|Participants received lenvatinib matched placebo orally, once daily continuously in each 28-day treatment cycle plus BSC
3083859|NCT01529203|Other|Azzalure and Restylane|All subjects will be injected with Azzalure and Restylane
3083860|NCT01529268|Active Comparator|DR cysteamine bitartrate capsule|Active DR cysteamine bitartrate capsule
3083861|NCT01529268|Placebo Comparator|DR cysteamine bitartrate placebo|Placebo DR cysteamine bitartrate capsule
3083862|NCT01529346|Experimental|PF-05089771 1600 mg|
3083863|NCT01529346|Experimental|PF-05089771 450 mg|
3083864|NCT01529346|Experimental|PF-05089771 150 mg|
3083865|NCT01529346|Active Comparator|Ibuprofen 400 mg|
3083866|NCT01529346|Placebo Comparator|Placebo|
3083867|NCT01529385|Experimental|Mild Compression Diabetic Sock|Diabetic socks that provide 18-25mm Hg of pressure to the lower extremities.
3083868|NCT01529385|Other|Standard Diabetic Sock|A standard diabetic sock that is designed to limit foot ulcer formation, but does not provide compression to the leg.
3083869|NCT01529450|Active Comparator|Refractory Group|Patients previously treated with non-LDE225 Smo inhibitor who were refractory.
3083870|NCT01529450|Active Comparator|Resistance Developed Group|Patients previously treated with non-LDE225 Smo inhibitor who were initially responsive but became resistant with progressive disease.
3083871|NCT01529502|Experimental|Fresh blood|
3083872|NCT01529502|Experimental|Old blood|
3083873|NCT01529502|Experimental|Old blood + inhaled Nitric Oxide|
3083874|NCT01529515|Experimental|Paliperidone palmitate 3-month (PP3M)|
3083875|NCT01529515|Placebo Comparator|Placebo|
3083876|NCT01529606|Active Comparator|Standard care|Fifty patients will be recruited into standard treatment group and they will receive composite resin restoration for all decayed teeth and standard preventive treatment (cleaning and fluoride varnish application) at baseline.
3083877|NCT01529606|Experimental|Plasma treatment|Fifty patients will be recruited into plasma treatment group and they will receive plasma treatment after cavity preparation, composite resin restoration, standard preventive treatment followed by plasma treatment for non-carious teeth.
3083878|NCT01529632|Experimental|QVA149|QVA149 plus placebo once daily for 28 days.
3083879|NCT01529632|Active Comparator|QAB149 + NVA237|Indacaterol maleate (QAB149) plus glycopyrronium bromide (NVA237) once daily for 28 days.
3083880|NCT01529645|Experimental|Group 1: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3083881|NCT01529645|Experimental|Group 2: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3083882|NCT01529645|Experimental|Group 3: aP booster|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3083883|NCT01529645|Experimental|Group 4: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
3083884|NCT01529645|Experimental|Group 5: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3083885|NCT01529645|Experimental|Group 6: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3083886|NCT01529645|Experimental|Group 7: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3083887|NCT01529645|Experimental|Group 8: TdaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3083888|NCT01529645|Experimental|Group 9: TDaP booster|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3083889|NCT01529645|Active Comparator|Group 10: Licensed TdaP booster|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart.
3083890|NCT01529749|Active Comparator|EFV/FTC/TDF|
3083891|NCT01529749|Experimental|EFV/FTC/TDF + Losartan|
3083892|NCT01529749|Experimental|FTC/TDF + MK-0518|
3083893|NCT01529749|Experimental|FTC/TDF+MK-0518+Losartan|
3083894|NCT01529827|Experimental|Treatment (reduced intensity allogeneic PBSCT)|PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan IV over 30 minutes on day -2. Patients undergo low-dose TBI BID on day -1. TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. GvHD PROPHYLAXIS: Patients receive tacrolimus IV or PO BID on days -1 to 100 with taper over 4-6 months, MMF PO or IV every 6-8 hours on days -1 to 60, and methotrexate IV over 15 to 30 minutes on days 1, 3, and 6.
3083895|NCT01530178|Active Comparator|Part A|Sitagliptin 25mg
3083896|NCT01530178|Active Comparator|Part B|Sitagliptin 50mg
3083897|NCT01530178|Active Comparator|Part C|Sitagliptin 100mg
3083898|NCT01530178|Placebo Comparator|Part D|Placebo oral tablet
3083899|NCT01530243|Placebo Comparator|Placebo|
3083900|NCT01530243|Active Comparator|Terazosin|
3083901|NCT01530243|Active Comparator|Tolterodine|
3083902|NCT01530243|Active Comparator|Tolterodine + Terazosin|
3083903|NCT01530256|Experimental|ALD518|
3083904|NCT01530334|Experimental|open label single arm with Gefitinib 250MG once daily|Gefitinib 250 mg/day open label until progression disease / toxicity / consent withdrawal
3083905|NCT01530399|Experimental|MDCO 1|MDCO-2010: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
3083906|NCT01530399|Experimental|MDCO 2|MDCO-2010: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
3083907|NCT01530399|Experimental|MDCO 3|MDCO-2010: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
3083908|NCT01530399|Experimental|MDCO 4|MDCO-2010: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
3083909|NCT01530399|Placebo Comparator|Saline|Commercially available saline (0.9% NaCl solution)
3083910|NCT01530399|Active Comparator|Tranexamic acid|Tranexamic acid: 12 mg/kg loading dose; 5 mg/kg/h infusion; 0.556 mg/mL CPB priming
3083911|NCT01530464|Active Comparator|Aminophylline|
3083912|NCT01530464|Active Comparator|Ambrisentan|
3083913|NCT01530464|Experimental|Aminophylline and ambrisentan|Treatment 3: Aminophylline, 500 mg plus Ambrisentan, 5 mg
3083914|NCT01530477|Experimental|Skeletal|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)],(total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
3083915|NCT01530477|Experimental|Body Composition|"Recruitment for each cohort will include approximately equal male/female split (no gender bias). Depending on the weight category, for each cohort, a minimum of 30 adult subjects will be measured on two of the three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], and 60 will be measured on all three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)], (total of evaluable 90 subjects).~** Subjects can enroll in both Skeletal and Body Composition cohorts. Analysis will be performed within each cohort.**"
3083916|NCT01530477|Experimental|Skeletal & Body Composition|"Skeletal and Body Composition was not a cohort that was actively recruited to, it is a cohort for reporting purposes. Subjects will be measured on two of three systems [Lunar Prodigy (GEHC), Lunar iDXA (GEHC) and Discovery A (Hologic)]Subjects were able to consent and enroll to both Skeletal and Body Composition cohorts and these subjects will be counted for under this joint cohort."
3468894|NCT03891459|Experimental|spray+ group|"In spray+ condition, participants learned oxytocin materials on a self-paced basis and then intranasally administered with saline (but it was told as oxytocin). Participants were instructed to refrain from smoking or drinking (except water) for 2 h before the experiment. The spray was administered to each participant three times, and each administration consisted of one inhalation into each nostril. Participants took a rest (they were told it was a time period waiting for treatment to produce effects) for 10min and then performed the experimental tasks."
3083918|NCT01531153|Active Comparator|Sugar Pill|Sugar Pill will be compared with the active medication Galantamine
3083919|NCT01531153|Active Comparator|Galantamine|Comparing the active medication with the placebo medication to see if the self administration cocaine decreases.
3083920|NCT01531205|Experimental|Drug and Hormonal Therapy with Salvage Surgery|Androgen Ablation (hormonal therapy before surgery), Cabazitaxel (chemotherapy before surgery), Salvage Surgery (radical prostatectomy), Post-operative Hormonal Therapy, Post-operative Follow-up
3083921|NCT01531335|Active Comparator|Standard care|Patients will receive normal nutritional regime of around 25 kcal per kg.
3083922|NCT01531335|Experimental|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg
3083923|NCT01531374|Experimental|Extreme Risk: TAVI Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Iliofemoral Access
3083924|NCT01531374|Experimental|Extreme Risk: TAVI Non-Iliofemoral|Extreme Risk Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI); Non-Iliofemoral Access
3083925|NCT01531374|Experimental|High Risk: TAVI|High Risk Surgical Patients: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3083926|NCT01531439|Active Comparator|Naloxone infusion 0.5 mcg/kg/hr|
3083927|NCT01531439|Experimental|Naloxone 2.5 mcg/kg/hr|Naloxone infusion 2.5 mcg/kg/hr
3083928|NCT01531673|Placebo Comparator|Group 1-6d Combined: Placebo|All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.
3083929|NCT01531673|Experimental|Group 1: VX-661 10 mg qd|All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.
3083930|NCT01531673|Experimental|Group 2a: VX-661 30 mg qd|All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.
3083931|NCT01531673|Experimental|Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h|All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3083932|NCT01531673|Experimental|Group 3a: VX-661 100 mg qd|All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.
3083933|NCT01531673|Experimental|Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h|All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3083934|NCT01531673|Experimental|Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h|All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3083935|NCT01531673|Experimental|Group 5a: VX-661 150 mg qd|All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.
3083936|NCT01531673|Experimental|Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h|All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3083937|NCT01531673|Experimental|Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h|All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.
3083938|NCT01531673|Experimental|Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h|All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.
3083939|NCT01531673|Placebo Comparator|Group 7: Placebo|All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
3083940|NCT01531673|Experimental|Group 7: VX-661 100 mg qd|All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.
3083941|NCT01531725|Experimental|BMS implantation|Patients meeting the inclusion criteria and none of the exclusion criteria are treated by implanting the study device (the ProKinetic bare metal stent). Since it is a single arm study design, no patients are enrolled to a control arm.
3083942|NCT01531738||Control|Normal weight healthy volunteers
3083943|NCT01531738||Bariatric Surgery|obese patients due to undergo gastric bypass or gastric banding
3083944|NCT01531803|Experimental|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g/L human albumin, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin). The duration of treatment is based on the subject's response to treatment until hemodynamic stability is achieved. If hemodynamic stability is not achieved within 72 hours of starting the study treatment, the subject will be withdrawn from the study and will be treated according to standard practice and data collected during the study period will be used for the safety evaluation."
3083945|NCT01531803|Placebo Comparator|Normal Saline Solution|Normal (0.9%) saline solution administered via IV infusions of 10 to 20 mL/kg as appropriate per standard of care based on the subject's clinical status and response to treatment.
3083946|NCT01531894|Experimental|GSK2110183 (afuresertib)|All patients received the GSK2110183 (afuresertib) treatment
3083947|NCT01531959|Active Comparator|Midodrine|
3083948|NCT01531959|Placebo Comparator|Placebo|
3083949|NCT01531998|Experimental|Siltuximab + Bortezomib + Lenalidomide|"Induction: Lenalidomide 25 mg orally Days 1-14; Bortezomib 1.3 mg/m2 intravenous Days 1, 4, 8 and 11; Dexamethasone 20 mg orally Days 1, 2, 4, 5, 8, 9, 11, 12. Siltuximab 11 mg/kg intravenous Day 1.~If delayed transplant, induction therapy continued up to 2 cycles beyond achieving a CR/nCR (minimum of 4 cycles of therapy and a maximum of 8 cycles of therapy) and then transition to maintenance regimen described below.~Maintenance therapy: Lenalidomide at last tolerated dose Day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.~Siltuximab 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy. Bortezomib at last tolerated dose Day 1 and Day 8 Dexamethasone at last tolerated dose or 20 mg weekly."
3083950|NCT01532089|Active Comparator|Arm A (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
3083951|NCT01532089|Experimental|Arm B (erlotinib hydrochloride, bevacizumab)|Patients receive erlotinib hydrochloride as in Arm A and bevacizumab IV over 30-90 minutes on day 1. (erlotinib will no longer be supplied and all patients will be removed from study treatment. No further follow-up by any study participants as of September 1, 2019)
3083952|NCT01532128|Experimental|Group 1|Period 1: rasagiline 1 mg Period 2: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 3: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg
3083953|NCT01532128|Experimental|Group 2|Period 1: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 2: rasagiline 1 mg Period 3: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg
3083954|NCT01532128|Experimental|Group 3|Period 1: 50 mg BIA 9-1067. 1 hour later rasagiline 1 mg Period 2: rasagiline 1 mg concomitantly with BIA 9-1067 50 mg Period 3: rasagiline 1 mg
3083955|NCT01532141|Experimental|Group 1|Period 1: 50 mg BIA 9-1067 alone Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
3083956|NCT01532141|Experimental|Group 2|Period 1: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 alone Period 3: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg
3083957|NCT01532141|Experimental|Group 3|Period 1: 50 mg BIA 9-1067 alone concomitantly single dose of rasagiline 1 mg Period 2: 50 mg BIA 9-1067 1 h before a single dose of rasagiline 1 mg Period 3: 50 mg BIA 9-1067 alone
3083958|NCT01532349|Active Comparator|400 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 400 IU/day (2,800 IU/weekly), which is the recommended dietary allowance. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
3083959|NCT01532349|Active Comparator|4000 IU vitamin D|Children will be randomly allocated to receive cholecalciferol supplementation 4000 IU/day (28,000 IU weekly) according to the KDOQI recommended supplementation for children with mild 25D deficiency. Study participants will be prescribed any clinically indicated additional cholecalciferol supplementation once the 3-month laboratory measures have been obtained, based on serum 25D levels at the end of the study period.
3083960|NCT01532388|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use.
3083961|NCT01532388|No Intervention|Control group|Untreated control group
3083962|NCT01532414|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
3083963|NCT01532414|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
3083964|NCT01532414|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
3083965|NCT01532453|Active Comparator|Standard Sun Protection Measures|Detailed information on standardised sun protection measures and application of self-provided sunscreen products. The Investigator may decide on an individual reimbursement of patient's expenditure (out of the centre's budget).
3083966|NCT01532453|Experimental|MD-3511356|Patients receive detailed information on standardised sun protection measures. Additionally, they will be provided free of charge with MD-3511356 for application to sun exposed skin areas once daily in the morning for 24 months. MD 3511356 lotion will be applied topically on the sun-exposed skin areas (face, neck, head, forearms and hands) in doses corresponding to the surface extent (see chapter 6.1). The dispensers will be provided with a dosage pump to allow application of reproducible amounts (each pump 0,5 g).
3083967|NCT01532570|Experimental|TA-650|
3083968|NCT01532648|Experimental|Budesonide MMX|Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
3083969|NCT01532648|Placebo Comparator|Placebo|Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
3083970|NCT01532687|Experimental|Arm I (gemcitabine hydrochloride and pazopanib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3083971|NCT01532687|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3083972|NCT01532700|Experimental|Ofatumumab with GSK2110183|
3083973|NCT01532817|Experimental|alphacore|noninvasive neurostimulation of the vagus nerve
3083974|NCT01532830|Experimental|Active|n-VNS active therapy
3083975|NCT01532869|Placebo Comparator|Placebo|
3083976|NCT01532869|Experimental|Tocilizumab|
3083977|NCT01532908|Experimental|Part 1: MBL-HCV1 and Telaprevir|
3083978|NCT01532908|Experimental|Part 2: MBL-HCV1 and Sofosbuvir|
3083979|NCT01532921||Subjects with Tricuspid Valve Repair|All patients indicated for a Tricuspid Valve (TV) repair procedure concomitantly to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® Tricuspid Annuloplasty Ring most appropriate to reconstruct the diseased valve.
3083980|NCT01532934|Experimental|brief therapy|motivational enhancement therapy for substance use
3083981|NCT01532934|Placebo Comparator|Standard Care|standard care
3083982|NCT01532973|Experimental|GT1 HCV 10-mg Elbasvir (Panel A)|Participants with GT1 HCV receive 10 -mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3083983|NCT01532973|Experimental|GTI HCV 50-g Elbasvir (Panel B)|Participants with GT1 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3083984|NCT01532973|Experimental|GT1 HCV 5-mg Elbavir (Panel C)|Participants with GT1 HCV receive 5-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3083985|NCT01532973|Experimental|GT1 HCV 200-mg Elbasvir (Panel D)|Participants with GT1 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part I of the study.
3083986|NCT01532973|Experimental|GT3 HCV 10-mg Elbasvir (Panel E)|Participants with GT3 HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3083987|NCT01532973|Experimental|GT3 HCV 50-mg Elbasvir (Panel F)|Participants with GT3 HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3083988|NCT01532973|Experimental|GT3 HCV 100-mg Elbasvir (Panel G)|Participants with GT3 HCV receive 100-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3083989|NCT01532973|Experimental|GT3 HCV 200-mg Elbasvir (Panel H)|Participants with GT3 HCV receive 200-mg elbasvir or matching placebo for 5 consecutive days during Part II of the study.
3083990|NCT01532973|Experimental|GT1a HCV 10-mg Elbasvir (Panel I)|Participants with GT1a only HCV receive 10-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
3083991|NCT01532973|Experimental|GT1a HCV 50-mg Elbasvir (Panel J)|Participants with GT1a only HCV receive 50-mg elbasvir or matching placebo for 5 consecutive days during Part III of the study.
3083992|NCT01532986|Other|Usual Care (Arm 1)|"Veterans randomized to the usual care arm will continue to receive care they would have received if they had not enrolled in the study; no care or resources that are made available in general by VA will be withheld from participants in either arm or to any Veterans who wish to use those resources.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
3083993|NCT01532986|Experimental|Intervention (Arm 2)|"A delivery system redesign, with nurse care managers, using standardized assessment tools and care coordination protocols to address unmet needs of Veterans with Parkinson's Disease (PD) by collaborating with these Veterans and their families, providers, and community partners.~Educational handout: brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook."
3083994|NCT01532999|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
3083995|NCT01532999|Sham Comparator|Present Centered Group Therapy|Present Centered Group Therapy (PCGT) serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
3083996|NCT01533038|Active Comparator|UroLift System|UroLift System procedure
3083997|NCT01533038|Active Comparator|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate surgery
3083998|NCT01533077|Experimental|Group 1|Period 1: BIA 9-1067 50 mg Period 2: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 3: BIA 9-1067 50 mg + Sinemet® 100/25 Period 4: Sinemet® 100/25
3083999|NCT01533077|Experimental|Group 2|Period 1: Sinemet® 100/25 Period 2: BIA 9-1067 50 mg Period 3: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 4: BIA 9-1067 50 mg + Sinemet® 100/25
3084000|NCT01533077|Experimental|Group 3|Period 1: BIA 9-1067 50 mg + Sinemet® 100/25 Period 2: Sinemet® 100/25 Period 3: BIA 9-1067 50 mg Period 4: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg
3084001|NCT01533077|Experimental|Group 4|Period 1: Sinemet® 100/25 1 h after the BIA 9-1067 50 mg Period 2: BIA 9-1067 50 mg + Sinemet® 100/25 Period 3: Sinemet® 100/25 Period 4: BIA 9-1067 50 mg
3084002|NCT01533116|Experimental|5 mg BIA 9-1067|5 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3084003|NCT01533116|Experimental|Placebo|Placebo once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28.
3084004|NCT01533116|Experimental|15 mg BIA 9-1067|15 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3084005|NCT01533116|Experimental|30 mg BIA 9-1067|30 mg BIA 9-1067 once-daily for 28 days single-dose of levodopa/carbidopa 100/25 mg on Day 21 single-dose of levodopa/benserazide 100/25 mg on Day 28
3084006|NCT01533181|Experimental|Arm I: OS-906 (linsitinib)|OS-906 daily, continuously, every 3 weeks.
3084007|NCT01533181|Active Comparator|Arm II (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes or PO QD on days 1-5. Patients may crossover to Arm I at the time of progressive disease.
3084008|NCT01533207|Experimental|Arm I (chemotherapy)|Patients receive adjuvant gemcitabine hydrochloride IV over 70-90 minutes on days 1 and 8 and docetaxel IV over 30-60 minutes on day 8. Patients also receive filgrastim SC on days 9-15 or pegfilgrastim SC on day 9 or 10. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo CT and/or MRI. Patients with no evidence of disease receive doxorubicin hydrochloride IV every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive filgrastim SC on days 2-8 or pegfilgrastim SC on day 2 or 3.
3084009|NCT01533207|Other|Arm II (no treatment)|Patients undergo clinical observation.
3084010|NCT01533246|Experimental|Treatment (linsitinib)|Patients receive linsitinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo serum and plasma sample collection at baseline, on day 1 of courses 2 and 4, and after completion of study treatment for correlative studies.
3084011|NCT01533259|Experimental|Stribild|Participants will switch to Stribild for 48 weeks.
3084012|NCT01533428|Experimental|Capsaicin 8%|Capsaicin 8% patch was applied for 30 minutes to the painful area(s) on Day 1
3084013|NCT01533428|Placebo Comparator|Placebo|Placebo patch was applied for 30 minutes to the painful area(s) on Day 1
3084014|NCT01533493|Placebo Comparator|Placebo|Subjects randomized to receive memantine-matched placebo in addition to open-label OROS-Methylphenidate
3084015|NCT01533493|Active Comparator|Memantine|Subjects randomized to receive memantine in addition to open-label OROS-Methylphenidate
3084016|NCT01533597|Active Comparator|Solifenacin|
3084017|NCT01533597|Experimental|Solifenacin plus Tamsulosin|
3084018|NCT01533688|Active Comparator|Golytely + placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely)+ placebo pill
3084019|NCT01533688|Placebo Comparator|Golytely Split + placebo|split dose(2 L day before procedure and 2 L day of procedure) of 4 liters of Golytely + placebo pill
3084020|NCT01533688|Experimental|Golytely Split + Bisacodyl|split dose (2 L day prior to procedure and 2 L day of procedure) of 4 liters of Golytely + bisacodyl 10 mg
3084021|NCT01533922|Experimental|Tiotropium + olodaterol High dose QD|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
3084022|NCT01533922|Experimental|Tiotropium + olodaterol Low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in a fixed dose combination once daily
3084023|NCT01533922|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
3084024|NCT01533922|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
3084025|NCT01533922|Placebo Comparator|Placebo QD|
3084026|NCT01533935|Active Comparator|Olodaterol 5 mcg QD|patient will receive olodaterol 5 mcg once daily
3084027|NCT01533935|Placebo Comparator|Placebo QD|placebo comparator for tiotropium + olodaterol
3084028|NCT01533935|Active Comparator|Tiotropium 5 mcg QD|patient will receive tiotropium 5 mcg once daily
3084029|NCT01533935|Experimental|Tiotropium + olodaterol low dose QD|patient will receive tiotropium 2.5 mcg + olodaterol 5 mcg in fixed dose combination once daily
3084030|NCT01533935|Experimental|Tiotropium + olodaterol high dose|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily
3084031|NCT01533948|Experimental|Treatment (axitinib)|Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3084032|NCT01533974|Experimental|ACT|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
3084033|NCT01533974|Active Comparator|CBT|
3084034|NCT01534013|Experimental|Closed-loop insulin delivery|The closed loop device (bio-inspired artificial pancreas device, subcutaneous glucose monitor and insulin pump) will be applied to participants with type 1 diabetes
3084035|NCT01534013|Active Comparator|Open-loop (Control visit)|Subcutaneous glucose monitor and pump will be applied to participants with type 1 diabetes
3084036|NCT01534052|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
3084037|NCT01534078|Experimental|Treatment Arm|Brentuximab Vedotin in combination with Adriamycin, Vinblastine and Dacarbazine
3084038|NCT01534182|Experimental|Fingolimod|Participants received 0.5 mg orally once a day.
3084039|NCT01534182|Active Comparator|Standard Disease Modifying Therapy (DMT)|Participants received interferon beta-1a (IFN), 44 mcg subcutaneously 3 times a week or glatiramer acetate (GA), 20 mg subcutaneously once a day.
3084040|NCT01534195|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
3084041|NCT01534195|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
3084042|NCT01534208|Experimental|Androxal 12.5 mg|Androxal 12.5 mg daily
3084043|NCT01534208|Experimental|Androxal 25 mg|Androxal 25 mg daily
3084044|NCT01534260|Experimental|sorafenib, vorinostat and bortezomib|Escalating cohorts of sorafenib, vorinostat and bortezomib
3084045|NCT01534273|Placebo Comparator|Placebo|Single oral dose and/or once daily (QD) oral dosing for 14 consecutive days
3084046|NCT01534273|Experimental|35 mg LY2886721|QD oral dosing for 14 consecutive days
3084047|NCT01534273|Experimental|70 mg LY2886721|Single oral dose or single oral dose followed by QD oral dosing for 14 consecutive days
3084048|NCT01534273|Experimental|140 mg LY2886721|Single oral dose
3084049|NCT01534351|Experimental|Finasteride|Finasteride 5 mg taken orally once daily and tamsulosin-matching placebo taken orally once daily for 12 months. The tamsulosin-matching placebo will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3084050|NCT01534351|Active Comparator|Tamsulosin|Tamsulosin 0.2 mg taken orally once daily and finasteride-matching placebo taken orally once daily for 12 months. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3084051|NCT01534351|Experimental|Finasteride and Tamsulosin|Finasteride 5 mg orally once daily and tamsulosin 0.2 mg orally once daily for 12 months, taken concomitantly. The tamsulosin will be taken approximately one half hour following the same meal each day. Medications may be taken separately or together.
3084052|NCT01534416|Experimental|Bupivacaine|Subjects receive paracervical block with bupivacaine-epinephrine
3084053|NCT01534416|Placebo Comparator|Saline|Subjects receive paracervical injection of normal saline
3084054|NCT01534520|Experimental|Group 1: Intravaginal 2% lidocaine gel|Intravaginal insertion of 4mL of 2% lidocaine gel
3084055|NCT01534520|Placebo Comparator|Group 2: Intravaginal placebo gel|Intravaginal insertion of 4mL of placebo gel ( K-Y Jelly)
3084056|NCT01534533|Placebo Comparator|Placebo|early atherosclerosis cases, received starch in hard shell gelatine capsules, once a day
3084057|NCT01534533|Experimental|Lutein group|early atherosclerosis cases, received 20mg lutein, once a day
3084058|NCT01534533|Experimental|Combination group|early atherosclerosis cases, received 20mg lutein plus 20mg lycopene, once a day
3084059|NCT01534533|Experimental|Normal lutein control group|20mg lutein for subjects free from atherosclerosis, once a day
3084060|NCT01534637|Experimental|Treatment (antiemetic, chemotherapy, and radiation therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy once daily on days 1-5 for 5.5 weeks. Patients also receive gemcitabine hydrochloride IV over 30 minutes once weekly and either fluorouracil IV continuously or capecitabine PO twice daily on days 1-5.~PROPHYLACTIC THERAPY: Beginning 1 hour before chemoradiotherapy, patients receive aprepitant PO on days 1-3. Treatment repeats every 7 days for 5.5 weeks in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION CHEMOTHERAPY: Two to four weeks after completion of chemoradiotherapy and prophylactic therapy, patients without disease progression or a declining performance status receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3084061|NCT01534663|Placebo Comparator|Placebo|The placebo for fish oil will be safflower oil. For glutamine, soy powder will serve as the placebo.
3084062|NCT01534663|Active Comparator|Glutamine/Fishoil|3.285 g of EPA and 3.285 g of Docosahexaenoic acid (DHA) and L-alanyl-glutamine (8g/d).
3084063|NCT01534689|Experimental|Erchonia FX-405™ Laser|The Erchonia FX-405™ Laser is a dual-diode laser emitting 15.5-17.5 milliWatts (mW) of 635 nanometer (nm) red laser light and 23.5-25.5 mW 405 nm blue laser light. The the power reaching the surface of the skin is 1 mW
3084064|NCT01534897|Experimental|GSK2118436|Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.
3084065|NCT01534910|Placebo Comparator|Sugar pill|placebo
3084066|NCT01534910|Active Comparator|Aged Garlic Extract|2400 mg of aged garlic extract
3084067|NCT01534962|Experimental|Ranolazine low dose|Ranolazine, low dose, oral, BID
3084068|NCT01534962|Experimental|Ranolazine intermediate dose|Ranolazine, intermediate dose, oral, BID
3084069|NCT01534962|Experimental|Ranolazin high dose|Ranolazine, high dose, oral, BID
3084070|NCT01534962|Placebo Comparator|Placebo|Placebo (sugar pill), oral, BID.
3084071|NCT01534975|Active Comparator|Iodixanol 320|"group 1 will receive iodixanol 320 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3084072|NCT01534975|Active Comparator|iohexol 350|"group 2 will receive iohexol 350 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3084073|NCT01534975|Active Comparator|iopamidol 370|"group 3 will receive iopamidol 370 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3084074|NCT01534975|Active Comparator|iodixanol 270|"group 4 will receive iodixanol 270 as the contrast agent during CT acquisition. this will reflect the intervention of that arm, by testing the diagnostic ability of this contrast agent to perform cardiac CT angiography"
3084075|NCT01535001|Active Comparator|MEDIC|Medicine, Exercise, Diet, Insole and Cognitive/patient education (MEDIC) for three months.
3084076|NCT01535001|Active Comparator|Standard treatment|Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
3084077|NCT01535014|Experimental|Dietressa (2 tablets 3 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (2 tablets 3 times daily) for 24 weeks.
3084078|NCT01535014|Experimental|Dietressa (1 tablet 6 times daily) for 24 weeks|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Dietressa (1 tablet 6 times daily) for 24 weeks.
3084079|NCT01535014|Placebo Comparator|Placebo (2 tablets 3 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (2 tablets 3 times daily) for 24 weeks.
3084080|NCT01535014|Placebo Comparator|Placebo (1 tablet 6 times daily)|Patients with Body Mass Index 30.0-34.9 (kg/m2) without previous anti-obesity treatment received Placebo (1 tablet 6 times daily) for 24 weeks.
3084081|NCT01535040|Active Comparator|Arm I - Memantine|Participants receive memantine hydrochloride PO BID) on days 1-81 in the absence of unacceptable toxicity.
3084082|NCT01535040|Placebo Comparator|Arm II - Placebo|Participants receive a placebo PO BID on days 1-81 in the absence of unacceptable toxicity.
3084083|NCT01535053|Experimental|Arm I (dactinomcin)|Patients receive dactinomycin IV over 15 minutes on day 1.
3084084|NCT01535053|Active Comparator|Arm II (leucovorin calcium and methotrexate)|Patients receive methotrexate IM on days 1, 3, 5, and 7 and leucovorin calcium PO on days 2, 4, 6, and 8 OR single agent methotrexate IV on days 1-5.
3084085|NCT01535118||Adults and Children with Allergic Rhinoconjunctivitis (ARC)|Adults and children with ARC who complete the survey
3084086|NCT01535222|Experimental|Cohort 1|3 patients: loading dose 0.005 mg/kg; infusion 0.0125 mg/kg/h; pump prime 0.02 mg
3084087|NCT01535222|Experimental|Cohort 2|3 pts: loading dose 0.011 mg/kg; infusion 0.0250 mg/kg/h; pump prime 0.04 mg
3084088|NCT01535222|Experimental|Cohort 3|6 patients: loading dose 0.027 mg/kg; infusion 0.0625 mg/kg/h; pump prime 0.09 mg
3084089|NCT01535222|Experimental|Cohort 4|6 patients: loading dose 0.054 mg/kg; infusion 0.1250 mg/kg/h; pump prime 0.18mg
3084090|NCT01535222|Experimental|Cohort 5|6 patients: loading dose 0.108 mg/kg; infusion 0.2500 mg/kg/h; pump prime 0.35 mg
3084091|NCT01535222|Placebo Comparator|Placebo|8 patients: commercially available NaCl as matching placebo to MDCO-2010 administered as IV infusion
3084092|NCT01535235|Active Comparator|ACE Inhibitor|Active group
3084093|NCT01535235|Placebo Comparator|Placebo|Placebo group
3084094|NCT01535261|Experimental|Ranibizumab arm|Intravitreal injection with standard dose of 0.5 mg/0.05mL PRN
3084095|NCT01535287|Active Comparator|Dexmedetomidine|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
3084096|NCT01535287|Placebo Comparator|Placebo|Single injection of Dexmedetomidine (study medication) compared to receiving Placebo in Myringotomy surgery decreases emergence agitation.
3084097|NCT01535326|Placebo Comparator|air insufflation|Use air insufflation during colonoscopy
3084098|NCT01535326|Active Comparator|water immersion|infuse water during insertion, remove water during withdrawal of colonoscopy
3084099|NCT01535326|Active Comparator|water exchange|infuse and remove water during insertion phase of colonoscopy
3084100|NCT01535365|Active Comparator|Heat|Application of Heat pad to site of muscle sprain.
3084101|NCT01535365|Active Comparator|Cold|Application of ice pack to muscle sprain.
3084102|NCT01535443|Experimental|Bromfenac|Drug: Bromfenac ophthalmic solution 1 drop 4 times per day
3084103|NCT01535560|Experimental|AL-60371|AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
3084104|NCT01535560|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days
3084105|NCT01535573|Active Comparator|Citalopram low dose|Citalopram 20 mg
3084106|NCT01535573|Active Comparator|Citalopram high dose|Citalopram 40 mg
3084107|NCT01535573|Placebo Comparator|Placebo|Placebo
3084108|NCT01535599|Experimental|AL-60371|AL-60371, 0.3% Otic Suspension, 4 drops to the affected ear(s) twice daily for 7 days
3084109|NCT01535599|Placebo Comparator|Vehicle|AL-60371 Vehicle, 4 drops to the affected ear(s) twice daily for 7 days
3084110|NCT01535638|Active Comparator|BI 207127 NA TFII medium dose|Film-coated tablet for oral administration
3084111|NCT01535638|Active Comparator|BI 207127 NA FF medium dose|Film-coated tablet for oral administration
3084112|NCT01535638|Active Comparator|BI 207127 NA FF modified medium dose|Film-coated tablet for oral administration
3084113|NCT01535664||dalfampridine-ER 10mg|Subjects with MS taking dalfampridine-ER 10mg and considered to be responders
3084114|NCT01535729||Cohort|
3084115|NCT01535807|Active Comparator|CorMatrix Group|"The treatment Cormatrix group will receive the CorMatrix EMC during surgery for the closure of the pericardium according to the specific recommended surgical technique."
3084116|NCT01535807|No Intervention|Control|"The control No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
3084117|NCT01535924|Experimental|Treatment (combination chemotherapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1 and 2. Treatment repeats every 21-28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3084118|NCT01535937|Experimental|Ketamine|0.5 mg/kg of ketamine IV over 40 minutes
3084119|NCT01535937|Active Comparator|midazolam|0.025 mg/kg IV over 40 minutes
3084120|NCT01535976|Placebo Comparator|Placebo|.9 normal saline infusion
3084121|NCT01535976|Active Comparator|Ketamine|Infusion of ketamine
3084122|NCT01536067|Experimental|Treatment (monoclonal antibody therapy)|"INDUCTION PHASE: Patients receive ofatumumab IV on days 1, 8, and 15 and bortezomib SC on days 8 and 15. Beginning on course 2, patients receive ofatumumab IV on days 1 and 15 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Beginning 8 weeks after course 4 of induction phase, patients receive ofatumumab IV on day 1 and bortezomib SC on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3084123|NCT01536093|Experimental|Colostrum|oropharyngeal administration of own mother's colostrum
3084124|NCT01536093|Placebo Comparator|Placebo|oropharyngeal administration of sterile water
3084125|NCT01536119|Experimental|Coparenting Breastfeeding Support Intervention|The intervention group will receive a in-hospital discussion, a video, a workbook,a breastfeeding booklet, access to a secure study website, two follow-up emails, and one telephone call.
3084126|NCT01536119|No Intervention|Usual Care Group|The usual care group will receive standard postpartum care in the hospital and in the community
3084127|NCT01536145|Experimental|Single agent CP-751,871|dose escalation design
3084128|NCT01536171||Shod versus Barefoot Running|two running conditions, with normal running shoes and barefoot
3084129|NCT01536184|Experimental|Receives COS Intervention|Circle of Security (COS) Family Intervention (B. Marvin model) is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour. The protocol itself involves a series of activities and repeated videotaped interactions between the child and their caregiver which are reviewed by the therapist who has established themselves with the caregiver as a secure base from which the attachment relationship may be explored.
3084130|NCT01536184|No Intervention|Control Group-Regular FASD Services|Regular FASD Services include general information on Fetal Alcohol Spectrum Disorder (FASD) with general behavioural management strategies and parental supports.
3084131|NCT01536197||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
3084132|NCT01536197||Gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
3084133|NCT01536197||Sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy surgery
3084134|NCT01536262|Other|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
3084135|NCT01536262|Other|Olodaterol|Olodaterol solution for inhalation - RESPIMAT
3084136|NCT01536262|Other|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol FDC solution for inhalation - RESPIMAT
3084137|NCT01536366|Experimental|Group 1|Period 1: BIA 9-1067 + repaglinide Period 2: Repaglinide
3084138|NCT01536366|Experimental|Group 2|Period 1: Repaglinide Period 2: BIA 9-1067 + repaglinide
3084139|NCT01536379|Experimental|Belimumab 10 mg|Subjects will receive belimumab 10 mg/ Kilogram (kg) infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care.
3084140|NCT01536379|Placebo Comparator|Placebo|Subjects will receive placebo infusion on Days 0, 14, 28 and every 4 weeks thereafter for a total of 7 infusions. The last dose of investigational product will be administered at the Week 20 visit; In addition to investigational product, all subjects will receive standard of care
3084141|NCT01536392|Experimental|Granisetron|Group A: 34.3 mg of granisetron formulated in transdermal patch replaced every 7 days. Transdermal patch placed/replaced prior to the intravenous (IV) infusion of cisplatin. At cycle 1, participants receive IV granisetron prior to IV cisplatin and prior to administration of transdermal patch.
3084142|NCT01536392|Experimental|Ondansetron|Group B: 8 mg of ondansetron orally thrice daily starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
3084143|NCT01536405|Experimental|MMRV (AMP)|Participants received two 0.5 mL subcutaneous injections of Mumps, Measles, Rubella, Varicella (MMRV) vaccine made with an alternative manufacturing process (AMP)
3084144|NCT01536405|Active Comparator|MMRV (2006 process)|Participants received two 0.5 mL subcutaneous injections of MMRV vaccine made with the 2006 manufacturing process
3084145|NCT01536418|Experimental|GSK1605786A, 500 milligrams, once daily|500 milligrams once daily, orally administered for 12 weeks
3084146|NCT01536418|Experimental|GSK1605786A, 500 milligrams twice daily|500 milligrams twice daily, orally administered for 12 weeks
3084147|NCT01536496|Active Comparator|Control (INR, PTT, fibrinogen, D-dimer)|Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
3084148|NCT01536496|Active Comparator|Test (r-TEG)|Patients randomized to the r-TEG guided haemostatic resuscitation group (Test Group) will receive blood component therapy per usual clinical practice. The test arm involves the use of rapid-TEG to diagnose and describe post-injury coagulopathy and to guide blood product replacement per institutional algorithm. In the Test Group, blood for r-TEG will be collected on admission, or upon entering the operating room, depending on the acuity of the injury (Baseline), and this will be followed by two additional r-TEG analyses during the first six hours at the discretion of the treating team (attending surgeon, anesthesiologist) and then two further r-TEG analyses at 12 hours and at 24 hours post-injury respectively. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
3084149|NCT01536535|Experimental|Mild UC|"Mild = Initiated on mesalazine, or on oral CS with Pediatric Ulcerative Colitis Activity Index (PUCAI) < 45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-Tumour Necrosis Factor alpha (TNFα) therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-MP at 1-1.5 mg/kg/day Colectomy"
3084150|NCT01536535|Experimental|Moderate to Severe UC|"Moderate/Severe = Initiated on IV CS, or oral CS with PUCAI ≥45~Patients can be treated with any of the therapies noted below:~Mesalazine: doses is rounded to the nearest 500mg increment, maximum dose of 75 mg/kg/day Oral corticosteroids:1-1.5 mg/kg/day, rounded up to the nearest 5 mg value~IV corticosteroids:~Additional Therapies:~Calcineurin inhibitor (cyclosporine, tacrolimus) or anti-TNFα therapy: These therapies may also be instituted if in the judgment of the attending physician is needed.~Immunomodulator or biologic therapy: thiopurine then dosing of azathioprine:2.5-3 mg/kg/day; 6-Mercaptopurine (MP) at 1-1.5 mg/kg/day Colectomy"
3084151|NCT01536561|Experimental|open-label, dose escalation|"Each subject will undergo two phases of study. The first phase, termed tracer Study, involves the injection of low-radioactivity doses (about 5 mCi) of 131-I anti-B1 for the purposes of determining the rate of whole body clearance of radiation so that a whole body radiation can be calculated. The calculated whole-body radiation dose per mCi administered can then be used to determined how many mCi will be required to deliver a specified whole-body radiation dose in the second phase of the study for each patient, termed radio-immunotherapy dose in a tracer-projected whole-body radiation dose will be used for dose escalation with a minimum of three subjects per dose level."
3084152|NCT01536574|Experimental|Requip PR|Ropinirole PR tablets of 2.0 mg, 4.0mg and 8.0 mg
3084153|NCT01536587|Other|Single Arm|Inhalation of salmeterol 50 µg twice daily over 4 weeks
3084154|NCT01536704|Experimental|Test nicotine lozenge (2 mg)|2 mg test nicotine lozenge to be chewed.
3084155|NCT01536704|Experimental|Test nicotine lozenge (4 mg)|4 mg test nicotine lozenge to be chewed.
3084156|NCT01536704|Active Comparator|Reference nicotine lozenge (2 mg)|2 mg reference nicotine lozenge to be chewed.
3084157|NCT01536704|Active Comparator|Reference nicotine lozenge (4 mg)|4 mg reference nicotine lozenge to be chewed.
3084158|NCT01536795|Experimental|WR279,396 with Tegaderm dressing|24 patients will be randomly allocated to WR279,396 treatment once-a-day for 20 days with using an occlusive polyurethane Tegaderm dressing
3084159|NCT01536795|Experimental|WR279,396 with Gauze and Tape Dressing|24 subjects will be randomly allocated to WR279,396 treatment once a day for 20 days without an optimized polyurethane dressing (gauze and tape only).
3084160|NCT01536860|Placebo Comparator|Control Test Drink|control drink
3084161|NCT01536860|Experimental|Experimental Test Drink 1|control drink containing ingredient 1
3084162|NCT01536860|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
3084163|NCT01536886|Placebo Comparator|LEO 90100 vehicle|Aerosol foam with no active ingredient
3084164|NCT01536886|Active Comparator|Betamethasone plus calcipotriol|Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
3084165|NCT01536886|Experimental|LEO 90100|LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
3084166|NCT01536886|Placebo Comparator|Ointment vehicle|Ointment with no active ingredients
3084167|NCT01536938|Active Comparator|Calcipotriol|"Calcipotriol aerosol foam: calcipotriol 50 mcg/g.~Applied once daily for up to 4 weeks"
3084168|NCT01536938|Active Comparator|Betamethasone|"Betamethasone dipropionate aerosol foam: betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
3084169|NCT01536938|Experimental|LEO 90100|"LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)~Applied once daily for up to 4 weeks"
3084170|NCT01536951|Placebo Comparator|Placebo|Placebo matching LY3009104 tablets in size and appearance will be administered orally in 1 out of 3 study periods in Part A and Part B.
3084171|NCT01536951|Experimental|LY3009104|"Part A. Single escalating dose of up to 40 milligrams (mg) of LY3009104 administered orally in 2 out of 3 study periods separated by at least a 3 day wash-out period between each dose.~Part B. Single dose of LY3009104 determined in Part A administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period."
3084172|NCT01536951|Active Comparator|400 mg moxifloxacin|Part B. 400 mg moxifloxacin will be administered orally in 1 out of 3 study periods separated by at least a 3 day wash-out period between each period.
3084173|NCT01537029|Experimental|Doxorubicin and cyclophosphamide|
3084174|NCT01537042|Experimental|Rotigotine|"Rotigotine Transdermal Patch~1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h."
3084175|NCT01537042|Placebo Comparator|Placebo|Transdermal patch matched according to patch size and appearance.
3084176|NCT01537068|Experimental|Desvenlafaxine|Serotonin-norepinephrine reuptake inhibitors (SNRIs) antidepressant drug
3084177|NCT01537068|Placebo Comparator|Placebo|Placebo treatment
3084178|NCT01537081|Experimental|Mucinex 2400 mg/day|The study is designed to meet regulatory requirement outside the US. The dosing regimen and assessments timepoints were dictated by IR GGE and do not match approved Mucinex labeling. Participants were instructed to take 2 Mucinex 600 mg tablets and 1 placebo tablet matching the 200 mg IR guaifenesin tablet by mouth, every 12 hours for 7 days. To ensure complete blinding, on Hours 6 and 18, this treatment group took 2 matching Mucinex placebo tablets combined with 1 IR guaifenesin placebo tablet.
3084179|NCT01537081|Active Comparator|Immediate-release Guaifenesin 800 mg/Day|The dosing regimen and assessments timepoints were dictated by immediate-release guaifenesin (IR GGE). Participants were instructed to take 1 immediate-release guaifenesin (IR GGE) 200 mg tablet and 2 matching Mucinex placebo tablets by mouth, every 6 hours for 7 days.
3084180|NCT01537081|Placebo Comparator|Placebo|Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
3084181|NCT01537120|Experimental|Placebo → Vildagliptin|Participants received placebo tablets orally, twice a day for 3 weeks, and then over the next 12 weeks received vildagliptin 50 mg tablets orally, twice daily
3084182|NCT01537133|Experimental|Inhaled corticosteroid|Fluticasone (250 mcg/puff, one puff, twice a day)
3084183|NCT01537133|Placebo Comparator|Placebo|Placebo fluticasone (one puff, twice a day)
3084184|NCT01537133|No Intervention|Healthy Control|
3084185|NCT01537133|No Intervention|Atopic Non-asthmatics|
3084186|NCT01537185|Experimental|Cohort 1 SPWCV+Alum 100 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3084187|NCT01537185|Experimental|Cohort 2 SPWCV+Alum 300 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3084188|NCT01537185|Experimental|Cohort 3 SPWCV+Alum 600 mcg|each individual receiving 3 vaccinations of same dose 28 days apart
3084189|NCT01537185|Placebo Comparator|Normal Saline Injection|"placebo group within each cohort receive 3 injections of normal saline 28 days apart~normal saline injection: 3 cohorts of normal saline injection"
3084190|NCT01537198||Pediatric Participants at High Risk of RSV|Pediatric participants at high risk of respiratory syncytial virus (RSV) in need of the prevention of serious lower respiratory tract disease caused by RSV were prescribed Synagis prophylaxis in usual practice according to the approved Korean product label. The decision to prescribe or not to prescribe Synagis was taken prior to a participant's enrollment in the study.
3084191|NCT01537211|Experimental|Microprocessor knee then Mechanical knee|
3084192|NCT01537211|Experimental|Mechanical Knee then Microprocessor knee|
3084193|NCT01537302|Experimental|Ocelot System|CTO crossing in femoropopliteal arteries using the Ocelot System
3084194|NCT01537315|Placebo Comparator|Matching Placebo|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
3084195|NCT01537315|Experimental|Hydroxychloroquine|Patients with cardiovascular disease (CVD) and chronic kidney disease (CKD) will be randomized to either hydroxychloroquine (HCQ) or matching placebo in a 3:1 ratio (approximately 39 to HCQ and 13 to placebo)
3084196|NCT01537367|Experimental|Enhanced contact only|"Patients allocated to the Enhanced contact only arm will receive:~HIV information and education~Specific to importance of coming to care regularly~Generic and tailored components~Approximately 10 minutes in length~Enhanced contact over time~Collect locator information~Follow-up contact after medical visit (face-to-face or phone)~Appointment reminders (telephone, e-mail, text message)~Periodic telephone contact across time (support, update locator info, refer any unmet needs to Case Manager)~Attempt to make immediate contact following a missed visit and re-schedule appointment (use locator contact info)"
3084197|NCT01537367|Experimental|Enhanced contact plus behavioral skills|Enhanced contact plus behavioral skills is the longer experimental intervention arm.
3084198|NCT01537367|Active Comparator|Standard of Care|Patients assigned to control arm will receive the standard services offered to all patients at the clinic.
3084199|NCT01537393|Other|0-7d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 0 to 7 days prior to transplant.
3084200|NCT01537393|Other|8-14d Preservation Time Group|Subjects in this arm will receive cornea tissue transplant with cornea tissue preserved for 8 to 14 days prior to transplant.
3084201|NCT01537419|Active Comparator|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
3084202|NCT01537419|Experimental|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
3084203|NCT01537432|Placebo Comparator|placebo|placebo
3084204|NCT01537432|Experimental|secukinumab|secukinumab
3084205|NCT01537549|Experimental|Juvenon|
3084206|NCT01537666|Experimental|Aerovanc 16 mg in healthy volunteers|
3084207|NCT01537666|Experimental|AeroVanc 32 mg in healthy volunteers|
3084208|NCT01537666|Experimental|AeroVanc 80 mg in healthy volunteers|
3084209|NCT01537666|Active Comparator|IV vancomycin in healthy volunteers|
3084210|NCT01537666|Experimental|AeroVanc 32 mg in CF patients|
3084211|NCT01537666|Experimental|AeroVanc 80 mg in CF patients|
3084212|NCT01537783|Experimental|Intervention group|In this arm, patients are treated with chlorhexidine scrubs once a day for 5 days and mupirocin nasal ointment inserted to both nostrils twice a day for 5 days. Both treatments are begun 7 days after enrollment, or when the abscess has healed fully if it has not healed by day 7.
3084213|NCT01537783|No Intervention|Standard of Care|In this arm, patients receive routine care of their abscess, which may or may not include either topical or oral antibiotics, at the discretion of the treating clinician.
3084214|NCT01537835|No Intervention|Standard Scrubs|Participants will be randomized to one of three types of uniforms. This arm is the standard scrub arm. The participants will wear new standard scrubs.
3084215|NCT01537835|Experimental|Antimicrobial Scrubs 1|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
3084216|NCT01537835|Experimental|Antimicrobial Scrubs 2|Participants will be randomized to one of three types of uniforms. In this arm, the participants will wear one of two types of antimicrobial uniforms. These are commercially available and registered with the Environmental Protective Agency.
3084217|NCT01537887|Placebo Comparator|Placebo|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
3084218|NCT01537887|Experimental|1200 milligrams (mg) LY2484595|Administered orally once daily for 10 days during 1 of the 3 crossover periods, separated by at least a 14-day washout period.
3084219|NCT01537887|Active Comparator|400 mg Moxifloxacin|Positive control, unblinded treatment administered orally once during 1 of 3 crossover periods, separated by at least a 14-day washout period.
3084220|NCT01537900|Experimental|Grazoprevir 100 mg|Participants received GZR 100 mg once daily (q.d.) for 7 days. Liver FNA was performed on Day 7.
3084221|NCT01537926|Experimental|N-acetylcysteine (NAC)|N-acetylcysteine 600mg by mouth every 12 hours for 90 days. N-acetylcysteine 1200mg by mouth every 12 hours for 270 days
3084222|NCT01537926|Placebo Comparator|Placebo|Placebo 1 cap by mouth every 12 hours for 90 days. Placebo 2 caps by mouth every 12 hours for 270 days.
3084223|NCT01538199|Experimental|TLT Treatment Group 1|The TLT group will receive 2 near-infrared radiation via Transcranial LED Therapy (TLT) treatments per week for 8 weeks
3084224|NCT01538199|Sham Comparator|TLT Treatment Group 2|The sham group will receive 2 treatments of the sham device per week for 8 weeks
3084225|NCT01538472|Experimental|Y Zevalin + BEAM|"Rituxan 250 mg/m2 preceding imaging dose of 111In Zevalin (5 mCi); additional infusion 250 mg/m2 Rituxan followed by therapeutic dose of 0.4 mCi/kg 90Y Zevalin received one week after Rituxan/111In Zevalin infusions. One week later, chemotherapy received with BCNU (300 mg/m2, intravenously (IV) day -6) VP-16 (200 mg/m2 IV every 12 hours, days -5 to -2) cytarabine (200 mg/m2 IV every 12 hours, days -5 to -2) and melphalan (140 mg/m2 IV day -1). Autologous stem cell infused on day 0 then Rituximab 1000 mg/m2 on days +1, and +8 post transplantation.~G-CSF 5 mg/kg given daily starting Day 0 till recovery of granulocytes of 4.0 * 109/L."
3084226|NCT01538615|Experimental|HOME Plus Intervention|described below
3084227|NCT01538615|No Intervention|Control|Control participants receive a monthly newsletter for the 10 months of the study with tips on healthy eating. The topics do not overlap the intervention content.
3084228|NCT01538628|Experimental|SpaceOAR|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the treatment group will undergo placement of 10 mL of SpaceOAR hydrogel
3084229|NCT01538628|No Intervention|Control|Men meeting the study eligibility criteria will be scheduled for fiducial marker placement using a transperineal approach with ultrasound guidance. Following successful fiducial marker placement, subjects will be randomized (2:1) to the treatment group or control group. Subjects randomized to the control group will not receive injection of the SpaceOAR hydrogel.
3084230|NCT01538719|Placebo Comparator|Placebo|2:1 randomization
3084231|NCT01538719|Active Comparator|Rilonacept|2:1 randomization
3084232|NCT01538745|Experimental|Ketamine|0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.
3084233|NCT01538745|Active Comparator|Morphine|0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.
3084234|NCT01538862|Experimental|Granulocyte Colony Stimulating Factor (GCSF)|GCSF 10mcg/kg/d subcutaneously (SQ) for 7 days
3084235|NCT01539070|Experimental|Eating and physical activity counseling|Participants randomized to intervention received a 6 week curriculum focused on obesity awareness and prevention. A trained nutritionist led diet, healthy growth and physical activity workshops, while a health educator led workshops on instilling healthy habits and routines in childhood. The nurse provided child care and developed relevant games and activities for children while parents attended the workshops.
3084236|NCT01539070|No Intervention|Usual care|According to the existing clinical practice guide within IMSS, obese children may be referred to a nutritionist if the physician considers it necessary, given general dietary advice by the attending physician, or, if necessary, sent for laboratory analyses of blood lipids and glucose. We gave the parents the height and weight results from the measurement of their child and recommended they share results with their physician in their next medical consultation.
3084237|NCT01539083|Experimental|Bortezomib + Cyclophosphamide + Dexamethasone [VCD Induction]|Bortezomib (Velcade) 1.3 milligram per square meter (mg/m^2) subcutaneously (SC) on Days 1, 4, 8, and 11; cyclophosphamide 300 mg/m^2 orally on Days 1, 8, and 15; and dexamethasone 20 mg orally on Days 1, 2, 4, 5, 8, 9, 11, and 12 in three 21-day treatment cycles. Participants who completed induction phase entered into the consolidation treatment phase.
3084238|NCT01539083|Experimental|Thalidomide + Prednisolone [TP Consolidation]|Thalidomide 100 mg orally, once daily until disease progression (up to maximum of 12 months) and prednisolone 50 mg orally, on every alternate day until disease progression.
3084239|NCT01539083|Experimental|Bortezomib + Thalidomide + Prednisolone [VTP Consolidation]|Bortezomib 1.3 mg/m^2 SC every 2 weeks for 32 weeks in addition to thalidomide 100 mg orally, once daily for a maximum of 12 months or until disease progression and prednisolone 50 mg orally, on every alternate day until disease progression.
3084240|NCT01539135|Active Comparator|Hi-Lo endotracheal tube|Hi-Lo endotracheal tube with barrel shaped cuff with 20 cc of methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
3084241|NCT01539135|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube with taper shaped cuff with 20 cc methylene blue instilled above the cuff once post intubation for the duration of the surgical procedure
3084242|NCT01539239|Experimental|Hydrus Aqueous Implant (Treatment)|Cataract surgery plus Hydrus Aqueous Implant
3084243|NCT01539239|Active Comparator|Cataract Surgery (Control)|Cataract surgery only
3084244|NCT01539291|Experimental|High-dose Idelalisib|Participants will receive idelalisib 300 mg twice daily (600 mg per day).
3084245|NCT01539291|Experimental|Standard-dose Idelalisib|Participants will receive idelalisib 150 mg twice daily (300 mg per day)
3084246|NCT01539317|Active Comparator|Topical liquid lidocaine|
3084247|NCT01539317|Placebo Comparator|Topical Saline|
3084248|NCT01539512|Active Comparator|Idelalisib + rituximab|Participants will receive idelalisib plus rituximab
3084249|NCT01539512|Placebo Comparator|Placebo + rituximab|Participants will receive placebo to match idelalisib plus rituximab
3084250|NCT01539525|Experimental|Motivational Interview|Motivational interview provided by a clinical research nurse or physician.
3084251|NCT01539525|Active Comparator|Motivational Interview-Electronic|Motivational Interview provided by an interactive computer program.
3084252|NCT01539525|Placebo Comparator|Treatment as Usual|No intervention- resource list provided.
3084253|NCT01539538|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3084254|NCT01539538|Active Comparator|morphine IV PCA|
3084255|NCT01539642|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3084256|NCT01539642|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
3084257|NCT01539694|Experimental|LD118033 contact lens|Investigational LD118033 multifocal low add soft contact lenses, to be worn on a daily wear basis.
3084258|NCT01539694|Active Comparator|PureVision multifocal contact lens|PureVision multifocal low add soft contact lens, to be worn on a daily wear basis.
3084259|NCT01539759|No Intervention|Interval IUD Placement|Women randomized to this arm will be scheduled for their IUD placement 4-8 weeks after their cesarean delivery
3084260|NCT01539759|Experimental|Immediate Postplacental IUD placement|Women randomized to this arm will receive on IUD at time of cesarean delivery, immediately after the delivery of the placenta
3084261|NCT01539837|Placebo Comparator|Placebo|Drug excipient
3084262|NCT01539837|Active Comparator|Deferiprone 20mg|20mg/kg/day deferiprone
3084263|NCT01539837|Active Comparator|Deferiprone 30mg|30mg/kg/day Deferiprone
3084264|NCT01539863|Experimental|Treatment at regular intervals|Participants will be scheduled to receive the intervention, maintenance care, i.e. care on a regular basis throughout the study period.Care may consist of manual treatment but also of e.g. advice concerning exercises, ergonomic adaptation and stress management
3084265|NCT01539863|Active Comparator|Treatment as needed|Participants will receivethe intervention, i.e.care only when requested by them, i.e. when experiencing a relapse or deterioration
3084266|NCT01539980|Experimental|Sericin scaffold|
3084267|NCT01540045||BASELINE|Outpatients from National Cancer Institute with stage III and IV NSCLC candidates for 1 st line chemotherapy paclitaxel-cisplatin based agreeing to participate in the study
3084268|NCT01540071|Experimental|NRX 194204|This was a single arm open-label study. All patients enrolled received 20 mg of IRX4204 per day orally, for six months, or longer if the patient had disease stabilization and was tolerating the experimental treatment.
3084269|NCT01540162||Group I|Patients of group I are exposed to the probiotic Mutaflor: 1 ml once a day during first week of life, and three times per week during the second and third week of life.
3084270|NCT01540162||Group II|Patients of group II remain unexposed to the probiotic Mutaflor.
3084271|NCT01540266|Experimental|first year psychology_structured|First year psychology students who watched the video where the physician gives structured information to the patient
3084272|NCT01540266|Active Comparator|First year psychology_non-structured|First year psychology students who watched the video where the physician gives non-structured information to the patient
3084273|NCT01540266|Experimental|First year medical_structured|First year medical students who watched the video where the physician gives structured information to the patient
3084274|NCT01540266|Active Comparator|First year mediclal_non-structured|First year medical students who watched the video where the physician gives non-structured information to the patient
3084275|NCT01540266|Experimental|Third year medical_structured|Third year medical students who watched the video where the physician gives structured information to the patient
3084276|NCT01540266|Active Comparator|Third year medical_non-structured|Third year medical students who watched the video where the physician gives non-structured information to the patient
3084277|NCT01540370||Patients with OAG and/or OHT|Patients with OAG and/or OHT
3084278|NCT01540409|Experimental|AVI-4658 (Eteplirsen)|Multiple-Dose Extension Study
3084279|NCT01540474|Experimental|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Single center, non-randomized, open label, dose escalation Phase 1 study with sporozoite challenge. The antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion. This is a first-in-human study of FMP012. 30 subjects, divided into 3 groups, will receive 3 doses of the FMP012/GLA-SE vaccine. Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3084280|NCT01540474|Experimental|Group 2: 10 ug FMP012 with 5 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3084281|NCT01540474|Experimental|Group 3: 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3084282|NCT01540474|Other|Control group-Challenged Only|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
3468895|NCT03891459|Placebo Comparator|control group|"In control condition, the materials and procedure were same with the spray+ condition except the nasal spray was told as saline instead. Oxytocin materials used in current experiments were adopted from previous study"
3084283|NCT01540487|Experimental|linagliptin/metformin(high dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (high dose) tablets single dose in randomized order
3084284|NCT01540487|Experimental|linagliptin/metformin(low dose)|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (low dose) tablets single dose in randomized order
3084285|NCT01540513|Experimental|I124-NM404 brain metastases or GBM imaging|injection of I-124NM404 for imaging
3084286|NCT01540565|Experimental|Treatment (veliparib)|Patients receive veliparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3084287|NCT01540773|Active Comparator|amino acid supplement|supplements with the proprietary amino acid derivative blend.
3084288|NCT01540773|Placebo Comparator|Placebo|Non-Active
3084289|NCT01540825|Experimental|BI 113608 high dose 1|Powder for oral solution
3084290|NCT01540825|Experimental|BI 113608 low dose 1|Powder for oral solution
3084291|NCT01540825|Experimental|BI 113608 low dose 2|Powder for oral solution
3084292|NCT01540825|Experimental|BI 113608 low dose 4|Powder for oral solution
3084293|NCT01540825|Experimental|BI 113608 low dose 5|Powder for oral solution
3084294|NCT01540825|Experimental|BI 113608 medium dose 1|Powder for oral solution
3084295|NCT01540825|Experimental|BI 113608 medium dose 2|Powder for oral solution
3084296|NCT01540825|Experimental|BI 113608 medium dose 3|Powder for oral solution
3084297|NCT01540825|Experimental|BI 113608 high dose 2|Powder for oral solution
3084298|NCT01540825|Experimental|BI 113608 high dose 3|Powder for oral solution
3084299|NCT01540825|Placebo Comparator|Placebo|Powder for oral solution
3084300|NCT01540838|Experimental|Infusion with paracetamol|Cefotaxime is administered as 12 hourly infusions, together with high dose paracetamol (acetaminophen)
3084301|NCT01540838|Active Comparator|Bolus with placebo|Cefotaxime is administered as bolus q.i.d. with a placebo of paracetamol
3084302|NCT01540851|Active Comparator|Care Navigator Intervention Group|Subjects randomized to the Care Navigator Intervention group will receive up to 10 telephone calls from a care navigator for 5 months post-operatively
3084303|NCT01540851|Active Comparator|Usual Care Group|Subjects in the Usual Care group receive the current standard post-operative TKA care
3084304|NCT01540981|Active Comparator|SOC - Standard of Care|Standard of care consists of pressure relief, creams, wound cleansing and dressings as needed
3084305|NCT01540981|Active Comparator|MIST Therapy with SOC|Standard of Care including pressure relief, wound cleansing, creams, and dressings as needed plus MIST Therapy daily for 5 days and then every other day for up to 7 more days
3084306|NCT01541215|Experimental|Lira + Met|
3084307|NCT01541215|Placebo Comparator|Placebo + Met|
3084308|NCT01541254|Other|Single Arm|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
3084309|NCT01541358|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET/CT)|Patients undergo fluorine F 18 sodium fluoride PET/CT scan.
3084310|NCT01541371|Experimental|Paliperidone ER|
3084311|NCT01541384|Experimental|Medication Dosage Reminders|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email).
3084312|NCT01541384|Experimental|Medicaiton Dosage Reminders + Coordinator Support|Subject will receive electronic pill bottle that will track adherence. They will also be able to activate available dosage reminders (text message, phone message, email). The study coordinator will also check adherence every 2 weeks and alert the transplant team when it drops below 90%. The transplant team will determine the next best course of action.
3084313|NCT01541384|Other|Usual Care with GlowCap|Subject will receive electronic pill bottle that will track adherence but all reminders will be deactivated.
3084314|NCT01541553|Active Comparator|PEP005 Gel, 0.015%|Cryotherapy followed by PEP005 Gel, 0.015%
3084315|NCT01541553|Placebo Comparator|Vehicle gel|Cryotherapy followed by vehicle gel
3084316|NCT01541644|Experimental|Acupuncture|All participants will receive acupuncture treatments over a total of 10 weeks.
3084317|NCT01541735|Placebo Comparator|Placebo|Placebo of calcined magnesia, capsules
3084318|NCT01541735|Experimental|Pantoprazole|The pantoprazole will be administered in 40mg capsules
3084319|NCT01541748||AXIS Allograft Dermis|Participants receiving AXIS Allograft Dermis for anterior, posterior or combined (anterior and posterior) female pelvic floor repair.
3084320|NCT01541826|Placebo Comparator|Color-matched rice powder pill|Color-matched rice powder pill
3084321|NCT01541826|Active Comparator|Chokeberry extract capsule|Chokeberry extract capsule
3084322|NCT01541826|Experimental|Chokeberry extract capsule (acute)|Chokeberry extract capsule pharmacokinetics
3084323|NCT01541865|Other|Renal Denvervation|All subjects who meet the inclusion criteria and are enrolled in this trial will be treated with the Vessix Renal Denervation System.
3084324|NCT01541891|Experimental|PRO-148 Ophthalmic Solution|Drug: PRO-148 Intervention name: PRO-148 applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
3084325|NCT01541891|Active Comparator|Arm B. SYSTANE® Ophthalmic Solution|Drug: SYSTANE® Intervention name: SYSTANE® applied in ocular surface of patients with mild to moderate dry eye syndrome q.i.d. for 60 days
3084326|NCT01541917|Experimental|Web-based coping skills training|Involves completion of a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support.
3084327|NCT01541917|Active Comparator|Online disease education|Involves viewing 12 educational websites about Juvenile Idiopathic Arthritis over the course of 12 weeks.
3084328|NCT01541930|Experimental|GK567|GK567: Metronidazole Gel 0.75% Once or twice daily, for 14 days, up to 30g
3084329|NCT01541969|Experimental|CR Neuromodulation|Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device. Participants receive the intervention according to the manufacturer/funder training given to the study team.
3084330|NCT01541969|Active Comparator|Tinnitus masking|Participants will receive the same Adaptive NeuroModulation (ANM) T30 CR® Neurostimulator device, but it will NOT be programmed according to the therapeutic algorithm (0-12 weeks).
3084331|NCT01542034|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3084332|NCT01542034|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3084333|NCT01542125|Experimental|Liposomal Lidocaine group|Patients in this groups received 4% Liposomal Lidocaine that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing
3084334|NCT01542125|Placebo Comparator|Placebo Group|This group received a placebo that was applied to the area immediately surrounding the pin site(s) and was covered with an opaque Tegaderm dressing.
3084335|NCT01542229|Experimental|Arm 1: PE + TAU|Prolonged Exposure Therapy +Treatment As Usual
3084336|NCT01542229|Active Comparator|Arm 2: Usual Treatment|Treatment As Usual
3084337|NCT01542255|Experimental|Combined Low Dose Treatment|"A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv"
3084338|NCT01542307|Experimental|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
3084339|NCT01542307|Placebo Comparator|Room Air|Medical air inhaled for 30 minutes during migraine attack
3084340|NCT01542372|Active Comparator|Medication augmentation|In one arm, the patients will be given a medication augmentation for SSRI/SSRN-resistant PTSD
3084341|NCT01542372|Active Comparator|CBT augmentation|In this arm, patients will receive CBT to treat SSRI/SSRN-resistant PTSD.
3084342|NCT01542398|Experimental|Family-Focused Psychosocial Intervention|Intervention Group
3084343|NCT01542398|No Intervention|Waiting List Control|
3084344|NCT01542502|Experimental|Anakinra|Treatment with daily subcutaneous injections of Anakinra 100 mg
3084345|NCT01542502|Placebo Comparator|Placebo|Treatment with daily subcutaneous injection of placebo
3084346|NCT01542528|Experimental|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
3084347|NCT01542528|No Intervention|Treatment as Usual (TAU)|Whatever care arrangement the parents have arranged for their child during the same two hour period over the same 15 week period.
3084348|NCT01542541|Experimental|Rifaximin|
3084349|NCT01542541|No Intervention|Control|Randomly-selected matched PET-CT scans performed on same day as intervention group.
3084350|NCT01542632|Experimental|Group 1|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous injection in one arm and placebo, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
3084351|NCT01542632|Experimental|Group 2|TDV, 0.5 mL, subcutaneous injection in one arm and TDV 0.5 mL, subcutaneous injection in the other arm on Day 0. Placebo, 0.5 mL, subcutaneous injection on Day 90.
3084352|NCT01542632|Experimental|Group 3|TDV, 0.5 mL, subcutaneous injection in one arm and TDV, 0.5 mL, subcutaneous injection in the other arm on Day 0. TDV, 0.5 mL, subcutaneous injection on Day 90.
3084353|NCT01542632|Experimental|Group 4|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and new formulation placebo, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
3084354|NCT01542632|Experimental|Group 5|TDV new formulation, 0.5 mL, subcutaneous injection in one arm and TDV new formulation, 0.5 mL, subcutaneous injection in the other arm on Days 0 and 90.
3084355|NCT01542632|Experimental|Group 6|1/10 TDV, 0.5 mL, subcutaneous injection on Days 1 and 90.
3084356|NCT01542645|Experimental|Methadone|Long-acting opioid
3084357|NCT01542645|Active Comparator|Fentanyl|Shorter-acting opioid
3084358|NCT01542684|Experimental|Azacytidine + GM-CSF|"Azacytidine administered intravenously (IV) or subcutaneously (SQ) at starting dose of 40 mg/m^2, daily for 4 days.~GM-CSF administered IV or subcutaneously at 250 mcg/m^2 one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.~Each treatment cycle will last at least 4 weeks"
3084359|NCT01542788|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 12 weeks.
3084360|NCT01542788|Placebo Comparator|Placebo|Participants were randomized to receive placebo to match SOF plus placebo to match RBV for 12 weeks.
3084361|NCT01542957|Experimental|Cognitive Behavioral + Dilemma Therapy|Combines Group Cognitive Behavioral Therapy with a Individual Dilemma-Focused Intervention
3084362|NCT01542957|Active Comparator|Cognitive Behavioral Therapy|Combined Group and Individual Cognitive Behavioral Therapy
3084363|NCT01543074|Placebo Comparator|BSE placebo & garlic oil placebo|Two BSE placebo capsules and one garlic oil placebo capsule per day for seven days
3084364|NCT01543074|Active Comparator|garlic oil plus BSE placebo|one garlic oil capsule plus 2 BSE placebo capsules per day for seven days
3084365|NCT01543074|Active Comparator|BSE plus garlic oil placebo|two BSE capsules plus one garlic oil placebo capsule per day for seven days
3084366|NCT01543074|Active Comparator|BSE & Garlic Oil|two BSE and one garlic oil capsule per day for seven days
3084367|NCT01543087|Other|One group of subjects|
3084368|NCT01543152|Experimental|Cohort 1 - IV cyclophosphamide 200 mg|
3084369|NCT01543152|Experimental|Cohort 2 - IV cyclophosphamide 0.5 g/m2|
3084370|NCT01543152|Experimental|Cohort 3 - IV cyclophosphamide 1.0 g/m2|
3084371|NCT01543152|Experimental|Cohort 4 - IV cyclophosphamide 2.0 g/m2|
3084372|NCT01543152|Experimental|Cohort 5 - IV cyclophosphamide 1.5 g/m2|
3084373|NCT01543178|Experimental|Rifaximin open-label|"Subjects will receive open-label rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up. Responders will continue into Maintenance Phase 1 (treatment free). Nonresponders will withdraw from the study.~Subjects who meet criteria for recurrence in Maintenance Phase 1 enter the double-blind period and are randomized 1:1 to receive rifaximin 550 mg or placebo."
3084374|NCT01543178|Experimental|Double-blind rifaximin (retreatment)|Subjects in this arm receive rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with rifaximin 550 mg TID for 2 weeks with a 4-week treatment-free follow-up.
3084375|NCT01543178|Placebo Comparator|Double-blind placebo (retreatment)|Subjects in this arm receive placebo TID for 2 weeks with a 4-week treatment-free follow-up (first retreatment) followed by Maintenance Phase 2 (6 weeks [treatment free]) followed by a second retreatment with placebo TID for 2 weeks with a 4-week treatment-free follow-up.
3084376|NCT01543204|Experimental|Etanercept 50 mg|Participants received etanercept 50 mg, twice weekly (BIW), subcutaneously (SC) for 12 weeks followed by 50 mg, once weekly (QW), SC for an additional 12 weeks.
3084377|NCT01543490|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
3084378|NCT01543490|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
3084379|NCT01543503||Cohort|
3084380|NCT01543568|Other|2.0 mg intravitreal Aflibercept|open label, Subjects seen monthly & given mandatory 2.0 mg aflibercept at baseline, months 1, 2 and 4. Pro re nata (PRN) retreatment at months 3 and 5 was performed upon evidence of disease on spectral domain-optical coherence tomography (SD-OCT)
3084381|NCT01543581|Active Comparator|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
3084382|NCT01543581|Placebo Comparator|Inactive placebo|Those to whom the inactive placebo is given.
3084383|NCT01543607|Experimental|Treatment|Radiofrequency ablation catheter
3084384|NCT01543685|Experimental|Indomethacin 40 mg TID|
3084385|NCT01543685|Experimental|Indomethacin 40 mg BID|
3084386|NCT01543685|Experimental|Indomethacin 20 mg TID|
3084387|NCT01543685|Active Comparator|Celecoxib 200 mg|
3084388|NCT01543685|Placebo Comparator|Placebo|
3084389|NCT01543776|Active Comparator|Arm I (fasting)|Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
3084390|NCT01543776|Experimental|Arm II (fed)|Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
3084391|NCT01543828|Experimental|indacaterol then placebo|In treatment 1: participants received indacaterol 75 µg one dose delivered via single-dose dry-powder inhaler (SDDPI) followed by treatment 2: placebo one dose via SDDPI between day 7 and 10. Albuterol was available for use as rescue medication.
3084392|NCT01543828|Placebo Comparator|placebo then indacaterol|In treatment 1, participants received placebo one dose delivered via SDDPI followed by treatment 2: indacaterol 75 µg one dose delivered via SDDPI between Day 7 and Day 10. Albuterol was available for use as rescue medication.
3084393|NCT01543958|Experimental|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
3084394|NCT01544023||Breast Reconstruction with TilOOP|
3084395|NCT01544062|Experimental|IV acetaminophen|Study subjects receiving IV acetaminophen
3084396|NCT01544062|Placebo Comparator|Normal saline|Study subjects receiving placebo
3084397|NCT01544088|Experimental|Arm 1: GCBT|Group Cognitive Behavioral treatment (GCBT)
3084398|NCT01544088|Active Comparator|Arm 2: Group Treatment|Present Centered Group Treatment
3084399|NCT01544114|Experimental|VIMOVO|"Three VIMOVO strengths will be used in this study: 250 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 250/20), 375 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 375/20), and 500 mg naproxen/20 mg esomeprazole magnesium (VIMOVO 500/20). The VIMOVO strength allocated to each participant will be determined by the participant's weight at baseline and based on investigator's discretion.~The target dose of the naproxen component will be within the range of 10-20 mg/kg/day divided twice daily (BID) with a maximum daily dose of 1000 mg."
3084400|NCT01544127|Experimental|MI-SI+TAU|Motivational Interviewing to Address Suicidal Ideation
3084401|NCT01544127|Experimental|MI-SI-R+TAU|Motivational Interviewing to Address Suicidal Ideation Revised
3084402|NCT01544127|Other|TAU Alone|Treatment as usual
3084403|NCT01544153|Other|WEB only|Control group receiving no additional intervention
3084404|NCT01544153|Experimental|WEB+SN|WEB plus social network intervention.
3084405|NCT01544153|Experimental|WEB+NRT|WEB plus nicotine replacement therapy product.
3084406|NCT01544153|Experimental|WEB+SN+NRT|WEB plus social network intervention and nicotine replacement therapy product.
3084407|NCT01544166|Experimental|Overall study|
3084408|NCT01544179|Experimental|Gefitinib|Gefitinib and cisplatin plus pemetrexed combination chemotherapy
3084409|NCT01544179|Placebo Comparator|Placebo|Placebo and cisplatin plus pemetrexed combination chemotherapy.
3084410|NCT01544309|Experimental|Atorvastatin administration group|
3084411|NCT01544309|Experimental|Rosuvastatin administration group|
3084412|NCT01544335||BIS|Subjects evaluated using Bioimpedance Spectroscopy
3084413|NCT01544348|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
3084414|NCT01544348|Active Comparator|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
3084415|NCT01544348|Experimental|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
3084416|NCT01544348|Experimental|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
3084417|NCT01544348|Experimental|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
3084418|NCT01544348|Experimental|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
3084419|NCT01544348|Experimental|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
3084420|NCT01544348|Experimental|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
3084421|NCT01544361|Placebo Comparator|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
3084422|NCT01544361|Experimental|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 milligram per kilogram (mg/kg) intravenous infusion over at least 60 minutes on Day 1.
3084423|NCT01544361|Experimental|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3084424|NCT01544361|Experimental|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3084425|NCT01544361|Experimental|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
3084426|NCT01544478|Experimental|V501|Participants received a 0.5-mL vaccination of V501 by intramuscular injection on Day 1, Month 2, and Month 6
3084427|NCT01544491|Experimental|Investigational arm|Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
3084428|NCT01544491|Active Comparator|Control arm|MMF continuation (in combination with tacrolimus and standard dose steroids)
3084429|NCT01544582||Boceprevir + PR|CHC genotype-1 participants included in study and prescribed boceprevir plus PR as routine clinical management.
3084430|NCT01544582||Telaprevir + PR|CHC genotype-1 participants included in study and prescribed telaprevir plus PR as routine clinical management.
3084431|NCT01544582||PR Alone|CHC genotype-1 participants included in study and prescribed PR alone as routine clinical management.
3084432|NCT01544595|Placebo Comparator|PASI 75 Responders|"PASI 75 responders participated in randomized withdrawal. Subjects who were PASI 75 responders at Week 52 visit of the core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies were randomized to continue same s.c. doses of secukinumab in PFS or receive placebo every 4 weeks up to Week 152 or until relapse. Participants on first full relapse received loading dose followed by routine dosing with secukinumab s.c. 150 mg or 300 mg regimen."
3084433|NCT01544595|Experimental|Partial responders|Partial responders were not randomized. Subjects who were partial responders at Week 52 visit in core studies (e.g.CAIN457A2302 or CAIN457A2303) and have been on secukinumab s.c. 150 mg or 300 mg in core studies did not participate in the randomized withdrawal. These subjects continued same treatment s.c. dose in PFS (secukinumab s.c. 150 mg or 300 mg) as they were receiving at the time of completing the maintenance period (Week 52) in the core studies.
3084434|NCT01544920|Active Comparator|Arm 1: peg-IFN + RBV|Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].
3084435|NCT01544920|Experimental|Arm 2: BOC + peg-IFN + RBV|Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].
3084436|NCT01544998|Experimental|Tadalafil plus Placebo, then Tadalafil plus Nesiritide|First intervention period: oral Tadalafil; after 1 hour, subcutaneous (sc) placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
3084437|NCT01544998|Experimental|Tadalafil plus Nesiritide, then Tadalafil plus Placebo|First intervention period: oral Tadalafil; after 1 hour, sc Nesiritide given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting. There was a one week washout period. Second intervention period: oral Tadalafil; after 1 hour, sc placebo given in the abdomen. After a lead in period of 15 min, a 30-min clearance was repeated, then acute saline load was given. During the 1 hour saline load, one 30-min clearance repeated with subject in supine position, then second 30-min clearance repeated with subject sitting.
3084438|NCT01545076|Experimental|IgPro20 low dose|
3084439|NCT01545076|Experimental|IgPro20 high dose|
3084440|NCT01545076|Placebo Comparator|Placebo|
3084441|NCT01545141|No Intervention|Surgery only|Surgical resection only, performed as standard of care for the disease
3084442|NCT01545141|Experimental|Chemokin Modulatory Regimen (5 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 5 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
3084443|NCT01545141|Experimental|Chemokin Modulatory Regimen (10 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 10 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
3084444|NCT01545141|Experimental|Chemokin Modulatory Regimen (20 MU/m2)|"Chemokine Modulatory Regimen monday through Friday prior to surgery:~400 mg celecoxib for 5 days IFN by intravenous infusion (IV) (Phase 1 dose escalation of 20 MU/m2) for 5 days Rintatolimod 200 mg by IV infusion for 5 days"
3084445|NCT01545193||Age 18-50|This is a younger study cohort who is anticipated to have a lower incidence of residual neuromuscular blockade
3084446|NCT01545193||Age 70-90|This is a older study cohort who is anticipated to have a higher incidence of residual neuromuscular blockade
3084447|NCT01545232|Active Comparator|1:1:1 Blood Transfusion Ratio|
3084448|NCT01545232|Active Comparator|1:1:2 Blood Transfusion Ratio|
3084449|NCT01545336|Experimental|Anastrozole|1 mg tablet by mouth once daily for 3 months
3084450|NCT01545336|Placebo Comparator|Placebo|Placebo tablet by mouth once daily for 3 months
3132413|NCT03425019|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
3084451|NCT01545375|Experimental|dPly-PhtD Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving GSK2189242A (dPly-PhtD) vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the dPly-PhtD vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the dPly-PhtD vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
3084452|NCT01545375|Placebo Comparator|Control Group|"Healthy Native American infants between, and including, 6 and 12 weeks (42-90 days) of age at the time of the first vaccination, receiving Placebo vaccine co-administered with Prevenar13™: 3 primary doses at 2, 4, 6 months of age and a booster dose at 12-15 months of age.~PedvaxHIB was given as study vaccine to a subset of subjects at 2, 4 and 12-15 months.~At the primary epoch, the Placebo vaccine was administered intramuscularly into the right anterolateral thigh and at the booster epoch, the Placebo vaccine was administered into the right deltoid or anterolateral thigh if the deltoid muscle size was not adequate.~At the primary epoch, the co-administered Prevenar13™ and PedvaxHIB vaccines were administered intramuscularly into the left anterolateral thigh and at the booster epoch, the Prevenar13™ and PedvaxHIB vaccines were administered into the left deltoid or anterolateral thigh if the deltoid muscle size was not adequate."
3084453|NCT01545388|Experimental|Metformin 500 mg q.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 metformin 250 mg tablets in the morning and 1 matching placebo tablet in the evening.
3084454|NCT01545388|Experimental|Metformin 250 mg b.i.d.|Participants will receive sitagliptin daily (continuing their pre-study dose), 1 metformin 250 mg tablet and 1 matching placebo tablet in the morning and 1 metformin 250 mg tablet in the evening.
3084455|NCT01545388|Placebo Comparator|Placebo|Participants will receive sitagliptin daily (continuing their pre-study dose), 2 matching placebo tablets in the morning and 1 matching placebo tablet in the evening.
3084456|NCT01545583|Placebo Comparator|Placebo intravenous|Placebo administered once intravenously
3084457|NCT01545583|Experimental|0.1 milligram (mg) LY3016859 intravenous|0.1 mg LY3016859 administered once intravenously
3084458|NCT01545583|Experimental|1 mg LY3016859 intravenous|1 mg LY3016859 administered once intravenously
3084459|NCT01545583|Experimental|10 mg LY3016859 intravenous|10 mg LY3016859 administered once intravenously
3084460|NCT01545583|Experimental|50 mg LY3016859 intravenous|50 mg LY3016859 administered once intravenously
3084461|NCT01545583|Experimental|250 mg LY3016859 intravenous|250 mg LY3016859 administered once intravenously
3084462|NCT01545583|Experimental|750 mg LY3016859 intravenous|750 mg LY3016859 administered once intravenously
3084463|NCT01545583|Placebo Comparator|Placebo subcutaneous|Placebo administered once subcutaneously
3084464|NCT01545583|Experimental|50 mg LY3016859 subcutaneous|50 mg LY3016859 administered once subcutaneously
3084465|NCT01545700|Placebo Comparator|Control, saline 0-4 hours|2 cc of saline
3084466|NCT01545700|Active Comparator|Dexamethasone 4 mg, 0-4 hours|Dexamethasone 4 mg administered intraoperatively
3084467|NCT01545700|Active Comparator|Dexamethasone 8 mg, 0-4 hours|Dexamethasone 8 mg administered intraoperatively
3084468|NCT01545700|Placebo Comparator|Placebo Comparator saline 8-24 hours|placebo, 2 cc saline
3084469|NCT01545700|Active Comparator|Dexamethasone 4 mg, 8-24 hours|Dexamethasone 4 mg administered intraoperatively
3084470|NCT01545700|Active Comparator|Dexamethasone 8 mg, 8-24 hours|Dexamethasone 8 mg administered intraoperatively
3084471|NCT01545765|Experimental|lidocaine 7% and tetracaine 7%|
3084472|NCT01545817|Experimental|Pazopanib followed by everolimus|First line pazopanib, followed by second line everolimus
3084473|NCT01545843|Active Comparator|No sleep deprivation|Sleep scheduling plus fluoxetine. 8 hours time in bed for two weeks plus fluoxetine for 8 weeks
3084474|NCT01545843|Experimental|Late bedtime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Bedtime delayed by 2 hours.
3084475|NCT01545843|Experimental|Early risetime sleep deprivation|Sleep scheduling plus fluoxetine. 6 hours time in bed for two weeks plus fluoxetine for 8 weeks. Risetime advanced by 2 hours.
3084476|NCT01545934|No Intervention|Standard Care|
3084477|NCT01545934|Experimental|Lifestyle intervention|
3084478|NCT01546038|Experimental|Arm A (Phase 1B)|PF-04449913 in combination with low dose ARA-C (LDAC)
3084479|NCT01546038|Experimental|Arm B (Phase 1B)|PF-04449913 in combination with Decitabine
3084480|NCT01546038|Experimental|Arm C (Phase 1B)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3084481|NCT01546038|Experimental|P2 Fit (Phase 2 Single Arm)|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3084482|NCT01546038|Other|P2 Unfit (Phase 2 Randomized)|Patients will be randomized 2:1 (low dose ARA-C in combination with PF-04449913: low dose ARA-C alone).
3084483|NCT01546142|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3084484|NCT01546142|Experimental|Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3084485|NCT01546155|Experimental|healthy controls|
3084486|NCT01546168|Experimental|esophageal deviation|esophageal deviation with IDE device during AF ablation
3084487|NCT01546168|No Intervention|temperature monitoring|luminal esophageal temperature monitoring, standard temperature monitoring alone
3084488|NCT01546194||Morning consent|Consent process consisting of information only provided on the morning of surgery
3084489|NCT01546194||Phone call and morning consent|Consent process consisting of information provided on the morning of surgery. In addition, a phone call on the day prior to surgery will be provided to subjects explaining that they will be approached about participation in a clinical research project
3084490|NCT01546285|Experimental|Blood Pressure Reading|Simultaneous blood pressure readings with DINAMAP PRO1000 and B40 monitor; total of 6 successful readings
3084491|NCT01546402|Experimental|Phacoemulsification with IOL implant|This group (Group B) includes patients who will undergo phacoemulsification with intraocular lens implantation. The dexamethasone implant will not be injected at the beginning of cataract surgery. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
3084492|NCT01546402|Experimental|Phacoemulsification with Ozurdex|This group (Group A) includes patients who will undergo phacoemulsification with intraocular lens implantation with intraoperative long acting steroid injection (Ozurdex ®). The dexamethasone implant will be injected at the beginning of cataract surgery, 4mm from the limbus using the specially designed injector. Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
3084493|NCT01546454|Experimental|Non-steroidal effects|Natural menstrual cycle versus Estrogen/Progesterone replacement cycle. Interventions include leuprolide acetate to induce hypogonadism and estradiol and progesterone to replace hormone levels.
3084494|NCT01546454|Experimental|Contraceptive effects|Oral contraceptive cycle versus Eligard treatment. Interventions include ethinyl estradiol-levonorgestrel combination and leuprolide acetate.
3084495|NCT01546454|Experimental|Steroid effects|Estrogen/Progesterone replacement cycle versus Eligard treatment. Interventions include leuprolide acetate, estradiol, and progesterone.
3084496|NCT01546519|Experimental|1|Control cohort with normal renal and normal hepatic function
3084497|NCT01546519|Experimental|2|Severe renal impairment and normal hepatic function
3084498|NCT01546519|Experimental|3|Mild hepatic impairment and normal renal function
3084499|NCT01546519|Experimental|4|Moderate hepatic impairment and normal renal function
3084500|NCT01546519|Experimental|5|Severe hepatic impairment and normal renal function
3084501|NCT01546623|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
3084502|NCT01546623|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
3084503|NCT01546636|Placebo Comparator|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
3084504|NCT01546636|Active Comparator|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
3084505|NCT01546649|Experimental|TAP-144-SR(6M)|TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks.
3084506|NCT01546649|Active Comparator|TAP-144-SR(3M)|TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks.
3084507|NCT01546675|Active Comparator|Traditional 1, Skeletal Stabilization 2|Subjects using the Traditional Socket and socket hypothesized to increase skeletal stabilization in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
3084508|NCT01546675|Experimental|Skeletal Stabilization 1, Traditional 2|Subjects using the socket hypothesized to increase skeletal stabilization and Traditional Socket and in a case cross-over design. The intervention is the socket designed to increase skeletal stabilization.
3084509|NCT01546688|Active Comparator|Zonisamide at targeted daily doses of 100-500 mg/day|
3084510|NCT01546688|Placebo Comparator|Placebo administered to match daily doses of 100-500 mg/day|
3084511|NCT01546857|Placebo Comparator|placebo|Placebo one dose in the evening of surgery and post op day #1.
3084512|NCT01546857|Active Comparator|Gabapentin|Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
3084513|NCT01546922|Active Comparator|First low dose HC followed by high dose HC|First low dose of hydrocortisone = 0.2-0.3 mg/kg body weight for 10 weeks followed by a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight
3084514|NCT01546922|Active Comparator|First high dose HC followed by low dose HC|First a high dose of hydrocortisone = 0.4-0.6 mg/kg body weight for 10 weeks followed by a low dose of hydrocortisone = 0.2-0.3 mg/kg body weight
3084515|NCT01547000|Placebo Comparator|Inactive placebo|
3084516|NCT01547000|Experimental|Extended-release Guanfacine|
3084517|NCT01547130|Active Comparator|BLS and Yoga exercise|Patients will take a bolus intake of 8 oz. (240mL) to 16 oz. (480mL) of lukewarm saline water and perform yoga poses.
3084518|NCT01547130|Active Comparator|PEG (HalfLytely)|Patients followed the preparation method according to the manufacturer's standard instructions.
3084519|NCT01547247|Experimental|cap-assisted water immersion colonoscopy|Cap-fitted colonoscopy using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3084520|NCT01547247|Active Comparator|water immersion colonoscopy|Standard colonoscopy without attached cap using purely water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3084521|NCT01547286|Experimental|Allergic asthmatic|
3084522|NCT01547299|Experimental|Enzalutamide alone|Enzalutamide 160 mg, orally, once daily
3084523|NCT01547299|Experimental|Enzalutamide & Leuprolide & Dutasteride|Enzalutamide 160 mg, orally, once daily and leuprolide 22.5 mg, intramuscular injection, every 3 months, and dutasteride, 0.5 mg, orally, once daily
3084524|NCT01547390|Experimental|Aspirin|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3084525|NCT01547390|Placebo Comparator|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3132414|NCT03425097|Experimental|Fexofenadine then Placebo|Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.
3084526|NCT01547598|Active Comparator|LUMIGAN® RC|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
3084527|NCT01547598|Active Comparator|DuoTrav®|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks. Then, DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
3084528|NCT01547715|Experimental|MenACWY - 2 - 10 Years old|Subjects between 2 and 10 years of age who received one injection of Meningococcal ACWY conjugate vaccine -CRM vaccine on day 1.
3084529|NCT01547715|Experimental|MenACWY - 11 - 18 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
3084530|NCT01547715|Experimental|MenACWY - 19 - 75 Years old|Subjects between 11 and 18 years of age who received one injection of Meningococcal ACWY conjugate vaccine-CRM vaccine on day 1.
3084531|NCT01547780|Experimental|Baseline brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to baseline brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
3084532|NCT01547780|Experimental|Repeat brain PET in acute TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to repeat brain positron emission tomography (PET) scan in Acute (< 5 months post-injury) traumatic brain injury (TBI) patients.
3084533|NCT01547780|Experimental|Single brain PET in Chronic TBI patient|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Chronic (5 months - 5 years post-injury) traumatic brain injury (TBI) patients.
3084534|NCT01547780|Experimental|Single brain PET in healthy subjects|Single intravenous injection of [C-11]PBR28, ~10-20 mCi, prior to brain positron emission tomography (PET) scan in Healthy Subjects.
3084535|NCT01547806|Experimental|Hematopoietic Progenitor Cells (HPC)|Subjects will undergo mobilization and collection of HPC, Apheresis for subsequent use in various clinical protocols.
3084536|NCT01548040|Experimental|quadriceps NMES using Kneehab XP|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation (NMES) using Kneehab XP on the affected leg, 20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
3084537|NCT01548040|Sham Comparator|quadriceps TENS|The sham device will look identical to the Kneehab XP device. All subjects in the control group will receive quadriceps Transcutaneous Electrical Nerve Stimulation (TENS) at a minimal sensory input using Kneehab XP on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.group will also complete the standard TKA post-surgery rehabilitation program used at the Hawkins Foundation
3084538|NCT01548287|Experimental|AZD5213 doseA|AZD5213 doseA daily
3084539|NCT01548287|Experimental|AZD5213 doseB|AZD 5213 doseB daily
3084540|NCT01548287|Experimental|AZD5213 doseC|AZD5213 doseC daily
3084541|NCT01548287|Placebo Comparator|Placebo|Placebo daily
3084542|NCT01548339|Active Comparator|Delayed|Laparoscopic cholecystectomy performed secondarily after an initial conservative treatment
3084543|NCT01548339|Experimental|Early|Laparoscopic cholecystectomy performed directly after the initial diagnosis
3084544|NCT01548404|Placebo Comparator|Placebo|Placebo (for Dupilumab) once weekly for 12 weeks by subcutaneous (SC) injection.
3084545|NCT01548404|Experimental|Dupilumab 300 mg|Dupilumab 300 mg once weekly for 12 weeks by SC injection.
3084546|NCT01548417|Active Comparator|Korlym (mifepristone)|600 mg daily taken orally for one week
3084547|NCT01548417|Placebo Comparator|Sugar Pill|placebo pill daily taken orally for one week
3084548|NCT01548573|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3084549|NCT01548599|Experimental|Multi-sectoral agricultural intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
3084550|NCT01548599|No Intervention|Control|Participants enrolled at one study location will receive the standard of care. At the end of the study, participants in this arm will be eligible for the finance training and those who pay the loan down payment will be eligible for a small loan to purchase a human powered water pump, hosing, fertilizer, and certified seeds.
3084551|NCT01548638|Experimental|Galantamine ER|The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
3084552|NCT01548690|Experimental|Ornithine·Phenylacetate|Ornithine Phenylacetate is administered intravenously, through a peripheral venous catheter. Each infusion should will be administered over a period of 120 hours.
3084553|NCT01548742|Experimental|Arm 1: Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR)
3084554|NCT01548742|Active Comparator|Arm 2: Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT)
3084555|NCT01548768|Experimental|Patients - DMARDs + TNF Inhibitors|Patients will receive a TNF inhibitor in addition to their current treatment in an open label protocol for increased disease activity and in the context of standard of care.
3084556|NCT01548768|Active Comparator|Patients - DMARDs only|Patients will receive their current treatment in an open label protocol in the context of standard of care.
3084557|NCT01548768|No Intervention|Healthy Volunteers|Subjects without RA who will function as controls.
3084558|NCT01548833|Experimental|Dailies Total 1|Delefilcon A, followed by narafilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3084559|NCT01548833|Active Comparator|TruEye|Narafilcon A, followed by delefilcon A and filcon II 3 in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3084560|NCT01548833|Active Comparator|Clariti|Filcon II 3, followed by narafilcon A and delefilcon A in randomized order. Each product worn for 1 week in a daily wear, daily disposable manner.
3084561|NCT01548885|Experimental|Study Staff Test BGMSs|All testing and lancings were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems(BGMS): FreeStyle Freedom Lite® BGMS; ACCU-CHEK® Aviva BGMS; TRUEtrack® BGMS; OneTouch® Ultra®2 BGMS; CONTOUR® NEXT EZ BGMS.
3084562|NCT01549002|Experimental|Intranasal Fentanyl|"Patients in this arm will receive intranasal Fentanyl (50 micrograms/mL) as their pre-I&D analgesic. The one time total dose to be used is 2 micrograms / kilogram, to a maximum of 100 micrograms. The medication will be delivered intranasally via an atomizer in 4 equally divided aliquots (2 per nare).~The abscess I&D will be followed according to protocol using topical and local anesthetic."
3084563|NCT01549002|Active Comparator|Intravenous Morphine|"Patients in this arm will receive intravenous morphine as their pre-I&D analgesic. The one time total dose to be used is 0.1 milligrams / kilogram, to a maximum of 8 milligrams. The medication will be delivered via slow IV push.~The abscess I&D will be followed according to protocol using topical and local anesthetic."
3084564|NCT01549041|Experimental|asenapine 10 mg daily in the evening|Patients will receive their entire daily dose of asenapine as a single dose in the evening
3084565|NCT01549041|Active Comparator|asenapine 5 mg twice daily|Patients will receive asenapine 5 mg daily in the morning and 5 mg daily in the evening
3084566|NCT01549223|Active Comparator|Standard Care Group|"Standard Care Group (reflects current clinical regimen at BWH) will receive a 500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request. The obstetrician and anesthesiologist will be asked to consider this infusion oxytocin. If inadequate uterine tone exists in which the obstetrician desires alternative uterotonic agents, these will be provided on their request (e.g. methylergonovine maleate (methergine) 0.2 mg IM (intramuscular) or carboprost tromethamine (hemabate) 0.25 mg IM. The time of the requests will be recorded.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
3084567|NCT01549223|Active Comparator|Protocol Group|"Protocol Group will receive 3 mL syringes marked study solution-oxytocin which contain 3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).~If inadequate uterine tone is noted at 9 min, the 1 mL syringe marked marked study solution-9 min, containing methylergonovine maleate (methergine) 0.2mg, will be given IM.~If inadequate uterine tone is noted at 12 min, the 1 mL syringe marked marked study solution-12 min, containing carboprost tromethamine (hemabate) 0.25 mg, will be given IM.~If uterine tone remains inadequate at 15 min, misoprostol 600 mcg will be given buccally."
3084568|NCT01549314||Subjects with CF taking ivacaftor|Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months
3084569|NCT01549314||Subjects with CF not taking ivacaftor|Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1
3084570|NCT01549314||Healthy subjects|Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.
3084571|NCT01549340||Participants with Allergic Rhinitis (AR)|Patients in a private allergy practice who were diagnosed with AR, with or without asthma, and advised to consider AIT between January 2005 and June 2011 and whose medical records were retrospectively reviewed.
3084572|NCT01549392|Active Comparator|DECT/MR Spectroscopy +Avastin|-15 Glioma Patients with progression will undergo DECT and MRS before Avastin (10 mg/kg iv q2 weeks until progression) and 3 months later
3084573|NCT01549392|Active Comparator|DECT/MR Spectroscopy no Avastin|15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1
3084574|NCT01549405|No Intervention|Control group|Control group: Group that without intercostal nerve block
3084575|NCT01549405|Experimental|nerve block|Group that performing intercostal block
3084576|NCT01549587|Active Comparator|Regular Oral Hygiene|toothpaste, toothbrush and dental floss
3084577|NCT01549587|Experimental|Advanced Oral Hygiene plus counseling|toothpaste, toothbrush, mouth rinse and dental floss plus specialized education
3084578|NCT01549613|Active Comparator|standard treatment with daptomycin|Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol
3084579|NCT01549613|Active Comparator|standard treatment of vancomycin|Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
3084580|NCT01549652|Experimental|Prevention of Opioid Withdrawal|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
3084581|NCT01549652|Experimental|Prevention of Physical Dependence|Chronic back pain patients will titrate onto sustained release oral morphine for 30 days; during morphine treatment, participants will be randomized to take either ondansetron 8 mg or matching placebo three times daily along with the oral morphine treatment. After thirty days, participants will return to the lab to undergo naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will then taper back to their original dose of morphine for one week.
3084582|NCT01549860|No Intervention|Standard of Care|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed. Minimum of one treatment per week and up to 3 times per week per investigator discretion for 4 weeks
3084583|NCT01549860|Experimental|SOC + Mist Therapy|30 to 40 mmHg compression, dressing for moist wound healing environment, debridement as needed plus non-contract low frequency ultrasound 3 x per week for 4 weeks.
3084584|NCT01549873|Active Comparator|Total intravenous anesthesia (TIVA)|
3084585|NCT01549873|Active Comparator|Inhaled anesthesia|
3084586|NCT01549886|Experimental|MGD + Rituximab + Y-90-Zevalin|"Moxtezafin Gadolinium: Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m^2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie / kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
3084587|NCT01549886|Active Comparator|Rituximab + Y-90-Zevalin|Day 1 Rituximab 250 mg/m^2 intravenous infusion. Day 8 Rituximab 250 mg/m^2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
3084588|NCT01549925|Other|standard surgical resection|standard surgical resection using clamps and surgical ligatures
3084589|NCT01549925|Active Comparator|LIGASURE|Resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
3084590|NCT01549951|Experimental|Orteronel+Prednisone|
3084591|NCT01549964|Experimental|Fasiglifam (TAK-875) 25 mg|Fasiglifam 25 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3084592|NCT01549964|Experimental|Fasiglifam (TAK-875) 50 mg|Fasiglifam 50 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3084593|NCT01549964|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. TAK-875 placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3084594|NCT01549964|Placebo Comparator|Placebo|Fasiglifam (TAK-875) placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Sitagliptin placebo-matching tablets, orally, once daily for a 24-week Treatment Period followed by an optional 80-week extension period for up to 104 weeks of treatment. Metformin ≥1500 mg or Maximum Tolerated Dose (MTD) needs to continue at a stable dose.
3084595|NCT01550224|Active Comparator|Participant Group 1 (methylated MGMT promoter)|Participants with methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have no expression of MGMT protein, will be assigned into Group 1, and will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
3084596|NCT01550224|Active Comparator|Participant Group 2 (non-methylated MGMT promoter)|Participants with non-methylated O6-methylguanine DNA methyltransferase (MGMT) promoter, ie, expected to have expression MGMT protein, will be assigned to into Group 2, and will initially receive daily, low doses (protracted dose schedule) of temozolomide (100 mg/m2) for 14 days in an attempt to inactivate MGMT activity. Following the protracted dose schedule, participants will receive vorinostat 500 mg orally 3 times daily for 3 days, followed by conventional doses of temozolomide (200 mg/m2 for 7 days).
3084597|NCT01550289|Experimental|Group 1: CYD dengue vaccine|Subjects will receive a dose of CYD dengue vaccine at 0, 6, and 12 months, respectively.
3084598|NCT01550289|Placebo Comparator|Group 2: Placebo|Subjects will receive a dose of placebo at 0, 6, and 12 months, respectively
3321112|NCT02016339|Active Comparator|Standard Care|24 hour consultation telephone line to the sleep nurses will be open for the patients. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy
3468896|NCT03891550|Experimental|SOF/VEL|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks
3084601|NCT01550341|Active Comparator|Buprenorphine|
3084602|NCT01550341|Placebo Comparator|Placebo|
3084603|NCT01550367|Experimental|Hydroxychloroquine + IL-2|One course of treatment (84 days) will consist of high dose (600,000 IU/kg) bolus IL-2 administered intravenously every 8 hours on days 1-5 and 15-19 (maximum 14 doses/5 days of administration) and hydroxychloroquine (HCQ) orally started two weeks prior to IL-2 infusions and continued while able to take oral medication for up to 3 courses.
3084604|NCT01550471|Experimental|1 Treatment Sequence-A and O, Q and B, P and P|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
3084605|NCT01550471|Experimental|2 Treatment Sequence-A and O, P and P, Q and B|Period 2-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
3084606|NCT01550471|Experimental|3 Treatment Sequence-Q and B, A and O, P and P|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID
3084607|NCT01550471|Experimental|4 Treatment Sequence-Q and B, P and P, A and O|Period 2-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 4-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
3132415|NCT03425097|Experimental|Placebo then Fexofenadine|Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.
3468897|NCT03891498|Experimental|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
3084608|NCT01550471|Experimental|5 Treatment Sequence-P and P, A and O, Q and B|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD Period 6-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID
3084609|NCT01550471|Experimental|6 Treatment Sequence-P and P, Q and B, A and O|Period 2-Placebo Nasal Spray QD and Placebo Inhalation Aerosol BID Period 4-QVAR Inhalation Aerosol 40 mcg BID and Beconase AQ Nasal Spray 168 mcg BID Period 6-Alvesco Inhalation Aerosol 80 BID and Omnaris Nasal Spray 200 mcg QD
3084610|NCT01550705|Experimental|Isoniazid|Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
3084611|NCT01550731|Experimental|PREPARE|The intervention group will review the PREPARE advance care planning website and PREPARE materials plus receive an advance directive. The control group will only receive an advance directive.
3084612|NCT01550731|Active Comparator|CONTROL|The control group will only receive an advance directive.
3084613|NCT01550744|Experimental|Group 1: Approved q12w maintenance regimen|Active ustekinumab study agent q12 weeks with sham/placebo as necessary to maintain blind
3084614|NCT01550744|Experimental|Group 2: Subject-tailored fixed-interval maintenance regimen|Subjects will undergo placebo withdrawal and will receive active study agent up to q24w intervals with sham/placebo injections to maintain the blind.
3084615|NCT01550757|No Intervention|Arm 1|Normal PACT Clinical Care
3084616|NCT01550757|Experimental|Arm 2|Normal PACT Clinical Care + Embedded Peer Mentor
3084617|NCT01550757|No Intervention|Arm 3|Normal Homeless Oriented PACT Clinical Care
3084618|NCT01550757|Experimental|Arm 4|Normal Homeless Oriented PACT Clinical Care + Embedded Peer Mentor
3084619|NCT01550809|Active Comparator|tBolus (traditional bolus)|Traditional mealtime insulin bolus based on the individual insulin-to-CHO ratio
3084620|NCT01550809|Experimental|iBolus (CGM-based insulin administration)|This is a CGM-based algorithm for prandial insulin administration. An individual patient's model characterizing a 5-hour postprandial period (0-5h PP) is obtained from a 6-day CGM period. A model with interval parameters accounting for patient's variability is calculated considering 20% uncertainty in insulin sensitivity and 10% in carbohydrates (CHO) estimation. Based on this model, constraints on plasma glucose are posed and a set-inversion problem lead to a set of solutions (the iBolus) that contains a bolus insulin dose, a specific mealtime basal insulin dose and the time for restoration of basal to baseline values.
3084621|NCT01550965|Experimental|Participants Receiving Adalimumab|Adults with active UC who had failed conventional therapy received Adalimumab 160 mg at Baseline Visit, 80 mg at Week 2 Visit, and 40 mg every other week (EOW) starting at Week 4. Non-responders to adalimumab were to be discontinued from treatment at Week 8. After Week 8, dose escalation to 40 mg weekly was allowed for flare or non-response.
3084622|NCT01551030|Experimental|Buparlisib|This is an open-label phase II study of the pan-class I selective phosphoinositide 3-kinase (PI3K) inhibitor Buparlisib in patients with metastatic urothelial carcinoma which has progressed despite treatment with prior cytotoxic chemotherapy.
3084623|NCT01551056|Experimental|AC-170 0.24%|
3084624|NCT01551056|Placebo Comparator|AC-170 0%|
3084625|NCT01551095|Experimental|PEGJ|Patients in this arm will receive self-propelled balloon PEGJ tube.
3084626|NCT01551173|Experimental|Fluvastatin sodium Extended Release Tablet|Oral Fluvastatin sodium Extended Release Tablet 80mg once daily for 12 weeks
3084627|NCT01551173|Active Comparator|Fluvastatin sodium Immediate Release Capsule|Oral Fluvastatin sodium Immediate Release Capsule 40mg twice daily for 12 weeks
3084628|NCT01551186|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 1010 cells of Lactobacillus rhamnosus GG on a twice-daily basis
3084629|NCT01551186|No Intervention|Standard of Care|Patients in the control arm will receive standard care
3084630|NCT01551199|Experimental|Multiple Channel Exposure Therapy|MCET-V is a cognitive-behavioral treatment for persons with comorbid PTSD and panic attacks
3084631|NCT01551212|Experimental|EVR/TAC|Tacrolimus minimization arm. Everolimus (C0-h: 3-8 ng/mL) + tacrolimus (C0-h: < 5 ng/mL)
3084632|NCT01551212|Active Comparator|TAC|Tacrolimus (C0-h: 6-10 ng/ml)
3084633|NCT01551264|Other|4-Year Bracing Arm|This group has been randomized to 4 years of bracing after correction of clubfoot using the Ponseti Method.
3084634|NCT01551264|Other|2-Year Bracing Arm|This group has been randomized to 2 years of bracing after correction of clubfoot using the Ponseti Method.
3084635|NCT01551303|Placebo Comparator|Placebo|Matched nasal spray placebo.
3084636|NCT01551303|Experimental|Oxytocin|Liquid intranasal oxytocin administered in a nasal spray.
3084637|NCT01551355|Experimental|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
3084638|NCT01551355|No Intervention|children - control group|The control preschool facilities continued with their usual preschool curriculum
3084639|NCT01551420|Active Comparator|Advanced upper limb prosthetic device IMU controlled|Subjects with upper limb amputation who are trained to use a DEKA Arm with IMU controls
3084640|NCT01551420|Active Comparator|Advanced upper limb prosthetic EMG-PR controlled|Subjects with TR or TH upper limb amputation who are trained to use a DEKA Arm with EMG-PR Controls
3084641|NCT01551550|Experimental|GDD & Amniotic Membrane Graft|After GDD implantation, amniotic membrane graft (AmnioGuard™, Bio-Tissue inc, Miami, FL) is used to cover the GDD tube.
3084642|NCT01551550|Active Comparator|GDD & Pericardial Graft|After GDD implantation, a pericardial graft (Tutoplast®, IOP Inc, Costa Mesa, CA) is used to cover the GDD tube.
3084643|NCT01551693|Experimental|STA-9090 Cohort A|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort A patients received STA-9090 200 mg/m2 once weekly (d1, 8, 15 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
3084644|NCT01551693|Experimental|STA-9090 Cohort B|Patients enrolled into two possible cohorts based on tumor expression of BRAF: Cohort A - BRAF mutant disease or Cohort B - BRAF wild type. Cohort B patients received STA-9090 150 mg/m2 twice weekly (d1, 4, 8, 11, 15, 18 of 28 day cycle). Patients were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal.
3084645|NCT01551745|Experimental|Vigil™ Vaccine|Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
3084646|NCT01551758|Experimental|FF/VI|once daily via a Novel Dry Powder Inhaler
3084647|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
3084648|NCT01551888|Experimental|Aclidinium/formoterol 400/12μg FDC|Aclidinium/formoterol 400/12μg fixed-dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
3084649|NCT01551888|Active Comparator|Formoterol|Formoterol 12μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
3084650|NCT01551979|Active Comparator|Active rTMS|High frequency rTMS stimulation of the vermis(lobule VII) of the cerebellum.
3084651|NCT01551979|Sham Comparator|Sham rTMS|Sham rTMS to the vermis (lobule VII) of the cerebellum.
3084652|NCT01552057|Experimental|Duloxetine 60 mg|Duloxetine hydrochloride up to 60 milligrams (mg) orally for 15 weeks
3084653|NCT01552057|Placebo Comparator|Placebo|Placebo orally for 15 weeks
3084654|NCT01552213|Active Comparator|Treatment for glucose intolerance|Regular visit with dietician, exercise, self blood glucose monitoring, Insulin therapy if determined necessary.
3084655|NCT01552213|Active Comparator|Minimum intervention control group|Single visit with dietician or health educator followed by routine care per provider.
3084656|NCT01552343|Experimental|Female - Desmopressin 25 μg|Female participants took 1 tablet of 25 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3084657|NCT01552343|Placebo Comparator|Female - Placebo|Female participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3084658|NCT01552343|Experimental|Male - Desmopressin 75 μg|Male participants took 1 tablet 75 μg every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3084659|NCT01552343|Placebo Comparator|Male - Placebo|Male participants took 1 tablet of placebo every night, approximately 1 hour prior to bedtime (with the intention to sleep), for a period of 1 month.
3084660|NCT01552369|Experimental|Preemptive Therapy|900 mg of Valganciclovir given orally twice daily to Preemptive Therapy subjects upon detection of CMV viremia until plasma PCR is negative on two consecutive weekly PCR test. All dosages adjusted for renal dysfunction. n=88
3084661|NCT01552369|Active Comparator|Prophylaxis|900 mg of Valganciclovir given orally once daily to subjects for 100 days post transplantation. All dosages adjusted for renal dysfunction. n=88
3084662|NCT01552408|Active Comparator|0.3 mg Ranibizumab|Cohort 1: Subjects will receive 4 IVT of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will be seen monthly (+/- 7 days) & will receive IVT of 0.3 mg ranibizumab on a pro re nata (PRN) schedule per retreatment criteria.
3084663|NCT01552408|Experimental|Targeted PRP with 0.3 mg Ranibizumab|Cohort 2: Subjects will receive 4 it of 0.3 mg ranibizumab every 28 days (+/- 7 days), then will then be seen monthly (+/- 7 days) & receive IVT of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at Day 7 they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide field angiography. Ultra wide field angiography will be performed every 3 months to indicate areas of peripheral ischemia, which will be selectively be treated with PRP at Month 6, Month 18, and Month 25, preserving areas of more perfused retina.
3084664|NCT01552603|Experimental|Artificial Pancreas Control|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
3084665|NCT01552681|Experimental|Baminercept|Subcutaneous injections of 100 mg every week for 24 weeks
3084666|NCT01552681|Placebo Comparator|Placebo|Subcutaneous injections of matched placebo every week for 24 weeks
3084667|NCT01552694|Experimental|Sitagliptin|100 mg sitagliptin/day for 2 months
3084668|NCT01552694|Placebo Comparator|Placebo|Matching placebo daily for 2 months
3084669|NCT01552772|Experimental|Aripiprazole IM Depot|
3084670|NCT01552876|Other|etafilcon A / nelfilcon A / Filcon II 3|etafilcon A worn first then nelfilcon A worn second with Filcon II 3 worn third.
3084671|NCT01552876|Other|nelfilcon A / etafilcon A / Filcon II 3|nelfilcon A worn first then etafilcon A worn second with Filcon II 3 worn third.
3084672|NCT01552889|No Intervention|Usual Care (UC)|Patients will receive only the care provided by their primary care physicians or other medical professionals outside of the study.
3084673|NCT01552889|Experimental|Collaborative Care (CC)|Patients randomized to the Collaborate Care (CC) arm of this study will receive brief screening, consultative, and referral services. This collaborative approach includes the patient, the patient's PCP, the cardiologist, and the nurse case manager (NCM), using evidence based recommendations for depression treatment and follow-up care.
3084674|NCT01552902|Experimental|Lisdexamfetamine dimesylate|
3084675|NCT01552902|Active Comparator|Methylphenidate Hydrochloride|
3084676|NCT01552902|Placebo Comparator|Placebo|
3084677|NCT01552915|Experimental|Lisdexamfetamine Dimesylate|
3084678|NCT01552915|Active Comparator|Methylphenidate Hydrochloride|
3084679|NCT01552915|Placebo Comparator|Placebo|
3084680|NCT01552928|Experimental|Anagrelide Therapeutic (0.5 mg)|
3084681|NCT01552928|Experimental|Anagrelide Supratherapeutic (2.5 mg)|
3084682|NCT01552928|Active Comparator|Moxifloxacin|
3084683|NCT01552928|Placebo Comparator|Placebo|
3084684|NCT01552954|Experimental|Intensive education of low salt diet|"For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks. (*Intervention in this trial is the intensity of education)"
3084685|NCT01552954|No Intervention|Conventional diet group|Education for low salt diet will be conducted as in office with brief communication with a patient and a physician.
3084686|NCT01553058|Active Comparator|Adalimumab (Humira)|Injection of the active drug Humira.
3084687|NCT01553058|Placebo Comparator|Placebo Injection|Injection of placebo in place of active Humira injection.
3084688|NCT01553058|Active Comparator|NB-UVB phototherapy|NB-UVB Phototherapy 3 times per week, no other intervention.
3084689|NCT01553084|Experimental|Effectiveness of Nicotine patch only|
3084690|NCT01553084|Experimental|Effectiveness of Combination NRT|
3084691|NCT01553084|Experimental|Effectiveness of Varenicline [Chantix]|
3084692|NCT01553136|Placebo Comparator|Sugar pill|
3084693|NCT01553136|Active Comparator|Varenicline|
3084694|NCT01553149|Experimental|Arm I (low-dose lenalidomide)|Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3084695|NCT01553149|Experimental|Arm II (high-dose lenalidomide)|Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3084696|NCT01553188|Experimental|Abiraterone, Prednisone and AMG|Abiraterone and prednisone will be given with maximum tolerated dose (MTD) of Trebananib (AMG)
3084697|NCT01553188|Active Comparator|Abiraterone and Prednisone only|Abiraterone and prednisone only
3084698|NCT01553188|Other|Run in|Dose escalation phase to determine MTD of AMG
3084699|NCT01553201|Experimental|Botulinum toxin (BoNT)|OnabotulinumtoxinA 100 Units diluted in 4cc saline, one time intramuscular administration
3084700|NCT01553201|Placebo Comparator|Placebo|Saline, 4cc, one time intramuscular administration
3084701|NCT01553279|Experimental|V419 and MCC-TT|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-TT (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of a measles, mumps, and rubella (MMR) vaccine (at 12 months of age).
3084702|NCT01553279|Experimental|V419 and MCC-CRM|Participants received 3 doses of V419 (at 2, 3, and 4 months of age) and 2 doses of MCC-CRM (at 3 and 4 months of age), followed by a single dose of Hib-MCC at 12 months of age. As routine vaccination, participants also received 2 doses of Prevnar 13® (at 2 and 4 months of age) and 1 dose of an MMR vaccine (at 12 months of age).
3084703|NCT01553292|Experimental|ECALMIST|Large volume 5ml/kg surfactant administered by vascular catheter while maintaining CPAP or ECALMIST; Early CPAP (continuous positive airway pressure) And Large volume Minimal Invasive Surfactant Therapy
3084704|NCT01553318|Active Comparator|Active Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 26 of the 51 participants will assigned to this arm of the study.
3084705|NCT01553318|Placebo Comparator|Placebo for Ketotifen|After meeting the full eligibility requirement, participants will be randomized. Approximately 25 of the 51 participants will assigned to this arm of the study. Subjects in this arm will receive the placebo drug.
3084706|NCT01553539|Experimental|Treatment (antiangiogenesis therapy)|Patients receive therapeutic angiotensin-(1-7) SC once daily in the absence of disease progression or unacceptable toxicity.
3084707|NCT01553591|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.
3084708|NCT01553591|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.
3084709|NCT01553591|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.
3084710|NCT01553708|Experimental|Epidermal growth factor with silver sulfadiazine cream|Epidermal growth factor with silver sulfadiazine cream was applied to the experimental wounds completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
3084711|NCT01553708|Active Comparator|Silver zinc sulfadiazine cream|Silver sulfadiazine cream was applied to cover the controlled-wound completely and then covered with sterile gauze. The wound was cleaned every 24 h and the cream was then applied again after cleaning process.
3084712|NCT01553747|Experimental|Eluxadoline 75 mg|Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.
3084713|NCT01553747|Experimental|Eluxadoline 100 mg|Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.
3084714|NCT01553747|Placebo Comparator|Placebo|Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.
3084715|NCT01553851|Experimental|GSK1120212|GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
3084716|NCT01553916|Experimental|Arm 1: Lithium carbonate + prophylactic cranial irradiation|"Lithium carbonate 300 mg PO BID for 7 days prior to the start of prophylactic cranial irradiation (PCI) and will be continued during PCI.~PCI will be given at 2.5 Gy per fraction, 5 days per week, for 2 weeks to a total dose of 25 Gy, starting on Day 8 after 7 days of lithium."
3084717|NCT01554163|Experimental|Etoricoxib 30 mg|Etoricoxib, 30 mg tablet, orally, once daily for 12 weeks.
3084718|NCT01554163|Active Comparator|Celecoxib 200 mg|Celecoxib, 200 mg capsule, orally, once daily for 12 weeks.
3084719|NCT01554176|Experimental|Filorexant 10 mg (Treatment Phase)|Treatment Phase: Participants in this group were administered filorexant 10 mg once daily at bedtime for 6 weeks.
3084720|NCT01554176|Placebo Comparator|Placebo (Treatment Phase)|Treatment Phase: Participants in this group were administered placebo once daily at bedtime for 6 weeks.
3084721|NCT01554176|Experimental|Filorexant 10 mg/Filorexant 10 mg (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered filorexant 10 mg once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
3132416|NCT03425188||remedē System Subjects|Subjects who were implanted with the remedē System and actively followed as part of the remedē System Pivotal Trial at the time of study closure.
3084722|NCT01554176|Placebo Comparator|Filorexant 10 mg/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week treatment phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received filorexant 10 mg once daily during the treatment phase.
3084723|NCT01554176|Placebo Comparator|Placebo/Placebo (Run-out Phase)|Run-out Phase: Following completion of the 6-week Treatment Phase, participants in this group were administered placebo once daily at bedtime for 2 weeks. Participants in this group had received placebo once daily during the Treatment Phase.
3084724|NCT01554241|Experimental|vitamin D3 800 IU/day|recommended daily dosage of 800 IU/day D3
3084725|NCT01554241|Experimental|2000 IU/day D3|D3 2000 IU/day
3084726|NCT01554241|Experimental|vitamin D3 4000 IU/day|D3 4000 IU/day
3084727|NCT01554241|Experimental|50,000 IU/week D3|D3 50,000 IU weekly
3084728|NCT01554371|Experimental|Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
3084729|NCT01554371|Experimental|Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort)|Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
3084730|NCT01554371|Experimental|Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort)|Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.
3084731|NCT01554488|Experimental|Arm 1|High dose inhaled fluticasone (1760mcg/day)
3084732|NCT01554488|Active Comparator|Arm 2|Low dose inhaled fluticasone (88mcg/day)
3084733|NCT01554514|Experimental|low dose rituximab|this is a single-arm trial
3084734|NCT01554527|Experimental|CPAP treatment|Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
3084735|NCT01554527|Other|No CPAP treatment|Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
3084736|NCT01554579|Placebo Comparator|Sugar pill|
3084737|NCT01554579|Experimental|Gefapixant|
3084738|NCT01554618|Experimental|EQW|Exenatide once weekly
3084739|NCT01554618|Placebo Comparator|Placebo|Placebo once weekly
3084740|NCT01554683|Active Comparator|High Dose Levetiracetam|Low Dose Levetiracetam administration via IV infusion over 20 min
3084741|NCT01554683|Active Comparator|Low Dose Levetiracetam|High Dose Levetiracetam administration via IV infusion over 20 min
3084742|NCT01554683|Placebo Comparator|Placebo administration|Saline administration via IV infusion over 20 min
3084743|NCT01554891||Cohort 1|100 OEF/OIF/OND veterans returning to Joint Base Lewis-McChord and Fort Bragg who screen positive for TBI on the Post Deployment Health Assessment (PDHA) TBI screen
3084744|NCT01554891||Cohort 2|100 OEF/OIF/OND veterans seeking care at Northern New England VA Research Consortium (NNEVARC) VA Medical Centers (VAMCs) who screen positive for TBI on VA Level 1 TBI screen
3084745|NCT01554891||Cohort 3|200 participants in WRNMMC and Fort Belvoir Community Hospital Brain Indices Study (100 with mild TBI; 100 without mild TBI).
3084746|NCT01554904|Other|Facial-Flex|The facial flex (FF) exerciser manufactured by Facial Concepts, Inc is an FDA approved Class I medical device for treatment of facial muscle laxity. Facial muscles tend to weaken with age. The combination of deteriorating elastic tissue and facial muscle weakness causes the face to sag. Facial flex consists of two plastic tipped curved lower bars which slide across each other. An external dynamic resistance is provided by elastic bands.
3084747|NCT01554982|Other|Ferric Citrate|Open label extension of those completing study KRX-0304
3321113|NCT02016339|Active Comparator|Intensive care|"Standard group care plus:~Involvement of the patient's partner or family. Extra education on sleep apnea syndrome and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence."
3321114|NCT02016352|Experimental|patient|patient CSF extraction with hydrocephalus
3084750|NCT01555125|Experimental|secukinumab 150 mg|Drug
3084751|NCT01555125|Experimental|secukinumab 300 mg|Drug
3084752|NCT01555125|Placebo Comparator|placebo|
3084753|NCT01555138|Experimental|Indacaterol|Indacaterol 150 mcg once daily (o.d.) delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3084754|NCT01555138|Active Comparator|Salmeterol/fluticasone propionate|Salmeterol 50 mcg /fluticasone propionate 500 mcg for inhalation delivered via a proprietary multi dose dry powder inhaler (MDDPI) device (Seretide® Accuhaler®) twice daily (b.i.d.)
3321115|NCT02016352|Other|witness|patient without hydrocephalus but with peridural catheter for anesthetic. Witness CSF extraction has realized on catheter.
3321116|NCT02016365|Experimental|Doxycycline and UDCA|Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)
3321119|NCT02016391|Experimental|Dexmedetomidine|
3321120|NCT02016404|Active Comparator|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, mono sodium glutamate (MSG), sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
3084755|NCT01555151|Experimental|Mometasone furoate 80 μg|Description: Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 80 ug delivered via the Concept1 device for 4 weeks.
3084756|NCT01555151|Experimental|Mometasone furoate 200 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 200 ug delivered via the Twisthaler® device for 4 weeks.
3084757|NCT01555151|Experimental|Mometasone furoate 320 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 320 ug delivered via the Concept1 device for 4 weeks.
3084758|NCT01555151|Experimental|Mometasone furoate 800 µg|Mometasone furoate (MF) 800 ug delivered via the Twisthaler® device for 2 weeks, followed by MF 200 ug delivered via the Twisthaler® device for 2 weeks or no treatment for 2 weeks, then randomized to MF 800 ug delivered via the Twisthaler® device for 4 weeks.
3084759|NCT01555164|Experimental|Ranolazine+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive ranolazine 500 mg + metformin 500 mg + placebo to match metformin twice daily on Days 1 through 7, followed by ranolazine 1000 mg + metformin 500 mg + placebo to match metformin twice daily from Day 8 through Week 24.~Participants are required to maintain their diet and exercise regimen."
3084760|NCT01555164|Placebo Comparator|Placebo+metformin|"Qualifying Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily for either 2 or 8 weeks (dependent on metformin dose and HbA1c level at Screening).~Treatment Period: Participants will receive metformin 1000 mg + placebo to match ranolazine twice daily through Week 24.~Participants are required to maintain their diet and exercise regimen."
3084761|NCT01555463|Experimental|Azelaic acid foam, 15% (BAY39-6251)|0.5 g azelaic acid (AzA) foam, 15% applied twice daily (BID) topical and nonocclusive on facial skin for 12 weeks.
3084762|NCT01555463|Placebo Comparator|Vehicle foam|0.5 g vehicle foam applied twice daily topical and nonocclusive on facial skin for 12 weeks.
3084763|NCT01555541|Experimental|Single-arm study|
3084764|NCT01555567|Experimental|Electrical stimulation|Subjects placed into this group will undergo electrical stimulation following anterior cruciate ligament reconstruction (ACLr). Subjects will be required to report 2 times per week for 6 weeks following ACLr for electrical stimulation therapy. Electrical stimulation therapy post-reconstruction will commence immediately post-ACLr and end at week 6.
3084765|NCT01555567|No Intervention|Standard of Care|This group will undergo standard ACL rehabilitation
3084766|NCT01555567|Experimental|Eccentric Exercise|Subjects placed into this group will undergo eccentric exercise strength training following ACLr. Subjects will be required to report 2 times per week for 6 weeks following ACLr. Eccentric strengthening will begin at week 6 post-ACLr and will end at week 12 post-ACLr.
3084767|NCT01555567|Experimental|Stimulation and Eccentrics|Subjects placed into this group will undergo a combined electrical stimulation and eccentric exercise intervention following ACLr. The electrical stimulation intervention will be delivered immediately following ACLr and will end at 6 weeks post-ACLr. Subjects will receive the electrical stimulation therapy 2 times per week for the first 6 weeks post-ACLr. At six weeks post-ACLr, subjects will begin the eccentric strengthening protocol. Subjects will eccentrically train 2 times per week for 6 weeks. The eccentric strengthening will end at 12 weeks post-ACLr.
3084768|NCT01555671|Active Comparator|meperidine administration group|Infusion bags were prepared and labelled as Bag A (meperidine group), containing 25 mg meperidine (Aldolan; Liba Laboratuarları, Istanbul, Turkey) .Providers and patients were blinded to the contents of the bags until the conclusion of the study. Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
3084769|NCT01555671|Placebo Comparator|plasebo group|Bag B (placebo group), containing 0.5ml of normal saline solution. Providers and patients were blinded to the contents of the bags until the conclusion of the study.Meperidine or placebo were administered by intravenous infusion by means of injectors containing 0.5ml of solution.
3084770|NCT01555697|Active Comparator|Memantine/high|memantine 20 mg
3084771|NCT01555697|Placebo Comparator|Placebo/high|placebo comparator for memantine 20 mg
3084772|NCT01555697|Active Comparator|Memantine/low|memantine 10 mg
3084773|NCT01555697|Placebo Comparator|Placebo/low|placebo comparator for memantine 10 mg
3084774|NCT01555762||Cohort|
3084775|NCT01555931|Experimental|Immediate|Placement within 48 hours of delivery
3084776|NCT01555931|Active Comparator|Control|Placement 4-8 weeks after delivery
3084777|NCT01555957|Experimental|low dose intravenous lipids|
3084778|NCT01555957|Placebo Comparator|high dose of intravenous lipids|
3084779|NCT01555983|Active Comparator|Vaporization of Cannabis 6.7% THC|Inhaling of standardized measured puffs of Vaporized High Dose 6.7% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3084780|NCT01555983|Active Comparator|Vaporization of Cannabis 2.9% THC|Inhaling standardized measured puffs of Vaporized Low Dose 2.9% THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3084781|NCT01555983|Placebo Comparator|Vaporization of Cannabis Placebo THC|Inhaling standardized measured puffs of Placebo THC. Monitored for 8 hours measuring psychoactive and analgesic effects.
3084782|NCT01556061|Experimental|D-MAC video laryngoscopy|The Dblade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with CMAC blade.
3084783|NCT01556061|Active Comparator|C-MAC video laryngoscopy|The CMAC blade is used to perfom laryngoscopy first but second laryngoscopy and intubation is performed with D-blade
3084784|NCT01556100|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
3084785|NCT01556165|Experimental|rasagiline|
3084786|NCT01556165|Placebo Comparator|placebo|
3084787|NCT01556204|Experimental|Robotic Surgery|Robotic surgery using the da Vinci Surgical System
3084788|NCT01556204|Active Comparator|Laparoscopy|Laparoscopic assisted resection of endometriosis will be performed using up to five 5mm ports.
3321121|NCT02016404|Placebo Comparator|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
3084789|NCT01556347|Experimental|Elimination of Immunologic Memory|A single arm multi-drug regimen is used to delete immunologic memory in order to reduce or eliminate alloreactive anti-HLA antibodies in highly sensitized heart transplant candidates. The intervention includes a protocol of Thymoglobulin, Rituximab, plasmapheresis and Bortezomib.
3084790|NCT01556425|Experimental|Vivitrol Only|The VIVITROL group will be offered one injection of VIVITROL every 4 weeks. Participants in the VIVITROL group will be required to take their scheduled injections to work and earn wages. If a participant misses a scheduled VIVITROL injection (more than 3 days from the scheduled date of administration), the participant will not be allowed to work until the injection is accepted. Additionally, missing a scheduled injection will result in a base pay reset from $8 per hour to $1 per hour. After the reset, the participant's base pay will increase by $1/hour to the maximum of $8/hour for every day that the participant works at least 5 minutes.
3084791|NCT01556425|Experimental|VIVITROL&Opiate Abstinence Reinforcement|This group will be offered VIVITROL and will be required to take it to attend the workplace and to maintain maximum pay. This group will also receive employment-based opiate abstinence reinforcement. This contingency will require participants to provide opiate-negative urine samples on M,W, and F to maintain their maximum pay. If a participant in this group provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
3084792|NCT01556425|Experimental|Opiate Abstinence Reinforcement Only|This group would receive employment-based opiate abstinence reinforcement, but this group will not receive VIVITROL.
3084793|NCT01556425|Other|Usual Care Control|This group will receive neither abstinence reinforcement nor VIVITROL injections, but they will be invited to attend the workplace and outpatient drug abuse counseling.
3084794|NCT01556438|Experimental|100 mg Tabalumab+Bortezomib (BTZ)IV+Dexamethasone (Dex)|Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle, each cyle is 21 days. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.
3084795|NCT01556438|Experimental|300 mg Tabalumab+BTZ IV+Dex|Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ.
3084796|NCT01556438|Experimental|300 mg Tabalumab+BTZ SC+Dex|Cohort 2-SC. 300 mg tabalumab (LY2127399)IV on day 1 of each cycle, each cycle is 21 days. BTZ, 1.3 mg/m^2, subcutaneously (SC) on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ. Cohort 2-SC was added per protocol amendment in February 2013.
3084797|NCT01556451|Experimental|Zoster Vaccine Live|Single subcutaneous injection of 0.65 mL in the deltoid region of arm on Day 1
3084798|NCT01556581|Active Comparator|Usual Care (UC)|The usual care (UC) group will be managed with stepped care approach, receiving a screening exam, advice, education, activity limitation profile and medications if needed, but no early physical therapy.
3084799|NCT01556581|Active Comparator|Early Physical Therapy (PT)|All subjects in this group will get usual care approach in addition to immediately receiving eight sessions of physical therapy based on a pragmatic treatment based classification system for treating low back pain.
3084800|NCT01556594|Experimental|Nasal Glucagon 1 mg|Nasal glucagon (NG) administered as single dose of 1 milligram (mg).
3084801|NCT01556594|Experimental|Nasal Glucagon 2 mg|NG administered as single dose of 2 mg.
3084802|NCT01556594|Active Comparator|SC Glucagon|Glucagon solution dose of 1 mg administered as a single subcutaneous (SC) injection.
3084803|NCT01556594|Experimental|Nasal Glucagon 3 mg|NG administered as single dose of 3 mg (composed of one dose of 1 mg NG immediately followed by one dose of 2mg NG).
3084804|NCT01556633|Experimental|Volunteers on dialysis|
3084805|NCT01556633|Experimental|Volunteers with reduced creatinine clearance|
3084806|NCT01556724|Active Comparator|0.2% ropivacaine nerve block (standard of care)|0.2% ropivacaine in lumbar plexus nerve catheter infusions for postoperative analgesia
3084807|NCT01556724|Experimental|0.1% ropivacaine infusion in nerve block catheter|0.1% ropivacaine in lumbar plexus nerve catheter infusions
3084808|NCT01556763|Placebo Comparator|Placebo|Matching placebo was administered as one capsule per day for 21 days.
3084809|NCT01556763|Experimental|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
3084810|NCT01556763|Experimental|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
3084811|NCT01556906|Experimental|Lomitapide|This is an open label trial where all patients receive lomitapide (AEGR733/BMS-201038)at escalating doses
3084812|NCT01556932|Experimental|Placebo then ABH|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
3084813|NCT01556932|Experimental|ABH then placebo|"All subjects randomized to two sequences of treatments: either placebo-ABH or ABH-placebo. All participants will receive both drug A and drug B.~After applying gel, Drug A or B, on wrists for 2 minutes, time 0. From baseline to 60 minutes of treatment two options will occur. At 60 minutes, if patients have at least 1 point reduction in their nausea score, they must wait 4 hours before switching to opposite drug. After administration of drug, the study procedures will be repeated. Or, at 60 minutes, if no change or increase in nausea score has been recorded, alternative treatment will be given. If the second treatment is ineffective at one hour (total time 2 hours) then alternative usual medications will be given. After completion of study treatment, patients are followed up for up to 8 hours."
3084814|NCT01556997|Experimental|XOMA 985|fixed-dose combination of perindopril arginine/amlodipine besylate(PERa/AMLb)
3084815|NCT01556997|Active Comparator|Amlodipine Besylate (AMLb)|
3084816|NCT01556997|Active Comparator|Perindopril Erbumine (PERe)|
3084817|NCT01557166|Experimental|Liraglutide 3.0 mg|
3084818|NCT01557166|Placebo Comparator|Placebo|
3084819|NCT01557244|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
3084820|NCT01557244|Experimental|Fesoterodine PR 8 mg|Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
3084821|NCT01557244|Active Comparator|Oxybutynin|Oxybutynin
3084822|NCT01557244|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
3084823|NCT01557244|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.
3084824|NCT01557283||Plaque psoriasis patients|Plaque psoriasis patients treated with Enbrel after the approval of the new belgian reimbursement criteria
3084825|NCT01557322||Biologic|
3084826|NCT01557322||non-biologic DMARD|
3084827|NCT01557348||Rituximab|Eligible participants will receive rituximab as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
3084828|NCT01557348||Alternative TNFi|Eligible participants will receive alternative TNFi treatment as second biologic therapy in routine clinical practice and were observed for 12 months from the start of the second biologic therapy.
3084829|NCT01557400|Experimental|Ataluren|Ataluren will be provided as a vanilla-flavored powder to be mixed with water, milk, fruit juice (except apple juice) fruit punch, or in semi-solid food (for example, yogurt, pudding, or applesauce). The dose level for ataluren will be 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening. Administration within 30 minutes after a meal will be recommended. Study drug dosing will be based on milligrams of drug per kilogram of body weight. Because of potential changes in participant body weight over time, weight-based dose adjustment can occur every 24 weeks as required. Study drug will be taken for up to 240 weeks.
3084830|NCT01557452|Experimental|Givinostat|Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014
3084831|NCT01557504|Experimental|Sitagliptin/metformin XR followed by placebo|Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
3084832|NCT01557504|Placebo Comparator|Placebo only|Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.
3084833|NCT01557517|Experimental|Clobetasol|Patients will rinse oral cavity with 10cc of clobetasol 0.05% for 2 minutes 3 times a day.
3084834|NCT01557517|Placebo Comparator|Placebo|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
3084835|NCT01557569|Active Comparator|Atomoxetine|Group receiving atomoxetine
3084836|NCT01557569|Placebo Comparator|Placebo|Group will receive placebo instead of atomoxetine
3084837|NCT01557582|Other|Right ventrical volumn comparison|Single arm study comparing Ventripoint Medical System (VMS) right ventricle volume measurement to gold standard cardiac Magnetic Resonance Imaging (cMRI) measurement in patients with Pulmonary Arterial Hypertension.
3084838|NCT01557595|Experimental|Adults with ADHD|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. Subjects will 19 years or older and have ADHD"
3084839|NCT01557699|Experimental|PMV via Puffhaler® Device|The dry powder measles vaccine will be administered via a Puffhaler® device. A single dose of 10 mg will be used.
3084840|NCT01557699|Experimental|PMV via SoloventTM device|The dry powder measles vaccine will be administered via a SoloventTM device. A single dose of 10 mg will be used.
3084841|NCT01557699|Active Comparator|Licensed Subcutaneous Measles Vaccine|Licensed measles vaccine will be administered subcutaneously as single dose of 0.5 ml.
3084842|NCT01557751|Other|Total knee arthroplasty subjects who are genotyped|All patients will have whole blood drawn for genotyping, and participate in the various assessments (psychosocial questionnaires, qualitative sensory testing, etc).
3084843|NCT01557790|Experimental|Proton RT|Subjects receive proton radiation for seminoma
3084844|NCT01557842|Active Comparator|Treatment Group|This group receives radiofrequency catheter ablation and drug treatment.
3084845|NCT01557842|Experimental|Control Group|This group receives only drug treatment.
3084846|NCT01557868|Active Comparator|Synvisc (hylan G-F 20)|
3084847|NCT01557868|Active Comparator|Euflexxa (1% sodium hyaluronate)|
3084848|NCT01557894|Experimental|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for Social Phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
3084849|NCT01557894|No Intervention|Waitlist control group|Waitlist control group
3084850|NCT01557920|Active Comparator|Propofol|The healthy subject will be anesthetized with Propofol. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
3084851|NCT01557920|Active Comparator|Sevoflurane|The healthy subject will be anesthetized with Sevoflurane. Respiratory measurements will be taken while the subject is anesthetized to calculate the airway closing pressure. After recovery from anesthesia, airway diameter and duty cycle will also be measured. In addition to breathing air mixture, subject will be given carbon dioxide to achieve end tidal CO2 levels of 4 mm and 8 mm above baseline. All respiratory measurements will be repeated at each level above baseline. Assessment of swallow patterns during anesthesia and wakefulness, as well as under differential CO2 levels will be assessed offline after recovery from anesthesia.
3084852|NCT01557946|Experimental|Major Depression|Participants with major depressive disorder received citalopram 20-40 mg daily for 6 weeks. MRI scans were acquired at baseline and days 3, 7, and 42.
3084853|NCT01557946|No Intervention|Healthy Volunteers|Healthy volunteer participants did not receive citalopram and performed one MRI scan.
3084854|NCT01557959|Experimental|Treatment (chemo, chemoprotection, antiangiogenesis therapy)|Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 1 hour on day 1, and pegfilgrastim subcutaneously on day 2. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of docetaxel, cisplatin, and pegfilgrastim, patients receive oral erlotinib hydrochloride once daily in the absence of disease progression or unacceptable toxicity.
3084855|NCT01558063|Active Comparator|Ketamine Dose 1|0.1 mg/kg, IV (in the vein) of Ketamine and MRI scan
3084856|NCT01558063|Active Comparator|Ketamine Dose 2|0.2 mg/kg, IV (in the vein) of Ketamine and MRI scan
3084857|NCT01558063|Active Comparator|Ketamine Dose 3|0.3 mg/kg, IV (in the vein) of Ketamine and MRI scan
3084858|NCT01558063|Active Comparator|Ketamine Dose 4|0.4 mg/kg, IV (in the vein) of Ketamine and MRI scan
3084859|NCT01558063|Active Comparator|Ketamine Dose 5|0.5 mg/kg, IV (in the vein) of Ketamine and MRI scan
3084860|NCT01558063|Placebo Comparator|Saline Solution|Saline infused over 40 minutes and MRI scan
3084861|NCT01558089||etanercept + methotrexate|
3084862|NCT01558128|Other|Amiodarone with cardioversion|If subject converts to normal sinus rhythm following amiodarone no further intervention is taken, if subject remains in atrial fibrillation following amiodarone they are cardioverted.
3084863|NCT01558271|Experimental|LY2189265|Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
3084864|NCT01558271|Placebo Comparator|Placebo/LY2189265|Once-weekly SC injection of placebo for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy.
3084865|NCT01558271|Active Comparator|Liraglutide|Once-daily SC injection of 0.3 mg of Liraglutide for the first week, followed by 0.6 mg of Liraglutide for the second week, and then 0.9 mg of Liraglutide for the remaining 50 weeks of open therapy.
3084866|NCT01558297|Experimental|Motivational Interviewing|
3084867|NCT01558297|Active Comparator|Nutritional Counseling|
3084868|NCT01558297|Active Comparator|Treatment as usual|
3084869|NCT01558596|Placebo Comparator|Sham|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
3084870|NCT01558596|Experimental|RIPC|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
3084871|NCT01558635|Experimental|Cardioblate CryoFlex Surgical Ablation|Subjects with longstanding persistent AF undergoing Maze III procedure using the Cardioblate CryoFlex Surgical Ablation System concomittant to Mitral valve surgery. During surgery, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor future episodes of AF.
3084872|NCT01558661|Experimental|AG-013736 (AXITINIB)|This is a single-arm phase II study evaluating the clinical efficacy of axitinib in the treatment of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (ACC).
3084873|NCT01558674|Experimental|MK-7145 8 mg (Part I:Period 1)|Single daily dose of 8 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
3084874|NCT01558674|Active Comparator|Furosemide 40 mg (Part I:Period 2)|Two daily doses of one 40 mg Furosemide tablet for 5 days administered in a fasted state
3084875|NCT01558674|Experimental|MK-7145 16 mg (Part I:Period 3)|Single daily dose of 16 mg MK-7145 for 5 days, capsules, orally administered in a fasted state
3084876|NCT01558674|Active Comparator|Furosemide/Torsemide Run-in (Part II:Period1)|Run-in of stable, clinically optimized maintenance dose regimen of furosemide or torsemide for at least 2 weeks
3084877|NCT01558674|Experimental|MK-7145 10 mg (Part II:Period 2)|Single daily dose of 10 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
3084878|NCT01558674|Experimental|MK-7145 16 mg (Part II:Period 3)|Single daily dose of 16 mg MK-7145 for 14 days, capsules, orally administered in a fasted state
3084879|NCT01558674|Experimental|MK-7145 24 mg (Part II:Period 4)|Single dose of 24 mg MK-7145 for 28 days, capsules, orally administered in a fasted state
3084880|NCT01558700|Experimental|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
3084881|NCT01558700|Placebo Comparator|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
3084882|NCT01558739|Experimental|INC424|Patients diagnosed with PMF, PPV MF, or PET-MF were treated with oral INC424 at a dose of 15 - 20 mg (dose based on Baseline platelet count) twice daily.
3084883|NCT01558752|Experimental|Titanium Shell with CORAIL stem|Patients in Group 1 will receive a total hip replacement with titanium shell and CORAIL stem.
3084884|NCT01558752|Active Comparator|Modular Titanium Femoral Stem (Tri-Lock)|Patients in Group 2 will receive a total hip replacement with Modular Titanium Femoral Stem (Tri-lock).
3084885|NCT01558791|No Intervention|Arm 1|"Participants will be screened as usual. These participants will have the TBI screening as usual, without the educational intervention."
3084886|NCT01558791|Experimental|Arm 2|Participants will be given the TBI handout (educational intervention) along with the usual TBI screen.
3084887|NCT01559012|Other|clonidine first - placebo second|in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
3084888|NCT01559012|Other|placebo first - clonidine second|in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days
3084889|NCT01559064||Age group A|Subjects 30 to 40 years old
3084890|NCT01559064||Age group B|Subjects 40 to 50 years old
3084891|NCT01559064||Age group C|Subjects over 50 years old
3084892|NCT01559090|Experimental|1|MEDI-546 100 mg IV
3084893|NCT01559090|Experimental|2|MEDI-546 300 mg IV
3084894|NCT01559090|Experimental|3|MEDI-546 1000 mg IV
3084895|NCT01559116|Experimental|tiotropium+olodaterol FDC low dose|tiotropium+olodaterol FDC low dose; 2 inhalations once daily (a.m. dosing)
3084896|NCT01559116|Experimental|tiotropium+olodaterol FDC high dose|tiotropium+olodaterol FDC high dose; 2 inhalations once daily (a.m. dosing)
3084897|NCT01559116|Active Comparator|tiotropium low dose|tiotropium low dose; 2 inhalations once daily (a.m. dosing)
3084898|NCT01559116|Active Comparator|tiotropium high dose|tiotropium high dose; 2 inhalations once daily (a.m. dosing)
3084899|NCT01559116|Active Comparator|olodaterol|one dose only; 2 inhalations once daily (a.m. dosing)
3084900|NCT01559116|Placebo Comparator|placebo|2 inhalations once daily (a.m. dosing)
3084901|NCT01559129|Placebo Comparator|Placebo|
3084902|NCT01559129|Experimental|Pomalidomide|Participants received 1 mg pomalidomide orally once a day for 52 weeks during the treatment phase and for up to 2 years during the open-label extension phase.
3084903|NCT01559259|Experimental|Ibuprofen/acetaminophen (lower dose)|
3084904|NCT01559259|Experimental|Ibuprofen/acetaminophen (middle dose)|
3084905|NCT01559259|Experimental|Ibuprofen/acetaminophen (high dose)|
3084906|NCT01559259|Active Comparator|Ibuprofen|
3084907|NCT01559259|Placebo Comparator|Placebo|
3084908|NCT01559311|Active Comparator|CRT-P OFF|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF"
3084909|NCT01559311|Experimental|CRT-P ON|"Patients randomized into the Echo-guided Group were implanted with a CRT-P device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:~• Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON"
3084910|NCT01559311|Active Comparator|DDDR|Patients randomized into the Control Group were implanted with a DDDR device (St. Jude Medical) standard therapy.
3084911|NCT01559389|Experimental|Female Partners|This arm comprises female partners who receive up to 16 weeks of solifenacin treatment for their UUI symptoms
3084912|NCT01559389|No Intervention|Male Partners|This arm comprises healthy male partners
3084913|NCT01559454|Active Comparator|Methadone|10-60 mg/day divided by 2-4 times a day
3084914|NCT01559454|Experimental|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day
3084915|NCT01559506|No Intervention|No device|Subject does not receive ABS system
3084916|NCT01559506|Experimental|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
3084917|NCT01559649||Group 1|Veterans admitted to MEDVAMC with a suspected ischemic or hemorrhagic stroke will be recruited. Individuals with a history of neurological disease other than stroke, head and neck structural surgery, or history of dysphagia unrelated to the current stroke will be excluded from participation. Individuals who are obtunded, medically unstable, greater than 5 days post-admission will be excluded. Patients with language or cognitive deficits who are judged by the attending neurologist to not have capacity to provide informed consent will be eligible to participate, but they must have an authorized representative available within 24 hours of admission to provide consent. Patients will undergo swallowing screening and videofluoroscopic swallowing study to establish validity of screening items
3084918|NCT01559649||Group 2|Stroke ward nurses. The nurses will administer and interpret the swallowing screening items. Speech pathologists will also make blinded, simultaneous interpretations of the screening items. Nurse and speech pathologist interpretation will be used to establish nursing reliability.
3084919|NCT01559675|Active Comparator|Hydrocortisone High Dose|Intervention: Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
3084920|NCT01559675|Experimental|Hydrocortisone Low Dose|Intervention: 1/3 Intravenous equivalent dose (IVED) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD) 1, followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
3084921|NCT01559844|Experimental|SOF+RBV|Sofosbuvir plus ribavirin for up to 48 weeks or until time of transplant, whichever occurs first.
3084922|NCT01559857|Active Comparator|Pioglitazone|50% of participants will be allocated to 12 weeks of treatment with 30 mg/day of Pioglitazone.
3084923|NCT01559857|Placebo Comparator|Sugar pill|50% of participants will be randomized to 12 weeks of treatment with placebo pill.
3084924|NCT01559922|Placebo Comparator|Placebo|Normal Saline
3084925|NCT01559922|Experimental|Artefill|Dermal Filler
3084926|NCT01559935|Experimental|Car-BiRD Therapy|Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD]
3084927|NCT01559948|Experimental|Lumbopelvic stabilization exercises plus sacroiliac joint belt|The participants will be instructed in the lumbopelvic stabilization program. Additionally, during the initial session, these participants receive a sacroiliac compression belt and be instructed to wear the belt during all waking hours for the first four weeks of the study.
3084928|NCT01559948|Active Comparator|Lumbopelvic stabilization exercise|The participants will be instructed in the lumbopelvic stabilization program.
3084929|NCT01560143|Other|Tigecycline|All subjects receive a single dose of tigecycline
3084930|NCT01560234|Experimental|AZD8848|
3084931|NCT01560234|Placebo Comparator|Placebo|
3084932|NCT01560260|Experimental|Treatment (linsitinib)|Patients receive linsitinib 150mg orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3084933|NCT01560286|Experimental|Group 1|4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
3084934|NCT01560377|Experimental|Subjects Imaged with PINPOINT|Colonic tissue perfusion assessed with PINPOINT for laparoscopic left colectomy in the lower tract.
3084935|NCT01560403|Experimental|Teduglutide|0.05 mg/kg/day
3084936|NCT01560416|Active Comparator|ARM A - Fulvestrant|Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
3084937|NCT01560416|Active Comparator|Arm B - Fulvestrant+Ganetespib|"Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle~Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression."
3084938|NCT01560429|Experimental|Patient controlled epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion until stable pain scores of ≤ 3 were reached while in PACU. Once stable, they were allocated to their preoperatively determined randomization which meant they still received 2/3rd of the anesthetic as a background infusion but also had the option to self-administer the remaining 1/3rd dose as patient controlled epidural analgesia (PCEA). Rescue analgesia was available upon request.
3084939|NCT01560429|Active Comparator|continuous epidural analgesia|An epidural catheter sited preoperatively so analgesics can be administered postoperatively. Patients were titrated on a continuous analgesic epidural infusion rate until stable pain scores of ≤ 3 were reached while in PACU (as described in the PCEA group). Once stable, they were allocated to their preoperatively determined randomization assignment which for the CEA group meant they remained on the continuous background epidural infusion rate previously determined to maintain pain scores ≤ 3 while in PACU. Rescue analgesia was available as needed.
3084940|NCT01560624|Experimental|UT-15C|Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID
3084941|NCT01560624|Placebo Comparator|Placebo|Matching placebo tablets (oral)
3084942|NCT01560780|Experimental|Arm 1: Prasugrel|prasugrel 10 mg by mouth daily
3084943|NCT01560780|Placebo Comparator|Arm 2: Placebo|placebo by mouth once daily
3084944|NCT01560819|Experimental|Study Participants|Participants did not receive any bowel preparation before Gut Microbial Transplantation (GMT). Audio-visual aids were used to help reduce participants' anxiety about GMT.
3084945|NCT01560871|Sham Comparator|Low-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 15% PImax. The walking program consisted of walking every day at an intensity of somewhat hard to hard on the Borg's Rating of Perceived Exertion (RPE) scale. Participants were encouraged to walk at 10 to 15 minutes, once to twice a day initially, then progressed to 45-50 minutes a day by the end of the six weeks, if they could tolerate."
3084946|NCT01560871|Experimental|High-intensity IMT Plus Walking|"Inspiratory Muscle Training (IMT) intensity was set at 60% PImax.~The walking program was the same as the one for the control group."
3084947|NCT01560923|Experimental|Sipuleucel-T + Oral Indoximod|Oral Indoximod will be self-administered by mouth twice daily (1200 mg) for 6 months starting after the last (3rd) infusion of sipuleucel-T. Indoximod is a sterile tan powder compounded in capsule form of 200 mg.
3084948|NCT01560923|Placebo Comparator|Sipuleucel-T + Placebo|Placebo is identical-looking to Indoximod and provided in the same manner.
3084949|NCT01560949|Experimental|Chemotherapy + Radiation|"SYSTEMIC PHASE: Chemotherapy with Oxaliplatin followed by Irinotecan followed by 5-FU. m FOLFIRINOX - oxaliplatin 75 mg/m2 d1 + irinotecan 150 mg/m2 d1 + 5-FUl 2,000 mg/m2 46h continuous infusion, every other week for 6 cycles (12 weeks).~CHEMORADIATION PHASE: This phase will start at least 2 weeks, but no more than 6 weeks after completion of the last cycle of mFOLFIRINOX. Chemoradiation with Gemcitabine: 350 mg/m2 IV over 35 minutes every week for 5 doses beginning day 1 (days 1, 8, 15, 22, 29)~Radiation: External beam radiation therapy will be delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions) to the GTV + 1.5 cm margin.~SURGERY- At least 4-6 weeks after last dose of Gemcitabine, if no local progression or distant metastasis. Patients whose scans show unequivocal local or distant progression are not candidates for surgery."
3084950|NCT01560975|Experimental|Sensimed Triggerfish|
3084951|NCT01560988|Experimental|Active Borage and Echium Seed Oils|Borage and echium oil capsules administered daily for six weeks, then a 6 week washout period, followed by ingestion of placebo (corn oil capsules) daily for 6 weeks.
3084952|NCT01560988|Experimental|Corn oil pills|Corn oil capsules daily for six weeks, then a 6 week washout period, followed by ingestion of Borage and echium oil capsules daily for 6 weeks.
3084953|NCT01561053|Experimental|High Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with high dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
3084954|NCT01561053|Experimental|Low Albumin + Immunoglobulin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% or immunoglobulin 5% (maintenance treatment period)
3084955|NCT01561053|Experimental|Low Albumin|Therapeutic plasma exchange with albumin 5% (intensive treatment period) + Low volume plasma exchange with low dose of albumin 20% (maintenance treatment period)
3084956|NCT01561053|No Intervention|Control (sham) group|Simulated plasma exchange procedure
3084957|NCT01561079|Experimental|Maternal buprenorphine treatment|Buprenorphine maintenance during pregnancy
3084958|NCT01561300|Placebo Comparator|Control|Nutrition intervention study with a control
3084959|NCT01561300|Experimental|Tea extract|Nutrition intervention study with a black tea extract
3084960|NCT01561313|Active Comparator|Current formulation adalimumab|One dose with 40 mg of current formulation of adalimumab in a pre-filled syringe
3084961|NCT01561313|Experimental|New formulation of adalimumab|One dose with 40 mg of new formulation of adalimumab in a pre-filled syringe
3321122|NCT02016417|Experimental|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
3084966|NCT01561469||Linezolid observational cohort|
3084967|NCT01561469||Vancomycin observational cohort|
3084968|NCT01561560|Other|DAILIES TOTAL1, then TRUEYE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
3084969|NCT01561560|Other|TRUEYE, then DAILIES TOTAL1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product was worn bilaterally on a daily wear, daily disposable basis for two weeks.
3084970|NCT01561703|Experimental|Anitibiotic|Patients will receive postoperative antibiotic after surgery.
3084971|NCT01561703|No Intervention|Control|Patients will NOT receive postoperative antibiotic
3084972|NCT01561716|Experimental|Crossover sequence 1|Resting/Wii Fit Free Run/Wii Fit 3 bouts/treadmill
3084973|NCT01561716|Experimental|Crossover sequence 2|Resting/Wii Fit Free Run/treadmill/Wii Fit 3 bouts
3084974|NCT01561716|Experimental|Crossover sequence 3|Resting/Wii Fit 3 bouts/Wii Fit Free Run/treadmill
3084975|NCT01561716|Experimental|Crossover sequence 4|Resting/Wii Fit 3 bouts/treadmill/Wii Fit Free Run
3084976|NCT01561716|Experimental|Crossover sequence 5|Resting/treadmill/Wii Fit Free Run/Wii Fit 3 bouts
3084977|NCT01561716|Experimental|Crossover sequence 6|Resting/treadmill/Wii Fit 3 bouts/Wii Fit Free Run
3084978|NCT01561755|Experimental|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
3084979|NCT01561755|Placebo Comparator|Placebo|Saline 2gr/kg over 2 days of saline
3084980|NCT01561833|Experimental|Sorafenib|Sorafenib, 400 mg PO twice daily
3084981|NCT01561898|Experimental|Paliperidone extended-release (JNS007ER)|
3084982|NCT01561963|Experimental|Apremilast and Rifampin|"Participants received the following 3 treatment regimens:~A single oral dose of 30 mg apremilast on Day 1 (Period 1);~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 (Period 2);~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 (Period 3)."
3084983|NCT01561976|Active Comparator|Metformin hydrochloride prolonged release|1000mg in fasting state
3084984|NCT01561976|Active Comparator|metformin hydrochloride prolonged release|1000mg In fed state
3084985|NCT01561976|Active Comparator|Metformin hydrochloride sustained release/Glimepiride|1000/2mg In fed state
3084986|NCT01562028|Experimental|Erlotinib plus bevacizumab|Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
3084987|NCT01562041|Experimental|Ranolazine 500 mg|Participants received ranolazine 500 milligrams (mg), orally, twice daily (b.i.d.) up to 14 days.
3084988|NCT01562132|Experimental|5FC plus fluconazole|Combination therapy with oral fluconazole and flucytosine
3084989|NCT01562132|Active Comparator|fluconazole alone|Fluconazole monotherapy
3084990|NCT01562275|Experimental|Dose escalation stage 1 (Arm A): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 40 mg) and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify maximum tolerated dose (MTD) or potential recommended Phase 2 dose (RP2D). Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3084991|NCT01562275|Experimental|Dose escalation stage 1 (Arm B): Cobimetinib and Ipatasertib|Participants will receive cobimetinib (GDC-0973) capsules (at a starting dose of 100 mg) on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules (at a starting dose of 200 mg) from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles. Doses will be increased to identify MTD or potential RP2D. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets.
3084992|NCT01562275|Experimental|Stage 2 (Indication specific dose expansion cohort)|Participants will receive cobimetinib (GDC-0973) capsules on Days 1, 4, 8, 11, 15, and 18 and ipatasertib (GDC-0068) capsules from Days 1 to 21 and then 7 days off study drugs from Days 22 to 28 in continuous 28-day cycles, at doses identified as MTD/potential RP2D from Stage 1. Treatment will continue until disease progression, unacceptable toxicity, or any other discontinuation criterion meets. This indication specific cohort will include participants with phosphatase and tensin homolog (PTEN)-loss triple-negative breast cancer and PTEN-loss endometrial carcinoma.
3084993|NCT01562314|Experimental|GWP42003|GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
3084994|NCT01562314|Placebo Comparator|Placebo|Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
3084995|NCT01562327||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA) received Tocilizumab according to individualized physician-prescribed regimens.
3084996|NCT01562379|No Intervention|No food|A control in which mothers will receive nutrition education about continued breastfeeding and adequate complementary feeding throughout the period of 6-18 months of age.
3084997|NCT01562379|Active Comparator|Plumpy Doz|In this control arm children will receive prepackaged, lipid-based Plumpy'Doz (Nutriset, Mulaunay, France) for daily consumption as a snack.
3084998|NCT01562379|Experimental|Wheat Soy Blend (WSB++)|Children will receive a WFP-developed Wheat-Soy Blend (WSB++) snack to be consumed daily.
3084999|NCT01562379|Experimental|Chickpea based complementary food supplement|Children will receive a Chickpea based complementary food supplement to be consumed daily.
3085000|NCT01562379|Experimental|Rice based complementary food supplement|Children will receive a locally developed rice based complementary food supplement.
3085001|NCT01562444|Other|TBE_R Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to rapid (R) schedule i.e., on days 0, 7 (+3) and 21 (+7) in the parent study (V48P7) and who were administered 1 booster dose of Encepur adults either 12-18 months after R schedule completion or in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination (for those subjects boostered before V48P7E1 study start, the blood draw occurred annually starting from >6 years up to >10 years after booster vaccination).
3085002|NCT01562444|Other|TBE_C Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to conventional (C) schedule i.e., on days 0, 28 (+10) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
3085003|NCT01562444|Other|TBE_AC Group|Subjects who had previously received the Tick borne encephalitis (TBE) primary vaccination according to accelerated conventional (AC) schedule i.e., on days 0, 14 (+3) and 300 (+21) in the parent study (V48P7) and were administered 1 booster dose of Encepur adults in the first extension study, V48P7E1 (NCT00387634), were included in this group. Subjects had blood drawn annually starting from year 6 up to year 10 after booster vaccination.
3085004|NCT01562548|Experimental|Arm 1|Guaifenesin 1 tablet BID
3085005|NCT01562548|Experimental|Arm 2|Guaifenesin 2 tablets BID
3085006|NCT01562548|Placebo Comparator|Arm 3|Placebo 1 tablet BID
3085007|NCT01562548|Placebo Comparator|Arm 4|Placebo 2 tablets BID
3085008|NCT01562613||Hypertensive patients|All eligible hypertensive patients treated with eprosartan
3085009|NCT01562678|Experimental|Liraglutide|
3085010|NCT01562678|Placebo Comparator|Placebo|
3085011|NCT01562743|Experimental|SPM 962|Rotigotine transdermal patch
3085012|NCT01562756|Experimental|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
3085013|NCT01562782|Experimental|South Asians|Participants in this group have only South Asian heritage. The intervention is Fructose + Glucose Beverage.
3085014|NCT01562782|Active Comparator|Caucasians|Participants in this group have only Caucasian heritage. The intervention is Fructose + Glucose Beverage.
3085015|NCT01562873|Experimental|Ruxolitinib-Cohort A|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
3085016|NCT01562873|Experimental|Ruxolitinib-Cohort B|Patients received Ruxolitinib 25 mg twice daily for up to 12 cycles (cycle duration=28 days) until evidence of disease progression or unacceptable toxicity. Patients enrolled sequentially into two possible cohorts based on pStat3+ expression score by central testing: Cohort A - moderate to high positive status defined as a score of >/=5 by central testing or Cohort B - low positive status defined as a score of 3-4. Each cohort was evaluated with a 2 stage design. Cohort B only opened if 2 objective responses were observed in 1st stage Cohort A patients (n=21).
3085017|NCT01562886|Experimental|Rilpivirine and Truvada|TDF/FTC (Truvada™) one tablet once plus Rilpivirine 25 mg daily
3085018|NCT01563003|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 16 weekly CBT sessions. This intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposures to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases
3085019|NCT01563003|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3085020|NCT01563029|Active Comparator|Arm 1|Fluticasone Furoate 100mcg inhalation powder once daily in the evening ICS powder
3085021|NCT01563029|Active Comparator|Arm 2|Fluticasone Furoate 50mcg inhalation powder once daily in the evening ICS powder
3085022|NCT01563029|Active Comparator|Arm 3|Fluticasone Furoate 25mcg inhalation powder once daily in the evening ics powder
3085023|NCT01563029|Active Comparator|Arm 4|Fluticasone Propionate 100mcg inhalation powder twice daily ICS powder
3085024|NCT01563029|Placebo Comparator|Arm 5|Placebo inhalation powder once daily in the evening Placebo powder
3085025|NCT01563055|Experimental|ofatumumab + chlorambucil|ofatumumab dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days; chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3085026|NCT01563081|Experimental|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution
3085027|NCT01563172|Experimental|Experimental dentifrice 0.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
3085028|NCT01563172|Experimental|Experimental dentifrice 1.5g, 45 seconds brushing group|Participants brush twice a daily for 45 seconds with experimental dentifrice.
3085029|NCT01563172|Experimental|Experimental dentifrice 0.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
3085030|NCT01563172|Experimental|Experimental dentifrice 1.5g, 2 minutes brushing group|Participants brush twice a daily for 2 minutes with experimental dentifrice.
3085031|NCT01563172|Active Comparator|Contol group|Participants brush twice a daily for 2 minutes with controll dentifrice.
3085032|NCT01563185|Experimental|DUEXIS|800 mg ibuprofen/26.6 mg famotidine
3085033|NCT01563198|Experimental|Comfort Talk® Training|The MRI units of three clinical sites form the group. Their personnel will be trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests
3085034|NCT01563237|Experimental|MIDI Arrow|Implantation of MIDI Arrow
3085035|NCT01563354|Experimental|Pasireotide LAR|Pasireotide long acting release (LAR) 60 mg will be administered as an intra muscular (i.m.) depot injection once every 28 days starting on Day 1
3085036|NCT01563354|Experimental|Everolimus|Everolimus 10 mg taken orally (p.o) once daily starting on Day 1
3085037|NCT01563354|Experimental|Pasireotide LAR and Everolimus Combination|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily starting on Day 1
3085038|NCT01563406|Experimental|Alcohol with 5 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
3085039|NCT01563406|Experimental|Alcohol with 15 second scrub|70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
3085040|NCT01563406|Experimental|Chlorhexidine with 5 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 5 seconds.
3085041|NCT01563406|Experimental|Chlorhexidine with 15 second scrub|3.15% chlorhexidine/70% isopropyl alcohol will be used to scrub catheter hubs for a duration of 15 seconds.
3085042|NCT01563536|Experimental|ABT-267 1.5 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (1.5 mg once daily) as monotherapy for 2 days, then ABT-267 (1.5 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
3085043|NCT01563536|Experimental|ABT-267 25 mg, then ABT-267, ABT-450/r, ABT-333, plus RBV|ABT-267 (25 mg once daily) as monotherapy for 2 days, then ABT-267 (25 mg once daily), ABT-450/r (150 mg/ 100 mg once daily) and ABT-333 (400 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) combination therapy for 12 weeks
3085044|NCT01563913|Experimental|Arm 1|Docosahexaenoic Acid (DHA)
3085045|NCT01563913|Placebo Comparator|Arm 2|Placebo
3085046|NCT01563978|Experimental|Dosing Regimen A|Oral treatment
3085047|NCT01563978|Placebo Comparator|Dosing Regimen B|Oral treatment
3085048|NCT01564277|Experimental|Arm I (1.5mg rasburicase)|Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
3085049|NCT01564277|Experimental|Arm II (3 mg rasburicase)|Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
3085050|NCT01564394|Experimental|Qigong|Qigong originated in China hundreds of years ago and has been practiced for centuries. It consists of a sequence of slow, flowing physical movements with concentration on the breath and awareness and may promote physical and mental relaxation and energy balance.
3085051|NCT01564394|Sham Comparator|Stretching control|The non-aerobic stretching will serve as an attention control group to control for non-specific factors; dose of attention and to mimic being in a group setting.
3085052|NCT01564407|Experimental|Safety Cohort|"Stable restrictive scar contractures resulting from abdominal surgical incision, not transversing a joint. The minimum scar length of 7 cm and a maximum scar area size of 80cm². The scar is divided into five injection areas with a minimum of 0.5 cm uninjected areas between the 5 sites.Drug Dosing for Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4 Subjects in Cohort 1 will undergo elective surgeries, at which time the treated scars will be removed, at week 6-8 post-treatment of the first dosed subject."
3085053|NCT01564407|Active Comparator|2.5M cells/cm2|Participants receive intervention treatment of 2.5 million cells/ cm2, single administration injected into the scar.
3085054|NCT01564407|Active Comparator|5M cells/cm2|Participants receive intervention treatment of 5 million cells /cm2, single administration
3085055|NCT01564407|Active Comparator|2.5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 2.5 million cells/ cm2, repeat dose administration @ 4 weeks
3085056|NCT01564407|Active Comparator|5M cells/cm2 at 4 weeks|Participants receive intervention treatment of 5 million cells / cm2 repeat dose administration @ 4 weeks
3085057|NCT01564459|Experimental|MK-6096 10 mg→MK-6096 10 mg|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive MK-6096 10 mg once daily for 2 weeks during double-blind treatment period.
3085058|NCT01564459|Placebo Comparator|MK-6096→Placebo|Participants receive MK-6096 10 mg during run-in once daily for 1 week and receive placebo once daily for 2 weeks during double-blind treatment period.
3085059|NCT01564485|Experimental|Cardiac CT|Patients randomized to cardiac CT will obtain a non-invasive assessment of their coronary arteries.
3085060|NCT01564485|Active Comparator|Usual Care|Patients randomized to usual care will be assigned to continuing usual medical care with their primary care physician
3468898|NCT03891407|Experimental|HIV Self-testing Group|Camp members will receive information about HIV self-testing from peer educators who will be nominated by you and other camp members in your camp. Camp members in the STEP project will receive pretest counseling and a 10 minute demonstration. They will receive 1 oral fluid HIV self-test kit to conduct the self-test at home or in a private location during the next 1 month and a phone number to call in case you need assistance when performing the self-test at home. They will also receive information about the nearest HIV Care and Treatment Center where they can seek a confirmatory HIV test and start HIV treatment in the event of a positive self-test result.
3468899|NCT03891407|No Intervention|Non-intervention Group|Camp members will be encouraged to seek HIV testing at the clinics.
3085063|NCT01564628||All study participants|Population from 2 sites, sequential design with all patients undergoing CADScor1 intervention followed by the diagnostic testing the patients were referred to (procedure done according to standard of care and not part of study; computerized tomographic angiography (CTA) and, if relevant, coronary angiography (CAG) at Site 1 and CAG at site 2).
3085064|NCT01564654||iTotal KRS|
3085065|NCT01564693||ANOREXIC CANCER PATIENTS|Nine lung cancer patients were diagnosed as anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
3468900|NCT03891680|Experimental|Botox injection|
3468901|NCT03891680|Active Comparator|Genicular Radio frequency|
3085066|NCT01564693||NON-ANOREXIC CANCER PATIENTS|Four lung cancer patients were diagnosed as non-anorexic based on the results obtained by the appetite assessment tools we used. These patients were studied by fMRI regarding the hypothalamic activity.
3085067|NCT01564693||CONTROL GROUP|Two healthy volunteers with normal appetite were studied by fMRI regarding the hypothalamic activity.
3085068|NCT01564706|Experimental|Healthy Volunteers|Healthy male or female subjects, between 18 and 85 years of age.
3085069|NCT01564758||Group 1|Subjects that are diagnosed with gram positive infection
3085070|NCT01564784|Experimental|Arm A|
3085071|NCT01564784|Active Comparator|Arm B|
3085072|NCT01564862|Experimental|Vortioxetine (Lu AA21004) QD|Vortioxetine (Lu AA21004) 10 mg, capsules, orally, once daily for one week; then dose adjustment to a maximum 20 mg, capsules, orally, once daily for up to 7 weeks.
3085073|NCT01564862|Active Comparator|Duloxetine QD|Duloxetine 60 mg, capsules, orally, for up to 8 weeks. Duloxetine 30 mg, capsule, orally, once daily for 1 week taper-down period.
3085074|NCT01564862|Placebo Comparator|Placebo QD|Placebo matching capsules, orally, once daily for up to 9 weeks (includes 1 week taper down period).
3085075|NCT01564914|Experimental|TRC105, Bevacizumab|Single arm study
3085076|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Separate Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle (1 cycle = 21 days) as a loading dose of 840 milligrams (mg), followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg per kilogram (mg/kg), followed by 6 mg/kg on Day 2 of each subsequent cycle. Vinorelbine IV infusion (will be administered after trastuzumab) on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg per meter-squared (mg/m^2) followed by 30-35 mg/m^2 on Day 2 and Day 9 of each subsequent cycle. Pertuzumab and trastuzumab will be administered sequentially in separate infusion bags, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
3085077|NCT01565083|Experimental|Pertuzumab + Trastuzumab + Vinorelbine: Single Infusion|Pertuzumab will be administered as IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent cycle. Trastuzumab will be administered as IV infusion on Day 2 of the first treatment cycle as a loading dose of 8 mg/kg, followed by 6 mg/kg on Day 1 of each subsequent cycle. Vinorelbine IV infusion on Day 2 and Day 9 of the first treatment cycle at a dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Day 1 and Day 8 of each subsequent cycle. If administration of all 3 drugs is well tolerated in Cycle 1, then on Day 1 of each subsequent cycle, pertuzumab 420 mg and trastuzumab 6 mg/kg will be administered in a single infusion bag, followed by vinorelbine until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end (up to 47 cycles).
3085078|NCT01565148|Experimental|Group 1|"Drug: iCo-007 350 mcg~iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4"
3085079|NCT01565148|Experimental|Group 2|"Drug: iCo-007 700 mcg~iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4"
3085080|NCT01565148|Experimental|Group 3|"Drug: iCo-007 350 mcg and Laser~iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation"
3085081|NCT01565148|Experimental|Group 4|"Drug: Ranibizumab and iCo-007 350 mcg~Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later"
3085082|NCT01565291|Experimental|Subjects With AD|Probable AD, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with mild/moderate dementia (Mini-Mental State Examination (MMSE) from 10 to 24)
3085083|NCT01565291|Experimental|Healthy Elderly Subjects|Cognitively normal with MMSE of 29 or higher; age 50 years or older
3085084|NCT01565330|Experimental|111 MBq (3 mCi) AD Group|Subjects with AD who received 111MBq (3 mCi) of florbetapir F 18; MBq=megabecquerel
3085085|NCT01565330|Experimental|111 MBq (3 mCi) Control Group|Healthy controls who received 111MBq (3 mCi) of florbetapir F 18
3085086|NCT01565330|Experimental|370 MBq (10 mCi) AD Group|Subjects with AD who received 370MBq (10 mCi) of florbetapir F 18
3085087|NCT01565330|Experimental|370 MBq (10 mCi) Control Group|Healthy controls who received 370MBq (10 mCi) of florbetapir F 18.
3085088|NCT01565343|Experimental|AD Subjects|Two bolus IV injections followed by brain PET scan up to 4 weeks apart
3085089|NCT01565343|Experimental|AD Subjects: Slow vs. Fast Bolus|"Two bolus IV injections followed by a brain PET scan up to 4 weeks apart.~The first injection given as a rapid bolus (< 5 second injection, with immediate flush). The second injection given as a slow bolus (approximately 20 to 30 second injection with a flush delayed by 10 seconds after dose administration)."
3085090|NCT01565343|Experimental|Healthy controls|Healthy male or female subjects; 35-55 years old. Two bolus IV injections followed by brain PET scan up to 4 weeks apart
3085091|NCT01565499|Experimental|Nab-Paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
3085092|NCT01565538|Experimental|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression.
3085093|NCT01565538|Experimental|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks until progression.
3085094|NCT01565551||Early-Presenting TBI: Acute Sites|This cohort of patients are studied after acute presentation within 24 hours of TBI to one of the three TRACK-TBI acute Level I Trauma Centers (SFGH, UPMC, UMCB).
3085095|NCT01565551||Late-Presenting TBI: Rehabilitation Center|This cohort of patients are studied after presentation to the TRACK-TBI rehabilitation site (MSMC).
3085096|NCT01565564|Active Comparator|The usual care arm|
3085097|NCT01565564|Active Comparator|The shared care arm|
3085098|NCT01565616|Experimental|Bone Marrow Transplant Recipients|Adults with sickle cell disease undergoing a bone marrow transplant from an HLA-identical sibling donor or an unrelated HLA-matched donor.
3085099|NCT01565642|Experimental|Decision support intervention|Decision aid and care plan meeting
3085100|NCT01565642|No Intervention|Control|Attention control information on dementia care
3085101|NCT01565668|Experimental|AC220 Dose Level 1|
3085102|NCT01565668|Experimental|AC220 Dose Level 2|
3085103|NCT01565694|Experimental|Solifenacin succinate|"Participants aged 5 years to < 18 years received solifenacin orally once a day, with sequential titrated doses for 12 weeks to identify the optimal dose during the dose-titration period. The initial dose was pediatric equivalent dose (PED) 5 mg.~After completing the dose titration period participants entered the fixed-dose period during which solifenacin was taken orally once a day for 40 weeks or until the end of study visit (Week 52)."
3085104|NCT01565707|Placebo Comparator|Placebo Children|Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
3085105|NCT01565707|Experimental|Solifenacin Succinate Suspension Children|Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
3085106|NCT01565707|Placebo Comparator|Placebo Adolescents|Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
3085107|NCT01565707|Placebo Comparator|Solifenacin Succinate Suspension Adolescents|Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
3085108|NCT01565850|Experimental|D/C/F/TAF|D/C/F/TAF FDC tablet plus DRV placebo plus COBI placebo plus FTC/TDF placebo
3085109|NCT01565850|Active Comparator|DRV+COBI+FTC/TDF|DRV tablet plus COBI tablet plus FTC/TDF 200/300 mg FDC tablet plus D/C/F/TAF placebo
3085110|NCT01565889|Experimental|Part A: SOF+EFV/FTC/TDF (Cohort 1)|Participants with a prestudy regimen of EFV/FTC/TDF will receive SOF+EFV/FTC/TDF FDC for 7 days, followed by EFV/FTC/TDF FDC (or EFV+FTC/TDF) for 7 days, coadministered once daily in the evening under fasting conditions.
3085111|NCT01565889|Experimental|Part A: SOF+EFV+ZDV/3TC (Cohort 2)|Participants with a prestudy regimen of EFV+ZDV/3TC will receive SOF+EFV+ZDV/3TC for 7 days followed by EFV+ZDV/3TC for 7 days. Sofosbuvir and EFV will be administered once daily in the evening under fasting conditions; ZDV/3TC will be administered twice daily, in the morning without regard to food and in the evening on an empty stomach.
3085112|NCT01565889|Experimental|Part A: SOF+RTV+ATV+FTC/TDF (Cohort 3)|Participants with a prestudy regimen of RTV+ATV+FTC/TDF will receive SOF+RTV+ATV+FTC/TDF for 7 days followed by RTV+ATV+FTC/TDF for 7 days coadministered once daily in the morning with food.
3085113|NCT01565889|Experimental|Part A: SOF+RTV+DRV+FTC/TDF (Cohort 4)|Participants with a prestudy regimen of RTV+DRV+FTC/TDF will receive SOF+RTV+DRV+FTC/TDF for 7 days followed by RTV+DRV+FTC/TDF for 7 days coadministered once daily in the morning with food.
3085114|NCT01565889|Experimental|Part A: SOF+RAL+FTC/TDF (Cohort 5)|Participants with a prestudy regimen of RAL+FTC/TDF will receive SOF+RAL+FTC/TDF for 7 days followed by RAL+FTC/TDF for 7 days. Sofosbuvir and FTC/TDF will be administered once daily in the morning with food; RAL will be administered twice daily, in the morning with food and in the evening without regard to food.
3085115|NCT01565889|Experimental|Part B: SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
3085116|NCT01565902|Experimental|Mild hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3085117|NCT01565902|Experimental|Moderate hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3085118|NCT01565902|Experimental|Severe hepatically impaired|Treatment with a single oral dose of 0.25 mg BAF312
3085119|NCT01565902|Experimental|Matched healthy subjects|Treatment with a single oral dose of 0.25 mg BAF312
3085120|NCT01565928|Experimental|MDV3100|
3085121|NCT01565941|Active Comparator|Tight Glycemic Control 1 (TGC-1)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
3085122|NCT01565941|Active Comparator|Tight Glycemic Control 2 (TGC-2)|Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
3085123|NCT01565980|Active Comparator|symptom assessment|6 weeks of symptom assessment phone calls.
3085124|NCT01565980|Experimental|Mindfulness intervention|Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
3085125|NCT01565993|Active Comparator|Hemoclip|In group HEMOCLIP, one or more clips were placed (based on the criteria of the endoscopist in accordance with the size of the pedicle), and the polyp was subsequently resected using a diathermy loop
3085126|NCT01565993|Active Comparator|Conventional Polipectomy|In group CONVENTIONAL POLYPECTOMY, a conventional polypectomy was performed, which was not aided beforehand by any other hemostatic technique
3085127|NCT01566084|Other|Normal sodium|Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
3085128|NCT01566084|Other|Low sodium|Subjects on a 1200 mg salt diet are given placebo pills in order to maintain them on a low salt diet. Subjects then cross-over to the normal sodium condition in the second half of the study.
3085129|NCT01566149|Active Comparator|MF/F 200/10 mcg MDI BID|Participants receiving MF/F 200/10 mcg MDI twice daily (BID) for 12 weeks
3085130|NCT01566149|Active Comparator|MF/F 400/10 mcg MDI BID|Participants receiving MF/F 400/10 mcg MDI BID for 12 weeks
3085131|NCT01566162|Experimental|Lurasidone|Lurasidone 40 - 80mg flexible dose
3085132|NCT01566214|Experimental|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
3085133|NCT01566214|No Intervention|Usual Care|For those randomly assigned to the usual care group, they will receive standard-of-care by their regular primary care provider.
3085134|NCT01566331|Experimental|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet.
3085135|NCT01566331|No Intervention|no intervention|Baby-guardTM system, without inflation
3085136|NCT01566409|Active Comparator|Active maintenance treatment|
3085137|NCT01566409|Placebo Comparator|Placebo maintenance treatment|
3085138|NCT01566435|Experimental|Arm 1-ACF Induction Therapy Followed by Chemoradiation Therapy|"ACF Induction Therapy (Cycle 1 and Cycle 2 - each cycle is every 3 weeks)~nab-Paclitaxel 100 mg/m^2 on Days 1, 8, and 15~Cisplatin 75 mg/m^2 on Day 1~5-FU 750 mg/m^2 on Days 1-3~If patient has complete or partial response, he/she will receive an additional ACF cycle (cycle 3). If patient has stable disease or progressive disease will not receive the third cycle of ACF.~Definitive Therapy~Cisplatin 100 mg/m^2 IV on Days 1, 22, and 43~Intensity modulated radiation therapy (IMRT) 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to area considered to be at intermediate risk. Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 5600 cGy in 35 fractions.~If patient cannot receive cisplatin then he/she will receive cetuximab 250 mg/m^2 IV week for 8 weeks"
3085139|NCT01566448|Experimental|Ketamine|Ketamine oral mouthwash 20mg/5ml swish and spit four times daily
3085140|NCT01566461|Experimental|Drug-Coated Balloon (DCB)|IN.PACT Admiral: Balloon Angioplasty
3085141|NCT01566461|Active Comparator|Standard PTA|Standard Percutaneous Balloon Angioplasty (PTA) Balloon: Balloon Angioplasty
3085142|NCT01566526||Patients Previously Treated with OZURDEX®|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
3085143|NCT01566539|Experimental|Healthy Volunteers - Intranasal Vasopressin (AVP)|The AVP group of healthy volunteers will self-administer vasopressin solution prior to completing the PD task.
3085144|NCT01566539|Experimental|Healthy Volunteers - Intranasal Oxytocin (OT)|The OT group of healthy volunteers will self-administer oxytocin solution prior to completing the PD task.
3085145|NCT01566539|Placebo Comparator|Healthy Volunteers - Intranasal Placebo|The placebo group of healthy volunteers will self-administer a placebo spray prior to completing the PD task.
3085146|NCT01566539|Experimental|Within Subject Group|Some healthy volunteer participants who received drug in their first session will receive placebo in their second session and vice-versa prior to completing the PD task. For each gender, half will receive AVP in one session and placebo in the other session, and half will receive OT in one session and placebo in the second session. In each group, half of the subjects will receive drug first and half will receive placebo first. Additionally, a group of subjects who receive placebo the first time will receive placebo the second time.
3085147|NCT01566539|Experimental|Faces Task - Vasopressin (AVP)|Healthy volunteers between the ages of 21-30 years will receive Faces Intranasal Vasopressin (AVP) prior to completing the Faces task during fMRI scanning.
3085148|NCT01566539|Placebo Comparator|Faces Task - Placebo|Healthy volunteers between the ages of 21-30 years will receive placebo prior to completing the Faces task during fMRI scanning.
3085149|NCT01566539|Experimental|Empathy Task - Oxytocin (OT)|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and OT at scan 2 prior to completing an empathy task.
3085150|NCT01566539|Placebo Comparator|Empathy Task - Placebo|Healthy volunteers between the ages of 18-30 years will receive placebo at scan 1 and placebo at scan 2 prior to completing an empathy task.
3085151|NCT01566539|Experimental|Anxious and Depressed Subjects - OT|Depressed or anxious men between the ages of 18 and 22 will receive intranasal OT prior to completing the Prisoner's Dilemma game task and MRI scan.
3085152|NCT01566539|Placebo Comparator|Anxious and Depressed Subjects - Placebo|Depressed or anxious men between the ages of 18 and 22 will receive intranasal placebo prior to completing the Prisoner's Dilemma game task and MRI scan.
3085153|NCT01566539|Experimental|Healthy Volunteers - Lorazepam|Healthy normal men between the ages of 18 and 22 will receive lorazepam prior to completing the Prisoner's Dilemma game task and MRI scan.
3085154|NCT01566604|Experimental|NVA237|NVA237 50 µg once daily delivered via a single dose dry powder inhaler
3085155|NCT01566604|Placebo Comparator|Placebo|Placebo once daily delivered via a single dose dry powder inhaler
3085156|NCT01566630|Experimental|RLX030|"In part 1, within each cohort, two (2) patients per cohort will be treated open label with RLX030 and two (2) patients will be treated double blind with RLX030 as intravenous infusion for 72 hours. There will be 3 cohorts in part 1 with different doses of RLX030.~In part 2, there is no open label treatment on RLX030. In part 2, patients will be randomized in a double-blind fashion to this arm with the optimal dose of RLX030 as intravenous infusion for 72 hours as determined from part 1."
3085157|NCT01566630|Placebo Comparator|Placebo|"In part 1, equal number of subjects will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours in 3 cohorts.~In part 2, patients will be treated with matching placebo of RLX030 as intravenous infusion for 72 hours"
3085158|NCT01566682||Indeterminate Pulmonary Lesions|Patients with Pulmonary Lesions as seen by CT
3085159|NCT01566695|Experimental|Oral Azacitidine|Arm 1: Oral azacitidine tablets 300 mg daily (QD) + best supportive care (BSC) on days 1 through 21 of each 28-day treatment cycle.
3085160|NCT01566695|Placebo Comparator|Placebo|Arm 2: Identically matching placebo tablets plus best supportive care on days 1 to 21 of each 28-day treatment cycle.
3085161|NCT01566721|Experimental|Cohort A: SC Herceptin by Needle/Syringe|Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
3085162|NCT01566721|Experimental|Cohort B: SC Herceptin by SID|Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.
3085163|NCT01566773|Experimental|PT001 MDI (Dose 1)|
3085164|NCT01566773|Experimental|PT001 MDI (Dose 2)|
3085165|NCT01566773|Experimental|PT001 MDI (Dose 3)|
3085166|NCT01566773|Experimental|PT001 MDI (Dose 4)|
3085167|NCT01566773|Experimental|PT001 MDI (Dose 5)|
3085168|NCT01566773|Experimental|PT001 MDI (Dose 6)|
3085169|NCT01566773|Placebo Comparator|PT001 Placebo MDI|
3085170|NCT01566773|Active Comparator|Spiriva® Handihaler® (Tiotropium Bromide)|
3085171|NCT01566838|Active Comparator|On-q pump|Patients in this arm will receive the standard acute pain management regimen during hospital admission and will be sent home after discharge with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
3085172|NCT01566838|Active Comparator|Standard of care|"Patients in this arm will not receive a pain catheter in addition to the standard of care for pain management. Standard of care will consist of a standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and maintained on a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures. Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV once, neuromuscular reversal agents, and an antiemetic (ondansetron 4mg). Patients will also be given additional narcotics (fentanyl) upon emergence, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will also be provided. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
3085173|NCT01566981|Experimental|Diabetes with ICT support (E-diabetes)|The group of randomly selected patients with DM type II, who will get the software application and web- based support Intervention: Computerised support to the Diabetes type II patients
3085174|NCT01566981|No Intervention|Diabetes without support|The group of randomly selected patients with DM type II, without software application and web-based support.
3085175|NCT01567020||Control|Non-blast-exposed and non-TBI, aged younger than 50
3085176|NCT01567020||Blast|Blast-exposed with or without a TBI diagnosis
3085177|NCT01567020||Non-Blast-Exposed TBI|Non-blast-exposed with TBI diagnosis
3085178|NCT01567020||Older|Non-blast-exposed and non-TBI, aged 50 or older
3085179|NCT01567085|Experimental|Eculizumab|"Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days."
3085180|NCT01567150|Active Comparator|novel dressing|Treatment with novel dressing
3085181|NCT01567150|No Intervention|Control|Control is treatment without novel dressing
3085182|NCT01567163|Experimental|ramucirumab (IMC-1121B) and docetaxel|"Cycle 1: docetaxel administered on Day 1 of 3-week cycle~Cycle 2: ramucirumab and docetaxel administered on Day 1 of 3-week cycle~Cycle 3 and beyond: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle~Extension Phase: ramucirumab and docetaxel administered on Day 1 of each 3-week cycle"
3085183|NCT01567306|Experimental|Allergovac Depot Group 1 Active|
3085184|NCT01567306|Experimental|Allergovac Depot Group 2 Active|
3085185|NCT01567306|Experimental|Allergovac Depot Group 3 Active|
3085186|NCT01567306|Experimental|Allergovac Depot Group 4 Active|
3085187|NCT01567306|Experimental|Allergovac Depot Group 5 Active|
3085188|NCT01567306|Placebo Comparator|Placebo - Group 6|
3085189|NCT01567371|Experimental|LiDCO rapid monitor|
3085190|NCT01567462|Active Comparator|Monopolar Electrocautery|The current treatment standard of care for patients who present de novo or with a recurrent bladder tumor is transurethral resection of the bladder tumor (TURBT) using monopolar electrocautery in the form a 90-degree loop electrode and has been used since its introduction in 1952. This intervention, accomplished endoscopically through the urethra, is both diagnostic and potentially therapeutic. An adequately performed TURBT will provide the pathologist with enough tissue to provide tumor grade and stage information.
3085191|NCT01567462|Active Comparator|PK Button Vaporization Electrode|Bipolar energy has been available for many years and has been readily adopted for the surgical treatment of benign prostatic enlargement and may provide advantages and solutions to the technical challenges of monopolar electrocautery. A further refinement on bipolar energy has been the recent introduction of the PlasmaKinetic (PK) Button Vaporization electrode which will be used in the intervention arm of this study. This electrode is already approved by the Food and Drug Administration (FDA) for this indication as well. The semi-spherical design of the electrode creates a plasma arc that glides over the tissue, transmitting energy to the cell layers adjacent to the arc which are then quickly vaporized.
3085192|NCT01567527|Active Comparator|1|Active Comparator: Treatment of Aripiprazole IM Depot
3085193|NCT01567527|Placebo Comparator|2|Placebo Comparator: Treatment of IM Depot Placebo
3085194|NCT01567826|Active Comparator|standard of care lipid therapy|standard-care lipid-lowering therapy: Zocor or Lipitor
3085195|NCT01567826|Experimental|aggressive lipid therapy|aggressive lipid therapy: Crestor
3085196|NCT01567839|Experimental|4% Lidocaine|1.8 mL of 4% lidocaine with 1:100,000 epinephrine
3085197|NCT01567839|Experimental|4% Articaine|1.8 mL of 4% articaine with 1:100,000 epinephrine
3085198|NCT01567839|Experimental|4% Prilocaine|1.8 mL of 4% prilocaine with 1:200,000 epinephrine
3085199|NCT01567852|Experimental|Ketamine First|This arm will receive ketamine for induction first, followed by alternating treatments between methohexital and ketamine
3085200|NCT01567852|Experimental|Methohexital First|This arm will receive Methohexital first for induction, followed by alternating treatments between ketamine and methohexital.
3085201|NCT01567865|Active Comparator|Reference Lot|Lot of Vaccine produced in existing facility
3085202|NCT01567865|Experimental|New Lot #1|First lot of vaccine produced in new facility
3085203|NCT01567865|Experimental|New Lot #2|Second lot of vaccine produced in new facility
3085204|NCT01567865|Experimental|New Lot #3|Third lot of vaccine produced in new facility
3085205|NCT01567891|Experimental|Cohort 1|This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells.
3085206|NCT01567943|Experimental|Contingency Management|Contingency Management plus treatment as usual
3085207|NCT01567943|No Intervention|Non-contingent control group|Treatment as usual plus reinforcement for attendance
3085208|NCT01568008||All participants|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
3085209|NCT01568021||OZURDEX®|Single dose of dexamethasone 700 ug intravitreal implant (OZURDEX®) which may be repeated over 1 year as per standard of care in clinical practice. No intervention was administered in this study.
3085210|NCT01568034|Experimental|Treatment Sequence A|"Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085211|NCT01568034|Experimental|Treatment Sequence B|"Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085212|NCT01568034|Experimental|Treatment Sequence C|"Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085213|NCT01568034|Experimental|Treatment Sequence D|"Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085214|NCT01568047|Placebo Comparator|Placebo|"PLC, Placebo~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085215|NCT01568047|Experimental|BIA 9-1067 - 5 mg|"5 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085216|NCT01568047|Experimental|BIA 9-1067 - 15 mg|"15 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085217|NCT01568047|Experimental|BIA 9-1067 - 30 mg|"30 mg BIA 9-1067 (OPC, Opicapone)~Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half"
3085218|NCT01568073|Experimental|BIA 9-1067|OPC, Opicapone
3085219|NCT01568073|Active Comparator|Entacapone|Comtan®; Active comparator
3085220|NCT01568073|Placebo Comparator|Placebo|PLC, Placebo
3085221|NCT01568112|Experimental|BG00012|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA placebo during the first 4 weeks.
3085222|NCT01568112|Placebo Comparator|Placebo|Participants received BG00012 placebo for 8 weeks and premedication with ASA placebo during the first 4 weeks.
3085223|NCT01568112|Experimental|BG00012 + ASA|Participants received BG00012 for 8 weeks (120 mg BID during the first week and 240 mg BID during the subsequent 7 weeks) and premedication with ASA during the first 4 weeks.
3085224|NCT01568112|Experimental|BG00012 Slow Titration|Participants received BG00012 for 8 weeks (120 mg once daily [QD] during Week 1, 120 mg BID during Week 2, 240 mg AM/120mg PM during Week 3, and 240 mg BID during Week 4, and 240 mg BID during Weeks 5 to 8) and premedication with ASA placebo during the first 4 weeks.
3085225|NCT01568255|Experimental|Vitamin D Treatment|Vitamin D Treatment Group
3085226|NCT01568255|Placebo Comparator|Placebo Group|Placebo at 50,000IU for 8 weeks
3085227|NCT01568320|Experimental|Endovascular|Endovascular Treatment (Zenith)
3085228|NCT01568424|Other|Treatment Group|Patients with acute right ventricular failure from any cause requiring use of the CentriMag RVAS to sustain life.
3085229|NCT01568528|Experimental|Oxytocin|The intranasal oxytocin intervention will be the administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. Each puff is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
3085230|NCT01568528|Placebo Comparator|Placebo|"Intranasal placebo The PBO/control will consist of the OT vehicle administered as three puffs in each nostril. Each puff is is 0.1ml in volume so the total volume administered will be 0.6 ml intranasally.~Treatment assignment will be by random allocation in blocks of six. Both experimenters and subjects will be blind to the treatment they are receiving."
3085231|NCT01568528|Other|Healthy Controls|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will not receive oxytocin or placebo. They will only receive psychiatric screening interview, MATRICS Consensus Cognitive Battery (MCCB) assessment, urine drug screen, vision testing, and the three social cognition tasks.
3085232|NCT01568593|Experimental|T2750|
3085233|NCT01568593|Active Comparator|Vismed|
3085234|NCT01568606|Experimental|Body Composition Analysis InBody Scale|
3085235|NCT01568827|Experimental|Blackraspberry slurry, washout, water|Blackraspberry slurry daily x 5 days, 2 day washout, 8 oz. water daily x 5 days
3085236|NCT01568827|Experimental|Water, washout, Blackraspberry slurry|8 oz. water daily x 5 days, 2 day washout, Blackraspberry slurry daily x 5 days
3085237|NCT01568866|Experimental|Carfilzomib plus Dexamethasone|Participants received 20 mg/m² carfilzomib administered by intravenous (IV) infusion on Days 1 and 2 of Cycle 1, followed by 56 mg/m² on Days 8, 9, 15, and 16 of Cycle 1 and for each 28-day cycle thereafter. Additionally, participants received 20 mg dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle.
3085238|NCT01568866|Active Comparator|Bortezomib plus Dexamethasone|Participants received bortezomib 1.3 mg/m² administered IV or subcutaneously (SC) on Days 1, 4, 8, and 11 of a 21-day cycle plus dexamethasone 20 mg administered on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
3085239|NCT01568892|Experimental|DTG 50 mg BID|Subjects will receive dolutegravir (DTG) 50 milligrams (mg) twice daily (BID) and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the Double-blind (DB) Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
3468902|NCT03891719|Experimental|Changes in nose symmetry|- Direct anthropometric assessment (frontal, oblique, lateral and basal views) and three- dimensional observations of the nose preoperatively and postoperatively in order to evaluate the nostril symmetry, the angles, ratios of the nose and its relation to the face.
3085240|NCT01568892|Experimental|Placebo BID in DB Phase; DTG 50 mg BID in Open-label Phase|Subjects will receive matching placebo BID and the components of their current failing antiretroviral regimen, except raltegravir or elvitegravir, for 7 days during the DB Phase. From Day 8, all subjects will continue to receive DTG 50 mg BID with an optimized background regimen in the Open-label Phase.
3085241|NCT01568905|Experimental|Arm 1 Low Level Nicotine Cigarette|(0.4 mg/g)
3085242|NCT01568905|Experimental|Arm 2 Intermediate Nicotine Level Cigarette|(5.7-5.8 mg/g)
3085243|NCT01568905|Experimental|Arm 3 High Level Nicotine Cigarette|(11.4-12.8 mg/g)
3085244|NCT01568944|Experimental|Oral Antibiotic and Oral Rinse|Each subject will received oral Amoxicillin/Amoxil/lansoprazole/Flagyl 250 mg of each three times a day for 8 days. Subjects will also rinse their mouths with 2 ounces of 0.12% chlorhexidine/peridex mouthrinse two times per day. Subjects will also receive mechanical debridement at the baseline visit. Intervention Amoxicillin/Amoxil/lansoprazol 500 mg/ Metronidazole/Flagyl 250 mg
3085245|NCT01568944|Other|Standard Treatment|Subjects assigned to standard treatment will receive full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
3085246|NCT01569022|Active Comparator|CPAP First, MAD|"CPAP treatment for sleep apnea~CPAP: CPAP Treatment for 12 weeks MAD: MAD treatment for 12 weeks"
3085247|NCT01569022|Experimental|MAD First, CPAP|"MAD treatment for sleep apnea~MAD: MAD Treatment for 12 weeks CPAP: CPAP treatment for 12 weeks"
3085248|NCT01569074|Experimental|Dosing A regimen|Oral treatment
3085249|NCT01569074|Experimental|Dosing B regimen|Oral treatment
3085250|NCT01569074|Experimental|Dosing C regimen|Oral treatment
3085251|NCT01569074|Experimental|Dosign D regimen|Oral treatment
3085252|NCT01569074|Placebo Comparator|Dosing E regimen|Oral treatment
3085253|NCT01569087|Experimental|Empegfilgrastim 3 mg|Patients will receive a single administration of empegfilgrastim at a dose of 3 mg subcutaneously , 24 h after the chemotherapy
3085254|NCT01569087|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy
3085255|NCT01569087|Active Comparator|Filgrastim|Patients will receive filgrastim subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy
3085256|NCT01569126|Experimental|5 milligrams (mg) LY110140 (SD)|5 mg administered once in the fasted state on Day 1
3085257|NCT01569126|Experimental|20 mg LY110140 (SD)|20 mg administered once in the fasted state on Day 1
3085258|NCT01569126|Experimental|40 mg LY110140 (SD)|40 mg administered once in the fasted state on Day 1
3085259|NCT01569126|Placebo Comparator|Placebo (MD)|Placebo once daily oral dosing for 28 consecutive days
3085260|NCT01569126|Experimental|20 mg LY110140 (MD)|20 mg once daily oral dosing for 28 consecutive days
3085261|NCT01569126|Experimental|40 mg LY110140 (MD)|40 mg once daily oral dosing for 28 consecutive days
3085262|NCT01569152|Experimental|Base Study Phase IIa: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
3085263|NCT01569152|Placebo Comparator|Base Study Phase IIa: Placebo|Participants received placebo dosed BID orally with MTX at the stable dose received upon study enrollment. Phase IIa lasted up to 24 weeks.
3085264|NCT01569152|Experimental|Safety Extension Period 3: MK-8457|Participants received MK-8457 100 mg BID orally with MTX at the stable dose received upon study enrollment. Period 3 was to last up to 2 years.
3085265|NCT01569191|No Intervention|No Treatment|Exposure to grass pollen only
3085266|NCT01569191|Active Comparator|Artificial Tear Supplement|Preservative free Hypromellose Eye Drops BP 0.3% w/v preservative free - MHRA product licence number:23097/0006
3085267|NCT01569191|Active Comparator|Cold compress|Cooled gel eye mask http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
3085268|NCT01569191|Active Comparator|Anti-allergic Medication|ELESTAT® (epinastine HCl ophthalmic solution) 0.05% Initial U.S. Approval: 2003 H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis
3085269|NCT01569295|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib plus bendamustine and rituximab
3085270|NCT01569295|Placebo Comparator|Placebo to match idelalisib+bendamustine+rituximab|Participants will receive placebo to match idelalisib plus bendamustine and rituximab
3085271|NCT01569438|Experimental|Gefapixant|Female participants receive gefapixant, a total dose titrated from 50 mg to highest tolerated dose (maximum of 300 mg) twice daily (BID), orally over a period of 6 days with food depending on safety and tolerability, and then maintain that dose for the course of a 4-week treatment period. Participants were allowed to decrease the dose if tolerability issues occurred.
3085272|NCT01569438|Placebo Comparator|Placebo|Female participants receive dose matched placebo tablets, BID, orally, with food for 4 weeks.
3085273|NCT01569451|Active Comparator|(Placebo and) Glatiramer Acetate|Subjects will receive an intravenous (IV) infusion of placebo (normal saline) on study days 1 (baseline visit) and 15 according to the infusion protocol. On study day 28, all subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily.
3085274|NCT01569451|Experimental|Rituximab and Glatiramer Acetate (R-GA)|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, subjects will initiate standard Glatiramer Acetate therapy, 20 mg injected subcutaneously daily. There is no placebo arm.
3085275|NCT01569464|Active Comparator|Rotigotine|Rotigotine patches titrated from 1 mg/ 24 hr - 3 mg /24 hr or until effective or maximum dose is reached.
3085276|NCT01569464|Placebo Comparator|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours~7 weeks"
3085277|NCT01569529||No ad exposure|Young adults, who enroll in the cessation program, one month prior to presenting the online advertisements (intervention).
3085278|NCT01569529||Ad exposure|Young Adults, who register for the cessation program, by clicking through the online advertisements (intervention).
3085279|NCT01569568||Subjects with OTCD|"males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
3085280|NCT01569568||Healthy controls|"males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning~1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing"
3085281|NCT01569594||Carotid Endarterectomy Subjects|Subjects undergoing patch angioplasty of the carotid artery following carotid endarterectomy using the CorMatrix ECM for Carotid Repair
3085282|NCT01569607|Experimental|Hebbian-type Stimulation|Participants will be randomized to receive motor training with Hebbian-type stimulation.
3085283|NCT01569607|Sham Comparator|Sham Stimulation|Participants will be randomized to receive sham stimulation.
3085284|NCT01569737||ella|
3085285|NCT01569763|Active Comparator|hysteroscopic rollerball resection/ablation|
3085286|NCT01569763|Experimental|Aurora Endometrial Ablation|
3085287|NCT01569815|Experimental|LCZ696 400 mg|LCZ696 400 mg once daily for 5 days
3085288|NCT01569828|Experimental|Renal Impaired Subjects|once daily administration of 400 mg LCZ696 for 5 days
3085289|NCT01569828|Experimental|Healthy Volunteers|once daily administration of 400 mg LCZ696 for 5 days
3085290|NCT01569841|Experimental|IDeg|
3085291|NCT01569841|Active Comparator|IGlar|
3085292|NCT01570036|Experimental|Herceptin + NeuVax vaccine|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year; the first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive vaccinations of NeuVax vaccine administered intradermally every 3 weeks for 6 total vaccinations, 30-120 minutes after completion of Herceptin infusion. The NeuVax vaccine series will begin immediately after completion of the third Herceptin infusion, but may be delayed to the fourth or fifth Herceptin infusion with prior approval from the PI. Patients will be blinded regarding assigned arm. After completion of primary vaccine series, patients will receive 4 NeuVax vaccine booster inoculations to be administered every 6 months x 4 for total treatment duration of 30 months.
3085293|NCT01570036|Active Comparator|Herceptin + GM-CSF only|Patients randomized to this arm will receive Herceptin every 3 weeks as monotherapy for 1 year. The first Herceptin infusion will be given no sooner than 3 weeks and no later than 12 weeks after completion of standard of care chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk. Patients will receive inoculations of GM-CSF only (250mcg) administered intradermally every 3 weeks for 6 total inoculations, 30-120 minutes after completion of Herceptin infusion. The GM-CSF only inoculation series will begin immediately after completion of the third Herceptin infusion. Patients will be blinded as to whether they are receiving NeuVax vaccine or GM-CSF only. After completion of six-inoculation primary vaccine series, patients will then receive a total of four GM-CSF only booster inoculations to be administered at 12, 18, 24, and 30 months from the date of the first Herceptin infusion.
3085294|NCT01570192|Experimental|IV meropenem; parenteral aminoglycoside|"Subjects assigned to this group will receive:~IV meropenem (2 g infused over 3 hrs q 8 hr);~a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)~tobramycin nebulization~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat potential Gram-positive pathogens."
3085295|NCT01570192|Active Comparator|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage to treat Gram-positive pathogens.~**NOTE: Empiric MRSA coverage is allowed in both arms. This therapy is advised for any subjects with known or suspected MRSA entering the study. Once microbiologic results are available, this coverage may be discontinued at the investigator's discretion."
3085296|NCT01570244|Experimental|Reference|multiple doses of Microgynon
3085297|NCT01570244|Active Comparator|Test|multiple doses of Microgynon + BI 201335
3085298|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Prophylaxis|Cohort 1 prophylaxis: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085299|NCT01570283|Experimental|Multivirus-specific T cells 5*10^6 mCTLs/m2 for Treatment|Cohort 1 treatment: Participants were administrated 5*10^6 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085300|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Prophylaxis|Cohort 2 prophylaxis: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085301|NCT01570283|Experimental|Multivirus-specific T cells 1*10^7 mCTLs/m2 for Treatment|Cohort 2 treatment: Participants were administrated 1*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085302|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Prophylaxis|Cohort 3 prophylaxis: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for prophylaxis of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085303|NCT01570283|Experimental|Multivirus-specific T Cells 2*10^7 mCTLs/m2 for Treatment|Cohort 3 treatment: Participants were administrated 2*10^7 mCTLs/m multivirusspecific T cells intravenously for treatment of EBV, CMV, Adenovirus, HHV6 and BK virus infections post allogeneic stem cell transplant.
3085304|NCT01570309|Active Comparator|Ergocalciferol|50,000 units of ergocalciferol once a week for 12 weeks
3085305|NCT01570309|Placebo Comparator|Sugar pill|
3085306|NCT01570348|Experimental|Treatment (allogeneic BMT)|"CONDITIONING THERAPY: Patients receive fludarabine phosphate IV over 30-60 minutes QD on days -6 to -2 and cyclophosphamide IV over 1-2 hours QD on days -6 and -5. Patients undergo total body irradiation on day -1.~TRANSPLANTATION: Patients undergo donor BMT on day 0.~IMMUNOSUPPRESSIVE THERAPY: Patients receive high-dose cyclophosphamide IV over 1-2 hours QD on days 3-4, tacrolimus IV daily or PO BID on days 5-180 with taper to day 365, and mycophenolate acid enteric coated or mycophenolate mofetil PO TID on days 0-35."
3085307|NCT01570361|Experimental|Catheter Ablation|Radiofrequency catheter ablation treatment in subjects with Paroxysmal Atrial Fibrillation (PAF)
3085308|NCT01570361|Active Comparator|Drug Treatment|Drug therapy (either rate or rhythm control) using current AF management guidelines
3085309|NCT01570387|Experimental|Phase I - cohort 1 (Pomalidomide 2mg) plus Dexamethasone|Pomalidomide 2 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
3085310|NCT01570387|Experimental|Phase I - cohort 2 (Pomalidomide 3mg) plus Dexamethasone|Pomalidomide 3 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
3085311|NCT01570387|Experimental|Phase I - cohort 3 (Pomalidomide 4mg) plus Dexamethasone|Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle
3085312|NCT01570387|Experimental|Phase II Expansion- (Pomalidomide 4mg) plus Dexamethasone|"Expansion Phase:~Pomalidomide 4 mg/day on days 1-28 plus dexamethasone 10-20 mg on days 1-21 of a 28 day cycle"
3085313|NCT01570491|Active Comparator|ultrasound-guided spinal anesthesia|participants will randomly assigned to use ultrasound-guided technique for block placement by Anesthesiologist.
3085314|NCT01570491|Placebo Comparator|standard spinal anesthesia|randomized participants will be given standard spinal anesthesia insertion technique for block placement by Anesthesiologist
3085315|NCT01570686|Experimental|Aliskiren: Fed|Aliskiren 300 mg once daily, taken 30 minutes after start of light breakfast
3085316|NCT01570686|Experimental|Aliskiren: Fasting|Aliskiren 300 mg once daily taken after after an overnight fast
3085317|NCT01570751|Experimental|IDeg followed by IGlar|
3085318|NCT01570751|Experimental|IGlar followed by IDeg|
3085319|NCT01570829|Experimental|Dietressa|Tablet for oral use. 1 tablet 6 times a day. The duration of Dietressa therapy is 24 weeks.
3085320|NCT01570829|Placebo Comparator|Placebo|Tablet for oral use. 1 tablet 6 times a day. The duration of Placebo therapy is 24 weeks.
3085321|NCT01570868|Experimental|Ponatinib 45 mg|Ponatinib at a dose of 45 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
3085322|NCT01570868|Experimental|Ponatinib 30 mg|Ponatinib at a dose of 30 mg orally, once daily. If a dose is missed or vomited, the next dose should not be increased to account for missing a dose. Total duration of therapy 3 to 5 years.
3085323|NCT01571232|Active Comparator|Ozurdex|Patients in this group receive Ozurdex at initial visit and at month 4
3085324|NCT01571232|Active Comparator|Avastin|Patients in this group receive Avastin Q1 month for 5 months.
3085325|NCT01571284|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg IV infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-Fluorouracil (5-FU) 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until disease progression (DP), unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
3085326|NCT01571362|Experimental|ALO-02|
3085327|NCT01571362|Placebo Comparator|Placebo|
3085328|NCT01571427|Placebo Comparator|Control group|No daily conversational sessions with interviewers using webcam/internet. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
3085329|NCT01571427|Active Comparator|Active social engagement group|Engage in 30 minutes video chat daily (5 times per week, except weekend) with interviewers for 6 weeks. Weekly web-based heath form must be submitted using internet/PC. If not, subjects receive prompts from study personnel.
3085330|NCT01571453|Experimental|Vortioxetine (Lu AA21004)|
3085331|NCT01571453|Active Comparator|Venlafaxine extended release|
3085332|NCT01571557||OZURDEX®|OZURDEX® (dexamethasone 700 ug intravitreal implant) administered according to standard of care.
3085333|NCT01571596|Experimental|KRN23|Escalating doses of KRN23 (0.05, 0.10, 0.30, and 0.60 mg/kg) will be administered SC every 28 days (up to 12 doses)
3085334|NCT01572038|Experimental|Pertuzumab + Trastuzumab + Taxane|Participants will receive pertuzumab and trastuzumab (Herceptin) IV plus a taxane in cycles of 3 weeks each until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first. Taxane chemotherapy can be either docetaxel, paclitaxel or nab-paclitaxel as per investigator's choice.
3085335|NCT01572207|Experimental|Immediate Exercise|Subjects assigned to the immediate group will be prescribed a home exercise program during the first meeting. During the 12 week training period, the subject will read pamphlets (sent by mail) once to twice a month about developing skills to manage MS symptoms and motivational pamphlets about physical activity. In addition, the subject will have a phone conversation every two to three weeks with research staff to discuss the progress of the exercise program and to complete a short survey about his/her physical activity level.
3085336|NCT01572207|Experimental|Delayed exercise|Subjects assigned to the delayed group will be asked to begin the same home exercise program 12 weeks following the first meeting. During the 12 week training period, the subject will receive pamphlets, have phone conversations with research staff, and complete physical activity surveys as described above.
3085337|NCT01572298|Active Comparator|allograft alone|guided bone regeneration with allograft alone (includes tenting screws and overlying allograft membrane material)
3085338|NCT01572298|Experimental|allograft with autograft|guided bone regeneration with allograft and autograft combined (includes tenting screws and overlying allograft membrane material)
3085339|NCT01572389|Experimental|Arm 1: HOPE|The Healthy Outcomes through Patient Empowerment (HOPE) intervention group is the intervention arm which will employ behavioral health coaching telephone sessions. Tele-coaching is a theoretically grounded, structured processes guided by intervention manuals.
3085340|NCT01572389|Active Comparator|Arm 2: EUC|The Enhanced Usual Care (EUC) group will serve as a concurrent control group to compare to the intervention arm of the study. Participants are screened for diabetes self-management behaviors and control and for active depressive and anxiety symptoms. Primary care providers are alerted of the patients' status and given decision support to enhance care for these uncontrolled conditions.
3085341|NCT01572428|Active Comparator|Narrow-Band Imaging (NBI)|Inspection with Narrow-Band Imaging(NBI) versus inspection with standard white light(usual care)
3085342|NCT01572428|Active Comparator|Standard White Light|Inspection with Standard White Light versus Narrow-Band Imaging(NBI)
3085343|NCT01572675||Group Arcoxia®|Participants who were either previously treated with Arcoxia® or initiated on study treatment with Arcoxia®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
3085344|NCT01572675||Group Celebrex®|Participants who were either previously treated with Celebrex® or initiated on study treatment with Celebrex®. Participant data in terms of dosage, treatment duration, and reasons for prescription was collected under actual conditions of use.
3085345|NCT01572727|Experimental|BKM120 and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel.
3085346|NCT01572727|Active Comparator|Placebo and paclitaxel|Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel.
3085347|NCT01572740|Experimental|Lira+Insulin|
3085348|NCT01572740|Placebo Comparator|Placebo+Insulin|
3085349|NCT01572792|Experimental|1|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
3085350|NCT01572792|Experimental|2|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
3085351|NCT01572792|Active Comparator|3|Aclidinium bromide 400 μg
3085352|NCT01572792|Active Comparator|4|Formoterol Fumarate 12 μg
3085353|NCT01572792|Placebo Comparator|5|Placebo
3085354|NCT01572844|Experimental|Treatment lesion|Lesion A, target lesion, 2cm x 2cm (+/- 1cm) treated with 1 pass Fractionated Carbon Dioxide (FCO2) Laser followed by application of 4 ml of 5% topical sodium thiosulfate solution (STS), 8 to 10 treatments over 6 months.
3085355|NCT01572844|No Intervention|No Treatment Lesion|Lesion B, similar area of calcinosis on the same patient, which did not receive treatment is evaluated.
3085356|NCT01572909|Active Comparator|Bendavia™|Bendavia™ administered intravenously at 0.05 mg/kg/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
3085357|NCT01572909|Placebo Comparator|Placebo|Placebo administered intravenously at 60 mL/hr at least 15, but no more than 60 minutes, prior to the anticipated time of the PCI, and continued for 1 hour after re-establishment of blood flow through the culprit vessel.
3085358|NCT01572922|Other|Iron-overloaded|"Patients with iron overload or excessive body iron burden, a serious condition resulting from increased dietary gastro¬intestinal absorption, multiple erythrocyte transfusions, or both.~Interventions: R2*-UTE, R2*-GRE, and if clinically indicated, liver biopsy."
3085359|NCT01572948|Placebo Comparator|Placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient.
3085360|NCT01572948|Active Comparator|Daliresp|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
3085361|NCT01573000|Experimental|Open-label, two-arm, Arm A and Arm B Crossover|Arm A Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 milliCurie (mCi) (35 mg) of I-131 TST infused over 30 minutes (inclusive of a 10-minute flush).• Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by a subject-specific mCi activity (35 mg) of I-131 TST to deliver the desired total body dose (TBD) infused over 30 minutes (inclusive of a 10-minute flush). The desired TBD was 65 cGy for subjects with a baseline platelet count of 100,001-149,999 cells/mm3 and 75 cGy for subjects with a baseline platelet count ≥150,000 cells/mm3. Obese subjects (subjects weighing more than 137% of their calculated lean body weight) were dosed based upon 137% of their calculated lean body mass
3085362|NCT01573000|Experimental|Arm B Crossover|Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
3085363|NCT01573052|Active Comparator|Chlordiazepoxide|Chlordiazepoxide 25mg capsule or matching placebo capsule
3085364|NCT01573052|Experimental|Gabapentin|Gabapentin 300mg capsule or matching placebo capsule
3085365|NCT01573169|Experimental|low weight molecular heparin|enoxaparin 0.4 ml subcutaneous per day
3085366|NCT01573169|Placebo Comparator|standard therapy|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
3085367|NCT01573260|Experimental|Argentinean Tango|A biweekly class of argentinean tango for a period of 3-months the intervention for this arm
3085368|NCT01573260|Placebo Comparator|A 'wait-list' control group|Intervention: Patient will receive information about exercise in PD. After 12 weeks, these patients will then start the same 12-weeks tango program.
3085369|NCT01573273|Experimental|TSST Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
3085370|NCT01573273|Placebo Comparator|TSST Women Placebo|Cocaine-dependent women received intranasal saline prior to completing a Social Stress Task.
3085371|NCT01573273|Experimental|MRI 1 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
3085372|NCT01573273|Placebo Comparator|MRI 1 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
3085373|NCT01573273|Experimental|MRI 2 Women Oxytocin|Cocaine-dependent women received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
3085374|NCT01573273|Placebo Comparator|MRI 2 Women Placebo|Cocaine-dependent women received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
3085375|NCT01573273|Experimental|TSST Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing a Social Stress Task.
3085376|NCT01573273|Placebo Comparator|TSST Men Placebo|Cocaine-dependent men received intranasal saline prior to completing a Social Stress Task.
3085377|NCT01573273|Experimental|MRI I Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the first of two fMRI cue-exposure tasks.
3085378|NCT01573273|Placebo Comparator|MRI I Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the first of two fMRI cue-exposure tasks.
3085379|NCT01573273|Experimental|MRI 2 Men Oxytocin|Cocaine-dependent men received 40 IUs of intranasal oxytocin prior to completing the second of two fMRI cue-exposure tasks.
3085380|NCT01573273|Placebo Comparator|MRI 2 Men Placebo|Cocaine-dependent men received intranasal saline prior to completing the second of two fMRI cue-exposure tasks.
3085381|NCT01573442|Experimental|Arm I|Patients receive testosterone (0.264mL) topical application daily for six months.
3085382|NCT01573442|Placebo Comparator|Arm II|Patients receive placebo (0.264mL) topical application daily for six months.
3085383|NCT01573533|Experimental|Rituximab|
3085384|NCT01573572|Experimental|Intravitreal Injections of Macugen|
3085385|NCT01573624|Active Comparator|Fluticasone Furoate (FF)|100mcg, inhaled
3085386|NCT01573624|Active Comparator|Fluticasone Furoate /Vilanterol (VI)|100/25mcg inhaled
3085387|NCT01573624|Experimental|Fluticasone Furoate/GSK573719|100/15.6-250mcg inhaled
3085388|NCT01573702|Other|Stereotactic Radiosurgery Followed by Erlotinib|Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib
3085389|NCT01573767|Active Comparator|Arm 1|Vilanterol 25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3085390|NCT01573767|Active Comparator|Arm 2|Vilanterol 12.5mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3085391|NCT01573767|Active Comparator|Arm 3|Vilanterol 6.25mcg inhalation powder inhaled once daily in the PM via the new powder inhaler
3085392|NCT01573767|Placebo Comparator|Arm 4|Placebo inhalation powder inhaled once daily in the PM via the new powder inhaler
3085393|NCT01573910|Experimental|Moxifloxacin|Moxifloxacin ophthalmic solution, 0.5%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
3085394|NCT01573910|Active Comparator|Ofloxacin|Ofloxacin ophthalmic solution, 0.3%, 1 drop instilled 3 times per day (TID) in each eye for 7 days with a test-of-cure (TOC) at Day 9
3085395|NCT01573949|Experimental|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
3085396|NCT01574079|Active Comparator|Traditional Physical Therapy|The control group will receive traditional physical therapy interventions directed at neuromuscular rehabilitation.
3085397|NCT01574079|Experimental|Physical Therapy plus Mirror Therapy|The mirror therapy will entail 15 minutes of exercises for the lower extremities focusing on ankle dorsiflexion, knee flexion, and hip flexion.
3085398|NCT01574105||Heparin Resistant|Patient whose slope calculated by a heparin dose response test is 89 sec/iu/ml or less.
3085399|NCT01574105||Heparin Sensitive|Patient whose slope calculated by a heparin dose response test is 90 sec/iu/ml or more.
3085400|NCT01574144||AVIVO™ PiiX Patch Monitor System|Heart failure patients monitored continuously for 30 days post-discharge.
3085401|NCT01574157|Active Comparator|Sodium Bicarbonate|Participants were prescribed 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily for six months
3085402|NCT01574157|Placebo Comparator|Placebo|Participants were prescribed an identical number of placebo tablets had they been assigned to the intervention, and took this daily for six months.
3085403|NCT01574183|Experimental|Vilazodone|Flexible dose up to 40 mg capsule daily
3085404|NCT01574183|Placebo Comparator|Placebo|Flexible dose up to 40 mg capsule daily
3085405|NCT01574248|Experimental|icatibant|30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
3085406|NCT01574248|Placebo Comparator|Placebo|Subcutaneous at time 0 and 6 hours
3085407|NCT01574287|Experimental|FACBC|
3085408|NCT01574326|Placebo Comparator|FDP-Placebo for Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received placebo for 2 weeks during the fixed dose period (FDP). Participants received sevelamer carbonate for 26 weeks in dose titration period (DTP).
3085409|NCT01574326|Experimental|FDP-Sevelamer Carbonate, DTP-Sevelamer Carbonate|Participants received sevelamer carbonate for 2 weeks during the FDP of the study. Participants received sevelamer carbonate for an additional 26 weeks in DTP.
3085410|NCT01574352|Experimental|Intervention camp|Children's behavior are controlled each week day for six weeks, and children participate in three hours of physical activity every day
3085411|NCT01574352|Experimental|Small intervention|Children are only informed of healthy behavior
3085412|NCT01574612|Experimental|topical cream acyclovir/hydrocortisone|topical cream acyclovir/hydrocortisone used
3085413|NCT01574651|Experimental|QVA149 plus placebo to tiotropium and placebo to formoterol|QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
3085414|NCT01574651|Active Comparator|Tiotropium plus Formoterol and placebo to QVA149|Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
3085415|NCT01574703|Experimental|placebo|
3085416|NCT01574703|Experimental|varenicline|
3085417|NCT01574703|Experimental|bupropion|
3085418|NCT01574703|Experimental|Nicotine Replacement Therapy Patch|
3085419|NCT01574716|Experimental|MORAb-004, gemcitabine, docetaxel|
3085420|NCT01574716|Active Comparator|Placebo, gemcitabine, docetaxel|
3085421|NCT01574807|Experimental|mepivacaine + lidocaine followed by lidocaine + lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine (3% mepivacaine/2% lidocaine with epinephrine - combination 1) and 2.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two seperate appointments spaced 2 weeks apart.
3085422|NCT01574807|Experimental|lidocaine + lidocaine followed by mepivacaine plus lidocaine|A repeated measures design utilizing a single group of subjects was employed with each subject serving as his/her own control. Each subject received two interventions: 1.) 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine and 2.) 1.8 cc 3% mepivacaine and 1.8 cc 2% lidocaine with 1:100,000 epinephrine followed by 1.8 cc 2% liocaine with 1:100,000 epinephrine at two separate appointments spaced two weeks apart.
3085423|NCT01575054|Experimental|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
3085424|NCT01575054|Other|Normal Saline (Placebo) Followed by botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
3085425|NCT01575080|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use Contour TS Blood Glucose Monitoring System.
3085426|NCT01575106|Experimental|Arm 1|There is only one cohort in this study. All subjects receive the same intervention, the application of heat pain using TSA or CHEPS.
3085427|NCT01575197|Active Comparator|Rotavirus Vaccine at age 6 & 10 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6 & 10 weeks of age.
3085428|NCT01575197|Experimental|Rotavirus vaccine at age 10 & 14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 10 & 14 weeks of age.
3085429|NCT01575197|Experimental|Rotavirus vaccine at age 6,10,&14 weeks|Participants are provided with the Human Rotavirus Vaccine (HRV) at 6, 10, & 14 weeks of age.
3085430|NCT01575275|Experimental|Diagnostic (aminolevulinic acid)|Patients receive aminolevulinic acid PO 2-4 hours before surgery.
3085431|NCT01575522|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 mg PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.
3085432|NCT01575561|Experimental|Lurasidone|Lurasidone 20, 40, 60,80 mg flexible dose
3085433|NCT01575756|Experimental|Octafibrin followed by Haemocomplettan® P or RiaSTAPTM|Participants received Octafibrin 70 mg/kg intravenously once followed by Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once 45 days later.
3085434|NCT01575756|Experimental|Haemocomplettan® P or RiaSTAPTM followed by Octafibrin|Participants received Haemocomplettan® P or RiaSTAPTM 70 mg/kg intravenously once followed by Octafibrin 70 mg/kg intravenously once 45 days later.
3085435|NCT01575769|Experimental|1|
3085436|NCT01575808|Experimental|GP1101|Prospective data collection: Subjects with occlusive disease of the SFA (Superficial Femoral Artery) implanted with GP1101 covered stent graft
3085437|NCT01575808|No Intervention|Retrospective Surgical Bypass Outcomes|Retrospective data collection (Apr 2012 - Apr 2014) of 68 surgical procedures (performed after Jan 2002) at six Japanese centers used to treat femoral-popliteal artery symptomatic PAD for purposes of establishing the invasiveness control data for hospital stay duration, avoidance of general anesthesia and avoidance of intra-operative transfusion. Eligibility criteria for inclusion werer established to be consistent with the experimental arm.
3085438|NCT01575834|Experimental|Romosozumab|Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
3085439|NCT01575834|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.
3085440|NCT01575860|Experimental|Phase I/II (Maintenance Lenalidomide in Lymphoma)|Total of 24 cycles of lenalidomide. Subjects received a starting daily dose of 10mg lenalidomide on days 1 through 28 of each 28 day cycle. Subjects initiated lenalidomide 28-100 days post-ASCT.
3085441|NCT01575873|Experimental|Denosumab|Participants received 60 mg denosumab by subcutaneous injection on day 1 and at months 6, 12, and 18. Participants also received placebo to risedronate orally once a day for 24 months.
3085442|NCT01575873|Experimental|Risendronate|Participants received 5 mg risedronate orally once a day for 24 months and placebo to densumab by subcutaneous injection on day 1 and at months 6, 12, and 18.
3085443|NCT01575899|Experimental|Levofloxacin-Amoxicillin/clavulanate|7-day levofloxacin, amoxicillin/clavulanate, rabeprazole for Hp eradication.
3085444|NCT01575899|Active Comparator|Clarithromycin-Amoxicillin|7-day clarithromycin, amoxicillin, rabeprazole for Hp eradication.
3085445|NCT01575912||schizophrenia SC|subjects with a diagnosis of schizophrenia (SC) according to the DSM-IV-TR, submitted to experimental pain tests
3085446|NCT01575912||major depression MD|subjects with a diagnosis of major depression (MD) according to the DSM-IV-TR, submitted to experimental pain tests
3085447|NCT01575912||controls C|subjects without any diagnosis of psychiatric disorder (C) submitted to experimental pain tests
3085448|NCT01576003|Experimental|Glutamine|Infants randomized to the Glutamine group will receive L-Glutamine (GLN) administered enterally at a dose of 0.6g/kg body weight/day (0.3g/kg/dose) in 2 divided daily doses for 6 months. GLN will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
3085449|NCT01576003|Placebo Comparator|L-alanine|Infants randomized to the placebo group will receive L-alanine (ALA) administered enterally at a dose of 0.6g/kg body weight/day in 2 divided doses (0.3g/kg/day twice a day) for 6 months. ALA will be dissolved in water, breast milk or formula and administered to the subject orally or through their enterostomy tube approximately every 12 hours (twice a day).
3085450|NCT01576003|No Intervention|Healthy Control|Healthy age-matched infants (n=12) will have serial stools collected on 4 occasions, each separated by 60 days.
3085451|NCT01576016|Experimental|Lead Safety|Patient implanted with an Accent MRI system to evaluate safety of the Tendril MRI lead
3085452|NCT01576016|Experimental|Accent MRI system MRI Scan Group|Patient implanted with an Accent MRI system will receive an MRI scan to evaluate safety and efficacy of the Accent MRI system in an MRI environment
3085453|NCT01576042|Other|Catheter ablation|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults
3085454|NCT01576042|Other|Antiarrhythmic medication|The choice of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death
3085455|NCT01576055|Experimental|TIGRIS Vascular Stent|GORE TIGRIS Vascular Stent
3085456|NCT01576055|Active Comparator|BARD LifeStent|BARD LifeStent
3085457|NCT01576120|Experimental|bowel prep regimen first boost 6 oz. and second boost 3 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 6 oz. SuPrep administered and 3hrs later 3 oz. SuPrep was administered if needed depends on the capsule progress in the GI
3085458|NCT01576120|Experimental|bowel prep regimen first boost 3 oz. and second boost 6 oz.|4L of PEG split into two doses:1.on the evening before the exam 2.on the morning of exam day.Upon SB Detection 3 oz. SuPrep administered and 3hrs later 6 oz. SuPrep was administered if needed depends on the capsule progress in the GI
3085459|NCT01576146|Experimental|Etelcalcetide|Participants received a bolus IV injection of etelcalcetide 3 times a week (TIW) at the end of each hemodialysis session for up to 144 weeks in the extension study. The starting dose was the same as the final dose administered in the parent study (20120331); the dose was adjusted per protocol-specified guidelines to achieve or maintain parathyroid hormone values in the 150 to 300 pg/mL range.
3085460|NCT01576159|Experimental|High-Impact Loading|Performed high-impact running exercise during intervention period.
3085461|NCT01576159|Experimental|Moderate-Impact Loading|Performed moderate-impact cycling exercise during intervention period.
3085462|NCT01576159|Experimental|Non-Impact Loading|Performed low-impact swimming exercise during intervention period.
3085463|NCT01576159|No Intervention|Control Group|Didn't participate any organized physical exercises
3085464|NCT01576172|Active Comparator|Arm I (abiraterone acetate and prednisone)|Patients receive abiraterone acetate PO QD and prednisone PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3085465|NCT01576172|Experimental|Arm II (abiraterone acetate, prednisone, and veliparib)|Patients receive veliparib PO BID on days 1-28. Patients also receive abiraterone acetate PO QD and prednisone PO BID on day 1 (day 8 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3085466|NCT01576276|Experimental|Morphine condition|
3085467|NCT01576276|Experimental|Ketorolac condition|
3085468|NCT01576341|Experimental|HX575 epoetin alfa (Sandoz)|Single arm
3085469|NCT01576367|Experimental|canakinumab|Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)
3085470|NCT01576406|Experimental|A1: normal hepatic function|
3085471|NCT01576406|Experimental|A2: normal hepatic function|
3085472|NCT01576406|Experimental|B: mild hepatic impairment|
3085473|NCT01576406|Experimental|C: moderate hepatic impairment|
3085474|NCT01576406|Experimental|D: severe hepatic impairment|
3085475|NCT01576471|Placebo Comparator|Placebo|
3085476|NCT01576471|Experimental|TSO 7500|
3085477|NCT01576484|Placebo Comparator|Placebo Matched to Alirocumab|Participants who received placebo in parent study (NCT01576484), has received a subcutaneous injection of placebo matched to alirocumab every 2 weeks for 4 years in this study.
3085478|NCT01576484|Experimental|Alirocumab 150 mg|Participants who received alirocumab in parent study (NCT01576484), has received a subcutaneous injection of alirocumab 150 milligram (mg) every 2 weeks for 4 years in this study.
3085479|NCT01576523|Experimental|Low, then medium, C1-esterase inhibitor dose|
3085480|NCT01576523|Experimental|Medium, then low, C1-esterase inhibitor dose|
3085481|NCT01576523|Experimental|Medium, then high, C1-esterase inhibitor dose|
3085482|NCT01576523|Experimental|Low, then high, C1-esterase inhibitor dose|
3085483|NCT01576523|Experimental|High, then low, C1-esterase inhibitor dose|
3085484|NCT01576523|Experimental|High, then medium, C1-esterase inhibitor dose|
3085485|NCT01576536||Healthy volunteers|Normal healthy volunteers
3085486|NCT01576588|Experimental|R-HDMP|"Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).~Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion."
3085487|NCT01576705|Experimental|Thyroxin + folinic acid|
3085488|NCT01576705|Active Comparator|Thyroxin+folinic acid placebo|
3085489|NCT01576705|Active Comparator|Thyroxin placebo+ folinic acid|
3085490|NCT01576705|Placebo Comparator|Thyroxin placebo+ folinic acid placebo|
3085491|NCT01576718|Experimental|Fp MDPI 50 mcg|"Fluticasone propionate (Fp) 50 mcg per dose twice a day (for a total daily dose of 100 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3085492|NCT01576718|Experimental|Fp MDPI 100 mcg|"Fluticasone propionate (Fp) 100 mcg per dose twice a day (for a total daily dose of 200 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3085493|NCT01576718|Experimental|Fp MDPI 200 mcg|"Fluticasone propionate (Fp) 200 mcg per dose twice a day (for a total daily dose of 400 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3468903|NCT03891264|Experimental|CBD Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 4-week trial of a liquid formulation of CBD.
3085494|NCT01576718|Experimental|Fp MDPI 400 mcg|"Fluticasone propionate (Fp) 400 mcg per dose twice a day (for a total daily dose of 800 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3085495|NCT01576718|Placebo Comparator|Placebo MDPI|"Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3085496|NCT01576718|Active Comparator|Flovent Diskus 250mcg|"Fluticasone propionate (Fp) 250 mcg per dose twice a day (for a total daily dose of 500 mcg) using a multidose dry powder inhaler (MDPI) for 12 weeks in an open-label manner.~During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms."
3085497|NCT01576783|Experimental|Docosahexaenoic Acid + Arachidonic Acid|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
3085498|NCT01576783|Placebo Comparator|Placebo|Corn oil supplement
3085499|NCT01576809|Experimental|Upper Respiratory Tract Infection|
3085500|NCT01576874|Experimental|oxytocin|Participants will be administered 40 IUs of oxytocin nasal spray at one study visit.
3085501|NCT01576874|Placebo Comparator|placebo|Participants will be administered 40 IUs of placebo nasal spray at one study visit.
3085502|NCT01576939|Experimental|IMRT Modulation|"All patients will undergo a computed tomography (CT) simulation study +/- a positron emission tomography (PET) scan using ≤ 3mm slices for radiation treatment planning. A standard, non-filling optimized IMRT (Intensity Modulated Radiation Therapy) plan will be generated and patients will be treated with megavoltage radiation over a course of > 6 weeks with a planned tumor dose of > 60 Gy. A medical doctor will perform weekly mucositis evaluation and grading for the measured site once a week during radiation therapy~Modulation of an IMRT plan to reduce the dose to less than 35 Gy delivered to adjacent normal mucosa surrounding the dental filling without compromising normal tissue or tumor doses."
3085503|NCT01576952|Experimental|ISV-303|0.075% bromfenac in DuraSite vehicle dosed BID
3085504|NCT01576952|Placebo Comparator|DuraSite Vehicle|DuraSite Vehicle dosed BID
3085505|NCT01577108|Experimental|Probiotics, GBS Test|Treated with 2 oral probiotics once daily before sleeping for 14 days
3085506|NCT01577108|Placebo Comparator|Non-probiotics, GBS test|Treated with 2 placebo capsules once daily before sleeping for 14 days
3085507|NCT01577160|Experimental|Paliperidone Extended Release (ER)|
3085508|NCT01577186|Experimental|Paliperidone Extended Release (ER)|
3085509|NCT01577238|Experimental|VivaGel|
3085510|NCT01577238|Placebo Comparator|HEC Placebo|
3085511|NCT01577329|Experimental|mindfulness meditation class|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
3085512|NCT01577329|No Intervention|wait list|Subjects assigned to the control group will continue with medical treatment as usual and be allowed to attend the mindfulness meditation class after week eight.
3085513|NCT01577381|Experimental|PF-04382923|
3085514|NCT01577381|Placebo Comparator|Placebo|
3085515|NCT01577537|Experimental|VivaGel|
3085516|NCT01577537|Placebo Comparator|HEC Placebo|
3085517|NCT01577706|Active Comparator|Alprazolam (A)|Alprazolam (Xanax), gel-capsule, 1mg, single-dose, 1-day
3085518|NCT01577706|Active Comparator|Dextroamphetamine (D)|Dextroamphetamine (Dexedrine), gel-capsule, 20mg, single-dose, 1-day
3085519|NCT01577706|Placebo Comparator|Placebo (P)|Placebo gel-capsule, single-dose, 1-day
3085520|NCT01577732|Experimental|Infanrix-IPV+Hib Group|Subjects aged between, and including 12 and 24 months received a single dose of Infanrix-IPV+Hib™. The vaccine was administered intramuscularly in the anterolateral side of the thigh.
3085521|NCT01577745|Experimental|MEDI0639 Cohort 1|Participants received MEDI0639 dose level 1 as a 60-minute intravenous (IV) infusion on Day 1 of each 21-day cycle.
3085522|NCT01577745|Experimental|MEDI0639 Cohort 2|Participants received MEDI0639 dose level 2 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3085523|NCT01577745|Experimental|MEDI0639 Cohort 3|Participants received MEDI0639 dose level 3 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3085524|NCT01577745|Experimental|MEDI0639 Cohort 4|Participants received MEDI0639 dose level 4 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3085525|NCT01577745|Experimental|MEDI0639 Cohort 5|Participants received MEDI0639 dose level 5 as a 60-minute IV infusion on Day 1 of each 21-day cycle.
3085526|NCT01577745|Experimental|MEDI0639 Cohort 6|Participants received MEDI0639 dose level 6 as a 60-minute IV infusion on Day 1 of each 21 day cycle.
3085527|NCT01577758|Experimental|MLN0264|MLN0264 starting dose 0.3 mg/kg escalated until Maximum Tolerated Dose (MTD) was determined, 30-minute infusion, on Day 1 of each 21-Day treatment cycle.
3085528|NCT01577966|Experimental|Sulfasalazine|
3085529|NCT01578031|Active Comparator|Obese Patients with Obstructive Sleep Apnea|Obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
3085530|NCT01578031|Active Comparator|Non-obese Patients with Obstructive Sleep Apnea|Non-obese adults between the 40 and 65 years of age with a new diagnosis of OSA as evidenced by an apnea/hypopnea index ≥ 15, ≤ 75 episodes per hour, who are naïve to CPAP use will be started on CPAP treatment.
3085531|NCT01578031|Other|Obese subjects without OSA|Control.
3085532|NCT01578031|Other|Non-obese subjects without OSA|Control.
3132417|NCT03425253|Experimental|BELKYRA® and Juvéderm® VOLUMA™ with Lidocaine|BELKYRA® was injected into subcutaneous preplatysma fat tissue in the submental area (at least 1 plus up to 5 optional treatments, for maximum of 6 treatments 8 weeks apart). When the investigator and participant agreed that no further intervention was required to achieve the desired result, participants were eligible to receive VOLUMA™ treatment. VOLUMA™ was injected along the mandibular border, with an optional touch-up visit 2 weeks later if applicable.
3085533|NCT01578044|Experimental|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescription.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban has not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
3085534|NCT01578044|Placebo Comparator|Control|Usual care
3085535|NCT01578187|Experimental|Hair2Go device|
3085536|NCT01578239|Experimental|177Lu-DOTA0-Tyr3-Octreotate|"30 mg Octreotide LAR treatment for symptom control continued until the end of study, unless the participant progressed or died.~Treatment consisted of a cumulative administered radioactivity of 29.6 Giga Becquerel (GBq) (800 mCi) 177Lu-DOTA0-Tyr3-Octreotate: Four administrations of 7.4 GBq (200 mCi).~Concomitant amino acids were given with each administration for kidney protection.~177Lu-DOTA0-Tyr3-Octreotate was administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, Octreotide s.c. rescue injections were allowed."
3085537|NCT01578239|Active Comparator|Octreotide LAR|"60 mg Octreotide LAR treatment every 4 weeks (i.m. injections) until the end of the study, unless the participant progressed or died.~In case participants experienced clinical symptoms (i.e. diarrhoea and flushing) associated with their carcinoid tumours, s.c. Octreotide rescue injections were allowed."
3085538|NCT01578278|Experimental|Bepotastine besilate formulation|Nasal Spray
3085539|NCT01578278|Experimental|Fluticasone propionate|Nasal Spray
3085540|NCT01578278|Experimental|Bepotastine besilate-fluticasone propionate|Nasal Spray
3085541|NCT01578278|Placebo Comparator|Placebo Comparator|Nasal Spray
3085542|NCT01578317|Experimental|AS03 adjuvanted|Adminsitered day 1, booster at Day 21
3085543|NCT01578317|Experimental|unadjuvanted|Administer day 1 and booster at Day 21
3085544|NCT01578330|Experimental|Fingolimod, FTY720|Patients received fingolimod 0.5 mg oral capsules daily with or without food.
3085545|NCT01578486|Experimental|salsalate|open-label trial of salsalate 3g/day
3085546|NCT01578499|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
3085547|NCT01578499|Active Comparator|Methotrexate or Bexarotene|Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
3085548|NCT01578551|Experimental|Arm A|Paclitaxel, Carboplatin, Bevacizumab, and Metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning chemotherapy, if possible, but chemotherapy will not be delayed for metformin loading.
3085549|NCT01578551|Active Comparator|Arm B|Paclitaxel, Carboplatin, and Bevacizumab
3085550|NCT01578577|No Intervention|Standard Care|This arm will serve as a control group and will not receive any intervention.
3085551|NCT01578577|Experimental|EHMI|Electronic Health Record-based Health Literacy Medication Therapy Management Intervention (EHMI)arm consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
3085552|NCT01578577|Experimental|Nurse Educator + EHMI|
3085553|NCT01578707|Active Comparator|Ofatumumab (Arm A)|An anti-CD20 monoclonal antibody
3085554|NCT01578707|Experimental|ibrutinib (Arm B)|A Bruton Tyrosine Kinase Inhibitor
3085555|NCT01578772|Experimental|Telmisartan|Open label
3085556|NCT01578850|Experimental|Group A|
3085557|NCT01578850|Placebo Comparator|Group B|
3085558|NCT01578902|Experimental|Hypofractionated radiotherapy using SABR|Stereotactic radiation: 35Gy in 5 fractions over 29 days
3085560|NCT01578980|Experimental|Outpatient Control-to-Range|Outpatient Control-to-Range: Testing system connectivity
3085561|NCT01579006||Cohort|
3085562|NCT01579045|Experimental|Sequence 1|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, senofilcon A, Filcon II 3"
3085563|NCT01579045|Experimental|Sequence 2|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, nelfilcon A, etafilcon A, Filcon II 3, senofilcon A"
3085564|NCT01579045|Experimental|Sequence 3|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, senofilcon A, Filcon II 3"
3085565|NCT01579045|Experimental|Sequence 4|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~Filcon II 3, etafilcon A, nelfilcon A, Filcon II 3, senofilcon A"
3085566|NCT01579045|Experimental|Sequence 5|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, senofilcon A, Filcon II 3"
3085567|NCT01579045|Experimental|Sequence 6|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, Filcon II 3, etafilcon A, Filcon II 3, senofilcon A"
3085568|NCT01579045|Experimental|Sequence 7|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, senofilcon A, Filcon II 3"
3085569|NCT01579045|Experimental|Sequence 8|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~nelfilcon A, etafilcon A, Filcon II 3, Filcon II 3, senofilcon A"
3085570|NCT01579045|Experimental|Sequence 9|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, senofilcon A, Filcon II 3"
3085571|NCT01579045|Experimental|Sequence 10|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, Filcon II 3, nelfilcon A, Filcon II 3, senofilcon A"
3085572|NCT01579045|Experimental|Sequence 11|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, senofilcon A, Filcon II 3"
3085573|NCT01579045|Experimental|Sequence 12|"Five separate sessions of bilateral lens wear of approximately 1 hour. This sequence is as follows:~etafilcon A, nelfilcon A, Filcon II 3, Filcon II 3, senofilcon A"
3085574|NCT01579084|Experimental|AGN-199201 Formulation A and B|AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.
3085575|NCT01579084|Experimental|AGN-199201 Formulation B and C|AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.
3085576|NCT01579084|Experimental|AGN-199201 Formulation C and A|AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.
3085577|NCT01579084|Other|AGN-199201 Formulation A and Vehicle|AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3085578|NCT01579084|Other|AGN-199201 Formulation B and Vehicle|AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3085579|NCT01579084|Other|AGN-199201 Formulation C and Vehicle|AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.
3085580|NCT01579084|Experimental|AGN-199201 Formulation A|AGN-199201 Formulation A applied to both sides of the face twice daily.
3085581|NCT01579084|Experimental|AGN-199201 Formulation B|AGN-199201 Formulation B applied to both sides of the face twice daily.
3085582|NCT01579084|Experimental|AGN-199201 Formulation C|AGN-199201 Formulation C applied to both sides of the face twice daily.
3085583|NCT01579084|Placebo Comparator|AGN-199201 Vehicle|AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.
3085584|NCT01579162|Experimental|Healthy Controls|Healthy controls will be recruited to have approximately equal numbers of men and women. Controls will be of healthy weight as defined by a BMI 18-25 and without liver disease or risk factors for liver disease.
3085585|NCT01579162|Experimental|chronic HCV patients with F0-F2 fibrosis|
3085586|NCT01579162|Experimental|chronic HCV patients with F3-F4 fibrosis|
3085587|NCT01579162|Experimental|NASH patients with F0-F2 fibrosis|
3085588|NCT01579162|Experimental|NASH patients with F3-F4 fibrosis|
3085589|NCT01579214|Active Comparator|Direct Text Message|Participants in the intervention period (September 2012 - November 2013) received daily short message service (SMS) messages for up to seven days with messages reporting an abnormal result
3085590|NCT01579214|No Intervention|Pre-Intervention|Participants enrolled in the pre-intervention period (January - August 2012) served as a control group.
3085591|NCT01579305|Experimental|Juvéderm® Volbella with Lidocaine|Subjects injected with Juvéderm® Volbella with Lidocaine in their lips
3085592|NCT01579305|Active Comparator|Restylane-L®|Subjects injected with Restylane-L® in their lips
3085593|NCT01579318|Experimental|Treatment|Participants received up to 4 cycles of treatment (3 daily treatments on Days 1, 5 and 8, in a 12-week cycle) of intratumoral injection(s) of tavo at a concentration of 1.0 mg/mL (maximum volume of 1 mL/day distributed over 2-4 lesions), followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid deoxyribonucleic acid (DNA) into tumor cells.
3085594|NCT01579474|Experimental|1. BI 201335 low dose plus PegIFN/RBV|low dose BI 201335 NA once daily for 12 or 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3085595|NCT01579474|Experimental|2. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 12 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3085596|NCT01579474|Experimental|3. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 24 or 48 weeks in treatment-experienced (relapser) patients
3085597|NCT01579474|Experimental|4. BI 201335 high dose plus PegIFN/RBV|high dose BI 201335 NA once daily for 24 weeks combined with PegIFN/RBV for 48 weeks in treatment-experienced (null responder, partial responder, breakthrough) patients
3085598|NCT01579513|Active Comparator|Intraoperative Methylprednisone|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass(CPB) in the first month of life that receive one dose of intravenous methylprednisolone (30 mg/kg) during anesthetic induction.
3085599|NCT01579513|Placebo Comparator|Placebo|Neonates with congenital heart disease requiring surgery utilizing cardiopulmonary bypass (CPB) in the first month of life that receive one dose of placebo (normal saline) during anesthetic induction.
3085600|NCT01579565|Experimental|OMS302|OMS302 diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3085601|NCT01579565|Placebo Comparator|Placebo|Placebo diluted in Balanced Salt Solution and administered as irrigation solution during Intraocular Lens Replacement surgery.
3085602|NCT01579578|Experimental|1|
3085603|NCT01579578|Placebo Comparator|2|
3085604|NCT01579669|Experimental|Use of Toolkit|All participants will have access to the toolkit
3085605|NCT01579747|Placebo Comparator|Nerve stimulation sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach using nerve stimulation
3085606|NCT01579747|Active Comparator|Ultrasound guided sciatic nerve block|Time taken to complete a sciatic nerve block via the lateral popliteal approach when using an ultrasound
3085607|NCT01579812|Experimental|Metformin|
3085608|NCT01579916|Experimental|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
3085609|NCT01579916|Placebo Comparator|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
3085610|NCT01580020|Experimental|Ranibizumab (Arm A)|"The PRN injection scheme applied in the core study will also be followed during this extension study:~Patients should be monitored monthly (starting at V1E) for VA and treatment is to be resumed when monitoring indicates loss of VA due to disease activity. Monthly injections should then be administered until stable VA is reached again for 3 consecutive monthly assessments (implying a minimum of 2 injections during stable VA). The interval between 2 doses should not be shorter than 1 month"
3085611|NCT01580020|Sham Comparator|Dexamethasone (Arm B)|A PRN re-treatment scheme will be applied for the Ozurdex arm during this extension study, i.e. patients may receive an implant at V1E or later as needed: Patients should be monitored monthly and if there is a decline from stable VA stability due to macular edema patients will receive another intravitreal implant. (700 µg; long acting release (LAR)) given that in the opinion of the investigator the patient would benefit from the re-treatment. However, a minimum period of 5 months in between implantations is required.
3085612|NCT01580072|No Intervention|Control group|Participants in the control group receive usual care.
3085613|NCT01580072|Experimental|Self monitoring for patients with COPD|
3085614|NCT01580072|Experimental|Nurse monitoring for patients with COPD|
3085615|NCT01580098|No Intervention|Control group|treatment as usual
3085616|NCT01580098|Experimental|Self-monitoring for patients with Diabetes mellitus type 2|Patients are self-monitoring and submitting their vital parameters.
3085617|NCT01580098|Experimental|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are measuring and entering the vital parameters of the patients.
3085618|NCT01580293|Experimental|Arm 1|On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds
3085619|NCT01580293|Experimental|Arm 2|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by 2 infusions per week over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3085620|NCT01580293|Experimental|Arm 3|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 5 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3085621|NCT01580293|Experimental|Arm 4|Prophylaxis treatment of BAY94-9027; 2 infusions per week over 10 weeks followed by infusion every 7 days over 26 weeks in the main trial; and at least 1 day per week in the extension for at least 100 ED
3085622|NCT01580306|Experimental|BI 201335 relevant treatment dose (A)|Capsule for oral administration
3085623|NCT01580306|Experimental|BI 201335 relevant treatment dose (B)|Capsule for oral administration
3085624|NCT01580410|Experimental|Arm I (mitomycin C)|Patients undergo surgical cytoreduction and receive mitomycin C by HIPEC.
3085625|NCT01580410|Experimental|Arm II (oxaliplatin)|Patients undergo surgical cytoreduction and receive oxaliplatin by HIPEC.
3085626|NCT01580423|Experimental|aprepitant|
3085627|NCT01580423|Placebo Comparator|inert powder|
3085628|NCT01580592|Experimental|Omalizumab 150mg|
3085629|NCT01580592|Experimental|Omalizumab 300mg|
3085630|NCT01580592|Placebo Comparator|Placebo|
3085631|NCT01580618|Placebo Comparator|Normal Saline|Loculated pleural effusion infused with normal saline twice a day for three days.
3085632|NCT01580618|Active Comparator|TNKase|Loculated pleural effusion infused with TNK twice a day for three days.
3085633|NCT01580670|Experimental|TA-650|"Responder criteria: Case where PCDAI score on the evaluation day was decreased by at least 15 points from that in the screening period and was ≤30.~Criteria for dose-increasing: When either of the following 2 items was satisfied after Week 14, the relevant patient would be considered to satisfy the criteria for dose increasing to 10 mg/kg.~PCDAI score on the evaluation day was increased by at least 15 points compared to the lowest PCDAI score observed at Week 2, 6 or 10~PCDAI score on the evaluation day exceeds 30"
3085634|NCT01580904|No Intervention|control group|Patients will not be followed by the pharmacist.
3085635|NCT01580904|Experimental|Intervention group|"Patients will be followed by the pharmacist by Pharmacotherapeutic monitoring and dosing parameters such as glucose and glycated hemoglobin.~Intervention: Pharmaceutical Care"
3085636|NCT01580969|Experimental|Dose Level 0: 100 mg bid|Patients receiving minocycline 100 mg bid, bevacizumab, and radiation therapy.
3085637|NCT01580969|Experimental|Dose Level 1: 200 mg bid|Patients receiving minocycline 200 mg bid, bevacizumab, and radiation therapy.
3085638|NCT01580969|Experimental|Dose Level 2: 400 mg bid|Patients receiving minocycline 400 mg bid, bevacizumab, and radiation therapy.
3085639|NCT01580995|Experimental|Valacyclovir|Valacyclovir 500 mg po bid
3085640|NCT01580995|Placebo Comparator|Placebo|Matching placebo twice daily
3085641|NCT01581008|Experimental|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
3085642|NCT01581008|Active Comparator|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
3085643|NCT01581021|Active Comparator|Thoracic Pedicle Screws|Group treated with pedicle screws in the thoracic spine
3085644|NCT01581021|Active Comparator|Laminar Hooks|Group treated with hooks in the thoracic spine
3085645|NCT01581281|Active Comparator|Amitriptyline|Drug to be administered twice daily.
3085646|NCT01581281|Active Comparator|Topiramate|Drug to be administered twice daily.
3085647|NCT01581281|Placebo Comparator|Placebo|To be administered twice daily.
3085648|NCT01581307|Experimental|2nd Line Chemotherapy With Radiotherapy|"Administration of 2nd line chemotherapy will consist of a modified FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin) will take place at least 2 weeks after the completion of first-line chemotherapy. Generally, second-line chemotherapy is given every two weeks for 6-10 cycles.~The goal of treatment with TheraSpheres is to allow a large dose of radiation to be delivered directly to the tumor(s) with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue."
3085649|NCT01581437|Other|64 pole basket catheter|all patients participating undergo mapping using the 64 pole basket catheter to assess for Atypical areas of drivers that may cause atrial fibrillation
3085650|NCT01581541|Experimental|PU-H71|PU-H71 will be administered intravenous (IV) over one hour, once weekly, 2 weeks out of 3, (i.e., on days 1 and 8) every 21 days
3085651|NCT01581593|Experimental|Kedrion IVIG 10%|Kedrion IVIG 10% treatment.
3085652|NCT01581619|Experimental|Partial Breast Irradiation|Partial Breast Irradiation using 40 Gy in 10 fractions over 2 weeks
3085653|NCT01581658|Experimental|BI10773 medium dose group 1|BI10773 medium dose tablet single dose group 1
3085654|NCT01581658|Experimental|BI10773 medium dose group 2|BI10773 medium dose tablet single dose group 2
3085655|NCT01581658|Experimental|BI10773 Medium dose group 3|BI10773 medium dose tablet single dose group 3
3085656|NCT01581658|Experimental|BI10773 Medium dose group 4|BI10773 medium dose tablet single dose group 4
3085657|NCT01581684|Experimental|BI 411034 low dose - group 1|Solution for oral administration
3085658|NCT01581684|Experimental|BI 411034 low dose - group 2|Solution for oral administration
3085659|NCT01581684|Experimental|BI 411034 medium dose - group 3|Solution for oral administration
3085660|NCT01581684|Experimental|BI 411034 medium dose - group 4|Solution for oral administration
3085661|NCT01581684|Experimental|BI 411034 medium dose - group 5|Solution for oral administration
3085662|NCT01581684|Experimental|BI 411034 high dose - group 6|Solution for oral administration
3085663|NCT01581684|Experimental|BI 411034 high dose - group 7|Solution for oral administration
3085664|NCT01581684|Experimental|BI 411034 high dose - group 8|Solution for oral administration
3085665|NCT01581684|Placebo Comparator|Placebo|Solution for oral administration
3085666|NCT01581710|Active Comparator|montelukast to placebo|14 days
3085667|NCT01581710|No Intervention|Washout|14 days
3085668|NCT01581710|Active Comparator|Placebo to montelukast|14 days
3085669|NCT01581931|Experimental|Linagliptin/metformin|fixed dose combination tablet (FDC)
3085670|NCT01581931|Experimental|Linagliptin and metformin|single tablets
3085671|NCT01581970|Experimental|Cetuximab/low dose Cyclophosphamide|Safety population as defined by all patients receiving at least one treatment with cyclophosphamide on Day 1.
3085672|NCT01582009|Experimental|Arm I: Oral Panobinostat and Oral Everolimus|Patients receive oral panobinostat once daily on days 1, 3, 4, 8, 10, and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3085673|NCT01582061|Experimental|Pasireotide 600 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 600 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 600 μg for glucose impaired metabolism patients. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 600 μg bid group includes all patients whose mean daily dose < 1500 μg /day.
3085674|NCT01582061|Experimental|Pasireotide 900 μg|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg. Mean daily dose category is defined on the mean daily dose considering the following grouping rule: 900 μg bid group includes all patients whose mean daily dose ≥ 1500 μg /day
3085675|NCT01582139|Experimental|Experimental Condition: (Heart-Rate Informed SSM+HMM)|An experimental condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is informed about heart rate
3085676|NCT01582139|No Intervention|Control Condition (SSM+HMM)|A control condition involving an exercise session where the Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) is not informed about heart rate.
3085677|NCT01582152|Experimental|TPI 287 + Bevacizumab|"Part I: Patients assigned to receive 1 of 4 dose levels of TPI 287 based on when joining the study.~Phase I Starting Dose of TPI287 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle. Bevacizumab given at 10 mg/kg by vein on Day 1 every 2 weeks of a 42 Day cycle.~Phase II Starting Dose of TPI287: Maximum Tolerated Dose (MTD) from Phase I."
3085678|NCT01582152|Experimental|Bevacizumab Group|"Phase II: Participants randomized to Arm A (bevacizumab alone at 10 mg/kg every 2 weeks) versus Arm B (bevacizumab at 10 mg/kg every 2 weeks plus TPI 287.~Participant may enroll in Crossover Group to receive TPI 287 and bevacizumab if disease gets worse at any time during treatment with bevacizumab alone."
3085679|NCT01582178|Experimental|Warm Water Immersion Colonoscopy|Colonoscopy using purely warm water (37°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3085680|NCT01582178|Active Comparator|Cool Water Immersion Colonoscopy|Colonoscopy using purely room temperature water (20-24°C) infusion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3085681|NCT01582243|Experimental|Vildagliptin plus metformin (SPC)|Eligible participants received oral vildagliptin 50 mg plus metformin 500 mg (SPC) twice daily from week 1 to week 24.
3085682|NCT01582282|Placebo Comparator|placebo|matched placebo BID
3085683|NCT01582282|Active Comparator|psyllium 3.4g BID|3.4g psyllium BID for a Total of 6.8g daily
3085684|NCT01582282|Active Comparator|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day
3085685|NCT01582308|Experimental|Treatment Sequence 1|Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
3085686|NCT01582308|Experimental|Treatment Sequence 2|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
3085687|NCT01582308|Experimental|Treatment Sequence 3|Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
3085688|NCT01582308|Experimental|Treatment Sequence 4|Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
3085689|NCT01582308|Experimental|Treatment Sequence 5|Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
3085690|NCT01582308|Experimental|Treatment Sequence 6|Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
3085691|NCT01582308|Experimental|Treatment Sequence 7|Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
3085692|NCT01582308|Experimental|Treatment Sequence 8|Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
3085693|NCT01582308|Experimental|Treatment Sequence 9|Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
3085694|NCT01582308|Experimental|Treatment Sequence 10|Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
3085695|NCT01582451|Experimental|LY2605541|Administered by subcutaneous (SQ) injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on fasting blood glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications (OAMs) whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
3085696|NCT01582451|Active Comparator|Insulin glargine|Administered by SQ injection once daily at bedtime. Initial dose based on dose of prestudy basal insulin and adjusted based on FBG. Insulin glargine will be used alone or in combination with up to 3 pre-study OAMs whose use is not excluded in combination with insulin. Treatment may last up to 52 weeks.
3085697|NCT01582477|Experimental|EXPAREL 20 mL (undiluted)|20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.
3085698|NCT01582477|Active Comparator|EXPAREL 40 mL (diluted)|20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.
3085699|NCT01582490|Active Comparator|Infiltration - EXPAREL|Group 2 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be administered via local infiltration into each surgical site per the surgeon's normal practice at the beginning of surgery.
3085700|NCT01582490|Experimental|Instillation - EXPAREL|Group 1 will receive diluted EXPAREL (i.e., the contents of one 20 mL vial, 266 mg, diluted with 20 mL of preservative-free 0.9% normal saline to a total of 40 mL) for postsurgical analgesia. Half of the resulting mixture (i.e., 20 mL) will be instilled into each breast pocket at the beginning of surgery.
3085701|NCT01582789|Active Comparator|enfilcon A/senofilcon A|Subjects were randomized to wear enfilcon A then Senofilcon A for two weeks.
3085702|NCT01582789|Active Comparator|senofilcon A/enfilcon A|Subjects were randomized to wear senofilcon A then enfilcon A for two weeks
3085703|NCT01582854|Active Comparator|Actovegin|Actovegin 2000 mg solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin 200 mg, tablets, orally, 3 times a day for up to 6 months.
3085704|NCT01582854|Placebo Comparator|Placebo|Actovegin placebo-matching solution, intravenous (IV) infusion for up to 20 days followed by 2 actovegin placebo-matching, tablets, orally, 3 times a day for up to 6 months.
3085705|NCT01582880|Experimental|Riboflavin Cross-linked donor cornea|the donor cornea used as a carrier for the Boston Keratoprosthesis will undergo crosslinking treatment before being trephined and prepared for implantation with the Keratoprosthesis.
3085706|NCT01582945|Experimental|Ketamine IV|Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks
3085707|NCT01582971|Experimental|Intervention|Reflexology: 4 weekly foot reflexology sessions delivered by friend/family member
3085708|NCT01582971|No Intervention|Control|Standard medical care: no reflexology
3085709|NCT01583101|Experimental|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
3085710|NCT01583101|Active Comparator|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
3085711|NCT01583166|Active Comparator|Bupivacaine + epinephrine|
3085712|NCT01583166|Placebo Comparator|Saline + epinephrine|
3085713|NCT01583179|No Intervention|Control group|will get only local anesthetic and epinephrine in block. no additive in block
3085714|NCT01583179|Experimental|buprenorphine|will receive local anesthetic, epinephrine and the additive buprenorphine to nerve block
3085715|NCT01583218|Experimental|Betrixaban|Daily oral (PO) betrixaban capsules for 35 to 42 days and subcutaneous (SQ) injections of enoxaparin placebo for 10 ± 4 days
3085716|NCT01583218|Active Comparator|Enoxaparin|Daily subcutaneous (SQ) injections of enoxaparin for 10 ± 4 days and oral (PO) betrixaban placebo capsules for 35 to 42 days
3085717|NCT01583296|Experimental|CBT and HRVB|Cognitive Behavioral Therapy (CBT) and Heart Rate Variability Biofeedback (HRVB)
3085718|NCT01583296|Active Comparator|Music Relaxation Therapy (MRT)|Music Relaxation Therapy (MRT): music relaxation and breathing at resting respiration rate
3085719|NCT01583374|Experimental|Apremilast 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
3085720|NCT01583374|Experimental|Apremilast 30 mg|Apremilast 30 mg was taken orally twice a day
3085721|NCT01583374|Placebo Comparator|Placebo|Identically matched placebo tablets were taken orally twice a day
3085722|NCT01583452|Experimental|Chewing Gum Group|Group of patients given chewing gum as part of the treatment for prevention of post-operative ileus right after surgery, besides the standard pharmacologic treatment and post-operative care.
3085723|NCT01583452|No Intervention|No intervention|By observing the clinical evolution of the participants not given chewing gum as a prevention for post-operative ileus, and just given the standard pharmacologic treatment and post-operative care.
3085724|NCT01583530|Active Comparator|Belimumab IV 240 mg|
3085725|NCT01583530|Experimental|Belimumab SC 2 x 120 mg|
3085726|NCT01583530|Experimental|Belimumab SC 1 x 240 mg|
3085727|NCT01583530|Experimental|Belimumab SC 1 x 200 mg|
3085728|NCT01583530|Experimental|Belimumab SC 2 x 120 mg weekly|
3085729|NCT01583530|Experimental|Belimumab SC 1 x 200 mg weekly|
3085730|NCT01583543|Experimental|Olaparib|400mg PO BID Continuous
3085731|NCT01583686|Experimental|1/Phase I|Non-myeloablative but lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) plus low dose aldesleukin.
3085732|NCT01583686|Experimental|2/Phase II|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL) + low-dose aldesleukin
3085733|NCT01583868|Experimental|B&L RD2135-01 lens C|Investigational Silicone hydrogel soft contact lens
3085734|NCT01583868|Experimental|B&L RD2135-01 lens D|Investigational Silicone hydrogel soft contact lens
3085735|NCT01583868|Active Comparator|PureVision2|Bausch & Lomb High definition soft contact lenses
3085736|NCT01583868|Active Comparator|Ciba Vision Air Optix Aqua|Ciba Vision Air Optix Aqua soft contact lens
3085737|NCT01583894||Chronic pain patients|
3085738|NCT01583985|Active Comparator|Opioid-intensive|Opioid-intensive prescribing strategy
3085739|NCT01583985|Active Comparator|Opioid-avoidant|Opioid-avoidant prescribing strategy
3085740|NCT01584024|Active Comparator|Resin infiltration|Resin infiltration of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
3085741|NCT01584024|Sham Comparator|Control|Sham treatment of early caries lesion in addition to preventative measures (oral hygiene, diet counseling, repeated fluoride varnish application)
3085742|NCT01584232|Experimental|LY2189265 + OAM|"LY2189265: 0.75 milligrams (mg), administered subcutaneously (SC), once weekly for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
3085743|NCT01584232|Active Comparator|Insulin glargine + OAM|"Insulin glargine: dose based on targeting fasting blood glucose ≤110 milligrams per deciliter (mg/dL), administered subcutaneously (SC), once daily for 26 weeks~Participants were to continue on their stable, pre-study, physician-prescribed dose of oral antihyperglycemic medication (OAM) throughout the study. OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin)."
3085744|NCT01584388|Experimental|Rituximab|
3085745|NCT01584440|Placebo Comparator|Placebo|Participants will receive placebo during Stage 1 and Stage 2 of the study.
3085746|NCT01584440|Experimental|AVP-923|Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
3085747|NCT01584440|Experimental|Placebo then AVP-923|Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.
3085748|NCT01584479||Low Risk Experimental Group|"1 visit - Low Risk~~1200 subjects~- Low Risk Experimental Group = 1 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
3085749|NCT01584479||Low risk Control Group|"2 visits - Low Risk~~1200 subjects~- Low risk Control Group = 2 visit intervention, no history of periodontitis, non-smoker, non-diabetic, IL-1 genotype (-)"
3085750|NCT01584479||High Risk Experimental Group|"1 visit - High Risk~~800 subjects High Risk Experimental Group = 1 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
3085751|NCT01584479||High Risk Control Group|"2 visits - High Risk~~800 subjects High Risk Control Group = 2 visit intervention, one or more of the following risk factors: history of periodontitis, smoker or diabetic, IL-1 genotype (+)"
3085752|NCT01584518|Active Comparator|CHF peptide|Diuresis based on CHF-P
3085753|NCT01584518|Active Comparator|Non CHF peptide|Diuresis based on clinical judgement without data for CHF-P
3085754|NCT01584544|Experimental|1000mg|capecitabine 1000mg/m2/d d1-14, d22-25 combined with concurrent radiotherapy will be given to enrolled patients.
3085755|NCT01584544|Experimental|1200mg|capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3085756|NCT01584544|Experimental|1350mg|capecitabine 1300mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3085757|NCT01584544|Experimental|1500mg|capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3085758|NCT01584544|Experimental|1650mg|capecitabine 1650mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
3085759|NCT01584609|Experimental|Penumbra System with Separator 3D|
3085760|NCT01584609|Active Comparator|Penumbra System alone|
3085761|NCT01584648|Experimental|Dabrafenib + Trametinib|Dabrafenib and Trametinib combination
3085762|NCT01584648|Active Comparator|Dabrafenib + Placebo|Dabrafenib and Trametinib placebo
3085763|NCT01584843|No Intervention|Non-treatment (10-20 PD)|Receive no treatment on Week 0
3085764|NCT01584843|Active Comparator|GSK1358820 1.25 U (10-20 PD)|Receive 1.25 U of GSK1358820 on Week 0
3085765|NCT01584843|Active Comparator|GSK1358820 2.5 U (10-20 PD)|Receive 2.5 U of GSK1358820 on Week 0
3085766|NCT01584843|No Intervention|Non-treatment (20-50 PD)|Receive no treatment on Week 0
3085767|NCT01584843|Active Comparator|GSK1358820 2.5 U (20-50 PD)|Receive 2.5 U of GSK1358820 on Week 0
3085768|NCT01584843|Active Comparator|GSK1358820 5.0 U (20-50 PD)|Receive 5.0 U of GSK1358820 on Week 0
3085769|NCT01585025|Experimental|Primary BAD|Defined as SeHCAT <10% without other causes such as Crohn's disease and/or ileal resection
3085770|NCT01585025|Experimental|Secondary BAD|With Crohn's disease or ileal resection
3085771|NCT01585025|Experimental|Idiopathic Diarrhoea Controls|Chronic diarrhoea with SeHCAT >15% and no Crohn's or ileal resection
3085772|NCT01585038|Active Comparator|Efavirenz|Efavirenz 600mg given nightly without food for 30 days
3085773|NCT01585038|Active Comparator|Rilpivirine|Rilpivirine 25mg given daily with meals for 30 days
3085774|NCT01585129|Experimental|Postpartum Antibiotics|Patients will receive one additional dose of postpartum antibiotics (Clinda, Gentamicin)
3085775|NCT01585129|Placebo Comparator|No postpartum antibiotics|No further postpartum antibiotics
3085776|NCT01585155|Experimental|TA-650|
3085777|NCT01585168|Experimental|Family history positive, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3085778|NCT01585168|Placebo Comparator|Family history positive, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3085779|NCT01585168|Experimental|Family history negative, Memantine first, then placebo|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3085780|NCT01585168|Placebo Comparator|Family history negative, placebo first, then Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
3085781|NCT01585194|Experimental|Treatment (nivolumab, ipilimumab)|"INDUCTION PHASE: Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes during weeks 1, 4, 7, and 10. Treatment continues for 12 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients not experiencing disease progression or unacceptable toxicity by week 12 of the induction phase receive nivolumab IV every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity."
3085782|NCT01585207|Experimental|Vigabatrin|3 tablets, bid for 8 weeks
3085783|NCT01585246|Other|Phase 1: The dose finding phase (DFP)|Patients received Saw Palmetto Soft Gel capsules in 320mg or 640mg or 960mg to determine the maximum therapeutic dose
3085784|NCT01585246|Active Comparator|Phase 2: RCT phase- Saw Palmetto|Patients received the predetermine the maximum therapeutic dose of Saw Palmetto Soft Gel capsules in phase 1, which is 960mg.
3085785|NCT01585246|Placebo Comparator|Phase 2: RCT phase- Placebo|Patients received Soybean Oil Soft Gel as the placebo treatment
3085786|NCT01585272|Experimental|Rivastigmine|Eligible patients, who are under rivastigmine capsule 3 mg b.i.d. treatment for 4 weeks before Visit 2, will be recruited, followed by treatment switch from oral capsule to transdermal patch for 48 weeks maintenance treatment.
3085787|NCT01585298|Experimental|Fingolimod|Fingolimod 0.5 mg by mouth once daily for 7 days.
3085788|NCT01585324|Experimental|Single Arm|
3085789|NCT01585428|Experimental|Cervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin.
3085790|NCT01585428|Experimental|NonCervical|Patients will receive a non-myeloablative lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of Young tumor infiltrating lymphocytes (TIL) plus high dose IV aldesleukin
3085791|NCT01585441|Experimental|Finasteride 5 mg|Participants randomly assigned to the finasteride 5 mg arm were instructed to take one capsule daily for three months.
3085792|NCT01585441|Placebo Comparator|Placebo|Participants randomly assigned to the placebo arm will instructed to take one capsule daily for three months.
3085793|NCT01585558|Experimental|Treatment Group 1|
3085794|NCT01585558|Experimental|Treatment Group 2|
3085795|NCT01585558|Placebo Comparator|Treatment Group 3|
3085796|NCT01585584|Experimental|Boceprevir|
3085797|NCT01585597|Experimental|Mild Hypothermia|Reduction of body temperature to 34 degrees centigrade. This will be accomplished using the Zoll Coolguard .
3085798|NCT01585766|Experimental|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
3085799|NCT01585766|Experimental|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
3085800|NCT01585766|Experimental|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
3085801|NCT01585766|Experimental|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
3085802|NCT01585766|Experimental|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
3085803|NCT01585766|Placebo Comparator|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1.
3085804|NCT01585779||Contour 3D® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Contour 3D® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Contour 3D® ring will occur in conjunction with another concomitant surgical repair procedure
3085805|NCT01585779||Tri-Ad® Implant|The subject population includes patients indicated for a TV repair procedure concomitant to left-sided heart surgery, and for whom the surgeon considers the implantation of a Tri-Ad® ring most appropriate to reconstruct the diseased valve. Patients with primary TV regurgitation will not be included in this study. Implantation with the Tri-Ad® ring will occur in conjunction with another concomitant surgical repair procedure
3085806|NCT01585831|Experimental|Testosterone gel 1%|Testosterone gel 1% applied to skin once per day for 1 year. Starting dose 1.25mL per day, titrated in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day. Titration based on testosterone levels with target level in mid-range of normal for Tanner stage.
3085807|NCT01585831|Placebo Comparator|Placebo gel|Placebo gel applied to skin once per day for 1 year. Starting dose 1.25mL per day. Dose randomly adjusted in 1.25mL increments for 1st 6 months of study after each study visit up to maximum of 5.0mL per day.
3085808|NCT01585961||Catheter Ablation|These patients have drug refractory, recurrent, symptomatic paroxysmal atrial fibrillation, are aged 18 years or older, and have provided written informed consent to participate in the study, including consent to undergo catheter ablation with the study device.
3085809|NCT01585987|Experimental|Arm A: Ipilimumab|Ipilimumab 10 mg/kg solution intravenously, 90 minute infusion, once every 3 weeks for 4 doses, then every 12 weeks until disease progression (for a maximum treatment period of 3 years from the first dose)
3085810|NCT01585987|Other|Arm B: Best Supportive care (BSC)|BSC may include the continuation of the Fluoropyrimidine that was used during the lead-in chemotherapy, but no other systemic anti cancer therapy
3085811|NCT01586026||Group A|Maintenance flushes at days 1-28
3085812|NCT01586026||Group B|Maintenance flushes at days 29-56
3085813|NCT01586026||Group C|Maintenance flushes at days 57+
3085814|NCT01586039|Active Comparator|Compact Fluorescent Light 90 lux|90 lux exposure of a commercially available Compact Fluorescent Light (CFL).
3085815|NCT01586039|Experimental|Blue-depleted LED light 90 lux|90 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
3085816|NCT01586039|Active Comparator|Compact Fluorescent Light 50 lux|50 lux exposure of a commercially available Compact Fluorescent Light (CFL).
3085817|NCT01586039|Experimental|Blue-depleted LED light 50 lux|50 lux exposure of a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
3085818|NCT01586091|Placebo Comparator|Placebo|Placebo per os at time 0 hours + placebo per os at 12 hours.
3085819|NCT01586091|Active Comparator|Levocetirizin|Levocetirizin 5mg at time 0 and placebo per os at 12 hours
3085820|NCT01586091|Active Comparator|Fexofenadine|Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours
3085821|NCT01586156|Active Comparator|Open Label Carvedilol|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight to the CRU (Clinical Research Unit) for the first-dose challenge of carvedilol. Subjects will take the medication for one week and at the end of one week, eligible subjects will be randomized to one of two groups (blinded). Group 1 will receive 3.125mg twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme. They will be given 3.125mg tablets to take twice daily for one week, followed by 6.25 mg twice daily for one week, followed by 12.5mg twice daily for one week with the option to increase to the max dose of 25mg twice daily for the remainder of the study.
3085822|NCT01586156|Placebo Comparator|Placebo Arm|Eligible subjects will receive open label carvedilol therapy at a dose 3.125 mg twice daily for one week. Subjects will be admitted overnight for the first-dose challenge of carvedilol. After one week run in phase, subjects will be placed on placebo. Subjects and Investigators will be blinded to the group assignment for the duration of the study.
3085823|NCT01586195|Experimental|Vemurafenib|Participants with untreated or previously treated locally advanced, unresectable, Stage IIIc or metastatic melanoma who have an activating exon 15 BRAF mutation other than V600E received vemurafenib 960 milligram (mg) orally twice daily (BID) until disease progression.
3085824|NCT01586312|Experimental|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intraarticular injection of 40 millions MSC.
3085825|NCT01586312|Active Comparator|Hyaluronic acid (Durolane)|Intraarticular injection of hyaluronic acid (60 mg)
3085826|NCT01586338|Experimental|Synvisc|Three intra-articular (IA) injections of Synvisc (2.25 ml glass syringe containing 16 mg hylan G-F 20) at intervals of one week. The total duration of observation was 26 weeks.
3085827|NCT01586364|Experimental|Ospemifene 60 mg Oral Tablet|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
3085828|NCT01586624|Experimental|Dose Escalation Phase Cohort 1 (Steady state dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085829|NCT01586624|Experimental|Dose Escalation Phase Cohort 2 (Steady state dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085830|NCT01586624|Experimental|Dose Escalation Phase Cohort 3 (Steady state dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085831|NCT01586624|Experimental|Dose Escalation Phase Cohort 4 (Steady state dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085832|NCT01586624|Experimental|Dose Escalation Phase Cohort 5a (Steady state dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085833|NCT01586624|Experimental|Dose Escalation Phase Cohort 5b (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085834|NCT01586624|Experimental|Dose Escalation Phase Cohort 6 (Steady state dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib)|Dose escalation to determine recommended dose and schedule for Phase 2 evaluation of vandetanib and selumetinib.
3085835|NCT01586624|Experimental|Expansion Phase (Steady state dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib)|Expansion cohort at the recommended phase 2 dose of vandetanib and selumetinib defined in the escalation phase.
3085836|NCT01586741|Active Comparator|Polypropylene mesh|Reconstruction of the abdominal wall diastasis with insertion of a polypropylene mesh on 30 patients.
3085837|NCT01586741|Active Comparator|quill suture|Reconstruction of the abdominal wall diastasis with double row absorbable suture ( Quill Self-retaining system) on 30 patients.
3085838|NCT01586741|No Intervention|conservative treatment|Regular abdominal exercises workout for three months for 30 patients.
3085839|NCT01586806|Placebo Comparator|Control|
3085840|NCT01586806|Active Comparator|Dexamethasone 1 mg|
3085841|NCT01586806|Active Comparator|Dexamethasone 4 mg|
3085842|NCT01586819|Active Comparator|Botulinum Toxin|The botulinum toxin will be injected into the wrinkles. The injections will take about 10 minutes to complete. Five follow-up visits will be scheduled at 1-7 days, 7-10 days, 2.5-3 weeks, and 12-14 weeks.
3085843|NCT01586819|Active Comparator|Chemical Peel Only|"After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water.~Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly."
3085844|NCT01586897|Experimental|Use of Medication Metronome|Providers allocated to intervention will automatically see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
3085845|NCT01586897|Active Comparator|Usual Care|PCPs allocated to the control arm will continue with usual care practices for laboratory monitoring.
3085846|NCT01586910|Experimental|Medtronic CoreValve® System TAVI|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
3085847|NCT01586910|Active Comparator|SAVR|Surgical Aortic Valve Replacement (SAVR)
3085848|NCT01586962|Experimental|Upper Respiratory Infections|
3085849|NCT01586975|Active Comparator|Clopidogrel 75 mg|Clopidogrel 75 mg daily
3085850|NCT01586975|Active Comparator|Aspirin 81 mg|open-label Aspirin 81 mg daily
3085851|NCT01586975|Active Comparator|Aspirin > 300mg|open-label Aspirin over 300 mg daily
3085852|NCT01587001|Active Comparator|Oral N-acetyl-cysteine|oral NAC 900mg three times daily for 8 weeks
3085853|NCT01587001|Placebo Comparator|Matching Placebo|oral placebo three times daily for 8 weeks
3085854|NCT01587027|Active Comparator|Sequence A|Aminophylline, Methazolamide, Aminophylline and Methazolamide
3085855|NCT01587027|Active Comparator|Sequence B|Methazolamide, Aminophylline, Aminophylline and Mathazolamide
3085856|NCT01587040|Experimental|SAR245408: Monotherapy|Participants received SAR245408 400 milligrams (mg) once daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days).
3085857|NCT01587040|Experimental|SAR245408: Combination Regimen|Participants received SAR245408 400 mg once daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245408 were available (up to 1959 days). Commercially available drugs were used as combination medications with SAR245408 (depending on the parental study, the following drugs were used in combination with SAR245408: paclitaxel and carboplatin, letrozole, trastuzumab, paclitaxel and trastuzumab).
3085858|NCT01587040|Experimental|SAR245409: Monotherapy|Participants received SAR245409 50 mg twice daily or at the established dose as monotherapy in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days).
3085859|NCT01587040|Experimental|SAR245409: Combination Regimen|Participants received SAR245409 50 mg twice daily or at the established dose as combination regimen in the parental study until disease progression, unacceptable toxicity, withdrawal of consent, or until commercial supplies of SAR245409 were available (up to 1917 days). Commercially available drugs were used as combination medications with SAR245409 (depending on the parental study, the following drugs were used in combination with SAR245409: letrozole, temozolomide, rituximab, bendamustine and rituximab).
3085860|NCT01587079|Experimental|PT003 (Dose 1)|PT003 MDI Dose 1
3085861|NCT01587079|Experimental|PT003 (Dose 2)|PT003 MDI Dose 2
3085862|NCT01587079|Experimental|PT003 (Dose 3)|PT003 MDI Dose 3
3085863|NCT01587079|Experimental|PT003 (Dose 4)|PT003 MDI Dose 4
3085864|NCT01587079|Experimental|PT003 (Dose 5)|PT003 MDI Dose 5
3085865|NCT01587079|Experimental|PT001|PT001 MDI
3085866|NCT01587079|Experimental|PT005|PT005 MDI
3085867|NCT01587079|Active Comparator|Spiriva® Handihaler®|Tiotropium Bromide
3085868|NCT01587105|No Intervention|Control|Usual Care Group
3085869|NCT01587105|Experimental|Comprehensive Care Management Service|Care Coordination through the Comprehensive Care Management Service at Seattle Children's Hospital
3085870|NCT01587118|Experimental|antidepressant plus asenapine|adjunctive asenapine
3085871|NCT01587274|Active Comparator|Opioid|Naproxen + opioid
3085872|NCT01587274|Active Comparator|Skeletal muscle relaxant|Naproxen + skeletal muscle relaxant
3085873|NCT01587274|Active Comparator|Naproxen alone|Naproxen + placebo
3085874|NCT01587651|Experimental|Prasugrel Maintenance Dose|Prasugrel 10 mg QD MD
3085875|NCT01587651|Active Comparator|Ticagrelor Maintenance Dose|Ticagrelor 90 mg twice-daily (BID) MD
3085876|NCT01587651|Experimental|Prasugrel Loading Dose|Prasugrel 60mg Loading Dose (LD), followed by prasugrel 10mg once-daily (QD) Maintenance Dose (MD)
3085877|NCT01587703|Experimental|Single and Repeat Dose finding cohort|All subjects will follow a 3+3 dose escalation design for GSK525762 and the dose will be escalated based on all available data, including PK data and the safety profile of prior cohorts, as well as the recommended dose from the Neuenschwander- Continuous Reassessment Method (N-CRM) design.
3085878|NCT01587703|Experimental|Expansion Cohort|Up to 150 additional subjects with NMC and other solid tumors may be enrolled in expansion cohorts. The recommended Phase 2 (Part 2) dose (RP2D) of GSK525762 will be determined based on the MTD or biologically active dose (example: clinical response), the safety profile and available pharmacodynamic data generated from all subjects in Parts 1
3085879|NCT01587703|Experimental|Besylate Sub study|Tablet and amorphous tablet in one of the two sequences (ABCD or BACD). Where Treatment A: RP2D/MTD as amorphous free-base tablet + low dose stable isotope in solution, fasted Treatment B: RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment C: half to one-third of RP2D/MTD as besylate tablet + low dose stable isotope in solution, fasted. Treatment D: RP2D/MTD as besylate tablet, fed
3085880|NCT01587885|Experimental|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
3085881|NCT01587885|Active Comparator|Omeprazole 20 mg|Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.
3085882|NCT01587898|Experimental|0.5mg GSK1278863|Once daily
3085883|NCT01587898|Experimental|2mg GSK1278863|Once daily
3085884|NCT01587898|Experimental|5mg GSK1278863|Once daily
3085885|NCT01587898|Experimental|Placebo|Once daily
3085886|NCT01587924|Experimental|0.5 mg GSK1278863|once daily
3085887|NCT01587924|Experimental|2 mg GSK1278863|once daily
3085888|NCT01587924|Experimental|5 mg GSK1278863|once daily
3085889|NCT01587924|Active Comparator|rhEPO|as required
3085890|NCT01587950|Placebo Comparator|Sterile water|Participants to receive 250 microlitres (μL) of sterile water.
3085891|NCT01587950|Experimental|Potassium nitrate 5% solution|Participants to receive 250 μL of potassium nitrate 5% solution.
3085892|NCT01587950|Experimental|Potassium nitrate 2.5% solution|Participants to receive 250 μL of potassium nitrate 2.5% solution.
3085893|NCT01587989|Active Comparator|A Methotrexate|
3085894|NCT01587989|Experimental|B Methotrexate Placebo|
3085895|NCT01588106||Test group|patients using CONTOUR Next USB
3085896|NCT01588106||Control group|patients using standard CONTOUR
3085897|NCT01588158|Active Comparator|Vicodin 5/325 mg|Half of the patients will be randomized to Vicodin
3085898|NCT01588158|Active Comparator|Acetaminophen 325 mg|Half of the patients will be randomized to Acetaminophen
3085899|NCT01588184|Experimental|Breast Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085900|NCT01588184|Experimental|Ovarian Cancer or Peritoneal Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085901|NCT01588184|Experimental|Renal Cell Carcinoma|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085902|NCT01588184|Experimental|Colorectal Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085903|NCT01588184|Experimental|Non-Squamous, Non-Small Cell Lung Cancer|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085904|NCT01588184|Experimental|Glioblastoma Multiforme|Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
3085905|NCT01588197|Experimental|ACC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy.~The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the rACC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
3085906|NCT01588197|Experimental|PFC Real Time fMRI Feedback|"Each participant will undergo thermal pain threshold assessments ten times using the Medoc Pathway System with MRI-compatible ATS Thermode (30mmX30mm; Medoc Inc, Israel). Participants will be instructed to focus on the thermal stimuli for the first 5 trials, and to engage in three cognitive pain inhibition strategies (Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, and the Control Strategy. The participants will be randomly assigned to receive Real Time fMRI Feedback of inverse activation in the PFC after each pain/rest block during the last 3 fMRI scans in the form of two simple thermometer images on the in-scanner computer display."
3085907|NCT01588236|Experimental|high dose KYG0395|Patients received high dose KYG0395 capsule (tid)
3085908|NCT01588236|Experimental|lower dose KYG0395|Patients received lower dose KYG0395 capsule (bid)
3085909|NCT01588236|Placebo Comparator|placebo|Patients received placebo (tid)
3085910|NCT01588353|Experimental|AK160 0.58 mg|
3085911|NCT01588366|Placebo Comparator|Placebo|Part A and B - Up to 4 capsules of placebo administered orally once a day for 28 days.
3085912|NCT01588366|Experimental|15 mg LY2409021|Part B - 1 capsule of 15 mg LY2409021 orally once a day for 28 days. (Arm added in September, 2012, per protocol amendment.)
3085913|NCT01588366|Experimental|60 mg LY2409021|Part A - 4 capsules of 15 mg LY2409021 administered orally once a day for 28 days.
3085914|NCT01588405|Experimental|UT-15C SR|
3085915|NCT01588418|Experimental|Exenatide first, then Placebo|Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
3085916|NCT01588418|Experimental|Placebo first, then Exenatide|Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
3085917|NCT01588444|Experimental|cancellous FDBA (LifeNet)|grafting with cancellous mineralized freeze-dried bone allograft (LifeNet Health)
3085918|NCT01588444|Experimental|cortical FDBA (LifeNet)|CORTICAL FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
3085919|NCT01588457|Active Comparator|Lithium|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, lithium [Li] at baseline. Lithium is one of these two mood stabilizers. The person may or may not stay solely on lithium throughout the study.
3085920|NCT01588457|Active Comparator|Divalproex|This open methods advancement study will randomize BD patients with clinically significant symptoms to treatment with one of two mood stabilizers, divalproex (DV)at baseline. Divalproex is one of these two mood stabilizers. The person may or may not stay solely on divalproex throughout the study.
3085921|NCT01588457|Active Comparator|Lithium plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + quetiapine [QT].
3085922|NCT01588457|Active Comparator|Lithium plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (lithium) + lamotrigine (LM).
3085923|NCT01588457|Active Comparator|Divalproex plus Quetiapine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + quetiapine [QT].
3085924|NCT01588457|Active Comparator|Divalproex plus Lamotrigine|Those who develop protocol defined depression will then be randomized to a mood stabilizer (divalproex) + lamotrigine (LM).
3085925|NCT01588470|Experimental|Pioglitazone|Only subjects with T2DM or non-diabetic subjects with coronary heart disease will receive Pioglitazone
3085926|NCT01588496|Experimental|Part A: Evolocumab|Participants received open-label evolocumab 420 mg subcutaneously once a month for 12 weeks.
3085927|NCT01588496|Experimental|Part B: Evolocumab|Participants received double-blind evolocumab 420 mg subcutaneously once a month for 12 weeks.
3085928|NCT01588496|Placebo Comparator|Part B: Placebo|Participants received double-blind placebo subcutaneously once a month for 12 weeks.
3085929|NCT01588509|Experimental|Romosozumab 140 mg|Participants received romosozumab 140 mg administered subcutaneously once a month for 3 months.
3085930|NCT01588509|Experimental|Romosozumab 210 mg|Participants received romosozumab 210 mg administered subcutaneously once a month for 3 months.
3085931|NCT01588548|Active Comparator|AZD1208|
3085932|NCT01588561|Active Comparator|Intravenous Nicotine (1.5 mg/70 kg)|Participants are given a siingle infusion of nicotine (1.5 mg/70 kg), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
3085933|NCT01588561|Placebo Comparator|Saline - placebo|Participants are given physiological saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans
3085934|NCT01588821|Experimental|Treatment Arm|Cabozantinib
3085935|NCT01588951|Experimental|No Leukemia Stem Cells - Consolidation|Without LSC, standard cytarabine consolidation
3085936|NCT01588951|Experimental|Leukemia Stem Cells - Consolidation|LSC present, randomized to cytarabine consolidation
3085937|NCT01588951|Experimental|Leukemia Stem Cells - Transplant|LSC present, randomized to allogeneic transplant
3085938|NCT01588990|Experimental|Bevacizumab: Phase A and Phase B|The trial will consist of 2 phases of treatment. Phase A: Participants will receive bevacizumab 7.5 mg/kg intravenous (IV) infusion on Day 1 every 3 weeks in combination with XELOX (capecitabine and oxaliplatin) or bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with mFOLFOX6 (oxaliplatin, leucovorin, and 5-fluouracil) until first disease progression or occurrence of unmanageable toxicity. Phase B: Upon documented first disease progression, participants will continue receiving bevacizumab 5 mg/kg IV on Day 1 every 2 weeks in combination with FOLFIRI (irinotecan, leucovorin, and 5-fluouracil) until second disease progression or occurrence of unmanageable toxicity. Phase B treatment should commence within 4 weeks of the date of documented first disease progression.
3085939|NCT01589094|Experimental|Gemcitabine and Cisplatin (DD GC)|This is a Multicenter Phase II study of dose-dense (DD) gemcitabine and cisplatin (GC) neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC) who are candidates for radical cystectomy.
3085940|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 1|1 mg/kg KBSA301
3085941|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 2|3 mg/kg KBSA301
3085942|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 3|10 mg/kg KBSA301
3085943|NCT01589185|Experimental|KBSA301, a monoclonal antibody dose 4|20 mg/kg KBSA301
3085944|NCT01589185|Experimental|Placebo|KBSA301-placebo
3085945|NCT01589237|Experimental|LCQ908|Patients initiated at 10 mg/day. After at least 8 weeks of treatment with a dose, optional up-titration to the next possible dose will be allowed. One down titration allowed from the highest dose attained.
3085946|NCT01589263|Active Comparator|ARM 1: onaBoNT-A + placebo|onaBoNT-A 200 U prostate injection and placebo oral capsule daily
3085947|NCT01589263|Active Comparator|ARM 2: Saline + Tamsulosin|Placebo prostate injection (saline) and tamsulosin 0.4 mg capsule daily.
3085948|NCT01589302|Experimental|Treatment (ibrutinib)|Patients will be treated with PCI-32765 capsules administered orally once daily at a dose of 420 mg for 28 day cycles. Weekly monitoring during the first month will occur followed by monthly evaluations for 2 additional months. Monitoring for patients at this point would be every 3 months with monthly CBC(complete blood count)and phone follow-up with a co-investigator on the study. A standard questionnaire will be used in this monthly phone assessment. Patients will continue to receive the study drug indefinitely as long as they are deriving clinical benefit (Complete Response or Partial Response or Stable Disease) and not experiencing any unacceptable toxicity. Subjects with disease progression will be removed from the study. Correlative laboratory samples, quality of life assessment, and immunologic data would be collected over time of therapy.
3085949|NCT01589315|Experimental|FEAST|Active right unilateral focal ECT
3085950|NCT01589445|Experimental|Pioglitazone (001 group)|The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
3085951|NCT01589445|Experimental|Metformin (002 group)|The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.
3085952|NCT01589484|Experimental|Shockwave lithotripsy (SWL)|All patients will be submitted to a noncontrast computed tomography before to shockwave lithotripsy (SWL). Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
3085953|NCT01589497|Active Comparator|RHZE-RHZE|Participants were administered rifampin-isoniazid-pyrazinamide-ethambutol (RHZE) from Day 1 to Day 14.
3085954|NCT01589497|Active Comparator|RHZE-RZE|Participants were administered RHZE from Day 1 to Day 2, then rifampin-pyrazinamide-ethambutol (RZE) from Day 3 to Day 14.
3085955|NCT01589497|Active Comparator|RHZE-RMZE|Participants were administered RHZE Day 1 to Day 2 and rifampin-moxifloxacin-pyrazinamide-ethambutol (RMZE) from Day 3 to Day 14.
3085956|NCT01589497|Active Comparator|RZE-RZE|Participants were administered only RZE from Day 1 through Day 14.
3085957|NCT01589510||Lumigan® 0.01%|Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.
3132418|NCT03425396|Experimental|Omadacycline 300/300 once every 24 hours|Participants received omadacycline 300 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
3085958|NCT01589601|No Intervention|Usual heart failure care|Patients will be managed by a cardiologist-directed team with expertise in the diagnosis and treatment of heart failure. Until discharge, inpatient care will focus on symptom relief and initiation of evidence-based therapies. Additional goals of care will include treatment of co-morbidities and patient education designed to assist with self-management techniques. However, after discharge, which is where the study actually takes place, patients will only receive outpatient follow-up with a heart failure cardiologist or nurse practitioner who will focus on medication titration to evidence-based dosing, titration of diuretic therapy, assessment of compliance with medical and dietary regimens, and serial monitoring of end-organ function.
3085959|NCT01589601|Active Comparator|Usual care + palliative care|Patients will receive an interdisciplinary, multicomponent palliative care intervention combined with state of the art heart failure management designed to assess and manage the multiple domains of quality of life at the end of life for patients with advanced heart failure, including physical symptoms, psychosocial concerns, and spiritual concerns, and to facilitate advance care planning.
3085960|NCT01589653|Experimental|Subject-driven titration|
3085961|NCT01589653|Experimental|Investigator-driven titration|
3085962|NCT01589770|Other|rheumatoid arthritis patients|People who have rheumatoid arthritis underwent cMRI
3085963|NCT01589770|Other|controls|people who do not have RA or other inflammatory disease underwent cMRI
3085964|NCT01589822|Experimental|EVICEL Fibrin Sealant: Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen.
3085965|NCT01589822|No Intervention|Standard of Care|Standard surgical technique for GI anastomosis.
3085966|NCT01589822|Experimental|Experimental: EVICEL Fibrin Sealant: Non-Randomized|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
3085967|NCT01589978|Experimental|PROMUS Element|Subjects who receive the PROMUS Element everolimus-eluting coronary stent
3085968|NCT01590017|Experimental|Cistplatin and Radiation Therapy|Cisplatin 40 mg/m2 (max = 70 mg) IV over 30-60 minutes given weekly on days 1, 8, 15, 22, 29 and 36 for a total of 6 weekly cycles. Radiation therapy over 8 weeks: External pelvic radiation therapy (41.4-45.0 Gy/1.8 Gy per fraction/23-25 fractions/five weeks), intracavitary brachytherapy (low dose: 35-43.6 Gy/1-2 implants; high dose: 18-28 Gy/2-4 implants), with parametrial boost to involved parametria (5.40 - 9.00 Gy/1.8 Gy/3-5 fractions/3-5 days).
3085969|NCT01590082|Experimental|Doxycycline, Ipilimumab, and Temozolomide|Doxycycline to start on day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts) twice a day until morning of Day 1 of Cycle 1. After the Day 1 of Cycle 1, participants receive first dose of Ipilimumab, and evening of same day, Temozolomide received by mouth once a day for 4 days. Doxycycline administration will continue twice daily for rest of cycle without interruption; Cycle 1 is 4 weeks of treatment. Starting Cycle 2, Doxycycline with temozolomide and ipilimumab administration start on Day 1. Each cycle is 3 weeks. 4 cycles of therapy given over a 3 month period to complete induction phase. After induction therapy, participants continue on Doxycycline.
3085970|NCT01590212|No Intervention|Care as usual|Participants received care in line with local guidelines
3085971|NCT01590212|Active Comparator|Mellow Bumps + care as usual|MB is a six week group-based antenatal programme designed to support families with additional health and social care needs. MB is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation.
3085972|NCT01590212|Active Comparator|Chill-out in Pregnancy + care as usual|CHiP is a relaxation programme that includes all the mother-centred components of Mellow Bumps but none of the baby or mother-baby relationship components. It runs for six weeks at two hours per week. It aims to decrease maternal stress levels.
3085973|NCT01590238|Experimental|Treatment with PRFM|Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp. Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
3085974|NCT01590264|Other|Bimodal rTMS|"Open-label and single-arm rTMS bimodal treatment with placement of magnet over Dorsolateral Prefrontal Cortex (DLPFC) and Temporoparietal Junction (TPJ) for 2 weeks of treatment (10 days)~Stimulation Settings:~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
3085975|NCT01590433|Experimental|Exenatide|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive exenatide will not be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of study team will know which they are receiving.
3085976|NCT01590433|Placebo Comparator|Placebo|Subjects will be randomly assigned to the exenatide study treatment group or to the placebo study treatment group. Subjects will have a 33 percent chance of being assigned to the placebo study treatment group and a 66 percent chance of being assigned to exenatide study treatment. Subjects will not be able to choose the study group to which they will be assigned. All study participants will receive individualized dietary counseling based on food logs. Subjects who receive placebo will be assigned to follow a reduced-calorie diet in addition to study treatment. Subjects will not know whether they are receiving exenatide or placebo, but the unblinded members of the study team will know which they are receiving.
3085977|NCT01590550||Single arm|Single arm for all patient receiving inpatient HD
3085978|NCT01590563|Experimental|SCu300A IUB|Insertion of a spherical IUD (intrauterine device) with one year follow-up
3085979|NCT01590758|Placebo Comparator|Topical placebo control|
3085980|NCT01590758|Experimental|Topical pexiganan cream 0.8%|
3085981|NCT01590771|Experimental|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during run-in period.
3085982|NCT01590771|Placebo Comparator|Placebo|Matching placebo once daily for 24 weeks. Participants will continue pre-study gliclazide or glimepiride with or without metformin for ≥10 weeks before and throughout the study.
3085983|NCT01590797|Experimental|Sitagliptin|Participants treated with sitagliptin 100 mg, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
3085984|NCT01590797|Placebo Comparator|Placebo|Participants treated with placebo matching sitagliptin, once daily, for 24 weeks. All participants will be under treatment with a stable dose of insulin with or without metformin for ≥10 weeks before and throughout the study. All participants will receive placebo during the Placebo Run-in period.
3085985|NCT01590810|Experimental|Panel A-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel A will be 2.0 mg to 90 mg.
3085986|NCT01590810|Experimental|Panel B-Healthy|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel B will be 5.0 mg to 160 mg.
3085987|NCT01590810|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 treatment periods, 6 participants will be randomly assigned to receive MK-8150, and 2 will be randomly assigned to receive matching placebo according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel C will be 160 mg to 1200 mg.
3085988|NCT01590810|Experimental|Panel D-Healthy|Within each panel, 8 subjects will be randomly assigned to MK-8150 and 2 subjects will be randomly assigned to placebo throughout the 5 periods according to a computer-generated allocation schedule. The dose range of MK-8150 for Panel D will be 50 mg to 500 mg.
3085989|NCT01590875|Experimental|Adenosine arm|25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose.
3085990|NCT01590875|No Intervention|Observation arm|25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation. This will serve as the control arm.
3085991|NCT01590888|Experimental|PBT2 250mg|
3085992|NCT01590888|Experimental|PBT2 100mg|
3085993|NCT01590888|Placebo Comparator|Sugar pill|
3085994|NCT01590979|Active Comparator|Ranolazine|The antianginal properties of the drug are due to inhibition of the late inward sodium current, demonstrated in animal experiments and human studies that it can prevent atrial and ventricular arrhythmias.
3085995|NCT01590979|Placebo Comparator|Placebo|Company generated placebo, will be similar in size and color to Ranolazine; and administered two times a day (12 hour intervals)
3085996|NCT01591005|Experimental|CEA with sonolysis|endarterectomy with sonolysis (continual transcranial Doppler monitoring)
3085997|NCT01591005|Placebo Comparator|CEA without sonolysis|endarterectomy without sonolysis
3085998|NCT01591005|Experimental|carotid stenting with sonolysis|carotid stenting with sonolysis (continual transcranial Doppler monitoring)
3085999|NCT01591005|Placebo Comparator|carotid stenting without sonolysis|carotid stenting without sonolysis
3086000|NCT01591018|Experimental|cardiac surgery with sonolysis|cardiac surgery (CABG or heart valve surgery) with sonolysis (continual transcranial Doppler monitoring)
3086001|NCT01591018|Placebo Comparator|cardiac surgery without sonolysis|cardiac surgery (CABG or heart valve surgery) without sonolysis (continual transcranial Doppler monitoring)
3086002|NCT01591044|Active Comparator|R940343 2mg, 2 puffs bid|R343 2mg, 2 puffs bid
3086003|NCT01591044|Placebo Comparator|Placebo|
3086004|NCT01591044|Active Comparator|R940343 1mg, 1 puff bid|R343 1mg, 1 puff bid
3086005|NCT01591161|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
3086006|NCT01591161|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
3086007|NCT01591317|Experimental|Prasugrel - 60 mg/10 mg|Prasugrel 60 mg loading dose given once orally, followed by 10 mg once a day orally for 10 days
3086008|NCT01591317|Experimental|Prasugrel - 30 mg/7.5 mg|Prasugrel 30 mg loading dose given once orally, followed by 7.5 mg once a day orally for 10 days
3086009|NCT01591317|Experimental|Prasugrel - 30 mg/5 mg|Prasugrel 30 mg loading dose given once orally followed by 5 mg once a day orally for 10 days
3086010|NCT01591330|Experimental|LY2140023 Reference Form|LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3086011|NCT01591330|Experimental|LY2140023 Test-Low|LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3086012|NCT01591330|Experimental|LY2140023 Test-Medium|LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3086013|NCT01591330|Experimental|LY2140023 Test-High|LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.
3086014|NCT01591382|Active Comparator|Ketamine|Participants received postoperative hydromorphone patient-controlled analgesia (PCA) and continuous ketamine (0.2 mg/kg/hour). Ketamine is being compared to the use of placebo, in addition to intravenous opioids, for postop pain control in opioid dependent patients who undergo major surgery.
3086015|NCT01591382|Placebo Comparator|Placebo|Participants received postoperative hydromorphone PCA and continuous ketamine-matching placebo (infusion of saline).
3086016|NCT01591408|Experimental|EEG biofeedback|Subjects will receive EEG biofeedback according to their own brain rhythms
3086017|NCT01591408|Sham Comparator|sham EEG biofeedback|Subjects will receive feedback according to someone else's brain rhythms collected during a different session.
3086018|NCT01591460|Experimental|Dual Combination Therapy|
3086019|NCT01591460|Experimental|Triple Combination Therapy|
3086020|NCT01591499|Experimental|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
3086021|NCT01591499|Active Comparator|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
3086022|NCT01591616|Other|Oraqix for tooth extraction|
3086023|NCT01591655|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%,
3086024|NCT01591655|Placebo Comparator|Vehicle|The vehicle of the mapracorat ophthalmic suspension
3086025|NCT01591681|Active Comparator|Pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
3086026|NCT01591681|No Intervention|Standard of Care|The control algorithm will run passively and not recommend control the patient's pump.
3086027|NCT01591733|Experimental|Treatment Arm|All participants will receive the FOLFIRINOX regimen, followed by capecitabine and short course radiation therapy.
3086028|NCT01591746|Experimental|Group A - Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast
3086029|NCT01591746|Placebo Comparator|Group B - Placebo|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast
3086030|NCT01591785|Active Comparator|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
3086031|NCT01591785|Placebo Comparator|Placebo ointment|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
3086032|NCT01591837|Experimental|Adults|Healthy volunteers aged 18 to 59 years received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
3086033|NCT01591837|Experimental|Older Adults|Healthy volunteers aged 60 years or older received a single 0.5 mL dose of CSL Influenza Vaccine by intramuscular or subcutaneous injection.
3086034|NCT01591863|Experimental|fidaxomicin|
3086035|NCT01592006|Experimental|HCV, LT, Pegasys, ribavirin, telaprevir|Patients are being asked to be part of this arm because they are orthotopic liver transplant recipients (OLT) and have the Hepatitis C Virus (HCV). They will be given the study drugs Pegasys, ribavirin and telaprevir
3086036|NCT01592045|Experimental|Sequence 1|UTC ch14.18 for two courses and NCI ch14.18 for three courses
3086037|NCT01592045|Experimental|Sequence 2|NCI ch14.18 for two courses and UTC ch14.18 for three courses
3086038|NCT01592071|Experimental|Replace reactive w/ non-reactive foods|Test results, individual dietary plan: 'Replace reactive foods with non-reactive foods'
3086039|NCT01592240|Experimental|Q28d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q28d dose group will receive subcutaneous administration of PF-04950615 or Placebo once a month.
3086040|NCT01592240|Experimental|Q14d Dosing Arm|A total of 7 dose groups in two dosing schedules, 50 subjects per dose group are planned. Q14d dose group will receive subcutaneous administration of PF-04950615 or Placebo every 2 weeks.
3086041|NCT01592292||Rituximab|Participants who have inadequate response or were intolerant to the first anti-tumor necrosis factor (anti-TNF) agent in rheumatoid arthritis (RA), receiving rituximab as per physician's discretion for RA treatment were observed for 12 months.
3086042|NCT01592292||Other anti-TNF agent|Participants who have inadequate response or were intolerant to the first anti-TNF agent in RA, receiving other anti-TNF agent, including adalimumab, etanercept and infliximab, as per physician's discretion for RA treatment were observed for 12 months.
3086043|NCT01592344|Experimental|StimRouter - active stimulation|StimRouter- active electrical stimulation is applied transdermally to a targeted peripheral nerve. This is accomplished via a fully implanted StimRouter lead that receives energy from a rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes. The EPT receives radio frequency (RF) commands from a Patient Programmer. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer. Up to eight stimulation programs may be saved on a Patient Programmer for on-demand selection by the study patient.
3086044|NCT01592344|Sham Comparator|StimRouter - Control|StimRouter- Electrical stimulation is withheld from the targeted peripheral nerve after fully implanting the StimRouter lead. The rechargeable programmed external pulse transmitter (EPT) with attached gel electrodes is placed for transdermal stimulation but no stimulation is delivered. The EPT which normally receives radio frequency (RF) commands from a Patient Programmer is not activated. A StimRouter Clinician Programmer is used to program the StimRouter EPT and Patient Programmer such that no stimulation occurs in the Control Arm of the study.
3086045|NCT01592396|Experimental|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 milligram (mg), subcutaneously on Day 1.
3086046|NCT01592409|Active Comparator|Active cannabis|In this condition, participants will receive a cigarette containing 12.5% active THC.
3086047|NCT01592409|Placebo Comparator|Placebo|In this condition, participants will receive a cannabis cigarette where the active THC has been removed (contains 0% THC).
3086048|NCT01592435||Pred. & Invest.-All Study Participants|"Cedera AccuStitch Software is standard of care software currently used at sites.~Carestream DR LLI software is investigational software used for reconstruction."
3086049|NCT01592500|Experimental|MOD-4023 low dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3086050|NCT01592500|Experimental|MOD-4023 middle dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3086051|NCT01592500|Experimental|MOD-4023 high dose|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3086052|NCT01592500|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
3086053|NCT01592695|Experimental|Tailored Intervention Group|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues associated with cigarette smoking.
3086054|NCT01592695|Active Comparator|Enhanced Standard of Care Group|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quit line along with pharmacotherapy to assist with smoking cessation.
3086055|NCT01592708|Active Comparator|Antiemetic anesthesia protocol|Scopolamine 1.5 milligram(mg) patch Propofol infusion remifentanil infusion 250mg erythromycin po for 2 doses Solumedrol 0.625mg IV droperidol 4mg IV Ondansetron Ketorolac 30mg IV ibuprofen 600mg po q6h Fentanyl Hydrocodone/Tylenol po
3086056|NCT01592747|Experimental|Memantine 1|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight-based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for up to 12 weeks.
3086057|NCT01592747|Experimental|Memantine 2|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for up to 12 weeks.
3086058|NCT01592747|Placebo Comparator|Placebo|Dosing will be once daily for up to 12 weeks.
3086059|NCT01592760|Experimental|air-Q SP|air-Q Self-Pressurizing Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
3086060|NCT01592760|Active Comparator|air-Q|air-Q Intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mercury Medical, Clearwater, FL, USA)
3086061|NCT01592760|Active Comparator|i-gel|i-gel, sizes 3, 4, and 5 (Intersurgical Inc., Liverpool, NY, USA)
3086062|NCT01592773|Experimental|Memantine|"To maintain the blind of the preceding study, patients who participated in MEM-MD-68 (NCT01592747) began this study with 6 weeks of double blind dosing during which all patients were either titrated to or remained on their maximum target dosages. This was followed by up-to 42 weeks of open-label dosing.~Patients who took open-label memantine in study MEM-MD-67 (NCT01999894) or MEM-MD-91(NCT01592786), received up to 48 weeks of open-label memantine at their maximum tolerated weight based target dosage."
3086063|NCT01592786|Experimental|Memantine Hydrochloride (HCl)|Once daily oral administration of open-label memantine for up to 48 weeks: 6-week dose-titration period followed by up to 42-week maintenance period.
3086064|NCT01592799|Other|Influenza Group|Children <15 years of age hospitalized for or presenting to an ER for acute ARI and/or isolated fever during the influenza season.
3086065|NCT01592851|Experimental|Arm 1|Dentifrice containing stannous fluoride
3086066|NCT01592851|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
3086067|NCT01592864|Experimental|Arm 1|Dentifrice containing stannous fluoride
3086068|NCT01592864|Active Comparator|Arm 2|Marketed dentifrice containing Sodium Monofluorophosphate
3086069|NCT01593020|Experimental|Paclitaxel + FEC or FAC Group|"ARM 1: Participants receive Paclitaxel 80 mg/m2 by vein over 1 hour weekly for 12 doses of a 21 day cycle.~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
3086070|NCT01593020|Experimental|Eribulin + FEC or FAC Group|"ARM 2: Participants receive Eribulin 1.4 mg/m2 by vein over 2-5 minutes on days 1 and 8 every 3 weeks for 4 cycles (21 day cycle).~Participants on both arms receive FEC or FAC for 4 cycles (21 day cycle) at the preference of the treating physicians."
3086071|NCT01593215|Active Comparator|Placebo first then yohimbine|placebo first, then yohimbine
3086072|NCT01593215|Active Comparator|Yohimbine first then placebo|Yohimbine first then placebo
3468904|NCT03891563||Sport specialists, MVPA|"AOSSM Criteria:~Participation in intensive training and/or competition in organized sports greater than 8 months per year (essentially year round)~Participation in 1 sport to the exclusion of participation in other sports (limited free play overall)~Involving prepubertal (seventh grade or roughly age 12 years) children.~AND~Activity Tracker Criteria:~Greater than 180 accumulated minutes of moderate-to-vigorous physical activity (MVPA) during participation in one sport type across one week of activity tracking~- Meets these criteria within either one or both years of follow-up"
3086075|NCT01593592|Experimental|Lactobacillus reuteri group|The active group that will receive the standard triple therapy and Lactobacillus reuteri
3086076|NCT01593592|Placebo Comparator|Control group|The control group that will receive the standard triple therapy and placebo
3086077|NCT01593670|Experimental|Patients With High Risk MDS|Patients who received treatment for high risk myelodysplastic syndromes (MDS). Treatment Received: Decitabine 10 mg/m^2/day intravenous (IV) over 1 hour days 1-5; Vorinostat 200 mg by mouth (PO) twice a day days 6-15; Il-2 activated donor natural killer cells (NK) infusion IV over 15 to 60 minutes day 17; Interleukin-2 6 million units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17. Repeat treatment course 6 to 8 weeks after cycle 1 start date.
3086078|NCT01593696|Experimental|Lymphodepleting regimen of Fludarabine and Cyclophosphamide|Lymphodepleting regimen of Fludarabine and Cyclophosphamide.
3086079|NCT01593696|Experimental|Intensive standard of care chemotherapy|Intensive standard of care chemotherapy, in lieu of the lymphodepleting chemotherapy regimen, to decrease tumor burden in preparation for the administration of the Chimeric antigen receptor (CAR) T cells.
3086080|NCT01593722|Active Comparator|diethylcarbamazine|diethylcarbamazine 8 mg/kg single oral dose
3086081|NCT01593722|Active Comparator|ivermectin|ivermectin 200 mcg/kg single oral dose
3086082|NCT01593748|Experimental|Experimental|Patients in Group 1 will get Gemcitabine 1000 mg/m2 intravenously on Day 1 and Day 8 and Pazopanib 800mg by mouth daily on a 21 day cycle. Cycles will continue until disease progression or patient withdrawal.
3086083|NCT01593748|Active Comparator|Standard of Care|Patients in Group 2 will get Gemcitabine 900 mg/m2 intravenously on Day 1 and Day 8. Additionally on Day 8, patients will have Docetaxel 100 mg/m2 given intravenously. on a 21 day cycle. If disease progression occurs on this treatment, patients will have the option to receive treatment with Gemcitabine and Pazopanib (group 1).
3086084|NCT01593787|Experimental|LCZ696 100 mg|All participants were started on LCZ696 100 mg once daily on day 1.
3086085|NCT01593787|Experimental|LCZ696 200 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 2 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 200 mg.
3086086|NCT01593787|Experimental|LCZ696 400 mg|All participants were started on LCZ696 100 mg once daily on day 1. For participants who received LCZ696 200 mg and did not achieve msDBP <80 mmHg and msSBP <130 mmHg at or after week 4 and had no signs of safety concerns at specified visits during the treatment epoch, the LCZ696 dose was increased to LCZ696 400 mg.
3086087|NCT01593852|Active Comparator|Regular X-ray dose settings|For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
3086088|NCT01593852|Experimental|Reduced X-ray dose settings|For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing
3086089|NCT01593917||Subjects previously implanted with a Trifecta™ valve in the Trifecta™ IDE Study|Subjects enrolled in this clinical study were implanted with the Trifecta™ aortic bioprosthetic valve during 2007, 2008 and 2009 as part of the Trifecta™ IDE Study conducted to obtain FDA approval.
3086090|NCT01594125|Experimental|Group I|patients with mild liver dysfunction according to their AST/ALT values and Child-Pugh score
3086091|NCT01594125|Experimental|Group II|patients with moderate liver dysfunction according to their AST/ALT values and Child-Pugh score
3086092|NCT01594281|Experimental|Ranibizumab mono|Interventional Core Phase: One intravitreal injection of ranibizumab 0.5 mg to the study eye monthly until stability regarding morphological parameters is confirmed (ie, no further improvement of morphology or no worsening of morphology for 3 consecutive months)
3086093|NCT01594281|Active Comparator|PRP mono|Interventional Core Phase: Panretinal laser photocoagulation (PRP) treatment administered to the study eye in accordance with the modified diabetic retinopathy study (DRS) guidelines for panretinal laser photocoagulation procedures
3086094|NCT01594281|Experimental|Ranibizumab+PRP|Interventional Core Phase: Ranibizumab 0.5 mg as described for the ranibizumab mono arm and PRP treatment as described for the PRP mono arm until stability regarding morphological parameters is confirmed
3086095|NCT01594294|Experimental|AOSEPT Plus|AOSEPT® Plus contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
3086096|NCT01594294|Active Comparator|ReNu MultiPlus|ReNu MultiPlus® contact lens solution used with etafilcon A contact lenses or lotrafilcon B contact lenses for 3 months (Investigational Phase)
3086097|NCT01594294|Other|Complete MPS Easy Rub|COMPLETE® MPS Easy Rub® Formula contact lens solution used with etafilcon A contact lenses (14 days) or lotrafilcon B contact lenses (30 days), Screening Phase
3086098|NCT01594333|Experimental|Methotrexate|Methotrexate: Tablet, Oral, Target dose 15-20mg weekly plus 1.0 mg folic acid 6 days/week
3086099|NCT01594333|Placebo Comparator|Placebo|Placebo: Tablet, Oral weekly plus 1.0mg folic acid 6 days/week
3086100|NCT01594385|Other|Seprafilm|The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.
3086101|NCT01594385|No Intervention|No Seprafilm|This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.
3086102|NCT01594411||All subjects|Subjects are enrolled at multiple participating primary care practices. The main inclusion criterion for enrollment is the occurrence of chest pain (or anginal equivalent) in a patient without known significant coronary artery disease (CAD) or a history of prior myocardial infarction.
3086103|NCT01594424|Experimental|IVIG + Tocilizumab|
3086104|NCT01594476|Experimental|Levonorgestrel IUS insertion at 3 weeks|IUD placement at 3 weeks after delivery.
3086105|NCT01594476|Experimental|Levonorgestrel IUS insertion at 6 weeks|IUD placement at 6 weeks after delivery.
3086106|NCT01594515|Experimental|BI 1015550 low dose A|Powder for oral solution
3086107|NCT01594515|Experimental|BI 1015550 low dose B|Powder for oral solution
3086108|NCT01594515|Experimental|BI 1015550 low dose C|Powder for oral solution
3086109|NCT01594515|Experimental|BI 1015550 low dose D|Powder for oral solution
3086110|NCT01594515|Experimental|BI 1015550 medium dose A|Powder for oral solution
3086111|NCT01594515|Experimental|BI 1015550 medium dose B|Powder for oral solution
3086112|NCT01594515|Experimental|BI 1015550 medium dose C|Powder for oral solution
3086113|NCT01594515|Experimental|BI 1015550 high dose A|Powder for oral solution
3086114|NCT01594515|Experimental|BI 1015550 high dose B|Powder for oral solution
3086115|NCT01594515|Placebo Comparator|Placebo|Solution for oral administration
3086116|NCT01594528|Experimental|SC|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with schizophrenia
3086117|NCT01594528|Experimental|controls|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects without any psychiatric trouble
3086118|NCT01594528|Experimental|MD|behavior as defined with facial, corporal and vocal indicators during experimental pain tests for subjects with major depression
3086119|NCT01594749|Experimental|Fosaprepitant Regimen|On Day 1, participants received fosaprepitant, 150 mg intravenous (IV) infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 12 mg, orally (PO) ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy, followed by 8 mg PO, 8 hours after first dose PLUS dexamethasone placebo, PO ~30 minutes prior to chemotherapy. On Days 2 and 3, participants received ondansetron placebo, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
3086120|NCT01594749|Active Comparator|Control Regimen|On Day 1, participants received fosaprepitant placebo, 150 mL IV infusion, ~30 minutes prior to chemotherapy PLUS dexamethasone 20 mg, PO ~30 minutes prior to chemotherapy PLUS ondansetron 16 mg total dose: 8 mg PO ~30-60 minutes prior to chemotherapy; followed by 8 mg PO, 8 hours after the first dose. On Days 2-3, participants received ondansetron 8 mg, PO every 12 hours. Rescue Therapy: For established cases of nausea or vomiting, medications may have been prescribed from these permitted choices: 5-HT3 antagonists (granisetron, dolasetron, tropisetron or ondansetron); phenothiazines (e.g. prochlorperazine, fluphenazine, perphenazine, thiethylperazine, or chlorpromazine); butyrophenones (e.g. haloperidol or droperidol); benzamides (e.g. metoclopramide or alizapride); benzodiazepines; corticosteroids; domperidone.
3086121|NCT01594762|Placebo Comparator|Topical placebo control|Drug: Topical placebo cream
3086122|NCT01594762|Experimental|Topical pexiganan cream 0.8%|Drug: Topical pexiganan cream 0.8%
3086123|NCT01594827|Experimental|Inhaled Vanc and Oral Abx|In the experimental arm CF participants are randomized to 28 days of inhaled sterile vancomycin (250 mg twice a day) as well as 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
3086124|NCT01594827|Active Comparator|Inhaled Placebo and Oral Abx|In the active comparator arm CF participants are randomized to 28 days of inhaled sterile placebo (saline) and are treated with 28 days of oral/skin antibiotics targeted to aggressively treat MRSA infection: oral rifampin, a second oral antibiotic (TMP/SMX or doxycycline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes. Patients will be followed for 3 months after completion of the treatment protocol.
3086125|NCT01594853|Experimental|exercise|Female carriers as well as healthy age and gender matched individuals will participate in an exercise paradigm.
3086126|NCT01594931|Experimental|pyronaridine/artesunate (6:2 mg/kg)|pyronaridine tetraphosphate 6 mg/kg and artesunate 2 mg/kg
3086127|NCT01594931|Experimental|pyronaridine/artesunate (9:3 mg/kg)|pyronaridine tetraphosphate 9 mg/kg and artesunate 3 mg/kg
3086128|NCT01594931|Experimental|pyronaridine/artesunate (12:4 mg/kg)|pyronaridine tetraphsophate 12 mg/kg and artesunate 4 mg/kg
3086129|NCT01594970|Experimental|Bimatoprost 0.01% (Naive Monotherapy)|1 drop in the affected eye(s), administered in the evening in previously treatment naive subjects for 12 weeks.
3086130|NCT01594970|Experimental|Bimatoprost 0.01% (Switched Monotherapy)|1 drop in the affected eye(s), administered in the evening in subjects who were previously on another monotherapy treatment for 12 weeks.
3086131|NCT01594970|Experimental|Bimatoprost 0.01% (with Adjunctive Therapy)|1 drop in the affected eye(s), administered in the evening in subjects who are also receiving adjunctive therapy for 12 weeks.
3086133|NCT01595282|Experimental|Ketorolac|Intramuscular injection of ketorolac 60 mg in 2cc -plus- placebo tablet (calcium carbonate 600 mg tablet). For subjects who are 50 kg or less, intramuscular injection of ketorolac 30 mg in 1cc -plus- placebo tablet (calcium carbonate 600 mg tablet)
3086134|NCT01595282|Active Comparator|Ibuprofen|Ibuprofen 800 mg tablet -plus- intramuscular injection of 2cc saline placebo. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet -plus- intramuscular injection of 2cc saline placebo
3086135|NCT01595386|Placebo Comparator|Normal Saline|The subjects will receive a bolus after successful completion of bypass and the post-pump adrenal corticotrophin hormone (ACTH) stim test equal to a 50mg/m2 dose of Hydrocortisone. This will be followed by a continuous infusion comparable to the rates a Hydrocortisone drip would run at. This infusion will be tapered down over the next 120 hours.
3086136|NCT01595386|Experimental|Hydrocortisone|Subjects enrolled in this arm of the study will receive a 50mg/m2 bolus of Hydrocortisone after successful completion of CPB and the post-pump ACTH stim test has been performed. This will be followed by a continuous infusion of Hydrocortisone that will be tapered over the next 120 hours.
3086137|NCT01595438|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3086138|NCT01595438|Active Comparator|Doripenem|IV treatment
3086139|NCT01595516|Active Comparator|Nebivolol|
3086140|NCT01595516|Active Comparator|Metoprolol|
3086141|NCT01595516|Placebo Comparator|Placebo|
3086142|NCT01595516|Other|Bradykinin|
3086143|NCT01595516|Other|Saline|
3086144|NCT01595516|Other|Vitamin C|
3086145|NCT01595529|Experimental|Active treatment|5 days of active therapy to match the physician-initiated therapy, Trimethoprim sulfamethoxazole, Cefixime or Cefdinir or Cephalexin (subjects originally receiving Cefdinir will receive Cefixime)
3086146|NCT01595529|Placebo Comparator|Placebo treatment|5 days of placebo treatment to match physician-initiated therapy
3086147|NCT01595646|Placebo Comparator|Saline|Saline placebo taken twice per day via intranasal route.
3086148|NCT01595646|Experimental|Insulin Detemir|20IU of Insulin Detemir taken twice per day (40IU total per day) via intranasal route
3086149|NCT01595646|Experimental|Insulin|20IU Insulin, administered twice per day (40IU total per day) via intranasal route
3086150|NCT01595854|Experimental|Test 2 (part 3)|low dose dabigatran + high dose ticagrelor
3086151|NCT01595854|Active Comparator|Test 1 (part 1 + 2)|high dose ticagrelor
3086152|NCT01595854|Experimental|Reference 1 (part 1 + 2)|medium dose dabigatran
3086153|NCT01595854|Experimental|Reference 2 (part 3)|low dose dabigatran
3086154|NCT01596062|Active Comparator|Simulect 40mg + Neoral + Myfortic + steroids|A cumulative dose of 40 mg of Simulect® (20mg at Day 0 (D0) and 20mg at Day 4 (D4)+ Neoral® + Myfortic® + corticosteroids
3086155|NCT01596062|Experimental|Simulect 80mg + Neoral + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Neoral® + Myfortic® + corticosteroids
3086156|NCT01596062|Experimental|Simulect 80mg + Certican + Myfortic + steroids|A cumulative dose of 80 mg of Simulect® (40mg at D0 and 40mg at D4) + Certican® + Myfortic® + corticosteroids
3086157|NCT01596088|Experimental|Drug: Dexrazoxane|"Dexrazoxane should be given once daily for 3 consecutive days. The dose is:~Day 1: 1000 mg/m2, Day 2: 1000 mg/m2, Day 3: 500 mg/m2 (body surface area)"
3086158|NCT01596127|Experimental|Intrathecal Rituximab|"Phase I Starting Dose: Rituximab administered via lumbar puncture at dose of 10 - 25 mg twice weekly according to the dose escalation.~Phase II Rituximab Starting Dose: Maximum tolerated dose from Phase I."
3086159|NCT01596231|Placebo Comparator|Placebo|This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
3086160|NCT01596231|Active Comparator|Kudzu|Kudzu 2mg
3086161|NCT01596283|Active Comparator|Standard fluid management|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
3086162|NCT01596283|Active Comparator|Goal directed fluid therapy|Prospective single-blinded randomized trial. Eligible patients will be consented for the trial prior to surgery. However randomization will not occur until the operating room. After the liver has been resected, intraoperative randomization will be done by envelopes.
3086163|NCT01596335|Experimental|TA-650|
3086164|NCT01596335|Active Comparator|VGIH|
3086165|NCT01596504|Experimental|Lixisenatide 20 μg|Subcutaneous injection of lixisenatide10 μg once daily (QD) for 2 weeks followed by 20 μg QD for 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3086166|NCT01596504|Active Comparator|Liraglutide 1.2 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for 7 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3086167|NCT01596504|Active Comparator|Liraglutide 1.8 mg|Subcutaneous injection of liraglutide 0.6 mg QD for 1 week followed by 1.2 mg QD for another 1 week and 1.8 mg QD for next 6 weeks under fasted conditions, on top of insulin glargine with or without metformin.
3086168|NCT01596582|No Intervention|Standard Care|Subjects randomized to the control arm will review the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled visit with their provider.
3086169|NCT01596582|Experimental|Risk Assessment|Subjects randomized to the experimental arm will complete the ACNI risk assessment tool after reviewing the web-based decision aid (http://www.colorectalcancerscreening4u.com) just prior to a scheduled office visit with their provider.
3086170|NCT01596595||Medically Indicated for ICD or CRT-D|Medically Indicated for ICD or CRT-D implantation per guidelines
3086171|NCT01596699|Experimental|Patients with Myeloid Malignancies|
3086172|NCT01596699|Experimental|Patients with Non-Malignancies|
3086173|NCT01596751|Experimental|Phase Ib: 600 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 600 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8."
3086174|NCT01596751|Experimental|Phase Ib: 800 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 800 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
3086175|NCT01596751|Experimental|Phase Ib: 1000 mg/Day PLX3397 Combined with Eribulin|"Treatments are given in 21 day cycles. For each cycle, treatment includes:~PLX3397 at a dose of 1000 mg/day taken by mouth in the form of 100-200 mg gelcaps~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
3086176|NCT01596751|Experimental|Phase II: 800 mg/Day PLX3397 Lead in +Combined with Eribulin|"Treatment begins with a 7 day Lead-in phase of PLX3397 alone, followed by 21 day cycles of PLX3397 in combination with eribulin.~Lead-in phase treatment:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest.~Treatment given in each 21 day cycle:~PLX3397 at a dose of 800 mg/day given by mouth in the form of 100-200 mg gelcaps for 5 days followed by 2 days of rest, repeated weekly~Eribulin at dose of 1.4 mg/m2 given intravenously on days 1 and 8"
3086177|NCT01596842|Active Comparator|Omega-3 fatty acid|
3086178|NCT01596842|Placebo Comparator|Olive oil|
3086179|NCT01596972|Experimental|Serum quantitative urine pregnancy test|uterine evacuation follow-up consisting of an at-home, self-administered SQ-UPT and standardized pregnancy symptom questionnaire in 1 week
3086180|NCT01596972|No Intervention|serum hCG|follow-up consisting of a 1 week return visit and serum hCG plus standardized pregnancy symptom questionnaire
3086181|NCT01597050|Active Comparator|Drug: R932333|R333 6% (60 mg/g), bid
3086182|NCT01597050|Placebo Comparator|Placebo|Placebo, bid
3086183|NCT01597128|Active Comparator|Flex HD|Mesh Type
3086184|NCT01597128|Active Comparator|Strattice|Use of a second mesh type
3086185|NCT01597141|Experimental|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
3086186|NCT01597141|Active Comparator|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention.
3086187|NCT01597193|Experimental|enzalutamide (80-mg with increase to 160 mg)|enzalutamide be provided as two or four 40-mg capsules by mouth daily
3086188|NCT01597193|Experimental|enzalutamide and anastrozole|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with anastrozole (1 mg) administered as one 1-mg tablet by mouth once daily.
3086189|NCT01597193|Experimental|enzalutamide and exemestane 25 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as one 25-mg tablet daily
3086190|NCT01597193|Experimental|enzalutamide and exemestane 50 mg|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with exemestane administered as two 25-mg tablets daily
3086191|NCT01597193|Experimental|enzalutamide and fulvestrant|enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with fulvestrant (500 mg) administered as two 250-mg intramuscular injections every 28 days
3086192|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
3086193|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
3086194|NCT01597245|Experimental|80 mg ixekizumab Dosing Regimen 3|Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
3086195|NCT01597245|Active Comparator|50 mg etanercept|Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
3086196|NCT01597245|Placebo Comparator|Placebo for ixekizumab|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
3086197|NCT01597258||Crizotinib (Xalkori)|
3086198|NCT01597375|Experimental|Placebo then Prasugrel|"Subjects with AERD first received placebo oral tablet for 4 weeks prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] and returned for the second aspirin challenge.~Because no period effect was observed, data obtained from all subjects while on placebo from either visit 2 or 3 were combined."
3086199|NCT01597375|Experimental|Prasugrel then Placebo|"Subjects with AERD first received prasugrel oral tablets [ (5 mg (for patients <60kg) or 10mg (> 60kg) daily, following a 60mg loading dose)] prior to their aspirin challenge/desensitization. After aspirin challenge/desensitization subjects were discharged to home to washout the study drug from the first treatment phase. At the end of the 2-week washout period, subjects crossed over to the alternate treatment for 4 weeks of Placebo oral tablet.~Because no period effect was observed, data obtained from all subjects while on Prasugrel from either visit 2 or 3 were combined."
3086200|NCT01597388|Experimental|AZD2014 with Fulvestrant|AZD2014 with Fulvestrant
3086201|NCT01597440|Experimental|N-Carbamylglutamate|Active NCG & Standard of Care
3086202|NCT01597440|Placebo Comparator|Placebo|Standard of Care therapy
3086203|NCT01597479|No Intervention|No dPNBs group|Patients in this group didn't receive any intervention in the postoperative period.
3086204|NCT01597479|Experimental|dPNBs group|"Patients in this group received ultrasound guided dPNBs on radial and median nerves (target nerves of TRA) in the postoperative period, before discharge.~The procedural objective of dPNBs was to place local anesthetic around the target nerves to achieve a long lasting, sensitive and selective block in the surgical area. dPNBs were performed with 5 ml/nerve of levobupivacaine 0,125%.~Ultrasound guidance allowed us to verify the correct distribution of LA around the target nerves target and optimize needle position if it was necessary, always avoiding the intraneural injection."
3086205|NCT01597492|Experimental|Belimumab plus Early Vaccination|Belimumab plus Early Vaccination
3086206|NCT01597492|Experimental|Belimumab plus Late Vaccination|Belimumab plus Late Vaccination
3086207|NCT01597505|Experimental|Surotomycin|250 mg Surotomycin over- encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg; and Placebo over encapsulated tablet administered orally, twice daily for 10 days
3086208|NCT01597505|Active Comparator|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
3086209|NCT01597557|Active Comparator|Magnesium Sulfate|Patients in this arm are give magnesium sulfate 2 grams intravenous drip before the cardioversion procedure
3086210|NCT01597557|Placebo Comparator|Placebo|Patients in this arm receive normal saline drip intravenously before the cardioversion procedure
3086211|NCT01597596|Experimental|Alglucosidase Alfa 4000 L material (Non-US participants)|Alglucosidase alfa 4000 L material for 52 weeks.
3086212|NCT01597596|Active Comparator|Alglucosidase Alfa 160 L material (US participants)|Alglucosidase alfa 160 L material for 52 weeks.
3086213|NCT01597622|Experimental|Open-label Belimumab|Belimumab 10 mg/kg administered intravenously every 4 weeks. All study subjects will receive standard SLE therapies during the study. Subjects will continue to receive belimumab treatment until such time belimumab becomes commercially available in a subject's country of participation, or the subject elects to participate in another belimumab continuation study for SLE, or until either the subject's physician withdraws the subject from the study, or upon the decision by the sponsor to discontinue further development of belimumab for SLE.
3086214|NCT01597635|Experimental|Part A|4 increasing doses of GSK2586881 given over 2 days
3086215|NCT01597635|Experimental|Part B|Repeat Medium-High dose of GSK2586881 (or placebo) over 3 days
3086216|NCT01597687|Experimental|Malaysia Group|Malaysian adults aged >19 years with prolonged cough of 2 weeks or more.
3086217|NCT01597687|Experimental|Taiwan Group|Taiwanese adults aged >19 years with prolonged cough of 2 weeks or more.
3086218|NCT01597687|Experimental|Thailand Group|Thailandese adults aged >19 years with prolonged cough of 2 weeks or more.
3086219|NCT01597791|Placebo Comparator|Foley catheter|Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
3086220|NCT01597791|Experimental|No Foley Catheter|Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
3086221|NCT01597843|Experimental|First educational intervention group|Group that receives intervention first. The intervention is a series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
3086222|NCT01597843|Experimental|Second intervention group|This arm receives a series of training sessions over study months 6-9. The training sessions are in person and on line and are directed at post superusers who will in turn educate post members on the utility and mechanics of use of MHV. They complete survey rounds 1 and 2 before the training and survey round 3 after the training.
3086223|NCT01597843|No Intervention|Education after data collection complete|This group received a similar intervention, but after all quantitative data collection complete.
3086224|NCT01597856|Experimental|SBIRT|"The SBIRT-VA manual codifies basic substance abuse screening, treatment, Motivational Interviewing and referral procedures. It is designed for providers with minimal substance abuse expertise and is easy for experienced substance abuse providers to deliver.~Study sessions include identifying the Veterans' values through a card sort, the change ruler, on which the Veteran rates his/her willingness to change current behavior, listing the pros and cons of changing."
3086225|NCT01597856|No Intervention|No additional treatment|Veterans assigned to the control condition will not receive any study-related therapy. A Veteran who completes a Compensation examination ordinarily has no further treatment, referral, or debriefing as part of the Compensation examination.
3086226|NCT01597908|Experimental|Dabrafenib plus Trametinib|BRAF inhibitor plus MEK inhibitor
3086227|NCT01597908|Active Comparator|Vemurafenib|BRAF inhibitor
3086228|NCT01597973|Active Comparator|colistin and meropenem|
3086229|NCT01597973|Active Comparator|colistin and placebo|
3086230|NCT01598064|Experimental|GK#10|GK#10 1 pk tid for 8 weeks
3086231|NCT01598064|Placebo Comparator|Placebo|Placebo 1 pack tid for 8 weeks
3086232|NCT01598090|Experimental|Part A: Peginterferon Lambda-1a + RBV + TVR|
3086233|NCT01598090|Experimental|Part B (Arm 1): Peginterferon Lambda-1a + RBV + TVR|
3086234|NCT01598090|Experimental|Part B (Arm 2): Peginterferon Lambda-2a + RBV + TVR|
3086235|NCT01598129|Experimental|CGTG-102|CGTG-102 dose escalation
3086236|NCT01598194|Experimental|Novel 22-gauge Core Biopsy Needle Standard Biopsy Needle|The 22-gauge core biopsy needle with reverse bevel design (EchoTip® Procore™) will be compared prospectively to the standard straight hollow-core 22-gauge or 25-gauge FNA needle already used in our clinical practice for the diagnosis of solid pancreatic lesions.
3086237|NCT01598207|Experimental|Marinol|
3086238|NCT01598207|Placebo Comparator|Placebo|
3086239|NCT01598298|Experimental|Arm I|Patients receive duloxetine hydrochloride orally (PO) once daily (QD) on days 1-7, twice daily (BID) on days 8-84, and then QD on days 85-91.
3086240|NCT01598298|Placebo Comparator|Arm II|Patients receive placebo PO QD on days 1-7, BID on days 8-84, and then QD on days 85-91.
3086241|NCT01598311|Experimental|CB-183,315|Participants took CB-183,315 250 mg twice daily (b.i.d.) and placebo capsules b.i.d. by mouth for 10 days.
3086242|NCT01598311|Active Comparator|Vancomycin|Participants took vancomycin 125 mg four times daily (q.i.d.) by mouth for 10 days.
3086243|NCT01598350|Experimental|Orthotic|Orthotic Use
3086244|NCT01598428|Other|cataract|
3086245|NCT01598506|Experimental|Hydromorphone|Laboring patients receive ED50 of hydromorphone one time intrathecally
3086246|NCT01598532|Experimental|Transcranial LED Treatment|All study subjects received treatment during 6-Week period (3x per week) for a total of 18 Transcranial LED Treatments using the MedX Health Phototherapy (light). Each session was 30 minutes in duration.
3086247|NCT01598545|Experimental|Hydromorphone|Laboring patients having a cesarean section will receive ED50 of hydromorphone one time intrathecally
3086248|NCT01598610|Experimental|Intended Users of the Monitoring System|Untrained subjects with diabetes use CONTOUR® PLUS Investigational BG Monitoring System.
3086249|NCT01598662|Active Comparator|1: IUD insertion 6 Weeks after delivery|"Device:Levonorgestrel-releasing intrauterine device marketed as Mirena.~Subjects randomized to interval placement will have their IUD placed in the office at six weeks postpartum or later. They must return for one visit within a month for a string check."
3086250|NCT01598662|Experimental|2: Immediate Post-placental insertion|"Device: Levonorgestrel-releasing intrauterine device marketed as Mirena~Subjects randomized to immediate post-placental placement within 10 minutes of delivery will have an IUD placed manually under sterile technique and with ultrasound guidance. An ultrasound will be performed within two days postpartum to verify proper placement and again at approximately six weeks postpartum."
3086251|NCT01598701|Experimental|Intravenous Acetaminophen|Patients will be receive doses of 1000 mg/100 mL of IV Acetaminophen (OFIRMEV). The drug will be infused over 15 minutes.
3086252|NCT01598701|Placebo Comparator|Placebo|Patients will be given 100 mL normal saline placebos at scheduled time intervals in place of IV acetaminophen.
3086253|NCT01598740|Experimental|CLP with spironolactone|
3086254|NCT01598740|Experimental|CLP without spironolactone|
3086255|NCT01598753|Active Comparator|Tramadol|
3086256|NCT01598753|Placebo Comparator|Placebo|
3086257|NCT01598753|Active Comparator|Cognitive Behavior Therapy for FM|
3086258|NCT01598753|Sham Comparator|Health Education|
3086259|NCT01598831|Active Comparator|ART-123|
3086260|NCT01598831|Placebo Comparator|Placebo|
3086261|NCT01598896|Experimental|Dronabinol + Clonidine|Dronabinol titrated to 5 mg three times daily, Clonidine 0.1 mg twice daily
3086262|NCT01598896|Placebo Comparator|Placebo|Placebo
3086263|NCT01598922|Experimental|Internet Cognitive Behavioral Therapy|Participants with major depressive disorder receive an 8-week long internet-based cognitive behavioral therapy program.
3086264|NCT01598922|No Intervention|Monitored Attention Control|Participants with major depressive disorder receive no treatment but are monitored closely for 8 weeks. Participants in this arm are offered the treatment at the end of the study.
3086265|NCT01598987|Experimental|Everolimus based regimen|"Conversion at Baseline from an immunosuppressive regimen which contains either cyclosporine (CsA) or tacrolimus (TAC) with or without mycophenolic acid (MPA), with or without corticosteroids in a regimen which contains everolimus combined reduced dose of either cyclosporine (CsA) or tacrolimus (TAC).~The dosing schedule was twice daily, 12 hours apart."
3086266|NCT01599104|Experimental|LCZ696 200 mg|LCZ696 200 mg tablet and placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) tablet once daily for 8 weeks
3086267|NCT01599104|Experimental|LCZ696 400 mg|LCZ696 200 mg tablet and a placebo to both LCZ696 (1 tablet) and Olmesartan (1 capsule) once daily for one week; then up-titrated to LCZ696 400 mg and placebo to Olmesartan (1 capsule) once daily for the remaining 7 weeks
3086268|NCT01599104|Active Comparator|Olmesartan 20 mg|Olmesartan 20 mg capsule and placebo to LCZ696 (2 tablets) once daily for 8 weeks
3086269|NCT01599234|Experimental|Sativex|Active treatment
3086270|NCT01599234|Placebo Comparator|Placebo|Control
3086271|NCT01599286|Experimental|Active Comparator|Parallel Trial Comparing NCG + Standard of Care Treatment
3086272|NCT01599286|Active Comparator|Placebo Comparator|Placebo and Standard of Care Therapy
3086273|NCT01599325|Experimental|Azacitidine|Azacitidine 75 mg/m^2/day subcutaneously (SC) for 7 days every 28 days until disease progression (DP), adverse events (AE), withdrawal of consent from further treatment, withdrawal of consent, death, lost to follow-up, or protocol violation.
3086274|NCT01599585|Experimental|In Home|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week). The sessions will be conducted in their homes using an Army approved secure web-based video conferencing system. BA has been successfully delivered in this time frame, and it has been delivered via in-home video conferencing technology.
3086275|NCT01599585|Active Comparator|In-Person|Participants in this condition will receive 8 sessions of BA treatment over the course of approximately 8 weeks (one session per week with allowance for rescheduled sessions). The sessions will be conducted in a clinic setting at The National Center for Telehealth & Technology.
3086276|NCT01599637|Experimental|IGE025|Patients will receive omalizumab administered subcutaneously every 4 weeks at the study center.
3086277|NCT01599637|Placebo Comparator|Placebo to IGE025|Placebo administered subcutaneously every 4 weeks at the study center.
3086278|NCT01599650|Experimental|1-ranibizumab monotherapy|Ranibizumab 0.5 mg
3086279|NCT01599650|Experimental|2-ranibizumab with laser|Ranibizumab 0.5 mg + laser
3086280|NCT01599650|Active Comparator|3-laser monotherapy|Laser monotherapy with Ranibizumab 0.5 mg from Month 6
3086281|NCT01599741|Experimental|ClarityIQ|Low-dose DSA (83% reducation compared to normal dose) with novel X-ray imaging technology.
3086282|NCT01599741|Active Comparator|AlluraXper|Normal dose DSA with conventional X-ray imaging technology.
3086283|NCT01599754|Experimental|Axitinib|
3086284|NCT01599754|Placebo Comparator|Placebo|
3086285|NCT01599793|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive cabozantinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
3086286|NCT01599806|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3086287|NCT01599806|Active Comparator|Doripenem|IV treatment
3086288|NCT01599832|Experimental|Treatment (pazopanib hydrochloride, DCE-MRI)|Patients receive pazopanib hydrochloride PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo dynamic contrast-enhanced MRI at baseline, day 8, and prior to courses 3, 5, and 7.
3086289|NCT01600014|Active Comparator|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days on the face or scalp
3086290|NCT01600014|Placebo Comparator|Vehicle gel|Topical field treatment once daily for 3 consecutive days on the face or scalp
3086291|NCT01600053|Experimental|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles
3086292|NCT01600092|Experimental|RotaTeq™ Experimental Formulation|Three 2.0 mL oral doses of RotaTeq™ experimental formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days)
3086293|NCT01600092|Active Comparator|RotaTeq™ Existing Formulation|Three 2.0 mL oral doses of RotaTeq™ existing formulation. Vaccination 1 will be administered between 6 and 12 weeks of age and the third vaccination will be administered before 32 weeks of age. Each vaccination will be separated from the next by ≥ 4 weeks (28 days).
3086294|NCT01600105|Experimental|Perfusion MRI|chronic liver disease who underwent/will undergo liver biopsy or will undergo liver transplant or liver resection as part of standard care during the previous 6 months.
3086295|NCT01600170|Active Comparator|Atorvastatin|Participants were given atorvastatin for 12 weeks at various doses based on their specific HAART treatment.
3086296|NCT01600170|Placebo Comparator|Placebo|Participants were given Placebo tablets for 12 weeks.
3086297|NCT01600222|Experimental|LEO 90100|
3086298|NCT01600287|Experimental|IAADS group|dosage of propofol adjusted automatically by IAADS
3086299|NCT01600287|Active Comparator|Manual group|dosage of propofol adjusted manually
3086300|NCT01600326|Active Comparator|Tenotomy Group|Subject enrolled in this arm will receive treatment for tendinitis and pain evaluation of pain pre and post treatment.
3086301|NCT01600326|Active Comparator|Plasma Injection Group|Treatment is Ultrasound guided platelet rich plasma injection.
3086302|NCT01600482|Experimental|CELT ACD device|The CELT ACD device is a vascular closure device.
3086303|NCT01600482|No Intervention|Manual Compression|Manual Compression
3086304|NCT01600495|Experimental|Experimental TENS|TENS Intervention Group(GIE) used for 30 minutes, during uterine contractions between 4-5 cm
3086305|NCT01600495|No Intervention|control Group|Formed by mothers who will not use EAC to receive the routine procedures of motherhood, but will be monitored and evaluated at the same time in the intervention group.
3086306|NCT01600586|Experimental|Pacifier-Activated-Lullaby system (PAL)|Pacifier-Activated-Lullaby system (PAL) group.
3086307|NCT01600586|No Intervention|No PAL group|No PAL. Standard of care procedures.
3086308|NCT01600638|Experimental|Zeltiq System Treatment Group|Individuals with sharp flank curvatures were treated on one (1) flank with the Zeltiq CoolSculpting System and the CoolCurve+ applicator at protocol-defined temperatures and durations.
3086309|NCT01600677|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with an EMMA MDU for use in their homes for the 90-day period immediately following discharge.
3086310|NCT01600677|Active Comparator|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
3086311|NCT01600703|Experimental|Sitagliptin|sitagliptin, 100mg, oral, single dose
3086312|NCT01600703|Placebo Comparator|Placebo|Placebo, oral, single dose
3086313|NCT01600716|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for a second onabotulinumtoxinA 100 U injection.
3086314|NCT01600716|Other|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1. After a minimum of 12 weeks, patients could request/qualify for an onabotulinumtoxinA injection.
3086315|NCT01600729||All Participants|Participants with facial lines. There was no intervention in this study.
3086316|NCT01600885|Active Comparator|Guanfacine then Placebo|During the first study session, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive a placebo before undergoing a ketamine-infusion fMRI.
3086317|NCT01600885|Active Comparator|Placebo then Guanfacine|During the first study session, the participant will receive a placebo before undergoing a ketamine-infusion fMRI. During the second study session, at least two weeks later, the participant will receive guanfacine before undergoing a ketamine-infusion fMRI.
3086318|NCT01600950|Experimental|LY2963016|A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
3086319|NCT01600950|Active Comparator|Lantus|A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
3086320|NCT01601067|Experimental|Arm 1: Integrated Prolonged Exposure Therapy|Integrated Prolonged exposure Psychotherapy (I-PE; PE integrated with elements of Integrated Cognitive Behavioral Therapy for alcohol use disorder)
3086321|NCT01601067|Active Comparator|Arm 2: Seeking Safety|Seeking Safety
3086322|NCT01601132|Experimental|theophylline|300mg (80mg/15ml elixir) theophylline
3086323|NCT01601132|Experimental|Colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
3086324|NCT01601236|Experimental|Acthar 8 U (0.1 mL) daily|Repository Corticotropin Injection
3086325|NCT01601236|Placebo Comparator|Placebo (0.1 mL) daily|Placebo
3086326|NCT01601236|Experimental|Acthar 16 U (0.2 mL) daily|Repository Corticotropin Injection
3086327|NCT01601236|Placebo Comparator|Placebo (0.2 mL) daily|Placebo
3086328|NCT01601236|Experimental|Acthar 32 U (0.4 mL) daily|Repository Corticotropin Injection
3086329|NCT01601236|Placebo Comparator|Placebo (0.4 mL) daily|Placebo
3086330|NCT01601431|Experimental|Cap Assisted Colonoscopy|Cap Assisted Colonoscopy uses a Cap which is a transparent hood which is attached to the distal end of the colonscope and allows depressing the colon folds in order to visualize hidden polyps behind the folds.
3086331|NCT01601431|Active Comparator|Conventional colonoscopy|A conventional colonoscopy does not use a Cap in order to perform the procedure
3086332|NCT01601470|Experimental|Period 1:Sildenafil;Period 2:LCZ696;Period 3:LCZ696+Sildenafil|During Treatment Period 1, on study Day 1, participants received a single dose of sildenafil followed by wash out on Day 2. In Period 2 (study Days 3-7), participants received LCZ696 once daily. In Period 3, on study Day 8, participants received LCZ696 , co-administered at the same time with a single dose of sildenafil.
3086333|NCT01601496|Experimental|FUSION Vascular Graft|All subjects who received a FUSION Vascular Graft at the baseline implant procedure.
3086334|NCT01601535|Experimental|Treatment|"Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5."
3086335|NCT01601626|Experimental|A: Standard-dose LPV/r w/RBT|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3086336|NCT01601626|Active Comparator|B: Double-dose LPV/r w/RIF|"ART: lopinavir 800 mg/ritonavir 200 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, weight-based dosing for rifampin, ethambutol, and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3086337|NCT01601626|Experimental|C: Standard-Dose LPV/r w/RBT + RAL|"ART: lopinavir 400 mg/ritonavir 100 mg twice daily + raltegravir 400 mg twice daily + two nucleoside reverse transcriptase inhibitors.~Anti-TB therapy: isoniazid 300 mg, rifabutin 300 mg, weight-based dosing for ethambutol and pyrazinamide, and pyridoxine 25 mg daily.~After completion of TB treatment through week 72: lopinavir 400 mg/ritonavir 100 mg twice daily + two nucleoside reverse transcriptase inhibitors (NRTIs)."
3086338|NCT01601652|Experimental|Omeagven|
3086339|NCT01601691|Experimental|Spacer|Subjects with spacer injection
3086340|NCT01601704|Experimental|NB32|
3086341|NCT01601704|Placebo Comparator|PBO|
3086342|NCT01601782|Experimental|Volume Imaging scan|New type of ultrasound scan using General Electric US scanner, Model is a GE Logiq E9.
3086343|NCT01601821|Active Comparator|Arm A (CsA+Rapamune+CS)|
3086344|NCT01601821|Experimental|Arm B (CsA+MMF+CS)|
3086345|NCT01601847|Active Comparator|Sustained|Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake
3086346|NCT01601847|Placebo Comparator|Diet-Limited|Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day
3086347|NCT01601860|Active Comparator|Control|Active Comparator: Control Group Pregnant women who receive assistance from the routine CRSM MATER care, not being assisted by the physiotherapist, but that will be evaluated at the same time in the intervention group.
3086348|NCT01601860|Experimental|Intervention Group|Experimental: Intervention Group Pregnant women who receive the application the combination of non-pharmacological resources according to cervical dilation: Walking (with cervical dilation between 4 and 5 cm) Alternating stance associated with ENT (cervical dilatation from 6 to 7 cm) Shower (with dilation> 7 cm);
3086349|NCT01601873|Experimental|PROPATEN|patients with heparin-bonded graft implantation
3086350|NCT01601873|Active Comparator|Standard Graft|patients undergoing ePTFE hemodialysis graft implantation
3086351|NCT01601977|Experimental|Intervention|AVAPS-AE
3086352|NCT01601977|Active Comparator|Usual care|Non-invasive ventilation
3086353|NCT01602068|Experimental|Dexamethasone Phosphate Ophthalmic|Dexamethasone Phosphate Ophthalmic: (40 mg/mL) solution delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
3086354|NCT01602068|Placebo Comparator|100 mM Sodium Citrate Buffer|Placebo (100 mM sodium citrate buffer solution) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA on Day -1 (the day before cataract surgery)
3086355|NCT01602120|Experimental|CFD4870g Sham|Participants who were administered sham comparator in Study NCT01229215 (CFD4870g), will receive lampalizumab 10 milligrams (mg), intravitreally (ITV), either once in every 4 weeks (Q4W) or once in every 8 weeks (Q8W) in accordance with their previously assigned treatment frequency assignment in Study CFD4870g followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
3086356|NCT01602120|Experimental|CFD4870g Lampalizumab|Participants will receive lampalizumab 10 mg, ITV, Q4W or Q8W in accordance with their previously assigned treatment frequency assignment in Study NCT01229215 (CFD4870g) followed by Q4W administration for the remainder of the extension study up to approximately 96 months.
3086357|NCT01602120|Experimental|GX29455 Sham|Participants who were administered sham comparator in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
3086358|NCT01602120|Experimental|GX29455 Lampalizumab|Participants who were administered lampalizumab in Study NCT02288559 (GX29455), will receive lampalizumab 10 mg, ITV, Q4W throughout the extension study up to approximately 54 months.
3086359|NCT01602172|Experimental|Brief Alcohol Intervention (BI)|The 3-part Brief Intervention (BI) consists of . Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
3086360|NCT01602172|Active Comparator|Attention Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity. Two weeks later, the Research Assistant calls subjects in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. This intervention is designed to provide all the information and assessments that that Brief Intervention participants as well as all the alcohol consumption and motivation to change measures-- it is designed to control for the attention that the BI participants receive w/o the motivational interventions
3086361|NCT01602172|Active Comparator|Control|These subjects receive a set of Lifestyle brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have. Subjects complete only drinking quantity measures at baseline and 6 months post baseline. The inclusion of this group tests whether completing more extensive questionnaires (in comparison the Attention Control group) decreases alcohol consumption.
3086362|NCT01602224|Experimental|100 mg Tabalumab+Dexamethasone (Dex)+Bortezomib (BTZ)|"Tabalumab 100 milligram (mg) administered once intravenously (IV) over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for 8 cycles.~Bortezomib 1.3 milligram per square meter (mg/m^2) administered once subcutaneously (SQ) on Days 1, 4, 8 and 11 every 21 days for a minimum 8 cycles.~All treatment may continue past 8 cycles."
3086363|NCT01602224|Experimental|300 mg Tabalumab+Dexamethasone+Bortezomib|"Tabalumab 300 mg administered once IV over 30 minutes on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
3086364|NCT01602224|Placebo Comparator|Placebo Comparator: Placebo + Dexamethasone + Bortezomib|"Placebo administered once IV on Day 1 every 21 days for 8 cycles.~Dexamethasone 20 mg administered once orally on Days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 days for a minimum 8 cycles.~Bortezomib 1.3 mg/m^2 administered once SQ on Days 1, 4, 8 and 11 every 21 days for 8 cycles.~All treatment may continue past 8 cycles."
3086365|NCT01602315|Experimental|Phase Ib: A-BYL719 FC whole tab+cetux|Oral film-coated tablets without swallowing dysfunction.
3086366|NCT01602315|Experimental|Phase II: 2-Cetuximab|Cetuximab in patients naive to cetuximab (phase ll)
3086367|NCT01602315|Experimental|Phase Ib: B-BYL719 FC drink sus+cetux|Crushed film-coated (FC) tablets as an oral suspension with swallowing dysfunction.
3086368|NCT01602315|Experimental|Phase II: 3-BYL719 + Cetuximab|BYL719 + cetuximab in patients resistant to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
3086369|NCT01602315|Experimental|Phase II: 1-BYL719 + Cetuximab|BYL719 + Cetuximab in Patients naive to cetuximab. BYL719 can be administered as FC whole/crushed only or DT via G-tube in addition, depending on the Phase Ib results
3086370|NCT01602315|Experimental|Phase Ib: C-BYL719 DT+cetux|Dispersible tablet with swallowing dysfunction administered via a gastrostomy tube (G-tube)
3086371|NCT01602315|Experimental|Phase II: Cross over|patients received BYL719 at RP2D in combination with cetuximab.
3086372|NCT01602341|Experimental|AN2728 Topical Ointment, 2% QD vs 0.5% QD|"AN2728 Topical Ointment, 2% applied once daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied once daily for 29 days to a target lesion~Treatments will be randomly assigned to target lesions A and B."
3086373|NCT01602341|Experimental|AN2728 Topical Ointment, 2% BID vs 0.5% BID|"AN2728 Topical Ointment, 2% applied twice daily for 29 days to a target lesion, and AN2728 Topical Ointment, 0.5% applied twice daily for 29 days to a target lesion.~Treatments will be randomly assigned to target lesions A and B."
3086374|NCT01602380|Experimental|faslodex+placebo|Blinded: Fulvestrant 500mg intramuscular injection (2x250mg) plus dummy Anastrozole tablets
3086375|NCT01602380|Active Comparator|arimidex +placebo|Blinded: Anastrozole 1mg tablets plus dummy Fulvestrant intramuscular injection (2x0mg)
3086376|NCT01602419||Patients using Wilate as standard of care treatment|This patient population is being treated with Wilate as standard of care treatment
3086377|NCT01602484|Experimental|Splint Pack|Group of post-op patients who have splint applied from prepared Plaster-of-Paris splint pack
3086378|NCT01602484|Active Comparator|Bulk Supplies|Group of post-op patients who have splint applied from bulk supplies
3086379|NCT01602510|Experimental|Lamotrigine CD|lamotrigine chewable dispersible tablets 25mg, 50mg, 100mg
3086380|NCT01602510|Placebo Comparator|Placebo|Placebo
3086381|NCT01602549|Experimental|Cohort|1:2 ratio, placebo, 50 mg administered orally once daily for 7-9 days
3086382|NCT01602562|Experimental|VACV (256U87; valaciclovir hydrochloride)|Adult patients (16-65 years): A VACV tablet (containing 500mg of valaciclovir) is orally given twice daily. Pediatric patients (1-16 years): VACV granules are orally given at a dose of 25 mg/kg b.w. twice daily. The maximum dose per treatment is limited to 500 mg. Pediatric patients weighing 40 kg or over may be orally given a VACV tablet (containing 500 mg of valaciclovir) twice daily.
3086383|NCT01602614||Group 1|≤ 27 weeks 6 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
3086384|NCT01602614||Group 2|≤ 27 weeks 6 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
3086385|NCT01602614||Group 3|≥ 28 weeks 0 days gestational age at birth and ≤ 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
3086386|NCT01602614||Group 4|≥ 28 weeks 0 days gestational age at birth and > 30 days chronologic age at study enrollment. Dose and duration of intravenous ganciclovir therapy is at the discretion of the treating physician and will not be dictated by the research protocol.
3086388|NCT01602679|Experimental|micronized progesterone, then placebo|Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).
3086389|NCT01602679|Placebo Comparator|Placebo, then micronized progesterone|Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
3086390|NCT01602692|Active Comparator|Tumescent solution with dilute epinephrine|Subjects in this arm of the study will be randomized to receive tumescent solution containing dilute epinephrine (1:1,000,000) during their breast reduction.
3086391|NCT01602692|Active Comparator|Tumescent solution with dilute lidocaine and epinephrine|Subjects in this arm of the study will receive tumescent solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000).
3086392|NCT01602731|Experimental|Automated Medication Dispensing Device|Subjects with <88% medication adherence, determined by 30-day pillcount, and with cognitive impairment (determined by Saint Louis University Mental Status score) proceeded to AMDD portion of study.
3086393|NCT01602744|No Intervention|Controll|The medications in this arm will not be screened.
3086394|NCT01602744|Active Comparator|Intervention screening medication group|STOPP/START screening tools are used for medication intervention
3086395|NCT01602965|Experimental|counseling monthly phone calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviours that need to be changed, problem-solving as to how to make the changes and physical activity levels.
3086396|NCT01602965|Active Comparator|self help informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies.
3086397|NCT01603056|Experimental|PANGRAMIN SLIT HDM MIX|PANGRAMIN SLIT HDM MIX Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
3086398|NCT01603056|Placebo Comparator|Placebo|Placebo Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
3086399|NCT01603082|Experimental|Ticagrelor|Ticagrelor - 180 mg loading dose
3086400|NCT01603082|Active Comparator|Clopidogrel|Clopidogrel - 600 mg loading dose
3086401|NCT01603277|Experimental|Anti-GM-CSF Monoclonal Antibody 400mg|
3086402|NCT01603277|Placebo Comparator|Normal Saline|
3086403|NCT01603355|Experimental|Tocilizumab|
3086404|NCT01603368|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938, 125 million bacteria/day
3086405|NCT01603368|Placebo Comparator|Placebo|The same oil drops as the active study product but without Lactobacillus reuteri
3086406|NCT01603420|Active Comparator|Radiation + 24mo luteinizing hormone-releasing hormone (LHRH)|Conformal RT 79.2 Gy(RBE) total dose + 24 months LHRH agonist (androgen suppression).
3086407|NCT01603420|Experimental|Radiation + Chemo + 6mo luteinizing hormone-releasing hormone|Conformal RT 79.2 Gy(RBE) total dose + Chemotherapy: Docetaxel 20mg/m2 x every 7 days x 8 weeks followed by 6 months LHRH (androgen suppression).
3086408|NCT01603459|Experimental|IncobotulinumtoxinA (Xeomin) (up to 800 Units)|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection"
3086409|NCT01603602|Experimental|BOTOX® 3 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 units (U) per kilogram (kg) of body weight (3 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly occupational therapy (OT).
3086410|NCT01603602|Experimental|BOTOX® 6 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
3086411|NCT01603602|Placebo Comparator|Placebo|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1. Participants received weekly OT.
3086412|NCT01603615|Experimental|BOTOX®|Participants received a maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into upper limb and/or lower limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment, de novo participants received at least 6 U/kg of body weight or a maximum of 8 U/kg of body weight (not to exceed 300 U). Rollover participants received up to a maximum of 8 U/kg of body weight (not to exceed 300 U) for treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Rolled over participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 3 or 6 U/kg into upper limb in previous study or were de novo participants who were not enrolled in previous study.
3086413|NCT01603628|Experimental|BOTOX® 4 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
3086414|NCT01603628|Experimental|BOTOX® 8 U/kg|Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
3086415|NCT01603628|Placebo Comparator|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
3086416|NCT01603641|Experimental|BOTOX®|Participants received maximum of 5 treatments of intramuscular injections of BOTOX® (botulinum toxin Type A) into a single lower limb muscles or divided between both lower limb muscles or into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart. Treatment dosing was according to investigator judgment not to exceed a maximum of 8 unit per kilogram (U/kg) of body weight (not to exceed 300 U) in treatment Cycle 1. Dose could be increased to a maximum of 10 U/kg (not to exceed 340 U) in treatment Cycles 2-5. Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 or 8 U/kg into the lower limb in the previous study or were de novo participants who were not enrolled in the previous study.
3086417|NCT01603875|Active Comparator|PrEP and Simulated PEP with PVRV by intramuscular route|
3086418|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intramuscular route|
3086419|NCT01603875|Experimental|PrEP and Simulated PEP with new CPRV by intradermal route|
3086420|NCT01603940|Active Comparator|Losartan|This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
3086421|NCT01603940|Active Comparator|Benazepril|This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
3086422|NCT01604109|Active Comparator|Tooth Mousse|10% w/v Calcium Phosphopeptide Amorphous Calcium Phosphate paste
3086423|NCT01604109|Placebo Comparator|placebo control paste|the paste without Calcium phosphopeptide - Amorphous Calcium Phosphate
3086424|NCT01604122||Patients|Patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
3086425|NCT01604122||Caregivers|Caregivers who are taking care of patients with TTR-FAP or TTR-CM. No drug will be administered; this is a non-interventional observational study.
3086426|NCT01604265|Placebo Comparator|Placebo|Placebo control.
3086427|NCT01604265|Experimental|Sativex|Active treatment.
3086428|NCT01604278|Active Comparator|NVA237 + indacaterol|
3086429|NCT01604278|Placebo Comparator|Placebo to NVA237 + indacaterol|
3086430|NCT01604291||Cohort|
3086431|NCT01604343|Experimental|Placebo then Sirukumab 50 mg or Sirukumab 100 mg|
3086432|NCT01604343|Experimental|Sirukumab 100 mg|
3086433|NCT01604343|Experimental|Sirukumab 50 mg + Placebo|
3086434|NCT01604408|Experimental|LY2495655|Participants received a 315-milligram (mg) dose of LY2495655, administered subcutaneously (SC), every 4 weeks (Q4W) for 20 weeks.
3086435|NCT01604408|Placebo Comparator|Placebo|Participants received a LY2495655-matching dose of placebo, administered SC, Q4W for 20 weeks.
3086436|NCT01604772|Experimental|Treatment (Akt inhibitor MK2206)|Patients receive Akt inhibitor MK2206 PO once weekly for 4 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086437|NCT01604785|Experimental|Experimental Treatment Group|Propofol at subanesthetic dose via IV push
3086438|NCT01604785|Active Comparator|Standard Treatment Group|Metaclopramide in combination with ketorolac and diphenhydramine via IV infusion
3086439|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 1|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
3086440|NCT01604824|Experimental|GOFm PCSK9 (Cohort 1): Alirocumab From Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
3086441|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1|Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
3086442|NCT01604824|Experimental|GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15|Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 ([matching placebo at Week 0 (Day 1), 10 and 14]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.
3086443|NCT01604850|Experimental|SOF+RBV+placebo|Participants were randomized to receive SOF+RBV for 12 weeks followed by placebo to match SOF plus placebo to match RBV for 4 weeks.
3086444|NCT01604850|Experimental|SOF+RBV|Participants were randomized to receive SOF+RBV for 16 weeks.
3086445|NCT01604941|Experimental|SPD602|50 mg/kg/day orally twice daily for 24 weeks
3086446|NCT01605032|Experimental|Treatment (busulfan, melphalan, bortezomib, autologous PBSCT)|"CONDITIONING: Patients receive busulfan IV over 3 hours on days -6 to -3, melphalan IV over 20 minutes on day -2, and bortezomib IV over 3-5 seconds on days -6, -3, 1, and 4.~TRANSPLANT: Patients undergo autologous PBSCT on day 0."
3086447|NCT01605071|Active Comparator|Early Postmenopausal|Postmenopausal women within 6 years of last menses who never used estrogen-based hormone therapy
3086448|NCT01605071|Active Comparator|Late Postmenopausal|Postmenopausal women more than 10 years since last menses who never used estrogen-based hormone therapy
3086449|NCT01605097|Experimental|HDR interstitial brachytherapy|HDR prostate brachytherapy with dose escalation to 1250 cGy to the MRI-defined dominant intraprostatic lesion
3086450|NCT01605136|Experimental|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
3086451|NCT01605136|Placebo Comparator|Placebo|One placebo subcutaneous implant every 2 months for 6 months.
3086452|NCT01605227|Experimental|cabozantinib|Subjects randomized to the cabozantinib arm will also receive placebo-matched prednisone capsules.
3086453|NCT01605227|Active Comparator|prednisone|Subjects randomized to the prednisone arm will also receive placebo-matched cabozantinib.
3086454|NCT01605292|Active Comparator|Palpation|Manual palpation of radial pulse, as sole guide to needle cannulation.
3086455|NCT01605292|Experimental|Ultrasound|Real-time ultrasound guidance to facilitate needle cannulation of artery.
3086456|NCT01605396|Experimental|Ridaforolimus + Dalotuzumab + Exemestane|Participants receive ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.
3086457|NCT01605396|Active Comparator|Ridaforolimus + Exemestane|Participants receive ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.
3086458|NCT01605435|Experimental|Ghrelin Group 1|Dose finding with each of the first two participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 2ug/kg (second visit) , 5 ug/kg (third visit), and 10 ug/kg (fourth visit).
3086459|NCT01605435|Experimental|Ghrelin Group 2|Dose finding with each of the final three participant coming to the CTRC for four visits greater than or equal to 72 hours apart and on each receiving subcutaneous injection of - placebo (first visit) and three escalating doses of ghrelin 5ug/kg (second visit) , 7.5 ug/kg (third visit), and 10 ug/kg (fourth visit).
3086460|NCT01605461|Experimental|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
3086461|NCT01605539|Placebo Comparator|Control|Subjects will receive pills that resemble the Cannabidiol capsule but do not have have its properties.
3086462|NCT01605539|Experimental|Cannabidiol 400|Subjects in Arm Cannabidiol 400 will receive 400 mg of cannabidiol
3086463|NCT01605539|Experimental|Cannabidiol 800|Subjects in Arm Cannabidiol 800 will receive 800mg of cannabidiol
3086464|NCT01605552|Experimental|Beating the Blues (BtB)|An 8-session, empirically supported, computerized, cognitive-behavioral intervention for depression (www.beatingthebluesus.com)
3086465|NCT01605552|Other|Usual Care|Patients and their primary care providers were informed of the positive depression screen, and follow-up was encouraged.
3086466|NCT01605669||Aortic stenosis patients|Patients with varying degrees of aortic stenosis without significant additional valvular disease will be considered eligible for this study. All participants will recieve a transthoracic echocardiogram and recorded cardiac auscultation.
3086467|NCT01605799|Active Comparator|IOK Treatment|Six to eight week treatment lasting one to 1.5 hours addressing maladaptive cognitions related to killing in war.
3086468|NCT01605799|Placebo Comparator|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
3086469|NCT01605825|Placebo Comparator|placebo/dalfampridine-ER|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
3086470|NCT01605825|Placebo Comparator|dalfampridine-ER/placebo|"Subjects will be randomized at day 1 to one of two blinded treatment sequences (A or B) in a 2:1 ratio respectively, according to a randomization created prior to the start of the study:~Period 1 = days 1, 8 and 15. Period 2 = Days 22, 29, and 36"
3086471|NCT01605877|Experimental|SN6AD2|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3086472|NCT01605890|Experimental|raltegravir / emtricitabine / tenofovir disoproxil fumarate|
3086473|NCT01605903|Experimental|Treatment with Ibuprofen|Children in the experimental group will receive grape-flavored ibuprofen 100mg/5 mL. Ibuprofen will be dispensed at 10mg/kg (max dose 600 mg) will be dispensed Q6 hours x 9 days.
3086474|NCT01605903|Active Comparator|Treatment with Acetaminophen|Children in the active comparator group will receive grape flavored acetaminophen 160 mg/5 ml. Acetaminophen will be dispensed at 15 mg/kg (max dose 650/mg) Q6 hours x 9 days.
3086475|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg|monotherapy
3086476|NCT01605916|Experimental|Selumetinib (AZD6244) 50 mg|monotherapy
3086477|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg|monotherapy
3086478|NCT01605916|Experimental|Selumetinib (AZD6244) 75 mg + Doce|Combination
3086479|NCT01605916|Experimental|Selumetinib (AZD6244) 25 mg + Doce|combination
3086480|NCT01605942|Experimental|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
3086481|NCT01605942|Placebo Comparator|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
3086482|NCT01606007|Active Comparator|Arm 1: Saxagliptin+Metformin XR+Placebo|
3086483|NCT01606007|Active Comparator|Arm 2: Dapagliflozin+Metformin XR+Placebo|
3086484|NCT01606007|Experimental|Arm 3: Saxagliptin+Dapagliflozin+Metformin XR|
3086485|NCT01606124|Experimental|Arm I (Green Tea Catechin Extract)|Patients receive Polyphenon E PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
3086486|NCT01606124|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
3086487|NCT01606137|Experimental|GW-1000-02|Active treatment
3086488|NCT01606176|Experimental|GW-1000-02|Each 100 μl actuation contains 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose was 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
3086489|NCT01606176|Placebo Comparator|Placebo|Each 100 μl actuation contains the excipients only. The maximum permitted dose was 48 actuations in any 24 hour period
3086490|NCT01606189|Experimental|GW-1000-02|Active treatment.
3086491|NCT01606189|Experimental|GW-2000-02|Active treatment.
3086492|NCT01606189|Placebo Comparator|Placebo|Placebo control.
3086493|NCT01606202|Experimental|GW-1000-02|Active treatment.
3086494|NCT01606202|Placebo Comparator|Placebo|Placebo control.
3086495|NCT01606228|Experimental|Paliperidone ER|
3086496|NCT01606254|Experimental|Paliperidone palmitate 50 mg|Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
3086497|NCT01606254|Experimental|Paliperidone palmitate 100 mg|Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
3086498|NCT01606254|Experimental|Paliperidone palmitate 150 mg|Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
3086499|NCT01606254|Experimental|Paliperidone palmitate 150/ 50 mg|Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
3086500|NCT01606306|Experimental|Crossover sequence 1|daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate
3086501|NCT01606306|Experimental|Crossover sequence 2|daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast
3086502|NCT01606306|Experimental|Crossover sequence 3|daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate
3086503|NCT01606306|Experimental|Crossover sequence 4|daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate
3086504|NCT01606306|Experimental|Crossover sequence 5|as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast
3086505|NCT01606306|Experimental|Crossover sequence 6|as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate
3086506|NCT01606319|Experimental|acetaminophen|acetaminophen given as needed for pain or fever
3086507|NCT01606319|Experimental|ibuprofen|ibuprofen given as needed for pain or fever
3086508|NCT01606670||Neupro® Treatment|Routine treatment with Neupro® (2, 4, 6, 8, 10, 12, 14, 16 mg/24 h) as per approved label in the EU, which is applicable in the EU member state Germany.
3086509|NCT01606735|Experimental|Dose 1|
3086510|NCT01606735|Experimental|Dose 2|
3086511|NCT01606735|Experimental|Dose 3|
3086512|NCT01606748|Experimental|Necitumumab, Gemcitabine and Cisplatin|The study will be conducted in two sequential periods: a 3-week PK run-in participants will be treated sequentially with single doses of cisplatin, gemcitabine, and necitumumab. Cycle 1 will begin immediately following the PK run-in period.
3086513|NCT01606761|Experimental|Group 1|Patients will receive placebo every 2 weeks from Week 0 through Week 22, followed by a subcutaneous (SC) sirukumab dose regimen every 2 weeks through Week 52.
3086514|NCT01606761|Experimental|Group 2|Patients will receive sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52.
3086515|NCT01606761|Experimental|Group 3|Patients will receive sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC administrations will be made at Weeks 2, 6, and every 4 weeks through Week 52.
3086516|NCT01606787|Experimental|mannitol arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
3086517|NCT01606787|Placebo Comparator|placebo arm|This study is a prospective randomized double blind placebo controlled trial comparing renal function outcomes in patients undergoing partial nephrectomy for renal tumors. Patients will be randomized in 1:1 fashion to receive mannitol or saline provided intravenously within 30 minutes prior to renal vascular clamping for performing partial nephrectomy.
3086518|NCT01606800|Experimental|44 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 44 additional weeks of Peg-IFN Alfa-2b + RBV.
3086519|NCT01606800|Experimental|20 Weeks of PEG-IFN alfa-2b + RBV|Participants achieving RVR at 4 weeks of treatment will receive 20 additional weeks of Peg-IFN Alfa-2b + RBV.
3086520|NCT01606852|No Intervention|usual sedative practice|"Subjects will have usual care sedation directed by their patient care team with no protocolized restriction on drug doses, selection or duration."
3086521|NCT01606852|Experimental|Patient controlled sedation|Subjects will be given the hand actuator connected to a Lifecare PCA Infusion System in the PCA + continuous mode with the syringe filled with 4 ucg/ml of dexmedetomidine. A loading dose (0.5 mcg/kg) will be given followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Bedside RNs will adjust the basal rate to a maximum of based on the number of bolus requests in the prior two hours. Subjects can also receive bolus supplemental sedative medications (benzodiazepines and/or opioids)if needed in the judgment of the patient-care nurse.
3086522|NCT01607073|Other|open label adjunctive add on|open label adjunctive add on of verapamil to existing medications. dosing begins at 1 mg/kg/d and increases weekly to target of 4 mg/kg/d in divided doses (three times/day)
3086523|NCT01607112|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3086524|NCT01607112|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3086525|NCT01607203|Active Comparator|hCG|5000 IU Pregnyl SC
3086526|NCT01607203|Active Comparator|hCG and GnRH agonist|5000 IU Pregnyl SC + 0.2 mg Decapeptyl daily SC
3086527|NCT01607255|Experimental|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
3086528|NCT01607255|Experimental|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
3086529|NCT01607255|Active Comparator|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
3086530|NCT01607346|Experimental|ezogabine/retigabine|Open-label
3086531|NCT01607398|Experimental|ADOAIR250|ADOAIR 250mcg inhalations, twice daily, from week0 - 12
3086532|NCT01607398|Placebo Comparator|Placebo|Placebo inhalation, twice daily, from week0 -12
3086533|NCT01607411|Placebo Comparator|Fluoride free toothpaste|toothpaste with no fluoride
3086534|NCT01607411|Experimental|1426ppm Fluoride Toothpaste|Experimental toothpaste containing 1426 ppm Fluoride
3086535|NCT01607411|Experimental|1000 ppm Fluoride Toothpaste|Experimental toothpaste containing 1000 ppm Fluoride
3086536|NCT01607411|Experimental|500 ppm Toothpaste|Experimental toothpaste containing 500 ppm Fluoride
3086537|NCT01607450|Other|Saline|12 hour saline (control) infusion prior to PET study
3086538|NCT01607450|Experimental|GLP-1 Low dose|GLP-1 Low Dose: 0.5 pmol/kg/min for 12 hours prior to PET study
3086539|NCT01607450|Experimental|GLP-1 Mid-Range Dose|GLP-1 Mid-Range Dose: 1.5 pmol/kg/min for 12 hours prior to PET study
3086540|NCT01607450|Experimental|GLP-1 High Dose|GLP-1 High Dose: 4.0 pmol/kg/min for 12 hours prior to PET study
3086541|NCT01607476|Experimental|Alzheimer's Disease|"Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first."
3086542|NCT01607476|Active Comparator|Cognitive Normal Elderly|Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
3086543|NCT01607476|Active Comparator|Cognitive Normal Young|Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
3086544|NCT01607554|Experimental|Irinotecan|The starting dose of irinotecan for the study is 180 mg/m2, given intravenously every 14 days. Each 14 day period will constitute one cycle of treatment.
3086545|NCT01607593||sertraline (Zoloft)|
3086546|NCT01607645|Experimental|Arm1: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -4 to 0, cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3.
3086547|NCT01607645|Experimental|Arm2: decitabine, idarubicin, cytarabine|Patients receive decitabine IV over 1 hour on days -9 to -5 and cytarabine and idarubicin as in Arm I.
3086548|NCT01607658|Placebo Comparator|Placebo|Placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
3086549|NCT01607658|Experimental|Experimental 1|Low dose TBS-2 (0.6 mg) testosterone intranasal gel administered prn
3086550|NCT01607658|Experimental|Experimental 2|Medium dose TBS-2 (1.2 mg) testosterone intranasal gel administered prn
3086551|NCT01607658|Experimental|Experimental 3|High dose TBS-2 (1.8 mg) testosterone intranasal gel administered prn
3086552|NCT01607853|Experimental|Daivobet® gel|
3086553|NCT01607892|Experimental|selinexor|
3086554|NCT01607905|Experimental|Arm A (Colorectal Cancer)|Participants with colorectal cancer and liver metastasis received oral selinexor as single agent in 8 schedules, Schedule1: ≤12milligrams per meter square(mg/m^2) 3 times weekly(TIW) during Weeks 1 and 3, twice weekly(BIW) during Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule2: >12mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle(28 days/cycle); Schedule3: ≥30mg/m^2 BIW(Days 1 and 3) up to 8 doses/cycle(28 days/cycle); Schedule4: ≥20mg/m^2 BIW(Days 1 and 2) up to 8 doses/cycle(28 days/cycle); Schedule5: ≥35mg/m^2 BIW(Days 1 and 4) up to 8 doses(28 days/cycle); Schedule6: ≥20mg/m^2 BIW(Days 1 and 4) after 500 mg(Week 1) to 1000 mg(Week 2 onwards) acetaminophen(given 1 hour prior to each selinexor dose) up to 8 doses/cycle (28 days/cycle); Schedule7: ≥50mg/m^2 once weekly(QW) up to 4 doses/cycle(28 days per cycle); Schedule8: ≥45mg/m^2 BIW(Days 1 and 3) up to 4 doses/cycle(21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086555|NCT01607905|Experimental|Arm B (Gynecological Cancer)|Participants with gynecological cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086556|NCT01607905|Experimental|Arm C (Squamous Cell Cancer)|Participants with squamous cell cancer received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086557|NCT01607905|Experimental|Arm D (Castrate-resistant Prostate Cancer)|Participants with castrate-resistant prostate cancer (CRPC) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086558|NCT01607905|Experimental|Arm E (Glioblastoma Multiforme)|Participants with glioblastoma multiforme (GBM) received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086559|NCT01607905|Experimental|Arm F (Melanoma)|Participants with Melanoma received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086560|NCT01607905|Experimental|Arm G (Other Solid Tumors)|Participants with other solid tumors received oral selinexor as a single agent in eight schedules, Schedule 1: ≤12 mg/m^2 TIW during Weeks 1 and 3, BIW during Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 2: >12 mg/m^2 TIW during Weeks 1 and 3, BIW in Weeks 2 and 4 up to 10 doses/cycle (28 days/cycle); Schedule 3: ≥30 mg/m^2 BIW (Days 1 and 3) up to 8 doses/cycle (28 days/cycle); Schedule 4: ≥20 mg/m^2 BIW (Days 1 and 2) up to 8 doses/cycle (28 days/cycle); Schedule 5: ≥35 mg/m^2 BIW (Days 1 and 4) up to 8 doses (28 days/cycle); Schedule 7: ≥50 mg/m^2 QW up to 4 doses/cycle (28 days per cycle); Schedule 8: ≥45 mg/m^2 BIW (Days 1 and 3) up to 4 doses/cycle (21 days/cycle), until disease progression, death, or unacceptable toxicity.
3086561|NCT01607957|Experimental|TAS-102|
3086562|NCT01607957|Placebo Comparator|Placebo|
3086563|NCT01608061|Experimental|DBS-f on|DBS-f on
3086564|NCT01608061|Sham Comparator|DBS-f off|DBS-f off
3086565|NCT01608087|Experimental|BI 695502|Subject to receive one intravenous (i.v.) infusion of BI 695502
3086566|NCT01608087|Active Comparator|bevacizumab A|Subject to receive one i.v. infusion of bevacizumab
3086567|NCT01608087|Active Comparator|bevacizumab B|Subject to receive one i.v. infusion of bevacizumab
3086568|NCT01608100|Experimental|ARCHITECT STAT High Sensitive Troponin I Assay testing|All subjects will have their blood tested by the investigational ARCHITECT STAT High SensitiveTroponin I assay.
3086569|NCT01608295|Experimental|Vilazodone; Viibryd|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
3086570|NCT01608295|Experimental|Paroxetine; Paxil|After screening and baseline test results are reviewed and eligibility criteria are confirmed, medications will be dispensed if patients continue to meet eligibility criteria and sign the informed consent form. All eligible subjects will be randomized to vilazodone or paroxetine group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups. Doses of the drugs will be adjusted according to individual tolerability and safety.
3086571|NCT01608308|Experimental|IV Acetaminophen|The experimental group will receive a preoperative dose of 1000mg IV acetaminophen over 15 minutes. This will occur at least 15 minutes before the start of surgery. Another 1000mg dose of IV acetaminophen will be administered 4 hours after the first dose. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
3086572|NCT01608308|Placebo Comparator|Control|The control group (Placebo) will receive 100 mL of 0.9% normal saline in place of IV acetaminophen in the same manner as the experimental group; the investigator/physician in question will be blinded to the agent that is being administered. Patients will be discharged with instruction to continue APAP 500 mg PO every 6-8 hours. A rescue analgesic containing oxycodone will also be provided (with APAP concentrations of 325 mg per Hospital and FDA recommendations).
3086573|NCT01608321|Experimental|rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
3086574|NCT01608321|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
3086575|NCT01608490|Experimental|RePneu Lung Volume Reduction Coil System|The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
3086576|NCT01608490|No Intervention|Control arm is standard medical care|The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.
3086577|NCT01608659||botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
3086578|NCT01608672||All participants|Botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
3086579|NCT01608724|Experimental|Open label|Saxagliptin, oral 5mg once a day(Q. D.)
3086580|NCT01608815|Experimental|Study Group|All participants will receive single dose of typhoid Vi polysaccharide vaccine on Day 0.
3086581|NCT01608971||Weight based protamine group|In this group the dose of protamine is calculated by the weight of the patients (400 IU/kg)
3086582|NCT01608971||Heparin level based protamine group|In this group the protamine dose will be calculated 1:1 according to the heparin level measured after termination of cardiopulmonary bypass.
3086583|NCT01609010|Active Comparator|Rituximab Monotherapy|Participants received 375 milligrams per square meter (mg/m2) rituximab intravenously (i.v.) weekly for 4 weeks. Participants achieving minor response (MR), partial response (PR), or completer response (CR) received a second cycle of treatment.
3086584|NCT01609010|Experimental|Rituximab, Interferon|Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
3086585|NCT01609023||Rituximab|Participants with chronic lymphocytic leukemia treated with rituximab in combination with chemotherapy according to SPC and routine clinical practice will be observed for 24 months.
3086586|NCT01609062|Experimental|BMN 110 Weekly at 2.0 mg/kg/week|
3086587|NCT01609062|Experimental|BMN 110 Weekly at 4.0 mg/kg/week|
3086588|NCT01609218|Experimental|80 mg LY2140023|Single oral dose of 80 milligrams (mg) LY2140023 administered alone
3086589|NCT01609218|Experimental|80 mg LY2140023 + 75 g aqueous activated charcoal|Single oral dose of 80 mg LY2140023 followed 1 hour later by single oral dose of 75 grams (g) aqueous activated charcoal.
3086590|NCT01609257|Experimental|Norovirus Bivalent VLP Vaccine|Norovirus Bivalent virus like particle (VLP) Vaccine (50 μg of GI.1 Norwalk VLP and 50 μg of GII.4 cVLP) adjuvanted with MPL and AI(OH)3, intramuscular (IM), Days 0 and 28.
3086591|NCT01609257|Placebo Comparator|Placebo|Saline Placebo (0.9% sodium chloride (NaCl) and preservative-free), intramuscular (IM), Days 0 and 28.
3086592|NCT01609296|Experimental|IN.PACT Admiral DEB|"The subjects in this trial will be treated with the IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon (hereinafter referred as IN.PACT Admiral™ DEB)manufactured by Medtronic. The IN.PACT Admiral™ is a CE (Conformité Europeénne, European Confirmity) marked medical device utilized within its intended use in the IN.PACT Global trial."
3086593|NCT01609348|Active Comparator|Venlafaxine|225 mg daily over 12 weeks
3086594|NCT01609348|Placebo Comparator|Sugar pill|
3086595|NCT01609478|Experimental|indacaterol acetate 75 µg|"indacaterol acetate 75 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3086596|NCT01609478|Experimental|indacaterol acetate 150 µg|"indacaterol acetate 150 µg od delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3086597|NCT01609478|Placebo Comparator|placebo|"placebo delivered via Concept 1 inhaler~Background therapy: mometasone furoate 200 mcg od"
3086598|NCT01609543|Experimental|Single Arm|
3086599|NCT01609556|Experimental|Dose Escalation: Schedule A (Mirvetuximab Soravtansine Q3W)|Participants will receive mirvetuximab soravtansine intravenous (IV) infusion on Day 1 of every 21-day (every 3 weeks [Q3W]) cycle. Dose escalation for this group schedule will start at 0.15 milligrams per kilogram (mg/kg) and proceed through 7.0 mg/kg. Doses calculated initially based on participant's total body weight (TBW); then from protocol amendment 5 onwards, calculated based on adjusted ideal body weight (AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
3086600|NCT01609556|Experimental|Dose Escalation: Schedule B (Mirvetuximab Soravtansine Weekly)|Participants will receive mirvetuximab soravtansine IV infusion on Days 1, 8, and 15 of every 28-day cycle. Dose escalation for this group schedule will start at 1.1 mg/kg (calculated based on AIBW) and proceed through 2.5 mg/kg. Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
3086601|NCT01609556|Experimental|Dose Expansion:EOC Participants(Mirvetuximab Soravtansine Q3W)|Participants with epithelial ovarian cancer (EOC) will receive mirvetuximab soravtansine 6.0 mg/kg (maximum tolerated dose [MTD]) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminated the study.
3086602|NCT01609556|Experimental|Dose Expansion: EC Participants(Mirvetuximab Soravtansine Q3W)|Participants with endometrial cancer (EC) will receive mirvetuximab soravtansine 6.0 mg/kg (MTD) IV infusion on Day 1 of every 21-day (Q3W) cycle (calculated based on AIBW). Participants will continue to receive mirvetuximab soravtansine (for clinical benefit) until unacceptable toxicity or withdrawal of consent, whichever comes first, or until the sponsor terminate the study.
3086603|NCT01609582|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 6 years.
3086604|NCT01609582|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 6 years.
3468905|NCT03891563||Non-sport specialist, any activity level|"AOSSM Criteria:~Participation in more than 1 sport at any physical activity level OR~Participation in none or low training and/or competition in organized sports for any period of time.~Involving prepubertal children.~AND~Activity Tracker Criteria:~Greater than or less than 180 accumulated minutes of MVPA across one week of activity tracking~- Meets these criteria during both years of follow-up"
3468906|NCT03891316||Anaesthesiologists balanced|Anaesthesiologists performing balanced anaesthesia with sevoflurane.
3086607|NCT01609842|Experimental|Phone reminders and pharmacist|An alerted inpatient pharmacist or a designated study team member will bring the clopidogrel medication to the patient who has received a coronary stent. The patient will return home and receive IVR refill reminder calls.
3468907|NCT03891316||Anaesthesiologists TIVA|Anaesthesiologists performing only total intravenous anaesthesia.
3086608|NCT01609842|Other|Usual Care|The sites will have no interaction with the study personnel. The investigators will use database information to compare with the intervention sites
3086609|NCT01609933|Experimental|2-DAA + PegIFN/RBV|2-direct-acting antiviral (2-DAA: ABT-450 [paritaprevir] 200 mg once daily [QD], ritonavir 100 mg QD, ABT-267 [ombitasvir] 25 mg QD) plus pegylated interferon alpha-2a (pegIFN) 180 mcg once weekly and Ribavirin (RBV) weight-based dosing, 1000 to 1200 mg divided twice daily (BID) for 24 weeks (Substudy 1) and followed by pegIFN and RBV alone for an additional 24 weeks (Substudy 2).
3086610|NCT01610011|Experimental|Glycine administration|Glycine will be administered once orally to all subjects to determine brain and plasma pharmacodynamics.
3086611|NCT01610037|Experimental|QVA149|
3086612|NCT01610037|Active Comparator|Tiotropium|
3086613|NCT01610037|Placebo Comparator|placebo|
3086614|NCT01610063|Experimental|Guided|A pharmacogenomic algorithm (GeneSight) guided treatment decisions for antidepressant medication selection and appropriate dosing.
3086615|NCT01610063|No Intervention|Unguided|Treatment as usual
3086616|NCT01610076|No Intervention|No Video - Control|"This group does not watch the 10 minute code status video before having the knowledge base video administered."
3086617|NCT01610076|Experimental|Code Status Video|"This group views a 10 minute video about code status prior to knowledge base survey administration"
3086618|NCT01610154|Experimental|Sitagliptin treatment|
3086619|NCT01610167|Active Comparator|NUPRO(r) Classic Prophy Paste|
3086620|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin(r) w/ fluoride.|
3086621|NCT01610167|Experimental|NUPRO Sensodyne Prophy Paste w/ Novamin|
3086622|NCT01610206|Active Comparator|gemcitabine|
3086623|NCT01610206|Experimental|Gemcitabine + pazopanib|
3086624|NCT01610271|Experimental|Air Barrier System|The Air Barrier System will be employed throughout the surgical procedure for this group of patients.
3086625|NCT01610271|No Intervention|Control|The Air Barrier System will not be used during the surgical procedure for this group of patients.
3086626|NCT01610284|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
3086627|NCT01610284|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
3086628|NCT01610297|Experimental|ICL670|Oral dose of ICL670 at 10 mg/kg daily
3086629|NCT01610336|Experimental|INC280 100 mg Cap QD Phase Ib|cap=capsule; QD=once daily
3086630|NCT01610336|Experimental|INC280 200 mg Cap QD Phase Ib|cap=capsule; QD=once daily
3086631|NCT01610336|Experimental|INC280 400 mg Cap QD Phase Ib|cap=capsule; QD=once daily
3086632|NCT01610336|Experimental|INC280 800 mg Cap QD Phase Ib|cap=capsule; QD=once daily
3086633|NCT01610336|Experimental|INC280 200 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
3086634|NCT01610336|Experimental|INC280 400 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
3086635|NCT01610336|Experimental|INC280 600 mg Cap BID Phase Ib|cap=capsule; BID=twice daily
3086636|NCT01610336|Experimental|INC280 200 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
3086637|NCT01610336|Experimental|INC280 400 mg Tab BID Phase Ib|tab=tablet; BID=twice daily
3086638|NCT01610336|Experimental|INC280 400 mg Cap BID Phase II|cap=capsule; BID=twice daily
3086639|NCT01610336|Experimental|INC280 400 mg Tab BID Phase II|tab=tablet; BID=twice daily
3086640|NCT01610414|Experimental|GSK1437173A Group|Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
3086641|NCT01610414|Placebo Comparator|Placebo Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.
3086642|NCT01610427|Experimental|HIV-1 Group|Antiretroviral Therapy-naïve HIV1-infected subjects, aged 18 to 55 years, from whom samples for cell-mediated immunity (CMI) were collected. No investigational vaccine was administered.
3086643|NCT01610453||ultrasound|primiparous women with prolonged labours will be eligible for examination
3086644|NCT01610492|Experimental|Cohort 1|10mg/kg belimumab intravenous (IV) administered at weeks 0 and 2, and then every 4 weeks, over a 24-week treatment period, resulting in a total of 8 doses, and will be assessed for the primary endpoint at week 28. Subjects will then enter the long term phase of the study and receive 10mg/kg belimumab every 4 weeks until week 100,or until they have been in complete remission for at least 3 months, resulting in up to 27 doses.
3086645|NCT01610557|Experimental|Group 1 - Ranibizumab-Ranibizumab-Bevacizumab Injection Series|"Group 1 eyes were assigned to Ranibizumab-Ranibizumab-Bevacizumab (RRB) treatment sequence and received intravitreal injections of ranibizumab at baseline, Weeks 4, and 8 (period 1), and Weeks 12, 16 and 20 (period 2), then crossed over to receive intravitreal injections of bevacizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3086646|NCT01610557|Experimental|Group 2 - Ranibizumab-Bevacizumab-Bevacizumab Injection Series|"Group 2 eyes were assigned to Ranibizumab-Bevacizumab-Bevacizumab (RBB) treatment sequence and received intravitreal injections of ranibizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of bevacizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3086647|NCT01610557|Experimental|Group 3 - Bevacizumab-Bevacizumab-Ranibizumab Injection Series|"Group 3 eyes were assigned to Bevacizumab-Bevacizumab-Ranibizumab (BBR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4, 8, 12, 16 and 20 (periods 1 and 2), then crossed over to receive intravitreal injections of ranibizumab at Weeks 24, 28 and 32 (period 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3086648|NCT01610557|Experimental|Group 4 - Bevacizumab-Ranibizumab-Ranibizumab Injection Series|"Group 4 eyes were assigned to Bevacizumab-Ranibizumab-Ranibizumab (BRR) treatment sequence and received intravitreal injections of bevacizumab at baseline and Weeks 4 and 8 (period 1), then crossed over to receive intravitreal injections of ranibizumab at Weeks 12, 16, 20, 24, 28 and 32 (periods 2 and 3).~Participants for whom one eye was enrolled in the study had this eye randomly assigned to one of four groups. Participants for whom both eyes were enrolled had the right eye randomly assigned; the left eye was assigned to the group with the schedule inverse to that for the right eye."
3086649|NCT01610570|Experimental|Phase I Dose Level -1|Dose Escalation Phase 9.0 mcg/kg.dose
3086650|NCT01610570|Experimental|Phase I Dose Level 1|Dose Escalation Phase 13.0 mcg/kg.dose
3086651|NCT01610570|Experimental|Phase I Dose Level 2|Dose Escalation Phase 17.5 mcg/kg.dose
3086652|NCT01610570|Experimental|Phase II - Expansion Phase|Expansion phase 17.5 mcg/kg.dose
3086653|NCT01610596|Experimental|Halobetasol Propionate Lotion 0.05%|Topical lotion, applied twice daily
3086654|NCT01610596|Placebo Comparator|Vehicle Lotion|Topical lotion, applied twice daily
3086655|NCT01610687|Experimental|GW-1000-02|Active treatment
3086656|NCT01610700|Experimental|GW-1000-02|Active treatment
3086657|NCT01610700|Placebo Comparator|Placebo|Control
3086658|NCT01610713|Experimental|GW-1000-02|Active treatment.
3086659|NCT01610752|Experimental|SmartMoms-Clinic|If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
3086660|NCT01610752|Experimental|SmartMoms-Phone|If picked for this group, you will have two individual sessions with a weight management counselor. At the first session, you will receive a scale and other technology to help manage your weight during pregnancy. Each week you will receive information from a weight management counselor via a Smartphone (you can use your own Smartphone or one will be provided to you). The information will cover topics to help manage your weight during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to measure your body weight (using a scale we will provide) as well as monitor your food intake and exercise habits with the Smartphone.
3086661|NCT01610752|No Intervention|Physician Directed|If picked for this group, you will receive weight management advice from your physician's office.
3086662|NCT01610791|Experimental|Single Arm|
3086663|NCT01611090|Experimental|Ibrutinib + BR|Ibrutinib 420 mg will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with bendamustine and rituximab (BR) for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
3086664|NCT01611090|Placebo Comparator|Placebo + BR|Matching placebo will be administered orally once daily on a continuous schedule. All subjects will receive background therapy with BR for a maximum of 6 cycles (a cycle is defined as 28 days, with the exception of Cycle 1, which will be 29 days to allow for rituximab dosing prior to bendamustine and study medication).
3086665|NCT01611155|Experimental|Arm I (management of therapy complications)|Patients receive venlafaxine PO BID beginning on day 1 of and continuing through completion of FOLFOX.
3086666|NCT01611155|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID beginning on day 1 of and continuing through completion of FOLFOX.
3086667|NCT01611194|Experimental|HBO2 at 1.5 Atomspheres Absolute (ATA)|Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
3086668|NCT01611194|Sham Comparator|Sham Control (1.2 Atomspheres)|Sham control 1.2 atms. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
3086669|NCT01611259|Experimental|Rituximab and Lenalidomide|Single arm: 6 cycles for patients with complete response, 8 cycles for subjects with stable disease or partial remission; cycles duration: 28 days Rituximab (Mabthera®): 375 mg/m² i.v. day 1 Lenalidomide (Revlimid®): 20 mg p.o. daily for 21 days
3086670|NCT01611298|Experimental|Single arm: Tetanus Toxoid|SCT Donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest
3086671|NCT01611454|Experimental|XPF thyroid collar|Administration of the XPF Thyroid Collar during the same type of interventional radiology procedures as Comparator arm above
3086672|NCT01611454|Active Comparator|Equivalent collar|Administration of the Standard 0.5mm lead-equivalent thyroid collar during the same type of interventional radiology procedures as Comparator arm above.
3086673|NCT01611558|Experimental|Arm: Ipilimumab, 10 mg/kg|Participants received 10 mg/kg of ipilimumab administered intravenously once every 3 weeks for 4 doses (Induction Phase). Then, once every 12 weeks (Maintenance Phase), until disease progression or unacceptable toxicity occurs.
3086674|NCT01611571|Active Comparator|Active Risedronate Placebo Teriparatide|Active Risedronate + Placebo Teriparatide for 18 months / Active Risedronate for 6 months
3086675|NCT01611571|Active Comparator|Active Risedronate Active Teriparatide|Active Risedronate + Active Teriparatide for 18 months / Active Risedronate for 6 months
3086676|NCT01611571|Active Comparator|Placebo Risedronate Active Teriparatide|Placebo Risedronate Active Teriparatide for 18 months / Active Risedronate for 6 months
3086677|NCT01611662|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, surgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes on day 1 and cisplatin IV on day 1 or divided over days 1 and 2. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-8 weeks after chemotherapy, patients undergo radical cystectomy.
3086678|NCT01611779|Experimental|Tongue suspension|Tongue-based suspension
3086679|NCT01611792|Experimental|Stabilization|
3086680|NCT01611792|Active Comparator|Strengthening and Conditioning|
3086681|NCT01611857|Experimental|Maximum Tolerated Dose|Phase I trial of Tivantinib plus FOLFOX for the treatment of patients with advanced solid tumors followed by a Phase II portion for patients with first-line metastatic GE cancer.
3086682|NCT01611883|Experimental|Ezetimibe|10 mg oral dose once daily for 24 weeks
3086683|NCT01611883|Placebo Comparator|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks
3086684|NCT01611935|Active Comparator|Vasopressin|Vasopressin will be given as an initial bolus (4 Units) followed by an infusion titrated between 0 units/min to 0.04 units per min to maintain a mean arterial blood pressure greater than or equal to 65 mmHg
3086685|NCT01611935|Placebo Comparator|Normal Saline|An initial bolus of normal saline will be given (10 cc) and an infusion of 0.1 ml per minute will be started and titrated down in as the mean arterial blood pressure reaches 65 mmHg or more.
3086686|NCT01611948|Active Comparator|Active Drug|125mg/d aprepitant for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3086687|NCT01611948|Placebo Comparator|Placebo pill|Placebo pill daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3086688|NCT01611974|Experimental|Maribavir 400 mg twice daily|
3086689|NCT01611974|Experimental|Maribavir 800 mg twice daily|
3086690|NCT01611974|Experimental|Maribavir 1200 mg twice daily|
3086691|NCT01612000|Experimental|PanBlok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3086692|NCT01612000|Experimental|PanBlok 3.8µg in 2% SE|3.8µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3086693|NCT01612000|Experimental|PanBlok 7.5µg No Adjuvant|7.5µg recombinant hemagglutinin, no adjuvant. 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3086694|NCT01612000|Experimental|PanBlok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3086695|NCT01612156|Active Comparator|2% lidocaine gel|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared with 2% lidocaine gel before use in the examination.
3086696|NCT01612156|Active Comparator|water based lubricant|Subjects in this arm will have all urethral catheters and urethral cotton tipped swabs prepared wtih water based lubricant before use in the pelvic floor examination.
3086697|NCT01612221|Experimental|Patients receiving N-acetylcysteine|Patients receiving NAC (N-acetylcysteine)
3086698|NCT01612221|Placebo Comparator|Placebo Group|Participants not receiving NAC (N-acetylcysteine)
3468908|NCT03891316||Surgeons|Surgeons working in the operating room while anaesthesia of the patients is randomly maintained with sevoflurane or propofol.
3086700|NCT01612494|Placebo Comparator|Normal Saline|
3086701|NCT01612494|Experimental|Hypertonic Saline|
3086702|NCT01612546|Experimental|Treatment (cyclodextrin-based polymer-camptothecin CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX101 IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. After the completion of 6 courses, patients achieving stable disease or better may receive treatment for an additional 6 months.
3086703|NCT01612676|Experimental|Drug|FE 202158
3086704|NCT01612702|Experimental|Dexamethasone|dexamethasone 10 mg administration 1 hour before surgery
3086705|NCT01612702|No Intervention|Control|No dexamethasone
3086706|NCT01612767|Experimental|Pro-Kinetic Energy Stent|
3086707|NCT01612780|Experimental|XprESS Multi-Sinus Dilation Tool|Balloon sinus dilation
3086708|NCT01612793||AlphaCore device|AlphaCore device group will consist of subjects enrolled into the study with chronic obstructive pulmonary disease and receive an electrical stimulation to the vagus nerve to help open the subjects airways during the subjects stay in the hospital.
3086709|NCT01612858|Experimental|Metformin|
3086710|NCT01612858|Experimental|Pioglitazone|
3086711|NCT01612884|Other|TEG|Clopidogrel non-response defined as MA≥69 Clopidogrel response defined as MA<69
3086712|NCT01612884|Other|Light transmittance aggregometry|Clopidogrel non-response defined as MPA ADP >42.9% Clopidogrel response defined as MPA ADP <42.9%
3086713|NCT01613014|Placebo Comparator|Sugar Pill|Matched Placebo sugar pill - target dose 2 pills BID
3086714|NCT01613014|Active Comparator|ABT-436|ABT-436 Target dose of 400 mg BID
3086715|NCT01613027||Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
3086716|NCT01613118|Experimental|RE-021 (Sparsentan) 200 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 200mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
3086717|NCT01613118|Experimental|RE-021 (Sparsentan) 400 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 400mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
3086718|NCT01613118|Experimental|RE-021 (Sparsentan) 800 mg|"RE-021 (Sparsentan) will be administered as a single oral morning dose. In this ARM the RE-021 (Sparsentan) dose will be 800mg.~Patients at </= 50kg will receive half of the RE-021 (Sparsentan) dose for the 8 week duration."
3086719|NCT01613118|Active Comparator|Irbesartan 300 mg|"The control will be administered irbesartan as a single oral dose of 150mg for the first week before escalating to 300mg for the remaining 7 weeks.~Patients at </= 50kg will receive 150mg irbesartan for the 8 week duration."
3086720|NCT01613131|Active Comparator|Mirena + Estradiol Gel|Subjects will be assigned to use of Estradiol gel for use with Mirena.
3086721|NCT01613131|Placebo Comparator|Mirena + Placebo Gel|Subjects will be assigned to use of placebo gel for use with Mirena.
3468909|NCT03891316||Anaesthesiologists PACU|Anaesthesiologists working in the postoperative care unit.
3468910|NCT03891316||Anaesthesiologists outside the operating room|Anaesthesiologists working outside of the operating room, for example pain service or anaesthesiological walk-in clinic
3468911|NCT03891316||Physicians not exposed|Physicians not having contact with patients on wards/outpatient clinics after exposure with sevoflurane
3468912|NCT03891316||Patients|Patients having undergone sevoflurane anesthesia for elective surgery
3086722|NCT01613222|Experimental|Pulse oximetry monitoring|The U-TruSignal with different sensors is feasible for noninvasive and continuous SpO2 monitoring and meets the specified measurement accuracy when compared to a co-oximetry gold reference.
3086723|NCT01613248|Experimental|MK-1602 1 mg|MK-1602 1 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086724|NCT01613248|Experimental|MK-1602 10 mg|MK-1602 10 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086725|NCT01613248|Experimental|MK-1602 25 mg|MK-1602 25 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086726|NCT01613248|Experimental|MK-1602 50 mg|MK-1602 50 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086727|NCT01613248|Experimental|MK-1602 100 mg|MK-1602 100 mg single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086728|NCT01613248|Placebo Comparator|Placebo|Placebo-matching MK-1602 single dose as treatment for a moderate or severe migraine headache. After 2 hours participants were able to take rescue medication if necessary.
3086729|NCT01613313|Experimental|Dose #1|single injection 0.058 mg Collagenase Clostridium Histolyticum
3086730|NCT01613313|Experimental|Dose #2|single injection 0.15 mg Collagenase Clostridium Histolyticum
3086731|NCT01613313|Experimental|Dose #3|single injection 0.29 mg Collagenase Clostridium Histolyticum
3086732|NCT01613313|Experimental|Dose #4|single injection 0.44 mg Collagenase Clostridium Histolyticum
3086733|NCT01613326|Experimental|NVA237|NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
3086734|NCT01613326|Active Comparator|Tiotropium|Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.
3086735|NCT01613339|Experimental|Body awareness therapy|
3086736|NCT01613339|No Intervention|Control|
3086737|NCT01613378||Rheumatoid Arthritis Cohort|The cohort included participants with moderate to severe rheumatoid arthritis (RA) in whom the treating physician made the decision to initiate tocilizumab treatment.
3086738|NCT01613417|Active Comparator|MRI with Gadoteridol|MRI after 0.1 mmol/kg IV ProHance, then with 0.1 mmol/kg Gadovist/Gadavist. MRI performed after both agents with identical sequences.
3086739|NCT01613417|Active Comparator|MRI with Gadobutrol|MRI after 0.1 mmol/kg IV Gadovist/Gadavist, then with 0.1 mmol/kg ProHance. MRI performed after both agents with identical sequences.
3086740|NCT01613599||Rituximab|Participants with granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) or microscopic polyangiitis (MPA) who received rituximab as per investigator's discretion were followed for a maximum of 4 years.
3086741|NCT01613716|Experimental|Ozurdex|Subjects will receive Ozurdex injections and will be monitored for macular edema.
3086742|NCT01613768|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3086743|NCT01614093|Active Comparator|Oxytocin/Placebo|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
3086744|NCT01614093|Active Comparator|Placebo/Oxytocin|Each participant will receive intranasal oxytocin 24IU or intranasal saline 24IU in random order. All results will be reported by treatment, the sample is too small for order effects.
3086745|NCT01614210|Experimental|All patients|All patients enrolled in the study.
3086746|NCT01614249|Placebo Comparator|Soybean oil soft gels|Participants on this arm will receive a dietary supplement of OmegaVia soybean oil soft gels as a placebo for 8 weeks with bi-weekly follow-up visits to monitor side effects and compliance.
3086747|NCT01614249|Experimental|Fish oil omega-3 EPA-rich soft gels|Participants will receive OmegaVia fish oil omega-3 EPA-rich soft gels to take orally for eight (8) weeks with bi-weekly follow-up visits for monitoring of side effects and compliance and data collection.
3086748|NCT01614392|Experimental|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
3086749|NCT01614392|Experimental|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
3086750|NCT01614457|Experimental|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
3086751|NCT01614457|Placebo Comparator|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
3086752|NCT01614470|Experimental|Part 1: Ivacaftor First, Then Placebo|Ivacaftor 150 milligram (mg) tablet orally twice daily for 8 weeks in treatment period 1 followed by placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
3086753|NCT01614470|Experimental|Part 1: Placebo First, Then Ivacaftor|Placebo matched to ivacaftor tablet orally twice daily for 8 weeks in treatment period 1 followed by ivacaftor 150 mg tablet orally twice daily for 8 weeks in treatment period 2. Washout out period of 4 to 8 weeks was maintained between each treatment period.
3086754|NCT01614470|Experimental|Part 2: Ivacaftor|Ivacaftor 150 mg tablet orally twice daily for 16 weeks.
3086755|NCT01614509|Experimental|Monotherapy group|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
3132419|NCT03425396|Experimental|Omadacycline 450/300 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 300 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
3086756|NCT01614509|Experimental|Combined group|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The Bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
3086757|NCT01614574|Experimental|Investigational|velaglucerase alfa
3086758|NCT01614600|Experimental|DAILIES® AquaComfort Plus®|Nelfilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 2 weeks
3086759|NCT01614613|Experimental|Intended BGM Users|Subjects were assigned to subgroups according to their initial glucose levels. SUBGROUP 1 goal: safely decrease subject glucose levels during the visit. SUBGROUP 2 goal: safely raise subject glucose levels. Also, blood samples were modified to obtain glucose concentrations across the needed glucose ranges while maintaining subject safety. Staff tested the blood samples using the 6 Blood Glucose Monitoring Systems. Bayer G3/Tatsu System;Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips; Freestyle Lite® Meter and Test Strips with ZipwikTM tabs;OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips;One Touch® VerioTM Pro/One Touch® VerioTM Test Strips;Truetrack® Meter/Truetrack® Test Strips
3086760|NCT01614743|Experimental|IncobotulinumtoxinA|
3086761|NCT01614743|Placebo Comparator|Placebo|
3086762|NCT01614769|Experimental|Placebo → Glimepiride 2 mg → Glimepiride 4 mg|Participants received placebo in the first period, 2 mg glimepiride in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
3086763|NCT01614769|Experimental|Glimepiride 2 mg → Glimepiride 4 mg → Placebo|Participants received 2 mg glimepiride in the first period, 4 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
3086764|NCT01614769|Experimental|Glimepiride 4 mg → Placebo → Glimepiride 2 mg|Participants received 4 mg glimepiride in the first period, placebo in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
3086765|NCT01614769|Experimental|Placebo → Glimepiride 4 mg → Glimepiride 2 mg|Participants received placebo in the first period, 4 mg glimepiride in the second period and 2 mg glimepiride in the third period, with a 7-day washout between each period.
3086766|NCT01614769|Experimental|Glimepiride 2 mg → Placebo → Glimepiride 4 mg|Participants received 2 mg glimepiride in the first period, placebo in the second period and 4 mg glimepiride in the third period, with a 7-day washout between each period.
3086767|NCT01614769|Experimental|Glimepiride 4 mg → Glimepiride 2 mg → Placebo|Participants received 4 mg glimepiride in the first period, 2 mg glimepiride in the second period and placebo in the third period, with a 7-day washout between each period.
3086768|NCT01614795|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 1 hour and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
3086769|NCT01614821|Experimental|Treatment Arm|PCI-32765; ibrutinib
3086770|NCT01614847|Experimental|Isotonic hyaluronate artificial tear|At random, subjects will receive isotonic hyaluronate artificial tear or a control (normal saline).
3086771|NCT01614847|Placebo Comparator|Normal saline|
3086772|NCT01614886|Experimental|1 step|
3086773|NCT01614886|Active Comparator|3 step|
3086774|NCT01614899|Experimental|SM-13496 40mg|
3086775|NCT01614899|Experimental|SM-13496 80mg|
3086776|NCT01614899|Placebo Comparator|Placebo|
3086777|NCT01614912|Experimental|SM-13496|
3086778|NCT01614925|Experimental|Emdogain|Periodontal surgery with the additional use of Straumann® Emdogain
3086779|NCT01614925|Active Comparator|Periodontal Surgery|Periodontal surgery alone
3086781|NCT01615120|Experimental|GTx-758 125mg|one GTx-758 tablet orally administered daily
3086782|NCT01615120|Experimental|GTx-758 250 mg|two GTx-758 tablets orally administered daily
3086783|NCT01615198|Experimental|LCZ696|Participants were treated with one LCZ696 100 mg tablet and one placebo of LCZ696 every day (qd) for 4 weeks along with placebo of Olmesartan 10 mg capsule qd. Participants were then up-titrated to LCZ 200 mg tablet and one placebo of LCZ696 qd for 6 weeks along with placebo of Olmesartan 20 mg capsule qd. Participants, who did not achieve their goal BP, were uptitrated to 2 LCZ696 200 mg tablets (LCZ696 400 mg) qd for 4 weeks along with placebo of Olmesartan 40 mg capsule qd.
3086784|NCT01615198|Active Comparator|Olmesartan|Participants were treated with olmesartan 10 mg qd for 4 weeks along with 2 placebo of LCZ696 tablets qd. Participants were then uptitrated to olmesartan 20 mg qd for 6 weeks along with 2 placebo of LCZ696 tablets qd. Participants, who did not achieve their goal BP, were uptitrated to olmesartan 40 mg qd for the remaining 4 weeks and 2 placebo LCZ696 tablets qd.
3086785|NCT01615263|Active Comparator|Double lumen tube|Lung isolation with a left double lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland.
3086786|NCT01615263|Active Comparator|Bronchial blocker|Lung isolation with a bronchial blocker with the inner channel closed (Fuji Uniblocker 9F, Fuji System Corporation, Tokyo, 113-0033, Japan) inserted via a 8.0 mm simple lumen endotracheal tube.
3086787|NCT01615328|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
3086788|NCT01615328|Experimental|Bonion|The ACDF surgery will be carried out with Bonion(TM), which is the PEEK cage with HA/DBM.
3086789|NCT01615367|Experimental|NEW Tx|25 people will be randomized to NEW Tx, a weekly individualized psychotherapy. Therapy is 20 weeks long.
3086790|NCT01615367|Active Comparator|Treatment as usual (TAU)|25 people will be randomized to TAU and will meet with their psychiatrist as often as clinically needed over the 20 week study duration.
3086791|NCT01615484|Experimental|Ex-vivo lung perfusion (EVLP) with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.
3086792|NCT01615484|No Intervention|Lung transplant from conventional brain-dead organ donor|No experimental procedures will be carried out.
3086793|NCT01615731|Active Comparator|Two sets of dilators|Two sets of osmotic dilators inserted 1 and 2 days pre-op
3086794|NCT01615731|Experimental|Mifepristone plus one set of dilators|One set of dilators plus mifepristone
3086795|NCT01615809|Experimental|Amphotericin B (ABELCET®)|"Drug: AMPHOTERICIN B Dosage form: Abelcet® 5mg/ml administered by inhalation. Dosage: 10 ml (50 mg) for the first week with a frequency twice a week. Dosage: from the second week onwards 5 ml (25 mg) with a frequency of a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.~Duration: 4-5 prophylaxis courses defined as each administration period during a neutropenia period, with a 4-6 weeks length considering the duration of neutropenia."
3086796|NCT01615822|Experimental|OZ439 100mg single dose|OZ439 100mg single dose oral suspension
3086797|NCT01615822|Experimental|OZ439 100mg plus MQ 250mg single doses|Single dose OZ439 100mg oral suspension in combination with single dose MQ 250mg tablet
3086798|NCT01615822|Experimental|OZ439 400mg single dose|OZ439 400mg single dose oral suspension
3086799|NCT01615822|Experimental|OZ439 400mg plus MQ 750mg single doses|Single dose OZ439 400mg oral suspension in combination with single dose MQ 750mg tablets
3086800|NCT01615822|Placebo Comparator|Placebo|Placebo
3086801|NCT01615939|Active Comparator|Single Shot Sciatic Nerve Block|Single shot sciatic nerve blocks will be performed by resident trainees supervised by faculty. Bupivacaine 0.625% with epinephrine 1:300,000 will be injected incrementally in 3-ml aliquots to a total volume of 0.4 ml/kg (minimum, 20 ml; maximum, 35 ml).
3086802|NCT01615939|Active Comparator|Continuous Sciatic Nerve Block|Continuous sciatic nerve block catheters will be performed using an insulated needle connected to the negative lead of a constant current nerve stimulator. The catheter will be advanced under ultrasound guidance. A test dose of 1.5% lidocaine with epinephrine will be injected to confirm catheter placement. All subjects will receive a portable pump that will infuse 0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr. The subjects will follow standard protocol discharge instructions in regards to removing the catheter themselves.
3086803|NCT01616056|Experimental|Bandage Contact Lenses|Patients wear bandage lenses continuously for at least 3 months in the absence of disease progression or unacceptable toxicity.
3086804|NCT01616082|Active Comparator|Overwight/Obese with no drug|After screening, overweight/obese subjects (BMI >27 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved.
3086805|NCT01616082|Active Comparator|Overweight/obese with Phentermine|After screening, overweight/obese (BMI >27.0 - ≤40.0) subjects will be started on a low calorie diet (approximately 900-1000 kcal/d) until a target weight loss is achieved. Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
3086806|NCT01616160|Experimental|Nasal polyps subjects|24 subjects with nasal polyps. Intervention: Each subject will receive Nasonex (mometasone furoate) 2 spray per nostril twice daily for 4 weeks.
3086807|NCT01616173|Active Comparator|Perineural Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine and perineural dexamethasone 8mg/2mL, and 50mL IV normal saline infusion
3086808|NCT01616173|Active Comparator|Intravenous Dexamethasone|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and IV dexamethsone 8mg in 50mL infusion
3086809|NCT01616173|Placebo Comparator|No Perioperative Steroids|Ultrasound guided sciatic nerve block with bupivicaine 0.5% with 1:300,000 epinephrine with saline and 50mL infusion
3086810|NCT01616459|Experimental|11Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830929A, or 11Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 11Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 11Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3086811|NCT01616459|Experimental|12Pn Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of GSK2830930A, or 12Pn, vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of 12Pn vaccine were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of 12Pn vaccine was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3086812|NCT01616459|Active Comparator|Synflorix Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Synflorix™ at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Synflorix™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Synflorix™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate).
3132420|NCT03425396|Experimental|Omadacycline 450/450 once every 24 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 24 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
3132421|NCT03425396|Experimental|Omadacycline 450/450 once every 12 hours|Participants received omadacycline 450 milligrams orally, once every 12 hours, fed on Day 1 and omadacycline 450 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
3086813|NCT01616459|Active Comparator|Prevnar13 Group|Healthy male or female subjects between, and including 6 to 12 weeks (42-90 days) of age at the time of first vaccination, received a 3-dose primary vaccination course of Prevnar13™ vaccine at 2, 3 and 4 months of age, followed by a booster dose of the same vaccine at 12-15 months of age, each dose being co-administered with one dose of Infanrix hexa™. The 3 first doses of Prevnar13™ were administered intramuscularly into the right anterolateral thigh and Infanrix hexa™ was administered intramuscularly into the left anterolateral thigh. The booster dose of Prevnar13™ was administered intramuscularly into the right deltoid (or thigh if the deltoid muscle size was not adequate) and that of Infanrix hexa™ was administered intramuscularly into the left deltoid (or thigh if the deltoid muscle size was not adequate ).
3086814|NCT01616563|Experimental|Diet and exercise|A combined diet and exercise program tailored to individuals incorporating behavioural modification support
3086815|NCT01616576|Experimental|Control first, then Experimental (Group A)|Initial subject use of Control Sound Processing Strategy for the first week, followed by subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the HiResolution™ Bionic Ear System for the second week.
3086816|NCT01616576|Experimental|Experimental first, then Control (Group B)|Initial subject use of Experimental (HiRes™ Optima) Sound Processing Strategy for the first week for the HiResolution™ Bionic Ear System, followed by subject use of the Control Sound Processing Strategy for the second week.
3086817|NCT01616654|Experimental|CD5789 25 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
3086818|NCT01616654|Experimental|CD5789 50 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
3086819|NCT01616654|Active Comparator|CD5789 100 mcg/g Cream|Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
3086820|NCT01616654|Placebo Comparator|Tazarotene 0.1% Gel|Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
3086821|NCT01616654|Experimental|Vehicle Cream|Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
3086822|NCT01616693|Experimental|Zinc and probiotic|Received daily zinc and probiotic supplements, in addition to rotavirus vaccine and trivalent oral polio vaccines.
3086823|NCT01616693|Active Comparator|Zinc alone|Received daily zinc and probiotic placebo supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
3086824|NCT01616693|Active Comparator|Probiotic alone|Received daily zinc placebo and probiotic supplement, in addition to rotavirus vaccine and trivalent oral polio vaccine.
3086825|NCT01616693|Placebo Comparator|Placebo|Received daily zinc placebo and probiotic placebo, in addition to rotavirus vaccine and trivalent oral polio vaccine.
3086826|NCT01616771|Other|glottis view assessment|Glottis view assessment using Macintosh laryngoscope & GVL selected by weight & smaller sized GVL in single patient
3086827|NCT01616953|Experimental|Ixmyelocel-T|iliac bone marrow aspirates are expanded ex vivo to enrich for adult multipotent cells (ixmyelocel-T) capable of regenerating bone and blood vessels and reducing inflammation. Following cell expansion, autologous ixmyelocel-T is then packaged and can be used as an autologous graft for treatment of bone defects.
3086828|NCT01616953|Active Comparator|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
3086829|NCT01617005||Tocilizumab in Moderate to Severe Active RA|Moderate to severe active RA participants, receiving tocilizumab treatment according to effective official Summary of Product Characteristics (SPC), will be observed. The choice of therapy will be based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
3086830|NCT01617070|Experimental|LNAA, washout, Kuvan, and LNAA+Kuvan|One group of 12 subjects, each under 4 conditions (each phase is 4 weeks)
3086831|NCT01617083|Active Comparator|Azithromycin|Antibiotic used to treat infections.
3086832|NCT01617083|Placebo Comparator|Placebo|Compound thickening agent with sugar and flavor additives.
3086833|NCT01617148|Experimental|Treatment with Aflibercept|Subjects were given 2 mg (0.05 mL) of intravitreal aflibercept injection administered every month for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
3086834|NCT01617187|Experimental|Asenapine 2.5 mg BID|
3086835|NCT01617187|Experimental|Asenapine 5 mg BID|
3086836|NCT01617187|Active Comparator|Olanzapine 15 mg QD|
3086837|NCT01617187|Placebo Comparator|Placebo BID|
3086838|NCT01617369|Experimental|Acute Hypertonic Saline Effect|2.8% NaCl inhaled 30 minutes before Mucociliary Clearance measured.
3086839|NCT01617369|Active Comparator|Sustained Hypertonic Saline Effect|2.8% NaCl inhaled 4 hours before Mucociliary Clearance measured.
3086840|NCT01617421|Experimental|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
3086841|NCT01617434|Experimental|Liraglutide|
3086842|NCT01617434|Placebo Comparator|Placebo|
3086843|NCT01617447|Placebo Comparator|Placebo|administered orally once daily
3086844|NCT01617447|Experimental|Aripiprazole|administered orally once daily
3086845|NCT01617460|Experimental|Aripiprazole|administered orally once daily
3086846|NCT01617577|Experimental|G-CSF (filgrastim) first phase|Subjects assigned to this arm receive G-CSF for 5 days during the first phase of the study. At week 7 these subjects cross over to receive placebo injections for five days
3086847|NCT01617577|Placebo Comparator|Placebo first phase|Subjects assigned to this arm receive placebo injections daily for 5 days; after wk 7 they crossover to receive 5 daily injections of injections of G-CSF.
3086848|NCT01617603|Experimental|High polyphenol milk chocolate|High polyphenol milk chocolate containing approximately 1 mg/g of epicatechin
3086849|NCT01617603|Active Comparator|Nestle Noir 70 % chocolate|Nestle Noir 70 % chocolate containing approximately 1 mg/g of epicatechin
3086850|NCT01617603|Placebo Comparator|Low polyphenol milk|Low polyphenol milk control (matched to product 1 as closely as possible for milk content, carbohydrate, fat and calories, made from cocoa butter, sugar, milk powder and small amount of cocoa liquor to improve taste, giving approximately 0.05mg/g epicatechin.
3086851|NCT01617629|Experimental|Cvac Treatment Group|Participants received Epithelial Mucin Surface Antigen 1 (MUC1) Dendritic Cell Vaccine (Cvac) treatment.
3086852|NCT01617655|Placebo Comparator|Placebo Q2W|Placebo for alirocumab subcutaneous (SC) injection every two weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
3086853|NCT01617655|Experimental|Alirocumab 150 mg Q2W|Alirocumab 150 mg SC injection Q2W on top of stable LMT for 78 weeks.
3086854|NCT01617668|Experimental|Paclitaxel with LCL161|Patients randomized to the experimental arm received paclitaxel 80 mg/m2 weekly + LECL161 1800 mg once weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
3086855|NCT01617668|Active Comparator|Paclitaxel without LCL161|Patients randomized to the control arm received paclitaxel 80 mg/m2 weekly for 12 weeks. Equal numbers of patients with gene expression signature positive and negative disease were included in each treatment arm.
3086856|NCT01617681|Experimental|Valsartan 0.25 mg/kg|Valsartan oral solution 0.25mg/kg once daily + matching placebo of valsartan oral solution 4 mg/kg once daily for 6 weeks (period 1)
3086857|NCT01617681|Experimental|Valsartan 4 mg/kg|Valsartan oral solution 4 mg/kg once daily + matching placebo of valsartan oral solution 0.25 mg/kg once daily for 6 weeks (period 1)
3086858|NCT01617681|Experimental|Valsartan 1 mg/kg|Open-label (Period 2) valsartan will be optionally titrated from 1 mg/kg to 2 mg/kg. Valsartan will continue to be optionally up titrated in 1 mg/kg increments every 4 weeks until maximum dose of 4 mg/kg is achieved. Duration 20 weeks.
3086859|NCT01617967|Experimental|Patisiran (ALN-TTR02)|Two administrations of patisiran will be administered once every 4 weeks [Q4W]) in 4 sequential cohorts with escalating doses followed by optional cohorts with an alternative dosing regimen (once every 3 weeks [Q3W]), and an alternative premedication regimen.
3086860|NCT01618019|Experimental|N-3 PUFA|5 capsules/day of n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
3086861|NCT01618019|Placebo Comparator|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
3086862|NCT01618162|Experimental|Insulin degludec/liraglutide|
3086863|NCT01618162|Placebo Comparator|Placebo|
3086864|NCT01618214|Experimental|Subject-driven titration|
3086865|NCT01618214|Active Comparator|Investigator-driven titration|
3086866|NCT01618227|Experimental|Rehabilitation with static progressive splinting|Static progressive splinting is a well-established adjunct for restoring motion in stiff joints. Such splints apply a static stress relaxation force to the wrist and forearm tissues, which is sequentially increased as motion is achieved.
3086867|NCT01618227|Experimental|Rehabilitation without splinting|
3086868|NCT01618240||Long term ventilated subjects|Muscle Strength Measurement, ventilator
3086869|NCT01618266||Ozurdex® (dexamethasone intravitreal implant)|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
3086870|NCT01618305|Experimental|Arm A (Women)|Pregnant women received ZDV/3TC + EFV
3086871|NCT01618305|Experimental|Arm B (Women)|Pregnant women received ZDV/3TC + RAL
3086872|NCT01618305|No Intervention|Arm A (Infants)|Infants born to women in Arm A; infants received no study intervention.
3086873|NCT01618305|No Intervention|Arm B (Infants)|Infants born to women in Arm B; infants received no study intervention.
3086874|NCT01618422|Sham Comparator|Directly Observed Therapy (DOTS)|The DOTS strategy (current standard strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
3086875|NCT01618422|Active Comparator|Directly Observed Therapy (DOTS) plus|The DOTS-Plus strategy (the strategy to be tested) includes additional measures including continuous drug resistance surveillance, culture, drug susceptibility testing for TB patients, and tailoring of individual drug regimen through the use of first and second-line drugs.
3086876|NCT01618669|Experimental|Regadenoson After Peak Exercise|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus, 3 minutes after exercise while in walk recovery and then a stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
3086877|NCT01618669|Active Comparator|Regadenoson Alone|On Day 1 participants received regadenoson, 0.4 mg in a 5 mL intravenous bolus (1 hour after exercise recovery), and then stress SPECT MPI. One to 14 days later participants received regadenoson at rest and then a stress SPECT MPI.
3086878|NCT01618695|Experimental|Perampanel|
3086879|NCT01618695|Placebo Comparator|Placebo|
3086880|NCT01618708|Experimental|Synvisc-One|Single intraarticular (IA) injection of Synvisc-One (48 mg of Hylan G-F 20 polymer) at Day 1. Participants were observed for 26 weeks in follow up period.
3086881|NCT01618708|Placebo Comparator|Placebo|Single IA injection of placebo matched to Synvisc-One at Day 1. Participants were observed for 26 weeks in follow up period.
3086882|NCT01618838|Other|CyberKnife Radiosurgery, Colonoscopy|CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).
3086883|NCT01618864|Other|Luxe|
3086884|NCT01618916|Experimental|1.0 milligrams per kilogram (mg/kg) LY3015014 Every 2 Weeks|1.0 mg/kg LY3015014 given subcutaneously (SC) once every 2 weeks for 29 days.
3086885|NCT01618916|Experimental|1.0 mg/kg LY3015014 Every 4 Weeks|1.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
3086886|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 2 Weeks|3.0 mg/kg LY3015014 given SC once every 2 weeks for 29 days.
3086887|NCT01618916|Experimental|3.0 mg/kg LY3015014 Every 4 Weeks|3.0 mg/kg LY3015014 given SC once every 4 weeks for 29 days.
3086888|NCT01618916|Placebo Comparator|Placebo Every 2 Weeks|Saline injection (to match LY3015014) given SC once every 2 weeks for 29 days.
3086889|NCT01618916|Placebo Comparator|Placebo Every 4 Weeks|Saline injection (to match LY3015014) given SC once every 4 weeks for 29 days.
3086890|NCT01618942|Experimental|male subjects|grouped by gender and applied pressure pain test
3086891|NCT01618942|Experimental|female subjects|grouped by gender and applied pressure pain test
3086892|NCT01618955|Active Comparator|VIBEX MTX|VIBEX MTX dose based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status
3086893|NCT01618968|Experimental|10 mg Methotrexate (MTX)|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3086894|NCT01618968|Experimental|15 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3086895|NCT01618968|Experimental|20 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3086896|NCT01618968|Experimental|25 mg MTX|MTX dose group was assigned based on the subject's current therapeutic regimen of MTX and rheumatoid arthritis disease status. The sequence of treatments A, B and C was randomly assigned.
3086897|NCT01619059|Experimental|Arm 1: Saxagliptin+Dapagliflozin+Metformin IR|
3086898|NCT01619059|Experimental|Arm 2: Placebo+Dapagliflozin+Metformin IR|
3086899|NCT01619085|Experimental|BIBF 1120|patient to receive a capsule containing BIBF 1120 twice a day
3086900|NCT01619410|Active Comparator|linezolid|
3086901|NCT01619410|Active Comparator|Clindamycin|
3086902|NCT01619423|Active Comparator|FOLFOX6 + PledOx 2 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3086903|NCT01619423|Active Comparator|FOLFOX6 + PledOx 5 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3086904|NCT01619423|Active Comparator|FOLFOX6 + PledOx 10 µmol/kg|PledOx active ingredient= Calmangafodipir; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3086905|NCT01619423|Placebo Comparator|FOLFOX6 + 0,9% NaCl|Placebo= 0.9% NaCl; FOLFOX6=Combination of FOLinic Acid, 5-Fluorouracil (5-FU), and Oxaliplatin.
3086906|NCT01619579|Experimental|Treatment|Subjects with Fibromyalgia undergo twice daily use of the non-invasive device for 4 weeks.
3086907|NCT01619774|Experimental|GSK2118436 + GSK1120212|GSK1120212 2 mg by mouth once a day, and GSK2118436 150 mg by mouth 2 times every day (1 time in the morning and 1 time in the evening, about 12 hours apart).
3086908|NCT01619839|Experimental|100 mg NKTR-181|100 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
3086909|NCT01619839|Experimental|200 mg NKTR-181|200 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days.
3086910|NCT01619839|Experimental|300 mg NKTR-181|300 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
3086911|NCT01619839|Experimental|400 mg NKTR-181|400 mg of NKTR-181 in tablet form, BID. Dosing to occur at Titration period up to 30 days and at Randomization period up to 24 days
3086912|NCT01619839|Placebo Comparator|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181.
3086913|NCT01619852|Active Comparator|Group L|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
3086914|NCT01619852|Placebo Comparator|.9% normal saline placebo|.9% normal saline administered as a bolus then as a maintenance infusion for the length of the surgical case.
3086915|NCT01619865|Experimental|68Ga-DOTATOC PET/CT|68Ga-DOTATOC Positron Emission Tomography (PET) for Diagnosis, Staging, and Measurement of Response to Treatment in Somatostatin Receptor Positive Tumors
3086916|NCT01619878|Experimental|Cohort 1|"One Artemether-lumefantrine (COA566) dispersible tablet taken orally twice a day during 3 days.~Infants age >28 days."
3086917|NCT01619982|Active Comparator|Cefazolin 25 mg/kg body weight and vancomycin|"All infants < 1 year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or any patient who requires surgery involving the aorta or the aortic valve will receive both Cefazolin and Vancomycin as preoperative prophylaxis against Surgical Site Infections. This has been recommended in recently published guidelines but not evaluated in children.~Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride 15 mg/kg body weight"
3086918|NCT01619982|Other|Cefazolin only 30mg/kg body weight|All infants less than one year of age with congenital heart diseases requiring cardiac surgery with cardiopulmonary bypass or all patients who required surgery involving the aorta or the aortic valve received cefazolin 30 mg/kg body weight as preoperative prophylaxis against surgical site infections
3086919|NCT01620047|Experimental|Femoral Nerve Fentanyl|Fentanyl 3 µg/ml delivered continuously through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3086920|NCT01620047|Active Comparator|Femoral Nerve Ropivacaine|Ropivacaine 0.1% continuously delivered through a femoral nerve sheath catheter for 24 hours post-total knee replacement. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3468913|NCT03891342|Experimental|Patients with sepsis/septic shock|Comaprison of fast or slow fluid bolus administration in patients with sepsis/septic shock 48hours before admission to ICU requiring fluid challenge as assessed by clinical examination
3086921|NCT01620047|Placebo Comparator|Intravenous Fentanyl with placebo|Control group which received 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump. All study drugs were continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
3086922|NCT01620060|Experimental|Lurasidone oral tablets|Lurasidone 20, 40, 80, 120 or 160 mg/day
3086923|NCT01620086|Experimental|Patients|Patients with Schizophrenia who meet entry criteria for the study and first receive active repetitive transcranial magnetic stimulation for four days over a control site located at the vertex and then are randomized to receive repetitive Transcranial Magnetic Stimulation for four days over the temporal cortex at both 1 Hz and 10 Hz.
3086924|NCT01620086|Experimental|Controls|These subjects are normal controls without schizophrenia who receive sham, repetitive transcranial magnetic stimulation at 1 Hz for two days and then receive active, repetitive Transcranial Magnetic stimulation for two days. All stimulation is delivered at the control site located over the vertex.
3086925|NCT01620138|Active Comparator|Pasireotide|"For non-cured patients with prolactinomas resistant to cabergoline, MRI will be performed immediately before and six months after the onset of pasireotide treatment. The anti-secretory effect will be evaluated by prolactin dosage every month.~For patients harboring a NFPA, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. In this case, the drug efficacy will be evaluated clinically by visual field and by MRI six months after pasireotide treatment."
3086926|NCT01620138|Active Comparator|cabergoline|In patients with non-functioning pituitary adenoma, treatment will be started at least 3 months after neurosurgery, when a pituitary MRI clearly shows the presence of a residual tumor without any possible misinterpretation of postsurgical changes. The drug response will be evaluated clinically by visual field and by Magnetic resonance imaging (MRI) before medical treatment and after six months of cabergoline treatment at maximum dose.
3086927|NCT01620177|Experimental|0% THC with 0.065 g/dL BAC|
3086928|NCT01620177|Experimental|2.5-3.5% THC with 0.065 g/dL BAC|
3086929|NCT01620177|Experimental|6.0-7.5% THC and 0.065 g/dL BAC|
3086930|NCT01620177|Experimental|2.5-3.5% THC with 0 g/dL BAC|
3086931|NCT01620177|Experimental|6.0-7.5% THC with 0 g/dL BAC|
3086932|NCT01620177|Experimental|0% THC with 0 g/dL BAC|
3086933|NCT01620190|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle formula)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086934|NCT01620216|Experimental|Group I (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086935|NCT01620216|Experimental|Group II (sutinib malate)|Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086936|NCT01620216|Experimental|Group III (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086937|NCT01620216|Experimental|Group IV (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
3086938|NCT01620216|Experimental|Group V (pacritinib)|Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086939|NCT01620216|Experimental|Group VI (ruxolitinib)|Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086940|NCT01620216|Experimental|Group VII (idelalisib)|Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3086941|NCT01620255|Placebo Comparator|Placebo|
3086942|NCT01620255|Experimental|Drug Dose Level 1|
3086943|NCT01620255|Experimental|Drug Dose Level 2|
3086944|NCT01620255|Experimental|Drug Dose Level 3|
3086945|NCT01620255|Experimental|Drug Dose Level 4|
3086946|NCT01620489|Experimental|Lira 1.8 mg|
3086947|NCT01620489|Placebo Comparator|Placebo|
3086948|NCT01620528|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
3086949|NCT01620528|Experimental|Elagolix 200 mg BID|Elagolix 200 mg twice daily (BID) for the 6-month Treatment Period
3086950|NCT01620528|Placebo Comparator|Placebo|Placebo BID for the 6-month Treatment Period
3086951|NCT01620567|Placebo Comparator|chickpeas/potatoes|1 potato/day or 1 cup chickpeas
3086952|NCT01620567|Active Comparator|avocados|1 avocados/day
3086953|NCT01620593|Placebo Comparator|Placebo|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy.
3086954|NCT01620593|Active Comparator|Metformin|Metabolic consequences including development of hyperinsulinemia and insulin resistance using metformin compared to placebo in men on castration therapy. In the rare case where a patient may not tolerate 500 mg three times a day, he may remain on the study taking only 500 mg twice a day.
3086955|NCT01620658|Active Comparator|standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
3086956|NCT01620658|Experimental|0.3mm XPF cap|Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
3086957|NCT01620658|Experimental|0.5mm XPF cap|Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
3086958|NCT01620762|Experimental|Cat-Pad Treatment 1|Cat-PAD Treatment 1
3086959|NCT01620762|Experimental|Cat-PAD Treatment 2|Cat-PAD Treatment regimen 2
3086960|NCT01620762|Placebo Comparator|Placebo|Placebo
3321123|NCT02016417|Active Comparator|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
3086963|NCT01620983|Experimental|Pain Coping Skills Training|The pain coping skills training will be delivered by physical therapists in eight one-hour sessions by telephone over a 2-month perioperative period. Patients will be taught a variety of skills designed to improve maladaptive pain related thoughts and actions to enhance recovery following arthroplasty.
3086964|NCT01620983|Active Comparator|Arthritis Education|The eight one-hour perioperative arthritis education sessions will be delivered by nurse educators via telephone and will use a presentation and discussion format. Figures and discussion sessions will present information on the nature of arthritis, what to expect following knee arthroplasty, treatment of osteoarthritis, the role of exercise, joint protection and making future treatment decisions.
3086965|NCT01620983|Other|Usual Care|Patients randomly assigned to this arm will undergo usual care following knee arthroplasty.
3086966|NCT01621009|Active Comparator|Active bupropion + counseling|Active bupropion SR plus eight 10-minute individual counseling sessions.
3086967|NCT01621009|Active Comparator|Active bupropion , No counseling|Active bupropion, No counseling, only medication checks
3086968|NCT01621009|Placebo Comparator|Placebo medication + counseling|Placebo bupropion plus eight 10-minute individual counseling sessions
3086969|NCT01621009|Placebo Comparator|Placebo medication, No counseling|Placebo bupropion, No counseling, just medication checks
3086970|NCT01621126|Experimental|Intra-op neuromonitoring|
3086971|NCT01621178|Active Comparator|Insulin glargine|Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3086972|NCT01621178|Experimental|0.75 mg Dulaglutide|0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3086973|NCT01621178|Experimental|1.5 mg Dulaglutide|1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
3086974|NCT01621191|Experimental|60 mg Duloxetine|Duloxetine 20 milligrams (mg) taken orally once every day for 1 week, followed by 40 mg taken orally once every day for 1 week, and then 60 mg taken orally once every day for 48 weeks
3086975|NCT01621230|Active Comparator|Epidural fentanyl|A continuous epidural infusion of fentanyl 10 mcg/cc at a basal infusion rate of 10 ml/hr with a patient-controlled epidural analgesia (PCEA) demand dose of 5 mL/hr for pain. Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed.
3086976|NCT01621230|Placebo Comparator|Epidural bupivacaine plus fentanyl|A continuous epidural infusion of bupivacaine plus fentanyl during the second stage (i.e. 10 cm dilation) of labor. Epidural infusion are 10 ml/hr basal infusion plus 5 ml/hr demand dose via patient-controlled epidural analgesia (PCEA). Meperidine 25 mg intravenously every 1 hour for breakthrough pain as needed .
3086977|NCT01621477|Experimental|Treatment|"All study participants.~Interventions: clofarabine, cytarabine, busulfan, plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, tacrolimus, mycophenolate mofetil"
3086978|NCT01621490|Experimental|Part 1-Cohort 1 and 2: Nivolumab|Nivolumab 3 mg/kg solution intravenously Every 2 weeks, Up to 2 years depending on response
3086979|NCT01621490|Experimental|Part 2-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3086980|NCT01621490|Experimental|Part 3-Arm A: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3086981|NCT01621490|Experimental|Part 3-Arm B: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
3086982|NCT01621490|Experimental|Part 4-Arm D: Nivolumab + Ipilimumab|Nivolumab 1 mg/kg combined with Ipilimumab 3 mg/kg solution intravenously and then Nivolumab 3 mg/kg solution intravenously as specified
3086983|NCT01621490|Experimental|Part 4-Arm E: Nivolumab|Nivolumab 3 mg/kg solution intravenously as specified
3086984|NCT01621542|Experimental|WT2725|WT2725; injection
3086985|NCT01621633|Experimental|Group 1: mild hepatic impairment|LCZ696 200 mg, given as a single oral dose
3086986|NCT01621633|Experimental|Group 2: moderate hepatic impairment|LCZ696 200 mg, given as a single oral dose
3086987|NCT01621633|Experimental|Group 3: healthy volunteers|LCZ696 200 mg, given as a single oral dose. Each healthy volunteer will match in race, age (±5 years), gender, weight (±15%) to an individual subject with hepatic impairment in groups 1 and 2
3086988|NCT01621672|Experimental|Revlimid|Revlimid dosing will be in the morning at the same time each day
3086989|NCT01621672|No Intervention|No further treatment|No treatment control.
3086990|NCT01621776|Active Comparator|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
3086991|NCT01621776|Active Comparator|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
3086992|NCT01621776|Active Comparator|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
3086993|NCT01621802|Experimental|Inv _MMR_CO Group|Subjects received one dose of the study vaccine Priorix along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
3086994|NCT01621802|Active Comparator|Com_MMR_CO Group|Subjects received one dose of the licensed vaccine M-M-R II (also known as M-M-R Vax Pro) Lot 1 or Lot 2 along with Kinrix and ProQuad vaccines at Visit 1 (Day 0).
3086995|NCT01621802|Experimental|Inv_MMR_I Group|Subjects received one dose of Priorix at Visit 1 (Day 0).
3086996|NCT01621802|Active Comparator|Com_MMR_I Group|Subjects received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
3086997|NCT01621802|Experimental|Inv _MMR_S Group|Subjects in this safety cohort received one dose of Priorix at Visit 1 (Day 0).
3086998|NCT01621802|Active Comparator|Com_MMR_S Group|Subjects in this safety cohort received one dose of M-M-R II (also known as M-M-R Vax Pro) vaccine from Lot 1 or Lot 2 at Visit 1 (Day 0).
3086999|NCT01621880|Active Comparator|Bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3087000|NCT01621880|Active Comparator|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
3087001|NCT01622010|Experimental|Standard care with video enhancement|"Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol. In addition are provided a copy of Keeping the Beat with Physiotherapy: Heart Failure edition education DVD related to heart failure, exercise and self management."
3087002|NCT01622010|Active Comparator|Standard care|Receive standard care of an invitation to attend an Allied Health Education Class. May be referred to physiotherapy from Heart Failure Clinic at Physician request per standard clinic protocol.
3087003|NCT01622231|Experimental|GW685698X|GW685698X 55mcg/day
3087004|NCT01622257|Experimental|Cavitation US|Cavitation ultrasound was done using ultrasonic cavitation machine 2 times per week for 3 months
3087005|NCT01622257|Experimental|Metformin|Metformin oral tablets 500 mg were given three times daily
3087006|NCT01622257|Experimental|Cavitation US + metformin|Combination of both Cavitation US + Metformin
3087007|NCT01622296|Active Comparator|Sodium Bicarbonate with Lidocaine|
3087008|NCT01622296|Placebo Comparator|Lidocaine with no buffer|
3087009|NCT01622348|Placebo Comparator|Placebo|Saline for Injection
3087010|NCT01622348|Active Comparator|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC once weekly based on body weight at screening, not to exceed 20 mg per injection
3087011|NCT01622348|Active Comparator|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wk based on body weight at screening, not to exceed 40 mg per injection
3087012|NCT01622543|Active Comparator|Folfox plus Bevacizumab and Reolysin|
3087013|NCT01622543|Active Comparator|Folfox plus Bevacizumab|
3087014|NCT01622569|Active Comparator|OPN-375 100 μg BID|"Double-Blind Treatment Phase: OPN-375 100 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
3087015|NCT01622569|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
3087016|NCT01622569|Active Comparator|OPN-375 200 μg BID|"Double-Blind Treatment Phase: OPN-375 200 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
3087017|NCT01622569|Active Comparator|OPN-375 400 μg BID|"Double-Blind Treatment Phase: OPN-375 400 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 400 μg BID x 8 weeks"
3087018|NCT01622660|Experimental|Gemcitabine and Pazopanib|This is a phase II trial of gemcitabine and pazopanib in previously untreated patients with advanced/metastatic urothelial carcinoma (UC) who are ineligible for cisplatin-based chemotherapy.
3087019|NCT01622673|Experimental|RAL, TUMS+RAL, MINTOX+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours After Raltegravir in treatment period 5. There was a 2-day washout between treatment periods.
3087020|NCT01622673|Experimental|TUMS+RAL, MINTOX+RAL, RAL, MINTOX Before RAL, MINTOX After RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3087021|NCT01622673|Experimental|MINTOX+RAL, RAL, TUMS+RAL, MINTOX Before RAL, MINTOX After RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours before Raltegravir in treatment period 4, followed by MINTOX® 2 hours after Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3087022|NCT01622673|Experimental|RAL, MINTOX+RAL, TUMS+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received Raltegravir in treatment period 1, followed by MINTOX® + Raltegravir in treatment period 2, followed by TUMS® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3087023|NCT01622673|Experimental|TUMS+RAL, RAL, MINTOX+RAL, MINTOX After RAL, MINTOX Before RAL|Participants received TUMS® + Raltegravir in treatment period 1, followed by Raltegravir in treatment period 2, followed by MINTOX® + Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3087024|NCT01622673|Experimental|MINTOX+RAL, TUMS+RAL, RAL, MINTOX After RAL, MINTOX Before RAL|Participants received MINTOX® + Raltegravir in treatment period 1, followed by TUMS® + Raltegravir in treatment period 2, followed by Raltegravir in treatment period 3, followed by MINTOX® 2 hours after Raltegravir in treatment period 4, followed by MINTOX® 2 hours before Raltegravir in treatment period 5. There was a minimum 2-day washout between treatment periods.
3087025|NCT01622699|Experimental|Transcutaneous bilirubin measurements|In this intervention group, the initial visual assessment of jaundice wille be followed by measurement by transcutaneous bilirubinometer
3087026|NCT01622699|Active Comparator|Visual assessment of neonatal jaundice|In this control group (standard of care) the visual assessment will be followed by measurement of blood bilirubin as indicated by the physician
3087027|NCT01622868|Experimental|Arm A (WBRT or SRS)|Patients undergo WBRT 5 days a week for 3 weeks for a total of 15 treatments, or SRS for 1 treatment.
3087028|NCT01622868|Experimental|Arm B (lapatinib ditosylate, WBRT or SRS)|Patients undergo WBRT or SRS as in Arm A. Patients also receive lapatinib ditosylate PO QD for 6 weeks.
3087029|NCT01623037|Experimental|CoolSculpting Treatment Group|The single arm will include all subjects treated on each flank with the CoolSculpting System and CoolCurve+ applicator. Treatment temperature and duration are defined in the protocol.
3087030|NCT01623050|Experimental|SinuSys Dilation System|Maxillary Sinus Dilation
3087031|NCT01623115|Placebo Comparator|Placebo|Placebo for alirocumab every 2 weeks (Q2W) on top of stable lipid-modifying therapy (LMT) for 78 weeks.
3087032|NCT01623115|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|Alirocumab 75 mg Q2W on top of stable LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when low-density lipoprotein cholesterol (LDL-C) levels ≥ 70 mg/dL (1.81 mmol/L) at Week 8.
3087033|NCT01623154|Other|BreathTek UBT|Comparison of Urea hydrolysis rate (UHR) values derived from Delta over Baseline (DOB)values obtained from the POCone and UBiT-IR300
3087034|NCT01623167|Experimental|Cohort 1: hATG, CsA, EPAG Day 14 to Month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 6
3087035|NCT01623167|Experimental|Cohort 2: hATG, CsA, EPAG Day 14 to Month 3|Receive horse ATG days 1- 4, receive CsA day 1 to month 6, and receive eltrombopag day 14 to month 3
3087036|NCT01623167|Experimental|Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18months, and receive eltrombopag day 1 to month 6
3087037|NCT01623167|Experimental|Extrension Cohort|Receive horse ATG days 1- 4, receive CsA day 1 to month 6 at higher dose, then reduced dose for 18 months, and receive eltrombopag day 1 to month 6
3087038|NCT01623271|Experimental|CRPS I Pain Subjects|"This is an open label study that involves taking Gralise pills (gastic-retentive gabapentin) for 8 weeks.~Day 1-15: Titration phase- titrate Gralise from 300 mg/day to 1800 mg/day Day 16-42: Maintenance phase- maintain the dose of 1800 mg/day Day 43-56: Taper phase- taper the Gralise from 100 mg/day to 300 mg/day"
3087039|NCT01623310|Experimental|OPN-375 400 μg BID|OPN-375 400 μg BID for 12 months
3087040|NCT01623323|Other|Fluticasone|
3087041|NCT01623466|Experimental|AG890-6.5|Evaluate levonorgestrel delivery in AG890-6.5
3087042|NCT01623466|Experimental|AG890-12.5|Evaluate levonorgestrel delivery in AG890-12.5
3087043|NCT01623479||Hypotrichosis of the Eyelashes|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
3087044|NCT01623531|Active Comparator|RiaSTAP|Intravenous fibrinogen(RiaSTAP) will be administered according to FIBTEM based calculation formula
3087045|NCT01623531|Placebo Comparator|Intravenous saline|Intravenous saline (placebo) will be calculated according to FIBTEM based calculation formula
3087046|NCT01623596|Experimental|Fingolimod|
3087047|NCT01623596|Active Comparator|Disease Modifying Therapy|2 classes - Interferon Beta preparation (Exctavia, Betaseron, Rebif, Avonex) or glatiramer acetate (Copaxone)
3087048|NCT01623739|Active Comparator|Type 1 implant placement|Placement of a dental implant: Implant is placed immediately following tooth extraction in one surgical procedure
3087049|NCT01623739|Active Comparator|Type 2 implant placement|Placement of a dental implant: Once the tooth is extracted. The site is left to heal for 4 to 8 weeks before a dental implant is placed during a second surgical procedure.
3087050|NCT01623752||Patients with Rheumatoid Arthritis|
3087051|NCT01623752||Patients with Psoriasis Arthritis|
3087052|NCT01623830|Experimental|Reactivation + VRE|Virtual reality exposure therapy (VRE) for the fear of flying (FOF) preceded by a reminder of the feared stimulus (a virtual reality clip of a virtual airplane taxiing and taking off) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions
3087053|NCT01623830|Active Comparator|Neutral Cue + VRE|VRE for the FOF preceded by a neutral cue (a virtual reality clip of a virtual living room) presented in the head mounted display 10 minutes prior to all VR exposure therapy sessions.
3087054|NCT01623869|Experimental|Treatment (trebananib)|Patients receive 30 mg/kg trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3087055|NCT01624090|Experimental|1/mithramycin|Single agent intravenous (IV) mithramycin
3087056|NCT01624142|Experimental|Evolocumab|Participants received 420 mg evolocumab every month (participants not on lipid apheresis) or every 2 weeks (participants on lipid apheresis) for up to 5 years. Participants could switch dosing regimens at week 12 or 24 based on LDL-C and serum unbound proprotein convertase subtilisin/kexin type 9 (PCSK9) levels.
3087057|NCT01624168|Placebo Comparator|Anxiety Management Education|
3087058|NCT01624168|Experimental|10 week tai chi intervention|10 week course in Evidence Based Tai Chi meeting 2 times per week
3087059|NCT01624168|Experimental|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
3087060|NCT01624194|Active Comparator|Oxytocin nasal spray|Prior to randomization, all subjects will participate in a 1-week open-label placebo lead-in trial. Each subject will be administered the placebo nasal spray at Stanford University and then their parent will continue administering the nasal spray to the subject for 1 week at home. Each subject will then be randomly assigned either to the active group or to the placebo (stratified by gender) and will be given the appropriate nasal spray bottle and their parents will be responsible for administering 3 puffs per nostril (4 IU/puff) to their child for a total dose of 24 IU oxytocin or placebo twice daily (BID; morning and evening) for 4-weeks. On completion of this 4-week treatment trial subjects will have the option of participating in a second double-blind trial in which they will be assigned to the alternate nasal spray, to that which they received during the first 4-week trial, for an additional 4-week period.
3087061|NCT01624194|Placebo Comparator|Placebo nasal spray|The placebo nasal spray bottles will be prepared by adding all of the ingredients used in the Syntocinon nasal sprays with the exception of the concentrated oxytocin solution.
3087062|NCT01624233|Experimental|80 mg ixekizumab|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.
3087063|NCT01624259|Experimental|1.5 mg LY2189265|"LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
3087064|NCT01624259|Active Comparator|Liraglutide|"Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks~Metformin: at least 1500 mg/day, oral, for 26 weeks"
3087065|NCT01624363||Patients undergoing EUS|Patients undergoing EUS for non-pancreatic treatment.
3087066|NCT01624467|Experimental|Necitumumab|800 mg necitumumab, administered once per week as an intravenous infusion (IV)
3087067|NCT01624506||Magnetic Sphincter Augmentation|Patients will be treated with magnetic sphincter augmentation via the LINX Reflux Management System
3087068|NCT01624506||Fundoplication|Patients treated with laparoscopic fundoplication
3087069|NCT01624662|Active Comparator|OPN-375 100 mcg|Double-Blind Treatment Phase: OPN-375 100 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
3087070|NCT01624662|Active Comparator|OPN-375 200 mcg|Double-Blind Treatment Phase: OPN-375 200 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
3087071|NCT01624662|Active Comparator|OPN-375 400 mcg|Double-Blind Treatment Phase: OPN-375 400 mcg BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
3087072|NCT01624662|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matched Placebo BID x 16 weeks; Open-Label Extension Phase: OPN-375 400 mcg BID x 8 weeks
3087073|NCT01624740|Experimental|Low Rate Followed By High Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received low rate stimulation (2 Hz) for 3-4 days, followed by high rate stimulation (1200 Hz) for 3-4 days.
3087074|NCT01624740|Experimental|High Rate Followed By Low Rate|The Precision Plus spinal cord stimulation screening trial leads were temporarily implanted by the investigator. Subjects received high rate stimulation (1200 Hz) for 3-4 days, followed by low rate stimulation (2 Hz) for 3-4 days.
3087075|NCT01624870||CoreValve aortic valve|Implantation of CoreValve aortic valve
3087076|NCT01624948|Experimental|Everolimus+Tacrolimus/Prednisone|This arm (group 1) will undergo mycophenolic acid (MPA) discontinuation with the addition of Zortress (everolimus) to their current regimen of tacrolimus and prednisone; All patients in group 1 will receive Zortress (everolimus) at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
3087077|NCT01624948|Active Comparator|Standard of care: 50% reduction of MPA|This arm (group 2) patients will continue with tacrolimus (target trough level of 6-10 ng/mL), prednisone, and undergo a 50% reduction of the MPA dose, which is the standard immunosuppression treatment for renal transplant recipients with evidence of BKV infection. At months 1, 2, and 3 post-randomization urine and plasma BKV levels will be re-checked. Renal allograft biopsies will be done for cause as clinically indicated.
3087078|NCT01624974|Experimental|MK-1029/Placebo|Participants received 4 weeks treatment with MK-1029 150 mg once daily (QD) + ML 10 mg QD in Period III and Placebo QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
3087079|NCT01624974|Experimental|Placebo/MK-1029|Participants received 4 weeks treatment with Placebo QD + ML 10 mg QD in Period III and MK-1029 150 mg QD + ML 10 mg QD in Period V. Period IV was a 4-week wash-out period during which participants received single-blind Placebo QD and open-label ML 10 mg QD.
3087080|NCT01625000|Experimental|MP-214 3mg|
3087081|NCT01625000|Experimental|MP-214 6mg|
3087082|NCT01625000|Experimental|MP-214 9mg|
3087083|NCT01625000|Active Comparator|Risperidone 4mg|
3087084|NCT01625000|Placebo Comparator|Placebo|
3087085|NCT01625013|Experimental|Synvisc-One|
3087086|NCT01625091|Active Comparator|naltrexone|The investigators will administer Naltrexone to women with hazardous drinking and assess the study outcomes.
3087087|NCT01625091|Placebo Comparator|placebo pill|The investigators will administer an inert placebo that looks similar to Naltrexone, to women with hazardous drinking and assess the study outcomes.
3087088|NCT01625104|Experimental|Group 1: Aggressive Intervention Strategy|"Hospitals were randomized to an aggressive intervention strategy or to business as usual. The hospitals randomized to the aggressive intervention strategy underwent the following:~Grand Rounds conducted by physician and nurse from the Coordinating Center. This included a formal presentation on the evidence supporting rapid time to treatment in STEMI patients and evidence based strategies for reducing treatment delays.~Discussion with staff regarding perceived barriers to treatment and suggestions/ideas for strategies to overcome these barriers~Follow-up monthly phone conferences to continue to discuss strategies and ideas sharing~Written plan from sites detailing plans to change processes of care."
3087089|NCT01625104|Placebo Comparator|Group 2: Control Strategy|"Hospitals randomized to the control group were instructed to conduct business as usual."
3087090|NCT01625169|Other|HIV + pregnant women|Etravirine pharmacokinetics in breast milk and plasma. Etravirine 200mg PO BID for 14 days with PK on days 5 and 14
3087091|NCT01625182|Experimental|Fingolimod (FTY720)|Participants received Fingolimod 0.5 mg orally once daily.
3087092|NCT01625182|Placebo Comparator|Placebo|Participants received matching placebo to Fingolimod orally once daily.
3087093|NCT01625221|Experimental|Magnetic anal sphincter augmentation|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
3087094|NCT01625286|Experimental|Part A: Intermittent schedule (2/5)|See intervention description below.
3087095|NCT01625286|Experimental|Part A: Intermittent schedule (4/3)|See intervention description below.
3087096|NCT01625286|Active Comparator|Part B: AZD5363 combined with paclitaxel|See intervention description below.
3087097|NCT01625286|Placebo Comparator|Part B: paclitaxel combined with placebo|See intervention description below.
3087098|NCT01625338|Experimental|SOF+RBV 12 Weeks|SOF+RBV for 12 weeks
3087099|NCT01625338|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3087100|NCT01625338|Experimental|SOF+RBV+Peg-IFN 12 Weeks|SOF+RBV+Peg-IFN for 12 weeks
3321124|NCT02016443|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
3087101|NCT01625377|Active Comparator|Tacrolimus|From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids. From randomization to month 6 : tacrolimus (C0 6-10 ng/ml) + mycophenolic acid 1440 mg/d ± oral corticosteroids
3087102|NCT01625377|Experimental|Everolimus (RAD001)|"From transplantation to randomization: Basiliximab (40mg) at Day 0 and Day 4 + tacrolimus (C0 6-10 ng/ml) from Day 3-Day 5 + mycophenolic acid 1440 mg/d ± oral corticosteroids.~From randomization to month 6 : everolimus (recommended starting dose of 2 mg/day, then adjusted to achieve the target 6 ≤ C0 ≤ 10 ng/mL, until W24) + mycophenolic acid 1440 mg/d ± oral corticosteroids. The dose of tacrolimus was reduced by 50% twice: at the introduction of everolimus and at week 8 post-transplantation. Tacrolimus had to be finally discontinued in week 12 post-transplantation (by week 16 at the latest)."
3087103|NCT01625416|Experimental|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
3087104|NCT01625416|No Intervention|Usual Care|Usual care control patients will be given a list of available community resources and encouraged to proceed using all resources available to them.
3087105|NCT01625455|Active Comparator|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
3087106|NCT01625455|Placebo Comparator|Placebo|Matching placebo will be given in place of aprepitant
3087107|NCT01625507|Experimental|PANDA intervention|12 week nutritional intervention, including 6 classroom/community sessions, plus two sample collection visits.
3087108|NCT01625689|Experimental|SIIL LAIV|SII LAIV is a live, trivalent seasonal influenza vaccine. The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
3087109|NCT01625689|Placebo Comparator|Placebo|Placebo identical in appearance to experimental vaccine.
3087110|NCT01625845|Experimental|Pentoxifylline + Standard Treatment|"Pentoxifylline: Pentoxifylline is phosphodiesterase inhibitor that interferes with proinflammatory cytokine signaling and synthesis. Participants will be instructed to take pentoxifylline 400 mg p.o. t.i.d. for 12 weeks.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
3087111|NCT01625845|Placebo Comparator|Placebo + Standard Treatment|"Placebos: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.~Standard Treatment: Beating the Blues (BtB) is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions."
3087112|NCT01625897|Experimental|MP-214 1.5-9mg|
3087113|NCT01625897|Active Comparator|Risperidone 2-12mg|
3087114|NCT01625910|Experimental|behavioral counseling|Receive counseling via motivational interviewing seeking to encourage health eating habits and increased physical activity
3087115|NCT01625910|Placebo Comparator|Instructions in school readiness and performance|Parents receive instructions in school readiness and performance
3087116|NCT01625923|Experimental|Olanzapine|An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
3087117|NCT01625988|Experimental|LY2951742|LY2951742: 150 milligrams (mg), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
3087118|NCT01625988|Placebo Comparator|Placebo|Placebo: 0.9% Sodium Chloride, Untied States Pharmacopoeia (USP), subcutaneous (SC) injection on Day 1 and then once every other week for a total of 6 doses during the 12-week Treatment Period.
3087119|NCT01626079|Experimental|MitraClip System|Percutaneous mitral valve repair using MitraClip System
3087120|NCT01626079|No Intervention|Control Group|Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.
3087121|NCT01626092|Experimental|Intent-To-Treat Patients|Patients with high-risk lysosomal and peroxisomal disorders treated with preparative regimen (Campath-1H 0.3 mg/kg intravenous (IV) on days -12 through -8, clofarabine 40 mg/m^2 IV on days -9 through -5, melphalan 140 mg/m^2 IV on day -4 and Total Body Irradiation with Marrow Boosting [ first dose of 200 cGy single dose; 5 doses of 160cGy for marrow boosting - 1000cGy cumulative exposure] by Volumetric-Modulated Arc Therapy [VMAT] on days -3 through -1). Hematopoietic stem cell transplantation will be infused on Day 0. Post-transplant immunosuppression to follow: Mycophenolate mofetil (MMF) begin day -3 and continue to day +30 or 7 days after engraftment, whichever is later; Cyclosporine A (CsA) begin day -3 and then taper at day +100 if related donor, day +180 for unrelated donor.
3087122|NCT01626118|Experimental|Indomethacin 40 mg TID|
3087123|NCT01626118|Experimental|Indomethacin 40 mg BID|
3087124|NCT01626118|Placebo Comparator|Placebo|
3087125|NCT01626118|Experimental|Indomethacin 20 mg TID|
3087126|NCT01626352|Experimental|Bendamustine/Ofatumumab|All patients in this study will receive ofatumumab and bendamustine as an IV infusion for 6 cycles (a cycle is defined as 21 days in length). Patients will receive as an IV infusion of bendamustine Days 1 and 2 of Cycles 1-6, ofatumumab Days 1 and 8 during Cycle 1 only and on Day 1 of Cycles 2-6.
3087127|NCT01626391|Experimental|TRx0237|
3087128|NCT01626391|Placebo Comparator|Placebo|
3087129|NCT01626456|Experimental|ALKS 9072, Low|
3087130|NCT01626456|Experimental|ALKS 9072, High|
3087131|NCT01626495|Experimental|CART-19 T Cells|The subject's thawed T cells will be modified in one or two different ways that will allow the cells to identify and kill the tumor cells (B cells). The T cells will be infused over 10-15 minutes on days Days 0, and 1. Day 14 is tentative based on response.
3087132|NCT01626664|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
3087133|NCT01626664|Active Comparator|investigator's choice|Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
3087134|NCT01626690|Experimental|Pre-Warming|
3087135|NCT01626690|Active Comparator|Control|
3087136|NCT01626820|Experimental|Fluviral Adults Group|Subjects 18-60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
3087137|NCT01626820|Experimental|Fluviral Elderly Group|Subjects above 60 years of age received 1 dose of Fluviral® vaccine, administered intramuscularly in the deltoid of the non-dominant arm, at Day 0.
3087138|NCT01626859|Experimental|MP-214 3mg|
3087139|NCT01626859|Experimental|MP-214 6mg|
3087140|NCT01626859|Experimental|MP-214 9mg|
3087141|NCT01626872|Experimental|MP-214 3mg|
3087142|NCT01626872|Experimental|MP-214 6mg|
3087143|NCT01626872|Experimental|MP-214 9mg|
3087144|NCT01626872|Active Comparator|Risperidone 4mg|
3087145|NCT01626885|Experimental|MP-214 1.5-9 mg|
3087146|NCT01626989|Active Comparator|BiPAP auto SV Advanced|BiPAP auto SV Advanced
3087147|NCT01626989|Experimental|BiPAP auto SV 4|Auto Servo Ventilation Device
3087148|NCT01627002|Experimental|PA401|PA401 is a potent inhibitor of neutrophil activation and transmigration under development as a novel parenteral anti-inflammatory therapy for respiratory indications such as chronic obstructive pulmonary disease (COPD) and Cystic Fibrosis (CF). PA401 is a genetically engineered and recombinantly expressed mutant of the bioactive form of human interleukin-8.
3087149|NCT01627002|Placebo Comparator|Placebo|Placebo
3087150|NCT01627067|Experimental|Everolimus + Exemestane + Metformin|Patients take one 25 mg tablet of exemestane once daily, everolimus 10 mg orally per day and metformin 500 mg orally per day for three days. If there are no dose limiting toxicities, dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily. Drugs will be taken immediately after a meal at the same time each day.
3087151|NCT01627249|Active Comparator|Ranibizumab|
3087152|NCT01627249|Experimental|Aflibercept|
3087153|NCT01627249|Experimental|Bevacizumab|
3087154|NCT01627288|Experimental|Boost Radiation: Dose Level 1|2.4 Gy X 25 fractions = 60 Gy
3087155|NCT01627288|Experimental|Boost Radiation: Dose level 2|2.6 Gy X 25 fractions = 65 Gy
3087156|NCT01627288|Experimental|Boost Radiation: Dose level 3|2.8 Gy x 25 fractions = 70 Gy
3087157|NCT01627288|Experimental|Experimental: Boost Radiation Dose Level 0|"If the 2 dose limiting toxicities are documented at dose level 1, therapy will be de-escalated to Dose level 0 defined below.~Dose level 0: 2.2 Gy X 25 fractions = 55 Gy"
3087158|NCT01627327|Experimental|fluticasone furoate/vilanterol|inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
3087159|NCT01627327|Active Comparator|tiotropium bromide|anticholinergic
3087160|NCT01627340|Experimental|Diabetes Group|Subjects diagnosed with type 2 diabetes within the five year period before study start who received 3 doses of Engerix™-B vaccine (HBV) at 0, 1 and 6 months. The vaccine was administered intramuscularly (IM) into the deltoid region of the non-dominant arm.
3087161|NCT01627340|Active Comparator|Control Group|Subjects with no diagnosis or documented history of diabetes who received 3 doses of Engerix™-B (HBV) vaccine at 0, 1 and 6 months. The vaccine was administered intramuscularly into the deltoid region of the non-dominant arm.
3321125|NCT02016443|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
3321126|NCT02016456|Experimental|Theta-Burst Stimulation|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
3087164|NCT01627574|Experimental|Motivational Intervention|There are two, 45-60 minute sessions of tailored Motivational Interviewing (MI). The first session occurs at the enrollment of the study, the second at 3 month follow-up.
3087165|NCT01627574|Active Comparator|Didactic Educational Intervention|There are two, 45-60 minute sessions of didactic educational intervention related to promoting awareness for sexual health involving contraception and STI prevention. The first session occurs at the enrollment of the study, the second at 3 month follow-up.
3087166|NCT01627691|Experimental|Lotus Valve System|Patients enrolled will receive the Lotus Valve.
3087167|NCT01627782|Placebo Comparator|Placebo 3 times/week|
3087168|NCT01627782|Experimental|Ketamine 3 times/week|
3087169|NCT01627782|Experimental|Ketamine 2 times/week|
3087170|NCT01627782|Placebo Comparator|Placebo 2 times/week|
3087171|NCT01627860|Active Comparator|Topiramate add-on therapy|
3087172|NCT01627860|Experimental|Topiramate monotherapy|
3087173|NCT01628016|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a modified dot probe task, in which a probe always appears in the location of neutral stimulus after the two stimuli (i.e. one is the depressive cue and the other is neutral) were simultaneously presented. In the ABMT,the probability that a probe appears in the location of neutral is 90%, and correspondingly,in the location of depressive stimuli is 10%.~ABMT intervention: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes (4 sessions a week, roughly one session every other day with for each session)."
3087174|NCT01628016|Placebo Comparator|Placebo training|Participants complete 8 sessions of placebo training(PT) during a two-week period. Placebo training is a classic dot probe task, in which a probe appears after either of the locations that the two stimuli (i.e. one is the depressive cue and the other is neutral) were presented, with the same frequencies. In the PT condition, each session also consists of 218 trials, and the time to complete a PT session is approximately 10 minutes as well.
3087175|NCT01628016|No Intervention|blank control|Participants only complete assessment at each point time.
3087176|NCT01628042|Experimental|Participants With Severe Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3087177|NCT01628042|Experimental|Participants With Moderate Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3087178|NCT01628042|Experimental|Participants With Mild Renal Insufficiency|Participants will receive a single oral dose of vibegron 100 mg on Day 1.
3087179|NCT01628042|Experimental|Healthy Matched Control Participants|Participants receive a single oral dose of vibegron 100 mg on Day 1.
3087180|NCT01628107|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
3087181|NCT01628120|Experimental|Epoetin Hospira|Epoetin Hospira will be administered by SC bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
3087182|NCT01628159|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
3087183|NCT01628198|Experimental|Renal denervation group|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
3087184|NCT01628250|Active Comparator|laparoscopic complete mesocolic excision|Randomized group of patients receiving laparoscopic colectomy with the concept of complete mesocolic excision
3087185|NCT01628250|Active Comparator|D3 laparoscopic colectomy|Randomized group of patients receiving laparoscopic colectomy with D3-resection
3087186|NCT01628367|Experimental|Membrane|Test (membrane): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the test group will receive a high-density PTFE (d-PTFE) membrane over the socket.
3087187|NCT01628367|Active Comparator|Collagen plug|Control (collagen plug): Extraction and immediate implant placement will be performed. The gaps between the implant and socket walls will be filled with a bone graft material. Sites in the control group will receive a collagen wound dressing over the socket.
3087188|NCT01628393|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 0.5 mg weekly for another 96 weeks.
3087189|NCT01628393|Experimental|Ozanimod 1 mg|Participants received ozanimod 0.5 mg oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and continue to receive ozanimod 1 mg weekly for another 96 weeks.
3087190|NCT01628393|Placebo Comparator|Placebo|Participants received placebo to ozanimod oral capsules daily for 24 weeks. Participants who completed the 24-week treatment period had the option to enter the blinded extension period and were randomized to receive ozanimod 0.5 mg or 1 mg weekly for 96 weeks.
3087191|NCT01628510|Active Comparator|Traditional NICU Positioning|Methods of positioning in the NICU have been used for several decades. These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper® The continued use of these methods of positioning is the control group in the current study.
3087192|NCT01628510|Experimental|Dandle Roo/Dandle Wrap|The new Dandle Roo and Dandle Wrap were developed by NICU professionals to support the neurodevelopment of the preterm infant, and this device is produced by Dandle Lion Medical. The Dandle Roo/Wrap provides all around contact, containment, and proprioceptive input, (which more closely mimics the uterine environment) and can decrease excitability and promote self-regulation, while also allowing for movement with recoil back to flexion.
3087193|NCT01628523||All ED patients requiring mechanical ventilation|
3087194|NCT01628549|Experimental|P005672-HCl approximately 0.75 mg/kg/day|One P005672-HCl 50 mg capsule and one Placebo capsule, oral administration, once daily for 12 weeks
3087195|NCT01628549|Experimental|P005672-HCl approximately 1.5 mg/kg/day|Two P005672-HCl 50mg capsules, oral administration, once daily for 12 weeks
3087196|NCT01628549|Experimental|P005672-HCl approximately 3.0 mg/kg/day|Two P005672-HCl 100mg capsules, oral administration, once daily for 12 weeks
3087197|NCT01628549|Placebo Comparator|Placebo|Two Placebo capsules matching P005672-HCl, oral administration, once daily for 12 weeks
3087198|NCT01628588||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
3087199|NCT01628601||POAG or OHT|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
3087200|NCT01628614||POAG or OHT|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
3087201|NCT01628692|Experimental|Cohort 1: (Genotype 1b) Daclatasvir + Simeprevir|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal for 12 weeks
3087202|NCT01628692|Experimental|Cohort 2: (Genotype 1b) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1b received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
3087203|NCT01628692|Experimental|Cohort 3: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprevir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day) for 12 weeks.
3087204|NCT01628692|Experimental|Cohort 4: (Genotype 1a) Daclatasvir + Simeprevir + Ribavirin|Participants with hepatitis C virus genotype 1a received daclatasvir, 30 mg, once daily with or without food + simeprivir, 150 mg, once daily with a meal + ribavirin, twice daily with food (patients weighing <75 kg received a total ribavirin dose of 1000 mg per day; those weighing >=75 kg received 1200 mg per day.
3087205|NCT01628718|Active Comparator|CPT-C|Cognitive Processing Therapy, cognitive version only (CPT-C) delivered in 12 60-minute one-on-one treatment sessions.
3087206|NCT01628718|Experimental|Adaptive Disclosure (AD)|Adaptive Disclosure delivered in eight 90-minute one-on-one treatment sessions.
3087207|NCT01628848|Experimental|SPM 962|SPM 962 transdermal patch
3087208|NCT01628848|Placebo Comparator|Placebo|Placebo transdermal patch
3087209|NCT01628874|Experimental|Lidocaine Injection|0.5 mL (5mg) of 1% lidocaine injection given with the J-Tip
3087210|NCT01628874|Active Comparator|lidocaine 2.5% and prilocaine 2.5% (EMLA) Cream|Patients in this arm will receive 1g EMLA cream if they are in the younger age group and 10g EMLA cream if they are in the older age group. This will be placed for a minimum of 30 minutes.
3087211|NCT01628913|Experimental|BEZ235|Patients received BEZ235 400 mg bid p.o. (by mouth, twice daily)
3087212|NCT01628913|Active Comparator|Everolimus|Patients received Everolimus 10 mg qd p.o. (by mouth, daily)
3087213|NCT01628926|Experimental|SPM 962|SPM 962 transdermal patch
3087214|NCT01628926|Active Comparator|Ropinirole|Ropinirole tablet
3087215|NCT01628926|Placebo Comparator|Placebo|SPM962 placebo patch and Ropinirole placebo tab
3087216|NCT01628965|Experimental|SPM 962|SPM 962 transdermal patch
3087217|NCT01629134||Volbella|Subjects treated with JUVÉDERM VOLBELLA™ according to the physician's experience and Directions for Use
3087218|NCT01629290|Active Comparator|Enamel Pro|Varnish containing 5%NaF
3087219|NCT01629290|Active Comparator|Duraphat|Varnish containing 5%NaF
3087220|NCT01629290|Active Comparator|Vanish|Varnish containing 5%NaF
3087221|NCT01629290|Placebo Comparator|Placebo|Bland varnish containing no NaF
3087222|NCT01629381|Experimental|Rivaroxaban|Oral Rivaroxaban 10 mg od for 7 days
3087223|NCT01629381|Placebo Comparator|Placebo|oral placebo od for 7 days
3321127|NCT02016456|Active Comparator|High Frequency stimulation|High frequency Transcranial Magnetic Stimulation using the standard protocol for depression, on left dorsolateral prefrontal cortex.
3087225|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 5mg|All subjects will be asked to take a 150mg size tablet (PGL4001 5mg or matching placebo: placebo 5) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 150mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
3087226|NCT01629563|Experimental|Ulipristal acetate (PGL4001) 10mg|All subjects will be asked to take a 300mg size tablet (PGL4001 10mg or matching placebo: placebo 10 ) orally daily for repeated periods 84 days. The first treatment course will start on the first 4 days of menstruation and will be orally administered, once daily (1 tablet of 300mg size), for 84 days. The following three treatment courses should be started in the first two days of a menstrual period.
3087227|NCT01629589|Experimental|Adacel® Vaccine Group|Participants randomized to receive a single dose of Adacel® vaccine
3087228|NCT01629589|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine
3087229|NCT01629615|Experimental|BKM120|
3087230|NCT01629667|Experimental|Tralokinumab 400 milligram (mg)|Participants will receive Tralokinumab 400 mg intravenous (IV) infusion Q4W for 68 Weeks.
3087231|NCT01629667|Experimental|Tralokinumab 800 mg|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
3087232|NCT01629667|Placebo Comparator|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
3087233|NCT01629693|Experimental|Air Optix|Lotrafilcon B contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
3087234|NCT01629693|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally (in both eyes) for at least 4 hours a day, 5 days a week, for 4 weeks, on a daily wear basis (removed nightly for cleaning and disinfection).
3087235|NCT01629706|Experimental|PV+ClearCare / PV+Renu (Phase 1)|Balafilcon A contact lens pre-soaked overnight in ClearCare cleaning and disinfecting system worn in 1 eye for two hours and four hours at a time, separate days, with Balafilcon A contact lens pre-soaked overnight in renu multi-purpose solution worn in the fellow eye
3087236|NCT01629706|Experimental|Habitual (Phase 2)|Phase 2: Habitual contact lenses worn bilaterally on a daily wear basis for 4 weeks with habitual lens care
3087237|NCT01629771||Lymphatic Filariasis|
3087238|NCT01629771||Patients without Lymphatic Filariasis|
3087239|NCT01629784|Other|CLE and sun counseling|
3087240|NCT01629797|Other|Acne Vulgaris|Patients with Acne vulgaris will receive educational teaching on Acne
3087241|NCT01629823|Sham Comparator|CPAP less than 1 cm H₂O|
3087242|NCT01629823|Experimental|CPAP 10cm H₂O|
3087243|NCT01629823|Experimental|CPAP 5cm H₂O|
3087244|NCT01629862|Active Comparator|Active CPAP|Therapeutic continuous positive airway pressure (CPAP).
3087245|NCT01629862|Placebo Comparator|Sham CPAP|Sham (non-therapeutic) continuous positive airway pressure.
3087246|NCT01629953|Active Comparator|Group Based Vocational Rehabilitation|Group vocational intervention
3087247|NCT01629953|Experimental|Supported Employment Condition|Group vocational intervention + supported employment
3087248|NCT01629966|Placebo Comparator|Placebo|Dose-matched placebo one per day, oral administration
3087249|NCT01629966|Experimental|Vilazadone 20mg|Vilazodone 20mg once per day, oral administration.
3087250|NCT01629966|Experimental|Vilazodone 40mg|Vilazodone 40mg once per day, oral administration
3087251|NCT01630109|Active Comparator|Metoclopramide 5 mg|Pro-motility agent
3087252|NCT01630109|Active Comparator|Metoclopramide 10 mg|Pro-motility agent
3087253|NCT01630109|Placebo Comparator|Placebo control|Placebo to be used as the control group
3087254|NCT01630135|Experimental|GW685698X|GW685698X 55mcg/day
3087255|NCT01630135|Placebo Comparator|Placebo|Placebo
3087256|NCT01630200|Active Comparator|Roflumilast|Active arm including patients who receive the study drug (500µg Roflumilast once daily)
3321128|NCT02016469|Experimental|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )given for the first day and 20g pectin given from the second to the sixth day for total five days
3321129|NCT02016469|Active Comparator|single fecal microbiota transplantation|300ml Bacterial suspension (from 60g fresh stool )given for the first day
3087257|NCT01630200|Placebo Comparator|Placebo|Control arm including patients who receive the placebo tablet (once daily)
3087258|NCT01630616|Experimental|Adolescents Odanacatib 10 mg|Study drug (single oral dose of odanacatib 10 mg) was administered following at least an 8-hour fast to adolescents.
3087259|NCT01630616|Experimental|Adolescents Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to adolescents.
3087260|NCT01630616|Placebo Comparator|Adolescents Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to adolescents.
3087261|NCT01630616|Experimental|Young Adults Odanacatib 50 mg|Study drug (single oral dose of odanacatib 50 mg) was administered following at least an 8-hour fast to young adults.
3087262|NCT01630616|Placebo Comparator|Young Adults Placebo|Study drug (single oral dose of placebo) was administered following at least an 8-hour fast to young adults.
3087263|NCT01630694|Active Comparator|Difficult intubation patients|patients who were difficult to intubate during previous anesthetics provided by the staff anesthesiologists.
3087264|NCT01630694|Placebo Comparator|Control|The control group will consist of patients with the easy laryngoscopy and intubation, recruited prospectively.
3087265|NCT01630811|Experimental|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg/quinidine sulfate 10 mg), oral, once daily
3087266|NCT01630811|Placebo Comparator|Placebo|Oral, once daily
3087267|NCT01630889|Experimental|Roxadustat|Participants previously randomized to roxadustat will receive roxadustat at the same dose and frequency assigned at the last dose in the previous FibroGen study. Dose adjustments will be implemented (up to a maximum roxadustat dose of 3.0 mg/kg or 400 mg, whichever is lower) every 4 weeks to maintain Hb levels at 10.0-12 grams (g)/deciliter (dL). However, if a participant, at any dose, experiences an event of excessive hematopoiesis then the participant's dose will be immediately reduced, or an event of rapidly declining Hb then the participant's dose will be immediately increased. Participants will be permitted to receive roxadustat for up to 8 years.
3087268|NCT01631071|Experimental|Elderly subjects aged over 60 years|
3087269|NCT01631071|Experimental|Adults from 18 to 60 years old inclusive|
3087270|NCT01631110|Experimental|Elderly subjects aged over 60 years|
3087271|NCT01631110|Experimental|Adults from 18 to 60 years old inclusive|
3087272|NCT01631149|Experimental|Deep surgical block|Continuous rocuronium infusion will be used to induce a deep surgical block with post tetanic twitch count of max 2. Rocuronium loading dose = 1.0 mg/kg, followed by 0.6-1.0 mg/kg per hour.
3087273|NCT01631149|Active Comparator|Moderate/normal surgical block|A normal block will be induced by an atracurium bolus dose followed by a mivacurium infusion to induce a train of four count of 1-2.
3087274|NCT01631188|Experimental|Aortic Valve Replacement|During surgery your doctor will utilize a new technique using surgical equipment that have already been FDA Approved for other indication. The combination of the equipment and technique will be experimental and will be closely evaluated during and after each case.
3087275|NCT01631214|Active Comparator|Alendronate/Alendronate|Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
3087276|NCT01631214|Experimental|Romosozumab/Alendronate|Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.
3087277|NCT01631227|Experimental|Eprosartan|Eprosartan + Placebo Eprosartan Mesylate
3087278|NCT01631227|Active Comparator|Eprosartan Mesylate|Eprosartan Mesylate + Placebo Eprosartan
3087279|NCT01631331|Experimental|Treatment (vismodegib and Mohs surgery)|Patients receive vismodegib PO daily for 3-6 months based on the size of basal cell carcinoma and then undergo Mohs surgery.
3087280|NCT01631435|Other|bowel prep regimen|Each study subject will undergo a bowel preparation followed by a PillCam procedure.
3087281|NCT01631474|Experimental|Low-dose active, BID|low dose of CB-03-01, 0.1% applied twice a day
3087282|NCT01631474|Experimental|Medium-dose active, BID|medium dose of CB-03-01, 0.5% applied twice a day
3087283|NCT01631474|Experimental|High-dose active, QD|high dose of CB-03-01, 1% applied once a day
3087284|NCT01631474|Experimental|High-dose active, BID|high dose of CB-03-01, 1% applied twice a day
3087285|NCT01631474|Placebo Comparator|Vehicle, QD or BID|vehicle cream, applied once or twice a day
3087286|NCT01631552|Experimental|Sacituzumab Govitecan-hziy (SG) 8 mg/kg|Participants will receive sacituzumab govitecan-hziy (SG) 8 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
3087287|NCT01631552|Experimental|SG 10 mg/kg|Participants will receive SG 10 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
3087288|NCT01631552|Experimental|SG 12 mg/kg|Participants will receive SG 12 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
3087289|NCT01631552|Experimental|SG 18 mg/kg|Participants will receive SG 18 mg/kg of body weight via intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until disease progression or unacceptable toxicity.
3087290|NCT01631630|Experimental|Pioglitazone|Subjects received pioglitazone, 15mg/day for 3 days; 30mg day for 3 days; 45mg/day thereafter, for a minimum total of 13 days
3087291|NCT01631630|Placebo Comparator|Placebo|Subjects received placebo on a similar dosing schedule, for a minimum total of 13 days
3087292|NCT01631656|Experimental|Azelaic Acid plus Laser|Azelaic acid 15% twice daily on half the face for 6 weeks, plus laser treatment with Nd:Yag laser once at 2 weeks.
3087293|NCT01631656|Active Comparator|Laser only|laser treatment on all face once at 2 weeks with no azelaic acid on one side of the face
3087294|NCT01631682|Active Comparator|Propranolol|a single dose of 40mg propranolol may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
3087295|NCT01631682|Active Comparator|Reactivation with time delay|For those not receiving propranolol on visit 2, one experimental CS will be reactivated, followed by a 10 minute break and subsequently extinction
3087296|NCT01631682|Experimental|Mifepristone|a single dose of 1800mg (200mg tablets) mifepristone may be given to begin visit 2, followed by 90min wait and subsequently CS reactivation
3087297|NCT01631682|Experimental|Intranasal oxytocin|A single 32IU dose of Syntocinon (intranasal oxytocin) is given to begin visit 2, followed by a 10 minute wait and subsequent CS reactivation.
3087298|NCT01631747|Active Comparator|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
3087299|NCT01631747|Experimental|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
3087300|NCT01631812|Experimental|SPM 962|
3087301|NCT01631825|Experimental|SPM 962|SPM 962 transdermal patch
3087302|NCT01631864|Experimental|LCZ696|LCZ696 400 mg plus placebo to amlodipine once daily for 8 weeks
3087303|NCT01631864|Active Comparator|amlodipine|amlodipine 10 mg plus placebo to LCZ696 once daily for 8 weeks
3087304|NCT01631929|Active Comparator|One bag|IV infusion of fluids, electrolytes and dextrose using one bag
3087305|NCT01631929|Experimental|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
3087306|NCT01632150|Experimental|Elotuzumab + Thalidomide + Dexamethasone + Cyclophosphamide|
3087307|NCT01632202|Active Comparator|Seprafilm Slurry|The investigators hypothesize that by placing a slurry of Seprafilm in the intrauterine cavity and creating a temporary physical barrier between the walls of the uterus, that we will be able to prevent iatrogenic intrauterine adhesions. Given that approximately 24 to 48 hours after placement, the membrane becomes a hydrated gel that is slowly resorbed within one week, we anticipate that the patient will have minimal to no discomfort; since no physical device is being left in the endometrial cavity, the uterus will not be contracting more than it does in its normal postoperative state.
3087308|NCT01632202|Placebo Comparator|Placebo|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
3087309|NCT01632215|Experimental|preoperative gabapentine,|Gabapentine
3087310|NCT01632215|Placebo Comparator|sugar pill|Placebo group
3087311|NCT01632241|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kilogram (kg) IV every 28 days for an additional 6 months.
3087312|NCT01632241|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3087313|NCT01632267||Depression and anxiety|Subjects with a primary diagnosis of depression or anxiety disorder.
3087314|NCT01632280|Active Comparator|Active tDCS|In this arm, participants will receive active tDCS (2mA, 20 min per session). The anode electrode will be placed over the right inferior frontal gyrus, defined as F8 (10-20 EEG system), with the cathode electrode placed over the contralateral supraorbital area, above the left eyebrow. During each session they will also perform a computerized task designed to engage the inhibitory control circuit when confronted with food stimuli.
3087315|NCT01632280|Sham Comparator|Sham tDCS|Participants will receive sham tDCS sessions with the same duration and electrode montage as in the real tDCS arm. In this case, current will be applied for 30 s only according to standard procedures, and participants will perform a control task where they will observe and provide responses for the same food and non-food pictures as in the active group task, but without requirement of inhibitory control for performance.
3087316|NCT01632306|Experimental|LY2090314 + Gemcitabine|LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
3087317|NCT01632306|Experimental|LY2090314 + FOLFOX|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
3087318|NCT01632306|Experimental|LY2090314 + Gemcitabine + Nab-paclitaxel|LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m^2 gemcitabine + 125 mg/m^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.
3087319|NCT01632345|Experimental|Doravirine 25 mg|Doravirine 25 mg + TRUVADA® Participants in this arm will receive doravirine 25 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3087320|NCT01632345|Experimental|Doravirine 50 mg|Doravirine 50 mg + TRUVADA® Participants in this arm will receive doravirine 50 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3087321|NCT01632345|Experimental|Doravirine 100 mg|Doravirine 100 mg + TRUVADA® Participants in this arm will receive doravirine 100 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3087322|NCT01632345|Experimental|Doravirine 200 mg|Doravirine 200 mg + TRUVADA® Participants in this arm will receive doravirine 200 mg in Part I and the selected doravirine dose (either 25 mg, 50 mg, 100 mg, or 200 mg) in Part II. These participants also receive placebo that matches efavirenz.
3087323|NCT01632345|Active Comparator|Efavirenz|Efavirenz + TRUVADA® Participants in this arm will receive efavirenz in Part I and in Part II. These participants also receive placebo that matches doravirine.
3087324|NCT01632423||POAG or OHT|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
3087325|NCT01632566|Placebo Comparator|Placebo|Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
3087326|NCT01632566|Experimental|LY3031207|Daily oral administration of 25 milligrams (mg) LY3031207 up to 450 mg LY3031207 for 28 days.
3087327|NCT01632566|Active Comparator|Celecoxib|Daily oral administration of 400 mg celecoxib for 28 days. Positive control for LY3031207.
3087328|NCT01632566|Other|LY3031207 + Simvastatin|Daily oral administration of 75 mg LY3031207 or 225 mg LY3031207 for 28 days. Single, oral 10 mg simvastatin open-label dose administered before and after 28-day dosing of LY3031207.
3087329|NCT01632579|Placebo Comparator|Placebo|Single dose of placebo administered orally on up to one occasion separated by at least a 3 week wash out period.
3087330|NCT01632579|Experimental|LY3023703|Up to 6 single escalating doses of LY3023703 [0.1 milligram (mg) up to 60 mg] administered orally on up to two occasions per participant separated by at least a 3 week wash out period.
3087331|NCT01632579|Active Comparator|400 mg Celecoxib|Positive control. Single 400 mg dose of celecoxib administered orally, open label, on one occasion separated by at least a 3 week washout period.
3087332|NCT01632683|Active Comparator|C-MAC|Providers will utilize the C-MAC video laryngoscope equipped with a D-blade to facilitate intubation
3087333|NCT01632683|Active Comparator|Glidescope|Providers will utilize the Glidescope video laryngoscope equipped with the #4 blade to facilitate intubation
3087334|NCT01632709|Active Comparator|Sympathetic nerve block of bupivacaine|Sympathetic nerve block of bupivacaine
3087335|NCT01632709|Placebo Comparator|Dry needling at the sympathetic ganglion|Placebo/ Dry needling at the sympathetic ganglion
3087336|NCT01632709|Active Comparator|Neuroma injection of bupivacaine|Neuroma injection of bupivacaine
3087337|NCT01632709|Placebo Comparator|dry needling at the neuroma|Placebo/ dry needling at the neuroma
3087338|NCT01632735|Experimental|Mobile Continuing Care|Behavioral: 12-week Structured Texting intervention focused on recovery monitoring, feedback for self-management, social support and education
3087339|NCT01632735|No Intervention|Standard Continuing Care as Usual|Continuing care as usual to 12-step facilitation (Anonymous group)
3087340|NCT01632800|Experimental|Single arm study|Each subjects will undergo escalating exposure to magnetic field
3087341|NCT01632878||Post Myocardial Infarction|One single cohort of Index post Myocardial Infarction patients
3087342|NCT01632891|Experimental|LPV/r-based ART|Participants were prescribed to LPV/r-based antiretroviral therapy (ART) for 15 days, which includes lopinavir/ritonavir plus emtricitabine/tenofovir disoproxil fumarate; followed by an nNRTI-based ART, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
3087343|NCT01632891|Experimental|nNRTI-based ART|Participants were prescribed to nNRTI-based ART for 15 days, which includes efavirenz, nevirapine, plus emtricitabine/tenofovir disoproxil fumarate, followed by an nNRTI-based ART and Trimethoprim/sulfamethoxazole prophylaxis to take from day 16 through day 30.
3087344|NCT01632904|Experimental|ruxolitinib and hydroxyurea (HU)-placebo|
3087345|NCT01632904|Active Comparator|HU and ruxolitinib-placebo|
3087346|NCT01632995|Experimental|Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
3087347|NCT01633060|Experimental|BKM120 100mg + Fulvestrant|BKM120 100 mg per day and fulvestrant given until progression or as described in the protocol.
3087348|NCT01633060|Placebo Comparator|Placebo + Fulvestrant|BKM120 matching placebo daily and fulvestrant given until progression or as described in the protocol.
3087349|NCT01633112|Experimental|fingolimod 0.5 mg|orally once daily
3087350|NCT01633112|Experimental|fingolimod 0.25mg|orally once daily
3087351|NCT01633112|Active Comparator|glatiramer acetate 20 mg|subcutaneous once daily
3087352|NCT01633788|Experimental|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
3087353|NCT01633788|Experimental|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
3087354|NCT01633788|Experimental|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
3087355|NCT01633788|Placebo Comparator|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
3087356|NCT01633827|Placebo Comparator|Placebo|Subjects will receive both a sugar pill and room air during their overnight sleep studies
3087357|NCT01633827|Active Comparator|Treatment|Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies
3087358|NCT01633853|Experimental|Vitamin D2 Treatment|Patients will be treated by vitamin D2. Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
3087359|NCT01633853|Active Comparator|1,25(OH)2 Vitamin D3|Patients will be treated by 1,25(OH)2 Vitamin D3. Oral 1,25(OH)2 Vitamin D3(Rocaltrol) by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
3087360|NCT01633892|Experimental|Fat Grafting|
3087361|NCT01633944|Placebo Comparator|Placebo|Twice Daily Dosing
3087362|NCT01633944|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
3087363|NCT01634048|Experimental|High protein low calorie meal replacements|Meal replacements with added protein powder(1.34g pro/kg).
3087364|NCT01634048|Sham Comparator|Normal protein, low calorie meal replacement group|The control group will have standard meal replacements (0.8g protein/kg body weight).
3087365|NCT01634100|Experimental|A (Reference)|Empagliflozin (BI 10773), Film-coated tablet, single dose
3087366|NCT01634100|Experimental|B (Test 1)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Rifampicin,Film-coated tablet single dose
3087367|NCT01634100|Experimental|C (Test 2)|Empagliflozin (BI 10773), Film-coated tablet, single dose, and Probenecid Tablet twice daily
3087368|NCT01634113|Experimental|tiotropium low dose|Once daily, delivered with Respimat® inhaler
3087369|NCT01634113|Experimental|tiotropium high dose|Once daily, delivered with Respimat® inhaler
3087370|NCT01634113|Placebo Comparator|placebo|Once daily, delivered with Respimat® inhaler
3087371|NCT01634139|Experimental|Tiotropium high dose QD|
3087372|NCT01634139|Experimental|Tiotropium low dose QD|
3087373|NCT01634139|Experimental|Placebo QD|
3087374|NCT01634152|Placebo Comparator|Placebo QD|
3087375|NCT01634152|Experimental|Tiotropium low dose QD|
3087376|NCT01634152|Experimental|Tiotropium medium dose QD|
3087377|NCT01634165|Experimental|0.3 U/kg LY2963016|Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
3087378|NCT01634165|Experimental|0.3 U/kg Lantus|Single 0.3 U/kg subcutaneous dose of Lantus
3087379|NCT01634165|Experimental|0.6 U/kg LY2963016|Single 0.6 U/kg subcutaneous dose of LY2963016
3087380|NCT01634165|Experimental|0.6 U/kg Lantus|Single 0.6 U/kg subcutaneous dose of Lantus
3087381|NCT01634178|Experimental|Sequence 1: Apremilast Fasted / Fed|In Period 1 participants will receive a single 30 mg apremilast tablet administered under fasted conditions and in Period 2 participants will receive a single 30 mg apremilast tablet administered after a high fat meal.
3087382|NCT01634178|Experimental|Sequence 2: Apremilast Fed / Fasted|In Period 1 participants will receive a single 30 mg apremilast tablet administered after a high fat meal and in Period 2 participants will receive a single 30 mg apremilast tablet administered under fasted conditions.
3087383|NCT01634191|Experimental|Elderly: Apremilast 30 mg|Participants aged 65 to 85 years received a single oral dose of 30 mg apremilast on Day 1.
3087384|NCT01634191|Experimental|Younger: Apremilast 30 mg|Participants aged 18 to 55 years received a single oral dose of 30 mg apremilast on Day 1.
3087385|NCT01634243|Experimental|SPM 962|SPM 962 transdermal patch
3087386|NCT01634256|Experimental|Fermented turmeric|
3087387|NCT01634256|Placebo Comparator|Placebo|
3087388|NCT01634269|Experimental|MDT-2111 TAVI 23 mm|Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
3087389|NCT01634360|Experimental|Perampanel (1-4 mg)|Subjects entered this open-label extension study from the double-blind core study (E2007-E044-204), and dosed placebo or perampanel. Subjects started this open-label extension study on perampanel 1 mg once daily for two weeks, followed by 2 mg once daily for two weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
3087390|NCT01634555|Experimental|ramucirumab (IMC-1121B) and FOLFIRI|Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
3087391|NCT01634620||FeNO|Participants with chronic obstructive pulmonary disease (COPD) will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
3087392|NCT01634659|Other|Delefilcon A, then narafilcon B|Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
3087393|NCT01634659|Other|Narafilcon B, then delefilcon A|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
3087394|NCT01634854|Active Comparator|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
3087395|NCT01634854|Active Comparator|Intravenous Oxytocin|"2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
3087396|NCT01635062|Experimental|calcitriol|Subjects will receive calcitriol (titrated up to 0.75 mcg daily) for 3 weeks.
3087397|NCT01635062|Placebo Comparator|placebo|Subjects will receive placebo for 3 weeks.
3087398|NCT01635101|Experimental|Low Dose Acetaminophen|Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours
3087399|NCT01635101|Experimental|High Dose Acetaminophen|Participants receive a low dose of acetaminophen (IV) for 24 hours
3087400|NCT01635101|Placebo Comparator|Placebo|Participants receive matching placebo (IV) for 24 hours
3087401|NCT01635153|Active Comparator|Protein calorie supplement plus micronutrient|
3087402|NCT01635153|Placebo Comparator|Micronutrient alone|
3087403|NCT01635218|Experimental|Individualized homeopathic treatment|Selection of the individualized homeopathic remedy based on Hahnemann´s methodology after the case history of each patient.
3087404|NCT01635218|Experimental|Fluoxetine|Selective serotonin reuptake inhibitor.
3087405|NCT01635218|Placebo Comparator|Placebo|Fluoxetine placebo plus individualized homeopathic placebo
3087406|NCT01635244|Active Comparator|Freestyle|Aortic valve replacement will be performed with a Freestyle stentless aortic bioprosthesis (Medtronic Cardiovascular; Minneapolis, MN).
3087407|NCT01635244|Active Comparator|Magna Ease|Aortic valve replacement will be performed with a Magna Ease aortic bioprosthesis (Edwards Lifesciences; Irvine, CA).
3087408|NCT01635244|Active Comparator|Trifecta|Aortic valve replacement will be performed with a Trifecta aortic bioprosthesis (St. Jude Medical; St. Paul, MN).
3087409|NCT01635283|Experimental|Treatment (tumor lysate-pulsed autologous dendritic cells)|Patients receive autologous glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 0, 14, and 28.
3087410|NCT01635439|Active Comparator|Propess|Propess insert is a preparation of PGE2 packaged in a hydrogel polymer matrix and designed for slow intravaginal release of 10 mg dinoprostone at a rate of 0.3 mg/h.
3087411|NCT01635439|Active Comparator|Prostin E2|PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2)3 mg/suppository.
3087412|NCT01635504|Experimental|botulinum toxin A|
3087413|NCT01635764|Experimental|Adalimumab Every Week|Adalimumab 40 mg every week.
3087414|NCT01635855|Experimental|Belotero|Belotero® Hyaluronic acid dermal filler
3087415|NCT01635881|Experimental|Emerge|Single arm with investigational Emerge™ 1.20 mm PTCA Dilatation Catheter
3087416|NCT01635920|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
3087417|NCT01635920|Active Comparator|AIR OPTIX® AQUA|Lotrafilcon B contact lens worn bilaterally for a minimum of 5 days per week, 8 hours per day, in daily wear modality for 4 weeks.
3087418|NCT01635933|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn in daily wear modality for 4 weeks. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3087419|NCT01635933|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn in daily wear modality for 4 weeks, with a replacement pair dispensed at 14 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3087420|NCT01635998|Experimental|Intervention arm|These subjects will undergo routine catheter ablation of atrial fibrillation PLUS renal sympathetic denervation with the Boston Scientific Vessix Renal Denervation System.
3087421|NCT01635998|No Intervention|Control arm|These subjects will undergo routine catheter ablation of atrial fibrillation only.
3087422|NCT01636063|Experimental|Mifepristone|Subjects will receive 200 mg of capsulized mifepristone orally for the purpose of cervical preparation before surgical abortion
3087423|NCT01636063|Active Comparator|Misoprostol|Subjects will receive 400 mcg of buccal misoprostol for the purposes of cervical preparation.
3087424|NCT01636076|Experimental|QMF149|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 µg o.d. delivered via Concept1 device
3087425|NCT01636076|Active Comparator|Salmeterol xinafoate/fluticasone propionate|Salmeterol xinafoate/fluticasone propionate 50/500 µg b.i.d, delivered via Accuhaler®
3087426|NCT01636102|Experimental|Arm 1|
3087427|NCT01636206|Placebo Comparator|Placebo|Placebo
3087428|NCT01636206|Experimental|Lifitegrast|Active
3087429|NCT01636258|No Intervention|Arm A: Control group|These participants will continue to receive their usual care from their primary medical care team.
3087430|NCT01636258|Experimental|Arm B|Arm includes diet instruction, exercise, stress management, and culinary education
3087431|NCT01636284|Experimental|JX-594 recombinant vaccina GM-CSF|JX-594 recombinant vaccina GM-CSF
3087432|NCT01636297|Experimental|Forced exercise|Exercise on stationary cycle that was controlled by a motor to augment voluntary cycling rate by 35%
3087433|NCT01636297|Experimental|Voluntary Exercise|Exercise on a stationary cycle without motor assistance
3087434|NCT01636297|No Intervention|No Exercise|Participants received no exercise intervention and served as the control group
3087435|NCT01636362|Experimental|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
3087436|NCT01636414|Active Comparator|Hemovac drain|
3087437|NCT01636414|Active Comparator|Re-infusion drain|
3087438|NCT01636414|Active Comparator|Tranexamic drain|
3087439|NCT01636453|Experimental|Liberty Stent arm|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
3087440|NCT01636661|Experimental|Transcranial Direct Current Stimulation|Receiving active tDCS
3087441|NCT01636661|Sham Comparator|Sham tDCS|tDCS equipment set to placebo setting.
3087442|NCT01636687|Placebo Comparator|Placebo|Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
3087443|NCT01636687|Experimental|Secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
3087444|NCT01636687|Experimental|Secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.
3087445|NCT01636713|Experimental|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
3087446|NCT01636713|Experimental|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
3087447|NCT01636713|Placebo Comparator|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
3087448|NCT01636765||All participants|Patients with facial erythema associated with rosacea. There was no intervention in this study.
3087449|NCT01636778|Experimental|SB-497115-GR|investigational product for thrombocytopenia
3087450|NCT01636882|Experimental|CVA21|Dose of CAVATAK up to 3 x 10⁸ TCID50 for an additional 9 treatments at 3-week intervals
3087451|NCT01636934|Experimental|Minocycline|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Minocycline 100 mg capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
3087452|NCT01636934|Placebo Comparator|Placebo|Two-arm, placebo-controlled pilot study to obtain preliminary estimates of treatment effects of minocycline in patients with non small cell lung cancer (NSCLC) being consented for concurrent chemoradiation (CXRT). Placebo capsules taken by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy. Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
3087453|NCT01636947|Experimental|Aprepitant Regimen|Participants receive one aprepitant 125 mg capsule by mouth (PO) once daily (QD) on Day 1 and one aprepitant 80 mg capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg intravenously (IV) QD and dexamethasone 12 mg PO on Day 1 and placebo for ondansetron 8 mg PO twice daily (BID) on Days 2 and 3.
3087454|NCT01636947|Active Comparator|Control Regimen|Participants receive one placebo capsule PO QD on Day 1 and one placebo capsule PO QD on Days 2 and 3 of Cycle 1. Participants also receive ondansetron 16 mg IV QD and dexamethasone 20 mg PO on Day 1 and ondansetron 8 mg PO BID on Days 2 and 3.
3087455|NCT01636960|Experimental|Participants receiving PegIFN alfa-2b|Participants receive PegIFN alfa-2b 6 µg/kg subcutaneously (SC) on Day 1 of each week for 8 weeks (Induction) and then 3 µg/kg SC once weekly for up to 252 weeks (Maintenance).
3087456|NCT01636986|Experimental|DT1|Delefilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
3087457|NCT01636986|Active Comparator|1DAVM|Etafilcon A contact lenses worn bilaterally on a daily wear, daily disposable basis for 4 weeks
3087458|NCT01637077|Experimental|Arm I (pain therapy)|Patients receive pregabalin PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
3087459|NCT01637077|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID, beginning on the first night of chemotherapy, for 12 weeks and then QD for 1 week.
3087460|NCT01637090|Experimental|all patients on study|"This will be a prospective, phase II non-randomized, open label study of single agent everolimus for the treatment of CTCL recurrent or refractory to at least one previous treatment other than topical medication. The purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations and assessment of tumor burden in tissue and blood.~This study will be conducted in 2 stages. During stage 1 we will enroll a maximum of 11 subjects to evaluate response rate and will only continue to stage 2, if we observe two or more responses. During stage 2, we will expand the study to an overall N of 28 patients."
3087461|NCT01637142|Experimental|LY2140023 + [14C]-LY2140023|Treatment Period 1: On Day 1, a single oral dose of 80 milligrams (mg) LY2140023 (parent compound) followed by a single 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) [14C]-LY2140023.
3087462|NCT01637142|Experimental|LY2140023 + [14C]-LY404039|Treatment Period 2: On Day 1, a single oral dose of 80 mg LY2140023 (parent compound) followed by a single 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi [14C]-LY404039 (active metabolite).
3087463|NCT01637246||POAG or OHT|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy
3087464|NCT01637272|Experimental|SOM230|Subjects with dumping syndrome treated with pasireotide
3087465|NCT01637402|Experimental|Standard Dose|1000 milligrams (mg) abiraterone acetate in combination with prednisone taken once a day until progression defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
3087466|NCT01637402|Experimental|Escalated Dose|Participants who progressed on the standard dose will be assigned 1000 milligrams (mg) abiraterone acetate in combination with prednisone taken twice a day for at least 12 weeks until progression as defined by RECIST criteria OR by the Prostate Cancer Working Group 2 (PCWG) criteria
3087467|NCT01637584|Experimental|Prazosin|Active medication arm. Prazosin is an FDA approved medication, originally designed as an anti-hypertension medication. Side effects of the medication in some include sleepiness and once asleep, sustained sleep.
3087468|NCT01637584|Placebo Comparator|Placebo|A placebo is a sugar pill, which will be used to compare with the results of the active medication
3087469|NCT01637623|Active Comparator|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic and blood pressure within range.
3087470|NCT01637623|Active Comparator|Allopurinol|Allopurinol 300 mg daily for 6 weeks
3087471|NCT01637623|Placebo Comparator|Placebo|Placebo capsule daily for 6 weeks
3087472|NCT01637870|Experimental|Negative pressure pump|Will have the Prevena negative pressure wound system placed at the time of surgery.
3087473|NCT01637922|Active Comparator|Methadone group|patients on stable methadone therapy (at least 30 days) up to a maximum of 180mg per day
3087474|NCT01637922|Active Comparator|Buprenorphine|patients on stable buprenorphine/naloxone therapy (at least 30 days) up to a maximum dose of 24mg/6mg per day.
3087475|NCT01637935||Pioglitazone exposed group|Defined as those patients having filled at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone group may also have exposure to other diabetic medications
3087476|NCT01637935||Pioglitazone unexposed group|Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
3087477|NCT01637961|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3087478|NCT01638000|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once daily for 12 weeks.
3087479|NCT01638000|Active Comparator|Solifenacin 5 mg|Participants who received solifenacin 5 mg once daily for 12 weeks.
3087480|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ1|Participants who completed 015K-CL-RAJ1 (NCT02305849) study and met eligible criteria received starting dose of 50 milligrams (mg) peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
3087481|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ3|Participants who completed 015K-CL-RAJ3 (NCT02308163) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
3087482|NCT01638013|Experimental|Participants who completed 015K-CL-RAJ4|Participants who completed 015K-CL-RAJ4 (NCT02305849) study and met eligible criteria received 100mg peficitinib tablet orally once daily after breakfast. Dose can be increased to 100mg or 150mg, and decreased to 50mg. For participants who did not have any safety problem, the dose was increased from 50 mg to 100 mg. For participants who did not have any safety problems, and confirmed a lack of clinical response (DAS28-ESR >= 3.2 after 4 weeks of peficitinib treatment), dose was increased to 150mg. The treatment was given in this study up to 6 months after peficitinib was approved.
3087483|NCT01638052|No Intervention|0.25% Bupivacaine|This is our standard of care concentration
3087484|NCT01638052|Experimental|0.25% Bupivacaine + Clonidine|These are not two separate drugs, but a mixture of Bupivacaine and Clonidine.
3087485|NCT01638312||HIV infection patient and health people|The study does not have intervention
3087486|NCT01638390|Other|Treatment of Myopia|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
3087487|NCT01638416|Active Comparator|Standard of care|Blood Transfusion Standard of care- oldest blood.
3087488|NCT01638416|Other|Arm B|Blood Transfusion Freshest blood.
3087489|NCT01638429|Experimental|Obese/overweight, prediabetic methane positive|Neomycin Rifaximin
3087490|NCT01638468|Experimental|AngioJet Ultra PE Thrombectomy System|Patients are treated with the AngioJet Ultra PE Thrombectomy System
3087491|NCT01638507|Other|Resolute Integrity|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (Resolute Integrity Stent)
3087492|NCT01638546|Experimental|Arm I (veliparib and temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO on days 1-5.
3087493|NCT01638546|Active Comparator|Arm II (placebo and temozolomide)|Patients receive placebo PO BID on days 1-7 and temozolomide as in Arm I.
3087494|NCT01638559|Experimental|Immunosuppression withdrawal|Gradual withdrawal of immunosuppressive treatment withdrawal as per protocol.
3087495|NCT01638819|Experimental|Autologous Cord Blood Stem Cells|
3087496|NCT01638819|Placebo Comparator|Placebo|Saline
3087497|NCT01639001|Experimental|Crizotinib|Crizotinib
3087498|NCT01639001|Active Comparator|Chemotherapy|Chemotherapy [Option at Investigator's Choice]
3087499|NCT01639040|Experimental|Placebo QW|Placebo (for Dupilumab) once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent topical corticosteroid (TCS) for up to 28 days
3087500|NCT01639040|Experimental|Dupilumab 300 mg QW|Dupilumab 300 mg once weekly (QW) for 4 weeks by subcutaneous injection with the background therapy of potent TCS for up to 28 days
3087501|NCT01639144|Active Comparator|Receiving PRP and PPP.|Administration of PRP and PPP to surgical site.
3087502|NCT01639144|No Intervention|Control|Group not receiving autogenous PRP and PPP.
3087503|NCT01639157|Experimental|Buspirone|Subjects will be maintained on 30 mg buspirone daily.
3087504|NCT01639157|Placebo Comparator|Placebo|Subjects will be maintained on placebo (i.e., 0 mg buspirone daily).
3087505|NCT01639222|Experimental|Calcium 500 mg and Vitamin D3 800 IU|"Period 1: Low calcium meals for up to 3 days.~Period 2: Calcium 500 mg and Vitamin D3 800 IU chewable tablets, orally, once daily for up to 3 days with low calcium meals."
3087506|NCT01639339|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, placebo patients who opt to participate will receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3087507|NCT01639339|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 100, with a final evaluation at Week 104 in the double-blind period. In the open-label extension period, patients who opt to participate will continue to receive belimumab 10 mg/kg IV every 28 days for an additional 6 months.
3087508|NCT01639352|Experimental|SOM230|60mg of SOM230 via injection intramuscularly every 28 days
3087509|NCT01639443|Experimental|Fast-tracked|"'Predictive no-show overbooking' intervention. Patients who volunteer to enroll in fast-track line, which gives them an opportunity to overbook their appointment for endoscopy earlier in a predictive no-show slots."
3087510|NCT01639443|No Intervention|Control|Patients who are scheduled routinely
3087511|NCT01639469|Experimental|Structured exercise|Structured exercise instruction by smartphone
3087512|NCT01639469|Active Comparator|lifestyle exercise|Lifestyle exercise program taught via smartphone
3087513|NCT01639495|Experimental|THERMOCOOL® SMARTTOUCH™ Catheter|
3087514|NCT01639560|Active Comparator|Varenicline|1 mg of varenicline twice per day for 12 weeks.
3087515|NCT01639560|Placebo Comparator|placebo|1 placebo tablet twice a day for 12 weeks
3087516|NCT01639599|Placebo Comparator|dexamethasone|dexamethasone 5mg iv during anesthesia induction
3087517|NCT01639599|Active Comparator|dexamethasone, haloperiol 1mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 1mg iv 30 min before end of anesthesia
3087518|NCT01639599|Active Comparator|dexamethasone + haloperidol 2mg|dexamethasone 5mg iv during anesthesia induction & haloperidol 2mg iv 30 min before end of anesthesia
3087519|NCT01639664|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
3087520|NCT01639664|No Intervention|Control group|standard practice
3087521|NCT01639703|Experimental|CT perfusion|arm with CT perfusion
3087522|NCT01639729|Experimental|Sequence 1 - Treatment A, B, C, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral
3087523|NCT01639729|Experimental|Sequence 2 - Treatment A, B, D, C|15 mcg: IV, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral,Sufentanil NanoTab Buccal
3087524|NCT01639729|Experimental|Sequence 3 - Treatment A, C, B, D|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Oral
3087525|NCT01639729|Experimental|Sequence 4 - Treatment A, C, D, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Buccal, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual
3087526|NCT01639729|Experimental|Sequence 5 - Treatment A, D, B, C|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Sublingual, Sufentanil NanoTab Buccal
3087527|NCT01639729|Experimental|Sequence 6 - Treatment A, D, C, B|15 mcg: Sufentanil IV, Sufentanil NanoTab Oral, Sufentanil NanoTab Buccal, Sufentanil NanoTab Sublingual
3087528|NCT01639742|Experimental|All Participants|All participants who had new texture round breast implants surgically implanted.
3087529|NCT01639755|Experimental|All Participants|Al participants who had new texture shaped breast implants surgically implanted.
3087530|NCT01639833|Experimental|Veriset Hemostatic Patch|Topical Hemostat
3087531|NCT01639833|Active Comparator|TachoSil®|Topical Hemostat
3087532|NCT01639872|Experimental|Clozapine|The blinded CLOZ will be titrated on a recommended standard schedule, supervised by a study physician (or other prescriber) who can make the necessary adjustments to account for symptom control and tolerability. The titration is recommended to begin at 12.5 mg and then increase while the open-label base antipsychotic is tapered with a recommended goal of decreasing the base antipsychotic by 25% each week. If clinically tolerated, the target dose of CLOZ is 400 mg/day.
3321130|NCT02016469|Active Comparator|give pectin 20g/d|pure give pectin 20g/d for five days
3321131|NCT02016495|Active Comparator|Magnesium + Lipoic Acid|
3087533|NCT01639872|Active Comparator|Risperidone|The blinded RISP will also be titrated in the first weeks, using a titration schedule, with a target dose of 4 mg/day, while the open label base antipsychotic is tapered in a similar fashion.
3087534|NCT01640054|Experimental|Dosing regimen|Open label Oral treatment 100mg once daily
3087535|NCT01640171|Other|Top Anesthesia 1 Eye SC Lidocaine 1 Eye|"One eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Acuvail Intra-vitreal Anti-VEGF Drug~Fellow Eye:~Proparacaine Hydrochloride 0.5% Drop Tetravisc 0.5% Gel Xylocaine 2% Injectable Anesthetic Acuvail Intra-vitreal Anti-VEGF Drug"
3087536|NCT01640184|Active Comparator|Active vitamin D|Patients in oral medicine group will be treated by active vitamin D and other general treatments according to the suggestions in Kidney Developement Improvement Global Outcomes (KDIGO) guidelines.
3087537|NCT01640184|Experimental|Ultrasonic ablation|Patients in Ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequency ablation.
3087538|NCT01640184|Active Comparator|Parathyroidectomy|Patients in parathyroidectomy group will be treated by parathyroid surgery.
3087539|NCT01640197|Placebo Comparator|Placebo|Methyl Cellulose administered in identical capsules as the active.
3087540|NCT01640197|Active Comparator|500mg resveratrol|Transmax from biotivia. 500mg resveratrol (98% purity) with 10mg piperine per capsule. 1 capsule taken daily.
3087541|NCT01640249|Placebo Comparator|Placebo|Participants received placebo capsule orally with approximately 200 to 300 milliliter (mL) of room temperature water in the morning.
3087542|NCT01640249|Experimental|LY3006072|Participants received LY3006072 capsules starting at 1 milligram (mg) and escalating doses of 3 mg, 10 mg, 20 mg and 40 mg.
3087543|NCT01640288|Other|Normal Subjects|Subjects with Normal Lung Function by Pulmonary Function Tests (e.g. Spirometry) with or without smoking as a risk factor (non-smokers, ex-smokers, current smokers)
3087544|NCT01640288|Other|Subjects with COPD|Subjects diagnosed with COPD by GOLD criteria.
3087545|NCT01640314|Experimental|Cell derived subunit trivalent nonadjuvanted vaccine|
3087546|NCT01640327|Experimental|TIVf|
3087547|NCT01640340|Experimental|Arm I (palonosetron hydrochloride)|Patients receive palonosetron hydrochloride IV 30 minutes prior to chemotherapy on day 1, aprepitant PO (by mouth) 60 minutes prior to chemotherapy on days 1-3, and dexamethasone PO 30 minutes prior to chemotherapy on days 1-4.
3087548|NCT01640340|Experimental|Arm II (ondansetron)|Patients receive ondansetron PO 30 minutes prior to chemotherapy on day 1 and aprepitant and dexamethasone as in Arm I.
3087549|NCT01640366|Experimental|PICO negative pressure|Single-use Negative Pressure Wound Therapy
3087550|NCT01640366|No Intervention|Standard of care dressing arm|Sterile gauze adhesive strips
3087551|NCT01640379|Experimental|TECH-N|Participants receive the Technology Enhanced Community Health Nursing Visit (CHN) within 5 days during which Sister to Sister and clinical assessment performed and text-messaging support
3087552|NCT01640379|No Intervention|Control|Participants receive enhanced standard of care
3087553|NCT01640548||Cohort|
3087554|NCT01640808|Experimental|NIK-333(peretinoin)|
3087555|NCT01640808|Placebo Comparator|Placebo|
3087556|NCT01640834|Experimental|100 mg LY2409021|"LY2409021: 100 milligrams (mg), 1 capsule, administered as a single oral dose on Day 2.~Placebo: 2 capsules, administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
3087557|NCT01640834|Experimental|300 mg LY2409021|"LY2409021: 300 milligrams (mg), 3 capsules (3 X 100-mg capsules), administered as a single oral dose on Day 2.~Glucagon: 1 mg administered via intramuscular injection on Day 3."
3087558|NCT01640834|Placebo Comparator|Placebo|"Placebo: 3 capsules administered as a single oral dose on Day 2.~Glucagon: 1 milligram (mg) administered via intramuscular injection on Day 3."
3087559|NCT01640873|Experimental|MK-8655 80 mg/MK-8655 320 mg|Participants received a single dose of MK-8655, 80 mg on Day 1 and then MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
3087560|NCT01640873|Placebo Comparator|Placebo|Participants received a single dose of placebo to MK-8655, 80 mg on Day 1 and then placebo to MK-8655 320 mg, once daily, starting on Day 3 for 14 consecutive days.
3087561|NCT01640925|Active Comparator|Chlorhexidine gluconate bathing|Upon study enrollment, patients will be bathed with a 2% chlorhexidine gluconate solution on study day 1 and every 48 hours until study completion. The patient will be bathed using standard bathing (non-medicated cloths or soap and water) on study day 2 and every 48 hours after that.
3087562|NCT01640925|Placebo Comparator|Standard bathing|Upon study enrollment, patients will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
3087563|NCT01640951|Experimental|AIN457 150 mg - Fixed Interval (FI)|1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
3087564|NCT01640951|Experimental|AIN457 150 mg - Start of relapse (SoR)|"Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
3087565|NCT01640951|Experimental|AIN457 300 mg - Fixed Interval (FI)|2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
3087566|NCT01640951|Experimental|AIN457 300 mg - Start of Relapse (SoR)|"Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks"
3087567|NCT01640951|Experimental|AIN457 300 mg - Open Label (OL)|Open Label - Secukinumab 300mg every 4 weeks
3087568|NCT01640964|Experimental|Part A: Terlipressin acetate|Patients received terlipressin acetate 2 mg intravenous (IV) bolus injection.
3087569|NCT01640964|Experimental|Part A: Serelaxin (RLX030)|Randomized patients received an intravenous serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min.; duration of infusion depends on time required for completion of magnetic resonance angiography (MRA) data acquisition
3087570|NCT01640964|Experimental|Part B Serelaxin (RLX030)|The patients enrolled in this part of the study received an intravenous (iv) serelaxin infusion at two different infusion rates: 80 μg/kg/day for 60 min followed by 30 μg/kg/day for at least 60 min; duration of infusion depends on time required for completion of Portal pressure gradient (PPG) data acquisition.
3087571|NCT01641042|Experimental|Healthy Group|The subjects in the Healthy group will be age-matched to the subjects in the At-risk group. Subjects will receive 2 doses of the investigational vaccine.
3087572|NCT01641042|Experimental|At-risk Group|This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
3087573|NCT01641081|Experimental|Experimental 1|Formoterol Fumarate in the Pressair Pressair Dry Powder Inhaler (DPI), Low Dose
3087574|NCT01641081|Experimental|Experimental 2|Formoterol fumarate in the Pressair Dry Powder Inhaler (DPI), High Dose
3087575|NCT01641081|Active Comparator|Active Comparator 1|Foradil Aerolizer, Low Dose
3087576|NCT01641081|Active Comparator|Active Comparator 2|Foradil Aerolizer, High Dose
3087577|NCT01641081|Placebo Comparator|Placebo|Dose matched placebo
3087578|NCT01641120|Experimental|30 gauge|Subjects used a 30 gauge needle for intramuscular injection of Avonex.
3087579|NCT01641120|Experimental|25 gauge|Subjects used a 25 gauge needle for intramuscular injection of Avonex.
3087580|NCT01641133|Active Comparator|Synflorix Group|Subjects who were primed with two doses of Synflorix vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
3087581|NCT01641133|Experimental|Prevnar 1 Group|Subjects who were primed with Prevnar 13 and Synflorix vaccines, administered intramuscularly into the right or left thigh, at 2 and 4 months of age respectively, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left thigh or in the deltoid, at 12-15 months of age.
3087582|NCT01641133|Experimental|Prevnar 2 Group|Subjects who were primed with two doses of Prevnar 13 vaccine, administered intramuscularly into the right or left thigh, at 2 and 4 months of age, received a booster dose of Synflorix vaccine, administered intramuscularly into the right or left anterolateral thigh or in the deltoid, at 12-15 months of age.
3087583|NCT01641159|Active Comparator|Buspirone plus TAU|Buspirone titrated to 60 mg/day for the 15-week active study
3087584|NCT01641159|Placebo Comparator|Placebo plus TAU|Placebo taken daily for the 15-week active study
3087585|NCT01641198|Active Comparator|Configuration 1|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at two sites, SC (Screw-Vent) at one site
3087586|NCT01641198|Experimental|Configuration 2|Device placement: B (Brånemark) at one site, SW (Swede-Vent) at two sites, SC (Screw-Vent) at two sites
3087587|NCT01641198|Experimental|Configuration 3|Device placement: B (Brånemark) at two sites, SW (Swede-Vent) at one site, SC (Screw-Vent) at two sites
3087588|NCT01641237|Experimental|Low ppm fluoride dentifrice|Low ppm fluoride as sodium fluoride in a silica base dentifrice
3087589|NCT01641237|Experimental|Medium ppm fluoride dentifrice|Medium ppm fluoride as sodium fluoride in a silica base dentifrice
3087590|NCT01641237|Experimental|High ppm fluoride dentifrice|High ppm fluoride as sodium fluoride in a silica base dentifrice
3087591|NCT01641237|Placebo Comparator|No fluoride dentifrice|no added fluoride in a silica base dentifrice
3087592|NCT01641367|Experimental|Cohort A|"Under Protocol version 1.0:~No resistance to NRTIs, PIs, or NNRTI~• Continue current second-line regimen; NRTIs could be modified~Changed under LOA#2 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue second-line regimen which may include LPV/RTV; NRTIs could be modified~Changed under LOA#3 to:~No LPV/RTV resistance and susceptible to at least one NRTI, regardless of NNRTI resistance or prior RAL exposure~• Continue PI backbone; NRTIs could be modified. If on a RAL-containing regimen, RAL must be discontinued."
3087593|NCT01641367|Experimental|Sub-cohort B1|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• Best available NRTIs, RAL, & DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• Best available NRTIs, RAL, & DRV/RTV"
3087594|NCT01641367|Experimental|Sub-cohort B2|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and without active hepatitis B infection at screening~• ETR, RAL, and DRV/RTV~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (and without active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (and without active hepatitis B infection at screening)~• ETR, RAL, and DRV/RTV"
3087595|NCT01641367|Experimental|Sub-cohort B3|"Under Protocol version 1.0:~Susceptible to DRV/RTV and ETR with or without resistance to NRTIs (and may have resistance to other PIs) and with active hepatitis B infection at screening~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC~Changed under LOA#2 to:~Resistance to LPV/RTV but susceptible to DRV/RTV and ETR and with no prior RAL exposure and regardless of NRTI resistance (with active hepatitis B infection at screening) OR Resistance to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and ETR and with no prior RAL exposure (with active hepatitis B infection at screening)~• RAL, DRV/RTV, and FTC/TDF or TDF+3TC"
3087596|NCT01641367|Experimental|Cohort C|"Under Protocol version 1.0:~Resistance to NRTIs and ETR or resistance to ETR alone (and may have resistance to PIs other than DRV)~• Best available NRTIs, RAL, and DRV/RTV~Changed under LOA#2:~Resistance to LPV/RTV and ETR but susceptible to DRV/RTV and with no prior RAL exposure and regardless of NRTI resistance OR Resistance to ETR and to all NRTIs (i.e. susceptible to none) but susceptible to DRV/RTV and with no prior RAL exposure~• Best available NRTIs, RAL, and DRV/RTV"
3087597|NCT01641367|Experimental|Cohort D|"Under Protocol version 1.0:~Multiple NRTI resistance and/or DRV/RTV resistance or prior RAL exposure:~• Best available regimen, including study-provided and any locally available drugs~Changed under LOA#2:~Not eligible for Cohort A, B, or C:~• Best available regimen, including study-provided and any locally available drugs~Updated under protocol v2.0:~• Best available ART regimen, including study-provided and any locally available non-experimental drugs"
3087598|NCT01641380|No Intervention|Control|Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment.
3087599|NCT01641380|Experimental|Text Messaging Intervention|Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication.
3087600|NCT01641445|Active Comparator|Topiramate|Topiramate (200 mg) taken orally daily
3087601|NCT01641445|Placebo Comparator|Sugar pill|"Placebo (sugar pill) taken orally daily"
3087602|NCT01641471|Experimental|Active TENS|Active TENS (EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using the TENS unit immediately following surgery and continuing throughout the 6 weeks postoperatively.
3087603|NCT01641471|Placebo Comparator|Placebo TENS|Placebo TENS (Placebo EMPI Select TENS) in combination with a femoral nerve catheter. Patients will begin using a sham TENS unit (appears identical to Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation) immediately following surgery and continuing throughout the 6 weeks postoperatively.
3087604|NCT01641640|Experimental|Sofosbuvir+PEG+RBV|
3087605|NCT01641653|Placebo Comparator|placebo|half of the patients will receive placebo (normal saline 2cc/) prior to entering the OR
3087606|NCT01641653|Active Comparator|Midazolam|half of the patients will receive Midazolam 1-2.5mg prior to entering the OR
3087607|NCT01641692|Experimental|GSK573719 15.6 mcg|GSK573719 (Umeclinidium bromide) 15.6 mcg once-daily
3087608|NCT01641692|Experimental|GSK573719 31.25 mcg|GSK573719 (Umeclinidium bromide) 31.25 mcg once-daily
3087609|NCT01641692|Experimental|GSK573719 62.5 mcg|GSK573719 (Umeclinidium bromide) 62.5 mcg once-daily
3087610|NCT01641692|Experimental|GSK573719 125 mcg|GSK573719 (Umeclinidium bromide) 125 mcg once-daily
3087611|NCT01641692|Experimental|GSK573719 250 mcg|GSK573719 (Umeclinidium bromide) 250 mcg once-daily
3087612|NCT01641692|Experimental|GSK573719 15.6 mcg twice-daily|GSK573719 (Umeclinidium bromide) 15.6 mcg twice-daily
3087613|NCT01641692|Experimental|GSK573719 31.25 mcg twice daily|Gsk573719 (Umeclinidium bromide) 31.25 mcg twice-daily
3087614|NCT01641692|Placebo Comparator|Matched Placebo|Matched Placebo arm
3087615|NCT01641809|Experimental|Arm 1 GSK1265744 10 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 10 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 10 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3087616|NCT01641809|Experimental|Arm 2 GSK1265744 30 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 30 mg + matching placebo + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 30 mg + matching placebo + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3087617|NCT01641809|Experimental|Arm 3 GSK1265744 60 mg|In the Induction Phase subjects will receive oral tablets of GSK1265744 60 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine) once daily from Day 1 to Week 24. Subjects continuing in the Maintenance Phase will receive oral tablets of GSK1265744 60 mg + Rilpivirine 25 mg once daily from Week 24 to Week 96.
3087618|NCT01641809|Active Comparator|Arm 4 Efavirenz 600 mg|In the Induction Phase and Maintenance Phase subjects will receive oral tablets of Efavirenz 600 mg + investigator-selected background NRTIs (either abacavir/lamivudine or tenofovir/emtricitabine).
3087619|NCT01641822|Active Comparator|AZLI|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: AZLI for 28 days followed by TIS for 28 days.
3087620|NCT01641822|Placebo Comparator|Placebo|Participants will be randomized to receive 3 cycles of treatment, each cycle consisting alternating regimens: placebo to match AZLI for 28 days followed by TIS for 28 days.
3087621|NCT01641835||Normals|No eye disease.
3087622|NCT01641861|Experimental|Control arm|control arm is dental caries removal using the conventional method. Dental caries will be removed using rotary instrument following the usual procedures employed by the dentist.
3087623|NCT01641861|Experimental|Intervention arm|Intervention arm is dental caries removal using Papacarie®. The dentist will apply Papacarie® to dental cavity in order to soften the carious dentine. Dental caries will be removed using hand instrument.
3087624|NCT01641900|Experimental|Schizophrenia|"Outpatients with a Structural Clinical Interview confirmed DSM-IV diagnosis of schizophrenia.~All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week."
3087625|NCT01641900|Experimental|Healthy Controls|Adult participants screened to exclude a personal history of mental illness, family history of schizophrenia spectrum disorder, and psychoactive medication use. All participants receive two interventions: 3 mg eszopiclone and Placebo Intervention conditions are separated by 1 week.
3087626|NCT01641926|Experimental|HBeAg(+) PEG-Intron|HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.
3087627|NCT01641926|Active Comparator|HBeAg(+) PEGASYS|HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
3087628|NCT01641926|Experimental|HBeAg(-) PEG-Intron|HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.
3087629|NCT01641926|Active Comparator|HBeAG(-) PEGASYS|HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.
3087630|NCT01641939|Active Comparator|Standard taxane therapy|Docetaxel will be administered at 75 milligram per meter square (mg/m^2) intravenous (IV) on Day 1 of a 21-day cycle, or paclitaxel will administered at 80 mg/m^2 IV weekly (Days 1, 8, and 15 of a 21 day cycle) according to investigator choice until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3087631|NCT01641939|Experimental|trastuzumab emtansine 2.4 mg|Trastuzumab emtansine will be administered on Day 1, 8, and 15 of a 21-day cycle at 2.4 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3087632|NCT01641939|Experimental|trastuzumab emtansine 3.6 mg|Trastuzumab emtansine will be administered on Day 1 of a 21-day cycle at 3.6 mg/kg IV infusion until progression of disease, intolerable toxicity, initiation of another anticancer therapy, or participants and/or physician decision to discontinue.
3087633|NCT01641952||Rituximab|Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
3087634|NCT01641978||ICU patients|neurological level in critical patients
3087635|NCT01641991|Experimental|Arm B: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3087636|NCT01641991|Experimental|Arm C: 0.50mL BioThrax®|BioThrax® 0.50mL subcutaneously on Days 0, 14, 28 and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3087637|NCT01641991|Experimental|Arm D: 0.25mL BioThrax®|BioThrax® 0.25mL subcutaneously on Days 0,14, and 28,and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3087638|NCT01641991|Experimental|Arm A: 0.50mL BioThrax®|BioThrax® 0.50 ml subcutaneously on Days 0, 14, and 0.50mL BioThrax® intramuscular 6 month boost; 75 subjects
3087639|NCT01642004|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3087640|NCT01642004|Experimental|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3087641|NCT01642056|Experimental|EPI-743, then Placebo|Received EPI-743, 15mg/kg up to a maximum dose of 200 mg orally or via gastric tube three times daily with meals, then placebo three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
3087642|NCT01642056|Placebo Comparator|Placebo, then EPI-743|Received Placebo three times daily orally or via gastric tube with meals, then EPI-743, 15mg/kg up to a maximum dose of 200 mg three times daily orally or via gastric tube with meals. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
3087643|NCT01642082|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3087644|NCT01642147|Experimental|Patients undergoing craniotomy|"Patients undergoing craniotomy who are scheduled for selective supratentorial tumor removal surgery will be randomly chosen and recruited.~Transcranial Doppler (TCD) measures,jugular venous bulb catheterization, radial artery catheterization, and tumor removal surgery under general anesthesia will be performed."
3087645|NCT01642147|Active Comparator|Patients undergoing abdominal surgery|Randomly chosen patients undergoing selective abdominal surgery. Transcranial Doppler (TCD) measures,radial artery catheterization, and major abdominal surgery under general anesthesia will be performed.
3087646|NCT01642212|Experimental|Oral Budesonide Suspension|Taken once or twice daily for up to 40 weeks
3087647|NCT01642212|Placebo Comparator|Matching Placebo|Taken once or twice daily for 20 weeks
3087648|NCT01642238|Experimental|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
3087649|NCT01642238|Active Comparator|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
3087650|NCT01642251|Experimental|Arm A (veliparib)|Patients receive veliparib PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3087651|NCT01642251|Active Comparator|Arm B (placebo)|Patients receive placebo PO BID on days 1-7, etoposide IV over 60-120 minutes on days 1-3, and cisplatin IV over 60-120 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3087652|NCT01642277|Experimental|Women using Solifenacin for OAB treatment|Solifenacin treated women: Women with OAB who are prescribed solifenacin
3087653|NCT01642277|No Intervention|Control: Women without OAB|Women without OAB who are not prescribed solifenacin.
3087654|NCT01642407|Experimental|Sildenafil|
3087655|NCT01642485|Active Comparator|Moxifloxacin 400 mg fasted|Moxifloxacin 400 mg fasted was administered on Day 3. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo. Additionally, Caucasian vs Japanese subjects were analysed.
3087656|NCT01642485|Experimental|Moxifloxacin 400 mg fed|"Moxifloxacin 400 mg fed was administered on Day 3 after Continental breakfast. For Day 1 and 2, there were 4 different sequences: Placebo and Insulin Clamp; Insulin Clamp and Continental breakfast; Continental breakfast and FDA breakfast; FDA breakfast and Placebo.~Additionally, Caucasian vs Japanese subjects were analysed."
3087657|NCT01642589|Experimental|Menactra® Group|Participants will receive Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)
3087658|NCT01642589|Active Comparator|Tdap - Adacel® Group|Participants will receive Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap - Adacel®)
3087659|NCT01642602|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release capsules orally once daily for up to 4 weeks.
3087660|NCT01642615|Experimental|Healing Phase: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg delayed-release capsules, orally, once daily for up to 8 weeks.
3087661|NCT01642615|Experimental|Maintenance Phase: Dexlansoprazole 30 mg|Participants who are healed at Week 8 will be randomized to receive 30 mg dexlansoprazole delayed-release capsules, orally, once daily for up to 16 weeks.
3087662|NCT01642615|Experimental|Maintenance Phase: Placebo|Participants who are healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 16 weeks.
3087663|NCT01642914|Experimental|Linaclotide 290 micrograms|Linaclotide 290 micrograms
3087664|NCT01642914|Experimental|Linaclotide 145 Micrograms|Linaclotide 145 micrograms
3087665|NCT01642914|Placebo Comparator|Placebo|Matching placebo
3087666|NCT01643044|Experimental|Alcohol intervention|Participants in this condition review tailored videos and normed feedback regarding their alcohol use and possible consequences of drinking. Next participants view a goal setting section describing possible ways to quit drinking alcohol and the participant is able to indicate a change goal (if any) and is helped through a specific change plan, should they set a change goal.
3087667|NCT01643044|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
3087668|NCT01643213|Experimental|BSC approved SCS Trial Therapy w/ OMG|Precision Plus SCS Trial Therapy w/ OMG. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved BSC SCS trial systems with the Observational Mechanical Gateway(OMG) to connect to non-BSC lead(s)
3087669|NCT01643213|Active Comparator|Non Boston Scientific SCS Trial Therapy|Non Boston Scientific SCS Trial Therapy. Spinal cord stimulation (SCS) trial therapy activated using FDA-approved non BSC SCS system that the subject was implanted with, and received SCS therapy from, prior to study enrollment
3087670|NCT01643382|Experimental|Tight glucose control|Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
3087671|NCT01643382|Active Comparator|Standard glucose control|Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.
3087672|NCT01643408|Experimental|Open-Label Erwinaze|
3087673|NCT01643473|Active Comparator|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
3087674|NCT01643473|Experimental|Tailored Adherence Intervention|Tablet-based tailored adherence intervention matched to patients' most salient adherence barriers
3087675|NCT01643616|Active Comparator|group US|"Ultrasound guided block :~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
3087676|NCT01643616|Active Comparator|group NS|"Nerve stimulation technique:~20ml Prilocaine 1% and 10ml Ropivacaine 0.75% (30ml Prilocaine 1% in outpatients)"
3087677|NCT01643668|Experimental|BuClo RIC + SCT|Busulfan and Clofarabine (BuClo) reduced intensity conditioning (RIC) followed by allogeneic stem cell Transplantation (SCT)
3087678|NCT01643707||Phase I|Control
3087679|NCT01643707||Phase II|Treatment
3087680|NCT01643772|Experimental|Oxycodone Hydrochloride 5 mg Capsules|Group 1: single dose Oxycodone Hydrochloride 5 mg Capsules after 10 hours fasting
3087681|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules|Group 2: single dose Oxycodone Hydrochloride 10 mg Capsules after 10 hours fasting
3087682|NCT01643772|Experimental|Oxycodone Hydrochloride 20 mg Capsules|Group 3: single dose Oxycodone Hydrochloride 20 mg Capsules after 10 hours fasting
3087683|NCT01643772|Experimental|Oxycodone Hydrochloride 10 mg Capsules(multi-dose)|Group 4: multi-dose 4 times per day Oxycodone Hydrochloride 10mg Capsules for 3 days, and one dose on 4th day morning
3087684|NCT01643798|Placebo Comparator|Saline|Participants received intravenous saline immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
3087685|NCT01643798|Active Comparator|Naloxone|Participants received intravenous naloxone (0.1mg/kg) immediately prior to sham and real rTMS of the left dorsolateral prefrontal cortex. The parameters of the stimulation paradigm are as follows: 10 Hz, 5 seconds on, 10 seconds off, 20 minutes, 4000 pulses).
3087686|NCT01643850|Experimental|MCS110|Participants will receive a single dose of 10mg/kg on day 1 administered by regular infusion.
3087687|NCT01643850|Placebo Comparator|Placebo|Part A: single-dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion) Part B: single dose placebo to match MCS110 (10 mg/kg, 1 h i.v. infusion administered i.v. at Day 1, followed by 6 doses of placebo to match MCS110 (10 mg/kg)
3087688|NCT01643850|Experimental|MCS110 3 mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion)
3087689|NCT01643850|Experimental|MCS110 5 mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion)
3087690|NCT01643850|Experimental|MCS110 10 mg/kg|Part C: MCS110 10 mg/kg (i.v. infusion)
3087691|NCT01643850|Experimental|MCS110 3 mg/kg & MCS110 10mg/kg|Part C: MCS110 3 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
3087692|NCT01643850|Experimental|MCS110 5 mg/kg & MCS110 10mg/kg|Part C: MCS110 5 mg/kg (i.v. infusion) & MCS110 10 mg/kg (i.v. infusion)
3087693|NCT01643876|Experimental|Palatal brushing|Palatal brushing after each meal for 3 months.
3087694|NCT01643902|Experimental|IV tPA|Treatment will be initiated within 4.5 hours of awakening, for patients who meet inclusion criteria
3087695|NCT01643928|Experimental|Rituximab-Pfizer|
3087696|NCT01643928|Active Comparator|Rituximab-EU+Rituximab-Pfizer|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses.
3087697|NCT01643928|Active Comparator|Rituximab-US+Rituximab-Pfizer|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses.
3087698|NCT01644058|Experimental|Immediate loading|Immediate loading of 2 endo-osseous mandibular implants
3087699|NCT01644149|Experimental|Stratis Jet Injector|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
3087700|NCT01644149|Active Comparator|Needle and Syringe|Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
3087701|NCT01644175|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 52 weeks.
3087702|NCT01644175|Experimental|Alirocumab|Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3087703|NCT01644188|Experimental|Alirocumab 75 /up to 150 mg Q2W|Alirocumab 75 mg every 2 weeks (Q2W) and oral placebo capsule for ezetimibe daily added to stable Lipid Modifying Therapy (LMT) for 104 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C level ≥70 mg/dL (1.81 mmol/L) at Week 8.
3087704|NCT01644188|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg capsule daily and subcutaneous placebo for alirocumab Q2W added to stable LMT for 104 weeks.
3087705|NCT01644240|Experimental|TD-8954 Dose 1|
3087706|NCT01644240|Placebo Comparator|Placebo|
3087707|NCT01644240|Experimental|TD-8954 Dose 2|
3087708|NCT01644292|Experimental|EPIC Wheels Training Intervention|EPIC Wheels skills training program
3087709|NCT01644331|Experimental|Tolvaptan|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral Tolvaptan (given at 0, 24 and 48 hours)
3087710|NCT01644331|Placebo Comparator|Placebo|Fixed-dose IV furosemide (1 x total daily oral dose given intravenously in divided doses Q12 hours OR 40 mg IV Q12 hours, whichever is greater) + oral placebo (given at 0, 24 and 48 hours)
3087711|NCT01644396|Other|Adalimumab|Participants received an initial adalimumab 80 mg subcutaneous dose, followed by adalimumab 40 mg subcutaneous every other week starting one week after the initial dose for up to 24 weeks.
3087712|NCT01644474|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule daily and subcutaneous (SC) placebo injection for alirocumab every 2 weeks (Q2W) for 24 weeks.
3087713|NCT01644474|Experimental|Alirocumab 75/Up to 150 mg Q2W|SC injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe daily for 24 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3087714|NCT01644500|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
3087715|NCT01644500|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.
3087716|NCT01644500|Active Comparator|Glimepiride|1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.
3087717|NCT01644565|Experimental|Group A-1|Recombinant fimbrial adhesin dscCfaE: 1 ug of dscCfaE ID on study days 0, 21 and 42
3087718|NCT01644565|Experimental|Group A-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5: 2.6 ug of Chimera ID on study days 0, 21 and 42
3087719|NCT01644565|Experimental|Group A-3|Modified E. coli heat labile enterotoxin LTR192G: 100 ng of LTR192G ID on study days 0, 21 and 42
3087720|NCT01644565|Experimental|Group B-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
3087721|NCT01644565|Experimental|Group B-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 2.6 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
3087722|NCT01644565|Experimental|Group C-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 5 ug of dscCfaE + 100 ng of LTR192G ID on study days 0, 21 and 42
3087723|NCT01644565|Experimental|Group C-2|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5 and Modified E. coli heat labile enterotoxin LTR192G: 12.9 ug of Chimera + 100 ng of LTR192G ID on study days 0, 21 and 42
3087724|NCT01644565|Experimental|Group D-1|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 25 ug dscCfaE + 100 ng LTR192G ID on study days 0, 21 and 42
3087725|NCT01644565|Experimental|Group D-2|Recombinant fimbrial adhesin dscCfaE and Modified E. coli heat labile enterotoxin LTR192G: 1250 ug dscCfaE + 50 ng LTR192G TCI on study days 0, 21 and 42
3087726|NCT01644617|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
3087727|NCT01644617|Experimental|MK-8237 6 Developmental Units (DU)|MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
3087728|NCT01644617|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
3087729|NCT01644643|Experimental|Ceftazidime - Avibactam ( CAZ-AVI)|IV treatment
3087730|NCT01644643|Active Comparator|Best Available Therapy|IV treatment
3087731|NCT01644695||Candidate for BARS procedure.|The subjects selected for this trial were over 18 years of age with an appropriate complex, incisional hernia. These patients were consented and treated with the BARS(bony anchoring reinforcement system)procedure.
3087732|NCT01644890|Experimental|NK105|
3087733|NCT01644890|Active Comparator|Paclitaxel|
3087734|NCT01645098|Experimental|Dexmedetomidine 1 mcg/kg|Patients receive a loading dose of dexmedetomidine 1 mcg/kg followed by a continuous infusion of 1 mcg/kg/hr.
3087735|NCT01645098|Experimental|Dexmedetomidine 0.5 mcg/kg|Patients receive a loading dose of dexmedetomidine 0.5 mcg/kg followed by a continuous infusion of 0.5 mcg/kg/hr.
3087736|NCT01645111|Active Comparator|Clevidipine|
3087737|NCT01645176|Experimental|Hydroxychloroquine/Atorvastatin open label|
3087738|NCT01645280|Placebo Comparator|Group 1|
3087739|NCT01645280|Experimental|Group 2|
3087740|NCT01645280|Experimental|Group 3|
3087741|NCT01645280|Experimental|Group 4|
3087742|NCT01645280|Experimental|Group 5|
3087743|NCT01645306|Placebo Comparator|Phosphate buffered saline (PBS), 1% sucrose, 4% mannitol|Placebo control with PBS, 1% sucrose and 4% mannitol
3087744|NCT01645306|Active Comparator|40 mg Revacept|low dose Revacept 40mg in PBS, 1% sucrose, 4% mannitol
3087745|NCT01645306|Active Comparator|120 mg Revacept|high dose revacept 120mg in PBS, 1% sucrose, 4% mannitol
3087746|NCT01645735|Experimental|Ceftaroline|Ceftaroline fosamil 600 mg Intravenous (IV) administration over 60 minutes, every 8 hours (q8h); dosing to be adjusted for renal function; treatment duration 5 to 14 days
3087747|NCT01645735|Active Comparator|Ceftriaxone plus vancomycin|Ceftriaxone 2 g IV over 30 minutes once per day (q24h) plus vancomycin 15 mg/kg IV every 12 hours (q12h) initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
3087748|NCT01645930|Experimental|Ixazomib+Lenalidomide+Dexamethasone|Ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15; lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15, and 22 of a 28-day treatment cycle until progressive disease (PD) or unacceptable toxicity (up to 20 cycles)
3087749|NCT01646021|Experimental|Ibrutinib|
3087750|NCT01646021|Experimental|Temsirolimus|
3087751|NCT01646073|Experimental|Adalimumab|Adalimumab 40 mg every other week (eow)
3087752|NCT01646073|Placebo Comparator|Placebo|placebo
3087753|NCT01646125|Experimental|AUY922 arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.~AUY922 was to be administered weekly."
3087754|NCT01646125|Active Comparator|chemotherapy arm|"Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.~Pemetrexed or docetaxel was to be was to be given once every three weeks."
3087755|NCT01646138|Experimental|Challenge Virus|The Ca/04/2009/H1N1 Vero Grown Challenge Virus was administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3087756|NCT01646151||Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
3087757|NCT01646177|Placebo Comparator|Placebo|Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, participants are assigned to Dosing Regimen 2.
3087758|NCT01646177|Active Comparator|50 mg etanercept|Administered by SC injections twice weekly starting at Week 0 up to Week 12. At Week 12, arm is assigned to Dosing Regimen 2
3087759|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 2|Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 264.
3087760|NCT01646177|Experimental|80 mg ixekizumab Dosing Regimen 1|Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, arm is assigned to Dosing Regimen 2.
3087761|NCT01646203|Experimental|IMC-TR1|"Part A - Dose Escalation:~Cohort 1A: 1.25 mg/kg, intravenously (IV), every 2 weeks of the 6-week treatment cycle~Cohorts 1B-9: Dose Escalation from 12.5 mg to 1600 mg (flat dose), intravenously (IV), every 2 weeks of the 6-week treatment cycles~Cohorts 10-12: Dose escalation from 800 mg to 1600 mg (flat dose), intravenously (IV), weekly during the 6-week treatment cycles~Part B - Disease Specific Cohort Expansion:~Participants will be enrolled into each of three tumor-specific cohort expansions. Participants will be treated with recommended Phase 2 dose."
3087762|NCT01646216|Experimental|Split-belt treadmill training|Split-belt treadmill exercise
3087763|NCT01646255|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3087764|NCT01646255|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3087765|NCT01646268|Experimental|Rotigotine|Rotigotine, daily doses, treatment group
3087766|NCT01646268|Placebo Comparator|Placebo|Placebo, daily doses, placebo group
3087767|NCT01646320|Experimental|Arm1: Dapagliflozin (10 mg) + Saxagliptin + Metformin IR|
3087768|NCT01646320|Experimental|Arm 2: Placebo + Saxagliptin + Metformin IR|
3087769|NCT01646346|Experimental|4D Conformal Image-Guided Partial Breast RT|This is a single arm trial designed to look at the results in women treated with partial breast irradiation twice daily for 5 days.
3087770|NCT01646385||etanercept|adult rheumatoid arthritis patients initiating therapy with etanercept as their first biologic therapy
3087771|NCT01646385||nbDMARD|biologic-naive adult rheumatoid arthritis patients with DAS28 >4.2 treated with non-biologic anti-rheumatic drugs(s).
3087772|NCT01646398|Experimental|>= 65-year age group-13vPnC|
3087773|NCT01646398|Active Comparator|>= 65-year age group-23vPS|
3087774|NCT01646645|Experimental|Group I|This is a single-arm non-randomized single institution phase 2 trial, designed to evaluate the therapeutic activity of CMVpp65-CTLs generated from seropositive HSCT donors when adoptively transferred into transplant recipients with persistent CMV infection or viremia. Patients eligible for this trial will be consenting recipients of related or unrelated HSCT who have an active CMV infection or persistent CMV viremia for ≥ 2 weeks despite treatment with anti-viral agents or who cannot be maintained on anti-viral therapy due to treatment related toxicity.
3087775|NCT01646671|Experimental|LCZ696 200 mg|All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
3087776|NCT01646671|Experimental|LCZ696 400 mg|All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of < 100 mmHg and mean sitting systolic blood pressure (msSBP) of < 160 mmHg at week 2 or a msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
3087777|NCT01646671|Experimental|LCZ696 400 mg plus other hypertension (HTN) medications|All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP < 90 mmHg and msSBP < 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.
3087778|NCT01646762|Experimental|Treatment (chemotherapy)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3087779|NCT01646814|Experimental|PL2200|Investigational product, PL2200
3087780|NCT01646814|Active Comparator|Aspirin tablets|Active comparator, 325 mg aspirin tablets
3087781|NCT01646827|Experimental|Deltoid|Deltoid injection site
3087782|NCT01646827|Experimental|Gluteal|Gluteal injection site
3087783|NCT01647217|Experimental|Terpinen-4-ol Treatment Arm|8 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (3 / 5 patients) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
3087784|NCT01647217|Placebo Comparator|Placepo Pads Contol Arm|9 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (5 / 4 patients) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.
3087785|NCT01647282|Experimental|Sc/RP with minocycline micropheres|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root. Local application of minocycline microspheres will be done after scaling and root planing (Sc/RP) has been completed
3087786|NCT01647282|Active Comparator|Sc/RP alone|Sc/RP is the subgingival mechanical removal of calculus and diseased cementum from the tooth root
3087787|NCT01647438|Other|Print Health Education|Participants receive print health education materials
3087788|NCT01647438|Experimental|Lifestyle Intervention|Six weekly health education classes and phone counseling.
3087789|NCT01647464||Contrast administration|Patients undergoing contrast-enhanced echo.
3087790|NCT01647516|Experimental|Ozanimod 0.5 mg|Participants received 0.5 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 0.5 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
3087791|NCT01647516|Experimental|Ozanimod 1 mg|Participants received 1 mg capsules of ozanimod hydrochloride daily during the induction period weeks 0-9 (an initial 8-day dose escalation regimen in the induction period that consisted of 4 days of ozanimod HCl 0.25 mg (equivalent to ozanimod 0.23 mg), followed by 3 days of ozanimod HCl 0.5 mg, (equivalent to ozanimod 0.46 mg) followed by the assigned treatment level for at least 8 weeks. Participants who completed the induction period and were responders at week 8, continued to receive the same dose of ozanimod during the maintenance period up to week 32. Participants who received ozanimod 1 mg capsules and completed the induction period and were non-responders at Week 8 and who completed the maintenance period or experienced a disease relapse, were given the option to enter the OLP and receive 1 mg ozaninod capsules daily up to 6 years. Participants who had not shown clinical improvement 8 weeks after initiation of the OLP were discontinued from the study.
3087792|NCT01647516|Placebo Comparator|Placebo|Identically matching placebo capsules daily for 32 weeks followed by an optional open label treatment period.
3087793|NCT01647542|Experimental|TAK-875 25 mg|TAK-875 25 mg tablets, orally, once daily for up to 24 weeks.
3087794|NCT01647542|Experimental|TAK-875 50 mg|TAK-875 50 mg tablets, orally, once daily for up to 24 weeks.
3087795|NCT01647542|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily for up to 24 weeks.
3087796|NCT01647581|Experimental|Clip|A clip is been placed at the polypectomy site.
3087797|NCT01647581|Placebo Comparator|No Clip|A hemoclip is not placed at the site of the polypectomy.
3087798|NCT01647711|Experimental|Afatinib|Establish the Maximal Tolerated Dose of a pulsatile, high-dose regimen of afatinib in patients with advanced solid tumors followed by treatment at that dose or a lower dose in patients with stage IV non-small cell lung cancer harboring EGFR T790M mutations who have progressed on therapy with a reversible tyrosine kinase inhibitor
3087799|NCT01647737|Active Comparator|MighTeaFlow|4-6 times daily lozenge containing green tea, jaborandi extracts, and 500 mg xylitol for 8 weeks
3087800|NCT01647737|Active Comparator|Xylitol|4-6 times daily lozenge containing jaborandi extract, and 500 mg xylitol for 8 weeks
3087801|NCT01647945|Placebo Comparator|Placebo|
3087802|NCT01647945|Experimental|FK506 level < 2|
3087803|NCT01647945|Experimental|FK506 level 2-3|
3087804|NCT01647945|Experimental|FK506 level 3-5|
3087805|NCT01647958|Experimental|Treatment Arm|Transoral incisionless esophago-gastric fundoplication using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following TIF2.0 protocol.
3087806|NCT01647958|Active Comparator|Control|Patients who are dependent upon daily PPIs will continue on single dose twice daily or increase to single dose twice daily for the first six months of the clinical trial. Patients will be offered TIF crossover procedure upon completion of month-6 follow-up visit.
3087807|NCT01648101|Experimental|Retigabine 900mg|900mg total daily dose
3087808|NCT01648101|Experimental|Retigabine 600mg|600mg total daily dose
3087809|NCT01648101|Placebo Comparator|Placebo|Placebo
3087810|NCT01648140|Experimental|T40|Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm
3087811|NCT01648140|Experimental|T60|Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
3087812|NCT01648140|Active Comparator|PRT|Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm
3087813|NCT01648140|Experimental|G4|Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm
3087814|NCT01648166||lung cancer cases|subjects with lung cancer who are greater than 17 years of age and live in Appalachian Kentucky
3087815|NCT01648166||control subjects|subjects without lung cancer, greater than 17 who reside in Appalachian Kentucky
3087816|NCT01648283|Experimental|Methadone arm|"Intravenous racemic methadone HCl, 6.0 mg bolus~Oral deuterated racemic methadone HCl, 11 mg capsule (IND#58,511)"
3087817|NCT01648322|Experimental|80 µg/kg/dose of F-627|This dose of F-627 given only to subjects that are to have TC chemotherapy.
3087818|NCT01648322|Experimental|240 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
3087819|NCT01648322|Experimental|320 µg/kg/dose of F-627|This dose of F-627 given to subjects receiving TC or TAC chemotherapy.
3087820|NCT01648322|Active Comparator|Neulasta® (pegfilgrastim)|Given to subjects receiving TC or TAC chemotherapy.
3087821|NCT01648348|Experimental|Arm I (bevacizumab and TRC105)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 8 and 11 of course 1 and days 1 and 8 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3087822|NCT01648348|Active Comparator|Arm II (bevacizumab)|Patients receive bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3087823|NCT01648452|Experimental|NT-501 CNTF-releasing implant|Ocular implantation of a NT-501 CNTF-releasing capsule (20 ng/day) in one eye (the study eye) at baseline
3321132|NCT02016495|Placebo Comparator|Placebo|
3087824|NCT01648491|Experimental|Stem Cell treatment|Muscle Biopsy and Injection of autologous stem cells
3087825|NCT01648530||Participants with Migraines|Participants who returned completed internet survey with positive screening for migraines. No intervention was administered in this study.
3087826|NCT01648582|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
3087827|NCT01648582|Experimental|0.75 mg Dulaglutide|0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
3087828|NCT01648582|Active Comparator|Insulin Glargine|Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
3087829|NCT01648699|Experimental|Osmotic Release Oral System (OROS) Hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
3087830|NCT01648764|Experimental|LY2334737 - Arm A|LY2334737 administered orally at escalating doses [40 milligrams (mg) - 200 mg] every other day for 21 days followed by 7 days without study drug (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
3087831|NCT01648764|Experimental|LY2334737 - Arm B|LY2334737 administered orally at escalating doses (40 mg - 200 mg) every day for 7 days followed by 7 days without study drug then repeated (28 day treatment cycle). Participants may receive additional treatment cycles until discontinuation criterion is met.
3087832|NCT01648790|Experimental|5 mg Prasugrel (ODT1)|5 mg Prasugrel as orally disintegrating tablet without Magnasweet® (ODT1) formulation administered once in the fasted state.
3087833|NCT01648790|Experimental|5 mg Prasugrel (ODT2)|5 mg Prasugrel as orally disintegrating tablet containing Magnasweet® (ODT2) formulation administered once in the fasted state.
3087834|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Suspension|5 mg Prasugrel as ODT2 formulation dispersed in water administered once, in the fasted state.
3087835|NCT01648790|Experimental|5 mg Prasugrel (ODT2)-Fed|5 mg Prasugrel as ODT2 formulation administered once, following a standardized breakfast.
3087836|NCT01648790|Experimental|2 mg Prasugrel (ODT2)|2 mg Prasugrel as ODT2 formulation administered once in the fasted state.
3087837|NCT01648920||FeNO|Participants with suspected but undiagnosed asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit. Following that they will have a Methacholine Challenge (MCC) test performed according to the ATS guidelines and the Allergy and Asthma Specialists Procedure for conducting MCC tests
3087838|NCT01649180|Experimental|Axitinib|Axitinib will be given orally and will continue until progression of disease.
3087839|NCT01649232|Experimental|active tDCS|The patients with ADHD received electro-stimulation at 20 sessions with 2 mAmp 1 session per day alternative days. The investigators used an ERP analysis derived of 20 channel EEG recordings during resting state and visual CPT to define the tDCS site and polarity at refractory ADHD patients to conventional treatments. Time courses, topography and amplitude of ERPs, correlated with clinical scores, were compared with the controls average (data base)to guide the selection of personal tDCS parameters. The following relation shown how many patients were submitted to intervention in each electrode, according to their polarity: Anodal tDCS: T5, T6, etc. Cathodal tDCS: T5, T6, etc.
3087840|NCT01649232|No Intervention|controls|Healthy people that not receive tDCS
3087841|NCT01649271|Experimental|Phase Ia, group 1|afatinib escalating dose with 3-weekly trastuzumab
3087842|NCT01649271|Experimental|Phase Ia, group 2|afatinib at MTD dose with weekly trastuzumab
3087843|NCT01649271|Experimental|Phase Ib|afatinib at MTD level with 3-weekly trastuzumab
3087844|NCT01649297|Experimental|empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
3087845|NCT01649297|Experimental|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
3087846|NCT01649297|Experimental|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
3087847|NCT01649297|Experimental|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
3087848|NCT01649297|Placebo Comparator|Placebo|Patients receive placebo matching Empagliflozin
3087849|NCT01649362|No Intervention|Control group|"No prefeeding oral stimulation~Infants in the control group received neither oral stimulation nor a pacifier before or during gavage feeding."
3087850|NCT01649362|Experimental|Oral stimulation, interventional group|"Infants in the interventional group received pre-feeding oral stimulation. The intervention started on infants born within 32 gestational weeks when the patients were stable and tube-fed, receiving more than 100 ml/kg/day of milk. On infants born after 32 weeks, the intervention started immediately after clinical stability was achieved.~The pre-feeding oral stimulation program consisted of a 15-minute stimulation program delivered by one of the eight trained nurses or one trained member from the medical staff in accordance with the stimulation program proposed by Fucile, Gisel and Lau.~The stimulation program was administered 15 to 30 minutes prior to tube feeding, once daily for at least 10 days. The program was stopped when the infants attained more than three oral feedings per day. The program was interrupted if the infants were medically unstable and/or had episodes of desaturation, apnoea and/or bradycardia during the intervention"
3087851|NCT01649375|Experimental|Secukinumab 75 mg|Secukinumab 75 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks.
3087852|NCT01649375|Experimental|Secukinumab 150 mg|Secukinumab 150 mg subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
3087853|NCT01649375|Placebo Comparator|Placebo|Placebo subcutaneous injection once weekly at baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks
3087854|NCT01649427|Experimental|Prograf|Control therapy: one capsule containing 0.5 mg, 1mg or 5mg Prograf®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
3087855|NCT01649427|Experimental|Tacroliums Hexal|Investigational therapy: one capsule containing 0.5mg, 1mg or 5mg Tacrolimus Hexal®, one tablet containing 180mg or 360mg Myfortic®, corticosteroids and one vial containing 20mg lyophilisate Simulect®
3087856|NCT01649557|Experimental|Open-label OPDC-34712|
3087857|NCT01649596|Active Comparator|Warming Gown|Comparison of two types of warming processes prior to, during, and after the surgery procedure.
3087858|NCT01649596|Other|Standard of Care Warming|Standard of care warming with hospital-issued blankets.
3087859|NCT01649609|Active Comparator|Reduction of standard immunosuppression|Low dose Tacrolimus with low dose Mycophenolate acid
3087860|NCT01649609|Active Comparator|mTOR Arm|Low dose Sirolimus with low dose Mycophenolate acid (mTOR Substitution)
3087861|NCT01649765|Experimental|Arm 1|belimumab 10mg/kg IV monthly
3087862|NCT01649765|Placebo Comparator|Arm 2|Normal Saline IV monthly
3087863|NCT01649791|Experimental|Treatment (lenalidomide as chemoprevention)|Patients receive lenalidomide PO once daily for 4 weeks. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3087864|NCT01649804|Experimental|RoActemra/Actemra single arm|
3087865|NCT01649856|Experimental|A: Rituximab SC|
3087866|NCT01649856|Active Comparator|B: Rituximab IV|
3087867|NCT01649869|Active Comparator|Active|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive valganciclovir HCl 16.0 mg/kg orally twice a day for 6 weeks
3087868|NCT01649869|Placebo Comparator|Placebo|27 Children between 1 month and 3 years of age (up to 4th birthday) with sensoneural hearing loss and documented CMV infection will receive placebo orally twice a day for 6 weeks
3087869|NCT01649947|Experimental|Cohort 2: Bevacizumab ineligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Hydroxychloroquine 200 mg PO BID
3087870|NCT01649947|Experimental|Cohort 1: Bevacizumab eligible patients|Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for Hydroxychloroquine 200 mg PO BID
3087871|NCT01650194|Experimental|Enzalutamide + Abiraterone + Prednisone|Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
3087872|NCT01650246|Experimental|lesinurad 400 mg|
3087873|NCT01650259||Oral antidiabetic drug (OAD)|
3087874|NCT01650259||Trazenta|
3087875|NCT01650285|Experimental|Cabazitaxel and radiation|Radiation therapy (RT) will be delivered to 64.8 Gy, using IMRT treatment Cabazitaxel will be administered IV every 21 days for 3 doses at the assigned dose level.
3087876|NCT01650298|No Intervention|Control|Remote transmissions were scheduled per each institution's device monitoring protocol. Anticoagulation was initiated/discontinued based on standard of care/guidelines as prescribed by doctor
3087877|NCT01650298|Experimental|Tailored Anticoagulation (TAC)|"Anticoagulation was initiated or discontinued based on atrial tachycardia / atrial fibrillation (AT/AF) burden as assessed through frequent remote transmissions via Merlin.net.~Patients sent in biweekly remote transmissions, automatic alert-triggered transmissions for AT/AF burden above a set threshold, and unscheduled patient-activated transmissions as needed"
3087878|NCT01650324|Experimental|DBPR108|
3087879|NCT01650324|Placebo Comparator|matching placebo|
3087880|NCT01650350|Experimental|Low Dose Naltrexone|LDN, 5 mg/day-(1 cycle = 28 days).
3087881|NCT01650402|Experimental|Intensive|Intensive anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 130 mmHg
3087882|NCT01650402|Active Comparator|Standard|Standard anti-hypertensive therapies using standard blood pressure medications to lower blood pressure to a level less than or equal to 145 mmHg
3087883|NCT01650519|Active Comparator|IV ibuprofen|Intravenous ibuprofen (800 mg) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 (Ibuprofen arm) and a corresponding volume of normal saline (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
3087884|NCT01650519|Active Comparator|IV ketorolac|A corresponding volume of normal saline (Ibuprofen arm) administered intravenously over 10 minutes at study hour 0 and again at study hour 4 and 30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) (ketorolac arm) will be administered intravenously over no less than 15 seconds at the end of the arthroscopic procedure
3087885|NCT01650545|Experimental|Liposomal Aerosol Cyclosporine|Arm 1) Aerosol liposomal cyclosporine Open label randomized trial using experimental inhalational therapy with liposomal aerosol cyclosporine in addition to standard immune suppression (tacrolimus , mycophenolate mofetil and prednisone) for 6 month duration at inhalational doses (5mg and 10 mg bid), to be defined by transplant type respectively (single, double lung transplant )
3087886|NCT01650545|Active Comparator|Conventional oral immune suppression|"Arm 2) Standard immune suppression consisting of typical oral immune suppression for lung transplant recipients typically tacrolimus, mycophenolate mofetil and prednisone.~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone rapamycin described in the subsequent section as well."
3087887|NCT01650558|Active Comparator|Standard of Care Prophylaxis (TS)|Standard of care prophylaxis with daily trimethoprim sulfamethoxazole (TS).
3087888|NCT01650558|Experimental|Chloroquine (CQ) prophylaxis|Discontinuation of standard of care TS prophylaxis and starting weekly chloroquine prophylaxis
3087889|NCT01650558|No Intervention|Discontinuation of standard of care|Control arm - Discontinuation of standard of care trimethoprim sulfamethoxazole.
3087890|NCT01650584|Experimental|ISTA Tears|Sterile ophthalmic solution
3087891|NCT01650584|Active Comparator|Systane|Sterile ophthalmic solution
3087892|NCT01650636|Experimental|Cognitive Behavioral Stress Management|
3087893|NCT01650636|Active Comparator|Health Information|
3087894|NCT01650779|Experimental|Agalsidase beta|
3087895|NCT01650805|Experimental|ponatinib|
3087896|NCT01650805|Active Comparator|imatinib|
3321133|NCT02016508|Experimental|autologous bone marrow stem cells|use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients
3087897|NCT01650831|Active Comparator|Clinical Suspicion of Hpylori|All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
3087898|NCT01650844|Experimental|School-based Telemedicine Enhanced Asthma Mangement Group|We will use a web-based system to assess asthma severity or control and will send a symptom report to the child's primary care physician (PCP). Children randomized to the SB-TEAM group, will receive a telemedicine visit in the school health office at the start of the school year to provide an initial asthma assessment. The telemedicine provider will deliver brief asthma education and referrals to community resources, and will send a guideline-based preventive medication prescription electronically to a local pharmacy. The pharmacy will deliver the medications to home and school, and the school nurse will administer the medication as directly observed therapy throughout the school year. Follow-up telemedicine assessments will occur twice during the study period. These follow-up visits will focus on assessment of control, assessment of ongoing triggers or co-morbid conditions, and brief asthma education.
3087899|NCT01650844|Active Comparator|Enhanced Usual Care Group|Children randomized to the enhanced usual care group will receive a symptom assessment using national care guidelines, a recommendation for appropriate preventive medications, and asthma education materials. We will use the web-based system to send a symptom report to the child's PCP with guideline-based recommendations for preventive care. We will provide systematic feedback to the family and providers at the same intervals as in the SB-TEAM group's telemedicine visits, by prompting providers to use care guidelines, and caregivers to schedule recommended follow-up visits with the PCP.
3087900|NCT01651000|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
3087901|NCT01651000|Placebo Comparator|Sugar pill to CTAP101 30 μg capsule|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
3087902|NCT01651039|Experimental|Panobinostat, Lenalidomide and Dexamethasone|All patients will receive oral panobinostat, lenalidomide and dexamethasone as per protocol.
3087903|NCT01651052|Experimental|Aortic Bioprosthesis, Model 11000|Aortic valve replacement therapy
3087904|NCT01651078||Main cohort|Patients with radiographic evidence of lesion regrowth following prior treatment with stereotactic radiosurgery (regardless of the process being suspected recurrent or progressive brain metastasis versus radiation necrosis) and who already scheduled for NeuroBlate procedure.
3087905|NCT01651104|Experimental|Adjuvanted Trivalent Influenza Virus Vaccine|
3087906|NCT01651117|No Intervention|Usual Care|Enrolled in two different time frames. No interventions will be provided to this arm. They will complete planned surveys, and blood draws (baseline, 6 months, and 12 months).
3087907|NCT01651117|Experimental|Peer Mentoring|Participants in this arm will be mentored for 6 months by a veteran who was once in poor control but is now in good control. They will then be further randomized to either becoming a mentor for 6 months or having no other additional active intervention. All participants in this arm will be evaluated in person at baseline, 6 months, 12 months, and 18 months.
3087908|NCT01651117|Experimental|Peer Mentoring FFM (from former mentee)|Participants in this arm will be mentored by the former mentee for 6 months and will be followed in person for an additional 6 months after the completion of the active intervention.
3087909|NCT01651195|Active Comparator|Probiotic tablet (military recruits)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
3087910|NCT01651195|Placebo Comparator|Placebo tablet (military recruits)|Crystalline cellulose 2 x 2, 3 weeks
3087911|NCT01651195|Active Comparator|Probiotic tablet (reserve officer candidates)|Lactobacillus rhamnosus 8-9 x 10 -9 2 x 2 3 weeks
3087912|NCT01651195|Placebo Comparator|Placebo tablet (reserve officer candidates)|Crystalline cellulose 2 x 2, 3 weeks
3087913|NCT01651208|Experimental|Motivational interviewing (MINT)|The MINT intervention will consist of 4 to 7 telephone encounters between a nurse trained in Motivational interviewing and a minority subject who recently received a coronary stent. All subjects in the MINT arm will be contacted every 3 months to complete 4 encounters. MINT is a well-known, scientifically tested behavioral counseling strategy developed as an amalgamation of principles drawn from several theoretical paradigms, the most important of which are Self-Determination Theory, Patient-Centeredness, Self-Efficacy theory, and the Stages of Change model.
3087914|NCT01651208|Active Comparator|Mailed DVD|A DVD that re-enforces an adequate behavior regarding adherence to anti-platelet will be compared to a MINT intervention. The DVD will also address many questions and concerns patients have after stent placement. The intervention is based on role theory and the effects of vicarious learning via electronic media with respect to Cardiovascular behaviors.
3087915|NCT01651260|Other|Endotracheal (ET) tube securement device|Single arm study evaluated an experimental ET tube securement device with a bite block.
3087916|NCT01651351|Experimental|Cohort 1|"Day 1:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min~Day 15:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min"
3087917|NCT01651351|Experimental|Cohort 2|"Day 1:~GLASSIA at 0.2 mL/kg/min~Placebo at 0.04 mL/kg/min~Day 15:~GLASSIA at 0.04 mL/kg/min~Placebo at 0.2 mL/kg/min"
3087918|NCT01651403|Experimental|Tenofovir DF (Blinded Randomized Treatment)|Participants will receive tenofovir disoproxil fumarate (tenofovir DF; TDF) for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
3087919|NCT01651403|Placebo Comparator|Placebo to match TDF (Blinded Randomized Treatment)|Participants will receive TDF placebo for 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3).
3087920|NCT01651403|Experimental|Tenofovir DF (Open-label Treatment)|Following 72 weeks (protocol amendment 2) or 48 weeks (protocol amendment 3) of blinded randomized treatment, participants will switch to open-label TDF treatment for an additional 120 weeks (protocol amendment 2) or 144 weeks (protocol amendment 3).
3087921|NCT01651403|Experimental|Tenofovir DF (Open-label Extension Phase)|Following the completion of study at Week 192, participants may have the option to receive open-label TDF until it is commercially available in that country for treatment of chronic HBV in participants of their age and weight.
3087922|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1|
3087923|NCT01651442|Active Comparator|Sleep Medication 1|
3087924|NCT01651442|Active Comparator|Non-drug Sleep Therapy 2 Following Non-drug Sleep Therapy 1|
3087925|NCT01651442|Active Comparator|Sleep Medication 2 Following Sleep Medication 1|
3087926|NCT01651442|Active Comparator|Non-drug Sleep Therapy 1 Following Sleep Medication 1|
3087927|NCT01651442|Active Comparator|Sleep Medication 1 Following Non-drug Sleep Therapy 1|
3087928|NCT01651780|Experimental|Bivalirudin|Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.
3087929|NCT01651780|Active Comparator|Unfractionated heparin (UFH)|The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.
3087930|NCT01651793|Active Comparator|Caffeinated cocoa|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
3087931|NCT01651793|Active Comparator|Cocoa|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
3087932|NCT01651793|Active Comparator|Caffeine|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
3087933|NCT01651793|Placebo Comparator|Placebo|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
3087934|NCT01651806|Active Comparator|Females receiving a uniform dose of TA|Women receiving a single dose of 1 gram of TA--includes all women that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3087935|NCT01651806|Active Comparator|Weighted dose of TA in female patients|Female patients receiving a weighted dose of TA. Will include all women that will get a weighted dose of the TA during surgery. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3087936|NCT01651806|Active Comparator|Tranexamic acid weighted dose male|Male patients randomized to the weighted dose of TA. Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss.
3087937|NCT01651806|Active Comparator|Uniform single dose TA male patient|Male patients receiving a single dose (1gram) of TA during TKA. Includes all men that will get 1 gram dose of the TA during surgery. Postop outcomes wil be measured for comparison Postop outcomes wil be measured for comparison, including hemoglobin, hematocrits and blood loss. Patients will be randomized into one of these two groups.
3087938|NCT01651806|No Intervention|Historical Cohort|"25 patients with no TA use in their surgical history.~A control group was established from a historical cohort of primary TKAs performed by the senior author (BL), none of which received TA. The most relevant Pubmed ID would be 24997651."
3087939|NCT01651936|Experimental|Base Study: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
3087940|NCT01651936|Placebo Comparator|Base Study: Placebo|Participants received placebo BID orally with MTX at the stable dose received upon study enrollment. The Base Study lasted up to 24 weeks.
3087941|NCT01651936|Experimental|Safety Extension: MK-8457|Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
3087942|NCT01651949|Active Comparator|Females|Healthy females 16 to 26 years of age received 9vHPV vaccine 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3087943|NCT01651949|Experimental|Heterosexual Males|Healthy heterosexual males 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3087944|NCT01651949|Experimental|Men who have Sex with Men|Healthy MSM 16 to 26 years of age received 9vHPV 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3087945|NCT01652001|Experimental|Malic Acid 1%|"Intervention group subjects was the delivery to the patients of a topical sialogogue, containing 1% malic acid, xylitol 10% and fluoride 0.05%(Xeros Dentaid Spray©, Dentaid, Barcelona, Spain).~Spray was transferred by foreign personnel into identical opaque flasks(without any brand name)labeled A."
3087946|NCT01652001|Placebo Comparator|Control|Control group was given a placebo with opaque flask(without any brand name)labeled B and with the same presentation and composition than Experimental group (excepting 1% malic acid).
3087947|NCT01652040|Experimental|RT+Tp|Resistance training using electrical stimulation and ankle weights and Testosterone patches
3087948|NCT01652040|Experimental|Tp|Applying Testosterone patches
3087949|NCT01652287|Active Comparator|BB-12 supplemented yogurt|Probiotic, Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12), supplemented strawberry yogurt, 4 ounces taken orally for 10 days
3087950|NCT01652287|Placebo Comparator|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
3087951|NCT01652469|Experimental|A: Erlotinib|Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
3087952|NCT01652469|Experimental|B: Docetaxel|Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.
3087953|NCT01652495|Active Comparator|methylprednisolone acetate group|Single intrabursal injection of methylprednisolone acetate
3087954|NCT01652495|Active Comparator|Triamcinolone acetonide group|Single intrabursal injection of Triamcinolone acetonide
3321134|NCT02016521|Experimental|Cooling Fabric|Garment made of 100% nylon fabric consisting of long sleeved shirt and full trouser.
3321135|NCT02016521|Placebo Comparator|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser.
3087957|NCT01652573|Experimental|Nasal calictonin|Subjects will received nasal calcitonin once daily
3087958|NCT01652573|Placebo Comparator|Saline Nasal spray|Patients will receive saline nasal spray once daily
3087959|NCT01652664|Experimental|Travoprost|Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
3087960|NCT01652664|Active Comparator|Timolol|Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
3087961|NCT01652690||Denosumab|Patients with postmenopausal osteoporosis (PMO) who received at least 1 injection of denosumab 60 mg subcutaneously in the Czech Republic and Slovakia.
3087962|NCT01652703|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3087963|NCT01652703|Placebo Comparator|Placebo Q4W|Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
3087964|NCT01652703|Experimental|Evolocumab 70 mg Q2W|Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3087965|NCT01652703|Experimental|Evolocumab 140 mg Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3087966|NCT01652703|Experimental|Evolocumab 280 mg Q4W|Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3087967|NCT01652703|Experimental|Evolocumab 420 mg Q4W|Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
3087968|NCT01652716|Experimental|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
3087969|NCT01652716|Active Comparator|Exenatide twice daily (BID)|Exenatide 5 mcg BID for 4 weeks followed by 10 mcg BID for 24 weeks
3087970|NCT01652729|Experimental|Exenatide once weekly suspension|Exenatide once weekly suspension 2mg subcutaneous injection
3087971|NCT01652729|Active Comparator|Sitagliptin 100mg|Overencapsulated Sitagliptin 100mg oral tablet once daily
3087972|NCT01652729|Placebo Comparator|Placebo|Placebo oral capsule once daily
3087973|NCT01652872|Active Comparator|Hb-Based Titration Group|Participants received darbepoetin alfa as a subcutaneous (SC) injection once every 4 weeks (Q4W) for up to 96 weeks. The dose of darbepoetin alfa was titrated based on the Hb concentration on the date of the visit, the corresponding Hb rate of rise (ROR), and the previously assigned dose. Doses were reduced if Hb exceeded 10.5 g/dL or Hb ROR exceeded 1.0 g/dL/4W. When darbepoetin alfa therapy was withheld per the dosing algorithm, placebo was administered. The starting dose of darbepoetin alfa was 0.45 micrograms/kilogram (mcg/kg) and the protocol specified doses ranged from 10 to 300 mcg.
3087974|NCT01652872|Experimental|Fixed Dose Group|Participants received darbepoetin alfa as a SC injection Q4W at the same dose as assigned at the time of randomization for the duration of the 96 week treatment period. There was 1 exception to the fixed dose strategy: if the Hb was > 12.0 g/dL, darbepoetin alfa therapy was withheld and placebo administered. Once the Hb fell to < 10.0 g/dL, darbepoetin alfa therapy resumed at the same dose. The starting dose of darbepoetin alfa was 0.45 mcg/kg and the protocol specified doses ranged from 10 to 300 mcg.
3087975|NCT01652885|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3087976|NCT01652976|Experimental|Treatment Arm|Dasatinib and mFOLFOX6
3087977|NCT01653028|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3087978|NCT01653132|Experimental|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
3087979|NCT01653132|Placebo Comparator|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
3087980|NCT01653158|Experimental|CP-751,871 combined with docetaxel|
3087981|NCT01653262|Experimental|Brivaracetam|"The subjects will be treated with Brivaracetam (BRV) tablets 200 mg/day during 12 weeks: four 25 mg tablets, twice daily.~Based on the Investigator's judgement, at any time, the dose can be decreased to BRV 150 mg/day, 100 mg/day, or 50 mg/day. Flexible dosing, can be up- and down-titrated as needed.~At the end of the Treatment Period, the subject will either enter the N01372 long-term follow-up study or down-titrate during 4 weeks."
3087982|NCT01653288|Experimental|Coping Coach|Receive access to Coping Coach online intervention at baseline for use (self-guided, with email reminders) over the next 6 weeks.
3087983|NCT01653288|Experimental|Coping Coach Waitlist Control|Treatment as usual from baseline to 12 week follow-up assessment. Then receive access to Coping Coach intervention after 12 week follow-up for use (self-guided, with email reminders) over the next 6 weeks.
3087984|NCT01653327|Active Comparator|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
3087985|NCT01653327|Placebo Comparator|Placebo|The placebo will consist of 4 ml of cherry syrup and 1 ml of normal saline.
3087986|NCT01653405|Experimental|Intervention Group|VA patients treated at anticoagulation clinics at 8 sites in VISN 1. The intervention included a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
3087987|NCT01653405|No Intervention|Control Group|VA patients treated at anticoagulation clinics at 116 sites outside of VISN 1.
3087988|NCT01653418|Experimental|V-BEAM + Stem Cell Infusion|Bortezomib IV or SC (1.3mg/m2) on Days -6, -3, +1 and +4 Carmustine IV (300mg/m2) on Day -7 Etoposide IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Cytarabine IV twice daily (100 mg/m2) on Days -6, -5, -4, and -3 Melphalan IV (140 mg/m2) on Day-2 Stem cell infusion on Day 0
3087989|NCT01653509|Experimental|Test patch|Patch containing acyclovir applied to cold sore
3087990|NCT01653509|Placebo Comparator|Placebo patch|Patch without acyclovir applied to cold sore
3087991|NCT01653587|Active Comparator|Transradial approach|Transradial approach percutaneous coronary intervention using the TR Band device to obtain hemostasis
3087992|NCT01653587|Active Comparator|Transfemoral approach|Transfemoral approach percutaneous coronary intervention using the AngioSeal vascular closure device STS Plus Platform to obtain hemostasis
3087993|NCT01653704|Experimental|active management of crises scenario|participants assigned to actively manage a crisis scenario
3087994|NCT01653704|Active Comparator|Observer role in crisis scenario|Observational role in management of crises scenario
3087995|NCT01653743|Experimental|MSJ-0011|
3087996|NCT01653743|Active Comparator|urinary hCG|
3087997|NCT01653782|Experimental|kUNDALINI YOGA|"Guided kundalini yoga sessions specific for low back pain for 1 hour, twice a week (120 minutes of instructor-led yoga) for 6 weeks. Cd recording for home practice recommended once per day.A written self care pamphlet The Back book"
3087998|NCT01653782|Active Comparator|Self care advice to stay active|Evidence based advice from caregiver to stay active and exercise
3087999|NCT01653782|Active Comparator|Exercise|"Guided exercise at a gym focusing on strength training. Twice a week during 6 weeks. A written self care pamphlet The Back book"
3088000|NCT01653847|Active Comparator|Group 1: Tacrolimus with MMF.|This group will receive a standard dose Tacrolimus and MMF. This will follow standard of care protocol at Northwestern Memorial Hospital's Comprehensive Transplant Center.
3088001|NCT01653847|Active Comparator|Group 2: Tacrolimus with Everolimus|This group will receive a low dose Tacrolimus with concentration controlled Everolimus
3088002|NCT01653847|No Intervention|Donors|One time blood samples will be collected from kidney donors to recipients in this study
3088003|NCT01653912|Experimental|GSK2110183, carboplatin and paclitaxel|Subjects will be treated with a maximum of six doses of carboplatin + paclitaxel in combination with continuous daily GSK2110183 followed by single agent GSK2110183 at the single-agent MTD of 125 mg or above oral daily.
3088004|NCT01653964|Experimental|Molecular breast imaging|Molecular Breast Imaging at 4 mCi dose and at 8 mCi dose, consecutively.
3088005|NCT01654068|Experimental|Radiation Therapy to Local Spine Metastasis|Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
3088006|NCT01654107|Experimental|Persistence Targeted Smoking Cessation|Persistence Targeted Smoking Cessation - 8 weeks counseling + 12 weeks nicotine lozenge
3088007|NCT01654107|Active Comparator|Clearing The Air|Clearing the Air Smoking Cessation intervention - 8 weeks counseling + 12 weeks nicotine lozenge
3088008|NCT01654224|Active Comparator|High Dose Inactivated Influenza Vaccine|For HDIV,0.5 ml of high dose inactivated influenza vaccine consisting of a total of 180mcg (60 mcg each strain) of influenza virus hemagglutinin
3088009|NCT01654224|Active Comparator|Standard Dose Inactivated Influenza Vaccine|For SDIV, 0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg of each strain) of influenza virus hemagglutinin
3088010|NCT01654250|Experimental|Active|NWP09
3088011|NCT01654250|Placebo Comparator|Placebo|Placebo
3088012|NCT01654263|Experimental|Group IA: Pneumococcal vaccine-naive, age 55 - 64|Open- label, 13-valent pneumococcal conjugate vaccine (PCV13) given as 0.5 mL intramuscular (IM) injection to 147 subjects vaccine-naive adults
3088013|NCT01654263|Experimental|Group IB: Pneumococcal vaccine-naive, age 65 - 74|Open- label, PCV13 given as 0.5 mL IM injection to 147 subjects vaccine-naive adults
3088014|NCT01654263|Experimental|Group IIA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3088015|NCT01654263|Experimental|Group IIAA: age 55 - 64, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3088016|NCT01654263|Experimental|Group IIB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection in the right arm and 0.5 mL PCV 13 IM in the left arm, to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3088017|NCT01654263|Experimental|Group IIBB: age 65 - 74, previous PPSV23|Open-label, randomized PCV13 given as a 0.5 mL IM injection to 147 subjects with previous 23-valent pneumococcal polysaccharide vaccine (PPSV23) 3-7 years prior to enrollment
3088018|NCT01654276|Experimental|Febuxostat|Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.
3088019|NCT01654289|Experimental|Mindfulness Meditation|Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and approximately 45 minutes per day at-home daily practice.
3088020|NCT01654289|Experimental|Exercise|The exercise intervention structure is consistent with many standardized exercise programs. The exercise program will match the meditation program in duration (8 weeks), attention (weekly 2½ hour group sessions), and intensity (daily 45 minute at-home practice).
3088021|NCT01654289|No Intervention|Wait-list control|"Apart from not attending any of the specific meditation or exercise training sessions, those in the control group will be treated in essentially the same manner as experimental participants."
3088022|NCT01654302|Active Comparator|Synera|lidocaine/tetracaine patch with heating component which consists of iron powder, activated carbon, sodium chloride, wood flour, water and filter paper.
3088023|NCT01654302|Placebo Comparator|Inactive Patch|placebo patch identical in appearance and composition (namely, the heating components) to the active patch other than lacking the lidocaine and tetracaine active ingredients.
3088024|NCT01654315|Experimental|Experimental: Myomo Only Group|"Experimental: Myomo Only Group Patients are administered rehabilitative therapy known as repetitive task specific practice (RTP) using only the Myomo robotic device targeting their affected arms on 3 days/week, in 1/2 hour increments, during an 8-week period."
3088025|NCT01654315|Experimental|Experimental: Myomo + RTP Group|Experimental: Myomo + RTP Group Patients are administered rehabilitative therapy using both the Myomo robotic device and RTP targeting their affected arms on 3 days/week in 1/2 hour increments, during an 8 week period. These patients engage in activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the device during the activities is reduced.
3088026|NCT01654315|Active Comparator|Active Comparator: RTP Group|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
3088027|NCT01654380|Experimental|Part A, Cohort A; LY2605541|Healthy participants received 5.1 milliunits/minute (mU/min) in Period 1, 10.2 mU/min in Period 2, and 15.3 mU/min in Period 3, administered intravenously (IV) over 8 hours. All periods were separated by a minimum 6-day washout period
3088028|NCT01654380|Active Comparator|Part A, Cohort A; Insulin Glargine|Healthy participants received insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period
3088029|NCT01654380|Experimental|Part A, Cohort B; LY2605541|Healthy participants received 15.3 mU/min in Period 1, 37.0 mU/min in Period 2, and 74.1 mU/min in Period 3, administered IV over 8 hours. All periods were separated by a minimum 6-day washout period.
3088030|NCT01654380|Active Comparator|Part A, Cohort B; Insulin Glargine|Healthy participants received insulin glargine (60 mU/m^2/min) administered IV over 8 hours in Period 4. All periods were separated by a minimum 6-day washout period.
3088031|NCT01654380|Experimental|Part B; LY2605541|Participants with T1DM received 15.3 mU/min in 1 of 4 study periods, administered IV up to 8 hours and received 74.1 mU/min in 1 of 4 Periods, administered IV up to 10 hours. Each dose was separated by a minimum 6-day washout period.
3088032|NCT01654380|Active Comparator|Part B; Insulin Glargine|Participants with T1DM received 1 insulin glargine dose per study period (10 and 20 mU/m^2/min) administered IV over 8 hours in 2 of 4 study periods. Each dose was separated by a minimum 6-day washout period.
3088033|NCT01654445|Experimental|TNK-tPA Tenecteplase|This is an open-label trial, all patients will receive tenecteplase.
3088034|NCT01654523|Other|Treatment arm|Open trial with no randomization
3088035|NCT01654536|Experimental|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg
3088036|NCT01654536|Active Comparator|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg
3088037|NCT01654549|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3088038|NCT01654549|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3088039|NCT01654601|Experimental|A Group|"1.1st Administration - DWCZP tablet 100mg Mutiple dose~2.2nd Administration - Clozaril tablet 100mg Mutiple dose"
3088040|NCT01654601|Experimental|B Group|"1.1st Administration - Clozaril tablet 100mg Mutiple dose~2.2nd Administration - DWCZP tablet 100mg Mutiple dose"
3088041|NCT01654666|Experimental|RIPC group|"Treatment:Patients in this group received standard medical therapy and remote ischemic preconditioning (RIPC) treatment.~Device:RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min,each patient in the RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
3088042|NCT01654666|Active Comparator|Control group|Treatment:Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
3088043|NCT01654666|Sham Comparator|Sham RIPC group|"Treatment:Patients in this group received standard medical therapy and sham remote ischemic preconditioning treatment.~Device:Sham RIPC consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min, each patient in RIPC group do it twice a day for at least two weeks before carotid artery stenting.~Procedure: Carotid Artery Stenting"
3088044|NCT01654796|Active Comparator|Low Field Magnetic Stimulation|Patients in this arm will receive 2 days of active low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of active low field magnetic stimulation (LFMS) in phase 2. LFMS is a novel, non-contact neuromodulation technique. LFMS is administered through a device while the patient lies on his/her back for 20 minutes.
3088045|NCT01654796|Placebo Comparator|Sham (LFMS)|Patients in this arm will receive 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by 2 days of sham (not active) low field magnetic stimulation (LFMS) in phase 2.
3088046|NCT01654796|Other|Crossover Arm|Patients in this group will receive two days of sham (not active) low field magnetic stimulation (LFMS) in phase 1, followed by two days of active low field magnetic stimulation (LFMS) in phase 2.
3088047|NCT01654861|Experimental|HDIVC|Gemcitabine (Gemzar), Intravenous and oral Ascorbic Acid (Vitamin C).
3088048|NCT01654887|Experimental|Lung Ultrasound|LUS first with the option of obtaining CXR second
3088049|NCT01654887|Active Comparator|Chest X-Ray|CXR first followed by LUS second
3088050|NCT01655043|Experimental|coronary artery disease patients|Patients with suspected coronary artery disease prospectively recruited for myocardial perfusion MRI. All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar, Lantheus) at both stress and rest. Stress to be induced using 5 ml intravenous (IV) regadenoson (Lexiscan, Astellas US LLC), and the effects of regadenoson were reversed with 50 mg IV aminophylline following the completion of stress imaging.
3088051|NCT01655069|Experimental|Children Treated with Placebo in 905-CL-076|Male and female children aged 5 to less than 12 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
3088052|NCT01655069|Experimental|Children Treated with Solifenacin in 905-CL-076|Male and female children aged 5 to less than 12 years old who received solifenacin in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 247.9 days in children.
3088053|NCT01655069|Experimental|Adolescents Treated with Placebo in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received placebo in Study 905-CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
3088054|NCT01655069|Experimental|Adolescents Treated with Solifenacin in 905-CL-076|Male and female adolescents aged 12 to less than 18 years old who received solifenacin in Study 905- CL-076 and received open-label solifenacin once daily in this study. The mean time on study drug in this study was 240.1 days in adolescents.
3088055|NCT01655329||Standard chest radiographs|The radiologists will be viewing two groups of chest images. The first group are standard chest radiographs.
3088056|NCT01655329||Modified chest radiographs|This group of chest radiographs will be presented with the modified image. The modified image is intended to increase the visibility of tubes, lines and wires on chest radiographs
3088057|NCT01655381|Experimental|Tocilizumab|Tocilizumab 8 milligrams per kilogram (mg/kg) administered intravenously once every 4 weeks during a minimum of 104 weeks.
3088058|NCT01655498|Experimental|Vaginal Bowel Control|A vaginal bowel control system intended to manage fecal incontinence.
3088059|NCT01655563|Active Comparator|Standard Dosing Arm|Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
3321136|NCT02016534|Experimental|Single arm|AMG 337 Monotherapy
3088060|NCT01655563|Experimental|Pharmacogenetic Arm|"Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours"
3088061|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 20 mg/m2|DT will be infused over 6 hours through the intravenous (IV) route at dose of 20 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
3088062|NCT01655693|Experimental|Doxorubicin Transdrug (DT) at 30 mg/m2|DT will be infused over 6 hours through the IV route at dose of 30 mg/m2 on Day 1 and will be repeated every 4 weeks until disease progression or unacceptable toxicity
3088063|NCT01655693|Active Comparator|Best Standard of Care|Patients randomized in the control group will receive treatment according to the investigator's choice, until disease progression or unacceptable toxicity
3088064|NCT01655719|Experimental|Pioglitazone Treatment|"If eligible, subjects can participate in 1 or both parts of this study as follows:~Part 1: In the initial main portion of the study subjects will receive 24 -28 weeks of therapy with pioglitazone at the dosage approved for the control of diabetes. Response will be evaluated per RECIST. Safety measure are outlined in the protocol including weekly weigh ins, calls, labs, exams, etc.~Part 2: A secondary protocol is then available to subjects who complete the main initial study with less than complete response per RECIST. They can undergo a radioiodine scan to see if the treatment with pioglitazone has sensitized their disease to radioiodine. If it has - they can pursue the radioiodine treatment."
3088065|NCT01655823|Placebo Comparator|Placebo (twice daily)|Placebo for injection (1 ml volume), twice a day for four consecutive days.
3088066|NCT01655823|Experimental|Low dose Tetrodotoxin (twice daily)|Low dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3088067|NCT01655823|Experimental|Mid-range dose of Tetrodotoxin (twice daily)|Mid-range dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3088068|NCT01655823|Experimental|Max dose Tetrodotoxin (once daily)|Max dose Tetrodotoxin injectable (1 ml volume), once a day in the morning for four consecutive days and Placebo for injection (1 ml volume), once a day in the afternoon for four consecutive days. Total of 4 treatment days.
3088069|NCT01655823|Experimental|Max dose Tetrodotoxin (twice daily)|Max dose Tetrodotoxin injectable (1 ml volume), twice a day for four consecutive days.
3088070|NCT01655901|Experimental|Active video gaming|Playing Kinect
3088071|NCT01655901|Experimental|Passive video gaming|Playing Xbox 360
3088072|NCT01655901|Experimental|Resting|Stay seated on a comfortable chair
3088073|NCT01656031|Experimental|high-dose cytarabine and clofarabine|high-dose cytarabine (2000 milligram/meter squared/day) administered intravenously over 3 hours followed by clofarabine administered intravenously over 2 hours daily for 5 consecutive days
3088074|NCT01656161|Experimental|Triptorelin embonate 22.5 mg|Participants received subcutaneous injections of triptorelin embonate 22.5 mg 6-month formulation administered on Day 1 and on Day 169.
3088075|NCT01656187|Experimental|Memantine, Then Placebo|Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
3088076|NCT01656187|Experimental|Placebo, Then Memantine|Participants first received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks. After a washout period of 4 weeks, they then received Memantine 10 mg capsule twice a day for 24 weeks.
3088077|NCT01656200|Experimental|Vaccine|Single dose live attenuated Japanese encephalitis vaccine SA14-14-2
3088078|NCT01656252|Experimental|Phase I- Cytarabine & Eltrombopag|Cycle 1= Cytarabine twice daily on Days 1, 3 and 5 and Eltrombopag (Open-Label) until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
3088079|NCT01656252|Experimental|Phase II- Sequence A|Cytarabine twice daily on Days 1, 3 and 5. Eltrombopag(dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
3088080|NCT01656252|Experimental|Phase II- Sequence B|Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
3088081|NCT01656304|Experimental|Treatment (monoclonal antibody, antiangiogenesis)|Patients receive bevacizumab IV over 30-90 minutes once every 14 days. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
3088082|NCT01656395|Experimental|MK-1029 10 mg|Participants receive MK-1029 10 mg tablets once daily (QD) for 12 weeks
3088083|NCT01656395|Experimental|MK-1029 30 mg|Participants receive MK-1029 30 mg tablets QD for 12 weeks
3088084|NCT01656395|Experimental|MK-1029 60 mg|Participants will receive MK-1029 two 30 mg tablets QD for 12 weeks
3088085|NCT01656395|Experimental|MK-1029 150 mg|Participants will receive MK-1029 150 mg tablets QD for 12 weeks
3088086|NCT01656395|Active Comparator|Montelukast 10 mg|Participants will receive Montelukast 10 mg tablets QD for 12 weeks
3088087|NCT01656395|Placebo Comparator|Placebo|Participants will receive Placebo tablets QD for 12 weeks
3088088|NCT01656395|Experimental|MK-1029 1 mg or 3 mg|Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
3088089|NCT01656395|Experimental|Montelukast 10 mg + MK-1029|Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
3088090|NCT01656408|Experimental|Panel A: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3088091|NCT01656408|Experimental|Panel B: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3088092|NCT01656408|Experimental|Panel C: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3088093|NCT01656408|Experimental|Panel D: Mild/Moderate Hypertension|MK-8150 or matching placebo once daily, capsules, oral, for 10 days
3088094|NCT01656408|Experimental|Panel E-Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
3088095|NCT01656408|Experimental|Panel F - Elderly|Single dose of MK-8150 or placebo on Study Day 1 followed by a wash-out of at least 5 days, then MK-8150 or placebo once daily at a lower dose for 10 days
3088096|NCT01656408|Experimental|Panel G - Healthy - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3088097|NCT01656408|Experimental|Panel H - Crossover|MK-8150 or matching placebo for 10 consecutive days in 2-period crossover with minimum 3 weeks washout period between the 2 treatment periods
3088098|NCT01656408|Experimental|Panel I - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3088099|NCT01656408|Experimental|Panel J - Dose Titration|MK-8150 or matching placebo will be administered once daily for 28 days. Dose may be adjusted on Day 8, Day 15, and Day 22.
3088100|NCT01656434|Experimental|NOMAC-E2|Participants received a NOMAC-E2 tablet (2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NOMAC-E2 tablets on Days 1 to 24 and placebo tablets on Days 25 to 28.
3088101|NCT01656434|Active Comparator|NETA-EE|Participants received a NETA-EE tablet (1 mg norethisterone acetate and 10 μg ethinylestradiol), taken orally once daily for 13 cycles. Each cycle was 28 days. For each cycle, participants received NETA-EE tablets on Days 1 to 24; EE 10 μg tablets on Days 25 and 26; and ferrous fumarate 75 mg tablets on Days 27 and 28.
3088102|NCT01656460|Experimental|Stereotactic radiation Arm 1|"Dose Levels/total Dose~1 16 Gy"
3088103|NCT01656460|Experimental|Stereotactic radiation Arm 2|2 20 Gy
3088104|NCT01656460|Experimental|Stereotactic radiation Arm 3|3 24 Gy
3088105|NCT01656460|Experimental|Stereotactic radiation Arm 4|4 28 Gy
3088106|NCT01656486|Experimental|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.
3088107|NCT01656629|Active Comparator|teriparatide|teriparatide 20 mcg sq for 3 months
3088108|NCT01656629|Active Comparator|Alendronate|70 mg po weekly for 3 months
3088109|NCT01656629|Active Comparator|calcium and vitamin D|calcium 630 mg vitamin D 500 units daily for 3 months
3088110|NCT01656733|Experimental|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
3088111|NCT01656733|Placebo Comparator|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
3088112|NCT01656759|No Intervention|Control Group|Control group. Will not receive the fibrin spray.
3088113|NCT01656759|Active Comparator|Treatment Group--Evicel Fibrin Spray|"Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured."
3088114|NCT01656772|Active Comparator|Manual Lasso navigation|Use of conventional manual navigation techniques with the Lasso catheter
3088115|NCT01656772|Experimental|Vdrive Lasso navigation|Use of the Vdrive to remotely and robotically control the manipulation of a Lasso catheter
3088116|NCT01656850|Experimental|Almond diet first, then NCEP Diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
3088117|NCT01656850|Experimental|NCEP diet first, then Almond diet|In a 28-wk randomized, cross-over, controlled feeding trial with a 2 week washout between alternative diets, subjects were assigned to receive NCEP or almond diet for 12 weeks after a 2-weeks run-in period
3088118|NCT01656889|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
3088119|NCT01656889|Placebo Comparator|Vehicle|Vehicle Control (fibrinogen solution & thrombin solution without cells)
3088120|NCT01656967|Experimental|AMBU Aura-I/aScope 2|First, the AMBU Aura-I LMA will be inserted. Then, the patient will be intubated with assistance of the AMBU aScope 2 disposable fiberoptic system.
3088121|NCT01656967|Experimental|LMA Fastrach|The LMA Fastrach Single Use Laryngeal Mask Airway will be placed, followed by blind intubation using the LMA Fastrach EndoTracheal Tube.
3088122|NCT01657019|Experimental|Lisdexamfetamine dimesylate|
3088123|NCT01657032|Experimental|Lactobacillus GG and Smectite|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~smectite, dose 3 g, once daily orally until diarrhea stopped"
3088124|NCT01657032|Placebo Comparator|Lactobacillus GG and Placebo|"Children received:~LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days and~placebo (glucose), dose 3 g, once daily orally until diarrhea stopped"
3088125|NCT01657162|Experimental|Alendronate|Participants received 70 milligrams (mg) of alendronate orally once per week beginning on Day 2 for up to 24 months after participating in Study BA058-05-003 during which participants received abaloparatide 80 micrograms (mcg) SC or abaloparatide-matching placebo daily for 18 months.
3088126|NCT01657253|Experimental|PRO-148|"PRO-148 containing: xanthan gum and sulphate chondroitin, ophthalmic solution~doses: 1 drop in each eye, quarter in day"
3088127|NCT01657253|Active Comparator|Systane®|"Systane containing: polyethylene glycol 400 0.4%, propylene glycol 0.3% and hydroxypropyl guar~doses: 1 drop in each eye, quarter in day"
3088128|NCT01657266|Experimental|PRO-155|"Bromfenac 0.09% (0.9mg/mL) Ophthalmic solution Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
3088129|NCT01657266|Active Comparator|Nevanac|"Nepafenac 0.1% (1mg/mL) Ophthalmic Suspension~Pre-medication: 1 drop each 15 minutes during 1 hour before surgery in the affected eye~Maintenance therapy: 1 drop 3 times a day for 30 days"
3088130|NCT01657292|Experimental|Oleogel-S10 ointment|Intra-individual comparison. Oleogel-S10 ointment is administered to one randomly assigned wound half.
3088131|NCT01657292|Other|Octenilin® wound gel|Intraindividual comparison: The other wound half receives disinfectant Octenilin® wound gel.
3088132|NCT01657305|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3088133|NCT01657305|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3088134|NCT01657344||ED Patients|All patients (age 0-18 regardless of race, ethnicity, or gender and of diagnosis or chronic health condition) who are registered in the ED.
3088135|NCT01657370|Placebo Comparator|Placebo|MK-1602 placebo-matching tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088136|NCT01657370|Experimental|MK-1602 1 mg|MK-1602 1 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088137|NCT01657370|Experimental|MK-1602 10 mg|MK-1602 10 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088138|NCT01657370|Experimental|MK-1602 25 mg|MK-1602 25 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088139|NCT01657370|Experimental|MK-1602 50 mg|MK-1602 50 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088140|NCT01657370|Experimental|MK-1602 100 mg|MK-1602 100 mg tablet orally for 3 doses: Dose 1 at the onset of a moderate or severe migraine (Day 1), Dose 2 in the evening of Day 3 and Dose 3 on Day 4. After 2 hours participants were able to take rescue medication if necessary.
3088141|NCT01657461|Experimental|IV t-PA with Solitaire™ revascularization device|Dual IV tPA therapy and adjunctive treatment with the Solitaire revascularization device
3088142|NCT01657461|Active Comparator|IV t-PA|Infusion of intravenous tissue plasminogen activator (IV t-PA)
3088143|NCT01657617|Experimental|Radiation Therapy|Boost Stereotactic Body Radiation Therapy (SBRT)
3088144|NCT01657760|Placebo Comparator|placebo|Intravenous saline control, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
3088145|NCT01657760|Active Comparator|citalopram infusion|40 mg citalopram in 250 ml saline infused over 1 hour, in a double-blind, crossover study, with infusion days at least 2 weeks apart.
3088146|NCT01657799|Experimental|Veliparib 200 mg BID + WBRT|Participants received veliparib 200 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3088147|NCT01657799|Experimental|Veliparib 50 mg BID + WBRT|Participants received veliparib 50 mg twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3088148|NCT01657799|Placebo Comparator|Placebo BID + WBRT|Participants received placebo twice a day (BID) orally concomitantly with whole brain radiation therapy (WBRT). Participants received a total of 30.0 Gy of WBRT given in 10 daily fractions of 3.0 Gy, excluding weekends and holidays.
3088149|NCT01657877|Experimental|CSP/SMFP Dentifrice|Dentifrice containing high fluoride content as SMFP and CSP
3088150|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 1|Dentifrice containing high fluoride content as SMFP and no CSP
3088151|NCT01657877|Active Comparator|SMFP Dentifrice Prototype 2|Dentifrice containing low fluoride content as SMFP and no CSP
3088152|NCT01657877|Active Comparator|CSP Dentifrice|Dentifrice containing CSP but no fluoride
3088153|NCT01657877|Placebo Comparator|Placebo Dentifrice|Dentifrice containing no CSP and no fluoride
3088154|NCT01657903|Experimental|NaF/KNO3 toothpaste, Low RDA|Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
3088155|NCT01657903|Experimental|NaF/KNO3 toothpaste, Medium RDA|Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
3088156|NCT01657903|Active Comparator|NaF/KNO3 toothpaste|Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
3088157|NCT01657903|Placebo Comparator|No fluoride/KNO3 toothpaste|Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.
3088158|NCT01658020|Experimental|DW224|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
3088159|NCT01658020|Active Comparator|Avelox|Moxifloxacin 400mg tablet P.O. once daily for 7days
3088160|NCT01658059|Experimental|group 1|homeopathic remedy first , placebo second
3088161|NCT01658059|Experimental|group 2|placebo first, homeopathic remedy second
3088162|NCT01658072|Experimental|Peri-Articular Injection|
3088163|NCT01658072|Active Comparator|Epidural Patient Controlled Analgesia (Epidural PCA)|
3088164|NCT01658150|Experimental|isradipine|open label
3088165|NCT01658228|Other|Donepezil Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Donepezil was started at 5 mg and increased to 10 mg daily or maximum tolerated dose while continuing antidepressants.
3321137|NCT02016547|Experimental|abciximab IV and thrombectomy|abciximab IV (0.25mg/kg by IV bolus, following by 0.125μg/kg by 12 hours IV drip) and thrombectomy
3321138|NCT02016547|Active Comparator|alteplase|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)
3088166|NCT01658228|Other|Placebo Treatment Group|For the initial 16 weeks of open-label antidepressant treatment, citalopram up to 20 mg daily or venlafaxine up to 225 mg daily was prescribed. At 16 weeks, all patients were randomized, double-blind, to add-on donepezil or placebo for 62 weeks. Placebo dose was increased during the study to match Donepezil dose increases while continuing antidepressants.
3088167|NCT01658228|Other|Citalopram|An open treatment 8 week flexible dosing schedule starting with citalopram 10mg/day for the first week, then increasing to 20 mg/day thereafter to treat the depression. At the week 8 visit, citalopram responders will continue citalopram treatment and will be randomized to add-on donepezil or placebo at the week 16 visit.
3088168|NCT01658228|Other|Venlafaxine|For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
3088169|NCT01658436|Experimental|BEZ235 300 mg/400 mg bid (Stage 1)|Stage 1 consisted of a single arm where patients received BEZ235 300mg or 400mg bid. Initially the study started with a dose of 400mg bid. However, following an amendment after the preliminary safety and tolerability data from the first 3 patients treated at the 400mg dose, the dosage was changed to 300mg bid.
3088170|NCT01658514|Experimental|Met DR|One dose of 1000 mg metformin delayed-release
3088171|NCT01658514|Active Comparator|Met XR|One dose of 1000 mg metformin extended-release
3088172|NCT01658514|Placebo Comparator|Placebo|One dose of Placebo
3088173|NCT01658579|Experimental|HOE901-U300 Morning Then Evening|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 millimole per liter (mmol/L).
3088174|NCT01658579|Experimental|HOE901-U300 Evening Then Morning|HOE901-U300 (new insulin glargine 300 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3088175|NCT01658579|Active Comparator|Lantus Morning Then Evening|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning for 8 weeks during treatment period A, followed by once daily in evening for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3088176|NCT01658579|Active Comparator|Lantus Evening Then Morning|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in evening for 8 weeks during treatment period A, followed by once daily in morning for 8 weeks during treatment period B. Dose titration seeking fasting plasma glucose 4.4-7.2 mmol/L.
3088177|NCT01658657|Experimental|PRA-guided therapy|Participants randomized to the PRA-guided therapy treatment arm will be prescribed anti-hypertensive medications based on renin activity level as defined at baseline.
3088178|NCT01658657|Active Comparator|Fixed-dose combination treatment-guided therapy|Participants randomized to the fixed-dose combination treatment-guided arm will be prescribed standard anti-hypertensive medications without regard to renin activity level.
3088179|NCT01658735|Active Comparator|H-Wave Device|H-Wave Device with Usual Care
3088180|NCT01658735|Active Comparator|TENS|Transcutaneous electrical nerve stimulation (TENS) Device with Usual Care
3088181|NCT01658735|Sham Comparator|Sham Electrotherapy|Sham Device plus Usual Care.
3088182|NCT01658839|Experimental|Travoprost|Travoprost ophthalmic solution, 0.004% (new formulation), one drop administered topically in the inferior cul-de-sac of the eye each morning at 9 AM (± 60 minutes) for 7 days
3088183|NCT01658904|Experimental|Cohort 1- CFZ 20 mg/m^2 (Day 1,2)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3088184|NCT01658904|Experimental|Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3088185|NCT01658904|Experimental|Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)|"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)~•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:~Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2~Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9~Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70."
3088186|NCT01658943|Experimental|Arm I (mFOLFOX regimen)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and fluorouracil IV over 46-48 hours on days 1-2 and 15-16.
3088187|NCT01658943|Experimental|Arm II (Akt inhibitor MK2206 and selumetinib)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, and selumetinib PO daily on days 1-28.
3088188|NCT01658995|Active Comparator|Post ESI implant - Doxycycline|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received Doxycycline 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
3088189|NCT01658995|Placebo Comparator|Post ESI implant - Placebo|Subjects will be randomized into this arm after experiencing dissatisfaction with bleeding after 13 weeks post ESI insertion and received placebo 100 mg oral capsules, twice daily for 10 days. After 10 days, subsequent treatment can requested by the subjects
3088190|NCT01659021|Experimental|Idelalisib+ofatumumab|"Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
3088191|NCT01659021|Active Comparator|Ofatumumab|"Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses)~Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation.~Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone."
3088192|NCT01659125|Experimental|OCFighter|OCFighter
3088193|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (CLL)|Participants with relapsed/refractory chronic lymphocytic leukaemia (CLL) received tirabrutinib 20 mg once daily.
3088194|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 40 mg once daily.
3088195|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 80 mg once daily.
3088196|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 160 mg once daily.
3088197|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 320 mg once daily.
3088198|NCT01659255|Experimental|Tirabrutinib 400 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 400 mg once daily.
3088199|NCT01659255|Experimental|Tirabrutinib 500 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 500 mg once daily.
3088200|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 600 mg once daily.
3088201|NCT01659255|Experimental|Tirabrutinib 300 mg Twice Daily (CLL)|Participants with relapsed/refractory CLL received tirabrutinib 300 mg twice daily.
3088202|NCT01659255|Experimental|Tirabrutinib 20 mg Once Daily (NHL)|Participants with relapsed/refractory non-Hodgkin's lymphoma (NHL) received tirabrutinib 20 mg once daily.
3088203|NCT01659255|Experimental|Tirabrutinib 40 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 40 mg once daily.
3088204|NCT01659255|Experimental|Tirabrutinib 80 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 80 mg once daily.
3088205|NCT01659255|Experimental|Tirabrutinib 160 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 160 mg once daily.
3088206|NCT01659255|Experimental|Tirabrutinib 320 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 320 mg once daily.
3088207|NCT01659255|Experimental|Tirabrutinib 480 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 480 mg once daily.
3088208|NCT01659255|Experimental|Tirabrutinib 600 mg Once Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 600 mg once daily.
3088209|NCT01659255|Experimental|Tirabrutinib 240 mg Twice Daily (NHL)|Participants with relapsed/refractory NHL received tirabrutinib 240 mg twice daily.
3088210|NCT01659268|Experimental|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
3088211|NCT01659268|Other|Exhibition-dialogued class|Students will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, each subgroup composed of 4-5 students will go to the and practical activity in skill lab using the low-fidelity mannequin for 35 minutes.
3088212|NCT01659320|Experimental|Minocycline|Open label treatment using minocycline.
3088213|NCT01659567||Chronic Hepatitis C|Participants with chronic hepatitis C, treated with pegylated interferon alfa-2a (Pegasys) and ribavirin (Copegus) according to the current standard of care and in line with current summaries of product characteristics/local labelling, will be observed for up to 96 weeks.
3088214|NCT01659736|Experimental|TMS Therapy|TMS treatment
3088215|NCT01659736|Sham Comparator|TMS-Sham|This is a sham TMS condition
3088216|NCT01659853|Experimental|Overall Study|"In this crossover study of CD07805/47 gel 0.5%/CD07805/47 Vehicle and azelaic acid gel 15%, 70 subjects were randomly assigned to treatment sequence.~During Period 1 (15 days), 35 subjects received topical CD07805/47 gel 0.5% in the morning and topical CD07805/47 gel vehicle in the evening, and 35 received topical azelaic acid gel twice daily according to FDA approved prescribing information. Subjects crossed over to the other treatment in Period 2 (15 days)."
3088217|NCT01659866|Other|Cipro-susceptible|Patients with ciprofloxacin-susceptible bacteria on their rectal swab cultures will receive ciprofloxacin, the standard of care, as prophylaxis for their prostate biopsy
3088218|NCT01659866|Active Comparator|Cipro-resistant|"Patients with ciprofloxacin-resistant bacteria on their rectal swab will receive one of the following drugs:~trimethoprim-sulfamethoxazole 1 double strength tablet orally 2 hours before the procedure and again 12 hours later~cefuroxime 500 mg orally 2 hours before the procedure then again 12 hours later~ceftriaxone 500 mg intramuscularly 2 hours before the procedure~gentamicin 2mg/kg intramuscularly 2 hours before the procedure~amikacin 5 mg/kg intramuscularly 2 hours before the procedure~aztreonam 500 mg intramuscularly 2 hours before the procedure~imipenem 500 mg intramuscularly 2 hours before the procedure~ceftriaxone 2000 mg intravenously 1 hour before the procedure~gentamicin 2 mg/kg intravenously 1 hour before the procedure~amikacin 5mg/kg intravenously 1 hour before the procedure~aztreonam 2000 mg intravenously 1 hour before the procedure~imipenem 1000 mg intravenously 1 hour before the procedure"
3088219|NCT01659996|Experimental|Menactra Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® at 15 to 18 months of age.
3088220|NCT01659996|Experimental|Menactra and Pentacel Vaccine Group|Participants will receive Meningococcal polysaccharide diphtheria toxoid conjugate (Menactra®) at 9 months of age and Menactra® + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed (Pentacel®) concomitantly at 15 to 18 months of age.
3088221|NCT01659996|Active Comparator|Pentacel Vaccine Group|Participants will receive only Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Pentacel®) at 15 to 18 months of age.
3088222|NCT01660022|Experimental|OZ439 100mg|100mg OZ439 single oral dose
3088223|NCT01660022|Experimental|OZ439 100 mg + PQP 160mg|100mg OZ439 single oral dose + 160mg Piperaquine single oral dose
3088224|NCT01660022|Experimental|OZ439 100 mg + PQP 480mg|100mg OZ439 single oral dose + 480mg Piperaquine single oral dose
3088225|NCT01660022|Experimental|OZ439 100 mg + PQP 1440mg|100mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3088226|NCT01660022|Experimental|OZ439 300mg|300mg OZ439 single oral dose
3088227|NCT01660022|Experimental|OZ439 300 mg + PQP 1440mg|300mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3088228|NCT01660022|Experimental|OZ439 800mg|800mg OZ439 single oral dose
3088229|NCT01660022|Experimental|OZ439 800 mg + PQP 1440mg|800mg OZ439 single oral dose + 1440mg Piperaquine single oral dose
3088230|NCT01660022|Placebo Comparator|Placebo|Placebo
3088231|NCT01660191|Active Comparator|Pitavastatin 4mg|Pitavastatin 4mg tablet by mouth once daily for 12 weeks
3088232|NCT01660191|Active Comparator|Atorvastatin 20mg|Atorvastatin 20mg tablet by mouth once daily for 12 weeks
3088233|NCT01660191|Active Comparator|rosuvastatin 5 mg|rosuvastatin 5 mg tablet by mouth once daily for 12 weeks
3088234|NCT01660230|Active Comparator|6 µg/kg 3K3A-APC, single-dose|Cohort 1: 6 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 20 mL IV infusion over 15 minutes
3088235|NCT01660230|Active Comparator|30 µg/kg 3K3A-APC, single-dose|Cohort 2: 30 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3088236|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, single-dose|Cohort 3: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3088237|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, single-dose|Cohort 4: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3088238|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, single-dose|Cohort 5: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3088239|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, single-dose|Cohort 6: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes
3088240|NCT01660230|Active Comparator|90 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 7: 90 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3088241|NCT01660230|Active Comparator|180 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 8: 180 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3088242|NCT01660230|Active Comparator|360 µg/kg 3K3A-APC, q12h for 5 doses|Cohort 9: 360 µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3088243|NCT01660230|Active Comparator|TBD µg/kg 3K3A-APC, q12h for 5 doses|Cohort 10: TBD (not to exceed 720) µg/kg 3K3A-APC, diluted in 0.9% sodium chloride in water and administered as an 100 mL IV infusion over 15 minutes; given every 12 hours for 5 doses
3088244|NCT01660230|Placebo Comparator|Matching Placebo, 0.9% NaCl in water|Cohorts 1-10: 0.9% sodium chloride in water and administered as either 20 mL IV infusion over 15 minutes (Cohort 1), or 100 mL IV infusion over 15 minutes (Cohorts 2-10)
3088245|NCT01660256|Experimental|OPC-12759 ophthalmic solution|OPC-12759 ophthalmic solution
3088246|NCT01660256|Placebo Comparator|Placebo|OPC-12759 ophthalmic solution 0%
3088247|NCT01660256|Active Comparator|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension
3088248|NCT01660321|Experimental|Natroba|Natroba (Spinosad) Topical Suspension, 0.9%
3088249|NCT01660334||Voriconazole|Subjects who are treated with voriconazole
3088250|NCT01660412|Active Comparator|pH altered first|The first injection administered will be the pH altered solution. The second injection will be the standard of care solution (opposite order). The remaining injections will be randomly assigned as either standard of care or pH altered.
3088251|NCT01660412|Active Comparator|Standard of Care first|The first injection administered will be the standard of care solution (SOC). The second injection will be the pH altered solution. The remaining injections will be randomly assigned as either standard of care or pH altered.
3468914|NCT03891342|Experimental|Major surgical patients|Comaprison of fast or slow fluid bolus administration in patients undergoing major surgery requiring fluid challenge as assessed by clinical examination
3468915|NCT03891277|Active Comparator|Ferrous succinate|Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
3088255|NCT01660672|Other|LEVETIRACETAM|Open label, dose escalation to optimal dose.
3088256|NCT01660698|Placebo Comparator|Placebo|maltodextrin powder
3088257|NCT01660698|Active Comparator|Probiotic|probiotic blended in maltodextrin
3088258|NCT01660711|Experimental|FOLFIRINOX chemotherapy|"5FU 2400 mg/m2 IV over 48 hours Irinotecan 180 mg/m2 IV day 1 Oxaliplatin 85 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1~Cycles administered every 14 days for 4 cycles before and 4 cycles after surgery."
3088259|NCT01660737||PASCALLERG® tablets in patients with hay fever|Patients with lactose intolerance and / or chromium hypersensitivity are excluded from the observational study.
3088260|NCT01660763|Experimental|Sufentanil NanoTab PCA System/15 mcg|
3088261|NCT01660763|Placebo Comparator|Placebo Sufentanil NanoTab PCA System|
3088262|NCT01660802|Experimental|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
3088263|NCT01660802|Sham Comparator|Sham|Sham administered in the study eye on Day 1.
3088264|NCT01660815|Experimental|Healthy Volunteers|Cognitively normal, healthy volunteers at least 45 years of age.
3088265|NCT01660893|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and oxymetazoline HCl 0.05%
3088266|NCT01660893|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
3088267|NCT01660893|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
3088268|NCT01660906|Experimental|Dasatinib (100 mg)|
3088269|NCT01661062|Experimental|Cone Beam CT|All patients will be included in the treatment arm of this study. For the purposes of this study patients will get CT scans every day for the length of their radiation therapy (in order to assess if CT every day provides additional information compared with CT scans performed less frequently). Although the exact amount of radiation patients get will be determined by their doctor, it is expected that they will get approximately 7 weeks, approximately 35 total cone beam CT scans.
3088270|NCT01661088|Experimental|Study Treatment|"Patients will receive FOLFIRINOX x 6 followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine (1g/m^2) on days 1, 8, 22, 29.~Intensity-modulated radiotherapy (IMRT): The prescribed dose was 50.0Gy in 2.0Gy per fraction.~Patients without metastatic disease will be offered surgical exploration."
3088271|NCT01661114|Experimental|Gemcitabine, 5-FU and Cisplatin|4 cycles - Gemcitabine, 5-FU and Cisplatin (2 months)-Continue treatment until progression of disease or intolerable toxicity
3088272|NCT01661140|Experimental|Methotrexate (MTX) Tapering Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will receive a double-blind MTX dose according to the MTX tapering scheme between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
3088273|NCT01661140|Active Comparator|Methotrexate (MTX) Maintenance Dosage|At Week 0 participants will start open-label tocilizumab and open-label MTX for 24 weeks. At Week 24, participants achieving a good/moderate European League Against Rheumatism (EULAR) disease response will be randomized to the MTX Tapering group or MTX Maintenance group. In this arm participants will continue to be administered a stable dose of MTX in a double-blind fashion between Week 24 and Week 56. Participants will also continue to receive open-label tocilizumab between Week 24 and Week 56. From Week 56 to Week 72 participants will receive tocilizumab monotherapy.
3088274|NCT01661179|Experimental|Vandetanib 300mg|300 mg/day vandetanib
3088275|NCT01661205|Experimental|AtriCure Bipolar System combined with a catheter ablation|Minimally invasive procedure using the AtriCure Bipolar System plus a catheter ablation performed approximately 1-10 days apart
3088276|NCT01661270|Placebo Comparator|Placebo|Placebo for aflibercept intravenous (IV) infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
3088277|NCT01661270|Experimental|Aflibercept|Aflibercept 4 mg/kg IV infusion on Day 1 of each cycle (1 cycle = 2 weeks) in combination with FOLFIRI regimen until disease progression, unacceptable toxicity or participant's refusal. FOLFIRI regimen: Irinotecan 180 mg/m^2 IV infusion and leucovorin 400 mg/m^2 IV infusion, 5-Fluorouracil IV bolus 400 mg/m^2 followed by continuous IV infusion 2400 mg/m^2.
3088278|NCT01661283|Experimental|Arm A|All patients with MPNST will continue everolimus 10 mg daily and bevacizumab 10 mg/kg dose every 14 days
3088279|NCT01661595|Active Comparator|Sildenafil / Placebo|50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 0-4. Placebo for weeks 5-8.
3088280|NCT01661595|Active Comparator|Tadalafil / Placebo|10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 0-4. Placebo for weeks 5-8.
3088281|NCT01661595|Active Comparator|Placebo / Sildenafil|Placebo for weeks 0-4. 50 mg/day Sildenafil: (Other Name: Viagra, Revatio) for weeks 5-8.
3088282|NCT01661595|Active Comparator|Placebo / Tadalafil|Placebo for weeks 0-4. 10 mg/day Tadalafil: (Other Name: Cialis, Adcirca) for weeks 5-8.
3088283|NCT01661621|Experimental|Group 1|Antimuscarinics (Detrusitol 4 mg QD)
3088284|NCT01661621|Experimental|Group 2|α-blockers (Doxazosin 4 mg QD)
3088285|NCT01661686|Active Comparator|Insertion of a partially covered SEMS|
3088286|NCT01661686|Active Comparator|Insertion of a Fully covered SEMS|
3088287|NCT01661712|Active Comparator|Transcutaneous electrical stimulation|One night of transcutaneous electrical stimulation (electrical current titrated according to skin sensation)
3088288|NCT01661712|Sham Comparator|Sham stimulation|One night of sham stimulation (no electrical current)
3088289|NCT01661764|Active Comparator|rs174535 (GG), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
3088290|NCT01661764|Placebo Comparator|rs174535 (GG), placebo|Oleic Acid
3088291|NCT01661764|Active Comparator|rs174535 (GT), fish oil supplements|Eicosapentanoic acid and docosahexanoic acid
3088292|NCT01661764|Placebo Comparator|rs174535 (GT), placebo|Oleic Acid
3088293|NCT01661764|Active Comparator|rs174535 (TT), fish oil supplement|Eicosapentanoic acid and docosahexanoic acid
3088294|NCT01661764|Placebo Comparator|rs174535 (TT), placebo|Oleic Acid
3088295|NCT01661790|Experimental|Bevacizumab & Cisplatin|Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
3088296|NCT01661790|Active Comparator|Cisplatin|Cisplatin 30mg by intrapleural given every two weeks
3088297|NCT01661881|Experimental|RB/RC|"Patients received 3 cycles of outpatient RB (rituximab 375 mg/m2 day 1, bendamustine 90 mg/m2 days 1 and 2 of a 4-week cycle), followed by interim CT restaging. Patients with progressive disease (PD) went off study. Those with stable disease (SD) or better went on to receive three cycles of inpatient RC (rituximab 375 mg/m2 day 1, cytarabine 3 g/m2 every 12 h for 4 doses). The cytarabine was dose reduced to:~2 g/m2 for age >60 years old, creatinine 114.9-176.8 lmol/l (for patients ≤60 years old), and pre-existing neurotoxicity;~1.5 g/m2 for age >60 years old AND creatinine 114.9-176.8 lmol/l, or for age >60 years old AND pre-existing neurotoxicity;~1 g/m2 for age > 60 years old AND creatinine 114.9-176.8 lmol/l AND pre-existing neurotoxicity.~Stem cell mobilization and collection, ASCT and post-transplantation supportive care were performed per institutional standard and not as part of this study."
3088298|NCT01661933|Experimental|Necator americanus, gluten challenge|Single arm, vertical.
3088299|NCT01661946|Active Comparator|Ranibizumab|intravitreal injection of 0.5mg ranibizumab in usual fashion
3088300|NCT01661946|Active Comparator|Bevacizumab|intravitreal injection of 1.25mg bevacizumab in usual fashion
3088301|NCT01661972|Experimental|Phase 1: Capecitabine and Aflibercept|A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
3088302|NCT01661972|Experimental|Phase 2: Capecitabine and Aflibercept|Once the RPTD of the doublet combination has been identified, an additional 50 subjects with metastatic colorectal cancer will be added to a single, Phase 2 arm
3088303|NCT01662024|Experimental|Endoscopic gastric restrictive procedure|Restrict gastric size by approximating tissue endolumenally via an incisionless/per-oral approach.
3088304|NCT01662063|Experimental|SC TCZ QW|Participants who received IV TCZ in the previous trial will be switched to SC TCZ 162 mg QW, and those who received SC TCZ will continue at their same dosage of SC TCZ 162 mg QW. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
3088305|NCT01662063|Experimental|SC TCZ Q2W|Participants who received SC TCZ will continue at their same dosage of SC TCZ 162 mg Q2W. Tocilizumab will be given for an additional 96 weeks in this open-label extension study.
3088306|NCT01662115|Active Comparator|Nicotine gum|100 subjects who will actually get the intervention medication
3088307|NCT01662115|Sham Comparator|regular chewing gum|100 subjects who will be part of a control group
3088308|NCT01662115|No Intervention|No gum|100 subjects who will not get neither the intervention nor the placebo gum.
3088309|NCT01662297|Active Comparator|Quetiapine|Veterans remaining on quetiapine for insomnia.
3088310|NCT01662297|Active Comparator|Trazodone|Veterans switching from quetiapine to trazodone for the treatment of insomnia.
3088311|NCT01662310|Experimental|Paliperidone: Run-in or Stabilization phase|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) once daily for 8 weeks. Dose will be increased from milligram per day (3 mg/day) after 5 days based on Investigator's discretion, up to maximum of 12 mg/day.
3088312|NCT01662310|Experimental|Paliperidone: Double blind (DB) phase|Participants who transitioned from run-in or stabilization phase received 3 to 12 mg fixed dose of paliperidone ER oral tablet once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
3088313|NCT01662310|Active Comparator|Placebo: DB phase|Participants who transitioned from run-in or stabilization phase received matching placebo to paliperidone ER once daily during DB phase of the study. Participants who will experience a relapse event during the DB phase or who will remain relapse free for the entire duration of the DB phase and participants, who will be enrolled at the time the study termination will enter in open label extension phase, wherein paliperidone ER oral tablet will be administered once daily as 3 to 12 mg.
3088314|NCT01662336||Lopinavir/Ritonavir + KASA|Patients were treated according to the standard of care provided by their respective study sites. Treatments with LPV/r and participation in the KASA program were according to the decision of the treating physician and the participant, and were not affected in any way by their decision to participate in the study.
3088315|NCT01662362|Other|Testing Donor Specimens with ESA Chagas|Test blood donor specimens that are ABBOTT PRISM Chagas Repeatedly Reactive with ESA Chagas. Donors will be asked to return for a follow-up blood draw.
3088316|NCT01662440|Active Comparator|R/JE - Conv|Subjects received Rabies and Japanese Encephalitis (JE) vaccines following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and JE vaccination on day 1 and 29, and placebo on day 8 in the left arm.
3088317|NCT01662440|Experimental|R/JE - Acc|Subjects received Rabies and JE vaccines following the accelerated schedule, ie, Rabies vaccination on days 1, 4, and 8, and placebo on day 29 in the right arm or leg; and JE vaccination on days 1 and 8, and placebo on day 29 in the left arm.
3088318|NCT01662440|Active Comparator|R - Conv|Subjects received Rabies vaccine following the conventional schedule, ie, Rabies vaccination on days 1, 8, and 29, and placebo on day 4 in the right arm or leg; and placebo on days 1, 8 and 29 in the left arm.
3088319|NCT01662440|Active Comparator|JE - Conv|Subjects received JE vaccine following the conventional schedule, ie, placebo on days 1, 4, 8 and 29 in the right arm or leg; and JE vaccination on days 1 and 29 and placebo injection on day 8 in the left arm.
3088320|NCT01662492|Experimental|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
3088321|NCT01662492|Experimental|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
3088322|NCT01662492|Placebo Comparator|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
3088323|NCT01662505|Experimental|Volasertib|Patient to receive escalating dose of volasertib
3088324|NCT01662531|Experimental|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) will be administered by IV infusion as routine weekly prophylaxis and episodic treatment for bleeding episodes.
3088325|NCT01662583|Experimental|Educational Text Message|Educational text message reminder
3088326|NCT01662583|Experimental|Plain Text Message|plain text message reminder
3088327|NCT01662583|Other|Written reminder only|written reminder at time of vaccination
3088328|NCT01662635||ALK-BREAK APART|"We reviewed 230 consecutive cases of NSCLC that were retrieved from oncologic molecular laboratory and diagnostic pathology unit at the Instituto Nacional de Cancerologia, Mexico city, between 2011 and 2014. Samples were sent to the unit of pathological anatomy, a Pathologist confirmed the histologic diagnosis. The only inclusion criterion was the availability of tissue for biomarker studies. Clinical and pathologic details of these patients were included in a database, obtained from medical records.~For ALK fusion testing, we applied dual-color, break-apart FISH, RT-qPCR, and immunohistochemistry. Interpretation of the results was done in double-blind manner without knowing the results by other methods."
3088329|NCT01662648|Experimental|Paliperidone ER: Lack of efficacy|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of efficacy.
3088330|NCT01662648|Experimental|Paliperidone ER: Lack of tolerability, compliance or other|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics for the main reason of lack of tolerability, compliance or other reasons.
3088331|NCT01662752|Other|Indocyanine green|Indocyanine green is used for intraoperative identification of sentinel lymph nodes in patients with early colonic cancer using near infrared laparoscopic imaging
3088332|NCT01662765|Experimental|Surgery|"Circular incision 2-3 mm below the skin level in the umbilicus through the subcutaneous fat towards the linea alba. Dissection of the subcutaneous tissue within the umbilicus and its deep connection to preperitoneal fat through the linea alba. Excision of the umbilical complex containing pilonidal cyst 3 mm below the umbilical ostium.~Approximation of the subcutaneous tissue with a single purse-string absorbable suture. The specimen, including the umbilical complex (pilonidal cyst, and involved skin and subcutaneous tissue), was transferred to department of pathology for histopathological examination."
3088333|NCT01662765|Active Comparator|Conservative|"Conservative treatment described as follow:~Under local anesthesia, extracting all protruding hair, and curetting the granulation tissue and pilonidal cyst deep in the umbilicus.~postoperative management include antibiotic treatment with ampicilline plus sulbactam and ornidazole, shaving surrounding skin, washing twice daily, and keeping umbilicus dry."
3088334|NCT01662778|Active Comparator|Monodisperse FP 1.5um|50 mg of monodisperse Fluticasone Propionate delivered as 1.5 microns aerosol followed by AMP PC20 challenge test
3088335|NCT01662778|Active Comparator|Monodisperse FP 6.0um|50 mg of monodisperse Fluticasone Propionate delivered as 6.0 microns aerosol followed by AMP PC20 challenge test
3088336|NCT01662778|Placebo Comparator|Placebo STAG|No active drug, just solvent delivered from STAG followed by AMP PC20 challenge test
3088337|NCT01662778|Active Comparator|MDI FP|Fluticasone Propionate , Metered dose inhaler, 250 mg dose followed by AMP PC20 challenge test
3088338|NCT01662791|Experimental|Case Group|All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
3088339|NCT01662791|No Intervention|Control Group|This arm consisted of subjects with Parkinson's Disease who had not experienced significant weight loss. These patients were in the study for one day.
3088340|NCT01662856|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3088341|NCT01662856|Active Comparator|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
3088342|NCT01662882|Experimental|AD Subjects|
3088343|NCT01662882|Experimental|MCI|MCI (mild cognitive impairment)
3088344|NCT01662882|Experimental|Healthy Controls|
3088345|NCT01662895|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 2 gm of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water. The reconstituted drug will be further diluted in normal saline to achieve a final concentration of 7.5 mg per ml.
3088346|NCT01662895|Placebo Comparator|Normal Saline|0.9% sodium chloride
3088347|NCT01662908|Experimental|edoxaban tosylate|
3088348|NCT01662908|Active Comparator|heparin/warfarin|
3088349|NCT01662960|Experimental|Mirror therapy|4 weeks of home-based mirror therapy. Participants practiced making movements with mirrored visual feedback of the low-functioning arm.
3088350|NCT01662960|Active Comparator|Divider therapy|4 weeks of home-based divider therapy (control therapy to mirror therapy; mirror replaced by a divider). Participants practiced making movements with no visual feedback of the low-functioning arm.
3088351|NCT01662986|Active Comparator|18 mcg tiotropium bromide|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3088352|NCT01662986|Placebo Comparator|placebo|Patient to receive one placebo inhalation powder capsule daily (in the morning) via HandiHaler
3088353|NCT01662999|Experimental|A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)|Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose
3088354|NCT01662999|Experimental|A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin|Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
3088355|NCT01662999|Experimental|B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose
3088356|NCT01662999|Experimental|B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin|Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
3088357|NCT01662999|Experimental|C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose
3088358|NCT01662999|Experimental|C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin|Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose
3088359|NCT01663012|Experimental|Drug: Etirinotecan pegol|145 mg/m2 dose
3088360|NCT01663103|Experimental|Rilonacept|12 weeks of treatment with rilonacept
3088361|NCT01663103|Placebo Comparator|Placebo|Twelve weeks of treatment with placebo
3321139|NCT02016573|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
3088362|NCT01663233|Experimental|LCZ696 and amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 200mg of LCZ696 in combination with 5 mg of amlodipine for 8 weeks.
3088363|NCT01663233|Active Comparator|Amlodipine|Participants, first treated with 5 mg of amlodipine for 4 weeks to determine if they were not adequately responding to amlodipine (had an office msSBP ≥145 mmHg and <180 mmHg) and who met all inclusion and exclusion criteria), were randomized to receive 5 mg of amlodipine and placebo to LCZ696 for 8 weeks.
3088364|NCT01663259|Experimental|Cetuximab|
3088365|NCT01663272|Experimental|cabozantinib with gemcitabine|The Study Treatment Period will consist of continued treatment during which time patients will receive cabozantinib and gemcitabine until either disease progression or the occurrence of unacceptable drug-related toxicity
3088366|NCT01663363|Experimental|wavefront-guided LASIK|LASIK correction of myopic refractive errors. Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System.
3088367|NCT01663402|Placebo Comparator|Placebo|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for up to 64 months.
3088368|NCT01663402|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for up to 64 months. Alirocumab dose up-titrated to 150 mg Q2W from Month 2 when Low-Density Lipoprotein Cholesterol (LDL-C) levels >=50 mg/dL (1.29 mmol/L) at Month 1; or if up-titration was missed due to unavailability of LDL-C value, it was up-titrated at month 4 based on LDL-C value at Month 2. For participants receiving 150 mg Q2W, alirocumab dose was down-titrated in a blinded manner to 75 mg Q2W if two consecutive values of LDL-C were <25 mg/dL (0.65 mmol/L). For participants receiving 75 mg Q2W, alirocumab dose was switched to placebo in a blinded manner if two consecutive values of LDL-C were <15 mg/dL (0.39 mmol/L).
3088369|NCT01663506||Cohort|
3088370|NCT01663532|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg, with allowed decrease to 300 mg for safety and return to 400 mg for efficacy if needed, every four weeks for 12 weeks
3088371|NCT01663532|Placebo Comparator|Placebo|Matching placebo
3088372|NCT01663623|Placebo Comparator|Placebo plus azathioprine|Placebo IV plus oral azathioprine 2 mg/kg/day; placebo administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to receive treatment with belimumab in a 6-month open-label extension phase. Placebo patients who opt to participate in the extension will receive belimumab 10 mg/kg IV every 28 days plus oral azathioprine 2 mg/kg/day for an additional 6 months.
3088373|NCT01663623|Experimental|Belimumab 10 mg/kg plus azathioprine|Belimumab 10 mg/kg IV plus oral azathioprine 2 mg/kg/day; belimumab administered on Days 0, 14, 28, and then every 28 days until the end of the study. If the results in the double-blind period show that belimumab is safe and effective, then participants have the option to continue treatment with belimumab in a 6-month open-label extension phase. Patients who opt to participate in the extension will continue to receive belimumab 10 mg/kg IV every 28 plus oral azathioprine 2 mg/kg/day days for an additional 6 months.
3088374|NCT01663636||SMS Vaccine|Mothers will be sent an SMS message reminding them to come for their scheduled vaccines 1 week prior to the date of 2nd and 3rd doses
3088375|NCT01663636||Usual care|Mothers under usual care will serve as a control
3088376|NCT01663714|Experimental|open-label, single arm|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
3088377|NCT01663727|Experimental|A|Paclitaxel + Bevacizumab [Avastin]
3088378|NCT01663727|Experimental|B|Paclitaxel + Placebo
3088379|NCT01663740|Experimental|Cohort A: Partcipants who Received Valganciclovir|Participants with donor positive (D+)/recipient negative (R-) cytomegalovirus (CMV) serology, who receive valganciclovir prophylaxis according to the local prescribing information, will be observed for spermatogenesis up to 52 weeks post-transplant.
3088380|NCT01663740|No Intervention|Cohort B: Untreated Participants|Participants with donor negative (D-)/R- CMV serology, who do not receive prophylaxis, will be observed for spermatogenesis up to 52 weeks post-transplant.
3088381|NCT01663779|Experimental|Ultrasound radial artery catheter|Ultrasound guided radial artery catheterization.
3088382|NCT01663779|Active Comparator|Palpation based artery catheterization|Blind insertion of radial artery catheterization
3088383|NCT01663857|Experimental|Phase 1b (Cohort 1) LY2228820 200 milligrams (mg)|"Cohort 1: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 milligrams per square meter (mg/m^2) administered intravenously (IV) over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3..~Cohort 1: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
3088384|NCT01663857|Experimental|Phase 1b (Cohort 2) LY2228820 300 mg|"Cohort 2: Cycles 1-6 (21 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Cohort 2: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
3088385|NCT01663857|Experimental|Phase 2 (Arm A) LY2228820 200 mg|"Arm A: Cycles 1-6 (21 day cycles)- LY2228820 200 mg administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm A: Cycles 7+ (28 day cycles)- LY2228820 300 mg administered orally every 12 hours on days 1-14."
3088386|NCT01663857|Placebo Comparator|Phase 2 (Arm B) Placebo|"Arm B: Cycles 1-6 (21 day cycles)- Placebo administered orally every 12 hours on days 1-10. Gemcitabine 1000 mg/m^2 administered IV over 30 minutes on days 3 and 10. Carboplatin dose Area Under Curve (AUC) 4 (maximum dose 600 mg) administered IV over 30 minutes on day 3.~Arm B: Cycle 7+ (28 day cycles)- Placebo administered orally on days 1-14 to maintain blind."
3088387|NCT01663896||Single or multi vessel disease|Pre- and post-PCI fractional flow reserve (FFR) and OCT were performed in participants.
3088388|NCT01663922|Experimental|St John's Wort, then Boceprevir|D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
3088389|NCT01663922|Experimental|Boceprevir, then St John's Wort|D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD
3088390|NCT01663935|Other|Levodopa/carbidopa 4mg/kg/day|Treatment drug taken orally three times daily
3088391|NCT01663987|Active Comparator|18 mcg tiotropium|Patient to receive one tiotropium bromide inhalation powder capsule daily (in the morning) via HandiHaler
3088392|NCT01663987|Placebo Comparator|Placebo|Patient to receive one placebo capsule daily (in the morning) identical to those containing tiotropium bromide inhalation powder via HandiHaler
3088393|NCT01664039|Experimental|TRAVATAN|Travoprost 0.004% ophthalmic solution with Polyquad®, 1 drop to the study eye(s), once a day in the evening, for 6 months
3088394|NCT01664039|Active Comparator|LUMIGAN|Bimatoprost 0.01% ophthalmic solution with BAK, 1 drop to the study eye(s), once a day in the evening, for 6 months
3088395|NCT01664052|Experimental|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
3088396|NCT01664052|Experimental|ESS 305/ESS 505 (Essure, BAY1454032/Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
3088397|NCT01664078|Experimental|InCraft® - AAA stent graft system|Intervention: Endovascular AAA repair using the InCraft device
3088398|NCT01664091|Experimental|TE-ADM with PMRT|Participants received immediate breast reconstruction using a sub-muscular tissue expander (TE) and acellular dermal matrix (ADM) sling placed during the same surgery. This was followed by post-mastectomy radiation therapy (PMRT) no sooner than a minimum of 6 weeks and optimally 6 months, if adjuvant chemotherapy was required. The prescribed chest-wall dose was 50 -50.4 gray (Gy) in 25-28 fractions given once daily over 5-7 weeks with a 0.5-centimeter (cm) bolus to the scar every other day. Permanent reconstruction was performed at least 5 months after completion of PMRT.
3088399|NCT01664104||RA Participants|Participants with moderate or severe RA who are under tocilizumab treatment in routine clinical practice (in accordance with the local label) will be observed for 6 months from the start of treatment.
3088400|NCT01664117||bDMARD Monotherapy|Patients with moderate to severe rheumatoid arthritis (RA) will be treated with bDMARD (biologic disease-modifying antirheumatic drug) monotherapy under routine clinical practice conditions at rheumatology clinics
3088401|NCT01664130|Experimental|Treatment (SBRT)|Patients undergo 5 fractions of prostate stereotactic body radiation therapy over 10-20 days with at least 40 hours between each fraction in the absence of disease progression or unacceptable toxicity.
3088402|NCT01664247|Experimental|IDeg + Lira|
3088403|NCT01664247|Experimental|Placebo + Lira|
3088404|NCT01664494||Capecitabine|Participants will receive capecitabine according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
3088405|NCT01664533||Erlotinib|Selection of the dose of erlotinib most suitable for each participant was left to the discretion of the physician, guided by the recommendation in the Summary of Product Characteristics. The recommended daily oral dose of erlotinib is 150 mg.
3088406|NCT01664559|Placebo Comparator|Placebo with 1cc normal saline IM|If the patient is randomized to the placebo arm, they will receive 1cc of normal saline via the intramuscular route.
3088407|NCT01664559|Experimental|Toradol, 30mg in 1cc IM|If the patient is randomized to the toradol (ketorolac) arm, they will receive 30mg of toradol in a 1cc volume via the intramuscular route.
3088408|NCT01664624|Experimental|Roflumilast + alogliptin|Roflumilast 500 μg, tablets, orally and alogliptin 25 mg, tablets, orally, once a day for 11 days.
3088409|NCT01664624|Experimental|Alogliptin alone|Placebo to roflumilast, tablets, orally and alogliptin, 25 mg, tablets, orally, once a day for 11 days.
3088410|NCT01664624|Experimental|Roflumilast alone|Roflumilast 500 μg, tablets, orally and placebo to alogliptin, tablets, orally, once a day, for 11 days.
3088411|NCT01664624|Active Comparator|Exenatide|Exenatide 5 μg subcutaneous injection twice a day for 11 days.
3088412|NCT01664741|Active Comparator|Nicotine patch - transdermal|21 mg nicotine patch
3088413|NCT01664741|Placebo Comparator|Placebo NRT|Matching placebo patch
3088414|NCT01664741|No Intervention|Healthy non-smoker comparison|Demographically-matched women and men who have never smoked
3088415|NCT01664793|Experimental|Intervention Group Year 1|The 4 Pillars Immunization Toolkit along with donated vaccines for early season vaccination, staff education and support.
3088416|NCT01664793|No Intervention|Control Group Year 1|Control sites will not receive assistance with increasing influenza vaccination in Year 1, they will follow guidelines for usual care.
3088417|NCT01664806|No Intervention|Coag mode 30 Watts Power|Elective laparoscopic cholecystectomy will be performed with 30 Watts power coag mode which is current standard of care.
3088418|NCT01664806|Experimental|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform Elective laparoscopic cholecystectomy. which is the experimental arm of the study's mode.
3088419|NCT01664858|Active Comparator|3T CMR-guided management|Patient to be managed according to the results of 3T CMR imaging
3088420|NCT01664858|Active Comparator|SPECT-guided management|Patients to be managed according to the results of SPECT
3321140|NCT02016573|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
3088421|NCT01664858|Active Comparator|NICE-guidelines based management|"Patients will be receive NICE-guidelines based management and will receive the imaging strategy specified by NICE according to their pre-test likelihood of having CHD.~10-29% - CT calcium score +/- CT coronary angiography; 30-60% - SPECT; 61-90% - X-Ray coronary angiography"
3088422|NCT01664897|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3088423|NCT01664923|Experimental|Enzalutamide|Enzalutamide 160 mg/day orally
3088424|NCT01664923|Active Comparator|Bicalutamide|50 mg/day orally
3088425|NCT01664949|Experimental|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
3088426|NCT01664949|Active Comparator|OPTIVE™|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
3088427|NCT01664975|Experimental|GDPT regimen|GDPT(gemcitabine,cisplatin,Prednisone,Thalidomide) regimen
3088428|NCT01664975|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3088429|NCT01665040|Experimental|Neurostimulation for chronic pain|Neurostimulation (spinal cord stimulation with or without peripheral nerve stimulation of the trunk) for chronic intractable pain of the trunk and/or limbs.
3088430|NCT01665053|Active Comparator|Promus Element Plus|PROMUS Element Plus is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
3088431|NCT01665053|Experimental|SYNERGY|SYNERGY is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
3088432|NCT01665092|Placebo Comparator|Control|Normal saline
3088433|NCT01665092|Experimental|Carnitine Low|Levo-Carnitine 6g
3088434|NCT01665092|Experimental|Carnitine Medium|Levo-Carnitine 12 g
3088435|NCT01665092|Experimental|Carnitine High|Levo-Carnitine 18 g
3468916|NCT03891277|Placebo Comparator|placebo|placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks.
3468917|NCT03891004|Experimental|Tissue Adhesives Only|For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
3088438|NCT01665157|Experimental|low-residue diet package (Enimaclin®)|Low-residue diet package with normal amount 2L PEG-ELS
3088439|NCT01665157|Placebo Comparator|Self-controlled diet|Self-controlled diet with normal amount of 2L PEG-ELS
3088440|NCT01665157|Experimental|Low-residue diet (Enimaclin®) package|Low-residue diet package with low volume 1.5L PEG-ELS
3088441|NCT01665170|Placebo Comparator|Placebo|Placebo arm
3088442|NCT01665170|Active Comparator|Verum|Verum arm - Pascoflair 425mg
3088443|NCT01665430|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.
3088444|NCT01665508|Experimental|Nebivolol|Testing will be performed at baseline (SAQ questionnaire, cardiopulmonary testing, resource utilization, metabolomics and vascular testing). This will be repeated on the same group of patients after 3 months of nebivolol treatment.
3088445|NCT01665599|Experimental|Testosterone gel (FE 999303)|"Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations.~Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion."
3088446|NCT01665768|Experimental|Everolimus and Rituximab|Everolimus daily for one year and IV rituximab four times during that year.
3088447|NCT01665807|Experimental|Nurse-administered IM|Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
3088448|NCT01665807|Experimental|Self-administered intradermal|Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
3088449|NCT01665807|Active Comparator|Repeat self-administration intradermal|Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study
3088450|NCT01665872|Experimental|Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention co-facilitated by mental health clinician and a Community Mental Health Ambassador (peer).
3088451|NCT01665872|Active Comparator|Standard of care - Cognitive-Behavioral Group Therapy|8-session Cognitive-Behavioral intervention based on Munoz et al's Mother Baby Manual, modified to meet the needs of mothers of children of all ages residing in public housing in New Haven, CT. Intervention administered by mental health clinician.
3088452|NCT01665911|Other|Arm 1|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3088453|NCT01665911|Other|Arm 2|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3088454|NCT01665911|Other|Arm 3|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3088455|NCT01665911|Other|Arm 4|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3088456|NCT01665911|Active Comparator|Arm 5|non-fluoridated milk, 200 ml 1.5 mg sodium fluoride in 100 ml milk, 1.5 mg sodium fluoride in 200 ml milk, 3 mg sodium fluoride in 100 ml milk, 3 mg sodium fluoride in 200 ml milk
3088457|NCT01665950|Experimental|Simvastatin-Simvastatin|Subjects will receive simvastatin in phase 1 (4 weeks) and phase 2 (4 weeks)
3088458|NCT01665950|Experimental|Placebo->Simvastatin|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the next 4 weeks
3088459|NCT01665950|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or simvastatin for the subsequent 4 weeks
3088460|NCT01666002|Experimental|Treatment|"st visit: Patient will come into clinic for initial laser treatment with Nd:YAG 1064 nm laser fitted with special handpiece.~nd visit: 2 weeks after initial laser treatment, patient will be seen for second treatment with Nd:YAG 1064 nm laser fitted with special handpiece."
3088461|NCT01666002|No Intervention|Placebo|"st visit: For the control group, no treatment will be given.~nd visit: 2 weeks after initial visit, patient will be seen for second visit"
3088462|NCT01666119|Experimental|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone)will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
3088463|NCT01666145|Experimental|Intraoperative Imaging|Laparoscopic microwave ablation surgery utilizing the Advanced Image Guidance system for needle placement.
3088464|NCT01666197|Experimental|diclofenac potassium 25 mg tablet|
3088465|NCT01666197|Placebo Comparator|placebo|
3088466|NCT01666210|Active Comparator|Dexamethasone Punctum Plug|Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days
3088467|NCT01666210|Placebo Comparator|Placebo Vehicle Punctum Plug|Placebo punctum plug insertion
3088468|NCT01666314|Other|Placebo + Orteronel 200 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 (28 days) followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088469|NCT01666314|Experimental|Orteronel 200 mg (Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 3 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088470|NCT01666314|Other|Placebo + Orteronel 300 mg (Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088471|NCT01666314|Experimental|Orteronel 300 mg (Japan)|Orteronel 300 mg, tablets, orally, twice daily in 28 day cycles in Japan for up to 2.8 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088472|NCT01666314|Other|Placebo + Orteronel 200 mg (Ex-Japan)|"Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 200 mg, tablets, orally, twice daily in 28 day cycles outside of Japan (Ex-Japan) for up to 3.1 years.~Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study."
3088473|NCT01666314|Experimental|Orteronel 200 mg (Ex-Japan)|Orteronel 200 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088474|NCT01666314|Other|Placebo + Orteronel 400 mg (Ex-Japan)|Orteronel placebo-matching tablets, orally, twice daily in Cycle 1 followed by orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088475|NCT01666314|Experimental|Orteronel 400 mg (Ex-Japan)|Orteronel 400 mg, tablets, orally, twice daily in 28 day cycles Ex-Japan for up to 3.1 years. Study drug will be administered concomitantly with prednisone (or commercially available equivalent) 5 mg twice daily (BID) continuously throughout the study.
3088476|NCT01666444|Experimental|PLD 40 mg/m2 plus VTX-2337|The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
3088477|NCT01666444|Active Comparator|PLD 40 mg/m2 plus placebo|The dosing schedule will be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus placebo on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus placebo on Day 3 only.
3088478|NCT01666652|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3088479|NCT01666652|Experimental|TDENV-PIV AS01E1|1 µg TDENV-PIV with AS01E1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3088480|NCT01666652|Experimental|TDENV-PIV AS03B1|1 µg TDENV-PIV with AS03B1 adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3088481|NCT01666652|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
3088482|NCT01666652|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3088483|NCT01666730|Experimental|Treatment (metformin hydrochloride, FOLFOX)|Patients receive metformin hydrochloride PO BID on days 1-14 and FOLFOX therapy comprising leucovorin calcium IV over 120 minutes, fluorouracil IV continuously over 46 hours, and oxaliplatin IV over 120 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3088484|NCT01666782|Experimental|High-Dose Influenza Vaccine|
3088485|NCT01666782|Active Comparator|Standard Trivalent Influenza Vaccine|
3088486|NCT01666912|Active Comparator|6 week postpartum contraceptive implant|randomized to receive contraceptive implant at normal 6 week postpartum visit
3088487|NCT01666912|Experimental|Immediate postpartum contraceptive implant|randomized to receive contraceptive implant prior to leaving the hospital postpartum
3088488|NCT01666951|Experimental|LCP-Tacro|LCP-Tacro Tablets, once daily (Veloxis Pharmaceuticals A/S, Horsholm, DK)
3088489|NCT01666951|Active Comparator|Prograf|Prograf Capsules, twice daily (Astellas Pharma US, Deerfield, IL)
3088490|NCT01667029|Experimental|sulfasalazine|1 g oral twice daily for 2 weeks
3088491|NCT01667029|Placebo Comparator|placebo|oral placebo pill twice daily for two weeks.
3088492|NCT01667107|Experimental|Posaconazole - CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
3088493|NCT01667107|Experimental|Posaconazole - Non-CF Participants|Posaconazole 400 mg oral solution twice daily administered with Calogen® to optimize absorption for a total of 6 weeks starting within 12 hours of leaving surgery, thereafter administered in the hospital or as an outpatient; the dose could be changed to posaconazole 200 mg 4 times per day if the participant is unable to meet the conditions for optimal absorption of posaconazole.
3088494|NCT01667224|Experimental|Actiponin|Actiponin(extract of Gynostema pentaphyllum, 450mg/day) for 12weeks
3088495|NCT01667224|Placebo Comparator|Placebo|Placebo(450mg/day) for 12weeks
3088496|NCT01667250|Active Comparator|GammaCore Active Device|Subjects will use an Active GammaCore Device
3088497|NCT01667250|Sham Comparator|GammaCore Sham Device|Subjects who treat with the gammacore sham device in Phase 2 will receive the active gammacore treatment during phase 3 (active treatment) of this study.
3088498|NCT01667406|Experimental|Kisspeptin-54, 1.6 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 1.6 nmol/kg
3088499|NCT01667406|Experimental|Kisspeptin-54, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
3088500|NCT01667406|Experimental|Kisspeptin-54, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
3088501|NCT01667406|Experimental|Kisspeptin-54, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
3088502|NCT01667406|Experimental|Kisspeptin-54 OHSS, 3.2 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 3.2 nmol/kg
3088503|NCT01667406|Experimental|Kisspeptin-54 OHSS, 6.4 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 6.4 nmol/kg
3088504|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 9.6 nmol/kg
3088505|NCT01667406|Experimental|Kisspeptin-54 OHSS, 12.8 single|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a single trigger injection of Kisspeptin, dose of 12.8 nmol/kg
3088506|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + 9.6|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of Kisspeptin, dose of 9.6 nmol/kg 10 hours later
3088507|NCT01667406|Experimental|Kisspeptin-54 OHSS, 9.6 + saline|Participant undergoing in vitro fertilisation (IVF) treatment and who is at high risk of ovarian hyper stimulation syndrome (OHSS) will receive a trigger injection of Kisspeptin, dose of 9.6 nmol/kg and a further injection of saline10 hours later
3088508|NCT01667419|Experimental|Cohort 1 Vemurafenib|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
3088509|NCT01667419|Placebo Comparator|Cohort 1 Placebo|Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
3088510|NCT01667419|Experimental|Cohort 2 Vemurafenib|Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
3088511|NCT01667419|Placebo Comparator|Cohort 2 Placebo|Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
3088512|NCT01667432||Peginterferon alfa-2a|Participants received peginterferon alfa-2a (PEGASYS®) 180 µg subcutaneously in the abdomen or thigh once weekly for 12 weeks.
3088513|NCT01667471|Experimental|RoActemra/Actemra|
3088514|NCT01667536|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
3088515|NCT01667549|Experimental|1M0.5|"Mothers will receive the intervention for 1 month beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3088516|NCT01667549|Experimental|1M1.5|"Mothers will receive the intervention for 1 month beginning when their infant is 1.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3088517|NCT01667549|Experimental|3M0.5|"Mothers will receive the intervention for 3 months beginning when their infant is 0.5 months old.~Intervention: Timing of Diet and Flavor Experience"
3088518|NCT01667549|No Intervention|Control|Mothers will not receive the intervention.
3088519|NCT01667562|Experimental|Erlotinib|Erlotinib will be administered as a single daily oral dose of 150 milligrams until disease progression, death or unacceptable toxicity.
3088520|NCT01667562|No Intervention|Diagnostic Phase|Participants with advanced or metastatic NSCLC were tested for EGFR mutations. Participants who did not have an EGFR mutation were excluded from the study.
3088521|NCT01667679|Experimental|OPTINOSE SUMATRIPTAN and Placebo|20 mg OPTINOSE SUMATRIPTAN Powder Delivered Intranasally With the Bi-directional Device nasally and Placebo Tablet
3088522|NCT01667679|Active Comparator|100mg Sumatriptan and OPTINOSE Placebo|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally
3088523|NCT01667731|Experimental|SOF+RBV 12 Weeks (GT 2/3, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype (GT) 2 or genotype 3 HCV infection will receive SOF+RBV for 12 weeks.
3088524|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 2/3, TE)|Treatment-experienced (TE) participants coinfected with HIV-1 and genotype 2 or genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
3088525|NCT01667731|Experimental|SOF+RBV 24 Weeks (GT 1, TN)|Treatment-naive (TN) participants coinfected with HIV-1 and genotype 1 HCV infection will receive SOF+RBV for 24 weeks.
3088526|NCT01667796|Experimental|Vitamin D3|Both those with MS and healthy controls will be given vitamin D3 5000 IU/day by mouth for 90 days.
3088527|NCT01667848|Experimental|group B: Insufflation with warm gas|Insufflation with warmed, humidified carbon dioxide insufflation during laparoscopic cholecystectomy using the optitherm® device attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
3088528|NCT01667848|Experimental|group A: Insufflation with cold gas|group A: Insufflation with cold gas during laparoscopic cholecystectomy, the use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A
3088529|NCT01667900|Experimental|0.5 mg Dulaglutide (Part A-Healthy)|0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods
3088530|NCT01667900|Experimental|0.75 mg Dulaglutide (Part A-Healthy)|0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
3088531|NCT01667900|Experimental|1.5 mg Dulaglutide (Part A-Healthy)|1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods
3088532|NCT01667900|Placebo Comparator|Placebo (Part A-Healthy)|Placebo administered once SQ to healthy participants in 1 of 3 treatment periods
3088533|NCT01667900|Experimental|0.5 mg Dulaglutide (Part B-T2DM)|0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks
3088534|NCT01667900|Experimental|0.75 mg Dulaglutide (Part B-T2DM)|0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
3088535|NCT01667900|Experimental|1.5 mg Dulaglutide (Part B-T2DM)|1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks
3088536|NCT01667900|Placebo Comparator|Placebo (Part B-T2DM)|Placebo administered to participants with T2DM once weekly SQ for 4 weeks
3088537|NCT01667926|Experimental|Ketamine|Subject will receive 6 infusions of ketamine over three weeks.
3088538|NCT01667926|Placebo Comparator|Placebo|Subjects will receive 6 infusions of normal saline over 3 weeks.
3088539|NCT01667978|Experimental|PI|Study group with PI: atazanavir ritonavir
3088540|NCT01667978|Placebo Comparator|Control|o PI therapy, control group
3088541|NCT01668004|Experimental|GLM 50 mg|GLM given subcutaneously at a dose of 50 mg once monthly for up to 12 months
3088542|NCT01668017|Experimental|Part 1: Pimasertib 30mg in Solid Tumor|
3088543|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in Solid Tumor|
3088544|NCT01668017|Experimental|Part 1: Pimasertib 60 mg in Solid Tumor|
3088545|NCT01668017|Experimental|Part 1: Pimasertib 30 mg in Hepatocellular Carcinoma (HCC)|
3088546|NCT01668017|Experimental|Part 1: Pimasertib 45 mg in HCC|
3088547|NCT01668030|Experimental|Bacitracin on left, Enzymatic agent on right|Subjects were randomized to receive enzymatic agent on right side of face and bacitracin on left.
3088548|NCT01668030|Experimental|Bacitractin on right, enzymatic agent on left|Subjects were randomized to receive enzymatic agent on left side of face and bacitracin on right.
3088549|NCT01668173|Experimental|AUY922|This is an open-label phase II trial to assess the efficacy of the HSP90 inhibitor, AUY922, in patients with PMF, post-PV MF, post-ET MF, and with PV/ET who are refractory to hydroxyurea, phlebotomy or anagrelide.
3088550|NCT01668355|Experimental|SMI-PACT|Patient Aligned Care Team (PACT) medical home model to address the physical healthcare needs of individuals with serious mental illness
3088551|NCT01668355|No Intervention|Usual Care|Usual Primary Care
3088552|NCT01668537|Experimental|Group 1|LF formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
3088553|NCT01668537|Experimental|Group 2|FD formulation of IMVAMUNE® 2 doses of 1 x 10E8 TCID50, s.c., 4 weeks apart
3088554|NCT01668602|Experimental|Cohort 1 - FastFES Training|Participants with chronic stroke in Cohort 1 will receive 18 training sessions of FastFES (fast treadmill walking with electrical stimulation).
3088555|NCT01668602|Experimental|Cohort 2 - FastFES and Fast Walking|Participants with chronic stroke in Cohort 2 who complete 3 sessions of FastFES and 3 sessions of fast walking.
3088556|NCT01668628||Incident PD patients|First treatment for end stage of renal disease (ESRD) by any peritoneal dialysis modality within 30 days prior to or following enrollment (patients may be enrolled prior to commencing first treatment if there is clear indication that the treatment modality is continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dilaysis (APD) and they consent in advance to enter the study) and patients who don't have any experience of dialysis treatment before this study
3088557|NCT01668628||Prevalent PD patients|Prevalent peritoneal dialysis(PD) patients who are under peritoneal dialysis treatment more than 6 months
3088558|NCT01668628||Prevalent HD patients|Prevalent hemodialysis(HD) patients who are under hemodialysis treatment more than 6 months
3088559|NCT01668654|Experimental|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
3088560|NCT01668667|Active Comparator|GSK1838262 600 mg|Once-daily dose with food in the evening at approximately 5 PM
3088561|NCT01668667|Active Comparator|GSK1838262 450 mg|Once-daily dose with food in the evening at approximately 5 PM
3088562|NCT01668667|Active Comparator|GSK1838262 300 mg|Once-daily dose with food in the evening at approximately 5 PM
3088563|NCT01668667|Placebo Comparator|GSK1838262 placebo match|Once-daily dose with food in the evening at approximately 5 PM
3088564|NCT01668719|Active Comparator|Arm I (bortezomib, lenalidomide, dexamethasone)|"INDUCTION: Patients receive bortezomib SC or IV on days 1, 4, 8, and 11; lenalidomide PO QD on days 1-14; and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity (patients who received a course of chemotherapy prior to registration will begin protocol treatment with course 2 and receive a total of 7 courses of protocol therapy).~MAINTENANCE: Patients receive bortezomib SC or IV on days 1, 8, and 15; lenalidomide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3321141|NCT02016586|No Intervention|Control Group|Subjects in the control group will continue to take the prenatal supplement primarily consisting of folic acid (400 mcg), elemental iron (60 mg) and will receive breastfeeding advice during prenatal visits.
3088565|NCT01668719|Experimental|Arm II (bortezomib, lenalidomide, dexamethasone, elotuzumab)|"INDUCTION: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1, 8, and 15 of courses 1 and 2 and on days 1 and 11 of courses 3-8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive bortezomib, lenalidomide, and dexamethasone as in Arm I. Patients also receive elotuzumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3088566|NCT01668784|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3088567|NCT01668784|Active Comparator|Arm 2: Everolimus|Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3088568|NCT01668797|Placebo Comparator|Placebo|Placebo comparator for 52 weeks
3088569|NCT01668797|Experimental|Brexpiprazole (OPC-34712)|Brexpiprazole (OPC-34712) for 52 weeks
3088570|NCT01668836|Experimental|men with resveratrol|12 men will receive a pill with 500mg of resveratrol daily for 30 days
3088571|NCT01668836|Experimental|women with resveratrol|12 women will receive a pill with 500mg of resveratrol daily for 30 days
3088572|NCT01668836|Active Comparator|men with caloric restriction|12 men will follow a 1000 calories per day diet for 30 days
3088573|NCT01668836|Active Comparator|women with caloric restriction|12 women will follow a 1000 calories per day diet for 30 days
3088574|NCT01668966|Experimental|Tocilizumab|Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenously (IV) every 4 weeks for up to 104 weeks.
3088575|NCT01669096|Experimental|GSK 692342 Group|Healthy male and female subjects, between and including 18 to 50 years of age, who received 2 doses of GSK 692342 vaccine administered intramuscularly in the deltoid region of the arm, at Days 0 and 30.
3088576|NCT01669122|Experimental|Prototype 1|4mg nicotine lozenge administered orally as a single dose treatment per subject
3088577|NCT01669122|Experimental|Prototype 2|4mg nicotine lozenge administered orally as a single dose treatment per subject
3088578|NCT01669122|Experimental|Prototype 3|4mg nicotine lozenge administered orally as a single dose treatment per subject
3088579|NCT01669122|Active Comparator|Reference Therapy|4mg nicotine lozenge (internationally marketed) to be administered orally as a single dose treatment per subject.
3088580|NCT01669174|Experimental|BYM338|
3088581|NCT01669174|Placebo Comparator|Placebo|
3088582|NCT01669343|Other|Post-menopausal Women Using Adjuvant Letrozole|Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
3088583|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose baseline|Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
3088584|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) Double dose|Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
3088585|NCT01669421|Experimental|Alpha-1 Antitrypsin (human) standard dose|4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
3088586|NCT01669434|Experimental|ACEI continuation|Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively
3088587|NCT01669434|Experimental|ACEI omission|Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.
3088588|NCT01669538|Experimental|Galantamine|"Galantamine hydrobromide-ER (extended release) is currently marketed for the treatment of Alzheimer's disease. The dosing regimen follows the FDA-approved guidelines. For the first week of study treatment, participants will take 8mg daily of galantamine-ER, preferably with food. 8mg is the lowest dose and this period is designed to introduce the medication into their system. After the initial week, participants will increase their daily dose to 16mg. They will remain on 16mg daily until the end of the treatment period for a total of 23 days on active study medication.~Galantamine will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
3088589|NCT01669538|Placebo Comparator|Placebo|"Participants assigned to the placebo (sugar pill) arm will take one capsule daily, preferably with food, for a total of 23 days. They will follow the same instructions and complete the same procedures as those in the active treatment.~Placebo ingredients (sucrose filler and gel capsules) will be purchased, encapsulated, and packaged into blister packs by the Investigational Drug Service at the University of Pennsylvania. Both active medication and placebo will look identical."
3088590|NCT01669577||severe trauma patients|analysis of blood samples and clinical features
3088591|NCT01669603|Experimental|Bifidobacterium animalis lactis Bl-04|Bifidobacterium animalis subspecies lactis Bl-04 as powder mixed into drink.
3088592|NCT01669603|Placebo Comparator|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
3088593|NCT01669629|Experimental|Delefilcon A/ Etafilcon A|6-10 days of delefilcon A soft contact lens wear first, then 6-10 days of etafilcon A soft contact lens wear
3088594|NCT01669629|Experimental|Etafilcon A / Delefilcon A|6-10 days of etafilcon A soft contact lens wear first then 6-10 days of delefilcon A soft contact lens wear
3088595|NCT01669642|Experimental|Ketamine|participants who get the ketamine sedation will be enrolled. there is no control or comparison group.
3088596|NCT01669720|Experimental|Aflibercept|Patients will be randomized 2:1, to receive Aflibercept,4mg/kg IV q2weeks until progression for a maximum of 2 years
3088597|NCT01669720|No Intervention|Observation|Patients will be randomized 2:1 to receive Aflibercept. Patients who are randomized to observation will be followed per the study table, but will receive no intervention.
3088598|NCT01669785|Active Comparator|Group C|"NUPRO Classic Prophy Paste~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains no Novamin or Fluoride..~Leave in contact for 60 seconds, rinse with water and expectorate."
3088599|NCT01669785|Experimental|Group A|"NUPRO Sensodyne Prophy Paste w/ Novamin~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 15% Novamin. Does not contain Fluoride.~Leave in contact for 60 seconds, rinse with water and expectorate"
3321142|NCT02016586|Experimental|Intervention|Lactation support in conjunction with a maternal nutritional supplement S348S0
3088600|NCT01669785|Experimental|Group B|"NUPRO Sensodyne Prophy Paste w/ Novamin w/ Fluoride~Administered on day one only. Unit dose cup contained enough paste for a single procedure. Contains 1.23% fluoride ion and 15% Novamin.~Leave in contact for 60 seconds, rinse with water and expectorate."
3088601|NCT01669798|Experimental|BIBF 1120|BIBF 1120 will be administered at a daily oral dose of 200 mg BID until disease progression or adverse effects prohibit further therapy.
3088602|NCT01669811|Experimental|D961H 20mg twice daily|Double-blinded
3088603|NCT01669811|Active Comparator|D961H 20mg once daily|Double-blinded
3088604|NCT01669863|Experimental|Use of ECMO in non-intubated patients|ECMO will be used in non-intubated patients with ARDS
3088605|NCT01669902||Cohort|
3088606|NCT01669928|Active Comparator|Evening medication|Anti hypertensive medication in the evening (between 18.00 and 23.00)
3088607|NCT01669928|Active Comparator|Morning medication|Antihypertensive medication in the morning(between 06.00 and 11.00)
3088608|NCT01670019|Experimental|Asenapine 5-20 mg daily|Asenapine will be started at 5 mg BID. The asenapine dose can be increased to 15 mg daily and then to 20 mg daily, or reduced to 5 mg daily, depending on therapeutic response and tolerability
3088609|NCT01670019|Placebo Comparator|Placebo 1-4 tablets daily|Matched, blinded placebo tablets will be administered at doses from 1-4 tablets daily depending on therapeutic response and tolerability
3088610|NCT01670045||Rheumatoid Arthritis Participants|Participants with moderate to severe rheumatoid arthritis (RA) according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score based on 28 Joint Count (DAS28) who were on tocilizumab treatment within 8 weeks prior to start of study will receive tocilizumab in accordance with the licensed label recommendations, and will be observed for 6 months. The study is designed as non-interventional, no additional intervention in terms of follow-up visit, complementary examination or medication is required.
3088611|NCT01670097|Experimental|Dexamethasone|"Dexamethasone 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days. In the open label phase, patients assigned to either arm asked to take Dexamethasone 4 mg orally twice a day for 7 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
3088612|NCT01670097|Placebo Comparator|Placebo|"Two placebo capsules taken twice a day for 4 days, followed by one capsule twice a day for 3 days. Patient to blow into spirometry machine 1 time a day to test lung function. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires. Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.~Participants randomized to either dexamethasone or placebo for 7 days in a blinded fashion; this will be followed by an open label phase in which patients in both arms would take dexamethasone for 7 days."
3088613|NCT01670110|Active Comparator|Pasireotide LAR (SOM230)|Active Pasireotide LAR
3088614|NCT01670110|Placebo Comparator|placebo injection|
3088615|NCT01670188|Active Comparator|Pneumatic SCD|Use of pneumatic SCD (VenaFlow System - DJO Global) on upper extremity with PICC line inserted.
3088616|NCT01670188|No Intervention|Non-SCD group|Standard care
3088617|NCT01670201|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
3088618|NCT01670279|Experimental|Cohort 1|14 day titration phase and two fixed dose phases. The first fixed dose phase is 14 days with a daily dose of 2mg brexpiprazole/placebo. The second fixed dose phase is 14 days with a daily dose of 3 mg brexpiprazole/placebo.
3088619|NCT01670279|Experimental|Cohort 2|14 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
3088620|NCT01670279|Experimental|Cohort 3|21 day titration phase and a 14 day fixed dose phase a daily dose of 3mg brexpiprazole/placebo.
3088621|NCT01670279|Placebo Comparator|Placebo|Placebo
3088622|NCT01670292|Other|Experimental: HVLA-SM|Experimental High Velocity Low Amplitude Spinal Manipulation
3088623|NCT01670487|Active Comparator|Vapocoolant (Pain Ease Medium Stream)|Application of the stream steadily 4 to 10 seconds onto the cannulation site.
3088624|NCT01670487|Placebo Comparator|Nature's Tears|Apply sterile water (see manufacturer above) steadily 4-10 seconds onto the cannulation site.
3088625|NCT01670500|Active Comparator|Doxorubicin-Cyclophosphamide|Doxorubicin q 2-3 wk x 4 Cyclophosphamide q 2-3 wk x 4
3088626|NCT01670500|Active Comparator|Cisplatin|Cisplatin q 3 wk x 4
3088627|NCT01670526|Experimental|Rivastigmine|Rivastigmine transdermal patch
3088628|NCT01670526|Placebo Comparator|Placebo|Placebo
3088629|NCT01670656|Experimental|NOMAC-E2 700/300 mcg|NOMAC-E2 700/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3088630|NCT01670656|Experimental|NOMAC-E2 900/300 mcg|NOMAC-E2 900/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3088631|NCT01670656|Experimental|ENG-E2 100/300 mcg|ENG-E2 100/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3088632|NCT01670656|Experimental|ENG-E2 125/300 mcg|ENG-E2 125/300 mcg will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3088633|NCT01670656|Placebo Comparator|Placebo|Placebo will be administered for two 28-day treatment periods, each period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3132422|NCT03425396|Active Comparator|Nitrofurantoin 100/100 once every 12 hours|Participants received nitrofurantoin 100 milligrams orally, once every 12 hours, fed on Day 1 and nitrofurantoin 100 milligrams orally, once every 12 hours on Days 2 through 7. Odd doses on Days 2 to 7 were administered in a fasted state. Even doses on Days 2 to 7 were administered approximately 2 hours following a light meal.
3132423|NCT03426267|Experimental|SDN-037|
3088634|NCT01670721|Experimental|Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)|Aflibercept 4 mg/kg intravenous (IV) infusion over 60 minutes followed by Irinotecan 180 mg/m^2 IV infusion over 90 minutes and Leucovorin 400 mg/m^2 IV infusion over 120 minutes at the same time followed by 5-FU 400 mg/m^2 IV bolus over 2-4 minutes followed by 5-FU 2400 mg/m^2 continuous IV infusion over 46 hours on Day 1 of each cycle (1 Cycle = 2 weeks), until DP, unacceptable toxicity, death, Investigator's decision or participant's refusal of further treatment.
3088635|NCT01670760|Experimental|Zero-Heat-Flux|This is a single arm study. All patients will have deep tissue temperature monitored from the nasopharyngeal and lateral forehead sites simultaneously.
3088636|NCT01670825|Experimental|Pulsed radiofrequency + local anesthetic injection|Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve
3088637|NCT01670825|Active Comparator|Corticosteroid injection + sham pulsed radiofrequency|"Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency"
3088638|NCT01671059||Tocilizumab|Participants with rheumatoid arthritis (RA) receiving tocilizumab either as combination therapy or monotherapy through routine clinical practice.
3088639|NCT01671085|Experimental|1.0 milligrams per kilogram (mg/kg) of LY3015014|1.0 mg/kg of LY3015014 given subcutaneously (SQ) on 2 dosing occasions occurring 4 weeks apart (Q4W) (Days 1 and 29).
3088640|NCT01671085|Placebo Comparator|Placebo|0.9% sodium chloride injection given SQ (to match LY3015014) on 2 dosing occasions Q4W (Days 1 and 29).
3088641|NCT01671111|Experimental|SSP-004814AQ|
3088642|NCT01671176|Other|Wide diameter bone anchored implant|Intervention: Implantation of a wide diameter bone anchored auditory implant either 3 or 4 mm in length, into the skull on the side of the ear where intervention is intended in order to restore hearing. In the case of a conductive or mixed hearing loss, that side is chosen. In patients with unilateral, profound sensori-neural hearing loss the implant is implanted on that side but the sound is transmitted to the side with the normal hearing ear via bone conduction stimulation.
3088643|NCT01671280||Azithromycin IV|Subjects who are treated with Azithromycin IV
3088644|NCT01671293|Experimental|Multicomponent remote care model|A remote intervention based on counseling (telephone-based).
3088645|NCT01671293|Active Comparator|Usual care|Usual care.
3088646|NCT01671319|Experimental|dose dense TC + pegfilgrastim|Docetaxel + Cyclophosphamide chemotherapy given every 2 weeks x 4 cycles plus pegfilgrastim given 24-48 hours post day 1 of each cycle
3088647|NCT01671332|Active Comparator|Docetaxel|
3088648|NCT01671332|Experimental|Docetaxel plus Suramin|
3088649|NCT01671345|Active Comparator|Intervention|Patients randomized to the intervention will view the intervention video
3088650|NCT01671345|Placebo Comparator|Control|Patients randomized to control will view an informative video about nutrition and exercise of similar length
3088651|NCT01671423|Active Comparator|Prednisone|In addition to standard care for cellulitis, subject will receive a single 60 mg dose of Prednisone orally during their initial visit.
3088652|NCT01671423|Placebo Comparator|Placebo|In addition to standard care for cellulitis, subjects will receive a single placebo pill to take during their initial visit.
3088653|NCT01671488|Experimental|Treatment|"The first dose will be given 10-14 days prior to the initiation of chemoradiation.~Patient will then receive 5-FU: 1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days and Mitomycin: 10 mg/m2, day 1 and 29 with IMRT radiation: 54 Gy in 30 fractions at 1.8 Gy per fraction.~The 2-4th dosages of ADXS11-001 will not be until after completion of all chemoradiation. The second dosage of ADXS11-001 will not be administered until a minimum of 10 days after completion of chemoradiation. The subsequent third and fourth treatment with of ADXS11 will be administered at 28 day intervals."
3088654|NCT01671605||CKD not on dialysis|Patients with CKD not on dialysis (CKD III-IV)
3088655|NCT01671605||Controls|Controls with normal kidney function (Control)
3088656|NCT01671748|Active Comparator|Standard Care|Standard treatment for VLUs is administered once a week, i.e. compression bandaging and non-adherent dressing, with debridement if required.
3088657|NCT01671748|Experimental|MIST and Standard Care|MIST ultrasound therapy is applied for between 3 and 12 minutes (depending on wound size) 3 times a week in combination with standard treatment for VLUs of compression bandaging and non-adherent dressing change 3 times a week, with debridement as required.
3088658|NCT01671839|Experimental|Subcutaneous tissue release|Device: Subcutaneous tissue release with the Cabochon System
3088659|NCT01672242|Experimental|HFNC|High Flow Nasal Cannula (HFNC) oxygen.
3088660|NCT01672242|Experimental|CPAP|Continuous Positive Airway Pressure (CPAP)
3088661|NCT01672294|Experimental|treatment|three facilitator-led end-of-life preparation and completion sessions with a facilitator with both patient and caregiver
3088662|NCT01672294|Active Comparator|attention control|three facilitator led sessions of listening to a relaxation CD.
3088663|NCT01672658|Experimental|Sensory Kinectics Balance System|Subjects will be randomized in to one of two groups. The group that will receive training on the SKBS device along with traditional vestibular and balance training.
3088664|NCT01672658|Active Comparator|Traditional Vestibular Rehabilitation|Traditional vestibular rehabilitation will include VOT exercises that will work toward increasing the gain of the system as well as walking, balance re-training, and functional mobility.
3088665|NCT01672710|Experimental|regimen of niacin, exercise, sauna,|4-5 week daily sauna, exercise and niacin with other supplements
3088666|NCT01672710|Other|waitlist|4 week waitlist with treatment as usual
3088667|NCT01672723|Experimental|Naltrexone|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
3132424|NCT03426267|Placebo Comparator|vehicle|
3132425|NCT03426345|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
3088668|NCT01672723|Placebo Comparator|Placebi|"Participants will take 4 doses of naltrexone over 4 days (25mg/day for days 1 and 2, 50mg/day for days 3 and 4) as well as 4 matched placebo pills for a total of 8 days. Capsules will be packaged into blister packs.~Participants will be asked to take the first drug, either naltrexone or placebo, once a day for three days prior to the first experimental session and when they arrive at the lab for the experimental procedure . After the first session, participants will take the second study drug for three days prior to the second experimental session and when they arrive for the second experimental procedure."
3088669|NCT01672736|Experimental|ASP7487, Velcade, Dexamethasone|ASP7487 administered orally 75, 100 and 150 mg) BID continuously for each cycle. Bortezomib administered at 1.3 mg/m2 twice weekly for the first 8 21 day cycles and once weekly beyond cycle 9 for 35 day cycles. Dexamethasone is administered on bortezomib administration days at 20 mg
3088670|NCT01672788|Experimental|Test 1|fixed dose combination tablet
3088671|NCT01672788|Active Comparator|Reference 1|empagliflozin tablets and metformin tablet
3088672|NCT01672788|Experimental|Test 2|fixed dose combination tablet
3088673|NCT01672788|Active Comparator|Reference 2|empagliflozin tablet and metformin tablet
3088674|NCT01672801|Placebo Comparator|Placebo|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Placebo comparator subjects will receive 8 total doses of liquid placebo orally 4 times a day for 8 total doses in pre-filled liquid placebo containing syringes
3088675|NCT01672801|Active Comparator|Nimodipine|All subjects in both arms will receive Clomid 100 mg tablets by mouth for 5 days prior to receiving either placebo comparator or active comparator. Active comparator subjects will receive Nimodipine 30mg liquid orally 4 times a day for 8 total doses in pre-filled syringes
3088676|NCT01672827|Experimental|[18F]Flutemetamol|
3088677|NCT01672853|Experimental|Treatment Arm A|Simtuzumab 75 mg for 96 weeks
3088678|NCT01672853|Experimental|Treatment Arm B|Simtuzumab 125 mg for 96 weeks
3088679|NCT01672853|Placebo Comparator|Treatment Arm C|Placebo for 96 weeks
3088680|NCT01672866|Experimental|SIM 75 mg|During the Randomized Double-Blind Phase, participants will receive SIM 75 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
3088681|NCT01672866|Experimental|SIM 125 mg|During the Randomized Double-Blind Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
3088682|NCT01672866|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM via subcutaneous injection once weekly for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 125 mg via subcutaneous injection once weekly for up to an additional 240 weeks.
3088683|NCT01672879|Experimental|SIM 200 mg|During the Randomized Double-Blind Phase, participants will receive SIM 200 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
3088684|NCT01672879|Experimental|SIM 700 mg|During the Randomized Double-Blind Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg via intravenous infusion every 2 weeks for up to an additional 240 weeks.
3088685|NCT01672879|Placebo Comparator|Placebo|During the Randomized Double-Blind Phase, participants will receive placebo to match SIM administered via intravenous infusion every 2 weeks for up to 240 weeks. During the optional Open-Label Phase, participants will receive SIM 700 mg administered via intravenous infusion every 2 weeks for up to an additional 240 weeks.
3088686|NCT01672892|Experimental|Intensity-Modulated Radiation Therapy|intensity-modulated radiation therapy (IMRT) to the pelvis of either 45 Gy or 50.4 Gy
3088687|NCT01672892|Active Comparator|Standard Radiation Therapy|Standard radiation therapy (4-field) to the pelvis of either 45 Gy or 50.4 Gy
3088688|NCT01672957||Renal Transplant Participants|Renal transplant participants who will be subjected to a combined immunosuppressive treatment containing mycophenolate mofetil, will be followed-up until the end of the study (after 12 months), or until the participant's death, withdrawal, or lost contact with the participant, whichever occurs first. The choice of treatment will be made prior to enrolment by the treating physician. The treatment will be administered according to applicable therapeutic protocol and Summary of Product Characteristics (SmPC).
3088689|NCT01672970||Cohort|
3088690|NCT01672983|Experimental|Arm 1|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3088691|NCT01672983|Experimental|Arm 2|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3088692|NCT01672983|Experimental|Arm 3|Participants with HCV GT1b received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
3088693|NCT01672983|Experimental|Arm 4|Participants with HCV GT1b received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 24 weeks.
3088694|NCT01672983|Experimental|Arm 5|Participants with HCV GT2 received ABT-450/ritonavir (100/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3088695|NCT01672983|Experimental|Arm 6|Participants with HCV GT2 received ABT-450/ritonavir (150/100 mg) and ABT-267 (25 mg) once daily for 12 weeks.
3088696|NCT01672996|Experimental|Arm 1 - Ioforminol 160mgI/mL|Single administration of Ioforminol 160mgI/mL given to the subject.
3088697|NCT01672996|Experimental|Arm 2 - Ioforminol 200mgI/mL|Given as a single administration to the subject
3088698|NCT01672996|Active Comparator|Arm 3 - Iopamidol 300mgI/mL|Given as a single administration to the subject
3088699|NCT01673009|Experimental|Administration of Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
3088700|NCT01673022|Experimental|IC Green Arm|One arm only: Receives IC Green for testing of study objective
3088701|NCT01673113|Experimental|Cryolipolysis|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device, which is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks. Sensory testing was done before and after the procedure.
3088702|NCT01673113|No Intervention|Control|All subjects were randomized to have either the left of right flank treated with single the Zeltiq CoolSculpting Device. The untreated flank served as the internal control for each subject.
3088703|NCT01673126|Active Comparator|Anodal tDCS|Patients received anodal tDCS (on DLPF cortex) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised)
3088704|NCT01673126|Sham Comparator|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
3088705|NCT01673178|Placebo Comparator|Placebo Arm|
3088706|NCT01673178|Experimental|25 mg|
3088707|NCT01673178|Experimental|50 mg|
3088708|NCT01673178|Experimental|100 mg|
3088709|NCT01673178|Experimental|150 mg|
3088710|NCT01673191|Experimental|OZURDEX intraocular implant|OZURDEX (dexamethasone posterior segment drug delivery system (DEX PS DDS), 0.7 mg
3088711|NCT01673191|Active Comparator|Steroid plus NSAID eye drop combination therapy|NSAID eye drop: Acular LS Steriod eye drop: Pred Forte
3088712|NCT01673256||SJM Confirm ICM Observational Group|
3088713|NCT01673282||Vimpat + Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs) to include at least 1 sodium channel blocking AED.
3088714|NCT01673282||Vimpat + Non-Na Channel Blocking AED|Patients prescribed adjunctive lacosamide (LCM) added to one or more baseline Anti-Epileptic Drugs (AEDs), none of which is a sodium channel blocking AED.
3088715|NCT01673347|Experimental|MENISCAL ALLOGRAFT|The meniscal allograft is taken from the meniscal knee joint and implanted surgically in to the great toe.
3088716|NCT01673373|Experimental|iCAST RX™ Stent Systen|All enrolled subjects will receive the iCAST RX™ Stent System
3088717|NCT01673386|Experimental|Tivozanib Hydrochloride|1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks, followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks.
3088718|NCT01673386|Active Comparator|Sunitinib|50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks, followed by 1.5 mg oral tivozanib hydrochloride daily on a 3 weeks on/1 week off schedule for 12 weeks.
3088719|NCT01673490|Experimental|Combodart/Duodart|Single arm testing the efficacy/safety of the combinnation of Dutasteride/Tamsulosin
3088720|NCT01673568|Active Comparator|abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company."
3088721|NCT01673568|No Intervention|no abdominal binder|no abdominal binder
3088722|NCT01673594|Experimental|Naltrexone|Arm 1: Naltrexone + SODAS MPH
3088723|NCT01673594|Placebo Comparator|Placebo|Arm 2: Placebo + SODAS MPH
3088724|NCT01673620|Experimental|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg combination tablet administered orally once daily for 2 weeks
3088725|NCT01673620|Placebo Comparator|Placebo|Matching placebo tablet administered orally once daily for 2 weeks
3088726|NCT01673646|Experimental|Pasireotide LAR 20mg|Enrolled patients were randomized to 20mg pasireotide LAR.
3088727|NCT01673646|Experimental|Pasireotide LAR 40mg|Enrolled patients were randomized to 40mg pasireotide LAR.
3088728|NCT01673646|Experimental|Pasireotide LAR 60mg|Enrolled patients were randomized to 60mg pasireotide LAR.
3088729|NCT01673698|Active Comparator|ReShape Duo Balloon|ReShape Duo Balloon
3088730|NCT01673698|Sham Comparator|Sham Comparator|Sham Comparator
3088731|NCT01673802|Experimental|CT imaging|Patients will undergo a standard of care Gadoxetate (Eovist) MRI for cholangiocarcinoma. Patients will then be immediately placed on the CT scanner. Patients will undergo a dual energy CT of the abdomen with no additional contrast.
3088732|NCT01673828|Experimental|Allopregnanolone|Allopregnanolone injection (intravenous solution) continuous infusion for 5 days
3088733|NCT01673828|Placebo Comparator|Placebo|Placebo injection (intravenous solution) continuous infusion for 5 days
3088734|NCT01673854|Experimental|Vemurafenib, 960 mg + Ipilimumab, 10 mg/kg|Participants received vemurafenib, 960 mg, twice daily for 6 weeks (Vem1 Phase). After a washout period of 3-10 days, patients received ipilimumab, 10 mg/kg, every 3 weeks for a maximum of 4 doses. At Week 24, participants received ipilimumab, 10 mg/kg, every 12 weeks until disease progression or unacceptable toxicity. Patients who did not progress or have unacceptable toxicity in the Vem1 Phase were retreated with vemurafenib (Vem 2 Phase) at the last dose level identified at the end of the Vem1 Phase until disease progression or unacceptable toxicity.
3088735|NCT01673867|Experimental|Arm A: Nivolumab|Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3088736|NCT01673867|Active Comparator|Arm B: Docetaxel|Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3088737|NCT01673893||ST elevation myocardial infarction|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~1st Group/Cohort - ST elevation myocardial infarction"
3088738|NCT01673893||Non-ST elevation myocardial infarction/ACS/UNSTABLE ANGINA|"The registry will record the use of the ClearWay™ Rx catheter during the index procedure, and assess whether or not the patient was readmitted within 30 days, related to the index procedure.~2nd Group/Cohort - Non-ST elevation myocardial infarction/ACS/Unstable Angina"
3088739|NCT01673919|Experimental|RoActemra/Actemra|
3088740|NCT01673984|Experimental|Decapeptyl® SR 22.5mg (Triptorelin)|
3088741|NCT01673984|Active Comparator|Current 3-monthly LHRH agonist|One of the following: Decapeptyl® SR 11.25mg (Triptorelin), Prostap® 3 DCS 11.25mg, Zoladex® LA 10.8mg
3088742|NCT01674010|Experimental|Lamotrigine or Valproic acid + ELND005|Lamotrigine or valproic acid plus ELND005 film coated tablets, 500mg BID for up to 48 weeks
3088743|NCT01674010|Placebo Comparator|Lamotrigine or Valproic acid + placebo|Lamotrigine or valproic acid plus matched placebo BID for up to 48 weeks
3088744|NCT01674062|Experimental|Pertuzumab + Trastuzumab (Cohorts 1 and 2)|Females with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer will receive dual-agent treatment with pertuzumab and trastuzumab. Trastuzumab will be administered IV as 2 milligrams per kilogram (mg/kg) once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, beginning on Day 2 of Cycle 1. Thereafter, both medications will be administered on Day 1 of each 3-week cycle. Treatment will continue for a minimum of 8 cycles and may be extended until disease progression, intolerable toxicity, or death.
3088745|NCT01674062|Experimental|Pertuzumab +/- Trastuzumab (Cohort 3)|Females with HER2-positive metastatic breast cancer will receive single-agent treatment with pertuzumab. Pertuzumab will be administered IV at a loading dose of 840 mg followed by a standard dose of 420 mg every 3 weeks, administered on Day 1 of each 3-week cycle. Participants with documented disease progression may have trastuzumab added to the regimen, per the dosing schedule described for Cohorts 1 and 2, to receive dual-agent treatment until disease progression, intolerable toxicity, or death.
3088746|NCT01674478|Experimental|Microlipid with fish oil group|This group will be given early enteral lipid supplementation with Microlipid and fish oil.
3088747|NCT01674478|Active Comparator|Microlipid group|This group will be given early enteral lipid supplementation only with Microlipid.
3088748|NCT01674569|Experimental|50 mg X-82 oral alternate days|50 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity develops
3088749|NCT01674569|Experimental|50 mg X-82 oral QD|50 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria.for 24 weeks or until unacceptable toxicity develops
3088750|NCT01674569|Experimental|100 mg X-82 oral alternate days|100 mg X-82 oral on alternate days with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria.for 24 weeks or until unacceptable toxicty develops
3088751|NCT01674569|Experimental|100 mg X-82 oral QD|100 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
3088752|NCT01674569|Experimental|200 mg X-82 oral QD|200 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs
3088753|NCT01674569|Experimental|300 mg X-82 oral QD|300 mg X-82 oral QD with intravitreous ranibizumab (Lucentis) therapy using predefined retreatment criteria for 24 weeks or until unacceptable toxicity occurs.
3088754|NCT01674621|Experimental|Abaloparatide Transdermal (50 mcg)|Abaloparatide Transdermal Microneedle Patch - 50 microgram (mcg) daily applications for up to 6 months
3088755|NCT01674621|Experimental|Abaloparatide Transdermal (100 mcg)|Abaloparatide Transdermal Microneedle Patch - 100 mcg daily applications for up to 6 months
3088756|NCT01674621|Experimental|Abaloparatide Transdermal (150 mcg)|Abaloparatide Transdermal Microneedle Patch - 150 mcg daily applications for up to 6 months
3088757|NCT01674621|Active Comparator|Abaloparatide Injection (80 mcg)|Abaloparatide-SC Subcutaneous Injection - 80 mcg daily injections for up to 6 months
3088758|NCT01674621|Placebo Comparator|Abaloparatide Transdermal Placebo (0 mcg)|Abaloparatide Transdermal Microneedle Patch - 0 mcg daily applications for up to 6 months
3088759|NCT01674634|Experimental|XIAFLEX / XIAPEX|AA4500 (collagenase clostridium histolyticum)
3088760|NCT01674647|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. Rivaroxaban will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with rivaroxaban will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. Rivaroxaban will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
3088761|NCT01674647|Active Comparator|Vitamin K antagonist (VKA)|A Direct Cardioversion Strategy can be performed only if sufficient anticoagulation is proven during the last 21 days prior to randomization and/or a transesophageal echocardiogram (TEE) is planned before cardioversion. VKA will be given for 1-5 days before planned direct cardioversion. The run-in of 1-5 days is needed due to potential pretreatment with VKA. Treatment with VKA will be continued for 42 days after the cardioversion. A Delayed Cardioversion Strategy will be chosen if sufficient anticoagulation is not proven during the last 21 days prior to randomization and no TEE is planned. VKA will be given for at least 21 (+4) days before the planned cardioversion, to a maximum of 56 (+4) days prior to planned cardioversion.
3088762|NCT01674712|Experimental|Fenofibrate/simvastatin 145/20 mg|
3088763|NCT01674712|Active Comparator|Simvastatin 20 mg|
3088764|NCT01674712|Active Comparator|Fenofibrate 145 mg|
3088765|NCT01674712|Experimental|Fenofibrate/simvastatin 145/40 mg|
3088766|NCT01674712|Active Comparator|Simvastatin 40 mg|
3088767|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3088768|NCT01674725|Experimental|ABT-450/r/ABT-267 and ABT-333|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks
3088769|NCT01675050|Experimental|Cyproheptadine first then Placebo|4 weeks of cyproheptadine or placebo with crossover to the other
3088770|NCT01675050|Experimental|Sugar Pill first then Cyprotheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
3088771|NCT01675063|Other|Retia Non-Invasive Sensors|Sensors will be placed on the patient and connected to an amplifier that produces a waveform for 8 hours post cardiac surgery.
3088772|NCT01675128|Experimental|Phase I Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 started 800 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
3088773|NCT01675128|Experimental|Phase I Dose Level II|Irinotecan 180 mg/m^2 every other week; ISIS 183750 1000 mg/every week will be administered intravenously on Cycle 1 Days 1, 3, 5, 8, 15 and 22 of a 28 day cycle, restaged every 8 weeks.
3088774|NCT01675128|Experimental|Phase II Dose Level I|Irinotecan 160 mg/m^2 every other week; ISIS 183750 1000mg every week will be administered as an intravenous infusion every week without break, i.e. Days 1, 8, 15 and 22 of a 28-day cycle. Patients will be re-staged every 8 weeks.
3088775|NCT01675141|Experimental|Lenalidomide Maintenance Therapy for Multiple Myeloma|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
3088776|NCT01675154|Placebo Comparator|SLx-4090 placebo/Orlistat Placebo|"Slx-4090(placebo) is dosed as 4 tablets of 50 mg, three times per day with meals.~Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.~This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment."
3088777|NCT01675154|Experimental|Orlistat/placebo|Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
3088778|NCT01675154|Experimental|Orlistat placebo /SLx-4090|Orlistat placebo 2 capsules, 60mg each three times per day with meals. Slx-4090 4 tablets, 50mg each. three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
3088779|NCT01675154|Experimental|Orlistat/SLx-4090|Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 4 tablets 50mg each, three times per day with meals. This trial is adaptive design/flexible design. The participants were either randomized from the start of the study or after the completion of each treatment.
3088780|NCT01675167|Placebo Comparator|Placebo Buccal Film|Twice Daily Dosing
3088781|NCT01675167|Experimental|Buprenorphine HCl Buccal Film|Twice Daily Dosing
3088782|NCT01675297|Experimental|Risendronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
3088783|NCT01675297|Active Comparator|Risedronate|Sedron tablet: one tablet once a week for 12months
3088784|NCT01675427|Experimental|Chronic hepatitis C patients|
3088785|NCT01675453|Active Comparator|7.2% NaCl /hydroxyethyl starch 200/0.5|On-pump CABG. 7.2% NaCl plus 6% hydroxyethyl starch 200/0.5 solution (HyperHAES) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
3088786|NCT01675453|Placebo Comparator|0.9% NaCl|On-pump CABG. 0.9% NaCl (isotonic saline) 4 mL/kg for 30 min, IV (in the vein), once, starting after the first hemodynamic measurement is obtained (before the beginning of CPB)
3088788|NCT01675492|Experimental|wave-front guided LASIK|
3088789|NCT01675531|Experimental|Targin|Targin
3088790|NCT01675544||Heart Failure Admission|Patients admitted for acute decompensated heart failure
3088791|NCT01675596|Experimental|Test|SAPIEN XT™ valve with the NovaFlex and NovaFlex+ delivery systems.
3088792|NCT01675622|Experimental|Oxycodone Capsules for cancer pain|
3088793|NCT01675622|Active Comparator|Morphine tablets for cancer pain|
3088794|NCT01675635|Experimental|OxyNorm Capsules|To determine the efficacy and safety of OxyNorm Capsules.
3088795|NCT01675635|Active Comparator|Morphine tablet|To determine the efficacy and safety of Morphine tablet.
3088796|NCT01675661|Active Comparator|NAC plus CM|N-acetylcysteine (NAC) plus Contingency Management (CM)
3088797|NCT01675661|Placebo Comparator|Placebo plus CM|Placebo plus Contingency Management (CM)
3088798|NCT01675765|Experimental|Immunotherapy plus chemotherapy|"Weeks 1 and 3: CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: CRS-207~Maintenance Vaccinations: CRS-207 every 8 weeks (starting at Week 34) until disease progression"
3088799|NCT01675765|Experimental|Immunotherapy with cyclophosphamide plus chemotherapy|"Weeks 1 and 3: cyclophosphamide (200 mg/m^2), CRS-207 (1 × 10^9 CFU)~Weeks 5, 8, 11, 14, 17 and 20 (up to 6 cycles every 21 days): pemetrexed (500 mg/m^2) and cisplatin (75 mg/m^2)~Weeks 23 and 26: cyclophosphamide one day before CRS-207~Maintenance Vaccinations: cyclophosphamide one day before CRS-207 every 8 weeks (starting at Week 34) until disease progression"
3088800|NCT01675778|Other|Hydromorphone|Every enrolled patients will receive a fixed dose (1mg) of intravenous hydromorphone. Pain scale change, patients' satisfaction, requirements for additional pain medications, side effects and adverse events will be recorded at 15 and 30 minutes. Patients' weight and height will be measured. Age, gender, and race/ethnicity will also be recorded. Blood draw for genetic study will be performed.
3088801|NCT01675830|Experimental|Head Retention Head Wrap device|All subjects recieved the experimental intervention with the Heat Retention Head Wrap device for during the rewarming phase of cardiopulmonary bypass surgery.
3088802|NCT01675882|Experimental|Viaskin Peanut 50 mcg|
3088803|NCT01675882|Experimental|Viaskin Peanut 100 mcg|
3088804|NCT01675882|Experimental|Viaskin Peanut 250 mcg|
3088805|NCT01675882|Placebo Comparator|Viaskin Placebo|
3088806|NCT01676012||five types of bronchoscopy|"Bronchoscopy will be performed in a standardized order using five different imaging modes.~Standard white light videobronchoscopy (WLB)~High Definition -Bronchoscopy~HD-bronchoscopy + surface enhancement (iScan-surface)~HD-bronchoscopy + tone enhancement (iScan-tone)~Auto Fluorescence Bronchoscopy (AFB - SAFE3000) in dual video mode"
3088807|NCT01676116|Experimental|Insulin degludec/liraglutide + OADs|
3088808|NCT01676116|Active Comparator|Liraglutide or exenatide + OADs|
3088809|NCT01676220|Experimental|HOE901-U300|
3088810|NCT01676220|Active Comparator|Lantus|
3088811|NCT01676311|Experimental|Huperzine A|Huperzine A will be administered to patients, titrating dose up from 100mcg/day to 600mcg per day over the course of 20 days - and remaining on the dose of 600mcg/day for the remainder of the drug phase (64 days) - for a total of 12 weeks on Huperzine A.
3088812|NCT01676311|Placebo Comparator|Placebo|Placebo will be administered to patients at the same frequency/intervals as the experimental arm (Huperzine-A).
3088813|NCT01676415|Active Comparator|Prednisone|Oral steroid medication
3088814|NCT01676415|Active Comparator|Topical Mometasone|Topical steroid medication
3088815|NCT01676532||Students attending SBHC|Students who attend the SBHC from either Sprucecourt Public School or any other participating schools.
3088816|NCT01676714|Experimental|Dovitinib|500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops.
3088817|NCT01676727||CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
3088818|NCT01676831|Experimental|topical resiquimod 0.06%|Topical resiquimod 0.06% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will be 3 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
3088819|NCT01676831|Experimental|topical resiquimod 0.03%|Topical resiquimod 0.03% will be applied in dosing frequencies that are periodically adjusted to tolerability. Dosing frequency will begin 5 times a week. The dosing frequency may be adjusted (1,2,3,5,or 7times per week) based on the physician assessment of tolerability. Treatment will occur for 8 weeks followed by 4 weeks rest followed by another 8 weeks of treatment with 4 weeks rest. At 24 weeks a final evaluation will be performed. Those with a partial response at week 24 will have the option to continue therapy for up to another 12 weeks.
3088820|NCT01676896|Experimental|Asthma in-school class|Provided in 16 15-minute sessions (4 hours total didactic time); scheduled 3 sessions/week. The content is provided by trained asthma educators. The Asthma Plan for Kids (AP-K) is a 7-step curriculum for children to use when responding to asthma symptoms. Skills practice with placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters with PEF score interpretation. Topics include (a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner.
3088821|NCT01676896|Experimental|Asthma Day Camp|The asthma day camp is provided in a single day session (5.5 hours total) by trained camp staff. The same skills (i.e., placebo metered dose inhaler (MDI) and peak expiratory flow (PEF) meters) and topics [a) identifying lung function, asthma warning signs, symptoms, and triggers; (b) learning skills to manage symptoms, including PEF meter score interpretation, communication with adults (e.g. teachers, coaches, family members), medication use and MDI technique; (c) evaluating asthma symptoms and the effectiveness of management; and (d) discussing how to stay active in a safe manner] are covered as those in the asthma in-school classes.
3088822|NCT01676896|Sham Comparator|Health Promotion in-school class|The mock comparison follows the in-school format of 16 15-minute sessions; scheduled 3 sessions/week. The content is provided by trained health educators and includes skills practice (i.e., handwashing and brushing teeth) and health promotion topics of nutrition, healthy snacks, preventing colds, and safe exercise.
3088823|NCT01676909|Experimental|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. After completing the 12 weekly groups, participants will return to complete once monthly booster group sessions for the next three months.
3088824|NCT01676909|Active Comparator|Medical Illness Education & Support Group|We selected a comparison condition that would provide parallel focus (i.e. medical illness) but not include use of the core ingredients undergirding the Living Well intervention including behavioral action planning, problem solving, in-session and between session practice using specific disease self-management techniques and involvement of peer co-facilitators to enhance modeling and improve self-efficacy and activation. As with Living Well, the content of the intervention will have broad applicability across diverse chronic disease conditions. The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition.
3088825|NCT01677182|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
3088826|NCT01677182|Experimental|Ramelteon (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 6 weeks.
3088827|NCT01677182|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 6 weeks.
3088828|NCT01677195|Active Comparator|ACCS100 High Dose|Participants will receive a total daily dose of 3 grams of ACCS100; 1 gram three times a day with meals.
3088829|NCT01677195|Active Comparator|ACCS100 Low Dose|Participants will receive a total daily dose of 1.5 grams of ACCS100; 500 mgs three times a day with meals.
3088830|NCT01677195|Placebo Comparator|Placebo|Participants will receive placebo capsules shown not to absorb mycotoxins three times a day with meals.
3088831|NCT01677286|Experimental|doxycycline 100 mg po bid x 12 months|Open-label doxycycline 100 mg twice daily by mouth will be administered to subjects for 12 months.
3088832|NCT01677299|Active Comparator|1000 mg EFB0026 (metformin immediate-release)|BID
3088833|NCT01677299|Experimental|1000 mg EFB0027 (metformin delayed-release)|BID
3088834|NCT01677299|Experimental|500 mg EFB0027 (metformin delayed-release)|BID
3088835|NCT01677299|Experimental|500 mg EFB0026 + 1000 mg EFB0027|BID
3088836|NCT01677312|Active Comparator|19G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 19G FNA needle when performing pancreatic biopsy.
3088837|NCT01677312|Active Comparator|25G FNA needle|Evaluate median number of passes to diagnosis (Diagnostic accuracy) and ability to procure histological samples using a 25G FNA needle when performing pancreatic biopsy.
3132426|NCT03426345|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 12 weeks.
3088838|NCT01677377|Experimental|Cohort 1, RBP-7000 60 mg|Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87.
3088839|NCT01677377|Experimental|Cohort 2, RBP-7000 90 mg|Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87.
3088840|NCT01677377|Experimental|Cohort 3, RBP-7000 120 mg|Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87.
3088841|NCT01677507|Experimental|timolol|To compare the variation in response to timolol between individuals
3088842|NCT01677507|Active Comparator|latanoprost|To compare the variation in response to latanoprost between individuals
3088843|NCT01677624|Experimental|E7040|
3088844|NCT01677741|Experimental|Part 1: Dabrafenib treatment|Three subjects will receive a single dose of 3 mg/kg dabrafenib on Day 1 and repeat dose will begin from Day 2, evenly divided in two daily doses. Once all 3 subjects have been fully evaluated for the first 28 days (including Day 15 PK) and no DLTs are observed, a next subject will be enrolled at the next higher dose levels (i.e., dose escalation to 3.75 mg/kg [+1] and may be further to 4.5 mg/kg [+2] and so on). If all 3 subjects have not been fully evaluated for the first 28 days or 1 DLT occurred, the fourth subject will be enrolled at the same dose level. If 2 or more DLTs are observed, the next subject will be enrolled at the next lower dose level (i.e., de-escalated to 2.25 mg/kg [-1] and may be further to 1.5 mg/kg [-2]). Similarly, the process is repeated for the fifth and sixth subjects in a cohort. All subjects will receive treatment till end of study.
3088845|NCT01677741|Experimental|Part 2: Cohort 1 Low-Grade Gliomas with BRAF V600 mutations|Subjects with low-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3088846|NCT01677741|Experimental|Part 2: Cohort 2 High-Grade Gliomas with BRAF V600 mutations|Subjects with high-grade gliomas with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3088847|NCT01677741|Experimental|Part 2: Cohort 3 LCH with BRAF V600 mutations|Subjects with LCH with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3088848|NCT01677741|Experimental|Part 2: Cohort 4 Melanoma and PTC with BRAF V600 mutations|Subjects with other tumors with BRAF V600 mutations will receive the single selected final dose (based on MTD and the age of the subjects) from Part 1 on Day 1. Repeat dosing will begin from Day 2, twice daily till end of study.
3088849|NCT01677767||Cohort|
3088850|NCT01677858|Experimental|Carfilzomib|"In phase 1 participants were assigned to one of four sequential dose-escalating cohorts to receive 45, 56, 70 or 88 mg/m² carfilzomib administered by intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle. Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15.~In phase 2 participants received carfilzomib at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study on days 1, 8 and 15 plus 40 mg dexamethasone IV or orally at the same schedule as used in the Phase 1 portion of the study.~Participants were treated until confirmed progressive disease, unacceptable toxicity, withdrew consent for further treatment, were lost to follow-up, died, or the sponsor closed the study."
3088851|NCT01677910|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose somatostatin analog (SSA) therapy (octreotide or lanreotide) participants were randomized to receive one 250 mg telotristat etiprate tablet plus one placebo-matching telotristat etiprate tablet administered three times daily for 12 Weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3088852|NCT01677910|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive, one telotristat etiprate 250 mg plus one placebo-matching telotristat etiprate tablet administered 3 times daily for 1 week, followed by two telotristat etiprate (250 mg) tablets administered three times daily for 11 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3088853|NCT01677910|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period on stable-dose SSA therapy (octreotide or lanreotide) participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks in the double-blind treatment period, followed by a 36 week open-label extension period.
3088854|NCT01677910|Experimental|Telotristat Etiprate Open-Label Extension|Patients previously assigned to 250 mg or 500 mg three times daily of telotristat etiprate were administered two 250 mg telotristat etiprate tablets three times daily in a 36 week open-label extension (OLE) period. Patients previously assigned to placebo were administered one 250 mg telotristat etiprate tablet plus one placebo-matching tablet three times daily for one week, followed by two 250 mg telotristat etiprate tablets three times daily for 35 weeks.
3088855|NCT01677936|Experimental|Raisin|Subjects randomized to the raisin treatment arm will consume raisins three times a day, prior to meals, and with a glass of water or non-caloric beverages (i.e. tea). Subjects will consume the raisins over a 12 week period.
3088856|NCT01677936|Active Comparator|Snack Group|Subjects randomized to the snack group will consume 100 calorie snack packs three times a day, before meals, and with water or other non-caloric beverages (i.e. tea). Subjects will consume the snack packs over a 12 week period.
3088857|NCT01677988|Experimental|Chemotherapy, Chemoradiation, Surgery|Neoadjuvant Chemotherapy- Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles for 3 cycles with growth factor support Chemoradiation Surgical Resection
3088858|NCT01678131|Experimental|Vaniprevir 600 mg|Participants received 600 mg vaniprevir only on days 1-7, and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3088859|NCT01678131|Experimental|Vaniprevir 600 mg + Peg-IFN + RBV|Participants received 600 mg vaniprevir on Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3088860|NCT01678131|Experimental|Vaniprevir 300 mg + Peg-IFN + RBV|Participants received 300 mg vaniprevir from Days 1-7; Peg-IFN alpha-2b once a week, RBV daily from Day 1 up to Day 21; and had postdose liver biopsy done by FNA and CNB from Day 7 up to Day 10.
3088861|NCT01678144|Experimental|Medtentia Annuloplasty Ring (MAR)|All eligible patients underwent surgical mitral valve repair using annuloplasty device - Medtentia Annuloplasty Ring (MAR)
3088862|NCT01678196|Experimental|VA-CRAFT|Family participants complete an on-line training course (VA-CRAFT) over a 3 month period
3088863|NCT01678196|Placebo Comparator|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
3088864|NCT01678209|Active Comparator|fMRI scans|Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart
3088865|NCT01678209|Experimental|Atomoxetine arm|These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits.
3088866|NCT01678209|Experimental|Methylphenidate arm|Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.
3088867|NCT01678313|Experimental|Study group|Doxazosin 4 mg daily plus celecoxib 200 mg every day (QD)
3088868|NCT01678313|Experimental|Control group|Doxazosin 4 mg every day (QD)
3088869|NCT01678443|Experimental|Treatment (yttrium-90 anti-CD45 monoclonal antibody BC8)|Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.
3088870|NCT01678560|Active Comparator|Usual Care|Monitoring every 3 months by face-to-face visits:These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.
3088871|NCT01678560|Active Comparator|Wireless Care|Frequent remote monitoring:These patients will be monitored using wireless modems as the method to obtain adherence and efficacy data.
3088872|NCT01678794|Experimental|Candesartan|
3088873|NCT01678794|Placebo Comparator|Placebo|
3088874|NCT01678807|Experimental|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablet administered sublingually once daily for 28 days
3088875|NCT01678807|Experimental|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablet administered sublingually once daily for 28 days
3088876|NCT01678807|Placebo Comparator|Placebo|Placebo rapidly dissolving tablet administered sublingually once daily for 28 days
3088877|NCT01678820|Experimental|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC plus placebo to sitagliptin plus placebo to simvastatin administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3088878|NCT01678820|Active Comparator|Sitagliptin|Sitagliptin 100 mg plus placebo to simvastatin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3088879|NCT01678820|Active Comparator|Simvastatin|Simvastatin 40 mg plus placebo to sitagliptin plus placebo to sitagliptin/simvastatin FDC administered orally once daily in the evening for 16 weeks. Participants will continue on their stable pre-screening metformin dose and dosing regimen of >=1500 mg daily for the duration of the study. Participants may receive glimepiride 1 mg once daily or 2 mg once daily (may be up-titrated to 6 mg once daily) as rescue therapy.
3088880|NCT01678846|Experimental|Good School Toolkit|Schools in the intervention arm will receive the Good Schools Toolkit materials and implementation support.
3088881|NCT01678846|No Intervention|Control|Schools in this arm will receive the Good Schools Toolkit materials and some implementation support after the end of the trial.
3088882|NCT01678885|Experimental|Sub-study 1, Dig Photo, Actical & IDEEA|During one week of the doubly labeled water (DLW), participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Intelligent Device for Energy Expenditure and Activity (IDEEA) monitor and Actical monitor. Whether the participants wear the monitors first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
3088883|NCT01678885|Experimental|Sub-study 2 - Dig Photo & Sensewear|During one week of the doubly labeled water (DLW) period, participants will use digital photography of foods. During the other week of the DLW phase, participants will wear the Sensewear armband. Whether the participants wear the monitor first or complete digital photography first will be randomozed. Participants who complete the first two weeks and have a BMI over 25kg/m2 will receive a partial supplement low-calorie diet (LCD) for 8 weeks. This diet plan is a 1000-1150 kcal/day diet that participants will complete in a free-living environment. All participants will return to follow-up at six and twelve months after they completed the LCD. Anthropometric and questionnaire data will be collected.
3088884|NCT01678898|Experimental|0.2 mg/kg|PRX-102 0.2 mg/kg every 2 weeks
3088885|NCT01678898|Experimental|1 mg/kg|PRX-102 1 mg/kg every 2 weeks
3088886|NCT01678898|Experimental|2 mg/kg|PRX-102 2 mg/kg every 2 weeks
3088887|NCT01678911|Placebo Comparator|Placebo then Gralise|Subjects may receive a pill with no medicine (placebo) for phase 1. Subject washout, then cross over to Gralise in Phase 2.
3088888|NCT01678911|Active Comparator|Gralise then Placebo|Subjects recieve Gralise (a long acting gabapentinoid) for phase 1.Subject washout, then cross over to placebo in Phase 2.
3088889|NCT01678924|Experimental|AGN-214868 Dose 1|AGN-214868 Dose 1 given as injections into the area of pain on Day 1.
3088890|NCT01678924|Experimental|AGN-214868 Dose 2|AGN-214868 Dose 2 given as injections into the area of pain on Day 1.
3088891|NCT01678924|Placebo Comparator|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
3088892|NCT01678924|Experimental|AGN-214868 Dose 3|AGN-214868 Dose 3 given as injections into the area of pain on Day 1.
3088893|NCT01678976|Experimental|Group 1 BIA 2-093 + Oxcarbazepine|Period 1 - Subjects recieved 900 mg of BIA 2-093 Period 2 - Subjects recieved 900 mg of oxcarbazepine
3088894|NCT01678976|Active Comparator|Group 2 Oxcarbazepine + BIA 2-093|Period 1 - Subjects recieved 900 mg of oxcarbazepine Period 2 - Subjects recieved 900 mg of BIA 2-093
3088895|NCT01679002|Experimental|Group A|"BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period~BIA 2-093 450 mg od - BIA 2-093 450 mg bid - OXC 900 mg bid"
3088896|NCT01679002|Experimental|Group B|"BIA 2-093 450 mg twice-daily period followed by oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period~BIA 2-093 450 mg bid - OXC 450 mg bid - BIA 2-093 900 mg od"
3088897|NCT01679002|Experimental|Group C|"oxcarbazepine 450 mg twice-daily period followed by BIA 2-093 900 mg once-daily period followed by BIA 2-093 450 mg twice-daily period~OXC 450 mg bid - BIA 2-093 900 mg od - BIA 2-093 450 mg bid"
3088898|NCT01679028|Placebo Comparator|Placebo Group A|150mg Placebo Single dose
3088899|NCT01679028|Experimental|T89 Group A|150mg T89 single dose
3088900|NCT01679028|Placebo Comparator|Placebo Group B|300mg placebo single dose
3088901|NCT01679028|Experimental|T89 Group B|300mg T89 single dose
3088902|NCT01679028|Placebo Comparator|Placebo Group C|225mg Placebo bid for 14 days
3088903|NCT01679028|Experimental|T89 Group C|225mg T89 bid for 14 days
3088904|NCT01679197|Experimental|Treatment|Metreleptin
3088905|NCT01679236|Active Comparator|Mindfulness Training for Smokers|Mindfulness Training for Smokers (MTS) is a 7-week intervention that provides instruction in mindfulness very similar to the way it is taught in Mindfulnes-Based Stress Reduction. In addition MTS provides mindfulness training targeted to specific smoking relapse challenges. The MTS intervention was designed around a weekly curriculum that provides instruction to help participants learn practices including mindfulness meditation, mindful walking and mindful eating. MTS participants are instructed to practice meditation 30 minutes per day with a guided meditation CD.
3088906|NCT01679236|Active Comparator|Interactive Learning for Smokers|Interactive Learning for Smokers (ILS) is a 7-week intervention that provides a closely matched active control group for MTS, but with substantive education and skills training for smoking cessation. To this end, ILS combines elements of two smoking cessation programs, the American Lung Association, Freedom from Smoking program and The Mayo Clinic Nicotine Dependence Center program. ILS participants were asked to practice 30 minutes of silent non-directed walking per day throughout the intervention and were instructed to use non-directed walking for relaxation, stress reduction and as a strategy for managing urges and withdrawal symptoms.
3088907|NCT01679301|Active Comparator|Continuous dose|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator.
3088908|NCT01679301|Experimental|Pulse dose ('sleep mode')|Users will be randomized to either receive oxygen via continuous dose oxygen or pulsed dose ('sleep' mode) for the first part of the night and will switch for the second part of the night using the SimplyGo Portable Oxygen Concentrator
3088909|NCT01679314|Active Comparator|Active AlphaCore device|AlphaCore active stimulation treatment
3088910|NCT01679314|Sham Comparator|Sham AlphaCore device|AlphaCore sham device
3088911|NCT01679405|Experimental|Dose level 1 (Part A)|30 mg BIBW 2992, Gemcitabin (1.000 mg/m² BSA i.v.)/Cisplatin (25 mg/m² BSA i.v.)
3088912|NCT01679405|Experimental|Dose level -1 (Part A)|30 mg BIBW 2992, Gemcitabin (800 mg/m² BSA i.v.)/Cisplatin (20 mg/m² BSA i.v.)
3088913|NCT01679600|Experimental|FC-RATE|Feedback-controlled robotics-assisted treadmill exercise
3088914|NCT01679600|Active Comparator|RATE|Robotics-assisted treadmill exercise
3088915|NCT01679613|Experimental|1 Nintedanib (Reference)|single dose, oral with 240 ml water
3088916|NCT01679613|Experimental|2 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
3088917|NCT01679613|Experimental|3 Nintedanib (Reference)|single dose, oral with 240 ml water
3088918|NCT01679613|Experimental|4 Nintedanib + Ketoconazole (Test)|Nintedanib single dose, Ketoconazole steady state, oral with 240 ml water
3088919|NCT01680016|Experimental|Zagreb(≥6 to ≤17 Years)|
3088920|NCT01680016|Experimental|Zagreb(≥51 Years)|
3088921|NCT01680016|Active Comparator|Essen(≥6 to ≤17 Years)|
3088922|NCT01680016|Active Comparator|Essen(≥51 Years)|
3088923|NCT01680159|Experimental|TA-650|
3088924|NCT01680172|Experimental|Ketamine|Single dose of ketamine (0.5 mg/kg)
3088925|NCT01680172|Placebo Comparator|Placebo|Single dose of placebo
3088926|NCT01680328|Other|Different injection speed and volume combinations|The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
3088927|NCT01680341|Experimental|IDegAsp Simple|
3088928|NCT01680341|Experimental|IDegAsp Step wise|
3088929|NCT01680458||fluconazole|Infant Subjects who are treated with fluconazole
3088930|NCT01680497|Experimental|JUVÉDERM VOLIFT™|All subjects receiving treatment with JUVÉDERM VOLIFT™.
3088931|NCT01680549|Active Comparator|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
3088932|NCT01680549|Placebo Comparator|Placebo|Placebo 600 mg po preoperatively and continued postoperatively 300 mg po q8hours X 3 days
3088933|NCT01680640|Active Comparator|Synbiotic|Fructo-oligosacharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis (BB-12) as minimum of 10 billion colony forming unit (CFU)/day (1 capsule a day).
3088934|NCT01680640|Placebo Comparator|Maltodextrin|4 grams of maltodextrin daily.
3088935|NCT01680653|Experimental|Mini-Glucagon and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
3088936|NCT01680653|Other|Carbohydrates and Remote Monitoring|"Subjects glucose data are remotely monitored at night using the University of Virginia (UVA) Diabetes Assistant (DiAs) Android Platform. Study staff intervenes with a fingerstick blood glucose measurement when sensor value falls below 70mg/dL. If fingerstick value is less than 70 mg/dL, hypoglycemic treatment is administered as below.~Administration of carbohydrate per camp protocol to treat nocturnal hypoglycemia. Expected treatment is 15-45g."
3088937|NCT01680653|Other|Carbohydrates No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with standard camp protocol administration of carbohydrates. Expected treatment is 15g-45g."
3088938|NCT01680653|Other|Mini-Glucagon and No Remote Monitoring|"Subjects wear a continuous glucose monitor for their own use, but they are not remotely monitored.~If hypoglycemia occurs and is acknowledged through standard camp protocol it will be treated with mini-glucagon.~Administer mini-glucagon as treatment for nocturnal hypoglycemia. Administer 0.01 cc per number of years in age via insulin syringe, subcutaneously. This amounts to 1 unit per age, for example: an 8 year old gets 8 units glucagon."
3088939|NCT01680666|Active Comparator|landmark guided|central line placement
3088940|NCT01680666|Active Comparator|ultrasound guided|central line placement
3088941|NCT01680783|Other|Usual Care|Patients who require noninvasive ventilation via Face mask for more than 8 hours will continue using noninvasive ventilation via facemask.
3088942|NCT01680783|Experimental|Non invasive ventilation via helmet|Patients requiring more than 8 hours of noninvasive ventilation via facemask will switch to non-invasive ventilation using a helmet instead of face mask for treatment of respiratory failure
3088943|NCT01680835|Experimental|Study cohort|All patients enrolled in this study will be treated with the EverFlex™ Self-Expanding Peripheral Stent System.
3088944|NCT01680861|Experimental|Tacrolimus and Everolimus|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml."
3088945|NCT01680861|Active Comparator|Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)|"Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.~EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day."
3088946|NCT01680887|Experimental|Varenicline|Oral 1.0 mg BID.
3088947|NCT01680887|Placebo Comparator|Placebo|Oral 1.0 mg BID.
3088948|NCT01680900|Experimental|experimental 1|vilazodone (viibryd). 20 mg or 40 mg/day for 8 weeks
3088949|NCT01680900|Placebo Comparator|placebo capsules (sugar pill)|Placebo capsules matched to the drug dose for 8 weeks
3088950|NCT01680965|Experimental|Ofatumumab|"Phase I:~Escalating dose of ofatumumab~Phase II:~Maximum tolerated dose (MTD) of Ofatumumab"
3088951|NCT01680991|Experimental|CLL: 1000 mg Obinutuzumab|Participants with chronic lymphocytic leukemia (CLL) will receive 1000 milligrams (mg) obinutuzumab as an intravenous (IV) infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. The first infusion on Cycle 1 Day 1 will be given over two days: Day 1 and Day 2. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3088952|NCT01680991|Experimental|DLBCL: 1000 mg Obinutuzumab|Participants with diffuse large B-cell lymphoma (DLBCL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3088953|NCT01680991|Experimental|FL: 1000 mg Obinutuzumab|Participants with follicular lymphoma (FL) will receive 1000 mg obinutuzumab as an IV infusion, on Day 1 of each 21-day cycle for a maximum of 8 cycles. Additional doses of obinutuzumab will be administered on Cycle 1 Day 8 and Day 15.
3088954|NCT01681004|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
3088955|NCT01681004|Active Comparator|Non-Surgical Management|Medications, SI joint injection, physical therapy and RF ablation of SI joint
3088956|NCT01681030|Experimental|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3088957|NCT01681030|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
3088958|NCT01681030|Active Comparator|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
3088959|NCT01681069|Active Comparator|IQP-VV-102|2 tablets twice a day
3088960|NCT01681069|Placebo Comparator|Placebo|2 tablets twice a day
3132427|NCT03426436|Other|Test|Obtain two consecutive 15-lead ECGs; The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
3132428|NCT03426566||patients with diabetes|Data from medical records from : non-ulcer patients with DM (diabetes mellitus) from the Diabetic Foot Centre (DFC) in Wroclaw. As it is a retrospective analysis no intervention is planned.
3132429|NCT03426631|Placebo Comparator|Placebo|Placebo before sleep
3132430|NCT03426631|Experimental|DAW1033B2 oral capsule|DAW1033B2 before sleep
3088961|NCT01681095|Experimental|Cardioplegia: Custodiol HTK Solution|"Custodiol HTK (histidine-tryptophan-ketoglutarate) cardioplegia: One liter of HTK solution (Custodiol; Koehler Chemi, Alsbach-Haenlien, Germany) contains the following components: 15 mmol/L sodium chloride, 9 mmol/L potassium chloride, 4 mmol/L magnesium chloride, 18 mmol/L histidine hydrochloride, 180 mmol/L histidine, 2 mmol/L tryptophan, 30 mmol/L mannitol, 0.015 mmol/L calcium chloride, 1 mmol/L potassium hydrogen 2-ketoglutarate, osmolarity 310 mOsm/kg, pH 7.02-7.20.~Custodiol-HTK was delivered to establish and maintain cardiac arrest. After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. Custodiol-HTK was delivered at a temperature of 4°C - 10°C."
3088962|NCT01681095|Active Comparator|Cold Blood Cardioplegia|"Cold Blood Cardioplegia: One liter of cold blood cardioplegic solution, mixed at a ratio of 4:1 per Beaumont standard of care (blood /cardioplegic solution), contains the following in a 500 cc bag of D5W (dextrose 5% in water): 50meq/L potassium chloride, 37.5 meq/L sodium bicarbonate and 7.5 meq/L magnesium sulfate.~After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 8°C."
3088963|NCT01681121|Experimental|ADX-N05|ADX-N05 to be taken once a day for 12 weeks
3088964|NCT01681121|Placebo Comparator|Placebo|Placebo to match ADX-N05 to be taken once a day for 12 weeks
3088965|NCT01681186|Experimental|LY2940680 (Part A)|Single escalating dose (50 mg up to 400 mg) of LY2940680 given once orally in up to 2 of 2 study periods
3088966|NCT01681186|Placebo Comparator|Placebo (Part A)|Placebo given once orally in up to 1 of 2 study periods
3088967|NCT01681186|Experimental|LY2940680 Capsule Fasted (Part B)|100 mg LY2940680 given once orally as a capsule (reference formulation) in fasted state in 1 of 4 study periods
3088968|NCT01681186|Experimental|LY2940680 Tablet Fasted (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fasted state in 1 of 4 study periods
3088969|NCT01681186|Experimental|LY2940680 Tablet Fed (Part B)|100 mg LY2940680 given once orally as a tablet (test formulation) in fed state following a standardized, high-fat breakfast in 1 of 4 study periods
3088970|NCT01681186|Experimental|LY2940680 Tablet Fasted + PPI (Part B)|30 mg lansoprazole (PPI) given orally once daily for 7 days. One hour after last dose, 100 mg LY2940680 given orally once as a tablet (test formulation) in fasted state in 1 of 4 study periods
3088971|NCT01681212|Experimental|Ipilimumab, 10 mg/kg + Dacarbazine, 850 mg/m^2|During the Induction Period, participants received ipilimumab, 10 mg/kg, as tolerated by intravenous (IV) infusion as 1 single dose during Weeks 1 (Day 1), 4, 7, and 10 for a total of 4 separate doses. During the Maintenance Phase, participants received ipilimumab, 10 mg/kg, as tolerated by IV infusion every 12 weeks, beginning at Week 24, until disease progression or unacceptable toxicity occurred or the patient withdrew consent. Participants also received dacarbazine, 850 mg/m^2, by IV infusion over 30 to 60 minutes, starting on Week 1 and repeated every 3 weeks until Week 22. Dacarbazine was dosed on the same day as ipilimumab, when applicable, after the ipilimumab dose.
3088972|NCT01681277|Experimental|BI 113608 high dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3088973|NCT01681277|Experimental|BI 113608 low dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3088974|NCT01681277|Experimental|BI 113608 medium dose bid|powder in the bottle for oral solution, oral administration with 240 ml water
3088975|NCT01681277|Experimental|BI 113608 high dose qd|powder in the bottle for oral solution, oral administration with 240 ml water
3088976|NCT01681368|Experimental|Birinapant for Advanced Ovarian,Fallopian Tube & Peritoneal Ca|single arm
3088977|NCT01681433|Experimental|Experimental: Arm A|OGX-427 + continuation of standard therapy with abiraterone acetate and prednisone
3088978|NCT01681433|Active Comparator|Control Arm: Arm B|Continuation of standard therapy with abiraterone acetate and prednisone
3088979|NCT01681472|Active Comparator|Levoleucovorin 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
3088980|NCT01681472|Active Comparator|Levoleucovorin 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
3088981|NCT01681472|Experimental|6R-MTHF 200 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
3088982|NCT01681472|Experimental|6R-MTHF 60 mg/m2|One i.v. bolus injection of study drug after the patient has been anaesthetized.
3088983|NCT01681511|Experimental|ICET™ TIC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
3088984|NCT01681511|Active Comparator|BARD® LUBRI-SIL® IC Foley Catheter|Route of Administration: Urinary Bladder Catheterization
3088985|NCT01681576|Experimental|LCZ696 followed by Valsartan|Period 1: LCZ696 400mg QD for 4 weeks then washout followed by Period 2: Valsartan 320mg QD for 4 weeks
3088986|NCT01681576|Experimental|Valsartan followed by LCZ696|Period 1: Valsartan 320mg QD for 4 weeks then washout followed by Period 2: LCZ696 400mg QD for 4 weeks
3088987|NCT01681628|Experimental|Thought Field Therapy|Thought Field Therapy delivered by trained community leaders.
3088988|NCT01681628|Other|Wait list|"Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test)."
3088989|NCT01681771|Experimental|Cogntive behaviour therapy|Internet based Cognitive behaviour therapy during 9 weeks
3088990|NCT01681771|Active Comparator|Discussion group|Internet moderated discussion group during 9 weeks
3088991|NCT01681810|Experimental|14Nitrogen sodium nitrite|sodium nitrite 40 mg three times a day for 12 weeks
3088992|NCT01681836|Experimental|Oral 15N-labeled sodium nitrate|Oral sodium nitrate 1,000 mg once first, then washout followed by oral sodium nitrite 20 mg once
3088993|NCT01681836|Experimental|Oral 15N-labeled sodium nitrite|Oral sodium nitrite 20 mg once first, then washout followed by oral sodium nitrate 1,000 mg once
3088994|NCT01681849|Experimental|Paroxetine Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive paroxetine for a three month period followed by an open label phase of three months.
3132431|NCT03426787|Experimental|Decision Aid|A decision supports tool that guides patients with Hepatitis C and Chronic Kidney Disease through choices about whether, when, and how to treat each illness.
3088995|NCT01681849|Placebo Comparator|Placebo Group|Women who have experienced early childhood abuse and have PTSD will be randomized in a double blind fashion to receive placebo for a three month period followed by an open label phase of paroxetine for three months.
3088996|NCT01681849|Other|PTSD Negative|Women who have experienced early childhood abuse and do not have PTSD will serve as a control group and complete baseline assessments. They do not undergo intervention therefore they are assessed at baseline only.
3088997|NCT01681992|Experimental|Inv_MMR_Min Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a minimum potency lot (Inv_MMR_Min), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3088998|NCT01681992|Experimental|Inv_MMR_Med Group|Subjects receive one dose of GlaxoSmithKline (GSK) Biologicals' measles, mumps, rubella (MMR) vaccine, Priorix (Inv_MMR), from a mid-range or medium potency lot (Inv_MMR_Med), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose from a separate lot of the Inv_MMR vaccine (Inv_MMR_Release), for the second dose. Inv_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3088999|NCT01681992|Active Comparator|Com_MMR Group|Subjects receive one dose of M-M-R II (Com_MMR) vaccine (Lot 1 or Lot 2), co-administered with Varivax (VV) and Havrix (HAV) vaccines at Day 0. All US subjects are also co-administered Prevnar 13 (PCV-13) vaccine. Approximately 6 weeks later, at Day 42, subjects are administered a dose of Com_MMR vaccine (Lot 1 or Lot 2), for the second dose. Com_MMR and VV vaccines are administered subcutaneously in the triceps region of the left and right arm, respectively. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3089000|NCT01682031|Placebo Comparator|Arm I (placebo, cisplatin, and radiotherapy)|Patients receive placebo PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin IV over 3 hours once in weeks 2, 5, and 8 and undergo radiotherapy 5 days a week in weeks 2-8.
3089001|NCT01682031|Experimental|Arm II (selenomethionine, cisplatin, and radiotherapy)|Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11. Patients also receive cisplatin and undergo radiotherapy as in arm I.
3089002|NCT01682044|Experimental|Treatment (colony-stimulating factor and monoclonal antibody)|Patients receive pegfilgrastim SC followed by rituximab IV 3 days later in weeks 1, 3, 5, 7, 15, 23, 31, and 39. Treatment continues in the absence of disease progression or unacceptable toxicity.
3089003|NCT01682083|Experimental|Dabrafenib and trametinib|Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.
3089004|NCT01682083|Placebo Comparator|Dabrafenib and trametinib placebos|Subjects received matching placebos orally for 12 months
3089005|NCT01682135|Experimental|Ramucirumab|Ramucirumab administered intravenously (IV) at escalating doses (6 milligrams per kilogram [mg/kg] up to 10 mg/kg) every 2-3 weeks for 6 weeks (1 Cycle). Treatment may continue until discontinuation criterion is met.
3089006|NCT01682148|Experimental|NMJ Targeted|NMJ targeted technique and low-concentration dilution (Dysport 100 U/mL). The same number and sites of injections/deposits per muscle were given as per prestudy. With a Dysport dilution of 300 U/mL the volume to be injected varied between 0.1 mL and 0.7 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment.
3089007|NCT01682148|Active Comparator|Current Clinical Practice|"Current clinical practice technique and high-concentration dilution (Dysport 300 U/mL).~A single injection per muscle was given in the midline of the band of NMJ zones. With a Dysport dilution of 100 U/mL the volume to be injected varied between 0.4 mL and 2.0 mL per muscle. The dose and the choice of muscles involved in the elbow flexion were the same as for the last prestudy treatment."
3089008|NCT01682213|Experimental|dabrafenib|This is a single institution phase II trial assessing the efficacy of adjuvant dabrafenib (GSK2118436) in patients with surgically resected AJCC stage IIIC melanoma characterized by a BRAFV600E/K mutation.
3089009|NCT01682460|Experimental|Refresh Tears Lubricant Eye Drops (Allergan)|Artificial tears eye drops QID for 1 month
3089010|NCT01682512|Experimental|Part I BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3089011|NCT01682512|Active Comparator|Part I Rituxan®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3089012|NCT01682512|Active Comparator|Part I MabThera®|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3089013|NCT01682512|Experimental|Part II BI 695500 group|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3089014|NCT01682512|Active Comparator|Part II rituximab group|rituximab, Two infusions separated by 2 weeks, Intravenous infusion
3089015|NCT01682538|Active Comparator|Orfadin capsules, fasting|Orfadin capsules, single dose, 30 mg
3089016|NCT01682538|Experimental|Orfadin suspension, fasting|Orfadin suspension 4 mg/mL, single dose 30 mg (7,5 mL)
3089017|NCT01682538|Experimental|Orfadin suspension, with food|Orfadin suspension 4mg/mL, single dose 30 mg (7,5 mL)
3089018|NCT01682603|Experimental|Botulinum toxin A|BoNT-A (BOTOX 300U)
3089019|NCT01682642|Active Comparator|Zoladex|After surgical vaporization of endometriosis patients are treated with Zoladex for 3 months.
3089020|NCT01682642|No Intervention|vaporization only|Surgical vaporization of the endometriosis is done and patients start IVF without additional treatment.
3089021|NCT01682681||Topiramate|
3089022|NCT01682720|Placebo Comparator|Placebo 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
3089023|NCT01682720|Experimental|SOF 12 Weeks (GT2/3)|Placebo to match SOF + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 12 weeks in participants with genotype 2 or 3 HCV infection.
3089024|NCT01682720|Experimental|SOF 24 Weeks (GT3)|SOF 400 mg tablet once daily + weight-based RBV (1000-1200 mg as 200 mg tablets in a divided daily dose) for 24 weeks in participants with genotype 3 HCV infection.
3089025|NCT01682759|Experimental|Omarigliptin|Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
3089026|NCT01682759|Active Comparator|Glimepiride|Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
3089027|NCT01682811|Experimental|Part 1 Levulan injection|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) injection and 3 hr incubation, and by Levulan treated lesions after 3 or 24 hr incubation.
3089028|NCT01682811|Experimental|Part 1 Levulan painting|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application and 3 hr incubation, and by Levulan treated lesions and 3 or 24 hr incubation.
3089029|NCT01682811|Experimental|Part 1 Levulan painted twice|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation.
3089030|NCT01682811|Experimental|Part 1 Levulan painted twice with microneedling|5-aminolevulinic acid uptake by control lesions after Levulan vehicle (placebo) surface application twice or by Levulan treated lesions twice and 24 hr incubation. All lesions prepared with microneedling.
3089031|NCT01682811|Experimental|Part 2 Dose level 1 50 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1 - 50 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
3089032|NCT01682811|Experimental|Part 2 Dose level 2 100 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2 - 100 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
3089033|NCT01682811|Experimental|Part 2 Dose level 3 200 J/cm^2|Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3 - 200 J/cm^2 633 nm red light to Levulan vehicle (placebo) treated control lesions or Levulan treated lesions and 24 hr incubation. Follow-ups on day 2 for punch biopsies, 14-28 days for evaluation of cutaneous adverse events, and every 3 months up to one year for lesion measurements.
3089034|NCT01682837|Experimental|KMgCit, KCit, KCl, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate (KMgCit) powder, Potassium Citrate (KCit) powder, Potassium Chloride (KCl) powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089035|NCT01682837|Experimental|KMgCit, KCit, Placebo, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089036|NCT01682837|Experimental|KMgCit, KCl, KCit, Placebo|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089037|NCT01682837|Experimental|KMgCit, KCl, Placebo, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089038|NCT01682837|Experimental|KMgCit, Placebo, KCit, KCl|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089039|NCT01682837|Experimental|KMgCit, Placebo, KCl, KCit|Participants who received study drug in the order: Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089040|NCT01682837|Experimental|KCit, KMgCit, KCl, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089041|NCT01682837|Experimental|KCit, KMgCit, Placebo, KCl|Participants who received study drug in the order: Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089042|NCT01682837|Experimental|KCit, KCl, KMgCit, Placebo|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089043|NCT01682837|Experimental|KCit, KCl, Placebo, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089044|NCT01682837|Experimental|KCit, Placebo, KMgCit, KCl|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089045|NCT01682837|Experimental|KCit, Placebo, KCl, KMgCit|Participants who received study drug in the order: Potassium Citrate powder, Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089046|NCT01682837|Experimental|KCl, KMgCit, KCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089047|NCT01682837|Experimental|KCl, KMgCit, Placebo, KCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Magnesium Citrate powder, Placebo, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089048|NCT01682837|Experimental|KCl, KCit, KMgCit, Placebo|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder, Placebo. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089049|NCT01682837|Experimental|KCl, KCit, Placebo, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Potassium Citrate powder, Placebo, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089050|NCT01682837|Experimental|KCl, Placebo, KMgCit, KCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089051|NCT01682837|Experimental|KCl, Placebo, KCit, KMgCit|Participants who received study drug in the order: Potassium Chloride powder, Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089052|NCT01682837|Experimental|Placebo, KMgCit, KCit, KCl|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089053|NCT01682837|Experimental|Placebo, KMgCit, KCl, KCit|Participants who received study drug in the order: Placebo, Potassium Magnesium Citrate powder, Potassium Chloride powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089054|NCT01682837|Experimental|Placebo, KCit, KMgCit, KCl|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Magnesium Citrate powder, Potassium Chloride powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089055|NCT01682837|Experimental|Placebo, KCit, KCl, KMgCit|Participants who received study drug in the order: Placebo, Potassium Citrate powder, Potassium Chloride powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089056|NCT01682837|Experimental|Placebo, KCl, KMgCit, KCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Magnesium Citrate powder, Potassium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089057|NCT01682837|Experimental|Placebo, KCl, KCit, KMgCit|Participants who received study drug in the order: Placebo, Potassium Chloride powder, Potassium Citrate powder, Potassium Magnesium Citrate powder. Study medications were taken twice daily after dissolution in 250 ml water. Each phase was followed by at least 1 week of washout.
3089058|NCT01682863|Experimental|QVA149 dose 1|QVA149 27.5/12.5 μg capsules
3089059|NCT01682863|Experimental|QVA149 dose 2|QVA149 27.5/25 μg capsules
3089060|NCT01682863|Active Comparator|QAB149|QAB149 75 μg capsules
3089061|NCT01682876|Placebo Comparator|2 through 5 years (1 Vac) MenACWY-CRM 1|Subjects 2 through 5 years received one vaccination of MenACWY-CRM
3089062|NCT01682876|Active Comparator|2 through 5 years (2 Vac) MenACWY-CRM 2|Subjects 2 through 5 years received two vaccinations of MenACWY-CRM
3089063|NCT01682876|Placebo Comparator|6 through 10 years (1 Vac) MenACWY-CRM 3|Subjects 6 through 10 years received one vaccination of MenACWY-CRM
3089064|NCT01682876|Active Comparator|6 through 10 years (2 Vac) MenACWY-CRM 4|Subjects 6 through 10 years received two vaccinations of MenACWY-CRM
3089065|NCT01682954|Experimental|Lifestyle counseling|Diabetes Prevention Program lifestyle intervention
3089066|NCT01682954|No Intervention|Usual Care|Usual care from primary care physician
3089067|NCT01683019|Active Comparator|Active Fixed Alpha Frequency Magnetic Stimulation|Sinusoidal magnetic field set to the subject's intrinsic alpha frequency (IAF).
3089068|NCT01683019|Active Comparator|Active Random Frequency Magnetic Stimulation|Magnetic field hops to random frequencies in the alpha band (8-13Hz), once per second.
3089069|NCT01683019|Sham Comparator|Inactive Sham Treatment|Generate sound similar to active treatment, except that no magnetic field is generated.
3089070|NCT01683058|Experimental|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg once monthly (every 28 days) for 24 weeks
3089071|NCT01683071|Experimental|(Part 1) EXPAREL 67 mg|5 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 15 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
3089072|NCT01683071|Experimental|(Part 1) EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
3089073|NCT01683071|Experimental|(Part 1) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
3089074|NCT01683071|Placebo Comparator|(Part 1) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
3089075|NCT01683071|Experimental|(Part 2) EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection femoral nerve block ≤2 h preoperatively
3089076|NCT01683071|Placebo Comparator|(Part 2) Placebo|20 mL normal saline as single-injection femoral nerve block ≤2 h preoperatively
3089077|NCT01683266|Experimental|HOE901-U300|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
3089078|NCT01683266|Active Comparator|Lantus|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily in morning or evening for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
3089079|NCT01683331|Active Comparator|Insulin treatment for hyperglycemia|Neutral Protamine Hagedorn (NPH) Insulin Titration Regimen, based on pre-dinner capillary blood glucose measurements (CPG) expressed in mg/dl; All NPH initiation doses and dose adjustments are presented in IU/day For pts. with CPG > 240, NPH initiation: 14, dose increases by 4; For pts. with CPG > 180 mg/dl, NPH initiation: 12, dose increases by 4; For pts. with CPG > 140 mg/dl, NPH initiation: 10, dose increases by 4; For pts. with CPG > 120 mg/dl, NPH initiation: 0, dose increases by 2; For pts. with CPG 100-119 mg/dl, NPH initiation: 0, maintain dose; For pts. with CPG 80-<100 mg/dl, NPH initiation: 0, dose decrease by 4; For pts. with CPG 60-<80 mg/dl, NPH initiation: 0, decrease by 8; For pts. with CPG <60 mg/dl, NPH initiation: 0, ½ of previous dose.
3089080|NCT01683331|No Intervention|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation.
3089081|NCT01683383|Active Comparator|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
3089082|NCT01683383|Experimental|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
3089083|NCT01683409|Placebo Comparator|Placebo|Administered orally, given as three placebo tablets in the morning and one placebo tablet in the evening for 24 weeks.
3089084|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg QD|Administered orally, 0.75 mg given as one 0.75 mg tablets and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3089085|NCT01683409|Experimental|Baricitinib 0.75 mg/0.5 mg BID|Administered orally, 0.75 mg given as one 0.75 tablet and 2 placebo in the morning and one 0.75 mg tablet in the evening for 24 weeks or 0.5 mg given as one 0.5 mg tablet and two placebo tablets in the morning and one 0.5 mg tablet in the evening. Placebo tablets given to maintain blind.
3089086|NCT01683409|Experimental|Baricitinib 1.5 mg/1 mg|Administered orally, 1.5 mg given as two 0.75 mg tablets and 1 placebo tablet in the morning and one placebo tablet in the evening for 24 weeks or 1 mg tablet and two placebo tablets in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3089087|NCT01683409|Experimental|Baricitinib 4 mg/2.75 mg|Administered orally, 4 mg given as one tablet and 2 placebo tablets in the morning and one placebo tablet in the evening for 24 weeks or 2.75 mg given as two 1 mg tablets and one 0.75 mg tablet in the morning and one placebo tablet in the evening for 24 weeks. Placebo tablets given to maintain blind.
3089088|NCT01683422|Experimental|Proton Radiation|"Pre-Proton-chemotherapy (PCT) Patients will receive a combination of the agents (Gemcitabine plus Erlotinib) for 8 weeks prior to PCT Gemcitabine 1000 mg/m2 IV, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43~PCT to be started in 4 to 8 weeks after completion of Pre-PCT Proton therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day for 5 ½ weeks.~Chemotherapy: Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed~Post-PCT to be started in 4 to 6 weeks after completion of PCT Oxaliplatin 130 mg/m2, day 1 Capecitabine 1000 mg/m2 po bid on days 2 to 15 for 14 days The CapOx regimen (Capecitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles"
3089089|NCT01683526|Active Comparator|Direct laryngoscopy|Intubation will be done using direct laryngoscopy
3089090|NCT01683526|Active Comparator|Video laryngoscopy|Intubation will be done using video laryngoscopy
3089091|NCT01683565|Experimental|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement
3089092|NCT01683565|Placebo Comparator|Canola Oil Placebo|
3089093|NCT01683604||Rheumatoid Arthritis (RA) Participants (All Groups)|Participants with severe RA were prescribed with tocilizumab in accordance with routine clinic practice, and were observed for 6 months.
3089094|NCT01683630||Confirmed influenza A and B cases|Cases of influenza A and B as diagnosed by PCR, viral culture or florescence microscopy
3089095|NCT01683812|Experimental|Cranial Cup Arm|Single arm
3089096|NCT01683838|Active Comparator|fampridine-SR 50mg/day|
3089097|NCT01683838|Placebo Comparator|Placebo|
3089098|NCT01683994|Experimental|combination of cabozantinib, docetaxel and prednisone|combination of cabozantinib, docetaxel and prednisone
3089099|NCT01683994|Active Comparator|PII/ Arm 1-docetaxel + prednisone only|docetaxel + prednisone only
3089100|NCT01683994|Active Comparator|PII/Arm 2 -docetaxel+ prednisone + cabozantinib|docetaxel+ prednisone + cabozantinib
3089101|NCT01684007|Experimental|Bilateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0], bilateral implantation
3089102|NCT01684007|Active Comparator|Contralateral|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] and AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1, contralateral implantation
3089103|NCT01684020|Experimental|ARTISS Human Fibrin Sealant|Prior to fixation of the external rhinoplasty skin flap, a thin layer of ARTISS human fibrin sealant will be applied over the nasal tissue and fixated to the skin flap for at least 3 minutes.
3089104|NCT01684020|No Intervention|Standard of Care|Fixation of the skin flap created during external rhinoplasty will use the standard of care
3089105|NCT01684033|Other|PureMoist - Biotrue|Opti-Free® PureMoist® MPDS used first, followed by Biotrue™ MPS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3089106|NCT01684033|Other|Biotrue - PureMoist|Biotrue™ MPS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3089107|NCT01684046|Other|PureMoist - RevitaLens|Opti-Free® PureMoist® MPDS used first, followed by RevitaLens MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3089108|NCT01684046|Other|RevitaLens - PureMoist|RevitaLens MPDS used first, followed by Opti-Free® PureMoist® MPDS. Each product used as indicated for 30 days with participant's habitual contact lenses.
3089109|NCT01684202|Experimental|OPC-41061|
3089110|NCT01684215|Experimental|Single-agent PD-0332991|Phase 1 Part 1
3089111|NCT01684215|Experimental|PD-0332991 in combination with letrozole|Phase 1 Part 2
3089112|NCT01684215|Experimental|PD-0332991 with letrozole|Phase 2
3089113|NCT01684410|Experimental|Alpha-1 HC 100 mg|100 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
3089114|NCT01684410|Experimental|Alpha-1 HC 200 mg|200 mg of aerosolized Alpha-1 HC inhaled daily via nebulizer for 3 weeks.
3089115|NCT01684410|Placebo Comparator|Placebo|Placebo inhaled daily via nebulizer for 3 weeks. Placebo (phosphate buffer saline with polysorbate).
3089116|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 12 - <18|Subjects aged from 12 - <18 years were administered with age and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR (immediate-release) tablet once daily (OD) under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kilogram (kg) received a dose (equivalent to 20 milligram [mg] in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
3089117|NCT01684423|Active Comparator|Comparator, Age: 12 - <18 years|Subjects aged from 12 - <18 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
3089118|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) tablet, OD, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days. Subjects with a body weight of 14 to less than 50 kg received a dose (equivalent to 20 mg in adults) ranging from 5 to 15 mg, and subjects with a body weight (comparable to adults) of greater than or equal to 50 kg received a dose of 20 mg.
3089119|NCT01684423|Experimental|Rivaroxaban (BAY59-7939) suspension, BID, Age: 6 - <12 years|Subjects aged from 6 - <12 years were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily (BID). Subjects with a body weight of 9 to less than 50 kg received a total daily dose (equivalent to 20 mg in adults) ranging from 6.4 to 15 mg and subjects with a body weight of greater than or equal to 50 kg received a total daily dose of 20 mg.
3089120|NCT01684423|Active Comparator|Comparator, Age: 6 - <12 years|Subjects aged from 6 - <12 years received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or INR-adjusted (vitamin K antagonist).
3089121|NCT01684436|Experimental|Punctal plug|Punctal plugs inserted into the study eye on Day 1.
3089122|NCT01684566|Experimental|Standard-Of-Care + episil(R)|Standard-Of-Care plus episil® administered as three consecutive pump-strokes for a total volume of 0.45 mL applied 3 times daily and additionally, as needed
3089123|NCT01684566|Other|Standard-Of-Care|Oral hygiene procedures
3089124|NCT01684592|Active Comparator|Standard care|Standard care for smokers during pregnancy and referral to 24/7 quitline postpartum (passive)
3089125|NCT01684592|Experimental|Standard care plus PPCC|Standard care for smoking during pregnancy and proactive phone-based postpartum continuing care (PPCC) for 6 months postpartum
3089126|NCT01684722|Active Comparator|Vitamin D + fish oil|Vitamin D and omega-3 fatty acids (fish oil)
3089127|NCT01684722|Active Comparator|Vitamin D + fish oil placebo|Vitamin D and fish oil placebo
3089128|NCT01684722|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and omega-3 fatty acids (fish oil)
3089129|NCT01684722|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
3089130|NCT01684748|Experimental|Olmesartan Medoxomil first, then No Drug|During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
3089131|NCT01684748|Experimental|No Drug first, then Olmesartan Medoxomil|During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.
3089132|NCT01684826|Experimental|ClarityIQ|Angiographic run with new algorithm and low dose (50% dose)
3089133|NCT01684826|Experimental|AlluraXper|Angiographic run with predecessor algorithm and dose (100% dose)
3089134|NCT01684839|Other|new surgical treatment|Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap taken from the homolateral dorsal branch of the digital nerve.
3089135|NCT01684878|Experimental|Part 1: Pertuzumab + Topotecan|Participants received pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
3089136|NCT01684878|Experimental|Part 1: Pertuzumab + Paclitaxel|Participants received pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death.
3089137|NCT01684878|Experimental|Part 2: Pertuzumab+Chemotherapy|Participants received pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
3089138|NCT01684878|Placebo Comparator|Part 2: Placebo+Chemotherapy|Participants received pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigator's assessment, unacceptable toxicity, withdrawal of consent, or death. Chemotherapy was administered as per investigators discretion.
3089139|NCT01684917|Experimental|Life style advice|reduce energy intake by 20% less than estimated energy expenditure.
3089140|NCT01684917|Active Comparator|UK background diet|Diet where energy intake will be matched with estimated energy expenditure.
3089141|NCT01684917|Other|Metabolomic inquiry|This inquiry took place prior to the randomized controlled trial and include 50 volunteers who will then be asked to volunteers of the weight loss study. Were randomly assigned to one of five different diets; red meat, fish, poultry, processed meat or a supplement and vegetarian option.
3089142|NCT01684930|Experimental|BR Juice (Beet-It Stamina Shot) and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3089143|NCT01684930|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3089144|NCT01684943|Experimental|Multiplex pharmacokinetic profiling|Multiplex pharmacokinetic profiling of regular human insulin, insulin aspart, insulin lispro, insulin glulisine, and regular human insulin. All subjects participated in the single study arm and received injections of each type of insulin. Blood samples were drawn at intervals for pharmacokinetic profiling.
3089145|NCT01684943|Experimental|Continuous insulin monitoring|Continuous insulin monitoring (CIM) of insulin lispro. Some subjects participated in the CIM sub-study, which is distinct from the Multiplex Pharmacokinetic Profiling study. This intervention involved administering insulin lispro and monitoring pharmacokinetic profile of the drug using blood samples and an investigational continuous insulin monitoring system.
3089146|NCT01685021|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-optimized Anti-CD19 Antibody
3089147|NCT01685060|Experimental|LDK378|Patients treated with ceritinib/LDK378 750 mg once-daily, fasted
3089148|NCT01685073|Experimental|Zolpidem|Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder
3089149|NCT01685073|Placebo Comparator|Placebo|Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder
3089150|NCT01685138|Experimental|LDK378 (Ceritinib)|Participants on this arm took oral LDK378 750 mg once daily.
3089151|NCT01685203|Experimental|Group 1|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
3089152|NCT01685203|Experimental|Group 2|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-naïve HCV GT1b-infected participants
3089153|NCT01685203|Experimental|Group 3|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, HCV GT1b-infected, pegylated-interferon/ribavirin (pegIFN/RBV) treatment null responder participants
3089154|NCT01685203|Experimental|Group 4|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, treatment-naïve, HCV GT4-infected participants
3089155|NCT01685203|Experimental|Group 5|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 12 weeks to adult noncirrhotic, treatment-experienced, HCV GT4-infected participants
3089156|NCT01685203|Experimental|Group 6|ABT-450 150 mg/ r 100 mg, ABT-267 25 mg , once daily and weight-based ribavirin (RBV; 1,000 mg/day if < 75 kg or 1,200 mg/day if ≥ 75 kg, divided twice daily) for 12 weeks to adult noncirrhotic, HCV GT4-infected, pegylated-interferon/RBV (pegIFN/RBV) treatment-experienced participants
3089157|NCT01685203|Experimental|Group 7|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, treatment-naïve participants with compensated cirrhosis
3089158|NCT01685203|Experimental|Group 8|ABT-450 150 mg/ r 100 mg, and ABT-267 25 mg once daily for 24 weeks to adult, HCV GT1b-infected, pegylated-interferon/RBV(pegIFN/RBV) treatment-experienced participants with compensated cirrhosis
3089159|NCT01685216|Experimental|velaglucerase alfa|IV infusion, 60 U/kg, every other week for 1 year
3089160|NCT01685229||Balloon Sinus Dilation|Subjects with chronic sinusitis electing to have a balloon sinus dilation
3089161|NCT01685229||Medical Management|Subjects with chronic sinusitis electing to continue with medical therapy
3089162|NCT01685242|Experimental|AC-170 0.24%|
3089163|NCT01685242|Placebo Comparator|AC-170 0%|
3089164|NCT01685320|Active Comparator|Direct laryngoscope|Includes cases in which the forces applied by Macintosh direct laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
3089165|NCT01685320|Active Comparator|Indirect laryngoscope|Includes cases in which the forces applied by GlideScope indirect laryngoscope onto soft tissue of the pharynx during glottis visualization and intubation were measured.
3089166|NCT01685372|Experimental|Fluzone High Dose|Fluzone High Dose 0.5 mL intramuscularly (IM) given once
3089167|NCT01685372|Active Comparator|Fluzone|Fluzone 0.5mL IM given once
3089168|NCT01685411|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, Tacrolimus, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion.
3089169|NCT01685437|Experimental|AA4500|collagenase clostridium histolyticum
3089170|NCT01685463|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive brain stimulation technology that can focally stimulate the brain of an awake individual. The brain stimulation techniques could theoretically improve the efficacy of smoking cessation.
3089171|NCT01685463|Placebo Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rTMS determination, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes will be connected to an Epix VT Transcutaneous Electrical nerve stimulation device.
3089172|NCT01685567|Experimental|MICHI NPS+f|The MICHI™ NPS+f is a flow reversal circuit consisting of two proprietary sheaths connected by standard surgical tubing. The sheaths each have a standard hemostasis valve and sidearm. An in-line flow regulator allows the clinician to modify to the flow through the circuit (either high flow or low flow) in addition to permitting temporary cessation of flow.
3089173|NCT01685606|Experimental|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor will be infused, irrespective of the number of CD34+ cells.
3089174|NCT01685684|Experimental|Oxycodone DETERx|
3089175|NCT01685684|Placebo Comparator|Placebo|
3089176|NCT01685697|Active Comparator|Laerdal Mask|Mask ventilation with a Laerdal face mask
3089177|NCT01685697|Experimental|F&P Mask|Mask ventilation with a F&P face mask
3089178|NCT01685801|Experimental|Ivacaftor, Placebo, Ivacaftor, Placebo (IPIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3089179|NCT01685801|Experimental|Ivacaftor, Placebo, Placebo, Ivacaftor (IPPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3089180|NCT01685801|Experimental|Placebo, Ivacaftor, Ivacaftor, Placebo (PIIP)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3089181|NCT01685801|Experimental|Placebo, Ivacaftor, Placebo, Ivacaftor (PIPI)|During the Crossover Period, study drug was administered in 2-week alternating cycles with a minimum of 4-week washout period between Cycle 1 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and Cycle 2 [(Period 1 - Day 1 to 14) (Period 2 - Day 15 to 29)] and between Cycle 2 and the Open-label Period (Day 1 to 57). During the Open-label Period, all participants received ivacaftor.
3089182|NCT01685840|Experimental|Usual Care|Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
3089183|NCT01685840|Experimental|Biomarker-Guided Care|Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.
3089184|NCT01685983|Experimental|Abiraterone actetate and Prednisolone|
3089185|NCT01685996|Experimental|zonisamide|participants will receive zonisamide capsules (up to 300 mg) to take once a day.
3089186|NCT01685996|Placebo Comparator|Placebo|Participants will receive placebo capsules to take once a day
3089187|NCT01686152|Experimental|Investigational Test Product|Imiquimod Cream, 3.75% (Teva)
3089188|NCT01686152|Active Comparator|Reference Listed Drug|Zyclara® (imiquimod Cream), 3.75% (Medicis)
3089189|NCT01686152|Placebo Comparator|Vehicle|Vehicle of Test Product (Teva)
3089190|NCT01686165|Experimental|Belinostat Yttrium Ibritumomab Tiuxetan|Patients receive belinostat IV over 30-60 minutes on days 1-5. Treatment with belinostat repeats every 21 days for 2 courses. Patients then receive rituximab IV on days 1 and either 7, 8, or 9, and yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
3089191|NCT01686373|Experimental|Activa Dose II Real tDCS|Actual delivery of electrical stimulation
3089192|NCT01686373|Placebo Comparator|Activa Dose II Sham tDCS|Sham delivery of electrical stimulation
3089193|NCT01686438|Experimental|CBT-I delivery by video teleconferencing|Groups of participants will receive a cognitive behavioral therapy for insomnia program delivered by a trained psychologist using video teleconferencing.
3089194|NCT01686438|Active Comparator|In-person CBT-I delivery|Groups of participants will receive a cognitive behavioral therapy for insomnia (CBT-I) program by meeting in-person with a trained psychologist.
3089195|NCT01686451|Experimental|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
3089196|NCT01686451|Active Comparator|Simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
3089197|NCT01686503|Experimental|2/5 dose intradermal IPV|Participants in this arm will receive 2/5 dose (0.2 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one-time dose intradermally using the NanoPass MicronJet 600 microneedle device
3089198|NCT01686503|Experimental|1/5 dose intradermal IPV|Participants in this study arm will receive 1/5 dose (0.1 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intradermally using the NanoPass MicronJet 600 microneedle device.
3089199|NCT01686503|Active Comparator|full dose intramuscular IPV|Participants in this study arm will receive the standard full dose (0.5 mL) of inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
3089200|NCT01686503|Active Comparator|2/5 dose intramuscular IPV|Participants in this study arm will receive 2/5 dose (0.2 mL) inactivated polio vaccine (IPOL, Sanofi Pasteur) as a one time dose intramuscularly.
3089201|NCT01686568|Experimental|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
3089202|NCT01686568|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing ethyl oleate.
3089203|NCT01686581||BOTOX®|BOTOX® (botulinum toxin Type A) administered according to physician prescription for the treatment of chronic migraine; all treatment decisions lie with the physician.
3089204|NCT01686633|Experimental|Arm1: Fluticasone Furoate/ Vilanterol 200/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 200/25 mcg once daily in the evening for 84 days.
3089205|NCT01686633|Experimental|Arm 2: Fluticasone Furoate/ Vilanterol 100/25 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF/ VI 100/25 mcg once daily in the evening for 84 days
3089206|NCT01686633|Experimental|Arm 3: Fluticasone Furoate 100 mcg|At Visit 3, eligible subjects for randomization will be stratified according to their baseline FEV1 performed at Visit 3 (<=65% or >65%) and randomized to one of the three treatment arms. Subjects in this arm will receive FF 100 mcg once daily in the evening for 84 days
3089207|NCT01686646|Active Comparator|highest dose Paracetamol + caffeine|highest dose of Paracetamol and caffeine
3089208|NCT01686646|Active Comparator|low-dose Paracetamol + caffeine|lowest dose of Paracetamol and caffeine
3089209|NCT01686646|Active Comparator|high dose paracetamol|highest dose paracetamol
3089210|NCT01686646|Active Comparator|low dose paracetamol|lowest dose paracetamol
3089211|NCT01686750|Experimental|Integrated care centers|"Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.~HIV voluntary counseling and testing & staging~Risk reduction services including free condoms, needle and syringe exchange, opiate substitution therapy~Substance abuse counseling~Sexually transmitted infection screening and treatment~Access to free antiretroviral therapy and adherence support~Peer community outreach"
3089212|NCT01686750|No Intervention|Standard services|In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
3089213|NCT01686828|Experimental|Acyline & placebo gel & placebo pill|Acyline (300mcg/kg) + placebo transdermal gel + placebo pill daily
3089214|NCT01686828|Experimental|Acyline & Testosterone 1.25g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (1.25g) daily + placebo pill daily
3089215|NCT01686828|Experimental|Acyline & Testosterone 5g & placebo pill|Acyline (300mcg/kg) + Testosterone gel (5g) daily + placebo pill daily
3089216|NCT01686828|Experimental|Acyline & Testosterone & Letrozole|Acyline (300mcg/kg) + Testosterone gel (5g) daily + letrozole (5mg) daily
3089217|NCT01686932|Experimental|Vildagliptin followed by Sitagliptin|Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
3089218|NCT01686932|Experimental|Sitagliptin followed by Vildagliptin|Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
3089219|NCT01686958|Experimental|MR-Guided Transurethral US Ablation|MR-Guided Transurethral US Ablation of Prostate Tissue
3089220|NCT01687036|Other|Cryoablation|Cryoablation
3089221|NCT01687088||chronic migraineurs|At least 8 migraine days per week and headache at least 15 days per month.
3089222|NCT01687088||controls|No significant headache or disability as defined by migraine disability scale.
3089223|NCT01687101|Experimental|STOPAIN topical gel|STOPAIN gel which is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
3089224|NCT01687114|Experimental|cranberry juice|27% cranberry juice
3089225|NCT01687166|Experimental|Blazer Open-Irrigated Ablation Catheter|Blazer Open-Irrigated Ablation Catheter and Ablation Catheter Cable used in conjunction with a compatible electroanatomic mapping system
3089226|NCT01687166|Active Comparator|FDA Approved Open-Irrigated Ablation Catheter|FDA approved Open-Irrigated Radiofrequency Ablation Catheter system and compatible electroanatomic mapping system for the treatment of paroxysmal atrial fibrillation.
3089227|NCT01687179|Experimental|"Sirolimus and Hydroxychloroquine"|"Subjects will take Sirolimus at an initial dose of 2mg followed by dose adjustment to keep Sirolimus trough levels between 5-15ng/ml consistent with the effective dose in the MILES trial. In addition to Sirolimus subjects will receive Hydroxychloroquine at 200 mg daily for 6 months. Once safety is established at the lower dose (Sirolimus and Hydroxychloroquine 200 mg), subjects enrolled henceforth will receive Sirolimus and Hydroxychloroquine 400 mg (200 mg twice a day) for 6 months."
3089228|NCT01687218|Active Comparator|Group 1|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3089229|NCT01687218|Active Comparator|Group 2|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3089230|NCT01687218|Active Comparator|Group 3|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
3089231|NCT01687218|Active Comparator|Group 4|Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3089232|NCT01687218|Active Comparator|Group 5|Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
3089233|NCT01687218|Active Comparator|Group 6|Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
3089234|NCT01687244|Experimental|rAd-IFN Dose 1x10^11vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
3089235|NCT01687244|Experimental|rAd-IFN dose 3x10^11 vps/ml|Subjects will be randomly assigned to one of two INSTILADRIN arms.
3089236|NCT01687257|Experimental|SOF+RBV|Participants will receive SOF+RBV for 48 weeks.
3089237|NCT01687257|Experimental|Observation, then SOF+RBV|Participants will undergo 24 weeks of observation and then receive SOF+RBV for 48 additional weeks.
3089238|NCT01687270|Experimental|SOF+RBV|Participants will receive sofosbuvir+RBV for 24 weeks.
3089239|NCT01687283|Experimental|fluticasone propionate|1 mg BID inhalation via nebulizer
3089240|NCT01687283|Active Comparator|budesonide suspension|2 mg BID inhalation via nebulizer
3089241|NCT01687296|Experimental|fluticasone Nebules/placebo tablet|2×0.5mg/2ml twice daily neblulized/placebo tablet, oral, once daily
3089242|NCT01687296|Active Comparator|oral prednisone/placebo inhalation solution|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) / placebo inhalation solution nebulized twice daily
3089243|NCT01687387|Experimental|IPH2102 at 1 mg/kg|lirilumab (IPH2102/BMS986015) at 1 mg/kg
3089244|NCT01687387|Experimental|IPH2102 at 0.1 mg/kg|lirilumab (IPH2102/BMS986015) at 0.1 mg/kg
3089245|NCT01687387|Placebo Comparator|Placebo (Normal saline solution)|Normal saline solution
3089246|NCT01687400|Experimental|Decitabine|Patients receive decitabine IV over 1 hour on days 1-10 of a 28-day cycle. Treatment continues for 2 cycles. Patients then receive decitabine IV over 1 hour on days 1-10, 1-5, or 1-3 (depending on response). Treatment continues in the absence of disease progression or unacceptable toxicity.
3089247|NCT01687413|Experimental|Radiotherapy|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
3089248|NCT01687413|Active Comparator|Radiotherapy, cisplatin|"Patients undergo postoperative IMRT once daily, 5 days a week, for 6 weeks. The prescribed radiotherapy dose will be 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)~Patients also receive cisplatin 40 mg/m2 IV on Days 1, 8, 15, 22, 29, and 36 of radiation therapy (6 doses for a total of 240 mg/m2).~Patients can consent to participate in either the randomized (physician chooses radiotherapy arm or radiotherapy & cisplatin arm) or non-randomized (patient chooses radiotherapy arm or radiotherapy & cisplatin arm) pathways"
3089249|NCT01687478|Experimental|Olanzapine + Fluoxetine|"Olanzapine starting dose is 5 milligram (mg) (1 tablet). May titrate up to 10 mg (2 tablets), or 15 mg (3 tablets) administered once daily by mouth for 8 weeks.~Fluoxetine starting dose is 20 mg. May titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
3089250|NCT01687478|Placebo Comparator|Placebo + Fluoxetine|"Placebo matches the Olanzapine tablet for blinding.~Fluoxetine starting dose is 20 mg, then may titrate up to 40 mg or 50 mg administered once daily by mouth for 8 weeks."
3089251|NCT01687595|Experimental|HerpV 240 μg + QS-21 50 μg|Participants will receive a combination of HerpV 240 micrograms (μg) and QS-21 50 μg injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1. At Week 24, participants who completed treatment period 1 will receive a booster dose of combination of HerpV 240 μg and QS-21 50 μg in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
3089252|NCT01687595|Placebo Comparator|Placebo|Participants will receive a placebo injection subcutaneously at Weeks 0, 2 and 4 in treatment period 1 and at Week 24 in treatment period 2. Each treatment period will be followed by a washout period of 1 week.
3089253|NCT01687673|Experimental|Treatment|Combination temsirolimus plus sorafenib
3089254|NCT01687712|Experimental|AFOLIA|One subcutaneous injection of 225IU AFOLIA (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
3089255|NCT01687712|Active Comparator|Gonal-f® RFF|One subcutaneous injection of 225IU Gonal-f® RFF (follitropin alfa) per day (initial dose) for the first 5 days. From day 6 dose could be adjusted up (to a max of 450IU per day) or down (to a min of 75IU per day) in multiple increments of 37.5IU.
3089256|NCT01687790|Experimental|molecular breast imaging|
3089257|NCT01687972|Active Comparator|Sutures|
3089258|NCT01687972|Active Comparator|Insorb Staples|
3089259|NCT01687998|Experimental|Evacetrapib|Evacetrapib 130 mg tablet, administered orally once daily for up to 4 years. Participants will also receive standard of care for high-risk vascular disease (HRVD).
3089260|NCT01687998|Placebo Comparator|Placebo|Placebo, tablet administered orally once daily for up to 4 years. Participants will also receive standard of care for HRVD.
3089261|NCT01688037|Experimental|NBI-98854 50 mg|NBI-98854 50 mg administered as two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
3089262|NCT01688037|Experimental|NBI-98854 100 mg and 50 mg|NBI-98854 100 mg administered as two (2) 50 mg capsules taken every morning between 7:00am - 10:00am for 2 weeks. After 2 weeks, NBI-98854 50 mg administered by two (2) 25 mg capsules by mouth, taken every morning between 7:00am - 10:00am for remaining 4 weeks.
3089263|NCT01688037|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
3089264|NCT01688050|Experimental|Endovascular Repair|
3089265|NCT01688102|Active Comparator|Oral Vitamin D3|Participants will receive oral vitamin D3 50,000 units weekly for 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of oral vitamin D.
3089266|NCT01688102|Active Comparator|Ultraviolet Light|Subjects will receive 16 treatments with ultraviolet light (narrow band UVB) over 8 weeks. If 25(OH)D levels remain <35 ng/ml, subjects will receive additional doses of narrow band UVB.
3089267|NCT01688141|No Intervention|Control|Usual care
3089268|NCT01688141|Active Comparator|Enhanced Management|Practices randomised to the intervention group will be offered an enhanced level of CKD disease management led by clinical nurse specialists based on an intervention previously piloted in high risk patients. Here, high risk patients identified will be invited to a CKD clinic for tailored management of bp and proteinuria and referral as needed.
3089269|NCT01688310|Active Comparator|Open surgical circumcision|Open surgical techniques, which are commonly used for circumcision in Mozambique, require good surgical skills and minor complications are common.
3089270|NCT01688310|Experimental|Gomco clamp with tissue adhesive|Coupling removal of the foreskin with the Gomco clamp followed by wound sealing with tissue adhesive results in a procedure that can be performed by generalist doctors using the same technique in all age groups.
3089271|NCT01688336|Experimental|FOLFIRINOX|FOLFIRINOX given to all subjects
3089272|NCT01688466|Experimental|0.5 mg/day with Dose Escalation|0.5 mg/day with Dose Escalation by 0.5 mg/day increments every 2 weeks to a maximum of 2.0 mg/day
3089273|NCT01688466|Experimental|0.5 mg/day without Dose Escalation|0.5 mg/day without Dose Escalation
3089274|NCT01688596|No Intervention|No Treatment|"The No Treatment group includes patients undergoing laparoscopic hysterectomy without local infiltration of bupivacaine."
3089275|NCT01688596|Active Comparator|Bupivacaine|"The Bupivacaine Arm includes all patients who will receive bupivacaine injection on their trocar sites after the laparoscopic hysterectomy is completed. Bupivacaine (0.25%) will be injected through the closed incisions ensuring subcutaneous tissue, fascia, muscle and pre-peritoneal space of the trocar incision sites are infiltrated. All incisions 8 mm and greater are injected with 10 cc while all incisions 5 mm or less are infiltrated with 5 cc."
3089276|NCT01688609|Experimental|Treatment (lapatinib, trastuzumab, paclitaxel, surgery)|"Drug exposure: Patients receive lapatinib ditosylate PO QD and trastuzumab IV over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.~Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy or mastectomy."
3089277|NCT01688635|Experimental|LY2963016|Single 0.5 units per kilogram (U/kg) dose of LY2963016 administered subcutaneously, twice during the study
3089278|NCT01688635|Experimental|US-approved Lantus|Single 0.5 U/kg dose of US-approved Lantus administered subcutaneously, twice during the study
3089279|NCT01688726|Experimental|SYSTANE BALANCE|SYSTANE® BALANCE eyedrops, 1 drop 4 times a day for a continuous period of 1 month
3089280|NCT01688726|Active Comparator|Minims Saline|Minims® Saline 0.9% eyedrops, 1 drop 4 times a day for a continuous period of 1 month
3089281|NCT01688739|Experimental|Erenumab|Participants received a single dose of erenumab by subcutaneous injection at doses of 1 mg, 7 mg, 21 mg, 70 mg, 140 mg, and 210 mg or by IV injection at a dose of 140 mg.
3089282|NCT01688739|Placebo Comparator|Placebo|Participants received a single dose of matching placebo administered by SC or IV injection.
3089283|NCT01688830|Experimental|BI 655075|
3089284|NCT01688830|Placebo Comparator|Placebo|
3089285|NCT01688830|Experimental|BI 655075 with dabigatran|
3089286|NCT01688843|Experimental|INGEVITY lead|INGEVITY lead implant
3089287|NCT01688856|Experimental|Arm+Hand CCFES|Uses an electrical stimulator that opens the paretic hand and extends the paretic elbow in response to and with an intensity proportional to movement of the contralateral arm and hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
3089288|NCT01688856|Experimental|Hand CCFES|Uses an electrical stimulator that opens the paretic hand in response to and with an intensity proportional to movement of the contralateral hand. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
3089289|NCT01688856|Active Comparator|Arm+Hand Cyclic NMES|Uses an electrical stimulator that delivers stimulation to open the hand and extend the elbow repeatedly with preprogrammed timing and intensity. The treatment dose will be approximately 2 hrs per day of self-administered stimulation-mediated exercise at home plus 70 min of functional task practice twice a week in the laboratory for 12 weeks.
3089290|NCT01688882|Experimental|QGE031|QGE031 240 mg Q2W s.c.
3089291|NCT01688882|Placebo Comparator|Placebo|Placebo to Match Q2W s.c.
3089292|NCT01688882|Experimental|Open Label QGE031|Open Label QGE031 Q2W s.c.
3089293|NCT01688895||Participants with Protoporphyrias|Individuals with a documented diagnosis of Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
3089294|NCT01688921|Experimental|STRATIS Needle-Free|Patients assigned to this arm will receive AFLURIA vaccine administered using the Stratis needle-free injection device.
3089295|NCT01688921|Active Comparator|Needle-Syringe|Patients assigned to this arm will receive AFLURIA vaccine administered using a needle and syringe.
3089296|NCT01688973|Experimental|Arm I (tivantinib)|Patients receive tivantinib PO BID on days 1-28.
3089297|NCT01688973|Experimental|Arm II (tivantinib and erlotinib hydrochloride)|Patients receive tivantinib PO BID and erlotinib hydrochloride PO QD on days 1-28.
3089298|NCT01688999|Experimental|Cabozantinib|Administered orally at a dose of 60 mg once daily on each day of a 28-day cycle.
3089299|NCT01689155||Study Group|Participants must have received Menactra Vaccine according to routine clinical practice.
3089300|NCT01689207|Experimental|Drug: A|Avibactam (AVI)
3089301|NCT01689207|Experimental|Drug: B|Aztreonam (ATM)
3089302|NCT01689207|Experimental|Drug: C|combination of Aztreonam-Avibactam (ATM-AVI)
3089303|NCT01689207|Placebo Comparator|Drug: D|Matching Placebo
3089304|NCT01689324|Experimental|Study Group|Participants will receive a single booster dose of Tdap vaccine (ADACEL®) on Day 0.
3089305|NCT01689337|Experimental|Sprifermin (AS902330), 30 mcg|
3089306|NCT01689337|Experimental|Sprifermin (AS902330), 100 mcg|
3089307|NCT01689337|Placebo Comparator|Placebo|
3089308|NCT01689350|No Intervention|Control Group|The cases in control group received traditional therapy that the initial dose of cyclophosphamide (CPA) was 0.2-0.6g/week injection according to clinical experience.
3089309|NCT01689350|Experimental|Experimental Group|Genetic: Genotype Detection To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM),with initial dose of CPA as 0.2g, 0.4g and 0.6g per week by injection, respectively.
3089310|NCT01689363|Experimental|Arm H|Intradermal injection of Amphadase (hyaluronidase 150 USP units/mL)
3089311|NCT01689363|Active Comparator|Arm P|Intradermal injection of Histatrol (histamine base 0.1 mg/mL)
3089312|NCT01689363|Placebo Comparator|Arm N|Intradermal injection of saline (0.02 mL)
3089313|NCT01689441|Experimental|Calcitriol|Calcitriol 2mcg IV x 1
3089314|NCT01689441|Placebo Comparator|Placebo|Normal saline 2cc IV x 1
3089315|NCT01689519|Active Comparator|Placebo + Vemurafenib|Participants will receive placebo orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 milligrams (mg) orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
3089316|NCT01689519|Experimental|Cobimetinib + Vemurafenib|Participants will receive cobimetinib 60 mg orally once daily on Days 1-21 of each 28-day cycle plus vemurafenib 960 mg orally twice a day on Days 1-28 of each 28-day cycle until disease progression, death, unacceptable toxicity, or withdrawal of consent, whichever occurs earliest.
3089317|NCT01689532|Experimental|Sirukumab 100 mg|
3089318|NCT01689532|Experimental|Sirukumab 50 mg and Placebo|
3089319|NCT01689649|Experimental|Topiramate|For children: Children will start on topiramate with a dosage of 0.5mg/kg in the evening, followed by 0.5mg/kg/day weekly increments until an initial target dose of 3mg/kg/day is reached. The total daily topiramate dose for children may, not exceed 9mg/kg/day. For adult patients: Adult patients start on topiramate with a dosage of 25mg/day in the evening, followed by weekly increments of 25 mg/day until an initial target dose of 100mg/day is reached. The dose of topiramate may be increased to the optimal dose with weekly increments of 0.5mg/kg/day and of 25 mg/day for children and adults, respectively at the discretion of the investigator.
3089320|NCT01689701|Experimental|Hizikia Fusiformis extract|
3089321|NCT01689701|Placebo Comparator|Placebo|
3089322|NCT01689740|Experimental|Lead in: 125 mg MDMA (Open Label)|Participants receive open-label MDMA with an initial dose of 125 mg, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
3089323|NCT01689740|Placebo Comparator|Active placebo dose MDMA (25 mg)|Participants receive initial dose of 25 mg MDMA, possibly followed by a supplemental dose of 12.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
3089324|NCT01689740|Experimental|Full dose MDMA (125 mg)|Participants receive initial dose of 125 mg MDMA, possibly followed by a supplemental dose of 62.5 mg, during two psychotherapy sessions scheduled 3-5 weeks apart.
3089325|NCT01689779|Active Comparator|Cholecalciferol|A maximum of 40 patients will receive a one-time oral dose of 100,000 IU cholecalciferol 3-7 days before their scheduled elective surgery.
3089326|NCT01689779|Placebo Comparator|Placebo|A maximum of 40 patients will receive a one-time oral sugar pill 3-7 days before their scheduled elective surgery.
3089327|NCT01689857|Experimental|Scarclinic™ Thin|Scarclinic™ Thin
3089328|NCT01689857|Active Comparator|Scarclinic™ Normal|Scarclinic™ Normal
3089329|NCT01689909|Active Comparator|Zolpidem-CR|Zolpidem 6.25 or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
3089330|NCT01689909|Placebo Comparator|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
3089331|NCT01690000|Active Comparator|Melatonin1|1 mg melatonin nightly
3089332|NCT01690000|Active Comparator|Melatonin3|3 mg melatonin given nightly
3089333|NCT01690000|Active Comparator|Placebo|Identical placebo given nightly
3089334|NCT01690052|Active Comparator|Cevimeline|Cevimeline vs Pilocarpine
3089335|NCT01690052|Active Comparator|Pilocarpine|Pilocarpine vs. Cevimeline
3089336|NCT01690117|Experimental|GE-REACH-program|GE-REACH-program
3089337|NCT01690117|No Intervention|control group|usual care
3089338|NCT01690130|Experimental|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual.The brain stimulation techniques could theoretically improve the efficacy of smoking cessation. Treatment was standardized at 100% magnetic field intensity relative to the participant's resting MT, at 10 pulses per second (10 Hz) for 5 seconds, with an intertrain interval of 10 seconds. Treatment session lasted for 15 minutes with 3000 pulses.
3089339|NCT01690130|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham-TMS procedures: After rMT determination and DLPFC cortex localization, participants were fitted with two electrodes on the scalp just below the hairline. Electrodes were connected to an Epix VT® Transcutaneous Electrical Nerve Stimulation Device (Empi; St. Paul, MN, USA)
3089340|NCT01690143|Experimental|Carfilzomib + high dose melphalan|Single arm.
3089341|NCT01690273|No Intervention|ankylosing spondylitis control|control group
3089342|NCT01690273|Experimental|mobility exercise|mobility exercises
3089343|NCT01690273|Experimental|mobility and elastic resistance exercise|AS patients was submitted to a program mobility exercise plus elastic resistance exercises
3089344|NCT01690299|Experimental|Apremilast 30 mg plus placebo injection|Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
3089345|NCT01690299|Experimental|Etanercept 50 mg plus placebo tablet|Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
3089346|NCT01690299|Placebo Comparator|Oral placebo tablets plus SC placebo injections|Identically matching placebo tablets and evaluator/subject-blinded SC injections
3089347|NCT01690520|Active Comparator|Arm I (standard of care)|"CONDITIONING REGIMEN: One of two possible conditioning regimens is chosen by the attending physician: Patients receive fludarabine phosphate IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 to -6., and undergo high dose TBI BID on days -4 to -1 OR Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 4 hours on days -5 to -4, and undergo middle intensity TBI QD on days -2 to -1.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV over 1 hour BID (adults) or TID (children) or PO on days -3 to 100 with taper beginning on day 101. Patients also receive MMF IV TID a day on days 0-7 then may receive MMF PO TID. Patients remain on MMF TID for a minimum of 30 days, and then may begin a taper if there is no evidence of GVHD and are well-engrafted from one donor unit."
3089348|NCT01690520|Experimental|Arm II (experimental)|"CONDITIONING REGIMEN: Patients receive the conditioning regimen chosen by the attending physician as in Standard of Care Arm.~TRANSPLANT: Patients undergo single-unit or double-unit unmanipulated UCB transplant on day 0. Patients also undergo infusion of ex vivo-expanded cord blood progenitor cell infusion at least 4 hours after completion of UCB transplant.~GVHD PROPHYLAXIS: Patients receive cyclosporine IV or PO and mycophenolate mofetil IV or PO as in Standard of Care Arm."
3089349|NCT01690546|Experimental|BUP/VLNXT to VIVITROL|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
3089350|NCT01690663|Placebo Comparator|Bupivacaine 0.25% mixed with 1ml normal saline|Bupivacaine 0.25% mixed with 1ml normal saline (placebo/control group)
3089351|NCT01690663|Active Comparator|Bupivacaine 0.25% with 1mg dexamethasone (1ml)|Bupivacaine 0.25% mixed with 1mg preservative free dexamethasone (1ml)
3089352|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 2mg dexamethasone|Bupivacaine 0.25% mixed with 2mg preservative free dexamethasone (1ml)
3089353|NCT01690663|Active Comparator|Bupivacaine 0.25% mixed with 4mg dexamethasone (1ml|Bupivacaine 0.25% mixed with 4mg preservative free dexamethasone (1ml
3089354|NCT01690923|Experimental|Nasal Mask First, then Pillows Mask|"Nasal mask is used for 7 nights, then followed by Pillows mask for 7 nights.~[Nasal mask=Mirage Activa, Micro, FX; Pillows mask=Swift FX]"
3089355|NCT01690923|Experimental|Pillows Mask, then Nasal Mask|Pillows mask for 7 nights, then followed by Nasal mask is used for 7 nights. [Nasal mask=MMirage Activa, Micro, FX; Pillows mask=Swift FX]
3089356|NCT01690988|Experimental|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
3089357|NCT01690988|Placebo Comparator|Normal saline (placebo)|Intravenous normal saline
3089358|NCT01690988|Experimental|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
3089359|NCT01691014||adalimumab|
3089360|NCT01691014||Etanercept|
3089361|NCT01691014||infliximab|
3089362|NCT01691014||Certolizumab|
3089363|NCT01691027|Experimental|Visuo-motor training for low vision|All participants undergo training on scotoma awareness, Line and Circle Tracing and Video games
3089364|NCT01691092|Experimental|Ketamine|All subjects will receive ketamine
3089365|NCT01691105|No Intervention|Academic Detailing (AD)|Standard of care for patients who are smokers and admitted to the hospital.
3089366|NCT01691105|Experimental|AD + Integrated Tobacco Order Set|Access to the Integrated Tobacco Order Set (ITOS) Nicotine Replacement Therapy with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center
3089367|NCT01691248|Active Comparator|Fidaxomicin|200 mg Fidaxomicin tablet once daily for no longer than 40 days
3089368|NCT01691248|Placebo Comparator|Placebo|Placebo tablet once daily for no longer than 40 days
3089369|NCT01691313|Experimental|vanoxerine 200mg|vanoxerine HCl 200mg single dose (2x 100 mg oral capsule)
3089370|NCT01691313|Placebo Comparator|placebo|placebo to match vanoxerine oral capsule
3089371|NCT01691313|Experimental|vanoxerine 300mg|vanoxerine HCl 300 mg single dose (3x 100mg oral capsules)
3089372|NCT01691313|Experimental|vanoxerine 400mg|vanoxerine HCl 400 mg single dose (4x 100 mg oral capsules)
3089373|NCT01691326|Experimental|6 months to < 36 months of age group|Participants at 6 months to < 36 months of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone® (Pediatric Dose).
3089374|NCT01691326|Experimental|3 years to < 9 years of age group|Participants at 3 years to < 9 years of age at the time of enrollment will receive Influenza Virus Vaccine, No Preservative; Fluzone®.
3089375|NCT01691339|Experimental|Fluzone vaccine (Group 1)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
3089376|NCT01691339|Experimental|Fluzone Intradermal vaccine (Group 2)|Adults 18 to < 65 years of age randomized to receive one dose of Fluzone Intradermal vaccine intradermally
3089377|NCT01691339|Experimental|Fluzone vaccine (Group 3)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone vaccine intramuscularly
3089378|NCT01691339|Active Comparator|Fluzone High-Dose Vaccine (Group 4)|Adults ≥ 65 years of age randomized to receive one dose of Fluzone High-Dose vaccine intramuscularly
3089379|NCT01691378|Experimental|WtoH Intervention|Window to Hope: Psychotherapy consists of 10 2-hour sessions for a maximum dose delivered of 20 hours. Therapy consists of small groups of up to 2 participants.
3089380|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
3089381|NCT01691430|Active Comparator|2 cranberry capsules|Experimental: 2 cranberry capsules
3089382|NCT01691430|Placebo Comparator|2 placebo capsules|Experimental: 2 placebo capsules qd
3089383|NCT01691482|Active Comparator|Albuterol/salbutamol followed by ipratropium|Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
3089384|NCT01691482|Active Comparator|Ipratropium followed by albuterol/salbutamol|Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium
3089385|NCT01691508|Experimental|Mepolizumab|Mepolizumab 100 mg subcutaneous once every 4 weeks upto Week 20
3089386|NCT01691508|Experimental|Placebo|Placebo subcutaneous once every 4 weeks upto Week 20
3089387|NCT01691521|Experimental|Mepolizumab IV|Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3089388|NCT01691521|Experimental|Mepolizumab SC|Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3089389|NCT01691521|Placebo Comparator|Placebo|Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)
3089390|NCT01691534|Experimental|TMC207, PA-824, pyrazinamide and clofazimine (J-PA-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazamine 100mg Days 4-14
3089391|NCT01691534|Experimental|TMC207, PA-824 and pyrazinamide (J-PA-Z)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus pyrazinamide 1500mg Days 1-14
3089392|NCT01691534|Experimental|TMC207, PA-824 and clofazimine (J-PA-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus PA-824 200mg Days 1-14 plus clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
3089393|NCT01691534|Experimental|TMC207, pyrazinamide and clofazimine (J-Z-C)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14 plus pyrazinamide 1500mg Days 1-14 plus clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
3089394|NCT01691534|Experimental|pyrazinamide (Z)|pyrazinamide 1500mg Days 1-14
3089395|NCT01691534|Experimental|clofazimine (C)|Clofazimine 300mg Days 1-3 and Clofazimine 100mg Days 4-14
3089396|NCT01691534|Active Comparator|Rifafour|Rifafour e-275 mg dosed by weight
3089397|NCT01691560|Experimental|5% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
3089398|NCT01691560|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3089399|NCT01691560|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
3089400|NCT01691560|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
3089401|NCT01691612|Experimental|D. pteronyssinus allergens|Single arm study exploring the role of Pin-1 enzyme in development of Asthma. Bronchoscopy before and 48 hours after installation of D. pteronyssinus allergens into the lung segments
3089402|NCT01691690|Experimental|IV Acetaminophen|Patients will receive pre-medication with oral midazolam Participants of this experimental arm of the study will receive Acetaminophen IV to evaluate opioid-sparing effect and pain score reduction..
3089403|NCT01691690|Placebo Comparator|Saline placebo infused intraoperatively|For this arm Morphine will be administered to manage pain.
3089404|NCT01691768|Experimental|Intervention|1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of Quality Improvement methodology to promote reliable service delivery
3089405|NCT01691768|Active Comparator|Control|monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
3089406|NCT01691781|Experimental|lisinopril|Lisinopril - open-label, 2.5-40mg daily
3089407|NCT01691794|Active Comparator|Atazanavir, 150 mg + Ritonavir, 100 mg (weight:15 to <20 kg)|Participants with baseline weight of 15 to <20 kg received 150 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3089408|NCT01691794|Active Comparator|Atazanavir, 200 mg + Ritonavir, 100 mg (weight: 20 to <40 kg)|Participants with baseline weight of 20 to <40 kg received 200 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3089409|NCT01691794|Active Comparator|Atazanavir, 300 mg + Ritonavir, 100 mg (weight: ≥ 40 kg)|Participants with baseline weight ≥ 40 kg received 300 mg of atazanavir plus 100 mg of ritonavir once daily with an optimized background therapy of 2 NRTIs for 24 weeks. In countries without locally approved pediatric indication for atazanavir, patients may continue to receive study treatment, with regular 12-week visits, until the age of 18 years.
3089410|NCT01691820|Experimental|Group S+|Cytomegalovirus (CMV) seropositive subjects aged between 10-17 years at enrollment in the study.
3089411|NCT01691820|Experimental|Group S-|Cytomegalovirus (CMV) seronegative subjects aged between 10-17 years at enrollment in the study.
3089412|NCT01691820|Experimental|Missing serostatus Group|Subjects with no confirmed serostatus, aged between 10-17 years at enrollment in the study.
3089413|NCT01691833|Experimental|Vitamin D|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
3089414|NCT01691833|Placebo Comparator|Placebo|Patients that are deficient in Vitamin D will be assigned to the randomized arm of the study. They will be randomly chosen to receive either the Vitamin D supplement or the placebo.
3089415|NCT01691833|No Intervention|Normovitaminosis|Patients with normovitaminosis( levels greater than or equal to 30ng/ml) will receive no intervention.
3089416|NCT01691859|Experimental|Mepolizumab|Subjects will receive 100 mg of mepolizumab (in 1ml polypropylene syringe) injected subcutaneously (SC) approximately every 4 weeks.
3089417|NCT01691885|Experimental|A/B|Placebo followed by Fluticasone Furoate Vilanterol Combination
3089418|NCT01691885|Placebo Comparator|B/A|Fluticasone Furoate Vilanterol Combination followed by Placebo
3089419|NCT01691898|Experimental|Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab|For the first 2 cycles, RTX 375 milligrams per square meter (mg/m^2) will be given by intravenous (IV) infusion on Day 1 and pinatuzumab vedotin 2.4 milligrams per kilogram (mg/kg) will be administered by IV infusion on Day 2 to Arm A participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and pinatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop disease progression (PD) will be further treated with RTX 375 mg/m^2 followed by polatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
3089420|NCT01691898|Experimental|Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 2.4 mg/kg will be administered by IV infusion on Day 2 to Arm B participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle. Participants who develop PD would be further treated with RTX 375 mg/m^2 followed by pinatuzumab vedotin 2.4 mg/kg IV infusion on Day 1, beginning no later than 42 days after the last dose of the prior study treatment until a second PD event relative to the tumor assessment, documenting PD on the initial study treatment, clinical deterioration, and/or intolerance to the crossover treatment for up to a maximum of 1 year (17 cycles on an every-21-day schedule).
3089421|NCT01691898|Experimental|Cohort C (FL): RTX + Polatuzumab|For the first 2 cycles, RTX 375 mg/m^2 will be given by IV infusion on Day 1 and polatuzumab vedotin 1.8 mg/kg will be administered by IV infusion on Day 2 to Cohort C participants (with r/r FL). In the absence of any infusion-related adverse events, RTX and polatuzumab may be administered on the same day (Day 1) in subsequent cycles beginning with the third cycle for up to a maximum of 1 year (17 cycles on an every-21-day schedule) or significant toxicity, PD, or withdrawal from study.
3089422|NCT01691898|Experimental|Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort E participants (with r/r FL and DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3089423|NCT01691898|Experimental|Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort G participants (with r/r FL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort G participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3089424|NCT01691898|Experimental|Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab|For the first cycle, obinutuzumab will be given by IV infusion on Days 1, 8, and 15. Polatuzumab vedotin 1.8 mg/kg IV infusion will be given on Day 2 of the first cycle to Cohort H participants (with r/r DLBCL). In the absence of any infusion-related adverse events, obinutuzumab and polatuzumab vedotin may be administered on the same day (Day 1) in subsequent cycles beginning with the second cycle of the dose-expansion period to cohort H participants up to a maximum of 8 cycles or significant toxicity, PD, or withdrawal from study.
3089425|NCT01691950||Reconstruction|Those who have undergone limb reconstruction following lower limb trauma
3089426|NCT01691950||Healthy volunteers|Healthy volunteers for control
3089427|NCT01692119|Experimental|regular, pharmacy-based intervention|providing medication in weekly dosing aids and regular contacts with the local pharmacy
3089428|NCT01692119|No Intervention|usual care|usual care
3089429|NCT01692197|Experimental|E7070 + Idarubicin + Cytarabine|E7070 400 mg/m2 IV over 1 hour on day 1 and day 8 (+/- 2 days on Day 8 only) followed by, Idarubicin 8 mg/m2 IV over 1 hour daily for 3 days (days 9-11) and Cytarabine 1.0 g/m2 IV over 24 hours daily on day 9-12 (age <60 years) or days 9-11 (age > 60 years). Dexamethasone 10 mg IV daily for 3-4 days with cytarabine.
3089430|NCT01692275|Active Comparator|Medical Care + Chiropractic Care|Medical care plus chiropractic manipulative therapy
3089431|NCT01692275|Active Comparator|Conventional Medical Care Only|Conventional medical care only
3089432|NCT01692301|Experimental|LCZ696 (sacubitril/valsartan)|Randomized patients received LCZ696 once daily for four weeks, then they force-titrated to a higher dose at Week 4 and stayed on this dose of LCZ696 once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696, its matching placebo) and 1 capsule (olmesartan matching placebo) were given during the entire study.
3089433|NCT01692301|Active Comparator|Olmesartan|Randomized patients received olmesartan once daily for four weeks, then force-titrated to a higher dose at Week 4 and stayed on this dose of olmesartan once daily for the remainder of the treatment period. At week 12, patients with uncontrolled BP allowed to have amlodipine then hydrochlorothiazide (HCTZ) added at intervals of 4 weeks from Week 12 up to Week 24. To maintain the double dummy, double-blind design, 2 tablets (LCZ696 matching placebo) and 1 capsule (olmesartan) were given during the entire study.
3089434|NCT01692340|Experimental|Isotopically labeled lycopene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3089435|NCT01692340|Experimental|Isotopically labeled phytoene|We will administer 3.2 mg isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3089436|NCT01692340|Experimental|Isotopically labeled phytofluene|We will administer 10 mg of isotopically labeled lycopene, phytoene or phytofluene mixed with olive oil and spread on an English muffin for consumption by participants.
3089437|NCT01692496|Experimental|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
3089438|NCT01692626|Experimental|Pimecrolimus on Left vs. Placebo on Right|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
3089439|NCT01692626|Experimental|Pimecrolimus on Right vs. Placebo on Left|Patients will apply a thin layer of the Pimecrolimus cream twice daily for four weeks (unless rash worsens sooner) to one half of face at the same time the are started on cetuximab. Patients will be provided with a placebo cream to apply to the other side of their face. The study coordinator will instruct the patient regarding which side of the face to apply the investigational cream. This will be randomly assigned by the study coordinator based on a randomization list generated by the biostatistics core and will only be known to the study coordinator.
3089440|NCT01692730|Experimental|Enhanced Web Assisted Intervention|Enhanced Web Assisted Tobacco Intervention. An enhanced and highly interactive website for cessation.
3089441|NCT01692730|Active Comparator|Basic Web Assisted Intervention.|Basic Web Assisted Tobacco Intervention. A basic website for cessation comparable to those for general adult populations, including established evidence-based cessation information and features.
3089442|NCT01692743|No Intervention|Standard of Care|Participants undergo usual follow up (routine and as needed office visits and telephone calls) and receive educational fact sheets from the Crohn's and Colitis Foundation of America.
3089443|NCT01692743|Experimental|Weekly Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
3089444|NCT01692743|Experimental|Home Monitoring Every Other Week|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
3089445|NCT01692756|Experimental|Kenalog or Placebo|Kenalog® (40mg) or saline placebo injection 1-2 days after ACL injury and 12-14 days later.
3089446|NCT01692756|Experimental|Kenalog then placebo|Subjects will initially receive 40mg injection of Kenalog® 1-2 days after injury and saline placebo at 12-14 days post injury.
3089447|NCT01692756|Experimental|Kenalog only|Subjects will receive two consecutive (40 mg) intra-articular injections of Kenalog®
3089448|NCT01692756|Placebo Comparator|Placebo|subjects will receive two consecutive intra-articular saline placebo injections at the same time periods.
3089449|NCT01692782|Experimental|SEP-225289 4mg|SEP-225289 4mg once daily taken as a combination of SEP-225289 2mg and placebo capsules to achieve 4mg QD doses
3089450|NCT01692782|Experimental|SEP-225289 8mg|SEP-225289 8mg once daily taken as a combination of SEP-225289 2mg and placebo to achieve 8mg QD doses
3089451|NCT01692782|Placebo Comparator|Placebo|4 capsules of placebo
3089452|NCT01692938||No Retinal Disease|
3089453|NCT01692938||Retinal Disease|
3089454|NCT01692951||Lung adenocarcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung adenocarcinoma was based on pathologic analysis.
3089455|NCT01692951||Control matched to adenocarcinoma|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
3089456|NCT01692951||Lung squamous cell carcinoma patients|Serum samples were collected from patients with lung cancer at the time of their diagnosis, prior to the initiation of treatment. Diagnosis of lung squamous cell carcinoma was based on pathologic analysis.
3089457|NCT01692951||Control matched to squamous cell|Control subjects without known cancer and aged from 40 to 75 years should meet at least one of the following criteria: (1) current or ex-smoker with at least a 10 pack-year history, (2) a first-degree relative with a history of lung cancer, or (3) a clinical diagnosis of COPD.
3089458|NCT01692964||InflammaDry|Patients suspected of having dry eye will be tested with the InflammaDry.
3089459|NCT01693029|Experimental|HX575 epoetin alfa|HX575, recombinant human epoetin alfa
3089460|NCT01693029|Active Comparator|US-licensed epoetin alfa|US-licensed recombinant human epoetin alfa
3089461|NCT01693068|Experimental|Pimasertib|
3089462|NCT01693068|Active Comparator|Dacarbazine|
3089463|NCT01693120|Experimental|Ablation|Phased RF ablation
3089464|NCT01693185|Experimental|Remifentanil|remifentanil of 0.04 mcg/kg/min with placebo (for midazolam) and placebo (for meperidine)
3089465|NCT01693185|Active Comparator|midazolam and meperidine|a bolus midazolam of 0.03 mg/kg a bolus meperidine of 1.0 mg/kg placebo (for remifentanil)
3089466|NCT01693250|Experimental|fitbit ultra|Adolescents in the intervention group will receive a Fitbit Ultra and will download an app to their smartphone. Participants will be asked to wear the Fitbit device and use the app every day for three months.
3089467|NCT01693250|Active Comparator|Pedometer|After completion of the baseline assessments, adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
3089468|NCT01693523|Experimental|Minocycline|Minocycline 100 mg by mouth two times a day (200 mg/day). Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
3089469|NCT01693523|Placebo Comparator|Placebo|Matching placebo capsules by mouth twice a day. Initial Dose (starts on first day of run-in phase or chemotherapy). Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
3089470|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.1 mg/kg Q2W)|Participants will receive intravenous (IV) infusion of MEDI4736 (durvalumab) 0.1 mg/kg every 2 weeks (Q2W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089471|NCT01693562|Experimental|Escalation Cohort (MEDI4736 0.3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 0.3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089472|NCT01693562|Experimental|Escalation Cohort (MEDI4736 1 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 1 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089473|NCT01693562|Experimental|Escalation Cohort (MEDI4736 3 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 3 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089474|NCT01693562|Experimental|Escalation Cohort (MEDI4736 10 mg/kg Q2W)|Participants will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089475|NCT01693562|Experimental|Escalation Cohort (MEDI4736 15 mg/kg Q3W)|Participants will receive IV infusion of MEDI4736 15 mg/kg every 3 weeks (Q3W) in the dose-escalation phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089476|NCT01693562|Experimental|Exploration Durvalumab 20 mg/kg (Q4W)|Participants will receive IV infusion of MEDI4736 20 mg/kg every 4 weeks (Q4W) in the dose-exploration phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089477|NCT01693562|Experimental|Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089478|NCT01693562|Experimental|Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W)|Participants with non-SCCHN human papilloma virus positive (Non-SCCHN HPV+) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089479|NCT01693562|Experimental|Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with non-small-cell lung cancer (NSCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089480|NCT01693562|Experimental|Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W)|Participants with hepatocellular carcinoma (HCC Total) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089481|NCT01693562|Experimental|Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with advance cutaneous melanoma (ACM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089482|NCT01693562|Experimental|Expansion UM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with uveal melanoma (UM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089483|NCT01693562|Experimental|Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with gastroesophageal cancer (GEC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089484|NCT01693562|Experimental|Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with triple-negative breast cancer (TNBC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089485|NCT01693562|Experimental|Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with pancreatic adenocarcinoma (PAC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089486|NCT01693562|Experimental|Expansion UC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with urothelial carcinoma (UC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089487|NCT01693562|Experimental|Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W)|Participants with glioblastoma multiforme (GBM) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089488|NCT01693562|Experimental|Expansion OC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with ovarian cancer (OC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089489|NCT01693562|Experimental|Expansion STS Cohort (MEDI4736 10 mg/kg Q2W)|Participants with soft- tissue sarcoma (STS) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089490|NCT01693562|Experimental|Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with small-cell lung cancer (SCLC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089491|NCT01693562|Experimental|Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W)|Participants with microsatellite instability (MSI)-high cancer will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose-expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3321145|NCT02016638|Experimental|polysomnography and AMBP on pregnant females|"Consecutive patients undergoing antenatal check up at the Antenatal Clinic at AIIMS hospital and obstetrics wards will be recruited and followed.Using Somnomedic systems, GmbH polysomnography machine by trained staff nurses and technicians at:~Obstetrics ward, AIIMS hospital"
3089492|NCT01693562|Experimental|Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W)|Participants with nasopharyngeal carcinoma (NPC) will receive IV infusion of MEDI4736 10 mg/kg Q2W in the dose- expansion phase for maximum of 12 months or until confirmed progressive disease, initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or development of other reason for treatment discontinuation, whichever occurs first.
3089493|NCT01693614|Experimental|DLBCL Cohort|Diffuse large B-cell lymphoma cohort
3089494|NCT01693614|Experimental|MCL Cohort|Mantle cell lymphoma cohort
3089495|NCT01693614|Experimental|FL Cohort|Follicular lymphoma cohort
3089496|NCT01693900|Experimental|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under an ultrasound guidance device with an in-plane technique by a single study investigator, in the preoperative area.
3089497|NCT01693900|Active Comparator|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room.
3089498|NCT01694108|Experimental|BCG-vaccine (SSI)|"Children born to mothers, who have accepted to participate, will be randomised to either intervention group or to the control group at birth. Block-randomisation stratified by hospital, gender and gestational age (≥37 weeks of gestation vs. < 37 weeks of gestation) will be performed electronically just before vaccination by the overall study electronic case report system (e-crf).~Children randomised to the BCG vaccination group will receive an intradermal BCG vaccine (Statens Serum Institute CG vaccine in the standard dose 0.05 ml in the upper, lateral part of the arm of the child by a specially trained midwife or a study physician."
3089499|NCT01694108|No Intervention|No Intervention|Control children will be treated as usual, since no suitable placebo exists.
3089500|NCT01694121|Experimental|MEN Count|3 session HIV intervention including a) HIV risk reduction, inclusive of gender equity and healthy relationship counseling and b) case management support for stable employment and housing.
3089501|NCT01694121|Active Comparator|Comparison|An attention comparison program similar to the MEN Count intervention in structure (3 one-on-one sessions delivered over 60-90 days) but focused on stress reduction and healthy lifestyle.
3089502|NCT01694186|Sham Comparator|sham injection|sham injection
3089503|NCT01694186|Experimental|FAI insert|FAI insert (0.18 mg fluocinolone acetonide)
3089504|NCT01694199|Active Comparator|Active study device with PRFE|This study arm receives pulsed radiofrequency energy (PRFE) from an active test device.
3089505|NCT01694199|Sham Comparator|Sham study device with no PRFE|This study arm receives no pulsed radiofrequency energy (PRFE) from a sham test device.
3089506|NCT01694420|Experimental|Quad FDC|FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
3089507|NCT01694433|Experimental|Calcipotriene Cream|The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
3089508|NCT01694433|Placebo Comparator|Placebo|The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
3089509|NCT01694485|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089510|NCT01694485|Experimental|Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089511|NCT01694485|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089512|NCT01694485|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089513|NCT01694485|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089514|NCT01694563|Other|Atrial Fibrillation|Patients with non-paroxysmal atrial fibrillation (persistent or longstanding persistent)who are scheduled to undergo elective concomitant open, on-pump cardiac surgical procedure and the Maze IV ablation procedure. This single arm registry is designed to monitor the AtriCure Synergy Ablation System for continued safety and efficacy during the peri-procedural and long term phase during commercial use.
3089515|NCT01694641|Experimental|time-lapse morphokinetic evaluation|"Embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse: upon fertilization embryos in a petri dish that allows individual assessment (Primo Vision Dish) are placed onto an automated time-lapse equipment in an incubator. The time-lapse equipment performs imaging in 10 minutes intervals. The software is presenting the up-to-date images and allows the operator to assess the time-lapse movie of the developmental history of the embryos to perform annotations and apply evaluation/selection algorithm. This morpho-kinetic TL algorithm (made up of standard moprhology as seen on time lapse and kinetci scores) is used for embryo selection, which actually describes the intervention."
3089516|NCT01694641|No Intervention|standard embryo monitoring|Upon fertilization embryos are observed once on days 1-3-5 by the embryologist to check for development. The single embryo for transfer is selected based on actual morphology as seen under light microscope.
3089517|NCT01694667|Active Comparator|Omega-3 Fatty Acids|Omega-3 Fatty Acids: Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA
3089518|NCT01694667|Placebo Comparator|Placebo|Placebo packets will have same orange-flavored pudding with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
3089519|NCT01694706|Experimental|Reference|faldaprevir medium, fasted
3089520|NCT01694706|Active Comparator|Test 1|faldaprevir medium, fed
3089521|NCT01694706|Active Comparator|Test 2|faldaprevir medium + omeprazole medium
3089522|NCT01694771|Experimental|Olodaterol and Tiotropium|2 puffs olodaterol from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
3089523|NCT01694771|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule tiotropium from Handihaler once daily in am, co-administered
3089524|NCT01694966|Active Comparator|Methylene Blue MMX® 200mg|Oral dose, 8 Methylene Blue MMX® tablets over a 4hr schedule
3089525|NCT01694966|Active Comparator|Methylene Blue MMX® 100mg|Oral dose, 4 Methylene Blue MMX® tablets and 4 Placebo tablets over a 4hr schedule
3089526|NCT01694966|Placebo Comparator|Placebo|Oral dose, 8 Placebo tablets over a 4hr schedule
3089527|NCT01695044|Experimental|Arm 1: PSMA ADC|Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
3089528|NCT01695135|Experimental|Abiraterone acetate plus prednisone|
3089529|NCT01695135|Experimental|Placebo plus prednisone|
3089530|NCT01695239|Experimental|Ixekizumab Q2W|Administered by 80 milligram (mg) subcutaneous (SC) injection every 2 weeks (Q2W).
3089531|NCT01695239|Experimental|Ixekizumab Q4W|Administered by 80 mg SC injection every 4 weeks (Q4W).
3089532|NCT01695239|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection.
3089533|NCT01695239|Active Comparator|Adalimumab Q2W|Administered by 40 mg SC injection Q2W.
3089534|NCT01695291|Placebo Comparator|Placebo|Participants randomized to placebo will receive pills that are identical in appearance to the study drug but contain no active medication.
3089535|NCT01695291|Experimental|Minocycline Augmentation|Those randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline (minimum 50 mg/day and maximum 200 mg/day). After randomization, participants will receive child proofed bottles that contain enough study medication until the next visit with an additional 3 days coverage in case of scheduling issues. All participants will have a minocycline level drawn at week 12 to confirm treatment adherence. Minocycline is FDA-approved in those ages 8 and above for treatment of infections and acne and has a favorable risk-benefit profile.
3089536|NCT01695304|Experimental|Intervention Arm|Households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water.
3089537|NCT01695304|No Intervention|Control Arm|Households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
3089538|NCT01695330|Experimental|Subcutaneous bortezomib|
3089539|NCT01695369|Active Comparator|Senofilcon A|Senofilcon A; Comfilcon A
3089540|NCT01695369|Experimental|Comfilcon A|Comfilcon A; Senofilcon A
3089541|NCT01695473|Experimental|Neoadjuvant BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in operating room (OR) scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
3089542|NCT01695668|Experimental|Lotemax|Loteprednol Etabonate 0.5%
3089543|NCT01695668|Active Comparator|Restasis|Cyclosporine
3089544|NCT01695746||C.E.R.A.|Participants with chronic renal anemia Stage III-IV, not on dialysis, will be administered Continuous Erythropoietin Receptor Activator (C.E.R.A.) according to routine clinical practice and will be followed up for the treatment duration of 24 weeks (6 months). Dosing and titration of C.E.R.A. treatment will be at the discretion of the investigator in accordance with local clinical practice or prescribing information. Dosing instructions as per the local label are - For correction of anemia: 0.6 microgram per kilogram (mcg/kg) of C.E.R.A. once every two weeks, and for Maintenance of hemoglobin (Hb) levels: Conversion to C.E.R.A. dose (120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks) depending on the previous weekly epoetin or darbepoetin dose.
3089545|NCT01695772|Experimental|Bevacizumab|
3089546|NCT01695954|Experimental|Arm A|Subjects assigned to Arm A will receive pitavastatin 2 mg at bedtime and efavirenz 600 mg at bedtime.
3089547|NCT01695954|Experimental|Arm B|Subjects assigned to Arm B will receive pitavastatin 2 mg daily and darunavir 800 mg with ritonavir 100 mg daily.
3089548|NCT01695993|No Intervention|Arm 1 - Standard Care Only|Patients will receive standard care only
3089549|NCT01695993|Other|Arm 2 - Expectancy-neutral Arm|"Patients receive:~Expectancy-neutral handout~Expectancy-neutral MP3~Acupressure bands"
3089550|NCT01695993|Experimental|Arm 3 - Expectancy-enhancing Arm|"Patients receive:~Expectancy-enhancing handout~Expectancy-enhancing MP3~Acupressure bands"
3089551|NCT01696032|Experimental|SGI-110 + Carboplatin|Stage 1 was a safety lead-in stage with a dose escalation design. Participants were evaluated with the combination of SGI-110 (guadecitabine) plus carboplatin (G+C), given as 28-day treatment cycles: guadecitabine administered subcutaneous (SC) daily on Days 1-5, at a starting dose of 45 mg/m2/day in Cohort 1, followed by carboplatin intravenous (IV) based on a targeted dose of area under the curve (AUC) 5 on Day 8. After dose limiting toxicities were noted, guadecitabine dose was reduced to 30 mg/m2/day for subsequent cycles for 4 participants. Cohort 2 received 30 mg/m2/day guadecitabine and carboplatin IV AUC 4.
3089552|NCT01696032|Experimental|SGI-110 + Carboplatin or TC|Stage 2 was an open-label, randomized, controlled trial. Eligible participants were randomly assigned in a 1:1 ratio to receive either (1) G+C combination treatment in 28-day cycles at 30 mg/m2 SC once daily on Days 1-5 and carboplatin IV AUC 4 on Day 8, or (2) treatment of choice (TC) of topotecan, pegylated liposomal doxorubicin (PLD), paclitaxel, or gemcitabine based on recommended dosing in 28-day cycles; participants initially randomized to TC were able to cross over to receive 30 mg/m2 G+C due to disease progression.
3089553|NCT01696045|Experimental|Ipilimumab 3 mg/kg|Ipilimumab (3 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
3089554|NCT01696045|Experimental|Ipilimumab 10 mg/kg|Ipilimumab (10 mg/kg) was administered intravenously (IV) over 90 minutes on Day 1 of each 21-day cycle for 4 cycles.
3089555|NCT01696058|Experimental|Olodaterol andTiotropium|2 puffs Olodaterol from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
3089556|NCT01696058|Other|Placebo and Tiotropium|2 puffs placebo inhalation solution from Respimat and one capsule Tiotropium by Handihaler once daily in am, co-administered
3089557|NCT01696071|Experimental|Treatment A|2 puffs of daily dose (5 mcg) in the evening and 2 puffs of matching placebo in the morning via Respimat inhaler
3089558|NCT01696071|Experimental|Treatment B|2 puffs of half daily dose (2.5 mcg) twice daily, in the evening and in the morning via Respimat inhaler
3089559|NCT01696084|Experimental|Arm A (CPX-351)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with CPX-351. The number of inductions and consolidations a subject received depended on response.
3089560|NCT01696084|Active Comparator|Arm B (7+3)|Subjects are eligible to receive up to 2 inductions and up to 2 consolidations with cytarabine and daunorubicin given as a 7 + 3, or 5 days of continuous infusion of cytarabine and 2 days of daunorubicin (5+2, second induction, consolidation courses) therapy. The number of inductions and consolidations a subject received depended on response.
3089561|NCT01696188|Experimental|In-plane group|This group will receive an interscalene catheter placed with in-plane approach.
3089562|NCT01696188|Experimental|Out-of-plane group|This group will receive an interscalene catheter with an out-of-plan approach.
3089563|NCT01696214|Placebo Comparator|Ipratropium|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and be assigned to a 24 week treatment of ipratropium 2.5 mL, 0.02% 3 times daily via mini nebulizer with placebo theophylline and placebo montelukast.
3089564|NCT01696214|Placebo Comparator|Theophylline|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to theophylline 400 mg once a day for 24 weeks with placebo ipratropium and placebo montelukast.
3089565|NCT01696214|Placebo Comparator|Montelukast|Participants will continue fluticasone 100 mg/salmeterol 50 mg once a day and will be assigned to montelukast 10 mg once a day for 24 weeks with placebo theophylline and placebo ipratropium.
3089566|NCT01696214|Placebo Comparator|fluticasone 250 mg/salmeterol 50mg|Participants will be assigned to inhaled fluticasone 250/salmeterol 50 twice a day for 24 weeks with placebo theophylline, placebo ipratropium, and placebo montelukast.
3089567|NCT01696279|Experimental|Lanthanum Carbonate|Participants will receive lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided and mixed equally between in three meals.
3089568|NCT01696279|Active Comparator|Calcium Carbonate|Participants will receive calcium carbonate orally at a total daily dose adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
3089569|NCT01696357||Adolescents with asthma|Ages 13-17 with an asthma diagnosis-both symptomatic and non-symptomatic- and with currently prescribed asthma medication.
3089570|NCT01696357||Adolescents without asthma|Ages 13-17 without an asthma diagnosis and without any other respiratory condition that presents with asthma-like symptoms.
3089571|NCT01696396|Placebo Comparator|Placebo Q4W/Abrilumab 210 mg Q3M|"Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089572|NCT01696396|Experimental|Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089573|NCT01696396|Experimental|Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M|"Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks."
3089574|NCT01696396|Experimental|Abrilumab 210 mg/Abrilumab 210 mg Q3M|"Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.~During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M)for 108 weeks."
3089575|NCT01696643|Experimental|CB-5945|0.25 milligrams (mg) CB-5945, administered orally, twice daily (BID) for 52 weeks
3089576|NCT01696643|Placebo Comparator|Placebo|Placebo, administered orally, BID for 52 weeks
3089577|NCT01696695||Metastatic Colorectal Carcinoma (mCRC) Participants|Newly diagnosed mCRC participants, who will receive first line capecitabine based chemotherapy according to effective official Summary of Product Characteristics, will be observed. The choice of therapy is based exclusively on the medical decision of the treating physician before study enrollment. The study protocol does not enforce treatment initiation and also do not specify any treatment regimen.
3089578|NCT01696760|Experimental|Arm I (acetylsalicylic acid and PCD)|Patients receive acetylsalicylic acid orally PO BID and wear PCD on days 1-28 after surgery.
3089579|NCT01696760|Experimental|Arm II (enoxaparin and PCD)|Patients receive enoxaparin subcutaneously SC QD and wear PCD on days 1-28 after surgery.
3089580|NCT01696773|Experimental|Tangerine tomato juice|Tangerine tomato juice will be fed
3089581|NCT01696773|Experimental|Red tomato juice|Red tomato juice will be fed
3089582|NCT01696877|Active Comparator|Degarelix|Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg at 14 (±3) days prior to surgery. A telephone follow-up interview (or an in-person clinic visit) to evaluate for adverse events will occur 28 (±21) days after prostatectomy. Patients will then be followed by their urologists according to standard institutional practices, but will require prostate-specific antigen evaluations every 3 (±1) months during year 1 and every 6 (±2) months during years 2-3.
3089583|NCT01696877|Experimental|Cyclophosphamide, GVAX and Degarelix|Cyclophosphamide will be given at a dose of 200 mg/m2 as a single intravenous infusion. 1 day later, prostate GVAX will be administered as five 0.8-mL intradermal injections of PC3 (2.5 × 108 cells) and five 0.5-mL intradermal injections of LNCaP (2.5 × 108 cells), for a total dose of 5 × 108 cells. On day 14, Degarelix will be administered as three 80 mg subcutaneous injections, for a total dose of 240 mg.
3089584|NCT01696929|Experimental|Tocilizumab|Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
3089585|NCT01696942|Experimental|Cimzia treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
3089586|NCT01696942|Active Comparator|Mesalamine treatment arm|Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.
3089587|NCT01696955|Experimental|Arm I (cetuximab and tivantinib)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15 and tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3089588|NCT01696955|Experimental|Arm II (cetuximab)|Patients receive cetuximab IV over 60-120 minutes on days 1 and 15. Patients who fail cetuximab as a single agent may receive single agent tivantinib PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3089589|NCT01696968|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3089590|NCT01696968|Active Comparator|Lung Screening|"Participants undergo a chest x-ray (one postero-anterior view) at baseline and annually for 2 years. Participants classified as smokers undergo an additional chest x-ray at year 3. Participants complete a BQF/M at baseline. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident lung cancers as all deaths that occur among both screened and control subjects during the trial."
3089591|NCT01696981|Active Comparator|Colorectal Screening|Participants undergo a colorectal examination with a flexible sigmoidoscope at baseline and year 5. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident colorectal cancers as all deaths that occur among both screened and control subjects during the trial.
3089592|NCT01696981|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3089593|NCT01696994|No Intervention|Control|Participants receive standard medical care. Participants complete a DHQ at baseline.
3089594|NCT01696994|Active Comparator|Ovarian Screening|Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.
3089595|NCT01697319|Experimental|BMN 110 at 2.0 mg/kg/week|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 144 weeks.
3089596|NCT01697345|Experimental|Vaginal Testosterone|Testosterone USP micronized powder supplied by Medisca Pharmacy will be compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream will be supplied in pre-filled syringes and each 0.5 mL dose will deliver 300 mcg of testosterone daily. The cream will be applied to the vaginal opening once daily for four weeks (28 days).
3089597|NCT01697358|Active Comparator|SCS + OMM|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead plus an individual Optimal Medical Management (OMM) treatment plan
3089598|NCT01697358|Active Comparator|OMM alone|The investigator and subject will determine an individual Optimal Medical Management (OMM) treatment plan
3089599|NCT01697449||Cohort|
3089600|NCT01697462||Cohort|
3089601|NCT01697501|Experimental|Chronic hepatitis B patients|
3089602|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycle 1|Participants were administered intravenous (IV) fosaprepitant at the following weight-adjusted doses: participants 4 months to <12 years old were administered 5 mg/kg (not to exceed 150 mg); participants 1 to <4 months old were administered 2.5 mg/kg; participants 0 to <1 month old were administered 1.25 mg/kg. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3089603|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 150 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 3 mg/kg (not to exceed 150 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3089604|NCT01697579|Experimental|Fosaprepitant 1.2 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 60 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 1.2 mg/kg (not to exceed 60 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3089605|NCT01697579|Experimental|Fosaprepitant 0.4 mg/kg-Cycle 1|Participants 12 to 17 years old were administered 20 mg IV fosaprepitant. Participants 2 to <12 years old were administered a weight-adjusted dose of 0.4 mg/kg (not to exceed 20 mg). Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3089606|NCT01697579|Placebo Comparator|Placebo Control-Cycle 1|Participants were administered IV normal saline at volume to match age and weight specific doses of fosaprepitant. Participants were also administered IV ondansetron (0.15 mg/kg x 3 doses for children 6 months to 17 years of age or per local standard of care for children <6 months of age), with or without dexamethasone.
3089607|NCT01697579|Experimental|Fosaprepitant 5 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from the 5 mg/kg fosaprepitant arm in Cycle 1 were administered fosaprepitant 5 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5- hydroxytryptamine 3 (5-HT3) antagonist with or without dexamethasone. Participants 1 year or less were required to receive ondansetron in all cycles as the 5-HT3 antagonist.
3321146|NCT02016651|Experimental|Right side position|Premature infants on mechanical ventilation are kept on their right side
3089608|NCT01697579|Experimental|Fosaprepitant 3 mg/kg-Cycles 2-6|For optional Cycles 2-6, participants from Cycle 1 fosaprepitant arms (3, 1.2, or 0.4 mg/kg) or Cycle 1 control arm were administered fosaprepitant 3 mg/kg IV (or age-adjusted equivalent). For Cycle 2, fosaprepitant was administered IV plus ondansetron with or without dexamethasone. For Cycles 3-6, fosaprepitant was administered IV plus a 5-HT3 antagonist with or without dexamethasone.
3089609|NCT01697592|Experimental|Omarigliptin 25 mg/Sulfonylureas (SUs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of SUs throughout the duration of the study.
3089610|NCT01697592|Experimental|Omarigliptin 25 mg/Glinides (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of glinides throughout the duration of the study.
3089611|NCT01697592|Experimental|Omarigliptin 25 mg/biguanides (BGs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of BGs throughout the duration of the study.
3089612|NCT01697592|Experimental|Omarigliptin 25 mg/Thiazolidinediones (TZDs) (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of TZDs throughout the duration of the study.
3089613|NCT01697592|Experimental|Omarigliptin 25 mg/α-GIs (Phase A+B)|Omarigliptin 25 mg administered orally once weekly for 52 weeks (24 weeks during Phase A and 28 weeks during Phase B). Participants continued pre-study basal medication of α-glucosidase (α-GIs) inhibitors throughout the duration of the study.
3089614|NCT01697592|Placebo Comparator|Placebo/SUs (Phase A) → Omarigliptin 25 mg/SUs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of SUs throughout the duration of the study.
3089615|NCT01697592|Placebo Comparator|Placebo/Glinides (Phase A) → Omarigliptin 25 mg/Gln. (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of glinides throughout the duration of the study.
3089616|NCT01697592|Placebo Comparator|Placebo/BGs (Phase A) → Omarigliptin 25 mg/BGs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of BGs throughout the duration of the study.
3089617|NCT01697592|Placebo Comparator|Placebo/TZDs (Phase A) → Omarigliptin 25 mg/TZDs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of TZDs throughout the duration of the study.
3089618|NCT01697592|Placebo Comparator|Placebo/α-GIs (Phase A) → Omarigliptin 25 mg/α-GIs (Phase B)|Placebo matching omarigliptin administered orally once weekly for 24 weeks during Phase A. Omarigliptin 25 mg is administered once weekly for 28 weeks during Phase B. Participants continued pre-study basal medication of α-GIs inhibitors throughout the duration of the study.
3089619|NCT01697696|Experimental|NVA237 dose 1|NVA237 dose 1
3089620|NCT01697696|Active Comparator|Long-acting beta 2-agonist (LABA)|QAB149
3089621|NCT01697709|Placebo Comparator|Placebo|Placebo medication
3089622|NCT01697709|Experimental|quetiapine|Quetiapine treatment
3089623|NCT01697748|Placebo Comparator|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
3089624|NCT01697748|Active Comparator|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
3089625|NCT01697956|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 42 day (6 week) Treatment Period.
3089626|NCT01697956|Placebo Comparator|Placebo Nasal Aerosol|Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 42 day (6 week) Treatment Period.
3089627|NCT01697969|Experimental|Pataday|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop once daily in both eyes for 14 days
3089628|NCT01698008|Experimental|Mobile application Diabetes Doctor|The intervention group will send in blood glucoses once a month using the mobile phone app, Diabetes Doctor. All subjects will be evaluated at initial, 3 month, and 6 month visits. They will receive HbA1c on each visit. After 3 months, a Diabetes Quality of Life (QOL) survey will be completed. A Usability and Satisfaction of Diabetes Doctor (USDD) survey will also be obtained. At the 3 month visit, they will also be given the chance to discontinue the mobile app and switch to standard of care. At 6 months, all mobile app users will complete the USDD and satisfaction and QOL survey. If they are not using the mobile app, then they will complete the QOL survey.
3089629|NCT01698008|No Intervention|Standard of Care|The standard of care arm will not use the mobile application Diabetes Doctor to communicate with their physician about their blood sugars. They will attend clinic visits and have evaluations initially, and at 3 and 6 months. They will also receive a HbAIc at each visit. They will do the same QOL survey at 3 months. At 6 months, they will be given the QOL survey.
3089630|NCT01698268|Experimental|TAP Group|Enrolled subjects will receive a TAP block with 0.5cc/kg of 0.25% ropivacaine.
3089631|NCT01698268|Active Comparator|Local Infiltration Group|Enrolled subjects will receive will receive local infiltration of 0.5 cc/kg of 0.25% ropivacaine.
3089632|NCT01698320|Placebo Comparator|Placebo MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of placebo MDPI (multi-dose dry powder inhaler), four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
3321147|NCT02016651|No Intervention|Supine position|Premature infants on mechanical ventilation are kept on their back
3089633|NCT01698320|Experimental|Albuterol MDPI-Albuterol MDPI|"During the 12-week double-blind period, participants take 2 inhalations of albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation, four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total daily dose of 720 micrograms per day.~The double-blind period is followed by a 40-week open-label period in which all study participants take albuterol MDPI 90 micrograms/inhalation, 2 inhalations every 4-6 hours as needed (PRN) and, if applicable, 2 inhalations 15-30 minutes prior to sports/exercise."
3089634|NCT01698333|Experimental|122-0551|
3089635|NCT01698463|Other|Identify Patients at Risk/Exercise Prescription|The intervention was delivered in two visits and two follow-up phone calls. Physician identifies that the patient is at risk of falls or fractures Visit one: individualized exercise prescription by a physiotherapist. Visit two: motivational interviewing (behavioural counselling) by kinesiologist Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
3089636|NCT01698502||Trained|Healthy, Endurance trained (Maximal oxygen uptake (VO2max), ml*min-1*kg-1>60), 20-30 year, BMI: 18,5-25kg/m2, males.
3089637|NCT01698502||Untrained|Healthy, sedentary (Maximal oxygen uptake (VO2max), ml*min-1*kg-1<50), 20-30 year, BMI: 18,5-25kg/m2, males.
3089638|NCT01698528|Experimental|Intervention Group|The experimental arm will be provided with a tablet computer with a newly designed software to help manage his or her diabetes care. This arm will communicate with his or her provider through the tablet computer to initiate and titrate basal insulin dose based on the 303 protocol. The individuals in this arm will also track their glucose values and medication adherence using the tablet computer by documenting when medication was taken or insulin was injected.
3089639|NCT01698528|No Intervention|Control Group|The individuals in the control group will receive usual care from the study Clinic as they always have. These individuals will be tracking their diabetes in the same way they have been by communicating with their health care provider and his or her office via fax/phone/e-mail. These individuals will not be provided with a tablet computer.
3089640|NCT01698554|Experimental|bimatoprost formulation A solution|Bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3089641|NCT01698554|Active Comparator|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3089642|NCT01698554|Placebo Comparator|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution single-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3089643|NCT01698554|Placebo Comparator|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % multi-dose vial applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
3089644|NCT01698684|Placebo Comparator|Placebo|
3089645|NCT01698684|Experimental|Avanafil 100 mg|
3089646|NCT01698684|Experimental|Avanafil 200 mg|
3089647|NCT01698710|Experimental|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
3089648|NCT01698775|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 24 weeks. Phase B: omarigliptin 12.5 mg or 25 mg capsule orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive matching placebo to glipizide daily in a blinded manner during Phase B of the study (Week 24 through Week 54).
3089649|NCT01698775|Active Comparator|Placebo to omarigliptin (Phase A) → Glipizide (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: matching placebo to omarigliptin orally once a week for 30 weeks. Participants who are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study (Week 1 through Week 24) will receive glipizide 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
3089650|NCT01698801|Experimental|Lenalidomide plus dexamethasone|Lenalidomide plus low-dose dexamethasone
3089651|NCT01698814|Experimental|AL-4943A|AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
3089652|NCT01698814|Placebo Comparator|AL-4943A Vehicle|AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
3089653|NCT01698879|Experimental|Single arm, three cohorts|Idarubicin, cytarabine, Mylotarg.
3089654|NCT01698905|Experimental|Nilotinib|Patients with minimum 3 years of tyrosine kinase inhibitor treatment (first with imatinib and then switched to nilotinib) since initial diagnosis, at least 2 years of nilotinib treatment prior to study entry and who achieved MR4.5 (local laboratory assessment) during nilotinib treatment, and determined by a Novartis designated central PCR lab assessment at screening
3089655|NCT01699022|Experimental|Injection Cyclofem|"Injection of Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
3089656|NCT01699087|Experimental|PRK ALLEGRETTO|Photorefractive keratectomy (PRK) surgery using the ALLEGRETTO WAVE EYE-Q excimer laser system for myopic wavefront-optimized ablation
3089657|NCT01699178|Experimental|Oral testosterone undecanoate|Oral testosterone undecanoate; continue dose from previous Phase III trial; 100-300 mg T (as TU), BID, for 12 months.
3089658|NCT01699178|Active Comparator|Transdermal testosterone gel (AndroGel)|Transdermal testosterone gel; continue dose from previous Phase III trial, 2.5-10 g/applied once daily for 12 months
3089659|NCT01699373|Experimental|Ultrasound-assisted|Pre-procedural ultrasound scan performed
3089660|NCT01699373|No Intervention|Manual Palpation|
3089661|NCT01699503|No Intervention|No Screening|Subjects who are randomized into the non-screening arm will receive the usual standard of care.
3089662|NCT01699503|Experimental|Screening Group|Subjects who are randomized into the screening arm of the study will be screened by the MIS. Subjects with MIS score of less than 5 points will be referred to the Collaborative Dementia Care Program for a subsequent diagnostic assessment, counseling and management.
3089663|NCT01699542|Active Comparator|Metal Stent|The WallFlex Biliary Fully Covered Esophageal Stent System is being evaluated for treatment of refractory anastomotic esophageal strictures.
3089664|NCT01699542|Active Comparator|Bougie Dilation|Esophageal Bougie Dilator commercially available devices used per Investigator preference are being evaluated for treatment of refractory anastomotic esophageal strictures.
3089665|NCT01699607|Experimental|amphetamine|There is only one arm to the study. All subjects will receive amphetamine at 0.5mg/kg prior to the second PET scan.
3089666|NCT01699685|Placebo Comparator|Sequence A|Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI
3089667|NCT01699685|Active Comparator|Sequence B|Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI
3089668|NCT01699698|Experimental|Test subject|
3089669|NCT01699750|Experimental|Air Optix Aqua|Lotrafilcon B contact lenses with OFPM and BIOTRUE for 30 days each
3089670|NCT01699750|Active Comparator|Acuvue Oasys|Senofilcon A contact lenses with OFPM and BIOTRUE for 30 days each
3089671|NCT01699763|Experimental|Subjects with and without Diabetes|All testing and lancing were performed by the study staff; Subjects with and without Diabetes did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using three Blood Glucose Monitoring Systems (BGMS): Contour® NEXT LINK BGMS; OneTouch® UltraLink® BGMS; Nova Max Link® BGMS.
3089672|NCT01699789|Active Comparator|Resources for Services|The Resources for Services condition offers time-limited technical assistance to individual agencies, coupled with outreach from a community engagement specialty, to participate in structured reviews of components of the Quality Improvement Program Intervention as implemented by the Resources for Services Expert Team.
3089673|NCT01699789|Experimental|Community Engagement and Planning|The Community Engagement and Planning arm supported 4 months of planning for the Community Engagement and Planning Council consisting representatives of all assigned programs in biweekly 2 hour meetings to fit trainings in the Quality Improvement Program to the community and develop strategies across programs to collaborate as a network. The CEP Council developed a written plan for training and monitoring and supported implementation of the training plan. CEP sites were provided with enrolled client lists.
3089674|NCT01699815|Active Comparator|Preemptive group|The preemptive group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered within 60 minutes prior to incision. Each infusion will be administered over 15 minutes as recommended by manufacturer package insert.
3089675|NCT01699815|Active Comparator|Closure group|The closure group will receive one dose of 1 gram of IV acetaminophen every 6 hours x 24 hours with the first dose administered upon onset of skin closure.
3089676|NCT01700036|Experimental|Treatment arm|Alpha-1-Antitrypsin (AAT) for the treatment of Steroid Refractory Acute Graft vs Host Disease.
3089677|NCT01700049|Experimental|Open Label oral vismodegib|This is a Phase 2B single-site, open-label, nonrandomized 24-week study of the efficacy and safety of vismodegib (150 mg PO daily) in subjects with high risk and/or locally advanced basal cell carcinoma (BCC). A total of 36 subjects with infiltrative/morpheaform, nodular, or superficial BCC will be enrolled in the study.
3089678|NCT01700140|Experimental|SyB D-0701: high dose group|
3089679|NCT01700140|Experimental|SyB D-0701: low dose group|
3089680|NCT01700140|Placebo Comparator|placebo group|
3089681|NCT01700179|Experimental|ACH-0143102 plus ribavirin daily|ACH-0143102 225 mg loading dose on Day 1 followed by 75 mg maintenance dose on Days 2-84. Weight-based RBV(as per label) for Days 1-84.
3089682|NCT01700192|Experimental|MK-8237|MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).
3089683|NCT01700192|Placebo Comparator|Placebo|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
3089684|NCT01700205|Active Comparator|Type of Formula: CMF|Infants are randomized to feed standard cow milk formula during first year of life
3089685|NCT01700205|Experimental|Type of Formula: EHF|Infants are randomized to feed extensively hydrolyzed infant formula during first year of life
3089686|NCT01700335|Experimental|SyB L-1101|"In Cohort 1, SyB L-1101 1200 mg/day group, Participants were administered 1200 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~In Cohort 2, SyB L-1101 1800 mg/day group, Participants were administered 1800 mg/day of SyB L-1101 intravenously for 3 consecutive days, followed by 11-day observation period.~For both Cohorts, the treatment period of 14 days constitutes 1 cycle, and the treatment was allowed for up to 8 cycles."
3089687|NCT01700387|Experimental|OnabotulinumtoxinA + Topiramate|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with topiramate. During the first month of the treatment period, subjects will titrate as follows:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
3089688|NCT01700387|Placebo Comparator|OnabotulinumtoxinA + Placebo|"Subject will receive 155 U onabotulinumtoxinA injections at 31 sites every 3 months for 12 months and treat daily with placebo. During the first month of the treatment period, subjects will titrate as follows:~Week 1: 1 tab qhs Week 2: 1 tab bid Week 3: 1 tab q am + 2 tabs qhs Week 4: 2 tabs bid"
3089689|NCT01700439|Experimental|EDWARDS INTUITY valve|All subjects enrolled into the study are implanted with the EDWARDS INTUITY Valve System.
3089690|NCT01700517|Sham Comparator|control group|Spinal anesthesia with 0.5% isobaric bupivacaine, in isolation. Punctures in the femoral and popliteal areas were made to mask the femoral and sciatic block, respectively, with no infusion of any medication.
3089691|NCT01700517|Experimental|Femoral nerve block|In addition to the spinal anesthesia, block of the femoral nerve guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. The technique used was femoral area puncture, at the level of the crural fold of skin, with a 0.5% (125mg) ropivacaine associated to 75 mcg of clonidine.
3089692|NCT01700517|Experimental|sciatic nerves block|In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
3089693|NCT01700530|Experimental|Statin|Statins (40mg/day)for an average of 12 weeks
3089694|NCT01700530|Experimental|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
3089695|NCT01700530|Active Comparator|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk) for 12 weeks
3089696|NCT01700621|Experimental|measles-rubella and rotavirus vaccines|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine and one 1.0 ml dose of oral Rotarix vaccine at 9 months of age
3089697|NCT01700621|Active Comparator|measles-rubella vaccine|receive one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine at 9 months of age
3089698|NCT01700673|Experimental|Myeloablative BMT|Azacitidine and sargramostim after myeloablative stem cell transplant
3089699|NCT01700673|Experimental|Non-myeloablative BMT|Azacitidine and sargramostim after non-myeloablative stem cell transplant
3089700|NCT01700673|Experimental|Standard consolidation|Azacitidine and sargramostim after standard consolidation
3089701|NCT01700725|Experimental|Nasal Irrigation - Saline|nasal irrigation using saline plus routine care for symptoms of CRS and fatigue
3089702|NCT01700725|Experimental|Nasal Irrigation - Xylitol|Nasal Irrigation with Xylitol plus routine care for symptoms of CRS and fatigue
3089703|NCT01700725|No Intervention|Control Group|Control group subjects continue to use routine care only
3089704|NCT01700816|Experimental|Bright light therapy|2500 Lux gaze directed every morning from 8 am until 8:30 am
3089705|NCT01700816|Placebo Comparator|Sham light|<1000 Lux gaze directed every morning from 8 am until 8:30 am
3089706|NCT01700829|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
3089707|NCT01700829|Active Comparator|Ketamine|0.5 mg/kg, I.V. (in the vein)
3089708|NCT01700907|Active Comparator|group DES|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
3089709|NCT01700907|Active Comparator|group SEVO|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
3089710|NCT01700959|Active Comparator|Melatonin|Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime.
3089711|NCT01700959|Placebo Comparator|Placebo|Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime.
3089712|NCT01700985|Experimental|122-0551|
3089713|NCT01700985|Placebo Comparator|Vehicle|
3089714|NCT01701011|Experimental|PRCI-monitoring|Coping intervention, Daily Record Keeping, Questionnaires
3089715|NCT01701011|No Intervention|Routine care control|Questionnaires
3089716|NCT01701011|No Intervention|Monitoring control|DRK and Questionnaires
3089717|NCT01701024|Active Comparator|ACYC|ACYC active, topically applied to the face for 12 weeks
3089718|NCT01701024|Placebo Comparator|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
3089719|NCT01701037|Experimental|Dabrafenib and Trametinib|Patients receive dabrafenib PO BID on days 1-28 adding trametinib on days 15-28 followed by surgery on days 28-30. Treatment continues in the absence of unacceptable toxicity.
3089720|NCT01701063|Experimental|Treatment-Naive or Prior Partial/Null Response|telaprevir + Peginterferon alfa-2b + Ribavirin
3089721|NCT01701102|Active Comparator|Mepivacaine 37.5 mg|
3089722|NCT01701102|Active Comparator|Mepivacaine 30 mg plus fentanyl 10 µg|
3089723|NCT01701102|Active Comparator|Mepivacaine 27 mg plus fentanyl 10 µg|
3089724|NCT01701102|Active Comparator|Mepivacaine 24 mg plus fentanyl 10 µg|
3089725|NCT01701115|Experimental|Low Dose (20 mL) Local Anesthetic|Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.
3089726|NCT01701115|Active Comparator|Control Dose (40 mL) Local Anesthetic|Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine
3089727|NCT01701193|Placebo Comparator|Physiological saline- Laparoscopic|Participants receiving intraperitoneal administration of physiological saline at the time of laparoscopic myomectomy.
3089728|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparoscopic|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of laparoscopic myomectomy.
3089729|NCT01701193|Placebo Comparator|Physiological saline- Laparotomy|Participants receiving intraperitoneal administration of physiological saline at the time of myomectomy (laparotomy).
3089730|NCT01701193|Experimental|L-Alanyl/L-Glutamine- Laparotomy|Participants receiving intraperitoneal administration of L-Alanyl-L-Glutamine at the time of myomectomy (laparotomy).
3089731|NCT01701245|No Intervention|Standard of care|No intervention, standard of care
3089732|NCT01701245|Active Comparator|GammaCore|Three stimulation treatments 2x/day 7 to 10 hours apart from one another. In addition, three stimulation treatments at the time of onset of symptoms of a headache attack.
3089733|NCT01701258|Active Comparator|CSA/MDD-amisulpride|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3089734|NCT01701258|Placebo Comparator|CSA/MDD-placebo|Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.
3089735|NCT01701258|Active Comparator|CSA/RES-amisulpride|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3089736|NCT01701258|Placebo Comparator|CSA/RES-placebo|Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.
3089737|NCT01701258|Active Comparator|MDD-amisulpride|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3089738|NCT01701258|Placebo Comparator|MDD-placebo|Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.
3089739|NCT01701258|Active Comparator|Control-amisulpride|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.
3089740|NCT01701258|Placebo Comparator|Control-placebo|Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.
3089741|NCT01701271|Experimental|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Androgenetic Allopecia in several types apply on the scalp drops of the hair loss prevention lotion
3089742|NCT01701362|Active Comparator|pregabalin|
3089743|NCT01701362|Placebo Comparator|placebo|
3089744|NCT01701375|Experimental|Arm 1|"PD 0332991 will be given orally days 1,2,3~Cytarabine (ara-C) will be given by continuous 72 hour intravenous infusion beginning on day 6~Mitoxantrone will be given over 2 hour infusion day 9, 12 hours after the completion of the ara-C infusion. The mitoxantrone dose may be reduced by 25-50% for patients who have received previous anthracyclines as determined by total previous anthracycline dose"
3089745|NCT01701401|Experimental|LDV/SOF 12 weeks|LDV/SOF administered for 12 weeks
3089746|NCT01701401|Experimental|LDV/SOF+RBV 12 weeks|LDV/SOF+RBV administered for 12 weeks.
3089747|NCT01701401|Experimental|LDV/SOF 24 weeks|LDV/SOF administered for 24 weeks
3089748|NCT01701401|Experimental|LDV/SOF+RBV 24 weeks|LDV/SOF+RBV administered for 24 weeks.
3089749|NCT01701414|Sham Comparator|Standard Care (SC)|The SC group will receive a sham injection of normal saline in order to blind both the participants and the treating physicians. A 7.5-MHz linear transducer will be placed on the side of the affected hip 1cm below the inguinal ligament. 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice.
3089750|NCT01701414|Experimental|Femoral Nerve Block (FNB)|"Participants randomized to the second group, FNB group, will receive an Ultrasound (US) guided femoral nerve block using a Sonosite TitanTM (Sonosite, Inc., Bothell, WA) with a 7.5-MHz linear array transducer. Using this technique, 25ml of 0.5% bupivacaine will be injected along the nerve sheath. The femoral, obturator, and lateral cutaneous nerve are anesthetized with this technique (thus the name 3-in-1 femoral block is often used), providing maximum analgesia to the hip."
3089751|NCT01701505|Experimental|Kovacaine Mist High Dose|400uL of Kovacaine Mist, as 2 sprays of 200uL.
3089752|NCT01701505|Experimental|Kovacaine Mist Mid Dose|200uL of Kovacaine Mist, as 2 sprays of 100uL.
3089753|NCT01701505|Experimental|Kovacaine Mist Low Dose|120uL of Kovacaine Mist, as 2 sprays of 60uL.
3468918|NCT03891004|Active Comparator|Subcuticular Suture Closure Method Only|For the suture arm we will only close the subcuticular layer. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
3089755|NCT01701674|Experimental|Combination Therapy|The combination of ipilimumab followed by lymphodepletion with chemotherapy, TIL infusion, and high dose IL-2.
3089756|NCT01701973|Other|Group A (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either LNMMA (L-N-Monomethyl-arginine) versus placebo."
3089757|NCT01701973|Other|Group B (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either pegvisomant versus placebo."
3089758|NCT01701973|Other|Group C (14 healthy subjects)|"In Aim 1: Healthy Lean adults are randomized in a double-blinded cross over fashion to sitagliptin versus placebo.~In Aim 2: Healthy Lean adults receive sitagliptin and are randomized in a double-blinded cross over fashion to pre-treatment with either Exendin 9-39 versus placebo."
3089759|NCT01701999|Experimental|Vaccine|
3089760|NCT01702025|Placebo Comparator|Placebo|"Administer a single dose of placebo (yellow corn meal in a capsule, gelatin ) in Normoxic Conditions.~Following a minimum of 7 days a single dose placebo will be administered (yellow corn meal in a gelatin capsule) in Hypoxic conditions."
3089761|NCT01702025|Active Comparator|Aminophylline|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) in Hypoxic conditions."
3089762|NCT01702025|Active Comparator|Methazolamide|"Administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.~Following a minimum of 7 days administer a single dose of 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
3089763|NCT01702025|Active Comparator|Aminophylline+Methazolamide|"Administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Normoxic Conditions.(Aminophylline+Methazolamide)~Following a minimum of 7 days administer a single dose of 400 mg Aminophylline (4-100 mg tablets) + 250 mg Methazolamide (10-25 mg tablets) in Hypoxic conditions."
3089764|NCT01702233|Experimental|Traumeel S inj.|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
3089765|NCT01702233|Active Comparator|Fortecortin/Dexamethasone 8 mg inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
3089766|NCT01702233|Placebo Comparator|Saline inj.|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
3089767|NCT01702246|Experimental|simvastatin|Simvastatin (Zocor), 40mg tablet, 40mg orally once daily, for 3 months
3089768|NCT01702259|Experimental|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
3089769|NCT01702259|Sham Comparator|Placebo device|Inactive Erchonia GLS device
3089770|NCT01702298|Experimental|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC once daily in the evening for 6 weeks. Participants will continue pre-study dose of metformin >=1000 mg per day.
3089771|NCT01702311|Active Comparator|Bedtime supplementation|Patients in this arm will have acqhs (before meals and at bedtime) and 3 am blood glucose testing and will receive sliding scale insulin supplementation as needed.
3089772|NCT01702311|No Intervention|no bedtime supplementation|Patients in this arm will have ac (before meals), qhs (at bedtime) and 3 am blood glucose testing; however, subjects in this group will NOT receive sliding scale insulin bedtime supplementation.
3089773|NCT01702363|Experimental|GSK573719|125mcg
3089774|NCT01702428|Experimental|INV_MMR_L1 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 1 (L1) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3089775|NCT01702428|Experimental|INV_MMR_L2 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 2 (L2) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3089776|NCT01702428|Experimental|INV_MMR_L3 Group|Subjects receive 1 dose of GSK's candidate combined measles, mumps and rubella (MMR) investigational vaccine (INV_MMR) Lot 3 (L3) co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively.
3089777|NCT01702428|Active Comparator|COM_MMR Group|Subjects receive 1 dose of COM_MMR Lot 1 and Lot 2 co-administered with VV and HAV vaccines at Visit 1 (Day 0). All US subjects are also given PCV-13 vaccine. The MMR vaccine is administered subcutaneously in the triceps region of the left arm while the VV vaccine is administered subcutaneously in the triceps region of the right arm. HAV and PCV-13 vaccines are administered intramuscularly in the anterolateral region of the right and left thigh, respectively. Pooled analysis is conducted for this group.
3089778|NCT01702454|Experimental|Fluarix Quadrivalent Primed Group|Subjects in this group were previously primed with 2 doses of Fluarix Quadrivalent vaccine in the primary study 115345 (NCT01439360) and received 1 dose of Fluarix Quadrivalent vaccine at Day 0 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
3089779|NCT01702454|Experimental|Fluarix Quadrivalent Unprimed Group|Subjects in this group were unprimed in the primary study 115345 (NCT01439360) and received 2 doses of Fluarix Quadrivalent vaccine at Days 0 and 28 in the current study. The vaccine was administered intramuscularly in the deltoid region of arm.
3089780|NCT01702519|Active Comparator|Reference|nicotine transdermal patch with the existing polyisobutylene adhesive
3089781|NCT01702519|Active Comparator|Treatement|nicotine transdermal patch with the alternate polyisobutylene adhesive
3089782|NCT01702532|Experimental|Nicotine Mouth Film|mint nicotine mouth film, buccal administration
3089783|NCT01702532|Active Comparator|Nicotine Lozenge|nicotine lozenge, buccal administration
3089784|NCT01702558|Experimental|Phase 1 (mBC) Cohort 1: T-DM1 + Capecitabine|In Phase 1, Cohort 1 participants (with mBC) will receive trastuzumab emtansine (T-DM1) at a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion (on Day 1 [on Day 2 for Cycle 1] of each 21-day cycle) along with capecitabine at de-escalating dose levels (starting from 750 milligrams per meter squared [mg/m^2]) via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, disease progression (PD), death, or study end.
3089785|NCT01702558|Experimental|Phase 1 (LA/mGC) Cohort 2: T-DM1 + Capecitabine|In Phase 1, Cohort 2 participants (with LA/mGC) will receive trastuzumab emtansine at a dose of 2.4 mg/kg via IV infusion on Day 1 (on Day 2 of first week) of every week along with capecitabine at MTD (determined in Cohort 1) via tablet orally twice daily on Days 1-14 followed by a 7-day rest period, in each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
3089786|NCT01702558|Active Comparator|Phase 2 (mBC): T-DM1 + Capecitabine|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle along with capecitabine at MTD via tablet orally twice daily on Days 1-14 of each 21-day cycle until unacceptable toxicity, withdrawal of consent, PD, death, or study end.
3089787|NCT01702558|Experimental|Phase 2 (mBC): T-DM1|In Phase 2, participants (with mBC) who will be randomized to this group, will receive trastuzumab emtansine at a dose of 3.6 mg/kg via IV infusion on Day 1 of each 21-day cycle until investigator-assessed PD, unacceptable toxicity, withdrawal of consent, death, or study end.
3089788|NCT01702571|Experimental|Trastuzumab Emtansine (All Participants)|This cohort will enroll all participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
3089789|NCT01702571|Experimental|Trastuzumab Emtansine (Asian Participants)|This cohort will enroll Asian race participants with HER2-positive, unresectable, LABC or mBC who have received prior anti-HER2 and chemotherapy treatment and have progressed on or after the most recent treatment for LABC or mBC, or within 6 months of completing adjuvant therapy. Participants will receive trastuzumab emtansine every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
3089790|NCT01702844|Experimental|nab paclitaxel|Patients will receive nab-paclitaxel once weekly for 3 weeks of every 4 week cycle
3089791|NCT01702961|Other|BEAM+R: Autologous Stem Cell Transplant|Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
3089792|NCT01702987|Placebo Comparator|Statin + placebo|9 patients taking statin medications and placebo.
3089793|NCT01702987|Active Comparator|Statin + ubiquinol|12 patients on statins and ubiquinol
3089794|NCT01703000|Experimental|NG PROMUS stent|Single-arm treatment group receiving interventional NG PROMUS study stent
3089795|NCT01703039|Experimental|sertraline + riluzole|sertraline 100 mg po daily and riluzole 50 mg po bid
3089796|NCT01703039|Active Comparator|sertraline + placebo|sertraline 100 mg po daily and placebo
3089797|NCT01703065|Experimental|Cabozantinib in metastatic CRPC|Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
3089798|NCT01703065|Experimental|Cabozantinib in non-metastatic CRPC|Non-Metastatic CRPC patients to receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
3089799|NCT01703091|Experimental|Ramucirumab plus Docetaxel|Ramucirumab 10 milligram per kilogram (mg/kg) on Day 1 of every 21 day cycle, administered as an intravenous (IV) infusion over approximately 60 minutes. Docetaxel 60 milligram per square meter (mg/m2) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
3089800|NCT01703091|Placebo Comparator|Placebo plus Docetaxel|Placebo (administered at a volume equivalent to a dose of milligram per kilogram (mg/kg)) on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes. Docetaxel 60 mg/m2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 60 minutes.
3089801|NCT01703117|Experimental|age matched cohort 50-95 years old|20-22 subjects between the ages of 50-95 will receive riluzole
3089802|NCT01703117|Placebo Comparator|24 subjects between 50-95 years old|20-22 subjects between 50-95 will receive placebo
3089803|NCT01703169|Experimental|Eltrombopag|Single arm study. Dose Escalation.
3089804|NCT01703208|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
3089805|NCT01703208|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
3089806|NCT01703221|Experimental|Omarigliptin 25 mg (Phase A+B)|Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
3089807|NCT01703221|Active Comparator|Sitagliptin (Phase A) switching to Omarigliptin (Phase B)|Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
3089808|NCT01703221|Placebo Comparator|Placebo (Phase A) switching to Omarigliptin (Phase B)|Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
3089809|NCT01703260|Experimental|Roflumilast + pioglitazone|Roflumilast dose and pioglitazone dose, orally for up to 4 months
3089810|NCT01703260|Experimental|Roflumilast|Roflumilast dose and pioglitazone matching-placebo dose orally for up to 4 months.
3089811|NCT01703260|Experimental|Pioglitazone|Pioglitazone dose, orally and roflumilast matching-placebo dose, orally for up to 4 months
3089812|NCT01703286|Experimental|Linagliptin 5mg|given once daily over 28 days
3089813|NCT01703286|Active Comparator|Glimepiride|given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
3089814|NCT01703286|Placebo Comparator|Placebo|given once daily over 28 days
3089815|NCT01703507|Experimental|Arm A (Ipilimumab and Whole Brain Radiation Therapy)|Patients receive ipilimumab IV over 90 minutes once in weeks 1, 4, 7, and 10. Patients also undergo WBRT 5 days a week in weeks 1-2.
3089816|NCT01703507|Experimental|Arm B (Ipilimumab and Stereotactic Radiosurgery)|Patients receive ipilimumab IV over 90 minutes as in Arm A. Patients also undergo SRS on day 1 in week 1.
3089817|NCT01703598|Experimental|DBS surgery|Single arm
3089818|NCT01703663|Experimental|EPAP|Provent Sleep Apnea Therapy.
3089819|NCT01703663|No Intervention|control|
3089820|NCT01703702|Experimental|Intervention|Subjects will receive florbetapir (18F) PET scans and physicians will have immediate access to PET scan results.
3089821|NCT01703702|Experimental|Control|Subjects will receive florbetapir (18F) PET scans but physicians will be blinded to PET scan results for 12 months
3089822|NCT01703741|Experimental|Testosterone gel (FE 999093)|Subjects received testosterone gel with initial dose as fixed on Day 56 (23 mg, 46 mg or 69 mg) during the 000023 study. The dose could further be down titrated based on serum testosterone levels at Day 90/91 of 000023 study. Testosterone gel was applied daily in morning using an applicator, to the shoulder/upper arm in a contralateral fashion for 6 months.
3089823|NCT01703819|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3089824|NCT01703819|Placebo Comparator|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3089825|NCT01703832|Experimental|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
3089826|NCT01703832|No Intervention|No intervention|no tablet intake and subjects will undergo the natural course
3089827|NCT01703845|Experimental|Tiotropium + Olodaterol (high dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
3089828|NCT01703845|Experimental|Tiotropium + Olodaterol (low dose)|Tiotropium and Olodaterol fixed dose combination (FDC) solution for inhalation - RESPIMAT
3089829|NCT01703858|Active Comparator|1 BI 113608|powder in the bottle for oral solution, oral administration with 240 mL water
3089830|NCT01703858|Experimental|2 BI 113608|conventional tablet formulation
3089831|NCT01703858|Experimental|3 BI 113608|conventional tablet formulation, fed
3089832|NCT01703858|Experimental|4 BI 113608|conventional tablet after pantoprazole administration
3089833|NCT01703858|Experimental|5 BI 113608|conventional tablet formulation, fasted, 0:30 min before fat breakfast
3089834|NCT01703988|Experimental|Nusinersen 3 mg|3 mg nusinersen on Days 1, 29, 85, intrathecal (IT) injection
3089835|NCT01703988|Experimental|Nusinersen 6 mg|6 mg nusinersen on Days 1, 29, 85, IT injection
3089836|NCT01703988|Experimental|Nusinersen 9 mg|9 mg nusinersen on Days 1 and 85, IT injection
3089837|NCT01703988|Experimental|Nusinersen 12 mg|12 mg nusinersen on Days 1, 29, 85, IT injection
3089838|NCT01704079|Active Comparator|CTAP101 30 μg capsules|1 CTAP101 30 μg capsule daily at bedtime for 12 weeks, with a possible increase to 2 CTAP101 30 μg capsules daily at bedtime for study duration, if needed (26 weeks total). Subjects not requiring a dose increase after 12 weeks would receive 1 CTAP101 30 μg capsule and one sugar pill (to CTAP101 30 μg capsule) for weeks 13-26.
3089839|NCT01704079|Placebo Comparator|Sugar pill to CTAP101 30 μg|1 sugar pill to CTAP101 30 μg capsule daily at bedtime for 12 weeks, with an increase to 2 sugar pills to CTAP101 30 μg capsules daily at bedtime for weeks 13-26.
3089840|NCT01704196|Active Comparator|Nepicastat|Nepicastat 120mg and 100mg riboflavin (once per day) for 11 weeks
3089841|NCT01704196|Placebo Comparator|Placebo|Placebo capsule containing 100mg riboflavin (once per day) for 11 weeks.
3089842|NCT01704261|Experimental|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
3089843|NCT01704261|Placebo Comparator|Placebo|Matching placebo to omarigliptin capsule administered orally once a week for 24 weeks. Participants continue pre-study concomitant therapy of open-label glimepiride tablet(s) orally once daily (total daily dose >=4 mg per day) and metformin tablet(s) orally once or twice daily (total daily dose >=1500 mg per day).
3089844|NCT01704287|Experimental|Pembrolizumab 2 mg/kg|Participants were initially randomized to receive pembrolizumab 2 mg/kg intravenously (IV) once every 3 weeks (Q3W). With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
3089845|NCT01704287|Experimental|Pembrolizumab 10 mg/kg|Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
3089846|NCT01704287|Active Comparator|Investigator-Choice Chemotherapy (ICC)|Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to ~66 months)
3089847|NCT01704287|Experimental|ICC→Pembrolizumab 2 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
3089848|NCT01704287|Experimental|ICC→Pembrolizumab 10 mg/kg|Participants who were initially randomized to ICC, subsequently experienced confirmed progressive disease (PD) and met all switching criteria at study treatment Week 12, had the opportunity to switch to receive pembrolizumab 2 mg/kg or 10 mg/kg. Participants received pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to PD, toxicity, or choice. (Up to ~66 months)
3089849|NCT01704404|Experimental|Dose 1 TD-4208|22 µg
3089850|NCT01704404|Experimental|Dose 2 TD-4208|44 µg
3089851|NCT01704404|Experimental|Dose 3 TD-4208|88 µg
3089852|NCT01704404|Experimental|Dose 4 TD-4208|175 µg
3089853|NCT01704404|Experimental|Dose 5 TD-4208|350 µg
3089854|NCT01704404|Experimental|Dose 6 TD-4208|700 µg
3089855|NCT01704404|Placebo Comparator|Placebo|Placebo
3089856|NCT01704456|Experimental|Mindfulness-based cognitive therapy (MBCT)|Women in the MBCT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
3089857|NCT01704456|Experimental|Cognitive Behavioural Therapy (CBT)|Women in the CBT Group Treatment arm will receive the treatment in small group format (8-9 women). Each session will be 2.25 hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
3089858|NCT01704495|Experimental|AZD5069 5 mg|AZD5069 oral capsules self-administered twice daily
3089859|NCT01704495|Experimental|AZD5069 15 mg|AZD5069 oral capsules self-administered twice daily
3089860|NCT01704495|Experimental|AZD5069 45 mg|AZD5069 oral capsules self-administered twice daily
3089861|NCT01704495|Placebo Comparator|Placebo|Placebo oral capsules self-administered twice daily
3089862|NCT01704521|Active Comparator|Lead-In|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin for 4 weeks followed by 12 weeks of PegInterferon + Ribavirin + Telaprevir followed by variable duration of PegInterferon + Ribavirin
3089863|NCT01704521|Active Comparator|No Lead-in|Kinetic assessment of response guided treatment per standard of care with PegInterferon + Ribavirin + Telaprevir for 12 weeks followed by variable duration of PegIntereron + Ribavirin
3089864|NCT01704599|Experimental|Humira then Humira plus 3 B vitamins|"Humira then Humira plus 3 B vitamins~The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject."
3089865|NCT01704651|Experimental|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative. Drug was continued for duration of hospital stay, but did not exceed 7 days.
3089866|NCT01704651|Placebo Comparator|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
3089867|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
3089868|NCT01704755|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV for 24 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks
3089869|NCT01704781|Experimental|Part A: lenalidomide dose escalation|"All patient receive intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide in a dose escalation (3+3) design.~Dose level -1: 2.5 mg Lenalidomide (CC-5013) in the event Dose level 1 is non tolerated dose (NTD) Dose level 1(start): 5 mg Lenalidomide (CC-5013) Dose level 2: 10 mg Lenalidomide (CC-5013) Dose level 3: 25 mg Lenalidomide (CC-5013)"
3089870|NCT01704781|Experimental|Part B: lenalidomide|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide (dose determined in Part A) two days prior to and at the day of immunization.
3089871|NCT01704781|Placebo Comparator|Part B: lenalidomide placebo|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) and oral lenalidomide for 6 immunizations (visit 2, 3, 4, 5, 6 and 7) & lenalidomide placebo two days prior to and at the day of immunization.
3089872|NCT01704846|Experimental|Treatment sequence 1|Test - Reference - Reference - Test
3089873|NCT01704846|Experimental|Treatment sequence 2|Reference - Test - Test - Reference
3089874|NCT01704976|Experimental|Intervention|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (5 Hz, noise 4) - T1
3089875|NCT01704976|Sham Comparator|Sham group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (1 Hz, noise 1) - T1
3089876|NCT01705080||A - EnligHTN for Severe Resistant HTN|"Office systolic Blood Pressure ≥160 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
3089877|NCT01705080||B - EnligHTN for Resistant HTN|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated GFR ≥45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
3089878|NCT01705080||C - EnligHTN for Resistant HTN & CKD|"Office systolic Blood Pressure ≥140 mmHg~Subject is taking ≥3 anti-hypertensive medications (including 1 diuretic), or subject has documented drug intolerance to 2 or more of the 4 major classes of anti-hypertensives (ACE/ARB, Calcium Channel Blockers, Beta Blockers, or diuretic) and is unable to take 3 anti-hypertensive drugs.~Patient has an estimated ≥15 GFR <45 mL/min per 1.73 m^2 using the Modification of Diet in Renal Disease (MDRD) formula"
3089879|NCT01705145|Experimental|Ivacaftor|"Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than [<] 14 kilograms [kg]) or 75 mg (for participants weighing greater than or equal to [>=] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study..~Part B: Ivacaftor 50 mg (for participants weighing <14 kg) or 75 mg (for participants weighing >=14 kg) q12h for 24 weeks during Part B of the study."
3089880|NCT01705236|Experimental|Fingolimod - Longitudinal Assessment|No study drug was provided. Fingolimod was to be prescribed according to local label. The decision to prescribe fingolimod had to be made independent of this study.
3089881|NCT01705288|Active Comparator|Control Group (Standard Laparotomy)|Patients undergoing standard anesthesia and standard exploratory laparotomy. Treatment will be per your surgeon's routine standards.
3089882|NCT01705288|Experimental|Rapid Recovery Group|"Protocol for rapid recovery laparotomy procedure involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), post-operative use of non-steroidal anti-inflammatory drugs, early eating after surgery, early walking, and certain goals for discharge from the hospital."
3089883|NCT01705496|Experimental|[124I]FIAU|Single dose study of [124I]FIAU in patients presenting with pain in a prosthetic knee or hip joint who will undergo PET-CT scanning.
3089884|NCT01705509|Other|Ranolazine Treatment Arm|All patients who meet the criteria of ischemia will receive ranolazine after enrollment. The initial CPET will serve as the control. The second CPET after 30-days of therapy will serve as the therapy arm. CPET parameters will be assessed and compared both on and off therapy.
3089885|NCT01705574|Experimental|E/C/F/TDF|E/C/F/TDF + ATV placebo + RTV placebo + FTC/TDF placebo
3089886|NCT01705574|Active Comparator|ATV + RTV+ FTC/TDF|ATV + RTV + FTC/TDF + E/C/F/TDF placebo
3089887|NCT01705574|Experimental|Open-Label Extension Phase|After 48 weeks of blinded treatment, participants will continue to take blinded study drug for 12 weeks and return for an unblinding visit at Week 60. Participants who are virologically suppressed at Week 48 during the double-blinded treatment phase will have the option to enter the open-label extension phase. Participants randomized to the E/C/F/TDF arm will continue to receive open-label E/C/F/TDF and participants randomized to the ATV+ RTV + FTC/TDF arm will be re-randomized to receive either open-label elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) or open-label ATV + RTV+ FTC/TDF.
3089888|NCT01705587|Experimental|Immediate teriparatide|Open label teriparatide given immediately following surgical repair of fracture
3089889|NCT01705587|Experimental|Delayed teriparatide|Open label teriparatide given six months following surgical repair of fracture
3089890|NCT01705652|Experimental|Nexrutine Surgery Group|Surgery Group: Nexrutine 500mg by mouth, three times per day, given prior to surgery.
3089891|NCT01705652|Experimental|Nexrutine Radiation Group|Radiation Group: Nexrutine 500mg by mouth, three times per day, given prior to and during radiation treatment.
3089892|NCT01705691|Active Comparator|Arm 1: Paclitaxel then AC|Paclitaxel 80 mg/m2 IV weekly for 12 doses followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
3089893|NCT01705691|Experimental|Arm 2: Eribulin then AC|Eribulin 1.4 mg/m2 IV on days 1 and 8 of a 21-day cycle for 4 cycles, followed by doxorubicin and cyclophosphamide IV every 21 days for 4 cycles
3089894|NCT01705717||cohort|
3089895|NCT01705730||Tocilizumab|Participants with rheumatoid arthritis (RA) received tocilizumab monotherapy according to individualized physician-prescribed regimens.
3089896|NCT01705964|Experimental|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
3089897|NCT01705964|Sham Comparator|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
3089898|NCT01705977|Placebo Comparator|Placebo plus standard therapy|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
3089899|NCT01705977|Experimental|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg IV plus standard therapy; belimumab administered on Days 0, 14, 28, and then every 28 days thereafter through Week 48, with a final evaluation at Week 52 in the double-blind period.
3089900|NCT01706003||Telemedicine Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated via telemedicine for migraine headaches
3089901|NCT01706003||In-Office Group|People who suffer from Migraine Headaches who own a computer and have internet access and will be treated in the clinician's office for migraine headaches
3089902|NCT01706081|Experimental|Acupuncture|Patients in the acupuncture group will receive acupuncture treatment twice weekly for six consecutive weeks.
3089903|NCT01706081|Experimental|Wait-list|Patients in the wait-list control group will cross over and receive acupuncture twice weekly for 6 consecutive weeks.
3089904|NCT01706146|Other|Non-Coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
3089905|NCT01706159|Experimental|rFXIII|
3089906|NCT01706159|Active Comparator|Placebo|
3089907|NCT01706198|Experimental|FF/VI|fluticasone furoate (FF) + vilanterol (VI) once daily via a Novel Dry Powder Inhaler
3089908|NCT01706198|Active Comparator|ICS or ICS/LABA maintenance therapy|inhaled corticosteroid (ICS) alone or in combination with a long acting beta2-agonist (LABA)
3089909|NCT01706250|Experimental|MAXCLARITY II|MaxClarity II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3089910|NCT01706250|Active Comparator|PROACTIV|Proactiv (2.5% BPO) Renewing Cleanser and Repairing Lotion and Revitalizing Toner. Available over the counter. Each subject applies both arms (MaxClarity II and Proactiv) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3089911|NCT01706263|Experimental|MAXCLARITY II|MAXCLARITY II (2.5% BPO) Foam Cleanser and Foam Treatment and (0.5% Salicylic Acid) Toner Foam. Available over-the-counter.
3089912|NCT01706328|Experimental|FF/VI Inhalation Powder NDPI|Subjects randomized to the FF/VI 100/25 arm will take an active inhalation of study medication during their morning dosing from their NDPI and will have an inhalation of dummy medication (placebo) as their morning ACCUHALER/DISKUS dose and as their evening dose.
3089913|NCT01706328|Active Comparator|Fluticasone Propionate/Salmeterol Inhalation Powder|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg arm will have an active dose of medication during both their morning and evening treatments from the ACCUHALER/DISKUS and a dummy placebo dose in the morning from their NDPI.
3089914|NCT01706458|Active Comparator|sipuleucel-T|Patients receive sipuleucel-T IV on weeks 0, 2, and 4.
3089915|NCT01706458|Experimental|sipuleucel-T with DNA Vaccine|Patients receive sipuleucel-T as patients in arm I and pTVG-HP plasmid DNA vaccine ID on weeks 6, 8, 10, and 12, and then at 6 and 9 months.
3089916|NCT01706536|Placebo Comparator|EP-101 Placebo|EP-101 Placebo AM + EP-101 Placebo PM
3089917|NCT01706536|Experimental|EP 101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
3089918|NCT01706536|Experimental|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
3089919|NCT01706536|Experimental|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
3089920|NCT01706536|Experimental|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
3089921|NCT01706549||Posthysterectomy pain|Observational study on posthysterectomy pain
3089922|NCT01706575|Experimental|Pegylated Interferon (Peginterferon) Alfa-2a|Participants receiving nucleos(t)ide analogues (NA) therapy with Hepatitis B surface Antigen (HBsAg) decline less than <0.5 log 10 international unit/milliliter (IU/ml) at baseline received peginterferon alfa-2a 180 microgram (mcg), subcutaneously (SC) once weekly for 48 weeks along with their NA therapy.
3089923|NCT01706588|Experimental|Diclofenac sodium 5 mg/mL|
3089924|NCT01706588|Experimental|Diclofenac sodium 12.5 mg/mL|
3089925|NCT01706588|Experimental|Diclofenac sodium 25 mg/mL|
3089926|NCT01706588|Experimental|Diclofenac sodium 50 mg/mL|
3089927|NCT01706588|Placebo Comparator|Placebo 1 mL|
3089928|NCT01706666|Experimental|Arm A (bortezomib)|Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
3089929|NCT01706666|Experimental|Arm B (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.
3089930|NCT01706666|Experimental|Arm C (bortezomib, lenalidomide)|Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.
3089931|NCT01706770|Experimental|enfilcon A|The test (experimental) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
3089932|NCT01706770|Active Comparator|galyfilcon A|The control (active comparator) lens is a silicone hydrogel contact lens following a daily wear 1 week planned replacement modality.
3089933|NCT01706822|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in laparoscopic LAR or proctosigmoidectomy
3089934|NCT01706926|Placebo Comparator|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 milligram [mg] per week) through oral or parenteral route.
3089935|NCT01706926|Experimental|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3089936|NCT01706926|Experimental|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3089937|NCT01706926|Experimental|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3089938|NCT01706952|Experimental|Cocaine|"Cocaine 4%. Three cotton neuropatties will be soaked with 4% cocaine. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This intervention will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
3089939|NCT01706952|Active Comparator|Adrenaline|"Adrenaline 1/1.000 Three cotton neuropatties will be soaked with Adrenaline 1/1,000. One neuropattie will be placed in the sphenoethmoidal recess, one in the middle meatus, and one in the anterior end of the middle turbinates on the side that the randomization has determined.~This will be done before the beginning of the surgery, and will be left in the nose for 10 minutes, this will be done just once. After the 10 minutes, the neuropatties will be taken out of the nose."
3089940|NCT01706965|Experimental|Kuvan|Kuvan once-daily dosing initiated with 10mg/kg for the first week followed by 20mg/kg for the remaining weeks of the study
3089941|NCT01706965|Active Comparator|Multivitamin|Daily multivitamin tablet
3089942|NCT01706978|Experimental|Soft Tissue Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
3089943|NCT01706978|Active Comparator|Bone Trephination|"Ten days prior to the standard rotator cuff repair, a trephination procedure will be carried out. The trephination procedure will take approximately 30 minutes to complete and will be carried out under local anesthesia. A needle will be placed through the skin over the shoulder and either into the bone or into the edge of the cuff tendon, depending on whether you are allocated to the bone trephination or soft tissue trephination groups. The needle will be used to make 6 small holes in either bone or the tendon in the shoulder in the area where the cuff is to be repaired."
3089944|NCT01707004|Experimental|Treatment (donor bone marrow transplant)|"Beginning between days -29 and -22, patients receive decitabine IV over 1 hour daily for 10 days, fludarabine phosphate IV over 30 minutes on days -5 to -2, and busulfan IV over 3 hours on days -5 to -2.~PREPARATIVE REGIMEN: Patients undergo total-body irradiation BID on day -1.~TRANSPLANT: Patients undergo allogeneic bone marrow transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus PO BID or IV continuously on days 5-180, mycophenolate mofetil PO TID on days 5-35, and filgrastim SC beginning day 5 until ANC >= 1,000/mm^3 for 3 consecutive days."
3089945|NCT01707030|Experimental|BAI Arm|Receiving a web-based brief intervention for alcohol problems
3089946|NCT01707030|Active Comparator|Usual Care|In usual care, Hepatitis C clinic staff will sometimes discuss alcohol use with patients, and this will be the experience of some of the controls
3089947|NCT01707043|Active Comparator|Taclonex Ointment First|All subjects will use Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas, then switch to Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days
3089948|NCT01707043|Active Comparator|Taclonex Scalp Suspension first|All subjects will use Taclonex Scalp® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Topical Suspension once daily to affected areas for three days, then switch to Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) Ointment once daily for three days to affected areas,
3089949|NCT01707095|Experimental|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
3089950|NCT01707095|Experimental|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
3089951|NCT01707108|Experimental|Dental Implants|Rehabilitation of missing teeth with Dental Implant (MIS Technologies)
3089952|NCT01707147||Patients with Type 2 Diabetes Mellitus|
3089953|NCT01707225|Experimental|Octreotide LAR Depot|Once enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.
3089954|NCT01707238|Experimental|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
3089955|NCT01707238|Active Comparator|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
3089956|NCT01707290|Experimental|Ivacaftor|Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
3089957|NCT01707290|No Intervention|Observational|Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
3089958|NCT01707368||all eligible patients|Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
3089959|NCT01707381|Active Comparator|Timolol Maleate|Timolol maleate ophthalmic solution 0.5% administered 1 drop BID once in morning and once in the evening for 4 weeks.
3089960|NCT01707381|Experimental|BOL-303259-X|BOL-303259-X topical ophthalmic solution administered 1 drop QD in the evening for 4 weeks.
3089961|NCT01707420|Active Comparator|Gabapentin|gabapentin, 20 mg/kg, single dose, 60 min prior to surgery
3089962|NCT01707420|Placebo Comparator|liquid placebo|subjects randomized to the liquid placebo arm will receive a single dose elixir of 0.4 mL/kg given 60 min prior to surgery
3089963|NCT01707472|Experimental|Simtuzumab in HIV Patients|HIV-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
3089964|NCT01707472|Experimental|Simtuzumab in HCV Patients|HCV-infected participants will receive simtuzumab every 2 weeks for 24 weeks.
3089965|NCT01707472|Experimental|Simtuzumab in HIV/HCV Co-Infected Patients|HIV/HCV co-infected participants will receive simtuzumab every 2 weeks for 24 weeks while continuing on standard therapy for HIV.
3089966|NCT01707654|Other|nerve graft|Simultaneous repair of the infected wound and digital nerve defect in the finger using a bipedicled nerve flap including nerve graft from the dorsal branch of the digital nerve.
3089967|NCT01707667|Experimental|Prucalopride|
3089968|NCT01707667|Active Comparator|PEG 3350|
3089969|NCT01707693|Experimental|Lifestyle Physical Activity Intervention|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
3089970|NCT01707693|Active Comparator|Information/Attention Comparison|the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer & LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
3089971|NCT01707992|Placebo Comparator|Placebo-Controlled Phase: Placebo|Participants will receive 2 capsules of placebo (matching to laquinimod 0.6 milligrams [mg]) once daily orally for up to 24 months.
3089972|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 0.6 mg|Participants will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for up to 24 months.
3089973|NCT01707992|Experimental|Placebo-Controlled Phase: Laquinimod 1.2 mg|Participants will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for up to 24 months.
3089974|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 0.6 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 0.6 mg treatment group after 01 January 2016, will receive 1 capsule of laquinimod 0.6 mg and 1 capsule of matching placebo once daily orally for 24 months.
3089975|NCT01707992|Experimental|Active Treatment Phase: Laquinimod 1.2 mg|Participants who completed the placebo-controlled phase on placebo and on laquinimod 1.2 mg treatment group prior to 01 January 2016, will receive laquinimod 1.2 mg (2 capsules of laquinimod 0.6 mg each) once daily orally for 24 months.
3089976|NCT01707992|No Intervention|Active Treatment Phase: Off Drug|Participants who were discontinued from treatment with laquinimod 1.2 mg during the placebo-controlled phase due to sponsor decision after 01 January 2016 will continue the active-treatment phase off drug for 24 months.
3089977|NCT01708122|Experimental|Fentanyl|Subjects will receive either 0.5mL or 1 mL of intranasal fentanyl (50mcg or 100mcg)
3089978|NCT01708122|Placebo Comparator|Placebo|Subjects will receive either 0.5mL or 1 mL of intranasal saline as placebo.
3089979|NCT01708161|Experimental|BYL719 + AMG 479|For: Dose escalation phase/Phase II Expansion Phase. Cohorts of 3-6 patients were to be enrolled sequentially until an MTD or a recommended Phase II dose were defined. All patients were to receive the combination treatment. Sequential cohorts may receive different doses of the combination. In the Phase II expansion, all patients were to receive the same combination treatment.
3089980|NCT01708174|Experimental|Sonidegib (LDE225)|600 mg orally for adults and 500 mg/m2 orally for children
3089981|NCT01708174|Active Comparator|Temozolamide (TMZ)|150 to 200 mg/m2 for 5 sequential days every 4 weeks according to prescribing information until the study was amended to a single arm study.
3089982|NCT01708187|Experimental|Clarix™1k graft|Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
3089983|NCT01708187|No Intervention|Control arm without Clarix™1k graft|Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue.
3089984|NCT01708213|Experimental|Dermal Filler - Aline HA|Single armed study
3089985|NCT01708278|Placebo Comparator|Sugar chew-Cohort 1|contains 350 mg of vitamin C and 10 mg niacin
3089986|NCT01708278|Active Comparator|Quercetin 1-Cohort 1|Quercetin chew containing 500 mg quercetin, 350 mg vitamin C and 10 mg niacin
3089987|NCT01708278|Active Comparator|Quercetin 2-Cohort 2|Quercetin chew containing 1000 mg quercetin, 350 mg vitamin C and 10 mg niacin
3089988|NCT01708278|Active Comparator|Quercetin 3-Cohort 3|Quercetin chew containing 2000 mg quercetin, 350 mg vitamin C and 10 mg niacin
3089989|NCT01708278|Placebo Comparator|Sugar chew-Cohort 2|contains 350 mg of vitamin C and 10 mg niacin
3089990|NCT01708278|Placebo Comparator|Sugar Chew-Cohort 3|contains 350 mg of vitamin C and 10 mg niacin
3089991|NCT01708291|Active Comparator|Mindfulness Based Stress reduction|attending 10 weekly sessions and comprised of an eight week mindfulness intervention program, and completing pre- and postevaluation measures on the first and last sessions
3089992|NCT01708291|Placebo Comparator|No Mindfulness based intervention|completing only re- and post-evaluation measures on the first and last sessions
3089993|NCT01708317|Other|ACASI|The group of patients that agreed to participate in the study and answer questions on our Audio-enhanced Computer-Assisted Self-Interview (ACASI)
3089994|NCT01708525|Experimental|Ultherapy®-treated tissue|Heavy water labeled tissue receiving an Ulthera® System Treatment
3089995|NCT01708590|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
3089996|NCT01708590|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease.
3089997|NCT01708590|Placebo Comparator|placebo|Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
3089998|NCT01708603|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3089999|NCT01708603|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3090000|NCT01708603|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
3090001|NCT01708603|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
3090002|NCT01708629|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3090003|NCT01708629|Experimental|140 mg brodalumab|Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to schedule 1, 2, 3, or 4.
3090004|NCT01708629|Active Comparator|ustekinumab|Administered by subcutaneous (SC) injection per the labeled dosing regimen.
3090005|NCT01708629|Placebo Comparator|Placebo|Administered by SC injection until week 12. At week 12 participants are assigned to 210 mg brodalumab.
3090006|NCT01708902|Experimental|linagliptin2.5mg / metformin500mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 500mg BID
3090007|NCT01708902|Experimental|linagliptin2.5mg / metformin1000mg BID|patient to receive a tablet containing linagliptin 2.5mg and metformin 1000mg BID
3090008|NCT01708902|Active Comparator|metformin 500mg BID|patient to receive a tablet containing metformin 500mg BID
3090009|NCT01708902|Active Comparator|metformin 1000mg BID|patient to receive a tablet containing metformin 1000mg BID
3090010|NCT01708902|Active Comparator|linagliptin 5 mg QD|patient to receive a tablet containing linagliptin 5mg once daily
3090011|NCT01708915|Active Comparator|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3090012|NCT01708915|Active Comparator|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3090013|NCT01708915|Active Comparator|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3090014|NCT01708915|Placebo Comparator|placebo|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
3090015|NCT01708941|Experimental|Arm A (higher dose ipilimumab, HDI)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
3090016|NCT01708941|Experimental|Arm B (higher dose ipilimumab)|"INDUCTION PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive higher dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
3090017|NCT01708941|Experimental|Arm C (lower dose ipilimumab + HDI)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses and recombinant interferon alfa-2b IV over 20 minutes 5 days a week for 4 weeks and then SC 3 times weekly for 8 weeks.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24 and recombinant interferon alfa-2b SC 3 times weekly for 48 weeks."
3090018|NCT01708941|Experimental|Arm D (lower dose ipilimumab)|"INDUCTION PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 3 weeks for 4 doses.~MAINTENANCE PHASE: Patients receive lower dose ipilimumab IV over 90 minutes once every 12 weeks for 4 doses beginning in week 24."
3090019|NCT01708954|Experimental|Arm A (erlotinib)|Patients receive erlotinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090020|NCT01708954|Experimental|Arm B (cabozantinib)|Patients receive cabozantinib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090021|NCT01708954|Experimental|Arm C (erlotinib+cabozantinib)|Patients receive erlotinib as patients in Arm A and cabozantinib as patients in Arm B. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090022|NCT01708954|Experimental|Arm Z (erlotinib+cabozantinib; step II)|Patients achieving disease progression in Arm A or Arm B may receive erlotinib and cabozantinib as patients in Arm C. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3090023|NCT01708967|Experimental|Catheter-free method|"We explored success rate, side effects, and vital signs in patients with catether-free method.~Intervention: one-time spray of epinephrine (1cc) plus 4% lidocaine (4cc)"
3090024|NCT01708967|Experimental|Catheter insertion method|We explored success rate, side effects, and vital signs in patients with catether insertion method : use both spray and catheter
3090025|NCT01709032|Experimental|Deferasirox and deferiprone|
3090026|NCT01709084|Experimental|Group 1|Patients will receive fixed dose combination (FDC) tablet of tenofovir disoproxil fumarate/emtricitabine/rilpivirine with a meal, until Week 48.
3090027|NCT01709084|Active Comparator|Group 2|Patients will receive FDC tablet of tenofovir disoproxil fumarate/emtricitabine /efavirenz on an empty stomach at bedtime, until Week 48.
3090028|NCT01709110|Experimental|Teriparatide|"Teriparatide 20 microgram (µg) administered by subcutaneous (SC) injection once daily for 24 months.~Placebo given orally once weekly for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
3090029|NCT01709110|Active Comparator|Risedronate|"Risedronate 35 milligram (mg) administered orally once weekly for 24 months.~Placebo given by SC injection once daily for 24 months.~Elemental Calcium 500 to 1000 milligram per day and Vitamin D 400 to 800 International Units per day, both administered orally once daily while receiving treatment."
3090030|NCT01709149|Experimental|CK-2017357|125 mg tablets
3090031|NCT01709149|Placebo Comparator|Placebo|Placebo tablets
3090032|NCT01709162|Experimental|Ipilimumab, 3 mg/kg|Participants received ipilimumab, 3 mg/kg, by intravenous infusion, every 3 weeks for a total of 4 doses or until disease progression, unacceptable toxicity, or withdrawal of consent
3090033|NCT01709162|Active Comparator|Chemotherapy|Participants received the investigator's choice of chemotherapy, administered per package instructions.
3090034|NCT01709227|Experimental|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
3090035|NCT01709227|Experimental|Peritoneal dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management will be directed by CICU attending and Nephrology service
3090036|NCT01709305|Active Comparator|Metformin + Sitagliptin + Glimepiride|During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3090037|NCT01709305|Experimental|Metformin + Sitagliptin + Repaglinide|During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3090038|NCT01709305|Experimental|Metformin + Sitagliptin + Acarbose|During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3090039|NCT01709305|Experimental|Metformin + Sitagliptin + Gliclazide|During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
3090040|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 500/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 500/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090041|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 700/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 700/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090042|NCT01709318|Experimental|Nomegestrol Acetate-17β-Estradiol (NOMAC-E2) 900/300 μg/day|Participants will receive nomegestrol acetate 17β-estradiol (NOMAC-E2) 900/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090043|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 75/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 75/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090044|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 100/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2) 100/300 μg for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090045|NCT01709318|Experimental|Etonogestrel-17β-Estradiol (ENG-E2) 125/300 μg/day|Participants will receive etonogestrel 17β-estradiol (ENG-E2)125/300 μg for three 28-day treatment periods, each treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090046|NCT01709318|Active Comparator|NuvaRing®|Participants will receive NuvaRing® (etonogestrel-ethinyl estradiol [ENG-EE] 120/15 μg) for three treatment periods, each 28-day treatment period (cycle) consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3090047|NCT01709331|Experimental|Corifollitropin alfa 150 μg + hCG|During a 16-week pretreatment phase, participants will receive twice-weekly subcutaneous (SC) injections of hCG 1500 or 3000 international units (IU). Eligible participants will then be enrolled in the combined treatment phase in which they will receive a single dose of corifollitropin alfa 150 μg by SC injection once every 2 weeks for 52 weeks. In addition, eligible participants will continue to receive twice-weekly hCG injections on the same schedule as the pretreatment phase.
3090048|NCT01709383|Active Comparator|Transcranial Direct Current Stimulation|TDCS was applied bilaterally, with the anodal electrode on the left temple and cathodal electrode on the right. TDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period
3090049|NCT01709383|Sham Comparator|Sham Stimulation|Sham tDCS was applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
3090050|NCT01709409|Experimental|Curosurf (Group 1)|Surfactant(Curosurf in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. The treatment dose for Curosurf® is 2.5 ml/kg (200mg/kg) for the first dose and 1.25 ml/kg (100mg/kg) for repeat doses, given by endotracheal method. There is a maximum of 3 doses in the study.
3090051|NCT01709409|Active Comparator|BLES (Group 2)|Surfactant(BLES in this arm) is given for treatment of RDS after the diagnosis has been made by the Neonatologist. For BLES the recommended dose is 5 ml/kg. given by endotracheal method. There is a maximum of 3 doses in the study.
3090052|NCT01709422|Active Comparator|Propofol|both midazolam (1mg if aged <= 70 years or 0.5mg in age >70 years) and meperidine 20 mg were given intravenously at the initiation of sedation, Thereafter, an initial bolus of propofol 20 mg intravenously. Sedation was maintained with repeated dose of 5 to 10 mg propofol.
3090053|NCT01709422|Active Comparator|Conventional|both midazolam 2 to 5 mg and meperidine 25 to 50 mg were given intravenously at the initiation of sedation. Sedation was maintained with repeated doses of 0.5 to 1.0 mg midazolam and 5 to 10 mg meperidine.
3090054|NCT01709474|Experimental|Vitamin D3 6000 IU|6000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose is reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
3090055|NCT01709474|Active Comparator|Vitamin D3 400 IU|400 IU/day of vitamin D3 by mouth daily.
3090056|NCT01709500|Experimental|Alirocumab 75 mg/up to 150 mg|Alirocumab 75 mg every two weeks (Q2W) added to stable dose of statin with or without LMT for 78 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL at Week 8.
3090057|NCT01709500|Placebo Comparator|Placebo|Placebo matched to alirocumab SC injection for 78-week treatment duration.
3090058|NCT01709513|Other|Atorvastatin (statin rechallenge arm)|Atorvastatin 20 mg over-encapsulated tablets orally once daily (QD) for 24 weeks and placebo (for alirocumab) subcutaneous (SC) injection every two weeks (Q2W) for 24 weeks added to stable lipid-modifying therapy (LMT).
3090059|NCT01709513|Active Comparator|Ezetimibe|Ezetimibe 10 mg over-encapsulated tablets orally QD for 24 weeks and placebo (for alirocumab) SC injection Q2W for 24 weeks added to stable LMT.
3090060|NCT01709513|Experimental|Alirocumab 75 mg/ up to 150 mg|Alirocumab 75 mg SC injection Q2W for 24 weeks and placebo (for atorvastatin/ezetimibe) over-encapsulated tablets orally QD for 24 weeks added to stable LMT. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on cardiovascular risk.
3090061|NCT01709578|Placebo Comparator|Placebo q2w|Placebo matched to sarilumab once every 2 weeks (q2w) was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3090062|NCT01709578|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3090063|NCT01709578|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg q2w was added to one or a combination of the nonbiologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide), except for simultaneous combination use of leflunomide and methotrexate for 24 weeks.
3090064|NCT01709695|Experimental|guanfacine hydrochloride XR|Flexible dose titration of guanfacine extended release (Intuniv; active medication). The medication is titrated in doses from 1 - 4 mg once daily
3090065|NCT01709695|Placebo Comparator|Placebo Group|Flexible dose titration of placebo
3090066|NCT01709708|Active Comparator|Marcaine|Group A will receive treatment with 0.3 mL of 0.5% Marcaine delivered bilaterally with the Tx360™ device to the mucosa associated with the Sphenopalatine Ganglion (SPG)
3090067|NCT01709708|Placebo Comparator|Saline|Group B will receive saline placebo delivered bilaterally with the Tx360TM device to the mucosa associated with the SPG.
3090068|NCT01709721|Experimental|Hydromorphone Hydrochloride (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride for the duration of therapy.
3090069|NCT01709721|Active Comparator|Hydromorphone Hydrochloride Titrated Downward/Control (Randomized/Double-Blind)|Subjects on hydromorphone hydrochloride titrated downward
3090070|NCT01709747|Experimental|Hydromorphone Hydrochloride|Hydromorphone hydrochloride for intrathecal administration, 12 months safety evaluation
3090071|NCT01709786||Patients with Suspected Hemorrhage|There is a single group of patients in this study -- those with suspected hemorrhage who satisfy the inclusion and exclusion criteria. The same set of measurements will be take from each patients and those measurements will be compared with one another to determine accuracy.
3090072|NCT01709799|Experimental|Cognitive Training plus Exercise|"Physical exercise will be achieved using traditional methods of aerobic exercise. Participants may choose between walking on a treadmill or riding on a stationary bike (Choices include recumbent or traditional sit-up bike.)~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
3090073|NCT01709799|Active Comparator|Cognitive Training plus Exergames|"Physical exercise in this group will be achieved using the Nintendo Wii Sports Resort and Wii Sports video games. A standardized gaming plan will be used for all participants, with play starting at 15 mins. and increasing 5 mins each week after, up to a maximum of 40 play minutes.~Every 4th week, participants will add 80mins./day of Insight gaming for cognitive training."
3090074|NCT01709799|Active Comparator|Cognitive Training|Participants will complete 80 mins/day during the 4th, 8th, 12th and 16th weeks of the intervention.
3090075|NCT01709838|Other|Deferasirox|All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
3090076|NCT01709864|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3090077|NCT01709864|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.
3090078|NCT01709903|Experimental|QVA149|QVA149 110/50 µg o.d., delivered via a single-dose dry powder inhaler (SDDPI), consisting of a fixed dose combination of indacaterol 110µg and NVA237 50µg
3090079|NCT01709903|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol 500/50 µg b.i.d., delivered via a dry powder inhaler Accuhaler® device
3090080|NCT01709981|Experimental|Colchicine|1.2mg colchicine 1 to 2 hours prior PCI, followed by 0.6mg one hour later
3090081|NCT01709981|Placebo Comparator|Placebo|Placebo 1-2 hours prior PCI, followed by placebo 1 hour later
3090082|NCT01710020|Experimental|CP-690,550|
3090083|NCT01710033|Placebo Comparator|Placebo|
3090084|NCT01710033|Experimental|CP-690,550 5 mg BID|
3090085|NCT01710033|Experimental|CP-690,550 15 mg BID|
3090086|NCT01710033|Experimental|CP-690,550 30 mg BID|
3090087|NCT01710046|Experimental|Cohort 1|
3090088|NCT01710046|Experimental|Cohort 2|
3090089|NCT01710137|Active Comparator|Varenicline|"12 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
3090090|NCT01710137|Placebo Comparator|Placebo|"12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally"
3090091|NCT01710254|Experimental|Regadenoson MRI|Participants with AF receiving regadenoson stress MRI, using Gadobenate dimeglumine
3090092|NCT01710306|No Intervention|Outreach|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: existing OEF/OIF/OND outreach. VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
3090093|NCT01710306|Experimental|Nurse Care Manager (NCM)|To evaluate and test differences in VA mental health care engagement for those who screen positive for PTSD by randomly assigned route: Study concierge nurse case manager (NCM). VA mental health care engagement is defined as participation in any of the following: PTSD psychotherapy, cognitive processing therapy, or prolonged exposure therapy.
3090094|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x4)|2 mg / Intravitreal / every 1 month x 3 months and at month 4 (Drug administered 4 times).
3090095|NCT01710332|Experimental|Intravitreal Aflibercept Injection (x6)|2 mg / Intravitreal / every 1 month x 6 months ((Drug administered 6 times).
3090096|NCT01710345|Experimental|Sufentanil NanoTab 20 mcg|Sufentanil NanoTab 20 mcg as needed every 60 minutes for 12 hours
3090097|NCT01710345|Experimental|Sufentanil NanoTab 30 mcg|Sufentanil NanoTab 30 mcg as needed every 60 minutes for 12 hours
3090098|NCT01710345|Placebo Comparator|Placebo NanoTab|Placebo NanoTab as needed every 60 minutes for 12 hours
3090099|NCT01710358|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50.~At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3090100|NCT01710358|Experimental|Baricitinib|"Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50.~Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3090101|NCT01710358|Active Comparator|Adalimumab|"Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52.~Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52.~Participants continued to take background methotrexate (MTX) therapy throughout study."
3090102|NCT01710501|Experimental|Grazoprevir 25 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 25 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by Response Guided Therapy (RGT). Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their Hepatitis C virus ribonucleic acid (HCV RNA) level at Treatment Week (TW) 4.
3090103|NCT01710501|Experimental|Grazoprevir 50 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 50 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
3090104|NCT01710501|Experimental|Grazoprevir 100 mg + PEG-IFN + RBV|After a maximum of a 45 day screening window, randomized participants receive 100 mg grazoprevir in combination with PEG-IFN and RBV for 12 weeks followed by 24 weeks of follow-up as determined by RGT. Participants may receive an additional 12 weeks of PEG-IFN plus RBV depending on their HCV RNA level at TW 4.
3090105|NCT01710514|Active Comparator|FE 999913 100 mg BID|FE 999913 100 mg vaginal tablet BID
3090106|NCT01710514|Active Comparator|FE 999913 100 mg TID|FE 999913 100 mg vaginal tablet TID
3090107|NCT01710527|Other|Metformin 500mg|Cross over, two treatment, two period, two sequence, cross over, single dose
3090108|NCT01710527|Other|Glucophage 500mg|Cross over, two treatment, two period, two sequence, sigle dose
3090109|NCT01710657|Placebo Comparator|Placebo|Matching placebo for 16 weeks.
3090110|NCT01710657|Experimental|Lacosamide 200 mg/day|Lacosamide treatment of 200 mg/day (100 mg bid (twice daily)) for 16 weeks.
3090111|NCT01710657|Experimental|Lacosamide 400 mg/day|Lacosamide treatment of 400 mg/day (200 mg bid (twice daily)) for 16 weeks.
3090112|NCT01710709|Experimental|Experimental|Aripiprazole, Intramuscular (IM) Depot
3090113|NCT01710787|Experimental|Kovacaine Mist, 3 sprays unilateral|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
3090114|NCT01710787|Experimental|Tetracaine Only, 3 sprays unilateral|Tetracaine HCl 3%
3090115|NCT01710787|Placebo Comparator|Placebo, 3 sprays unilateral|Placebo
3090116|NCT01710800|Placebo Comparator|Placebo arm|Patients will be randomized to receive either PPI or placebo and then undergo a 24 hour pH study with impedance to measure the number of reflux episodes
3090117|NCT01710800|Active Comparator|Esomeprazole|Patients were randomly assigned to receive 40 mg esomeprazole twice daily prior to undergoing a 24 hour pH study with impedance to measure the number of reflux episodes
3090118|NCT01710839|Experimental|Targeted Pan Retinal laser combined with 0.5mg ranibizumab|Cohort 1 (n=24), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses of 0.5 mg ranibizumab followed by PRN treatment with ranibizumab 0.5 mg; after receiving the first loading dose of ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) based on 200° wide field angiography with possibility of a second session of TRP at M4/M7, if non-perfusion persists based on angiogram.The 200°wide field angiography will indicate areas of peripheral ischemia which will be selectively treated, preserving areas of more perfused retina.
3090119|NCT01710839|Active Comparator|Ranibizumab 0.5mg|Cohort 2 (n=6), previously treated with at least 2 consecutive or more intravitreal injections of any anti-VEGF agent with persistent or recurrent macular edema will receive 6 loading doses followed by PRN monthly treatment with ranibizumab 0.5 mg.
3090120|NCT01710891|Active Comparator|Direct Laryngoscopy|Patients will undergo their first intubation attempt with direct laryngoscopy using the CMAC device without video assistance. The video monitor with be covered with a hood.
3090121|NCT01710891|Experimental|CMAC|Patients will undergo their first intubation attempt using the CMAC videolaryngoscope using video assistance
3090122|NCT01711177|Sham Comparator|Normal control|Normal patient placebo
3090123|NCT01711177|Sham Comparator|Glaucoma suspect|Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
3090124|NCT01711177|Experimental|Newly diagnosed glaucoma|Treated with Travoprost (0.04%)
3090125|NCT01711216||women received dydrogesterone for irregular menstrual cycle|Adult women received dydrogesterone for irregular menstrual cycle as per standard clinical practice of the treating physician
3090126|NCT01711294|Active Comparator|19 G Flex Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G Flex)
3090127|NCT01711294|Active Comparator|22 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (22 G)
3090128|NCT01711294|Active Comparator|19 G Needle|Device: Expect™ Endoscopic Ultrasound Aspiration Needle (19 G)
3090129|NCT01711359|Experimental|Baricitinib + MTX|Baricitinib 4 milligram (mg) administered orally once daily through Week 52. Participants received methotrexate (MTX) orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3090130|NCT01711359|Experimental|Baricitinib|Baricitinib 4 mg administered orally once daily through Week 52. Participants received MTX placebo orally once weekly through Week 52. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3090131|NCT01711359|Active Comparator|MTX|MTX administered orally once weekly with dose ranging from 10 to 20 mg per week through Week 52. Participants also received baricitinib placebo orally once daily. Starting at Week 24, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily and MTX orally once weekly.
3090132|NCT01711372|Placebo Comparator|Controls who played Groundskeeper game|Controls played a go/no go task on Sifteo cubes to asses for attentional capabilities.
3090133|NCT01711372|Active Comparator|Probands played groundskeeper game|Patients with ADHD played a go/no go task on Sifteo cubes to asses for attentional capabilities
3090134|NCT01711424||OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
3090135|NCT01711541|Experimental|Arm I (veliparib, combination chemotherapy)|Patients receive veliparib PO BID on days 1-7, paclitaxel IV over 60 minutes on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then continue on to concomitant chemoradiotherapy.
3090136|NCT01711541|Experimental|Arm II (placebo, combination chemotherapy)|Patients receive placebo PO BID on days 1-7. Patients also receive paclitaxel and carboplatin as in Phase I. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Within 10 days from completion of course 2, patients begin concomitant chemoradiotherapy.
3090137|NCT01711619|Experimental|SQS plus OMM|subcutaneous nerve stimulation plus optimized medical management
3090138|NCT01711619|Active Comparator|OMM|optimized medical management
3090139|NCT01711645|Experimental|Adacel® Tdap vaccine|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
3090140|NCT01711658|Placebo Comparator|IMRT + cisplatin + placebo|Intensity Modulated Radiation Therapy (IMRT) with cisplatin and placebo
3090141|NCT01711658|Active Comparator|IMRT + cisplatin + lapatinib|IMRT with cisplatin and lapatinib
3090142|NCT01711736|Experimental|GSK2282512A Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of quadrivalent influenza GSK2282512A vaccine.~Quadrivalent influenza GSK2282512A vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
3090143|NCT01711736|Active Comparator|Fluarix Group|"Subjects aged between 6 to 35 months inclusive received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluarix vaccine.~Fluarix vaccine was administered intramuscularly in the left anterolateral thigh (subjects < 12 months of age) or the deltoid muscle (subjects ≥ 12 months of age)."
3090144|NCT01711853|Experimental|Dabigatran Etexilate|patient to receive a capsule containing 75 mg of dabigatran etexilate
3090145|NCT01711866|Experimental|Rotigotine|"First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.~Subjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.~Subjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
3090146|NCT01711879|Active Comparator|Aflibercept with Laser|A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks
3090147|NCT01711879|Experimental|Aflibercept|2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks.
3090148|NCT01711918|Experimental|Domperidone|Participants will received domperidone at a dose of 10mg given up to three times per day
3090149|NCT01711983|Experimental|Test Device|ASD closure with the GORE® CARDIOFORM Septal Occluder
3090150|NCT01712009|Experimental|Prophylactic naproxen|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic naproxen 500 mg orally twice a day (BID) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
3090151|NCT01712009|Experimental|Prophylactic loratadine|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis in addition to prophylactic loratadine 10 mg once a day (QD) for 5 days in each of the 4 cycles, beginning on the day of pegfilgrastim administration.
3090152|NCT01712009|Other|No prophylactic treatment|Participants received adjuvant or neoadjuvant chemotherapy with pegfilgrastim prophylaxis.
3090153|NCT01712061|Active Comparator|Arm 1 PF-04634817|
3090154|NCT01712061|Placebo Comparator|Arm 2 Placebo|
3090155|NCT01712074|Experimental|30 mg QD of PF-05212377|
3090156|NCT01712074|Placebo Comparator|Placebo|
3090157|NCT01712178|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
3090158|NCT01712178|Active Comparator|Current formulation adalimumab 40 mg every other week|Current formulation adalimumab 40 mg every other week
3090159|NCT01712204|Placebo Comparator|Placebo|Placebo plus Febuxostat
3090160|NCT01712204|Experimental|AC-201|AC-201 plus Febuxostat
3090161|NCT01712230|Placebo Comparator|Placebo|Monthly placebo injections for 6 months
3090162|NCT01712230|Active Comparator|GnRH agonist|Monthly GnRH agonist injections for 6 months
3090163|NCT01712230|Active Comparator|GnRH agonist + exercise|Monthly GnRH agonist injections for 6 months plus supervised cardiovascular exercise intervention
3090164|NCT01712256|Experimental|Re-boosting with Vacc-4x|Intradermal Vacc-4x (1.2 mg) given with Leukine® (rhu-GM-CSF) (0.06 mg) at day 1 and day 15.
3090165|NCT01712334|Experimental|eRapid Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari eRapid nebulizer for 2 weeks.
3090166|NCT01712334|Active Comparator|Jet Nebulizer|Dornase alfa (Pulmozyme®) inhaled once daily by the Pari LC Plus jet nebulizer for 2 weeks.
3090167|NCT01712360|Experimental|NAFT500 (pediatric)|Topical once a day for two weeks
3090168|NCT01712360|Experimental|NAFT600 (pediatric)|Topical once a day for two weeks
3090169|NCT01712360|Experimental|NAFT500 (adult)|Topical once a day for two weeks
3090170|NCT01712360|Experimental|NAFT600 (adult)|Topical once a day for two weeks
3090171|NCT01712399|Experimental|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years.
3090172|NCT01712438|Experimental|Human cl rhFVIII|
3090173|NCT01712490|Experimental|A + AVD|A+AVD consists of brentuximab vedotin (ADCETRIS®) 1.2 milligram per kilogram (mg/kg) plus doxorubicin 25 milligram per square meter (mg/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
3090174|NCT01712490|Active Comparator|ABVD|ABVD consists of doxorubicin 25 mg/m^2, bleomycin 10 units per square meter (units/m^2), vinblastine 6 mg/m^2, and dacarbazine (DTIC) 375 mg/m^2.
3090175|NCT01712516|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) Single Dose Dry Powder Inhaler (SDDPI
3090176|NCT01712516|Active Comparator|QAB149|27.5 ug b.i.d.
3090177|NCT01712516|Active Comparator|NVA237|12.5 ug b.i.d.
3090178|NCT01712516|Placebo Comparator|Placebo|b.i.d.
3090179|NCT01712685|Experimental|Renal Cell Carcinoma|
3090180|NCT01712711|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3090181|NCT01712711|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3090182|NCT01712776|Active Comparator|Vapocoolant (Pain Ease Medium Stream )|Application of Vapocoolant (Pain Ease Medium Stream) for 4-10 seconds onto venipuncture site.
3090183|NCT01712776|Placebo Comparator|Nature's Tears Sterile Water|Application of sterile water stream (nature's tears) for 4-10 seconds onto the venipuncture site.
3090184|NCT01712984|Experimental|QIV ID Vaccine Group|Participants will receive the intradermal quadrivalent influenza vaccine
3090185|NCT01712984|Active Comparator|TIV ID1 Vaccine Group|Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage
3090186|NCT01712984|Active Comparator|TIV ID2 Group|Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage
3090187|NCT01713036|Experimental|Pimasertib|
3090188|NCT01713283|Experimental|SOF+RBV 12 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 12 weeks.
3090189|NCT01713283|Experimental|SOF+RBV 24 Weeks|Treatment-naive and treatment-experienced participants will receive SOF+RBV for 24 weeks.
3090190|NCT01713348|Experimental|CGM - intervention arm|Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator with the glucose alarms switched off.
3090191|NCT01713348|Active Comparator|SMBG - Control arm|Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study.
3090192|NCT01713400|Experimental|Ustekinumab|Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
3090193|NCT01713400|Placebo Comparator|Placebo|Placebo, Tacrolimus, and Sirolimus. Placebo: Identical volume to that of ustekinumab. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
3090194|NCT01713530|Experimental|IDegAsp BID+/-OADs|
3090195|NCT01713530|Experimental|IDeg OD plus IAsp +/-OADs|
3090196|NCT01713582|Experimental|AL 10 mg QD 14-21|Participants received 10 mg birabresib/OTX015 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 14 of a 21-day cycle.
3090197|NCT01713582|Experimental|AL 20 mg QD 14-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090198|NCT01713582|Experimental|AL 40 mg QD 14-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090199|NCT01713582|Experimental|AL 20 mg BID 21-21|Participants received 20 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
3090200|NCT01713582|Experimental|AL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090201|NCT01713582|Experimental|AL 40 mg BID 14-21|Participants received 40 mg birabresib/OTX015 administered PO, twice a day (BID), with the first daily dose in a fasted state, on Days 1 to 14 of a 21-day cycle.
3090202|NCT01713582|Experimental|AL 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090203|NCT01713582|Experimental|AL 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090204|NCT01713582|Experimental|AL 160 mg QD 14-21|Participants received 160 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090205|NCT01713582|Experimental|AML de novo 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090206|NCT01713582|Experimental|AML/MDS 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090207|NCT01713582|Experimental|OHM 10 mg QD 21-21|Participants received 10 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090208|NCT01713582|Experimental|OHM 20 mg QD 21-21|Participants received 20 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090209|NCT01713582|Experimental|OHM 40 mg QD 21-21|Participants received 40 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090210|NCT01713582|Experimental|OHM 80 mg QD 21-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090211|NCT01713582|Experimental|OHM 40 mg BID 21-21|Participants received 40 mg birabresib/OTX015 administered PO, BID, with the first daily dose in a fasted state, on Days 1 to 21 of a 21-day cycle.
3090212|NCT01713582|Experimental|OHM 120 mg QD 21-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 21 of a 21-day cycle.
3090213|NCT01713582|Experimental|OHM 120 mg QD 14-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090214|NCT01713582|Experimental|OHM 120 mg QD 5-7|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 5 of a 7-day cycle.
3090215|NCT01713582|Experimental|OHM 120 mg QD 7-21|Participants received 120 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 7 of a 21-day cycle
3090216|NCT01713582|Experimental|OHM/DLBCL 80 mg QD 14-21|Participants received 80 mg birabresib/OTX015 administered PO, QD, in a fasted state on Days 1 to 14 of a 21-day cycle.
3090217|NCT01713608|Experimental|OZ439 Dose level 1 (300mg)|• Cohort 1 (12 subjects: 8 Active [A] and 4 on Placebo [P]) Active dose will consist of 300mg OZ439 drinking solution administered once daily for 3 days
3090218|NCT01713608|Experimental|OZ439 Dose level 2|• Cohort 2 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
3090219|NCT01713608|Experimental|OZ439 dose level 3|Cohort 3 (12 subjects: 8 A, 4P). Subjects on active will receive X amount of OZ439 (dose level to be determined based on safety and tolerability of previous dose level) drinking solution once daily for 3 days
3090220|NCT01713621|Experimental|OZ439 100mg|Single dose of 100mg of OZ439 administered as an oral suspension
3090221|NCT01713621|Experimental|OZ439 500mg|Single dose of 500mg of OZ439 administered as an oral suspension
3090222|NCT01713660|Other|FS Corneal Incisions|
3090223|NCT01713686|Experimental|Ulthera System Treatment|A single triple-depth Ulthera System treatment of the decolletage delivering treatment at 4.5mm, 3.0mm and 1.5mm depths.
3090224|NCT01713868|Other|Safe Sleep Edu and Breastfeeding mHealth|Participants will receive Safe Sleep Nursery Education and Breastfeeding Mobile Health messaging
3090225|NCT01713868|Other|Breastfeeding Edu and Safe Sleep mHealth|Participants will receive the Breastfeeding Nursery Education and the Safe Sleep Mobile Health messaging
3090226|NCT01713868|Other|Safe Sleep Edu and Safe Sleep mHealth|Participants will receive Safe Sleep Nursery Education and Safe Sleep Mobile Health messaging
3090227|NCT01713868|Other|Breastfeed Edu and Breastfeed mHealth|Participants will receive Breastfeeding Nursery Education and Breastfeeding Mobile Health messaging
3090228|NCT01713933|Experimental|Ultherapy™ treatment|Each enrolled subject will receive a bilateral Ultherapy™ treatment of the upper arms
3090229|NCT01713946|Experimental|Everolimus LT target of 3 - 7 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.
3090230|NCT01713946|Experimental|Everolimus HT target of 9 -15 ng/mL|Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.
3090231|NCT01713946|Placebo Comparator|Placebo|Participants received placebo plus 1 to 3 antiepileptic drugs.
3090232|NCT01713998|Active Comparator|Group A|Subjects will receive an increased density Ulthera System Treatment over the full face but with the energy turned down to the second highest level of four possible energy settings on one side of the face.
3090233|NCT01713998|Active Comparator|Group B|Subjects will receive an increased density guideline Ulthera System Treatment over the full face but with the energy turned down to the lowest level of four possible energy settings on one side of the face.
3090234|NCT01713998|Active Comparator|Group C|Subjects will receive an increased density guideline Ulthera System Treatment over the full face with the exception that a 4 MHz transducer will be used on the upper face in place of a7 MHz transducer, with the energy turned down to the lowest level of four possible energy settings.
3090235|NCT01714024|Experimental|Healthy Volunteers|Subjects who are non-diabetic, with no history of smoking within the past two years and no metabolic bone disease diagnosis.
3090236|NCT01714024|Experimental|Diabetic Subjects|Subjects must have Type 2 diabetes mellitus as diagnosed by a physician or in medication history. The condition must be currently diagnosed and treated by medications and/or insulin.
3090237|NCT01714024|Experimental|Osteopenic Subjects|Subjects must be diagnosed with osteoporosis or osteopenia and must be currently under the care of a physician and treatment with oral bisphosphonates
3090238|NCT01714063||Age 5-6.5|Group 1 will consist of 16 children aged 5-6.5 years
3090239|NCT01714063||Aged 6.6- 8 years|Group 2 will consist of 16 children aged 6.6- 8 years
3090240|NCT01714232|Experimental|Study Staff Test BGMSs|All testing and lancing were performed by the study staff; subjects did not perform any lancing or self-testing in this study. Study Staff lanced the fingers of subjects and tested the blood samples using five Blood Glucose Monitoring Systems (BGMS): Contour® PLUS BGMS; OneTouch® SelectSimple™ BGMS; Accu-Chek® Performa BGMS; Accu-Chek® Active BGMS; Freestyle Freedom® BGMS.
3090241|NCT01714310|Experimental|Adjunctive fluoxetine|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive fluoxetine at end of study week 4.
3090242|NCT01714310|Placebo Comparator|Adjunctive placebo|Participants previously titrated with open-label lisdexamfetamine randomized to adjunctive placebo at end of study week 4.
3090243|NCT01714310|Other|Open Lisdexamfetamine Titration|All participants initially titrated with open-label lisdexamfetamine from baseline to end of study week 4.
3090244|NCT01714323|Other|Standard care|At discharge, the participant receives the standard care provided by the hospital. This consists of a handout with information to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
3090245|NCT01714323|Experimental|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication and (2) Interactive Voice Response (IVR) Triage to Telephone Counseling.
3090246|NCT01714336|Placebo Comparator|placebo|Normal saline will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
3090247|NCT01714336|Active Comparator|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg each administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
3090248|NCT01714492||Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|subjects implanted with the Sigma Posterior Stabilizing Rotating Platform TKA including a polyethylene insert with 4 beads
3090249|NCT01714505|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3090250|NCT01714505|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. The subject will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3090251|NCT01714544|Experimental|Cloderm Cream|Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
3090252|NCT01714609|Placebo Comparator|Placebo|Subjects randomized to placebo will take two tablets of placebo by mouth twice daily.
3090253|NCT01714609|Experimental|Sorafenib|Subjects randomized to Sorafenib will take Sorafenib 400 mg by mouth twice daily.
3090254|NCT01714635|Experimental|Tecnis Multifocal Intraocular lens #1|A low diopter add multifocal intraocular lens
3090255|NCT01714635|Experimental|Tecnis Multifocal Intraocular Lens #2|A low diopter add multifocal intraocular lens
3090256|NCT01714635|Active Comparator|Monofocal Intraocular Lens|Commercially available monofocal intraocular lens (IOL)
3090257|NCT01714687|Active Comparator|balloon sinus dilation|Balloon sinus dilation will be conducted in-office under local anesthesia.
3090258|NCT01714687|Active Comparator|medical therapy|Medical therapy as needed per subject's specific disease and as determined by the investigators' clinical judgment.
3090259|NCT01714726|Experimental|1|MEDI2070 iv infusion
3090260|NCT01714726|Placebo Comparator|2|placebo iv infusion
3090261|NCT01714726|Experimental|open-label|MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
3090262|NCT01714804|Experimental|Prospective|Accell Evo3
3468919|NCT03891082|Active Comparator|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border.The absorbable suture is fed posteriorly and vertically to enter the posterior wall of the uterine cavity at the same level as the upper anterior entry point.
3468920|NCT03891082|Active Comparator|Bakri balloon|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium.
3090265|NCT01714921||ICD patients|Patients with an indication for an ICD implantation according to the guidelines treated with a Protecta™, Protecta™ XT or any equivalent following product
3090266|NCT01714947|Experimental|Alisertib|"Part A: [^14C]-alisertib 35 mg, oral solution containing 80 - 100 microcuries (μCi) of total radioactivity (1.19 - 1.48 mCi/mmol), orally, single dose on Day 1.~Part B: Alisertib 50 mg, enteric coated tablets, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 3 Cycles)."
3090267|NCT01715064|No Intervention|Control|non-exercise control consisting of movie watching.
3090268|NCT01715064|Experimental|Exercise|1 hour of moderate intensity exercise.
3090269|NCT01715129|Experimental|11.25mg|11.25mg, SC on Day 1 and Day 92
3090270|NCT01715207|Experimental|Atenolol & Aliskiren|Atenolol tablet and Aliskiren 150mg or 300mg tablet by mouth per day for 6month
3090271|NCT01715207|Other|Atenolol|Atenolol tablet(Negative controls, Open-label)
3090272|NCT01715233|Experimental|Metastatic Esophageal, Gastroesophageal & Gastric Cancer|Participants receive Modified Docetaxel 40mg/m2, Leucovorin 400mg/m2 and Fluorouracil 400mg/m2 on day 1, Fluorouracil 1000mg/m2 per day on days 1 and 2 and Cisplatin 40mg/m2 (or Carboplatin) on day 3 in Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.
3468921|NCT03891095|Experimental|Intranasal oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)
3090275|NCT01715298|Experimental|NVA237|NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3090276|NCT01715298|Placebo Comparator|Placebo|Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks
3090277|NCT01715415|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3090278|NCT01715415|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3090279|NCT01715571|Experimental|Viberect treatment|Participants in this arm have documented mild to moderate ED of organic etiology and will be given the Viberect device for 4 weeks of daily home use in preparation for sexual activity. Men will be asked to use the device and attempt sexual intercourse at least 3 times weekly
3090280|NCT01715805|Other|Placebo + ADT Lead-in|Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
3090281|NCT01715805|Placebo Comparator|Placebo + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
3090282|NCT01715805|Experimental|Cariprazine + ADT (Double-Blind)|Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
3090283|NCT01715805|Other|Placebo + ADT (Continued Treatment)|Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
3090284|NCT01715831|Experimental|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.
3090285|NCT01715857||Chinese Patients Requiring Surgery with Sevoflurane Anesthesia|Participants who were scheduled for surgery requiring sevoflurane anesthesia with endotracheal intubation or laryngeal mask airway (LMA) per approved product information of sevoflurane in China
3090286|NCT01715883|Experimental|Sodium Nitrite|"Sodium Nitrite will be administered at three time points:~At the time of organ procurement, a pre-prepared syringe of sodium nitrite will be added to each of the 2.8 liter bags of Perfadex solution to flush the donor lungs.~At the time of transplant just prior to reperfusion of lungs, the donor lungs are flushed with a cold pneumoplegia solution after the bronchial (1st) anastomosis and with warm pneumoplegia solution after the portal vein (3rd, last) anastomosis. The drug will be added to pneumoplegia solution just prior to both the flushes.~Sodium Nitrite will be delivered intravenously to the recipient immediately prior to lung reperfusion as a single infusion at rate of 4 mL/min for the first 30 min, followed by 2.2 mL/min for the next 60 min."
3090287|NCT01715896|Experimental|Golimumab 50 mg alternating with Placebo|Participants received alternating doses of golimumab 50 milligram (mg) (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3090288|NCT01715896|Experimental|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
3090289|NCT01715948|Experimental|CROS hearing aid|The CROS uses two hearing aids that fit behind each ear. The hearing aid fitted with a retainer earhook on the side of the poor ear houses a microphone and a transmitter. The hearing aid fitted on the normal ear side houses a receiver that is connected to a slim tube and open ear tip. The CROS does not amplify sound but rather transmits sound from the side of the unaidable ear to the contralateral ear, overcoming the head shadow effect that presents with SSD.
3090290|NCT01715948|Experimental|Bone-anchored hearing device (BAHD)|The BAHD (such as the Baha by Cochlear or Bone-Bridge by MED-EL) also helps to alleviate the negative effect of head shadow and the difficulty with speech perception in noise that present with SSD. Also known as an osseointegrated aural prosthesis, the BAHD is implanted in individuals with SSD to stimulate the ear with the normal cochlea. The BAHD requires that a titanium screw be surgically implanted in the temporal bone on the side of the poor ear. This titanium screw is connected to a percutaneous abutment. An electromechanical sound processor (external transducer) is coupled onto the abutment and can be removed when necessary. Sound can now be routed to the better ear by transcranial bone conduction.
3090291|NCT01716013|Experimental|BondEase|Topical Skin Adhesive
3090292|NCT01716013|Active Comparator|CWCD|Conventional Wound Closure Devices (CWCD) including: sutures, staples, or adhesive strips
3090293|NCT01716039|Active Comparator|MTX 12.5|Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
3090294|NCT01716039|Active Comparator|MTX 25 mg|Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
3090295|NCT01716039|Placebo Comparator|Placebo|Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab
3090296|NCT01716104|Experimental|Afalaza (2 tablets twice a day)|
3090297|NCT01716104|Placebo Comparator|Placebo (2 tablets twice a day)|
3090298|NCT01716117|Experimental|Surpass Flow Diverter|The objective of this study is to determine the safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in the internal carotid artery up to the terminus.
3090299|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 12 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 12 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 12 weeks. Participants with detectable HCV RNA at TW4 received an additional 12 weeks of study therapy for a total of 24 weeks of treatment.
3090300|NCT01716156|Experimental|Grazoprevir 100 mg + RBV 24 Weeks|Grazoprevir 100 mg tablet once per day by mouth for 24 weeks and RBV capsules twice per day by mouth at a total daily dose from 800 to 1400 mg based on participant weight for 24 weeks.
3090301|NCT01716169|Experimental|Helicoll|"Helicoll will be applied to one chronic wound (approximately 6 months or more duration).~Wound designations of control or Helicoll were placed in a sealed envelope prior to study start. When a subject was enrolled, wounds were identified as A or B. Then the envelope was opened which designated whether A or B would receive control or Helicoll."
3090302|NCT01716195|Experimental|Response Adapted Chemoradiation|Paclitaxel 175 mg/m2 + Carboplatin area under curve (AUC) 6 followed by response adapted Radiation Therapy (5 - 6 weeks) + Paclitaxel
3090303|NCT01716208|Experimental|Ofatumumab + Fresh Frozen Plasma|Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).
3090304|NCT01716221|Experimental|Bupropion & Citalopram|100mg Bupropion & 20mg Citalopram taken orally one time per day or 100mg Bupropion & 10mg Citalopram taken orally one time per day or 50mg Bupropion & 20mg Citalopram taken orally one time per day 0r 50mg Bupropion & 10mg Citalopram taken orally one time per day
3090305|NCT01716221|Active Comparator|Bupropion & Placebo|100mg Bupropion & Placebo taken orally one time per day or 50mg Bupropion & Placebo taken orally one time per day
3090306|NCT01716221|Active Comparator|Placebo & Citalopram|Placebo & 20mg Citalopram taken orally one time per day or Placebo & 10mg Citalopram taken orally one time per day
3090307|NCT01716221|Placebo Comparator|Placebo & Placebo|Placebo & Placebo taken orally one time per day
3090308|NCT01716234|Experimental|POS 12 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3090309|NCT01716234|Experimental|POS 12 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3090310|NCT01716234|Experimental|POS 18 BID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3090311|NCT01716234|Experimental|POS 18 BID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) until recovery from neutropenia or up to 28 days.
3090312|NCT01716234|Experimental|POS 18 TID 2 to <7 Years|Participants aged 2 to <7 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3090313|NCT01716234|Experimental|POS 18 TID 7 to <18 Years|Participants aged 7 to <18 years received posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3090314|NCT01716234|Experimental|POS 12 TID 3 months to <2 Years|Participants aged 3 months to <2 years received posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) until recovery from neutropenia or up to 28 days.
3090315|NCT01716455|Experimental|SSP-004184 (Mild Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3090316|NCT01716455|Experimental|SSP-004184 (Moderate Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3090317|NCT01716455|Experimental|SSP-004184 (Severe Renal Impairment)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3090318|NCT01716455|Experimental|SSP-004184 (End Stage Renal Disease)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3090319|NCT01716455|Experimental|SSP-004184 (Healthy Elderly Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1
3090320|NCT01716455|Experimental|SSP-004184 (Matched Healthy Subjects)|All subjects will take a single dose of SSP-004184 (75 mg/kg, oral capsule) on Day 1. Healthy subjects matched to renally impaired subjects in arms 1 through 4. (Note: One healthy subject can match more than one renally impaired subject.)
3090321|NCT01716468|Other|Advanced or metastatic cancer|Patients chosen must be diagnosed with advanced or metastatic cancer of the following tumor types (colorectal, prostate, brain, breast, pancreatic, hepatobiliary, melanoma, sarcoma, non-small cell /small cell lung, genitourinary cancers).All participants will be assigned to a ketogenic diet. There are no randomization to other separate arms since this is a safety and feasibility study.
3090322|NCT01716520|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3090323|NCT01716520|Experimental|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3090324|NCT01716520|Experimental|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
3090325|NCT01716533|Other|Recurrence group|Male or female subjects aged 18 years or older at the time of enrollment, who experienced recurrence of Clostridium difficile infection (CDI) after clinical response to antibiotic treatment to treat the initial CDI episode.
3090326|NCT01716533|Other|Sustained response group|Male or female subjects aged 18 years or older at the time of enrollment, who did not experience recurrence of CDI after clinical response to the antibiotic treatment to treat the initial CDI episode.
3090327|NCT01716533|Other|Failure to antibiotic Group|Male or female subjects aged 18 years or older at the time of enrollment, withdrawn due to failure of antibiotic treatment to treat the initial CDI episode.
3090328|NCT01716533|Other|Unclassified Group|Male or female subjects aged 18 years or older at the time of enrollment, who couldn't be classified as sustained response, recurrence, or failure to antibiotic due to missing data.
3090329|NCT01716559||Cohort|
3090330|NCT01716585|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3090331|NCT01716585|Experimental|Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV|Double-blind placebo for 12 weeks, followed by open-label ABT-450/r/ABT-267 (150 mg/100 mg/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3090332|NCT01716663||Experimental: Catheter Ablation|These patients have drug refractory recurrent symptomatic paroxysmal AF, are 18 years and older, and are able and willing to provide written informed consent to participate in the study and comply with study requirements.
3090333|NCT01716715|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28.
3090334|NCT01716715|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
3090335|NCT01716754|Experimental|QGE031 240 mg every 2 weeks (q2w)|Participants received QGE031 240 mg subcutaneously (s.c.) q2w for 16 weeks.
3090336|NCT01716754|Experimental|QGE031 240 mg q4w|Participants received QGE031 240 mg s.c. q4w for 16 weeks.
3090337|NCT01716754|Experimental|QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
3090338|NCT01716754|Experimental|QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
3090339|NCT01716754|Experimental|QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
3090340|NCT01716754|Experimental|QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
3090341|NCT01716754|Active Comparator|Omalizumab (as per locally approved dosing table)|Participants received omalizumab as per locally approved dosing table s.c. q2w or q4w for 16 weeks.
3090342|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q2w|Participants received matching placebo to QGE031 240 mg s.c. q2w for 16 weeks.
3090343|NCT01716754|Placebo Comparator|Placebo to QGE031 240 mg q4w|Participants received placebo to QGE031 240 mg s.c. q2w for 16 weeks.
3090344|NCT01716754|Placebo Comparator|Placebo to QGE031 180 mg q2w|Participants received QGE031 180 mg s.c. q2w for 16 weeks.
3090345|NCT01716754|Placebo Comparator|Placebo to QGE031 120 mg q2w|Participants received QGE031 120 mg s.c. q2w for 16 weeks.
3090346|NCT01716754|Placebo Comparator|Placebo to QGE031 36 mg q2w|Participants received QGE031 36 mg s.c. q2w for 16 weeks.
3090347|NCT01716754|Placebo Comparator|Placebo to QGE031 12 mg q2w|Participants received QGE031 12 mg s.c. q2w for 16 weeks.
3090348|NCT01716754|Placebo Comparator|Placebo to omalizumab|Participants received placebo to omalizumab s.c. q2w or q4w for 16 weeks.
3090349|NCT01717001||ConforMIS|Patients with ConforMIS implants
3090350|NCT01717001||Standard Total Knee Implant|Patients implanted with standard total knee implant
3090351|NCT01717014|Experimental|Covidien Radial Reload Stapler with Tri-Staple Technology|Covidien Radial Reload Stapler with Tri-Staple Technology in open low anterior resection or anterior proctosigmoidectomy
3090352|NCT01717040|Experimental|Pioglitazone|
3090353|NCT01717040|Placebo Comparator|Placebo|
3090354|NCT01717053|Experimental|Abiraterone acetate|Abiraterone Acetate, Radiotherapy and Short Term Androgen Deprivation. Prednisone will be prescribed concurrently with Abiraterone acetate.
3090355|NCT01717209|Experimental|Combined nitric oxide and prostacyclin|iNO (20 ppm continuously) and iPGI2 (0.05 micrograms/kg/min continuously)
3090356|NCT01717287|Experimental|Raltegravir Film-coated Tablet|Raltegravir film-coated tablet 400 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
3090357|NCT01717287|Experimental|Raltegravir Chewable Tablet|Raltegravir chewable tablet weight-based dose up to 300 mg administered orally twice-daily, in combination with other anti-retroviral therapy for 24 weeks
3090358|NCT01717313|Experimental|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week for 24 weeks (Phase A) followed by omarigliptin 25 mg administered orally once a week plus placebo to metformin daily (Phase B). Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
3090359|NCT01717313|Placebo Comparator|Placebo to Omarigliptin|Placebo to omarigliptin administered orally once a week for 24 weeks (Phase A) followed by placebo to omarigliptin administered orally once a week plus metformin daily for an additional 30 weeks (Phase B). Open-label metformin was to be initiated for participants meeting protocol-specified glycemic criteria during Phase A, but was otherwise prohibited. Open-label glimepiride daily may be initiated as glycemic rescue therapy during Phase B.
3090360|NCT01717326|Experimental|A1: TN NC Grazoprevir 100 mg + Elbasvir 20 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally once daily (QD) for 12 weeks, Elbasvir 20 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally twice daily (BID) for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090361|NCT01717326|Experimental|A2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a and GT1b participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule and Placebo capsule orally QD for 12 weeks, RBV capsules orally BID for 24 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090362|NCT01717326|Experimental|A3: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1b only participants receive Grazoprevr 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3090363|NCT01717326|Experimental|B1: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090364|NCT01717326|Experimental|B2: TN NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090365|NCT01717326|Experimental|B3: TN NC/GT1a Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a only participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3090366|NCT01717326|Experimental|B4: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant
3090367|NCT01717326|Experimental|B5: TN C Grazoprevir 100 mg + Elbasvir 50 mg for 12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3090368|NCT01717326|Experimental|B6: TN C Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090369|NCT01717326|Experimental|B7: TN C Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
3090370|NCT01717326|Experimental|B8: NR Grazoprevir 100 mg + Elbasvir 50 mg +RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090371|NCT01717326|Experimental|B9: NR Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3090372|NCT01717326|Experimental|B10: NR Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090373|NCT01717326|Experimental|B11: NR Grazoprevir 100 mg + Elbasvir 50 mg-18 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks
3090374|NCT01717326|Experimental|B12: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090375|NCT01717326|Experimental|B13: TN HIV NC Grazoprevir 100 mg + Elbasvir 50 mg-12 wk|GT1a/non-a participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks
3090376|NCT01717326|Experimental|C1: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg + RBV-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks, Elbasvir 50 mg capsule orally QD for 8 weeks, and RBV capsules orally BID for 8 weeks at a total daily dose from 800 to 1400 mg based on participant weight.
3090377|NCT01717326|Experimental|C2: TN NC/GT1b Grazoprevir 100 mg + Elbasvir 50 mg-8 wk|GT1b participants receive Grazoprevir 100 mg tablet orally QD for 8 weeks and Elbasvir 50 mg capsule orally QD for 8 weeks
3090378|NCT01717326|Experimental|D1: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-12 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 12 weeks, Elbasvir 50 mg capsule orally QD for 12 weeks, and RBV capsules orally BID for 12 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090379|NCT01717326|Experimental|D2: TN NC/GT3 Grazoprevir 100 mg + Elbasvir 50 mg + RBV-18 wk|GT3 participants receive Grazoprevir 100 mg tablet orally QD for 18 weeks, Elbasvir 50 mg capsule orally QD for 18 weeks, and RBV capsules orally BID for 18 weeks at a total daily dose from 800 to 1400 mg based on participant weight
3090380|NCT01717391|Experimental|Fluorothymidine F 18 PET/CT|Fluorothymidine F 18 (FLT) PET/CT imaging ordered pre-radiation therapy, during weeks 1 and 2 of radiation therapy, and then at 1 month and 12 months after radiation therapy. The FLT PET/CT imaging ordered pre-radiation therapy is used for bone marrow sparing IMRT radiation therapy.
3090381|NCT01717456|Active Comparator|Educational-Medical-Behavioral|Educational-Medical-Behavioral intervention includes education, fiber supplements [Metamucil 1-4 packets (3.4-13.6 g)/day], laxatives or anti-diarrheals [Miralax 1-2 packets (17-34 g)/day or Imodium 0.5-2 tablets (1-4 mg)/day], pelvic floor muscle exercises [100 10-second squeezes/day], tips on how to prevent fecal incontinence, daily diary, and protective pads or garments [as needed].
3090382|NCT01717456|Placebo Comparator|Standard Care|Standard care includes fiber supplements 1-4 packets (3.4-13.6 g)/day], daily diary, and protective pads or garments [as needed].
3090383|NCT01717638|Experimental|B+R246_12_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090384|NCT01717638|Experimental|B+R246_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090385|NCT01717638|Experimental|B+R246_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 4 and 6 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090386|NCT01717638|Experimental|B246_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090387|NCT01717638|Experimental|B246_18_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3,5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ at 18 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090388|NCT01717638|Experimental|B246_24_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 2, 4 and 6 months of age and routine vaccines at 3, 5 and 7 months of age, followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. One third of subjects from this group received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090389|NCT01717638|Experimental|B+R234_12_48|Previously received 3 doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 12 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090390|NCT01717638|Experimental|B+R234_18_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 18 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090391|NCT01717638|Experimental|B+R234_24_48|Previously received rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine + routine vaccines at 2, 3 and 4 months of age followed by a booster dose of rMenB+OMV NZ vaccine at 24 months of age. All subjects received a 5th dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090392|NCT01717638|Experimental|B12 14_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 12 and14 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090393|NCT01717638|Experimental|B18 20_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 18 & 20 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090394|NCT01717638|Experimental|B24 26_48|Previously received two catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine at 24 & 26 months of age. All subjects received a 3rd dose of rMenB+OMV NZ vaccine in the present study at 4 years of age.
3090395|NCT01717638|Experimental|B48_50|Newly recruited 4 year old naive subjects who received 2 catch-up doses of rMenB+OMV NZ, ie, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, two months apart, in the present study.
3090396|NCT01717742|Active Comparator|tPA and placebo|
3090397|NCT01717742|Experimental|tPA and DNase|
3090398|NCT01717768|Experimental|Part 1: 120 mg BID|Oral TSX-002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
3090399|NCT01717768|Experimental|Part 1: 240 mg BID|Oral TSX-002 240 mg BID (total dose = 480 mg/day) for a duration of 15 days
3090400|NCT01717768|Experimental|Part 2: 120 mg BID|Single cohort, open-label, nonrandomized oral TSX 002 120 mg BID (total dose = 240 mg/day) for a duration of 15 days
3090401|NCT01717768|Experimental|Part 3: A-B-C 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3090402|NCT01717768|Experimental|Part 3: B-C-A 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3090403|NCT01717768|Experimental|Part 3: C-A-B 120 mg QD|"Open-label, randomized, 3-way crossover of 3 treatments, A, B, and C.~Treatment A: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes after a high-calorie, high-fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment B: Oral TSX-002 (1 x 120-mg capsules) administered 4 hours after a high-calorie, high fat meal. No food was allowed 4 hours before the high calorie, high-fat meal and no food was allowed for at least 10 hours after dosing.~Treatment C: Oral TSX-002 (1 x 120-mg capsules) administered 30 minutes before a high-calorie, high-fat meal. No food was allowed 4 hours before the high-calorie, high-fat meal and no food was allowed for at least 10 hours after dosing."
3090404|NCT01717768|Experimental|Part 4 Cohort 1: 60 mg BID/ 60 mg TID|Oral TSX-002 60 mg BID for 15 days then 60 mg TID for 15 days
3090405|NCT01717768|Experimental|Part 4 Cohort 2: 90 mg BID/ 90 mg TID|Oral TSX-002 90 mg BID for 15 days then 90 mg TID for 15 days
3090406|NCT01717768|Experimental|Part 4 Cohort 3: 180 mg QD|Oral TSX-002 180 mg once daily (QD) for 15 days
3090407|NCT01717768|Experimental|Part 4 Cohort 4: 120 mg BID|Oral TSX-002 120 mg BID for 15 days
3090408|NCT01717859|Other|Tocilizumab|All subjects will receive tocilizumab.
3090409|NCT01717872|Active Comparator|Macintosh laryngoscope blade|A photo of the larynx will be taken with the Macintosh laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the Percent of Glottic Opening (POGO) score by a blinded assessor.
3090410|NCT01717872|Active Comparator|Miller laryngoscope blade|A photo of the larynx will be taken with the Miller laryngoscope blade lifting and not lifting the epiglottis. The view of the larynx will be assessed using the percent of glottic opening score by a blinded assessor.
3090411|NCT01717898|Experimental|Abiraterone/prednisone + BEZ235|In Phase I, a dose escalation of BEZ235 will be performed using a standard 3 + 3 design to determine the maximum tolerated dose (MTD) of BEZ235 given in combination with continuous fixed doses of Abiraterone Acetate and prednisone. This BEZ235 dose will be used in the phase II portion of the study.
3090412|NCT01717976|Experimental|Intervention|primary care based nurse telephone support
3090413|NCT01717976|No Intervention|Control|usual care
3090414|NCT01717989||Cohort|Patients with end-stage renal disease (ESRD) treated at small dialysis organizations (SDOs).
3090415|NCT01718028|Experimental|SYSTANE® BALANCE|Propylene glycol 0.6% ocular emulsion, 1 drop in each eye 4 times a day for 30 days
3090416|NCT01718028|Active Comparator|LARMABAK®|Sodium chloride 0.9% saline solution, 1 drop in each eye 4 times a day for 30 days
3090417|NCT01718353|Experimental|Docetaxel + Prednisone (Treatment A)|Docetaxel 75 mg/m^2 intravenous (IV) infusion on Day 1 of Cycle 1 and every 3 weeks (q3w) thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Cabazitaxel 25mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until disease progression (DP), death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
3090418|NCT01718353|Experimental|Cabazitaxel + Prednisone (Treatment B)|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of Cycle 1 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily. Participants with <30% PSA reduction from baseline at the end of Cycle 4 switched to Docetaxel 75mg/m^2 IV infusion on Day 1 of Cycle 5 and q3w thereafter, in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, death, unacceptable toxicity or participant's refusal of further study treatment. Participants with ≥30% PSA reduction from baseline at the end of Cycle 4, continued on the same treatment which they received before switching until DP, death, unacceptable toxicity or participant's refusal of further study treatment.
3090419|NCT01718483|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3090420|NCT01718483|Placebo Comparator|Placebo|
3090421|NCT01718509|Experimental|SPD489 (Lisdexamfetamine dimesylate)|
3090422|NCT01718509|Placebo Comparator|Placebo|
3090423|NCT01718522||Intervention Group|Patients treated with sensor augmented pump (SAP) therapy with insulin pump Paradigm VEO® and use continuous glucose monitoring (CGM).
3090424|NCT01718535||CYP2C19 Genotyping|
3090425|NCT01718691|Experimental|SyB L-0501＋rituximab|
3090426|NCT01719003|Experimental|Empagliflozin low dose qd|Empagliflozin low dose once daily
3090427|NCT01719003|Experimental|Empagliflozin high dose qd|Empagliflozin high dose once daily
3090428|NCT01719003|Experimental|OL empa high dose + met 1000 mg bid|Open label empagliflozin high dose split twice daily + metformin 1000 mg twice daily - Patients are no longer enrolled into this arm because of change in the inclusion criteria in protocol version 2.0 all patients are now enrolled into remaining double-blind arms. Patients already enrolled in the open-label arm according to protocol version 1.0 can complete the study.
3090429|NCT01719003|Experimental|Empagliflozin low dose + met 500 mg bid|Empagliflozin low dose split twice daily + metformin 500 mg twice daily
3090430|NCT01719003|Experimental|Empagliflozin low dose + met 1000 mg bid|Empagliflozin low dose split twice daily + metformin 1000 mg twice daily
3090431|NCT01719003|Experimental|Empagliflozin high dose + met 500 mg bid|Empagliflozin high dose split twice daily + metformin 500 mg twice daily
3090432|NCT01719003|Experimental|Empagliflozin high dose + met 1000mg bid|Empagliflozin high dose split twice daily + metformin 1000 mg twice daily
3090433|NCT01719003|Experimental|Metformin 500 mg bid|Metformin 500 mg twice daily
3090434|NCT01719003|Experimental|Metformin 1000 mg bid|Metformin 1000 mg twice daily
3090435|NCT01719172|Experimental|Veriset™ Hemostatic Patch|Topical hemostat
3090436|NCT01719224|Active Comparator|Elevated body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
3090437|NCT01719224|Active Comparator|supine body position|We collect data about the apnea- hypopnea index, obstructive and central apneas, as well as oxygen, by comparing supine to 45 degrees elevated body position.
3090438|NCT01719367|Experimental|Atenolol|Patients will undergo a standardized, graded exercise protocol before and after receiving a dose of oral atenolol.
3090439|NCT01719380|Experimental|LGX818 + cetuximab|
3090440|NCT01719380|Experimental|LGX818 + BYL719 + cetuximab|
3090441|NCT01719653|Active Comparator|MiraLAX 306 g (Day-Prior)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 51 g at 12 noon; Gatorade 64 oz mixed with Miralax 255 g from about 6 PM to 9 PM
3090442|NCT01719653|Experimental|MiraLAX 357 g (Day-Prior)|MiraLAX 357 g and Gatorade 64 oz (1/2 gallon) consumed the day-prior to the colonoscopy as follows: Miralax 68 g at 12 noon; Gatorade 64 oz mixed with Miralax 289 g from about 6 PM to 9 PM.
3090443|NCT01719653|Experimental|MiraLAX 306 g (Split-Dose)|MiraLAX 306 g and Gatorade 64 oz (1/2 gallon) consumed as a split-dose as follows: Gatorade 32oz mixed with Miralax 153 g from about 6 PM to 8 PM the day prior to the colonoscopy; Gatorade 32oz mixed with Miralax 153 g from about 2-4 hours prior to the colonoscopy.
3090444|NCT01719653|Active Comparator|MoviPrep (Split-Dose)|MoviPrep consumed as a split-dose as follows: MoviPrep 1 liter consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 0.5 liter of clear liquids; MoviPrep 1 liter consumed from 3-4 hours prior to the colonoscopy followed by 0.5 liter of clear liquids.
3090445|NCT01719653|Active Comparator|SUPREP (Split-Dose)|SUPREP consumed as a split-dose as follows: SUPREP 16 oz consumed from about 6 PM to 7 PM the day prior to the colonoscopy followed by 32 oz of clear liquids; SUPREP 16 oz consumed from 3-4 hours prior to the colonoscopy followed by 32 oz of clear liquids.
3090446|NCT01719744|Experimental|ENMD-2076|ENMD-2076 capsules, 275 mg once daily, by mouth.
3090447|NCT01719757|Experimental|Oxycodone/naloxone|Trade name is Targin. Oxycodone (10mg)/naloxone (5mg) or Oxycodone (20mg)/naloxone (10mg) tablets. Twice daily per oral. Dose adjustment and asymmetric dose are allowed up to 80/40mg per day
3090448|NCT01719783|Experimental|LAIV H5N2|Two doses of live monovalent influenza vaccine A/17/turkey/Turkey/05/133 ( live monovalent (LAIV H5N2) given intranasally
3090449|NCT01719783|Placebo Comparator|Placebo|two doses of placebo solution intranasal
3090450|NCT01719861|Experimental|Desipramine HCl|Desipramine is a tricyclic antidepressant (TCA).
3090451|NCT01719900|Experimental|Pulse Fibre|The intervention group will receive a biscuit containing 5g/serving of yellow pea fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
3090452|NCT01719900|Placebo Comparator|Control|The placebo group will receive a biscuit an isocaloric control biscuit that is similar in taste and texture and without pulse fibre to be eaten 3 times per day approximately 30 minutes prior to their 3 largest meals.
3090453|NCT01720043|Experimental|All participants|All participants enrolled
3090454|NCT01720069|Active Comparator|Dose 1 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3090455|NCT01720069|Active Comparator|Dose 2 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3090456|NCT01720069|Active Comparator|Dose 3 VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
3090457|NCT01720173|Experimental|Treatment (dalantercept)|Patients receive dalantercept SC on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3090458|NCT01720225|Experimental|Decitabine|Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
3090459|NCT01720225|Experimental|Azacitidine|Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
3090460|NCT01720251|Placebo Comparator|placebo|SC injections of placebo
3090461|NCT01720251|Experimental|AllerT low dose|SC injections of AllerT 25 or 50 micrograms
3090462|NCT01720251|Experimental|AllerT full dose|SC injections of AllerT 50-100 micrograms
3090463|NCT01720264|Experimental|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
3090464|NCT01720277|Experimental|HD Fluzone Vaccine|NH facilities randomized to receive high dose trivalent influenza vaccine (HD Fluzone) for the residents.
3090465|NCT01720277|Active Comparator|SD Fluzone Vaccine|NH facilities randomized to standard dose trivalent influenza vaccine (SD Fluzone) for the residents.
3090466|NCT01720316|Active Comparator|glycine|Glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks Double-blind
3090467|NCT01720316|Placebo Comparator|Placebo|placebo, TID dosing, 6 weeks Double-blind
3090468|NCT01720316|Active Comparator|glycine, open-label|glycine, up to 0.8 g/kg, administered with TID dosing for 6 weeks
3090469|NCT01720446|Experimental|Semaglutide 0.5 mg|
3090470|NCT01720446|Experimental|Semaglutide 1.0 mg|
3090471|NCT01720446|Placebo Comparator|Semaglutide placebo 0.5 mg|
3090472|NCT01720446|Placebo Comparator|Semaglutide placebo 1.0 mg|
3090473|NCT01720524|Placebo Comparator|placebo|iv placebo of normal saline or 10% dextrose
3090474|NCT01720524|Experimental|sildenafil|Active study drug
3090475|NCT01720602|Experimental|Treatment (vorinostat, AI therapy)|Patients receive vorinostat PO 5 days a week for 3 weeks. Patients also receive AI therapy comprising either anastrozole PO daily, letrozole PO daily, or exemestane PO daily for 4 weeks. Courses repeat every 28 days in the absence of disease progression and unacceptable toxicity.
3090476|NCT01720667|Experimental|Intravenous levetiracetam|Intravenous levetiracetam 40 to 60 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
3090477|NCT01720667|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 to 40 mg/kg load. 1.5 mg/kg 8 hourly maintenance
3090478|NCT01720797|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation (PROPEL™) procedure used to achieve rapid orthodontic tooth movement. Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice. Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice, will take place. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
3090479|NCT01720797|Other|Non Micro-osteoperforation|Prior to intervention a swish of 5cc of chlorhexidine for one minute, twice, will take place. Chlorhexidine rinses are to begin twice a day for a week.
3090480|NCT01721044|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
3090481|NCT01721044|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3090482|NCT01721044|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3090483|NCT01721057|Placebo Comparator|Placebo|"Placebo administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 milligram (mg) orally once daily through Week 24.~Participants will continue to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study."
3090484|NCT01721057|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally once daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3090485|NCT01721057|Experimental|Baricitinib 4 mg|"Baricitinib 4 mg administered orally once daily through Week 24. Starting at Week 16, participants who are nonresponders will be rescued with baricitinib 4 mg orally daily through Week 24.~Participants will continue to take background cDMARD therapy throughout study."
3090486|NCT01721070|Experimental|SUF NT 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually. Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil.
3090487|NCT01721070|Experimental|Ketoconazole 400 mg, SUF NT 15 mcg|"Ketoconazole 400 mg administered once daily for three days. One dose of SUF NT 15 mcg was co-administered sublingually with the third (last) ketoconazole dose.~Subjects also received one dose of oral naltrexone 50 mg in the evening before and the morning of each SUF NT dosing to block the opioid effects of the sufentanil."
3090488|NCT01721096||XIENCE PRIME - Long Length (LL)|Long Lesion Arm patients (n=323) are treated by at least one Long Size stent (28, 33 and 38 mm length).There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
3090489|NCT01721096||XIENCE PRIME - Core Size|Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.
3090490|NCT01721109|Experimental|EVG/COBI/FTC/TDF|Participants will receive treatment for 48 weeks and then had the option to enter an Extension Phase to receive EVG/COBI/FTC/TDF until 1) the age of 18, 2) EVG/COBI/FTC/TDF becomes commercially available in the country the participant is enrolled, or 3) Gilead elects to terminate the development of EVG/COBI/FTC/TDF in that country.
3090491|NCT01721161|Experimental|BIIB033|Participants will receive BIIB033 once every 4 weeks for 20 weeks (a total of 6 doses).
3090492|NCT01721161|Placebo Comparator|Placebo|Participants will receive Placebo via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
3090493|NCT01721200|Other|Decision Support Tool|This study will examine the efficacy of a web-based educational decision support tool.
3090494|NCT01721200|Other|Usual Care|Usual Care Group will receive their biologic drug teaching from their rheumatologist.
3090495|NCT01721226|Sham Comparator|Control Arm|Participants in the Control Arm will receive standard discharge services according to the standards of care for that facility. In addition, participants in this arm will view an educational video on opiate overdose prevention. Study participants in the Control Arm will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
3090496|NCT01721226|Experimental|CARE tool and cell phone/text messaging|The Intervention Arm will complete the CARE tool device, a technology based HIV-counseling tool, and will receive text message reminders about HIV medical appointments and the importance of taking HIV medications. Study participants in this arm will be followed after release/study enrollment, just like participants in the Control Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
3090497|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 300 mg|Subjects receive Ezogabine/Retigabine 300 mg equally divided TID over Wk 1
3090498|NCT01721317|Placebo Comparator|Titration Phase: Placebo 300 mg|Subjects receive matching Placebo
3090499|NCT01721317|Experimental|Titration Phase: Ezogabine/Retigabine 450 mg|Subjects receive Ezogabine/Retigabine 450 mg equally divided TID over Wk 2
3090500|NCT01721317|Placebo Comparator|Titration Phase: Placebo 450 mg|Subjects receive matching Placebo
3090501|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 600 mg|Subjects receive Ezogabine/Retigabine 600 mg equally divided (200 mg TID) over Wk 3 or until they achieve their optimal tolerated dose as assessed by the Investigator
3090502|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 600 mg|Subjects receive matching Placebo
3090503|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 750 mg|Subjects receive Ezogabine/Retigabine 750 mg equally or unequally divided TID over Wk 4 or until they achieve their optimal tolerated dose as assessed by the Investigator
3090504|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 750 mg|Subjects receive matching Placebo
3090505|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 900 mg|Subjects receive Ezogabine/Retigabine 900 mg equally or unequally divided TID over Wk 5 or until they achieve their optimal tolerated dose as assessed by the Investigator
3090506|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 900 mg|Subjects receive matching Placebo
3090507|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1050 mg|Subjects receive Ezogabine/Retigabine 1050 mg equally or unequally divided TID over Wk 6 or until they achieve their optimal tolerated dose as assessed by the Investigator
3090508|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1050 mg|Subjects receive matching Placebo
3090509|NCT01721317|Experimental|Dose-Optimization Phase: Ezogabine/Retigabine 1200 mg|Subjects receive Ezogabine/Retigabine 1200 mg equally divided (400 mg TID) over Wk 7 or until they achieve their optimal tolerated dose as assessed by the Investigator
3090510|NCT01721317|Placebo Comparator|Dose-Optimization Phase: Placebo 1200 mg|Subjects receive matching Placebo
3090511|NCT01721317|Experimental|Maintenance Phase:Ezogabine/Retigabine|Subjects receive Ezogabine/Retigabine at the daily dose achieved (equally or unequally divided TID) at the end of the Dose-Optimization Phase for 8 Weeks (600 mg, 750 mg, 900 mg, 1050 mg, or 1200 mg)
3090512|NCT01721317|Placebo Comparator|Maintenance Phase: Placebo|Subjects receive matching Placebo
3090513|NCT01721330|Active Comparator|Naltrexone|Active Naltrexone administered twice daily up to a maximum total dose of 100mg/day.
3090514|NCT01721330|Placebo Comparator|Placebo|Naltrexone-masked placebo administered twice daily up to a maximum total dose of 100mg/day.
3090515|NCT01721369||Transient Loss of Consciousness (T-LOC)|Transient Loss of Consciousness (T-LOC). Treatment according to normal clinical practice.
3090516|NCT01721408|Experimental|Group A|
3090517|NCT01721408|Active Comparator|Group B|
3090518|NCT01721447|Experimental|Echo arm|Subjects with atrial fibrillation who are undergoing a TEE procedure will be assessed using Optison echocardiography contrast agent
3090519|NCT01721460|Experimental|Dexmedetomidine during MER|The study is performed in patients undergoing DBS electrode implantation to their STN for the treatment of parkinson's disease. Microelectrode recording (MER) is performed as part of STN electrode implantation surgery, to increase the precision of the stimulating electrode placement. The study includes administration of dexmedetomidine while recording electrical activity at a single location to evaluate the effects of this drug on the MER.
3090520|NCT01721473||cigarette smokers with heavy marijuana use|With heavy marijuana use
3090521|NCT01721473||cigarette smokers with heavy caffeine use|with heavy caffeine use
3090522|NCT01721473||cigarette smokers w/o heavy caffeine and marijuana use|cigarette smokers without the heavy use of marijuana or caffeine
3090523|NCT01721473||non-smokers|not a regular cigarette user
3090524|NCT01721473||cigarette smokers with non-menthol cigarette preference|non-menthol cigarette preference
3090525|NCT01721473||cigarette smokers with menthol cigarette preference|menthol cigarette preference
3090526|NCT01721486|Experimental|Study Group|IV acetaminophen 15 mg/kg (up to 1000 mg) administered intraoperatively over a 15 minute infusion.
3090527|NCT01721486|Active Comparator|Control Group|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30 minutes) prior to induction of anesthesia in the pre-operative area.
3090528|NCT01721564|Experimental|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
3090529|NCT01721603|Experimental|Dabrafenib + Trametinib + gamma knife radiosurgery|
3090530|NCT01721681|Experimental|FACTOR X|"At the Baseline Visit, eligible children will receive a bolus dose of 50 IU/kg FACTOR X. After the Baseline Visit, children will be treated with FACTOR X prophylactically for a period of 6 months (26 weeks).~A dosing regimen of 40-50 IU/kg twice a week is recommended, but is not mandatory. Each dose of FACTOR X must not exceed 60 IU/kg."
3090531|NCT01721746|Experimental|BMS-936558 3 mg/kg (IV)|BMS-936558 3 mg/kg solution for injection by intravenous (IV), every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3090532|NCT01721746|Active Comparator|Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)|"Dacarbazine: 1000mg/m2, Powder for IV solution, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Carboplatin: Area under the concentration-time curve (AUC) 6, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~Paclitaxel: 175 mg/ m2, solution for injection, IV, every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
3468922|NCT03891095|Experimental|L-DOPA|L-DOPA, a neuropeptide who is a key modulator of complex socioaffective responses including reward, social decision making, learning. Subjects receiving 187.5 mg Madopar (L-DOPA treatment, including 150 mg L-3,4-dihydroxyphenylalanine, together with 37.5 mg benserazide, which promotes higher levels of dopamine in the brain while minimizing side effects from peripheral dopamine)
3090534|NCT01721772|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may switch to nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3090535|NCT01721772|Active Comparator|Dacarbazine, 1000 mg/m^2|Participants received dacarbazine, 1000 mg/m^2, solution administered IV every 3 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion. Eligible participants may cross-over to nivolumab open label treatment, either 3 mg/kg every 2 weeks or 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
3090536|NCT01721837||Atrial fibrillation and mild to moderate renal impairment|
3090537|NCT01721876|Experimental|Volasertib and Cytarabine|
3090538|NCT01721876|Placebo Comparator|Placebo and Cytarabine|
3090539|NCT01721954|Active Comparator|Control Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab repeated every two weeks until evidence of treatment failure.
3090540|NCT01721954|Experimental|Experimental Arm|Systemic chemotherapy with FOLFOX6m plus or minus bevacizumab plus SIR-Spheres microspheres.
3090541|NCT01721967|Experimental|Ranolazine|Ranolazine, 500 mg for 60 days
3090542|NCT01722045|Experimental|Open label IAI|
3090543|NCT01722071|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
3090544|NCT01722071|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
3090545|NCT01722097|Active Comparator|Deep neuromuscular blockade|Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
3090546|NCT01722097|Placebo Comparator|Moderate neuromuscular blockade|Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron
3090547|NCT01722162|Experimental|Arm A: (start levocetirizine after bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily before bed starting on Day 8 of Cycle 1. 5 mg daily before bed Days 1-4 of each cycle starting with cycle 2."
3090548|NCT01722162|Experimental|Arm B: (start levocetirizine before bevacizumab/capecitabine)|"Bevacizumab IV 5 mg/kg on Days 1 each 2-week cycle.~Capecitabine PO 850 mg/m2 twice a day on Days 1-7 of each 2 week cycle.~Levocetirizine PO 5 mg daily starting 7 days prior to initiation of bevacizumab and capecitabine therapy. 5 mg daily Days 1-14 starting with cycle 2."
3090549|NCT01722266|Placebo Comparator|Placebo|Daily Injection
3090550|NCT01722266|Active Comparator|Liraglutide 1.8mg|Daily Injection
3090551|NCT01722266|Active Comparator|Liraglutide 1.2mg|Daily injections
3090552|NCT01722266|Active Comparator|Liraglutide 0.6 mg|Daily injection
3090553|NCT01722292|Experimental|Phase 1b: LY2940680 + C + E|"Phase 1b Dose Escalation: Cycles 1-6 (21 day cycles) LY2940680 administered orally, once daily at escalating doses (100 milligrams [mg] up to 400 mg) in combination with etoposide (E) 100 milligram per square meter (mg/m^2) administered by intravenous (IV) infusion on days 1, 2, 3 of each cycle and carboplatin (C) Area Under the Curve [AUC] 5 (mg•min/mL) administered by IV infusion on day 1 each cycle.~Phase 1b Maintenance: Cycles 7+ (21 day cycles) LY2940680 administered orally, once daily at the same dose as induction. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
3090554|NCT01722292|Placebo Comparator|Phase 2: Placebo + C + E|"Induction: Cycles 1-6 (21 day cycles) Placebo administered orally once daily in combination with etoposide 100 mg/m2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles) Placebo administered orally once daily. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation."
3090555|NCT01722292|Experimental|Phase 2: LY2940680 + C+ E|"Induction: Cycles 1-6 (21 day cycles) LY2940680 (dose to be determined in Phase 1b portion) administered orally once daily in combination with etoposide 100 mg/m^2 administered by IV infusion on days 1, 2, 3 of each cycle and carboplatin AUC 5 administered by IV infusion on day 1 each cycle.~Maintenance: Cycles 7+ (21 day cycles). LY2940680 (dose to be determined in Phase 1 portion) administered orally once daily."
3090556|NCT01722318|Active Comparator|Plecanatide 0.3mg|Plecanatide 0.3mg, one tablet by mouth daily for 12 weeks
3090557|NCT01722318|Active Comparator|Plecanatide 1.0mg|Plecanatide 1.0mg one tablet by mouth daily for 12 weeks
3090558|NCT01722318|Active Comparator|Plecanatide 3.0mg|Plecanatide 3.0mg, one tablet by mouth daily for 12 weeks
3090559|NCT01722318|Active Comparator|Plecanatide 9.0mg|Plecanatide 9.0mg, one tablet by mouth daily for 12 weeks
3090560|NCT01722318|Placebo Comparator|Placebo|Placebo, one tablet by mouth daily for 12 weeks
3090561|NCT01722331|Experimental|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered subcutaneously (SC) once a week at Weeks 0 and 4 and then every 12 weeks.
3090562|NCT01722331|Experimental|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC once a week at Weeks 0 and 4 and then every 12 weeks.
3090563|NCT01722331|Placebo Comparator|Placebo|Matching placebo administered SC once a week at Weeks 0 and 4.
3090564|NCT01722435||OST completers|Patients who are likely to complete OST during the next 12 or 18 months
3090565|NCT01722487|Experimental|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
3090566|NCT01722487|Active Comparator|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle.The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
3090567|NCT01722552|Experimental|adherence feedback|Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was <95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
3090568|NCT01722552|Active Comparator|standard of care|Control subjects will use the electronic monitoring devices just like the intervention arm, but will receive standard of care. They will not receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time, and they will not have access to the summaries of their previous month's behavior for use in interactive counseling sessions, though they will be encouraged to engage in counseling.
3090569|NCT01722604|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
3090570|NCT01722604|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
3090571|NCT01722643|Experimental|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
3090572|NCT01722643|Active Comparator|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment-quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
3090573|NCT01722669|Experimental|Quercetin|Single dose of quercetin with or without ascorbic acid
3090574|NCT01722669|Active Comparator|Isoquercetin|Single dose of isoquercetin with or without ascorbic acid
3090575|NCT01722734|No Intervention|Control|Patients in the control arm only got a generic health message at the end of the study.
3090576|NCT01722734|Active Comparator|Short Message|Patients in this arm receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals.
3090577|NCT01722734|Active Comparator|Long message|Patients in this arm receive six long text message reminders (reminders including justification for why patients should finish medication) within 60 hours of treatment initiation at 12 hour intervals.
3090578|NCT01722877|Experimental|JetStream Atherectomy|Jetstream NAVITUS System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic disease and thrombus in peripheral vasculature.
3468923|NCT03891095|Placebo Comparator|Placebo|Participants in the Placebo group received spray and oral placebos. 24 IU saline (spray placebo) 187.5 mg calcium carbonate (oral placebo)
3468924|NCT03891303||Transfused group (TR)|Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
3090581|NCT01722994|Experimental|Group 1 Punch Biopsy Wound with chromic gut suture|One of two absorbable sutures is used to close punch wounds.
3090582|NCT01722994|Experimental|Group 2 Punch Biopsy Wound with PDS|This is one of two absorbable sutures used to close punch biopsy wounds.
3090583|NCT01723072|Experimental|1 Omalizumab|omalizumab once a month via subcutaneous injection.
3090584|NCT01723072|Placebo Comparator|2 Placebo|placebo of omalizumab once a month via subcutaneous injection
3090585|NCT01723163|Experimental|Intervention|Abstinence Reinforcement Therapy (ART)
3090586|NCT01723163|Other|Control|Telephone Counseling
3090587|NCT01723228|Experimental|Rasagiline 1.0 mg/day|Rasagiline 1 mg oral tablets once daily for 24 weeks
3090588|NCT01723228|Placebo Comparator|Placebo|Placebo oral tablets once daily for 24 weeks
3090589|NCT01723254|Experimental|PF-06444753|
3090590|NCT01723254|Experimental|PF-06444752|
3090591|NCT01723254|Placebo Comparator|Placebo|Intramuscular
3090592|NCT01723384|Active Comparator|Naltrexone|Intermittent oral naltrexone to be taken on an as-needed basis for 8 weeks.
3090593|NCT01723384|Placebo Comparator|Placebo|Intermittent oral placebo to be taken on an as-needed basis for 8 weeks
3468925|NCT03891303||Non-transfused (non-TR)|Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
3090594|NCT01723397|Active Comparator|Nasaleze spray|"Nasaleze spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
3090595|NCT01723397|Placebo Comparator|Placebo spray|"Placebo spray 1 puff via spray device in each nostril 3 times daily for 1 week followed by allergen challenge"
3090596|NCT01723514|Experimental|Erenumab|Healthy participants and participants with migraine received subcutaneous doses of erenumab on days 1, 29 and 57.
3090597|NCT01723514|Placebo Comparator|Placebo|Healthy participants and participants with migraine received subcutaneous doses of placebo on days 1, 29 and 57.
3090598|NCT01723696|Placebo Comparator|placebo tablet+prenatal vitamin|A daily placebo tablet
3090599|NCT01723696|Active Comparator|Vitamin C +prenatal vitamin|500 mg vitamin C /day
3090600|NCT01723722|Active Comparator|1 (Phenobarbital and Methadone)|"The following is a dosing guide for methadone:~The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours.~For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score:~NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose~≥16 0.15 mg/kg/dose~Maximum dose of methadone will be 0.15 mg/kg/dose.~After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours.~If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm."
3090601|NCT01723722|Active Comparator|2 (Phenobarbital and Diluted Deodorized Tincture of Opium)|"The following is a dosing guide for dDTO:~The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours.~The starting dose will be determined using a sliding scale in response to the last NAS score before starting.~NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day~≥16 0.8 mg/kg/day~The maximum dose of DTO will be 0.8 mg/kg/day.~After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level.~If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm."
3090602|NCT01723826|Experimental|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
3090603|NCT01723904|Experimental|Rotigotine|"- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period.~Duration of the Titration Period: Between 1 week and 5 weeks.~- Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period.~Duration of the Maintenance Period: Between 3 weeks and 7 weeks."
3090604|NCT01724021|Experimental|Arm A|Participants in Arm A received one cycle of rituximab 375 mg/m^2 intravenously (IV), then three cycles of rituximab 1400mg subcutaneously (SC), followed by four cycles of rituximab 375 mg/m^2 IV in combination with a standard chemotherapy of cyclophosphamide, hydroxydaunorubicin, Oncovin, prednisone/prednisolone (CHOP), cyclophosphamide, vincristine, prednisone/prednisolone (CVP), or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
3090605|NCT01724021|Experimental|Arm B|Participants in Arm B received four cycles of rituximab 375 mg/m^2 IV followed by four cycles of rituximab 1400mg SC in combination with a standard chemotherapy of CHOP, CVP, or bendamustine. Rituximab was administered on Day 1 of each treatment cycle followed by administration of the preselected chemotherapy. Cycles were repeated every 14, 21, or 28 days, depending on the combination chemotherapy regimen selected by the investigator.
3090606|NCT01724060||Gastric bypass|Patients due for gastric bypass surgery
3090607|NCT01724060||Gastric banding|Patients due for gastric banding
3090608|NCT01724060||Sleeve gastrectomy|Patients due for sleeve gastrectomy
3090609|NCT01724060||Endobarrier|Patients due to undergo endoscopic Endobarrier insertion
3090610|NCT01724060||Exenatide|Patients due to be commenced on Exenatide
3090611|NCT01724060||Liraglutide|Patients due to be commenced on Liraglutide
3090612|NCT01724060||Lifestyle|Patients due to be commenced on a lifestyle intervention programme
3090613|NCT01724060||Elective surgery or endoscopy|Patients due to have non bariatric surgery (i.e. cholecystectomy) or an elective diagnostic endoscopy
3090614|NCT01724177|Experimental|Lenalidomide|Lenalidomide 25mg by mouth (PO) daily until progressive disease or unacceptable toxicity
3090615|NCT01724216|Experimental|pulse sequence software|The central aim of this study is to acquire a set of images and associated technical and clinical information to facilitate regulatory submission of the pulse sequences being studied by GEHC. Segment 1 allows to collect a minimum of 10 subjects then evaluate if additional scans/enrollment needed Segment 2 will allow an additional 90 subjects if data needed
3090616|NCT01724359|Experimental|Paliperidone ER|
3090617|NCT01724489|Active Comparator|Growth Hormone|Growth Hormone is Genotropin, provided by Pfizer Inc. It is self administered daily for 18 months using a 5 mg injection pen device. Dose will be titrated based on IGF-1 levels.
3090618|NCT01724489|Placebo Comparator|Placebo|Placebo will be provided by Pfizer Inc. It will appear identical to active growth hormone and will be administered in the same manner.
3090619|NCT01724528|Experimental|Febuxostat|Febuxostat for 7-9 days
3090620|NCT01724528|Active Comparator|Allopurinol|Allopurinol for 7-9 days
3090621|NCT01725126|Experimental|Part A - GSK2890457|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3090622|NCT01725126|Experimental|Part B - GSK2890457 + Liraglutide|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3090623|NCT01725126|Experimental|Part C - GSK2890457 + Metformin|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3090624|NCT01725126|Placebo Comparator|Part A - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3468926|NCT03890991|Experimental|SCOPE-DM only|Participation in SCOPE-DM programme without supply of glucometers and accessories
3090625|NCT01725126|Placebo Comparator|Part B - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3090626|NCT01725126|Placebo Comparator|Part C - Placebo|Subjects will titrate up from a maximially tolerated dose over a 7-day period. Treatment Period is 6 weeks
3090627|NCT01725217|Experimental|MenACWY-CRM|MenACWY-CRM
3090628|NCT01725282|Placebo Comparator|Placebo|Participants received matching placebo tablets once daily before bedtime for 7 weeks.
3090629|NCT01725282|Experimental|Quetiapine 50 mg|Participants received quetiapine extended release (XR) 50 mg tablets once daily before bedtime for 7 weeks.
3090630|NCT01725282|Experimental|Quetiapine 150 mg|After 2 days of up-titration, participants received quetiapine XR 150 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 50 mg tablets once daily for 1 week.
3090631|NCT01725282|Experimental|Quetiapine 300 mg|After 4 days of up-titration, participants received quetiapine XR 300 mg tablets once daily before bedtime for 6 weeks followed by quetiapine XR 150 mg tablets once daily for 1 week.
3090632|NCT01725308|Placebo Comparator|Placebo|Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3090633|NCT01725308|Experimental|FK949E 150 mg|After 2 days of up-titration, participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3090634|NCT01725308|Experimental|FK949E 300 mg|After 4 days of up-titration, participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I and were evaluated against the transition criteria to transfer to Treatment Period II. If transition criteria were not met, participants underwent to a dose-tapering period (1 week) and a follow-up period (1 week) thereafter. If transition criteria were met, participants went into Treatment Period II.
3090635|NCT01725308|Experimental|Placebo / FK949E|Participants received placebo administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive placebo for 4 weeks, followed by a 1-week dose adjustment period, and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3090636|NCT01725308|Experimental|FK949E 150 mg / FK949E|After 2 days of up-titration, participants received FK949E 150 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 150 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3090637|NCT01725308|Experimental|FK949E 300 mg / FK949E|After 4 days of up-titration, participants received FK949E 300 mg administered orally once daily at bedtime for 8 weeks in Treatment Period I. Participants who met the transition criteria continued to Treatment Period II which consisted of a transition period in which participants continued to receive FK949E 300 mg for 4 weeks followed by a 1-week dose-adjustment period and a treatment period in which participants received either open-label FK949E 150 mg or 300 mg (depending on dose increase or reduction guidelines) administered orally for 39 weeks. Participants underwent a dose-tapering period (1 week) and a follow-up period (1 week) thereafter.
3090638|NCT01725386||Monotherapy|Capecitabine as monotherapy according to prescribing information and normal clinical practice.
3090639|NCT01725386||Combination Therapy|Capecitabine as part of combination therapy according to prescribing information and normal clinical practice.
3090640|NCT01725451|Experimental|Testosterone Unshaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each unshaved axilla in 1 of 6 treatment periods.
3090641|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Spray|Deodorant spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3090642|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3090643|NCT01725451|Experimental|Testosterone Unshaved + Deodorant Antiperspirant Stick|Deodorant antiperspirant combination stick applied to unshaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3090644|NCT01725451|Experimental|Testosterone Shaved|No deodorant or antiperspirant: Single 30 mg dose of testosterone applied topically to each shaved axilla in 1 of 6 treatment periods.
3090645|NCT01725451|Experimental|Testosterone Shaved + Deodorant Antiperspirant Spray|Deodorant antiperspirant combination spray applied to shaved axillae. At least 2 minutes wait time. Then, single 30 mg dose of testosterone applied topically to each axilla in 1 of 6 treatment periods.
3090646|NCT01725529|Experimental|TMC435 150 mg|Patients will receive 12 weeks TMC435 150 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue to receive treatment with PegIFNα-2a and RBV until Week 48.
3090647|NCT01725529|Experimental|TMC435 100 mg|Patients will receive 12 weeks TMC435 100 mg once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV), followed by PegIFNα-2a and RBV alone. Response-guided treatment criteria will be used to determine total treatment duration of 24 or 48 weeks for patients in the TMC435 treatment groups. Patients in the control group will continue PegIFNα-2a and RBV until Week 48.
3090648|NCT01725529|Placebo Comparator|Control|Patients will receive placebo once daily (q.d.) plus peginterferon-alpha (PegIFNα-2a) and ribavirin (RBV) for 48 weeks.
3090649|NCT01725750|Experimental|Bright White Light (BWL)|"Participants will self-administer bright white light daily using a Litebook® (The Litebook Company Ltd.). The Litebook is a small (6 x 5 x 1) and lightweight (8 oz.) box."
3090650|NCT01725750|Active Comparator|Dim Red Light (DRL)|Participants will self-administer dim red light daily using a device that appears identical to Bright White Light (BWL) Litebook but that uses red LEDs emitting DRL.
3090651|NCT01725815|Experimental|HARP Intervention|
3090652|NCT01725815|No Intervention|No Intervention: Control|Participants in usual care will continue to obtain any mental health or peer-support services that they would otherwise be receiving.
3090653|NCT01725984||AdVance|Subjects previously implanted with the AdVance Male Sling
3090654|NCT01725984||AdVance XP|Subjects previously implanted with the AdVance XP male sling
3090655|NCT01726023|Experimental|Ceftazidime-Avibactam plus metronidazole|
3090656|NCT01726023|Active Comparator|Meropenem|
3090657|NCT01726036|Active Comparator|Gomco Circumcision Clamp|Gomco circumcision clamp used for neonatal circumcision.
3090658|NCT01726036|Active Comparator|Mogen Circumcision Clamp|Mogen circumcision clamp used for neonatal circumcision.
3090659|NCT01726049|Active Comparator|Sildenafil|Sildenafil orally 3 times 20mg for 2 weeks , followed by 3 times 60 mg for 10 weeks
3090660|NCT01726049|Placebo Comparator|Placebo|placebo orally 3 times 20mg tablets, followed by 3 times 60 mg for 10 weeks
3090661|NCT01726270|Experimental|tamsulosin hydrochloride|patients will take drug for 8 weeks in this exploratory study
3090662|NCT01726335|Experimental|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
3090663|NCT01726504|Experimental|electro-acupuncture|"The electric stimulator is applied to bilateral ST25andSP14 with dilatational wave10/50 Hz and electric current0.1-1.0mA.They are given acupuncture with 0.3×50mm or 0.35×75mm needles by inserting30-70mm and twirling lifting andthrusting 3 times.Dosage:The needle arrives the abdominal muscle layer(patients feel painful and acupuncturists feel touching hard).~Bilateral ST37 are given conventional acupuncture with 0.30mm×40mm needles by inserting 25-30mm and twirling lifting and thrusting for 3.Dosage:Local sour and heavy feeling is the appropriate dose.~Every session lasts for 30min/day.The participants are treated continuously for 8 weeks.During 8-week treatment the first 2 weeks,5 sessions per week,and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total."
3090664|NCT01726504|Sham Comparator|sham electro-acupuncture|"The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave, 10/50 Hz and electric current 0.5mA. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. The needle is inserted by 3mm-5mm (the needle can be vertically fixed on the skin).~Bilateral ST37 are given acupuncture with 3mm-5mm (the needle can be vertically fixed on the skin).~Length of Treatment and the treatment sessions are the same as treatment group."
3090665|NCT01726517|Experimental|LDV/SOF 8 Weeks (TN)|Treatment-naive (TN) participants will be randomized to receive LDV/SOF for 8 weeks.
3090666|NCT01726517|Experimental|LDV/SOF+RBV 8 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF plus RBV for 8 weeks.
3090667|NCT01726517|Experimental|LDV/SOF 12 Weeks (TN)|Treatment-naive participants will be randomized to receive LDV/SOF for 12 weeks.
3090668|NCT01726517|Experimental|LDV/SOF 12 Weeks (TE)|Treatment-experienced (TE) participants (had virologic failure following prior therapy with a protease-inhibitor [PI]+pegylated interferon [PEG]+RBV regimen) will be randomized to receive LDV/SOF for 12 weeks.
3090669|NCT01726517|Experimental|LDV/SOF+RBV 12 Weeks (TE)|Treatment-experienced participants (had virologic failure following prior therapy with a PI+PEG+RBV regimen) will be randomized to receive LDV/SOF plus RBV for 12 weeks.
3090670|NCT01726621|Other|Insulin dependent diabetics|Subjects currently using an insulin pump transferred to use the Medtronic MiniMed 620G and 640G insulin pumps and Guardian Link transmitter
3090671|NCT01726673|Experimental|tDCS + robotic arm therapy|Transcranial Direct Current Stimulation (tDCS) 2mA for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
3090672|NCT01726673|Placebo Comparator|tDCS sham + robotic arm therapy|Transcranial Direct Current Stimulation sham condition (0 mA) for 20 minutes over the primary motor cortex (M1) in the affected hemisphere immediately followed by robotic arm therapy for 60 minutes, 3x per week for 12 weeks (36 sessions total)
3090673|NCT01726738|Experimental|BRAF (dabrafenib) and MEK (trametinib) inhibitors|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
3090674|NCT01726803|Active Comparator|Usual Care|Usual care arm will receive management as recommended by practice guidelines and directed by the primary care provider. The recommended stepped care approach is used with initial management of advice and education only and no referral to physical therapy during the initial 4 weeks.
3090675|NCT01726803|Experimental|Early Physical Therapy with Usual Care|The Early Physical Therapy arm will receive the same advice and education intervention received by the usual care group and will be referred to receive 4 sessions of physical therapy during the first 4 weeks. The physical therapy protocol involves spinal manipulation and exercise.
3090676|NCT01727024|Experimental|Indacaterol (QAB149) Breezhaler®|In period 1, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days, followed by a 7-day washout. In period 2, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days.
3468927|NCT03890991|Active Comparator|SCOPE-DM with 3 months' supply of glucometer|Participation in SCOPE-DM programme with 3 months' supply of glucometers and accessories
3090677|NCT01727024|Active Comparator|Tiotropium Respimat®|In period 1, participants received Tiotropium 2.5 mcg, in 2 consecutive puffs, once daily via Respimat® device for 7 days, followed by a 7-day washout. In period 2, participants received Indacaterol 150 mcg once daily via Breezhaler® device for 7 days.
3090678|NCT01727089|Active Comparator|Arm I (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3090679|NCT01727089|Experimental|Arm II (bevacizumab, anti-endoglin monoclonal antibody TRC105)|Patients receive bevacizumab as in Arm I and anti-endoglin monoclonal antibody TRC105 IV over 1-4 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3090680|NCT01727141|Experimental|QVA149|27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)
3090681|NCT01727141|Active Comparator|QAB149|27.5 ug b.i.d.
3090682|NCT01727141|Active Comparator|NVA237|12.5 ug b.i.d.
3090683|NCT01727141|Placebo Comparator|Placebo|b.i.d
3090684|NCT01727154||Sipuleucel-T|
3090685|NCT01727180||Chronic kidney disease|
3090686|NCT01727258|Experimental|Mouth Rinse|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of Fluoride Toothpaste provided. Rinse with water after brushing teeth. Then rinse for 60 seconds with 10 mL of the experimental Mouth Rinse 12027-033 (KOX).
3090687|NCT01727258|Active Comparator|Fluoride Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Fluoride Toothpaste (NEG) provided.
3090688|NCT01727258|Active Comparator|Potassium Nitrate Toothpaste|Twice daily for 28 days, brush in usual manner for at least one minute using at least a one-inch strip of the Potassium Nitrate Toothpaste (POS) provided.
3090689|NCT01727297|Other|REVEAL Implantable Cardiac Monitor|
3090690|NCT01727336|Experimental|Dalantercept 0.9 mg/kg plus axitinib|Subcutaneous (SC) injection of dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.
3090691|NCT01727336|Placebo Comparator|Placebo plus axitinib|Subcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing
3090692|NCT01727336|Experimental|Dalantercept 0.6 mg/kg|Part 1 dose escalation arm 0.6 mg/kg dalantercept once every 3 weeks
3090693|NCT01727336|Experimental|Dalantercept 0.9 mg/kg|Part 1 dose escalation arm 0.9 mg/kg dalantercept once every 3 weeks
3090694|NCT01727336|Experimental|Dalantercept 1.2 mg/kg|Part 1 dose escalation arm 1.2 mg/kg dalantercept once every 3 weeks
3090695|NCT01727336|Experimental|Dalantercept 1.5 mg/kg|Part 1 dose escalation arm 1.5 mg/kg dalantercept once every 3 weeks
3090696|NCT01727414|Other|OROS-Methylphenidate and placebo for inattentive type pts|Children with ADHD-inattentive type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
3090697|NCT01727414|Other|OROS-Methylphenidate and placebo for combined type pts|Children with ADHD-combined type type. Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
3090698|NCT01727505|Active Comparator|Sequence A: Conventional-Volume Guarantee|This is a crossover study. Infants will be assigned to one of two sequences. Sequence A consists of a 24-hour period during which the infant receives conventional mechanical ventilation followed by a second 24 hour period during which the infant receives volume guarantee ventilation.
3090699|NCT01727505|Active Comparator|Sequence B: Volume Guarantee-Conventional|This is a crossover study. Infants will be assigned to one of two sequences. Sequence B consists of a 24-hour period during which the infant receives volume guarantee ventilation followed by a second 24 hour period during which the infant receives conventional mechanical ventilation.
3090700|NCT01727700|Placebo Comparator|Placebo|Matching Placebo Once-Daily
3090701|NCT01727700|Experimental|Aripiprazole 5 mg or 10 mg|Aripiprazole 5 mg or 10 mg Immediate Release Once-Daily
3090702|NCT01727700|Experimental|Aripiprazole 10 mg or 20 mg|Aripiprazole 10 mg 20 mg Immediate Release Once-Daily
3090703|NCT01727713|Experimental|Aripiprazole|Aripiprazole Immediate Release Once-Daily
3090704|NCT01727726|Placebo Comparator|Placebo + ADT|Matching Placebo and assigned ADT
3090705|NCT01727726|Experimental|Brexpiprazole + ADT|Brexpiprazole, flexible dose and assigned ADT
3090706|NCT01727726|Active Comparator|Seroquel XR + ADT|Seroquel XR, flexible dose and assigned ADT
3090707|NCT01727765|Experimental|Experimental|6 weeks of inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to up to 50% of pre-training maximal inspiratory mouth pressure and will be adapted weekly to reflect the improvement in inspiratory muscle strength
3090708|NCT01727765|Sham Comparator|Sham Comparator|6 weeks of sham inspiratory muscle training, 6 days per week. The intensity of training will be equivalent to 5% of pre-training inspiratory mouth pressure throughout the 6 week period.
3090709|NCT01727791|Experimental|open label|
3090710|NCT01727895|Experimental|Beta-glucan|Commercial available Beta-glucan derived from bakers yeast (S. Cerevisiae): Glucan #300® produced by Transferpoint, Columbia, United States. 2 capsules of 500mg Glucan #300®, daily, for seven days.
3090711|NCT01727895|No Intervention|Control group|
3090712|NCT01728077|Experimental|Brivaracetam|At Entry Visit (EV), subjects will start on the individualized Brivaracetam (BRV) dose that they had reached at the completion of the previous study. Dose adjustments of the Investigational Medicinal Product (IMP) are allowed at any time based on the clinical judgment of the investigator. The BRV dose can be increased or decreased in increments of 50 mg/day based on the individual subject's seizure control and/or tolerability; however, the BRV dose should not exceed 200 mg/day during the study and must always be administered as a symmetrical morning and evening dose. Upon completion or early discontinuation from this study, there will be a Down-Titration Period in steps of 50 mg/day on a weekly basis until 20 mg/day for 1 week is reached, followed by a Post-Treatment Period (between 2 and 4 weeks) during which the subject will not receive study drug. No down-Titration Period will be applicable if subjects are continued on BRV after they complete this study.
3090713|NCT01728116|Experimental|Device (EndoBarrier)|Device for glycemic control
3090714|NCT01728116|Sham Comparator|Sham Procedure|sham procedure
3090715|NCT01728194|Experimental|Escitalopram|Target dose 20mg for 12 weeks
3090716|NCT01728194|Other|Control|Non-psychiatric comparison participants.
3090717|NCT01728246|Experimental|Tramadol/Paracetamol (APAP)|
3090718|NCT01728246|Active Comparator|Non-Tramadol/APAP|
3090719|NCT01728324|Experimental|Randomised 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (randomised)
3090720|NCT01728324|Experimental|Randomised 16-week arm|BI 207127-placebo, FDV-placebo and RBV-placebo for 8 weeks followed by BI 207127 in combination with FDV and RBV for 16 weeks (randomised)
3090721|NCT01728324|Experimental|Allocated 24-week arm|BI 207127 in combination with FDV and RBV for 24 weeks (allocated to patients with compensated cirrhosis)
3090722|NCT01728337|Active Comparator|Dysport and Xeomin|30 U of Dysport® was injected on the right side of the forehead and 12 U Xeomin® was injected on the left side of the forehead (dose-equivalence 2.5:1).
3090723|NCT01728337|Active Comparator|Xeomin and Dysport|30 U Dysport® was injected on the left side of the forehead and 12 U Xeomin® was injected on the right side of the forehead (dose-equivalence 2.5:1).
3090724|NCT01728376|Experimental|Daptomycin - 12 to 17 year olds|Participants ages 12-17 years old were administered daptomycin 7 mg/kg infused once daily, intravenously (IV), over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3090725|NCT01728376|Active Comparator|Comparator - 12 to 17 year olds|Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3090726|NCT01728376|Experimental|Daptomycin - 7 to 11 year olds|Participants ages 7 to 11 years old were administered daptomycin 9 mg/kg, infused once daily, IV over 30 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3090727|NCT01728376|Experimental|Daptomycin - 1 to 6 year olds|Participants ages 1 to 6 years old were administered daptomycin 12 mg/kg, infused once daily, IV over 60 minutes; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. After conclusion of IV therapy, can continue on oral therapy (not daptomycin, but at discretion of investigator).
3090728|NCT01728376|Active Comparator|Comparator - 7 to 11 year olds|Participants ages 7-11 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3090729|NCT01728376|Active Comparator|Comparator - 1 to 6 year olds|Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
3090730|NCT01728454|Placebo Comparator|Placebo|Following the Stage 1 no treatment baseline assessment period, placebo matching capsules, orally, once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 milligrams (mg)/day separated by an off-drug interval (ODI) in Stage 3.
3090731|NCT01728454|Experimental|Telapristone acetate 6 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 6 mg capsules, orally once daily for 18 weeks in Stage 2. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 6 mg/day separated by an ODI in Stage 3.
3090732|NCT01728454|Experimental|Telapristone acetate 12 mg|Following the Stage 1 no treatment baseline assessment period, telapristone acetate (Proellex®) 12 mg capsules, orally once daily for 18 weeks. Eligible participants had the option to receive 2 additional 16-week cycles of active treatment at 12 mg/day separated by an ODI in Stage 3.
3090733|NCT01728584|Experimental|Standard NMB and Standard Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted Train of Four [TOF] ratio of 10%)/Standard insufflation pressure (starting pressure of 12 mmHg).
3090734|NCT01728584|Experimental|Standard NMB and Low Insufflation Pressure|Treatment condition for this arm is Standard NMB (depth of blockade at a targeted TOF ratio of 10%)/Low insufflation pressure (starting pressure of 8 mmHg).
3090735|NCT01728584|Experimental|Deep NMB and Standard Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Standard insufflation pressure (starting pressure of 12 mmHg).
3090736|NCT01728584|Experimental|Deep NMB and Low Insufflation Pressure|Treatment condition for this arm is Deep NMB (depth of blockade of 1-2 PTCs)/Low insufflation pressure (starting pressure of 8 mmHg).
3090737|NCT01728623|Experimental|E7080|
3090738|NCT01728636|Experimental|Tranexamic Acid|Tranexamic acid 10mg/kg loading dose given pre-incision and 1mg/kg/hr infusion throughout intraoperative period
3090739|NCT01728636|Placebo Comparator|Placebo|Normal saline placebo loading dose 0.5ml/kg and infusion at 0.5ml/kg/hr throughout operative course
3090740|NCT01728779|Experimental|Nelfinavir w/Stereotactic Body Radiation Therapy (SBRT)|Patients with metastatic lesions of the lung, liver, or bone will be candidates for treatment. Within three weeks of the initial treatment planning, a 15 Gy dose (per lesion site) of SBRT will be administered. Prior to SBRT, patients will initiate Nelfinavir oral therapy twice daily for 7 days. Once SBRT is completed, the patient will repeat the same Nelfinavir therapy for an additional 7 days for a total of 14 days of treatment.
3090741|NCT01728792|Experimental|Group 1: TDV SC_2 Doses Day 0|Takeda's Tetravalent Dengue Vaccine Candidate (TDV), 0.5 mL, subcutaneous (SC) injection, one dose in each arm, Day 0 using a needle/syringe.
3090742|NCT01728792|Experimental|Group 2: TDV IM_2 Doses Day 0|TDV, 0.5 mL, intramuscular (IM) injection, one dose in each arm, Day 0 using a needle/syringe.
3090743|NCT01728792|Experimental|Group 3: TDV IM_2 Doses Days 0 and 90|TDV, 0.5 mL, IM injection, one dose on Day 0 and one dose on Day 90 using a needle/syringe.
3090744|NCT01728792|Experimental|Group 4: TDV SC_2 Doses Day 0|TDV, 0.5 mL, SC injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
3090745|NCT01728792|Experimental|Group 5: TDV IM_2 Doses Day 0|TDV, 0.5 mL, IM injection, one dose in each arm, Day 0 using the PharmaJet Stratis™ device.
3090746|NCT01728805|Experimental|KW-0761|anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
3090747|NCT01728805|Active Comparator|Vorinostat|vorinostat 400 mg once daily
3090748|NCT01728844|Active Comparator|beta-tricalcium phosphate alone|beta-tricalcium phosphate alone
3090749|NCT01728844|Experimental|GFeBGS 0.1%|GFeBGS consisting of beta-tricalcium phosphate + 0.1% recombinant human basic fibroblast growth factor (rh-bFGF)
3090750|NCT01728844|Experimental|GFeBGS 0.3%|GFeBGS consisting of beta-tricalcium phosphate + 0.3% rh-bFGF
3090751|NCT01728844|Experimental|GFeGBS 0.4%|GFeBGS consisting of beta-tricalcium phosphate + 0.4% rh-bFGF
3090752|NCT01729026|Experimental|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
3090753|NCT01729026|Active Comparator|Wait-list, Then Adoption after 3 Months|After 3 months on a wait-list, Veterans will choose a dog from the San Antonio Humane Society with the help of a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
3090754|NCT01729039|Experimental|gaze stability|standard balance rehabilitation plus vestibular-specific exercises
3090755|NCT01729039|Placebo Comparator|control|standard balance rehabilitation plus placebo eye exercises
3090756|NCT01729156|Other|Healthy controls|Healthy controls receiving 1000 mg metformin twice daily for 3 months
3090757|NCT01729156|Placebo Comparator|Placebo|Placebo
3090758|NCT01729156|Active Comparator|Metformin|"Metformin Sandoz, 1000 mg twice daily for 3 months"
3090759|NCT01729208|Experimental|Dual Focus Soft Contact Lens|Dual Focus Soft Contact Lens
3090760|NCT01729208|Placebo Comparator|Single Vision Soft Contact Lens|Single Vision Soft Contact Lens
3090761|NCT01729247||FeNO|Participants with asthma will have a fractional exhaled nitric oxide (FeNO) measurement taken by NIOX MINO® Instrument (09-1100) according to the 'Perform FeNO Measurement' guidelines on page 7 of the NIOX MINO® User Manual (February 2011) during their study visit.
3090762|NCT01729338|Experimental|Velcade, cyclophosphamide, Revlimid|"INDUCTION (28-day cycles for 8 cycles):~VELCADE 1.3 mg/m2 subcutaneously (SC) days 1, 8 and 15~Cyclophosphamide 300 mg/m2 orally (PO) days 1, 8 and 15~Dexamethasone 40 mg PO days 1,8 and 15~MAINTENANCE (28-day alternating cycles until stopped for toxicity, relapse or death):~Odd cycles (9, 11, 13, etc.) lenalidomide 10 mg PO days 1-21~Even cycles (10, 12, 14, etc.) VELCADE 1.3 mg/m2 SC days 1, 15"
3090763|NCT01729494|Experimental|Group A|Alemtuzumab + belatacept + mycophenolate mofetil /Enteric coated mycophenolate sodium + early cessation of steroids
3090764|NCT01729494|Experimental|Group B|Rabbit antithymocyte globulin + belatacept + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
3090765|NCT01729494|Active Comparator|Group C|Rabbit antithymocyte globulin + tacrolimus + mycophenolate mofetil /Enteric coated (EC) mycophenolate sodium + early cessation of steroids
3090766|NCT01729559|Experimental|5000 Units unfractionated Heparin Q 8 hr|Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
3090767|NCT01729559|Active Comparator|30mg enoxaparin Q12 hr|Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.
3090768|NCT01729598|Experimental|Valproic Acid|Valproic acid 250 mg or 500mg by mouth twice daily.
3090769|NCT01729598|Placebo Comparator|Placebo|Placebo capsule by mouth twice daily.
3090770|NCT01729728|Experimental|Tapentadol|
3090771|NCT01729754|Experimental|Tildrakizumab 200 mg|Participants receive tildrakizumab 200 mg subcutaneously (SC) on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo (PBO) twice weekly until Week 12 and once weekly from Week 12 to Week 28.
3090772|NCT01729754|Experimental|Tildrakizumab 100 mg|Participants receive tildrakizumab 100 mg SC on Weeks 0, 4, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244, plus etanercept placebo twice weekly until Week 12 and once weekly from Week 12 to Week 28.
3090773|NCT01729754|Placebo Comparator|Placebo|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive tildrakizumab 200 mg or tildrakizumab 100 mg on Weeks 12, 16, 28, 40 and 52 and, optionally, every 12 weeks thereafter until Week 244.
3090774|NCT01729754|Active Comparator|Etanercept 50 mg|Participants receive matching placebo to tildrakizumab SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and once weekly from Week 12 to Week 28. Participants who don't achieve PASI-75, receive tildrakizumab 200 mg after Week 28 (Weeks 32, 36 and 48) and, optionally, every 12 weeks thereafter until Week 244.
3090775|NCT01729819|Experimental|Combination|Tolterodine tartrate extended release capsules + Desmopressin orally disintegrating tablets
3090776|NCT01729819|Active Comparator|Tolterodine|Tolterodine tartrate extended release capsules + Placebo orally disintegrating tablets
3090777|NCT01729845|Experimental|Treatment (decitabine, MEC)|"Patients receive decitabine IV on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3).~INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy."
3090778|NCT01729871|Experimental|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
3090779|NCT01729871|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
3468928|NCT03890991|Active Comparator|SCOPE-DM with 6 months' supply of glucometer|Participation in SCOPE-DM programme with 6 months' supply of glucometers and accessories.
3090780|NCT01729923|Experimental|Treatment (capecitabine, celecoxib, radiation therapy)|"Patients proceed to surgery, radiation therapy with ADAPT therapy followed by maintenance ADAPT therapy, or ADAPT therapy. Eligible patients undergo surgical resection at baseline or upon achievement of resectable disease after radiation therapy.~RADIATION + ADAPT: Patients undergo radiation therapy 5 days per week and receive capecitabine PO BID and celecoxib PO BID 5 days per week during radiation.~ADAPT: Patients receive capecitabine PO BID on days 1-14 and celecoxib PO BID on days 1-21. Courses repeat every 21 days for up to 3 years in the absence of disease progression or unacceptable toxicity."
3090781|NCT01730040|Active Comparator|Atorvastatin 40 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received atorvastatin 40 mg over-encapsulated tablets orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablets orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3090782|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3090783|NCT01730040|Experimental|Alirocumab 75 mg/up to 150 mg + Atorvastatin 20 mg|Participants, who were receiving atorvastatin 20 mg over-encapsulated tablets orally at baseline, received Alirocumab 75 mg SC injection Q2W, atorvastatin 20 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3090784|NCT01730040|Active Comparator|Atorvastatin 80 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received Atorvastatin 80 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
3090785|NCT01730040|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received rosuvastatin 40 mg over-encapsulated tablets orally QD, placebo for alirocumab SC injection Q2W, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks.
3090786|NCT01730040|Active Comparator|Ezetimibe 10 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received ezetimibe 10 mg over-encapsulated tablets orally QD, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3090787|NCT01730040|Experimental|Alirocumab 75 mg/ up to 150 mg + Atorvastatin 40 mg|Participants, who were receiving atorvastatin 40 mg over-encapsulated tablets orally at baseline, received alirocumab 75 mg SC injection Q2W, atorvastatin 40 mg over-encapsulated tablets orally QD, and placebo for ezetimibe over-encapsulated tablets orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3090788|NCT01730053|Active Comparator|Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received rosuvastatin 20 mg over-encapsulated tablet orally once daily (QD), placebo for alirocumab SC injection every two weeks (Q2W), and placebo for ezetimibe over-encapsulated tablet orally QD added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3090789|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for alirocumab SC injection Q2W added to stable LMT for 24 weeks.
3090790|NCT01730053|Experimental|Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg|Participants, who were receiving rosuvastatin 10 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg SC injection Q2W, rosuvastatin 10 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3090791|NCT01730053|Active Comparator|Rosuvastatin 40 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received rosuvastatin 40 mg over-encapsulated tablet orally QD, placebo for alirocumab Q2W SC injection, and placebo for ezetimibe QD over-encapsulated tablet orally added to stable LMT for 24 weeks.
3090792|NCT01730053|Active Comparator|Ezetimibe 10 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received ezetimibe 10 mg over-encapsulated tablet orally QD, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for alirocumab Q2W SC injection added to stable LMT for 24 weeks.
3090793|NCT01730053|Experimental|Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg|Participants, who were receiving rosuvastatin 20 mg over-encapsulated tablet orally at baseline, received alirocumab 75 mg Q2W SC injection, rosuvastatin 20 mg over-encapsulated tablet orally QD, and placebo for ezetimibe over-encapsulated tablet orally QD added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) at Week 8, based on baseline disease characteristic and medical history.
3090794|NCT01730339|Active Comparator|Group 1|
3090795|NCT01730339|Active Comparator|Group 2|
3090796|NCT01730378|Experimental|Prepandrix Group|Subjects in this group received 2 doses of Prepandrix™ vaccine at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
3090797|NCT01730378|Active Comparator|Fluarix Group|Subjects in this group received 1 dose of Fluarix™ vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid region of non-dominant arm.
3090798|NCT01730534|Experimental|Dapagliflozin|Dapagliflozin + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
3090799|NCT01730534|Placebo Comparator|Placebo|Placebo + standard of care therapy for Type 2 Diabetes and for co-morbidities and cardiovascular risk factors
3090800|NCT01730586|Experimental|Abraxane|Abraxane 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
3090801|NCT01730729|Experimental|Treatment (cabergoline)|Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3090802|NCT01730846|Experimental|Doxazosin 4mg/day|doxazosin 4mg/day
3090803|NCT01730846|Placebo Comparator|Placebo|placebo control
3090804|NCT01730846|Experimental|Doxazosin 8mg/day|doxazosin 8mg/day
3090805|NCT01730872|Experimental|Prednisolone|Prednisolone Sodium Phosphate Ophthalmic Solution, 1%
3090806|NCT01730872|Placebo Comparator|Placebo|Tears Naturale II Ophthalmic Solution, 1%
3090807|NCT01730950|Active Comparator|Bevacizumab|Bevacizumab every 2 weeks
3090808|NCT01730950|Experimental|Bevacizumab + RT|Radiation therapy with bevacizumab every 2 weeks
3090809|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.01%|1 drop to study eye once daily
3090810|NCT01731002|Experimental|AR-13324 Ophthalmic Solution 0.02%|1 drop to study eye once daily
3090811|NCT01731002|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|1 drop to study eye once daily
3090812|NCT01731041|Experimental|Ticagrelor 180mg|Patients randomized to this arm will be administered 180 mg of ticagrelor (experimental arm, loading dose).
3090813|NCT01731041|Active Comparator|Ticagrelor 90mg|Patients randomized to this arm will be administered 90 mg dose of ticagrelor (active comparator, standard dose).
3090814|NCT01731119|Experimental|Flexible Dose Latuda©|Lurasidone (Latuda©)dose will be determined solely by the clinician in accordance with the best interests of each participant.
3090815|NCT01731171|Experimental|Probiotic Supplement|The probiotic supplement compound will consist of capsules containing approximately 10^8 colony forming units of the probiotic organisms, LactobacillusGG and Bifidobacteria lactis strain Bb12. The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. The participant will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
3090816|NCT01731171|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
3090817|NCT01731470|Experimental|Liposomes|Liposomes
3090818|NCT01731600|Experimental|N8-GP|
3090819|NCT01731678|Experimental|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
3090820|NCT01731691|Experimental|α1 Proteinase Inhibitor in HIV disease|α1Proteinase Inhibitor (120mg/kg Prolastin-C) weekly for 8 weeks
3090821|NCT01731691|Placebo Comparator|Placebo in HIV disease|Placebos weekly for 8 weeks
3090822|NCT01731691|No Intervention|Uninfected controls|Blood collection only for 8 weeks
3090823|NCT01731886|Active Comparator|Arm A|Subjects will receive the current standard of care treatment. Lenalidomide and dexamethasone for four 28-day cycles followed by steam cell collection and autologous peripheral blood stem cell transplant. After 90 days, start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
3090824|NCT01731886|Active Comparator|Arm B|Subjects will receive the new treatment that will be compared with the standard of care. Lenalidomide and dexamethasone for eight 28-day cycles. After four cycles your stem cells will be collected (stem cell collection). After an additional four cycles of lenalidomide (a total of 8 cycles), start the maintenance phase (lenalidomide days 1-21 every 28 days for two years or until your disease progresses).
3090825|NCT01731912|Experimental|Treatment (degarelix acetate, EBRT)|Patients receive degarelix acetate SC on day 1. Treatment repeats every 4 weeks for up to 6 courses. Beginning at week 15, patients also undergo standard EBRT for 8.5 weeks.
3090826|NCT01731938|Experimental|Fibrin Sealant (FS) Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3090827|NCT01731938|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3090828|NCT01731951|Experimental|Arm A: Imetelstat 9.4 mg/kg (Myelofibrosis [MF])|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 milligram per kilogram (mg/kg), intravenously (IV) as 2-hour infusion on Day 1 of each 21-day cycle in Core Phase up to 9 cycles. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3090829|NCT01731951|Experimental|Arm B: Imetelstat 9.4 mg/kg as Induction + Maintenance (MF)|Participants with MF regardless of spliceosome mutation status or presence of ring sideroblasts received imetelstat 9.4 mg/kg, IV as 2-hour infusion on Days 1, 8, and 15 of 21-day cycle in Cycle 1 followed by 9.4 mg/kg on Day 1 of each 21-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3468929|NCT03890991|No Intervention|Control|Usual care by healthcare provider/ clinics of Tsao Foundation without participation in SCOPE-DM programme
3468930|NCT03891108|Active Comparator|Treatment A: BMS-986231 Formulation A|Participants will be administered Treatment A: BMS-986231 Formulation A as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
3090830|NCT01731951|Experimental|Arm D: Imetelstat 9.4 mg/kg (Blast-phase MF/Acute Myeloid Leukemia)|Participants with blast-phase myelofibrosis/acute myeloid leukemia (MF/AML) received imetelstat 9.4 mg/kg, IV as 2-hour infusion weekly on Days 1, 8, 15, 22 of a 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3090831|NCT01731951|Experimental|Arm E: Imetelstat 7.5 - 9.4 mg/kg (MF [with Spliceosome Mutation or Ring Sideroblasts])|Participants with MF and spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3090832|NCT01731951|Experimental|Arm F: Imetelstat 7.5 - 9.4 mg/kg (MF [without spliceosome mutation and ring sideroblasts])|Participants with MF without spliceosome mutations or ring sideroblasts present received 2 cycles (Cycles 1-2) of imetelstat 9.4 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or imetelstat 7.5 mg/kg twice weekly on Days 1, 3 for 2 cycles of 28-day cycle (Cycles 3-4) followed by imetelstat 7.5 mg/kg 3-times-weekly on Days 1, 3, 5 of Cycles 5 and beyond of 28-day cycle up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3090833|NCT01731951|Experimental|Arm G: Imetelstat 7.5 - 9.4 mg/kg (MDS/MPN or MDS with Spliceosome Mutations or Ring Sideroblasts)|Participants with either myelodysplastic syndromes/ myeloproliferative neoplasm (MDS/MPN) or MDS and spliceosome mutations or ring sideroblasts present received 2 cycles of 28-day cycle (Cycles 1-2) of imetelstat 7.5 mg/kg, IV as 2-hour infusion on Day 1 of a 28-day cycle followed by maintenance therapy with the same regimen or the possibility of dose escalation to imetelstat 9.4 mg/kg weekly if response to the initial dose was insufficient up to 9 cycles in the Core Phase. Participants could receive imetelstat beyond Cycle 9 in the Extension Phase if they did not meet any of the withdrawal criteria, did not have disease progression and were receiving clinical benefit from treatment as determined by the investigator. Following treatment discontinuation, participants entered the Event Monitoring Phase for collection of survival status, disease status, and subsequent treatment information (Up to approximately 5.7 years).
3090834|NCT01731990|Experimental|Canakinumab (ACZ885)|Monthly subcutaneous doses of Canakinumab 150 mg/1 mL for 12 months
3090835|NCT01731990|Placebo Comparator|Placebo|Monthly subcutaneous doses of placebo of Canakinumab 150 mg/1 mL for 12 months
3090836|NCT01732107|Experimental|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule.
3090837|NCT01732263|Experimental|SSP-004184 (Child-Pugh A Liver Impaired)|The Child-Pugh Score is a scoring system used to determine the prognosis with cirrhosis and need for liver transplantation. Scoring is based upon albumin, ascites, total bilirubin, prothrombin time, and encephalopathy. Each category is based on a scoring system of 1-3 with 3 being the worst and a total score range of 5-15. It is broken into categories A (score of 5-6), B (score of 7-9), and C (score of 10-15) with worsening from A to C for prognosis.
3090838|NCT01732263|Experimental|SSP-004184 (Child-Pugh B Liver Impaired)|
3090839|NCT01732263|Experimental|SSP-004184 (Child-Pugh C Liver Impaired)|
3090840|NCT01732263|Experimental|SSP-004184 (Matched Healthy Subjects)|
3090841|NCT01732406||Acomegaly with Pegvisomant|Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly.
3090842|NCT01732406||Acromegaly with somatostatin analog|Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly
3090843|NCT01732406||Active Acromegaly|Patients not on drugs for treatment of acromegaly
3090844|NCT01732419|Experimental|Home-based training|"After the first three supervised training sessions in the hospitals, patients in the home-based training group are instructed to wear a heart rate monitor during exercise training at home. Prescribed exercise exists of two or three exercise sessions per week, of one hour at 70 - 85% of their maximum heart rate.~Once a week the heart rate data is uploaded and evaluated by an exercise specialist together with the patient by telephone."
3090845|NCT01732419|Active Comparator|Centre-based training|Patients in the centre-based training group will perform all trainings sessions under direct supervision of a physical therapist specialized in CR. Training sessions will be performed on an cycle ergometer, starting with a warm up phase of 5 min, followed by 50 min of cycling at 70-85% of the maximal HR and a cooling down period of 5 min. During the training period, physical therapists will record attendance, training duration and actual training intensity. After the 12-week training period patients receive individual advice from their physical therapist on physical activities.
3090846|NCT01732445|Experimental|Supportive care (ruxolitinib phosphate and danazol)|Patients receive ruxolitinib phosphate PO BID and danazol PO TID on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. At the treating physician's discretion, patients may continue treatment past 6 courses if they are without disease progression.
3090847|NCT01732458|Experimental|Aprepitant Dose 1: Equivalent to 125 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 125 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered intravenously (IV) immediately prior to anesthesia.
3090848|NCT01732458|Experimental|Aprepitant Dose 2: Equivalent to 40 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 40 mg in adults on Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
3090849|NCT01732458|Experimental|Aprepitant Dose 3: Equivalent to 10 mg in Adults|Pediatric participants receive a single dose of apprepitant that is equivalent to 10 mg in adults Day 1 between 1 and 3 hours prior to expected induction of anesthesia, plus placebo for odansetron administered IV immediately prior to anesthesia.
3090850|NCT01732458|Active Comparator|Ondansetron|Pediatric participants in the control regimen are administered ondansetron IV on Day 1 immediately prior to induction of anesthesia plus a matching placebo dose to aprepitant as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia.
3090851|NCT01732471|Experimental|Kuvan®|
3090852|NCT01732484|Other|iMics1 NY-60|eyes with implantation of iMics1 NY-60 IOL
3090853|NCT01732484|Other|AcrySof SN60WF|eyes with implantation of AcrySof SN60WF IOL
3090854|NCT01732510|Experimental|Part 1: MK-8226 0.3 mg/kg|MK-8226 administered intravenously (IV) at a weight-based dose every 2 weeks for a period of 12 weeks.
3090855|NCT01732510|Experimental|Part 1: MK-8226 1 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3090856|NCT01732510|Experimental|Part 1: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3090857|NCT01732510|Experimental|Part 1: MK-8226 10 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3090858|NCT01732510|Placebo Comparator|Part 1: Placebo (pooled)|Dose-matched placebo administered IV every 2 weeks for a period of 12 weeks.
3090859|NCT01732510|Experimental|Part 2: MK-8226 3 mg/kg|MK-8226 administered IV at a weight-based dose every 2 weeks for a period of 12 weeks.
3090860|NCT01732510|Placebo Comparator|Part 2: Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
3090861|NCT01732536|Experimental|S8 Sinus Implant|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
3090862|NCT01732536|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
3090863|NCT01732549|Experimental|Tasquinimod|1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
3090864|NCT01732549|Placebo Comparator|Placebo|1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
3090865|NCT01732588|Active Comparator|Regimen A - 120mg OZ439 PIB|120mg single dose of OZ439 as powder in bottle (PIB) formulation
3090866|NCT01732588|Experimental|Regimen B - 120 mg OZ439 IR caplet|120 mg single dose of OZ439 immediate release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
3090867|NCT01732588|Experimental|Regimen C - 120 mg OZ439 caplet via Enterion capsule|120 mg single dose of OZ439 caplet formulation containing nanoparticulate, administered orally via the Enterion capsule and delivered to the proximal small bowel
3090868|NCT01732627|Experimental|Group 1: MenACYW Conjugate Vaccine|Adult participants aged greater than or equal to (≥) 56 years received a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W 135) Tetanus Toxoid (MenACYW) Conjugate vaccine on Day 0.
3090869|NCT01732627|Active Comparator|Group 2: Menomune® A/C/Y/W 135 vaccine|Adult participants aged ≥56 years received a single dose of Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined (Menomune®) vaccine on Day 0.
3090870|NCT01732640|Experimental|Study Arm|Eligible patients will begin with a 14-day lead-in period with afatinib alone. This will be followed immediately by 2 cycles of induction chemotherapy (IC) with carboplatin AUC 6 IV Day 1, paclitaxel 175mg/m2 IV Day 1, and oral afatinib as a continuous daily dosing. Each cycle is repeated every 21 days. After completion of 2 cycles of IC, patients will be assessed for response by CT/MRI and clinical exam. After the induction, all patients will receive Intensity Modulated Radiation Therapy (IMRT) with weekly cisplatin 40mg/m2 IV. Chemoradiotherapy (CRT) will begin 2-3 weeks after the completion of the second cycle of IC. The patients will be evaluated with a MRI or CT, and FDG PET approximately 12 weeks after completion of CRT.
3090871|NCT01732692|Experimental|MOVIPREP (Morning-only dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), twice within same morning of colonoscopy.
3090872|NCT01732692|Other|MOVIPREP (Split-dose)|MOVIPREP 250 ml solution every 15 minutes for up to one hour (4 doses in 1 hour=1 litre of solution), once the evening before colonoscopy and once the morning of colonoscopy.
3090873|NCT01732718|Experimental|Atorvastatin, then Placebo|Participants first received Atorvastatin 40 mg tablets once daily for 6 weeks. After a washout period of 4 weeks, they then received placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks.
3090874|NCT01732718|Placebo Comparator|Placebo, Then Atorvastatin|Participants first received Placebo (matching Atorvastatin 40 mg tablets) once daily for 6 weeks. After a washout period of 4 weeks, they then received Atorvastatin 40 mg tablets once daily for 6 weeks.
3090875|NCT01732757|Active Comparator|Lastacaft®|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
3090876|NCT01732757|Active Comparator|Pataday™|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
3090877|NCT01732757|Placebo Comparator|Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%)|One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
3090878|NCT01732770|Experimental|Denosumab 60 mg|Participants received denosumab 60 mg subcutaneous injection once every 6 months for 12 months and placebo to zoledronic acid by intravenous infusion on Day 1.
3090879|NCT01732770|Active Comparator|Zoledronic Acid 5 mg|Participants received zoledronic acid 5 mg by intravenous infusion on Day 1 and placebo to denosumab by subcutaneous injection on Day 1 and at Month 6.
3090880|NCT01732783||Metastatic Colorectal Cancer|Participants with wild-type RAS metastatic colorectal cancer who were receiving panitumumab in combination with chemotherapy.
3090881|NCT01732796|Experimental|Allocated 24 weeks BI 207127 + BI 201335|24 weeks of BI 207127 and BI 201335 in combination with Ribavirin
3090882|NCT01732796|Experimental|Randomized 16 weeks BI 7127+BI1335 + RBV|16 weeks of BI 207127 and QD BI 201335 RBV, followed by additional 8 weeks of placebo BI 207127+ placebo BI 201335 in combination with placebo RBV
3090883|NCT01732796|Experimental|Randomized 24weeks BI 7127+ BI1335 + RBV|24 weeks of BI 207127and BI 201335 in combination with RBV
3090884|NCT01732809|Active Comparator|abobotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received abobotulinumtoxin A in one of the sides of the forehead.
3090885|NCT01732809|Active Comparator|onabotulinumtoxin A|Patients were randomized to the side of the forehead (left or right) in which the products were administered. All the patients received onabotulinumtoxin A in one of the sides of the forehead.
3090886|NCT01732822|Experimental|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
3090887|NCT01732822|Active Comparator|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
3090888|NCT01732835|Experimental|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
3090889|NCT01732874|Other|Expecta 200 mg|Breastfeeding mothers of pre-mature infants randomly assigned to 200 mg Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
3090890|NCT01732874|Other|Expecta 1 Gram|Breastfeeding mothers of pre-mature infants randomly assigned to one Gram of Expecta to be taken orally once a day. Expecta to be taken for approximately 8 weeks post-partum or a shorter time if infant is discharged sooner from NICU.
3090891|NCT01733056|Placebo Comparator|Healthy Volunteer|Healthy volunteers without skin disease that received administration of Fluzone
3090892|NCT01733056|Experimental|Azathioprine|Patients with skin diseases taking azathioprine that received administration of Fluzone
3090893|NCT01733056|Experimental|TNF alpha blocker|Patients with skin diseases taking azathioprine that received administration of Fluzone
3090894|NCT01733069||No treatment|
3090895|NCT01733121|Experimental|NBI-98854|Dose titration to determine a subject's optimal dose in the range of 25 to 75 mg NBI-98854. Dose titration is performed in increments of 25 mg. NBI-98854 administered as one (1) 25 mg capsule, two (2) 25 mg capsules, or one (1) 25 mg capsule and one (1) 50 mg capsule by mouth, taken every morning between 7:00am - 10:00am for 6 weeks.
3090896|NCT01733121|Placebo Comparator|Placebo|Capsule containing no active substance, manufactured to mimic NBI-98854 25 mg and 50 mg capsules.
3090897|NCT01733186|Experimental|CARTISTEM®|Drug name and ingredients: CARTISTEM [allogeneic-unrelated, umbilical cord blood-derived mesenchymal stem cells, ex vivo cultured, combined with sodium hyaluronate] Dosage: Administer 0.5 mL of the combination product per cm^2 of the cartilage defect
3090898|NCT01733212|Experimental|Ginger|2 gm powder of ginger filled in a capsule
3090899|NCT01733212|Placebo Comparator|Placebo|2 gm of placebo pill (A capsule)
3090900|NCT01733238|Experimental|PNT2258|PNT2258 120 mg/m2 will be administered as a 2-hour intravenous infusion on days 1-5 of a 21-day cycle. Treatment may continue (unless there is disease progression or the occurrence of unacceptable toxicity) for a total of 6 cycles of therapy.
3090901|NCT01733277||With neuropathic pain (PainDETECT ≥ 13)|Magnetic Resonance Imaging (MRI)
3090902|NCT01733277||No neuropathic pain (PainDETECT<13)|Magnetic Resonance Imaging (MRI)
3090903|NCT01733316|Experimental|All Participants|"Cystagon® Phase: From Screening and during Months 1, 2, 3 participants receive their usual dose of Cystagon® every 6 hours (Q6H).~RP103 Phase: During Months 3.5, 4, 5, 6, 7 participants receive RP103 every 12 hours (Q12H).~Long Term Phase: On or after Month 7, for the remainder of study participants receive RP103 Q12H."
3090904|NCT01733329|Experimental|Misoprostol|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 400 mcg misoprostol (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
3090905|NCT01733329|Placebo Comparator|Folic Acid|women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to 10 mg Folic acid (2 tablets) (n=60) placed in buccal space after umbilical cord clamping by anesthesiologist. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.
3090906|NCT01733407|Placebo Comparator|Sugar pill|Placebo arm
3090907|NCT01733407|Active Comparator|L-serine|amino acid supplementation with L-serine
3090908|NCT01733472|Placebo Comparator|RA-arm|RA-arm: the patients in this arm will receive intrathecal anaesthesia consisting of bupivacaine 15 mg
3090909|NCT01733472|Experimental|GA-arm, remifentanil|GA-arm: patients in this arm will receive general anaesthesia consisting of Target Controlled Infusion (TCI) of remifentanil and propofol
3090910|NCT01733628||Bevacizumab + Chemotherapy|Patients who received the addition of Bevacizumab (BV) every 2-3 weeks to Chemotherapy (CT) with either oxaliplatin or irinotecan plus fluoropyrimidines in patients with Metastatic Colorectal Cancer (MCRC), either paclitaxel or capecitabine in patients with Metastatic Breast Cancer (MBC), as first-line therapy.
3090911|NCT01733680|Active Comparator|Amiloride|"Drug: Subjects will take 5mg qd Amiloride for 2 weeks, 10mg qd Amiloride for 3 weeks, 15 mg qd Amiloride for 3 weeks.~Behavioral: Each week subjects will complete the AISRS, BRIEF-A, and CGI."
3090912|NCT01733680|Placebo Comparator|Placebo|Drug: Subjects will take placebo for 8 weeks Behavioral: Each week subjects will complete questionnaires: AISRS, BRIEF-A, and CGI
3090913|NCT01733732|Experimental|Systane Balance|SYSTANE® BALANCE Lubricant Eye Drops, 1 drop in each eye 4 times a day for 30 days
3090914|NCT01733732|Active Comparator|Systane Gel|SYSTANE® Gel, 1 drop in each eye 4 times a day for 30 days
3090915|NCT01733745|Experimental|SYSTANE® Family|SYSTANE® Lid Wipes administered to treated eye(s) once a day; SYSTANE® BALANCE lubricant eye drops administered to treated eye(s), 1 drop 4 times a day; SYSTANE® Vitamins, 2 softgels ingested daily. Duration of treatment was 3 months.
3090916|NCT01733745|Active Comparator|Standard of Care|Microfiber towels (as warm compresses, with or without saline eye drops) warmed to the maximum comfortable temperature and placed over closed eyes for 8 minutes, 1 time a day. Duration of treatment was 3 months.
3090917|NCT01733758|Experimental|Albiglutide 30 mg weekly|Subjects will be randomly assigned to double blind albiglutide 30 mg weekly treatment for 52 weeks
3090918|NCT01733758|Experimental|Albiglutide 50 mg weekly|Subjects will be randomly assigned to double blind albiglutide 50 mg weekly until Week 52
3090919|NCT01733758|Placebo Comparator|Placebo|Subjects will be randomly assigned to double blind matching albiglutide placebo administered weekly. Subjects will then cross-over to double-blind treatment with albiglutide 30 mg weekly at Week 24 until Week 52
3090920|NCT01733758|Active Comparator|Liraglutide 0.9 mg daily|Subjects will be randomly assigned to open-label liraglutide for 52 weeks
3090921|NCT01733953|Experimental|Atorvastatin|6-Months Atorvastatin Therapy; 40mg oral, once daily
3090922|NCT01733953|Placebo Comparator|Sugar Pill (Placebo)|6-Months Placebo (sugar pill); oral, once daily
3090923|NCT01734161|Active Comparator|Dexamethasone|One dose of 8 mg of intravenous dexamethasone diluted in 50 ml of normal saline given as an infusion over 10 minutes.
3090924|NCT01734161|Placebo Comparator|Placebo|One dose of 50 ml of 0.9% normal saline that will be given as an infusion over 10 minutes.
3090925|NCT01734239|Experimental|Pneumovax™ 23: Participants Between 2 and 49 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
3090926|NCT01734239|Experimental|Pneumovax™ 23: Participants >=50 Years|Participants received a single, 0.5-mL intramuscular injection of Pneumovax™ 23 on Day 1
3090927|NCT01734317|Experimental|Dressing|Mepilex Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
3090928|NCT01734382|Experimental|Part 1: Tocilizumab (TCZ) Q2W|Participants will receive tocilizumab intravenous (IV) infusions (12 mg/kg for participants < 30 kg; 8 mg/kg for participants >/= 30 kg) once every other week (Q2W) up to 24 weeks or until occurrence of a protocol defined laboratory abnormality in Part 1 of the study.
3090929|NCT01734382|Experimental|Part 2: TCZ IV 12 mg/kg Q3W/Q4W|Participants with weight < 30 kg will receive tocilizumab IV infusions of 12 mg/kg once every three weeks (Q3W) up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 12 mg/kg once every four weeks (Q4W) up to Week 52 in Part 2 of the study.
3090930|NCT01734382|Experimental|Part 2: TCZ IV 8 mg/kg Q3W/Q4W|Participants with weight >/= 30 kg will receive tocilizumab IV infusions of 8 mg/kg Q3W up to 52 weeks or until occurrence of neutropenia, thrombocytopenia, or liver enzyme abnormality as per protocol criteria. Participants who complete 5 consecutive infusions of Q3W and have a laboratory abnormality of neutropenia, thrombocytopenia or elevated liver enzymes as per protocol criteria, after resolution of this laboratory abnormality will switch to tocilizumab IV infusions of 8 mg/kg Q4W up to Week 52 in Part 2 of the study.
3090931|NCT01734395||Galantamine|Patients will receive galantamine 8 mg/day for the first 4 weeks and the dose of galantamine will be increased up to 24 mg (if tolerable).
3090932|NCT01734434||Pregnant women|24 weeks or more of gestation
3090933|NCT01734512|Experimental|Everolimus|Everolimus tablet will be taken daily by mouth with water. Twenty-eight days will constitute one course and subsequent courses will immediately follow with no break in the administration of the drug. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Patients will also be provided with a drug diary for everolimus. The maximum time on study is 24-months, but if there is no disease progression or adverse events, the patient may speak with a doctor about continuing the treatment off-study.
3090934|NCT01734525|Experimental|Anidulafungin|Patients at risk will receive therapy with anidulafungin
3090935|NCT01734551|Active Comparator|Morphine|Initial dose is 0.4mg/kg/day, divided every 3-4 hours, given PO with feeds. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
3090936|NCT01734551|Active Comparator|Clonidine|Dose is started at 5 mcg/kg/day, given PO with feeds, divided every 3-4 hours. Drug is required until symptoms of withdrawal no longer cause the infant feeding, behavior, or elimination problems, up to 3 months.
3090937|NCT01734655||All Participants|Participants will be asked to complete the MEQ, the Eating Inventory Questionnaire, The Mindful Attention Awareness Scale (MAAS), and the Neighborhood Environment Walkability Scale (NEWS). Participants will then be asked to sequentially respond to each of the 28 items and the response choices from the MEQ and briefly discuss their reaction to the items and response choices. Finally, participants will either participate in a focus group or an individual cognitive interview, giving them the opportunity to elaborate on their responses to the MEQ. The first 11 participants completed focus groups and the remaining 29 participants completed individual cognitive interviews.
3090938|NCT01734746|Experimental|Tracerinjection|The intervention concerns tracerinjection (both blue dye and the radioactive isotope beingtechnetium-99-m-labeled albumin nanocolloid) in the ligamentum ovarii proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), close to the ovary and just below the peritoneum.
3090939|NCT01734772|Experimental|Reference (Part 1/A, Part 2/C)|multiple doses of dabigatran (alone)
3090940|NCT01734772|Experimental|Test 1 (Part 1/Treatment B)|concomitant administration of dabigatran and ticagrelor
3090941|NCT01734772|Experimental|Test 2 (Part 2/Treatment D)|staggered administration of ticagrelor and dabigatran
3090942|NCT01734785|Active Comparator|Linagliptin|5 mg once daily
3090943|NCT01734785|Experimental|Empaglifozin + Linagliptin low dose|1 tablet once daily
3090944|NCT01734785|Experimental|Empagliflozin + Linagliptin high dose|1 tablet once daily
3090945|NCT01734811|Placebo Comparator|Placebo|The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation
3090946|NCT01734811|Experimental|Biological vaccine|The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
3090947|NCT01734850|Experimental|No busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes without busulfan preconditioning
3090948|NCT01734850|Experimental|1 x 4mg/kg busulfan preconditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with single 4mg/kg busulfan dose administered as pre-conditioning for transplant
3090949|NCT01734850|Experimental|2 x 4mg/kg busulfan pre-conditioning|Cal-1 modified HSPC and Cal-1 modified CD4+ T lymphocytes, with two 4mg/kg busulfan doses administered as pre-conditioning for transplant
3090950|NCT01734889|Experimental|Orfadin suspension|Drug: nitisinone, oral suspension
3090951|NCT01734902|Experimental|1 Hyoscine butylbromide|drops, oral administration with 240 mL water
3090952|NCT01734902|Experimental|2 Hyoscine butylbromide|sugar coated tablets, oral administration with 240 mL water
3090953|NCT01734993|Experimental|Tocilizumab|Moderate to severe rheumatoid arthritis participants from France, who completed the Week 97 visit of the WA22762 LTE study and considered as responders (defined as having improvement in DAS28 of >1.2 points) will continue tocilizumab treatment within this local LTE study for a maximum of 156 weeks, or until SC TCZ becomes commercially available, whichever occurs first.
3090954|NCT01735175|Active Comparator|Neulasta®|During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.
3090955|NCT01735175|Experimental|LA-EP2006|During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.
3090956|NCT01735201|Experimental|AGN-199201 Dose A Once Daily|AGN-199201 Dose A applied once daily to the face for 28 days.
3090957|NCT01735201|Experimental|AGN-199201 Dose B Once Daily|AGN-199201 Dose B applied once daily to the face for 28 days.
3090958|NCT01735201|Experimental|AGN-199201 Dose C Once Daily|AGN-199201 Dose C applied once daily to the face for 28 days.
3090959|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Once Daily|AGN-199201 Vehicle applied once daily to the face for 28 days.
3090960|NCT01735201|Experimental|AGN-199201 Dose A Twice Daily|AGN-199201 Dose A applied twice daily to the face for 28 days.
3090961|NCT01735201|Experimental|AGN-199201 Dose B Twice Daily|AGN-199201 Dose B applied twice daily to the face for 28 days.
3090962|NCT01735201|Experimental|AGN-199201 Dose C Twice Daily|AGN-199201 Dose C applied twice daily to the face for 28 days.
3090963|NCT01735201|Placebo Comparator|AGN-199201 Vehicle Twice Daily|AGN-199201 Vehicle applied twice daily to the face for 28 days.
3090964|NCT01735214||Patients with POAG or OHT|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
3090965|NCT01735279|Placebo Comparator|Placebo|The placebo group will receive 3g per day of mineral oil during 90 days treatment
3090966|NCT01735279|Experimental|Omega3|The omega 3 group will receive 3g per day of fish oil during 90 days treatment
3090967|NCT01735396|Experimental|Abiraterone Acetate|Abiraterone acetate 1000mg orally daily until the time of disease progression, in the absence of prohibitive toxicities.
3090968|NCT01735617|Experimental|Hydrocortisone Modified Release Capsules|Chronocort Modified Release Capsules, 5mg, 10mg and 20mg Dosing frequency twice-daily (mane and nocte) Dose setting by titration to achieve optimal biochemical and therapeutic response
3090969|NCT01735630|Experimental|ELND005|ELND005 film coated tablets, BID for 12 weeks
3090970|NCT01735630|Placebo Comparator|Placebo|Matched placebo BID for 12 weeks
3090971|NCT01735877|Experimental|Mirror therapy|All eligible patients will be randomly allocated into 2 groups. Group 1 will be given Mirror therapy
3090972|NCT01735877|Sham Comparator|Control group|Group 2 will be given sham mirror therapy
3090973|NCT01735916|Active Comparator|CRT-P ON|CRT-P Implant CRT-P ON
3090974|NCT01735916|Placebo Comparator|CRT-P OFF|CRT-P Implant CRT-P OFF
3090975|NCT01735981|Experimental|video game exercise|Video game exercise using Dance Dance Revolution
3090976|NCT01735981|Other|control|hand-held video game control
3090977|NCT01735994|Experimental|Healthy Weight Intervention|Eating Disorder Prevention Program
3090978|NCT01735994|Other|Brochure wait list|Brochure wait list control group
3090979|NCT01736085|No Intervention|Material Group|Subjects will receive self-help materials
3090980|NCT01736085|Active Comparator|Materials plus Voucher|Subjects will receive self-help materials and a voucher for 2 week's worth of nicotine patches
3090981|NCT01736085|Active Comparator|Materials plus Patches|Subjects will receive self-help materials and a 2 week's worth of nicotine patches
3090982|NCT01736085|Active Comparator|Counseling|Subjects will receive up to 5 sessions of telephone counseling
3090983|NCT01736085|Active Comparator|Counseling plus Voucher|Subjects will receive up to 5 sessions of telephone counseling plus a voucher for 2 week's worth of nicotine patches.
3090984|NCT01736085|Active Comparator|Counseling plus Patches|Subjects will receive up to 5 sessions of telephone counseling plus 2 week's worth of nicotine patches.
3090985|NCT01736124|Experimental|Computerized Cognitive Training (CCT)|Randomly selected subjects perform a variety of computer games tailored to address their personal cognitive deficits.
3090986|NCT01736124|Active Comparator|Active control|Randomly selected subjects perform a variety of computer games that are engaging but not designed to enhance cognitive skills.
3090987|NCT01736176|Experimental|Levodopa-Carbidopa Intestinal Gel|"Participants had the PEG-J tube placement procedure performed on Study Day 1 and, at the discretion of the investigator, began initiation and titration of LCIG infusion. Dosing was determined individually. The starting total daily dose of LCIG was based solely on the daily dose of the oral levodopa taken immediately prior to Study Day 1 and was adjusted to obtain the optimal clinical response for the individual participant.~Participants received treatment for up to 60 weeks; participants who completed their Week 60 visit before LCIG was commercially available had the option to extend their LCIG therapy, if in the opinion of the investigator, the participant would benefit from continued LCIG treatment."
3090988|NCT01736189||Participants treated with adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 104 weeks
3090989|NCT01736215||Participants with cancer related anemia|Participants with cancer related anemia receiving chemotherapy will be observed for response to erythropoietin treatment.
3090990|NCT01736241|Experimental|LY3053102|A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
3090991|NCT01736241|Placebo Comparator|Placebo|A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
3090992|NCT01736254|Experimental|Gemfibrozil|Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1
3090993|NCT01736254|Experimental|Evacetrapib|Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)
3090994|NCT01736254|Experimental|Evacetrapib + Gemfibrozil|Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.
3090995|NCT01736267|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the Nucleus ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
3090996|NCT01736358|Experimental|Intranasal Ketoralac|A single dose of Sprix (31.5 mg) will be administered to patients 20 minutes before the end of surgery. 15.75 mg of Sprix will be sprayed in each nostril.
3090997|NCT01736358|Placebo Comparator|Placebo|A single dose of placebo will be administered 20 minutes before the end of surgery. 15.75 mg of the placebo will be sprayed in each nostril.
3090998|NCT01736397|Experimental|Ferric Citrate|Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
3090999|NCT01736397|Placebo Comparator|Placebo|Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.
3091000|NCT01736475|Experimental|Prophylaxis|
3091001|NCT01736475|Experimental|On-demand|
3091002|NCT01736527|Experimental|LE Gel|A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
3091003|NCT01736540|Other|Magnetic Resonance Imaging (MRI)|All participants were subjected to a non-invasive hepatic and cardiac MRI within 60 days of enrollment to measure iron overload.
3091004|NCT01736553||Infants with Spinal Muscular Atrophy|Infants diagnosed Spinal Muscular Atrophy
3091005|NCT01736553||Healthy controls|Healthy control infants
3091006|NCT01736566|Experimental|Family History + Whole Genome Sequencing|Doctors and their patients receive a Genome Report and an Annotated Family History Report.
3091007|NCT01736566|Active Comparator|Family History Only|Doctors and their patients receive an Annotated Family History Report only.
3091008|NCT01736579|Experimental|IGIV, 10% at 0.2 g/kg body weight|IGIV, 10% at 0.2 g/kg body weight every 2 weeks for up to 3 years, 6 months.
3091009|NCT01736579|Experimental|IGIV, 10% at 0.4 g/kg body weight|IGIV, 10% at 0.4 g/kg body weight every 2 weeks for up to 3 years, 6 months
3091010|NCT01736657|Experimental|Red cell exchange in sickle cell|Open arm; Red cell blood exchange for patients with sickle cell disease
3091011|NCT01736683|Experimental|Sotatercept 0.1 mg/kg|Sotatercept 0.1 mg/kg
3091012|NCT01736683|Experimental|Sotatercept 0.3 mg/kg|Sotatercept 0.3 mg/kg
3091013|NCT01736683|Experimental|Sotatercept 0.5 mg/kg|Sotatercept 0.5 mg/kg
3091014|NCT01736683|Experimental|Sotatercept 1.0 mg/kg|Sotatercept 1.0 mg/kg
3091015|NCT01736683|Experimental|Sotatercept 1.5 mg/kg|Sotatercept 1.5 mg/kg
3091016|NCT01736683|Experimental|Sotatercept 2.0 mg/kg|Sotatercept 2.0 mg/kg
3091017|NCT01736696|Experimental|5 mg BID|5 mg BID for 13 days and once on Day 14
3091018|NCT01736696|Experimental|10 mg BID|10 mg BID for13 days and once on Day 14*
3091019|NCT01736696|Experimental|20 mg BID|20 mg BID for 13 days and once on Day 14
3091020|NCT01736696|Experimental|30 mg BID|30 mg BID for 13 days and once on Day 14
3091021|NCT01736696|Experimental|60 mg QD|60 mg QD for 14 days
3091022|NCT01736696|Experimental|50 mg BID|50 mg BID x 13 days and once on day 14
3091023|NCT01736852|Experimental|CRB plus Pitocin|
3091024|NCT01736852|Active Comparator|Pitocin|
3091025|NCT01736865|Placebo Comparator|placebo|One placebo pill daily for 1 year
3091026|NCT01736865|Active Comparator|cholecalciferol|One cholecalciferol pill daily for 1 year
3091027|NCT01736917|Experimental|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone|"Patients must have no nausea and/or vomiting for 24 hours and must not have used other anti-emetics for 72 hours prior to starting protocol treatment. Treatment must not start until this criteria is satisfied.~Any germ cell chemotherapy regimen utilizing Cisplatin (20mg/m2 x 5 days).~Acute emesis prophylaxis:~Any 5HT3 receptor antagonist may be used D1 - 5 or D1, 3 and 5 if palonosetron is used per institutional standards.~Dexamethasone 20mg PO (orally) daily, D1 and 2~Fosaprepitant 150mg IV on day 3~Delayed emesis prophylaxis:~Fosaprepitant 150mg IV on D5~Dexamethasone 4mg PO BID (twice a day) on D6, 7 and 8~PRN antiemetics allowed at the discretion of the treating investigator~No additional doses of 5HT3 receptor antagonist, dexamethasone, or fosaprepitant will be given during the acute or delayed treatment periods"
3091028|NCT01736930|Active Comparator|Predictive pump suspension algorithm|The study laptop will be running actively during the night and suspending the patient's pump if the algorithm predicts hypoglycemia based on the patient's continuous glucose sensor trend.
3091029|NCT01736930|No Intervention|Standard of Care|The control algorithm will run passively and not recommend suspensions or resumption to the patient's pump.
3091030|NCT01736943|Experimental|Bortezomib + Doxil|Bortezomib will be given subcutaneously at 1.5mg/m2 on days 1, 4, 8 and 11 of a 3 week cycle. Doxil will be administered once every three weeks as a single intravenous infusion at a dose of 40 mg/m2 (day 4 of each cycle).
3091031|NCT01737021|Experimental|Psycho-educational intervention|Psycho-education
3091032|NCT01737021|No Intervention|Treatment as usual|
3091033|NCT01737268|Experimental|FK949E Elderly Participants|After 2 days of dose-titration, elderly participants received either FK949E 150 mg or FK949E 300 mg once daily at bedtime from day 3 to week 52. Dose increase and reduction was allowed following dose increase or reduction guidelines and at the investigator's discretion. After which, participants went through a follow-up period of 1 week. For participants, who completed or discontinued treatment at FK949E 300 mg, a dose-tapering period was placed before proceeding to the follow-up period, and FK949E 150 mg was administered once daily for 1 week in this period.
3091034|NCT01737281|Experimental|Proactive outreach|Proactive outreach to deliver 7 sessions of telephone counseling and nicotine replacement therapy.
3091035|NCT01737281|Active Comparator|Usual care|Usual smoking cessation care from clinical staff
3091036|NCT01737398|Active Comparator|Inotersen|300 mg inotersen administered subcutaneously (SC) 3 times on alternate days in the first week and then once-weekly for 64 weeks
3091037|NCT01737398|Active Comparator|Placebo|Placebo administered SC 3 times on alternate days in the first week and then once-weekly for 64 weeks
3091038|NCT01737593|Active Comparator|Acetaminophen PR|Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
3091039|NCT01737593|Active Comparator|Acetaminophen PO-low dose|Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
3091040|NCT01737593|Active Comparator|Acetaminophen PO-high dose|Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
3091041|NCT01737684|Experimental|Participants With Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
3091042|NCT01737684|Experimental|Healthy Matched Control Participants|Participants who are healthy will receive a single oral dose of vibegron 100 mg.
3091043|NCT01737684|Experimental|Participants With Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency will receive a single oral dose of vibegron 100 mg.
3091044|NCT01737697|Experimental|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
3091045|NCT01737697|Placebo Comparator|Placebo (acute phase)|Placebo ( silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals.
3091046|NCT01737697|Experimental|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
3091047|NCT01737697|Placebo Comparator|Placebo (subacute phase)|Placebo (silicified microcrystalline cellulose) randomized to mimic doses of experimental drug administered once a day (qd) prior to the morning meal for 12 days.
3091048|NCT01737710|Experimental|92 Non-atopic controls vaccinated with Fluzone® Intradermal|Non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3091049|NCT01737710|Experimental|Moderate to severe AD vaccinated with Fluzone® Intradermal|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3091050|NCT01737710|Active Comparator|Moderate to severe AD vaccinated with Fluzone® (Intramuscular)|92 moderate to severe atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
3091051|NCT01737710|Active Comparator|Non-atopic controls vaccinated with Fluzone® (Intramuscular)|20 non-atopic controls who will receive a single dose of the seasonal 2012-2013 Fluzone® (Intramuscular) influenza vaccine from 0.5 mL single dose vials.
3091052|NCT01737710|Experimental|Mild AD participants vaccinated with Fluzone® Intradermal|20 mild atopic dermatitis participants who will receive a single dose of the seasonal 2012-2013 Fluzone® Intradermal influenza vaccine via a single-dose pre-filled microinjection system (0.1mL).
3091053|NCT01737762|Experimental|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
3091054|NCT01737762|Placebo Comparator|Vehicle|Vehicle Control(fibrinogen solution & thrombin solution without cells)
3091055|NCT01737840|Experimental|pantoprazole|Intravenous pantoprazole 40 mg flacon
3091056|NCT01737840|Active Comparator|ranitidine|Intravenous ranitidine 50 mg
3091057|NCT01737879|Experimental|Peginesatide / Epoetin Alfa|Participants were treated with peginesatide administered intravenously (IV) every 4 weeks for 24 weeks. Participants were then to be converted back to epoetin alfa administered by IV 3 times a week for 32 weeks.
3091058|NCT01737931|Experimental|Topical Steroid|Topical medication of steroid (Dexamethasone) to the application sites after the patch removal
3091059|NCT01737931|Experimental|Topical antihistamine|Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal
3091060|NCT01737931|No Intervention|No-treatment|No treatment to the application sites after the patch removal
3091061|NCT01737944|Experimental|10mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3091062|NCT01737944|Experimental|15mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3091063|NCT01737944|Experimental|20mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3091064|NCT01737944|Experimental|25mg Methotrexate (MTX) Group|Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection
3091065|NCT01737996|Experimental|All patients|For the first 9 days patients receive BI 207127 low dose or high dose, then BI 207127 high dose with faldaprevir
3091066|NCT01738191|Active Comparator|Atomoxetine|The study drug target dose is Atomoxetine (ATM) 80 milligram (mg) per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
3091067|NCT01738191|Placebo Comparator|Placebo|Patients in the placebo arm will follow the same titration schedule as those in the active arm. Patients will titrate up to target dose by starting 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose to 80mg daily.
3091068|NCT01738321||Cardiac patients|Patients undergoing cardiac surgery
3091069|NCT01738321||Non-cardiac patients|Patients undergoing any surgery other than cardiac surgery
3091070|NCT01738438|Experimental|Cabozantinib|Cabozantinib was given at a dose of 60 mg orally once per day for 21 day cycles. Treatment continued in the absence of disease progression or unacceptable toxicity.
3091071|NCT01738477|Experimental|Boostrix Group 2|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who were randomized to the Lot A, Lot B or Lot C groups in study NCT00109330, received a second dose of Boostrix in this study.
3091072|NCT01738477|Active Comparator|Boostrix Group 1|Healthy male of female subjects, aged 19 to 30 years of age at the time of booster vaccination, who received Massachusetts Public Health Biologic Laboratories combined tetanus and diphtheria vaccine in study NCT00109330, received the first dose of Boostrix in this study.
3091073|NCT01738503|Experimental|(8 mg) RBP-6000: 50 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 50 mg are given at 28 day intervals.
3091074|NCT01738503|Experimental|(12 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 12 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals
3091075|NCT01738503|Experimental|(24 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
3091076|NCT01738503|Experimental|(8 mg) RBP-6000: 100 mg|Participants are stabilized by day -5 on Subutex 8 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 100 mg are given at 28 day intervals.
3091077|NCT01738503|Experimental|(14 mg) RBP-6000: 200 mg|"Participants are stabilized by day -5 on Subutex 14 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 200 mg are given at 28 day intervals.~Participants who receive RBP-6000 containing 200 mg buprenorphine and reach Day 112 (and have received all 4 planned SC injections) have the option to participate in the Positron Emission Tomography (PET) Pilot substudy. In the PET Pilot sub-study participants remain on 200 mg SC injections at 28 day intervals for an additional 6-9 intervals until they complete an magnetic resonance imaging (MRI) and a PET scan and pharmacokinetic samples at week 1 and week 4 post injection."
3091078|NCT01738503|Experimental|(8-24 mg) RBP-6000: 300 mg|Participants are stabilized by day -5 on a Subutex between 8-24 mg. During the study, four subcutaneous (SC) injections containing RBP-6000 300 mg are given at 28 day intervals.
3091079|NCT01738581|Experimental|rTMS + SMR, then rTMS + CTL|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) and sensorimotor retraining (SMR). Second phase of treatment: rTMS and control treatment (CTL) (CTL therapy consisted of non-specific therapy that includes stretching, massage, range of motion).
3091080|NCT01738581|Experimental|rTMS + CTL, then rTMS + SMR|First phase of treatment: Repetitive transcranial magnetic stimulation (rTMS) with non-specific therapy that includes stretching, massage, range of motion. Second phase of treatment: rTMS and sensorimotor retraining (SMR).
3091081|NCT01738594|Experimental|Arm A (carfilzomib)|Patients receive carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16.
3091082|NCT01738594|Experimental|Arm B (carfilzomib, romidepsin)|Patients receive carfilzomib as in Arm A and romidepsin IV over 4 hours on days 1, 8, and 15.
3091083|NCT01738646|Experimental|Vorinostat & Bevacizumab|Patients will be administered bevacizumab every 2 weeks and vorinostat will be taken on days 1-7 and 15-21 of each 28-day cycle at 400 mg per day.
3091084|NCT01738672|Experimental|Nitrous Oxide|Parturients who request labor analgesia will be offered inhaled nitrous oxide for labor analgesia.
3091085|NCT01738737|Experimental|Stretching|Seven stretching exercises for lower limbs during 24 sessions
3091086|NCT01738737|Experimental|Placebo laser + Stretching|application of placebo laser therapy during nine sessions plus stretching exercises during 24 sessions
3091087|NCT01738737|Experimental|Active laser + Stretching|application of active laser therapy during nine sessions plus stretching exercises during 24 sessions
3091088|NCT01738737|Experimental|Active Laser|Application of active laser only during 24 sessions
3091089|NCT01738737|No Intervention|Control|Control group that will receive a small book with informations about knee osteoarthritis and postural orientation.
3091090|NCT01738750|Experimental|Cost Information Included|Group of patients that will receive cost information for both the laparoscopic and open surgical procedures prior to choice of procedure.
3091091|NCT01738750|No Intervention|No Cost Information Included|Group of patients that will not receive cost information for the laparoscopic and open surgical procedures prior to choice of procedure.
3091092|NCT01738919|Active Comparator|Non-subluxated - splinting|Conservative treatment with splinting for 6 weeks.
3091093|NCT01738919|Active Comparator|Non-subluxated - operation|Operative treatment with extension block technique
3091094|NCT01738971|No Intervention|control (standard care)|standard verbal and written advice on contraception from pharmacy
3091095|NCT01738971|Experimental|rapid access|rapid access to family planning service
3091096|NCT01738971|Experimental|progestogen only pill|one month progestogen only pill
3091097|NCT01738984|Experimental|MomZing Web Program|Features include selection one to three 10-minute videos demonstrating yoga, aerobics, and strengthening, specifically designed for mothers with infants 2 to 8 months of age. Women will sequence together videos personalized to their fitness level, preference for exercise type, and a choice to actively exercise with her baby or alone. Exercises with a baby will be tailored to the infant's weight and include interactions that promote cognitive development and mother-child bonding.
3091098|NCT01738984|Experimental|Standard exercise DVD|Exercise DVD that demonstrates yoga or strengthening exercises a mother can perform with her infant.
3091099|NCT01739231|Experimental|ACE527 alone|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
3091100|NCT01739231|Experimental|ACE527 plus dmLT|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT) at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
3091101|NCT01739231|Active Comparator|Control: Part A and B|In Part A of the study, subjects were split into two cohorts whereby enrollment of the second cohort depended on the safety profile of the first cohort. In Part A, subjects received three oral doses of CeraVacx placebo at 0, 1, and 2 months. For Part B of the study, eligible subjects who expressed interest of the study were administered H10407 challenge strain 5-7 months after the three-dose vaccination series.
3091102|NCT01739231|Active Comparator|Control: Part B only|Eligible participants were screened and administered H10407 challenge strain concurrently with other arms in Part B of the study. Their results for Part B are combined with that of the Control Arm in Part A, which received three oral doses of CeraVacx placebo.
3091103|NCT01739309|Experimental|Abemaciclib|200 milligram (mg) abemaciclib administered orally every 12 hours on days 1 through 28 of a 28-day cycle
3091104|NCT01739335|Experimental|Mifepristone|'Mifepristone Oral Tablet [Korlym] (2 x 300mg =600 mg total, once daily, at bedtime) for 7 days
3091105|NCT01739335|Placebo Comparator|Placebo|Placebo Oral tablet (2 sugar pills, once daily, at bedtime) for 7 days
3091106|NCT01739348|Experimental|Arm A. Verubecestat 12 mg [Part I]; 12 mg [Part II]|[Part I] Verubecestat 12 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
3091107|NCT01739348|Experimental|Arm B. Verubecestat 40 mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 40 mg once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3091108|NCT01739348|Experimental|Arm C. Verubecestat 60mg/40mg [Part I]; 40 mg [Part II]|[Part I] Verubecestat 60 mg once daily until the first IA in Study Part I (Base Study). Following IA, participants in this group were switched to Verubecestat 40 mg once daily, for the remainder of Study Part I (total dosing period: 78 weeks). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3091109|NCT01739348|Placebo Comparator|Arm D. Placebo [Part I]; Verubecestat 40 mg [Part II]|[Part I] Placebo once daily for 78 weeks in Study Part I (Base Study). [Part II] Participants completing Study Part I and continuing to Study Part II (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3091110|NCT01739361|Experimental|Acetaminophen|Patients will receive acetaminophen at the dose of 1 gram by mouth or by enteral feeding tube every six hours for a total of 72 hours.
3091111|NCT01739361|Placebo Comparator|Placebo|Patients will receive placebo by mouth or by enteral feeding tube every six hours for 72 hours.
3091112|NCT01739400|Experimental|Macitentan|Macitentan 10 mg tablet, once daily.
3091113|NCT01739595|Experimental|Androxal 12.5 mg|Androxal (enclomiphene citrate), 12.5 mg oral capsules taken once daily
3091114|NCT01739595|Experimental|Androxal 25 mg|Androxal (enclomiphene citrate), 25 mg oral capsules taken once daily
3091115|NCT01739595|Placebo Comparator|Placebo|Placebo oral capsules taken one time daily
3091116|NCT01739699|Experimental|Acetaminophen|Subjects will receive 1000mg of intravenous acetaminophen every 6 hours for 24 hours beginning with dural closure.
3091117|NCT01739699|Other|Placebo|Subjects will receive 100cc of normal saline every 6 hours for 24 hours beginning at dural closure.
3091118|NCT01739764|Experimental|Vemurafenib 480mg BID|Participants received oral vemurafenib at 480 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
3091119|NCT01739764|Experimental|Vemurafenib 720mg BID|Participants received oral vemurafenib at 720 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
3091120|NCT01739764|Experimental|Vemurafenib 960mg BID|Participants received oral vemurafenib at 960 mg BID, depending on the last dose in the antecedent protocol until progression of disease or as long as the participant is deriving clinical benefit, as judged by the investigator, death, withdrawal of consent, unacceptable toxicity, loss to follow-up, or decision of the sponsor to terminate the study, whichever occurs first.
3091121|NCT01739790|Placebo Comparator|Sugar Pill|Identical placebo pills twice daily for 8 weeks Placebo pills manufactured to mimic appearance of intervention drug n-acetylcysteine and prescribed with identical frequency and duration.
3091122|NCT01739790|Active Comparator|N-Acetylcysteine|1800 mg twice daily for 8 weeks
3091123|NCT01739803|Experimental|Intervention Group|Behavioral contract intervention
3091124|NCT01739803|No Intervention|Control Group|No intervention
3091125|NCT01739933|Active Comparator|Dexmedetomidine|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 5 mcg/mL dexmedetomidine. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr."
3091126|NCT01739933|Active Comparator|Propofol|"Route and Concentration. The study drug will be administered intravenously (IV) by continuous infusion at concentrations of 10 mg/mL propofol. Patients will only receive study drug while in the ICU and on mechanical ventilation, and thus will be monitored with continuous telemetry as per usual ICU practice.~Dosing Range. Study drug dose will be titrated in a double-blind manner according to clinical effect to achieve a goal or target Richmond Agitation Sedation Score set by the managing clinical team. For patients in the propofol group, dose will range from 5-50 mcg/kg/min."
3091127|NCT01740089|Experimental|Algeron 1.5 μg/kg|Algeron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3091128|NCT01740089|Experimental|Algeron 2.0 μg/kg|Algeron 2.0 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3091129|NCT01740089|Active Comparator|PegIntron|PegIntron 1.5 μg/kg of body weight weekly subcutaneously in combination with ribavirin daily orally in a daily dose of 800 mg (patients with body weight < 65 kg), 1000 mg (patients with body weight of 65-85 kg inclusive), 1200 mg (patients with body weight of 86-105 kg inclusive) or 1400 mg (patients with body weight > 105 kg).
3091130|NCT01740128|Experimental|Multimodal then Treadmill training|Participants will undergo harness-supported multimodal balance training exercises while simultaneously performing skilled hand exercises. Following a washout period of at least 6 weeks, Participants will undergo body weight supported treadmill training using the Lokomat apparatus.
3091131|NCT01740128|Active Comparator|Treadmill then Multimodal training|Robotic body weight supported treadmill training will be applied using the Lokomat apparatus. Following a washout period of at least 6 weeks, Participants will undergo harness-supported balance training exercises while simultaneously performing skilled hand exercises.
3091132|NCT01740206|Active Comparator|Amphetamine and/or methylphenidate|Patients who took their amphetamine and/or methylphenidate the morning of surgery.
3091133|NCT01740206|Experimental|Hold stimulant medication|Patients who did not take their stimulant medication the morning of surgery.
3091134|NCT01740258|Experimental|Bevaczimab, Radiation Therapy, Temozolomide|"In Part A, newly-diagnosed patients with Grade 4 malignant gliomas will receive standard radiation therapy, daily Temodar 75mg/M for 6-8 weeks. Bevacizumab will be given concurrently with radiation therapy and Temodar, 10 mg/kg every two weeks.~If they are stable at the end of Part A, they will continue to Part B. In Part B patients will receive up to 12 cycles of bevacizumab and Temodar. Bevacizumab will be given on Days 1 and 15 of a 28-day cycle. Temodar will be 200 mg/meter squared daily for 5 days (days 1-5) of each cycle.~If they have not progressed, patients will start Part C. In Part C, patients will receive bevacizumab 10mg/kg approximately every 2 weeks or 15 mg/kg approximately every 3 weeks.~If patients progress during Part B or C, they will start Part D. In Part D, patients will receive bevacizumab-based therapy containing bevacizumab in combination with a chemotherapy and/or biologic agent, as determined by the Duke treating physician."
3091135|NCT01740297|Experimental|Phase 1b: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ plaque-forming units (PFU)/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until complete response (CR), all injectable tumors had disappeared, confirmed disease progression per the modified immune-related response criteria (irRC), or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab administered intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
3091136|NCT01740297|Active Comparator|Phase 2: Ipilimumab|Participants received ipilimumab 3 mg/kg intravenously every 3 weeks for a total of 4 infusions starting at week 1.
3091137|NCT01740297|Experimental|Phase 2: Talimogene Laherparepvec + Ipilimumab|Participants received talimogene laherparepvec at an initial dose of 10⁶ PFU/mL injected into 1 or more skin, nodal, or subcutaneous tumors. Subsequent doses of talimogene laherparepvec at 10⁸ PFU/mL began 3 weeks after the first dose and were administered every 2 weeks until CR, all injectable tumors had disappeared, confirmed disease progression per the modified irRC, or intolerance of study treatment, whichever occurred first. Participants also received 3 mg/kg ipilimumab intravenously every 3 weeks for a total of 4 infusions starting at the time of the third dose of talimogene laherparepvec (week 6).
3091138|NCT01740323|Placebo Comparator|Placebo|Placebo
3091139|NCT01740323|Experimental|Curcumin|500 mg BID
3091140|NCT01740362|Other|Healthy volunteers|Healthy volunteers
3091141|NCT01740362|Experimental|Mild renal impairment|patients with mild (>50 and ≤80 mL/min) renal impairment
3091142|NCT01740362|Experimental|Moderate renal impairment|patients with moderate (≥30 and ≤50 mL/min) renal impairment
3091143|NCT01740362|Experimental|severe renal impairment|patients with severe (<30 mL/min) renal impairment
3091144|NCT01740388|Experimental|Besifloxacin|besifloxacin ophthalmic suspension 0.6% administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
3091145|NCT01740388|Placebo Comparator|Vehicle|vehicle of besifloxacin ophthalmic suspension administered 2 times daily (BID) for 3 days to participants with a clinical diagnosis of bacterial conjunctivitis
3091146|NCT01740401|Experimental|Cyclophosphamide, Ipilimumab|"Treatment:~Cyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)~Ipilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
3091147|NCT01740414|Active Comparator|MN-166 (formerly AV411) First|Participants who began 14-day maintenance on MN-166 (50 mg) first, before switching to Placebo maintenance.
3091148|NCT01740414|Placebo Comparator|Placebo First|Participants who began 14-day maintenance on Placebo first, before switching to MN-166 (50 mg) maintenance.
3091149|NCT01740427|Experimental|PD-0332991 + Letrozole|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3091150|NCT01740427|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3091151|NCT01740440|Other|BMR Face treatment|BMR Face treatment used once a day for 12 weeks
3091152|NCT01740713|Experimental|Deferiprone, dose level 1|single dose level of 8.3 mg/kg every 8 hours for a corresponding total daily dose of 25 mg/kg/day.
3091153|NCT01740713|Experimental|Deferiprone, dose level 2|single dose level of 16.7 mg/kg every 8 hours for a corresponding total daily dose of 50 mg/kg/day.
3091154|NCT01740713|Experimental|Deferiprone, dose level 3|single dose level of 33.3 mg/kg every 8 hours for a corresponding total daily dose of 100 mg/kg/day.
3091155|NCT01740726|Experimental|Behavioral Activation|
3091156|NCT01740726|Active Comparator|Fluoxetine|
3091157|NCT01740791|Experimental|Velpatasvir 5 mg (GT 1a)|Participants with genotype (GT) 1a HCV infection will receive velpatasvir 5 mg or placebo once daily for 3 days under fasted conditions.
3091158|NCT01740791|Experimental|Velpatasvir 25 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
3091159|NCT01740791|Experimental|Velpatasvir 50 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
3091160|NCT01740791|Experimental|Velpatasvir 100 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 100 mg or placebo once daily for 3 days under fasted conditions.
3091161|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1a)|Participants with GT 1a HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
3091162|NCT01740791|Experimental|Velpatasvir 150 mg (GT 1b)|Participants with GT 1b HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
3091163|NCT01740791|Experimental|Velpatasvir 150 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
3091164|NCT01740791|Experimental|Velpatasvir 25 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 25 mg or placebo once daily for 3 days under fasted conditions.
3091165|NCT01740791|Experimental|Velpatasvir 50 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 50 mg or placebo once daily for 3 days under fasted conditions.
3091166|NCT01740791|Experimental|Velpatasvir 150 mg (GT 3)|Participants with GT 3 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
3091167|NCT01740791|Experimental|Velpatasvir 150 mg (GT 4)|Participants with GT 4 HCV infection will receive velpatasvir 150 mg or placebo once daily for 3 days under fasted conditions.
3091168|NCT01740791|Experimental|Velpatasvir up to 400 mg (GT 2)|Participants with GT 2 HCV infection will receive velpatasvir up to 400 mg or placebo once daily for 3 days under fasted conditions.
3091169|NCT01740817|Experimental|Intralipid 20%, then saline|Participants first received lipid infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received saline infusion of 30ml/h x48h.
3091170|NCT01740817|Experimental|Saline, then Intralipid|Participants first received saline infusion of 30ml/h x48h. After a washout period of 4-6 weeks, they then received lipid infusion of 30ml/h x48h.
3091171|NCT01741012|Experimental|Gardasil|0.5 ml single dose Gardasil vaccine given at three separate visits
3091172|NCT01741259|Experimental|Meperidine PCEA|Epidural Meperidine (5mg/ml) bolus of 20 mg, lockout of 30 min, hourly limit of 50 mg.
3091173|NCT01741259|Experimental|Meperidine PCEA with basal|Epidural meperidine (5mg/ml) basal rate of 10 mg/hr, bolus 20 mg, lockout 30 min, hourly limit 40 mg
3091174|NCT01741272|Active Comparator|Group A (Usual Care)|Will be immobilized in a sling for 6 weeks. Intervention: Procedure: Sling
3091175|NCT01741272|Experimental|Group B (Early ROM)|Will use the sling for comfort only. Intervention: Procedure: No sling
3091176|NCT01741350|Experimental|CHRP Group|Patients assigned to Community-friendly Health Recovery Program (CHRP) will receive a weekly HIV risk reduction group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. The CHRP intervention is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
3091177|NCT01741350|Active Comparator|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
3091178|NCT01741454|Active Comparator|Tamsulosin plus placebo 7-day treatment|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
3091179|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 7-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
3091180|NCT01741454|Active Comparator|Tamsulosin plus placebo 21-day treamtnet|Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
3091181|NCT01741454|Experimental|Tamsulosin plus Tolterodine ER 21-day treatment|"Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.~Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity."
3091182|NCT01741480|Placebo Comparator|Routine care|General hospital ward patients will receive routine care.
3091183|NCT01741480|Experimental|Intervention arm|The intervention with early warning system monitoring is to have the rapid response team assess the patients real-time.
3091184|NCT01741532|Experimental|Deferiprone|Deferiprone 80 mg/mL oral solution
3091185|NCT01741532|Placebo Comparator|Placebo|Matching placebo solution
3091186|NCT01741545|Experimental|Cohort A: Genotype-2,-3 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 12 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 12 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
3091187|NCT01741545|Experimental|Cohort B: Genotype-1b,-4 (Lambda/RBV/DCV)|"Lambda 180 μg solution for subcutaneous (SC) injection, once weekly for 24 weeks~Ribavirin (RBV) 200 mg tablet by mouth (oral), twice daily for 24 weeks~Daclatasvir (DCV) 60mg tablet by mouth (oral), once daily for 12 weeks"
3091188|NCT01741688||Tocilizumab|Participants with moderate to severe rheumatoid arthritis (RA), according to the American College of Rheumatology (ACR) criteria and the Disease Activity Score Based on 28 Joints (DAS28), in whom the attending physician has decided to start treatment with tocilizumab (according to the local label).
3091189|NCT01741701|Experimental|Oxaloacetate (OAA)|active capsule containing 100 mg OAA and 100 mg ascorbate, taken daily
3091190|NCT01741701|Placebo Comparator|Placebo|placebo capsules that contain only 100 mg ascorbate, taken daily
3091191|NCT01741792|Experimental|Blinatumomab|By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.
3091192|NCT01742065|No Intervention|Usual Care|Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
3091193|NCT01742065|Active Comparator|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
3091194|NCT01742078|Experimental|7.5 mg LY2541546 - IV|Single dose of 7.5 mg LY2541546 administered intravenously (IV)
3091195|NCT01742078|Experimental|25 mg LY2541546 - IV|Single dose of 25 mg LY2541546 administered IV
3091196|NCT01742078|Experimental|75 mg LY2541546 - IV|Single dose of 75 mg LY2541546 administered IV
3091197|NCT01742078|Experimental|225 mg LY2541546 - IV|Single dose of 225 mg LY2541546 administered IV
3091198|NCT01742078|Experimental|750 mg LY2541546 - IV|Single dose of 750 mg LY2541546 administered IV
3091199|NCT01742078|Experimental|150 mg LY2541546 - SC|Single dose of 150 mg LY2541546 administered subcutaneous (SC)
3091200|NCT01742078|Placebo Comparator|Placebo|Single dose of placebo administered IV or SC
3091201|NCT01742078|Experimental|225 mg LY2541546 - IV, OL|Single dose of 225 mg LY2541546 administered IV, open label (OL)
3091202|NCT01742078|Experimental|750 mg LY2541546 - IV, OL|Single dose of 750 mg LY2541546 administered IV, OL
3091203|NCT01742091|Experimental|180 mg LY2541546 SC Q4W|180 milligram (mg) LY2541546 administered subcutaneous (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
3091204|NCT01742091|Experimental|270 mg LY2541546 SC Q2W|270 mg LY2541546 administered (SC) once every 2 weeks (Q2W) for 8 weeks.
3091205|NCT01742091|Experimental|270 mg LY2541546 SC Q4W|270 mg LY2541546 administered (SC) once every 4 weeks (Q4W) for 8 weeks. Placebo administered SC at Weeks 2 and 6 to maintain the blind.
3091206|NCT01742091|Experimental|540 mg LY2541546 IV Q4W|540 mg administered intravenous (IV) once every 4 weeks (Q4W) for 8 weeks. Placebo administered IV at Weeks 2 and 6 to maintain the blind.
3091207|NCT01742091|Experimental|750 mg LY2541546 IV Q2W|750 mg administered (IV) once every 2 weeks (Q2W) for 8 weeks.
3091208|NCT01742091|Placebo Comparator|Placebo Q2W|Placebo administered IV or SC once every 2 weeks for 8 weeks.
3091209|NCT01742117|Experimental|Genotype-Guided Therapy|Subjects will be genotyped prospectively for CYP2C19*2, *3 and *17 alleles and will receive treatment based on their genotype. In this group, patients who have the CYP2C19 reduced function allele [i.e., *2 allele (heterozygous or homozygous) or *3 allele (heterozygous or homozygous)] patients will receive ticagrelor 90 mg bid. The WT YP2C19 patients will receive clopidogrel 75 mg once daily.
3091210|NCT01742117|Active Comparator|Conventional Therapy|Subjects will receive clopidogrel once daily after the index PCI and will be retrospectively genotyped for CYP2C19*2, *3 and *17 alleles after completion of one year of treatment with clopidogrel.
3091211|NCT01742208|Experimental|Sotagliflozin 400 mg - Pioneer Group|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before breakfast for 29 days; open label administration.
3091212|NCT01742208|Placebo Comparator|Placebo - Expansion Group|Two placebo-matching sotagliflozin tablets, once daily, orally, before breakfast for 29 days; double-blind administration.
3091213|NCT01742208|Experimental|Sotagliflozin 400 mg - Expansion Group|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before breakfast for 29 days; double-blind administration.
3091214|NCT01742286|Experimental|LDK378|All participants were administered a single-agent LDK378 (Ceritinib) orally, once daily, continuously in fasted or fed conditions.
3091215|NCT01742364|Experimental|Bioject Intradermal (ID) Pen|Intradermal administration of BCG vaccine via the Bioject ID Pen.
3091216|NCT01742364|Active Comparator|Needle and syringe|Intradermal administration of BCG vaccine via needle and syringe.
3091217|NCT01742832|Active Comparator|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
3091218|NCT01742832|Placebo Comparator|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
3091219|NCT01742897|Experimental|TTS-fentanyl|Transdermal therapeutic system (TTS) fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
3091220|NCT01742936|Experimental|Spinal fusion|Patients undergoing a posterior spinal fusion and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
3091221|NCT01742936|Experimental|Cardiac bypass|Patients undergoing surgery requiring cardiopulmonary bypass and having clotting factors checked by both hand held CoaguChek and Hospital Laboratory.
3091222|NCT01742949|Active Comparator|Thermosmart|Subjects receive heated humidification
3091223|NCT01742949|Placebo Comparator|No humidification|Subjects use dry CPAP / APAP
3091224|NCT01743001|Experimental|Macitentan|Subjects receive macitentan 10 mg oral tablet once daily
3091225|NCT01743001|Placebo Comparator|Placebo|Subjects receive macitentan-matching placebo oral tablet once daily
3091226|NCT01743027|Experimental|AL-4943A|AL-4943A ophthalmic solution, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3091227|NCT01743027|Active Comparator|PATADAY|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3091228|NCT01743027|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution, 0.1%, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3091229|NCT01743027|Placebo Comparator|Vehicle|AL-4943A ophthalmic solution vehicle, 1 drop per eye Day 0, followed by 1 drop per eye Day 14
3091230|NCT01743040||CADence plus Standard Angiogram|All patients who were indicated for angiogram due to results of SPECT nuclear stress test
3091231|NCT01743040||CADence plus CT Angiogram|All patients who were not indicated for angiogram due to results of SPECT nuclear stress test underwent CT angiogram
3091232|NCT01743092|Other|Tutorial Workbook|Tutorial Workbook Group only receives a Tutorial Workbook Group
3091233|NCT01743092|Experimental|Tutorial Workbook Group plus webinar|Tutorial Workbook Group plus webinar will receive in addition, a webinar as an additional resource.
3091234|NCT01743131|Placebo Comparator|Standard GVHD Prophylxis + Placebo|"Standard GVHD prophylaxis and placebo.~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
3091235|NCT01743131|Experimental|Standard GVHD Prophylxis + Abatacept|"Standard GVHD prophylaxis and abatacept (investigational product).~Standard GVHD prophylaxis is calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate."
3091236|NCT01743469|Experimental|Hepatocellular Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3091237|NCT01743469|Experimental|Ovarian Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3091238|NCT01743469|Experimental|Renal Cell Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3091239|NCT01743469|Experimental|Gastric Carcinoma Cohort|1 capsule of tasquinimod (0.25 mg or 0.5 mg or 1 mg) taken orally each day until disease progression, lost to follow-up, withdrawal or death.
3091240|NCT01743521|Experimental|Group A - 8 weeks total therapy|8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
3091241|NCT01743521|Experimental|Group B - 12 weeks total therapy|12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
3091242|NCT01743521|Experimental|Group C - 24 weeks total therapy|24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
3091243|NCT01743560|Experimental|Everolimus and Exemestane|Postmenopausal women diagnosed with oestrogen receptor positive locally advanced or metastatic breast cancer will receive RAD001 at a dose of 10mg daily p.o. and exemestane 25mg daily p.o. for 48 weeks.
3091244|NCT01743677|Experimental|CP-690,550 100 mg|
3091245|NCT01743677|Placebo Comparator|Placebo|
3091246|NCT01743677|Active Comparator|Moxifloxacin hydrochloride|
3091247|NCT01743729|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution (5.0%)
3091248|NCT01743729|Placebo Comparator|Placebo|
3091249|NCT01743859|Experimental|Azacitidine + Lenalidomide + Off Therapy|Patients will receive 7 days of azacitidine followed by 3 weeks of lenalidomide. They will then have 2 weeks off therapy, for a maximum of 12 cycles.
3091250|NCT01743963|Experimental|Decision Support Intervention|Clinical pharmacists mediated computerized decision support
3091251|NCT01743963|Active Comparator|Usual Care|Clinicians' typical approach for GID monitoring
3091252|NCT01743976|Experimental|Donepezil|donepezil 5 mg every day
3091253|NCT01743976|Placebo Comparator|Placebo|Placebo (sugar pill) every day
3091254|NCT01743989|Experimental|Nilotinib 24-month treatment|Participants were treated with nilotinib 300mg BID for 24 months and, thereafter, entered the 36-month TFR phase
3091255|NCT01743989|Experimental|Nilotinib 36-month treatment|Participants were treated with nilotinib 300mg BID for 36 months and, thereafter, entered the 24-month TFR phase
3091256|NCT01743989|Experimental|Not randomized|Participants were treated with nolotinib 300mg BID for 24 months, but did not achieve a sustained molecular response after 24 months of treatment.
3091257|NCT01744093|Active Comparator|Doxycycline|100 mg twice daily (BID orally) x 6 months
3091258|NCT01744093|Placebo Comparator|Placebo (sugar pill)|100 mg twice daily (BID orally) x 6 months
3091259|NCT01744197|Experimental|Arm 1|First application: Synera (lidocaine 70mg/tetracaine 70mg) patch; Second application: Placebo patch
3091260|NCT01744197|Experimental|Arm 2|First application: Placebo patch; Second application: Synera (lidocaine 70mg/tetracaine 70mg) patch
3091261|NCT01744340|Experimental|head and neck|Cetuximab, 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly there after Eribulin Mesylate 1.4mg/m2
3091262|NCT01744340|Experimental|Colon- closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
3091263|NCT01744353|Experimental|Dose level 1|Abraxane 125 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3091264|NCT01744353|Experimental|Dose level 2/ MTD|Abraxane 150 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3091265|NCT01744353|Experimental|Dose level 3|Abraxane 175 mg/m2, day 1 Oxaliplatin 85 mg/m2, day 1 leucovorin 400 mg/m2, day 1 5-FU Infusion 1200 mg/m2/ days 2 days IV infusion
3091266|NCT01744392|Experimental|education intervention|The intervention provides a personalized Meducation calendar to all patients enrolled in the study (identified in package as Example Calendar). The Meducation Calendar will include medications for diabetes (sugar), high blood pressure, cholesterol, heart medications and blood thinning medications. The medication calendars contains the following for each medication 1) the name, 2) the time of day, including a pictorial display, it should be taken 3) the number of times each day to take the medication, and 4) the indication for the medication.
3091267|NCT01744483|Active Comparator|PVC ETT|Polyvinylchloride cuff endotracheal tube
3091268|NCT01744483|Experimental|PUC ETT|Polyurethane cuff endotracheal tube
3091269|NCT01744483|Experimental|PUC-CASS ETT|Polyurethane cuff with continuous aspiration of subglottic secretions endotracheal tube
3091270|NCT01744496|Experimental|Rotigotine|Rotigotine Transdermal Patches
3091271|NCT01744496|Placebo Comparator|Placebo|Placebo Transdermal Patches
3091272|NCT01744574|Placebo Comparator|Placebo|Placebo - subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
3091273|NCT01744574|Experimental|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily, orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date. They will also receive smoking cessation behavioral counseling.
3091274|NCT01744665|Experimental|Treatment Free Remission|Patients entered a monitoring phase for 2 years and received 300 mg nilotinib mg bid. Patients who achieved MR4.5 entered a Consolidation Phase and were treated with nilotinib for 2 years. If MR4.5 was sustained during the Consolidation phase, patients were eligible to stop taking niltoinib during the treatment-free remission (TFR) phase.
3091275|NCT01744691|Experimental|ibrutinib|All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.
3091276|NCT01744704|Experimental|rhNGF 0.5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3091277|NCT01744704|Experimental|rhNGF 5 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3091278|NCT01744704|Experimental|rhNGF 60 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3091279|NCT01744704|Experimental|rhNGF 20 µg/mL Sentinel|1 x 35 µL drop 3 subjects
3091280|NCT01744704|Experimental|rhNGF 20 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3091281|NCT01744704|Experimental|rhNGF 180 µg/mL Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3091282|NCT01744704|Placebo Comparator|Placebo Part A|3 x 35 µL drops applied at 4 h intervals 6 subjects
3091283|NCT01744704|Experimental|rhNGF 20 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects
3091284|NCT01744704|Experimental|rhNGF 60 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
3091285|NCT01744704|Experimental|rhNGF 180 µg/mL Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
3091286|NCT01744704|Placebo Comparator|Placebo Part B|3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
3091287|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI 85-95th Percentile)|Clindamycin IV: Children ages 2 to 11 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3091288|NCT01744730|Active Comparator|Clindamycin IV-ages 2 to 11 Years Old (BMI Greater Than 95th)|Clindamycin IV: Children ages 2 to 11 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3091289|NCT01744730|Active Comparator|Clinidamycin IV-ages 12 to 17 (BMI 85-95th Percentile)|Clindamycin IV: Children ages 12 to 17 years old with BMI 85th to 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3091290|NCT01744730|Active Comparator|Clindamycin IV-ages 12 to 17 (BMI Greater Than 95th)|Clindamycin IV: Children ages 12 to 17 years old with BMI greater than 95th percentile. Their schedule of IV Clindamycin administration included 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day was allowed for children receiving clindamycin as part of clinical care.
3091291|NCT01744782|Experimental|RP103|From Day 1 and throughout the duration of participation, RP103 (Cysteamine Bitartrate Delayed-release Capsules) was administered every 12 hours (Q12H), supplied as 75 mg and 25 mg capsules.
3091292|NCT01744821|Active Comparator|Arm A: Vitamin D3 Group|Patients will take Vitamin D3 by mouth in the weeks prior to and including the morning of surgery. If blood test done at the start of the study shows that patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given two 25,000 IU Vitamin D3 Tablets (for a total of 50,000 IU) to take once a week until surgery. If baseline Vitamin D level is >30ng/ml, patients will be given on 2,000 IU Vitamin D3 tablet to take once a day until day of surgery.
3091293|NCT01744821|Placebo Comparator|Arm B: Placebo Group|Patients will take a placebo by mouth prior to and including the morning of surgery. If bloods tests done at the start of study show that the patients have a low (< or = 30 ng/ml) Vitamin D level, patients will be given 2 placebo tablets to take once a week until surgery. If baseline Vitamin D level is > 30 ng/ml, patients will be given on placebo tablet to take once a day until surgery.
3091294|NCT01744860||"INCa molecular genetics laboratory in-house methods"|"BRAF V600 mutations were analysed using INCa (Institut National du Cancer [French National Cancer Institute]) molecular genetics laboratories using in-house methods"
3091295|NCT01744860||Cobas 4800 Mutation Test|BRAF V600 mutations were analysed using Cobas 4800 mutation test
3091296|NCT01744977|Experimental|Adherence Packaging Intervention Group|[MeadWestvaco Packaging Intervention Arm] At baseline, the intervention arm will receive instructions from the RA on obtaining medication refills and the first fill of their statin medication from the VA pharmacy. At this time, the pharmacist will provide counseling including 1) use of adherence packaging, 2) to only use statin medications from the adherence packaging 3) purpose of LDL-related medications 4) how to take the medications.
3091297|NCT01744977|No Intervention|Education Only Group|Control Arm patients will receive primary care and LDL management according to the discretion of their provider. At baseline, patients will receive similar written information on how to obtain medication refills and the importance of taking their cholesterol medications as prescribed. The 6-month interval was selected to maintain contact with patients.
3091298|NCT01745055|Experimental|CP-690,550 (tofacitinib) 30 mg q12h|Individual dose of methotrexate with the addition of CP-690,550 30 mg q12h
3091299|NCT01745094|Experimental|Concomitant Group|concomitant administration of mirabegron to solifenacin treated patients
3091300|NCT01745120|Experimental|LentiGlobin BB305 Drug Product|
3091301|NCT01745133|Placebo Comparator|vehicle|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
3091302|NCT01745133|Active Comparator|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks x
3091303|NCT01745133|Active Comparator|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays for 8 weeks + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
3091304|NCT01745146|Experimental|Anger Self-Management Training (ASMT)|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
3091305|NCT01745146|Active Comparator|Personal Readjustment and Ed (PRE)|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment. Significant other (friend or relative) invited to participate in 3 of 8 sessions
3091306|NCT01745211|Experimental|755nm Alexandrite laser with array handpiece|Device: 755nm Alexandrite laser with array handpiece
3091307|NCT01745367|Active Comparator|Placebo in combination with paclitaxel|Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
3091308|NCT01745367|Experimental|Tivo in combination with paclitaxel|1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
3091309|NCT01745380|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
3091310|NCT01745380|Placebo Comparator|Placebo|Placebo - 2 sprays will be administered at the start of the procedure, if anesthesia is insufficient, a third spray will be administered.
3091311|NCT01745393|Experimental|Clinic Quality Improvement + Behavioral Counseling|This multilevel intervention includes advice and a referral from a pediatrician, behavioral counseling by study staff, and community systems navigation, all designed to reduce pediatric secondhand smoke exposure. Over the course of 12 weeks participants receive a home visit designed to orient them to the program and trained health counselors provide multiple individualized phone counseling sessions designed to build coping skills, urge management skills, and self-efficacy. Counseling also includes assistance with goal setting and navigation of local resources.
3091312|NCT01745393|Active Comparator|Clinic Quality Improvement + Attention Control|The attention control intervention parallels the format of the experimental group but focuses on family nutrition information. The intervention includes a home visit to orient the participant to the program and multiple phone counseling sessions conducted by a trained health counselor.
3091313|NCT01745627|Experimental|Laser Treatment|
3091314|NCT01745822|Experimental|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate, 300 mg tablets
3091315|NCT01745822|Placebo Comparator|Placebo|matching placebo (of tenofovir disoproxil fumarate)
3091316|NCT01745848|Experimental|Study Drug|Roflumilast 500 μcg, once daily, for 30 days
3091317|NCT01745952|Experimental|figure-of-eight active rTMS coil|rTMS is administered using the figure-of-eight active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3091318|NCT01745952|Experimental|round active rTMS coil|rTMS is administered using the round active coil, at 90% of the resting motor threshold over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3091319|NCT01745952|Sham Comparator|sham rTMS coil (figure-of-eight)|rTMS is administered using the figure-of-eight sham coil, over the epileptogenic region, in trains of 500 pulses with a total of 1500 pulses per day, during weekdays on two consecutive weeks.
3091320|NCT01746017|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 4 study periods in Part A
3091321|NCT01746017|Experimental|LY2922470 (Part A)|Single ascending dose of LY2922470 [starting at 1 milligram (mg)] administered orally to healthy participants in up to 3 of 4 study periods in Part A
3091322|NCT01746017|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
3091323|NCT01746017|Experimental|LY2922470 (Part B)|Single ascending dose of LY2922470 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
3091324|NCT01746043|Experimental|Armodafinil + Placebo|Armodafinil 150 mg by mouth once a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3091325|NCT01746043|Experimental|Minocycline + Placebo|Minocycline 100 mg by mouth 2 times a day for 6 weeks. Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3091326|NCT01746043|Experimental|Armodafinil + Minocycline|Armodafinil 150 mg by mouth once a day for 6 weeks. Minocycline 100 mg by mouth 2 times a day for 6 weeks.Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3091327|NCT01746043|Placebo Comparator|Placebos|Placebo 1 capsule by mouth 2 times a day for 6 weeks. Intervention agents start the day of CXRT, or within 5 days of the start CXRT, and continue for a total of 6 weeks. Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
3091328|NCT01746095|Experimental|Vancomycin hydrochloride inhalation powder|32 or 64 mg twice daily (BID)
3091329|NCT01746095|Placebo Comparator|Placebo inhalation powder|Matching placebo inhalation powder BID
3091330|NCT01746108|Experimental|At-risk-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are at an increased risk of pneumococcal infection.
3091331|NCT01746108|Experimental|At-risk-Primed Group|"Subjects who have been previously vaccinated~with at least one dose of a pneumococcal conjugate vaccine i.e. either Synflorix (10Pn-PD-DiT), Prevenar or Prevenar13.~with plain polysaccharide pneumococcal vaccine more than 2 years and less than 5 years before enrollment.~and are at an increased risk of pneumococcal infection."
3091332|NCT01746108|Active Comparator|Healthy-Unprimed Group|Subjects who have not been previously vaccinated with any pneumococcal vaccine and are healthy.
3091333|NCT01746108|Active Comparator|Healthy-Primed Group|Subjects who have been previously vaccinated with at least one dose of a pneumococcal vaccine and are healthy.
3091334|NCT01746173|Experimental|CHOEP + High Dose Therapy + Auto SCT|Patients received 6 cycles of induction chemotherapy: Cyclophosphamide, Doxorubicin, Vincristine, Etoposide and Prednisone (CHOEP) (5 if previously received 1 cycle of CHOP). CHOP was given at standard doses, with a dose of etoposide of 100 mg/m2 intravenously (IV) or 200 mg/m2 orally added on days 1-3 of each cycle. Patients who did not achieve a partial (PR) or complete (CR) remission at restaging after either 3 or 6 cycles were taken off study. Responders after 6 cycles had stem cell (SC) mobilization using filgrastim and plerixafor (if necessary) within 4 weeks of the end of induction. SC mobilization, harvesting, and reinfusion were performed per standard institutional protocol. A minimum collection of 2x106 CD34+ cells/kg was required to proceed to autologous stem cell transplant. Conditioning was comprised of gemcitabine 2700 mg/m2 on days -8 and -3, IV busulfan 105 mg/m2 days -8 to -5, and melphalan 60 mg/m2 given daily on days -3 and -2 (per MD Andersen protocol).
3091335|NCT01746225|Experimental|A: nab-Paclitaxel 150 mg/m2 days 1,15|"Arm A: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 150 mg/m2 administered on days 1, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
3091336|NCT01746225|Experimental|B: nab-Paclitaxel 100 mg/m2 days 1,8,15|"Arm B: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 100 mg/m2 administered on days 1, 8, 15 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
3091337|NCT01746225|Experimental|C: nab-Paclitaxel 75 mg/m2 days 1,8,15,22|"Arm C: Induction* nab-Paclitaxel 125 mg/m2 on days 1,8,15 every 28 days for 3 cycles followed by maintenance nab-Paclitaxel 75 mg/m2 administered on days 1, 8, 15, 22 of each 28-day cycle (total 300mg/m2 per cycle) until progression or unacceptable toxicity.~*Following Amendment 1, the dose in the induction phase dose in all three arms was reduced to 125 mg/m² from 150 mg/m²."
3091338|NCT01746264|Experimental|Vitamin D3|Vitamin D3 supplementation at 100,000 IU once a month for 3 months
3091339|NCT01746368|Experimental|Nurse-Supported Advance Care Planning Intervention|The Nurse-Supported Advance Care Planning Intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices.
3091340|NCT01746368|Active Comparator|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices. Subjects in this arm who desired information about risks, benefits, and alternatives of specific choices before randomization were scheduled for the Care-as-Usual session after they received that information from the Primary Care Provider.
3091341|NCT01746420|Placebo Comparator|Placebo Control|Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
3091342|NCT01746420|Experimental|0.45 mg rhPDGF-BB|Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
3091343|NCT01746420|Experimental|0.75 mg rhPDGF-BB|Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
3091344|NCT01746420|Experimental|1.5 mg rhPDGF-BB|Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
3091345|NCT01746420|Experimental|3.0 mg rhPDGF-BB|Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
3091346|NCT01746511|Active Comparator|Glycerin Suppository|"Based on our institution's protocol, infant will receive a glycerin shave within one hour of initiation of phototherapy and then every eight hours while under phototherapy.~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
3091347|NCT01746511|Experimental|No Glycerin Suppository|"Infants will receive no scheduled glycerin suppositories, while under phototherapy (unless otherwise directed by attending physician).~Subjects will be block randomized (varying block sizes of 2 to 8). Babies in both groups will be fed according to NICU standard birth weight protocols. Stratified enrollment will occur with 2 separate groups:~Infants who are NPO (< 20 mL/kg/day of fluids enterally at the time of therapy) vs.~Those being enterally fed at least 20 mL/kg/day of total fluids at the time of therapy."
3091348|NCT01746732|Experimental|Ortho-Cyclen|Ortho-Cyclen (35 microgram (mcg) ethinyl estradiol and 250 mcg norgestimate) administered orally, once daily (QD), for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) in one of two treatment periods. Treatment A
3091349|NCT01746732|Experimental|Ortho-Cyclen + Evacetrapib|Ortho-Cyclen administered orally, QD, for 28 days (lead-in period). Then, Ortho-Cyclen orally QD for 28 Days (Days 1 to 28) and 130 mg evacetrapib orally, QD, for 21 days (Days 1 to 21) in one of two treatment periods. Treatment B
3091350|NCT01746745|Experimental|[^14C]-LY2940680|Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 ([^14C]-LY2940680)
3091351|NCT01746784|Experimental|N6022|Subjects randomized to study drug will receive N6022 by intravenous infusion once per day for 7 days
3091352|NCT01746784|Placebo Comparator|Normal saline|Subjects randomized to placebo will receive normal saline administered intravenously using the same volume as the active drug group
3091353|NCT01746862|Experimental|Saizen Test Group|
3091354|NCT01746862|Active Comparator|Saizen Control Group|
3091355|NCT01746901|Placebo Comparator|Treatment A|
3091356|NCT01746901|Experimental|Treatment B|
3091357|NCT01746901|Experimental|Treatment C|
3091358|NCT01746901|Active Comparator|Treatment D|
3091359|NCT01746901|Experimental|Treatment E|
3091360|NCT01746901|Active Comparator|Treatment F|
3091361|NCT01746940|Placebo Comparator|Group 1, Placebo Topical Solution|Group 1: Placebo group -Placebo solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . All placebo subjects, regardless of Von Frey filament test results, will undergo Phase 1 recovery (i.e. at least 90 minutes after cotton pledget removal) and associated required study procedures (including the final 12 lead ECG). After a minimum of 24 hours from the time of study drug pledget removal, the subject may continue the procedure, and the treatment reverts to standard anesthetic management (suitable products at the discretion of the investigator). Alternatively, at the investigator's discretion, the diagnostic procedure or surgery may be delayed until study termination.
3091362|NCT01746940|Active Comparator|Group 2, Cocaine HCl 4% Topical Solution|Group 2: Cocaine HCI 4% Group - Cocaine HCl 4% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total amount of Cocaine HCl 4% topical solution used will be recorded.
3091363|NCT01746940|Active Comparator|Group 3, Cocaine HCl 10% Topical Solution|Group 3: Cocaine HCI 10% Group - Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.18, about 15 grams of force) to determine and record pain on a pain scale of 0 to 10. If a score of 0 is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total amount of Cocaine HCl 10% topical solution used will be recorded.
3091364|NCT01746979|Active Comparator|Gemcitabine plus TH-302|
3091365|NCT01746979|Placebo Comparator|Gemcitabine plus placebo|
3091366|NCT01747330|Experimental|Creon micro, minimicrospheres|
3091367|NCT01747343|Experimental|Underwear/Differential Reinforcement|All subjects will wear underwear followed by wearing underwear while receiving differential reinforcement.
3091368|NCT01747447|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3091369|NCT01747447|Active Comparator|Vitamin D placebo + fish oil|
3091370|NCT01747447|Active Comparator|Vitamin D + fish oil placebo|
3091371|NCT01747447|Active Comparator|Vitamin D + fish oil|
3091372|NCT01747486|Experimental|Target dose of 1-5x10e8|Arm 1: Target dose of 1-5x10e8 CART-19 cells (calculated as range of 10-50% transduced cells in 1 x10e9 total cells)
3091373|NCT01747486|Experimental|Target dose of 1-5x10e7|Arm 2: Target dose of 1-5x10e7 CART-19 cells (calculated as the range of 10-50% transduced cells in 1 x10e8 total cells)
3091374|NCT01747499|Experimental|Cohort 1|"Conditioning treatment~Transplant on Day 0~15 mg/m^2 azacitidine Days 7-11~15 mg/m^2 azacitidine Days 35-39~15 mg/m^2 azacitidine Days 63-67~15 mg/m^2 azacitidine Days 91-95"
3091375|NCT01747499|Experimental|Cohort 2|"Conditioning treatment~Transplant on Day 0~30 mg/m^2 azacitidine Days 7-11~30 mg/m^2 azacitidine Days 35-39~30 mg/m^2 azacitidine Days 63-67~30 mg/m^2 azacitidine Days 91-95"
3091376|NCT01747499|Experimental|Cohort 3|"Conditioning treatment~Transplant on Day 0~37.5 mg/m^2 azacitidine Days 7-11~37.5 mg/m^2 azacitidine Days 35-39~37.5 mg/m^2 azacitidine Days 63-67~37.5 mg/m^2 azacitidine Days 91-95"
3091377|NCT01747499|Experimental|Cohort 4|"Conditioning treatment~Transplant on Day 0~45 mg/m^2 azacitidine Days 7-11~45 mg/m^2 azacitidine Days 35-39~45 mg/m^2 azacitidine Days 63-67~45 mg/m^2 azacitidine Days 91-95"
3091378|NCT01747499|Experimental|Phase II Cohort|"Conditioning treatment~Transplant on Day 0~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 7-11~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 35-39~Dose determined in Phase I - 45 mg/m^2 azacitidine Days 63-67~Dose determined in Phase I - 45 mg/m^2 attitudinize Days 91-95"
3091379|NCT01747551|Active Comparator|mFOLFOX6 + Ziv-aflibercept|Patients received mFOLFOX6 and ziv-aflibercept every 2 weeks. Ziv-aflibercept 4mg/kg was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
3091380|NCT01747551|Active Comparator|mFOLFOX6 + Placebo|Patients received mFOLFOX6 and placebo every 2 weeks. Placebo was given via intravenous (IV) infusion over 1 hour. Immediately following this was administration of mFOLFOX6: oxaliplatin 85 mg/m2 IV and leucovorin 400 mg/m2 IV were given concurrently over 120 minutes, followed by fluorouracil 400 mg/m2 IV bolus injection and then fluorouracil 2,400 mg/m2 IV infusion over 46 hours. Patients continued on treatment until radiological or clinical progression, unacceptable toxicity, or death.
3091381|NCT01747629|Placebo Comparator|Placebo MDPI|Placebo multi-dose dry powder inhaler (MDPI) administered as 2 inhalations four times a day for 12 weeks.
3091382|NCT01747629|Experimental|Albuterol MDPI|Albuterol multi-dose dry powder inhaler (MDPI) at a dose of 720 micrograms per day administered as 2 inhalations of 90 mcg /inhalation four times a day for 12 weeks.
3091383|NCT01747655||Duodopa|Participants given Duodopa gel administered with a portable pump directly into the proximal small intestine by a jejunal extension tube of the percutaneous endoscopic gastrostomy (PEG-J)
3091384|NCT01747655||Standard of Care|Participants that return to oral or transdermal anti-parkinson's disease medications
3091385|NCT01747772|Experimental|Shear Wave Sonoelastography for Fibrosis Assessment|Shear Wave sonoelastography (SWE) was performed in patients who were scheduled for a non-focal liver biopsy.
3091386|NCT01747811|Experimental|wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
3091387|NCT01747811|Placebo Comparator|wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
3091388|NCT01747837|No Intervention|standard ICD implantation alone|These subjects will undergo standard ICD implantation alone (if not already present)
3091389|NCT01747837|Experimental|Boston Scientific Vessix Renal Denervation System|"These subjects will undergo standard ICD implantation (if not already present) plus renal sympathetic denervation.~Ablation arm"
3091390|NCT01747850|Experimental|Sativex|Intervention consist on Sativex Spray (Δ9-tetrahydrocannabinol/cannabidiol). Study subjects will be randomized in blocks of ten to one of the two groups (Sativex vs. placebo) in a double blind manner. There will be a gradual increase of the maximal allowed dose starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays per day at the end of week 2. There will be a total of 12 weeks of drug exposure. All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement/Cognitive Behavioral Therapy.
3091391|NCT01747850|Placebo Comparator|Placebo spray|Participants will receive a combination of Placebo spray associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy
3091392|NCT01747850|Experimental|Pilot Study|The first five subjects will be treatment-seekers that fit our inclusion/exclusion criteria and that will be treated open-label. These subjects will be instructed to use the Sativex Spray according to the induction schedule provided above. These first subjects will allow us to determine if our schedule for dosing is appropriate for the subsequent phase of the study.
3091393|NCT01747876|Experimental|LEE011|
3091394|NCT01747915|Experimental|Study Drug Level 1|
3091395|NCT01747915|Experimental|Study Drug Level 2|
3091396|NCT01747915|Placebo Comparator|Placebo|
3091397|NCT01747928|Experimental|Group 1|
3091398|NCT01748045|Experimental|inhaled Nitric Oxide|iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
3091399|NCT01748045|Placebo Comparator|Nitrogen Gas|Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
3091400|NCT01748071||Sufentanil group|Grouped by intravenous injection of sufentanil at the time of anesthesia induction
3091401|NCT01748071||Fentanyl group|Grouped by intravenous injection of fentanyl at the time of anesthesia induction
3091402|NCT01748071||Saline group|Grouped by intravenous injection of saline before the time of anesthesia induction
3091403|NCT01748227|Other|Peer-Coached Pain Self-Management|Participants (n=20) were assigned to a peer coach, who delivered self-management instruction one-on-one over a 4-month period.
3091404|NCT01748240|Experimental|Azacitidine and oral vorinostat|"Patients who meet eligibility criteria will be administered vorinostat orally at 300mg two times daily for 7 days. AZA will be administered SC at 75 mg/m2/day x 7 consecutive days or at maximum tolerated dose if a dose reduction of AZA was needed before entering the trial with a minimum dose of 50mg/m2/d for 7 consecutive days.~Each cycle will last 28 days with AZA starting on day 1 of each cycle and vorinostat starting on day 3."
3091405|NCT01748292|Active Comparator|Monthly IVT ranibizumab|Monthly intravitreal injections (IVT) ranibizumab for 24 months, not less than 21 days apart to not more than 35 days apart
3091406|NCT01748292|Experimental|Treat and Extend IVT ranibizumab|0.5 mg intravitreal injections (IVT) ranibizumab for 3 consecutive months followed by a treat and extend protocol in which follow-up intervals are increased when there is no clinical and SD-OCT evidence of disease activity by 2-week intervals and patients are treated at every visit. (Comparator arm)
3091407|NCT01748552|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo administered to healthy participants in up to 1 of 3 study periods in Part A
3091408|NCT01748552|Experimental|LY2922083 (Part A)|Single ascending dose of LY2922083 (starting at 0.5 milligrams [mg]) administered orally to healthy participants in up to 2 of 3 study periods in Part A
3091409|NCT01748552|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo administered to participants with type 2 diabetes mellitus (T2DM) in up to 1 of 3 study periods in Part B
3091410|NCT01748552|Experimental|LY2922083 (Part B)|Single ascending dose of LY2922083 administered orally to participants with T2DM in up to 2 of 3 study periods in Part B. Dose determined by Part A
3091411|NCT01748643|Experimental|Deep neuromuscular blockade, reversal with sugammadex|a continuous rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with Sugammadex 4mg/kg. Patients are extubated when the train of four ratio is > 0.9.
3091412|NCT01748643|Active Comparator|normal neuromuscular blockade, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when TOF ratio > 0.9.
3091413|NCT01748695|Experimental|Placebo followed by V158866|Placebo once per day for 4 weeks followed by V158866 450mg once per day for 4 weeks
3091414|NCT01748695|Experimental|V158866 followed by Placebo|V158866 450mg once per day for 4 Weeks followed by Placebo once per day for 4 Weeks
3091415|NCT01748760|Experimental|CLASP-A intervention|Adolescent participants and parents will receive adjunctive psychosocial intervention.
3091416|NCT01748760|Active Comparator|Treatment as Usual|Adolescent participants and parents will not receive study intervention
3091417|NCT01748799|Other|Sequence 1|Self-titrated placebo - Self-titrated Sativex - Fixed dose Sativex - Fixed dose placebo
3091418|NCT01748799|Other|Sequence 2|Fixed dose placebo - Fixed dose Sativex - Self-titrated Sativex - Self-titrated placebo
3091419|NCT01748799|Other|Sequence 3|Fixed dose placebo - Fixed dose Sativex - Self-titrated placebo - Self-titrated Sativex
3091420|NCT01748799|Other|Sequence 4|Fixed dose Sativex - Fixed dose placebo - Self-titrated placebo - Self-titrated Sativex
3091421|NCT01748799|Other|Sequence 5|Self-titrated Sativex - Self-titrated placebo - Fixed dose Sativex - Fixed dose placebo
3091422|NCT01748799|Other|Sequence 6|Self-titrated Sativex - Self-titrated placebo - Fixed dose placebo - Fixed dose Sativex
3091423|NCT01748799|Other|Sequence 7|Self-titrated placebo - Self-titrated Sativex - Fixed dose placebo - Fixed dose Sativex
3091424|NCT01748799|Other|Sequence 8|Fixed dose Sativex - Fixed dose placebo - Self-titrated Sativex - Self-titrated placebo
3091425|NCT01748825|Experimental|ARM 1 AZD1775 200 mg Once Daily|
3091426|NCT01748825|Experimental|ARM 2 AZD1775 225 mg Once Daily|
3091427|NCT01748825|Experimental|ARM 3 AZD1775 225 mg Twice Daily|
3091428|NCT01748825|Experimental|ARM 4 AZD1775 225 mg Twice Daily (week 1-only dosing)|
3091429|NCT01748825|Experimental|ARM 5 AZD1775 250 mg Once Daily|
3091430|NCT01748825|Experimental|ARM 6 AZD1775 300 mg Once Daily|
3091431|NCT01748825|Experimental|ARM 7 AZD1775 300 mg Twice Daily|
3091432|NCT01748825|Experimental|ARM 8 AZD1775 400 mg Once Daily|
3091433|NCT01748825|Experimental|ARM 9 Expansion Cohort 1: AZD1775 225 mg Twice Daily|
3091434|NCT01748825|Experimental|ARM 10 Expansion Cohort 2: AZD1775 300 mg Once Daily|
3091435|NCT01748916|Experimental|Papaya-Carrot-Tomato|Test meals were consumed in the following order: 1. Papaya 2. Carrot 3. Tomato.
3091436|NCT01748916|Experimental|Papaya-Tomato-Carrot|Test meals were consumed in the following order: 1. Papaya 2. Tomato 3. Carrot
3091437|NCT01748916|Experimental|Tomato-Papaya-Carrot|Test meals were consumed in the following order: 1. Tomato 2. Papaya 3. Carrot
3091438|NCT01748916|Experimental|Tomato-Carrot-Papaya|Test meals were consumed in the following order: 1. Tomato 2. Carrot 3. Papaya
3091439|NCT01748916|Experimental|Carrot-Papaya-Tomato|Test meals were consumed in the following order: 1. Carrot 2. Papaya 3. Tomato
3091440|NCT01748916|Experimental|Carrot-Tomato-Papaya|Test meals were consumed in the following order: 1. Carrot 2. Tomato 3. Papaya
3091441|NCT01748942|Experimental|Arm I (treatment)|Patients receive dexamethasone IV at the time of surgery and PO every 8 hours for up to 4 days following surgery.
3091442|NCT01748942|Active Comparator|Arm II (control)|Patients receive dexamethasone IV at the time of surgery and placebo PO every 8 hours for up to 4 days following surgery.
3091443|NCT01748955|Active Comparator|Bupropion|Participants will receive bupropion XL for 8 weeks.
3091444|NCT01748955|Active Comparator|paroxetine CR|Participants will receive Paroxetine CR for 8 weeks.
3091445|NCT01748994|Placebo Comparator|Placebo|Administration of placebo to upper- and lower-body obese women
3091446|NCT01748994|Active Comparator|Drug|Administration of pioglitazone to upper- and lower-body obese women
3091447|NCT01749033|Active Comparator|Group 1 classic|Group 1 Using the classic inserting technique and completely deflated LMA (Laryngeal Mask Airway)recommended in the LMA manual.
3091448|NCT01749033|Active Comparator|Group 2 pre inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA (Laryngeal Mask Airway) from the manufacturer
3091449|NCT01749033|Active Comparator|Group 3 ELL-PIC technique|Group 3 (ELL-PIC): Using the ELL-PIC technique.
3091450|NCT01749215|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
3091451|NCT01749215|Placebo Comparator|Placebo|Placebo capsules daily - up to 300 mg
3091452|NCT01749293|Experimental|Haploidentical Transplant|All subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
3091453|NCT01749410||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective medical record review.
3091454|NCT01749501|Active Comparator|Rocuronium|0.6 mg/kg once
3091455|NCT01749501|Placebo Comparator|Placebo|Placebo
3091456|NCT01749605|Active Comparator|nitrofurantoin 100 mg|
3091457|NCT01749605|Active Comparator|Ciprofloxacin 250 mg|
3091458|NCT01749631||Difficult to Intubate (DTI) Participants|Male or non-pregnant females over 18 years of age with Mallampati score III or IV who were undergoing surgery using sevoflurane as the anesthetic agent as judged by the investigator and in compliance with the drug market authorization and approved product labeling.
3091459|NCT01749735|Experimental|Armeo training with continuous tDCS|Subjects will receive 10 sessions of transcranial Direct Current Stimulation (tDCS)/Armeo training over 2 weeks. Training sessions will last for 40 minutes and will focus on repetitive tasks using the Armeo device that. To deliver the stimulation, the anode will be placed over the primary motor cortex (M1) of the affected hemisphere, while the cathode will be placed over the unaffected M1 area. Direct current will be transferred by a saline-soaked pair of surface sponge electrode (35cm2). Continuous stimulation will be delivered at an intensity of 1mA while the subject undergoes the 40-minute Armeo motor training sessions.
3091460|NCT01749735|Sham Comparator|Armeo training with sham tDCS|Subjects will receive the same number of 40-minute training sessions (i.e. 10 sessions) as the subjects in the experimental group. Training will take place over a period of two weeks as per the experimental group. Also, electrodes will be positioned on the scalp as per the experimental group. However, for sham transcranial Direct Current Stimulation (tDCS), the current will be delivered for only 30 seconds. The current intensity will be gradually increased and decreased to diminish its perception.
3091461|NCT01749800|Experimental|Cognitive test with/without GVS|Subjects with attention span deficits and no significant motor impairments undergo solely a cognitive test. The test is carried out in multiple trials. For some of the trials (randomly selected), subjects receive galvanic vestibular stimulation (GVS). For other trials, subjects received sham GVS. GVS is delivered using a device by A-M Systems.
3091462|NCT01749800|Active Comparator|Armeo Spring +GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with galvanic vestibular stimulation (GVS). Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. GVS is delivered using a device by A-M Systems.
3091463|NCT01749800|Sham Comparator|Armeo Spring + sham GVS|Subjects with both attention span deficits and significant motor impairments undergo robot-assisted upper-limb rehabilitation in combination with sham GVS. Robot-assisted training is carried out using the Armeo Spring system by Hocoma AG. Sham stimulation is delivered by connecting the subject to a device by A-M Systems, but the device is not active.
3091464|NCT01749904|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
3091465|NCT01749904|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
3091466|NCT01749930|Experimental|BOL-303259-X|BOL-303259-X ophthalmic solution QD (PM) and vehicle QD (AM) administered for 3 months (Visit 6) into the study eye(s).
3091467|NCT01749930|Active Comparator|Timolol|Timolol maleate ophthalmic solution, 0.5%, administered BID for 3 months (Visit 6) into study eye(s).
3091468|NCT01749956|Experimental|FOLFOX6/Aflibercept/Radiation/Surgery|"Preoperative Chemoradiation: (6 weeks)~5-FU: 225 mg/m2 per day by intravenous continuous infusion (IVCI), Days 1 thru 42;~Radiation: 50.4 Gy (1.8 Gy/day or 28 fractions) Mon thru Fri, Weeks 1 thru 6;~Aflibercept: 4 mg/ kg, via IV infusion, Days 1 and 15.~Surgery at least 6 weeks after last day of aflibercept: Patients will undergo abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines.~Postoperative Chemotherapy and Aflibercept Treatments (four 28-day cycles):~Aflibercept (administered first): 4 mg/kg IV for approximately 1 hour (no more than 2 hours) on Days 1 and 15 of each cycle.~Modified FOLFOX6:~Leucovorin: 400 mg/m2 as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~Oxaliplatin: 85 mg/m2 IV as a 2-hour infusion prior to 5-FU on Days 1 and 15 of each cycle.~5-FU: 400-mg/m2 bolus for 2 to 4 minutes followed by 2400 mg/m2 for 46 hours on Days 1 and 15 of each cycle."
3091469|NCT01749982|Placebo Comparator|Placebo|Placebo tablets
3091470|NCT01749982|Experimental|Choline bitartrate|Choline bitartrate 700 mg by mouth daily
3091471|NCT01749982|Experimental|Betaine|Betaine 1000 mg by mouth daily
3091472|NCT01749982|Experimental|Choline bitartrate + Betaine|Choline bitartrate 700 mg + Betaine 1000 mg daily
3091473|NCT01750086|Active Comparator|Denosumab 60mg subcutaneous injection|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
3091474|NCT01750086|Active Comparator|Alendronate 70mg weekly x 8 weeks|Each subject will receive one teriparatide 40-mcg subcutaneous injection at each study visit.
3091475|NCT01750190|Experimental|Roxadustat|Participants will receive roxadustat tablets orally 3 times a week (TIW). The initial dose will be according to the tiered weight-based approach, with starting roxadustat doses of 70 milligrams (mg) TIW to participants weighing <70 kilograms (kg) and roxadustat doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 grams/deciliter (g/dL) and Hb increase from baseline (BL) of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 234.9 weeks.
3091476|NCT01750190|Placebo Comparator|Placebo|Participants will receive roxadustat-matching placebo tablets orally TIW. The initial dose will be according to the tiered weight-based approach, with starting roxadustat-matching placebo doses of 70 mg TIW to participants weighing <70 kg and roxadustat-matching placebo doses of 100 mg TIW to participants weighing ≥70 kg. Dose-titration (up to a maximum dose of 300 mg) will be performed based upon regular measurement of Hb levels until the participant achieves central Hb value of ≥11.0 g/dL and Hb increase from BL of ≥1.0 g/dL at 2 consecutive study visits, separated by at least 5 days. Once target Hb level is reached, the participant will enter the maintenance period during which roxadustat dosage will be adjusted every 4 weeks to maintain participant's Hb level within the target range of 10.0 g/dL and 12.0 g/dL. The maximum treatment duration will be up to 208.1 weeks.
3091477|NCT01750229|Sham Comparator|Sham|Frequency Setting - Sham
3091478|NCT01750229|Experimental|1200 Hz|Frequency Setting - 1200 Hz
3091479|NCT01750229|Experimental|3030 Hz|Frequency Setting - 3030 Hz
3091480|NCT01750229|Experimental|5882 Hz|Frequency Setting - 5882 Hz
3091481|NCT01750242||Parkinson's disease Subjects|Subjects with advanced Parkinson's Disease implanted with Medtronic DBS system in the subthalamic nucleus (STN).
3091482|NCT01750255|Placebo Comparator|Control|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
3091483|NCT01750255|Active Comparator|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment.
3091484|NCT01750268|Experimental|Topiramate|Topiramate capsules daily - up to 300 mg
3091485|NCT01750268|Placebo Comparator|Placebo|Placebo capsules daily - up 300 mg
3468931|NCT03891108|Experimental|Treatment B: BMS-986231 Formulation B|Participants will be administered Treatment B: BMS-986231 Formulation B as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
3468932|NCT03891108|Experimental|Treatment C: BMS-986231 Formulation C|Participants will be administered Treatment C: BMS-986231 Formulation C as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
3468933|NCT03891108|Experimental|Treatment D: BMS 986231 Formulation D|Participants will be administered Treatment D: BMS 986231 Formulation D as a 48-hour IV infusion on Day 1, followed by review of safety and tolerability data during and after the infusion.
3091489|NCT01750346|Active Comparator|0.05% AH-8|Participants in the 0.05% AH-8 arm received the higher dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
3091490|NCT01750346|Active Comparator|0.025% AH-8|Participants in the 0.025% AH-8 arm received the lower dose of the study drug, Acetyl Hexapeptide 8 (AH-8), which is sold under the brand name, Argireline.
3091491|NCT01750346|Placebo Comparator|Placebo|Participants in the Placebo arm received the placebo.
3091492|NCT01750398|Experimental|ADT plus IV testosterone|"Men with castration-resistant prostate cancer will initiate androgen deprivation therapy (ADT) with an LHRH agonist (e.g. goserelin or leuprolide) for a total of 6 months. After this initial lead-in castration phase, patients will receive intermittent intramuscular testosterone cypionate or testosterone enanthate (T) at a dose of 400 mg while continuing on ADT."
3091493|NCT01750502||coronary-artery-disease group|Participants, who are diagnosed as coronary-artery-disease which including acute coronary syndromes and stable ischemic heart disease, will receive at least one stent.
3091494|NCT01750502||non-coronary-artery-disease group|Participants, who are diagnosed as non-coronary-artery-disease without acute coronary syndromes and stable ischemic heart disease, will not receive stent.
3091495|NCT01750684|Placebo Comparator|Saline|Patients randomized (1:1) to the placebo arm will receive an initial intravenous infusion of saline for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
3091496|NCT01750684|Active Comparator|AC105|Patients randomized (1:1) to the active drug arm will receive an initial intravenous infusion of AC105 for 30 minutes within a pre-specified time window (12, 9, 6 hours post-injury). Patients will receive 5 additional infusions of the same dose and duration at 6 -hour intervals.
3091497|NCT01750697|Experimental|Rituximab|
3091498|NCT01750840||Stimulation Group|All patients will receive either the Biomet® EBI Bone Healing System, Biomet OrthoPak® Non-invasive Bone Growth Stimulator System or Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator Systems.
3091499|NCT01750879|Active Comparator|Peanut Flour|Oral Immunotherapy with peanut flour.
3091500|NCT01750879|Placebo Comparator|Oat Flour|Oral Immunotherapy with oat flour.
3091501|NCT01750918|Experimental|Part 1: Dabrafenib and Panitumumab|In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams [mg] twice daily) and panitumumab (6 milligrams per kilogram [mg/kg] every-2-week [Q2W]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
3091502|NCT01750918|Experimental|Part 1: Dabrafenib, Trametinib and Panitumumab|In Part 1 after the dabrafenib/panitumumab combination dose is defined, subsequent cohorts will evaluate the addition of trametinib based on a panitumumab dose that is one dose level lower than the dabrafenib/panitumumab dose defined in Cohort 1. Trametinib starting at 1.5 mg once daily will be added to the combination of dabrafenib and panitumumab. Dose escalation will follow a 3+3 dose escalation procedure until the full monotherapy doses of all agents are evaluated or the maximum tolerated dose is determined.
3091503|NCT01750918|Experimental|Part 2: Dabrafenib and panitumumab|In Part 2, subjects will be assigned to expansion cohorts at a selected dose of dabrafenib in combination with panitumumab
3091504|NCT01750918|Experimental|Part 2: Dabrafenib, Trametinib and Panitumumab|In Part 2, subjects will be assigned to expansion cohorts at selected dose of trametinib plus dabrafenib in combination with panitumumab.
3091505|NCT01750918|Experimental|Part 4a: Trametinib and Panitumumab|Subject will be administered starting dose of Trametinib 2 mg once daily and Panitumumab 6mg/kg Q2W. If the initial combination dose of trametinib and panitumumab in Cohort 1 (starting dose) is not tolerable, the lower dose combination defined in de-escalation cohorts (Cohort -1A, -1B and/or -1C) may be evaluated. Cohort -1A: Trametinib 1.5 mg once daily and Panitumumab 6 mg/kg Q2W; Cohort -1B: Trametinib 2 mg once daily and Panitumumab 4.8 mg/kg Q2W; Cohort-1C: Trametinib 1.5 mg once daily and Panitumumab 4.8 mg/kg Q2W
3091506|NCT01750918|Experimental|Part 4b: Trametinib and Panitumumab|In Part 4B cohort expansion, subjects will be assigned to expansion cohorts at a selected dose of trametinib in combination with panitumumab. Enrollment in expansion cohorts will be initiated once dose escalation for the trametinib /panitumumab combination has been completed. Subjects with advanced/metastatic CRC with either a BRAF-mutation (Cohort 1E) or who developed secondary resistance to prior anti-EGFR therapy (Cohort 2E).
3091507|NCT01750918|Experimental|Part 3a: Dabrafenib and Panitumumab|Subjects will be randomized to receive dabrafenib plus panitumumab. Dose levels for dabrafenib, and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
3091508|NCT01750918|Experimental|Part 3b: Dabrafenib, Trametinib and Panitumumab|Subjects will be randomized to receive study treatment as dabrafenib plus trametinib plus panitumumab. Dose levels for dabrafenib, trametinib and panitumumab in Part 3 will be chosen based on emerging PK, PD, and tolerability data from Part 1 and Part 2.
3091509|NCT01750918|Experimental|Part 3c: Chemotherapy comparator|Subjects will be randomized to receive chemotherapy comparator. The chemotherapy comparator will consist of a standard chemotherapy regimen with or without the addition of a biological agent, based on local practice preferences. The available chemotherapy regimens includes 5-fluorouracil-based chemotherapy
3091510|NCT01750931|Other|Meloxicam GSK 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
3091511|NCT01750931|Other|Mobic 15mg|A randomized, balanced, open label, crossover, two period, two treatment, two sequence, single dose, oral bioequivalence study under fed condition
3091512|NCT01751022|Experimental|Attain Performa LV Lead (Models 4298, 4398, 4598)|N/A: single arm study, separate analysis for each lead model (total of 3).
3091513|NCT01751061|Experimental|Decision aid|Web-based decision aid (decision support tool) provided to surrogate decision maker
3091514|NCT01751061|Active Comparator|Usual care|usual care in an intensive care unit setting
3091515|NCT01751087|Other|Osmotic dilators + placebo (vit c) + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal placebo on Day 2.
3091516|NCT01751087|Active Comparator|Osmotic dilators + placebo (vit c) + misoprostol|Women will receive osmotic dilators on Day 1, oral placebo on Day 1, and buccal misoprostol 400 mcg on Day 2.
3091517|NCT01751087|Active Comparator|Osmotic dilators + mifepristone + placebo (vit B12)|Women will receive osmotic dilators on Day 1, oral mifepristone 200 mg on Day 1, and buccal placebo on Day 2.
3091518|NCT01751113|Active Comparator|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
3091519|NCT01751113|Active Comparator|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
3091520|NCT01751113|Active Comparator|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
3091521|NCT01751139|Other|Total Group|Subjects six months of age and older at the time of enrolment, recruited from randomly selected households originating from preselected mapped communities. Preferably the recruitment period occurred outside of the peak dengue transmission season, and continued until each site had reached its foreseen target. The expected period for recruiting the target sample size was approximately three months. Recruitment of replacement subjects was done during the low dengue transmission and the recruitment period depended on the number of subjects that need to be replaced. Enrolled subjects were subjects who either lived in households in study areas with support from the Family Health Physician Program (FHP) or the Larval Index Rapid Assay (LIRA) or with field research experience in the community (preferred) or where a similar system of mapped communities with potential for surveillance existed.
3091522|NCT01751165|Experimental|HZ/su-0,2 Group|Subjects will receive HZ/su vaccine on a 0,2-month schedule.
3091523|NCT01751165|Experimental|HZ/su-0,6 Group|Subjects will receive HZ/su vaccine on a 0,6-month schedule.
3091524|NCT01751165|Experimental|HZ/su-0,12 Group|Subjects will receive HZ/su vaccine on a 0,12-month schedule.
3091525|NCT01751178|Active Comparator|Mouthwash with Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash with alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
3091526|NCT01751178|Active Comparator|Mouthwash without Alcohol|rinse with 10ml 0.2% w/v Chlorhexidine Digluconate Mouthwash without alcohol for 1 timed minute twice daily for 6 weeks following brushing with a full brush head of standard toothpaste for 1 timed minute.
3091527|NCT01751230|Experimental|WIC E-Moms|If picked for this group, you will receive a personalized diet and exercise plan to help you lose the weight you gained during your pregnancy. All information will be given to you using a SmartPhone, such as an iPhone. You can use your own phone or one can be loaned to you for the study. You will also be loaned a scale so you can weigh yourself at home. You will also get advice and services from your WIC clinic.
3091528|NCT01751230|No Intervention|WIC Moms|You will get advice and services for nutrition and weight management after pregnancy from your WIC clinic.
3091529|NCT01751308|Experimental|Phase 1: Cabazitaxel 20 mg/m^2|Cabazitaxel 20 mg/m^2 intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression (DP) or discontinuation due to adverse event (AE) or death (from any cause).
3091530|NCT01751308|Experimental|Phase 1: Cabazitaxel 25 mg/m^2|Cabazitaxel 25 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3091531|NCT01751308|Experimental|Phase 1: Cabazitaxel 30 mg/m^2|Cabazitaxel 30 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3091532|NCT01751308|Experimental|Phase 1: Cabazitaxel 35 mg/m^2|Cabazitaxel 35 mg/m^2 IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3091533|NCT01751308|Experimental|Phase 2: Cabazitaxel 30 mg/m^2|Cabazitaxel at the maximum tolerated dose (MTD) as determined in phase 1 (30 mg/m^2) IV infusion on Day 1 of each 21-day cycle until DP or discontinuation due to AE or death (from any cause).
3091534|NCT01751386|Experimental|Baclofen|Baclofen 10 mg t.i.d.
3091535|NCT01751386|Placebo Comparator|Placebo|Placebo t.i.d.
3091536|NCT01751399|Experimental|LY2605541-Normal Hepatic Function|Participants with normal hepatic function will receive a single subcutaneous (SC) dose of 0.075 milligrams per kilogram (mg/kg) LY2605541
3091537|NCT01751399|Experimental|LY2605541-Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
3091538|NCT01751399|Experimental|LY2605541-Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
3091539|NCT01751399|Experimental|LY2605541-Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single SC dose of 0.075 mg/kg LY2605541
3091540|NCT01751412|Experimental|Proton Radiation|Delivered daily (Monday-Friday) for two to five weeks.
3091541|NCT01751451|Experimental|Abiraterone acetate|"Group 1~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months"
3091542|NCT01751451|Experimental|Abiraterone acetate and Degarelix|"Group 2~Abiraterone acetate 1000 mg daily x 8 months~Prednisone 5 mg once daily x 8 months~Degarelix subcutaneous depot injection q 1 month x 8 months"
3091543|NCT01751451|Experimental|Degarelix|"Group 3~• Degarelix subcutaneous depot injection q 1 month x 8 months"
3091544|NCT01751568|Experimental|Cohort 1: ≥ 2 to < 6 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
3091545|NCT01751568|Experimental|Cohort 2: ≥ 6 to < 12 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets, starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
3091546|NCT01751568|Experimental|Cohort 3: : ≥ 4 weeks to < 2 years of age on TB treatment|Participants in this cohort received chewable raltegravir tablets (as a dispersible tablet), starting dose of 12 mg/kg (up to a maximum of 800 mg) orally twice daily, in addition to two NRTIs to treat HIV as part of standard of care, and a rifampicin-containing regimen to treat TB. After a study visit at Day 5 to 8, a fourth ARV medication was added to the regimen.
3091547|NCT01751646|Experimental|Group A: Vitamin D3 50,000 IU|Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
3091548|NCT01751646|Placebo Comparator|Group B: Vitamin D3 placebo|Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
3091549|NCT01751724|Experimental|Caffeine Arm|Subjects randomized to this arm will receive blinded Caffeine citrate.
3091550|NCT01751724|Placebo Comparator|Placebo Arm|Subjects randomized to this arm will receive blinded Placebo (equivalent volume of normal saline).
3091551|NCT01751802|Experimental|Ecopipam|Active substance being tested, orally once a day at bedtime
3091552|NCT01751802|Placebo Comparator|Placebo|Inactive substance being tested, orally once a day at bedtime
3091553|NCT01751867|Experimental|3-Day Dose schedule|Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
3091554|NCT01751867|Experimental|5-Day Dose schedule|Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.
3091555|NCT01751906|Experimental|Absorb BVS|Subjects receiving Absorb BVS
3091556|NCT01751906|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition
3091557|NCT01751971|Active Comparator|Inspired Oxygen First|Participants breathe air with additional inspired oxygen (40%) for 1 night during an overnight sleep study (15 L/min via venturi mask). 1 week later participants will crossover to Sham (sham comparator).
3091558|NCT01751971|Sham Comparator|Sham First|Participants breathe air without additional inspired oxygen for 1 night during sleep (15 L/min via Venturi mask). 1 week later participants will crossover to Inspire Oxygen (active intervention).
3091559|NCT01752036|Other|Treatment|Post-Operative Stereotactic Radiosurgery
3091560|NCT01752400|Experimental|AUY922|Via intravenous infusion on Days 1, 8 and 15 of each 21 day cycle (once per week). Infusion lasts approximately 60 minutes
3091561|NCT01752413|Experimental|Ferrous gluconate 325mg|Those found iron depleted by ferritin measure will receive 325 mg Ferrous gluconate twice a day for 100 days. They will be deferred as a whole blood donor for 120 days until completion of iron therapy. They will receive standard dietary counseling.
3091562|NCT01752413|Active Comparator|Nutrition counseling|For those consenting to this study but who demonstrate adequate ferritin levels (>20 micrograms/L female, >30 micrograms/L males), they will not receive oral iron or additional deferral period but will be allowed to donate after the standard 56 days. They will receive standard counseling about iron rich foods. Rate and frequency of subsequent donations will be tracked and compared to those receiving iron supplementation.
3091563|NCT01752426|Experimental|Heavy Water + PCI-32765|Subjects given 50ml 70% 2H2O (Heavy Water) 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks (labeling phase). Subjects given first dose in clinic. Subjects then given individual doses of 2H2O to consume at home; after the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765. PCI-32765 administered with 8 ounces (~240mL) of water at a dose of 420 mg (3 x 140mg capsules) orally once daily and continued daily. Treatment duration is 12 cycles, with each cycle consisting of 28 days.
3091564|NCT01752634|Experimental|Secukinumab (AIN457) 75 mg s.c.|Secukinumab 75 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
3091565|NCT01752634|Experimental|Secukinumab (AIN457) 150 mg s.c.|Secukinumab 150 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4.
3091566|NCT01752634|Experimental|Secukinumab (AIN457) 300 mg s.c.|Secukinumab 300 mg at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4
3091567|NCT01752634|Placebo Comparator|Placebo s.c.|Placebo at BSL, Weeks 1, 2, 3 and 4, followed by dosing every four weeks starting at Week 4. Non-responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 16. Responder (assessed at Week 16) were re-randomized to receive AIN457 150mg or AIN457 300 mg starting at Week 24.
3091568|NCT01752712|Experimental|CBSST + oxytocin|Cognitive Behavioral Social Skills Training with adjunct oxytocin nasal spray treatment. Participants will receive 80 IU/day of oxytocin administered intranasally in two doses (40 IU morning and evening).
3091569|NCT01752712|Placebo Comparator|CBSST + placebo|Cognitive Behavioral Social Skills Training with placebo nasal spray. The placebo nasal spray bottles will be matched in appearance to the oxytocin nasal spray bottles and similarly administered intranasally in two doses (morning and evening).
3091570|NCT01752842|Experimental|Fenofibrate|One fenofibrate 160 mg capsule per day for 12 weeks
3091571|NCT01752842|Placebo Comparator|Placebo for fenofibrate|One inert sugar pill per day for 12 weeks
3091572|NCT01752855|Experimental|New formulation of adalimumab 40 mg every other week|New formulation adalimumab 40 mg every other week
3091573|NCT01752907|Experimental|General Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a general chemotherapy side effects education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
3091574|NCT01752907|Experimental|Bone Pain Education DVD|Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
3091575|NCT01752920|Experimental|Low Dose Group|Patients who received derazantinib orally at dose levels from 25 mg every other day (QOD) - 200 mg daily (QD) on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
3091576|NCT01752920|Experimental|Middle Dose Group|Patients who received derazantinib orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
3091577|NCT01752920|Experimental|High Dose Group|Patients who received derazantinib orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
3091578|NCT01752920|Experimental|Expanded Cohort Group|Patients who received derazantinib orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule until documented progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria.
3091579|NCT01752933|Experimental|SGI-110|SGI-110 administered subcutaneously (SC) daily on Days 1 - 5 every 28 days
3091580|NCT01752985|Experimental|Arm A: BMS-813160 150 mg & Placebo matching with BMS-813160|BMS-813160 150 mg capsules by mouth in AM and Placebo matching with BMS-813160 in PM for 12 weeks
3091581|NCT01752985|Experimental|Arm B: BMS-813160 300 mg|BMS-813160 300 mg capsules by mouth twice daily for 12 weeks
3091582|NCT01752985|Placebo Comparator|Arm C: Placebo matching with BMS-813160|Placebo matching with BMS-813160 0 mg capsules by mouth twice daily for 12 weeks
3091583|NCT01753076|Experimental|Ozanezumab IV|Administered by IV route. Treatment period - 48 Weeks
3091584|NCT01753076|Placebo Comparator|Placebo|Normal saline by IV route. Treatment period - 48 weeks
3091585|NCT01753115|Experimental|BioThrax + Ciprofloxacin PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
3091586|NCT01753115|Experimental|BioThrax + Ciprofloxacin no PK|"BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.~Ciprofloxacin: 500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48)."
3091587|NCT01753115|Experimental|BioThrax only|BioThrax: route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule.
3091588|NCT01753193|Experimental|Anifrolumab|Participants will receive IV infusion of anifrolumab 1000 milligrams (mg) every 4 weeks (Q4W) from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter will receive 300 mg Q4W for up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
3091589|NCT01753297|Active Comparator|Triptorelin, 11.25 mg|Triptorelin, powder and solvent for suspension (prolonged released form)
3091590|NCT01753297|No Intervention|Active surveillance|Active surveillance after radical prostatectomy (RP)
3091591|NCT01753310|Active Comparator|Dysport®|Dysport® (intramuscular injection), between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
3091592|NCT01753310|Placebo Comparator|Placebo|Placebo, up to 2mL
3091593|NCT01753323|Experimental|Part 1 - Cohort 1: P. vivax: KAF156 400mg QD|Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.
3091594|NCT01753323|Experimental|Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD|Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.
3091595|NCT01753323|Experimental|Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose|Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.
3091596|NCT01753336|Experimental|Dysport®|Dysport®, up to 500 units (U)/vial using 2mL dilution
3091597|NCT01753362|Placebo Comparator|placebo|subcutaneous daily injection
3091598|NCT01753362|Active Comparator|liraglutide|subcutaneous daily injection
3091599|NCT01753401|Experimental|Period 2: Placebo/Acthar|Participants receive Placebo in Part 1, but after completion of Week 8 in the double-blind phase, patients who received Placebo may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen during Part 2 may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
3091600|NCT01753401|Experimental|Period 2: Acthar/Acthar|After completion of Week 8 in the double-blind phase, patients who received Acthar may choose to participate in the optional open-label phase where they will receive an Acthar maintenance regimen for 44 weeks. The initial Acthar regimen will be assigned based on the study medication regimen the patient received at the completion of the double-blind phase (Visit 6, Week 8). Acthar regimen may be adjusted based on the Investigator's judgment with the goal of achieving a stable Acthar regimen no later than Week 28. Once the stable Acthar regimen is achieved, the Investigator should consider tapering the steroid regimen to a low daily dose or completely discontinue.
3091601|NCT01753401|Placebo Comparator|Period 1: Placebo|Participants receive matching placebo (in 0.5 mL daily or in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
3091602|NCT01753401|Experimental|Period 1: Acthar|Participants receive Acthar (40 units in 0.5 mL daily or 80 units in 1 mL every other day) for 4 weeks. In Weeks 5-8, they will taper the study medication. Participants will continue on their stable steroid regimen during this phase of the study. After completion of Week 8 in the double-blind phase, they may choose to participate in the optional open-label phase. Participants will continue on their stable steroid regimen during this phase of the study.
3091603|NCT01753518|Active Comparator|Subcuticular suture|Subcuticular suture has been used for many years to close skin incisions.
3091604|NCT01753518|Active Comparator|Subcuticular staple|Subcuticular staples are a newer modality than suture, but are currently an accepted and widely used skin closure technique.
3091605|NCT01753557|Experimental|Treatment-Naive|
3091606|NCT01753557|Experimental|Treatment-Relapsed|
3091607|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype1|
3091608|NCT01753570|Experimental|RBV+IFN beta, Genotype1|
3091609|NCT01753570|Experimental|MP-424+RBV+IFN beta, Genotype2|
3091610|NCT01753713|Experimental|Anti-angiogenic Therapy Naive Patients|Patients who have progressed without anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3091611|NCT01753713|Experimental|Anti-angiogenic Therapy Patients|Patients who have progressed on anti-angiogenic therapy. Patients receive dovitinib orally (PO) 5 days a week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3091612|NCT01753739|Experimental|Bepotastine besilate Concentration 1|Bepotastine besilate nasal spray, BID for 14 days.
3091613|NCT01753739|Active Comparator|Placebo|Placebo nasal spray BID for 14 days
3091614|NCT01753739|Experimental|Bepotastine besilate Concentration 2|Bepotastine besilate nasal spray, BID for 14 days.
3091615|NCT01753739|Experimental|Bepotastine besilate Concentration 3|Bepotastine besilate nasal spray, BID for 14 days.
3091616|NCT01753739|Experimental|Bepotastine besilate Concentration 4|Bepotastine besilate nasal spray, BID for 14 days.
3091617|NCT01753830|Experimental|Durolane|Single intraarticular injection of Durolane
3091618|NCT01753830|Placebo Comparator|PBS|Single intraarticular injection of PBS
3091619|NCT01753856|Experimental|Teriparatide|"20 micrograms (µg) teriparatide administered subcutaneously (SC) once every day for 6 months.~Demeclocycline (DEM): Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 milligrams (mg) DEM will be taken orally every 6 hours; Days 4 to15: DEM will not be administered.~Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 milligrams per day (mg/day) administered orally.~Vitamin D: Approximately 800 to 1200 International Units per day (IU/day) administered orally."
3091620|NCT01753856|Active Comparator|Denosumab|"60 mg denosumab administered SC once in 6 months.~DEM: Beginning 18 days prior to randomization: Days 1, 2, 3 and 16, 17, 18: 150 mg DEM will be taken orally every 6 hours; Days 4 to 15: DEM will not be administered.~TET: Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.~Calcium: Approximately 1000 mg/day administered orally.~Vitamin D: Approximately 800 to 1200 IU/day administered orally."
3091621|NCT01753999|Active Comparator|Standard CPAP|Use of a standard CPAP (continuous positive airway pressure) device with constant pressure for 4 weeks to improve breathing during sleep
3091622|NCT01753999|Active Comparator|CPAP - Flex|Use of CPAP-Flex (continuous positive airway pressure) device with decreased pressure during expiration for 4 weeks to improve breathing during sleep
3091623|NCT01754129||Participants with Parkinson's disease|Participants with advanced levodopa-responsive Parkinson's disease and severe motor fluctuations and hyper-/dyskinesia who were prescribed and treated in accordance with the local levodopa/carbidopa intestinal gel product label
3091624|NCT01754194||Procedure Type 1|Gastric Sleeve Resection
3091625|NCT01754194||Procedure Type 2|Roux-en-Y Gastric Bypass
3091626|NCT01754207|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3091627|NCT01754259|Experimental|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
3091628|NCT01754259|Placebo Comparator|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
3091629|NCT01754350|Experimental|ketogenic diet and transient fasting|Calorie-restricted, ketogenic diet and transient fasting during reirradiation
3091630|NCT01754350|Active Comparator|standard nutrition|nutrition according to recommendations of the German society for nutrition during reirradiation
3091631|NCT01754376|Experimental|Treatment Arm|"Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression."
3091632|NCT01754389|Active Comparator|Arm A (Standard of Care)|Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously on days 1, 3, 6 and 11 post-transplant
3091633|NCT01754389|Experimental|Arm B (Experimental)|Bortezomib intravenously 1, 4 and 7 days post-transplant Tacrolimus intravenously and orally, Day -3 through 3-6 months post-transplant Methotrexate intravenously 1,3,6 and 11 days post-transplant
3091634|NCT01754389|Experimental|Arm C (Experimental)|Bortezomib intravenously 1,4 and 7 days post-transplant Sirolimus, intravenously and orally, Day -3 through 3-6 months post-transplant Tacrolimus, intravenously and orally, Day -3 through 3-6 months post-transplant
3091635|NCT01754402|Experimental|Cohort 1: benda 120mg + pom 3mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3091636|NCT01754402|Experimental|Cohort 2: benda 120mg + pom 4mg|"Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3091637|NCT01754402|Experimental|Expansion|"Pomalidomide 3mg: once daily oral (PO) dosing on days 1-21, every 28 days~Bendamustine 120 mg: once intravenous (IV) dosing on day 1, every 28 days~Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days"
3091638|NCT01754467|Experimental|NEAT!|Participants will use the NEAT! smartphone application and accelerometer over a 1 month period.
3091639|NCT01754480|Experimental|Fibrin Sealant Grifols|Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
3091640|NCT01754480|Active Comparator|Surgicel®|Surgicel® is a sterile, absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3091641|NCT01754493|Experimental|Treatment with Duloxetine|Patients will receive open treatment with Duloxetine
3091642|NCT01754519|Experimental|Treatment (radiation therapy)|Patients undergo wide local excision breast surgery and SFRT over 60-100 minutes once negative margins are obtained.
3091643|NCT01754623|Experimental|Chemotherapy Followed by Radiation Treatment|"Gemcitabine, Taxotere, Xeloda (GTX): 21 day cycle x 3 Gemcitabine 750mg/m^2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m^2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m^2 on days 1-14 Radiation: stereotactic body radiation therapy stereotactic body radiation therapy (SBRT).~After radiation, participants will be re-evaluated for surgery."
3091644|NCT01754688||Jaundice infants|Bilirubin Induced Neurologic Dysfunction II score
3091645|NCT01754714|Experimental|1000 mg SAMe (S-adenosyl-L-methionine)|
3091646|NCT01754714|Experimental|1500 mg SAMe|
3091647|NCT01754714|Experimental|2000 mg SAMe|
3091648|NCT01754714|No Intervention|No treatment|
3091649|NCT01754727||Participants with Ankylosing Spondylitis (AS)|Participants with ankylosing spondylitis treated with adalimumab in routine clinical practice.
3091650|NCT01754753|Active Comparator|Telephone friendship groups|"Participants allocated to telephone friendship groups will take part in 12 weekly group telephone discussions. The participant will be called, by a trained Age UK Sheffield volunteer, in their own home. The group discussions will take place for about an hour each week and involve between 6-8 participants. Participants will be introduced to weekly group calls by the volunteer who will call each participant individually for around 20 minutes each week for up to six weeks before the group is established.~The group may have a particular focus or talk about different topics each week. The individual participants are joined together through a teleconferencing system (provided by Community Network)."
3091651|NCT01754753|No Intervention|Usual health and social care|Participants allocated to the control arm will not receive any research intervention. However, they will participate in the research by completing questionnaires about their health and wellbeing.
3091652|NCT01754766|Experimental|AGN-229666 Dose A|One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
3091653|NCT01754766|Experimental|AGN-229666 Dose B|One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
3091654|NCT01754766|Placebo Comparator|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
3091655|NCT01754909|Active Comparator|enalapril|Use of enalapril in subjects undergoing radiotherapy for lung cancer.
3091656|NCT01754909|Placebo Comparator|placebo|Use of placebo in subjects undergoing radiotherapy for lung cancer
3091657|NCT01754922||Exposed|Veterans deployed to OEF/OIF/OND and environmentally exposed to high levels of particulate matter
3091658|NCT01754922||Control|OEF/OIF/OND Veterans deployed to regions other than Southwest Asia
3091659|NCT01755026|Active Comparator|2 gram dose of cefazolin|2 gram dose of pre-operative cefazolin
3091660|NCT01755026|Experimental|4 gram Dose|4 gram dose of pre-operative prophylaxis
3091661|NCT01755091|Placebo Comparator|Sugar Pill|Placebo, once per day (QD) by mouth, 60 minutes before bedtime for 6 weeks after 1-week run-in
3091662|NCT01755091|Experimental|2.5 mg/day|Dronabinol, 2.5 mg QD by mouth, 60 minutes before bedtime for 6 weeks after 1-week placebo run-in
3091663|NCT01755091|Experimental|10 mg/day|Dronabinol, 10 mg QD by mouth, 60 minutes before bedtime for 4 weeks after 1-week placebo run-in and 2-week dose escalation
3091664|NCT01755143|Experimental|MRI Group|Subjects randomized to the Magnetic Resonance Imaging group will undergo a series of MRI scans at the 9-12 week visit post-implant.
3091665|NCT01755143|Sham Comparator|Control Group|Subjects randomized to the control group will not undergo a series of MRI scans but will come into the study office for a one hour waiting period at the 9-12 week post-implant visit.
3091666|NCT01755156|Experimental|Omarigliptin (Phase A) → Omarigliptin (Phase B)|Phase A: Omarigliptin 25 mg capsule administered orally once weekly for 24 weeks. Phase B: Omarigliptin 25 mg capsule administered orally once weekly and matching placebo to glimepiride tablet/capsule administered orally once daily for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
3091667|NCT01755156|Placebo Comparator|Placebo to omarigliptin (Phase A) → Glimepiride (Phase B)|Phase A: matching placebo to omarigliptin orally once a week for 24 weeks. Phase B: Matching placebo to omarigliptin capsule administered orally once weekly and glimepiride 1 or 2 mg tablet/capsule administered orally once daily (titrated up to 6 mg daily) for 80 weeks. Participants will continue pre-study metformin throughout the duration of the study. If necessary, rescue therapy may be initiated (open-label glimepiride during Phase A and insulin glargine during Phase B).
3091668|NCT01755169|Experimental|Ketamine 0.25 mg/kg/dose|A 5mL solution of 0.25 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3091669|NCT01755169|Experimental|Ketamine 0.5 mg/kg/dose|A 5mL solution of 0.5 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3091670|NCT01755169|Experimental|Ketamine 1 mg/kg/dose|A 5mL solution of 1 mg/kg/dose of ketamine will be given three times daily for 2 weeks.
3091671|NCT01755169|Placebo Comparator|Placebo|
3091672|NCT01755195|Experimental|Cabozantinib|60 mg tablets orally once a day in a 28-day cycle.
3091673|NCT01755234|Active Comparator|Sevoflurane|Sevoflurane administered by inhalation (laryngeal mask airway or endotracheal tube)
3091674|NCT01755234|Active Comparator|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
3091675|NCT01755416|Placebo Comparator|Closed loop with sensor and Insulin|subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
3091676|NCT01755416|Active Comparator|Closed loop with sensor, Insulin and Liraglutide|Subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner, on Day 1.
3091677|NCT01755455|Active Comparator|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
3091678|NCT01755455|Placebo Comparator|Placebo|Identical-appearing tablet taken by mouth daily for 6 weeks
3091679|NCT01755546|Experimental|EN3409|Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
3091680|NCT01755598|Experimental|M72AS01 Group|Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
3091681|NCT01755598|Placebo Comparator|Control group|Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
3091682|NCT01755637|Experimental|Albendazole tablet (Aqua Based)|Albendazole tablets 400 milligram (mg) manufactured under aqua based solvent condition taken orally with 200 millilitre (mL) of water as single dose treatment.
3091683|NCT01755637|Active Comparator|Albendazole tablet (Alcohol Based)|Albendazole tablets 400 mg manufactured under ethanol based solvent condition taken orally with 200 mL of water as single dose treatment.
3321148|NCT02016664|Experimental|Chronic pain patients on oral ketamine|"Days 1-7:~Subjects will be given a 7 day supply of 10 mg ketamine tablets three times per day for seven days and to return to clinic on Day 7. They will be instructed not to take their morning dose of ketamine and to eat a light breakfast on Day 7. Upon arrival, the patient will have a 20 gauge (saline locked) IV started in the antecubital fossa to allow for five blood samples: Time Zero,30, 60,90 and 120 minutes. The first blood sample at Time 0 will be obtained just before the patient takes his/her oral dose of ketamine.~Days 8-14:~The subjects will be given a supply of 20 mg ketamine capsules and instructed to take them three times per day, at specified times, and to return to clinic on Day 14. The instructions and procedures at the second clinic visit will be the same as on Day 7."
3321149|NCT02016677||observation|no specific treatment. Long term observation the results of any breast lifting or reduction surgeries
3321150|NCT02016703|Experimental|5 g group|5g erythritol dissolved in 250 ml (2% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3321151|NCT02016703|Experimental|15 g group|15g erythritol dissolved in 250 ml (6% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3091689|NCT01755702|Placebo Comparator|Arm 1|Placebo
3091690|NCT01755702|Active Comparator|Arm 2|paracetamol marketed forumulation
3091691|NCT01755702|Active Comparator|Arm 3|ibuprofen marketed formulation
3091692|NCT01755702|Experimental|Arm 4|experimental paracetamol + caffeine formulation
3091693|NCT01755767|Experimental|Tivantinib 240 mg BID Cohort|The tivantinib dosage of 240 mg tablets administered by mouth twice daily (BID), once in the morning and once in the evening, with food, for a total daily dose of 480 mg.
3091694|NCT01755767|Experimental|Tivantinib 120 mg BID Cohort|Tivantinib 120 mg is administered by oral tablet BID, once in the morning and once in the evening, with food, for a total daily dose of 240 mg (amended dosing group; primary analysis group).
3091695|NCT01755767|Placebo Comparator|Placebo Matching 240 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
3091696|NCT01755767|Placebo Comparator|Placebo Matching 120 mg BID Cohort|Matching placebo is administered by oral tablet(s) BID, once in the morning and once in the evening, with food.
3091697|NCT01755858|Experimental|Bendavia|Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.
3091698|NCT01755858|Placebo Comparator|Placebo|Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.
3091699|NCT01755949|Active Comparator|Chronic atrial fibrillation, colchicine|Colchicine 0.6 mg PO BID. Subjects not undergoing ablation.
3091700|NCT01755949|Placebo Comparator|Chronic atrial fibrillation, placebo|Matching placebo. Subjects not undergoing ablation.
3091701|NCT01755949|Active Comparator|Pre-ablation, sinus rhythm, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
3091702|NCT01755949|Placebo Comparator|Pre-ablation, sinus rhythm, placebo|Matching placebo. Subjects undergoing ablation.
3091703|NCT01755949|Active Comparator|Pre-ablation, AF, colchicine|Colchicine 0.6 mg PO BID. Subjects undergoing ablation.
3091704|NCT01755949|Placebo Comparator|Pre-ablation, AF, placebo|Matching placebo. Subjects undergoing ablation.
3091705|NCT01756053|Active Comparator|ABT-089|"During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to active ABT-089 during study medication period 1 will take four 10mg capsules daily (40mg daily) during the 10-day medication period. During study medication period 2, these subjects will take four capsules of the matched placebo capsules."
3091706|NCT01756053|Placebo Comparator|Placebo|"These are matched placebo capsules manufactured by the study drug supplier.~During both 10-day study medication periods (Days 1-10 & Days 32-41), subjects will take 4 capsules daily. Administration of study medication will be double-blind and in counter-balanced order.~Those randomized to matched placebo during study medication period 1 will take four capsules daily during the 10-day medication period. During study medication period 2, these subjects will take four 10mg capsules (40mg daily) of the active ABT-089 capsules."
3091707|NCT01756079|Experimental|PegIFN-2b + RBV+ boceprevir|Participants will receive PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) for 4 weeks and then will receive 44 additional weeks of treatment with PegIFN-2b (once weekly, 1.5 µg/kg subcutaneously) + RBV (capsules, orally, weight-based dose from 800-1400 mg/day divided into two daily doses) + boceprevir (capsules, orally, 800 mg three times per day).
3091708|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2|SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks.
3091709|NCT01756157|Experimental|SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1|SC CINRYZE with rHuPH20 Dose Level 2 twice weekly (every 3 or 4 days) for 8 weeks followed by SC CINRYZE with rHuPH20 Dose Level 1 twice weekly (every 3 or 4 days) for 8 weeks.
3091710|NCT01756209|Active Comparator|Acetaminophen|Acetaminophen 15 mg/kg oral single dose (n=40)
3091711|NCT01756209|Active Comparator|Ibuprofen|Ibuprofen 10 mg/kg oral single dose (n=40)
3091712|NCT01756209|Experimental|Acetaminophen + magnesium 400 mg|Acetaminophen 15 mg/kg oral single dose (n=40) + magnesium 400 mg
3091713|NCT01756209|Experimental|ibuprofen + magnesium 400 mg|ibuprofen 10 mg/kg oral single dose (n=40) + magnesium 400 mg
3091714|NCT01756235||Participants with Rheumatoid Arthritis|Participants with rheumatoid arthritis treated with adalimumab in routine clinical practice.
3091715|NCT01756274|Experimental|Neonates 'Left-over' Blood Samples|Blood samples used in this study were 'left-over samples'. The blood samples were from heel sticks of neonates, collected (into a tube) and sent to the laboratory. Two left-over samples could be obtained from a single neonate. Laboratory professionals tested the BG concentration using three Bayer Blood Glucose Monitoring Systems (BGMS): Contour® NEXT BGMS, Contour® PLUS BGMS, and Contour® Next EZ BGMS.
3091716|NCT01756300|Experimental|Resistant Hypertension|The catheter-based (device: Celsius® ThermoCool® RD) renal denervation will serve to treat resistant hypertension.
3091717|NCT01756352|Experimental|GBM Avastin receiving 18F-FET|Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin
3091718|NCT01756456|Experimental|1_rhNGF10_Phase 1_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35μg of rhNGF).
3091719|NCT01756456|Experimental|2_rhNGF20_Phase 1_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
3091720|NCT01756456|Placebo Comparator|3_vehicle group_Phase 1_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
3091721|NCT01756456|Experimental|4_rhNGF10_Phase 2_treatment|active treatment with rhNGF 10 μg/ml. One drop six times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
3091722|NCT01756456|Experimental|5_rhNGF20_Phase 2_treatment|active treatment with rhNGF 20 μg/ml. One drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
3091723|NCT01756456|Placebo Comparator|6_vehicle group_Phase 2_treatment|vehicle control arm. Ophthalmic solution of the same composition as the test product with the exception of rhNGF. One drop six times a day for the entire period
3091724|NCT01756833|Active Comparator|Doxycycline|100 mg capsules, twice a day, for a period of two years.
3091725|NCT01756833|Placebo Comparator|Placebo|100 mg capsules, twice a day, for a period of two years.
3091726|NCT01756846|Other|usual care|Daily practice of the cardiologist or attending emergency doctor, in order to diagnose a patient with chest pain. In this period attending doctors assess the risk of a patient with chest pain, based on his/hers experience and various criteria (for example described in European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, without a formal risk score).
3091727|NCT01756846|Other|use of HEART risk score|see intervention
3091728|NCT01756885|Active Comparator|Standard Varenicline Treatment|"12 weeks of active varenicline + 12 weeks of placebo + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Days 85-168: Placebo - 1.0mg twice daily orally"
3091729|NCT01756885|Experimental|Extended Varenicline Treatment|"24 weeks of active varenicline + smoking cessation counseling~Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-168: 1.0mg twice daily orally"
3091730|NCT01756898|Experimental|Low dose ASB17061|Oral administration of low dose ASB17061 taken once daily for 28 consecutive days.
3091731|NCT01756898|Experimental|Middle dose ASB17061|Oral administration of middle dose ASB17061 taken once daily for 28 consecutive days.
3091732|NCT01756898|Experimental|High dose ASB17061|Oral administration of high dose ASB17061 taken once daily for 28 consecutive days.
3091733|NCT01756898|Placebo Comparator|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
3091734|NCT01756976||Investigational Device|The 510k cleared OrthoPAT Advance will be used in this standard of care arm.
3091735|NCT01756976||Control Group|The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.
3091736|NCT01757067|Active Comparator|ablation procedure vs medical therapy|PVC ablation vs medical therapy
3091737|NCT01757067|No Intervention|Compare 2 arms for safety, symptoms|Compare control of PVC's between 2 groups.
3091738|NCT01757171|Experimental|Arm A (taxane naïve)|No prior Taxane treatment. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
3091739|NCT01757171|Experimental|Arm B (prior taxane therapy)|Subject previously treated with taxane. Cabazitaxel will be administered 20 mg/m2 IV over 1 hour every 3 weeks
3091740|NCT01757184|Experimental|Double-blind Sebelipase Alfa|Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
3091741|NCT01757184|Placebo Comparator|Double-blind Placebo|Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
3091742|NCT01757184|Experimental|Open-label Sebelipase Alfa/Sebelipase Alfa|Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
3091743|NCT01757184|Experimental|Open-label Placebo/Sebelipase Alfa|Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
3091744|NCT01757197|Experimental|All Patients|Toclizumab will be administered on Day 0. The administration of tocilizumab will be every 2 weeks for a total of 8 doses.
3091745|NCT01757275|Experimental|Esomeprazole|
3091746|NCT01757275|Active Comparator|Cimetidine|
3091747|NCT01757288|Active Comparator|PACLITAXEL (Phase II, Arm A)|PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY
3091748|NCT01757288|Experimental|NAB-PACLITAXEL (Phase II, Arm B)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 40 mg/m2 IV/30min/wk x6 wks
3091749|NCT01757288|Experimental|NAB-PACLITAXEL (Phase I)|NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks
3091750|NCT01757301|Active Comparator|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
3091751|NCT01757301|Experimental|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
3091752|NCT01757392|Experimental|Candin® 0.3 mL|Monthly intralesional injections of Candin® 0.3 ml until lesion resolves or up to 6 injections.
3091753|NCT01757405|Experimental|≤ 3 doses of 90 µg/kg rFVIIa BI|
3091754|NCT01757405|Experimental|One dose of 270 µg/kg rFVIIa BI|
3468934|NCT03890926||radioactive Iodine-125 seed implantation|All enrolled patients received the intervention previously as a conventional treatment.
3091757|NCT01757561||Propofol-Abnormal|patients with preoperative SjvO2<55%,using the TIVA technology with propofol,
3091758|NCT01757561||Propofol-Normal|patients with preoperative SjvO2≥55%,using the TIVA technology with propofol,
3091759|NCT01757561||Sevoflurane-Abnormal|patients with preoperative SjvO2<55%,using the VIMA technology with sevoflurane,
3091760|NCT01757561||Sevoflurane-Normal|patients with preoperative SjvO2≥55%,using the VIMA technology with sevoflurane,
3091761|NCT01757665|Experimental|Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M|Aortic/Mitral valve replacement therapy
3091762|NCT01757678|Other|Standard of care: FFR, ICA, cCTA, FFRct|(ICA) Invasive coronary angiography with (FFR) fractional flow reserve measurement in standard of care environment, and cCTA (computed coronary tomography angiography) and FFRct Analysis (fractional flow reserve computed tomography)
3091763|NCT01757691|Experimental|Fingolimod 0.5mg/daily|Oral capsule dose was given once daily for 48 weeks
3091764|NCT01757691|Placebo Comparator|Placebo|Patients received oral dose of placebo from Weeks 0-18, followed by oral dose of fingolimod 0.5/mg capsule from Weeks 18-48
3091765|NCT01757704|Experimental|Open pleurae & conventional filling of heart|In this group both pleurae will be opened and the ventilator disconnected during cardiopulmonary bypass to ensure bilateral pulmonary collapse. However, after completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine and manual de-airing performed in a conventional manner and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is complete and patient has been weaned off the cardiopulmonary bypass the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
3091766|NCT01757704|Experimental|Intact pleurae & staged filling of heart|In this group both pleurae will be left intact and the ventilator disconnected during cardiopulmonary bypass. After completion of the left heart procedure, the heart will be filled with blood actively from the heart-lung machine in a staged manner after adequate cardiac contraction has been established. De-airing will be obtained by active cardiac contraction and staged mechanical ventilation and de-airing monitored by intraoperative trans-esophageal echocardiography (TEE). After de-airing is deemed complete and patient has been weaned off the cardiopulmonary bypass (CPB) the residual air in the left heart will be quantitatively assessed by TEE and Trans-cranial Echo-Doppler (TCD) over a period of 10 minutes.
3091767|NCT01757717|Experimental|Ir-192 high dose rate (HDR)|This pilot study is an investigation into the use of Ir-192 high dose rate (HDR) afterloader-based brachytherapy with catheter placement using image-guided surgical navigation techniques for patients with painful/symptomatic metastatic or recurrent lesions in the spine and/or pelvis that have been maximally treated with external beam radiation therapy.
3091768|NCT01757821|Experimental|6-Hz Priming|real 6-Hz primed low-frequency rTMS
3091769|NCT01757821|Sham Comparator|Sham 6-Hz Priming|Sham 6-Hz Primed low-frequency rTMS
3091770|NCT01757821|Active Comparator|Real 1-Hz rTMS only|real 1-Hz rTMS only
3091771|NCT01757847|Active Comparator|Brief MOVE-II active control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
3091772|NCT01757847|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), has been effective in reducing distress, increasing quality of life, and improving other indices of health in a wide range of conditions from depression to diabetes. The ACT protocol for this study focuses on reducing binge eating and distress and improving functioning in individual who are overweight or obese. The protocol focuses on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life. The protocol will be delivered in four 2-hour weekly group sessions to patients with overweight or obesity who have completed the VA San Diego MOVE program.
3091773|NCT01757964|Experimental|Bacteriotherapy|Study stool recipient's will receive approximately 30 grams of processed donor stool through a tube into their stomach for the transplant.
3091774|NCT01758289||Paricalcitol IV|Eligible participants with diagnosis of chronic kidney disease stage V undergoing hemodialysis, treated with paricalcitol IV per routine clinical practice according to prescribing information approved in Venezuela and clinical criteria.
3091775|NCT01758432|Experimental|Module 1 (90 mg bolus)|90 mg PRT064445 given as a single IV
3091776|NCT01758432|Experimental|Module 1 (210 mg bolus)|210 mg PRT064445 given as a single IV bolus
3091777|NCT01758432|Experimental|Module 1 (420 mg bolus)|420 mg PRT064445 given as a single IV bolus
3091778|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg infusion) 4 mg/min|600 mg PRT064445 given as follows: 420 mg IV over ~14 minutes (~30 mg/min), followed by a continuous infusion of 180 mg (4 mg/min over 45 minutes)
3091779|NCT01758432|Experimental|Module 1 (420 mg bolus + 180 mg bolus) 30mg/min|600 mg PRT064445 given as follows: up to 420 mg IV over ~14 minutes (~30 mg/min), followed by a second bolus of 180 mg IV over ~6 minutes (~30 mg/min), 45 minutes after completion of the bolus
3091780|NCT01758432|Experimental|Module 1 (420 mg bolus + 480 mg infusion) 4mg/min|900 mg PRT064445 given as follows: 420 mg IV, followed by a continuous infusion of 480 mg (4 mg/min over 120 minutes
3091781|NCT01758432|Placebo Comparator|Module 1 Placebo|Placebo administered intravenously (IV) as a bolus, two bolus doses or a bolus followed by continuous infusion.
3091782|NCT01758523|Experimental|dutasteride|4 mg oral loading dose of dutasteride followed by 1 mg/day dutasteride for 12 weeks.
3091783|NCT01758523|Placebo Comparator|Sugar Pill|Placebo pills prepared to appear the same as active medication and taken in the same number as active medication for 12 weeks.
3091784|NCT01758588|No Intervention|Observation arm|Subjects will be monitored closely for disease progression, however will receive no intervention.
3091785|NCT01758588|Experimental|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 50 micrograms once a week for up to 3 years.
3091786|NCT01758731|Experimental|Olaparib with C225 and Radiation Therapy|Patients will begin taking Olaparib at the assigned dose three days prior to their first Cetuximab infusion. Patients will receive an initial dose of Cetuximab, 400 mg/m², intravenously over 120 minutes on Day 1. The initial dose of C225 will precede the start of radiation by 5-7 days. All patients will receive RT to a total dose of 69.3 Gy in 33 fractions over 6½ weeks. Weekly C225 will be administered at 250 mg/m2 in combination with daily RT. Patients will be assigned to receive Olaparib (25, 50, 100 or 200 mg bid) in combination with RT and C225. Olaparib will be taken twice daily, beginning three days prior to first scheduled C225 infusion. A further dose level of 300mg or 400mg may be considered should the 200mg Olaparib dose be well tolerated in this C225/RT combination schedule.
3091787|NCT01758900|Active Comparator|Air insufflation regulator|Room air will be used for insufflation as the Active Comparator arm
3091788|NCT01758900|Experimental|CO2 insufflation regulator|Device: CO2 insufflation regulator
3091789|NCT01759160|Active Comparator|Marsh|Marsh Plasma TCI with high initial target
3091790|NCT01759160|Active Comparator|Schnider|Schnider Plasma TCI with high initial target
3091791|NCT01759251||vestibular vertigo|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe betahistine dihydrochloride at dose 48 mg/day in accordance with locally approved label
3091792|NCT01759264||Moderate-to-severe Crohn's disease|Adalimumab induction therapy participants with moderate-to-severe Crohn's Disease
3091793|NCT01759277|Active Comparator|Control|Femoral perineural local anesthetic infusion
3091794|NCT01759277|Experimental|Experimental|Adductor canal perineural local anesthetic infusion
3091795|NCT01759290||Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
3091796|NCT01759368|Active Comparator|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring.
3091797|NCT01759368|No Intervention|Control group|Control group received usual care that includes multidisciplinary care approach in which patients receive guidance and support for self-care. In the care of heart failure (HF) patients, the cardiac team plays a central role in monitoring and interpreting patient symptoms, optimizing medication and providing education. The cardiac team consists of two physicians, one specialized heart failure nurse and a physiotherapist who helps after a hospitalization period. As part of the care process, patients capable of carrying out self-care are identified and they are encouraged to regularly measure their blood pressure, heart rate and weight at home. So far, the information exchange between heart failure patients and care personnel has taken place during patients' visits to the clinic and by telephone. Systematic collection and exploitation of the self-measurement data has been difficult, since it depends on the patient's own activity
3091798|NCT01759381|No Intervention|No Negative Pressure Wound Therapy Device|This control group will not receive the negative pressure wound therapy device. Post operative dressings will be per the surgeon's standard routine.
3091799|NCT01759381|Experimental|NPWT Arm Therapy|This group will receive NPWT as opposed to the standard incisional dressing following complex spinal surgery.
3091800|NCT01759407|Active Comparator|Femoral Nerve Block|Ropivicaine 0.2% with epinephrine 1:200,000 will be used for patients between 10kg and up to 25kg in weight; ropivicaine 0.5% with epinephrine 1:200,000 will be used for patients greater than or equal to 25kg
3091801|NCT01759407|No Intervention|Standard Anesthetic Management|
3091802|NCT01759420||IV Ondansetron|Adult emergency department patients receiving 4mg of IV ondansetron as part of their treatment plan.
3091803|NCT01759446|Placebo Comparator|Placebo taken first|Placebo powder snorted with all other arms taken crossover therafter
3091804|NCT01759446|Active Comparator|Generic H/A taken first|Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
3091805|NCT01759446|Active Comparator|Vycavert taken first|Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
3091806|NCT01759446|Active Comparator|Generic H/A plus i taken first|Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
3091807|NCT01759446|Active Comparator|Generic H/A plus p taken first|Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
3091808|NCT01759511|Experimental|Simtuzumab|Participants will receive simtuzumab.
3091809|NCT01759602|Experimental|C1-esterase inhibitor (Cinryze)|This is a phase 1b open-label, interventional proof-of-concept study in patients with neuromyelitis optica (NMO) in which all subjects will receive 3 daily infusions of 2000 Units of intravenous CINRYZE at the onset of an NMO exacerbation in addition to standard of care high-dose steroids, plus an additional 2 infusions of 1000 Units of intravenous CINRYZE during a second treatment phase with plasma exchange, if necessary.
3091810|NCT01759862|Experimental|Aminophylline|"Patients will receive aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.~Theophylline drug levels will be monitored daily for 4 days."
3091811|NCT01759862|Placebo Comparator|Control|"Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.~Drug levels will be monitored daily for 4 days."
3091812|NCT01760187|Experimental|Cohort 1|12 Japanese and 12 Caucasian subjects. 10 out of 12 will receive 10 mg lomitapide and 2 will receive placebo.
3091813|NCT01760187|Experimental|Cohort 2|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 20 mg lomitapide and 2 will receive placebo.
3091814|NCT01760187|Experimental|Cohort 3|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 40 mg lomitapide and 2 will receive placebo.
3091815|NCT01760187|Experimental|Cohort 4|8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive 60 mg lomitapide and 2 will receive placebo.
3091816|NCT01760239|Experimental|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP <90% and <120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
3091817|NCT01760239|No Intervention|Control|Patients in this group will receive usual care from their clinic. The CDS tool will not be activated.
3091818|NCT01760291|Experimental|WATCHMAN|WATCHMAN LAA Closure Technology
3091819|NCT01760304|Experimental|Budesonide / Formoterol|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
3091820|NCT01760304|Placebo Comparator|Placebo|This is a crossover study, where every patient will receive in a blinded fashion either Budesonide/Formoterol (Symbicort ® ) or placebo
3091821|NCT01760447|Experimental|Sitagliptin/Metformin|Participants received one tablet of sitagliptin/metformin and one tablet of metformin-placebo, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
3091822|NCT01760447|Placebo Comparator|Metformin|Participants received one tablet of metformin and one tablet of placebo to sitagliptin/metformin, administered twice daily prior to the morning and evening meals, for up to 20 weeks in the base study alone, or for up to 54 weeks if the participant also entered the extension study. Participants in this arm were enrolled in protocol MK-0431A-170.
3091823|NCT01760447|Experimental|Sitagliptin/Metformin XR|Participants received two tablets of sitagliptin/metformin XR and two tablets of metformin XR placebo, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
3091824|NCT01760447|Placebo Comparator|Metformin XR|Participants received two tablets of metformin XR and two tablets of placebo to sitagliptin/metformin XR, administered once daily with a meal, for up to 54 weeks. Participants in this arm were enrolled in protocol MK-0431A-289.
3091825|NCT01760473|Experimental|Bup 8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally.
3091826|NCT01760473|Experimental|Bup 16|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally.
3091827|NCT01760473|Experimental|Bup/Nal 8/2|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 2 mg of Naloxone.
3091828|NCT01760473|Experimental|Bup/Nal 8/8|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 8 mg of Naloxone.
3091829|NCT01760473|Experimental|Bup/Nal 8/16|Intranasal challenge drug: 8 mg of Buprenorphine administered intranasally with 16 mg of Naloxone.
3091830|NCT01760473|Experimental|Bup/Nal 16/4|Intranasal challenge drug: 16 mg of Buprenorphine administered intranasally with 4 mg of Naloxone.
3091831|NCT01760473|Active Comparator|Heroin|Intranasal challenge drug: 24 mg of heroin administered intranasally.
3091832|NCT01760473|Sham Comparator|Placebo|Intranasal challenge drug: Intranasal lactose powder.
3091833|NCT01760473|Active Comparator|Naloxone 4 mg|Intranasal challenge drug: Intranasal Naloxone 4mg.
3091834|NCT01760785|Active Comparator|divalproex sodium|
3091835|NCT01760785|Placebo Comparator|sugar pill|
3091836|NCT01760876|Experimental|Biofreedom stent|Coronary intervention
3091837|NCT01760954|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
3091838|NCT01760954|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
3091839|NCT01761019|Other|Taclonex topical suspension|Taclonex topical suspension will be used daily to affected areas of skin with psoriasis for 12 weeks
3091840|NCT01761084|Experimental|Exercise and behaviour change strategies|The exercise program will include strength training, balance training and cardiovascular exercise that is individually tailored to the participants' abilities. The physical therapist will also implement strategies to assist with behaviour change, such as documenting progress in a log, participating in action planning and coping planning, and using techniques in the spirit of motivational interviewing.
3091841|NCT01761084|No Intervention|General health or social discussion|Participants in the control group will receive equal attention, but will not be prescribed exercise, or participate in counselling about exercise. The physical therapist will discuss topics related to general health.
3091842|NCT01761162||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
3091843|NCT01761175|Active Comparator|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block
3091844|NCT01761175|Active Comparator|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block
3091845|NCT01761266|Active Comparator|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3091846|NCT01761266|Active Comparator|Sorafenib|Participants received sorafenib 400 mg tablets, orally, twice daily (BID) in continuous 28-day treatment cycles up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3091847|NCT01761292|Experimental|Givinostat|Givinostat will be administered as 2 oral doses daily while the child is in fed state.
3091848|NCT01761565|Experimental|Single dose of SUF NT 15 mcg then 40 doses of SUF NT 15 mcg|"Period 1: Single dose of SUF NT 15 mcg~Period 2: 40 consecutive doses of SUF NT 15 mcg taken every 20 minutes"
3091849|NCT01761643|No Intervention|Standard of Care (SoC)|"This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.~All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey."
3091850|NCT01761643|Active Comparator|SoC + iTab|"Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.~Subjects will have visits with the study coordinator to introduce the iTAB texting system.~Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers."
3091851|NCT01761747|Experimental|Ponatinib Treatment Arm|Ponatinib taken by mouth daily
3091852|NCT01762059|Experimental|Bi-homonal Bionic Pancreas|Closed-loop blood glucose control with a bi-hormonal bionic endocrine pancreas designed by Edward Damiano and Firas El-Khatib of Boston University. The device will deliver insulin lispro (Humalog) and glucagon based on blood glucose levels estimated by a continuous glucose monitoring device (Dexcom G4 Platinum) and a proprietary dosing algorithm. Blood glucose control will be automated for 5 days during which volunteers will sleep in a hotel and roam freely in downtown Boston during the day. There will be no restrictions on diet or exercise.
3091853|NCT01762059|Active Comparator|Usual Care|Usual care for 5 days (insulin pump therapy according to usual practice), volunteers will sleep at home and maintain their usual schedule during the day, there will be no restrictions on diet or exercise, they will wear a blinded CGM
3091854|NCT01762345|Experimental|pessary device|pessary (disposable intra-vaginal device)
3091855|NCT01762501|Experimental|Azilsartan|Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
3091856|NCT01762501|Active Comparator|Amlodipine|Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
3091857|NCT01762631||Cohort 1|All participants enrolled between November 2012 and March 2013 under the original protocol.
3091858|NCT01762631||Cohort 2|After Cohort 1 was completed, the study investigators changed the protocol to eliminate the photograph/weight of the powdered formula alone in each bottle to reduce burden. All other protocol procedures remained the same. Cohort 2 participants enrolled between April 2013 and May 2014.
3091859|NCT01762722|Experimental|Desaturation|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3321152|NCT02016703|Experimental|25 g group|25g erythritol dissolved in 250 ml (10% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3321153|NCT02016703|Experimental|20 g group|20g erythritol dissolved in 250 ml (8% w/v) consumed within 15 min between meals (tested vs. 250 ml isosweet saccharose placebo under same conditions)
3091862|NCT01762800|Experimental|fluticasone propionate/salmeterol|Randomised treatment at Visit 2
3091863|NCT01762800|Experimental|tiotropium bromide|Randomised treatment at Visit 2
3091864|NCT01762904|Experimental|Whole group of 135 units of measurement|"The arm is composed of 135 units of measurement, it means, 540 determinations to test 2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol and two controls.~The principal unit of measurement it will be four determinations of bacterial counts in a subject for antiseptics and controls to test each of the application sites, and determination as to each separately sampling for each area for each antiseptic forearm. The same subject may be assessed up to three separate occasions provided only after a minimum period of two weeks between each determination.~Interventions:~Biological: Bacterial culture of the prepared skin's areas with two antiseptics and two controls~Other: Preparing skin's areas to be tested with two antiseptics and two controls"
3091865|NCT01762943|Experimental|Women with Postpartum Depression (PPD)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
3091866|NCT01762943|Experimental|Women without any psychiatric history (Control)|4 monthly (intramuscular) IM injections of leuprolide acetate (Lupron) 3.75 mg; micronized estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day; progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day. Participants will also receive placebo.
3091867|NCT01762982|Experimental|Test|Benzalkonium chloride (0.13%) Disinfectant Spray water
3091868|NCT01762982|Active Comparator|Positive Control|Sodium lauryl sulfate (SLS) (0.3% weight by weight [w/w]) water solution
3091869|NCT01762982|Placebo Comparator|Negative Control 1|Normal saline water (0.9% weight by volume [w/v])
3091870|NCT01762982|Placebo Comparator|Negative Control 2|Empty Finn Chamber
3091871|NCT01763047|Active Comparator|etafilcon A/lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
3091872|NCT01763047|Active Comparator|lotrafilcon B/etafilcon A|Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
3091873|NCT01763164|Experimental|MEK162|
3091874|NCT01763164|Active Comparator|Dacarbazine|
3091875|NCT01763203|Experimental|Care Management+Community Health Worker|Care management
3091876|NCT01763203|Active Comparator|Usual Care|Written materials
3091877|NCT01763333|Experimental|1 BI 1026706 single rising dose part|single rising doses of BI 1026706
3091878|NCT01763333|Experimental|2 BI 1026706 bioavailability part|bioavailability part of BI 1026706
3091879|NCT01763346|Active Comparator|metformin|subjects receiving metformin
3091880|NCT01763346|Experimental|gastric banding|subjects receiving LAP-BAND
3091881|NCT01763606|Experimental|Enoxaparin|Patients assigned to enoxaparin.
3091882|NCT01763606|Experimental|Aspirin|Patients assigned to Aspirin.
3321154|NCT02016729|Experimental|AMG 232|AMG 232 is an anti-cancer agent
3091883|NCT01763645|Experimental|BCD-021 (CISC BIOCAD)|BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-021 in combination with carboplatin and paclitaxel. BCD-021 will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each course). Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
3091884|NCT01763645|Active Comparator|Avastin (F. Hoffmann-La Roche Ltd)|In this arm patients will receive 6 courses of treatment with Avastin in combination with carboplatin and paclitaxel. Avastin will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks on Day 1. Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion every 3 weeks on Day 1 and carboplatin (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel every 3 weeks on Day 1.
3091885|NCT01763684|Active Comparator|Signature Custom Guides|Oxford Partial Knee implanted using Signature Custom Guides
3091886|NCT01763684|Active Comparator|Conventional Instrumentation|Oxford Partial Knee implanted using Conventional Instrumentation
3321155|NCT02016729|Experimental|AMG 232 & Trametinib|AMG 232 and Trametinib are anti cancer agents
3321156|NCT02016742|Experimental|RDC5 dose level 1|Single dose of RDC5
3091889|NCT01763827|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once a day for up to 12 weeks.
3091890|NCT01763827|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
3091891|NCT01763827|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091892|NCT01763827|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091893|NCT01763827|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3091894|NCT01763827|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3091895|NCT01763866|Placebo Comparator|A10 PBO Q2W|Participants received atorvastatin 10 mg once daily during the 4 week lipid stabilization period and then in combination with placebo (PBO) subcutaneous injection once every 2 weeks (Q2W) and placebo tablets once daily for up to 12 weeks.
3091896|NCT01763866|Placebo Comparator|A10 PBO QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month (QM) and placebo tablets once a day for up to 12 weeks.
3091897|NCT01763866|Active Comparator|A10 EZE (Q2W)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe (EZE) orally once a day for up to 12 weeks.
3091898|NCT01763866|Active Comparator|A10 EZE (QM)|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091899|NCT01763866|Experimental|A10 EvoMab Q2W|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab (EvoMab) by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3091900|NCT01763866|Experimental|A10 EvoMab QM|Participants received atorvastatin 10 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3091901|NCT01763866|Placebo Comparator|A80 PBO Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3091902|NCT01763866|Placebo Comparator|A80 PBO QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month and placebo tablets once a day for up to 12 weeks.
3091903|NCT01763866|Active Comparator|A80 EZE (Q2W)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091904|NCT01763866|Active Comparator|A80 EZE (QM)|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091905|NCT01763866|Experimental|A80 EvoMab Q2W|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3091906|NCT01763866|Experimental|A80 EvoMab QM|Participants received atorvastatin 80 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3091907|NCT01763866|Placebo Comparator|R5 PBO Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3321157|NCT02016742|Experimental|RDC5 dose level 2|Single dose of RDC5
3321158|NCT02016742|Experimental|RDC5 dose level 3|Single dose of RDC5
3321159|NCT02016742|Experimental|RDC5 dose level 4|Single dose of RDC5
3321160|NCT02016768||operation|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
3321161|NCT02016794||Patients|Patients suffering from degenerative cervical condition that requires anterior decompression and fusion in a single or multiple levels
3321162|NCT02016807||1-Treat OroEsophageal Mucositis|Prothelial: Arm 1 Patients with oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3091908|NCT01763866|Placebo Comparator|R5 PBO QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3091909|NCT01763866|Experimental|R5 EvoMab Q2W|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3091910|NCT01763866|Experimental|R5 EvoMab QM|Participants received rosuvastatin 5 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3091911|NCT01763866|Placebo Comparator|R40 PBO Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3091912|NCT01763866|Placebo Comparator|R40 PBO QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3091913|NCT01763866|Experimental|R40 EvoMab Q2W|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3091914|NCT01763866|Experimental|R40 EvoMab QM|Participants received rosuvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3091915|NCT01763866|Placebo Comparator|S40 PBO Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every 2 weeks for up to 12 weeks.
3091916|NCT01763866|Placebo Comparator|S40 PBO QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with placebo subcutaneous injection once every month for up to 12 weeks.
3091917|NCT01763866|Experimental|S40 EvoMab Q2W|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3091918|NCT01763866|Experimental|S40 EvoMab QM|Participants received simvastatin 40 mg a day during the 4-week lipid stabilization period and then with 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3091919|NCT01763905|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091920|NCT01763905|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.
3091921|NCT01763905|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.
3091922|NCT01763905|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.
3091923|NCT01763918|Placebo Comparator|Placebo Q2W|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for up to 12 weeks.
3091924|NCT01763918|Placebo Comparator|Placebo QM|Participants received placebo subcutaneous injection once every month (QM) for up to 12 weeks.
3091925|NCT01763918|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for up to 12 weeks.
3091926|NCT01763918|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month for up to 12 weeks.
3091927|NCT01763931|Experimental|Digoxin|Digoxin administration for 2 weeks prior to surgery.
3091928|NCT01763931|No Intervention|No drug administration prior to surgery|Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.
3091929|NCT01763970|Experimental|Hypofractionated SBRT|800 cGy delivered in 5 fractions every day to total dose of 4000 cGy
3091930|NCT01763996|Experimental|Sequence 1: Febuxostat 80 mg + Placebo|Febuxostat 80 mg, capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat placebo-matching capsules, orally, once daily for up to 6 weeks in Period 2.
3091931|NCT01763996|Experimental|Sequence 2: Placebo + Febuxostat 80 mg|Febuxostat placebo-matching capsules, orally, once daily for 6 weeks in Period 1, followed by febuxostat 80 mg, capsules, orally, once daily for up to 6 weeks in Period 2.
3091932|NCT01764022|Experimental|BCD-022|BCD-022 is a product code for trastuzumab biosimilar manufactured by CJSC BIOCAD, Russia. In this arm patients will receive 6 courses of treatment with BCD-022 in combination with paclitaxel. Patients will receive BCD-022 at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
3091933|NCT01764022|Active Comparator|Herceptin®|In this arm patients will receive 6 courses of treatment with Herceptin® (F. Hoffmann-La Roche Ltd., Switzerland) in combination with paclitaxel. Patients will receive Herceptin® at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations), + paclitaxel 175 mg/m2 every 3 weeks as 3 hour intravenous infusion (6 administrations).
3091934|NCT01764256|Experimental|10 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 10 μg of active ingredient.
3091935|NCT01764256|Experimental|30 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 30 μg of active ingredient.
3091936|NCT01764256|Experimental|60 μg P2-VP8|3 doses of P2-VP8 subunit rotavirus vaccine (Lot # 1746) produced in E. coli was adsorbed onto aluminum hydroxide (0.6 mg/dose) adjuvant prior to administration. Each dose contained 60 μg of active ingredient.
3091937|NCT01764256|Placebo Comparator|Placebo|3 doses of placebo delivered intramuscularly.
3091938|NCT01764386|Experimental|NB + CLI|Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
3091939|NCT01764386|Other|Usual Care|"Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff."
3091940|NCT01764464|Other|Group A|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
3091941|NCT01764464|Other|Group B|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo). 10 day washout (no intervention). 14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
3091942|NCT01764607|Experimental|Sirolimus treatment|Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma. After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
3091943|NCT01764633|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference.
3091944|NCT01764633|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference.
3091945|NCT01764659||All enrolled patients|Contrast-enhanced 4D computed tomography
3091946|NCT01764685|Experimental|Topiramate + Medical Management|Topiramate titrated up to 150 mg/day over 5 weeks then maintained for 6 weeks + Medical Management sessions for 15-25 minutes per study visit
3091947|NCT01764685|Placebo Comparator|Placebo Pill + Medical Management|Sugar pill with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
3091948|NCT01764841|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Participants received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
3091949|NCT01764841|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Participants received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
3091950|NCT01764841|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
3091951|NCT01764841|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
3091952|NCT01764854|Experimental|AZD1722- in patient|Tenapanor administered in a clinical pharmacology unit
3091953|NCT01764854|Placebo Comparator|Placebo- in patient|Placebo (size and color matched to experimental drug) administered in a clinical pharmacology unit
3091954|NCT01764854|Experimental|AZD1722 out-patient|Tenapanor
3091955|NCT01764854|Experimental|Placebo out-patient|Placebo
3091956|NCT01764919|Experimental|[124I]FIAU|Single intravenous injection of [124I]FIAU in patients with diabetic foot infection
3091957|NCT01764945|Experimental|1 BI 201335|low dose
3091958|NCT01764945|Experimental|2 BI 201335|high dose
3091959|NCT01765153|Experimental|Endurance first|Participants to start with Endurance Training. Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for training in the Precision Training 5x/wk for 2 months.Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. This is followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
3091960|NCT01765153|Experimental|Precision first|Participants to start with Precision Training. Participants train to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto. Training was 5x/wk for 2 months, followed by a 2-month rest period. Participants then returned for Endurance Training 5x/wk for 2 months. Participants are trained to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training. followed by another 2-month rest. Measures of walking speed, distance, skill, confidence, as well as mood were obtained at least 3 times before any training, then monthly thereafter.
3091961|NCT01765179|Experimental|Oral testosterone undecanoate|
3091962|NCT01765192|Experimental|Roflumilast plus montelukast, then placebo plus montelukast|Participants in sequence 1 received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received placebo plus montelukast 10 mg orally once daily for 4 weeks.
3091963|NCT01765192|Experimental|Placebo plus montelukast, then roflumilast plus montelukast|Participants in sequence 2 received placebo plus montelukast 10 mg orally once daily for 4 weeks followed by a 4-week washout period and then received roflumilast 500 μg plus montelukast 10 mg orally once daily for 4 weeks.
3091964|NCT01765270|Active Comparator|Saxagliptin|Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
3091965|NCT01765270|Placebo Comparator|Placebo|Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
3091966|NCT01765426|Experimental|Group 1: TDV using PharmaJet® Injector|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] one dose injection in arm 1 and placebo: phosphate buffered saline (PBS) one dose injection in arm 2, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3091967|NCT01765426|Experimental|Group 2: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and placebo: PBS, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3091968|NCT01765426|Experimental|Group 3: TDV using Needle and Syringe|TDV one dose injection in arm 1 and placebo: PBS one dose injection in arm 2, using needle and syringe, intradermal, on Day 0 and TDV injection using needle and syringe, intradermal, one dose on Day 90.
3091969|NCT01765426|Experimental|Group 4: TDV using PharmaJet® Injector|TDV injection, one dose in each arm, using needle-free PharmaJet® Injector, intradermal, on Day 0 and TDV, injection using needle-free PharmaJet® Injector, intradermal, one dose on Day 90.
3091970|NCT01765465|Experimental|Rowachol|Rowachol treatment with 200mg PO tid, on postoperative 1 days to 3 months
3091971|NCT01765465|Placebo Comparator|Placebo|Placebo treatment with 200mg PO tid, on postoperative 1 days to 3 months
3091972|NCT01765530|Experimental|ETT cleaning manuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
3091973|NCT01765530|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
3091974|NCT01765543|Experimental|Vemurafenib + Rifampin|There will be 3 intervention periods in the study: Period A (Days 1 to 7), Period B (Days 8 to 16), and Period C (Days 17 to 24). Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 milligrams (mg) as film-coated tablets orally alone on Day 1 (Period A); with rifampin (at a dose of 600 mg as capsules orally) on Day 17 (Period C); and rifampin alone at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 16 (Period B) and from Days 18 through 23 (Period C).
3091975|NCT01765569|Experimental|Vemurafenib + Digoxin|Single oral dose of digoxin 0.25 mg tablet on Day 1 in Period A, followed by vemurafenib 960 mg tablet orally BID from Day 8 to Day 28 in Period B, and then single oral dose of digoxin 0.25 mg on Day 29, and vemurafenib 960 mg orally BID from Day 29 to Day 35 in Period C.
3091976|NCT01765582|Experimental|Arm A: Concurrent FOLFOXIRI + Bevacizumab|Participants will receive concurrent FOLFOXIRI along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4 month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3091977|NCT01765582|Experimental|Arm B: Sequential FOLFOXIRI + Bevacizumab|Participants will receive alternating 4-week administrations of FOLFOX/bevacizumab and folinic acid (leucovorin), 5-FU, and irinotecan (FOLFIRI) /Bevacizumab with a treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3091978|NCT01765582|Experimental|Arm C: FOLFOX + Bevacizumab|Participants will receive FOLFOX along with 5 mg/kg of bevacizumab with treatment cycle of 2 weeks during first 4-month induction phase (plus optional 2 months of induction for participants who exhibit good response and tolerate the regimen) followed by administration of 5-FU with bevacizumab or capecitabine with bevacizumab as per investigator's discretion in maintenance phase. Following progression on first-line therapy (PD1), bevacizumab (dose equivalent, 2.5 mg/kg/week) will be administered as second-line therapy in combination with fluoropyrimidine based chemotherapy at the investigator's discretion.
3091979|NCT01765647|Experimental|AGY|All participants will receive the same, open-label dose of AGY
3091980|NCT01765673||Vibrotactile Stimulation in Dysphagia|A Vibrotactile stimulation device will be evaluated in patients with chronic moderate to severe dysphagia for more than 6 months post onset due to stroke or following radiation treatment for head and neck cancer to assess which frequency, mode, pressure characteristics are most helpful in increasing the rate of swallowing, increasing the urge to swallow, assisting with the initiation of swallowing and not affecting discomfort.
3091981|NCT01765712|Placebo Comparator|Control Group|Patients will be randomized into the treatment arm using a computer generated randomization table (simple randomization). Patients in the control arm of the study will undergo Anterior cruciate ligament reconstruction using Autologous bone patellar tendon bone autograft. At the end of the surgery, their graft donor site will have bone graft chips placed into the bony defect and the wound will be closed using sutures.
3091982|NCT01765712|Experimental|Platelet Rich Plasma|Patients randomized into the treatment arm of the study will undergo Anterior cruciate ligament reconstruction with Autologous bone patellar tendon bone autografts. At the start of the surgery,just after the administration of anesthesia, 10cc of blood will be withdrawn from the patients IV by the anesthesiologist. This sample will be spun down into 3-5cc of Platelet Rich Plasma which will be added to the patients bone graft chips and placed into the donor site at the end of the case.
3091983|NCT01765751|Active Comparator|Manual Cervical Distraction High Force|Manual Cervical Distraction forces will be limited to greater than 50N in the high force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3091984|NCT01765751|Active Comparator|Manual Cervical Distraction Medium Force|Manual Cervical Distraction forces will be limited to between 20N-50N in the medium force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3091985|NCT01765751|Sham Comparator|Manual Cervical Distraction Low Force|Manual Cervical Distraction forces will be limited to less than 20N in the low force group. Dosing for this clinical trial is limited to 3 sets of 5 repetitions with a hand contact on one cervical vertebra of highest clinical importance and 3 sets of 5 repetitions with a hand contact on the occiput.
3091986|NCT01765764|Experimental|Bimatoprost Solution BID|Bimatoprost solution twice a day (BID) in the morning and in the evening applied to each eyebrow for 7 months.
3091987|NCT01765764|Experimental|Bimatoprost Solution QD|Vehicle to bimatoprost solution in the morning and bimatoprost solution once a day (QD) in the evening applied to each eyebrow for 7 months.
3091988|NCT01765764|Placebo Comparator|Vehicle to Bimatoprost Solution BID|Vehicle to bimatoprost twice a day (BID) in the morning and the evening applied to each eyebrow for 7 months.
3091989|NCT01765803|Experimental|Mellaril (thioridazine)|A single 50 gm dose of thioridizine (Mellaril) will be given orally at the beginning of the study
3091990|NCT01765920|Experimental|Ergoferon (5 ml 3 times a day)|"Oral use. Dose per administration: 1 dosing spoon (5ml) without food. For best effect, the solution should be held in the mouth before swallowing.~Dosing scheme. One dose every 30 minutes for the first 2 hours, followed by three more doses spaced regularly during the rest of the day. From day 2 to 5: 1 spoon taken 3 times daily."
3091991|NCT01765920|Placebo Comparator|Placebo (5 ml 3 times a day)|Oral use. Placebo using Ergoferon scheme.
3091992|NCT01765972|Other|Test 1/Spectacles/Test 2/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 1 (etafilcon A with Lacreon), spectacles, TEST 2 (etafilcon A with Lacreon with print) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
3091993|NCT01765972|Other|Test 2/Test 3/ Spectacles/Test 1|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 2 (etafilcon A with Lacreon with print), TEST 3 (etafilcon A with print), spectacles and TEST 1 (etafilcon A with Lacreon) in both eyes for 8 +/-1 hours.
3091994|NCT01765972|Other|Test 3/Test 1/ Test 2/ Spectacles|Subjects assigned randomly to this arm will wear the study lenses sequentially as TEST 3 (etafilcon A with print), TEST 1 (etafilcon A with Lacreon), TEST 2 (etafilcon A with Lacreon with print) and spectacles in both eyes for 8 +/-1 hours.
3091995|NCT01765972|Other|Spectacles/Test 2/Test 1/Test 3|Subjects assigned randomly to this arm will wear the study lenses sequentially as spectacles, TEST 2 (etafilcon A with Lacreon with print), TEST 1 (etafilcon A with Lacreon) and TEST 3 (etafilcon A with print) in both eyes for 8 +/-1 hours.
3091996|NCT01766024|Experimental|BCD-033 → Rebif|Volunteers in this group initially will receive a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the reference drug Rebif® (interferon beta-1a) at a dose of 44 µg.
3091997|NCT01766024|Experimental|Rebif → BCD-033|Volunteers in this group initially will receive a single sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg (on Day 1) and then, after at least 14 days, a single sc injection of the study drug BCD-033 (interferon beta-1a) at a dose of 44 µg.
3091998|NCT01766037|Experimental|Aspiration Therapy|Aspiration Therapy and Lifestyle Therapy
3091999|NCT01766037|Active Comparator|Lifestyle Therapy|Lifestyle Therapy only
3092000|NCT01766050|Experimental|Arm: Inje Cocktail + Belatacept|"Inje Cocktail consisting of (200 mg Caffeine, 50 mg losartan tablet, 40 mg Omeprazole capsule, 30 mg Dextromethorphan capsule and 5 mg Midazolam oral syrup) administered on Days 1, 4, 7 and 11~Belatacept 10 mg/kg Intravenous (IV) solution, administered on Day 4"
3092001|NCT01766076|Experimental|atorvastatin, Lipitor®|"Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.~Peripheral blood mononuclear cells (PBMC) will be collected for immune activation assays using flowcytometry"
3092002|NCT01766076|Placebo Comparator|Placebo|Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry
3092003|NCT01766102|Active Comparator|Intra-operative Mammography|Intra-operative Specimen Mammography
3092004|NCT01766102|Active Comparator|Standard Mammography|Standard Specimen Mammography
3092005|NCT01766206|Experimental|MenACWY-CRM Group|Healthy subjects from 2 months to 55 years of age in South Korea, who received MenACWY-CRM (Menveo) vaccination, according to routine clinical care.
3092006|NCT01766219|Experimental|Arm 1: (6,8-bis[benzylthio]octanoic acid) 2,300 mg/m²|"Participants will not be treated with CPI-613 during pre-Cycle 1 and will only be treated with 3 weeks on/1 week off at 2,300 mg/m² as a starting dose. If none of these 3 participants develop a dose-limiting toxicity through Cycle 1, the dose for the 3-weeks-on-1-week-off treatment cycles will be 3,000 mg/m² in all subsequent participants in this trial.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
3092007|NCT01766219|Experimental|Arm 2: (6,8-bis[benzylthio]octanoic acid) 1,200/3,00 mg/m²|"Participants will received pre-cycle 1 week dose at 1200 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
3092008|NCT01766219|Experimental|Arm 3 (6,8-bis[benzylthio]octanoic acid) 600/3,000 mg/m²|"Participants will received pre-cycle 1 week dose at 600 mg/m² and dosing will escalate to 3,000 mg/m² for the three weeks on, one week off cycle.~Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients responding to treatment may receive up to 4 more courses of treatment."
3092009|NCT01766310|Placebo Comparator|placebo|placebo tablet in the same appearance and taste with folic acid orally once a day for 8 weeks of the study
3092010|NCT01766310|Experimental|folic acid|Folic acid tablet 5mg per day orally (5mg/tablet) once a day for 8 weeks of the study
3092011|NCT01766336|Experimental|Group 1 ELND005/ELND005|Patients who received ELND005 during Study AG201 will continue on the same maintenance dose for 36 weeks.
3092012|NCT01766336|Experimental|Group 2 PLACEBO/ELND005|Patients who received placebo during Study AG201 will receive ELND005 at the same dosing regimen as the active group in Study AG201 for 36 weeks.
3092013|NCT01766401|Placebo Comparator|Placebo|Matching placebo tablets, oral administration
3092014|NCT01766401|Experimental|Vilazadone|Vilazadone tablets, oral administration
3092015|NCT01766440|Experimental|Calcitriol 3 mcg/g ointment|Topical application every 12 hours for 14 consecutive days
3092016|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 0.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 0.5 h after the initiation of cangrelor infusion.
3092017|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (7 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 7 doses (12, 24, 36, 48, 60, 72, and 84 h).~On Day 5: 12 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
3092018|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 180mg at 1.5 hr|On Day 1: Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours. Ticagrelor (180 mg) was administered at 1.5 h after the initiation of cangrelor infusion.
3092019|NCT01766466|Experimental|Cangrelor IV + Ticagrelor 90mg (6 doses)|"On Day 1: Following completion of cangrelor and ticagrelor dosing, patients were discharged and instructed to take 90 mg ticagrelor every 12 hours for 6 doses (12, 24, 36, 48, 60, and 72 h).~On Day 5: 24 h post last ticagrelor dose (90 mg), patients received another open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours."
3092020|NCT01766713|Experimental|Ezetimibe|10 mg/day of Ezetimibe
3092021|NCT01766713|Placebo Comparator|Placebo|one tablet per day (identical to ezetimibe)
3092022|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg once daily (QD)|Vildagliptin 50mg QD plus stabilized or maximum tolerated dose of Metformin
3092023|NCT01766778|Active Comparator|LAF237 (vildagliptin) 50mg twice daily (BID)|Vildagliptin 50mg BID plus stabilized or maximum tolerated dose of Metformin
3092024|NCT01766817|Experimental|Arm 1: BMS 986020, 600 mg. once daily|BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks
3092025|NCT01766817|Experimental|Arm 2: BMS-986020, 600 mg twice daily|BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks
3092026|NCT01766817|Placebo Comparator|Arm 3: Placebo matching with BMS-986020|Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks
3092027|NCT01766921|Experimental|aH5N1c - High dose|
3092028|NCT01766921|Experimental|aH5N1c - Low dose|
3092029|NCT01767064|Experimental|Posted commitment letter|The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
3092030|NCT01767064|No Intervention|Control|Usual care with no posted letters.
3092031|NCT01767103|Experimental|Normal Hepatic Function (healthy volunteers)|Healthy volunteers with normal hepatic function received a single 33 mg/kg dose of Ferriprox®.
3092032|NCT01767103|Experimental|Mild Hepatic Failure|Subjects with mild hepatic failure as defined by the Child-Pugh Class C: 5-6 points received a single 33 mg/kg dose of Ferriprox®.
3092033|NCT01767103|Experimental|Moderate Hepatic Failure|Subjects with moderate hepatic failure as defined by the Child-Pugh Class B: 7-9 points received a single 33 mg/kg dose of Ferriprox®.
3092034|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3092035|NCT01767116|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
3092036|NCT01767142|Experimental|Outer Thigh CoolSculpting Treatment|Treatment with the CoolSculpting System and a modified belt applicator will be performed on one outer thigh; the remaining thigh is considered the untreated control. Subjects will receive one cooling cycle applied to the thigh area intended for treatment with a protocol-defined cooling rate and duration of 120 minutes.
3092037|NCT01767155|Experimental|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles up to 9 cycles
3092038|NCT01767155|Active Comparator|doxorubicin/ standard chemotherapy|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
3092039|NCT01767194|Experimental|Arm I (temozolomide, irinotecan hydrochloride, temsirolimus)|CLOSED TO ACCRUAL 06/17/2016 Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride IV over 90 minutes on days 1-5, and temsirolimus IV over 30 minutes on days 1 and 8.
3092040|NCT01767194|Experimental|Arm II (temozolomide, irinotecan hydrochloride, dinutuximab)|Patients receive temozolomide PO on days 1-5, irinotecan hydrochloride over 90 minutes on days 1-5, dinutuximab IV over 10-20 hours on days 2-5, and sargramostim SC or IV over 2 hours on days 6-12.
3092041|NCT01767285|Experimental|Immediate Postpartum Etonogestrel Implant|Etonogestrel implant placed in the hospital after delivery, before discharge home.
3092042|NCT01767285|Active Comparator|Delayed postpartum etonogestrel implant|These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.
3092043|NCT01767376|Experimental|Nimenrix+ Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine co-administered with one dose of Boostrix vaccine, at Month 0, administered by intramuscular injection into the deltoid muscle.
3092044|NCT01767376|Experimental|Nimenrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Nimenrix vaccine at Month 0 and one dose of Boostrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
3092045|NCT01767376|Experimental|Boostrix Group|Healthy male or female subjects, between and including 11 and 25 years of age, who received one dose of Boostrix vaccine at Month 0 and one dose of Nimenrix vaccine at Month 1. Both vaccines were administered by intramuscular injection into the deltoid muscle.
3092046|NCT01767415|Experimental|Indigo Carmine|Intraoperative stereotactic injection of Indigo Carmine
3092047|NCT01767467|Experimental|Vaccine Group|Subjects will receive the candidate HZ vaccine (GSK 1437173A).
3092048|NCT01767467|Placebo Comparator|Placebo Group|Subjects will receive the placebo vaccine.
3092049|NCT01767493|Experimental|[18F]Florbetapir PET imaging|[18F]Florbetapir and PET imaging
3092050|NCT01767506|Experimental|Intervention|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more. In addition, surveillance and treatment with azithromycin of newcomer and traveler families within 2 weeks of arrival to or return to the community.
3092051|NCT01767506|Active Comparator|Usual Care|Communities will receive usual care, including annual mass drug administration with azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
3092052|NCT01767519|Experimental|BOTOX®|Treatment Cycle 1: BOTOX injected at Day 1 with one solifenacin placebo capsule taken orally once daily for up to 24 weeks. After a minimum of 12 weeks, patients could request/qualify for a second BOTOX injection.
3092053|NCT01767519|Active Comparator|solifenacin|Treatment Cycle 1: Oral solifenacin taken once daily starting at Day 1 for up to 24 weeks with intradetrusor injection of BOTOX placebo on Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
3092054|NCT01767519|Placebo Comparator|placebo|Treatment Cycle 1: One solifenacin placebo capsule taken orally once daily starting at Day 1 for up to 24 weeks with an intradetrusor injection of BOTOX placebo at Day 1. After a minimum of 12 weeks, patients could request/qualify for a BOTOX injection.
3092055|NCT01767597|Active Comparator|ELISA testing|HBV infection status determined by enzyme-linked immuno-assay (ELISA)
3092056|NCT01767597|Experimental|Rapid testing|HBV infection status determined initially by a rapid test, then confirmed by enzyme-linked immuno-assay (ELISA).
3092057|NCT01767636|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3092058|NCT01767688|Experimental|Moderate Hepatic Impairment Group|
3092059|NCT01767688|Experimental|Healthy Matched Control Group|
3092060|NCT01767701|Experimental|Raltegravir|All eligible patients will complete a 3 months observation period (no medications) followed by 3 months on treatment period. During the treatment period patients will be treated with open label raltegravir 400mg twice daily.
3092061|NCT01767792|Experimental|Bevacizumab|Follow participant for 2 years and assess hearing response rates
3092062|NCT01767857|Experimental|Xilonix|MABp1 administered IV every two weeks, plus best supportive care
3092063|NCT01767857|Placebo Comparator|Placebo|Placebo administered IV every two weeks, plus best supportive care
3092064|NCT01767909|Experimental|Insulin (Humulin® R U-100)|120 subjects will take two daily doses of INI (20 IU bid for a total daily dose of 40 IU) approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
3092065|NCT01767909|Placebo Comparator|Placebo|120 subjects will take two daily doses of placebo approximately 30 minutes after breakfast and dinner for 12 months. A 6-month open label period will follow in which all participants will receive INI.
3092066|NCT01767935|Experimental|Treatment (cryosurgery and radiation therapy)|Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3092067|NCT01767987|Active Comparator|Ranolazine|Oral treatment Intervention: Drug: Ranolazine 1000 mg
3092068|NCT01767987|Placebo Comparator|Placebo|Oral treatment Intervention: Drug: Placebo
3092069|NCT01768000|Experimental|Family Cognitive Adaptation Training|Participants in this group will receive the Family CAT manual and DVD
3092070|NCT01768000|No Intervention|Control group|Participants in this arm will support their family members as usual, and will not receive the Family CAT manual and DVD provided to those in the experimental arm of the study.
3092071|NCT01768013|Experimental|LEO 90105 Ointment|
3092072|NCT01768117|Experimental|rLP2086|
3092073|NCT01768286|Experimental|LDV/SOF 12 Weeks|Participants will receive LDV/SOF FDC for 12 weeks.
3092074|NCT01768286|Experimental|LDV/SOF+RBV 12 Weeks|Participants will receive LDV/SOF FDC plus RBV for 12 weeks.
3092075|NCT01768286|Experimental|LDV/SOF 24 Weeks|Participants will receive LDV/SOF FDC for 24 weeks.
3092076|NCT01768286|Experimental|LDV/SOF+RBV 24 Weeks|Participants will receive LDV/SOF FDC plus RBV for 24 weeks.
3092077|NCT01768325|Active Comparator|EUS-Guided biopsy needle (ProCore)|"Comparison of ProCore core biopsy needle to QuickCore core biopsy needle.Cook Medical core biopsy needle.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
3092078|NCT01768325|Active Comparator|EUS-TCB needle (Quick-Core)|"Comparison of core biopsy needles.~The number of needle passes requiring to acquire adequate specimen~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
3092079|NCT01768520|Experimental|Entelon tab. 150mg|
3092080|NCT01768520|Active Comparator|Celebrex cap.|
3092081|NCT01768520|Placebo Comparator|Placebo|
3092082|NCT01768559|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks post-randomization, then at a maintenance dose of 20 mcg QD up to Week 26 on top of insulin glargine with or without metformin.
3092083|NCT01768559|Active Comparator|Insulin Glulisine QD|Insulin glulisine QD from randomization up to Week 26 on top of Insulin glargine with or without metformin.
3092084|NCT01768559|Active Comparator|Insulin Glulisine TID|Insulin glulisine thrice daily (TID) from randomization up to Week 26 on top of Insulin glargine with or without metformin.
3092085|NCT01768572|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) and placebo intravenous (IV) infusion once every 4 weeks (q4w) was added to one or a combination of the nonbiologic disease modifying antirheumatic drug (DMARD), hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3092086|NCT01768572|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w and placebo IV infusion q4w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3092087|NCT01768572|Active Comparator|Tocilizumab q4w|Tocilizumab 4 mg/kg or 8 mg/kg IV infusion q4w and placebo SC injection q2w was added to one or a combination of the nonbiologic DMARD, hydroxychloroquine, methotrexate, sulfasalazine and/or leflunomide for 24 weeks, except for the simultaneous use of leflunomide and methotrexate.
3092088|NCT01768637|Experimental|Chronic Kidney Disease|Patients with pre-dialysis stages 4-5 Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
3092089|NCT01768637|Active Comparator|Normal controls|Patients without Chronic Kidney Disease will receive open-label aspirin 81 mg once daily for 2 weeks, then 2 weeks of aspirin 81 mg plus clopidogrel 75 mg once daily.
3092090|NCT01768676|Experimental|avanafil|100 mg
3092091|NCT01768676|Placebo Comparator|Placebo|placebo
3092092|NCT01768832|Experimental|Treadmill|Individuals assigned to the Treadmill group will complete two one hour treadmill training sessions per week for 12 weeks.
3092093|NCT01768832|Experimental|Tango|Individuals assigned to the Tango group will complete two one hour dance classes twice per week for 12 weeks.
3092094|NCT01768832|Active Comparator|Stretching|Individuals assigned to Stretching will complete two one hour stretching classes per week for 12 weeks.
3092095|NCT01768845|Experimental|Transplant|After a preparative regimen the patient will receive an infusion of one or two umbilical cord blood unit(s) (UBC). The UBC unit(s) will be thawed according to methods of Rubinstein et al. If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis. On day +30, +60, +100, +180, and +365 the chimeric status of patients will be interpreted by variable number tandem repeat (VNTR) analysis. Immune reconstitution (Digeorge Panel) will also be checked at these time points.
3092096|NCT01768858||Participants receiving adalimumab|Adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC) received 40 mg adalimumab every two weeks.
3092097|NCT01769105|Active Comparator|Standard Lid Hygiene Regime|Patients receive detailed verbal and written instruction to perform lid hygiene twice daily
3092098|NCT01769105|Active Comparator|Lipiflow|Patients receive a singe Lipiflow-treatment
3092099|NCT01769170|Placebo Comparator|Placebo|Matching placebo administered orally twice weekly
3092100|NCT01769170|Active Comparator|Brincidofovir|100 mg brincidofovir administered orally twice weekly
3092101|NCT01769196|Experimental|Simtuzumab|Participants will receive simtuzumab for up to 254 weeks.
3092102|NCT01769196|Placebo Comparator|Simtuzumab Placebo|Participants will receive simtuzumab placebo for up to 254 weeks.
3092103|NCT01769209|Experimental|Bortezomib + Chemotherapy|Patients receive bortezomib on Days 1, 4, 8, and 11; doxorubicin hydrochloride on Day 1; PEG-asparaginase on Days 5 and 22; vincristine sulfate on Days 1, 8, 15, and 22; dexamethasone daily on Days 1 to 14; cytarabine on Day 1, and methotrexate on Day 15.
3092104|NCT01769222|Experimental|Ipilimumab 25 mg|Participants receive ipilimumab intratumorally on Day 1
3092105|NCT01769222|Experimental|Ipilimumab 25 mg and radiation therapy|Participants receive ipilimumab intratumorally on Day 1 and undergo local radiation therapy (10 Gy/fraction) within 48 hours for at least 3 fractions
3092106|NCT01769248|Active Comparator|Fine needle aspiration|fine needle aspiration
3092107|NCT01769248|Active Comparator|Fine needle biopsy|Fine needle biopsy
3092108|NCT01769274|Experimental|PF-05089771 1600 mg|
3092109|NCT01769274|Placebo Comparator|Placebo comparator: matching placebo|Single oral dose of placebo for PF-05089771 1600 mg
3092110|NCT01769326|Experimental|MusicGlove Group|Subject participates in 3 weeks of exercising with the experimental device: MusicGlove at a minimum of 3 days per week, 1 hour per day with the exercise program
3092111|NCT01769326|Active Comparator|Control Group for Music Glove|Subject participates in 3 weeks of conventional hand exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
3092112|NCT01769326|Experimental|Resonating Arm Exerciser (RAE)|Subject participates in 3 weeks of exercising with the experimental device: RAE at a minimum of 3 days per week, 1 hour per day with the exercise program
3092113|NCT01769326|Active Comparator|Control Group for RAE|Subject participates in 3 weeks of conventional arm exercise program, at a minimum of 3 days per week, 1 hour per day with the exercise program.
3092114|NCT01769339|Experimental|Miconazole plus Hydrocortisone|
3092115|NCT01769352|Active Comparator|PredA q1h WA + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution every 1 hr while awake (WA) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
3092116|NCT01769352|Active Comparator|PredA qid + Kelac qid|Prednisolone acetate (PredA) 1% ophthalmic solution four times a day (qid) and Ketorolac (Kelac) 0.5% ophthlmic solution four times a day (qid)
3092117|NCT01769365|Experimental|7-day quadruple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days,~metronidazole 500 mg twice daily for 7 days"
3092118|NCT01769365|Experimental|10-day sequential therapy|"pantoprazole 40 mg twice daily for 5 days and amoxicillin 1 g twice daily for 5 days, followed by~pantoprazole 40 mg twice daily for 5 days, clarithromycin 500 mg twice daily for 5 days, metronidazole 500 mg twice daily for 5 days."
3092119|NCT01769365|Active Comparator|7-day standard triple therapy|"pantoprazole 40 mg twice daily for 7 days,~clarithromycin 500 mg twice daily for 7 days,~amoxicillin 1 g twice daily for 7 days."
3092120|NCT01769378|Placebo Comparator|Placebo|Placebo administered subcutaneously (SQ) once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
3092121|NCT01769378|Experimental|Dulaglutide|Dulaglutide 1.5 milligram (mg) administered SQ once weekly for 24 weeks added to the participant's prescribed glimepiride dose.
3321163|NCT02016807||2-Treat Upper Alimentary Mucositis|Prothelial: Arm 2 Patients with gastric/small intestinal mucositis (delayed nausea, vomiting as prominent symptom/sign) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3092122|NCT01769391|Experimental|Necitumumab +Paclitaxel+Carboplatin|"Necitumumab 800 milligram (mg) administered intravenously (IV) on Days 1 and 8 of every 3 week cycle.~Paclitaxel 200 milligram per square meter (mg/m²) administered IV on Day 1 of every 3 week cycle.~Carboplatin Area Under the Curve (AUC)6 (mg•min/mL) administered IV on Day 1 of every 3 week cycle.~The combination of paclitaxel-carboplatin and necitumumab may continue for a maximum of 6 cycles. Necitumumab may continue until Progressive Disease (PD), toxicity requiring cessation, protocol noncompliance, or withdrawal of consent."
3092123|NCT01769391|Active Comparator|Paclitaxel + Carboplatin|Paclitaxel 200 mg/m² administered IV on Day 1 of every 3 week cycle. Carboplatin AUC=6 administered IV on Day 1 of every 3 week cycle. The combination of paclitaxel-carboplatin may continue for a maximum of 6 cycles. After completion of chemotherapy, participants will be followed until radiographic documentation of PD.
3092124|NCT01769404|Experimental|LY2605541|Stable dose of LY2605541 (0.2 to 0.6 units per kilogram [U/kg]) administered subcutaneously (SQ) once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
3092125|NCT01769404|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 to 0.6 U/kg) administered SQ once daily for at least 14 days in 1 of 2 treatment periods. Dose based on prestudy basal insulin dosing regimen.
3092126|NCT01769456|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3092127|NCT01769469||Subjects Enrolled in ATN 110 or ATN 113|A subset of 100 participants who are enrolled in the ATN 110 or ATN 113 study will be recruited for participation in this study. There is no treatment or intervention for this study; however, all subjects will be on daily coformulated tenofovir/emtricitabine (TDF/FTC (Truvada®)) as part of the ATN 110 or ATN 113 study.
3092128|NCT01769508|Experimental|Combined Therapy|Combined Modality Treatment of Radiation therapy, 5-Fluorouracil, Oxaliplatin and Lapatinib followed by Surgery
3092129|NCT01769573|Experimental|100 TCID50|RG-HRV16 dose of 100 TCID50 administered intranasally (0.25ml per nostril) one time.
3092130|NCT01769573|Experimental|1,000 TCID50|RG-HRV16 dose of 1,000 TCID50 administered intranasally (0.25ml per nostril) one time.
3092131|NCT01769573|Experimental|10,000 TCID50|RG-HRV16 dose of 10,000 TCID50 administered intranasally (0.25ml per nostril) one time.
3092132|NCT01769573|Placebo Comparator|Placebo|Diluent administered intranasally (0.25ml per nostril) one time.
3092133|NCT01769573|Experimental|500 TCID50|RG-HRV16 dose of 500 TCID50 administered intranasally (0.25ml per nostril) one time.
3092134|NCT01769586|Active Comparator|Diphenhydramine|Increments of 25 mcg to maximum of 3 times (total 75 mcg)
3092135|NCT01769586|Active Comparator|Midazolam|1.5 mg increments up to 3 times (maximum 4.5 mg)
3092136|NCT01769612||CL Detect Rapid Test and Microsopy Samples|Samples taken to be evaluated in the CL Detect and Microscopy assays
3092137|NCT01770145|Experimental|APOKYN|"APOKYN (apomorphine hydrochloride injection) is used as needed to treat off-episode motor symptoms, such as muscle stiffness, slow movements, and difficulty starting movements, in people with advanced Parkinson's disease (PD).~In the study, subjects will complete an L-Dopa Baseline Period in which they record daily time to on following their regularly scheduled L-Dopa morning dose for 7 days. At the end of the baseline period, patients will start trimethobenzamide therapy during a minimum 3-Day Anti-Emetic Pretreatment Period. Patients determined to remain eligible at the end of the required Anti-Emetic Pretreatment Period will be initiated on APOKYN therapy by an investigator. Once the appropriate dose is identified by a study investigator, patients will inject APOKYN at their regularly scheduled levodopa morning dose time (levodopa will be delayed by 40 minutes) daily during a 7-day APOKYN Treatment Period and record time to on following the APOKYN injection."
3092138|NCT01770314|Experimental|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
3092139|NCT01770314|No Intervention|Control|The control group is a waitlist control. Participants will be given access to painACTION after the intervention period and follow up assessments are completed.
3092140|NCT01770353|Experimental|Pilot Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
3092141|NCT01770353|Experimental|Expansion Phase: Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis
3092142|NCT01770366|Placebo Comparator|Usual Care|Patients will receive usual care from the post-surgical clinic team.
3092143|NCT01770366|Experimental|Intervention Condition|Intervention participants will receive the Weight and Exercise Lifestyle Support (WELS) intervention, which involves use of a wireless activity monitor and weight scale, as well as access to a patient portal website displaying data from these devices.
3092144|NCT01770379|Experimental|Secukinumab 75 mg|Secukinumab 75 mg s.c.
3092145|NCT01770379|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c.
3092146|NCT01770379|Placebo Comparator|Placebo|Placebo patients will be re-randomized 1:1 to secukinumab 75 or 150mg s.c. (non-responders at Week 16 will be re-assigned to new treatment at Week 16; responders at Week 16 will be re-assigned to new treatment at Week 24)
3092147|NCT01770392|Active Comparator|Test|multiple doses of Rifampicin + single dose of Nintedanib
3092148|NCT01770392|Experimental|Reference|single dose of Nintedanib
3092149|NCT01770431|Experimental|Huaier Granule group|"Huaier Granule group; specifications: 20g / bag; manufacturer: Qidong Gaitianli Medicines Co., Ltd..~Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 96 weeks after surgery or until study termination. The subjects should not take any other anticancer drugs or immunomodulatory agents, except for Huaier Granule."
3092150|NCT01770431|No Intervention|Bank-control group|"Blank-control group, not taking Huaier Granule, other anticancer drugs, or immunomodulatory agents.~During the study, patients who need antiviral therapy, in both the test group and control group, can be treated according to the therapeutic principles."
3092151|NCT01770483|Experimental|study group|Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months
3092152|NCT01770483|Active Comparator|control group|Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months
3092153|NCT01770509|Active Comparator|Standard of care|Standard of care: Dressings +Compression garments
3092154|NCT01770509|Experimental|Application of NMBM|Daily application of NMBM
3092155|NCT01770652|Experimental|Normal renal function|Healthy volunteers, defined as having an estimated glomerular filtration rate (eGFR) ≥90 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3092156|NCT01770652|Experimental|Mild Renal Impairment|Mild impairment, defined as having an eGFR 60-89 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3092157|NCT01770652|Experimental|Moderate Renal Impairment|Mild impairment, defined as having an eGFR 30-59 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3092158|NCT01770652|Experimental|Severe Renal Impairment|Severe impairment, defined as having an eGFR 15-19 mL/min/1.73m^2. All subjects received a single 33 mg/kg oral dose of deferiprone.
3092159|NCT01770691|Experimental|TIPI vaginal pessary|Each subject will use different SMD'S (Slightly modified designs) of the TIPI vaginal pessary. Not all subjects will use all types of SMD's
3092160|NCT01770743|Experimental|AV7909 (Day 0 and 14)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 14
3092161|NCT01770743|Experimental|AV7909 (Day 0 and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0 and Day 28
3092162|NCT01770743|Experimental|AV7909 (Day 0, 14, and 28)|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
3092163|NCT01770743|Experimental|AV7909 Reduced Dose|Route of administration: Intramuscular Dose: 0.25 mL Schedule: Day 0, Day 14,and Day 28
3092164|NCT01770743|Active Comparator|BioThrax|Route of administration: Intramuscular Dose: 0.5 mL Schedule: Day 0, Day 14,and Day 28
3092165|NCT01770860|Active Comparator|6660|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3092166|NCT01770860|Active Comparator|4314|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3092167|NCT01770860|Active Comparator|8336|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3092168|NCT01770860|Placebo Comparator|4840|Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site.
3092169|NCT01770860|No Intervention|0000|"Device: 0000~At each daily visit, designated study personnel will cut out the center pad of the bandage and apply only the adhesive tabs around the assigned wound site.~Other Names:~Sheer Strips~BAND-AID® with QuiltVent™ Pad Technology~Five dermabrasion wounds will be created on each subject's back by a licensed physician. Four of the wounds will be covered with four different commercially-available bandages (6660, 4314, 8336 and 4840), and one wound will be left open to the air to serve as a no treatment control (0000). Treatments and control will be randomized to application site."
3092170|NCT01770912|Placebo Comparator|Lactated Ringers|1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
3092171|NCT01770912|Active Comparator|Triamcinolone acetonide|1 cc of triamcinolone acetonide (20 mg) injected once after the TMJ rinsing procedure.
3092172|NCT01771055|Experimental|Galactose|Galactose
3092173|NCT01771055|Placebo Comparator|Standard resuscitation|Standard surgical methods of controlling bleeding
3092174|NCT01771250|Experimental|Insulin Peglispro|Stable dose of insulin peglispro (0.2 - 0.8 units per kilogram [U/kg]) administered subcutaneously (SC) once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3092175|NCT01771250|Active Comparator|Insulin Glargine|Stable dose of insulin glargine (0.2 - 0.8 U/kg) administered SC once daily for at least 21 days in one of two treatment periods. Dose based on prestudy basal insulin dosing regimen.
3092176|NCT01771627|Experimental|Arm I (varenicline)|Patients undergo general smoking cessation counseling and receive varenicline PO QD on days 1-28. Courses repeat every 28 days for up to 12 weeks.
3092177|NCT01771627|Active Comparator|Arm II (nicotine patch)|Patients undergo general smoking cessation counseling and receive nicotine patch continuously for 12 weeks.
3092178|NCT01771666|Experimental|ISB and ICG|"The dose of Isosulfan blue (ISB) dye and Indocyanine green (ICG) solution will be started.~(IC-GREEN) SPY Elite Imaging willbe used to capture the images of axillary cavity."
3092179|NCT01771731|Experimental|Cannabis|Contents of 1 cannabis cigarette (4.7% THC/5.1% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
3092180|NCT01771731|Placebo Comparator|Placebo|Contents of 1 placebo cigarette (0% THC/0% CBD) will be vaporized and inhaled at 12pm on Day 1; 8am, 2pm and 8pm on Days 2-4; and 8am on Day 5.
3321164|NCT02016807||3-Treat Lower Alimentary Mucositis|ProThelial: Arm 3 Patients with lower GI mucositis develop chemoradiation diarrhea as their \ prominent symptom/sign[n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3321165|NCT02016807||4-Prevent Oral Mucositis|ProThelial: Arm 4 Patients anticipated to develop oroesophageal mucositis (with pain, erythema, ulceration and difficult pain swallowing as prominent symptom/signs) [n=30] Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and spit. (Phase IV)
3092181|NCT01771809|Experimental|SHP647 75 mg|Participants will receive 75 milligrams (mg) of SHP647 subcutaneous (SC) injection every 4 weeks for 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen. During the first 72 weeks, a one time dose escalation to 225 mg of SHP647 SC injection every 4 weeks is allowed after 8 weeks of the study for participants who experience clinical deterioration or unacceptably low level of response to the investigational product. The decision to escalate will be guided by the response and relapse criteria tempered by clinical judgment. Following the first 72 weeks, participants will receive 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
3092182|NCT01771809|Experimental|SHP647 225 mg|Participants will receive 225 mg of SHP647 SC injection every 4 weeks for 72 weeks followed by 75 mg of SHP647 SC injection every 4 weeks for an additional 72 weeks in the anterolateral right/left thigh or the deltoid area or the abdomen.
3092183|NCT01771913|Sham Comparator|centrifuged fat graft|female patients who underwent breast reconstruction and present with volume insufficiency will undergo centrifuged fat graft for contour and volume refinements.
3092184|NCT01771913|Active Comparator|ADSCs enriched centrifuged fat graft|female patients who underwent breast reconstruction and present volume insufficiency will undergo ADSCs enriched fat grafting for volume and irregularity contour improvement
3092185|NCT01771952|Experimental|Synvisc-One™|Patients randomized into this group will receive a single 6cc dose of Synvisc-One™ under sterile conditions. After cutaneous numbing with vasocoolant spray, the superolateral aspect of the patellofemoral joint will be draped and prepared with betadine soaked sterile gauze using concentric circles around the injection site. A 22 gauge needle will be advanced into the patellofemoral joint using a superolateral approach. Subjects will be monitored for minimum 5 minutes post injection to evaluate for adverse events.
3092186|NCT01771952|Sham Comparator|Sham Treatment|Patients randomized into this group will receive, under sterile conditions, a sham injection. Sterile preparation and injection procedures will be exactly the same as described above except, nothing will be injected into the joint. This procedure will include a needle stick through the joint without arthrocentesis or injection.
3092187|NCT01771965|No Intervention|Usual care|No intervention.
3092188|NCT01771965|Experimental|CB Intervention|Cognitive Behavioral one-on-one single session administered by phone
3092189|NCT01771991|Experimental|Topical Sodermix Dismutase|Patients with measurable radiation induced fibrosis of the neck. Patients will be randomized to applying Topical Sodermix Dismutase in the form of Sodermix(SOD) to the area of neck skin fibrosis twice a day for 12 weeks.
3092190|NCT01771991|Placebo Comparator|Placebo group|Cetaphil cream
3092191|NCT01772134|Experimental|Umeclidinium bromide 62.5 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 62.5mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3092192|NCT01772134|Active Comparator|Umeclidinium bromide 125 + Fluticasone propionate/Salmeterol|Long-acting muscarinic antagonist (LAMA), 125mcg plus Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3092193|NCT01772134|Placebo Comparator|Placebo + Fluticasone propionate/Salmeterol|Inhaled corticosteriod (ICS), 250mcg/ Long acting Beta agonist (LABA), 50mcg
3092194|NCT01772147|Experimental|Umeclidinium bromide|Long-acting muscarinic antagonist (LAMA)
3092195|NCT01772147|Active Comparator|Fluticasone propionate/Salmeterol|Inhaled corticosteroid (ICS)/Long-acting beta agonist (LABA)
3092196|NCT01772160||Herpes Zoster Group|Male or female subjects aged 50 years or above, presenting with a herpes zoster (HZ) episode.
3092197|NCT01772316|Experimental|Tocilizumab Subcutaneous (SC)|Participants received Tocilizumab 162 milligram (mg) given as 0.9 milliliter (mL) of a 180 milligram per milliliter (mg/mL) solution administered once a week (for participants entering from NCT01194414) or once every two weeks (for participants entering from NCT01232569) by SC injection and as a single fixed dose irrespective of body weight.
3092198|NCT01772368|Experimental|FS MDPI 100/6.25 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.
3092199|NCT01772368|Experimental|FS MDPI 100/12.5mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.
3092200|NCT01772368|Experimental|FS MDPI 100/25|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.
3092201|NCT01772368|Experimental|FS MDPI 100/50|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.
3092202|NCT01772368|Active Comparator|Fp MDPI 100 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate.
3092203|NCT01772368|Active Comparator|Advair Diskus 100/50 mcg|Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.
3092204|NCT01772472|Active Comparator|Trastuzumab|
3092205|NCT01772472|Experimental|Trastuzumab emtansine|
3092206|NCT01772537|No Intervention|Open repair of thoracoabdominal aneurysms|These will be patients undergoing an open repair of thoracoabdominal aneurysms with or without cardiopulmonary bypass. The will be observational only.
3092207|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms isoflurane|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive isoflurane as their primary anesthetic.
3092208|NCT01772537|Active Comparator|Stent graft repair of thoracoabdominal aneurysms propofol|These patients are patients receiving repair of thoracoabdominal aneurysms using stent grafts. These patients will be randomized to receive propofol as their primary anesthetic.
3092209|NCT01772550|Experimental|20 Gauge BD Nexiva Diffusics|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch).
3092210|NCT01772550|Active Comparator|18 Gauge Conventional Catheter|During their routinely scheduled contrast-enhanced computed tomography procedure, subjects in this arm will receive IV contrast media injected via the non-fenestrated 18GA Conventional Catheter (18 GA x 1.25 inch Smiths Medical Jelco® IV Catheter).
3092211|NCT01772550|Experimental|BD Nexiva Diffusics - Nonrandomized|Subjects whose veins were not suitable for an 18 GA IV Catheter were assigned to this non-randomized arm. During their routinely scheduled CECT procedure, subjects receive IV contrast medium injected via the fenestrated 20GA BD Nexiva Diffusics single port IV catheter (20GA x 1.00 inch)
3092212|NCT01772576|Experimental|Reliance 4-Front|Single arm, all patients will be implanted with the Reliance 4-Front lead
3092213|NCT01772654|Experimental|Left Temporal Lobe Epilepsy Subjects|Arterial Spin Labeled (ASL) MRI sequence
3092214|NCT01772654|Active Comparator|Control Subjects|Arterial Spin Labeled (ASL) MRI sequence
3092215|NCT01772693|Experimental|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR guided Focused Ultrasound
3092216|NCT01772693|Sham Comparator|Sham ExAblate Transcranial MRgFUS|Sham treatment with ExAblate MR guided Focused Ultrasound
3092217|NCT01772758|Experimental|Protocol 1: AOC|measurements at baseline and 2 hours following the antioxidant cocktail that is comprised of over the counter vitamins (vitamin C 1000mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) that will be given in two doses, 30 minutes apart.
3092218|NCT01772758|Experimental|Protocol 2: BH4 (5mg)|measurements at baseline and 3 hours following the single dose of 5mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
3092219|NCT01772758|Experimental|Protocol 2: BH4 (20mg)|measurements at baseline and 3 hours following the single dose of 20mg/kg Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4).BH4 has been shown in past studies to increase NO bioavailability.
3092220|NCT01772758|No Intervention|Healthy Controls|baseline measurements were done with no intervention
3092221|NCT01772823|Experimental|3MV Behavioral Intervention Group|3MV Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3092222|NCT01772823|Experimental|PCC Behavioral Intervention Group|PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP
3092223|NCT01773070|Other|All Participants|Participants who received ABT-450, ABT-333 or ABT-267 at any dose level in an eligible prior AbbVie Phase 2 or 3 study for the treatment of chronic HCV, followed for up to 3 years post-treatment.
3092224|NCT01773109|Experimental|Eligible patients will receive etirinotecan pegol at a dose of|single-arm, open-label study is designed to investigate the efficacy and safety of etirinotecan pegol in patients with metastatic or recurrent NSCLC after failure of 2nd line therapy. Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Patients will be followed clinically every week for the first cycle with laboratory parameters (section 6.2.1) and physical exam. Response will be determined with RECIST version 1.1 after 2 cycles of therapy. Patients with Stable disease (SD), partial response (PR) or complete response (CR) will continue on additional therapy for up to six cycles. In the absence of disease progression in subjects completing six full cycles, further treatment beyond cycle #6 will be left to the discretion of the treating physician and his/her staff. Patients with progressive disease will be taken off study and will be followed for OS
3092225|NCT01773122|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3092226|NCT01773122|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3092227|NCT01773122|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
3092228|NCT01773122|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
3092229|NCT01773135||preterm group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver preterm (before 37 weeks of gestation)
3092230|NCT01773135||full term group|pregnant healthy women aged from 17 to 35 who suffered from symptoms of threatened preterm labor in the form of Presence of uterine contractions (at least 4 in 20 minutes or 8 in 60 minutes), Cervical dilation > 1 and < 4 cm, and/or Cervical effacement ≥ 80%. collection of blood sample and tocolysis administration will be done this group will deliver full term (after 37 weeks of gestation)
3092231|NCT01773187|Experimental|Pacritinib|Pacritinib 400 mg QD
3092232|NCT01773187|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for primary or secondary myelofibrosis with the exclusion of JAK inhibitors (inhibitors of Janus kinases)
3092233|NCT01773226|Experimental|"Autologous Protein Solution APS(TM)"|Patients who have been treated with a single, intra-articular injection.
3092234|NCT01773291|Experimental|acupuncture|acupuncture on GV26 and 12 Well points
3092235|NCT01773291|Experimental|laser acupuncture|laser acupuncture on GV26 and 12 Well points
3092236|NCT01773291|Sham Comparator|control group|laser acupuncture without laser output in control group.
3092237|NCT01773421|Experimental|Part A|
3092238|NCT01773421|Experimental|Part B|
3092239|NCT01773473|Experimental|Insulin Lispro Mix25|Insulin Lispro Mix25 administered subcutaneously (SC) using prefilled pen twice daily for 26 weeks.
3092240|NCT01773473|Experimental|Insulin Lispro Mix50|Insulin Lispro Mix50 administered SC using prefilled pen twice daily for 26 weeks.
3092241|NCT01773889|Experimental|Denileukin Diftitox/SC Pegylated IFNα-2A|Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
3092242|NCT01773954|Experimental|Intravitreal Aflibercept Injection More|Patient receives treatment at baseline and week 4 visit. The first time extension criteria are met the follow-up interval will be increased by 4 weeks. Each time the extension criteria is met the interval will be extended by 2 weeks to a maximum of 16 weeks. If a patient is being followed at an 8 week interval but fails to meet extension criteria at a particular visit, treatment will be administered as usual and the follow up interval will be reduced to 4 weeks. If patient is being followed at 10-16 week interval but fails to meet extension criteria at a particular visit, treatment will be administered but the follow-up interval will be reduced by 2 week increments.
3092243|NCT01773967|Experimental|LGG|LGG 10^10 cfu PO bid x 5 days
3092244|NCT01773967|Placebo Comparator|Placebo|micro-crystalline cellulose PO bid x 5 days
3092245|NCT01773993||Pregabalin|Subjects who are treated with pregabalin
3092246|NCT01774045|Experimental|PDC-1421|Dosage form: 380mg PDC-1421 per Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
3092247|NCT01774045|Placebo Comparator|Placebo control|Dosage form: Capsule. Dosage: single dose (1, 3, 6, 10 capsule(s)). Frequency: once daily, p.o., after meal. Duration: single dose at Day 1, and observing for three Days.
3092248|NCT01774084|Active Comparator|PreOp, NutriciaNordica AB|PreOp: 50 kcal/100 mL in the form of maltodextrin and fructose. One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
3092249|NCT01774084|Placebo Comparator|Water|Water: One bottle of 800 ml to be ingested at bedtime, and at midnight by the latest, and another bottle with 400 ml approximately 2 hours before surgery started.
3092250|NCT01774097|Experimental|ALD-301|Participants will receive ALD-301 via intramuscular injection
3092251|NCT01774097|Placebo Comparator|Placebo (vehicle)|Participants will receive placebo (vehicle)via intramuscular injection
3092252|NCT01774110|Experimental|early standardized task training|Persons in the experimental group will receive ESTT (early standardized task specific training) for gait treatment after stroke.
3092253|NCT01774149|Active Comparator|Delayed Diastat|Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
3092254|NCT01774149|Experimental|Diastat|Few Touch Application with Diastat module turned on in week 4 post-enrollment.
3092255|NCT01774253|Experimental|Vismodegib|Vismodegib will be dosed at 150mg-300mg orally (max dose: 300mg) once a day on days 1 to 28 of a 28-day cycle. In the absence of unacceptable toxicity or disease progression, treatment may continue for as long as tolerated.
3092256|NCT01774305|Experimental|dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
3092257|NCT01774305|Placebo Comparator|saline|We administrate the saline single bolus (0.25ml/kg,intravenously, for 10 min) at time of muscle layer closing.
3092258|NCT01774344|Experimental|Regorafenib|160 mg orally (p.o.) every day (qd) for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC (Best Supportive Care)
3092259|NCT01774344|Placebo Comparator|Placebo|4 matching placebo tablets for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off) plus BSC
3092261|NCT01774591|Active Comparator|azilsartan medoximil.|Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
3092262|NCT01774591|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
3092263|NCT01774604|Experimental|Indomethacin|Indomethacin 100 mg Per Rectum (PR) x 1 in peri-procedural period
3092264|NCT01774604|Placebo Comparator|Placebo|Placebo suppositories (#2)
3092265|NCT01774721|Experimental|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing.
3092266|NCT01774721|Active Comparator|gefitinib|Gefitinib is provided as 250 mg tablets, continuous oral daily dosing.
3092267|NCT01774760|Experimental|Patients with stage III-IV head and neck cancer|18F-EF5 PET/CT scan
3092268|NCT01774786|Experimental|Pertuzumab + Trastuzumab + Chemotherapy|Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
3092269|NCT01774786|Placebo Comparator|Placebo + Trastuzumab + Chemotherapy|Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine [capecitabine or 5-fluorouracil]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
3092270|NCT01774799|Experimental|Advance care planning intervention|At baseline, health care proxies in the intervention arm will be shown a 12-minute Advance Care planning video that describes 3 levels of treatment in advanced dementia: comfort basic and intensive. After viewing the video, the proxies will be asked their preferred level of care for the resident and this choice will be communicated to the residents primary care team in a written form.
3092271|NCT01774799|Active Comparator|Usual care|Residents in control nursing homes with receive the usual advance care planning that occurs in their nursing home.
3092272|NCT01774851|Experimental|Arm 1a|MM-111 + Paclitaxel + Trastuzumab
3092273|NCT01774851|Active Comparator|Arm 1b|Paclitaxel + Trastuzumab
3092274|NCT01774903|Experimental|TTS-fentanyl|
3092275|NCT01774929|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
3092276|NCT01774968|Experimental|Human Regular U-500 Insulin TID|Human Regular U-500 Insulin (U-500R) titrated based on blood glucose readings, administered subcutaneously (SC), three times a day (TID) for 24 weeks.
3092277|NCT01774968|Experimental|Human Regular U-500 Insulin BID|U-500R Insulin titrated based on blood glucose readings, administered SC, two times a day (BID) for 24 weeks.
3092278|NCT01774981|Placebo Comparator|Placebo (Part A)|Part A: Placebo administered by 60 minute Intravenous (IV) infusion at Week 1 and Week 4.
3092279|NCT01774981|Experimental|10 mg LY3016859 (Part A)|Part A: 10 milligram (mg) LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3092280|NCT01774981|Experimental|100 mg LY3016859 (Part A)|Part A: 100 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3092281|NCT01774981|Experimental|750 mg LY3016859 (Part A)|Part A: 750 mg LY3016859 administered by 60 minute IV infusion at Week 1 and Week 4.
3092282|NCT01774981|Placebo Comparator|Placebo (Part B)|Part B: Placebo administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3092283|NCT01774981|Experimental|50 mg LY3016859 (Part B)|Part B: 50 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3092284|NCT01774981|Experimental|250 mg LY3016859 (Part B)|Part B: 250 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3092285|NCT01774981|Experimental|750 mg LY3016859 (Part B)|Part B: 750 mg LY3016859 administered by 60 minute IV infusion at Weeks 1, 4, 7, 10 and 13.
3092286|NCT01775124|Experimental|Ranibizumab 0.5 mg monthly|Monthly intravitreal injections of ranibizumab 0.5 mg in the core treatment period and PRN intravitreal injections of the same dose guided by best-corrected visual acuity (BCVA) stabilization in the extension treatment period
3092287|NCT01775124|Experimental|Ranibizumab 0.5 mg pro re nata (PRN)|PRN intravitreal injections of ranibizumab 0.5 mg guided by best-corrected visual acuity (BCVA) stabilization in the 23 month treatment period
3092288|NCT01775137|Experimental|TBM100|TIP 112 mg/b.i.d
3092289|NCT01775189|Placebo Comparator|Treatment A|
3092290|NCT01775189|Experimental|Treatment B|
3092291|NCT01775189|Placebo Comparator|Treatment C|
3092292|NCT01775189|Active Comparator|Treatment D|
3092293|NCT01775371|Experimental|Patient Controlled Analgesia|PCA (loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes)
3092294|NCT01775371|Active Comparator|Usual Care|Usual opioid analgesia determined by the provider
3092295|NCT01775410|Experimental|Wolverine System|Wolverine System to perform atherectomy while using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque from diseased lower extremity arteries
3092296|NCT01775501|Experimental|Experimental Treatment Arm|FOLFOX (Leucovorin, Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally, twice daily FOLFOX: injected via portacath once every two weeks
3092297|NCT01775553|Experimental|Carfilzomib|All patients will receive Carfilzomib
3092298|NCT01775670|Experimental|Off-the-Shelf Splint|Subjects in this arm will be managed with off-the-shelf splints for TMC arthrosis.
3092299|NCT01775670|Active Comparator|OT Splint|Subjects in this arm will be managed with a custom-made splint made by the Massachusetts General Hospital Occupational Therapists.
3092300|NCT01775722|Other|Pulsed Dye Laser|port wine stain treatment using Pulse Dye Laser
3092301|NCT01775722|Experimental|Bipolar Radiofrequency&Pulsed Dye Laser|Port wine stain using Combined Bipolar Radiofrequency&Pulsed Dye Laser
3092302|NCT01775735|Experimental|Treatment|The treatment is continuous stimulation with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
3092303|NCT01775735|Active Comparator|Control|The control is intermittent stimulation for 20 seconds every 90 minutes with an occipital nerve stimulator, specifically the BSC Precision™ ONS System for 6 months post-randomization
3092304|NCT01775774|Experimental|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.
3092305|NCT01775787|Other|Tobacco Flavor/ Tobacco & Menthol Flavor|"Subjects randomized to Tobacco Flavor group 7-10 days, then crossed over to Tobacco and Menthol Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
3092306|NCT01775787|Other|Tobacco & Menthol Flavor/Tobacco Flavor|"Subjects randomized to Tobacco and Menthol Flavor for 7-10 days,then crossed over to Tobacco Flavor for 7-10 days.~Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor (18mg/mL nicotine)"
3092307|NCT01775800|Experimental|Treatment modification|Patients in this arm will be treated to different targets of blood pressure, parathyroid hormone and serum phosphorus.
3092308|NCT01775800|No Intervention|Usual care|Patients will receive the usual hemodialysis care with no modifications
3092309|NCT01775852|Active Comparator|ACT-IM|The ACT-IM arm is a brief, one-day intervention that includes two components: 1) Illness Management for Migraine and, 2) Acceptance and Commitment Therapy for emotional difficulties that go along with, or are exacerbated by migraine.
3092310|NCT01775852|No Intervention|Waitlist/Treatment as Usual|The Waitlist/Treatment as Usual (WL/TAU)condition completes the same assessments as the active treatment group but does not undergo the active treatment (workshop) until after the 12-week follow-up visit. At that point, the WL/TAU participants are given the opportunity to join a treatment workshop.
3092311|NCT01775865|Experimental|Salsalate|Salsalate capsule 1.5 g/day twice per day by mouth for 4 weeks
3092312|NCT01775865|Placebo Comparator|Placebo|Placebo capsule twice per day by mouth for 4 weeks
3092313|NCT01775865|No Intervention|Young Control|No intervention; Baseline measurements only
3092314|NCT01775904|Experimental|LY2886721 Capsule (water, fasting)|Reference formulation. A single oral dose of 70 milligrams (mg) LY2886721 in a capsule given with water and without a meal in one of four periods.
3092315|NCT01775904|Experimental|LY2886721 ODT (no water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given without water and without a meal in one of four periods.
3092316|NCT01775904|Experimental|LY2886721 ODT (water, fed)|A single oral dose of a 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and after a high-fat breakfast in one of four periods.
3092317|NCT01775904|Experimental|LY2886721 ODT (water, fasting)|A single oral dose of 70 mg LY2886721 in an orally disintegrating tablet (ODT) given with water and without a meal in one of four periods.
3092318|NCT01775930|Experimental|Carfilzomib|Patients receive Carfilzomib at dose of 20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
3092319|NCT01775995|Experimental|Meditation-CBT|Participants receiving the meditation-CBT intervention, in addition to usual care for CLBP and opioid therapy management.
3092320|NCT01775995|Other|Wait-list Control|Participants receiving usual care for CLBP and opioid therapy management.
3092321|NCT01776008|Experimental|Treatment (MK2206, anastrozole, goserelin acetate)|Patients receive Akt inhibitor MK-2206 PO on days 2, 9, 16, and 23; anastrozole PO daily on days 1-28; and goserelin acetate SC on day 1 (premenopausal patients only). Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3092322|NCT01776268|Experimental|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
3092323|NCT01776268|No Intervention|No oral priming|No oral priming
3092324|NCT01776307|Experimental|BBI608 in combination with cetuximab|
3092325|NCT01776307|Experimental|BBI608 in combination with panitumumab|
3092326|NCT01776307|Experimental|BBI608 in combination with capecitabine|
3092327|NCT01776424|Experimental|Rivaroxaban [2.5mg] + Aspirin|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily. (Long-term open-label extension was added to make rivaroxaban 2.5 mg twice daily + aspirin 100 mg once daily available to COMPASS trial subjects until the rivaroxaban treatment is commercially available for this indication or for approximately 3 years from regulatory approval of the long term open label extension in a country, whichever comes first.)
3092328|NCT01776424|Experimental|Rivaroxaban [5mg] + Placebo(1)|Rivaroxaban 5 mg twice daily and Aspirin Placebo once daily
3092329|NCT01776424|Active Comparator|Aspirin + Placebo(2)|Rivaroxaban Placebo twice daily and Aspirin 100 mg once daily
3092330|NCT01776541|Experimental|aH5N1c-High Dose|Subjects received 2 injections of a high dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
3092331|NCT01776541|Experimental|aH5N1c-Low dose|Subjects received 2 injections of a low dose of cell culture-derived adjuvanted monovalent inactivated subunit H5N1 vaccine three weeks apart.
3092332|NCT01776554|Experimental|aH5N1c-High dose|
3092333|NCT01776554|Experimental|aH5N1c-Low dose|
3092334|NCT01776632|Experimental|Physical activity|Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
3092335|NCT01776632|Active Comparator|Cancer screening|Latinas exposed to Faith in Action intervention on cancer screening and prevention.
3092336|NCT01776645|Experimental|Compassion cultivation training|
3092337|NCT01776723|Experimental|I: Dose Escalation - Ruxolitinib|"Phase I: Dose Escalation. In Phase I, participants will be allocated to dose levels starting at 10 mg/d (twice a day [BID] dosing) according to the rolling six Phase I design."
3092338|NCT01776723|Experimental|II: Maximum Tolerated Dose - Ruxolitinib|Phase II: Treatment at Maximum Tolerated Dose (MTD).
3092339|NCT01777126|Active Comparator|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
3092340|NCT01777126|Experimental|Oral Nutrition Protocol (ONP) group|Oral intake was increased progressively with oral fluids and easily digestible food, independent of bowel movements. The corresponding energy content from the meals and oral fluids were calculated. Fortimel Jucy®, 200 ml containing 300 kcal, was used as the formulary energy sip. Extra fluids, up to two liter per day, were given intravenously, at the discretion of the treating physician. If the patient tolerated the ONP well, the oral intake was considered equal in terms of calories as the corresponding oral meal in the ONP. From the sixth day, the patient was allowed to eat at will. Only if oral intake remained insufficient after 5 days, which was left to the opinion of the treating physician, PN could be initiated in this group.
3092341|NCT01777139|Experimental|Retigabine IR|All subjects will initially receive a starting dose of retigabine IR at 900 mg/day and after the first week of the OLE study, the dose of retigabine IR may be increased or decreased in increments or decrements of decrements of 150 mg/day on weekly basis based on efficacy and tolerability. The overall daily dose of retigabine IR must be maintained between a minimum dose of 600 mg/day and a maximum dose of 1200 mg/day.
3092342|NCT01777152|Active Comparator|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
3092343|NCT01777152|Experimental|A+CHP|brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
3092344|NCT01777191|Experimental|80 mg Ixekizumab Auto-Injector|Ixekizumab administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, then one 80 mg SC injection every 2 weeks (Q2W) at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection every 4 weeks (Q4W).
3092345|NCT01777191|Experimental|80 mg Ixekizumab Prefilled Syringe|Ixekizumab administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection Q2W at week 2, 4, 6, 8 and 10. Starting from Week 12, 80 mg Ixekizumab Prefilled Syringe was administered by one 80 mg SC injection Q4W.
3092346|NCT01777217|Active Comparator|solifenacin succinate|Solifenacin succinate, 5mg or 10 mg once daily
3092347|NCT01777217|Placebo Comparator|Placebo|Drug: Placebo oral
3092348|NCT01777269|Experimental|Duodart|Fixed dose combination of dutasteride 0.5mg and tamsulosin 0.4mg. A capsule once daily during 12 months
3092349|NCT01777269|Placebo Comparator|Sugar Pill|A capsule once daily during 12 months
3092350|NCT01777282|Active Comparator|Albiglutide + Sulfonylurea|Albiglutide in combination with background sulfonylurea
3092351|NCT01777282|Active Comparator|Albiglutide + Biguanide|Albiglutide in combination with background biguanide
3092352|NCT01777282|Active Comparator|Albiglutide + Glinide|Albiglutide in combination with background glinide
3092353|NCT01777282|Active Comparator|Albiglutide + Thiazolidinedione|Albiglutide in combination with background thiazolidinedione
3092354|NCT01777282|Active Comparator|Albiglutide + Alpha-glucosidase inhibitor|Albiglutide in combination with background alpha-glucosidase inhibitor
3321166|NCT02016807||5- Prevent Upper Alimentary Mucositis|ProThelial: Arm 5 Patients anticipated to develop gastric/small intestinal mucositis (delayed nausea vomiting as prominent symptom/sign) [n=30]. Intervention: ProThelial 1.5 gram Taken tid x 2 days then bid swish and swallow. (Phase I)
3092357|NCT01777308|Experimental|Menitorix Group|"Subjects who were primed with Menitorix™ (Hib-MenC-TT) + Priorix™ (MMR) vaccines in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
3092358|NCT01777308|Experimental|Meningitec + Hiberix Group|"Subjects who were primed with Meningitec™ (MCC) + Hiberix™ (Hib) + Priorix™ (MMR) vaccine in the primary study HIB-MENC-TT-016 (NCT00326118) received one dose of Nimenrix™ (MenACWY-TT) booster vaccine at Month 72 post primary vaccination (booster visit 1).~The MenACWY-TT vaccine was administered intramuscularly (IM) in the deltoid region of the non-dominant arm."
3092359|NCT01777321|Experimental|SC HZ/su Group|Subjects will receive HZ/su vaccine administered SC on a 0,2-month schedule.
3092360|NCT01777321|Active Comparator|IM HZ/su Group|Subjects will receive HZ/su vaccine administered IM on a 0,2-month schedule.
3092361|NCT01777334|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
3092362|NCT01777334|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
3092363|NCT01777412|Experimental|Bevacizumab|Bevacizumab 10 mg/kg intravenous infusion at onset of exacerbation and, if needed, a second time during the plasma exchange phase.
3092364|NCT01777425||rhinosinusitis patients|patients having undergone endoscopic sinus surgery (ESS) for bilateral inflammatory sinonasal disease from January 2008 until December 2010.
3092365|NCT01777438||control group|a control group of AR patients who visited the ear nose and throat (ENT) department of the University Hospitals Leuven in the same time period
3092366|NCT01777438||patients having SCIT|patients who started immunotherapy at the Department of Allergology of the University Hospitals Leuven between November 2007 and February 2010.
3092367|NCT01777490|Active Comparator|Arm 1: Control - Caregiver|Caregivers in the control arm will be referred to the VA Caregiver Support Program (usual care), as a resource for them as they care for the patient in the home.
3092368|NCT01777490|Experimental|Arm 2: HI FIVES - Caregiver|Caregivers will take part in three phone training sessions and will attend four group training sessions at the VA. They will also be given the option of participating in 2 booster phone training sessions post-group sessions. Caregivers will be asked to provide one in-person (baseline) and three phone assessments (3, 9, and 15 months). Patients will also be enrolled and contact will be limited to assessments
3092369|NCT01777490|Active Comparator|Arm 1: Control - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
3092370|NCT01777490|Experimental|Arm 2: HI-FIVES - Patient|The patient of each caregiver will also be enrolled and contact will be limited to assessments.
3092371|NCT01777542|Active Comparator|Treatment Period 1|One half of subjects will be randomly assigned to receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1) , and the other half of subjects will be randomly assigned to receive placebo.
3092372|NCT01777542|Placebo Comparator|Treatment Period 2|Subjects that initially received Recombinant Human Insulin Growth Factor 1 (rhIGF-1) will now receive placebo, and subjects that initially received placebo will now receive Recombinant Human Insulin Growth Factor 1 (rhIGF-1).
3092373|NCT01777568|Experimental|30% oxygen|Inspired oxygen will be maintained at 30%.
3092374|NCT01777568|Experimental|80% oxygen|Inspired oxygen will be maintained at 80%.
3092375|NCT01777581|Experimental|milnacipran|Milnacipran, flexibly dosed
3092376|NCT01777581|Placebo Comparator|Sugar pill (placebo)|Placebo
3092377|NCT01777620|Active Comparator|BOTOX®|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
3092378|NCT01777620|Placebo Comparator|Placebo|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
3092379|NCT01777763|Experimental|Posaconazole 200 mg|Posaconazole 200 mg (two 100 mg tablets) twice daily (BID) on Day 1 followed by 200 mg (two 100 mg tablets) once daily (QD) for up to 28 days
3092380|NCT01777763|Experimental|Posaconazole 300 mg|Posaconazole 300 mg (three 100 mg tablets) BID on Day 1 followed by 300 mg (three 100 mg tablets) QD for up to 28 days
3092381|NCT01777776|Experimental|Phase Ib|Phase Ib will randomize 18 patients with BRAF mutant melanoma, who are naïve or who have progressed on prior therapy to evaluate the safety and tolerability of the combination of LEE011 and LGX818.
3092382|NCT01777776|Experimental|Phase II arm 1a|Phase II arm 1a will randomize 60 patients that are naïve to prior BRAF inhibitor therapy to LGX818+LEE011 to evaluate the effect of adding LEE011 to a BRAFi in this population.
3092383|NCT01777776|Experimental|Phase II arm 1b|Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
3092384|NCT01777776|Experimental|Phase II arm 2|Phase II arm 2 will evaluate a single arm LEE011+LGX818 in 40 patients resistant to prior BRAF inhibitor therapy. Single agent LGX818 has shown limited activity in patients with melanoma who have failed prior BRAF inhibitor treatment; the contribution of LEE011 in this combination will be evaluated.
3092385|NCT01777932||Cohort|
3092386|NCT01777945||Participants Receiving Capecitabine/Docetaxel|Participants received capecitabine and docetaxel according to individualized physician-prescribed regimens.
3092387|NCT01777997|Experimental|FTC/RPV/TDF|
3092388|NCT01778010|Placebo Comparator|Modafinil 0mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (0 mg/day) for 15 days, and underwent a dose response of cocaine.
3092389|NCT01778010|Experimental|Modafinil 200mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (200 mg/day) for 15 days, and underwent a dose response of cocaine.
3092390|NCT01778010|Experimental|Modafinil 400mg + Cocaine 0, 12, 25, 50 mg|Participants were maintained on modafinil (400 mg/day) for 15 days, and underwent a dose response of cocaine.
3092391|NCT01778023|Experimental|hGH:12months treatment|
3092392|NCT01778023|Active Comparator|hGH: 6 month un-treatment + 6 month treatment|
3092393|NCT01778049|Experimental|Empagliflozin 10 mg dose|Empagliflozin open label treatment period
3092394|NCT01778049|Experimental|Placebo add on 10 mg dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo add on run-in
3092395|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
3092396|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose.|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
3092397|NCT01778049|Experimental|Empagliflozin/Linagliptin 10/5 mg Dose|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
3092398|NCT01778049|Experimental|Empagliflozin 25 mg dose|Empagliflozin open label treatment period
3092399|NCT01778049|Experimental|Empagliflozin/Linagliptin 25/5 mg Dose.|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
3092400|NCT01778049|Experimental|Placebo add on 25 mg dose|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo add on run-in
3092401|NCT01778062|Experimental|Indacaterol|Indacaterol 150 µg once daily
3092402|NCT01778062|Placebo Comparator|Placebo|Placebo once daily
3092403|NCT01778127|Experimental|Group A: Minimal Rewards|Participants use an activity monitor and the interactive website. They will receive minimal rewards based on their physical activity levels.
3092404|NCT01778127|Experimental|Group B: Immediate Incentives|"Participants use an activity monitor and the interactive website.~In addition to minimal rewards, participants will receive immediate incentives as they move from one level to the other on the website."
3092405|NCT01778127|Experimental|Group C: Control|Participants in the control group will receive an activity monitor and educational materials, but will not have access to the interactive website. No rewards will be offered for their participation.
3092406|NCT01778179|Active Comparator|Group 1|"Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) plus sunscreen for 2 weeks. At week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (From Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~The investigational drug (Tri-Luma® cream) plus sunscreen will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
3092407|NCT01778179|Placebo Comparator|Group 2|"Subjects (group 2) will be treated daily for their solar lentigines with sunscreen alone for 2 weeks. At week 2, all the subjects will have the solar lentigines will treated by cryotherapy (CRY-AC3® device).~Post-procedure phase (Week 2 up to Week 13)~Topical antibiotic treatment phase (Week 2 up to Week 5 - visit 2 to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.~Treatment phase 2 (from week 5 up to week 13 - visit 3 up to visit 5):~Sunscreen alone will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
3092408|NCT01778296|Experimental|Surgical flap|The neurocutaneous island flap is based on the dorsal branch of the digital nerve
3092409|NCT01778426||Patients with Medtronic neurostimulator|Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.
3092410|NCT01778465|Experimental|Low salicylate diet, then Normal Diet|Patients followed a low salicylate diet for one week, then they followed a Normal diet for another week.
3092411|NCT01778465|Experimental|Normal diet, then Low Salicylate diet|Patients followed a Normal diet for one week, then they followed a Low Salicylate diet for another week.
3092412|NCT01778530|Experimental|TRC105 for Recurrent Glioblastoma|
3092413|NCT01778556|Experimental|Leptin naive|Studied for 5 days without metreleptin, then 14 days while taking metreleptin
3092414|NCT01778556|Experimental|On-leptin|Studied for 5 days while taking metreleptin, then 14 days during metreleptin withdrawal
3092415|NCT01778634|Placebo Comparator|Placebo (5% dextrose)|Placebo
3092416|NCT01778634|Experimental|Azithromycin|Azithromycin intravenous (2 mg/ml) 20 mg/kg every 24h x 3 days
3092417|NCT01778751|No Intervention|Control|Veterans will receive diabetes educational materials and management per their primary provider
3092418|NCT01778751|Experimental|Intervention|Veterans randomized to the intervention arm will be enrolled in the HT program, provided with standard telemonitoring equipment by HT nursing staff (current HT practice at DVAMC is use of the Health Buddy 3 device for patients with landline phones and the Cardiocom Interactive Voice Response System for patients with cell phones), and will receive the study intervention for 6 months. Veterans without depressive symptoms on baseline PHQ-9 assessment (PHQ-9 < 10) will not initially be entered into the depressive symptom management component of the intervention, but will be monitored for new symptoms throughout the intervention.
3092419|NCT01778855|Active Comparator|Normothermia|IV t-PA and normothermia
3092420|NCT01778855|Active Comparator|Hypothermia|IV t-PA and hypothermia
3092421|NCT01778985|Experimental|Premarin|Premarin cream 0.625mg/1gm. Applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
3092422|NCT01778985|Placebo Comparator|Placebo|Placebo cream, applied to vagina by applicator as 1gm nightly for 2 weeks then 1gm 2 nights per week for 4-6 weeks or until day of surgery.
3092423|NCT01779024|Experimental|ASA/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first ASA visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second ASA visit.
3092424|NCT01779024|Placebo Comparator|ASA/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first ASA visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second ASA visit
3092425|NCT01779024|Experimental|fMRI/Ghrelin|Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the first fMRI visit; Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the second fMRI visit.
3092426|NCT01779024|Placebo Comparator|fMRI/Placebo|Intravenous placebo [packed in Dextrose 5% / Water USP 50mL bags and made identical to ghrelin in terms of appearance, texture, and odor] was administered on the first fMRI visit; Intravenous acyl-ghrelin [a loading dose (3 mcg/kg), followed by a continous infusion (16.9 ng/kg/min)] was administered on the second fMRI visit
3092427|NCT01779141||CSII|Patients using CSII with or without CGM.
3092428|NCT01779167|Experimental|All Patients|Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM
3092429|NCT01779219|Active Comparator|iMRI-guided|Intervention: iMRI-guided brain tumour biopsy. The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet imager will be used in all cases. After the patient's positioning, the preoperative reference examination is routinely carried out. The entry point, target and optimal biopsy trajectory are then defined by the operator on the basis of the obtained iMRI images. Serial tissue samples are collected. Following each operation, a control iMRI (T1-weighted, axial, 4 mm scan examination) is routinely performed to confirm and document the proper targeting and to exclude postoperative hyperacute intraparenchymal bleeding.
3092430|NCT01779219|Active Comparator|non-iMRI|Intervention: Stereotactic frameless brain tumour biopsy. A frameless STx biopsy is performed for each patient from the control group with the use of a neuronavigation system. The entry point, target and optimal biopsy trajectory are defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
3092431|NCT01779375|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
3092432|NCT01779375|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
3092433|NCT01779440|Other|Electronic Decision Support System|The Electronic Decision Support System is a web-based computer program designed to motivate, educate, and engage people with severe mental illness into evidence-based smoking cessation treatment.
3092434|NCT01779440|Placebo Comparator|Control Computer Program|A computer program aimed to educate people about smoking cessation treatment.
3092435|NCT01779648|Active Comparator|Simultaneous compression+Fixed refill time|Simultaneous bilateral compression with fixed venous refill time through the whole duration of pneumatic compression
3092436|NCT01779648|Active Comparator|Alternate compression+Adjusted refill time|alternate bilateral compression with adjusted venous refill time which would change several times during pneumatic compression
3092437|NCT01779700|Active Comparator|Fingolimod|0.5mg of fingolimod, oral administration, daily, for 8 weeks.
3092438|NCT01779700|Placebo Comparator|placebo|placebo, oral administration, daily, for 8 weeks.
3092439|NCT01779856|Other|REVEAL Insertable Cardiac Monitor (ICM)|Monitoring of cardiac arrhythmic events and the relationship between such events and the characteristics.
3092440|NCT01779869|Experimental|Single group assignment - imaging|All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.
3092441|NCT01780324|No Intervention|No lidocaine|This group will have urinary catheterization without lidocaine (per standard procedure)
3092442|NCT01780324|Experimental|Lidocaine|The Intervention is the application of intraurethral lidocaine 5 minutes prior to urethral catheterization.
3092443|NCT01780337|Active Comparator|Oxytocin|Patients will be administered an intranasal dose of the study drug, 20 IU oxytocin. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
3092444|NCT01780337|Placebo Comparator|Saline|Patients will be administered an intranasal dose of saline. Repeat electrophysiologic measurements will be assessed at 15 minutes and 30 minutes after administration of the study medication/placebo. During the waiting periods in between the electrophysiologic measurements, we will continue with the standard protocol for an AF ablation, including transseptal puncture and left atrial mapping, performed prior to initiation of general anesthesia and actual delivery of ablation lesions. This 'preablation' period normally takes 45 minutes to one hour.
3092445|NCT01780350|Experimental|ResQGARD ITD|Subjects receive a ResQGARD ITD.
3092446|NCT01780389|Experimental|Milnacipran|Open-label flexibly dosed milnacipran
3092447|NCT01780454|Experimental|Combined Bone Marrow and Kidney Transplantation|Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
3092448|NCT01780506|Experimental|E/C/F/TAF (Double-Blind Phase)|E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks
3092449|NCT01780506|Active Comparator|E/C/F/TDF (Double-Blind Phase)|E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks
3092450|NCT01780506|Experimental|Open-Label Extension Phase|After study unblinding, participants who complete 144 weeks of the study had the option to receive open-label E/C/F/TAF until commercially available, or until Gilead Sciences terminated the study in that country.
3092451|NCT01780545|Experimental|Experimental Arm: Arm A|Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle.
3092452|NCT01780545|Active Comparator|Control Arm: Arm B|Docetaxel (75 mg/M2) will be administered IV on day 1 of each 21 day cycle for a maximum of 10 cycles.
3092453|NCT01780584|Active Comparator|Oral T3 low dose & placebo|Oral T3 low dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) starting on induction of anesthesia and then every 24 hours alternating with placebo, which was given 12 hours after the first dose of oral T3 and then every 24 hours until 60 hours post anesthesia induction (3 doses oral T3, 3 doses placebo)
3092454|NCT01780584|Placebo Comparator|Placebo|Placebo (saccharin lactic) administer through nasogastric tube, given starting on induction of anesthesia and then every 12 hours until 60 hours post-anesthesia induction (6 doses total)
3092455|NCT01780584|Experimental|Oral T3 high dose|Oral T3 high dose administer through nasogastric tube 0.5 mcg/kg (max 10 mcg) q12h starting on induction of anesthesia until 60 hours post-anesthesia (6 doses oral T3)
3092456|NCT01780662|Experimental|Treatment (brentuximab vedotin, gemcitabine hydrochloride)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.
3092457|NCT01780831|Experimental|Cohort 1|"HIV-1-exposed full-term infants. Infants received two single doses of RAL: first dose within 48 hours of birth and second dose at 7-10 days of life:~RAL-naive: 3 or 2 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life.~RAL-exposed: 1.5 mg/kg within 48 hours of birth and 3 mg/kg at 7-10 days of life."
3092458|NCT01780831|Experimental|Cohort 2|"HIV-1-exposed full-term infants. Daily RAL through 6 weeks of life with first dosing within 48 hours of birth and between 12-60 hours of birth for in utero RAL-naive and RAL-exposed infants, respectively.~Daily RAL through 6 weeks of life: 1.5 mg/kg once daily during Days 1-7 of life, 3.0 mg/kg twice daily during Days 8-28 of life, and 6.0 mg/kg twice daily during Days 29-42 of life."
3092459|NCT01780870|No Intervention|Control Group|Obese, otherwise healthy people who are not receiving any nutritional,surgical or behavioral therapy
3092460|NCT01780870|Active Comparator|Weight loss group|Full Meal replacement Protocol
3092461|NCT01780922|Active Comparator|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
3092462|NCT01780922|Active Comparator|Cranberry Extract Beverage|Beverage containing cranberry: one dose of 15.2 ounces consumed within 15 minutes
3092463|NCT01780922|Placebo Comparator|Non-Cranberry Beverage|Beverage absent cranberry: one dose of 15.2 ounces consumed within 15 minutes
3092464|NCT01780935|Experimental|RBZ 0.5 mg: VA only (Group I)|RBZ 0.5 mg: Visual Acuity (VA) only (Group I) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA) loss due to neovascular (wet) age-related macular degeneration (nAMD)
3092465|NCT01780935|Experimental|RBZ 0.5 mg: VA and/or OCT (Group II)|RBZ 0.5 mg: VA and/or OCT (Group II) 0.5 mg intravitreal injections of ranibizumab with retreatment based on best-corrected visual acuity (BCVA)loss due to neovascular (wet) age-related macular degeneration (nAMD) and/or signs of wet AMD disease activity on optical coherence tomography (OCT).
3092466|NCT01780974|Placebo Comparator|Placebo|Three placebo oil capsules per day (2 caps morning, 1 cap evening) + 2 placebo LA capsules per day. Capsules will be taken with food or a meal.
3092467|NCT01780974|Experimental|Lipoic acid plus omega-3 fatty acids|Three 1-gram fish oil concentrate capsules per day (2 caps morning, 1 cap evening) containing a daily dose of 675 mg docosahexaenoic acid (DHA) and 975 mg eicosapentaenoic acid (EPA) plus 2 LA capsules per day with a daily dose of 600 mg. Capsules will be taken with food or a meal.
3092468|NCT01780987|Experimental|Apixaban|
3092469|NCT01780987|Active Comparator|UFH/Warfarin|
3092470|NCT01781078|Experimental|MRI Group|Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
3092471|NCT01781078|Experimental|Control Group|Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
3092472|NCT01781169|Experimental|Obese group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
3092473|NCT01781169|Experimental|Normal-weight group|Oral supplementation of vitamin D (cholecalciferol), 50000 IU/wk for 8 weeks.
3092474|NCT01781208|Experimental|Ultrasound-based Acoustic Radiation Force Imaging|The liver was scanned using ultrasound and ultrasound-based acoustic radiation force impulse imaging technique (ARFI).
3092475|NCT01781234|Experimental|Intranasal Insulin|Intranasal Insulin
3092476|NCT01781234|Placebo Comparator|Placebo|Placebo
3092477|NCT01781286|Active Comparator|High Protein|Higher Protein Soy-based Snacks
3092478|NCT01781286|Active Comparator|Low Protein|Typical, Low Protein Snacks
3092479|NCT01781286|No Intervention|No Snack|No Snack
3092480|NCT01781299|Active Comparator|AlloDerm RTU|Participants within this arm will have the acellular dermal matrix AlloDerm RTU implanted at the time of tissue expander placement.
3092481|NCT01781299|Active Comparator|SurgiMend PRS|Participants within this arm will have the acellular dermal matrix SurgiMend PRS implanted at the time of tissue expander placement.
3092482|NCT01781403|Experimental|Capecitabine, Temozolomide, Radiotherapy|"The total dose of radiotherapy will be 50.4 Gy, with a daily dose of 1.8 Gy administered on 5 days of each week, comprising a total of 45 Gy to the whole pelvis, followed by a 5.4 Gy boost to the primary tumor.~The doses and schedules for capecitabine will be fixed, with only temozolomide being prescribed using a dose-escalation schedule. Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break)."
3092483|NCT01781429|Experimental|BVD-523|
3092484|NCT01781468|Experimental|Arm I|Patients receive 150 mg armodafinil orally every day in the morning for 8 weeks.
3092485|NCT01781468|Placebo Comparator|Arm II|Patients receive placebo orally every day in the morning for 8 weeks.
3092486|NCT01781468|Experimental|Arm III|Patients receive 250 mg armodafinil orally every day in the morning for 8 weeks.
3092487|NCT01781481||Children and youth with IBD|Children/youth (ages 8-17) with confirmed diagnoses of IBD.
3092488|NCT01781572|Experimental|Phase Ib|"The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.~Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).~Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).~Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle)."
3092489|NCT01781572|Experimental|Phase II|"The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.~Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination."
3092490|NCT01781611|Experimental|extended release dipyridamole/aspirin|extended release dipyridamole 200mg/aspirin 25mg twice daily for 24 weeks
3092491|NCT01781611|Active Comparator|aspirin|half a tablet of a 81mg aspirin twice daily for 24 weeks
3092492|NCT01781637|Experimental|omalizumab group|Patients will receive omalizumab.
3092493|NCT01781637|Placebo Comparator|placebo|Patients will receive placebo.
3092494|NCT01781806|Active Comparator|Cohort H (PrEP)|"Participants in the H cohort will be provided with a CPP, including daily oral emtricitabine/tenofovir-based PrEP.~High Risk Cohort Criteria (one or more of the following has to be met):~No condom use during anal intercourse with ≥3 male sex partners who are HIV-positive or of unknown HIV status during the last three months.~STD diagnosis during the last 12 months.~Previous PEP use during the last 12 months (* see exclusion criteria)~Has at least one HIV infected sexual partner for ≥4 weeks."
3092495|NCT01781806|Active Comparator|Cohort LM (PEP)|Participants who do not meet criteria for High Risk (Cohort H) will be assigned to the LM (low moderate) cohort and will receive a customized prevention package based on baseline assessments (in the same manner as the Cohort H Participants). In addition, they will receive education on the availability and use of post-exposure prophylaxis.
3321167|NCT02016807||6- Prevent Lower Alimentary Mucositis|ProThelial: Arm 6 Patients anticipated to develop chemoradiation diarrhea as their prominent symptom/sign [n=30]. Intervention: ProThelial 1.5 gram taken tid x 2 days then bid swish and swallow. (Phase I)
3092496|NCT01781832|Experimental|(ARFI)-Derived Shear Wave Velocities|"This is an ultrasound-based new technique using Acoustic Radiation Force Impulse (ARFI). Shear Wave speeds are derived using ARFI.~During ultrasound scanning a sound wave is sent towards tissue. The tissue's movement in response to the wave is measured in Shear Wave Velocity, which can estimate tissue stiffness. This technique may help detect bladder wall thickness and fibrosis (thickening) in the urinary bladder of pediatric patients."
3092497|NCT01781962||All Participants|Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
3092498|NCT01781975|Experimental|Imatinib Mesylate|400 mg imatinib given once daily basis.
3092499|NCT01781975|Placebo Comparator|Placebo|Placebo given once daily basis.
3092500|NCT01782131|Experimental|Posaconazole (POS)|Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
3092501|NCT01782131|Active Comparator|Voriconazole|Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.
3092502|NCT01782222|Experimental|Rotigotine, high dose|Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
3092503|NCT01782222|Experimental|Rotigotine, low dose|Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
3092504|NCT01782222|Placebo Comparator|Placebo|Placebo transdermal patches
3092505|NCT01782313|Experimental|Treatment (tivozanib)|Patients receive tivozanib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3092506|NCT01782326|Experimental|QVA149|QVA149 (110/50 μg) once daily
3092507|NCT01782326|Active Comparator|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone (50/500μg) b.i.d
3092508|NCT01782378|Active Comparator|Real LED Treatment Series|Participants in this group receive a series of 15 real LED treatments with the helmet and intranasal devices: Transcranial NIR, 830nm LED Helmet and two intranasal nose clips (633 nm, and 810 nm, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two NIR 870nm LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. LEDs are FDA-cleared, non-significant risk. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
3092509|NCT01782378|Sham Comparator|Sham LED Treatment Series|Participants in this group first receive a series of 15 sham LED treatments with the helmet and intranasal devices containing sham LEDs (no photons were emitted): Transcranial LED Helmet and two intranasal nose clips (sham LEDs, Vielight, Inc., Toronto), 28-minute treatment, 2 days/ week, 7.5 weeks, at least 48 hours between treatments. Additionally, two sham LED cluster heads (MedX Health, Toronto) were placed over the L and R ears during the last 4 minutes of the treatment session. These participants were offered an optional Second Real Series of identical 15 real LED treatments. Both the participant and the person performing the treatment wore goggles that block red wavelength (from the red intranasal). Real or Sham LED devices look and feel identical.
3092510|NCT01782469||Rheumatoid Arthritis (RA) participants|Male or female participants at least 18 years of age with diagnosis of RA
3092511|NCT01782482|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3092512|NCT01782482|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color worn on a daily wear basis for 7 days. Lenses were worn bilaterally for a minimum of 5 days per week, 8 hours per day.
3092513|NCT01782495|Experimental|Arm A|Liver transplant recipients with HCV genotype 1 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3092514|NCT01782495|Experimental|Arm B|Liver transplant recipients with HCV genotype 1a or genotype 1b (dependent on prior treatment experience and response) infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3092515|NCT01782495|Experimental|Arm C|Liver transplant receipts with HCV genotype 1b infection who were treatment naïve or prior responders to interferon treatment without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 24 weeks.
3092516|NCT01782495|Experimental|Arm D|Liver transplant recipients with HCV genotype 1a infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (dosed 1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3092517|NCT01782495|Experimental|Arm E|Liver transplant recipients with HCV genotype 1b infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3092518|NCT01782495|Experimental|Arm F|Liver transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3092519|NCT01782495|Experimental|Arm G|Liver transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
3321168|NCT02016820|Experimental|Omeprazole (suspension)|Open-label, with all subjects receiving omeprazole
3092520|NCT01782495|Experimental|Arm H|Renal transplant recipients with HCV genotype 1a infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3092521|NCT01782495|Experimental|Arm I|Renal transplant recipients with HCV genotype 1b infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) for 12 weeks.
3092522|NCT01782495|Experimental|Arm J|Liver transplant recipients with HCV genotype 4 infection without cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3092523|NCT01782495|Experimental|Arm K|Liver transplant recipients with HCV genotype 4 infection with Child Pugh A cirrhosis received ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily) plus weight-based ribavirin (1,000 or 1,200 mg daily divided twice a day) for 24 weeks.
3092524|NCT01782664|Experimental|100 mg GSK2586184|Subjects will be randomized to 100 mg GSK2586184 twice daily for up to 84 days
3092525|NCT01782664|Experimental|200 mg GSK2586184|Subjects will be randomized to 200 mg GSK2586184 twice daily for up to 84 days
3092526|NCT01782664|Experimental|400 mg GSK2586184|Subjects will be randomized to 400 mg GSK2586184 twice daily for up to 84 days
3092527|NCT01782664|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo twice daily for up to 84 days
3092528|NCT01782664|Experimental|400 mg GSK2586184 (Cohort B)|Subjects will take 400 mg GSK2586184 twice daily for up to 84 days
3092529|NCT01782690||Erlotinib plus Gemcitabine|Patients with metastatic pancreatic cancer, who were planned to receive combination therapy of erlotinib and gemcitabine based on the investigator's assessment.
3092530|NCT01782742|Active Comparator|Bexarotene treatment Arm|"75 mg of Bexarotene BID for week 1, then increasing to 150 mg BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
3092531|NCT01782742|Placebo Comparator|Placebo|"1 placebo capsule BID for week 1, then increasing to 2 placebo capsules BID for weeks 2 to 4.~Weeks 5 to 8 is Open-label phase (150 mg BID for 4 weeks)"
3092532|NCT01782859|Placebo Comparator|Placebo|Control group
3092533|NCT01782859|Active Comparator|Prednisone/hydrocortisone|"Steroid group will receive the following:~20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital~100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by 3. Second and last dose of 100 mg hydrocortisone IV"
3092534|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|
3092535|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|
3092536|NCT01782872|Active Comparator|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|
3092537|NCT01782872|Active Comparator|Interscalene Block (ISB) - Systemic Control|
3092538|NCT01782885|Active Comparator|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts.
3092539|NCT01782885|Experimental|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks
3092540|NCT01782898|Active Comparator|Esmolol|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
3092541|NCT01782898|Placebo Comparator|.9 normal saline|.9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
3092542|NCT01782963|Experimental|Treatment Arm|"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)~Consolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15"
3092543|NCT01783054|Experimental|chemotherapy, surgery, genetic expression|"All patients enrolled on study will start study treatment on a chemotherapy treatment regimen of Gemcitabine and abraxane. Treatment will be given on days 1, 8 and 15 of each cycle for 2 cycles over the course of 12 weeks.~Patients will move on to surgery, 4-8 weeks after chemotherapy treatment. Patients must be recovered from any adverse effects of the chemotherapy before proceeding with surgery.~As part of this study, tissue samples will be collect from each patient at the time of surgery for gene expression testing"
3092544|NCT01783080|Experimental|Behavioral Activation for Return to Work|BA is a manualized psychotherapy with comparable efficacy to cognitive behavioral treatment and antidepressant medication for acute treatment of depression. In this study, BA's focus was shifted to target work dysfunction by activating the patient into employment-related goals. BA-W consisted of 12 50-minute weekly sessions. Conceptualizing work dysfunction as a product of avoidance patterns and low levels of positive reinforcement, the treatment addressed maladaptive coping strategies such as avoidance as maintaining work dysfunction beyond remission of symptoms. Rather than broadly activating patients, activity scheduling focused on tasks such as sending out resumes, calling for job interviews, and networking to meet potential employers.
3092545|NCT01783236|Placebo Comparator|Saline Placebo|Subjects will receive a saline placebo infusion administered over 15 minutes every 6 hours for 24 hours.
3092546|NCT01783236|Active Comparator|IV Acetaminophen|Subjects will receive an infusion of 1 g of intravenous acetaminophen administered over 15 minutes every 6 hours for 24 hours with a maximum dose of 4 grams.
3092547|NCT01783418|Experimental|Mindfulness intervention|
3092548|NCT01783418|Active Comparator|Wait-list control|
3092549|NCT01783444|Experimental|Capecitabine 1250 mg/m2|Capecitabine (1250 mg/m2 twice daily) for two weeks, followed by one week rest period in 3-weeks cycles (investigational arm).
3092550|NCT01783444|Experimental|Everolimus 10 mg|Everolimus (10 mg daily) (investigational arm).
3092551|NCT01783444|Active Comparator|Everolimus 10 mg + Exemestane 25 mg|Everolimus (10 mg daily) with Exemestane (25 mg daily) (control arm).
3092552|NCT01783470|Experimental|beta3-adrenergic receptor agonist|single dose. Each subject was randomized to receive placebo at one visit and then the beta3-adrenergic receptor agonist on another study day.
3092553|NCT01783483|Active Comparator|Suture Wire|The closure technique should be per surgeon and institutional preference, with documentation of the wiring technique including the wiring configuration and number of wires used. A minimum of 6 wires that cross the midline sternotomy should be used (e.g. 6 simple wires, 3 double wires, 3 figure of 8 wires, etc.).
3092554|NCT01783483|Experimental|SternaLock Blu closure system|"Patients will receive treatment option for sternal closure with the SternaLock Blue closure system at a minimum of 2 X plates on the sternal body and 1 L plate (or equivalent) on the manubrium. This technique is the standard configuration for this study, and is intended to ensure that at least 3 plates are used to achieve adequate fixation and stability, while allowing for variations in the plating configuration as a result of patient anatomy and surgeon preference. Various Sternal Blu plates may be used on the manubrium as described below, as can an additional plate on the sternal body."
3092555|NCT01783496|Active Comparator|Framed Tip|Treatment with Thermage CPT Framed Tip
3092556|NCT01783496|Experimental|Pattern Tip|Treatment with the Thermage CPT Pattern Tip
3092557|NCT01783496|Experimental|Pattern Tip Group 2|Treatment with the Thermage CPT Pattern tip
3092558|NCT01783496|Experimental|Total Tip|Treatment with the Thermage CPT Total tip
3092559|NCT01783496|Experimental|Framed and Patterned Tip|Split face treatment with the Thermage CPT Framed and Patterned tips
3092560|NCT01783496|Experimental|Total and Patterned Tip|Split face treatment with the Thermage CPT Total and Patterned tips
3092561|NCT01783522|Experimental|Arm I (preventative nutritional supplementation)|Patients receive glutamine PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3092562|NCT01783522|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID. Courses repeat every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3092563|NCT01783548|Experimental|BDP Nasal Aerosol 80 mcg/day|BDP nasal aerosol: 80 mcg dose once daily in the morning. Participants/parents administer 40 mcg BDP (one spray per nostril) during the 12-week Treatment Period.
3092564|NCT01783548|Placebo Comparator|Placebo Nasal Aerosol|Placebo nasal aerosol: Participants/parents administer placebo (no medication) (one spray per nostril) once daily in the morning during the 12-week Treatment Period.
3092565|NCT01783561|Active Comparator|early caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 15 minutes within the first 2 hours of life. If the infant is in the early caffeine group, the blinded drug will be IV caffeine citrate 20mg/kg in the first 2 hours and placebo at 12 hours of life.
3092566|NCT01783561|Placebo Comparator|Routine caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. If the infant is in the routine caffeine group, the blinded drug will be placebo in the DR and IV caffeine citrate 20mg/kg at 12 hours of life.
3092567|NCT01783574|Active Comparator|Testosterone|Testosterone cream will be applied to skin for 8 weeks. Starting dose is 10 mg daily and will be titrated based on blood levels.
3092568|NCT01783574|Placebo Comparator|Placebo|Placebo cream will appear identical to the testosterone cream and will be applied to skin for 8 weeks.
3092569|NCT01783639|Experimental|Arm 1|"Device: WIRION™ Embolic Protection System~Interventions: Carotid Artery Stent"
3092570|NCT01783678|Experimental|Genotype 2 treatment-naive|Treatment-naive (TN) participants with HIV-1 and genotype 2 HCV coinfection will receive sofosbuvir plus RBV for 12 weeks.
3092571|NCT01783678|Experimental|Genotype 2/3 treatment-experienced|Treatment-experienced (TE) participants with HIV-1 and genotype 2 or 3 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
3092572|NCT01783678|Experimental|Genotype 1/3/4 treatment-naive|Treatment naive (TN) participants with HIV-1 and genotype 1, 3, or 4 HCV co-infection will receive sofosbuvir plus RBV for 24 weeks.
3092573|NCT01783730||Participants with high rheumatoid arthritis disease activity|Participants who received adalimumab treatment
3092574|NCT01783743|Experimental|Intervention arm|"Community treatment assistants (CTA ) will receive usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.~In addition to the usual training, these CTA's will also receive an additional modest half day training for TT case recognition which is called the TT training program and TT Screening Card to help them identify TT cases and refer them for surgery."
3092575|NCT01783743|No Intervention|Usual Assessment arm|Community treatment assistants will receive only usual training, including the basic background of trachoma/trichiasis recognition, drug administration, and azithromycin dosing.
3092576|NCT01783821|Experimental|Budesonide and Formoterol|Subjects randomized to this arm will receive combined standard aerosolized doses of budesonide (0.5 mg) and formoterol (20 mcg) twice daily, with at least 6 hours between doses, for 5 days for a total of 10 doses or until hospital discharge or death, with the first dose administered as soon as possible following randomization but not later than 4 hours.
3092577|NCT01783821|Placebo Comparator|Placebo|Subjects randomized to this arm will receive normal saline, the quantity, appearance and timing of the doses the same as the intervention arm.
3092578|NCT01783847|Experimental|Recombinant human erythropoietin (EPO)|Intravenous EPO 10,000 IU for 5-13 years of age and 20,000 IU for >13 years/ day for 3 days
3092579|NCT01783847|Active Comparator|Methylprednisolone|Just Intravenous Methyl prednisolone 250 mg every 6 hours for 3 days.
3092580|NCT01783847|Other|Observation|Observation
3092581|NCT01783860|Experimental|Oral Azithromycin|Two 250 mg capsules (500 mg) of Azithromycin for the first day and 250mg/day for the next 4 days.
3092582|NCT01783860|Active Comparator|Doxycycline|Oral doxycycline 100mg capsule every 12 hours for one month
3092583|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q4|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF [vascular endothelial growth factor] Trap-Eye, BAY86-5321) every 4 weeks (2Q4) over 48 weeks.
3092584|NCT01783886|Experimental|Intravitreal Aflibercept Injection 2Q8|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every 4 weeks until Week 16 and every 8 weeks (2Q8) thereafter, over 48 weeks.
3092585|NCT01783886|Active Comparator|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks over 48 weeks.
3321169|NCT02016820|Other|Lifestyle Modification|Treated with lifestyle modification (upright feeding, smaller meals, elevation of the head of the bed, etc.)
3092586|NCT01783912|Experimental|Cognitive/Motivational Intervention Group|"This arm of the project will address the following questions:~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~After completion of experimental individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?"
3092587|NCT01783912|Active Comparator|Attention Control Group|"This arm of the project will address the following question:~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate that those who are in the experimental treatment group?~After completion of control individual sessions, do the participants in the control group utilize the quit line services at the same, greater or lesser rate than those who are in the Cognitive/Motivational Intervention Group?"
3092588|NCT01783912|No Intervention|Motivated Smokers Comparison Group|"This arm of the project will address the following question:~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Motivated Smokers Comparison group?~Do participants in the Motivated Smokers Comparison group (identified as motivated to quit upon recruitment) utilize the quit line services at the same, greater or lesser rate than those who are in the Active Control group?~Participants will not receive any intervention but will be consented and enrolled into this group and assessed for utilization of the tobacco quit line services."
3092589|NCT01783938|Experimental|Cohort A: Nivolumab followed by Ipilimumab|"Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1.~Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period."
3092590|NCT01783938|Experimental|Cohort B: Ipilimumab followed by Nivolumab|"Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period.~Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1."
3092591|NCT01783990||Active|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), and urine microalbumin:creatinine ratio were collected at study entry, annually, and exit to Follow-Up Study II. Variable-diversity-joining (VDJ) and a stored blood sample were collected at study entry and study exit. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, magnetic resonance imaging (MRI) / magnetic resonance angiography (MRA), cardiac echocardiogram, or neuropsychology testing were collected once during the study when the child was 10 years old.
3092592|NCT01783990||Passive|Complete blood counts (CBCs), reticulocytes, differential, lactate dehydrogenase (LDH), bilirubin and alanine transaminases (ALTs), cystatin C, blood urea nitrogen (BUN), Creatinine, fetal hemoglobin (HbF), pit counts, Howell Jolly Body (HJB), variable-diversity-joining (VDJ), urine microalbumin:creatinine ratio and a stored blood sample were collected at study entry and exit to Follow-Up Study II. Additional tests that include liver/spleen scan, abdominal sonogram, pulmonary function testing, MRI/MRA, cardiac echocardiogram, or neuropsychology testing were collected as part of clinical care.
3092593|NCT01784029|Experimental|Low Dose|"VItamin D3 1,000 IU~1 x day, 8 weeks"
3092594|NCT01784029|Experimental|Weekly High Dose|"Vitamin D3 50,000 IU~1x week, 8 weeks"
3092595|NCT01784029|Experimental|Daily High Dose|"Vitamin D3 5,000 IU~1x day, 8 weeks"
3092596|NCT01784068|Experimental|Nilotinib followed by treatment-free|Patients who received a minimum of 2 years of first line nilotinib treatment and with pre-screen PCR results in ≥ MR4.5 entered the consolidation phase of the study (52 weeks - nilotinib 300 mg BID). Patients with Minimal Residual Disease (MRD) at the end of this phase entered the Treatment-Free Remission (TFR) phase where no treatment was given. Non eligible patients will enter the continuation phase of the study. Patients with MRD at the end of the continuation phase will enter the TFR-2 phase of the study where no treatment is given. Non eligible patients will enter the prolonged continuation phase of the study. If at any time during TFR or TFR-2 the patient loses MMR, nilotinib treatment will be immediately re-initiated (nilotinib 300 mg BID).
3092597|NCT01784211|Experimental|LY2605541 (Part A)|0.5 units per kilogram (U/kg) LY2605541 subcutaneously (SC) once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
3092598|NCT01784211|Active Comparator|Glargine (Part A)|0.5 U/kg insulin glargine SC once daily for 15 days. Part A involved 3 clamp procedures on Days 8, 11, and 14. Participants remained on their regular physician-prescribed mealtime insulin.
3092599|NCT01784211|Experimental|First LY2605541 + Exercise,Then LY2605541 Alone (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20).Participants remained on their regular physician-prescribed mealtime insulin.
3092600|NCT01784211|Experimental|First LY2605541 Alone, Then LY2605541 + Exercise (Part B)|0.5 U/kg LY2605541 SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17). Participants remained on their regular physician-prescribed mealtime insulin.
3092601|NCT01784211|Active Comparator|First Glargine + Exercise, Then Glargine Alone (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 17 (no exercise on Day 20). Participants remained on their regular physician-prescribed mealtime insulin.
3092602|NCT01784211|Active Comparator|First Glargine Alone, Then Glargine + Exercise (Part B)|0.5 U/kg insulin glargine SC once daily for an additional 6 days, beginning on Day 16. Exercise challenge on Day 20 (no exercise on Day 17).
3092603|NCT01784419|Experimental|ivacaftor-placebo|The ivacaftor-placebo arm receives a 2 week course of ivacaftor 150 mg twice daily followed by a 2 week washout period followed by a 2 week placebo course.
3092604|NCT01784419|Experimental|placebo-ivacaftor|The placebo-ivacaftor arm receives a 2 week placebo course followed by a 2 week washout period followed by a 2 week course of ivacaftor 150 mg twice daily.
3092605|NCT01784523|No Intervention|Standard treatment|patients randomized to standard treatment will not receive hydroxychloroquine.
3092606|NCT01784523|Experimental|Hydroxychloroquine|Patients will be randomized to receive standard of care or standard of care + hydroxychloroquine. Dose will be weight-adjusted: 200 mg daily for patients weighing <60kg; and 400 mg daily (200 mg twice a day)for patients weighing >60kg.
3092607|NCT01784588|Active Comparator|Solyx Single Incision Sling System|Solyx Single Incision Sling System
3092608|NCT01784588|Active Comparator|Obtryx II Sling System|Obtryx II Sling System
3092609|NCT01784614|Experimental|0.1 milligrams (mg) LY2624803|Single dose of 0.1 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3092610|NCT01784614|Experimental|1.0 mg LY2624803|Single dose of 1.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3092611|NCT01784614|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3092612|NCT01784614|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods
3092613|NCT01784614|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods
3092614|NCT01784666|Experimental|Isradipine-Isradipine|Subjects will receive isradipine in phase 1 (4 weeks) and phase 2 (4 weeks)
3092615|NCT01784666|Experimental|Placebo -> Isradipine|Placebo non-responders after the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the next 4 weeks
3092616|NCT01784666|Placebo Comparator|Placebo-Placebo|Placebo nonresponders for the 1st 4 weeks will be re-randomized 1:1 to placebo or isradipine for the subsequent 4 weeks
3092617|NCT01784770||Azithromycin IV|Subjects who are treated with Azithromycin IV for Legionnaires' disease
3092618|NCT01784796|Experimental|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction program
3092619|NCT01784796|Active Comparator|Health education program|8 week Health Education program
3092620|NCT01784848|Experimental|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity.
3092621|NCT01784848|Active Comparator|Clinical treatment|Optimized clinical treatment including medical management of hypertension.
3092622|NCT01784861|Experimental|Phase I Dose Level 0: X-82 + Everolimus|"X-82 100 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3092623|NCT01784861|Experimental|Phase I Dose Level 1: X-82 + Everolimus|"X-82 150 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3092624|NCT01784861|Experimental|Phase I Dose Level 2: X-82 + Everolimus|"X-82 200 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3092625|NCT01784861|Experimental|Phase II: X-82 + Everolimus|"X-82 (dose determined by Phase I portion to be 300 mg) mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~28 days =1 cycle"
3092626|NCT01784861|Experimental|Phase I Dose Level 3: X-82 + Everolimus|"X-82 300 mg by mouth once daily~Everolimus 10mg by mouth once daily for each cycle~Everolimus and X-82 should be taken at the same time every day~28 days =1 cycle"
3092627|NCT01784861|Experimental|Phase I Dose Level 4: X-82 + Everolimus|"Everolimus 10mg by mouth once daily for each cycle MUST BE TAKEN FIRST~X-82 400 mg by mouth once daily 2 HOURS AFTER everolimus dose~28 days =1 cycle"
3092628|NCT01784926|Other|IOL repositioning|Operation method: Intraocular lens repositioning by scleral suturing
3092629|NCT01784926|Other|IOL exchange|Operation method: Intraocular lens exchange with retropupillary iris-claw lens
3092630|NCT01784965|Placebo Comparator|placebo|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
3092631|NCT01784965|Active Comparator|liraglutide|Both groups receive dietary weight loss intervention In addition one group received liraglutide and one group received placebo
3092632|NCT01785069|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
3092633|NCT01785069|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
3092634|NCT01785069|Experimental|Revision-Augmentation|Women who had revision of a previous breast augmentation with NATRELLE® 410 implants.
3092635|NCT01785069|Experimental|Revision-Reconstruction|Women who had revision of a previous breast reconstruction with NATRELLE® 410 implants.
3092636|NCT01785095|Experimental|FSH|FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator.
3092637|NCT01785134|Sham Comparator|Control|Gastric bypass operation without omentectomy.
3092638|NCT01785134|Active Comparator|Omentectomy|Gastric bypass operation in conjunction with removal of greater omentum
3092639|NCT01785160|Active Comparator|Raltegravir|coated tablets, oral administration with 240 ml water
3092640|NCT01785160|Experimental|Raltegravir + Faldaprevir|coated tablets and soft gelatine capsule, oral administration with 240 ml water
3092641|NCT01785186|Experimental|Arm 1 (R35)|Arm 1 (R35): HR35ZE isoniazid, rifampicin 35 mg/kg, pyrazinamide, ethambutol
3092642|NCT01785186|Experimental|HRZQ|Arm 2 (Q): HRZQ isoniazid, rifampicin standard, pyrazinamide, SQ109 300 mg
3092643|NCT01785186|Experimental|HR20ZQ|Arm 3 (R20Q): HR20ZQ isoniazid, rifampicin 20 mg/kg, pyrazinamide, SQ109 300 mg
3092644|NCT01785186|Experimental|HR20ZM|Arm 4 (R20M): HR20ZM isoniazid, rifampicin 20 mg/kg, pyrazinamide, moxifloxacin 400 mg
3092645|NCT01785186|Active Comparator|HRZE|HRZE: Isoniazid, rifampicin standard, pyrazinamide, ethambutol
3092646|NCT01785459|Active Comparator|standard care|intravenous Prochlorperazine
3092647|NCT01785459|Experimental|treatment|0.5% bupivacaine
3092648|NCT01785472|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily(qd) for eight weeks along with placebo of Olmesartan 20 mg capsule once daily.
3092649|NCT01785472|Experimental|LCZ696 400 mg|Patients will start with one LCZ696 200 mg tablet and one placebo of LCZ696 once daily (qd) for one week, thereafter all patients in the treatment group will be up-titrated to two LCZ696 200 mg tablets (400 mg of LCZ696) qd for the remaining seven weeks. Placebo of Olmesartan 20 mg capsule once daily also will be taken.
3092650|NCT01785472|Active Comparator|Olmesartan 20 mg|Patients will be treated with Olmesartan 20 mg for eight weeks once daily along with placebo of LCZ696 tablets once daily.
3092651|NCT01785524|Experimental|BR Juice (Beet-It Stamina Shot) & Supervised Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of beetroot juice and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3092652|NCT01785524|Placebo Comparator|BR Juice Placebo and Exercise Training|Subjects consume 70 ml of Beetroot Juice (Beet-It Stamina Shot; Placebo) to assess acute effects of beverage supplementation at the start (between Testing Visits 1 & 2) and at the end of the trial (between Visits 3 & 4). It also allows for comparisons of the combination of placebo beverage and chronic training effects (between Visits 2 & 3) to when the subject has not consumed the beverage (Visits 1 & 4). All subjects will consume Beet-It Stamina Shot (Placebo) 3 hours prior to all beverage tolerance visits, Testing Visits 2 & 3 and for all supervised exercise training visits during the 12 week intervention.
3092653|NCT01785602|Experimental|QAW039|Participants received QAW039 450 mg daily by mouth.
3092654|NCT01785602|Placebo Comparator|Placebo|Participants received matching placebo to QAW039.
3092655|NCT01785615|Experimental|Atorvastatin|44 women randomized to 80 mg atorvastatin for 6weeks
3092656|NCT01785615|Placebo Comparator|sugar pill|44 women randomized to placebo for 6 weeks
3092657|NCT01785628|Experimental|Sarcosine capsule|Oral capsules of Sarcosine (0.5g capsule) 1g / bid for 8 weeks.
3092658|NCT01785628|Placebo Comparator|Placebo capsule|Oral capsules of Placebo (Dextrin 0.5g capsule) 1g / bid for 8 weeks.
3092659|NCT01785680|Active Comparator|Current protocol|These treatment arm is the standard care for moderate malnutrition. This includes a fortified cereal supplement treatment until the child reaches MUAC of above 12.5. Currently, MAM and SAM are treated separately, overseen by different agencies. Breastfeeding is often overlooked.
3092660|NCT01785680|Experimental|Integrated Protocol|Integrated protocol for treatment of children with MAM and SAM in humanitarian emergencies has the potential to result in a more streamlined, cost-effective program, higher recovery, and higher program coverage, allowing easier access to malnourished children, thus curing more children of malnutrition and preventing its lifelong effects.
3092661|NCT01785810|Experimental|Maraviroc|Phase II, single arm, single center trial, assessing the efficacy of the combination of tacrolimus, methotrexate and maraviroc as graft-versus-host disease (GVHD) prophylaxis after unrelated donor peripheral blood stem-cell transplantation in patients with hematologic malignancies. Patients enrolled on this trial will receive a standard conditioning regimen with fludarabine and busulfan followed by a peripheral blood stem cell infusion from an unrelated donor, standard GVHD prophylaxis and standard antiviral and antifungal prophylaxis. In addition, all patients will receive maraviroc from day -3 to d+ 90.
3092662|NCT01785849|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
3092663|NCT01785849|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
3092664|NCT01785875|Experimental|Etelcalcetide|Participants received etelcalcetide at a starting dose of 5 mg three times a week (TIW) for up to 52 weeks. Etelcalcetide dose could be increased at weeks 5, 9, 17, 25, 33, 41, and 49 to a maximum dose of 15 mg to achieve predialysis serum parathyroid hormone levels ≤ 300 pg/mL.
3092665|NCT01786109|Experimental|Dronabinol 2.5 mg|One dose of dronabinol 2.5 mg was taken orally with water.
3092666|NCT01786109|Experimental|Dronabinol 5 mg|One dose of dronabinol 5 mg was taken orally with water.
3092667|NCT01786109|Placebo Comparator|Placebo|One dose of placebo was taken orally with water.
3092668|NCT01786148|Active Comparator|Educational music mobile app|A prerecorded program of songs on various topics in a mobile phone application (app). It is designed to provide education about non-health related topics and will be equivalent in length to the intervention app.
3092669|NCT01786148|Experimental|Live Network mobile phone App|The LN is a prerecorded mobile phone application (app). It employs a radio talk show format in which a Disc Jockey entertains HIV medication-, adherence-, and self-management-related questions and comments from callers and poses them to expert care providers, whose responses to these questions are augmented by songs that shed additional light on these issues.
3092670|NCT01786161|Experimental|Vancomycin with continuous infusion|24 hours continuous infusion
3092671|NCT01786161|Active Comparator|Vancomycin with intermittent dose interval|infusion rate 1000mg/hr
3092672|NCT01786174|Experimental|Gilenya (fingolimod)|0.5mg Gilenya (fingolimod) orally once daily for 28 days +/- 3 days
3092673|NCT01786174|Placebo Comparator|Placebo|0.5mg placebo (sugar pill) orally once daily for 28 days +/- 3 days
3092674|NCT01786187|Active Comparator|Symptom Experience Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
3092675|NCT01786187|Experimental|Light Physical Activity Group|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
3092676|NCT01786239|Experimental|Omega-3 capsules & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
3092677|NCT01786239|Other|Placebo & Risperidone|Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.
3092678|NCT01786252|Experimental|Drug: human chorionic gonadotropin (hCG)|"Drug: human chorionic gonadotropin (hCG). A single intrauterine infusion of 500IU hCG dissolved in IVF media (Global-trademark) will be administered to participants in the experimental group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic where a uterine lavage and an endometrial biopsy will be performed to obtain a sample of uterine secretory proteins and endometrial tissue, respectively, for research analysis."
3092679|NCT01786252|Placebo Comparator|"IVF media (Global-trademark)"|Placebo Comparator for hCG. A single intrauterine infusion of IVF media without hCG will be administered to participants in the control group three days after oocyte retrieval. Two days after this infusion, participant will return to clinic and a sample of uterine secretory proteins and endometrial tissue, will be obtained via uterine lavage and endometrial biopsy, respectively, for research analysis.
3092680|NCT01786330|Experimental|Intervention|Group receives elastic abdominal binders after surgery. Binder used is Procare manufactured by DJO, LLC. Binders are to be worn for 24 hours after surgery.
3092681|NCT01786330|Active Comparator|Control|Group receives standard of care
3092682|NCT01786343|Experimental|Decitabine - 5 Day Regimen|Decitabine 20 mg/m2 by vein daily for 5 days.
3092683|NCT01786343|Experimental|Decitabine - 10 Day Regimen|Decitabine 20 mg/m2 by vein daily for 10 days.
3092684|NCT01786512|Placebo Comparator|Dose-escalation Cohort 1: Placebo|Participants received placebo tablets twice a day (BID) for 7 days.
3092685|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil (OM) Matrix F1 (M-F1) tablets twice a day for 7 days.
3092686|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg M-F2|Participants received 25 mg omecamtiv mecarbil Matrix F2 (M-F2) tablets twice a day for 7 days.
3092687|NCT01786512|Experimental|Dose-escalation Cohort 1: Omecamtiv Mecarbil 25 mg SCT-F2|Participants received 25 mg omecamtiv mecarbil swellable core technology F2 (SCT-F2) tablets twice a day for 7 days.
3092688|NCT01786512|Placebo Comparator|Dose-escalation Cohort 2: Placebo|Participants received placebo tablets twice a day for 7 days.
3092689|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F1|Participants received 50 mg omecamtiv mecarbil M-F1 tablets twice a day for 7 days.
3092690|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg M-F2|Participants received 50 mg omecamtiv mecarbil M-F2 tablets twice a day for 7 days.
3092691|NCT01786512|Experimental|Dose-escalation Cohort 2: Omecamtiv Mecarbil 50 mg SCT-F2|Participants received 50 mg omecamtiv mecarbil SCT-F2 tablets twice a day for 7 days.
3092692|NCT01786512|Placebo Comparator|Expansion Phase: Placebo|Participants received placebo tablets twice a day for 20 weeks.
3092693|NCT01786512|Experimental|Expansion Phase: Omecamtiv Mecarbil 25 mg M-F1|Participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day for 20 weeks.
3092694|NCT01786512|Experimental|Expansion Phase: OM M-F1 PK-based Titration|All participants received 25 mg omecamtiv mecarbil M-F1 tablets twice a day. At week 8 the dose escalated to 50 mg twice a day if the week 2 predose plasma concentration of OM was less than the predefined cutoff of 200 ng/mL.
3092695|NCT01786551|Experimental|Eplerenone|Eplerenone 50 mg daily for 14 days
3092696|NCT01786603|Experimental|Rasagiline|Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.
3092697|NCT01786603|Placebo Comparator|Placebo|Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.
3092698|NCT01786629|Experimental|SUPREP Bowel Prep Kit|SUPREP Bowel Prep Kit
3092699|NCT01786629|Active Comparator|FDA approved bowel preparation|FDA approved bowel preparation containing electrolytes
3092700|NCT01786668|Experimental|Tofacitinib 2 mg|
3092701|NCT01786668|Experimental|Tofacitinib 5 mg|
3092702|NCT01786668|Experimental|Tofacitinib 10 mg|
3092703|NCT01786668|Placebo Comparator|Placebo|
3092704|NCT01786707|Experimental|Autologous SC and HOT|Autologous stem cells and hyperbaric oxygen therapy
3092705|NCT01786707|Active Comparator|Control group|Patients in a control group will continue with standard medical treatment (Insulin and Metformin)
3092706|NCT01786876|Experimental|Radiolabeled SPD557|
3092707|NCT01786902|Experimental|DA-3002 Treatment group|1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)
3092708|NCT01786902|No Intervention|Non-treatment control group|Height be measured with no treatment
3092709|NCT01786954|Experimental|Icare then Goldmann then Tonopen|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.
3092710|NCT01786954|Experimental|Icare then Tonopen then Goldmann|Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.
3092711|NCT01786967|Experimental|Fesoterodine Fumarate|Participants will receive 4 mg of study drug for first 2 weeks, and then 8 mg of study drugs for 2 weeks.
3092712|NCT01786993|Experimental|Multi-point pacing arm|MultiPoint Pacing
3092713|NCT01786993|Active Comparator|Biventricular arm|Traditional Biventricular Pacing
3092714|NCT01787006|Experimental|Cetuximab, Cisplatin, 5-FU, Radiotherapy|"Cetuximab: Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total, IV~5-fluorouracil (5-FU): 1000mg/m2 per day as continuous infusion on day 8-11 and 36-39, 750mg/m2/day as continuous infusion on day 71-74 and 99-102~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 8-11, 36-39, 71-74 and 99-102)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
3321170|NCT02016833||Cancer patients|Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day
3092715|NCT01787006|Active Comparator|Cisplatin, 5-FU, Radiotherapy|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 and 29-32, 750mg/m2/day as continuous infusion on day 64-67 and 92-95~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle (day 1-4, 29-32, 64-67 and 92-95)~radiotherapy: 59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery."
3092716|NCT01787032|Experimental|Period 3: BI 113608+Voriconazole|tablets with 240 ml water
3092717|NCT01787032|Experimental|Period 2: BI 113608+Ketoconazole|tablets with 240 ml water
3092718|NCT01787032|Experimental|Period 1: BI 113608|tablets with 240 ml water
3092719|NCT01787097|Active Comparator|COPD|Participants with COPD
3092720|NCT01787097|Active Comparator|Symbicort® total dose 400ug/12ug|Symbicort® total dose 400ug/12ug: is a combination of FORM (6ug) and ICS (Budesonide, (BUD) 200ug)
3092721|NCT01787097|Active Comparator|Symbicort® total dose 800ug/24ug|Symbicort® total dose 800ug/24ug: is a combination FORM (12ug) and BUD (400ug) at a higher-dose
3092722|NCT01787097|Active Comparator|BUD total dose 800ug|BUD total dose 800ug: is an intermediate dose of ICS
3092723|NCT01787175|Experimental|Integrated Medication Manager|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
3092724|NCT01787175|No Intervention|Standard EHR|Experienced providers that participated in the EHR simulations. Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned the VA's CPRS to use (standard EHR). Providers were randomly assigned which system to use.
3092725|NCT01787188|Experimental|Meloxicam Test Capsules low dose QD|Meloxicam Test Capsules low dose QD
3092726|NCT01787188|Experimental|Meloxicam Test Capsules high dose QD|Meloxicam Test Capsules high dose QD
3092727|NCT01787188|Placebo Comparator|Placebo Capsule QD|Placebo Capsule QD
3092728|NCT01787240|Placebo Comparator|Placebo|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
3092729|NCT01787240|Experimental|Escitalopram 10mg|After a screening visit, the patient will undergo a baseline assessment and will be randomized to escitalopram 10mg or placebo.
3092730|NCT01787279|Experimental|Peginterferon alpha-2a, 180 mcg/48 weeks|Eligible participants with HI3vAg (a type of Hepatitis B surface antigen) negative chronic hepatitis B will be administered peginterferon alpha-2a (PEGASYS), 40kD, 180 micrograms (mcg) subcutaneously once weekly for 48 weeks. The untreated Follow-up will be for 24 weeks.
3092731|NCT01787292|Experimental|Stretching Exercise Intervention|A. Light stretching and balance exercises under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted to be under 50% of age-related maximum.
3092732|NCT01787292|Experimental|Aerobic Exercise Intervention|B. Interval aerobic cycling under supervised trainer. 3 times per week for 20-45 minutes. HR will be targeted between 50-85% of age-related maximum.
3092733|NCT01787292|Experimental|Self Monitoring Intervention|C. 6 month self-monitored training phase during which time participants will exercise using a take home bike ergometer.
3092734|NCT01787331|Experimental|Treatment (itraconazole)|Patients receive twice/day 300mg itraconazole (oral)
3092735|NCT01787383|Active Comparator|Ingenol mebutate gel 0.05 %|
3092736|NCT01787383|Active Comparator|Ingenol mebutate gel 0.015 %|
3092737|NCT01787461|Experimental|Imedeen|Imedeen is the study product
3092738|NCT01787461|Placebo Comparator|Placebo|
3321171|NCT02016846|Placebo Comparator|Placebo|
3092740|NCT01787591|Experimental|Acute Fat-Free Milk Ingestion|Participants will ingest 1 cup of fat-free milk with 15 mg deuterium-labeled alpha-tocopherol.
3092741|NCT01787591|Experimental|Acute Low-Fat Milk Ingestion|Participants will ingest 1 cup of low-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
3092742|NCT01787591|Experimental|Acute Full-Fat Milk Ingestion|Participants will ingest 1 cup of full-fat milk with 15 mg deuterium-labeled alpha-tocopherol.
3092743|NCT01787591|Experimental|Acute Soy Milk Ingestion|Participants will ingest 1 cup of soy milk with 15 mg deuterium-labeled alpha-tocopherol.
3092744|NCT01787604|Active Comparator|Aortic Root Reimplantation Procedure|Aortic Root Reimplantation Procedure
3092745|NCT01787604|Active Comparator|Aortic Valve Reimplantation Procedure|Aortic Valve Reimplantation Procedure
3092746|NCT01787760|Experimental|Test Soft Contact Lens B|Lenses will be worn in a daily disposable modality
3092747|NCT01787760|Experimental|Test Soft Contact Lens C|Lenses will be worn in a daily disposable modality
3092748|NCT01787760|Active Comparator|Spectacle Lenses|Control spectacle lenses worn daily.
3092749|NCT01787799|Experimental|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System)
3092750|NCT01787825|Other|PillCam SB2 then CapsoCam SV-1|PillCam SB2 capsule then CapsoCam SV-1 capsule
3092751|NCT01787825|Other|CapsoCam SV-1 then PillCam SB2|CapsoCam SV-1 capsule then PillCam SB2 capsule
3092752|NCT01787838|Other|health education, audit and feedback|Focused health education for staff and patients.
3092753|NCT01787916|Experimental|Liraglutide|Liraglutide, s.c., 1.8 mg, die, 24 weeks
3092754|NCT01787916|Placebo Comparator|Placebo|Liraglutide placebo (visually identical to study drug) will be given s.c. 1.8 mg for 24 weeks
3092755|NCT01788046|Placebo Comparator|Placebo|Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
3092756|NCT01788046|Experimental|Etelcalcetide|Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW for 26 weeks.
3092757|NCT01788150|Experimental|Svelte Drug-Eluting Coronary Stent|Coronary Stenting
3092758|NCT01788150|Active Comparator|Medtronic Resolute Integrity Drug-Eluting Stent|Coronary Stenting
3092759|NCT01788163|Other|Locally advanced/metastatic NSCLC pats.|Patients with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
3092760|NCT01788215|Active Comparator|Doxycycline|Subjects randomized to receive doxycycline for a period of 12 weeks. A 12-week period thereafter will occur off study medication. The dose of doxycycline to be used in this study is 200mg/day in divided doses of 100mg twice daily. The dose of doxycycline being used in this study is 100mg because it is the standard approved dose.
3092761|NCT01788215|Placebo Comparator|Sugar Pill|The administered placebo is to be continued for a period of 12 weeks. A 12-week period thereafter will occur off placebo control
3092762|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine 18-64 Years Group|Subjects 18-64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
3092763|NCT01788228|Experimental|Influenza A (H5N1) Virus monovalent vaccine > 64 Years Group|Subjects >64 years of age received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia) at Days 0 and 21. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm at Day 0 and dominant arm at Day 21.
3092764|NCT01788358|Experimental|Nifedipine GITS/Candesartan Cilexetil FDC (BAY98-7106)|Subjects received nifedipine gastrointestinal therapeutic system (GITS) / candesartan cilexetil fixed dose combination (FDC) (BAY98-7106) tablet orally, once daily in the morning of Visit 1 (Week 0) for 28 or 52 weeks. The starting dose (30/8 milligram [mg] or 30/16 mg) was determined based on local practice and clinical judgment by the investigator. Based on the experience of symptomatic and asymptomatic hypotension, peripheral edema or significant tolerability, the doses were up-titrated to the highest target dose (60/32 mg).
3092765|NCT01788423|Experimental|Audiologist-Based|Audiologist selects hearing aid for patient
3092766|NCT01788423|Experimental|Consumer Decides|Consumer selects hearing aid
3092767|NCT01788423|Placebo Comparator|Placebo|Patient fitted with hearing aid that is acoustically transparent.
3092768|NCT01788566|Experimental|Gemcitabine + Cisplatin + Necitumumab|"Necitumumab administered intravenously (IV) 800 milligram (mg) on Days 1 and 8 of each 3-week cycle.~Gemcitabine administered IV at 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of each 3 week cycle for a maximum of 6 cycles.~Cisplatin administered IV at 75 mg/m^2 on Day 1 of each 3 week cycle for a maximum of 6 cycles."
3092769|NCT01788631|Active Comparator|Regadenoson Arm|1.44 mcg/kg/hour infused over 48 hours
3092770|NCT01788631|Placebo Comparator|Placebo Arm|Placebo infused over 48 hours
3092771|NCT01788943||Slow metabolizers|Individuals with an NMR <0.26 will be classified as slow metabolizers.
3092772|NCT01788943||Normal metabolizers|Participants with an NMR >= 0.26 will be classified as normal metabolizers.
3092773|NCT01789047|Active Comparator|Topiramate|Topiramate as adjunct to amantadine.
3092774|NCT01789047|Placebo Comparator|Placebo (sugar pill)|Placebo
3092775|NCT01789138|Experimental|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention: see 'Interventions' for more details.
3092776|NCT01789138|No Intervention|Adherence counseling, standard of care|Standard of care: Antiretroviral therapy adherence is discussed with patient (study participant) according to usual practice in the medical institution no special protocol followed.
3092777|NCT01789203|Active Comparator|Ciprofloxacin|Ciprofloxacin will be administered as two-250 mg capsules, administered once daily for 3 months post-transplant
3092778|NCT01789203|Placebo Comparator|Placebo|Matching placebo will be administered as two-capsules given once daily for 3 months post-transplant
3092779|NCT01789255|Experimental|Supportive care (vorinostat, tacrolimus, methotrexate)|Patients receive vorinostat PO BID on days -10 to 100. Beginning on day -3, patients receive tacrolimus IV continuously or PO BID (or cyclosporine IV continuously or PO in patients unable to tolerate tacrolimus) with taper on days 100-180.Patients also receive methotrexate IV QD on days 1, 3, 6, and 11.
3092780|NCT01789281|Experimental|Everolimus|Participants who were receiving everolimus in a Novartis-sponsored study, were not progressing on the current study treatment and were unable to access everolimus treatment outside of a clinical trial. Participants receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol were allowed to continue Sandostatin LAR Depot treatment.
3092781|NCT01789320|Experimental|triamcinolone acetonide (Triesence®)|TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) in a total volume of 100 uL administered via microneedle directly to the suprachoroidal space (SCS)
3092782|NCT01789476|Experimental|CR845|Peripheral kappa opioid receptor agonist
3092783|NCT01789476|Placebo Comparator|Placebo|Matched placebo
3092784|NCT01789567|Other|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
3092785|NCT01789606|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|
3092786|NCT01789775|Placebo Comparator|CD07805/47 gel Placebo|Placebo
3092787|NCT01789775|Experimental|CD07805/47 gel|Intervention: Drug: CD07805/47 gel
3092788|NCT01789814|Active Comparator|Prasugrel|Prasugrel oral loading dose of 60 mg administered preceding cardiac intervention
3092789|NCT01789814|Active Comparator|Clopidogrel|Clopidogrel oral loading dose of 600 mg administered preceding cardiac intervention
3092790|NCT01789840|Experimental|Prostate artery embolization (PAE)|Prostate artery embolization using Embosphere Microspheres
3092791|NCT01789840|Active Comparator|Transurethral resection of the prostate (TURP)|Transurethral Resection of the Prostate (TURP)
3092792|NCT01789905||Tigecycline (Tygacil)|Subjects who are treated with tigecycline
3092793|NCT01789970|Placebo Comparator|Placebo|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets twice a day that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
3321172|NCT02016846|Active Comparator|Intervention|Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.
3321173|NCT02016859||Critically ill patients admitted to ICU|those patients who are admitted to ICU with multiorgan failure/injury
3321174|NCT02016859||Neutropinc Fever patients|admitted to ER, haemato-oncology or oncology
3092794|NCT01789970|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets twice a day at the dosage deemed successful for managing their pain during the titration period.
3092795|NCT01790048|Experimental|Whey permeate RUSF|75 kcal/kg/day (314 k Joules (kJ)/kg/day) of whey RUSF. Whey RUSF contains whey permeate, Whey Permeate (WPC) 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier. Whey permeate RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
3092796|NCT01790048|Active Comparator|Soy Protein RUSF|75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources. Soy RUSF will be locally produced and will undergo quality assurance and safety testing for aflatoxin and microbial contamination at the Malawi Bureau of Standards and Eurofins Scientific Inc., Des Moines, Iowa, USA.
3092797|NCT01790113|Active Comparator|Univer™ II|Univers™ II Total Shoulder Replacement
3092798|NCT01790113|Experimental|Eclipse™|Eclipse™ Total Shoulder Replacement
3092799|NCT01790126|Active Comparator|ARN-509|ARN-509 Tablets, 240 mg/day administered orally
3092800|NCT01790126|Active Comparator|LHRH agonist + ARN-509|Choice of LHRHa per investigator discretion/site practice guidelines (e.g, Eligard®, Zoladex®, Lupron Depot®, Trelstar®) and ARN-509 Tablets, 240 mg/day administered orally
3092801|NCT01790126|Active Comparator|LHRH agonist|Choice of LHRHa per investigator discretion/site practice guidelines (e.g., Eligard®, Zoladex®, Lupron Depot®, Trelstar®).
3092802|NCT01790178|Experimental|Ultrasound Guided Biopsy|Ultrasound guided biopsy will be used in all patients.
3092803|NCT01790178|No Intervention|Non-Ultrasound Guided Group|The control group will have non-ultrasound guided biopsies performed, which is the current standard of care.
3092804|NCT01790243|Experimental|Lutonix Drug Coated Balloon|Formerly called the Moxy Drug Coated Balloon, the Lutonix Drug Coated Balloon (Lutonix DCB) is a paclitaxel coated balloon catheter
3092805|NCT01790243|Active Comparator|Standard Uncoated Angioplasty Balloon|PTA Catheter
3092806|NCT01790295|Experimental|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 62 days (day -67) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
3092807|NCT01790438|Experimental|LY2605541|Administered by subcutaneous (SC) injection once daily in the morning or at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on Fasting Blood Glucose (FBG). LY2605541 will be given alone or in combination with up to 3 pre-study oral antihyperglycemic medications [OAM(s)] whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks.
3092808|NCT01790438|Active Comparator|Human Insulin NPH|Administered by SC injection once daily at bedtime. Initial dose is 10 units (or less for some of the participants in Korea) and is adjusted weekly based on FBG. Human insulin NPH will be used alone or in combination with up to 3 pre-study OAM(s) whose use is not excluded in combination with insulin. Treatment may last up to 26 weeks. Some participants who are unable to achieve glycemic control after at least 12 weeks of treatment with a single injection of NPH may be asked to add a second injection prior to the morning meal.
3092809|NCT01790490|Experimental|K1|Ketamine 0.41 mg/kg infused over 52 min (K1)
3092810|NCT01790490|Experimental|K2|Ketamine 0.71 mg/kg infused over 52 min (K2)
3092811|NCT01790490|Experimental|LZP|Lorazepam 2 mg infused over 52 minutes (LZP)
3092812|NCT01790503|Experimental|Phase 1b dose escalation - 600mg/day PLX3397 cohort|600mg/day PLX3397, Radiation Therapy, and Temozolomide
3092813|NCT01790503|Experimental|Phase 1b dose escalation - 800mg/day PLX3397|800mg/day PLX3397, Radiation Therapy, and Temozolomide
3092814|NCT01790503|Experimental|Phase 1b dose escalation - 1000 mg/day PLX3397 cohort|1000 mg/day PLX3397, Radiation Therapy, and Temozolomide
3092815|NCT01790503|Experimental|Phase 2 - Recommended phase 2 dose of PLX3397|Recommended phase 2 dose of PLX3397 (800mg/day), Radiation therapy, and Temozolomide
3092816|NCT01790516|Experimental|Cisplatin|Cisplatin
3092817|NCT01790516|Experimental|Cetuximab|cetuximab
3092818|NCT01790568|Experimental|Vorinostat|Vorinostat, in combination with standard of care medications tacrolimus and methotrexate, for GVHD prophylaxis after unrelated donor stem cell transplant.
3092819|NCT01790581|Active Comparator|Balance Training|
3092820|NCT01790581|Experimental|Balance Training w/ STARS|
3092821|NCT01790594|Active Comparator|Immunosuppression without Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Tacrolimus (or generic). The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed, then adjusted to target trough levels of 8-12 ng/ml during the first 24 weeks post-transplant, then adjusted to target trough levels of 5-8 ng/ml thereafter.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
3321175|NCT02016859||Patients of Hip's Fracture|admitted to orthopedic departement
3092822|NCT01790594|Experimental|Immunosuppression Including Belatacept|"Induction: 5 day course of methylprednisolone or equivalent;~Induction: Anti-thymocyte Globulin (Rabbit);~Maintenance Immunosuppression: Belatacept~Maintenance Immunosuppression: Tacrolimus (or generic)- The site investigator will identify a starting tacrolimus dose at his or her discretion, in order to achieve the target trough levels no later than 5 days post-transplantation. Tacrolimus dosing will be initiated on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed. The dosage will be adjusted to achieve the following therapeutic trough levels: 5-8 ng/ml during the first 24 weeks post-transplant and then 3-5 ng/ml until day 280 (week 40). Subjects may be withdrawn if they meet all the criteria defined below.~Maintenance Immunosuppression: Mycophenolate mofetil (or Myfortic (mycophenolate sodium), or generic)."
3092823|NCT01790633|Active Comparator|Standard testing with ELISA|HBV, HCV, and HIV infection status determined by enzyme-linked immuno-assay (ELISA).
3092824|NCT01790633|Experimental|Rapid testing|HBV, HCV, and HIV infection status determined by a rapid test
3092825|NCT01790659|Experimental|WR 279,396|(Paromomycin and Gentamicin Topical Cream)
3092826|NCT01790659|Experimental|Paromomycin|Paromomycin alone
3092827|NCT01790685|Other|CRVO|Central Retinal Vein Occlusion
3092828|NCT01790685|Other|BRVO|Branch Retinal Vein Occlusion
3092829|NCT01790750|Other|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
3092830|NCT01790828||Xyntha group|Xyntha will be administered according to physician's discretion.
3092831|NCT01790932|Experimental|BKM120|"BKM120: 100 mg capsule once daily each day of a 28 day cycle .~Treatment with BKM120 will continue until disease progression, unacceptable toxicity or withdrawal for other reasons."
3092832|NCT01790984|Experimental|High sugar low starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with low sugar to starch content, with foods containing a high sugar to starch content to reach a target ratio of starch to sugar of 1:1.2
3092833|NCT01790984|Experimental|Low sugar high starch diet|A high sugar, low starch diet was provided by the exchange of two thirds of the participants daily intake of carbohydrate. This was achieved by exchanging foods with a high sugar to starch content, with foods containing a low sugar to starch content to reach a target ratio of starch to sugar of 5:1
3092834|NCT01791127||Pacemaker Therapy|Patients with a market-released BIOTRONIK pacemaker system including one or two Siello S leads.
3092835|NCT01791153|Experimental|Part 1: Tocilizumab qw + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3092836|NCT01791153|Experimental|Part 1: Tocilizumab q2w + 26 weeks prednisone taper|Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3092837|NCT01791153|Placebo Comparator|Part 1: Placebo + 26 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
3092838|NCT01791153|Placebo Comparator|Part 1: Placebo + 52 weeks prednisone taper|Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
3092839|NCT01791153|Experimental|Part 2: Open-Label Tocilizumab qw|Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
3092840|NCT01791205||Monotherapy|Eligible participants who received any biologic drug as a monotherapy in the 12 months prior to the study entry will be observed for Phase I. Participants who were enrolled in Phase I and received tocilizumab (TCZ) as a monotherapy will be observed for 18 months from the first infusion of TCZ in Phase II, where TCZ was prescribed according to the approved product information, local treatment guidelines and/or routine clinical practice.
3092841|NCT01791205||Combination Therapy|Eligible participants who received any biologic drug in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the 12 months prior to study entry will be observed for Phase I.
3092842|NCT01791244|Active Comparator|Technical support for the RebiSmart™ device|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 microgram (mcg) subcutaneously (SC) 3 times a week in accordance to the summary of product characteristics (SPC) along with technical support for RebiSmart.
3092843|NCT01791244|Experimental|Subject support program (MinSupport Plus)|Subjects will be administered Rebif® by the RebiSmart™ device at a dose of either 22 or 44 mcg SC 3 times a week in accordance to the SPC along with subject support program MinSupport Plus which includes technical support for RebiSmart™ device, personal coaching regarding treatment and understanding of the disease, lifestyle guide and web support.
3092844|NCT01791413|Active Comparator|depot medroxyprogesterone acetate|
3092845|NCT01791413|No Intervention|No depot medroxyprogesterone acetate|
3092846|NCT01791465|Experimental|Bydureon treatment|Treatment for 16 weeks with extended-release Exenatide (Bydureon)
3092847|NCT01791491|Experimental|Belatacept|
3092848|NCT01791517|Other|Lens A (senofilcon A)|Subjects randomized to Lens A will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3092849|NCT01791517|Other|Lens B (galyfilcon A)|Subjects randomized to Lens B will be further randomized to 1 of 12 unique solution sequences; each subject will receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3092850|NCT01791517|Other|Lens C (etafilcon A)|Subjects randomized to Lens C will be further randomized to 1 of 12 unique solution sequences; each subject will l receive all four study solutions in a random order (Solution 1(Test), Solution 2(Test), Solution 3(Test), Solution 4(Control)).
3092851|NCT01791725|Experimental|ELND005 BID|ELND005 250 mg BID
3092852|NCT01791725|Experimental|ELND005 QD|ELND005 250 mg QD
3092853|NCT01791725|Placebo Comparator|Placebo|Placebo BID
3092854|NCT01791803|Experimental|Hypnotherapy|Patients admitted with a cardiopulmonary illness received a 90 minute free hypnotherapy session within 2 weeks of discharge, and a standardized tape for smoking cessation and relaxation for continued use after the session. They also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after discharge.
3092855|NCT01791803|Experimental|Nicotine Replacement Therapy|Patients recieved a free one month supply of Nicotine replacement therapy to include patches and Gum, lozenges or sprays. Patients also received self-help brochures, and counseling during hospitalization and by telephone at 1,2,4,8 and 12 weeks after hospitalization.
3092856|NCT01791803|Experimental|Hypnotherapy and Nicotine replacement|The group received similar hypnotherapy session and tape, similar brochure and counseling protocol, as well as free nicotine replacement supplies for a month after discharge.
3092857|NCT01791803|No Intervention|Self-Quit group|Patients were given brief counseling during hospitalization and will not be contacted until 26 weeks after hospitalization.
3092858|NCT01791894|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 2 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3092859|NCT01791972|Experimental|Albuterol Spiromax / Placebo Spiromax|Albuterol Spiromax, 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on Day 1. Placebo Spiromax (2 inhalations), single dose on approximately Day 7.
3092860|NCT01791972|Experimental|Placebo Spiromax / Albuterol Spiromax|Placebo Spiromax, (2 inhalations), single dose on Day 1. Albuterol Spiromax 180 mcg (2 inhalations of 90 mcg/inhalation), single dose on approximately Day 7.
3092861|NCT01792024|Experimental|Treatment (LITT)|Patients undergo Magnetic Resonance imaging (MR) guided laser thermal therapy with Visualase Thermal Therapy device.
3092862|NCT01792115|Active Comparator|Vit E 200 IU/d|Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
3092863|NCT01792115|Active Comparator|Vitamin E 400|Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
3092864|NCT01792115|Active Comparator|Vitamin E 800|Subjects randomized to vitamin E 800 IU /day for 24 weeks; invited to optional extension of open- label vitamin E 800 IU /day for up to 120 weeks following the initial 24 week period.
3092865|NCT01792284|Experimental|LY2605541 Fixed Time Dosing|"Participant-specific dose of LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks in the Lead-in Period and in Randomization Period 1 or Randomization Period 2.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on self-monitored blood glucose (SMBG). Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 milligrams/deciliter (mg/dL) Insulin adjustment and glucose correction between 71 and 100 mg/dL."
3092866|NCT01792284|Experimental|LY2605541 Variable Time Dosing|"Participant-specific dose of LY2605541 administered SQ on a variable time schedule (8- and 40-hour dosing intervals) for 12 weeks in Randomization Period 1 or Randomization Period 2. Dosing schedules were to remain approximately the same throughout the 12 weeks.~Participant-specific dose of insulin lispro SQ when >20% of calories were consumed (pre-meal).~Insulin dose and adjustments to insulin dose were determined by insulin algorithms based on SMBG. Target glucose values were as follows:~Preprandial and bedtime BG between 71 and 130 mg/dL Insulin adjustment and glucose correction between 71 and 100 mg/dL."
3092867|NCT01792518|Experimental|linagliptin 5mg|linagliptin 5 mg once daily
3092868|NCT01792518|Placebo Comparator|placebo|matching placebo for linagliptin dose once daily
3092869|NCT01792635|No Intervention|Part A (Pilot Study)|
3092870|NCT01792635|Experimental|Monotherapy (Part B)|
3092871|NCT01792817|Sham Comparator|Sham GammaCore device|The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.
3092872|NCT01792817|Experimental|GammaCore Device|Non-Invasive Vagus Nerve Stimulator
3092873|NCT01792830|No Intervention|Control HbA1c < 7%|Subjects not requiring coronary artery bypass graft surgery (CABG), with no history of diabetes with HbA1c <7% not requiring subcutaneous insulin in the hospital will be discharged on no antidiabetic therapy.
3092874|NCT01792830|Active Comparator|Diabetic/ Metformin and 50-Glargine HbA1c 7%- 9%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of basal (glargine) insulin at 50% of total daily hospital dose.
3092875|NCT01792830|Active Comparator|Diabetic/ Metformin and 80-Glargine HbA1c 7%-9%%|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c 7%- 9% will be discharged on oral metformin and a single dose of basal (glargine) insulin at 80% of total daily hospital dose or with basal bolus regimen at same inpatient total daily insulin dose.
3092876|NCT01792830|Active Comparator|No diabetes/ Metformin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia requiring subcutaneous (SC) insulin therapy in the hospital will be discharged on oral metformin.
3092877|NCT01792830|Active Comparator|Diabetic/antidiabetic regimen|Subjects requiring coronary artery bypass graft surgery (CABG) with a history of diabetes with HbA1c <7% will be discharged on their same outpatient antidiabetic regimen. Subjects will receive one of the three treatment options based on their blood glucose levels: Metformin alone, both metformin and glargine insulin or glargine alone.
3092878|NCT01792830|Active Comparator|No diabetes/ Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with no history of diabetes with HbA1c <7% and persistent hyperglycemia will be given subcutaneous (SC) insulin therapy in the hospital.
3092879|NCT01792830|Active Comparator|Diabetes/Insulin only|Subjects requiring coronary artery bypass graft surgery (CABG) with an admission HbA1c >9% and persistent hyperglycemia will be given basal insulin (glargine) once daily, at the same time of the day and rapid-acting insulin (glulisine) before meals.
3092880|NCT01792986|Other|water-only 24-hour fasting once per week for 6 weeks|
3092881|NCT01793051|Experimental|Minocycline|"Minocycline 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance chemotherapy for MM.~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
3092882|NCT01793051|Placebo Comparator|Placebo|"Placebo 200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).~Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit."
3092883|NCT01793142||Viviant treatment group|Viviant treatment group
3092884|NCT01793610|Active Comparator|Comparator-dose (40 mg) MDMA and Psychotherapy|Participants receive an initial dose of comparator-dose MDMA (40 mg) during each of the two experimental sessions.
3092885|NCT01793610|Experimental|Active Dose 2 (100 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 2 MDMA (100 mg) during each of the two experimental sessions.
3092886|NCT01793610|Experimental|Active Dose 1 (125 mg) MDMA and Psychotherapy|Participants receive an initial dose of Active Dose 1 MDMA (125 mg) during each of two experimental sessions.
3092887|NCT01793688||Sulbactam Sodium/Ampicillin Sodium|Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) by intravenous injection or intravenous drip infusion from the first dosing date or the second dosing date: Pneumonia, Lung Abscess, Peritonitis.
3092888|NCT01793792|Other|Device: LVIS|"The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.~Device: LVIS™ and LVIS™ Jr. MicroVention Low-profile Visualized Intraluminal Support Device"
3092889|NCT01793883|Active Comparator|40 mg Laninamivir Octanoate DPI|40 mg Laninamivir Octanoate and matching placebo
3092890|NCT01793883|Active Comparator|80 mg Laninamivir Octanoate DPI|80 mg Laninamivir
3092891|NCT01793883|Placebo Comparator|Placebo|Matching Placebo
3092892|NCT01793909|Other|Single Leg Exercise|Supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
3092893|NCT01793935|Experimental|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera
3092894|NCT01793935|Placebo Comparator|Placebo|Placebo
3092895|NCT01794000|Experimental|Prasugrel|Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
3092896|NCT01794000|Placebo Comparator|Placebo|Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
3092897|NCT01794039|Experimental|Arm A (lenalidomide, dexamethasone)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may crossover to arm B.
3092898|NCT01794039|Experimental|Arm B (pomalidomide, dexamethasone)|Patients receive pomalidomide PO daily on days 1-21 and dexamethasone as in arm A. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3092899|NCT01794117|Experimental|Arm A/Anakinra 100 mg/day|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg at week 8.
3092900|NCT01794299|Experimental|ATIR|
3092901|NCT01794312|Experimental|T4020|One drop every 2 days
3092902|NCT01794312|Placebo Comparator|Vehicle|One drop every 2 days
3092903|NCT01794455|Experimental|Phase 1: Sertraline|Eight-week trial of sertraline mono therapy, dosing ranging from 50mg- 200mg daily.
3092904|NCT01794455|Experimental|Phase 2: Candesartan|For subjects who do not remit to sertraline, they will receive candesartan for 12 weeks, with doses ranging from 4mg - 32mg daily.
3092905|NCT01794689|Experimental|Morphine US then Morphine FA|Participants randomized to receive Morphine and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
3092906|NCT01794689|Placebo Comparator|Placebo US then Placebo FA|Participants randomized to receive the saline placebo and the Uninterrupted Sleep (US) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of uninterrupted sleep (US). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of forced awakenings (FA). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the US and FA sleep conditions are completed.
3092907|NCT01794689|Experimental|Morphine FA then Morphine US|Participants randomized to receive Morphine and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the Morphine injection (0.08mg/kg) via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
3092908|NCT01794689|Placebo Comparator|Placebo FA then Placebo US|Participants randomized to receive the saline placebo and the Forced Awakenings (FA) condition first. After a polysomnography (PSG) screening night, participants were randomized to receive two consecutive nights of forced awakenings (FA). With a minimum of a two week washout period, participants then completed the opposing sleep condition of two nights of uninterrupted sleep (US). They will receive the injection via IV bolus over 30 seconds during each experimental quantitative sensory testing session that occurs after the FA and US sleep conditions are completed.
3092909|NCT01794702|Experimental|Clofarabine + Cytarabine + Decitabine + Idarubicin|"Phase I - Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)~Phase II - Clofarabine 15 mg/m2 by vein over approximately 1 hour daily (number of days selected based on Phase I portion).~Decitabine 20 mg/m2 by vein over approximately 1 hour daily for 5 days (days 1-5) Idarubicin 10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 6-8) Cytarabine 1 g/m2 by vein over approximately 2 hours daily for 5 days (days 6-10)"
3092910|NCT01794741|Active Comparator|Dymista nasal spray|azelastine 137mcg per spray/fluticasone propionate 50mcg per spray one spray per nostril twice a day for three months
3092911|NCT01794741|Active Comparator|fluticasone propionate nasal spray|fluticasone propionate nasal spray 50mcg per spray per nostril twice a day
3092912|NCT01794780|Experimental|Indacaterol|LABA: Indacaterol, once a day, 150μg each time
3092913|NCT01794780|Experimental|Tiotropium Bromide|LAMA: Tiotropium Bromide, once a day, 18 μg
3092914|NCT01794780|Experimental|Salmeterol/Fluticasone|LABA/ICS: Salmeterol/Fluticasone, twice a day, 50/250 μg, 50/500 μg
3092915|NCT01794780|Experimental|Budesonide/ formoterol|Budesonide/formoterol, twice daily, two suction each time, 160/4.5 μg
3092916|NCT01794780|Experimental|Indacaterol +Tiotropium|Indacaterol, once a day, 150μg each time +Tiotropium Bromide, once a day, 18 μg
3092917|NCT01794780|Experimental|LABA/ICS (Or budesonide/ formoterol)+ Tiotropium|Salmeterol / fluticasone Or budesonide / formoterol
3092918|NCT01794780|Experimental|Oral theophylline|
3092919|NCT01794780|Experimental|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
3092920|NCT01794806|Experimental|Tooth extraction and grafting|Tooth extraction and grafting with allograft
3092921|NCT01794806|Sham Comparator|Tooth extraction|Tooth extraction
3092922|NCT01794845|Experimental|Erbitux, Taxotere, LD Fractionated RT|Erbitux, Taxotere and Low Dose Fractionated Radiation Therapy (LDFRT)
3092923|NCT01794923|Experimental|Ibuprofen 5% topical gel BID|IBU BID (Treatment A)
3092924|NCT01794923|Placebo Comparator|Placebo topical gel BID|Placebo BID (Treatment B)
3092925|NCT01794923|Experimental|Ibuprofen 5% topical gel TID|IBU TID (Treatment C)
3092926|NCT01794923|Placebo Comparator|Placebo topical gel TID|Placebo TID (Treatment D)
3092927|NCT01794949|Experimental|Non-diabetic patients receiving the Resolute stent|Non-diabetic patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
3092928|NCT01794949|Experimental|Diabetic patients receiving the Resolute stent|Non-insulin dependent diabetes mellitus (NIDDM) patients presenting with Acute Coronary Syndrome (ACS), receiving the Resolute stent.
3092929|NCT01795079|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
3092930|NCT01795079|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
3092931|NCT01795105||Aripiprazole (Abilify® Tablets/Abilify® ODT)|
3092932|NCT01795495|Active Comparator|Remifentanil|This arm will receive remifentanil alone as is the current practice.
3092933|NCT01795495|Experimental|Remifentanil plus methadone|This arm will receive the current analgesic remifentanil plus and adjunct dose of methadone hydrochloride.
3092934|NCT01795495|Experimental|Remifentanil plus magnesium|This arm will receive the current analgesic remifentanil plus an adjunct dose of magnesium sulfate.
3092935|NCT01795534|Experimental|Beetroot shot then placebo shot|"Intervention: Participants will first consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK)"
3092936|NCT01795534|Placebo Comparator|Placebo shot then beetroot shot|"Intervention: Participants will first consume a Nitrate-depleted beetroot shot: 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate)(Beet It, James White Drinks Ltd, Ipswich, UK).~Following a four day wash out, participants will then consume a Beetroot shot: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate) (Beet It, James White Drinks Ltd, Ipswich, UK)."
3092937|NCT01795547|Experimental|Aripiprazole and aripiprazole once-monthly|
3092938|NCT01795547|Active Comparator|Paliperidone and paliperidone palmitate|
3092939|NCT01795638|Active Comparator|Sodium chloride|Sodium chloride 1 meq/kg (0.4 ml/kg of 2.5meq/ml formulation for injection)q6hrs on days of life 7-35. Intervention was given enterally if feedings were at least 100 ml/kg/day; otherwise medication was diluted in equal amounts of dextrose 5% water and administered intravenously.
3092940|NCT01795638|Placebo Comparator|sterile water|Sterile water, 0.4 ml/kg q6hrs on days of life 7-35. Placebo is given enterally when infant is tolerating at least 100 ml/kg/day; otherwise the product is diluted in equal amounts of dextrose 5% water and administered intravenously.
3092941|NCT01795716|Experimental|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
3092942|NCT01795716|Active Comparator|Glivec|Single and multiple oral Glivec 400mg qd
3092943|NCT01795833|Experimental|Text Messages|Short text messages related to healthy lifestyle will be sent to half the subjects three times per week, in addition to one off 'one-to-one structured education' during the study period.
3092944|NCT01795833|No Intervention|Control|Half of the subjects who has received only one off 'one-to-one structured education about healthy lifestyle during the study period
3092945|NCT01795859|Experimental|SD-809 ER Tablets|SD-809 ER tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
3092946|NCT01795859|Experimental|SD-809 Tablets|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white). All are administered three times a day, with the 6 mg final dose is placebo.
3092947|NCT01795898|Experimental|Fentanyl transdermal patch|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
3092948|NCT01795937|Experimental|Part 1: Faldaprevir + Itraconazole|Interaction of Faldaprevir and Itraconazole
3092949|NCT01795937|Experimental|Part 2:Faldaprevir+Rosuvastatin+Atorvast|Interaction of Faldaprevir, Rosuvastatin and Atorvastatin
3468935|NCT03891147|Experimental|Electro-acupunture (EA) group|"Patients will receive the treatment of electro-acupuncture with acupoints (i) Riyue (GB-24) ; (2) Danshu (B19) ; (3) Ganshu (B18) ; (4) Qimen (LR14) ; (5) Yanglingquan (GB34)~The EA will be conducted by using disposable acupuncture needles (0.30 mm in diameter and 25-40 mm in length). The needles are inserted at a depth of 10-30 mm vertically or obliquely into acupoints, on which electrical stimulation with continuous waves with 2 Hz and 100 Hz are delivered for 15 min for each frequency through an electrical acupuncture treatment instrument (Hwarto, SDZ-II). The intensities of stimulation are adjusted to a level at which patients feel most comfortable. Each session lasts for 30 minutes."
3092951|NCT01796236|Active Comparator|Minimally invasive surgery and BA400|This arm involves no soft tissue reduction around the BA400 implant.
3092952|NCT01796236|Active Comparator|Traditional surgery and BA300|This arm involves traditional soft tissue reduction around the BA300 implant
3092953|NCT01796301|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3092954|NCT01796301|Active Comparator|Teriparatide|Participants received 20 μg/day teriparatide administered by subcutaneous injection for 12 months.
3092955|NCT01796392|Experimental|EBV and Optimal Medical Management|This study arm will undergo EBV treatment along with optimal medical management, including smoking cessation program, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
3092956|NCT01796392|Other|Optimal Medical Management|This study arm will receive maximal medical management, including smoking cessation program support if necessary, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
3092957|NCT01796470|Experimental|Entospletinib + idelalisib|"Entospletinib plus idelalisib at one of 4 dose combinations (400 mg/100 mg; 600 mg/100 mg; 800 mg/100 mg; 800 mg/150 mg).~After discontinuation of entospletinib+idelalisib combination therapy, and following a washout period, participants may continue to receive entospletinib 400 mg monotherapy."
3092958|NCT01796548|Experimental|Oxybutynin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
3092959|NCT01796665|Experimental|Test product|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.
3092960|NCT01796665|Active Comparator|Reference product|Acanya Gel applied to the affected areas of the face once daily.
3092961|NCT01796665|Placebo Comparator|Placebo product|Placebo of the Test product applied to the affected areas of the face once daily.
3092962|NCT01796860|Other|AFO|All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).
3092963|NCT01796912|Active Comparator|First Lipoprotein Apheresis, then sham apheresis|Three months of weekly lipoprotein apheresis, 1 month washout, then three month sham apheresis
3092964|NCT01796912|Sham Comparator|First Sham Apheresis, then Lipoprotein Apheresis|Three months of weekly sham apheresis, 1 month washout, then three month lipoprotein Apheresis
3092965|NCT01796964|Experimental|ESBA1008|ESBA1008 solution, 7 intravitreal (IVT) injections, as specified in protocol
3092966|NCT01796964|Active Comparator|EYLEA|Aflibercept, 8 intravitreal (IVT) injections, as specified in protocol
3092967|NCT01796977|Active Comparator|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing is a closed-cell foam wound dressing enriched with gaseous and dissolved oxygen for use in the management of wounds.
3092968|NCT01796977|Placebo Comparator|Standard Gauze Dressing|A sterile 4x4 covered by an adhesive Tegaderm will serve as the comparator for this study.
3092969|NCT01797029|Experimental|Vaccine|
3092970|NCT01797029|Placebo Comparator|Placebo|
3092971|NCT01797081|Experimental|Botulinum toxin Type A (24U)|24 units (U) botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3092972|NCT01797081|Experimental|Botulinum toxin Type A (12U)|12U botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3092973|NCT01797081|Other|Placebo/Botulinum toxin Type A (24U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (24U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
3092974|NCT01797081|Other|Placebo/Botulinum toxin Type A (12U)|Placebo (normal saline) one treatment injected into bilateral Crow's Feet Line areas on Day 1 and subsequent treatments if applicable until day 180. Botulinum toxin Type A (12U) injected into bilateral Crow's Feet Line areas at any additional treatments from day 180 onward. Based on retreatment criteria participants were eligible for up to 5 treatment cycles (2 Placebo + 3 botulinum toxin type A).
3092975|NCT01797094|Experimental|Botulinum toxin Type A (44U)|44 units (U) botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3092976|NCT01797094|Experimental|Botulinum toxin Type A (32U)|32 units (U) botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area on Day 1. Based on retreatment criteria participants were eligible for up to 5 treatment cycles.
3092977|NCT01797120|Active Comparator|Fulvestrant & Everolimus|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus everolimus daily x 12 cycles.
3092978|NCT01797120|Placebo Comparator|Fulvestrant & Placebo|Fulvestrant Day 1 & 15 of Cycle 1, then Day 1 of all subsequent cycles (every 28 days for 12 cycles) plus placebo daily x 12 cycles.
3092979|NCT01797159|Experimental|Hippocampal-sparing PCI|Hippocampal-sparing PCI 25 Gy in 10 fractions
3092980|NCT01797185|Experimental|SPARC1104 group 1|
3092981|NCT01797185|Experimental|SPARC1104 group 2|
3092982|NCT01797185|Experimental|SPARC1104 group 3|
3092983|NCT01797263|Experimental|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
3092984|NCT01797263|Active Comparator|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
3092985|NCT01797302|Active Comparator|Vitamin D3 2000 IU|Vitamin D3 2000 IU tablet once daily by mouth for 6 months
3092986|NCT01797302|Active Comparator|Vitamin D3 1000 IU|Vitamin D3 1000 IU tablet by mouth once daily for 6 months
3092987|NCT01797302|Placebo Comparator|Vitamin D3 600 IU|Vitamin D3 600 IU tablet by mouth once daily for 6 months
3092988|NCT01797328|Active Comparator|cold provocation|cold arm
3092989|NCT01797328|Active Comparator|to avoid feeling cold|warm arm
3092990|NCT01797432|Experimental|Combined IL Kenalog and Restylane|Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp
3092991|NCT01797445|Experimental|E/C/F/TAF (Double-Blind)|"E/C/F/TAF plus E/C/F/TDF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
3092992|NCT01797445|Active Comparator|E/C/F/TDF (Double-Blind)|"E/C/F/TDF plus E/C/F/TAF placebo for 144 weeks~After 144 weeks, participants will continue to take their blinded study drug until treatment assignments have been unblinded."
3092993|NCT01797445|Experimental|Open-Label E/C/F/TAF|After the unblinding visit, in countries where E/C/F/TAF is not commercially available, participants (except in UK) who complete 144 weeks of study will be given the option to receive open-label E/C/F/TAF and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
3092994|NCT01797458|Experimental|Hall Technique|This technique uses preformed Stainless Steel Crowns (SSCs) to restore carious primary molars. Local anaesthesia, caries removal or tooth preparation are not required.
3092995|NCT01797458|Experimental|Non-Restorative Caries Treatment|This is a less operative approach, here carious lesions are opened removing the overhanging enamel and making the cavity accessible for biofilm removal. No carious dentine will be removed from the pulpal wall and no local anaesthesia will be placed. Fluoride varnish (Duraphat ®) will be applied to the cavity. Parents/children will be trained to clean the cavity by brushing using a buccolingual technique.
3092996|NCT01797458|Active Comparator|Conventional Restoration|This technique corresponds to the conventional way of treating cavitated carious lesions involving complete caries removal, use of local anaesthesia (when needed), and a compomer (Dyract ®) restoration. Cotton wool roll isolation and continuous aspiration will be used.
3092997|NCT01797471|Experimental|LEAD RT|"Lattice Extreme Ablative Dose (LEAD) Radiation Therapy (RT) on Day 1 at dose of 18 Gy followed by;~Conventionally fractionated radiation therapy beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy;~Conventional Platinum Chemotherapy Doublet at discretion of treating physician beginning on day 2."
3092998|NCT01797484|Active Comparator|Ranolazine|Ranolazine 500mg bid orally 7 days Ranolazine 750mg bid orally 35 days
3092999|NCT01797484|No Intervention|No additional medication|No additional medication - control group
3093000|NCT01797536|Experimental|Mild Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with mild hepatic insufficiency, defined as a score of 5 to 6 on the Child-Pugh scale
3093001|NCT01797536|Experimental|Moderate Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with moderate hepatic insufficiency, defined as a score of 7 to 9 on the Child-Pugh scale
3093002|NCT01797536|Experimental|Severe Hepatic Insufficiency|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants with severe hepatic insufficiency, defined as a score of 10 to 15 on the Child-Pugh scale
3093003|NCT01797536|Experimental|Healthy Participants|Single oral dose of 5 x 10 mg capsules of elbasvir administered to participants matched to the mean of all hepatic insufficiency participants for age, gender, and weight
3093004|NCT01797562|Experimental|Positive Response Rates: 7 new and 4 reformulated allergens|Subjects will be patched with TRUE Test Panels 1.3, 2,2 and 3.2. Panel 1 allergens nickel sulfate (0.60 mg/cm2), potassium dichromate (0.054 mg/cm2), fragrance mix (0.050 mg/cm2) and ethylenediamine dihydrochloride (0.050 mg/cm2), Panel 2 allergen Methyldibromoglutaronitrile (0.0053 mg/cm2) and Panel 3 allergens Gold sodium thiosulfate (0.075 mg/cm2), Hydrocortisone-17-butyrate (0.020 mg/cm2), Bacitracin (0.60 mg/cm2), Parthenolide (0.0030 mg/cm2), Disperse blue 106 (0.050 mg/cm2 in PVP), 2-Bromo-2-nitropropane-1,3-diol (Bronopol) (0.25 mg/cm2) will be evaluated
3093005|NCT01797575|Active Comparator|Aspirin|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3093006|NCT01797575|Active Comparator|N-acetyl-cysteine|research subject will be taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3093007|NCT01797575|Active Comparator|Aspirin and NAC|research subject will be taking aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations.
3093008|NCT01797575|Placebo Comparator|Sugar Pill|research subject will be taking 4 capsules of matching sugar pill( placebo) in the morning and 2 capsules of matching placebo in the evenings in addition to his/her mood stabilizing drug (lithium, anticonvulsants, any atypical antipsychotics) or combinations
3093009|NCT01797705|Experimental|All subjects|All subjects underwent a sleep study with DeVilbiss AutoAdjust CPAP with revised algorithm simultaneously with hand-scored PSG.
3093010|NCT01797731|Active Comparator|Conventional System|Conventional tibial extramedullary alignment system used by surgeon during surgery.
3093011|NCT01797731|Experimental|KneeAlign System|Digital hand-held surgical navigation system for tibial component placement used by surgeon during surgery.
3093012|NCT01797783|Experimental|DAILIES® AquaComfort Plus® Multifocal|Nelfilcon A multifocal contact lens with comfort additive worn for 30 days on a daily wear, daily disposable basis
3093013|NCT01797783|Active Comparator|Focus® DAILIES® Progressives|Nelfilcon A multifocal contact lens worn for 30 days on a daily wear, daily disposable basis
3093014|NCT01797822|Experimental|Artificial tears first, then Dexamethasone|Artificial tears four times a day both eyes for two weeks, then Dexamethasone 0.01% four times a day both eyes for two weeks
3093015|NCT01797835|Placebo Comparator|Usual Care|Youth in usual care will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. They will also receive an informational brochure.
3093016|NCT01797835|Experimental|CHAT brief MI intervention|Youth in CHAT will receive screening for alcohol and drug use. Those youth who are at risk will have a chance to talk to their provider about their use. In addition, these youth will CHAT. CHAT is a brief motivational intervention that takes places in the primary care setting. It is a 15-20 minute intervention for adolescents age 12-18 focused on discussing alcohol and drug use. They will also receive a booster call one month later to check in on how they are doing.
3093017|NCT01797965|Experimental|BIIB019|BIIB019 150 mg subcutaneous (SC) every 4 weeks
3093018|NCT01798004|Experimental|Treatment (induction therapy, consolidation therapy, ASCT)|"INDUCTION THERAPY:~COURSES 1-2: Patients receive cyclophosphamide IV over 15-30 minutes and topotecan hydrochloride IV over 30 minutes on days 1-5. Treatment repeats every 3 weeks for 2 courses.~COURSES 3 AND 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide IV over 1-2 hours on days 1-3. Treatment repeats every 3 weeks for 2 courses.~COURSE 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2, vincristine sulfate IV over 1 minute on days 1-3, and doxorubicin hydrochloride IV over 24 hours on days 1-3. Treatment repeats every 3 weeks for 1 course.~Treatment continues in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Beginning 4-8 weeks following the 5th course of induction therapy, patients receive busulfan IV over 3 hours on days -6 to -3 and melphalan IV on day -1. Patients undergo ASCT on day 0.~Some patients also undergo EBRT after induction and consolidation."
3093019|NCT01798056|Experimental|GSK1437173A Group|Subjects received the first dose of GSK 1437173A at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of GSK 1437173A vaccine was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
3093020|NCT01798056|Placebo Comparator|Placebo Group|Subjects received the first dose of placebo at least 10 days (up to 1 month) before start of chemotherapy cycle or at the first day (allowing a window of +/- 1 day) of the first (or second) chemotherapy cycle. The second dose of placebo was administered between 1 and 2 months after the first vaccination and at the first day (allowing a window of +/- 1 day) of a subsequent cycle of chemotherapy. The study products were administered intramuscularly into a deltoid muscle. The choice of and use of chemotherapy, or any other medication related to the patients' current conditions, were based on the local standard of care for the patients.
3093021|NCT01798134|Other|DEB-TACE|"Transarterial Chemoembolization with TANDEM™ - DOX Microspheres (DEB-TACE)~Treatment: Lobes; Dosing: TANDEM™/Doxorubicin; Second Treatment:TANDEM™/Doxorubicin"
3093022|NCT01798186|Experimental|Cannabis 5% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 5% THC and in a room with no ventilation.
3093023|NCT01798186|Experimental|Cannabis 11% THC, No Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC and in a room with no ventilation.
3093024|NCT01798186|Experimental|Cannabis 11% THC, Ventilation|Participants in this condition will be passively exposed to second-hand cannabis smoke from cannabis containing 11% THC in a room with active ventilation.
3093025|NCT01798225|Placebo Comparator|Control|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) pills.
3093026|NCT01798225|Experimental|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Doxycycline 100mg x 14 pills)
3093027|NCT01798264|Experimental|10 mcg./day|ITCA 650 (exenatide in DUROS)
3093028|NCT01798264|Experimental|20 mcg/day|ITCA 650 (exenatide in DUROS)
3093029|NCT01798264|Experimental|40 mcg/day|ITCA 650 (exenatide in DUROS)
3093030|NCT01798264|Experimental|80 mcg/day|ITCA 650 (exenatide in DUROS)
3093031|NCT01798316|Active Comparator|IV Acetaminophen|IV Acetaminophen administered on admission to post-anesthesia care unit
3093032|NCT01798316|Active Comparator|Standard of care|Standard of care pain management regimen including opioids administered on admission to post-anesthesia care unit
3093033|NCT01798394|Active Comparator|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
3093034|NCT01798394|Placebo Comparator|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
3093035|NCT01798485|Experimental|Ganetespib and Docetaxel|Ganetespib (150 mg/m^2) and docetaxel (75 mg/m^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
3093036|NCT01798485|Active Comparator|Docetaxel|Docetaxel (75 mg/m^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.
3093037|NCT01798550|Experimental|Reduced Dose (0.8 mg/kg)|Enoxaparin 0.8 mg/kg (using total body weight) twice daily
3093038|NCT01798550|Active Comparator|Standard Dose (1 mg/kg)|Enoxaparin 1 mg/kg (using total body weight) twice daily
3093039|NCT01798589|Experimental|Ethylenediamine dihydrochloride|Ethylenediamine dihydrochloride in methylcellulose 50 mcg/cm2 Ethylenediamine dihydrochloride in polyvinylpyrrolidone 50 mcg/cm2 Methylcellulose (negative control 1) Polyvinylpyrrolidone (negative control 2)
3093040|NCT01798641|Experimental|Open Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be open at this time. The adjustment is done in the out-patient clinic.
3093041|NCT01798641|Placebo Comparator|Closed Shunt|The programmable valve, MIETHKE proGAV® / MIETHKE proSA®, will be closed during this time. The adjustment is done in the out-patient clinic.
3093042|NCT01798706|Experimental|Lixisenatide|Lixisenatide 10 mcg once daily (QD) for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
3093043|NCT01798706|Placebo Comparator|Placebo|Placebo (matched to lixisenatide) QD for 24 Weeks.
3093044|NCT01798849|Experimental|Panel A-Healthy|Within each of the 5 rising dose treatment periods, 6 participants received a single dose of MK-8892 0.5 mg, 2.0 mg, 6.0 mg, 14 mg or 2.0 mg fed, and 2 participants received placebo. Dosing periods will alternate with Panel B.
3093045|NCT01798849|Experimental|Panel B-Healthy|Within each of the 4 rising dose treatment periods, 6 participants received a single dose of MK-8892 1.0 mg, 4.0 mg, 9.0 mg or 12 mg, and 2 participants received placebo. Dosing periods will alternate with Panel A.
3093046|NCT01798849|Experimental|Panel C-Mild/Moderate Hypertension|Within each of the 5 single dose treatment periods, 6 participants with mild to moderate hypertension received a single dose of MK-8892 0.5 mg, 1.0 mg, 2.0 mg or 6.0 mg, and 2 participants received placebo. Dosages will be determined by the results of Panels A and B.
3093047|NCT01798927|Other|Ankle foot orthosis fitting|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
3093048|NCT01798966|Experimental|SENSIMED Triggerfish|Sensimed Triggerfish device will be worn by each subject for 24h
3093049|NCT01798992|No Intervention|Non-failing control|Patients with normal ejection fraction who underwent a single myocardial biopsy and received no β-blocker therapy
3093050|NCT01798992|Active Comparator|Metoprolol succinate|Idiopathic dilated cardiomyopathy patients randomized to metoprolol succinate titrated to a goal of 200 mg by mouth daily for 18 months
3093051|NCT01798992|Active Comparator|Metoprolol succinate + doxazosin|Idiopathic dilated cardiomyopathy patients who were randomized to receive metoprolol succinate and doxazosin titrated to a goal of 200 mg and 8 mg by mouth daily for 18 months
3093052|NCT01798992|Active Comparator|Carvedilol|Idiopathic dilated cardiomyopathy patients who were randomized to receive carvedilol titrated to a goal of 25 mg by mouth twice daily for 18 months
3093053|NCT01799135|Experimental|Experimental Arm|"Stereotactic Body Radiation Therapy: either 54 Gy in 3 fractions or 50-60 Gy in 5 fraction over a span of 15 days at most.~DCE-MRI was performed at four time points during therapy: at baseline prior to SBRT, 1-2 days after the first treatment fraction, 1-2 weeks after the end of the SBRT course, and 3 months after completing radiotherapy.~4D-CT scan 3 months after completing radiotherapy."
3093054|NCT01799213|Experimental|Active Treatment|Eligible subjects will be randomized to Meloxicam 15 mg po per day (QD) vs placebo
3093055|NCT01799213|Placebo Comparator|Placebo|Eligible subjects will be randomized to Meloxicam 15 mg po QD vs placebo
3093056|NCT01799226|Active Comparator|Toothpaste without Triclosan|This arm will use a toothpaste that does not contain triclosan
3093057|NCT01799226|Experimental|Triclosan|This arm will use colgate total which contains triclosan
3093058|NCT01799239|Experimental|First Test product; then SenSura|"The subject in this arm first test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details.~After cross-over the subject test SenSura which is CE-marked and commerical available."
3093059|NCT01799239|Active Comparator|First SenSura, Then Test product|"The subject in this arm first test SenSura which is CE-marked and commerical available.~After cross-over the subject test the Test product The test product is a newly developed ostomy appliance with a new top film. Due to company confidentiality the product is not described in further details."
3093060|NCT01799278|Experimental|All Patients|MLN8237 at 50 mg twice daily for 7 days repeated every 21 days. Therapy will continue until disease progression, unacceptable toxicity as a result of MLN8237, or withdrawal of patient consent.
3093061|NCT01799590|Experimental|Topiramate|
3093062|NCT01799720|Experimental|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet. Follow-up 30 days
3093063|NCT01799720|Experimental|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 2 took 2 capsules/day of one of the most oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
3093064|NCT01799720|Experimental|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Participants from group 3 only took diet and no capsules. Follow-up 30 days
3093065|NCT01799889|Experimental|CLL, Entospletinib MM/SDD|Participants with CLL, receive original formulation (mono-mesylate [MM]) of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib (spray dried dispersion [SDD]) 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093066|NCT01799889|Experimental|FL, Entospletinib MM/SDD|Participants with FL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093067|NCT01799889|Experimental|DLBCL, Entospletinib MM/SDD|Participants with DLBCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093068|NCT01799889|Experimental|MCL, Entospletinib MM/SDD|Participants with MCL, receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093069|NCT01799889|Experimental|non-FL iNHL, Entospletinib MM/SDD|Participants with non-FL iNHL (ie, participants with LPL/WM, SLL, or MZL), receive original formulation of entospletinib 800 mg (4 × 200 mg tablets) (before amendment 8) or new formulation of entospletinib 400 mg (2 × 200 mg tablets) (after amendment 8) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093070|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 100 mg|Participants with CLL, who are prior B-cell receptor (BCR) inhibitor naive, receive new formulation of entospletinib 100 mg (1 × 100 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093071|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 200 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 200 mg (1 × 200 mg tablet) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093072|NCT01799889|Experimental|CLL; Prior BCR Inhibitor Naive, Entospletinib SDD 400 mg|Participants with CLL, who are prior BCR inhibitor naive, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093073|NCT01799889|Experimental|CLL (Non-Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to Bruton tyrosine kinase (BTK) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093074|NCT01799889|Experimental|CLL (Non-Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL and simple progression (non-Richters), who are exposed to phosphatidylinositol 3-kinase (PI3K) inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093075|NCT01799889|Experimental|CLL (Richters) Prior BTK Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to BTK inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093076|NCT01799889|Experimental|CLL (Richters) Prior PI3K Inhibitor, Entospletinib SDD|Participants with CLL, who transform to Richters or Richters-like syndrome and are exposed to PI3K inhibitor, receive new formulation of entospletinib 400 mg (2 × 200 mg tablets) orally twice daily. Treatment with entospletinib will continue until disease progression or unacceptable toxicity.
3093077|NCT01799941|Other|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
3093078|NCT01799993|Experimental|Amikacin inhale (BAY41-6551)|Participants received 400 mg (3.2 mL) aerosolized Amikacin (BAY41-6551) solution every 12 hours via Pulmonary Drug Delivery System (PDDS) Clinical from Day 1 to Day 10.
3093079|NCT01799993|Placebo Comparator|Placebo|Participants received 3.2 mL aerosolized placebo solution every 12 hours via PDDS Clinical from Day 1 to Day 10.
3093080|NCT01800058||Circulating prostatic tumor cells in the peripheral blood|"Patients that satisfy inclusion criteria, and after signing informed consent, will extract 1 blood sample (7.5 mL):~prior to any treatment;~following AD and prior to RT; and~following the end of RT (1-3 months afterwards).~six to twelve months following the end of RT in those patients with 0 CTCs in the first determination and positive CTCs in the second or third determination~The quantification of CTC in blood samples will be done with the CellSearch® system."
3093081|NCT01800201|No Intervention|Control|The control group will have their claims data analyzed for a 12 month period. We will be examining these data for hospital admissions, new vascular events (AMI, stroke, acute coronary syndrome admission), or repeat or new cardiovascular procedures.
3093082|NCT01800201|Experimental|Intervention|The intervention group (1) will use GlowCaps, a remote monitoring and reminder pill bottle; (2) assigned an engagement advisor from the study team; (3) asked to provide study team with names and contact information of up to 3 family members or friends as support partners for med adherence. The study team will contact these people in order listed until 1 agrees to this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on med adherence; and (5) will determine preferences for Way to Health platform communication methods.The group receiving the program intervention will also have their claims data analyzed for the 12 months post-enrollment.
3093083|NCT01800318|Experimental|Sham NESAP with 24% oral sucrose|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3093084|NCT01800318|Experimental|NESAP with oral water|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. 10 minutes before the heel stick, the Empi Select TENS unit will be turned on with settings 3.5mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given"
3093085|NCT01800318|Experimental|NESAP with 24% oral sucrose|"NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. The Empi Select TENS unit will be turned on ten minutes before the heel stick at settings 3.5 mA, 10 Hz. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of 24% oral sucrose solution given along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3093086|NCT01800318|Placebo Comparator|Sham NESAP with oral water|"Sham NESAP: Four Stim Care electrodes with gel backing will be placed on the infant's lower leg at acupuncture points. However, the Empi Select TENS unit will not be turned on. The TENS unit will be hidden from investigators so that they are blinded to the status of the unit.~Infant will receive 1 ml of sterile water given via oral syringe along with a pacifier two minutes before the heel stick. Investigators will be blinded to the solution given."
3093087|NCT01800786|Active Comparator|OSA-CPAP group|OSA patient will use CPAP for 3 months
3093088|NCT01800786|No Intervention|OSA -no CPAP|newly diagnosed OSA patient will not wear CPAP for 3 months
3093089|NCT01800838|Experimental|Treatment (silicon phthalocyanine 4 and PDT)|Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
3093090|NCT01800877|Other|Liberal Approach|In the liberal approach group, we will titrate vasopressors to maintain mean arterial pressures between 75 and 80 mmHg.
3093091|NCT01800877|Other|Restrictive Approach|We will titrate vasopressors to maintain mean arterial pressures between 60 and 65 mmHg.
3093092|NCT01800890|Other|Treatment sequence 1|"Subjects randomised to Treatment sequence 1 will test three different products:~Coloplast A~Coloplast B~SenSura Click~The subjects test the three test products in a randomized order: ABS; BSA, SAB"
3093093|NCT01800890|Experimental|Treatment sequence 2|"Subjects randomised to Treatment sequence 2 will test three different products:~Coloplast C (C)~Coloplast B (B)~SenSura Click (S)~The subjects test the three test products in a randomized order: CBS; BSC, SCB"
3093094|NCT01800890|Experimental|Treatment sequence 3|"Subjects randomised to Treatment sequence 3 will test three different products:~Coloplast A (A)~Coloplast C (C)~SenSura Click (S)~The subjects test the three test products in a randomized order: ACS; CSA, SAC"
3093095|NCT01800903|Active Comparator|Sequence 1|SpeediCath catheter then ZN-D catheter then ZN-C catheter
3093096|NCT01800903|Experimental|Sequence 2|SpeediCath catheter then ZN-C catheter then ZN-D catheter
3093097|NCT01800903|Experimental|Sequence 3|ZN-D catheter then SpeediCath catheter then ZN-C catheter
3093098|NCT01800903|Experimental|Sequence 4|ZN-D catheter then ZN-C catheter then SpeediCath catheter
3093099|NCT01800903|Experimental|Sequence 5|ZN-C catheter then SpeediCath catheter then ZN-D catheter
3093100|NCT01800903|Experimental|Sequence 6|ZN-C catheter then ZN-D catheter then SpeediCath catheter
3093101|NCT01800916|Experimental|Treatment sequence 1|"The subjects randomised to Treatment sequence 1 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (B)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ABS; BSA; SAB"
3093102|NCT01800916|Experimental|Treatment sequence 2|"The subjects randomised to Treatment sequence 2 are going to test~Coloplast Adhesive baseplate B (B)~Coloplast Adhesive baseplate C (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: CBS; BSC; SCB"
3093103|NCT01800916|Experimental|Treatment sequence 3|"The subjects randomised to Treatment sequence 3 are going to test~Coloplast Adhesive baseplate A (A)~Coloplast Adhesive baseplate B (C)~SenSura 1-piece (S)~The subjects test the three test products in a randomised order: ACS; CSA; SAC"
3093104|NCT01800968|Active Comparator|Liraglutide|Increasing dose from 0.6mg, 1.2mg to 1.8mg SQ daily.
3093105|NCT01800968|Placebo Comparator|Placebo|Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg SQ daily.
3093106|NCT01801007|Other|Flow Re-Direction Endoluminal Device|
3093107|NCT01801111|Experimental|Alectinib|Participants will receive alectinib treatment continuously starting from Day 1 Cycle 1 (in 28-day cycles) until disease progression, death, or withdrawal for any other reasons, whichever occurs first. After PD, participants without EGFR mutation will continue treatment with alectinib alone and participants with EGFR mutation will receive alectinib in combination with erlotinib as per discretion of the treating physician.
3093108|NCT01801124|Experimental|EXPAREL|undiluted EXPAREL 266 mg
3093109|NCT01801241|Active Comparator|Anatomic TSA using SOC Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will use the pre operative CT scan at least two weeks prior to surgery to define the glenoid pathology, select the implant of choice and plan the placement of that implant in the desired position. This information will be available to the surgeon at the time of surgery but the SmartBone models and the IRI will not be available. The surgeon will have pre operative x-rays and the pre operative CT scan provided by the radiology department for intra - use. The surgeon will perform the surgery using any of the instruments provided for guide pin placement operative the. These include a wide variety of free hand and adjustable guides that assist the surgeon for placement of the guide pin for location and trajectory.
3093110|NCT01801241|Experimental|Anatomic TSA Using IRI Instrumentation|During Anatomic Total Shoulder Arthroplasty, the surgeon will have use of the SmartBone model of the patient's anatomy and glenoid guide-pin location, and the Intelligent Reuseable Instrument for placement of the glenoid implant.
3093111|NCT01801280|Active Comparator|Mycophenolate mofetil (C)|Mycophenolate mofetil (C) b.i.d. every 12 hours for 2 weeks.
3093112|NCT01801280|Other|Mycophenolate mofetil+Pantoprazole (C+P)|Mycophenolate mofetil b.i.d and Pantoprazole o.m. for 2 weeks.
3093113|NCT01801280|Other|Mycophenolate sodium (M)|Mycophenolate sodium (M) b.i.d. every 12 hours for 2 weeks.
3093114|NCT01801280|Other|Mycophenolate sodium+Pantoprazole (M+P)|Mycophenolate mofetil b.i.d and Pantoprazole 40mg o.m. for 2 weeks.
3093115|NCT01801358|Experimental|Arm A|AEB071 and MEK162 combined
3093116|NCT01801358|Experimental|Arm B|MEK162 alone
3093117|NCT01801436|Experimental|Bortezomib|Bortezomib 1.3 milligram (mg) per meter square (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
3093118|NCT01801449|Experimental|Rilonacept Treatment|Rilonacept loading dose of 4.4 mg/kg/week followed by maintenance dose of 2.2 mg/kg/week. Total duration of the study 24 months. Maintenance dose could be escalated to 4.4 mg/kg/week or further to 6.6 mg/kg/week for 3 months only.
3093119|NCT01801475|Active Comparator|Pregnant women|Full term pregnant women scheduled for Cesarean section and will be given Ondansetron as standard-of-care prior to surgery.
3093120|NCT01801475|Active Comparator|Non-pregnant women|Non-pregnant women scheduled for surgery at Stanford who will be given Ondansetron prior to their surgery as standard-of-care.
3093121|NCT01801475|No Intervention|Neonates|"Babies of the pregnant women enrolled in the study; no ondansetron is given to babies in this Aim 1 of the study."
3093122|NCT01801735|Experimental|Meloxicam Test Capsules|One Capsule QD
3093123|NCT01801865|Experimental|MRI for Neonates|All participants will receive an MRI in the NICU scanner in the GE OPTIMA 1.5T MRI at CCHMC.
3093124|NCT01801917|Placebo Comparator|Placebo|5 placebo tablets daily during non-titration phase
3093125|NCT01801917|Experimental|BAF312 2mg|1 tablet of BAF312 2 mg + 4 tablets of Placebo daily during non-titration phase
3093126|NCT01801917|Experimental|BAF312 10 mg|5 tablets of BAF312 2 mg daily during non-titration phase
3093127|NCT01801930|Experimental|Dose level 1|
3093128|NCT01801930|Experimental|Dose level 2|
3093129|NCT01801930|Experimental|Dose level 3|
3093130|NCT01801930|Experimental|Dose level 4|
3093131|NCT01802073|Experimental|Oral Vancomycin|1) For children who weight < or = 30 kg, the vancomycin dose will be 50 mg/kg/day given orally 3 times per day for the 1st month and continue with the same dose for subsequent months if the clinical laboratory studies improved and are normal. If the laboratory studies are not normal the dose will be increased to 75 mg/kg/day given orally 3 times per day for the 2nd month and 100mg/kg/day given orally 3 times per day the 3rd month. If the laboratory studies do not improve by the end of the 3rd month since starting the vancomycin, the vancomycin will be stopped and the child will not continue the study. 2) For adults and children who weigh >30 kg, the vancomycin dose will be 500 mg given orally 3 times per day for the 1st month and continue with this dose if the clinical laboratory studies improve and are normal. If the laboratory studies are not normal the dose will be increased to 750 mg 3 times per day for the 2nd month and 1000 mg 3 times per day the 3rd month.
3093132|NCT01802151|Placebo Comparator|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules once daily for 4 weeks.
3093133|NCT01802151|Experimental|B. subtilis R0179 (10 billion CFU)|"B. subtilis R0179 (approximately 10 billion CFU/capsule) once daily for 4 weeks.~* CFU (Colony Forming Unit)"
3093134|NCT01802151|Experimental|B. subtilis R0179 (1 billion CFU)|B. subtilis R0179 (approximately 1 billion CFU/capsule) once daily for 4 weeks.
3093135|NCT01802151|Experimental|B. subtilis R0179 (0.1 billion CFU)|B. subtilis R0179 (approximately 0.1 billion CFU/capsule) once daily for 4 weeks.
3093136|NCT01802216|No Intervention|Control/Delayed Treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Rescue scaling and root planing only to sites of periodontal disease progression (since prior examination) of greater than 3mm. Subjects will be informed of their assignment to the delayed treatment group and provided referral list of local dentists should patient not feel comfortable waiting until end of study for full intensive periodontal disease treatment. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
3093137|NCT01802216|Active Comparator|Intensive periodontal disease treatment|Baseline panoramic x-ray (Panorex) and complete oral examinations at every visit. Intensive periodontal disease treatment to include administration of local anesthetic to up to two quadrants for scaling and root planing with ultrasonic and hand instruments. Minocycline will be applied to any sites with probing depth >=5mm. Hopeless teeth in scaled quadrants will be extracted. Written and verbal instruction in oral hygiene. Provision of oral hygiene supplies.
3093138|NCT01802281|Active Comparator|Hysteropexy|Uphold® LITE
3093139|NCT01802281|Active Comparator|Hysterectomy and USLS|Vaginal hysterectomy and uterosacral ligament suspension (USLS)
3093140|NCT01802320|Experimental|Treatment (Akt inhibitor MK2206)|Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3093141|NCT01802333|Experimental|Arm I (standard dose cytarabine, daunorubicin hydrochloride)|"INDUCTION/RE-INDUCTION: Patients receive standard dose cytarabine IV continuously on days 1-7 and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 15. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
3093142|NCT01802333|Experimental|Arm II (high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTION: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15 minutes on days 1-2.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy."
3093143|NCT01802333|Experimental|Arm III (vorinostat, high-dose cytarabine, idarubicin)|"INDUCTION/RE-INDUCTIONI: Patients receive vorinostat PO TID on days 1-3, high-dose cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6. Patients with residual blasts may receive re-induction treatment beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.~CONSOLIDATION: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days 4-6, and idarubicin IV over 15 minutes on days 4-5.~TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or consolidation therapy. (Permanently closed to accrual, effective 6/2/2015) Patients previously randomized to Arm III may continue treatment with or without vorinostat."
3093144|NCT01802385|No Intervention|Placebo|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day) + placebo
3093145|NCT01802385|Experimental|Sertraline 400mg|Standard cryptococcal meningitis therapy with amphotericin (0.7-1.0 mg/kg/day) + fluconazole (800-1200mg/day plus adjunctive sertraline therapy at 400mg/day for 2 weeks, then 200mg for 12 weeks, and then tapered over 3 weeks.
3093146|NCT01802411|Active Comparator|EXPAREL 266 mg|Intercostal nerve block using single total administration of 20 mL EXPAREL (bupivacaine liposome injectable suspension) 266 mg (approximately 88 mg [6.6 mL] to each of three nerve segments)
3093147|NCT01802411|Placebo Comparator|Placebo|Intercostal nerve block using single total administration of 20 mL normal saline (6.6 mL to each of three nerve segments)
3093148|NCT01802437|Experimental|Talk Therapy 4-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 4 weeks of therapy, participants with at less than a 20% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy frequency or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy
3093149|NCT01802437|Experimental|Talk Therapy 8-Week Decision Point|Interpersonal psychotherapy that focuses on an adolescents relationship and communication skills in the context of of their depression. After 8 weeks of therapy, participants with at less than a 40% reduction in Hamilton Rating Scale for Depression (HRSD) score will be further randomized into 2 groups, increased dose of interpersonal psychotherapy or introduction of fluoxetine therapy starting with 10 mg per day for the first week and 20 mg per day in the following 5 weeks. If HRSD scores meet target, patients continue to receive initial dose of interpersonal psychotherapy.
3093150|NCT01802515|Active Comparator|Atomoxetine, low dose|1 capsule containing 40mg of atomoxetine by mouth everyday for 8 weeks followed by 1 week of daily placebo capsules.
3093151|NCT01802515|Active Comparator|Atomoxetine, high dose|One capsule containing 80mg of atomoxetine by mouth everyday for 8 weeks, followed by 1 week of daily 40mg atomoxetine capsules
3093152|NCT01802515|Placebo Comparator|Placebo (sugar pill)|1 placebo capsule by mouth everyday for 8 weeks of treatment invention followed by one week of placebo capsule during study medication taper.
3093153|NCT01802554|Experimental|Pleasant Events Program (PEP)|The Pleasant Events Program (PEP) is a Behavioral Activation (BA) treatment for depression. Participants receive 4 weekly sessions of face-to-face therapy (60 minutes each) to increase caregiver participation in pleasurable activities. Two additional phone sessions focus on continued behavioral activation for caregivers as well as problem-solving barriers to activation.
3093154|NCT01802554|Active Comparator|Information-Support (IS)|Participants in the Information-Support (IS) control condition were provided with a resource manual consisting of topics commonly covered in support groups or information packets provided by community agencies. Topics included problem-solving and communication skills, cognitive reframing and behavioral management, self-care help, caregiver fact sheets on a range of social and mental health issues, placement information, financial and legal issues, and lists of local organizations and community resources available. Each IS session allowed caregivers to select issue(s) from the resource manual to discuss. The therapist covered the material based on the caregivers' needs. When requested by the caregiver, supportive psychotherapy was also provided.
3093155|NCT01802580|Experimental|Intervention - internet reminder survey|Treatment phase is 12 months. During the intervention, each subject will receive fluocinonide 0.05% ointment, a standard treatment for psoriasis. If their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. They will be asked to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed. They will receive weekly surveys via internet to complete.
3093156|NCT01802580|Experimental|Standard of care, no internet survey|Standard treatment for psoriasis. If it is felt that their psoriasis could be suitably treated with fluocinonide, then they will be asked to participate in the study. At the initial study visit, fluocinonide will be dispensed to the subjects in a small jar with a MEMS® electronic monitoring cap attached. Subjects will be asked to apply the medication twice daily. All subjects will be assigned to treatment with topical fluocinonide to the entire affected area, excluding face and genitals. Subjects will be instructed to apply the smallest amount of study medication sufficient to cover the affected areas. At the end of the treatment phase, subjects will have a feedback session with specific results of adherence behavior revealed.
3093157|NCT01802632|Experimental|Daily dose of AZD9291|Daily oral dose of AZD9291
3093158|NCT01802710|Experimental|Psychological support|Ten weekly sessions, which the first 8 were in group and the last 2 were individuals. It consists on a) an informational session; b) Beck's cognitive-behavioural therapy; and c) progressive-muscle relaxation according to Jacobson
3093159|NCT01802710|Active Comparator|No psychological support|Patients of this group only received the conventional medical treatment, not receiving any psychological support
3093160|NCT01802775|Experimental|edoxaban/aspirin|Open label edoxaban will be provided. Subjects randomized to this treatment arm will receive edoxaban 60 mg once daily (QD) (two 30 mg tablets) for a total of approximately 3 months on a background of aspirin 100 mg QD.
3093161|NCT01802775|Active Comparator|clopidogrel/aspirin|Open label clopidogrel will be provided. Subjects randomized to this treatment arm will receive clopidogrel 75 mg QD (one 75 mg tablet) for a total of approximately 3 months on a background of aspirin 100 mg QD. A loading dose of clopidogrel 300 mg (four 75mg tablets) will be given to subjects as the first dose as early as possible after adequate hemostasis (i.e., within 4 hours of hemostasis).
3093162|NCT01802879|Experimental|Panobinostat - 10 to 40 mg/day TIW QoW|10 to 40mg/day TIW QoW (3 times/week every other week) as per parent protocol design
3093163|NCT01803074|Experimental|Part A-Group 1: BMS-955176 (5 mg) or Placebo|"BMS-955176 5 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093164|NCT01803074|Experimental|Part A-Group 2: BMS-955176 (10 mg) or Placebo|"BMS-955176 10 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093165|NCT01803074|Experimental|Part A-Group 3: BMS-955176 (20 mg) or Placebo|"BMS-955176 20 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093166|NCT01803074|Experimental|Part A-Group 4: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093167|NCT01803074|Experimental|Part B-Group 5: BMS-955176 + Atazanavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
3093168|NCT01803074|Experimental|Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir|"BMS-955176 40 mg solution by mouth once daily for 28 days~Atazanavir 1 x 300 mg capsules by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days"
3093169|NCT01803074|Experimental|Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine|"Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days~Ritonavir 1 x 100 mg tablet by mouth once daily for 28 days~Tenofovir 1 x 300 mg tablet by mouth once daily for 28 days~Emtricitabine 1 x 200 mg capsule once daily for 28 days"
3093170|NCT01803074|Experimental|Part C-Group 8: BMS-955176 (40 mg) or Placebo|"BMS-955176 40 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093171|NCT01803074|Experimental|Part A-Group 9: BMS-955176 (80 mg) or Placebo|"BMS-955176 80 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093172|NCT01803074|Experimental|Part A-Group 10: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093173|NCT01803074|Experimental|Part A-Group 11 (Optional): BMS-955176 (≤120 mg) or Placebo|"BMS-955176 ≤120 mg solution by mouth once daily for 14 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
3093174|NCT01803074|Experimental|Part B-Group 12: BMS-955176 (80 mg) + Atazanavir|"BMS-955176 80 mg solution by mouth once daily for 28 days~Atazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
3093175|NCT01803074|Experimental|Part C-Group 13: BMS-955176 (120 mg) or Placebo|"BMS-955176 120 mg solution by mouth once daily for 10 days~OR~Placebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
3093176|NCT01803204|Experimental|Booklet - Preoperative Educational|This group received the booklet in the preoperative consult, they will monitoring during the postoperative phase
3093177|NCT01803204|No Intervention|Control|This group don't received booklet, they will be monitored during the postoperative period to control
3093178|NCT01803269|Active Comparator|Arm A (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3093179|NCT01803269|Experimental|Arm B (CRLX101)|Patients receive cyclodextrin-based polymer-camptothecin CRLX10 cyclodextr1 IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093180|NCT01803282|Experimental|Part A: ADX 200 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 200 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093181|NCT01803282|Experimental|Part A: ADX 600 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 600 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093182|NCT01803282|Experimental|Part A: ADX 1800 mg|Participants with advanced solid tumors who fail or are intolerant to standard therapy or for whom no standard therapy exists, will receive 1800 mg ADX as monotherapy via IV infusion (approximately 30 minutes) every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug
3093183|NCT01803282|Experimental|Part B: PAC, ADX 800 mg|Participants with PAC will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (gemcitabine and nab paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093184|NCT01803282|Experimental|Part B: LAC, ADX 1200 mg|Participants with lung adenocarcinoma (LAC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and pemetrexed, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093185|NCT01803282|Experimental|Part B: LSC, ADX 1200 mg|Participants with lung squamous cell carcinoma (LSC) will receive ADX 1200 mg every 3 weeks via IV infusion in addition to the 21-day cycle chemotherapy (carboplatin and paclitaxel, on Day 1) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093186|NCT01803282|Experimental|Part B: EGC, ADX 800 mg|Participants with esophagogastric adenocarcinoma (EGC) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+oxaliplatin+5-fluorouracil {5-FU} [mFOLFOX6], on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093187|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with colorectal cancer (CRC) will receive first-line (FL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093188|NCT01803282|Experimental|Part B: FL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive FL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (mFOLFOX6 and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093189|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 5 mg/kg|Participants with CRC will receive second-line (SL) treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (leucovorin+irinotecan+5-FU [FOLFIRI] and bevacizumab 5 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093190|NCT01803282|Experimental|Part B: SL CRC, ADX 800 mg+BEV 10 mg/kg|Participants with CRC will receive SL treatment with ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (FOLFIRI and bevacizumab 10 mg/kg, on Days 1 and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093191|NCT01803282|Experimental|Part B: BRCA, ADX 800 mg|Participants with breast cancer (BRCA) will receive ADX 800 mg every 2 weeks via IV infusion in addition to the 28-day cycle chemotherapy (paclitaxel, on Days 1, 8, and 15) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3093192|NCT01803464|Experimental|Botox plus low-magnitude vibration|Cerebral palsy and Botox + vibration
3093193|NCT01803464|Experimental|Botox|Cerebral palsy and Botox
3093194|NCT01803464|No Intervention|Cerebral palsy control|Cerebral palsy without treatment
3093195|NCT01803464|No Intervention|Typically developing control|Typically developing
3093196|NCT01803607|Experimental|Odanacatib 50 mg|Participants will receive odanacatib 50 mg once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 international units (IU) of Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
3093197|NCT01803607|Placebo Comparator|Placebo|Participants will receive dose-matched placebo to odanacatib once weekly for 24 months. Additionally, all participants will receive weekly supplementation with 5600 IU Vitamin D3 and, if required, will be provided with an open-label daily calcium supplement of 500 mg (sourced locally as calcium carbonate or calcium citrate) to ensure a total daily intake (from both dietary and supplemental sources) of approximately 1200 mg of elemental calcium.
3093198|NCT01803646|Experimental|AM-101 injection|AM-101
3093199|NCT01803646|Placebo Comparator|Placebo injection|Placebo
3093200|NCT01803737|Active Comparator|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
3093201|NCT01803737|Experimental|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
3093202|NCT01803880|Active Comparator|Mechanical Debridement|Mechanical shaver removes areas of damaged tissue
3093203|NCT01803880|Active Comparator|RF-based Debridement|Electrical energy removes areas of damaged tissue (Coblation®)
3093204|NCT01804036|Active Comparator|Zolpidem (Ambien) Treatment|A three week treatment of Zolpidem
3093205|NCT01804036|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
3093206|NCT01804049|Placebo Comparator|Placebo|60 participants will be randomized to placebo pills.
3093207|NCT01804049|Active Comparator|Metformin|60 enrolled participants will be randomized to metformin.
3093208|NCT01804062||no treatment|no treatment, prospective observational
3093209|NCT01804075|Active Comparator|methadone|"Methadone (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Methadone 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of methadone will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 4 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of methadone is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
3093210|NCT01804075|Active Comparator|morphine|"Morphine (1 mg/mL) administered orally every 4 hours. The following is a dosing guide:~NAS Score Morphine 8-12 0.05 mg/kg/dose >=13 0.1 mg/kg/dose~Maximum dose of morphine will be 0.2 mg/kg/dose. (NeoFax)~Additional doses, 0.05 mg/kg, may be given every 4 hours as needed and added to the next 24 hour's doses divided every 6 hours, until NAS scores are consistently <8 for 48 hours.~If the maximum dose of morphine is reached and if withdrawal is not controlled, the infant will be started on clonazepam (0.005 mg/kg/dose q 12h) per current treatment."
3093211|NCT01804101|Experimental|Arm I (lower-dose liposomal cytarabine-daunorubicin CPX-351)|"INDUCTION/RE-INDUCTION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3093212|NCT01804101|Experimental|Arm II (closed to accrual effective 4/21/14)|"INDUCTION/RE-INDUCTION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRp continue on to consolidation.~CONSOLIDATION: Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1 and 3. Treatment repeats every 40 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3093213|NCT01804114|Active Comparator|Local anesthetic continuous infusion|Pain management following hernia repair
3093214|NCT01804114|Placebo Comparator|Placebo continuous infusion|Placebo pain management following hernia repair
3093215|NCT01804140||Cohort|
3093216|NCT01804257|Experimental|Digital Health Feedback System (DHFS)|Ingestion Sensor, Wearable Sensor
3093217|NCT01804465|Experimental|Immediate IpilimumabTreatment|Arm 1 (Immediate Treatment) Ipilimumab Q3wks x 4 started 1 day following the final dose of SipT.
3093218|NCT01804465|Experimental|Delayed IpilimumabTreatment|Arm 2 (Delayed Treatment) Ipilimumab Q3wks x 4 started 3 weeks following the final dose of SipT.
3093219|NCT01804582|Experimental|Family Navigator Consultation|"This group of parents will be contacted by a Family Navigator to assist them in accessing psychosocial resources based on their child and family needs. Components of this intervention are the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
3093220|NCT01804582|No Intervention|Usual Care|No specific study intervention is provided to this group of parents. This control group will received the usual care that they have been receiving from their child's providers.
3093221|NCT01804673|Experimental|Fentanyl-ITS|
3093222|NCT01804816|Experimental|Acupuncture|10 standardized verum acupuncture (VA) sessions twice a week, over 5 weeks. The 5 weeks of acupuncture were scheduled after the period of no acupuncture for each subject.
3093223|NCT01804816|Placebo Comparator|No Acupuncture|"No acupuncture treatment or other study intervention over 5 weeks. All subjects had a 5 week period of no acupuncture prior to the 5 weeks of acupuncture sessions."
3093224|NCT01804842|Active Comparator|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
3093225|NCT01804842|Experimental|1000 mg Met DR qAM|One dose of 1000 mg metformin delayed-release in the morning
3093226|NCT01804842|Experimental|1000 mg Met DR qPM|One dose of 1000 mg metformin delayed-release in the evening
3093227|NCT01804881|Experimental|Lifestyle counseling|Group program using Craving Change(tm) material was the intervention for dietary counseling, 6 group sessions
3093228|NCT01804881|Placebo Comparator|Wait list control|Wait list, offered group program using Craving Change(tm) material at end of study
3093229|NCT01804946|Experimental|Ergoferon (1 tablet 3 times a day)|1 tablet per 1 intake: on day 1 of the treatment 8 tablets (1 tablet every 30 minutes for the first 2 hours, then 1 tablet 3 times a day with equal intervals starting on the same day. From day 2 to day 5 1 tablet TID.
3093230|NCT01804946|Active Comparator|Oseltamivir(Tamiflu): 75 mg two times a day.|Oseltamivir for 5 days (75 mg b.i.d.).
3093231|NCT01805024|Experimental|Omigapil|Omigapil treatment oral administration once per day after breakfast Cohort 1 Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
3093232|NCT01805037|Experimental|Treatment (brentuximab vedotin, rituximab)|"INDUCTION: Patients receive brentuximab vedotin IV over 30 minutes once weekly for 3 weeks and rituximab IV once weekly for 4 weeks. Patients unable to achieve CR may receive additional optional consolidation therapy identical to induction therapy.~MAINTENANCE THERAPY: Patients receive brentuximab vedotin IV once every 3 weeks and rituximab IV once every 6 weeks. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
3093233|NCT01805089|Active Comparator|Melatonin 3 mg|Taken orally, once per day, at/around 9:00pm
3093234|NCT01805089|Placebo Comparator|Placebo|Taken orally, once per day, at/around 9:00pm
3093235|NCT01805154||CRT patients|Patients who have received any market approved St Jude Medical CRT-D or CRT-P device
3093236|NCT01805180|Other|Arm 1: Spectra Optia followed by COBE Spectra|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the Spectra Optia device followed by the COBE Spectra device.
3093237|NCT01805180|Other|Arm 2: COBE Spectra followed by Spectra Optia|Controlled evaluation of Granulocyte/Polymorphonuclear Cell Collection on the COBE Spectra device followed by Spectra Optia.
3093238|NCT01805297|Active Comparator|Vitrectomy with Aflibercept Injection|Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
3093239|NCT01805297|Active Comparator|Standard Vitrectomy|Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
3093240|NCT01805323||All Participants|Patients with macular edema previously treated with dexamethasone intravitreal implant (OZURDEX®) according to general clinical practice.
3093241|NCT01805440|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 500 mg twice daily by mouth for 6 weeks.
3093242|NCT01805440|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 500 mg twice daily by mouth for 6 weeks.
3093243|NCT01805440|No Intervention|Healthy Comparison|Subjects are not randomized, and do not receive any treatment intervention.
3093244|NCT01805687|Other|Zileuton extended release|Oral, 1200 mg (2 x 600 mg tablets)
3093245|NCT01805791|Placebo Comparator|Placebo|Placebo, oral tablets, three times a day
3093246|NCT01805791|Experimental|HMPL-004 1800 mg/day|1 600 mg HMPL-004 tablet, 2x400 mg placebo tablets taken 3 times a day
3093247|NCT01805791|Experimental|HMPL-004 2400 mg/day|2 x 400 mg HMPL tablets, 1 x 600 mg placebo tablet, taken 3 times per day
3093248|NCT01805882|Experimental|A: HCV GT-1, tx naïve, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment naïve patients
3093249|NCT01805882|Experimental|B: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9669|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9669 500mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
3093250|NCT01805882|Experimental|C: HCV GT-1, tx naïve, 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977), Ledipasvir 90mg (GS-5885), GS-9451 80mg, once daily, for 6 weeks in HCV genotype 1, treatment naïve patients
3093251|NCT01805882|Experimental|D: HCV GT-1, tx-relapsed, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, for 12 weeks in HCV genotype 1, treatment-relapsed patients who previously received Sofosbuvir plus Ribavirin
3093252|NCT01805882|Experimental|E: HCV GT-4, tx naïve/expd, 12 wks Sofosbuvir/Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 4 treatment naïve subjects and interferon treament experienced subjects
3093253|NCT01805882|Experimental|F: HCV GT-1, tx naïve/expd 6 wks Sofosbuvir/Ledipasvir/GS-9451|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) and GS-9451 80mg, once daily, 6 weeks in HCV genotype 1 treatment naïve and treatment experienced subjects with advanced liver disease
3093254|NCT01805882|Experimental|G: HCV GT-1, tx naïve, 4 wks Sofosbuvir, Ledipasvir, GS-9451|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
3093255|NCT01805882|Experimental|H: HCV GT-1, tx naïve, 4 wks Sofos/Ledip/GS-9451/GS-9669|Oral Treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885) with GS-9451 80mg, and GS-9669 250mg, once daily, 4 weeks in HCV genotype 1 treatment naïve subjects with early stage liver disease
3093256|NCT01805882|Experimental|D Retx: HCV GT-1, Re-Treatment, 12 wks Sofosbuvir, Ledipasvir|Oral treatment with Sofosbuvir 400mg (GS-7977) and Ledipasvir 90mg (GS-5885), once daily, 12 weeks in HCV genotype 1 subjects who failed HCV therapy in Arm B or Arm G or Arm H
3093257|NCT01805895|Experimental|Minocycline|This intervention arm will receive a total of 5 doses of Minocycline. Dose 1 of Minocycline will be 400mg IV within 12-hours of onset of symptoms. Dose 2 of Minocycline will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
3093258|NCT01805895|No Intervention|Control|This arm will not receive any minocycline. This arm will receive standard of care treatment.
3093259|NCT01806064|Experimental|TRC105 and Axitinib|Patients randomized to receive TRC105 at 3 mg/kg on day 1, 7 mg/kg on day 4, and 10 mg/kg on day 8 and weekly thereafter in combination with axitinib 5 mg twice daily
3093260|NCT01806064|Active Comparator|Axitinib|Patients randomized to receive axitinib 5 mg twice daily
3093261|NCT01806168|Active Comparator|Low-frequency (1 Hz) rTMS|Low-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3093262|NCT01806168|Active Comparator|High-frequency (10 Hz) rTMS|High-frequency active stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3093263|NCT01806168|Placebo Comparator|Sham rTMS|Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC) on 5 consecutive days every week for 2 weeks, for a total of 10 therapy sessions, with 37.5 minutes per session.
3093264|NCT01806259|Experimental|ketorolac 30 mg|Active drug to be compared with placebo
3093265|NCT01806259|Placebo Comparator|NaCl 0.9% 3mL|Placebo looking like the Active drug
3093266|NCT01806298|Experimental|Saizen®|
3093267|NCT01806389||Buprenorphine|Buprenorphine maintained women at delivery of their infant
3093268|NCT01806506|Experimental|Laparoscopic sleeve gastrectomy|The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
3093269|NCT01806506|Experimental|Roux-en-Y Gastric Bypass|The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
3093270|NCT01806545|Active Comparator|SRM003|One time implant (2 SRM003 pieces) on surgery day. Post-surgery, up to 26 weeks follow-up for assessment of efficacy/safety.
3093271|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
3093272|NCT01806571|Experimental|Treatment (nilotinib, daunorubicin hydrochloride, cytarabine)|"INDUCTION THERAPY: Patients receive daunorubicin hydrochloride IV over 10 minutes on days 1-3, cytarabine IV continuously on days 1-7, and nilotinib PO BID on days 4-14. Patients achieving CR or CRi proceed to consolidation therapy. Patients not achieving a significant decrease in bone marrow recovery or CR/CRi upon bone marrow recovery receive another course of induction therapy.~CONSOLIDATION THERAPY: Patients receive cytarabine IV every 12 hours on days 1, 3, and 5, and nilotinib PO BID on days 4-14. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR or CRi proceed to maintenance therapy.~MAINTENANCE THERAPY: Patients receive nilotinib PO BID on days 1-84. Treatment repeats every 84 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3093273|NCT01806584|Active Comparator|SRM003|
3093274|NCT01806584|Other|Participating Site's standard practice|
3093275|NCT01806597|Experimental|secukinumab 150mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
3093276|NCT01806597|Experimental|secukinumab 300 mg|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.
3093277|NCT01806597|Placebo Comparator|Placebo|201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.
3093278|NCT01806623|Experimental|Fluconazole|
3093279|NCT01806662|Experimental|Treatment Arm (Ustekinumab first, Then Placebo)|Since there is a crossover design, each patient will be in the treatment arm for 16 weeks of the study.
3093280|NCT01806662|Placebo Comparator|Placebo Arm (Placebo first, Then Ustekinumab)|Since there is a crossover design, each patient will be in the placebo arm for 16 weeks of the study. If a patient begins in the placebo arm, they will switch over to the treatment arm at week 16.
3093281|NCT01806675|Experimental|Glioblastoma Multiforme (GBM)|Patients with glioblastoma multiforme (GBM) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and 6 weeks (or standard of care follow-up)
3093282|NCT01806675|Experimental|Gynecological Cancers|Patients with gynecological cancer undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
3093283|NCT01806675|Experimental|Renal Cell Cancer (RCC)|Patients with renal cell cancer (RCC) undergo 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging at baseline and at 9 t0 12 weeks (or standard of care follow-up)
3093284|NCT01806688|Experimental|Experimental Snack #1|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #1 is a gluten-free high protein snack comprised of a 30g serving of buckwheat groats. The placebo comparator reference product is a gluten-free snack with similar energy density, but 1/2 the protein as snack #1, comprised of a 32g serving of corn nuts. The placebo comparator non-caloric control is water.
3093285|NCT01806688|Experimental|Experimental Snack #2|One of three interventions to be administered at each visit, an experimental snack, a placebo comparator reference product or a placebo comparator non-caloric control. The experimental snack #2 is a gluten-free high protein and high fibre snack comprised of a 50g serving of a buckwheat and pinto bean flour pita bread. The placebo comparator reference product is a gluten-free snack with similar energy density, but less protein and fibre than snack #2, comprised of a 50g serving of rice bread. The placebo comparator non-caloric control is water.
3093286|NCT01806714|Experimental|Text-based reminder for HPV vaccine/WCC|Parents of adolescents will receive text-based reminders if their adolescent is due for HPV vaccine (dose 1, 2 or 3) or well child care visit
3093287|NCT01806714|Active Comparator|Control arm|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
3093288|NCT01806740|Experimental|Gadoterate meglumine|there is one single arm of patients (no comparative arm)
3093289|NCT01806779|Experimental|Chantix|For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
3093290|NCT01806779|Experimental|Chantix + Zyban|For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
3093291|NCT01806857|Other|Nuedexta then Matching Placebo|Subjects in this arm will receive treatment with Nuedexta first for 28 days (±3 days) and then crossed over to receive treatment with matching placebo for 28 days (±3 days).
3093292|NCT01806857|Other|Matching Placebo then Nuedexta|Subjects in this arm will receive treatment with matching placebo first for 28 days (±3 days) and then crossed over to receive treatment with Nuedexta for 28 days (±3 days).
3093293|NCT01806896|Experimental|20 mg Arm Cohort A|
3093294|NCT01806896|Placebo Comparator|Placebo Arm Cohort A|
3093295|NCT01806896|Experimental|5 mg Arm Cohort B|
3093296|NCT01806896|Placebo Comparator|Placebo Arm Cohort B|
3093297|NCT01807000|Experimental|Radiolabeled Prucalopride Succinate|
3093298|NCT01807026|Experimental|Cohort A: 70 mg LY2886721|Participants with Alzheimer's disease received a single, 70-milligrams (mg) (1 capsule), oral dose of LY2886721.
3093299|NCT01807026|Placebo Comparator|Cohort A: Placebo|Participants with Alzheimer's disease received a single, oral dose of LY2886721-matching placebo (1 capsule).
3093300|NCT01807026|Experimental|Cohort B: 70 mg LY2886721|Healthy participants received a single, 70-mg (1 capsule), oral dose of LY2886721.
3093301|NCT01807026|Placebo Comparator|Cohort B: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (1 capsule).
3093302|NCT01807026|Experimental|Cohort C: 280 mg LY2886721|Healthy participants received a single, 280-mg (4 x 70 mg capsules), oral dose of LY2886721.
3093303|NCT01807026|Placebo Comparator|Cohort C: Placebo|Healthy participants received a single, oral dose of LY2886721-matching placebo (4 capsules).
3093304|NCT01807065|Experimental|Arm A (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes days 22, 36, and 50.
3093305|NCT01807065|Experimental|Arm B (radiation therapy, sipuleucel-T)|Patients undergo external beam radiation therapy in weeks 1-2. Patients also receive sipuleucel-T as in Arm A.
3093306|NCT01807091|Experimental|Treatment (chemotherapy)|Participants received intensive initial or salvage induction chemotherapy regimens. These regimens would usually be administered in the inpatient setting, however participants received them outpatient. This study did not dictate the choice of induction chemotherapy regimen. The regimen was decided upon by patient and their treating oncologist and clinical care team. The induction chemotherapy regimens administrations spanned 4-7 days.
3093307|NCT01807104|Active Comparator|Anterior Approach Total Hip|Total hip arthroplasty performed through an anterior surgical approach. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach
3093308|NCT01807104|Active Comparator|Posterior Approach Total Hip|The additional arm is the posterior approach total hip, which the Anterior Approach is being compared too. Compare results of total hip arthroplasty performed through either an Anterior or Posterior Surgical Approach.
3093310|NCT01807156|Experimental|Tivozanib|Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1. If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule. Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
3093311|NCT01807221|Experimental|Finerenone(BAY94-8862)[2.5mg] + Placebo|Oral - 2.5mg once daily (OD) for 30 days. Potential up-titration to 5mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3093312|NCT01807221|Experimental|Finerenone (BAY94-8862)[5mg] + Placebo|Oral - 5mg OD for 30 days. Potential up-titration to 10 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3093313|NCT01807221|Experimental|Finerenone (BAY94-8862)[7.5mg] + Placebo|Oral - 7.5mg OD for 30 days. Potential up-titration to 15 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3093314|NCT01807221|Experimental|Finerenone (BAY94-8862)[10mg] + Placebo|Oral - 10mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3093315|NCT01807221|Experimental|Finerenone (BAY94-8862)[15mg] + Placebo|Oral - 15mg OD for 30 days. Potential up-titration to 20 mg OD after 30 days or 60 days. Treatment duration 90 days. Placebo OD for 90 days.
3093316|NCT01807221|Active Comparator|Eplerenone [25 mg] + Placebo|Oral - 25mg every other day (EOD). Potential up-titration to 25mg OD after 30 days and 50mg OD after 60 days.Placebo OD for 90 days.
3093317|NCT01807234|Experimental|Ketorolac/Placebo|Ketorolac 31.5 mg single dose nasal spray and Placebo
3093318|NCT01807234|Experimental|Sumatriptan/Placebo|Sumatriptan 20 mg single dose nasal spray and placebo
3093319|NCT01807234|Placebo Comparator|Ketorolac Placebo/Sumatriptan placebo|single dose Ketorolac placebo, single dose Sumatriptan placebo
3093320|NCT01807299|Experimental|Physical Training|The training group will make physical exercise for three months (three times a week).
3093321|NCT01807299|Other|Sedentary|The sedentary group will be oriented not to make any type of physical training for three months.
3093322|NCT01807299|Placebo Comparator|Placebo|The omega 3 group will receive 2g per day of mineral oil during 90 days treatment
3093323|NCT01807299|Experimental|Omega 3|The omega 3 group will receive 2g per day of fish oil during 90 days treatment
3093324|NCT01807455|Experimental|Restylane Vital Lidocaine|
3093325|NCT01807520|Experimental|Secukinumab (AIN457) 150 mg|Participants assigned to secukinumab 150 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
3093326|NCT01807520|Experimental|Secukinumab (AIN457) 300 mg|Participants assigned to secukinumab 300 mg were dosed weekly for five weeks, then once every four weeks up to and including Week 132. To maintain the blinding, patients received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment are administered by sub-cutaneous injections.
3093327|NCT01807520|Placebo Comparator|Placebo|Patients assigned to placebo were dosed weekly for five weeks, then at Week 8 and Week 12. At Week 16, placebo patients were randomized in a 1:1 ratio, to receive secukinumab either 150 mg or 300 mg and were dosed weekly for five weeks starting at Week 16, then once every four weeks up to and including Week 132. All doses of study treatment are administered by sub-cutaneous injections.
3093328|NCT01807585|Experimental|VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA.
3093329|NCT01807585|Active Comparator|RFA (ClosureFast)|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or RFA.
3093330|NCT01807585|Experimental|Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site, a non-randomized cohort of 2 subjects per clinical site (roll-in phase) were enrolled and treated with VenalSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
3093331|NCT01807598|Experimental|Brentuximab vedotin|Subjects receive a 30-minute IV infusion of brentuximab vedotin once every 21 days for 8 courses, in the absence of disease progression or unacceptable toxicity.
3093332|NCT01807624|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - 3 sprays will be administered at the start of the procedure
3093333|NCT01807637|Experimental|transcranial direct current stim|tDCS will be applied using a Soterix constant current stimulator with 5 x 5 cm (25cm2) carbon rubber electrodes (Covidien 664 REFX 2x2) applied to the scalp with 10-20 conductive paste. The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere [established during TMS motor threshold testing (Baseline Testing) and the functional MRI assessment]. The cathodal electrode will be placed over the contralateral motor cortex.
3093334|NCT01807637|Placebo Comparator|sham tDCS|Sham stimulation will be performed by turning the stimulator off after the initial sensory experience (30 seconds).
3093335|NCT01807650|Experimental|Oleogel-S10, non-adhesive wound dressing|A split-thickness skin graft (STSG) donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to Oleogel-S10 treatment and non-adhesive wound dressing (intra-individual comparison). Oleogel-S10 was administered (1 cm or 100 mg per cm2 wound area corresponding to thickness of about 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
3093336|NCT01807650|Other|Non-adhesive wound dressing only|A STSG donor site wound >15cm2 in size was divided in 2 halves. One half was randomized to treatment with non-adhesive wound dressing only (intra-individual comparison). Non-adhesive wound dressings are standard of care (SOC) in the treatment of STSG donor sites. Wound dressings were changed every 3 to 4 days.
3093337|NCT01807871|Experimental|nicotine patch, experimental use|Participants will continue to use nicotine patch after they lapse and resume smoking as long as smoking is less than 75% of pre study levels.
3093338|NCT01807871|Active Comparator|nicotine patch, labeled use|Participants will discontinue using the nicotine patch when they resume smoking. This is the current FDA approved use of the nicotine patches.
3093339|NCT01807923|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
3093340|NCT01807923|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
3093341|NCT01807923|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
3093342|NCT01807949|Placebo Comparator|Placebo|Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
3093343|NCT01807949|Experimental|LUM 600 mg qd/IVA 250 mg q12h|LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
3093344|NCT01807949|Experimental|LUM 400 mg q12h/ IVA 250 mg q12h|LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.
3093345|NCT01808066|Experimental|Play Groundskeeper|This study will employ design-based research models (Laurel, 2003) to the executive-functioning training game GroundsKeeper by CogCubed; we will assess the quality of digital designs for learning (Barab & Squire, 2004) using established qualitative data collection to analyze game play and player reaction over a three week period of time. We will assess the participants for their ability to stay engaged in play by observing their engagement in the game, time played, frequency of play, and the ability to complete a session over the course of three weeks while in school.
3093346|NCT01808092|Experimental|CAZ-AVI|Intra-Venous treatment
3093347|NCT01808092|Active Comparator|Meropenem|Intra-Venous treatment
3093348|NCT01808118|Experimental|Double-Blind Adalimumab|40 mg every other week (eow), Weeks 28-68. Blinded adalimumab was discontinued in participants who met the criteria for flare.
3093349|NCT01808118|Experimental|Open-label (OL) Adalimumab|40 mg every other week (eow), Weeks 0-28. If participants flared during the double-blind period, they had an opportunity to receive at least 12 weeks of open-label adalimumab 40 mg eow.
3093350|NCT01808118|Placebo Comparator|Placebo|Placebo every other week (eow), Weeks 28-68. Placebo was discontinued in participants who met the criteria for flare.
3093351|NCT01808144|Experimental|lesinurad 400 mg + febuxostat 80 mg|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 3, dated 07 October 2015.
3093352|NCT01808144|Experimental|lesinurad 200 mg + febuxostat 80 mg|
3093353|NCT01808196|Experimental|Losartan|Participants with eosinophilic esophagitis receive Losartan daily
3093354|NCT01808209|Experimental|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3093355|NCT01808209|Active Comparator|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
3093356|NCT01808222|Experimental|FACBC|Participants receiving a bolus of anti-[18F]FACBC injected with PET-CT detection of cancer recurrence.
3093357|NCT01808248|Experimental|SOF+PEG+RBV|Participants will receive SOF+PEG+RBV for 12 weeks.
3468936|NCT03891147|No Intervention|Usual care group|Participants randomized to usual care will continue regular follow up arranged by their visiting physicians in public or private sectors. Current usual care of these patients is limited to symptomatic treatment and dietary advice only during the follow-up session in out-patient clinic until the end of observation period (week 10).
3093360|NCT01808313|Experimental|ambrisentan|ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
3093361|NCT01808326|Experimental|chlorambucil|chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 treatment cycles
3093362|NCT01808339|Experimental|FF AM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the morning (approximately 09:00) and placebo in the evening (approximately 21:00) for 14 days (+/- 2 days).
3093363|NCT01808339|Experimental|FF PM dose|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects will receive FF 100 mcg in the evening (approximately 21:00) and placebo in the morning (approximately 09:00) for 14 days (+/-2 days).
3093364|NCT01808339|Placebo Comparator|Placebo|All the subjects in this study will take part in 3 treatment periods and will receive all three treatments (one per period) in a random manner. In one of the treatment periods, subjects in this arm will receive Placebo in the evening and morning (at approximately 09:00 and 21:00) for 14 days (+/- 2 days).
3093365|NCT01808508|Active Comparator|Group 1- Continuous positive airway pressure (CPAP)|Group 1 will receive therapeutic CPAP for 4 months.
3093366|NCT01808508|Placebo Comparator|Group 2-Sham Continuous positive airway pressure (CPAP)|Group 2 are individuals with OSAS who will receive sham or placebo continuous positive airway pressure (CPAP) for 4 months.
3093367|NCT01808508|No Intervention|Group 3- No Intervention|Group 3 are individuals with normal breathing during sleep who will not receive any intervention and will be used as a control group.
3093368|NCT01808534|Experimental|Treatment (palifosfamide)|Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3093369|NCT01808547|Experimental|ISV-303|
3093370|NCT01808547|Placebo Comparator|Durasite Vehicle|
3093371|NCT01808560|Experimental|LipiFlow Pre-treatment|Subjects randomized to the LipiFlow Pre-Treatment group receive a 12-minute LipiFlow System treatment for MGD in both eyes one month prior to cataract surgery.
3093372|NCT01808560|No Intervention|Untreated Control|Subjects randomized to the untreated control group receive no MGD treatment prior to cataract surgery.
3093373|NCT01808560|Experimental|LipiFlow Post-treatment|Subjects in the untreated control group receive a 12-minute crossover treatment with the LipiFlow System in both eyes three months after cataract surgery.
3093374|NCT01808573|Experimental|neratinib plus capecitabine|neratinib 240 mg orally, once daily with food, continuously in 21 day cycles, and capecitabine 1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
3093375|NCT01808573|Active Comparator|lapatinib plus capecitabine|lapatinib 1250 mg orally, once daily, continuously in 21 day cycles, and capecitabine 2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal, taken on days 1 to 14 of each 21 day cycle.
3093376|NCT01808612|Experimental|20 mg Fluoxetine|20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
3093377|NCT01808612|Experimental|40 mg Fluoxetine|40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
3093378|NCT01808612|Placebo Comparator|Placebo|Placebo (capsules) administered orally, once daily, for 6 weeks
3093379|NCT01808651|Experimental|Fluoxetine|Flexible dosing of 20 to 40 milligrams (mg) administered orally, once daily, for approximately 52 weeks
3093380|NCT01808690|Experimental|Metformin|Metformin will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to placebo.
3093381|NCT01808690|Placebo Comparator|Placebo|Placebo will be given at a dose of 1000 mg twice a day orally for three months to assess changes in insulin resistance compared to metformin.
3093382|NCT01808755|Experimental|D Mannose|1 gr. every 8 hours for 2 weeks, subsequently 1 gr. every 12 hours for 22 weeks
3093383|NCT01808755|Active Comparator|trimethoprim/sulfamethoxazole|intervention was a 5-days course of trimethoprim/sulfamethoxazole cp 160 mg/800 mg twice a day. Then one week of antibiotic every 4 weeks for the following 23 weeks
3093384|NCT01809054|Active Comparator|Arixtra Arm|Arixtra (2.5 mg SQ/QD) subcutaneous injection daily for 2 weeks followed by aspirin 325 mg for 5 weeks
3093385|NCT01809054|Active Comparator|Pneumatic compression stockings arm|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel) for 2 weeks with concomitant Aspirin 325 mg daily for 5 weeks.
3093386|NCT01809106|Active Comparator|Morphine|
3093387|NCT01809106|Experimental|Oxycodone|
3093388|NCT01809106|Experimental|Buprenorphine|
3093389|NCT01809106|Experimental|Fentanyl|
3093390|NCT01809132|Experimental|Anakinra & Pentoxifylline & Zinc Sulfate|anakinra 100mg subcutaneous injection daily for 14 days pentoxifylline 400 mg orally three times daily for 28 day zinc sulfate 220 mg orally for 180 days
3093391|NCT01809132|Active Comparator|Methylprednisolone|methylprednisolone 32 mg orally daily for 28 days
3093392|NCT01809132|No Intervention|Observational|Individuals who choose not to participate in the interventional arm of the trial will be receive standard care and be observed for 6 months. They will be enrolled to have baseline and interval health information and laboratory results collected.
3093393|NCT01809197|Experimental|Air Optix/OFPM|Lotrafilcon B contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with OPTI-FREE MPDS lens care system
3093394|NCT01809197|Active Comparator|Acuvue Oasys/Habitual MPS|Senofilcon A contact lenses (sphere, toric and multifocal), worn on a daily wear basis for 30 days, with habitual MPS lens care system
3093395|NCT01809210|Experimental|Selumetinib+standard chemotherapy|Selumetinib plus gemcitabine; or pemetrexed and cisplatin or carboplatin
3093396|NCT01809262|Experimental|olodaterol 2 mcg|solution for inhalation
3093397|NCT01809262|Experimental|olodaterol 5 mcg|solution for inhalation
3093398|NCT01809262|Experimental|olodaterol 10 mcg|solution for inhalation
3093399|NCT01809262|Experimental|olodaterol 20 mcg|solution for inhalation
3093400|NCT01809262|Experimental|olodaterol 40 mcg|solution for inhalation
3093401|NCT01809262|Placebo Comparator|placebo|solution for inhalation
3093402|NCT01809314||NeoRecormon in Symptomatic Anemia|Participants with symptomatic anemia who are receiving epoetin beta (NeoRecormon) according to standard of care and the Summary of Product Characteristics will be observed for 4 months. Treatment must be selected at the discretion of the prescriber prior to enrollment and will not be chosen by the Sponsor in this non-interventional study.
3093403|NCT01809327|Experimental|Canagliflozin 100 mg|Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
3093404|NCT01809327|Experimental|Canagliflozin 300 mg|Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.
3093405|NCT01809327|Experimental|Metformin XR|Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.
3093406|NCT01809327|Experimental|Canagliflozin 100 mg + Metformin XR|Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
3093407|NCT01809327|Experimental|Canagliflozin 300 mg + Metformin XR|Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.
3093408|NCT01809639|Experimental|Progesterone|400mg of oral micronized progesterone (Prometrium®) on days one, two, and three then 200mg on days four and five
3093409|NCT01809639|Placebo Comparator|Placebo|
3093410|NCT01809834|Active Comparator|Etafilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
3093411|NCT01809834|Experimental|Stenfilcon A|Each participant was randomized to wear the test lens in one eye and the control lens in the other simultaneously
3093412|NCT01809938|Active Comparator|Black Tea|
3093413|NCT01809938|Active Comparator|Tea with Milk|
3093414|NCT01810016|Experimental|Arm A|Ipilimumab (IV) followed by NY-ESO-1 recombinant protein mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
3093415|NCT01810016|Experimental|Arm B|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
3093416|NCT01810016|Experimental|Arm C|Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC (SC) every 3 weeks for 4 doses.
3093417|NCT01810042|Experimental|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
3093418|NCT01810263|Experimental|high protein supplement|high protein supplement given
3093419|NCT01810263|No Intervention|Control|no intervention
3093420|NCT01810289|Experimental|MJAP Clinics Intervention|START intervention. This is a stepped wedge design so each clinic will experience both conditions.
3093421|NCT01810289|No Intervention|MJAP Clinics Pre-Intervention|Standard of care. This is a stepped wedge design so each clinic will experience both conditions.
3093422|NCT01810380|Placebo Comparator|Placebo|
3093423|NCT01810380|Experimental|Brexpiprazole|Patients randomised to brexpiprazole received 1mg/day on Day 1, 2mg/day on Day 2, 3mg/day on Day 3 (uptitration); the dose could be adjusted from Day 4 onwards to 2, 3, or 4mg/day to optimise the clinical effect and tolerability.
3093424|NCT01810380|Other|Quetiapine extended release|Active Reference. Patients randomised to quetiapine received 300mg/day on Day 1, 600mg/day on Days 2 and 3 (uptitration); the dose could be adjusted from Day 4 onwards to 400, 600, or 800mg/day to optimise the clinical effect and tolerability.
3093425|NCT01810432|Experimental|Evacetrapib (Fasted)|130 milligram (mg) oral dose of evacetrapib once daily in a fasted state for 10 days.
3093426|NCT01810432|Experimental|Evacetrapib (Fed)|130 mg oral dose of evacetrapib once daily following a high-fat breakfast for 10 days.
3093427|NCT01810666|Experimental|Recombinant Factor VIII|
3093428|NCT01810692||Group 1|
3093429|NCT01810692||Group 2|
3093430|NCT01810783|Experimental|Brexpiprazole|
3093431|NCT01810939|Active Comparator|Patiromer|Patiromer was administered twice a day as a powder mixed with water.
3093432|NCT01810939|Placebo Comparator|Placebo|Placebo was administered twice a day as a powder mixed with water.
3093433|NCT01810952|Experimental|Glargine/Lispro Insulin Arm|"Drug: Glargine insulin was administered per above.~Drug: Lispro insulin 0.2 unit/kg/day was administered per above. A coverage dose of 0.1 unit/kg/day of lispro for each 10 mg of prednisone or its equivalent was divided between 3 meals. The maximum starting coverage dose was 0.4 units/kg per day.~The prandial dose of lispro was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG is >200 mg/dL. The prandial dose of lispro was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: prednisone or equivalent dose was determined by severity of exacerbation and clinician's judgement."
3093434|NCT01810952|Experimental|Glargine/Lispro/NPH Insulin Arm|"Drugs Glargine and Lispro insulin included similar starting doses of glargine and lispro.~Drug: A coverage dose of NPH insulin 0.1 unit/kg/day for each 10 mg of prednisone or its equivalent was given twice daily with the administration of the glucocorticoid. Maximum starting coverage dose was 0.4 units/kg per day. NPH dose was increased by 10% if the pre-lunch, pre-dinner, or bedtime SG is between 141-200 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was greater than 200 mg/dL. It was decreased by 10% if the pre-lunch, pre-dinner, or bedtime SG was between 70-89 mg/dL, and by 20% if the pre-lunch, pre-dinner or bedtime SG was less than 70 mg/dL.~Drug: the dose of prednisone or equivalent glucocorticoid was determined by severity of exacerbation and clinician's judgement."
3093435|NCT01810991|Experimental|Nd:YAG Laser|Nd:YAG 1440nm Laser
3093436|NCT01811004|Experimental|Botox®|Botox®
3093437|NCT01811004|Experimental|miraDry®|miraDry®
3093438|NCT01811004|Experimental|Nd: YAG laser|Nd: YAG laser 1440nm
3093439|NCT01811030|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3093440|NCT01811147|Experimental|High Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant.
3093441|NCT01811147|Experimental|Low Risk Depression|Interventions will include the prescribing of Selective serotonin reuptake inhibitor or Serotonin-norepinephrine reuptake inhibitor antidepressants, bupropion or other antidepressant..
3093442|NCT01811147|No Intervention|Healthy Control|There is no intervention, but rather phone follow ups conducted as check ins to determine the continued eligibility of the healthy control participant.
3093443|NCT01811147|No Intervention|Bipolar|Bipolar participants are checked in with via phone conversations every three months, and have the opportunity to be scheduled for non-study visits to manage their symptoms.
3093444|NCT01811186|Other|Group A|Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
3093445|NCT01811186|Other|Group B|Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.
3093446|NCT01811212|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3093447|NCT01811225|Experimental|Low-Dose Contraceptive, then High-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the high dose progesterone, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM)."
3093448|NCT01811225|Experimental|High-Dose Contraceptive, then Low-Dose|"Females, 18-35 years old, non-pregnant, using oral contraceptive for at least the last 3 months before enrollment will be given Tri-Sprintec and generic Prometrium.~Participants in this arm will begin with the high progesterone dose, which is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice daily (7AM and 7PM). Then participants in this arm will move to the low dose progesterone, which is seven days of placebo Tri-sprintec + placebo generic Prometrium twice daily (7AM and 7PM)."
3093449|NCT01811238|Experimental|Oxycodone/Naloxone|Single-arm study
3093450|NCT01811303|Experimental|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose containing 40 mg D-fagomine, in 200 ml water
3093451|NCT01811303|Placebo Comparator|Control|Sucrose 50 g without d-fagomine, in 200 ml water
3093452|NCT01811316|Active Comparator|Probiotics Lozenge (twice a day)|Subjects take their lozenge twice a day, one lozenge in the morning after brushing and one lozenge in the evening after brushing.
3093453|NCT01811316|Active Comparator|Probiotics Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
3093454|NCT01811316|Placebo Comparator|Placebo Lozenge (once a day)|Subjects take their lozenge once a day, one lozenge at night after brushing.
3093455|NCT01811355|Active Comparator|Mexiletine|Mexiletine, capsule, 150mg, PO BID, 14 days
3093456|NCT01811355|Placebo Comparator|Placebo|Placebo, capsule, PO BID, 14 days
3468937|NCT03891017|Experimental|vacuum casting|Vacuum casting will be performed using the Ottobock vacuum casting system. For our vacuum casting procedures, we will be following the protocols outlined in the Harmony Fabrication Quick Guide
3093457|NCT01811472|Placebo Comparator|Placebo|Patients randomized to Placebo arm, received matching placebo to 5 mg, 10 mg and 20 mg pradigstat (LCQ908) once daily for 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3093458|NCT01811472|Experimental|pradigastat (LCQ908) 5mg/10mg|Patients, randomized to pradigastat 5/10 mg, initially began with pradigastat (LCQ908) 5 mg once daily and then were up-titrated, if pradigastat (LCQ908) 5 mg once daily was tolerated, to pradigastat 10 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3093459|NCT01811472|Experimental|pradigastat (LCQ908) 10mg/20mg|Patients, randomized to pradigastat 10/20 mg, initially began with pradigastat (LCQ908) 10 mg once daily and then were up-titrated, if pradigastat (LCQ908) 10 mg once daily was tolerated, to pradigastat 20 mg once daily at Week 2. Total treatment duration was 24 weeks. Each patient was to receive 3 tablets a day. All patients were required to remain on their American Heart Association (AHA) diet for the entire duration of the study.
3093460|NCT01811485|Experimental|LMF237 50/250 mg|Patients took LMF237 50/250 mg twice daily for 14 weeks
3093461|NCT01811485|Experimental|LMF237 50/500 mg|Patients took LMF237 50/500 mg (with a starting dose of LMF 237 50/250 mg for 2 weeks) twice daily for 14 weeks
3093462|NCT01811485|Placebo Comparator|Placebo|Patients took matching placebo of LMF237 (vildagliptin 50 mg) twice daily for 14 weeks
3093463|NCT01811563|Active Comparator|Stryker|Subjects will be receiving the Stryker Triathlon total knee replacement
3093464|NCT01811563|Active Comparator|Zimmer|Subjects will be receiving a Zimmer NexGen total knee replacement
3093465|NCT01811654|No Intervention|Standard Care|Patients in this group will receive treatment per standard care. Standard Care is defined as consisting of physical therapy, activity modification (relative rest), and/or oral analgesic therapy. A specific physical therapy (PT) protocol will be implemented.
3093466|NCT01811654|Active Comparator|Intra-Articular Hyaluronic Acid-Euflexxa|Patients assigned to this group will receive treatment per standard care AND three (3) consecutive weekly injections of intra-articular hyaluronan (Euflexxa). Oral analgesics will be used at the lowest dose and for the shortest time possible to treat PFPS symptoms.
3093467|NCT01811680|Experimental|supervised treadmill training|Supervised treadmill training on variable sensing treadmill.
3093468|NCT01811693|Experimental|Dose Tier 1|Glycerly Trinitrate (Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal
3093469|NCT01811693|Experimental|Dose Tier 2|Glycerly Trinitrate (Nitroglycerine) 10mg/24hour (0.4mg/hour) transdermal
3093470|NCT01811693|Experimental|Dose Tier 3|Glycerly Trinitrate (GTN, Nitroglycerine) 5mg/24hour (0.2mg/hour) transdermal plus a single metered dose 0.4mg of sublingual GTN
3093471|NCT01811706|Experimental|Dalfampridine and then placebo|Participant first receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks. After a washout period of 2 weeks, they then receive Placebo tablet orally every 12 hours, for a 4 weeks period.
3093472|NCT01811706|Experimental|Placebo, Then Dalfampridine|Participant first receive Placebo tablet orally every 12 hours, for a 4 weeks period. After a washout period of 2 weeks, they then receive Dalfampridine at an oral dose of 10mg every 12 hours, for 4 weeks.
3093473|NCT01811732|Experimental|Delafloxacin plus placebo|Delafloxacin 300 mg IV every 12 hours for a minimum of 10 and up to a maximum of 28 doses
3093474|NCT01811732|Active Comparator|Vancomycin plus Aztreonam + placebo|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 and up to a maximum of 28 doses (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
3093475|NCT01811875|Experimental|Optivate 500IU|Optivate 500IU
3093476|NCT01811940|Experimental|Adderall-ER and Topiramate|Adderall-ER will be taken once per day in the morning or early afternoon since it may be activating. The dose is titrated to 60 mg per day or the maximum tolerated dose over two weeks and maintained for the duration of the study. Topiramate will be taken twice per day in the morning and the evening and titrated to 200mg/day or the maximum tolerated dose over the course of 6 weeks and maintained for the duration of the study.
3093477|NCT01811940|Placebo Comparator|Placebo|Placebo will be packaged in matching gelatin capsules similar to the pills in the active arm. Placebo will be taken as frequently and for the same duration as those taken in the active arm.
3093478|NCT01811953|Experimental|1 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fasted conditions
3093479|NCT01811953|Experimental|2 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
3093480|NCT01811953|Experimental|3 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fasted conditions
3093481|NCT01811953|Experimental|4 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
3093482|NCT01811953|Experimental|5 Empagliflozin/Metformin (T)|fixed-dose-combination tablet, oral with 240 ml water under fed conditions
3093483|NCT01811953|Experimental|6 Empagliflozin + Metformin (R)|tablets, oral with 240 ml water under fed conditions
3093484|NCT01812005|Experimental|Cohort A (alisertib, rituximab)|Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3093485|NCT01812005|Experimental|Cohort B (alisertib, rituximab)|Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3093486|NCT01812044|Other|subtenons anesthetic and topical control|Group 1 (subtenons anesthetic and topical control): 0.5 cc of local anesthetic (preservative-free bupivacaine 0.75%) administered via a cannula subtenons through each surgical wound with 0.5 cc of Hypromellose 0.3% gel applied topically to each surgical wound at end of surgery
3093487|NCT01812044|Other|topical anesthetic and subtenons control|Group 2 (topical anesthetic and subtenons control): 0.5 cc of lidocaine 3.5% ophthalmic gel applied topically to each surgical wound and 0.5 cc of normal saline (NS) administered via a cannula subtenons through each surgical wound at end of surgery
3093488|NCT01812044|Other|topical control and subtenons control|Group 3 (topical control and subtenons control): 0.5 cc of topical Hypromellose 0.3% gel applied topically to each surgical wound and 0.5 cc of NS administered via a cannula subtenons through each surgical wound at end of surgery
3093489|NCT01812057|Experimental|Dexamethasone|Dexamethasone 8 mg IV given intraoperatively as a one-time dose.
3093490|NCT01812057|Placebo Comparator|Placebo|Sodium chloride 0.9% (5 ml) given IV intraoperatively as a one time dose.
3093491|NCT01812109|Experimental|Hutchison Technologies Inspectra StO2 NIRS|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy (NIRS) evaluation of acute scrotum per protocol
3093492|NCT01812473||Patients admitted to the Intensive Care Unit|All patients admitted to the Intensive Care Unit, treated with voriconazole are eligible for the study.
3093493|NCT01812655|Experimental|Virtual Reality|Virtual reality using a software program designed for burn patients during burn wound care
3093494|NCT01812655|Active Comparator|Passive distraction|watching a movie
3093495|NCT01812655|No Intervention|UC provided by the nurses|
3093496|NCT01812668|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.
3093497|NCT01812681||Low vitamin D level|The premature infants with low cord blood vitamin D level
3093498|NCT01812681||Normal Vitamin D|The premature infants with normal vitamin D level
3093499|NCT01812707|Placebo Comparator|Placebo|Placebo (for alirocumab) every 2 weeks (Q2W) for 12-weeks in combination with atorvastatin stable dose.
3093500|NCT01812707|Experimental|Alirocumab 50 mg Q2W|Alirocumab 50 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3093501|NCT01812707|Experimental|Alirocumab 75 mg Q2W|Alirocumab 75 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3093502|NCT01812707|Placebo Comparator|Alirocumab 150 mg Q2W|Alirocumab 150 mg Q2W for 12-weeks in combination with atorvastatin stable dose.
3093503|NCT01812759|Experimental|Fentanyl Nasal Spray + Hydromorphone PCA|Fentanyl 100 mcg nasal spray administered plus hydromorphone PCA. All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
3093504|NCT01812759|Experimental|Placebo Nasal Spray + Hydromorphone PCA|Placebo nasal spray administered plus hydromorphone PCA . All study patients receive demand dosing patient-controlled analgesia (PCA) with intravenous hydromorphone. Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
3093505|NCT01812837|Experimental|20 minutes incubation - with pretreatment|
3093506|NCT01812837|Experimental|40 minutes incubation - with pretreatment|
3093507|NCT01812837|Experimental|60 minutes incubation - with pretreatment|
3093508|NCT01812837|Sham Comparator|60 minutes incubation - no pretreatment|
3093509|NCT01813019|Experimental|AFQ056|"Following baseline, approximately 60 patients who are considered eligible will be randomized to AFQ056 arm and will receive the dosing regimen of 4 weeks AFQ056 b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks AFQ056 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg AFQ056 b.i.d)~*patients that do not tolerate 200 mg b.i.d may be down-titrated to 150 mg b.i.d."
3093510|NCT01813019|Placebo Comparator|Placebo|Following baseline, approximately 60 patients who are considered eligible will be randomized to Placebo arm and will receive the dosing regimen of 4 weeks Placebo b.i.d up-titration period of 50 mg,100 mg, 150 mg and 200 mg , followed by 12 weeks Placebo 200 mg fixed dose* and then a 3 week down-titration of 100 mg, 50 mg and 25 mg Placebo b.i.d) *patients that do not tolerate 200 matching placebo AFQ056 mg b.i.d may be down-titrated to 150 mg b.i.d.
3093511|NCT01813058|Placebo Comparator|Placebo|Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery.
3093512|NCT01813058|Active Comparator|Tranexamic acid|Tranexamic acid 100 mg/ml; 50 mg/kg loading dose = 0.5 ml/kg LD given over 15 minutes and 10 mg/kg/hr = 0.1 ml/kg/hr infusion for the duration of the surgery.
3093513|NCT01813071|Experimental|Part A (Adults): Cohort A1|One oral dose of ~3x10^4 cfu WRSS1(10 participants) or placebo (3 participants)
3093514|NCT01813071|Experimental|Part A (Adults): Cohort A2|Three oral doses of ~3x10^5 cfu WRSS1(10 participants) or placebo (3 participants)
3093515|NCT01813071|Experimental|Part A (Adults): Cohort A3|Three oral doses of ~3x10^6 cfu WRSS1(10 participants) or placebo (3 participants)
3093516|NCT01813071|Experimental|Part B (Children): Cohort B1|One oral dose of ~3x10^3 cfu WRSS1(12 participants) or placebo (4 participants)
3093517|NCT01813071|Experimental|Part B (Children): Cohort B2|Three oral doses of ~3x10^4 cfu WRSS1(12 participants) or placebo (4 participants)
3093518|NCT01813071|Experimental|Part B (Children): Cohort B3|Three oral doses of ~3x10^5 cfu WRSS1(12 participants) or placebo (4 participants)
3093519|NCT01813071|Experimental|Part B (Children): Cohort B4|Three oral doses of ~3x10^6 cfu WRSS1(12 participants) or placebo (4 participants)
3093520|NCT01813110|Placebo Comparator|Placebo|Identical olive oil capsules
3093521|NCT01813110|Experimental|Omega-3|4 g prescription omega-3 concentrate (4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks)
3093522|NCT01813149|Experimental|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at affected and unaffected sites.
3093523|NCT01813214|Experimental|Vemurafenib Monotherapy|Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease
3093524|NCT01813214|Experimental|Vemurafenib + Cobimetinib Combination Therapy|"Vemurafenib 960 mg po BID until unacceptable toxicity or progression of disease~Cobimetinib will be given 60mg QD for 21 days on, then 7 days off, in a 28-day treatment cycle."
3093525|NCT01813357|Placebo Comparator|Placebo|sugar pill that is encapsulated so as to appear identical to the active agent
3093526|NCT01813357|Experimental|Rosuvastatin|Rosuvastatin 20mg daily
3093527|NCT01813422|Placebo Comparator|Placebo|Participants received placebo to evolocumab administered by subcutaneous injection once a month for 76 weeks.
3093528|NCT01813422|Experimental|Evolocumab|Participants received 420 mg evolocumab administered by subcutaneous injection once a month for 76 weeks.
3093529|NCT01813435|Experimental|Experimental treatment strategy|"All patients in the treatment group will receive acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy.~Dosage and frequency:~Ticagrelor: 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd)"
3093530|NCT01813435|Active Comparator|Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy.~Dosage and frequency:~Brilique(Ticagrelor): 90 mg b.i.d. ASA: of 75mg qd (- ≤ 100 mg qd) Clopidogrel: 75 mg qd"
3093531|NCT01813474|Experimental|olaparib tablet monotherapy|olaparib tablet
3093532|NCT01813721||Group 1|All patients enrolled
3093533|NCT01813734|Experimental|Ponatinib Treatment Arm|Ponatinib 30 mg PO daily
3093534|NCT01813890|Experimental|Tapentadol IR 50 mg|
3093535|NCT01813890|Experimental|Tapentadol IR 75 mg|
3093536|NCT01813890|Placebo Comparator|Placebo|
3093537|NCT01814007|Experimental|CoolSculpting Treatment Group|CoolSculpting treatments will be performed on all subjects with 1 cooling cycle on the lower abdomen, plus simultaneous treatment of both flanks, one cooling cycle each. Two control units will be utilized at protocol-defined temperatures and durations.
3093538|NCT01814046|Experimental|cells + high dose aldesleukin|Patients receiving cells + high dose aldesleukin
3093539|NCT01814046|Experimental|cells and no high dose aldesleukin|Patients receiving cells and no high dose aldesleukin
3093540|NCT01814072|Experimental|Condition 1|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions; 3) Report to Primary Care Physician
3093541|NCT01814072|Experimental|Condition 2|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements; 5) Buddy training via webinars
3093542|NCT01814072|Experimental|Condition 3|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
3093543|NCT01814072|Experimental|Condition 4|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
3093544|NCT01814072|Experimental|Condition 5|1) Lifestyle Core; 2) 12 telephone sessions; 3) Buddy training via webinars
3093545|NCT01814072|Experimental|Condition 6|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Recommendations to use meal replacements
3093546|NCT01814072|Experimental|Condition 7|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages
3093547|NCT01814072|Experimental|Condition 8|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
3093548|NCT01814072|Experimental|Condition 9|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician
3093549|NCT01814072|Experimental|Condition 10|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Buddy training via webinars
3093550|NCT01814072|Experimental|Condition 11|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages; 5) Buddy training via webinars
3093551|NCT01814072|Experimental|Condition 12|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages
3093552|NCT01814072|Experimental|Condition 13|1) Lifestyle Core; 2) 24 telephone sessions; 3) Buddy training via webinars
3093553|NCT01814072|Experimental|Condition 14|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Recommendation to use meal replacements
3093554|NCT01814072|Experimental|Condition 15|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages
3093555|NCT01814072|Experimental|Condition 16|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Regular text messages, 5) Buddy training via webinars
3093556|NCT01814072|Experimental|Condition 17|1) Lifestyle Core; 2) 12 Telephone Coaching Sessions
3093557|NCT01814072|Experimental|Condition 18|1) Lifestyle Core; 2) 12 telephone sessions; 3) Recommendations to use meal replacements; 4) Buddy training via webinars
3093558|NCT01814072|Experimental|Condition 19|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
3093559|NCT01814072|Experimental|Condition 20|1) Lifestyle Core; 2) 12 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
3093560|NCT01814072|Experimental|Condition 21|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
3093561|NCT01814072|Experimental|Condition 22|1) Lifestyle Core; 2) 12 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendations to use meal replacements
3093562|NCT01814072|Experimental|Condition 23|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
3093563|NCT01814072|Experimental|Condition 24|1) Lifestyle Core; 2) 12 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
3093564|NCT01814072|Experimental|Condition 25|1) Lifestyle Core; 2) 24 telephone coaching sessions
3093565|NCT01814072|Experimental|Condition 26|1) Lifestyle Core; 2) 24 telephone sessions; 3) Recommendation to use meal replacements; 4) Buddy training via webinars
3093566|NCT01814072|Experimental|Condition 27|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Buddy training via webinars
3093567|NCT01814072|Experimental|Condition 28|1) Lifestyle Core; 2) 24 telephone sessions; 3) Regular text messages; 4) Recommendation to use meal replacements
3093568|NCT01814072|Experimental|Condition 29|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Buddy training via webinars
3093569|NCT01814072|Experimental|Condition 30|1) Lifestyle Core; 2) 24 telephone coaching sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements
3093570|NCT01814072|Experimental|Condition 31|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Regular text messages
3093571|NCT01814072|Experimental|Condition 32|1) Lifestyle Core; 2) 24 telephone sessions; 3) Report to Primary Care Physician; 4) Recommendation to use meal replacements; 5) Regular text messages, 6) Buddy training via webinars
3093572|NCT01814137|Experimental|IDegAsp BID + IAsp OD|
3093573|NCT01814137|Experimental|IDeg OD + IAsp TID|
3093574|NCT01814241|Experimental|Open label peanut OIT|Open label orally ingested peanut flour with maintenance dose of 1450mg
3093575|NCT01814332|Experimental|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
3093576|NCT01814332|Placebo Comparator|Placebo|Placebo compound treatment for comparison with IP
3093577|NCT01814371|Active Comparator|Individualized Approach|The decolonization regimen will be performed only by those household members who experienced SSTI in the prior year.
3093578|NCT01814371|Active Comparator|Household Approach|All members of the household will perform the decolonization regimen.
3093579|NCT01814397||Women starting AI therapy|There is only a single cohort. Postmenopausal women with ER positive breast cancer who are starting treatment with anastrozole 1 mg daily, letrozole 2.5 mg daily, or exemestane 25 mg daily. Choice of therapy is at the discretion of the treating physician.
3093580|NCT01814553|Experimental|Afatinib 40 mg + Loperamide (Cohort 1)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
3093581|NCT01814553|Experimental|Afatinib 40 mg + loperamide prophylactic (Cohort 2)|afatinib starting 40 mg daily; Cohort 1 will receive loperamide at first sign of diarrhea; Cohort 2 will receive loperamide starting C1D1.
3093582|NCT01814670|Experimental|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
3093583|NCT01814696|No Intervention|Control|Subjects will continue to receive usual medical care from their doctor(s).
3093584|NCT01814696|Experimental|MedSentry System|Subjects will continue to receive usual medical care from their doctor(s). Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
3093585|NCT01814748|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
3093586|NCT01814748|Placebo Comparator|Placebo|Placebo to omarigliptin, once weekly, for 24 weeks. Open-label metformin daily was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
3093587|NCT01814761||Pts with POAG or OH (Previously Treatment Naive)|Previously treatment naïve patients with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
3093588|NCT01814761||Pts with POAG or OH (Switched Monotherapy)|Patients previously on another monotherapy treatment with Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) who require treatment with bimatoprost 0.01% (Lumigan® 0.01%).
3093589|NCT01814774||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3093590|NCT01814774||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3093591|NCT01814787|Experimental|CHICA Type 2 Diabetes Module|Children treated at the two intervention clinic sites will have be treated using the CHICA system AND will be provided access to the newly developed CHICA Type 2 Diabetes Module. The CHICA Type 2 Diabetes Module will assist pediatricians in identification of those children 10 years of age or older who are at increased risk for type 2 diabetes, it will provide pediatric physicians guidelines to screen for type 2 diabetes, and it will coordinate the diagnosis and long-term management of the condition.
3093592|NCT01814787|No Intervention|Usual Care|Those patients who are assigned to the control group will have the CHICA system but will NOT be cared for using the CHICA Type 2 Diabetes Module. The CHICA system will notify the physician of the child's BMI percentile on the physician worksheet. However, the CHICA system will not ask for any additional information related to risk factors for type 2 diabetes on the pre-screening form, no advice will be provided to the physician on the physician worksheet, nor will just-in-time documents or automated reminder calls be made available. Identification of patients at risk for type 2 diabetes and care of those patients will occur through routine practices for that clinic.
3093593|NCT01814800|Experimental|RI-002 Treatment|Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
3093594|NCT01814813|Experimental|Arm 1, HSPPC-96 + concomitant bevacizumab|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles), plus bevacizumab 10 mg/kg intravenous (IV) on day 1 of each cycle, until progression. HSPPC-96 should be administered at least 60 minutes prior to starting bevacizumab infusion. (1 cycle=14 days)~Note: If HSPPC-96 treatment has ended but there is no evidence of disease progression, the patient should continue to receive bevacizumab at the specified dose until progression."
3093595|NCT01814813|Experimental|Arm 2, HSPPC-96 with bevacizumab at progression|"HSPPC-96 0.4mL intradermal on days 1 and 8 of cycles 1 and 2, then on day 1 of each cycle, up to a maximum of 12 doses (10 cycles). At progression: bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until further progression. (1 cycle = 14 days)~NOTE: It is possible that HSPPC-96 vaccination may end prior to evidence of progression. In this instance it is important to wait until there is confirmed evidence of progression before initiating treatment with bevacizumab.~Upon confirmation of progression the patient should initiate bevacizumab within 7-42 days from the last dose of vaccine."
3093596|NCT01814813|Active Comparator|Arm 3, Bevacizumab|Bevacizumab 10mg/kg intravenous (IV) on day 1 of each cycle, until progression. (1 cycle = 14 days)
3093598|NCT01814878|Experimental|Tramadol Hydrochloride/Acetaminophen ER|Participants will be administered 2 oral tablets of extended release (ER) tramadol HCl (75 milligram [mg])/acetaminophen (650 mg) and 2 tablets of placebo matching to immediate release (IR) tramadol HCl/acetaminophen orally every 12 hours up to 36 hours, and 2 tablets of placebo matching to IR tramadol HCl/acetaminophen every 6 hours up to 42 hours.
3093599|NCT01814878|Active Comparator|Tramadol HCl/Acetaminophen IR|Participants will be administered 2 oral tablets of IR tramadol HCl (37.5 mg)/acetaminophen (325 mg) and 2 tablets of placebo matching to ER tramadol HCl/acetaminophen at 0, 12, 24 and 36 hours, and 2 tablets of IR tramadol HCl/acetaminophen at 6, 18, 30 and 42 hours.
3093600|NCT01815008|Experimental|Clopidogrel|Clopidogrel 75 mg daily by mouth for 1 week then Clopidogrel 75 mg daily with aspirin 81 mg daily
3093601|NCT01815099|Experimental|rTMS Treatment|Clinical participants will receive rTMS
3093602|NCT01815138|Experimental|hCG given at time of GnRHa trigger|"Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger.~Placebo administered 35 hours after GnRH agonist trigger"
3093603|NCT01815138|Active Comparator|hCG given 35 hours after GnRHa trigger|"Placebo administered at the time of GnRH agonist trigger~Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger."
3093604|NCT01815229|Experimental|tracheal lavages|"After the placement of the endotracheal tube (Hi-Lo™ Evac Mallinckrodt), tracheal lavages will be performed.~A simultaneous blood sample of approx 5cc, will be collected by venipuncture or by sampling from intravenous or arterial line if available. The same procedure for collection of tracheal sample and blood will be repeated at the end of the surgical procedure and immediately prior to removal of the ETT. A total of approx 10cc blood will be collected for research purposes."
3093605|NCT01815229|Placebo Comparator|Healthy Control|To replicate activation, neutrophils were isolated from 30mL blood of healthy volunteers and cocultured with TLF from subjects with or without sore throat pain.
3093606|NCT01815333|Experimental|Feraheme|Magnetic resonance imaging (MRI) acquired prior to the injection of Feraheme® and repeated at approximately 48 hours and 72 hours from the time of injection (scan time). The scan time will be adjusted, as needed. The MRI scan prior to the Feraheme injection is the routine scan. The scans at 48 and 72 hours are investigational.
3093607|NCT01815424|Placebo Comparator|Placebo BID|
3093608|NCT01815424|Experimental|5mg BID CP-690,550|
3093609|NCT01815424|Experimental|10mg BID CP-690,550|
3093610|NCT01815502|Experimental|Dobutamine + Sildenafil|Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
3093611|NCT01815502|Placebo Comparator|Dobutamine + placebo|Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
3093612|NCT01815515|Experimental|18F-DCFBC|Participants with hormone-naive prostate cancer (HNPC) and castration-resistant prostate cancer (CRPC) with metastatic lesions detected on conventional imaging modalities (contrast-enhanced computed tomography [CECT] and bone scintigraphy [BS]) undergo PET imaging with 18F-DCFBC radiotracer.
3093613|NCT01815645|Active Comparator|Standard treatment Alone|Participants in the Standard Treatment Alone group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted
3093614|NCT01815645|Experimental|ST+CM|Participants in the Standard treatment plus Contingency Management (ST+CM) group will receive 12 weeks of the exact treatment provided by the Ambulatory service where the study is being conducted plus CM.
3093615|NCT01815671|Other|Lateral horizontal body position|Subjects randomized to receive colonoscopy in the lateral horizontal position, This is the standard position. The other position - tilt down is the intervention
3093616|NCT01815671|Other|Lateral tilt down body position|Subjects randomized to receive colonoscopy in the lateral tilt down position
3093617|NCT01815736|Experimental|E/C/F/TAF|"Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
3093618|NCT01815736|Active Comparator|Stay on Baseline Treatment Regimen (SBR)|"Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.~Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF."
3093619|NCT01815840|Experimental|Vismodegib Intermittent Schedule|Vismodegib intermittent schedule of 12 weeks vismodegib followed by 8 weeks placebo, repeated 3 times with a final course of vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
3093620|NCT01815840|Experimental|Vismodegib Induction Followed by Intermittent Schedule|Vismodegib beginning with 24 weeks induction followed by intermittent schedule 8 weeks placebo, 8 weeks vismodegib (total 72 weeks), followed by 52 weeks treatment-free follow up
3093621|NCT01815918|Placebo Comparator|Placebo|Patients receive a saline placebo before surgery, 8 hours after the first dose and 16 hours after the first dose.
3093622|NCT01815918|Active Comparator|Treatment|Patients receive 3 100 mg of hydrocortisone: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
3093623|NCT01816048|Experimental|TAK-700|"TAK-700 will be administered at 300 mg orally (PO)twice daily (BID) continuously on 28-day treatment cycles.~The most common way of assessing bone metastasis is planar bone scintigraphy or single photon emission computed tomography (SPECT), though both lack high spatial resolution and thus make small metastases detection inaccurate. Positron emission tomography (PET) is a successful imaging modality with a higher resolution than SPECT, but has not been widely adopted in bone imaging. One of the most promising PET imaging agents for detection of bone metastasis is 18F-Sodium Fluoride (Fluorine F 18 Sodium Fluoride, or NaF). NaF uptake is characterized by high and rapid bone uptake accompanied by very rapid blood clearance, which results in a high bone-to-background ration in a short time."
3093624|NCT01816061|Experimental|Experimental - COMPASS|Goal-setting sessions
3093625|NCT01816061|Active Comparator|Control - COMPASS|Informative phone calls
3093626|NCT01816074|Experimental|Maternal Medication then meds|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to enhanced medication
3093627|NCT01816074|Experimental|BPT then continued beh tx|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to enhanced behavioral treatment.
3093628|NCT01816074|Experimental|Maternal Medication then BPT|The mothers in this treatment arm are given an active medication to treat ADHD (Vyvanse) in the first phase of the study, and in the second phase are randomized to combined treatment (adding Behavior Parent Training).
3093629|NCT01816074|Experimental|BPT then maternal medication|The mothers in this treatment arm are given Behavior Parent Training in the first phase of the study, and in the second phase are randomized to active ADHD medication, Vyvanse.
3093630|NCT01816230|Experimental|NiCord®|NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
3093631|NCT01816243|Experimental|Transdermal Therapeutic System (TTS)-fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. Oral morphine syrup is allowed to titrate the dose of TTS-fentanyl. The study duration will be 30 days after first patch application.
3093632|NCT01816295|Placebo Comparator|Placebo Solution|Placebo Solution applied topically once daily for 12 weeks.
3093633|NCT01816295|Experimental|Testosterone Solution|Testosterone Solution 60 milligram (mg) applied topically once daily with possible titration down to 30 milligram per day (mg/day) or up to 120 mg/day for 12 weeks and optional extension for 24 weeks.
3093634|NCT01816451|Experimental|interval|The running training for interval group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine. The interval training group intensities ranged between 84-87% of maximal heart rate (HRmax) (vigorous intensity), 88-93%HRmax (near maximum intensity) and 94-99% HRmax (maximum intensity).
3093635|NCT01816451|Experimental|continuous|The running training for continuous group were performed on a treadmill for a period of 14 weeks, with a frequency of three times a week, lasting 20-minutes per session thus completing 46 sessions of training. The intensity and volume of training both were adapted according to the recommendations of the American College of Sports Medicine.The continuous group ran at an intensity of ~87% of maximal heart rate (HRmax)
3093636|NCT01816451|No Intervention|control|The control group did not do the running training program. Control did their normal physical activities.
3093637|NCT01816477|Active Comparator|Thoracic epidural|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
3093638|NCT01816477|Experimental|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
3093639|NCT01816594|Experimental|BKM120 + Trastuzumab + paclitaxel|BKM120 (oral, pan-class I PI3K inhibitor) in combination with trastuzumab and paclitaxel.
3093640|NCT01816594|Placebo Comparator|BKM120 PBO + Trastuzumab + paclitaxel|BKM120 placebo in combination with trastuzumab and paclitaxel
3093641|NCT01816685|Experimental|CPAP|Patients in the CPAP group will be instructed to wear an autotitrating positive airway pressure (APAP) device any time they sleep prior to surgery and on postoperative days 0, 1, and 2.
3093642|NCT01816685|No Intervention|Routine Care|
3093643|NCT01816711||Hip fracture, Frail elderly, Non-supplemented|Frail elderly with a hip fracture who did not received vitamin D supplementation
3093644|NCT01816711||Hip fracture, Frail elderly, Supplemented|Frail elderly with a hip fracture who received vitamin D supplementation
3093645|NCT01816763|Experimental|tablet based NRS pain one week, followed by nurse pain screen|tablet-based patient self-report of the 'NRS pain one week'
3093646|NCT01816763|Experimental|tablet based PEG, followed by nurse pain screen|tablet-based enhanced pain screening with the PEG (pain intensity, emotional, and functional pain interference)
3093647|NCT01816763|Experimental|DVPRS, followed by nurse pain screen|Defense Veterans Pain Rating Scale on tablet followed by usual nursing staff documented pain screening with NRS pain now
3093648|NCT01816776|Experimental|Treatment Group|Subjects implanted with the remedē system device and randomized to the Treatment group will receive optimal medical therapy and have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).
3093649|NCT01816776|Other|Control group|Subjects implanted with the remedē system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remedē system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).
3093650|NCT01816893|Sham Comparator|Euglycemic hyperinsulinemic clamp|participant undergoes a euglycemic hyperinsulinemic clamp
3093651|NCT01816893|Active Comparator|Hypoglycemic hyperinsulinemic clamp|participant undergoes a hypoglycemic hyperinsulinemic clamp
3093652|NCT01816906|Active Comparator|MCP Insole|"The intervention is Footwear: MCP. MCP insoles are commonly used within Diabetic sandals in India."
3093653|NCT01816906|Active Comparator|PU insole|"The intervention is Footwear: PU. Insoles made of Polyurethane(PU) are given to the participants in the intervention arm."
3093654|NCT01816945|Experimental|Access to MOMBA web-based application|Study will provide the subject with a smartphone, pay the data plan, and facilitate access to the web-based application for purposes of researching the acceptability of the application, the operating and functioning of it, and its impact on maternal mental health.
3093655|NCT01816945|No Intervention|Smartphone only|Study will provide the subject with a smartphone and pay the data plan. Weekly assessments are completed through internet survey links sent via text message.
3468938|NCT03891017|Active Comparator|hydrostatic casting|For the aqua casting system, we will be using an in-house manufactured device. This device will be created following guidelines from the PCAST Technical Manual
3093656|NCT01816984|Experimental|Arm I (BKM120 PO and cetuximab 500 mg IV 14 days)|"Patients receive PI3K inhibitor BKM120 PO QD 100 mg/day on days -7 to 0. Patients complete 1 week washout. 3 patients receive BKM120 PO 80mg / day and cetuximab 500 mg IV /14 days and after dose escalation, 9 patients receive BKM120 PO 100mg / day and cetuximab 500 mg IV /14 days thereafter.~All patients receive PI3K inhibitor BKM120 PO QD day on days 1-28 and cetuximab IV over 60-120 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3093657|NCT01817075|Experimental|Arm I (CHG cleansing wipe)|Patients receive CHG cleansing with topical skin wipes QD for 90 days.
3093658|NCT01817075|Active Comparator|Arm II (control)|Patients receive control cleansing with topical skin wipes QD for 90 days.
3093659|NCT01817374|Other|2D US grayscale plus quantitative VCEUS|"Patients with breast cancer receiving neoadjuvant chemotherapy will undergo a 2D grayscale imaging followed by quantitative VCEUS imaging:~prior to initiation of treatment (baseline);~at 14 (± 4 days) after initiation of neoadjuvant chemotherapy (early treatment);~at 28 days (± 4 days) after initiation of neoadjuvant chemotherapy (inter-regimen);~at completion of therapy prior to definitive surgery (usually 2-3 months after initiation of treatment). Each patient will undergo a total of four VCEUS examinations."
3093660|NCT01817491|Active Comparator|Reduced Fat Vegan Diet|Plant based diet with as few added oils and fats as possible.
3093661|NCT01817491|Active Comparator|American Heart Association Diet|Diet emphasizing fruits, vegetables and whole grains but also low fat dairy, low fat meat and fish.
3093662|NCT01817530|Placebo Comparator|Cohort 1: Placebo|Placebo for elagolix and placebo for E2/NETA twice daily (BID)
3093663|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID|Elagolix 300 mg BID alone
3093664|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus LD E2/NETA QD|Elagolix 300 mg BID plus low-dose (LD) E2/NETA once daily (QD)
3093665|NCT01817530|Experimental|Cohort 1: Elagolix 300 mg BID plus SD E2/NETA QD|Elagolix 300 mg BID plus standard-dose (SD) E2/NETA QD
3093666|NCT01817530|Placebo Comparator|Cohort 2: Placebo|Placebo for elagolix and E2/NETA QD
3093667|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD|Elagolix 600 mg QD alone
3093668|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus LD E2/NETA QD|Elagolix 600 mg QD plus LD E2/NETA QD
3093669|NCT01817530|Experimental|Cohort 2: Elagolix 600 mg QD plus SD E2/NETA QD|Elagolix 600 mg QD plus SD E2/NETA QD
3093670|NCT01817582|Experimental|Lotemax Gel 0.5% and Restasis 0.05%|Participants will administer lotemax gel 0.5 % BID in both eyes (OU) for 2 weeks, then administer both lotemax gel 0.5% and restasis emulsion 0.05% BID OU for 2 weeks, then administer restasis emulsion 0.05% BID OU for 8 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
3093671|NCT01817582|Experimental|Lotemax Gel 0.5%|Participants will administer lotemax gel 0.5% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
3093672|NCT01817582|Active Comparator|Restasis 0.05%|Participants will administer restasis emulsion 0.05% BID OU for 12 weeks. Participants will also receive preservative-free Soothe Lubricant Eye Drops as needed (up to 4 times per day).
3093673|NCT01817712|Experimental|Individual Placement and Support (IPS)|The IPS intervention must achieve a rating of >66 of a possible 75 points on the Supported Employment Fidelity Scale. The fidelity ratings are conducted by the National IPS Fidelity Monitor at biannual on-site monitoring visits.
3093674|NCT01817712|Active Comparator|VA Transitional Work Program (TWP)|TWP will adhere to a lower rating (less than or equal to 55 of a possible 75 points) on the Supported Employment Fidelity Scale rated by the National Fidelity Monitor. The TWP specialist participates in face-to-face supervision with the local Compensated Work Therapy (CWT) team according to the CWT manager's schedule.
3093675|NCT01817725|Experimental|Engerix-B|Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for >20 years old and 20μg for < or =20 years old
3093676|NCT01817751|Experimental|Treatment (sorafenib tosylate, valproic acid, sildenafil)|"Sorafenib 400 mg orally twice a day;~Valproic acid (to levels ≥ Lower Level of Normal (LLN) orally twice a day;~Sildenafil 50 mg orally twice a day~A cycle consists of 4 weeks.~*The first 6 patients evaluable for qualifying toxicity assessment will be treated as a safety lead-in; enrollment will be gated (the first 3 evaluable patients must complete 4 weeks of the combination therapy before the next 3 patients start combination treatment on protocol)"
3093677|NCT01817764|Experimental|Umeclidinium/vilanterol Arm|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via the NDPI and placebo administered as one inhalation each morning and evening via ACCUHALER/DISKUS
3093678|NCT01817764|Active Comparator|Fluticasone propionate/salmeterol Arm|The subjects will receive FSC 250/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS and placebo administered once-daily in the morning via NDPI
3093679|NCT01817777|Experimental|Metformin Small Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin small pack arm will receive medication free of charge in a small pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
3093680|NCT01817777|Experimental|Metformin Large Pack Arm|All subjects in the study will be initially followed for an 8-week observational phase during which subjects will visit the pharmacy and purchase metformin following their usual routines. After 8-weeks subjects will be randomised to one of the 2 treatments arms. Subjects in the metformin large pack arm will receive medication free of charge in a large, monthly pack. Dosing of metformin will not be dictated by the protocol. Subjects will remain on their prescribed dose of metformin throughout the study, unless a change is recommended by their physician.
3093681|NCT01817790|Experimental|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
3093682|NCT01817790|Placebo Comparator|Placebo nasal spray|Two sprays of placebo per nostril to be administered in morning.
3468939|NCT03891134|Experimental|enriched Branched Chain Amino Acid intervention|enriched Branched Chain Amino Acid nutrition supplement 3.6 g twice a day for 5 weeks then withdrawal nutrition supplement for 12 weeks
3093683|NCT01817855|Experimental|1|"Groups 1-4 multiple ascending doses of AZD7624 Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 patients will receive matching placebo."
3093684|NCT01817855|Placebo Comparator|2|"Groups 1-4 multiple ascending doses of placebo Healthy subjects will participate in groups 1-3. In each group 6 subjects will receive AZD7624 and 2 will receive matching placebo.~COPD patients will participate in group 4. In this group, 8 patients will receive AZD7624 and 2 will receive matching placebo."
3093685|NCT01817907|Placebo Comparator|Placebo|Subjects will receive a sugar pill during their placebo night sleep study.
3093686|NCT01817907|Active Comparator|Trazodone|Subjects will receive trazodone during their treatment night sleep study
3093687|NCT01817959|Experimental|Reparixin group|Continuous iv infusion
3093688|NCT01817959|Placebo Comparator|Placebo group|Continuous iv infusion
3093689|NCT01818063|Experimental|Arm 1 (paclitaxel, carboplatin)|Patients receive paclitaxel IV and carboplatin IV on day 1 (course 1 only) or day 2 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3093690|NCT01818063|Experimental|Arm 2 (veliparib, paclitaxel, carboplatin)|Patients receive veliparib PO BID on days 1-5. Patients also receive paclitaxel IV and carboplatin IV on day 3 (course 1 only) or day 4 (courses 2-12). Treatment repeats every 7 days for 12 courses in the absence of disease progression or unacceptable toxicity. Beginning 21 days after the last course, patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3093691|NCT01818141|Active Comparator|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
3093692|NCT01818141|Active Comparator|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
3093693|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Abdomen)|Participants ≤55 years of age will receive 1 subcutaneous (SC) injection of 0.5 Units per kilogram (U/kg) of LY2605541 in the abdominal wall on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
3093694|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Upper Arm)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the upper arm on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
3093695|NCT01818245|Experimental|LY2605541: Cohort A (Injection site: Thigh)|Participants ≤55 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the thigh on Day 1 in 1 of 3 treatment periods. There was a washout period of 16-28 days between each treatment period.
3093696|NCT01818245|Experimental|LY2605541: Cohort B (Injection site: Abdomen)|Participants ≥65 years of age will receive 1 SC injection of 0.5 U/kg of LY2605541 in the abdominal wall on Day 1.
3093697|NCT01818258|Active Comparator|Severe Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
3093698|NCT01818258|Active Comparator|Normal Nutrition/Mild Malnutrition|ZDV+3TC+LPV/r Zidovudine (ZDV, Retrovir®) 10 mg/ml oral syrup administered twice daily at WHO weight band dose for 48 weeks; Lamivudine (Epivir®, 3TC) 10 mg/ml for oral solution administered twice daily at WHO weight band dose for 48 weeks; Lopinavir/ritonavir (Kaletra®, LPV/r) 80/20 mg/ml oral solution administered twice daily at the WHO weight band dose for 48 weeks
3093699|NCT01818284|Experimental|Filgrastim + Plerixafor|"Each donor receives Filgrastim 5 µg/kg subcutaneously in the morning daily for 4 days. The dose of Filgrastim based on the donor's actual body weight. Donors will continue Filgrastim until completion of apheresis. Each donor receives Plerixafor 240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization. The dose-volume of Plerixafor based on the donor's actual body weight. Apheresis procedure to start the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor. The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 cluster of differentiation 34 (CD34+) cells/kg (recipient's weight) is obtained."
3093700|NCT01818297|Active Comparator|Treatment|Treatment settings of Medtronic PrimeAdvanced® neurostimulator system implant
3093701|NCT01818297|Other|Control|Control settings of Medtronic PrimeAdvanced® neurostimulator system implant
3093702|NCT01818336|Experimental|all subjects|"Intervention: Penicillin skin test kit~Subjects with negative intradermal tests will be given single oral amoxicillin challenge dose and followed for 72 hours for IgE dependent reactions."
3093703|NCT01818414|Experimental|Misoprostol|Misoprostol 400 mcg buccal 3 hours prior to D&E as an adjunct to same-day Dilapan-S.
3093704|NCT01818414|Placebo Comparator|Folic Acid|Folic acid 4 mg buccally 3 hours prior to D&E as an adjunct to same-day Dilapan-S
3093705|NCT01818427|Experimental|plasma|infusion of 2 units of plasma
3093706|NCT01818427|No Intervention|standard air medical care|control group
3093707|NCT01818492|Experimental|NI-0501|
3093708|NCT01818518||Preterm Labor|Group who goes into labor prior to 32 weeks of gestation
3093709|NCT01818518||Prelabor rupture of membranes|Group who have prelabor rupture of membranes are those who break their bag of water prior to 32 weeks gestation in the absence of labor.
3093710|NCT01818518||Premature birth before 32 weeks gestation|Premature birth before 32 weeks gestation not including PTL or PROM
3093711|NCT01818531|Experimental|Adductor canal block|Patients in this arm will receive an adductor canal block prior to undergoing a medial compartment knee arthroplasty.
3093712|NCT01818531|Active Comparator|Lumbar plexus block|Patients in this arm will receive a lumbar plexus block prior to undergoing a medial compartment knee arthroplasty.
3468940|NCT03890939|Experimental|BiPAP AutoSV Advanced System One|
3468941|NCT03890939|Experimental|Dreamstation BiPAP AutoSV|
3468942|NCT03890939|Active Comparator|ResMed S7 VPAP Adapt device|
3093713|NCT01818596|Experimental|E/C/F/TAF|Participants will receive E/C/F/TAF for 144 weeks. Following Week 144, in countries where E/C/F/TAF is not available (except for the United Kingdom), participants will be given the option to continue in the study and receive E/C/F/TAF for another 48 weeks, or until the product becomes available through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever comes first.
3093714|NCT01818700|Other|Single arm-Norspan patch (Buprenorphine)|This trial is single arm with Norspan patch. Treatment with NORSPAN Ò will be started from 5 μg/h (1 patch a week) for 2 weeks, and proper titration (up-titration) will be allowed at visit 2(wk 2) and at visit 3(wk 4) according to the investigator's decision. The up-titration will be considered by investigator's judgement as follows; (1) if the rescue medication was used more than 2 times per day, on average or (2) based on the daily average NRS(Numeric Rating Scale), if the NRS was changed to worsen since the previous visit, (3) Investigator's judgement by considering any titration needed situation (e.g. dose, frequency of rescue medication).
3093715|NCT01818726|Experimental|Serum ferritin level ≥ 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
3093716|NCT01818726|Experimental|Serum ferritin level < 1,000 μg/l|Transfusion-dependent adult patients with AA and serum ferritin < 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product
3093717|NCT01818739|Experimental|sentinel lymph node detection|Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.
3093718|NCT01818752|Experimental|Carfilzomib, Melphalan, Prednisone|Participants received carfilzomib administered in combination with melphalan and prednisone for nine 42-day cycles. Carfilzomib was administered as an intravenous (IV) infusion on days 1, 2, 8, 9, 22, 23, 29, and 30 of each 42-day cycle. The carfilzomib dose was at 20 mg/m² on cycle 1, days 1 and 2 followed by 36 mg/m² thereafter. On days 1 to 4, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
3093719|NCT01818752|Active Comparator|Bortezomib, Melphalan, Prednisone|Participants received bortezomib in combination with melphalan and prednisone for nine 42-day cycles. Bortezomib was administered either IV or subcutaneously at 1.3 mg/m² during cycles 1 to 4 on days 1, 4, 8, 11, 22, 25, 29, and 32 followed by 1.3 mg/m² during cycles 5 to 9 on days 1, 8, 22, and 29. On days 1 to 4 of each cycle, melphalan was administered at 9 mg/m² and prednisone was administered at 60 mg/m².
3093720|NCT01818765|Experimental|Procedure|"Pre-procedure speckle-tracking echocardiography assessment of latest activation~Trans-ventricular-septal placement of LV pacing lead~Acute response assessment"
3093721|NCT01818804|Active Comparator|n-3PUFA|n-3 polyunsaturated fattyacids from fish oil
3093722|NCT01818804|Placebo Comparator|olive oil|Olive oil
3093723|NCT01819129|Experimental|Faster-acting insulin aspart (FIAsp)|Meal time faster-acting insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
3093724|NCT01819129|Active Comparator|Insulin aspart|Meal time insulin aspart is given in combination with once daily insulin glargine and metformin in a basal-bolus regimen. Insulin glargine and metformin treatment are open labelled background medication.
3093725|NCT01819194|Experimental|senofilcon A|Acuvvue Oasys with Hydaclear Plus with 38% water.
3093726|NCT01819233|Experimental|Behavioral dietary intervention|Beginning 2-4 weeks after completion of lumpectomy, patients receive food diaries to complete for 7-10 days. Dietary counselors then give patients guidelines for dietary modifications to reduce caloric intake by 25% of their normal diet. Patients follow caloric restricted diet for 10 weeks (2 weeks prior to radiation therapy, during 6 weeks of radiation therapy, and at least 2 weeks after radiation therapy). Patients undergo radiation therapy QD 5 days a week for 6 weeks.
3093727|NCT01819272|Experimental|600 mg DR|600 mg delayed-release metformin once daily in the morning
3093728|NCT01819272|Experimental|800 mg DR|800 mg delayed-release metformin once daily in the morning
3093729|NCT01819272|Experimental|1000 mg DR|1000 mg delayed-release metformin once daily in the morning
3093730|NCT01819272|Active Comparator|1000 mg XR|1000 mg extended-release metformin once daily in the evening
3093731|NCT01819272|Active Comparator|2000 mg XR|2000 mg extended-release metformin once daily in the evening
3093732|NCT01819272|Placebo Comparator|Placebo|Placebo once daily in the morning
3093733|NCT01819311|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program
3093734|NCT01819311|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
3093735|NCT01819415|No Intervention|Naive|Patients starting on intravitreal anti-VEGF treatment, not receiving Omega-3 supplements. They serve as wet-AMD controls.
3093736|NCT01819415|Active Comparator|Anti-VEGF plus AREDS-1 supplementation.|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-1 plus Lutein supplementation formula.
3093737|NCT01819415|Experimental|Anti-VEGF plus AREDS-2|Patients already receiving intravitreal anti-VEGF treatment assigned to take AREDS-2 supplementation formula, that includes Omega-3 metabolites (DHA and EPA).
3093738|NCT01819415|No Intervention|Control|Patients undergoing vitrectomy surgery for epiretinal membrane or macular hole had their vitreous samples to serve as controls.
3093739|NCT01819506|Experimental|Targeted Task Practice|"Targeted task practice is defined as a therapy program aimed at patient-specific upper extremity motor impairment levels and systematically progressed to assure an ongoing just right match between task-difficulty and patient-ability. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length."
3093740|NCT01819506|Active Comparator|Non-Targeted Task Practice|Non-targeted task practice is a standard of care treatment consisting of task practice with no guidance from the measurement framework to systematically address specific upper extremity motor impairment levels or progress rehabilitation therapy. Participants attended occupational therapy 3 times per week for 4 weeks. Each therapy session was 2 hours in length.
3093741|NCT01819597|Other|EDAS surgery|EDAS surgery is an established form of indirect revascularization. The study arm in this study will receive EDAS surgery
3093742|NCT01819727|Active Comparator|BMN 165, 20mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
3093743|NCT01819727|Active Comparator|BMN 165, 40mg/day|Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and > 900 μmol/L).
3093744|NCT01819844|Experimental|Closed-loop blood glucose control|Type 1 diabetes, Type 2 diabetes, total daily dose (TDD) of insulin that is > 1 u/kg or > 2 u/kg.
3093745|NCT01819883||Active Acromegaly|All study subjects with acromegaly will be studied twice - once during the active stage of their disease (pre-treatment) and a second time: 3 months after treatment of acromegaly. Controls will be studied at one time point.
3093746|NCT01819883||Healthy controls|
3093747|NCT01819922|Experimental|PF-05175157|
3093748|NCT01819922|Placebo Comparator|Placebo|
3093749|NCT01819935||linezolid (Zyvox)|
3093750|NCT01819935||Vancomycin|
3093751|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.005%|Open-label, dose escalation, 3 days treatment
3093752|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 3 days treatment|Randomized, 3 days treatment
3093753|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.018% for 2 days treatment|Randomized 2 days treatment
3093754|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 3 days treatment|Randomized 3 days treatment
3093755|NCT01820260|Active Comparator|Part 2: Ingenol mebutate gel 0.027% for 2 days treatment|Randomized 2 days treatment
3093756|NCT01820260|Placebo Comparator|Part 2: Placebo for 3 days treatment|Randomized 3 days treatment
3093757|NCT01820260|Placebo Comparator|Part 2: Placebo for 2 days treatment|Randomized 2 days treatment
3093758|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.008%|Open-label, dose escalation, 3 days treatment
3093759|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.012%|Open-label, dose escalation, 3 days treatment
3093760|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.027%|Open-label, dose escalation, 3 days treatment
3093761|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 3 days treatment
3093762|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.06%|Open-label, dose escalation, 2 days treatment
3093763|NCT01820260|Experimental|Part 1A: Ingenol mebutate gel 0.018%|Open-label, dose escalation, 3 days treatment
3093764|NCT01820260|Experimental|Part 1B: Ingenol mebutate gel 0.04%|Open-label, dose escalation, 2 days treatment
3093765|NCT01820364|Experimental|LGX818 single agent|Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
3093766|NCT01820416|Experimental|Low-Level Laser Therapy|Low-level laser applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
3093767|NCT01820416|Placebo Comparator|Disabled Laser|Low-level laser device with laser diodes disabled. Also applied for approximately 4 minutes to the area around the pinna, the back of the neck, and the top of the head.
3093768|NCT01820416|No Intervention|Control|Visit laboratory using same schedule as experiment and placebo. No Low-level laser or any treatment applied. Used to assess normal test-retest variability.
3093769|NCT01820559|Active Comparator|ESL 1200 mg|eslicarbazepine acetate 1200 mg
3093770|NCT01820559|Active Comparator|ESL 800 mg|eslicarbazepine acetate 800 mg
3093771|NCT01820559|Placebo Comparator|Placebo|Placebo tablets
3093772|NCT01820572|Experimental|Belatacept|Belatacept 5 mg/kg intravenous 30 minute infusion on Days 1, 15, 29, 43, 57 then every 28 days for 24 months
3093773|NCT01820572|Active Comparator|CNI|"Tacrolimus 4-11 ng/mL tablet orally according to package insert for 24 months~Cyclosporine 50-250 ng/mL tablet orally according to package insert for 24 months"
3093774|NCT01820585|Placebo Comparator|Placebo|Tablets
3093775|NCT01820585|Active Comparator|ESL 400 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3093776|NCT01820585|Active Comparator|ESL 800 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3093777|NCT01820585|Active Comparator|ESL 1200 mg|Eslicarbazepine acetate (BIA 2-093) tablets
3093778|NCT01820637|Experimental|Test device arm (DES SFA)|Patients in this arm will receive the study device: the Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)
3093779|NCT01820754|Experimental|Ipilimumab|Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery) Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses
3093780|NCT01821105|Experimental|Preoperative PET and CT Scans|Patients undergo preoperative whole-body PET scans and CT scans of the abdomen and pelvis. Patients then receive fluoro-deoxyglucose (FDG)IV 60-90 minutes prior to surgery and undergo intraoperative CT scans using a handheld probe and computer navigation system.
3093781|NCT01821118|Experimental|1|
3093782|NCT01821118|Placebo Comparator|2|
3093783|NCT01821300||Down syndrome|No intervention occurred as this was a cross sectional observational study.
3093784|NCT01821300||Control|No intervention occurred as this was a cross sectional observational study.
3093785|NCT01821352|Active Comparator|Erchonia Obesity Laser|The Erchonia® Obesity Laser is made up of 10 independent 17 milliWatts (mW), 532 nanometer (nm) green laser diodes, each diode positioned 120 degrees apart from the next with each titled at a 30 degree angle. The Erchonia® Obesity Laser is a pulsed wave variable frequency device.
3093786|NCT01821352|Placebo Comparator|Placebo Laser|Laser device emitting sham green light that has no therapeutic effect.
3093787|NCT01821378|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
3093788|NCT01821378|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2
3093789|NCT01821378|Placebo Comparator|Placebo|Placebo Comparator 20 or 80 mg once daily
3093790|NCT01821391|Experimental|NDL-PDT/c-PDT|Metvix natural daylight photodynamic therapy and Metvix conventional photodynamic therapy
3093791|NCT01821391|Experimental|NDL-PDT/placebo c-PDT|Metvix natural daylight photodynamic therapy and Metvix-placebo conventional photodynamic therapy
3093792|NCT01821417|Experimental|Microtextured dental implant|Randomized for microtextured dental implant treatment
3093793|NCT01821417|Active Comparator|Dental implant|Randomized dental implant treatment with machined-collar implants
3093794|NCT01821534||All Participants|Healthy volunteers. No treatment (intervention) was administered.
3093795|NCT01821560|Placebo Comparator|Sugar pill|Placebo-treated subjects will follow the identical schedule as Baclofen subjects.
3093796|NCT01821560|Active Comparator|Baclofen|Baclofen will be dispensed in pill form. Baclofen will be prescribed at 20 mg 4 times per day. Each baclofen pill will be 10 mg. Thus, 2 pills will be taken at each scheduled dose for a total of 8 pills a day over a period of 8 weeks. In this way, the titration schedule, taper and potential dose reductions can be managed.
3093797|NCT01821625|Experimental|Thrombocytopenic (Low Platelet) Patients|"All study patients will undergo intervention in this study.~The intervention will be a lead-in with eltrombopag and antiviral triple therapy (interferon, ribavirin and boceprevir)."
3093798|NCT01821729|Experimental|Experimental Arm|FOLFIRINOX, Losartan, Proton Beam Radiation Therapy
3093799|NCT01821807||26 gauge quincke|Patients (n=150) will be treated with 26 gauge quincke spinal needle for spinal anesthesia for cesarean section.
3093800|NCT01821807||26 gauge atraucan|Patients (n=110) will be treated with 26 gauge atraucan spinal needle for spinal anesthesia for cesarean section.
3093801|NCT01821937|Experimental|faldaprevir(high dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
3093802|NCT01821937|Experimental|Faldaprevir(low dose)|10 subjects (approximate sex ration: 1:1) will be assigned to trial by single and multiple dose.
3093803|NCT01822119|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
3093804|NCT01822132|Experimental|Extended release naltrexone|One dose of intramuscular injection of 380mg extended-release naltrexone.
3093805|NCT01822132|Placebo Comparator|Placebo|One dose of intramuscular injection of placebo.
3093806|NCT01822197|Experimental|Phototherapy|Bright light phototherapy will be administered for 30 minutes daily over one week in the morning (Days 0-7)
3093807|NCT01822223|Experimental|Laser-ablated dental implant-abutments|Laser-ablated dental implant abutments will be attached to surgically placed dental implants.
3093808|NCT01822223|Active Comparator|Smooth implant-abutments|Smooth dental implant-abutments will be attached to surgically placed dental implants.
3093809|NCT01822301|Experimental|Repeat Facial fat grafting|
3093810|NCT01822353|Experimental|Milk allergy|Dietary supplement, milk in increasing dosages, delivered daily and orally.
3093811|NCT01822353|Experimental|Egg allergy|Dietary supplement, egg protein given in increasing dosages, delivered daily and orally.
3093812|NCT01822353|Experimental|Nut allergy|Dietary supplement, nut cream including nut allergens, delivered in increasing dosages, daily and orally.
3093813|NCT01822366|No Intervention|Usual Care Comparison Condition|Half of the participating children/guardian dyads will receive no intervention (usual care) to serve as a control.
3093814|NCT01822366|Experimental|Trauma-focused CBT group therapy|Half of the participating children/guardian dyads will receive the 12-week Trauma-focused Cognitive Behavioral Therapy (TF-CBT) group treatment.
3093815|NCT01822457|Experimental|Nike FuelBand (NFB)|Patients will receive a Nike Fuel Band to encourage exercise.
3093816|NCT01822457|No Intervention|control|Standard follow-up
3093817|NCT01822496|Experimental|EGFR: Erlotinib|Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
3093818|NCT01822496|Active Comparator|EGFR: No Erlotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
3093819|NCT01822496|Experimental|ALK: Crizotinib|Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.
3093820|NCT01822496|Active Comparator|ALK: No Crizotinib|Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.
3093821|NCT01822535|No Intervention|No Drug: Tetraplegia|"Tetraplegia: Lesion level T1 and above, American Spinal Injury Association (ASIA) impairment levels A and B, ages 18-68 years.~Exposure of up to 2 hours in a cool room."
3093822|NCT01822535|No Intervention|No Drug: AB Controls|AB Controls: Matched for age and gender to subjects with tetraplegia. Exposure of up to 2 hours in a cool room.
3093823|NCT01822535|Experimental|Drug (midodrine): Tetraplegia|Persons with tetraplegia who completed Visit 1 (no drug). Participants are administered midodrine hydrochloride (10 mg tablet) by a physician before exposure of up to 2 hours in a cool room. (Visit 2)
3093824|NCT01822548|Experimental|Vildagliptin & metformin|Vildagliptin 100 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
3093825|NCT01822548|Active Comparator|Glibenclamide & metformin|Glibenclamide maximum dose of 10 mg tablet and metformin (max dose=2500 mg) tablet daily oral administration
3093826|NCT01822561|Experimental|Eplerenone|All patients in this study will receive Eplerenone 50mg once daily for 4 weeks.
3093827|NCT01822574|Active Comparator|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
3093828|NCT01822574|Active Comparator|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
3093829|NCT01822574|Active Comparator|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
3093830|NCT01822587|Placebo Comparator|Placebo|Administered once orally following cue exposure on each of the first two days of testing.
3093831|NCT01822587|Active Comparator|Propranolol 40mg|Administered once orally following cue exposure on each of the first two days of testing.
3093832|NCT01822587|Active Comparator|Propranolol, 80mg|Administered once orally following cue exposure on each of the first two days of testing.
3093833|NCT01822665|Active Comparator|Paracetamol Tablet|Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
3093834|NCT01822665|Active Comparator|Ibuprofen Tablet|Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
3093835|NCT01822665|Placebo Comparator|Placebo Tablet|Placebo tablets, 2 tablets QID administered with water.
3093836|NCT01822665|Active Comparator|Ibuprofen Capsule|Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water
3093837|NCT01822678|Experimental|Group 1|Group 1: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
3093838|NCT01822678|Experimental|Group 2|Group 2: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
3093839|NCT01822678|Placebo Comparator|Group 3|Group 3: Placebo (change in daily number of tablets administered, according to clinical response).
3093840|NCT01822691|Experimental|INCB024360 Treatment|Participants were treated with 600 mg orally, twice a day for 16 weeks, unless clear evidence of disease progression or toxicity was evident.
3093841|NCT01822756|Experimental|Regimen A -ruxolitinib, gemcitabine|Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food. The morning dose of RUX was to be taken before the chemotherapy infusion, Gemcitabine IV, on days when they were given together (Days 1, 8, and 15 of each cycle).
3093842|NCT01822756|Experimental|Regimen B-ruxolitinib, gemcitabine, nab-paclitaxel, filgrastim|"Ruxolitinib (RUX) was self-administered by the subject orally in the morning and evening, approximately 12 hours apart, without regard to food.~Gemcitabine was provided as open-label, commercial product and was administered intravenously (IV) over 30 minutes on Days 1, 8, and 15 of each 28-day cycle. Reduced doses of gemcitabine administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle could also be explored.~nab-Paclitaxel, as open-label, commercial product, was administered IV over 30 minutes on Days 1, 8, and 15 of each 28-day cycle."
3093843|NCT01822821|Experimental|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
3093844|NCT01822821|Placebo Comparator|Placebo|Patients will receive up to four doses of IV placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
3093845|NCT01822886|Experimental|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD (progression disease)
3093846|NCT01822899|Experimental|Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS|Subjects will receive UMEC/ VI 62.5/25 mcg, one inhalation administered once-daily in the morning via the NDPI and one placebo ACCUHALER/DISKUS administered as one inhalation each morning and evening.
3093847|NCT01822899|Active Comparator|Fluticasone propionate/Salmeterol + placebo NDPI|Subjects will receive FSC 500/50 mcg, administered as one inhalation each morning and evening via ACCUHALER/DISKUS + placebo administered once daily in the morning via NDPI.
3093848|NCT01822925|Experimental|DA-9801 300mg|DA-9801 will be administered in tablet form, 100mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3093849|NCT01822925|Experimental|DA-9801 600mg|DA-9801 will be administered in tablet form, 200 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3093850|NCT01822925|Experimental|DA-9801 900mg|DA-9801 will be administered in tablet form, 300 mg taken 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 12 weeks.
3093851|NCT01822925|Placebo Comparator|Placebo|Placebo (same formulation as DA-9801 but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 12 weeks.
3093852|NCT01823107|Experimental|Meso BioMatrix Device|All subjects will have the Meso BioMatrix device implanted along with a tissue expander during the first stage of breast reconstruction. During the second stage of breast reconstruction, the tissue expander is replaced with a breast implant.
3093853|NCT01823146|Experimental|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
3093854|NCT01823146|Placebo Comparator|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
3093855|NCT01823224|Experimental|Group 1|"Group 1 will receive IV acetaminophen 1000mg plus 2 oral capsules sugar pills 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses of acetaminophen totaling or equaling 2000mg"
3093856|NCT01823224|Experimental|Group 2|"Group 2 will receive an IV salt water infusion plus 2 capsules of oral acetaminophen 1 hour prior to surgical incision and 4 hours after initial dose, for a total of two doses totaling or equaling 2000mg."
3093857|NCT01823289|Experimental|Itraconazole Sequential Therapy|
3093858|NCT01823328|Active Comparator|Ketamine|Subjects in the ketamine arm will receive ketamine for sedation prior to rapid sequence intubation (RSI).
3093859|NCT01823328|Active Comparator|Etomidate|Subjects in the etomidate arm will receive etomidate for sedation prior to rapid sequence intubation (RSI).
3093860|NCT01823341|Active Comparator|Pump suspension algorithm|The pump suspension algorithm will be running actively on the study laptop during the night and suspend the pump if the algorithm predicts hypoglycemia.
3093861|NCT01823341|No Intervention|Standard of Care|The control algorithm will run passively and not suspend the patient's pump.
3093862|NCT01823497|Active Comparator|Parent/Nurse Controlled Analgesia|Parent/Nurse Controlled Analgesia will be the method of morphine delivery.
3093863|NCT01823497|Active Comparator|Continuous Opioid Infusion|Continuous Opioid Infusion will be the method used to deliver morphine to group 2
3093864|NCT01823510|Experimental|Ticagrelor + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
3093865|NCT01823510|Active Comparator|Clopidogrel + Aspirin|Loading-dose plus daily-dosing for 5-7 days.
3093866|NCT01823536|Experimental|MenACWY-CRM (≥7-≤10 years of age)|Subjects, who had previously received 2 injections of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
3093867|NCT01823536|Experimental|MenACWY-CRM_1 (≥7-≤10 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 2-5 years of age, were administered 1 injection of the same vaccine at 7-10 years of age.
3093868|NCT01823536|Experimental|Vaccine naive (≥7-≤10 years of age)|Vaccine naive subjects, age-matched to the ≥7-≤10 years of age groups, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3093869|NCT01823536|Experimental|MenACWY-CRM_1 (≥11-≤15 years of age)|Subjects, who had previously received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine at 7-10 years of age, were administered 1 injection of the same vaccine at 11-15 years of age.
3093870|NCT01823536|Experimental|Vaccine naive (≥11-≤15 years of age)|Vaccine naive subjects, age-matched to the ≥11-≤15 years of age group, received 1 injection of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
3093871|NCT01823614||Naïve patients, >500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is more than 500 cells per mm3
3093872|NCT01823614||Naïve patients, 350-500|The group contains patients who have not any ARV therapy experience and the level of CD4 count is between 350 and 500 cells per mm3
3093873|NCT01823614||Naïve patients, <350|The group contains patients who have not any ARV therapy experience and the level of CD4 count is less than 350 cells per mm3
3093874|NCT01823614||ARVT <6 months|The group contains patients who have ARVT experience and obtain ART treatment less than 6 months
3093875|NCT01823614||ARVT from 6 months to 3 years|The group contains patients who have ARVT experience and obtain ART treatment from 6 months to 3 years
3093876|NCT01823614||ARVT >3 years|The group contains patients who have ARVT experience and obtain ART treatment more than 3 years
3093877|NCT01823653|Experimental|Treated Thigh|Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)
3093878|NCT01823679|Experimental|Capecitabine 1000 mg/m²|"Participants will receive oral capecitabine twice-a-day (BID) as 500 mg/m² doses on days 1 to 14.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3093879|NCT01823835|Experimental|Phase Ia - Cohort 1|100 mg GDC-0810 once daily (QD) in fasting state.
3093880|NCT01823835|Experimental|Phase Ia - Cohort 2|200 mg GDC-0810 QD in fasting state.
3093881|NCT01823835|Experimental|Phase Ia - Cohort 3|400 mg GDC-0810 QD in fasting state.
3093882|NCT01823835|Experimental|Phase Ia - Cohort 4|600 mg GDC-0810 QD in fasting state.
3093883|NCT01823835|Experimental|Phase Ia - Cohort 5|600 mg GDC-0810 QD in non-fasting state.
3093884|NCT01823835|Experimental|Phase Ia - Cohort 6|300 mg GDC-0810 twice daily (BID) in fasting state.
3093885|NCT01823835|Experimental|Phase Ia - Cohort 7|800 mg GDC-0810 QD in fasting state.
3093886|NCT01823835|Experimental|Phase Ia - Cohort 8|800 mg GDC-0810 QD in non-fasting state.
3093887|NCT01823835|Experimental|Phase Ia - Cohort 9|400 mg GDC-0810 BID in fasting state.
3093888|NCT01823835|Experimental|Phase IIa - Cohort A1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had confirmed ER-a (ESR1) mutation of the ligand binding domain (LBD).
3093889|NCT01823835|Experimental|Phase IIa - Cohort A2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and confirmed ER-a (ESR1) mutation of the LBD.
3093890|NCT01823835|Experimental|Phase IIa - Cohort B1|600 mg GDC-0810 QD. Additionally, participants in this arm did not receive any prior treatment with fulvestrant and had progressed following ≤1 prior therapy with an aromatase inhibitor (AI).
3093891|NCT01823835|Experimental|Phase IIa - Cohort B2|600 mg GDC-0810 QD. Additionally, participants in this arm had prior treatment with fulvestrant and progressed following ≤1 prior therapy with an AI.
3093892|NCT01823835|Experimental|Phase Ib - Cohort C1|400 mg GDC-0810 + 125 mg Palbociclib QD.
3093893|NCT01823835|Experimental|Phase Ib - Cohort D1|≤600 mg GDC-0810 QD + LHRH agonist once monthly.
3093894|NCT01823861|Experimental|Mobile phone-based intervention|Standard care plus automated voice message to support post-abortion contraception use every two weeks for total of three months and direct follow up phone call by family planning counsellor depending on response to voice message.
3093895|NCT01823861|No Intervention|Standard care|Face-to-face post-abortion family planning (PAFP) counselling, follow-up at one or two weeks, clinic phone number, existing 'Hotline' phone number.
3093896|NCT01823991|Experimental|COGNUTRIN (VITABLUE and n-3 fatty acids)|Participants will be provided with two bottles containing Lovaza and VitaBlue. Participants will be asked to take 1 tablet of Lovaza two times a day and 1 tablet of VitaBlue three times a day.
3093897|NCT01823991|Placebo Comparator|Placebo Administration|Participants will be provided with two bottles containing placebo. Participants will be asked to take 1 tablet of one placebo two times a day and 1 tablet of other placebo three times a day.
3093898|NCT01824082|Experimental|Ropivacaine 0.5%|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: normal saline.
3093899|NCT01824082|Placebo Comparator|Normal saline (salt water) infusion|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of normal saline placebo fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects assigned this treatment for their initial infusion will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment: ropivacaine 0.5%.
3093900|NCT01824160|Other|Repair of RV-PA Conduit Disruption|Covered stenting of RV-PA conduit injury
3093901|NCT01824290|Experimental|Tadalafil|"Period 1: 20 mg or 40 mg administered orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final tadalafil doses for Period 1 (6-month double-blind) were assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431).Tadalafil doses would range from 5 milligram (mg) to 40 mg depending on body weight cohorts. Heavy weight cohort ≥40 kilogram (kg), Middle weight cohort ≥25 kg to <40 kg: administered orally by tablets once a day. Light weight cohort <25 kg: administered orally by suspension once a day.~Participants receiving tadalafil in Period 1 continued to receive tadalafil during Period 2 (2-year open-label extension)."
3093902|NCT01824290|Placebo Comparator|Placebo|"Period 1: Participants received placebo orally by tablets once a day.~Period 2: 20 mg for middle weight and 40 mg for heavy weight administered orally by tablets once a day.~Final placebo dose for Period 1 (6-month double-blind) was be assigned after the weight cohort completion from H6D-MC-LVIG (NCT01484431) to maintain blinding depending on body weight cohort.~Participants receiving placebo in Period 1 Period 2 (2-year open-label extension) would receive tadalafil in Period 2 at the corresponding tadalafil dose in that participant's weight group."
3093903|NCT01824303|Experimental|LiRIS 400 mg|LiRIS 400 mg: investigational drug-delivery system which contains Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
3093904|NCT01824303|Placebo Comparator|LiRIS Placebo|LiRIS Placebo: investigational drug-delivery system which contains Lactose and no Lidocaine; the system remains in the bladder for 14 days. If eligible, participants could participate in the Open Label Extension where all participants were treated with LiRIS 400 mg.
3093905|NCT01824342|Experimental|Denosumab|Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
3093906|NCT01824355|Experimental|Intended Users of the Monitoring System|"Untrained subjects with diabetes used the Ninja 3 PLUS Investigational BG Monitoring System. General enrollment criteria for the 'Intended Users' population:~At least 60% of subjects were younger than 65 years of age.~At least 20% had type 1 diabetes.~At least 50% with type 2 diabetes were insulin users."
3093907|NCT01824394|Experimental|nMARQ Catheter|nMARQ Catheter System
3093908|NCT01824394|Active Comparator|NaviStar ThermoCool Catheters|THERMOCOOL® Navigational family of catheters
3093909|NCT01824446|Experimental|Radiolabeled SPD602|
3093910|NCT01824472|Active Comparator|CPAP+CC|Continuous Positive Airway Pressure (CPAP) therapy for sleep apnea and contact control (CC) (placebo/sham for cognitive-behavioral therapy for insomnia)
3093911|NCT01824472|Sham Comparator|sham CPAP+CC|sham CPAP (ineffective CPAP--placebo/sham for sleep apnea) and contact control (placebo/sham for cognitive-behavioral therapy for insomnia)
3093912|NCT01824472|Active Comparator|CPAP+CBT|CPAP therapy for sleep apnea and cognitive-behavioral therapy (CBT) for insomnia
3093913|NCT01824498|Experimental|Low Fat, High Fat, Low Fat High Omega 3|See Intervention Description
3093914|NCT01824498|Experimental|Low Fat, Low Fat High Omega 3, High Fat|See Intervention Description
3093915|NCT01824498|Experimental|High Fat, Low Fat, Low Fat High Omega 3|See Intervention Description
3093916|NCT01824498|Experimental|High Fat, Low fat High Omega 3, Low Fat|See Intervention Description
3093917|NCT01824498|Experimental|Low Fat High Omega 3, High Fat, Low Fat|See Intervention Description
3093918|NCT01824498|Experimental|Low Fat High Omega 3, Low Fat, High Fat|See Intervention Description
3093919|NCT01824576|Experimental|ITPR|Use of the ITPR for 120 minutes.
3093920|NCT01824589|Active Comparator|Group A|tidal volume setting of 6ml/kg with the -7cm H2O ITPR as first device
3093921|NCT01824589|Active Comparator|Group B|tidal volume setting of 8ml/kg with the -7cm H2O ITPR as first device
3093922|NCT01824589|Active Comparator|Group C|tidal volume setting of 6ml/kg with the -12cm H2O ITPR as first device
3093923|NCT01824589|Active Comparator|Group D|tidal volume setting of 8ml/kg with the -12cm H2O ITPR as first device
3093924|NCT01824602|Experimental|Group 1|Eslicarbazepine acetate 1800 mg
3093925|NCT01824602|Experimental|Group 2|Eslicarbazepine acetate 1200 mg
3093926|NCT01824602|Experimental|Group 3|Eslicarbazepine acetate 600 mg
3093927|NCT01824602|Placebo Comparator|Group 4|Placebo pills
3093928|NCT01824693|Experimental|Arm I (busulfan, cyclophosphamide, melphalan)|"CONDITIONING REGIMEN: Patients receive busulfan IV QD, every 12 hours, or every 6 hours over 2-3 hours on days -8 to -5, cyclophosphamide IV QD over 60 minutes on days -4 and -3, and melphalan IV over 15-30 minutes on day -1.~TRANSPLANT: Patients undergo allogeneic HCT no sooner than 24 hours after the last dose of chemotherapy.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
3093929|NCT01824693|Experimental|Arm II (busulfan, fludarabine phosphate)|"CONDITIONING REGIMEN: Patients receive busulfan as in Arm I and fludarabine phosphate IV over 1 hour on days -5 to -2.~TRANSPLANT: Patients undergo allogeneic HCT as in Arm I.~Patients receive tacrolimus IV or PO on days -1 to 98 (related donor) or 180 (unrelated donor) and mycophenolate mofetil IV over 2 hours or PO every 8 hours on days 1-30 (related donor) or 45 (unrelated donor)."
3093930|NCT01824823|Experimental|Arm A (afatinib)|Patients receive afatinib PO QD on days 1-28.
3093931|NCT01824823|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28.
3093932|NCT01824901|Experimental|Phase I|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 2-15 of course 1 and days 1-14 of all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3093933|NCT01824901|Experimental|Arm I (docetaxel; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who experience progressive disease may then register to step II treatment and receive FGFR inhibitor AZD4547 PO BID on days 1-14.
3093934|NCT01824901|Experimental|Arm II (docetaxel and AZD4547; phase II step I)|Patients receive docetaxel IV over 60 minutes on day 1 and FGFR inhibitor AZD4547 PO BID on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3093935|NCT01824901|Experimental|Phase II step II|Patients receive FGFR inhibitor AZD4547 PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3093936|NCT01824979|Experimental|Pilairo mask|Pilairo nasal pillows mask during CPAP titration
3093937|NCT01824979|Active Comparator|Other CPAP mask|Other CPAP mask during CPAP titration
3093938|NCT01825057|Active Comparator|See One|"Providers in See One only receive MI workshop training, giving them an opportunity to see the MI intervention and learn how to conduct it. The trainer encourages them to screen their patients for substance misuse and apply MI as indicated."
3093939|NCT01825057|Experimental|Do One|Following workshop training, MI-trained CL clinicians directly supervise providers' live bedside provision of MI to patients twice before beginning the trial and once midstream. In addition, providers have the option to request additional live supervision from CL clinicians during the trial, consistent with the apprenticeship model.
3093940|NCT01825057|Experimental|Order One|"Following the workshop, providers either administer MI themselves or order a MI for delivery by one of the MI-trained CL clinicians. Only providers in Order One can specifically request MI through a separate CL order in the electronic health record. The physicians or PAs directly place MI orders. Nurses contact physicians or PAs to place the MI order. The CL clinicians are trained in MI via a clinical trials training approach: 1) a 2-day skill-building workshop; 2) three post-workshop supervised practice cases based on review of audio recorded sessions; and 3) follow-up monthly group supervision to maintain and monitor the CL clinicians' MI practice. CL clinicians also learned supervisory practices to provide live supervision to providers in Do One."
3093941|NCT01825122|Placebo Comparator|Placebo|placebo
3093942|NCT01825122|Experimental|Active, nadolol|Active
3093943|NCT01825200|Active Comparator|Flublok|Flublok containing 3x45µg (135µg total) of recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
3093944|NCT01825200|Placebo Comparator|Afluria|Afluria, containing 3x15µg (45µg total), of trivalent, inactivated influenza vaccine (licensed IIV) containing influenza antigen derived from A/H1N1 and A/H3N2 and influenza B viruses in a total volume of 0.5 mL
3093945|NCT01825408|Active Comparator|Doxycycline, 3 weeks|Subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 3 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
3093946|NCT01825408|Active Comparator|Doxycycline, 6 weeks|Subjects with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)will receive Doxycycline 100mg BID or if allergic to doxycycline, then Augmentin 875mg BID for 6 weeks duration. These patients will also receive a course of Prednisone (30mg x 3d, 20mg x 3d, 10mg x3d, 10mg every other day for 6 days (3 doses)) which is standard of care treatment for patients with chronic sinusitis with nasal polyps.
3093947|NCT01825408|Active Comparator|Azithromycin, 3 weeks|Subjects with Chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 3 weeks duration.
3093948|NCT01825408|Active Comparator|Azithromycin, 6 weeks|Subjects with chronic Rhinosinusitis without Nasal Polyps will receive Azithromycin 250mg daily, or if allergic to azithromycin, then Augmentin 875mg BID for 6 weeks duration.
3093949|NCT01825512|Experimental|Deferiprone|75-100 mg/kg/day seven days per week
3093950|NCT01825512|Active Comparator|Deferasirox|20 to 40 mg/kg/day seven days per week
3093951|NCT01825577|Experimental|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
3093952|NCT01825655|Active Comparator|Cetirizine|zyrtec 10mg, oral, one time
3093953|NCT01825655|Placebo Comparator|Sugar pill|Placebo, one pill, one time
3093954|NCT01825785|Placebo Comparator|Placebo|Participants were randomized to receive matching placebo administered by subcutaneous injection once every 2 weeks (Q2W) or once every 4 weeks (Q4W) for 3 months.
3093955|NCT01825785|Experimental|Romosozumab|Participants were randomized to receive romosozumab administered by subcutaneous injection at doses of 1 mg/kg Q2W, 2 mg/kg Q4W, 2 mg/kg Q2W, or 3 mg/kg Q4W for 3 months.
3093956|NCT01825798|Placebo Comparator|Placebo Hydrochloride Oral Solution|
3093957|NCT01825798|Experimental|Metformin|
3093958|NCT01825837|Experimental|BIA 2-093 1800 mg (Group 1)|BIA 2-093 1800 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3093959|NCT01825837|Experimental|BIA 2-093 900 mg (Group 2)|BIA 2-093 900 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3093960|NCT01825837|Experimental|BIA 2-093 300 mg (Group 3)|BIA 2-093 300 mg once daily (Part II followed a double-blind, parallel-group design in which participants were randomly assigned to treatment with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily). Study medication was administered orally, once daily in the evening.
3093961|NCT01825837|Experimental|ESL (Part I)|In Part I, all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks.
3093962|NCT01825876|Active Comparator|Warfarin|15 milligrams (mg) warfarin administered as a single oral dose
3093963|NCT01825876|Experimental|Evacetrapib + Warfarin|130 mg evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 10
3093964|NCT01825889|Experimental|Evacetrapib (Participants With Renal Impairment)|Single oral dose of 130 milligrams (mg) evacetrapib on Day 1 to participants with severe renal impairment.
3093965|NCT01825889|Experimental|Evacetrapib (Healthy Participants)|Single oral dose of 130 mg evacetrapib on Day 1 to participants with normal renal function.
3093966|NCT01825941|Active Comparator|Metoclopramide + Diphenhydramine|Metoclopramide 10 milligrams + Diphenhydramine 50 milligrams, administered as an intravenous drip over 15 minutes
3093967|NCT01825941|Placebo Comparator|Metoclopramide + placebo|Metoclopramide 10mg + placebo, administered intravenously over 15 minutes
3093968|NCT01826201|Experimental|10% MOL4239 ointment & placebo ointment|10% MOL4239 ointment to one target lesion and placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
3093969|NCT01826214|Experimental|LDE225-400|Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
3093970|NCT01826214|Experimental|LDE225-800|Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.
3093971|NCT01826227|Experimental|Positron Emission Tomography|This is a pilot study to determine the ability of intraoperative PET probe to detect and localize recurrent disease. Patients with evidence for a first recurrence of ovarian, fallopian tube or primary peritoneal carcinoma, with evidence of 18F-FDG avid disease on 18F-FDG PET/CT and who are able to undergo secondary CRS are eligible. 20 patients will be studied. All patients will undergo secondary cytoreduction guided by intraoperative PET probe survey. Intraoperative count levels as well as exvivo counts of the resected specimens will be done. Specimens detected with probe only will be labeled so and will be submitted to pathology for histopathologic confirmation.
3093972|NCT01826370||Linagliptin|
3093973|NCT01826422|Experimental|EPA and DHA|Supplementation of 2.7 g/d of EPA and DHA were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes were specially for children to improved the feeding process and its presentation is in gelatin capsules. The supplement is purified fish oil with pharmaceutical grade.
3093974|NCT01826422|Placebo Comparator|Placebo Comparator|Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
3093975|NCT01826448|Experimental|Dose extension cohort|Patients will take PLX3397 and vemurafenib at the recommended phase 2 dose. This will be determined by the tolerability and safety of these drugs in the previous 3 cohorts.
3093976|NCT01826448|Experimental|Cohort 3|Patients will take 1000mg/day of PLX3397 and 960mg BID of vemurafenib
3093977|NCT01826448|Experimental|Cohort 2|Patients will take 800mg/day of PLX3397 and 960mg BID of vemurafenib
3093978|NCT01826448|Experimental|Cohort 1|Patients will take 800mg/day of PLX3397 and 720mg BID of vemurafenib
3093979|NCT01826487|Placebo Comparator|Placebo|Participants will receive placebo matching to ataluren orally 3 times a day (TID) at morning, midday, and evening for 48 weeks.
3093980|NCT01826487|Experimental|Ataluren|Participants will receive ataluren suspension orally TID, 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 48 weeks.
3093981|NCT01826513|Experimental|Unblinded Investigational Arm|Participants participated in an unblinded investigational phase of the trial prior to, and separate from, the single-blind cross-over phase of the trial. Data was collected from the his phase to aid the final development of the algorithm before proceeding to algorithm validation (ie. cross-over phase).
3093982|NCT01826513|Active Comparator|Standard AutoSet algorithm|Participants first received therapy with the Standard AutoSet algorithm for one night, and then received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) the following night.
3093983|NCT01826513|Experimental|Modified AutoSet algorithm|Participants first received therapy with the Modified AutoSet algorithm (an AutoSet device with an algorithm developed for sleep breathing parameters specific to females) for one night, and then received therapy with the standard AutoSet algorithm the following night.
3093984|NCT01826604|Experimental|Alexis O C-section retractor|Alexis O C-section retractor will be used.
3093985|NCT01826604|Other|Control- Conventional retractors|Conventional retractors for C-sections will be used.
3093986|NCT01826812||Dry Eye|"The patients with Sjogren Syndrome related or non-Sjogren Syndrome related dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
3093987|NCT01826812||Controls|"The patients without dry eye. The participants will be asked some questions. Before and after reading a text silently in 30 minutes 30 minutes sustained reading, a detailed dry eye exam will be performed."
3093988|NCT01826825||Clock in the box|Those patients with and without probable cognitive impairment based on the Clock-in-the-box assessment.
3093989|NCT01826825||Mini-Cog|Those patients with and without probable cognitive impairment based on the Mini-Cog assessment.
3093990|NCT01826851|Experimental|Exparel|266 mg Exparel, single-dose injection.
3093991|NCT01826851|Placebo Comparator|Placebo|0.9% Normal saline, single-dose injection.
3093992|NCT01826981|Experimental|Cohort 1,Group 1: LDV/SOF + RBV 12 wk (GT1 SOF retreatment)|LDV/SOF + RBV for 12 weeks in participants with genotype 1 HCV infection and who failed to achieve sustained virologic response (SVR) in a previous Gilead sofosbuvir study
3093993|NCT01826981|Experimental|Cohort 1,Group 2:SOF+Peg-IFN+RBV 12 wk (GT2,3 SOF retreatment)|SOF + PEG + RBV for 12 weeks in participants with genotype 2 or 3 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
3093994|NCT01826981|Experimental|Cohort 2,Group 1: LDV/SOF+RBV 12 wk (GT 1 TE, liver disease)|LDV/SOF+RBV for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
3093995|NCT01826981|Experimental|Cohort 2,Group 2: LDV/SOF+GS-9669 12wk (GT1 TE, liver disease)|LDV/SOF + GS-9669 for 12 weeks in treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis
3093996|NCT01826981|Experimental|Cohort 2,Group 3: LDV/SOF 12 wk (GT3 TN)|LDV/SOF for 12 weeks in treatment-naive participants with genotype 3 HCV infection
3093997|NCT01826981|Experimental|Cohort 2,Group 4: LDV/SOF+RBV 12 wk (GT3 TN)|LDV/SOF + RBV for 12 weeks in treatment-naive participants with genotype 3 HCV infection
3093998|NCT01826981|Experimental|Cohort 2,Group 5: LDV/SOF 12 wk (GT6 TE/TN)|LDV/SOF for 12 weeks in treatment-naive or treatment-experienced participants with genotype 6 HCV infection
3093999|NCT01826981|Experimental|Cohort 2,Group 6: LDV/SOF+RBV 12 wk (GT3 TE)|LDV/SOF + RBV for 12 weeks in treatment-experienced participants with genotype 3 HCV infection
3094000|NCT01826981|Experimental|Cohort 3,Group 1: LDV/SOF 12 wk (GT1 cirrhotic CPT B)|LDV/SOF for 12 weeks in participants with genotype 1 HCV infection and Child-Pugh Turcotte (CPT) B cirrhosis
3094001|NCT01826981|Experimental|Cohort 4,Group 1: SOF+VEL 25mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (25 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3094002|NCT01826981|Experimental|Cohort 4,Group 2:SOF+VEL 25mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL(25 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3094003|NCT01826981|Experimental|Cohort 4,Group 3: SOF+VEL 100mg 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg) for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3094004|NCT01826981|Experimental|Cohort 4,Group 4: SOF+VEL 100mg+RBV 8 wk (GT3 TN noncirrhotic)|SOF+VEL (100 mg)+RBV for 8 weeks in treatment-naive noncirrhotic participants with genotype 3 HCV infection
3094005|NCT01826981|Experimental|Cohort 5,Group 1: LDV/SOF + RBV 24 wk (SOF retreatment)|LDV/SOF+RBV for 24 weeks in participants with genotype 1, 2, 3, or 6 HCV infection and who failed to achieve SVR in a previous Gilead sofosbuvir study
3094006|NCT01826981|Experimental|Cohort 6,Group 1: LDV/SOF 12 wk (GT1, HBV coinfection)|LDV/SOF for 12 weeks in participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection
3094007|NCT01827046|Experimental|MIS plus rt-PA management|Subjects randomized to the Minimally Invasive Surgery (MIS) plus rt-PA management arm will undergo minimally invasive surgery followed by up to 9 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
3094008|NCT01827046|No Intervention|Medical management|Subjects randomized to medical management will receive the standard medical therapies for the treatment of intracerebral hemorrhage, which includes ICU care only and no planned surgical intervention.
3094009|NCT01827163|Experimental|Paclitaxel With Trastuzumab and Lapatinib|Paclitaxel (T) at 175 mg/m2 q 2 weeks x 4 with filgrastim/pegfilgrastim + trastuzumab (H) + daily oral lapatinib (L), followed by trastuzumab q 3 weeks x 15 doses + daily oral lapatinib (HL). Pegfilgrastim 6mg will be given subcutaneously (SQ) on day # 2 of each paclitaxel administration. Filgrastim may be used in lieu of pegfilgrastim at physician's discretion. Trastuzumab will be administered weekly (4 mg/kg bolus followed by 2 mg/kg weekly) starting with paclitaxel treatment cycle # 1. After 4 cycles of paclitaxel, pts will receive trastuzumab on a q 3 weeks x 15 doses (to complete about one year). The q 3 week trastuzumab may be started from 1-3 weeks after the last dose of paclitaxel. A total of 15 infusions of trastuzumab will be given q 3 weeks after the completion of paclitaxel during the HL phase. Lapatinib will be given orally at 1000 mg daily, starting with paclitaxel during the THL phase & continued for the remaining year during the HL phase for about a year.
3094010|NCT01827254||Non-Interventional Study|
3094011|NCT01827267|Experimental|neratinib monotherapy|240 mg once daily with food, continuously in 21 day cycles
3094012|NCT01827267|Experimental|neratinib plus temsirolimus|240 mg neratinib plus 8 mg temsirolimus IV with optional dose escalation to 15 mg temsirolimus
3094013|NCT01827306|Active Comparator|Biofreeze|Apply 5 minutes before therapy by applying a small coin sized amount to the painful area. Subjects will then complete a standard shoulder therapy program.
3094014|NCT01827306|No Intervention|Control|Subjects in this arm will complete a standard shoulder therapy program as normal, with no intervention.
3094015|NCT01827332|Active Comparator|Oxytocin|intranasal administration
3094016|NCT01827332|Placebo Comparator|Saline|intranasal administration
3094017|NCT01827358|Experimental|Group 1|Subjects receive a 5-day course of mupirocin calcium ointment 2 % 20 mg intranasally applied every 8 hours and a topical skin application (umbilical and perianal area) of mupirocin calcium cream 2% 20 mg applied every 8 hours for a total of 15 doses
3094018|NCT01827358|No Intervention|Group 2|No treatment
3094019|NCT01827371|Experimental|Arm C|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 22.
3094020|NCT01827371|Experimental|Arm B|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 15.
3094021|NCT01827371|Experimental|Arm A|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via syringe and needle on Days 1 and 29.
3094022|NCT01827371|Experimental|Arm D|88 subjects receive IMVAMUNE® 1x10^8 TCID50/0.5 mL subcutaneously (SC) via Stratis™ on Days 1 and 29.
3094023|NCT01827462|Experimental|18-30 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, Quadrivalent, inactivated influenza vaccine (IIV4) was given."
3094024|NCT01827462|Experimental|60-80 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
3094025|NCT01827462|Experimental|80-100 year olds at enrollment|"Licensed seasonal Fluzone (inactivated influenza vaccine):~Trivalent, inactivated influenza vaccine (TIV) was given through the 2013-2014 season.~Beginning with 2014-2015 season, High-Dose trivalent, inactivated influenza vaccine (TIV High-Dose) was given."
3094026|NCT01827475|Active Comparator|Ibuprofen|Ibuprofen 800 mg
3094027|NCT01827475|Active Comparator|Acetaminophen|Acetaminophen 1 gm
3094028|NCT01827475|Experimental|Ibuprofen-acetaminophen combination|Ibuprofen 800 mg plus acetaminophen 1 gm
3094029|NCT01827592|Experimental|EBX 10|Elobixibat 10 mg/day
3094030|NCT01827592|Experimental|EBX 5|Elobixibat 5 mg/day
3094031|NCT01827592|Placebo Comparator|PLCBO|Placebo
3094032|NCT01827670|Experimental|0.454% stannous fluoride dentifrice|Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
3094033|NCT01827670|Active Comparator|0.76% sodium monofluorophosphate dentifrice|Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.
3094034|NCT01827787|Experimental|Cohort 1: HR+/HER2-|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
3094035|NCT01827787|Experimental|Cohort 2: TNBC|"Eribulin: 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of each 21 day cycle~Participants remained on single agent eribulin until disease progression or withdrawal for other reasons."
3094036|NCT01827839|Experimental|HZ Group|Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
3094037|NCT01827930|Experimental|Imatinib 600 (Randomized trial)|Randomized Cohort: Adapted strategy of dosage of Imatinib Mesylate : 600mg/d po
3094038|NCT01827930|Active Comparator|Imatinib 400 (Randomized trial)|Randomized Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
3094039|NCT01827930|Other|Imatinib400 (Cohort)|Parallel Cohort: Standard strategy of dosage of Imatinib Mesylate : 400mg/d po
3094040|NCT01827943|Experimental|Temsirolimus|Temsirolimus was administered intravenously at a dose of 25 mg in a weekly 30 min infusion and was associated to anti-H1 treatment. One cycle corresponded to 4 weeks of treatment.
3094041|NCT01828021|Experimental|margetuximab|Monotherapy of Anti-HER2 monoclonal antibody
3094042|NCT01828034|Experimental|Gemcitabine, Cisplatin and MEK162|Phase I component of the study, a classic 3+3 cohort dose escalation scheme will be used to identify the MTD of MEK162 when administered with gemcitabine at dose 800 mg/m2 and cisplatin given at dose 20 mg/m2 week 2 & 3 of a 3 week cycle. The final cohort will receive gemcitabine 1000mg/m2 and cisplatin 20mg/m2 week 2 and 3 of a 3 week cycle in combination with MEK162 at the MTD as determined above. In the phase II part of the study, patients will receive MEK162 at the MTD dose plus gemcitabine and cisplatin at the dose level determined acceptable in the phase I portion. In the phase II part of the study, patients will receive MEK162 at 45mg BID plus gemcitabine (800 mg/m2) and cisplatin (20 mg/m2) as determined by the phase I portion.
3094043|NCT01828073||Cohort 1: Full term infants exposed in utero to maternal RAL|Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
3094044|NCT01828073||Cohort 2: LBW infants exposed in utero to maternal RAL|Infants, who were expected to be ≤2500 grams at birth (i.e. LBW) at time of enrollment, born to women with HIV-1 infection who received at least one dose of RAL 400 mg within 2 to 24 hours prior to delivery. The group also includes the mothers of these infants.
3468943|NCT03891225|Experimental|Amniotic Membrane implantation Arm|All consecutive patients undergone pancreaticoduodenectomy with high FRS will be treated with implantation of AM, by overlapping it over the pancreo-jejunal anastomosis.
3468944|NCT03891186|Experimental|Experimental Group|"Participants will be randomly allocated to either Metacognitive Training (MCT) (experimental group). In both groups will be maintained the treatment as usual (TAU)."
3094047|NCT01828112|Experimental|Ceritinib|Patients in this arm received 750 mg of ceritinib.
3094048|NCT01828112|Active Comparator|Chemotherapy|Patients in this arm received chemotherapy of either pemetrexed or docetaxel as determined by BIRC.
3094049|NCT01828164|Experimental|Treatment Arm|20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated.
3094050|NCT01828164|Sham Comparator|Control Arm|The transducers are not activated on the control side of the device.The subjects wear the device for 20 minutes per day for the duration of the study. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the control arm consist of the side of the mouth with the transducers deactivated.
3094051|NCT01828216|Active Comparator|Conventional polysomnography|Conventional PSG will be performed as in-patient at Prince of Wales Hospital for every subject in this group, recording electroencephalogram, electro-oculogram, submental electromyogram, bilateral anterior tibial electromyogram, electrocardiogram, chest & abdominal wall movement by inductance plethysmography, airflow measured by a nasal pressure transducer & supplemented by oronasal airflow thermistor, & finger pulse oximetry.
3094052|NCT01828216|Active Comparator|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events.
3094053|NCT01828255|Experimental|SENSIMED Triggerfish®|Device: portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
3094054|NCT01828281|Active Comparator|Therapeutic CPAP|Therapeutic CPAP
3094055|NCT01828281|Sham Comparator|control|subtherapeutic CPAP using 4 cm water
3094056|NCT01828476|Experimental|ARM A|Abiraterone with ABT-263
3094057|NCT01828476|Experimental|ARM B|Abiraterone with both ABT-263 and Hydroxychloroquine
3094058|NCT01828515|Experimental|Vilazodone and Hydrocortisone, then Placebo and Hydrocortisone|Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment. After a 23 day medication washout the procedure will be repeated using placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment.
3468945|NCT03891186|Active Comparator|Control Group|The control group will not participate in the MCT program. In both groups will be maintained the TAU.
3468946|NCT03891069|Experimental|Interventional arm|Participants will be invited to play the five different Exergames, for a total of 5 minutes.
3094059|NCT01828515|Experimental|Placebo and Hydrocortisone, then Vilazodone and Hydrocortisone|Placebo daily for 19 days and hydrocortisone 160 mg x 4 days (days 16-19) following placebo pre-treatment. After a 23 day medication washout the procedure will be repeated using Vilazodone titrated to 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days (19 days) and hydrocortisone 160 mg x 4 days (days 16-19) following vilazodone pre-treatment.
3094060|NCT01828554|Experimental|Xeloda (Capecitabine)|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
3094061|NCT01828567|Experimental|Intervention|Primary care phone-based prevention coaching using shared decision making following a Healthy Living Assessment
3094062|NCT01828567|No Intervention|Control|Usual care
3094063|NCT01828593|Placebo Comparator|Placebo|Matching Placebo
3094064|NCT01828593|Active Comparator|SBI 2.5 g|Serum-derived bovine immunoglobulin protein isolate (SBI) 2.5 g
3094065|NCT01828593|Active Comparator|SBI 5.0g|Serum-derived bovine immunoglobulin protein isolate (SBI)5.0g
3094066|NCT01828983|Experimental|Telephone support groups|Telephone support groups, each with participants and a trained group leader. Each hour-long telephone group will meet bi-monthly for six months for a total of 12 meetings. Groups are structured with education, skills building, and support. Participants will receive and use a Spouse Workbook with information and activities.
3094067|NCT01828983|Active Comparator|Education webinars|Education Webinar session topics are the same that are covered in the intervention arm without telephone interaction/support and skills building components. Each session is 30-minutes. Each participant receives a Spouse Workbook with information and activities.
3094068|NCT01829048|Experimental|PF-02545920|
3094069|NCT01829048|Placebo Comparator|Placebo|
3094070|NCT01829113|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg intravenously (IV) will be administered over 9 days. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle.
3094071|NCT01829113|Placebo Comparator|Placebo|Three loading doses of placebo will be administered intravenously (IV) over 9 days. Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. The Treatment Phase will be followed by a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle.
3094072|NCT01829165|Experimental|rTMS Treatment|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered using neuro-navigation based on participants' own fMRI images. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
3094073|NCT01829165|Sham Comparator|Sham Treatment|"rTMS will be delivered for 20 sessions over 4 weeks. Placebo 10Hz rTMS will be delivered through sham stimulation electrodes. The rTMS coil will be positioned using neuro-navigation based on participants' own fMRI images, mimicking active rTMS treatment. Daily treatment regiments will last 36.5minutes and sham rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sham sessions for adverse events and/or side effects.~Upon completing the sham 20 sessions participants are unblinded and offered 20 further treatments of guaranteed open-label treatment. The open-label treatment would follow the active rTMS treatment protocol."
3094074|NCT01829191|Experimental|Test Lens A|Test lenses will be worn in a daily wear modality
3094075|NCT01829191|Experimental|Test Lens C|Test lenses will be worn in a daily wear modality
3094076|NCT01829217|Experimental|Sunitinib|42 day cycle, taken orally every day for the first 28 days followed by 14 days off
3094077|NCT01829230|Experimental|Test lens C|Test lens C from previous study
3094078|NCT01829230|Active Comparator|Test lens A|Test lens A from previous study
3094079|NCT01829243|Experimental|Milnacipran|Eligible subjects will receive milnacipran (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
3094080|NCT01829243|Placebo Comparator|Placebo|Eligible subjects will receive placebo (12.5 mg-200 mg/day) in the forces titration schedule in flexible doses to the maximum tolerated dose starting with 12.5 mg qd for 1 day, 12.5 mg bid for 2 days, 25 mg bid for 4 days, 50 mg bid for 7 days and 100 mg bid thereafter. Patients who cannot tolerate higher doses will have a step-wise reduction in doses (e.g. 200 mg/day dose will be reduced to 100 mg/day; 100 mg/day will be reduced to 50 mg/day). Drug will be discontinued at the end of the study.
3094081|NCT01829295|Experimental|Methotrexate|oral methotrexate
3094082|NCT01829295|Experimental|Mycophenolate Mofetil|oral mycophenolate mofetil
3094083|NCT01829347|Experimental|ELAD (plus Standard of Care)|ELAD is a human cell-based bio-artificial liver support system developed to improve survival of patients with acute liver failure and to provide liver support continuously to a subject with compromised liver function. Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
3094084|NCT01829347|Other|Standard of Care (Control)|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
3094085|NCT01829360|Experimental|Standard then Alternative: High Dose|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose (dose 9 x dose frequency 4)
3094086|NCT01829360|Experimental|Alternative: High Dose then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose (dose 9 x dose frequency 4) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
3094087|NCT01829360|Experimental|Alternative: High Dose Frequency then Standard|Children in this arm are assigned to the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9) in the first round of intervention and then to the standard treatment for the second round of intervention (dose 6 x dose frequency 6)
3094088|NCT01829360|Experimental|Standard then Alternative: High Dose Frequency|Children in this arm are assigned to the standard treatment for the first round of intervention (dose 6 x dose frequency 6) and then the alternative treatment that maximizes dose frequency (dose 4 x dose frequency 9)
3094089|NCT01829399|Experimental|Injected with Bupivacaine|A subcutaneous axillary ring of 10 to 15 mL of 0.25% Bupivacaine with epinephrine 1:200,000 will be injected in the arm 15 minutes prior to tourniquet inflation.
3094090|NCT01829399|Sham Comparator|Injected with saline|A subcutaneous axillary ring of 10 to 15 mL of normal saline will be injected in the arm 15 minutes prior to tourniquet inflation.
3094091|NCT01829425|Active Comparator|Anticholinergic medications|Either of two standard, long acting anti-cholinergic medications (Long acting Tolterodine or Extended Release Oxybutynin)will be given. Subjects receive 8 weeks of medication counseling in conjunction with the medications. Medications will be continued for 1 year.
3094092|NCT01829425|Active Comparator|Hypnotherapy|Subjects will receive approximately weekly hypnotherapy sessions over 8 weeks and will receive/download digital recordings for home practice. Subjects will be encouraged to practice self-hypnosis +/or listen to their recordings for 1 year.
3094093|NCT01829464|Placebo Comparator|Placebo|TAK-875 placebo-matching tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up 24 weeks.
3094094|NCT01829464|Experimental|TAK-875 25 mg|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
3094095|NCT01829464|Experimental|TAK-875 50 mg|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg, tablets, orally for up to 24 weeks
3094096|NCT01829503|Experimental|decitabine and cytarabine|
3094097|NCT01829516|Experimental|Oxytocin|50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal oxytocin.
3094098|NCT01829516|Placebo Comparator|Placebo|"50 moderate to heavy social alcohol users will receive a single dose 40 IU of intranasal placebo.~NOTE: This is a cross-over design and subjects will participate in both arms."
3094100|NCT01829919|Experimental|Brisdelle (paroxetine mesylate)|Brisdelle (paroxetine mesylate) Capsules taken orally with 240 mL of water for 20 days.
3094101|NCT01829997|Experimental|nanOss Bioactive 3D BVF|Bilateral, instrumented posterolateral fusion surgery where nanOss Bioactive 3D will be hydrated with autologous BMA and placed bilaterally on a bed of local autograft bone spanning the transverse processes of the treated segment. If an interbody fusion is performed, only a PLIF or TLIF with PEEK IBF devices may be performed.
3094102|NCT01830127|Experimental|cohort A CPA|Cohort A CPA BI 207127/QD Faldaprevir Ribavirin
3094103|NCT01830127|Experimental|cohort A CPB|Cohort B CPB BI 207127/QD Faldaprevir Ribavirin
3094104|NCT01830140|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
3094105|NCT01830140|Active Comparator|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
3094106|NCT01830205|Experimental|Group A (Normal renal function): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3094107|NCT01830205|Experimental|Group B (End Stage Renal Disease): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3094108|NCT01830205|Experimental|Group C (Moderate renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3094109|NCT01830205|Experimental|Group D (Severe renal impairment): Daclatasvir|Daclatasvir 60 mg tablet by mouth single dose on Day 1
3094110|NCT01830543|Experimental|rivaroxaban 2.5 mg twice daily|rivaroxaban 2.5 mg tablet twice daily plus low-dose aspirin (ASA) 75 to 100 mg once daily and clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by rivaroxaban 15 mg tablet (or 10 mg for subjects with moderate renal impairment) once daily plus low-dose ASA for 12 months
3094111|NCT01830543|Experimental|vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) once daily (target International Normalized Ratio (INR) 2.0 to 3.0) plus low-dose ASA, 75 to 100 mg per day, and clopidogrel 75 mg once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) followed by dose-adjusted VKA once daily (target INR 2.0 to 3.0 or 2.0 to 2.5 at the investigator discretion) plus low-dose ASA for 12 months
3094112|NCT01830543|Experimental|rivaroxaban 15 mg once daily|rivaroxaban 15 mg (or 10 mg for subjects with moderate renal impairment) once daily plus clopidogrel 75 mg tablet once daily (or prasugrel 10 mg tablet once daily or ticagrelor 90 mg tablet twice daily) for 12 months
3094113|NCT01830595|Active Comparator|Recombinant Lactoferrin|Recombinant lactoferrin will be administered by mouth twice daily
3094114|NCT01830595|Placebo Comparator|Placebo|Matched placebo will be administered by mouth twice daily
3094115|NCT01830621|Active Comparator|BBI608|BBI608 480 mg two times daily (960 mg total daily dose)+ Best Supportive Care
3094116|NCT01830621|Placebo Comparator|Placebo|Placebo two times daily + Best Supportive Care
3094117|NCT01830699|Active Comparator|Rilonacept|160 mg of rilonacept will be injected in the subacromial bursa of participants in this arm.
3094118|NCT01830699|Placebo Comparator|Corticosteroid|80 mg (2 cc of 40 mg/mL) Kenalog intra-bursal once
3094119|NCT01830816|Experimental|Normal Renal Function: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
3094120|NCT01830816|Experimental|Severe Renal Impairment: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
3094121|NCT01830816|Experimental|End-stage Renal Disease: Ixazomib|In the 15 day period that constitutes Part A of the trial, participants received a single oral dose of ixazomib 3.0 mg capsules. Participants from Part A had the option of continuing the study by participating in Part B, where they received ixazomib (4, 3, or 2.3 mg per protocol) capsules, orally on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
3094122|NCT01830842|Placebo Comparator|Nicotine, placebo|Nonsmokers will be measured following a nicotine polacrilex lozenge (2mg) on one occasion and placebo on another occasion.
3094123|NCT01830842|Other|Nicotine withdrawal or satiety|Smokers will be measured in a normal satiated condition and following 24-hours of smoking abstinence
3094124|NCT01830855|Experimental|rLP2086 lot 1|
3094125|NCT01830855|Experimental|rLP2086 lot 2|
3094126|NCT01830855|Experimental|rLP2086 lot 3|
3094127|NCT01830855|Active Comparator|Control|Havrix (HAV) and Saline
3094128|NCT01830881|Placebo Comparator|placebo-cherry syrup and ibuprofen|5 mL oral placebo-cherry syrup and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
3094129|NCT01830881|Active Comparator|Midazolam and ibuprofen|5 mL oral midazolam oral syrup (2 mg/mL) and 800 mg oral ibuprofen 30-60 minutes prior to procedure 20 mL injection 1% lidocaine without epinephrine
3094130|NCT01830920|Placebo Comparator|Placebo|An identical appearing placebo will be administered.
3094131|NCT01830920|Experimental|THR-184 Dose 1|THR-184 initial pre-surgery low dose followed by (3) post surgery doses at the low dose.
3094132|NCT01830920|Experimental|THR-184 Dose 2|THR-184 initial pre-surgery mid-dose followed by (3) post surgery doses at the low dose.
3094133|NCT01830920|Experimental|THR-184 Dose 3|THR-184 initial pre-surgery high dose followed by (3) post surgery doses at the low dose.
3094134|NCT01830920|Experimental|THR-184 Dose 4|THR-184 initial pre-surgery high dose followed by (3) post surgery doses ~80% of the pre-surgery dose.
3094135|NCT01830933|Experimental|BreastCARE Intervention|"Intervention Clinic Patients: The RA will welcome the patient upon arrival at the clinic and again explain study procedures and field any questions. The RA will have the patient sign the HIPAA authorization form and then demonstrate how to enter information and answer questions on the tablet-PC and the patient will indicate their consent electronically before beginning the assessment.~Intervention Patient Report. Once the patient completes the BreastCare Computer survey, the program will immediately generate a personal feedback report containing information about her risk factors and recommendations to reduce her risk. This report will be printed and given to the patietns before she meets with her doctor."
3094136|NCT01830933|No Intervention|BreastCARE Comparison|"Patients will be randomized into the intervention or comparison groups at the time of recruitment. Block-randomization will be used to assign patients to intervention or comparison groups.~Comparison Clinic Patients. Contact and baseline interview procedures will be the same for patients from the comparison clinics, however there will be no computer assessment at the time of their clinic visit. An RA will meet the patient 10 minutes prior to her appointment time to obtain written HIPAA authorization."
3094137|NCT01830972|Experimental|Crossover Participants|"Participants completing the 48-week study (UX001-CL201; NCT01517880) were enrolled into Part I of the study:~Part I: participants continued on 6 g/day SA-ER for 12 weeks~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment 4 times per day [QID]) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
3094138|NCT01830972|Experimental|Naïve Participants|"Treatment naïve participants with GNE myopathy were enrolled into Part II of the study:~Part II: 12 g/day SA (1.5 g of SA-ER and 1.5 g of SA-IR treatment QID) for 36 months~Part III: 6 g/day or 12 g/day SA (both SA-ER and SA-IR)~Part IV: 6 g/day or 12 g/day SA (SA-ER only)"
3094139|NCT01831076|Active Comparator|Treatment (exemestane, surgery)|Patients receive exemestane orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
3094140|NCT01831076|Experimental|treatment (exemestane, tamoxifen, surgery)|Patients receive exemestane plus tamoxifen orally daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
3094141|NCT01831089|Experimental|Treatment|PM01183 + paclitaxel +/- bevacizumab
3094142|NCT01831154|Experimental|Tight Glycemic Group|The tight glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial bolus of insulin and insulin infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 149 mg/dl or any time intraoperatively the blood glucose elevated above 149 mg/dl.The titration of insulin for the tight glycemic group maintained blood glucose levels between 110-149 mg/dl throughout the intraoperative period. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the intensive care unit the protocol ended and all subjects received the same glycemic control.
3094143|NCT01831154|Experimental|Conventional Glycemic Group|The conventional glycemic group received a continuous intravenous infusion of regular insulin in the intraoperative period titrated per a modified Portland Protocol from Vanderbilt University Medical Center, Tennessee. The initial insulin bolus and infusion was initiated prior to induction of anesthesia if the morning blood glucose was greater than 180 mg/dl or any time intraoperatively that the blood glucose elevated above 180 mg/dl. The insulin infusion was titrated throughout the intraoperative period to maintain blood glucose levels between 150-180 mg/dl.The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes. Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
3094144|NCT01831154|Experimental|Standard Glycemic Group|The standard glycemic group received intravenous injections of regular insulin in the intraoperative period titrated per the usual care protocol utilized at the study site. The initial bolus of insulin was initiated prior to induction of anesthesia if the morning blood glucose is greater than 180 mg/dl or any time intraoperatively that the blood glucose rises above 180 mg/dl. The intraoperative blood glucose was titrated to blood glucose levels sampled every 30 minutes.Upon transfer to the ICU the intraoperative protocol ended and all subjects received the standardized glycemic control for the ICU.
3094145|NCT01831219||ROBODOC|The ROBODOC group received total hip arthroplasty using the ROBODOC Surgical system for preparation of the femoral canal for a femoral stem implant.
3094146|NCT01831219||Conventional|The conventional group received total hip arthroplasty using the conventional manual tools including a broach to prepare the femoral cavity for femoral stem replacement.
3094147|NCT01831232|Experimental|Treatment (pravastatin sodium, idarubicin, and cytarabine)|Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3094148|NCT01831258|Experimental|SensAwake On|The comfort feature 'SensAwake' will be turned on
3094149|NCT01831258|Active Comparator|SensAwake Off|The comfort feature 'SensAwake' will be turned off
3094150|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV single ascending dose (SAD)|Participants will receive andecaliximab 0.3 milligrams per kilogram (mg/kg) on Day 1.
3094151|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (SAD)|Participants will receive andecaliximab 1.0 mg/kg on Day 1.
3094152|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (SAD)|Participants will receive andecaliximab 2.5 mg/kg on Day 1.
3094153|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (SAD)|Participants will receive andecaliximab 5.0 mg/kg on Day 1.
3094154|NCT01831427|Placebo Comparator|Placebo Pooled (SAD)|Participants will receive placebo on Day 1.
3094155|NCT01831427|Experimental|Andecaliximab 0.3 mg/kg IV multiple ascending doses (MAD)|Participants will receive andecaliximab 0.3 mg/kg on Days 1, 15, and 29.
3094156|NCT01831427|Experimental|Andecaliximab 1.0 mg/kg IV (MAD)|Participants will receive andecaliximab 1.0 mg/kg on Days 1, 15, and 29.
3094157|NCT01831427|Experimental|Andecaliximab 2.5 mg/kg IV (MAD)|Participants will receive andecaliximab 2.5 mg/kg on Days 1, 15, and 29.
3094158|NCT01831427|Experimental|Andecaliximab 5.0 mg/kg IV (MAD)|Participants will receive andecaliximab 5.0 mg/kg on Days 1, 15, and 29.
3094159|NCT01831427|Experimental|Andecaliximab 150 mg SC (Adaptive MAD)|Participants will receive andecaliximab 150 mg on Days 1, 8, 15, 22, and 29.
3094160|NCT01831427|Placebo Comparator|Placebo Pooled (MAD)|Participants will receive placebo on Days 1, 15, and 29.
3094161|NCT01831466|Experimental|Treatment Group A|
3094162|NCT01831466|Experimental|Treatment Group B|
3094163|NCT01831466|Placebo Comparator|Treatment Group C|
3094164|NCT01831466|Experimental|Treatment Group D|
3094165|NCT01831466|Experimental|Treatment Group E|
3094166|NCT01831466|Placebo Comparator|Treatment Group F|
3094167|NCT01831544|Experimental|MVAD® Pump|Implant of HeartWare MVAD® System
3094168|NCT01831726|Experimental|TKI258|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
3094169|NCT01831765|Experimental|Meal time FIAsp and insulin detemir|
3094170|NCT01831765|Active Comparator|Meal time insulin aspart and insulin detemir|
3094171|NCT01831765|Experimental|Post meal FIAsp and insulin detemir|
3094172|NCT01831791|Experimental|Dutasteride Arm|Subjects will receive 1 capsule of Dutasteride 0.5 mg orally once daily for 52 weeks (12 months).
3094173|NCT01831804|Experimental|Cohort 1 Part A|Healthy subjects in this arm will receive single applications of GSK1278863 or placebo (with 6:2 ratio) on intact skin in two escalating dosing periods each separated by 10 days. The first application will be with a single dose of 0.3 mg and second application will be single dose of 3 mg.
3094174|NCT01831804|Experimental|Cohort 2 Part A|Subjects with diabetic foot ulcer (DFU) will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on intact skin and second application directly on DFU. Dose will be based on wound area and review from previous cohort data.
3094175|NCT01831804|Experimental|Cohort 3 Part A|Subjects with DFU will receive single application of GSK1278863 or placebo directly on DFU. Dose will be based on wound area and review from previous cohort data.
3094176|NCT01831804|Experimental|Cohort 4 Part A|Subjects with DFU will receive a single application of GSK1278863 or placebo (with 6:2 ratio) in two dosing periods separated by 10 days. The first application will be made on DFU and second application on intact skin. Dose will be based on wound area and review from previous cohort data.
3094177|NCT01831804|Experimental|Cohort 5 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3094178|NCT01831804|Experimental|Cohort 6 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3094179|NCT01831804|Experimental|Cohort 7 Part B|Subjects with DFU will receive Standard of care (SOC) up to 15 days and then will be randomized to one of the three arms: GSK1278863 + SOC, or SOC only, or placebo + SOC with ratio of 12:2:2. Doses for the cohorts in Part B will be determined from safety, tolerability and PK data from Part A. subjects will first be given a single application of GSK1278863 or placebo at the dose chosen for that cohort, followed by a 7-day washout period, and then repeat applications for 14 days, starting on Day 8.
3094180|NCT01831817|Experimental|5% calcium sodium phosphosilicate/ sodium monofluorophosphate|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3094181|NCT01831817|Active Comparator|0% calcium sodium phosphosilicate/sodium monofluorophosphate|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
3094182|NCT01831817|Active Comparator|Sodium monofluorophosphate|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
3094183|NCT01831817|Active Comparator|Sodium fluoride|Dentifrice containing 1100 ppmF as sodium fluoride
3094184|NCT01831856|Experimental|F373280|
3094185|NCT01831856|Placebo Comparator|Placebo|
3094186|NCT01831921|Experimental|Lifestyle Weight-Loss|Participants in the Behavioral: Lifestyle Weight Loss arm will take part in a group program aimed at achieving modest weight loss (5-7%) through promoting healthy eating and increasing physical activity. The intervention sessions will take place at churches and other community locations and will be coordinated and facilitated by Latino Health Advisors (LHAs). The lifestyle intervention will be delivered in 2 phases: Phase 1 will last for 6 months and consist of weekly group meetings; Phase 2 will last for 18 months and consist of one LHA-led group session or one telephone contact from the LHA per month. Participants in this treatment arm will also receive individual visits with a registered dietitian during months 1, 3, and 6 of phase 1. All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
3094187|NCT01831921|Active Comparator|Enhanced Usual Care|Participants in the Behavioral: Counseling arm will receive two individual sessions with a registered dietitian and monthly newsletters that focus on existing community resources.All participants will be seen for assessment visits as baseline, 6, and 12 months. Some participants will also complete 18 and 24 month visits, depending on the date of randomization.
3094188|NCT01831934|Experimental|MELAS group:13-60 years of age.|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
3094189|NCT01831934|Experimental|Control Group: 18-65 years of age|Fluzone® 2010-2011 Formula or 2011-2012 depending on year
3094190|NCT01831960|Experimental|Cortexolone 17α-Propionate|Topical cream, 1.0% concentration, applied every twelve hours
3094191|NCT01832038|Experimental|Lacosamide|Lacosamide treatment of 100 - 400 mg/day for long-term
3094192|NCT01832090|Experimental|Radiesse® Injectable Dermal Filler|Device: Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine-HCl)
3094193|NCT01832090|Active Comparator|Delayed Treatment|Untreated controls crossed over to treatment with Radiesse Dermal Filler mixed with 2% lidocaine-HCl (final concentration: 0.3% lidocaine) at 3 months
3094194|NCT01832155|Experimental|yoga intervention|The yoga intervention received eight 60 minute weekly Hatha yoga intervention classes and asked to practice additional 30 minute yoga per day at home.
3094195|NCT01832155|Other|wait list control|The wait list control group received the same 8-week Hatha yoga intervention involving group and home-based exercise sessions after the yoga intervention group completed the intervention at the end of 8 weeks.
3094196|NCT01832259|Placebo Comparator|Placebo arm|Participants receiving placebo
3094197|NCT01832259|Experimental|Pazopanib arm|Participants receiving Pazopanib
3094198|NCT01832402|Experimental|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD). FPNS administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of FPNS. Participant will rest for 30 minutes after walk test. FPNS administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. FPNS administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
3094199|NCT01832402|Placebo Comparator|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test. Walk test administered before first dose of placebo nasal spray. Participant will rest for 30 minutes after walk test. Placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes. Questionnaires completed at baseline, before each walk test, and at end of final walk test. Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
3094200|NCT01832480|Active Comparator|MTZ 2 g|Single dose MTZ
3094201|NCT01832480|Experimental|MTZ 500 mg twice daily x 7 days|Multi dose MTZ
3094202|NCT01832493|Experimental|Cardiac Resynchronization Therapy|Patients implanted with a cardiac resynchronization therapy device
3094203|NCT01832506|Experimental|MSC2156119J|
3094204|NCT01832532|Experimental|Treatment group- liraglutide|Treatment group- liraglutide daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.
3094205|NCT01832532|No Intervention|Control group|Control group
3094206|NCT01832610||HeartWare® VAS|Ventricular Assist Device (HeartWare® VAS)
3094207|NCT01832727|Experimental|Cohort 180 mg 5/14 Schedule (Phase 1b)|Oprozomib 180 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094208|NCT01832727|Experimental|Cohort 210 mg 5/14 Schedule (Phase 1b)|"Oprozomib 210 mg treatment once daily for 5 consecutive days bimonthly (days 1, 2, 3, 4, and 5 of a 14-day cycle) with 20 mg dexamethasone once daily on days 1, 2, 8, and 9 (referred to as the 5/14 schedule). Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 5/14 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
3094209|NCT01832727|Experimental|Cohort 150/180 mg 5/14 Schedule (Phase 1b)|Oprozomib 150 mg once daily treatment for 5 consecutive days (days 1, 2, 3, 4, and 5 of a 14-day cycle) followed by a step-up in oprozomib once daily dose to 180 mg starting in cycle 2 and moving forward. Dexamethasone 20 mg once daily was administered on days 1, 2, 8, and 9 of each 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094210|NCT01832727|Experimental|Cohort 210 mg 2/7 Schedule (Phase 1b)|"Oprozomib 210 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.~This was the first cohort to enroll participants into the 2/7 schedule. The Cohort Safety Review Committee (CSRC) reviewed safety data and made dose adjustments for oprozomib in 30 mg increments for all cohorts."
3094211|NCT01832727|Experimental|Cohort 240 mg 2/7 Schedule (Phase 1b)|Oprozomib 240 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094212|NCT01832727|Experimental|Cohort 270 mg 2/7 Schedule (Phase 1b)|Oprozomib 270 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094213|NCT01832727|Experimental|Cohort 300 mg 2/7 Schedule (Phase 1b)|Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094214|NCT01832727|Experimental|Cohort 330 mg 2/7 Schedule (Phase 1b)|Oprozomib 330 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094215|NCT01832727|Experimental|Phase 2 300 mg 2/7 Schedule|The Cohort Safety Review Committee (CSRC) determined this dose as the recommended phase 2 dose (RP2D). Oprozomib 300 mg once daily on Days 1, 2, 8, and 9 of a 14-day treatment cycle in combination with 20 mg dexamethasone once daily on Days 1, 2, 8, and 9 of a 14-day cycle. Treatment was administered in 14-day cycles until disease progression, unacceptable toxicity, or study treatment discontinuation for any reason.
3094216|NCT01832753|Placebo Comparator|Treatment Phase: Months 6-18|"Subject who are found to have SCH at the 6-month visit will be randomized to receive either levothyroxine or placebo during months 6-12. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be 1 blood draw visit at month 7.5 (6 weeks after randomization) and 1 study visit at month 12 that will provide the opportunity for dose adjustments if needed.~From months 12-18, all subjects will receive levothyroxine. Levothyroxine dose will be between 0.5 - 1 mcg/kg/day. There will be one blood draw visit at month 13.5 that will provide the opportunity for dose adjustments if needed."
3094217|NCT01832753|No Intervention|Observation Phase: Months 0-6|"Subjects will be observed for the first 6 months of the study to ensure that the subclinical hypothyroidism is persistent. Subjects who do not have SCH at 6 months will not proceed to the treatment phase.~Subjects that have TSH >10 mIU/L during the 6 month Observational Phase will not be considered subclinical and will not qualify to continue the study. They will be referred to an endocrinologist for treatment."
3094218|NCT01832766|Active Comparator|dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
3094219|NCT01832766|Placebo Comparator|sugar pill|one capsule given by mouth at 8:00 a.m.
3094220|NCT01832818|Experimental|NuNec Cervical Disc|Each patient will be implanted with the NuNec Cervical Disc in a single level from C3 to C7. Postoperatively, patient evaluated at discharge, 6 weeks, 3, 6, 12 and 24 months.
3094221|NCT01832961|Experimental|flutter valve exercises|30 minutes of breathing exercises with flutter device
3094222|NCT01832961|Sham Comparator|flutter-sham exercises|30 minutes of breathing exercise with flutter-sham device
3094223|NCT01833026|Experimental|COPD assessment and management recommendations|"Patients with a physician-diagnosed COPD or asthma suspicious for COPD being managed by the physician randomized to the intervention group will perform a spirometry test and provide information regarding their medical history on their initial visit, which is 90 minutes before their doctor's appointment. A letter containing the interpretation of spirometry test results, and recommendations for guideline based therapy based on GOLD guidelines will be available to the primary care doctor at the time of the patient's clinic visit. The doctor may review the results and use his or her own judgment in moving forward with the subject's diagnosis and management. A copy of the spirometry results and assessment based on the GOLD criteria at the time of the test of your subject will be uploaded to his or her electronic health record for future reference.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews."
3094224|NCT01833026|Placebo Comparator|Usual Care|"Patients with a physician-diagnosed COPD or physician-diagnosed asthma suspicious for COPD being managed by the physician randomized to the usual care group will provide medical history, not initially have a spirometry, and will be observed as usual care.~Outcomes will be assessed every 3 months for up to one year through patient telephone calls and medical chart reviews. At the conclusion of the research study which will be 12 months from the patients' initial visit, patients being managed by the physician randomized to the usual care group will have a spirometry test and these results will not be shared with the doctor or the patients during the study but will be uploaded to the electronic health record after the end of the study for future reference."
3094225|NCT01833065|Experimental|EBX 10|Elobixibat 10 mg/day
3094226|NCT01833065|Experimental|EBX 5|Elobixibat 5 mg/day
3094227|NCT01833065|Placebo Comparator|PLCBO|Placebo
3094228|NCT01833078|Other|7 day ghrelin dosing - all participants|All participants will receive an injection of ghrelin (7.5mcg/kg) dose subcutaneously once daily on Days 1, 2 and 7 in the research center and will self-administer the subcutaneous injection before breakfast on Days 2-6 at home.
3094229|NCT01833117|Experimental|FID 119515A|FID 119515A, 1 drop instilled in the study eye, single dose
3094230|NCT01833117|Active Comparator|Blink|Blink® Tears, 1 drop instilled in the study eye, single dose
3094231|NCT01833130|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 units (U) total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
3094232|NCT01833130|Placebo Comparator|Placebo (Normal saline)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
3094233|NCT01833143|Experimental|Bortezomib|Bortezomib will be administered by subcutaneous injection twice weekly for 2 weeks (Days 1, 4, 8, and 11) at 1.3 mg/m2/dose followed by a 10-day rest period for a 21 day cycle. Dose modifications are permitted as per a prescribed algorithm. Acyclovir at 400mg daily is recommended as prophylaxis for herpes zoster. Restaging scans, with evaluation of response, will be done every 2 cycles (6 weeks of treatment ± 7 days). Treatment will continue until clinical disease progression, unacceptable toxicity, treatment delay > 2 weeks, or at the discretion of the treating physician or patient.
3094234|NCT01833169|Experimental|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
3094235|NCT01833247||Epilepsy inpatients|Patients with epilepsy recorded in an inpatient video-EEG monitoring unit after a seizure.
3094236|NCT01833403|Other|Measurement of insulin sensitivity|All participants will undergo a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity
3094237|NCT01833455|Placebo Comparator|PVC Suppression then Placebo|This arm will undergo attempted PVC suppression using flecainide for 28 days and then undergo no PVC suppression using placebo for 28 days.
3094238|NCT01833455|Placebo Comparator|Placebo then PVC Suppression|This arm will undergo no PVC suppression using placebo for 28 days and then undergo attempted PVC suppression using flecainide for 28 days.
3094239|NCT01833481||THA using direct-anterior surgical approach|Patients will have undergone THA using a direct-anterior surgical approach and will undergo fluoroscopy surveillance while walking.
3094240|NCT01833481||THA using anterior-lateral approach|Patients will have undergone THA using an anterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
3094241|NCT01833481||THA using posterior-lateral approach|Patients will have undergone THA using a posterior-lateral surgical approach and will undergo fluoroscopy surveillance while walking.
3094242|NCT01833494|Experimental|PA21|
3094243|NCT01833520|Experimental|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I.~Up to 3 groups of 3 participants will be enrolled in the Phase I portion of the study, and up to 6 participants will be enrolled in Phase II."
3094244|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3094245|NCT01833533|Experimental|ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV|ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily) for 12 weeks plus placebo RBV (twice daily) for 12 weeks
3094246|NCT01833546|Experimental|Evofosfamide 240 mg|
3094247|NCT01833546|Experimental|Evofosfamide 340 mg|
3094248|NCT01833546|Experimental|Evofosfamide 480 mg|
3094249|NCT01833546|Experimental|Evofosfamide 340 mg + Gemcitabine|
3094250|NCT01833741|Experimental|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
3094251|NCT01833754|Experimental|Group 1: Stage 4 Renal Impairment|Participants with stage 4 renal impairment (defined as an estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
3094252|NCT01833754|Experimental|Group 2: ESRD Requiring Hemodialysis|Participants with end stage renal disease (ESRD) requiring hemodialysis received a single subcutaneous injection of 210 mg romosozumab on day 1.
3094253|NCT01833754|Experimental|Group 3: Healthy Participants|Healthy participants (eGFR ≥ 80 mL/min/1.73 m²) received a single subcutaneous injection of 210 mg romosozumab on day 1.
3094254|NCT01833832|Experimental|Cytoreductive surgery followed by HIPEC|Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
3094255|NCT01833845|Experimental|Ribavirin+HCQ|Administration of RBV monotherapy for a period of 8 weeks following administration of up to 16 weeks combination therapy with ribavirin(RBV) plus Hydroxychloroquine(HCQ).
3094256|NCT01833897|Experimental|Ketamine and DCS treatment|Standard of Care: Subjects will receive treatment with either quetiapine, olanzapine-fluoxetine, or lurasidone. If after about 2 week, subjects are symptomatic, subjects will receive infusion of ketamine hydrochloride (0.5 mg/kg). After the ketamine phase, subject who show improvement will begin an 8-week treatment of oral D-cycloserine.
3094257|NCT01833936|Active Comparator|Group 1- Compex® muscle stimulator|Group 1 will receive an active muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will use the stimulator for three 20 minute sessions per day.
3094258|NCT01833936|Sham Comparator|Group 2 -(inactive) muscle stimulator|Group 2 will receive a placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
3094259|NCT01833988|Experimental|Bi-hormonal Bionic Pancreas|Bi-hormonal Bionic Pancreas
3094260|NCT01833988|Active Comparator|Usual Care|Usual Care
3094261|NCT01834027|Experimental|Jazz music|Jazz music will be played through headphones to post-surgical hysterectomy patients while they are in the post anesthesia care unit.
3094262|NCT01834027|Active Comparator|No music|The patients in this group with have headphones but no music will be played.
3094263|NCT01834222||1|Korean adults aged 50 years and older who receive Prevenar13™ in a routine clinical setting
3094264|NCT01834261|Active Comparator|Oxytocin|Healthy adult subjects will receive several puffs of Syntocinon Nasal Spray, 40IU, once, prior to MRI and/or MEG scanning.
3094265|NCT01834261|Placebo Comparator|Placebo|Healthy adult subjects will receive several puffs of Syntocinon Placebo Formulation, 40IU, once, prior to MRI and/or MEG scanning.
3094266|NCT01834274|Experimental|Fasiglifam 50 mg|Fasiglifam (TAK-875) 50 mg tablets, orally, once daily, Sitagliptin placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
3094267|NCT01834274|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, tablets, once daily, TAK-875 placebo-matching tablets, orally, once daily, and metformin stable dose ≥1500 mg (or maximum-tolerated dose), tablets, orally, daily for up to 24 weeks.
3094268|NCT01834326|Active Comparator|Palatal Oral Mucosa (POM) Graft|Standard of care palatal oral mucosa (POM) graft will be taken from the palate and then surgically placed onto the defect area
3094269|NCT01834326|Experimental|Ex vivo Produced Oral Mucosa Equivalent|Palatal biopsy will be harvested for fabrication of autogenous ex vivo produced oral mucosa equivalent (EVPOME) and then surgically placed onto the defect area
3094270|NCT01834404|Experimental|Phentermine-Topiramate ER|Qualifying participants were assigned to the Phentermine-Topiramate ER for a minimum of 5 days. The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
3094271|NCT01834404|Placebo Comparator|Placebo|Qualifying participants were assigned to placebo for a minimum of 5 days. Placebo pills matched the study drug in appearance for the 2 dose levels.
3094272|NCT01834586|Other|Anesthetic Topical Adhesive Synera|"Anesthetic Topical Adhesive Synera. For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week."
3094273|NCT01834651|Experimental|Treatment (cabozantinib)|Cabozantinib 60mg orally daily until disease progression
3094274|NCT01834716|Experimental|Aerobics exercise|Participants in this group will be randomized to aerobics exercise (the equivalent of walking briskly for 50 minutes three times per week).
3094275|NCT01834716|Experimental|Non-Aerobics Exercise|Participants in this group will be randomized to a non-aerobics (attending classes of toning and stretching a minimum of three times per week) exercise group.
3094276|NCT01834729|Experimental|Alfuzosin|"In Part A, subjects randomized to this arm will receive a single dose of oral alfuzosin immediate release (IR) 2.5 mg.~In Part B, only constipated patients will receive oral alfuzosin (10 mg extended release (ER)) capsules."
3094277|NCT01834729|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a single placebo capsule identical to the study drug.
3094278|NCT01835015|Experimental|CLG561, Concentration Level A|Single 50 μL intravitreal injection of CLG561, Dose Level A
3094279|NCT01835015|Experimental|CLG561, Concentration Level B|Single 50 μL intravitreal injection of CLG561, Dose Level B
3094280|NCT01835015|Experimental|CLG561, Concentration Level C|Single 50 μL intravitreal injection of CLG561, Dose Level C
3094281|NCT01835015|Experimental|CLG561, Concentration Level D|Single 50 μL intravitreal injection of CLG561, Dose Level D
3094282|NCT01835015|Experimental|CLG561, Concentration Level E|Single 100 μL intravitreal injection of CLG561, Dose Level E
3094283|NCT01835132|Experimental|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
3094284|NCT01835145|Experimental|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3094285|NCT01835145|Experimental|Arm II (temozolomide or dacarbazine)|Patients receive temozolomide PO daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. If temozolomide is not available, patients receive dacarbazine IV over 15-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3094286|NCT01835158|Active Comparator|Arm I (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD for 6 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3094287|NCT01835158|Active Comparator|Arm II (sunitinib malate)|Patients receive sunitinib malate PO QD for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3094288|NCT01835223|Experimental|Treatment (tivozanib - 1 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3094289|NCT01835223|Experimental|Treatment (tivozanib - 1.5 mg)|Patients receive tivozanib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3094290|NCT01835262|Active Comparator|Morphine|Morphine Group -- Receiving morphine at 0.1 mg /kg given as IVP
3094291|NCT01835262|Experimental|Ketamine Group|Ketamine Group - - Receiving ketamine at 0.3 mg/given as IVP
3094292|NCT01835379|Experimental|Oasis|Oasis
3094293|NCT01835379|Other|Standard|Standard Care
3094294|NCT01835431|Experimental|Insulin degludec/insulin aspart|
3094295|NCT01835431|Active Comparator|Insulin detemir|
3094296|NCT01835470|Experimental|Abatacept|Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study
3094297|NCT01835496|No Intervention|Ferriprox|single 1500 mg dose of Ferriprox
3094298|NCT01835548|Experimental|NT0102|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given 20-60 mg of NT0102 as oral disintegrating tablet (ODT) once daily for one week during the double-blind treatment period.
3094299|NCT01835548|Placebo Comparator|Placebo|After the screening/washout period, all participants will receive study drug NT0102 once daily for 4 weeks during the dose optimization period. After completion of the dose optimization period, the optimized dose of the study drug will be selected, and participants will stay on that dose for 1 week (dose stabilization period). At the end of this period, participants will be randomized to a treatment. Participants in this arm will be given placebo as matching ODT once daily for one week during the double-blind treatment period.
3094300|NCT01835587|Experimental|CC-486|Dose of 150 mg, 200 mg, or 300 mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
3094301|NCT01835626|Experimental|Vismodegib and Radiation Therapy|150mg Vismodegib will be taken once a day, daily. Radiation therapy will be started after the patient has completed taking vismodegib for 12 weeks. The patient will take daily vismodegib through the completion of radiation therapy. The patient will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
3094302|NCT01835743|Active Comparator|Erchonia HPS Laser|The Erchonia HPS Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
3094303|NCT01835743|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia HPS Laser but does not emit any therapeutic light.
3094304|NCT01835756|Active Comparator|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light.
3094305|NCT01835756|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia MLS but does not emit any therapeutic light.
3094306|NCT01835899|Experimental|Placebo to BI 1015550|placebo
3094307|NCT01835899|Experimental|BI 1015550 low dose 1|powder for oral solution
3094308|NCT01835899|Experimental|BI 1015550 low dose 2|powder for oral solution
3094309|NCT01835899|Experimental|BI 1015550 medium dose 1|powder for oral solution
3094310|NCT01835899|Experimental|BI 1015550 medium dose 2|powder for oral solution
3094311|NCT01835912|Placebo Comparator|Flavoured water placebo for acute dosing|500 milliliters flavoured water (placebo for the acute dosing intervention of sodium citrate)
3094312|NCT01835912|Experimental|Sodium Citrate Dihydrate Acute|dose: 0.5 g/kg of body mass dissolved in 500 milliliters of flavoured water
3094313|NCT01835912|Placebo Comparator|Flavoured water placebo chronic dosing|500 milliliters flavoured water (placebo for the chronic dosing intervention of sodium citrate)
3094314|NCT01835912|Experimental|Sodium Citrate Dihydrate Chronic|3 days of 0.1g/kg of body mass of sodium citrate and 4th day at 0.3 g/kg of body mass of sodium citrate in 500 milliliters of flavoured water
3094315|NCT01836029|Experimental|chemotherapy and cetuximab plus VTX-2337|"VTX-2337 (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
3094316|NCT01836029|Active Comparator|chemotherapy and cetuximab plus placebo|"Placebo (3.0 mg/m2) will be administered on Day 8 and Day 15 of a 21-day cycle for 6 cycles, followed by dosing on Days 8 and 22 of 28-day cycles until disease progression.~Cisplatin (100 mg/m2) OR carboplatin (AUC 5 mg/mL/min) will be administered on Day 1 of a 21-day cycle for a maximum of 6 cycles.~5-FU (1000 mg/m2) will be administered on Days 1-4 of a 21-day cycle for a maximum of 6 cycles.~Cetuximab (initial dose: 400 mg/m2; remaining doses: 250 mg/m2) will be administered weekly until disease progression."
3094317|NCT01836042||Randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients randomized to group
3094318|NCT01836042||Randomized cataract surgery|Cataract surgery alone, patients randomized to group
3094319|NCT01836042||Non-randomized iStent|Implantation of one iStent in conjunction with cataract surgery, patients not randomized to group
3094320|NCT01836133||Erlotinib 150 mg|Participants received 150 mg erlotinib once daily, orally, as tablets, until disease progression or unacceptable toxicity, up to 3 years.
3094321|NCT01836185|Experimental|Evacetrapib (Healthy)|Group 1: 130 milligrams (mg) evacetrapib administered once, orally, to participants with normal hepatic function
3094322|NCT01836185|Experimental|Evacetrapib (Hepatic, Mild)|Group 2: 130 mg evacetrapib administered once, orally, to participants with mild hepatic impairment
3094323|NCT01836185|Experimental|Evacetrapib (Hepatic, Moderate)|Group 3: 130 mg evacetrapib administered once, orally, to participants with moderate hepatic impairment
3094324|NCT01836185|Experimental|Evacetrapib (Hepatic, Severe)|Group 4: 130 mg evacetrapib administered once, orally, to participants with severe hepatic impairment
3094325|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 1)|Part A, Period 1. Participants will receive a single 20-milligram (mg) oral dose of LY2409021 on Day 1.
3094326|NCT01836198|Experimental|LY2409021+Gemfibrozil (Part A, Cohort 1)|Part A, Period 2. Participants will receive a morning (AM) and evening (PM) oral dose of 600 mg gemfibrozil on Days 1-20 and an AM oral dose only of 600 mg gemfibrozil on Day 21. Participants will also receive a single 20-mg oral dose of LY2409021 on Day 4.
3094327|NCT01836198|Experimental|LY2409021 Only (Part A, Cohort 2)|Part A, Period 1. Participants will receive a single 20-mg oral dose of LY2409021 on Day 1.
3094328|NCT01836198|Experimental|LY2409021+Ketoconazole (Part A, Cohort 2)|Part A, Period 2. Participants will receive a once-daily 400-mg oral dose of ketoconazole on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
3094329|NCT01836198|Experimental|LY2409021+Clarithromycin (Part B)|Part B. Participants will receive a twice-daily 500-mg oral dose of clarithromycin on Days 1-21 and a single 20-mg oral dose of LY2409021 on Day 4.
3094330|NCT01836276|Experimental|African American (AA) Smokers|AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
3094331|NCT01836276|Active Comparator|White Smokers|White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
3094332|NCT01836445|Experimental|Keep It Up! Intervention|The KIU! intervention is a multi-media online HIV prevention program developed specifically for young (18-29 years old) men who have sex with men (MSM) who recently tested HIV negative. Intervention content includes discussions of community involvement, scenarios on hooking-up online, communication skills in relationships (including negotiating safer sex), condom use, HIV knowledge, and HIV/STI risks. Information is presented in various formats like games, animation, and videos to address gaps in HIV knowledge, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors. The intervention is completed across three sessions, done at least 24 hours apart (i.e. at least 3 days), and takes about 2 hours total to complete.
3094333|NCT01836445|Active Comparator|HIV Knowledge Control|The control condition reflects HIV information that is currently available on many websites so as to understand how the KIU! intervention improves upon what is currently available online. It is not tailored to YMSM, non-interactive, and focused on HIV/STI knowledge. The control is completed across three sessions done at least 24 hours apart (i.e. at least 3 days).
3094334|NCT01836458|Experimental|Dose 1: 30 mg|Single dose of KAE609 30 mg
3094335|NCT01836458|Experimental|Dose 2: 20 mg|Single dose of KAE609 20 mg
3094336|NCT01836458|Experimental|Dose 3: 10 mg|Single dose of KAE609 10 mg
3094337|NCT01836458|Experimental|Dose 4: 15 mg|Single dose of KAE609 15 mg
3094338|NCT01836471|Experimental|QAW039 450 mg qd Non-atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Non-atopic patients randomized in ratio of approximately 1:1.
3094339|NCT01836471|Placebo Comparator|Placebo Non-atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Non-atopic randomized in ratio of approximately 1:1.
3094340|NCT01836471|Experimental|QAW039 450 mg qd Atopic|QAW039 450 mg (3 capsules of QAW039 150 mg) qd combined with background ICS (100 μg fluticasone, bid). Atopic patients randomized in a ratio of approximate 1:1:1
3094341|NCT01836471|Active Comparator|Fluticasone 150 mcg bid Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with 150 μg ICS and with background ICS (100 μg fluticasone, bid). As a consequence total ICS was 250 μg fluticasone bid. Atopic patients randomized in ratio of approximately 1:1:1
3094342|NCT01836471|Placebo Comparator|Placebo Atopic|Placebo to QAW039 (3 capsules of Placebo of QAW039 150 mg) combined with background ICS (100 μg fluticasone, bid). Atopic patients andomized in ratio of approximately 1:1:1
3094343|NCT01836523|Experimental|Liraglutide 0.6 mg + insulin|
3094344|NCT01836523|Experimental|Liraglutide 1.2 mg + insulin|
3094345|NCT01836523|Experimental|Liraglutide 1.8 mg + insulin|
3094346|NCT01836523|Placebo Comparator|Liraglutide placebo 0.6 mg + insulin|
3094347|NCT01836523|Placebo Comparator|Liraglutide placebo 1.2 mg + insulin|
3094348|NCT01836523|Placebo Comparator|Liraglutide placebo 1.8 mg + insulin|
3094349|NCT01836549|Experimental|Treatment (imetelstat sodium)|"Molecular Biology Phase: Patients will receive one infusion of imetelstat prior to surgery. Surgery will take place 12-24 hours after the infusion of imetelstat. Patients will continue to receive therapy on the same schedule as the Phase II patients starting 14-21 days after surgery.~Phase II: Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
3094350|NCT01837069|Active Comparator|Treatment|Lifestyle counseling (nutrition, physical activity, medication compliance and smoking cessation) Atorvastatin 80mg PO QD Metoprolol 25mg PO BID if HR is elevated Lisinopril 2.5 mg PO QD if SBP is elevated
3094351|NCT01837069|No Intervention|Control|Standard of care
3094352|NCT01837524|Experimental|Grocery-Store-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted during grocery shopping trips at a local supermarket. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will be similar in content to that delivered in an in-office visit, including how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
3094353|NCT01837524|Active Comparator|Office-Based Visit Arm|25 participants will be randomized to this arm. They will receive a baseline 30-minute phone call with the study dietitian to determine their current health problems, dietary patterns, shopping and cooking habits and health goals. They will then have 3 in-person visits with the dietitian conducted in an office at one of our medical office buildings. These in-person visits will be conducted monthly over a 3 month period. The information delivered in the visits will include how to pick the best types of foods or ingredients for a given health condition, how to read and understand food labels, healthy recipes, how to track food and drink intake, and basic nutritional knowledge.
3094354|NCT01837537||no treatment|no treatment, prospective observational
3094355|NCT01837550|Active Comparator|Control group|no professional support
3094356|NCT01837550|Experimental|Intervention group|Professional support via Internet
3094357|NCT01837654|Experimental|Plantarflexion - 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
3094358|NCT01837654|Experimental|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
3094359|NCT01837680|Active Comparator|Levemir|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will take half of the short-acting dose with breakfast and the other half with lunch. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
3094360|NCT01837680|Active Comparator|NPH|Initial daily total insulin doses will be determined as per a weight based protocol depending on what trimester the patient is in. Sixty percent of the total daily insulin dose will be allotted to the morning total dose of insulin, while the remaining 40% will be allotted to the evening total dose. Of the morning dose, 2/3 will be allotted to the long acting insulin and 1/3 to short acting insulin. She will get the entire dose of short-acting insulin with breakfast. The evening insulin dose (40% of the total dose) will be divided in two: half the dose will be taken as short-acting insulin with dinner, and the other half as long acting insulin at bedtime. Doses are rounded down if decimals are present.
3094361|NCT01837719|Experimental|Treatment A: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, following a light meal on Day 1 or 8
3094362|NCT01837719|Experimental|Treatment B: Atazanavir/Cobicistat FDC|Participants received a single fixed-dose combination (FDC) of atazanavir, 300 mg/cobicistat, 150 mg, following a light meal on Day 1 or 8
3094363|NCT01837719|Experimental|Treatment C: Atazanavir + Cobicistat coadministered|Participants received a single dose of atazanavir, 300 mg as capsule, coadministered with cobicistat,150 mg as tablet, in the fasted state on Day 15 or 22
3094364|NCT01837719|Experimental|Treatment D: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, in the fasted state on Day 15 or 22
3094365|NCT01837719|Experimental|Treatment E: Atazanavir/Cobicistat FDC|Participants received a single FDC dose of atazanavir, 300 mg/cobicistat, 150 mg, following a high-fat meal on Day 29
3094366|NCT01837797|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
3094367|NCT01837797|Experimental|Brexpiprazole 1 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
3094368|NCT01837797|Experimental|Brexpiprazole 3 mg|Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
3094369|NCT01837823|Experimental|rosuvastatin|All subjects will receive rosuvastatin 40mg/day
3094370|NCT01837901|Sham Comparator|Sham|OkuStim is used to determine the phosphene threshold, device is turned on but no stimulation is performed.
3094371|NCT01837901|Experimental|150%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 150% of the patient's phosphene threshold.
3094372|NCT01837901|Experimental|200%|OkuStim is used to determine the phosphene threshold, and then to administer transcorneal electrostimulation with a stimulation strength corresponding to 200% of the patient's phosphene threshold.
3094373|NCT01837966|Active Comparator|Lavender oil|Lavender oil aromatherapy
3094374|NCT01837966|Placebo Comparator|Placebo|Placebo -- unscented oil aromatherapy
3094375|NCT01838044|Experimental|Arm A|The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.
3094376|NCT01838044|Other|Arm B|The group of patients who are randomized to receive celecoxib monotherapy during the first study period.
3094377|NCT01838200|Experimental|Cohort 1, Group 1 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
3094378|NCT01838200|Experimental|Cohort 1, Group 2 (BCG 0.8-3.2 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test received BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
3094379|NCT01838200|Experimental|Cohort 1, Group 3 (BCG 4.0-16.0 × 10^6 CFU)|Patients with an induration <10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
3094380|NCT01838200|Experimental|Cohort 2 (BCG 0.16-0.64 × 10^6 CFU)|Patients with an induration ≥10 mm in diameter after the baseline PPD reactivity test were to receive BCG (IL) on Day 1, followed by isoniazid (orally, daily) starting 28 days after the BCG injection and continuing for 4 weeks, and ipilimumab (IV) administered every 3 weeks starting 5 weeks after the BCG injection and continuing for a total of 4 doses.
3094381|NCT01838226|Experimental|Group Prevention Clinics|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to cardiovascular disease (CVD)-related behaviors (e.g., smoking and weight reduction).
3094382|NCT01838226|No Intervention|Treatment as usual control|Usual VA care
3094383|NCT01838304|Active Comparator|Monitoring|Standard of care sedation by CRNA using proposal with manual recording of drug dosing
3094384|NCT01838304|Experimental|Probability ramp control|Propofol titrated to deep sedation using PRC software.
3094385|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients without Diabetes|
3094386|NCT01838317|Experimental|Pioglitazone & Chemotherapy in Patients with Diabetes|
3094387|NCT01838447|No Intervention|Usual care group|This group will receive daily cholecalciferol (vitamin D3) based on the Adequate Intake (AI) for infants and the Recommended Dietary Allowance (RDA) for children over 1 year. Specific dose amounts are 400 IU per day for infants (0-1 year), and 600 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a placebo solution.
3094388|NCT01838447|Experimental|High Dose Group|This group will receive cholecalciferol (vitamin D3) based on the age-specific tolerable daily upper intake level (UL). Specific dose amounts are 1600 IU per day for infants (0-1 year), and 2400 IU per day for children between 1-17 years. Infants under 12 months of age who are formula fed will be given a dose of 1200 IU per day to account for vitamin D in formula.
3094389|NCT01838499|Experimental|MEDI8968|
3094390|NCT01838499|Placebo Comparator|Saline|
3094391|NCT01838551|Experimental|Levoketoconazole DL0|Levoketoconazole Tablets Dose Level 0 Once Daily
3094392|NCT01838551|Experimental|Levoketoconazole DL1|Levoketoconazole Tablets Dose Level 1 Twice Daily
3094393|NCT01838551|Experimental|Levoketoconazole DL2|Levoketoconazole Tablets Dose Level 1 Twice Daily
3094394|NCT01838551|Experimental|Levoketoconazole DL3|Levoketoconazole Tablets Dose Level 3 Twice Daily
3094395|NCT01838551|Experimental|Levoketoconazole DL4|Levoketoconazole Tablets Dose Level 4 Twice Daily
3094396|NCT01838551|Experimental|Levoketoconazole DL5|Levoketoconazole Tablets Dose Level 5 Twice Daily
3094397|NCT01838551|Experimental|Levoketoconazole DL6|Levoketoconazole Tablets Dose Level 6 Twice Daily
3094398|NCT01838551|Experimental|Levoketoconazole DL7|Levoketoconazole Tablets Dose Level 7 Twice Daily
3094399|NCT01838590|Experimental|SOF+RBV 12 Weeks|Participants will receive SOF+RBV for 12 weeks.
3094400|NCT01838590|Experimental|SOF+RBV 24 Weeks|Participants will receive SOF+RBV for 24 weeks.
3094401|NCT01838616|Experimental|Tapentadol Prolonged Release (PR)|
3094402|NCT01838616|Active Comparator|Oxycodone/Naloxone Prolonged Release|
3094403|NCT01838642|Active Comparator|RET mutation positive participants|Rearranged during transfection (RET) mutation positive
3094404|NCT01838642|Active Comparator|RET mutation negative participants|Rearranged during transfection (RET) mutation negative
3094405|NCT01838655|Experimental|Nitisinone|Oral administration of nitisinone
3094406|NCT01838681|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
3094407|NCT01838681|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available ADT
3094408|NCT01838694|Placebo Comparator|Placebo|Multiple doses of matched vehicle (no active ingredients) administered intravenously over 60 minutes.
3094409|NCT01838694|Experimental|Ala-Cpn10|Recombinant minimally modified Chaperonin10 (Cpn10) Multiple doses in the range 10mg twice weekly to 100mg twice weekly administered intravenously by infusion over 60 minutes.
3094410|NCT01838785|Experimental|18F-DTBZ AV-133|18F-DTBZ AV-133 imaging
3094411|NCT01838863|Experimental|Plasma|If the patient is randomized to experimental arm, 2 units of frozen type AB plasma (FP24) will be thawed in the Plasmatherm Dry Thawing and Warming Device according to the operator manual as approved by the FDA in the ambulance and infusion will commence as soon as the type AB plasma is ready, and will continue during transport to the emergency department (ED). After infusion of 2 units of type AB plasma is completed, subsequent care will proceed per institutional, Advanced Trauma Life Support (ATLS) guided resuscitation with acute packed red blood cells (pRBC) administration determined by the hemodynamic response and additional blood component administration guided by rapid thrombelastography (rTEG) and coagulation panel assessment in conjunction with clinical scenario.
3094412|NCT01838863|Active Comparator|Standard|If the patient is randomized to the standard arm, the patient will be given intravenous crystalloid fluid (normal saline) as the initial resuscitation fluid with 2 large bore IVs based on the current ATLS guidelines, the standard of care. Subsequent care will proceed per institutional, ATLS guided resuscitation with acute packed red blood cells pRBC administration determined by the hemodynamic response and additional blood component administration guided by rTEG and coagulation panel assessment in conjunction with clinical scenario.
3094413|NCT01838876|Experimental|Cariprazine + ADT|Cariprazine, flexible dose (titrated to a dose of 3.0 milligrams (mg) adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability), oral administration, once daily plus antidepressant drug therapy (ADT) for 26 weeks.
3094414|NCT01838941|Experimental|Betaine|Betaine will be given orally to all participants and dose will be adjusted to body weight.
3094415|NCT01838980|Experimental|Colonoscopy|
3094416|NCT01839058||Non Cardiac Chest Pain Patients|Patients with Chest Pain where Coronary Artery Disease has been formally ruled out are to undergo esophageal manometry testing.
3094417|NCT01839058||Healthy Controls|Healthy volunteers without esophageal symptoms are to undergo esophageal manometry testing.
3094418|NCT01839110|Active Comparator|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day
3094419|NCT01839110|Placebo Comparator|Placebo|Placebo by mouth twice per day
3094420|NCT01839110|No Intervention|Observational|Patients with pulmonary hypertension who have normal RV function (RVEF >=45%) will undergo same procedures in the observational arm but will not receive an intervention.
3094421|NCT01839188|Experimental|PR5I (V1); Pediacel® (V2); PR5I (V3)|[Vaccination 1]: Single doses of PR5I (V419) + NeisVac-C® + Prevenar 13® by intramuscular (IM) injection + oral RotaTeq®, given at 2 months of age. [Vaccination 2]: Single doses of Pediacel® + NeisVac-C® + Prevenar 13® by IM injection + oral RotaTeq®, given at 4 months of age. [Vaccination 3]: Single dose of PR5I (V419) by IM injection + oral RotaTeq®, given at 6 months of age.
3094422|NCT01839279|Experimental|Tizanidine|Oral dose of 2 and 4 milligram (mg) tablets
3094423|NCT01839279|Placebo Comparator|Placebo|Placebo followed by a single dose 400 mg moxifloxacin tablets.
3094424|NCT01839279|Active Comparator|Moxifloxacin|Single dose of 400 mg moxifloxacin followed by placebo.
3094425|NCT01839318|Experimental|DAILIES AquaComfort Plus|Nelfilcon A contact lenses worn first, followed by etafilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
3094426|NCT01839318|Active Comparator|1-DAY ACUVUE MOIST|Etafilcon A contact lenses worn first, followed by nelfilcon A and omafilcon A in randomized order. Each product worn for 1 day, 12 hours.
3094427|NCT01839318|Active Comparator|Proclear 1 day|Omafilcon A contact lenses worn first, followed by etafilcon A and nelfilcon A in randomized order. Each product worn for 1 day, 12 hours.
3468947|NCT03891030|Experimental|Checklist Based Box system|Pregnant mothers will receive scheduled person-centered health educations starting from: they are identified as suspected pregnant mother up to attending their third PNC visit. In between the first ANC and the third PNC drop out tracing mechanisms will be applied, for mothers who fail to utilize the recommended maternal health services.
3132588|NCT03439124|Active Comparator|IV standard-of-care cephalosporin|"Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP. It is a third-generation cephalosporin with activity against typical bacterial pathogens of CAP requiring hospitalization, and is widely used for the treatment of various bacterial infections in neonates, infants, children, and adults.~Ceftazidime was used as standard-of-care cephalosporin for the treatment of HAP. It is also a third-generation cephalosporin, but with broader activity against Gram-negative aerobic bacilli, including Pseudomonas aeruginosa.~Vancomycin is a glycopeptide antibiotic that is active against staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). At the discretion of the blinded investigator, patients received vancomycin in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed."
3132589|NCT03439137|Experimental|MT-6548|
3094430|NCT01839487|Experimental|Run-in Phase - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (mcg/kg) PEGPH20 with 125 milligrams/square meter (mg/m^2) NAB and 1000 mg/m^2 GEM as intravenous (IV) infusion. In Cycle 1 Week 1, PEGPH20 will be administered alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15 and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1 8 and 15. NAB+GEM will be given 2 to 4 hours after PEGPH20 dose. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior and 8 to 12 hours after completion of each PEGPH20 infusion.
3094431|NCT01839487|Active Comparator|Run-in Phase - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
3094432|NCT01839487|Experimental|Phase 2: Stage 1 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and Day 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning and 8 to 12 hours after the completion of each PEGPH20 infusion.
3094433|NCT01839487|Active Comparator|Phase 2: Stage 1 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
3094434|NCT01839487|Experimental|Phase 2: Stage 2 - PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine|Participants will receive 3.0 mcg/kg PEGPH20 with 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion. In Cycle 1 Week 1, PEGPH20 will be given alone on Days 1 and 4 and NAB+GEM will be given on Day 2 at approximately 24 hours after first dose of PEGPH20. In Cycle 1 Weeks 2 and 3, PEGPH20 will be given twice/week on Days 8, 11, 15, and 18 and NAB+GEM will be given once/week at 2 to 4 hours after PEGPH20 administration on Days 8 and 15. In Cycle 2 onwards, PEGPH20, NAB, and GEM will be given once/week on Days 1, 8, and 15. NAB+GEM will be given 2 to 4 hours after dose of PEGPH20. Each cycle will be of 4-weeks with Week 4 of every cycle as a rest week (no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to beginning and 8 to 12 hours after completion of each PEGPH20 infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given subcutaneously (SC).
3094435|NCT01839487|Active Comparator|Phase 2: Stage 2 - AG: Nab-paclitaxel + Gemcitabine|Participants will receive 125 mg/m^2 NAB and 1000 mg/m^2 GEM as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion. Enoxaparin 40 mg/day or 1 mg/kg/day will be given SC.
3094436|NCT01839604|Experimental|AZD9150|There are two parts, dose escalation phase (Part A) and dose expansion phase (Part B).
3094437|NCT01839656|Experimental|Nusinersen 6 mg|
3094438|NCT01839656|Experimental|Nusinersen 12 mg|
3094439|NCT01839695|Experimental|Valiant Mona LSA Stent Graft System|TEVAR procedure using Medtronic Stent Graft
3094440|NCT01839708|Experimental|Lifestyle Counseling|Intervention group: in addition to usual WIC care, watch the DVDs at home, complete action plan worksheets, call in to moderated (MI) group discussions.
3094441|NCT01839708|No Intervention|No Lifestyle Counseling|Comparison group: usual WIC care; read printed materials at home
3094442|NCT01839799|Experimental|Arm 1 - FOLFIRINOX|"FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy.~On Day 1(+ 2days to accommodate scheduling difficulties):~Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~FOLFIRINOX:~Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated"
3094443|NCT01839799|Experimental|Arm 2 - Gemcitabine / Abraxane|"Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles over 8 weeks~Chemoradiation:~Radiation to begin no sooner than 28 days from last day of chemotherapy. On Day 1 (+ 2days to accommodate scheduling difficulties) Infusional 5-FU (225 mg/m2 continuous infusion during radiation) and radiation therapy as defined.~Gemcitabine / Abraxane Gemcitabine 1000 mg/m2 Days 1, 8, 15 Abraxane 125 mg/m2 Days 1, 8, 15 Two cycles, if tolerated"
3094444|NCT01839916|Experimental|Treatment (DLI)|Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity.
3094445|NCT01840072|Experimental|Active antihypertensive treatment|Active antihypertensive treatment
3094446|NCT01840072|No Intervention|Usual care|Discontinue all home BP medications.
3094447|NCT01840163|Other|CanSORT Online Tool|Comprehensive decision tool
3094448|NCT01840163|Other|Static version of CanSORT tool|Static version (non-interactive) version of CanSORT decision tool
3132590|NCT03439137|Active Comparator|Darbepoetin alfa|
3094449|NCT01840228|Active Comparator|Micronized progesterone suppository|Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
3094450|NCT01840228|Placebo Comparator|Placebo suppository|One placebo suppository vaginally daily until 36 6/7 weeks' gestation.
3094451|NCT01840319||1|Patients previously included in the initial protocol WYETH 3074A1-4448 / B1811030. (To collect only status survival data 30 days after the last dose of treatment)
3094452|NCT01840345|Experimental|N-acetyl-L-cysteine|n-acetyl-l-cysteine 1200 mg BID x 4 weeks
3094453|NCT01840410|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
3094454|NCT01840410|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At Month 1, if treatment was needed, sham was administered. At Month 2, participants could switch to open-label ranibizumab on an as needed basis.
3094455|NCT01840579|Experimental|Pembrolizumab 2 mg/kg|In Part A, participants receive intravenous (IV) Pembrolizumab 2 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
3094456|NCT01840579|Experimental|Pembrolizumab 10 mg/kg|In Part A, participants receive IV Pembrolizumab 10 mg/kg on Day 1 of Cycle 1 (28 days), Cycle 2 and any additional cycles (14 days).
3094457|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
3094458|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Pemetrexed|In Part B, participants receive IV Pembrolizumab 200 mg + IV Carboplatin Area Under The Curve (AUC) 5 mg/mL/minute + IV Pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pemetrexed in combination with IV pembrolizumab is permitted per standard of care, followed by IV pembrolizumab 200 mg every 3 weeks.
3094459|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute + IV Paclitaxel 200 mg/m^2 on Day 1 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
3094460|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Nab-paclitaxel|In Part C, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 6 mg/mL/minute on Day 1 of each 21-day cycle + IV Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
3094461|NCT01840579|Experimental|Pembrolizumab+Ipilimumab|In Part D, participants receive IV Pembrolizumab 200 mg on Day 1 of each 21-day cycle + IV Ipilimumab 1 mg/kg on Day 1 of every other 21-day cycle (every 42 days) for a maximum of 18 cycles of Ipilimumab (35 doses of Pembrolizumab).
3094462|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
3094463|NCT01840579|Experimental|Pembrolizumab+Carboplatin/Etoposide|In Part E, participants receive IV Pembrolizumab 200 mg + IV Carboplatin AUC 5 mg/mL/minute on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
3094464|NCT01840579|Experimental|Pembrolizumab+Cisplatin/Etoposide+G-CSF|In Part E, participants receive IV Pembrolizumab 200 mg + IV Cisplatin 75 mg/m^2 on Day 1 of each 21-day cycle + IV Etoposide 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles + lasting granulocyte colony-stimulating factor (G-CSF) (pegfilgrastim) 3.6 mg on Day 4 of Cycle 1. After completion of the initial therapy, maintenance therapy with IV pembrolizumab 200 mg every 3 weeks.
3094465|NCT01840605|Experimental|TAU-284|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day, once after breakfast and once before bed.
3094466|NCT01840605|Active Comparator|ketotifen fumarate|Two TAU-284 5mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day, once after breakfast and once before bed.
3094467|NCT01840722|No Intervention|NIDA Standard HIV Education|NIDA Standard HIV Education Participants in this condition will be given HIV education using NIDA standard pre and post-test counseling, HIV and HCV rapid testing, and an information packet on existing community drug abuse and HIV/HCV resources
3094468|NCT01840722|Experimental|MI-based HIV Risk Reduction|MI-based HIV Risk Reduction -- In addition to what is received in the HIV-Ed group, participants in this condition will also receive a CDC evidence-based brief intervention for high-risk women focused on an individualized plan for enhancing motivation to reduce risk behaviors and to use health and behavioral health services in the community.
3094469|NCT01840943|Experimental|CAELYX|Participants will receive CAELYX 50 mg per square meter intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing PK evaluation.
3094470|NCT01840943|Active Comparator|Topotecan hydrochloride (HCl)|Participants will receive topotecan HCl 1.25 mg per square meter per day, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
3094471|NCT01841021|Experimental|Brentuximab Vedotin Treatment|Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.
3094472|NCT01841047|Other|Radiotherapy|Evaluation of the combination of radiotherapy with helical tomotherapy (54 Gy) followed by surgery in retro-peritoneal liposarcomas.
3094473|NCT01841060|Experimental|Radiofrequency ablathermy|Percutaneous radiofrequency ablation (RFA)
3094474|NCT01841073|Experimental|Inulin|Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.
3094475|NCT01841073|Placebo Comparator|Cellulose|Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.
3094476|NCT01841216|Experimental|Low Back Pain|Lower Body Exercises with and without resistance
3094477|NCT01841216|Experimental|Healthy|Lower Body Exercises with and without resistance
3094478|NCT01841281|Active Comparator|Low Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level less than or equal to 20 ppb will be enrolled in the Low Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
3094479|NCT01841281|Active Comparator|High Exhaled Nitric Oxide (NO)|"Subjects with a baseline exhaled NO level greater than or equal to 25 ppb will be enrolled in the High Exhaled Nitric Oxide arm.~All subjects will receive L-arginine and placebo in this cross-over design study."
3094480|NCT01841554|Experimental|Single|
3094481|NCT01841567|Other|dressing|
3094482|NCT01841593|Experimental|Group A|DAYS 1 to 7: raltegravir 400 mg BID DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: amlodipine 5 mg OD
3094483|NCT01841593|Experimental|Group B|DAYS 1 to 7: amlodipine 5 mg OD DAYS 8 to 14: raltegravir 400 mg BID PLUS amlodipine 5 mg OD DAYS 15 to 21: raltegravir 400 mg BID
3094484|NCT01841606|Experimental|Ondansetron|4mg of IV ondansetron 5 minutes prior to initiation of spinal anesthesia
3094485|NCT01841606|Placebo Comparator|Placebo|10mL of IV normal saline 5 minutes prior to initiation of spinal anesthesia
3094486|NCT01841619|Active Comparator|IVIg as a monotherapy|IVIg will be used as a first line treatment. Topical treatment will be stopped at the beginning of IVIg therapy.
3094487|NCT01841632|Experimental|MultiStem|"Dose escalation~Cohort 1~Drug: MultiStem, Dose 1 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 2~Drug: MultiStem, Dose 2 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 3~Drug: MultiStem, Dose 3 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)~Cohort 4~Drug: MultiStem, Dose 4 of MultiStem; Route and time: Two infusions; First: intra portal at liver transplantation (day 1), second: intra venous (day 3)"
3094488|NCT01841697|Experimental|Omarigliptin 25 mg once weekly|Participants receive omarigliptin 25 mg once a week plus placebo to sitagliptin once daily for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
3094489|NCT01841697|Active Comparator|Sitagliptin 100 mg once daily|Participants receive sitagliptin 100 mg once daily plus placebo to omarigliptin once a week for 24 weeks. Participants continue pre-study stable dose of metformin (total daily dose ≥1500 mg) throughout the study. Participants may receive glimepiride (total daily dose of 1-6 mg) as rescue therapy.
3094490|NCT01841762|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
3094491|NCT01841970|Other|HET Arm|Active arm. A single procedure with HET was used to treat Grade I and Grade II hemorrhoids
3094492|NCT01842061|Experimental|Active Living Program|Participants in the intervention group will receive a self-management program designed to reduce sedentary behaviour and increase physical activity. Specifically, they will be given an EASY Program Manual with strategies to break up sitting time during the day and increase utilitarian activity; this will include a section on how to set, monitor and maintain achievable goals. They will also be offered a pedometer program, group education sessions and encouraged to use public transport by providing free bus tickets.
3094493|NCT01842061|Active Comparator|Education|Control group participants will be offered monthly drop-in sessions that target information on general health and well-being unrelated to physical activity.
3094494|NCT01842308|Experimental|Treatment|"CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.~TRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
3094495|NCT01842334|Experimental|D-cycloserine|250 mg D-cycloserine once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy.
3094496|NCT01842334|Placebo Comparator|Placebo|one placebo capsule once weekly an hour before receiving cognitive behavioral therapy treatment along with Nicotine Replacement Therapy
3094497|NCT01842438|Experimental|Behavioral: psychosexual intervention|6-sessions of couple support focused on relationships and psychosexual functioning
3094498|NCT01842438|No Intervention|Control|This group will not receive the intervention during the life-span of the project
3094499|NCT01842464||Anterior Sacro-Spinous Support|Anterior sacro-spinous mesh implants supported patients
3094500|NCT01842581|Experimental|Rifaximin 550 mg BID|Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
3094501|NCT01842581|Experimental|Rifaximin 550 mg BID + Lactulose|Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.
3094502|NCT01842594|Experimental|Sirolimus and hydroxychloroquine|Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally once daily(QD) for 2 cycles . Each treatment cycle is 28 days.
3094503|NCT01842607|Experimental|Mepolizumab Arm|Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
3094504|NCT01842620|Experimental|OXEMET 1000 mg coated tablets|Generic undergoing bioequivalence study against reference
3094505|NCT01842620|Active Comparator|GLAFORNIL 500 mg tablets|Reference drug for bioequivalence study
3094506|NCT01842633|Experimental|Paracetamol/ Caffeine Caplets|Two caplets of paracetamol/caffeine combination plus 2 placebo caplets to be administered
3094507|NCT01842633|Active Comparator|Ibuprofen Caplets|Two ibuprofen caplets plus two placebo caplets to be administered
3094508|NCT01842633|Placebo Comparator|Placebo Caplets|Four placebo caplets to be administered
3094509|NCT01842646|Experimental|PF-04449913 Treatment|Treatment will be administered on an outpatient basis. All patients will be treated with an oral dose PF-04449913 at 100 mg daily in 4-week cycles for a total of 4 cycles. Patients who demonstrate no evidence of progressive disease (i.e. stable disease or better) may continue on treatment until disease progression or loss of response, limiting toxicity, or death.
3094510|NCT01842789|Other|Acessa Procedure w/o TAG|Acessa Procedure without the use of Targeting Animation Guidance
3094511|NCT01842789|Other|Acessa Procedure with TAG|Acessa Procedure with Targeting Animation Guidance
3094512|NCT01842815|Experimental|755nm Alexandrite Laser Single Pass (Right Side).|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The right side will be treated once within the same visit.
3094513|NCT01842815|Experimental|755nm Alexandrite Laser Double Pass (Left Side)|755nm Alexandrite Laser for Treatment of unwanted, non cosmetic tattoos. The left side of the tattoo will be treated twice within the same visit 20 minutes apart.
3094514|NCT01842841|Experimental|velaglucerase alfa|15 to 60 U/kg, EOW via intravenous infusion
3094515|NCT01842906|Experimental|Theravent|A singe use, disposable, positive end expiratory pressure device worn over the nostrils while sleeping.
3094516|NCT01842906|Sham Comparator|Control|A visibly identical sham device that does not provide positive end expiratory pressure.
3094517|NCT01842958|Active Comparator|4.1 mm implant diameter|Placement of a Straumann Bone Level Implants, 4.1 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
3094518|NCT01842958|Experimental|3.3 mm implant diameter|Placement of a Straumann Bone Level Implants, 3.3 mm implant diameter, for single tooth replacement in the anterior and pre-molar region
3094519|NCT01843023|Experimental|Extended Release Naltrexone|Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [Vivitrol®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.
3094520|NCT01843023|Active Comparator|Treatment as Usual|Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.
3094521|NCT01843062|Experimental|Selumetinib|Selumetinib plus Radioactive Iodine Therapy
3094522|NCT01843062|Placebo Comparator|Placebo|Placebo plus Radioactive Iodine Therapy
3094523|NCT01843192||VATS for suspected or confirmed NSCLC|Single arm study
3094524|NCT01843205|Placebo Comparator|Placebo|Subjects will be maintained on placebo.
3094525|NCT01843205|Experimental|Buspirone|Subjects will be maintained on buspirone.
3094526|NCT01843348|Active Comparator|TAC+MPA|
3094527|NCT01843348|Experimental|TAC+Certican|
3094528|NCT01843348|Experimental|CycA+Certican|
3094529|NCT01843374|Experimental|Tremelimumab|Tremelimumab
3094530|NCT01843374|Placebo Comparator|Placebo|Placebo
3094531|NCT01843465||Cryoablation of atrial fibrillation|
3094532|NCT01843621|Experimental|Total vaccinated|The total vaccinated cohort included all enrolled subjects who received the DEN vaccine F17 for whom data were available. These subjects were Thai children previously enrolled and vaccinated in study Dengue-003
3094533|NCT01843660|Experimental|Tramadol Hydrochloride (HCl)-Paracetamol|
3094534|NCT01843673|Experimental|in-room imaging systems|Patients undergo FBCT once before treatment and once weekly for a total of 6-7 scans, dual CBCT up to 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian kV OBI 5 times weekly for a total of 33-35 scans, 2-D x-ray with Brain Lab ExacTrac 5 times weekly for a total of 33-35 scans, 2-D x-ray with Varian MV OBI once weekly for a total of 6-7 scans, and EPID imaging up to 5 times weekly for a total of 33-35 scans while undergoing IGART.
3094535|NCT01843751|Active Comparator|Physician Office|Buprenorphine/naloxone via physician office (B-PO) x 10 months
3094536|NCT01843751|Experimental|Specialist Center|Buprenorphine/naloxone via specialist center (B-SC) x 3 months followed by B-PO x 7 months. The specialist center in this trial will be a methadone clinic.
3094537|NCT01843777|Active Comparator|Standard-of-Care|"The standard-of-care control group will review and practice with the audiologist content such as: 1) information on hearing-aid batteries and how to change them, 2) cleaning/daily care of the hearing aids, and 3) inserting and removing the hearing aids."
3094538|NCT01843777|Experimental|Treatment|The treatment group, on the other hand, will use a motivational tool (exploring importance) in a manner that is consistent with the spirit of motivational interviewing.
3094539|NCT01843803|Experimental|patient inventory tool|prior to the encounter with his/her provider, the patient completes an inventory that includes information about patient contextual factors (e.g., life circumstances), resources and preferences for care delivery. This information is presented to the provider to facilitate care delivery.
3094540|NCT01843803|Active Comparator|attention control|prior to the encounter, the patient will view a brief video containing general health information.
3094541|NCT01843842|Experimental|Ergoferon (5 ml 3 times a day)|
3094542|NCT01843842|Placebo Comparator|Placebo (5 ml 3 times a day)|
3094543|NCT01843920|Active Comparator|Post surgery without glaucoma drops|This will be for the group that had gas duration surgery using SF6 (Sulfur Hexafluoride) or C3F8 (perfluoropropane gas tamponade) and only uses the standard post-operative topical drops.
3094544|NCT01843920|Experimental|Post surgery with glaucoma drops|This will be for the group that had gas duration surgery (using SF6 or C3F8). In addition to the standard post-operative topical drops, glaucoma drops, Timolol-dorzolamide (timolol 0.5%-dorzolamide 2%) will be given.
3094545|NCT01843933|No Intervention|Standard monitoring and blinded to capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion will be used to collect and record data but staff will be blinded to the monitor output.
3094546|NCT01843933|Active Comparator|Capnography|Capnography will be added to standard monitoring practices. A portable capnography monitor (Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion) will be used to collect and record data.
3094547|NCT01843972|Experimental|BI 691751 dose 2 (part I)|single dose given as oral solution
3094548|NCT01843972|Experimental|BI 691751 dose 3 (part I)|single dose given as oral solution
3094549|NCT01843972|Experimental|BI 691751 dose 4 (part I)|single dose given as oral solution
3094550|NCT01843972|Experimental|BI 691751 dose 5 (part I)|single dose given as oral solution
3094551|NCT01843972|Experimental|BI 691751 dose 6 (part I)|single dose given as oral solution
3094552|NCT01843972|Experimental|BI 691751 dose 7 (part I)|single dose given as oral solution
3094553|NCT01843972|Experimental|BI 691751dose 1 (part I)|single dose given as oral solution
3094554|NCT01843972|Placebo Comparator|Placebo (part I)|placebo solution
3094555|NCT01843972|Experimental|BI 691751 tablet (part II)|single dose given as 1 tablet
3094556|NCT01843972|Active Comparator|BI 691751 solution (part II)|single dose given as oral solution
3094557|NCT01844076|Experimental|Phase I Level -2|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg once per day (days 1-21) for a 21 day cycle"
3094558|NCT01844076|Experimental|Phase I Level -1|"Phase I (Quinacrine and Capecitabine): The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.~Each group will have 1 to 6 patients enrolled in it. If the patients in a lower group do not have any significant side effects the next patient will start at the next group dose.~Group 1: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), and quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
3094559|NCT01844076|Experimental|Phase I Level 0|Group 3: capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 200 mg twice a day (days 1-21) for a 21 day cycle
3094560|NCT01844076|Experimental|Phase II|"Phase II will use the treatment outlined in phase I, using the recommended phase II dose (RP2D) derived from Phase I.~Patients will receive capecitabine at a dose of 1000 mg/m^2 twice per day (days 1-14), quinacrine at a dose of 100 mg twice per day (days 1-21) for a 21 day cycle"
3094561|NCT01844115|Placebo Comparator|Placebo|Dose-matched placebo tablets, oral administration
3094562|NCT01844115|Experimental|Vilazodone|Vilazodone tablets, oral administration
3094563|NCT01844193|No Intervention|Standard Therapy|This arm of the study will follow the standard therapy course after total knee arthroplasty.
3094564|NCT01844193|Experimental|Standard Therapy + NMES|This arm will follow the standard course of therapy but also incorporate daily neuromuscular electrical stimulation into the daily therapy regimen after total knee arthroplasty through use of the Compex Rehab device.
3094565|NCT01844284|Experimental|Absorb™ BVS|Subjects receiving Absorb™ BVS
3094566|NCT01844284|Active Comparator|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
3094567|NCT01844375|Experimental|Carbohydrate group|The carbohydrate (CHO) group will be given the carbohydrate drink (12.5% carbohydrates, 50 kcal/100 ml, 240 mOsmol/l, pH 5.0) 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except the carbohydrate drink. The pharmacy department is responsible for preparing the carbohydrate drink.
3094568|NCT01844375|Active Comparator|Control group|The control group will be given pure water 800 mL of one of the drinks the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning of the operation day. The last drink will be no later than 3 hours before the scheduled induction of anesthesia. Of note, the last meal on the day before the operation will be no later than 1800 h. Following this meal, no food or drink will be allowed except pure water.
3094569|NCT01844388|Experimental|Carboxymethylcellulose Based Eye Drop Formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
3094570|NCT01844388|Active Comparator|REFRESH CONTACTS®|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
3094571|NCT01844479|Active Comparator|Standard innersole|"Per sequence cross over design. Order of testing innersoles was randomized and each testing condition lasted 15 minutes.~The industry standard diabetic innersole will be used as the active comparator"
3094572|NCT01844479|Experimental|Diabetic Foot Orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
3468948|NCT03891030|No Intervention|Routine maternal health care|Pregnant mothers in this arm will receive the usual routine maternal health care.
3468949|NCT03891212|Experimental|The prone group|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours.
3468950|NCT03891212|No Intervention|The supine group|Patients assigned to the supine group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
3468951|NCT03891238|Experimental|Avelumab Arm|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
3468952|NCT03890952|Experimental|Arm B Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients not undergoing salvage surgery
3468953|NCT03890952|Experimental|Arm A Nivolumab and bevacizumab|Nivolumab and bevacizumab in patients undergoing salvage surgery
3468954|NCT03891173|Experimental|L-DOS47 in combination with cisplatin + vinorelbine|L-DOS47 (6/9/12 µg/kg) is administered by iv on Day 1 and 8 of each 21-day treatment cycle, in combination with iv administration of standard cisplatin (80 mg/m2) on Day 2 + vinorelbine (30 mg/m2) on Day 2 and 9.
3468955|NCT03891173|Active Comparator|Cisplatin + vinorelbine alone|Administration by iv of standard Cisplatin (80 mg/m2) on Day 1 + vinorelbine (30 mg/m2) on Day 1 and 8 of each 21-day treatment cycle.
3094577|NCT01844531|Experimental|FDC empagliflozin dose 1 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
3094578|NCT01844531|Active Comparator|empagliflozin dose 1 + metformin tablets|single tablets after intake of a high fat, high caloric meal
3094579|NCT01844531|Experimental|FDC empagliflozin dose 2 and metformin|fix dose combination tablet after intake of a high fat, high caloric meal
3094580|NCT01844531|Active Comparator|empagliflozin dose 2 + metformin tablets|single tablets after intake of a high fat, high caloric meal
3094581|NCT01844583|Experimental|Esomeprazole 40 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Esomeprazole, 40 mg, delayed-release capsules, orally, once daily on Days 1 to 10 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
3094582|NCT01844583|Experimental|Rifampin 600 mg + Alisertib 50 mg|"Alisertib 50 mg, tablets, orally, once on Day 1, followed by twice daily on Days 4 to 10, followed by a 14-day rest period in Cycle 1.~Rifampin 600 mg, capsules, orally, once daily on Days 1 to 10 in Cycle 2 plus alisertib, 50 mg, tablets, orally, once on Day 8, followed by twice daily on Days 11 to 17, followed by a 14-day rest period in Cycle 2.~Alisertib 50 mg, tablets, orally, twice daily on Days 1 to 7 beginning with Cycle 3 (21-day cycles) to the end of study (Up to 15 Cycles)."
3094583|NCT01844687|Other|Active marijuana (MJ) with 0 mg CBD|Active MJ cigarettes contain 5.30% THC
3094584|NCT01844687|Other|Active MJ with 200 mg CBD|Active MJ cigarettes contain 5.30% THC
3094585|NCT01844687|Other|Active MJ with 400 mg CBD|Active MJ cigarettes contain 5.30% THC
3094586|NCT01844687|Other|Active MJ with 800 mg CBD|Active MJ cigarettes contain 5.30% THC
3094587|NCT01844687|Other|Inactive MJ with 0 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3094588|NCT01844687|Other|Inactive MJ with 200 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3094589|NCT01844687|Other|Inactive MJ with 400 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3094590|NCT01844687|Other|Inactive MJ with 800 mg CBD|Inactive MJ cigarettes contain 0.01% THC
3094591|NCT01844700|Active Comparator|Ziprasidone|(20-160mg/d, bid) for 12 weeks
3094592|NCT01844700|Active Comparator|Aripiprazole, quetiapine, risperidone|Aripiprazole (2-30mg/d), Quetiapine (25-800mg/d) or Risperidone (0.1-8mg/d) for 12 weeks
3094593|NCT01844765|Experimental|Newly diagnosed and untreated Ph+ CML in first CP|Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.
3094594|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in CP|Resistant or Intolerant to either imatinib or dasatinib
3094595|NCT01844765|Experimental|Resistant/intolerant Ph+ CML in AP|Resistant or intolerant to either imatinib or dasatinib - at the end no patients were enrolled in this arm.
3094596|NCT01844778|Active Comparator|TIS/TIP|During the first cycle of treatment, participants received nebulized TIS, 300 mg twice per day for 28 days followed by 28 days off-treatment. During the second cycle, participants received 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3094597|NCT01844778|Active Comparator|COLI/TIP|During the first cycle, participants received nebulized COLI, 1 million or 2 million units twice or thrice per day (or the participant's usual dose and regimen) for 56 days (no off-treatment period) or 28 days on-treatment followed by 28 days off-treatment (cycling regimen), depending on local treatment guidelines. During the second cycle, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3094598|NCT01844778|Active Comparator|TIP/TIP|During the first and second cycles, participants received TIP, 112 mg (four 28 mg capsules) twice per day for 28 days followed by 28 days off-treatment.
3094599|NCT01844817|Experimental|OGX-427|Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1. Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8, 15, and 22 of each 28 day cycle during the Treatment Phase.
3094600|NCT01844817|Placebo Comparator|Placebo|Three loading doses of placebo will be administered Days -9 to -1. Following the loading dose period, placebo will be administered weekly Days 1, 8, 15, and 22 of each 28 day cycle.
3094601|NCT01844830|Experimental|Kovacaine Mist|Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
3094602|NCT01844830|Placebo Comparator|Placebo|Placebo - Subjects weighing more than 10kg and less than 20kg, will receive 1 spray of 100µL; Subjects weighing more than 20kg and less than 40kg, will receive 2 sprays of 100µL (200µL total); subjects weighting more than 40kg will receive 2 sprays of 200µL (400µL total);
3094603|NCT01844856|Experimental|Eravacycline, 1.0 mg/kg q12h|Eravacycline was administered intravenously (IV) at a dose of 1.0 milligram per kilogram of body weight (mg/kg) every 12 hours (q12h) for a minimum of 4 days and a maximum of 14 days. Eravacycline treatment was to be stopped when symptoms of complicated intra-abdominal infection (cIAI) resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3094604|NCT01844856|Active Comparator|Ertapenem, 1.0 g q24h|Ertapenem was administered IV at a dose of 1.0 gram (g) every 24 hours (q24h) for a minimum of 4 days and a maximum of 14 days. Ertapenem treatment was to be stopped when symptoms of cIAI resolved, there was treatment failure, or the maximum allowed number of infusion days was reached.
3094605|NCT01844895|Experimental|Abatacept (Autoinjector and Prefilled Syringe)|"Abatacept (prefilled syringe) 125 mg/device solution subcutaneously weekly for 3 months~Abatacept (autoinjector) 125 mg/device solution subcutaneously weekly for 1 month"
3094606|NCT01844986|Experimental|Olaparib tablets p.o. 300mg twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
3094607|NCT01844986|Placebo Comparator|Placebo tablets p.o. twice daily|Olaparib/placebo tablets p.o 300mg twice daily for up to 3 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity
3094608|NCT01845025|Experimental|FOM 12 mcg + FP|Formoterol 12 mcg + fluticasone propionate 100 mcg, 250 mcg or 500 mcg for inhalation
3094609|NCT01845025|Active Comparator|fluticasone propionate (FP)|fluticasone propionate 100 mcg, 250 mcg or 500 mcg + Placebo to Match Formoterol 12 mcg for inhalation
3094610|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin, fed|3 single tablets under fed conditions
3094611|NCT01845077|Experimental|5 mg Linagliptin/1500 mg Metformin FDC|2 FDC tablets under fasted conditions
3094612|NCT01845077|Active Comparator|5 mg Linagliptin/1500 mg Metformin|4 single tablets under fasted conditions
3094613|NCT01845077|Experimental|5 mg Linagliptin/1000 mg Metformin FDC|1 fixed dose combination(FDC) tablet under fasted conditions
3094614|NCT01845077|Active Comparator|5 mg Linagliptin/1000 mg Metformin|3 single tablets under fasted conditions
3094615|NCT01845077|Experimental|5mg Linagliptin/1000mg Metformin, FDCfed|1 FDC tablet under fed conditions
3094616|NCT01845155|Experimental|Music Therapy|Neuro-Music-Therapy according to the Heidelberg Model
3094617|NCT01845155|Active Comparator|Counselling|Counselling
3094618|NCT01845220|Active Comparator|Broccoli Sprout Extract|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
3094619|NCT01845220|Placebo Comparator|Placebo|Each subject will act as his/her own control and receive both treatment and placebo on adjacent skin regions.
3094620|NCT01845636|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item University of Pennsylvania Smell Identification Test (UPSIT) immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
3094621|NCT01845792|Experimental|Cabazitaxel with Abiraterone Acetate|Cabazitaxel administered as a single intravenous dose every 3 weeks, in combination with abiraterone acetate and prednisone taken daily.
3094622|NCT01845792|Active Comparator|Cabazitaxel Alone|Cabazitaxel administered as a single intravenous dose every 3 weeks
3094623|NCT01845818||Ankylosing Spondylitis and Psoriatic Arthritis|Participants with AS and PsA and in whom adalimumab treatment is initiated. All medication will be prescribed in the usual manner in accordance with the terms of the marketing authorization and in line with the Belgian reimbursement criteria.
3094624|NCT01845831|Experimental|Sitagliptin + glargine (Hospital)|Sitagliptin and glargine once daily + correction doses of aspart or lispro if needed
3094625|NCT01845831|Active Comparator|Basal bolus (Hospital)|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
3094626|NCT01845831|Experimental|Metformin and Sitagliptin|Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months
3094627|NCT01845831|Experimental|Metformin and sitagliptin + glargine 50%|Patients with HbA1c between 7% and 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (50% of the inpatient glargine dose) for 6 months
3094628|NCT01845831|Experimental|Metformin and sitagliptin + glargine 80%|Patients with HbA1c > 9% will be discharged on metformin and sitagliptin (Janumet ® 500/50 mg) twice daily plus glargine insulin (80% of the inpatient glargine dose) for 6 months
3094629|NCT01845974|Experimental|Low Flow Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
3094630|NCT01845974|Active Comparator|High Flow Catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
3094631|NCT01846039|Experimental|JUVÉDERM VOLUMA®|Participants treated with JUVÉDERM VOLUMA® up to 3 mLs administered by intradermal injection.
3094632|NCT01846104|Experimental|50-μg booster dose RVEc|Subjects will be receive one 50-μg dose of RVEc
3094633|NCT01846208|Experimental|Egg OIT Randomized|Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
3094634|NCT01846208|Experimental|Baked Egg Randomized|"Subjects who passed a baked egg oral food challenge (OFC) at baseline were randomized to receive baked egg in the form of home-baked goods and safe commercial products with up to four oral food challenges as directed by the protocol."
3094635|NCT01846208|Experimental|Egg OIT Assigned|Subjects who failed a baked egg oral food challenge (OFC) at baseline were assigned to receive egg oral immunotherapy (OIT) in the form of egg white solid with up to four oral food challenges as directed by protocol.
3094636|NCT01846221|Experimental|Clonidine|Participants randomized to this arm of the study receive 100 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
3094637|NCT01846221|Experimental|Fentanyl|Participants randomized to this arm of study will receive 100 mcg fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
3468956|NCT03891160|Experimental|Group A - 3D models|Group A will receive 3-D printed models will be used for pre-VAD planning. For patients in Group A, the surgeon will complete a questionnaire 1) after reviewing 2D imaging data and 2) after reviewing a patient specific 3D model. The investigators primary outcome measure will be an improvement in the clarity of cannula and VAD site demonstration. The investigators hypothesize that the 3D models will more clearly demonstrate the sites of cannula and VAD placement as compared to 2D imaging.
3094640|NCT01846299|Experimental|Ranibizumab|A 0.5 mg ranibizumab intravitreal injection was given to the study eye at baseline, and then as needed based on evidence of disease activity.
3094641|NCT01846299|Sham Comparator|Sham control|Sham injection was given to the study eye at baseline, and then treatment was given based on evidence of disease activity. At month 1, if treatment was needed, sham was administered. At month 2, participants switched to open-label ranibizumab on an as needed basis.
3094642|NCT01846416|Experimental|Atezolizumab (MPDL3280): 1L Participants|Participants with no prior chemotherapy for advanced NSCLC disease will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until disease progression.
3094643|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Participants|Participants who progress during or following a prior platinum-based chemotherapy regimen without restriction to maximum number of prior therapies will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
3094644|NCT01846416|Experimental|Atezolizumab (MPDL3280): 2L+ Brain Metastases Participants|Participants with previously treated brain metastases and who progress during or following a prior platinum-based chemotherapy regimen without restriction to the maximum number of prior therapies, will receive atezolizumab IV as a fixed dose of 1200-mg on Day 1 of each 21-day cycle until no longer deemed to be experiencing clinical benefit as assessed by the investigator.
3094645|NCT01846442|Placebo Comparator|Placebo|
3094646|NCT01846442|Experimental|0.25% DHEA|
3094647|NCT01846442|Experimental|0.5% DHEA|
3094648|NCT01846442|Experimental|1.0% DHEA|
3094649|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh A|Participants with chronic liver disease and classified as Child-Pugh Grade A had a score of 5-6 (out of 15) which correlates with a good prognosis. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3094650|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh B|Participants with chronic liver disease and classified as Child-Pugh Grade B had a score of 7-9 (out of 15) which correlates with significant functional liver compromise. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3094651|NCT01846455|Experimental|Hepatic Impairment: Child-Pugh C|Participants with chronic liver disease and classified as Child-Pugh Grade C had a score of 10-15 (out of 15) which correlates with decompensated liver disease. Each participant received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3094652|NCT01846455|Experimental|HCV Without Hepatic Impairment|Participants with hepatitis C virus (HCV) without hepatic impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3094653|NCT01846455|Active Comparator|No Hepatic Disease or Impairment|Participants with no hepatic disease or impairment received one sublingual tablet of Suboxone® (2mg buprenorphine with 0.5 mg naloxone) on Day 1.
3094654|NCT01846494||Hepatitis C Virus (HCV) patients exposed to BMS-986094|Hepatitis C infected patients with previous exposure to BMS-986094
3094655|NCT01846494||HCV patients not exposed to BMS-986094|Hepatitis C patients without exposure to BMS-986094
3094656|NCT01846507|Experimental|Tranexamic acid|Subjects will complete a baseline menses (no treatment) followed by 3 menses using tranexamic acid.
3094657|NCT01846611|Experimental|Arm A: trabectedin + DOXIL|Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
3094658|NCT01846611|Active Comparator|Arm B: DOXIL|Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
3094659|NCT01846624|Experimental|Decitabine, then midostaurin|"INDUCTION THERAPY Subjects receive decitabine intravenously (IV) over 1 hour on days 1 to 10 and midostaurin orally (PO) twice daily (BID) on days 11 to 28. Treatment repeats every 28 days until documented bone marrow response is achieved or for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving documented bone marrow response by course 6 continue treatment with induction therapy; patients achieving response after course 6 proceed to post-remission therapy.~POST-REMISSION THERAPY Subjects receive decitabine IV over 1 hour on days 1 to 5 and midostaurin PO BID on days 6 to 28. Treatment repeats every 28 days for up to 12 courses (including induction therapy) in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up for up to 1 year."
3094660|NCT01846702|Placebo Comparator|Placebo|Single dose of placebo matching LY3084077 administered subcutaneously (SC).
3094661|NCT01846702|Experimental|LY3084077|Single escalating doses (1 mg up to 300 mg) of LY3084077 administered SC.
3094662|NCT01846728|Experimental|Estrogen suppression|Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
3094663|NCT01846741|Other|Model 106 VNS Therapy System|
3094664|NCT01846871|Experimental|Tivozanib|1.5 mg daily for 3 weeks, with 1 week off.
3094665|NCT01846988|Active Comparator|Group 1 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks APAP settings then 4 weeks CPAP settings.
3094666|NCT01846988|Active Comparator|Group 2 crossover treatment|crossover treatment (REMstar Auto A-Flex) Placed on REMstar Auto A-Flex machine with APAP settings for 4-8 weeks then randomized to 4 weeks CPAP settings then 4 weeks APAP settings.
3094667|NCT01846988|Active Comparator|APAP pressurized comparison|randomization periods for 6-8 weeks. An in-hospital APAP titration study will average 90th pressure percentile and average CPAP pressure derived from the device will be compared to the CPAP pressure determined by CPAP titration PSG. Subjects will then be randomized to Group 1 first, or Group 2 first, then crossover to the other group.
3094668|NCT01847001|Experimental|Propranolol + Neoadjuvant Chemotherapy|"Subjects will receive 2 types of chemotherapy regimens plus propranolol treatment.~Regimen I, involves paclitaxel (may be substituted with nab-paclitaxel; maybe given with premedication), and~Regimen II involves doxorubicin (maybe given with anti-nausea therapy) and cyclophosphamide (maybe given with Pegfilgrastim).~If your tumor is HER2 positive, you will also receive trastuzumab and pertuzumab.~After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor.~DOT imaging will be done at 4 additional time points, including beo."
3094669|NCT01847014|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
3094670|NCT01847027|Active Comparator|Active supplement|NutraStem, 2 tablets daily, Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg).
3094671|NCT01847027|Placebo Comparator|Sugar pill|"The placebo is identical in appearance to the NutraStem® supplement and contains the following ingredients in a Vegi Capsule:~MCC200 DICALCIUM PHOSPHATE BROWN LAKE BLEND (SENSIENT # 09127 ) RED DYE DB-088 (COLORCON) MAGNESIUM STEARATE BLUE #1 ALUM LAKE (POWDER)"
3094672|NCT01847092|Active Comparator|AZD1722|AZD1722 in 5, 15, 30, or 60 mg capsules. Starting dose is 15 mg BID PO for 12 Weeks
3094673|NCT01847092|Placebo Comparator|Placebo|Placebo capsule BID PO for 12 Weeks
3094674|NCT01847131|Active Comparator|oxymetazoline|0.05% oxymetazoline nasal sprays 2 sprays in each nostril twice daily
3094675|NCT01847131|Placebo Comparator|placebo|placebo nasal spray 2 sprays in each nostril twice daily
3094676|NCT01847196|Experimental|Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
3094677|NCT01847209|Experimental|CT Marking and VATS lung wedge resection|Each patient with a lung nodule meeting criteria will undergo marking with fiducials followed at the same time by Video-Assisted Thoracic Surgery (VATS) lung wedge resection under CT fluoroscopy.
3094678|NCT01847274|Active Comparator|Niraparib|2:1 Ratio administered once daily continuously during a 28 day cycle.
3094679|NCT01847274|Placebo Comparator|Placebo|Administered once daily continuously over a 28 day cycle.
3094680|NCT01847313|Active Comparator|Liraglutide|Liraglutide 0.6 mg daily
3094681|NCT01847313|No Intervention|Control|Standard diabetes care including renin angiotensin aldosterone system inhibitor or antagonist
3094682|NCT01847430|Experimental|HBV Group|Subjects received a single dose of Engerix™-B Kinder vaccine (HBV). The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3094683|NCT01847443|Experimental|Test nicotine gum (2 mg)|A single dose of Nicotine Mint Gum (2 mg) to be chewed.
3094684|NCT01847443|Experimental|Test nicotine gum (4 mg)|A single dose of Nicotine Mint Gum (4 mg) to be chewed.
3094685|NCT01847443|Active Comparator|Reference nicotine gum (2 mg)|A single dose of reference nicotine gum (2 mg) to be chewed.
3094686|NCT01847443|Active Comparator|Reference nicotine gum (4 mg)|A single dose of reference nicotine gum (4 mg) to be chewed.
3094687|NCT01847469|Experimental|Zonisamide|Participants in this arm will receive zonisamide for 12 weeks.
3094688|NCT01847469|Placebo Comparator|Placebo|Participants in this arm will receive placebo medication for 12 weeks.
3094689|NCT01847547||Dabigatran|
3094690|NCT01847547||Warfarin|
3094691|NCT01847560||Dabigatran|
3094692|NCT01847560||Warfarin or other New Oral Anticoagulant (NOAC)|
3094693|NCT01847638|Active Comparator|Prolensa (bromfenac 0.07%)|Subjects will instill one drop Prolensa (bromfenac 0.07%) into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
3094694|NCT01847638|Active Comparator|Ilevro (nepafenac 0.3%)|Subjects will instill one drop into the study (operative) eye once daily for a maximum of 25 days. Dosing will begin three days prior to surgery (Day 3), continue on the day of surgery and for 21 days after surgery.
3094695|NCT01847755|Experimental|120 Hyperbaric treatments at 1.5 ATA|Patient receives 120 treatments of Hyperbaric at 1.5 ATA. Non randomized trial. Pt will have cognitive assessments and Spect scans at various treatment points. Oxygen is at 1.5 atmospheric pressure.
3094696|NCT01847885|Experimental|Smartpatch Treatment Group|Subjects in the Treatment Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
3094697|NCT01847885|Sham Comparator|Smartpatch Control Group|Subjects in the Control Group will have a Smartpatch Lead placed in the shoulder, will use the Smartpatch Peripheral Nerve Stimulation (PNS) System, but will not receive any electrical stimulation.
3094698|NCT01848041|Experimental|RVL-1201 once daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye in the morning; one full drop of vehicle (placebo) per eye approximately 8 hours after the morning dose
3094699|NCT01848041|Experimental|RVL-1201 twice daily|RVL-1201 0.1% ophthalmic solution dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
3094700|NCT01848041|Placebo Comparator|RVL-1201 vehicle (placebo)|RVL 1201 ophthalmic solution vehicle (placebo) dosed one full drop per eye BID; approximately 8 hours between the morning dose and the afternoon dose
3094701|NCT01848054|Experimental|BNX Sublingual Tablets Induction|"Day 1-2 (Blinded Induction): BNX sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
3094702|NCT01848054|Active Comparator|Buprenorphine Induction|"Day 1-2 (Blinded Induction): Generic buprenorphine sublingual tablets~Day 3-28 (Open-label Maintenance): BNX sublingual tablets"
3094703|NCT01848067|Experimental|Treatment (alisertib, abiraterone acetate, prednisone)|Patients receive alisertib PO BID on days 1-7, abiraterone acetate PO daily, and prednisone PO BID. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3094704|NCT01848145|Experimental|Ofatumumab|Rapid Infusion of Ofatumumab
3094705|NCT01848158|Experimental|Acupuncture|Acupuncture treatment three times per week for up to two weeks.
3094706|NCT01848158|Sham Comparator|Sham Acupuncture|Sham acupuncture three times per week for up to two weeks
3094707|NCT01848184||PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for primary ventral hernia repair by open approach with intra-peritoneal positioning
3094708|NCT01848210|Experimental|Coumarin 30 mg + Troxerutin 180 mg|Coumarin 30 mg, troxerutin 180 mg fixed-dose combination tablets, orally, three times daily for up to 16 weeks.
3094709|NCT01848210|Placebo Comparator|Placebo|Coumarin + troxerutin placebo-matching tablets, orally, three times daily for up to 16 weeks.
3094710|NCT01848288|Experimental|CENTURION|First surgical eye randomized to CENTURION® Vision System, with second surgical eye (fellow eye) assigned to INFINITI® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
3094711|NCT01848288|Active Comparator|INFINITI|First surgical eye randomized to INFINITI® Vision System, with second surgical eye (fellow eye) assigned to CENTURION® Vision System. Second eye surgery conducted within 14 days of the first eye surgery. Duration of surgery less than 30 minutes each eye.
3094712|NCT01848353|Active Comparator|Standard payment, phase 1|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3094713|NCT01848353|Active Comparator|Standard payment, phase 2|All participants will perform exercise training. Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3094714|NCT01848353|Active Comparator|Ramp-down payment, phase 3|All participants will perform exercise training. This phase will last from weeks 33-48 (phase 3). Participants in this arm will receive a fixed amount of money for exercise session lasting at least 20 minutes, but the value of the payments will decrease weekly (ramp-down) until reaching zero in week 41. All exercise recommendations and outcome tests will be same for this group as the experimental group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3094715|NCT01848353|Experimental|Incentivized payment, phase 1|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they increase exercise frequency (number of days) during weeks 1-16 (phase 1). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
3094716|NCT01848353|Experimental|Incentivized payment, phase 2|All participants will perform exercise training. Participants in this arm will receive an increasing amount of money when they exercise for longer than 20 minutes per session during weeks 17-32 (phase 2). All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior
3094717|NCT01848353|Experimental|Raffle payment, phase 3|All participants will perform exercise training. In weeks 33-48 (phase 3)participants in this arm will receive fewer financial incentives than in the prior 32 weeks but they will be delivered through a raffle system to utilize a variable reinforcement approach. All exercise recommendations and outcome tests will be same for this group as the active comparator group so that the two groups differ only in the financial incentives they receive for exercise behavior.
3094718|NCT01848353|No Intervention|Normal weight, low activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have low physical activity and fitness like the intervention group. Therefore differences in their results with the intervention group will reflect the effects of overweight/obesity on the variables of interest.
3094719|NCT01848353|No Intervention|Normal weight, high activity group|This group of participants will complete only the baseline tests and assessments and will serve as a reference group. They will be selected to have higher physical activity and fitness than the intervention group. They will therefore serve as a healthy reference group and differences in their results with the intervention group will reflect the effects of both overweight/obesity and physical activity on the variables of interest.
3094720|NCT01848366|Experimental|Biowave Treatment|Twelve weekly treatments
3094721|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, PTZ+C; Cycles 3 & 4: HDMTX 12 h, C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 12-hour infusion and cisplatin is administered alone
3094722|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 4 h, C; Cycles 3 & 4: HDMTX 12 h, PTZ + C|Cycles 1 and 2: HDMTX administered as a 4-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin
3094723|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, PTZ+C; Cycles 3 & 4: HDMTX 4 h, C|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and pantoprazole is administered with cisplatin Cycles 3 and 4: HDMTX administered as a 4-hour infusion and cisplatin is administered alone
3094724|NCT01848457|Experimental|Cycles 1 & 2: HDMTX 12 h, C; Cycles 3 & 4: HDMTX 4 h, C + PTZ|Cycles 1 and 2: HDMTX administered as a 12-hour infusion and cisplatin is administered alone Cycles 3 and 4: HDMTX administered as a 4-hour infusion and pantoprazole is administered with cisplatin
3094725|NCT01848483|Experimental|AIDS EPC Package plus MI|AIDS EPC Package plus MI: AIDS Early Palliative Care (EPC) Package and Motivational Interviewing (MI) At least one early Palliative Care visit plus four weekly MI sessions within a 3 month period of time.
3094726|NCT01848483|Other|Standard of Care (SOC)|Standard of Care (SOC): Routine Infectious Disease Program HIV-care clinic appointment
3094727|NCT01848756|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle. Subjects will continue treatment on a 28-day cycle at the discretion of the principal investigator based on safety.
3094728|NCT01848821|Other|OASIS half of wound|OASIS will be applied to one half of the wound and standard of care consisting of wound vac only will be applied to the other half.
3094729|NCT01848821|Other|Standard therapy half of wound|Standard therapy to half of wound will consistent of non-stick mesh and wound VAC application.
3094730|NCT01848834|Experimental|Cohort A: Triple Negative Breast Cancer|Participants receive pembrolizumab, 10 mg/kg, intravenously (IV) once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3094731|NCT01848834|Experimental|Cohort B: Head & Neck Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3094732|NCT01848834|Experimental|Cohort C: Urothelial Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3094733|NCT01848834|Experimental|Cohort D: Gastric Cancer|Participants receive pembrolizumab, 10 mg/kg, IV once every 2 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3468957|NCT03891160|No Intervention|Group B - Control|Group B will be the controls and will not receive a 3D model.
3094734|NCT01848834|Experimental|Cohort B2: Head & Neck Cancer Expansion|Participants receive pembrolizumab, 200 mg, IV once every 3 weeks, and continue to receive drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years).
3094735|NCT01848847|Experimental|Full Bladder|Hysteroscopy conducted under full bladder.
3094736|NCT01848847|Experimental|Empty Bladder|Hysteroscopy conducted under empty bladder.
3094737|NCT01848899|Experimental|Ioxaglate Arm|
3094738|NCT01848899|Experimental|Iodixanol arm|
3094739|NCT01848938|Active Comparator|Smartphone treatment|Smartphone treatment with PFMT.
3094740|NCT01848938|No Intervention|Waiting list|Waiting list for three months. They receive the smartphone application after follow-up.
3094741|NCT01848977|Experimental|vascular occlusion test|"The pediatric SomaSensor™ probe of INVOS® and the 15-mm sensor of InSpectra™ are placed on each thenar muscle in the same subject. The side on which the probe will be placed is randomly determined. INVOS® updates data every 5 s and data (SrO2) will be manually recorded. The data of InSpectra™ (StO2) are automatically collected and sampled every 2 s.~Vascular occlusion test (VOT) is done as follows:Adult-size blood pressure cuffs are placed around each upper arm. The both cuffs are simultaneously inflated to 30 mmHg above the initial systolic blood pressure and kept inflated until the SrO2 or StO2 decreased to 40%. When the value reaches 40% or just below it, the cuff on the same side is deflated rapidly. The data will be collected until the SrO2 and StO2 values returned to the baseline."
3094742|NCT01848990|Experimental|Commercial Hylenex Recombinant (Formulation 1)|Hylenex Formulation 1: For 6 months, participants received their regular treatment of rapid-acting continuous subcutaneous insulin infusion (CSII) (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the commercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
3094743|NCT01848990|Experimental|Precommercial Hylenex Recombinant (Formulation 2)|Hylenex Formulation 2: For 6 months, participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine). Additionally, during this 6-month treatment period, the participants received a pretreatment dose of the precommercial form of Hylenex recombinant, delivered at 150 units (U) through their insulin infusion cannula each time they changed infusion sets (every 2 to 3 days).
3094744|NCT01848990|Active Comparator|Standard Rapid-Acting Insulin CSII|Participants received their regular treatment of rapid-acting CSII (for example, insulin lispro, insulin aspart, and insulin glulisine) for 6 months.
3094745|NCT01849055|Placebo Comparator|Placebo|Placebo matching LY3023703 administered orally, once daily (QD), for 28 days
3094746|NCT01849055|Experimental|LY3023703|Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days
3094747|NCT01849055|Active Comparator|Celecoxib|400 mg celecoxib administered orally, QD, for 28 days. (Positive control.)
3094748|NCT01849068|Experimental|Ezetimibe|
3094749|NCT01849068|Placebo Comparator|Placebo|
3094750|NCT01849172|Experimental|electroacupuncture|Electroacupuncture at RN4, EX-CA1，ST25, SP6 (double sides). One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
3094751|NCT01849172|Sham Comparator|sham electroacupuncture|Sham electroacupuncture at non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides).Specially constructed EA apparatus were used with no skin penetration, electricity output, or de qi requirement for needle manipulation One session will be given every two days, 3 sessions per week (24 sessions in all) and each session lasts for 30 minutes.
3468958|NCT03890965|Experimental|Experimental|Adult patients with chronic sequelae in the upper limb after neurological damage
3094753|NCT01849276|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive metformin hydrochloride orally twice a day on days 1-15 and cytarabine IV over 3 hours twice on days 4-10.
3094754|NCT01849289|Experimental|Insulin Degludec|
3094755|NCT01849289|Experimental|Insulin Glargine|
3094756|NCT01849419|Experimental|Single group|Healthy volunteers received all drug conditions (MDMA, oxytocin, and placebo) using a within-subjects design.
3094757|NCT01849458||BioFiber|Subjects implanted with BioFiber Scaffold or BioFiber-CM Scaffold
3094758|NCT01849497|Experimental|Evolocumab PFS|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled syringe (PFS). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
3094759|NCT01849497|Experimental|Evolocumab AI/pen|Participants received evolocumab 140 mg every 2 weeks for 4 weeks (Day 1, Week 2, and Week 4) subcutaneously using a prefilled autoinjector/pen (AI/pen). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 2 and 4.
3094760|NCT01849562|Active Comparator|Sovaprevir 200 mg, ACH-3102 150/50 mg, RBV 1000-1200mg|Sovaprevir 200 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
3094761|NCT01849562|Active Comparator|Sovaprevir 400 mg, ACH-3102 150/50mg,RBV1000-1200mg|Sovaprevir 400 mg QD + ACH-3102 150 mg loading dose on Day 1 followed by 50 mg QD + RBV weight-based 1000-1200mg QD for 12 weeks
3094762|NCT01849562|Placebo Comparator|Placebo|Placebo for Sovaprevir capsule QD + placebo for ACH-3102 150 mg loading dose on Day 1 followed by 50 mg capsule QD + placebo for weight-based RBV QD for 12 weeks
3094763|NCT01849575|Active Comparator|Intervention|The intervention: Giving communication about risk of cardiovascular disease in the form of written and graphical information about silent atheroscslerosis measured by carotid ultrasound examination as carotid intima-media thickness, highlighted as vascular age, and plaque formation, visualized as a traffic light (green - no plaque, red - plaque).The ultrasound results are given to the study person and his/her physician, in addition to information about conventional risk factors for cardiovascular disease
3094764|NCT01849575|No Intervention|Control|The comaparator is that the study person and his/her physician do not get any information about carotid ultrasound results on silent atherosclerosis. They are only informed about results of measured conventional CVD risk factors
3468959|NCT03890978|Experimental|intervention|The intervention group will receive EBF promotional messages from the time of discharge until 6 months post delivery.
3094765|NCT01849588|Experimental|Treatment Arm|Sorafenib taken orally twice per day
3094766|NCT01849692|Experimental|ESBA1008 1.2 mg/10 μL|Cohort 1: One intravitreal injection on Day 0, followed by one intravitreal (IVT) injection of ESBA1008 6 mg/50 μL on Day 28
3094767|NCT01849692|Experimental|ESBA1008 1 mg/8.3 μL|Cohort 2: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3094768|NCT01849692|Experimental|ESBA1008 0.6 mg/10 μL|Cohort 3: One intravitreal injection on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3094769|NCT01849692|Experimental|ESBA1008 0.5 mg/8.3 μL|Cohort 4: One intravitreal infusion on Day 0, followed by one intravitreal injection of ESBA1008 6 mg/50 μL on Day 28
3094770|NCT01849692|Active Comparator|Ranibizumab 0.5 mg in 50 μL|Cohorts 1-4: One intravitreal injection on Day 0, followed by another intravitreal injection on Day 28
3094771|NCT01849770|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 12 weeks.
3094772|NCT01849770|Active Comparator|Mexiletine, 900 milligrams|Mexiletine, 900 milligrams by mouth per day for 12 weeks.
3094773|NCT01849770|Placebo Comparator|Placebo|Placebo, by mouth per day for 12 weeks.
3094774|NCT01849822|Experimental|Neural Prosthetic System|The Neural Prosthetic System consists of two Neuroport Arrays, which are described in detail in the intervention description. Both Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subjects will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought. They will then use the end effector to perform various reach and grasp tasks.
3094775|NCT01849848|Experimental|SyB L-0501|
3094776|NCT01849874|Experimental|MEK162|
3094777|NCT01849874|Active Comparator|Physician's choice chemotherapy|
3468960|NCT03890978|Other|control|the control group will receive child health care-related messages (except breastfeeding messages) from the time of discharge until 6 months post delivery.
3094779|NCT01850030|Experimental|Dydrogesterone 30 mg|
3094780|NCT01850030|Experimental|Micronized Progesterone 600 mg|
3468962|NCT03890757||serratus anteriorblock|Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe
3094783|NCT01850394|Placebo Comparator|Control group|physiologic saline 25 ml
3094784|NCT01850394|Active Comparator|TXA-250 group|A total of 25-ml solution with 250-mg tranexamic acid
3094785|NCT01850394|Active Comparator|TXA-500 group|A total of 25-ml solution with 500-mg tranexamic acid
3094786|NCT01850446|Experimental|Ergoferon|The treatment period is 5 days. Oral Dose per administration: 1 tablet. The tablet should be kept in the mouth until completely dissolution, the drug is taken without regard to food intake.
3094787|NCT01850446|Active Comparator|Oseltamivir (Tamiflu)|"The treatment period is 5 days.~1 capsule (75 mg) twice a day during the meal or regardless of meal."
3094788|NCT01850485||normothermia, 36 degrees|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 36 degrees, difference is temperature, in this group 36
3094789|NCT01850485||33 degrees, therapeutic hypothermia|microcirculation after cardiac arrest by SDF and NIRS, in patients treated with 33 degrees, difference is temperature, in this group 33
3094790|NCT01850524|Active Comparator|IXAZOMIB|"IXAZOMIB 4.0 mg capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40 mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
3094791|NCT01850524|Placebo Comparator|Placebo|"IXAZOMIB matching-placebo capsules orally once on Days 1,8,15 and lenalidomide 25 mg capsules orally on days 1-21 and dexamethasone 40mg tablets orally on Days 1,8, 15 and 22, during every 28-day cycle for the first 18 cycles.~After Cycle 18 dexamethasone was discontinued and participants continued to receive ixazomib placebo-matching capsule and lenalidomide at reduced doses until progressive disease or unacceptable toxicity, whichever comes first, up to data cut-off date 2 December 2019."
3094792|NCT01850550|No Intervention|Control|"Participants in the control condition will be given written information at the baseline visit from the NIH website Aim for a Healthy Weight to provide a basic understanding of weight loss and access to basic online resources, but will not participate in group weight loss sessions with peer leaders."
3094793|NCT01850550|Experimental|Weight Loss Groups|Participants in this arm will receive peer-led facilitation within groups using an adaptation of the Diabetes Prevention Program.
3094794|NCT01850563|Other|HBO feasibility|
3094795|NCT01850589|Other|Conservative Therapy|"Conservative therapy:~Subjects counseled by vascular attending/fellow during office appointment to stop smoking.~Counseling consists of:~Self-help materials including Smart Move: A Stop Smoking Guide from the American Cancer Society A brief educational discussion on the benefits of smoking cessation.~Patients randomized to Group 1 will be offered adjunctive treatment with nicotine replacement therapy at no cost."
3094796|NCT01850589|Other|Aggressive Therapy|"8 week comprehensive smoking cessation and pharmacotherapy program consisting of:~One hour group counseling sessions, focusing on patient education and behavior modification.~Behavior modifications including recognition; coping skills; stress management; and relapse prevention skills.~Counseling including information on nutrition, exercise, and chemical dependency.~Counseling sessions will be held 256C Mason Avenue. Pharmacotherapy adjuncts offered at no cost are as follows: Chantix (varenicline) GlaxoSmithKline, Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
3094797|NCT01850602|Experimental|PA21|
3094798|NCT01850602|Active Comparator|Sevelamer hydrochloride|
3468963|NCT03890718|Experimental|Donat lenticul|
3468964|NCT03890835|Active Comparator|Mineral Trioxide Aggregate (MTA)|
3468965|NCT03890835|Experimental|Biodentine|
3094799|NCT01850615|Experimental|FIAsp and basal insulin + metformin|Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
3094800|NCT01850615|Active Comparator|Basal insulin + metformin|Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
3094801|NCT01850641|Experimental|PA21|
3094802|NCT01850745||Control|Retrospective control group. Usual treatment with peginterferon-2a and ribavirin. No multidisciplinary support program
3094803|NCT01850745||Validation cohort|Prospective group. Usual treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
3094804|NCT01850745||Pilot cohort|Prospective intervention group. Usual pharmacological treatment with peginterferon-2a and ribavirin. Multidisciplinary support program.
3094805|NCT01850823|Placebo Comparator|placebo|Placebo
3094806|NCT01850823|Active Comparator|NASONEX® Nasal Spray (Schering Corporation)|Mometasone Nasal spray
3094807|NCT01850823|Experimental|Mometasone Nasal Spray (Watson Laboratories, Inc)|Mometasone Nasal spray
3094808|NCT01851330|Experimental|LDV/SOF 8 Week|Participants will receive LDV/SOF FDC for 8 weeks.
3094809|NCT01851330|Experimental|LDV/SOF+RBV 8 Week|Participants will receive LDV/SOF FDC plus RBV for 8 weeks.
3094810|NCT01851330|Experimental|LDV/SOF 12 Week|Participants will receive LDV/SOF FDC for 12 weeks.
3094811|NCT01851590|Experimental|Resin Lacquer|Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
3094812|NCT01851590|Active Comparator|Amorolfine|Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
3094813|NCT01851590|Active Comparator|Terbinafine|250 mg of Terbinafine taken orally once daily for 3 months (Generics).
3094814|NCT01851655|Experimental|Plyometric Exercise - High intensity|The exercises should produce a higher peak vertical ground reaction force than those in the low group based on literature findings (e.g. single leg jumps, jumps from higher heights, higher percent effort).
3094815|NCT01851655|Active Comparator|Plyometric Exercise - Low intensity|A lower peak vertical ground reaction force will be generated in the low intensity group compared to the high intensity group based on findings in the literature (e.g. lower box heights, only two-legged jumps, lower percent effort)
3094816|NCT01851720|Active Comparator|Control group / Standard of Care|"IV fentanyl bolus 25-50 mcg every 1-2 hrs as needed for pain~(Bolus dose can be titrated up in 25 mcg increments if necessary)~Maximum dose of 100 mcg/hr"
3094817|NCT01851720|Active Comparator|Low dose IV fentanyl PCA|"Initially: 10 mcg demand dose every 12 minutes~No initial bolus and no continuous infusion~Demand dose increased 10 mcg every 12 minutes if necessary~Maximum dose of 100 mcg/hr"
3094818|NCT01851772|Experimental|Treatment|"Subjects enrolled will undergo brachytherapy treatment in combination with EBRT. The maximum length of treatment will be 56 days. The treating physician will determine the appropriate course of treatment based on the physician's current practice or experience using Iridium-192 or Cesium HDR after-loaders to administer cervical brachytherapy treatments.~Subjects enrolled will be treated with approximately 80-90 Gy total treatment dose over 4-6 fractions. Examples of commonly used dose regimens in the US are listed in section 7.6.7. This study will include data collection from the initiation of EBRT through administration of the final Xoft Axxent treatment fraction, and at one (1) month and three (3) months."
3094819|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological and GI) + Omeprazole|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
3094820|NCT01851863|Active Comparator|Flupentixol-Melitracen(psychological) + Omeprazole|The patients in Group 2 were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
3094821|NCT01851863|Active Comparator|Flupentixol-Melitracen(without explanation) + Omeprazole|In Group 3, the patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
3094822|NCT01851863|Active Comparator|proton pump inhibitor|Prescribe Omeprazole.
3094823|NCT01851876|Experimental|Endometrial injury|The patients in this group will be subjected to endometrial injury procedure in preceding IVF cycle.
3094824|NCT01851876|No Intervention|No endometrial injury|The patients in this group will not be subjected to endometrial injury procedure in presiding IVF cycle. The patients will be stimulated with standard IVF protocol.
3094825|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) post infusion|Cangrelor IV + Oral prasugrel (60mg) administered within 5 minutes after cangrelor IV discontinuation
3094826|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (5 doses)|Prasugrel discontinued 48h (n=6) prior to initiation of cangrelor infusion (2h)
3094827|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) at 1.5h|Cangrelor IV + oral prasugrel (60mg) administered at 1.5h after the cangrelor infusion start time.
3094828|NCT01852019|Experimental|Day 1 - Cangrelor + Prasugrel (60mg) a 1.0h|Cangrelor IV + oral prasugrel (60mg) administered at 1.0h after the cangrelor infusion start time.
3094829|NCT01852019|Experimental|Day 8 - Prasugrel (10mg) Dosing (6 doses)|Prasugrel discontinued 24h prior to initiation of cangrelor infusion (2h)
3094830|NCT01852032|Experimental|Breast cancer Patients|Tomosynthesis Breast Scanning is done and breast CT Scanning is done.
3094831|NCT01852045|Experimental|OnabotulinumtoxinA 50 U|OnabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 (NCT01852058) if qualified.
3094832|NCT01852045|Experimental|OnabotulinumtoxinA 100 U|OnabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
3094833|NCT01852045|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) injected into the detrusor wall on Day 1. Participants were eligible for retreatment in study 191622-121 if qualified.
3094834|NCT01852058|Experimental|OnabotulinumtoxinA 50 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 50 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
3094835|NCT01852058|Experimental|OnabotulinumtoxinA 100 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 100 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
3094836|NCT01852058|Experimental|OnabotulinumtoxinA 200 U|Following treatment with onabotulinumtoxinA (botulinum toxin Type A) 200 U (not to exceed 6 U/kg) intramuscular injection into the detrusor wall in study 120, participants were eligible for retreatments in this study as needed with a minimum 12-week interval between doses for a maximum of 3 retreatments. Blinded dose increases (one level) were allowed based on clinical response from cycle to cycle (not to exceed 6 U/kg).
3094837|NCT01852071|Experimental|Gene Therapy|Infusion of autologous EFS-ADA Lentiviral (LV) CD34+ cells
3094838|NCT01852084|Experimental|enVista® One-Piece Hydrophobic Acrylic Toric IOL|Toric cylinder power of either 1.25 diopters (D), 2.00 D, or 2.75 D
3094839|NCT01852084|Experimental|enVista control lens|Spherical control lens
3094840|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 1)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
3094841|NCT01852110|Placebo Comparator|Placebo (Stage 1)|Matching placebo to MK-7622 capsule once daily, taken orally.
3094842|NCT01852110|Experimental|MK-7622 Low Dose - 5 mg (Stage 2)|Single 5 mg MK-7622 capsule once daily, taken orally.
3094843|NCT01852110|Experimental|MK-7622 Mid Dose - 15 mg (Stage 2)|Single 15 mg MK-7622 capsule once daily, taken orally.
3094844|NCT01852110|Experimental|MK-7622 High Dose - 45 mg (Stage 2)|Single 45 mg MK-7622 capsule once daily, taken orally. Dose escalated as follows: 15 mg MK-7622 once daily for 1 week; 30 mg MK-7622 once daily for 1 week; and 45 mg MK-7622 once daily for the remainder of treatment.
3094845|NCT01852110|Placebo Comparator|Placebo (Stage 2)|Matching placebo to MK-7622 capsule once daily, taken orally.
3094846|NCT01852162|Experimental|Dabigatran|Dabigatran 150mg
3094847|NCT01852162|Placebo Comparator|Placebo|Placebo
3094848|NCT01852175|Active Comparator|Prasugrel|Prasugrel 60mg loading dose and 10 mg maintenance dose
3094849|NCT01852175|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
3094850|NCT01852201|No Intervention|Best medical therapy|"Patients randomized to the control group will receive best conventional MT for acute ischemic stroke as determined by the attending stroke physician. Standardization of medical management in both arms will occur according to the following:~General medical management according to AHA/ASA guidelines~Admission to monitored or intensive care unit for at least 24 hours~Aggressive hypertensive-hypervolemic therapy should be used only in the case of symptomatic blood pressure fluctuations or if blood pressure drops below the normal range for the patient~Antithrombotics: ASA 325 mg PO qd for 7 days (clopidogrel may be used as adjunctive therapy if indicated for cardiac disease) then per discretion of treating physician~Close monitoring of BP and glucose with treatment according to AHA/ASA guidelines~Follow-up imaging study required in any patient with neurologic deterioration"
3094851|NCT01852201|Experimental|Endovascular treatment|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
3094852|NCT01852214|Active Comparator|Prasugrel first, then ticagrelor|Patients randomized to prasugrel will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (ticagrelor), which will be administered for 1-week.
3094853|NCT01852214|Active Comparator|Ticagrelor first, then prasugrel|Patients randomized to ticagrelor will receive prasugrel loading dose followed by maintenance dose. Randomized treatment will be maintained for 1-week (7±2 days). After completion of the 1-week treatment period, patients will discontinued the study medications for 2-4 weeks (wash-out period) and then will cross over to the alternate treatment (prasugrel), which will be administered for 1-week.
3094854|NCT01852292|Experimental|Buparlisib + weekly Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib 100 mg daily and paclitaxel 80 mg/m^2 weekly.
3094855|NCT01852292|Placebo Comparator|Buparlisib matching placebo + Paclitaxel|Patients who were randomized to this arm on a 1:1 randomization, took buparlisib matching placebo 100 mg daily and paclitaxel 80 mg/m^2 weekly.
3094856|NCT01852344|Other|Placebo Easy|Healthy participant to be given 20 mgs of a placebo one hour before task performance and will perform an easy task.
3094857|NCT01852344|Other|Placebo Hard|Healthy participants are given 20 mgs of placebo one hour before task performance and will perform a hard task.
3094858|NCT01852344|Other|Methylphenidate Easy|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform an easy task.
3094859|NCT01852344|Other|Methylphenidate Hard|Healthy participants are given 20 mgs of methylphenidate one hour before task performance and will perform a hard task.
3094860|NCT01852383|Experimental|Duloxetine|"A minimum 1-week psychotropic medication washout, and a washout of 3 weeks for fluoxetine and monoamine oxidase inhibitors(MAOIs), was required. Duloxetine was prescribed at 20 mg daily for the first week, 30 mg daily for the second week, then 60 mg daily for another 4 weeks. Patients could subsequently be raised to 90 mg daily for another 2-4 weeks and then to a maximum dose of 120 mg daily.~At all visits, the study psychiatrist had the option of adjusting the dose based on clinical response and side effects.~Administration was as a single a.m. dose."
3094861|NCT01852513|Active Comparator|QNASL nasal spray|QNASL 320 mcg once-daily administered as two sprays in each nostril; 2 weeks of treatment
3094862|NCT01852513|Placebo Comparator|Placebo nasal spray|Placebo nasal spray once-daily administered as two sprays in each nostril; 2 weeks of treatment
3094863|NCT01852591|Experimental|PCV 13|Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant
3094864|NCT01852669|Experimental|Inversion, Hydration, ESWL|ESWL with hydration and inversion
3094865|NCT01852669|Active Comparator|ESWL, Hydration|ESWL with hydration
3094866|NCT01852799|Experimental|PAD Followed by ASCT|"Drug: Bortezomib, Adriamycin (Doxorubicin) /Epidoxorubicin(EPI), Dexamethasone.~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
3094867|NCT01852812|Experimental|Montelukast 4 mg OG/1-5 year olds|Participants receive montelukast 4 mg OG in one sachet orally (PO) once daily (QD) at bed time for 4 weeks with an option to continue for an additional 8 weeks (12 weeks total)
3094868|NCT01852812|Experimental|Montelukast 5 mg CT/6-9 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
3094869|NCT01852812|Experimental|Montelukast 5 mg CT/10-15 year olds|Participants receive montelukast 5 mg CT in one tablet PO QD at bed time for 12 weeks
3094870|NCT01852825|Experimental|NAC + MK-8237 (Part 2)|Nasal Allergen Challenge (NAC) treatment consisting of 1800 Biological Units (BU) of HDM extract on Days -14, 56 and 84; starting on Day 1 a single tablet of MK-8237 with 12 Development Units (DUs), administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
3094871|NCT01852825|Placebo Comparator|NAC + Placebo (Part 2)|NAC treatment consisting of 1800 BU of HDM extract on Days -14, 56 and 84; starting on Day 1 a single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
3094872|NCT01852825|Experimental|NAC (Part 1)|Nasal Allergen Challenge (NAC) consisting of 100 µl fixed volume of 10,000 biological units (BU) of HDM extract delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1
3094873|NCT01852942|Experimental|Losartan|
3094874|NCT01852942|Placebo Comparator|Sugar Pill|
3094875|NCT01852955|Active Comparator|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure.
3094876|NCT01852955|Placebo Comparator|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
3094877|NCT01853046|Experimental|Regorafenib(Stivarga, BAY73-4506)-Normal/Mild Renal Impairment|Participants with normal/mild renal impairment received Regorafenib 160 mg o.d.as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
3094878|NCT01853046|Experimental|Regorafenib (Stivarga, BAY73-4506)-Severe Renal Impairment|Participants with severe renal impairment received Regorafenib 160 mg o.d. as a single dose in Stage 1, Day 1 with a washout of at least 5 days, followed by multiple dosing in an intermittent administration schedule (3 week on / 1 week off) over 2 cycles in Stage 2 (56 days). Cycle 2 started immediately after Cycle 1. A Cycle for this study is defined as 28 days.
3094879|NCT01853072|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3094880|NCT01853072|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3094881|NCT01853085||Patients with POAG or OHT|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
3094882|NCT01853137|Experimental|FLMGM Treatment Group|
3094883|NCT01853137|No Intervention|Untreated Class II Control Group|
3094884|NCT01853215|Experimental|Sternal intraosseous vascular access|Sternal intraosseous vascular access using T.A.L.O.N. Intraosseous System.
3094885|NCT01853228|Experimental|Decitabine and cytarabine|
3094886|NCT01853254|Experimental|Peginterferon alfa-2a monotherapy or combined with ribavirin|The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.
3094887|NCT01853280|Experimental|L-Methylfolate|15 mg of L-Methylfolate (Deplin®) daily for 12 weeks as a supplement to OROS-Methylphenidate.
3094888|NCT01853280|Placebo Comparator|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
3094889|NCT01853332||Cross-Sectional|New participant: The purpose of the study is to learn about physical health in midlife and how it has been influenced by experiences and relationships. The study specifically targets health differences and the development of heart disease and diabetes.
3094890|NCT01853332||Longitudinal|Former participants (or the partner of a former participant) of the Adolescent and Family Development Project, Young Adult Development Project, Across Generations Project, and/or Paths Over Time Project may already know that this research shows how people grow, individually and as part of a familial and social network, throughout the course of life. This study focuses on learning about former participants' physical health in midlife and how it has been influenced by their experiences and relationships.
3094891|NCT01853371|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions, with 4 weeks interval between each session and the other.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
3094892|NCT01853371|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department.
3132591|NCT03439189|Experimental|Emricasan 5mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
3094893|NCT01853384|Experimental|HP802-247 plus compression therapy|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
3094894|NCT01853384|Placebo Comparator|HP802-247 Vehicle plus compression therapy|fibrinogen solution & thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.
3094895|NCT01853397|Experimental|Treatment at level 1|Single treatment with Liposonix System (Model 2) using single pass technique at level 1 (180 J/cm2)
3094896|NCT01853397|Experimental|Treatment at level 2|Single treatment with Liposonix System (Model 2)using the single pass technique at treatment level 2 (140 J/cm2)
3094897|NCT01853397|Experimental|Treatment at level 3|Single treatment with Liposonix System (Model 2)using single pass technique at level 3 (120 J/cm2)
3094898|NCT01853397|Active Comparator|Treatment with 3 passes at 60 J/cm2|Single treatment with Liposonix System (Model 2) using grid repeat technique with 3 passes at 60 J/cm2 (180 J/cm2 total fluence)
3094899|NCT01853462|Experimental|Proprioceptive Neuromuscular Facilitation (PNF)|Supervised PNF training
3094900|NCT01853462|Experimental|Balance|Supervised balance training
3094901|NCT01853475|Experimental|Treatment A|PQP tablets 1440mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
3094902|NCT01853475|Experimental|Treatment B|PQP tablets 960mg and OZ439+TPGS 800mg co-administered as a single oral dose fasted.
3094903|NCT01853475|Active Comparator|Treatment C - Reference|PQP Tablets 1440 mg and OZ439 PIB 800mg + full fat cow's milk
3094904|NCT01853553|Experimental|Spironolactone|Active arm
3094905|NCT01853553|Placebo Comparator|Sugar Pill|Placebo
3094906|NCT01853605|Experimental|Augmentation|Women undergoing breast augmentation.
3094907|NCT01853605|Experimental|Reconstruction|Women undergoing breast reconstruction.
3094908|NCT01853605|Experimental|Revision-Augmentation|Women undergoing revision of previous breast augmentation.
3094909|NCT01853605|Experimental|Revision-Reconstruction|Women undergoing revision of previous breast reconstruction.
3094910|NCT01853618|Experimental|Pilot 1/Arm A1-Tremelimumab + RFA or TACE|Escalating doses of Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
3094911|NCT01853618|Experimental|2/Arm A2 - Tremelimumab + RFA or TACE|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
3094912|NCT01853618|Experimental|3/Arm B - Tremelimumab + TACE|Tremelimumab + Transarterial Catheter Chemoembolization (TACE)
3094913|NCT01853618|Experimental|4/Arm C (never opened)|Tremelimumab + Radiofrequency Ablation (RFA) or Transarterial Catheter Chemoembolization (TACE)
3094914|NCT01853618|Experimental|5/Arm D - Tremelimumab + Cryoablation|Tremelimumab + Cryoablation
3094915|NCT01853618|Experimental|6/Arm E - Tremelimumab + RFA|Tremelimumab + Radiofrequency Ablation (RFA)
3094916|NCT01853644|Experimental|Treatment (Tivozanib)|Tivozanib 1.5mg orally given daily for 3 weeks with one week off to complete a 4 week cycle until disease progression or adverse effects prohibit further therapy
3094917|NCT01853696|Active Comparator|Loteprednol|Loteprednol etabonate 0.5% gel applied topically 4 times daily for 2 months, 3 times daily for 1 month, twice daily for one month and once daily for 7 months
3094918|NCT01853696|Active Comparator|Prednisolone acetate|Prednisolone acetate 1% ophthalmic solution applied 4 times daily for two months, 3 times daily for one month, twice daily for one month, and once daily for 7 months
3094919|NCT01853774|Experimental|Tailored Navigation|Participants will receive tailored navigation phone calls to assist them with barriers in making a clinic appointment or attending the clinic. The tailored navigation intervention protocol will be used to guide individuals from an especially hard-to-reach, multicultural, and underinsured population into primary care clinics and, subsequently, track the effects of this intervention through a clinic navigation program to complete Colorectal cancer screening.
3094920|NCT01853774|No Intervention|Control|Participants in the control arm will receive phone calls to support data collection and tracking, but not receive tailored messages
3094921|NCT01853878|Experimental|GSK2302032A Group|The patients received 13 administrations GSK2302032A product, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
3094922|NCT01853878|Placebo Comparator|Placebo group|The patients received 13 administrations of a placebo, as per the following schedule: For the first five doses: 1 dose every 3 weeks. For the remaining 8 doses: 1 dose every 12 weeks.
3094923|NCT01853930|Other|Laboratory training|Patients will be trained in the laboratory with feedback by a rehabilitation therapist
3094924|NCT01853930|Other|Home-based training|Patients will self instruct using the computer-based training with remote intervention by a therapist
3094925|NCT01854034|Experimental|AUY922 Treatment Arm|AUY922 administered once weekly via intravenous, 70 mg/m2
3094926|NCT01854047|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1), followed by a single 300 mg injection q2w from Week 2 to Week 22 added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3094927|NCT01854047|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1), followed by a single 200 mg injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3094928|NCT01854047|Experimental|Dupilumab 300 mg q4w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 300 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3094929|NCT01854047|Experimental|Dupilumab 200 mg q4w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 1) followed by a Placebo alternating with single 200 mg injection of Dupilumab q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3468966|NCT03890848|Experimental|Wechat application intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
3094930|NCT01854047|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 (Week 1) followed by a single injection q2w from Week 2 to Week 22 added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3094931|NCT01854138|No Intervention|Control|Retrospectively reviewed patients who underwent Total Knee or Hip Arthroplasty and received traditional gauze dressing to cover their clean surgical wound.
3094932|NCT01854138|Experimental|Prevena Knee/Hip|Prospectively enrolled patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty and receiving Prevena Incision Management System on the clean surgical wound.
3094933|NCT01854177|Active Comparator|Aprepitant|Aprepitant 125 mg
3094934|NCT01854177|Placebo Comparator|Placebo|Inert capsule
3094935|NCT01854242||Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
3094936|NCT01854268|Experimental|Healthy adults who receive capsaicin|Single treatment consisting of healthy adults.
3094937|NCT01854281||Patent foramen ovale dive A group|Divers with a previously diagnosed patent foramen ovale observed after Dive A.
3094938|NCT01854281||Closure dive A group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive A.
3094939|NCT01854281||patent foramen ovale dive B group|Divers with a previously diagnosed patent foramen ovale observed after Dive B.
3094940|NCT01854281||closure dive B group|Divers with a patent foramen ovale previously closed by a catheter-based procedure observed after Dive B.
3094941|NCT01854359|Other|Active treatment|Idebenone (150mg tablets) administered orally as five tablets, three times per day with food.
3094942|NCT01854528|Experimental|3-DAA/RBV|3-DAA (ABT-450/r/ABT-267 [150 mg/ 100 mg/ 25 mg once daily] and ABT-333 [250 mg twice daily]) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3094943|NCT01854528|Active Comparator|TPV/RBV|TPV (750 mg every 8 hours) coadministered with pegIFN (180 micrograms subcutaneously [SC] weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks, followed by pegIFN (180 micrograms SC weekly) and weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for either 12 or 36 weeks, per local prescribing information.
3094944|NCT01854593|Active Comparator|Bevacizumab injection and vitrectomy|0.16 mg/0.05 ml bevacizumab intravitreal injection one day before vitrectomy.
3094945|NCT01854593|Sham Comparator|Sham injection and vitrectomy|Sham injection one day before vitrectomy.
3094946|NCT01854632|Experimental|SIIL Live Attenuated Influenza Vaccine|Single 0.5 mL dose of trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
3094947|NCT01854632|Placebo Comparator|Matched placebo|Single 0.5mL inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
3094948|NCT01854645|Experimental|GFF MDI|Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
3094949|NCT01854645|Experimental|GP MDI|Glycopyrronium (GP) MDI (PT001)
3094950|NCT01854645|Experimental|FF MDI|Formoterol Fumarate (FF) MDI (PT005)
3094951|NCT01854645|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
3094952|NCT01854645|Placebo Comparator|Placebo|Placebo MDI
3094953|NCT01854658|Experimental|FF MDI (PT005)|FF MDI administered as two puffs BID
3094954|NCT01854658|Experimental|GP MDI (PT001)|GP MDI administered as two puffs BID
3094955|NCT01854658|Experimental|GFF MDI (PT003)|GFF MDI administered as two puffs BID
3094956|NCT01854658|Placebo Comparator|Placebo MDI|Inhaled placebo administered as two puffs BID
3094957|NCT01854697|Experimental|Arm A: 3-DAA + RBV in GT1a|ABT-450/r/ABT-267 150 mg/100 mg/25 mg once daily (QD) and ABT-333 250 mg twice daily (BID) and weight-based RBV for 12 weeks (3 direct-acting antivirals [DAAs] with RBV in GT1a)
3094958|NCT01854697|Active Comparator|Arm B: TPV/PR in GT1a|Telaprevir (TPV) 750 mg every 8 hours (q8h) and pegIFN 180 µg/week and weight-based RBV (PR) for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1a)
3094959|NCT01854697|Experimental|Arm C: 3-DAA + RBV in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID and weight-based RBV for 12 weeks (3 DAAs with RBV in GT1b)
3094960|NCT01854697|Experimental|Arm D: 3-DAA in GT1b|ABT-450/r/ABT-267 150 mg/100 mg/25 mg QD and ABT-333 250 mg BID for 12 weeks (3 DAAs without RBV in GT1b)
3094961|NCT01854697|Active Comparator|Arm E: TPV/PR in GT1b|Telaprevir 750 mg q8h and pegIFN 180 µg/week and weight-based RBV for 12 weeks followed by an additional 12 or 36 weeks of pegIFN and weight-based RBV according to response guided therapy per the prescribing information for telaprevir (telaprevir with pegIFN/RBV in GT1b)
3094962|NCT01854710|Other|Treatment sequence ABC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3094963|NCT01854710|Other|Treatment sequence ACB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3094964|NCT01854710|Other|Treatment sequence BCA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3094965|NCT01854710|Other|Treatment sequence BAC|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3094966|NCT01854710|Other|Treatment sequence CAB|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3094967|NCT01854710|Other|Treatment sequence CBA|Treatment: A = Inhaled loxapine (2 doses of 10 mg 2 hours apart) + oral placebo, B = Inhaled placebo + oral placebo, C = Oral moxifloxacin 400 mg + Inhaled placebo
3132592|NCT03439189|Experimental|Emricasan 25mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
3094968|NCT01854775|Experimental|Cohort 1: Age 12 to < 18 Years and Weight ≥ 35 kg|HIV-infected, ARV treatment-naive adolescents (12 to < 18 years of age weighing ≥ 35 kg) will receive E/C/F/TAF (150/150/200/10 mg) fixed-dose combination (FDC) once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
3094969|NCT01854775|Experimental|Cohort 2: Age 6 to < 12 Years and Weight ≥ 25 kg|Virologically suppressed HIV-infected children (6 to < 12 years of age weighing ≥ 25 kg) will receive E/C/F/TAF (150/150/200/10 mg) FDC once daily for 48 weeks. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF become commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
3094970|NCT01854775|Experimental|Cohort 3: Age ≥2 Years and Weight ≥ 14 to <25 kg|Virologically suppressed HIV-infected children (≥ 2 years of age weighing ≥ 14 to < 25 kg) will receive E/C/F/TAF (90/90/120/6 mg) FDC once daily for 48 weeks. Participants who attain a weight of ≥ 25 kg during the course of the study will switch to adult E/C/F/TAF (150/150/200/10 mg) tablets. Participants who complete 48 weeks of study treatment will have the option to receive E/C/F/TAF in an extension phase of the study until: a) the participant turns 18 years old and E/C/F/TAF is commercially available for adults in the country in which the participant is enrolled; b) age-appropriate E/C/F/TAF became commercially available in the country in which the participant is enrolled; or c) Gilead elects to terminate development of E/C/F/TAF in that country.
3094971|NCT01854827|Experimental|IVIG active treatment|Intravenous immunoglobulin (IVIG) 10% 1 gm/kg body weight/dose Day 3-5,30, 60 post HPE
3094972|NCT01854879|Experimental|Nucleus 6|
3094973|NCT01854905||Patients Attending Consultation for LASIK|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
3094974|NCT01854918|Active Comparator|Standard of Care|Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 48, participants began treatment with evolocumab at a dose of either 140 mg every 2 weeks (Q2W) or 420 mg every month (QM), based on participant choice, for approximately 2 years during the all-investigational product [all-IP] period.
3094975|NCT01854918|Experimental|Evolocumab + Standard of Care|Participants received subcutaneous evolocumab plus standard of care during the first year of the study (SOC-controlled period) and for approximately 2 years during the all-IP period. Evolocumab was administered at a dose of 140 mg every 2 weeks (Q2W) or 420 mg every month (QM) based on participant choice.
3094976|NCT01854944|Experimental|Brexpiprazole 1mg to 4mg|"Three cohorts of subjects will be evaluated:~- Cohorts 1 and 3 will receive high doses of brexpiprazole, and Cohort 2 will receive low doses of brexpiprazole."
3094977|NCT01855048|Experimental|N-Rephasin® SAL200|N-Rephasin® SAL200, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg
3094978|NCT01855048|Placebo Comparator|INT200-Placebo|Placebo
3094979|NCT01855074|Experimental|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
3094980|NCT01855126|Experimental|Blue light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two blue Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the blue light mask was worn nightly for 8 weeks. There will be a two week washout period between each intervention
3094981|NCT01855126|Placebo Comparator|Red light|The study protocol consisted of two 8-week intervention/control periods in which each participant wore either the intervention (blue light) or control (red light) mask every night, with the order of presentation of the two conditions randomized by the study's biostatistician. A light mask housing two red Light Emitting Diodes (LED) arrays delivered a train of blue or red light pulses of 2 second duration that were presented every 30 s for no longer than 2 hr, resulting in a maximum total of approximately 240 pulses per night. the red light mask was worn nightly for 8 weeks, with a two week washout period between each intervention
3094982|NCT01855243|Active Comparator|glargine plus supplemental glulisine|Patients who will be recruited to be treated with glargine/glulisine, will received 50% of TDD as detailed demonstrated in Umpierrez et al., studies . as This includes administration of glargine (Lantus®) once every night plus glulisine (Apidra®) before each meal for BG ≥ 150 mg/dL. Glargine dose will be calculated as 0.2 U/kg/day for admission BG less than 200 mg/dL or 0.3 U/kg/day for BG exceeding 200 mg/dL. Glargine was given using Solostar Flex-Pen® once daily in the evening around 8:00 pm. Glulisine was given using the Solostar Flex-Pen® three times just before the meals for BG > 150 mg/dL according to hospital sliding scale. To avoid hypoglycemia, if for any reason, a subject missed a meal, the dose of glulisine will be held.
3094983|NCT01855243|Active Comparator|70/30 insulin plus supplemental lunch insulin|Modified split-mixed insulin protocol adopted by Umpierrez et al., will be applied to patients treated with 70/30 insulin. Insulin dose will be started at 0.4 U/kg/day for admission BG less than 200 mg/dL or 0.5 U/kg/day for BG above 200 mg/dL. Two thirds of total daily dose (TDD)will be given before breakfast and 1/3 of TDD before dinner. Supplemental lunchtime regular insulin dose will given for BG > 150 mg/dL . Patients previously treated with 70/30 insulin before admission initially will receivethe same regimen as at in home.
3094984|NCT01855243|Active Comparator|Sliding Scale insulin (SSI)|For SSI group, regular insulin will be administered three times daily subcutaneously approximately 30 min before meal for BG > 150 mg/dL (or every 8 hours if a patient was not eating) according to hospital sliding scale table
3094985|NCT01855360|Experimental|TUDCA and Doxycycline|INTERVENTION: Patients meeting study criteria were prescribed TUDCA taken orally, 250 mg three times daily. and doxycycline taken orally, 100 mg twice daily.
3094986|NCT01855399|Experimental|Peer Coaching + Decision Aid|All participants will be assigned to one of up to 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants in the TEC arm will be scheduled for an initial visit with their coach to review the decision aid, which has incorporated their personal baseline data.
3094987|NCT01855399|Active Comparator|Peer Coaching Alone|Participants randomized to the 'print materials' group will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches in both arms will call their assigned peers once a week to provide support for their action steps.
3094988|NCT01855412||Claudication (Rutherford 2-3)|Patients who have been diagnosed with PAD and are classified as on the Rutherford Scale as Rutherford 2-3. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3094989|NCT01855412||CLI Rutherford 4-5|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 4-5. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3094990|NCT01855412||CLI Rutherford 6|Patients who have been diagnosed with PAD and classified on the Rutherford Scale as Rutherford 6. Patients may be treated with any FDA-cleared endovascular PAD treatment.
3094991|NCT01855425|Other|Investigational CBCT|Radiation
3094992|NCT01855750|Placebo Comparator|Treatment Arm A: placebo + R-CHOP|Treatment Arm A = placebo + R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)
3094993|NCT01855750|Experimental|Treatment Arm B: ibrutinib + R-CHOP|Treatment Arm B = ibrutinib + R-CHOP
3094994|NCT01855789|Experimental|Non-Randomized Participants (TCZ + MTX)|All participants will receive initial treatment with open-label TCZ + MTX. Participants who complete 24-week treatment with open-label TCZ + MTX and did not achieve a DAS28 score </=3.2 at Week 24, will continue receiving TCZ + MTX in open label manner up to Week 52.
3094995|NCT01855789|Experimental|Randomized Participants (TCZ + MTX)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX up to Week 52.
3094996|NCT01855789|Active Comparator|Randomized Participants (TCZ + PBO)|Participants who complete the initial 24-week treatment with open-label TCZ + MTX and achieve a DAS28 score </=3.2 at Week 24, will be randomized to receive TCZ along with MTX matched placebo (PBO) up to Week 52.
3094997|NCT01855828|Experimental|Chemo plus Pertuzumab,Trastuzumab|During weeks 1-12, patients will receive pertuzumab, trastuzumab, and paclitaxel at the same time; during weeks 13-24 patients will receive pertuzumab and trastuzumab at the same time with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC).
3094998|NCT01855919|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for first 3 days and 20 mg for last 4 days of week.
3094999|NCT01855919|Placebo Comparator|Placebo|Placebo administered orally once every day for 15 weeks.
3095000|NCT01855945|Experimental|Group A|3.75 µg H3N2c HA + 0.125 mL MF59
3095001|NCT01855945|Experimental|Group B|7.5 µg H3N2c HÁ + 0.250 mL MF59
3095002|NCT01855945|Experimental|Group C|15 µg H3N2c unadjuvanted
3095003|NCT01855958|Experimental|DIMST|The investigators used acupuncture needles with guide tubes (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd., 218, China) that were 40 mm in length and 0.25 mm in diameter. The needling in DIMST was applied using an electro acupuncture device (Cosmotron, São Paulo, Brazil) in the dermatomes corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). DIMST using was administered maintaining a distance from the spinous process line of 2 cm. The anatomic sites of peripheral DIMST were the muscles vastus medialis, rectus femoris, vastus lateralis, tibialis anterior; and the pes anserinus bursae. All subjects received one 30min session using a frequency of 2 Hz.
3095004|NCT01855958|Sham Comparator|Placebo-sham|The investigators used the same electro acupuncture device (Cosmotron, Sao Paulo, Brazil), which was previously set to prevent the current to pass through the electrodes. Subjects were informed that it would be a stimulus of low intensity and high frequency that they probably would not have any sense of it. The electrodes were placed on the same points where the active stimulation was applied while the nerve stimulation unit was left in front of the subject, for 30 minutes. This positioning ensured that the intermittent diode simulating the electrical stimulus was visible and audible.
3095005|NCT01855997||Adult CHB Participants Treated With Peg-IFN Alfa-2a|Adult participants with CHB infection, and who have completed at least 24 weeks of Peg-IFN alfa-2a with/without nucleoside analogue therapy and at least 24 weeks of follow-up, will be included. Participants will be recruited from Roche clinical trials or general practice; no treatment will be administered in this non-interventional study.
3095006|NCT01856114|Experimental|Fentanyl Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Fentanyl tablet to put in between upper gum and cheek. Study physician will determine the morphine equivalent daily dose (MEDD) in real time using standardized equianalgesic ratios. Based on clinical practice and similarly to the dose used for breakthrough pain, an FBT dose equivalent to 20-50% of the MEDD used. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
3095007|NCT01856114|Placebo Comparator|Placebo Buccal Tablet|After a six minute walk test, participant will sit down and rest for up to 1 hour. They will then be given a Placebo tablet to put in between upper gum and cheek. After 30 minutes, participant asked about any side effects they may be having, and repeat the walking test. During each walk test, participant asked 6 times how hard it is to catch their breath. The total distance walked will also be recorded. Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
3468967|NCT03890848|Active Comparator|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
3095008|NCT01856192|Experimental|Arm A (rituximab, combination chemotherapy, lenalidomide)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1; prednisone PO on days 1-5; and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3095009|NCT01856192|Active Comparator|Arm B (rituximab, combination chemotherapy)|Patients receive rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3095010|NCT01856218|Experimental|UX003|"During the initial 14-week treatment period of the study, participants receive 2 mg/kg UX003 every other week (QOW) for 12 weeks. At Week 14, participants continue on UX003 therapy and begin a forced dose titration period for an additional 24 weeks at the dose sequence of 1, 4, and 2 mg/kg UX003 QOW as follows: 1 mg/kg UX003 for 8 weeks beginning on Week 14; then 4 mg/kg UX003 for 8 weeks beginning on Week 22; then 2 mg/kg UX003 for 8 weeks beginning on Week 30. Following the 24 week forced dose titration period, participants who continue on treatment (continuation period) received 2 mg/kg UX003 QOW beginning at Week 38 for up to an additional 36 weeks.~After the first phase of the study, participants who elect to continue drug treatment are transitioned to the long-term extension phase, where they are treated with UX003 at 4 mg/kg beginning at Week 74, for up to an additional 168 weeks."
3095011|NCT01856257|Active Comparator|Thymoglobulin®+tacrolimus+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF)
3095012|NCT01856257|Experimental|Thymoglobulin®+belatacept+MMF|Induction with Thymoglobulin®, methylprednisolone, and maintenance with belatacept and mycophenolate mofetil (MMF)
3095013|NCT01856257|Experimental|Basiliximab+20 weeks of tacrolimus+MMF + belatacept|"Induction basiliximab and methylprednisolone, administration of NULOJIX® (belatacept) 24 hours post reperfusion (+/-12 hrs); maintenance immunosuppression with 1. )20 week course of Prograf® (tacrolimus) or equivalent 2.) CellCept® (mycophenolate mofetil- MMF), or Myfortic® (mycophenolate sodium), or equivalent.~Subjects participating in this arm may have tacrolimus reinstated, at a dose to be determined by the site investigator, if any of the following events occur: 1 - An acute rejection episode 2- Request of the subject or site Investigator."
3095014|NCT01856270|Experimental|Amitriptyline Immediate|The Amitriptyline Immediate group will begin study drug immediately after enrollment. Immediate Drug participants will be started on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
3095015|NCT01856270|Experimental|Amitriptyline Delayed|The Amitriptyline Delayed group will start the study drug at the Day 30 visit on one 10 mg capsule each evening. The dosage will be adjusted upwards to 25 mg daily for Week 2 to a maximum of 50 mg daily by Week 3.
3095016|NCT01856309|Experimental|Sirukumab 100 mg|
3095017|NCT01856309|Experimental|Sirukumab 50 mg / placebo|
3095018|NCT01856491|Other|RELIANCE 4-FRONT™ Passive Fixation|Single arm, all patients will be implanted with the RELIANCE 4-FRONT™ Passive Fixation lead
3095019|NCT01856530|Experimental|Oxytocin|Liquid intranasal oxytocin, 24 IU, administered once
3095020|NCT01856530|Placebo Comparator|Placebo|Matched placebo nasal spray
3095021|NCT01856543|Placebo Comparator|Eucerin|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Pts should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
3095022|NCT01856543|Experimental|Mometasone Furoate 0.1%|Patient education regarding amount to be applied (amount depending on body habitus) and area of treatment field will be reinforced by the R.N. prior to the first radiation treatment. Part of patient education may involve application of the cream. Patients will be instructed to apply cream to the upper outer quadrant, upper inner quadrant, lower outer quadrant, and lower inner quadrant, as well as irradiated nodal fields. They will be instructed to apply cream in a thin, uniform layer twice a day, in the morning and evening, and not within the immediate 4 hours prior to radiation treatment. Patients will be informed that application immediately following radiation treatment is acceptable for those scheduled to receive morning treatments. Patients will be provided diaries to record the date and time they applied the study cream. Patients should return the completed diaries on their weekly status checks and at the 2 weeks +/- 2 business days following the completion of RT.
3095023|NCT01856569||observational|
3095024|NCT01856582|Experimental|CD34+ selected stem cell infusion|An infusion of selected CD34+ stem cells will be given without any preparative regimen.
3095025|NCT01856595|Experimental|PF-06291874|
3095026|NCT01856595|Placebo Comparator|Placebo|
3095027|NCT01856673|Experimental|ARM 1: Component-Based Intervention|Common Elements Treatment Approach (CETA) only
3095028|NCT01856673|Experimental|ARM 2: Community Group Therapy|Narrative Community Group Therapy (NCGT) only
3095029|NCT01856673|Other|ARM 3: Standby group|Standby group without intervention, but under monthly monitoring.
3095030|NCT01856686|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
3095031|NCT01856686|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
3095032|NCT01856712|Active Comparator|oral naltrexone|an initial 50 mg oral dose of naltrexone prior to hospital discharge plus a 30-day prescription for oral naltrexone
3095033|NCT01856712|Experimental|injectable naltrexone|a single 380 mg intramuscular injection of naltrexone (duration of action = 30 days)prior to hospital discharge followed by a second injection one month later.
3095034|NCT01856764|Experimental|0.5% Roflumilast Cream|Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.
3095035|NCT01856764|Placebo Comparator|Vehicle Cream|Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.
3095036|NCT01856790|Experimental|Closed Loop Insulin Delivery|"Each participant recruited into the study will undergo two inpatient closed loop admissions.~The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.~Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.~Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy."
3095037|NCT01856907|Experimental|Sitagliptin-Metformin|50 mg/1000 mg twice a day (BID)
3095038|NCT01856907|Placebo Comparator|Placebo pill|1 pill/BID for 16 weeks
3095039|NCT01856907|Active Comparator|Metformin|1000 mg BID
3095040|NCT01856933|Experimental|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
3095041|NCT01857063|Experimental|Montelukast/Placebo|Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
3095042|NCT01857063|Experimental|Placebo/Montelukast|Participants receive placebo chewable tablets for 7 days during Period 1 and receive montelukast 5 mg chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.
3095043|NCT01857102|Active Comparator|etafilcon A/etafilcon A for Astigmatism|Subjects were randomized to one of two sequences of lens wear.
3095044|NCT01857102|Experimental|etafilcon A for Astigmatism/etafilcon A|Subjects were randomized to one of two sequences of lens wear.
3095045|NCT01857206|Experimental|TIVc|Subjects ≥4 to ≤17 years of age received one or two doses of mammalian cell-culture-derived trivalent influenza vaccine based on their previous vaccination status.
3095046|NCT01857206|Active Comparator|TIVf|Subjects ≥4 to ≤17 years of age received one or two doses of egg-derived trivalent influenza vaccine based on their previous vaccination status.
3095047|NCT01857232|Other|Control|OND + DEX + FOS followed by oral DEX
3095048|NCT01857232|Placebo Comparator|Placebo|OND + APD403 followed by oral PLACEBO
3095049|NCT01857232|Experimental|Low dose APD403|OND + APD403 followed by oral APD403 low dose
3095050|NCT01857232|Experimental|Mid dose APD403|OND + APD403 followed by oral APD403 mid dose
3095051|NCT01857232|Experimental|High dose APD403|OND + APD403 followed by oral APD403 high dose
3095052|NCT01857258|Experimental|Green Tea|Participants will be provided a confection containing green tea concentrate
3095053|NCT01857258|Active Comparator|Control|Participants will be provided a confection devoid of green tea concentrate
3095054|NCT01857297|Experimental|Adults (aged 18 to 59 years)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3095055|NCT01857297|Experimental|Older Adults (aged 60 years or older)|The study vaccine (Enzira® vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3095056|NCT01857310|Experimental|Folic acid and zinc supplementation|5 mg folic acid and 30 mg elemental zinc, taken orally, daily for 6 months.
3095057|NCT01857310|Placebo Comparator|Placebo|Matching placebo, taken orally daily for 6 months.
3095058|NCT01857323|Experimental|Albuterol Spiromax®|The approximate 50-day treatment period consisted of 180 mcg (90 mcg/dose cycle, 2 dose cycles) twice daily study medication administration with Albuterol Spiromax with dose-counter.
3095059|NCT01857362|Active Comparator|Nitisinone 2 x 10 mg|Two nitisinone 10 mg capsules by mouth as a single dose
3095060|NCT01857362|Experimental|Nitisinone 1 x 20 mg capsule|One nitisinone 20 mg capsule by mouth as a single dose
3095061|NCT01857531|Experimental|Ganaxolone -- Nicotine Patch|"Pre-Quit Period:~Ganaxolone -- 400mg daily for the first 3 days, 800mg daily for the next 3 days and 1200mg daily for the remainder of the first 2 wks.~Nicotine Patches -- 21mg/24h nicotine patches applied daily during wks. 3 and 4.~Post-Quit Period:~Ganaxolone -- 1200mg daily for wk. 5, 800mg daily for 3 days, and 400mg daily for 3 days.~Nicotine Patches -- 21mg/24h for 4 wks., 14mg/24h for 1 wk., and 7mg/24h for 1 wk."
3095062|NCT01857583|Experimental|SRI 15mg (15 mL/min ≤ CLCR < 20mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
3095063|NCT01857583|Experimental|MiRI 30mg (50 mL/min ≤ CLCR ≤ 80mL/min)|Mild Renal Impairment group orally administered 30mg DU-176b once daily for 14 days.
3095064|NCT01857583|Active Comparator|Fondaparinux (20 mL/min ≤ CLCR < 30mL/min)|Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.
3095065|NCT01857583|Experimental|SRI 15mg (20 mL/min ≤ CLCR < 30mL/min)|Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.
3095066|NCT01857622|Experimental|SRI 15mg|DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks.
3095067|NCT01857622|Experimental|Normal/MiRI low-dose group|DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors (body weight of ≤ 60 kg or the presence of concurrent treatment with quinidine or verapamil). DU-176b was orally administered at a dose of 15 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
3095068|NCT01857622|Experimental|Normal/MiRI high-dose group|DU-176b was orally administered at a dose of 60 mg once daily for 12 weeks in subjects who had none of the dose adjustment factors. DU-176b was orally administered at a dose of 30 mg once daily for 12 weeks to subjects who had any of the dose adjustment factors, irrespective of the number of dose adjustment factors.
3095069|NCT01857713|Active Comparator|Reza Band UES Assist Device|Patient is own control. Compare baseline to last follow-up after using device
3095070|NCT01857869|Experimental|GSK257049-0,1,7M Group|Subjects receiving 2 doses of GSK257049 vaccine given at 0 and 1 months and followed 6 months later (At Month 7) by another dose of GSK257049 vaccine.
3095071|NCT01857869|Experimental|GSK257049-0,1,2M Group|Subjects receiving 3 doses of GSK257049 vaccine given one month apart (0,1 and 2 months).
3095072|NCT01857869|Experimental|Infectivity Control Group|Volunteers who did not receive any immunization but underwent sporozoite challenge
3095073|NCT01857882|Experimental|Decision Support Workshop|The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
3095074|NCT01857882|No Intervention|Standard Care|Routine pre-consultation education
3095075|NCT01857973|Experimental|Hybrid Closed Loop|In-clinic evaluation of the HCL System under various conditions.
3095076|NCT01857986|Experimental|Study group|Subjects in the study group will be connected to the AnapnoGuard 100 control unit operating in the normal clinical mode (automatic CO2 leak measurement above the cuff, cuff pressure control, evacuation of secretions and tracheal rinsing)
3095077|NCT01857986|Active Comparator|Control group|Subjects in the control group will be connected to the AnapnoGuard 100 control unit. In the control group, the cuff pressure control of the AnapnoGuard 100 control unit will be disabled (OFF). CO2 level above the cuff will be recorded. Suction and rinsing function will operate after the system detects no CO2.
3095078|NCT01858194|Experimental|Renal sympathetic denervation|Catheter-based Renal Sympathetic Denervation Ablation Arm
3095079|NCT01858194|Placebo Comparator|VT ablation alone|No further therapy in addition to VT ablation
3095080|NCT01858363|Experimental|Paclitaxel-coated balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
3095081|NCT01858363|Placebo Comparator|Bare balloon|Subjects with de novo occluded/stenotic or re-occluded/restenotic lesions will be randomly assigned to treatment with a Paclitaxel-coated balloon or bare balloon.
3095082|NCT01858376|Other|Capros dietary supplement|Subjects will take Capros supplement (1 capsule) twice a day for 12 weeks.The subjects then will have blood drawn seven times throughout the course of the study.
3095083|NCT01858389|Experimental|Cohort A|Patients with NSCLC whose tumor has a documented T790M mutation in exon 20 of the Epidermal Growth Factor Receptor.
3095084|NCT01858389|Experimental|Cohort B|Patients with NSCLC. No requirement of a specific molecular signature, but excluding known T790M mutations.
3095085|NCT01858428|Active Comparator|Bare PTA|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
3095086|NCT01858428|Experimental|Drug-Coated PTA|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
3095087|NCT01858532|Active Comparator|Atrasentan|0.75 mg atrasentan once daily by mouth for up to 52 months
3095088|NCT01858532|Placebo Comparator|Placebo|Placebo once daily by mouth for up to 52 months
3095089|NCT01858545|Experimental|Experimental|MatriStem MicroMatrix and MatriStem Wound Matrix
3095090|NCT01858545|Active Comparator|Comparator|Cellular Dermal Replacement Tissue
3095091|NCT01858558|Experimental|aMIL Arm|Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)
3095092|NCT01858558|Active Comparator|No aMIL|Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)
3095093|NCT01858636||Angio-Seal VIP Vascular Closure|
3095094|NCT01858701|Other|AO for Astig / Biofinity Toric|Lotrafilcon B toric contact lenses worn in Period 1, followed by comfilcon A toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
3095095|NCT01858701|Other|Biofinity Toric / AO for Astig|Comfilcon A toric contact lenses worn in Period 1, followed by lotrafilcon B toric contact lenses in Period 2, as randomized. Each product will be worn bilaterally on a daily wear basis for 30 days, removed nightly. A minimum 1-day washout of no contact lens wear will precede each wear period.
3095096|NCT01858753|Experimental|Autologous fibroblasts|Autologous fibroblasts grown in culture from skin biopsy taken from patient. The cells will be injected into the scars to be treated.
3095097|NCT01858753|Placebo Comparator|Sterile saline|Sterile saline will be injected into the scar to be evaluated.
3095098|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3095099|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3095100|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3095101|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)|Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3095102|NCT01858766|Experimental|SOF+VEL 25 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3095103|NCT01858766|Experimental|SOF+VEL 100 mg 12 Weeks (GT3)|Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3095104|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
3095105|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
3095106|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
3095107|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
3095108|NCT01858766|Experimental|SOF+VEL 25 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.
3095109|NCT01858766|Experimental|SOF+VEL 25 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.
3095110|NCT01858766|Experimental|SOF+VEL 100 mg 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.
3095111|NCT01858766|Experimental|SOF+VEL 100 mg + RBV 8 Weeks (GT2)|Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.
3468968|NCT03891056|Active Comparator|Gastric bypass|Twenty patients will be randomly assigned to perform a laparoscopic gastric bypass.
3095112|NCT01859013|Experimental|Topiramate|Four (4) weeks of meal replacement therapy, followed by 28-weeks of topiramate therapy. Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks.
3095113|NCT01859013|Placebo Comparator|Sugar Pill|Four (4) weeks of meal replacement therapy, followed by 28-weeks of placebo (sugar pill) therapy.
3095114|NCT01859078|Experimental|Baricitinib + Digoxin|"Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16.~Baricitinib - 10 mg administered orally, QD, on Days 8 through 16."
3095115|NCT01859143|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3095116|NCT01859143|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3095117|NCT01859195||Focus Group Stage|~20-24 participants, to comprise 3-6 focus groups
3095118|NCT01859195||Cognitive Interview Stage|~12-16 participants in individual cognitive interviews
3095119|NCT01859247|Active Comparator|Dorsal Premotor rTMS|0.2 Hz rTMS for 15 minutes
3095120|NCT01859247|Active Comparator|Primary motor cortex rTMS|0.2 Hz rTMS for 15 minutes
3095121|NCT01859247|Active Comparator|Supplemental Motor Area rTMS|0.2 Hz rTMS for 15 minutes
3095122|NCT01859247|Active Comparator|Anterior Cingulate rTMS|0.2 Hz rTMS for 15 minutes
3095123|NCT01859247|Sham Comparator|Sham rTMS|0.2 Hz rTMS for 15 minutes
3095124|NCT01859312|Experimental|Continuous Subcutaneous Hydrocortisone Infusion|Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.
3095125|NCT01859325|Experimental|Vaccine|HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 g (1500 g of the HIV-1 gag/pol plasmid and 1500 g of the HIV-1 net/tat/vif, env plasmid) at week 0, 4, 12, and 36. Each construct of HIV-MAG pDNA vaccine (1500 g each) will be mixed and combined with 1000 g of the IL-12 pDNA adjuvant. The resulting mixture will be divided into 2 IM injections and administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS device. IL-12 pDNA adjuvant will be mixed with the HIV-MAG pDNA vaccine prime, as noted above, and administered at a dose of 1000 g (500 g in each IM injection) at week 0, 4, 12, and 36. rVSV HIV gag booster vaccine--The total dose, 1x107 pfu, will be administered as 1 mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the right deltoid at week 24 and 48.
3095126|NCT01859325|Placebo Comparator|Placebo|Placebo for the IL-12 pDNA adjuvant and HIV-MAG pDNA vaccine (sodium chloride for injection, USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using the TDS device. Placebo for the rVSV HIV gag (sodium chloride for injection, USP 0.9%) will be administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right deltoid at week 24 and 48.
3095127|NCT01859390|Experimental|AquADEKs-2|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period. For those subjects randomized to the AquADEKs-2 arm, two AquADEKs-2 softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 16 weeks.
3095128|NCT01859390|Active Comparator|Control multivitamin|Two control multivitamin softgel capsules will be taken orally on a once daily basis with pancreatic enzymes and a glass of milk or fat-containing meal for 4 weeks for the screening run in period for all participants and for 16 weeks for those randomized to this comparative therapy.
3095129|NCT01859403|Placebo Comparator|Usual Care|Usual care for veterans as part of the MOVE! program
3095130|NCT01859403|Active Comparator|Personalized Genomics|Personalized genomics information from the FIT Test, Pathway Genomics
3095131|NCT01859494|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the NINJA 3 Investigational Blood Glucose Monitoring System.
3095132|NCT01859507|Experimental|BOTOX group|Injection of BOTOX in the perineal muscles in resistant cases of vaginismus. Proper informed consent forms will be signed. The injection procedure is done under local anesthesia for most of our patients. We followed up the patient by phone calls for possible adverse effects following the procedure for 4 days.The patient is then instructed to attend dilatation sessions twice weekly in the clinic, in the presence of the husband, for 3-4 weeks. We use silicone dilators, of ascending sizes, covered by lubricated condoms. In the initial phase of the dilatation procedure we start each session with the appropriate size of the dilator according to the capacity of the introitus and the degree of vaginismus, and thereafter increase the size gradually.
3095133|NCT01859611|Experimental|Radiofrequency|Radiofrequency (RF) treatment with the TriActive+ RF device on the peri-oral and/or peri-orbital areas of the face once a week for eight weeks.
3095134|NCT01859637|Experimental|Zarzio®/Filgrastim HEXAL®|Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
3095135|NCT01859702|Experimental|VIGADEXA|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution, 1 drop instilled in the study eye 2 days before surgery, followed by 1 drop instilled 4 times a day the day before surgery. On the day of surgery, 1 drop was instilled 60 minutes prior to the procedure.
3095136|NCT01859715|Active Comparator|Oxycodone group|Subjects given either oxycodone 5mg by ED provider decision or by triage nurse randomization.
3095137|NCT01859715|Active Comparator|Nausea-observational group|Patients given ondansetron 4mg by ED provider decision or by triage nurse. This is an observational cohort only.
3095138|NCT01859715|Active Comparator|Hydrocodone/Acetaminophen group|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
3095139|NCT01859741|Experimental|OMP-59R5 Combination with Etoposide and Cisplatin|
3095140|NCT01859741|Experimental|Etoposide and Cisplatin plus Placebo|
3095141|NCT01859793|Placebo Comparator|Matching Placebo|Matching Placebo for Sitagliptin
3095142|NCT01859793|Active Comparator|Sitagliptin|100mg pill, PO administered once daily.
3095143|NCT01859923|Experimental|Group 1: 12 to 17 Years of Age|Participants 12 to 17 years old (inclusive) received adult formulation of delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) plus optimized background regimen (OBR) up to Day 182. Participants continued to receive OBR up to Day 365.
3095144|NCT01859923|Experimental|Group 2: 6 to 11 Years of Age|Participants 6 to 11 years old (inclusive) received adult formulation delamanid 50 mg (1x50 mg tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
3095145|NCT01859923|Experimental|Group 3: 3 to 5 Years of Age|Participants 3 to 5 years old (inclusive) received 25 mg pediatric formulation of delamanid (DPF - suspension prepared using dispersible tablet), orally, BID plus OBR up to Day 182. Participants continued to receive OBR up to Day 365.
3095146|NCT01859923|Experimental|Group 4: Birth to 2 Years of Age|"Participants from birth to 2 years old (inclusive) received DPF (suspension prepared using dispersible tablet) for 182 days plus OBR. Participants continued to receive OBR up to Day 365. The DPF dose was based on the participant's body weight during the baseline visit:~Participants >10 kilograms (kg) received DPF 10 mg BID plus OBR~Participants >8 kg and ≤10 kg received DPF 5 mg BID plus OBR~Participants ≥5.5 kg and ≤8 kg received DPF 5 mg once per day (QD) plus OBR~Delamanid dose was adjusted as needed for Group 4 participants based on the weight measurement at specified study visits [Visits 5 (Day 28), 7 (Day 56), 9 (Day 84), 11 (Day 126) and 12 (Day 154)]."
3095147|NCT01859949|Experimental|Genotropin (somatropin)|
3095148|NCT01859988|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection every week (qw) from Week 1 to Week 15.
3095149|NCT01859988|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
3095150|NCT01859988|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 15.
3095151|NCT01859988|Experimental|Dupilumab 200 mg q2w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single injection of Placebo (for Dupilumab) alternating with single 200 mg injection of Dupilumab q2w from Week 1 to Week 15.
3095152|NCT01859988|Experimental|Dupilumab 300 mg q4w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab every 4 weeks (q4w) and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
3095153|NCT01859988|Experimental|Dupilumab 100 mg q4w|Two subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1, followed by a single 100 mg injection of Dupilumab q4w and Placebo (for Dupilumab) qw when Dupilumab not administered from Week 1 to Week 15.
3095154|NCT01860079|Active Comparator|Early discharge group|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
3095155|NCT01860079|No Intervention|Standard discharge group|Patients who stay longer (96-120 hours) as of a standard procedure
3095156|NCT01860170|Active Comparator|Cohort 1-Bortezomib (Velcade®)|Bortezomib (Velcade®) 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3095157|NCT01860170|Active Comparator|Cohort 2-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3095158|NCT01860170|Active Comparator|Cohort 3-Bortezomib (Velcade®)|Bortezomib (Velcade®) 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3.
3095159|NCT01860287|Placebo Comparator|Placebo group|Healthy volunteers receive placebo during session (within-subjects design).
3095160|NCT01860287|Experimental|buprenorphine (0.2 mg) group|Healthy volunteers receive buprenorphine (0.2 mg) during session (within-subjects design).
3095161|NCT01860287|Experimental|buprenorphine (0.4 mg) group|Healthy volunteers receive buprenorphine (0.4 mg) during session (within-subjects design).
3095162|NCT01860521|Active Comparator|Programmed Intermittent Epidural Bolus|
3095163|NCT01860521|Active Comparator|Continuous Epidural Infusion|
3095164|NCT01860534|Experimental|Eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
3095165|NCT01860534|No Intervention|no eye patches covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and patched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
3095166|NCT01860573|Active Comparator|Standard amino acids|Receive 1-2 gm/kg/day amino acids at birth and advanced by 0.5 gm/kg/day for goal of 4 gm/kg/day
3095167|NCT01860573|Experimental|High amino acids|Receive 3-4 gm/kg/day amino acids at birth and advanced to goal of 4 gm/kg/day as soon as possible after birth
3095168|NCT01860586|Experimental|Bevacizumab|Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)
3095169|NCT01860651|Active Comparator|Web-monitoring|"There is two arms for intervention:~1) Patients in treatment with medicine administrated at home and 2) patients in treatment with biologicals."
3468969|NCT03891056|Active Comparator|Slevee gastrectomy|Twenty patients will be randomly assigned to perform a sleeve gastrectomy
3095170|NCT01860651|No Intervention|Control|"Patients in treatment with medicine administrated at home: routine outpatient controls, four times a year.~Patients in treatment with biologicals: retrospective routine treatment algorithm"
3095171|NCT01860677|Active Comparator|Active stimulation|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies. The device has been designated by the FDA to be minimally invasive and has FDA approval to be used to reduce symptoms associated with anxiety, depression, pain and insomnia. The unit is locked at the factory to deliver a maximal output of 4 mA of current and has a timer that prevents it from staying on longer than 20 minutes. Current will be limited to a maximum of 2 mA.
3095172|NCT01860677|Placebo Comparator|Sham stimulation|Participants are outfitted with a device that is identical to the Fisher Wallace Cranial Stimulator in appearance but does not deliver any current.
3095173|NCT01860703|Experimental|Arm A - Maximum Therapeutic Dose|Single dose of 33 mg/kg rounded to the nearest 250 mg of deferiprone tablets
3095174|NCT01860703|Experimental|Treatment Arm B - Supratherapeutic Dose|Single dose of 50 mg/kg rounded to the nearest 250 mg of deferiprone tablets
3095175|NCT01860703|Experimental|Arm C - Placebo Control|Single dose of matching deferiprone and moxifloxacin placebo tablets.
3095176|NCT01860703|Experimental|Arm D - Positive Control|Single dose of one 400 mg moxifloxacin tablet.
3095177|NCT01860807|Experimental|Ibudilast|Ibudilast 50 mg twice daily
3095178|NCT01860807|Placebo Comparator|Placebo|matching placebo twice daily
3095179|NCT01860846||Participants with moderate to severe Crohn's Disease|Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
3095180|NCT01860950|Active Comparator|anodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder (Brand Phoresor-II Auto) . BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
3095181|NCT01860950|Active Comparator|anodal tDCS plus pain-education|"Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder.~Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing."
3095182|NCT01860950|Experimental|cathodal tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC. BCI entails listening to a 3-minute audio recording designed to mimic key components of cognitive behavioral therapy (CBT) for pain.
3095183|NCT01860950|Experimental|cathodal tDCS plus pain-education|Participants were provided pain education during a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode attached to the right shoulder and the cathode electrode was placed over the left DLPFC. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
3095184|NCT01860950|Sham Comparator|sham tDCS plus BCI|Participants underwent Brief Cognitive intervention (BCI) during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session.
3095185|NCT01860950|Sham Comparator|sham tDCS plus pain-education|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session. Pain Education information included Pain Physiology, info on the Gate Theory of Pain, and Central Pain Processing.
3095186|NCT01860976|Experimental|Abatacept|Abatacept 125 mg/syringe (125 mg/mL) solution subcutaneously once a week for 168 days double blind/197 days open label/365 days long term extension
3095187|NCT01860976|Placebo Comparator|Placebo|Placebo matching with Abatacept 0 mg solution subcutaneously once a week 168 days double blind
3095188|NCT01860989|Experimental|Cohort 1|6-12 subjects with Plasmodium falciparum malaria will receive 75 mg KAE609 as a single dose
3095189|NCT01860989|Experimental|Cohort 2|6-12 subjects with Plasmodium falciparum malaria will receive 150 mg KAE609 as a single dose
3095190|NCT01860989|Experimental|Cohort 3|6 to 12 subjects with Plasmodium falciparum malaria will receive 225 mg KAE609 as a single dose
3095191|NCT01860989|Experimental|Cohort4|6- 12 subjects with Plasmodium falciparum malaria will receive 300 mg KAE609 as a single dose
3095192|NCT01861002|Experimental|AML Arm|"Participants with Acute Myeloid Leukemia (AML)~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal (IT) Cytarabine"
3095193|NCT01861002|Experimental|ALL Arm|"Patients with Acute Lymphocytic Leukemia~Intervention:~Azacytidine (Dose Level 1 @ 75 mg/m2/day)~Fludarabine 30 mg/m2/dose~Cytarabine 2000 mg/m2/dose~Intrathecal Methotrexate (IT MTX)"
3095194|NCT01861028||Phase I|A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
3095195|NCT01861028||Phase II|The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.
3095196|NCT01861054|Experimental|Treated patients - Total|Patients eligible will be treated with Reparixin as add-in monotherapy
3095197|NCT01861301|Experimental|Treatment (tivantinib)|Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
3095198|NCT01861457|Experimental|Nozin® Nasal Sanitizer®|Non-antibiotic, alcohol-based antiseptic
3095199|NCT01861457|Placebo Comparator|Phosphate-buffered saline|Placebo
3095200|NCT01861522|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3095201|NCT01861522|Placebo Comparator|Placebo|Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3095202|NCT01861574|Experimental|Both Real TMS|Participants in the Both Real TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Real TMS 4 hours after surgery.
3095203|NCT01861574|Sham Comparator|Sham then Real TMS|Participants in the Sham then Real TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and 20 minutes of Real TMS 4 hours after surgery.
3095204|NCT01861574|Sham Comparator|Real then Sham TMS|Participants in the Real then Sham TMS group receive 20 minutes of Real TMS 45 minutes after gastric-bypass surgery and then 20 minutes of Sham TMS 4 hours after surgery.
3095205|NCT01861574|Sham Comparator|Both Sham TMS|Participants in the Both Sham TMS group, receive Sham TMS 45 minutes after gastric-bypass surgery and then another 20 minutes of Sham TMS 4 hours after surgery
3095206|NCT01861587|Experimental|Real tDCS:Active Comparator|For Real tDCS, stimulation will be delivered in 20-minute-sessions using 2mA current. The anode will be placed over left BA9 or the motor cortex corresponding with the painful area (if applicable). The cathode will be placed over right BA43 (for GI pain) or right BA9 (located via the international 10-20 EEG system).
3095207|NCT01861587|Experimental|Sham tDCS: Sham Comparator|For sham tDCS, the device will be turned on for 30 seconds and then turned off for the duration of the 20-minute session.
3095208|NCT01861665|Active Comparator|Marcaine administered pre-incision.|Pre-operative administration, using both the specific drug - Marcaine 0.25%- and total amount - 5cc per incision.
3095209|NCT01861665|Active Comparator|Marcaine administered post-incision|Marcaine 0.25% administered post-incision, total amount 5cc per incision.
3095210|NCT01861704|Active Comparator|Lyric|Silver Lyric device
3095211|NCT01861704|Active Comparator|Lyric2|Lyric2 (Barracuda) device
3095212|NCT01861756|Experimental|Diabetes Medication Choice Decision Aid|
3095213|NCT01861756|No Intervention|Standard care|
3095214|NCT01861925||Normal eye|Astigmatism smaller than 1.5 diopters
3095215|NCT01861925||Large regular astigmatism|Astigmatism of > 1.5 diopters, regular astigmatism.
3095216|NCT01861925||Large irregular astigmatism|Astigmatism of > 1.5 diopters, irregular astigmatism.
3095217|NCT01862029|Experimental|Roflumilast|
3095218|NCT01862133||Patient Preferences|Patients were eligible if they had visited their primary care physician at least twice in the previous 1 year and were fluent in English. Each patient subject used an online program to record their preferences what each of their providers can see. The electronic medical record (EMR) will then apply them to data displays.
3095219|NCT01862133||Primary Care Providers|All healthcare providers (physicians, nurses, and other clinic staff) were eligible to participate in this study. For those enrolled, display of patient data in the EMR was dictated by the patient subject's preferences for who should see what data.
3095220|NCT01862159||Operated patients|Patients undergoing laparoscopic gastric bypass surgery between 1st of May 2007 until 30th of september 2012
3095221|NCT01862250|Experimental|Clonidine infants with HIE|Infants in this group will receive Intravenous clonidine at 1µg/kg/dose either every 6 or 8 hrs from the start of cooling to the end of re-warming
3095222|NCT01862328|Experimental|MLN4924 and Docetaxel (Arm 1)|
3095223|NCT01862328|Experimental|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|
3095224|NCT01862328|Experimental|MLN4924 + Gemcitabine (Arm 3)|
3095225|NCT01862419|Experimental|Alert|Text page sent to patient's covering provider and unit pharmacist informing them of the presence of AKI as detected by changes in serum creatinine.
3095226|NCT01862419|No Intervention|Usual Care|Usual care arm. No alert will be provided to the patient's covering provider or unit pharmacist.
3095227|NCT01862484|Experimental|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
3095228|NCT01862484|Sham Comparator|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet.
3095229|NCT01862536|Placebo Comparator|Placebo|Placebo tablet
3095230|NCT01862536|Experimental|Tadalafil|Daily use of tadalafil (study drug) at 40 mg orally.
3095231|NCT01862614|Experimental|Buffered Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc buffered 4% articaine.
3095232|NCT01862614|Active Comparator|Articaine at 1st Appointment|Subjects received an infiltration injection of 1.8cc 4% articaine (unbuffered).
3095233|NCT01862640|Placebo Comparator|Placebo|Matching placebo once daily
3095234|NCT01862640|Experimental|Brexpiprazole 1 mg|Titrate up from 0.25 milligrams (mg)/day brexpiprazole to 1 mg/day brexpiprazole
3095235|NCT01862640|Experimental|Brexpiprazole 2 mg|Titrate up from 0.25 mg/day brexpiprazole to 2 mg/day brexpiprazole
3095236|NCT01862796|Experimental|Obese underfeeding (UF)|Obese randomized to received a 35% calorie reduced diet
3095237|NCT01862796|Experimental|Obese weight maintaining (WMEN)|Randomized to receive a weight-maintaining diet
3095238|NCT01862796|Experimental|Lean weight maintaining (WMEN)|Normal weight individuals receiving a weight-maintaining energy needs diet
3095239|NCT01862874|Experimental|V501|Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
3095240|NCT01862874|Placebo Comparator|Placebo|Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.
3095241|NCT01862991|Placebo Comparator|Dilapan-Placebo|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S)(4mm x 65mm). The patient will be administered a placebo pill orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3095242|NCT01862991|Active Comparator|Dilapan-Mifepristone|The clinician will place 4 or 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator.Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3095243|NCT01862991|Experimental|Mifepristone|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients that are over 22 weeks gestation will receive 1mg of intra-amniotic digoxin the day prior to the procedure.
3095244|NCT01863017|Sham Comparator|Sham tDCS|Five consecutive sessions of no tDCS. Each session will last approximately 30 minutes. Current will be applied for 20 minutes. Less than 3 minutes of tDCS has been shown to induce no lasting effects. Normal weight control participants will receive one sham session and one active session.
3095245|NCT01863017|Experimental|Active tDCS|Five consecutive sessions of tDCS administered. Each session will take about 30 minutes. Normal weight control participants will receive one sham session and one active session.
3095246|NCT01863030||Phasix mesh|Mesh being used for approved use. Mesh for ventral and incisional hernias.
3095247|NCT01863134|Experimental|Eptifibatide|Patients were given a bolus of eptifibatide (Integrillin; 180µg/kg of body weight) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
3095248|NCT01863134|Placebo Comparator|Placebo|Patients were given placebo infusion (0,9% Natrium Chloride) and an intravenous infusion of 2 µg/kg/min followed by acetylsalicylic acid (150mg orally daily until the day of the procedure) and enoxaparin (1mg/kg subcutaneous - with the last dose 12 hours before surgery).
3095249|NCT01863186|Active Comparator|Lofexidine HCl (2.4mg dose)|225 subjects will be randomized to receive 2.4 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 2.4 mg (one tablet in each dose will be a placebo tablet to maintain the blind) for up to 7 days.
3095250|NCT01863186|Active Comparator|Lofexidine HCl (3.2mg dose)|225 subjects will be randomized to receive 3.2 mg total daily dose of lofexidine HCl during the double-blind period of the study. Subjects will take 4 tablets QID for a total daily dose of 3.2 mg for up to 7 days.
3095251|NCT01863186|Placebo Comparator|Placebo|150 subjects will be randomized to receive placebo during the double-blind period of the study. Subjects will take 4 tablets QID for up to 7 days.
3095252|NCT01863186|Other|Open Label Lofexidine HCl|During the open-label portion of the study, subjects will be given the option to receive lofexidine HCl tablets for up to 7 days. Dosing regimens are at the discretion of the Investigator.
3095253|NCT01863368|Experimental|Systane Ultra|Systane® ULTRA lubricant eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
3095254|NCT01863368|Active Comparator|Optive|OPTIVE® lubricating eyedrops, 1 drop in each eye 4 times a day for 35 days (Phase I), followed by 55 days additional use as needed (Phase II).
3095255|NCT01863433|Experimental|Trivalent Influenza Vaccine|The study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2013/2014 influenza season). The vaccine will be administered by intramuscular or deep subcutaneous injection.
3095256|NCT01863498|Active Comparator|PCA pain control|Patients will have PCA for pain control
3095257|NCT01863498|Active Comparator|Epidural pain control|Patients will have an epidural for pain control
3095258|NCT01863563|Experimental|QuickClot|QuickClot sponge will be applied for one minute each site of tonsillectomy and Adenoidectomy.
3095259|NCT01863667|Experimental|Omarigliptin|Participants receive an omarigliptin (MK-3102) 25 mg capsule once weekly and glimepiride placebo tablet(s) once daily, for 54 weeks.
3095260|NCT01863667|Active Comparator|Glimepiride|Participants receive glimepiride 1 mg and/or 2 mg tablet(s) (maximum dose 6 mg/day) once daily and an omarigliptin placebo capsule once weekly, for 54 weeks.
3095261|NCT01863680|Experimental|COL-1620|
3095262|NCT01863732|Experimental|Secukinumab (AIN457) 75mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
3095263|NCT01863732|Experimental|Secukinumab (AIN457) 75 to 150mg Grp1|Group 1: AIN457 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
3095264|NCT01863732|Experimental|Secukinumab (AIN457) 150mg Grp2|Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
3095265|NCT01863732|Experimental|Pbo in Core then AIN457 75mg Grp1|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 75 mg was dosed.Secukinumab in PFS for s.c. self-administration Q4W
3095266|NCT01863732|Experimental|Pbo in Core then AIN457 75 to 150mg Grp1|Participants were on Placebo in Core and then in extension randomized to Group 1: secukinumab (AIN457) 75 mg plus placebo 150 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), was up titrated to AIN457 150 mg only. Secukinumab in PFS for s.c. self-administration Q4W
3095267|NCT01863732|Experimental|Pbo in Core then AIN457 150mg Grp2|Participants were on Placebo (Pbo) in Core and then in extension randomized to Group 2: AIN457 150 mg plus placebo 75 mg dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only AIN457 150 mg was dosed. Secukinumab in PFS for s.c. self-administration Q4W
3095268|NCT01863758|Experimental|Human-cl rhFVIII|Up to 60-80 IU/kg of intravenous Human-cl rhFVIII was administered at an individually determined dose and dose interval.
3095269|NCT01863771|Experimental|Golimumab|
3095270|NCT01863771|Placebo Comparator|Placebo|
3095271|NCT01863849|Experimental|Age group 1: adults (18-59 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
3095272|NCT01863849|Experimental|Age group 2: elderly (> 60 years)|"Intervention: Vaccination with Fluval AB suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
3095273|NCT01863953|Experimental|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
3095274|NCT01863953|Active Comparator|Bimatoprost Ophthalmic Solution 0.01% and Vehicle|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening and vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
3095275|NCT01863953|Active Comparator|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
3095276|NCT01864005|Experimental|Ticagrelor|
3095277|NCT01864005|Active Comparator|clopidogrel|
3095278|NCT01864148|Experimental|BIIB033, 3 mg/kg|"BIIB033 3 mg/kg once every 4 weeks intravenous (IV) infusion up to Week 72.~Avonex once-weekly intramuscular (IM) injection up to Week 84."
3095279|NCT01864148|Experimental|BIIB033, 10 mg/kg|"BIIB033 10 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3095280|NCT01864148|Experimental|BIIB033, 30 mg/kg|"BIIB033 30 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3095281|NCT01864148|Experimental|BIIB033, 100 mg/kg|"BIIB033 100 mg/kg once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3095282|NCT01864148|Placebo Comparator|Placebo|"Placebo once every 4 weeks IV infusion up to Week 72.~Avonex once-weekly IM injection up to Week 84."
3095283|NCT01864174|Active Comparator|Arm 1: Metformin XR and Placebo matching with Metformin XR|"Metformin Extended Release (XR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin XR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
3095284|NCT01864174|Active Comparator|Arm 2: Metformin IR and Placebo matching with Metformin IR|"Metformin Immediate Release (IR) 500 mg tablets (500-2000 mg per day) by mouth twice daily (BID) for 24 weeks~Placebo matching with Metformin IR 0 mg tablets by mouth twice daily (BID) for 24 weeks"
3095285|NCT01864200|Experimental|CroFab|crotalidae polyvalent immune fab (ovine) per approved labeling
3095286|NCT01864200|Placebo Comparator|Saline placebo|Saline placebo
3095287|NCT01864291|Experimental|Non-NF2 ABI surgery|All subjects will be part of a single arm involving placement of the ABI541 Auditory Brainstem Implant (ABI) device. The Nucleus 24 was discontinued and is no longer available.
3095288|NCT01864434||Patients with a Stryker Triathlon CR TKA|Patients implanted with a Stryker Triathlon Posterior Cruciate Retaining Total Knee Arthroplasty.
3095289|NCT01864434||Patients with a Zimmer PCR TKA|Patients implanted with a Zimmer NexGen Posterior Cruciate Retaining Total Knee Arthroplasty.
3095290|NCT01864525|Placebo Comparator|Inactive capsule|Participants will receive a pill/capsule with an inactive ingredient during the placebo arm of this study.
3095291|NCT01864525|Experimental|Octanoic acid|Participants will receive a pill/capsule with octanoic acid (amount determined by the participant's weight) during the experimental arm of this study.
3095292|NCT01864538|Experimental|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
3095293|NCT01864564|No Intervention|Routine Screening|"Obese women will be screened at 24-28 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
3095294|NCT01864564|Experimental|Early Screening|"Obese women will be randomized to be screened at 14-19.9 weeks of gestation for gestational diabetes using the standard U.S. screening method of a 1-hour, 50-g glucose challenge test followed by a 3-hour, 100-g glucose tolerance test if abnormal. Women identified as having diabetes will be treated according to standards of care. Women who do not have diabetes at 14-19.9 weeks will be re-screened at 24-28 weeks per the standard of care.~All women will have a hemoglobin A1c and 1,5-anhydroglucitol checked at 14-18 weeks and 24-28 weeks gestation."
3095295|NCT01865084|Experimental|Placebo|Placebo taken orally once daily.
3095296|NCT01865084|Experimental|0.3 mg/kg Tadalafil|0.3 milligram per kilogram (mg/kg) tadalafil taken orally once daily.
3095297|NCT01865084|Experimental|0.6 mg/kg Tadalafil|0.6 mg/kg tadalafil taken orally once daily.
3095298|NCT01865448|Active Comparator|omega-3 DHA|Patients in this group will receive 500 mg/day supplement of DHA omega-3 fatty acid in capsule form, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme.
3095299|NCT01865448|Placebo Comparator|Control|Patients in control group will receive an placebo capsule, in addition to the vitamin and oligoelement supplements which are part of the standard weight-loss programme
3095300|NCT01865487|Placebo Comparator|2-Dose Placebo|Placebo QFT Neg and Pos, 2 Doses, days 0,56
3095301|NCT01865487|Experimental|2-Dose 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56
3095302|NCT01865487|Experimental|2-Dose 15/500 H56ug/IC31nmol|15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
3095303|NCT01865487|Experimental|2-Dose 50/500 H56ug/IC31nmol|50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56
3095304|NCT01865487|Placebo Comparator|3-Dose, Placebo|Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112
3095305|NCT01865487|Experimental|3-Dose, 5/500 H56ug/IC31nmol|5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112
3095306|NCT01865552|Experimental|SB4 and EU sourced Enbrel in Part A|SB4 followed by EU sourced Enbrel
3095307|NCT01865552|Experimental|EU sourced Enbrel and SB4 in Part A|EU sourced Enbrel followed by SB4
3095308|NCT01865552|Experimental|SB4 and US sourced Enbrel in Part B|SB4 followed by US sourced Enbrel
3095309|NCT01865552|Experimental|US sourced Enbrel and SB4 in Part B|US sourced Enbrel followed by SB4
3095310|NCT01865552|Other|EU and US sourced Enbrel in Part C|EU sourced Enbrel followed by US sourced Enbrel
3095311|NCT01865552|Other|US and EU sourced Enbrel in Part C|US sourced Enbrel followed by EU sourced Enbrel
3095312|NCT01865708|Other|Ethanol lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
3095313|NCT01865747|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily.
3095314|NCT01865747|Active Comparator|Everolimus (Afinitor)|Everolimus (Afinitor) 10 mg tablet once daily.
3095315|NCT01865812|Experimental|OCA: 10 mg|obeticholic acid, oral administration, 10 mg, 8 weeks
3095316|NCT01866098|Experimental|Naltrexone 50mg|Oral Naltrexone 50mg capsule taken once daily for 52 weeks
3095317|NCT01866098|Placebo Comparator|Placebo|Oral placebo capsule taken once daily for 52 weeks
3095318|NCT01866098|Experimental|Naltrexone 25mg|Oral Naltrexone 25mg capsule taken once daily for 52 weeks
3095319|NCT01866150||Cohort|
3095320|NCT01866163|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)
3095321|NCT01866163|Placebo Comparator|Vehicle|Aerosol foam vehicle
3095322|NCT01866293|Experimental|Cabozantinib (XL184)|Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.
3095323|NCT01866306|Experimental|Healthy 10 TCID50 (Part 1)|Healthy participants were treated with 10 Tissue Culture Infective Dose 50 (TCID50) administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095324|NCT01866306|Experimental|Healthy 100 TCID50 (Part 1)|Healthy participants were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095325|NCT01866306|Experimental|Healthy 1000 TCID50 (Part 1)|Healthy participants were treated with 1000 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095326|NCT01866306|Experimental|Asthmatic non-LABA 10 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 10 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095327|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095328|NCT01866306|Experimental|Asthmatic LABA 100 TCID50 (Part 1)|Participants with mild to moderate asthma, concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095329|NCT01866306|Experimental|Asthmatic non-LABA 100 TCID50 (Part 2)|Participants with mild to moderate asthma, not concomitantly treated with LABA, were treated with 100 TCID50 administered by spraying an atomized viral suspension of RV16UB into a single nostril.
3095330|NCT01866319|Experimental|Ipilimumab|Participants receive ipilimumab, 3 mg/kg intravenously (IV), once every 3 weeks (Q3W) for a total of 4 doses (up to approximately 3 months).
3095331|NCT01866319|Experimental|Pembrolizumab Q2W|Participants receive pembrolizumab, 10 mg/kg IV, once every 2 weeks (Q2W) for up to approximately 24 months.
3095332|NCT01866319|Active Comparator|Pembrolizumab Q3W|Participants receive pembrolizumab, 10 mg/kg IV, Q3W for up to approximately 24 months.
3095333|NCT01866410|Experimental|Treatment (cabozantinib-s-malate, erlotinib hydrochloride)|Patients receive cabozantinib-s-malate PO daily and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3095334|NCT01866423|Experimental|Treatment (orteronel)|Patients receive orteronel 300 mg PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3095335|NCT01866592|Other|Single-Arm, open-label extension trial|Single-arm, open label extension trial to continue treatment with Humira (Adalimumab) subcutaneous injection 80mg initial dose followed by 40mg maintenance dose every other week for up to 52 weeks.
3095336|NCT01866826|Experimental|HIV Infected Subjects|Human immunodeficiency virus (HIV) infected subjects with viral suppression on antiretroviral (ART). Double-blinded/placebo controlled trial with cross-over design. Rifaximin
3095337|NCT01866826|Placebo Comparator|HIV Infected Subjects Placebo|HIV infected subjects with viral suppression on ART. Double-blinded/placebo controlled trial with cross-over design. Placebo
3095338|NCT01866839|Experimental|CD34+ cell positively selected graft stem cell recipient|Recipients received a myeloablative conditioning regimen of cyclophosphamide (120 mg/kg total), fludarabine (125 mg/m2 total) and total body irradiation (1200 cGy with lung shielding to 600 cGy), followed by an infusion of a stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS® system. Older subjects will receive a lower dose of irradiation (800 or 600 cGy based on age) to reduce the regimen intensity.
3095339|NCT01866917|Experimental|TAP|Patients will receive Ropivicaine 0.5% 20cc injectate from a study labeled syringe
3095340|NCT01866917|Placebo Comparator|Saline|Patients will receive Normal saline 20cc injectate from a study labeled syringe
3095341|NCT01866943|Placebo Comparator|Group 1|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
3095342|NCT01866943|Experimental|Group 2|Patients undergo primary total hip arthroplasty and have a wash of 100cc of normal saline plus 1.5 g (100 mg/mL)Tranexamic Acid is applied to the tissues under the skin prior to skin closure. The wash sits in the wound for 5 minutes then is suctioned out and the skin is closed.
3095343|NCT01867008|Experimental|Nucleus CI422 Cochlear Implant with Nucleus 6 (N6) Sound Processor|
3095344|NCT01867021|Experimental|Agriflu|A single 0.5 mL dose of Investigational vaccine TIV (Agriflu) at visit 1, administered intramuscularly
3095345|NCT01867021|Active Comparator|Fluvirin|A single 0.5 mL dose of control vaccine TIVf (Fluvirin) at visit 1, administered intramuscularly
3095346|NCT01867047|Experimental|Continuation Group|Subjects randomized to this group will continue their ACE-I through the day of surgery
3095347|NCT01867047|Experimental|Cessation Group|Subjects randomized to this group will stop their ACE-I two days prior to surgery (last dose >48 hours prior to surgery)
3095348|NCT01867086|Experimental|Vigil™ Vaccine|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
3468970|NCT03890809|Experimental|Normal liver function|Single dose
3468971|NCT03890809|Experimental|Mild liver impairment|Single dose
3095349|NCT01867164|Experimental|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
3095350|NCT01867164|Experimental|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
3095351|NCT01867216|Placebo Comparator|Placebo|Multiple oral dose of placebo administered to participants with diabetes once or twice daily for 28 days
3095352|NCT01867216|Experimental|LY2922470|Multiple ascending dose of LY292470 (starting at 60 mg) administered orally to participants with diabetes once or twice daily for 28 days
3095353|NCT01867294|Experimental|Arm I (Study I)|Patients apply spironolactone topically to face BID for 4 weeks.
3095354|NCT01867294|Experimental|Arm I (Study II)|Patients apply spironolactone topically to face and body BID for 4 weeks.
3095355|NCT01867294|Placebo Comparator|Arm II (Study I)|Patients apply placebo topically to face BID for 4 weeks.
3095356|NCT01867294|Active Comparator|Arm II (Study II)|Patients receive modified preemptive therapy regimen consisting of skin moisturizer topically BID, sunscreen topically as needed, hydrocortisone topically QD, and doxycycline PO BID for 4 weeks.
3095357|NCT01867307|Experimental|Healthy Controls|healthy controls
3095358|NCT01867307|Experimental|Patients|patients with type 2 diabetes mellitus
3095359|NCT01867424|Active Comparator|Participants with Advanced Disease|Advanced disease: who have failed hormone therapy and who have sufficient tissue from a soft tissue or metastatic bone lesion (measuring 1.5cm in diameter at computed tomography (CT) or magnetic resonance imaging (MRI) scan) available for organic anion-transporting polypeptide 1B3 (OATP1B3) immunohistochemistry (IHC) or must have a soft tissue or metastatic bone lesion that can be biopsied and be willing to undergo percutaneous biopsy to obtain tissue for OATP1B3 expression.
3095360|NCT01867424|Active Comparator|Participants with Localized Disease|Localized disease: must have image guided biopsy confirmed prostate cancer and sufficient tissue available for OATP1B3 IHC.
3095361|NCT01867515|Active Comparator|Younger normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 18 and 35~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
3095362|NCT01867515|Active Comparator|Hearing-impaired listeners|"individuals with bilateral sensorineural hearing losses with thresholds between 25 and 70 dB HL and no losses greater than 70 dB HL at frequencies of 4000 Hz or below~age 18 to 65 Acoustic distortion of speech"
3095363|NCT01867515|Active Comparator|Older normally-hearing listeners|"Participants with auditory thresholds within the normal limits.~age between 36 and 65~individuals with hearing thresholds of 20 dB HL or better at all octave frequencies between 250 Hz and 4000 Hz Acoustic distortion of speech"
3095364|NCT01867580|Experimental|V.A.C.Ulta with Prontosan instillation|Treatment Arm
3095365|NCT01867580|Active Comparator|V.A.C.Ulta without instillation|Control Arm
3095366|NCT01867606|Experimental|Arm I (serum-derived bovine immunoglobulin protein isolate)|"Patients receive SBI PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3095367|NCT01867606|Placebo Comparator|Arm II (placebo)|"Patients receive placebo PO BID on days 1-28.~Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3095368|NCT01867632||Prospective group|Prospective cohort where all patients routinely received ADM during cleft palate surgery. A tailored piece of Acellular Dermal Matrix will be placed between the oral and nasal layers at the time of a Furlow Palatoplasty for repair of a Cleft Palate.
3095369|NCT01867632||Retrospective group|Retrospective cohort of cleft palate patients treated at the same institution and by the same surgeon. These patients received ADM selectively for certain cases (tenuous nasal layer closure, tight oral closure, wide cleft).
3095370|NCT01867658|Experimental|Progel® Pleural Air Leak Sealant|
3095371|NCT01867671|Experimental|Peanut Oral Immune Therapy (OIT)|Peanut OIT for 134 weeks followed by peanut avoidance for 26 weeks.
3095372|NCT01867671|Placebo Comparator|Peanut Placebo|Peanut placebo for 134 weeks followed by peanut avoidance for 26 weeks. The placebo extract will be derived from oat flour source material.
3095373|NCT01867710|Experimental|AA + prednisone 5 mg twice daily|Abiraterone acetate in combination with prednisone 5 mg twice daily
3095374|NCT01867710|Experimental|AA + prednisone 5 mg once daily|Abiraterone acetate in combination with prednisone 5 mg once daily dose
3095375|NCT01867710|Experimental|AA + prednisone 2.5 mg twice daily|Abiraterone acetate in combination with prednisone 2.5 mg twice daily
3095376|NCT01867710|Experimental|AA + dexamethasone 0.5 mg once daily|Abiraterone acetate in combination with dexamethasone 0.5 mg once daily
3095377|NCT01868009|Experimental|ELLIPTA Period 1 and DISKUS Period 2 Arm|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.
3095378|NCT01868009|Experimental|DISKUS Period 1 and ELLIPTA Period 2 Arm|Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
3095379|NCT01868022|Experimental|Arm A: GSK3052230 + paclitaxel/carboplatin|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + paclitaxel (constant infusion for 3 hrs) and carboplatin (constant infusion for 30 to 60 minutes) iv on Day 1 of each 21-day cycle. The number of cycles of paclitaxel/carboplatin will be limited to 4 to 6 cycles.
3095380|NCT01868022|Experimental|Arm B: GSK3052230 + docetaxel|Subject will receive GSK3052230 as 30-minute intravenous (i.v.) infusion once a week (Day 1, Day 8, Day 15) of each 21-day cycle + docetaxel as 1 hour iv infusion on Day 1 of each 21-day cycle. Subjects may continue to receive docetaxel until disease progression or as long as they are considered to derive benefit from treatment.
3095381|NCT01868022|Experimental|Arm C: GSK3052230 + pemetrexed and cisplatin|Subject will receive GSK3052230 as 30 minute iv infusion once a week (Day 1, Day 8, Day 15) of each 21 day cycle + pemetrexed iv infusion over 10 minutes on Day 1 of each 21 day cycle followed 30 minutes later by iv Cisplatin infused over 2 hours
3095382|NCT01868035|Experimental|Single Arm|tositumomab and iodine I-131 tositumomab
3468972|NCT03890809|Experimental|Moderate liver impairment|Single dose
3095383|NCT01868074|No Intervention|Usual|Participants who are not randomized to the fitted insole intervention
3095384|NCT01868074|Experimental|Insole|Participants randomized to use of a custom-molded insole during pregnancy
3095385|NCT01868165||Cohort of older adults taking antihypertensives|Adults aged 80 and over treated with antihypertensive drugs
3095386|NCT01868243|Experimental|Dabigatran|Dabigatran 110 mg BID
3095387|NCT01868243|Active Comparator|Warfarin|Warfarin adjusted-dose
3095388|NCT01868334|Experimental|Intervention with the Toolkit|"Pillar 1: Convenient Vaccination Services Pillar 2: Patient notification Pillar 3: Enhanced Office Systems Pillar 4: Motivation~13 clinical practices (intervention sites) will receive the Toolkit in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates. In Year 2, those who choose to continue will maintain use of the Toolkit and online resources available but will receive no active intervention from study staff."
3095389|NCT01868334|No Intervention|12 clinical practices (control sites)|12 diverse clinical practices will receive no additional assistance in Year 1 to increase their adult influenza, PPSV, Tdap/Td vaccination rates, they will follow guidelines for usual care. In Year 2 however they will become intervention sites and receive the 4 Pillars Toolkit for use in increasing vaccination rates
3095390|NCT01868425|Experimental|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|aggressive multimodal plus standard care, which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
3095391|NCT01868425|Placebo Comparator|placebo pills and injectables|standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane
3095392|NCT01868477|Experimental|Erythropoietin alpha|Patients will receive erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be switched to the combination arm. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study.
3095393|NCT01868477|Experimental|Deferasirox + Erythropoietin alpha|Patients will receive deferasirox dispersible tablet (DT) 10 mg/kg/day or deferasirox film-coated tablet (FCT) 7 mg/kg/day in combination with erythropoietin 40,000 units/week. If after 4 weeks erythroid improvement is inadequate, erythropoietin dose will be escalated to 60,000 units/week. If after 12 weeks of treatment, erythroid improvement in inadequate, patients will be discontinued from the study. At any time when erythroid response is achieved, erythropoietin treatment will be stopped until end of study. Patients will continue deferasirox treatment.
3095394|NCT01868503|Experimental|Lapatinib Plus Radiation Therapy|Patients receive lapatinib ditosylate PO QD on day 1 until completion of radiation therapy. Beginning on day 7, patients undergo radiation therapy for 5-7 weeks and will have their blood banked for laboratory biomarker analysis.
3095395|NCT01868542|Experimental|3-0-3 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial.During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values, the following insulin detemir dose adjustments were done : >6.1 mmol/L (>110 mg/dL) +3U insulin detemir, 4.4-6.1 mmol/L (80-100 mg/dL) No adjustment in insulin detemir, < 4.4 mmol/L (<80 mg/dL) -3U insulin detemir.
3095396|NCT01868542|Experimental|2-4-6-8 Algorithm|A once daily dosage of Insulin detemir (Levemir®) 100 U/mL 3 mL FlexPen® for subcutaneous administration was selected for this trial. During the treatment period insulin detemir was adjusted by the subject themselves (self-titration). Self-titration was performed every 3 days based on the lowest of three previous consecutive pre-breakfast SMPG values.Based on this glucose value, self-adjustment of insulin detemir dose was done. Metformin and Sulfonlylurea were allowed as OADs. For SMPG values , the following insulin detemir dose adjustments were done : >10.0 mmol/L (180 mg/dL) +8U insulin detemir, 9.1-10.0 mmol/L (163-180 mg/dL) +6U insulin detemir, 8.1-9.0 mmol/L (145-162 mg/dL) +4 U insulin detemir, 7.1-8.0 mmol/L (127-144 mg/dL) +2U insulin detemir, 6.1-7.0 mmol/L (109-126 mg/dL) +2U insulin detemir, 4.1-6.0 mmol/L (73-108 mg/dL) No adjustment in insulin detemir, 3.1-4.0 mmol/L (56-72 mg/dL) -2U insulin detemir, <3.1 mmol/L (<56 mg/dL) -4U insulin detemir.
3095397|NCT01868594|Experimental|Subetta group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included
3095398|NCT01868594|Placebo Comparator|Placebo group|Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.
3095399|NCT01868633|Active Comparator|Dexamethasone & spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 8mg (2ml) of Dexamethasone given intraoperatively
3095400|NCT01868633|Placebo Comparator|Placebo injection and spinal morphine|intrathecal morphine administered at time of spinal anesthesia. After cesarean delivery 2ml of placebo (Normal saline) drawn to mimic active drug given intraoperatively
3095401|NCT01868646|Experimental|Subetta|
3095402|NCT01868646|Placebo Comparator|Placebo|
3095403|NCT01868776|Experimental|buffered lidocaine|4% lidocaine with 1:100,000 epinephrine/0.18 mEq/mL sodium bicarbonate.
3095404|NCT01868776|Active Comparator|nonbuffered lidocaine|4% lidocaine with 1:100,000 epinephrine
3095405|NCT01868789|Experimental|Weightbearing CT (AAFD group)|Weightbearing CT scan of affected foot
3095406|NCT01868789|Active Comparator|Weightbearing CT (control group)|Weightbearing CT scan of normal foot
3095407|NCT01868893|Experimental|Obinutuzumab + Chlorambucil|Obinutuzumab was administered intravenously for 6 cycles (28-day cycles) as: 100 mg on Day 1, 900 mg on Day 2, and 1000 mg on Days 8 and 15 for Cycle 1; and 1000 mg on Day 1 of Cycles 2 to 6. Chlorambucil was administered orally at a dose of 0.5 mg/kg body weight on Days 1 and 15 for Cycles 1 through 6 (28-day cycles).
3095408|NCT01868997|Placebo Comparator|Placebo|A placebo infusion (normal saline) administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions.
3095409|NCT01868997|Experimental|Teprotumumab|Teprotumumab administered q3W by IV infusion over a period of 24 weeks for a total of 8 infusions. All participants start treatment at a dose of 10 mg/kg. At Week 3, the dose is escalated to 20 mg/kg and kept constant for the remainder of the study.
3095410|NCT01869075|Experimental|AMI - Knowledge Translation toolkit|AMI - Knowledge Translation (KT) toolkit includes use of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
3095411|NCT01869075|No Intervention|AMI - Usual Care|Usual care
3095412|NCT01869075|Experimental|MGS - Knowledge Translation Toolkit|Knowledge Translation toolkit involves use of pre-printed orders, audit and feedback, pharmacist as reminder and education of staff
3095413|NCT01869075|No Intervention|MGS - Usual Care|Usual Care
3095414|NCT01869075|Experimental|HFS - Knowledge Translation Toolkit|Knowledge Translation Toolkit consists of pre-printed orders, audit and feedback, pharmacist as a reminder and education of staff
3095415|NCT01869075|No Intervention|HFS - Usual Care|Usual Care
3095416|NCT01869192|Active Comparator|Arm A|Arm A: Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then surgery, then Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
3095417|NCT01869192|Active Comparator|Arm B|Arm B: Docetaxel 75 mg/m2 IV day 1 plus Capecitabine 1000 mg/m2/dose po bid x 14 days q 3 weeks for 4 cycles, then surgery, then Epirubicin 90 mg/m2 day 1 IV and Cyclophosphamide 600 mg/m2 day 1 IV q 3 weeks for 4 cycles, then radiation therapy as indicated. Post surgical chemotherapy must be initiated within 35 days after completion of definitive surgical treatment
3095418|NCT01869348|No Intervention|Wait list control|This group will receive no intervention until after data collection for the randomized trial is completed. Then, they will receive the monitor intervention.
3095419|NCT01869348|Experimental|Monitor intervention|This arm will receive the monitor intervention, including provision of a wristband activity monitor and mini-tablet as well as weekly counseling phone calls
3095420|NCT01869374|Experimental|Magnetic Seizure Therapy (MST)|MagVenture MagPro MST device
3095421|NCT01869374|Active Comparator|RUL ECT|Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
3095422|NCT01869439|Experimental|External wounds measured for length by width using a ruler|This is a single arm study of subjects who have an external wound that is currently measured for length and width using a ruler. A study subject may have up to 3 qualifying external wounds.
3095423|NCT01869634|Active Comparator|HIV positive naive to ART|HIV subjects will receive open-label darunavir 800 mg in combination with ritonavir 100 mg tablets and fixed-dose combination viread + emtricitabine (Truvada®) to be taken once daily without regard to food. Subjects will undergo upper endoscopy, CT cardiac angiogram, intimal-medial thickening, and peripheral blood collection before and after 12 months of ART.
3095424|NCT01869634|No Intervention|normal control volunteers|HIV negative age-matched controls will undergo the same interventions and procedures without receiving ART at study entry and after 12 months.
3095425|NCT01869647|Active Comparator|"high likelihood of stone group"|"Subjects in the high likelihood of stone group will be eligible to get either ULDCT or expectant management. The choice will be determined by the primary clinician in conjunction with the patient. If ULDCT is elected, the scan will be read diagnostically by the radiologist and the clinician will treat the patient based on these results. If the expectant management option is chosen, no CT will be done during the ED visit and they will be treated as if they have a kidney stone. Participants in this group will receive Ultra low dose CT scan."
3095426|NCT01869647|Active Comparator|"moderate likelihood of stone group"|"Subjects in the moderate likelihood of stone group will be given the option to receive either a standard dose CT or ULDCT. Again, the decision of which imaging option to choose will be made by the primary clinician in conjunction with the patient. Participants in this group will receive regular or low dose CT scan."
3095427|NCT01869647|Active Comparator|"low likelihood of stone group"|"In the low likelihood of stone group the RA will present the data from the stone score to the physician and explain that patient is unlikely to have a kidney stone and they will be advised that probability of a stone is very low and that alternate imaging choices may be warranted. If they still choose to order a CT Flank Pain Protocol they will be asked to provide reasoning and the patient will receive a regular dose CT Flank Pain Protocol. Participants in this group will not receive imaging."
3095428|NCT01869686|Experimental|Denosumab|single subcutaneous injection
3095429|NCT01869699|Placebo Comparator|Normal saline placebo|Normal saline 100 mLs intravenous, administered over 15 minutes
3095430|NCT01869699|Experimental|Acetaminophen|Acetaminophen 1 gram/100 mLs intravenous, single dose administered over 15 minutes
3095431|NCT01869725|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.
3095432|NCT01869764|Experimental|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid PO daily for 7-14 days.
3095433|NCT01869764|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 7-14 days.
3095434|NCT01869777|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment. Patients with AML undergo a second measurement just prior to the nadir marrow. Patients also undergo bioelectrical impedance measurements prior to any invasive procedures (bone marrow biopsy, leukapheresis, PICC line placement, etc.).
3095435|NCT01869959|Placebo Comparator|Placebo|Participants received placebo-matching LY2405319 injected subcutaneously (SC) once daily for 28 days.
3095436|NCT01869959|Experimental|3 mg LY2405319|Participants received 3 milligrams (mg) LY2405319 injected SC once daily for 28 days.
3095437|NCT01869959|Experimental|10 mg LY2405319|Participants received 10 mg LY2405319 injected SC once daily for 28 days.
3095438|NCT01869959|Experimental|20 mg LY2405319|Participants received 20 mg LY2405319 injected SC once daily for 28 days.
3095439|NCT01870076|Experimental|Healing Touch Intervention|Healing Touch performed one hour prior to bed.
3095440|NCT01870076|Sham Comparator|Healing Touch Sham|Healing Touch Sham provided one hour prior to bed.
3095441|NCT01870076|Active Comparator|Control, Presence|Control, Presence Intervention in the room one hour prior to bed.
3095442|NCT01870076|No Intervention|Control, No Presence|No Presence in the room one hour prior to bed.
3095443|NCT01870297|Experimental|LY3025876|Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
3095444|NCT01870297|Placebo Comparator|Placebo|Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
3095445|NCT01870297|Experimental|LY3025876 + Liraglutide|Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
3095446|NCT01870297|Placebo Comparator|Placebo + Liraglutide|Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
3095447|NCT01870388|Experimental|Baricitinib (Healthy)|Group 1: 4 milligrams (mg) baricitinib administered once, orally, to participants with normal hepatic function.
3095448|NCT01870388|Experimental|Baricitinib (Moderate)|Group 2: 4 mg baricitinib administered once, orally, to participants with moderate hepatic impairment.
3095449|NCT01870388|Experimental|Baricitinib (Mild)|Group 3: 4 mg baricitinib administered once, orally, to participants with mild hepatic impairment. Enrollment is contingent on data from Groups 1 and 2.
3095450|NCT01870401|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3095451|NCT01870401|Active Comparator|PTA Catheter|Standard Uncoated PTA Catheter
3095452|NCT01870583|Active Comparator|Combination iodine and chlorhexidine|The combincation skin preparation will utilize the iodine based preparation first followed by the chlorhexidine based skin preparation prior to cesarean delivery.
3095453|NCT01870583|Active Comparator|Chlorhexidine|Chlorhexidine based skin preparation solution applied to skin prior to cesarean delivery
3095454|NCT01870583|Active Comparator|Iodine povidone|Iodine povidone based skin preparation solution applied to skin prior to cesarean delivery
3095455|NCT01870596|Experimental|Arm A (cytarabine, Chk1 inhibitor SCH 900776)|Patients receive cytarabine IV continuously over 72 hours on days 1-3 and 10-12 and Chk1 inhibitor SCH 900776 IV over 30 minutes on days 2, 3, 11, and 12.
3095456|NCT01870596|Active Comparator|Arm B (cytarabine)|Patients receive cytarabine as in Arm A.
3095457|NCT01870726|Experimental|Phase Ib|To estimate the safe dose of the combination INC280 and buparlisib
3095458|NCT01870726|Experimental|Phase II|To estimate anti-tumor efficacy of INC280 single agent and in combination with buparlisib
3095459|NCT01870739|Experimental|sacubitril/valsartan (LCZ696)|"Single drug treatment period: Patients received LCZ696 200mg once daily (q.d.) + placebo to 20 mg olmesartan q.d for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (400 mg qd LCZ696 + placebo to 40 mg qd olmesartan) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
3095460|NCT01870739|Active Comparator|olmesartan|"Single drug treatment period: Patients received 20 mg olmesartan q.d + placebo to LCZ696 200mg once daily (q.d.) for 2 weeks. After 2 weeks, patients were dosed at the maintenance dose level (40 mg olmesartan q.d + placebo to 400 mg qd LCZ696) for 10 weeks.~Add-on Period: After 12 weeks on single-drug treatment, patients continued in the study on the blinded maintenance dose and if required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to the treatment regimen and titrated according to the investigator's discretion to achieve target blood pressure."
3095461|NCT01870778|Experimental|Serelaxin (RLX030)|Participants received continuous intravenous infusion of serelaxin 30 ug/kg/day for 48 hours.
3095462|NCT01870778|Placebo Comparator|Placebo|Participants received continuous intravenous infusion of matching placebo to serelaxin for 48 hours.
3095463|NCT01870843|Experimental|Escitalopram|Participants will receive escitalopram 10 mg per day for 1 week and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
3095464|NCT01870856|Experimental|Spectacles, Stage 1|Spectacles per participant's habitual perscription worn for 2 weeks
3095465|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 1|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3095466|NCT01870856|Experimental|DAILIES TOTAL1, Stage 2|Delefilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3095467|NCT01870856|Active Comparator|1-DAY ACUVUE, Stage 2|Etafilcon A contact lenses worn in both eyes at least 5 days per week, at least 6 hours per day, for 2 weeks in a daily disposable mode
3095468|NCT01870869|Experimental|Augmentation|Women who had breast augmentation with NATRELLE® 410 implants.
3095469|NCT01870869|Experimental|Reconstruction|Women who had breast reconstruction with NATRELLE® 410 implants.
3095470|NCT01870869|Experimental|Revision-Augmentation|Women who had revision of previous breast augmentation with NATRELLE® 410 implants.
3095471|NCT01870869|Experimental|Revision-Reconstruction|Women who had revision of previous breast reconstruction with NATRELLE® 410 implants.
3095472|NCT01870921|Experimental|Ticargrelor|90 mg/tablet, 1 tablet bid
3095473|NCT01870973|Experimental|root canal treatment|root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin, if allergic 300 mg clindamycin)
3095474|NCT01870973|Active Comparator|no root canal treatment|no root canal treatment, anesthesia with 2% lidocaine with 1:100,000 epinephrine, pain medication (1000 mg acetaminophen and 600 mg ibuprofen every 6 hours)five day supply, antibiotic (500 mg penicillin if allergic 300 mg clindamycin)
3095475|NCT01870999|Experimental|400 mg Aripiprazole IM Depot|400 mg aripiprazole IM (intramuscular) depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3095476|NCT01870999|Experimental|300 mg Aripiprazole IM Depot|300 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3468973|NCT03890809|Experimental|Severe liver impairment|Single dose
3095477|NCT01870999|Experimental|200 mg Aripiprazole IM depot|200 mg aripiprazole IM depot intramuscular injection once every 4 weeks for 5 months. All participants were on a stable dose of 10 mg aripiprazole tablets once daily in the morning for at least 14 days prior to randomization and continued 10 mg aripiprazole tablets once daily on days 1 to 14.
3095478|NCT01871077|Experimental|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
3095479|NCT01871090|Active Comparator|Interrogation with unpaired remote transmitter|Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
3095480|NCT01871090|No Intervention|Interrogation with programmer|Interrogation with programmer according to usual standard of care
3095481|NCT01871142|Experimental|Randomized crossover assignment|Participants will receive, in a random order, a placebo prior to exercise in normoxia, a placebo prior to exercise in hypoxia, 1000 mg of Aes-103 prior to exercise in hypoxia, and 3000 mg of Aes-103 prior to exercise in hypoxia. Each intervention is separated by a 7 day washout period.
3095482|NCT01871285|Experimental|MSE Dose Group 1|Morning and evening dose of buprenorphine HCl buccal film (300 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
3095483|NCT01871285|Experimental|MSE Dose Group 2|Morning and evening dose of buprenorphine HCl buccal film (450 μg) + placebo capsule in one period, and then placebo film + over-encapsulated ATC opioid (morphine sulfate or oxycodone) at 50% MSE daily dose in the alternate period
3095484|NCT01871402|Experimental|Active Arm|Topical lotion, applied twice daily
3095485|NCT01871402|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
3095486|NCT01871441|Experimental|Treatment (haploidentical allogeneic HSCT)|"Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28."
3095487|NCT01871506|Experimental|Standard Care (SC)|"Participants randomized to standard care (SC) will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice."
3095488|NCT01871506|Experimental|Intensive Counseling (IC)|"Participants randomized to intensive counseling (IC) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:~Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).~Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication [varenicline, bupropion, or combination NRT (patch + lozenge)] at no cost to the participant."
3095489|NCT01871519|Other|Balloon Kyphoplasty|This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.
3095490|NCT01871532|Experimental|Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International unit (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, with a final increase of 25 IU, up to maximum dose of 100 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
3095491|NCT01871532|Active Comparator|Standard Low Dose Gonal-f® Protocol|Gonal-f was administered subcutaneously daily at a starting dose of 50 International Units (IU) for Week 1, then dose was gradually increased by 12.5 IU for two weeks, up to maximum dose of 125 IU, until Week 4 for subjects with minimal response. After adequate follicular development was achieved, the subject was administration human chorionic gonadotropin (hCG) within 24-48 hours of last Gonal-f injection as per investigator discretion.
3095492|NCT01871545|Experimental|Magnetic Resonance Imaging|dynamic contrast-enhanced MRI measuring arterial and portal flow
3095493|NCT01871545|No Intervention|Healthy Controls|
3095494|NCT01871558|Active Comparator|SU+metformin + Basal Insulin|Randomized patient will remain on their previous dual therapy by SU+metformin, which will be kept unchanged, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
3095495|NCT01871558|Experimental|Metformin/vildagliptin + Basal Insulin|Randomized patient will receive Vildagliptin 50 mg twice daily (b.i.d) + continued therapy with Metformin, + start of Basal Insulin up-titrated as per usual algorithms primarily based on FPG
3095496|NCT01871805|Experimental|Alectinib: Phase I (Dose Escalation)|Participants will receive escalating doses of alectinib capsules orally until disease progression, death or withdrawal for any other reasons.
3095497|NCT01871805|Experimental|Alectinib (Phase II: RP2 dose)|Participants will receive recommended Phase II dose as determined from Phase I until disease progression, death or withdrawal for any other reasons.
3095498|NCT01871870|Experimental|Artificial Pancreas Control Software|Type 1 Diabetes Mellitus subjects who fit the inclusion/exclusion criteria will undergo artificial pancreas closed-loop study for 28 hours. For the entire study, the adaptive component of Artificial Pancreas Control Software will be used to control the subject's blood glucose.
3095499|NCT01872078|Experimental|AZD4901 20 mg once a day|AZD4901 20 mg once a day
3095500|NCT01872078|Experimental|AZD4901 20mg twice a day|AZD4901 20mg twice a day
3095501|NCT01872078|Experimental|AZD4901 40 mg twice a day|AZD4901 40 mg twice a day
3095502|NCT01872078|Experimental|Placebo to match AZD4901|
3095503|NCT01872325||Training site|All emergency medical dispatchers at a central ambulance communication centre in Ontario will participate in an educational program designed to improve cardiac arrest diagnostic accuracy.
3095504|NCT01872325||Control site|All emergency medical dispatchers at a central ambulance communications centre geographically remote from the Training Site and has a similar rate to the Training Site for cardiac arrests, bystander CPR rate, and survival
3095505|NCT01872338|Active Comparator|Mindfulness-Based Cognitive Therapy + Treatment As Usual|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
3095506|NCT01872338|Other|Treatment As Usual|VA standard care for suicide prevention
3095507|NCT01872611|Experimental|Nepafenac|With prednisolone acetate standard of care, Nepafenac Ophthalmic Suspension, 0.3%, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3095508|NCT01872611|Placebo Comparator|Vehicle|With prednisolone acetate standard of care, Nepafenac vehicle, 1 drop instilled in the operative eye 1 day prior to surgery, continuing on the day of surgery, and for 90 days following surgery. An additional 1 drop will be administered 30 to 120 minutes prior to surgery.
3095509|NCT01872689|Placebo Comparator|Monotherapy (Cohort A): Placebo|Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
3095510|NCT01872689|Experimental|Monotherapy (Cohort A): Lebrikizumab|Participants will receive monotherapy with lebrikizumab at a dose of 250 milligrams (mg) administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
3095511|NCT01872689|Placebo Comparator|Combination Therapy (Cohort B): Placebo + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at maximum tolerated dose (MTD) administered orally along with placebo matched to lebrikizumab administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
3095512|NCT01872689|Experimental|Combination Therapy (Cohort B): Lebrikizumab + Pirfenidone|Participants will receive pirfenidone at a stable dose of 2403 mg per day (three 267 mg capsules three times a day [9 capsules daily] for a total of 2403 mg/day) or at MTD administered orally along with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period.
3095513|NCT01872715|Experimental|Oracea|"Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.~Oral dose for 12 weeks"
3095514|NCT01872819|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive 1 of 160 possible interventions based on high throughput drug sensitivity assay.
3095515|NCT01872910|Placebo Comparator|Placebo|"Part A: Single oral administration of placebo matching corresponding LY3023703 dose administered orally once as a capsule post dental surgery.~Part B: Single oral administration of placebo matching corresponding LY3023703 administered orally once as a capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3095516|NCT01872910|Experimental|30 milligrams (mg) LY3023703|"Part A: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-milligrams (mg) capsule post dental surgery.~Part B: Single oral administration of 30 milligrams (mg) LY3023703 administered orally once as a 30-mg capsule, post dental surgery and post dialysate probe placement.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3095517|NCT01872910|Active Comparator|400 mg Celecoxib|"Part A: Single oral administration of 400 mg celecoxib (Positive control) administered orally once as two 200-mg capsules post dental surgery (Positive control).~Participants received two 200-mg celecoxib capsules during Pre-Part B.The purpose of Pre-Part B was to develop proficiency in the dialysate placement, collection, and maintenance techniques before moving to Part B.~Celecoxib was not administered in Part B.~Part B of this study assessed whether LY3023703 selectively inhibited the prostaglandin E(PGE) surge in the wound dialysate during the postoperative period."
3095518|NCT01873417|Experimental|Dimethyl Fumarate|120 mg DMF twice daily (BID) for the first 7 days and 240 mg DMF BID thereafter for 12 weeks of treatment. Participants will be instructed to take the DMF dose with food (with a meal or within 1 hour after a meal).
3095519|NCT01873495|Experimental|Omacetaxine: Consolidation/Maintenance|
3095520|NCT01873586|Experimental|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold (posterolateral gutter at the symptomatic side)
3095521|NCT01873586|Active Comparator|Local autograft|Local autograft (posterolateral gutter at the contralateral side)
3095522|NCT01873729|Experimental|Naltrexone|Naltrexone
3095523|NCT01873742|Experimental|The use of STIC feedback system|This will constitute the experimental condition, using of STIC feedback system.
3095524|NCT01873742|Experimental|Treatment as usual|This condition will not include the use of the STIC feedback system.
3095525|NCT01873846|Experimental|Silicone Hydrogel Contact Lens|Contact lenses to be worn in each eye on a daily wear basis for 2 weeks. Participants will be provided with Bausch + Lomb Biotrue® multi-purpose solution and contact lens cases for daily rinsing, cleaning, disinfecting, and storing their lenses.
3095526|NCT01873859|Active Comparator|On-metformin|Diabetic patients receiving contrast media without discontinuing metformin.
3095527|NCT01873859|No Intervention|Off-metformin|Diabetic patients receiving contrast media with discontinuation of metformin.
3095528|NCT01873950|Experimental|Ranolazine 1500mg|Ranolazine
3095529|NCT01873950|Experimental|Dofetilide 500mcg|Dofetilide
3095530|NCT01873950|Experimental|Verapamil HCl 120 mg|Verapamil
3095531|NCT01873950|Experimental|Quinidine sulfate 400mg|Quinidine sulfate
3095532|NCT01873950|Placebo Comparator|Placebo|Placebo
3095533|NCT01873989|Experimental|Testosterone replacement|Testosterone replacement for hypogonadism.
3095534|NCT01873989|Other|Waitlist control|This arm involves watchful waiting.
3095535|NCT01874054|Experimental|Brentuximab Vedotin + Bendamustine|Brentuximab vedotin 1.8 mg/kg every 3 weeks for up to 16 cycles by IV infusion and bendamustine 90 mg/m2 on Days 1 and 2 every 3 weeks by IV infusion for up to 6 cycles
3095536|NCT01874119|Experimental|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
3095537|NCT01874119|Placebo Comparator|Placebo|During placebo admission, intravenous 0.9% saline every 48 hours during 6-day hospital admission
3095538|NCT01874132|Experimental|Aerobic exercise training|Dose response
3095539|NCT01874132|Experimental|Aerobic and resistance exercise training|Dose response
3095540|NCT01874132|No Intervention|Control|Non-exercising control group
3095541|NCT01874145|Active Comparator|GA 20 mg/mL every day|Glatiramer acetate (GA) 20 mg in 1 mL SC injection administered every day (QD) for the 4 months of the core study.
3095542|NCT01874145|Experimental|GA 40 mg/mL 3 times a week|"Glatiramer acetate (GA) 40 mg in 1 mL SC injection administered three times a week (TIW) for the 4 months of the core study.~During the Extension period, all participants to continue treatment with GA 40 mg/mL TIW until this dose regimen is commercially available for the treatment of RRMS patients."
3095543|NCT01874262|Experimental|Active group|The software application used on the patients' smart phones in the active group, will contain both the e-diary and the mobile-phone based patient support. Patients will receive feedback by the mobile-phone based support not only on the data they enter into the mobile-phone based patient support but also on their reported daily ticagrelor use.
3095544|NCT01874262|Placebo Comparator|The control group|In this group the patients will have access to the e-diary only, in which they will report their daily use of ticagrelor. The patients in the control group will not receive any feed-back.
3095545|NCT01874275|Experimental|VECTTOR|nerve stimulator treatment twice daily for duration of study - 365 days
3095546|NCT01874275|Placebo Comparator|Device - sham|placebo treatment - no electrical stimulation treatment twice daily for duration of study, 180 days - if VECTTOR arm experiencing improvement, subjects in Device-Sham arm will be crossed over into the VECTTOR group and followed for an additional 180 days, for a total study involvement (duration) of 365 days>
3095547|NCT01874288|Experimental|DI-Leu16-IL2 0.5 mg/m^2|Participants will receive DI-Leu16-IL2 0.5 mg/m^2 subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
3095548|NCT01874288|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
3095549|NCT01874288|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
3095550|NCT01874288|Experimental|DI-Leu16-IL2 4.0 mg/m^2|Participants will receive DI-Leu16-IL2 4.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles
3095551|NCT01874288|Experimental|DI-Leu16-IL2 6.0 mg/m^2|Participants will receive DI-Leu16-IL2 6.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle) for a total of 4 cycles.
3095552|NCT01874340|Experimental|AIN457 low dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 low dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
3095553|NCT01874340|Placebo Comparator|Placebo|Matching placebo will be administered intravenously. Approximately 105 patients will be randomized to placebo (65 in Stage 1 and 40 in Stage 2).
3095554|NCT01874340|Experimental|AIN457 middle dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 middle dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis
3095555|NCT01874340|Experimental|AIN457 high dose|AIN457 will be administered intravenously. Approximately 65 patients will be randomized to AIN457 high dose in Stage 1. An additional 40 patients may be randomized to this group if it is one of the two selected dose groups to be expanded for Stage 2 following an Interim Analysis.
3095556|NCT01874392|Experimental|T1DM|Adults aged 21-65 years with type 1 diabetes mellitus for at least one year who are using an insulin infusion pump with rapid-acting insulin for at least six months
3095557|NCT01874431|Experimental|Finerenone (BAY94-8862) (1.25 mg)|1.25 mg dose oral once daily for 90 days
3095558|NCT01874431|Experimental|Finerenone (BAY94-8862)(2.5 mg)|2.5 mg dose oral once daily for 90 days
3095559|NCT01874431|Experimental|Finerenone (BAY94-8862)(5 mg)|5 mg dose oral once daily for 90 days
3095560|NCT01874431|Experimental|Finerenone (BAY94-8862)(7.5 mg)|7.5 mg dose oral once daily for 90 days
3095561|NCT01874431|Experimental|Finerenone (BAY94-8862) (10 mg)|10 mg dose oral once daily for 90 days
3095562|NCT01874431|Experimental|Finerenone (BAY94-8862) (15 mg)|15 mg dose oral once daily for 90 days
3095563|NCT01874431|Experimental|Finerenone (BAY94-8862)(20 mg)|20 mg dose oral once daily for 90 days
3095564|NCT01874431|Placebo Comparator|Placebo|Placebo oral dose once daily for 90 days
3095565|NCT01874535|Active Comparator|GERD Los Angeles A and B-4 week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 4 week group
3095566|NCT01874535|Active Comparator|GERD Los Angeles A and B-8-week group|Patients with Los Angeles A and B esophagitis prescribed with esomeprazole (40 mg)daily- 8 week group
3095567|NCT01874665|Experimental|Cohort A|Participants with KIT exon 11-mutant GIST.
3095568|NCT01874665|Experimental|Cohort B|Participants with GIST that lack KIT exon 11 mutations (Cohort B).
3095569|NCT01874756|Experimental|LY500307 150mg|LY500307 150mg
3095570|NCT01874756|Placebo Comparator|placebo|placebo 6 pills of inactive drug
3095571|NCT01874756|Experimental|LY500307 75mg|LY500307 75mg
3095572|NCT01874756|Experimental|LY500307 25mg|LY500307 25mg
3095573|NCT01874951|Placebo Comparator|Placebo|In this arm, patients will receive placebo for three weeks.
3095574|NCT01874951|Experimental|Naltrexone|In this arm, patients will receive low dose naltrexone for three weeks.
3095575|NCT01875159|Experimental|Caffeine|Caffeine citrate 6 mg/kg/day
3095576|NCT01875159|No Intervention|Active Comparator: no caffeine|Compare extended use of caffeine citrate 6 mg/kg/day to no caffeine (usual care) in regard to extent of intermittent hypoxia from 35 weeks postmenstrual age (PMA) to 40 weeks PMA.
3132593|NCT03439189|Experimental|Emricasan 50mg|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day. The MBT will be performed at screening, at week 24/ week 48/ at early termination.
3095578|NCT01875237|Experimental|Stem Cell Transplant + Modified T-Cells + Chemotherapy|The first component is stem cell transplant. Goal is to administer more than 3 x 106 CD34+ cells/kg of peripheral blood progenitor cells (PBPC). The second component is the planned DLI infusion. iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64. The transplant day is referred to as day zero (D0), treatment plan activities prior or after D0 are denoted as day minus (D-) or day plus (D+). Patients receive standard reduced intensity regimen using fludarabine, melphalan, and alemtuzumab to achieve engraftment with a low risk of GVHD. At approximately 60 days post transplant patients who are alive and without GVHD, receive DLI to enhance graft-vs.-malignancy and immune reconstitution.
3095579|NCT01875250|Experimental|Arm A - Enzalutamide for 3 months|Enzalutamide for 3 months
3095580|NCT01875250|Experimental|Arm B - Enzalutamide for 3 months + PSA-TRICOM|Enzalutamide 3 months + PSA-TRICOM (Prostvac-V/F) on weeks 1, 3, 5, 9,13,17 and 21
3095581|NCT01875367|Experimental|Arm A: T-IV + T-SC vial + T-SC device|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
3095582|NCT01875367|Experimental|Arm B: T-IV + T-SC device + T-SC vial|Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.
3095583|NCT01875445|Placebo Comparator|Placebo|Matched dosage of inositol daily.
3095584|NCT01875445|Active Comparator|Inositol|Powder form, 2g TID up to 6g TID
3095585|NCT01875471|Active Comparator|delefilcon A|Spherical daily disposable soft contact lens
3095586|NCT01875471|Experimental|narafilcon A|Spherical daily disposable soft contact lens Class 1 UV blocking
3095587|NCT01875510|Active Comparator|Fish-oil emulsions|Fish-oil emulsions:Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg.
3095588|NCT01875510|Placebo Comparator|soybean-oil emulsion|Preterm infants will receive a soybean-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and the third day and after 3gr/kg
3095589|NCT01875731|Experimental|BPS (Bacterial Pneumonia Score)|Strategy based on BPS guided antibiotic use
3095590|NCT01875731|Active Comparator|Guideline|Strategy based on enforced guideline guided antibiotic use
3095591|NCT01875783|Experimental|OCT imaging|All study participants will undergo optical coherence tomography imaging and will be referred to a retina specialist for further standard care evaluation and management if they are identified as having diabetic macular edema or the scan quality is not sufficient to evaluate macular status.
3095592|NCT01875848|Experimental|buprenorphine/naloxone|induction onto buprenorphine/naloxone from opioid treatment
3095593|NCT01875848|Active Comparator|opioid dose escalation|increase of up to 25% of current opioid dose
3095594|NCT01875861|Experimental|Intervention|Evidence-Based Quality Improvement plus external facilitation to promote uptake of quality improvement tools and improvement strategies available as part of a national initiative (the MIAMI Project) to disseminate recommendations, tools, and improvement strategies relevant to metabolic monitoring and management.
3095595|NCT01875861|No Intervention|Comparison|"Usual care, in the context of the MIAMI Project."
3095596|NCT01875874|Experimental|ELAD plus standard of care|Continuous ELAD treatment for a minimum of 3 days to a maximum of 10 days in addition to a standard of care for subjects with acute liver failure.
3095597|NCT01875978|Active Comparator|Phytosterols & placebo|Group A:daily 1.8g phytosterols powder for 4 weeks first;group B:placebo for 4 weeks first
3095598|NCT01875991|Experimental|Autoinjector A|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector A for 4 weeks.
3095599|NCT01875991|Experimental|Autoinjector B|Participants self-injected 50 mg etanercept once a week (RA) or twice a week (PsO) using Autoinjector B for 4 weeks.
3095600|NCT01876043|Experimental|plitidepsin|plitidepsin
3095601|NCT01876082|Experimental|PAZOPANIB|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
3095602|NCT01876082|Active Comparator|Vinblastine and Methotrexate|vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
3095603|NCT01876212|Experimental|Vaccine + dasatinib|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 2, day 1 (week 5).~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
3095604|NCT01876212|Experimental|Vaccine + dasatinib from cycle 1|"Patients will start vaccine on cycle 1, day 1 and dasatinib on cycle 1, day 1.~All patients will receive dasatinib at a starting dose of 70 mg twice daily by mouth in the outpatient setting. Dasatinib will be supplied as 50 mg and 20 mg tablets. Patients will take 1 of the 50 mg tablets and 1 of the 20 mg tablets twice daily, approximately every 12 hours, at the same time each day.~The DC vaccine will be administered by a single intradermal injection of approximately 10e7 cells, with all the DCs being administered on days 1 and 15 of each cycle. The intradermal administration will be in the vicinity of the four nodal drainage groups of the four extremities."
3095605|NCT01876251|Experimental|PF-03084014 plus docetaxel|PF 03084014 will be administered orally, continuously, twice daily at doses from 80 to 150 mg in combination with docetaxel given every 3 weeks at doses from 75 to 100 mg/m^2
3095606|NCT01876329||Rheumatoid Arthritis|Patients with seropositive or seronegative Rheumatoid Arthritis
3095607|NCT01876329||Autoimmune Thyroid Disease (AITD)|Participants with autoimmune thyroid disease without other known systemic or organ specific autoimmune illnesses.
3095608|NCT01876329||Control|Participants without Rheumatoid Arthritis, AITD, or other systemic or organ specific autoimmune illnesses
3095609|NCT01876368|Experimental|LCZ696 200 mg|Patients will be treated with one LCZ696 200 mg tablet and one placebo of olmesartan 20 mg capsule once daily for 8 weeks.
3095610|NCT01876368|Active Comparator|Olmesartan 20 mg|Patients will be treated with one placebo of LCZ696 200 mg tablet and one olmesartan 20 mg capsule once daily for 8 weeks.
3095611|NCT01876381|Experimental|OPC-41061|
3095612|NCT01876420|Experimental|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
3095613|NCT01876446|Experimental|Treatment (pegylated irinotecan NKTR 102)|Patients receive pegylated irinotecan NKTR 102 IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
3095614|NCT01876485|Experimental|Arm 1: Empowering Patients in Chronic Care (EPIC)|Patients in the intervention arm will receive the Empowering Patients in Chronic Care group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
3095615|NCT01876485|Active Comparator|Arm 2: Enhanced Usual Care (EUC)|The Enhanced Usual Care (EUC) arm will serve as a concurrent control group to compare to the intervention arm of the study. Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
3095616|NCT01876511|Experimental|Cohort A: MSI Positive Colorectal Cancer|
3095617|NCT01876511|Experimental|Cohort B: MSI Negative Colorectal Cancer|
3095618|NCT01876511|Experimental|Cohort C: MSI Positive Non-Colorectal Cancer|
3095619|NCT01876706|Experimental|UroLift® System|Single-arm of qualified subjects receiving UroLift® System intervention.
3095620|NCT01876732|Experimental|Vitamin B12|Those with an MMA over 800nmol/L are given 1000mcg of intramuscular (IM) vitamin B12 weekly for the first month and then monthly for 3 consecutive months.
3095621|NCT01876784|Experimental|Vandetanib|Vandetanib 300 mg tablet, orally once daily until disease progression or death.
3095622|NCT01876784|Placebo Comparator|Placebo|Placebo matched to vandetanib tablet, orally once daily until disease progression or death.
3095623|NCT01876810|Experimental|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
3095624|NCT01876810|Placebo Comparator|Placebo pill|One lactose pill twice a day for two weeks.
3095625|NCT01876823|Experimental|es-citalopram and Memantine Treatment|concurrent es-citalopram plus memantine were administered for 48 weeks.
3095626|NCT01876901|Experimental|2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA)|Patients treated with 2-stage pull-through colo-anal anastomosis without prophylactic derivation (2SCA) in centers who routinely performing this intervention.
3095627|NCT01876901|Experimental|Colo-anal anastomosis (CAA)|Patients operated with colo-anal anastomosis (CAA) in centers who routinely performing this intervention.
3095628|NCT01876953|Experimental|Dasatinib 100mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
3095629|NCT01876953|Experimental|Dasatinib 140mg/day + Cytarabine 200mg/m2/day + Idarubicin 12mg/m2/day|Patients receive cytarabine IV continuously over 168 hours on days 1-7, dasatinib PO QD on days 1-7, and idarubicin hydrochloride IV on days 1-3. Patients with non-responsive disease on day 30 may receive a second course of therapy (re-induction therapy) within 1 week in the absence of unacceptable toxicity.
3095630|NCT01876979|Active Comparator|IMF Screws|Use of IMF screws as a means to wire the jaws.
3095631|NCT01876979|Active Comparator|Erich Arch Bars|Use of Erich Arch bars in the wiring of the jaws.
3095632|NCT01876992|Experimental|Metformin|"Doses will be increased incrementally. Decisions to escalate the metformin dose will be made based upon tolerability of side effects as described in the schedule of evaluations to follow. All subjects will be monitored for safety while receiving metformin. Any participant with blood glucose of <60mg/dl at any time while receiving metformin will have therapy stopped and will be withdrawn from the study.~For children <50kg:~Baseline:250mg po qd, Week 2:250mg po bid, Week 4:500mg po am/250mg po pm, Week 8:500mg po bid.~For children ≥50kg:~Baseline:500mg po qd, Week 2:500mg po bid, Week 4:1000mg po am/500mg po pm, Week 8:1000mg po bid.~For adults:~Baseline:500mg po qd,Week2:500mg po bid,Week 4:1000mg po am/500mg po pm,Week 8:1000mg po bid."
3095633|NCT01876992|No Intervention|Obese Controls|"Three obese but otherwise healthy adult participants will be recruited into the study as controls. These will be individuals who are not currently (or previously) on any diabetic medication including metformin.~There will be a single study visit and no medication will be administered. They will be administered a meal and pre and post-prandial blood samples will be drawn."
3095634|NCT01877083|Experimental|Lenvatinib|
3095635|NCT01877148|Experimental|Physiotherapy + anodal tDCS|The patients will be submit to anodal tDCS applied in the motor cortex and after the patient will be submit to a 30 minutes of physiotherapy protocol.
3095636|NCT01877148|Sham Comparator|Physiotherapy + sham tDCS|The patients will be submit to sham tDCS and after the patient will be submit to a 30 minutes of physiotherapy protocol.
3095637|NCT01877161|Experimental|Middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
3095638|NCT01877161|Sham Comparator|Control group|Repetitive magnetic stimulation (Sham)
3095639|NCT01877161|Experimental|Superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
3095640|NCT01877187|Other|Lipiodol|Lipiodol, 10cc per TACE.
3095641|NCT01877239||Full Analysis Set|Full Analysis Set (FAS): The FAS contains any patient that has given written informed consent.
3095642|NCT01877265|Experimental|LY2605541 - Source 1|Each healthy participant will receive a single subcutaneous (SC) injection of 0.5 units per kilogram (U/kg) of LY2605541 on Day 1 of 1 of 3 treatment periods
3095643|NCT01877265|Experimental|LY2605541 - Source 2|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1of 3 treatment periods
3095644|NCT01877265|Experimental|LY2605541 - Source 3|Each healthy participant will receive single SC injection of 0.5 U/kg of LY2605541 on Day 1 of 1 of 3 treatment periods
3095645|NCT01877278|Active Comparator|active|Group wearing the active device emitting pulsed electromagnetic fileds
3095646|NCT01877278|Placebo Comparator|placebo|Group wearing the device non-emitting pulsed electromagnetic fileds
3095647|NCT01877408|Active Comparator|Open surgical circumcision|The open surgical technique, which is commonly used for circumcision in South Africa, requires good surgical skills and minor complications are common.
3095648|NCT01877408|Experimental|Unicirc device with tissue adhesive|Coupling removal of the foreskin using the disposable Unicirc device with wound sealing using tissue adhesive results in a procedure that can be performed by generalist doctors with minimal training.
3095649|NCT01877421|Experimental|2 mg KSL-W (Phase 1, 1a)|one 2 mg KSL-W tablet at day 0 at Phase 1
3095650|NCT01877421|Experimental|4 mg KSL-W (Phase 1, 2a; Phase 2a, 1b)|one 4 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. one 4 mg KSL-W tablet on days 1-6; two 4 mg KSL-W tablets on days 7-13 and days 14-20; and three 4 mg tablets at days 21-27 at Phase 2a.
3095651|NCT01877421|Experimental|6 mg KSL-W (Phase 1, 3a; Phase 2a, 2b)|One 6 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 6 mg KSL-W tablet on days 1-6; two 6 mg KSL-W tablets on days 7-13 and days 14-20; and three 6 mg tablets at days 21-27 at Phase 2a.
3095652|NCT01877421|Experimental|10 mg KSL-W (Phase 1, 4a; Phase 2a, 3b)|One 10 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 10 mg KSL-W tablet on days 1-6; two 10 mg KSL-W tablets on days 7-13 and days 14-20; and three 10 mg tablets at days 21-27 at Phase 2a.
3095653|NCT01877421|Experimental|20 mg KSL-W (Phase 1, 5a; Phase 2a, 4b)|One 20 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 20 mg KSL-W tablet on days 1-6; two 20 mg KSL-W tablets on days 7-13 and days 14-20; and three 20 mg tablets at days 21-27 at Phase 2a.
3095654|NCT01877421|Experimental|30 mg KSL-W (Phase 1, 6a; Phase 2a, 5b)|One 30 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 30 mg KSL-W tablet on days 1-6; two 30 mg KSL-W tablets on days 7-13 and days 14-20; and three 30 mg tablets at days 21-27 at Phase 2a.
3095655|NCT01877421|Experimental|50 mg KSL-W (Phase 1, 7a; Phase 2a, 6b)|One 50 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 50 mg KSL-W tablet on days 1-6; two 50 mg KSL-W tablets on days 7-13 and days 14-20; and three 50 mg tablets at days 21-27 at Phase 2a.
3095656|NCT01877421|Experimental|75 mg KSL-W (Phase 1, 8a; Phase 2a, 7b)|One 75 mg KSL-W tablet on day 0 at both Phase 1 and Phase 2a. One 75 mg KSL-W tablet on days 1-6; two 75 mg KSL-W tablets on days 7-13 and days 14-20; and three 75 mg tablets at days 21-27 at Phase 2a.
3095657|NCT01877421|Experimental|100 mg KSL-W (Phase 1, 9a)|one 100 mg KSL-W tablet at day 0 at Phase 1
3095658|NCT01877421|Placebo Comparator|Placebo|Placebo
3095659|NCT01877538||[11C]donepezil PET|[11C]donepezil is a radiopharmaceutical. It is evaluated whether the binding of [11C]donepezil in various peripheral tissues is in accordance with known distribution of the parasympathetic nervous system.
3095660|NCT01877551|Active Comparator|tauroursodeoxycholic acid|This group will receive 1.75 grams per day of tauroursodeoxycholic acid given once daily for 30 days.
3095661|NCT01877551|Placebo Comparator|placebo|This group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
3095662|NCT01877642|Other|Open Label (lorazepam 1 mg + Inhaled loxapine 10 mg)|Inhaled Staccato loxapine 10 mg + IM lorazepam 1 mg to confirm tolerability of combined treatment
3095663|NCT01877642|Other|Treatment Sequence ABC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3095664|NCT01877642|Other|Treatment Sequence ACB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3095665|NCT01877642|Other|Treatment Sequence BCA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3095666|NCT01877642|Other|Treatment Sequence BAC|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3095667|NCT01877642|Other|Treatment Sequence CAB|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3095668|NCT01877642|Other|Treatment Sequence CBA|Treatment: A = Lorazepam 1 mg IM + inhaled placebo, B = Lorazepam 1 mg IM + inhaled loxapine 10 mg, C= Placebo IM + inhaled loxapine 10 mg
3468974|NCT03890692|Experimental|patients will undergo flexible nasoendoscopy|Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists
3095671|NCT01877668|Experimental|Tofacitinib 5 mgBID x 12 months|
3095672|NCT01877668|Experimental|Tofacitinib 10 mg BID x 12 months|
3095673|NCT01877668|Active Comparator|Adalimumab 40 mg q2 weeks x 12 months|
3095674|NCT01877668|Placebo Comparator|Placebo x3 months, then tofacitinib 5 mg BIDx 9 months|
3095675|NCT01877668|Placebo Comparator|Placebo x 3 months, then tofacitinib 10 mg BID x 9 months|
3095676|NCT01877720|Experimental|NAVA-PS|noninvasive NAVA first for 15 minutes and then PSV for 15 minutes
3095677|NCT01877720|Experimental|PS-NAVA|noninvasive PSV first for 15 minutes and then NAVA for 15 minutes
3095678|NCT01877915|Experimental|Rivaroxaban 2.5 mg|Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
3095679|NCT01877915|Placebo Comparator|Placebo|Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
3095680|NCT01877941|Active Comparator|Cardiac output monitoring|Patients undergoing surgery who will have their cardiac output monitored by pulmonary artery catheter (PAC) and endotracheal cardiac output monitoring (ECOM) during surgery and during post-surgical recovery, will also have sensors placed on the arm, finger and leg to calculate pulse wave transit time (PWTT) using the estimated Continuous Cardiac Output system (ecCCO).
3095681|NCT01878006|Experimental|Morphine|Morphine injection 10 mg/70kg
3095682|NCT01878006|Placebo Comparator|Placebo|Saline injection
3095683|NCT01878084|Other|all study participants|"This study represents a split-mouth study where the right or left/ upper or lower premolar could be assigned to either the control group (socket left empty) or test group (socket filled with bioactive glass (sol-gel)~The extraction sockets will be allocated either to the control : Extraction socket will be left empty~or~Test: Extraction socket will be augmented using bioactive glass (sol-gel)"
3095684|NCT01878097|Experimental|Green Dot Bystander Training|Green Dot intervention
3095685|NCT01878097|Active Comparator|Control|Awareness Eduation
3095686|NCT01878149||VEO® Lateral Access and Interbody Fusion System|
3095687|NCT01878149||eXtreme Lumbar Interbody Fusion (XLIF®)|
3095688|NCT01878175|Experimental|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
3095689|NCT01878214|Experimental|Intervention group|Targeted messaging
3095690|NCT01878214|Active Comparator|Control group|Standard messaging
3095691|NCT01878253|Experimental|Investigational|This arm will include all subjects who are implanted with the investigational Sidus Stem-Free Total Shoulder Arthroplasty System.
3095692|NCT01878292|Placebo Comparator|Placebo|Dose-matched placebo tablets, once per day, oral administration
3095693|NCT01878292|Experimental|Vilazodone 15 mg|15 mg vilazodone tablets, once per day, oral administration
3095694|NCT01878292|Experimental|vilazodone 30 mg|30 mg vilazodone tablets, once per day, oral administration
3095695|NCT01878383||Non-pregnant women/active HSV lesions|Women presenting to local health department
3095696|NCT01878383||Pregnant women/no active HSV lesions|Women presenting in active labor
3095697|NCT01878526|Experimental|Omeprazole plus alginic acid and placebo of domperidone|
3095698|NCT01878526|Experimental|Omeprazole plus domperidone and placebo of alginic acid|
3095699|NCT01878604||Homozygous Familial Hypercholesterolemia|Gene Analysis for Homozygous Familial Hypercholesterolemia cases
3095700|NCT01878656|Active Comparator|Sevoflurane|administration of sevoflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
3095701|NCT01878656|Active Comparator|Desflurane|administration of desflurane with oxygen and nitrous oxide as same ratio of 3 L/min for maintenance of general anesthesia
3095702|NCT01878799|Experimental|HIV|Subjects with HIV and HCV
3095703|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Adult Group|Subjects 18-60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
3095704|NCT01878812|Experimental|Fluarix/Influsplit Tetra® Elderly Group|Subjects >60 years of age receiving Fluarix/Influsplit Tetra® 2013-2014, administered intramuscularly in the deltoid region of the non-dominant arm.
3095705|NCT01878825|Experimental|Fluviral 18-60 Years Group|Subjects aged between 18 and 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.
3095706|NCT01878825|Experimental|Fluviral >60 Years Group|Subjects aged > 60 years, received 1 dose of Fluviral™ vaccine on Day 0. The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm
3095707|NCT01878890|Experimental|Efavirenz: 600 mg|Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
3095708|NCT01878890|Experimental|Efavirenz: 1200 mg|Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
3095709|NCT01878890|Experimental|Efavirenz: 1800 mg|Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
3095710|NCT01878890|Experimental|Efavirenz: 2200 mg|Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
3095711|NCT01879059|Experimental|Exercise|5 days of inactivity followed by a 1 day return to physical activity
3095712|NCT01879176|Experimental|CytoSorb|For the intervention group, the CytoSorb filter will be installed on the CPB machine in a parallel circuit to the body circulation. The flow through the filter will be driven by a roller pump with 200ml.min-1 .
3095713|NCT01879176|No Intervention|Control|No filter will be installed on the CPB machine.
3095714|NCT01879319|Experimental|Evolocumab AMD|Participants received evolocumab 420 mg once a month subcutaneously using an automated mini-doser (AMD) (one 3.5 mL injection) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
3095715|NCT01879319|Experimental|Evolocumab AI/pen|Participants received evolocumab 420 mg once a month subcutaneously using an autoinjector/pen (AI/pen) (three 1.0 mL injections) for 8 weeks (Day 1, Week 4, and Week 8). Participants self-administered evolocumab in the clinic on Day 1 under supervision and then self-administered in a home setting at Weeks 4 and 8.
3095716|NCT01879332|Placebo Comparator|Placebo|Matching placebo tablets for oral administration
3095717|NCT01879332|Experimental|BIA 2-093 3000 mg once daily|Subjects in Cohort 2 received a dose of 3000 mg once daily (5 x 600 mg eslicarbazepine acetate tablets)
3095718|NCT01879332|Experimental|BIA 2-093 3600 mg once daily|Subjects in Cohort 1 received a dose of 3600 mg once daily (6 x 600 mg eslicarbazepine acetate tablets)
3095719|NCT01879345|Experimental|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093 600 mg
3095720|NCT01879345|Experimental|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
3095721|NCT01879345|Placebo Comparator|Placebo|placebo tablets
3095722|NCT01879371|Active Comparator|Ibuprofen (Brufen®)|film-coated tablet
3095723|NCT01879371|Active Comparator|Ibuprofen (Nurofen Immedia®)|film-coated tablet
3095724|NCT01879371|Experimental|Ibuprofen+caffeine|fixed-dose-combination (FDC)
3095725|NCT01879410|Experimental|UMEC/ VI via NDPI + placebo ACCUHALER/DISKUS arm|Subjects will receive one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning via the NDPI and one inhalation of placebo in the morning and evening via ACCUHALER/DISKUS inhaler
3095726|NCT01879410|Active Comparator|FSC via ACCUHALER/DISKUS + placebo NDPI arm|Subjects will receive one inhalation of FSC 250/50 mcg in the morning and evening via ACCUHALER/DISKUS inhaler and one inhalation of placebo administered once-daily in the morning via NDPI
3095727|NCT01879540|Experimental|aTIV|Adult subjects ≥65 years of age received one dose of a trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant (aTIV), formulation 2013/2014 Northern Hemisphere
3095728|NCT01879553|Experimental|TIV (18 to ≤ 60 years)|Adult subjects 18 to ≤60 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
3095729|NCT01879553|Experimental|TIV (≥ 61 years)|Adult subjects ≥61 years received one dose of a trivalent, surface antigen inactivated subunit influenza virus vaccine (TIV) formulation 2013/2014 Northern Hemisphere
3095730|NCT01879579|Experimental|Mobile Insulin Titration Intervention|Mobile Insulin Titration Intervention (MITI) arm patients will relay their fasting blood glucose levels to the study staff via text message. The patient will receive insulin titration instructions through a weekly phone call with a diabetes nurse.
3095731|NCT01879579|No Intervention|Current Best Practice|Current Best Practice (CBP) arm patients will be treated according to the current best practice of insulin titration. They will attend scheduled clinic visits during which the provider will review their blood glucose logs and provide insulin titration instructions.
3095732|NCT01879618|Experimental|Fragmin|Fragmin given according to the flexible dosing regimen outlined in the protocol
3095733|NCT01879683|Experimental|LiRIS® 400 mg|LiRIS® 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period.
3095734|NCT01879722|Experimental|TAK-063 3 mg|TAK-063 3 mg, tablets, orally, once daily for 7 days.
3095735|NCT01879722|Experimental|TAK-063 10 mg|TAK-063 10 mg, tablets, orally, once daily for 7 days.
3095736|NCT01879722|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for 7 days.
3095737|NCT01879722|Experimental|TAK-063 30 mg|TAK-063 30 mg, tablets, orally, once daily for 7 days.
3095738|NCT01879722|Experimental|TAK-063 100 mg|TAK-063 100 mg, tablets, orally, once daily for 7 days.
3095739|NCT01879722|Placebo Comparator|Placebo|Placebo matching TAK-063, tablets, orally, once daily for 7 days.
3095740|NCT01879735|Experimental|ICG's effect on 11C-CSar transport|"Examine the effect of ICG on the kinetics of the hepatic transport of 11C-CSar. If no effect is seen on the kinetics, ICG will be used during the infusion method experiments."
3095741|NCT01879735|Experimental|Infusion method|Determine wether bolus or constant infusion of 11C-CSar is optimal for the PET/CT scanning. If ICG does not affect the kinetics of 11C-CSar it will be used during these experiments to calculate hepatic blood flow.
3095742|NCT01879800|No Intervention|Treatment As Usual/Waitlist|Treatment As Usual/Waitlist
3095743|NCT01879800|Experimental|Acceptance and Commitment Therapy plus Illness Management|Acceptance and Commitment Training plus Illness Management (ACT-IM) Patients in the ACT-IM group will attend a 1-day group workshop. Three broad areas will be covered: 1) Illness Management will cover the importance of physical and psychological self-care for the management of co-morbid depression/anxiety and vascular problems 2) Behavioral Change Training will involve i) teaching patients how to recognize ineffective patterns of behavior and habits, ii) exploring and setting life goals and those related to mental and physical health, and iii) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 3) Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations .
3095744|NCT01879826|Sham Comparator|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
3095745|NCT01879826|Experimental|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
3095746|NCT01879852|Active Comparator|Standard Rehabilitation|Standard meniscectomy rehabilitation including knee range of motion and strengthening exercises.
3095747|NCT01879852|Experimental|Standard Rehabilitation + Quadriceps intensive strengthening|The intervention includes high-intensity neuromuscular electrical stimulation and eccentric exercises for the quadriceps muscle in addition to the standard rehabilitation protocol.
3095748|NCT01880047|Active Comparator|Eltrombopag|Subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status. Randomization will be performed at the time of informed consent with a computer generated randomization table. Subjects and investigators will be blinded to assignment and treatment in this phase.
3095749|NCT01880047|Placebo Comparator|Placebo|Subjects will be randomly allocated in a two to one ratio to receive treatment or placebo. All subjects in the study will receive 75 mg eltrombopag and then be randomized to receive either an additional 25 mg of eltrombopag or matching placebo tablet dispensed by the research pharmacy. Subjects and investigators will be blinded to randomization. Randomization will be stratified according to splenectomy status.
3095750|NCT01880073|Experimental|FemVue device|FemVue would be used in conjunction with the laparoscopic chromopertubation to determine if it is as effective.
3095751|NCT01880086|Experimental|Clomiphene citrate|The initial dose of clomiphene citrate will be 25 mg (po, pill by mouth) every other day. This will be started at visit 2, week 0 of the study following diagnosis of low baseline testosterone (serum total testosterone <350 ng/dl in men <55 years, <300 ng/dl in men 55-65 years). Clomiphene citrate dose will be titrated up to a maximum of 50 mg daily according to serum total testosterone levels measured at follow-up visits during the 3 month duration of the study.
3095752|NCT01880086|Placebo Comparator|Placebo|Placebo pill will be administered (po, pill by mouth) every other day starting at week 0 of the study in men diagnosed with low testosterone. Treatment will be delayed in these men until the 3 month completion of the study, at which time this group may also receive testosterone replacement therapy.
3095753|NCT01880099|Placebo Comparator|placebo|Placebo (sugar Pill) will be given daily for 7 weeks.
3095754|NCT01880099|Active Comparator|galantamine 8mg|Galantamine extended release (8mg) will be given daily for 7 weeks.
3095755|NCT01880099|Active Comparator|Galantamine 16mg|Galantamine extended release (16mg) will be given daily for 5 weeks starting at week 3 after a two week titration with 8mg galantamine.
3095756|NCT01880320|Experimental|CD0271 0.3% /CD1579 2.5% Gel|active arm
3095757|NCT01880320|Active Comparator|CD0271 0.1% / CD1579 2.5%|Comparator arm
3095758|NCT01880320|Placebo Comparator|Topical Gel Vehicle|Placebo arm
3095759|NCT01880424|Placebo Comparator|controlled arm|
3095760|NCT01880424|Experimental|treatment arm|
3095761|NCT01880437|Experimental|Vismodegib|
3095762|NCT01880515|Experimental|Tetracycline|Patients will receive tetracycline 250mg every 12 hours for 1 month plus general dermatological recommendations (sunscreen and emollient cream)
3095763|NCT01880515|No Intervention|No Tetracycline|This arm only with general dermatologic recommendations. Patients in this arm can receive tetracycline after week 4 of assessment only if rash grade 3-4 occur
3095764|NCT01880528|Experimental|Arm I (lisinopril)|Beginning within 7 days of beginning radiation therapy, patients receive lisinopril PO QD on days 1-7.
3095765|NCT01880528|Placebo Comparator|Arm II (placebo)|Beginning within 7 days of beginning radiation therapy, patients receive placebo PO QD on days 1-7.
3095766|NCT01880554|Other|Contrast-enhanced intraoperative ultrasound|Contrast-enhanced intraoperative ultrasound
3095767|NCT01880593|Experimental|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study
3095768|NCT01880593|Placebo Comparator|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
3095769|NCT01880697|Experimental|TIVc (≥18 to ≤ 60 years) + TIVc (≥ 61 years)|Subjects in each age cohort received one dose of the cell-derived trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVc) formulation 2013/2014 Northern Hemisphere
3095770|NCT01880723|Experimental|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
3095771|NCT01880723|Placebo Comparator|Saline (healthy only)|nebulized 3 ml normal saline using a Power Neb2 nebulizer
3095772|NCT01880736|Experimental|IDeg OD Flexible Dose|
3095773|NCT01880736|Experimental|IDeg OD Fixed Dose|
3095774|NCT01880736|Experimental|IDeg OD Simple|
3095775|NCT01880736|Experimental|IDeg OD Stepwise|
3095776|NCT01880840|Active Comparator|Astepro 0.15% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
3095777|NCT01880840|Active Comparator|Astepro 0.1% Nasal Spray|Nasal Spray at a dosage of 1 spray per nostril twice daily
3095778|NCT01881009|Experimental|Inpatient overnight|Participants in this group will have an overnight evaluation to test safety of the closed-loop system therapy device.
3095779|NCT01881009|Experimental|Summer Camp Session|Participants in this group will receive either the sensor augmented pump or the close loop controller on the first night, then alternated treatment type each night for the duration of the study.
3095780|NCT01881087|Experimental|Levo-7.5 mg|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 7.5 mg. Single Dose.
3095781|NCT01881087|Experimental|Levo-9.37|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 9.37 mg. Single Dose.
3095782|NCT01881087|Active Comparator|Levo-11.25|Hyperbaric Levobupivacaine 0.75% Spinal Administration by a Whitacre Needle 27G. Dosage: 11.25 mg. Single Dose.
3095783|NCT01881113|Experimental|AC-170 0.24%|
3095784|NCT01881113|Placebo Comparator|AC-170 0%|
3095785|NCT01881126|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
3095786|NCT01881126|Active Comparator|travatan 0.004% and timolol 0.5%|Travatan 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
3095787|NCT01881230|Experimental|nab-Paclitaxel plus Gemcitabine|Treatment Arm A: nab-Paclitaxel 125 mg/m^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
3095788|NCT01881230|Experimental|nab-Paclitaxel plus Carboplatin|Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
3095789|NCT01881230|Active Comparator|Gemcitabine plus Carboplatin|Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
3095790|NCT01881373|Experimental|CHL program|Multiple component environmentally focused intervention designed with a community engagement process.
3095791|NCT01881373|Other|Delayed Optimized CHL program|Comparison community that participated in community engagement process and received delayed optimized program.
3095792|NCT01881373|No Intervention|Temporal|Communities assessed for temporal trends in anthropometry.
3095793|NCT01881412|Experimental|Inhaled corticosteroid (fluticasone)|Child receives: 1) standardized asthma discharge instructions, and the intervention which is 2) inhaled corticosteroid prescription with accompanying instructions.
3095794|NCT01881412|Placebo Comparator|Routine Asthma Care|Child receives: 1) Standard Asthma Discharge Instructions. No intervention in this arm (placebo controlled)
3095795|NCT01881620|Experimental|COMBI TEP : PET / enhanced CT scan|COMBI TEP : PET / enhanced CT scan
3095796|NCT01881737|Experimental|Pregnenolone|Pregnenolone up to 500 mg per day
3095797|NCT01881750|Experimental|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
3095798|NCT01881750|Placebo Comparator|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
3095799|NCT01881776|Active Comparator|Single ISB (SISB) group|Patients in this group received single injection (SISB) interscalene brachial plexus block
3095800|NCT01881776|Active Comparator|Continuous ISB (CISB) group|Patients in this group received continuous (CISB) interscalene brachial plexus block
3095801|NCT01881776|No Intervention|General anesthesia (GA) group|Patients in this group received general anesthesia (GA)
3095802|NCT01881789|Experimental|Oprozomib 150 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
3095803|NCT01881789|Experimental|Oprozomib 180 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 180 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
3095804|NCT01881789|Experimental|Oprozomib 210 mg 5/14 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
3095805|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
3095806|NCT01881789|Experimental|Oprozomib 240 mg 2/7 + Lenalidomide + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with lenalidomide 25 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 24 cycles, whichever occurred first. After completing 24 cycles of treatment, participants with stable disease or better could have continued on oprozomib with or without dexamethasone pretreatment.
3095807|NCT01881789|Experimental|Oprozomib 210 mg 2/7 + Cyclophosphamide + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with oral cyclophosphamide 300 mg/m² on days 1, 8, and 15 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23, until progression of disease, unacceptable toxicity, or for 8 cycles, whichever occurred first. After completing 8 cycles of treatment, participants with stable disease or better were to continue on oprozomib with dexamethasone premedication for a total of 24 cycles or until progression of disease or unacceptable toxicity. After completing 24 cycles of treatment, participants without evidence of disease progression could have continued on oprozomib with or without dexamethasone pretreatment.
3095808|NCT01881828|Experimental|Metformin|Metformin 2000 mg per day
3095809|NCT01881828|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
3095810|NCT01881867|No Intervention|Cohort I (no therapy)|Patients receive no treatment (observation) after completion of standard sipuleucel-T therapy.
3095811|NCT01881867|Experimental|Cohort II (glycosylated recombinant human interleukin-7)|Patients receive glycosylated recombinant human interleukin-7 SC every week for 4 weeks (on days 0, 7, 14, and 21) beginning 3-7 days after completion of standard sipuleucel-T therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3095812|NCT01882062|Experimental|Triheptanoin 1g/kg/day|All patients received Triheptanoin oil at 1g/kg/day during 1 month
3095813|NCT01882088|Experimental|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
3095814|NCT01882257|No Intervention|Normal sleep breathing|Home-based sleep studies indicate no obstructive sleep apnea or nocturnal hypoventilation. No intervention.
3095815|NCT01882257|Experimental|BiPAP -Auto for sleep apnea|Patients whose home-based sleep study detects obstructive sleep apnea, but no nocturnal hypoventilation. Noninvasive ventilatory support will be prescribed according to standard clinical criteria.
3095816|NCT01882257|Experimental|BiPAP (AVAPS) for nocturnal hypoventilation|Patients whose home-based sleep study detects nocturnal hypoventilation in the presence or absence of obstructive sleep apnea. Noninvasive ventilatory support will be prescribed according to standard clinical criteria. BiPAP/AVAPS (Phillips Respironics) is worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation.
3095817|NCT01882413||Patients with Planned Cataract Removal|Patients with planned cataract removal surgery are evaluated for the presence of inflammatory dry eye disease. No treatment is administered.
3095818|NCT01882439|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
3095819|NCT01882439|Experimental|Treatment Sequence B|Tofacitinib 10 mg BID for 6 months
3095820|NCT01882439|Placebo Comparator|Treatment Sequence C|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
3095821|NCT01882439|Placebo Comparator|Treatment Sequence D|Placebo for 3 months then tofacitinib 10 mg BID for 3 months
3132594|NCT03439189|Placebo Comparator|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day. The MBT will be performed at screening, at week 24/week 48/at early termination.
3095822|NCT01882465|Other|etafilcon A/2-HEMA, EGDMA/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095823|NCT01882465|Other|etafilcon A/hefilcon A/2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the etafilcon A lens first, the hefilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095824|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/etafilcon A/hefilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the etafilcon A lens second and the hefilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095825|NCT01882465|Other|2-HEMA, EGDMA Non-ionic/hefilcon A/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the 2-HEMA, EGDMA Non-ionic material lens first, the hefilcon A lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095826|NCT01882465|Other|hefilcon A/2-HEMA, EGDMA Non-ionic/etafilcon A|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the 2-HEMA, EGDMA Non-ionic material lens second and the etafilcon A lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095827|NCT01882465|Other|hefilcon A/etafilcon A /2-HEMA, EGDMA Non-ionic|Subjects were randomized to one of six unique sequences. Subjects randomized to this sequence will wear the hefilcon A lens first, the etafilcon A lens second and the 2-HEMA, EGDMA Non-ionic material lens third. The lenses are to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
3095828|NCT01882543|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
3095829|NCT01882543|Placebo Comparator|Placebo|1 x placebo capsule daily
3095830|NCT01882647|Experimental|Active Arm|Topical lotion, applied twice daily
3095831|NCT01882647|Placebo Comparator|Vehicle Arm|Topical lotion, applied twice daily
3095832|NCT01882725|Experimental|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser contains 3 independent diodes mounted in scanner devices and positioned equidistant from each other and titled at a 30 degree angle. Each scanner emits 17 milliwatts (mW), 635 nm of red laser light.
3095833|NCT01882764|Experimental|HMPL-004 1800 mg/day|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of HMPL-004 (600 mg TID; total dose 1800 mg/day) daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
3095834|NCT01882764|Placebo Comparator|Placebo|"Subjects qualifying for entry into the Maintenance Phase of the study were randomized to take an oral dose of Placebo tablets TID, daily, for 52 weeks.~Those subjects who demonstrated clinical remission or response after completing the HMPL-004-03 Induction Study, or after completing the Open Label Phase of this study, were eligible for enrollment in the Maintenance Phase of this study."
3095835|NCT01882803|Experimental|Duvelisib|
3095836|NCT01882829|Experimental|Nuedexta (dextromethorphan/quinidine)|45/10 mg every 12 hours x 8 weeks
3095837|NCT01882868|Experimental|Aflibercept + FOLFIRI|Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m^2 (2 hours) and irinotecan 180 mg/m^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m^2.
3095838|NCT01882907|Experimental|vildagliptin|vildagliptin add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
3095839|NCT01882907|Active Comparator|pioglitazone|Pioglitazone add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy
3095840|NCT01882985|Experimental|Treatment (docetaxel and lycopene)|Patients receive docetaxel IV over 1 hour on day 2 and lycopene PO once daily on days 1-21. Treatment repeats every 21days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
3095841|NCT01883141|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure
3095842|NCT01883362|Experimental|Standard of Care with Midostaurin|Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).
3095843|NCT01883362|Active Comparator|Standard of Care|Patients received standard of care alone in the post SCT setting
3095844|NCT01883427|Placebo Comparator|Placebo: Saline+glucose nasal spray|Subjects received nasal spray containing both saline+glucose twice daily for 3 months
3095845|NCT01883427|Active Comparator|Nasal spray with glucose oxidase+glucose|Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months.
3095846|NCT01883440|Placebo Comparator|Saline+glucose|A nasal spray with isotone saline + 5% glucose in a bag-on-valve nasal spray device. The spray will be administered with one puff in each nostril 5 times day one and thereafter trice daily for a total treatment time of one week
3095847|NCT01883440|Active Comparator|Glucose oxidase + glucose|A nasal spray (bag-on-valve device) with 200U/ml glucose oxidase + 5% glucose in isotone saline. One puff in each nostril 5 times daily day one and 3 times daily thereafter. A total treatment time of one week.
3095848|NCT01883453|Placebo Comparator|Saline+glucose nasal spray|A nasal spray with isotone saline + 5% glucose, dosing one puff 5 times daily in each nostril at the first treatment day and thereafter trice daily for a total of one week
3095849|NCT01883453|Active Comparator|Nasal spray with glucose oxidase+glucose|A nasal spray with 200U/ml of glucose oxidase + 5% glucose. Treatment starts with 5 puffs in each nostril at the first day, and thereafter trhee times daily for a total treatment time of one week.
3095850|NCT01883492|Experimental|BIOLOX delta head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~Biolox delta head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
3095851|NCT01883492|Active Comparator|CoCr head|"Uncemented Femoral Stem is inserted into femoral medullary canal. Uncemented Acetabular Cup is inserted into acetabular cavity with or without fixation screw(s).~Acetabular Liner, which is made of E1 highly crosslinked polyethylene, is fitted into Acetabular cup.~CoCr head is inserted onto the taper of the Femoral stem, and is articulating against Acetabular Liner made of E1."
3095852|NCT01883635|Active Comparator|Individual Exercise Intervention|Survivor-only progressive walking and resistance exercise
3095853|NCT01883635|Experimental|Dyadic Exercise Intervention|Dyadic progressive walking and resistance exercise
3095854|NCT01883804|Experimental|Study group|All participants selected to continue with Methyldopa administration.
3095855|NCT01883856|Active Comparator|Silicone Plate Ahmed Glaucoma Valve|Silicone plate Ahmed Glaucoma Valve
3095856|NCT01883856|Experimental|Porous Plate Ahmed Glaucoma Valve|Porous Plate Ahmed Glaucoma Valve
3095857|NCT01883895|Other|exercise treatment|"Concentric exercise: subject will utilize a dumbbell with elbow flexion exercise.~Isometric exercise: Subjects will perform 5 sets of sustained muscle contraction.~Control: Subjects will undergo a control arm where they will rest for approximately 10 minutes.~Pain testing conducted by Forgionei-Barber pressure pain-stimulator for both the control and exercise treatments."
3095858|NCT01883986|Experimental|Intervention|This is a 3 month nurse-led telephone based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer.
3095859|NCT01883986|No Intervention|Usual Care|Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
3095860|NCT01883999|Experimental|GORE® EXCLUDER® Iliac Branch Endoprosthesis|GORE® EXCLUDER® Iliac Branch Endoprosthesis
3095861|NCT01884025|Experimental|Get Moving and Get Well|Walking class developed for Veterans with serious mental illness and administered as part of the PRRC
3095862|NCT01884025|Sham Comparator|Health and Humor Class|Equally engaging attention control condition
3095863|NCT01884064|Experimental|inhibitory rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
3095864|NCT01884064|Placebo Comparator|Sham rTMS|Sham Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, 1800 pulses, delivered to premotor cortex. Patients held a pencil and made movements that did not elicit dystonic symptoms during rTMS. Intervention was delivered every day for 5 days.
3095865|NCT01884311|Experimental|Subgam-VF|Subgam-VF is a 16% IgG and will be administered weekly, by subcutaneous infusion. The total duration of treatment will be for 26 weeks.
3095866|NCT01884337|Experimental|Apixaban (2.5 mg)|Apixaban 2.5 mg tablets by mouth twice daily, 12 days for TKR subjects or 35 days for THR subjects
3095867|NCT01884350|Experimental|Arm 1: Apixaban (Primary SOC information)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information
3095868|NCT01884350|Experimental|Arm 2: Apixaban (Additional Educational Program)|Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program
3095869|NCT01884519|Experimental|Fluarix/Influsplit 18-60 Years Group|Subjects 18-60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3095870|NCT01884519|Experimental|Fluarix/Influsplit > 60 Years Group|Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2013-2014 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3095871|NCT01884545|Active Comparator|Standard Risk Assessment (SRA)|Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
3095872|NCT01884545|Experimental|SRA plus Health Coaching (HC)|In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
3095873|NCT01884545|Experimental|SRA plus Genetic Risk Counseling (GRC)|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
3095874|NCT01884545|Experimental|SRA+HC+GRC|In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.
3095875|NCT01884571|Experimental|Immunosuppression Regimen|Basiliximab Methylprednisolone Prednisone Tacrolimus Mycophenolate mofetil
3095876|NCT01884597|Active Comparator|Cohort 1|12 monthly, intravitreal injections of 2.0mg ranibizumab followed by 12 monthly, intravitreal injections of 1.0mg ranibizumab
3095877|NCT01884597|Active Comparator|Cohort 2|6-months of monthly, intravitreal injections of ranibizumab 2.0mg followed by 18 months of monthly, intravitreal injections of ranibizumab 1.0mg
3095878|NCT01884597|Active Comparator|Cohort 3|24 months of monthly, intravitreal injections of ranibizumab 1.0mg
3095879|NCT01884675|Experimental|Ambrisentan|Subjects in this arm will receive ambrisentan 5 mg tablet once daily during the treatment period.
3095880|NCT01884675|Placebo Comparator|Placebo|Subjects in this arm will receive ambrisentan-matching placebo tablet once daily during the treatment period.
3095881|NCT01884688|Experimental|ENK Cell Infusion|Expanded Natural Killer Cell Infusion
3095882|NCT01884844|Experimental|Vitamin D3|Vitamin D3, Cholecalciferol, 5000IU po qday for 12 weeks
3095883|NCT01884844|Placebo Comparator|Placebo|methylcellulose po qday for 12weeks
3095884|NCT01885000|Experimental|Brimonidine tartrate 0.5% gel|Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
3095885|NCT01885000|Placebo Comparator|Vehicle|Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.
3095886|NCT01885104|Experimental|PEG 3350|Participants will receive a 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
3095887|NCT01885104|Placebo Comparator|Placebo|Participants will receive a 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days. Bisacodyl laxative tablets, 5.0 mg, 1 to 3 tablets in a single daily dose, will be provided for use as a rescue medication if a participant has not had a bowel movement for 72 hours after start of treatment.
3095888|NCT01885117|Experimental|TIVf (18 to ≤ 60 years)|Adult subjects aged 18 to ≤ 60 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
3095889|NCT01885117|Experimental|TIVf (≥ 61 years)|Adult subjects aged ≥ 61 years received one dose of trivalent, surface antigen inactivated subunit influenza virus vaccine (TIVf), formulation 2013/2014 Northern Hemisphere
3095890|NCT01885182|Experimental|Oxycodone/Naloxone|5/2.5mg, 10/5mg, 20/10mg or 40/20mg
3095891|NCT01885182|Active Comparator|Oxycodone|5mg, 10mg, 20mg or 40mg
3095892|NCT01885195|Experimental|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
3095893|NCT01885208|Experimental|Semaglutide 1.0 mg|
3095894|NCT01885208|Active Comparator|Exenatide ER 2.0 mg|
3095895|NCT01885559|Placebo Comparator|ACE-I + placebo|Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg
3095896|NCT01885559|Active Comparator|ACE-I + ARB|Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.
3095897|NCT01885871|Experimental|Picosecond QS Nd:YAG Laser|Laser Treatment with Investigational Device
3095898|NCT01885897|Experimental|Study treatment|Weekly dose of ALT-803 at assigned dose, ranging from 1mcg/kg to 30 mcg/kg (based on phase 1 dose escalation schedule,) IV once a week for 4 weeks.
3095899|NCT01885910|Experimental|doxy + aczone|Subjects will start treatment with doxycycline 100mg once daily and Aczone 5% gel applied to the face twice daily and those who improve significantly are continued on Aczone gel alone to see if it can maintain therapeutic response
3095900|NCT01885936|Experimental|Albuterol|Initially 4 mg daily for one week, then 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
3095901|NCT01885936|Placebo Comparator|Placebo Comparator|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
3095902|NCT01886105|Experimental|SmEDTMP/Autologous Stem Cell Infusion/RT|"DAY 1 Tracer dose 153Sm-EDTMP administration (1 mCi/kg) SPECT/High-resolution CT at 4 hours. SPECT/CT (low resolution) at 24 and 48 hrs~DAY 7 Individualized treatment dose 153Sm-EDTMP administration (max 30 mCi/kg) SPECT scans at 4, 24 and 48 hours~DAY 21 (2 weeks following treatment dose) Auto-Stem cell infusion~DAY 40 (approx. two weeks after stem cell rescue) Initiate EBT upon count recovery~1 MONTH following completion of all therapy Response assessment with repeat imaging (CT/MRI, Tc-99m bone scan) 18F-MISO/FDG PET"
3095903|NCT01886235|Experimental|Diagnosis (intravital microscopy)|Patients receive fluorescein sodium IV followed by intravital microscopic observation over 10-15 minutes during excision of the melanoma.
3095904|NCT01886287|Experimental|Octreotide Long-acting Release (LAR)|Octreotide LAR will be administered at a dose of 60 mg intramuscularly (IM) every 4 weeks.
3095905|NCT01886300||Cohort|
3095906|NCT01886313|Active Comparator|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily, for 6 weeks
3095907|NCT01886313|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 10ul in each nostril, twice daily, for 6 weeks
3095908|NCT01886378|Experimental|UX007|UX007 dosing titrated to a target dose of 25-35% of total caloric intake or maximum tolerated dose. Participants are followed to evaluate the effects of UX007 over 24 weeks (Treatment Period), then continued treatment in the Extension Period for an additional 54 weeks for a total of 78 weeks of treatment.
3095909|NCT01886690|Experimental|New Eye Drop Formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
3095910|NCT01886690|Active Comparator|REFRESH PLUS®|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
3095911|NCT01886716|Experimental|Anxiety Attention Training only|Participants will receive Anxiety Attention Training and placebo Alcohol training.
3095912|NCT01886716|Experimental|Alcohol Attention Training only|Participants will receive Alcohol Attention Training and placebo Anxiety training.
3095913|NCT01886716|Experimental|Anxiety + Alcohol Attention Training|Participants will receive both Anxiety Attention Training and Alcohol Attention Training.
3095914|NCT01886716|Placebo Comparator|Control Training|Participants will receive placebo Anxiety Training and placebo Alcohol training.
3095915|NCT01886781|Experimental|Lactobacillus plantarum 299v|Lactobacillus plantarum 299v capsules
3095916|NCT01886781|Placebo Comparator|Crytalline cellulose powder|Placebo capsule, filled with micro-crystalline cellulose powder
3095917|NCT01886781|No Intervention|Run in period|Run in period of one to two weeks, no treatment. At baseline randomization and treatment commenced.
3095918|NCT01886781|No Intervention|Wash out period|Wash out period of two weeks, no treatment.
3095919|NCT01886807|Other|(DL group)|direct laryngoscopy for nasotracheal intubation without oxygen insufflation
3095920|NCT01886807|Other|(DL-O2 Group)|direct laryngoscopy for nasotracheal intubation with oxygen insufflation
3095921|NCT01886807|Experimental|(VL Group)|nasotracheal intubation using the Truview PCD video laryngoscope
3132595|NCT03439657|Experimental|Co-Ad Group|Adults aged ≥50 years of age who received the first dose of GSK1437173A and one dose of Prevenar13 at Day 1 and the second dose of GSK1437173A at Month 2. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
3095922|NCT01886833||Mother-Infant Pair|"The study will involve consenting mother-infant pairs from Kamwala health facility in Lusaka where the Maternal Child Health (MCH). Those generally interested will be invited to the research clinic, where more detailed information about the study is offered. Motivated mothers will be recruited and taken through the written informed consent process by the study nurse.~Enrolled mother-infant pairs will undergo baseline procedures as earlier described. They will then be followed prospectively until about December 2016. They will be expected to come to the clinic for scheduled visits at baseline, 1, 3, 12, 15 and 42 months. They will be urged to come to the clinic for unscheduled visit should the infant be unwell at any time, and particularly each time the infant experiences diarrhoea."
3468975|NCT03890861|Experimental|Physical activity intervention|The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
3468976|NCT03890861|Active Comparator|Active control|The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
3095926|NCT01886937|Experimental|37.5 mg Phentermine daily for 7 days|"In this arm, participants receive 37.5mg phentermine for one week followed by 2 weeks of placebo.~Other names for phentermine:~adipex ionamin"
3095927|NCT01886937|Placebo Comparator|Placebo (for phentermine 37.5mg)|In this arm, participants receive Placebo (for 37.5mg phentermine) for two weeks followed by phentermine 37.5mg for 7 days.
3095928|NCT01886963|Active Comparator|Control - Blinded use of SPY Elite|Group A will consist of intraoperative abdominal wall imaging prior to incision, followed by ventral hernia repair with subcutaneous advancement flaps without viewing the imaging contained within the Spy Elite system. A digital photograph will be taken before and immediately after initial incision, as well as immediately prior to and after closure. The patient will have digital photographs of the surgical wound taken by the surgical team daily until discharge, and on follow-up visits at one week, two weeks, four weeks and twelve weeks. After twenty patients have completed phase I, the surgical team will be unblinded to Spy Elite imaging. The Spy Elite imaging and all digital photographs of all patients will be reviewed.
3095929|NCT01886963|Experimental|SPY - Unblinded Use of SPY Elite|Group B will have incision and advancement flap performed based on assessment of blood supply using the Spy Elite system, as well as potential flap revision if portions of the flap appear under-perfused in the pre-closure imaging. Patients will be blinded to whether or not their intraoperative Spy Elite imaging was used for operative planning. All patients will have digital photographs of the surgical wound taken by a blinded member of the surgical team daily until discharge, and on follow-up visits at one to two weeks, four weeks, and 12 weeks post-operatively. Digital photographs will be reviewed by a blinded surgeon, who will assess the wound for complications.
3095930|NCT01887132|Experimental|Open-Label Donepezil|
3095931|NCT01887132|Experimental|Donepezil - Blinded|
3095932|NCT01887132|Placebo Comparator|Placebo|
3095933|NCT01887171|Experimental|Tacrolimus + HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
3095934|NCT01887171|No Intervention|HTK|During back-table operation 1000 ml of HTK solution cooled to 2-4˚C would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin under gravity pressure of 40 cm H2O.
3095935|NCT01887210|Experimental|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
3095936|NCT01887210|Active Comparator|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
3095937|NCT01887327|Placebo Comparator|Placebo|Participants receive placebo and phototherapy
3095938|NCT01887327|Experimental|Stannsoporfin 3.0 mg/kg|Participants receive stannsoporfin (3.0 mg/kg) and phototherapy
3095939|NCT01887327|Experimental|Stannsoporfin 4.5 mg/kg|Participants receive stannsoporfin (4.5 mg/kg) and phototherapy
3095940|NCT01887353|Active Comparator|Ranolazine|
3095941|NCT01887353|Placebo Comparator|Placebo|
3095942|NCT01887418|Experimental|QuickShot™ - 100 mg Treatment A|QuickShot™Testosterone - Auto-injector device for SC use
3095943|NCT01887418|Experimental|QuickShot™ - 50 mg Treatment B|QuickShot™Testosterone- Auto-injector device for SC use
3095944|NCT01887418|Active Comparator|Delatestryl 200 mg IM Treatment C|Commercially available Testosterone enanthate 200 mg IM dosage - 'standard of care' arm for reference
3095945|NCT01887470|Experimental|Full dose preparation; AM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated prior to noon on the following day.
3095946|NCT01887470|Experimental|Full dose preparation; PM colonoscopy|Four hourly doses of lactulose for oral solution are taken in the evening. The colonoscopy is initiated after noon on the following day.
3095947|NCT01887470|Experimental|Split dose preparation; AM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated prior to noon.
3095948|NCT01887470|Experimental|Split dose preparation; PM colonoscopy|Three hourly doses of lactulose for oral solution are taken in the evening prior to the day of the colonoscopy procedure; one dose is taken on the morning of the procedure. The colonoscopy is initiated after noon.
3132596|NCT03439657|Active Comparator|Control Group|Adults aged ≥50 years of age who received one dose of Prevenar13 at Day 1, the first dose of GSK1437173A at Month 2 and the second dose of GSK1437173A at Month 4. Both vaccines were administered intramuscularly, GSK1437173A was administered in the deltoid muscle of the non-dominant arm, while Prevenar13 was administered in the deltoid muscle of the dominant arm
3095949|NCT01887587|Experimental|(modified VXLD) plus MLN9708|"Vincristine-1.5 mg/m2 to a max dose of 2 mg IV on days 1, 8, 15 and 22~Dexamethasone- 10 mg/m2 orally or IV on days 1-14~Doxorubicin- 60 mg/m2 on day 1 by IV bolus.~MLN9708 (Ixazomib)- 2.3 mg orally on days 1, 8 and 15. Escalations will be to 3mg or 4 mg, respectively, on days 1, 8 and 15 based on the dosing schema.~For patients without central nervous system (CNS) involvement:~Cytarabine 100 mg administered intrathecally on day 1 (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir)~Methotrexate 12 mg administered intrathecally on day 8~For patients with CNS involvement:~-Cytarabine 100 mg administered intrathecally on day 1 (+/-1 day) (cytarabine dose should be reduced to 50 mg if given through a central ommaya reservoir) Triple intrathecal chemotherapy with cytarabine 30 mg, methotrexate 15 mg and hydrocortisone 15 mg on (Day 1, 8, 15 and 22 (+/-1 day))."
3095950|NCT01887600|Experimental|Roxadustat|Participants received roxadustat according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for at least 52 weeks up to a maximum of 104 weeks.
3095951|NCT01887600|Placebo Comparator|Placebo|Participants received matching placebo according to the tiered weight-based approach, with starting doses of 70 mg given thrice weekly (TIW) to participants weighing up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received matching placebo for at least 52 weeks up to a maximum of 104 weeks.
3095952|NCT01887678|Experimental|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one intra articular (IA) injection) on treatment days 1, 8 and 15.
3095953|NCT01887678|Placebo Comparator|Placebo injectable solution|Injection volume of placebo is 4.2 mL as well (taken from the 10.0 mL vial by unblinded staff member, rest to be kept for drug accountability)
3095954|NCT01887717|Experimental|TheraSphere|Participants will receive TheraSphere at a dose consistent with the approved product label to the treated lobe of the liver. TheraSphere will be administered through the hepatic artery. The target dose will be 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% will be permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere will be permitted if a treatable progression is detected during follow-up evaluations. Any re-treatment will take place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants can receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations will be permitted.
3095955|NCT01887717|Active Comparator|Sorafenib|Participants will receive sorafenib, oral tablets, 400 milligrams (mg) twice daily in accordance with the package insert. Treatment is to continue until the participant is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity will be allowed.
3095956|NCT01887912|Experimental|C. difficile Vaccine Group|Participants received 1 injection of 0.5 mL C. difficile toxoid vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
3095957|NCT01887912|Placebo Comparator|Placebo Group|Participants received 1 injection of 0.5 mL placebo matched to vaccine at Days 0 (Injection 1), 7 (Injection 2), and 30 (Injection 3).
3095958|NCT01887990|Active Comparator|Suicidal, Depression with Ketamine|suicidal ideation and depression (no substance use disorder) 0.2 mg/kg IV ketamine administered as a one time dose
3095959|NCT01887990|Placebo Comparator|Suicidal, Depression with Saline|Suicidal ideation and depression (no substance use disorder) comparable amount of placebo (saline)
3095960|NCT01887990|Active Comparator|Suicidal, opioid use with ketamine|suicidal ideation,depression, opioid use disorder 0.2 mg/kg IV ketamine one time dose
3095961|NCT01887990|Placebo Comparator|Suicidal, opioid use with Saline|Patients with suicidal ideation and depression with opioid use disorder who are given comparable amount of placebo (saline) as would have been used with the Ketamine arm
3095962|NCT01888003|Active Comparator|Anemia Treatment Group (AMG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive an ESA (PROCRIT) and iron (Venofer) preoperatively.
3095963|NCT01888003|Other|Conventional Treatment Group (CTG)|Group of patients who are diagnosed preoperatively as being anemic (defined as a Hgb < 13.0 g/dL and MCV < 100 fL, with a hematocrit between 30% and 39%, for males and females), who will receive our current, conventional perioperative standard of care, which does not involve any preoperative anemia management (other than laboratory testing). CTG patients will undergo routine perioperative laboratory testing/screening.
3095964|NCT01888003|Other|Non Anemia Group (NAG)|Group of patients who are not anemic preoperatively, who will receive our current, conventional perioperative standard of care.
3095965|NCT01888367|Experimental|DFA-02 Antibiotic Gel|Up to 20 mL of DFA-02 antibiotic gel will be placed in the surgical incision after closure of the fascia and before skin closure.
3095966|NCT01888367|Placebo Comparator|DFA-02 Placebo Gel|Up to 20 mL of DFA-02 placebo gel will be placed in the surgical incision after closure of the fascia and before skin closure.
3095967|NCT01888367|No Intervention|Standard of Care|Prior to final closure of the surgical incision, the incision will be irrigated with normal saline and no gel will be applied.
3095968|NCT01888432|Experimental|Everolimus + reduced tacrolimus|Everolimus + reduced tacrolimus ± corticosteroids
3095969|NCT01888432|Active Comparator|Standard tacrolimus|Standard tacrolimus ± corticosteroids
3095970|NCT01888484|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
3095971|NCT01888497|Experimental|Arm A|
3095972|NCT01888497|Experimental|Arm B|
3095973|NCT01888497|Active Comparator|Arm C|
3095974|NCT01888497|Placebo Comparator|Arm D|
3095975|NCT01888640|Active Comparator|ActiveTENS|Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
3095976|NCT01888640|Placebo Comparator|Placebo TENS|This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
3095977|NCT01888640|No Intervention|No TENS (Standard Care)|Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.
3095978|NCT01888874|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, twice daily (BID) during Weeks 1 to 12. Participants who were responders (having at least 20 percent [%] improvement on TJC68 and SJC66) remained on placebo while nonresponders were re-randomized to GLPG0634 100 milligram (mg) once daily (QD) or 50 mg BID during Weeks 13 to 24.
3095979|NCT01888874|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
3095980|NCT01888874|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
3095981|NCT01888874|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
3095982|NCT01888874|Experimental|GLPG0634 25 mg BID|Participants received GLPG0634 25 mg capsules, orally, BID during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 25 mg BID while nonresponders were re-randomized to 50 mg BID during Weeks 13 to 24.
3095983|NCT01888874|Experimental|GLPG0634 50 mg BID|Participants received GLPG0634 50 mg capsules, orally, BID during Weeks 1 to 24.
3095984|NCT01888874|Experimental|GLPG0634 100 mg BID|Participants received GLPG0634 100 mg capsules, orally, BID during Weeks 1 to 24.
3095985|NCT01888900|Experimental|Hepatitis C Virus Genotype 1A with QUAD|Subjects will be started on combination therapy with asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks.
3095986|NCT01888900|Experimental|Hepatitis C Virus Genotype 1B with DUAL|Subjects will receive combination therapy with asunaprevir and daclatasvir alone for 24 weeks and undergo paired liver biopsies, pre-treatment and either at 2 or 4 weeks after starting therapy.
3095987|NCT01888952|Experimental|Roflumilast and Prednisone|"Roflumilast 500 mcg will be administered orally daily for 21 consecutive days (a 21-day cycle).~In Cycle 1, prednisone 60 mg/m2 up to a maximum of 100 mg oral (PO) daily will be taken on Days 8 through 14 at the same time as roflumilast.~In Cycle 2 and subsequent cycles, prednisone 60 mg/m2 PO up to a maximum of 100 mg daily will be taken on Days 1 through 7 at the same time as roflumilast."
3095988|NCT01888965|Experimental|Dovitinib|Dovitinib 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years
3095989|NCT01889069|Experimental|Rituximab|Participants will receive at least 4 doses of rituximab 1400 mg SC once a month during the Induction period, and at least 6 doses of rituximab 1400 mg SC once every two months during the Maintenance period, in addition to standard chemotherapy. Standard chemotherapy regimen included cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP); or cyclophosphamide, vincristine and prednisone (CVP); or bendamustine as per standard local practice.
3095990|NCT01889238|Experimental|Enzalutamide|160 mg administered as four 40 mg soft gelatin capsules orally once daily
3095991|NCT01889251|Experimental|Ocriplasmin|Ocriplasmin administered as a single intravitreal injection to the study eye at baseline
3095992|NCT01889251|Sham Comparator|Sham injection|Single sham injection to the study eye at baseline
3095993|NCT01889355|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
3095994|NCT01889563|Experimental|Physical exercise training program|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
3095995|NCT01889563|No Intervention|No Physical Exercise Training Program|No Physical Exercise Training Program
3095996|NCT01889602|Experimental|Topiramate 100mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
3095997|NCT01889602|Experimental|Topiramate 150mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 150mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
3095998|NCT01889602|Experimental|Topiramate 200mg|Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 200mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
3095999|NCT01889667|Experimental|ORMD-0801 Dose # 1|Oral Insulin Formulation
3096000|NCT01889667|Experimental|ORMD-0801 Dose # 2|Oral Insulin Formulation
3096001|NCT01889667|Placebo Comparator|Placebo|Oil Capsules
3096002|NCT01889797|Active Comparator|Arm A: Rituximab|Rituximab 375 mg/m² IV weekly for 4 weeks.
3096003|NCT01889797|Experimental|Arm B: GA101|GA101 1,000 mg IV weekly for 4 weeks.
3096004|NCT01889862|Active Comparator|BMN165 20mg/day|BMN165 20mg/day self-administered daily
3096005|NCT01889862|Placebo Comparator|20 mg/day Placebo|20 mg/day Placebo self-administered daily
3096006|NCT01889862|Active Comparator|BMN165 40mg/day|BMN165 40mg/day self-administered daily
3096007|NCT01889862|Placebo Comparator|40 mg/day Placebo|40 mg/day Placebo self-administered daily
3468977|NCT03891121|Experimental|Occlusal splint|Patients were treated with occlusal splint.
3096008|NCT01890031|No Intervention|Low Risk, No ICAT|Low risk, not randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
3096009|NCT01890031|Other|Low risk, ICAT|Low risk, randomized to use the Interactive Cholesterol Advisory Tool, no study physician visits
3096010|NCT01890031|Other|Low risk, ICAT, and study physician|Low risk, assigned to use the Interactive Cholesterol Advisory Tool, and study physician visits.
3096011|NCT01890031|Other|Moderate risk, no ICAT|Moderate risk, study physician visits, and not randomized to use the Interactive Cholesterol Advisory Tool
3096012|NCT01890031|Other|Moderate risk, ICAT|Moderate risk, study physician visits, and randomized to use the Interactive Cholesterol Advisory Tool
3096013|NCT01890109|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by subcutaneous injection.
3096014|NCT01890109|Experimental|Erenumab|Participants received a single dose of 70 mg erenumab administered by subcutaneous injection.
3096015|NCT01890122|Active Comparator|Metformin HCl 500 mg|Metformin hydrochloride (HCl) 500 mg, capsules, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; alogliptin and metformin HCl fixed dose combination (FDC) placebo-matching tablets, orally, twice a day for up to 26 weeks.
3096016|NCT01890122|Active Comparator|Alogliptin 12.5 mg|Alogliptin 12.5 mg, tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day; alogliptin and metformin HCl FDC placebo-matching tablets, orally, twice a day for up to 26 weeks.
3096017|NCT01890122|Experimental|Alogliptin 12.5 mg + Metformin HCl 500 mg FDC|Alogliptin 12.5 mg and metformin HCl 500 mg FDC, tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
3096018|NCT01890122|Placebo Comparator|Placebo|Alogliptin and metformin FDC placebo-matching tablets, orally, twice a day; alogliptin placebo-matching tablets, orally, twice a day; metformin placebo-matching capsules, orally, twice a day for up to 26 weeks.
3096019|NCT01890148|Experimental|1|oral BD administration of 45 mg AZD5069
3096020|NCT01890226|No Intervention|Control|
3096021|NCT01890226|Experimental|Experimental: Intervention|Participants randomized to the intervention arm will receive the mobile personal health record.
3096022|NCT01890265|Experimental|Pamrevlumab|Participants will receive pamrevlumab 30 milligram/kilogram (mg/kg) by intravenous (IV) infusion every 3 weeks for a total of 16 infusions over 45 weeks.
3096023|NCT01890265|Placebo Comparator|Placebo|Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 16 infusions over 45 weeks.
3096024|NCT01890265|Active Comparator|Sub-Study: Pamrevlumab+Pirfenidone or Nintedanib|"Participants will receive pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with pamrevlumab in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
3096025|NCT01890265|Placebo Comparator|Sub-Study: Placebo+Pirfenidone or Nintedanib|"Participants will receive placebo matching pamrevlumab by IV infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator participants will be administered at a dose of 15 mg/kg for the first 2 dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.~Pirfenidone or nintedanib will be dosed according to the instructions in their respective labels and the prescribing physician."
3096026|NCT01890343|Experimental|Frontotemporal Disorder|Subjects with frontotemporal disorder (FTD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F and a one-time IV bolus injection of 185 MBq of 18F-FDG.
3096027|NCT01890343|Experimental|Cognitively Normal|Cognitively normal (CN) subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
3096028|NCT01890343|Experimental|Alzheimer's Disease|Subjects with Alzheimer's disease (AD) received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
3096029|NCT01890421|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
3096030|NCT01890434|Experimental|Gadobutrol 0.1 mmol/kg body weight|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
3096031|NCT01890473|Experimental|Arm 1: Abatacept (autoinjector)|Abatacept 125 mg/syringe subcutaneously through autoinjector, one dose in 71 days
3096032|NCT01890473|Experimental|Arm 2: Abatacept (prefilled syringe)|Abatacept 125 mg/syringe subcutaneously with prefilled syringe, one dose in 71 days
3096033|NCT01890512||ImageReady Pacemaker|patients previously implanted with a Boston Scientific MR Conditional pacemaker(ImageReady)
3096034|NCT01890642|Sham Comparator|J tip Noise|This group will have a J tip deployed without medication to create the noise that the device makes. They will also receive Pain Ease spray if > age 1 yr or sucrose if < 1 yr
3096035|NCT01890642|Other|Pain Ease|This group will receive Pain Ease Spray only if > 1 yr or sucrose only if child < 1 yr
3096036|NCT01890642|Experimental|J tip|This group will receive 1% buffered lidocaine via Jet Injection. They will receive placebo cooling spray (normal saline spray) to maintain blinding if > 1 yr and will receive sucrose is < 1 yr
3096037|NCT01890707|Active Comparator|Deep Sedation|Deep sedation
3096038|NCT01890707|Other|General Anesthesia|Administration of general anesthesia. Propofol given IV, succinylcholine and rocuronium given IV and Sevoflurane via the endotracheal tube.
3132597|NCT03440229|No Intervention|Emuslfier-free diet|This is western style diet prepared without any emulsifiers. Emulsifier free brownies and sorbet are provided daily.
3132598|NCT03440229|Experimental|Emulsifier-containing diet|This is a western style diet prepared without any emulsifiers with the exception of the CMC that is included in brownies and sorbet that are provided daily.
3468978|NCT03891121|Experimental|Botulinum toxin|Patients were treated with botulinum toxin injection.
3468979|NCT03891121|Experimental|Both|Patients were treated with occlusal splint and botulinum toxin injection together.
3096039|NCT01890746|Experimental|Eltrombopag arm|Subjects received induction chemotherapy consisting of daunorubicin bolus intravenous (IV) infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by Eltrombopag once daily orally starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the dose was increased until a platelet count of at least 200 Gi/L was achieved/until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
3096040|NCT01890746|Placebo Comparator|Placebo arm|Subject received induction chemotherapy consisting of daunorubicin bolus IV infusion on Days 1-3 + cytarabine continuous IV infusion on Days 1-7 followed by matching placebo once daily oral dose starting on Day 4 of initial induction chemotherapy. If platelet count was not greater than 100 Gi/L after 7 days the matching placebo was given until a platelet count of at least 200 Gi/L was achieved/ until remission was assessed/ maximum of 42 days from the start of the chemotherapy induction. Subjects who were not aplastic after first cycle of induction chemotherapy received a second induction chemotherapy with a modified daunorubicin dose on Days 1-3 + cytarabine on Days 1-7.
3096041|NCT01890759|Experimental|Meningococcal Diphtheria Toxoid Vaccine|Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart
3096042|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Fasting|lisdexamfetamine dimesylate 70 mg capsule administered under fasted conditions
3096043|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Vanilla Yogurt|Lisdexamfetamine Dimesylate 70mg capsule mixed into vanilla yogurt
3096044|NCT01890785|Experimental|Lisdexamfetamine Dimesylate Orange Juice|Lisdexamfetamine Dimesylate 70mg capsule mixed into orange juice
3096045|NCT01890915||Tetraplegia|Persons with spinal cord injury, level of injury C4-T1, American Spinal Injury Association (ASIA) impairment levels A-B and duration of injury greater than 1 year. Ages 18-65 years old.
3096046|NCT01890915||Control|Age and gender-matched able-bodied controls. Ages 18-65 years old.
3096047|NCT01890954|Active Comparator|DiAs-closed-loop system|eight hours using Closed Loop Control (DiAs) under both, miss insulin bolus for 30 grams of carbohydrates snack or under bolus for an 80 grams of carbohydrates lunch
3096048|NCT01890954|No Intervention|Sensor Augmented Pump|8 hours observational under both, missed insulin bolus for 30 gr carbohydrates snack and under bolus for an 80 gr carbohydrates lunch. Sensor augmented pump used the patients own insulin settings (basal rate, meal boluses and correction boluses) and a CGM provided by the study team to be used during admission. No DiAs use during this admisssion
3096049|NCT01890967|Experimental|20 mg LY3015014 Q4W|"20 milligrams (mg) LY3015014 given subcutaneously (SC) once every 4 weeks (Q4W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096050|NCT01890967|Experimental|120 mg LY3015014 Q4W|"120 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096051|NCT01890967|Experimental|300 mg LY3015014 Q4W|"300 mg LY3015014 given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096052|NCT01890967|Experimental|100 mg LY3015014 Q8W|"100 mg LY3015014 given SC once every 8 weeks (Q8W) for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096053|NCT01890967|Experimental|300 mg LY3015014 Q8W|"300 mg LY3015014 given SC Q8W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096054|NCT01890967|Placebo Comparator|Placebo Q4W|"Placebo given SC Q4W for 16 weeks.~Participants will remain on stable diet and physician-prescribed statin therapy, if tolerated, with or without ezetimibe."
3096055|NCT01891305|Experimental|VT-1161 200/50mg|
3096056|NCT01891305|Experimental|VT-1161 600/150mg|
3096057|NCT01891305|Experimental|VT-1161 1200/300mg|
3096058|NCT01891305|Placebo Comparator|Matching placebo|
3096059|NCT01891331|Experimental|VT-1161 300mg QD|
3096060|NCT01891331|Experimental|VT-1161 600mg QD|
3096061|NCT01891331|Experimental|VT-1161 600mg BID|
3096062|NCT01891331|Active Comparator|Fluconazole 150mg|
3096063|NCT01891344|Experimental|Ovarian cancer|rucaparib
3096064|NCT01891357|Experimental|Paclitaxel + Lapatinib + Trastuzumab|Paclitaxel 80 mg/m2 weekly for 12 weeks with lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12 weeks, biopsy before and after three weeks of study treatment
3321177|NCT02016911|Experimental|Subjects with hepatic impairment|
3096067|NCT01891669|Experimental|Part 1|
3096068|NCT01891721|Experimental|Specific Perceptual Training - Brain Fitness Program (BFP)|In each session, participants will work on 4 of the 6 BFP exercises (15 min per exercise). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3096069|NCT01891721|Experimental|Broad Cognitive Training - Cognitive Package (Cogpack)|In each session, participants will work on a different subset of 4 to 6 Cogpack exercises. Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3096070|NCT01891721|Active Comparator|Control Treatment - Commercial Computer Games (Sporcle)|In each session, participants will play between 8 and 16 games (1 to 15 min per game). Duration of training is 1 hour per day, 3 days per week, for 12 weeks, for a total of 36 hours.
3321178|NCT02016911|Active Comparator|Subjects with normal hepatic function|
3321179|NCT02016937||group g|general anesthesia, n: 21
3096071|NCT01891734|Experimental|Problem Solving Therapy plus Moving Forward (PST-MF)|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
3096072|NCT01891734|Active Comparator|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
3096073|NCT01891864|Experimental|GP2015 Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
3096074|NCT01891864|Active Comparator|Enbrel ® Etanercept|Solution for subcutaneous injection in pre-filled syringe. The drug is administered in a dose of 50 mg twice weekly for the first 12 weeks and 50 mg once weekly thereafter
3096075|NCT01891890|Active Comparator|Lamotrigine|Lamotrigine 7.0 mg/kg tablets or chewable tablets administered daily in 2 equally divided doses
3096076|NCT01891890|Active Comparator|Oxcarbazepine|Oxcarbazepine 25 mg/kg tablets or liquid administered daily in 2 equally divided doses
3096077|NCT01891890|Active Comparator|Levetiracetam|Levetiracetam 30 mg/kg tablet or liquid administered daily in 2 equally divided doses
3096078|NCT01891968|Experimental|Bortezomib|Bortezomib administered via subcutaneous route at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11 of a 21 day cycle. A course of treatment will be 21 days.
3096079|NCT01891994|Experimental|Eltrombopag|Administration of eltrombopag at a dose of 150mg/day for 6 months
3096080|NCT01892007|Experimental|Cogmed RM (adaptive)|Online training intervention: An adaptive version of Cogmed RM working memory training. Task difficulty (number of to-be-remembered items) increases based on individual performance, in order to maintain average daily performance levels of approximately 60% of trials correct. Participants complete 35-45 minutes of active training per day, 5 days a week for 5 weeks.
3096081|NCT01892007|Placebo Comparator|Cogmed RM (non-adaptive, placebo)|Online training intervention: A non-adaptive placebo version of Cogmed RM working memory training. Tasks are fixed at a low-difficulty practice level (three to-be-remembered items) and do not increase in difficulty over the course of the intervention. Participants complete 35-45 minutes of active placebo training per day, 5 days a week for 5 weeks.
3096082|NCT01892020|Experimental|Treatment sequence 1 (Group A)|Group A will receive BIAsp 50 BID during the first 4 weeks (treatment period 1) then switch to BHI 50 BID for further 4 weeks (treatment period 2)
3096083|NCT01892020|Experimental|Treatment sequence 2 (Group B)|Group B will receive BHI 50 BID during the first 4 weeks (treatment period 1), then switch to BIAsp 50 BID for further 4 weeks (treatment period 2)
3096084|NCT01892163|Active Comparator|Ozurdex PRN dosing|Ozurdex PRN dosing versus Ozurdex fixed dosing
3096085|NCT01892163|Experimental|Ozurdex fixed dosing|
3096086|NCT01892189|Experimental|Sequence 1: Placebo + TAK-063 3 mg + TAK-063 30 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 milligram (mg), orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096087|NCT01892189|Experimental|Sequence 2: TAK-063 3 mg + TAK-063 30 mg + Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096088|NCT01892189|Experimental|Sequence 3: TAK-063 30 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096089|NCT01892189|Experimental|Sequence 4: Placebo + TAK-063 3 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096090|NCT01892189|Experimental|Sequence 5: TAK-063 3 mg + TAK-063 300 mg+ Placebo|"Period 1, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
3321180|NCT02016937||group S|spinal anesthesia, n: 21
3096091|NCT01892189|Experimental|Sequence 6: TAK-063 300 mg + Placebo + TAK-063 3 mg|"Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 3 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096092|NCT01892189|Experimental|Sequence 7: Placebo + TAK-063 30 mg + TAK-063 300 mg|"Period 1, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight:~Period 2, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period"
3096093|NCT01892189|Experimental|Sequence 8: TAK-063 30 mg + TAK-063 300 mg + Placebo|"Period 1, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight.~Period 1 & 2 are followed by 7 day washout period."
3096094|NCT01892189|Experimental|Sequence 9: TAK-063 300 mg + Placebo + TAK-063 30 mg|Period 1, Day 1: TAK-063 300 mg (participants enrolled before protocol amendment 3) or 10 mg (participants enrolled after protocol amendment 3), tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 2, Day 1: TAK-063 placebo-matching tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight; Period 3, Day 1: TAK-063 30 mg tablets, orally, single dose and ketamine, intravenous administration according to a bolus infusion adjusted to the participant's weight. Period 1 & 2 are followed by 7 day washout period
3096095|NCT01892267|Experimental|Self-propelled PEGJ feeding tube|Patients in this arm will receive self-propelled balloon PEGJ tube.
3096096|NCT01892267|Active Comparator|Standard PEGJ feeding tube|Patients in this arm will receive the standard commercially availabel PEGJ tube.
3096097|NCT01892293|Experimental|Autologous genetically modified T cells|Patients with a confirmed diagnosis of myeloma, with measurable disease, and who have received prior therapy for their myeloma that includes an IMiDs and a proteasome inhibitor and who have relapsed or progressive disease, will receive treatment with NY-ESO-1c259-modified T cells. An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
3096098|NCT01892306|Experimental|Treatment as usual plus UP CBT|Existing psychiatrist-administered psychopharmacotherapy plus weekly transdiagnostic CBT
3096099|NCT01892306|Active Comparator|Treatment as usual|Existing psychiatrist-administered psychopharmacotherapy
3096100|NCT01892345|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction Period: Participants received eculizumab (900 milligrams [mg]) via intravenous (IV) infusion once a week (every 7 ± 2 days) for 4 weeks followed by eculizumab 1200 mg for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received eculizumab (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
3096101|NCT01892345|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient. Induction Period: Participants received matching placebo (900 mg) via IV infusion once a week (every 7 ± 2 days) for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose (Week 4). This was followed by the Maintenance Period: Participants received matching placebo (1200 mg) via IV infusion every 2 weeks (every 14 ± 2 days) from the sixth dose (Week 6) onwards.
3096102|NCT01892436|Experimental|Secukinumab 75mg|Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator
3096103|NCT01892436|Experimental|Secukinumab 150mg|Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator
3096104|NCT01892436|Experimental|Placebo - AIN457A 75mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5 mL solution solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg
3096105|NCT01892436|Experimental|Placebo - AIN457 150mg|Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 1 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg
3096106|NCT01892501|Other|hypermetabolic mediastinal lymph nodes in PET,|hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
3096107|NCT01892540|Experimental|Cohort 1: Standard positioning device|Patients undergo clinical FDG-PET/CT followed by prone breast PET/CT and/or prone breast PET/MRI with or without DTPA.
3096108|NCT01892540|Experimental|Cohort 2: New positioning device|
3096109|NCT01892540|Experimental|Cohort 3: Current positioning device until new is available|
3096110|NCT01892657|Experimental|Facial Moisturizer with SPF 50+|All subjects received Cetaphil Daily Facial Moisturizer with SPF 50+
3132599|NCT03440320|Experimental|MY-Skills Intervention - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
3096111|NCT01892709|Experimental|Hydromorphone|"All eligible patients will receive 1 mg IV hydromorphone. Thereafter, they will be repeatedly asked the question, Do you want more pain medicine? This question will be asked 30 minutes after they answered no or 30 minutes after the completion of the next dose of 1 mg IV hydromorphone, which occurs when the patients answers yes. Patients will receive a maximum of 4 mg IV hydromorphone over a 4 hour period."
3096112|NCT01892722|Experimental|Fingolimod|Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
3096113|NCT01892722|Active Comparator|Interferon beta-1a|An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
3096114|NCT01892722|Experimental|Fingolimod-Younger Cohort|The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage <2)
3096115|NCT01892865|Active Comparator|Historical means method|Operative time will be predicted using historical service means. Schedule will be constructed using this time
3096116|NCT01892865|Experimental|Predictive Modeling System (PMS)|Operative time will be predicted using a regression model. Schedule will be constructed using this time
3096117|NCT01893203|Other|BF-200 ALA vs MAL|BF-200 ALA cream and MAL (Metvix, Galderma) used in a randomized split-face design
3096118|NCT01893281|Experimental|Topical Testosterone Solution|Topical Testosterone Solution 30 milligrams up to 120 milligrams per day (mg/day) administered topically to axillae titrated based on testosterone levels.
3096119|NCT01893346|Experimental|CAZ-AVI|This arm will include 4 cohorts. Patients will be stratified by age.
3096120|NCT01893372|Experimental|Eltrombopag|Eltrombopag 200 mg by mouth daily in a 28 day cycle.
3096121|NCT01893372|Experimental|Eltrombopag + Hypomethylating Agent (HMA)|"Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.~The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent."
3096122|NCT01893411|Experimental|16 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3096123|NCT01893411|Experimental|12 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3096124|NCT01893411|Experimental|4 Units per kg body weight incobotulinumtoxinA (Xeomin)|
3096125|NCT01893567|Experimental|Clobex spray|
3096126|NCT01893632|Experimental|Gabapentin|All study medication will be over-capsulated with riboflavin to assess compliance using quantitative fluoroscopy. All participants will take three capsules three times per day throughout the study period. During week 1, GBP will be titrated over a five-day period to the dose target (GBP 1200 mg three times daily) or the maximum tolerated dose. Medication dosing will continue at GBP 1200 mg three times daily or placebo through the end of the study period (week 12). Dose reductions will be made for tolerability if necessary.
3096127|NCT01893632|Placebo Comparator|Placebo|Capsules filled with riboflavin.
3096128|NCT01893801|Experimental|nab-paclitaxel+Cisplatin+gemcitabine|This is a phase Ib/II open-label, pilot study evaluating the preliminary efficacy and safety of nab-paclitaxel 125mb/m2, cisplatin 25mg/m2, and gemcitabine 1000mg/m2, all administered intravenously (IV) on Days 1 and 8 every 21 days until development of toxicity that is unacceptable in the opinion of the patient or the Investigator or upon disease progression.
3096129|NCT01893827|Active Comparator|XR-NTX|Xr-NTX 380mg IM injection monthly x 6 months
3096130|NCT01893827|Active Comparator|Oral Naltrexone|Oral naltrexone 50mg/day x 6 months
3096131|NCT01893879|Experimental|(RS)2-(3-benzoylphenyl)-propionic acid|"Patients receive study drug PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
3096132|NCT01893879|Placebo Comparator|placebo for study drug|"Patients receive placebo PO TID for up to 1 year in the absence of disease progression or unacceptable toxicity.~Laboratory biomarker analysis will be performed."
3096133|NCT01893905|Experimental|CS+SG|Chondroitin sulfate 1200mg+ glucosamine sulfate 1500mg orally administered once a day for 24 weeks
3096134|NCT01893905|Placebo Comparator|Placebo|Placebo of chondroitin sulfate + glucosamine sulfate orally administered once a day for 24 weeks
3096135|NCT01893983|Experimental|Motivational Coaching|Telephone based Motivational Coaching sessions
3096136|NCT01893983|No Intervention|Referral alone|This is the current standard of care
3096137|NCT01894022|Experimental|Ambrisentan Arm|All subjects will receive ambrisentan initially at a dose of 5 mg once daily (OD). Based on the investigator's best judgment, the subject may continue on 5 mg OD, or be up-titrated to 10 mg OD. The dose may also be adjusted back to 5 mg OD at investigator discretion.
3096138|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 1|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3096139|NCT01894087|No Intervention|Enhanced usual care - Cohort 1|
3096140|NCT01894087|Active Comparator|Therapist-led brief intervention (TBI) - Cohort 2|"Participants will receive a therapist-led, computer-assisted intervention session with a master's level therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3096141|NCT01894087|No Intervention|Enhanced usual care - Cohort 2|
3096142|NCT01894100|Other|Delayed Intervention Group|This group will not receive shoe lifts during the first 3 months after baseline. At 3 months, they will begin the shoe lift correction for leg length inequality.
3096143|NCT01894100|Experimental|Immediate Intervention Group|At baseline, participants in this group will begin shoe lift correction for leg length inequality.
3096144|NCT01894152||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
3096145|NCT01894178|Active Comparator|Parker Flex-Tip® Tracheal Tube|Intubation of obese patients with the Parker Flex-Tip® Tracheal Tube
3096146|NCT01894178|Active Comparator|Portex® Tracheal Tube|Intubation of obese patients with the Portex® Tracheal Tube
3096147|NCT01894230|Experimental|Genotype results plus usual care|SLCO1B1*5 allele testing, results reported at randomization: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization.
3096148|NCT01894230|Active Comparator|Usual care only|SLCO1B1*5 allele testing, results reported at end of study: genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
3096149|NCT01894243|Other|Normal hepatic function|"Patients with:~(i) negative result for serum hepatitis B surface antigen and hepatitis C antibody (ii) total bilirubin ≤1.5 x institutional upper limit of normal (ULN), albumin and prothrombin time within normal limits and must not have ascites (unless related to disease under study) or encephalopathy (iii) aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST), alanine aminotransferase or serum glutamic pyruvic transaminase (ALT) ≤2.5 x institutional ULN unless liver metastases are present in which case it must be ≤5 x ULN"
3096150|NCT01894243|Other|Mild hepatic impairment|As defined by the Child-Pugh Classification System.
3096151|NCT01894243|Other|Moderate hepatic impairment|As defined by the Child-Pugh Classification System.
3096152|NCT01894256|Other|Normal renal function|Patients with calculated serum creatinine clearance ≥81 mL/min (using Cockcroft-Gault equation).
3096153|NCT01894256|Other|Mild renal impairment|Patients with calculated serum creatinine clearance 51-80 mL/min (using Cockcroft-Gault equation).
3096154|NCT01894256|Other|Moderate renal impairment|Patients with calculated serum creatinine clearance 31-50 mL/min (using Cockcroft-Gault equation).
3096155|NCT01894477|Experimental|Arm A|"Arm A: Treosulfan, Fludarabine Phosphate~Treosulfan intravenously (IV) over 2 hours on days -6 to -4 and fludarabine phosphate IV over 30 minutes on days -6 to -2."
3096156|NCT01894477|Experimental|Arm B|"Arm B: Treosulfan, Fludarabine Phosphate, TBI~Treosulfan and fludarabine phosphate as in Arm A and undergo low -dose total-body irradiation (TBI) on day 0"
3096157|NCT01894503|Experimental|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
3096158|NCT01894516|Placebo Comparator|Placebo|Participants received GLPG0634 matching placebo capsules, orally, once daily (QD) during Weeks 1 to 12 and GLPG0634 100 milligram (mg) QD during Weeks 13 to 24.
3096159|NCT01894516|Experimental|GLPG0634 50 mg QD|Participants received GLPG0634 50 mg capsules, orally, QD during Weeks 1 to 12. Participants who were responders (having at least 20% improvement on TJC68 and SJC66) remained on 50 mg QD while nonresponders were re-randomized to 100 mg QD during Weeks 13 to 24.
3096160|NCT01894516|Experimental|GLPG0634 100 mg QD|Participants received GLPG0634 100 mg capsules, orally, QD during Weeks 1 to 24.
3096161|NCT01894516|Experimental|GLPG0634 200 mg QD|Participants received GLPG0634 200 mg capsules, orally, QD during Weeks 1 to 24.
3096162|NCT01894555|Experimental|Aspirin|Participants treated with aspirin - there is no control group. Participant's baseline will act as their control.
3096163|NCT01894568|Experimental|Insulin Peglispro|Insulin Peglispro administered subcutaneously (SC) once daily for 26 weeks in combination with Oral Antihyperglycemic Medications (OAMs).
3096164|NCT01894568|Active Comparator|Insulin Glargine|Insulin Glargine administered SC once daily for 26 weeks in combination with OAMs.
3096165|NCT01894581|Experimental|Obese Women|Women with a BMI of greater than or equal to 30 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
3096166|NCT01894581|Active Comparator|Normal Weight|Women with a BMI of between 18-25 kg/m2 underwent all study interventions, including taking 5 g daily of LOVAZA for one cycle. Women underwent 8 hours of frequent blood sampling every 10 minutes both at baseline and after LOVAZA supplementation. Each frequent blood sampling included IV administration of GnRH at 6 hours.
3096167|NCT01894607|Experimental|Contrast Enhanced Intraoperative Ultrasound|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier.~Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having."
3096168|NCT01894620|Placebo Comparator|rTMS with sham coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
3096169|NCT01894620|Active Comparator|rTMS with real coil|rTMS real-sham and rTMS sham-real interventions. Each patient will receive both real and sham treatment in two different blocks of time. The assessments after the sham treatment will serve as placebo effect compared to those after real treatment.
3096170|NCT01894672|Experimental|LGX818|LGX818 capsules will be administered orally on a once -daily schedule (QD) dosing at a dose of 300 mg/day, 2 weeks on followed by a 2 week break. This schedule of 2 weeks on, followed by 2 weeks off, will continue for the duration of time the patients remains on the clinical trial. After the follow up visit patients will be contacted approximately every 12 weeks until they have received a subsequent therapy or until they have been off treatment for a year to monitor their survival.
3096171|NCT01894776|Experimental|Maraviroc|"Two period pharmacokinetic drug-drug interaction Period one -Maraviroc alone; Period two -Maraviroc and Rifabutin~Substance: Maraviroc (Celsentri, MVC) tablets, 300 mg; dose: oral, 300 mg (1 tablet) twice daily~Substance: Rifabutin (mycobutin, RFB) capsules, 150 mg; dose: oral, 300 mg (2 capsules) once daily"
3096172|NCT01894841|Experimental|CLASP Intervention|A 6 month adjunctive intervention consisting of 3 individual meetings, one family session, and 11 brief phone contacts with patient and identified significant other.
3321181|NCT02016937||group E|epidural anesthesia, n: 21
3096173|NCT01894841|Other|Safety Assessment and follow up Evaluation|Treatment as usual plus enhanced monitoring.
3096174|NCT01894906|Placebo Comparator|Control|Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
3096175|NCT01894906|Experimental|Soluble Ferric Pyrophosphate|Group/ cohort designation: Cellulose dialysis membrane (CT-190)/ Polyamide membrane. Each subject will receive one control treatment and 5 treatments with SFP added to dialysate. The 5 SFP treatments will encompass 5 different conditions which may impact the intradialytic transfer of iron to the subject: new dialyzer, reused dialyzer, low blood/dialysate flow rate, low machine delivered bicarbonate concentration, and a different synthetic dialysis membrane (PAES).
3096176|NCT01894919|Experimental|2H3H511_V|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. The subjects in this group received a 5th dose of Bexsero® vaccine in the present study.
3096177|NCT01894919|No Intervention|2H3H511_NV|In the parent study V72_28 (NCT01339923), subjects received three primary doses and one booster dose of Bexsero® vaccine at 2.5, 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
3096178|NCT01894919|Experimental|3H5_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
3096179|NCT01894919|No Intervention|3H5_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 3.5 and 5 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
3096180|NCT01894919|Experimental|68_11_V|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects received a 4th dose of Bexsero® vaccine in the present study.
3096181|NCT01894919|No Intervention|68_11_NV|In the parent study V72_28 (NCT01339923), subjects received two primary doses and one booster dose of Bexsero® vaccine at 6 and 8 months and at 11 months of age, respectively. These subjects were evaluated only for persistence.
3096182|NCT01894919|Experimental|02_2_5_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
3096183|NCT01894919|No Intervention|02_2_5_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
3096184|NCT01894919|Experimental|02_6_10_V|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects received a 3rd dose of Bexsero® vaccine in the present study.
3096185|NCT01894919|No Intervention|02_6_10_NV|In the parent study V72_28 (NCT01339923), these subjects received two catch-up doses of Bexsero® vaccine, two months apart. These subjects were evaluated only for persistence.
3096186|NCT01894919|Experimental|NAIVE 123|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
3096187|NCT01894919|Experimental|NAIVE_4A|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
3096188|NCT01894919|Experimental|NAIVE_4B|Newly recruited naïve subjects who received two catch-up doses of Bexsero® vaccine, one month apart, in the present study.
3096189|NCT01894984||Risperidone|Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
3096190|NCT01894984||Oral atypical anti-psychotic|Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
3096191|NCT01895036|Experimental|Naltrexone|PO naltrexone titration on a mixed inpatient/outpatient basis, followed by administration of Vivitrol four days following the 1st dose of naltrexone
3096192|NCT01895062|Experimental|active cNEP @ -45cmw|cNEP @ -45 cmw is applied to the anterior surface of the neck with a soft collar attached to a vacuum source.
3096193|NCT01895062|No Intervention|no intervention|Routine care is administered without the application of cNEP.
3096194|NCT01895088|Experimental|Patients prev. impl. with ACI 7000 PDT|AcuFocus Corneal Inlay ACI 7000 PDT
3096195|NCT01895101|Placebo Comparator|pericardial lavage with 200 ml normothermic saline solution|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm also receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid."
3096196|NCT01895101|No Intervention|No pericardial lavage|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~In this arm the subjects receives as in standard care no pericardial lavage."
3096197|NCT01895101|Experimental|2 gr tranexamic acid diluted in 200 ml normothermic saline|"According to the anaesthetic protocol of the Amphia Hospital (Breda, the Netherlands), all patients scheduled for cardiac surgery receive intravenously 2 gr TA before sternal incision and 2 gr TA after cardiopulmonary bypass.~This arm receives also pericardial lavage with 2 gr TA diluted in 200 ml normothermic saline solution (NaCl 0.9%)."
3096198|NCT01895127|Active Comparator|Standard of Care|"Plasmapheresis (PP) x 3, at 40-60 cc/kg.~Immunoglobulin (IVIg), to be administered after each PP"
3096199|NCT01895127|Experimental|Soliris (eculizumab)|"1200 mg first dose (Time: Screening/Week 0, after Biopsy Proven AMR)~900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)~1200 mg week 5~Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9"
3321182|NCT02016937||group V|vaginal birth, without anesthesia, n: 21
3096200|NCT01895270|Experimental|Isradipine|Isradipine controlled-release formulation, 10 mg/day maintenance dose, will be administered according to the following dose procedures: Isradipine ingestion will occur under supervision 6 days per week, and a take-home dose will be given on Saturday for participants to take on Sunday. The initial dose of isradipine or placebo will be given on Day 3 of Week 1. The initial dose of isradipine will be 5 mg/day; the dose will increase to 10 mg/day on Day 3 of Week 3 and will continue through Day 2 of Week 7. On Day 3 of Week 7, isradipine will be decreased to 5 mg/day for 7 days. On Days 3-5 of Week 8, all participants will receive placebo. If ISR side effects are too severe at the 10-mg dose, isradipine will be decreased to 5 mg/day. If ISR side effects are too severe at 5 mg/day, isradipine will be discontinued and the participant will be discharged from the study and referred to local treatment agencies.
3096201|NCT01895270|Placebo Comparator|Placebo|Placebo will consist of microcrystalline cellulose. Two placebo capsules will be administered per day starting week 1 day 3 through the end of the isradipine taper.
3096202|NCT01895309|Experimental|SB4 (proposed biosimilar to etanercept)|SB4 50 mg/week via subcutaneous injection
3096203|NCT01895309|Active Comparator|Enbrel (etanercept)|Enbrel 50 mg/week via subcutaneous injection
3096204|NCT01895322|Experimental|OPC-41061|
3096205|NCT01895335|Experimental|Teriflunomide|Teriflunomide 14 mg or 7 mg according to local labelling once daily (QD) orally for 48 weeks.
3096206|NCT01895361|Experimental|High-dose SelG1 (Selg1 5.0 mg/kg)|IV Infusion, once every 4 weeks through Week 50
3096207|NCT01895361|Experimental|Low-dose SelG1 (Selg1 2.5 mg/kg)|IV Infusion, once every 4 weeks through Week 50
3096208|NCT01895361|Placebo Comparator|Placebo|IV Infusion, once every 4 weeks through Week 50
3096209|NCT01895452|Experimental|ALKS 9072, Low Dose|
3096210|NCT01895452|Experimental|ALKS 9072, High Dose|
3096211|NCT01895543|Experimental|EBX10|Elobixibat 10 mg
3096212|NCT01895608|Experimental|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant can safely perform the primary balance or gait task.
3096213|NCT01895608|Active Comparator|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
3096214|NCT01895608|Experimental|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
3096215|NCT01895608|Active Comparator|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
3096216|NCT01895634|Experimental|Treatment|Intervention Device: Rev-01
3096217|NCT01895647|Experimental|Biceps stimulation|EMS
3096218|NCT01895647|Experimental|Quadriceps stimulation|EMS
3096219|NCT01895647|No Intervention|Control|Control group without electric muscle stimulation
3096220|NCT01895777|Experimental|dabigatran etexilate|Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
3096221|NCT01895777|Active Comparator|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
3096222|NCT01895855|Experimental|PXVX0200|Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10^8 CFU
3096223|NCT01895855|Placebo Comparator|Placebo|Biological: Placebo physiological saline
3096224|NCT01895946|Experimental|Part A: Formulation Switch|AZD5363 tablet twice daily followed by AZD5363 capsule twice daily on an intermittent regimen (4 days on, 3 days off).
3096225|NCT01895946|Experimental|Part B: Food effect|AZD5363 tablet twice daily on an intermittent regimen (4 days on, 3 days off) with/without food on one occasion
3096226|NCT01895972|Experimental|Latanoprostene Bunod|Latanoprostene bunod 0.024% instilled into the eye once daily (QD) over a 1-year treatment period.
3096227|NCT01896050||AI therapy|Subjects who started treatment with any of the three aromatase inhibitor (AI) medications
3096228|NCT01896050||Tamoxifen|Subjects who started treatment with tamoxifen
3096229|NCT01896115|Experimental|Short PW|Patients with a Vercise DBS system programmed to 30 microseconds pulse width
3096230|NCT01896115|Experimental|Conventional PW|Patients with a Vercise DBS system programmed to 60 microseconds pulse width
3096231|NCT01896115|Experimental|Ventral current steering|Patients with a Vercise DBS system programmed to steer current ventrally
3096232|NCT01896115|Experimental|Dorsal current steering|Patients with a Vercise DBS system programmed to steer current dorsally.
3096233|NCT01896128|Experimental|Armodafinil|150 mg armodafinil administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
3096234|NCT01896128|Placebo Comparator|Placebo|inactive agent administered 2 hours prior to start of therapeutic regimen for 10 consecutive days
3096235|NCT01896193|Experimental|SOF+RBV 16 Weeks|SOF+RBV for 16 weeks
3096236|NCT01896193|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3096237|NCT01896206|Experimental|CNAP monitor|Subjects undergoing bariatric surgery and monitored using the CNAP monitor.
3096238|NCT01896232|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 30 mg daily and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
3096239|NCT01896232|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW, and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and could have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
3096240|NCT01896271|Experimental|treatment|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion; SABR dose varying from 8Gy-20Gy in 1-3 fractions.
3096241|NCT01896297|Other|dabigatran etexilate|75mg BID by oral
3096242|NCT01896544|Active Comparator|Cholecalciferol Dose II|Oral suspension cholecalciferol 400,000 IU
3096243|NCT01896544|Placebo Comparator|Placebo|Oral suspension of placebo cholecalciferol
3096244|NCT01896544|Active Comparator|Cholecalciferol Dose I|Oral suspension cholecalciferol 200,000 IU
3096245|NCT01896557|Experimental|omeprazole|Omeprazole 20 mg (oral route) twice a day will be given to the subjects for one week. This intervention will be compared with ranitidin 150 mg (oral route) twice a day.
3096246|NCT01896557|Experimental|ranitidine|Ranitidine 150 mg (oral route) twice a day will be given to the subjects for one week.
3096247|NCT01896687|Experimental|Scrambler therapy|Scrambler therapy applied to region of low back pain for 30 minutes x 10 days
3096248|NCT01896687|Sham Comparator|Sham Scrambler treatment|Sham treatment applied to region above low back pain at nontherapeutic dose for 30 minutes x 10 days
3096249|NCT01896700|Experimental|Methylphenidate|"Intervention: An escalating dose of methylphenidate taken by mouth: 20mg for 2 weeks, 40mg for 2 weeks, 60mg for 2 weeks. All doses divided twice/day.~Other name: Ritalin"
3096250|NCT01896700|Placebo Comparator|Placebo|Placebo pill, bid for 6 weeks
3096251|NCT01896726|Experimental|Baricitinib + Microgynon|Microgynon [30 micrograms (µg) ethinyl estradiol and 150 µg levonorgestrel] administered orally, once daily (QD), on Days 1 and 29. Baricitinib, 10 milligrams (mg), administered orally QD on Days 23 through 30.
3096252|NCT01896856|Experimental|Phase 1: Dose Escalation|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Various doses of SGI-110 are tested to determine the maximum tolerated dose in combination with irinotecan."
3096253|NCT01896856|Experimental|Phase 2: Arm A SGI-110 + irinotecan|"Subjects receive SGI-110 on days 1-5 and irinotecan on days 8 and 15 of each 28-day cycle.~Growth factor support (filgrastim and peg-filgrastim) is given during cycle 1 with option to give additional growth factor support at subsequent cycles per clinician judgement."
3096254|NCT01896856|Active Comparator|Phase 2: Arm B regorafenib or TAS-102|"Subjects received either regorafenib or TAS-102 based on physician and patient preference. Subjects that had received one of these standard of care drugs (regorafenib or TAS-102) prior to enrollment received the other on study.~Regorafenib taken daily from days 1-21 of each 28-day cycle or TAS-102 taken twice daily on days 1-5 and 8-12 of each 28-day cycle.~Subjects who had disease progression on Arm B were given the option to receive Arm A study drugs after a 14 day wash-out period."
3096255|NCT01896869|Experimental|Ipilimumab + Vaccine (Arm A)|Ipilimumab and vaccine will be administered every 3 weeks for 4 doses, then every 8 weeks.
3096256|NCT01896869|Experimental|FOLFIRINOX (Arm B)|Administered every 14 days (one cycle)
3096257|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 25U per eye|Main Period: one injection session, 25 Units per eye. Open-Label Extension: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
3096258|NCT01896895|Experimental|IncobotulinumtoxinA (Xeomin) 12.5U per eye|Main Period: one injection session, 12.5 Units per eye. Open-Label Extension Period: one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection.
3096259|NCT01896895|Placebo Comparator|Placebo|"Main Period: Placebo to IncobotulinumtoxinA (Xeomin)(12.5 or 25U/eye), one injection session.~Open-Label Extension: IncobotulinumtoxinA (Xeomin), one injection session, up to 35 Units per eye. Mode of administration: intramuscular injection."
3096260|NCT01896921|Experimental|Maraviroc + Raltegravir or Dolutegravir|Maraviroc 300 mg tablet twice a day plus Raltegravir 400 mg tablet twice a day or Dolutegravir 50 mg tablet once a day for 48 weeks
3096261|NCT01896934|Experimental|Sertraline|50-200mg daily
3096262|NCT01896986||PRD patrients|"Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus)~Subgroups:~receiving immunosuppressant therapy~not on immunosuppressant therapy"
3096263|NCT01896986||IBD patients|"Children/adolescent females 12-26 years diagnosed with IBD.~Subgroups:~3. receiving immunosuppressant therapy 4. not on immunosuppressant therapy"
3096264|NCT01897025|Active Comparator|real-tDCS with MI-BCI|"10 sessions of the following: 20 minutes of tDCS prior to each session of motor training with the MI-BCI system.~Direct current at an intensity of 1mA with anode placed over the M1 motor cortex of the affected hemisphere and the cathode placed over the unaffected M1.~After initial calibration, MI-BCI training will involve motor imagery of reaching tasks using the clock game interface of the MIT-Manus robotic system to perform multi-directional reaching movements. Upon detection of the intention to move towards the target on BCI, the robotic arm will complete the reaching movement towards the target. Each training session will last for 40 minutes excluding set-up time."
3096265|NCT01897025|Sham Comparator|sham-tDCS with MI-BCI|"10 sessions of sham tDCS with BCI motor training, each session of which will be conducted as follows:~The same electrode placement and stimulation parameters will be employed for sham tDCS as for real tDCS. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation. This method of sham stimulation has also been validated (Gandiga et al., 2006). Current intensity will be increased and decreased gradually to decrease perception.~MI-BCI training will be the same as the real-tDCS group and will similarly last for 40 minutes."
3096266|NCT01897077|Experimental|Peanut Allergic|Only one intervention will be given. Peanut allergic study subjects, will receive gradually increasing doses of the dissolving peanut film.
3096267|NCT01897077|Active Comparator|Healthy Volunteers|Healthy volunteers will receive active peanut dissolving films in an expedited manner in order to determine safety dissolving films.
3096268|NCT01897233|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A Cohort 1: Participants aged 6 through 8 years will receive LUM 200 milligram (mg) in fixed-dose combination with IVA 250 mg orally every 12 hours (q12h) for 14 days.~Part A Cohort 2: Participants aged 9 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 14 days.~Part B: Participants aged 6 through 11 years will receive LUM 200 mg in fixed-dose combination with IVA 250 mg orally q12h for 24 weeks."
3096269|NCT01897285|Experimental|All study participants: AQUACEL® foam adhesive dressings|Original adhesive + test adhesive
3096270|NCT01897402|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
3096271|NCT01897402|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
3096272|NCT01897493|Active Comparator|Digoxin|0.5 milligram (mg) digoxin administered orally once daily (QD) on Day 1
3096273|NCT01897493|Experimental|Evacetrapib + Digoxin|130 mg evacetrapib administered orally, QD for 14 days (Days 6 through 19) with a single oral dose of 0.5 mg digoxin coadministered on Day 15
3096274|NCT01897532|Experimental|Linagliptin|
3096275|NCT01897532|Placebo Comparator|Placebo|
3096276|NCT01897714|Experimental|Phase I: Melflufen 15 mg + Dexamethasone|Intravenous (IV) infusion of 15 milligram (mg) melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
3096277|NCT01897714|Experimental|Phase I: Melflufen 25 mg + Dexamethasone|IV infusion of 25 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
3096278|NCT01897714|Experimental|Phase I: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
3096279|NCT01897714|Experimental|Phase I: Melflufen 55 mg + Dexamethasone|IV infusion of 55 mg melflufen on Day 1 of each 21-day treatment cycle, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycle.
3096280|NCT01897714|Experimental|Phase I + II: Melflufen 40 mg + Dexamethasone|IV infusion of 40 mg melflufen on Day 1 of each 21-day or 28-day treatment cycles, in combination with 40 mg dexamethasone (oral or IV) on Days 1, 8 and 15 of each 21-day treatment cycles. For any patients on the 28-day treatment schedule, an additional dose of 40 mg dexamethasone was administered on Day 22 of each treatment cycle.
3096281|NCT01897714|Experimental|Phase II: Melflufen 40 mg (Single Agent)|IV infusion of 40 mg melflufen on Day 1 of each 28-day treatment cycle.
3096282|NCT01897727|Active Comparator|Spironolactone|Spironolactone 25 mg administered following baseline measurements and uptitrated to 50 mg if BP > 140/90 mm Hg throughout the 3 month study.
3096283|NCT01897727|Sham Comparator|Standard of care BP treatment|Antihypertensive medication added and/or uptitrated to keep BP < 140/90 mm Hg throughout the study.
3096284|NCT01897766||Somatropin|Patients administered Somatropin.
3096285|NCT01897792|Experimental|Vitamins C and E|Vitamin C (1,000 mg i.v.) and Vitamin E (1,000 IU p.o. via the naso-gastric tube) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
3096286|NCT01897792|Placebo Comparator|0.9% saline and sugar pill|100 ml of 0.9% saline (for i.v. Vitamin C) and a p.o. placebo (sugar pill for the p.o. Vitamin E) administered every 8 hours starting within one hour after admission to the Emergency department for up to 5 days or until discharge from the ICU, whichever comes first.
3096287|NCT01897896|Experimental|Rollover Cohort: SD-809 ER|Participants who completed study SD-809-C-15 (NCT01795859, including 1-week washout period and Week 13 evaluation), will receive 6 milligrams (mg) SD-809 ER tablet once daily as a starting dose in this study. Dose titration will be continued through Week 8 to optimize dose. Dose of SD-809 ER can be adjusted weekly in increments of 6 milligrams per day (mg/day) (6 or 12 mg/day after a total daily dose of 48 mg is reached) based on chorea control and adverse events. Daily doses of SD-809 ER 12 mg and higher will be administered twice daily. Maximum total daily dose of SD-809 ER will be 72 mg/day (36 mg twice daily), unless participant is receiving a strong CYP2D6 inhibitor(such as, paroxetine, buproprion, fluoxetine), in which case maximum total daily dose will be 42 mg (21 mg twice daily). Long-term treatment with SD-809 ER at a stable dose (further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
3096288|NCT01897896|Experimental|Switch Cohort: SD-809 ER|Participants who were receiving an approved dosing regimen of tetrabenazine for at least 8 weeks prior to screening, will be converted overnight from their existing tetrabenazine regimen to SD-809 ER regimen to achieve targeted steady-state area under the curve (AUC) of total (alpha+beta)- Dihydrotetrabenazine (HTBZ) metabolites that is predicted to be comparable to that of participant's prior tetrabenazine regimen. Participants will remain on initial dose of SD-809 ER through Week 1. Dose adjustment will be continued through Week 4 to optimize the dose. Dose of SD-809 ER can be adjusted weekly (upward or downward) in increments of 6 mg per day (6 mg/day or 12 mg/day after a total daily dose of 48 mg is reached), based on chorea control and treatment regimen tolerability. Long-term treatment with SD-809 ER at a stable dose (although further dose adjustments are permitted, if clinically indicated) will be continued until SD-809 ER become commercially available in United States.
3096289|NCT01898013|Active Comparator|Pregnenolone|"Pregnenolone fixed escalating up to 500mg/day will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): 50mg PO, BID x 1 week, Visit 4 (week 2): 150mg PO, BID x 1 week, Visit 5 (week 3): 250mg PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered by 100mg per day and then discontinued."
3096290|NCT01898013|Placebo Comparator|Placebo|"Placebo will be administered exactly the same as the active comparator (pregnenolone) and will consist of the following schedule:~Visit 1 (week -1, screening visit) and pain symptom assessment (no study medication) Visit 2 (week 0) placebo lead-in (all participants) Visit 3 (week 1, baseline visit): placebo PO, BID x 1 week, Visit 4 (week 2): placebo PO, BID x 1 week, Visit 5 (week 3): placebo PO, BID for two weeks. Visit 6 (week 5): No medication will be dispensed; study medication will be tapered in the exact manner as active study medication and then discontinued."
3096291|NCT01898078|Experimental|Alisertib 50 mg Fed + Fasted|Alisertib 50 mg, enteric-coated tablets (ECT), orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, twice daily (BID) on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
3321183|NCT02016950||Permanent pacemaker|Pre-existing permanent pacemakers
3321184|NCT02016976|Active Comparator|EMLA analgesic cream|Patients who have had EMLA analgesic cream applied to area before pacemaker implantation
3096292|NCT01898078|Experimental|Alisertib 50 mg Fasted + Fed|Alisertib 50 mg, ECT, orally, in fasted state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 1 (24-day cycles), followed by alisertib 50 mg, ECT, orally, in fed state, once on Day 1, followed by alisertib 50 mg, ECT, orally, BID on Days 4 through 10, followed by a 14-day rest period in Cycle 2, followed by alisertib 50 mg, ECT, orally, BID on Days 1-7, followed by a 14-day rest period in Cycle 3 and onwards (21-day cycles) until disease progression, occurrence of an unacceptable alisertib-related toxicity.
3096293|NCT01898091|Experimental|Neem Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
3096294|NCT01898091|Placebo Comparator|Placebo Mouthrinse|Participants will rinse for 30 seconds with the measured 10ml dose of the assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
3096295|NCT01898130|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3096296|NCT01898195|Active Comparator|Standard Care|Participants in this arm will receive varenicline for smoking cessation.
3096297|NCT01898195|Experimental|Standard Care + Text message|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts.
3096298|NCT01898195|Experimental|Standard Care + Text Message + ABT|Participants in this arm will receive varenicline, plus twice daily adherence/motivational texts and seven phone developed Adherence Behavioral Therapy sessions
3096299|NCT01898208|Experimental|Control|Standard Mayo practices (bacterial culture and susceptibility testing) will be used. FilmArray testing will not be performed.
3096300|NCT01898208|Experimental|FilmArray test|Standard Mayo practices will be used AND FilmArray testing will be performed. Results of the FilmArray Blood Culture ID Panel test will be communicated to the service by phone in real-time, 24 hours a day, 7 days a week.
3096301|NCT01898208|Experimental|FilmArray plus antimicrobial stewardship|Standard Mayo practices will be used. FilmArray testing will be performed and reported as above, for intervention group 1. IN ADDITION, an expert will review the subject's FilmArray Blood Culture ID Panel result and medical record and contact the primary service if a modification of antimicrobial therapy may be appropriate.
3096302|NCT01898286|Experimental|DiaPep277®|Administration of DiaPep277® to patients previously enrolled in the Phase 3 Study 1001 (NCT01103284)
3096303|NCT01898299|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) treatments will take place for 20 minutes per day for 5 consecutive days
3096304|NCT01898299|Sham Comparator|Sham tDCS|Sham tDCS(inactive)treatment (transcranial Direct Current Stimulation) will take place for 20 minutes per day for 5 consecutive days.
3096305|NCT01898403|Experimental|Sentinel Lymph Node (SLN) Detection|All patients receive peri-tumoral, intradermal injections of isosulfan blue and indocyanine green solution for detection of melanoma in lymph nodes. In addition, lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC) will be conducted for all participants with the same objective.
3096306|NCT01898429|Active Comparator|Left-sided SCC DBS|Active Stimulation of the left-sided electrode
3096307|NCT01898429|Active Comparator|Right-sided SCC DBS|Active stimulation of the right-sided electrode
3096308|NCT01898442|Active Comparator|Ticagrelor 180|Standard ticagrelor 180mg loading dose
3096309|NCT01898442|Experimental|Ticagrelor 270mg|High ticagrelor 270mg loading dose
3096310|NCT01898442|Experimental|Ticagrelor 360mg|High ticagrelor 360mg loading dose
3096311|NCT01898598|Placebo Comparator|Placebo|Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
3096312|NCT01898598|Experimental|Vismodegib|Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
3096313|NCT01898611|Active Comparator|Ghrelin plus resistance training|Ghrelin 7.5 mcg/kg as a once daily subcutaneous dose for 12 weeks plus resistance training
3096314|NCT01898611|Placebo Comparator|Placebo plus resistance training|Placebo as a once daily subcutaneous dose for 12 weeks plus resistance training
3096315|NCT01898689|Experimental|RIGHT side Ropivacaine 0.1% and LEFT side Ropivacaine 0.4%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.1% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.4% was infused at 2 mL/h for 6 hours.
3096316|NCT01898689|Active Comparator|RIGHT side Ropivacaine 0.4% and LEFT side Ropivacaine 0.1%|Bilateral sciatic perineural catheters were inserted and ropivacaine administered as a basal infusion concurrently. For the right catheter, ropivacaine 0.4% was infused at 8 mL/h basal for 6 hours. For the left catheter, ropivacaine 0.1% was infused at 2 mL/h for 6 hours.
3096317|NCT01898754|Experimental|Pre-ART Oligonucleotide Assay (OLA)|Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
3096318|NCT01898754|No Intervention|No OLA (Standard of Care [SOC])|The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
3096319|NCT01898806|Experimental|IL TAC 2.5 mg/ml|"Intralesional Triamcinolone 2.5 mg/ml (IL TAC 2.5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20"
3096320|NCT01898806|Experimental|IL TAC 5 mg/ml|"Intralesional Triamcinolone 5mg/ml (IL TAC 5 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
3096321|NCT01898806|Experimental|IL TAC 10 mg/ml|"Intralesional Triamcinolone 10mg/ml (IL TAC 10 mg/ml):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20."
3321185|NCT02016976|Active Comparator|Routine treatment|Patients who have received routine treatment (Dormicum 2.5 mg and Pethidine 25 mg) before and during pacemaker implantation
3096322|NCT01898806|Placebo Comparator|Placebo|"Intralesional Saline (Placebo):~Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months. Injections will be performed at baseline, weeks 4, 8, 12, 16 and 20. Open label treatment with IL kenalog at the dose deemed most appropriate may be administered after the 1st 6 months in nonresponders or partial responders."
3096323|NCT01898884|Experimental|Single dose of VP 20629 or placebo|Four groups of 8 subjects each will receive a single dose of VP 20629 (150 mg, 450 mg, 900 mg, or 1200 mg) or placebo.
3096324|NCT01898884|Experimental|Multiple doses of VP 20629 or placebo|Three groups of 8 subjects each will receive multiple doses of VP 20629 (300 mg, 600 mg, or 900 mg total daily dose) or placebo. VP 20629 or placebo will be administered every 8 hours for 7 days with a single morning dose on Day 8.
3096325|NCT01898923|Experimental|ON101 Cream|ON101 Cream (1.25%),15g ointment per tube. Twice daily for up to 16 weeks.
3096326|NCT01898923|Other|Aquacel® Hydrofiber® dressing|Aquacel® Hydrofiber® dressings will be changed daily, on alternate days or three times a week according to need, but not longer than 7 days.
3096327|NCT01899053|Experimental|Dose Escalation Treatment Arm A|TAK-228 2 or 4 mg, capsule (milled or unmilled), orally, once daily every day (QD), and TAK-117 100, 200 or 300 mg, capsule, orally, once on Monday, Wednesday and Friday each week (MWF QW) for up to 13 cycles (each cycle was 28 days), up to approximately 52 weeks.
3096328|NCT01899053|Experimental|Dose Escalation Treatment Arm B|TAK-228 3, 4, 6 or 8 mg, capsule (milled or unmilled), orally, once on Monday, Tuesday and Wednesday each week (MTuW QW), and TAK-117 100 or 200 mg, capsule, orally, once on MTuW QW for up to 9 cycles (each cycle was 28 days), up to approximately 38.7 weeks.
3096329|NCT01899053|Experimental|Dose Escalation Treatment Arm C|TAK-228 3 mg, capsule (milled or unmilled), orally, once on MTuW QW, and TAK-117 300 or 400 mg, capsule, orally, once on MTuW QW for up to 17 cycles (each cycle was 28 days), up to approximately 64.3 weeks.
3096330|NCT01899053|Experimental|Drug-Drug Interaction (DDI) Expansion Cohort|TAK-228 4 mg, capsule (milled), orally, once on MTuW QW except on Days 15, 16 and 17 of Cycle 1, and TAK-117 200 mg, capsule, orally, once on MTuW QW except on Days 1, 2 and 3 of Cycle 1 for up to 8 cycles (each cycle was 28 days), up to approximately 31.4 weeks.
3096331|NCT01899144|Experimental|Albuterol Spiromax 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the DPIs contains Albuterol Spiromax 90 mcg; the other three devices contained placebo."
3096332|NCT01899144|Experimental|Albuterol Spiromax 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the DPIs contain Albuterol Spiromax 90 mcg for a total dose of 180 mcg; the MDIs contained placebo."
3096333|NCT01899144|Active Comparator|ProAir HFA 90 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, one of the MDIs contains ProAir HFA 90 mcg; the other three devices contained placebo."
3096334|NCT01899144|Active Comparator|ProAir HFA 180 mcg|"At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind.~In this arm, both of the MDIs contain ProAir HFA 90 mcg for a total dose of 180 mcg; the DPIs contained placebo."
3096335|NCT01899144|Placebo Comparator|Placebo|At each treatment visit, participants receive 1 actuation from each of 4 pre-arranged device combinations comprising 2 dry powder inhalers (DPIs) and 2 metered-dose inhalers (MDIs) in order to maintain the study blind. In this arm, all devices contain placebo.
3096337|NCT01899300|Experimental|Metal Stent|The WallFlex™ Esophageal Fully Covered Metal Stent (FCMS)is being evaluated for the treatment of refractory benign esophageal strictures caused by caustic ingestion.
3096338|NCT01899677|Experimental|symbiotic|symbiotic preparation 1/2 sachet twice daily during 30 days
3096339|NCT01899677|Placebo Comparator|distilled water|2 x 0.5 cc distilled water will be given during 30 days
3096340|NCT01899729|Experimental|IMO-8400 Regimen 1|IMO 8400 at 0.075 mg/kq q wk x 12 wks
3096341|NCT01899729|Experimental|IMO-8400 Regimen 2|IMO-8400 at 0.15 mg/kg q wk x 12 wks
3096342|NCT01899729|Experimental|IMO-8400 Regimen 3|IMO_8400 at 0.3 mg/kg q wk x 12 wks
3096343|NCT01899729|Placebo Comparator|Placebo|Saline (placebo) q wk x 12 wks
3096344|NCT01899729|Experimental|IMO-8400 Regimen 4|IMO_8400 at 0.6 mg/kg q wk x 12 wks
3096345|NCT01899742|Experimental|Umeclidinium/Vilanterol|Long-acting muscarinic antagonist (LAMA)/Long-acting Beta agonist (LABA)
3096346|NCT01899742|Active Comparator|Tiotropium|Long-acting muscarinic antagonist (LAMA)
3096347|NCT01899768|Experimental|Part A|Subjects will receive treatment A (placebo) or treatment B (GSK2339345) in 3 visits of part A (one treatment per visit) in one of the following four sequences: ABA, ABB, BAA, and BAB.
3096348|NCT01899768|Experimental|Part B|Subjects will receive treatment A or treatment B in 2 visits of part B (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 microliter (mcL) of a capsaicin solution of strength ranging from 0.49 micromolar (mcM) to 1000 mcM, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 4 and 5.
3096349|NCT01899768|Experimental|Part C|Subjects will receive treatment A or treatment B in 2 visits of part C (one treatment per visit) in one of the following two sequences: AB and BA. Subjects will then orally inhale 10 mcL of a citric acid solution of strength ranging from 0.03 to 4.0 M, which will be administered using a breath activated dosimeter approximately 5 minutes post-dosing with treatment A or B at Visits 6 and 7.
3096350|NCT01899911|Experimental|Vital Signs Patch (VSP)|Infrared and Red absorbance measurement on chest
3096351|NCT01900054|Experimental|TAU-284|Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
3096352|NCT01900067|Active Comparator|Active warming|BARRIER® EasyWarm Active Self-Warming Blanket
3096353|NCT01900067|No Intervention|Control|no active warming, standard of care
3096354|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%
3096355|NCT01900249|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%
3096356|NCT01900249|Placebo Comparator|Placebo|Placebo Ophthalmic Solution, 1 drop per eye twice a day for 12 weeks.
3096357|NCT01900314|Active Comparator|Active rTMS|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the FDA-approved device label (10 Hz) to a targeted area of the brain. After these sessions, a second fMRI will be completed then 5 additional tapering treatments of rTMS over a 2 week period.
3096358|NCT01900314|Sham Comparator|Sham rTMS|20 sham sessions, within a 4 week period, where subjects receive inactive treatments (0 Hz) of repetitive Transcranial Magnetic Stimulation (rTMS). After 20 sessions and completion of a second fMRI scan, patients in this group will then be unblinded and transitioned to the active arm and will receive a full course (25 sessions) of active rTMS over a 6 week period.
3096359|NCT01900392|No Intervention|Control Arm|No other financial incentive other than for the 3-, 6-, 9-, & 12-month weigh-ins and surveys. Participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). Two weigh-ins will be required during Phase II, one at 9 months and the other at 12 months.
3096360|NCT01900392|Experimental|Direct payment|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible to receive an incentive for each day their goal is met during the first 6 months of the study. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
3096361|NCT01900392|Experimental|Lottery|"In addition to the incentives for the 3-, 6-, 9-, & 12-month weigh-ins, participants who meet their daily goal will be eligible for the daily lottery during the first 6 months of the study. The expected daily winning for the lottery is the same as for the direct payment arm. All daily incentive earnings will be paid out after verifying participants' weights during an in person weigh in at a Weight Watchers location at months 3 and 6. Winnings will be proportional to weight loss. For example, if a participant's goal was to lose 6 pounds by month 3, but he/she only lost 3 pounds, that participant would only receive 50% of their total eligible winnings.~Similar to the control arm, participants will receive daily feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weigh-ins at 9- and 12-months will also be required."
3096362|NCT01900431|Placebo Comparator|Placebo|Placebo (for Sarilumab) subcutaneous (SC) injection every 2 weeks (q2w) for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with Methotrexate (MTX) 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
3096363|NCT01900431|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 16 weeks during principal treatment period (Part A) with background therapy of Prednisone (or equivalent oral corticosteroid) ≥15 mg/day and <80 mg/day as single therapy or in combination with MTX 10 to 25 mg/week and folic acid per local prescribing practice. Responders continued with the same treatment regimen up to Week 50 during extension treatment period (Part B) and non-responders were proposed to be treated with open-label Sarilumab 200 mg q2w in open-label treatment period (Part-C).
3096364|NCT01900444|Experimental|IMOJEV Group|Participants who received a single dose of IMOJEV in study JEC12 (NCT01396512) will receive a booster dose in this study.
3096365|NCT01900561|Experimental|IVR Intervention|The intervention will consist of two components, both with content design based on established theories for self-management support: 1) automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach, and 2) personally tailored newsletters that incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Intervention-group participants will receive four automated assessment and self-management support calls over a 3-month period (at baseline, 1-month, 2-month, 3-months). Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
3096366|NCT01900561|No Intervention|Enhanced Usual Care|Because of the strong evidence documenting symptom burden in PC survivors, the investigators believe that providing control subjects with some information about symptom self-management is warranted. The investigators further believe, based on the investigators' prior experience conducting RCTs, that offering some type of educational material for Veterans randomized to the control arm will increase their willingness to enroll in the study (as opposed to a pure usual care arm where they would not receive any such materials). Therefore, survivors randomized to the control condition will receive written material at the time of enrollment designed to educate them about PC symptoms and symptom management. Material will be approximately six pages in length, also written at or below an 8th grade reading level, and will include a summary of common symptoms experienced by prostate cancer survivors.
3096367|NCT01900652|Experimental|Arm A: Emibetuzumab plus Erlotinib|750 milligram (mg) Emibetuzumab flat dose given as a 1.5 hour intravenous (IV) infusion on Days 1 and 15 of a 28-day cycle and Erlotinib 150 mg given orally once daily on a 28-day cycle.
3096368|NCT01900652|Experimental|Arm B: Emibetuzumab|750 mg Emibetuzumab flat dose given as a 1.5-hour IV infusion on Days 1 and 15 of a 28-day cycle.
3096369|NCT01900665|Experimental|Solanezumab|Solanezumab 400 milligrams (mg) every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will take this regimen for up to an additional 208 weeks.
3096370|NCT01900665|Placebo Comparator|Placebo|Placebo every 4 weeks for 76 weeks with an additional 4 weeks of assessments. Participants who complete the full 80 weeks of treatment/assessment and decide to continue will switch to solanezumab 400 mg every 4 weeks for up to an additional 208 weeks.
3096371|NCT01900704|Experimental|SER120 750 ng|SER120 750 ng
3096372|NCT01900704|Experimental|SER120 1500 ng|SER120 1500 ng
3096373|NCT01900704|Placebo Comparator|Placebo|Placebo
3096374|NCT01900899|Experimental|ACWY-TT group|Subjects primed and boosted with the MenACWY-TT vaccine.
3096375|NCT01900899|Active Comparator|MenCCRM group|Subjects primed and boosted with the Meningitec vaccine.
3096376|NCT01901055|Experimental|Active CPAP treatment|Treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP)
3096377|NCT01901055|Placebo Comparator|Sham-CPAP|Device that appears like the treatment of obstructive sleep apnea, a continuous positive airway pressure device, but that does not provide treatment.
3096378|NCT01901146|Experimental|ABP 980|"Participants received ABP 980 at an initial dose of 8 mg/kg by intravenous (IV) infusion, then 6 mg/kg IV infusion every 3 weeks (Q3W) for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants continued receiving 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
3096379|NCT01901146|Active Comparator|Trastuzumab|"Participants received trastuzumab at an initial dose of 8 mg/kg IV infusion, then 6 mg/kg IV infusion Q3W for 3 additional cycles plus 175 mg/m² paclitaxel Q3W for 4 cycles during the neoadjuvant phase.~Surgery (lumpectomy or mastectomy with sentinel lymph node dissection or axillary lymph node dissection) was completed 3 to 7 weeks after the last dose of study drug in the neoadjuvant phase.~After surgery (adjuvant phase) participants were re-randomized to either continue receiving 6 mg/kg trastuzumab IV Q3W or transition to 6 mg/kg ABP 980 IV Q3W for up to 1 year from the first day of study drug administration in the neoadjuvant phase."
3096380|NCT01901185|Experimental|Etanercept / Autoinjector A|Participants self-injected 50 mg etanercept subcutaneously using autoinjector A at the study center on Day 1 and then once a week from Weeks 1 to 5 (total of 6 injections).
3096381|NCT01901211|Experimental|Exergaming|In this arm, the participants will participate in the exergaming intervention.
3096382|NCT01901211|No Intervention|Comparison Arm|In this arm of the study, participants will engage in their typical physical activity routines for the ten week duration. Participants will receive a call from the RA each week. The RA will ask the child to report on all the physical and social activities that they engaged in for that week.
3096383|NCT01901250|Experimental|Xylitol GB|Xylitol gummy bears 7.8g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
3096384|NCT01901250|Placebo Comparator|Fiber GB|Sugar free fiber gummy bears 20g/day throughout the 9 month kindergarten year, oral health education, fluoride varnish, and dental sealant
3096385|NCT01901289|Experimental|Drug-Eluting Stent|
3096386|NCT01901302|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
3096387|NCT01901302|Placebo Comparator|Placebo|Placebo BID for a 12-week treatment period
3096388|NCT01901328|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice dailly (BID) for a 12-week treatment period
3096389|NCT01901328|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
3096390|NCT01901341|Experimental|CB-5945|0.25 milligrams (mg) CB-5945 administered orally twice daily (BID) for a 12-week treatment period
3096391|NCT01901341|Placebo Comparator|Placebo|Placebo administered orally BID for a 12-week treatment period
3096392|NCT01901393|Experimental|IV ibuprofen|800mg ibuprofen
3096393|NCT01901393|Active Comparator|ketorolac|30mg ketorolac
3096394|NCT01901419|Experimental|High-dose NTG|Nitroglycerin infusion 1-5 mcg/kg/min
3096395|NCT01901419|Active Comparator|Low-dose NTG|Nitroglycerin infusion 0-0.1 mcg/kg/min
3321186|NCT02016989|Other|Physiological salt solution|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
3096397|NCT01901575|Experimental|Remifentanil IV PCA|patients with PVC's prior to administration of remifentanil
3096398|NCT01901588|Experimental|Dexmedetomidine|dexmedetomidine/precedex
3096399|NCT01901588|Placebo Comparator|Placebo|patients receive saline solution.
3096400|NCT01901614|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
3096401|NCT01901614|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
3096402|NCT01901653|Experimental|Rovalpituzumab tesirine|Rovalpituzumab tesirine will be administered as a single agent, at increasing dose levels as permitted based on real-time assessment of safety and tolerability, intravenously over 30 minutes. Doses will be repeated on Day 1 of each 21-day or 42-day cycle until either unacceptable toxicity or evidence of disease progression occurs.
3096403|NCT01901809|Active Comparator|Bolus furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 40mg IV every 12 hrs, with total dose of 80 mg IV over 24 hrs will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose every 12 hrs. (i.e if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose will be furosemide 80mg IV twice daily)."
3096404|NCT01901809|Active Comparator|Continuous infusion furosemide and no dopamine|"If the patient is not on a prior diuretic dose, a standard dose of furosemide 80mg IV over 24 hrs, will be initiated.~If the patient is already on a prescribed diuretic dose, their outpatient dose will be doubled and administered as the equivalent IV dose continuously over 24 hrs. . (i.e. if the prescribed dose is furosemide 80mg by mouth twice daily, the inpatient treatment dose would be furosemide 160mg IV to be administered continuously over 24 hrs)."
3096405|NCT01901809|Active Comparator|Bolus furosemide plus dopamine|Intermittent furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
3321187|NCT02016989|Experimental|CACICOL20|The purpose of this study is to evaluate efficiency of CACICOL20 for bacterial keratitis. It is a double blinded comparison of epithelial defect in two groups of patients randomized between CACICOL20 and physiological salt solution.
3096406|NCT01901809|Active Comparator|Continuous furosemide plus dopamine|Continuous furosemide diuretic therapy as outlined with the addition of dopamine at 3 µg/kg/min
3096407|NCT01901848|Experimental|CPT+ICSC|This arm includes 12 sessions of combined Cognitive Processing Therapy (CPT) and Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
3096408|NCT01901848|Active Comparator|ICSC only|This arm includes 12 sessions of Integrated Care for Smoking Cessation (ICSC), involvement in smokefreeVET.gov's text messaging program for smoking cessation, Bupropion use, and nicotine replacement therapy.
3096409|NCT01901874|Experimental|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
3096410|NCT01902004|Active Comparator|Escitalopram and Memantine|Participants will take a combination of Escitalopram and Memantine for 12 months
3096411|NCT01902004|Active Comparator|Escitalopram and placebo|Participants will take a combination of Escitalopram and placebo for 12 months
3096412|NCT01902134|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
3096413|NCT01902134|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
3096414|NCT01902134|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
3096415|NCT01902134|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
3096416|NCT01902134|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
3096417|NCT01902134|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
3096418|NCT01902173|Experimental|Treatment (uprosertib, dabrafenib, trametinib)|"Dabrafenib mesylate and uprosertib: Patients receive dabrafenib PO BID and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dabrafenib mesylate, trametinib dimethyl sulfoxide, and uprosertib: Patients receive dabrafenib PO BID, trametinib PO QD, and uprosertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3096419|NCT01902303|Placebo Comparator|Matching Placebo|Matching Placebo
3096420|NCT01902303|Experimental|BTL-TML-HSV|Experimental Product
3096421|NCT01902459|Active Comparator|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch consists of human fibrinogen and human thrombin embedded in a flexible composite patch component.
3096422|NCT01902459|Other|Standard of Care|Standard of Care (SoC) is manual compression with or without a topical absorbable hemostat.
3096423|NCT01902628||Participants with CKD|This single cohort included participants with CKD not receiving dialysis (Stages 3 and 4), with renal anemia, treated with MIRCERA according to usual clinical practice.
3096424|NCT01902758|Experimental|ambrisentan and theophylline|ambrisentan (5mg) once daily for 2 consecutive days theophylline (400mg) once daily for 2 consecutive days
3096425|NCT01902758|Placebo Comparator|placebo|matched placebo tablets wil be given at the same time to the comparison group as the medications to the experimental group
3096426|NCT01902901|Active Comparator|Usual care|Requested carrier status testing.
3096427|NCT01902901|Experimental|Whole Genome Sequencing|These participants will receive the carrier status testing they requested from their provider, plus whole genome sequencing.
3096428|NCT01902953|Experimental|Lymphoseek and VBD SLN dissection|Ex-Vivo Lymphoseek and VBD SLN dissection
3096429|NCT01903005|Experimental|Open-label BNX sublingual tablets|Weeks 1-24: Higher bioavailability BNX sublingual tablets (open-label) were titrated at doses ranging from 5.7/1.4 mg to 17.1/4.2 mg, to a dose that relieved opioid cravings and withdrawal symptoms with minimal side effects.
3096430|NCT01903031|Experimental|NuvaRing and no ART (Arm A)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days).
3096431|NCT01903031|Experimental|NuvaRing with EFV plus ≥2 NRTIs (Arm B)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). EFV is a non-nucleoside reverse transcriptase inhibitor taken at a dose of 600 mg once daily.
3096432|NCT01903031|Experimental|NuvaRing with ATV/r plus TDF + ≥1 NRTIs (Arm C)|Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). ATV/r is a combination protease inhibitor taken at a dose of 300/100 mg once daily. Tenofovir disoproxil fumarate (TDF) is a nucleoside reverse transcriptase inhibitor (NRTI) taken at a dose of 300 mg daily.
3096433|NCT01903187|Experimental|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
3096434|NCT01903187|Active Comparator|Sham procedure|Sham procedure
3096435|NCT01903252|Experimental|TP05 (Mesalazine) 1600mg|week 1 - week 12 (blinded), week 13 - week 38 (OpenLabel)
3096436|NCT01903252|Active Comparator|Asacol 400 mg (Tillotts Pharma)|week 1 - week 12 (blinded), switch to TP05 for weeks 13-38 (open label)
3096437|NCT01903265|Experimental|TNX-102 SL 2.8 mg|Patients will take 1 tablet of TNX-102 SL sublingually each day at bedtime for 12 weeks.
3096438|NCT01903265|Placebo Comparator|Placebo|Patients will take 1 tablet of placebo sublingually each day at bedtime for 12 weeks.
3096439|NCT01903356||Patients with T2DM|
3096440|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Test|Single oral dose of 130 milligram (mg) evacetrapib tablet on Day 1 of up to 2 of 3 periods
3096441|NCT01903434|Experimental|Evacetrapib -- Solid Fraction Reference|Single oral dose of 130 mg evacetrapib tablet on Day 1 of up to 2 of 3 periods
3096442|NCT01903460|Experimental|LUM001|LUM001 administered orally once each day
3096443|NCT01903460|Placebo Comparator|Placebo|Placebo administered orally once each day
3096444|NCT01903525|Placebo Comparator|Placebo|The placebo capsules are supplied as 950 mg capsules consisting of 475 mg corn oil and 475 mg soy oil. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the placebo for 12 weeks.
3132600|NCT03440320|Active Comparator|MY-Plan control - online|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of light exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain.
3096445|NCT01903525|Experimental|Docosahexaenoic Acid (DHA)|The DHASCO capsules are supplied as 950 mg capsules with an effective dose of 500 mg DHA per capsule. Both DHA and placebo are flavored with sweet orange flavoring and masking agents. Subjects will be instructed to take 2 capsules at breakfast and 2 capsules at dinner (with food). Subjects will take their first dose in the office to assure their ability to swallow the pills. Subjects will be dosed with the DHA for 12 weeks.
3096446|NCT01903564||normal|pregnant women with uncomplicated pregnancies
3096447|NCT01903564||high-risk|pregnant women with pregnancies complicated by fetal arrhythmia or the risk of fetal arrhythmia
3096448|NCT01903720|Experimental|OZURDEX®|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
3096449|NCT01903798|Active Comparator|Prednisolone (Lille <0.45)|At Day 8, after randomization, this participants will continue prednisolone 40 mg/day (current standard of care) for 21 days.
3096450|NCT01903798|Experimental|Prednisolone, rilonacept (Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive rilonacept (Arcalyst®) once a week for 21 days. After randomization at Day 8, study participants will be given 320 mg subcutaneously (two injections of 2.0 ml, 160 mg each). On Day 15 and Day 22, study participants will be given 160 mg subcutaneously (one injection of 160 mg).
3096451|NCT01903798|Active Comparator|Prednisolone (Lille >0.45)|Prednisolone (40 mg/day) for the first 7 days, after randomization at Day 8, they will stop all therapy.
3096452|NCT01903798|Experimental|Prednisolone, mycophenolate(Lille <0.45)|This group will continue Prednisolone (40mg/day). Additionally, they will receive mycophenolate mofetil (CellCept®) for a total of 21 days. After randomization at Day 8, they will receive CellCept® at a dose of 1000 mg per day for the first four days followed by 2000 mg per day (two 500 mg tablets bid) for the remaining 17 days.
3096453|NCT01903811|Experimental|Arm I (dexamethasone, low-dose carfilzomib)|Patients receive dexamethasone IV and low-dose carfilzomib IV over 2-10 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients with progression cross-over to Arm II.
3096454|NCT01903811|Experimental|Arm II (dexamethasone, high-dose carfilzomib)|Patients receive dexamethasone IV and high-dose carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. (Note that course 1 is given at a reduced dose over 2-10 minutes.) Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3096455|NCT01903837|Experimental|Low Dose|Olanzapine + low dose samidorphan tablets taken once daily
3096456|NCT01903837|Experimental|Medium Dose|Olanzapine + medium dose samidorphan tablets taken once daily
3096457|NCT01903837|Experimental|High Dose|Olanzapine + high dose samidorphan tablets taken once daily
3096458|NCT01903837|Placebo Comparator|Placebo|Olanzapine + placebo tablets taken once daily
3096459|NCT01903863|Experimental|Scheduled fresh frozen plasma|Patients enrolled in this arm will receive scheduled fresh frozen plasma treatment every 48 hours.
3096460|NCT01903863|Active Comparator|Control|Patients in this arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
3096461|NCT01903876|Placebo Comparator|General Health promotion|A 3-hour general mental health web-based program.
3096462|NCT01903876|Experimental|Bystander & Sexual Violence Prevention|A 3-hour web-based program designed to teach male college student bystanders to intervene.
3096463|NCT01903993|Active Comparator|Docetaxel|Participants received docetaxel 75 milligram per meter square (mg/m^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.
3096464|NCT01903993|Experimental|Atezolizumab|Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.
3096465|NCT01904058|Experimental|LUM001 and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
3096466|NCT01904058|Placebo Comparator|Placebo and Ursodeoxycholic Acid (UDCA)|Administered orally once daily
3096467|NCT01904071|Experimental|UFNB|Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
3096468|NCT01904071|Experimental|UFIB|Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
3096469|NCT01904071|Active Comparator|IVMS|IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg
3096470|NCT01904149|Experimental|DKP/TRAM followed by DKP/TRAM|Dexketoprofen/Tramadol-single dose followed by Dexketoprofen/Tramadol-multiple doses
3096471|NCT01904149|Active Comparator|DKP followed by DKP|Dexketoprofen-single dose followed by Dexketoprofen-multiple doses
3096472|NCT01904149|Active Comparator|TRAM followed by TRAM|Tramadol-single dose followed by Tramadol-multiple doses
3096473|NCT01904149|Other|Placebo followed by DKP/TRAM|Placebo single dose followed by Dexketoprofen/Tramadol-multiple doses
3096474|NCT01904149|Other|Placebo followed by DKP|Placebo single dose followed by Dexketoprofen-multiple doses
3096475|NCT01904149|Other|Placebo followed by TRAM|Placebo single dose followed by Tramadol-multiple doses
3321188|NCT02017002|Active Comparator|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
3321189|NCT02017002|Placebo Comparator|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
3096478|NCT01904383||Trazenta|
3096479|NCT01904448|Experimental|Auditory Brainstem Implant|single-arm study of auditory brainstem implantation in children
3096480|NCT01904526|Experimental|Guanfacine|Guanfacine 3 mg/day immediate release followed by Guanfacine 4mg/day extended release followed by Guanfacine 6 mg/day extended release
3096481|NCT01904604|Placebo Comparator|Placebo Patch|Subjects apply placebo Viaskin® patch daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an oral food challenge (OFC) and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using the same 21-day graduated dosing period used in the blinded phase) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
3096482|NCT01904604|Experimental|100 µg Peanut Patch|Subjects apply low-dose DBV712 Viaskin® patch containing 100 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC crossover to active treatment (using same 21-day graduated dosing period used in blinded phase for subjects 4-<6 years old at enrollment or who had Grade 2 reaction or higher within previous 2 months) and dose with a high-dose DBV712 Viaskin® patch containing 250 μg peanut protein for a total active treatment period of 30 months (130 weeks).
3096483|NCT01904604|Experimental|250 µg Peanut Patch|Subjects apply high-dose DBV712 Viaskin® patch containing 250 micrograms (μg) peanut protein daily for a 52-week blinded period. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21-day graduated dosing period; subsequently patch changed every 24 hours. At Week 52, subjects complete an OFC and are unblinded. Following blinded phase, subjects who have not demonstrated sustained unresponsiveness at the Week 52 OFC continue active treatment with a high-dose DBV712 Viaskin® patch for a total active treatment period of 30 months (130 weeks).
3096484|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Twice Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
3096485|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 1 Once Daily|Stage 1: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp once daily for 28 days.
3096486|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Twice Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 28 days.
3096487|NCT01904721|Experimental|Stage 1: Bimatoprost Solution 2 Once Daily|Stage 1: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp once daily for 28 days.
3096488|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 1 Twice Daily|Stage 2: Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3096489|NCT01904721|Experimental|Stage 2: Bimatoprost Solution 2 Twice Daily|Stage 2: Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3096490|NCT01904721|Placebo Comparator|Stage 2: Bimatoprost Vehicle Twice Daily|Stage 2: Bimatoprost Vehicle applied evenly onto pre-specified area on the scalp twice daily for 6 months.
3096491|NCT01904760|Experimental|dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
3096492|NCT01904760|Placebo Comparator|control|Drug: Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
3096493|NCT01904773|Placebo Comparator|Placebo|
3096494|NCT01904773|Experimental|low dose AZD5213|
3096495|NCT01904773|Experimental|high dose AZD5213|
3096496|NCT01904864|Active Comparator|NovaFerrum®|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.
3096497|NCT01904864|Active Comparator|Ferrous Sulfate|Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.
3096498|NCT01904903|Other|HER2 therapies, cardiac medications|"Cardiac intervention - beta-blockers and ACE-inhibitors titrated to the maximum tolerated doses~Oncology intervention - patients will receive one of the three following HER2 targeted therapies at the discretion of the treating oncologist:~Trastuzumab: loading dose of 8 mg/kg IV, followed by a maintenance dose of 6 mg/kg every 3 weeks, or a loading dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg every week.~Pertuzumab: loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks, administered concomitantly with trastuzumab.~Ado trastuzumab emtansine (TDM1): 3.6mg/kg IV every three weeks."
3096499|NCT01905241|Experimental|Anatomic TSA using RTI|During Anatomic Total Shoulder Arthroplasty (TSA), the surgeon will have use of the SmartBone and the bone cement mold made from the SmartBone (the RTI) to transfer the preoperative plan for glenoid implant positioning to the patient's anatomy.
3096500|NCT01905254|Other|Transient elastography and liver biopsy|All patients with Autoimmune hepatitis (AIH) were investigated with Transient Elastography before liver biopsy
3096501|NCT01905267|Experimental|Treatment|Participants randomized to the experimental condition will receive 8 weeks of individual treatment with Rumination-Focused Cognitive Behavior Therapy
3096502|NCT01905267|No Intervention|Control|Participants randomized to the control arm will complete questionnaires and receive mood monitoring for the duration of the study
3096503|NCT01905423||Paga (annual MDA)|"This group includes eligible residents of the village of Paga. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Paga received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
3096504|NCT01905423||Lewomada (annual MDA)|"This group includes eligible residents of the village of Lewomada. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Lewomada received a total of three rounds of MDA over a period of 24 months (once every 12 months)."
3132601|NCT03440411|Active Comparator|ARM pom-dex Early (A-I)|Patients will receive treatment at biochemical relapse with pom-dex Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
3096505|NCT01905423||Pruda (semiannual MDA)|"This group includes eligible residents of the village of Pruda. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pruda received a total of five rounds of MDA over a period of 24 months (once every 6 months)."
3096506|NCT01905423||Pekalongan (annual MDA)|"This group includes the villages of Banyurip Ageng and Jenggot. This cohort will receive once yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will be administered by the Indonesian Ministry of Health as part of their national filariasis elimination program.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
3096507|NCT01905423||Pekalongan (semiannual MDA)|"This group includes the villages of Kertoharjo and Pabean. This cohort will receive twice yearly MDA (Albendazole 400 mg plus diethylcarbamazine 6 mg/kg) which will also be administered by the Indonesian Ministry of Health.~Pekalongan study sites were dropped after the first year follow-up due to lower than expected rates of lymphatic filariasis."
3096508|NCT01905540|Experimental|SSP-004184AQ (single dose)|40 mg/kg (oral capsule form) given once on Day 1
3096509|NCT01905540|Experimental|SSP-004184SS (single dose)|21.8 mg/kg (oral capsule form) given once on Day 1
3096510|NCT01905540|Experimental|SSP-004184AQ (2 doses)|40 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
3096511|NCT01905540|Experimental|SSP-004184SS (2 doses)|21.8 mg/kg (oral capsule form) given twice (12 hours apart) on Day 1
3096512|NCT01905553|Experimental|SSP-004184SS (fed)|21.8 mg/kg (oral capsule form) given once on Day 1 under fed conditions
3096513|NCT01905553|Experimental|SSP-004184SS (fasted)|21.8 mg/kg (oral capsule form) given once on Day 1 under fasted conditions
3096514|NCT01905592|Active Comparator|Physician's choice|Physician may select from 4 active comparators
3096515|NCT01905592|Experimental|niraparib|Patients will be randomized 2:1 to receive niraparib 300 mg (3x100 mg capsules) once daily for 21 continuous days
3096516|NCT01905657|Experimental|Pembrolizumab 2 mg/kg|Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes Q3W for up to 2 years.
3096517|NCT01905657|Experimental|Pembrolizumab 10 mg/kg|Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years.
3096518|NCT01905657|Active Comparator|Docetaxel 75 mg/m^2|Participants received docetaxel 75 mg/m^2 IV over 1 hour Q3W for up to 2 years.
3096519|NCT01905683|Experimental|16-20 Units per kg body weight incobotulinumtoxinA|
3096520|NCT01905943|Experimental|Obinutuzumab|Participants will receive obinutuzumab either alone as single agent or in combination with chemotherapy (Fludarabine/Cyclophosphamide [FC], Bendamustine or Chlorambucil) at the investigator's discretion. Each cycle is of 28-days duration.
3096521|NCT01905956|Active Comparator|IQP-AK-102|2 capsules per dose, three times daily
3096522|NCT01905956|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily
3096523|NCT01906008|Experimental|Minocycline|Group 2 receives minocycline 200 mg orally for the first dose, then 100 mg orally every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
3096524|NCT01906008|Placebo Comparator|Placebo|Group 1 receives a placebo 200 mg orally for the first day of chemotherapy, then 100 mg doses every 12 hours for 4 months beginning at chemotherapy initiation. Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit. Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
3096525|NCT01906346|Experimental|Low Value Alternative Reinforcer|A low value reinforcer will be made available as an alternative to cocaine and placebo.
3096526|NCT01906346|Experimental|Medium Value Reinforcer|A medium value reinforcer will be made available as an alternative to cocaine and placebo.
3096527|NCT01906346|Experimental|High Value Reinforcer|A high value reinforcer will be made available as an alternative to cocaine and placebo.
3096528|NCT01906372|Experimental|Acthar Gel|Acthar Gel (Adrenocorticotropic Hormone Gel)in refractory PM and DM patients using an open label design for 6 months. We will enroll 10 active and refractory PM/DM patients over a 15 month period, followed by 6 months of additional follow-up for each subject. Study subjects will self-administer subcutaneously H.P. Acthar Gel 80 units (1 ml) twice a week for a period of six months. Outcome measures were not evaluated on subjects who did not reach the 8 week time point in the trial.
3096529|NCT01906476|Experimental|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
3096530|NCT01906476|Active Comparator|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
3096531|NCT01906515|No Intervention|Control Group|Control Group received standard anesthesia care including intraoperative blood sampling when estimated blood loss was ≥15% of total blood volume and transfusion when hemoglobin was ≤10 g/dL.
3096532|NCT01906515|Experimental|SpHb Group.|Continuous non-invasive hemoglobin monitoring (SpHb monitoring) was provided to the anesthesiologist to influence administration of care
3096533|NCT01906658|Experimental|Acthar 80 U (1.0 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 80 U (1.0 mL) SC twice weekly
3096534|NCT01906658|Experimental|Acthar 24 U (0.3 mL) SC daily|Acthar (Repository Corticotropin Injection) 24 U (0.3 mL) SC daily
3096535|NCT01906658|Experimental|Acthar 56 U (0.7 mL) SC twice weekly|Acthar (Repository Corticotropin Injection) 56 U (0.7 mL) SC twice weekly
3096536|NCT01906658|Experimental|Acthar 16 U (0.2 mL) SC daily|Acthar (Repository Corticotropin Injection) 16 U (0.2 mL) SC daily
3096537|NCT01906866|Active Comparator|Circadin 2/5/10 mg|
3096538|NCT01906866|Placebo Comparator|Placebo|Placebo arm
3096539|NCT01907087|Experimental|BMN190|recombinant human tripeptidyl peptidase-1 (rhTPP1/cerliponase alfa)
3096540|NCT01907100|Placebo Comparator|Placebo + pemetrexed/cisplatin|Placebo controlled arm
3096541|NCT01907100|Experimental|Nintedanib 200mg + pemetrexed/cisplatin|Experimental arm
3096542|NCT01907113|Experimental|BI 10773 / Group 2|Single Dose Administration (type 2 diabetes and mild renal impairment)
3096543|NCT01907113|Experimental|BI 10773 / Group 3|Single Dose Administration (type 2 diabetes and moderate renal impairment)
3096544|NCT01907113|Experimental|BI 10773 / Group 4|Single Dose Administration (severe renal impairment 8)
3096545|NCT01907113|Experimental|BI 10773 / Group 5|Single Dose Administration (kidney failure)
3096546|NCT01907113|Experimental|BI 10773 / Group 1|Single Dose Administration (type 2 diabetes and normal renal function)
3096547|NCT01907217|Active Comparator|Bilateral ECT Mecta 5000M|Modified bilateral ECT (bitemporal electrode positions) twice weekly at 1.5 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
3096548|NCT01907217|Experimental|High-dose unilateral ECT Mecta 5000M|High-dose right modified unilateral ECT twice weekly at 6 times the seizure threshold. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0mg/kg) for muscle relaxation.
3096549|NCT01907269|Experimental|Video-based intervention|"Video-based intervention providing personalized feedback regarding patients' risk of subsequent fractures, customized information regarding osteoporosis care, and messaging to activate patients to become more engaged in improving osteoporosis treatment and doctor-patient communication. This novel content will use story-telling delivered via the Internet and DVDs. The content will be uniquely tailored to each person based on their reported barriers to care, age and race/ethnicity. The video-based intervention materials will be augmented by a personal phone call and interactive voice response messaging."
3096550|NCT01907269|No Intervention|Usual care|
3096551|NCT01907321|Experimental|Expiratory muscle strength training (EMST)|Participants will complete 5 weeks of EMST training, 5 repetitions per set, 5 sets per day, 5 days per week.
3096552|NCT01907321|Placebo Comparator|Placebo expiratory training|Same look and feel of EMST with no resistance. Same protocol - 5 repetitions of 5 sets, 5 days per week
3096553|NCT01907334|Active Comparator|Advair Diskus100/50 µg and Advair Diskus 100/50 µg|The Advair Diskus 100/50 µg and Advair Diskus 100/50 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
3096554|NCT01907334|Active Comparator|Advair Diskus 100/50 µg and Flovent Diskus 100 µg|The Advair Diskus 100/50 µg and Flovent Diskus 100 µg will be administered in a blinded fashion. One hour after receiving the dose of Advair and Flovent a methacholine challenge will be performed to determine the PC40R5. After the PC40R5 has been reached or a negative result after the highest methacholine concentration, 64 mg/mL, subjects will inhale albuterol through a valved holding chamber to reverse bronchoconstriction and their lung function will be monitored until it has returned to within 20% of that day's baseline R5.
3468980|NCT03890783||Patients after surgery of oropharyngeal cancers|Patients after surgery of oropharyngeal cancers with soft palate with free flap reconstruction and adjuvant radiotherapy
3468981|NCT03891199|No Intervention|Control|Traditional THA.
3096557|NCT01907490|Experimental|1|Ha44 Gel 0.74%, topical solution, maximum feasible amount applied for 10 minutes
3096558|NCT01907516|Active Comparator|Cell phone-internet first|Cell phone-internet home glucose reporting system first
3096559|NCT01907516|Placebo Comparator|Voicemail first|Voicemail home blood glucose reporting first
3096560|NCT01907607|Experimental|PD-0332991|"Adult patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib.~PD-0332991 is formulated as gelatin capsules of 100 mg and 25 mg respectively."
3096561|NCT01907737|Active Comparator|Active tDCS and active PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
3096562|NCT01907737|Other|Active tDCS and sham PNS|1 session of active transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
3096563|NCT01907737|Other|Sham tDCS and active PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and active peripheral nerve stimulation (PNS)
3096564|NCT01907737|Sham Comparator|Sham tDCS and sham PNS|1 session of sham transcranial direct current stimulation (TDCS) of the hemisphere affected by the stroke and sham peripheral nerve stimulation (PNS)
3096565|NCT01907815|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Trametinib orally once daily (PO QD) and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3096566|NCT01907828|Experimental|Cardiac ablation + renal artery ablation|Renal artery ablation with the EnligHTN™ Renal Denervation System
3096567|NCT01907828|Active Comparator|Cardiac ablation|Cardiac ablation
3096568|NCT01907854|Experimental|Liraglutide + metformin + sitagliptin placebo|
3096569|NCT01907854|Experimental|Sitagliptin + metformin + liraglutide placebo|
3096570|NCT01907906|Experimental|Arm 1: Mirasol-treated WB then untreated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
3096571|NCT01907906|Experimental|Arm 2: Untreated WB then Mirasol-treated WB|Screening Period (14 days); Treatment Period 1 (49 days): Donation of WB, UNTREATED on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49); WB Donation Deferral Period (35-49 days); Treatment Period 2 (49 days): Donation of WB treated with Mirasol System for Whole Blood on Day 0, LR-pRBCs manufactured & stored 21 days, radiolabeled RBCs reinfused on Day 21 and samples collected over 28 days (Days 21-49) Study Exit on Treatment Period 2, Day 49
3096572|NCT01908062|Active Comparator|Treatment as Usual|The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups.
3468982|NCT03891199|Active Comparator|Intervention|Robotic-arm assisted THA.
3096573|NCT01908062|Experimental|Extended Release Naltrexone|Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.
3096574|NCT01908101|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1, 8, and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3096575|NCT01908127|Active Comparator|tell- show- do procedure|"Group I (Tell- Show- Do Group): Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant in the operation room.~In the second session,injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
3096576|NCT01908127|Experimental|film modelling|"Group II (Filmed modelling Group): the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.~In the second session, injection of loal anesthesia solution including a mandibular alveolar nerve block technique and the occlusal cavity preparation was performed."
3096577|NCT01908140|Experimental|Aclidinium Bromide / Formoterol Fumarate|Aclidinium Bromide 400 μg / Formoterol Fumarate 12 μg BID for 24 Weeks
3096578|NCT01908140|Active Comparator|Salmeterol / Fluticasone propionate|Salmeterol 50 μg / Fluticasone propionate 500 μg BID for 24 Weeks
3096579|NCT01908205|Experimental|Intranasal Oxytocin (Syntocinon)|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
3096580|NCT01908205|Placebo Comparator|Placebo|The proposed dosing schedule is 0.4 IU/kg, taken twice daily, for a maximum of 24 IUs per dose
3096581|NCT01908426|Experimental|Cabozantinib (XL184)|Cabozantinib (XL184) 60 mg tablet once daily
3096582|NCT01908426|Placebo Comparator|Placebo|Oral cabozantinib-matched placebo tablet once daily
3096583|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 1|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 6 hours
3096584|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 2|The microprobe array continuous glucose sensor will be applied to healthy volunteers for 24 hours
3096585|NCT01908530|Experimental|Microprobe Glucose Sensor Phase 3 and 4|The microprobe array continuous glucose sensor will be applied to participants with type 1 diabetes
3096586|NCT01908582|Experimental|Evacetrapib|"Period 1:~130 milligram (mg) evacetrapib administered orally, once on Day 1"
3096587|NCT01908582|Experimental|Evacetrapib + Rifampin|"Period 2:~Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9 to 22)~Evacetrapib: 130 mg administered orally once on Day 16"
3096588|NCT01908634|Active Comparator|Milk-based Strawberry Beverage no meal|Milk-based Strawberry beverage without meal
3096589|NCT01908634|Experimental|Water-based Strawberry Beverage no meal|Water-based Strawberry beverage without meal
3096590|NCT01908634|Active Comparator|Milk-based strawberry Beverage with meal|Milk-based Strawberry beverage with meal
3096591|NCT01908634|Experimental|Water-based strawberry Beverage with meal|Water-based Strawberry beverage with meal
3096592|NCT01908699|Experimental|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.
3096593|NCT01908699|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.
3096594|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
3096595|NCT01908751|Experimental|Sliding Hip Screw and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
3096596|NCT01908751|Experimental|Cancellous Screws and Vitamin D supplementation|Participants allocated to the vitamin D Group will be given a six-month supply of vitamin D3 supplementation. Participants in the vitamin D Group will receive a bottle of 2,000 International Units (IU) vitamin D3 drops (Ddrops®, Ddrops Company). Participants will be instructed to take two drops daily for six months, for a total daily dose of 4,000 IU.
3096597|NCT01908751|Experimental|Cancellous Screws and Vitamin D placebo|Participants in the placebo group will receive an identical bottle of placebo drops with no active ingredient. Similarly, they will be instructed to take two drops daily for six months. The placebo supplement is also manufactured by the Ddrops Company.
3096598|NCT01908803|Experimental|AL-60371/AL-817|AL-60371/AL-817 otic suspension, 200 μL in affected ear(s) through tympanostomy tube on Day 1 (Visit 1)
3096599|NCT01908803|Active Comparator|CIPRODEX|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension, 4 drops in affected ear(s) twice daily through tympanostomy tube for 7 days
3096600|NCT01908816|Experimental|ranibizumab|0.5 mg ranibizumab applied in an individualized regimen as IVT injection of 0.05 mL.
3096601|NCT01908829|Experimental|Combination (solifenacin + mirabegron)|Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.
3096602|NCT01908829|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period
3096603|NCT01908829|Active Comparator|Solifenacin 10 mg|Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.
3096604|NCT01908842|Active Comparator|Buprenorphine; then OL BNX film, then BNX tablets|Days 1-2: Generic buprenorphine sublingual tablets (blinded); Days 3 to 14: Buprenorphine/naloxone sublingual film (open-label); Days 15-21: BNX sublingual tablets (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
3096605|NCT01908842|Experimental|BNX tablets, then OL BNX tablets, then BNX film|Days 1-2: BNX sublingual tablets (blinded); Days 3 to 14: BNX sublingual tablets (open-label); Days 15-21: Buprenorphine/naloxone sublingual film (open-label); Day 22: Offered option in continuing in open-label follow-up study of BNX sublingual tablets
3096606|NCT01908907|Active Comparator|DHA oil|DHA oil administered 50 mg/d (0.18ml)as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
3096607|NCT01908907|Placebo Comparator|(MCT) control oil|MCT oil administered 0.18ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
3096608|NCT01908972|Active Comparator|Prednisolone|Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
3096609|NCT01908972|Experimental|Propranolol|Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
3096610|NCT01909011|Experimental|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
3096611|NCT01909011|Sham Comparator|Sham CES|The CES sham group will receive sham CES (device off)for 20 minutes 5 times per week for two weeks.
3096612|NCT01909141|Active Comparator|arm 1:letrozole-pioglitazone -metformin group|Arm 1 will receive letrozole 2.5 mg/day starting from the 3rd day of the cycle and for 5 days and (combined pioglitazone 15 mg+ metformin 850 mg) once daily from the first day of the cycle for 10 days.
3096613|NCT01909141|Active Comparator|arm 2: clomiphene citrate-pioglitazone-metformin|Arm 2 will receive clomiphene citrate 100 mg/day starting from the 3rd day of the cycle for 5 days and (combined pioglitazone 15 mg + metformin 850 mg) once daily from the first day of the cycle for 10 days.
3096614|NCT01909154|Experimental|Mesenchymal stromal cell therapy|Autologous bone marrow adult mesenchymal stem cells expanded in vitro. Administered by Intrathecal injection (subarachnoid and intramedullary). Depending on centromedullary post-traumatic injury: bone marrow stromal stem cells administration (MSCs) at the minimum dose of 100x106 followed by subarachnoid administration of 30x106 MSCs,3 months later
3096615|NCT01909180|Experimental|Cardiac|Revolution CT Cardiac Imaging Scan
3096616|NCT01909180|Experimental|Body/Extremity|Revolution CT Body and/or Extremity Imaging Scan
3096617|NCT01909180|Experimental|Neuro|Revolution CT Brain and Spinal Cord Imaging Scan
3096618|NCT01909336|Active Comparator|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)|Group 1: 0.3% Saline in 3.3% dextrose (intravenous)
3096619|NCT01909336|Active Comparator|Group 2: 0.45% Saline in 5% dextrose (intravenous)|Group 2: 0.45% Saline in 5% dextrose (intravenous)
3096620|NCT01909336|Active Comparator|Group 3: 0.9% Saline in 5% dextrose (intravenous)|Group 3: 0.9% Saline in 5% dextrose (intravenous)
3096621|NCT01909453|Experimental|LGX818 450 mg + MEK162|LGX818 450 mg QD + MEK162 45 mg BID
3096622|NCT01909453|Active Comparator|Vemurafenib|Vemurafenib 960 mg BID
3096623|NCT01909453|Experimental|LGX818 300 mg + MEK162|LGX818 300 mg QD + MEK162 45 mg BID
3096624|NCT01909453|Experimental|LGX818|LGX818 300 mg QD
3096625|NCT01909466|Other|Gluteal Injection|
3096626|NCT01909466|Other|Deltoid Injection|
3096627|NCT01909570|Experimental|Elective single embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer would be of a single embryo followed by the cryotransfer or a single embryo in case of no fresh conception
3096628|NCT01909570|Active Comparator|Double embryo transfer|After the FIV/ICSI procedure, in this arm the embryo transfer woub be of two fresh embryos
3096629|NCT01909674|Experimental|Oronasal Mask|Initial administration of oronasal CPAP mask
3096630|NCT01909674|Experimental|Nasal Mask|Initial administration of nasal CPAP mask
3096631|NCT01909713|Experimental|Facial Cleanser and Moisturizer SPF 30|All subjects used Cetaphil® DermaControl™ Oil Control Foam Wash and Cetaphil® DermaControl™ Oil Control Moisturizer SPF 30 at least once daily for 22 days.
3096632|NCT01909778|Experimental|BI 201335|BI 201335 two single oral doses, separated by 14 days washout period
3096633|NCT01909791|Experimental|Prompt Laser + Deferred Aflibercept|Focal/grid laser followed by intravitreal aflibercept if vision worsens
3096634|NCT01909791|Active Comparator|Observation + Deferred Aflibercept|No treatment to start followed by intravitreal aflibercept if vision worsens (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
3096635|NCT01909791|Experimental|Prompt Aflibercept|Intravitreal aflibercept at baseline and every 4 weeks as needed (deferred laser may be added to intravitreal aflibercept if certain criteria are met)
3096636|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
3096637|NCT01909804|Experimental|SOF+VEL 25mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3096638|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
3096639|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) without cirrhosis|Participants with genotype 3 HCV infection without cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3096640|NCT01909804|Experimental|SOF+VEL 25 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg for 12 weeks.
3096641|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3096642|NCT01909804|Experimental|SOF+VEL 100 mg (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg for 12 weeks.
3096643|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT3) with cirrhosis|Participants with genotype 3 HCV infection with cirrhosis will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3096644|NCT01909804|Experimental|SOF+VEL 25 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.
3096645|NCT01909804|Experimental|SOF+VEL 25 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 12 weeks.
3096646|NCT01909804|Experimental|SOF+VEL 100 mg (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.
3096647|NCT01909804|Experimental|SOF+VEL 100 mg+RBV (GT1)|Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 12 weeks.
3096648|NCT01909973|Experimental|MedLink System|For 12 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
3096649|NCT01909973|No Intervention|Treatment As Usual|Patients will continue to receive treatment as usual from their primary care doctor. Patients in this arm will also receive a free mobile phone for the 12 weeks of the intervention.
3096650|NCT01910064|Experimental|GK530G|GK530G is the fixed-dose combination gel of Adapalene and Benzoyl Peroxide, BPO
3096651|NCT01910116|Placebo Comparator|Placebo|Placebo 2 capsules, twice daily, for 12 weeks.
3096652|NCT01910116|Active Comparator|Shinbaro|Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
3096653|NCT01910129|Active Comparator|gammaCore|Active stimulation treatment
3096654|NCT01910129|Placebo Comparator|sham gammaCore|Inactive stimulation treatment
3096655|NCT01910181|Experimental|Vemurafenib: Pharmacokinetic Cohort|Participants will receive vemurafenib orally as 960 mg twice daily on Days 1 to 21 (morning dose only on Day 21), with a drug holiday from Days 22 to 27, and from Day 28 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
3096656|NCT01910181|Experimental|Vemurafenib: Expansion Cohort|Participants will receive vemurafenib orally as 960 mg twice daily from Day 1 until progression, unacceptable toxicity, consent withdrawal, decision by the investigator or Sponsor, or protocol/eligibility violation.
3096657|NCT01910298|Active Comparator|Breast Reconstruction, Direct to Implant (DTI) with Strattice™|Participants underwent immediate post-mastectomy breast reconstruction with a breast implant and Strattice™ reconstructive tissue matrix (surgical mesh).
3096658|NCT01910298|Active Comparator|Two Stage Breast Reconstruction|Participants underwent immediate, two-stage post-mastectomy breast reconstruction without reinforcement. Initial placement of a tissue expander that was inflated for approximately one to six months, and then replaced with an implant.
3096659|NCT01910311|Experimental|Baricitinib|Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
3096660|NCT01910311|Experimental|Baricitinib + Rifampicin|Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
3468983|NCT03890640|Experimental|Ultrasound-guided TECI|After assessment of the epidural space using the loss of resistance technique with saline under ultrasound guidance, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
3468984|NCT03891043|Placebo Comparator|Group A, Placebo group|Placebo consisted in a pill of 100 micrograms of starch, to be taken twice a day.
3096663|NCT01910519|Experimental|H5N1 vaccine plus AS03 adjuvant|"H5N1 vaccine plus AS03 adjuvant: Influenza A Vaccine with AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
3096664|NCT01910519|Experimental|H5N1 vaccine without adjuvant|"H5N1 vaccine without adjuvant: Influenza A Vaccine without AS03 adjuvant~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant given 21 days apart (i.e., Administer day 1, booster at Day 21)."
3096665|NCT01910636|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
3096666|NCT01910688|Experimental|RFA treatment (Radiofrequency ablation)|If eligible for enrollment, patients receive initial RFA treatment at 0 month. Patients return to the study site at 3.5 months to review weight data since initial RFA. If the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 4 months. All patients are seen at 7.5months and if the patient has not reached ideal body weight, the patient is scheduled for endoscopy with RFA at 8 months. All patients are seen at the study site at 12 months for final clinic weight.
3096667|NCT01910792|Active Comparator|Group 2|Patients who have had gastric bypass surgery will be exposed to a Sperti Lamp 3x/week
3096668|NCT01910792|Active Comparator|Group 1|Patients with fat malabsorption syndromes will be exposed to a Sperti Lamp 3x/week
3096669|NCT01910831|Experimental|DerMend Moisturizing Bruise Formula|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Applied twice daily for 12 weeks. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
3096670|NCT01910831|Placebo Comparator|Non-active placebo control|Apply LEFT treatment to LEFT arm or (vica versa) RIGHT treatment to RIGHT arm. Will not be known to the subject which arm is on the active treatment and which is on the placebo control. Each subject will have one arm/hand that is either a)the experimental treatment or b) the placebo control.
3096671|NCT01911065|Experimental|Zostavax™ vaccine group|Participants > 50 years will receive a single dose 0.65 ml Zostavax™ (live, attenuated zoster vaccine) administered by subcutaneous injection.
3096672|NCT01911065|No Intervention|Natural-acquired VZV immunity|Participants 40-49 years of age will not receive any intervention with the objective of examining the influence of age and inherited factors on the varicella zoster virus (VZV)-specific immune response in those with a naturally-acquired VZV immunity (a prior history of chicken pox).
3096673|NCT01911169|Experimental|Vitamin D 5000|5,000 IU vitamin D (cholecalciferol) given orally daily
3096674|NCT01911169|Active Comparator|Vitamin D 400|cholecalciferol 400 IU daily by mouth
3096675|NCT01911221|Experimental|rMenB+OMV NZ|A single 0.5mL dose of the study vaccine will be administered intramuscularly in the deltoid muscle.
3132602|NCT03440411|Experimental|ARM pom-cyclo-dex Early(B-I)|Patients will receive treatment at biochemical relapse with pom-cyclo-dex Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance
3321190|NCT02017041||buprenorphine/naloxone|Opioid substitution therapy patient taking buprenorphine/naloxone, MedSignals and smartphone app.
3321191|NCT02017054||Cath patients|Patients with previous cardiac cath via the radial access who are planned for additional radial access cardiac cath
3096676|NCT01911260|Active Comparator|Growth Deficit+zinc amino acid chelate|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3096677|NCT01911260|Placebo Comparator|Growth Deficit receiving placebo|"Children with one and a half or more standard deviations below the mean height for age and gender of the reference population (Z-score under -1.6) were included in the Growth Deficit group (GD).~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3096678|NCT01911260|Placebo Comparator|Normal Height receiving placebo|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3096679|NCT01911260|Active Comparator|Normal Height+zinc amino acid chelate|"For the Normal Stature group (NS), HAZ was set up as being between -1 and +1 standard deviations from the mean height reference for age and sex.~During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student."
3096680|NCT01911273|Experimental|PF 03446962 plus best supportive care (BSC)|
3096681|NCT01911273|Placebo Comparator|Placebo plus best supportive care (BSC)|Placebo, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
3096682|NCT01911351|No Intervention|standard management|Patients randomized to this arm will receive standard management alone for their minor procedure.
3096683|NCT01911351|Experimental|Nitrous Oxide|Patients randomized to this arm will receive nitrous oxide plus standard management for their minor procedure.
3096684|NCT01911390|Placebo Comparator|Control Arm|No bean or rice bran additive in smoothie or muffin.
3096685|NCT01911390|Active Comparator|Bean powder|1/4 cup beans (17.5 grams powder)/day in smoothie or muffin.
3096686|NCT01911390|Active Comparator|Rice bran|15 grams rice bran/day in smoothie or muffin.
3096687|NCT01911390|Active Comparator|Bean powder and rice bran|9 grams bean powder/day and 8 grams rice bran /day in smoothie or muffin.
3096688|NCT01911403|Active Comparator|Angio-Seal|Closure procedure by Angio-Seal
3096689|NCT01911403|Active Comparator|Manual compression|Closure procedure by manual compression
3096690|NCT01911429|Experimental|Lurasidone 40 mg|Lurasidone 40 mg once daily
3096691|NCT01911429|Experimental|Lurasidone 80 mg|Lurasidone 80 mg once daily Arm received the Lurasidone 40mg dose first, from Days 1-3, and then received the Lurasidone 80 mg dose from day 4 to Week 6
3096692|NCT01911429|Placebo Comparator|Placebo|Placebo 40 or 80 mg once daily
3096693|NCT01911442|Experimental|Lurasidone 20 mg|Lurasidone 20 mg once daily
3096694|NCT01911442|Experimental|Lurasidone 60 mg|Lurasidone 60 mg once daily
3096695|NCT01911442|Placebo Comparator|Placebo|Placebo once daily
3096696|NCT01911546|Experimental|everolimus + low-dose tacrolimus|Patients receiving everolimus will be on low dose tacrolimus.
3096697|NCT01911689||acute pancreatitis|acute pancreatitis group：(a) acute onset of abdominal pain; (b) pancreatitis at first onset; (c) three-fold elevated amylase or lipase, excluding other causes of elevated enzymes; and (5) abdominal MR examination.
3096698|NCT01911689||controlgroup|normal control group：without pancreatic disorders.The exclusion criteria in this study were as follows: (a) inability to cooperate when MR imaging was performed; (b) a history of chronic pancreatitis; (c) AP due to pancreatic carcinoma; (d) hypoproteinemia; and (e) with hypoproteinemia and other peritoneal/ retroperitoneal infection diseases ;(f) with iron deposition disorder (e.g. diabetes or blood system diseases).
3096699|NCT01911780|Experimental|telmisartan + HCTZ + amlodipine|telmisartan 80 mg + hydrochlorothiazide (HCTZ) 12.5 mg fixed dose combination (FDC) and amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
3096700|NCT01911780|Active Comparator|telmisartan + HCTZ + placebo|telmisartan 80 mg + HCTZ FDC tablet and placebo matching amlodipine 5 mg capsule (after the 8-week double-blind period, patients will continue the 52-week open label extension period taking 1 telmisartan 80 mg and hydrochlorothiazide 12.5 FDC tablet and 1 amlodipine 5 mg tablet)
3096701|NCT01911819|Experimental|Sinus augmentation using Bio-oss|Sinus augmentation using Bio-oss
3096702|NCT01911819|Experimental|Sinus augmentation using Equimatrix|Sinus augmentation using Equimatrix
3096703|NCT01911819|Experimental|Sinus augmentation using OSSIF-i sem|Sinus augmentation using OSSIF-i sem
3096704|NCT01911845|Experimental|ABT-450/r/ABT-267 and ABT-333, plus RBV|ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if <75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks
3096705|NCT01911910|No Intervention|Standard care|Usual care that would be provided by the NHS Health Check or equivalent.
3096706|NCT01911910|Experimental|Electronic coaching plus standard care|Tailored coaching for participants randomised to use the HAPPY e-coaching tool. Access to lifestyle and heart health scores and personalised advice to improve suboptimal behaviour.
3096707|NCT01912222|Experimental|IXAZOMIB Arm 1|"Experimental: Arm 1 (Normal hepatic function) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 4 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3096708|NCT01912222|Experimental|IXAZOMIB Arm 2|"Experimental: Arm 2 (Moderate hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 2.3 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3096709|NCT01912222|Experimental|IXAZOMIB Arm 3|"Experimental: Arm 3 (Severe hepatic impairment) In the 15 day period that constitutes Part A of the trial, patients will receive a single oral 1.5 mg dose of IXAZOMIB capsule on Day 1.~Patients from Part A will then have the option of continuing the study by participating in Part B, starting immediately after Part A, where they will receive IXAZOMIB on Days 1, 8, and 15 of a 28-day cycle"
3096710|NCT01912274|Experimental|Pracinostat with azacitadine|60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days 75 mg/m2 azacitadine for the first 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous (IV) infusion if SC injections are intolerable
3096711|NCT01912287|Experimental|Yoga|The yoga intervention will apply Kundalini Yoga practices as taught by Yogi Bhajan. This is a well-known, accessible style of practice in the U.S. that incorporates all of the traditional components of yoga including physical postures and exercises, breathing techniques, relaxation exercises and meditation practices. It is a safe style of yoga that is registered with the Yoga Alliance that is readily and routinely adapted for therapeutic purposes. The 12-week yoga intervention will consist of 12 group classes and assigned daily home practice led by qualified and certified yoga instructors. Each group yoga session will include physical postures/exercises, breathing techniques, meditation and deep relaxation practice that are all easy to learn and do not require extensive practice or athletic ability to perform.
3096712|NCT01912287|Active Comparator|Cognitive Behavioral Therapy (CBT)|"The 12 session CBT treatment will be based on the standardized protocol developed at one of our centers (CARD) and widely available [88]. This protocol is comprised of four primary treatment modules including cognitive restructuring, progressive muscle relaxation, worry exposures, and in vivo exposure exercises. The initial sessions describe the cognitive behavioral model of worry and GAD. Each session consists of a different lesson. These lessons initially cover basic information about the nature of the anxiety and worry, the possible function and negative consequences of worrying, the maladaptive and paradoxical effects of attempting to control and suppress one's thoughts, the basic cognitive errors of probability overestimation and catastrophic thinking, adaptive strategies to deal with worries, such as problem solving, worry exposure, which may involve exploring and exposing the patient to negative images and scenarios that might be behind some of the worrisome thoughts."
3096713|NCT01912287|Sham Comparator|Stress Education|SE will also include 12 weeks of group and home practice sessions. SE will control for attention from instructors, expectancy effects, and group support effects, Stress Education (SE) will be employed as an active control intervention. SE is currently used in NIH-funded protocols at the Benson-Henry Institute for Mind-Body Medicine at MGH. In this condition, participants will be provided with detailed and extensive information about stress and health, but will not receive any CBT, yoga, or other mind-body training techniques.
3096714|NCT01912339|Experimental|Treatment|Treatment: Rezūm System
3096715|NCT01912339|Other|Control|Control: Rigid Cystoscopy
3096716|NCT01912352|Experimental|Methylphenidate|Participants were treated with methylphenidate (ranging from to 63mg) for 8 weeks. Doses of methylphenidate were titrated depending on symptoms and adverse eff ects at the 2nd and 4th weeks of treatment.
3096717|NCT01912456|Experimental|Higher-volume placebo, then low-volume C1-esterase inhibitor|A higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
3096718|NCT01912456|Experimental|Low-volume C1-esterase inhibitor, then higher-volume placebo|A low-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a higher-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
3096719|NCT01912456|Experimental|Low-volume placebo, then higher-volume C1-esterase inhibitor|A low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks then a higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks.
3096720|NCT01912456|Experimental|Higher-volume C1-esterase inhibitor, then low-volume placebo|A higher-volume dose of C1-esterase inhibitor will be administered subcutaneously twice a week for up to 16 weeks, then a low-volume dose of placebo will be administered subcutaneously twice a week for up to 16 weeks.
3096721|NCT01912495|Experimental|Boceprevir, peginterferon ribavirin|All patients were intended to be treated in the 12 week peginterferon, ribavirin and boceprevir arm.
3096722|NCT01912599|Active Comparator|Non-Glaucomatous|Patients with no history of glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
3096723|NCT01912599|Active Comparator|Glaucoma|Patients that are currently being treated for moderate to severe normal-tension glaucoma. Subjects will be fitted with Sensimed Triggerfish for 24 observation of IOP and with a blood pressure monitor for 24 hour observation of blood pressure trends.
3096724|NCT01912612|Experimental|Arm 1 (Patients with pain, duloxetine)|Duloxetine 30 mg daily x 1 week, then 60 mg daily x 4 weeks, then 30 mg daily x 2 weeks.
3096725|NCT01912612|No Intervention|Arm 2 (Patients without pain -- control)|Patient reported pain and symptoms assessment for comparison at baseline.
3096726|NCT01912716|Experimental|high-dose indomethacin|200mg rectal indomethacin
3096727|NCT01912716|Active Comparator|standard dose indomethacin|100mg rectal indomethacin
3096728|NCT01912729|Experimental|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a trained peer coach.
3096729|NCT01912729|Experimental|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a mobile phone application. Additionally, participants will have access to a private social network that connects them with other participants in the study. The social network will be moderated by a clinician coach.
3096730|NCT01912729|No Intervention|Wait List Control|Participants may be asked to wait for up to 8 weeks until minimum group size is met. After 4 weeks from baseline, if a group has not yet started, we will conduct another assessment. These participants will serve as the Wait List Control group.
3096731|NCT01912768|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 90 days
3096732|NCT01912768|Active Comparator|renu fresh|Renu fresh multi-purpose solution used with soft contact lenses (study lenses) on a daily basis for 90 days
3096733|NCT01912781|Experimental|FID 120974A|FID 120947A contact lens disinfecting solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
3096734|NCT01912781|Active Comparator|Boston Simplus|Boston Simplus multi-action solution used with gas permeable contact lenses (study lenses) on a daily basis for 90 days
3096735|NCT01912807|Experimental|Dextrose (D5NS)|The participants received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis and Dextrose 5% in 0.9 % Normal Saline (D5NS) was used as a second antiemetic, at an intravenous rate calculated based on their weight and determined for the purpose of the study.
3096736|NCT01912807|Active Comparator|Ondansetron (Control)|The control group received Dexamethasone (dose 0,15 mg/Kg) as standard antiemetic prophylaxis. Ondansetron (dose 0,05 mg/Kg) was used as a second prophylactic antiemetic.
3096737|NCT01912872|Experimental|Omalizumab + budesonide and formoterol|Participants will receive Omalizumab every 2 or 4 weeks depending on IgE level and body weight and will also receive budesonide and formoterol according to maximum daily dose.
3096738|NCT01912872|Active Comparator|Budesonide and formoterol|Participants will receive budesonide and formoterol according to maximum daily dose.
3096739|NCT01912963|Experimental|Phase I: Dose Level 1 (D1)|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (D1)~Cycle duration=21 days~The Phase I run-in potentially evaluates 2 dose levels of eribulin in combination with pertuzumab and trastuzumab. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
3096740|NCT01912963|Experimental|Phase II Cohort A: Without Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
3096741|NCT01912963|Experimental|Phase II Cohort B: With Prior Pertuzumab Exposure|"Pertuzumab: 840 mg/cycle 1 then 420 mg/cycle IV on day 1~Trastuzumab: 8 mg/kg/cycle 1 then 6 mg/kg cycle IV on day 1~Eribulin: 1.4 mg/m2/cycle IV on days 1 and 8 (recommended phase II dose)~Cycle duration=21 days~In the Phase II study, participants enrolled into two possible cohorts based on prior pertuzumab exposure. Participants first receive antibody administration then eribulin. In the treatment phase, participants receive up to 6 cycles of combination therapy unless disease progression (PD) or withdrawal for other reasons (w/d). Participants who complete 6 cycles have the option to continue with antibody therapy only until PD or w/d in the extension phase."
3096742|NCT01913041||Investigation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
3096743|NCT01913314|Experimental|[^14C]-LY2835219|Single 150 milligram (mg) oral dose solution of LY2835219 containing 5 micro-curies of (µCi) [^14C] labeled drug
3096744|NCT01913340|Active Comparator|Erythropoietin|1000 U/kg/dose x 5 doses
3096745|NCT01913340|Placebo Comparator|Normal saline|
3096746|NCT01913353|Experimental|Group 1|Two vaccinations; MVA BN ®; administered 4 weeks apart (Day 0 and Day 28) followed by a single vaccination of ACAM2000® vaccine 4 weeks after the second MVA BN® vaccination (Day 56).
3096747|NCT01913353|Active Comparator|Group 2|A single vaccination of ACAM2000® will be administered at Day 0.
3096748|NCT01913405|Experimental|BAX855|"Pre-operative loading dose: Single loading dose, pre-surgery administered based on each study participant's individual PK results as well as target trough level for type and character of surgery, dental or invasive procedure being performed. In general, major surgery will target an 80-150% FVIII trough level, and minor surgery will target an initial 30-100% FVIII trough level.~Intra-operative and post-operative dosing of BAX855 must be based on pre-dosage measurements of FVIII and the type and character of the surgery performed."
3096749|NCT01913470|Experimental|Losartan then Placebo|0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks then placebo pill for 8 weeks
3096750|NCT01913470|Experimental|Sugar pill|placebo pill taken for 8 weeks then 0.4mg/kg/day (max 25mg) for one week and then increase to 0.8mg/kg/day (max 50mg) for 7 additional weeks
3096751|NCT01913483|Experimental|Bivalirudin|Bivalirudin was administered as an intravenous (IV) bolus and infusion for the duration of the procedure (mean duration of 48.6 minutes). The bolus (0.75 milligrams (mg)/kilogram [kg]) was administered via systemic IV administration. Immediately after the bolus, an IV infusion of bivalirudin was initiated at a dose of 1.75 mg/kg/hour (h) (or 1 mg/kg/h for participants with an estimated glomerular filtration rate [eGFR] <30 milliliters/minute [mL/min]).
3096752|NCT01913483|Active Comparator|Unfractionated Heparin|UFH was administered as an IV bolus for the duration of the procedure (mean duration of 48.6 minutes). UFH was administered via weight-based IV bolus at a dose of 50 units (U)/kg to 70 U/kg. Additional bolus doses were administered per standard-of-care use.
3096753|NCT01913535|Active Comparator|Low Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096754|NCT01913535|Active Comparator|High Dose Drug-Drug Arm|Patients in this arm will receive CERC-501 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096755|NCT01913535|Other|Placebo/Low-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 10.0 mg/day for 3 days (in Phase 2)
3096756|NCT01913535|Other|Placebo/High-Dose Drug Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and CERC-501 20.0 mg/day for 3 days (in Phase 2)
3096757|NCT01913535|Placebo Comparator|Placebo/Placebo Arm|Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)
3096758|NCT01913600|Other|Resolute Integrity|Resolute Integrity Stent
3096759|NCT01913639|Experimental|FOLFOX Plus Regorafenib|Regorafenib 160 mg daily on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets + mFOLFOX on Day 1 and Day 15 of each cycle. Each cycle consists of 28 days. All patients will receive systemic chemotherapy with the mFOLFOX regimen and regorafenib. The specific version of the FOLFOX regimen used at MSKCC is mFOLFOX6. mFOLFOX6 will be given on Day 1 of each cycle. Patients will receive Oxaliplatin 85 mg/m2 IV (over 120 minutes), leucovorin 400 mg/m2 IV (over 120 minutes), 5-FU 400 mg/m2 IVP, and 5-FU 1200 mg/m2/day CIVI x 2 days, every two weeks. Treatment will be performed on the scheduled day ± 7 days. In case of discontinuation of FOLFOX due to cumulative toxicity and administration as a single agent during the study, regorafenib for patient convenience will be administered 160 mg daily for 3 weeks on/1 week off. The 3 weeks on/1 week off schedule is supported by the single agent regorafenib data in colon cancer and GIST.
3096760|NCT01913795|Active Comparator|Environmental Intervention|4 classroom air purifiers and school integrated pest management environmental intervention
3096761|NCT01913795|Placebo Comparator|Sham and Control|4 sham air purifiers and no school integrated pest management environmental intervention
3096762|NCT01913795|Placebo Comparator|Active Air Purifier and Control|4 air purifiers and no school integrated pest management environmental intervention
3096763|NCT01913795|Sham Comparator|Sham and Integrated Pest Management|4 classroom sham air purifiers and school integrated pest management
3096764|NCT01914003||CSID Mutations|Individual has one or more known CSID mutations.
3096765|NCT01914003||Control|Individual does not have any known CSID mutations.
3096766|NCT01914159|Experimental|Ranibizumab|
3096767|NCT01914393|Experimental|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg, flexibly dosed, once daily
3096768|NCT01914510|Experimental|ENMD-2076|ENMD-2067 will be taken orally at a dose of 275 mg, once a day, everyday. Patients with a body surface area of less than 1.65 m2 will receive a starting dose of 250 mg, once a day, everyday.
3096769|NCT01914666|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. Tapering week doses of 40 mg for first week and 20 mg for second week.
3096770|NCT01914679|Experimental|Sham followed by device|4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments
3096771|NCT01914757|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
3096772|NCT01914757|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
3096773|NCT01914757|Placebo Comparator|Placebo|Placebo administered subcutaneously
3096774|NCT01914926|Active Comparator|Metoprolol Study Group|Patients Receiving metoprolol administered at a dose of 0.15 mg/kg (to a maximum dose of 10 mg)
3096775|NCT01914926|Active Comparator|Diltiazem Study Group|Patients receiving diltiazem administered parenterally at a dose of 0.25 mg/kg (to a maximum dose of 30 mg)
3096776|NCT01915095|Active Comparator|Motor task+ Magnetic stimulation|Participants will be asked to complete a precision grip with the index and thumb finger at the same time as flexing or extending the wrist. magnetic stimulation to the brain will be administered and measurements will be taken during movement.
3096777|NCT01915095|Active Comparator|rTMS/sham rTMS|Participant will be randomly assigned to one of 3 groups: repetitive transcranial magnetic stimulation (rTMS), sham (fake) rTMS, or sham (fake) rTMS over control brain area will be administered to the brain. the stimulation will be targeting finger and wrist muscles during movement.
3096778|NCT01915095|Active Comparator|Training + rTMS/ Sham rTMS|Participants will be asked to follow a target line on the computer as accurately as possible while performing precision grips or foot movement . Magnetic stimulation will be given during rest and movement.
3096779|NCT01915108|No Intervention|group R0|remifentanil Ce of 0 ng/ml
3096780|NCT01915108|Active Comparator|group R0.5|remifentanil Ce of 0.5 ng/ml
3096781|NCT01915108|Active Comparator|group R1.0|remifentanil Ce of 1.0 ng/ml
3096782|NCT01915108|Active Comparator|group R1.5|remifentanil Ce of 1.5 ng/ml
3096783|NCT01915173|Experimental|Supplement + Expanded Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
3096784|NCT01915173|Placebo Comparator|Placebo + Standard Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
3096785|NCT01915173|Experimental|Supplement + Standard Interview|Supplement, 2 tablets sublingually 3 times a day for 2 weeks.
3096786|NCT01915173|Placebo Comparator|Placebo + Expanded Interview|Placebo, 2 tablets sublingually 3 times a day for 2 weeks.
3096787|NCT01915303|Experimental|pasireotide +/- cabergoline|pasireotide alone or with cabergoline
3321192|NCT02017067|No Intervention|control|Maintain regular physical activity as usual, and received health education material about their disease, importance of nutrition and risks factors.
3096789|NCT01915563|No Intervention|SBT and extubation|After a SBT patients will be extubated as usual
3096790|NCT01915563|Experimental|SBT and rest 60 min before extubation|After SBT patients will be reconnected to mechanical ventilation during 60 min before extubation
3096791|NCT01915732|Experimental|Duac™Once Daily Gel|Subjects will use Duac™Once Daily Gel (once daily in the evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
3321193|NCT02017067|Experimental|hydraulic resistance circuit training|12 weeks resistance training
3096792|NCT01915732|Active Comparator|1% clindamycin phosphate gel|Subjects will use 1% clinidamycin phosphate gel (twice daily in the morning and evening)for 12 weeks. The subjects will be evaluated for change in lesion counts, ISGA, SGA , local tolerability, and AEs/SAEs at Weeks0, 1, 2, 4, 8, and 12 (or at early withdrawal). In addition, quality of life measures will be performed at every study visit
3096793|NCT01915771|Experimental|lomitapide|It will comprise of 2 single oral doses with at least a 14-day washout between doses.
3096794|NCT01915823|Active Comparator|Dymista|"(azelastine hydrochloride and fluticasone propionate) Nasal Spray, 137mcg/50mcg: Mode of Administration: Topical/intranasal spray~Dose: 548 mcg azelastine hydrochloride / 200 mcg fluticasone propionate, total daily dose Regimen: 1 spray per nostril twice daily"
3096795|NCT01915823|Placebo Comparator|Dymista vehicle|Dose: vehicle only Regimen: 1 spray per nostril twice daily
3096796|NCT01915849|Experimental|Sequence 1: LIK066 15 mg/Placebo/LIK066 50 mg/LIK066 150 mg|Period 1- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 2- Placebo treatment once daily for 4 days Period 3 - LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 150 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096797|NCT01915849|Experimental|Sequence 2: LIK066 50 mg/LIK066 15 mg/LIK066 150 mg/Placebo|Period 1- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 4- Placebo treatment once daily for 4 days. 14 days washout periods between treatment periods.
3096798|NCT01915849|Experimental|Sequence 3: LIK066 150 mg/LIK066 50 mg/Placebo/LIK066 15 mg|Period 1- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 2- LIK066 50 mg treatment once daily (q.d.) for 4 days. Period 3- Placebo treatment once daily for 4 days. Period 4- LIK066 15 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096799|NCT01915849|Experimental|Sequence 3: Placebo/LIK066 150 mg/LIK066 15 mg/LIK066 50 mg|Period 1- Placebo treatment once daily (q.d.) for 4 days. Period 2- LIK066 150 mg treatment once daily (q.d.) for 4 days. Period 3- LIK066 15 mg treatment once daily (q.d.) for 4 days. Period 4- LIK066 50 mg treatment once daily (q.d.) for 4 days. 14 days washout periods between treatment periods.
3096800|NCT01915914|Experimental|fluticasone propionate|To evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream (twice per week) in reducing the risk of relapse when added to regular daily moisturization using PHYSIOGEL Lotion in paediatric subjects with stabilized atopic dermatitis
3096801|NCT01915914|Active Comparator|physiogel|To compare the efficacy and safety of fluticasone propionate 0.05% cream (twice per week) added to regular daily moisturization using Physiogel Lotion with Physiogel Lotion alone in paediatric subjects with stabilized atopic dermatitis
3096802|NCT01915940|Experimental|13 mg Bimatoprost Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye and placebo eye drops twice a day in each eye for 6 months.
3096803|NCT01915940|Active Comparator|Timolol 0.5% + Placebo Ocular Insert|Washout and placebo ocular insert in each eye for at least 4 weeks, followed by Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus placebo ocular insert for 6 months.
3096804|NCT01916109|Experimental|Gemcitabine, Carboplatin, and Panitumumab (GCaP)|Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.
3096805|NCT01916226|Experimental|FPNS arm|Subject will receive two sprays (200 mcg per day)of FP into each nostril once daily (OD) every morning for 14 days
3096806|NCT01916226|Placebo Comparator|FPNS Placebo arm|Subject will receive two sprays of FP placebo into each nostril OD every morning for 14 days
3096807|NCT01916226|Experimental|Cetirizine arm|Subject will receive Cetirizine capsule by mouth OD in the morning for 14 days
3096808|NCT01916226|Placebo Comparator|Cetirizine Placebo arm|Subject will receive Cetirizine Placebo capsule by mouth OD in the morning for 14 days
3096809|NCT01916304|Experimental|Levothyroxine sodium new formulation|Levothyroxine (25-225 μg), tablets, orally, once daily for up to 12 to 20 weeks. Dose administered depends on the thyroid stimulating hormone level.
3096810|NCT01916629|Active Comparator|Photocil for Psoriasis|Active Drug - Photocil for Psoriasis
3096811|NCT01916629|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3096812|NCT01916655|Placebo Comparator|Usual Care|standard and typical PAP (Positive Airway Pressure) educational and support protocol
3096813|NCT01916655|Experimental|Self-Management Care|Individualized self-management educational and support protocol
3096814|NCT01916655|Experimental|Self-Management Mobile Care|Individualized self-management educational and support protocol delivered in part by mobile health tool
3096815|NCT01916681|Experimental|Cervical foley & Misoprostol|Patients randomized to this arm will receive a cervical foley and misoprostol to induce their labor.
3096816|NCT01916681|Experimental|Misoprostol only|Patients randomized to this arm will receive misoprostol only to induce their labor.
3096817|NCT01916681|Experimental|Cervical foley alone|Patients randomized to this arm will receive a cervical foley to induce their labor.
3096818|NCT01916681|Experimental|Cervical foley & Pitocin|Patients randomized to this arm will receive a cervical foley and pitocin to induce their labor.
3096819|NCT01916824|Experimental|Participants with Major Depressive Disorder|Persons with a primary diagnosis of Major Depressive Disorder who start taking any FDA-approved antidepressant prescribed within standard dose range for 6 weeks
3096820|NCT01916824|No Intervention|Healthy Controls|Persons without a history of Major Depressive Disorder and without a current diagnosis of any mental illness
3096821|NCT01916928||Non-viable pregnancy|Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation or with miscarriage, defined as fetal death prior to 20 weeks gestation.
3096822|NCT01916941|Active Comparator|Prazosin|Prazosin titrated to 16 mg daily x 6 weeks
3096823|NCT01916941|Placebo Comparator|Placebo|Placebo X 6 weeks
3096824|NCT01916967|Experimental|Desloratadine 5 mg|Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
3096825|NCT01916967|Experimental|Desloratadine 10 mg|Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
3096826|NCT01916967|Placebo Comparator|Placebo|Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks
3096827|NCT01916980|Experimental|Desloratadine: Eczema/Dermatitis|Participants with eczema/dermatitis receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient antipruritic efficacy and there is no safety concern.
3096828|NCT01916980|Experimental|Desloratadine: Dermal Puritus|Participants with dermal pruritus receive desloratadine 5 mg, taken as one 5-mg tablet, orally once daily in the evening for up to 12 weeks. After Week 4, the dose of desloratadine can be increased from 5 mg/day to 10 mg/day (two 5-mg tablets, orally once daily in the evening for up to 8 weeks), if criteria for dose up-titration are met, there is insufficient anti-pruritic efficacy and there is no safety concern.
3096829|NCT01917006|Experimental|OnabotulinumtoxinA Dose 1|OnabotulinumtoxinA Dose 1 injected into specified muscle per protocol on Day 1.
3096830|NCT01917006|Experimental|OnabotulinumtoxinA Dose 2|OnabotulinumtoxinA Dose 2 injected into specified muscle per protocol on Day 1. Participants were eligible for another treatment after 12 weeks.
3096831|NCT01917006|Experimental|OnabotulinumtoxinA Dose 3|OnabotulinumtoxinA Dose 3 injected into specified muscle per protocol on Day 1.
3096832|NCT01917006|Experimental|OnabotulinumtoxinA Dose 4|OnabotulinumtoxinA Dose 4 injected into specified muscle per protocol on Day 1.
3096833|NCT01917006|Experimental|OnabotulinumtoxinA Dose 5|OnabotulinumtoxinA Dose 5 injected into specified muscle per protocol on Day 1.
3096834|NCT01917006|Experimental|OnabotulinumtoxinA Dose 6|OnabotulinumtoxinA Dose 6 injected into specified muscle per protocol on Day 1.
3096835|NCT01917006|Placebo Comparator|Placebo|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
3096836|NCT01917084|Experimental|Passive range of motion (ROM) exercise|A 10 - 15 minute passive range of motion (ROM) exercise program will be administered daily during hospitalization for up to 21 days or until discharge (whichever comes first).
3096837|NCT01917136|Experimental|11c-acetate and 18F-FDG, and cardiac MRI|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate and a 10 millicurie injection of 18F-FDG At baseline/6 months follow up, a cardiac MRI will be performed.
3096838|NCT01917188|Active Comparator|Full simulation and education|Patients who will receive full simulation and education session prior to discharge.
3096839|NCT01917188|Other|See simulation room, usual education|Patients will be shown the simulation room prior to discharge but will only receive usual education.
3096840|NCT01917188|No Intervention|Usual care|Patients will receive usual care by bedside nurse.
3096841|NCT01917214||Non-Interventional Study|
3321194|NCT02017080||Hyperthyroid pregnant women|Autoimmune hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound clinical examination
3321195|NCT02017080||Hypothyroid pregnant women|Autoimmune hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
3096844|NCT01917344|Other|Adults with PKU|MRI, EEG, neuropsychological testing, neurological examination, blood draw, diet diary, physical examination. These activities were performed for the study, but no drug or other interventions took place.
3096845|NCT01917513|Experimental|G-EYE™ colonoscopy|G-EYE™ colonoscopy
3096846|NCT01917513|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
3096847|NCT01917526|Active Comparator|oxygen mask|Oxygen mask with oxygen flow 5 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
3096848|NCT01917526|Active Comparator|Oxygen cannula|Oxygen cannula with oxygen flow 4 L/min will be given to allocated post general anesthesia patients. The incidence and causes of hypoxemia will be recorded.
3096849|NCT01917656|Experimental|Liraglutide+Metformin|Liraglutide 1.8 mg administered once daily subcutaneously, in combination with pre-trial tablet metformin of unchanged dose.
3096850|NCT01917656|Active Comparator|Sulphonylurea and Metformin|Subjects continued on pre-trial sulphonylurea tablet treatment, in combination with pre-trial tablet metformin of unchanged dose.
3096851|NCT01917682||Study Cohort|Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
3096852|NCT01917747|Active Comparator|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before and after any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test and any other follow up, as is standard practice.
3096853|NCT01917747|Experimental|Patient Navigator Group|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed.
3096854|NCT01917773|Experimental|Octreotide|All patient received octreotide. We compared pre (fasting) and post octreotide colonic motility index.
3096855|NCT01917812|Placebo Comparator|Blinded Digital Activity Tracker|Blinded Digital Activity Tracker = Group wears the tracker but is blinded to the numeric physical activity feedback information provided by the tracker.
3096856|NCT01917812|Experimental|Unblinded Digital Activity Tracker / No Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~No Smart Text Messaging = Group does not receive personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
3321196|NCT02017080||Healthy pregnant women|Euthyroid women with uncomplicated pregnancies, with antithyroid antibodies within reference ranges
3096857|NCT01917812|Experimental|Unblinded Digital Activity Tracker / Smart Text Messaging|"Unblinded Digital Activity Tracker = Group unblinded to the numeric physical activity feedback information provided by the digital activity tracker.~Smart Text Messaging = Group receives personalized, health coaching via smart text messages.~Note that the study occurred over two study phases after the 1-week blinded run-in. In the first 2-week phase, participants were randomized to unblinded or blinded tracking. In the second 2-week phase, the unblinded participants were randomized to receive smart texts or no texts."
3096858|NCT01917968|Active Comparator|Uphold Lightweight Vaginal Support System|Transvaginal repair with mesh (Uphold LITE)
3096859|NCT01917968|Active Comparator|Traditional native tissue repair|Sacrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
3096860|NCT01918033|Experimental|Desloratadine 5 mg|Participants receive one desloratadine 5 mg tablet and one placebo tablet orally once daily for up to 2 weeks
3096861|NCT01918033|Experimental|Desloratadine 10 mg|Participants receive two desloratadine 5 mg tablets orally once daily for up to 2 weeks
3096862|NCT01918033|Placebo Comparator|Placebo|Participants receive two placebo tablets orally once daily for up to 2 weeks
3096863|NCT01918072||Stepped wedge participants|"Designated Women's Health Providers with one or more episodes of care for women patients during each period of the intervention.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
3096864|NCT01918072||Electronic consultation survey participants|"Designated Women's Health Providers who completed surveys about use of electronic consultations.~Designated Women's Health Provider: Primary care provider who are proficient in women's health, and should have a minimum of 10% of their patient panels being comprised by women."
3096865|NCT01918072||Quality assessment participants|Primary care providers delivering women's health care for one or more of the following conditions: abnormal uterine bleeding; menopausal symptoms; urinary incontinence.
3096866|NCT01918085|Other|Peristomal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from the Peristomal skin
3096867|NCT01918085|Other|Pre-stripped abdominal skin|The peel force used to remove two types of adhesive strips (Hydrocolloid strip and strata strip) from healthy abdominal skin
3096868|NCT01918189|Experimental|10 week Pain EASE access|behavioral pain self-management intervention (Pain EASE) delivered via the Internet
3096869|NCT01918306|Experimental|1PHIbA Arm A - cisplatin + GDC - 0941|"Determine the safety and tolerability of GDC-0941 given in combination with cisplatin in patients with AR- TN MBC. Determination of the maximally tolerated dose (MTD) of GDC-0941.~Cohort 1, 3 of 3 patients received:~Cisplatin 25 mg/m2 IV D1, 8, 15 GDC-0941 260 mg PO, days 2-6, 9-13, 16-20, 23-27, 28 day cycle GDC-0941 dose to start at Max dose of 260mg.~If no patient in the first cohort of 3 experiences a DLT, an additional cohort of 3 patients will be treated at the same dose level.~If 1 patient experiences a DLT in the first cohort, an additional cohort of 3 patients will be treated at the same dose level.~If ≤1 patient has a DLT in 6 treated at this same dose, this will be considered a tolerable dose to move to phase II~If patients experience a DLT considered related to GDC-0941, the patient may remain on GDC-0941 and/or Cisplatin after resolution of the DLT. All such cases will be considered a DLT for the purposes of defining the MTD."
3096870|NCT01918306|Experimental|1PHIbB - Arm B - Cisplatin + GDC 0941 dose level -1|"If 2 or more patients in 3 or 6 patients treated at a given dose experience DLT, the dose will be de-escalated to the next lower dose level. Once the lowest dose level is reached, if a DLT occurs, the regimen will be considered too toxic and the corresponding cohort within the study will be discontinued.~Determination of the maximally tolerated dose (MTD) of GDC-0941."
3096871|NCT01918306|Active Comparator|2PHII1 Arm 1 - Cisplatin|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC.~Patients will be randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 1 Cisplatin Only Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle)."
3096872|NCT01918306|Experimental|2PHII2 - Arm 2 - Cisplatin + GDC - 0941|"Evaluate the efficacy, as measured by the overall response rate (ORR), of Cisplatin +GDC-0941 versus Cisplatin alone in patients with AR- TN MBC. Patients are randomized in a 1:1 fashion to arm 1: cisplatin, or arm 2: cisplatin + GDC-0941.~Arm 2 Cisplatin + GDC-0941 Patients received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
3096873|NCT01918306|Experimental|2PHIICO|"Arm 2: Crossover post-progression~Patients who are randomized to Cisplatin alone (Arm 1) can crossover to receive Cisplatin + GDC-0941 upon disease progression.~Patient received:~Cisplatin given intravenously (IV) over 1 hour for three consecutive weeks, then off one week (days 1, 8, and 15 of a 28 day cycle).~GDC-0941 260 mg PO, administered orally on days 2-6, 9-13, 16-20, 23-27 of a 28 day cycle."
3096874|NCT01918332|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.
3096875|NCT01918332|Active Comparator|Valsartan 160mg, Rosuvastatin 20mg placebo|Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
3096876|NCT01918332|Active Comparator|Valsartan 160mg placebo, Rosuvastatin 20mg|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.
3096877|NCT01918332|Placebo Comparator|Placebo|Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.
3096878|NCT01918371||Patients with RVO|Patients with retinal vein occlusion (RVO) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
3096879|NCT01918371||Patients with DME|Patients with diabetic macular edema (DME) receiving anti-VEGF injection(s) (ranibizumab, bevacizumab or aflibercept) in accordance with standard of care practices. This is a retrospective chart review study.
3096880|NCT01918761|Experimental|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 (i.v) q21d Dacomitinib 45mg/ orally (continuous)
3321197|NCT02017106|Experimental|Concomitant phlebectomies|Removal of varicose tributaries during Endovenous laser ablation
3321198|NCT02017106|Active Comparator|Sequential Phlebectomies|Endovenous laser ablation only
3096881|NCT01918774|Other|Cognitive behavior therapy for work success|Fifty participants will take part in the 12 week CBTw program. All participants will receive standard SE services during the study. The longitudinal design will consist of assessments of competitive employment outcomes, important psychosocial outcomes, and background and demographic variables at baseline and at two follow-up periods' immediately following the conclusion of the CBTw program and six months after the conclusion of the program.
3096882|NCT01918800|Experimental|Fatigue: Take Control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
3096883|NCT01918800|Active Comparator|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
3096884|NCT01919112|Experimental|High dose anodal tDCS|High dose tDCS (2 milliamps twice daily) for 5 days will be administered concomitantly with swallowing exercises
3096885|NCT01919112|Active Comparator|Low dose anodal tDCS|This arm will use a low dose of current administered via tDCS (2 milliamps once daily) for 5 days will be administered concomitantly with swallowing exercises
3096886|NCT01919112|Sham Comparator|Sham Stimulation|Twice daily swallowing exercises only
3096887|NCT01919164|Placebo Comparator|Placebo|Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
3096888|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles|Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
3096889|NCT01919164|Experimental|Sprifermin (AS902330) 30 mcg- 4 Cycles|Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
3096890|NCT01919164|Experimental|Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
3096891|NCT01919164|Placebo Comparator|Sprifermin (AS902330) 100 mcg- 4 Cycles|Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.
3096892|NCT01919190|Active Comparator|EXPAREL|EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP
3096893|NCT01919190|Sham Comparator|Placebo|The placebo control will be established using a grade-2 sham, no infiltration will occur
3096894|NCT01919216|Active Comparator|Open Track|Open treatment with 20mg of citalopram, increased to 40mg if depression has not remitted at week 4.
3096895|NCT01919216|Placebo Comparator|Placebo Track|Blinded treatment with either citalopram 20mg or placebo, increased to citalopram 40mg or placebo at week 4 if depression has not remitted.
3096896|NCT01919229|Active Comparator|Letrozole|Letrozole 2.5 mg alone once daily
3096897|NCT01919229|Experimental|LEE011 400 mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 400 mg (2 capsules of 200 mg each) once daily.
3096898|NCT01919229|Experimental|LEE011 600mg + letrozole|Letrozole 2.5 mg once daily and ribociclib 600 mg (3 capsules of 200 mg each) once daily.
3096899|NCT01919307|Experimental|Auricular acupuncture|Subjects will then receive auricular acupuncture (NADA Protocol) twice weekly for eight consecutive weeks. Subjects will be evaluated for seizure frequency changes by self-reported diary; adverse events; study feasibility; and mental and physiological symptoms at baseline, 12 weeks (completion of acupuncture), and 16 weeks (1 month after treatment follow up, end of study). A single sham procedure will be tested following treatment completion for use in future studies.
3096900|NCT01919398|Experimental|LY2940680|"Cohort 1: 100 mg LY2940680 administered orally daily in 28-day cycles. Cohort 2: 200 mg LY2940680 administered orally daily in 28-day cycles. Cohort 3: 400 mg LY2940680 administered orally daily in 28-day cycles.~Treatment with LY2940680 continued until disease progression, unacceptable toxicity, or other discontinuation criteria were met."
3096901|NCT01919411|Experimental|Amoxicillin-Potassium Clavulanate|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of augmentin (amoxicillin-clavulanate) 500mg orally twice a day after surgery.
3096902|NCT01919411|Placebo Comparator|Placebo|All patients in the study will undergo endoscopic sinus surgery. This arm will receive 7 days of placebo orally twice a day after surgery.
3096903|NCT01919450|Active Comparator|10 Second Delay|A 10 second delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3096904|NCT01919450|Active Comparator|2 Minute Delay|A 2 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3096905|NCT01919450|Active Comparator|4 Minute Delay|A 4 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3096906|NCT01919450|Active Comparator|1 Minute Delay|A 1 minute delay is imposed between the Lexiscan (Regadenoson) injection and start of myocardial perfusion PET imaging.
3096907|NCT01919489|Experimental|Liraglutide + OADs|Liraglutide once daily in combination to oral anti-diabetic agents (OADs)
3096908|NCT01919489|Active Comparator|Glargine + OADs|Glargine once daily in combination to oral anti-diabetic agents (OADs)
3096909|NCT01919606|Experimental|EXPAREL Group 1|EXPAREL 266 mg diluted with saline to a volume of 40 mL
3096910|NCT01919606|Experimental|EXPAREL Group 2|EXPAREL 266 mg diluted with saline to a volume of 60 mL
3096911|NCT01919697|Experimental|Plecanatide 3.0 mg|Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
3096912|NCT01919697|Experimental|Plecanatide 6.0 mg|Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks
3096913|NCT01919723|Active Comparator|Ticagrelor and Eptifibatide bolus|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg each 10 min apart)
3096914|NCT01919723|Active Comparator|Ticagrelor & Eptifibatide bolus+infusion|Ticagrelor 180 mg i.v. Eptifibatide (2 boluses 180µg/Kg, 10 min apart, followed by 2µg/Kg/min infusion for 2 hours)
3096915|NCT01919801|Experimental|Icatibant|Icatibant at a dose of 30 mg will be administered as a single subcutaneous injection
3096916|NCT01919801|Placebo Comparator|Placebo|Placebo will be administered as a single subcutaneous injection
3096917|NCT01919814|Active Comparator|Appethyl™, then Placebo|Participants receive Appethyl™ liquid once four hours after breakfast. After a washout period of at least one week, they received the placebo drink once four hours after breakfast.
3096918|NCT01919814|Placebo Comparator|Placebo, then Appethyl™|Participants receive the placebo drink once four hours after breakfast. After a washout period of at least one week, they received Appethyl™ liquid once four hours after breakfast.
3096919|NCT01919970|Experimental|Cognitive Behavioral Therapy Condition|This arm is the experimental condition; it consists of 12 weekly CBT sessions. The therapy protocol will begin with an introductory education session which will include development of a fear hierarchy, followed by 11 sessions of in vivo exposures to feared triggers.
3096920|NCT01919970|Active Comparator|Treatment as Usual|This arm acts as the comparison condition. Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3096921|NCT01919996|Experimental|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
3096922|NCT01920061|Experimental|Arm A|
3096923|NCT01920061|Experimental|Arm B|
3096924|NCT01920061|Experimental|Arm C|
3096925|NCT01920061|Experimental|Expansion Arm 1|
3096926|NCT01920061|Experimental|Expansion Arm 2|
3096927|NCT01920152|Experimental|Autologous PRP Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of autologous Platelet-Rich Plasma one week apart from each other.
3096928|NCT01920152|Active Comparator|Hyaluronic Acid Hip Injection|Patients randomized to this group of treatment will receive 3 blinded hip intra-articular injections of hyaluronic acid (SUPARTZ hyaluronate/2.5ml) one week apart each other.
3096929|NCT01920178|Active Comparator|PinPointe Foot Laser|Active laser
3096930|NCT01920178|Sham Comparator|Sham laser group|Treatment with only localizing (aiming) beam of Pinpointe Foot Laser
3096931|NCT01920282|Active Comparator|Nebivolol|Subjects will be provided with daily 5 mg of nebivolol for the first 2 weeks. Subjects receive additional daily doses of 10 mg nebivolol for the remainder of the study period. The dose remains at 5 mg per day, however, if BP falls below 110/70 during the first 2 weeks. Subjects will continue taking the drug during the 2-week follow-up period.
3096932|NCT01920282|Active Comparator|Lifestyle Modification|Subjects will receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals were instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 minutes per week of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conformed to the Dietary Approach to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contained 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein. Sodium consumption was set at 2,400 mg/day for all subjects.
3096933|NCT01920282|Experimental|Nebivolol plus Lifestyle Modification|Subjects begin with 5 mg/day of nebivolol and increase to 10 mg/day if brachial blood pressure is greater than 120/80 mmHg during the first 2 weeks of therapy. Subjects also receive weekly lifestyle counseling by a registered dietitian to ensure adequate progress and compliance. Sample menus, 14-days of meal plans, and grocery shopping lists are provided to each individual. Individuals will be instructed to reduce their daily caloric intake by 500-1000 calories and to perform a minimum of 150 min/wk of moderate-intensity physical activity or 3000 steps/day above baseline levels. The diet plan conforms to the Dietary Approaches to Stop Hypertension dietary guidelines emphasizing low fat dairy products, fruits and vegetable and contains 55% calories as carbohydrates, 30% calories as fat, and 15% calories as protein with sodium consumption set at 2,400 mg/day for all subjects.
3096934|NCT01920477|Experimental|Ofatumumab|Subject received subcutaneous administration of ofatumumab 20 mg once every 4 weeks through Week 56, with an additional 20 mg dose (that is 40mg total) at both Week 0 and Week 4.
3096935|NCT01920477|Placebo Comparator|Placebo|Subject received subcutaneous administration of matching placebo of ofatumumab once every 4 weeks through Week 56, with an additional dose at both Week 0 and Week 4.
3096936|NCT01920555|Active Comparator|Ketamine 0.1mg|Patients in this arm will receive 0.1 mg/kg of Ketamine - one single infusion
3096937|NCT01920555|Active Comparator|Ketamine 0.2mg|Patients in this arm will receive 0.2 mg/kg of Ketamine - one single infusion
3096938|NCT01920555|Active Comparator|Ketamine 0.5mg|Patients in this arm will receive 0.5 mg/kg of Ketamine - one single infusion
3096939|NCT01920555|Active Comparator|Ketamine 1.0mg|Patients in this arm will receive 1.0 mg/kg of Ketamine - one single infusion
3096940|NCT01920555|Placebo Comparator|Midazolam (Active Placebo)|Patients in this arm will receive 0.045 mg/kg of midazolam - one single infusion
3096941|NCT01920568|Experimental|Denosumab 120 mg|Subjects will be administered with Denosumab 120 mg subcutaneous (SC) injection for a maximum of 13 doses and placebo IV infusion over &gt;=15 minutes once every 4 weeks.
3096942|NCT01920568|Experimental|Zoledronic acid 4 mg|Subjects will be administered with Zoledronic acid 4 mg IV infusion over a minimum of 15 minutes for a maximum of 13 doses and placebo SC once every 4 weeks.
3096943|NCT01920594|Experimental|GSK1278863|Subject will receive GSK1278863 300mg on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 100mg once daily for 4 days starting from Day 0.
3468985|NCT03891043|Experimental|Group B, Selenium group|Selenium consisted in a pill of 100 micrograms, to be taken twice a day.
3468986|NCT03890770|Experimental|Normal renal function|Single dose
3096944|NCT01920594|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo on Day-1 (12 +/- 4 hours prior to planned surgery) as a loading dose followed by GSK1278863 matching placebo once daily for 4 days starting from Day 0.
3096945|NCT01920711|Experimental|LCZ696|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of LCZ696 during the double blind period is 200 mg b.i.d.
3096946|NCT01920711|Active Comparator|Valsartan|Single Blind Run-in Period (3-8 weeks): Patients will start on Valsartan 80 mg b.i.d. for 1-2 weeks followed by LCZ696 100 mg b.i.d. for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients can only be randomized from the run-in period if they meet all of the run-in safety criteria. Target dose of Valsartan during the double blind period is 160 mg b.i.d.
3096947|NCT01920802|Experimental|olanzapine|5mg BID olanzapine for up to 4 weeks
3096948|NCT01920802|Experimental|iloperidone|6mg BID iloperidone up to 4 weeks
3096949|NCT01920802|Placebo Comparator|placebo|BID placebo up to 4 weeks
3096950|NCT01920854|Experimental|Soluble Ferric Pyrophosphate|Group/Cohort Designation: Ascending doses of SFP. Each subject will receive a defined dose of SFP IV administered under double-blind conditions. Pharmacokinetics of iron will be measured using a validated assay for iron and transferrin bound iron.
3096951|NCT01920854|Placebo Comparator|Control|Group/Cohort Designation: Each subject will receive placebo IV administered under double-blind conditions.
3096952|NCT01920893|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 as a loading dose followed by a single injection every week (QW) from Week 1 to 15 added to Mometasone furoate nasal spray (MFNS).
3096953|NCT01920893|Experimental|Dupilumab 300 mg QW|Dupilumab, 2 Subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection QW from Week 1 to 15 added to MFNS.
3096954|NCT01920958||TachoSil®|TachoSil®, sterile absorbable patch, topical application, used during surgery in participants who had lymphadenectomy according to the Summary of Product Characteristics.
3096955|NCT01921101|Other|intensive medical nutrition|participants will receive intensive medical nutrition from hospital admission to discharge
3096956|NCT01921101|Other|control|participants will not receive intensive nutritional support from hospital admission to discharge
3096957|NCT01921166|Active Comparator|clomiphene plus gonadotropins|clomiphene plus gonadotropins
3096958|NCT01921166|Active Comparator|Leuprolide flare|Leuprolide flare
3096959|NCT01921179|Experimental|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
3096960|NCT01921179|Active Comparator|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
3096961|NCT01921205|Experimental|Lacosamide|
3096962|NCT01921205|Placebo Comparator|Placebo|
3321199|NCT02017119|Experimental|Lactulose|Lactulose 15ml oral intake 8hrs daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
3468987|NCT03890770|Experimental|Mild renal disease|Single dose
3096965|NCT01921257|Experimental|Treatment|Cat-PAD and Placebo
3096966|NCT01921270|Experimental|Dysport Injections|Participants with OMD who have been previously treated with any botulinum toxin Type A will be injected with Dysport®.
3096967|NCT01921296|Experimental|Cyclobenzaprine|Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.
3096968|NCT01921322|Experimental|Pump|Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
3096969|NCT01921322|Active Comparator|MDI|Multiple daily insulin injections used for treatment
3096970|NCT01921348|Experimental|Treatment|34 participants will be randomized to wear acupressure pellets in the designated acupressure points and apply pressure as instructed by the study personnel.
3096971|NCT01921348|Sham Comparator|Sham|33 participants will be randomized to wear acupressure pellets in non-specific areas of the ear and apply pressure as instructed by the study personnel.
3096972|NCT01921387|Experimental|Treatment (90Y-BC8-DOTA, chemotherapy, PBSC)|Patients receive yttrium Y 90 anti-CD45 monoclonal antibody BC8 IV on day -14. Patients also receive carmustine IV over 3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, cytarabine IV over 4 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2. Patients then undergo autologous PBSC transplant on day 0.
3096973|NCT01921452|Experimental|POC TSH Kits + Third Generation TSH Kit|
3096974|NCT01921517|Experimental|Low Magnitude Mechanical Stimulation|10 minutes daily of 30 Hz/0.3g stimulation using a vibrating platform.
3096975|NCT01921517|Placebo Comparator|Sham Low Magnitude Mechanical Stimulation|10 minutes daily of placebo treatment using a sham vibrating platform.
3096976|NCT01921634|Other|Standard analysis|Standard pathological analysis currently used.
3096977|NCT01921634|Other|Modified Pathologic Analysis|After undergoing standard pathologic analysis, each specimen will then undergo the modified pathologic analysis.
3096978|NCT01921751|Experimental|Chemotherapy + high intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent high intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
3096979|NCT01921751|Experimental|Chemotherapy + low intensity radiation|Induction chemotherapy with four cycles of gemcitabine and nab-paclitaxel [randomized to this arm after 3rd cycle and no progression]; followed by concurrent low intensity radiation therapy and capecitabine; followed by consolidation chemotherapy with gemcitabine and nab-paclitaxel until progression or unacceptable toxicity
3096980|NCT01921751|Active Comparator|Chemotherapy|Gemcitabine and nab-paclitaxel until progression or unacceptable toxicity [randomized to this arm after 3rd cycle and no progression]
3096981|NCT01921829|No Intervention|Usual Care|Participants randomized to the Usual Care group (control arm) will receive escalating diuretics and medical therapy per HF guidelines published by the American College of Cardiology (ACC)/American Heart Association (AHA) and Heart Failure Society of America (HFSA), dosed in variable fashion at the discretion of the treating cardiologist.
3096982|NCT01921829|Experimental|Protocolized Diuretic Strategy|Participants randomized to the Protocolized Diuretic Strategy group will receive escalating diuretics according to an algorithm targeting a goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide). If UO is < 3 L/day, diuretic regimen will be increased. If UO is 3-5 L/day, diuretic regimen will be continued at current doses. If UO is > 5 L/day, diuretic regimen will be reduced.
3096983|NCT01921894|Experimental|Cholecalciferol 4000 IU|Cholecalciferol 4000 IU oral chewable tablet once daily for 8 weeks
3096984|NCT01921894|Experimental|Cholecalciferol 2000 IU|Cholecalciferol 2000 IU oral chewable tablet once daily for 8 weeks
3096985|NCT01921894|Active Comparator|Cholecalciferol 200 IU|Cholecalciferol 200 IU oral chewable tablet once daily for 8 weeks
3096986|NCT01922011|Experimental|Daptomycin|Intravenous (IV) daptomycin was dosed as follows: age 12 years to <18 years (7 mg/kg); age 7 years to < 12 years (9 mg/kg); age 24 months to <7 years (12 mg/kg); age 12 months to <24 months (12 mg/kg). Drug was infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
3096987|NCT01922011|Active Comparator|Vancomycin or Nafcillin|IV vancomycin (or equivalent), 10 to 15 mg/kg, was infused over 60 (± 10) minutes q6h (± 1 hour) or IV nafcillin (or β-lactam equivalent) at 100-200 mg/kg/day, in divided doses was infused over 60 (± 10) min q6h (± 1 hour)
3096988|NCT01922024||Prospective Fresh Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against composite (comparator) which is based on routine clinical microbiology and a second PCR test
3096989|NCT01922024||Retrospective Frozen Clinical Specimens|Patients with suspicion of lower respiratory tract infection (pneumonia), samples tested with Unyvero LRT 55 cartridge and results compared against routine clinical microbiology
3096990|NCT01922037|Experimental|Participants With Allergic Asthma|Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.
3096991|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 1|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
3096992|NCT01922050|Experimental|Part 1: LEO 43204 Formulation 2|Open-Label, Dose-Escalation, Once-Daily, 2-Day Treatment
3096993|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose X|Double-Blind, Once-Daily, 2-Day Treatment
3096994|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 1 Dose Y|Double-Blind, Once-Daily, 2-Day Treatment
3096995|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose XX|Double-Blind, Once-Daily, 2-Day Treatment
3096996|NCT01922050|Experimental|Part 2: LEO 43204 Formulation 2 Dose YY|Double-Blind, Once-Daily, 2-Day Treatment
3096997|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 1|Double-Blind, Once-Daily, 2-Day Treatment
3096998|NCT01922050|Placebo Comparator|Part 2: Placebo Formulation 2|Double-Blind, Once-Daily, 2-Day Treatment
3096999|NCT01922089|Experimental|LCZ696 Condensed|Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
3097000|NCT01922089|Experimental|LCZ696 Conservative|Up-titration to LCZ696 200 mg bid over 6 weeks
3097001|NCT01922102|Experimental|Group I|0.5 mg ranibizumab driven by visual acuity stability criteria
3097002|NCT01922102|Experimental|Group II|0.5 mg ranibizumab driven by disease activity criteria
3097003|NCT01922102|Active Comparator|Group III|verteporfin PDT
3097004|NCT01922115|Active Comparator|TROSPIUM CHLORIDE|Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).
3097005|NCT01922115|Placebo Comparator|PLACEBO|Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).
3097006|NCT01922219|Other|Cognitive Behavioral Therapy|Depressed individuals who enroll in this study will receive 14 sessions of cognitive behavioral therapy provided by an experienced psychiatrist or psychologist over 12 weeks (twice-a-week for the first two weeks, and weekly after that).
3097007|NCT01922258|Placebo Comparator|Placebo|Matching Placebo Once-Daily
3097008|NCT01922258|Experimental|Brexpiprazole (flexible dose range 0.5 to 2 mg)|Titrate up from 0.25 mg/day brexpiprazole to 1 mg/day brexpiprazole. After achieving 1 mg/day target dose may be increased or decreased based on efficacy and tolerability. Allowable flexible doses will be 0.5 mg/day, 1 mg/day, or 2 mg/day.
3097009|NCT01922271|Experimental|NVA237 followed by tiotropium|Period 1: NVA237 plus placebo to tiotropium on day 1, followed by a 7 day washout. Period 2: tiotropium plus placebo to NVA237 on day 8. Salbutamol was used as rescue medication.
3097010|NCT01922271|Experimental|Tiotropium followed by NVA237|Period 1: tiotropium plus placebo to NVA237 on day 1, followed by a 7 day washout. Period 2: NVA237 plus placebo to tiotropium on day 8. Salbutamol was used as rescue medication.
3097011|NCT01922336|Experimental|SB2|SB2 (Study drug)
3097012|NCT01922336|Active Comparator|EU Remicade|EU sourced Remicade (Reference drug)
3097013|NCT01922336|Active Comparator|US Remicade|US sourced Remicade (Reference drug)
3097014|NCT01922349|Placebo Comparator|Placebo (Multiple dose)|Placebo
3097015|NCT01922349|Experimental|Dose 1, Single dose|Low dose
3097016|NCT01922349|Experimental|Dose 2, Single dose|Medium dose
3097017|NCT01922349|Experimental|Dose 3, Single dose|High dose
3097018|NCT01922349|Experimental|Dose 4, Multiple dose|Low dose
3097019|NCT01922349|Experimental|Dose 5, Multiple dose|Medium dose
3097020|NCT01922349|Experimental|Dose 6, Multiple dose|High dose
3097021|NCT01922349|Placebo Comparator|Placebo (Single dose)|Placebo
3097022|NCT01922739|Experimental|Hydrocodone ER|Participants were administered hydrocodone ER tablets orally at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain. If enrolled under the original protocol, there was a double-blind titration period of four weeks to adjust the dose taken in study 3103 (NCT01789970). If enrolled under the amended protocol, there was an open-label adjustment period of three weeks to adjust the dose taken in study 3103 (NCT01789970). Both versions of protocol 3104 followed the titration/adjustment period with a open-label treatment period of 22 weeks.
3097023|NCT01922934|Experimental|Intervention|"350 randomly-selected patients at 4 clinics get a toolbox of weight loss options, including self-monitoring tools; education materials; recreation center passes; commercial weight loss program (Weight Watchers); intensive group counseling (Colorado Weigh); meal replacements; and obesity pharmacotherapy. The initial assessment, a computer program, takes diet and exercise history and helps patients choose personal treatment goals. Interested patients get a starter kit with self-monitoring tools and meal replacements. Subjects must show self-monitoring of diet and exercise to get more intensive therapies. Patients pay a $5-$10 co-pay for the therapies. They select a primary intensive therapy, but are able to add/change depending on results, adherence and budget availability."
3097024|NCT01922934|No Intervention|Control|Registry patients not selected to be offered the toolbox will receive usual care for weight management. Usual care for obesity at DH includes brief weight loss advice provided by PCPs or prescribing of weight loss medication, for which patients pay out of pocket.
3097025|NCT01922986|Experimental|Active rTMS with conventional therapy|20 minutes of active rTMS followed by conventional stroke therapy
3097026|NCT01922986|Sham Comparator|sham rTMS with conventional therapy|20 minutes of sham rTMS stimulation followed by conventional stroke therapy
3097027|NCT01923129|Experimental|24 hour postop catheter removal|group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
3097028|NCT01923129|No Intervention|72 hour postoperative catheter removal|catheter removed on postoperative day 3 (72 hours postoperatively)
3321200|NCT02017119|Experimental|Lactulose-paraffin|Paraffin 15g daily for 6 months. The dose may be modified depending on the number of total bowel movements, (the expected range is 2 - 4 per day).
3321201|NCT02017132|Active Comparator|Pomegranate extract|1.1g pomegranate extract capsule administered daily to each participant for 8 weeks
3321202|NCT02017132|Placebo Comparator|Placebo capsule|1.1g placebo capsule taken daily by each participant for 8 weeks
3097032|NCT01923181|Experimental|1:Semaglutide tablets : 2.5 mg|2.5 mg for 26 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097033|NCT01923181|Experimental|2:Semaglutide tablets: 2.5 mg/5 mg|2.5 mg for 4 weeks, then 5.0 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097034|NCT01923181|Experimental|3:Semaglutide tablets: 5.0 mg/10 mg|5.0 mg for 4 weeks, then 10 mg for 22 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097035|NCT01923181|Experimental|4:Semaglutide tablets:5.0 mg/10 mg/20 mg|5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097036|NCT01923181|Experimental|5:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 4 weeks, then 10 mg for 4 weeks, then 20 mg for 4 weeks, then 40 mg for 14 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
3097037|NCT01923181|Experimental|6:Semaglutide tablets:5.0 mg/10 mg/20 mg/40 mg|5.0 mg for 8 weeks, then 10 mg for 8 weeks, then 20 mg for 8 weeks, then 40 mg for 2 weeks All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097038|NCT01923181|Experimental|7:Semaglutide tablets: 5.0 mg/10 mg/20 mg/40 mg|"5.0 mg for 2 weeks, then 10 mg for 2 weeks, then 20 mg for 2 weeks, then 40 mg for 20 weeks.~All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone."
3097039|NCT01923181|Placebo Comparator|8:Placebo tablets|All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097040|NCT01923181|Active Comparator|9:Semaglutide injections :0.25 mg/0.50 mg/1.0 mg|0.25 mg for 4 weeks, then 0.50 mg for 4 weeks, then 1.0 mg for 18 weeks. All arms include 26 weeks of treatment and a 5 week follow-up period. The trial medication will be add-on to metformin therapy or as monotherapy in the case where the subject is treated with diet and exercise alone.
3097041|NCT01923285|Experimental|AXIUM Neurostimulator System|The AXIUM Neurostimulator System is an investigational spinal cord stimulation device that is designed to stimulate the dorsal root ganglion (DRG) of the spine located on the back surface of the spinal cord where nerves exit the backbone. The device has 2 parts that are placed surgically (implanted) : 1) a pulse generator which is placed under the skin in the buttocks or abdomen, and 2) up to four wires (leads) that have one end attached to the pulse generator, and the other end secured to the tissue near the target treatment area.
3097042|NCT01923285|Active Comparator|Control Spinal Cord Stimulation Device|The Control Spinal Cord Stimulation Device is a commercially available spinal cord stimulator indicated for the treatment of chronic lower limb pain.
3132603|NCT03440411|Experimental|ARM pom-dex Late (A-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
3321203|NCT02017145|No Intervention|no reapplication|This group will not have chloraprep reapplied after their surgery and prior to dressing application.
3097043|NCT01923311|Experimental|Cohort 1 (12 to < 18 years of age)|"Part A: No participants will be enrolled in Part A, as PK data is currently available for this age group.~Part B: Participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3097044|NCT01923311|Experimental|Cohort 2 (6 to < 12 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days. Participants with HIV-1 RNA > 1,000 copies/mL will receive EVG along with a newly constructed background regimen that includes a Pl/r for 48 weeks. Participants with HIV-1 RNA > 1,000 copies/mL can continue after Week 48.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. Participants who complete the 48-week follow-up in both Part A and Part B will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3097045|NCT01923311|Experimental|Cohort 3 (2 to < 6 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3097046|NCT01923311|Experimental|Cohort 4 (4 weeks to < 2 years of age)|"Part A: Participants with HIV-1 RNA < 50 copies/mL will receive EVG plus a background regimen that includes a PI/r for 10 days.~Part B: Following confirmation of exposure to EVG and based on safety and PK data assessed in Part A, participants will receive EVG plus a background regimen that includes a PI/r for up to 48 weeks. After Week 48, participants will be given the option to continue EVG therapy until the participant turns 18 and EVG is available for use in adults in the country in which the participant is enrolled, or the age appropriate EVG formulation becomes available for use in the country in which the participant is enrolled, or Gilead Sciences elects to terminate development of EVG in the applicable country."
3097047|NCT01923363|Experimental|Standard Dose to High Dose Piperacillin/Tazobactam|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Then, they will be switched to higher dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
3097048|NCT01923389|Placebo Comparator|Placebo|
3097049|NCT01923389|Experimental|100 mg PF-05231023|
3097050|NCT01923428|Experimental|5 mg BID|AZD1722
3097051|NCT01923428|Experimental|20 mg BID|AZD1722
3097052|NCT01923428|Experimental|50 mg BID|AZD1722
3097053|NCT01923428|Placebo Comparator|Placebo|
3097054|NCT01923467|Experimental|Project Quit plus NRT patches|All participants in the program will be offered the opportunity to complete the Project Quit stop smoking program. Project Quit is an individually-tailored, web-based program which has been scientifically proven to help people succeed at their quit attempts. All eligible participants will also receive a 2-week supply of Nicotine patches 21 mg.
3321204|NCT02017145|Experimental|reapplication|This group will have chloraprep reapplied following their lower extremity surgical procedure and prior to dressing application.
3321205|NCT02017158|Experimental|Virtual Sprouts|The Virtual Sprouts intervention arm will play Virtual Sprouts in a school-based implementation of the game.
3321206|NCT02017158|No Intervention|Control group|The control group will consist of students who will not play the Virtual Sprouts game at school.
3097058|NCT01923740|Experimental|Absorb BVS System|Absorb BVS System: Subjects receiving Absorb BVS System
3097059|NCT01923740|Active Comparator|XIENCE V EECSS|XIENCE V EECSS: Subjects receiving XIENCE V
3097060|NCT01923805|Experimental|Treatment Group|Vitagel
3097061|NCT01923805|No Intervention|Control|Standard of care for surgical hemostasis.
3097062|NCT01923896|Experimental|Behavioral Intervention & DCS|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and D-cycloserine (0.7mg/kg DCS) to be taken acutely one hour prior to the onset of the first treatment session each day
3097063|NCT01923896|Active Comparator|Behavioral Intervention & Placebo|Behavioral Feeding Intervention (15 total treatment sessions over 5 days) and placebo (lactose powder) by method of intake (bottle; formula; tube)
3097064|NCT01923961|Experimental|HDF NaCl, Then HD, Then Standard Pre-HDF|Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
3097065|NCT01923961|Experimental|HD, Then Standard Pre-HDF, Then HDF NaCl|Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
3097066|NCT01923961|Experimental|Standard Pre-HDF, Then HDF NaCl, Then HD|Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
3321207|NCT02017184|Experimental|Research arm|This trial contains one group which will undergo the described protocol while connected to both sensors: a rectal thermistor and a non invasive thermistor.
3321208|NCT02017197|Other|Sequence A|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #1~Phase 4: generic warfarin #2"
3468988|NCT03890770|Experimental|Moderate renal failure|Single dose
3097067|NCT01924169|Experimental|Lenalidomide|Lenalidomide administered at the dose of 5 mg/day on Monday, Wednesday and Friday for 3 months. If Immunoglobulin G (IgG) levels improve by at least 25% of baseline, lenalidomide administration continued for 3 months on, and 3 months off for 2 years. If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years. Seasonal influenza vaccination (Trivalent Influenza Vaccine, Fluzone High Dose) administered yearly, during the fall/winter season and pneumococcal immunization (Pneumococcal Polysaccharide Vaccine, Pneumovax) administered once between month 6 and month 21.
3097068|NCT01924182|Other|IT group (Intrathecal Morphine Sulfate)|SynchroMed Infusion System and Intrathecal Morphine Sulfate
3097069|NCT01924182|Other|Conventional Medical Management|Conventional Medicine, and then SynchroMed Infusion System and Intrathecal Morphine Sulfate
3097070|NCT01924299|Experimental|Baricitinib + Ketoconazole|"Baricitinib - 10 milligrams (mg) administered orally once on Day 1 of Period 1 and on Day 6 of Period 2.~Ketoconazole - 400 mg administered orally once daily (QD) for 6 days (Day 3 through Day 8) in Period 2."
3097071|NCT01924299|Experimental|Baricitinib + Fluconazole|"Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.~Fluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Day 4 through Day 9) in Period 2."
3097072|NCT01924364|Experimental|Fat grafting with TGI|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
3097073|NCT01924364|Sham Comparator|Fat grafting without TGI - Standard of care|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be NOT processed by the Tissue Genesis Cell Isolation System™ (TGI-CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
3097074|NCT01924390|Active Comparator|mineralized FDBA alone|Socket grafting with mineralized freeze-dried bone allograft alone
3097075|NCT01924390|Experimental|Combination of mineralized and deminieralized FDBA|Socket grafting with a combination of mineralized and demineralized freeze-dried bone allograft alone
3097076|NCT01924429|Experimental|On Drug then off Drug|Participants receive fMRI #1 on drug, #2 off drug Escalating stepped titration: 30, 50 or 70mg
3097077|NCT01924429|Experimental|Off drug then on drug|Participants receive fMRI #1 off drug, #2 on drug Escalating stepped dose titration: 30, 50, 70mg
3097078|NCT01924442||On-Pump|Cardiac bypass using Heart Lung Machine
3097079|NCT01924442||Off-Pump|Cardiac bypass surgery on beating heart
3097080|NCT01924533|Experimental|Olaparib+ paclitaxel|olaparib + paclitaxel
3097081|NCT01924533|Placebo Comparator|Placebo+paclitaxel|placebo+ paclitaxel
3097082|NCT01924559|Active Comparator|Direct Laryngoscopy & standard clothing|Residents will intubate manikin using DL while wearing standard clothing.
3097083|NCT01924559|Active Comparator|Direct Laryngoscopy & Biohazard Gear|Residents will intubate manikins using DL while in Biohazard gear.
3097084|NCT01924559|Experimental|Glidescope & standard clothing|Residents will intubate manikins using Glidescope while wearing standard clothing.
3097085|NCT01924559|Active Comparator|Glidescope & Biohazard Gear|Residents will intubate manikins using Glidescope while wearing Biohazard gear.
3097086|NCT01924559|Active Comparator|Supraglottic Airway & standard clothing|Residents will intubate manikins using Supraglottic Airway while wearing standard clothing.
3097087|NCT01924559|Active Comparator|Supraglottic Airway and Biohazard gear|Residents will intubate manikins using Supraglottic airway while wearing biohazard gear.
3097088|NCT01924689|Experimental|Clostridium novyi-NT spores|
3097089|NCT01924754||Standard intramuscular injection (NS-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by standard intramuscular (IM) injection using a needle and syringe (NS-IM)
3097090|NCT01924754||PharmaJet needle-free Stratis device (JI-IM)|HPV vaccination regimen: Standard 3 dose (0.5mL) delivered by IM injection using the PharmaJet needle-free Stratis device (JI-IM)
3097091|NCT01924754||PharmaJet needle-free Tropis device (JI-ID)|HPV vaccination regimen: Reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device (JI-ID)
3097092|NCT01924767|Experimental|BI 10773 (dose group 3)|multiple doses as tablet
3097093|NCT01924767|Experimental|BI 10773 (dose group 4)|multiple doses as tablet
3097094|NCT01924767|Experimental|BI 10773 (dose group 1)|multiple doses as tablet
3097095|NCT01924767|Experimental|BI 10773 (dose group 2)|multiple doses as tablet
3097096|NCT01924806|Active Comparator|WoundWand™ Debridement Device|Group I - Coblator IQTM Controller plus WoundWandTM Debridement Device. Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound.
3097097|NCT01924806|Active Comparator|Standard of Care sharp debridement|Group II - Standard of Care (SoC) surgical (sharp) debridement. Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound.
3097098|NCT01924845|Experimental|BMN 701 20 mg/kg|BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
3097099|NCT01924871|Active Comparator|Desflurane group|1.5 MAC desflurane until extubation
3097100|NCT01924871|Active Comparator|Desflurane with remifentanil group|1.0 MAC desflurane with 1.0ng/ml targeted concentration infusion of remifentanil
3097101|NCT01924949|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
3097102|NCT01924975|Active Comparator|Landmark group|An operator is not allowed to use an ultrasound. A 22 or 24 G catheter will be advanced blindly toward the expected location of the saphenous vein at the level of the medial malleolus. Once blood appears in the hub, then the catheter will be advanced into the saphenous vein.
3321209|NCT02017197|Other|Sequence B|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: Marevan®~Phase 4: generic warfarin #2"
3097103|NCT01924975|Active Comparator|Ultrasound group|An operator will identify the saphenous vein by using ultrasound with a linear transducer (L15-7io) in short axis view. A 22 or 24 G catheter will be advanced until the tip of the needle is seen on the ultrasound image. The needle is then advanced until blood appears in the hub. The catheter is then advanced into the saphenous vein.
3097104|NCT01924988|Experimental|Prostatic Embolization|Therapeutic occlusion of the prostate arteries
3097105|NCT01925014|Experimental|Low-dose CT|Diagnostic CT with low-dose radiation
3097106|NCT01925014|Active Comparator|Standard-dose CT|Diagnostic CT with standard-dose radiation
3097107|NCT01925144|Experimental|Baricitinib|Baricitinib - 10 milligram (mg) tablet administered orally, once, on Day 1.
3097108|NCT01925144|Experimental|Baricitinib + Omeprazole|Baricitinib - 10 mg tablet administered orally, once, on Day 10. Omeprazole - 40 mg capsule administered orally once daily (QD) for 8 days (Days 3 through 10).
3097109|NCT01925170|Experimental|Mammography and Molecular Breast Imaging|Participants underwent conventional mammography and molecular breast imaging after a 740-millibecquerel (mBQ) (8-mCi) Technetium (99mTc) sestamibi injection.
3097110|NCT01925183|Experimental|28 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with undetectable HCV-RNA at treatment week 8 will be treated with 24 weeks of BOC/PEGIFN/RBV triple-therapy resulting in a total treatment duration of 28 weeks.
3097111|NCT01925183|Experimental|48 weeks of treatment duration|All patients will receive 4 weeks of PEGIFN/RBV lead-in. Patients with detectable HCV-RNA at treatment week 8 will receive 44 weeks of BOC/PEGIFN/RBV triple-therapy and a total treatment duration of 48 weeks
3097112|NCT01925209|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received study medication with BYM338 at 10 mg/kg from Day 1 to Week 52 and up to Week 104, administered by intravenous (i.v.) infusion every 4 weeks.
3097113|NCT01925209|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received study medication with BYM338 at 3 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3097114|NCT01925209|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received study medication with BYM338 at 1 mg/kg from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3097115|NCT01925209|Placebo Comparator|Placebo|Participants received matching placebo to BYM338 from Day 1 to Week 52 and up to Week 104, administered by i.v. infusion every 4 weeks.
3097116|NCT01925274|Experimental|Arm A|PF-05212384 plus Irinotecan
3097117|NCT01925274|Active Comparator|Arm B|Cetuximab plus Irinotecan
3097118|NCT01925339|Experimental|Test (immediate restoration)|Test (immediate restoration): immediate restoration will be placed on immediately placed implants.
3097119|NCT01925339|Experimental|Control: delayed restoration|Control: delayed restoration: immediate placed implants will be restored at 4 months.
3097120|NCT01925404|Experimental|Frequent User Arm|Park users will be able to earn rewards or prizes by coming more frequently to the park
3097121|NCT01925404|Experimental|Free Physical Activity Classes/programs|We will offer at least 100 free physical activity classes at the park
3097122|NCT01925404|Experimental|Combined arm|We will offer free classes and the frequent user program at the park
3097123|NCT01925404|No Intervention|Control|Business as usual, no special physical activity programs offered
3097124|NCT01925417|Experimental|RBX2660 (microbiota suspension)|enema-based delivery of RBX2660
3097125|NCT01925469|Experimental|Benzocaine|Benzocaine spray (14%), an FDA approved drug, will be used to assess whether this provides additional pain relief at time of hysterosalpingogram.
3097126|NCT01925469|Placebo Comparator|Saline spray|A saline placebo spray will be used in the placebo group.
3097127|NCT01925612|Experimental|Part 1: BV(1.2 mg/kg) + RCHOP|"Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.2 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
3097128|NCT01925612|Experimental|Part 1: BV(1.8 mg/kg) + RCHOP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 1 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard RCHOP chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients in this arm were randomized into the 1.8 mg/kg brentuximab vedotin dosing cohort, to be administered in combination with RCHOP."
3097129|NCT01925612|Experimental|Part 2: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 2 of the study is a phase 2, non-randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy (rituximab, cyclophosphamide, doxorubicin, and prednisone). Patients in this treatment arm were enrolled into a dosing cohort with 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
3097130|NCT01925612|Active Comparator|Part 3: RCHOP|"Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone."
3097131|NCT01925612|Experimental|Part 3: BV(1.8 mg/kg) + RCHP|"Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, prednisone~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive RCHOP treatment alone. Randomization in this part of the study is for the purpose of evaluating the safety of 1.8 mg/kg brentuximab vedotin in combination with RCHP versus standard RCHOP chemotherapy.~Part 3 of the study is a phase 2, randomized, open-label, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin 1.8 mg/kg when administered in combination with RCHP chemotherapy compared to RCHOP chemotherapy alone. Patients in this treatment arm were randomized to receive 1.8 mg/kg brentuximab vedotin administered in combination with RCHP."
3097132|NCT01925677|Experimental|da Vinci® Single-Site™|Robotic-assisted single-incision laparoscopic nephrectomy.
3097133|NCT01925703|Experimental|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
3097134|NCT01925768|Experimental|Apremilast 30 mg|30 mg Apremilast tablets administered twice daily (BID) for 24 weeks during the double-blind placebo-controlled phase; followed by 30 mg Apremilast BID for 28 weeks of active treatment phase (up to the 52 week visit); original treatment assignments remain blinded until all participants have completed their 52 week visit or have discontinued. After the Wk 52 visit, all participants in the extension phase will continue to receive treatment with apremilast 30 mg BID until the end of the study (ie, up to Week 104 visit) or until early discontinuation from the trial.
3097135|NCT01925768|Placebo Comparator|Placebo|Oral placebo BID during the placebo controlled phase weeks 0 to 24; placebo treated participants whose improvement is <10% in both swollen and tender joint counts at Week 16 are eligible for early escape (based on the measure of clinical benefit from their current treatment as evidenced by improvement (or lack of improvement) in 1) the physician (evaluator's) global assessment (EGA), 2) patients pain (pain NRS), 3) the patient global assessments (PGA), and 4) the health assessment questionnaire disability index (HAQ-DI); Placebo-treated patients who early escape are transitioned to apremilast 30 mg PO BID during the active treatment phase up to their Week 52 visit; all those who complete the 52-week treatment phase will enter an open-label extension phase for an additional 52 weeks or until early discontinuation from the trial.
3097136|NCT01925781|Experimental|e-Cigarette|STAM 1100mAh CE4 eGo Clearomizer e-Cigarette
3097137|NCT01925781|Active Comparator|Nicotine polacrilex|Nicotine Replacement gum
3097138|NCT01925950|Placebo Comparator|Placebo|Control
3097139|NCT01925950|Experimental|orBec|Investigational drug
3097140|NCT01925989|Experimental|Insulin Peglispro/Insulin Glargine|Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin.
3097141|NCT01925989|Active Comparator|Insulin Glargine/Insulin Peglispro|Insulin glargine administered to participants with T1DM SQ QD for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen. Participants continue to use mealtime insulin. Insulin peglispro (LY2605541) administered to participants with T1DM subcutaneously (SQ) once daily (QD) for 28 to 35 days in one of two treatment periods. Dose is based on participant's prestudy basal insulin dosing regimen.
3097142|NCT01925989|No Intervention|Control|Control Arm. Untreated healthy participants.
3097143|NCT01926015|Experimental|Concomitant RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) and DTP-IPV (0.5 mL subcutaneous injection) administered concomitantly at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
3097144|NCT01926015|Active Comparator|Staggered RotaTeq™ and DTP-IPV|RotaTeq™ (2 mL oral dose) administered at Visit 1 (Day 1), Visit 3 (6-8 weeks after Visit 1), and Visit 5 (6-8 weeks after Visit 3) and DTP-IPV (0.5 mL subcutaneous injection) administered at Visit 2 (>=4 weeks after Visit 1), Visit 4 (6-8 weeks after Visit 2), and Visit 6 (6-8 weeks after Visit 4).
3097145|NCT01926028|Experimental|NDV-3A|Experimental Vaccine: a purified, recombinant antigen (rAls3) formulated with aluminum hydroxide adjuvant
3097146|NCT01926028|Experimental|NDV-3|Experimental Vaccine: a purified, recombinant antigen (rAls3 with 6-His tag) formulated with aluminum hydroxide adjuvant
3097147|NCT01926028|Placebo Comparator|Placebo|Placebo: aluminum hydroxide adjuvant
3097148|NCT01926119|Experimental|TMS Intervention - 5 days|Application of Transcranial Magnetic Stimulation (TMS) once per day over 5 days.
3097149|NCT01926444|Experimental|GIC-1001 low dose|GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)
3097150|NCT01926444|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3097151|NCT01926444|Experimental|GIC-1001 , high dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3097152|NCT01926444|Placebo Comparator|GIC-1001 matching placebo|Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)
3097153|NCT01926496|Experimental|Ingenol Mebutate|Arm A: Ingenol mebutate gel 0.015% applied daily for 3 consecutive days to the selected treatment area followed by 8 weeks' rest. Retreatment for another 3 consecutive days if the treatment field is not completely cleared of AKs at Week 8
3097154|NCT01926496|Active Comparator|Imiquimod|Arm B: Imiquimod 5% cream applied 3 days per week for 4 weeks to the selected treatment area followed by 4 weeks' rest. Retreatment for another 4 weeks if the treatment field is not completely cleared of AKs at Week 8
3097155|NCT01926509|Experimental|MK-8892 Panel A|Participants will be administered MK-8892 once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 3 mg (Days 15-21), 4 mg (Days 22-28).
3097156|NCT01926509|Experimental|MK-8892 Panel B|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), 4 mg (Days 22-28).
3097157|NCT01926509|Experimental|MK-8892 Panel C|Participants will be administered MK-8892 orally, once daily at following dose levels: 1 mg (Days 1-7), 2 mg (Days 8-14), 4 mg (Days 15-21), up to 8 mg (Days 22-28).
3097158|NCT01926509|Placebo Comparator|Placebo (Panels A and B)|Participants will be administered placebo to MK-8892 once daily for 28 days.
3097159|NCT01926626|Experimental|Nicotine Patch+Moclobemide|After 1 week of pre-cessation nicotine patch treatment (21 mg/24 h patches), participants will receive moclobemide (400 mg/day in 2 divided doses) for 11 weeks, ending 10 weeks after the target quit date. Nicotine patch treatment will continue at 21 mg/24 h for an additional week prior to the quit date, and then for 6 weeks after the quit date, followed by 14 mg/24 h for 2 weeks and 7 mg/24 h for 2 weeks. All treatment will terminate 10 weeks after the quit date.
3097160|NCT01926782|Placebo Comparator|Placebo Q2W|Two subcutaneous (SC) injections of placebo (for alirocumab) Q2W with or without stable statin therapy for 48 weeks.
3468989|NCT03890770|Experimental|Severe renal failure|Single dose
3097161|NCT01926782|Experimental|Alirocumab 75 mg/ Up 150 mg Q2W|One SC injection of each Alirocumab 75 mg and placebo Q2W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
3097162|NCT01926782|Experimental|Alirocumab 300 mg/ Up 150 mg Q4W|Two SC injections of Alirocumab 150 mg Q4W alternating with two SC injections of placebo Q4W with or without stable statin therapy for 48 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels ≥ 70 mg/dL (1.81 mmol/L) (for very high CV risk participants) or ≥ 100 mg/dL (2.59 mmol/L) (for moderate and high CV risk participants) at Week 8.
3097163|NCT01926886|Experimental|Trastuzumab|Participants with HER2+ eBC who completed the first 6 cycles of trastuzumab IV infusion as part of the (neo) adjuvant treatment will be included to continue to receive 12 cycles of trastuzumab to complete a total of 18 cycles of trastuzumab. Participants will receive trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).
3097164|NCT01926886|No Intervention|Health Care Professionals|Health Care Professionals (HCPs) included for polling purposes. HCPs were not enrolled in the study.
3097165|NCT01926977|Active Comparator|Ranibizumab 0.5mg Intravitreal injection|Intravitreal injection of Ranibizumab 0.5mg once
3097166|NCT01926977|Active Comparator|Aflibercept 2.0mg Intravitreal injection|Intravitreal Aflibercept 2.0mg once
3097167|NCT01927055|Active Comparator|Droxidopa|Droxidopa 100 mg, 200 mg, 300 mg
3097168|NCT01927055|Placebo Comparator|Placebo|Placebo
3097169|NCT01927120|Experimental|GVHD Regimen|Graft versus host disease (GVHD) prophylaxis regimen IL-2 with Sirolimus and Tacrolimus after allogeneic hematopoietic cell transplant (HCT).
3097170|NCT01927341|Experimental|Phase Ib: Dose escalation|Phase Ib: Dose escalation.
3097171|NCT01927341|Experimental|Phase II: Patients with mutant RAS mCRC|Patients with mutant RAS mCRC who have not been pretreated with an EGFR inhibitor (EGFRi), including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3097172|NCT01927341|Experimental|Phase II: Patients with acquired mutant RAS mCRC|Patients with acquired mutant RAS mCRC who have been pretreated with anti-EGFR monoclonal antibody therapy, but have not been pre-treated with EGFR tyrosine kinase inhibitor therapy.
3097173|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (pretreated)|Patients with WT RAS mCRC who have been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3097174|NCT01927341|Experimental|Phase II: Patients with WT RAS mCRC (not pretreated)|Patients with WT RAS mCRC who have not been pretreated with an EGFRi, including EGFR tyrosine kinase inhibitor therapy and/or anti-EGFR monoclonal antibody therapy.
3097175|NCT01927367|Other|Clinical Decision Support System for AF|Providers randomized to use the Clinical Decision Support System (CDSS, a web-based tool).
3097176|NCT01927367|No Intervention|Usual Care|Usual Care - providers are not eligible to access / use the CDSS.
3468990|NCT03890770|Experimental|End-stage renal disease requiring dialysis|Two single doses administered with washout
3468991|NCT03890497|Active Comparator|Full dose of IPV|IPV first dose between 9 -13 months with second dose administered 2 months later.
3097179|NCT01927497|Experimental|Biological mesh closure|Biological mesh reconstruction of the pelvic floor after extralevator abdomino perineal resection
3097180|NCT01927497|Active Comparator|Primary perineal closure|Primary perineal closure after extralevator abdomino perineal resection
3097181|NCT01927562|Experimental|Duodenal Treatment|The Duodenal Remodeling procedure utilizes both a trans-oral over the wire and endoscopic approach to minimally invasively ablating and remodeling the duodenum.
3097182|NCT01927575|Active Comparator|Standard X-Ray + CT|Standard X-Ray + CT arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
3097183|NCT01927575|Active Comparator|Standard X-Ray + MRI|Standard X-Ray + MRI arm to be used as comparative arm for investigational imaging device. Investigators will determine standard of care to be used on a per subject basis.
3097184|NCT01927575|Experimental|Tomo|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
3097185|NCT01927627|Experimental|Enzalutamide|Oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
3097186|NCT01927718|Experimental|Thalidomide + Lenalidomide|"Thalidomide 100 mg by mouth daily for 28 days in a 28 day cycle started after the clinical documentation of biochemical progression.~Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle."
3097187|NCT01927757|Experimental|Etanercept|Participants received etanercept 50 mg administered subcutaneously once a week with methotrexate for 24 weeks
3097188|NCT01927861|Experimental|0.033 mg/kg/day|
3097189|NCT01927861|Experimental|0.066 mg/kg/day|
3097190|NCT01927887|Experimental|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
3097191|NCT01928030|Experimental|recombinant human hyaluronidase|Phase 1. 450 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1, 3, 5, and 7 Phase 2: 900 units recombinant human hyaluronidase (rHuPH20) administered SC on days 1 to 21
3097192|NCT01928186|Experimental|Diagnostic (FLT PET)|Patients undergo FLT PET at baseline and 1-6 weeks after the start of treatment.
3468992|NCT03890497|Active Comparator|Fractional Dose of IPV|fIPV first dose between 9 -13 months with second dose administered 2 months later
3097193|NCT01928199|Active Comparator|Sitagliptin|"Sitaglipitin tablets will be administered orally for 3 months from randomization~Initial dose will be 100mg/daily, adjusted per renal function:~Creatinine clearance > or = 50mL/min: 100mg/day Creatinine clearance > or = 30 and <50mL/min: 50mg/day Creatinine clearance <30 mL/min or on dialysis: 25mg/day"
3097194|NCT01928199|Placebo Comparator|Placebo|Placebo tablets (identical to active comparator in appearance) will be administered orally for 3 months. Starting dose and adjustment based on renal function will be identical to active comparator
3097195|NCT01928225|Experimental|Human Papillomavirus vaccine|Participants receive the experimental quadrivalent Human Papillomavirus vaccine at entry, week 4 and week 26.
3097196|NCT01928225|Placebo Comparator|Saline placebo|The participants receive saline placebo at entry, week 4 and week 26.
3097197|NCT01928290|Experimental|Arm A: FOLFIRINOX (HER2-negative)|"Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
3097198|NCT01928290|Experimental|Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)|"Trastuzumab 8 mg/kg on Cycle 1 Day 1 then 4 mg/kg on Day 15 and Day 1 of all future cycles.~Irinotecan 180 mg/m2 IV on Days 1 & 15.~Oxaliplatin 85 mg/m2 IV on Days 1 & 15.~Leucovorin 400 mg/m2 IV on Days 1 & 15.~Fluorouracil 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1 and Day 15."
3097199|NCT01928329|Placebo Comparator|Placebo|2 mg, 1 per week via subcutaneous placebo self injection
3097200|NCT01928329|Experimental|Exenatide (Bydureon)|2 mg, of drug administration 1 per week via subcutaneous self injection
3097201|NCT01928381|Placebo Comparator|placebo capsules|Capsules to match pregabalin and AZD5213
3097202|NCT01928381|Experimental|AZD5213 + pregabalin|AZD5213 in combination with pregabalin
3097203|NCT01928381|Active Comparator|pregabalin|pregabalin capsules
3097204|NCT01928394|Experimental|Arm N - Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097205|NCT01928394|Experimental|Arm N-I, Level 1: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 1 mg/kg solution every 3 weeks for 4 doses followed by Nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097206|NCT01928394|Experimental|Arm N-I, Level 2: Nivolumab+Ipilimumab|Nivolumab 1 mg/kg solution intravenously plus Ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097207|NCT01928394|Experimental|Arm N-I, Level 2b: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously plus Ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097208|NCT01928394|Experimental|Arm N-I, Level 2c: Nivolumab+Ipilimumab|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097209|NCT01928394|Experimental|Arm N-I, Level 2d: Nivolumab+Ipilimumab+Cobimetinib|Nivolumab 3 mg/kg solution intravenously every 3 weeks combined with ipilimumab 1 mg/kg every 6 weeks and cobimetinib 60mg once daily 21days on/7 days off until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3097210|NCT01928433|Experimental|Finafloxacin 5 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 5 days."
3097211|NCT01928433|Experimental|Finafloxacin 10 days|"Intervention:~Finafloxacin 800 mg i.v. once daily and Ciprofloxacin placebo i.v. twice daily. Finafloxacin 800 mg tablets once daily and Ciprofloxacin placebo oral twice daily Finafloxacin verum (i.v. and oral) for a total of 10 days."
3097212|NCT01928433|Active Comparator|Ciprofloxacin 10 days|"Intervention:~Ciprofloxacin 400 mg i.v. twice daily and Finafloxacin placebo i.v. once daily Ciprofloxacin 500 mg oral twice daily and Finafloxacin placebo tablets once daily Ciprofloxacin (i.v. and oral) for a total of 10 days."
3097213|NCT01928446|Experimental|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
3097214|NCT01928446|Placebo Comparator|Placebo|Placebo tablets will be given to the subjects for the duration of follow-up (1 year). Dose adjustments will mimic the intervention arm of the study
3097215|NCT01928472|Experimental|Group A|H7N9c low dose with adjuvant
3097216|NCT01928472|Experimental|Group B|H7N9c medium dose with adjuvant
3097217|NCT01928472|Experimental|Group C|H7N9c high dose with adjuvant
3097218|NCT01928472|Experimental|Group D|H7N9c high dose without adjuvant
3097219|NCT01928485|Active Comparator|Arm A (active surveillance)|Patients undergo active surveillance for 52 weeks.
3097220|NCT01928485|Experimental|Arm B (Sunphenon)|Patients receive Sunphenon PO QD for 52 weeks in the absence of disease progression or unacceptable toxicity.
3097221|NCT01928524|Experimental|DOS2W Dose level 1A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
3097222|NCT01928524|Experimental|DOS2W Dose level 2A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
3097223|NCT01928524|Experimental|DOS2W Dose level 3A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
3097224|NCT01928524|Experimental|DOS2W Dose level 4A|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 2 weeks.
3097225|NCT01928524|Experimental|DOS3W Dose level 1B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
3097226|NCT01928524|Experimental|DOS3W Dose level 2B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
3097227|NCT01928524|Experimental|DOS3W Dose level 3B|Treatment with Docetaxel, Oxaliplatin and S1. Treatment is given every 3 weeks.
3097228|NCT01928680|Experimental|Cisplatin/Capecitabine|"Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.~This is a single arm phase II clinical trial."
3097229|NCT01928693|Active Comparator|Besivance 0.6% Ophthalmic Suspension|A topical fluoroquinolone antimicrobial indicated for the treatment of bacterial conjunctivitis.
3097230|NCT01928693|Active Comparator|Zymaxid 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
3097231|NCT01928693|Active Comparator|Vigamox 0.5% Ophthalmic Solution|A topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis.
3097232|NCT01928719|Experimental|Reduced Nicotine Content Cigarettes|the experimental group will smoke cigarettes with Gradually Reduced Nicotine Content (RNC) (11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg per cigarette) cigarettes, each smoked for 3 weeks, except for the last period which will last 6 weeks to evaluate a longer-term adherence to the lowest nicotine content cigarette.
3097233|NCT01928719|Placebo Comparator|Same Nicotine Content Cigarettes|The Same Nicotine Control Group (SNC) will continue to smoke research cigarettes with a usual nicotine content (about 11.6 mg per cigarette)
3097234|NCT01928758|Experimental|Reduced Nicotine Content Cigarettes|The experimental group will smoke cigarettes with gradually Reduced Nicotine Content (11.6, 7.4, 3.3, 1.4, 0.7 and 0.2 mg per cigarette) cigarettes, with each nicotine level smoked for 3 weeks, except the lowest level which continues for 6 weeks
3097235|NCT01928758|Placebo Comparator|Usual Nicotine Content Cigarettes|Research cigarettes with a usual nicotine content (around 11.6mg per cigarette)
3097236|NCT01928771|Experimental|Benralizumab 30 mg q.4 weeks|Benralizumab administered subcutaneously every 4 weeks
3097237|NCT01928771|Experimental|Benralizumab 30 mg q.8 weeks|Benralizumab administered subcutaneously every 8 weeks
3097238|NCT01928771|Placebo Comparator|Placebo|Placebo administered subcutaneously
3097239|NCT01928797|No Intervention|Control group|The care provider will use blood pressure and heart rate data to administer vasopressor use. In the control group, vasopressors (phenylephrine and ephedrine) will be used as considered appropriate to maintain BP within 20% of baseline. The CO data is measured and blinded to the anesthesiologists in the control group, therefore the anesthesiologist choice of ephedrine or phenylephrine is based on the individual anesthesiologist standard of care preference
3097240|NCT01928797|Experimental|Study group|The care provider will use the cardiac output monitor data (intervention) to guide vasopressors (Phenylephrine and ephedrine) in addition to blood pressure and heart rate data based on a standardized protocol in addition to the blood pressure and heart rate data available in the control group.
3097241|NCT01928849|Placebo Comparator|Cherry syrup|"Cherry Syrup: Patients randomized to the Control arm of the trial will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and the placebo."
3097242|NCT01928849|Experimental|Valproic Acid|"Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid."
3097243|NCT01928862|Experimental|Prepopik® ½ Sachet x 2 (9-12 years)|Prepopik® ½ Sachet x 2 (9-12 years)
3097244|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (9-12 years)|Prepopik® 1 Sachet x 2 (9-12 years)
3097245|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (9-12 years)|Local standard of care
3097246|NCT01928862|Experimental|Prepopik® 1 Sachet x 2 (13-16 years)|Prepopik® 1 Sachet x 2 (13-16 years)
3097247|NCT01928862|Active Comparator|Oral polyethylene glycol (PEG) based preparation (13-16 years)|Local standard of care
3097248|NCT01928927|Experimental|Arm A: Telmisartan|
3097249|NCT01928927|No Intervention|Arm B: No Study Drug|Participants received no study drug and followed the week 0-48 evaluation schedule.
3097250|NCT01928940|Experimental|dabrafenib + trametinib|Combination therapy of dabrafenib and trametinib
3097251|NCT01929018|Experimental|Exercise, activity, and self-management|Exercise, Walking Program, and Health Self-Management Support. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to deliver the interventions.
3097252|NCT01929018|No Intervention|Home and phone visit|No intervention will be applied. Participants will be visited at home once monthly and contacted by phone once weekly over 12 weeks to monitor health status.
3097253|NCT01929031|Other|Caffeine-Ibuprofen|Study Stage 1: One Caffeine 100 mg tablet after dental surgery; Arm Type: Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one ibuprofen 400 mg tablet, while awake, over 5 days; Arm Type: Active Comparator
3097254|NCT01929031|Other|Placebo-Ibuprofen/Caffeine|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine tablet, while awake, over 5 days; Arm Type: Experimental
3097255|NCT01929031|Other|Ibuprofen/Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Ibuprofen 400 mg/Caffeine 100 mg tablet after dental surgery: Arm Type Experimental - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type Experimental
3097256|NCT01929031|Other|Ibuprofen-Ibuprofen|Study Stage 1: One Ibuprofen 400 mg tablet after dental surgery; Arm Type Active Comparator - Study Stage 2: Subsequent to stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake, over 5 days; Arm type; Active Comparator
3097257|NCT01929031|Other|Caffeine-Ibuprofen/Caffeine|Study Stage 1: One Caffeine 100 mg tablet after dental surgery. Arm Type; Active Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400mg/Caffeine 100 mg tablet, while awake, over 5 days; Arm Type: Experimental
3097258|NCT01929031|Other|Placebo-Ibuprofen|Study Stage 1: One Placebo tablet after dental surgery Arm Type: Placebo Comparator - Study Stage 2: Subsequent to Stage 1, every 6-8 hours one Ibuprofen 400 mg tablet, while awake over 5 days; Arm Type: Active Comparator
3097259|NCT01929044|Experimental|Buscopan® (hyoscine butylbromide)|1st injection of Buscopan® solution 20mg, if necessary 2nd injection after 20min of the 1st injection
3097260|NCT01929044|Active Comparator|654-II(anisodamine)|1st injection of 654-II solution 10mg, if necessary 2nd injection after 20min of the 1st injection
3097261|NCT01929057||Acne patients|This group consists of patients who have at least moderate to severe acne on their back
3097262|NCT01929057||Healthy Controls|This group contains participants who do not have any active acne lesions on their back
3097263|NCT01929083|Experimental|Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
3097264|NCT01929083|Placebo Comparator|Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
3097265|NCT01929109|Experimental|LY2409021 Control|Healthy participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
3097266|NCT01929109|Experimental|LY2409021 Mild Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
3097267|NCT01929109|Experimental|LY2409021 Moderate Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
3097268|NCT01929109|Experimental|LY2409021 Severe Renal Impairment|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of the study.
3097269|NCT01929109|Experimental|LY2409021 End Stage Renal Disease|Participants received a single 80 mg dose of LY2409021 orally on Day 1 of Period 1 of the study and a single 80 mg dose of LY2409021 orally on Day 1 of Period 2 of the study.
3097270|NCT01929135|Experimental|Medicated 2% atorvastatin dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a medicated 2% atorvastatin dentifrice 2 times a day for two minutes each time, for 30 days.
3097271|NCT01929135|Placebo Comparator|Non-medicated dentifrice|A group of 19 patients received non surgical periodontal therapy accompanied by instruction for oral hygiene, using a non-medicated dentifrice as placebo 2 times a day for two minutes each time, for 30 days.
3097272|NCT01929226|Experimental|ETI-204|A single intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1
3097273|NCT01929226|Placebo Comparator|Placebo for ETI-204|A single intravenous dose of ETI-204-placebo infused over 90 minutes on Day 1
3097274|NCT01929291||Boostrix Group|Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.
3097275|NCT01929317|Experimental|Ropinirole CR high-dose group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase, where Ropinirole CR dose will titrated (2 mg /day/week) from 18 mg/day up to a maximum 24mg/day at intervals of 1 week or longer for 8 weeks, till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg /day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
3097276|NCT01929317|Experimental|Ropinirole CR maintenance group|The subjects will receive Ropinirole CR 16mg/day for 4 weeks in screening phase. After randomization the subject will enter dose increase effect verification phase and Ropinirole CR dose will maintained at 16mg/day and placebo will be increased at intervals of 1 week for 8 weeks till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose for 4 weeks. This will be followed by a down titration phase of one week and long term phase of 39 weeks in which the subjects will receive incremental doses (2 mg/day/week) of Ropinirole CR from 18 mg/day till to a maximum of 24 mg/day till subject reaches a dose level above which further symptomatic improvement cannot be expected; the subject will be maintained on that dose. Subjects completing the long term phase will undergo a down titration phase of 1 to 2 weeks.
3097277|NCT01929343|Experimental|lidocaine following cue-induced craving|Lidocaine will be administered immediately following craving induction. Lidocaine will administered at a loading dose of 2mg/kg(milligrams per kilogram) initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
3097278|NCT01929343|Active Comparator|lidocaine following neutral stimulus|Lidocaine will be administered immediately following neutral stimulus. Lidocaine will administered at a loading dose of 2mg/kg initial bolus over 5 minutes lidocaine followed by continuous infusion at 2mg/kg /hour for 4 hours.
3097279|NCT01929343|Placebo Comparator|saline|Saline will be administered at same volume of lidocaine in active arms.
3097280|NCT01929395|Active Comparator|Arm 1 addition of supine MRI to conventional imaging|Arm 1 objective will be to determine whether the addition of supine MRI to conventional imaging with mammography and or sonography and prone MRI will result in a lower positive margin rate in patients undergoing breast conserving surgery.
3097281|NCT01929395|Active Comparator|Arm 2 randomize to SOC vs supine MRI + SOC|Arm 2 of the study patients with non-palpable invasive breast cancer or DCIS who desire breast conservation will be randomized to either a usual care group, or a group receiving a supine MRI in addition to conventional imaging (mammogram and prone MRI) and undergoing breast cancer resection without the wire localization technique.
3097282|NCT01929460|Other|Drug (Standard group)|"Standard group: this group will receive three days of oral antibiotics after their EUS-guided pancreas cyst aspiration.~Ciprofloxacin 500mg by mouth twice a day for three days."
3097283|NCT01929460|Placebo Comparator|Intervention group|"Intervention group: this group will receive three days of oral PLACEBO after their EUS-guided pancreas cyst aspiration~Oral Placebo, one cap twice a day for three days."
3097284|NCT01929642|Experimental|Sirolimus or Everolimus|Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)
3097285|NCT01929681|Experimental|LFMS - active treatment|"Low Field Magnetic Stimulation (LFMS) active treatment~Active low field magnetic stimulation treatment applied with the LFMS Device; the device is on and magnetic field stimulation is present."
3097286|NCT01929681|Sham Comparator|LFMS - sham treatment|"Low Field Magnetic Stimulation - sham treatment~Inactive low field magnetic stimulation (no stimulation) treatment applied with the LFMS Device; the device is on, however no magnetic field stimulation is present."
3097287|NCT01929707|Experimental|LY3050258|Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.
3097288|NCT01929707|Placebo Comparator|Placebo|Single dose of placebo matching LY3050258 administered in up to one of two periods.
3097289|NCT01929759|Other|Drug switching|Single-arm with switch from baseline antiretroviral therapy with Atripla to Stribild for total of 8 weeks.
3321210|NCT02017197|Other|Sequence C|"Phase 1 (run-in): generic warfarin #1~Phase 2: generic warfarin #1~Phase 3: generic warfarin #2~Phase 4: Marevan®"
3097290|NCT01929863|Experimental|Arm A|Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
3097291|NCT01929863|Experimental|Arm B|Subjects will receive metformin 850 mg BID for 7 days, placebo (matching 45 mg GSK2330672) BID on Days 1 and 2 and placebo (matching 90 mg GSK2330672) BID on Days 3 to 7 in treatment period 1. Subjects will receive metformin 850 mg BID for 7 days, GSK2330672 45 mg BID on Days 1 and 2 and GSK2330672 90 mg BID on Days 3 to 7 in treatment period 2. Treatment periods will be separated by a washout period of 13 to 15 days in which subjects will continue metformin 850 mg BID only
3097292|NCT01929876|Experimental|Cobimetinib + Itraconazole|
3097293|NCT01929889|Experimental|Iloperidone|Patients currently taking an antipsychotic medication other than Fanapt® will switch from their current medicine to Fanapt® in a cross-titration at a rate that is determined by the study physician. Treatment with iloperidone will be initiated and dosage will increase until the subject has achieved clinical stability, or has achieved the maximum dose, or 8 weeks have elapsed. Subjects who do not achieve clinical stability (as defined in the inclusion criteria) for the final 2 weeks in this 8-week period at the maximum dose of iloperidone will be discontinued from the study. If patients achieve stabilization, the lowest effective dose will be maintained. Subjects who have achieved clinical stability will then enter the 12-week treatment phase of the study.
3097294|NCT01929980|Experimental|Bortezomib|"Four doses of bortezomib, 1.3mg/m2, will be given intravenously (through a needle in a vein) or subcutaneously (under the skin) on Days 1, 4, 8, 11.~The format of receiving medications is- Therapy Dose and Route Frequency Rituximab 375 mg/m2 intravenously Once on day 1. Plasmapheresis 2 hours prior to Bortezomib Day 1,4, 8 and 11 Bortezomib 1.3 mg/m2 intravenously Day 1,4,8 and 11"
3097295|NCT01929993|Experimental|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode.
3097296|NCT01929993|Active Comparator|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth.
3097297|NCT01930045|Experimental|Ralt→MAL4Ralt→Ralt4MAL→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Raltegravir (Ralt) alone in Period 1, MAALOX (MAL) followed 4 hrs later by Ralt in Period 2, Ralt followed 4 hrs later by MAL in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3097298|NCT01930045|Experimental|MAL4Ralt→Ralt4MAL→Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt followed 4 hrs later by MAL in Period 2, Ralt alone in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3097299|NCT01930045|Experimental|Ralt4MAL→Ralt→MAL4Ralt→MAL6Ralt→Ralt6MAL|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, Ralt alone in Period 2, MAL followed 4 hrs later by Ralt in Period 3, MAL followed 6 hrs later by Ralt in Period 4, Ralt followed 6 hrs later by MAL in Period 5
3097300|NCT01930045|Experimental|Ralt→Ralt4MAL→MAL4Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt alone in Period 1, Ralt followed 4 hrs later by MAL in Period 2, MAL followed 4 hrs later by Ralt in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3097301|NCT01930045|Experimental|MAL4Ralt→Ralt→Ralt4MAL→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: MAL followed 4 hrs later by Ralt in Period 1, Ralt alone in Period 2, Ralt followed 4 hrs later by MAL in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3097302|NCT01930045|Experimental|Ralt4MAL→MAL4Ralt→Ralt→Ralt6MAL→MAL6Ralt|Part 1 was comprised of periods 1, 2 and 3; Part 2 was comprised of periods 4 and 5; with each study period separated by a washout period of at least 2 days. Part 1 was separated from Part 2 by a Pause. Each period had single oral dose treatments as follows: Ralt followed 4 hrs later by MAL in Period 1, MAL followed 4 hrs later by Ralt in Period 2, Ralt alone in Period 3, Ralt followed 6 hrs later by MAL in Period 4, MAL followed 6 hrs later by Ralt in Period 5
3097303|NCT01930058|Experimental|Panel A: HCV GT3 MK-8876 150 mg|Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.
3097304|NCT01930058|Experimental|Panel B: HCV GT3 MK-8876 800 mg|Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.
3097305|NCT01930058|Experimental|Panel E: HCV GT1a MK-8876 800 mg|Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.
3097306|NCT01930162|Experimental|HSC835|Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.
3097307|NCT01930175|Placebo Comparator|Placebo|single dose iv of Placebo
3097308|NCT01930175|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
3097309|NCT01930175|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg initiated following a safety review of patients receiving VAY736 3 mg/kg or placebo.
3097310|NCT01930188|Experimental|Semaglutide 0.5 mg + sitagliptin placebo|
3097311|NCT01930188|Experimental|Semaglutide 1.0 mg + sitagliptin placebo|
3097312|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 1.0 mg|
3097313|NCT01930188|Active Comparator|Sitagliptin 100 mg + semaglutide placebo 0.5 mg|
3097314|NCT01930214||None/mild calcification|Presence of readily apparent radiopacities within the vascular wall at the site of the stenosis.
3097315|NCT01930214||Moderate Calcification|Presence of radiopacities only during the cardiac cycle before contrast injection with calcium extended partially into the target lesion.
3097316|NCT01930214||Severe calcification|Presence of radiopacities noted without cardiac motion prior to contrast injection involving both sides of the arterial wall in at least one location, total length of calcium (including segmented) must be at least 15mm and extend partially into the target lesion.
3097317|NCT01930435|Experimental|Sterile Humidification Device, MyPurMist|Sterile Humidification Device Twice a day, 15 minutes each 12 weeks
3097318|NCT01930487|Experimental|supplement w/ antioxidants then placebo|dietary supplement with antioxidants, followed by placebo supplement
3097319|NCT01930487|Experimental|placebo then supplement w/ antioxidants|placebo supplement, followed by dietary supplement with antioxidants
3097320|NCT01930643|Experimental|Electric muscle stimulation(EMS)|EMS:use programmed middle frequency electric stimulation device(HELEX 573)for both quadriceps stimulation, 32 minutes per day, 5 time per week.
3097321|NCT01930643|No Intervention|Control|Patients with routine passive rehabilitation program.
3097322|NCT01930747|Experimental|deep neuromuscular block|deep neuromuscular block is given after first measurement of lap workspace one bolus dose of 1 mg/kg rocuronium is given
3097323|NCT01930747|Experimental|inhalation with 1 MAC Sevoflurane|1 MAC Sevoflurane inhalation is given after first measurement of lap workspace
3097324|NCT01930747|Experimental|remifentanyl|remifentanyl infusion is given after first measurement of lap workspace
3097325|NCT01930799|Other|All Enrolled Patients|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
3097326|NCT01930890|Experimental|BIIB023 3 mg/kg|Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
3097327|NCT01930890|Experimental|BIIB023 20 mg/kg|Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.
3097328|NCT01931059|Experimental|Risperidone then Placebo|This group will receive 2 mg (>200lbs), 1.5mg (150-200lbs.) or 1 mg (< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
3097329|NCT01931059|Experimental|Placebo then Risperidone|This group will receive a placebo on the first day and 2mg (> 200lbs.), 1.5mg (150-200lbs), or 1 mg (<150lbs.) of risperidone oral solution on the second day
3321211|NCT02017197|Other|Sequence D|"Phase 1 (run-in): Marevan®~Phase 2: Marevan®~Phase 3: generic warfarin #2~Phase 4: generic warfarin #1"
3321212|NCT02017197|Other|Sequence E|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: Marevan®~Phase 4: generic warfarin #1"
3097332|NCT01931150|Experimental|Dapsone LEFT, Moisturizer RIGHT|Dapsone 5% gel to LEFT side of face and chest BID (morning and evening) Moisturizer to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
3097333|NCT01931150|Experimental|Dapsone RIGHT, Moisturizer LEFT|Moisturizer to LEFT side of face and chest BID (morning and evening) Dapsone 5% gel to RIGHT side of face and chest BID (morning and evening) AND oral antibiotics (doxycycline 100 mg bid OR minocycline 100 mg once daily or other antibiotic daily)
3097334|NCT01931163|Experimental|Everolimus|Cisplatin 20 mg/m2 IV infusion over 60 minutes, weekly (Days 1, 8, 15) x 4 cycles Everolimus 10mg by mouth daily
3097335|NCT01931202|Placebo Comparator|Double Blind-Placebo|Blinded treatment with placebo, one pill a day. If after the 4 weeks, the patient has not remitted, they will be increased to 2 pills a day.
3097336|NCT01931202|Active Comparator|Double Blind-Escitalopram|Blinded treatment with either escitalopram 10mg, increased to escitalopram 20mg at week 4 if depression has not remitted.
3097337|NCT01931202|Active Comparator|Open Treatment with Escitalopram|Open treatment with 10mg of escitalopram, increased to 20mg if depression has not remitted at week 4.
3097338|NCT01931462|Experimental|Certus 140™|During the operation: use of Certus 140™ microwave device for pre-coagulation of the kidney tissue adjacent to the tumor.
3097339|NCT01931475|Experimental|Duloxetine|"Double Blind Treatment Phase:~60 milligram (mg) duloxetine administered by mouth once a day (QD). Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD for 12 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks.~Taper Phase: 1-week taper where participants taking 60 mg QD duloxetine during the study had their dosage reduced to 30 mg to minimize discontinuation-emergent adverse events (DEAEs)."
3097340|NCT01931475|Placebo Comparator|Placebo|"Double Blind Treatment Phase:~Placebo administered by mouth once a day (QD) for 13 weeks.~Extension Treatment Phase:~60 mg duloxetine administered by mouth QD for 13 weeks. Started on duloxetine 30 mg QD for 1 week and then titrated up to 60 mg duloxetine QD.~Taper Phase: 1-week taper - Placebo administered for 1 week if the participant discontinued from double blind treatment phase, or duloxetine 30 mg QD administered for 1 week if the participant discontinued from extension treatment phase or completed treatment. 1 week taper is to minimize discontinuation-emergent adverse events (DEAEs)."
3097341|NCT01931527|No Intervention|Obese subjects with normal uric acid|Subjects with a body mass index = or > 30 kg/m² with normal uric acid (= or < 5 mg/dL)
3097342|NCT01931527|Experimental|Obese subjects with high uric acid|"Subjects with a body mass index = or > 30 kg/m² with high uric acid (>6 mg/dL)~Intervention: one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min"
3097343|NCT01931566|Placebo Comparator|Low Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to low risk group for developing MCI-AD for up to 5 years.
3097344|NCT01931566|Placebo Comparator|High Risk Placebo|Pioglitazone placebo-matching tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
3097345|NCT01931566|Experimental|High Risk Pioglitazone|Pioglitazone 0.8 mg, sustained release (SR) tablets, orally, once daily to participants assigned to high risk group for developing MCI-AD for up to 5 years.
3097346|NCT01931670|Placebo Comparator|Placebo|Placebo twice daily (BID) for the 6-month Treatment Period
3097347|NCT01931670|Experimental|Elagolix 150 mg QD|Elagolix 150 mg once daily (QD) for the 6-month Treatment Period
3097348|NCT01931670|Experimental|Elagolix 200 mg BID|Elagolix 200 mg BID for the 6-month Treatment Period
3097349|NCT01931709|Experimental|Diagnostic (FDG PET and DCE-MRI)|Patients undergo FDG PET and DCE-MRI 1-2 weeks prior to chemotherapy initiation, between 1-12 weeks after initiation of the first course of chemotherapy, and after the completion of chemotherapy (within 4 weeks prior to surgery).
3097350|NCT01931735|Experimental|Randomized Meniscectomy|This group will have a partial meniscectomy
3097351|NCT01931735|Active Comparator|Randomized Lavage|This group will have arthroscopy and lavage
3097352|NCT01931735|Other|Standard of Care Meniscectomy Pre-Amend|Pre-Amendment: surgeons determined standard of care option, meniscectomy, best benefited the patient. Therefore, the patient was not randomized.
3097353|NCT01931735|Other|Standard of Care Meniscectomy Post-Amend|Post Amendment: patients received a meniscectomy as a standard of care and were observed for 24-months post-operative.
3097354|NCT01931839|Experimental|Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h|Participants who received lumacaftor (LUM, VX-809) 600 milligram (mg) plus ivacaftor (IVA, VX-770) 250 mg fixed-dose combination (FDC) tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening, in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3097355|NCT01931839|Experimental|Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening in this study VX12-809-105 up to Week 96.
3097356|NCT01931839|Experimental|Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in the previous study VX12-809-103 or VX12-809-104, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3097357|NCT01931839|Experimental|Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in the previous study VX12-809-103 or VX12-809-104, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
3097358|NCT01931839|No Intervention|Arm 5 Part A: Observational Cohort|Participants who received either LUM 600 mg plus IVA 250 mg FDC tablet orally in the morning and IVA 250 mg film-coated tablet orally in the evening OR LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening OR placebo matched to LUM and IVA in the morning and evening, in the previous study VX12-809-103 or VX12-809-104, and will be observed (will not receive study drug) in this study VX12-809-105 for up to 2 years.
3097359|NCT01931839|Experimental|Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in Cohort 4 of the previous study VX09-809-102, and will receive the same treatment in this study VX12-809-105 up to Week 96.
3097360|NCT01931839|Experimental|Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h|Participants who received placebo matched to LUM and IVA tablet in Cohort 4 of the previous study VX09-809-102, and will receive LUM 400 mg plus IVA 250 mg FDC tablet orally in the morning and evening in this study VX12-809-105 up to Week 96.
3097361|NCT01931865|Experimental|IncobotulinumtoxinA|The total dose will depend on the extent of the area involved by pain. The injections will be carried out through a 1cc syringe using a ½ to 1 inch needle intramuscularly or subcutaneously (or both). The ttoal dose will not exceed 100 units.
3097362|NCT01931878|Placebo Comparator|Placebo , saline|The subject may be randomly assigned to receive Placebo, saline
3097363|NCT01931878|Active Comparator|IncobotulinumtoxinA Treatment|The subjects will be randomized to received injections of active study drug, incobotulinumtoxinA (Xeomin)
3097364|NCT01931956|Experimental|Non-High Risk|Includes patients who are candidate for mitral valve repair or replacement surgery, including cardiopulmonary bypass (i.e. non-high risk). The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT00209274.
3097365|NCT01931956|Experimental|High Risk|Includes patients with a predicted procedural mortality risk calculated using the Society For Thoracic Surgeon (STS) surgical risk calculator of ≥12% or, in the judgment of a cardiac surgeon, the patient is considered a high risk surgical candidate due to the presence of pre-defined risk factors. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant. This arm was evaluated as a separate study NCT01940120.
3097366|NCT01931956|Experimental|Compassionate Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
3097367|NCT01931956|Experimental|Emergency Use|Patients that did not meet REALISM High Risk or Non-High Risk eligibility criteria were evaluated for consideration for either Emergency Use (EU) or Compassionate Use (CU). The objective of the Compassionate and Emergency Use Group of the EVEREST II REALISM study is to provide access to the MitraClip Device, in a non-commercial setting, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip® implant.
3097368|NCT01931995|Active Comparator|TMS to positively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
3097369|NCT01931995|Active Comparator|TMS to negatively correlated DLPFC|High frequency TMS to a target region of dorsolateral prefrontal cortex which is positively correlated with the subgenual cingulate cortex
3097370|NCT01932060|Experimental|Oxytocin Infusion 1|Oxytocin Infusion 15 U/hr to begin after the delivery of the fetus and to terminate at the time of patient discharge from the post-anesthesia care unit.
3097371|NCT01932060|Active Comparator|Oxytocin Infusion 2|Oxytocin infusion 2.5 U/hr to begin after the delivery of the fetus and to terminate at the time of discharge from the post-anesthesia care unit.
3097372|NCT01932112|Other|adenosine arm|single arm study
3097373|NCT01932164|Experimental|cleft lip and palate|5 Patients with cleft unilateral lip and palate that have already performed the alignment of dental arches through the recommended orthodontic treatment will be selected to be submited to alveolar bone tissue engineering surgery
3097374|NCT01932242|Experimental|Sequence A|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 14 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 120.
3097375|NCT01932242|Experimental|Sequence B|An intravenous dose of 16 mg/kg ETI-204 infused over 90 minutes on Days 1 and 120 and an intravenous dose of ETI-204-Placebo infused over 90 minutes on Day 14.
3097376|NCT01932294||MedaMACS participants|All participants who have met the inclusion criteria.
3097377|NCT01932437|Experimental|Cohort 1|"3 subjects will receive an IM dose of 4 mg/kg ETI-204, administered as two injections with a maximum volume of 2 mL at each injection site.~1 subject will receive an IM dose of ETI-204-placebo in an identical fashion."
3097378|NCT01932437|Experimental|Cohort 2|"6 subjects will receive an IM dose of 8 mg/kg ETI-204, administered as two injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
3097379|NCT01932437|Experimental|Cohort 3|"6 subjects will receive an IM dose of 16 mg/kg ETI-204, administered at four sites, with administration of 4 mL at one site and the remaining volume given in three additional injections with a maximum volume of 4 mL at each injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
3097380|NCT01932437|Experimental|Cohort 4|"6 subjects will receive an IM dose of 20 mg/kg ETI-204, administered at up to five sites, with the injection volume distributed equally between injections and a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
3097381|NCT01932437|Experimental|Cohort 5|"6 subjects will receive an IM dose of 24 mg/kg ETI-204, administered at up to six sites, with administration of 5 mL at one site and the remaining volume given in up to five additional injections distributed equally with a maximum volume of 4 mL per injection site.~2 subjects will receive an IM dose of ETI-204-placebo in an identical fashion."
3097382|NCT01932606|Experimental|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
3097383|NCT01932606|Placebo Comparator|Saline|Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure.
3097384|NCT01932697|Experimental|Treatment (docetaxel, hyperfractionated IMRT)|Patients receive docetaxel IV over 1 hour on days 1 and 8 and undergo hyperfractionated IMRT BID 5 days a week on days 1-12 for a total of 20 fractions.
3097385|NCT01932762|Experimental|GT2: Grazoprevir + Elbasvir + RBV (Arm A1)|During Part A of the study, GT2 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
3097386|NCT01932762|Experimental|GT2: Grazoprevir + RBV (Arm B1)|During Part B of the study, GT2 participants will receive 100 mg grazoprevir + standard weight-based dosing of RBV for 12 weeks.
3097387|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir + RBV (Arm B2)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir + standard weight-based dosing of RBV for 12 weeks.
3097388|NCT01932762|Experimental|GT 4,5,6: Grazoprevir + Elbasvir (Arm B3)|During Part B of the study, GT4/GT5/GT6 participants will receive 100 mg grazoprevir + 50 mg elbasvir for 12 weeks.
3097389|NCT01932788|Active Comparator|Vitamin D 4000 IU|Subjects randomized into this arm will receive supplementation with 4000 IU/day vitamin D3 in gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3.
3097390|NCT01932788|Placebo Comparator|placebo gummy vitamin|Supplementation with placebo gummy vitamin form, plus the standard prenatal vitamin (containing 400 IU vitamin D3)
3097391|NCT01932970|Experimental|Etelcalcetide|Participants were treated with 5 mg etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times per week (TIW) for 4 weeks.
3097392|NCT01932996|Active Comparator|Integrated Intensive Smoking + Alcohol|IS+A: 12-week treatment with nicotine patch plus nicotine gum/lozenge. An integrated intensive smoking along with an intensive alcohol intervention covering smoking cessation + alcohol abstinence using cognitive behavioral therapy, CBT, and will include weekly individual sessions for 3 months followed by study data collection visits for 3 months.
3097393|NCT01932996|Placebo Comparator|Usual Care|UC: 12-week treatment with nicotine patch plus nicotine gum/lozenge along with a one time brief smoking cessation and brief alcohol counseling both based on the USPHS's Guidelines
3097394|NCT01933048|Other|Healthcare Worker Administration|FluMist administered by a Healthcare Worker
3097395|NCT01933048|Experimental|Self-Administration|FluMist self-administered by subject
3097396|NCT01933113|Experimental|DBS of the Lateral Hypothalamic Area|"Single Arm: Deep Brain Stimulation of LHA for maximum RMR On days 1-4, subjects stayed in the inpatient unit to have metabolic weight, temperature, and resting metabolic rate (RMR) measured at different settings.~Metabolic testing RMR measurement: A clear plastic hood was placed over the head and chest Oxygen intake and carbon dioxide out-put were measured to determine how many calories were burned during the next 15-30 minutes. Each hour for the next seven hours, DBS settings were changed and the above process was repeated. On Day 4, a DXA scan was performed to assess body composition. Primary endpoint is the determination of optimal settings"
3097397|NCT01933217|Experimental|Methylphenidate|The study medication will consist of identical capsules filled Concerta® over-encapsulated to preserve double-blinding. The weekly dosages will be low, medium, and high based on weight cut-offs. Participants weighing less than 25kg will receive 18mg (low), 27mg (medium), and 36mg (high) dosages and participants weighing above 25kg will receive 18mg (low), 36mg (medium), and 54mg (high) dosages during the 3-week upward titration trial. Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
3097398|NCT01933217|Placebo Comparator|Placebo|The study medication will consist of identical capsules filled with an inert white power (placebo). Weekly ratings monitoring behavioral and side effect symptoms score and the Pittsburgh Side Effects Rating Scale.
3132604|NCT03440411|Active Comparator|ARM pom-cyclo-dex Late (B-II)|"Patients will be randomized at biochemical relapse and they will start treatment with pom-cyclo-dex at the onset of CRAB symptoms/significant paraprotein increase.~Pomalidomide: 4 mg/day on days 1-21 Cyclophosphamide: 50 mg every other day Dexamethasone: 40 mg on days 1, 8, 15, 22 For 28-day cycles until progression or intolerance"
3097399|NCT01933230|Other|Excel Cryo Cooling System Collar|An Excel Cryo Cooling System collar will be placed around the neck for a 2 hour neck cooling period. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level and pressure both in the head and in the blood.
3097400|NCT01933243|Experimental|Fish oil|Fish oil for 12 weeks
3097401|NCT01933243|Placebo Comparator|Placebo pill|Placebo pills for 12 weeks
3097402|NCT01933334|Experimental|Pirfenidone: 4-Week Titration Group|Participants will receive one 267 milligrams (mg) oral pirfenidone capsule three times daily (TID) (801 mg per day [mg/day]) for 2 weeks followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 2 weeks (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 12 weeks maintenance period).
3097403|NCT01933334|Experimental|Pirfenidone: 2-Week Titration Group|Participants will receive one 267 mg oral pirfenidone capsule TID (801 mg/day) for 1 week followed by two 267 mg oral pirfenidone capsules TID (1602 mg/day) for 1 week (titration period) and then three 267 mg oral pirfenidone capsules TID (2403 mg/day) for 14 weeks (maintenance period).
3097404|NCT01933399|Other|Standard of Care|Medication based on physician prescriptions or overcounter use not germane to the study. Subjects also receive physical therapy for 2 weeks.
3097405|NCT01933399|Experimental|Extensible lumbosacral orthoses plus standard of care|This group receives a flexible/extensible lumbosacral orthosis, one that is commonly available over the counter
3097406|NCT01933399|Experimental|Inextensible lumbosacral orthoses and standard of care|This group receives an inextensible lumbosacral orthoses which leads to 14% increase in trunk stiffness compared to the other conditions.
3097407|NCT01933425|Active Comparator|Deep neuromuscular block followed by no neuromuscular block|"Deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg followed by no neuromuscular blockade with sugammadex 8 mg/kg and placebo reversal.~Measurements of intraabdominal distance during deep neuromuscular blockade and without neuromuscular blockade"
3097408|NCT01933425|Placebo Comparator|No neuromuscular block followed by deep neuromuscular block|"No neuromuscular blockade with placebo followed by deep neuromuscular blockade (PTC 0-1) with rocuronium 1 mg/kg and reversal with sugammadex 8 mg/kg.~Measurements of intraabdominal distance during no neuromuscular blockade and during deep neuromuscular blockade."
3097409|NCT01933464|Experimental|Cromolyn|Subjects in this arm will be asked to apply their assigned medication twice daily to their entire face. The medication they will be receiving is cromolyn sodium ophthalmic solution, 4%.
3097410|NCT01933464|Placebo Comparator|Vehicle|Participants in this group will be assigned a solution consisting of only the inactive ingredients in cromolyn sodium ophthalmic solution to apply to their entire face twice daily.
3097411|NCT01933594|Experimental|Cohort 1-Arm 1A (Romidepsin)|Participants in Cohort 1, Arm 1A received Romidepsin intravenously (IV) over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097412|NCT01933594|Placebo Comparator|Cohort 1-Arm 1B (Placebo for Romidepsin)|Participants in Cohort 1, Arm 1B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 0.5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097413|NCT01933594|Experimental|Cohort 2-Arm 2A (Romidepsin)|Participants in Cohort 2, Arm 2A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097414|NCT01933594|Placebo Comparator|Cohort 2-Arm 2B (Placebo for Romidepsin)|Participants in Cohort 2, Arm 2B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 2 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097415|NCT01933594|Experimental|Cohort 3-Arm 3A (Romidepsin)|Participants in Cohort 3, Arm 3A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097416|NCT01933594|Placebo Comparator|Cohort 3-Arm 3B (Placebo for Romidepsin)|Participants in Cohort 3, Arm 3B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0 study visit. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097417|NCT01933594|Experimental|Cohort 4-Arm 4A (Romidepsin)|Participants in Cohort 4, Arm 4A received Romidepsin IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of Romidepsin was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097418|NCT01933594|Placebo Comparator|Cohort 4-Arm 4B (Placebo for Romidepsin)|Participants in Cohort 4, Arm 4B received 0.9% sodium chloride for injection IV over 4 hours (beginning at Hour 0) at the Day 0, 14, 28, and 42 study visits. Dose of sodium chloride for injection placebo was 5 mg/m^2, with total dose based on the participant's body surface area (determined by participant's height and weight).
3097419|NCT01933672|Experimental|PF-04937319 once-daily|
3097420|NCT01933672|Experimental|PF-04937319 split-dose|
3097421|NCT01933672|Active Comparator|Sitagliptin once-daily|
3097422|NCT01933776|Experimental|Group 1: Adults|Participants 18 through 64 years of age will receive a single booster dose of Tdap vaccine (ADACEL).
3097423|NCT01933776|Experimental|Group 2: Children|Participants 4 through 8 years of age will receive a single booster dose of Tdap vaccine (ADACEL)
3097424|NCT01933789|Experimental|Feedback Group|Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
3097425|NCT01933789|No Intervention|Comparison/Usual Care Group|Subjects will only complete surveys and assessments.
3097426|NCT01933880|Experimental|OROS-MPH Group|Participants with ADHD will receive OROS -MPH starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance.
3097427|NCT01933880|Active Comparator|Normal Group|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
3097428|NCT01933919|Placebo Comparator|placebo|"In the double-blind placebo-controlled phase participants received one placebo tablet a day in week 1, then one placebo tablet twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by one tablet/day/week up to a maximum of three tablets twice a day. From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to two tablets/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by one tablet/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
3097429|NCT01933919|Experimental|Fluvoxamine|"In the double-blind placebo-controlled phase participants received 25 mg fluvoxamine once a day in week 1, 25 mg twice a day (BID) in week 2 followed by a dose adjustment period from weeks 3 to 6 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg (three tablets BID). From weeks 7 to 10 participants received the same dose that was given during week 6. At the end of the 10-week treatment period there was a dose-tapering period of up to 4 weeks where the dose of decreased by up to 50 mg/day each week.~In the open-label long-term phase participants received 25 mg fluvoxamine once a day for the first week, 25 mg BID in week 2 followed by a flexible dose period from weeks 3 to 52 where the dose could be escalated by 25 mg/day/week up to a maximum of 150 mg/day (three tablets BID). At the end of the 52-week treatment period there was a dose-tapering period of up to 4 weeks where the dose was decreased by up to 50 mg/day each week."
3097432|NCT01933984|Experimental|Individualized dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)"
3097433|NCT01933984|Active Comparator|Fixed dosing|"Ventilator support~Determining personal target airway resistance~Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent~Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days~Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days~No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met"
3097434|NCT01934010|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
3097435|NCT01934140|Experimental|ACWY-TT group|All subjects vaccinated with MenACWY-TT in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a booster dose of MenACWY-TT in this study.
3097436|NCT01934140|Active Comparator|MenPS group|All subjects vaccinated with Mencevax ACWY in study MENACWY-TT-015 will be assigned to this group. At Month 120 after primary vaccination, these subjects will be vaccinated with a dose of MenACWY-TT in this study.
3097437|NCT01934192|Experimental|Initial randomization: GSK962040 Arm|Subjects in the GSK962040 Arm will receive 50 mg once daily enteral dose administered through NG tube up to 7 days.
3097438|NCT01934192|Placebo Comparator|Initial randomization: Placebo Arm|Subjects in the placebo arm will receive once daily dose enteral dose administered through NG tube up to 7 days.
3097439|NCT01934192|Experimental|Treatment change due to intolerance: GSK962040 Arm|Subjects that develop intolerance and that originally received Placebo will receive 50 mg once daily enteral dose administered through NG tube + placebo IV
3097440|NCT01934192|Active Comparator|Treatment change due to intolerance: Metoclopramide Arm|Subjects that develop intolerance and that originally received GSK962040 will receive metoclopramide 10 mg IV every 6 h + placebo NG
3097441|NCT01934218|Active Comparator|Gel-One|3 mL, a single intra-articular injection of Gel-One
3097442|NCT01934218|Placebo Comparator|Phosphate Buffered Saline (PBS)|3 mL, a single intra-articular injection of PBS
3097443|NCT01934231|Experimental|Single arm|Each participant will take Potassium Clavulanate (CVA)/ Amoxicillin (AMPC) corresponding 6.4/90 mg/kg/day in two divided doses (every 12 hours) just before lactation or meal for 7 days depending on his/her body weight at the start of treatment (Day 1). The actual daily dose depends on the body weight of the participant.
3097444|NCT01934335|Experimental|Vandetanib|Vandetanib, 300 mg, PO, q day for 7-14 days prior to surgery
3097445|NCT01934335|Placebo Comparator|Placebo|Placebo, PO, q day for 7-14 days prior to surgery.
3097446|NCT01934556|Active Comparator|Monthly|Monthly Cohort (30 eyes) - Study eyes will receive intravitreal injections of 0.3 mg ranibizumab every 4 weeks for 24 months.
3132605|NCT03440424|Experimental|Cohort A: Mild Hepatic Impairment (Child Pugh Class A)|Participants with mild hepatic impairment will receive a single 10 milligram (mg) dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 milliliters (mL) of water following an overnight fast of at least 10 hours.
3132606|NCT03440424|Experimental|Cohort B: Moderate Hepatic Impairment (Child Pugh Class B)|Participants with moderate hepatic impairment will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
3097447|NCT01934556|Active Comparator|TREX|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits. At the fourth visit (Week 12), if the central foveal thickness is ≤ 325 μm then the eye will receive 0.3 mg ranibizumab and begin the extension phase of the study. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD (Spectral Domain)-OCT criteria. Treatment is rendered at every visit. The time between visits is individualized based on each subject's response to treatment. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
3097448|NCT01934556|Active Comparator|GILA|(60 eyes) - Monthly intravitreal injections of 0.3 mg ranibizumab for four visits combined with guided laser photocoagulation to all microaneurysms in the area of DME at visit 2 (Week 4) and then again every 3 months, if leakage is present on fluorescein angiography. If the central foveal thickness is ≤ 325 μm at visit 4 (Week 12), eyes will receive 0.3 mg ranibizumab and the extension phase will begin. For all subsequent visits in the extension phase, appropriate changes to the treatment interval with 0.3 mg ranibizumab (i.e. extend, maintain, reduce) will be made based on pre-specified SD-Optical coherence tomography criteria. If the central foveal thickness is > 325 μm at week 12, then the patient will continue to receive monthly intravitreal injections of 0.3 mg ranibizumab and possible guided laser every 3 months until the central foveal thickness is ≤ 325 μm. Once the central foveal thickness is ≤ 325 μm, then the study eye will begin the extension phase of the study.
3097449|NCT01934582|Experimental|Open label extension|
3097450|NCT01934790|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
3097451|NCT01934894|Experimental|cabazitaxel and lapatinib combination|"Cabazitaxel 1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)~Lapatinib PO once daily (dose to be determined)~Treatment cycles will be repeated every 3 weeks."
3097452|NCT01934972|Experimental|CR + DCS|Subjects will receive Cognitive Remediation and active study drug.
3097453|NCT01934972|Active Comparator|CR + placebo|Cognitive Remediation and placebo
3097454|NCT01935180|No Intervention|Standard colonoscopy|
3097455|NCT01935180|Active Comparator|Cap assisted colonoscopy|A transparent cap will be affixed to tip of the high-definition wide angle colonoscope.
3097456|NCT01935622|Experimental|Doxycycline 100 mg|Doxycycline 100 mg twice daily for 14 days
3097457|NCT01935622|Experimental|Doxycycline 20 mg|Doxycycline 20 mg twice daily for 14 days
3097458|NCT01935622|Placebo Comparator|Placebo|Placebo
3097459|NCT01935700|Experimental|colchicine treated patients|2 tablets (0.5 mg/tablet) of colchicine three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial
3097460|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of gelofusine without a cooling vest."
3097461|NCT01935791|Experimental|Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon|Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine Visit 2 Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min without a cooling vest.
3097462|NCT01935791|Active Comparator|Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative|"Visit 1. Participants underwent F-fluorodeoxyglucose (18F-FDG) positron emission tomography, computerised tomography-(PET)CT, whilst wearing a cooling vest and receiving an infusion of gelofusine.~No brown adipose tissue (BAT) identified on visit 1, therefore no visit 2."
3097463|NCT01935791|Experimental|Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius. Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
3097464|NCT01935791|Experimental|Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius."
3097465|NCT01935791|Experimental|Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees celsius."
3097466|NCT01935791|Experimental|Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control|"Visit 1 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3 - Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius."
3097467|NCT01935791|Experimental|Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control|"Visit 1- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 3- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest."
3097468|NCT01935791|Experimental|Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon|"Visit 1 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine. They were situated in an ambient temperature of 22-25 degrees Celsius.~Visit 2- Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of gelofusine and wearing a cooling vest.~Visit 3 Each participant had calorimetry testing and thermal imaging whilst receiving an infusion of Glucagon at a dose of 50ng/kg/min. They were situated in an ambient temperature of 22-25 degrees Celsius"
3097469|NCT01935934|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3097470|NCT01936181|Experimental|SB2 (proposed biosimilar to inflixmab)|SB2 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 70
3097471|NCT01936181|Active Comparator|Remicade (infliximab)|Remicade 3 mg/kg at week 0, 2, 6 then every 8 weeks thereafter via intravenous infusion up to Week 46
3097472|NCT01936181|Experimental|Remicade (infliximab), switch to SB2|SB2 3mg/kg at week 54, 62, 70
3097473|NCT01936181|Active Comparator|Remicade (infliximab), continue as Remicade|Remicade 3mg/kg at week 54, 62, 70
3097474|NCT01936259|Active Comparator|Comprehensive Mini Humeral Stem|"The Comprehensive® Shoulder System with mini stem component, which will be the control device for this clinical investigation and was 510(k) cleared under K060692 on May 30, 2006.~The humeral stem component is manufactured from Ti6Al4V alloy. The taper has a machine finish and accepts the taper adaptor of the humeral head component. The proximal region of the bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy, while the distal portion is polished. Seventeen stem diameters are available - 4 mm to 20 mm, in 1-mm increments."
3097475|NCT01936259|Experimental|Comprehensive Nano Humeral Component|The stemless humeral component is manufactured from Ti6Al4V alloy. It consists of a central tapered region and six outer wings. The taper has a machine finish and accepts the taper adaptor of the humeral head component. A small groove is included just below the taper to accept an inserter/impactor. The bone-contacting outer surface features a porous coating of plasma-sprayed titanium alloy for cementless fixation in the proximal humerus. Six sizes are available - 30 mm, 32 mm, 34 mm, 36 mm, 38 mm, and 40 mm.
3097476|NCT01936324|Experimental|Phase 1|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 7 days in healthy volunteers
3097477|NCT01936324|Experimental|Phase 2a|Olumacostat Glasaretil Gel, 7.5%, or Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
3097478|NCT01936363|Experimental|Pimasertib (once daily) plus SAR245409|
3097479|NCT01936363|Experimental|Pimasertib (twice daily) plus SAR245409 placebo|
3097480|NCT01936389|Experimental|0.5%|0.5% Rho-Kinase Inhibitor
3097481|NCT01936389|Experimental|0.7%|0.7% Rho-Kinase Inhibitor
3097482|NCT01936467|Experimental|Standard suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the standard suction FNA technique: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
3097483|NCT01936467|Experimental|Capillary suction|These are patients who will have endoscopic ultrasound-guided fine needle aspiration using the capillary suction FNA technique: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
3097484|NCT01936519|Active Comparator|Calcineurin Inhibitor with Mycophenolic Acid|Calcineurin inhibitor immunosuppression with mycophenolic acid
3097485|NCT01936519|Experimental|Everolimus with Mycophenolic Acid|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
3097486|NCT01936623|Experimental|Computerized Brief Intervention|Computerized Brief Intervention is delivered using a talking, animated cartoon-like parrot that provides patient feedback, empathic reflection, and personalization regarding their drug use.
3097487|NCT01936623|Other|Delayed Computerized Brief Intervention|Participants receive only a substance abuse assessment at baseline. At three-month follow-up, they then receive the computerized brief intervention.
3097488|NCT01936649|Experimental|AdreView (Iobenguane I 123 Injection)|Two administrations of single intravenous (i.v) injection of Iobenguane I 123 10 millicuries (mCi) (370 MBq) over 1 to 2 minutes within an interval of 5 to 14 days.
3097489|NCT01936662|Experimental|Largyngeal Mask Airway for EGD procedure|Patients randomized to LMA to maintain airway through EGD procedure
3097490|NCT01936662|Active Comparator|Endotracheal Tube for EGD procedure|Patients were randomized to ETT to maintain airway for EGD procedure. This is the standard of care at this hospital
3097491|NCT01936844|Experimental|Anakinra (short)|Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
3097492|NCT01936844|Placebo Comparator|Placebo|Placebo injections twice daily for the first 3 days then once daily for days 4-14.
3097493|NCT01936857|Experimental|Buprenorphine/naloxone|Office based treatment of opioid dependence with buprenorphine/naloxone
3097494|NCT01936857|Active Comparator|Methadone Maintenance Therapy|Referral to methadone maintenance therapy for treatment of opioid dependence.
3097495|NCT01936870||Fesoterodine (Toviaz)|
3097496|NCT01936896|Experimental|Alpha-1 anti-trypsin (AAT)|We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)
3097497|NCT01936909|Experimental|Anakinra (short)|Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
3097498|NCT01936909|Experimental|Anakinra (long)|Anakinra 100 mg daily for 12 weeks
3097499|NCT01936909|Placebo Comparator|Placebo|Placebo injections daily for 12 weeks
3321213|NCT02017197|Other|Sequence F|"Phase 1 (run-in): generic warfarin #2~Phase 2: generic warfarin #2~Phase 3: generic warfarin #1~Phase 4: Marevan®"
3097500|NCT01936948|Active Comparator|Clip closure + EndoCut|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the EndoCut electrocautery mode.
3097501|NCT01936948|Active Comparator|Clip closure + Coagulation|Clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp using clips. Resection is done using the Coagulation electrocautery mode.
3097502|NCT01936948|No Intervention|No clip closure + EndoCut|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the EndoCut electrocautery mode.
3097503|NCT01936948|No Intervention|No clip closure + Coagulation|No clipping of the mucosal defect after resection of a ≥20mm non-pedunculated study polyp. Resection is done using the Coagulation electrocautery mode.
3097504|NCT01937026|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
3097505|NCT01937026|Experimental|Baricitinib + Probenecid|Oral doses of 1000 mg probenecid once daily on Days 3 through 7, with a single oral dose of 4 mg baricitinib co-administered on Day 5
3097506|NCT01937117|Experimental|Trastuzumab and Pertuzumab|Preoperative treatment with trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV) and pertuzumab (840 mg as a loading dose, then 420 mg every 3 weeks, IV) every 3 weeks for 4 doses (total 12 weeks or 3 months of treatment) as assessed by Positron Emission Tomography (PET)
3097507|NCT01937130|Experimental|IDN-6556 5 mg|Dosed twice daily
3097508|NCT01937130|Experimental|IDN-6556 25 mg|Dosed twice daily
3097509|NCT01937130|Experimental|IDN-6556 50 mg|Dosed twice daily
3097510|NCT01937130|Placebo Comparator|Placebo|Dosed twice daily
3097511|NCT01937195|Experimental|AccuCath Intravenous Catheter System|AccuCath Intravenous Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal.
3097512|NCT01937260|Experimental|Brodalumab 140mg SC|open label, all subjects receive brodulamab
3097513|NCT01937260|Experimental|Midazolam (MDZ) 2mg oral, Brodalumab 210mg SC|MDZ 2mg oral (Day 1 and Day 9), Brodalumab 210mg SC (Day 2)
3097514|NCT01937299|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
3097515|NCT01937299|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with travoprost 0.004% ophthalmic solution, 1 drop in each eye at bedtime, for 6 weeks
3097516|NCT01937312|Experimental|SIMBRINZA|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
3097517|NCT01937312|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in each eye 3 times a day (8 AM, 3 PM, 10 PM), with prostaglandin analogue, 1 drop in each eye at bedtime, for 6 weeks
3097518|NCT01937351|Experimental|Pantheris Treatment Arm|Intervention: Atherectomy using the Pantheris system.
3097519|NCT01937364|Placebo Comparator|Placebo|Placebo every eight hours as inpatients for 72 hours or until discharge if less than 72 hours.
3097520|NCT01937364|Active Comparator|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
3097521|NCT01937390||LAMA/LABA Patients|
3097522|NCT01937520|Experimental|acupuncture|acupuncture will be administered after induction for a period of 30 minutes, followed by a 30 minute rest period and then resumption of acupuncture for 30 minutes.
3097523|NCT01937520|Placebo Comparator|device|no acupuncture will be done on this group of subjects
3097524|NCT01937559|Experimental|Topical Tranexamic acid (TXA)|Tranexamic acid (TXA) applied topically
3097525|NCT01937559|Placebo Comparator|Saline|Normal saline
3097526|NCT01937559|Active Comparator|Tranexamic acid (TXA)|Tranexamic acid (TXA) administered intravenously
3097527|NCT01937598|Experimental|Sitagliptin, then Placebo|
3097528|NCT01937598|Experimental|Placebo, then Sitagliptin|
3097529|NCT01937624||Diagnostic ultrasound and radiographic imaging|- The diagnostic musculoskeletal ultrasound and x-rays will both be used to image bones in perpendicular and orthogonal planes over the distal radius visualizing the physis.
3097530|NCT01937715|Experimental|Arm A|PF-05212384 plus FOLFIRI
3097531|NCT01937715|Active Comparator|Arm B|Bevacizumab plus FOLFIRI
3097532|NCT01937871|Placebo Comparator|Placebo|Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.
3097533|NCT01937871|Experimental|5 mg Tadalafil|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period"
3097534|NCT01937871|Other|0.2 mg Tamsulosin|"Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period.~Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period"
3097535|NCT01937884|Experimental|Early Parenteral Nutrition|Patients receive supplemental parenteral nutrition within 12 hours of enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
3097536|NCT01937884|Active Comparator|Late Parenteral Nutrition|Patients receive supplemental parenteral nutrition 96 hours after enrollment. Titrated with enteral nutrition to achieve target goal calories and protein.
3097537|NCT01937975|Experimental|Participants with End Stage Renal Disease on Hemodialysis|Participants with End Stage Renal Disease on hemodialysis received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days..
3097538|NCT01937975|Experimental|Participants with Severe Renal Impairment|Participants with Severe Renal Impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
3097539|NCT01937975|Experimental|Healthy Participants|Healthy participants (estimated glomerular filtration rate >=80 mL/min/1.73 m^2) received once daily Grazoprevir 100 mg tablet and Elbasvir 50 mg tablet for 10 days.
3132607|NCT03440424|Experimental|Cohort C: Healthy Participants (Control)|Healthy participants matched to participants with hepatic impairment in Cohorts A and B (matched with regards to age, sex, body mass index [BMI]) will receive a single 10 mg dose (1 × 10 mg lemborexant [E2006] tablet) in the morning with 240 mL of water following an overnight fast of at least 10 hours.
3097540|NCT01938001|Experimental|Rituximab and Lenalidomide|Participants received rituximab 375 mg/m^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but < 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
3097541|NCT01938001|Active Comparator|Rituximab and Placebo|Participants received riituximab 375 mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
3097542|NCT01938040|Active Comparator|Ibuprofen|800mg administered IV in 100cc of normal saline over 5 minutes
3097543|NCT01938040|Placebo Comparator|Sugar water|100mL of normal saline to be administered over 5 minutes
3097544|NCT01938066|Active Comparator|Negative Pressure with Procellera|Arm 2 is Negative Pressure Therapy and Procellera Dressing under the sponge dressing of the Negative Pressure Therapy. The dressing will be changed at the end of 5 days. This is the intervention arm of the study.
3097545|NCT01938066|Sham Comparator|Negative Pressure Therapy only|Arm 1 is Negative Pressure Therapy only with no Procellera Dressing and the dressing is changed every other day per standard of care when you use Negative Pressure Therapy with no dressing underneath the sponge.
3097546|NCT01938079|Active Comparator|Sedative without Ketamine|Subjects will receive sedative drug regimen without Ketamine.
3097547|NCT01938079|Experimental|Sedative with Ketamine|Subjects will receive sedative drug regimen with Ketamine.
3097548|NCT01938170|Experimental|FluMist|Subjects receiving vaccine at home
3097549|NCT01938378|Other|Pediatric patients undergoing TPE|octaplas™
3097550|NCT01938391|Other|OAS + BA|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS), is used prior to adjunctive balloon angioplasty (BA)
3097551|NCT01938430|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3097552|NCT01938430|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3097553|NCT01938430|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3097554|NCT01938430|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3097555|NCT01938430|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3.
3097556|NCT01938430|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
3097557|NCT01938430|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
3097558|NCT01938430|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
3097559|NCT01938430|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3097560|NCT01938430|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3097561|NCT01938430|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3097562|NCT01938430|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3097563|NCT01938430|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
3097564|NCT01938430|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
3097565|NCT01938573|Experimental|Sirolimus, cisplatin, gemcitabine|Sirolimus day -2, cisplatin 70 mg/m2 IV Day 1 and gemcitabine hydrochloride 1000 mg/m2 IV days 1 and 8 every 21 days for 4 cycles followed by cystectomy (surgery)
3097566|NCT01938625|Experimental|Part 1|Participants with Metavir fibrosis score F1-F2 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with cyclosporine or tacrolimus as stable immunosuppressant therapy.
3097567|NCT01938625|Experimental|Part 2|Participants with Metavir fibrosis score F1-F4 will receive treatment with combinational regimen of simeprevir, daclatasvir, and ribavirin along with tacrolimus as stable immunosuppressant therapy.
3097568|NCT01938664|Experimental|Candesartan w Cognitive Behavior Therapy|Titration up to 8mg through week 1. Continue on 8mg thru wk 8. CBT optional thru study.
3097569|NCT01938664|Placebo Comparator|Placebo w Cognitive Behavior Therapy|Sugar pill to mimic Candesartan for study duration. CBT optional thru study.
3097570|NCT01938846|Experimental|BI 860585|Multiple ascending doses of BI 860585 administered continuously in a 28-day cycle, including food interaction cohorts
3097571|NCT01938846|Experimental|BI 860585 + paclitaxel|Multiple ascending doses of BI 860585 in combination with fixed dose paclitaxel
3097572|NCT01938846|Experimental|BI 860585 + exemestane|Multiple ascending doses of BI 860585 in combination with fixed dose exemestane
3097573|NCT01938989|Other|Clear, then Blue Light Filter|Clear clip-on glasses first, followed by blue light filter clip-on glasses, as worn over habitual correction
3097574|NCT01938989|Other|Blue Light Filter, then Clear|Blue light filter clip-on glasses first, followed by clear clip-on glasses, as worn over habitual correction
3097575|NCT01939002|Experimental|BIIB017 plus current FLS therapy|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus current FLS management regimen as determined by the clinician.
3097576|NCT01939002|Experimental|BIIB017 plus naproxen|Following a 4-week run-in period (starting 1 day after the Screening Visit) in which participants administer non-pegylated IFN therapy, participants receive BIIB017 at an initial dose of 63 μg followed by 94 μg dose at Week 2 and 125 μg every 2 weeks from Week 4 to Week 46, plus 500 mg naproxen administered twice daily up to 24 hours prior to BIIB017 treatment and continuing for 48 hours following the BIIB017 injection for the first 8 weeks of treatment, and as recommended by the treating physician subsequently.
3097577|NCT01939028|Experimental|Diagnostic (SLN mapping, biopsy, surgery)|Patients undergo SLN mapping using isosulfan blue and/or indocyanine green solution injected directly into the cervix. Following SLN identification and biopsy, patients undergo hysterectomy, bilateral salpingo-oophorectomy, and/or complete pelvic lymphadenectomy. Patients expressing SLN positive for metastasis undergo para-aortic lymphadenectomy.
3097578|NCT01939145|Active Comparator|Normal Saline|The use of Normal Saline as the solution for Negative Pressure Wound Therapy with instillation.
3097579|NCT01939145|Active Comparator|Prontosan|The use of Prontosan as the solution in Negative Pressure Wound Therapy with Instillation.
3097580|NCT01939158|Experimental|ACWY1d group|Subjects will receive 1 dose of the MenACWY-TT vaccine
3097581|NCT01939158|Experimental|ACWY2d group|Subjects will receive 2 doses of the MenACWY-TT vaccine 2 months apart
3097582|NCT01939158|Experimental|Co-ad group|Subjects will receive 1 dose of the MenACWY-TT vaccine co-administered with Prevenar 13™
3097583|NCT01939158|Active Comparator|PCV-13 group|Subjects will receive 1 dose of Prevenar 13™ and 1 dose of the MenACWY-TT vaccine 2 months later
3097584|NCT01939197|Experimental|ARM A|ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
3097585|NCT01939197|Experimental|ARM B|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for participants receiving atazanavir once-daily or raltegravir twice-daily
3097586|NCT01939197|Experimental|ARM C|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir once-daily
3097587|NCT01939197|Experimental|ARM D|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for participants receiving darunavir twice-daily
3097588|NCT01939197|Experimental|ARM E|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for noncirrhotic (at screening) GT1b-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097589|NCT01939197|Experimental|ARM F|ABT-450/r/ABT-267 and ABT-333 for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097590|NCT01939197|Experimental|ARM G|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-naive participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097591|NCT01939197|Experimental|ARM H|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for cirrhotic (at screening) GT1b-infected sofosbuvir-experienced participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097592|NCT01939197|Experimental|ARM I|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 12 weeks for noncirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097593|NCT01939197|Experimental|ARM J|ABT-450/r/ABT-267 and ABT-333 coadministered with RBV for 24 weeks for cirrhotic (at screening) GT1a-infected participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily
3097594|NCT01939197|Experimental|ARM K|ABT-450/r/ABT-267 coadministered with RBV for 12 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
3097595|NCT01939197|Experimental|ARM L|ABT-450/r/ABT-267 coadministered with RBV for 24 weeks for participants receiving any of the following: atazanavir once-daily, raltegravir twice-daily, dolutegravir once-daily or twice-daily, darunavir once-daily
3097596|NCT01939275|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET scan)|Patients receive copper Cu 64-DOTA-trastuzumab IV on day 1 and then undergo PET/CT scan on days 2 or 3.
3097597|NCT01939288|Experimental|Group 1|Half of recruited subjects (n=5)
3097598|NCT01939288|Experimental|Group 2|Other half of recruited subjects (n=5)
3097599|NCT01939301|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide
3097600|NCT01939301|Placebo Comparator|Placebo|Oxygen
3097601|NCT01939314|Active Comparator|Bupivacaine|Bupivicaine .03ml to each nare
3097602|NCT01939314|Placebo Comparator|Normal Saline|normal saline .03 ml to each nare
3097603|NCT01939353|Experimental|Centanafadine SR 100-500 mg|Following a 1-week SB placebo run-in treatment, participants with <30% improvement and ≥28 total score on Adult ADHD-RS-IV scale score received centanafadine (CTN) 100 mg, sustained release (SR) tablet, once daily (1 tablet in the morning) on Days 1 and 2, followed by 200 mg, SR tablets, twice daily (1 tablet in the morning and 1 tablet 5 hours later) on Days 3 and 4, followed by 300 mg, SR tablets, twice daily (2 tablets in the morning and 1 tablet 5 hours later) on Days 5, 6, and 7. After 1 week of treatment, CTN doses were maintained or titrated in 100-mg increments up to the maximum of 500 mg daily or reduced based on the safety and tolerability, as judged by the investigator at Weeks 2, 3 and 4.
3097604|NCT01939366|Experimental|Cebranopadol 300 µg|
3097605|NCT01939366|Experimental|Cebranopadol 600 µg|
3097606|NCT01939366|Active Comparator|Pregabalin|
3097607|NCT01939366|Placebo Comparator|Matching Placebo|
3097608|NCT01939366|Experimental|Cebranopadol 100 µg|
3097609|NCT01939405|No Intervention|standard physical activity counseling|
3097610|NCT01939405|Experimental|built environment use counseling|personalized counseling on active use of the built environment
3097611|NCT01939496|Experimental|Canagliflozin 100 mg|Each patient will receive 100 mg of canagliflozin once daily for 6 weeks.
3097612|NCT01939496|Experimental|Canagliflozin 300 mg|Each patient will receive 300 mg of canagliflozin once daily for 6 weeks.
3097613|NCT01939496|Placebo Comparator|Placebo|Each patient will receive matching placebo once daily for 6 weeks.
3097614|NCT01939548|Experimental|PF-02545920 (5mg)|
3097615|NCT01939548|Placebo Comparator|Placebo|
3097616|NCT01939548|Experimental|PF-02545920 (15mg)|
3097617|NCT01939899|Experimental|IXAZOMIB|Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
3097618|NCT01939938|Experimental|All Subjects-Nasal and Oronasal PAP Mask|Each subject will be imaged in a dynamic MRI with both a oronasal and nasal mask at pressures of 5, 10, and 15 cm of H2O.
3097619|NCT01939977|Experimental|Paricalcitol|Paricalcitol oral capsules.
3097620|NCT01939977|Active Comparator|Calcifediol|Calcifediol oral drops.
3097621|NCT01940120|Experimental|High Risk Registry Arm|Includes patients with a predicted procedural mortality of 12% or higher. The high risk registry arm of the study is powered to show superiority of safety of treatment with the MitraClip compared to mitral valve surgery. The patients who are enrolled in this arm will undergo percutaneous mitral valve repair using MitraClip implant.
3097622|NCT01940146|Placebo Comparator|SPARC Placebo|
3097623|NCT01940146|Experimental|SPARC1310 I|
3097624|NCT01940146|Experimental|SPARC1310 II|
3097625|NCT01940146|Experimental|SPARC1310 III|
3097626|NCT01940276|Experimental|Abiraterone Acetate and Prednisone|abiraterone acetate will be administered by the patient at a dose of 1000mg orally once daily with prednisone 5 mg BID in 4-week cycles
3097630|NCT01940354|Experimental|Vascular access via study device|AccuCath IV Catheter System will be used for IV therapy during interventional radiology procedure. Intervention includes vascular access, fluid infusion, and blood sample removal.
3097631|NCT01940354|Active Comparator|Vascular access via control device|Conventional IV Catheter System (current catheter) will be used for IV therapy during interventional radiology procedure. Interventions include vascular access, administration of fluids, and blood sample removal.
3097632|NCT01940471|Experimental|TAF 25 mg|TAF + TDF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3097633|NCT01940471|Active Comparator|TDF 300 mg|TDF + TAF placebo for 96 weeks (per amendment 1 & 2) or 144 weeks (per amendment 3)
3097634|NCT01940471|Experimental|Open-label TAF|All participants who complete the double-blind period (96 weeks or 144 weeks) will be eligible to receive open-label TAF until Week 384 of the study.
3097635|NCT01940484||Chronic Renal Anemia Participants|Participants with chronic kidney disease and who are on hemodialysis and on methoxy polyethylene glycol epoetin beta as per physician's discretion for treatment of chronic renal anemia will be observed for a period of 6-12 months.
3097636|NCT01940497|Experimental|Trastuzumab (Vial)|Participants will receive trastuzumab 600 mg SC using a vial q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
3097637|NCT01940497|Experimental|Trastuzumab (SID)|Participants will receive trastuzumab 600 mg SC using SID q3w (1 cycle) for 1 year (4 cycles in combination with adjuvant or neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).
3097638|NCT01940510|Experimental|Healthy subjects|
3097639|NCT01940523|Active Comparator|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
3097640|NCT01940523|Active Comparator|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
3097641|NCT01940705|Active Comparator|Standard of care (SoC)|standard of care hearing-aid orientation as provided by clinical audiologist
3097642|NCT01940705|Experimental|SoC plus hearing-aid informational guide|standard of care hearing-aid orientation as provided by clinical audiologist plus a take-home informational guide regarding their hearing aids
3097643|NCT01940705|Experimental|SoC plus hearing aid DVD|SoC hearing-aid orientation as provided by clinical audiologist plus a take-home hearing aid digital video disc
3097644|NCT01940705|Experimental|Soc plus teach-back technique|standard of care hearing-aid orientation as provided by clinical audiologist plus a teach-back technique session reviewing information on the hearing aids
3097645|NCT01940887|Experimental|E10030 + bevacizumab or aflibercept|E10030 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
3132608|NCT03440619|Experimental|INVSENSOR00013 Test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00013 investigational device.
3097646|NCT01940887|Active Comparator|Sham + bevacizumab or aflibercept|E10030 sham injection + bevacizumab 1.25 mg intravitreal injection or aflibercept 2 mg intravitreal injection
3097647|NCT01940900|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3097648|NCT01940900|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3097649|NCT01940939|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 100 stimulation trains of 20 stimuli each (i.e., 2000 stimuli) and an inter-train interval of 9 sec. Treatment will be applied in sequential order to the left dorsolateral prefrontal cortex (DLPFC). Intervention: Device: Repetitive Transcranial Magnetic Stimulation
3097650|NCT01940939|Sham Comparator|Sham rTMS|Sham rTMS stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.Intervention: Device: Repetitive Transcranial Magnetic Stimulation
3097651|NCT01941030|Experimental|Orbital Atherectomy System|Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
3097652|NCT01941030|Active Comparator|Balloon Angioplasty|Balloon Angioplasty (BA) alone
3097653|NCT01941095|Experimental|Tocilizumab|Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.
3097654|NCT01941186|Experimental|Patient Decision Aid|After positive screen for a developmental concern the intervention group will receive the Patient Decision Aid (PDA), as well as, a text message reminder to follow up with Early Intervention.
3097655|NCT01941186|No Intervention|Routine Care|After screening positive for a potential development delay those in the control arm will receive routine care, in this case, a handout explaining Early Intervention services.
3097656|NCT01941472|Experimental|Septic shock|Adult patients (at least 18 years of age) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of invasive hemodynamic monitoring. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
3097657|NCT01941485|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
3097658|NCT01941498|Experimental|WaveLight Refractive Suite|LASIK surgery (laser in situ keratomileusis) per standard of care
3097659|NCT01941537|Experimental|ILV-094|Forty patients will be enrolled in the ILV-094 treatment arm. A loading IV dose of 600 mg of ILV-094 will be given at baseline (Day 0), followed by five additional IV doses of 300 mg of ILV-094 every two weeks (Weeks 2, 4, 6, 8, and 10).
3097660|NCT01941537|Placebo Comparator|Placebo comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
3097661|NCT01941628|Experimental|Rocuronium|In this group rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
3097662|NCT01941628|Active Comparator|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
3097663|NCT01941745|Placebo Comparator|half normal saline|Single dose of half normal saline at 2 ml/kg given intratracheally times one dose
3097664|NCT01941745|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)in 2 ml/kg given intratracheally times one dose
3097665|NCT01941745|Experimental|High dose rhCC10|5 mg/kg of rhCC10 given in 2 ml/kg and administered intratracheally times one dose
3097666|NCT01941927|Experimental|Trametinib, GSK2141795|"Trametinib (GSK1120212)~Oral~2 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops~GSK2141795~Oral~25 mg~Daily~Number of Cycles: until progression or unacceptable toxicity develops"
3097667|NCT01941940|Experimental|Tocilizumab|Tocilizumab at a fixed dose of 162 milligrams (mg) will be administered as subcutaneous (SC) injection alone or along with methotrexate and/or other non-biological DMARDs irrespective of body weight, once every week for a total of 52 weeks. After 52-weeks of treatment, at the discretion of the treating physician, participants can continue the study treatment with SC tocilizumab until it becomes commercially available in Italy.
3097668|NCT01942135|Experimental|Arm A|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
3097669|NCT01942135|Active Comparator|Arm B|Given until objective progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.
3097670|NCT01942148|Experimental|Aripiprazole|Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study
3097671|NCT01942161|Experimental|Low (2 mg/day)|Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).
3097672|NCT01942161|Experimental|Mid (6 - 12 mg/day)|Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.
3321214|NCT02017236|Experimental|Volitinib ,after high fat meal intake|A:single oral Volitinib after high fat meal intake
3097673|NCT01942161|Experimental|High (24 - 30 mg/day)|Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.
3097674|NCT01942486|Experimental|Investigational Coating|
3097675|NCT01942590|Experimental|Clenbuterol|Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
3097676|NCT01942590|Placebo Comparator|Placebo Comparator|Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.
3097677|NCT01942668|Experimental|Treatment 1|Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
3097678|NCT01942668|Experimental|Treatment 2|Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.
3097679|NCT01942668|Experimental|Treatment 3|Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
3097680|NCT01942668|Experimental|Treatment 4|Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.
3097681|NCT01942668|Placebo Comparator|Placebo|Two Placebo softgel capsules taken orally once a day for twelve months.
3097682|NCT01942694|Placebo Comparator|Placebo|One pill daily
3097683|NCT01942694|Active Comparator|Vitamin D (Cholecalciferol)|One vitamin D pill daily
3097684|NCT01942707|Active Comparator|Abdominoplasty without Scarpa´s Facia|Anchor-line abdominoplasty where the Scarpa's Fascia will be removed.
3097685|NCT01942707|Experimental|abdominoplasty with Scarpa's Fascia|Anchor-line abdominoplasty where the Scarpa's Fascia will be preserved.
3097686|NCT01942720|Other|Capsule endoscopy|
3097687|NCT01942733|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant treatment (ADT)
3097688|NCT01942785|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label commercially available Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) antidepressant treatment (ADT)
3097689|NCT01942993|Experimental|Vemurafenib|960 mg (four tablets of 240 mg each) of vemurafenib PO BID
3097690|NCT01943110|Experimental|Saline injection with ID adapters|"Each participant will receive six injections of 0.1 ml of sterile saline solution into the skin:~Upper deltoid with the side-load ID adapter~Upper deltoid with the AD ID adapter~Suprascapular (behind the shoulder) with the side-load ID adapter~Suprascapular with the AD ID adapter~Forearm with the side-load ID adapter~Forearm with the AD ID adapter"
3097691|NCT01943227||6ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 6ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
3097692|NCT01943227||9ml/kg|"Enthalpy measured in patients receiving controlled positive pressure ventilation 9ml/kg Tidal volume.~The VQm monitor samples the gas at a rate of 3 L/min, returning the analyzed gas to the circuit. As the exhaled gas passes through the analytical chamber, the temperature and humidity are measured essentially continuously (40Hz). These data are combined with pressure measurements to determine the exhaled gas volume and then the heat content (enthalpy) is calculated."
3097693|NCT01943292|Experimental|Defactinib|Oral defactinib (VS-6063) administered twice a day (BID) during a 21 day cycle.
3097694|NCT01943344|Experimental|Treatment|Subjects that receive VIVASURE CLOSURE DEVICE™
3097695|NCT01943435|Active Comparator|Medical Care|"Non-steroidal anti-inflammatory drugs (NSAIDs); adjunctive analgesics; adjunctive anti-depressants. Participants assigned to this group will see a board certified physical medicine and rehabilitation physician for a history and examination, after which a determination will be made about a course of treatment that involve medications that are individualized to the needs of each patient.~NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol~Adjunctive analgesics: acetaminophen, tramadol, or gabapentin~Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine~Lumbar epidural injection: these will be prescribed by the physician if warranted due to severity of symptoms or lack of adequate response to oral medications."
3097696|NCT01943435|Active Comparator|Group Exercise|Group Exercise: community setting. This arm will involve attendance at community based group exercise classes that are taught by senior physical fitness instructors. These classes are designed specifically for older adults. Exercise frequency will be 2 times per week, for a total of 12 visits over the 6-week research period. These exercise classes will be attended at local community senior centers which cater to the needs of older adults. The subjects can self-select which particular exercise class they prefer to attend, based upon their level of fitness and physical function.
3097697|NCT01943435|Active Comparator|Manual therapy and exercise|"This group of subjects will be treated with a combination of manual therapy and rehabilitative exercise procedures that are commonly used in the physical therapy and chiropractic professions. Subjects will be treated at a frequency of 2 times per week, for a total of 12 visits over the 6-week research period. Treatments will be provided by licensed physical therapists and chiropractors using a combination of Joint Mobilizations (spine, sacroiliac, hip), muscle stretching and strengthening exercises.~Individualized exercises: clinical setting. These exercises will be tailored to the individual needs of each research participant by the treating physical therapist or chiropractor."
3097698|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 3 mg/kg|
3097699|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 10 mg/kg|
3097700|NCT01943461|Experimental|Dose-escalation Cohort: Avelumab 20 mg/kg|
3097701|NCT01943461|Experimental|Expansion Cohort: Avelumab 10 mg/kg|
3097702|NCT01943474|Experimental|AccuCath IV Catheter Device|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
3097703|NCT01943474|Active Comparator|Conventional IV Catheter Device|Conventional IV catheter (current catheter) will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal
3097704|NCT01943539|Experimental|EVO Game Play|Neuro-typical controls and ADHD will receive EVO game play.
3097705|NCT01943552|Experimental|ipratropium|500 mcg four times a day
3097706|NCT01943552|Placebo Comparator|placebo|
3097707|NCT01943565|Active Comparator|Hydromorphone 25mcg|The arm will receive 25mcg intrathecal hydromorphone to supplement the spinal anesthesia
3097708|NCT01943565|Active Comparator|Hydromorphone 50mcg|The arm will receive 50mcg intrathecal hydromorphone to supplement the spinal anesthesia
3097709|NCT01943565|Active Comparator|Hydromorphone 100mcg|The arm will receive 100mcg intrathecal hydromorphone to supplement the spinal anesthesia
3097710|NCT01943591|Experimental|15-caliber platinum coils|Endovascular embolization coiling using 15-caliber platinum coils
3097711|NCT01943591|Active Comparator|10-caliber coils|Endovascular embolization coiling using standard 10-caliber platinum coils
3097712|NCT01943799|Experimental|OAV Alone|Participants will continue their prebaseline OAV regimen alone from baseline to Week 48.
3097713|NCT01943799|Experimental|OAV + GS-4774 2 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 2 yeast units (YU) from baseline to Week 20.
3097714|NCT01943799|Experimental|OAV + GS-4774 10 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 10 YU from baseline to Week 20.
3097715|NCT01943799|Experimental|OAV + GS-4774 40 YU|Participants will continue their prebaseline OAV regimen from baseline to Week 48, and will receive GS-4774 40 YU from baseline to Week 20.
3097716|NCT01943825|Experimental|CYD Dengue Vaccine: Group 1|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, respectively.
3097717|NCT01943825|Experimental|CYD Dengue Vaccine: Group 2|Participants received 3 doses of CYD dengue vaccine, one each at 0, 6 and 12 months, respectively.
3097718|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 3|Participants received 3 doses of CYD dengue vaccine, one each at 0, 2 and 6 months, and 2 doses of JE (IXIARO) vaccine at 0 and 1 months, respectively.
3097719|NCT01943825|Experimental|CYD Dengue and JE Vaccine: Group 4|Participants received 2 doses of JE (IXIARO) vaccine at 0 and 1 months; and 3 doses of CYD dengue vaccine at 7, 9 and 13 months, respectively.
3097720|NCT01943851|Experimental|Part 1: GSK525762 QD Cohort|Subject will be administered a 5 milligram (mg) starting dose of GSK525762, oral tablets, QD. Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM for QD dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
3097721|NCT01943851|Experimental|Part 1: GSK525762 BID Cohort|Subject will be administered a starting dose of GSK525762, oral tablets, 20 mg BID (12 hours apart, total daily dose of 40 mg). Dose escalations will be performed in Part 1 and dose adjustments are allowed to address tolerability and safety issues. Thereafter, subjects will be enrolled in a standard 3+3 design. Separate dose escalation cohorts will be opened for subjects with AML, NHL, and MM, for BID dosing. Dose escalation will continue until an MTD is determined or until a dose of 200 mg per day is reached.
3097722|NCT01943851|Experimental|Part 2: GSK525762 dose expansion cohort|After the MTD has been determined in Part1, Part 2 dose expansion cohorts will be opened for AML, NHL and MM.
3097723|NCT01943864|Experimental|Trametinib (single tablet)|Subjects will receive, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3097724|NCT01943864|Experimental|Trametinib PK study (multiple tablet)|Subjects will receive on Day 1, trametinib as four tablets of 0.5 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3097725|NCT01943864|Experimental|Trametinib PK study (single tablet)|Subjects will receive Day 2 onwards, trametinib once daily as a single tablet of 2 mg administered orally with eight ounces of water under fasting conditions either one hour before or 2 hours after a meal.
3097726|NCT01943916|Experimental|Imagio OA/US (US and OA/US)|Imagio OA/US (gray scale and opto-acoustic)
3097727|NCT01943916|Experimental|Imagio gray scale ultrasound|Imagio gray scale ultrasound alone
3097728|NCT01944046|Placebo Comparator|DB Placebo Nasal Spray|Placebo treatment during weeks 0-24 double blind phase
3097729|NCT01944046|Active Comparator|DB Oxytocin Nasal Spray|DB Oxytocin- quadruply masked treatment with intranasal oxytocin during weeks 0-24 of study during double blind phase of study
3097730|NCT01944046|Active Comparator|open label intranasal oxytocin|non masked treatment with intranasal oxytocin from weeks 24-48 in those participants who completed first 24 weeks of double blind treatment
3097731|NCT01944098|Experimental|Lidocaine|Intraoperative continuous IV infusion of Lidocaine at 2mg/kg/hr
3097732|NCT01944098|Active Comparator|Placebo|Intraoperative continuous placebo infusion of dextrose at 2mg/kg/hr
3097733|NCT01944293|Experimental|Ketamine|0.5 mg/kg, I.V. (in the vein)
3097734|NCT01944293|Active Comparator|Midazolam|0.02 mg/kg, I.V. (in the vein)
3097735|NCT01944319|Active Comparator|Control group|The participants in control group will accept routine meropenem therapy
3097736|NCT01944319|Experimental|Study group|The participants in study group will accept meropenem therapy based on a PPK and PD model.
3097737|NCT01944371|Experimental|disulfiram 500mg|500mg disulfiram by mouth per day for 3 days
3097738|NCT01944371|Experimental|disulfiram 1000mg|1000mg disulfiram by mouth per day for 3 days
3097739|NCT01944371|Experimental|disulfiram 2000mg|2000mg disulfiram per mouth per day for 3 days
3097740|NCT01944423|Experimental|PSRT_DCS|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill of d-cycloserine (DCS) one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
3132609|NCT03440723|Active Comparator|Standard Dilation Exam|Participants receive two standard digital cervical dilation examinations conducted by two different physicians.
3321215|NCT02017236|Experimental|Volitinib,after general diet|B:single oral Volitinib, after general diet
3097741|NCT01944423|Placebo Comparator|PSRT_PBO|Individuals in this condition will receive 7 weeks of panic and smoking reduction treatment (PSRT) and one pill placebo dose one hour prior to sessions 3, 4, and 5 (i.e., 3 single doses). Participants will also be given nicotine replacement therapy as part of PSRT (i.e., the patch).
3097742|NCT01944462|Experimental|Pharmacist Pneumococcal Vaccine Program (PPVP)|Individuals receiving the PPVP intervention which consists of the educational program delivered on site at the collaborating senior center.
3097743|NCT01944631|Placebo Comparator|Placebo|Nasal spray 4 times a day over 4 to 10 days
3097744|NCT01944631|Experimental|Iota-Carrageenan nasal spray|Nasal spray 4 times a day over 4 to 10 days
3097745|NCT01944644|Active Comparator|Active Low Field Magnetic Stimulation|LFMS will follow a previously published protocol for the treatment of a Major Depressive Episode (Rohan et al. 2004). Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
3097746|NCT01944644|Sham Comparator|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
3097747|NCT01944670|Experimental|Internal Joint Stabilizer Group|Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)
3097748|NCT01944722|Experimental|BD Onclarity™ HPV assay on BD Viper™ LT|The LBC specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. Colposcopy will be performed on subjects who have abnormal cytology or HPV positive test results or from a random sampling of subjects with normal cytology and HPV negative test results.
3097749|NCT01944774|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL.
3097750|NCT01944774|Experimental|Nemonoxacin 650 mg|Nemonoxacin 650 mg/325mL
3097751|NCT01944774|Active Comparator|Moxifloxacin 400 mg|Moxifloxacin 400mg/250mL
3097752|NCT01944839|Experimental|E10030 + ranibizumab|E10030 1.5 mg intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3097753|NCT01944839|Active Comparator|Sham + ranibizumab|E10030 sham intravitreal injection + ranibizumab 0.5 mg intravitreal injection
3097754|NCT01944878||Patients with chronic hepatitis|Patients with chronic hepatitis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
3097755|NCT01944878||Patients with liver cirrhosis|Patients with liver cirrhosis, who experienced HVPG measurement via transjugular approach and EGD within 3 months of HVPG measurement
3097756|NCT01944930|Experimental|Narrow Band Imaging Laparoscopy First|Study has single cohort assessed in crossover design. In this arm NBI laparoscopy will be performed first, followed by standard white-light laparoscopy.
3097757|NCT01944930|Experimental|Standard White-Light Laparoscopy First|Study has single cohort assessed in crossover design. In this arm standard white-light laparoscopy will be performed first, followed by NBI laparoscopy.
3097758|NCT01944969|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available antidepressant (ADT)
3321216|NCT02017249|Experimental|Arginine|24.15g of arginine supplement in powder form will be administered orally 3 times per day for 7 days before surgery and 7 days after surgery.
3097760|NCT01945034|Experimental|Topical IBU twice daily|
3097761|NCT01945034|Placebo Comparator|Placebo twice daily|
3097762|NCT01945034|Experimental|Topical IBU three times daily|
3097763|NCT01945034|Placebo Comparator|Placebo three times daily|
3097764|NCT01945086|Experimental|Ustekinumab 45 mg|
3097765|NCT01945086|Experimental|Ustekinumab 90 mg|
3097766|NCT01945086|Placebo Comparator|Placebo|
3097767|NCT01945112|Experimental|Paper Tape|Paper tape will be applied to study participants' blister prone areas or a randomly selected spot (if no blister history on that foot) - with untaped areas of the same foot as control.
3097768|NCT01945138|No Intervention|Control|Control Group: patients receive conventional multiple daily injection insulin therapy with basal and bolus dosing during the 72 hour study period.
3097769|NCT01945138|Experimental|Closed Loop Insulin|Closed Loop Insulin Group: patients receive continuous subcutaneous insulin controlled by experimental closed loop system during the 72 hour study period.
3097770|NCT01945216||Alogliptin 25mg, tablets, orally, once daily, up to 36 months|
3097771|NCT01945242||Alogilptin 25mg, tablets, orally, once daily, up to 12 months|
3097772|NCT01945281|Experimental|Caspofungin|Caspofungin 2 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
3097773|NCT01945281|Active Comparator|Amphotericin B Deoxycholate|Amphotericin B deoxycholate 1 mg/kg intravenous once daily for ≥14 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment
3097774|NCT01945294|Experimental|Arm 1: 16-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 4 weeks of BOC + PR, for a total of 16 weeks of treatment. At Week 16, participants underwent 12 weeks of follow-up (participation complete at Week 28).
3097775|NCT01945294|Experimental|Arm 2: 28-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with undetectable HCV RNA were randomized to receive an additional 16 weeks of BOC + PR, for a total of 28 weeks of treatment. At Week 28, participants underwent 12 weeks of follow-up (participation complete at Week 40).
3132610|NCT03440723|Experimental|Dilation Exam with DilaCheck|Participants receive two cervical dilation examinations using DilaCheck devices conducted by two different physicians.
3132611|NCT03440918|Active Comparator|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
3097776|NCT01945294|Experimental|Arm 3: 48-week Treatment Arm|All screened and enrolled participants initially underwent a 12-week (4 weeks PR + 8 weeks BOC + PR) lead-in treatment period prior to randomization to Arms 1 or 2 (participants with undetectable HCV RNA) or allocation to Arm 3 (participants with detectable HCV RNA). After completing the 12-week lead-in, participants with detectable HCV RNA were allocated to receive an additional 24 weeks of BOC + PR and an additional 12 weeks of PR, for a total of 48 weeks of treatment. At Week 48, participants underwent 12 weeks of follow-up (participation complete at Week 60).
3097777|NCT01945489|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) 100U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
3097778|NCT01945489|Other|Placebo/OnabotulinumtoxinA|Placebo (Normal saline) injected into the detrusor on Day 1, followed by an injection of onabotulinumtoxinA 100U after a minimum of 12 weeks (if applicable).
3097779|NCT01945580|Active Comparator|Xenform|Prolapse Repair with Xenform Soft Tissue Repair Matrix
3097780|NCT01945580|Active Comparator|Control|Prolapse Repair with Native Tissue Only
3097781|NCT01945593|Experimental|Fixed BAX855 prophylaxis|45-80 IU/kg twice weekly to once per week.
3097782|NCT01945593|Experimental|Pharmacokinetic (PK)-tailored BAX 855 prophylaxis|PK-tailored prophylactic BAX855 regimen based on participant's individual PK profile to maintain a Factor VIII (FVIII) trough level
3097783|NCT01945710|Experimental|Eribulin-LF Schedule 1|"Schedule 1: Eribulin-LF administered as IV infusion on Day 1 of a 21-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2.~Schedule 1a: Eribulin-LF administered as IV infusion on Day 1 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered inappropriate)."
3097784|NCT01945710|Experimental|Eribulin-LF Schedule 2|Schedule 2: Eribulin-LF administered as IV infusion on Day 1 and Day 15 of a 28-day cycle starting at 1 mg/m^2 escalating up to 3.5 mg/m^2 (only to be investigated in the event that a 21-day cycle is considered appropriate).
3097785|NCT01945775|Experimental|talazoparib|Patient will be randomized 2:1 to receive talazoparib oral capsules (1.0 mg) once daily for 21 continuous days
3097786|NCT01945775|Active Comparator|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
3097787|NCT01945866|Active Comparator|Sham + intravitreal ranibizumab 0.3 mg|Intravitreal ranibizumab will be given on the day of randomization. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first. Follow-up intravitreal injections of ranibizumab will be given up to every 4 weeks using defined treatment criteria.
3097788|NCT01945866|Experimental|Intravitreal dexamethasone+intravitreal ranibizumab 0.3mg|The initial intravitreal ranibizumab injection will be given on the day of randomization. The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
3097789|NCT01945944|Placebo Comparator|Placebo|Placebo (0.9% saline), 3mL every 6 hrs for up to 7 days
3097790|NCT01945944|Experimental|Hypertonic Saline|Hypertonic saline (3%), 3mL every 6hrs for up to 7 days
3097791|NCT01945970|Experimental|Black tea extract|Spray dried aqueous extract of a representative batch of black tea
3097792|NCT01945970|Active Comparator|Positive control|Spray dried aqueous extract of a batch of tea extract that has shown to improve FMD previously
3097793|NCT01945970|Placebo Comparator|Placebo|Food grade colouring, artificial tea flavour and an amount of caffeine matched to the caffeine in the Black tea extract
3097794|NCT01945996|Active Comparator|TExT-MED only|Patients will receive TExT-MED intervention, but supporters will not receive additional messages
3097795|NCT01945996|Experimental|TExT-MED FANS|Patients get TExT-MED intervention, supporter gets FANS curriculum
3097796|NCT01946126||Chronic Migraine Diagnosis|This is a retrospective chart review for patients diagnosed with Chronic Migraine. There is no intervention in this study.
3097797|NCT01946126||Other Headache Diagnoses|This is a retrospective chart review of patients with headache diagnoses other than Chronic Migraine. There is no intervention in this study.
3097798|NCT01946152|Experimental|Treatment (pomalidomide, dexamethasone, filgrastim-sndz)|"INDUCTION: Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO on days 1, 8, 15, and 22, and filgrastim-sndz SC on days 22-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive lower-dose pomalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3097799|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + Enzalutamide + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
3097800|NCT01946165|Experimental|Abiraterone Acetate + Prednisone + LHRHa|Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
3097801|NCT01946178|Experimental|Focused ultrasound treatment|Patients in this arm will receive fibroid treatment using the Mirabilis High-Intensity Focused Ultrasound Treatment System.
3097802|NCT01946191|Experimental|Coaching Group|"24 months of personalized coaching through the EHR patient portal, with 24 scheduled contacts~Online self-monitoring~Real-time updates to primary care physicians"
3097803|NCT01946191|Active Comparator|Tracking Group|-Online self-monitoring
3097806|NCT01946243|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir F 18 as part of this study.
3321217|NCT02017249|Placebo Comparator|Silica and cellulose placebo powder|3.5 teaspoons of placebo powder will be mixed with a sweet beverage and given orally 3 times per day for 7 days prior to surgery and 7 days after surgery.
3097807|NCT01946282|Active Comparator|FIT Invitation Only|"Fecal Immunochemical Test (FIT) mailed to patient homes free of charge.~Intervention: Fecal Immunochemical Test (FIT) kits and an invitation letter to complete colorectal cancer screening are mailed to the homes of study eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3 consistent with guideline recommended annual FIT for colorectal cancer screening. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
3097808|NCT01946282|Active Comparator|FIT plus $5 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $5 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
3097809|NCT01946282|Active Comparator|FIT plus $10 Incentive|"Fecal Immunochemical Test (FIT) mailed to patient homes, plus an incentive to complete the test.~Intervention: FIT kits and invitation letter with a $10 gift card incentive to complete screening are mailed to the homes of 1000 randomly assigned eligible patients. A postage paid return mailer is included. Automated and live phone call reminders are made at the time of invitation and within one week of invitation. Up to two live phone call reminders are attempted 2 to 3 weeks post invitation.~Follow up for patients who return a normal test in Year 1 will consist of repeat screening invitations in Year 2 and Year 3. Follow up for patients who return an abnormal test will consist of navigation to complete colonoscopy."
3097810|NCT01946412|No Intervention|Observational Arm|
3097811|NCT01946412|Experimental|Ivacaftor|"Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the Week 84 Visit. The ivacaftor dose will be:~50 mg q12h for subjects 2 to <6 years of age and <14 kg,~75 mg q12h for subjects 2 to <6 years of age and ≥ 14 kg, or~150 mg q12h for subjects ≥ 6 years of age."
3097812|NCT01946425|Experimental|Age 6 Months to <36 Months (Study Group 1)|Participants at 6 months to < 36 months of age at enrollment
3097813|NCT01946425|Experimental|Age 3 Years to <9 Years Group (Study Group 2)|Participants at 3 years to < 9 years of age at enrollment
3097814|NCT01946438|Experimental|Adult Fluzone® Quadrivalent, Influenza Vaccine (Group 1)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
3097815|NCT01946438|Experimental|Adult Fluzone® Intradermal, Influenza Vaccine (Group 2)|Participants age 18 to < 65 years randomized to receive a dose of Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation)
3097816|NCT01946438|Experimental|Elderly Fluzone® Quadrivalent, Influenza Vaccine (Group 3)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation)
3097817|NCT01946438|Experimental|Elderly Fluzone® High-Dose, Influenza Vaccine (Group 4)|Participants age ≥ 65 years randomized to receive a dose of Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)
3097818|NCT01946529|Active Comparator|Group A (Standard Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
3097819|NCT01946529|Active Comparator|Group B (High Risk)|Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
3097820|NCT01946802||Frontal 4 channel EEG|Consecutive comatose patients admitted to the emergency ICU for postresuscitation care following successful cardiopulmonary resuscitation after nontraumatic out-of-hospital and in-hospital cardiac arrest.
3097821|NCT01946880|Experimental|Mycophenolate Mofetil Withdrawal|These subjects will taper off MMF per the protocol-specified schedule over 12 weeks and remain off MMF for the rest of their study participation (up to Week 60 or until the primary endpoint of disease reactivation is met, whichever comes first).
3097822|NCT01946880|Active Comparator|Mycophenolate Mofetil Maintenance|These subjects will continue MMF treatment (1000-3000 mg/day) for the rest of their study participation (up to Week 60).
3097823|NCT01947127||High lactate|Initial venous lactate level equal to or more than 2.0 mmol/L
3097824|NCT01947127||Low lactate|Initial venous lactate level less than 2.0 mmol/L
3097825|NCT01947153|Experimental|Fixed dose combination|Linagliptin/Metformin
3097826|NCT01947153|Experimental|Free combination|Linagliptin and Metformin
3097827|NCT01947283|Experimental|Intervention Patients & Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers.~For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
3097828|NCT01947283|Experimental|Intervention Patients, Control Providers|"Participants in this arm are intervention patients who will receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~For intervention patients, the DECIDE PA is designed to help patients identify concerns about their condition or treatment and generate questions for providers regarding these concerns. The DECIDE PA intervention consists of 3-4 brief training sessions for patients delivered by Care Managers."
3097829|NCT01947283|No Intervention|Control Patients, Intervention Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Intervention providers, who will receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care. For intervention providers, the DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making."
3097830|NCT01947283|No Intervention|Control Patients & Providers|"Participants in this arm are control patients who will not receive the DECIDE-PA intervention.~These patients receive care from Control providers, who will not receive the DECIDE-PC intervention.~Control patients will receive a pamphlet called Managing Your Mental Health Care."
3097831|NCT01947283|No Intervention|Non-Randomized Controlled Trial Patients|Participants in this arm are patients who did not participate in the Randomized Controlled Trial. One to two patients will be recruited for each enrolled provider (Control and Intervention). One clinical session per patient will be audio recorded. These clinical recordings will be used to provide feedback only for Intervention providers during part 1 of the DECIDE-PC intervention.
3097832|NCT01947283|No Intervention|Control Providers|Participants in this arm are providers who were randomized to the Control group. Control providers will not receive the DECIDE-PC intervention.
3097833|NCT01947283|Experimental|Intervention Providers|Participants in this arm are providers who were randomized to the Intervention group. Intervention providers will receive the DECIDE-PC intervention. The DECIDE PC is designed to help providers improve therapeutic alliance, patient-provider communication, continuance in care, and satisfaction with services for patients in order to improve shared decision making.
3097834|NCT01947335|No Intervention|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention
3097835|NCT01947335|Active Comparator|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
3097836|NCT01947491|Experimental|DFD01 Spray|DFD01 Spray twice daily for 28 days
3097837|NCT01947491|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily for 28 days
3097838|NCT01947491|Active Comparator|Comp01 Lotion|Comp01 Lotion twice daily for 14 days
3097839|NCT01947491|Placebo Comparator|Vehicle Lotion|Vehicle Lotion twice daily for 28 days
3097840|NCT01947517||Parasol Punctal Occluder Group|Randomized to receive Brand A punctal plugs
3097841|NCT01947517||Superflex Punctal Occluder Group|Randomized to receive Group B punctal plugs
3097842|NCT01947582|Other|Application of ankle foot orthosis|All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.
3097843|NCT01947647|Experimental|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
3097844|NCT01947647|Active Comparator|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
3097845|NCT01947816||Humira|Humira 40 mg (marketed product) eow for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration, for up to 52 weeks.
3097846|NCT01947855|Experimental|Empagliflozin low dose|Empagliflozin low dose tablet once daily
3097847|NCT01947855|Experimental|Empagliflozin high dose|Empagliflozin high dose tablet once daily
3097848|NCT01947855|Placebo Comparator|Placebo|Placebo tablet once daily
3097849|NCT01947894||Adult Growth Hormone deficient Patients|Patients with GHD on Genotropin® replacement therapy.
3097850|NCT01947907|Experimental|ACP-001, dose-level 1|Once weekly subcutaneous injection of ACP-001
3097851|NCT01947907|Experimental|ACP-001, dose-level 2|Once weekly subcutaneous injection of ACP-001
3097852|NCT01947907|Experimental|ACP-001, dose-level 3|Once weekly subcutaneous injection of ACP-001
3097853|NCT01947907|Active Comparator|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone (rhGH)
3097854|NCT01947946|Experimental|Benra 30 mg q.4 Weeks|Fixed 30 mg dose of benralizumab (every 4 weeks)
3097855|NCT01947946|Experimental|Benra 30 mg - Placebo q.8 Weeks|Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
3097856|NCT01947946|Placebo Comparator|Placebo|A (Dummy) injection
3097857|NCT01948050|Experimental|real tDCS stimulation|non-invasive transcranial direct current stimulation (tDCS) at 2 milliamiampers (2mA)for 20 minutes at each session, on five consecutive days.
3097858|NCT01948050|Sham Comparator|Sham tDCS|sham non-invasive transcranial direct current stimulation (tDCS) consisting of 30 seconds of tDCS stimulation at 2mp and 19 minutes and 30 seconds of tdcs at 0mp stimulation,on five consecutive days.
3097859|NCT01948063|Placebo Comparator|Control|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
3321218|NCT02017262|Experimental|Self-management group|8 weekly sessions of group self-management
3097860|NCT01948063|Experimental|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg of Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
3097861|NCT01948076|Placebo Comparator|resident without GE vscan|baseline physical exam use
3097862|NCT01948076|Active Comparator|resident with GE vscan|residents with augmentation of physical exam by ultrasound
3097863|NCT01948141|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3097864|NCT01948193|Experimental|Study Group|Participants will receive Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T combined vaccine (investigational vaccine) at 6, 10 and 14 weeks of age.
3097865|NCT01948258|Other|Clearblue Advanced Fertility Monitor|Use of Clearblue Fertility Monitor
3097866|NCT01948310|Active Comparator|Ranolazine plus Exercise|Ranolazine 1000mg pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
3097867|NCT01948310|Placebo Comparator|Placebo plus Exercise|Placebo pill twice per day plus aerobic exercise three times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold.
3097868|NCT01948375|Experimental|real needle- placebo needle|Participants received acupuncture with real needle in the first period, and with pragmatic placebo acupuncture needle in the second period.
3097869|NCT01948375|Experimental|placebo needle - real needle|Participants received acupuncture with pragmatic placebo needle in the first period, and with real acupuncture needle in the second period.
3097870|NCT01948388|Active Comparator|corticotrophin 80 units|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) weekly
3097871|NCT01948388|Active Comparator|corticotrophin 80 units twice a week|Ten (10) patients will receive 80 units of corticotrophin Subcutaneous (SC) twice a week
3097872|NCT01948518|Experimental|Oral sildenafil 20 mg|oral sildenafil, single dose at baseline
3097873|NCT01948739|Experimental|BMI control of MAHI Exo-II|MAHI EXO-II exoskeleton augmented with BMI system will be used to actively include the patient in the control loop, thereby making the therapy 'active' and engaging patients with various impairment severity in rehabilitation tasks. Patients will receive longitudinal training with the BMI-robotic interface for 3-4 sessions per week, over a period of 3 months.
3097874|NCT01948791|Experimental|ENA713|Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.
3097875|NCT01948830|Active Comparator|Group I ranibizumab 0.5 mg monthly|Ranibizumab 0.5 mg/0.05 mL (Monthly regimen) up to month 11
3097876|NCT01948830|Active Comparator|Group II ranibizumab 0.5 mg TER|Ranibizumab 0.5 mg/0.05 mL (TER) treat and Extend regimen up to month 11
3097877|NCT01948908|Experimental|200 mcL VOA|Intranasal midazolam administered in 200 mcL VOA
3097878|NCT01948908|Experimental|500 mcL VOA|Intranasal midazolam administered in 500 mcL VOA.
3097879|NCT01948908|Experimental|1000 mcL VOA|Intranasal midazolam administered in 1000 mcL VOA.
3097880|NCT01948947|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
3097881|NCT01948947|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
3097882|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Normal Renal Function)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
3097883|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Mild Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
3097884|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Moderate Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
3097885|NCT01948986|Experimental|Ertugliflozin 15 mg (T2DM with Severe Renal Impairment)|Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
3097886|NCT01948986|Experimental|Ertugliflozin, 15 mg (Healthy Part. with Normal Renal Funct.)|Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
3097887|NCT01949051|Experimental|Levocabastine Arm|Subjects will be assigned to one of six treatment sequences (ABC, BCA, CAB, ACB, BAC, CBA) in accordance with the randomisation schedule. A = Two, 50 microgram (mcg) sprays per nostril of levocabastine QD in the morning. Total dose of 200 mcg. Two, 0 mcg sprays from placebo to match vehicle in the evening; B = Two, 50 mcg sprays per nostril of levocabastine BID in the morning and evening. Total dose of 400 mcg; C = Two, 0 mcg sprays per nostril from placebo vehicle in morning and evenings.
3097888|NCT01949090|Experimental|GSK2789869A F1 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3097889|NCT01949090|Experimental|GSK2789869A F2 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3097890|NCT01949090|Experimental|GSK2789869A F3 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3097891|NCT01949090|Experimental|GSK2789869A F4 Group|Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3097892|NCT01949090|Placebo Comparator|Placebo Group|Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.
3321219|NCT02017262|Active Comparator|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
3097893|NCT01949116|Experimental|Low-dose methotrexate (LDMTX)|From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
3097894|NCT01949116|Placebo Comparator|Placebo|From study entry through Week 1, participants received 5 mg of placebo once a week. For participants who were clinically stable at the Week 1 study visit, the dose of placebo was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of placebo was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to placebo, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of placebo, all participants continued taking folic acid for an additional 4 weeks.
3097895|NCT01949142|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
3097896|NCT01949142|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
3097897|NCT01949155|Experimental|OTO-201|"OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery."
3097898|NCT01949155|Sham Comparator|Sham|"Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery."
3097899|NCT01949337|Experimental|Arm A: (enzalutamide)|Patients receive enzalutamide 160 mg PO QD. Treatment will continue until confirmed disease progression or unacceptable toxicity.
3097900|NCT01949337|Experimental|Arm B: (enzalutamide, abiraterone, prednisone)|Patients receive enzalutamide 160 mg PO QD, abiraterone 1000 mg PO QD, and prednisone 5 mg PO BID. Treatment will continue until confirmed disease progression or unacceptable toxicity.
3097901|NCT01949389|Experimental|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
3097902|NCT01949480|Active Comparator|Traditional approach paravertebral nerve block|After final needle placement, a hanging drop technique will be used to rule out intrapleural placement while the patient inhales and exhales deeply. After correct needle placement, 10 mL of 0.5% Ropivacaine will be injected incrementally through each needle after negative aspiration, followed by insertion of the nerve block catheter to a depth 5 cm beyond the tip of the needle. An additional 10 mL of 0.5% Ropivacaine will then be injected in 5 mL increments with negative aspiration in between, through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
3097903|NCT01949480|Experimental|Ultrasound assisted paravertebral nerve block|The 22 gauge catheter will be threaded through the needle and placed at previously found distance to paravertebral space on obtained ultrasound image. An additional 10 ml of 0.5% Ropivacaine will be administered through the catheter yielding a total activation dose of 20 ml of 0.5% Ropivacaine. The catheter will be secured with Steri-strips and a transparent occlusive dressing.
3097904|NCT01949532|Experimental|Normal Renal Function|Participants with normal renal function (creatinine clearance [CrCl] ≥ 75 mL/min) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
3097905|NCT01949532|Experimental|End Stage Renal Disease|Participants with end-stage renal disease (on hemodialysis) received carfilzomib 20 mg/m² intravenous infusion (IV) on days 1 and 2 of cycle 1, followed by 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15 and 16 of cycle 2 and all subsequent cycles. Participants continued treatment until confirmed progressive disease, unacceptable toxicity, withdrawal of consent, study closure, or death.
3097906|NCT01949545|Experimental|Normal Hepatic Function|Participants with normal hepatic function (bilirubin and aspartate aminotransferase (AST) ≤ the upper limit of normal (ULN)) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3097907|NCT01949545|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (bilirubin > 1-1.5 x ULN or AST > ULN, but bilirubin ≤ ULN) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3097908|NCT01949545|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (bilirubin > 1.5-3 x ULN, any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3321220|NCT02017275|Experimental|BuMA group|Implant BuMA stent only
3321221|NCT02017275|Active Comparator|EXCEL group|Implant EXCEL stent
3321222|NCT02017288||Cancer|Participants diagnosed with incident oral cancer
3097909|NCT01949545|Experimental|Severe Hepatic Impairment|(Bilirubin > 3 × ULN; any AST) Participants with severe hepatic impairment (bilirubin > 3 x ULN; any AST) received carfilzomib 20 mg/m² administered by intravenous (IV) infusion on days 1 and 2 of cycle 1, followed by a planned step-up to 27 mg/m² IV on days 8, 9, 15, and 16 of cycle 1. Participants who adequately tolerated dosing at 27 mg/m² in cycle 1 received carfilzomib 56 mg/m² IV on days 1, 2, 8, 9, 15, and 16 of cycle 2 and subsequent 28-day cycles until confirmed progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death.
3097910|NCT01949662|Experimental|Lorazepam + Haloperidol|Participants given a single dose of lorazepam 3 mg by vein, in addition to a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
3097911|NCT01949662|Active Comparator|Placebo + Haloperidol|Participants receive placebo, preservative free 0.9% normal saline, by vein plus a standardized dose of haloperidol 8 mg/day by vein, while in palliative care unit. Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete
3097912|NCT01949779||TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
3097913|NCT01949844|Other|Suspected coronary artery disease (CAD)|"This pilot study has a single arm/group of subjects with suspected CAD based on the following inclusion criteria:~Prior nuclear myocardial perfusion scan (PET/SPECT) with a visual interpretation of definitely abnormal, or prior myocardial infarction; or,~Clinically stable individuals with suspected coronary artery disease on the basis of coronary angiography.~The study protocol involved only a myocardial perfusion MRI procedure for detection of ischemia (perfusion deficits) using an improved protocol with the administration of a vasodilator drug (Regadenoson/Lexiscan®) and gadolinium-based MRI contrast agent (Optimark®; dose: 0.2 mmol/kg). Lexiscan® was used off-label as a vasodilator drug during the MRI scan (0.4 mg/5mL) supplied by the manufacturer, Astellas Pharma U.S."
3097914|NCT01949870|Other|Selumetinib|25mg/day, 50mg/day and 75mg/day
3097915|NCT01950013|No Intervention|Passive Control|Hearing aid alone
3097916|NCT01950013|Experimental|Training|Auditory Training Program. Hearing aid plus auditory training
3097917|NCT01950013|Sham Comparator|Active control|Sham comparator: Active control. Hearing aid plus audio-book use
3097918|NCT01950039|Active Comparator|Betaine|
3097919|NCT01950039|Placebo Comparator|Placebo|
3097920|NCT01950078||surgical patients|grouped by receiving surgery
3097921|NCT01950078||Healthy volunteers group|grouped by healthy college students
3097922|NCT01950169|Active Comparator|Risedronate|35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)
3097923|NCT01950169|Active Comparator|Nutritional supplement|Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)
3097924|NCT01950169|Active Comparator|Calcium and vitamin D3|An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)
3097925|NCT01950260|Experimental|Levothyroxine|In the intervention arm patients will start levothyroxine therapy at 4 weeks after RAI therapy. The initial dose of levothyroxine will be 25 mcg/day. It will be increased to 50 mcg/day 2 weeks later and then adjusted at 8 weeks post RAI based on a full face-to-face clinical and biochemical evaluation.
3097926|NCT01950260|Placebo Comparator|Placebo|In the control arm patients will receive placebo capsules and be evaluated for levothyroxine therapy during a full face-to-face evaluation at 8 weeks.
3097927|NCT01950273|Experimental|BI695500|BI695500, once a week for 4 weeks (4 administrations in total)
3097928|NCT01950273|Active Comparator|MabThera|MabThera, once a week for 4 weeks (4 administration in total)
3097929|NCT01950299|Experimental|Anakinra (standard dose)|Anakinra 100 mg daily for 14 days
3097930|NCT01950299|Experimental|Anakinra (high dose)|Anakinra 100 mg twice daily for 14 days
3097931|NCT01950299|Placebo Comparator|Placebo|Placebo for 14 days
3097932|NCT01950364|Experimental|Arm A: Brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
3097933|NCT01950364|Experimental|Arm B: Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
3097934|NCT01950663|Experimental|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
3097935|NCT01950741|Experimental|aflibercept|Aflibercept 2 mg is injected into the vitreous cavity. Injections are given monthly three times, then are given bi-monthly to 12 months (month 0, 1, 2, 4, 6, 8, and 10; total 7 injections for 1 year).
3097936|NCT01950780|Experimental|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
3097937|NCT01950819|Experimental|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
3097938|NCT01950819|Active Comparator|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
3097939|NCT01951066|Experimental|Group 1 (dexamethasone implant/anti-VEGF)|Patients in group 1 received an injection of an dexamethasone implant at baseline followed by PRN anti-VEGF injections after crossover at week 16.
3097940|NCT01951066|Experimental|Group 2 (anti-VEGF/dexamethasone implant)|Patients in group 2 received prn anti-VEGF injections followed by injection of a dexamethasone implant after crossover at week 16.
3097941|NCT01951092|Experimental|Single Arm intervention study|All subjects receive text messages for: 1) medication reminders; 2) appointment reminders; 3) a text message addressing barriers (e.g., reminders to attend AA meetings). Each subject will undergo baseline assessments, choose personalized messages at that time. Subsequently monthly phone calls with study coordinator regarding frequency/changing messages, and then month 3 assessment, and month 6 (final assessment) with option for qualitative interview.
3097942|NCT01951105|No Intervention|Observation|Individuals identified as having a recovering phenotype (SBPp) will be assigned to the observational arm and will be asked to continue his/her normal regime and return for the week 12 and week 24 visits for follow-up.
3097943|NCT01951105|Active Comparator|Carbidopa/Levodopa & Naproxen|"Individuals identified as having a persisting phenotype (SBPr) will be treated with Carbidopa/Levodopa on a flexible dose-titration designed intervention based on dose-response TID throughout the 12 week treatment period.~Naproxen (250mg) capsules will be administered orally, one capsule TID, throughout the 12 week treatment period."
3097944|NCT01951105|Placebo Comparator|Placebo & Naproxen|Individuals identified as having a persisting phenotype (SBPr) will be treated with placebo capsule plus 250mg naproxen tablet three times a day for 12 weeks.
3097945|NCT01951118|Experimental|Donepezil Treatment & Atropine Challenge|Atropine nasal spray is administered at baseline for the atropine challenge which involves administration of the 40-item UPSIT immediately before and 45 minutes after atropine administration. Immediately after the atropine challenge, donepezil treatment is started and continues for 52 weeks.
3097946|NCT01951157|Active Comparator|A - docetaxel|75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks
3097947|NCT01951157|Experimental|B - lurbinectedin (PM01183)|3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks
3097948|NCT01951157|Experimental|C - gemcitabine + lurbinectedin (PM01183)|800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks
3097949|NCT01951170|Experimental|Tocilizumab|Participants were administered subcutaneous tocilizumab for the treatment of rheumatoid arthritis for 24 weeks.
3097950|NCT01951261|Active Comparator|telemonitoring and telephone control|Early discharge from hospital with telemonitoring, telephone control and three nurse scheduled visits.
3097951|NCT01951261|No Intervention|home care|Early discharge from hospital with home care provided by hospital respiratory nurses and pulmonologists (daily visits).
3097952|NCT01951326|Active Comparator|RHB-104|5 RHB-104 capsules administered orally BID
3097953|NCT01951326|Placebo Comparator|Placebo|5 placebo capsules administered orally BID
3097954|NCT01951339|Experimental|Sitagliptin plus placebo|100 mg sitagliptin plus 2 mg placebo once daily for three months
3097955|NCT01951339|Active Comparator|Glimepiride plus placebo|2 mg glimepiride plus 100 mg placebo once daily for three months
3097956|NCT01951352|Experimental|Soap recipient|The forearms of all subjects will eventually be washed with the same soaps. There is only one arm for this study.
3097957|NCT01951391|Other|Control Soap vs. Benzalkonium Chloride Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with benzalkonium chloride soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The benzalkonium chloride forearm will be swabbed at baseline and 6 hours.
3097958|NCT01951391|Other|Control Soap vs. Triclocarban Soap|Each subject's will have one forearm washed with a control soap and then the other forearm will be washed with triclocarban soap. The control forearm will be swabbed for bacteria at baseline, 10 minutes, 6 hours, and 24 hours. The triclocarban forearm will be swabbed at baseline and 6 hours.
3097959|NCT01951417|Experimental|Adapalene/BPO Gel/Foam Wash/Moisturizer|Adapalene BPO Gel Pump (once daily) in conjunction with a Foam Wash (twice daily) and Moisturizer SPF 30 (once daily)
3097960|NCT01951573|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses first, followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
3097961|NCT01951573|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses first, followed by delefilcon A multifocal contact lenses. Each product worn bilaterally (ie, in both eyes) for 9-12 hours, with a 1-8 day washout separating the 2 wear periods.
3097962|NCT01951586|Placebo Comparator|Placebo|Participants received placebo matching to denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received 4 mg zoledronic acid administered as an IV infusion Q4W or Q3W.
3097963|NCT01951586|Experimental|Denosumab|Participants received 120 mg denosumab by subcutaneous injection once every 4 weeks plus one loading dose on study day 8 in addition to platinum-based standard chemotherapy. Participants with bone metastases also received placebo to zoledronic acid administered as an IV infusion Q4W or Q3W.
3097964|NCT01951625|Experimental|Vericiguat (BAY1021189) (10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
3097965|NCT01951625|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
3097966|NCT01951625|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
3097967|NCT01951625|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
3097968|NCT01951625|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
3097969|NCT01951638|Experimental|Vericiguat (BAY1021189)(10 mg)|2.5 mg orally once daily for 2 weeks, up-titration to 5 mg orally once daily for 2 weeks, up-titration to 10 mg orally once daily for 8 weeks
3097970|NCT01951638|Experimental|Vericiguat (BAY1021189) (5 mg)|2.5 mg orally once daily for 2 weeks, then 5 mg orally once daily for 10 weeks (with sham titration)
3097971|NCT01951638|Experimental|Vericiguat (BAY1021189) (2.5 mg)|2.5 mg orally once daily for 12 weeks (with sham titrations)
3097972|NCT01951638|Experimental|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg orally once daily for 12 weeks (with sham titrations)
3097973|NCT01951638|Placebo Comparator|Placebo|Orally once daily for 12 weeks (with sham titrations)
3097974|NCT01951651|Experimental|Exenatide|Exenatide 10 micrograms injected subcutaneously twice daily for 6 months
3097975|NCT01951651|Experimental|Glipizide|Glipizide 5 mg (tablet), one tablet twice daily orally for 6 months
3097976|NCT01951703|Active Comparator|Control, senofilcon A|Subjects received Control lens, senofilcon A during the first two weeks of the study then Test lens, senofilcon A in the last two weeks of the study.
3097977|NCT01951703|Experimental|Test, senofilcon A|Subjects received Test lens, senofilcon A during the first two weeks of the study then Control lens, senofilcon A in the last two weeks of the study.
3097978|NCT01951768|Experimental|Garamycin Sponge (Gentamicin-Collagen Sponge)|Garamycin Sponge (Gentamicin-Collagen sponge) applied daily plus systemic antibiotic and standard ulcer care
3097979|NCT01951768|Active Comparator|Systemic Antibiotic|Systemic antibiotic therapy and standard ulcer care
3097980|NCT01951820|Active Comparator|Benzocaine|Benzocaine topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
3097981|NCT01951820|Experimental|Pliaglis|Pliaglis topical numbing gel will be applied to the gums before injection with other intervention, injection of local anesthetic articaine.
3097982|NCT01951950|Active Comparator|Nicardipine|"Subjects will receive a 15 mcg/kg bolus of nicardipine as needed followed by an infusion initiated at 5 mg/hr. Nicardipine may be titrated every 5 minutes, increasing 5 mg/hr and administering 15 mcg/kg bolus every minute to a maximum dose of 15 mg/hr. If systolic blood pressure (SBP) is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of nicardipine, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
3097983|NCT01951950|Active Comparator|Esmolol|"Subjects will receive a 0.5 mg/kg bolus of esmolol as needed followed by an infusion initiated at 50 mcg/kg/min. Esmolol may be titrated every 5 minutes, increasing 50 mcg/kg/min and administering 0.5 mg/kg bolus every minute to a maximum dose of 200 mcg/kg/min. If SBP is not maintained < 140 mmHg 5 minutes after achieving the maximum dose of esmolol, medication failure will be declared and rescue drug (medication to be determined per anesthesiologist discretion) will be administered. Infusions may be titrated down if SBP decreases below 90 mmHg."
3097984|NCT01951963|Experimental|Ketamine|Ketamine, single dose, 0.3 mg/kg, IV
3097985|NCT01951963|Active Comparator|Morphine|Morphine, single dose, 0.05 mg/kg, IV
3097986|NCT01952015|Experimental|AIN457|"All subjects were assigned to receive 150 mg secukinumab (AIN457) by subcutaneous injections. AIN457 was administered at baseline, weeks 1, 2, 3, 4. Prior to receiving the week 8 dose, all subjects were assigned to the following treatment group based on clinical components of their Clinical Global Impression (CGI) evaluation at week 8.~No up-titration group received 1 injection of 150 mg AIN457 at weeks 8, 12, and each visit from week 16 until week 48.~Up-titration group received 2 injections of 150 mg AIN457 at weeks 8, 9, 12 and each visit from week 16 until week 48.~Subjects who received 150 mg AIN457 can be up-titrated to 300 mg AIN 457 at any visit starting at week 16 based on clinical components of their CGI evaluation and investigator's discretion."
3097987|NCT01952041|Experimental|Device: Smartphone|Participants in the smartphone intervention arm received treatment as usual in addition to receiving a smartphone with the study application. The study application identified relapse risk and prompted the clinical team to provide enhanced services.
3097988|NCT01952041|Active Comparator|Treatment as Usual|Treatment as usual included outpatient case management, linkage to services and medication monitoring.
3097989|NCT01952054|Experimental|Denosumab|Participants receive a single subcutaneous (SC) administration of Denosumab 120 mg every 4 weeks (+/- 5days). Starting week 5, in addition to receiving Denosumab every 4 weeks, participants receive a hormonal agent chosen by each physician, excluding the agent that participants received at adjuvant therapy setting.
3097990|NCT01952080|Experimental|teduglutide|Open label teduglutide, subcutaneously injected.
3097991|NCT01952080|No Intervention|Standard of Care|
3097992|NCT01952145|Experimental|Insulin degludec/liraglutide OD plus metformin|
3097993|NCT01952145|Active Comparator|Insulin glargine OD plus metformin|
3097994|NCT01952301|Active Comparator|xenogeneic collagen matrix|Xenogeneic collagen matrix device placed on treatment wound bed site
3097995|NCT01952301|Active Comparator|Free Gingival Graft|Traditional free gingival graft (autogenous graft device harvested from patient's palate) placed on treatment site wound bed
3097996|NCT01952366||Depressed patients|Patients admitted to specialist health care service of old age psychiatry
3097997|NCT01952418|No Intervention|"Standard monitor (24)"|"Endoscopists in this arm will perform colonoscopy using the standard size video monitor (24)."
3097998|NCT01952418|Active Comparator|"Large monitor (32)"|"Subjects randomized to this group will perform colonoscopy while viewing a large video monitor (32)."
3097999|NCT01952444|Experimental|Group 1 ETI-204 and Ciprofloxacin|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1, immediately followed by an IV dose of ciprofloxacin 400 mg infused over 60 minutes, followed by oral doses of ciprofloxacin (750 mg every 12 hours) from Day 2 to Day 8 and a final dose on the morning of Day 9.
3098000|NCT01952444|Other|Group 2 ETI-204 Alone|Participants will receive a single IV dose of 16 mg/kg ETI-204 infused over 90 minutes on Day 1.
3098001|NCT01952470|Experimental|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa.
3098002|NCT01952470|Active Comparator|Isotonic Saline|Once daily, 5ml inhaled 0.9% normal saline.
3098003|NCT01952574|Placebo Comparator|Placebo|"Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
3098004|NCT01952574|Experimental|Erenumab 7 mg QM|"Participants received erenumab 7 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
3098005|NCT01952574|Experimental|Erenumab 21 mg QM|"Participants received erenumab 21 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
3098006|NCT01952574|Experimental|Erenumab 70 mg QM|"Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection during the double-blind treatment phase.~In the open-label treatment phase participants received 70 mg erenumab QM from week 12 to week 264 (last dose). After Protocol Amendment 3, participants still on study had their dose increased to 140 mg QM."
3321223|NCT02017288||Control|Participants without oral lesions or cancers matched to oral cancer/precursor participants on age, gender, smoking/betel nut habits
3321224|NCT02017288||Precursor|Participants clinically diagnosed with oral lesions
3098007|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg PFS|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using a prefilled syringe (PFS) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
3098008|NCT01952574|Experimental|CHU Substudy: Erenumab 140 mg AI/Pen|Participants in the open-label treatment phase in the United States randomized to self-administer 140 mg erenumab via two 70 mg injections using an autoinjector/pen (AI)/pen) on CHU substudy day 1 (under study site supervision), and at home on day 29 (week 4) and day 57 (week 8).
3098009|NCT01952600||Chronic Kidney Disease (CKD)|Patients who have advanced chronic kidney disease, but are not currently on either hemodialysis (HD) or peritoneal dialysis (PD).
3098010|NCT01952600||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
3098011|NCT01952600||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
3098012|NCT01952665|Active Comparator|comfilcon A|Daily wear soft contact lens comfilcon A
3098013|NCT01952665|Active Comparator|lotrafilcon B|Daily wear soft contact lens lotrafilcon B
3098014|NCT01952678||DaTscan™ - Non-Caucasian Participants|Non-Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
3098015|NCT01952678||DaTscan™- Caucasian Participants|Caucasian participants previously administered DaTscan™, with an initial diagnosis of suspected PD or ET who underwent DaTscan SPECT imaging to assist with the participant's final clinical diagnosis of PD or ET.
3098016|NCT01952691|Experimental|kinesiotaping|all patients were implemented a kinesiotaping to align the hallux to correct position
3098017|NCT01952834|Experimental|GoodBelly Probiotic and Vancomycin|Good Belly Probiotic 2.7 oz Daily x 6 weeks Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
3098018|NCT01953003|Experimental|Arm A : iv vinflunine plus Capecitabine|Vinflunine dose 280 mg/m² on day 1 of each cycle every 3 weeks, Capecitabine 825 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest.
3098019|NCT01953003|Active Comparator|capecitabineArm B : capecitabine|1250 mg/m² twice daily orally for 14 consecutive days beginning on day 1 of each cycle followed by 1 week of rest
3098020|NCT01953081|Experimental|TD-8954|TD-8954 single infusion for 1 hour and 4 injections of saline every 6 hours
3098021|NCT01953081|Active Comparator|Metoclopramide|Metoclopramide 4 doses every 6 hours for 24 hours and 1 hour infusion of saline
3098022|NCT01953211||Healthy reproductive age women|These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
3098023|NCT01953224|Experimental|Game-based intervention|This arm will receive the game intervention, which will include provision of a mobile smartphone device, cellular data service, the game application loaded onto the device, credit to load approximately 40-50 songs onto the device, headphones, and an armband for wearing the device. Participants will also receive weekly counseling calls.
3098024|NCT01953224|No Intervention|Wait list control|This group will receive no intervention until after completion of the final assessment of the randomized trial. Then, they will receive the full intervention.
3098025|NCT01953237|Active Comparator|Control|Individuals randomized to the control condition will be provided with a smartphone free of charge with unlimited use of the phone's voice and internet capabilities. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period. All participants will be contacted by research staff to trouble-shoot problems with the smartphone at the end of the first week, but will receive no additional contact from research staff until the end of the trial.
3098026|NCT01953237|Experimental|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
3098027|NCT01953328|Placebo Comparator|A5 Placebo Q2W|Participants received atorvastatin 5 mg (A5) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
3098028|NCT01953328|Placebo Comparator|A5 Placebo QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month (QM) for 12 weeks.
3098029|NCT01953328|Experimental|A5 Evolocumab Q2W|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3098030|NCT01953328|Experimental|A5 Evolocumab QM|Participants received atorvastatin 5 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
3098031|NCT01953328|Placebo Comparator|A20 Placebo Q2W|Participants received atorvastatin 20 mg (A20) once daily during the 4 week lipid stabilization period and then in combination with placebo subcutaneous injection once every 2 weeks for 12 weeks.
3098032|NCT01953328|Other|A20 Placebo QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with placebo subcutaneous injection once every month for 12 weeks.
3098033|NCT01953328|Experimental|A20 Evolocumab Q2W|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
3098034|NCT01953328|Experimental|A20 Evolocumab QM|Participants received atorvastatin 20 mg a day during the 4-week lipid stabilization period and then in combination with 420 mg evolocumab by subcutaneous injection once a month for 12 weeks.
3098035|NCT01953354|Experimental|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period
3098036|NCT01953354|Placebo Comparator|Placebo|Six doses of TSO placebo orally over a ten-week period
3321225|NCT02017314|Active Comparator|Group 5|Patients with BMI > 50
3321226|NCT02017314|Active Comparator|Group IV|Patients with BMI between 40 and 49.9
3098037|NCT01953432|Experimental|Doxazosin|Doxazosin is a long-acting and selective alpha 1-NE blocker, which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system.
3098038|NCT01953432|Placebo Comparator|Placebo|Matched placebo daily dosing.
3098039|NCT01953575|Experimental|Active Eosinophilic Esophagitis|Subjects with an eosinophil count greater than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
3098040|NCT01953575|Experimental|Inactive Eosinophilic Esophagitis|Subjects with an eosinophil count less than 15 eosinophil per high-powered field (Eos/HPF) and do not have trouble swallowing during the clinical endoscopy
3098041|NCT01953575|Placebo Comparator|Control group|Subjects are those undergoing clinically indicated upper endoscopy for nonesophageal symptoms in whom a normal-appearing esophagus was found at the time of endoscopy
3098042|NCT01953601|Experimental|Arm A. Verubecestat 12 mg (Part 1); 12 mg (Part 2)|[Part 1] Verubecestat 12 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 12 mg once daily for an additional 260 weeks.
3098043|NCT01953601|Experimental|Arm B. Verubecestat 40 mg (Part 1); 40 mg (Part 2)|[Part 1] Verubecestat 40 mg once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3098044|NCT01953601|Placebo Comparator|Arm C. Placebo (Part 1); Verubecestat 40 mg (Part 2)|[Part 1] Placebo once daily for 104 weeks in Part 1 (Base Study). [Part 2] Participants completing Part 1 and continuing to Part 2 (Extension Study) receive Verubecestat 40 mg once daily for an additional 260 weeks.
3098045|NCT01953692|Experimental|Cohort 1: Myelodysplastic Syndrome (MDS)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
3098046|NCT01953692|Experimental|Cohort 2: Relapsed Refractory/Refractory (rR/R) Multiple Myeloma (MM)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
3098047|NCT01953692|Experimental|Cohort 3: Relapsed/Refractory (R/R) Hodgkin lymphoma (HL)|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
3098048|NCT01953692|Experimental|Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)|Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
3098049|NCT01953692|Experimental|Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas|Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.
3098050|NCT01953692|Experimental|Cohort 4C: R/R Follicular Lymphoma (FL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
3098051|NCT01953692|Experimental|Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
3098052|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 20 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles.
3098053|NCT01953692|Experimental|Cohort 5: R/R DLBCL pembrolizumab+lenalidomide 25 mg|Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles.
3098054|NCT01953783|Experimental|IXAZOMIB|"Part A: Participants will receive a single dose of 4.1-milligram (mg) [14C]-IXAZOMIB oral solution containing approximately 500-nCurie (nCi) of total radioactivity on Day 1 and remain at the clinic for 8 days. On Days 14 and 21, participants may be administered a single 4.0-mg capsule of IXAZOMIB. Participants will return to the clinic in the evening before Days 14, 21, 28, and 35 for a 24-hour overnight clinic visit.~Part B: Eligible participants from Part A may continue into Part B once they have completed their Day 35 assessments in Part A. Participants may receive IXAZOMIB capsules administered orally at a dose of 4.0-mg once weekly on Days 1, 8, and 15 of 28-day cycles. Participants will continue in this study until disease progression or unacceptable toxicity."
3098055|NCT01953874|Experimental|MV ASV+OMT|Minute Ventilation-targeted adaptive servo-ventilation therapy plus optimized medical treatment
3098056|NCT01953874|Active Comparator|OMT only|Optimized Medical Treatment for heart failure in accordance with applicable guidelines (ACCF/AHA Guideline for the Management of Heart Failure and HFSA Heart Failure Guidelines.
3098057|NCT01953913|Experimental|Afatinib|Patient will receive afatinib once daily
3098058|NCT01954017|Experimental|STP206|Biological
3098059|NCT01954017|Placebo Comparator|Control|Sterile water
3098060|NCT01954056|Active Comparator|Hydrocortisone|hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line
3098061|NCT01954056|Placebo Comparator|Placebo|Saline placebo
3098062|NCT01954082|Experimental|myo-Inositol 5% Injection|Within 12-72 hours of birth, infants will receive 80 mg myo-inositol 5% Injection per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
3098063|NCT01954082|Placebo Comparator|5% glucose(dextrose)|Within 12-72 hours of birth, infants will receive 80 mg 5% glucose(dextrose) USP for intravenous infusion per kilogram per day, administered in divided doses every 12 hours (40 mg/kg/dose). Study drug will be administered daily and continued until the earliest of 34 completed weeks PMA, 10 weeks (70 days) chronologic age, or the time of discharge. myo-Inositol 5% Injection will be administered IV until enteral feedings are established, at which time the same dose and formulation will be administered enterally every 12 hours.
3098064|NCT01954121|Experimental|Levetiracetam|Levetiracetam 1000 mg/day
3098065|NCT01954121|Active Comparator|Carbamazepine|Carbamazepine 400 mg/day
3098066|NCT01954251|Experimental|Co-Ad Group|The subjects assigned to the Co-Ad group will receive one injection of the FLU-D-QIV vaccine and one injection of the HZ/su study vaccine during the first visit and a second injection of the HZ/su study vaccine during the third visit, two months later.
3098067|NCT01954251|Active Comparator|Control Group|The subjects assigned to the Control group will receive all vaccines separately: one injection of the FLU-D-QIV vaccine at the first visit, one injection of the HZ/su study vaccine at the third visit and a second injection of the HZ/su study vaccine at the fourth visit, all two months apart.
3098068|NCT01954264|Other|Overall Study Group|Subjects aged between 6 months to 9 years old, who were infected or not infected with Plasmodium falciparum parasite. Infection status was assessed using a blood smear slide and determined using microscopy.
3098069|NCT01954342||Pregnant|Obese pregnant women
3098070|NCT01954394|Experimental|Alirocumab 75 or 150 mg Q2W|Alirocumab 75 mg or 150 mg every 2 weeks (Q2W) added to stable lipid-modifying therapy (LMT) for up to 168 additional weeks (or until the product was commercially available) in participants who completed the parent studies EFC12492, R727-CL-1112, EFC12732 and LTS11717.
3098071|NCT01954628|Experimental|AQX-1125|1 x AQX-1125 capsule daily
3098072|NCT01954628|Placebo Comparator|Placebo|1 x Placebo capsule daily
3098073|NCT01954745|Experimental|Cabozantinib|Patients will be treated with cabozantinib 60 mg daily administered orally continuously for 28-day cycles. Tumor assessments will be performed every 8 weeks until documented disease progression by RECIST criteria or drug intolerance.
3098074|NCT01954771|Active Comparator|Control Group|Patients will receive conventional care and keep on their usual SMBG(Self-monitoring of blood glucose) methods. Additionally, each patient will also wear a CGMS(continous glucose monitoring system) device for 72h in the first week and the last week, respectively.
3098075|NCT01954771|Active Comparator|SMBG-4 Group|Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
3098076|NCT01954771|Active Comparator|SMBG-7 Group|Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
3098077|NCT01954927|Active Comparator|Gabapentin|Patients will be randomized to receive one dose of gabapentin.
3098078|NCT01954927|Placebo Comparator|Placebo|Patients will be randomized to receive one dose of placebo.
3098079|NCT01955005|Experimental|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
3098080|NCT01955005|Active Comparator|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
3098081|NCT01955044|Experimental|"high dose LCPUFA"|"the high dose LCPUFA supplement is a drop that will be administered to ELBW infants."
3098082|NCT01955044|Experimental|"low dose LCPUFA"|"the low dose LCPUFA supplement is a drop that will be administered to ELBW infants."
3098083|NCT01955044|Placebo Comparator|placebo|"the placebo is a drop that will be administered to ELBW infants."
3098084|NCT01955083|Experimental|Pillar implant|"Arm 1- Pillar implant (Study group):~15 subjects undergo pillar implant surgery of the soft palate for the treatment of snoring."
3098085|NCT01955083|Active Comparator|Radiofrequency|"Arm 2- Radiofrequency (control group):~15 subjects undergo radiofrequency of the soft palate for the treatment of snoring."
3098086|NCT01955122|Other|Group A|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~a Standard view colonoscopy followed immediately by an EndoRings™ colonoscopy."
3098087|NCT01955122|Other|Group B|"Tandem Colonoscopy- Each patient will undergo 2 colonoscopy procedures:~an EndoRings™ colonoscopy followed immediately by a Standard view colonoscopy."
3098088|NCT01955161|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
3098089|NCT01955161|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
3098090|NCT01955161|Experimental|Idalopirdine 60 mg|Idalopirdine adjunct to 10 mg Donepezil
3098091|NCT01955369||Amyotrophic lateral sclerosis patients|Patients were included into the registry if they had a new diagnosis of ALS, a minimum age of 18 years and lived in Rhineland-Palatinate for at least 6 months before date of diagnosis. Diagnosis was based upon the revised El Escorial criteria.
3098092|NCT01955382|Experimental|AS + oAC|All children will receive Artesunate (AS) 2.4 mg/kg IV at 0 and 12 h, 24 h, and 48 h. Children in the AS+oAC group will be given weight-based doses of oAC (Actidose Aqua) (Table 1) at 0, 6, 12, and 18 h. All children will then receive amodiaquine.
3098093|NCT01955382|Placebo Comparator|AS only (water)|Children in the AS only group will receive a weight-based volume of clean water (Bottled Water) to drink rather than the oAC.
3098094|NCT01955434|Experimental|Treatment (SMAC mimetic LCL161 and cyclophosphamide)|Patients receive SMAC mimetic LCL161 PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3098095|NCT01955473|Experimental|Sym004|
3098096|NCT01955564|Experimental|Cohort 1|NW-3509a - 1mg or placebo
3098097|NCT01955564|Experimental|Cohort 2|NW-3509a 2mg or placebo
3098098|NCT01955564|Experimental|Cohort 3|NW-3509a 5mg or placebo
3098099|NCT01955564|Experimental|Cohort 4|NW-3509a 10 mg or placebo
3098100|NCT01955564|Experimental|Cohort 5|NW-3509a 20 mg or placebo
3098101|NCT01955564|Experimental|Cohort 6|NW-3509a 30 mg or placebo
3098102|NCT01955629|Experimental|Aflibercept + XELOX (Oxaliplatin and Capecitabine)|Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m^2 q3w and Capecitabine 850 mg/m^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.
3098103|NCT01955707|Experimental|natalizumab|300 mg single intravenous (IV) injection
3098104|NCT01955707|Placebo Comparator|Placebo|A single IV dose of placebo
3098105|NCT01955720|Experimental|healthy subjects aged 45-64|Sequential Crossover to Placebo or BI 655075
3321227|NCT02017314|Active Comparator|Group III|Patients with BMI between 35 and 39.9
3098106|NCT01955720|Experimental|healthy elderly subjects aged 65-80 year|Sequential Crossover to Placebo or BI 655075
3098107|NCT01955720|Experimental|mild renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
3098108|NCT01955720|Experimental|mod renal impairment aged 45-80 years|Sequential Crossover to Placebo or BI 655075
3098109|NCT01955733|Experimental|BI 695500|BI 695500, Two infusions separated by 2 weeks, Intravenous infusion
3098110|NCT01955837|Experimental|TAS-102|
3098111|NCT01955837|Placebo Comparator|Placebo|
3098112|NCT01955954|Experimental|Canary Breathing System|Treatment with Canary Breathing System
3098113|NCT01956032||Participants with Parkinson's disease|"Participants diagnosed with Parkinson's disease and have continued disabling motor complications despite optimized per-oral or other treatment regimens suitable for Duodopa treatment in accordance with the Swedish Summary of Products Characteristics.~Other name for Duodopa is Levodopa Carbidopa Intestinal Gel (LCIG)."
3098114|NCT01956071|Experimental|WAPD|Participants were asked to complete three tasks while simultaneously pedaling at a sustainable and self-selected pace. The three tasks were: 1) compose and send an email; 2) search a topic on the internet, and 3) complete an on-line questionnaire.
3098115|NCT01956097|Experimental|HX106 590mg|HX106 590mg/day
3098116|NCT01956097|Experimental|HX106 1180mg|HX106 1180mg/day
3098117|NCT01956097|Placebo Comparator|Placebo|Placebo
3098118|NCT01956110|Experimental|A|Follitropin Delta (FE 999049)
3098119|NCT01956110|Active Comparator|B|Follitropin Alfa (GONAL-F)
3098120|NCT01956123|Experimental|A|Follitropin Delta (FE 999049) (COS cycle 2)
3098121|NCT01956123|Active Comparator|B|Follitropin Alfa (GONAL-F) (COS cycle 2)
3098122|NCT01956123|Experimental|C|Follitropin Delta (FE 999049) (COS cycle 3)
3098123|NCT01956123|Active Comparator|D|Follitropin Alfa (GONAL-F) (COS cycle 3)
3098124|NCT01956240|Experimental|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
3098125|NCT01956240|Experimental|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
3098126|NCT01956279|Experimental|Pregnenolone (Arm 1)|Pregnenolone
3098127|NCT01956279|Placebo Comparator|Placebo (Arm 2)|Placebo
3098128|NCT01956435|Other|Excimer Light Treatment Right Leg, Control Left Leg|Excimer light treatment will be performed on the right leg of every subject, no treatment on the left or control leg of the subject.
3098129|NCT01956435|Other|Excimer Light Treatment Left Leg, Control Right Leg|Excimer light treatment will be performed on the left leg of every subject, no treatment on the right or control leg of the subject.
3321228|NCT02017314|Active Comparator|Group II|patients with BMI between 30 and 34.9
3098131|NCT01956773|Experimental|MeTree - Patient|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to patients as clinical decision support.
3098132|NCT01956773|Experimental|MeTree - Provider|MeTree collects family health history data and generates risk scores and specific risk-based recommendation for preventive care to providers as clinical decision support.
3098133|NCT01957085||Hospitalized Patients|Observation only. All patients admitted to Temple University Hospital on the study day. Observational only, no intervention.
3098134|NCT01957111||Individuals with insomnia|
3098135|NCT01957111||Good sleepers|
3098136|NCT01957137|Other|Continuous|The device parameter will be continuous.
3098137|NCT01957137|Other|Cycling Parameter #1|The device parameter will be cyclic program #1.
3098138|NCT01957137|Other|Cycling Parameter #2|The device parameter will be cyclic program #2.
3098139|NCT01957137|Other|Cycling Parameter #3|The device parameter will be cyclic program #3.
3098140|NCT01957137|Other|No Stimulation|Following the randomized portion of the study, an assessment was conducted to estimate the effect of a month of no stimulation on incontinence.
3098141|NCT01957150|Experimental|Fluticasone Furoate/Vilanterol 100/25 micrograms (mcg) QD|Subjects will self administer FF/VI 100/25 mcg inhalation powder once daily for 156 weeks via the NDPI.
3098142|NCT01957150|Experimental|Vilanterol 25 mcg QD|Subjects will self administer VI 25 mcg inhalation powder once daily for 156 weeks via the NDPI.
3098143|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via a DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
3098144|NCT01957163|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
3098145|NCT01957163|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
3098146|NCT01957202|Experimental|Arm 1|Each Subject will be assigned to a sequence of three treatments (e.g ABC, BCD, ACD): A=Two, 50 microliter (mcqL) sprays per nostril of FF, total dose 100 microgram (mcg); B=Two, 50 mcqL sprays per nostril of levocabastine, total dose 200 mcg; C=Two, 50 mcql sprays per nostril of FF/levocabastine FDC, total daily dose 100 mcg FF and 200 mcg levocabastine; D=Two, 50 mcql sprays per nostril of placebo. There will be a wash out period of 14-28 days between two treatment periods
3321229|NCT02017314|Active Comparator|Group I|Patients with BMI <30
3321230|NCT02017340|Placebo Comparator|Placebo|250 patients will receive the placebo
3321231|NCT02017340|Active Comparator|Nilvadipine|250 patient will receive the active drug Nilvadipine 8mg
3321232|NCT02017353|Experimental|Curcuphyt|Intake of Curcuphyt capsules, 2 g per day during 2 weeks
3098147|NCT01957215|Experimental|Indomethacin patch|Indomethacin patch to be applied on the sprained ankle twice a day (BID).
3098148|NCT01957215|Placebo Comparator|Placebo patch|Placebo patch to be applied on the sprained ankle BID.
3098149|NCT01957384|Experimental|Treatment 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 1 are randomised to secondly test either:~Coloplast Test product 2 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 2"
3098150|NCT01957384|Experimental|Treatment 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Coloplast Test product 2 are randomised to secondly test either:~Coloplast Test product 1 and thereafter Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)~Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)and thereafter Coloplast Test product 1"
3098151|NCT01957384|Experimental|Treatment 3,First Standard care (see below)|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects first testing Standard Care Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active) are randomised to secondly test either:~Coloplast Test product 1 and thereafter Coloplast Test product 2~Coloplast Test product 2 and thereafter Coloplast Test product 1"
3098152|NCT01957397|Experimental|Coloplast Test 1|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test1 first and thereafter Coloplast Test 2~Finally the all subject test Coloplast Test 3"
3098153|NCT01957397|Experimental|Coloplast Test 2|"The subjects are randomised to two arms~In both arms the subjects start measuring the performance of own product to collect baseline data.~In this arm the subjects are randomised to test Coloplast Test 2 first and thereafter Coloplast Test 1~Finally the all subject test Coloplast Test 3"
3098154|NCT01957410|Experimental|Ketamine Intravenous (IV)|Patients will receive a single IV dose of ketamine given as a continuous infusion.
3098155|NCT01957410|Placebo Comparator|Placebo Intravenous (IV)|Patients will receive a single IV dose of placebo given as a continuous infusion.
3098156|NCT01957462|Experimental|FirstColplast Test V, Then Coloplast Test X|The subject tests two experimental coloplast products in a randomised order. Coloplast Test product V and after cross over ColoplastTest product X
3098157|NCT01957462|Experimental|First Coloplast Test X, Then Coloplast Test V|The subjects test the two experimental Coloplast products in a randomised order: Coloplast Test product X and after cross over Coloplast Test product V
3098158|NCT01957475|Experimental|First Coloplast Test product Z; then Coloplast Test product Y|The subjects first test Coloplast Test product Z and after cross-over Coloplast Test product Y
3098159|NCT01957475|Experimental|First Coloplast Test product Y, Then Coloplast Test product Z|The subjects first test test product Y and after cross-over test product Z
3098160|NCT01957488|Experimental|Treatment sequence 1; First Coloplast Test product 1|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 1 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 2"
3098161|NCT01957488|Experimental|Treatment seqence 2; First Coloplast Test product 2.|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast Test product 2 and secondly test either:~Coloplast Test product 1 and thereafter Coloplast SenSura~Coloplast Sensura and thereafter Coloplast Test product 1"
3098162|NCT01957488|Experimental|Treatment sequence 3, First Coloplast SenSura|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of treatment to periods.~Subjects are first allocated to test Coloplast SenSura and secondly test either:~Coloplast Test product 2 and thereafter Coloplast Test product 1~Coloplast Test product 1 and thereafter Coloplast Test product 2"
3098163|NCT01957553|Experimental|Treatment sequence 1, First Coloplast Test product|Subjects first allocated to Coloplast Test product will after cross-over test SenSura
3098164|NCT01957553|Experimental|Treatment seqence 2; First SenSura|Subjects first allocated to SenSura will after cross-over test Coloplast Test product
3098165|NCT01957579|Experimental|MEDI-551|
3098166|NCT01957644|Experimental|Schedule A|Volasertib (d1 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3098167|NCT01957644|Experimental|Schedule B|Volasertib (d 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3098168|NCT01957644|Experimental|Schedule C|Volasertib (d 1 and 7 - one hour iv.) + Azacitidine 75 mg/m2 once daily on Days 1-7 (7 consecutive days) (28-day cycle)
3098169|NCT01957657|Experimental|Healthy volunteers group 1|Healthy volunteers with normal renal function
3098170|NCT01957657|Experimental|Renal function group 2|Patients with mild renal impairment
3098171|NCT01957657|Experimental|Renal function group 3|Patients with moderate renal impairment
3098172|NCT01957657|Experimental|Renal function group 4|Patients with severe renal impairment
3098173|NCT01957709|Experimental|Basic science (interferon gamma and MHC expression)|Patients receive recombinant interferon gamma subcutaneously weekly for 4 weeks before surgery.
3098174|NCT01957761||Clostridium difficile infection|
3098175|NCT01957787|Experimental|Cryoablation|Participants will undergo a cryoablation procedure with the Galil Medical Cryoablation System according to the manufacturer's guidelines. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators. Tumors in both lungs are to be treated at an appropriate interval, determined on an individual basis. Treatment of bilateral index tumors in a single treatment session will not be performed. All participants will receive cryoablation of up to 6 metastatic lung tumors. Treatment of all study index tumors are to be completed within an 8-week window.
3098176|NCT01957865|Experimental|Fixed SMS, real-time monitoring|SMS will be sent daily for one month, then weekly for two months. Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
3098177|NCT01957865|Experimental|Triggered SMS, real-time monitoring|Participants will have real-time adherence monitoring and social supporters will be notified of gaps in adherence of 48+ hours in the last six months of the study.
3098178|NCT01957865|No Intervention|control|Real-time adherence monitoring only (no SMS)
3098179|NCT01957930|Experimental|Intensified insulin treatment|Basal (Monotard) insulin; ones a day Bolus (Actrapid) insulin; thrice a day
3098180|NCT01957930|Active Comparator|Standard treatment|Mixed Insulin (2-3 times a day)
3098181|NCT01957930|No Intervention|Healthy controls|These people were solely controls for the iontophoresis method used in the study. With no intervention or follow-up-
3098182|NCT01958008|Experimental|BI 113608 low dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3098183|NCT01958008|Experimental|BI 113608 medium dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3098184|NCT01958008|Experimental|BI 113608 high dose b.i.d.|Film-coated tablet, oral administration with 240 mL water
3098187|NCT01958060|Experimental|BI 1034020 intravenous part|single rising doses
3098188|NCT01958060|Experimental|BI 1034020 subcutaneous part|single rising doses
3098189|NCT01958073|Experimental|Conjugated Estrogen Vaginal Cream|Conjugated estrogen vaginal cream 0.5g per vagina 2 times weekly
3098190|NCT01958073|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
3098191|NCT01958073|Placebo Comparator|Placebo|Per vagina
3098192|NCT01958112|Experimental|GSK1120212 (trametinib) and GSK2141795|GSK1120212 (trametinib) 1.5 mg QD + GSK2141795 50 mg QD in 28 day cycles
3098193|NCT01958125|Active Comparator|gammacore|gammacore active device to be used noninvasively to the vagal nerve in the neck.
3098194|NCT01958125|Placebo Comparator|inactive gammacore|same as the active treatment, but without the therapy treatment provided
3098195|NCT01958164|Experimental|Actilyse 2 mg/2 ml|First dose of Actilyse 2mg/2ml will be given at time 0. Second dose will be given at 120 if CVAD function has not been restored.
3098196|NCT01958164|Sham Comparator|Saline solution (NaCl 0.9%)|Saline solution will be given at time 0. First dose of Actilyse 2mg/2ml will be given to patients if CVAD function has not been restored.
3098197|NCT01958281|Experimental|SOF 200 mg + RBV 200 mg (Cohort 1)|Participants with genotype 1 or 3 HCV infection will receive SOF 200 mg (2 × 100 mg tablets) plus RBV once daily for 24 weeks.
3098198|NCT01958281|Experimental|SOF 400 mg + RBV 200 mg (Cohort 2)|Participants with genotype 1 or 3 HCV infection will receive SOF 400 mg (4 × 100 mg tablets or 1 × 400 mg tablet) plus RBV once daily for 24 weeks.
3098199|NCT01958281|Experimental|LDV/SOF (Cohort 3)|Participants with genotype 1 or 4 HCV infection will receive LDV/SOF once daily for 12 weeks.
3098200|NCT01958294|Other|MICHI Neuroprotection System|Subjects enrolled into this study will be male or female subjects who are candidates for carotid angioplasty and stenting, who, after meeting all of the eligibility criteria, undergo transcervical Carotid Artery Stenting with carotid flow reversal using the MICHI Neuroprotection System.
3098201|NCT01958320|Experimental|Early treatment|"Infants randomized to the early treatment group will receive pharmacologic treatment of the PDA to produce PDA closure. Within 24-36 hr following the last treatment dose an echocardiogram will be obtained to document the degree of ductus closure or patency.~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
3098202|NCT01958320|Active Comparator|Conservative Treatment|"Infants randomized to the Conservative Treatment approach will receive no pharmacologic treatment of the PDA but will be followed to determine if they meet criteria for later PDA rescue treatment (Infants will be eligible for rescue treatment of their persistent PDA if they meet the rescue treatment criteria.)~Echocardiograms will be obtained at 1) 10-14 days after study entry (if the PDA was open and of moderate size on the last echocardiogram), and 2) at the time of hospital discharge (if the PDA was open (any size) on the last echocardiogram). The echocardiogram obtained at discharge will be used to determine the need for outpatient follow-up."
3098203|NCT01958346|Sham Comparator|Fiberoptic Intubation Alone|Intubation with fiberoptic scope assistance
3098204|NCT01958346|Experimental|Fiberoptic Intubation with lingual traction|Intubation with fiberoptic scope assistance and lingual traction maneuver provided by a second anesthesiologist
3098205|NCT01958437|Experimental|Cognitively intact older adults - ACTIVE tDCS|Group receives active brain stimulation
3098206|NCT01958437|Active Comparator|MCI ACTIVE tDCS|Group receives active brain stimulation
3098207|NCT01958437|Sham Comparator|Cognitively intact older adults - SHAM tDCS|Group receives sham brain stimulation
3098208|NCT01958437|Sham Comparator|MCI SHAM tDCS|Group receives sham brain stimulation
3098209|NCT01958476|Active Comparator|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
3098210|NCT01958476|Active Comparator|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
3098211|NCT01958489|Experimental|Pravastatin|Single 40 milligram (mg) oral dose of pravastatin administered on Day 1.
3098212|NCT01958489|Experimental|Evacetrapib + Pravastatin|Oral doses of 130 mg evacetrapib administered once daily on Days 2 through 11, with a single oral dose of 40 mg pravastatin coadministered on Day 11.
3098213|NCT01958593|Placebo Comparator|Comparator|Participants will receive placebo during each of two experimental sessions.
3098214|NCT01958593|Experimental|3,4-methylenedioxymethamphetamine|Participants will receive full-dose MDMA during each of two experimental sessions.
3098215|NCT01958606|Experimental|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
3098216|NCT01958606|Active Comparator|Traditional aerobic training|Moderate intensity continuous aerobic exercise on a treadmill
3098217|NCT01958619|Experimental|Treatment A: 1440mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (1440mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3098218|NCT01958619|Experimental|Treatment B: 960mg PQP tablets & 800mg OZ439 + TPGS|Piperaquine phosphate tablets (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3098219|NCT01958619|Experimental|Treatment C: 960mg PQP granules & 800mg OZ439 + TPGS|Piperaquine phosphate granules for oral solution (960mg) and OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3098220|NCT01958619|Experimental|Treatment D: 800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension under fasted conditions.
3098221|NCT01958645|Experimental|A|MEDI8111
3098222|NCT01958645|Placebo Comparator|B|Placebo for MEDI8111
3098223|NCT01958671|Experimental|Ertugliflozin 5 mg/Ertugliflozin 5 mg|Phase A: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 5 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3098224|NCT01958671|Experimental|Ertugliflozin 15 mg/Ertugliflozin 15 mg|Phase A: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Ertugliflozin 15 mg administered once daily for 26 weeks. Participants not rescued with metformin in Phase A, will receive placebo to metformin. Participants rescued with metformin in Phase A will continue to receive metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3098225|NCT01958671|Other|Placebo/Metformin|Phase A: Placebo to ertugliflozin administered once daily for 26 weeks. Participants requiring rescue therapy will receive open-label metformin. Phase B: Participants not rescued with open-label metformin in Phase A will also receive blinded metformin up to twice daily for 26 weeks in addition to placebo. Participants rescued with metformin in Phase A will continue to receive open-label metformin. Participants requiring rescue therapy during Phase B will receive open-label glimepiride.
3098226|NCT01958788|Experimental|Cognitive-Behavioural Treatment|12 sessions of cognitive-behavioral treatment targeting negative beliefs about uncertainty
3098227|NCT01958827|Experimental|Adalimumab 80 mg|All participants were to receive subcutaneous injections of open-label adalimumab 80 mg every other week from Week 0 to Week 50.
3098228|NCT01958918|Experimental|Ranibizumab|1 intravitreal injection monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT signs of wet AMD disease activity
3098229|NCT01958918|Active Comparator|Aflibercept|1 intravitreal injection monthly for the first 3 months, followed by 1 intravitreal injection every 2 months
3098230|NCT01959035|Experimental|Aripiprazole once-monthly|
3098231|NCT01959048|Experimental|fecal microbiota transplant|fecal microbiota transplantation
3098232|NCT01959113|Experimental|Autologous Microbiome Transplant|Each individual's autologous microbiome transplant cream will be applied to one of their arms. This arm is the treatment arm.
3098233|NCT01959113|Placebo Comparator|Placebo Arm|This arm will have a base moisturizer alone applied to it during the third visit.
3098234|NCT01959165|Experimental|MEDI7183 dose 1|Double blinded
3098235|NCT01959165|Experimental|MEDI7183 dose 2|Double blinded
3098236|NCT01959165|Experimental|MEDI7183 dose 3|Double blinded
3098237|NCT01959165|Placebo Comparator|Placebo|Double blinded
3098238|NCT01959178|Experimental|LD127025 MF|Mid add daily disposable soft contact lens worn on a daily wear basis for 1 week.
3098239|NCT01959178|Active Comparator|Air Optix Aqua MF|Medium add daily disposable soft contact lens worn on a daily wear basis for one week.
3098240|NCT01959230|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
3098241|NCT01959230|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
3098242|NCT01959243|Experimental|Brimonidine Tartrate|Participants will apply 1 drop of brimonidine tartrate ophthalmic solution 0.025% into each eye 4 times daily for up to 4 consecutive weeks.
3098243|NCT01959243|Placebo Comparator|Brimonidine Tartrate Vehicle|Participants will apply 1 drop of the vehicle of brimonidine tartrate ophthalmic solution into each eye 4 times daily for up to 4 consecutive weeks.
3098244|NCT01959334|Active Comparator|Glucagon IM|Glucagon dose of 1 milligram (mg) administered intramuscularly (IM).
3098245|NCT01959334|Experimental|Nasal Glucagon (NG|Nasal Glucagon (NG) doses of 3 mg administered intra-nasally.
3098246|NCT01959347|Sham Comparator|Miduretheral Sling (Control)|Miduretheral Sling (Control)
3098247|NCT01959347|Experimental|MUS+BPTx|Miduretheral Sling with behavioral/pelvic floor therapy
3098248|NCT01959412|Experimental|Treatment Period Sequence 1|Indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcgin the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening
3098249|NCT01959412|Experimental|Treatment Period Sequence 2|Indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later 37.5 in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening
3098250|NCT01959412|Experimental|Treatment Period Sequence 3|Indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 55mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo n the evening, 14 days later placebo in the morning + matching placebo in the evening
3098251|NCT01959412|Experimental|Treatment Sequence Period 4|Indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 27.5 mcg in the morning + 27.5 mcg in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening
3098252|NCT01959412|Experimental|Treatment Period Sequence 5|Indacaterol 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later placebo in the morning + matching placebo in the evening, 14 days later 150mcg in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 75 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening
3098253|NCT01959412|Experimental|Treatment Period Sequence 6|Placebo in the morning + matching placebo in the evening, 14 days later indacaterol 37.5 mcg in the morning + matching placebo in the evening, 14 days later 27.5 mcg in the morning + 27.5mcg in the evening, 14 days later indacaterol 55 mcg in the morning + matching placebo in the evening, 14 days later indacaterol 150 mcg in the morning + matching placebo in the evening, 14 days later 75 mcg in the morning + matching placebo in the evening
3098254|NCT01959425|Experimental|Off OAT Group (Test)|Discontinuation of OAT Therapy
3098255|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
3098256|NCT01959464|Experimental|Crinone vaginal progesterone gel|"Crinone is a bioadhesive vaginal gel containing micronized progesterone in an emulsion system containing a water swellable but insoluble polymer, polycarbophil. Crinone 8% is formulated to provide a long-acting vaginal retention, and is prescribed daily. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg of progesterone. The reported time to maximum progesterone concentration is 6.8 +/- 3.3 hours with use of a single dose of Crinone 8%. Absorption half-life is approximately 25-50 hours and an elimination half-life of 5-20 minutes.~On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream."
3098257|NCT01959464|Placebo Comparator|Placebo vaginal gel|The couple will be given a prefilled applicator containing either Crinone gel (progesterone) or placebo vaginal gel, data collection sheets and laboratory requisitions. On the evening of day 3, the female will insert the applicator into the vagina, administer the gel, and have intercourse within 1 hour of insertion of the cream.
3098258|NCT01959490|Experimental|Cohort 1P (HER2 positive)|Patients receive a run-in Pertuzumab treatment of 840 mg IV over 60 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, docetaxel IV, and carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3098259|NCT01959490|Experimental|Cohort 1T (HER2 positive)|Patients receive a run-in Trastuzumab treatment of 8 mg/kg IV over 90 minutes on day -14 followed by Trastuzumab IV over 30-60 minutes and Pertuzumab IV over 30-60 minutes, Docetaxel IV, and Carboplatin IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3098260|NCT01959490|Experimental|Cohort II (HER2 negative)|Patients receive Bevacizumab IV over 30-60 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11; Doxorubicin IV and Cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 3, 5, and 7; and Paclitaxel IV over 3 hours on day 1 of weeks 9, 11, 13, and 15.
3098261|NCT01959503|Experimental|Progel Vascular Sealant|Progel Vascular Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
3098262|NCT01959503|Active Comparator|Gelfoam Plus|Gelfoam Plus Sealant after confirmation of anastomotic leakage during intra-procedure leak test.
3098263|NCT01959516|Experimental|Sequence A ⇒ B|Participants will receive sequence A = glycopyrronium + placebo to tiotropium during 28 days, followed by a 14 day washout period, then sequence B= tiotropium + placebo to glycopyrronium for 28 days.
3098264|NCT01959516|Experimental|Sequence B ⇒ A|Participants will receive sequence B= tiotropium + placebo to glycopyrronium during 28 days, followed by a 14 day washout period, then sequence A= glycopyrronium + placebo to tiotropium for 28 days.
3098265|NCT01959529|Experimental|Insulin degludec (IDeg)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
3098266|NCT01959529|Active Comparator|Insulin glargine (IGlar)|All subjects will continue their current antidiabetic therapy except for the basal insulin component (if any) that will be replaced by the investigational product.
3098267|NCT01959542|Experimental|MRIs and PSA Blood Test|"Visit 1 (8 weeks after starting ADT): PSA blood test and prostate MRI~Visit 2 (6 weeks after starting EBRT): PSA blood test and prostate MRI~Visit 3 (on last day of EBRT): PSA blood test~Visit 4 (6 months after starting ADT): PSA blood test and prostate MRI"
3098268|NCT01959581|Other|Movement enhancing device|Guided play while wearing a movement assisting device
3098269|NCT01959607|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
3098270|NCT01959607|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3098271|NCT01959607|Active Comparator|THS 2.2 then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT gum [Nicorette® 2mg])."
3098272|NCT01959607|Active Comparator|NRT then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT gum [Nicorette® 2mg])~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3098273|NCT01959672|Experimental|Treatment (chemotherapy, oregovomab, SBRT, surgery)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV, leucovorin calcium IV over 30 minutes, and fluorouracil IV over 24 hours on days 1 and 8. Treatment repeats every 3 weeks for 7 courses.~IMMUNOTHERAPY: Patients with CA125 level >= 10 receive oregovomab IV over 15-30 minutes on day 15. Treatment repeats every 3 weeks for 3 courses (weeks 1, 4, 7) and post- radiation therapy for 1 course (week 14). Patients may receive an additional 3 courses concurrently with chemotherapy upon recovery from surgery based on CA125 level. Patients also receive nelfinavir mesylate PO BID for 5 weeks beginning on day 15 of week 9.~STEREOTACTIC RADIATION THERAPY: Beginning in week 11, patients undergo SBRT in 5 fractions over 5 consecutive days. Upon completion of radiation therapy, patients resume nelfinavir mesylate for 14 days (week 12-13). Patients without metastasis and with resectable disease undergo surgery in week 17-18."
3098274|NCT01959685|Experimental|Dose escalting|Placebo, 125 mg Androxal, 250 mg Androxal each given as a single dose
3098275|NCT01959698|Experimental|Treatment (carfilzomib, rituximab, chemotherapy)|Patients receive carfilzomib IV over 10-30 minutes on days 1, 2, 8, and 9; rituximab IV over 3-8 hours on day 3; etoposide IV over 1 hour on days 4-6; carboplatin IV over 1 hour on day 5; and ifosfamide IV over 24 hours on day 5. Treatment repeats every 21-28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3098276|NCT01959841|Experimental|ASP2151(200 mg)|once daily
3098277|NCT01959841|Experimental|ASP2151(400mg)|once daily
3098278|NCT01959841|Experimental|valaciclovir|1000 mg three times daily
3098279|NCT01959880|Other|Primary Augmentation|The Augmentation cohort will include patients who have post-lactational mammary involution or wish general breast enlargement.
3098280|NCT01959880|Other|Primary Reconstruction|"The Reconstruction cohort will include patients with loss of breast due to mastectomy or with deformities secondary to disease, malignancy, trauma, and congenital deformity.~Congenital deformities will include deformities of the breast itself as well as skeletal abnormalities reflected in breast deformity or asymmetry."
3098281|NCT01959880|Other|Revison Augmentation|Patients in this cohort will have had previous breast augmentation with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast augmentation surgery.
3098282|NCT01959880|Other|Revision Reconstruction|Patients in this cohort will have had previous breast reconstruction with silicone or saline filled implants and are having a revision surgery to correct or improve the result of any previous breast reconstruction surgery.
3098283|NCT01959919||Arm 1: Device|
3098284|NCT01959932|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
3098285|NCT01959932|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
3098286|NCT01959932|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
3098287|NCT01959945|Experimental|Study Group 1, Flublok|Participants at 9 years to 17 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
3098288|NCT01959945|Active Comparator|Study Group 2, Fluarix|Participants at 9 years to 17 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
3098289|NCT01959945|Experimental|Study Group 3, Flublok|Participants at 6 years to 8 years of age at enrollment, Flublok® Quadrivalent Influenza Virus Vaccine
3098290|NCT01959945|Active Comparator|Study Group 4, Fluarix|Participants at 6 years to 8 years of age at enrollment, Fluarix Quadrivalent® Influenza Virus Vaccine
3098291|NCT01960075|Active Comparator|Fosphenytoin (FOS)|Administer 20 mg/Kg fosphenytoin intravenously up to a maximum dose of 1500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 1500 fosphenytoin over 10 minutes.
3098292|NCT01960075|Active Comparator|Valproic acid|Administer 40 mg/Kg valproic acid intravenously up to a maximum dose of 3000 mg (75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 3000 valproic acidover 10 minutes.
3098293|NCT01960075|Active Comparator|Levetiracetam|Administer 60 mg/Kg levetiracetam intravenously up to a maximum dose of 4500 mg ( 75 Kg) over 10 minutes. Those weighing more than 75 Kg receive a fixed dose of 4500 levetiracetam over 10 minutes.
3098294|NCT01960114|Experimental|Acetaminophen ER|
3098295|NCT01960114|Placebo Comparator|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
3098296|NCT01960140|Experimental|Simvastatin|Single oral dose of 40 milligrams (mg) simvastatin on Day 1.
3098297|NCT01960140|Experimental|Baricitinib + Simvastatin|Oral doses of 10 mg baricitinib once daily (QD) on Days 3 to 7, with a single oral dose of 40 mg simvastatin coadministered on Day 6.
3098298|NCT01960257|Experimental|DHFS with IS-RM|Digital Health Feedback System (DHFS) Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) over-encapsulated with ingestion sensor - 2 capsules orally daily (QD) administered orally preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
3098299|NCT01960257|Active Comparator|SOC DOT|Isoniazid 300 mg -1 tablet orally QD plus rifampin 300 mg - 2 capsules orally QD, OR Rifamate (combination of isoniazid 150 mg and rifampin 300 mg) - 2 capsules orally QD preferably on an empty stomach first thing in the morning for 10-16 weeks, depending on time left to complete TB treatment.
3098300|NCT01960296|Experimental|Clopidogrel|Continue home dose of clopidogrel into surgery
3098301|NCT01960296|Active Comparator|Discontinue|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
3098302|NCT01960348|Active Comparator|patisiran (ALN-TTR02)|
3098303|NCT01960348|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3098304|NCT01960387|Experimental|Clofarabine and Cytarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5. Cytarabine at a dose of 1g/m2 daily will then be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
3098305|NCT01960400|Active Comparator|GMI + tDCS|Graded motor imagery (GMI) + tDCS
3098306|NCT01960400|Placebo Comparator|GMI + sham TDCS|Graded motor imagery (GMI) + sham tDCS
3098307|NCT01960413|Experimental|Montelukast added to Hydroxyurea|Oral montelukast therapy taken daily for eight weeks with current hydroxyurea regiment
3098308|NCT01960413|Placebo Comparator|Placebo added to Hydroxyurea|Oral placebo taken daily for eight weeks with current hydroxyurea regiment
3098309|NCT01960465|Experimental|African Americans|138 Self identified African American
3098310|NCT01960465|Active Comparator|non African Americans|53 Caucasians and 29 Other race (non African-Americans) Veterans.
3098311|NCT01960530|No Intervention|Endogenous Cortisol|No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3098312|NCT01960530|Other|Dexamethasone|1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP
3098313|NCT01960530|Experimental|Infacort®|20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3098314|NCT01960530|Active Comparator|Hydrocortisone Tablet|20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3098315|NCT01960530|Active Comparator|i.v Hydrocortisone Injection|20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points.
3098316|NCT01960725|Active Comparator|Standard Dosing Group|Group will receive RV5 vaccine at 2, 4, and 6 months of age
3098317|NCT01960725|Experimental|Alternate Dosing Group|Group will receive RV5 vaccine at 2-5 weeks, 2 and 4 months of age
3098318|NCT01960790||Participants who received Humira®|Humira® 40 mg (marketed product) every other week (eow) for subcutaneous injection after initial dosage of 160 mg and 2nd dosage of 80 mg in two weeks after the initial administration
3098319|NCT01960816|Experimental|InFlux System|Intervention: Procedure: thermal coagulation of tissue in the nasal airway
3098320|NCT01960842|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment.~The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour)."
3098321|NCT01960855|Placebo Comparator|Placebo BID|Placebo twice daily (BID) for 12 weeks.
3098322|NCT01960855|Experimental|ABT-494 3 mg BID|ABT-494 3 mg twice daily (BID) for 12 weeks.
3098323|NCT01960855|Experimental|ABT-494 6 mg BID|ABT-494 6 mg twice daily (BID) for 12 weeks.
3098324|NCT01960855|Experimental|ABT-494 12 mg BID|ABT-494 12 mg twice daily (BID) for 12 weeks.
3098325|NCT01960855|Experimental|ABT-494 18 mg BID|ABT-494 18 mg twice daily (BID) for 12 weeks.
3098326|NCT01960907|No Intervention|Observational|"Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.~They will follow their usual care path as provided by their local NHS"
3098327|NCT01960907|Experimental|Interventional|"Patients will receive a system form monitoring their health status.~The system is composed by:~a touch-screen pc for the administration of daily questionnaires~RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern~a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.~Subjects will receive medical treatment following the activation of alarms by the monitoring devices.~Monthly phone interviews will be performed to collect data about their level of utilization of the health care system."
3098328|NCT01960998|Experimental|Telehealth with Pelvic Floor Muscle Training|Participants in this group will participate in an evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 1 month before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively. In addition to the pelvic floor muscle training, content will also include general perioperative care; wetness, odor and skin care management; and outcome measures.
3098329|NCT01960998|Active Comparator|Telehealth without Pelvic Floor Muscle Training|Participants in this group will receive a telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 3 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
3098330|NCT01961089|Experimental|Normal|Arm: Normal eyes Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3098331|NCT01961089|Active Comparator|Mild Cataract|Arm: Eyes with mild cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3098332|NCT01961089|Experimental|Severe cataract|Arm: Eyes with severe cataract Interventions: Galilei Lens Professional, IOLMaster, Lenstar
3098333|NCT01961115|Experimental|Treatment (epacadostat, MELITAC 12.1)|Patients receive epacadostat PO BID on days 1-98 and receive MELITAC 12.1 peptide vaccine ID/SC on days 21, 28, 35, 56, 77, and 98 for up to 3 additional courses in the absence of disease progression or unacceptable toxicity.
3098334|NCT01961167|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
3098335|NCT01961271|Experimental|Buprenorphine transdermal patch|Subjects will be on either 5mg, 10mg, 15mg, 20mg, 25mg, 30mg or 40mg doses for 17 weeks. Dose titration will occur every week for the first 6 weeks, and will be maintained for the next 11 weeks.
3098336|NCT01961297|Experimental|Sodium oxybate|Oral administration of a single dose of sodium oxybate (0.75-2.0 gm)
3098337|NCT01961323|Experimental|Nebivolol|Nebivolol 5 mg (titrated to a maximal dose of 10mg for optimal blood pressure) for 6 months
3098338|NCT01961349|Placebo Comparator|Group 1|Group 1 (placebo group) is treated by Anaesthesiologist
3098339|NCT01961349|Active Comparator|Group 2|Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist
3098340|NCT01961349|Active Comparator|Group 3|Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist
3098341|NCT01961362||Pulmonary fibrosis patients|Patients with pulmonary fibrosis of any cause (idiopathic, connective tissue disease, chronic hypersensitivity pneumonitis)
3098342|NCT01961531|Experimental|Accuboost APBI|28Gy delivered in 5 daily fractions
3098343|NCT01961544|Experimental|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
3098344|NCT01961609|Experimental|Secukinumab (AIN457) 300 mg|Participants self-administered 300 mg secukinumab loading dose subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4, and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks. Participants not meeting this NICE criterion returned to routine treatment under the care of their usual Clinical Team.
3098345|NCT01961609|Experimental|Secukinumab (AIN457) 150 mg|Participants self-administered secukinumab 150 mg loading dose subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then every 4 weeks. Following the Primary Endpoint at 16 weeks, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Participants not achieving the NICE criteria at the Primary Endpoint were up titrated to 300mg. Following assessment at week 48, participants meeting the NICE criteria of adequate response were eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Participants not achieving the NICE criteria at 48 weeks on the 150mg dose were up titrated to 300mg.
3098346|NCT01961687|Other|Resorbable Mesh|Phasix Mesh
3098347|NCT01961882|Experimental|OCV-501 arm|
3098348|NCT01961882|Placebo Comparator|Placebo arm|
3098349|NCT01961921|Experimental|ALN-TTR02 (patisiran)|
3098350|NCT01962025|Active Comparator|Buttonhole needling technique|the intervention is the Buttonhole needling technique for home hemodialysis
3098351|NCT01962025|No Intervention|Step Ladder Group|Patients will use step ladder needling technique
3098352|NCT01962103|Experimental|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle.
3098353|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 120 mg/m^2|nab-paclitaxel 120 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098354|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 150 mg/m^2|nab-paclitaxel 150 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098355|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 180 mg/m^2|nab-paclitaxel 180 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098356|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 210 mg/m^2|nab-paclitaxel 210 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098357|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 240 mg/m^2|nab-paclitaxel 240 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098358|NCT01962103|Experimental|Phase 1: Nab-Paclitaxel 270 mg/m^2|nab-paclitaxel 270 mg/m^2 IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity to establish the RP2D.
3098359|NCT01962103|Experimental|Phase 2: Ewing's Sarcoma|Participants with Ewing's sarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
3098360|NCT01962103|Experimental|Phase 2: Neuroblastoma|Participants with neuroblastoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
3098361|NCT01962103|Experimental|Phase 2: Rhabdomyosarcoma|Participants with rhabdomyosarcoma: nab-paclitaxel at the RP2D (240 mg/m^2 in participants weighing > 10 kg and 11.5 mg/kg in participants weighing ≤ 10 kg) IV on Days 1, 8 and 15 of a 28-day cycle until disease progression, death, withdrawal of consent, or unacceptable toxicity.
3098362|NCT01962207|Experimental|ACWY<2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
3098363|NCT01962207|Experimental|ACWY≥2 Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with MenACWY-TT.
3098364|NCT01962207|Experimental|MenCCRM Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Meningitec.
3098365|NCT01962207|Experimental|MenPS Group|Subjects will receive a dose of MenACWY-TT 10 years after primary vaccination with Mencevax ACWY.
3098366|NCT01962298|Placebo Comparator|Single rocuronium dose - placebo|The patients will receive a single rocuronium dose, and no reversal agent.
3098367|NCT01962298|Active Comparator|Single rocuronium dose - sugammadex|The patients will receive a single rocuronium dose and sugammadex 2mg/kg as a reversal agent
3098368|NCT01962298|Active Comparator|Repeated rocuronium dose - neostigmine|The patients will receive multiple rocuronium doses and neostigmine 70 mcg/kg as a reversal agent
3098369|NCT01962298|Active Comparator|Repeated rocuronium dose - sugammadex|The patients will receive multiple rocuronium doses and neostigmine 2mg/kg as a reversal agent
3098370|NCT01962298|Active Comparator|Continuous rocuronium dose|The participants will receive a continuous rocuronium infusion and sugammadex 4 mg/kg as a reversal agent
3098371|NCT01962428|Experimental|high loading dose of ticagrelor|Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
3098372|NCT01962428|Active Comparator|conventional loading dose of ticagrelor|Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
3098373|NCT01962441|Experimental|SOF+RBV 16 weeks|SOF+RBV for 16 weeks
3098374|NCT01962441|Experimental|SOF+RBV 24 weeks|SOF+RBV for 24 weeks
3098375|NCT01962441|Experimental|SOF+RBV+Peg-IFN 12 weeks|SOF+RBV+Peg-IFN for 12 weeks
3098376|NCT01962441|Experimental|Retreatment Substudy|Participants from the SOF+RBV arms (16 weeks or 24 weeks) who experienced virologic failure on treatment, or during the posttreatment period at or before Posttreatment Week 24 may be eligible to enroll into the Retreatment Substudy to receive SOF+RBV+Peg-IFN for 12 weeks.
3098377|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride toothpaste|Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
3098378|NCT01962493|Active Comparator|Sodium fluoride toothpaste|Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
3098379|NCT01962493|Other|Chlorhexidine digluconate mouthwash|0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes
3098380|NCT01962558|Experimental|VNS Treatment|Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period.
3098381|NCT01962558|Sham Comparator|VNS Control|Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained.
3098382|NCT01962688|Experimental|Handheld ultrasound - inpatient|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy
3098383|NCT01962688|Sham Comparator|Sham ultrasound - inpatient|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding
3098384|NCT01962688|Experimental|Handheld ultrasound - ambulatory|Handheld Ultrasound IVC Diameter Guided Diuretic Therapy Handheld ultrasound of the IVC diameter is used to guide diuretic therapy in the ambulatory setting during normal clinic visits.
3098385|NCT01962688|Sham Comparator|Sham ultrasound - ambulatory|Conventional Symptom Guided Diuretic Therapy conventional clinical care as would occur outside of the study. These patients receive a sham ultrasound to facilitate blinding in the ambulatory setting during normal clinic visits.
3098386|NCT01962714|Experimental|Loving-Kindness Meditation|A 12-week duration, 90-minute per session Loving-Kindness Meditation (LKM) course, taught in groups of 10 participants.
3098387|NCT01962714|Active Comparator|Cognitive Processing Therapy - Cognitive Only|A 12-week duration, 90-minute per session Cognitive Processing Therapy (CPT) course, taught in groups of 10 participants.
3098388|NCT01962870|Placebo Comparator|Placebo|Placebo Nasal Spray
3098389|NCT01962870|Active Comparator|Vasopressin|Vasopressin Nasal Spray
3098390|NCT01962896|Experimental|Erlotinib + sirolimus|
3098391|NCT01962922|Active Comparator|LCP-Tacro|Envarsus XR
3098392|NCT01962922|Active Comparator|Tacrolimus - IR|Tacrolimus
3098393|NCT01962961|Experimental|PharmaNAC 1800 mg|PharmaNAC 900 mg orally twice daily for 8 weeks
3098394|NCT01962961|Experimental|PharmaNAC 3600 mg|PharmaNAC 1800 mg orally twice daily for 8 weeks
3098395|NCT01962961|Placebo Comparator|Placebo|Matching placebo pills given twice daily for 8 weeks
3098396|NCT01962987|Experimental|Diclofenac Sodium 3% gel - Test|The diclofenac sodium 3% test gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Test Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3098397|NCT01962987|Active Comparator|Diclofenac Sodium 3% gel - Reference|The Reference diclofenac sodium 3% gel (Solaraze®) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Reference (Solaraze®) Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3098398|NCT01962987|Placebo Comparator|Placebo gel|The placebo gel (contains no active ingredient) is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough placebo gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
3098399|NCT01963078|Placebo Comparator|PTSD placebo Day 1, Oxytocin Day 2|Participants PTSD will self-administer matching placebo (containing all ingredients except OT) at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3098400|NCT01963078|Experimental|PTSD Oxytocin Day 1, Placebo Day 2|Participants with PTSD will self-administer 24 IUs of OT nasal spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3098401|NCT01963078|Placebo Comparator|Resilient Placebo Day 1, Oxytocin Day 2|Resilient controls will self-administer matching placebo spray at 10:30 a.m. on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3098402|NCT01963078|Experimental|Resilient Oxytocin Day 1, Placebo Day 2|Resilient controls will self-administer 24 IUs of OT nasal spray at 10:30 a.m.on Day 1 of study procedures, approximately 45-minutes prior the scanning sessions. This dose and timing of administration were selected based on similar fMRI studies (Domes, et al., 2007; Domes, et al., 2010; Kirsch, et al., 2005).
3098403|NCT01963091|Experimental|oxytocin|
3098404|NCT01963091|Placebo Comparator|placebo|
3098405|NCT01963117|Experimental|Combined hypertermia and RT|Combined hypertermia and radiothearpy
3098406|NCT01963143|Experimental|Treatment Sequence 1 - Adults|Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3098407|NCT01963143|Experimental|Treatment Sequence 2 - Adults|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days, followed by Gammaplex 5% - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3098408|NCT01963143|Experimental|Pediatrics|Gammaplex 10 - 5 intravenous infusions at a dose of 300 to 800 mg/kg/infusion, given every 21 to 28 days
3098409|NCT01963169|Experimental|TO-BoneHealth Group|The group will use the 8-week TO-BoneHealth program, which includes: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
3098410|NCT01963169|Experimental|TO-BoneHealth Plus Group|The group will use the TO-BoneHealth Plus program intervention, which includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
3098411|NCT01963169|No Intervention|Control Group|No specific intervention will be provided to the control group participants. To keep in contact with participants, a monthly e-mail will be sent to inform them of upcoming follow-up surveys. At the end of the study (upon completion of all five surveys), the control group participants will receive a CD version of the TO-BoneHealth program via mail.
3098412|NCT01963234|Experimental|Seva|Up to 100 patients in each of 3 intervention clinics will receive access to the Seva mobile health system for drug use disorders.
3098413|NCT01963260|Experimental|Part 1: MK-8723 1 mg/kg in Healthy Participants|MK-8723 1 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3098414|NCT01963260|Experimental|Part 1: MK-8723 3 mg/kg in Healthy Participants|MK-8723 3 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3098415|NCT01963260|Experimental|Part 1: MK-8723 10 mg/kg in Healthy Participants|MK-8723 10 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3098416|NCT01963260|Experimental|Part 1: MK-8723 30 mg/kg in Healthy Participants|MK-8723 30 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3098417|NCT01963260|Experimental|Part 1: MK-8723 100 mg/kg in Healthy Participants|MK-8723 100 mg/kg administered as a single IV infusion to healthy participants in Part 1.
3098418|NCT01963260|Placebo Comparator|Part 1: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to healthy participants in Part 1.
3098419|NCT01963260|Experimental|Part 2: MK-8723 10 mg/kg in ITP Participants|MK-8723 10 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3098420|NCT01963260|Experimental|Part 2: MK-8723 30 mg/kg in ITP Participants|MK-8723 30 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3098421|NCT01963260|Placebo Comparator|Part 2: MK-8723 100 mg/kg in ITP Participants|MK-8723 100 mg/kg administered as a single IV infusion to participants with ITP in Part 2.
3098422|NCT01963260|Placebo Comparator|Part 2: Matching Placebo to MK-8723|Matching placebo to MK-8723 administered as a single IV infusion to participants with ITP in Part 2.
3098423|NCT01963403|Active Comparator|EE 30mcg/LNG 150mcg|combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
3098424|NCT01963403|Placebo Comparator|Placebo|Placebo
3098425|NCT01963481|Experimental|Exemestane and cyclophosphamide|"A treatment cycle is defined as 4 weeks:~One tablet (25 mg) of exemestane and one tablet (50 mg) of cyclophosphamide given daily by mouth until disease progression or unacceptable adverse events."
3098426|NCT01963611|Experimental|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3098427|NCT01963611|Experimental|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3098428|NCT01963611|Experimental|Plovamer acetate 10 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
3098429|NCT01963611|Experimental|Plovamer acetate 20 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
3098430|NCT01963611|Active Comparator|Copaxone 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
3098431|NCT01963676|Experimental|transcranial direct current stimulation (tDCS)|13 subjects total. 2mA stimulation for 20 minutes.
3098432|NCT01963676|Sham Comparator|Sham stimulation|13 subjects total. An initial 40sec of stimulation at 2mA followed by a small current pulse every 550msec for the remainder of the 20 minute period.
3098433|NCT01963767|Experimental|NT-020|Participants received two pills of NT-020 plus Biovin (900 mg proprietary formulation of blueberry, carnosine, green tea, plus 200 U Vitamin D3, 40 mg Biovin), with one to be taken in the morning and the other in the evening.
3098434|NCT01963767|Placebo Comparator|Placebo|Subjects took two pills, one in the morning and one in the evening, that were matched in size and shape to the active compound.
3098435|NCT01963793|Other|placebo (left) / aprepitant (right)|placebo (on defined treatment area on left side of the body) / aprepitant (on defined treatment area on right side of the body)
3098436|NCT01963793|Other|aprepitant (left) / placebo (right)|aprepitant (on a treatment area on the left side of the body) / placebo (on a treatment area on the right side of the body)
3098437|NCT01963845|Placebo Comparator|Placebo|Placebo
3098438|NCT01963845|Experimental|Active drug|Sitagliptin 100 mg
3098439|NCT01963923|Experimental|Rehabilitation Group|The rehabilitation group must complete at least 16 sessions of the Pulmonary Rehabilitation Program
3098440|NCT01963923|No Intervention|Control Group|The control group must complete only the outcome measures and continue with their clinical routine as specified by their physicians.
3098441|NCT01964092|Experimental|Individual Placement and Support|Individual Placement and Support (IPS) is a well-defined intervention aiming to help people with disabilities participate in the competitive labor market by working in jobs they prefer with the professional help that they need. IPS actively facilitates job acquisition and provides ongoing support once the client is employed.
3098442|NCT01964092|Active Comparator|Ordinary employment schemes|The control group will receive treatment as usual in terms of the ordinary employment schemes offered to this group, primarily Work with assistance and/or Traineeship in a sheltered business.
3098443|NCT01964105|Experimental|3D Imaging Simulation|Intervention Group: 3D Image Simulation + Standard Preoperative Evaluation Goal: 50 patients
3098444|NCT01964105|No Intervention|Standard Preoperative Evaluation|"Control Group: Patients will receive standard preoperative evaluation (2D imaging).~Goal: 50 patients"
3098445|NCT01964105|Other|Non-Randomized Cohort: 3D Imaging|"Patients who refuse the option of randomization but otherwise meet the inclusion and exclusion criteria will be offered participation in this study as part of a non-randomized cohort.~Goal: 50 Patients"
3098446|NCT01964222|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to patients randomized to the experimental/intervention group.
3098447|NCT01964222|No Intervention|Control|Participants randomized to the control group will receive usual care and will be shown Siteman Cancer Center website about clinical trials.
3098448|NCT01964300|Experimental|Treatment (peginterferon alfa-2b)|Patients receive peginterferon alfa-2b subcutaneously (SC) weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3098449|NCT01964326|Experimental|Atorvastatin calcium 10 mg|
3098450|NCT01964352|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
3098451|NCT01964352|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3098452|NCT01964352|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3098453|NCT01964352|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
3098454|NCT01964378|Experimental|Cebranopadol|Once daily oral administration. 200, 400 or 600 µg film coated tablets. Dosage 200 µg to 1000 µg per day.
3098455|NCT01964378|Active Comparator|Morphine Prolonged Release|Twice daily oral administration. 15, 30 or 45 mg morphine sulfate capsules. Dosage 30 to 150 mg per day.
3098456|NCT01964430|Experimental|nab-Paclitaxel 125 mg/m^2 plus gemcitabine 1000 mg/m2|Participants received nab-Paclitaxel 125 mg/m^2 administered as an intravenous (IV) infusion over 30 to 40 minutes, followed by gemcitabine 1000 mg/m^2 as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
3098457|NCT01964430|Active Comparator|Gemcitabine 1000 mg/m^2|Participants received gemcitabine 1000 mg/m^2 administered as an IV infusion over 30 to 40 minutes on Days 1, 8 and 15 of each 28-day treatment cycle for 6 cycles, unless there was evidence of radiologic disease recurrence, unacceptable toxicity, subject or physician decision, withdrawal of consent, or death.
3098458|NCT01964521|Experimental|Mepilex Transfer Ag|Mepilex Transfer Ag is a transfer dressing designed for low to high exuding wounds and used to prevent microbial growth. It is worn for up to two weeks at a time.
3098459|NCT01964547|Active Comparator|Sativex|"Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.~Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability."
3098460|NCT01964547|Placebo Comparator|Placebo|Oromucosal spray, containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Dose: 100 µL oromucosal spray to be administered up to a maximum of 12 sprays per day. There was an initial dose-titration period during which patients gradually increased their dose of study drug according to individual response and tolerability.
3098461|NCT01964716|Experimental|Multidose Vial Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the multidose vial formulation. Each dose is 0.5 mL
3098462|NCT01964716|Active Comparator|Single-Dose Syringe Group|Subjects will receive three doses of 13-valent pneumococcal conjugate vaccine in the single-dose syringe formulation. Each dose is 0.5 mL
3098463|NCT01964755|Experimental|Chemotherapy + Antiviral-Based Therapy|"Combination Chemotherapy for up to six (6) 21-day cycles and Antiviral-Based Therapy:~Chemotherapy: Up to 6 cycles, 21 days each:~Doxorubicin: 20 mg/m2 intravenously (IV) on Day 1 per study protocol;~Rituximab: 375mg/m2 (optional) IV on Day 1 per study protocol;~Methotrexate: 3.5 gm/m2 IV on Day 2 per study protocol;~Leucovorin: 10 mg/m2 IV starting approximately 24 hours after start of Methotrexate infusion, and then 25 mg orally every 6 hours for at least 10 doses per study protocol;~Antiviral-Based Therapy~Zidovudine: Starting 750 mg/m2 IV on Day 2, then 1200 mg orally twice daily for 10 doses per study protocol;~Hydroxyurea: 1,000 mg orally twice daily starting Day 2 for a total of 10 doses per study protocol."
3098464|NCT01964898|Experimental|BA for cardiac patients who smoke|Behavioral Activation Treatment for cardiac patients who smoke (BAT-CS). Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management after they leave the hospital. BA sessions will occur over the 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
3098465|NCT01964898|Active Comparator|Standard Care|Participant will receive (a) 1 hour of standard smoking cessation counseling in the hospital and (b) 5 packets of printed self-help materials for smoking cessation mailed 1, 3, 6, 9, and 12 weeks after hospital discharge. An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
3098466|NCT01964924|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|"PART 1: Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression continue to Part 2.~PART 2: Patients receive trametinib as in Part 1 and also receive Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3098467|NCT01964950||Alogliptin|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with Sulfonylurea (SU) or without SU within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
3098468|NCT01964963||Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
3098469|NCT01964976||Alogliptin + Biguanides|All participants who received alogliptin 25 milligram (mg), tablets, orally, once daily for up to 12 months along with biguanide or without biguanide within 3 months from the start of administration of alogliptin and during the treatment period of alogliptin as per routine clinical practice were observed in this study.
3098470|NCT01965002|Experimental|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive device that is fully integrated with an MR imaging system and used for the ablation of soft tissue. The treatment process begins with the physician acquiring a set of MR images, identifying 1+ target volume(s) of fibroid tissue to be ablated, and drawing the treatment contours. The therapy planning software computes the type and number of sonications required to treat the defined volume while minimizing total treatment time. MR images taken during the sonication provide a diagnostic quality image of the target tissue and a quantitative, real-time temperature map overlay to confirm the therapeutic effect of the treatment. The transducer is then automatically moved to the succeeding treatment point and the process is repeated until the entire volume has been treated. About 100 individual sonications can be delivered over a 3-hour period to complete a treatment.
3098471|NCT01965067|Active Comparator|C group|normal thermal condition with core temperatures between 36.5°C and 37°C
3098472|NCT01965067|Experimental|H group|mild hypothermia with core temperatures between 34.5°C and 35°C
3098473|NCT01965158|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
3098474|NCT01965158|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
3098475|NCT01965262|Active Comparator|Hema-copolymer Lens|Participants were randomized to wear the Hema-copolymer lens pair for one week during the cross over study.
3098476|NCT01965262|Active Comparator|etafilcon A Lens|Participants were randomized to wear the etafilcon A lens pair for one week during the cross over study.
3098477|NCT01965288|Experimental|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
3098478|NCT01965288|Active Comparator|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating the schedule for the second pair without a washout period.
3098479|NCT01965327|Experimental|Interferon Gamma-1b (ACTIMMUNE)|All individuals in this study will be given active medication (interferon gamma-1b) for 12 weeks. This will be administered according to a dose-escalation schedule.
3098480|NCT01965366|Active Comparator|Dexamethasone + VRE|0.5 mg DEX + virtual reality exposure therapy
3098481|NCT01965366|Placebo Comparator|Placebo + VRE|Placebo + virtual reality exposure therapy
3098482|NCT01965431|Experimental|BI 207127 + Faldaprevir|Tablets/capsules
3098483|NCT01965431|Active Comparator|Moxifloxacin (Avalox®)|Tablets
3098484|NCT01965431|Experimental|BI 207127 placebo + Faldaprevir placebo|Tablets/capsules
3098485|NCT01965535|Experimental|LDV/SOF|LDV/SOF FDC tablet plus placebo to match RBV for 24 weeks
3098486|NCT01965535|Experimental|LDV/SOF + RBV|Placebo to match SOF/LDV FDC plus placebo to match RBV for 12 weeks, followed by LDV/SOF FDC plus RBV for 12 weeks.
3098487|NCT01965561|Experimental|CRoC|Use of Combat Ready Clamp (CRoC)
3098488|NCT01965561|Experimental|AAJT|Use of Abdominal Aortic and Junctional Tourniquet
3098489|NCT01965561|Experimental|JETT|Junctional Emergency Treatment Tool
3098490|NCT01965561|Experimental|SJT|SAM Junctional Tourniquet
3098491|NCT01965600|Experimental|Cohort 1|
3098492|NCT01965600|Experimental|Cohort 2|
3098493|NCT01965652|Experimental|Naldemedine|Participants received 0.2 mg naldemedine tablets orally once daily for 52 weeks.
3098494|NCT01965652|Placebo Comparator|Placebo|Participants received matching placebo tablets orally once daily for 52 weeks.
3098495|NCT01965665|Experimental|Medihoney HCS dressing|weekly Medihoney pin site care until frame removal. Standard size dressings and application technique will be used at each pin site with prefabricated materials.
3098496|NCT01965756|Experimental|Metformin, Then Placebo|Participants first received metformin for 8 weeks, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached. After 8 weeks, subjects were switched to matching placebo for an additional 8 weeks.
3098497|NCT01965756|Experimental|Placebo, Then Metformin|Participants first received placebo for 8 weeks. After 8 weeks, subjects were switched to metformin, according to the following dosing schedule: 500 mg by mouth daily for 1 week, then daily dose (in divided doses) increased by 500 mg per week until a maximum of 2000 mg/d (1000mg twice daily) was reached.
3098498|NCT01965834|Experimental|Fenofibrate Therapy|Fenofibrate orally daily for each 28 day cycle, per study protocol.
3098499|NCT01965860|Experimental|PROSPECT|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire and perform a simple and a complex exercise on the simulator.
3098500|NCT01965860|No Intervention|CONTROL|The trainee will continue clinical education without additional curriculum, but will be allowed to study independently.
3098501|NCT01965860|Experimental|E-LEARNING|the trainee will study four modules of E-learning (basic endovascular skills module, iliac artery module, superficial femoral artery module and postoperative care module). After studying each module the trainee will complete a Multiple Choice Questionnaire, no simulation.
3098502|NCT01965899|Experimental|Insertable Cardiac Monitor Implant|
3098503|NCT01965938|Active Comparator|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
3098504|NCT01965938|Other|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
3098505|NCT01966003|Experimental|ABP 215|Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
3098506|NCT01966003|Active Comparator|Bevacizumab|Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
3098507|NCT01966042|Experimental|Stem Cell Therapy|"All subjects enrolled in the study underwent:~Local Sedation; Bone Marrow Aspiration; Minithoracotomy; Autologous bone marrow mononuclear cells infusion."
3098508|NCT01966068|Experimental|MyAsthma Web Portal|The portal, MyAsthma, will provide asthma education, collect patient-reported outcomes, evaluate medication use and side effects, and track parents' concerns and goals. Parents will log into the web portal each month (for a total of 3 portal visits in 6 months), and the information entered by parents will be shared through the electronic health record with the child's primary care provider.
3098509|NCT01966107|Experimental|Aclidinium Bromide|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
3098510|NCT01966107|Placebo Comparator|Placebo|Two-week washout/run-in period [for patients on a long-acting muscarinic antagonist (LAMA)] followed by a maximum of 36-month double-blind treatment period.
3098511|NCT01966120|Active Comparator|BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with BF-200 ALA.
3098512|NCT01966120|Placebo Comparator|Placebo to BF-200 ALA gel|Photodynamic therapy with BF-RhodoLED in combination with a nanoemulsion gel formulation similar to BF-200 ALA, but without the active ingredient 5-aminolevulinic acid.
3098513|NCT01966159|Experimental|SYNERGY Investigational Device|SYNERGY Stent System
3098514|NCT01966159|Active Comparator|PE Plus Investigational Device|PE Plus Stent System
3098515|NCT01966354|Experimental|Long axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Long axis, in-plane needle:~Jugular vein is ultrasonographically visualized in a longitudinal fashion (long axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
3098516|NCT01966354|Experimental|Short axis, out-of-plane needle|"Ultrasound-guided Internal jugular venous approach~Short axis, out-of-plane needle:~Jugular vein is ultrasonographically visualized in a transverse fashion (short axis) and the needle is inserted perpendicular to the longitudinal axis of the transducer (out-of-plane)."
3098517|NCT01966354|Experimental|Oblique axis, in-plane needle|"Ultrasound-guided Internal jugular venous approach~Oblique axis, in-plane needle:~Jugular vein is ultrasonographically visualized in an oblique axis (intermediate view between long and short axis) and the needle is inserted in the same ultrasound plane, aligned with the longitudinal axis of the transducer."
3098518|NCT01966380|Experimental|Device, dressing|Intervention: Device, Leia dressing
3098519|NCT01966380|Active Comparator|Dressing , device|Intervention: Device: Hydroactive surgical dressing
3098520|NCT01966419|Active Comparator|Ornithine phenylacetate|Participants receive ornithine phenylacetate for up to 5 days via continuous IV infusion in addition to standard of care (SOC)
3098521|NCT01966419|Placebo Comparator|Placebo|Participants receive matching placebo up to 5 days via continuous IV infusion in addition to SOC
3098522|NCT01966432|Other|SBIRT|"This is a single arm, non-randomized study. However, based on participants' substance use status, participants will be categorized into three groups:~Screening group. Patients who screen for no use of cigarettes, alcohol, or other drugs. Patients are re-screened at followup visits.~Screening, Brief Intervention group. Patients who screen positive for cigarette, alcohol, or other drug use.~Screening, Brief Intervention, and Referral to Treatment group. Patients who screen positive for use and have a positive AUDIT-C and/or positive DAST-10 assessment for problematic alcohol or drug use."
3098523|NCT01966445|Experimental|GSK2849330 Part 1|1 hour infusion administered intravenously at intervals of one week or more (escalating doses).
3098524|NCT01966445|Experimental|GSK2849330 Part 2|Intravenous infusion administered at the dose and schedule established in Part 1
3098525|NCT01966458|Experimental|HeartWare® VAS (HVAD)|Implant of HeartWare® Ventricular Assist System
3098526|NCT01966458|Active Comparator|Control LVAD|Implant of FDA-approved LVAD approved for destination therapy
3132612|NCT03440918|Experimental|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
3321233|NCT02017366|No Intervention|Control|Control group = standard of Care regimen: 1000ml = 1000 kCal TPN postop from day 1 until day 7. Oral feeds are started from day 5 onwards if no arguments for clinical leak (cervical anastomosis) or barium swallow is normal. Oral intake consists of regular post gastrectomy diet (building up from fluids over semi-solids to solids) with eventually added high nitrogen energy drinks.
3468993|NCT03890341|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-64530440|Participants will receive single oral dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and midazolam 2 mg with under fed conditions (high fat meal) on Day 1 followed by JNJ-64530440 2,000 mg on Days 6 under fasted conditions ; JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg under fed conditions on Day 13; JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) from Days 14 to 18; single oral dose of JNJ-64530440 2,000 mg plus single oral dose of OC and midazolam 2 mg on Day 19 under fed conditions (high fat meal); and JNJ-64530440 2,000 mg once daily under fed conditions (standard meal) on Days 20 to 22.
3098529|NCT01966718|Experimental|Repository corticotropin injection|Repository corticotropin injection, 80 United States Pharmacopeia (USP) Units per mL, dosed as 1 mL (80 Units) subcutaneous injection every 72 hours for 12 weeks
3468994|NCT03890302|Experimental|Cohort A|0.5 mg/kg study drug, or placebo, administered once
3098531|NCT01966770|Active Comparator|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
3098532|NCT01966770|Active Comparator|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
3098533|NCT01966770|Active Comparator|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
3098534|NCT01966770|Active Comparator|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
3098535|NCT01966770|Active Comparator|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
3098536|NCT01966770|Active Comparator|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
3098537|NCT01966796||PSI II|PSI less than 70 or equal to 70
3098538|NCT01966796||PSI III|PSI 70-90
3098539|NCT01966796||PSI IV|PSI 90-130
3098540|NCT01966796||PSI V|PSI more than 130
3098541|NCT01966809|Experimental|Photofrin photodynamic therapy.|Photofrin photodynamic therapy. Drug - 2.5 mg/kg, light - 240 mJ/cm2.
3098542|NCT01966900|Active Comparator|Group A|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 6; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
3098543|NCT01966900|Active Comparator|Group B|"Biological/Vaccine: CN54gp140 mixed with GLA-AF~Vaccination at Months 0, 1, 2 and 12; each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF"
3098544|NCT01966926|Experimental|Daily Weight Tracking|weighing frequency instructions and tips
3098545|NCT01966926|Experimental|Weekly Weight Tracking|weighing frequency instructions and tips
3098546|NCT01966978|Active Comparator|Control: Metformin, Insulin Detemir, Insulin Aspart|Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
3098547|NCT01966978|Active Comparator|Metformin, insulin determir, Liraglutide|"Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)"
3098548|NCT01967069|Active Comparator|DFD01 Spray|DFD01 Spray twice daily
3098549|NCT01967069|Placebo Comparator|Vehicle Spray|Vehicle Spray twice daily
3098550|NCT01967121|Experimental|'Compex unit's Active Recovery® program'|The Compex electrical stimulation system utilized in this study is intended for external application with electrodes to create a muscular contraction and help enhance recovery after eccentric muscular activity.
3098551|NCT01967121|Other|Ice application|A randomized pre and post-test research design will be used to compare three interventions (control, ice, compex) to alleviate the physical symptoms of delayed-onset muscle soreness (DOMS).
3098552|NCT01967121|No Intervention|Control|This is a control group where subjects will not perform an intervention.
3098553|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Neg|LTBI Negative 3 Doses
3098554|NCT01967134|Experimental|H56:IC31 (15 ug H56) LTBI Pos|LTBI Positive 3 Doses
3098555|NCT01967134|Experimental|H56:IC31 (50 ug H56) LTBI Pos|LTBI Positive 3 Doses
3098556|NCT01967147|Experimental|Systane Balance|Propylene Glycol, 0.6% eye drops, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
3098557|NCT01967147|Active Comparator|Saline|Preservative-Free 0.9% Saline solution, 1 drop in each eye, 4 times per day, during Phase I (Day 0-35), followed by 1 drop in each eye as needed during Phase II (Day 35-90).
3098558|NCT01967173|Experimental|Crossover sequence 1|Flovent Diskus® 250 mcg,followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 100/50 mcg
3098559|NCT01967173|Experimental|Crossover sequence 2|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Flovent Diskus® 100 mcg
3098560|NCT01967173|Experimental|Crossover sequence 3|Flovent Diskus® 100 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
3098561|NCT01967173|Experimental|Crossover sequence 4|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 100 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg
3098562|NCT01967173|Experimental|Crossover sequence 5|Flovent Diskus® 500 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 100/50 mcg
3098563|NCT01967173|Experimental|Crossover sequence 6|Advair Diskus® 250/50 mcg, followed by Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 500 mcg, followed by Flovent Diskus® 250 mcg
3098564|NCT01967173|Experimental|Crossover sequence 7|Flovent Diskus® 250 mcg, followed by Flovent Diskus® 500 mcg, followed by Advair Diskus® 100/50 mcg, followed by Advair Diskus® 250/50 mcg
3468995|NCT03890302|Experimental|Cohort B|2 mg/kg study drug, or placebo, administered once
3098565|NCT01967173|Experimental|Crossover sequence 8|Advair Diskus® 100/50 mcg, followed by Flovent Diskus® 250 mcg, followed by Advair Diskus® 250/50 mcg, followed by Flovent Diskus® 500 mcg
3098566|NCT01967225|Experimental|Tedizolid Phosphate (Sivextro, BAY1192631)|Participants received 200 mg BAY1192631 solution or tablet once daily (intravenous (I.V.) or oral (PO))
3098567|NCT01967225|Active Comparator|Linezolid|Participants received 600 mg Linezolid solution or tablet twice daily, every 12 ± 3 hours (intravenous (I.V.) or oral (PO))
3098568|NCT01967277|Placebo Comparator|Incandescent red light source|A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
3098569|NCT01967277|Active Comparator|Handi-Dome Laser|Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.
3098570|NCT01967342|Experimental|Pain Ed|Pain Education: A psychosocial treatment group focusing on providing core pain education to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
3098571|NCT01967342|Experimental|CBT for Pain|Cognitive-Behavioral Therapy for Pain: A psychosocial treatment group focusing on providing core pain education and cognitive-behavior skills to low-income patients who may not have received this information due to existing barriers that often includes limited health literacy. This condition also included medical treatment as usual.
3098572|NCT01967342|Active Comparator|Usual Care|Usual Care (Medical Treatment-as-Usual: A control/comparison condition in which patients receive on-going standard care at the federally qualified health center partnering in this research. Facets of care may include medication, surgery, chiropractic, and physical therapy, among others, which are available to all patients in all arms.
3098573|NCT01967433|Experimental|Diphenhydramine|Diphenhydramine 50 mg IV 3 minutes prior to administration of other sedatives
3098574|NCT01967433|Placebo Comparator|Placebo|0.9% sodium chloride 10 ml IV 3 minuted prior to administration of other sedatives
3098575|NCT01967537|Experimental|68Gallium DOTATATE imaging|68Gallium DOTATATE imaging
3098576|NCT01967550|Experimental|diclofenac diethylamine, DDEA 2.32% gel|diclofenac diethylamine, DDEA 2.32% gel
3098577|NCT01967550|Placebo Comparator|Placebo|Vehicle control
3098578|NCT01967576|Experimental|1/Arm 1-Axitinib|Axitinib 5 mg twice a day on a 28-day cycle
3098579|NCT01967628|Experimental|Vitamin D3 (cholecalciferol)|Vitamin D3 (1000 international units) daily for 3 months.
3098580|NCT01967628|Placebo Comparator|Sugar capsule|Placebo comparator made of sugar in a capsule
3098581|NCT01967641|Experimental|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be followed at the Substance Use Research Center (SURC) and maintained on 16/4 mg Bup/Nx.
3098582|NCT01967706|Active Comparator|mTHS then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3098583|NCT01967706|Active Comparator|mCC then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
3098584|NCT01967706|Active Comparator|mTHS then NRT|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NRT)"
3098585|NCT01967706|Active Comparator|NRT then mTHS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NRT)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS)."
3098586|NCT01967719|Active Comparator|mTHS 2.2 then mCC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3098587|NCT01967719|Active Comparator|mCC then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
3098588|NCT01967719|Active Comparator|mTHS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mTHS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
3098589|NCT01967719|Active Comparator|NNS then mTHS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of mTHS 2.2)."
3098590|NCT01967732|Active Comparator|THS 2.2 then CC|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of CC)."
3098591|NCT01967732|Active Comparator|CC then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CC)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3098592|NCT01967732|Active Comparator|THS 2.2 then NNS|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of THS 2.2)~Day 2 = wash-out~Day 3 = 2nd intervention (single administration of NNS)"
3098593|NCT01967732|Active Comparator|NNS then THS 2.2|"Each subject will follow the below study design:~Day 0 = Wash-out (1 day)~Day 1 = 1st intervention (single administration of NNS)~Day 2 = wash-out~Day 3 = 2nd intervention (single product use of THS 2.2)."
3098594|NCT01967784|Experimental|Study Group|Participants age 9 to 17 years will receive a dose of Quadrivalent Influenza Vaccine
3468996|NCT03890302|Experimental|Cohort C|4 mg/kg study drug, or placebo, administered once
3468997|NCT03890302|Experimental|Cohort D|8 mg/kg study drug, or placebo, administered once
3098596|NCT01967836|Other|Glad Press 'n Seal|Cohort Subjects will use Glad Press 'n Seal product as a moisture barrier to an IV line
3098597|NCT01967862|Experimental|Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)|Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.
3098598|NCT01967888|Experimental|Reparixin|Solution for intravenous (IV) infusion with active compound
3098599|NCT01967888|Placebo Comparator|Placebo|Physiologic solution
3098600|NCT01967940|Experimental|Part 1 Sentinel Cohort (TAF)|TAF + their current failing ARV regimen for 10 days in Part 1
3098601|NCT01967940|Experimental|Part 1 Randomized Cohort (TAF)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive TAF + their current failing ARV regimen for 10 days in Part 1.
3098602|NCT01967940|Placebo Comparator|Part 1 Randomized Cohort (Placebo)|Following review of safety and efficacy data from the Sentinel Cohort, participants will be randomized to receive placebo + their current failing ARV regimen for 10 days in Part 1.
3098603|NCT01967940|Experimental|Part 2 E/C/F/TAF+ATV|Following a 14-day period to confirm eligibility, participants in the Randomized Cohort TAF group with a > 0.5 log10 decline in HIV-1 RNA and all participants completing the Randomized Cohort Placebo group will receive E/C/F/TAF+ATV for 48 weeks in Part 2. After completion of Part 2, all participants will be eligible to continue to receive E/C/F/TAF plus ATV in the extension phase until E/C/F/TAF becomes commercially available, or until Gilead Sciences terminates development of E/C/F/TAF in the applicable country.
3098604|NCT01968031|Experimental|Istradefylline 20 mg/day|"Istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3098605|NCT01968031|Experimental|Istradefylline 40 mg/day|"Istradefylline 40 mg and placebo to match istradefylline 20 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3098606|NCT01968031|Placebo Comparator|Placebo|"Placebo to match istradefylline 20 mg and placebo to match istradefylline 40 mg:~A daily, oral, double-blind treatment dose of both tablets will be taken in the morning for 12 weeks."
3098607|NCT01968057|Experimental|Baricitinib|Single oral dose of 4 milligrams (mg) baricitinib on Day 1
3098608|NCT01968057|Experimental|Baricitinib + Ciclosporin|Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4
3098609|NCT01968070|Experimental|LY3127760 (Single)|Single oral dose of up to 900 milligram (mg) LY3127760 administered in up to 3 of 3 study periods.
3098610|NCT01968070|Placebo Comparator|Placebo (Single)|Single oral dose of placebo administered in up to 2 of 3 study periods. Placebo matches LY3127760 in appearance.
3098611|NCT01968070|Experimental|LY3127760 (Multiple)|Multiple ascending oral doses of up to 900 mg LY3127760 administered once or twice daily (QD or BID) for 28 days.
3098612|NCT01968070|Placebo Comparator|Placebo (Multiple)|Multiple oral doses of placebo administered QD or BID for 28 days. Placebo matches LY3127760 in appearance.
3098613|NCT01968070|Active Comparator|Celecoxib (Multiple)|Multiple oral doses of 400 mg celecoxib administered QD for 28 days.
3098614|NCT01968135|Placebo Comparator|Sugar Pill|Placebo Sugar Pill
3098615|NCT01968135|Experimental|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
3098616|NCT01968213|Experimental|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3098617|NCT01968213|Placebo Comparator|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3098618|NCT01968317|Experimental|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
3098619|NCT01968317|Experimental|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
3098620|NCT01968356|Experimental|3M CHG/IPA Prep Colorless|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098621|NCT01968356|Experimental|3M CHG/IPA Prep Tint|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098622|NCT01968356|Active Comparator|ChloraPrep Hi-Lite Orange|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098623|NCT01968356|Placebo Comparator|Normal Saline|Applied topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098624|NCT01968382|Experimental|IMM 124-E 2400 mg/day|Imm-124-E (2400 mg/day) will be provided in two divided doses daily in the form of powder to be mixed with water. Subjects will get 1 active drug powder and 1 placebo powder with each dosing for a total of 4 sachets daily.
3098625|NCT01968382|Experimental|IMM 124-E 4800 mg/day|Imm-124-E (4800 mg/day) will be provided in two divided doses daily in the form of 2400 mg in the form of a powder to be mixed with water. The total number daily will be 4 sachets.
3098626|NCT01968382|Placebo Comparator|Placebo (High protein milk powder)|Subjects will receive 2 sachets of placebo powder to be mixed with water in the morning and 2 sachets of placebo powder (to be mixed with water) in the evening for a total of 4 sachets of placebo daily.
3098627|NCT01968421|Experimental|OM-85|The subjects will be randomly received two courses of 7mg of OM-85 to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
3098628|NCT01968421|Placebo Comparator|Placebo|The subjects will be randomly received two courses of 7mg of matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
3098629|NCT01968434|Experimental|protective cough syrup|"syrup containing honey, plantago lanceolata, grindelia robusta, helichrysum italicum ina syrup form. The cough syrup is a CE marked medical device acting in a non pharmacological way to reduce cough.~Dosage: 20 ml divided in three doses per day for the duration of the study (4 nights, 3 days)"
3098630|NCT01968434|Active Comparator|carbocisteine cough syrup|Dosage 20-25 mg/kg/day three times a day (3 days/4 nights)
3098631|NCT01968447|Experimental|hypocapnia|arterial pCO2 of 3.5 kPa
3098632|NCT01968447|Active Comparator|normocapnia|arterial PCO2 of 6.5-7.0 kPa
3098633|NCT01968551|Experimental|Cohort 1|"Participants will receive E/C/F/TAF FDC + DRV once daily with food for 48 weeks.~Based on safety and efficacy data from Cohort 1 at Week 4, the participants will be randomized into Cohort 2. The participants in Cohort 1 will continue receiving E/C/F/TAF FDC + DRV through 48 weeks."
3098634|NCT01968551|Experimental|Cohort 2, Treatment Group 1|Participants will be randomized to receive E/C/F/TAF FDC+DRV once daily with food for 48 weeks.
3098635|NCT01968551|Active Comparator|Cohort 2, Treatment Group 2|Participants will be randomized to continue on their baseline DRV-containing ARV regimen for 48 weeks.
3098636|NCT01968694|Experimental|IV Lidocaine|IV lidocaine dosed at 8mg/kg IV (maximum 500 mg) and infused over 30 minutes
3098637|NCT01968694|Placebo Comparator|IV diphenhydramine|IV diphenhydramine 50mg total dosed as a 10mg IV bolus and then 40mg IV infusion over 30 minutes
3098638|NCT01968707|Active Comparator|ChloraPrep Hi-Lite Orange|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098639|NCT01968707|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098640|NCT01968707|Experimental|3M CHG/IPA Prep Tint 10.5 mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098641|NCT01968707|Experimental|3M CHG/IPA Prep Tint 26-mL|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3098642|NCT01968811|Experimental|Avance foam, abdominal dressing kit|
3098643|NCT01968954|Experimental|Bococizumab (PF-04950615;RN316)|
3098644|NCT01968954|Placebo Comparator|Placebo|
3098645|NCT01968967|Experimental|Bococizumab (PF-04950615; RN316)|
3098646|NCT01968967|Placebo Comparator|Placebo|
3098647|NCT01968980|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
3098648|NCT01968980|Placebo Comparator|Placebo|
3098649|NCT01969058|Active Comparator|Isotretinoin Arm|Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
3098650|NCT01969058|No Intervention|No study treatment Arm|No Isotretinoin treatment
3098651|NCT01969084|Experimental|Linagliptin|Subjects given Linagliptin
3098652|NCT01969084|Placebo Comparator|Sugar pill|Subjects given sugar pill/placebo
3098653|NCT01969162||All Participants|Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
3098654|NCT01969201|Experimental|Fostimon®|75 IU/vial, powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone,IBSA Institut Biochimique SA)
3098655|NCT01969201|Active Comparator|Gonal-F®|75 IU/vial powder and solvent for solution for subcutaneous injection (Follicle Stimulating Hormone; Merck Serono)
3098656|NCT01969214|Experimental|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water,to be taken orally~1 tablet, 3 times a day"
3098657|NCT01969240|Active Comparator|Chest Pain Choice Decision Aid|Patients randomized to the decision aid arm.
3098658|NCT01969240|No Intervention|Usual Care|Patients randomized to the usual care arm (no decision aid used)
3098659|NCT01969409|Placebo Comparator|Placebo|These subjects will receive i.v. placebo (5% dextrose in water) administered identically to the rituximab.
3098660|NCT01969409|Experimental|Rituximab|Rituximab i.v. given on two occasions, with 14 days between doses.
3098661|NCT01969435|Experimental|Melphalan, carmustine, etoposide, cytarabine (BEAM)|"Day -7, carmustine intravenous (IV) infusion~Days -6, -5, -4, and -3, etoposide and cytarabine (IV) infusions twice a day~Day -2, melphalan HCl (propylene glycol-free)(IV) infusion~Day 0, stem cell transplant."
3098662|NCT01969448|Active Comparator|Inframammary Fold Incision Cohort|"Inframammary fold incision which is in the crease under the breast.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3098663|NCT01969448|Active Comparator|Lateral Radial Incision Cohort|"Lateral radial incision~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3098664|NCT01969448|Other|Non-Randomized Cohort|"Patients in which the surgeon feels that for oncologic reasons must have a specific incision (either inframammary fold or lateral radial incision) and cannot be randomized due to concerns of compromising clinical care but otherwise meet the inclusion and exclusion criteria will be offered participation as part of a non-randomized cohort.~Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)~Intraoperatively prior to mastectomy~At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)~Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)"
3098665|NCT01969500|Active Comparator|Treatment as Usual|Treatment as usual includes outpatient case management, linkage to services and medication monitoring.
3098666|NCT01969500|Experimental|Mobile Application|Mobile Application system designed to improve coping with psychotic symptoms, social functioning, and medication adherence.
3098667|NCT01969539|Experimental|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
3098668|NCT01969539|Experimental|Combivent Respimat - ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation with /CVT-R via ventilator adapter
3098669|NCT01969708|Active Comparator|aflibercept|2.0 mg aflibercept every 4 weeks
3098670|NCT01969708|Active Comparator|bevacizumab|1.25 mg bevacizumab every 4 weeks
3098671|NCT01969721|Experimental|T+O FDC dosage 1|Low dose
3098672|NCT01969721|Experimental|T+O FDC dosage 2|High dose
3098673|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 1|Low dose
3098674|NCT01969721|Active Comparator|ICS/LABA FDC Dosage 2|High dose
3098675|NCT01969747|Experimental|Empagliflozin low|Empagliflozin low once daily
3098676|NCT01969747|Experimental|Empagliflozin medium|Empagliflozin medium once daily
3098677|NCT01969747|Experimental|Empagliflozin high|Empagliflozin high once daily
3098678|NCT01969747|Placebo Comparator|Placebo|Placebo once daily
3098679|NCT01969799|Experimental|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System.
3098680|NCT01969799|Placebo Comparator|Aerosolized placebo|Aerosolized placebo twice daily for 10 days administered using the eFlow Inline System
3098681|NCT01969812|Experimental|Evie Slow-Release Insemination Device|Preliminary studies in Europe have shown increased pregnancy rates using slow-release insemination. Evie slow-release insemination device is a device that is FDA approved. This device has been used in Europe, it has not yet been used at Carolinas Medical Center, by the Women's Institute. The technique for using this device involves loading a pump syringe with the prepared sperm, placing a balloon-secured catheter and syringe in the patient's sounded uterus, and connecting the insemination syringe to the catheter. The slow-release insemination occurs for 4 hours after the insertion of the catheter. The removal procedure, which can be performed by the patient if desired, involves deflating the catheter balloon and removing the catheter.
3098682|NCT01969812|Active Comparator|Traditional Intrauterine Insemination|Traditional IUI is one of the treatment modalities for infertility that allows sperm to bypass the cervix and shortens the distance to the fallopian tubes for fertilization. The pregnancy rates for IUI with clomiphene citrate for couples with relatively unexplained infertility have been found to be 7.6% (for women 21-39 years old with up to 3 cycles of IUI with clomiphene).
3098683|NCT01969851|Experimental|Lacosamide|
3098684|NCT01969916|Other|Regadenoson|
3098685|NCT01970007|Experimental|Zilver Vena Venous Self-Expanding Stent|
3098686|NCT01970176|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
3098687|NCT01970176|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
3098688|NCT01970241|Experimental|NPH with steroid dose|"Receive NPH with each corticosteroid dose during the study duration (2-5 days).~Low dose corticosteroids High dose corticosteroids Eating and 6a-8p 0.15 units NPH/kg 0.3 units NPH/kg NPO(nothing by mouth) or 8p-6a 0.1 units NPH/kg 0.2 units NPH/kg"
3098689|NCT01970241|Active Comparator|Control - Background and correction insulin|Receive usual care with background insulin and correction factor for duration of study (2-5 days)
3098690|NCT01970371|Experimental|Plazomicin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received 15 milligram per killogram (mg/kg) plazomicin therapy (plus meropenem or tigecycline) as a 30-minute intravenous (IV) infusion once daily for 7 to 14 days.
3098691|NCT01970371|Active Comparator|Colistin in Combination with Meropenem or Tigecycline|Cohort 1: Patients received a 5 mg/kg IV loading dose (300 mg maximum) colistin (plus meropenem or tigecycline) followed by a 5 mg/kg/d maintenance dose divided into every 8 hours (q8h) or every 12 hours (q12h) for 7 to 14 days.
3098692|NCT01970371|Experimental|Plazomicin in Combination with Adjunctive Antibiotic|Cohort 2: Patients received 15 mg/kg as a 30 minute IV infusion once daily. BSI, HABP or VABP patients received plazomicin and any supplemental antibiotic therapy, according to Investigator's choice, for 7 to 14 days. cUTI or AP patients received plazomicin monotherapy only for 4 to 7 days with an option to switch to oral therapy on or after Day 5.
3098693|NCT01970397|Experimental|JUVEDERM® Ultra XC|Perioral lines treated with JUVEDERM® Ultra XC
3098694|NCT01970397|Experimental|Belotero Balance®|Perioral Lines treated with Belotero Balance®
3098695|NCT01970475|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
3098696|NCT01970475|Active Comparator|Adalimumab|Participants received adalimumab 40 mg subcutaneously on day 1 and every 2 weeks thereafter until week 22.
3098697|NCT01970488|Experimental|ABP 501|"Participants received 80 mg ABP 501 subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~Participants with a PASI 50 response at week 16 continued to receive 40 mg APB 501 until week 48."
3098698|NCT01970488|Active Comparator|Adalimumab|"Participants received 80 mg adalimumab subcutaneously on week 1/day 1 (initial loading dose) and 40 mg at week 2 and every 2 weeks thereafter until week 16.~At week 16 participants with a PASI 50 response were re-randomized to treatment with adalimumab or were transitioned to ABP 501 until week 48."
3098699|NCT01970527|Experimental|Treatment (stereotactic body radiotherapy, ipilimumab)|Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3098700|NCT01970540|Experimental|lurbinectedin (PM01183) / doxorubicin|
3098701|NCT01970592|Experimental|POWER|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking.
3098702|NCT01970787|Experimental|RFA|Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions
3098703|NCT01970865|Experimental|PF-06463922|
3098704|NCT01970865|Other|Crizotinib|ALK+ NSCLC patients who are treatment naïve may be eligible to receive crizotinib following PF-06463922 as a substudy to the main study.
3098705|NCT01970878|Experimental|GFF MDI (PT003)|
3098706|NCT01970878|Experimental|GP MDI (PT001)|
3098707|NCT01970878|Experimental|FF MDI (PT005)|
3098708|NCT01970878|Active Comparator|Open-label tiotropium bromide inhalation powder|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
3098709|NCT01970943|No Intervention|No Intervention|PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.
3098710|NCT01970943|Placebo Comparator|Saline Injection (Placebo)|PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.
3098711|NCT01970982|Experimental|Tobacco Heating System (THS 2.2)|Ad libitum use of THS 2.2 for 5 days in confinement
3098712|NCT01970982|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 days in confinement
3098713|NCT01970982|Active Comparator|Conventional cigarette (CC)|Ad libitum use of Subject's own preferred brand of CC for 5 days in confinement
3098714|NCT01970995|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3098715|NCT01970995|Active Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3098716|NCT01970995|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting
3098717|NCT01971086||acute rhinitis|
3098718|NCT01971203|Experimental|seroquel xr|quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day 16 weeks of treatment including CBT
3098719|NCT01971203|Placebo Comparator|placebo plus CBT|treatment group receiving placebo pill plus CBT
3098720|NCT01971255|Experimental|High Titer (HAI > or = 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of ≥1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3098721|NCT01971255|Experimental|Low Titer (HAI < 1:40)|Subjects with prechallenge hemagglutination inhibition (HAI) titers of <1:40 were assigned to this group. The human challenge virus, Ca/04/2009/H1N1r Challenge Virus, will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
3098722|NCT01971346|Other|Etanercept|100 mg Etanercept injections per week for 3 months.
3098723|NCT01971385|Active Comparator|2% Squaric Acid Sensitization|2% Squaric Acid solution will be applied for sensitization to the inner arm.
3098724|NCT01971385|Placebo Comparator|Placebo Solution|Patients in placebo group will be given dimethyl sulfoxide.
3098725|NCT01971463|Experimental|Normal Saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
3098726|NCT01971476|Experimental|All patients|Volasertib will be administered as intravenous infusion
3098727|NCT01971554|Experimental|MK-8666 50 mg|MK-8666, 50 mg, oral, once a day (QD) for Days 1 to 14.
3098728|NCT01971554|Experimental|MK-8666 150 mg|MK-8666, 150 mg, oral, QD, for Days 1 to 14
3098729|NCT01971554|Experimental|MK-8666 500 mg|MK-8666, 500 mg, oral, QD for Days 1 to 14
3098730|NCT01971554|Placebo Comparator|Placebo|Placebo, oral, QD for Days 1 to 14
3098731|NCT01971567|Active Comparator|HIRREM|High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM) is a novel, noninvasive, electroencephalic-based feedback technology to facilitate relaxation and auto-calibration of neural oscillations by using auditory tones to reflect brain frequencies in near real time.
3098732|NCT01971567|Placebo Comparator|Placebo|Subjects in this arm will receive a sham-HIRREM placebo, for which the scalp sensors have no active recording capability, and for which the auditory tonal feedback is randomly generated rather than based on current brain frequencies and amplitudes.
3098733|NCT01971580|Other|Ambrisentan first, Placebo second|These patients will be randomized to have ambrisentan during the first study period, and placebo during the second study period.
3098734|NCT01971580|Other|Placebo first, Ambrisentan second|These patients will be randomized to have placebo during the first study period, and ambrisentan during the second study period.
3098735|NCT01971593|Other|Eplerenone after drug free period|Patients will be given eplerenone 50mg for 12 months after an initial 3 month drug free period
3098736|NCT01971593|Other|Eplerenone before drug free period|Patients will be given eplerenone 50mg for 12 months, followed by a 3 month drug free period
3098737|NCT01971645|Experimental|Group D|Group D patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) with 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) perineurally for their femoral block. Group D will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
3098738|NCT01971645|Placebo Comparator|Group R|Group R patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group R will also receive a gluteal intramuscular injection of saline of volume equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml).
3098739|NCT01971645|Active Comparator|Group M|Group M patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) combined with a volume of saline equivalent to 0.1 mg/kg preservative-free dexamethasone (max. volume 0.4 ml) perineurally. Group M will also receive a gluteal intramuscular injection of 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg).
3098740|NCT01971723|Active Comparator|T+ Supplement|This arm requires the participants to take a prescribed dose of the T+ supplement for 4 weeks while completing an exercise regiment.
3098741|NCT01971723|Placebo Comparator|Placebo|This arm requires the participants to take a prescribed dose of a calorie matched placebo for 4 weeks while completing an exercise regiment.
3098742|NCT01972061|Experimental|CMG group|Foot stimulation will be applied during a cystometrogram (CMG).
3098743|NCT01972061|Active Comparator|3 hours group|Foot stimulation will be applied daily for 3 hours in the evening.
3098744|NCT01972061|Active Comparator|1/2 hour group|Foot stimulation will be applied daily for 1/2 hour in the evening.
3098745|NCT01972061|Active Comparator|3 hour hand group|Hand stimulation will be applied daily for 3 hours in the evening.
3098746|NCT01972074|Experimental|Memantine|"Participants in the placebo arm will receive placebo (no active ingredients) in capsule form twice daily. It will be administered twice daily for 12 weeks. Participants will undergo neuroimaging before and after the 12-week treatment phase.~Placebo: Capsule"
3098747|NCT01972074|Placebo Comparator|Placebo|"Participants in the memantine arm will receive memantine in capsule form twice daily. It will be administered twice daily for 12 weeks (including a 4-week titration phase to a maximum dose of 20 mg per day). Participants will undergo neuroimaging before and after the 12-week treatment phase.~Memantine: Capsule"
3098748|NCT01972074|No Intervention|Control Group|Healthy controls will undergo neuroimaging twice (12 weeks apart) and will receive no intervention during the 12-week window.
3098749|NCT01972152|Experimental|G-Pen(TM) 1 mg|G-Pen(TM) (glucagon injection), single 1 mg subcutaneous (SC) injection
3098750|NCT01972152|Experimental|G-Pen(TM) 0.5 mg|G-Pen(TM) (glucagon injection), single 0.5 mg SC injection
3098751|NCT01972152|Active Comparator|Lilly Glucagon(TM) 1 mg|Lilly Glucagon(TM) [glucagon for injection (rDNA origin)], single 1 mg SC injection
3098752|NCT01972204|Experimental|Intensive adherence instruction|Intensive adherence instruction group will receive 5 visits and receive the instruction on the use of Aricept with educational brochure
3098753|NCT01972204|Sham Comparator|Control|The control group will receive 5 visits and receive the instruction on the use of Aricept as per usual practice.
3098754|NCT01972217|Active Comparator|Olaparib|200 mg or 300 mg bid
3098755|NCT01972217|Placebo Comparator|Placebo|placebo to match olaparib bid
3098756|NCT01972308|Experimental|Patient advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients.
3098757|NCT01972308|Other|usual care|Patient receives asthma care as usual from their asthma provider
3098758|NCT01972438|Experimental|ASEDs - Saline|Participants administer autologous serum eye drops (ASEDs) daily for the first three months, then crossover to administer control (normal saline) eye drops daily beginning at Month 3 through Month 6.
3098759|NCT01972438|Placebo Comparator|Saline - ASEDs|Participants administer control (normal saline) eye drops daily for the first three months, then crossover to administer autologous serum eye drops (ASEDs) daily beginning at Month 3 through Month 6.
3098760|NCT01972464|Placebo Comparator|placebo|In this group women will receive a placebo pill which will appear similar to progesterone and will be inert.
3098761|NCT01972464|Experimental|Progesterone|In this group women will receive oral micronized progesterone twice a day.
3098762|NCT01972516|Experimental|Tivozanib|Tivozanib hydrochloride will be administered orally, at a dose of 1.5 mg/day, beginning on Day 1 of Cycle 1. Subjects will receive tivozanib hydrochloride once daily for 3 weeks followed by 1 week off treatment. One cycle is defined as 4 weeks. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicities.
3098763|NCT01972516|No Intervention|Standard Care|Participants in the non-interventional arm will not receive study treatment, and will receive standard clinical observation and study assessments. Patients will continue to be observed in the absence of disease progression or unacceptable toxicities.
3098764|NCT01972529|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3098765|NCT01972529|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3098766|NCT01972529|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
3098767|NCT01972529|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3098768|NCT01972568|Experimental|Atacicept 75 mg|
3098769|NCT01972568|Experimental|Atacicept 150 mg|
3098770|NCT01972568|Placebo Comparator|Placebo|
3098771|NCT01972659|Active Comparator|sugammadex and placebo|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 placebo: isotonic saline (%0.9 NaCl) 50 mg/kg iv bolus plus 15 mg/kg continuous infusion until the end of surgery
3098772|NCT01972659|Experimental|sugammadex and magnesium sulphate|sugammadex: 4 mg/kg iv bolus at the end of the surgery at a TOF count of 1 magnesium: 50 mg/kg iv bolus plus continuous infusion until the end of surgery
3098773|NCT01972724|Experimental|Pioglitazone 15 mg (Double-Blind)|Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3098774|NCT01972724|Experimental|Pioglitazone 30 mg (Double-Blind)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3098775|NCT01972724|Experimental|Pioglitazone 30 mg (Open-Label)|Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea administered according to the prescribing information of the approved Korean label, for up to 24 weeks.
3098776|NCT01972776|Experimental|QBM076 Part 1 Cohort 1|Participants received QBM076 25 mg twice daily (bid) for 14 days.
3098777|NCT01972776|Experimental|QBM076 Part 1 Cohort 2|Participants received QBM076 75 mg bid for 14 days.
3098778|NCT01972776|Experimental|QBM076 Part 1 Cohort 3|Participants received QBM076 150 mg bid for 14 days.
3098779|NCT01972776|Placebo Comparator|Placebo Part 1|Participants in each cohort received matching placebo for 14 days.
3098780|NCT01972776|Experimental|QBM076 Part 2|Participants received QBM076 150 mg bid for 8 weeks.
3098781|NCT01972776|Placebo Comparator|Placebo Part 2|Participants received matching placebo for 8 weeks.
3098782|NCT01972789|Experimental|Intensive retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of any IRF or SRF on OCT.
3098783|NCT01972789|Experimental|Relaxed retinal fluid regimen|Ranibizumab 0.5mg is given monthly for the first 3 months followed by an individualised treatment regimen as determined by disease activity defined by a loss of ≥5 letters, new retinal haemorrhage, presence of IRF or SRF >200 um on OCT.
3098784|NCT01972841|Experimental|1: Solifenacin 5 mg + Mirabegron 25 mg|Participants who received solifenacin 5 mg and mirabegron 25 mg once a day for 12 weeks.
3098785|NCT01972841|Experimental|2: Solifenacin 5 mg + Mirabegron 50 mg|Participants who received solifenacin 5 mg and mirabegron 50 mg once a day for 12 weeks.
3098786|NCT01972841|Placebo Comparator|3: Placebo|Participants who received matching placebo once a day for 12 weeks.
3098787|NCT01972841|Active Comparator|4: Solifenacin 5 mg|Participants who received solifenacin 5 mg once a day for 12 weeks.
3098788|NCT01972841|Active Comparator|5:Mirabegron 25 mg|Participants who received mirabegron 25 mg once a day for 12 weeks.
3098789|NCT01972841|Active Comparator|6: Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day for 12 weeks.
3098790|NCT01973036|Active Comparator|Oxytocin|This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
3098791|NCT01973036|Experimental|Foley Catheter and Oxytocin|A 30cc/16 French (16F) foley catheter will be inserted by the provider under direct visualization or by palpation, ensuring that the catheter is appropriately and adequately positioned. Oxytocin will be administered concurrently at a rate of 2 milliunits/milliliter (as noted under oxytocin active comparator). If the catheter remains in place after 12 hours, it will be deflated and removed and oxytocin infusion will continue.
3098792|NCT01973205|Placebo Comparator|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
3098793|NCT01973205|Experimental|Acetaminophen 250 mg and aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and aspirin 250 mg
3098794|NCT01973218|Experimental|rMenB|Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
3098795|NCT01973218|Active Comparator|Placebo/MenACWY|Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.
3098796|NCT01973231|Experimental|Metformin + liraglutide 1.8 mg|
3098797|NCT01973231|Active Comparator|Metformin + lixisenatide 20 microg|
3098798|NCT01973283|Experimental|Medication Treatment|Participants are treated with a flexible-dose antidepressant medication for a period of 8 weeks.
3098799|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for both study interventions (acetazolamide and upfront spironolactone).~See interventions for more details."
3098800|NCT01973335|Experimental|High-dose loop diuretics, upfront spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with upfront spironolactone. This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide.~See interventions for more details."
3098801|NCT01973335|Experimental|Acetazolamide/low-dose loop diuretics, no spironolactone|"2x2 factorial design: This group is the experimental group for the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
3098802|NCT01973335|Active Comparator|High-dose loop diuretics, no spironolactone|"2x2 factorial design: This group receives high-dose loop diuretics as an active comparator to the study intervention with acetazolamide. This group receives no intervention with regards to the spironolactone arm.~See interventions for more details."
3098803|NCT01973348|Experimental|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
3098804|NCT01973348|Active Comparator|2-hour eye patching|2-hour eye patching for moderate amblyopia
3098805|NCT01973348|Experimental|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
3098806|NCT01973348|Active Comparator|6-hour eye patching|6-hour eye patching for severe amblyopia
3098807|NCT01973387|Experimental|Treatment Arm A|
3098808|NCT01973387|Experimental|Treatment Arm B|
3098809|NCT01973413|Experimental|Closed-Loop Control with DiAs System|Subjects will use the Diabetes Assistant (DiAs) and will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. Subjects will be remotely monitored throughout the night in real time.
3098810|NCT01973413|Placebo Comparator|Control Group, Sensor-Augmented Pump Therapy|Subjects will wear a Tandem t:slim insulin pump and a Dexcom G4 Platinum sensor with active low and high sensor glucose alarms. They will not use the Diabetes Assistant (DiAs) nor have remote monitoring.
3098811|NCT01973439|Other|Abacavir Once versus Twice Daily|This is a single arm study. Intervention 1: PK assessment while on Twice Daily Abacavir (Week 0) Intervention 2: PK assessment while on Once Daily Abacavir (Week 4)
3098812|NCT01973491|Experimental|ATX-MS-1467|
3098813|NCT01973569|Experimental|Denosumab 6 months|denosumab administered subcutaneously every 6 months
3098814|NCT01973569|Experimental|Denosumab 3 months|denosumab administered subcutaneously every 3 months
3098815|NCT01973569|Placebo Comparator|placebo|placebo administered subcutaneously to match denosumab
3098816|NCT01973595|Experimental|Almonds then no almonds|Adults will consume 1.5 ounces of almonds or almond paste per day and children will consume 0.5 ounces of almonds or almond paste per day for 3 weeks.
3098817|NCT01973595|Other|No almonds then almonds|No almonds will be consumed by participants for 3 weeks.
3098818|NCT01973608|Experimental|MSB0010445 Low Dose Cohort 0.3 mg/kg|
3098819|NCT01973608|Experimental|MSB0010445 Intermediate Dose Cohort 1.0 mg/kg|
3098820|NCT01973608|Experimental|MSB0010445 High Dose Cohort 1.8 mg/kg|
3098821|NCT01973608|Experimental|MSB0010445 High Dose Cohort 2.4 mg/kg|
3098822|NCT01973777|Experimental|IUB|There is one arm of women who will have IUBs inserted
3098823|NCT01973972|Experimental|Weight management/shared medical appointment (WM/SMA)|Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
3098824|NCT01973972|Active Comparator|Shared medical appointments (SMA)|Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
3098825|NCT01973998|Experimental|Roflumilast|500 ug tablet daily for 180 days
3098826|NCT01973998|Placebo Comparator|Placebo|Placebo 1 tablet daily x 180 days
3098827|NCT01974050|Other|Text message monitoring|Use of text messaging to monitor post-vaccination
3098828|NCT01974089||Pneumonia and dysphagia|Patients with community aquired pneumonia and oropharyngea dysphagia
3098829|NCT01974089||Pneumonia|Patients with community aquired pneumonia
3098830|NCT01974102|Active Comparator|lifestyle|Attentional control group will receive weekly meeting to view relaxing video and facilitate discussion along with counseling on nutrition and physical activity for 8 weeks.
3098831|NCT01974102|Experimental|therapy|Active group will receive weekly mindfulness based parenting stress reduction (PMH) plus nutrition and physical activity counseling for 8 weeks.
3098832|NCT01974141|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3098833|NCT01974141|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3098834|NCT01974245|Placebo Comparator|Placebo|100 drops/week for 12 weeks
3098835|NCT01974245|Active Comparator|Cholecalciferol|Drug: Cholecalciferol - 100,000 IU/week
3098836|NCT01974323|Experimental|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3098837|NCT01974323|Placebo Comparator|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
3098838|NCT01974687|Experimental|Group A: Healthy|Healthy participants will receive sequentially higher doses of uprifosbuvir (10 mg - 300 mg) capsules or matching placebo capsules once daily (QD) on Day 1 (Cohorts 1a-3a, 5a), Days 1 and 7 (Cohort 4a), or Day 1 - Day 7 (Cohort 6a). Dosing of next cohort will be based on review of available safety and PK data. Dosing will occur under fasted conditions with the exception of Cohort 4a, in which drug administration will occur under both fasted and fed conditions.
3098839|NCT01974687|Experimental|Group B: GT1 HCV-infected, treatment naive on Day 1|HCV GT1 participants with no prior direct-acting antiviral (DAA) exposure will receive a single dose of uprifosbuvir (10 mg - 300 mg) for 1 day across sequential dose cohorts. Dosing will commence following review of available safety and PK data from respective dose cohorts in Group A. All dosing will occur under fasted conditions.
3098840|NCT01974687|Experimental|Group C: GT1 HCV-infected on Days 1-7|HCV GT1 participants will receive uprifosbuvir (50 mg - 400 mg in capsules or 300 mg or 450 mg in tablets) or matching placebo capsules QD for 7 days. Dosing will commence following review of available safety and PK data of Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3098841|NCT01974687|Experimental|Group D: GT2 through GT6 HCV-infected on Days 1-7|HCV GT2 - GT6 participants will receive uprifosbuvir (50 mg - 300 mg) capsules QD for 7 days. Dosing will commence following review of available safety and PK data from Group A. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3098842|NCT01974687|Experimental|Group E: GT1 HCV-infected on Days 1-7, mild hepatic impairment|HCV GT1 participants with mildly impaired hepatic function will receive uprifosbuvir (150 mg - 450 mg) capsules QD for 1 or 7 days. Dosing of subsequent cohorts will be based on review of available safety and PK data. Fed vs. fasted dosing will be dependent on food effect results from Group A.
3098843|NCT01974687|Experimental|Group F: GT1 HCV-infected on Days 1-7, + Itraconazole|HCV GT1 participants will receive itraconazole 200 mg twice daily (BID) on Day -5 and itraconazole 200 mg QD from Day -4 to Day 11. Participants will also be co-administered uprifosbuvir 300 mg from Day 1 to Day 7.
3098844|NCT01974700|Active Comparator|Levetiracetam|
3098845|NCT01974700|No Intervention|No anti-epileptic treatment|
3098846|NCT01974752|Experimental|selumetinib 75mg twice daily|selumetinib 75mg twice daily in combination with dacarbazine.
3098847|NCT01974752|Placebo Comparator|placebo twice daily|placebo twice daily in combination with dacarbazine.
3098848|NCT01974817|Experimental|Vaccine|Patients will receive one dose of 0.5 ml 13-valent conjugate pneumococcal vaccine (Prevnar-13) intra-muscularly.
3098849|NCT01974895|Experimental|FluLaval Quadrivalent Group|Subjects received 1 or 2 doses of FluLaval® Quadrivalent vaccine at Day 0 or Days 0 and 28, depending on age and vaccine priming status.
3098850|NCT01974895|Active Comparator|Fluzone Group|Subjects received 1 or 2 doses of Fluzone® vaccine at Day 0 or Days 0 and 28, depending on age and priming status.
3098851|NCT01975090|Experimental|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter
3098852|NCT01975220|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fasted conditions
3098853|NCT01975220|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 3 single tablets under fed conditions
3098854|NCT01975220|Experimental|Low dose, fasted|2 fixed low dose combination (FDC) tablets vs. 4 single tablets under fed conditions
3098855|NCT01975246|Experimental|Telmisartan+amlodipine+HCTZ|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and hydrochlorothiazide (HCTZ) 12.5 mg tablet
3098856|NCT01975246|Active Comparator|Telmisartan+amlodipine|telmisartan 80 mg + amlodipine 5 mg fixed dose combination (FDC) and placebo matching hydrochlorothiazide 12.5 mg tablet
3098857|NCT01975285|Active Comparator|Dexamethasone group|Dexamethasone 4mg(1 ml) per 20cc
3098858|NCT01975285|Placebo Comparator|Saline group|Saline 1 ml per 20cc
3098859|NCT01975376|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous
3098860|NCT01975376|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
3098861|NCT01975389|Experimental|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous.
3098862|NCT01975389|Placebo Comparator|Placebo|Placebo comparator, every 2 weeks, subcutaneous.
3098863|NCT01975428|Other|Control|All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
3098864|NCT01975428|Active Comparator|DM Pgm + device|"Disease management (DM) program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic."
3098865|NCT01975519|Experimental|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose pazopanib or every two week administration during cycle 1, and starting on cycle 2 day 1 and beyond, TRC105 may be administered every two weeks. This is also in combination with standard dose pazopanib.
3098866|NCT01975675|Experimental|LDV/SOF (treatment naive)|Treatment-naive participants will receive LDV/SOF for 12 weeks.
3098867|NCT01975675|Experimental|LDV/SOF+RBV (treatment naive)|Treatment-naive participants will receive LDV/SOF plus RBV for 12 weeks.
3098868|NCT01975675|Experimental|LDV/SOF (treatment experienced)|Treatment-experienced participants will receive LDV/SOF for 12 weeks.
3098869|NCT01975675|Experimental|LDV/SOF+RBV (treatment experienced)|Treatment-experienced participants will receive LDV/SOF plus RBV for 12 weeks.
3098870|NCT01975701|Experimental|BGJ398X|To estimate anti-tumor efficacy of BGJ398
3098871|NCT01975831|Experimental|Escalation: 0.3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (0.3 mg/kg every 2 weeks [Q2W] for 13 cycles) and tremelimumab (3 mg/kg every 4 weeks [Q4W] for 6 cycles, then every 12 weeks [Q12W]). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098872|NCT01975831|Experimental|Escalation: 1 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (1 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098873|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 3 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 13 cycles) and tremelimumab (3 mg/kg Q4W for 6 cycles, then Q12W). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098874|NCT01975831|Experimental|Escalation: 3 mg/kg Durva + 1 mg/kg Treme|Subjects received durvalumab (3 mg/kg Q2W for 12 or 13 cycles) and tremelimumab (1 mg/kg Q4W for 6 cycles, then Q12W or Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098875|NCT01975831|Experimental|Expansion: Ovarian Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098876|NCT01975831|Experimental|Expansion: Colorectal Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098877|NCT01975831|Experimental|Expansion: Non-triple Negative Breast Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098878|NCT01975831|Experimental|Expansion: Renal Cell Carcinoma|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098879|NCT01975831|Experimental|Expansion: Cervical Cancer|Subjects received durvalumab (10 mg/kg Q2W for 13 cycles or 1500 mg Q4W for 12 cycles) and tremelimumab (1 mg/kg or 75 mg Q4W for 4 cycles). Optional extended treatment comprised durvalumab monotherapy administered at the recommended fixed dose of 1500 mg Q4W.
3098880|NCT01975909|Active Comparator|Transcranial Magnetic Stimulation (TMS)|A Magstim 200 (Magstim, UK) and 14cm circular coil positioned tangential to the head will be used to deliver stimuli at 100% of maximum stimulator output. Transcranial Magnetic Stimulation will be applied to three regions: 1) 4cm lateral to the right of the inion, 2) centered on the inion, 3) 4cm lateral to the left of the inion. Five pulses separated by 6 seconds will be delivered with a counter-clockwise current, followed by the same five pulses delivered with a clockwise current, for a total of 10 pulses per region, and 30 pulses per session.
3098881|NCT01975909|Sham Comparator|Sham Transcranial Magnetic Stimulation|A sham condition of Transcranial Magnetic Stimulation will be used and follow the same protocol as the active stimulation; however no magnetic pulses will be delivered through the scalp.
3098882|NCT01975922|Experimental|Enhanced Milieu Teaching|"Parents receive 28 intervention sessions in which they learn to use language support strategies with their children.~Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline."
3098883|NCT01975922|No Intervention|Community Services|Children receive speech-language services in the community. Children are assessed at baseline, 4 months after baseline, 10 months after baseline, and 16 months after baseline.
3098884|NCT01975935|Placebo Comparator|Placebo|Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
3098885|NCT01975935|Experimental|Amlexanox|Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
3098886|NCT01975948|Experimental|Mental Health PSP: Physicians|Physicians training in Adult Mental Health Practice Support Program
3098887|NCT01975948|Active Comparator|Treatment as Usual: Physicians|Those administering treatment as usual for depression
3098888|NCT01975948|Experimental|Mental Health PSP: Patients|Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
3098889|NCT01975948|Active Comparator|Treatment as Usual: Patients|Those receiving treatment as usual for depression
3098890|NCT01975974||Ultrasound|Ultrasound guided peripheral vascular access
3098891|NCT01976104|Experimental|Group A (avatrombopag, lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3098892|NCT01976104|Placebo Comparator|Group B (placebo, lower baseline platelet count)|placebo (3 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3098893|NCT01976104|Experimental|Group C (avatrombopag, higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets) once daily on Days 1 through 5
3098894|NCT01976104|Placebo Comparator|Group D (placebo, higher baseline platelet count)|placebo (2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3468998|NCT03890302|Experimental|Cohort E|Starting dose of 2 mg/kg or approximately half the maximum tolerated dose (MTD) in Part 1 (Cohorts A-D), whichever is lower, up to 4 mg/kg; or placebo. Administered 4 times (approximately once every 2 weeks).
3098897|NCT01976299|Experimental|Active Treatment|Standard of Care with the AVERT system
3098898|NCT01976299|No Intervention|Standard of Care|
3098899|NCT01976312|Experimental|Ranibizumab 0.5 mg|PRN intravitreal injection
3098900|NCT01976312|Sham Comparator|Sham injection|As of Month 3, ranibizumab 0.5 mg PRN intravitreal injections
3098901|NCT01976338|Experimental|Ranibizumab 0.5 mg|PRN Intravitreal injection
3098902|NCT01976338|Sham Comparator|Sham injection|As of Month 6 ranibizumab 0.5 mg PRN intravitreal injection
3098903|NCT01976364|Experimental|Tofacitinib|
3098904|NCT01976390|Active Comparator|Zortress (Everolimus)|Zortress will be started on day of transplant and initially dosed at 0.75 mg twice a day (12 hours apart) dosed simultaneously with Neoral.
3098905|NCT01976390|Active Comparator|Rapamune (Sirolimus)|Rapamune will be dosed on day of transplant at 5 mg/d, decreasing to 3 mg/d.
3098906|NCT01976416|Experimental|Hydroxyurea|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
3098907|NCT01976416|Placebo Comparator|Placebo|Fixed dose 20 ± 2.5 mg/kg/day, administered once a day in tablet form (100mg or scored 1000mg) for twelve months
3098908|NCT01976507|Experimental|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
3098909|NCT01976572|Placebo Comparator|Candesartan alone|Single dose of 16 mg candesartan was administered orally on Day 1.
3098910|NCT01976572|Active Comparator|T0hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-0 of 3 dosing time-points means the single dose of candesartan was administered at the same time relative to the first daily dose of colestilan.
3098911|NCT01976572|Active Comparator|T-1hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T-1 of 3 dosing time-points means the single dose of candesartan was administered at 1 hour before relative to the first daily dose of colestilan.
3098912|NCT01976572|Active Comparator|T+3hr|Colestilan was administered orally 5 g t.i.d (total dose 15 g/day) in the fed state immediately after meals from Day 3 to Day 24 and single dose of 16 mg candesartan was administered orally on Day 7, 13 and 19 at 1 of 3 dosing time-points relative to the first daily dose of 5 g colestilan t.i.d. T+3 of 3 dosing time-points means the single dose of candesartan was administered at 3 hour after relative to the first daily dose of colestilan.
3098913|NCT01976624||Ganfort®|Patients who received treatment with bimatoprost/timolol (Ganfort®) for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
3098914|NCT01976650||OZURDEX®|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
3098915|NCT01976663|Experimental|VOLIFT® XC NLFs|Nasolabial folds treated with JUVEDERM VOLIFT® XC.
3098916|NCT01976663|Active Comparator|Control NLFs|Nasolabial folds treated with Control.
3098917|NCT01976728|Experimental|LutrePulse 10 µg/pulse|Gonadorelin acetate 10 µg/pulse
3098918|NCT01976728|Experimental|LutrePulse 15 µg/pulse|Gonadorelin acetate 15 µg/pulse
3098919|NCT01976728|Experimental|LutrePulse 20 µg/pulse|Gonadorelin acetate 20 µg/pulse
3098920|NCT01976728|Placebo Comparator|Placebo|Placebo
3098921|NCT01976741|Experimental|Rogaratinib total dose escalation|Participants with any type of solid tumor received escalating doses of Rogaratinib oral solution or tablet. The actual dose-escalation cohorts were 100 mg (50 mg BID), 200 mg (100 mg BID), 400 mg (200 mg BID), 800 mg (400 mg BID), 1200 mg (600 mg BID), and 1600 mg (800 mg BID). The participants in the 100 mg and 200 mg dose-escalation cohorts received oral solution and the participants in all the subsequent dose-escalation cohorts received tablet. And as an exception, on C1D-3 in the 200 mg dose-escalation cohort, the participants received tablet instead of oral solution.
3098922|NCT01976741|Experimental|Rogaratinib dose expansion (All Comers)|"Participants with cancer types other than bladder cancer (BC), squamous cell carcinoma of the head and neck (SCCHN), and squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d.~(1600 mg/day) in 21-days cycles."
3098923|NCT01976741|Experimental|Rogaratinib dose expansion (BC)|Participants with bladder cancer (BC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
3098924|NCT01976741|Experimental|Rogaratinib dose expansion (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
3098925|NCT01976741|Experimental|Rogaratinib dose expansion (sqNSCLC)|Participants with squamous non-small cell lung cancer (sqNSCLC) received 800 mg Rogaratinib oral tablet b.i.d. (1600 mg/day) in 21-days cycles.
3098926|NCT01976806|Experimental|Aspirin & Docosahexaenoic acid|Aspirin 81 mg 1 tablet by mouth daily and Docosahexanoic acid (DHA) 500 mg 4 capsules by mouth daily (total daily dose of 2 grams DHA) for 3 months
3098927|NCT01976806|Active Comparator|Aspirin & Placebo|Aspirin 81 mg by mouth daily and placebo (50% corn oil/50% soybean oil) 4 capsules by mouth daily for 3 months
3098928|NCT01976819|Experimental|TW speaking valve/HME|Use of the TW speaking valve/HME
3098929|NCT01976845|Experimental|Propofol|Propofol 20 mg IV (2 ml)
3098930|NCT01976845|Active Comparator|Midazolam|Midazolam 2 mg IV (2 ml)
3098931|NCT01976845|Placebo Comparator|Saline|Saline 2 ml
3098932|NCT01976871|Experimental|Oral Dopamine Agonist to Rotigotine|During the study, we will switch patients who are not satisfied with their current oral dopamine agonist to rotigotine. Cross-titration will allow determination of the lowest effective dose of rotigotine. We will use as initial guidance the equivalence determined from the Parkinson's Disease trials, in which 1 mg rotigotine was shown to be approximately equivalent to 1-1.5 mg ropinirole or 0.25 -0.375 mg pramipexole. Tolerability, adverse events, and RLS symptom control will be evaluated. These data will provide clinicians with practical guidance to optimize RLS treatment while minimizing adverse events.
3098933|NCT01976975||Mood disorder patients|Patients with depressive and/or manic or hypomanic symptoms
3098934|NCT01976975||Healthy controls|Participants with no lifetime history of psychiatric illness
3098935|NCT01976988|Active Comparator|Post-op Heparin|Postoperative venous thromboprophylaxis (Control Arm/current standard practice: subcutaneous Heparin 5000 units started 23 hours after the end of surgery and continued every 8 hours for the remainder of the patients hospital course
3098936|NCT01976988|Experimental|Pre-op Heparin|Treatment arm: subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
3098937|NCT01977040||Vasa Previa|Women with the diagnosis of Vasa Previa made during the pregnancy or at time of delivery who delivered between January 1, 2000 and December 31, 2012.
3098938|NCT01977092|Experimental|Motivational interviewing case management|MICM intervention combines aspects of motivational interviewing along with case management to influence HIV risk and recovery from alcohol and drug problems. Participants assigned to the MICM condition will be contacted to receive 3 individual sessions within the first 4 weeks of entering the study. Thereafter they will have contact with the MICM therapist monthly throughout the duration of their enrollment in the study (12 months).
3098939|NCT01977092|Other|Resource referrals|Respondents will receive SLH services as usual along with a list of resources that can be used to address a variety of problems.
3098940|NCT01977222|Experimental|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|
3098941|NCT01977352|Active Comparator|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
3098942|NCT01977352|Experimental|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
3098943|NCT01977456|Experimental|Eptifibatide|All subjects will receive the standard dose of IV rt-PA. All subjects will promptly receive an IV bolus of 135mcg/kg eptifibatide followed by an IV infusion of 0.75 mcg/kg/min eptifibatide for 2 hours.
3098944|NCT01977482|Experimental|GSK1278863 4 mg|Subjects will take GSK1278863 4 mg blinded once daily (OD) orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098945|NCT01977482|Experimental|GSK1278863 6 mg|Subjects will take GSK1278863 6 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098946|NCT01977482|Experimental|GSK1278863 8 mg|Subjects will take GSK1278863 8 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098947|NCT01977482|Experimental|GSK1278863 10 mg|Subjects will take GSK1278863 10 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098948|NCT01977482|Experimental|GSK1278863 12 mg|Subjects will take GSK1278863 12 mg blinded OD orally for 4 weeks with a glass of water. From Week 4, study medication will continue to be administered OD and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098949|NCT01977482|Active Comparator|Control|Subjects will take GSK1278863 matching placebo blinded OD orally for 4 weeks with a glass of water. From Week 4, rhEPO will be administered and the dose will be adjusted based on Hgb levels dose every 4 weeks till Week 24.
3098950|NCT01977547|Active Comparator|Short storage|Red blood cells storage duration of equal to or less than 7 days.
3098951|NCT01977547|Active Comparator|Standard issue|Red blood cells storage duration of 2 to 42 days with an expected average length of storage of about 17-21 days.
3098952|NCT01977573|Experimental|GSK1278863|Subjects will be administered GSK1278863 QD. Starting dose will be based on data from previous studies with GSK1278863 and dose-response modelling, as well as Baseline Hgb concentration. After 4 Week of fixed dose period, dose may be adjusted to achieve Hgb 9.0 to 10.5 g/dL
3098953|NCT01977573|Other|Control|All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered.
3098954|NCT01977599|No Intervention|No Text Message Reminder (Control) Arm|Control Arm, in which patients are invited to breast screening as per standard West of London Breast Screening Protocol (i.e. without a text message appointment reminder). Uptake of breast screening in this group will be compared with the text message reminder group to test for significant differences.
3098955|NCT01977599|Experimental|Text Message Reminder Arm|Patients randomly allocated to this arm of the study will be sent a text message reminding them of the time, date and venue of their breast screening appointment 48 hours in advance.
3098956|NCT01977612|Active Comparator|Stainless Steel Staples|Skin closure with stainless steel staples
3098957|NCT01977612|Experimental|4-0 monofilament Sutures|Skin closure with 4-0 monofilament sutures
3098958|NCT01977625|Active Comparator|Lisdexamfetamine|Lisdexamfetamine or Vyvanse
3098959|NCT01977625|Placebo Comparator|Sugar Pill|Placebo pill, capsules
3098960|NCT01977651|Experimental|Enzalutamide 160 mg|Participants received 160 mg of enzalutamide orally once a day, for 4 months. At the end of the 4-month treatment period, participants who were assessed as deriving benefit from enzalutamide treatment continued in the extension period. The total study drug treatment duration for the extended period depended on individual clinical benefit. If a participant experienced a Grade 3 or higher toxicity that was attributed to enzalutamide and could not be ameliorated by the use of adequate medical intervention, treatment with enzalutamide was allowed to be interrupted for 1 week or until the toxicity grade improved to Grade 2 or lower severity. Subsequently, enzalutamide was restarted at the original dose 160 mg per day or a reduced dose 120 or 80 mg per day in consultation with the medical monitor.
3098961|NCT01977677|Experimental|Treatment (radiation therapy, temozolomide, plerixafor)|Within 4 weeks of surgery, patients undergo radiation therapy and receive temozolomide PO over 42 days. Beginning 8 days prior to completion of chemoradiotherapy, patients receive plerixafor IV continuously for 2-4 weeks. Patients also receive temozolomide PO 5 days a month beginning 35 days after completion of radiation therapy.
3098962|NCT01977690|No Intervention|Standard Management|Patients wore no brace.
3098963|NCT01977690|Experimental|Clavicle Brace Wearing|Patient has to wear clavicle brace for one month.
3098964|NCT01977781|Experimental|Tacrolimus|Topical tacrolimus suspension will be formulated and aseptically prepared from commercially available intravenous tacrolimus, PROGRAF® (Astellas Pharma US, Inc), and transferred into a sterile dropper container by the MEEI pharmacy. A formulation of 0.05% (5mg/10ml) concentration of tacrolimus with diluting solvent, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
3098965|NCT01977781|Active Comparator|Methylprednisolone Sodium Succinate|Topical methylprednisolone sodium succinate suspension will be formulated and aseptically prepared from commercially available sterile dry powder vial preservative-free for intravenous use, SOLU-MEDROL® (Pfizer, Inc.). A formulation of 0.5% (5mg/1ml) concentration of methylprednisolone with diluting solvents, LiquiTears Ophthalmic Solution (Major Pharmaceuticals, Inc.) will be used. Patients will be instructed to keep refrigerated each bottle after opening for 9 days and keep frozen the unopened bottles up to 45 days. They will also be instructed to shake the bottles at least 20 times before using it.
3098966|NCT01977794|Experimental|Bisoprolol failed group|Subjects who failed monotherapy with bisoprolol 5 milligram (mg) before trial inclusion will be randomized to bisoprolol failed group to receive Bisoprolol/Amlodipine FDC tablet
3098967|NCT01977794|Experimental|Amlodipine failed group|Subjects who failed monotherapy with amlodipine 5 mg before trial inclusion will be randomized to amlodipine failed group to receive Bisoprolol/Amlodipine FDC tablet.
3098968|NCT01977820|Experimental|Sapropterin|
3098969|NCT01977820|Placebo Comparator|Placebo|
3098970|NCT01977898|Experimental|Morphine|Patients randomized to the treatment group (morphine) will receive preservative-free morphine 0.3 mL (150 mcg) intrathecally.
3098971|NCT01977898|Placebo Comparator|Saline|Patients randomized to the control group will receive normal saline 0.3 mL intrathecally.
3098972|NCT01977937|Experimental|Gabapentin|Gabapentin 15 milligrams per kilogram will be given orally one time pre-operatively. Gabapentin will be continued at a dose of 10 milligrams per kilogram every eight hours orally starting as soon as the patient is admitted to his or her floor bed in the hospital.
3098973|NCT01977937|Placebo Comparator|Simple Syrup|Simple syrup compounded by the Oregon Health and Science University research pharmacy will be administered in the same volume as if the patient were receiving the Gabapentin both pre-operatively and every eight hours after the patient is admitted to his or her floor bed in the hospital.
3098974|NCT01978093|Experimental|HibCY Group|Subjects received 4 doses of Hib-MenCY-TT (MenHibrix®) vaccine at Day 0, Month 2, Month 4 and Month 10-13 , 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
3098975|NCT01978093|Active Comparator|PedHIB Group|Subjects received 3 doses of PedvaxHIB® vaccine at Day 0, Month 2 and Month 10-13, 3 doses of Pediarix® vaccine at Day 0, Month 2 and Month 4, 2 doses of Rotarix® vaccine at Day 0 and Month 2, 4 doses of Prevnar 13® vaccine at Day 0 and Month 2, Month 4 and Month 10-13 and 2 doses of Havrix® vaccine at Month 10-13 and Month 16-19.
3098976|NCT01978119|Experimental|Sequence 1|Subjects in this Arm will receive Regimen A followed by Regimen B. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler
3098977|NCT01978119|Experimental|Sequence 2|Subjects in this Arm will receive Regimen B followed by Regimen A. Regimen B: FSC (250/50 mcg) administered BID by Multi-Dose Inhaler followed by Placebo administered BID by Capsule-Based Inhaler. Regimen A: Placebo administered BID by Multi-Dose Inhaler followed by FSC (250/50 mcg) administered BID by Capsule-Based Inhaler
3098978|NCT01978145|Experimental|Regimen A|Placebo administered BID by multi-dose inhaler followed by FSC (250/50 mcg) administered BID by capsule-based inhaler.
3098979|NCT01978145|Experimental|Regimen B|FSC (250/50 mcg) administered BID by multi-dose inhaler followed by placebo administered BID by capsule-based inhaler.
3098980|NCT01978184|Experimental|gemcitabine and abraxane|Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.
3098981|NCT01978184|Experimental|gemcitabine, abraxane and hydroxychloroquine|"Gemcitabine and Abraxane will be administered on an outpatient basis on Days 3, 10, 17, 31, 38, and 45 as an intravenous infusion. The dose on Day 3 will be 1000 mg/m of gemcitabine followed by a 125 mg/m2 of abraxane and the infusion will take 1 hour. The second dose and infusion time may be decreased. Prior to each gemcitabine infusion, subjects will be pre-medicated with an FDA-approved anti-emetic (anti-nausea medication) in an effort to prevent nausea, at the discretion of the study physician.~Hydroxychloroquine is an oral drug (capsule) that subjects will take once or twice a day at home. The dose of hydroxychlorquien will be 1200mg. This is an experimental drug. Subjects will take their first dose of hydroxychloroquine on Day 1 (48 hours before the first infusion of gemcitabine/abraxane), and will continue to take it every day until the day before surgery."
3098982|NCT01978236|Experimental|Cohort A|The first cohort of 15 subjects will receive oral dabrafenib 150 mg twice daily orally for 7 to 14 days prior to surgery in Cohort A; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
3098983|NCT01978236|Experimental|Cohort B|The second cohort of 15 subjects will receive dabrafenib 150 mg twice daily combined with trametinib 2 mg once daily (Cohort B) orally for 7 to 14 days prior to surgery; Subjects will be treated for at least 7 days prior to craniotomy, but not more than 14 days. Subjects in either cohort with intracranial and/or extracranial metastases remaining after surgery may resume treatment with the combination of dabrafenib 150 mg BID and trametinib 2 mg once daily no earlier than 72 hours after surgery
3098984|NCT01978262|Other|healthy woman|All women are to receive the quadrivalent influenza vaccine
3098985|NCT01978314|Experimental|Cohort 1|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
3098986|NCT01978314|Experimental|Cohort 2|eGFR renal function 30-59 mL/min for stage 3, moderate CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
3098987|NCT01978314|Experimental|Cohort 3|eGFR renal function 15-29 mL/min for stage 4, severe CKD 75 mg / 6mL VFI™ and 5mL of Iohexol
3098988|NCT01978314|Experimental|Cohort 4|a diagnosis of either RIFLE stage I or Acute Kidney Injury Network (AKIN) stage 2 AKI 75 mg / 6mL VFI™ and 5mL of Iohexol
3098989|NCT01978314|Experimental|Cohort 5|eGFR renal function ≥60 mL/min for normal function 75 mg / 6mL VFI™ and 5mL of Iohexol
3098990|NCT01978509|Active Comparator|Low volume prep (Prepopik)|Low volume prep for colonoscopy (Prepopik)
3098991|NCT01978509|Active Comparator|Moderate volume prep (Moviprep)|Moderate volume prep for colonoscopy (Moviprep)
3098992|NCT01978509|Active Comparator|High volume prep (Golytely)|High volume prep for colonoscopy (Golytely)
3098993|NCT01978600|Experimental|SIMBRINZA™|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, 1 drop 3 times a day (8AM, 3PM, 10PM) in each eye for 4 weeks
3098994|NCT01978600|Active Comparator|Timolol Maleate 0.5%|Timolol Maleate 0.5%, 1 drop twice a day (8AM, 8PM) in each eye for 4 weeks
3098995|NCT01978743|Experimental|Raltegravir|Switch from Atripla (EFV/FTC/TDF) to raltegravir (RAL) + Truvada (FTC/TDF). Raltegravir will be administered 400mg twice-a-day with Truvada for 8 weeks.
3098996|NCT01978912|Experimental|Cohort 1|one time 5 μg/disc dose of KTP-001 by intradiscal injection
3098997|NCT01978912|Experimental|Cohort 2|one time 15 μg/disc dose of KTP-001 by intradiscal injection
3098998|NCT01978912|Experimental|Cohort 3|one time 50 μg/disc dose of KTP-001 by intradiscal injection
3098999|NCT01978912|Experimental|Cohort 4|one time 150 μg/disc dose of KTP-001 by intradiscal injection
3099000|NCT01978938|Experimental|Eravacycline|Eravacycline was administered IV at a dose of 1.5 mg per kilogram (kg) of body weight every 24 hours (q24h). At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 200 mg PO twice a day for a total therapy of 7 dosing cycles.
3099001|NCT01978938|Active Comparator|Levofloxacin|Levofloxacin (750 mg) was administered IV q24h. At minimum, the first 3 doses were administered IV. After an IV-to-PO transition, provided adequate clinical improvement, participants were administered 750 mg PO once a day for a total therapy of 7 dosing cycles.
3099002|NCT01979016|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
3099003|NCT01979016|Experimental|Dupilumab 200 mg qw|Two subcutaneous injections of Dupilumab 200 milligram (mg) (for a total of 400 mg) as a loading dose on Day 1, followed by a single 200 mg injection qw from Week 1 to Week 15.
3099004|NCT01979029|Experimental|preserving the left colic artery|We preserve the left colic artery and resect the No. 253 lymph node during the rectal surgery.
3099005|NCT01979029|Experimental|not preserving the left colic artery|We preserve the high ligation of the inferior mesenteric artery during the rectal surgery.
3099006|NCT01979133|Experimental|icariin|Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
3099007|NCT01979159|Experimental|Combined Aphasia-ApraxiaTreatment|Administration of Combined Aphasia and Apraxia of Speech Treatment )(CAAST) to 4 persons with aphasia and apraxia of speech in the context of single-subject designs
3099008|NCT01979185|Active Comparator|Simvastatin|Administered as a single oral 20 mg dose on Day 1.
3099009|NCT01979185|Experimental|Simvastatin + SSP-004184SS|Simvastatin (20 mg) + SSP-004184SS (30 mg/kg) administered concomitantly as a single oral dose on Day 1.
3099010|NCT01979276|Experimental|Pomalidomide, Romidepsin, Dexamethasone|Pomalidomide, 4 mg by mouth daily on days 1-21 of 28 day cycle Dexamethasone, 40 mg by mouth on days 1, 8, 15, and 22 of 28 day cycle Romidepsin, IV on days 1 and 15 of 28 day cycle, dose level to be determined Dexamethasone
3099011|NCT01979445|Experimental|Prasugrel 30 Min After Cangrelor|Prasugrel 60 milligram (mg) administered orally 30 min after the discontinuation of cangrelor infusion on Day 1 (2.5 hours [hrs] after initiation of cangrelor infusion).
3099012|NCT01979445|Experimental|Clopidogrel Within 5 Min After Cangrelor|Clopidogrel 600 mg administered orally within 5 min after the discontinuation of the cangrelor infusion on Day 1 (2 hrs after initiation of cangrelor infusion).
3099013|NCT01979445|Experimental|Clopidogrel 1.5 Hrs During Cangrelor|Clopidogrel 600 mg administered orally 1.5 hrs after the initiation of cangrelor infusion on Day 1.
3099014|NCT01979445|Experimental|Clopidogrel 1 Hr During Cangrelor|Clopidogrel 600 mg administered orally 1 hr after the initiation of cangrelor infusion on Day 1.
3099015|NCT01979523|Experimental|Arm A (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients who experience objective disease progression may crossover to Arm B. (no patients will be enrolled to Arm B or Crossover therapy as of 11/6/2015)
3099016|NCT01979523|Experimental|Arm B (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3099017|NCT01979614|Experimental|Serelaxin|Serelaxin was administered at a dose of 30 μg/kg/24h by intravenous infusion for 48 hours
3099018|NCT01979614|Placebo Comparator|Placebo|Placebo was administered by intravenous infusion for 48 hours
3099019|NCT01979835|Experimental|GF|Women who have a GyneFix Viz inserted
3099020|NCT01979952|Experimental|Nintedanib|150 mg twice daily
3099021|NCT01979952|Placebo Comparator|Placebo|twice daily dosing
3099022|NCT01980056|Experimental|Vosaroxin: All Patients|All patients will receive vosaroxin according to the dose cohort in which they are enrolled.
3099023|NCT01980095|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of 2 different antibiotics and a proton pump inhibitor combined in a single capsule.
3099024|NCT01980095|Placebo Comparator|Placebo|Capsules that look like the RHB-105 product but contain no active ingredient.
3099025|NCT01980485|Active Comparator|Feedback on lung age and exhaled carbon monoxide|
3099026|NCT01980485|Sham Comparator|No lung age feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
3099027|NCT01980524|Experimental|acipimox+|250 mg at 0 and 180 minutes (one day)
3099028|NCT01980524|Placebo Comparator|Placebo|1 Tablet at 0 and 180 minutes (one day)
3099029|NCT01980589|Experimental|Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)|Participants received carfilzomib, cyclophosphamide and dexamethasone for up to eight 28-day cycles, or until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
3099030|NCT01980628|Experimental|ibrutinib|ibrutinib capsules: 560 mg once daily
3099031|NCT01980654|Experimental|Main Study Arm 1|Subjects enrolled into this arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.
3099032|NCT01980654|Experimental|Exploratory Study Arm 2|Subjects enrolled into this arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.
3099033|NCT01980706|Placebo Comparator|Placebo|Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
3099034|NCT01980706|Active Comparator|30 Mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
3099035|NCT01980706|Active Comparator|90 mg Baclofen|Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
3099036|NCT01980771|Experimental|BTWB intervention|Barbershops are assigned to either experimental or active control condition. Men recruited from experimental barbershops receive a single-session group intervention focused on HIV prevention.
3099037|NCT01980771|Active Comparator|Cancer prevention and screening|Barbershops are assigned to either experimental or control condition. Men recruited from control barbershops receive information on cancer prevention and control.
3099038|NCT01980888|Experimental|Idelalisib+bendamustine+rituximab|Participants will receive idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
3099039|NCT01980888|Placebo Comparator|Placebo+bendamustine+rituximab|Participants will receive placebo to match idelalisib for 96 weeks plus bendamustine+rituximab for 21 weeks.
3099040|NCT01980914|Experimental|Type 2 diabetes group|Patients over age 70 who have had type 2 diabetes for at least 5 years and are being treated with insulin. All patients will have a BMI of between 20 and 35 Kg/M2, and an A1C between 7 and 8.5 %.
3099041|NCT01980940|Experimental|Pt 1: ETOR 75 DMSO/ETOR 150 PG/ETOR 75 PG/ETOR 150 DMSO|Single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel. All treatments were applied topically.
3099042|NCT01980940|Experimental|Pt 1: ETOR 75 PG/ETOR 75 DMSO/ETOR 150 DMSO/ETOR 150 PG|Single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel. All treatments were applied topically.
3099043|NCT01980940|Experimental|Pt 1: ETOR 150 DMSO/ETOR 75 PG/ETOR 150 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel. All treatments were applied topically.
3099044|NCT01980940|Experimental|Pt 1: ETOR 150 PG/ETOR 150 DMSO/ETOR 75 PG/ETOR 75 DMSO|Single-dose etoricoxib 150 mg (4.30 mL) 4% PG gel, followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
3099045|NCT01980940|Experimental|Pt 1: ETOR OD/ ETOR 150 DMSO/ ETOR 75 DMSO/ ETOR 75 PG|Single-dose etoricoxib 163 mg (4.30 mL) 4% DMSO gel (DMSO formulation administered in error/overdose [OD]), followed by single-dose etoricoxib 150 mg (3.94 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (1.97 mL) 4% DMSO gel, followed by single-dose etoricoxib 75 mg (2.15 mL) 4% PG gel. All treatments were applied topically.
3099046|NCT01980940|Other|Pt 1: Placebo (Deviation)|Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
3099047|NCT01980940|Experimental|Pt 2: ETOR 50 DMSO|Etoricoxib 50 mg (1.31 mL, 4% DMSO gel) applied topically twice daily to the affected knee for a period of 2 weeks.
3099048|NCT01980940|Placebo Comparator|Pt 2: Placebo|Matching placebo to etoricoxib 50 mg 1.31 mL 4% DMSO gel applied topically twice daily to the affected knee for a period of 2 weeks.
3099049|NCT01980992|Active Comparator|Wheat OIT|Active treatment participants receive Vital Wheat Gluten, and have up to four oral food challenges as directed by the protocol.
3099050|NCT01980992|Placebo Comparator|Placebo|Placebo for Vital Wheat Gluten followed by crossover to open-label active therapy (Vital Wheat Gluten), and up to three oral food challenges as directed by the protocol.
3099051|NCT01981057||Numeta|parenteral receipt prescribed with Numeta
3099052|NCT01981057||Individual|individually prescribed parenteral receipt
3099053|NCT01981096|Experimental|Fibromyalgia Integrative Training|8 week (16 sessions) combined intervention with cognitive-behavioral therapy and neuromuscular training
3099054|NCT01981096|Active Comparator|Cognitive Behavioral Therapy|8 week (16 session) cognitive-behavioral therapy treatment.
3099055|NCT01981122|Experimental|Concurrent Arm|Subjects will receive sipuleucel-T concurrently with enzalutamide (160 mg orally once daily). Enzalutamide treatment will start 2 weeks prior to the first leukapheresis and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
3099056|NCT01981122|Experimental|Sequential Arm|Subjects will receive sipuleucel-T followed by enzalutamide (160 mg orally once daily). Enzalutamide treatment will start approximately 10 weeks after the first infusion of sipuleucel-T and continue for 52 weeks or until disease progression or unacceptable toxicity, whichever occurs first.
3099057|NCT01981187|Experimental|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
3099058|NCT01981356|Experimental|Acceptance and Commitment Therapy (ACT)|Participants randomized to the ACT condition will be provided with the opportunity to attend 4 ACT sessions. The treatment protocol is adapted from and virtually identical to that presented in Gaudiano and Herbert (2006). Each ACT session will serve as a standalone session, with all essential elements of the treatment briefly presented. Participants in the ACT condition will also receive treatment as usual.
3099059|NCT01981356|Active Comparator|Treatment as Usual (TAU)|TAU consists of psychopharmacology, case management, and psychotherapy. Additionally, patients randomized to the TAU condition will meet with ACT facilitators for 15 minutes every other day to provide additional support and answer questions, while ensuring not to discuss or suggest the use of therapeutic techniques related to ACT.
3099060|NCT01981473||etanercept|Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3099061|NCT01981473||adalimumab|Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3099062|NCT01981473||infliximab|Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
3099063|NCT01981551|Experimental|PF-03084014 in Desmoid Tumors/Aggressive Fibromatosis|PF-03084014 will be administered orally at 150 mg twice a day in 21-day cycles
3099064|NCT01981564|Experimental|Asthma Express Intervention|Clinic visit for asthma education + nurse home visits
3099065|NCT01981564|Active Comparator|Standard Asthma Education Control group|Standard asthma education during nurse home visits
3099066|NCT01981590|Experimental|All enrolled patients|All enrolled patients that underwent a scheduled cardiac catheterization involving an atrial fibrillation (AF) ablation procedure as per clinical practice
3099067|NCT01981616|Experimental|Vedolizumab 750 mg|Vedolizumab 750 mg, intravenous (IV) infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
3099068|NCT01981616|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV infusion, once on Day 1. Also 3 doses of a hepatitis B vaccine series on Days 4, 32 and 60, and 2 doses of an oral cholera vaccine on Days 4 and 18.
3099069|NCT01981759|Placebo Comparator|Placebo|Participants receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from week 1-12 (12 visits).
3099070|NCT01981759|Experimental|D-Cycloserine|Participants will receive a weekly dose of placebo by mouth one hour before Cognitive Behavioral Therapy (CBT) sessions from weeks 1-2 (2 visits), then a weekly 50 mg dose of D-Cycloserine by mouth one hour before CBT sessions from weeks 3-12 (10 visits).
3099071|NCT01981772|Experimental|buffered lidocaine|administration of 4% buffered lidocaine with 1:100,000 epinephrine
3099072|NCT01981772|Active Comparator|nonbuffered lidocaine|administration of 4% lidocaine with 1:100,000 epinephrine
3099073|NCT01981863|Experimental|Epsilonaminocaproic acid|One arm: Epsilonaminocaproic acid 10 gr IV, followed by 1 gr/hr infusion Second arm: placebo
3099074|NCT01981863|Placebo Comparator|Placebo, Antifibrinolytic activity|Placebo: same IV volume as experimental arm
3099075|NCT01981954|Experimental|Solifenacin succinate|Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.
3099076|NCT01981967|Experimental|Primary Vaccination Group|Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.
3099077|NCT01981967|Active Comparator|Booster Vaccination Group|Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier
3099078|NCT01982123|Experimental|SPECT/CT Mid-& Post-RT|Investigational 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation therapy (up to 1 week post-treatment), and at 3-6 months post-treatment.
3099079|NCT01982240|Active Comparator|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
3099080|NCT01982240|Active Comparator|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
3099081|NCT01982240|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
3099082|NCT01982240|Other|Bisacodyl|Rescue medication
3099083|NCT01982292|Experimental|RLX030 (serelaxin)|Randomized patients received an IV infusion of 30 μg/kg/day of serelaxin for 48 hours at randomization and at Weeks 4 and 8
3099084|NCT01982292|Placebo Comparator|Placebo|Randomized patients received an IV infusion of placebo of serelaxin for 48 hours at randomization and at Weeks 4 and 8
3099085|NCT01982331|Experimental|LAIV H2N2 vaccine|LAIV H2N2 vaccine A/17/California/66/395 (H2N2) live monovalent influenza vaccine delivered intranasally 2 doses 1 month apart
3099086|NCT01982331|Placebo Comparator|Placebo|Placebo is composed of a lyophilizate containing the same concentrations of stabilizers as LAIV vaccine. It is prepared onsite in an identical fashion to the vaccine and delivered intranasally.
3099087|NCT01982435|Other|Group I - Monthly|Enrolled subjects will receive multiple open-label intravitreal injections of 0.3 mg ranibizumab administered every 28 days (+/- 7 days from the last treatment) for 12 months in the monthly group.
3132613|NCT03440944|Active Comparator|Ultrasound Guided Peripheral IV Catheter|Patients if randomized to this group will receive a standard ultrasound guided peripheral IV. The IV is 4.88cm in length.
3132614|NCT03440944|Active Comparator|Midline Catheter|Patients if randomized to this group will receive a midline catheter. The catheter is 10cm in length.
3099088|NCT01982435|Other|Group II - Treat-and-Extend|Enrolled subjects will initially receive 3 loading doses of open-label Ranibizumab 0.3 mg given via intravitreal injection every 28 days (+/- 7 days from the last treatment). After the third loading dose, the follow-up interval is determined by the Principal Investigator based on OCT results as stated in the protocol. The follow-up interval is increased by 2 weeks (+/- 7 days) at each visit up to a maximum interval of 12 weeks (+/- 7 days). There is criteria built into the protocol in case a reduction in the follow-up intervals becomes necessary based upon worsening OCT results.
3099089|NCT01982448|Experimental|Arm A: Cisplatin|Cisplatin given by IV infusion at a dose of 75 mg/m2 every 3 weeks (1 cycle) for 4 cycles as preoperative chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to crossover to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
3099090|NCT01982448|Experimental|Arm B: Paclitaxel|Paclitaxel given by IV infusion at a dose of 80 mg/m2 weekly for 12 weeks (4 cycles) as neoadjuvant chemotherapy. Participants with inadequate clinical response after 12 weeks (as judged either clinically or radiologically by a provider) were able to 'crossover' to an alternative provider-selected preoperative chemotherapy regimen. Definitive breast surgery following no later than 42 days after administration of last chemotherapy.
3099091|NCT01982539|Experimental|Zipsor® (Liquid filled capsules)|25mg/every 6hrs/up to 4 days treatment
3099092|NCT01982643|Experimental|naltrexone plus bupropion|extended-release depot naltrexone (XR-NTX; as Vivitrol®)plus extended-release bupropion tablets (BRP; as Wellbutrin XL®)
3099093|NCT01982682|Experimental|Treatment (TBI, DLI, cyclophosphamide, CD34+ donor HSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -8, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANT: Patients undergo CD34+ (cluster of differentiation 34+) selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning by day 42, and mycophenolate mofetil IV BID on days -1 to 28."
3099094|NCT01982695|Active Comparator|Lisinopril|
3099095|NCT01982695|Active Comparator|Losartan|
3099096|NCT01982773|Experimental|Virtual Hope Box Smartphone App|Use of the smartphone app, Virtual Hope Box on their personal smartphone
3099097|NCT01982773|Active Comparator|EnhancedTreatment As Usual|Subjects will be issued printed materials guiding them in coping with suicidal thoughts, which include information about coping strategies and emergency contact information.
3099098|NCT01982786|Active Comparator|Arm 1|IGRT* 60 Gy in 20 fractions OR IGRT 78 Gy in 39 fractions
3099099|NCT01982786|Active Comparator|Arm 2|"IGRT 37.5 Gy in 15 fractions~+ HDR brachytherapy boost 15 Gy"
3099100|NCT01982812|Experimental|Oral Levetiracetam|Oral Levetiracetam administered by NG tube.
3099101|NCT01982812|Active Comparator|Standard AED|Standard AED regimen
3099102|NCT01982942|Experimental|ibudilast|Subjects will receive up to 100 mg/d ibudilast for 96 weeks.
3099103|NCT01982942|Placebo Comparator|Placebo Oral Capsule|Subjects will receive placebo for 96 weeks.
3099104|NCT01982955|Experimental|Phase 1b: Tepotinib 300 milligram (mg)|Participants received Tepotinib 300 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
3099105|NCT01982955|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 milligram (mg) along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
3099106|NCT01982955|Experimental|Phase 2: Tepotinib and Gefitinib|Participants randomized to receive Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
3099107|NCT01982955|Experimental|Phase 2: Pemetrexed and Cisplatin/Carboplatin|Participants randomized to receive 500 milligram per square meter (mg/m^2) of Pemetrexed as intravenous infusion over 10 minutes in combination with Cisplatin (75 mg/m2 as an intravenous infusion over 2 hours) or Carboplatin (intravenously at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator) on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity or withdrawal from treatment or up to 6 cycles if or 4 cycles followed by Premetrexed maintenance monotherapy.
3099108|NCT01982955|Experimental|Phase 2: Single-arm Cohort (MET+ T790M positive)|Participants with MET+ T790M positive Non-small Cell Lung Cancer (NSCLC) received a Tepotinib recommended Phase 2 dose 500 mg once daily along with 250 mg Gefitinib tablets orally once daily over a 21-day treatment cycle until progressive disease, intolerable toxicity or withdrawal from treatment.
3099109|NCT01982968|No Intervention|Control|Subjects to receive standard anti-reflux treatment per clinical discretion
3099110|NCT01982968|Active Comparator|Surgery|Subjects will receive laparoscopic fundoplication surgery
3099111|NCT01983020|Experimental|Ketamine|Ketamine infused at 0.25 mg/kg/hour.
3099112|NCT01983020|Experimental|Lidocaine|Lidocaine infused at 0.5 mg/kg/hour.
3099113|NCT01983020|Experimental|Ketamine and Lidocaine|Ketamine infused at 0.25 mg/kg/hour along with lidocaine at 0.5 mg/kg/hour
3099114|NCT01983020|Placebo Comparator|Placebo|Placebo (saline) given to compare usual treatment against active agents in post operative pain management.
3099115|NCT01983111|Experimental|buprenorphine|Patch
3099116|NCT01983111|Active Comparator|tramadol/acetaminophen|Oral tablet
3099117|NCT01983228|No Intervention|Arm 1: Usual Care|Participants randomized to the usual care control condition will receive pedometers and an informational brochure.
3099118|NCT01983228|Experimental|Arm 2: Intervention Group|Participants assigned to the intervention group will receive personalized recruitment materials, including a letter and brochure describing the program and the benefits of walking for pain. They will also receive pedometers. Participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
3099119|NCT01983254|Experimental|Coping skills training|6 sessions of weekly telephone-based coping skills training delivered by trained interventionist
3099120|NCT01983254|Active Comparator|education program|6 week access to a web-based, critical illness-specific education program
3099121|NCT01983293|Experimental|QLV based implant strategy|QLV represents the pacing site with the largest amount of dyssynchrony as measured by the left ventricular electrical delay. The QLV based implant strategy finds the left ventricle vein branch and left ventricular lead cathode with the longest QLV measurement and places the lead at this location and programs the device using this lead cathode.
3099122|NCT01983293|Placebo Comparator|Standard of care implant strategy|The placement of LV lead will be carried out according to the physician's standard of care implant approach.
3099123|NCT01983553||CYD Dengue Vaccine Group|Participants who received 3 injections of 0.5 milliliter (mL) CYD dengue vaccine, 1 injection each at 0, 6, and 12 months, subcutaneously in study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
3099124|NCT01983553||Control Group|Participants who received either 0.5 mL Rabies vaccine (Verorab®) or placebo control, subcutaneously as a first injection on Day 0, placebo for second and third injections at 6 and 12 months, respectively in the study CYD23, were followed up for safety in this study for 4 years after the 3rd vaccination at Month 12 in CYD23.
3099125|NCT01983566|Active Comparator|BI 207127 fasted|patient to receive BI 207127 as a single dose in fasted state
3099126|NCT01983566|Experimental|BI 207127 high fat|patient to receive BI 207127 as a single dose after a high fat breakfast
3099127|NCT01983566|Experimental|BI 207127 low fat|patient to receive BI 207127 as a single dose after a low fat breakfast
3099128|NCT01983566|Experimental|BI 207127 with Omeprazole|patient to receive BI 207127 as a single dose after 4 days treatment with Omeprazole 40 mg once a day
3099129|NCT01983683|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
3099130|NCT01983683|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
3099131|NCT01983787||Pharmacokinetics Piperacillin|Patients with cystic fibrosis , treated with Piperacillin/Tazobactam, given as continuous infusion for a period of two weeks.
3099132|NCT01983826|Experimental|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
3099133|NCT01983826|Placebo Comparator|Placebo capsule|Microcrystalline cellulose (daily) for 8 weeks
3099134|NCT01983839||Pharmacokinetics Moxifloxacin|Patients with community-acquired pneumonia treated with moxifloxacin
3099135|NCT01983878|Experimental|Ramucirumab|Ramucirumab 8 milligrams per kilogram (mg/kg) administered intravenously (IV) once every 2 weeks. Treatment will continue until there is evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance or withdrawal of consent.
3099136|NCT01983930|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
3099137|NCT01983930|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 20 minute meditation
3099138|NCT01983969|Experimental|Azacitidine + Vorinostat + Gemcitabine + Busulfan + Melphalan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1. Dexamethasone 8 mg by vein twice a day from Day -11 AM to Day -2 PM. Caphosol oral rinses 30 mL four times a day used from Day -9. Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9. Pyridoxine 100 mg by vein or mouth three times a day from Day -1. Vorinostat 1000 mg by vein on Day -11 through Day -2. Gemcitabine loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8. Melphalan 60 mg/m2 by vein on Days -3 and -2. Azacitidine starting dose 15 mg/ m2 by vein on Day -11. Stem cell transplant on Day 0. Patients with CD20+ tumors receive rituximab 375 mg/m2 by vein on Days -9.
3099139|NCT01984164|Active Comparator|Candesartan|To achieve blood pressure control, we will use a stepwise protocol as follows: candesartan (blinded) 8mg→ 16mg→ 32mg. Both groups will also receive (unblinded) , if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg →10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
3099140|NCT01984164|Active Comparator|Lisinopril|To achieve blood pressure control we will use a stepwise protocol as follows: lisinopril (blinded) 10mg→ 20mg→ 40mg. Both groups will also receive (unblinded), if needed to achieve blood pressure control, HCTZ 12.5mg→ 25mg, Amlodipine 2.5mg→ 5mg→ 10mg and metoprolol succinate extended release 12.5mg→ 25mg→ 50mg. Antihypertensive medications will be increased every 2 weeks until control is achieved.
3099141|NCT01984229|Experimental|Cohort A|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 18). Alectinib will be administered as a 40 milligrams (mg) single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 18 (Period 3) posaconazole will be administered as a 400-mg twice daily (BID) oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
3099142|NCT01984229|Experimental|Cohort B|There will be 3 dosing periods in the study: Period 1 (Days 1 to 7), Period 2 (Days 8 to 14), and Period 3 (Days 15 to 21). Alectinib will be administered as a single oral dose at the dose selected based on Cohort A data on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants). On Days 8 to 14 (Period 2) and Days 15 to 21 (Period 3) posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal. The follow-up assessments will occur within 10 to 14 days after the last dose of posaconazole.
3099143|NCT01984242|Experimental|Atezolizumab and Bevacizumab|Atezolizumab 1200 milligrams (mg) and bevacizumab 15 milligrams per kilogram (mg/kg) will be administered as intravenous (IV) infusions every 3 weeks (q3w) on Day 1 and Day 22 of each 6-week cycle until disease progression.
3099144|NCT01984242|Experimental|Atezolizumab|Atezolizumab 1200 mg will be administered as IV infusion q3w on Day 1 and Day 22 of each 6-week cycle until disease progression. Upon disease progression, participants (except European Union [EU] participants) can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
3132615|NCT03441178|Experimental|Colectomy/Gynecological/Thoracic|Any colectomy/gynecological/thoracic procedure where ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
3099145|NCT01984242|Active Comparator|Sunitinib|Sunitinib 50 mg will be administered orally once daily on Days 1 to 28 of each 6-week cycle until disease progression. Upon disease progression, participants can crossover to receive atezolizumab and bevacizumab combination until disease progression, lack of clinical benefit, unacceptable toxicity, withdrawal from study, or study completion or termination.
3099146|NCT01984294|Experimental|LDV/SOF+RBV|Participants will receive LDV/SOF plus RBV for 8 weeks.
3099147|NCT01984294|Experimental|LDV/SOF + GS-9669 250 mg|Participants will receive LDV/SOF plus GS-9669 250 mg for 8 weeks.
3099148|NCT01984294|Experimental|LDV/SOF + GS-9669 500 mg|Participants will receive LDV/SOF plus GS-9669 500 mg (2 x 250 mg) for 8 weeks.
3099149|NCT01984398|Experimental|12.5 mg Androxal (formulations A and B)|12.5 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
3099150|NCT01984398|Experimental|25 mg Androxal (formulations A and B)|25 mg Androxal formulation A and 12.5 mg Androxal formulation B, a single dose of each formulation
3099151|NCT01984424|Other|Part A: Atorvastatin 20 mg => Placebo|Participants received atorvastatin 20 mg orally for 10 weeks (period 1) followed by placebo orally for 10 weeks (period 2), separated by a 2-week washout period.
3099152|NCT01984424|Other|Part A: Placebo => Atorvastatin 20 mg|Participants received placebo orally for 10 weeks (period 1) followed by atorvastatin 20 mg orally for 10 weeks (period 2), separated by a 2-week washout period.
3099153|NCT01984424|Active Comparator|Part B: Ezetimibe|Participants received 10 mg ezetimibe orally only a day and placebo to evolocumab by subcutaneous injection once a month for 24 weeks.
3099154|NCT01984424|Experimental|Part B: Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo to ezetimibe orally once a day for 24 weeks.
3099155|NCT01984424|Experimental|Part C: Open-label Evolocumab|Participants who completed part B and were eligible to proceed to open-label extension part C and could choose quarterly between evolocumab 420 mg once a month or evolocumab 140 mg every 2 weeks for up to 2 years.
3099156|NCT01984515|Experimental|Team Red Primary Care|Eligible patients will receive the Referral Management System in primary care
3099157|NCT01984684|Experimental|Delafloxacin|Delafloxacin 300 mg IV Q12H for 6 doses, then Delafloxacin 450 mg oral tablet Q12H for a minimum of 10 up to a maximum of 28 doses total
3099158|NCT01984684|Active Comparator|Vancomycin plus Aztreonam|Vancomycin 15 mg/kg IV plus two grams Aztreonam every 12 hours for a minimum of 10 up to a maximum of 28 doses total (Aztreonam was discontinued as soon as possible if a gram-negative organism was not identified in baseline cultures)
3099159|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0 and 6|Girls aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL intramuscular (IM) injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
3099160|NCT01984697|Experimental|Boys 9 to 14 Years V503 at Months 0 and 6|Boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 6. An additional dose of V503 0.5 mL IM was administered at Month 36.
3099161|NCT01984697|Experimental|Girls and Boys 9 to 14 Years V503 at Months 0 and 12|Girls and boys aged 9 to 14 years received a 2-dose regimen of V503 0.5 mL IM injection at Months 0 and 12. An additional dose of V503 0.5 mL IM was administered at Month 36.
3099162|NCT01984697|Experimental|Girls 9 to 14 Years V503 at Months 0, 2, and 6|Girls aged 9 to 14 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
3099163|NCT01984697|Active Comparator|Young Women 16 to 26 Years V503 at Months 0, 2, and 6|Young Women aged 16 to 26 years received a 3-dose regimen of V503 0.5 mL IM injection at Months 0, 2, and 6. An additional dose of V503 0.5 mL IM was administered at Month 36 for a subset of participants.
3099164|NCT01984892|Experimental|IT and IM injections Poly-ICLC|Enrolled patients will receive two cycles of Poly-ICLC treatment. Each priming (intratumoral injections - IT) and boosting (intramuscular injections - IM) treatment course will constitute one cycle.
3099165|NCT01985126|Experimental|Part 1|During Stage 1 of Part 1, participants will be randomized to receive daratumumab treatment regimens in Group A and Group B. If in Stage 1, 1 or both of the treatment groups is considered to be ineffective and/or not well tolerated, then that treatment group will be terminated. Participants in Group B will be given the option to cross over to Group A if the investigator deems it in the best interest of the participants.
3099166|NCT01985126|Experimental|Part 2|Based on the Part 1 response rate, Group A or B daratumumab treatment will be selected as the treatment regimen for participants enrolled in Part 2.
3099167|NCT01985321|Experimental|Merlin - ethanol/glycolic acid solution|36 applications over a 96 hour period
3099168|NCT01985321|Placebo Comparator|Placebo/Ethanol|36 applications over a 96 hour period
3099169|NCT01985334|Experimental|A1 (any SABA and/or SAMA)|Patients treated with any SABA and/or SAMA as monotherapy or in free or fixed dose combination will be assigned to glycopyrronium or will remain in their baseline therapy (3:1) during 90 days of treatment
3099170|NCT01985334|Experimental|A2 (glycopyrronium)|Patients treated with any SABA and/or SAMA as monotherapy or in free or FDC at enrollment and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
3099171|NCT01985334|Experimental|B1 (any LAMA or LABA and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to remain in their baseline treatment with LABA or LAMA
3099172|NCT01985334|Experimental|B2 (glycopyrronium and mMRC=1)|Patients treated with any LABA or LAMA monotherapy and mMRC score =1 point at Visit 1 and randomized to switch in treatment with glycopyrronium (50 μg o.d.)
3099173|NCT01985334|Experimental|C1 (any LABA and ICS)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to remain in their baseline treatment with LABA and ICS in free or FDC
3099174|NCT01985334|Experimental|C2 (indacaterol/glycopyrronium)|Patients treated with any LABA and ICS in free or FDC at enrollment and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.)
3099175|NCT01985334|Experimental|D1 (any LAMA or LABA and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to remain their baseline in treatment with LABA or LAMA
3099176|NCT01985334|Experimental|D2 (indacaterol/glycopyrronium and mMRC>1)|Patients treated with any LABA or LAMA monotherapy and mMRC score >1 point at Visit 1 and randomized to switch in treatment with indacaterol maleate and glycopyrronium bromide FDC (110/50 μg o.d.).
3099177|NCT01985360|Active Comparator|Invasive Strategy (INV)|Routine invasive strategy with cardiac catheterization followed by revascularization (Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Surgery) plus optimal medical therapy.
3099178|NCT01985360|Active Comparator|Conservative Strategy (CON)|Optimal medical therapy with cardiac catheterization and revascularization reserved for patients with OMT failure.
3099179|NCT01985425|Experimental|Active Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
3099180|NCT01985425|Placebo Comparator|Placebo Colchicine|On the day of surgery, the intervention group will receive 2 doses of colchicine placebo 0.6 mg orally. The first dose will be administered within 4 hours before surgery. The second dose will be given between 6:00PM and 11:59PM after surgery. All patients will receive colchicine 0.6 mg or placebo twice daily orally for 10 days.
3099181|NCT01985542|Active Comparator|subcutaneous immunotherapy|Starts with birch pollen subcutaneous immunotherapy
3099182|NCT01985542|No Intervention|no immunotherapy|not starting with birch pollen subcutaneous immunotherapy
3099183|NCT01985581|Experimental|Placebo first then GXR|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took placebo and second intervention period subject took GXR. GXR dose was optimized to between 1 and 4mg.
3099184|NCT01985581|Placebo Comparator|GXR first then Placebo|patient will continue to take stable dosage of usual stimulant(Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine). In the first intervention period subject took GXR and second intervention period subject took placebo. GXR dose was optimized to between 1 and 4mg.
3099185|NCT01985685|Experimental|Thiamine|200mg intravenous thiamine in 50ml 5% dextrose, single dose
3099186|NCT01985685|Placebo Comparator|Placebo|50ml intravenous 5% dextrose, single dose
3099187|NCT01985763|Experimental|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.
3099188|NCT01985932|Other|Functional MRI|Subjects in this arm receive functional MRI during radiation therapy treatment planning.
3099189|NCT01985958|Experimental|Single arm|In this trial, we will deliver low-dose (8Gy in a single fraction) radiotherapy (SBRT or any other acceptable delivery method as determined by the treating physician) for palliation of symptoms in patients in whom it is clinically indicated. This dose is far lower than what has been used in the definitive settings described above. This is a safe dose, and is entirely consistent with the dose range used for routine palliation. Therefore, this trial does not involve an experimental intervention; the research aspect of this protocol is the evaluation of the immune response to clinically indicated palliative radiotherapy.
3099190|NCT01985971|Experimental|EF5|
3099191|NCT01986010|Experimental|HCMV seropositive (+) V160 Low Dose Intramuscular (IM)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099192|NCT01986010|Experimental|HCMV seronegative (-) V160 Low Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099193|NCT01986010|Experimental|HCMV+ V160 Medium Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099194|NCT01986010|Experimental|HCMV- V160 Medium Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099195|NCT01986010|Experimental|HCMV+ V160 High Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099196|NCT01986010|Experimental|HCMV- V160 Medium Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3099197|NCT01986010|Experimental|HCMV- V160 High Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099198|NCT01986010|Experimental|HCMV+ V160 High Dose plus MAPA 225 µg IM|Participants seropositive for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3099199|NCT01986010|Experimental|HCMV+ V160 Maximum Dose IM|Participants seropositive for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099200|NCT01986010|Experimental|HCMV- V160 High Dose plus MAPA 225 µg IM|Participants seronegative for HCMV at Baseline will receive vaccination with V160 plus MAPA adjuvant by IM injection on Day 1, Month 1, and Month 6
3099201|NCT01986010|Experimental|HCMV- V160 Maximum Dose IM|Participants seronegative for HCMV at Baseline will receive V160 vaccination by IM injection on Day 1, Month 1, and Month 6
3099202|NCT01986010|Placebo Comparator|HCMV+ Placebo IM|Participants seropositive for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
3099203|NCT01986010|Placebo Comparator|HCMV- Placebo IM|Participants seronegative for HCMV at Baseline will receive placebo by IM injection on Day 1, Month 1, and Month 6
3099204|NCT01986010|Experimental|HCMV+ V160 Medium Dose Intradermal (ID)|Participants seropositive for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
3099205|NCT01986010|Experimental|HCMV- V160 Medium Dose ID|Participants seronegative for HCMV at Baseline will receive V160 vaccination by ID injection on Day 1, Month 1, and Month 6
3099206|NCT01986010|Placebo Comparator|HCMV+ Placebo ID|Participants seropositive for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
3099207|NCT01986010|Placebo Comparator|HCMV- Placebo ID|Participants seronegative for HCMV at Baseline will receive placebo by ID injection on Day 1, Month 1, and Month 6
3099208|NCT01986062|Experimental|AR11 (amphetamine sulfate) (1 week) - double blind|AR11, administered orally, BID, for one week (crossover to placebo administration week 2)
3099209|NCT01986062|Placebo Comparator|Placebo (1 week) - double blind|Placebo, administered orally, BID, for one week (crossover to AR11 administration week 2)
3099210|NCT01986101|Placebo Comparator|Placebo|once daily orally
3099211|NCT01986101|Experimental|SM-13496 20 - 60 mg/day|once daily orally
3099212|NCT01986101|Experimental|SM-13496 80 - 120 mg/day|once daily orally
3099213|NCT01986114|Experimental|SM-13496 20-120mg|once daily orally SM-13496 20-120 mg flexibly dosed
3099214|NCT01986140|Experimental|PAXMAN Orbis Scalp Cooler|Scalp Cooling
3099215|NCT01986140|Other|Control No treatment|Control
3099216|NCT01986231|Experimental|Open-Label Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg.
3099217|NCT01986348|Experimental|Arm A: Selinexor 60 mg and Surgery|Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.
3099218|NCT01986348|Experimental|Arm B: Selinexor 50 mg/m^2|Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
3099219|NCT01986348|Experimental|Arm C: Selinexor 60 mg|Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
3099220|NCT01986348|Experimental|Arm D: Selinexor 80 mg|Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.
3099221|NCT01986361|Experimental|flurbiprofen 8.75 mg lozenge|A single flurbiprofen lozenge is sucked until fully dissolved.
3099222|NCT01986361|Placebo Comparator|Placebo lozenge|A single placebo lozenge is sucked until fully dissolved.
3099223|NCT01986647|Experimental|On the Move Exercise - exercise leader|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by exercise leader
3099224|NCT01986647|Active Comparator|Standard program - exercise leader|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by exercise leader
3099225|NCT01986647|Active Comparator|On the Move - staff activity personnel|On the Move group exercise - 2 times per week for 12 weeks. Each session lasts approximately 1 hour. Timing and coordination exercises to improve walking. Led by activity personnel.
3099226|NCT01986647|Active Comparator|Standard - staff activity personnel|Standard impairment based seated group exercise program. 2 times per week for 12 weeks, approximately 1 hour class. Led by staff activity personnel
3099227|NCT01986686|No Intervention|Observational|The observation group will be followed clinically with no further intervention until the primary endpoint is reached.
3099228|NCT01986686|Active Comparator|Surgery|The surgery group will be offered colon resection.
3099229|NCT01986790|Experimental|Plain Language|This intervention group will receive a plain-language table describing the features and costs of health insurance plans, with definitions of health insurance terms incorporated into the table.
3099230|NCT01986790|Experimental|Plain Language + Visuals|This intervention group will receive the plain-language table plus visuals that focus on specific features of the plans. Participants will be able to view the information about each health insurance feature one feature at a time, in the order they prefer.
3099231|NCT01986790|Experimental|Plain Language + Narratives|This intervention group will receive the plain language table plus narratives about how others might use and rate the insurance plans.
3099232|NCT01986829|Experimental|Treatment (ablation)|"Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion.~Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)"
3099233|NCT01986855|Experimental|Ertugliflozin (5 mg)|Ertugliflozin, 5 mg, oral, one 5 mg ertugliflozin tablet and one placebo tablet, once daily for 52 weeks
3099234|NCT01986855|Experimental|Ertugliflozin (15 mg)|Ertugliflozin, 15 mg, oral, one 5 mg and one 10 mg tablet, once daily for 52 weeks
3099235|NCT01986855|Placebo Comparator|Placebo|Matching placebo
3099236|NCT01986881|Experimental|Ertugliflozin, 15 mg|Ertugliflozin 15 mg administered orally once daily for up to approximately 6 years
3099237|NCT01986881|Experimental|Ertugliflozin, 5 mg|Ertugliflozin 5 mg administered orally once daily for up to approximately 6 years
3099238|NCT01986881|Placebo Comparator|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to approximately 6 years
3099239|NCT01986907|Experimental|Ranibizumab|Administered as an Intravitreal injection
3099240|NCT01986920|Active Comparator|A-101 25%|Low dose group
3099241|NCT01986920|Active Comparator|A-101 32.5%|Mid Dose Group
3099242|NCT01986920|Active Comparator|A-101 40%|High Dose Group
3099243|NCT01986920|Placebo Comparator|A-101 Vehicle|Placebo group
3099244|NCT01986933|Experimental|Group1|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3099245|NCT01986933|Experimental|Group2|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3099246|NCT01986933|Experimental|Group3|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3099247|NCT01986933|Experimental|Group4|Part A: nemolizumab (CIM331) Part B: nemolizumab (CIM331)
3099248|NCT01986933|Experimental|Group5|Part A: Placebo Part B: nemolizumab (CIM331)
3099249|NCT01986946|Experimental|Intravenous opioids|This is the standard of care method for post-operative analgesia following lumbar spine fusion surgery. Participants randomly assigned to this arm will receive Intravenous Patient-Controlled Analgesia (IVPCA) with dilaudid (or other opioid) for post-operative pain control.
3099250|NCT01986946|Experimental|Epidural Catheter|The intervention to be tested in this study against standard intravenous opioids is infusion of local anesthetic and dilaudid via epidural catheter for post-operative pain control in patients undergoing lumbar spine fusion surgery.
3099251|NCT01986985|Other|Single arm PET MRI|single group evaluation of PET/MRI system scan for diagnostic quality of image
3132616|NCT03441269|Active Comparator|400mg/dose|Oral Ibuprofen dose of 400mg/dose for mild to moderate acute pain in ED patients.
3132617|NCT03441269|Active Comparator|600mg/dose|Oral Ibuprofen dose of 600mg/dose for mild to moderate acute pain in ED patients.
3132618|NCT03441269|Active Comparator|800mg/dose|Oral Ibuprofen dose of 800mg/dose for mild to moderate acute pain in ED patients.
3099252|NCT01987089|Experimental|CBT-I|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician. Session 1 serves as an orientation. No active treatment is delivered at this time. Sessions 2 & 3 are used to deliver the three main components of the intervention which are Sleep Restriction (SRT), Stimulus Control, and Sleep Hygiene. All but two of the remaining sessions are dedicated to the titration of total sleep time and to ensuring patient adherence. One session (session 5) entails the delivery of a specific form of cognitive therapy. The final session (session 8) is used to engage in a relapse-prevention didactic, i.e., to review first, how insomnia becomes chronic and second, the strategies that are likely to abort an extended episode of insomnia.
3099253|NCT01987089|Placebo Comparator|QDT|"This form of placebo therapy has been commonly used in prior studies investigating behavioral interventions for insomnia. The therapist presents the QDT as a means to eliminate conditioned arousal, occurring after nocturnal arousal using 8 sessions on a weekly basis. The therapist initially helps the subject to develop a chronological 12-item hierarchy of commonly practiced activities on awakening at night, like opening eyes and clock watching. As a next step, the subject develops 6 imaginable scenes of himself/herself engaged in neutral activities like reading a newspaper. The therapist then helps the subject pair the neutral scenes with the items from the 12-item hierarchy, which is then practiced by the subject 2 hours before bedtime."
3099254|NCT01987102|Experimental|Cohort 1|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 15mg/m2)"
3099255|NCT01987102|Experimental|Cohort 2|"1 MAP cycle (incl. 2 HDMTX Courses using Calcium Folinate rescue 15mg/m2)~1 MAP cycle (incl. 2 HDMTX Courses using [6R] 5,10-methylenetetrahydrofolate rescue 7,5mg/m2 or 30mg/m2*)~*Dose will depend on outcome from Cohort 1"
3099256|NCT01987219|Active Comparator|Albuterol-sulphate|Albuterol-sulphate (Proventil ®) Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
3099257|NCT01987219|Active Comparator|Ipratropium-bromide (Atrovent ®)|IpratroAnti-cholinergic(Atrovent ®) 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.pium-bromide
3099258|NCT01987219|Placebo Comparator|Placebo|Placebo Saline solution 3 cc NA
3099259|NCT01987232|Experimental|Carfilzomib Combination|Participants received carfilzomib on days 2, 3, 9, and 10 of each 21-day cycle as per the dose escalation schema, carboplatin at a target area under the curve (AUC) of 5 on day 1 of each cycle, and etoposide 100 mg/m² on days 1, 2, 3 of each 21-day cycle for up to 6 cycles. Participants with stable disease or better continued to receive carfilzomib alone until progressive disease (PD), unacceptable toxicity, withdrawal of consent, study closure, or death, whichever occurred earliest.
3099260|NCT01987349|Other|Group A: age 8-17 yo identical twins|Participants will be randomized to receive either Fluzone® (intramuscular) or FluMist® (intranasal)
3099261|NCT01987349|Other|Group B: 18-30 yo identical twins|Participants to receive FluMist® (intranasal)
3099262|NCT01987349|Other|Group C: 18-30 yo fraternal twins|Participants to receive FluMist® (intranasal)
3099263|NCT01987349|Other|Group D: 40-49 yo identical twins|Participants to receive FluMist® (intranasal)
3099264|NCT01987349|Other|Group E: 40-49 yo fraternal twins|Participants to receive FluMist® (intranasal)
3099265|NCT01987349|Other|Group F: 70-100 yo twins|Participants to receive Fluzone® (intramuscular)
3099266|NCT01987349|Other|Group G: 70-100 yo non-twins|Participants to receive Fluzone® (intramuscular)
3099267|NCT01987401||Iraq and Afghanistan Era Veterans|Veterans who served during the Iraq and Afghanistan Era
3099268|NCT01987414|Experimental|Group A|Forearm rotation orthosis (6 weeks); Forearm rotation orthosis plus occupational therapy task-oriented approach (6 weeks)
3099269|NCT01987414|Active Comparator|Group B|no treatment (6 weeks); occupational therapy task-oriented approach (6 weeks)
3099270|NCT01987427|Experimental|A|lorcaserin + phentermine placebo
3099271|NCT01987427|Experimental|B|lorcaserin + phentermine-HCl + phentermine placebo
3099272|NCT01987427|Experimental|C|lorcaserin + phentermine-HCl
3099273|NCT01987453|Experimental|LDV/SOF+RBV 12 weeks (Group 1)|Participants who failed a prior SOF+RBV ± pegylated interferon (Peg-IFN) regimen will receive LDV/SOF FDC plus RBV for 12 weeks.
3099274|NCT01987453|Experimental|LDV/SOF 24 weeks (Group 2)|Participants who failed a prior LDV/SOF ± RBV regimen will receive LDV/SOF FDC for 24 weeks.
3099275|NCT01987453|Experimental|LDV/SOF+RBV 24 weeks (Group 3)|Participants with advanced compensated or decompensated cirrhosis who failed a prior SOF+RBV regimen will receive LDV/SOF FDC plus RBV for 24 weeks.
3099276|NCT01987479|Experimental|Tocilizumab Alone or in Combination with Methotrexate or DMARD|Participants will receive a weekly SC injection of tocilizumab 162 milligrams (mg) as monotherapy or in combination with methotrexate or other non-biologic DMARDs for 24 weeks.
3099277|NCT01987505|Experimental|Subcutaneous Rituximab|Participants with CD20+ non-Hodgkin's follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL), who had already received at least one full dose of intravenous (IV) rituximab will be treated with subcutaneous (SC) rituximab. Participants with FL will be administered 1400 mg rituximab during induction therapy (once monthly for 4-7 cycles) and maintenance therapy (once every 2 months for 6-12 cycles). Participants with DLBCL will be administered 1400 mg SC of rituximab once monthly for 4-7 cycles. Treatment duration is expected to last up to 7 months for participants with DLBCL and up to 32 months for participants with FL.
3099278|NCT01987557|Experimental|Treadmill Intervention 1: Rate Group|Participants in this condition will walk with a cadence (steps per minute) that is approximately 35% faster than comfortable walking pace. In this condition, participants will maintain a step length that is similar to that of their comfortable walking pace.
3099279|NCT01987557|Experimental|Magnitude treadmill group|In this condition participants will walk on a treadmill with weights on their ankles to elicit a greater magnitude of instrinsic feedback from force sensitive golgi tendon organs
3099280|NCT01987557|Placebo Comparator|regular treadmill walking|participants will walk at a comfortable self-selected pace on a treadmill
3099281|NCT01987583|Experimental|Wet cupping and conventional treatment|"Wet cupping: Will be administered through 3 sessions every other day, on the 17th, 19th and 21st days of the lunar month.~Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department."
3099282|NCT01987583|Active Comparator|Conventional treatment|Conventional treatment: Is the usual anti-HTN treatment taken by the patients at the King Abdulaziz university hospital outpatient department
3099283|NCT01987596|Experimental|Arm I (fixed filgrastim)|Patients receive filgrastim SC QD started at 24 hours after completion of chemotherapy and stopped when ANC reaches at least 1,000/uL post nadir.
3099284|NCT01987596|Experimental|Arm II (flexible filgrastim)|Patients receive filgrastim SC QD started on the first day after chemotherapy when ANC falls below 1,000/uL and stopped when ANC reaches at least 1,000/uL post nadir.
3099285|NCT01987609|Experimental|Hylenex|Psoriatic plaques in this arm will be injected with Hylenex every week for 4 weeks.
3099286|NCT01987609|Placebo Comparator|Normal Saline|Psoriatic plaques in this arm will be subcutaneously injected with sterile normal saline every week for four weeks
3099287|NCT01987752||Combigan® Ophthalmic Solution|Patients treated with Combigan® Ophthalmic Solution as per local standard of care in clinical practice.
3099288|NCT01987765||Relestat Ophthalmic Solution 0.05%|Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.
3099289|NCT01987817|Experimental|AR101 powder provided in capsules|Study product provided as peanut protein in pull-apart capsules
3099290|NCT01987817|Placebo Comparator|Placebo powder provided in capsules|Placebo formulation in pull-apart capsules containing only inactive ingredients
3099291|NCT01987830|Other|TMZ-PET scans/ MRI-PET Scan|"The investigators plan to study patients with recurrent glioblastoma whose clinical care plan includes treatment with bevacizumab and temozolomide. Patients taking daily temozolomide 50 mg/m2/day will undergo a PET scan using radiolabeled temozolomide (TMZ-PET) at 3 time points: 7-13 days after initiation of temozolomide but before beginning bevacizumab (baseline- temozolomide steady-state scan), 1 day after initiation of bevacizumab (day 15) and 1 month after initiation of bevacizumab (day 45). Arterialized venous blood samples will be collected during the imaging in order to measure radioactivity, blood metabolites, and the relationship between radiotracer uptake and tumor features such as blood-brain barrier (BBB) breakdown and tumor blood flow.~In addition, we will explore the link between flow, permeability, and tumor temozolomide retention. These studies will be performed using our human simultaneous MRI-PET imaging camera."
3099292|NCT01987895|Experimental|Cadazolid|Subjects receive oral cadazolid 250 mg twice daily (bid) and oral vancomycin-matching placebo 4 times per day (qid) for 10 days
3099293|NCT01987895|Active Comparator|Vancomycin|Subjects receive oral vancomycin 125 mg qid and oral cadazolid-matching placebo bid for 10 days
3099294|NCT01987908|Experimental|Cohort A (Drug)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo for 28 days
3099295|NCT01987908|Placebo Comparator|Cohort A (Placebo)|Subjects randomized 3:1 to receive 4 times daily dosing of 1,000 mg of Aes 103 or placebo
3099296|NCT01987908|Experimental|Cohort B (Drug)|In this adaptive design, the dose frequency and the total amount given per day to Cohort B will be adjusted depending on the tolerability, clinical pharmacology and clinical endpoint results of Cohort A. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
3099297|NCT01987908|Placebo Comparator|Cohort B (Placebo)|The dosing regiment of placebo will match that of the Aes-103 treatment in Cohort B. Study terminated prior to completion of Cohort A due to unblinding between study product and placebo groups for participant, site and Sponsor. The study was stopped before initiation of Cohort B.
3099298|NCT01987960|Placebo Comparator|Placebo|Placebo adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER)
3099299|NCT01987960|Experimental|Brexpiprazole|Brexpiprazole adjunct to open-label treatment with a commercially available approved treatment for PTSD (PAR/SER). Brexpiprazole dosing was 1mg/day for one week, followed by 2mg/day for 3 weeks. Thereafter the dose was flexible and could be adjusted from 1 to 3 mg/day.
3099300|NCT01987986|Experimental|AA4500 0.06 mg (low dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3099301|NCT01987986|Experimental|AA4500 0.48 mg (mid-dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3099302|NCT01987986|Experimental|AA4500 0.84 mg (high dose)|"AA4500 (Collagenase Clostridium Histolyticum)~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3099303|NCT01987986|Placebo Comparator|Placebo|"Placebo~Each subject could receive up to three treatment sessions. Each treatment session was separated by approximately 21 days."
3099304|NCT01988012|Experimental|Tocilizumab|Adults with rheumatoid arthritis will be treated with tocilizumab for 24 weeks followed by an 8 week follow-up period without treatment.
3099305|NCT01988090|Experimental|High Dose Vitamin D ARM|50,000 IU Vitamin D supplement
3099306|NCT01988090|Active Comparator|800 IU Vitamin D Supplement|800 IU Vitamin D Supplement
3099307|NCT01988103|Experimental|Apremilast 20mg|Apremilast 20 mg tablets orally twice a day (BID)
3099308|NCT01988103|Experimental|Apremilast 30mg|Apremilast 30 mg tablets orally BID
3099309|NCT01988103|Placebo Comparator|Placebo|Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks
3099310|NCT01988129|Experimental|Intervention|Workplace-based fatigue risk management program consisting of sleep health education and sleep disorders screening. The 32 fire department stations were paired according to the previous calendar years' workload. One station from each pair was randomly assigned to receive the intervention program. Sleep education sessions were scheduled according to station. On the education day(s) assigned to that stations, all personnel present that day were instructed to attend, and 542/601 did so.
3099311|NCT01988129|No Intervention|Control|"Current practice. Firefighters in the Control Stations continued their normal role and were not invited to attend the sleep education and sleep disorders screening program. There was no formal contact with the control group.~As part of normal operational requirements, a small number of firefighters are reassigned to other stations each day and therefore 18/588 firefighters from control stations happened to be reassigned to an intervention station on the day of the education session and attended the session."
3099312|NCT01988246|Sham Comparator|Sham Injection|"Patients will be sequentially randomized to treatment with a sham injection at the time of surgery. The sham injection is accomplished by pressing an empty syringe against the eye wall without penetration. This will be administered post cataract excision by the Prinicipal Investigator. The patient will be masked as to which Arm they are assigned."
3099313|NCT01988246|Active Comparator|Intravitreal Aflibercept Injection|Patients will be sequentially randomized to treatment with Aflibercept 2 mg via intravitreal injection (0.05 mL or 50 microliters) at the time of surgery. This will be administered post cataract excision by the Principal Investigator. The patient will be masked as to which Arm they are assigned.
3099314|NCT01988376|Experimental|Women with cervical cancer receive Surepath for screening|Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
3099315|NCT01988376|Active Comparator|Women receive conventional Pap smear for screening|Women who will receive conventional Pap smear for screening
3099316|NCT01988402|Active Comparator|Allopurinol|Patients in this arm receive allopurinol, 100 mg daily for 14 days and then 200 mg daily for 14 days
3099317|NCT01988402|Placebo Comparator|Sugar pill (Placebo)|Patients in this arm receive one placebo (sugar) pill per day for 14 days then 2 placebo pills for 14 days.
3099318|NCT01988415|Other|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile in one eye (active comparator [i.e., control]) and investigational software (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration) in the fellow eye (experimental).
3099319|NCT01988493|Experimental|Phase 1b: Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
3099320|NCT01988493|Experimental|Phase 1b: Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
3099321|NCT01988493|Experimental|Phase 1b: Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
3099322|NCT01988493|Experimental|Phase 2: Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
3099323|NCT01988493|Experimental|Phase 2 Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
3099324|NCT01988662|Experimental|Ranibizumab|104 patients with an eligible study eye were randomized to be treated with Ranibizumab IVT. 0.5 mg of commercially available Ranibizumab were used for intravitreal injection adminstered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
3099325|NCT01988662|Active Comparator|Aflibercept|101 patients with an eligible study eye were randomized to be treated with Aflibercept IVT. 2.0 mg of commercially available Aflibercept were used for intravitreal injection admistered by an unblinded injecting physician. 3 injections were performed (Baseline, Month 1, Month 2).
3099326|NCT01988779|Active Comparator|oral placebo with nebulized intranasal levofloxacin|Placebo oral tablet by mouth daily for 14 consecutive days along with nebulized levofloxacin 125 mg twice daily for 14 consecutive days
3099327|NCT01988779|Active Comparator|oral antibiotics with nebulized intranasal placebo|Levofloxacin 500 mg by mouth once daily for 14 consecutive days, along with intranasal placebo solution twice daily for 14 consecutive days.
3099328|NCT01988857|Experimental|dTpa Group|
3099329|NCT01988922|Experimental|Ketamine arm- *1/*1|1.*1/*1- oral racemic ketamine 0.4 mg/kg
3099330|NCT01988922|Experimental|Ketamine arm - *1/*6|2. *1/*6- oral racemic ketamine 0.4 mg/kg
3099331|NCT01988922|Experimental|Ketamine arm - *6/*6|3. *6/*6- oral racemic ketamine 0.4 mg/kg
3099332|NCT01989130|Experimental|Real-time results with Cepheid Xpert CT/NG Test|Diagnosis of +/- CT/NG within 2 hours of specimen entering laboratory
3099333|NCT01989130|Active Comparator|Batched results with Roche AMPLICOR CT/NG test|Diagnosis of +/- CT/NG within 1 to 4 days of visit to the ED
3099334|NCT01989156|Experimental|THS 2.2 Menthol (mTHS 2.2)|Ad libitum use of THS 2.2 Menthol for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3099335|NCT01989156|Active Comparator|Menthol Conventional Cigarette (mCC)|Ad libitum use of subject's own preferred brand of mCC for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3099336|NCT01989156|Sham Comparator|Smoking abstinence (SA)|Abstinence from smoking for 5 Days in a Confinement Setting and 86 Days in an Ambulatory Setting
3099337|NCT01989169|Active Comparator|Midazolam|Administered as a single oral 6 mg dose on Day 1.
3099338|NCT01989169|Experimental|SSP-004184SS + Midazolam|Midazolam (6 mg) + SSP-004184SS (30 mg/kg) concomitantly administered as a single oral dose on Day 1.
3099339|NCT01989195|Experimental|CORONARY DISEASE SUBJECT|ALL SUBJECTS IN THIS STUDY HAVE PREVIOUSLY DOCUMENTED CORONARY ARTERY DISEASE BY ANGIOGRAPHY
3099340|NCT01989208|Placebo Comparator|Sugar capsule|One normal healthy subject and two heart failure subjects will be randomized and given placebo throughout the trial period.
3099341|NCT01989208|Experimental|SG1002|200 mg capsule of SG1002 (alpha sulfur/sodium sulfate)
3099342|NCT01989221|Other|Placebo followed by Sancuso|Placebo at baseline for one week followed by Sancuso® (granisetron transdermal system) 3.1 mg/24 hours for two weeks
3099343|NCT01989455|Experimental|Cohort 1|"Single dose of 500mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
3099344|NCT01989455|Experimental|Cohort 2|"Single dose of 1000mg deferiprone or placebo administered via intravenous infusion and oral solution.~Randomization will be done for all 16 subjects at the same time: 14 will be randomized to receive deferiprone and 2 to receive placebo.~Subjects enrolled to cohort 2 will receive an oral dose of deferiprone."
3099345|NCT01989455|Experimental|Cohort 3|"Single dose of 1500mg deferiprone or placebo administered via intravenous infusion.~Randomization will be done for all 16 subjects at the same time, 14 will be randomized to receive deferiprone and 2 to receive placebo."
3099346|NCT01989455|Experimental|Cohort 4|"Single dose of 2000mg deferiprone or placebo administered via intravenous infusion.~First 2 subjects to enroll: 1 will be randomized to receive deferiprone and the other to receive placebo.~Next 14 subjects enrolled: 13 will be randomized to receive deferiprone and 1 to receive placebo."
3099347|NCT01989468|Experimental|Secukinumab (AIN457) 150 mg s.c.|1 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3099348|NCT01989468|Experimental|Secukinumab (AIN457) 300 mg s.c.|2 s.c. Secukinumab 150 mg autoinjector at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3099349|NCT01989468|Placebo Comparator|Placebo|Matching Placebo at Baseline, Weeks 1, 2, 3, 4, followed by dosing every four weeks starting at Week 4.
3099350|NCT01989546|Experimental|1/Talazoparib (BMN 673)|Single agent
3099351|NCT01989572|Experimental|Arm I (sargramostim, peptide vaccine)|Patients receive sargramostim SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3099352|NCT01989572|Experimental|Arm II (sargramostim placebo, peptide vaccine)|Patients receive sargramostim placebo SC on days 1-14 and peptide vaccine comprising tyrosinase, gp100 antigen, and MART-1 antigen mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3099353|NCT01989572|Experimental|Arm III (sargramostim, peptide placebo)|Patients receive sargramostim SC on days 1-14 and peptide placebo mixed with either incomplete Freund's adjuvant or Montanide ISA-51 VG SC on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3099354|NCT01989572|Placebo Comparator|Arm IV (placebo, peptide placebo)|Patients receive placebo SC on days 1-14 and peptide placebo on days 1 and 15 (course 1) and day 1 (course 2 and subsequent courses).
3099355|NCT01989572|Experimental|Arm V (sargramostim)|Patients receive sargramostim SC on days 1-14.
3099356|NCT01989572|Placebo Comparator|Arm VI (sargramostim placebo)|Patients receive sargramostim placebo SC on days 1-14.
3099359|NCT01989689|Experimental|Etanercept/Placebo|The subjects will receive subcutaneous etanercept therapy at 50mg twice weekly for 3 months then will be switched to placebo therapy for an additional 3 months.
3099360|NCT01989689|Active Comparator|Placebo/Etanercept|The subjects will receive placebo injections for 3 months then will be switched to etanercept therapy for an additional 3 months.
3099361|NCT01989754|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 13 weeks, then the dose may be increased to 300 mg once daily.
3099362|NCT01989754|Placebo Comparator|Placebo|Each patient will receive placebo (inactive medication) once daily.
3099363|NCT01989793|Active Comparator|Losartan|For those subjects randomized to the losartan group, they will receive losartan 25mg by mouth daily for 8 weeks, then increase to 50mg by mouth daily for another 8 weeks, then increase to 100mg by mouth daily for a final 8 weeks.
3099364|NCT01989793|Placebo Comparator|Placebo|For those subjects randomized to placebo, they will receive a placebo to take for 24 weeks total.
3099365|NCT01989910|Active Comparator|Raltegravir|Raltegravir 400mg oral twice daily
3099366|NCT01989910|Active Comparator|Efavirenz|Efavirenz 600mg oral at bedtime
3099367|NCT01990261||Erlotinib|Participants diagnosed with locally advanced or metastatic non-small cell lung with known carcinoma epidermal growth factor receptor (EGFR) status received erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
3099368|NCT01990300||Alogliptin/Pioglitazone combination tablets|Alogliptin/Pioglitazone combination tablets, taken orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
3099369|NCT01990313|Experimental|Activa PC+S|
3099370|NCT01990339||Lansoprazole|Lansoprazole (Takepron), tablets, orally, once daily for up to 8 weeks. Reflux esophagitis: the usual adult dosage is 30 mg of lansoprazole. For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. Nonerosive gastroesophageal reflux disease: the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.
3099371|NCT01990495|Active Comparator|Exercise vs. usual care|The study involves two arms randomized to exercise and usual care groups
3099372|NCT01990495|Active Comparator|Usual care|This group will be randomized to receive usual clinical care. No other interventions will be assigned to this group.
3099373|NCT01990534|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 in every 3-week cycle, until there is evidence of disease progression or unacceptable toxicity occurs (Up to 16 cycles). The dose could be decreased or delayed or discontinued in participants who develop treatment-associated non-hematologic, hematologic toxicity or peripheral neuropathy to brentuximab vedotin.
3099374|NCT01990560|Experimental|Mifepristone|Mifepristone 300mg tablets taken once daily with dose increase of no more than 300mg once monthly and to a maximum dose of 1200mg daily as indicated by symptom response
3099375|NCT01990573|Experimental|methadone HCl 0.3 mg/kg|0.3mg/kg IV methadone HCl
3099376|NCT01990573|Experimental|methadone HCl 0.4 mg/kg|0.4mg/kg IV methadon HCl
3099377|NCT01990573|Active Comparator|control group|control no methadone, standard of care opioids.
3099378|NCT01990612|No Intervention|Expectant Management|Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.
3099379|NCT01990612|Other|Elective Induction of Labor|Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days
3099380|NCT01990664|Experimental|senofilcon A|Contact lenses to be worn in a daily wear modality
3099381|NCT01990664|Experimental|senofilcon A for Astigmatism|Contact lenses to be worn in a daily wear modality
3132619|NCT03441581|Experimental|Eluxadoline 100 mg with BAM|IBS-D participants with evidence of Bile Acid Malabsorption (BAM) treated with eluxadoline 100 mg oral tablets twice daily (BID) with food for 4 weeks.
3132620|NCT03441581|Experimental|Eluxadoline 100 mg without BAM|IBS-D participants without evidence of BAM treated with eluxadoline 100 mg oral tablets BID with food for 4 weeks.
3099382|NCT01990677|Active Comparator|25mg Eplerenone- Chronic CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
3099383|NCT01990677|Placebo Comparator|Placebo- Chronic CSCR Diagnosis|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
3099384|NCT01990677|Active Comparator|25mg Eplerenone- Acute CSCR Diagnosis|Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.
3099385|NCT01990677|Active Comparator|Placebo- Acute CSCR Diagnosis.|Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.
3099386|NCT01990703|Experimental|Early IUD Insertion Group|Immediate post-placental placement of the levonorgestrel IUD
3099387|NCT01990703|Active Comparator|Standard Postpartum Insertion Group|Placement of the levonorgestrel IUD 4-6 weeks postpartum
3099388|NCT01990742|Experimental|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention homes.
3099389|NCT01990742|No Intervention|Standard care|Usual care will be provided to residents in the control homes.
3099390|NCT01990768|Experimental|1 gram Tranexamic Acid (TXA)|Loading dose of 1 gram TXA given prior to hospital arrival followed by a 1 gram TXA infusion over 8 hours after hospital arrival
3099391|NCT01990768|Experimental|2 grams TXA|Loading dose of 2 gram TXA given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
3099392|NCT01990768|Placebo Comparator|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival
3099393|NCT01990794||Study Volunteers|"Volunteers (males and females) were instructed to take the cobalt dietary supplement in the morning according to the manufacturer's label, which suggested a serving of 1 mg cobalt (~2 mL) daily in water or juice as maintenance. Dietary supplementation lasted for approximately three months."
3099394|NCT01990820|Active Comparator|Adenoidectomy without balloon dilation|Subjects will have Adenoidectomy + maxillary sinus irrigation, without balloon dilation.
3099395|NCT01990820|Experimental|Adenoidectomy with balloon dilation|Adenoidectomy + balloon dilation of maxillary sinus ostia using Acclarent Relieva Balloon Sinuplasty + irrigation
3099396|NCT01990859|Experimental|Arm A: Ipilimumab|Ipilimumab Intravenous Injection 3 mg/kg for every 3 weeks upto 4 doses
3099397|NCT01990898|Experimental|Cyclosporine|Drug: Cyclosporine, Pill form, dosage calculated upon patient study visit, frequency - twice daily, duration - 3 months.
3099398|NCT01990950|Experimental|Zenith® Fenestrated AAA Endovascular Graft|
3099399|NCT01991067|Active Comparator|HSCT patients / TBE virus vaccine|Study population: patients who had undergone an allogeneic HSCT 11 to 13 months ago Eligible patients will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME-IMMUN®. Whenever possible, the patients will receive complete primary vaccination with a third dose of TBE vaccine (study visit 9 - 9 to 12 months after the first vaccination).
3099400|NCT01991067|Active Comparator|healthy volunteers / TBE virus vaccine|Clinical healthy volunteers will receive at least two TBE vaccinations (study visit 1 - day 0, study visit 2 -1month after the first vaccination) with a total of two doses of the TBE vaccine FSME IMMUN®. Whenever possible, the volunteers will receive complete primary vaccination with a third dose of TBE vaccine FSME IMMUN® (study visit 9 - 12 months after the first vaccination).
3099401|NCT01991197|Experimental|Sitagliptin|"Double blind phase (week 0-16):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks.~Placebo Comparator: Gliclazide matched placebo One gliclazide matched placebo capsule daily for 4 weeks. If no severe hypoglycaemic episodes one gliclazide matched placebo capsule twice daily for 4 weeks. If no severe hypoglycaemic episodes two gliclazide matched placebo capsules twice daily for 8 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
3099402|NCT01991197|Active Comparator|Gliclazide|"Double-blind phase (week 0-16):~Gliclazide 80mg once daily for 4 weeks Then if no severe hypoglycaemic episodes increase to Gliclazide 80mg twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes increase to Gliclazide 160mg twice daily for 8 weeks Placebo Comparator: Sitagliptin matched placebo Two tablets (or one tablet in participants with moderate kidney disease) once daily for 16 weeks.~Open-label phase (week 16-32):~Sitagliptin two 50mg tablets (or one 50mg in participants with moderate kidney disease) once daily for 16 weeks."
3099403|NCT01991314|Experimental|Ferrous sulphate|Ferrous sulphate 200mg twice daily for 6 weeks
3099404|NCT01991470|Experimental|Enlite sensors|Each subject will first wear enlite sensors and will come for clinic visit for YSI (Yellow Spring Instruments). Then each subject will wear enlite 3 sensors and will come for clinic visit for YSI (Yellow Spring Instruments) or SMBG (Self-Monitoring of Blood Glucose) testing. SMBG testings are for subjects 2-6 years of age and cannot tolerate YSI. In addition. In addition, subjects aged 2-6 years old will not participate in Enlite phase. They only participate in Enlite 3 phase.
3099405|NCT01991483|Experimental|LY2928057 (No ESA)|Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
3099406|NCT01991483|Experimental|LY2928057 (Reduced ESA)|Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
3099407|NCT01991483|Placebo Comparator|Placebo (No ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
3099408|NCT01991483|Placebo Comparator|Placebo (Reduced ESA)|Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
3099409|NCT01991522|Experimental|Curriculum Group|The curriculum group will undergo a comprehensive curriculum in colonoscopy utilizing a virtual reality (VR) colonoscopic simulator. This curriculum involves 6 hours of interactive, small-group didactic teaching on colonoscopy interlaced with 8 hours of supervised one-on-one endoscopy VR simulation training with experienced endoscopists.
3099410|NCT01991522|Active Comparator|Self-directed learning group|The self-directed group will receive 8 hours of colonoscopic virtual reality (VR) simulation practice with an experienced endoscopist present, but without structured training.
3099411|NCT01991548|Other|Diabetic participants with study devices|
3099412|NCT01991743|Active Comparator|Drug:Group 2.5|Administration of 2.5 mg bupivacaine
3099413|NCT01991743|Active Comparator|Group 5|Administration of 5 mg bupivacaine.
3099414|NCT01991743|Active Comparator|Group 7.5|Administration of 7.5mg bupivacaine.
3099415|NCT01991743|Active Comparator|Group 10|Administration of 10 mg bupivacaine.
3099416|NCT01991795|Experimental|Ticagrelor 60 mg|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
3099417|NCT01991795|Placebo Comparator|Ticagrelor placebo|Initially ticagrelor 90 mg or corresponding placebo was the selected dose, but reduced to ticagrelor 60 mg or corresponding placebo in Clinical Study Protocol Amendment No 1.
3099418|NCT01991808|Experimental|DCE-MRI|
3099419|NCT01991821|Experimental|APD421|IV APD421 single dose
3099420|NCT01991821|Placebo Comparator|Placebo|IV placebo single dose
3099421|NCT01991860|Experimental|APD421|APD421 (amisulpride), at 5mg given by single intravenous (IV) administration by slow push over one minute at induction of anaesthesia.
3099422|NCT01991860|Placebo Comparator|Placebo|Matching placebo given by single IV administration by slow push over one minute at induction of anaesthesia
3099423|NCT01991977|Experimental|Diagnostic (PET, pMRI, DTI, IMRT, temozolomide)|Patients undergo 18F DOPA-PET, pMRI and DTI within 14 days before radiation therapy, 3-6 weeks after radiation therapy, and during follow-up. Patients also undergo IMRT over 30 fractions and receive temozolomide.
3099424|NCT01991990|Placebo Comparator|Placebo|
3099425|NCT01991990|Experimental|RoActemra/Actemra|
3099426|NCT01992016|Experimental|Arm I (localized prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment. Patients may then undergo robotic or open radical prostatectomy.
3099427|NCT01992016|Experimental|Arm II (metastatic prostate cancer)|Patients receive ranolazine PO BID for 1 day. Patients undergo FDG-PET/CT scan at baseline and after ranolazine treatment.
3099428|NCT01992094|Experimental|QIVc|Influenza vaccine
3099429|NCT01992094|Active Comparator|TIV1c|Influenza vaccine
3099430|NCT01992094|Active Comparator|TIV2c|Influenza vaccine
3099431|NCT01992107|Experimental|QIVc (≥4 to <18 years)|Subjects received one or two doses of QIVc-Quadrivalent Cell-based Influenza Vaccine recommended for 2013-2014 season
3099432|NCT01992107|Active Comparator|TIV1c (≥4 to <18 years)|"Subjects received one or two doses of TIV1c (Trivalent Inactivated Cell-based Influenza Vaccine containing one strain from B lineage (B1 strain) recommended for 2013-2014 season"
3099433|NCT01992107|Active Comparator|TIV2c (≥4 to <18 years)|"Subjects received one or two doses of TIV2c (Trivalent Inactivated Cell-based Influenza Vaccine containing B strain from the alternate lineage (B2 strain) recommended for 2013-2014"
3099434|NCT01992159|Placebo Comparator|Placebo|Participants received placebo matching to romosozumab administered by subcutaneous injection once a month for 12 months.
3099435|NCT01992159|Experimental|Romosozumab 70 mg|Participants received 70 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3099436|NCT01992159|Experimental|Romosozumab 140 mg|Participants received 140 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3099437|NCT01992159|Experimental|Romosozumab 210 mg|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3099438|NCT01992172|Active Comparator|Photocil for Atopic Dermatitis|Active Drug - Photocil for Atopic Dermatitis
3099439|NCT01992172|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3099440|NCT01992185|Active Comparator|Photocil for Vitiligo|Active Drug - Photocil for Vitiligo
3099441|NCT01992185|Placebo Comparator|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
3099442|NCT01992354|Experimental|Single Arm|Evaluation of PET MR device for image assessment and device performance
3099443|NCT01992380|Experimental|Healthy Volunteer Subjects|Healthy males or females 50 years or older with no evidence of cognitive impairment
3099444|NCT01992380|Experimental|MCI subjects|Subjects 50 years or older with mild cognitive impairment (MCI)
3099445|NCT01992380|Experimental|Probable AD Subjects|Subjects 50 years or older with probable Alzheimer's Disease (AD)
3099446|NCT01992523|Experimental|Ticagrelor mashed pills|Ticagrelor loading dose (LD) 180 mg as mashed pills
3099447|NCT01992523|Active Comparator|Ticagrelor integral pills|Ticagrelor loading dose (LD) 180 mg as integral pills
3099448|NCT01992536|Experimental|Ia: MenABCWY+OMV|Investigational
3099449|NCT01992536|Placebo Comparator|Ib: Placebo|Saline
3099450|NCT01992536|Experimental|IIa: MenABCWY+¼OMV|Investigational
3099451|NCT01992536|Placebo Comparator|IIb: Placebo|Saline
3099452|NCT01992536|Experimental|IIIa: MenABCWY+OMV|Investigational
3099453|NCT01992536|Experimental|IIIb: MenABCWY+¼OMV|Investigational
3099454|NCT01992536|Experimental|IVa: MenABCWY+OMV|Investigational
3099455|NCT01992536|Experimental|IVb: MenABCWY+¼OMV|Investigational
3099456|NCT01992536|Placebo Comparator|IVc: Placebo|Saline
3099457|NCT01992549|Experimental|Human-cl rhFVIII|
3321234|NCT02017366|Active Comparator|Enteral feeding|Treatment group: start jejunostomy feeds from day 1, with target of 1000ml = 1000kCal (= 40cc/hour). To equilibrate energy intake during build up fase, Glucose 20% is given at a total cumulative dose taking into account the dose of j-drip, cumulative not exceeding 40cc/hr. Oral feeds are started at the same time as in the control group (reg. day 5) Jejunostomy feeds are then continued for 6 weeks together with oral intake with a continuous energy administration of 1000kCal, and then stopped. After this time, patients should be on regular full diet in both groups. If failure and step-back needed, temporary switch to Glc 20% is done to maintain fluid and calory administration.
3321235|NCT02017392|Experimental|Compound Lidocaine Cream|The cuff of endotracheal tube is covered by 1-2g compound lidocaine cream before the general anesthesia.
3321236|NCT02017392|No Intervention|blank control|No intervention.
3321237|NCT02017405|Other|5g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 5.0 g total daily dose of SBI on Day 1 followed by 5.0 g Placebo on Day 2 or a 5.0 g total daily dose of Placebo on Day 1 followed by 5.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 2.5g SBI will be taken two times a day for 14 days during the open-label phase."
3321238|NCT02017405|Other|10g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 10.0 g total daily dose of SBI on Day 1 followed by 10.0 g Placebo on Day 2 or a 10.0 g total daily dose of Placebo on Day 1 followed by 10.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 5.0 g SBI will taken two times a day for 14 days during the open-label phase."
3099466|NCT01992757||Cardiac surgery with cardiopulmary bypass|
3099467|NCT01992874|Experimental|Pimasertib Capsule/Pimasertib Tablet|
3099468|NCT01992874|Experimental|Pimasertib Tablet/Pimasertib Capsule|
3099469|NCT01993017|Experimental|AHA Depression Screen & Treat|"Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized."
3099470|NCT01993017|Active Comparator|Depression Screen & Notify Arm Type :|Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion.
3099471|NCT01993017|Placebo Comparator|No Depression Screen|Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms.
3099472|NCT01993030|Experimental|HQ® Matrix Medical Wound Dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed. An operative removal of the HQ® Matrix Medical Wound Dressing is not required as it becomes spontaneously detached from the regenerated skin areas.
3099473|NCT01993030|Active Comparator|Sidaiyi® wound dressing|After harvesting the graft, the donor site wounds were treated with the dressing material. Dressing changes if needed.
3099474|NCT01993108|Experimental|Healthy Controls|Healthy individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
3099475|NCT01993108|Experimental|Adult Attention-Deficit/Hyperactivity Disorder|ADHD individuals will receive a one-time, randomized dose of 40mgs of Methylphenidate, 40mgs of Naltrexone, and a placebo one hour before the fMRI scanning session.
3099476|NCT01993186|Experimental|UX007|"Participants randomized to receive UX007 enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
3099477|NCT01993186|Placebo Comparator|Placebo|"Participants randomized to receive placebo enter a 2-week dose titration period to achieve study drug treatment comprising up to 35% of total daily calories or to the maximum tolerated dose level and maintained at the 35% total daily calorie dose level for a 6-week treatment period.~Following completion of the Week 8 study visit, placebo participants continue treatment with open-label UX007 at the 35% dose level for an additional 44 weeks (Weeks 8-52)."
3099478|NCT01993238|Experimental|Liposonix with pre-treatment analgesia|Liposonix System (Model 2) treatment of subcutaneous adipose tissue with pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
3099479|NCT01993329|Experimental|Gefapixant 50/ Gefapixant 300/ Placebo|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099480|NCT01993329|Experimental|Gefapixant 50/ Placebo/ Gefapixant 300|Gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099481|NCT01993329|Experimental|Gefapixant 300/ Gefapixant 50/ Placebo|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099482|NCT01993329|Experimental|Gefapixant 300/ Placebo/ Gefapixant 50|Gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 1, placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099483|NCT01993329|Experimental|Placebo/ Gefapixant 50/ Gefapixant 300|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 2, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099484|NCT01993329|Experimental|Placebo/ Gefapixant 300/ Gefapixant 50|Placebo to match gefapixant 50 mg and placebo to match gefapixant 300 mg twice daily for 3.5 days during Period 1, gefapixant 300 mg and placebo (for gefapixant 50 mg) twice daily for 3.5 days during Period 2, gefapixant 50 mg and placebo (for gefapixant 300 mg) twice daily for 3.5 days during Period 3. Each period is separated by at least a 7-day wash-out period.
3099485|NCT01993615|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery at the femoroacetabular joint, followed by a standardized post-operative rehabilitation protocol in physical therapy.
3099486|NCT01993615|Active Comparator|Physical Therapy|An impairment-based supervised in-clinic physical therapy program.
3099487|NCT01993667|Active Comparator|Acetazolamide normal dose|Experimental : Acetazolamide 125 mg twice daily
3099488|NCT01993667|Experimental|Acetazolamide low dose|Experimental: Acetazolamide 62.5 mg twice daily
3099489|NCT01993823|Experimental|G238|Five drops into the ear canal twice daily for 14 days
3099490|NCT01993823|Active Comparator|Clotrimazole|Five drops into the ear canal twice daily for 14 days
3099491|NCT01993836|Active Comparator|Total Intravenous Anesthesia with Propofol|Patients in this arm will receive general anesthesia with propofol as the primary amnestic agent.
3099492|NCT01993836|Active Comparator|General anesthesia with Isoflurane|Patients in this arm will undergo general anesthesia with isoflurane as the primary amnestic agent.
3099493|NCT01993849|Active Comparator|N-Acetylcysteine (NAC)|Oral N-acetylcysteine 1200 mg twice daily dosing for 8 weeks
3099494|NCT01993849|Placebo Comparator|Placebo|Oral placebo (matched in appearance to active treatment) twice daily dosing for 8 weeks
3099495|NCT01993875|Experimental|Lubiprostone|
3099496|NCT01993875|Placebo Comparator|Placebo|
3099497|NCT01993888|Experimental|EVARREST® Fibrin Sealant Patch|EVARREST® Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts - a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3099498|NCT01993888|Other|Standard of Care (SoC)|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical. For this study, SoC will be initiated with continuous firm manual compression with or without gauze or sponge and with or without a topical absorbable hemostat (example SURGICEL).
3099499|NCT01993927||Voglibose 0.2 mg or OD Tablets 0.2 mg|Voglibose 0.2 mg or OD Tablets 0.2 mg will be administered orally three times daily immediately before each meal.
3099500|NCT01993940|Experimental|Naldemedine|Participants received 0.2 mg naldemedine orally once daily for 12 weeks.
3099501|NCT01993940|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 12 weeks.
3099502|NCT01994109|Active Comparator|MYOBLOC 2500 U|Subjects will receive specified dose of MYOBLOC
3099503|NCT01994109|Active Comparator|MYOBLOC 3500 U|Subjects will receive specified dose of MYOBLOC
3099504|NCT01994109|Placebo Comparator|Placebo|Subjects will receive volume matched Placebo
3099505|NCT01994226|Active Comparator|Low-dose colchicine|500 mcg every eight hours for four days
3099506|NCT01994226|Active Comparator|Naproxen|Single initial dose of 750 mg followed by 250 mg every eight hours for up to seven days
3099507|NCT01994291|Active Comparator|Arm 1|Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
3099508|NCT01994291|Experimental|Arm 2|Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
3099509|NCT01994395|Experimental|Stride Management Assist (SMA) System|Participants will be randomized into either the SMA group or impairment based (IPT) group. The SMA group (task specific training) will be trained to simulate the demands of overground walking using the Stride Management Assist Device in outpatient physical therapy.
3099510|NCT01994395|Active Comparator|Impairment based therapy|Impairment based therapy will include traditional functional mobility training physical therapy. It will match the SMA group in intensity but will be focused on balance and other functional goals rather than explicitly on walking in outpatient physical therapy.
3099511|NCT01994486|Experimental|Telaprevir and Sofosbuvir|All subjects will receive Telaprevir twice a day, 1125mg capsule and Sofosbuvir 400 mg capsule once daily. Both will be given for 12 weeks.
3099512|NCT01994538|Active Comparator|Longer (14 day) duration antimicrobial treatment|14 days of ciprofloxacin or trimethoprim/sulfamethoxazole
3099513|NCT01994538|Placebo Comparator|Shorter (7 day) duration antimicrobial treatment|7 days of ciprofloxacin or trimethoprim/sulfamethoxazole, followed by 7 days of placebo
3099514|NCT01994590|Experimental|Dovitinib + Abiraterone Acetate + Prednisone|"Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle. Starting dose will be 400 mg daily.~Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.~Participant to take 5 mg oral prednisone, twice daily."
3099515|NCT01994629|Experimental|MenACWY-CRM|MenACWY-CRM
3099516|NCT01994629|Active Comparator|MenACWY-TT|MenACWY-TT
3099517|NCT01994720|Experimental|ticagrelor|
3099518|NCT01994720|Active Comparator|Acetylsalicylic acid (ASA)|
3099519|NCT01994746|Experimental|Nasal Glucagon|At one visit, a glucagon dose of 3 mg was administered in a nostril with a prefilled delivery device that delivers a single dose upon activation.
3099520|NCT01994746|Active Comparator|Intramuscular Glucagon|At a separate visit, 1 mg of glucagon was administered into the deltoid muscle of the non-dominant arm (intramuscular [IM]).
3099521|NCT01994785|Active Comparator|EGD capnography open|Capnographic monitoring during EGD - Data made available to study staff throughout procedure
3099522|NCT01994785|Active Comparator|EGD capnography blinded|Capnographic monitoring during EGD - Data made available to study staff only if necessary for safety reasons
3099523|NCT01994785|Active Comparator|Colonoscopy capnography open|Capnographic monitoring during Colonoscopy - Data made available to study staff throughout procedure
3099524|NCT01994785|Active Comparator|Colonoscopy capnography blinded|Capnographic monitoring during Colonoscopy - Data made available to study staff only if necessary for safety reasons
3099525|NCT01994837|Experimental|ABT-199|Continuous dosing of venetoclax (ABT-199) QD (once daily) beginning with dose-escalation on Week 1 Day 1. Participants received a dose of 20 mg of ABT-199 on Week 1 Day 1, 50 mg on Day 2, 100 mg on Day 3, 200 mg on Day 4, 400 mg on Day 5, 800 mg on Day 6 and QD thereafter.
3099526|NCT01994850|Experimental|Phase I/II|"Total of six 21-day cycles of brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP). Cycle 1 rituximab dose divided between Days 1 and 2 to prevent severe infusion reactions in rituximab naïve patients; brentuximab vedotin and cytotoxic chemotherapy administered on Day 2. Cycles 2 through 6 brentuximab vedotin and R-CHP administered on Day 1. Prednisone (or steroid equivalent) administered Days 1-5 of each cycle (prior to rituximab infusion).~Cycle 1:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 100 mg/m2 IV; Day 2: Rituximab 275 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg or 1.2 mg/kg (Phase I data established a MTD of 1.8 mg/kg brentuximab vedotin)~Cycles 2-6:~Days 1-5: Prednisone (or equivalent) 100 mg PO/IV; Day 1: Rituximab 375 mg/m2 IV, Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg/m² IV, Brentuximab vedotin 1.8 mg/kg"
3099527|NCT01994863|Experimental|First Coloplast Test product; then Standard Care (see below)|"The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
3099528|NCT01994863|Experimental|First Standard Care (see below); Then coloplast test product|"The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation."
3099529|NCT01994876|Experimental|First Coloplast Test 1|"The subjects first test their own product to collect a baseline measurement~The subjects are randomised to first test Coloplast Test 1 and thereafter Coloplast Test 2"
3099530|NCT01994876|Experimental|First Coloplast Test 2|"The subjects first test their own product to collect baseline measurements~The subjects are randomised to first test Coloplast Test 2 and thereafter Coloplast Test 1"
3099531|NCT01994889|Experimental|Tafamidis - 20 mg|Active Treatment-Low dose
3099532|NCT01994889|Experimental|Tafamidis - 80 mg|Active Treatment-High Dose
3099533|NCT01994889|Placebo Comparator|Placebo|Placebo control
3099534|NCT01994902|Experimental|First Coloplast test product|"The subjects test:~test period 1: Coloplast test product test period 2: SenSura Convex Light"
3099535|NCT01994902|Experimental|First SenSura Convex Light|"The subjects test:~test period 1: SenSura Convex Light test period 2: Coloplast test product"
3099536|NCT01994954|No Intervention|Arm A:Standard therapy|Infants' oxygen will be increased, decreased, or maintained based on brief structured assessments during monthly clinic visits. Polysomnograms will be utilized prior to final discontinuation of oxygen. RHO will only be utilized on the night prior to and during the polysomnogram to compare these two modalities.
3099537|NCT01994954|Experimental|Arm B:RHO|"Infants will have the same monthly clinic assessments as in Arm A, but also will utilize RHO to potentially increase, decrease or maintain oxygen between monthly visits.~Parents will transmit a minimum of 4 days of stored RHO data (min 8 hrs per day) every 4-7 days. Changes in oxygen needs will be made based on standardized objective criteria. To determine discontinuation of oxygen, RHO will be utilized instead of polysomnography."
3099538|NCT01994993|Active Comparator|Group 1 (ampicillin +gentamycin +metronidazole)|Ampicillin and gentamycin and metronidazole
3099539|NCT01994993|Active Comparator|Group 2 (ampicillin +gentamicin+clindamycin)|ampicillin and gentamicin and clindamycin
3099540|NCT01994993|Active Comparator|Group 3 (piperacillin-tazobactam and gentamicin)|piperacillin-tazobactam and gentamicin
3099541|NCT01994993|Active Comparator|Group 4 (metronidazole)|Per standard of care antibiotics, and Metronidazole
3099542|NCT01994993|Active Comparator|Group 5 (metronidazole/clindamycin/piperacillin-tazobactam)|metronidazole, clindamycin, or piperacillin-tazobactam
3099543|NCT01995045|Experimental|Bupivicaine & Triamcinolone|Retrobulbar anesthesia with Bupivicaine Hydrochloride and Triamcinolone Acetonide
3099544|NCT01995045|Active Comparator|Bupivicaine|Retrobulbar anesthesia with Bupivicaine Hydrochloride
3099545|NCT01995071|Experimental|Arm 1 Non-cirrhotic|ABT-493 Dose A (100 mg once daily [QD]) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099546|NCT01995071|Experimental|Arm 2 Non-cirrhotic|ABT-493 Dose B (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099547|NCT01995071|Experimental|Arm 3 Non-cirrhotic|ABT-493 Dose C (700 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099548|NCT01995071|Experimental|Arm 4 Non-cirrhotic|ABT-493 Dose D (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099549|NCT01995071|Experimental|Arm 5 Compensated cirrhotic|ABT-493 Dose E (200 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099550|NCT01995071|Experimental|Arm 6 Non-cirrhotic|ABT-530 Dose A (15 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099551|NCT01995071|Experimental|Arm 7 Non-cirrhotic|ABT-530 Dose B (120 mg QD) for 3 days,followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099552|NCT01995071|Experimental|Arm 8 Non-cirrhotic|ABT-530 Dose C (400 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099553|NCT01995071|Experimental|Arm 9 Non-cirrhotic|ABT-530 Dose D (40 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099554|NCT01995071|Experimental|Arm 10 Compensated cirrhotic|ABT-530 Dose E (120 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099555|NCT01995071|Experimental|Arm 11 Non-cirrhotic|ABT-493 Dose F (300 mg QD) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099556|NCT01995071|Experimental|Arm 12 Non-cirrhotic|ABT-530 Dose F (≤ 400 mg) for 3 days, followed by ABT-450/r/ABT-267 (150 mg/ 100 mg/ 25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks
3099557|NCT01995123|Experimental|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
3099558|NCT01995123|Active Comparator|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health. In addition, this arm will receive standard smoking cessation therapy, nicotine patch, and either nicotine gum or nicotine lozenge.
3099559|NCT01995136|Experimental|TRAVATAN Z|Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.
3099560|NCT01995175|Other|Prospective Cohort|Newborn subjects followed up for LRTI symptoms from birth until they are 2 years of age and for incidence of wheeze and asthma up to 6 years of age.
3099561|NCT01995201|Experimental|Part 1: All patients|
3099562|NCT01995201|Experimental|Part 2 A: Sustained clinical remission|
3099563|NCT01995201|Experimental|Part 2 B: Low disease activity|
3099564|NCT01995266|Experimental|Asunaprevir + Daclatasvir|"Asunaprevir 100mg soft capsule by mouth twice daily for 24 weeks and~Daclatasvir 60mg tablet by mouth once daily for 24 weeks"
3099565|NCT01995357|Experimental|First Coloplast Teast A; then Coloplast Test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Coloplast Test B; Standard product; Training + Coloplast Test A; Training + Coloplast Test B"
3099566|NCT01995357|Experimental|First Coloplast Test A; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test A; Standard product; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
3099567|NCT01995357|Experimental|First Coloplast Test B; Then Colopast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test B; Coloplast Test A; Standard product; Training + Coloplast Test B; Training + Coloplast Test A"
3099568|NCT01995357|Experimental|First Coloplast Test B; Then Standard product|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Coloplast Test b; Standard product; Coloplast Test A; Training + Coloplast Test B; Training + Coloplast Test A"
3099569|NCT01995357|Experimental|First Standard product; Then Coloplast Test A|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test A; Coloplast Test B; ; Training + Coloplast Test A; Training + Coloplast Test B"
3099570|NCT01995357|Experimental|First Standard Product, Then Coloplast test B|"There are six arms in this study. The first part of the study investigated the two test products and one comparator product. In the second part of the study the subjects test the two test products again but receive training meanwhile.~The test sequence in this arm is:~Standard product; Coloplast Test B; Coloplast Test A; ; Training + Coloplast Test B; Training + Coloplast Test A"
3099571|NCT01995461|Experimental|BTESI|a prospective, non-randomized, case series investigating bilateral transforaminal epidural steroid injections (BTESI)
3099572|NCT01995487|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
3099573|NCT01995487|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems:~Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent~Delivery system (Rapid Exchange [RX] Coronary System)~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area."
3099574|NCT01995513|Experimental|Enzalutamide & Abiraterone/prednisone|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily
3099575|NCT01995513|Active Comparator|Enzalutamide placebo & Abiraterone/prednisone|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.
3099576|NCT01995526|Experimental|Insulin Peglispro|Single subcutaneous dose of 1.3 Units per kilogram (U/kg) insulin peglispro on Day 1.
3099577|NCT01995539|Experimental|iPro2 Use|All subjects wearing iPro2, having therapy regimens, and having baseline and EOS A1C tests
3099578|NCT01995552|Other|External Loop Recorder|This is a non-randomized study. All the patients will be enrolled will received the ELR system.
3099579|NCT01995825|Experimental|Brand lamotrigine then Generic lamotrigine|Crossover trial. Each arm will receive Brand lamotrigine tablet for two periods and Generic lamotrigine for two periods.
3099580|NCT01995825|Experimental|Generic lamotrigine then Brand lamotrigine|Crossover trial. Each arm will receive Generic lamotrigine tablet for two periods and Brand lamotrigine for two periods.
3099581|NCT01995838|Experimental|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
3099582|NCT01995838|Placebo Comparator|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
3099583|NCT01996241|Experimental|Intervention Village Clusters|Receive multi-level, structural and norms-based intervention
3099584|NCT01996241|No Intervention|Control Village Clusters|No multi-level, structural and norms-based intervention
3099585|NCT01996254|Experimental|SPRINT Group 1|Subjects in Group 1 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
3099586|NCT01996254|Sham Comparator|SPRINT Group 2|Subjects in Group 2 will have a Lead placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System for a total of 8 weeks. They will receive 4 weeks of stimulation and 4 weeks with no stimulation.
3099587|NCT01996319|Active Comparator|Treatment sequence I|QVA149 once a day during 21 days cross-over to placebo once a day for up to 21 days
3099588|NCT01996319|Active Comparator|Treatment sequence II|Placebo once a day during 21 days cross-over to QVA149 once a day for 21 days
3099589|NCT01996332|Experimental|Tarceva Arm|
3099590|NCT01996592||cesarean section deliveries|those subjects having an elective cesarean section will complete an informed consent form, complete the preoperative questionnaire, and then be contacted for 60 days postoperatively
3099591|NCT01996644|Experimental|Setraline|250 mg DCS (setraline) versus placebo plus exposure
3099592|NCT01996644|Placebo Comparator|placebo|Placebo group plus exposure
3099593|NCT01996657||Standard intensity of anticoagulation|After mechanical valve replacement，patients should be gave oral anticoagulants，such as warfarin.and The intensity of anticoagulation for this group was standard intensity (INR:2.5-3.5).
3099594|NCT01996657||Low intensity and adjusted by elevated D-dimer|The intensity of anticoagulation maintained at low level initiatively, D-dimer testing were analyzed at 3 month later. In case of D-dimer level elevated, adjusted the intensity to standard level.
3099595|NCT01996657||Low intensity without adjustment|The intensity of anticoagulation for this group was kept at low intensity without adjustment (INR:1.8-2.6),
3099596|NCT01996709|Experimental|Clear Care|Hydrogen peroxide-based contact lens solution used with habitual contact lenses for 90 days
3099597|NCT01996709|Active Comparator|Habitual MPS|Habitual contact lens solution used with habitual contact lenses for 90 days
3099598|NCT01996748|Experimental|DF277|Two administrations daily for 7 days
3099599|NCT01996748|Placebo Comparator|Placebo|Two administrations daily for 7 days
3099600|NCT01996813|Experimental|Prospective Case|Patients with a BMI of 30 kg/m^2 or greater who underwent shoulder arthroscopy in the beach chair position and were monitored intraoperatively using near-infrared spectroscopy while wearing thigh-high compression stockings.
3099601|NCT01996813|No Intervention|Historical Control|Patients with a BMI of 30 kg/m^2 or greater who underwent elective shoulder arthroscopy in the beach-chair position and were monitored intraoperatively using near-infrared spectroscopy but without wearing compression stockings.
3099602|NCT01996826|Active Comparator|Avastin® (bevacizumab)|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL (2.5 mg) bevacizumab. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical bevacizumab (1% solution). Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3099603|NCT01996826|Placebo Comparator|0.9% NaCl & Refresh Liquigel|"Treatment will begin on Day 0, immediately upon the conclusion of the penetrating keratoplasty procedure with an injection of 0.1 mL 0.9% NaCl. Starting Day 1 post-transplant surgery, subjects will begin treatment with topical Refresh Liquigel. Topical treatment will be self-administered 4 times a day for 4 weeks.~The study treatments (both topical and subconjunctival injection) are to be given in addition to standard of care treatments. Also, all patients will follow a standard post-operative follow-up visit schedule."
3099604|NCT01996839|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
3099605|NCT01996839|Active Comparator|Vehicle (BID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered two times daily (BID).
3099606|NCT01996839|Experimental|Loteprednol Etabonate Gel (TID)|Loteprednol Gel 0.38% administered three times daily (TID).
3099607|NCT01996839|Active Comparator|Vehicle (TID)|Vehicle of Loteprednol Etabonate Gel 0.38% administered three times daily (TID).
3099608|NCT01996904|Experimental|arthroscopic repair|"Lateral-anterosuperior portal (Miracle Portal) was used to repair subscapularis tendon. Bursa anterior to the subscapularis tendon was usually removed for the accurate positioning of the suture-hook. Subscapularis tendon was released, pulled and sutured with suture-hook. One or two suture anchors of Modified Mason-Allen technique was used to secure the tendon."
3099609|NCT01996904|Active Comparator|arthroscopic debridement|Open and arthroscopic cuff debridement procedures have been described in the literatures for management of massive rotator cuff tears; these generally result in decreased pain and overall improvement in patient's function.
3099610|NCT01996917|Active Comparator|Prineo closure|One breast will have skin closure with Prineo.
3099611|NCT01996917|No Intervention|Standard Suture|One breast will be closed in the standard fashion with suture.
3099612|NCT01996943|Placebo Comparator|Placebo|The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.
3099613|NCT01996943|Active Comparator|Ethanol|Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.
3099614|NCT01997125|Experimental|Open Label|Neural bridge system implant and external stimulator
3099615|NCT01997216|Other|Delefilcon A MF, then AOAMF|Delefilcon A multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
3099616|NCT01997216|Other|AOAMF, then Delefilcon A MF|Lotrafilcon B multifocal contact lenses, followed by delefilcon A multifocal contact lenses, as randomized. Each product was worn bilaterally (in both eyes) for 9 hours. The wear periods were separated by 2 ± 1 days.
3099617|NCT01997229|Experimental|Eculizumab|Biological/Vaccine: Eculizumab; Induction phase: 3 vials of study drug (equivalent to 900 mg of eculizumab) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (equivalent to 1200 mg of eculizumab) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (equivalent to 1200 mg of eculizumab) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
3099618|NCT01997229|Placebo Comparator|Placebo|Placebo contains the same buffer components without the active ingredient; Induction phase: 3 vials of study drug (placebo) weekly for 4 doses (every 7 days ± 2 days) followed by 4 vials of study drug (placebo) 1 week later for the fifth dose (Week 4); Maintenance phase: 4 vials of study drug (placebo) every 2 weeks (14 days ± 2 days) from the fifth dose onwards (Week 6 through Week 26).
3099619|NCT01997281|Experimental|DF-cereal|"dietary fiber-enriched cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 79 g (285.7 kcal) for dinner and breakfast, 38.5g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
3099620|NCT01997281|Other|conventional cereal|"conventional cereal is provided with milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount of cereal: 80g (285.7 kcal) for dinner and breakfast, 40g (142.9 kcal) for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
3099621|NCT01997333|Active Comparator|Capecitabine|Capecitabine will be administered on Days 1 through 14 of each 21 day cycle.
3099622|NCT01997333|Experimental|Drug: CDX-011|CDX-011 administered as an intravenous infusion on Day 1 of each 21 day cycle.
3099623|NCT01997411|Experimental|Nasal Glucagon (NG)|Nasal glucagon (NG) doses of 2.0 mg and 3.0 mg for participants 4 to less than 12 years of age and 3.0 mg for those 12 to less than 17 years of age were administered in a nostril with a prefilled delivery device that delivered a single dose upon activation.
3099624|NCT01997411|Active Comparator|Intramuscular (IM) Glucagon|Participants who weighed at least 25 kilograms (kg)/55 pounds (lbs) were dosed 1 mg of IM glucagon; participants who weighed less than 25 kg/55 lbs, IM glucagon dosed with 0.5 mg
3099625|NCT01997437|Other|Tissue-engineered airway transplantation|Stem-cell seeded bioartificial tracheal scaffold
3099626|NCT01997515|Active Comparator|Group K (Ketamine)|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
3099627|NCT01997515|Placebo Comparator|Group P (Placebo)|Group P (placebo) will receive the same amount of saline.
3099628|NCT01997723|Experimental|OSA testing|Cross-over design, single group/arm Interventions: polysomnography with simultaneous portable monitoring and home portable monitoring administered to each participant in random order.
3099629|NCT01997892||Chronic Kidney Disease (CKD)|Participants with CKD on dialysis and treated with PEG epoetin beta for a minimum of 14 weeks immediately prior to being switched to darbepoetin alfa.
3099630|NCT01997905|Experimental|AtriClip LAA Exclusion Device|AtriClip delivered via minimally invasive surgical procedure
3099631|NCT01998243|Experimental|IGB group A|the intervention in the group A : was to place a preoperative intragastric balloon (IGB-BIB®) in the stomach for 6 months before surgery plus an hypocaloric diet 1200 Kilocalories (Kcal)
3099632|NCT01998243|Placebo Comparator|control group B|the intervention in this control group B was the specified diet (a hypocaloric diet of 1200 Kilocalories (Kcal)
3099633|NCT01998269||Adult patients with diabetes and hypertension|
3099634|NCT01998360|Experimental|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and sealing wound with tissue adhesive
3099635|NCT01998360|Active Comparator|Surgical control|Surgical circumcision using forceps guided, dorsal slit, or sleeve method
3099636|NCT01998399|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
3099637|NCT01998399|Placebo Comparator|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
3099638|NCT01998438|Experimental|small dose|10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery
3099639|NCT01998438|Experimental|medium dose|20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery
3099640|NCT01998438|Experimental|large dose|30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery
3099641|NCT01998477|Experimental|TIVc|flu vaccine
3099642|NCT01998477|Active Comparator|TIV|flu vaccine
3099643|NCT01998581|Experimental|JUVEDERM VOLBELLA® XC|Lips injected with JUVEDERM VOLBELLA® XC
3099644|NCT01998581|Active Comparator|Restylane-L®|Lips injected with Restylane-L®
3099645|NCT01998633|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
3099646|NCT01998737||Women under osteoporosis suspicion|
3099647|NCT01998737||Healthy women|
3099648|NCT01998880|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3099649|NCT01998880|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3099650|NCT01998880|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3099651|NCT01998893|Experimental|MabThera/Rituxan|
3099652|NCT01998906|Experimental|HER-2+ Trastuzumab, Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer (HER2+) were treated with trastuzumab 8 milligrams per kilogram (mg/kg), intravenous (IV), on Day 1 of Cycle 1, followed by 6 mg/kg, IV, on Day 1 of Cycle 2 to up a maximum of Cycle 17. Participants also received doxorubicin 60 mg/ square meter (m^2), IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF: cyclophosphamide 600 mg/m^2, IV; methotrexate 40 mg/m^2, IV; and 5-fluorouracil 600 mg/m^2, IV, on Day 1 of Cycles 8 through 10.
3099653|NCT01998906|Active Comparator|HER-2+ Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene positive breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
3099654|NCT01998906|Active Comparator|HER-2- Doxorubicin/Paclitaxel/CMF|Participants with HER2 proto-oncogene negative breast cancer were treated with doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 of Cycles 1 through 3. Followed by paclitaxel 175 mg/m^2, IV, alone on Day 1 of Cycles 4 through 7. Participants also received CMF on Day 1 of Cycle 8 through 10.
3099655|NCT01998919|Experimental|Tarceva + gemcitabine/platinum|
3099656|NCT01998919|Placebo Comparator|Placebo + gemcitabine/platinum|
3099657|NCT01998958|Experimental|Esketamine 14 mg|Participants in Panel B will self-administer intranasal esketamine 14 milligram or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, and 25 during the optional open-label phase. During the optional open-label phase, participants will start with treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3099658|NCT01998958|Experimental|Esketamine 28 mg|Participants in Panel A will self-administer intranasal esketamine 28 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3099659|NCT01998958|Experimental|Esketamine 56 mg|Participants in Panel A and Panel B will self-administer intranasal esketamine 56 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase. During the optional open-label phase, participants in Panel A will self-administer intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 and participants in Panel B will self-administer intranasal esketamine on Days 15, 18, 22, and 25. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3099660|NCT01998958|Experimental|Esketamine 84 mg|Participants in Panel A will self-administer intranasal esketamine 84 mg or placebo on Days 1, 4, 8, and 11 during the double-blind phase and intranasal esketamine on Days 15, 18, 22, 25, 32, 39, 46, 60, and 74 during the optional open-label phase. During the optional open-label phase, all participants will start treatment with a 56-mg dose of intranasal esketamine on Day 15 (the dose of esketamine can be adjusted if desired based on the Investigator's clinical judgment of efficacy and tolerability).
3099661|NCT01998958|Placebo Comparator|Placebo|Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
3099662|NCT01998984|Experimental|2 days placebo and 2 days drug|Placebo and drug
3099663|NCT01998984|Experimental|1 day placebo and 3 days drug|Placebo and drug
3099664|NCT01998984|Placebo Comparator|4 days placebo|Placebo
3099665|NCT01998984|Experimental|4 days drug|Drug
3099666|NCT01999114|Experimental|BTDS|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr
3099667|NCT01999114|Experimental|BTDS with naltrexone|Buprenorphine transdermal patches 10, 40 (2 x 20), and 80 (4 x 20) mcg/hr and naltrexone 50 mg tablets
3099668|NCT01999114|Active Comparator|Naltrexone|Naltrexone 50 mg tablets
3099669|NCT01999114|Placebo Comparator|Placebo|Matching placebo for transdermal patches and/or naltrexone tablets and/or moxifloxacin tablets
3099670|NCT01999114|Active Comparator|Moxifloxacin|Moxifloxacin 400-mg tablets
3099671|NCT01999192|Experimental|Dose Level 1 Tregalizumab|25mg Tregalizumab s.c. weekly
3099672|NCT01999192|Experimental|Dose Level 2 Tregalizumab|100mg Tregalizumab s.c. weekly
3099673|NCT01999192|Experimental|Dose Level 3 Tregalizumab|200mg Tregalizumab s.c. weekly
3099674|NCT01999192|Placebo Comparator|Placebo|Placebo s.c. weekly
3099675|NCT01999218|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
3099676|NCT01999218|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg QD from Day 1 to Week 104
3099677|NCT01999218|Active Comparator|Glimepiride up to 8 mg|Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104
3099678|NCT01999231|Experimental|1μg/ml ESAT6-CFP10|The 1μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3099679|NCT01999231|Experimental|5μg/ml ESAT6-CFP10|The 5μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3099680|NCT01999231|Experimental|10μg/ml ESAT6-CFP10|The 10μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3099681|NCT01999231|Experimental|20μg/ml ESAT6-CFP10|The 20μg/ml ESAT6-CFP10 is given 0.1ml alone to volunteers in the RIGHT or LEFT forearm according to a randomisation scheme.
3099682|NCT01999322|Experimental|FIAsp|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
3099683|NCT01999322|Active Comparator|Insulin Aspart|The trial duration is approximately 13 weeks and consists of a 1-week screening period, a 2-week run-in period, a 6-week treatment period and 1 week plus a 30-day follow-up period
3099684|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
3099685|NCT01999335|Experimental|Oprozomib 150 mg 5/14 + Pomalidomide 2 mg + Dexamethasone|Participants received oprozomib 150 mg once daily on days 1 to 5 and days 15 to 19 (5/14 schedule) of each 28-day treatment cycle, in combination with pomalidomide 2 mg/day on days 1 to 21 and dexamethasone 20 mg on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
3099686|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
3099687|NCT01999335|Experimental|Oprozomib 240 mg 2/7 + Pomalidomide 4 mg + Dexamethasone|Participants received oprozomib 240 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
3099688|NCT01999335|Experimental|Oprozomib 210 mg 2/7 + Pomalidomide 4 mg + Dexamethasone: Expansion Phase|Participants received oprozomib 210 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of each 28-day treatment cycle, in combination with pomalidomide 4 mg on days 1 through 21 and dexamethasone 20 mg/day on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle until disease progression or unacceptable toxicity.
3099689|NCT01999348||Patients with POAG or OHT|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
3099690|NCT01999400|Experimental|Arm 1: Pentasa then Delzicol then Apriso then Lialda|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
3099691|NCT01999400|Experimental|Arm 2: Pentasa then Delzicol then Lialda then Apriso|"Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
3099692|NCT01999400|Experimental|Arm 3: Apriso then Delzicol then Pentasa then Lialda|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose."
3099693|NCT01999400|Experimental|Arm 4: Apriso then Delzicol then Lialda then Pentasa|"Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
3099694|NCT01999400|Experimental|Arm 5: Lialda then Delzicol then Pentasa then Apriso|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose."
3099695|NCT01999400|Experimental|Arm 6: Lialda then Delzicol then Apriso then Pentasa|"Lialda 1200 mg tablet x 1 with 240 mL water, single dose.~Washout period of 10 days.~Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.~Washout period of 10 days.~Apriso 375 mg capsule x 3 with 240 mL water, single dose.~Washout period of 10 days.~Pentasa 500 mg capsule x 2 with 240 mL water, single dose."
3099696|NCT01999465|Active Comparator|Standard NMES cohort|Patients who will apply standard NMES device.
3099697|NCT01999465|Sham Comparator|Sham NMES cohort|Patients who will apply sham NMES device.
3099698|NCT01999517|Active Comparator|Intravenous Nitroglycerin|IV Nitroglycerin with IV Fluids
3099699|NCT01999517|Placebo Comparator|Placebo|IV Fluids
3099700|NCT01999530|Experimental|Prazosin Hydrochloride|Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
3099701|NCT01999569|No Intervention|Control|Control cycle. No intervention.
3099702|NCT01999569|Experimental|Letrozole|5mg daily
3099703|NCT01999777|Experimental|USL261|5 mg intranasal midazolam
3099704|NCT01999777|Placebo Comparator|Placebo|intranasal placebo
3099705|NCT01999868|Experimental|UST, ABA/UST Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of abatacept (ABA) (125 mg) subcutaneous injections weekly from Week 12 to 39, in addition to ustekinumab placebo subcutaneous injections at Weeks 16 and 28.
3099706|NCT01999868|Active Comparator|UST, UST/ABA Placebo|Participants received 2 subcutaneous injections of open-label ustekinumab (UST) (45 mg for participants weighing <=100 kg at study entry or 90 mg for those weighing >100 kg at study entry), at Weeks 0 and 4 during the lead-in phase and were then randomized to receive blinded (masked) treatment of ustekinumab (45 mg if <=100 kg or 90 mg if >100 kg at study entry) subcutaneous injections at Weeks 16 and 28, in addition to abatacept (ABA) placebo subcutaneous injections weekly from Week 12 to 39.
3099707|NCT01999894|Experimental|Memantine|Once daily oral administration of memantine for 48 weeks: 6-week double-blind dose-titration period followed by a 42-week maintenance period.
3099708|NCT01999920|Experimental|Vilazodone|Vilazodone treatment. Dosage will begin at 10mg/day and will be increased to 20mg/day after 1 week, and 40mg/day after two weeks (optional). Dosage can be held steady or lowered at any time during the study as clinically indicated in the event of adverse effects. Twelve weeks of treatment, total.
3099709|NCT01999920|Placebo Comparator|Placebo|Pill placebo.
3099710|NCT01999946|Experimental|Extended-Release Naltrexone (XR-NTX)|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
3099711|NCT01999946|No Intervention|Enhanced Treatment As Usual (ETAU)|Enhanced Treatment As Usual arm will not receive any study medication, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment, including agonist maintenance (methadone and buprenorphine programs), drug-free outpatient and 12-step resources, and residential treatment including supportive housing programs will be provided. These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards.
3099712|NCT01999946|No Intervention|Methadone Treatment Program (MTP)|Quasi-Experimental cohort, will be participants recruited from NYC Rikers Island jail's Key Extended Entry Program (KEEP)'s jail methadone maintenance program, they will not receive any intervention from study, but will receive enhancement counseling centered on post-release treatment involvement and a patient-drug educational handout with direct referrals to re-entry community treatment.These counseling and referral efforts are designed to exceed standard, out-of-treatment experiences, and will ensure both arms are offered tangible health benefits above and beyond that of the usual jail incarceration period in accordance with DHS prisoner research standards. MTP participants are new KEEP methadone participants not enrolled in community methadone at the time of arrest.
3099713|NCT01999972|Experimental|Axitinib in combination with crizotinib, escalation phase|Dose Escalation Advanced solid tumor that is resistant to standard therapy or for which no standard therapy is available
3099714|NCT01999972|Experimental|Expansion Phase Cohort 1|Dose Expansion, Cohort 1: axitinib in combination with crizotinib Advanced renal cell cancer [RCC] with no prior systemic therapy
3099715|NCT01999972|Experimental|Expansion Phase Cohort 2|Dose Expansion, Cohort 2: axitinib in combination with crizotinib Advanced renal cell cancer with at least one but no more than two prior systemic treatment regimens directed at advanced RCC
3099716|NCT01999985|Experimental|Dose Escalation and Dose Expansion|"Dose escalation followed by dose expansion. Escalation cohort: Afatinib and Dasatinib. This study is divided into two parts. The first 8 - 18 people will be entered in the first part, called Phase 1A. Then this part will end.~Expansion cohort:: Afatinib and Dasatinib. The next 20 people will enter into the second part, called Phase 1B."
3099717|NCT02000115|Experimental|Randomized IDE Cohort, Portico Valve|"Portico transcatheter aortic valve and Portico delivery system.~Status: ACTIVE, NOT ENROLLING."
3099718|NCT02000115|Active Comparator|Randomized IDE Cohort, CAV|"Any FDA approved, commercially-available transcatheter aortic valve (CAV).~Status: ACTIVE, NOT ENROLLING."
3099719|NCT02000115|Experimental|Nested Valve-in-Valve Registry|"Subjects who have documented failed aortic surgical valve prosthesis and are deemed eligible to receive a transcatheter Portico valve~Status: ACTIVE, ENROLLING."
3099720|NCT02000115|Experimental|FlexNav Delivery System Study|"Portico transcatheter aortic valve and FlexNav delivery system~Status: ACTIVE, NOT ENROLLING"
3099721|NCT02000154|Experimental|SyB L-1101|
3099722|NCT02000180|Experimental|Progressive Group|The progressive learning group will undertake 6 hours of interactive small-group didactic sessions, interlaced with up to 6 hours of self-directed instruction initially on the low-fidelity box simulator, with feedback provided one-on-one by an expert academic endoscopist. Participants in the progressive learning group can switch to the high-fidelity simulator at their discretion, but cannot return to the low-fidelity simulator. On the high fidelity VR simulator they can progress through six modules each in colonoscopy and endoscopic polypectomy in a self-directed fashion, with one-on-one feedback by an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback. The entirety of this will be delivered over two days.
3099723|NCT02000180|No Intervention|High-Fidelity Group|The high-fidelity group will undertake 6 hours of interactive small-group didactic and hands-on sessions on the theory of colonoscopy, led by an expert academic gastroenterologist. The sessions will be interlaced with up to six hours of self-directed instruction on the high-fidelity VR simulator. Six task-specific modules of increasing difficulty in colonoscopy and colonoscopic polypectomy will be taught solely on the VR simulator with one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques, answer questions and provide feedback as necessary. The entirety of this will be delivered over two days.
3468999|NCT03890562|Experimental|Auricular acupressure for NAS infants|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
3132621|NCT03441633||Group 1. Apixaban|"Patients who are on treatment with apixaban.~1a. patients who have initiated with apixaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~1b. patients who previously have been treated with VKA in the 12 months before index date."
3469000|NCT03890432|Experimental|GLUCOSAFE 2|Insulin-therapy and nutrition support guided by the GLUCOSAFE 2 software.
3469001|NCT03890432|Active Comparator|Local protocol control group|Insulin-therapy and nutrition support guided by the local protocols (electronic or paper version) of the ICU/HUG.
3099725|NCT02000440|Experimental|Losmapimod (GW856553X)|The subjects will be administered with 7.5 mg (1 tablet) of losmapimod following the completion of the Baseline (time zero) assessments. Subjects will continue to take one tablet in the morning and one tablet in the evening for approximately 2 weeks. After all the pre-dose assessments are completed at the Week 2 visit, subjects will be administered the first 15 mg (2 tablets) dose. Subjects will continue to take two tablets in the morning and two tablets in the evening every day for approximately 22 weeks. Doses of study treatment will be separated by at least 6 hours
3099726|NCT02000531|Experimental|Erlotinib-Chemotherapy|Erlotinib in first-line treatment, followed by chemotherapy in the second-line treatment
3099727|NCT02000531|Active Comparator|Chemotherapy-Erlotinib|Chemotherapy in first-line treatment, followed by erlotinib in the second-line treatment
3099728|NCT02000583|Experimental|Aerobic Exercise Group|Exercise 150 minutes per week (over 3 to 5 days) for 52 weeks
3099729|NCT02000583|Other|Control Group|Standard of Care exercise recommendations
3099730|NCT02000622|Experimental|Olaparib|Olaparib tablet 300mg bd po
3099731|NCT02000622|Active Comparator|Physician's choice chemotherapy|Capecitabine 2500 mg/m2 d1-14 q 21, or Vinorelbine 30 mg/m2 d1,8 q 21, or Eribulin 1.4 mg/m2 d1,8 q 21
3099732|NCT02000752|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman.
3099733|NCT02000752|Sham Comparator|Sham acupuncture|Regarding to the control group with sham acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the placebo point with a sterilized 0.25x40 mm steel needle. The control point is located at the same horizontal level than the Ren Mai 6 point, but at 0.6d to the left of the anterior midline of the mother. In this case, the sterilized steel needle of 0.25x25 mm is inserted 15 mm into the tissue.
3099734|NCT02000817|Experimental|Otelixizumab 9 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-9 mg)
3099735|NCT02000817|Experimental|Otelixizumab 18 mg|Each subject will receive otelixizumab 3 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-18 mg)
3099736|NCT02000817|Experimental|Otelixizumab 27 mg|Each subject will receive otelixizumab 4.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-27 mg)
3099737|NCT02000817|Experimental|Otelixizumab 36 mg|Each subject will receive otelixizumab 1.5 mg diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days (cumulative dose-36 mg)
3099738|NCT02000817|Placebo Comparator|Placebo|Each subject will receive otelixizumab matching placebo diluted with 0.9% weight /volume sodium chloride intravenously daily for 6 consecutive days
3099739|NCT02000908|Experimental|Realief Therapy|Each patient will be given 15-18 treatments depending on response of 30-minute duration of photobiomodulation with the Realief Therapy system, scheduled every three times weekly for 5-6 weeks. The treatments will include laser exposure of any or all of 27 differentiated areas of the legs, feet, cervical spine region and lumbar spine region, for durations of 3 to 30 minutes, based on the symptom presentation at the time. Power densities will vary from 5 to 12 watts, based on the symptom presentations through the course of therapy.
3099740|NCT02000908|Sham Comparator|Sham Treatment|"The placebo group will receive sham treatment, during which a heat probe will be guided over both lower extremities over a period of 30 minutes, consistent with the treatment arm. The laser device will be activated during the treatment so that the visual and auditory environment prior to therapy will be the same for both treatment and sham control.~After 8 weeks of sham treatment the subjects in this arm will be offered the photobiomodulation combined with physiotherapy."
3099741|NCT02000921|Experimental|CN + combusted & non-combusted products|Subjects will be asked to smoke the assigned conventional nicotine content (CN) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
3099742|NCT02000921|Experimental|VLNC + combusted & non-combusted products|Subjects will be asked to smoke the assigned very low nicotine content (VLNC) cigarettes, instead of their normal brand, for 8 weeks and will also be given access to use other combusted and non-combusted tobacco and medicinal nicotine products during that time.
3099743|NCT02000921|Experimental|VLNC with non-combusted products|Subjects will be asked to smoke very low nicotine content (VLNC) cigarettes instead of their usual cigarettes for an 8 week period and will be given the opportunity to use non-combusted types of tobacco and medicinal tobacco products.
3099744|NCT02000973|Placebo Comparator|Normal saline|General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
3099745|NCT02000973|Experimental|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine 8ml
3099746|NCT02000973|Experimental|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
3099747|NCT02000973|Experimental|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
3099748|NCT02001051|Other|Operative Arm|operative arm
3099749|NCT02001051|Other|Delayed Operative Arm|delayed operative arm
3099750|NCT02001064|Experimental|Care4Today v2.0 mobile application + electronic monitoring of adherence|"Care4Today v2.0 mobile application~Participants in the experimental application arm will use the Care4Today v2.0 mobile application for antiretroviral medication adherence support. Alert messages generated via the app will be targeted to the specific schedule and needs of the individual.~Electronic monitoring of adherence:~Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap."
3099751|NCT02001064|No Intervention|Electronic monitoring of adherence|Participants' adherence to antiretroviral therapy medication is measured via Medication Event Monitoring System (MEMS) cap.
3099752|NCT02001181|Experimental|Treatment group A|
3099753|NCT02001181|Placebo Comparator|Treatment B|
3099754|NCT02001194|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Control Arm will receive no financial incentive.
3099755|NCT02001194|Experimental|Individual|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 if that participant met the step goal during the prior day.
3099756|NCT02001194|Experimental|Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $50 only if all four team members met the step goal during the prior day.
3099757|NCT02001194|Experimental|Individual Plus Team|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each participant will also be notified as to how many of their teammates reached the goal the previous day. Every day one team from the arm will be chosen at random as the winning team. Each participant on the winning team receives $20 if the participant met the step goal during the prior day the participants met their own goal. Each participant will also receive an additional $10 for every one of the other three team members that also met the goal.
3099758|NCT02001558|Experimental|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily.
3099759|NCT02001558|Active Comparator|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily.
3099760|NCT02001688|Experimental|Kamada-AAT for Inhalation, 80mg|Daily inhalation of Kamada-AAT for Inhalation, 80mg
3099761|NCT02001688|Placebo Comparator|Placebo|Placebo administered by inhalation daily
3099762|NCT02001688|Experimental|Kamada-AAT for Inhalation, 160mg|Daily inhalation of Kamada-AAT for Inhalation, 160mg
3099763|NCT02001714|Experimental|Group Behavioral Treatment|Participants will attend a group behavioral treatment class and follow-up visits.
3099764|NCT02001714|No Intervention|No Treatment|Subjects will not attend group behavioral treatment class.
3321239|NCT02017405|Other|20g Serum-derived bovine immunoglobulin protein isolate (SBI)|"Phase 1: Twelve subjects will receive either a 20.0 g total daily dose of SBI on Day 1 followed by 20.0 g Placebo on Day 2 or a 20.0 g total daily dose of Placebo on Day 1 followed by 20.0 g SBI on Day 2 during the double-blind, crossover phase.~Phase 2: 20.0 g SBI will be taken two times a day for 14 days during the open-label phase."
3321240|NCT02017405|Other|Matching Placebo|Placebo will be taken either on Day 1 or on Day 2 based on the randomization during the double-blind, crossover phase.
3321241|NCT02017418|Experimental|zeaxanthin|placebo zeaxanthin
3099768|NCT02001987|Experimental|Tocilizumab|Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection once a week administered as monotherapy or in combination with methotrexate or other csDMARDs (at investigator's discretion) for 24 weeks. Participants who complete the core study period will be allowed to enter a long-term-extension (LTE) period to continue study treatment for up to a maximum of another 52 weeks or until the commercial availability of SC tocilizumab, whichever occurs first.
3099769|NCT02002091||Complications,no specific treatment|After screening for complications, a non specific multi interventional treatment is applied to patients. After one year of follow up, we will compare two groups: with and without chronic kidney disease, on the advent of cardiovascular events. An adjustment is done for age and major risk factors.
3099770|NCT02002182|Experimental|Treatment-Vaccine Group|Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.
3099771|NCT02002182|No Intervention|Control Group|Observational control group treated with standard of care therapy only
3099772|NCT02002208|Experimental|OC000459 Tablets|50 mg orally once a day
3099773|NCT02002208|Placebo Comparator|Placebo Tablets|Orally once a day
3099774|NCT02002221|Experimental|Vildagliptin (LAF237)|Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
3099775|NCT02002221|Placebo Comparator|Placebo|In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
3099776|NCT02002494||volunteers in different positions|"The following will be compared in the same volunteer:~Bilateral internal jugular venous flow in supine and prone position~Bilateral internal jugular venous flow in supine and park bench position~Bilateral internal jugular venous flow in prone and park bench"
3099777|NCT02002533|Experimental|Arm I (BBT intervention)|Patients undergo BBT intervention, comprising insomnia education, stimulus control, discouragement of napping and encouragement of exercise, and sleep compression over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
3099778|NCT02002533|Active Comparator|Arm II (control)|Patients undergo HEAL comprising nutritional education and suggestions for symptom management over two 60 minute face-to-face sessions in weeks 1 and 3 or 4, and four 15 minute telephone sessions in weeks 2, 3, 5, and 6 or 2, 4, 5, and 6.
3099779|NCT02002650|Experimental|Pre-ERCP group|Pre-ERCP rectal Indomethacin in all patients.
3099780|NCT02002650|Active Comparator|Post-ERCP group|Post-ERCP rectal Indomethacin in high-risk patients.
3099781|NCT02002689|Experimental|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.
3099782|NCT02002702|Experimental|Serelaxin 10 mcg/kg/Day|Participants received 10 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
3099783|NCT02002702|Experimental|Serelaxin 30 mcg/kg/Day|Participants received 30 mcg/kg/day serelaxin as continuous i.v. infusion for 48 hours.
3099784|NCT02002702|Placebo Comparator|Placebo|Participants received continuous i.v. infusion of placebo matched to serelaxin for 48 hours.
3099785|NCT02002767|Experimental|Participants with renal impairment|Participants with severe renal impairment will receive a single dose of velpatasvir.
3099786|NCT02002767|Active Comparator|Participants with normal renal function|Participants with normal renal function will receive a single dose of velpatasvir.
3099787|NCT02002832|Experimental|Lurasidone group|
3099788|NCT02002832|Active Comparator|Risperidone group|
3099789|NCT02002871|Experimental|Blue light|Irradiation with PSOCT02 device emitting blue light at a wavelength of 453nm
3099790|NCT02002871|No Intervention|Control|contralateral untreated control plaque on the same patient.
3099791|NCT02002884|Experimental|8 Units per kg body weight incobotulinumtoxinA (Xeomin)|8 Units per kg body weight (maximum of 200 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 300 Units per injection cycle. Overall maximum dose per injection cycle: 500 Units.
3099792|NCT02002884|Experimental|6 Units per kg body weight incobotulinumtoxinA (Xeomin)|6 Units per kg body weight (maximum of 150 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 225 Units per injection cycle. Overall maximum dose per injection cycle: 375 Units.
3099793|NCT02002884|Experimental|2 Units per kg body weight incobotulinumtoxinA (Xeomin)|2 Units per kg body weight (maximum of 50 Units) will be injected per treated upper limb per injection cycle. Additionally, lower limb treatment may be administered, depending on clinical pattern: up to 75 Units per injection cycle. Overall maximum dose per injection cycle: 125 Units.
3099794|NCT02002936|Experimental|SyB C-1101|
3099795|NCT02002975||Pioglitazone 15 to 30 mg|administered orally once daily before or after breakfast for 3 years.
3099796|NCT02003014||Pioglitazone 15 mg to 30 mg|administered orally once daily
3099797|NCT02003053|Experimental|IMT|In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
3099798|NCT02003053|Sham Comparator|Sham|In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge.
3099799|NCT02003183||Suspected CTE|A total of 22 participants with suspected CTE were studied. Each received clinical and neuropsychological assessments, [F-18]FDDNP-PET scans, and magnetic resonance imaging (MRI) scans, or computed tomography scans if they could not tolerate MRI (to assist in PET region of interest identification).
3099800|NCT02003352|Experimental|Functional Neurological Rehabilitation|Functional Neurological and physical/vestibular rehabilitation strategies
3099801|NCT02003365|Experimental|FX006 10 mg|Single 3 mL intra-articular (IA) injection
3099802|NCT02003365|Experimental|FX006 40 mg|Single 3 mL intra-articular (IA) injection
3099803|NCT02003365|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection
3099804|NCT02003391|Experimental|DuoTrav|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 8 weeks.
3099805|NCT02003391|Active Comparator|Beta-blocker|Participant's current beta-blocker monotherapy, 1 drop instilled in the study eye twice daily (morning and evening) for 4 weeks, followed by travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution, 1 drop instilled in the study eye once daily (evening) for 4 additional weeks.
3099806|NCT02003404||Control Abdominal Skin|Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.
3099807|NCT02003404||Peristomal Abdominal Skin|Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.
3099808|NCT02003508||Pre-school based vaccination program (not vaccine eligible)|Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
3099809|NCT02003508||Post-school based vaccination program (vaccine eligible)|Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
3099810|NCT02003534|Experimental|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
3099811|NCT02003573|Experimental|volasertib + decitabine|dose escalation and MTD (Maximum Tolerated Dose) Extension (Note: Decitabine is a Backbone Treatment and Volasertib is Investigational Medicinal Product (IMP))
3099812|NCT02003625|Placebo Comparator|A. GCSF + Placebo|GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis [days -4, -3, -2, -1] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.
3099813|NCT02003625|Experimental|B. GCSF + meloxicam|"B. GCSF + meloxicam:~Patients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10^6 CD34+ cells/kg are collected."
3099814|NCT02003638|Experimental|Niacin|Niacin titrated up to 6 grams taken orally every day for 12 weeks
3099815|NCT02003638|Placebo Comparator|Placebo|Placebo taken orally every day for 12 weeks
3099816|NCT02003898|Experimental|Medtronic MiniMed 530G Insulin Pump|All subjects received diabetes treatment using the Medtronic MiniMed 530G insulin pump.
3099817|NCT02003911|Experimental|Azithromycin suspension|"Azithromycin suspension at 10mg/kg/dose (max 500mg)~Once daily for 3 days"
3099818|NCT02003911|Placebo Comparator|Placebo suspension|"Same volume as active drug~Once daily for 3 days"
3099821|NCT02003963|Experimental|Exergame Intervention|"Participants randomly assigned to the exergame condition will participate in the intervention condition of Klub Kinect. Klub Kinect is a 12-week intervention occurring for 90-minute sessions, 3 times per week. During each 90-minute intervention session, adolescents will engage in 60-minute bouts of aerobic gaming. Adolescents attending an exergaming session will attend concurrently."
3099822|NCT02003963|No Intervention|Control (Self-Directed Care)|The control condition will receive no contact or intervention other than telephone reminders of their final clinic visit.
3099823|NCT02004093|Experimental|Chemotherapy + Pertuzumab|
3099824|NCT02004093|Active Comparator|Chemotherapy|
3099825|NCT02004132|Experimental|Axiron|Axiron administered topically via metered dose pump to each underarm on Day 1
3099826|NCT02004158|Experimental|Positive psychology|Positive psychology intervention
3099827|NCT02004236|Experimental|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
3099828|NCT02004236|Experimental|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
3099829|NCT02004236|Placebo Comparator|tRNS with sham|This group receive 35 sessions with sham
3099830|NCT02004262|Experimental|Primary Cohort: Cy/GVAX + CRS-207|"200 mg per square meter (mg/m^2) cyclophosphamide (Cy) administered by intravenous (IV) infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (GVAX, 5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 colony forming units [CFU]) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3099831|NCT02004262|Experimental|Primary Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3099832|NCT02004262|Active Comparator|Primary Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The Primary Cohort comprised those subjects who failed at least 1 gemcitabine-based regimen administered for pancreatic cancer in any setting and failed at least 2 prior chemotherapy regimens administered for pancreatic cancer in the metastatic setting."
3099833|NCT02004262|Experimental|2nd-line Cohort: Cy/GVAX + CRS-207|"200 mg/m^2 Cy administered by IV infusion on Day 1 of Weeks 1 and 4; GVAX pancreas vaccine (5 × 10e8 cells) administered by intradermal injection on Day 2 of Weeks 1 and 4; CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3099834|NCT02004262|Experimental|2nd-line Cohort: CRS-207|"CRS-207 (1 × 10e9 CFU) administered by IV infusion on Day 1 of Weeks 1, 4, 7, 10, 13, 16.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3099835|NCT02004262|Active Comparator|2nd-line Cohort: Chemotherapy|"Investigator's choice of one of the following: gemcitabine (1000 mg/m^2) administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle; capecitabine (1000 mg/m^2) administered orally twice a day on Days 1 through 14 of a 21-day cycle; fluorouracil with or without leucovorin (2400 mg^m2) administered by IV infusion over 46 hours on Days 1 and 15 of a 28-day cycle; irinotecan (150 mg/m^2) administered by IV infusion on Days 1 and 15 of a 28-day cycle; or erlotinib (100 mg) administered orally once a day for a 21-day cycle.~The 2nd-line Cohort comprised those subjects who received and failed 1 prior chemotherapy regimen administered for pancreatic cancer in the metastatic setting."
3099836|NCT02004288|Experimental|Lactobacillus reuteri Protectis DSM17938|One chewable tablet twice per day with L reuteri Protectis DSM 17938, 1x108 CFU/tablet (colony forming unit)
3099837|NCT02004288|Placebo Comparator|Placebo|One chewable tablet twice per day with placebo per day
3099838|NCT02004353||Cochlear® Hearing Implants, hearing loss|Implanted Adolescents and Adults with permanent hearing loss
3099839|NCT02004366|Experimental|Linagliptin In-hospital|Linagliptin once daily+ correction doses of aspart or lispro if needed
3099840|NCT02004366|Active Comparator|Basal Bolus In-hospital|Glargine once daily and rapid-acting insulin before meals + correction doses of aspart or lispro if needed
3099841|NCT02004366|Experimental|Linagliptin on discharge|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day. If contraindication to oral anti-diabetics (OAD), discharge patient on linagliptin once daily.
3099842|NCT02004366|Experimental|Linagliptin+50%Glargine dose on d/c|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
3099843|NCT02004366|Experimental|Linagliptin+80%Glargine dose on d/c|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
3099844|NCT02004522|Experimental|Duvelisib|Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules
3099845|NCT02004522|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
3132622|NCT03441633||Group 2. VKA|"Patients who are on treatment with VKA.~2a. patients who have initiated with VKA as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~2b. patients who previously have been treated with VKA in the 12 months before index date."
3099846|NCT02004613|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 mcg/kg/hr at the end of bypass, the dose will be increased to 0.2 mcg/kg/hr. Postoperatively patients will continue to receive the study medication at a rate of 0.4mcg/kg/hr. The study medication infusion will be continued for a total of 24 hours from the initial administration time intra-operatively.
3099847|NCT02004613|Placebo Comparator|Placebo|normal saline administration matching dexmedetomidine rate of infusion.
3099848|NCT02004847|Experimental|High Intensity (HI) vs control|PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
3099849|NCT02004847|Experimental|Low Intensity (LI) vs control|PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
3099850|NCT02004873|Experimental|Micra Pacemaker Implant|
3099851|NCT02004886|Experimental|MK-0893 (40 mg)|MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893.
3099852|NCT02004886|Experimental|MK-0893 (120 mg)|MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893
3099853|NCT02004886|Active Comparator|Metformin (2000 mg)|Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893.
3099854|NCT02004886|Placebo Comparator|Placebo|Placebo tablets matching the MK-0893 and placebo tablets matching metformin.
3099855|NCT02004977|Experimental|Intervention arm|The role of the intervention arm (schools) is to improve access to the school breakfast program
3099856|NCT02004977|No Intervention|Comparison arm|the role of the comparison arm (schools) is to maintain usual breakfast program at school
3099857|NCT02004990|Experimental|Single cleansing procedure of 10% povidone iodine cleansing|10% povidone iodine cleansing
3099858|NCT02005016|Experimental|Intervention|All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
3099859|NCT02005029|Placebo Comparator|Placebo|One time IV dose of placebo
3099860|NCT02005029|Experimental|Erythromycin|One time IV dose of 100 mg Erythromycin
3099861|NCT02005211|Experimental|AZD3293|AZD3293 will be administered as single dose of an oral solution in Part 1 and single and multiple doses of an oral solution in Part 2. The ascending doses are planned to be 15, 50 and 150 mg for young subjects in Part 1 and 15 and 50 mg for elderly subjects in Part 2. Before proceeding to next dose level, safety, tolerability and pharmacokinetic data from the previous cohort(s) will be evaluated by a Safety Review Committee. Part 2 will start after confirming safety and tolerability in Part 1.
3099862|NCT02005211|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3099863|NCT02005250||hyperthyroidism|61 pre- and postmenopausal women with hyperthyroidism
3099864|NCT02005250||hypothyroidism|32 pre- and postmenopausal women with hypothyroidism
3099865|NCT02005276|No Intervention|Control|Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day.
3099866|NCT02005276|Experimental|Basic Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day."
3099867|NCT02005276|Experimental|Combined Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 5 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day."
3099868|NCT02005276|Experimental|Jackpot Lottery|"Participants receive either an email or text message daily (based on the participant's preference) stating whether the participant achieved the 7000 step goal during the previous day. Each day a lottery will be held, and participants will be eligible to collect monetary rewards only if the participant met the step goal the day before. The names of the winners will be announced during each lottery. The daily lotteries are as follows:~About a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day."
3099869|NCT02005354|Active Comparator|Trans-cutaneous Electrical Nerve Stimulation (TENS)|"The Intervention-TENS group will have 2 electrodes applied proximal to the painful area along neuro-anatomical distribution (electrode-one placed 5cm superior and 2cm medial to the posterior superior iliac spine and electrode-two placed 5cm medial to the posterior superior iliac spine) in the same way as the control-TENS group.~The concealed electrical parameter in this group will be within the therapeutic window, that is, well above the sensory detection threshold but below the pain threshold giving a strong but comfortable sensation. From previous studies, this is likely to be 50-110Hz.~The device will be activated prior to entry into the treatment room and 2 minutes before administration of local anaesthetic and for 2 minutes after removal of the biopsy needle. This will cover the expected duration of pain as assessed in the pilot study.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
3099870|NCT02005354|Placebo Comparator|Trans-cutaneous Electric Nerve Stimulation (TENS)|"Patients in the CT group will have 2 gel-electrodes applied proximal to the sampling area (usually the right posterior superior iliac crest).~The Control-TENS device will be identical in appearance to the Intervention-TENS device with a functioning display panel. The concealed electrical parameter in this group will be titrated to and set at the sensory detection.~All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)"
3321242|NCT02017418|Active Comparator|combinatory supplement|placebo combinatory supplement
3099871|NCT02005393|Other|FICE Imaging System followed by NBI|Images Captured with FICE Image Acquisition System (experimental) followed by NBI Image Acquisition System (standard of care); always in that order. Imaging took place in esophagus, gastric, duodenum and/or colon.
3099872|NCT02005471|Active Comparator|Bendamustine + Rituximab|Participants will receive bendamustine 70 milligrams per meter squared (mg/m^2) via intravenous (IV) infusion on Days 1 and 2 of each 28-day cycle for 6 cycles, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
3099873|NCT02005471|Experimental|Venetoclax + Rituximab|Participants will be initially placed on a venetoclax 5 weeks ramp-up period, and will receive an initial dose of 20 milligrams (mg) via tablet orally once daily (QD). Then the dose will be incremented weekly up to a maximum dose of 400 mg. Participants will then continue receiving venetoclax 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards, as directed by the investigator, in combination with rituximab 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
3099874|NCT02005471|Experimental|Bendamustine + Rituximab Crossover Substudy|Participants entering the Crossover Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Crossover Day 1 of the Substudy.
3099875|NCT02005471|Experimental|Venetoclax + Rituximab Re-Treatment|Participants entering the Re-Treatment Substudy will have a 5-week venetoclax dose ramp-up period to reach the target dose of 400 mg QD. Following the venetoclax ramp-up period, Participants will receive 6 cycles of rituximab consisting of a single infusion on the first day of each 28-day cycle. Participants will continue to take their daily dose of venetoclax during the rituximab cycles. Participants who have not progressed following the completion of the 6 cycles will continue to receive venetoclax monotherapy until disease progression or for a maximum of 2 years from Cycle 1 Re-Treatment Day 1 of the Substudy.
3099876|NCT02005484|Experimental|Trastuzumab Monotherapy|Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit
3099877|NCT02005510|Experimental|In-home HPV Screening|"Usual care PLUS a mailed in-home high-risk HPV testing kit (accompanied by an invitational letter, research information sheet, and illustrated instructions for using the kit). Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
3099878|NCT02005510|Placebo Comparator|Usual Care|"Usual care. Usual care consists of patient-, provider-, clinic- and systems-level services to promote adherence to Pap screening, including an annual birthday letter with Pap screening reminders, telephone outreach from primary care providers, and automatic alerts in the electronic medical record for overdue women."
3099879|NCT02005536|Experimental|Study Group|Participants will receive one booster dose of SP059 (IMOVAX POLIO®)
3099880|NCT02005549|Experimental|Neoadjuvant Therapy|
3099881|NCT02005562|Experimental|Mycophenolate Mofetil, Adapted Dose|Participants received 3 grams (g) mycophenolate mofetil (MMF) tablets per os (p.o.) in divided doses (every 12 hours [q12h]) adapted to mycophenolic acid (MPA) by area under the curve (AUC) beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by interleukin-2R (IL-2R) was administered at Day 0 per standard of care at the site at the investigator's discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 nanograms (ng) per (/) milliliter (mL) from Day 0 to (-) Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg intravenously (i.v.) was administered before or after the transplantation, and 0.5 milligrams (mg) per kilogram (kg) p.o. daily from Day 1 - Day 7.
3099882|NCT02005562|Active Comparator|Mycophenolate Mofetil, Fixed Dose|Participants received 2 g MMF tablets p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing through Week 52. In addition, induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion. At 72 hours post-transplantation, participants received cyclosporine 100-1500 ng/mL from Day 0 - Week 4, 800-1200 ng/mL from Week 4 - Week 12 and 500-800 ng/mL from Week 12 - Week 52. Solumedrol 500 mg i.v. was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 - Day 7.
3099883|NCT02005601|Experimental|Duloxetine|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
3099884|NCT02005601|Placebo Comparator|Control|Patients will receive 0mg of duloxetine
3099885|NCT02005627|Active Comparator|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 standardised quality units tablet (SQ-T) once daily.
3099886|NCT02005627|Placebo Comparator|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
3099887|NCT02005666|Experimental|Test-Cadila healthcare limited|Drug:-Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3099888|NCT02005666|Active Comparator|Reference|Drug:-DUAC® Gel (of Stiefel Laboratories, USA) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3099889|NCT02005666|Placebo Comparator|Placebo|Drug:-Placebo (Vehicle Gel) Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
3099890|NCT02005692|Experimental|DynaSense sensor|
3099891|NCT02005887|Experimental|triptorelin + letrozole|Arm A: Triptorelin 3.75 mg i.m. on day 1 every 28 days for 6 cycles + letrozole 2.5 mg/day orally for 6 cycles
3099892|NCT02005887|Experimental|degarelix + letrozole|Arm B: Degarelix 240 mg s.c. on day 1 of cycle 1, followed by 80 mg s.c. on day 1 of cycles 2 to 6 + letrozole 2.5 mg every day orally for 6 cycles
3099893|NCT02006056|Experimental|Secondary prophylaxis|Patients already experiencing mild nausea/vomiting within 24 hours before radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
3099894|NCT02006056|Experimental|Primary prophylaxis|Patients experiencing no nausea and vomiting 24 hours before commencement of radiotherapy. Intervention is 8mg of ondansetron (Ondissolve) on the day of radiation treatment at least 1 hour prior to treatment and repeated approx. 608 hours later in the day (bid). For patients who are treated with 20Gy/5 fractions, or 30Gy/10 fractions, they will take ondansetron twice (bid) on each day of treatment, at least 1 hour prior to treatment, and also on weekends or holidays in between treatment.
3099895|NCT02006108|Experimental|Feraheme|"Intravenous injection of Feraheme, 5 mg Fe/kg~Interventions:~Drug: Feraheme Procedure: MR Scan"
3099896|NCT02006121|Active Comparator|Apomorphine hydrochloride|Apo-go® Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
3099897|NCT02006121|Placebo Comparator|Placebo|Placebo: saline infusion
3099898|NCT02006160|Active Comparator|treatment|dalfampridine
3099899|NCT02006160|Placebo Comparator|control|placebo
3099900|NCT02006264|Active Comparator|TDF Intravaginal Ring|Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
3099901|NCT02006264|Placebo Comparator|Placebo Intravaginal Ring|The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
3099902|NCT02006342|Experimental|Insulin Glargine plus Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring, with the addition of subcutaneous Insulin Glargine within 2 hours of diagnosis.
3099903|NCT02006342|Active Comparator|Control - Regular Insulin|Patient's with Diabetic Ketoacidosis receiving standard of care treatment with regular insulin drip, IV fluids and close monitoring.
3099904|NCT02006420||ARFI-SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
3099905|NCT02006420||Healthy Volunteers: ARFI/SVI Ultrasound|Ultrasound imaging of forearm and thigh, lasting approximately 5-10 minutes.
3099906|NCT02006472|Experimental|Pridopidine 45 mg|Twice daily
3099907|NCT02006472|Experimental|Pridopidine 67.5 mg|Twice daily
3099908|NCT02006472|Experimental|Pridopidine 90 mg|Twice daily
3099909|NCT02006472|Experimental|Pridopidine 112.5 mg|Twice daily
3099910|NCT02006472|Placebo Comparator|Placebo|Twice daily
3099911|NCT02006576|Placebo Comparator|COPD, Placebo|Placebo three times daily
3099912|NCT02006576|No Intervention|Control subject|Control subjects, no intervention
3099913|NCT02006576|Experimental|COPD, ibuprofen|600 mg ibuprofen three times daily for 48 weeks
3099914|NCT02006628|Active Comparator|GWP42003 1000 milligrams (mg)/day|Participants received GWP42003 (100 mg/milliliter [mL]), 5 mL twice daily (BID) administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
3099915|NCT02006628|Placebo Comparator|Placebo|Participants received placebo (0 mL cannabidiol [CBD]), volume matched to the 5 mL BID dose level, administered orally, 5 mL in the morning and 5 mL in the evening for 6 weeks.
3099916|NCT02006641|Placebo Comparator|Placebo|Placebo adjunct to 10 mg Donepezil
3099917|NCT02006641|Experimental|Idalopirdine 10 mg|Idalopirdine adjunct to 10 mg Donepezil
3099918|NCT02006641|Experimental|Idalopirdine 30 mg|Idalopirdine adjunct to 10 mg Donepezil
3099919|NCT02006654|Placebo Comparator|Placebo|Placebo adjunct to base treatment with an AChEI
3099920|NCT02006654|Experimental|Idalopirdine 60 mg (or 30 mg)|Idalopirdine adjunct to base treatment with an AChEI
3099921|NCT02006667|Experimental|Trastuzumab, Gemcitabine, Cisplatin|Participants received an initial loading dose of 4 milligrams per kilogram (mg/kg) trastuzumab intravenous (i.v.) on Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v until disease progression; 1200 mg per square meter (m2) gemcitabine i.v. on Days 1, 8, and 15 of Cycles 1 through 6; and 70 mg/m2 cisplatin i.v. on Day 2 of Cycles 1 through 6.
3099922|NCT02006693|Other|XEN® Gel Stent|The XEN®45 Gel Stent (XEN45 implant) was placed in the study eye as a standalone procedure.
3099923|NCT02006693|Other|XEN® Gel Stent with Cataract Surgery|The XEN® Gel Stent (XEN45 implant) with cataract surgery, occurred if the participant was diagnosed with a cataract.
3099924|NCT02006706|Experimental|MabThera/Rituxan|
3099925|NCT02006719|Experimental|Collagenase Clostridium Histolyticum|Up to 3 injections of .58 mg/1 mL of collagenase clostridium histolyticum (CCH), minimum of 21 days apart and home shoulder exercise.
3099926|NCT02006719|Placebo Comparator|Placebo|Up to 3 1-mL injections of placebo, minimum of 21 days apart and home shoulder exercise.
3099927|NCT02006732|Experimental|tiotropium + olodaterol low dose|Once daily 2 puffs solution for inhalation Respimat
3099928|NCT02006732|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3099929|NCT02006732|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3099930|NCT02006732|Placebo Comparator|placebo|Once daily 2 puffs solution for inhalation Respimat
3099931|NCT02006758||Uncontrolled hypertension patients|The study will enroll 500 patients planned to undergo a renal denervation procedure (with the 'EnligHTN™ Renal Denervation System') for the treatment of their uncontrolled hypertension.
3099932|NCT02006836|Other|Diabetic|Diabetic patients use metformin or only on diet control(met or diet).18 of the patients were on metformin treatment and 2 patients were on diet control due to the early stage of this disease. On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of diabetic patients enrolled for the case control period.
3099933|NCT02006836|Other|Healthy|On the first test day we utilized 50 g of glucose dissolved in 200 ml water. The second day was washout day. On the third day we used 922 g of Majia pomelos which contained 50 g carbohydrate.This group of volunteers enrolled for the case control period.
3099934|NCT02006836|Other|Diabetic 2 - without pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 4th to 6th day with a constant dose of insulin and did not consumed Majia pomelos after meals, and this intervention was defined as blank.
3099935|NCT02006836|Other|Diabetic 2 - with pomelo|Patients of Diabetic 2 group were on CSII treatment with insulin subcutaneous pump.The scheme and dose of CSII for each patients were adjusted on the first 3 test days to optimize glucose control, followed by 3-day CSII treatment without change of insulin dose. On the 7th test day, patients consumed 100g Majia pomelos after meals (breakfast, lunch and dinner) for 3 test days. This arm refers to the group on the 7th to 9th day with a constant dose of insulin and consumed 100g Majia pomelos after meals (breakfast, lunch and dinner).
3099936|NCT02006888|Experimental|IBI-10090 low dose|IBI-10090 low dose
3099937|NCT02006888|Experimental|IBI-10090 med dose|IBI-10090 med dose
3099938|NCT02006888|Placebo Comparator|Placebo|Placebo
3099939|NCT02006979|Experimental|Exercise|an acute bout of exercise performed ≤24 hours prior to each cycle of anthracyclines and no exercise for 48 hours post
3099940|NCT02006979|No Intervention|No exercise|no exercise for 72 hours prior or 48 hours post each cycle of anthracyclines
3099941|NCT02007070|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.
3099942|NCT02007096|Experimental|Transabdominal Plane Block|Receiving Transabdominal Plane Block with 0.25% bupivacaine
3099943|NCT02007096|Placebo Comparator|Non Transabdominal Plane Block|Receiving placebo saline injection
3099944|NCT02007109||Nausea measurement by VAS and BARF|"All patients will be asked to rate their nausea on both the VAS and the BARF scales. For the nausea scales, the script would be: Have you thrown up or felt like you were going to throw up before? How did your tummy feel then? We call that feeling of being sick to the stomach as nausea.~For the BARF scale:These faces show children who feel no nausea at all, who feel a little bit nauseated, who feel even more nauseated, and these are children who have the most nausea it is possible to feel. (Point to the each face at the appropriate time). Which face is more like you feel right now? For the VAS scale: On this line the far left indicates No nausea and the far right Worst nausea ever. Can you show me on this line how much nausea you have right now?"
3099945|NCT02007200|Experimental|Treatment (soy isoflavones)|Patients receive soy isoflavones PO for approximately 14 days before undergoing surgery.
3099946|NCT02007252|Experimental|ACZ885|Participants received ACZ885 150 mg subcutaneously (s.c.) once per month for 12 months.
3099947|NCT02007252|Placebo Comparator|Placebo|Participants received matching placebo to ACZ885 s.c. once per month for 12 months.
3099948|NCT02007278|Active Comparator|vildagliptin and metformin|Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks
3099949|NCT02007278|Active Comparator|glimepiride and metformin|Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin
3099950|NCT02007369|Experimental|WhatsApp|Provide peer support and deliver relapse prevention messages through WhatsApp for 8 weeks and telephone follow ups
3099951|NCT02007369|Experimental|Facebook|Provide peer support and deliver relapse prevention messages through Facebook for 8 weeks and telephone follow ups
3099952|NCT02007369|No Intervention|Control|Telephone follow ups and received a self-help book only
3099953|NCT02007434|Experimental|Paradigm 1 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL (based on Baseline CR-SMFRS grade 2 or 3, respectively) on Day 0 and a cold compress applied to the treatment area.
3099954|NCT02007434|Placebo Comparator|Paradigm 1/ Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0 and a cold compress applied to the treatment area.
3099955|NCT02007434|Experimental|Paradigm 2 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics (lidocaine/epinephrine) and a cold compress applied to the treatment area.
3099956|NCT02007434|Placebo Comparator|Paradigm 2 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, topical and injectable anesthetics and a cold compress applied to the treatment area.
3099957|NCT02007434|Experimental|Paradigm 3 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents (loratadine and ibuprofen), topical and injectable anesthetics and a cold compress applied to the treatment area.
3099958|NCT02007434|Placebo Comparator|Paradigm 3 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3099959|NCT02007434|Experimental|Paradigm 4 / Deoxycholic Acid Injection|Participants received deoxycholic acid 2 mg/cm² administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3099960|NCT02007434|Placebo Comparator|Paradigm 4 / Placebo|Participants received placebo administered in 0.2 mL injections, either 6 or 8 mL on Day 0, a compression chin strap, oral antihistamine and anti-inflammatory agents, topical and injectable anesthetics and a cold compress applied to the treatment area.
3099961|NCT02007512|Experimental|Enzalutamide & exemestane|Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.
3321243|NCT02017431|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific inhaled allergen challenge
3099962|NCT02007512|Active Comparator|Placebo & exemestane|Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.
3099963|NCT02007577|Active Comparator|salsalate 3500mg in 2 divided doses a day|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
3099964|NCT02007577|Placebo Comparator|placebo|Participants will take 3 placebo tablets with breakfast and 4 placebo tablets with dinner
3099965|NCT02007720|Placebo Comparator|Placebo|Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
3099966|NCT02007720|Experimental|Serelaxin|Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
3099967|NCT02007863|Experimental|Umbilical Cord Blood + Chemotherapy|Umbilical Cord Blood transfusion + Chemotherapy (Fludarabine + Busulfan + Melphalan)
3099968|NCT02007954|Experimental|DEBDOX|
3099969|NCT02008149|No Intervention|Standard of care group|SCI individuals receiving conventional rehab
3099970|NCT02008149|Experimental|FES-rowing group|Individuals with SCI participating in an FES-rowing program
3099971|NCT02008227|Experimental|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3099972|NCT02008227|Active Comparator|Docetaxel|Docetaxel 75 milligrams per meter square (mg/m^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3099973|NCT02008318|Experimental|Phase (ph) 2: Galunisertib + BSC|Ph 2. 150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
3099974|NCT02008318|Placebo Comparator|Ph 3: Placebo + BSC|Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive BSC according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
3099975|NCT02008318|Experimental|Ph 3: Galunisertib + BSC|150 milligrams Galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Participants will receive best supportive care (BSC) according to institutional guidelines. Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit. This arm is contingent on the data from the phase 2 arm.
3099976|NCT02008396|Placebo Comparator|Inactive Placebo with Psychotherapy|Subjects will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
3099977|NCT02008396|Experimental|75 mg to 125 mg MDMA with Psychotherapy|Participants will receive 75 to 125 mg during two psychotherapy sessions lasting approximately 7 hours; first session dose lower than second session dose.
3099978|NCT02008526|Experimental|TXT-PHE|"Gay-specific, Theory-based Text Messages Transmitted by Peer Health Educators (TXT-PHE)~This condition is interactive and tailored to the needs of the individual participant. PHEs initiate (i.e., push) text messages to participants and also respond to participant-initiated queries and participant responses to the PHE messages (i.e., pull).~Participants receive five pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
3099979|NCT02008526|Experimental|TXT-Auto|"Group 2: Gay-specific, Theory-based Text Messages Transmitted by Automation (TXT-Auto)~Participants assigned to this group receive automatic text-messages.~Following the initial welcome message, participants receive five pre-written messages per day sent on a predetermined schedule.~During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
3099980|NCT02008526|No Intervention|Assessment Only (AO)|During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
3099981|NCT02008565|Placebo Comparator|Placebo - Exercise plus Biofeedback|"Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
3099982|NCT02008565|Experimental|Loperamide - Exercise plus Biofeedback|"Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits."
3099983|NCT02008565|Placebo Comparator|Placebo - Education Only|"Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
3099984|NCT02008565|Experimental|Loperamide - Education Only|"Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.~Participants receive education and a NIDDK Bowel Control Educational pamphlet."
3099985|NCT02008617|Active Comparator|Study Drug|Ultrasound guided posterior genicular nerve infiltration with 30mL of Bupivicaine 0.20% with epinephrine 1:300,000 (Study Drug)
3099986|NCT02008617|Sham Comparator|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
3099987|NCT02008682|Experimental|Liraglutide 1.8 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
3099988|NCT02008682|Active Comparator|Sitagliptin 100 mg + metformin|2-week screening period, 26-week treatment duration, and a 1-week follow-up period
3099989|NCT02008773|Active Comparator|valacyclovir|3000mg daily oral 16 weeks
3099990|NCT02008773|Placebo Comparator|placebo|placebo 6 capsules daily oral 16 weeks
3099991|NCT02008877|Experimental|ganetespib / sirolimus|28-day cycles of ganetespib + sirolimus
3099992|NCT02008890|Experimental|Secukinumab 300mg|"Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148."
3099993|NCT02008890|Experimental|Secukinumab 150mg|"Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.~In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.~For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148."
3099994|NCT02008890|Placebo Comparator|Placebo|Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
3099995|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 300 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3099996|NCT02008916|Experimental|Secukinumab 10 mg/kg i.v. / 150 mg s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
3099997|NCT02008916|Placebo Comparator|Placebo i.v. and s.c.|Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection at weeks 8 and 12. At week 16, patients were re-randomised to one of the active treatment arms, to receive secukinumab s.c. Q4W until the end of the study.
3099998|NCT02008942|Experimental|PL2200 Aspirin Capsules|PL2200 Aspirin Capsules
3099999|NCT02008942|Active Comparator|Enteric-coated aspirin caplets|Enteric-coated aspirin caplets
3100000|NCT02009046|Experimental|SEI Classroom Curriculum|Participants receive the SEI classroom curriculum.
3100001|NCT02009046|Active Comparator|Control Classroom Curriculum|Participants receive the control classroom curriculum.
3100002|NCT02009046|Experimental|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and three school wide components (peer advocacy and education, parent education, clinical services linkages).
3100003|NCT02009046|Active Comparator|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components (clinical services linkages).
3100004|NCT02009163|Experimental|Lisdexamfetamine dimesylate|Administer one capsule (50 or 70 mg) orally daily at approximately 7:00 AM.
3100005|NCT02009163|Placebo Comparator|Placebo|Administer one capsule orally daily at approximately 7:00 AM.
3100006|NCT02009332|Experimental|Phase 1: ABI-009 100 mg/week|Phase 1, Cohort 1: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
3100007|NCT02009332|Experimental|Phase 1: ABI-009 200 mg/week|Phase 1, Cohort 2: ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
3100008|NCT02009332|Experimental|Phase 1: ABI-009 100 mg 2×/week|Phase 1, Cohort 2b: ABI-009 injectable suspension, 100 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, twice per week (total dose 200 mg per week) for 6 weeks
3100009|NCT02009332|Experimental|Phase 1: ABI-009 300 mg/week|Phase 1, Cohort 3: ABI-009 injectable suspension, 300 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
3100010|NCT02009332|Experimental|Phase 1: ABI-009 400 mg/week|Phase 1, Cohort 4: ABI-009 injectable suspension, 400 mg in 80 mL 0.9% saline, administered intravesically and retained for 2 hours, once per week for 6 weeks
3100011|NCT02009332|Experimental|Phase 2: ABI-009 400 mg/week + Gemcitabine 2000 mg/week|ABI-009 injectable suspension, 200 mg in 80 mL 0.9% saline, administered intravesically and retained for 1 hour, once per week for 6 weeks; Gemcitabine, 2000 mg in 100 mL saline, administered intravesically after voiding of ABI-009 and retained for 1 hour, once per week for 6 weeks
3100012|NCT02009397|Experimental|Ipilimumab and GM-CSF|IV ipilimumab followed by subcutaneous GM-CSF, for up to 4 cycles
3100013|NCT02009501|Active Comparator|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
3100014|NCT02009501|Active Comparator|VAC Ulta Therapy|VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.
3100015|NCT02009696||Pacemaker Therapy|Patients with a ProMRI Pacemaker System
3100016|NCT02009722|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal hydromorphone will be 40 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
3100017|NCT02009722|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one-time dose of intrathecal hydromorphone or intrathecal morphine as part of their spinal anesthesia. The starting dose of intrathecal morphine will be 100 micrograms. This will be adjusted in subsequent patients based on the previous patient's success or failure according to an up-and-down methodology utilizing a biased coin design.
3100018|NCT02009865|Experimental|Epanova 2 g/day|Arm 1
3100019|NCT02009865|Placebo Comparator|Olive Oil 2 g/day|Arm 2
3100020|NCT02009878|Other|tolvaptan 3.75 mg|tolvaptan 3.75 mg
3100021|NCT02009878|Other|tolvaptan 7.5 mg|tolvaptan 7.5 mg
3100022|NCT02009878|Other|tolvaptan 15 mg|tolvaptan 15 mg
3100023|NCT02010021|No Intervention|No drug treatment|Post-menopausal women with stage I-III breast cancer will have surgical resection of tumor and tumor tissue will be used to study cell growth signaling pathways ex-vivo.
3321244|NCT02017431|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific inhaled allergen challenge
3100024|NCT02010021|Active Comparator|Letrozole-presurgical|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
3100025|NCT02010151|Experimental|NAD-CPR|When dispatcher detects a patient with OHCA, the dispatcher activates trained neighborhoods by informing events nearby using short message service via cellular phone. The neighborhood within geographically accessible area who could perform effective CPR and defibrillation would be alerted with event of OHCA and the nearest AED.
3100026|NCT02010151|No Intervention|Conventional dispatcher assisted CPR|When dispatcher detects OHCA, they instruct the caller with CPR instructions. This is conventional dispatcher assisted CPR performed in Seoul.
3100027|NCT02010203|Experimental|Phase I: HS-410 Low Dose|In the open label Phase 1 portion, HS-410 is given as 1*10^6 cells per dose for 12 weekly injections followed by 3 monthly injections.
3100028|NCT02010203|Experimental|Phase II: HS-410 Low-Dose Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^6 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
3100029|NCT02010203|Experimental|Phase II: High-Dose HS-410 Plus BCG|In the Phase 2 portion, HS-410 is given as 1*10^7 cells per dose weekly for 6 weeks in combination with BCG, followed by 6 weeks of HS-410 alone, and then 3 courses of three once-weekly doses of HS-410 in combination with BCG.
3100030|NCT02010203|Placebo Comparator|Phase II: Placebo Plus BCG|In the Phase 2 portion, a placebo is given weekly for 6 weeks in combination with BCG, followed by 6 weeks of placebo alone, and then 3 courses of three once-weekly doses of placebo in combination with BCG.
3100031|NCT02010203|Experimental|Phase II: High-Dose HS-410|In the Phase II portion, if patients will not receive BCG, HS-410 is given as 1*10^7 cells per dose weekly for 12 weeks, and then 3 courses of three once-weekly doses of HS-410.
3100032|NCT02010216|Experimental|tocilizumab [RoActemra/Actemra]|Participants received tocilizumab 8 mg/kg by intravenous infusion every 4 weeks for 12 weeks (3 cycles).
3100033|NCT02010255|Experimental|Cohort A, Group 1 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3100034|NCT02010255|Experimental|Cohort A, Group 1 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3100035|NCT02010255|Experimental|Cohort A, Group 2 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3100036|NCT02010255|Experimental|Cohort A, Group 2 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3100037|NCT02010255|Experimental|Cohort B, Group 3 (12 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with Fibrosis Stage F0-F3
3100038|NCT02010255|Experimental|Cohort B, Group 3 (24 wk): F0-F3 Fibrosis|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with Fibrosis Stage F0-F3
3100039|NCT02010255|Experimental|Cohort B, Group 4 (12 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with CPT Class A (CPT score 5-6)
3100040|NCT02010255|Experimental|Cohort B, Group 4 (24 wk): CPT Class A (5-6)|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with CPT Class A (CPT score 5-6)
3100041|NCT02010255|Experimental|Cohort B, Group 5 (12 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class B (CPT score 7-9)
3100042|NCT02010255|Experimental|Cohort B, Group 5 (24 wk): CPT Class B (7-9)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class B (CPT score 7-9)
3100043|NCT02010255|Experimental|Cohort B, Group 6 (12 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 12 weeks in participants with CPT Class C (CPT score 10-12)
3100044|NCT02010255|Experimental|Cohort B, Group 6 (24 wk): CPT Class C (10-12)|LDV/SOF (90/400 mg) plus RBV (starting at 600 mg, then adjusted ± based on tolerability [weight-based maximum: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg]) for 24 weeks in participants with CPT Class C (CPT score 10-12)
3100045|NCT02010255|Experimental|Cohort B, Group 7 (12 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 12 weeks in participants with FCH
3100046|NCT02010255|Experimental|Cohort B, Group 7 (24 wk): FCH|LDV/SOF (90/400 mg) plus RBV (weight-based: < 75 kg = 1000 mg, ≥ 75 kg = 1200 mg) for 24 weeks in participants with FCH
3100047|NCT02010359|Experimental|Lovaza|Lovaza 4 grams daily (2 1-gram capsules twice daily) will be given for 8 weeks
3100048|NCT02010359|Placebo Comparator|Placebo|An inactive Placebo (2 pills twice daily) will be given for 8 weeks
3100049|NCT02010567|Experimental|CLRX101 MTD/RP2D|During Phase Ib, we will evaluate the safety and determine the MTD/RP2D of CRLX101 + capecitabine (Cape) and radiation therapy (XRT) in patients with rectal cancer using the traditional 3+3 dose escalation design. Adverse events (AEs) will be evaluated via the CTCAE version 4.0. Patients in Phase Ib will also be followed for pathological response if they have resectable disease.
3100050|NCT02010567|Experimental|Chemoradiotherapy + Surgery|In Phase II, CRLX101 will be administered at the RP2D in combination with capecitabine and radiation in patients with locally advanced rectal cancer for a total of 5-6 weeks, depending on the total radiation dose. A total of 3 doses of CRLX101 will be administered every other week. Surgery will take place at least 6 weeks after the completion of chemoradiotherapy.
3100051|NCT02010632|Experimental|Generic clopidogrel product|Apolets® 75 mg tablet
3100052|NCT02010632|Active Comparator|Original clopidogrel product|Plavix® 75mg tablet
3100053|NCT02010645|Experimental|Eltrombopag + Decitabine|"Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.~Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle."
3100054|NCT02010684|No Intervention|Wait-listed Control Group|Participants in the Wait-listed Control Group will receive augmented access and communication with a primary care provider. The augmentation would consist of providing the participant with a letter to be shared with their primary care doctor indicating their Hb A1c level and depression score at the time of eligibility screening. The research team will also attach a list of local mental health service providers to the letter. The participants randomized to the wait-listed control group will also be offered access to the intervention after the trial is completed in the event that the randomized controlled trial (RCT) has significant results.
3100055|NCT02010684|Experimental|Empowerment and CBT Classes|"Participants will attend weekly 2-hour group Empowerment and CBT classes for 12 weeks led by two trained health educators. Participants will learn cognitive behavioral therapy (CBT) techniques to manage their mood. After CBT, participants will learn a diabetes education format that is grounded in empowerment theory that employs group problem solving, individualized goal setting, and personal behavioral change experiments designed to help patients set priorities and to become better self-managers of both diabetes and their mood. As part of the intervention activities, group members will be advised to monitor their blood sugar levels, blood pressure, and mood on a daily basis."
3100056|NCT02010697|Experimental|Messages targeting nonsmokers|Messages targeting nonsmokers include 10 mailings for nonsmokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
3100057|NCT02010697|Experimental|Messages targeting smokers|Messages targeting smokers include 10 mailings for smokers sent over 10 weeks. The mailed materials include postcards, informational materials, CDs, DVDs, coupons for cessation-related incentives such as nicotine patches, and links to secured websites. The mail campaign is augmented with brief phone calls to ensure receipt of mailings and to reinforce targeted messages.
3100058|NCT02010697|No Intervention|Usual care|one time mailing with a self-help quit kit
3100059|NCT02010775|Active Comparator|BOTOX® 24U|Botulinum Toxin Type A (BOTOX®) 24U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3100060|NCT02010775|Active Comparator|BOTOX® 48U|Botulinum Toxin Type A (BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3100061|NCT02010775|Active Comparator|BOTOX® 72U|Botulinum Toxin Type A (BOTOX®) 72U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3100062|NCT02010775|Active Comparator|BOTOX® 96U|Botulinum Toxin Type A (BOTOX®) 96U total dose administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3100063|NCT02010775|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
3100064|NCT02010996|Experimental|Vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
3100065|NCT02010996|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
3100066|NCT02011113|Experimental|Pomalidomide plus dexamethasone|
3100067|NCT02011386||Treatment|Treatment: Injection Golimumab 50 mg every month on the same date
3100068|NCT02011464|Experimental|Exparel infiltration|Exparel infiltrated into the posterior compartment of the knee
3100069|NCT02011464|Placebo Comparator|Control|Saline infiltrated into posterior compartment
3100070|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 1|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3100071|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 1|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3100072|NCT02011490|Experimental|Healthy Control Participants: Part 1|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered by direct injection into a peripheral vein.
3100073|NCT02011490|Experimental|Severe Renal Insufficiency Participants: Part 2|Participants with severe renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3100074|NCT02011490|Experimental|Moderate Renal Insufficiency Participants: Part 2|Participants with moderate renal insufficiency will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3100075|NCT02011490|Experimental|Healthy Control Participants: Part 2|Healthy control participants will receive a single dose of 4 mg/kg sugammadex administered as an IV bolus over 10 seconds. Dose will be administered into a peripheral vein through an IV catheter connected to an IV tubing with injection port. The IV tubing is connected to a saline bag. Free-flowing access to the vein will be confirmed immediately prior to dose administration, and dose will be followed by saline flush.
3100076|NCT02011516|Placebo Comparator|Sugar pill, psychosocial intervention|twice weekly appointments with a certified clinician
3100077|NCT02011516|Active Comparator|Baclofen, psychosocial intervention|20 mg. q.i.d. twice weekly appointments with a certified clinician
3100078|NCT02011893|Experimental|Burst Stimulation|Burst Stimulation using the Prodigy system
3100079|NCT02011893|Active Comparator|Tonic Stimulation|Tonic Stimulation using the Prodigy system
3100080|NCT02011945|Experimental|dasatinib Only|dasatinib 100 mg QD(CP) or 140 mg QD (AP)
3100081|NCT02011945|Experimental|Dose Level 1|Nivolumab 1 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
3100082|NCT02011945|Experimental|Dose Level 2|Nivolumab 3 mg/kg q 2 weeks + dasatinib 100 mg QD (CP) or 140 mg QD (AP)
3100083|NCT02012192|Experimental|Ganetespib + Paclitaxel|Drug: ganetespib, dose will depend on phase I results, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle); Drug: paclitaxel, 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression.
3100084|NCT02012192|Active Comparator|Paclitaxel|Drug: paclitaxel: 80 mg/m2, given iv once weekly for 3 out of 4 weeks (days 1, 8, 15 of each 4-weeks/28-days cycle), until progression
3100085|NCT02012218|Experimental|ADT and Brexpiprazole|ADT and Brexpiprazole
3100086|NCT02012283|Experimental|Vegetable Intake with Spices Added|Subjects consuming vegetables with mixed-spices added.
3100087|NCT02012283|Active Comparator|Vegetable Intake without Spices Added|Subjects consuming vegetables without spice.
3100088|NCT02012348|Placebo Comparator|Control soap|Forearms of subjects in this arm will be washed with control (non-antibacterial) soap
3100089|NCT02012348|Experimental|Antibacterial soap with triclocarban|The forearms of subjects in this group will be washed with antibacterial soap containing triclocarban
3100090|NCT02012348|Active Comparator|Antibacterial soap + benzalkonium chloride|The forearms of subjects in this group will be washed with antibacterial soap containing benzalkonium chloride
3100091|NCT02012452|Experimental|tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
3100092|NCT02012452|Sham Comparator|health education treatment|Participants will be provided education on a variety of health topics and will set health goals around each topic
3100093|NCT02012491|Active Comparator|misoprostol plus mifepristone|800 micrograms vaginal misoprostol, preceded by 200 milligrams oral mifepristone 24 hours prior
3100094|NCT02012491|Active Comparator|misoprostol|800 micrograms of vaginal misoprostol alone
3100095|NCT02012582|Experimental|VAS203 15 mg/kg|Three 5 mg/kg/12-hours infusion with 12 hours break after each infusion. Total dose: 15 mg/kg
3100096|NCT02012582|Experimental|VAS203 20 mg/kg|10 mg/kg/24 hours, 48 hour continuous infusion. Total dose: 20 mg/kg
3100097|NCT02012582|Experimental|VAS203 30 mg/kg|10 mg/kg/24 hours, 72 hour continuous infusion. Total dose: 30 mg/kg
3100098|NCT02012582|Placebo Comparator|Saline|0.9 % Sodium chloride infusion
3100099|NCT02012686|Placebo Comparator|Control group|numerical rating scale of TENS non-applied group
3100100|NCT02012686|Active Comparator|TENS group|numerical rating scale of TENS applied group
3100101|NCT02012959|Experimental|Tolvaptan Early Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 millimoles/liter [mmol/L]) were randomized to either the Early or Late Withdrawal Group. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Discontinued tolvaptan treatment immediately after randomization.~All participants were observed up to 14 days post randomization."
3100102|NCT02012959|Experimental|Tolvaptan Late Withdrawal|"All participants initially received tolvaptan once daily for the first 2 days. A third day of treatment was permitted if a participant had not reached the desired sodium target improvement per the investigator's judgment.~At the end of Day 2 (or Day 3), responders (participants who achieved an increase in serum sodium by ≥4 mmol/L) were randomized to either the Early or Late Withdrawal Group in Treatment Phase B. Non-responders could continue treatment with tolvaptan for an additional 2 days.~Continued treatment for 2 additional days.~All participants were observed up to 14 days post randomization."
3100103|NCT02013037|Experimental|Eculizumab|Administration of Eculizumab to heart transplant recipients at Cedars Sinai Medical Center with a panel reactive antibody (PRA) ≥ 70%, for the prevention of antibody-mediated rejection.
3100104|NCT02013050|Placebo Comparator|Placebo|Control
3100105|NCT02013050|Experimental|SGX942|Investigational Drug i) 1.5 mg/kg ii) 3.0 mg/kg iii) 6.0 mg/kg
3469002|NCT03890432|Other|Historical control group|"Retrospective data with standard care before the beginning of the pilot study in order to minimize the cross-over effect due to the fact that caregivers are going to have in charge patients in both groups (intervention and control group) at the same time."
3469003|NCT03890393||patients with episodic headache|
3100108|NCT02013180||prostate cancer|prostate adenocarcinoma in pathologic evaluation
3100109|NCT02013180||control|benign prostatic diseases in pathologic evaluation
3100110|NCT02013206|Experimental|Never Smokers|Never Smokers (participants who smoked ≤ 100 cigarettes in entire lifetime or had never smoked cigarettes) received erlotinib [Tarceva] 150 mg orally daily until disease progression or unacceptable toxicity.
3321245|NCT02017431|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by inhaled saline challenge
3469004|NCT03890393||patients with chronic headache|
3469005|NCT03890393||healthy controls|
3469006|NCT03890653|Experimental|Performance-Based Financing|At least one primary healthcare centre per ward and one General Hospital per selected LGA (in 50% of LGAs in each of the 3 states) and one secondary hospital per State will be contracted by the State Primary Health Care Development Agency ) , to deliver specified services at an agreed price. Selection of which services to focus on is based on priorities identified by the Federal Government of Nigeria and the states in 2010-2015. Initial prices for each service were based on shadow prices of providing the service and have been adjusted based on implementation experience.
3469007|NCT03890653|Experimental|Decentralized Facility Financing|In the other half of the LGA's in each treated state, at least one facility per ward will receive Decentralized Facility Financing (DFF) or equivalent financing that is not be linked to any service delivery targets. These payments would be made on a quarterly basis.
3100111|NCT02013206|Experimental|Current/Former Smokers|Current Smokers (participants who smoked > 100 cigarettes in entire lifetime and either quit smoking < 1 year ago or were currently smoking) or Former Smokers (participants who smoked > 100 cigarettes in entire lifetime and quit smoking ≥ 1 year ago) received erlotinib [Tarceva] 150 mg orally daily, increasing to a maximum of 300 mg orally daily until disease progression or unacceptable toxicity.
3100112|NCT02013245|Experimental|MTBVAC group 1|Intervention: MTBVAC live vaccine (low dose 5 x 10E03 CFU/0.1mL)
3100113|NCT02013245|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose 5 x 10E04 CFU/0.1mL)
3100114|NCT02013245|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose 5 x 10E05 CFU/0.1mL)
3100115|NCT02013245|Active Comparator|BCG Control Group|Intervention: Commercially available BCG live vaccine (dose 5 x 10E05 CFU/0.1mL)
3100116|NCT02013375|Experimental|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
3100117|NCT02013388|Experimental|10 mg|single oral daily dose of 10 mg N91115 for 14 days
3100118|NCT02013388|Placebo Comparator|Placebo|single oral daily dose of placebo for 14 days
3100119|NCT02013388|Experimental|50 mg|single oral daily dose of 50 mg N91115 for 14 days
3100120|NCT02013388|Experimental|50 mg (single dose)|single oral dose of 50 mg N91115
3100121|NCT02013388|Experimental|250 mg|single oral daily dose of 250 mg N91115 for 14 days (fasted)
3100122|NCT02013388|Experimental|250 mg (Fed)|single oral daily dose of 250 mg N91115 for 1 day (fed fat meal)
3100123|NCT02013388|Experimental|500 mg|single oral daily dose of 500 mg N91115 for 14 days
3100124|NCT02013388|Placebo Comparator|Placebo-Day 1 only|Single oral dose of placebo (Day 1 only)
3100125|NCT02013531|Experimental|Brexpiprazole|Up to 3 mg/day, once daily dose, tablets, orally
3100126|NCT02013544|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
3100127|NCT02013544|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
3100128|NCT02013609|Experimental|Brexpiprazole|Up to 3mg/day, once daily dose, tablets, orally
3100129|NCT02013622|Experimental|Brexpiprazole|Up to 4 mg/day, once daily dose, tablets, orally
3100130|NCT02013674|Experimental|Group 1: 20 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 4 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 0.2x 10^8 (20 million) Allo-hMSCs.
3100131|NCT02013674|Experimental|Group 2: 100 million Allogeneic hMSCs|Fifteen (15) patients to be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1x 10^8 (100 million) Allo-hMSCs.
3100132|NCT02013687|Experimental|2 µg + Alhydrogel|vaccine
3100133|NCT02013687|Experimental|10 µg + Alhydrogel|vaccine
3100134|NCT02013687|Experimental|30 µg + Alhydrogel|vaccine
3100135|NCT02013687|Experimental|100 µg + Alhydrogel|vaccine
3100136|NCT02013765|Experimental|Trastuzumab Monotherapy|Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
3100137|NCT02013778|Experimental|TACE + HCQ|Subjects will receive HCQ plus standard of care TACE.
3100138|NCT02013791|Other|Stage 1 Cohort 1|Vehicle administered to study eye and Sham administered to non-study eye on Day 1.
3100139|NCT02013791|Experimental|Stage 1 Cohort 2|Cyclosporine New Ophthalmic Formulation Dose A administered to study eye and Vehicle administered to non-study eye on Day 1.
3100140|NCT02013791|Experimental|Stage 1 Cohort 3|Cyclosporine New Ophthalmic Formulation Dose B administered to study eye and Vehicle administered to non-study eye on Day 1.
3100141|NCT02013791|Experimental|Stage 1 Cohort 4|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1.
3100142|NCT02013791|Experimental|Stage 1 Cohort 5A|Cyclosporine New Ophthalmic Formulation Dose D administered to the study eye and vehicle administered to the non-study eye on Day 1.
3100143|NCT02013791|Experimental|Stage 1 Cohort 6A|Cyclosporine New Ophthalmic Formulation Dose E administered to study eye and Vehicle administered to non-study eye on Day 1.
3100144|NCT02013791|Experimental|Stage 1 Cohort 6B|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1.
3100145|NCT02013791|Experimental|Stage 1 Cohort 6C|Cyclosporine New Ophthalmic Formulation Dose C administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
3100146|NCT02013791|Experimental|Stage 1 Cohort 6D|Cyclosporine New Ophthalmic Formulation Dose F administered to study eye and Vehicle administered to non-study eye on Day 1 and retreatment at Week 12 if applicable.
3100147|NCT02013817|Experimental|MabThera/Rituxan|
3100148|NCT02013830|Experimental|Avastin + Xeloda|
3100149|NCT02014051|Experimental|SyB C-1101|
3100150|NCT02014116|Experimental|Cohort 1 Dose Escalation|LY3009120 50 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100151|NCT02014116|Experimental|Cohort 2 Dose Escalation|LY3009120 100 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100152|NCT02014116|Experimental|Cohort 3 Dose Escalation|LY3009120 200 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100153|NCT02014116|Experimental|Cohort 4 Dose Escalation|LY3009120 400 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
3100154|NCT02014116|Experimental|Cohort 5 Dose Escalation|LY3009120 500 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
3100155|NCT02014116|Experimental|Cohort 6 Dose Escalation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met
3469008|NCT03890653|No Intervention|Control|This is a pure control arm with no additional interventions.
3100156|NCT02014116|Experimental|Cohort A Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100157|NCT02014116|Experimental|Cohort B Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100158|NCT02014116|Experimental|Cohort C Dose Confirmation|LY3009120 300 mg given orally twice daily every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3100159|NCT02014129|Experimental|Cohort 1 - 100 mg Abemaciclib|100 milligram (mg) abemaciclib administered orally every 12 hours (Q12H) in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
3100160|NCT02014129|Experimental|Cohort 2 - 150 mg Abemaciclib|150 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
3100161|NCT02014129|Experimental|Cohort 3 - 200 mg Abemaciclib|200 mg abemaciclib administered orally Q12H in 28 day cycles. (Cycle 1 = 32 days.) Participants remained on treatment until discontinuation criteria were met.
3100162|NCT02014272|Experimental|Test|RIN 150 contains 150 rifampicin and 75 mg isoniazid
3100163|NCT02014272|Active Comparator|Reference|Individual references of rifampicin and isoniazid
3100164|NCT02014363|Experimental|ETS6103 (low dose)|ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
3100165|NCT02014363|Experimental|ETS6103 (high dose)|ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks).
3100166|NCT02014363|Active Comparator|Amitriptyline|Amitriptyline tablets (encapsulated) Standard dosing regime
3100167|NCT02014363|No Intervention|Lead-in phase|"Citalopram tablets:~Standard dosing regime"
3100168|NCT02014376|Experimental|SD-101 Dermal Cream (6%)|SD-101 dermal cream (6%) applied topically once daily over the entire body for 90 days.
3100169|NCT02014376|Experimental|SD-101 Dermal Cream (3%)|SD-101 dermal cream (3%) applied topically once daily over the entire body for 90 days.
3100170|NCT02014376|Placebo Comparator|Vehicle (0%)|Vehicle dermal cream (SD-101 0%) applied topically once daily over the entire body for 90 days.
3100171|NCT02014402|Experimental|IG1202-A (Vascular)|
3100172|NCT02014402|Experimental|IG1202-B (Hepatic)|
3100173|NCT02014402|Experimental|IG1202-C (Soft Tissue)|
3100174|NCT02014402|Experimental|IG1202-D (Spinal)|
3100175|NCT02014441|Experimental|Talimogene Laherparepvec|"Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter.~Participants were treated with talimogene laherparepvec until they achieved a complete response (CR), all injectable tumors had disappeared, clinically relevant (resulting in clinical deterioration or requiring change of therapy) disease progression per modified World Health Organization (WHO) response criteria beyond 6 months of therapy, or intolerance of study treatment, whichever occurred first."
3100176|NCT02014467|Experimental|Denosumab 60mg|injection
3100177|NCT02014467|Placebo Comparator|Placebo|injection
3100178|NCT02014480|Experimental|Umeclidinium|All subjects will receive UMEC in the dose of 62.5 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3100179|NCT02014480|Experimental|Vilanterol|All subjects will receive VI in the dose of 25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3100180|NCT02014480|Experimental|Umeclidinium/Vilanterol|All subjects will receive UMEC/VI in the dose of 62.5/25 mcg as inhalation powder in the NDPI once daily in the morning over 14 days in a cross over design.
3100181|NCT02014519|Other|Study Group|Subjects, male and female, aged 18 years and above who had agreed to collection of blood sample.
3469009|NCT03890406|Experimental|Group D|Deep neuromuscular blockade
3469010|NCT03890406|Active Comparator|Group M|Moderate neuromuscular blockade
3469011|NCT03890471|Experimental|Preoperative telephone call|Patients will receive routine preoperative counseling in the clinic plus a provider initiated telephone call 3 days before surgery.
3469012|NCT03890471|No Intervention|No preoperative telephone call|Patients will receive routine preoperative counseling in the clinic.
3469013|NCT03890549||obstructive sleep apnea group|The patients were diagnosed by thoracic and ENT (Eye-Nose-Throat) specialist through polysomnography.
3469014|NCT03890510|Active Comparator|Low PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 6~9% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
3132623|NCT03441633||Group 3. Dabigatran|"Patients who are on treatment with dabigatran.~3a. patients who have initiated with dabigatran as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~3b. patients who previously have been treated with VKA in the 12 months before index date."
3469015|NCT03890510|Active Comparator|High PPV Group|After anesthesia induction, patients will receive spine surgery under general anesthesia in the prone position. Ringer's lactate solution will be infused at 1ml/（kg·h ） as a basal speed. Ringer's lactate solution at a volume of 250ml will be used as a bolus dose. Repeat bolus doses will be given to maintain PPV at 13~16% when necessary. Intraoptic pressure and optic sheath diameter will be measured at multiple time points.
3469016|NCT03890796|Experimental|Dementia Care Education and Activity Scheduling Group (DE&AS)|Will received both dementia care education and activity scheduling
3469017|NCT03890796|Sham Comparator|Dementia Care Education Group (DE)|Will received dementia care education
3469018|NCT03890601||Biological APS|50 Asymptomatic patients with aPL antibodies and prolonged APTT
3469019|NCT03890601||Obstetrical APS|50 patients with Obstetrical aPL syndrome
3469020|NCT03890601||Thrombosis APS|APS with a personal history of venous or arterial thrombosis (50 patients)
3469021|NCT03890627||Thoracic bio-reactance measurement of cardiac output|
3469022|NCT03890328|Experimental|RF group|radiofrequency-assisted spleen-preserving therapy group.
3469023|NCT03890328|No Intervention|CT group|Conventional Treatment of Blunt Splenic Injury group.
3100195|NCT02014584|Experimental|Dutasteride Arm|Subjects will receive dutasteride 0.5 milligrams (mg) administered orally once daily for 24 Weeks
3100196|NCT02014584|Placebo Comparator|Placebo Arm|Subjects will receive placebo administered orally once daily for 24 Weeks
3100197|NCT02014597|Experimental|Normal - No glaucoma|HOCD
3100198|NCT02014597|Experimental|Glaucoma|HOCD
3100199|NCT02014740|Experimental|Liraglutide|• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued.
3100200|NCT02014740|Active Comparator|Metformin|M-group will be treated with Metformin for the duration of the study. Metformin (from 500 mg twice daily to a maximum of 1000 mg twice daily) regimen will be continued to achieve fasting glucose between 80 and 140 mg/dl
3100201|NCT02015039|Active Comparator|Botulinum Toxin Therapy Only|
3100202|NCT02015039|Experimental|Botulinum Toxin Therapy plus Occupational Therapy|Intervention
3100203|NCT02015065|Experimental|Vandetanib in Children|Children with measurable localized or metastatic wt-GIST
3100204|NCT02015065|Experimental|Vandetanib in Adults|Adults with measurable localized or metastatic wt-GIST
3100205|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) + PANVAC|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks. PANVAC-V 2 x 10^8 pfu subcutaneous (SQ) at week 0 only; PANVAC-F 1 x 10^9 pfu SQ at weeks 3, 7, 11, and 15
3100206|NCT02015104|Experimental|Bacillus Calmette-Guerin (BCG) Alone|Intravesical TICE BCG (50mg) once weekly starting in week 3 for a total of 6 weeks
3100207|NCT02015195|Experimental|Acetic Acid 5%|Acetic Acid (5%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100208|NCT02015195|Experimental|Sodium Bicarbonate Slurry (50%)|Sodium Bicarbonate Slurry (50%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100209|NCT02015195|Experimental|Papain Slurry (70%)|Papain Slurry (70%) Dosage form: Liquid slurry Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100210|NCT02015195|Experimental|Household ammonia (10%)|Ammonia (10%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100211|NCT02015195|Experimental|Lidocaine (4%)|Lidocaine (4%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100212|NCT02015195|Experimental|Isopropyl Alcohol (70%)|Isopropyl Alcohol (70%) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100213|NCT02015195|Experimental|Hot Water (40 degrees Celsius)|Hot Tap Water (40 degrees Celsius) Dosage form: Liquid Dosage: 5 ml topical Frequency: every 2 minutes Duration: 30 minutes
3100214|NCT02015221|Experimental|ACTitouch|ACTitouch in sustained gradient compression mode during all waking hours (at least 10 hours per day) and intermittent pneumatic compression mode for 2 hours each day.
3100215|NCT02015221|Active Comparator|Standard Compression Garments|Standard Compression Garments of compression levels 30mmHg to 40mmHg during all waking hours each day.
3100216|NCT02015234|Experimental|TNX-102 SL|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 12 months
3100217|NCT02015390|Active Comparator|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects that involves the induction of a biomembrane about a poly(methylmethacrylate)(PMMA) cement spacer within the defect and, following cement removal, autogenous bone grafting (harvested using Reamer-Irrigator-Aspirator) or allogeneic bone graft is used to pack the defect while preserving the biomembrane. The typical time interval between the two stages is 6-8 weeks. The biomembrane not only assists in retaining the bone graft, but serves as a rich source of vascular supply and growth factors which constitute an excellent biological milieu for the graft to consolidate and heal the defect.
3321246|NCT02017431|Experimental|Particle depleted diesel exhaust|Exposure for 2 hours to particle depletion diesel exhaust followed by inhaled allergen challenge
3321247|NCT02017457|Experimental|Azacytidine + Donor lymphocyte infusion|"Azacytidine will be administered subcutaneously for 5 days. During the first cycle, a dose of 100mg/m2/day will be used and for the following cycles a dose of 35mg/m2/day will be administered. Each cycle will consist in 28 days. All patients will receive at least 6 cycles of Azacytidine and the total number of cycles will depend on the response to treatment.~Donor lymphocyte infusion will be performed on day 1 of cycle 2, 4 and 6 of Azacytidine. The amount of cells infused will depend on donor origin."
3321248|NCT02017470|Experimental|Gender-tailored women's heart health outpatient programme|The programme consists of general cardiologist, advanced practice nurse, dietician, physiotherapist and occupational therapist. The participant will be asked to participate in one-on-one interviewing, focus group discussions, and the forthcoming health promotion strategies that are developed based on the data collected
3321249|NCT02017470|No Intervention|Conventional general cardiology outpatient programme|
3321250|NCT02017509||Rectal Cancer Patients|Patients with a diagnosis adenocarcinoma of the rectum will provide a tumor sample from their diagnostic biopsy and surgical procedure for research purposes, including RNA gene expression analysis. In addition to a standard MRI, patients will have an Intravoxel Incoherent Motion MRI (IVIM) and a Dynamic Contrast Enhanced MRI (DCE-MRI) for research purposes.
3321251|NCT02017548|Experimental|Life-extension default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards life extension (vs. comfort oriented care) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be provided unless patients specifically opt-out from such selections. It also will state that upon discharge from the hospital, long-term care (vs. hospice care) will be provided unless the patient chooses otherwise.
3100218|NCT02015390|Active Comparator|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. It involves the implantation of a fenestrated cylindrical titanium mesh cage packed with autogenous bone graft (harvested using Reamer-Irrigator-Aspirator) or with allogeneic bone graft.
3100219|NCT02015442|Experimental|High sucrose diet|High sucrose diet for 7 days
3100220|NCT02015442|Experimental|Low sucrose diet|Low sucrose diet for 7 days
3100221|NCT02015481|Experimental|Cabaletta 30gr.|weekly IV of Cabaletta 30gr.
3100222|NCT02015520|Experimental|Arm 1: Clazakizumab (Dose # A) (Double-Blind)|Clazakizumab Dose # A injection by subcutaneous for 12 weeks + background Methotrexate
3100223|NCT02015520|Experimental|Arm 2: Clazakizumab (Dose # B) (Double-Blind)|Clazakizumab Dose # B injection by subcutaneous for 12 weeks + background Methotrexate
3100224|NCT02015520|Experimental|Arm 3: Clazakizumab (Dose # C) (Double-Blind)|Clazakizumab Dose # C injection by subcutaneous for 12 weeks + background Methotrexate
3100225|NCT02015520|Experimental|Arm 4: Placebo matching with Clazakizumab (Double-Blind)|Clazakizumab Dose # D injection by subcutaneous for 12 weeks + background Methotrexate
3100226|NCT02015546|Experimental|Vilazodone 10mg|Vilazodone 10 mg/d arm (10mg/d initiation dose, titrated to 40 mg/d in 2 weeks, continued for 8 week trial)
3100227|NCT02015546|Experimental|Vilazodone 20mg|vilazodone 20 mg arm (20mg/d initiation dose, titrated to 40 mg/d in 1 week, continued for 8-week trial)
3100228|NCT02015546|Experimental|Vilazodone 40mg|vilazodone 40 mg/d arm (40 mg/d initiation and continuation dose for 8-week trial.
3100229|NCT02015637|Experimental|Delafloxacin|900mg orally (2 x 450 mg tablets) administered once
3100230|NCT02015637|Active Comparator|ceftriaxone|Ceftriaxone 250 mg intramuscular injection administered once
3100231|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase I|Participants received an initial loading dose of trastuzumab 4 milligrams per kilogram (mg/kg), intravenously (IV), over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 40 mg/ square meter (m^2), IV, every 3 weeks, from Week 1; if no dose limiting toxicity (DLT) was observed in greater than or equal to (≥) two-thirds (2/3) of cohort for 2 treatment cycles, the dose was increased to 50 mg/m^2, IV, and continued for 6 cycles. Participants also received paclitaxel 60 mg/ m^2, IV, once per week, from Week 19; if no DLT was observed in ≥ 2/3 of cohort for 2 treatment cycles, the dose was increased to 70 mg/m^2, IV, and subsequently 80 mg/m^2, IV, and continued until disease progression.
3100232|NCT02015676|Experimental|Trastuzumab, Myocet, Paclitaxel; Phase II|Participants received an initial loading dose of trastuzumab 4 mg/kg, IV, over 1.5 hours during Week 1, followed by 2 mg/kg, IV, over 30 minutes once per week from Week 2 to Week 52 or until disease progression. Participants also received myocet, 50 mg/m^2, IV, every 3 weeks, from Week 1 for 6 cycles. Participants also received paclitaxel 80 mg/m^2, IV, once per week, from Week 19 until disease progression.
3100233|NCT02015754|Experimental|DEBIRI|
3100234|NCT02015793|Experimental|Low Induction Dose|Participants received the low loading dose of adalimumab (80 mg at Week 0) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 2, 4, and 6.
3100235|NCT02015793|Experimental|Standard Induction Dose|Participants received the standard loading dose of adalimumab (160 mg at Week 0 and 80 mg at Week 2) followed by the standard maintenance dose of adalimumab (40 mg every other week) at Weeks 4 and 6.
3100236|NCT02015819|Experimental|Treatment (neural stem cells, flucytosine, leucovorin)|"Patients receive CD-expressing neural stem cells intracranially on days 1 and 15. Flucytosine is taken orally every 6 hours on days 4-10 and 18-24. Depending on when a subject enters the study, they may also be given leucovorin orally every 6 hours on days 4-10 and 18-24. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Dose escalation used the following dose levels:~Dose Level 1 (NSC 5x10^7 and 5-FC 37.5 mg/kg)~Dose Level 2 (NSC 1x10^8 and 5-FC 37.5 mg/kg)~Dose Level 3 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg)~Dose Level 4 (NSC 1.5x10^8 and 5-FC 37.5 mg/kg) + Leucovorin + Microdialysis"
3100237|NCT02016105|Experimental|GP2017 Adalimumab|Study arm with intervention being studied in the protocol. Adalimumab Solution for subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
3100238|NCT02016105|Active Comparator|Humira ® Adalimumab|Humira® Adalimumab as a subcutaneous injection with an initial dose of 80 mg s.c. in Week 0, followed by 40 mg s.c. eow, starting at Week 1 and ending at Week 51.
3100239|NCT02016170|Experimental|Ticagrelor 180mg|Patients on prasugrel will switch to ticagrelor with a 180mg loading dose
3100240|NCT02016170|Experimental|Ticagrelor 90mg|Patients on prasugrel will switch to ticagrelor with a 90mg maintenance dose
3100241|NCT02016170|Active Comparator|Prasugrel 10mg|Patients already on prasugrel, will maintain prasugrel
3100242|NCT02016183||Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil/Hydrochlorothiazide 4 mg/6.25 mg or 8 mg/6.25 mg combination tablets, orally, once daily for up to 12 months. This drug should not be used as a first-line drug for hypertension treatment. Participants received interventions as part of routine medical care.
3100243|NCT02016235|Experimental|Dent Disease Intervention|Dent Disease subjects will receive 2 week supplementation with phosphorus
3100244|NCT02016235|Experimental|Kidney Stone subjects|Kidney stone with or without phosphate leak subjects will receive 2 week supplementation with phosphorus
3100245|NCT02016235|Placebo Comparator|Dent Disease Observation|Dent disease subjects will not get phosphorus
3100246|NCT02016300|Experimental|Unloader Bracing|This group will be randomly selected and assigned to wear an unloader brace post-operatively during the study period.
3100247|NCT02016300|Active Comparator|Non-Bracing Arm|This group will be randomly selected and assigned to wear no brace post-operatively.
3100248|NCT02016482|Active Comparator|Adalimumab (ADA)|Period A: ADA 40 mg subcutaneous every other week (sc eow) for 25 weeks starting 1 week after initial loading dose of 80 mg. Period B: Placebo at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
3100249|NCT02016482|Placebo Comparator|Placebo|Period A: Placebo sc eow for 25 weeks. Period B: ADA 80 mg sc at Week 26 followed by ADA 40 mg sc eow from Week 27 through Week 51.
3100250|NCT02016560|Experimental|Exploratory Cognitively Healthy Subjects|Subjects will receive an IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline.
3100251|NCT02016560|Experimental|Exploratory MCI Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
3100252|NCT02016560|Experimental|Exploratory AD Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 at baseline. Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of flortaucipir at baseline, 9 months and 18 months.
3100253|NCT02016560|Experimental|Confirmatory Subjects|Subjects will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 and flortaucipir at baseline.
3100254|NCT02016612|Active Comparator|Reduction, Mastopexy No Implant, No Seri|Patients undergoing reduction or mastopexy but no implant is used and no Seri Surgical Scaffold support is used
3100255|NCT02016612|Active Comparator|Mastopexy, Implant no Seri Scaffold|Mastopexy with implant, No Seri Surgical Scaffold support is used
3100256|NCT02016612|Active Comparator|Breast Reduction with Seri Support|Patients undergoing breast reduction with the use of Seri Surgical scaffold support
3100257|NCT02016612|Active Comparator|Augmentation Mastopexy, Implant and Seri|Augmentation Mastopexy patients where Seri Surgical scaffold is used
3100258|NCT02016625|Experimental|1 Cyclosporine + Faldaprevir|
3100259|NCT02016625|Experimental|2 Tacrolimus + Faldaprevir|
3100260|NCT02016690||Immunocompromised children|Children with immunocompromised conditions or Down syndrome at high-risk of serious RSV disease who received palivizumab during the RSV season
3100261|NCT02016716|Experimental|Romosozumab 90 mg/mL|Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.
3100262|NCT02016716|Experimental|Placebo 90 mg/mL|Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.
3100263|NCT02016716|Experimental|Romosozumab 70 mg/mL|Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.
3100264|NCT02016716|Placebo Comparator|Placebo 70 mg/mL|Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.
3100265|NCT02016755|Experimental|AMG0001|Hepatocyte Growth Factor (HGF) Plasmid
3100266|NCT02016885|Experimental|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
3100267|NCT02016885|Experimental|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
3100268|NCT02016885|Experimental|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
3100269|NCT02016885|Experimental|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
3100270|NCT02016885|Placebo Comparator|Vehicle|Vehicle Topical Wipes
3100271|NCT02016898|Experimental|Sponge placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
3100272|NCT02016898|Experimental|Irrigation placement of Mitomycin-C|Randomization will be stratified by age (age ≥65 or age < 65), baseline IOP (IOP ≥ 28 mmHg or IOP < 28 mmHg), and concurrent cataract surgery.
3100273|NCT02016963|Experimental|Raxibacumab arm|A maximum of 25 subjects (to include 3 evaluable female subjects) will receive a second dose of raxibacumab equal to that of the previous dose >= 4 months following the first dose.
3100274|NCT02017015|Experimental|nab-paclitaxel with gemcitabine|nab-paclitaxel at 125 mg/m^2, intravenous (IV) infusion over 30 to 40 minutes followed by gemcitabine at 1000 mg/ m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
3100275|NCT02017093|Experimental|Error Enhancement|Training of the upper extremity, using a robotic devise with error enhanced forces and traditional therapy.
3100276|NCT02017093|Experimental|Control treatment|Training of the upper extremity, using a robotic devise without forces applied and traditional therapy.
3100277|NCT02017171|Experimental|Allopurinol|Oral allopurinol at a dose of 100 mg per day for 4 weeks and then at a dose ranging from 200 to 400 mg per day depending on kidney function
3100278|NCT02017171|Placebo Comparator|Placebo|Oral placebo tablets
3100279|NCT02017210||Lean/normal weight|Individuals with body mass index (BMI)<25 kg/m^2 in the baseline study
3100280|NCT02017210||Overweight/Obese Insulin-Sensitive|Individuals with BMI>25kg/m^2 who were deemed insulin-sensitive by the hyperinsulinemic -euglycemic clamp (with M/I value above median for men and women separately)
3100281|NCT02017210||Overweight/Obese Insulin-Resistant|Individuals with BMI>25kg/m^2 who were deemed insulin-resistant by the hyperinsulinemic -euglycemic clamp (with M/I value under median for men and women separately)
3100282|NCT02017223|Experimental|Knowme Device Wear|Participants wear KNOWME devices and use mobile phone interface for three days outside of school. This is a pre-post design with no control group
3100283|NCT02017327|Experimental|Monoprost|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3100284|NCT02017327|Active Comparator|Lumigan 0.01%|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3100285|NCT02017327|Active Comparator|Lumigan 0.03% Unit Dose|1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
3100286|NCT02017444|Placebo Comparator|Placebo|Matched placebo tablet B.D for 12 weeks
3100287|NCT02017444|Active Comparator|AZD4017 (11b-HSD1 inhibitor)|AZD4017 400mg tablet B.D. for 12 weeks
3100288|NCT02017535|Active Comparator|6 IPT-A Sessions|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) only.~During the Continuation IPT-A sessions, the therapist will continue to emphasize the interpersonal strategies that were learned and practiced during the acute phase, and address any current interpersonal problems before they result in a recurrence of depressive symptoms. Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions."
3100289|NCT02017535|Active Comparator|6 IPT-A Sessions + Continue Current Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who have responded to acute phase treatment (CGI-I = much improved or very much improved) will attend 4 biweekly IPT-A sessions followed by 2 monthly sessions and will continue their acute phase fluoxetine dosing regimen and will meet with the psychiatrist on a monthly basis."
3100290|NCT02017535|Experimental|10 IPT-A Sessions + Begin Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received only IPT-A during acute phase and who showed a partial response (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will begin treatment with fluoxetine during the continuation phase.The dosage schedule will be 10mg per day for the first week and 20mg per day for the following 5 weeks. If no treatment response is observed by the 6th week, the dosage can be increased to 40mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and biweekly thereafter. Pharmacotherapy sessions will include assessment of vital signs, adverse effects, safety, and symptomatic response."
3100291|NCT02017535|Experimental|10 IPT-A Sessions + Increase Dose of Fluoxetine|"Participants in this group will receive interpersonal psychotherapy for adolescents (IPT-A) and fluoxetine treatment.~Adolescents who received IPT-A and fluoxetine during the acute phase and were partial responders (CGI-I = minimally improved) will attend 8 weekly IPT-A sessions followed by 2 monthly sessions and will have their fluoxetine dose increased to 60mg. Partial responders will meet with the psychiatrist biweekly for the first 2 months and monthly for the second 2 months."
3100292|NCT02017574|Experimental|Implicit Group|Receives little feedback about task performance during learning
3100293|NCT02017574|Active Comparator|Control|Receives detailed feedback about task performance during learning
3100294|NCT02017860|Experimental|Everolimus|Patients who received everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that had reached its study objectives, were not progressing on the current study treatment as defined by the parent protocol and were unable to access everolimus treatment outside of a clinical trial were enrolled.
3100295|NCT02017899|Experimental|S. sonnei 1790GAHB - 1 mcg|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 1 mcg
3100296|NCT02017899|Experimental|S. sonnei 1790GAHB - 5 mcg|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 5 mcg
3100297|NCT02017899|Experimental|S. sonnei 1790GAHB - 25 mcg|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 25 mcg
3100298|NCT02017899|Experimental|S. sonnei 1790GAHB - 50 mcg|Subjects enrolled in COHORT D receiving 3 injections of S. sonnei 1790GAHB - 50 mcg
3100299|NCT02017899|Experimental|S. sonnei 1790GAHB - 100 mcg|Subjects enrolled in COHORT E receiving 3 injections of S. sonnei 1790GAHB - 100 mcg
3100300|NCT02017899|Placebo Comparator|Placebo|2 subjects enrolled in each COHORT A, B, C, D, E receiving 3 injections of Placebo. These were pooled in one Placebo group in the analyses
3100301|NCT02017964|Experimental|Treatment (combination chemotherapy)|"INDUCTION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on days 1, 15, and 29; cyclophosphamide IV over 1 hour on days 1-3; methotrexate IV over 24 hours on days 15 and 29; etoposide IV over 60-120 minutes on days 43-45; and carboplatin IV over 1 hour on days 43-45. Treatment repeats every 63 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CONTINUATION THERAPY: Patients receive vincristine sulfate IV over 1 minute or infused via minibag on day 1, cyclophosphamide IV over 1 hour on days 1-3, etoposide IV over 60-120 minutes on days 21-23, and carboplatin IV over 1 hour on days 21-23. Treatment repeats every 42 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3100302|NCT02018042|Experimental|Abatacept|Patients will be treated with abatacept 125mg subcutaneous (SC) self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.
3100303|NCT02018107|Experimental|N-13 ammonia to image liver PET perfusion|This single-arm study involves the non-therapeutic administration of a radiopharmaceutical, N-13 ammonia or F-18 fluorodeoxyglucose, one to two doses, during the tumor ablation procedure. The N-13 ammonia perfusion PET scan is a diagnostic imaging test. The tumor ablation procedure is performed according to our standard clinical practice and is not itself a research activity. The use of N-13 ammonia to image liver perfusion with a PET scanner is the research portion of the procedure. The participant will receive one or two IV doses of N-13 ammonia (10 mCi/dose) for intraprocedural assessment of ablation results. Not more than two doses will be administered and one or both doses will be administered on the day of the tumor ablation procedure only
3100304|NCT02018315|Experimental|Triheptanoin|Triheptanoin (C7 oil, liquid) dosed at 1 g/kg body weight divided and administered 4 times per day via mouth or g-tube for 3 months.
3100305|NCT02018445|Other|Accell Evo3 DBM & Local Autograft|Accell Evo3 DBM (posterolateral gutter symptomatic side) and Local Autograft (posterolateral gutter contralateral non-symptomatic side)
3100306|NCT02018458|Experimental|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
3132624|NCT03441633||Group 4. Rivaroxaban|"Patients who are on treatment with rivaroxaban.~4a. patients who have initiated with rivaroxaban as treatment naïve (no prior prescription of VKA previous to the 12 months before index date).~4b. patients who previously have been treated with VKA in the 12 months before index date."
3132625|NCT03441789|Experimental|Otezla plus Enstilar foam|Subjects randomized to this group will receive Otezla 30mg by mouth twice daily and Enstilar applied to affected areas once daily
3100307|NCT02018458|Experimental|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
3100308|NCT02018562|Experimental|Intervention|"The talking tracheostomy trial involves placement of a talking tracheostomy tube (Portex Blueline Ultra Suctionaid Tracheostomy Tube) by respiratory therapist after obtaining an order from an authorized prescriber (Physician or Nurse Practitioner). The Speech-Language Pathologist (SLP) sets up the tracheostomy tube for speech and then determines the optimal air flow required for voicing. This amount of air flow is communicated to the ICU staff for further use.~We will ensure that the SLP meets with the patient for a minimum of 3 sessions within a week to optimize the use of a talking tracheostomy tube.~i. SLP will also assess the duration of successful speech during each session~ii. Sentence intelligibility will also be assessed during the 3rd session. This session will be audio-taped and reviewed by a second rater for sentence intelligibility.~iii. SLP will determine the level of independence with talking tracheostomy during the 3rd session."
3100309|NCT02018562|No Intervention|Control|This group will also receive talking tracheostomy tube trial as standard of care but a week later after the pre and post assessments have been completed
3100310|NCT02018627|Experimental|Xeris glucagon|Xeris glucagon 50 micrograms, subcutaneous injection
3100311|NCT02018627|Active Comparator|Lilly glucagon|Lilly glucagon 30 micrograms, subcutaneous injection
3100312|NCT02018653|Experimental|Calcium Alumina-Silicate (CASAD)|CASAD 1 gram orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
3100313|NCT02018653|Placebo Comparator|Placebo|Placebo orally every 6 hours for up to 6 days. Questionnaire completion at baseline about diarrhea and other symptoms.
3100314|NCT02018809|Experimental|MAP Daily Notification|The subject's MAP receives daily notification about whether subject took statin.
3100315|NCT02018809|Experimental|MAP Weekly Notification|The subject's MAP receives weekly about how often the subject took statin during previous week.
3100316|NCT02018809|Experimental|MAP Missed Doses|The subject's MAP receives notification if the subject missed >2 consecutive daily doses of statin.
3100317|NCT02018809|Other|Usual Care|Usual care with GlowCap.
3100318|NCT02018822|Experimental|All Participants|Participants who needed at least two tooth restorations
3100319|NCT02018887|Experimental|LY2969822 (Part A)|Single dose of LY2969822 administered orally in 2 of 3 study periods.
3100320|NCT02018887|Placebo Comparator|Placebo (Part A)|Single dose of placebo administered orally in 1 of 3 study periods.
3100321|NCT02018887|Experimental|LY2969822 (Part B)|LY2969822 administered orally for 14 days.
3100322|NCT02018887|Placebo Comparator|Placebo (Part B)|Placebo administered orally for 14 days.
3100323|NCT02018887|Experimental|LY2969822 (Part C)|LY2969822 administered orally for 14 days.
3100324|NCT02018887|Placebo Comparator|Placebo (Part C)|Placebo administered orally for 14 days.
3100325|NCT02019069|Experimental|Liposomal cytarabine-daunorubicin CPX-351|"1st INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV at a dose of 65 units/m2/day over 90 minutes on days 1, 3, and 5.~2nd INDUCTION: Patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3.~CONSOLIDATION: Beginning on day 28, patients receive liposomal cytarabine-daunorubicin CPX-351 IV a dose of 65 units/m2/day over 90 minutes on days 1 and 3."
3100326|NCT02019108|Experimental|Gait Modification Group|Participants will complete 4 months of a home-based progressive walking program with toe-out gait modification aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with a study therapist and will be instructed to perform a toe-out gait, with the aid of a mirror during walking. Focus will also be on increasing the time and distance of walking. These goals will be emphasized for the home-based portion of the intervention as well.
3100327|NCT02019108|Active Comparator|Walking Only Group|Participants will complete 4 months of a home-based progressive walking program aimed at improving physical activity level. This group will perform continuous treadmill walking during regular sessions with the study therapist with focus on increasing the time and distance of walking. This goal will be emphasized for the home-based portion of the intervention as well.
3100328|NCT02019264|Experimental|Lorcaserin hydrochloride (HCL)10 mg|APD356 10 mg twice daily
3100329|NCT02019264|Placebo Comparator|Placebo|Placebo twice daily
3100330|NCT02019277|Experimental|Trastuzumab SC, Pertuzumab, and Taxane|Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.
3100331|NCT02019420|Experimental|Tedizolid phosphate IV|Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
3100332|NCT02019420|Active Comparator|Linezolid IV|Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.
3100333|NCT02019472|Experimental|Group 1 (adalimumab 40 mg)|Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
3132626|NCT03441789|Placebo Comparator|Otezla plus vehicle foam|Subjects in this group will take Otezla 30mg by mouth twice daily and vehicle foam applied to affected areas once daily
3100334|NCT02019472|Experimental|Group 2 (sirukumab 100 mg)|Sirukumab 100 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. Subjects may meet the early escape criteria at Week 16 (< 20% improvement from baseline in both swollen and tender joint counts) but no sirukumab dose adjustments will made for these subjects. However, these subjects will receive placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
3100335|NCT02019472|Experimental|Group 3 (sirukumab 50 mg)|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52. Between sirukumab injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks through Week 50. At Week 16, subjects who have < 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive sirukumab 100 mg every 2 weeks through Week 52 and placebo injections every 2 weeks between the sirukumab injections (ie, subjects that early escape will receive a weekly injection of alternating sirukumab and placebo, to preserve the blind).
3100336|NCT02019550|Experimental|First Rebif Rebidose, Then Rebiject II|Subjects will self-inject Rebif at a dose of 44 microgram (mcg) subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 2 (4 weeks) for the next 4 weeks.
3100337|NCT02019550|Experimental|First Rebiject II, Then Rebif Rebidose|Subjects will self-inject Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebiject II self-injector device in Treatment Period 1 for 4 weeks followed by self-injecting Rebif at a dose of 44 mcg subcutaneously three times a week by using Rebif Rebidose self-injector device in Treatment Period 2 for the next 4 weeks.
3100338|NCT02019563|Experimental|MTA/FS pulpotomy Group|Children randomized to this arm will undergo a mineral trioxide aggregate (MTA) pulpotomy after hemostasis is achieved using ferric sulfate (FS).
3100339|NCT02019563|Active Comparator|RCT Group|Children randomized to this group will undergo the root canal therapy (RCT) technique.
3100340|NCT02019602|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.~Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
3100341|NCT02019667|Experimental|Placebo|Participants with SSADH Deficiency when on placebo for six months
3100342|NCT02019667|Experimental|Study Drug|Participants with SSADH Deficiency receiving SGS-742 when on study drug for six months
3100343|NCT02019719|Experimental|GSK1278863 4 milligrams (mg)|Subjects will receive GSK1278863 4 mg once daily for 4 weeks
3100344|NCT02019719|Experimental|GSK1278863 6 mg|Subjects will receive GSK1278863 6 mg once daily for 4 weeks
3100345|NCT02019719|Experimental|GSK1278863 8 mg|Subjects will receive GSK1278863 8 mg once daily for 4 weeks
3100346|NCT02019719|Experimental|GSK1278863 10 mg|Subjects will receive GSK1278863 10 mg once daily for 4 weeks
3100347|NCT02019719|Placebo Comparator|Placebo|Subjects will receive placebo once daily for 4 weeks
3100348|NCT02019758|Active Comparator|Oral Viscous Budesonide (OVB)|Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
3100349|NCT02019758|Active Comparator|Active Fluticasone MDI|Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
3100350|NCT02019888||Normal hearing adults|Adults between 20 and 79 years old with hearing at all audiometric frequencies between 250 and 8000 Hz at less than or equal to 25 dB HL
3100351|NCT02019888||Adults with sensory neural hearing loss|Adults between 20 and 79 years old with sensory neural hearing at one or more audiometric frequencies between 250 and 8000 Hz.
3100352|NCT02019888||Adults with middle ear disorders|Adults between 20 and 89 years old with middle ear disorders: tympanic membrane perforation, serous otitis media, cholesteatoma, otosclerosis, and unspecified middle ear disorders.
3100353|NCT02019927|Experimental|Non-arthritic ischemic optic neuropathy|Treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
3100354|NCT02019927|Experimental|Multiple Sclerosis|Treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
3100355|NCT02019927|Experimental|Ocular Trauma|Treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
3100356|NCT02019927|Sham Comparator|Sham - Non-arthritic ischemic optic neuropathy|Sham treatment of decreased vision due to NAION with the transcorneal electrical stimulation device (6+ months post-event).
3100357|NCT02019927|Sham Comparator|Sham - Multiple Sclerosis|Sham treatment of decreased vision due to multiple sclerosis with the transcorneal electrical stimulation device (3+ months post visual changes).
3100358|NCT02019927|Sham Comparator|Sham - Ocular Trauma|Sham treatment of decreased vision due to ocular trauma with the transcorneal electrical stimulation device (3+ months post-trauma).
3100359|NCT02019940|Experimental|Riluzole|Riluzole 50 mg orally twice per day
3100360|NCT02019979|Experimental|metformin /carbohydrate restricted diet|metformin and carbohydrate restricted diet added to platinum based chemotherapy regimen
3100361|NCT02020018|Experimental|Prospective group|Negative pressure wound therapy (Prevena Incision Management System) applied immediately postoperatively.
3100362|NCT02020018|Active Comparator|Retrospective arm|Conventional sterile dry wound dressing applied immediately postoperatively.
3100363|NCT02020031|Experimental|Vancomycin 500mg intraosseous|Vancomycin 500mg is given via intraosseous regional administration (IORA) into a proximal tibial cannula, after tourniquet inflation and immediately prior to skin incision.
3100364|NCT02020031|Active Comparator|Vancomycin 1g IV|Vancomycin 1g is administered via forearm vein, given over a one-hour infusion, timed to finish approximately 30 minutes prior to tourniquet inflation.
3100365|NCT02020135|Experimental|Arm 1: PSMA ADC|Subjects started the extension study at the same dose received upon completion of the core PSMA ADC 2301 study. Each Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) dose was administered as an IV infusion over approximately 60 minutes once every three weeks (Q3W) for up to eight doses, unless a dose delay or dose reduction was required.
3100366|NCT02020252||Touchscreen Participants|New lung, gastric and pancreatic cancer patients presenting to the University of Chicago outpatient oncology clinics, a large research institution located on Chicago's Southside, were identified for study accrual, using the electronic scheduling system.
3100367|NCT02020278|Experimental|Tolvaptan|"Participants enrolled in this trial were eligible to receive open-label tolvaptan if they had a clinical need as determined by the investigator and met the eligibility criteria for optional tolvaptan treatment.~Daily dose levels would have included 3.75 milligrams (mg), 7.5 mg, 15 mg, 30 mg, and 60 mg."
3100368|NCT02020304|Experimental|Room temperature|room temperature combined spinal epidural dose (60-75 degrees F)
3100369|NCT02020304|Active Comparator|refrigerated temperature|refrigerated temperature combined spinal epidural dose (~<43 degrees F)
3100370|NCT02020369|Experimental|FVIIa: 75 µg/kg first, then 225 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
3100371|NCT02020369|Experimental|FVIIa: 225 µg/kg first, then 75 µg/kg|Coagulation Factor VIIa (Recombinant): First Intervention (3 months), Second Intervention (3 months), repeat cycle until study completion.
3100372|NCT02020408|Experimental|[11C]raclopride, [11C]DASB, amphetamine|One time administration of oral amphetamine based on subject's weight (0.5 mg/kg). One PET scan using [11C]DASB. Two PET scans using [11C]raclopride.
3100373|NCT02020512|Experimental|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
3100374|NCT02020577|Experimental|combination arm|Patients to receive afatinib once daily plus weekly cetuximab infusion
3100375|NCT02020590|Experimental|ALLOB® Implantation|One arm: ALLOB® Implantation
3100376|NCT02020616|Experimental|LY3053102|Stage 1: Escalating dose (7 milligrams [mg] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks
3100377|NCT02020616|Placebo Comparator|Placebo|Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks
3100378|NCT02020616|Active Comparator|Exenatide Extended-Release (ER)|Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks
3100379|NCT02020616|Experimental|LY3053102 + Exenatide ER|Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks
3100380|NCT02020785|Active Comparator|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
3100381|NCT02020785|Placebo Comparator|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
3100382|NCT02020863|Experimental|Closed Loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed via a closed loop (automated) system that will determine rate, amount, and timing of fluid administration.
3100383|NCT02020889|Experimental|Mepolizumab 300 mg|Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
3100384|NCT02020889|Placebo Comparator|Placebo|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections; individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
3100385|NCT02020941|Experimental|Treatment (carfilzomib, dexamethasone)|"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.~MAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3100386|NCT02020967||Acromegaly patients|
3100387|NCT02021071||XperGuide|Image-guided needle procedures with XperGuide performed prior to this study within institution (retrospective data).
3100388|NCT02021071||XperGuide with virtual path planning|Image-guided needle procedures with XperGuide with virtual path planning
3100389|NCT02021292|Experimental|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
3100390|NCT02021292|Placebo Comparator|Placebo|Matching placebo oral tablet, to be taken once daily.
3100391|NCT02021318|Experimental|Roxadustat|Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg (milligram) given thrice weekly (TIW) to participants weighing up to 70 kg (kilogram) and 100 mg given TIW to participants weighing more than 70 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL (gram per deciliter) and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat up to a maximum of 104 weeks.
3132627|NCT03441984|Experimental|Subjects with treatment sequence ABC|The subjects in Part 1 of the study, will receive a single dose of treatment A= adult TRIUMEQ (DTG 50 mg/ABC 600 mg/3TC 300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment B=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment C=Pediatric TRIUMEQ (DTG 5 mg/ABC 60 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3100392|NCT02021318|Active Comparator|Darbepoetin alfa|Participants received initial dose of darbepoetin alfa based upon the weight (either 0.45 μg/kg (microgram per kilogram), as a single subcutaneous or intravenous (IV) injection once weekly or 0.75 μg/kg, as a single subcutaneous injection once every 2 weeks) as per European Summary of Product Characteristics (EU SmPC) along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks.
3100393|NCT02021331|Active Comparator|immediate implant placement without provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will have no temporary crown on the implant.
3100394|NCT02021331|Experimental|immediate implant placement with immediate provisionalization|The subject will have the tooth removed and an implant placed right away. In this arm the subject will get a temporary crown on the implant.
3100395|NCT02021461|Experimental|ESL Banana taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3100396|NCT02021461|Experimental|ESL Grape taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3100397|NCT02021461|Experimental|ESL Tutti-Frutti taste|Subjects were to be enrolled until there were at least 30 evaluable subjects (of whom at least 60% were <7 years of age). Evaluable subjects were those who completed 3 Visual analogue scale (VAS), 1 for each of the 3 tasting steps with the 3 flavoured oral suspensions.
3100398|NCT02021565|Experimental|Immediate Intervention Group|"Receives the in-home training intervention immediately after completing the baseline assessment.~The intervention includes three home visits from an AT Specialist (Occupational or Physical Therapist) who observes the dyad perform three ADL transfers, provides recommendations, equipment, home modifications, training, and follow-up training as needed."
3100399|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
3100400|NCT02021643|Experimental|Sofosbuvir+RBV+PEG 12 weeks|Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
3100401|NCT02021643|Experimental|Sofosbuvir+RBV 12 weeks|Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
3100402|NCT02021643|Experimental|Sofosbuvir+RBV 16 weeks|Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
3100403|NCT02021643|Experimental|Sofosbuvir+RBV 24 Weeks|Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.
3100404|NCT02021656|Experimental|LDV/SOF|Treatment-experienced and treatment-naive participants will receive LDV/SOF for 12 weeks.
3100405|NCT02021669|Experimental|Omega-3 supplement|Two grams of the EPA form of omega-3 plus 50 mg of sertraline daily for 10 weeks
3100406|NCT02021669|Placebo Comparator|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
3100410|NCT02021812|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
3100411|NCT02021929|Experimental|Sorafenib|400 mg (2 capsules) taken by mouth once a day
3100412|NCT02021929|Placebo Comparator|Placebo|2 capsules taken by mouth once a day
3100413|NCT02021942|Experimental|SOM230 LAR|SOM230 LAR in a dosage of 60 mg i.m. once every 4 weeks
3100414|NCT02021955|No Intervention|usual care|Primary care providers treat their patients discharged from hospital for a COPD exacerbation as usual.
3100415|NCT02021955|Experimental|guideline treatment recommendations|Primary care clinicians receive treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
3100416|NCT02022007|Active Comparator|Metformin XR|Metformin 2000 mg daily (QD) for 16 weeks
3100417|NCT02022007|Active Comparator|Saxagliptin|Saxagliptin 5 mg QD for 16 weeks
3100418|NCT02022007|Experimental|Saxagliptin-Metformin XR|"Saxagliptin-Metformin XR (combination pill)~5mg Saxagliptin/2000 mg Metformin XR QD for 16 weeks"
3100419|NCT02022020||Group 1|
3100420|NCT02022033|Experimental|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
3100421|NCT02022085|Experimental|Baha Attract System|"This transcutaneous solution is based on a magnet coupling using magnets on both side of the skin;~One implant magnet~One external magnet on which a sound processor is attached, i.e. the Sound Processor magnet (SP magnet)"
3100422|NCT02022111|Active Comparator|Intervention Program of Care|"Patient Education and Behavioral Activation by a Care Coordinator;~Supporting Self-Care;~Psychiatrist and Diabetologist Reviews; and~Decision-support Electronic Health Record System"
3100423|NCT02022111|Placebo Comparator|Control Arm|Participants randomized to the control arm will receive the existing standard of care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
3100424|NCT02022657|Active Comparator|33%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100425|NCT02022657|Active Comparator|33%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100426|NCT02022657|Active Comparator|67%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100427|NCT02022657|Active Comparator|67%/100%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100428|NCT02022657|Active Comparator|100%/33%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100429|NCT02022657|Active Comparator|100%/67%|Participants will be randomized to one of 6 sequences consisting of two directly observed dosing regimens expressed as % of daily dosing of Truvada
3100430|NCT02022670|Placebo Comparator|Placebo|inert oral capsules (0 mg sodium nitrite morning; 0 mg sodium nitrite in evening) for 10 weeks
3100431|NCT02022670|Experimental|Sodium Nitrite 80 mg/d|80 mg/day (40 mg in morning; 40 mg in evening) oral capsules for 10 weeks
3100432|NCT02022670|Experimental|Sodium Nitrite 160 mg/d|160 mg/day (80 mg in morning; 80 mg in evening) oral capsules for 10 weeks
3100433|NCT02022735|Experimental|Bilateral stimulation|Participants will receive Deep Brain Stimulation Bilaterally.
3100434|NCT02022735|Experimental|Left stimulation|Participants will receive Deep Brain Stimulation on the left side only
3100435|NCT02022735|Experimental|Right stimulation|Participants will receive Deep Brain Stimulation on the right side only
3100436|NCT02022735|No Intervention|Off stimulation|Participants will receive no brain stimulation
3100437|NCT02022748|Experimental|Sequence 1|hemodialysis patients: subjects will receive treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 1 and treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 2.
3100438|NCT02022748|Experimental|Sequence 2|hemodialysis patients: subjects will receive treatment B (ticagrelor oral 90 mg just prior to dialysis session) in period 1 and treatment A (ticagrelor oral 90 mg 1 day following the dialysis session but 2 days before the next dialysis session) in period 2.
3100439|NCT02022748|Experimental|Treatment H|Healthy subjects: ticagrelor oral 90 mg on 1 day of treatment
3100440|NCT02022826|Experimental|SmartPill Monitoring System|patients with symptoms of Gastroparesis will undergo the SmartPill monitoring system test
3100441|NCT02023099|Experimental|Substudy 1, Arm A: DB 2-DAA|Double-blind (DB) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2 direct-acting antiviral agents [2-DAA]) once daily (QD) for 12 weeks in participants without cirrhosis
3100442|NCT02023099|Placebo Comparator|Substudy 1, Arm B: DB Placebo, Followed by OL 2-DAA|DB placebo QD for 12 weeks followed by open-label (OL) 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants without cirrhosis
3100443|NCT02023099|Experimental|Substudy 2, Arm C: OL 2-DAA|OL 150 mg ABT-450/100 mg ritonavir/25 mg ABT-267 (2-DAA) QD for 12 weeks in participants with compensated cirrhosis
3100444|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 12 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based ribavirin (RBV; 400 to 1,000 mg/day, divided twice daily) for 12 weeks
3100445|NCT02023112|Experimental|ABT-450/r/ABT-267 plus RBV for 16 weeks|ABT-450/r/ABT-267 (150/100/25 mg once daily) plus weight-based RBV (400 to 1,000 mg/day, divided twice daily) for 16 weeks
3100446|NCT02023125|Experimental|Group 1: Treatment A first, then Treatment B|Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Each period will be separated by at least 10 days.
3100447|NCT02023125|Experimental|Group 1: Treatment B first, then Treatment A|Treatment B (Fed Treatment): Following an overnight fast of at least 10 hours, participants will start a high-fat, high-calorie meal 30 minutes prior to study drug administration; study participants should eat this meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal. Treatment A (Fasted Treatment): Following an overnight fast of at least 10 hours, a single 600-mg oral dose of alectinib will be administered. Each period will be separated by at least 10 days.
3100448|NCT02023125|Experimental|Group 2: Alectinib Alone, Alectinib + Esomeprazole|Period 1 (Days 1 to 10): Following an overnight fast of at least 10 hours, participants will start a standardized meal and should consume the meal in 30 minutes or less. The single 600-mg oral dose of alectinib will be administered 30 minutes after the start of the meal on Day 1 of Period 1. Period 2 (Days 11 to 20): Participants will receive oral esomeprazole 40 mg once daily for 6 days (Days 11-16) in the morning after an overnight fast of at least 10 hours, and at least 1 hour before a regular breakfast; On Day 16, following an overnight fast of at least 10 hours, a single oral dose of 40 mg esomeprazole will be administered 1.5 hours prior to the start of a standardized meal. Following a standardized meal, a single oral 600 mg dose of alectinib will then be administered.
3100449|NCT02023151|Other|Omalizumab|Active
3100450|NCT02023242|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent .
3100451|NCT02023242|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
3100452|NCT02023268|Experimental|T2762|
3100453|NCT02023268|Active Comparator|Vismed®|
3100454|NCT02023411|Active Comparator|teriparatide|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive 20 microgram of teriparatide , subcutaneous between 8-9 p.m., daily.
3100455|NCT02023411|Placebo Comparator|placebo|10 diabetic patients with inactive Charcot's foot who are calcium and Vit.D sufficient will receive placebo , subcutaneous between 8-9 p.m. , daily.
3100456|NCT02023515|Experimental|Stress Management|Approximately half of the participants will be randomized to a stress management arm. Participants will undergo Emotional Brain Training during a 90 minute session once per week for ten weeks in order to rewire the brain and improve stress management techniques.
3100457|NCT02023515|Active Comparator|standard behavioral weight loss|Half of participants will receive a standard behavioral weight loss program in 90 minute sessions once per week for 10 weeks
3100458|NCT02023697|Experimental|Radium-223 dichloride (Standard dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
3100459|NCT02023697|Experimental|Radium-223 dichloride (High dose)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update).
3100460|NCT02023697|Experimental|Radium-223 dichloride (Extended standard dose)|One injection to be administered every 4 weeks up to 12 injections. The dose per injection is 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update).
3100461|NCT02023801|Experimental|Aurora Treatment Arm|Endometrial Ablation
3100462|NCT02023866|Experimental|Cysteamine Bitartrate Delayed-release|Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
3100463|NCT02023879|Placebo Comparator|Placebo Q2W|"Period 1: Placebo (for Alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable non-statin lipid modifying therapy (LMT) or diet alone for 24 weeks.~Period 2: Alirocumab 150 mg SC injection every 4 weeks (Q4W) from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and low-density lipoprotein cholesterol (LDL-C) values. Subsequent down titration to 150 mg Q4W was allowed."
3100464|NCT02023879|Other|Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator)|"Period 1: Alirocumab 75 mg SC injection Q2W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
3100465|NCT02023879|Experimental|Alirocumab 150 mg Q4W/Up to 150 mg Q2W|"Period 1: Alirocumab 150 mg SC injection Q4W alternating with placebo (for alirocumab) Q4W added to stable non-statin LMT or diet alone for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when targeted LDL-C levels at Week 8 were not achieved i.e. LDL-C ≥70 mg/dL (1.81 mmol/L) or ≥100 mg/dL (2.59 mmol/L) depending on cardiovascular risk or <30% LDL-C reduction from baseline.~Period 2: Alirocumab 150 mg SC injection Q4W from Week 24 until second quarter 2017 or until the drug is commercially available in the country, whatever occurred first. Alirocumab dose could be either up-titrated to 150 mg Q2W from Week 36 or maintained according to the investigator judgement and LDL-C values. Subsequent down titration to 150 mg Q4W was allowed."
3100466|NCT02023918|Experimental|Pegvisomant arm|Pegvisomant 20 mg subcutaneously Qday x 28 days will be administered by the study subject.
3100467|NCT02023944|Other|Intervention|12-week course on memory and aging, consists of psychoeducation and skills training
3100468|NCT02023944|No Intervention|Control, No Intervention|"No Intervention, considered treatment as usual"
3100469|NCT02023983|Experimental|Early discharge|
3100470|NCT02023983|Active Comparator|Standard discharge|
3100471|NCT02024087|Experimental|Dalantercept 0.6 mg/kg plus sorafenib 400 mg|Cohort 1: Participants received dalantercept 0.6 mg/kg by subcutaneous (SC) injection once every 3 weeks plus sorafenib 400 mg orally (PO) once daily
3100472|NCT02024087|Experimental|Dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 2: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
3100473|NCT02024087|Experimental|Expansion cohort - dalantercept 0.4 mg/kg plus sorafenib 400 mg|Cohort 3: Participants will receive dalantercept 0.4 mg/kg SC injection once every 3 weeks plus sorafenib 400 mg PO once daily
3100474|NCT02024165||Electrode Sensor, FSE|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or FSE
3100475|NCT02024165||Electrode Sensor, Ultrasound|Pregnant women between the ages of 18-50 with a single viable fetus in cephalic presentation monitored with Electrode Sensor, and/or Ultrasound
3100476|NCT02024204|Active Comparator|Uncontrolled LRS|Patients who have uncontrolled lower respiratory symptoms (ACT < 20) at time of Visit 1 will be provided with study Advair (Fluticasone propionate 230mcg/salmeterol 21mcg) for a total of 3 months and receive medication adherence counseling Patients who have uncontrolled LRS at V1, but do not fit criteria for Step 3,4 or 5 asthma therapy according to NIH EPR III asthma guidelines will be deferred from the study until they have been seen by their physician and tried on ICS therapy.
3100477|NCT02024204|Other|Controlled LRS|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
3100478|NCT02024386|Experimental|Riociguat 0.5 mg|Riociguat 0.5 mg tablets, one-time oral dose of 0.5 mg
3100479|NCT02024386|Experimental|Riociguat 1.0 mg|Riociguat 0.5 mg tablets, one-time oral dose of 1.0 mg
3100480|NCT02024386|No Intervention|Control arm|No drug
3100481|NCT02024477|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
3100482|NCT02024477|Active Comparator|saxagliptin|Saxagliptin 5mg once daily for 12 weeks
3469024|NCT03890588|Experimental|CKD enhanced clinical decision support (CKD-CDS Intervention)|Priority Wizard CDS tool is enhanced to incorporate chronic kidney disease(CKD) management. This presents patients and their primary care providers (PCPs) multiple opportunities to consider an evolving array of timely, evidence-based treatment options to improve CKD care. The CDS also provides CV risk factor management like the basic Priority Wizard present in the usual care arm.
3100485|NCT02024607|Experimental|ARM A- BBI608 in combination with FOLFOX6|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. This regimen will be repeated every 14 days thereafter.
3100486|NCT02024607|Experimental|ARM B- BBI608 in combination with FOLFOX6 and Bevacizumab|BBI608 is administered orally twice daily, continuously. Oxaliplatin 85 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following oxaliplatin/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2 over 46-48 hours) continuous intravenous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
3100487|NCT02024607|Experimental|ARM C- BBI608 in combination with CAPOX|BBI608 is administered orally twice daily, continuously. CAPOX regimen will be administered orally (capecitabine) and IV (oxaliplatin). Capecitabine 850 mg/m^2 will be administered orally twice-daily for 14 consecutive days and be repeated every 21 days. Oxaliplatin will be administered IV and be repeated every 21 days thereafter. If capecitabine is tolerated at the 850 mg/m^2 twice daily dose, dosage may be increased to 1000 mg/m^2 twice daily as tolerated after the first cycle.
3100488|NCT02024607|Experimental|ARM D- BBI608 in combination with FOLFIRI|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated every 14 days thereafter.
3100489|NCT02024607|Experimental|ARM E- BBI608 in combination with FOLFIRI and Bevacizumab|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. Bevacizumab 5 mg/kg will be administered intravenously following oxaliplatin/leucovorin infusion. This regimen will be repeated every 14 days thereafter.
3100490|NCT02024607|Experimental|ARM F- BBI608 in combination with Regorafenib|BBI608 is administered orally twice daily, continuously. Regorafenib 120 mg will be administered orally once daily, with a low-fat meal and be continued for 21 consecutive days of every 28 days thereafter. If regorafenib is tolerated in the first cycle, dosage may be increased to 160 mg once daily as tolerated after the first cycle.
3100491|NCT02024607|Experimental|Arm G- BBI608 in combination with Irinotecan|BBI608 is administered orally twice daily, continuously. Irinotecan 180 mg/m^2 will be administered intravenously. This regimen will be repeated every 14 days thereafter.
3100492|NCT02024646|Experimental|210 mg brodalumab|Administered via subcutaneous injections.
3100493|NCT02024646|Experimental|140 mg brodalumab|Administered via subcutaneous injection.
3100494|NCT02024646|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
3100495|NCT02024698|Active Comparator|omafilcon A|Study participants are randomized to wear omafilcon A lenses.
3100496|NCT02024698|Active Comparator|etafilcon A|Study participants are randomized to wear etafilcon A lenses.
3100497|NCT02024711|Experimental|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
3100498|NCT02024711|Active Comparator|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
3100499|NCT02024724|Active Comparator|Dexamethasone|4 mg of Dexamethasone and 4 mL of 0.25% bupivacaine
3100500|NCT02024724|Active Comparator|Triamcinolone|40 mg of Triamcinolone and 4 mL of 0.25% bupivacaine
3100501|NCT02024750|Experimental|Tailored Resources|Use of PRISM screening tool to identify self-management needs and to provide tailored group session resources over 1 year
3100502|NCT02024750|No Intervention|Usual Care|Patients and families obtain routine multidisciplinary diabetes care
3100503|NCT02024867|Active Comparator|10 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
3100504|NCT02024867|Experimental|3 days of Trimethoprim-Sulfamethoxazole|Oral Trimethoprim-Sulfamethoxazole dosed at 10 mg Trimethoprim/kg/day divided twice a day, to a maximum of 640 mg Trimethoprim/day
3100505|NCT02024932|Experimental|BVS857 Part A Open label (Cohort 1)|Participants received single doses of 0.01 mg/kg BVS857 intravenously (i.v.) on day 1, 0.01 mg/kg BVS857 subcutaneously (s.c.) on day 15, 0.03 mg/kg BVS857 s.c. on day 29, 0.06 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57.
3100506|NCT02024932|Experimental|BVS857 Part A double blind (Cohort 2)|Participants received single doses of 0.03 mg/kg BVS857 i.v on day 1, 0.03 mg/kg BVS857 s.c. on day 15, 0.06 mg/kg BVS857 s.c. on day 29, 0.10 mg/kg BVS857 s.c. on day 43 and 0.10 mg/kg BVS857 s.c. on day 57. (BVS857 concentrations differed on days 43 and 57.)
3100507|NCT02024932|Placebo Comparator|Placebo Part A double blind (Cohort 2)|Participants received single doses of matching placebo i.v. on day 1 and matching placebo s.c. on days 15, 29, 43 and 57.
3100508|NCT02024932|Experimental|BVS857 Part B open-label (Cohort 4)|Participants received 0.1 mg/kg BVS857 i.v. weekly for 12 weeks.
3100509|NCT02024932|Experimental|BVS857 Part B double blind (Cohort 5)|Participants received 0.06 mg/kg (maximum 6 mg) BVS857 i.v. weekly for 12 weeks.
3100510|NCT02024932|Placebo Comparator|Placebo Part B double blind (Cohort 5)|Participants received matching placebo i.v. to BVS857 weekly for 12 weeks.
3100511|NCT02024971||Pioglitazone/Metformin Hydrochloride|Pioglitazone/metformin hydrochloride combination tablets, orally, for 12 months as prescribed by the standard of care.
3100512|NCT02025075|Experimental|Deep Neuromuscular Block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (neuromuscular function monitor).
3100513|NCT02025075|Active Comparator|Moderate Neuromuscular block (NMB)|Muscle paralysis with rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 twitches in the train-on-four (neuromuscular function monitor).
3100514|NCT02025179|Experimental|Teriparatide and vibration|"Experimental: Teriparatide and vibration~Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months~Device: Vibration 10 min/day for 12 months"
3100515|NCT02025205|Experimental|ELVR with Endobronchial Valves|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
3100516|NCT02025205|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice.
3100517|NCT02025426|Active Comparator|Phenylephrine|Phenylephrine for maintaining blood pressure within 10 % of baseline
3100518|NCT02025426|Active Comparator|Ephedrine|Ephedrine for maintaining blood pressure within 10 % of baseline
3100519|NCT02025439|Experimental|rTMS Alone followed by rTMS+AMA|Subjects assigned to rTMS Alone will receive 30 sessions of rTMS. Two rTMS sessions will be provided per day, four days per week.After first completing rTMS Alone, subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
3100520|NCT02025439|Experimental|AMA Alone followed by rTMS+AMA|Subjects who are assigned to the Amantadine Alone group will receive 28 doses of Amantadine (100mg BID) every day for 28 days. After first completing Amantadine Alone subjects will receive rTMS plus Amantadine. A total of 30 rTMS sessions are provided, 2 rTMS sessions per day, four days per week, while receiving 200mg of Amantadine daily.
3100521|NCT02025530||Cases|A structured questionnaire will be administered to women who have experienced a late ≥ 28 weeks gestation stillbirth, who have a singleton pregnancy with no congenital abnormality.
3100522|NCT02025530||Controls|A structured questionnaire will be administered to controls. These are women matched to the case group by gestation and unit of birth, who have a normal ongoing singleton pregnancy with no congenital abnormality.
3100523|NCT02025621|Experimental|Levosimendan|levosimendan 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
3100524|NCT02025621|Placebo Comparator|Placebo|placebo 0.2 µg/kg/min for first hour, followed by 0.1 µg/kg/min for an additional 23 hours
3100525|NCT02025634|Experimental|Intravenous acetaminophen|Infusion of Intravenous acetaminophen (Ofirmev)
3100526|NCT02025634|Placebo Comparator|Placebo (0.9% Normal Saline Infusion)|Infusion of 100 ml of 0.9 NS Normal Saline
3100527|NCT02025647||Innerview MHCDS|Innerview, Mental Health Clinical Decision Support tool
3100528|NCT02025725|Experimental|10 mg Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
3100529|NCT02025725|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
3100530|NCT02025751|Experimental|Metoclopramide Nasal Spray|Metoclopramide Nasal Spray 10 mg, 30 minutes before meals and at bedtime (QID) for 4 weeks
3100531|NCT02025751|Placebo Comparator|Placebo Nasal Spray|Placebo Nasal Spray 30 minutes before meals and at bedtime (QID) for 4 weeks
3100532|NCT02025829||Clinically Stable|Patients with cystic fibrosis and are clinically stable, 10 subjects with one copy of F508del and 4 subjects with at least one copy of G551D
3100533|NCT02025829||Exacerbation|Patients with cystic fibrosis admitted for treatment of a pulmonary exacerbation with IV antibiotics, 10 subjects with one copy of F508del
3100534|NCT02025907|Experimental|Canagliflozin (JNJ-28431754)|Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
3100535|NCT02025907|Placebo Comparator|Placebo|Each participant will receive placebo (inactive medication) once daily for 28 weeks.
3100536|NCT02025985|Experimental|Part 1: Cohort A-Ovarian carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 milligram per meter square (mg/m^2) of selinexor oral tablets twice weekly (BIW) (doses at least 36 hours apart) with light meal and 120 milliliters (mL) of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 once weekly (QW). This treatment continued until progression of disease (PD) or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
3100537|NCT02025985|Experimental|Part 1: Cohort B-Endometrial carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with endometrial carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IVb, IIIc) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
3100538|NCT02025985|Experimental|Part 1: Cohort C-Cervical carcinoma: Selinexor up to 60 mg/m^2 BIW|Participants with cervical carcinoma who had received at least one line of chemotherapy for relapsed or advanced (Stage IV) disease received a dose of 50 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 12 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
3100539|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 1: Selinexor up to 50 mg/m^2 BIW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 35 mg/m^2 of selinexor oral tablets BIW (doses at least 36 hours apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 50 mg/m^2 of selinexor oral tablets BIW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
3132628|NCT03441984|Experimental|Subjects with treatment sequence BCA|The subjects in Part 1 of the study, will receive treatment B in TP1, treatment C in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3100540|NCT02025985|Experimental|Part 2: Cohort A-Ovarian carcinoma Schedule 2: Selinexor up to 60 mg/m^2 QW|Participants with ovarian carcinoma who were platinum refractory or platinum resistant and had received at least one line of chemotherapy for relapsed disease received a dose of 50 mg/m^2 of selinexor oral tablets QW (doses at least 5 days apart) with light meal and 120 mL of water in a 4-week treatment cycles. After 6 weeks of treatment, a dose of 60 mg/m^2 of selinexor oral tablets QW were administrated if the participants had no major toxicity. During dose reduction, participants received a minimum dose of 35 mg/m^2 QW. This treatment continued until PD or unacceptable toxicity or any discontinuation criteria or withdrawal of consent by the participant, or non-compliance by the participant with protocol requirements.
3100541|NCT02026011|Experimental|Naltrexone|Naltrexone 50 mg/day
3100542|NCT02026011|Placebo Comparator|Sugar pill|Matched placebo
3100543|NCT02026063|Experimental|250 mg Telotristat Etiprate|One telotristat etiprate (250 mg) tablet administered three times daily.
3100544|NCT02026063|Experimental|500 mg Telotristat Etiprate|Two telotristat etiprate (250 mg) tablets administered three times daily.
3100545|NCT02026141|Experimental|Dexmedetomidine arm|"Standardized pre-op meds and spinal anesthetic.~Once the patient's spinal is performed, patient will receive the following:~Start with bolus of 0.5micrgram/kg over 10 minutes, and then infusion of 0.5 microgram/kg/hr~Infusion will be stopped after the last staple or suture is performed on the incision.~Both groups will have a midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation as defined by ASA."
3100546|NCT02026141|Placebo Comparator|Saline Placebo|"Patients will receive the standardized pre-op meds and spinal anesthetic. Once the spinal anesthetic is performed,~Patient will receive the same infusion rates as in the Dexmedetomidine arm, however with Normal Saline as a Placebo.~midazolam 0.5mg prn q 5minutes to be used as a rescue to achieve moderate sedation."
3100547|NCT02026193|Experimental|oocyte vitrification|All retrieved mature oocytes will be vitrified.
3100548|NCT02026193|Active Comparator|embryo freezing|All retrieved oocytes will be fertilized, and resulting embryos will be frozen.
3100549|NCT02026206|Experimental|LLLT group|low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles.
3100550|NCT02026206|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 20 min/day over 5 days prior to the expected onset of menstruation during three menstrual cycles. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
3100551|NCT02026258|Active Comparator|Orthodontics no piezocision|Subjects will have orthodontic treatment without corticision with piezotome. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
3100552|NCT02026258|Experimental|Orthodontics with piezotome corticision|Subjects receiving orthodontic treatment in conjunction with piezotome-corticision. Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment. The time taken to reach complete alignment for each patient and the rate of tooth alignment will be calculated.
3100553|NCT02026297|Placebo Comparator|Control, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care NOT including tranexamic acid.
3100554|NCT02026297|Experimental|Treated, low risk PPH|Patients at lower risk for postpartum hemorrhage during cesarean delivery, to receive standard of care AND tranexamic acid.
3100555|NCT02026453|No Intervention|Usual care|Physicians and nurses obtain admission medication history.
3100556|NCT02026453|Experimental|Pharmacist obtains home med hx|Pharmacist obtains admission medication history, although usual care practices may also continue.
3100557|NCT02026453|Experimental|Pharm tech obtains home med hx|Pharmacy technician obtains admission medication history, although usual care practices may also continue.
3100558|NCT02026687|Active Comparator|Epidural analgesia|The epidural anesthesia is applied at a low thoracic level, primarily Th10-Th11. A bolus dose of fentanyl together with a continuous infusion of bupivacain 2.5 mg/ml, fentanyl 1.8 µg/ml and epinephrine 2.5 µg/ml is used during surgery. Infusion rate is chosen by the attending anesthetist. Postoperatively the epidural anesthesia is continued until the morning of the third postoperative day using bupivacain 1 mg/ml, fentanyl 2 µg/ml and epinephrine 2µg/ml. Infusion rate is set by the responsible physician, maximum rate is 10 ml/hour.
3100559|NCT02026687|Experimental|Intrathecal analgesia|The patient is given one intrathecal dose of plain bupivacaine (Marcain® spinal) 5 mg/ml, 15 mg together with morphine (Morphine Special®) 0,4 mg/ml, 0.2 mg and clonidine (Catapresan®) 150 µg/ml, 75 µg. The intrathecal mixture is given through a lumbal puncture at level L2/3, L3/4 or L4/5 before the induction of general anesthesia.
3100560|NCT02027025|Active Comparator|SPARC 1103 low dose|The subjects will receive SPARC 1103 low dose
3100561|NCT02027025|Active Comparator|SPARC1103 high dose|The subjects will receive SPARC1103 high dose
3100562|NCT02027025|Placebo Comparator|SPARC Placebo|The subjects will receive SPARC Placebo
3100563|NCT02027311|Experimental|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
3100564|NCT02027311|Experimental|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
3100565|NCT02027376|Experimental|LDE225 (sonidegib) plus docetaxel|Eligible patients will be included and treated with docetaxel intravenously (75mg/m2)in every three weeks cycles and LDE225 will be administered orally at three dose levels 400, 600 and 800mg QD. Treatment will be repeated on day 1 of a 21-day cycle until radiographic or symptomatic progression, unacceptable toxicity or withdraws informed consent.
3100566|NCT02027402|Experimental|Drain insertion|Laparoscopic cholecystectomy with drain insertion is performed in this arm.
3100567|NCT02027402|No Intervention|no drain insertion|In this arm, investigators perform only laparoscopic cholecystectomy, and not insert a drain
3100568|NCT02027428|Experimental|Abraxane + Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.
3100569|NCT02027428|Other|Best Supportive Care (BSC)|Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes best supportive care only.
3100570|NCT02027545|Experimental|Decision Aid|Patients of primary care providers randomly assigned to the Decision Aid intervention (DA) that includes an individualized decision aid, provider education, and modified performance measure/reminder.
3100571|NCT02027545|Other|No Decision Aid|Patients of primary care providers will be randomly assigned to the pragmatic control (PC) that includes provider education and modified performance measure/reminder, but no decision aid.
3100572|NCT02027558|Experimental|Behavioral treatment|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
3100573|NCT02027558|Active Comparator|Active control|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
3100574|NCT02027623|Experimental|Motor skill training|The motor skill training condition involves supervised, massed practice of novel, challenging functional activities that are difficult or painful for the participant to perform due to his low back pain.
3100575|NCT02027623|Active Comparator|Strength and flexibility exercise|The strength and flexibility exercise condition involves performance of 1) strengthening exercises that target all trunk muscles, and 2) flexibility exercises that target all trunk and lower extremity motions.
3100576|NCT02027701|Experimental|IgPro20|20% liquid formulation (200 mg/mL) of human normal immunoglobulin for SC use administered SC weekly: 0.2 g/kg bw (low-dose IgPro20) for up to 48 weeks. Subjects who experience CIDP relapse on 0.2 g/kg IgPro20 will have an increase to 0.4 g/kg IgPro20 immediately and will continue on high-dose until they have completed a total of 48 weeks of IgPro20 treatment.
3100577|NCT02027844|Experimental|Cartoon|cartoon watching by children during inhalational induction of anesthesia in the operating room
3100578|NCT02027844|Active Comparator|Paretnal presence|parental presence with their children during inhalational induction of anesthesia in the operating room
3100579|NCT02027844|Experimental|Combined|parental presence and cartoon watching by children during inhalational induction of anesthesia in the operating room
3100580|NCT02027883|Active Comparator|Nominal Parameter|Nominal T shock setting
3100581|NCT02027883|Experimental|Experimental Parameter|Educated T shock setting
3100582|NCT02028065|Experimental|Sugammadex 4 mg/kg|Administration of 3 single IV doses of sugammadex 4 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3100583|NCT02028065|Experimental|Sugammadex 16 mg/kg|Administration of 3 single IV doses of sugammadex 16 mg/kg, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3100584|NCT02028065|Placebo Comparator|Placebo|Administration of 3 single IV doses of placebo, with an approximately 5-week washout between Dose 1 and Dose 2 and between Dose 2 and Dose 3
3100585|NCT02028169||Participants Receiving Anti-TNF for PsA|Participants who are actively working (full-time or part-time) with rheumatologist-confirmed PsA for which the physician has initiated treatment with an anti-TNF.
3100586|NCT02028182|Experimental|Positive reactions, Concordance with reference allergen|Subjects were patch tested with an experimental allergen panel containing ascending doses of Lyral (0.10 mg/cm2, 0.20 mg/cm2 and 0.40 mg/cm2) and a negative control. A second panel containing 20 mg of 5% Lyral in petrolatum was applied for evaluation of concordance. The panels were worn for approximately 48 hours. Skin reactions were assessed at 3, 4 and 21 days following application.
3100587|NCT02028208|Experimental|Ammoniated mercury|Subjects will be patch tested with 4 experimental doses of ammoniated mercury, 0.013 mg/cm², 0.040 mg/cm², 0.12 mg/cm², and 0.36 mg/cm², a negative control and corresponding reference allergens, 1.0% ammoniated mercury in petrolatum and 0.5% elemental mercury in petrolatum. Patch tests will be worn for 48 hours.
3100588|NCT02028208|Experimental|Aluminum chloride and aluminum lactate|Subjects will be patch tested with 4 experimental doses of aluminum chloride, 0.040 mg/cm², 0.12 mg/cm², 0.36 mg/cm² and 0.72 mg/cm², 4 experimental doses of aluminum lactate 0.047 mg/cm², 0.14 mg/cm², 0.42 mg/cm² and 0.84 mg/cm², a negative control and corresponding reference allergens, 2.0% aluminum chloride in petrolatum and 12.0% aluminum lactate in petrolatum. Patch tests will be worn for 48 hours.
3100589|NCT02028208|Experimental|Sodium tetrachloropalladaate (Palladium)|Subjects will be patch tested with 5 experimental doses of sodium tetrachloropalladate 0.011 mg/cm², 0.033 mg/cm², 0.10 mg/cm², 0.30 mg/cm² and 0.60 mg/cm², a negative control and corresponding reference allergens, 3.0% sodium tetrachloropalladate in petrolatum and 1.0% palladium chloride 1.0% in petrolatum. Patch tests will be worn for 48 hours.
3100590|NCT02028221|Placebo Comparator|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
3100591|NCT02028221|Experimental|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the remaining duration of he intervention period.
3100592|NCT02028247|Experimental|Personalized Cognitive-behavioral therapy|Personalized Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 90 minutes each, based on a treatment protocol that has been designed specifically for youth with high-functioning autism spectrum disorders.
3100593|NCT02028247|Active Comparator|Standard Practice Cognitive-behavioral therapy|Standard Practice Cognitive-behavioral therapy involves 16 weekly individual therapy sessions, up to 60 minutes each, based on a treatment protocol that represent the standard practice psychotherapy for anxiety that has been found to be effective in multiple trials in youngsters without autism spectrum disorders.
3100594|NCT02028247|Other|Treatment as Usual|Participants randomized to the TAU condition will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions) for a 16-week period. Treatment changes (e.g., medication increase, starting psychotherapy in community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
3100595|NCT02028325|Experimental|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
3100596|NCT02028676|Experimental|Clinically Driven Monitoring (CDM)|
3100597|NCT02028676|Active Comparator|Laboratory plus Clinical Monitoring (LCM)|
3100598|NCT02028676|Active Comparator|Arm A: abacavir (ABC)+lamivudine (3TC)+NNRTI|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO non-nucleoside reverse transcriptase inhibitor (NNRTI): either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3100599|NCT02028676|Experimental|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3100600|NCT02028676|Experimental|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|ZDV [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO NNRTI: either nevirapine or efavirenz based on availability (provided by national ART programmes in Uganda/Zimbabwe). Nevirapine syrup or tablet dosed twice-daily according to weight-bands following WHO. Efavirenz tablets dosed once-daily according to weight-bands following WHO.
3100601|NCT02028676|Experimental|Once-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed once-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed once-daily according to weight-bands following WHO
3100602|NCT02028676|Active Comparator|Twice-daily ABC+3TC|ABC [abacavir]: syrup or tablet, dosed twice-daily according to weight-bands following WHO 3TC [lamivudine]: syrup or tablet, dosed twice-daily according to weight-bands following WHO
3100603|NCT02028676|Active Comparator|Continued cotrimoxazole prophylaxis|Once-daily doses 5-<15 kg: 200 mg of trimethoprim + 40 mg sulfamethoxazole 15-<30 kg: 400 mg trimethoprim + 80 mg sulfamethoxazole >=30 kg: 800 mg trimethoprim + 160 mg sulfamethoxazole
3100604|NCT02028676|Experimental|Stopped cotrimoxazole prophylaxis|Children had been taking once-daily cotrimoxazole prophylaxis since at least ART initiation. Children randomised to this experimental arm stopped taking cotrimoxazole prophylaxis.
3100605|NCT02028715|Placebo Comparator|Experimental (Normal Saline)|Morphine patient-controlled-anesthesia (PCA) for the initial 24 hours post-operation with a low-dose basal rate (0.5mg/hr) and patient administered boluses prn. Oral oxycodone from 24-48 hours post-operation will be used prn for pain and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay. Normal saline 100cc IV will be infused as placebo every 6 hours for a total of eight doses with the first dose being given at time of anesthesia induction.
3100606|NCT02028715|Active Comparator|Experimental (IV Acetaminophen)|Morphine PCA for the initial 24 hours post-operation with low-dose basal rate (0.5mg/hr) with patient administered boluses prn. IV acetaminophen 1,000mg will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction. Oral oxycodone from 24-48 hours post-operation will be used prn and then patients will be transitioned to oral combined oxycodone/acetaminophen for the remainder of their hospital stay.
3100607|NCT02028754|Experimental|Sodium Carboxymethylcellulose and Conventional Therapy|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days plus conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
3100608|NCT02028754|Active Comparator|Conventional Therapy|Conventional therapy of levofloxacin for 7 days post-cataract surgery and prednisolone for 30 days post-cataract surgery each in the study eye up to 4 times a day.
3100609|NCT02028767|Experimental|Fixed Dose Combination (FDC)|12.5 mg Empagliflozin / 500mg metformin fixed dose combination
3100610|NCT02028767|Active Comparator|Separate tablets|Empagliflozin and Metformin tablets
3100611|NCT02028780|Experimental|Idarucizumab single doses|different infusion durations
3100612|NCT02028780|Experimental|Idarucizumab with dabigatran|short infusion with 2 capsules dabigatran
3100613|NCT02028871|Active Comparator|Intranasal Insulin First|Intranasal Insulin First, Placebo Second
3100614|NCT02028871|Placebo Comparator|Placebo First|Placebo First, Intranasal Insulin Second
3469025|NCT03890588|No Intervention|Usual Care|A basic Priority Wizard CDS tool for cardiovascular (CV) risk factor management (previously know as the CV Wizard) includes algorithmically derived identification of high CV risk patients and prioritized treatment suggestions for lipids, Blood Pressure (BP), glycemic control, weight, tobacco, and aspirin use based on distance from goal, current medications, labs, allergies, and safety considerations. Has no decision support specific to CKD care.
3469026|NCT03890380|Experimental|Magneto Wire|Patients treated with Magneto Wire
3469027|NCT03890315||Neuropathic pain|Adult patients with upper extremity neuropathic pain due to radiculopathy Duration of >1 month Unilateral extremity pain will be recruited
3100617|NCT02029040|Experimental|3% hypertonic saline group|Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
3100618|NCT02029040|Placebo Comparator|0.9% normal saline group|Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy. The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of 15 minutes.
3100619|NCT02029196|Experimental|e-vapour product (EVP)|Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).
3100620|NCT02029196|Active Comparator|Conventional cigarette (CC)|Subjects who continue smoking their usual conventional cigarette (CC) brand.
3100621|NCT02029235|Active Comparator|Acetaminophen/Ibuprofen (AIBU) Group|Acetaminophen 500 mg and Ibuprofen 400 mg
3100622|NCT02029235|Active Comparator|Acetaminophen/Hydrocodone (AH) Group|Acetaminophen 325 mg and Hydrocodone 5 mg
3100623|NCT02029274|Experimental|BAF312 0.5mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 0.5 mg over a 10 day period. After, participants continued on 0.5 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
3100624|NCT02029274|Experimental|BAF312 2mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
3100625|NCT02029274|Experimental|BAF312 10 mg|During period 1, participants were uptitrated daily from BAF312 0.25 mg to 10.0 mg over a 10 day period. After, participants continued on 10.0 mg daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
3100626|NCT02029274|Placebo Comparator|Placebo|During period 1, participants received matching placebo daily for up to 24 weeks. During period 2, participants were uptitrated daily from BAF312 0.25 mg to 2.0 mg over a 10 day period. After, participants continued on 2.0 mg daily for up to 24 weeks.
3100627|NCT02029417|Experimental|Treatment (cytarabine, omacetaxine mepesuccinate, decitabine)|"INDUCTION CHEMOTHERAPY: Patients receive cytarabine SC BID and omacetaxine mepesuccinate SC BID on days 1-14. Treatment for induction therapy repeats every 28 days for up to 4 courses or until patients achieve CR in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION THERAPY: Patients alternate courses between decitabine and OAG. Patients receive decitabine IV on days 1-5. Patients alternate with OAG courses, comprising cytarabine SC BID on days 1-7 and omacetaxine mepesuccinate SC BID on days 1-7. Treatment repeats every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3100628|NCT02029495|Experimental|210 mg brodalumab|Administered via subcutaneous injections
3100629|NCT02029495|Experimental|140 mg brodalumab|Administered via subcutaneous injection
3100630|NCT02029495|Placebo Comparator|Placebo|Administered via subcutaneous injection until week 24.
3100631|NCT02029521|Experimental|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg.
3100632|NCT02029521|Placebo Comparator|Placebo Calcium Citrate|The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
3100633|NCT02029638|Experimental|RICG, BMT and high dose PT/Cy+SOC|"Reduced-intensity conditioning regimen (RICG), bone marrow transplantation (BMT), high dose post-transplant cyclophosphamide (PT/Cy) and Standard of Care (SOC).~Participants will receive: ATG (pre-transplant), pre-medicated with acetaminophen, diphenhydramine; steroid taper of methylprednisolone; fludarabine (2-6 days before transplant), and low-dose cyclophosphamide (pre- transplant); total body irradiation the day before transplant. Participants will receive a living renal transplant followed by BMT. High-dose cyclophosphamide will be given on days 3 and 4 post-transplant with MESNA. Filgrastim will be given on day 5 post-transplant and continue until absolute neutrophil recovery. Standard immunosuppression of tacrolimus, MMF, and prednisone will begin on day 5 post-transplant and be given ≥26 weeks post-transplant. Eligible participants will be gradually withdrawn from medication over a period of 24-40 weeks."
3100634|NCT02029703|Sham Comparator|Sham injection|Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
3132629|NCT03441984|Experimental|Subjects with treatment sequence CAB|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment A in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3469028|NCT03890315||Control|Age and gender matched control patients will also be recruited to show whether differences exist in outcome measures.
3469029|NCT03890523|Experimental|Segmented Airway Stent for Gastro-Respiratory fistula|Segmented covered metallic airway stent modified with 3D printing was used for gastro-respiratory fistula.
3469030|NCT03890458|Experimental|Experimental|
3469031|NCT03890458|No Intervention|Control|
3100635|NCT02029703|Active Comparator|Synvisc-One Injection|Subjects randomized into the Synvisc-One group will receive a single 6 mL intra-articular injection of Synvisc-One under sterile conditions. The unblinded treating physician will prepare the treatment site according to his/her standard practice guidelines (i.e. after cutaneous numbing with a vasocoolant spray and / or local lidocaine injection), an 18 gauge needle will be advanced into one of three compartments of the knee using the injectors' technique of choice. Subjects will be monitored for a minimum 5 minutes post injection to evaluate for adverse events.
3100636|NCT02029755|Experimental|TAP block|postoperative analgesia with sono-guided transversus abdominis plane block and intravenous patient controlled analgesia (IV-PCA). Bilateral sono-guided TAP block will be performed after the induction of general anesthesia. 20 ml of 0.25% ropivacaine will be injected to the transversus abdominis plane under ultrasound guidance at each side (total 40 ml). IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3100637|NCT02029755|Active Comparator|Local infiltration|postoperative analgesia with local anesthetics infiltration at surgical wound and intravenous patient controlled analgesia (IV-PCA). 20 ml of 0.5% ropivacaine will be injected at the surgical wound by the surgeon before the closure of wound. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3100638|NCT02029755|Active Comparator|PCA only|postoperative analgesia with intravenous patient controlled analgesia. IV-PCA with morphine will be ready for postoperative pain control at the end of the surgery.
3100639|NCT02029872|Active Comparator|Individual plus household|Standard decolonization regimen for individual plus household: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
3100640|NCT02029872|Active Comparator|Individual alone|Standard decolonization regimen for the individual alone: 7 day course of nasal mupirocin calcium 2% ointment applied inside the nose twice daily, plus a 4% chlorhexidine gluconate (soap) used in the shower/bath every day for 7 days. For individuals colonized within the throat we will add chlorhexidine gluconate oral rinse 0.12% used in a gargle and spit fashion twice daily for 7 days.
3100641|NCT02029911|Experimental|Aurora Treatment Arm|Endometrial Ablation
3100642|NCT02029976|Active Comparator|attention control condition|Child and parent participants randomized to the attention control condition will receive a Newsletter Program or mailed monthly newsletter with general family-focused health information.
3100643|NCT02029976|Experimental|after school weight management program|The 9-month after school weight management program called SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together), with a focus on healthy food and activity practices will be directed by a school nurse and will include: 1) quarterly parent/child coaching sessions with the school nurse held in the participant's home; 2) 14 child group sessions led by the school nurse, held in a school setting 1-2 times a month; 3) 5 parent group sessions led by a school nurse held in a school setting.
3100644|NCT02029989|Experimental|Extended Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference and Comprehensive Medication Management
3100645|NCT02029989|Active Comparator|Usual Treatment Group|Glucose and Lipids and Glycosylated Hemoglobin A1c and Blood Pressure and Heart Rate and Body Mass Index and Waist and Hip Circumference
3100646|NCT02030002|Experimental|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
3100647|NCT02030002|Active Comparator|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
3100648|NCT02030041|Experimental|Simvastatin and placebo|"Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl.~This arm will receive Simvastatin 40 mg once daily and placebo once weekly, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
3100649|NCT02030041|Active Comparator|Simvastatin and vitamin D|"Eleven participants will be vitaminD deficient with LDL-C between 100 to 130mg/dl.~This arm will receive simvastatin 40 mg once daily and vitaminD 60,000 units once weekly , and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week"
3100650|NCT02030041|Active Comparator|Vitamin D and placebo|Eleven participants will be vitamin D deficient with LDL-C between 100 to 130mg/dl This arm will receive vitamin D 60,000 units once weekly and placebo once daily, and will perform moderate intensity exercise for twelve weeks. Participants will be advised to walk a minimum of 3000 steps in 30 minutes on 5 days each week
3100651|NCT02030080|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm.
3100652|NCT02030080|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm.
3100653|NCT02030080|Experimental|Feedback 50th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 50th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
3100654|NCT02030080|Experimental|Feedback 75th Percentile + Lottery|At the end of each week, participants will be told the average daily step count for their team for the previous week. They will also be told the average for the 75th percentile in their arm. If their team's average daily step count is ≥ 7000 steps, they'll be eligible to collect winnings from a weekly lottery. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
3100655|NCT02030119|Active Comparator|Control|The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved their goal for the prior day.
3132630|NCT03441984|Experimental|Subjects with treatment sequence ACB|The subjects in Part 1 of the study will receive, treatment A in TP1, treatment C in TP2 and treatment B in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3100656|NCT02030119|Experimental|Gain Framing|Participants will be told that they will earn money for each day they walk at least 7000 steps. Each participant will receive either an email or text message (based on the participant's preference) stating whether or not he/she achieved the goal for the prior day and can collect the earnings. Non-adherent participants will receive messages about how much they would have earned had they met their target step goal.
3100657|NCT02030119|Experimental|Loss Framing|The participants will be told that their account has been credited a certain amount of money for the upcoming 30 days. However, for each day they do not meet their goal of at least 7000 steps, they will lose a small portion of that money. The participant will receive either an email or text message (based on the participant's preference) stating whether the participant achieved the goal for the prior day. Non-adherent participants will receive messages about how much the participant would have kept had they met the target step goal.
3100658|NCT02030119|Experimental|Daily Lottery|Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
3100659|NCT02030288|Experimental|Relational Agent plus Treatment as Usual|"Relational Agents are onscreen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
3100660|NCT02030288|No Intervention|Treatment as Usual|Patients are routinely screened yearly for unhealthy alcohol use. Providers are prompted to provide elements of a brief intervention if the patient scores 5 or above on the AUDIT-C. Providers are also prompted to refer patients if they meet certain criteria for specialty alcohol treatment.
3100661|NCT02030405|Experimental|Ixazomib (MLN9708)|Participants receive ixazomib PO (orally) on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3100662|NCT02030535|Experimental|Tiotropium/Olodaterol FDC|patient will receive tiotropium and olodaterol in a fixed dose combination
3100663|NCT02030535|Experimental|Tiotropium and Olodaterol FC|patient will receive tiotropium and olodaterol in a free combination
3100664|NCT02030535|Placebo Comparator|Placebo|patient will receive placebo
3100665|NCT02030574|Experimental|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
3100666|NCT02030600|Experimental|IDeg OD ± OADs followed by IGlar OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
3100667|NCT02030600|Active Comparator|IGlar OD ± OADs followed by IDeg OD ± OADs|The trial includes two 32-week treatment periods in a cross-over design. Total trial duration for the individual subjects will be up to 67 weeks.
3100668|NCT02030821|Active Comparator|Tranexamic Acid (TXA)|"TXA will be administered as a 1 gm dose IV prior to the procedure then as a repeat dose of 1 gram at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
3100669|NCT02030821|Active Comparator|Epsilon-aminocaproic acid (Amicar)|"Administered 5g in 250mL of IV normal saline over 15 minutes prior to the procedure and then an infusion of 5g at the time of wound closure. These doses are currently used at Duke for Total Knee Arthroplasties (TKAs) and Total Hip Arthroplasties (THAs) per standard of care by the orthopaedic team.~All data needed for this study including blood loss, need for transfusion, preoperative and lowest postoperative hematocrit and hemoglobin, and complications will be collected during the hospitalization."
3100670|NCT02030834|Experimental|Cohort A|murine CART19
3100671|NCT02030834|Experimental|Cohort B|T cell/histiocyte-rich Diffuse Large B Cell Lymphoma (DLBCL) treated with murine CART19
3100672|NCT02030834|Experimental|Cohort C|Diffuse Large B Cell Lymphoma (DLBCL) treated with humanized CART19
3100673|NCT02030847|Experimental|Arm1|"phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia."
3100674|NCT02030886|Other|Ocular hypertension subjects|All subjects will be monitored by Sensimed Triggerfish (TF) for 24 hours.
3100675|NCT02031146|Other|LP|Participants undergo lumbar puncture for CSF evaluation
3100676|NCT02031146|No Intervention|No LP|Participants do not undergo lumbar puncture and CSF is not examined.
3100677|NCT02031237||Stereotactic Radiosurgery (SRS)|"Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series."
3100678|NCT02031237||Whole Brain Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series."
3100679|NCT02031237||Stereotactic Radiation Therapy|"Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.~MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series."
3100680|NCT02031276|Placebo Comparator|Double-blind Placebo IV|Participants randomized to receive double-blind placebo for risankizumab by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
3100681|NCT02031276|Experimental|Double-blind Risankizumab 200 mg IV|Participants randomized to receive double-blind risankizumab 200 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
3100682|NCT02031276|Experimental|Double-blind Risankizumab 600 mg IV|Participants randomized to receive double-blind risankizumab 600 mg by intravenous (IV) injection for 12 weeks in Period 1, followed by open-label risankizumab 600 mg IV in Period 2, then open-label risankizumab 180 mg by subcutaneous (SC) injection in Period 3.
3100683|NCT02031302||Lotus Valve|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
3100684|NCT02031302||Lotus with Depth Guard|All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.
3100685|NCT02031432|Experimental|Cebranopadol|"Cebranopadol 200 µg to 1000 µg per taken taken once a day in the morning.~Allowed dose levels in the Maintenance Phase were 200, 400, 600, 800, or 1000 µg per day."
3100686|NCT02031458|Experimental|Atezolizumab|
3100687|NCT02031471|Experimental|Tocilizumab|Adults with rheumatoid arthritis received a fixed dose of tocilizumab during the 24-week open-label core study and those entering the long term extension (LTE) period further received a fixed dose up to a maximum of 28 weeks or until tocilizumab was commercially available and/or reimbursed whichever came first. A fixed dose of 162 mg tocilizumab was administered subcutaneously once weekly.
3100688|NCT02031536|Experimental|Arm A (everolimus)|Patients receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3100689|NCT02031536|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3100690|NCT02031627|Experimental|pneumatic compression - 1 hour per day|Pneumatic compression device - 12 consecutive days undergoing a 1 hour treatment regimen.
3100691|NCT02031627|Experimental|pneumatic compression - 2 hours per day|Pneumatic compression device - 5 consecutive days undergoing 1 hour treatment in the am and 1 hour of treatment in the pm.
3100692|NCT02031627|Experimental|pneumatic compression - 4 hours per day|Pneumatic compression device - 5 consecutive days undergoing treatment twice per day consisting of 2 consecutive 1 hour treatments in the am and the pm (4 hours total)
3100693|NCT02031640|Experimental|BDP 320 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
3100694|NCT02031640|Experimental|BDP 640 mcg BAI|Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.
3100695|NCT02031640|Active Comparator|BDP 320 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
3100696|NCT02031640|Active Comparator|BDP 640 mcg MDI|Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.
3100697|NCT02031640|Placebo Comparator|Placebo BAI and MDI|Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.
3100698|NCT02031679|Experimental|AZD1981|"AZD1981 for oral administration will be available in tablet form. AZD1981 tablets will be provided in 10 mg strengths.~The drug will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
3100699|NCT02031679|Placebo Comparator|Placebo|"The placebo will be available in tablet form. The placebo contains the same ingredients as the AZD1981 with the exception of the active compound.~The placebo will be self-administered by the subject. Subjects will take 4 tablets in the morning, 4 tablets in the afternoon, and 4 tablets in the evening.~The tablets should be swallowed whole with a glass of water."
3100700|NCT02031770|Other|A: Treatment/Control|Patients will start with sodium bicarbonate treatment then switch to control (no treatment)
3100701|NCT02031770|Other|B: Control/Treatment|Patients will start with control (no treatment) then switch to sodium bicarbonate treatment
3100702|NCT02031978||WIC Program Participants|The cohort is made up of infants. Pregnant women enrolling in WIC for the first time for that pregnancy and mothers/caregivers of infants younger than 2.5 months of age enrolling in WIC for the first time are recruited to participate.
3100703|NCT02032173|Experimental|Ranibizumab 0.5mg|Intravitreal injection with standard dose of 0.5 mg/0.05mL Pro re nata (PRN)
3100704|NCT02032212|Experimental|Sequence 1|Subjects use the unflavoured EVP on Day 1, the flavoured EVP on Day 2, the nicotine inhalator on Day 3 and the conventional cigarette on Day 4.
3100705|NCT02032212|Experimental|Sequence 2|Subjects use the flavoured EVP on Day 1, the unflavoured EVP on Day 2, the conventional cigarette on Day 3 and the nicotine inhalator on Day 4.
3100706|NCT02032212|Experimental|Sequence 3|Subjects use the nicotine inhalator on Day 1, the conventional cigarette on Day 2, the unflavoured EVP on Day 3 and the flavoured EVP on Day 4.
3100707|NCT02032212|Experimental|Sequence 4|Subjects use the conventional cigarette on Day 1, the nicotine inhalator on Day 2, the flavoured EVP on Day 3 and the unflavoured EVP on Day 4.
3100708|NCT02032238|Experimental|laser photocoagulation with bevacizumab|Combining laser photocoagulation and Anti-VEGF Injections in a pre-defined manner
3100709|NCT02032238|No Intervention|Bevacizumab, no laser photocoagulation|patients receive Anti-VEGF injections (Bevacizumab) only
3100710|NCT02032407|Experimental|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
3100711|NCT02032420|Experimental|STAR|Introductory training by video depicting 4 sequential maneuvers for reacquisition of needle image in ultrasound: see, tilt, align, rotate.
3100712|NCT02032420|Active Comparator|ART|Introductory training with a video depicting 3 probe position aspects for reacquisition of needle image by ultrasound: alignment, rotation, tilt.
3100713|NCT02032433|Active Comparator|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol)
3100714|NCT02032433|Active Comparator|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone)
3100715|NCT02032550|Experimental|Preference Based Decision Aid|The experimental arm of preference based decision aid intervention will complete a web-based conjoint analysis instrument for preference assessment.
3100716|NCT02032550|No Intervention|Usual Care|Participants randomized into this group will have usual care from their doctors without any intervention
3100717|NCT02032641|Experimental|Laser Treatment Side|"Each patient was randomized to have one of two scars treated with Laser Genesis. The treatment was administered by manually scanning the rapidly pulsed laser in an even, painting motion throughout the entire treatment zone. The eyebrow hairs were covered with white tape to prevent inadvertent alopecia. The laser handpiece was oriented perpendicular to the skin at all times, at a distance of 1-2 cm. Patients were instructed throughout to give verbal feedback regarding if the area was too hot as an additional safeguard against epidermal damage."
3100718|NCT02032641|No Intervention|Control side|Each patient had a scar which was randomized to not undergo treatments with Laser Genesis, and was used as a control. Patients were not allowed to undergo laser or any other scar treatments with the exception of sun protection for the control scar for the duration of the study.
3100719|NCT02032680|Experimental|Web-based family psycho-education treatment|The e-health/web-based intervention provides: three therapist facilitated group forums; a function to send facilitators questions; a library of previously answered questions; and a library of educational materials.
3100720|NCT02032680|Active Comparator|In-persons Multi-Family Group Psycho-Education treatment|This arm provides the evidence based multi-family psychoeducational treatment, termed Multi-Family Group Psycho-Education (MFG) that is the standard of care in the VA.
3100721|NCT02032680|Other|Treatment as Usual|The Treatment as usual (TAU) group provides a benchmark against which to measure the impact of the two individual interventions (MFG & DSW) independent from each other. Through enhancements of TAU, such as regular monitoring which will be done in the assessment process and by the provision of information to VA psychiatrist when there are concerns or problems with the psychiatric status of their patients, we will be taking reasonable steps to ensure the safety of the participants who are assigned to TAU.
3100722|NCT02032706|Experimental|Positional feedback|Deliver therapy when the supine position is detected
3100723|NCT02032758|Experimental|Golfers With Golfer's Cramp|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting before and after a single dose of 10 mg Propranolol.
3100724|NCT02032758|Other|Golf Pros|Subjects in this arm will be tested with the Opal device, the Science and Motion PuttLab (SAM), and the Surface Electromyography (EMG) to collect movement parameters while putting. The subjects in this arm will not receive any study drug.
3100725|NCT02032810|Experimental|Dose Escalation|Dose Escalation of Panobinostat + Ipilimumab. Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg) along with a dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
3100726|NCT02032875|Experimental|Post-liver Transplant Cohort|Participants with liver transplant received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets daily for 12 weeks and were followed for 24 weeks post treatment.
3100727|NCT02032875|Experimental|Cirrhotic Cohort|Cirrhotic participants received daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (based on baseline hemoglobin and creatinine clearance and tolerated dose) tablets orally for 12 weeks and were followed for 24 weeks post-treatment. Cirrhotic participants who received a liver transplant while on study treatment were eligible (>3 months post transplant) for a treatment extension of daclatasvir 60 mg, sofosbuvir 400 mg, and ribavirin (dose based on hemoglobin level) tablets orally for an additional 12 weeks
3100728|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks|Treatment-naïve participants received daclatasvir 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
3100729|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks|Treatment-naïve participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 8 weeks
3100730|NCT02032888|Experimental|Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks|Treatment-experienced participants received daclatasvir, 30, 60, or 90 mg, and sofosbuvir, 400 mg, once daily for 12 weeks
3100731|NCT02032901|Experimental|A1:Daclatasvir + Sofosbuvir in treatment-naive subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
3100732|NCT02032901|Experimental|A2:Daclatasvir + Sofosbuvir in treatment-experienced subjects|Daclatasvir 60 mg tablet and Sofosbuvir 400 mg tablet orally once daily for 12 weeks
3100733|NCT02033005||Breastfed infants|>80% of feeds consisting of breast milk at both scanning points
3100734|NCT02033005||Formula-fed infants|>80% of feeds consisting of formula milk at both scanning points
3100735|NCT02033005||Mixed-fed infants|20%-80% of feeds consisting of breast milk.
3100736|NCT02033083|Active Comparator|Laminaria|Patients in this arm will receive laminaria cervical dilators one day before D&E procedure.
3100737|NCT02033083|Active Comparator|Dilapan-S|Patients in this arm will receive Dilapan-S cervical dilators one day before D&E procedure.
3100738|NCT02033174|Other|Sugar water first, then alcohol|8 participants have received oral fat diet plus water with sugar (equivalent caloric intakes as sugar with water in the control group). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and a daily total amount of 16 g/m2 of alcohol, of different beverages (red wine, vodka, brandy or rum)
3100739|NCT02033174|Other|Alcohol first then sugar water|8 participants have received oral fat diet plus alcoholic beverages (a daily total amount of 16 g/m2 of alcohol, of different beverages : red wine, vodka, brandy or rum). Then they receive the same oral fat-enriched diet (1486 kcal/m2) with 654 kcal/m2 (44%) as fat and water with sugar (equivalent caloric intakes as sugar with water in the control group).
3100740|NCT02033200|Experimental|Active|Stendra 200 mg
3100741|NCT02033200|Placebo Comparator|Placebo|placebo
3100742|NCT02033213|Active Comparator|Restrictive group|Patients who received ≤ 8ml/kg/h of intraoperative fluid. A fluid administered during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
3469032|NCT03890575|Experimental|Airway Stent for Malignant Stricture|Patients with malignant stricture were implanted with covered metallic segmented stent modified with 3D printing.
3100743|NCT02033213|Active Comparator|Liberal group|Patients who received > 8 ml/kg/h of fluid. A fluid used during surgery: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells.
3100744|NCT02033317|Experimental|patiromer|
3100745|NCT02033369|Experimental|Pramipexole|Six weeks of treatment with oral pramipexole, initiated at 0.25 mg/day and titrated to a maximum daily dose of 2.5 mg.
3100746|NCT02033369|No Intervention|Healthy Control|Healthy volunteers were matched to MDD group subjects by age, gender, and ethnicity, and will have no lifetime psychiatric disorders.
3100747|NCT02033382||Healthy Controls|Age and gender matched healthy controls
3100748|NCT02033382||Patients|Participants diagnosed with Schizophrenia, schizophreniform disorder, or schizoaffective disorder, depressed type that are naive to anti-psychotic treatment.
3100749|NCT02033499|No Intervention|No testing|No testing
3100750|NCT02033499|Other|standard messaging|SMBG standard messaging
3100751|NCT02033499|Other|enhanced messaging|SMBG enhanced messaging
3100752|NCT02033694||Participants With 2 Years Follow up|Participants with NIRS-IVUS imaging at baseline and assigned to follow up for Non-Index Culprit Lesion related Major Adverse Cardiac Events (NC-MACE) for 2 years
3100753|NCT02033759|Active Comparator|Traditional circumferential measurements|Traditional screening with volumetric analysis Patient Anxiety Questionnaire
3100754|NCT02033759|Experimental|Bio-Impedance Testing|Traditional Screening with Volumetric Analysis and Bio-Impedance Analysis Patient Anxiety Questionnaire
3100755|NCT02033850|Experimental|APT-II group|"Intervention: rehabilitation of attention using the Attention Process Training-II.~Participants in the APT-II group will receive overall up to 40 hours of individual attention process training. Therapy will be administered in one two-hour session each week over a total of 20 weeks."
3100756|NCT02033850|No Intervention|standard care group|Participants in the standard care group will not receive cognitive training or rehabilitation interventions, will be instructed to have an usual lifestyle, and will be conventionally provided of medication and clinic consultations
3100757|NCT02033876|Experimental|Ursodiol|Ursodeoxycholic acid (UDCA) 600mg in delayed (ileocolonic)-release to be taken twice daily
3100758|NCT02033876|Placebo Comparator|Placebo|matching placebo capsules to be taken twice daily
3100759|NCT02033889|Experimental|Ertuglifozin 5 mg|Ertugliflozin 5 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
3100760|NCT02033889|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally, once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received glimepiride/placebo. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
3100761|NCT02033889|Placebo Comparator|Placebo/Glimepiride|Placebo to ertugliflozin, orally once daily from Day 1 to Week 104. Up to 26 weeks, participants meeting glycemic rescue criteria were rescued with open-label glimepiride, and if they met rescue criteria again, and they were on maximal tolerated doses of glimepiride, they received basal insulin. After Week 26, non-rescued participants who had a fasting finger-stick glucose ≥110 mg/dL received blinded glimepiride. If a participant met glycemic rescue criteria after 26 weeks, and they were on maximal tolerated dose of glimepiride, then rescue with basal insulin was initiated.
3100762|NCT02033993|Active Comparator|Arm 1|Nab-Paclitaxel - 260mg/m2: q21 days
3100763|NCT02033993|Active Comparator|Arm 2|Paclitaxel - 175mg/m2: q21 days
3100764|NCT02034006|Experimental|Ranibizumab|Patients treated with a single ranibizumab 0.5 mg/0.05ml intravitreal injection
3100765|NCT02034019|Active Comparator|OTX-DP (Dexamethasone Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing dexamethasone
3100766|NCT02034019|Placebo Comparator|PVPP (Placebo Punctum Plug)|Resorbable hydrogel drug delivery vehicle containing no drug
3100767|NCT02034058|Other|Wingspan Stent System|Placement of the Wingspan Stent
3469033|NCT03890263|Experimental|Opioid deprescribing and self-management|
3469034|NCT03890276|Active Comparator|HMS EL&C training without video|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will be able to: 1) distinguish normal and abnormal findings, 2) competently and confidently manage normal labor and birth to help prevent complications, 3) employ evidence-based practices, 4) rapidly identify and manage complications when they arise and 5) provide respectful care
3100770|NCT02034162|Active Comparator|Mebendazole|Mebendazole will be administered as a single 500-mg chewable tablet in a double-blind manner at the baseline visit (Day 1) and in an open-label manner at Visit 4 (Day 21).
3100771|NCT02034162|Placebo Comparator|Placebo|Matching placebo will be administered as a single-dose chewable tablet in a double-blind manner at the baseline visit (Day 1).
3100772|NCT02034175|Experimental|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
3100773|NCT02034175|Active Comparator|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
3100774|NCT02034409|Sham Comparator|Sham|Treatment to index knee with sham device for 48 weeks
3100775|NCT02034409|Experimental|PLIUS|Treatment to index knee with PLIUS device for 48 weeks
3100776|NCT02034435|Active Comparator|Aim1-Low Sodium then High Sodium|"Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made."
3100777|NCT02034435|Active Comparator|Aim 1-high salt diet then low salt diet|"Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.~Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made."
3100778|NCT02034435|Active Comparator|Aim2- low salt diet and epleronone then amlodipine|Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.
3100779|NCT02034435|Active Comparator|aim2- low salt diet and amlodipine then epleronone|Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.
3100780|NCT02034474|Experimental|tocilizumab|Tocilizumab will be administered at day 0, week 4 and week 8 via an iv drip over 60 min. Dose is 8mg/kg but may be reduced to 4mg/kg if intolerable. Maximum dose will be 800mg.
3100781|NCT02034474|Placebo Comparator|Placebo|Placebo will be administered intravenously via an iv drip over 60 min
3100782|NCT02034513|Experimental|IDeg OD + IAsp followed by IGlar OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
3100783|NCT02034513|Active Comparator|IGlar OD + IAsp followed by IDeg OD + IAsp|Each treatment period consists of a 16-week wash-out period and a 16-week maintenance period
3100784|NCT02034552|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|
3100785|NCT02034552|Experimental|Radium-223 with abiraterone&prednisone|
3100786|NCT02034552|Experimental|Radium-223 with enzalutamide|
3100787|NCT02034565|Experimental|Treatment A: Apixaban tablet|Apixaban Film coated Tablet Single dose 10 mg orally
3100788|NCT02034565|Experimental|Treatment B: Apixaban oral solution|Apixaban Solution Single dose 10 mg orally
3100789|NCT02034578|Experimental|Arm A: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe
3100790|NCT02034578|Experimental|Arm B: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT
3100791|NCT02034578|Experimental|Arm C: Apixaban|Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT
3100792|NCT02034591|Experimental|Arm A-Apixaban|Solution Apixaban 5 mg ( 0.4 mg/ml oral solution x 12.5 ml) through mouth or oral syringe
3100793|NCT02034591|Experimental|Arm B-Apixaban|Oral Solution Apixaban 5 mg single dose (0.4 mg/mL oral solution x 12.5 mL) after 180 mL of Boost Plus®, followed by 60 mL of Boost Plus® via same NGT
3100794|NCT02034591|Experimental|Arm C-Apixaban|Single dose crushed Apixaban tablet 5 mg (5 mg tablet crushed and suspended in 60 mL Dextrose 5% in water (D5W)) through NGT
3100795|NCT02034708|Experimental|Dotarem®/Gadovist®|Dotarem®-enhanced MRI, then Gadovist®/Gadavist®-enhanced MRI
3100796|NCT02034708|Experimental|Gadovist®/Dotarem®|Gadovist®/Gadavist®-enhanced MRI then Dotarem® enhanced MRI
3100797|NCT02034799|Other|Standard of Care (SoC)|Standard of Care (SoC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
3100798|NCT02034799|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
3100799|NCT02034877|Experimental|1|
3100800|NCT02034916|Experimental|talazoparib|"Cohort 1) Subjects with a documented PR or CR to a prior platinum-containing regimen for metastatic disease with disease progression > 8 weeks following the last dose of platinum~Cohort 2) Subjects who have received > 2 prior chemotherapy regimens for metastatic disease and who have had no prior platinum therapy for metastatic disease"
3100801|NCT02035202|Experimental|CBT2go|Participants assigned to this condition will attend one session with a therapist to identify cognitive and behavioral strategies around four areas: 1) mood/psychotic symptoms, 2) medication adherence, 3) socialization, and 4) relapse prevention. Subsequently they will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks, and they will receive personalized cognitive and behavioral strategies linked to their momentary responses with bi-monthly telephone support.
3100802|NCT02035202|Active Comparator|EMA-only|Participants assigned to this condition will answer questions on a mobile device (smartphone) 3 times per day for 12 weeks but will not receive personalized cognitive and behavioral strategies.
3100803|NCT02035202|No Intervention|Standard Care|Participants assigned to this condition will only participate in the assessments.
3100804|NCT02035267|Placebo Comparator|Placebo - Grade 1|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 1 (mild).
3100805|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 1|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 (mild).
3100806|NCT02035267|Placebo Comparator|Placebo - Grade 4|Participants received placebo administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants With CR SMFRS Grade 4 (extreme).
3100807|NCT02035267|Experimental|ATX-101 deoxycholic acid injection - Grade 4|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments. Participants with CR SMFRS Grade 4 (extreme).
3100808|NCT02035332|Experimental|Aurora Treatment Arm|Endometrial Ablation
3100809|NCT02035345|Experimental|Carboplatin|"Carboplatin will be prepared as a single 500ml infusion. Potentially 6 cycles Carboplatin (Amount of total dose) will be administered intravenously by the treating nurse according to the following schedule:~First hour - Administer 1 percent of total dose (5ml with tubing primed)~Second hour - Administer 9 percent (45 mL)~Third hour - Administer 90 percent (450 mL)"
3100810|NCT02035475|Active Comparator|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
3100811|NCT02035475|Active Comparator|Maryland Bipolar Cautery|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
3100812|NCT02035553|Placebo Comparator|Placebo|Placebo, two tablets, once daily by mouth
3100813|NCT02035553|Experimental|Pimavanserin 40 mg|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
3100814|NCT02035696|Experimental|TIVc-High Dose|Subjects (6 to <48 months old) received two doses of 0.75 mL of TIVc vaccine
3100815|NCT02035696|Experimental|TIVc-Full Dose|Subjects(6 to <48 months old) received two doses of 0.50 mL of TIVc vaccine
3100816|NCT02035696|Experimental|TIVc- Half Dose|Subjects (6 to <48 months old)received two doses of 0.25 mL of TIVc vaccine
3100817|NCT02035696|Active Comparator|TIVe|Subjects (6 to <48 months old) received two doses of TIVe vaccine(IM/0.25mL -for ages 6 to <36 months and IM/ 0.5 mL -for ages 36 to <48 months)
3100818|NCT02035748|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal injection
3100819|NCT02036294|Other|Usual Care|Usual Care: Standard healthcare services will be received. Study participants in this arm will not receive any additional study interventions.
3100820|NCT02036294|Experimental|BREATHE program|Study participants randomized to this arm will be offered the BREATHE program an integrated multifaceted intervention that includes comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
3100821|NCT02036320|Experimental|etafilcon A with additive printed limbal ring|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
3100822|NCT02036320|Active Comparator|etafilcon A|Each subject will insert the trial lens while being observed by a technician prior to assessment by the study investigator.
3100823|NCT02036424|Active Comparator|Bevacizumab|1.25 mg intravitreal injection given monthly during a 6 month period
3100824|NCT02036424|Active Comparator|Ozurdex|Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections
3100825|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 25mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg once every 2 weeks (Q2W) (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg once weekly (Q1W) during Cycle 1 (28-day cycle).
3100826|NCT02036502|Experimental|Part 1:pembro 2mg/kg+len 10 mg+dex 40 mg|Participants in Part 1 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 2 mg/kg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
3100827|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
3100828|NCT02036502|Experimental|Part 2:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W during Cycle 1 (28- day cycle).
3100829|NCT02036502|Experimental|Part 2:pembro 200 mg+len 10 mg+dex 40 mg|Participants in Part 2 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 10 mg (Days 1-21) and dexamethasone 40 mg Q1W during Cycle 1 (28-day cycle).
3100830|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 40 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 40 mg Q1W weekly during each 28-day cycle.
3100831|NCT02036502|Experimental|Part 3:pembro 200 mg+len 25 mg+dex 20 mg|Participants in Part 3 with refractory or relapsed and refractory multiple myeloma (rrMM) received pembrolizumab 200 mg Q2W (Days 1 and 15) in combination with lenalidomide 25 mg (Days 1-21) and dexamethasone 20 mg Q1W weekly during each 28-day cycle.
3100832|NCT02036502|Experimental|Part 3:pembro 200 mg+carf 56 mg/m^2+dex 20 mg|Participants in Part 3 with relapsed or refractory multiple myeloma (rMM) received pembrolizumab 200 mg Q3W in combination with carfilzomib 56 mg/m^2 (Days 1, 2, 8, 9, 15, 16) and dexamethasone 20 mg once or twice weekly (Days 1, 2, 8, 9, 15, 16, 22, 23) during each 28-day cycle.
3100833|NCT02036515|Experimental|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily for 52 weeks
3100834|NCT02036515|Experimental|Ertugliflozin 15 mg|Ertugliflozin, 15 mg, oral, once daily for 52 weeks
3100835|NCT02036515|Placebo Comparator|Placebo|Matching placebo to ertuglifozin, oral, once daily for 52 weeks
3100836|NCT02036541|Experimental|AqueSys XEN 45 Glaucoma Implant|
3100837|NCT02036580|Experimental|Low Dose|Investigational product Tralokinumab
3100838|NCT02036580|Experimental|High Dose|Investigational product Tralokinumab
3100839|NCT02036580|Placebo Comparator|Placebo|Placebo
3100840|NCT02036645|Experimental|MEDI1814 IV|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
3100841|NCT02036645|Placebo Comparator|IV Placebo|Upto 10 cohorts of subjects are planned to be dosed by IV injection, with single and multiple ascending doses ranging from 25-1800mg.
3100842|NCT02036645|Experimental|MEDI1814 Sub Cutaneous Injection|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
3100843|NCT02036645|Placebo Comparator|Subcutaneous Placebo|2 cohorts of subjects are planned to be dosed by sub cutaneous injection, one single ascending dose and one multiple ascending dose cohort
3100844|NCT02036775|Experimental|Treatment sequence 1|Treatment 1, Washout 6 days, Reference product, Washout 6 days, Treatment 2
3100845|NCT02036775|Experimental|Treatment sequence 2|Treatment 2, Washout period 6 days, Treatment 1, Washout 6 days, Reference product
3100846|NCT02036775|Experimental|Treatment sequence 3|Reference product, Washout 6 days, Treatment 2, Washout 6 days, Treatment 1
3100847|NCT02036775|Experimental|Treatment Sequence 4|Treatment 2, Washout 6 days, Reference product, Washout 6 days, Treatment 1
3100848|NCT02036775|Experimental|Treatment sequence 5|Reference product, Washout 6 days, Treatment 1, Washout 6 days, Treatment 2
3100849|NCT02036775|Experimental|Treatment Sequence 6|Treatment 1, Washout 6 days, Treatment 2, Washout 6 days, Reference product
3100850|NCT02036840||Penicillin allergy|
3100851|NCT02036853|Experimental|Schedule A|Subjects previously treated with triheptanoin
3100852|NCT02036853|Experimental|Schedule B|Naïve to triheptanoin
3469035|NCT03890276|Experimental|HMS training with video supplementation|Participant health care providers will receive a 1-2 day training in the new 'Helping Mothers Survive Essential Labor and Childbirth' (HMS EL&C) training module. They will ALSO receive the training with interspersed with short video clips that that aim to improve understanding and skills acquisition ('Videos used to supplement live trainer'). Video supplementation is meant to standardize the cascaded training in the future as the training is offered at a much larger scale in low and middle income countries.
3469036|NCT03890250|Sham Comparator|Sham group|Following the assessments, sham group will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer. In Sham training group, NMES will be applied to the same region after aerobic exercise, current frequency is 5 Hz, current transit time is 300 μs, 10 seconds warning, 30 seconds electrical stimulation in 20 seconds rest period. The rehabilitation program will be administered two days a week for 8 weeks under the supervision of a physiotherapist.
3469037|NCT03890250|Experimental|NMES group|"Following the assessments, both groups will participate in a 20-30 minute low-medium intensity aerobic exercise training with cycling ergometer.~After the aerobic exercise in NMES group, bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds."
3469038|NCT03890107||Pediatric tympanostomy tube patients|Patients diagnosed with otitis media and scheduled for tympanostomy tube placement will be imaged with the OtoSight
3469039|NCT03890120|Experimental|Blinded Phase: Cilofexor|Cilofexor for 96 weeks
3469040|NCT03890120|Placebo Comparator|Blinded Phase: Placebo|Placebo for 96 weeks
3469041|NCT03890120|Experimental|Open-Label Phase: Cilofexor|Cilofexor for 96 weeks
3469042|NCT03890224|No Intervention|Control group|no home non-invasive ventilation (NIV), only hospital NIV
3469043|NCT03890224|Active Comparator|Non-targeted home NIV|Nocturnal home non-invasive ventilation (NIV)
3469044|NCT03890224|Active Comparator|Targeted home NIV|Nocturnal home non-invasive ventilation (NIV) with high monitoring
3100863|NCT02037061|Placebo Comparator|normal saline|Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.
3100864|NCT02037061|Active Comparator|bupivacaine|Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.
3100865|NCT02037165|Experimental|Test Treatment 1: BI 1026706|BI 1026706 plus matching placebo to BI 1026706 Powder for Oral Solution (PfOS) and placebo tablet
3100866|NCT02037165|Experimental|Test Treatment 2: BI 1026706|BI 1026706 and placebo tablet
3100867|NCT02037165|Experimental|Reference Treatment 1: BI 1026706|Matching placebo to BI 1026706 PfOS and placebo tablet
3100868|NCT02037165|Experimental|Reference Treatment 2: Celecoxib|Celecoxib hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
3100869|NCT02037165|Experimental|Reference Treatment 3: Pregabalin|Pregabalin hard capsule as active comparator plus matching placebo to BI 1026706 PfOS
3100870|NCT02037204|Experimental|Cartilage repair surgery|Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
3100871|NCT02037230|Experimental|MK-1775/ Gemcitabine/ Radiation Therapy|
3100872|NCT02037256|Experimental|A Treatment (bortezomib and filgrastim)|GROUP A: Bortezomib administered in the evening after comploetion of G-CSF collection or on day 6 of mobilization with G-CSF.
3100873|NCT02037256|Experimental|B Treatment (bortezomib and filgrastim)|GROUP B: Bortexomib administered on days 4 & day 7, before administration of filgrastim.
3100874|NCT02037295|Experimental|OF_UF Vancomycin|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then vancomycin
3100875|NCT02037295|Placebo Comparator|OF_UF Placebo|Healthy volunteers assigned overfeeding diet, underfeeding diet, and then placebo
3100876|NCT02037295|Experimental|UF_OF Vancomycin|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then vancomycin
3100877|NCT02037295|Placebo Comparator|UF_OF Placebo|Healthy volunteers assigned underfeeding diet, overfeeding diet, and then placebo
3100878|NCT02037347|Experimental|Palifermin|Palifermin 60 micrograms/kg/day IV for 3 consecutive days
3100879|NCT02037425|Other|onabotulinumtoxinA|At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
3100880|NCT02037438|Active Comparator|CONV Arm|Conventional (CONV) care for the diagnosis and treatment of sleep disorders
3100881|NCT02037438|Experimental|PCCM ARM|Patient-Centered Outcomes and Coordinated Care Management (PCCM) for the diagnosis and treatment of sleep disorders
3100882|NCT02037477|Experimental|Sequence A (Cohort 1): Vonoprazan + Esomeprazole|Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.
3469045|NCT03890224|Active Comparator|Rescue home NIV|home non-invasive ventilation (NIV) on demand
3469046|NCT03890094||Sufentanil and Midazolam|Patients who had undergone bronchoscopy applying topical lidocaine, sufentanil and midazolam under conscious sedation in the First Affiliated Hospital of Guangzhou Medical University from September 2013 to July 2017 were included in this study.
3469047|NCT03890055|Experimental|Clinical trial group|（Carboplatin/cisplatin + etoposide）+ （Anlotinib Hydrochloride 12 mg/day ，Each cycle was defined as 2 weeks on-treatment fol- lowed by 1 week off-treatment）, after 4-6 cycles of treatment, the treatment was continued with anlotinib until disease progression.
3469048|NCT03890068|Experimental|anlotinib|anlotinib for maintenance treatment a dose of 12 mg once daily (day1-14 PO) in 21-day cycles
3469049|NCT03889990|Other|healthy smokers|"Healthy smokers males, aged >18years, with >10 pack/years,receiving no medications~Intervention: the use of an IQOS"
3469050|NCT03890198|Experimental|chimeric Antigen Receptor T cell|LCAR-C182A Cells
3100883|NCT02037477|Experimental|Sequence B (Cohort 1): Esomeprazole + Vonoprazan|Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
3100884|NCT02037477|Experimental|Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium|Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.
3100885|NCT02037477|Experimental|Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan|Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.
3100886|NCT02037555|Experimental|AT-III (Human)|"Single intravenous dose of AT-III (Human) sufficient to achieve an absolute increase of 20% (percentage points) above pretreatment AT levels according the following formula:~AT-III (Human) dose (IU) required = (20) × (subject weight in kg) / 1.4"
3100887|NCT02037555|Placebo Comparator|Placebo|Single intravenous administration of placebo at a volume equivalent to the volume for the calculated AT-III (Human) dose.
3100888|NCT02037568|No Intervention|Caregiver Self-Directed|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; treatment as usual psychosocial care; caregiver workbook.
3100889|NCT02037568|Experimental|Caregiver Intervention|Orientation class; laboratory biomarker analysis; questionnaire administration; survey administration; Psychoeducation and Relaxation (fPER), which included one-on-one psychoeducation, and stress management intervention.
3100890|NCT02037776|Placebo Comparator|Rikkunshito Placebo|
3100891|NCT02037776|Active Comparator|Rikkunshito|
3100892|NCT02037893|Experimental|Antipyrine and Benzocaine Otic solution|antipyrine 54 mg and benzocaine 14 mg. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3100893|NCT02037893|Active Comparator|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3100894|NCT02037893|Active Comparator|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 ml. Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3100895|NCT02037893|Placebo Comparator|Placebo|Placebo otic solution will be glycerin that is dehydrated . Apply drops along the wall of the ear canal until filled and repeating every 3 hours for 24 hours unless the subject is sleeping
3100896|NCT02037984|Experimental|Adult V114: 1x:1x:1x|Adults receive a single vaccination on Day 1.
3100897|NCT02037984|Experimental|Adult V114: 2x:2x:2x|Adults receive a single vaccination on Day 1.
3100898|NCT02037984|Experimental|Infant V114: 1x:1x:1x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100899|NCT02037984|Experimental|Infant V114: 2x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100900|NCT02037984|Experimental|Infant V114: 2x:2x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100901|NCT02037984|Experimental|Infant V114: 0.5x:0.5x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100902|NCT02037984|Experimental|Infant V114: 1x:1x:2x|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100903|NCT02037984|Active Comparator|Infant Prevnar 13®|Infants receive 4 total vaccinations given at 2, 4, 6, and 12 to 15 months of age.
3100904|NCT02038010|Experimental|Treatment (PI3K inhibitor BYL719, ado-trastuzumab emtansine)|Patients receive PI3K inhibitor BYL719 PO daily on days 1-21 and ado-trastuzumab emtansine IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3100905|NCT02038023|Other|IV iron|Intravaneous iron(1000 mg low molecular weight iron dextran over 60 minutes) for moderate to severe iron deficient anemia of pregnancy in women intolerant of or unresponsive to oral iron.
3100906|NCT02038036|Experimental|Ruxolitinib|Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
3100907|NCT02038036|Active Comparator|Best Available Therapy (BAT)|Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
3100908|NCT02038049|Experimental|VAY736|Intravenous infusion of VAY736
3100909|NCT02038049|Placebo Comparator|Placebo to VAY736|Matching placebo (infusion bag) administered intravenously. Placebo randomized patients were offered optional VAY736 administration after week 16
3100910|NCT02038075|Experimental|Brief Cognitive Behavioral Therapy (BCBT)|In addition to TAU, participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
3100911|NCT02038075|Active Comparator|Treatment As Usual (TAU)|Participants in TAU receive usual care from military clinicians as well as non-military clinicians from the local community, as determined by participants' primary mental health care provider. All mental health, substance abuse, and medical treatment are provided within the military health care system at no cost to participants.
3100912|NCT02038179|Experimental|Allopurinol, Then Placebo|Participants will be asked to take 4 weeks of allopurinol (300 mg oral per day), then will crossover (after 2-4 week washout period) and take placebo for an additional 4 weeks.
3100913|NCT02038179|Experimental|Placebo, Then Allopurinol|Participants will be asked to take 4 weeks of placebo, then will crossover (after 2-4 week washout period) and take allopurinol (300 mg oral per day) for an additional 4 weeks.
3132631|NCT03441984|Experimental|Subjects with treatment sequence BAC|The subjects in Part 1 of the study will receive a single dose each of, treatment B in TP1, treatment A in TP2 and treatment C in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3100914|NCT02038218|Experimental|DM-CHOC-PEN|"Two Cohorts of patients will be treated every once every 21 days with a single infusion of DM-CHOC-PEN as an out-patient. Patients will be divided into:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
3100915|NCT02038543|Experimental|Primary hyperoxaluria patients|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the Clinical Research and Trials Unit (CRTU). The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
3100916|NCT02038569|Experimental|LEO 80185 gel|
3100917|NCT02038647|Experimental|Alisertib (MLN8237) + Paclitaxel|Alisertib 40 mg, tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 60 mg/m^2 intravenously (IV) once a week for 3 weeks on Days 1, 8, and 15 in a 28-day until disease progression (Up to 17 Cycles).
3100918|NCT02038647|Placebo Comparator|Placebo + Paclitaxel|Alisertib placebo-matching tablets, orally, twice a day, 3 days on/4 days off for 3 weeks on Days 1-3, 8-10, and 15-17 in a 28-day cycle along with paclitaxel 80 mg/m^2 IV once a week for 3 weeks on Days 1, 8, and 15 in a 28-day cycle until disease progression (Up to 22 Cycles).
3100919|NCT02038764|Placebo Comparator|Placebo|Placebo
3100920|NCT02038764|Experimental|PF-06342674|
3100921|NCT02038790|Experimental|Suboxone sublingual film 8/2|Participants took a single dose of Suboxone sublingual film 8/2 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
3100922|NCT02038790|Active Comparator|Zubsolv sublingual tablets 5.7/1.4|Participants took a single dose of Zubsolv sublingual tablets 5.7/1.4 either on Day 0 or Day 1, depending on the how each participant was randomized in this cross-over study.
3100923|NCT02038829|Placebo Comparator|Placebo|Placebo bid
3100924|NCT02038829|Experimental|SUN-101 3 mcg|SUN-101 3 mcg bid
3100925|NCT02038829|Experimental|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
3100926|NCT02038829|Experimental|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
3100927|NCT02038829|Experimental|SUN-101 50 mcg|SUN-101 50 mcg bid
3100928|NCT02038829|Active Comparator|Aclidinium 400 mcg|Aclidinium 400 mcg bid
3100929|NCT02038881|Experimental|Group 1 (standard regimen)|One injection at Day 0 and Day 28 with IMVAMUNE® (MVA-BN®)
3100930|NCT02038881|Experimental|Group 2 (double dose regimen)|Two injections at Day 0 and two injections at Day 28 with IMVAMUNE® (MVA-BN®)
3100931|NCT02038881|Experimental|Group 3 (booster regimen)|One injection at Day 0 and Day 28 and one booster injection at week 12 with IMVAMUNE® (MVA-BN®)
3100932|NCT02038894|Active Comparator|Intubated with Sevoflurane (IS)|Anesthetic technique during (EGD)
3100933|NCT02038894|Active Comparator|Intubated with Propofol (IP)|Anesthetic technique during (EGD)
3100934|NCT02038894|Active Comparator|Native Airway - no intubation|Anesthetic technique during (EGD)
3100935|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (50)|Hepatitis A vaccine, intramuscular (IM), on Day 1, followed by norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus virus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MLP) and 500 µg aluminum hydroxide, IM on Day 28.
3100936|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3100937|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3100938|NCT02038907|Experimental|GI.1/GII.4 (15/15) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3100939|NCT02038907|Experimental|GI.1/GII.4 (15/50) - MPL (15)|IM hepatitis A vaccine on Day 1, followed by IM norovirus bivalent vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, on Day 28.
3100940|NCT02038907|Experimental|GI.1/GII.4 (50/50) - MPL (15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 15 µg MLP and 500 µg aluminum hydroxide, IM, on Day 28.
3100941|NCT02038907|Experimental|GI.1/GII.4 (15/15)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3100942|NCT02038907|Experimental|GI.1/GII.4 (15/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3100943|NCT02038907|Experimental|GI.1/GII.4 (50/50)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3100944|NCT02038907|Experimental|GI.1/GII.4 (50/150)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 28.
3100945|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167)|Hepatitis A vaccine, IM, on Day 1, followed by norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 28.
3100946|NCT02038907|Experimental|GI.1/GII.4 (15/50) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3100947|NCT02038907|Experimental|GI.1/GII.4 (50/150) x2|Norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 150 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3100948|NCT02038907|Experimental|GI.1/GII.4 (15/50) - Al(OH)3 (167) x2|Norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 167 µg aluminum hydroxide, IM, on Day 1 and Day 28.
3100949|NCT02038920|Experimental|Induction Phase: Vedolizumab, 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
3100950|NCT02038920|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV infusion once at Weeks 0, 2 and 6 in the induction phase.
3100951|NCT02038920|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved Crohn's Disease Activity Index (CDAI)-70 response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
3100952|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved CDAI-70 response at Week 10 and were randomized to receive placebo in maintenance phase.
3100953|NCT02038920|Placebo Comparator|Maintenance Phase: Placebo Continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved CDAI-70 response at Week 10 received placebo in maintenance phase without randomization.
3100954|NCT02038920|Experimental|Open-Label: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 as a maximum duration in open-label phase.
3100955|NCT02038933|Experimental|Nivolumab (3 mg/kg)|Nivolumab 3 mg/kg solution intravenously every 2 weeks until progression or unacceptable toxicity
3100957|NCT02038959|No Intervention|Usual Care and Educational Materials|Participants with Parkinson disease will receive educational materials from the National Parkinson Foundation, complete a baseline assessment survey and virtual visit with a physician independent rater, then continue with their usual care in their communities for the duration of the study. After 12 months, they will have another virtual study assessment with an independent rater, after which they will receive a free, one-time virtual consultation with a Parkinson disease specialist in their state.
3100958|NCT02038959|Experimental|Virtual Visits and Educational Materials|Participants with Parkinson disease randomized to the virtual visit intervention will receive educational materials from the National Parkinson Foundation, complete a baseline assessment and virtual study assessment with a physician independent rater, and then receive four virtual care visits with a Parkinson disease specialist in their state. Specialists will provide recommendations for care to participants and their designated local health care provider. At 12 months, these individuals will again be assessed by the independent rater, who will be blind to treatment assignment.
3100959|NCT02039115|Experimental|prednisone|Daily oral prednisone is taken for 6 weeks, at a dose of 40mg/day in week 1, 30mg/day in week 2, 20mg/day week 3 and 4, 10mg/day in week 5, and 5mg/day in week 6. Prednisone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage complete Barretts excision.
3100960|NCT02039115|Placebo Comparator|placebo|Placebo tablets will be taken in the same manner as the prednisone arm.
3100961|NCT02039219|Placebo Comparator|Placebo|Placebo
3100962|NCT02039219|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.
3100963|NCT02039375|Experimental|"Hopkins post tPA monitoring protocol"|"Patients treated with IV tPA (intravenous tissue Plasminogen Activator) for acute stroke will be monitored in a non-ICU setting following the Hopkins post tPA monitoring protocol, a new schedule for vital signs and neurochecks. These patients will have vital signs and neurochecks every 15 minutes for two hours, then once upon admission to the stroke unit and after one hour, then every two hours for 8 hours and then every four hours until 24 hours post tPA."
3100964|NCT02039414||Obese, Inactive|Pregnant women with a BMI≥30kg/m2 and sedentary lifestyle
3100965|NCT02039414||Obese, Active|Pregnant women with a BMI≥30kg/m2 and exercising >150min/week
3100966|NCT02039427|Placebo Comparator|Placebo|Normal saline(Placebo) 2 ml 5 min before induction Normal saline 2 ml 10 min before end of surgery
3100967|NCT02039427|Active Comparator|Preketorolac|Ketorolac 30 mg 5 min before induction Normal saline 2 ml 10 min before end of surgery
3100968|NCT02039427|Active Comparator|Postketorolac|Normal saline 2 ml 5 min before induction Ketorolac 30 mg 10 min before end of surgery
3100969|NCT02039427|Active Comparator|Dexamethasone|Dexamethasone 10 mg (total volume 2 ml) 5 min before induction Normal saline 2 ml 10 min before end of surgery
3100970|NCT02039505|Placebo Comparator|Induction Phase: Cohort 1, Placebo|Vedolizumab placebo-matching, intravenous (IV) infusion, once at Weeks 0, 2 and 6 in the induction phase.
3100971|NCT02039505|Experimental|Induction Phase: Cohort 1, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2, and 6 in the induction phase.
3100972|NCT02039505|Experimental|Induction Phase: Cohort 2, Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 in the induction phase.
3100973|NCT02039505|Experimental|Maintenance Phase: Placebo|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive placebo in maintenance phase.
3100974|NCT02039505|Experimental|Maintenance Phase: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab in induction phase and achieved clinical response at Week 10 and were randomized to receive vedolizumab in maintenance phase.
3100975|NCT02039505|Placebo Comparator|Maintenance Phase: Placebo continuation|Vedolizumab placebo-matching, IV infusion, once at Weeks 14, 22, 30, 38, 46 and 54 in maintenance phase. Participants received vedolizumab placebo-matching in induction phase and achieved clinical response at Week 10 received placebo in maintenance phase without randomization.
3100976|NCT02039505|Experimental|Open-Label Cohort: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once at Weeks 0, 2 and 6 and then every 8 weeks thereafter up to Week 94 in open-label cohort.
3100977|NCT02039674|Experimental|Part1 CohortA2 (Pembro2mg/kg+Paclitaxel [Pa]+Carboplatin [C])|Cohort A participants receive pembrolizumab (2 mg/kg) via intravenous (IV) infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (Aare Under the Curve [AUC] 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
3100978|NCT02039674|Experimental|Part 1 Cohort B2 (Pembro 2mg/kg+Pa+C+Bevacizumab [B])|Cohort B2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3100979|NCT02039674|Experimental|Part 1 Cohort C2 (Pembro 2mg/kg+Pemetrexed [Pe]+C)|Cohort C2 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
3100980|NCT02039674|Experimental|Part 1 Cohort D1 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3100981|NCT02039674|Experimental|Part 1 Cohort E (Pembro 2mg/kg+Erlotinib)|Cohort E participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS erlotinib (150 mg) via oral tablet once a day on every day of each 3-week cycle.
3100982|NCT02039674|Experimental|Part 1 Cohort F (Pembro 2mg/kg+Gefitinib)|Cohort F participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS gefitinib (250 mg) via oral tablet once a day on every day of each 3-week cycle.
3100983|NCT02039674|Experimental|Part 2 Cohort G+ (Pembro 200mg+C+Pe)|Cohort G+ participants receive pembrolizumab (200 mg) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle.
3100984|NCT02039674|Experimental|Part 2 Cohort H (Pembro+I)|Cohort H participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle (at the recommended Phase II dose determined in Cohort D).
3100985|NCT02039674|Experimental|Part 1 Cohort A10 (Pembro+Paclitaxel [Pa]+Carboplatin [C])|Cohort A10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
3100986|NCT02039674|Experimental|Part 1 Cohort B10 (Pembro+Pa+C+Bevacizumab [B])|Cohort B10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS paclitaxel (200 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 6 [6 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS bevacizumab (15 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3100987|NCT02039674|Experimental|Part 1 Cohort C10 (Pembro 10mg/kg+Pemetrexed [Pe]+C)|Cohort C10 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle.
3100988|NCT02039674|Experimental|Part 2 Cohort G- (Placebo+C+Pe)|Cohort G- participants receive placebo (normal saline solution) via IV infusion on Day 1 of each 3-week cycle PLUS carboplatin (AUC 5 [5 mg/mL/min]) via IV infusion on Day 1 of each 3-week cycle PLUS pemetrexed (500 mg/m^2) via IV infusion on Day 1 of each 3-week cycle PLUS.
3100989|NCT02039674|Experimental|Part 1 Cohort D2 (Pembro 10mg/kg+Ipilimumab [I])|Cohort D2 participants receive pembrolizumab (10 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (3 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3100990|NCT02039674|Experimental|Part 1 Cohort D4 (Pembro 2mg/kg+Ipilimumab [I])|Cohort D1 participants receive pembrolizumab (2 mg/kg) via IV infusion on Day 1 of each 3-week cycle PLUS ipilimumab (1 mg/kg) via IV infusion on Day 1 of each 3-week cycle.
3100991|NCT02039687|Experimental|1 mg per day ARA 290|1 mg ARA 290 administered subcutaneously for 28 consecutive days
3100992|NCT02039687|Experimental|4 mg per day ARA 290|4 mg ARA 290 administered subcutaneously for 28 consecutive days
3100993|NCT02039687|Experimental|8 mg per day ARA 290|8 mg ARA 290 administered subcutaneously for 28 consecutive days
3100994|NCT02039687|Placebo Comparator|placebo|1 mL placebo administered subcutaneously for 28 consecutive days
3100995|NCT02039726|Experimental|Quizartinib|Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.
3100996|NCT02039726|Active Comparator|Salvage chemotherapy|Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.
3100997|NCT02039778|Experimental|Stem Cell Radiotherapy and Temozolomide|"One treatment of 2.0 Gy will be given daily 5 days per week for a total of 60.0 Gy over 6 weeks.~Intensity Modulated Radiation Therapy (IMRT) Is Mandated; Proton therapy (Intensity-modulated proton therapy [IMPT] preferred) is an acceptable treatment modality.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
3100998|NCT02039817|Experimental|Healthy Volunteers|All subjects receive a single 50 mg oral dose of IDN-6556
3100999|NCT02039817|Experimental|Severe Renal Impairment|All subjects receive a single 50 mg oral dose of IDN-6556
3101000|NCT02039856|Experimental|EBQI-Supported WH-PACT Implementation|Evidence-based Quality Improvement (EBQI) is a structured research-clinical partnership approach to facilitating implementation of new care models, including multilevel stakeholder engagement, quality improvement (QI) education/training, technical support, formative feedback, external practice facilitation, and national policy guidance.
3101001|NCT02039856|Active Comparator|Routine WH-PACT Implementation|National policy guidance
3101002|NCT02039908|Active Comparator|Methylphenidate 7-day dosing|During the school year, children in this arm will receive 7-day dosing of medication.
3101003|NCT02039908|Active Comparator|Methylphenidate 5-day dosing|During the school year phase, these children will receive 5-day dosing with weekend holidays.
3101004|NCT02039947|Experimental|Cohort A|Subjects will receive dabrafenib 150 milligram (mg) twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity.
3101005|NCT02039947|Experimental|Cohort B|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3101006|NCT02039947|Experimental|Cohort C|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3101007|NCT02039947|Experimental|Cohort D|Subjects will receive dabrafenib 150 mg twice daily and trametinib 2 mg once daily until evidence of disease progression, death, or unacceptable toxicity
3101008|NCT02040077|Experimental|Computer + Fluency|Will receive computerized intervention and will be required to periodically demonstrate mastery of information before proceeding to the next module in the computerized intervention.
3101009|NCT02040077|Active Comparator|Computer Only|Will receive computerized intervention but will not be required to demonstrate mastery of information as part of the intervention.
3101010|NCT02040077|Active Comparator|Treatment as Usual|Will receive publicly available pamphlets that contain same information as the computerized intervention. Will not have access to computerized intervention and will not be required to demonstrate mastery of information as part of the intervention.
3101011|NCT02040090|Experimental|KamRAB|KamRAB 20 IU/kg body weight via IM injection, once on Day 0
3101012|NCT02040090|Active Comparator|FDA approved HRIG product|Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB.
3101013|NCT02040116|Other|rituximab infusion|Every patient is getting the same therapy of rituximab. If day 1 is tolerated at standard infusion then day 14 and beyond will be given as rapid infusion over 90 minutes
3101014|NCT02040259||Mechanical thrombectomy, Trevo Retriever|Mechanical thrombectomy, Trevo Retriever
3101015|NCT02040298|Active Comparator|3 months Clemastine, 2 months Placebo|4mg clemastine twice daily for first 3 months -- crossover -- equivalent quantity/frequency of placebo for last 2 months
3101016|NCT02040298|Active Comparator|3 months Placebo , 2 months Clemastine|Placebo for first 3 months -- crossover -- 4mg clemastine twice daily for last 2 months.
3101017|NCT02040428|Experimental|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3101018|NCT02040428|Active Comparator|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
3132432|NCT03426995|Experimental|GSK3358699, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose, during TP (1 to 3) with planned escalated doses as 1 mg, 10 mg and 35 mg. Dose of 1 mg will be given as solution and doses of 10 mg and 35 mg, will be given as a capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
3132433|NCT03426995|Experimental|GSK3358699, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive GSK3358699, as single escalation dose during TP (1 to 3) with planned escalated doses as 3 mg, 20 mg and 45 mg. Dose of 3 mg will be given as solution and that of 20 and 45 mg, as capsule. Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive GSK3358699 at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of GSK3358699. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
3132434|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 1|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 1 mg and a matching placebo capsule to the study drug GSK3358699, 10 mg and 35 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 1 will receive Placebo at a dose level already given in TP 1-3, and will then receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge. LPS dose will be based on data of study 207654 (NCT03306589).
3132435|NCT03426995|Placebo Comparator|Placebo, Part A, Cohort 2|Part A will comprise of 4 TPs. The subjects in this cohort will receive matching Placebo solution to the study drug GSK3358699 solution for 3 mg and a matching placebo capsule to the study drug GSK3358699, for 20 and 45 mg capsule, during TP (1 to 3). Each TP will be of 1 day and separated by a washout Period of 14-days. Post completion of the dose-escalation TPs, an additional dosing TP 4 will be included where the subjects from each TP (1 to 3), will receive control blisters induced on forearm (0.2 % cantharidin) at Day -10. The subjects in cohort 2 will receive Placebo at a dose level already given in TP 1-3, and will then receive 60 microgram per meter^2 of in vivo GM CSF challenge as an intravenous infusion during TP 4, post administration of Placebo. The subjects will then have blisters induced on the forearm approximately 20 minutes after the challenge GM-CSF infusion. GM-CSF dose will be based on data of study 207654 (NCT03306589).
3132436|NCT03426995|Experimental|Part B, GSK3358699 under Fasted followed by Fed conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fasted condition in TP1 followed by fed condition in TP2. This cohort intended to evaluate the effect of food.
3101019|NCT02040532|Experimental|Open-label gabapentin|Dose titration of 100mg for 1 week, 300mg for 3 weeks, and 600mg for 3 weeks.
3101022|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
3101023|NCT02040623|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
3101024|NCT02040623|Placebo Comparator|Placebo|Placebo Ophthalmic Solution 2 drops per eye twice a day
3101025|NCT02040766|Experimental|BDP 80 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (40 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3101026|NCT02040766|Experimental|BDP 160 mcg BAI|"Beclomethasone dipropionate (BDP) was administered via a breath-actuated inhaler (BAI) twice daily (80 mcg twice a day).~Placebo MDI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3101027|NCT02040766|Active Comparator|BDP 80 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (40 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3101028|NCT02040766|Active Comparator|BDP 160 mcg MDI|"Beclomethasone dipropionate (BDP) was administered via a metered-dose inhaler (MDI) twice daily (80 mcg twice a day).~Placebo BAI twice daily for blinding.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3101029|NCT02040766|Placebo Comparator|Placebo BAI and MDI|"Placebo was administered via breath-actuated inhaler (BAI) twice daily. Additionally placebo was administered via metered-dose inhaler (MDI) twice daily.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) at 90 mcg ex-actuator) or equivalent was used as rescue medication throughout the study."
3101030|NCT02040779|Experimental|BDP 80 mcg BAI|40 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 80 mcg/day.
3101031|NCT02040779|Experimental|BDP 160 mcg BAI|80 mcg beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily for a total of 160 mcg/day.
3101032|NCT02040779|Placebo Comparator|Placebo BAI|Placebo breath-actuated inhaler (BAI) twice daily.
3101033|NCT02040792|Placebo Comparator|Placebo|Placebo
3101034|NCT02040792|Experimental|44 mcg|TD-4208
3101035|NCT02040792|Experimental|88 mcg|TD-4208
3101036|NCT02040792|Experimental|175 mcg|TD-4208
3101037|NCT02040792|Experimental|350 mcg|TD-4208
3101038|NCT02040805|Experimental|Group Cognitive-Behavioral Therapy|Sixteen sessions of group therapy facilitated by a psychologist.
3101039|NCT02040805|Experimental|Peer Facilitated Support Group|Fifteen sessions of peer-facilitated group support.
3101040|NCT02040844|Other|Cat-PAD Treatment 1|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762].No further treatment received in CP007A
3101041|NCT02040844|Other|Cat-PAD Treatment 2|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762].No further treatment received in CP007A.
3101042|NCT02040844|Other|Cat-PAD Treatment 3|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]. No further treatment received in CP007A.
3101043|NCT02040857|Experimental|Palbociclib With Adjuvant Endocrine Therapy|"Palbociclib 125 mg PO qd 21 days on, 7 days off~Endocrine Therapy: Tamoxifen 20mg, Letrozole 2.5mg, Anastrozole 1mg, or Exemestane 25mg PO qd"
3101044|NCT02040870|Experimental|LDK378|daily dosing, 28-day cycle patients
3101045|NCT02041091|Experimental|Tabalumab Auto-Injector|Tabalumab given Week 0 as a loading dose of 240 milligram (mg) given as two subcutaneous (SC) injections each of 120 mg followed by 120 mg SC injection every two weeks for 12 weeks. Participants may continue on this treatment regimen for 52 weeks.
3101046|NCT02041091|Experimental|Tabalumab Prefilled Syringe|Tabalumab given Week 0 as a loading dose of 240 mg given as two SC injections each of 120 mg followed by 120 mg SC injections every two weeks for 12 weeks. Participants may continue to on this treatment regimen for 52 weeks.
3101047|NCT02041104|Experimental|Bread with added beta-glucans|Experimental food is bread with high amount of barley beta-glucans. Experimental bread contains approximately 3,4 % (w/w) beta-glucans. Participants will consume 6 g of beta-glucans daily (approximately 200 g of bread per day). Beta-glucans are natural polysaccharides found in grain endosperm and are mostly represented in oat and barley. Beta-glucans are linear homopolymers of D- glycopyranosyl residues with mixed linkage (1-4, 1-3)-β-D-glucans. Their molecular structure enable beta-glucans their functional action that mostly depends of their viscosity and solubility (1). Testing bread has integrated flour with high amount of barley beta-glucans (ReducholTM). Beta-glucans are concentrated in flour up to 15 % with dry milling, sieving and air classification of barley flour.
3101048|NCT02041104|Placebo Comparator|Bread without added beta-glucans|Placebo bread without added barley beta-glucans in testing product.
3101049|NCT02041221|Experimental|SPARC1316 Dose 1|Subjects will be administered with SPARC1316 dose 1
3101050|NCT02041221|Placebo Comparator|Placebo|The subjects will receive placebo.
3101051|NCT02041221|Experimental|SPARC1316 Dose 2|Subjects will be administered with SPARC1316 dose 2
3101052|NCT02041221|Experimental|SPARC1316 Dose 3|Subjects will be administered with SPARC1316 dose 3
3101053|NCT02041221|Experimental|SPARC1316 Dose 4|Subjects will be administered with SPARC1316 dose 4
3101054|NCT02041221|Experimental|SPARC1316 Dose 5|Subjects will be administered with SPARC1316 dose 5
3101055|NCT02041286|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes use the Karajishi Contour Investigational BG Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
3132437|NCT03426995|Experimental|Part B, GSK3358699 under Fed followed by Fasted conditions|The subjects in this arm will receive single oral dose of GSK3358699, at a dose level evaluated in Part A, under fed condition in TP1 followed by fasted condition in TP2. This cohort intended to evaluate the effect of food.
3101056|NCT02041299|Experimental|Deferiprone|Patients randomized to the deferiprone arm will be prescribed either tablets or liquid medication. Deferiprone is taken orally, at a dosage that is calculated in terms of milligrams per kilogram of body weight (mg/kg) and is divided into 3 equal doses taken approximately 8 hours apart. The daily dosage is 75 mg/kg (25 mg/kg per dose) for patients with less severe iron load, and 99 mg/kg (33 mg/kg per dose) for those with more severe iron load.
3101057|NCT02041299|Active Comparator|Deferoxamine|Patients randomized to the deferoxamine arm will be prescribed the drug as per the approved US prescribing information. Deferoxamine is administered as a subcutaneous infusion over 8-12 hours, 5 to 7 days a week. The dosage is 20 mg/kg (children) or 40 mg/kg (adults) in patients with less severe iron load, and up to 40 mg/kg (children) or 50 mg/kg (adults) in those with more severe iron load.
3101058|NCT02041325|Experimental|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
3101059|NCT02041325|Placebo Comparator|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
3101060|NCT02041377|Experimental|Intended Users of the Monitoring System|"Subjects with diabetes used the Karajishi TS Investigational Blood Glucose Monitoring System with no training. The criteria for the intended use population:~At least 60% of subjects will be younger than age 65~At least 10% of subjects will have type 1 diabetes"
3101061|NCT02041429|Experimental|Phase I Dose Level 0: Paclitaxel + Ruxolitiniib 10 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 10 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 10 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
3101062|NCT02041429|Experimental|Phase I Dose Level 1: Paclitaxel + Ruxolitiniib 15 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 15 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 15 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
3101063|NCT02041429|Experimental|Phase I Dose Level 2: Paclitaxel + Ruxolitiniib 20 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 20 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
3101064|NCT02041429|Experimental|Phase I Dose Level 3: Paclitaxel + Ruxolitiniib 25 mg|"Paclitaxel 80 mg/m2 IV weekly + Ruxolitinib 25 mg orally twice daily for 4 cycles~1 cycle = 21 days~Participants with stable disease or better will have the opportunity to continue on single agent 20 mg Ruxolitinib until disease progression, unacceptable toxicity or patient withdrawal."
3101065|NCT02041494|Active Comparator|Synthetic|Patients in this arm will have their ventral hernia repaired utilizing Ventralight, a synthetic prosthetic mesh made of polypropylene.
3101066|NCT02041494|Active Comparator|Biologic|Patients in this arm will have their ventral hernia repaired utilizing Strattice, a biologic prosthetic mesh derived from porcine dermis.
3101067|NCT02041520|Experimental|Omega 3 fatty acids|omega 3 fatty acids, 2.4 g per day, requiring intake 2 capsules (600mg each one) in the morning and two at night (Zonelabs, Marblehead MA) for 6 months.
3101068|NCT02041520|Placebo Comparator|Placebo|Placebo (olive oil gelcaps) in similar presentation as omega 3 fatty acids, requiring intake 2 capsules in the morning and two at night (Perfect Source, Fullerton CA, product code number PER 1016, lot number 8A0019/1600-1)
3101069|NCT02041533|Experimental|Arm A: Nivolumab subjects|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
3101070|NCT02041533|Active Comparator|Arm B: Investigator's Choice Chemotherapy|"Investigator's Choice Chemotherapy administered in 3-week cycles up to a maximum of 6 cycles of Intravenous injection until disease progression, unacceptable toxicity or completion of the 6 cycles, whichever comes first~Squamous subjects:~Gemcitabine 1250 mg/mg(2) administered on Day 1 and Day 8 with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle; or~Gemcitabine 1000 mg/mg(2) administered on Day 1 and Day 8 with Carboplatin (AUC 5) administered on Day 1 of each cycle; or~Paclitaxel 200 mg/m(2) with Carboplatin (AUC 6) administered on Day 1 of each cycle~Non-Squamous subjects:~Pemetrexed 500 mg/m(2) with Cisplatin 75 mg/m(2) administered on Day 1 of each cycle~Pemetrexed 500 mg/m(2) Carboplatin (AUC 6) administered on Day 1 of each cycle~Optional crossover:~Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent or study closure"
3101071|NCT02041702|Experimental|Cardiac MRI Scan Group|
3101072|NCT02041702|No Intervention|Control Group|
3101073|NCT02041923|Placebo Comparator|Attention Control|Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
3101074|NCT02041923|Experimental|H-HOPE Intervention|H-HOPE was administered twice daily by the mother.
3101075|NCT02041962|Active Comparator|Educational Control|Patients will receive their usual care from providers at their clinic. They will also receive in the mail a self-guided workbook.
3101076|NCT02041962|Experimental|Chronic Care Model for Mood Disorders|Life Goals Collaborative Care
3101077|NCT02042014|Experimental|QTI571|Participants will receive QTI571 during 3 years.
3101078|NCT02042131|Active Comparator|Treatment As Usual (TAU)|"TAU includes the following intervention components:~suicide risk assessment~supportive listening~provision of professional and crisis contact information~referral to mental health treatment and community resources~verbal contract for safety"
3101079|NCT02042131|Experimental|Standard Crisis Response Plan (S-CRP)|"CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
3101080|NCT02042131|Experimental|Enhanced Crisis Response Plan (E-CRP)|"The E-CRP includes the following intervention components:~suicide risk assessment~supportive listening~identify personal warning signs~identify self-management skills~identify reasons for living~identify social support contacts~provision of professional and crisis contact information~referral to mental health treatment and community resources"
3101081|NCT02042183|Experimental|Lubiprostone|Participants receive lubiprostone twice daily (BID) up to 12 weeks
3101082|NCT02042183|Placebo Comparator|Placebo|Participants receive placebo BID up to 12 weeks
3101083|NCT02042274|Experimental|Fish oil supplement|Fish oil supplements providing up to 3g per day of EPA and DHA
3101084|NCT02042404|Experimental|Mild to severe hearing impairment|Sound amplification provided via the EarLens System assistive hearing device.
3101085|NCT02042443|Experimental|Trametinib|Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3101086|NCT02042443|Experimental|Chemotherapy|Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15 (courses repeat every 28 days); or B) capecitabine PO BID on days 1-14 (courses repeat every 21 days). Patients treated until disease progression or unacceptable toxicity.
3101087|NCT02042534|Experimental|Rivaroxaban|Rivaroxaban group for 1 month : initial 5 days after randomization rivaroxaban 10mg QD will be administered. Rivaroxaban 20mg QD, but 15mg in case of Cr CL will be administered for remaining 25 days.
3101088|NCT02042534|Active Comparator|Warfarin|Patients allocated to warfarin receive warfarin plus aspirin 100mg until INR value exceed 1.7 followed by warfarin monotherapy with target INR value of 2.5 [2.0 - 3.0].
3101089|NCT02042872|Experimental|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
3101090|NCT02042872|No Intervention|No Intervention|Participants will receive no therapy and serve as a control group and have the same outcome measures completed at parallel time points.
3101091|NCT02042911|Experimental|SyB L-0501|
3101092|NCT02043015|Other|Comprehensive HIV prevention services|A comprehensive package of HIV prevention services, including condom choices, Condom-compatible lubricant choices, Couples HIV counseling and testing (CVCT), Staff and provider MSM and LGBT sensitization training, HIV Testing and Risk-reduction counseling, Linkage to care, Pre-exposure prophylaxis with FTC/TDF
3101093|NCT02043132|Active Comparator|Tranexamic acid|Infusion Tranexamic acid on study subjects. They will be randomized to receive an infusion of the standard dose of Tranexamic acid (10mg/kg) One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
3101094|NCT02043132|Placebo Comparator|Normal Saline|Infusion of placebo on study subjects. They will be randomized to receive an infusion of placebo (an equivalent volume of normal saline). One dose will be given by the bedside nurse within 60 minutes prior to surgery and a second dose will be given at wound closure. Infusion will be given along with standard preoperative and operative infusion; no additional infusion will be necessary.
3101095|NCT02043145||Axillary Hyperhidrosis|Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3101096|NCT02043145||Focal Spasticity|Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3101097|NCT02043145||Glabellar Lines|Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.
3101098|NCT02043197||Outpatients with neurological disorders and depression.|Outpatients with mild or moderate symptoms of depression prescribed by Fevarin® in accordance with the approved local label.
3101099|NCT02043301|Active Comparator|Single 150 mg PF-04950615 dose administered to the abdomen|
3101100|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the upper arm|
3101101|NCT02043301|Experimental|Single 150 mg PF-04950615 dose administered to the thigh|
3101102|NCT02043366|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
3101103|NCT02043366|Active Comparator|Butorphanol|Butorphanol is intravenously administrated at a dose of 20μg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
3101104|NCT02043366|Active Comparator|Flurbiprofen axetilⅠ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before anesthesia induction and intraoperative pain management was with remifentanil
3101105|NCT02043366|Active Comparator|Flurbiprofen axetilⅡ|Flurbiprofen axetil is intravenously administrated at a dose of 1.0mg/ kg before the skin closure and intraoperative pain management was with remifentanil
3101106|NCT02043366|Active Comparator|Butorphanol-Flurbiprofen axetil|A dose of 10μg/ kg butorphanol and a dose of 0.5mg/ kg flurbiprofen axetil are intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
3101107|NCT02043366|Sham Comparator|Sufentanil|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with sufentanil
3101108|NCT02043379|Experimental|IVIG|Those randomized to the study arm will receive a dose of IVIG 1 gram/kg at 12 hours post-cardiopulmonary bypass. This is a one time only dose and will be administered per hospital standards for IVIG administration.
3101109|NCT02043379|Placebo Comparator|Normal Saline|Subject's randomized into the placebo arm of the study will receive a volume of normal saline that is comparative to that if they were to receive IVIG. This will be at 12 hours post-cardiopulmonary bypass. This volume is to ensure blinding of study drug. This infusion will be administered as if the subject is receiving IVIG according to hospital policy.
3101110|NCT02043509|Experimental|MiQuit|12 weeks of MiQuit text support plus a standard NHS leaflet giving information and advice on stopping smoking in addition to usual care
3101111|NCT02043509|No Intervention|Control|Usual care plus the same standard NHS leaflet giving information and advice on stopping smoking
3101112|NCT02043548|Active Comparator|Group A: Tocilizumab|Tocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
3101113|NCT02043548|Placebo Comparator|Group B: Placebo|Placebo arm - no active drug
3101114|NCT02043574|Other|Stretching (Control)|Six months of stretching
3101115|NCT02043574|Experimental|Treadmill Exercise|Six months of treadmill training
3101116|NCT02043652|Experimental|Chloroquine and primaquine|Patients will receive 3-day treatment with chloroquine and 7-day treatment with primaquine in accordance to treatment guidelines in Brazil for P vivax malaria. All patients will receive the same treatment as there is no comparison arm.
3469051|NCT03890159|Experimental|Computer Assisted Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours, and patients will progress to the difficulty level automatically. Their performance during this process (response time etc.) will be recorded.
3469052|NCT03890159|Experimental|Conventional Cognitive Rehabilitation|The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests.
3101119|NCT02043704|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
3101120|NCT02043704|Placebo Comparator|Saline|Subjects will receive a 100mL dose of IV saline every 6 hours for 24 hours. The first dose will be administered prior to anesthesia induction, approximately 30 minutes before skin incision. A total of 4 doses will be given.
3101121|NCT02043782|Experimental|First Coloplast Test|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Coloplast Test; Secondly to either~Own product (baseline)~Competitor soft convex"
3101122|NCT02043782|Experimental|First Competitor soft convex|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Competitor soft convex; Secondly to either~Own product (baseline)~Coloplast Test"
3101123|NCT02043782|Experimental|First Own product|"The subjects are randomised 1:1:1 into six possible treatment groups to ensure random allocation of the treatments to the periods.~First subjects are allocated to Own product; Secondly to either~Coloplast Test~Competitor soft convex"
3101124|NCT02043808||Dabigatran|
3101125|NCT02043808||Warfarin|
3101126|NCT02043899|Experimental|Single Arm Trial|This was a single arm trial, all patients were to undergo the same assessments and interventions.
3101127|NCT02043938|Experimental|Healthy Volunteers|All healthy volunteers will receive four sessions of anesthesia with different common drug combinations while having SedLine EEG sensors placed on their forehead during these sessions to study the effects of these drugs on the brain. The sessions were: propofol (P), sevoflurane (S), propofol with remifentanil (PR), and sevoflurane with remifentanil (SR).
3101128|NCT02044094|Experimental|depot buprenorphine|Participants were treated with RBP-6000 300-mg in a single subcutaneous injection on Days 1 and 29 following a prior 14 day stabilization period (day -14 to day -1) of buprenorphine and naloxone (SUBOXONE) . Challenges consist of participants receiving on three consecutive days intramuscular (IM) injections of hydromorphone 0 mg (placebo), 6 mg and 18 mg doses during weeks 1-12 in randomized sequential order.
3101129|NCT02044159|Experimental|Hydrocortisone|Patients randomized to the hydrocortisone arm will receive a 2 mg/kg hydrocortisone IV bolus on enrolment followed by 1 mg/kg of hydrocortisone IV q6h until the patient has not had an escalation in therapy for at least 12 hours. If the patient meets these criteria their hydrocortisone will be weaned to 1 mg/kg every 8 hours which will be continued until they are off all vasoactive infusions for 12 hours. If following the initial hydrocortisone wean, the patient requires fluid boluses and/or an increase in their vasoactive infusion(s), their hydrocortisone will be increased back to 1 mg/kg of hydrocortisone IV q6h until they meet stability criteria again. Duration of treatment will range from a minimum of 20 hours to a maximum of 7 days of study drug.
3101130|NCT02044159|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive a placebo solution consisting of normal saline equivalent in volume to the appropriate dose of hydrocortisone. Hydrocortisone and placebo will be identical in appearance, volume and smell as hydrocortisone is made up in normal saline and dissolves completely with no visible precipitate. The dosing regimen will be identical to the hydrocortisone arm.
3101131|NCT02044367|Experimental|Test 1 (Treatment A)|multiple dose of dabigatran
3101132|NCT02044367|Experimental|Test 2 (Treatment B)|multiple dose of dabigatran
3101133|NCT02044367|Experimental|Reference|multiple dose of dabigatran
3101134|NCT02044380|Experimental|Afatinib|patient to receive a tablet containing 40 mg afatinib once a day, with the option to reduce the dose to 30 or 20 mg/day, based on individual tolerability
3101135|NCT02044393|Experimental|Reference|single dose BI 691751
3101136|NCT02044393|Experimental|Test|multiple doses of itraconazole + single dose BI 691751
3101137|NCT02044419|Experimental|lomitapide sprinkled in applesauce|Contents of single 20 mg capsule of lomitapide sprinkled in applesauce
3101138|NCT02044419|Experimental|lomitapide sprinkled in mashed banana|Contents of single 20 mg capsule of lomitapide sprinkled in mashed banana
3101139|NCT02044419|Experimental|lomitapide (intact)|Intact capsule of 20 mg lomitapide
3101140|NCT02044458|Active Comparator|Stylette|Stylette: a thin wire inserted into a catheter to maintain rigidity, used to guide the insertion of the Foley catheter.
3101141|NCT02044458|No Intervention|No Stylette|No Stylette: 22 French Foley catheter placed without stylette or guide.
3101142|NCT02044510|Experimental|Mirabegron|Patients randomised to this arm start with mirabegron 25mg PO daily for two weeks, and then at 2 weeks titrate to 50mg PO daily, and maintain that dose for the duration of the study (8 additional weeks).
3101143|NCT02044510|Placebo Comparator|Placebo|Inert placebo pill, matching active treatment pill.
3101144|NCT02044796|Experimental|Treatment (filgrastim, mitoxantrone, cladribine, cytarabine)|"INDUCTION CHEMOTHERAPY (G-CLAM): Patients receive G-CLAM chemotherapy comprising filgrastim SC daily on days 0-5, mitoxantrone hydrochloride IV over 60 minutes on days 1-3, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Patients achieving CRi, partial remission, or persistent disease may receive a second course of induction chemotherapy. Patients achieving CR or CRp may continue on to Consolidation Chemotherapy.~CONSOLIDATION CHEMOTHERAPY (G-CLA): Beginning within 6 weeks of achieving CR/CRp/CRi, patients receive G-CLA comprising filgrastim SC on days 0-5, cladribine IV over 2 hours daily on days 1-5, and cytarabine IV over 2 hours daily on days 1-5. Treatment continues for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3469053|NCT03890159|No Intervention|Waiting list controls|These patients will get no intervention as means of cognitive rehabilitation, but will get their usual treatments.
3101145|NCT02044874|Experimental|APD356 10 mg b.i.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
3101146|NCT02044874|Experimental|APD356 10 mg q.d.|APD356 - lorcaserin hydrochloride 10 mg tablet administered once daily and one matching placebo tablet administered once daily for 12 weeks
3101147|NCT02044874|Placebo Comparator|Placebo 10 mg b.i.d|Placebo tablet matching the APD356-lorcaserin hydrochloride 10 mg tablet administered twice daily for 12 weeks
3101148|NCT02044991|Active Comparator|Treatment|Participants randomized to this arm will receive a corticosteroid. This is 40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
3101149|NCT02044991|Placebo Comparator|Placebo|Participant's randomized to this condition will receive a placebo injection once weekly
3101150|NCT02045095|Experimental|Schedule A: MLN7243 1 mg|MLN7243 1 milligram (mg), infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or disease progression (PD) or discontinuation of study for another reason, or until study is stopped.
3101151|NCT02045095|Experimental|Schedule A: MLN7243 2 mg|MLN7243 2 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD, or discontinuation of study for another reason, or until study is stopped.
3101152|NCT02045095|Experimental|Schedule A: MLN7243 4 mg|MLN7243 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
3101153|NCT02045095|Experimental|Schedule A: MLN7243 8 mg|MLN7243 8 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
3101154|NCT02045095|Experimental|Schedule A: MLN7243 12 mg|MLN7243 12 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
3101155|NCT02045095|Experimental|Schedule A: MLN7243 18 mg|MLN7243 18 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
3101156|NCT02045095|Experimental|Schedule A: MLN7243 Homozygous Mutant 4 mg|MLN7243 homozygous mutant 4 mg, infusion, intravenously over 10-minutes, on Days 1, 4, 8, and 11 followed by 10 days of rest in a 21-day treatment cycle for a maximum of 12 months, or until symptomatic deterioration or PD or discontinuation of study for another reason, or until study is stopped.
3101157|NCT02045108|Experimental|Active TDCS + Active Retraining|2.0 milliamps (mA) of TDCS applied during active alcohol avoidance retraining
3101158|NCT02045108|Experimental|Sham TDCS + Active Retraining|.1 mA of TDCS applied during active alcohol avoidance retraining
3101159|NCT02045108|Experimental|Active TDCS + Sham retraining|2.0 mA of TDCS applied during sham alcohol avoidance retraining
3101160|NCT02045108|Sham Comparator|Sham TDCS + Sham Retraining|0.1 mA of TDCS applied during sham alcohol avoidance retraining
3101161|NCT02045212|Experimental|RPh201|3/6 month treatment schedule, consisting of bi-weekly SC administration of the RPh201
3101162|NCT02045212|Placebo Comparator|Placebo|3/6 month treatment schedule, consisting of bi-weekly SC administration of the Placebo
3101163|NCT02045238|Placebo Comparator|Normal Saline|Patients will receive inhaled normal saline, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
3101164|NCT02045238|Experimental|Hypertonic Saline|Patients will receive inhaled Hypertonic Saline 3%, initially with a 2 hour interval, and clinical evaluation prior to each inhalation. When they attain sat>94% AND respiratory rate <60 AND RDAI score <4, the interval between inhalations will be changed to 4 hours. If they maintain these criteria for a whole 4 hour interval, they are discharged. If they do not improve enough to be discharged in 24 hours from the first inhalation, they are considered as admitted to hospital.
3101165|NCT02045264|Experimental|Icatibant (30 mg)|30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area
3101166|NCT02045277|Experimental|IDP-118 Lotion|halobetasol propionate [HP], tazarotene [Taz]
3101167|NCT02045277|Active Comparator|IDP-118 Monad HP Lotion|HP
3101168|NCT02045277|Active Comparator|IDP-118 Monad Taz Lotion|Taz
3101169|NCT02045277|Active Comparator|IDP-118 Vehicle Lotion|Vehicle
3101170|NCT02045433|Experimental|SABR Boost Therapy|
3101171|NCT02045511|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
3101172|NCT02045511|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
3101173|NCT02045732|Experimental|Cohort 1|
3101174|NCT02045732|Experimental|PF-06342674 1.5 mg/kg|
3101175|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q2 Weeks)|
3101176|NCT02045732|Experimental|PF-06342674 6.0 mg/kg (q1 Week)|
3469054|NCT03890237|No Intervention|Control|Business as usual, no intervention
3469055|NCT03890237|Experimental|Her Spaces|Starts in year 1; intervention package with 11-13 year old girls for 10 months; standard parental and community engagement. All programming ends after 10 months.
3469056|NCT03890237|Experimental|Act With Her|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
3469057|NCT03890237|Experimental|Act With Her + Asset Transfer|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; asset transfer for girls over 10 months; 6 dedicated sessions with parents; and community-level system strengthening up to 24 months.
3101180|NCT02045836|Experimental|Co-Ad Group|Subjects received one dose of the GSK1437173A study vaccine and one dose of the Pneumovax™ 23 vaccine at Day 0 and a second dose of GSK1437173A study vaccine at Month 2. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
3101181|NCT02045836|Active Comparator|Control Group|Subjects received one dose of the Pneumovax™ 23 vaccine at Day 0, one dose of the GSK1437173A study vaccine at Month 2 and a second dose of the GSK1437173A study vaccine at Month 4. GSK1437173A vaccine was administered intramuscularly, in the deltoid region of the non-dominant arm. Pneumovax™ 23 was administered intramuscularly, in the deltoid region of the dominant arm.
3101182|NCT02045862|Active Comparator|Mirabegron 50 mg|Participants received mirabegron 50 mg once a day for 52 weeks.
3101183|NCT02045862|Active Comparator|Solifenacin 5 mg|Participants received solifenacin 5 mg once a day for 52 weeks.
3101184|NCT02045862|Experimental|Solifenacin 5 mg + Mirabegron 50 mg|Participants received solifenacin 5 mg and mirabegron 50 mg once a day for 52 weeks.
3101185|NCT02045875|Experimental|Dulera adherence monitoring|Adherence Monitoring Dulera; Identification of adherence barrier(s); Motivational Interviewing Adherence Strategies to promote adherence
3101186|NCT02045875|Active Comparator|Dulera Standard of Asthma Care|Dulera standard of asthma care
3101187|NCT02045979|Experimental|BI 695501|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501
3101188|NCT02045979|Active Comparator|adalimumab-EU source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-EU source
3101189|NCT02045979|Active Comparator|adalimumab-US source|Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing adalimumab-US source
3101190|NCT02046005|Active Comparator|General Rheumatoid Arthritis Education|Arm 1 participants will receive general information about RA.
3101191|NCT02046005|Experimental|PRE-RA|Arm 2 participants will receive personalized RA risk education by the PRE-RA risk tool.
3101192|NCT02046005|Experimental|PRE-RA Plus|Arm 3 participants will receive personalized RA risk education by the PRE-RA risk tool and health educator.
3101193|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until progressive disease (PD)/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
3101194|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 400 mg/m^2 + DEX 40 mg (NDMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle until PD/death or unacceptable toxicity [13 cycles in the Induction Phase continuing in the Maintenance Phase for up to 36 Months] and cyclophosphamide (CYC) 400 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle for 13 cycles or until PD/death or unacceptable toxicity in participants with NDMM.
3101195|NCT02046070|Experimental|Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide 300 mg/m^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients >75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.
3101196|NCT02046122|Experimental|Idarubicin + Cytarabine + DLI|Chemotherapy combined with adoptive transfer of HLA-haploidentical donor lymphocyte infusion (DLI)
3101197|NCT02046135|Experimental|Sodium bicarbonate|At the start of the surgery, the patient will receive NaHCO3 as a continuous infusion of D5% 1/3NS + 100 meq/L NaHCO3 + 20 meq/L KCl at maintenance IVF (solution contains ~154 meq of sodium which is equivalent to normal saline). The NaHCO3 infusion will continue for the first 24 hours after the discontinuation of CPB. After 24 hours of receiving the NaHCO3 infusion, the IVF administered to the patient will be the standard solutions used in the PICU at CCMC.
3101198|NCT02046135|Active Comparator|Sodium Chloride|At the start of surgery, patients in the control arm will receive D5% Normal Saline + 20 meq/L KCl at maintenance IVF. After 24 hours, standard IVF, not containing NaHCO3 or Na acetate will be administered for the duration of the PICU stay as required, determined by the clinicians primarily caring for the patient postoperatively.
3101199|NCT02046148|Experimental|GBS Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
3101200|NCT02046148|Active Comparator|Placebo Group|Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Placebo, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
3101201|NCT02046174|Experimental|Macrobead Implantation Arm|patients who will undergo up to 4 implantations of RENCA macrobeads (no less than 3 months apart), at an amount of 8 RENCA macrobeads per kilogram of body weight
3101202|NCT02046174|No Intervention|Best Supportive Care Arm|patients who will receive, or continue receiving, best supportive care, defined as management of symptoms aimed at maintaining or improving quality of life, but not including approved therapies targeting the patient's malignancy
3101203|NCT02046200|Experimental|Ivermectin|Ivermectin 30 mg single dose
3101204|NCT02046200|Placebo Comparator|Sugar pill|Matched placebo, single dose
3101205|NCT02046265|Experimental|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3101206|NCT02046265|Experimental|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3101207|NCT02046265|Experimental|Step up to Prevention|Participant receives both the knowledge session and the tailored belief sessions and the participant is offered the HPV vaccine only by their nurse practitioner in clinic. This combined intervention is call Step Up to Prevention.
3101208|NCT02046265|Active Comparator|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
3101209|NCT02046317|Experimental|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
3101210|NCT02046317|Active Comparator|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
3101211|NCT02046369|Experimental|Luradisone|Luradisone 20- 80 mg administered once daily
3101212|NCT02046369|Placebo Comparator|Placebo|Placebo administered once daily
3101213|NCT02046382|Experimental|IV Acetaminophen|Subjects will receive a 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
3101214|NCT02046382|Placebo Comparator|Normal Saline|Subjects will receive a 100mL dose of saline every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
3101215|NCT02046525|Experimental|Auto fecal microbitoa therapy|autologous fecal microbiota therapy
3101216|NCT02046525|Placebo Comparator|Saline enema|Saline enema
3101217|NCT02046564|Experimental|ASC-01|The dose of 3-12mg/100mg(Aripiprazole/Sertraline Combination)will be orally administered once daily
3101218|NCT02046564|Placebo Comparator|Placebo|The dose of 0mg/100mg (Placebo/Sertraline Combination ）will be orally administered once daily
3101219|NCT02046603|Experimental|Tocilizumab Monotherapy|Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.
3101220|NCT02046603|Experimental|Tocilizumab in Combination With Methotrexate or Other DMARDs|Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.
3101221|NCT02046616|Experimental|Tocilizumab Alone or Combined with Methotrexate or Other DMARD|All participants will receive tocilizumab as a single fixed dose (monotherapy) or in combination with methotrexate or other non-biologic DMARDs, irrespective of body weight, for 24 weeks.
3101222|NCT02046772|Experimental|Bupivacaine + Morphine Chloride|People in this arm will receive treatment with morphine chloride in addition to a low dose solution of the local intradural anaesthetic bupivacaine.
3101223|NCT02046772|Active Comparator|Bupivacaine standard dose|People in this arm will receive treatment with the standard dose of the local intradural anaesthetic bupivacaine
3101224|NCT02046863|Experimental|Automated Programming|Subjects will have DBS settings changed as guided by prototype DBS-Expert software. Tremor, bradykinesia, and dyskinesia will be assessed at each DBS setting.
3101225|NCT02046902||Heart disease|Adults with a diagnosis of coronary artery disease and may have had a percutaneous coronary intervention.
3101226|NCT02046902||Healthy adults|Adults without a diagnosis of coronary artery disease. Focus groups will be held.
3101227|NCT02046941|Experimental|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction. The investigators chose this treatment for the following reasons: 1) rigor of development demonstrated across multiple studies, 2) large and predictable effects with published, quantified effect sizes, 3) a demonstrated pattern of generalization to untrained items, illustrating experimental control, 4) an established multi-modal stimulation protocol, and 5) use of repeated practice, which is associated with neural plasticity.
3101228|NCT02046980|Experimental|Gufoni|Gufoni maneuver for apogeotropic horizontal BPPV at the first day
3101229|NCT02046980|Experimental|Vibration|Vibration maneuver for apogeotropic horizontal BPPV at the first day
3101230|NCT02046980|Sham Comparator|Sham|Sham maneuver for apogeotropic horizontal BPPV at the first day
3101231|NCT02046993|Experimental|Smart phone based telemonitoring of HBP|". Patients do HBP monitoring~. record their BP readings into the smart phone with downloaded application."
3101232|NCT02046993|Active Comparator|Enhanced usual care|". Patients to do HBP measurement~. Record BP readings in their diary"
3101233|NCT02047032|Experimental|acupuncture|BL33 and BL35 of both sides are used. Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
3101234|NCT02047032|Active Comparator|Solifenacin plus PFMT|Both PFMT and solifenacin will be given for 36 weeks. Solifenacin will be taken 5mg once daily, before or after meal. PFMT includes intensive exercises conducted in hospital and home exercises. Intensive exercises will be done once every week for the first 12 weeks and once every four weeks for the 13th to 36th week. Home exercises will be done three times daily for 36 weeks.
3101235|NCT02047045|Experimental|Electro-acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 min, 5 times/week for the first 2 weeks, and 3 times/week for the next 6 weeks.
3101236|NCT02047045|Active Comparator|Prucalopride|Prucalopride Succinate taken orally, 2mg/day in the morning before breakfast
3101237|NCT02047110|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.
3101238|NCT02047110|Experimental|Risankizumab 18 mg|Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks
3101239|NCT02047110|Experimental|Risankizumab 90 mg|Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
3101240|NCT02047110|Experimental|Risankizumab 180 mg|Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period
3101241|NCT02047227|Experimental|Pergoveris®|
3101242|NCT02047227|Active Comparator|GONAL-f®|
3101243|NCT02047253|Experimental|Carfilzomib|Carfilzomib is administered twice-weekly on consecutive days (days 1, 2, 8, 9, 15, 16) as a 30-minute intravenous infusion for 3 weeks every 4 weeks (1 cycle) with dexamethasone given as pre-medication. The dose of carfilzomib is 20 mg/m2 on days 1 and 2 of cycle 1 and is then escalated in succeeding weeks and cycles to 56 mg/m2 if no dose limiting toxicities occur. Acyclovir is given orally at 400 mg twice daily during therapy but may be discontinued at some point. Therapy will continue until side effects become unacceptable, the disease progresses, or the doctor withdraws the patient.
3101244|NCT02047305|Experimental|Radiofrequency ablation|To study the safety and effectiveness of radiofrequency ablation (RFA) using the HALO ablation system in completely eradicating the diseased epithelium in patients with ESCN
3101245|NCT02047318|Experimental|LUM001 (Maralixibat)|LUM001 also known as Maralixibat (MRX) administered orally up to twice each day
3101246|NCT02047344|Experimental|Antroquinonol (Hocena)|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
3101247|NCT02047500|Experimental|TH-302 plus Nab-paclitaxel plus Gemcitabine|
3101248|NCT02047604|Experimental|Cohort A - SAN-300 0.5 mg/kg QW|SAN-300 0.5 mg/kg subcutaneous once weekly for six weeks
3101249|NCT02047604|Experimental|Cohort B - SAN-300 1.0 mg/kg QW|SAN-300 1.0 mg/kg subcutaneous once weekly for six weeks
3101250|NCT02047604|Experimental|Cohort C - SAN-300 2.0 mg/kg QOW|SAN-300 2.0 mg/kg subcutaneous every other week for six weeks
3101251|NCT02047604|Experimental|Cohort D - SAN-300 4.0 mg/kg QOW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
3101252|NCT02047604|Experimental|Cohort E - SAN-300 4.0 mg/kg QW|SAN-300 4.0 mg/kg subcutaneous every other week for six weeks
3101253|NCT02047604|Placebo Comparator|Placebo|Placebo dosing
3101254|NCT02047643|Experimental|On-algorithm first, then Off-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
3101255|NCT02047643|Experimental|Off-algorithm first, then On-algorithm|Users will participate in two sports camp sessions while wearing an insulin pump, continuous glucose monitor, and accelerometer/heart rate monitor (to detect exercise), which can communicate electronically to a pump shutoff algorithm that insulin delivery should be shut off. On one sports day, the algorithm is turned on; on the other day, the algorithm is turned off.
3101256|NCT02047734|Experimental|Ozanimod 0.5 mg|Ozanimod 0.5 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
3101257|NCT02047734|Experimental|Ozanimod1 mg|Ozanimod 1 mg oral capsules daily and a weekly intramuscular placebo injection (identical in appearance to Interferon) for 24 months.
3101258|NCT02047734|Active Comparator|Interferon β-1a|interferon beta-1a (IFN β-1a) 30 µg intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally daily for 24 months.
3101259|NCT02047903||Afatinib|
3101260|NCT02047929|Active Comparator|Facilitator-Led|This approach to dissemination allows clinics some freedom to tailor the Asthma Shared Decision Making (SDM) Toolkit and training process for their specific environment and patient population while maintaining fidelity of certain key elements that are felt to be essential for success. The expertise of the trained Practice Facilitator will help guide the process of implementation at the practice level.
3101261|NCT02047929|Active Comparator|Traditional|"The most commonly used dissemination technique is active diffusion, which includes didactic presentations, academic detailing, exposure to journal publications and subject matter experts, and educational material distribution. We have defined this type of dissemination, traditional dissemination. For the purpose of this study, practices randomized to traditional dissemination will receive a lunchtime presentation by a physician champion / subject matter expert on shared decision making. The presentation will give an overview of the Asthma Shared Decision Making (SDM) Toolkit, access to the internet link with additional information, and a copy of all printed materials associated with the Toolkit."
3101262|NCT02047929|No Intervention|Control|A third group will be randomized into an arm with no formal dissemination. This arm will receive information only through passive exposure to the concepts of shared decision making. This would include introduction to the SDM concepts through the media, conferences, or social networks. Having this control in place will allow the research team to isolate the effect of both the FLOW approach and the traditional approach to dissemination.
3101263|NCT02047981|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years.~In Niger during year 3, all communities will be offered azithroymcin."
3101264|NCT02047981|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood mortality in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~In Niger during year 3, all communities will be offered azithroymcin."
3101265|NCT02048072|Experimental|Gilenya|Autonomic testing during first dose adminstration of Gilenya.
3101266|NCT02048241|Other|Placebo plus Parent Management Training|Pills matching Intuniv Tablets without active medication combined with weekly Parent Management Training
3101267|NCT02048241|Experimental|Intuniv plus Parent Management Training|Administration of Intuniv in increasing doses from 1 mg to 2 mgs to 3 mgs to 4 mgs as tolerated over a period of 4-6 weeks, combined with weekly Parent Management Training
3101268|NCT02048670|Experimental|Chronic Subjective Dizziness Syndrome Subjects|Subjects diagnosed with Chronic Subjective Dizziness Syndrome (CDS) will wear the BalanceBelt while performing test involving walking and balance.
3101269|NCT02048670|Active Comparator|Healthy Subjects|Age matched healthy subjects without complaints of balance or dizziness problems will wear the BalanceBelt while performing test involving walking and balance.
3101270|NCT02048722|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3101271|NCT02048826|Experimental|FINGER I|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with first setting at a minimum of 3 days per week, 1 hour per day with the exercise program
3101272|NCT02048826|Experimental|FINGER II|Subjects participate in 3 weeks of exercising with the experimental device: FINGER robot with a second setting at a minimum of 3 days per week, 1 hour per day with the exercise program
3101273|NCT02048878||Insomnia group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
3101274|NCT02048878||Matched Control Group|"Assessment of physiologic hyper-arousal across the two following domains:~Sympathetic neural activity: recording at the level of the muscle by microneurography and at the level of the heart by spectral analysis of heart rate variability from the ECG signal obtained during sleep and wakefulness.~Neurophysiologic arousal: recording of multiple sleep latency test (MSLT), recording of wake electroencephalography (EEG), and quantitative sleep EEG recording and analysis."
3101275|NCT02048891|Active Comparator|hCG trigger|Ovulation trigger with Ovitrelle 250 microgram, luteal support with vaginal progesterone: gel Crinone 8% daily.
3101276|NCT02048891|Experimental|GnRH agonist trigger|ovulation trigger with Decapeptyl 0.2 mg, luteal support with 2 injections of 1,500 U hCG.
3101277|NCT02049151|Experimental|Tecemotide|
3101278|NCT02049151|Placebo Comparator|Placebo|
3101279|NCT02049307|Active Comparator|Treatment|Losartan 100mg daily
3101280|NCT02049307|Placebo Comparator|Placebo|Matching placebo
3101281|NCT02049385|Experimental|Diazoxide|Subjects received 200-400 mg daily of diazoxide orally for three weeks; the dose was, adjusted depending on side effects and response.
3101282|NCT02049385|Experimental|Placebo|Subjects received a matched placebo for three weeks
3101283|NCT02049437|Active Comparator|Arm A: TCZ, then placebo|ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
3101284|NCT02049437|Placebo Comparator|Arm B: Placebo, then TCZ|ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
3101285|NCT02049450|Experimental|INC424 (ruxolitinib) - Study Treatment|Regularly transfused adult patients with thalassemia and spleen enlargement.
3101286|NCT02049476|Experimental|Dexamethasone Pellet|This is a proof of concept study; therefore all enrolled patients will receive the intervention according to its FDA-approved indication.
3101287|NCT02049502|Experimental|fecal microbiota transplant|fecal microbiota transplant
3101288|NCT02049749|No Intervention|Delayed CARE|40 child-caregiver pairs will be randomized to usual treatment plus delayed CARE (control). Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual. Following the final interview (3-4 months after enrollment for each subject) all participants randomized to the control arm (usual treatment plus delayed CARE) will receive the CARE training, if desired.
3101289|NCT02049749|Experimental|Immediate CARE|40 child-caregiver pairs will be randomized to usual treatment plus immediate CARE. The trainings are administered to groups of 4-10 caregivers at a time and are led by two mental health providers trained in the CARE curriculum. The children do not attend the training; however, caregivers are expected to practice the skills that they learn in CARE with their child between sessions. The curriculum involves 6 sessions over 6-8 weeks. Each session will be 1-2 hours.
3101290|NCT02049814|Experimental|Metformin + Voglibose 0.2 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to voglibose 0.2 mg, tablets, orally, three times daily, for Weeks 1 and 2, followed by voglibose 0.3 mg, tablets, orally, three times daily, Weeks 3 through 12.
3101291|NCT02049814|Active Comparator|Metformin + Acarbose 50 mg|Metformin tablets, at the maximum tolerated dose ≥1000 mg/day, orally, for 12 weeks, in addition to acarbose 50 mg, tablets, orally, three times daily, Weeks 1 and 2, then acarbose 100 mg, tablets, orally, three times daily, Weeks 3 through 12.
3101292|NCT02049866|Experimental|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months.
3101293|NCT02049931|Experimental|No brace group|Patients in the no brace treatment group were allowed to ambulate without any braces as long as it would be tolerable.
3101294|NCT02049931|Active Comparator|Rigid brace group|Patients in the rigid brace immobilization group were strictly maintained on bed rest until fitted a thoraco-lumbo-sacral orthosis. Brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
3101295|NCT02049931|Active Comparator|Soft brace group|Because soft back brace was a custom-made, it began to be worn when enrollment for the study. Brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
3101296|NCT02049944|Experimental|Cefazolin|All subjects undergoing elective term cesarean delivery will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision.
3101297|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Exemestane|Sapanisertib 5 mg, unmilled active pharmaceutical ingredient (API) capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 12 cycles).
3101298|NCT02049957|Experimental|Phase 1 (Part 1): Sapanisertib 5 mg + Fulvestrant|Sapanisertib 5 mg, unmilled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection, intramuscularly (IM), once on Day 1 of each cycle (Up to 57 cycles).
3101299|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Exemestane|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 8 cycles).
3101300|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 3 mg + Fulvestrant|Sapanisertib 3 mg, milled API capsule, once daily in a 28-day cycle up to 14 cycles plus fulvestrant 500 mg, injection, IM, once on Day 1 of each cycle (Up to 14 cycles).
3101301|NCT02049957|Experimental|Phase 1 (Part 2): Sapanisertib 4 mg + Exemestane|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 18 cycles).
3101302|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg + Exemestane (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus exemestane 25 mg, tablets, once daily in a 28-day cycle (Up to 14 cycles) in everolimus sensitive participants.
3101303|NCT02049957|Experimental|Phase 2:Sapanisertib 4 mg+Fulvestrant (Everolimus Sensitive)|Sapanisertib 4 mg, milled API capsule once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 17 cycles) in everolimus sensitive participants.
3101304|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Exemestane (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily, in a 28-day cycle plus once daily in a 28-day cycle (Up to 12 cycles) in everolimus resistant participants.
3101305|NCT02049957|Experimental|Phase 2: Sapanisertib 4 mg+Fulvestrant (Everolimus Resistant)|Sapanisertib 4 mg, milled API capsule, once daily in a 28-day cycle plus fulvestrant 500 mg, injection IM, once on Day 1 of each cycle (Up to 9 cycles) in everolimus resistant participants.
3101306|NCT02050048|Experimental|High Volume Group (Intervention Arm)|"Patients will be randomized to receive intravenous Lactated Ringer's solution. In the high volume group (intervention arm), patients will receive fluids prior to, during, and after the completion of the procedure. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
3101307|NCT02050048|Active Comparator|Low Volume Group (Control Arm)|Patients will be randomized to receive intravenous Lactated Ringer's solution. In the low volume group (control arm), patients will receive fluids at the start of the ERCP. The fluids will be administered via infusion at a rate of 1.5 cc/kg/hr. Fluids may be continued through the 90 minute post-procedure observation period.
3469058|NCT03890237|Experimental|Act With Her (simple)|Starts in year 1; core intervention package with 10-13 year old girls and boys for 10 months; 6 dedicated sessions with parents; does not include community-level systems strengthening. All programming ends after 10 months.
3469059|NCT03890211|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, the mother will be encouraged to provide KMC whenever possible. For hypothermic infants, if the temperature is not rising by ½°C per hour with KMC alone, the Infant Warmer will be offered as an addition. In these cases, the heat will be provided by placing the Infant Warmer over the infant's back while the mother provides KMC. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the Infant Warmer by being placed directly on the warmer as it lies flat. Use of hat and socks will be encouraged by additional clothes will only be added in addition to the warmer per caregiver request, as it reduces heat transfer.
3101310|NCT02050321|Experimental|Acitretin and Vemurafenib|Vemurafenib is self-administered at a dose of 960 mg (four 240 mg tablets) twice daily. The first dose should be taken in the morning and the second dose should be taken in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Acitretin will initially be dosed at 25 mg orally per day with dosing altered every two weeks with a 50 mg dose.
3101311|NCT02050334|Experimental|CC100 (3 single doses)|CC100 (3 single increasing doses by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
3101312|NCT02050334|Experimental|CC100 (2 single doses) & placebo(1 dose)|CC100 (2 single increasing doses by mouth) and placebo (1 single dose by mouth). Dosing will occur every 2 to 7 days for a study duration of 5 to 15 days from the 1st dose.
3101313|NCT02050373|Experimental|Low-Level laser|In the laser group, an indium phosphide, galium and aluminum (InGaAIP) diode laser (660nm, 40mW, 0.16 J, 4 J/cm2) was used to irradiate oral mucosa. Subjects received the LLLT from the first day of the conditioning regimen and continued until D+7. Laser therapy was applied by a single dentist expertise in laser irradiation. The tip touched the mucosa of the lips, right and left buccal mucosa, right and left lateral tongue, ventral tongue and buccal floor, giving a total of 10 points per region.
3101314|NCT02050373|No Intervention|Control|In the control group, patients receive only the preventive protocol bone marrow transplant industry, consisting of mouthwashes and sodium fluoride. For ethical reasons, individuals who present oral mucositis grade 2 (WHO) will receive LLLT.
3101315|NCT02050841|Experimental|Octaplas|Qualified patients will receive Octaplas as per protocol.
3101316|NCT02050919|Experimental|Treatment (sorafenib, chemotherapy, radiation, surgery)|Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155, epirubicin hydrochloride IV over 3-5 minutes, and ifosfamide IV over 90 minutes on days 15-17, 36-38 (ifosfamide only), 57-59, 99-101, 120-122, and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins, undergo EBRT boost on days 91-98.
3101317|NCT02051296|Experimental|minocycline|perioperative minocycline for 5 days, starting 2 hours prior to surgery then 100mg BID
3101318|NCT02051296|Placebo Comparator|Placebo|PLacebo
3101319|NCT02051335|Experimental|Sequence 1 (ABDC)|Roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3469060|NCT03890211|No Intervention|Control|Data such as infant temperature, date of birth, etc. will be collected from those who enroll in the control group. No experimental intervention will be administered.
3101320|NCT02051335|Experimental|Sequence 2 (BCAD)|Roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3101321|NCT02051335|Experimental|Sequence 3 (CDBA)|Roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3101322|NCT02051335|Experimental|Sequence 4 (DACB)|Roflumilast Dose A tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 1, followed by roflumilast placebo-matching tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 2, followed by roflumilast Dose A tablets, orally, donepezil placebo-matching overencapsulated tablets, orally, and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 3, followed by roflumilast placebo-matching tablets, orally, donepezil 10 mg, overencapsulated tablets, orally and scopolamine 0.5 mg subcutaneous injection, once, Day 1, Period 4. Each treatment period is separated by a 14-day washout period.
3101323|NCT02051426|Experimental|D-serine|single P.O. administration of D-serine (2.1g)
3101324|NCT02051426|Placebo Comparator|Placebo|single P.O. administration of corn starch
3101325|NCT02051452|Experimental|Methylphenidate|Methylphenidate
3101326|NCT02051452|Placebo Comparator|placebo|Saline
3101327|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
3101328|NCT02051686|Active Comparator|Tranexamic Acid|Group I will receive 10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
3101329|NCT02051686|Placebo Comparator|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
3101330|NCT02051764|Experimental|Follow-up Flortaucipir PET Scan|
3101331|NCT02051790|Experimental|Clinical Practice Scans|Approximately 250 florbetapir F 18 scans and final scan reports interpreted in a clinical setting will be collected from physicians across the country. These results will then be compared to expert panel interpretations for the same scans.
3101332|NCT02051816|Active Comparator|VL and AO|Video laryngoscopy and apneic oxygenation
3101333|NCT02051816|Active Comparator|DL and AO|Direct Laryngoscopy and apneic oxygenation
3101334|NCT02051816|Active Comparator|VL and no AO|Video Laryngoscopy and no apneic oxygenation
3101335|NCT02051816|Active Comparator|DL and no AO|Direct Laryngoscopy and no apneic oxygenation
3101336|NCT02052011|Experimental|Intervention Group|Subjects will take extended release Ranolazine for 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
3101337|NCT02052011|Placebo Comparator|Placebo Control|Subjects will take placebo pill twice daily for 4 weeks.
3101338|NCT02052141|Experimental|500/1000|500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks
3101339|NCT02052141|Experimental|1000/500|1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks
3101340|NCT02052310|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on a tiered, weight-based dosing scheme (low weight [≤70 kilograms (kg)] and high weight [>70 to 160 kg] participants will receive 70 and 100 milligrams [mg] roxadustat, respectively). Dose adjustment to achieve correction and subsequent maintenance of target hemoglobin (Hb) values (10-12 grams [g]/deciliter [dL]) will be based upon regular monitoring of Hb. The maximum roxadustat dose is 3.0 mg/kg per dose or 400 mg per administration (whichever is lower).
3101341|NCT02052310|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW, with starting doses and dose adjustment rules as per United States Package Insert (USPI) or summary of product characteristics (SmPC). Participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC) as per the country-specific product label (USPI or SmPC) or local standard of care (SOC).
3101342|NCT02052414|Experimental|Gralise (Gabapentin ER)|"All patients will be treated with Gralise. Patients who are on pregabalin or gabapentin (lyrica or neurontin) will need to wash off the medication before starting Gralise.~Patients who are ready to take Gralise will start with starter pack, and will gradually titrate the dose up to 1800mg per day. After that, patient will take 1800mg per day out of the bottle.~Patient will be seen in clinic at 4weeks intervals for first 4 visits, and then there will be end of the study visit on week 15. On visit 4, week 12 of treatment, patients will be taught to taper off the study medication."
3101343|NCT02052440|Experimental|Baclofen 10mg three times daily|Baclofen 10mg by mouth three times daily
3101344|NCT02052440|Placebo Comparator|Sugar Pill given three times daily|Placebo sugar bill
3101345|NCT02052466||Reverse TSA patients|Patients having undergone reverse TSA at the Cleveland Clinic with a high quality preoperative CT of the operative shoulder and who are at least 24 months post surgery.
3101346|NCT02052544||Study patients|Patients receiving unfractionated heparin (UFH)
3101347|NCT02052557|Active Comparator|Bupivacaine|30 milliliters (ml) of 0.5% marcaine with epinephrine
3101348|NCT02052557|Active Comparator|Bupivacaine liposome suspension|exparel 20ml, diluted with 10ml sterile saline for total of 30ml
3101349|NCT02052596|Experimental|GSK1437173A Group|Subjects received one injection of Boostrix vaccine and one injection of the GSK1437173A vaccine during the first visit and a second injection of the GSK1437173A vaccine during the third visit, two months later.
3101350|NCT02052596|Active Comparator|Control Group|Subjects received all vaccines separately i.e. one injection of Boostrix vaccine at the first visit, one injection of the GSK1437173A vaccine at the third visit and a second injection of the GSK1437173A vaccine at the fourth visit, all two months apart.
3101351|NCT02052635|Experimental|Ticagrelor|90 mg oral tablet
3101352|NCT02052635|Active Comparator|Clopidogrel|300 mg oral tablet
3101353|NCT02052661|Experimental|Engerix-B Kinder Group|Subjects who were previously primed and boosted with four doses of Infanrix™ hexa in the first two years of life, received a single dose of Engerix™-B Kinder vaccine. The vaccine was administered intramuscularly into the deltoid of the non-dominant arm.
3101354|NCT02052752|Experimental|Test Product|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3101355|NCT02052752|Active Comparator|Vehicle gel|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3101356|NCT02052752|Placebo Comparator|Positive control|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
3101357|NCT02052895||Sepsis/SIRS|Patients with sepsis or SIRS
3101358|NCT02052895||Control|Patients without SIRS, sepsis, or end stage renal disease
3101359|NCT02052895||End Stage Renal Disease|Patients with end stage renal disease, without SIRS or sepsis
3101360|NCT02052960|Experimental|CetuGEX™ plus chemotherapy|720 mg weekly administration
3101361|NCT02052960|Active Comparator|Cetuximab plus chemotherapy|250 mg/m2 weekly administration
3101362|NCT02053168|Other|Resorbable Mesh|Phasix Mesh
3101363|NCT02053259|Experimental|Adaptive Goals with Immediate Reinforcement|Adaptive Physical Activity Goals, Immediate Financial Reinforcement
3101364|NCT02053259|Experimental|Adaptive Goals with Delayed Reinforcement|Adaptive Physical Activity Goals, Delayed Financial Reinforcement
3101365|NCT02053259|Experimental|Static Goals with Immediate Reinforcement|Static Physical Activity Goals, Immediate Financial Reinforcement
3101366|NCT02053259|Active Comparator|Static Goals with Delayed Reinforcement|Static Physical Activity Goals, Delayed Financial Reinforcement
3101367|NCT02053376|Experimental|regorafenib|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with regorafenib (120 mg) (160 mg for second and subsequent treatment cycles) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle
3101368|NCT02053493|Active Comparator|Isosorbide Mononitrate|Isosorbide Mononitrate with dose up-titration (30 to 120 mg/day over 4 weeks)
3101369|NCT02053493|Placebo Comparator|Isosorbide Mononitate Placebo|Isosorbide Mononitrate placebo with dose up-titration (30 to 120 mg/day over 4 weeks)
3101370|NCT02053610|Experimental|obinutuzumab + chlorambucil (GClb)|Participants received 1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles).
3101371|NCT02053610|Active Comparator|rituximab + chlorambucil (RClb)|Participants received 375 mg/m^2 rituximab IV infusion on Day 1 of Cycle 1 then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6 (28-day cycles) plus chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 cycles).
3101372|NCT02053610|Active Comparator|Chlorambucil (Clb)|Participants received chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle (6 Cycles). Participants with Progressive Disease or within 6 months of follow-up were allowed to cross over to receive obinutuzumab + chlorambucil.
3101373|NCT02053753|Experimental|Drug Product CP4|Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.
3101374|NCT02053753|Experimental|Drug Product CP2|Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.
3101375|NCT02054130|Placebo Comparator|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
3101376|NCT02054130|Experimental|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
3101377|NCT02054130|Experimental|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
3101378|NCT02054130|Experimental|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
3101379|NCT02054156|Active Comparator|azithromycin and TIS|azithromycin and tobramycin solution for inhalation (TIS) Azithromycin 3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
3101380|NCT02054156|Placebo Comparator|placebo and TIS|placebo and tobramycin solution for inhalation (TIS) Placebo 3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months Tobramycin solution for inhalation (TIS), 300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
3101381|NCT02054325|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml.
3101382|NCT02054325|Active Comparator|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5ml.
3101383|NCT02054338|Experimental|vinflunine plus gemcitabine|vinflunine 320 mg/m² D1 plus gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks
3469061|NCT03889717|Experimental|400 iu|neonates who will receive vitamin d dose at 400 iu per day
3101384|NCT02054338|Active Comparator|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² D1 followed by Gemcitabine 1250 mg/m² D1 and D8 every 3 weeks
3101385|NCT02054481|Experimental|Arm 1|BI 655066 s.c.
3101386|NCT02054481|Experimental|Arm 2|BI 655066 s.c.
3101387|NCT02054481|Experimental|Arm 3|BI 655066 s.c.
3101388|NCT02054481|Active Comparator|Arm 4|Ustekinumab s.c.
3101389|NCT02054520|Experimental|Arm 1A HyperAcute®-Melanoma (HAM) + Ipilimumab|Arm 1A will receive ipilimumab at 3 mg/kg given every 3 weeks for 4 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3101390|NCT02054520|Active Comparator|Arm 2A Ipilimumab Alone|Arm 2A will receive ipilimumab alone at 3 mg/kg every 3 weeks for a total of four doses.
3101391|NCT02054520|Experimental|Arm 1B HyperAcute®-Melanoma (HAM) + nivolumab|Arm 1B will receive nivolumab alone at 3 mg/kg given every 2 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3101392|NCT02054520|Active Comparator|Arm 2B Nivolumab alone|Arm 2B will receive nivolumab alone at 3 mg/kg given every 2 weeks
3101393|NCT02054520|Experimental|Arm 1C HyperAcute®-Melanoma (HAM) + pembrolizumab|Arm 1C will receive pembrolizumab at 2 mg/kg given every 3 weeks and 300 Million HyperAcute®-Melanoma (HAM) Immunotherapy cells per each immunization, given every week for 4 weeks, every 2 weeks for 5 months, every month for 6 months, and every 3 months for one year.
3101394|NCT02054520|Active Comparator|Arm 2C Pembrolizumab alone|Arm 2C will receive pembrolizumab at 2 mg/kg given every 3 weeks
3101395|NCT02054572|Experimental|[¹⁴C]Etelcalcetide|Participants received a single dose of 10 mg radiolabelled etelcalcetide administered by intravenous (IV) bolus injection at the end of hemodialysis on day 1.
3101396|NCT02054702|Experimental|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
3101397|NCT02054702|Experimental|Aripiprazole|Aripiprazole - Up to 20 mg/day, once daily dose, tablets, orally
3101398|NCT02054715|Experimental|Arm I (print educational)|Participants undergo a print educational intervention during which they meet with a site coordinator and are instructed to read the NCI booklet titled Taking Part in Cancer Treatment Studies, comprised primarily of information about the nature and conduct of cancer clinical trials.
3101399|NCT02054715|Experimental|Arm II (multimedia psychoeducational)|Participants undergo a multimedia psychoeducational intervention during which they meet with a site coordinator and are instructed to view a DVD and read a booklet titled Clinical Trials: Are They Right For You? Participants are encouraged to watch the DVD and read the booklet again at home.
3101400|NCT02054754|Experimental|Dexanabinol Dose Level 1|Single oral dose of dexanabinol
3101401|NCT02054754|Experimental|Dexanabinol Dose Level 2|Single oral dose of dexanabinol
3101402|NCT02054754|Experimental|Dexanabinol Dose Level 3|Single oral dose of dexanabinol
3101403|NCT02054754|Experimental|Dexanabinol Dose Level 4|Single oral dose of dexanabinol
3101404|NCT02054754|Experimental|Dexanabinol Dose Level 5|Single oral dose of dexanabinol
3101405|NCT02054754|Placebo Comparator|Placebo|Single oral dose of matching placebo
3101406|NCT02054897|Experimental|Semaglutide 1.0 mg|
3101407|NCT02054897|Experimental|Semaglutide 0.5 mg|
3101408|NCT02054897|Placebo Comparator|Semaglutide placebo 1.0 mg|
3101409|NCT02054897|Placebo Comparator|Semaglutide placebo 0.5 mg|
3101410|NCT02055053|Experimental|anesthetic intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the treatment group will receive infusion of 15 cc 0.5% Bupivicaine.
3101411|NCT02055053|Placebo Comparator|Saline intervention|After deployment of therapeutic mesh in the preperitoneal space of the abdomen wall during the procedure, the placebo group will receive the infusion of 15 cc 0.9% Saline.
3101412|NCT02055118|Experimental|idursulfase-IT|10 mg administered via IT using IDDD (intrathecal drug delivery device) once a month for 52 weeks.
3101413|NCT02055118|Other|Nontreatment control|Patients will receive weekly standard of care treatment with IV Elaprase only.
3101414|NCT02055157|Experimental|Cohort 1|Cohort 1: 2.5 ug/kg
3101415|NCT02055157|Experimental|Cohort 2|Cohort 2: 7.5 ug/kg,
3101416|NCT02055157|Experimental|Cohort 3|Cohort 3: 15 ug/Kg
3101417|NCT02055157|Experimental|Cohort 4|Cohort 4: 30 ug/kg
3101418|NCT02055352|Experimental|Budesonide/indacaterol|Participants will receive a fixed combination of fluticasone and salmeterol during 4 weeks followed by a free combination of budesonide and indacaterol for the remainig of study.
3101419|NCT02055352|Active Comparator|Fluticasone / salmeterol|Fixed combination of fluticasone and salmeterol
3101420|NCT02055365|Experimental|Hepatitis B vaccination|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
3101421|NCT02055404|Experimental|Delefilcon A|Delefilcon A spherical contact lens with molded marks randomly assigned to one eye, with etafilcon A toric contact lens in the fellow eye for contralateral wear approximately 2 hours in duration
3101422|NCT02055404|Other|Etafilcon A|Etafilcon A toric contact lens randomly assigned to one eye, with delefilcon A spherical contact lens with molded marks in the fellow eye for contralateral wear approximately 2 hours in duration
3101423|NCT02055430|Active Comparator|percutaneous nephrostomy|percutaneous nephrostomy insertion (6-8 Fr in size) for initial urinary drainage followed by definitive stone management.
3101424|NCT02055430|Active Comparator|Bilateral double J ureteric stents|double J ureteric stent insertion (4.8-6 Fr JJ in size) for initial urinary drainage followed by definitive stone management.
3469062|NCT03889717|Active Comparator|1000 iu|neonates who will receive vitamin d dose 1000 iu per day
3469063|NCT03889808||Non immunosuppressed patients|without treatment or treated with Salicylates and that have not received immunosuppressive therapy, steroids, or biologics in the last 6 months.
3469064|NCT03889808||Patients with immunosuppressive therapy|Azathioprine, 6-Mercaptopurine, Methotrexate in standard dosage at least the past 6 months and that have not received steroids or biologics in the last 6 months.
3469065|NCT03889808||Patients with biologic agents|in standard dosage at least the past 6 months and that have not received steroids in the previous 6 months.
3469066|NCT03889808||Patients with steroid treatment|Must have received daily steroid treatment ≥ 20 mg for ≥ 2 weeks.
3469067|NCT03889808||Healthy subjects|A healthy subject is defined as not having and immunosuppressive underlying condition, not receiving immunosuppressive therapy, has not received antibiotic treatment in the last 6 months, has no past C. difficile infections and has not been in contact with the health care system or hospitalized in the previous 6 months.
3469068|NCT03889821|Active Comparator|Child-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM).
3469069|NCT03889821|Experimental|Child- and Parent-focused Treatment|Participants in this group participate in 12 sessions of the Parent-implemented Early Start Denver Model (P-ESDM). Parents also participate in 6 separate, individual sessions of Mindfulness Based Stress Reduction (MBSR).
3469070|NCT03889847|Experimental|silicone DLT|Fibreoptic intubation with silicone double lumen tube
3469071|NCT03889847|Experimental|PVC DLT|Fibreoptic intubation with PVC double lumen tube
3469072|NCT03890042|Active Comparator|Dienogest group|
3469073|NCT03890042|Active Comparator|Gynera group|
3469074|NCT03889886|Placebo Comparator|Vehicle|Vehicle
3469075|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (0.1%)|Low concentration of SDP-4
3469076|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (1.0%)|Mid concentration of SDP-4
3469077|NCT03889886|Experimental|SDP-4 Ophthalmic Solution (3.0%)|High concentration of SDP-4
3469078|NCT03889756|Experimental|Ketamine|Ketamine is an FDA-approved anesthetic agent that is commonly used to induce surgical anesthesia due to its low incidence of significant respiratory depression and hypotension. It as a N-methyl-D-aspartate (NMDA) receptor antagonist and glutamatergic modulator, and has been demonstrated in multiple controlled clinical trials to have rapidly acting antidepressant and anti-suicidal effects in adults.
3469079|NCT03889756|Placebo Comparator|Midazolam|Midazolam, the active control in this study, is a medication that is approved by the Food and Drug Administration as a sedative for both children and adults.It is a benzodiazepine with a short half-life that was chosen so as to blind the psychotomimetic effects of Ketamine.
3469080|NCT03890003|Experimental|AID System Containing Insulin Lispro|The automated insulin delivery (AID) system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a PLGS algorithm, and a continuous glucose monitor (CGM) component.
3469081|NCT03890029|Other|Intervention|"Once potential participants have given consent and determined eligible, they will undergo an initial assessment.Pre, post- and follow-up testing. This consists of verbal scales including emotional well-being scales and mental health symptom scales. They will be administered in a group 30-60 minute session. Neuropsychological testing and psychophysiological tests given will require 90 minutes. Neuropsychological testing will be completed at pre and post testing only. In order to ensure unbiased assessment, pre- and post- and follow-up testing will be conducted by individuals blinded to study condition.~Randomization. After pre-testing, all individuals will be randomly assigned to either the active treatment group or minimal attention control condition. After this, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. After five weeks, all participants will be post-tested."
3469082|NCT03890029|Other|Control|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training
3101444|NCT02055638|Experimental|SRX246|SRX246 capsules, 120mg bid for 4 weeks followed by 160mg bid for 4 weeks
3101445|NCT02055638|Placebo Comparator|Placebo|Placebo capsules to match the amount of SRX246 capsules for 8 weeks
3101446|NCT02055781|Experimental|Pacritinib, Once Daily|Pacritinib 400 mg QD
3101447|NCT02055781|Experimental|Pacritinib, Twice Daily|Pacritinib 200 mg BID
3101448|NCT02055781|Active Comparator|Best Available Therapy|BAT includes any physician-selected treatment for myelofibrosis, such as approved JAK2 inhibitors administered according to package insert for patients with thrombocytopenia, and may include any treatment received before study entry.
3101449|NCT02055820|Experimental|Venetoclax + G-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + obinutuzumab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
3101450|NCT02055820|Experimental|Venetoclax + R-CHOP Arm|Phase I: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle will consist of 21 days. Phase II: Participants will receive 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle will consist of 21 days. For both phase I and II, participants with ongoing response without excessive toxicity may receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
3469083|NCT03889977|Experimental|Exercise|Resistance exercise 45 min following breakfast
3469084|NCT03889977|No Intervention|Control|No exercise (resting) following breakfast
3469085|NCT03889964||patients with stable COPD|
3469086|NCT03890016||snakebite victims|Victims of snakebite presenting to the Emergency Department of Jubilee Mission Medical College and Research Institute
3469087|NCT03889912|Experimental|Cemiplimab|Three dose cohorts are planned and will follow a 3 + 3 dose-escalation design with cohort expansion
3469088|NCT03889678||Peripheral IV|Patients with peripheral intravenous line in place undergoing elective surgery
3469089|NCT03889691||Control group|The control group consisted of patients who verbal explanation of the surgical procedure and the potential postoperative complications was given with a written informed consent document
3101451|NCT02055898|Experimental|Placebo first, then sodium oxybate|Subjects received a single dose of placebo comparator (fresh potable water) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of sodium oxybate (3.0g as liquid) at bedtime for 4 nights
3101452|NCT02055898|Experimental|Sodium oxybate first, then placebo|Subjects received a single dose of sodium oxybate (3.0g as liquid) at bedtime on 4 nights during an inpatient stay of 5 days in the research centre. This was followed by an interval of at least 2 weeks. They were then admitted again and received a single dose of placebo comparator (fresh potable water) at bedtime for 4 nights
3101453|NCT02055976|Experimental|Population A|A total of 9 groups in two population. Population A comprises hypercholesterolemic Japanese subjects whose LDL-C is not controlled by a stable dose of atorvastatin. A subject who is receiving a stable dose of atorvastatin will be randomized into one out of 5 dose groups.
3101454|NCT02055976|Experimental|Population B|A total of 9 groups in two population. Population B comprises hypercholesterolemic Japanese subjects who are naïve for a treatment by lipid lowering drug and whose fasting LDL-cholesterol is not controlled. A subject who is treatment naïve will be randomized into one out of 4 dose groups.
3101455|NCT02056171|Experimental|Quetiapine|A randomized group will receive quetiapine as treatment for delirium.
3101456|NCT02056171|Placebo Comparator|Placebo|A randomized group will receive placebo, and not quetiapine.
3101457|NCT02056288|Active Comparator|Ultrasound Guided Supraclavicular block|Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml), using the technique described by Marhofer et al. In order to decrease variance in success rates, the ultrasound guided nerve block will be performed by 1 of the 4 anesthesiology co-investigators, each of whom have successfully performed over 100 ultrasound guided blocks in the past. Supraclavicular blocks were performed using the higher frequency of the probe and placing it in a coronal-oblique-plane in the supraclavicular fossa.
3101458|NCT02056288|Active Comparator|IV Opioids|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
3101459|NCT02056301|Active Comparator|Patient Controlled Analgesia|One group will have a patient controlled device connected to an intravenous patient controlled analgesia (IV PCA). This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes.
3101460|NCT02056301|Active Comparator|epidural Catheter|The other group will have an epidural catheter inserted under sterile conditions in the thoracic epidural space after anesthesia has been induced. This will be connected to a patient controlled epidural analgesia (PCEA) device for postoperative pain control that works in a similar manner except the medication (a combination of local anesthetics and hydromorphone) will be administered in the thoracic epidural space.
3101461|NCT02056340|Active Comparator|Atorvastatin|Patients will be administered study medication (atorvastatin 40 mg) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
3101462|NCT02056340|Placebo Comparator|Placebo|Patients will be administered study medication (matched placebo) orally once daily for 5 days, for a maximum of 7 days for those who remain hospitalized.
3101463|NCT02056392|Experimental|Selumetinib 75mg|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
3101464|NCT02056392|Active Comparator|Moxifloxacin 400 mg|Volunteers will receive moxifloxacin 400mg administered by mouth, as a capsule
3101465|NCT02056392|Placebo Comparator|Selumetinib 75mg placebo|Volunteers will receive selumetinib 75mg placebo, administered by mouth, as a capsule.
3101466|NCT02056431|Experimental|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
3101467|NCT02056431|No Intervention|IVR Control Group|Participants will receive 3 non-interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) containing general messages regarding diabetic education.
3101468|NCT02056626|Active Comparator|arm 2|partial reinforcement, 6.25 mg twice daily, 25% of time (15 days)
3101469|NCT02056626|Active Comparator|arm 3|controlled dosing schedule 6.25 mg twice daily (15 days)
3101470|NCT02056626|Active Comparator|arm 4|controlled dosing schedule 6.25 mg twice daily, every other day (15 days)
3101471|NCT02056626|Active Comparator|arm 1|standard therapy, 25 mg twice daily (15 days)
3101472|NCT02056639|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 27 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
3101473|NCT02056639|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
3101474|NCT02056652|Experimental|Pessary|Use of the Bioteque cup pessary. Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
3101475|NCT02056652|No Intervention|No pessary|No pessary will be used. Subjects will receive standard obstetrical management
3101476|NCT02056834||chronOS Inject|Closed proximal tibial fractures of type Schatzker I - VI, AO-OTA 41, AO-OTA 42 with bone defect
3101477|NCT02057042|Experimental|PS-cCBT|peer-assisted computerized CBT
3101478|NCT02057042|Active Comparator|EUC|Enhanced usual care
3101479|NCT02057068|Experimental|SLEEP-E Dyads Intervention|"SLEEP-E Dyads Six-Week Tele-Health Intervention~. Daily core video modules on sleep education, sleep hygiene and behavioral and environmental factors influencing sleep.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Move Out time consisting of activity enhancement and exercise.~. Daily and on-demand video modules designed to promote and provide guided instruction for daily Stand Down time (meditation, therapeutic breathing and self-care).~. SLEEP-E Dyads book~. Two tele-video conferences to discuss evaluation results, obtain buy-in for the prescribed intervention and address dysfunctional beliefs and attitudes about sleep. The second call involves checking-in, encouragement, reinforcement and coaching"
3101480|NCT02057068|No Intervention|Usual Care Group|During the intervention period there is no data collection or contact with research staff other than for scheduling outcomes visits.
3101481|NCT02057081|Experimental|Treatment|Intensive 14-session psychoeducational rehabilitation and skills-building intervention for couples.
3101482|NCT02057081|Active Comparator|Control|Didactic 14-session educational group intervention for families.
3101483|NCT02057198|Active Comparator|Fidaxomicin|200 mg. 2 times a day for 10 days
3101484|NCT02057198|Active Comparator|Metronidazole|500 mg.orally 3 times daily for 10 days
3101485|NCT02057198|Active Comparator|Vancomycin|125 mg. orally 4 times a day for 10 days
3101486|NCT02057250|Experimental|Sarilumab 150 mg by AID|Sarilumab 150 mg subcutaneous (SC) injection every 2 weeks (q2w) administered by AID with one or a combination of non-biologic disease-modifying anti-rheumatic drug (DMARD) (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3101487|NCT02057250|Experimental|Sarilumab 150 mg by PFS|Sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3101488|NCT02057250|Experimental|Sarilumab 200 mg by AID|Sarilumab 200 mg SC injection q2w administered by AID with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3101489|NCT02057250|Experimental|Sarilumab 200 mg by PFS|Sarilumab 200 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD (hydroxychloroquine, methotrexate, sulfasalazine and/or Leflunomide, except for simultaneous combination use of leflunomide and methotrexate) in AID assessment phase for 12 weeks. Participants who completed 12 weeks AID assessment phase entered in open-label extension phase and received sarilumab 150 mg SC injection q2w administered by PFS with one or a combination of non-biologic DMARD for 52 weeks.
3101490|NCT02057393|Experimental|Indocyanine Green|Single arm study, each subject receives 0.9ml ICG, methylene blue and technetium 99.
3101491|NCT02057406|Active Comparator|2:1 EPA/DHA|400/200 EPA/DHA fish oil 2 grams
3101492|NCT02057406|Active Comparator|High EPA|Almost pure EPA 2 grams
3101493|NCT02057406|Placebo Comparator|Placebo|Matched placebo corn oil capsules
3101494|NCT02057458|Experimental|Acute Study: Sildenafil first, then Placebo|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
3101495|NCT02057458|Experimental|Acute Study: Placebo first, then Sildenafil|In randomized order, on two separate days, endothelial function and exercise capacity will be determined 1 hour following a single dose of sildenafil (50 mg) or placebo.
3101496|NCT02057458|Experimental|Sub-Chronic Study Sildenafil|Following the acute study, patients will be instructed to take 20 mg of sildenafil, three times a day, for 4 weeks. Endothelial function will be determined within 48 hours following the last dose.
3101497|NCT02057523|Experimental|Acthar|Acthar 80 units twice weekly for 6 months. If endpoint is not reached, duration may be increased to 12 months.
3101498|NCT02057549|Experimental|Haloperidol plus Conventional Therapy|Intravenous dose of haloperidol 5 mg in addition to conventional therapy. Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
3101499|NCT02057549|Active Comparator|Conventional Therapy alone|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
3101500|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.01%|Netarsudil 0.01%, Latanoprost 0.005% fixed combination ophthalmic solution
3101501|NCT02057575|Experimental|PG324 Ophthalmic Solution 0.02%|Netarsudil 0.02%, Latanoprost 0.005% fixed combination ophthalmic solution
3101502|NCT02057575|Active Comparator|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
3101503|NCT02057575|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
3101504|NCT02057640|Experimental|Combination therapy: Panobinostat, dexamethasone, MLN9708|Panobinostat: 20mg, on day 1, 3, 5, 15, 17, 19, 28 Dexamethasone: 20mg, on day 1, 2, 8, 9, 15, 16, 28 MLN9708: 4mg on day 1, 8, 15, 28
3101505|NCT02057666|Experimental|Tasquinimod|One capsule (0.25, 0.50 or 1 mg), taken orally once a day with water and food (preferably the main evening meal).
3101506|NCT02057666|Placebo Comparator|Placebo|One capsule, taken orally once a day with water and food (preferably the main evening meal).
3101507|NCT02057692|Experimental|LUM001|LUM001 for oral administration
3101508|NCT02057692|Placebo Comparator|Placebo|Placebo administered orally once each day
3101509|NCT02057718|Experimental|LUM001 (Maralixibat)|Participants will receive LUM001, also known as Maralixibat (MRX) twice a day (BID).
3101510|NCT02057757|Experimental|Nitazoxanide (NTZ)|Participants will receive NTZ for 5 days. Participants younger than 12 years will receive an oral suspension formulation of NTZ; participants 12 years and older will receive NTZ tablets.
3101511|NCT02057757|Placebo Comparator|Placebo|Participants will receive placebo for 5 days. Participants younger than 12 years will receive an oral suspension formulation of placebo; participants 12 years and older will receive placebo tablets.
3101512|NCT02057835|Experimental|BI 691751 low dose 1|BI 691751 low dose 1
3101513|NCT02057835|Experimental|BI 691751 low dose 2|BI 691751 low dose 2
3101514|NCT02057835|Experimental|BI 691751 middle dose|BI 691751 middle dose
3101515|NCT02057835|Experimental|BI 691751 high dose|BI 691751 high dose
3101516|NCT02057939|Experimental|Enzalutamide|Enzalutamide, Androgen Deprivation, and Radiation Therapy
3101517|NCT02057952|No Intervention|Usual Care Control|No intervention.
3101518|NCT02057952|Active Comparator|In Person Weight Management|Education and exercise in a community health center environment.
3101519|NCT02057952|Experimental|Video Conference Weight Management|Education and exercise delivered through video conference.
3101520|NCT02058069|Experimental|Robotic Assisted Total Knee Arthroplasty|
3101521|NCT02058095|Active Comparator|Tadalafil|Subject will receive Tadalafil daily for a total of 12 weeks
3101522|NCT02058095|Placebo Comparator|Placebo|Subject will receive Placebo daily for a total of 12 weeks
3101523|NCT02058108|Experimental|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
3101524|NCT02058108|Placebo Comparator|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
3101525|NCT02058147|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
3101526|NCT02058147|Active Comparator|Insulin Glargine|Insulin glargine QD for 30 weeks. Dose individually adjusted.
3101527|NCT02058147|Active Comparator|Lixisenatide|Lixisenatide 10 mcg QD for 2 weeks, then 20 mcg QD (maintenance dose).
3101528|NCT02058160|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|FRC once daily (QD) for 30 weeks. Dose individually adjusted.
3101529|NCT02058160|Active Comparator|Insulin glargine|Insulin glargine 100 U/mL QD for 30 weeks. Dose individually adjusted.
3101530|NCT02058251|Experimental|Oxytocin|Each participant will self-administer a 40 IU dose of intranasal oxytocin.
3101531|NCT02058251|Placebo Comparator|Control|Each participant will self-administer a 40 IU dose of intranasal saline.
3101532|NCT02058290|Active Comparator|IV Morphine Sulfate or Sponsor-approved Equivalent|Standard of Care (SOC)
3101533|NCT02058290|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3101534|NCT02058368|Experimental|Arm 1|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatin placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet once daily (OD) (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 dutasteride 0.5 milligram (mg) capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
3101535|NCT02058368|Experimental|Arm 2|Run-in phase: All subjects qualifying for the study will entered into a placebo run-in phase will receive one soft gelatine placebo capsule (swallowed whole and not chewed) and one oral disintegrating placebo tablet OD (dissolved on the tongue then swallowed not chewed), following the first meal each day for four weeks. Randomized treatment phase: Subjects will be instructed to take 1 placebo dutasteride 0.5mg capsule (swallowed whole and not chewed) and one tamsulosin 0.2mg tablet OD (dissolved on the tongue then swallowed not chewed) following the first meal each day for 104 weeks.
3101536|NCT02058498|Experimental|Liver Transplant Patients|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log.
3101537|NCT02058511|Experimental|Intervention Group|"all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs"
3101538|NCT02058563|Experimental|INV_MMR Group|Subjects will receive 1 dose of GSK Biologicals' trivalent Measles, Mumps, and Rubella Virus Vaccine (Priorix®).
3101539|NCT02058563|Active Comparator|COM_MMR Group|Subjects will receive 1 dose of Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine.
3101540|NCT02058589|Experimental|GSK1437173A Group|Subjects, aged 18 years or older, received 2 doses of the GSK 1437173A vaccine, adjuvanted with AS01B at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
3101541|NCT02058589|Placebo Comparator|Placebo Group|Subjects, aged 18 years or older, received 2 doses of Placebo (lyophilised sucrose reconstituted with saline [NaCl] solution) at Day 0, and Month 1, administered intramuscularly, in the deltoid muscle of an arm.
3101542|NCT02058628|Experimental|Arm 1|A total of 110 subjects will receive clindamycin + BPO once daily in the evening for 12 weeks as per the randomization schedule.
3101543|NCT02058628|Experimental|Arm 2|A total of 110 subjects will receive azelaic acid twice daily (1 in the morning and 1 in the evening) for 12 weeks as per the randomization schedule.
3101544|NCT02058836|Experimental|Botox Injection|The participant will be given an injection of Botox along the spermatic cord under ultrasound guidance. Before drug administration, a nerve block using bupivacaine will be completed to numb the area for treatment. This will be a 10 mL injection done one time at the initial patient visit.
3101545|NCT02058836|Placebo Comparator|Saline Injection|The patient will receive an inactive injection of normal saline along the spermatic cord under ultrasound guidance. This will be a 10 ml injection done once at the initial visit. Before the injection of saline, a spermatic cord block using bupivacaine will be completed to numb the area for treatment.
3101546|NCT02058849|Experimental|Beetroot|Beetroot 10 grams concentrated organic beetroot crystals
3101547|NCT02058849|Placebo Comparator|Placebo|Placebo
3101548|NCT02058940|Experimental|Exenatide|
3101549|NCT02058966|Placebo Comparator|Placebo followed by Placebo|Subjects will receive placebo, then one hour later, placebo
3101550|NCT02058966|Experimental|Placebo followed by Methamphetamine|Subjects will receive placebo, then one hour later, methamphetamine
3101551|NCT02058966|Experimental|Entacapone followed by Placebo|Subjects will receive entacapone, then one hour later, placebo
3101552|NCT02058966|Experimental|Entacapone followed by Methamphetamine|Subjects will receive entacapone, then one hour later, methamphetamine
3101553|NCT02058992||Ramelteon 8 mg administered orally once daily|
3101554|NCT02059005|Experimental|Specialized Community Disease Management|Specialized Community Disease Management
3101555|NCT02059005|Active Comparator|Treatment As Usual|Treatment as Usual: standard post-hospital discharge with medical monitoring.
3101556|NCT02059057|Experimental|LVRC System|
3101557|NCT02059070|Experimental|0.125% Bupivacaine|Group 1) Post-operative 0.125% Bupivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
3101558|NCT02059070|Experimental|0.2% Ropivacaine|Group 2) Post-operative 0.2% Ropivacaine Interscalene brachial plexus block, 6ml/hr, continuous.
3101559|NCT02059135|Active Comparator|Recombinant Human Antithrombin (ATryn)|ATryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
3101560|NCT02059135|Placebo Comparator|Normal Saline 0.9%|Placebo (Normal Saline 0.9%, matched for volume of active treatment) consisting of a loading dose over 15 minutes followed by continuous infusion.
3101561|NCT02059148|Experimental|LY2835219 Standard|Single oral dose of LY2835219 given with a standard meal in one of three study periods.
3101562|NCT02059148|Experimental|LY2835219 Fasted|Single oral dose of LY2835219 given with no food in one of three periods.
3101563|NCT02059148|Experimental|LY2835219 High-Fat|Single oral dose of LY2835219 given with a high fat meal in one of three periods.
3101564|NCT02059161|Experimental|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
3101565|NCT02059161|Active Comparator|Lantus|Lantus dosed subcutaneously once daily at bedtime for 52 weeks. Doses were individually titrated post-randomization to the suggested target for fasting fingerstick glucose levels of >70 mg/dL (3.9 mmol/L) and ≤100 mg/dL (5.6 mmol/L).
3101566|NCT02059174|Experimental|MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
3101567|NCT02059174|Experimental|EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293|MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
3101568|NCT02059187|Experimental|MK-1293|MK-1293 administered subcutaneously once daily in the evening.
3101569|NCT02059187|Active Comparator|Lantus™|Lantus™ administered subcutaneously once daily in the evening.
3101570|NCT02059213|Active Comparator|ADT Alone|Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
3101571|NCT02059213|Experimental|ADT + Ibrance®|Ibrance® (125mg taken daily by mouth days 1-21 of a 28 day cycle) in addition to Androgen Deprivation Therapy (ADT): Bicalutamide (an active non-steroidal antiandrogen; 50mg taken daily by mouth) and Zoladex (LHRH agonist administered by injection), or Lupron Depot (LHRH agonist, administered by injection).
3101572|NCT02059239|Experimental|Chemo plus Autologous Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by autologous transplant
3101573|NCT02059239|Experimental|Chemo plus Allogeneic Transplantation|Bendamustine 200 mg/ m2/ day on Days - 24 and Day - 23 followed by a short break of 10 - 14 days, followed by Melphalan, Carmustine, Etoposide, Cytarabine (BEAM) and alemtuzumab, plus rituximab for all b-cell malignancies, followed by allogeneic transplant
3101574|NCT02059265|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3101575|NCT02059278|Experimental|T-2345|T-2345 Ophthalmic Solution dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
3101576|NCT02059278|Experimental|Xalatan|Xalatan (Latanoprost 0.005% Ophthalmic Solution) dosed 1 drop QD in the eye(s) in the evening (8 pm +/- 30 minutes)
3101577|NCT02059291|Experimental|crFMF: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
3101578|NCT02059291|Placebo Comparator|crCMF: placebo|"During epoch 2, participants received matching placebo to canakinumab 150 mg Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab.~150mg, participants were uptitrated to open-label canakinumab 300 mg."
3101579|NCT02059291|Experimental|HIDS/MKD: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration.
3101580|NCT02059291|Placebo Comparator|HIDS/MKD: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
3132632|NCT03441984|Experimental|Subjects with treatment sequence CBA|The subjects in Part 1 of the study will receive a single dose each of, treatment C in TP1, treatment B in TP2 and treatment A in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3101581|NCT02059291|Experimental|TRAPS: 150 mg|During Epoch 2, participants received canakinumab 150mg (or 2mg/kg for participants weighing <= 40kg) q4w for 16 weeks. If participants were eligible for blinded escape, they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between day 8 and day 28, and then received blinded uptitration to canakinumab 300 mg q4w from day 29 through day 112. If patients on the highest allowed canakinumab dose of 300 mg (or 4 mg/kg for patients weighing ≤ 40 kg) q4w and re-flared (PGA ≥ 2 and CRP ≥ 30 mg/L) were not eligible for further up-titration
3101582|NCT02059291|Placebo Comparator|TRAPS: placebo|During epoch 2, participants received matching placebo to canakinumab 150 mg qw4. Participants who required blinded escape,they received a single add-on dose of canakinumab (150 mg or 2mg/kg for participants weighing <= 40kg) between Day 8 and 28 and then received blinded one dose of placebo and one dose of canakinumab q4w from day 29 through day 112. If flare or re-flare still occurred after receipt of canakinumab 150mg, participants were uptitrated to open-label canakinumab 300 mg.
3101583|NCT02059395|Active Comparator|Time based|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course
3101584|NCT02059395|Experimental|Mastery based|Participants do follow the content of the Canadian Heart and Stroke Foundation Heartsaver Course content based on their own pace (timeframe)
3101585|NCT02059408|No Intervention|Usual Care|The patients in this arm will receive normal primary care.
3101586|NCT02059408|Active Comparator|Screen-Educate|Education program to improve blood pressure control among hypertensive non-diabetic persons. The Screen and Educate arm recommends using creatinine, cystatin C and albuminuria for detection and risk stratification, followed by guideline-concordant CKD management appropriate for CKD stage.
3101587|NCT02059408|Active Comparator|Screen-Educate and Intensify Treatment|Education and treatment program to improve blood pressure control among hypertensive non-diabetic persons. The Screen-Educate and Intensify Treatment adds a pharmacist-led CKD management program and attempts to improve BP management and patient-centered outcomes among persons with newly stratified higher risk CKD based on creatinine, cystatin c and albuminuria.
3101588|NCT02059434|Experimental|LAS190792 Dose 1 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101589|NCT02059434|Experimental|LAS190792 Dose 2 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101590|NCT02059434|Experimental|LAS190792 Dose 3 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101591|NCT02059434|Experimental|LAS190792 Dose 4 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101592|NCT02059434|Experimental|LAS190792 Dose 5 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101593|NCT02059434|Experimental|LAS190792 Dose 6 (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101594|NCT02059434|Placebo Comparator|Placebo (Part 1)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101595|NCT02059434|Experimental|LAS190792 Dose 1 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101596|NCT02059434|Experimental|LAS190792 Dose 2 (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101597|NCT02059434|Active Comparator|Tiotropium 18 μg|Single dose, oral inhalation by HandiHaler® single-dose DPI
3101598|NCT02059434|Active Comparator|Indacaterol 150 μg|Single dose, oral inhalation by Breezhaler® single-dose DPI
3101599|NCT02059434|Placebo Comparator|Placebo (Part 2)|Single dose, oral inhalation by Genuair® single-dose dry powder inhaler (DPI)
3101600|NCT02059512|Active Comparator|Group 1|Intramyocardial administration of autologous bone marrow mononuclear cells during the operation coronary artery bypass grafting 0.2 ml - 10 injection in the zone of blood supply LAD.
3101601|NCT02059512|Placebo Comparator|Group 0|Intramyocardial administration of 0.9 % NaCl (sodium chloride) 0.2 ml - 10 injection in the zone of blood supply LAD during the operation coronary artery bypass grafting.
3101602|NCT02059512|Active Comparator|Group 2|Intramyocardial and intracoronary administration of autologous bone marrow mononuclear cells during coronary artery bypass grafting intramyocardial 0.2 ml - 10 injection in the zone of blood supply LAD.
3101603|NCT02059642|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product Route, frequency: Administered orally once daily
3101604|NCT02059642|Experimental|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) Dose, route, and frequency: 1400 mg administered orally once daily
3101605|NCT02059902|Placebo Comparator|Normal pain management|Normal saline (bolus followed by continuous infusion)
3101606|NCT02059902|Experimental|Lidocaine|Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)
3101607|NCT02059928|Experimental|Intraosseous device placement|Intraosseous device
3101608|NCT02059980|Experimental|Response inhibition training|Eight 45-minute sessions of computerized training on response inhibition over a 4 week period
3101609|NCT02059980|Placebo Comparator|Placebo Control Training|Eight 45-minute sessions of computerized placebo control training over a 4 week period
3101610|NCT02059993|Other|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night; continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
3101611|NCT02059993|No Intervention|Control|The control subjects received standardised anti-hypertension medications according to the current guildline.
3101612|NCT02060058|Experimental|Patients with 32 week therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is undetectable during 8-24 weeks, boceprevir+PEG-IFN/RBV triple therapy will be administered from week 5 to week 32.~Dosage of drugs: Boceprevir 800mg tid po, PegIntron 1.5 mcg/kg im QW, and Ribavirin 800 to 1400 mg/day PO divided BID Regimen adjusted according to body weight.~Stop trial intervention for patients with 32 week therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm A)."
3101613|NCT02060058|Experimental|Patients with 48 weeks therapy|"For non-cirrhotic patients whose response of previous HCV therapy with PEG-IFN/RBV were relapse or partial response, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 (boceprevir+ PEG-IFN/RBV). If HCV RNA is detectable at week 8 and undetectable at week 24, boceprevir+ PEG-IFN/RBV triple therapy will be administered from week 5 to week 32, followed by additional 12 weeks of PEG-IFN/RBV therapy.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for patients with 48 weeks therapy: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm B)."
3101614|NCT02060058|Experimental|Null responder or cirrhotic patients|"For null responder or cirrhotic patients, PEG-IFN/RBV lead-in therapy is performed during 0-4 weeks, then add boceprevir from week 5 to 48.~Dosage of drugs: as Patients with 32 week therapy Stop trial intervention for for null responder or cirrhotic patients: for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped (Stop trial intervention for boceprevir, PEG-IFN and RBV for arm C)."
3101615|NCT02060370|Experimental|Sunitinib|"Sunitinib starting dose 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
3101616|NCT02060383|Experimental|Incretin based therapy (randomized group)|Participants randomized to the incretin based arm started with sitagliptin once daily. If sitagliptin did not control the participant's hyperglycemia, sitagliptin was stopped and participants switched to liraglutide once daily. If despite treatment with liraglutide, hyperglycemia was not controlled then the participant was eligible for rescue therapy with addition of insulin.
3101617|NCT02060383|Experimental|Insulin (randomized group)|Participants randomized to the insulin arm started with once daily dose of basal insulin. The dose was up or down titrated at the discretion of the investigator. If blood glucose levels remained uncontrolled on basal insulin, participant switched to basal insulin plus prandial insulin.
3101618|NCT02060383|Other|Non-Randomized Arm|"This arm represents the non-randomized participants: Cushing's Disease (CD) or Acromegaly participants, who received pasireotide s.c. or LAR (long-acting release) respectively, but who were not randomized to the Incretin or Insulin arms.~For the purpose of analysis, this non-randomized arm is further split into 3 groups:~Baseline insulin group (BL insulin) includes participants who were receiving insulin at study entry~Oral antidiabetic drugs (OAD) group includes participants who developed hyperglycemia that was controlled by metformin and/or other background anti-diabetic treatment~No OAD group includes participants who did not receive any anti-diabetic medication during the core phase of the trial"
3101619|NCT02060461|Experimental|FS200 femtosecond laser LASIK|LASIK flap created with an FS200 femtosecond laser system
3101620|NCT02060461|Experimental|IntraLase femtosecond laser LASIK|LASIK flap created with an IntraLase femtosecond laser system
3101621|NCT02060526|Active Comparator|45 mg Q2W|rhHNS 45 mg administered intrathecally Q2W (once every 2 weeks ie, every 14 days), for 48 weeks via the surgically implanted IDDD (or LP)
3101622|NCT02060526|Active Comparator|45 mg Q4W|rhHNS 45 mg administered intrathecally Q4W (once every 4 weeks ie, every 28 days), for 48 weeks via the surgically implanted IDDD (or LP)
3101623|NCT02060526|Placebo Comparator|Placebo|The comparator group will receive no treatment with rhHNS.
3101624|NCT02060539|Experimental|Biofinity XR|Participants dispensed Biofinity XR lenses over two weeks of lens wear
3101625|NCT02060838||Acute normovolemic hemodilution (ANH)|Patients undergoing acute normovolemic hemodilution (ANH) as part of their cardiac surgery.
3101626|NCT02060890||Group A|Patients will undergo collection of tumor at the time of tumor resection and after confirmation of tumor progression and will have blood samples drawn pre-surgery and during standard of care follow-up visits. Patients will then be provided with a specialized tumor board recommendations for personalized treatment options for up to 4 medications based on the specimen analysis results within 35 days of surgery. Patients may then elect to initiate recommended therapy within 42 days of surgery.
3101627|NCT02060903|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
3101628|NCT02060903|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to hair and scalp for 10 minutes. Applied at home by a subject/caregiver.
3101629|NCT02061202|Experimental|Mometasone Furoate|1 puff daily (220mcg) for 16 weeks
3101630|NCT02061202|Placebo Comparator|Placebo|1 puff daily for 16 weeks. Training inhaler that does not contain any medication (placebo).
3101631|NCT02061280|Experimental|MICT Trial Design|"Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily"
3101632|NCT02061280|Active Comparator|LASST Trial Design|"Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.~Randomized to one of 3 study treatments:~fluticasone/salmeterol 250/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone/salmeterol 100/50 Dry Powder Inhaler one inhalation twice daily, or fluticasone 100mcg Dry Powder Inhaler one inhalation twice daily."
3101633|NCT02061358|Experimental|Cohort 1 - 3 mg UV-4B|Subjects receiving UV-4B 3 mg oral solution or placebo
3101634|NCT02061358|Experimental|Cohort 2 - 10 mg UV-4B|Subjects receiving UV-4B 10 mg oral solution or placebo
3101635|NCT02061358|Experimental|Cohort 3- 30 mg UV-4B|Subjects receiving UV-4B 30 mg oral solution or placebo
3101636|NCT02061358|Experimental|Cohort 4 - 90 mg UV-4B|Subjects receiving UV-4B 90 mg oral solution or placebo
3101637|NCT02061358|Experimental|Cohort 5 - 180 mg UV-4B|Subjects receiving UV-4B 180 mg oral solution or placebo
3101638|NCT02061358|Experimental|Cohort 6 - 360 mg UV-4B|Subjects receiving UV-4B 360 mg oral solution or placebo
3101639|NCT02061358|Experimental|Cohort 7 - 720 mg UV-4B|Subjects receiving UV-4B 720 mg oral solution or placebo
3101640|NCT02061358|Experimental|Cohort 8 - 1000 mg UV-4B|Subjects receiving UV-4B 1000 mg oral solution or placebo
3101641|NCT02061384|Experimental|13-cis retinoic acid|20mg 13-cis retinoic acid twice daily (BID) with meals for 20 weeks
3101642|NCT02061384|Experimental|Calcitriol 0.25 mcg|oral calcitriol 025 mcg BID subjects 11-20 for 20 weeks
3101643|NCT02061397|Experimental|simvastatin treatment arm|Eligible patients on sirolimus or everolimus will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
3101644|NCT02061540|Experimental|LUM001|LUM001 administered orally once each day
3101645|NCT02061592|Active Comparator|Etafilcon A Control Lens|etafilcon A
3101646|NCT02061592|Experimental|Etafilcon A Test Lens|etafilcon A
3101647|NCT02061683|Experimental|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
3101648|NCT02061696|Active Comparator|Standard Manual Compression|Standard manual compression at the access site applied as per standard of care protocol for sheath removal.
3101649|NCT02061696|Active Comparator|AXERA 2 Access System|The Vascular Access device used is the AXERA 2 Access System for patients randomized to this arm.
3101650|NCT02061748||dabigatran|
3101651|NCT02061748||warfarin|
3101652|NCT02061774|Active Comparator|acetaminophen|1g intravenous acetaminophen over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours; maximum dose of 4 grams in 24 hours
3101653|NCT02061774|Placebo Comparator|PlaceboComparator|Placebo Comparator 0.9% NaCl 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
3101654|NCT02061813|Experimental|Abametapir lotion 0.74% w/w|Applied 0.2 mL topically under occlusive condition
3101655|NCT02061813|Placebo Comparator|Vehicle lotion|Applied 0.2 mL topically under occlusive condition
3101656|NCT02061813|Other|Sodium Lauryl Sulfate|Positive control applied 0.2 mL topically under occlusive condition
3101657|NCT02061813|Other|Saline 0.9%|Negative control applied 0.2 mL topically under occlusive condition
3101658|NCT02061969|Active Comparator|Insulin glargine|Insulin glargine starting at 0.1 unit/kg/day added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
3101659|NCT02061969|Experimental|linagliptin|Oral linagliptin 5mg once daily added to ongoing metformin if the patient is already on it. The duration will be for a 6-month period.
3101660|NCT02062008|Other|Cardiac patients receiving PET/MR|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
3101661|NCT02062151|Experimental|NAS babies|Acupuncture for NAS
3101662|NCT02062177|Experimental|propofol group|70 patients (35 upper endoscopy - 35 colonoscopy)
3101663|NCT02062177|Active Comparator|midazolam group|70 patients (35 upper endoscopy - 35 colonoscopy)
3101664|NCT02062294||Cohort|
3101665|NCT02062359|Experimental|All Participants|Patients will receive the standard National Cancer Institute (NCI) Surgery Branch non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of the anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ engineered peripheral blood lymphocyte (PBL) and aldesleukin
3101666|NCT02062385|Experimental|V260 with staggered EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered China Expanded Program on Immunizations (EPI) as follows: Oral poliovirus vaccine (OPV) administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and diphtheria, tetanus, acellular pertussis vaccine (DTaP) administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
3101667|NCT02062385|Placebo Comparator|Placebo with staggered EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and staggered EPI as follows: OPV administered as a 1 g oral solution at age ~2.5, 3.5, and 4.5 months, and DTaP administered as a 0.5 mL intramuscular injection at age ~3.5, 4.5, and 5.5 months
3101668|NCT02062385|Experimental|V260 with concomitant EPI|V260 administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
3101669|NCT02062385|Placebo Comparator|Placebo with concomitant EPI|Placebo administered as a 2 mL oral solution at age ~2, 3, and 4 months, and concomitant EPI as follows: OPV administered as a 1 g oral solution at age ~2, 3, and 4 months and DTaP administered as a 0.5 mL intramuscular injection at age ~3, 4, and 5 months
3101670|NCT02062398|Experimental|The Reprieve system implantation|The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations.
3101671|NCT02062437||Total hip replacement using a ceramic friction pair|Patients treated with total hip replacement using a ceramic friction pair Biolox® Delta, with Meije Duo® stem associated with Dynacup® cup
3101672|NCT02062450||Primary surgery with Dual Mobility Cup|Patients having a Primary Hip acetabular replacement, using a Dual Mobility Cup.
3101673|NCT02062450||Revision surgery with Dual Mobility Cup|Patients having a Revision Hip acetabular replacement, using a Dual Mobility Cup.
3101674|NCT02062502|Experimental|VARIVAX™ NSP + M-M-R II™|VARIVAX™ New Seed Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
3101675|NCT02062502|Active Comparator|VARIVAX™ 2007 Process + M-M-R II™|VARIVAX™ 2007 Process 0.5 mL administered in the left arm and M-M-R II™ vaccine 0.5 mL administered in the right arm by subcutaneous injection on Day 1 and Day 91
3101676|NCT02062580|Active Comparator|Delayed BCG|BCG delayed to 8 weeks of age
3101677|NCT02062580|Other|Early BCG|BCG at birth; standard of care
3101678|NCT02062593|Active Comparator|Coronary angioplasty and optimum medical therapy|Percutaneous coronary intervention and optimal medical therapy
3101679|NCT02062593|Placebo Comparator|Sham procedure and optimum medical therapy|Placebo percutaneous coronary intervention and optimal medical therapy with risk factor modification and anti-anginal therapy
3101680|NCT02062606||AIS|Surgical implantation of the K2M MESA Rail™ Deformity System in the treatment of Adolescent Idiopathic Scoliosis (AIS).
3101681|NCT02062632|Experimental|Group I (doxepin hydrochloride)|Patients receive doxepin hydrochloride oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm II on day 3.
3101682|NCT02062632|Placebo Comparator|Group II (placebo)|Patients receive placebo oral solution (swish, gargle for 30 seconds, and slowly swallow) on day 1. Patients then crossover to Arm I on day 3.
3101683|NCT02062645|Experimental|amlodipine/valsartan|All patients will receive amlodipine/valsartan 5/160 mg daily in screening and up titrated to amlodipine/valsartan 10/160 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks.
3101684|NCT02062658|Experimental|Ketamine, Exposure & Response Prevention|0.5mg/kg IV Ketamine infusion followed by condensed course of Exposure and Response Prevention (EX/RP)
3101685|NCT02062710|Experimental|A, B, then C|"Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
3101686|NCT02062710|Experimental|A, C, then B|"Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period."
3101687|NCT02062710|Experimental|B, A, then C|Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3101688|NCT02062710|Experimental|B, C, then A|"Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).~Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period."
3101689|NCT02062710|Experimental|C, A, then B|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3101690|NCT02062710|Experimental|C, B, then A|Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.
3101691|NCT02062801|Active Comparator|Prophylactic ephedrine|Ephedrine 10mg iv once at time of combined spinal epidural insertion
3101692|NCT02062801|Placebo Comparator|Normal saline (placebo) control group|1ml normal saline intravenously once at time of combined spinal epidural insertion
3101693|NCT02062879|Experimental|Ketamine|Ketamine 90mg/30 mL PCA (3 mg/mL)
3101694|NCT02062879|Active Comparator|Hydromorphone|Hydromorphone 6mg/30 mL PCA (0.2 mg/mL)
3101695|NCT02062905|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3101696|NCT02062905|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3101697|NCT02063035|Experimental|Tranexamic acid|Participants undergoing spinal surgery will receive a single, topical dose of tranexamic acid. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
3101698|NCT02063035|Placebo Comparator|Placebo|Participants undergoing spinal surgery will receive a single, topical dose of matching placebo. The surgeon will irrigate the study medication in the wound prior to closure, and aspirate it after five minutes. Drains will be placed after the study drug has been aspirated.
3101699|NCT02063087|Active Comparator|Decision Aid|Head CT Decision Aid
3101700|NCT02063087|No Intervention|Usual Care|Clinicians and patients do not have access to the Head CT Decision Aid
3101701|NCT02063178|Experimental|Counselor-Initiated|Participants will receive 28 telephone sessions over a 12 month period by interventionists trained in behavior change skills and motivational interviewing techniques. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be encouraged to replace 2 meals and a snack with meal replacements (provided). Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week. The Toolbox includes additional treatment options (e.g., food scales, exercise videos, cookbooks) for those who wish to take advantage of them. There will be several challenges that will provide a specific goal (e.g. increase self-monitoring), with a small award for completion.
3101702|NCT02063178|Active Comparator|Self-Paced|The Self-paced group uses a less intense approach, where the participants can receive the same telephone counseling sessions as the counselor-initiated group, only if they call the counselor. Participants will be asked to monitor food intake and physical activity using the LoseIt website/app and weight daily using a Body Trace e-scale. Participants will receive feedback on self-monitoring through e-mail only upon request. Dietary goals will be based on weight and participants' weight-loss progress. Participants will be asked to gradually increase their moderate to vigorous exercise to 225-250 minutes per week.
3101703|NCT02063217|Experimental|Sleep Induction|7.5 grams of sodium oxybate
3101704|NCT02063217|Experimental|Sleep Deprivation|Sleep deprivation for up to 36 hours with no naps or other sleep periods
3101705|NCT02063217|No Intervention|Control|Participant will sleep as normal under the same controlled conditions in a clinical research unit
3101706|NCT02063230|Experimental|Selumetinib HV|Healthy volunteers (HV)
3101707|NCT02063230|Experimental|Selumetinib mild impairment|Mild (Child Pugh A) hepatic impaired patients
3101708|NCT02063230|Experimental|Selumetinib moderate impairment|Moderate (Child Pugh B) hepatic impaired patients
3101709|NCT02063230|Experimental|Selumetinib severe impairment|Severe (Child Pugh C) hepatic impairment patients
3101710|NCT02063516|Experimental|Guardian|Device: Guardian Laryngeal Mask
3101711|NCT02063516|Experimental|Proseal|Device:Proseal Laryngeal Mask Airway
3101712|NCT02063659|Experimental|250 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
3101713|NCT02063659|Experimental|500 mg Telotristat Etiprate|Following a 3 to 4-week run-in period, participants were randomized to receive one 250 mg telotristat etiprate tablet and one placebo-matching telotristat etiprate tablet administered three times daily for one week, followed by two 250 mg telotristat etiprate tablets administered three times daily for 11 weeks in the 12 week double-blind treatment period, followed by a 36 week open-label extension period.
3101714|NCT02063659|Placebo Comparator|Placebo|Following a 3 to 4-week run-in period, participants were randomized to receive two placebo-matching telotristat etiprate tablets administered three times daily for 12 weeks, followed by a 36 week open-label extension period.
3101715|NCT02063672|Experimental|Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3101716|NCT02063672|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
3101717|NCT02063698|Experimental|Arm I (auranofin)|Patients receive auranofin PO on day 2.
3101718|NCT02063698|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on day 2.
3101719|NCT02063724|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
3101720|NCT02063737|Sham Comparator|Control Group|The control group will receive text-message assessments only at the start, during, and end of shift. These queries will attempt to capture the worker's self-reported sleepiness, fatigue, and occurrence of work-related injury during shift work.
3101721|NCT02063737|Experimental|Intervention Group|The intervention group will receive the same text-message assessments as the control group. In addition, these subjects will receive text-message interventions for high level fatigue for reducing fatigue and sleepiness during shift work if they report a high-level of fatigue or sleepiness at the start or during their shift. These subjects will then receive additional text message queries at the end of their shifts to determine if they adopted a strategy for reducing perceived sleepiness or fatigue.
3101722|NCT02063828|Experimental|Group A|Group A - Device Guided Breathing Low Dose
3101723|NCT02063828|Experimental|Group B|Group B - Device guided breathing high dose
3101724|NCT02063828|Sham Comparator|Group C|Group C - Usual Breathing Control Group
3101725|NCT02063854|Active Comparator|NE-58095 IR 2.5 mg Once Daily on Awakening|NE-58095 immediate release (IR) 2.5 mg tablet, orally, once, daily, at time of wakening + NE-58095 delayed release (DR) placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101726|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly on Awakening|NE-58095 DR 25 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101727|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly Following Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101728|NCT02063854|Experimental|NE-58095 DR 25 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 25 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101729|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly on Awakening|NE-58095 DR 37.5 mg tablet, orally, once, monthly, at time of wakening + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101730|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly Following Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101731|NCT02063854|Experimental|NE-58095 DR 37.5 mg Once Monthly 30 Min. After Breakfast|NE-58095 DR 37.5 mg tablet, orally, once, monthly, 30 minutes after breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, following breakfast + NE-58095 DR placebo-matching tablet, orally, once, monthly, at time of wakening + NE-58095 IR placebo-matching tablet, orally, once, daily, at time of wakening, for up to 12 months. Calcium lactate hydrate 195 mg, once, daily, after dinner was taken as a background medication.
3101732|NCT02063867|No Intervention|Arm 1: Usual Care|Routine policy for showering or bathing non-critical care patients
3101733|NCT02063867|Active Comparator|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
3101734|NCT02063880|Experimental|Urgent ART|"Initiation of highly active antiretroviral therapy (HAART) within 48 hours of enrollment.~Antiretroviral therapy will include regimens recommended by the Kenyan Ministry of Health."
3101735|NCT02063880|Active Comparator|Early ART|Initiation of HAART 7-14 days after enrollment.
3101736|NCT02063984|Experimental|Intensive Outpatient Treatment (IOP) + Contingency Management (CM) + Working Memory Training (WMT)|IOP + CM + WMT
3101737|NCT02063984|Active Comparator|IOP + CM|IOP + CM
3101738|NCT02064166|Experimental|Insulin|40 IU of intranasal insulin daily
3101739|NCT02064166|Placebo Comparator|Placebo|Placebo arm using intranasal normal saline
3101740|NCT02064205|Active Comparator|polydextrose or glucose syrup at breakfast|Breakfast with pre-load four hours before lunch
3101741|NCT02064205|Placebo Comparator|Pre-load with yogurt and polydextrose or glucose later|Breakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
3101742|NCT02064231|Experimental|Coloplast Test A, Coloplast Test B, Own product|The subjects first test Coloplast Test A and thereafter Coloplast Test B and finally their own product for 14 days
3101743|NCT02064231|Experimental|Coloplast Test C , Coloplast Test D, Own product|The subjects first test Coloplast Test C and thereafter Coloplast Test D and finally their own product for 14 days
3101744|NCT02064270|Active Comparator|Negative Pressure Wound Therapy|Single-Use Negative Pressure Wound Therapy (NPWT)
3101745|NCT02064270|Active Comparator|Standard dressings|Standard postsurgical dressings
3469090|NCT03889691||Study group|Participants in the study group asked to watch impacted lower third molar extraction video which was previously uploaded to the internet with their own device. This video includes only visual components of the surgery such as anesthesia, incision, extraction and suturing. Patients in the second group were also informed verbally about the surgical procedure-possible postoperative complications and was given with a written informed consent document.
3469091|NCT03889873|Experimental|Drinking; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
3101750|NCT02064439|Experimental|Arm 1|Rivaroxaban 10 mg once daily for 12 months
3101751|NCT02064439|Experimental|Arm 2|Rivaroxaban 20 mg once daily for 12 months
3101752|NCT02064439|Active Comparator|Arm 3|ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months
3101753|NCT02064582|Other|Enzalutamide, Leuprolide, radiation|Single arm Enzalutamide 160 mg daily for 6 months Leuprolide acetate 22.5mg every 3 months or 45mg every 6 months Radiation therapy as standard of care
3101754|NCT02064816|Experimental|Rebif® Morning Administration|
3101755|NCT02064816|Experimental|Rebif® Evening Administration|
3101756|NCT02064868|Experimental|Serelaxin + Standard of Care|Serelaxin (30 µg/kg/day) as continuous 48 hour intravenous infusion plus standard of care.
3101757|NCT02064868|Other|Standard of Care (SOC)|All patients were required to receive standard of care background heart failure (HF) management during the study, according to local guidelines/international standards. This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
3101758|NCT02064894|Experimental|oral morphine and oral ibuprofen|Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame
3101759|NCT02064894|Experimental|morphine and placebo of ibuprofen|Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study
3101760|NCT02064894|Active Comparator|ibuprofen and placebo of morphine|Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study
3101761|NCT02064907|Experimental|Dexlansoprazole OD Tablets + Dexlansoprazole Capsules|Two Dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by one dexlansoprazole 60 mg, capsule, orally, once daily for 5 days in Period 2.
3101762|NCT02064907|Experimental|Dexlansoprazole Capsules + Dexlansoprazole OD|Dexlansoprazole 60 mg, capsules, orally, once daily for 5 days in Period 1, followed by a 7 day washout period, followed by two dexlansoprazole 30 mg, delayed-release orally disintegrating tablets, orally, once daily for 5 days in Period 2.
3101763|NCT02064920|Placebo Comparator|Placebo|Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.
3101764|NCT02064920|Experimental|Donepezil|During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.
3101765|NCT02064959|Experimental|Hypothermia|Hypothermia to 33°C
3101766|NCT02064959|Active Comparator|Normothermia|standard care - normothermia (37°C)
3101767|NCT02064985|Experimental|Ticagrelor 45mg|A single dose of ticagrelor 45 mg on Day 1 followed by 45 mg twice daily (bid) on Days 3-6 and a 45mg single dose on Day 7.
3101768|NCT02064985|Experimental|Ticagrelor 60mg|A single dose of ticagrelor 60 mg on Day 1 followed by 60 mg twice daily (bid) on Days 3-6 and a 60mg single dose on Day 7.
3101769|NCT02064985|Experimental|Ticagrelor 90mg|A single dose of ticagrelor 90 mg on Day 1 followed by 90 mg twice daily (bid) on Days 3-6 and a 90mg single dose on Day 7.
3101770|NCT02065245|Experimental|Pilot phase - Group 1|Group 1 participants will receive Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 20 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
3101771|NCT02065245|Experimental|Pilot Phase - Group 2|Group 2 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
3101772|NCT02065245|Experimental|Pilot Phase - Group 3|Group 3 - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
3101773|NCT02065245|Experimental|Randomized Phase - Group A|Group A - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
3101774|NCT02065245|Experimental|Randomized phase - Group B|Group B - Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 200 million allo-hMSCs/kg delivered via peripheral intravenous infusion.
3101775|NCT02065245|Experimental|Randomized Phase - Group C|Group C - Placebo delivered via peripheral intravenous infusion. Participants in this group have the option to receive one additional infusion of 100million allo-hMSCs/kg with a 12 to 18 month interval.
3101776|NCT02065245|Experimental|Addendum B - Antibiotic free cell Group|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs): 100 million penicillin/streptomycin-free allo-hMSCs/kg delivered via peripheral intravenous infusion. Participants in this group have the option to receive an additional 3 infusions of 100million allo-hMSCs/kg per infusion with a 12 to 18 month interval.
3101777|NCT02065336|Experimental|ARC-520 Cohort 1|a single intravenous (IV) dose of double-blind ARC-520 Injection 1.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
3101778|NCT02065336|Placebo Comparator|ARC-520 Cohort 2|a single IV dose of double-blind ARC-520 Injection 2.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
3101779|NCT02065336|Experimental|ARC-520 Cohort 3|a single IV dose of double-blind ARC-520 Injection 3.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
3101780|NCT02065336|Experimental|ARC-520 Cohort 4|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-negative immune active chronic HBV infection
3101781|NCT02065336|Experimental|ARC-520 Cohort 5|a single IV dose of double-blind ARC-520 Injection 4.0 mg/kg in combination with entecavir administered to participants with HBeAg-positive immune active chronic HBV infection
3101782|NCT02065336|Experimental|Placebo Normal Saline Cohorts 1-5|a single IV dose of double-blind normal saline in combination with entecavir administered to participants with HBeAg-negative or -positive immune active chronic HBV infection
3101783|NCT02065336|Experimental|ARC-520 Cohort 6|two IV doses of open-label ARC-520 2.0 mg/kg administered to participants with HBeAg-positive immune active chronic HBV
3101784|NCT02065336|Experimental|ARC-520 Cohort 7|a single IV dose of open-label ARC-520 4.0 mg/kg administered to treatment-naïve, HBeAg-negative or -positive participants with chronic hepatitis B (CHB)
3101785|NCT02065336|Experimental|ARC-520 Cohort 8|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg every [Q]4 weeks) administered to HBeAg-negative participants with CHB receiving chronic entecavir therapy who completed Cohorts 1 through 4
3101786|NCT02065336|Experimental|ARC-520 Cohort 9|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q6 weeks or Q8 weeks) administered to HBeAg-positive participants with CHB receiving chronic entecavir therapy who completed Cohorts 5 or 6
3101787|NCT02065336|Experimental|ARC-520 Cohort 10|open-label multi-dose extension cohort: multiple IV doses of open-label ARC-520 (4.0 mg/kg Q4 weeks) administered to a mixed cohort (HBeAg-negative and -positive participants) who were naïve (within the last 6 months) to entecavir treatment and completed Cohort 7
3101788|NCT02065336|Experimental|ARC-520 Cohort 11|a single IV dose of open-label ARC-520 5.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
3101789|NCT02065336|Experimental|ARC-520 Cohort 12|a single IV dose of open-label ARC-520 6.0 mg/kg administered to treatment-naïve, HBeAg-positive participants with CHB
3101790|NCT02065453|Other|Disposable Device - Left & Reusable Devices - Right|One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien).
3101791|NCT02065453|Other|Disposable Device - Right & Reusable Devices - Left|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
3101792|NCT02065479|Active Comparator|Ticagrelor|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
3101793|NCT02065479|Experimental|Prasugrel|The primary endpoint is the non-inferiority in platelet reactivity of prasugrel versus ticagrelor among CYP2C19 loss of function allele carriers.
3101794|NCT02065518|Active Comparator|Standard Rehabilitation Protocol (SRP)|All participants will receive the current standard of care, the physical therapy rehabilitation protocol for knee injuries at the WRNMMC and MGMCSC sites. This program includes treatment supervised by a physical therapist at the physical therapy clinics.
3101795|NCT02065518|Experimental|NMES w/ SRP|In addition to the standard rehabilitation protocol, two treatment groups will receive a portable lightweight device (300PV unit) that provides clearly defined electrical stimuli. NMES training will consist of performing four 30-minute stimulation sessions per week for 12 weeks; each 30-minute session will entail 15 minutes/leg with 15 contractions per leg. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device (EMPI, St. Paul, MN).
3101796|NCT02065518|Experimental|Strength Walking w/ SRP|The Strength Walking groups will participate in a Home-Based Pedometer-Driven Walking Program. All participants in this group will be given a pedometer to monitor their daily steps and, at week 7, a weighted exercise vest to begin the strengthening component. In addition to the standard WRNMMC rehabilitation protocol, a series of 10-minute lessons focused on increasing physical activity through lifestyle education and the use of a pedometer as a motivational tool and personal fitness tracker will be incorporated into their testing sessions for the first 6 weeks. At week 7, participants will be given a weighted vest to begin the strengthening component.
3101797|NCT02065518|Experimental|NMES/Strength Walking w/ SRP|In addition to the standard rehabilitation protocol, one group will receive NMES training and will participate in a Home-Based Pedometer-Driven Walking Program. This group will follow the protocol for both the NMES training and Strength Walking.
3101798|NCT02065557|Experimental|Adalimumab Induction Standard Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and matching placebo at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
3101799|NCT02065557|Experimental|Adalimumab Induction High Dose|Participants randomized to receive adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
3101800|NCT02065557|Experimental|Adalimumab Induction High Dose - Open Label|(After Amendment 4) participants assigned to open-label adalimumab 2.4 mg/kg (maximum dose of 160 mg) at Baseline and at Week 1, 1.2 mg/kg (maximum dose of 80 mg) at Week 2, followed by 0.6 mg/kg (maximum dose of 40 mg) at Week 4 and Week 6.
3101801|NCT02065557|Placebo Comparator|Maintenance Placebo|(Prior to Amendment 4) participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to maintenance placebo. Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after the second flare.
3101802|NCT02065557|Experimental|Adalimumab Maintenance Standard Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance standard dose (0.6 mg/kg [maximum dose of 40 mg] every other week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
3101803|NCT02065557|Experimental|Adalimumab Maintenance High Dose|Participants demonstrating a clinical response per PMS (defined as a decrease in PMS ≥ 2 points and ≥ 30% from Baseline) at Week 8 randomized to adalimumab maintenance high dose (0.6 mg/kg [maximum dose of 40 mg] every week). Participants were to continue their blinded treatment during the maintenance period until Week 52 unless they had ≥ 2 flares and got open label rescue therapy after second flare.
3101804|NCT02065570|Experimental|Induction: Standard Induction Dose|Participants randomized to receive received blinded adalimumab 160 mg at Baseline and matching placebo at Week 1, adalimumab 80 mg and matching placebo at Week 2, matching placebo at Week 3, and then adalimumab 40 mg every other week (eow) starting at Week 4 through Week 12.
3101805|NCT02065570|Experimental|Induction: Higher Induction Dose|Participants randomized to receive blinded adalimumab 160 mg at Baseline, Week 1, Week 2, and Week 3. At Week 4, participants receive adalimumab 40 mg eow through Week 12.
3101806|NCT02065570|Experimental|Maintenance: Clinically Adjusted (CA) Regimen|Participants randomized to the CA regimen receive adalimumab 40 mg eow beginning at Week 12. The adalimumab dose will be escalated to every week (ew) starting as early as Week 14 and up to Week 54 based on Crohn's Disease Activity Index (CDAI) or high-sensitivity C-reactive protein (hs-CRP) values, using results from the prior or current study visit. Once participants in the CA regimen are escalated, they remain on adalimumab 40 mg ew dosing.
3101807|NCT02065570|Experimental|Maintenance: Therapeutic Drug Monitoring (TDM) Regimen|At Weeks 14, 28 and 42, the adalimumab dose for participants randomized to the TDM will be determined by protocol-established dose adjustment criteria. Doses will be determined using blinded serum concentrations at the prior visit (Weeks 12, 26 and 40, respectively) as well as the CDAI or hs-CRP values from the current or prior study visit. Participants who meet criteria for dose escalation at Weeks 14, 28 or 42 will receive 40 mg ew.
3101808|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-SD|Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.
3101809|NCT02065622|Experimental|Induction (Main Study + Japan Sub-study): I-HD|Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.
3101810|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-SD|Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.
3101811|NCT02065622|Experimental|Maintenance (Main Study + Japan Sub-study): M-HD|Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.
3101812|NCT02065622|Experimental|Maintenance (Main Study): TDM Regimen|Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.
3101813|NCT02065687|Experimental|Arm I (paclitaxel, carboplatin, metformin hydrochloride)|"Patients receive paclitaxel IV over 3 hours on day 1, carboplatin IV over 30 minutes on day 1, and metformin hydrochloride PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising metformin hydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
3101814|NCT02065687|Active Comparator|Arm II (paclitaxel, carboplatin, placebo)|"Patients receive paclitaxel IV and carboplatin IV as in Arm I. Patients also receive placebo PO BID (approximately every 10-12 hours apart) on days 1-21 (QD in course 1). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising placebo PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~In both arms, patients who achieve SD or PR and still have measurable disease at the completion of course 6 may continue to receive paclitaxel IV and carboplatin IV (with metformin hydrochloride or placebo) for an additional 4 courses at the discretion of the treating investigator."
3101815|NCT02065713|Experimental|Golimumab in combination with methotrexate|"Golimumab 50mg, subcutaneous, once monthly, for 24 weeks, in combination with MTX.~MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity"
3101816|NCT02065713|Active Comparator|Placebo in combination with methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity.
3101817|NCT02065791|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily
3101818|NCT02065791|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily
3101819|NCT02065895|Experimental|HIGH error, LOW error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control equal blood glucose (NO error).
3101820|NCT02065895|Experimental|HIGH error, NO error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control higher than blood glucose (HIGH error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
3101821|NCT02065895|Experimental|NO error, HIGH error, LOW error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-values-used-for-control higher than blood glucose (HIGH error), then third with glucose-value-used-for-control lower than blood glucose (LOW error).
3101822|NCT02065895|Experimental|NO error, LOW error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control equal blood glucose (NO error), then second with glucose-value-used-for-control lower than blood glucose (LOW error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
3101823|NCT02065895|Experimental|LOW error, NO error, HIGH error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third with glucose-value-used-for-control higher than blood glucose (HIGH error).
3101824|NCT02065895|Experimental|LOW error, HIGH error, NO error|Subjects were randomized to receive overnight and breakfast closed-loop glucose control glucose on three occasions: first with glucose-value-used-for-control lower than blood glucose (LOW error), then second with glucose-value-used-for-control equal blood glucose (NO error), then third glucose-value-used-for-control higher than blood glucose (HIGH error),
3101825|NCT02066051|Experimental|IPL Treatment|Subjects who had inactive chronic graft versus host disease (GVHD) after allogeneic bone marrow transplantation and severe dry eye symptoms related to ocular rosacea unresponsive to conventional management were recruited. Subjects were treated with 4 monthly sessions of intense pulsed light (IPL) and meibomian gland expression.
3101826|NCT02066129|Active Comparator|Fluticasone 44 mcg|"Fluticasone 44 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
3101827|NCT02066129|Active Comparator|Fluticasone 220 mcg|"Fluticasone 220 mcg 2 puffs twice daily for 7 days initiated at the onset of yellow zone symptoms."
3101830|NCT02066233|Active Comparator|Subjects with Barrett's Esophagus|All subjects will receive transnasal endoscopy (EG Scan II) followed by standard endoscopy.
3101831|NCT02066233|Active Comparator|Subjects with Reflux and/or Heartburn|All subjects will receive EG Scan II (transnasal endoscopy) followed by standard endoscopy.
3101832|NCT02066298|Experimental|Mometasone then Tiotropium then Placebo|Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD, followed by Placebo
3101833|NCT02066298|Experimental|Mometasone then Placebo then Tiotropium|Mometasone 220mcg BID, followed by Placebo, followed by Tiotropium Respimat 5mcg QD
3101834|NCT02066298|Experimental|Placebo then Mometasone then Tiotropium|Placebo, followed by Mometasone 220mcg BID, followed by Tiotropium Respimat 5mcg QD
3101835|NCT02066298|Experimental|Placebo then Tiotropium then Mometasone|Placebo, followed by Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID
3101836|NCT02066298|Experimental|Tiotropium then Placebo then Mometasone|Tiotropium Respimat 5mcg QD, followed by Placebo, followed by Mometasone 220mcg BID
3101837|NCT02066298|Experimental|Tiotropium then Mometasone then Placebo|Tiotropium Respimat 5mcg QD, followed by Mometasone 220mcg BID, followed by Placebo
3101838|NCT02066311|Experimental|nelfinavir|Nelfinavir tablets will be taken by oral administration, 750mg (three 250 mg tablets) three times a day
3101839|NCT02066389|Placebo Comparator|Placebo|Participants received placebo capsules twice daily for 12 weeks.
3101840|NCT02066389|Experimental|Upadacitinib 3 mg BID|Participants received 3 mg upadacitinib twice daily (BID) for 12 weeks.
3101841|NCT02066389|Experimental|Upadacitinib 6 mg BID|Participants received 6 mg upadacitinib twice daily (BID) for 12 weeks.
3101842|NCT02066389|Experimental|Upadacitinib 12 mg BID|Participants received 12 mg upadacitinib twice daily (BID) for 12 weeks.
3101843|NCT02066389|Experimental|Upadacitinib 18 mg BID|Participants received 18 mg upadacitinib twice daily (BID) for 12 weeks.
3101844|NCT02066389|Experimental|Upadacitinib 24 mg QD|Participants received 24 mg upadacitinib once daily (QD) for 12 weeks.
3101845|NCT02066402|Experimental|Tedizolid Phosphate (Sivextro, BAY119-2631)|Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
3101846|NCT02066402|Active Comparator|Linezolid|Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.
3101847|NCT02066415|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection.
3101848|NCT02066415|Experimental|Erenumab 70 mg|Participants received 70 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
3101849|NCT02066415|Placebo Comparator|Erenumab 140 mg|Participants received 140 mg erenumab on day 1 and at weeks 4 and 8 by subcutaneous injection.
3101850|NCT02066467||Heart failure patients|"Subjects with art failure who receive stable optimal pharmacologic therapy~Moderate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) ≤ 35% and QRS duration ≥ 120 ms~Left bundle branch block (LBBB) with QRS duration ≥ 130 ms, EF ≤ 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.~The study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4® Lead Family' ."
3101851|NCT02066727|Active Comparator|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
3101852|NCT02066727|Placebo Comparator|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
3101853|NCT02066740|Experimental|EverFlex™ stent with Entrust™ delivery system|
3101854|NCT02066792|Experimental|Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs/placebo after the session). The type of pill (i.e. dcs vs. placebo) will be determined after the session.
3101855|NCT02066792|Active Comparator|Pre-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one dcs before and one placebo after the session).
3101856|NCT02066792|Placebo Comparator|Placebo|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one placebo after the session).
3101857|NCT02066792|Active Comparator|Non-Tailored Post-Session DCS|Individuals in this condition will receive 5 weeks of CBT for social anxiety disorder and two pills (i.e. one placebo before and one dcs after the session).
3101858|NCT02066857|Active Comparator|Generic plaster or fiberglass cast group|Patients will be randomized to receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture for 6 weeks.
3101859|NCT02066857|Active Comparator|"Generic off the shelf removable splint group"|"Subjects will be randomized and receive a generic off the shelf removable splint for treatment of non-displaced distal radius fracture for 6 weeks."
3101860|NCT02066896|Sham Comparator|Sham Comparator: Sham Lasertherapy|Sham lasertherapy in parotid, submandibular and sublingual glands for six weeks.
3101861|NCT02066896|Active Comparator|Active Comparator: Lasertherapy|Low level lasertherapy in parotid, submandibular and sublingual glands for six weeks.
3101862|NCT02066922|Experimental|DAILIES TOTAL1|Delefilcon A contact lens randomly assigned to one eye, with narafilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
3101863|NCT02066922|Active Comparator|TRUEYE|Narafilcon A contact lens randomly assigned to one eye, with delefilcon A contact lens in the fellow eye for contralateral wear. Both products worn in a daily wear, daily disposable mode approximately 8 hours a day for approximately 1 week, with spectacles worn over contact lenses if needed to provide acceptable vision.
3101864|NCT02067000||Obstructive Sleep Apnea|
3101865|NCT02067039|Experimental|HIV self-testing|The intervention group of MSM (HIV negative or unaware of HIV status) will receive 4 rapid HIV test kits - 2 oral fluid tests (OraQuick), and 2 finger-stick blood tests (Sure Check). Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period, and men in the intervention arm will be allowed to order additional test kits to replenish the ones they use or give away. At month 12, all HIV-negative or those who are unaware of their HIV status participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a dried blood spot (DBS) specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
3101866|NCT02067039|No Intervention|Information only|All comparison group of MSM (HIV negative or unaware of HIV status) will take a baseline survey. Men in the randomized controlled trial will complete short follow-up surveys at 3-month intervals during the 12-month follow-up period. At month 12, all HIV-negative and unaware of their HIV status comparison arm participants will be sent 1 oral fluid test (OraQuick), 1 finger-stick blood test (Sure Check), and a DBS specimen collection kit to be mailed to Emory University after collecting a blood sample for laboratory testing.
3101867|NCT02067273|Experimental|TMS Intervention for 5 days|Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days
3101868|NCT02067273|Experimental|TMS Intervention for 1 day|Application of Transcranial Magnetic Stimulation (TMS) for 1 day
3101869|NCT02067468|Experimental|HPV test|Women with ASC-US cytology are HPV tested and those HPV positive are refer to Colposcopy
3101870|NCT02067468|Active Comparator|COLPOSCOPY|Women with ASC-US cytology are immediately refer to colposcopy
3101871|NCT02067468|Active Comparator|CYTOLOGY|Women with ASC-US Cytology are follow-up with cytology at 6 and/or 12 months and be referred to colposcopy if any of these cytologies is ASC-US or higher
3101872|NCT02067533|Experimental|flexion position|
3101873|NCT02067533|Experimental|extension position|
3101874|NCT02067585|Experimental|LAGB|Standardized Lipid meals will be served to Laparoscopic adjustable gastric banding patients.
3101875|NCT02067585|Experimental|LRYGB|Standardized Lipid meals will be served to the Laparoscopic Rou-en-Y gastric bypass patients.
3101876|NCT02067585|Experimental|Non-surgical|Standardized Lipid meals will be served to the non-surgical obese patients
3101877|NCT02067663||Mirena Group|Women who have a postplacental Mirena IUD placed. (LNG-IUS)
3101878|NCT02067663||Paragard Group|Women who have a postplacental Paragard IUD placed. (Copper IUD - T380A)
3101879|NCT02067676|Experimental|CJCV1 2 μg / Alum 0 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101880|NCT02067676|Experimental|CJCV1 2 μg / Alum 125 μg (1B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 2 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101881|NCT02067676|Experimental|CJCV1 5 μg / Alum 0 μg (2A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101882|NCT02067676|Experimental|CJCV1 5 μg / Alum 125 μg (2B)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 5 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101883|NCT02067676|Experimental|CJCV1 10 μg / Alum 0 μg (3A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 0 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101884|NCT02067676|Experimental|CJCV1 10 μg / Alum 125 μg (1A)|Two vaccinations (one on Day 0 and one on Day 28) with an intramuscular dose of Capsule-Conjugate Campylobacter Vaccine (CJCV1) equivalent to 10 μg of polysaccharide and 125 μg of Alhydrogel®, aluminum hydroxide adjuvant (Alum)
3101885|NCT02067728|Active Comparator|Usual Care|Usual care is provided to patients in practice groups not undergoing intervention of FNPA tool
3101886|NCT02067728|Experimental|FNPA tool intervention|FNPA tool practice intervention comprising of two components: 1) FNPA assessment which screens for obesigenic behaviors; 2) Brief Action Planning conversation designed to assist the family develop a health behavior change goal based on obesigenic risks on the assessment tool.
3101887|NCT02067858|Other|Stereotactic Radiosurgery|"3 fractions x 20 Gy 4 fractions x 12 Gy~Lesion dependent"
3469092|NCT03889873|Experimental|Drinking; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
3469093|NCT03889873|Experimental|Drinking; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
3101890|NCT02068027|Experimental|Clonidine Gel 0.1%|Clonidine hydrochloride topical gel, 0.1%
3101891|NCT02068027|Placebo Comparator|Placebo|Placebo gel of identical appearance as active treatment
3101892|NCT02068118|No Intervention|Standard care|Standard follow-up, with conventional monitoring involving consultations and monitoring by their general practitioners or referring cardiologists
3101893|NCT02068118|Experimental|Tele-cardiology group|Telecardiology Program
3101894|NCT02068157|Experimental|Treatment (porfimer sodium, image-guided I-PDT)|Patients receive porfimer sodium IV over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2.
3101895|NCT02068222|Experimental|ABT-450/r and ABT-530 plus RBV|ABT-450/r (150 mg/100 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) plus weight-based RBV (dosed 1,000 or 1,200 mg daily divided twice a day) for 12 weeks.
3101896|NCT02068352|Experimental|0.3% OPA-15406|OPA-15406 0.3% ointment was applied topically twice daily (BID) to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
3101897|NCT02068352|Experimental|1% OPA-15406|OPA-15406 1% ointment was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
3101898|NCT02068352|Placebo Comparator|Vehicle Ointment|OPA-15406 1%-matching placebo (vehicle ointment) was applied topically BID to the selected treatment area(s) at approximately 12-hour intervals for 8 weeks.
3101899|NCT02068443|Active Comparator|Alogliptin Alone|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride placebo-matching, tablets, orally, 2 tablets after breakfast and 1 tablet after dinner for 24 weeks.
3101900|NCT02068443|Experimental|Alogliptin + Metformin Hydrochloride QD|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 500 mg QD (250 mg x 2 tablets, once daily), tablets, orally, once, daily, after breakfast and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after dinner for 24 weeks.
3101901|NCT02068443|Active Comparator|Alogliptin + Metformin Hydrochloride BID|Alogliptin 25 mg, tablets, orally, once, daily, after breakfast and metformin hydrochloride 250 mg BID (twice daily), tablets, orally, 1 tablet after breakfast and 1 tablet after dinner and 1 metformin hydrochloride placebo-matching, tablet, orally, once, daily, after breakfast for 24 weeks.
3101902|NCT02068495||Candesartan cilexetil/Amlodipine besilate|8 milligram (mg)/2.5 mg or 8 mg/5 mg, orally, once daily
3101903|NCT02068508||Pioglitazone|Pioglitazone 15 mg to 30 mg, orally, once daily
3101904|NCT02068599|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
3101905|NCT02068599|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
3101906|NCT02068599|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the target knee during the treatment period from day 1 through day 28.
3101907|NCT02068768||Operated Subjects|Subjects scheduled to receive an Avenue® L Interbody Fusion System (LDR Spine) for fusion of the lumbar spine from L2-S1
3101908|NCT02068820|Active Comparator|ISB dye, standard white light|SLN mapping utilizing da Vinci surgical system with Isosulfan Blue (ISB) dye and standard white light imaging.
3101909|NCT02068820|Experimental|ICG dye, FireFly fluorescence imaging|SLN mapping utilizing da Vinci surgical system with ISB dye and standard white light first, and then additionally, Indocyanine Green (ICG) dye and FireFly fluorescence imaging.
3101910|NCT02068846|Active Comparator|Ciprofloxacin|Active treatment twice daily for 28 days
3101911|NCT02068846|Placebo Comparator|Placebo|Placebo treatment twice daily for 28 days
3101912|NCT02068885|Experimental|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
3101913|NCT02068885|Experimental|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
3101914|NCT02068885|Active Comparator|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
3101915|NCT02069015|Experimental|Enhanced discharge|Patient education about hypertension delivered through a touch-screen kiosk at 4 time points in addition to standard discharge.
3101916|NCT02069015|No Intervention|Standard discharge|Standard discharge is patient instruction, instructions for follow-up to primary care and medication/prescription
3469094|NCT03889873|Experimental|Drinking; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as a low-risk drinker and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
3469095|NCT03889873|Experimental|Smartphone; No network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using first-person pronouns.
3101917|NCT02069041|Experimental|Ramucirumab + FOLFOX4|"8 milligram/kilogram (mg/kg) ramucirumab given intravenously (IV) on Day 1 followed by FOLFOX4 (folinic acid + fluorouracil + oxaliplatin chemotherapy regimen) given IV on Day 1 of 2 week cycles:~FOLFOX4 every 2 weeks:~85 milligram per square meter (mg/m²) oxaliplatin IV on Day 1 200 mg/m² folinic acid(FA) IV on days 1 and 2 400 mg/m² 5-FU bolus on days 1 and 2 600 mg/m2 5-FU 22-h continuous infusion on Days 1 and 2~Participants may continue to receive treatment until discontinuation criteria are met."
3101918|NCT02069093|Experimental|Dexamethasone based mouthwash|Participants swished and spat 10mL of 0.5mg/5mL dexamethasone steroid mouthwash (investigational treatment) 4 times daily (qid) orally for 2 minutes each for 8 weeks. Participants remained without food or drink (NPO) for one hour after administration of the mouthwash. Also, participants received everolimus 10 mg and exemstane 25 mg (study treatments) according to local regulations.
3101919|NCT02069119|Experimental|OPC-108459|OPC-108459 solution will be intravenously administered by 30-minute infusion in the forearm.
3101920|NCT02069119|Placebo Comparator|Placebo|placebo solution will be intravenously administered by 30-minute infusion in the forearm.
3101921|NCT02069184|Experimental|IV Acetaminophen|IV form, total of 4 doses (each 1000 mg), each every 6th hourly to a maximum dose of 4000 mg in 24 hours.
3101922|NCT02069184|Experimental|Saline as placebo|IV form, total 4 units, each given every 6th hourly in 24 hours.
3101923|NCT02069353|Experimental|Cardiac arrest|Survivors of cardiac arrest at high risk of neurological deterioration. Participants will undergo placement of a Spencer Probe Depth Electrode and QFlow 500™ Perfusion Probe in addition to the institutional standard multimodal neurological monitoring.
3101924|NCT02069379|No Intervention|Controls|metabolically healthy controls will participate in baseline assessments only, and will not be randomized to the placebo and metformin treatment arms.
3101925|NCT02069379|Experimental|Metformin|16 weeks treatment with metformin (insulin sensitizing treatment)
3101926|NCT02069379|Placebo Comparator|Placebo|Placebo comparator to metformin treatment
3101927|NCT02069392|Active Comparator|Cognitive remediation training with nicotine|Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
3101928|NCT02069392|Placebo Comparator|Cognitive remediation training without nicotine|Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
3101929|NCT02069704|Experimental|Bevacizumab biosimilar (BEVZ92)|Bevacizumab 25 mg/mL (strength: 100 mg/4 mL).
3101930|NCT02069704|Active Comparator|Avastin® (bevacizumab, ref. product)|Bevacizumab 25mg/ml (strength: 100mg/4ml)
3101931|NCT02069847|Experimental|Esophageal stricture, Budesonide|Budesonide 1mg twice a day for a total of 8 weeks following endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR)
3101932|NCT02069847|No Intervention|Control group|Retrospective collect data for subjects who undergo endoscopic submucosal dissection or endoscopic mucosal resection
3101933|NCT02070237|Active Comparator|Enoxaparin Once Daily|This arm will have patients randomized to receive 40 mg sub-cutaneous injection of Lovenox (enoxaparin) once daily.
3101934|NCT02070237|Active Comparator|Enoxaparin Twice Daily|This arm will have patients randomized to receive weight based (0.5 mg/kg) sub-cutaneous injection of Lovenox (enoxaparin) twice daily.
3101935|NCT02070276|No Intervention|Standard Clinical Practice|"This arm is considered the current clinical standard for spinal anesthesia; its used as a control sample and statistical reference. During the induction phase the patient is fitted with a non-invasive blood pressure monitoring, three-lead ECG, pulse oximetry and peripheral intravenous device. The pressure control is set as the standard every 5 minutes until the procedure under spinal anesthesia, the cuff pressure is placed on the arm that is going to be on top during spinal anesthesia.~Data is recorded and vital signs of the patient and is put an infusion of crystalloid (0.9% NaCl or Ringer's acetate) with administration of 500 ml during the entire procedure until the beginning of the operation."
3101936|NCT02070276|Experimental|Trans-thoracic echocardiography|"In addition to the current clinical standard (arm A of the study) a trans-thoracic echocardiography is performed with the aim of assessing patient's volume status, identifying if he is responsive to fluid and could benefit from their administration. The echocardiography is performed with the subcostal projection to assess the size of the abdominal inferior vena cava and its collapsing during breathing.~According to different pre-established parameters, the patient is defined as unresponsive to fluids or responsive. If it's not responsive, he proceed to spinal anesthesia. Otherwise investigators proceed to the administration of crystalloid (NaCl 0.9% or Hartmann's solution second clinical evaluation) and at the end he's rerun an echocardiographic assessment."
3101937|NCT02070276|Experimental|Passive Leg Raising Test|"In addition to the arm A of the study, is performed a measurement of end-tidal CO2 (EtCO2) by trans-nasal canula with a patient positioned in semi-recumbent position. After, investigators run the Passive Leg Raising Test (PLRT): the position of the bed is changed in such manner to bring the trunk from 45° to 0° and accordingly the legs from 0° to 45°. Measurements are performed before and during the maneuver : an etCO2 increasing more than 12% from baseline was interpreted as fluid-responsive.~If the patient is not responsive to fluids, the patient is moving to the spinal anesthesia. If the patient is responsive investigators proceed to bolus administration, the patient returns to the initial PLRT position and is run again the PLRT until the patient is no longer responsive to fluids."
3101938|NCT02070302|Active Comparator|Botulinum Toxin Type A|After appropriate consent, each patient will receive 40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
3101939|NCT02070302|Placebo Comparator|Placebo|.4cc/muscle of Normal saline will be injected into two injection sites each into Opponens Pollicis (OP) and the Abductor Pollicis Brevis (APB)
3101940|NCT02070380|Experimental|MultiHance 0.1 then Dotarem 0.1 mmol/kg|MultiHance 0.1 mmol/kg Then Dotarem 0.1 mmol/kg
3101941|NCT02070380|Experimental|MultiHance 0.05 then Dotarem 0.1 mmol/kg|MultiHance 0.05 mmol/kg Then Dotarem 0.1 mmol/kg
3101942|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.1 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.1 mmol/kg
3101943|NCT02070380|Active Comparator|Dotarem 0.1 then MultiHance 0.05 mmol/kg|Dotarem 0.1 mmol/kg Then MultiHance 0.05 mmol/kg
3101944|NCT02070484|Experimental|NuCel|Stemcell allograft
3101945|NCT02070484|Active Comparator|Demineralized Bone Matrix (DBM)|Demineralized Bone Matrix (DBM) bone graft substitute
3101946|NCT02070588|Active Comparator|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3101947|NCT02070588|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3101948|NCT02070640|Experimental|NIRF-C|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence (NIRF-C) and standard of care intraoperative cholangiography. 2.5 mg of indocyanine green is injected 30-60 minutes prior to surgery. Visualization of the biliary tree during surgery is achieved with a near-infrared light source and camera.
3101949|NCT02070692|Experimental|Tamoxifen|Participants will be randomized to receive either tamoxifen 10mg twice daily for seven days, or placebo twice daily for seven days, to be started on the third day of an episode of bleeding.
3101950|NCT02070692|Placebo Comparator|Placebo|Placebo tablets twice daily for seven days, to be started on the third day of a bleeding episode.
3101951|NCT02070744|Experimental|PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h|Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.
3101952|NCT02070744|Placebo Comparator|PC Phase: VX 661 placebo q12h + IVA placebo q12h|Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.
3101953|NCT02070744|Experimental|PC Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.
3101954|NCT02070744|Placebo Comparator|PC Phase: VX -661 placebo qd + IVA placebo q12h|Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.
3101955|NCT02070744|Experimental|OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h|Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.
3101956|NCT02070757|Experimental|Ceftolozane/tazobactam|Participants receive 3000 mg ceftolozane/tazobactam intravenous IV (comprising 2000 mg ceftolozane and 1000 mg tazobactam) every 8 hours for 8-14 days.
3101957|NCT02070757|Active Comparator|Meropenem|Participants receive 1000 mg meropenem IV every 8 hours for 8-14 days.
3101958|NCT02070965|Experimental|DFD01 Spray Group 1|DFD01 Spray, bid, 28 days
3101959|NCT02070965|Active Comparator|Comp01 Lotion|Comp01 Lotion, bid, 14 days
3101960|NCT02070965|Experimental|DFD01 Spray Group 2|DFD01 Spray, bid, 14 days
3101961|NCT02070978|Experimental|Atacicept 75 mg|
3101962|NCT02070978|Experimental|Atacicept 150 mg|
3101963|NCT02070978|Experimental|Placebo/Atacicept 150 mg|
3101964|NCT02070991|Experimental|Macitentan|oral tablet, 10 mg once daily.
3101965|NCT02070991|Placebo Comparator|Placebo|Matching placebo, once daily.
3101966|NCT02071082|Experimental|HIV treatment-naive and HBV treatment-naive|HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
3101967|NCT02071082|Experimental|HIV-suppressed|HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
3101968|NCT02071095|Experimental|Arm A: Poly-ICLC|Arm A (N=15): Patients will receive an injection of 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir) subcutaneously on day 1 and day 2.
3101969|NCT02071095|Placebo Comparator|Arm B: Normal Saline|Arm B: (N=5): Patients will receive an injection of normal saline subcutaneously on day 1 and day 2.
3101970|NCT02071108|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
3101971|NCT02071173|Experimental|Enrolled Patients|Subjects undergo an implant procedure to receive at least one investigational lead -- ACUITY X4 left ventricular (LV) CRT lead, RELIANCE 4-FRONT right ventricular (RV) ICD lead
3101972|NCT02071225|Experimental|Obinutuzmab + Bendamustine|Participants will receive obinutuzumab and bendamustine in 28-days cycles for a maximum of 6 cycles
3101973|NCT02071290|Sham Comparator|Sham Remote Ischemic Conditioning|Sham inflation of pneumatic tourniquet pressure cuff at 0 mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
3101974|NCT02071290|Experimental|Remote Ischemic Conditioning|Inflation of pneumatic tourniquet pressure cuff at 250mmHg on the thigh for 5 minutes and release for 5 minutes (repeated for 4 cycles) applied to trauma patients on arrival to hospital
3101975|NCT02071420|Experimental|Experimental Group|This group will receive the seated active workstation intervention, the ergonomic intervention and the email intervention for 16 weeks.
3101976|NCT02071420|Active Comparator|Active Control|This group will receive the ergonomic intervention and email intervention only for 16 weeks. This group will not receive a seated active workstation.
3101977|NCT02071706|Other|Single-Arm PET/MRI|Single-group evaluation of PET/MRI for diagnostic quality of image
3101978|NCT02071771|Other|DACP T, Then 1DAM A|Nelfilcon A toric contact lenses worn first, with etafilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
3101979|NCT02071771|Other|1DAM A, Then DACP T|Etafilcon A toric contact lenses worn first, with nelfilcon A toric contact lenses worn second. Each product worn bilaterally on a daily wear, daily disposable basis for 10 days.
3101980|NCT02071810|Experimental|BIA 9-1067 5 mg|BIA 9-1067 (OPC, Opicapone) 5 mg
3101981|NCT02071810|Experimental|BIA 9-1067 10 mg|BIA 9-1067 (OPC, Opicapone) 10 mg
3101982|NCT02071810|Experimental|BIA 9-1067 20 mg|BIA 9-1067 (OPC, Opicapone) 20 mg
3101983|NCT02071810|Experimental|BIA 9-1067 30 mg|BIA 9-1067 (OPC, Opicapone) 30 mg
3101984|NCT02071810|Experimental|Placebo|Placebo, PLC
3101985|NCT02071823|Experimental|Group A Fed/Fasted|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fed Washout Period (7days) Period 2: Fasted"
3101986|NCT02071823|Experimental|Group B Fasted/Fed|"A single 50 mg dose of BIA 9-1067 (2 x 25 mg capsules) was to be administered on:~Period 1: Fasted Washout Period (7days) Period 2: Fed"
3101987|NCT02071849|Experimental|Aortic Valve Repair|Implantation of HAART 200 Aortic Valve Annuloplasty Device for bicuspid aortic valve reconstruction
3101988|NCT02071914|Experimental|CT-P27 10mg/kg|CT-P27 will be administrated once in IV infusion.
3101989|NCT02071914|Experimental|CT-P27 20mg/kg|CT-P27 will be administrated once in IV infusion.
3101990|NCT02071914|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
3101991|NCT02072096|Experimental|Strategy A (Glucose-Dependent)|Participants may receive oral and injectable (glucagon-like peptide-1 receptor agonists [GLP-1 RA]) therapies that exert a glucose-dependent mode of action. Medications allowed in this arm include: metformin, pioglitazone, acarbose, linagliptin, sitagliptin, liraglutide, exenatide once weekly (QW), and exenatide twice daily (BID). Choice of therapy is based on investigator's discretion. Treatment used in label. Treatment may last up to 72 weeks.
3101992|NCT02072096|Active Comparator|Strategy B (Reference)|Participants will receive glimepiride and may receive basal insulin glargine as a first line injectable therapy. Medications allowed in this arm include: glimepiride, metformin, pioglitazone, acarbose, linagliptin, sitagliptin and basal insulin glargine. Choice of therapy is based on investigator's discretion. Treatment used in label. Insulin glargine is titrated according treatment algorithm. Treatment may last up to 72 weeks.
3101993|NCT02072174|Experimental|Anaferon for Children|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
3101994|NCT02072174|Placebo Comparator|Placebo|On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily.
3101995|NCT02072200|Experimental|Modified release prednisone|Single arm / Lodotra
3101996|NCT02072226|Active Comparator|Alteplase Placebo + Aspirin|Participants will receive single dose of IV alteplase placebo and aspirin orally.
3101997|NCT02072226|Experimental|Alteplase + Aspirin Placebo|Participants will receive single dose of IV alteplase and aspirin placebo orally.
3101998|NCT02072421|Other|Non-SOS|
3101999|NCT02072434|Experimental|Edoxaban|Edoxaban oral tablet, 60 mg-once daily (QD), reduced to 30 mg based on protocol-defined parameters, for up to 49 days
3102000|NCT02072434|Active Comparator|Warfarin|"Participants naïve to anticoagulation, taking anticoagulants other than a Vitamin K antagonist (VKA) or taking a VKA but with a prothrombin time (PT) international normalized ratio (INR) of less than 2.0 receive enoxaparin until they reach a PT INR of at least 2.0, before taking warfarin.~All participants in this arm receive warfarin oral tablet QD at their doctor's prescribed dose, for up to 49 days."
3102001|NCT02072668|Other|Rivaroxaban for 4 wks, Placebo for 4 wks|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
3102002|NCT02072668|Other|Placebo for 4 wks, rivaroxaban for 4 wks|Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
3102003|NCT02072824|Experimental|Study Drug Level 1|
3102004|NCT02072824|Experimental|Study Drug Level 2|
3102005|NCT02072824|Placebo Comparator|Placebo|
3102006|NCT02072928||BOTOX®|Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.
3102007|NCT02072941|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
3102008|NCT02072941|No Intervention|Control|The control arm will review an easy-to-read AD. Controls will review the AD for ≥15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
3102009|NCT02072980|Other|16hrs/15mins|Delefilcon A contact lenses worn bilaterally (in both eyes) for 16 waking hours (1 day) in Period 1, followed by 15 minutes in Period 2. A fresh pair of lenses was dispensed for Period 2.
3102010|NCT02072980|Other|15mins/16hrs|Delefilcon A contact lenses worn bilaterally for 15 minutes in Period 1, followed by 16 waking hours (1 day) in Period 2. A fresh pair of lenses was dispensed for Period 2.
3102011|NCT02073162|Active Comparator|Liberal group|At induction-Hartmanns 10 ml/kg During surgery-Hartmanns 8 ml/kg/h After surgery-IV fluids ≥1.5 ml/kg/h Continue IV fluids ≥24hrs
3102012|NCT02073162|Experimental|Restrictive group|At induction-Hartmanns ≤5 ml/kg During surgery-Hartmanns 5 ml/kg/h After surgery-IV fluids, ≤0.8 ml/kg/h Cease IV fluids ASAP,aim for early oral fluids
3102013|NCT02073279|Experimental|Satralizumab|Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
3102014|NCT02073279|Placebo Comparator|Placebo|Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study.
3102015|NCT02073331||CorMatrix ECM|Data collection for information on the use of CorMatrix ECM for pericardial reconstruction
3102016|NCT02073435||Post-Implementation Group|Living Donor Liver Transplant patients with evidence based donor pain management solution.
3102017|NCT02073435||Pre-Implementation Group|Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution.
3102018|NCT02073448|Experimental|GK530G|Fixed-dose combination gel of Adapalene and Benzoyl Peroxide
3102019|NCT02073448|Active Comparator|CD0271|Adapalene 01% Gel
3102020|NCT02073448|Active Comparator|CD1579|Benzoyl Peroxide 2.5% Gel
3102021|NCT02073461|Experimental|CD1579 2.5%|Benzoyl Peroxide 2.5%
3102022|NCT02073461|Experimental|CD1579 5%|Benzoyl Peroxide 5%
3102023|NCT02073461|Placebo Comparator|Vehicle|Vehicle
3102024|NCT02073487|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.
3102025|NCT02073487|Active Comparator|Trastuzumab + Pertuzumab + Paclitaxel|Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.
3102026|NCT02073565|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
3102027|NCT02073565|Active Comparator|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
3102028|NCT02073656|Experimental|LDV/SOF 12 Weeks|LDV/SOF for 12 weeks
3102029|NCT02073656|Experimental|Retreatment Substudy|LDV/SOF plus RBV for 24 weeks
3102030|NCT02073682|Experimental|Edoxaban group|After 5 days of low molecular weight heparin (LMWH), patients receive edoxaban treatment daily - tablet for oral use
3102031|NCT02073682|Active Comparator|Dalteparin group|Participants receive Dalteparin treatment daily -solution for subcutaneous injection
3102032|NCT02073747|Placebo Comparator|Normal Saline Control Group|Control group will be administered a one hour normal saline inhaled treatment.
3102033|NCT02073747|Active Comparator|Albuterol Trial Group|Trial group to be administered one hour treatment of ten milligrams of inhaled albuterol
3102034|NCT02073929|Active Comparator|Active|Liraglutide s.c. 1,8mg daily for 26 weeks
3102035|NCT02073929|Placebo Comparator|Placebo|Placebo s.c. daily for 26 weeks
3102036|NCT02073968|Experimental|Treatment (PET-adjusted IMRT, carboplatin, paclitaxel)|"RADIOTHERAPY: Patients undergo PET-adjusted IMRT or proton beam radiation therapy five days a week for 5 weeks.~CONCURRENT CHEMOTHERAPY: Patients receive carboplatin IV over 3 hours and paclitaxel IV over 1 hour once weekly for 6 weeks beginning week 1 of thoracic radiotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning approximately 4-6 weeks after the completion of all radiation therapy and when esophagitis and chemotherapy-induced neuropathy are grade 1 or less, ANC > 1500, and platelet count > 100,000, patients may receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1. Treatment may repeat every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity at the discretion of the treating physicians."
3102037|NCT02074059|Experimental|Aerosolized lucinactant (25 mg/kg)|25 mg total phospholipids (TPL)/kg: Lucinactant for inhalation with nCPAP
3102038|NCT02074059|Experimental|Aerosolized lucinactant (50 mg/kg)|50 mg TPL/kg: Lucinactant for inhalation with nCPAP
3102039|NCT02074059|Experimental|Aerosolized lucinactant (75 mg/kg)|75 mg TPL/kg: Lucinactant for inhalation with nCPAP
3102040|NCT02074059|Experimental|Aerosolized lucinactant (100 mg/kg)|100 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
3102041|NCT02074059|Experimental|Aerosolized lucinactant (150 mg/kg)|150 mg TPL/kg: Lucinactant for inhalation with nCPAP; repeat dosing possible if criteria met.
3102042|NCT02074059|Active Comparator|nCPAP alone|nCPAP therapy alone
3102043|NCT02074345|Experimental|TAK-816 0.5 mL|Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.
3102044|NCT02074358|Experimental|Treatment A: Apixaban + Placebo (Saline solution)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by Saline solution (placebo) 0 IU/kg infusion for 30 min Intravenously
3102045|NCT02074358|Experimental|Treatment B: Apixaban + Cofact (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
3102046|NCT02074358|Experimental|Treatment C: Apixaban + Beriplex P/N (4-Factor PCC)|Apixaban 10 mg Tablet orally [Day 1-Day 3: twice daily (BID), Day 4: Single Dose (SD)] followed 3hr later by a Beriplex P/N (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously
3102047|NCT02074384|Other|Continuous Glucose Monitoring|Participants will wear Continuous Glucose Monitoring for two weeks.
3102048|NCT02074384|Other|Self Monitoring Blood Glucose|Participants will self test for two weeks.
3102049|NCT02074384|Other|Clinicians|Clinicians completing study visits.
3102050|NCT02074514|Experimental|Sofosbuvir+RBV 16 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 16 weeks.
3102051|NCT02074514|Experimental|Sofosbuvir+RBV 24 weeks|Participants with HCV genotypes 1 and 3 will receive sofosbuvir plus ribavirin for 24 weeks.
3102052|NCT02074553|Experimental|Part 1 (Fasted): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation (four 150 mg capsules) orally in Part 1 of the study according to following treatment sequences. Treatment A (Reference Treatment: formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (Test Treatment: formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (Test Treatment: formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (Test Treatment: formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102053|NCT02074553|Experimental|Part 1 (Fasted): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102054|NCT02074553|Experimental|Part 1 (Fasted): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102055|NCT02074553|Experimental|Part 1 (Fasted): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib as a capsule formulation orally in Part 1 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102056|NCT02074553|Experimental|Part 2 (Fed): Treatment A then B then C then D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment A (formulation containing 50% SLS) on Day 1 of the first intervention period; then Treatment B (formulation containing 25% SLS) on Day 1 of second intervention period (Day 11); then Treatment C (formulation containing 12.5% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment D (formulation containing 3% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102057|NCT02074553|Experimental|Part 2 (Fed): Treatment B then D then A then C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment B (formulation containing 25% SLS) on Day 1 of the first intervention period; then Treatment D (formulation containing 3% SLS) on Day 1 of second intervention period (Day 11); then Treatment A (formulation containing 50% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment C (formulation containing 12.5% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102058|NCT02074553|Experimental|Part 2 (Fed): Treatment C then A then D then B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment C (formulation containing 12.5% SLS) on Day 1 of the first intervention period; then Treatment A (formulation containing 50% SLS) on Day 1 of second intervention period (Day 11); then Treatment D (formulation containing 3% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment B (formulation containing 25% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102059|NCT02074553|Experimental|Part 2 (Fed): Treatment D then C then B then A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after start of the meal will receive 600 mg of alectinib as a capsule formulation orally in Part 2 of the study according to following treatment sequences. Treatment D (formulation containing 3% SLS) on Day 1 of the first intervention period; then Treatment C (formulation containing 12.5% SLS) on Day 1 of second intervention period (Day 11); then Treatment B (formulation containing 25% SLS) on Day 1 of third intervention period (Day 21); followed by Treatment A (formulation containing 50% SLS) on Day 1 of fourth intervention period (Day 31). A washout period of at least 10 days will be maintained between each intervention period.
3102060|NCT02074709|Active Comparator|TAP block|TAP block with plain bupivacaine
3102061|NCT02074709|Active Comparator|Wound infiltration|Wound infiltration with liposomal bupivacaine
3102062|NCT02074735|Placebo Comparator|Placebo|Placebo schedule will mimic the schedule of the active comparator citicoline. Placebo will be started at the randomization visit (week 0, mimicking 500 mg/day of citicoline), then increased at week 2 to mimic 1000 mg/day citicoline, then increased to mimic 1500 mg/day of citicoline at week 4, and then increased to mimic 2000 mg/day of citicoline at week 6 until the end of week 12.
3102063|NCT02074735|Active Comparator|Citicoline|Citicoline will be started at 500 mg/day at the randomization visit (week 0), then increased to 1000 mg/day at week 2, then 1500 mg/day at week 4, and then 2000 mg/day at week 6 until the end of week 12.
3102064|NCT02074982|Experimental|AIN457 300 mg|patients received AIN457 (secukinumab) 300 mg (two secukinumab 150 mg injections) s.c. (subcutaneously) once every week at weeks 0, 1,2,3, followed by monthly dosing starting at week 4 to week 48 inclusive
3102065|NCT02074982|Active Comparator|Ustekinumab|patients received ustekinumab 45/90 mg (weight depended, according to label) s.c. (subcutaneously) and/or placebo secukinumab injections once every week at weeks 0,1,2, and 3 followed by monthly dosing starting at week 4 to week 48 inclusive
3102066|NCT02074995|Experimental|BVS857 Grp 1A open label|0.03 mg/kg of BVS857intravenously in open label manner
3102067|NCT02074995|Experimental|BVS857 Group 1B/1C, 2, 3, 4 Double Blind|
3102068|NCT02074995|Placebo Comparator|Placebo Group 1B/1C, 2, 3, 4|
3102069|NCT02075008|Experimental|QGE031 every 4 weeks (q4w)|QGE031 240 mg subcutaneously q4w
3102070|NCT02075047|Placebo Comparator|1|
3102071|NCT02075047|Experimental|ziprasidone|
3102072|NCT02075073|Experimental|SB3|SB3, single dose of 6 mg/kg via intravenous infusion (study drug)
3102073|NCT02075073|Active Comparator|EU sourced Herceptin®|EU sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
3102074|NCT02075073|Active Comparator|US sourced Herceptin®|US sourced Herceptin®, single dose of 6 mg/kg via intravenous infusion (reference drug)
3102075|NCT02075125|Experimental|Prasugrel 60 mg|Prasugrel 60 mg as loading dose and followed by 10 mg/day as maintenance dose
3102076|NCT02075125|Experimental|Ticagrelor 180 mg|Ticagrelor 180 mg as loading dose and followed by 90 mg twice a day as maintenance dose
3102077|NCT02075203|Experimental|AERAS-404 (15 mcgH4/500 nmol IC31)|2 doses on Study Days 0 and 56
3102078|NCT02075203|Active Comparator|Bacillus Calmette-Guérin (BCG)|1 Dose on Study Day 0
3102079|NCT02075203|Placebo Comparator|Placebo|2 Doses on Study Days 0 and 56
3102080|NCT02075255|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
3102081|NCT02075255|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
3102082|NCT02075255|Placebo Comparator|Placebo|Placebo administered subcutaneously every 4 weeks
3102083|NCT02075320|Experimental|Stationary Digital Chest Tomosynthesis|All patients will be included in the experimental group.
3102084|NCT02075463|Experimental|GSK1278863 Arm|Subjects will receive a fixed starting dose of 12 milligrams (mg) GSK1278863 once daily (QD) orally for first 4 weeks. From Week 4 the dose of GSK1278863 will be adjusted based on Hgb levels and evaluated every 4 weeks until Week 16. This starting dose may be changed during the study if there is an early indication of either lack of efficacy or the rate of rise in Hgb is too rapid
3102085|NCT02075476|Active Comparator|Hemiarthroplasty Global Fx(DePuy)|in this technique the prosthesis is implanted in similar approach to shoulder anatomy
3102086|NCT02075476|Experimental|reverse arthroplasty Delta Xtent(DePuy)|In this technique the prosthesis is implanted in the inverse mode of shoulder anatomy
3102087|NCT02075515|Experimental|HZ/su Lot A|Subjects will receive Lot A of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3102088|NCT02075515|Experimental|HZ/su Lot B|Subjects will receive Lot B of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3102089|NCT02075515|Experimental|HZ/su Lot C|Subjects will receive Lot C of the HZ/su vaccine at 0 and 2 months. The HZ/su vaccine composed of unique randomized combinations of an adjuvant lot and one gE lot.
3102090|NCT02075541|Experimental|10-AS01E group|Subjects in this group will receive the investigational NTHi vaccine.
3102091|NCT02075541|Placebo Comparator|Control group|Subjects in this group will receive placebo.
3102092|NCT02075554|Other|CALIBER|1 or 2 levels of DDD between L2 and S1, treated with transforaminal interbody fusion
3102093|NCT02075606|Experimental|Somatuline Autogel®|Somatuline Autogel® to treat Functioning Midgut NeuroEndocrine Tumours (NET)
3102094|NCT02075632|Experimental|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% will be applied by the participants topically on the affected areas per label instructions for 14 days.
3102095|NCT02075658|Other|Conventional Insufflation and Trocars|Subjects enrolled in this study arm will have their procedure performed using either the conventional insufflator and trocars. This system have been cleared for use by the FDA's 510 (k)process and are currently employed in clinical practice, including at UC Irvine Medical Center.
3102096|NCT02075658|Active Comparator|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port).
3102097|NCT02075840|Experimental|Alectinib|Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
3102098|NCT02075840|Active Comparator|Crizotinib|Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
3469096|NCT03889873|Experimental|Smartphone; Network; First-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using first-person pronouns.
3469097|NCT03889873|Experimental|Smartphone; No network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt does not instruct to write about social network (important people, friends, family); participant will write using third-person pronouns.
3102101|NCT02076022|Active Comparator|Standard fat grafting|Once harvested the aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
3102102|NCT02076022|Experimental|Enhanced Fat Grafting|"Approximately 60 cc of lipoaspirate will be collected from the subject to be processed with the Tissue Genesis Cell Isolation System™ (CIS) to yield approximately 35cc of Stromal Vascular Fraction (SVF).Once harvested the aspirated fat will then be divided into two portions: one portion will be processed as standard graft material (standard/control graft) while the other portion will be used in a processing step that concentrates the adipose stromal cells.~The aspirated fat processed as standard graft material will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and allowed to decant before separating the fluid and oil layers from the fat tissue fractions, and transferred into 50 ml syringes. This graft preparation will be performed in the operating room."
3102103|NCT02076100|Experimental|Part I GT3 Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3102104|NCT02076100|Experimental|Part II GT1a Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3102105|NCT02076100|Experimental|Part III GT2b Participants|Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
3102106|NCT02076113|Active Comparator|Ventral|Ventral Decompression with Fusion
3102107|NCT02076113|Active Comparator|Dorsal|Dorsal Decompression with Fusion or Dorsal Laminoplasty
3102108|NCT02076152|Experimental|FMISO PET & MRI Group 1|"Bevacizumab:~-- Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~MRI -- Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
3102109|NCT02076152|Experimental|FMISO PET & MRI Group 2|"Bevacizumab + CCNU:~Bevacizumab will be administered at a dose of 10 mg/kg i.v. every 14 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~CCNU will be administered at a dose of 110 mg/m2 every 42 days per standard of care and the drug label. A cycle is defined as 28 days (1 month).~-FMISO PET Scan~FMISO will be intravenously injected at a dose of 3.7 MBq/kg (0.1 mCi/kg) (maximum 260 MBq, 7 mCi) in < 15 mL. The IV will remain in place for injection of the gadolinium for the MRI scan. There will be one injection of FMISO in the PET protocol. Approximately 90 minutes after the injection, the PET scan will begin.~The PET scan will be approximately 60-75 minutes.~- MRI~Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
3102110|NCT02076165|Experimental|ABC-I|"Participants completed a 5 session intervention, Acceptance and the Behavioral Changes to Treat Insomnia (ABC-I). This was considered the new treatment being studied."
3102111|NCT02076165|Active Comparator|CBT-I|"Participants received a 5-session intervention, cognitive-behavioral therapy for insomnia (CBT-I). This was considered the standard care treatment."
3469098|NCT03889873|Experimental|Smartphone; Network; Third-person|In this narrative writing task, the participant is asked to imagine him/herself as someone who has reduced their smartphone usage and describe this future self; the prompt instructions include writing about social network (important people, friends, family); participant will write using third-person pronouns.
3469099|NCT03889925|Experimental|Autologous conditioned plasma group|Participants in this group will receive a three-injection series of autologous conditioned plasma over the course of 3 consecutive weeks.
3102114|NCT02076243|Experimental|nab-paclitaxel|weekly dosed nab-paclitaxel chemotherapy (days 1, 8 , 15 of a 28 day cycle) administered as an I.V. infusion over approximately 30 minutes. Dosage is determined by weight and height of participant.
3102115|NCT02076321|Other|Acetaminophen|control group
3102116|NCT02076321|Other|NSAID (Ibuprofen)|Study group
3102117|NCT02076334|Active Comparator|Compression + normal garment|Far Infrared Fabric during exercise + Spandex at night
3102118|NCT02076334|Active Comparator|Normal Garment + Test garment at night|Spandex during exercise + Far Infrared Fabric at night
3102119|NCT02076334|Sham Comparator|Normal Garment + normal garment|Spandex during exercise + Spandex at night
3102120|NCT02076334|Active Comparator|Test garment + Test garment|Far Infrared Fabric during exercise + Far Infrared Fabric at night
3102121|NCT02076399|Experimental|Fostamatinib Disodium|Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
3102122|NCT02076399|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
3102123|NCT02076412|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
3102124|NCT02076412|Other|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
3102125|NCT02076425|Experimental|PCIT-ED|Parent-Child Interaction Therapy - Emotional Development (PCIT-ED) is a promising early intervention for depression that directly targets developing affective systems and builds on the empirical literature on emotion development and prevention.
3102126|NCT02076425|No Intervention|Wait List|No intervention while subjects wait for PCIT-ED in the second phase of the study.
3102127|NCT02076776|Active Comparator|Repetitive Task Practice (RTP)|This group focuses on RTP.
3102128|NCT02076776|Experimental|Voluntary cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
3102129|NCT02076776|Experimental|Assisted cycling + RTP|This group involves one biking session and one RTP session three times per week for eight weeks.
3102130|NCT02076919|Experimental|LHA510 Part 1|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye as a single dose during Part 1
3102131|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 1|Inactive ingredients, 1 drop instilled in the study eye as a single dose during Part 1
3102132|NCT02076919|Experimental|LHA510 Part 2|LHA510 Ophthalmic Suspension in 1 of 4 concentrations, 1 drop instilled in the study eye once, twice, or three times daily for 7 days during Part 2
3102133|NCT02076919|Placebo Comparator|LHA510 Vehicle Part 2|Inactive ingredients, 1 drop instilled in the study eye once, twice, or 3 times daily for 7 days during Part 2
3102134|NCT02076997|Experimental|Individualized High Dose Methotrexate|Individualized high dose methotrexate given as a 24-hour infusion.
3102135|NCT02077140|Experimental|MDT-10013|Subjects will receive MDT-10013.
3102136|NCT02077140|Active Comparator|Standard of Care|Subjects will receive standard of care.
3102137|NCT02077374|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
3102138|NCT02077374|Placebo Comparator|Placebo|Placebo BID
3102139|NCT02077465|Experimental|Andecaliximab|Participants will receive andecaliximab every 2 weeks for a total of 3 infusions.
3102140|NCT02077465|Placebo Comparator|Placebo to match andecaliximab|Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.
3102141|NCT02078102|Other|Treatment|"Meloxicam and Filgrastim will be administered in fixed doses to each patient enrolled on this study. The treatments will be administered in a staggered dose schedule for a total treatment duration of 7 days prior to apheresis.~15 mg tablets of Meloxicam will be taken orally for 5 consecutive days.~10 µg/kg of Filgrastim will be subcutaneously injected for 5 consecutive days. Filgrastim may be subcutaneously injected for an additional 3 days if patients do not meet the primary endpoint for cell collection."
3102142|NCT02078180|Active Comparator|generic bupropion IR75|One oral dose of generic bupropion IR75
3102143|NCT02078180|Active Comparator|generic bupropion IR100|One oral dose of generic bupropion IR100
3102144|NCT02078180|Active Comparator|generic bupropion SR100|One oral dose of generic bupropion SR100
3102145|NCT02078180|Active Comparator|generic bupropion SR150|One oral dose of generic bupropion SR150
3102146|NCT02078180|Active Comparator|generic bupropion XL150|One oral dose of generic bupropion XL150
3102147|NCT02078180|Active Comparator|generic bupropion XL300|One oral dose of generic bupropion XL300
3102148|NCT02078193|Experimental|Belatacept|Participants will be converted from their current MMF to once a month infusions of Belatacept
3102149|NCT02078219|Experimental|RDEA3170 1|RDEA3170 5mg followed by RDEA3170 7.5mg
3102150|NCT02078219|Experimental|RDEA3170 2|RDEA3170 10mg followed by RDEA3170 12.5mg
3102151|NCT02078219|Experimental|RDEA3170 3|RDEA3170 12.5mg followed by RDEA3170 15mg
3102152|NCT02078219|Placebo Comparator|RDEA3170 4|RDEA3170 Placebo
3102153|NCT02078219|Other|Allopurinol|Allopurinol 200mg
3102154|NCT02078284|Experimental|Cohort 1 with 0.5 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3102155|NCT02078284|Active Comparator|Cohort 1 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3102156|NCT02078284|Experimental|Cohort 2 with 1 unit of CPP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3102157|NCT02078284|Active Comparator|Cohort 2 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3102158|NCT02078284|Experimental|Cohort 3 with 2 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3102159|NCT02078284|Active Comparator|Cohort 3 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)
3102160|NCT02078284|Experimental|Cohort 4 with 3 units of CPP|A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)
3102161|NCT02078284|Active Comparator|Cohort 4 with 1 unit of LSP|A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP
3102162|NCT02078492|Experimental|Group 1 - 10 mg of Ketorolac|Subjects will be administered 10 mg of Ketorolac for pain relief.
3102163|NCT02078492|Experimental|Group 2 - 15mg|Subjects will be administered 15mg of Ketorolac.
3102164|NCT02078492|Experimental|Group 3 - 30mg|Subject will receive 30mg of Ketorolac as a part of standard care.
3102165|NCT02078557|Experimental|MK-8892|Starting dose of 1 mg daily (oral); the dose may be titrated up on the 8th, 15th, and 22nd day of treatment to 2 mg, 3 mg, or 4 mg, respectively, for the duration of the study (28 days) as tolerated. For participants who reach one or more of the down-dosing criteria, there is an opportunity to decrease the dose back to a previously well-tolerated dose level, or to ½ of the starting dose.
3102166|NCT02078713|Experimental|Contraceptive Decision Support Tool|Patients whose contraceptive counseling visits are scheduled with providers randomized to this arm will use the intervention immediately before their visit and bring the generated printout to their visit. Providers randomized to this arm will be free to integrate the tool and printout into their contraceptive counseling however they see fit.
3102167|NCT02078713|No Intervention|Usual Care (Control)|Patients in this arm will receive usual family planning care.
3102168|NCT02078726|Active Comparator|Glucagon|1 mg glucagon given during colonoscopy
3102169|NCT02078726|Placebo Comparator|Placebo|1 mL normal saline
3102170|NCT02078752|Experimental|Part 1|
3102171|NCT02078817|Experimental|ketamine|Intravenous ketamine 0.5 mg/kg over 40 minutes will be given 6 times over 2 weeks.
3102172|NCT02078882|Experimental|Abatacept 125 mg weekly|Open label treatment with Abatacept
3102173|NCT02078960|Experimental|Omacetaxine mepesuccinate.|The study will consist of up to a 7-day screening period, and treatment for up to 12 months, in Phase 1 and Phase 2 portions, depending on response and tolerability. Patients will also have an end-of-treatment follow-up visit approximately 28 days after the last dose of omacetaxine. Each patient will be monitored for progression and survival for at least 1 year after their last dose of omacetaxine, death, or lost to follow-up, whichever comes first, regardless of patients receiving other anticancer treatment.
3102174|NCT02079025|Active Comparator|LR-TRUS|Low-resolution transrectal ultrasound guided prostate biopsy (standard of care)
3102175|NCT02079025|Experimental|UHR-TRUS|Ultra-high resolution transrectal ultrasound guided prostate biopsy
3102176|NCT02079038|Active Comparator|Totalis™ Direct Decompression Procedure|Totalis
3102177|NCT02079038|Active Comparator|Comparator Procedure|Comparator Surgical Procedure
3102178|NCT02079077|Other|Acetylsalicylic Acid (ASA)|ASA 81 mg. p.o. daily for two months
3102179|NCT02079077|Other|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. o.d. p.o. for two months.
3102180|NCT02079246|Experimental|Idalopirdine (Lu AE58054) 60 mg|Idalopirdine 60 mg adjunct to 10 mg donepezil. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study.
3102181|NCT02079246|Experimental|Idalopirdine 60 mg + memantine|Idalopirdine 60 mg as adjunct to 10 mg donepezil and memantine (patient's individualised maintenance dose, either immediate-release (IR) 20 mg/day (recommended target dose) or extended release (XR) 28 mg/day (recommended target dose). Memantine was administered to approximately 100 patients included in the OLEX-MEM. The dose of idalopirdine could be decreased from 60 mg to 30 mg if 60 mg was not well tolerated. The dose of donepezil was to be maintained throughout the study. The dose of memantine could be changed at any time throughout the study.
3102182|NCT02079311|Experimental|Active self-warming blanket|Active warming with BARRIER® EasyWarm active self-warming blanket during the perioperative phase
3102183|NCT02079311|Active Comparator|Forced air warming device|Active warming with forced air warming (FAW) during the intraoperative phase.
3102184|NCT02079519|Experimental|Bevacizumab 5 mg/kg|Participants received bevacizumab 5 mg/kg intravenously every 2 weeks for 6 months until disease progression or termination of the study. Participants showing a continuous benefit of therapy could receive treatment for a maximum of 12 months.
3102185|NCT02079532|Experimental|MabThera (Rituximab)|
3102186|NCT02079610|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
3102187|NCT02079610|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
3102188|NCT02079636|Experimental|Abemaciclib + Pemetrexed|150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3102189|NCT02079636|Experimental|Abemaciclib + Gemcitabine|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3102190|NCT02079636|Experimental|Abemaciclib + Ramucirumab|150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3102191|NCT02079636|Experimental|Abemaciclib + LY3023414|100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3102192|NCT02079636|Experimental|Abemaciclib + Pembrolizumab|100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3102193|NCT02079649|Experimental|AL-53817|AL-53817 Ophthalmic Solution, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3102194|NCT02079649|Experimental|AL-78843|AL-78843 Ophthalmic Solution, 0.03%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3102195|NCT02079649|Active Comparator|Maxidex|Dexamethasone Ophthalmic Suspension, 0.1%, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3102196|NCT02079649|Placebo Comparator|Vehicle|AL-53817 Vehicle, 1 drop in each eye twice daily for 6-8 days followed by 1 drop in each eye once on the last day of dosing (Day 7, 8, or 9)
3469100|NCT03889925|Experimental|Autologous conditioned plasma with hyaluronic acid group|Participants in this group will receive a two-injection series of autologous conditioned plasma and hyaluronic acid (Hymovis, Fidia Pharmaceuticals) and a third injection on the third week of autologous conditioned plasma.
3102199|NCT02079805|Experimental|Azilsartan 20 mg|Participants will receive azilsartan 20 mg once daily in the morning before or after breakfast.
3102200|NCT02079805|Active Comparator|Telmisartan 40 mg|Participants will receive telmisartan 40 mg once daily in the morning before or after breakfast.
3102201|NCT02079844|Experimental|Placebo + Roflumilast 100 μg + Roflumilast 250 μg|Roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3102202|NCT02079844|Experimental|Roflumilast 100 μg + Roflumilast 250 μg + Placebo|Roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3102203|NCT02079844|Experimental|Roflumilast 250 μg + Placebo + Roflumilast 100 μg|Roflumilast 250 μg tablets, orally, once, daily, Days 1 through 8, Period 1, followed by a 14 day washout period, followed by roflumilast placebo-matching tablets, orally, once, daily, Days 1 through 8, Period 2, followed by a 14 day washout period, followed by roflumilast 100 μg tablets, orally, once, daily, Days 1 through 8, Period 3. All participants will take a stable dose of second generation antipsychotics throughout the duration of the treatment period.
3102204|NCT02079909|Experimental|T-817MA-H|224 mg T-817MA once daily for first 4 weeks and 448 mg T-817MA once daily for the following weeks.
3102205|NCT02079909|Experimental|T-817MA-L|224 mg T-817MA once daily
3102206|NCT02079909|Placebo Comparator|Placebo|Placebo once daily
3102207|NCT02079987|Experimental|ED-to-home care transition intervention|The ED-to-home care transition intervention is a coaching intervention. It is a 4-week program that uses an Area Agency on Aging healthcare coach to conduct a home visit and at least 3 follow-up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
3102208|NCT02079987|Experimental|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
3102209|NCT02080091||Chronic DME|Patients with vision impairment associated with chronic diabetic macular edema (DME)
3102210|NCT02080195|Experimental|Nonmyeloablative Conditioning and BMT|Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.
3102211|NCT02080221|Experimental|FOLFOXA|"1 cycle = 14 days Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
3102212|NCT02080260|Experimental|Single Arm|Oral Regorafenib
3102213|NCT02080273|Placebo Comparator|Colgate Cavity Protection toothpaste|Brush whole mouth 2x/day with Colgate Cavity Protection toothpaste. This study treatment is currently marketed/sold in Poland
3102214|NCT02080273|Active Comparator|Colgate Total toothpaste|Brush whole mouth 2x/day with Colgate Total toothpaste . This study treatment is currently marketed/sold in Poland
3102215|NCT02080273|Active Comparator|Parodontax|Brush whole mouth 2x/day with Parodontax toothpaste. This study treatment is currently marketed/sold in Poland.
3102216|NCT02080312|Experimental|intratympanic injection|Magnevist (gadopentetate dimeglumine, Bayer Health Care) will be diluted eightfold with sterile saline (1:7 v/v) in a 1 ml syringe and injected intra-tympanically with a 23-25g needle up to 0.4 ml or less if contrast reflux is noted under direct visualization. Anesthesia with topical phenol is available for this procedure.
3102217|NCT02080364|Experimental|Azeliragon 5mg|Azeliragon (TTP488) 5mg orally once daily for 18 months
3102218|NCT02080364|Placebo Comparator|Placebo|Placebo orally once daily for 18 months
3102219|NCT02080403|Experimental|Treatment|Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip®) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months.
3102220|NCT02080403|No Intervention|Control|Mechanical Subgingival Debridement at Baseline and 3 months.
3102221|NCT02080455|Experimental|Lomitapide & Atorvastatin - Taken Together|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
3102222|NCT02080455|Experimental|Lomitapide & Atorvastatin - Approx. 12 hours between|"2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)~11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
3102223|NCT02080468|Experimental|Arm 1: Lomitapide & EE/Norgestimate - Taken Together|Lomitapide & EE/Norgestimate - Taken Together 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 8 through day 28)
3102224|NCT02080468|Experimental|Arm 2: Lomitapide & EE/Norgestimate - Taken 12 Hours Apart|Lomitapide & EE/Norgestimate - Taken 12 hours apart 2 single oral doses of lomitapide (20 mg) (Day 1 & Day 22) 21 single oral doses of EE/Norgestimate(Day 9 through day 29)
3102225|NCT02080481|Experimental|Infiniti Plus needle guidance system|ultrasound guidance with the InfinitiPlus (TM) needle guidance system
3102226|NCT02080481|Other|conventional block needle|ultrasound guidance with a conventional block needle
3102227|NCT02080507|Active Comparator|Active Neuronetics rTMS stimulator|Device: Active Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the active group, magnetic power output will be delivered to the subject through the coils.
3102228|NCT02080507|Sham Comparator|Inactive Neuronetics rTMS stimulator|Device: Inactive Neuronetics Transcranial Magnetic Stimulator. The Neuronetics transcranial magnetic stimulator is an FDA approved device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
3102229|NCT02080546|Active Comparator|Cut/Coag|
3102230|NCT02080546|Experimental|V-mode|
3102231|NCT02080637|Active Comparator|Ambrisentan|Oral ambrisentan 2.5 - 5 mg, single dose, once daily
3102232|NCT02080637|Placebo Comparator|Placebo|Oral placebo 2.5 - 5 mg, single dose, once daily
3102233|NCT02080780|Experimental|2% Diltiazem & Clarithromycin XL|"3 parts:~- Single Dose, Diltiazem (Day 1)~- Multiple Dose, Clarithromycin XL (Days 4-9)~- Single Dose, Diltiazem (Day 8)"
3102234|NCT02080819|No Intervention|Healthy Control|Non drug using healthy controls
3102235|NCT02080819|Placebo Comparator|Placebo|Placebo BID for 7 weeks
3102236|NCT02080819|Experimental|Medication|Levodopa/carbidopa 400/100 BID for 7 weeks
3102237|NCT02080832|Experimental|Medication (Citalopram 20mg)|Citalopram (20mg dose)
3102238|NCT02080832|Placebo Comparator|Placebo|
3102239|NCT02080832|Experimental|Medication (Citalopram 40mg)|Citalopram 40mg dose
3102240|NCT02080871|Experimental|Gore VIABAHN BX|Balloon expandable stenting of iliac occlusive disease
3102241|NCT02081001|Experimental|G-Pump™ (glucagon infusion)|G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
3102242|NCT02081001|Active Comparator|Novo Nordisk GlucaGen®|Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
3102243|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 75 ug|G-Pen Mini™ (glucagon injection), two 75 microgram subcutaneous injections given approximately 4-5 hours apart
3102244|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 150 ug|G-Pen Mini™ (glucagon injection), two 150 microgram subcutaneous injections given approximately 4-5 hours apart
3102245|NCT02081014|Experimental|G-Pen Mini™ (glucagon injection) 300 ug|G-Pen Mini™ (glucagon injection), two 300 microgram subcutaneous injections given approximately 4-5 hours apart
3102246|NCT02081079|Experimental|Genotype 4|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 4 hepatitis C virus (HCV) infection
3102247|NCT02081079|Experimental|Genotype 5|LDV/SOF for up to 12 weeks in treatment-naive and treatment-experienced participants with genotype 5 hepatitis C virus (HCV) infection
3102248|NCT02081196|Experimental|CoolSculpting of the Flank With Alternate Treatment Parameters|Each subject served as their own control with 1 flank treated with CoolSculpting; the contralateral flank was untreated.
3102249|NCT02081248|Active Comparator|Standard Consent|This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
3102250|NCT02081248|Experimental|Easy-to-Read Informed Consent|This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
3102251|NCT02081365|Experimental|High Anxiety Computerized Dental Anxiety Treatment|Computer based CBT intervention before the scheduled dental appoinment (1.5 hours)
3102252|NCT02081365|No Intervention|High Anxiety Wailist Control|
3469101|NCT03890185|Experimental|A: Chemo+RT low dose|Chemo + Low dose RT: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin (CDDP) 75mg/m2 IV D1 and radiation therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for a total of 2 cycles every 21 days.
3469102|NCT03890185|Active Comparator|B: Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
3469103|NCT03890172||study group|in this group the investigators will be managing diabetic wounds with platelet rich plasma treatment.
3102255|NCT02081417|Other|Peer led|"Number sessions of the intervention of an evidenced based practice called Seeking Safety led by a Peer (6 sessions will be used to define treatment completion)"
3102256|NCT02081417|Other|Clinician led|"Number intervention groups of an evidence based practice called Seeking Safety led by a master's level Clinician (6 sessions will be used to define treatment completion)."
3102257|NCT02081443|Experimental|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
3102258|NCT02081443|Active Comparator|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
3102259|NCT02081456|Active Comparator|Therapeutic Ultrasound|Therapeutic ultrasound applied for a period of 5 minutes to the most painful region of the neck, then a second 5 minute dose at the most painful region of the upper extremity
3102260|NCT02081456|Experimental|Soft Tissue Mobilization|Passive soft tissue mobilization to the neck and upper extremity
3102261|NCT02081534|Experimental|1 mg bid|1 mg AZD1722 bid
3102262|NCT02081534|Experimental|3 mg bid|3 mg AZD1722 bid
3102263|NCT02081534|Experimental|10 mg bid|10 mg AZD1722 bid
3102264|NCT02081534|Experimental|30 mg bid|30 mg AZD1722 bid
3102265|NCT02081534|Experimental|3 mg od|3 mg AZD1722 od
3102266|NCT02081534|Experimental|30 mg od|30 mg AZD1722 od
3102267|NCT02081534|Placebo Comparator|Placebo|Placebo (double dummy technique)
3102268|NCT02081573|Experimental|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
3102269|NCT02081586|Experimental|6 Weeks Phone CBT plus smartphone app|Following baseline, six 30-minute sessions of phone CBT to address any beliefs, assumptions, attitudes, or perceptions that are not constructive to diabetes self-management. CBT phone app will assist patients to practice skills related to improving self-management via more constructive ways of thinking.
3102270|NCT02081586|Experimental|8 Weeks Phone CBT plus smartphone app|Following baseline, patients will receive 8 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
3102271|NCT02081586|Experimental|12 weeks phone CBT plus smartphone app|Following baseline, patients will receive 12 weeks of phone CBT to address non-constructive beliefs, assumptions, attitudes or perceptions related to diabetes self-management. They will have a smartphone apps to practice CBT skills between sessions.
3102272|NCT02081586|Active Comparator|Standard Diabetes Care at PCP|Patients will remain in usual care and not receive study intervention. This will include usual diabetes care at PCP.
3102273|NCT02081599|Experimental|Teneli (Teneligliptin) /Teneli + insulin|Teneligliptin for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
3102274|NCT02081599|Placebo Comparator|Placebo/Teneli (Teneligliptin) + insulin|Placebo for 16 weeks (double-blind period) followed by teneligliptin for an additional 36 weeks (open-label period) in combination with insulin.
3102275|NCT02081638|Active Comparator|Elite Controller|Elite controllers not on ART
3102276|NCT02081638|Active Comparator|Treated Progressors|HIV infected on ART
3102277|NCT02081677|Active Comparator|etafilcon A|Marketed control soft contact lens
3102278|NCT02081677|Experimental|Prototype E1|Investigational soft contact lens
3102279|NCT02081677|Experimental|Prototype E2|Investigational soft contact lens
3102280|NCT02081677|Experimental|Prototype E3|Investigational soft contact lens
3102281|NCT02081690|Experimental|Macitentan|Macitentan tablet, dose of 10 mg, once daily
3102282|NCT02081807||Dabigatran|
3102283|NCT02081807||Warfarin|
3102284|NCT02081846|Experimental|Home Nurse Visit|Families in this arm will receive a nurse home visit within 96 hours of discharge.
3102285|NCT02081846|Active Comparator|Control|This arm will receive standard of care.
3102286|NCT02081859|Placebo Comparator|Conventional grading|Embryos will be scored based on conventional criteria.
3102287|NCT02081859|Active Comparator|Embryoscope data|Embryos will be scored based on both conventional rating and embryoscope data.
3102288|NCT02081950|Experimental|Enoxaparin sodium|Enoxaparin sodium (80mg) is administered subcutaneously as a single dose, in 2 periods.
3102289|NCT02081963|Experimental|Nebulized amikacin|Participants receive nebulized amikacin BID for 14 days in combination with standard treatment.
3102290|NCT02081963|Other|Nebulized normal saline|Participants received nebulized normal saline BID for 14 days in combination with standard treatment.
3102291|NCT02082119|Experimental|High Grade Glioma|To evaluate safety and feasibility of hypofractionated IMRT in addition to chemotherapy, concomitant and adjuvant, in patients with newly diagnosed High Grade Glioma after biopsy.total dose of 60 Gy/ 4 Gy fraction/15 fractions (BED10 84 Gy) will prescribed to the PTV1; a total dose of 42 Gy/2.8 Gy fraction/15 fractions (BED10 53.76 Gy) will prescribed to PTV2 with SIB.
3469104|NCT03890172||control group|In this group patients will receive the standard treatment in form of debridement and dressing twice weekly
3469105|NCT03889899|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
3469106|NCT03889665|Experimental|Suspension training group|
3102292|NCT02082145|No Intervention|Control|Treated according to local protocol for diabetic peripheral neuropathy
3102293|NCT02082145|Experimental|NMES|Treated with neuromuscular stimulation of both legs, for 10 weeks
3102294|NCT02082158|Active Comparator|Local Respirator Model|Subjects randomized to the local respirator model will wear that model while performing study procedures.
3102295|NCT02082158|Active Comparator|Non-Local Respirator Model|Subjects randomized to the non-local respirator design will wear that model while performing study procedures.
3102296|NCT02082158|Experimental|Prototype 1 Respirator Design|Subjects randomized to the prototype 1 respirator design will wear that model while performing study procedures.
3102297|NCT02082158|Experimental|Prototype 2 Respirator Design|Subjects randomized to the prototype 2 respirator design will wear that model while performing study procedures.
3102298|NCT02082158|Experimental|Prototype 3 Respirator Design|Subjects randomized to the prototype 3 respirator design will wear that model while performing study procedures.
3102299|NCT02082158|Experimental|Prototype 4 Respirator Design|Subjects randomized to the prototype 4 respirator design will wear that model while performing study procedures.
3102300|NCT02082184|Experimental|Sensor Based Glucose Monitoring System|Standard system use for 6 months. Followed by open access to the device for 6 months.
3102301|NCT02082184|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
3102302|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part A)|Part A: Dose escalation (750mg, 2000mg) of Emibetuzumab administered intravenously (IV), on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
3102303|NCT02082210|Experimental|Emibetuzumab + Ramucirumab (Part B)|Part B: Recommended 750mg Emibetuzumab dose from Part A to be administered IV, on days 1 and 15 every 28 day cycle in combination with a fixed dose of 8mg/kg ramucirumab administered IV on Days 1 and 15 every 28 day cycle.
3102304|NCT02082262|Experimental|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
3102305|NCT02082288|Experimental|Edessy ICSI Outcome Embryo Score|ICSI
3102306|NCT02082340|Experimental|Intervention arm|The intervention includes the following components: self-administered drug intake strategy, TB knowledge and socio-psychological counseling session, SMS text messages, phone calls, educational leaflet
3102307|NCT02082340|No Intervention|Control arm|patients included in the control arm will receive traditional - clinical Directly Observed Therapy (DOT) as recommended by WHO
3102308|NCT02082392|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
3102309|NCT02082392|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
3102310|NCT02082392|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
3102311|NCT02082392|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders.
3102312|NCT02082483|Experimental|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
3102313|NCT02082483|No Intervention|Regular Screening|Patients randomized to regular screening will be tested as per the current standard described in guidelines published by the National Kidney Foundation (e.g. annually while wait-listed for transplantation). If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
3102314|NCT02082522|Experimental|Photodynamic therapy-Photofrin plus SMC|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin followed by the illumination of the tumor using a fiber optic device. Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals. Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen.
3102315|NCT02082522|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care (SMC) is defined as stenting procedure plus chemotherapy regimen. The chemotherapy regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
3102316|NCT02082678|Active Comparator|Ondansetron|Ondansetron will be given 0.5 mg twice a day (BID). The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
3102317|NCT02082678|Placebo Comparator|Placebo|Placebo will be given 0.5 mg/ BID. The dose may be increased from 0.5 mg/BID to 1.0 mg/BID at week 4 for participants with less than 30% reduction in HAMD and/or alcohol use. An additional dose increase to 2.0 mg/BID and 4.0 mg/BID is allowed at weeks 8 and 10, respectively, for participants with less than a 50% reduction in HAMD scores and/or alcohol use.
3102318|NCT02082717|Experimental|Neut (4%sodium bicarbonate additive)|4% sodium bicarbonate additive during intravenous potassium chloride replacement.
3102319|NCT02082717|Active Comparator|Control|standard of practice potassium chloride replacement (with no additive)
3102320|NCT02082769|Experimental|Febuxostat 40 mg QD|Febuxostat 40 mg, orally, once daily for up to 24 weeks
3102321|NCT02082769|Experimental|Febuxostat 80 mg QD|Febuxostat 80 mg, orally, once daily for up to 24 weeks
3102322|NCT02082769|Active Comparator|Allopurinol 100mg QD|Allopurinol 100mg, orally, three times daily for up to 24 weeks
3102323|NCT02082912|Experimental|D-cycloserine|Subjects will take D-cycloserine and use the HandMentor Pro for robotic therapy
3102324|NCT02082912|Active Comparator|Placebo|Subjects will take a placebo pill and use the HandMentor Pro for robotic therapy
3102325|NCT02082977|Experimental|Part 1:GSK2816126 50 mg twice-weekly|Eligible subjects will receive GSK2816126 with a starting dose of 50 milligrams (mg) twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102326|NCT02082977|Experimental|Part 1:GSK2816126 100 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102327|NCT02082977|Experimental|Part 1:GSK2816126 200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102328|NCT02082977|Experimental|Part 1:GSK2816126 400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102329|NCT02082977|Experimental|Part 1:GSK2816126 800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102330|NCT02082977|Experimental|Part 1:GSK2816126 1200 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102331|NCT02082977|Experimental|Part 1:GSK2816126 1800 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102332|NCT02082977|Experimental|Part 1:GSK2816126 2400 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102333|NCT02082977|Experimental|Part 1:GSK2816126 3000 mg twice-weekly|Eligible subjects will receive GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).
3102334|NCT02082977|Experimental|Part 2: All subjects|Subjects with Germinal Center B-cell-like Diffuse Large B-cell Lymphoma (GCB-DLBCL)-mutant and wild type, Transformed Follicular Lymphoma (TFL)-mutant and wild type as well as with multiple myeloma (MM) will be enrolled in Part 2 of the study. Subjects enrolled in Part 2 will receive recommended Phase II dose (RP2D).
3102335|NCT02083107|Experimental|sublingual misoprostol & rectal placebo|"will receive 400 microgram of misoprostol (Sigma) sublingual 2 tablets and rectal placebo2 tablets."
3102336|NCT02083107|Placebo Comparator|rectal & sublingual placebo|"will receive rectal placebo2 tablets and sublingual placebo2 tablets."
3102337|NCT02083107|Experimental|rectal misoprostol & sublingual placebo|"will receive 400 microgram of misoprostol (Sigma) rectal 2 tablets and sublingual placebo2 tablets."
3102338|NCT02083185|Experimental|Relugolix 80 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 80 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
3102339|NCT02083185|Experimental|Relugolix 120 mg|Relugolix 320 mg (loading dose), tablets, orally, on Day 1 followed by relugolix 120 mg, tablets, orally, once daily for 48 weeks plus an optional 48 week extension at the investigator's discretion.
3102340|NCT02083185|Active Comparator|Leuprorelin 22.5 mg|Leuprorelin 22.5 mg, subcutaneous, injection on Day 1 and every 12 Weeks for up to 4 injections (48 weeks).
3102341|NCT02083263|Experimental|Bilevel|Bilevel, 3 months. The treatment was performed twice a day, 1 hour each treatment.
3102342|NCT02083263|Active Comparator|PEP mask|PEP mask, 3 months. The treatment was performed twice a day, 1 hour each treatment.
3102343|NCT02083354|Experimental|Arm 1|All subjects will receive the combination of dabrafenib (150 mg) and trametinib (2 mg) in the morning at approximately the same time every day. The second dose of dabrafenib (150 mg) alone will be administered approximately 12 hours after the morning dose. Subjects will continue study treatment until disease progression, death, unacceptable toxicity, withdrawal of consent, or study closure
3102344|NCT02083380|Experimental|A) Artefenomel 800mg: piperaquine 640mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
3102345|NCT02083380|Experimental|B) Artefenomel 800mg: piperaquine 960mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
3102346|NCT02083380|Experimental|C) Artefenomel 800mg: piperaquine 1440mg|One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
3102347|NCT02083406|Experimental|Treatment A: OZ439 Prototype 1|800mg OZ439 prototype formulation 1 and 960mg PQP single doses
3102348|NCT02083406|Experimental|Treatment B: OZ439 Prototype 2|800mg OZ439 prototype formulation 2 and 960mg PQP single doses
3102349|NCT02083406|Experimental|Treatment C: OZ439 Prototype 3|800mg OZ439 prototype formulation 3 and 960mg PQP single doses
3102350|NCT02083653|Experimental|Arm A: Sym004 (12 mg/kg)|Sym004 will be administered as an intravenous infusion at a dose of 12 milligrams per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.
3102351|NCT02083653|Experimental|Arm B: Sym004 (9/6 mg/kg)|Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.
3102352|NCT02083653|Active Comparator|Arm C: Investigator's Choice|Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.
3102353|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|
3102354|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|
3102355|NCT02083679|Experimental|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|
3102356|NCT02083679|Experimental|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|
3102357|NCT02083783|Experimental|TRI102|Active, amphetamine extended-release oral suspension
3102358|NCT02083783|Placebo Comparator|Placebo|Placebo
3102359|NCT02083809|Placebo Comparator|Placebo|500ml saline or lactated ringer without oxytocin added
3102360|NCT02083809|Active Comparator|Treatment group|Intravenous oxytocin mixed with saline or lactated ringer
3102361|NCT02083861|Experimental|Active ultrasound device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
3102362|NCT02083861|Placebo Comparator|Placebo ultrasound device|Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
3102363|NCT02083926|Experimental|Ketamine infusion|A ketamine infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
3102364|NCT02083926|Experimental|Saline infusion|A saline infusion was given on day 0 (28) at a dose of 0.5mg/kg over 40 minutes. Assessments were conducted pre-infusion, 3-h post-infusion, and days 1 (1+28), 2 (2+28), 3 (3+28), 5 (5+28), 7 (7+28), 10 (10+28) and 14 (14+28) post-infusion.
3102365|NCT02083965|Experimental|rFVIIIFc 1000 / 3000 PK Assessment|"A single intravenous (IV) injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
3102366|NCT02083965|Experimental|rFVIIIFc 3000 / 1000 PK Assessment|"A single IV injection of rFVIIIFc 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of rFVIIIFc 50 IU/kg at a strength of 1000 IU/vial.~Following the PK assessment, participants will receive either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Participants will be allowed to switch from one regimen to another if approved by the Investigator."
3102367|NCT02084056|Experimental|FDC first, fasted|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fasted
3102368|NCT02084056|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fasted
3102369|NCT02084056|Experimental|FDC first, fed|Linagliptin/Metformin FDC followed by single tablets of linagliptin and metformin, fed
3102370|NCT02084056|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin followed by Linagliptin/Metformin FDC, fed
3102371|NCT02084069|Active Comparator|Treatment|Atorvastatin 40 mg once daily from 3 days before surgery up to five days after surgery
3102372|NCT02084069|Placebo Comparator|Control|Placebo
3102373|NCT02084082|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
3102374|NCT02084082|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
3102375|NCT02084082|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
3102376|NCT02084082|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
3102377|NCT02084134|Active Comparator|steroid treatment arm|Receives intravenous hydrocortisone 100mg and following surgery intravenous dexamethasone 0.5mg
3102378|NCT02084134|No Intervention|non-steroid treatment|Subjects will not receive any steroids at the time of surgery or after surgery unless symptoms of adrenal insufficiency develop (i.e. nausea, vomiting, dizziness, or low blood pressure).
3102379|NCT02084160||CLD from HIS-EX-408/PLT-BID-1108|"Chronic liver disease subjects from previous Exalenz trial HIS-EX-408 and PLT-BID1108"
3102380|NCT02084238|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
3102381|NCT02084511|Experimental|BI 1026706 low dose|BI 1026706 low dose
3102382|NCT02084511|Experimental|BI 1026706 high dose|BI 1026706 high dose
3102383|NCT02084511|Experimental|Placebo reference|Placebo reference
3102384|NCT02084511|Experimental|Celecoxib reference|Celecoxib capsule
3102385|NCT02084628|Experimental|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
3102386|NCT02084706|Active Comparator|Triamcinolone (20 g) and 2% Lidocaine injection over A1 pulley|Group one subjects will receive an injection of 0.5mL (20 g) of Triamcinolone and 0.5 mL of 2% Lidocaine over the A1 pulley.
3102387|NCT02084706|Experimental|J-tip lidocaine administration, then steroid injection|"Group two subjects will receive a needle free J-tip administration of 0.5mL of 2% lidocaine prior (2-10 minutes) to needle injection of 0.5mL of Triamcinolone (20 g) over the A1 pulley."
3102388|NCT02084797|Experimental|all study participants|All study participants received all interventions. V2R Antagonist: 30mg Tolvaptan tablet ingested 2 hours before exercise. V2R agonist: 0.2mg DDAVP tablet ingested 2 hours before exercise Placebo
3102389|NCT02085070|Experimental|Melanoma patients|"After establishing eligibility criteria, for patients with melanoma the investigator will determine at least one lesion that requires local therapy (surgical resection or LITT) based on size, location, and/or risk of hemorrhage; this will be considered the surgical lesion. All other eligible brain lesions will be considered clinically evaluable lesions and will be followed by modified RECIST (mRECIST) criteria to determine best response."
3102390|NCT02085070|Other|Non-small cell lung cancer patients|"NSCLC patients are not required to have a surgical lesion but must have at least one clinically evaluable lesion in the central nervous system. Patients on NSCLC are required to have formalin-fixed, paraffin-embedded tumor tissue available for biomarker analysis."
3102391|NCT02085135|Experimental|Titration Schedule 1|
3102392|NCT02085135|Experimental|Titration Schedule 2|
3102393|NCT02085161|Placebo Comparator|placebo|patient will receive placebo once daily, 2 puffs in the morning
3102394|NCT02085161|Experimental|tiotropium + olodaterol high dose with BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
3102395|NCT02085161|Active Comparator|tiotropium|patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning
3102396|NCT02085161|Experimental|tiotropium + olodaterol with exercise training and BM|patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning
3102397|NCT02085252|Experimental|Leuprorelin 11.25 mg|Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
3102398|NCT02085252|No Intervention|Active surveillance|Active surveillance is close medical monitoring of prostate cancer for any changes.
3102399|NCT02085356|Experimental|Intervention women with partners|Women will enroll with male partners and both members of the couple will attend the Protect your Family intervention
3102400|NCT02085356|Experimental|Intervention women without partners|Women will enroll alone and will attend the Protect your Family Intervention without a partner
3102401|NCT02085356|No Intervention|Control women with partners|Women will enroll with male partners and both members of the couple will attend time-matched video sessions
3102402|NCT02085356|No Intervention|Control women alone|Women will enroll alone and will attend time-matched video sessions
3102403|NCT02085447|Experimental|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
3102404|NCT02085460|Placebo Comparator|Placebo|6 times daily
3102405|NCT02085460|Experimental|2% Rebamipide liquid|6 times daily
3102406|NCT02085460|Experimental|4% Rebamipide liquid|6 times daily
3102407|NCT02085473|Active Comparator|Cohort 1|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'W' mL/min.
3102408|NCT02085473|Experimental|Cohort 2|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'X' mL/min.
3102409|NCT02085473|Experimental|Cohort 3|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Y' mL/min.
3102410|NCT02085473|Experimental|Cohort 4|Participants received 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at a flow rate of 'Z' mL/min.
3102411|NCT02085551|Experimental|Mechanical thrombectomy by the Indigo System|
3102412|NCT02085720|Experimental|Chinese elderly OSAS|Subjects will be recruited in the community elderly center with home sleep study done. Those with significant OSAS will be prescribed with CPAP therapy and subsequent compliance is monitored.
3102413|NCT02085785|Experimental|Coached|Participants randomized to the coached arm will receive the same educational and self-monitoring materials as the self-directed group. In addition, participants in the coached arm will receive 11 calls from a health coach and a single visit to their home by an exercise specialist.
3102414|NCT02085785|Active Comparator|Self-directed|Participants randomized to the self-directed arm will receive the same educational and self-monitoring materials as the coached group, but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
3102415|NCT02085785|Other|Screened|Individuals who were contacted to inform them about the study or who contacted study personnel to express an interest in participating. This group is presented in order to present statistics on feasibility regarding recruitment
3102416|NCT02085980|Experimental|Laser Treatment|Laser Treatment
3102417|NCT02086110|Active Comparator|Prebiotic only first, then synbiotic|This group will receive prebiotic only (bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the first five weeks, followed by a two week break with no treatment, and then will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the next five weeks.
3102418|NCT02086110|Active Comparator|Synbiotic first, then prebiotic only|This group will receive the synbiotic (Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally) for the first five weeks, followed by a two week break with no treatment, and then will receive the prebiotic only (bovine milk oligosacharrides, administered orally twice per day for a daily total of 0.3 g per pound of body weight) for the next five weeks.
3102419|NCT02086162|Experimental|Behavioral intervention|Web-based motivational decision support system
3102420|NCT02086162|Active Comparator|Educational intervention|Computerized version of the National Cancer Institute (NCI) Educational Pamphlet
3102421|NCT02086175|Experimental|Imprime PGG and Rituximab|The study drug, Imprime PGG, will be administered intravenously at a dose of 4mg/kg weekly for 4 weeks. Rituximab will be administered intravenously by institutional standards concurrently at a dose of 375mg/m2 weekly for 4 weeks. Response will be assessed with CT scans 10 weeks +/- 3 days following the completion of treatment
3102422|NCT02086331|Active Comparator|Healthy|Healthy volunteers, deemed to have normal metabolic and cardiovascular biology by trial criteria
3102423|NCT02086331|Active Comparator|PAD|Symptomatic peripheral arterial disease
3102424|NCT02086331|Active Comparator|DM|Symptomatic diabetic peripheral neuropathy
3102425|NCT02086500|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during emergency medical transport
3102426|NCT02086500|Placebo Comparator|Control|Identical volume of saline during emergency medical transport
3469107|NCT03889457||Patients with venous thromboembolic disease|Patients with deep vein thrombosis, superficial or muscular vein thrombosis, pulmonary embolism, over 18 years of age.
3102428|NCT02086565|Experimental|Portal training and home visits|Portal training and home visits from a community health worker to promote care coordination and use of the patient portal
3102429|NCT02086565|Active Comparator|portal training|Participants are assured internet access and taught to use the patient portal
3102430|NCT02086591|Experimental|Doxycycline|Doxycycline 200 mg twice daily
3102431|NCT02086682||General Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the inpatient dialysis unit. This was an observational study, with no interventions.
3102432|NCT02086682||Critical Care Cohort|The group included adult hospitalized patients requiring hemodialysis at the intensive care unit. This was an observational study, with no interventions.
3469108|NCT03889470|Active Comparator|200 microgram NTG|200 microgram NTG through the radial sheath
3469109|NCT03889470|Placebo Comparator|Saline|Saline infusion through the radial sheath
3102433|NCT02086708|Experimental|Shear Wave Sonoelastography, Fibrosis stage|Shear Wave sonoelastography is performed on patients who are scheduled for a non-focal liver biopsy.
3102434|NCT02086786|Experimental|Gluteus (Risperidone ISM)|Risperidone ISM (75 mg) injection in the gluteal muscle at 28-day intervals
3102435|NCT02086786|Experimental|Deltoid (Risperdione ISM)|Risperidone ISM (75 mg) injection in the deltoid muscle at 28-day intervals
3102436|NCT02086968|Active Comparator|Injectafer|2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
3102437|NCT02086968|Active Comparator|Ferrous Sulfate tablets|Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
3102438|NCT02087046|Other|Stimulation|ANS Totally Implantable Deep Brain Stimulation System
3102439|NCT02087059|Experimental|Ruxolitinib|Ruxolitinib was administered orally twice daily at the starting dose of 5 mg, 15 mg or 20 mg bid based on Baseline platelet counts. The dosage was subsequently adjusted for safety and efficacy so that each patient was titrated to their most appropriate dose.
3102440|NCT02087085|Experimental|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye, administered by intravitreal injections using the Brimonidine Drug Delivery System (Brimo DDS®) applicator every 3 months from Baseline (Day 1) through Month 21.
3102441|NCT02087085|Sham Comparator|Sham|Sham treatment (control) in the study eye, administered by intravitreal injections using a needleless drug delivery system (DDS) applicator every 3 months from Baseline (Day 1) through Month 21.
3102442|NCT02087150|No Intervention|Medical management (MM)|Medical management will consist of 6 weeks of daily intranasal steroid (triamcinolone acetonide)
3102443|NCT02087150|Experimental|Eustachian tube balloon catheter (ETBC) plus MM|Eustachian tube dilation with the ETBC plus medical management
3102444|NCT02087163|Experimental|Movement Enhancement Technique|Movement Enhancement Technique Clear Aligner
3102445|NCT02087176|Experimental|AZD 1775, antimitotic, pegfilgrastim|AZD 1775, antimitotic agent + pegfilgrastim 21 day Cycle, maximum of 4 cycles
3102446|NCT02087176|Placebo Comparator|Placebo + antimitotic + pegfilgrastim|Placebo + antimitotic+pegfilgrastim 21 day cycle, maximum of 4 cycles
3102447|NCT02087241|Experimental|AZD1775 + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
3102448|NCT02087241|Experimental|Placebo + carboplatin + pemetrexed|Randomised: AZD1775 + pemetrexed + carboplatin followed by maintenance AZD1775 + pemetrexed versus pemetrexed and carboplatin followed by maintenance pemetrexed.
3102449|NCT02087306|Experimental|Brincidofovir|"Subjects who weighed <50 kg received 2 mg/kg (not to exceed 100 mg) BCV twice weekly administered orally as the appropriate volume of 10-mg/mL liquid suspension.~Subjects who weighed ≥50 kg received 100 mg BCV twice weekly administered orally as one 100 mg tablet (or the appropriate volume of 10-mg/mL liquid suspension if unable to swallow solid medicine)."
3102450|NCT02087423|Experimental|MEDI4736|see below
3102451|NCT02087514|Active Comparator|Transfusion of PRBC stored for 1 week|Subjects will receive blood transfusion with packed red blood cells stored for 1 week.
3102452|NCT02087514|Experimental|Transfusion of PRBC stored for 2 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 2 weeks.
3102453|NCT02087514|Experimental|Transfusion of PRBC stored for 3 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 3 weeks.
3102454|NCT02087514|Experimental|Transfusion of PRBC stored for 4 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 4 weeks.
3102455|NCT02087514|Experimental|Transfusion of PRBC stored for 5 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 5 weeks.
3102456|NCT02087514|Experimental|Transfusion of PRBC stored for 6 weeks|Subjects will receive blood transfusion with packed red blood cells stored for 6 weeks.
3102457|NCT02087670|Active Comparator|controlled, supervised exercise protocol|controlled, supervised exercise protocol within a cardiac rehabilitation program
3102458|NCT02087670|Placebo Comparator|community based exercise|educational program and not supervises exercise program
3102459|NCT02087748|Active Comparator|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
3102460|NCT02087748|Placebo Comparator|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
3102461|NCT02087774|No Intervention|Control School|Control School received no intervention.
3102462|NCT02087774|Experimental|6 minutes activity|Implementation of 6 minutes of physical activity daily into the school day routine. Children can jog in place, do jumping jacks or dance.
3102463|NCT02087904|Experimental|ABT-981 low dose|25 mg ABT-981 subcutaneous (SC) every 2 weeks (E2W)
3102464|NCT02087904|Experimental|ABT-981 medium dose|100 mg ABT-981 SC E2W
3102465|NCT02087904|Experimental|ABT-981 high dose|200 mg ABT-981 SC E2W
3102466|NCT02087904|Placebo Comparator|Placebo|Placebo
3102467|NCT02087943|Experimental|Apremilast 40 mg|Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
3102468|NCT02087943|Experimental|Apremilast 30 mg|Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
3102469|NCT02087943|Experimental|Placebo + Apremilast 40 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
3102470|NCT02087943|Experimental|Placebo + Apremilast 30 mg|Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
3102471|NCT02087943|Placebo Comparator|Placebo|Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.
3102472|NCT02087956|Active Comparator|Personalized Support for Progress (PSP)|In Personalized Support for Progress (PSP), patients meet with a navigator to prioritize their concerns using a decision aid, develop a plan based on their identified priorities, and execute the plan.
3102473|NCT02087956|Active Comparator|Enhanced Screening and Referral (ESR)|(ESR)- participant will receive personal report of their current needs and list of resources available in the community.
3102474|NCT02087995|Experimental|Continuous Glucose Monitoring System|Single-Arm, CGM Device Glucose challenge performed during a clinic session to obtain accuracy data for the CGM system compared to a venous reference measurement
3102475|NCT02088034|Experimental|Promotora-led Intervention|The Promotora-led Intervention consists of a core curriculum or 12 group sessions of 90 minute duration over a 12-week period and will be followed by a maintenance phase of 10 biweekly and then monthly 90-minute sessions during months 4 through 12. One promotora will lead each session in Spanish, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
3102476|NCT02088034|Active Comparator|Usual care|One physician visit at Puentes de Salud or Congreso Health Center to discuss healthy lifestyle behaviors that promote weight loss and diabetes prevention. During that visit, UC participants will also receive standard educational materials in Spanish from the NIDDK Weight-control Information Network covering the same topics. UC participants will receive another physician visit upon completion of 1-year follow-up to review laboratory assessments.
3102477|NCT02088034|Active Comparator|Metformin Therapy|Participants randomized to the metformin arm of the study will receive this medication from months 1 through 12 after randomization. Subjects will receive 850 mg daily for 1 month and increase to 850 mg twice daily thereafter if no side effects are experienced.
3102478|NCT02088047|Experimental|Profoveate|The experimental group will receive the ProFoveate™ intervention along with pre (baseline) and post (end line)intervention assessment. Steel pellets (1.2 mm) will be placed strategically on ears following instructions on how to use the ProFoveate™ pellets. Parents will be provided with a Patient Diary Sheet and will be instructed to perform and document daily checks for placement of the pellets. Parents will be given a one month supply of stainless steel pellets at the initial study visit. Child participants will wear the stainless steel ProFoveate™ pellets for four weeks.
3102479|NCT02088047|No Intervention|NonProFoveate|Participants in the control group will have no intervention. They will receive the initial pre testing (baseline) followed by post testing after 4 weeks.
3102480|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g three times daily|Sodium zirconium cyclosilicate 10 g three times daily for 48 hours (acute phase)
3102481|NCT02088073|Placebo Comparator|Placebo once daily|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days.
3102482|NCT02088073|Experimental|Sodium zirconium cyclosilicate 5 g once daily|Sodium zirconium cyclosilicate (ZS) 5 g once daily for 28 days (maintenance phase)
3102483|NCT02088073|Experimental|Sodium zirconium cyclosilicate 10 g once daily|Sodium zirconium cyclosilicate (ZS) 10 g once daily for 28 days (maintenance phase)
3102484|NCT02088073|Experimental|Sodium zirconium cyclosilicate 15 g once daily|Sodium zirconium cyclosilicate (ZS) 15 g once daily for 28 days (maintenance phase)
3102485|NCT02088177|Experimental|Long-acting injectable naltrexone|Two doses of long-acting injectable naltrexone, 380 mg by intramuscular injection in the gluteal muscle at study day 1 and again between study days 28-30.
3102486|NCT02088216|Active Comparator|N-Acetylcysteine group|Participants received 600 mg of oral N-acetylcysteine BID for 12 months.
3102487|NCT02088216|Other|Control group|Participants received as-needed therapy.
3102488|NCT02088385|Experimental|Hemospray|Hemospray (TC-325, Cook Medical Inc, Winston-Salem, NC, USA), an adsorptive nanopowder hemostatic agent
3102489|NCT02088385|Active Comparator|Combined Conventional Technique|Standard dual therapy with saline adrenaline injection and hemoclip / heater probe application
3102490|NCT02088541|Experimental|Selinexor approximately 55 mg/m^2 (60 to 120 mg based on BSA)|Participants under protocol versions (PV) less than (<) 5.0 (those who had one prior line of acute myeloid leukemia (AML) therapy), receive oral selinexor tablets at a dose of approximately 55 mg/m^2 (milligrams per square meter) (60 to 120 mg based on body surface area [BSA]) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
3102491|NCT02088541|Experimental|Selinexor 60 mg (PV <5) (Equivalent to 35 mg/m^2)|Participants under PV < 5.0 (those who had one prior line of AML therapy), receive oral selinexor tablets at a fixed dose of 60 mg (equivalent to 35 mg/m^2), based on BSA, twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
3102492|NCT02088541|Experimental|Selinexor 60 mg (PV >=5) (Equivalent to 35 mg/m^2)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), receive oral selinexor tablets at a dose of 60 mg (equivalent to 35 mg/m^2) twice weekly, on Day 1 and 3 of each week of 4-week cycle (28 days per cycle).
3102493|NCT02088541|Active Comparator|Physician's Choice 1 (PV <5)|Participants under PV < 5.0 (those who had one prior line of AML therapy) received Best Supportive Care (BSC) which included blood product transfusions, antimicrobials, growth factors as needed, and hydroxyurea.
3102494|NCT02088541|Active Comparator|Physician's Choice 2 (PV >=5)|Participants under PV >= 5 (PV 5: those who had at least one prior line of AML therapy, PV 5.1: who had at least two prior line of AML therapy), received BSC along with subcutaneous injection of arabinoside cytosine (Ara-C), 20 mg, twice daily, for 10 days, repeated at 28 to 42 day intervals.
3102495|NCT02088697|Experimental|ASC-01 placebo|A single oral dose of ASC-01 Placebo (sertraline 100 mg)
3102496|NCT02088697|Active Comparator|Sertraline tablet|A single oral dose of sertraline tablets (sertraline 100 mg)
3102497|NCT02088788|Experimental|"Board (Rad Board)"|Radial artery catheterization is performed using radio-opaque armboard
3102498|NCT02088788|Active Comparator|No Board|Regular radio-penetrating armboard is used (the one normally used during non-study procedures) with a radio-opaque pelvic shield
3102499|NCT02088905|Experimental|Parent Child Interaction Therapy|Families will either receive Parent Child Interaction Therapy or be placed on a wait-list control group
3102500|NCT02088905|No Intervention|Wait list control|Families will wait 18 weeks for treatment, serving as controls.
3102501|NCT02089113|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3102502|NCT02089113|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3102503|NCT02089191|Other|DACP/MyDay|Nelfilcon A contact lenses worn in Period 1, with stenfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
3102504|NCT02089191|Other|MyDay/DACP|Stenfilcon A contact lenses worn in Period 1, with nelfilcon A contact lenses in Period 2. Each product worn bilaterally for 12 hours over 1 day.
3102505|NCT02089230|Experimental|Phase I Cohort 1 - MEK 162|Phase I Starting Dose of MEK 162: 30 mg by mouth twice a day in a 28 day cycle.
3102506|NCT02089230|Experimental|Phase I Cohort 2 - MEK 162|Phase I Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
3102507|NCT02089230|Experimental|Phase II Cohort 3 - MDK 162|Phase II Starting Dose of MEK 162: 45 mg by mouth twice a day in a 28 day cycle.
3102508|NCT02089334|Experimental|RX-0201 plus everolimus (Stage 1 & 2)|RX-0201 and everolimus will be taken together as described in the Interventions description.
3102509|NCT02089347|Experimental|SP306 Group|Participants randomized to receive SP306 vaccine intramuscularly
3102510|NCT02089347|Active Comparator|DT Group|Participants randomized to receive DT vaccine subcutaneously
3102511|NCT02089464|Active Comparator|NBS-rTMS + task-oriented rehabilitation|NBS-guided rTMS + task-oriented rehabilitation
3102512|NCT02089464|Sham Comparator|Sham rTMS + task-oriented rehabilitation|Sham rTMS + task-oriented rehabilitation
3102513|NCT02089659|Experimental|Part 1: Moderate Hepatic Insufficiency|Participants with moderate hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have moderate hepatic insufficiency based on the Child-Pugh scale.
3102514|NCT02089659|Experimental|Part 1: Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine on Day 1 of Part 1.
3102515|NCT02089659|Experimental|Part 2: Mild Hepatic Insufficiency|Participants with mild hepatic insufficiency receive a single oral dose of 100 mg doravirine on Day 1 of Part 1. All participants in this arm were to have mild hepatic insufficiency based on the Child-Pugh scale. This arm was to be enrolled and investigated only if a clinically meaningful increase in exposure of doravirine was observed in participants with moderate hepatic insufficiency in Part 1.
3102516|NCT02089737||Panitumumab 6 mg/kg|Panitumumab 6 mg/kg, intravenous drip infusion over a 60-minute period, once every 2 weeks
3102517|NCT02089997||75 mg of sodium risedronate|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.
3102518|NCT02090075|Active Comparator|apixaban|apixaban 5 mg or 2.5 mg po bid
3102519|NCT02090075|Placebo Comparator|warfarin|warfarin with target INR of 2-3
3102520|NCT02090088||All Subjects|All Subjects
3102521|NCT02090283|Experimental|SD-101 Dermal Cream (6%)|All participants applied SD-101 dermal cream topically, once a day, to the entire body for the duration of the study.
3102522|NCT02090374|Experimental|Poly ICLC dose escalation|Poly ICLC nasal challenge dose escalation 10ug, 100ug, 500ug
3102523|NCT02090374|Experimental|Poly ICLC highest dose|Poly ICLC nasal challenge single dose of 1000ug
3102524|NCT02090374|Experimental|Poly I:C single dose|Poly I:C nasal challenge single dose 500ug
3102525|NCT02090374|Experimental|R848 high dose|R848 nasal challenge 10ug
3102526|NCT02090374|Experimental|R848 low dose|R848 nasal challenge low dose 1-2ug (0.02ug/kg)
3102527|NCT02090374|Experimental|Grass pollen|Timothy grass pollen nasal challenge
3102528|NCT02090374|Experimental|Vitamin D supplementation|Vitamin D 4000U orally daily
3102529|NCT02090374|Experimental|Tuberculin|Tuberculin PPD nasal challenge
3102530|NCT02090413|Experimental|DMF + ASA 150 mg BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 150 mg is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3102531|NCT02090413|Experimental|DMF + ASA 75 mg QAM|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA 75 mg is taken in the morning (QAM) and ASA-Placebo is taken in the evening (QPM) from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3102532|NCT02090413|Experimental|DMF + ASA-Placebo BID|"DMF 120 mg taken BID for the first 7 days and 240 mg BID from Week 2 through Week 48.~ASA-Placebo is taken BID from Day 1 through Week 4. (Between Weeks 5 and 8, ASA is prohibited; between Weeks 9 and 48, ASA is allowed as needed.)"
3102533|NCT02090426|No Intervention|Standard Care|Individuals in the standard care arm receive standard discharge planning from the hospital with no followup by Link2Care team members.
3102534|NCT02090426|Experimental|Link2Care|Participants are assigned to a multidisciplinary care team (Link2Care) comprised of a registered nurse, licensed practical nurse, social worker, intervention specialist, community health worker, and health coaches. A representative from the care team engages with the patient at bedside during the hospital admission and plans for the immediate period following discharge. The Program, as a whole, involves a series of home visits, scheduling of and accompaniment to initial primary care and specialty care visits, and support for individuals as they navigate various social service agencies to enroll in public programs including TANF, SNAP, and programs that promote housing stability.
3102535|NCT02090634|Experimental|Personalized Reminder Texting + Psychoeducation (iTAB)|Participants in the individualized Texting for Adherence Building (iTAB) arm will receive daily text messaging reminders for antiretroviral and psychotropic medication adherence. These text messages will be targeted to the specific schedule and needs of the individual. Participants will also receive a text message that assesses mood. Finally, participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications.
3102536|NCT02090634|Active Comparator|Psychoeducation (CTRL)|Participants will receive a one-time psychoeducational intervention reviewing the importance of adherence to anti-HIV and psychotropic medications. They will also receive daily text messages to assess mood, but these messages will not receive the medication reminder text messages.
3102537|NCT02090725|Experimental|3-4 Diaminopyridine (DAP)|
3102538|NCT02090764|Experimental|Ozenoxacin|ozenoxacin cream 1%
3102539|NCT02090764|Placebo Comparator|Placebo|Placebo cream
3102540|NCT02090777|Other|Health Coach|Health Coach is conducted to see if it improves ophthalmic care for glaucoma patients.
3102541|NCT02090855||Flutemetamol (18F)|There are no interventions in this study. This study is to assess the images taken previously from another study, GE-067-007.
3102542|NCT02090894|Experimental|UV Light|
3102543|NCT02090959|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for up to 144 weeks.
3102544|NCT02091089|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
3102545|NCT02091102|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3102546|NCT02091167|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
3102547|NCT02091167|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 30 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
3102548|NCT02091206|Experimental|GWP42003-P 5 mg/kg/day Dose|Participants received GWP42003-P 5 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 5 mg/kg/day over 3 days and remained at this dose for the rest of the 21-day treatment period (19 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3102549|NCT02091206|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the rest of the 21-day treatment period (15 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3102550|NCT02091206|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the rest of the 21-day treatment period (11 days). The 21-day treatment period was followed by a 10-day taper (10% per day) period.
3102551|NCT02091206|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to one of the 3 dose levels (5, 10, or 20 mg/kg/day), administered orally, half in the morning and half in the evening for 21 days. To maintain the blinded aspect of the study, participants titrated the placebo dose over 3 to 11 days according to the matched investigational medicinal product (IMP) group (3, 7, and 11 days for the 5, 10, or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the rest of the 21-day treatment period. The 21-day treatment period was followed by a 10-day taper (10% per day of the matched dose) period.
3102552|NCT02091284|Experimental|real tDCS|Ten sessions (every other day) of bilateral transcranial Direct Current Stimulation (tDCS: 2 milliamperes, 3 x 7 cm2, during 20 minutes) over dorsolateral Prefrontal Cortex (cathodal left / anodal right).
3102553|NCT02091284|Sham Comparator|sham-tDCS|Ten sessions (every other day) of placebo control (sham procedure) of transcranial Direct Current Stimulation (sham-tDCS) during 20 minutes with electrodes placed over the dorsolateral Prefrontal Cortex (cathodal left / anodal right). Current was delivered for 20 seconds and was turned off for the rest of the stimulation period. In this way, subjects experienced the initial itching sensation at the beginning of stimulation, but received no current for the rest of the session.
3102554|NCT02091362|Placebo Comparator|Placebo|Single daily dose of placebo matching LY2409021 administered orally in 1 of 2 treatment periods.
3102555|NCT02091362|Experimental|LY2409021|Single daily dose of 20 milligrams (mg) LY2409021 administered orally in 1 of 2 treatment periods.
3102556|NCT02091375|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3102557|NCT02091375|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
3102558|NCT02091414|Experimental|MMF, CsA, Corticosteroids|Participants received mycophenolate mofetil (MMF) 1.0 grams (g), orally (PO), twice daily (BID) from within 24 hours of transplantation through Week 24. Participants also received an initial loading dose of cyclosporine A (CsA) 4 to 6 milligrams per kilogram (mg/kg) within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 nanograms per milliliter (ng/mL) through Week 24. Participants also received corticosteroids as per the practice of each participating center.
3102559|NCT02091440|Other|HW005 Ventricular Assist System|Implant of the HW005 Ventricular Assist System.
3102560|NCT02091466|Active Comparator|Pre-warming|The intervention is to warm patients before the anesthesia procedure in experimental groups
3102561|NCT02091466|No Intervention|Control|Patients received no active warming before the anesthesia procedure in control groups
3102562|NCT02091531|Experimental|MLN0128|Patients will be treated with the established phase II dose of MLN0128 (4mg po daily continuously; 1 cycle=4 weeks) to assess mechanisms of sensitivity and resistance in men with CRPC who have received either enzalutamide and/or abiraterone.
3102563|NCT02091726|Experimental|Unicirc with tissue adhesive|Circumcision with Unicirc instrument, followed by wound sealing with cyanoacrylate
3102564|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (100 Units)|"Main period (1 treatment cycle): Subjects to receive 100 Units.~Extension period (3 treatment cycles): Subjects to receive 100 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3102565|NCT02091739|Experimental|IncobotulinumtoxinA (Xeomin) (75 Units)|"Main period (1 treatment cycle): Subjects to receive 75 Units.~Extension period (3 treatment cycles): Subjects to receive 75 Units per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3102566|NCT02091739|Placebo Comparator|Placebo|"Main period (1 treatment cycle): Subjects to receive placebo injection.~Extension period (3 treatment cycles): Subjects will be randomized to receive either 75 or 100 Units IncobotulinumtoxinA per treatment cycle.~Mode of administration: Four injections per treatment cycle (parotid and submandibular glands, bilateral)"
3102567|NCT02091778|Experimental|Fast Gelling Dressing|
3102568|NCT02091856|Experimental|Conventional-CBT (C-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the mindfulness paradigm.
3102569|NCT02091856|Experimental|Religious CBT (R-CBT)|This arm represents the classical Cognitive Behavioral Therapy (CBT) approach for major depression disorder (MDD) plus a set of exercises devised from the general Christian belief.
3102570|NCT02091856|No Intervention|Wait List Control Group (WLCG)|This arm represents the wait-list comparison group.
3102571|NCT02091869|Experimental|Paper Asthma Action Plan|Participants will utilize a paper-based asthma action plan to record asthma symptoms, peak flows, and medication usage.
3102572|NCT02091869|Experimental|Mobile Phone|Participants will record asthma symptoms, medication usage, and peak flow data on their phones.
3102573|NCT02091882|Experimental|Aripiprazole IEM Tablet + Placebo IEM Tablet + MIND1 System|"Participants were placed a patch by the clinical staff prior to each ingestible event marker (IEM) tablet ingestion. Participants received one IEM tablet approximately every 2 hours, for a total of 4 ingestions on Day 1 at 0, 2, 4 and 6 hours.~Following placement of the patch by clinic staff, participants ingested one 10 mg aripiprazole-embedded IEM tablet without food at Hour 0, one placebo-embedded IEM tablet without food at approximately Hour 2, one placebo-embedded IEM tablet with a high fat meal at approximately Hour 4, and one placebo-embedded IEM tablet without food at approximately Hour 6. Clinic staff recorded the time of each ingestion of an IEM and the time detected by MIND1 System."
3102574|NCT02091921|Experimental|Experimental|All subjects will receive Ticagrelor.
3469110|NCT03889288|No Intervention|conventional management of postoperative pain|Patients who have had an aortic valve replacement surgery have a conventional management of pain after surgery. The pain is treated by morphine using a patient-controlled analgesia for the administration. Patients are recruiting prospectively or possibly retrospectively. The management is usual, nothing from the conventional care of patients change, only data will be collected.
3102576|NCT02091986|Active Comparator|Symbicort pMDI 80/2.25 µg|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
3102577|NCT02091986|Active Comparator|Symbicort pMDI 80/4.5µg|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
3102578|NCT02091986|Active Comparator|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
3102579|NCT02092025||Azilsartan|Azilsartan 20 mg - 40 mg, tablet, orally, once daily for up to 12 months in participants based upon the disease severity. Participants will receive interventions as part of routine medical care.
3102580|NCT02092116|Other|Part A|"Pre-treatment phase of 2-4 weeks (Visit 1- Visit 2a) followed by viral reactivation phase of 3 weeks (Visit 2 to Visit 7) consisting of one cycle of romidepsin infusions at a dosing of 5 mg/m2 on days 0, 7, and 14.~Post-activation phase of ~9 weeks (Visit 8 to Visit 11) to assess the effect of romidepsin on the size of latent HIV-1 reservoir."
3102581|NCT02092116|Other|Part B|"Pre-treatment phase of 2-4 weeks (Visit 1-Visit 2) followed by a therapeutic HIV-1 immunization phase of 12 weeks (Visit 2 to Visit 7) in which 1.2 mg Vacc-4x was administered together with 0.06 mg rhuGM-CSF at Visits 2, 3, 4, 5, 6 and 7 follow by a follow-up period of 2 weeks (Visit 8).~A viral reactivation phase of 3 weeks (Visit 9-Visit 11) consisting of one cycle of 3 romidepsin infusions (5 mg/m2) followed by a post-treatment observation phase of ~9 weeks (Visit 12-Visit 13) to assess the effect of the investigational treatment on the size of the latent HIV-1 reservoir.~A monitored antiretroviral pause of up to 16 weeks (Visit 14-Visit 33)."
3102582|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Elderly Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
3102583|NCT02092168|Experimental|BIA 9-1067 30 mg (once daily) - Young Subjects|BIA 9-1067 was administered as oral doses of 30 mg (5 and 25 mg capsules), once-daily in the morning, during 7 days.
3102584|NCT02092181|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 mg daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or, for those in the placebo arm, two placebo tablets.
3102585|NCT02092181|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 25 mg daily or placebo at visit 2. At visit 3 all subjects who have tolerated Mirabegron 25 md daily (no adverse events on this dose) will be up-titrated to Mirabegron 50 mg daily. This will be dispensed as two 25mg tablets or , for those in the placebo arm, two placebo tablets.
3102586|NCT02092220|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 11 days.
3102587|NCT02092220|Active Comparator|Usual Care|Usual Care diabetes management, standard of care for diabetes including use of an insulin pump with or without CGM according to the participant's usual practice, for 11 days.
3102588|NCT02092285|Experimental|Golimumab|The first induction dose of subcutaneous (SC) golimumab 200 mg was administered at Day 0. The second induction dose of SC golimumab 100 mg was administered two weeks later at Week 2. Responders at Week 6 received a maintenance dose of golimumab (50 mg for participants with a body weight <80 kg or 100 mg for participants with a body weight ≥80 kg) every 4 weeks during the Maintenance Phase for 48 weeks, yielding a total of 54 weeks treatment.
3102589|NCT02092298|Experimental|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg for 60 minutes, performed 2-8 weeks after completion of systemic chemotherapy. Loading dose Sodium Thiosulfate 7.5 gm/M2 infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by infusion pump over 12 hours.
3102590|NCT02092311|Experimental|Combined Microscopic Varicocelectomy|Patients in this arm were operated with Combined Mini-incision Microscopic approach
3102591|NCT02092311|Active Comparator|Inguinal and Subinguinal Varicocelectomy|Patients in this arm have the same including criteria as Experimental arm but they were operated with conventional and currently popular approach of Microscopic Inguinal and Sub inguinal varicocelectomy suggested by Goldstien and associates
3102592|NCT02092324|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO every other day, QD, or BID on days 1-28. Each patient will be followed for a maximum of 96 weeks (24 cycles, 1 cycle is 4 weeks long). If the study drug continues to be effective, the patient may be eligible to continue on study drug past 24 cycles.
3102593|NCT02092350|Experimental|Immediate Treatment|Participants receive grazoprevir 100 mg tablet, orally, once per day (QD) + elbasvir 50 mg tablet, orally, QD, for 12 weeks.
3102594|NCT02092350|Experimental|Deferred Treatment|Participants receive placebos to both grazoprevir and elbasvir for 12 weeks, and after a 4-week break, grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks.
3102595|NCT02092350|Experimental|Intensive PK|Participants receive grazoprevir 100 mg tablet, orally, QD + elbasvir 50 mg tablet, orally, QD for 12 weeks with intensive PK testing.
3102596|NCT02092389||Moderate to Severe Ulcerative Colitis|Patients with moderate to severe ulcerative colitis (UC) who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant (azathioprine [AZA]/ 6-mercaptopurine [6-MP]); or who are intolerant to or have medical contraindications for such therapies and are hence prescribed adalimumab for the treatment of moderate to severely active UC.
3102597|NCT02092415|Experimental|Normal subjects|Normal subjects, all of whom undergo brief application of junctional tourniquet
3102598|NCT02092441|Active Comparator|Alcohol prep pad group|isopropyl alcohol prep pad
3102599|NCT02092441|Placebo Comparator|Normal Saline prep pad|normal saline prep pad
3102600|NCT02092467|Experimental|Treatment Arm 1|
3102601|NCT02092467|Experimental|Treatment Arm 2|
3102602|NCT02092467|Active Comparator|Treatment Arm 3|TNF inhibitor Arm - adalimumab will be used in US, Canada and Puerto Rico; etanercept will be used in all other countries.
3102603|NCT02092610|Active Comparator|Standard Implant BI300|The product was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
3102604|NCT02092610|Experimental|Novel Implant BI300|The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
3102605|NCT02092649|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
3102606|NCT02092649|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
3102607|NCT02092662||Stroke|Stroke patients at the subacute phase
3102608|NCT02092662||Healthy controls|healthy age-matched voluntiers
3102609|NCT02092857|Active Comparator|34 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 34 mg/100 kcal of arachidonic acid
3102610|NCT02092857|Active Comparator|25 mg/100 kcal arachidonic acid|10 weeks exclusive feeding with infant formula containing 25 mg/100 kcal of arachidonic acid
3102611|NCT02092857|Placebo Comparator|Infant formula without arachidonic acid|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
3102612|NCT02092909|Experimental|IMO-8400 at escalating dose levels|IMO-8400 at escalating dose levels by subcutaneous injection
3102613|NCT02092961|Experimental|Dosing Group A|Oral treatment and subcutaneous injection.
3102614|NCT02092961|Active Comparator|Dosing Group D|Oral treatment and subcutaneous injection.
3102615|NCT02092961|Placebo Comparator|Dosing Group E|Placebo bid for 6 weeks followed by switch to 100 mg fostamatinib bid for 24 weeks, plus placebo subcutaneous injection every 2 weeks.
3102616|NCT02092987|Experimental|NYU Caregiver Intervention|The New York University (NYU) caregiver intervention arm received the NYU caregiver intervention in addition to social work support and educational materials.
3102617|NCT02092987|Active Comparator|REACH OUT|The Resources for Enhancing Caregiver Health Offering Useful Treatments (REACH OUT) intervention arm received the REACH OUT caregiver intervention in addition to social work support and educational materials.
3102618|NCT02093026|Experimental|Rituximab|Participants will receive rituximab 1 gram intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants will receive methotrexate 10-25 milligrams per week (mg/week) orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid greater than or equal to (>=) 5 mg/week or equivalent. Participants will receive retreatment (next course of rituximab repeat treatment) within 2 weeks of meeting the retreatment criteria as defined in the protocol (minimum of 24 weeks after the first [Day 1] infusion of the last course of rituximab). Repeat treatment will be based on the investigator's decision of prior clinical response to rituximab, clinical need and evidence of active disease (Disease Activity Score in 28 joints >=2.6). Retreatment with rituximab will be continued until withdrawal of consent or study treatment completion on 31 December 2011, whichever is sooner.
3102619|NCT02093221|Experimental|Alpha1-PI 180 mg/kg/wk, 26 weeks|180 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
3102620|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 26 weeks|90 mg/kg weekly infusions of Alpha1-PI for 26 weeks.
3102621|NCT02093221|Placebo Comparator|Placebo, 26 weeks|Weekly infusions of placebo for 26 weeks.
3102622|NCT02093221|Experimental|180 mg/kg/wk Alpha1-PI, 13 weeks|180 mg/kg weekly infusions of Alpha1-PI for 13 weeks.
3102623|NCT02093221|Experimental|90 mg/kg/wk Alpha1-PI, 13 weeks|90 mg/kg weekly infusions of Alpha1-PI for 13 weeks
3102624|NCT02093221|Placebo Comparator|Placebo, 13 weeks|Weekly infusions of placebo for 13 weeks.
3102625|NCT02093234|Active Comparator|Mobile health care application|Patients will be assisted with managing their health by a cell phone application used to promote self care for patients with diabetes.
3102626|NCT02093234|Active Comparator|Community Health Worker (CHW)|CHWs assist study patients in managing there health care in various ways.
3102627|NCT02093234|Experimental|CHWs and mobile health care application|Patients will receive assistance in managing their health from both CHWs and the mobile health cell phone application
3102628|NCT02093351|Experimental|Cohort 1 - Tamoxifen|Olaparib-alone Steady state PK, Tamoxifen-alone steady state PK, Combined olaparib and Tamoxifen steady state PK.
3102629|NCT02093351|Experimental|Cohort 2 - Anastrozole|Olaparib-alone Steady state PK, Anastrozole-alone steady state PK, Combined olaparib and Anastrozole steady state PK.
3102630|NCT02093351|Experimental|Cohort 3 - Letrozole|Olaparib-alone Steady state PK, Letrozole-alone steady state PK, Combined olaparib and Letrozole steady state PK.
3102631|NCT02093390|Experimental|TAK-385 + fluconazole|TAK-385 40 mg, tablet, orally once on Day 1 and fluconazole 400 mg, tablet, orally on Day 6 then 200 mg, tablet, orally once daily on Days 7 to 9 followed by a single dose of TAK-385 in combination with fluconazole 200 mg on Day 10 then fluconazole 200 mg, tablet, orally once daily alone on Days 11 to 14.
3102632|NCT02093390|Experimental|TAK-385 + atorvastatin|TAK-385 40 mg, tablet, orally once on Day 1 and atorvastatin 80 mg, tablet, orally once daily on Days 6 to 9 followed by a single dose of TAK-385 in combination with atorvastatin 80 mg on Day 10 then atorvastatin 80 mg, tablet, orally once daily alone on Days 11 to 14.
3102633|NCT02093520|Active Comparator|MILD|The MILD procedure is an image-guided minimally-invasive lumbar decompression
3102634|NCT02093520|Active Comparator|Epidural Steroid Injection (ESI)|An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.
3102635|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (>) 23 kg to <= 35 kg; 1800 mg/day for participants weighing > 35 kg to <= 50 kg; 2400 mg/day for participants weighing > 50 kg to <= 90 kg.
3102636|NCT02093663|Experimental|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to <= 23 kg; 2400 mg/day for participants weighing > 23 kg to <= 35 kg; 3600 mg/day for participants weighing > 35 kg to <= 50 kg; 4800 mg/day for participants weighing > 50 kg to <= 90 kg.
3102637|NCT02093702|Active Comparator|Unstructured Physical Activity and Exercise Education Delivery|50 subjects will receive the standard approach to physical activity and exercise education from a Certified Diabetes Educator.
3102638|NCT02093702|Experimental|Structured Physical Activity and Exercise Education Delivery|50 subjects will receive physical activity and exercise education and behaviour counseling from a qualified Exercise Specialist (Registered Kinesiologist). These subjects will receive access to a community health and fitness centre as well as exercise instruction and on-going support and motivation from a YMCA Wellness Coach who focuses on establishing healthy behaviors towards the attainment of personal goals. Subjects will be requested to complete a lifestyle questionnaire at each appointment with their Wellness Coach. Subjects will receive a Physical Activity and Exercise Journal that will help them keep track of their weekly physical activity and exercise activities.
3102639|NCT02093793|Experimental|High Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
3102640|NCT02093793|Active Comparator|Commercial Rate Spinal Cord Stimulation|PRECISION SCS Adapted for High-Rate SCS
3102641|NCT02093819|Experimental|BI 416970 single rising dose part|single rising dose given as tablet
3102642|NCT02093897|Experimental|rVIII-SingleChain|Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
3102643|NCT02093923|Experimental|DX-2930, Cohort 1|Participants will receive 30 milligram (mg) dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
3102644|NCT02093923|Experimental|DX-2930, Cohort 2|Participants will receive 100 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
3102645|NCT02093923|Experimental|DX-2930, Cohort 3|Participants will receive 300 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
3102646|NCT02093923|Experimental|DX-2930, Cohort 4|Participants will receive 400 mg dose of DX-2930 subcutaneous (SC) injection once and followed by the second dose after 2 week into the upper arm.
3102647|NCT02093923|Placebo Comparator|Placebo|Participants will receive placebo matched to 30, 100, 300 and 400 mg dose of DX-2930 SC injection once and followed by the second dose after 2 week into the upper arm.
3102648|NCT02093949||Studied|Between September 2013 and July 2014, 105 patients were enrolled in 3 centers performing routinely Atrial Fibrillation ablation guided by spatio-temporal electrogram dispersion without pulmonary vein Isolation
3102649|NCT02093949||Control|The validation set included a cohort of 47 patients with symptomatic drug-refractory AF who underwent ablation using a conventional approach.
3102650|NCT02093962|Experimental|TH-302 and pemetrexed|TH-302 in combination with pemetrexed
3102651|NCT02093962|Active Comparator|Placebo and pemetrexed|Matching placebo in combination with pemetrexed
3102652|NCT02094118|Active Comparator|Standard of care red blood cell transfusion|Red blood cells that are administered in the normal fashion.
3102653|NCT02094118|Experimental|Point-of-Care washed red blood cell transfusion|Red blood cells that are washed at the point-of-care.
3102654|NCT02094300|Experimental|Endovascular|
3102655|NCT02094417|Experimental|AMG531 (Dose 1)|
3102656|NCT02094417|Experimental|AMG531 (Dose 2)|
3102657|NCT02094417|Experimental|AMG531 (Dose 3)|
3102658|NCT02094417|Experimental|AMG531 (Dose 4)|
3102659|NCT02094443|Experimental|Alisporivir 300 mg BID|Alisporivir (ALV) 300 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
3102660|NCT02094443|Experimental|Alisporivir 400 mg BID|ALV 400 mg twice daily (BID) with ribavirin for 12 or 24 weeks based on Week 2 response, with a safety follow-up of at least 4 weeks, during which patients did not receive any study medication
3102661|NCT02094534|Experimental|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
3102662|NCT02094534|Placebo Comparator|Placebo|Fish oil in capsules, identical in appearance to ORMD-0801
3102663|NCT02094573|Experimental|Brigatinib 90 mg|Brigatinib 90 mg, tablets, orally, once daily in each Cycle of 28 days until disease progression or intolerable toxicity (median duration of exposure was 402 days).
3102664|NCT02094573|Experimental|Brigatinib 90 mg - 180 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days followed by brigatinib 180 mg, orally once daily in Cycle 1 of 28 days followed by brigatinib 180 mg, orally once daily in Cycle 2 and onward Cycles of 28 days until disease progression or intolerable toxicity (median duration of exposure was 522 days).
3102665|NCT02094586|Experimental|PXVX0200 Lot A|PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
3102666|NCT02094586|Experimental|PXVX0200 Lot B|PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
3102667|NCT02094586|Experimental|PXVX0200 Lot C|PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
3102668|NCT02094586|Placebo Comparator|Placebo|Placebo physiological saline
3102669|NCT02094612|Active Comparator|Usual Care|Usual clinic ADHD care
3102670|NCT02094612|Experimental|Usual Care plus Assessment|Usual clinic ADHD care plus the Quotient®
3102671|NCT02094664|No Intervention|Standard oxygen via nasal cannula|Standard therapy
3102672|NCT02094664|Active Comparator|Heated and humidified oxygen|Heated and humified oxygen
3102673|NCT02094677|Active Comparator|filcon II 3 and etafilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
3102674|NCT02094677|Active Comparator|filcon II 3 and nelfilcon A|Participants were randomized to a test and control lens for each group in a contralateral design.
3102675|NCT02094716|Experimental|Permethrin Foam 4%/ Permethrin Foam 4%|First treatment with Permethrin Foam 4% with potential to re-treat with Permethrin Foam 4%, if necessary.
3102676|NCT02094716|Experimental|Permethrin Foam 5%/ Permethrin Foam 5%|First treatment with Permethrin Foam 5% with potential to re-treat with Permethrin Foam 5%, if necessary.
3102677|NCT02094716|Placebo Comparator|Vehicle Foam / Permethrin Foam 4%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 4%, if necessary.
3102678|NCT02094716|Placebo Comparator|Vehicle / Permethrin Foam 5%|First treatment with Vehicle with potential to re-treat with Permethrin Foam 5%, if necessary.
3102679|NCT02094755||Single cohort|Single cohort will receive Blood draw only.
3102680|NCT02094872|Experimental|Arm I (molecularly targeted therapy)|Patients undergo collection of tissue and blood samples for DNA and RNA analysis via sequencing. Based on the results of the DNA and RNA analysis, patients receive molecularly targeted therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3102681|NCT02094885|Experimental|Bioseal Fibrin Sealant|A porcine-derived fibrin sealant consisting of thrombin and fibrinogen
3102682|NCT02094885|Other|Manual compression|Manual compresssion (MC) include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants.
3102683|NCT02094898|Experimental|Ketamine infusion|This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
3102684|NCT02094937|Experimental|Arm 1 FF/VI 100/25 mcg|Subjects will receive Fluticasone Furoate/Vilanterol 100/25 mcg once-daily via a dry powder inhaler for 8 weeks in the open-label treatment period.
3102685|NCT02094937|Experimental|Arm 2 FF 100 mcg|Subjects will receive Fluticasone Propionate matching placebo twice-daily (morning and evening) and Fluticasone Furoate 100 mcg once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3102686|NCT02094937|Experimental|Arm 3 FP 250 mcg|Subjects will receive Fluticasone Propionate 250 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3102687|NCT02094937|Experimental|Arm 4 FP 100 mcg|Subjects will receive Fluticasone Propionate 100 mcg twice-daily (morning and evening) and Fluticasone Furoate matching placebo once daily in the evening, via a dry powder inhaler for 12 weeks in the double-blind treatment period
3102688|NCT02095106|Other|Traditional cast first|Patients in this group will first receive a traditional fiberglass cast for two weeks, after which this cast will be removed and a waterproof cast applied.
3102689|NCT02095106|Other|Waterproof cast first|Patients in this group will receive a waterproof cast for 2 weeks, after which the waterproof cast will be removed and a traditional fiberglass cast will be applied for an additional two weeks.
3102690|NCT02095145|Experimental|Group I (pomegranate-extract pill)|Patients receive pomegranate-extract pill PO QD for 52 weeks (+/- 1 week).
3102691|NCT02095145|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD for 52 weeks (+/- 1 week).
3102692|NCT02095158|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
3102693|NCT02095197|Other|No Catheter delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~No Catheter Delivery will be used to deliver the medication."
3102694|NCT02095197|Active Comparator|Catheter targeted delivery|"Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.~Catheter targeted delivery will be used to deliver the medication."
3102695|NCT02095223|Experimental|Electromyographic Biofeedback Group|Participants in the electromyographic biofeedback supplemented exercise will be instructed on correct setup and use of the electromyographic biofeedback unit. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group. Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
3102696|NCT02095223|Active Comparator|Traditional Exercise Group|Participants in will be instructed on a 14 day exercise protocol on the day of enrollment. The protocol is comprised of 4 exercises focused on both non-weight bearing and weight bearing quadriceps strengthening. A compliance log will be given to each participant and will be reviewed at each supervised exercise session and at the final study visit. Participants will be instructed to discontinue exercise and contact the principle investigator if they experience knee pain due to the intervention.
3102697|NCT02095340|Experimental|Positive Training|
3102698|NCT02095340|Sham Comparator|Neutral Training|
3102699|NCT02095535||Study group|All study participants
3102700|NCT02095561|Experimental|HPV Self testing|HPV self testing offered by CHWs during home visits
3102701|NCT02095561|No Intervention|HPV at health centers|Community Health Workers instructed women about cervical cancer and HPV testing and advised them on how to seek screening at health centers.
3102702|NCT02095678|Experimental|HCC or metastatic Liver Lesions|Patients with HCC or metastatic liver lesions who are refered to the abdominal imaging and biopsy clinic will have a liver biopsy performed. 3-5 days after a clinical MRI indicating a cancerous lesion, patients will return for the free-breathing MRI and a liver biopsy. These images will be compared to the clinical MRI and to images of the benign lesions.
3102703|NCT02095678|Active Comparator|Benign Liver Lesion|Patients with benign liver lesions will be referred to the study team. 3-5 days after a clinical MRI an experimental, free-breathing MRI will be performed on these patients. The results will be compared to their clinical MRI images and to images of HCC or metastatic lesions
3102704|NCT02095691|Experimental|Resistant Hypertension|The Celsius® ThermoCool® Renal Denervation catheter will serve to treat resistant hypertension.
3102705|NCT02095873|Experimental|Glo1-inducer then placebo|Glyoxalase 1 Inducer (8 weeks), then washout (6 weeks), then Placebo (8 weeks).
3102706|NCT02095873|Experimental|Placebo then Glo1-inducer|Placebo (8 weeks), then washout (6 weeks), then Glyoxalase 1 Inducer (8 weeks).
3102707|NCT02095951|Experimental|Pre-emptive Ethanol Lock Therapy Group|Participants receive ethanol lock before blood cultures grow germ
3102708|NCT02095951|Active Comparator|Standard Ethanol Lock Therapy Group|Participants receive ethanol lock if and only after blood cultures grow germ
3102709|NCT02096003|Active Comparator|Intrathecal morphine|0.25mg ( 250mcg) intrathecal morphine added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections
3102710|NCT02096003|Experimental|Intrathecal hydromorphone|50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
3102711|NCT02096029|Experimental|Nicotine Replacement Therapy (NRT)|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
3102712|NCT02096029|Active Comparator|Ask, Advise, Refer (physician brief advice)|Ask, Advise, Refer (physician brief advice)
3102713|NCT02096081|Experimental|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
3102714|NCT02096081|Active Comparator|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points
3102715|NCT02096107|Active Comparator|Low intensity Tacrolimus|Low tacrolimus, everolimus, and steroids
3102716|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
3102717|NCT02096263|Experimental|Infanrix hexa Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Infanrix hexa (lot A, lot B or lot C as per the group allocation) co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and Hiberix at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3102718|NCT02096263|Active Comparator|Pediarix Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pediarix and ActHIB co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Infanrix and ActHIB at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3102719|NCT02096263|Active Comparator|Pentacel Group|Subjects between, and including, 6 and 12 weeks of age at the time of the vaccination received, in the Primary Phase of the study, 3 doses of Pentacel and Engerix co-administered with Prevnar13 at 2, 4 and 6 months of age and Rotarix at 2 and 4 months of age. The injectable vaccines were administered by intramuscular injection in the anterolateral thigh, while Rotarix was administered orally. Subjects received a booster dose of Pentacel at 15-18 months of age by intramuscular injection in the anterolateral thigh.
3102720|NCT02096276||Exposure Group_Prospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and prospective (i.e., registration to registry is done before the outcome of the pregnancy is known)
3102721|NCT02096276||Exposure Group_Retrospective|Pregnant women within the United States (US) who are exposed to Boostrix vaccine during pregnancy or within 28 days preceding conception and with known pregnancy outcomes. Reporting of exposed pregnancies is voluntary and retrospective (i.e., pregnancy outcome is already known at the time of registration to Registry)
3102722|NCT02096458|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg delayed-release orally disintegrating tablets at Assessment 1 Day 1, Assessment 2 Day 1, and Assessment 3 Day 1.
3102723|NCT02096471|Experimental|Agent PD-0325901|The primary aim of the study will be to assess quantitative radiographic response in a target lesion. Subjects will receive PD-0325901 by mouth on a bid dosing schedule of 2 mg/m2/dose with a maximum dose of 4 mg bid. Each course is 4 weeks duration, and subjects will receive drug on a 3 week on/1 week off schedule. Subjects may receive additional courses beyond course 8 only if there is at least 15% reduction in volume of the target tumor. Subjects who have a 20% or greater reduction in target tumor volume at the end of 12 courses can continue on therapy for up to an additional year (maximum of 24 total courses). However, subjects who do not achieve at least 15% reduction in volume of the target tumor after 8 courses (~8 months) will be considered treatment failures and taken off study.
3102724|NCT02096575|Experimental|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~In addition, the Nitrous oxide group will receive two placebo pills. Nitrous oxide will be administered via a disposable scented nasal mask to blind patients to the intervention. Nitrous oxide will be administered at a fixed ratio of 60% nitrous oxide and 40% oxygen. The nasal mask will be placed on the patient's nose and the nitrous oxide will be administered continuously."
3102725|NCT02096575|No Intervention|Standard care group|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. All patients will receive local anesthesia via a standardized paracervical block with 18 cc of 1% lidocaine buffered with 2 ml of 8.4% sodium bicarbonate and 0.2 ml of 4 units of vasopressin.~The standard care group will receive one 5/325 mg Percocet, and 1 mg of lorazepam, 30 minutes before the procedure. The standard care group will receive oxygen by mask intraoperatively."
3102726|NCT02096588|Experimental|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily. Treatment will start 7 days prior to the planned doxorubicin/cyclophosphamide chemotherapy initiation and will continue for a total of 25 weeks.
3102727|NCT02096588|Active Comparator|No drug|Participant not randomized to simvastatin will participate in all aspects of the study, including planned doxorubicin/cyclophosphamide chemotherapy, with the exception of simvastatin administration.
3102728|NCT02096679|Experimental|[14C]-AZD9291 20mg (oral solution)|Volunteers will receive 20 mg [14C]-AZD9291 containing a nominal 1 μCi activity, administered by mouth, as a solution.
3102729|NCT02096692||ICD System Therapy|Patients with a ProMRI ICD System
3102730|NCT02096705|Experimental|Group 1: Dapagliflozin|Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
3102731|NCT02096705|Placebo Comparator|Group 2: Dapagliflozin Placebo|Dapagliflozin Placebo 0 mg oral Tablet once daily for 24 weeks + Background Insulin
3102732|NCT02096718|Experimental|Afatinib in moderate renal impaired|Single Dose Afatinib in moderate renal impaired subjects
3102733|NCT02096718|Experimental|Afatinib in severe renal impaired|Single Dose Afatinib in severe renal impaired subjects
3102734|NCT02096718|Other|Afatinib in healthy subjects|Single Dose Afatinib in healthy subjects matched by gender, race, age and BMI to moderate and severe renal impaired subjects
3102735|NCT02096731||LABA + tiotropium|
3102736|NCT02096731||LABA mono|
3102737|NCT02096731||neither tiotropium nor LABA|
3102738|NCT02096731||tiotropium + LABA|
3102739|NCT02096731||tiotropium mono|
3102740|NCT02096744|Experimental|Catapres-TTS-3 crossover 1|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)
3102741|NCT02096744|Experimental|Catapres-TTS-3 crossover 2|subject to receive 0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)
3102742|NCT02096744|Experimental|Catapres-TTS-1 crossover 1|subject to receive 0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously
3102743|NCT02096835|Experimental|Acustimulation|Transcutaneous electrical acupoint stimulation (TEAS) starts 30 min before surgery and lasts until patient leaves the postanesthetic care unit.Dexamethasone 10mg i.v. after induction.
3102744|NCT02096835|Active Comparator|Tropisetron|Tropisetron 5mg iv. at the start of skin closure.Sham transcutaneous electrical acupoint stimulation.Dexamethasone 10mg i.v.after induction.
3102745|NCT02096835|Sham Comparator|Control|Sham transcutaneous electrical acupoint stimulation. Dexamethasone 10mg i.v.after induction.
3102746|NCT02096861|Experimental|CT-P13 - CT-P13|CT-P13 followed by CT-P13 from Week 30
3102747|NCT02096861|Active Comparator|CT-P13 - Remicade|CT-P13 followed by Remicade from Week 30
3102748|NCT02096861|Active Comparator|Remicade - Remicade|Remicade followed by Remicade from Week 30
3102749|NCT02096861|Experimental|Remicade - CT-P13|Remicade followed by CT-P13 from Week 30
3102750|NCT02096900|Active Comparator|zolpidem|zolpidem given orally 0.25mg/kg pre-operatively single dose
3102751|NCT02096900|Active Comparator|midazolam|midazolam will be given at 0.5mg/kg, pre-operatively single dose
3102752|NCT02096952|Experimental|Methylphenidate extended-release liquid|Methylphenidate extended-release liquid formulation
3102753|NCT02097030|Active Comparator|etafilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3102754|NCT02097030|Active Comparator|nelfilcon A lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3102755|NCT02097030|Active Comparator|filcon II 3 lens|Participants were randomized to either the etafilcon A or the nelfilcon A lens for three days and then both groups wore the filcon II 3 lens for three days, without washout period between lens types.
3102756|NCT02097056|Experimental|donepezil HCl 23 mg|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
3102757|NCT02097108|Other|Raltegravir|Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
3469111|NCT03889288|Experimental|Medical device - electronic-pain killer|In addition to the conventional management of postoperative pain, patients benefit from perioperative treatment sessions with medical device. Patients are recruiting prospectively.
3102759|NCT02097238|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3102760|NCT02097277|Placebo Comparator|Treatment A: Placebo (Matching with BMS-986036 - Daily)|Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
3102761|NCT02097277|Experimental|Arm 2: Treatment B: BMS-986036 (1 mg Daily)|BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
3102762|NCT02097277|Experimental|Treatment C: BMS-986036 (5 mg Daily)|BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
3102763|NCT02097277|Experimental|Treatment D: BMS-986036 (20 mg Daily)|BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
3102764|NCT02097277|Experimental|Treatment E: BMS-986036 (20 mg Weekly)|"BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks~Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks"
3102765|NCT02097290|Experimental|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
3102766|NCT02097303|Other|Single arm|All subjects receive concurrent administration of Radium Ra223 Dichloride and Abiraterone Acetate plus Prednisone
3469112|NCT03889405|Experimental|Study group|Healthy 32 weeks or more pregnant women, at an early stage of labor.
3102768|NCT02097472|Experimental|Adult Cohort 1, PATH-wSP, 600 mcg|A single injection of 600 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 600 mcg PATH-wSP in the alternate arm.
3102769|NCT02097472|Placebo Comparator|Adult Cohort 1, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
3102770|NCT02097472|Experimental|Adult Cohort 2, PATH-wSP, 1000 mcg|A single injection of 1000 mcg PATH-wSP in one arm, followed 4 weeks later by a single injection of 1000 mcg PATH-wSP in the alternate arm.
3102771|NCT02097472|Placebo Comparator|Adult Cohort 2, Saline|A single injection of saline in one arm, followed 4 weeks later by a single injection of saline in the alternate arm.
3102772|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Active control|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
3102773|NCT02097472|Experimental|Toddler Cohort 1 PATH-wSP 300 mcg+Saline|A single injection of PATH-wSP 300 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 300 mcg in the left thigh 8 weeks later.
3102774|NCT02097472|Active Comparator|Toddler Cohort 1: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
3102775|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+Active control|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of each of the two active comparator vaccines (Synflorix and Pentavac) in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
3102776|NCT02097472|Experimental|Toddler Cohort 2 PATH-wSP 600 mcg+saline|A single injection of PATH-wSP 600 mcg in the left thigh and a single injection of saline in the right thigh along with a separate single injection of saline in the right thigh. These 3 injections are followed by a single injection of PATH-wSP 600 mcg in the left thigh 8 weeks later.
3102777|NCT02097472|Active Comparator|Toddler Cohort 2: Active Control Only|A single injection of saline in the left thigh and a single injection of each of the two active comparator vaccines in the right thigh. These 3 injections are followed by a single injection of saline in the left thigh 8 weeks later.
3102778|NCT02097485|Active Comparator|Abametapir Lotion 0.74% w/w|Topically administered to hair and scalp for 10 minutes application.
3102779|NCT02097485|Placebo Comparator|Vehicle Lotion|Administered to scalp and hair for 10 minutes application.
3102780|NCT02097537|Experimental|Methacholine Chloride|children with bronchial asthma
3102781|NCT02097641|Experimental|Human Mesenchymal Stromal Cells (hMSCs)|A single dose of 10 million cells/kg PBW (predicted body weight) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
3102782|NCT02097641|Placebo Comparator|Plasma-Lyte A (placebo)|A single dose of Plasma-Lyte A was administered intravenously over approximately 60-80 minutes.
3102783|NCT02097719|Active Comparator|bimatoprost 0.01% and hypromellose 0.3%|Bimatoprost 0.01% and hypromellose 0.3% lubricant eye drops (for masking purposes) each administered to both eyes once daily for 12 weeks.
3102784|NCT02097719|Active Comparator|travoprost 0.004% and timolol 0.5%|Travoprost 0.004% and timolol 0.5% each administered to both eyes once daily for 12 weeks.
3102785|NCT02097732|Active Comparator|B: No induction|Participants will undergo stereotactic radiosurgery (SRS) followed 2-3 weeks later by ipilimumab, which is given once every 3 weeks for a total of 4 doses.
3102786|NCT02097732|Experimental|A: Induction|Patients will receive 2 doses of ipilimumab, which is given once every 3 weeks, prior to stereotactic radiosurgery (SRS), followed by 2 more doses of ipilimumab, for a total of 4 doses.
3102787|NCT02097745|Experimental|MabThera/Rituxan|
3102788|NCT02097823|Experimental|Aprepitant First, Olanzapine Second|"Will receive aprepitant (weight based dose, see below) in first cycle of chemotherapy and olanzapine (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
3102789|NCT02097823|Experimental|Olanzapine First, Aprepitant Second|"Will receive olanzapine (weight based dose, see below) in first cycle of chemotherapy and aprepitant (weight based dose, see below) in the second cycle of chemotherapy. All doses will be given starting 30 minutes before chemotherapy on day 1.~Olanzapine dosing:~>60kg - 10mg orally daily for 4 doses 40-59.9kg - 5mg orally daily for 4 doses 20-39.9kg - 2.5mg orally daily for 4 doses <20kg - 1.25mg orally daily for 4 doses~Aprepitant dosing:~>40kg - 125mg orally on day 1, then 80mg orally daily on days 2,3 35-39.9kg - 80mg orally daily for 3 doses 20-34.9kg - 40mg orally daily for 3 doses <20kg - 1.5-2mg/kg orally daily for 3 doses"
3102790|NCT02097849|Active Comparator|Non-Pegylated IFN Treated Plus Vaccinations|"Participants on a stable approved dose of a non pegylated IFN for ≥3 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
3102791|NCT02097849|Experimental|Tecfidera Treated Plus Vaccinations|"Participants on a stable approved dose of Tecfidera (240 mg BID) for ≥6 months will receive 3 vaccinations on Day 1 intramuscularly in the specified order:~Td 0.5 mL PPSV23 0.5 mL MCV4 0.5 mL"
3102792|NCT02097992|Experimental|SD placebo and MD roflumilast then MD placebo|Participants will receive placebo (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily.
3102793|NCT02097992|Experimental|SD placebo and MD placebo then MD roflumilast|Participants will receive placebo (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
3102794|NCT02097992|Experimental|SD roflumilast and MD placebo then MD roflumilast.|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with placebo daily, followed by a 4 week washout period, followed by a 4 week treatment with 500ug roflumilast daily.
3102795|NCT02097992|Experimental|SD roflumilast and MD roflumilast then MD placebo|Participants will receive 500ug roflumilast (single dose) followed by a 4 week treatment with 500ug roflumilast daily, followed by a 4 week washout period, followed by a 4 week treatment with placebo daily
3102796|NCT02098109|Experimental|XM02 Filgrastim (Granix) and Plerixafor|"XM02 Filgrastim (Granix) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
3102797|NCT02098109|Active Comparator|Filgrastim (Neupogen) and Plerixafor|"Filgrastim (Neupogen) 10 mg/kg Days 1 through 4 (Days 5 through 8 may be required if target collection goal has not be met)~Plerixafor 0.24 mg/kg Day 4 (Days 5 through 7 may be required if target collection goal has not be met)~Apheresis on Day 5 (may need to be done on Days 6-8 if target collection goal has not been met)~Patients who undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be followed through Day +100 post-infusion (+/- 30 days) to assess for transplant outcomes (neutrophil and platelet engraftment, and readmission rate). Patients who successfully mobilize > 2.0 x 10^6 CD34+ cells/kg but do not undergo infusion of the mobilized PBSC product within 6 months of the last apheresis procedure will be discontinued from follow-up."
3102798|NCT02098304|Other|Sound and Unsound Molars|Imaging of unrestored sound molars (ICDAS 0), and third Molars (ICDAS 1,2 or 3) with the Calcivis Caries Activity Imaging System
3102799|NCT02098369|Other|Usual care|Written education material (basic)
3102800|NCT02098369|Experimental|Proactive|Written education material (basic) Additional education material PELICAN-Proactive [In addition to the usual care, participants will receive educational material and a proactive telephone peer coaching program (coaches call participants)]
3102801|NCT02098369|Experimental|Reactive|Written education material (basic) Additional education material PELICAN-Reactive [In addition to the usual care, participants will receive educational material and a reactive telephone peer coaching program (participants call coaches)]
3102802|NCT02098395|Experimental|Liraglutide 1.8 mg + insulin|
3102803|NCT02098395|Experimental|Liraglutide 1.2 mg + insulin|
3102804|NCT02098395|Experimental|Liraglutide 0.6 mg + insulin|
3102805|NCT02098395|Placebo Comparator|Liraglutide placebo 0.3 ml + insulin|
3102806|NCT02098395|Placebo Comparator|Liraglutide placebo 0.2 ml + insulin|
3102807|NCT02098395|Placebo Comparator|Liraglutide placebo 0.1 ml + insulin|
3102808|NCT02098733||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg or 30 mg/3 mg, orally once daily before or after breakfast
3102809|NCT02098746||Pioglitazone/glimepiride|Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast.
3102810|NCT02098993|Experimental|Unfractionated heparin|"Subjects will be randomized within 24 hours of diagnosis to one of two treatment arms, Arm A, anticoagulation and standard of care, or Arm B, no anticoagulation and standard of care. Weight-adjusted UFH will be given at doses of 80 units per kilogram followed by 18 units per kilogram per hour intravenously for 7 days, or until discharge, if discharge is shorter than 7 days. UFH will be monitored by standard protocol to maintain the activated partial thromboplastin time in the therapeutic range per institutional guidelines.~The experimental arm will receive standard of care, too, which will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions."
3102811|NCT02098993|No Intervention|Standard of care|Standard care will include the following: intravenous fluids, antibiotics, supplemental oxygen, incentive spirometry, pain management, red blood cell transfusions, and exchange transfusions.
3102812|NCT02099006|Experimental|Medications|Each study subject will be sequentially exposed to each of the study drugs and the placebo in a random order. The study is designed as a double blinded, crossover study.
3102813|NCT02099006|Placebo Comparator|Placebo|The compounding base alone will be used as a placebo. Each participant will be given each drug and the placebo sequentially in random order.
3102814|NCT02099084|Experimental|Teduglutide First, then Placebo|Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days, followed by a 14-day washout period, and placebo administered subcutaneously for 7 days.
3102815|NCT02099084|Placebo Comparator|Placebo First, then Teduglutide|Placebo administered subcutaneously for 7 days, followed by a 14-day washout period, and Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days.
3102816|NCT02099110|Experimental|Ertugliflozin 5 mg + sitagliptin 100 mg|Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
3102817|NCT02099110|Experimental|Ertugliflozin 15 mg + sitagliptin 100 mg|Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
3102818|NCT02099110|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, once daily for 52 weeks
3102819|NCT02099110|Experimental|Ertugliflozin 15 mg|Ertugliflozin, oral, once daily for 52 weeks
3102820|NCT02099110|Active Comparator|Sitagliptin 100 mg|Sitagliptin 100 mg, oral, once daily for 52 weeks
3102821|NCT02099266|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen the morning of UCB transplant.
3102822|NCT02099461|Other|No treatment|Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.
3102823|NCT02099461|Experimental|Denosumab 60 mg|Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
3102824|NCT02099461|Experimental|Denosumab 120 mg|Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.
3102825|NCT02099682||Lansoprazole 15 mg|Lansoprazole 15 mg orally once daily
3102826|NCT02099708||Lansoprazole 15 mg|Lansoprazole 15 mg, capsules or orally disintegrating (OD) tablets, orally, once, daily for up to 12 months.
3102827|NCT02099721|Active Comparator|Group A: Secondary prevention patients- device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects receive an ICD/CRT-D implant."
3102828|NCT02099721|No Intervention|Group B: Secondary prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for secondary prevention of sudden cardiac arrest.~These subjects choose not to receive an ICD/CRT-D implant."
3102829|NCT02099721|Active Comparator|Group C: 1.5 Prevention patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects receive an ICD/CRT-D implant."
3102830|NCT02099721|No Intervention|Group D: 1.5 prevention patients - no device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF).~These subjects choose not to receive an ICD/CRT-D implant."
3102831|NCT02099721|Other|Group E: Primary, non-1.5 patients - device implant|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects receive an ICD/CRT-D implant."
3102832|NCT02099721|No Intervention|Group F: Primary, non-1.5 patients - no device|"Patients who are guideline indicated for an ICD/CRT-D for primary prevention of sudden cardiac arrest fall into this group if they do NOT fall into the 1.5 prevention group. These patients do not have one of the 4 additional risk factors (syncope/pre-syncope, non-sustained ventricular tachycardia (NSVT), frequent preventricular contractions (PVCs), or low left ventricular ejection fraction (low LVEF) which would put them into the 1.5 prevention group.~These subjects choose not to receive an ICD/CRT-D implant."
3102833|NCT02099786|Experimental|COMP-VA|Hearing testing at each treatment and at 1 month following treatment.
3102834|NCT02099786|Experimental|Usual Care|Hearing testing done according to Audiology Clinic protocol
3102835|NCT02099799|Active Comparator|Pedometer and Internet Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
3102836|NCT02099799|No Intervention|Usual Care|Verbal instructions and written materials about exercise.
3102837|NCT02099838|Experimental|Pioglitazone and Metformin|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of pioglitazone and metformin twice a day (before breakfast and before dinner) orally for 12 weeks.
3102838|NCT02099838|Placebo Comparator|Placebo|Type 2 diabetic patients only took SUs previously. During a week for washout before the trial, they received diet and sport instructions, kept the SUs unchanged and didn't use any drugs affecting blood glucose. All participants added 1 tablet of placebo twice a day (before breakfast and before dinner) orally for 12 weeks.
3102839|NCT02099864|Experimental|Treatment (Enzalutamide)|Patients receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo a tumor biopsy of a metastatic site at study entry (prior to initiation of enzalutamide) and after the time of progression. Per the investigator, patients may continue treatment beyond progression.
3102840|NCT02100007|Experimental|ME-344|ME-344 IV, 10 mg/kg on Days 1, 8, 15 and 22 of each 28 day cycle Topotecan IV, 4 mg/m2 on Days 1, 8 and 15 of each 28 day cycle
3102841|NCT02100072|Experimental|Nd:YAG 1440 nm laser|
3102842|NCT02100124|Experimental|Reproductive Life Planning (RLP)|RLP is an online adaptation of the Centers for Disease Control and Prevention (CDC) reproductive life planning toll that guides women to identify their reproductive goals and individual requirements for contraception.
3102843|NCT02100124|Experimental|Reproductive Life Planning Plus (RLP+)|RLP+ additionally includes contraceptive action planning, aimed at helping women select solutions for potential problems they may encounter with contraceptive adherence.
3102844|NCT02100124|Active Comparator|Information-only control|The information-only control will deliver on-line information about their contraceptive benefits coverage and information about all FDA-approved contraceptive methods.
3102845|NCT02100189|Experimental|Screening (esophageal cytology, FISH)|Participants swallow the capsule (Oesotest from Actimed) and then wait 10 minutes before the sponge is pulled out through the esophagus by gentle traction on the string. Cytology samples from the sponge are harvested and analyzed by FISH. Participants then undergo standard EGD or upper endoscopy.
3102846|NCT02100228|Experimental|Apixaban|
3102847|NCT02100228|Active Comparator|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
3102848|NCT02100280|Experimental|deep block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block.
3102849|NCT02100280|No Intervention|moderate block|After induction of anesthesia, continuous neuromuscular monitoring is started after calibration and stabilization of the signal as recommended by good clinical research practice; 50 Hz tetanic stimulation for 5 s, calibration, stabilization for at least 2 min 2. After stabilization, rocuronium 0.6 mg/kg is administered IV within 5 s for tracheal intubation. Maintenance dose of 0.1-0.2 mg/kg rocuronium is administered as needed for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
3102850|NCT02100319||Azilsartan at a dose of 20 to 40 mg, orally, once daily|Azilsartan tablets
3102851|NCT02100410|Experimental|Iteration 2-87-1|Delefilcon A toric contact lenses T1 and T2 worn contralaterally (1 in each eye) for approximately 30 minutes
3102852|NCT02100410|Experimental|Iteration 2-87-2|Delefilcon A toric contact lenses T3 and T4 worn contralaterally (1 in each eye) for approximately 30 minutes
3102853|NCT02100410|Experimental|Iteration 2-87-3|Delefilcon A toric contact lenses T5 and T6 worn contralaterally (1 in each eye) for approximately 30 minutes
3102854|NCT02100475|Experimental|Insulin degludec/liraglutide + Metformin|
3102855|NCT02100475|Active Comparator|Insulin degludec/liraglutide + Insulin Aspart + Metformin|
3102856|NCT02100514|Experimental|Bococizumab (PF-04950615; RN316)|Bococizumab (PF-04950615; RN316)
3102857|NCT02100514|Placebo Comparator|placebo|
3102858|NCT02100579|Active Comparator|Active Group|Ultrasound-guided adductor canal blockade with 10 ml of 0.25% bupivacaine
3102859|NCT02100579|Placebo Comparator|Control Group|Ultrasound-guided sham block with 10 ml of preservative free normal saline
3102860|NCT02100631|Experimental|PXVX0200 in Older Adults|PXVX0200 Single dose; liquid suspension after reconstitution with buffer; > 2x10^8 CFU in a liquid suspension
3102861|NCT02100631|Placebo Comparator|Placebo in Older Adults|Placebo physiological saline
3102862|NCT02100631|Other|Historical Control: Adults Aged 18-45|This arm consists of historical data from subjects who received a single dose of PXVX0200 in study PXVX-VC-200-004. The data was included in study PXVX-VC-200-005 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
3102863|NCT02100644|Experimental|Lamotrigine|The study objective is to examine whether the VPA dose can be reduced by additional administration of LTG in Japanese pre-menopausal female epilepsy patients, whose seizures are well controlled by VPA monotherapy. Then VPA is the standard product in this stuudy, not the investigational product.
3102864|NCT02100657|Experimental|plitidepsin + bortezomib + dexamethasone|"Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).~Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.~Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk"
3102865|NCT02100670|Experimental|1% diclofenac sodium plus 3% menthol|1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3102866|NCT02100670|Experimental|1% diclofenac sodium plus 0.09% menthol|1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3102867|NCT02100670|Experimental|3% menthol|3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3102868|NCT02100670|Placebo Comparator|Placebo with 0.09% menthol gel|Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.
3102869|NCT02100696|Experimental|Cohort 1: Etrolizumab (Open-Label Induction (OLI) Phase)|Participants assigned to this arm will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) for 14 weeks during the induction phase.
3102870|NCT02100696|Placebo Comparator|Cohort 2: Placebo (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind placebo SC injection Q4W for 14 weeks during the induction phase.
3102871|NCT02100696|Experimental|Cohort 2: Etrolizumab (Double-Blind Induction Phase)|Participants randomized to this arm will receive treatment with double-blind etrolizumab 105 mg SC injection Q4W for 14 weeks during the induction phase.
3102872|NCT02100696|Placebo Comparator|Placebo Responders: Placebo (Maintenance Phase)|Participants who received placebo during the induction phase, Cohort 2: Placebo (Double-Blind Induction Phase), and achieve a clinical response with placebo at Week 14 will continue to receive blinded placebo from Week 16 up to Week 66 during the maintenance phase.
3102873|NCT02100696|Placebo Comparator|Etrolizumab Responders: Placebo (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive placebo SC injection Q4W from Week 16 up to Week 66.
3102874|NCT02100696|Experimental|Etrolizumab Responders: Etrolizumab (Maintenance Phase)|Participants who received etrolizumab during the induction phase, Cohort 1: Etrolizumab (Open-Label Induction Phase) and Cohort 2: Etrolizumab (Double-Blind Induction Phase), and achieved a clinical response at Week 14 will be re-randomized by Week 16 for the double-blind maintenance phase. Clinical responders re-randomized to this arm will receive etrolizumab 105 mg SC injection Q4W from Week 16 up to Week 66.
3102875|NCT02100748|Experimental|TRV130 1 mg|TRV130 1 mg IV Q4H x 48 h
3102876|NCT02100748|Experimental|TRV130 2 mg|TRV130 2 mg IV Q4H x 48 h
3102877|NCT02100748|Experimental|TRV130 3 mg|TRV130 3 mg IV Q4H x 48 h
3102878|NCT02100748|Experimental|TRV130 4 mg|TRV130 4 mg IV Q4H x 48 h
3102879|NCT02100748|Active Comparator|Morphine|Morphine 4 mg IV Q4H x 48 h
3102880|NCT02100748|Placebo Comparator|Placebo|Placebo (D5W) IV Q4H x 48 h
3102881|NCT02100813|Other|Part 1: LEO 43204|Open-label, dose escalation, 2 days treatment
3102882|NCT02100813|Active Comparator|Part 2: LEO 43204 x dose|X dose for 2 days treatment
3102883|NCT02100813|Active Comparator|Part 2: LEO 43204 Y dose|Y dose for 2 days treatment
3102884|NCT02100813|Placebo Comparator|Part 2: Placebo|Placebo for 2 days treatment
3102885|NCT02100826|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3102886|NCT02100826|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3102887|NCT02100839|Experimental|AEM-28|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.032 mg/mL to 3.54 mg/mL~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks; dose range 1 mg/kg to 3.54 mg/kg."
3102888|NCT02100839|Placebo Comparator|Normal Saline|"Single Ascending Dose: Single IV dose for each cohort.~Multiple Ascending Dose: Three (3) IV doses for each cohort, one (1) dose every two (2) weeks."
3102889|NCT02100930|Experimental|Neuroblastoma|This is a single-arm, open label, open access study to provide the anti-GD2 murine IgG3 MoAb 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) to patients with high-risk neuroblastoma (NB). This immunotherapy has shown efficacy against minimal residual disease (MRD) in such patients.
3102890|NCT02100969|Experimental|HIZENTRA ®|Hizentra is a subcutaneous (under the skin) immunoglobin (SCIg). Participants will receive Hizentra in a minimum of one infusion per week and a maximum of 4 infusions per week. Dose and rate depend on the visit and how each participant tolerates the drug. Max cc per site is 50 cc per site per hour.
3102891|NCT02101008|Other|Disulfiram and chelated zinc|There is only one arm. All patients are treated wtih disulfiram and chelated zinc.
3102892|NCT02101021|Experimental|Momelotinib|Participants will receive momelotinib plus nab-paclitaxel and gemcitabine.
3102893|NCT02101021|Placebo Comparator|Placebo|Participants will receive placebo to match momelotinib plus nab-paclitaxel and gemcitabine.
3102894|NCT02101034|Experimental|Phase I: Dose Level 1|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3102895|NCT02101034|Experimental|Phase I: Dose Level 2|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3102896|NCT02101034|Experimental|Phase II Arm 1: Platin-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3102897|NCT02101034|Experimental|Phase II Arm 2: Cetuximab-Resistant HPV-Unrelated SCCHN|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3102898|NCT02101034|Experimental|Phase II Arm 3:|"PD 0332991 will be administered on Days 1 through 21 of each 28 day cycle.~Cetuximab will be administered intravenously on a weekly schedule. The first dose will be 400 mg/m2. The remaining weekly dose will be 250 mg/m2. Participants will continue to receive weekly cetuximab at 250 mg/m2 for the duration of their participation on study."
3102899|NCT02101060|Experimental|exercise|16-week progressive aerobic and resistance exercise training
3102900|NCT02101060|No Intervention|control|usual care controls
3102901|NCT02101112|Experimental|Apixaban, 10 mg (whole tablets)|Participants received a single dose of apixaban, 10 mg, given orally as 2 5-mg whole commercial tablets (reference)
3102902|NCT02101112|Experimental|Apixaban, 10 mg (crushed and suspended in water)|Participants received a single dose of apixaban, 10 mg, given by mouth as 2 5-mg whole commercial tablets crushed and suspended in 30 mL of water
3102903|NCT02101112|Experimental|Apixaban, 10 mg (crushed and mixed with applesauce)|Participants received a single dose of 10 mg, given by mouth as 2 5-mg apixaban commercial tablets crushed and mixed with 30 g of applesauce
3102904|NCT02101190|Experimental|Group 1 - Hepatic impaired subjects|Group 1 - subjects with moderate chronic hepatic impairment treated with BIA 9-1067
3102905|NCT02101190|Experimental|Group 2 - Healthy subjects|Group 2 - healthy subjects treated with BIA 9-1067
3102906|NCT02101281|Experimental|Group 1 - rhNGF 20 μg/mL|(first planned dose): drop (35 μL) corresponding to 0.70 μg of rhNGF (recombinant human Nerve Growth Factor) was instilled into each eye twice a day (b.i.d.) every 12±2 h for a total daily dose of 2.8 μg (both eyes), for 28 consecutive days. The total dose was 78.4 μg/28 days.
3102907|NCT02101281|Experimental|Group 2 - rhNGF 4 μg/mL|after completion of Group 1 treatment, one drop (35 μL) corresponding to 0.14 μg of rhNGF (recombinant human Nerve Growth Factor) instilled into each eye b.i.d. every 12±2 h for a total daily dose of 0.56 μg, for 28 consecutive days. Total dose was 15.68 μg/28 days.
3102908|NCT02101294|Experimental|Interossei Lumbricals Neuro Interface|Comparison of report of symptoms of carpal tunnel syndrome when typing with standard QWERTY keyboard to report of symptoms of carpal tunnel syndrome when typing with Interossei Lumbricals Neuromuscular Technology Interface Therapy device.
3102909|NCT02101359|Experimental|T2380|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~At the beginning of surgery, 200 μL of T2380 were administrated intracamerally."
3102910|NCT02101359|Active Comparator|Mydriatics and anesthetic|"Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.~Topical Mydriatic treatments were instilled three times before surgery."
3102911|NCT02101411||clopidogrel|treated with cloopidogrel
3102912|NCT02101411||ticagrelor|treated with ticagrelor
3102913|NCT02101411||cilostazol|treated with clopidogrel+cilostazol
3102914|NCT02101437|Placebo Comparator|control|normal subjects.
3102915|NCT02101437|Active Comparator|clopidogrel|subjects received clopidogrel 75mg qd.
3102916|NCT02101437|Active Comparator|ticagrelor|subjects received ticagrelor 90mg qd.
3102917|NCT02101437|Active Comparator|cilostazol|subjects received cilostazol 100mg bid.
3102918|NCT02101515|Placebo Comparator|Usual Labor|Immediate delivery after 3 hours with epidural or 2 hours without epidural
3102919|NCT02101515|Experimental|Extended|"Immediate delivery after 4 hours with an epidural or 3 hours without an epidural~Intervention: one additional hour for the second stage of labor~Length of second stage in extended arm is 3 hours without epidural and 4 hours with epidural."
3102920|NCT02101554|Experimental|Embeda|One arm, open label, active
3102921|NCT02101788|Active Comparator|Arm A (letrozole, tamoxifen, paclitaxel, PLD, topotecan)|Patients receive clinician's choice of either letrozole PO QD on days 1-28, tamoxifen citrate PO BID on days 1-28, paclitaxel IV over 1 hour on days 1, 8, and 15, pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or topotecan IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients developing progressive disease may cross over to Arm B.
3102922|NCT02101788|Experimental|Arm B (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3102923|NCT02101918|Experimental|Treatment (ziv-aflibercept, perfusion CT)|Patients receive ziv-aflibercept IV over 60-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography perfusion imaging at baseline, day 21 of course 1, and at time of progression.
3102924|NCT02101983|Experimental|Outpatient HiDAC Consolidation|Patients will receive 2 cycles of 1.5 grams/m2/day of intravenous cytarabine once daily for six consecutive days. Toxicity will be monitored through the duration of treatment. Observation will be complete upon count recovery and resolution of toxicity after the second cycle.
3102925|NCT02101983|Active Comparator|Quality of Life Comparison Group|Patients receiving outpatient intravenous cytarabine will complete the EORTC QLQ-C30 quality of life form on the last day of each cycle of chemotherapy.
3102926|NCT02102100|Experimental|Menthol-Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
3102927|NCT02102100|Experimental|Non-Menthol Preferring Smokers|Each subject in this arm received a random sequence of 3 different inhaled menthol conditions across 3 test sessions (a single menthol condition for each test session). In each test session, a random order of one saline, and 2 nicotine (0.25 mg and 0.5 mg /70 kg) infusions were given one hour apart, concurrent with the randomized menthol inhalation condition for that test session.
3102928|NCT02102204|Experimental|Etelcalcetide|Participants received etelcalcetide three times a week (TIW) by bolus injection at the end of hemodialysis. The minimum etelcalcetide dose in this study was 2.5 mg and the maximum dose was 15 mg. Etelcalcetide dose was titrated to maintain parathyroid hormone levels within 2x to 9x the upper limit of normal based on the reference range of the assay used at the individual study center.
3102929|NCT02102230|Experimental|CBT-I|Group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
3102930|NCT02102230|Active Comparator|CBT-I-MA|Group Cognitive-Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
3102931|NCT02102230|Placebo Comparator|PC|Desensitization Treatment for Insomnia (DTI)
3102932|NCT02102399|Experimental|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
3102933|NCT02102399|Experimental|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
3102934|NCT02102464|Experimental|LipiFlow|Single 12-minute LipiFlow treatment
3102935|NCT02102464|No Intervention|Untreated Control|Untreated Control (No Intervention)
3102936|NCT02102464|Experimental|Crossover LipiFlow Treatment|Crossover LipiFlow treatment of the untreated control group after 3 months
3102937|NCT02102490|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib given orally once every 12 hours for 28 days (1 cycle). Participants may continue to receive treatment until discontinuation criteria are met.
3102938|NCT02102724|Experimental|Fish Oil|Participants will receive fish oil gelcaps that contain 1.6 grams of omega-3 fatty acids (800 mg of EPA, 600 mg DHA, 200 mg other omega-3 fatty acids) for 12 weeks.
3102939|NCT02102724|Placebo Comparator|Placebo|Participants will receive 1 gram of oleic sunflower oil for 12 weeks.
3102940|NCT02102932|Experimental|12.5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order
3102941|NCT02102932|Experimental|5 mg empagliflozin/850 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order
3102942|NCT02102932|Experimental|12.5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order
3102943|NCT02102932|Experimental|5 mg empagliflozin/500 mg metformin|24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order
3102944|NCT02103062|Experimental|Abraxane (nab®paclitaxel)|Abraxane (nab®paclitaxel) 125 milligrams per meter squared on days 1, 8 and 15 of a 28 day cycle
3102945|NCT02103114|Experimental|Anti-thrombin III|
3102946|NCT02103114|Placebo Comparator|Placebo|
3102947|NCT02103127|Experimental|755nm Alexandrite laser with lens array|
3102948|NCT02103153|Experimental|Picosure Laser System|
3102949|NCT02103218|Experimental|Risky sex prevention|education, activities, empowerment, racial pride building
3102950|NCT02103218|Active Comparator|Healthy behaviors|General health education, activities
3102951|NCT02103270|Placebo Comparator|Oat Flour 600 mg|Arm C that is maintained on placebo (oat flour) throughout the study; this arm will receive 600 mg oat flour beginning on week 104. This will be true even if a subject in the placebo group meets criteria at week 104
3102952|NCT02103270|Active Comparator|Peanut Protein 4,000mg|Arm A on peanut OIT until week 104 (maintenance) and once meeting criteria [i.e. 1) on OIT treatment for minimum 104 weeks, 2) taking daily maintenance dose of 4,000 mg protein for at least 13 weeks, 3) no severe reactions to home dosing from Week 91-Week 104, and 4) no reactions at the Week 104 DBPCFC] will be assigned to avoid peanut (i.e. will consume 600 mg oat flour daily) and will proceed to tolerance and desensitization phase.
3102953|NCT02103270|Active Comparator|Peanut Protein 300 mg|Arm B on peanut OIT until week 104 and once meeting criteria specified in description of Arm A, will be assigned to be maintained on 300 mg peanut protein (i.e. 600 mg peanut flour) daily and will proceed to the tolerance and desensitization testing phase.
3102954|NCT02103309|Other|DACP, then 1DAM|Nelfilcon A contact lenses worn first, then etafilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
3102955|NCT02103309|Other|1DAM, then DACP|Etafilcon A contact lenses worn first, then nelfilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable mode.
3102956|NCT02103439|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)
3102957|NCT02103439|Active Comparator|PegIntron|PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
3102958|NCT02103478|Experimental|Phase 1 Dose Escalation|Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
3102959|NCT02103478|Experimental|Phase 2 Dose Confirmation|Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
3102960|NCT02103478|Experimental|Phase 2 Fixed-Dose Combination|Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
3102961|NCT02103608|Experimental|Percentage of hair reduction|This is an open label, prospective study to evaluate safety and efficiency of Silk'n Glide on the face. During the study, the subjects will perform up to 6 face treatments, two weeks apart. The treatment's safety and efficiency will be evaluated at 4 weeks of after last treatment and at 12 weeks after last treatment .
3102962|NCT02103816|Experimental|SmartLipo Triplex laser system along with the SideLaze800 hand|
3102963|NCT02103855|Experimental|belatacept|"Belatacept 5 mg/kg IVPB q 2 wks x 5 doses followed by 5 mg/kg IVPB q month. The belatacept dose will be infused IV over 30 minutes.~Day 14: Reduce tacrolimus dose by 25% Day 30: Reduce tacrolimus dose by additional 25% Day 45: Reduce tacrolimus dose by additional 25% Day 60: Stop tacrolimus."
3102964|NCT02104141||Operated Subjects|ROIA Interbody Cage with VerteBRIDGE plating
3102965|NCT02104167||Operated Subjects|ROIC interbody cage with VerteBRIDGE plating
3102966|NCT02104180|Active Comparator|TulleGras M.S.|
3102967|NCT02104180|Active Comparator|Urgotul|
3102968|NCT02104414|Active Comparator|Exparel|266mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
3102969|NCT02104414|Active Comparator|Bupivacaine HCl with epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
3102970|NCT02104414|Placebo Comparator|Normal Saline|30mL Normal Saline
3102971|NCT02104427|Experimental|TG-0054 combined with G-CSF|1. G-CSF: 10 μg/kg/day, administrated via SC injections from Day 1 to Day 8; 2. TG-0054: 3.14 mg/kg, administrated via 15-min IV infusion from Day 5 to Day 9 as needed to reach the target collection goal
3102972|NCT02104505|Active Comparator|700 mg Gamma Tocopherol daily x 14days|Gamma Tocopherol supplement
3102973|NCT02104505|Placebo Comparator|Placebo|Safflower oil capsules
3102974|NCT02104557||prevention of pregnancy|Non intervention
3102975|NCT02104557||management of endometriosis-associated pain|Non intervention
3102976|NCT02104583|Experimental|Eleclazine 3 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
3102977|NCT02104583|Experimental|Eleclazine 6 mg|Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
3102978|NCT02104583|Placebo Comparator|Placebo|Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
3102979|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102980|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102981|NCT02104739|Placebo Comparator|Saxagliptin, then Exenatide, then Placebo|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102982|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102983|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102984|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablets and Placebo (normal saline) injections
3102985|NCT02104739|Experimental|Exenatide, then Saxagliptin, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102986|NCT02104739|Experimental|Exenatide, then Placebo, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102987|NCT02104739|Experimental|Saxagliptin, then Exenatide, then Placebo, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102988|NCT02104739|Experimental|Saxagliptin, then Placebo, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102989|NCT02104739|Experimental|Placebo, then Exenatide, then Saxagliptin, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102990|NCT02104739|Experimental|Placebo, then Saxagliptin, then Exenatide, then Exenatide ER|Exenatide Single subcutaneous injection (10 mcg); Saxagliptin Single dose orally (5 mg); Placebo tablet and Placebo (normal saline) injection; Subcutaneous injection (2mg) weekly for 6 weeks
3102991|NCT02104752|Experimental|Curcumin|Curcumin capsules (Theracurmin formulation of curcumin nanoparticles). Subjects randomized to curcumin will receive 360 mg/day (divided into twice daily oral doses).
3102992|NCT02104752|Placebo Comparator|Sugar Pill|Matched placebo, 2 capsules twice daily.
3102993|NCT02104765|Experimental|5 mg LY2951742 Single Dose|5 mg LY2951742 given subcutaneously once
3102994|NCT02104765|Experimental|50 mg LY2951742 Single Dose|50 mg LY2951742 given subcutaneously once
3102995|NCT02104765|Experimental|120 mg LY2951742 Single Dose|120 mg LY2951742 given subcutaneously once
3102996|NCT02104765|Experimental|300 mg LY2951742 Single Dose|300 mg LY2951742 given subcutaneously once
3102997|NCT02104765|Experimental|300 mg LY2951742 Multiple Dose|300 mg LY2951742 given subcutaneously once every 4 weeks (Q4W)
3102998|NCT02104765|Placebo Comparator|Placebo Single Dose|Placebo given subcutaneously once
3102999|NCT02104765|Placebo Comparator|Placebo Multiple Dose|Placebo given subcutaneously once every 4 weeks (Q4W)
3103000|NCT02104804|Experimental|Saxagliptin 5mg|Saxagliptin 5mg, administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3103001|NCT02104804|Placebo Comparator|Placebo|Placebo administered to subjects with Type 2 diabetes inadequately controlled with insulin alone or with insulin plus metformin
3103002|NCT02104817|Experimental|EPANOVA|Epanova + statin, once daily
3103003|NCT02104817|Active Comparator|Corn oil|Corn oil + Statin
3103004|NCT02104830|Experimental|Empegfilgrastim 6 mg|Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
3103005|NCT02104830|Experimental|Empegfilgrastim 7.5 mg|Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy and placebo #2 in a dose of 0.0083 ml/kg in 24-27 hour after chemotherapy, then patient received placebo #2 in dose 0.0083 ml/kg until ANC ≥ 10x109/L or during 14 days
3103006|NCT02104830|Active Comparator|Filgrastim|Patients will receive filgrastim at a dose of 5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy and placebo #1 in dose 1.0 ml subcutaneously, 24 h after the chemotherapy.
3103007|NCT02104895|Active Comparator|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
3103008|NCT02104895|Experimental|Partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI)
3103009|NCT02104947|Experimental|idarucizumab|idarucizumab Only 1 treatment, no placebo or comparator
3103010|NCT02105012|Experimental|BD MDI 320 µg|Budesonide metered dose inhaler (BD MDI) 320 µg (PT008) administered as 2 inhalations BID
3103011|NCT02105012|Experimental|BD MDI 160 µg|BD MDI 160 µg (PT008) administered as 2 inhalations BID
3103012|NCT02105012|Experimental|BD MDI 80 µg|BD MDI 80 µg (PT008) administered as 2 inhalations BID
3103013|NCT02105012|Experimental|BD MDI 40 µg|BD MDI 40 µg (PT008) administered as 2 inhalations BID
3103014|NCT02105012|Placebo Comparator|Placebo MDI|Placebo MDI administered as 2 inhalations BID
3103015|NCT02105246|Experimental|Home-based|Referral to a home-based cardiac rehabilitation program (intervention).
3103016|NCT02105246|Active Comparator|Center-based|Referral to a center-based cardiac rehabilitation program (standard of care).
3103017|NCT02105272|Experimental|OPC-1085EL ophthalmic solution|Once daily
3103018|NCT02105272|Active Comparator|Latanoprost ophthalmic solution|Once daily
3103019|NCT02105285|Experimental|OPC-1085EL ophthalmic solution|Once daily
3103020|NCT02105285|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
3103021|NCT02105324|Experimental|Bionic Pancreas|Bionic Pancreas diabetes management, a wearable bionic pancreas system that automatically delivers insulin and glucagon using a continuous glucose monitoring (CGM) device, for 5 days.
3103022|NCT02105324|Experimental|Usual Care|Usual Care diabetes management in a diabetes camp environment including a nurse or nursing student assigned to each cabin and review and adjustment of the insulin regimen daily by a physician or nurse practitioner, all participants using the participant's own insulin pump and a continuous glucose monitor if they use one as part of their usual care, for 5 days.
3103023|NCT02105415|Active Comparator|Etomidate|weight based dose of 0.15mg/kg
3103024|NCT02105415|Experimental|Ketamine / Propofol Admixture|weight based dose of 0.5mg/kg of ketamine and 0.5mg/kg of propofol
3103025|NCT02105454|Experimental|GZR 100 mg + EBR 50 mg + RBV for 12 weeks|Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks
3103026|NCT02105467|Experimental|Immediate Treatment Group|Participants received blinded grazoprevir 100 mg / elbasvir 50 mg fixed-dose combination (FDC) tablet orally once daily for 12 weeks followed by a 24-week follow-up period
3103027|NCT02105467|Placebo Comparator|Deferred Treatment Group|Participants received blinded placebo tablet orally once daily for 12 weeks; after a 4-week unblinding/washout period participants received open label grazoprevir 100 mg / elbasvir 50 mg FDC tablet orally once daily for 12 weeks. Follow-up was continued for an additional 24 weeks.
3103028|NCT02105558|Experimental|Epidural anesthesia|Trial of labor after cesarean with an epidural for anesthesia: Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered.
3103029|NCT02105558|Experimental|Combined spinal and epidural anesthesia|Trial of labor after cesarean with a combined spinal and epidural (CSE) for anesthesia: the epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr.
3103032|NCT02105662|Experimental|Grazoprevir+Elbasvir|Participants receive a fixed-dose combination (FDC) of grazoprevir 100 mg plus elbasvir 50 mg once daily for 12 weeks and are followed-up for 24 weeks.
3103033|NCT02105688|Experimental|Immediate Treatment Arm: Grazoprevir/Elbasvir|In Part A, participants receive grazoprevir 100 mg plus elbasvir 50 mg FDC (MK-5172A) once daily for 12 weeks (blinded) and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
3103034|NCT02105688|Placebo Comparator|Deferred Treatment Arm: Placebo > Grazoprevir/Elbasvir|In Part A, participants receive placebo to MK-5172A once daily for 12 weeks (blinded), followed by 4 weeks of follow-up. Afterwards, participants received 12 weeks of open-label treatment with the MK-5172A FDC and were followed-up for 24 weeks. In Part B, participants could enroll in a 3-year follow-up period where they were followed every 6 months for 3 years in an observational cohort (no treatment was administered during Part B).
3103035|NCT02105701|Experimental|Grazoprevir + Elbasvir 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg fixed-dose combination (FDC) tablets once daily (q.d.) by mouth for 12 weeks.
3103036|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 12 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules twice daily (b.i.d.) by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 12 weeks.
3103037|NCT02105701|Experimental|Grazoprevir + Elbasvir 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth for 16 weeks.
3103038|NCT02105701|Experimental|Grazoprevir + Elbasvir + RBV 16 weeks|Participants receive grazoprevir 100 mg/elbasvir 50 mg FDC tablets q.d. by mouth, along with RBV capsules b.i.d. by mouth (weight-based dosing; 800 to 1400 mg total daily dose), for 16 weeks.
3103039|NCT02105740|Experimental|Hypnosis|Use of hypnosis in the reduction of the levels of pain, depression and anxiety.
3103040|NCT02105740|Active Comparator|Control|Comparison of the effects of hypnosis between the control group and the experimental group regarding pain, anxiety and depression with the application of the scales.
3103041|NCT02105948|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
3103042|NCT02105948|Placebo Comparator|Arm 2|Each subject will receive placebo (0.9% sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) along with optimized standard of care background therapy.
3103043|NCT02105961|Experimental|Arm 1|Each subject will receive 100 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
3103044|NCT02105961|Experimental|Arm 2|Each subject will receive 300 mg mepolizumab SC injection every 4 weeks (13 administrations during 52 week treatment period) along with their baseline standard of care COPD medication
3103045|NCT02105961|Experimental|Arm 3|Each subject will receive placebo (0.9percent sodium chloride) SC injection every 4 weeks (13 administrations during 52 week treatment period) their baseline standard of care COPD medication
3103046|NCT02105974|Experimental|Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder|Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)
3103047|NCT02105974|Experimental|Vilanterol 25 Inhalation Powder|Long-acting beta2-agonist (LABA)
3103048|NCT02105987|Experimental|ABC/DTG/3TC|Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
3103049|NCT02105987|Active Comparator|Comparator|Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
3103050|NCT02106065|Experimental|In-person Education and Skill-Building Rehabilitation (ESBR-i) Condition|Education and Skill-Building Rehabilitation delivered in clinic
3103051|NCT02106065|Experimental|Education and Skill-Building Rehabilitation over Video (ESBR-V) Condition|Education and Skill-Building Rehabilitation delivered via video telehealth.
3103052|NCT02106065|Active Comparator|Usual Care Condition|Usual Care plus supplemental paper education materials
3103053|NCT02106156||Chronic Hepatitis C|Participants with chronic hepatitis C planned for treatment with peginterferon alfa-2a alone or in combination with ribavirin according to routine clinical practice will be observed in this study.
3103054|NCT02106195|Experimental|Belumosudil 200 mg|Belumosudil 200 mg (two 100 mg capsules) orally once daily for 28 days
3103055|NCT02106325|Experimental|Ketamine|IV Ketamine .25mg/kg
3103056|NCT02106325|Placebo Comparator|Diphenhydramine|25mg Diphenhydramine
3103057|NCT02106351|Experimental|Group A|Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb).
3103058|NCT02106351|Experimental|Group B|Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb).
3103059|NCT02106351|Experimental|Group C|"Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).~Group C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
3103060|NCT02106390|Experimental|rMenB+ACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3103061|NCT02106390|Active Comparator|rMENB|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3103062|NCT02106390|Active Comparator|MenACWY|Approximately 250 healthy infants who will be vaccinated at 3, 5, 7 and 13 months of age.
3103063|NCT02106403|Experimental|Prototype disinfectant spray formulation|0.13% w/w Benzalkonium Chloride (BAC) and 1% Menthone Glycerin Acetal (MGA). After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3103064|NCT02106403|Active Comparator|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3103065|NCT02106403|Placebo Comparator|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
3103066|NCT02106442||Sodium Risedronate 75 mg|75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking. Participants receive sodium risedronate 75 mg as part of routine medical care.
3103067|NCT02106455||17.5 mg of sodium risedronate|17.5 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive weeks.
3103068|NCT02106494|Experimental|APF530 500 mg SC|APF530 500 mg (granisetron 10 mg) SC and ondansetron placebo IV (0.15 mg/kg) and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1 in association with HEC
3103069|NCT02106494|Active Comparator|ondansetron 0.15 mg/kg IV|Ondansetron 2 mg/mL solution to be administered at 0.15 mg/kg IV (up to a maximum of 16 mg) and APF530 placebo SC and fosaprepitant 150 mg IV and dexamethasone 12 mg IV on Day 1 of Cycle 1
3103070|NCT02106728|Experimental|Multi-Family Therapy|Multi-family group therapy involving eight to ten families who meet as a group with two therapists for a duration of 8, 1.5h sessions.
3103071|NCT02106728|Active Comparator|Supportive Family Therapy|Family supportive counseling consists of people with eating disorders and their family members meeting with a family therapist. This is treatment as usual in the Eating Disorders Program at University Health Network.
3103072|NCT02106832|Experimental|Ciprofloxacin DPI 28 Days on/off (Cipro 28)|Subjects received ciprofloxacin (BAYQ3939) 32.5 milligram (mg) corresponding to 50 mg dry powder for inhalation (DPI) administered twice daily (BID) (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 active cycles).
3103073|NCT02106832|Experimental|Ciprofloxacin DPI 14 Days on/off (Cipro 14)|Subjects received ciprofloxacin 32.5 mg corresponding to 50 mg DPI administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 active cycles).
3103074|NCT02106832|Placebo Comparator|Placebo 28 Days on/off (Placebo 28)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 28-day on-treatment phase followed by a 28-day off-treatment phase (48 weeks treatment phase = 6 cycles).
3103075|NCT02106832|Placebo Comparator|Placebo 14 Days on/off (Placebo 14)|Subjects received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours); a treatment cycle consisted of a 14-day on-treatment phase followed by a 14-day off-treatment phase (48 weeks treatment phase = 12 cycles).
3103076|NCT02106884|Experimental|Arm A|Nab-paclitaxel - IV - 125 mg/m2 - 3xq4wks Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
3103077|NCT02106884|Active Comparator|Arm B|Gemcitabine - IV - 1000 mg/m2 - 3xq4wks
3103078|NCT02106910|Experimental|Participants with Barrett's and No History of Ablation|Participants with a diagnosis of BE, presenting for routine care endoscopy for surveillance or treatment of their BE.
3103079|NCT02106910|Experimental|Participants with Barrett's and a History of Ablation|Participants with Barrett's Esophagus (BE) with low grade dysplasia (LGD) or high grade dysplasia (HGD) and achieved complete eradication of BE via radiofrequency ablation (RFA).
3103080|NCT02106923|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs 3 single tablets under fasted conditions
3103081|NCT02106923|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs 3 single tablets under fed conditions
3103082|NCT02106923|Experimental|Low dose, fasted|2 fixed dose combination (FDC) tablets vs 4 single tablets under fasted conditions
3103083|NCT02106962|Experimental|Clotting time Using Tranexamic Acid 5%|Measure Native AV Fistula clotting time after dialysis using 5% Tranexamic Acid compared to normal Clotting time of Native AV Fistula after dialysis
3103084|NCT02106962|Experimental|Clotting Time Using Tranexamic Acid 25%|Measure Native AV Fistula clotting time after dialysis using 25% Tranxemic Acid compared to normal clotting time of native AV Fistula after dialysis
3103085|NCT02106975|Active Comparator|Ascorbic Acid|200mg/kg/day divided over 4 doses. Administered every 6 hours for 96 hours
3103086|NCT02106975|Placebo Comparator|5% Dextrose in Water|50ml every 6 hours for 96 hours
3103087|NCT02107014|Other|Low Dose Naltrexone (LDN)|Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.
3103088|NCT02107092|Experimental|Sodium Zirconium Cyclosilicate|Open label oral administration of sodium zirconium cyclosilicate 10g once daily for 11 months.
3103089|NCT02107131|Active Comparator|Monthly Intravitreal ranibizumab 0.3mg|Monthly Intravitreal ranibizumab 0.3mg injections.
3103090|NCT02107131|Active Comparator|PRN Intravitreal ranibizumab 0.3mg|PRN Intravitreal ranibizumab 0.3mg injections.
3103091|NCT02107157|Experimental|755nm Alexandrite laser with cap array|
3103092|NCT02107196|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
3103093|NCT02107196|Placebo Comparator|Placebo|Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.
3103094|NCT02107274|Active Comparator|Azithromycin and Placebo for Azithromycin|Patients randomised to the treatment arm are to receive 1000 mg of azithromycin once a week for 12 weeks followed by placebo for azithromycin once weekly for another 12 weeks
3103095|NCT02107274|Placebo Comparator|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
3103096|NCT02107300|Experimental|NeutraSal|NeutraSal, dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
3103097|NCT02107300|Placebo Comparator|Placebo|Placebo dosed 2 times per day at waking and bedtime (indications 2-10 times per day or PRN), swish and spit, daily for a term of 12 weeks.
3103098|NCT02107313|Other|Fed Cohort|PBT2 250 mg is administered orally following a high fat breakfast
3103099|NCT02107313|Other|Fasted Cohort|PBT2 250 mg is administered orally following a 10 hour period of fasting
3103100|NCT02107339|Experimental|methadone group|Patient will receive methadone 0.2 mg/kg at induction of anesthesia (single dose)
3103101|NCT02107339|Active Comparator|Hydromorphone group|Patients will receive hydromorphone 2 mg at the end of the surgical procedure
3103102|NCT02107443|Experimental|Arm I: Geriatric Assessment Intervention|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA and receive the intervention; GA summary plus GA targeted recommendations which is provided to the oncology team to discuss and implement if they so choose.
3103103|NCT02107443|Active Comparator|Arm II: Usual Care|At the first study visit with their oncologist, patients and their caregivers (if participating) complete the GA (no GA summary or recommendations are provided).
3103104|NCT02107482|Active Comparator|Levia Narrow Band UVB|Levia Narrow Band UVB dosing for subjects with skin type I: starting dose of 195 mj/cm2, for subjects with skin type II: starting dose of 330 mj/cm2, for subjects with skin type III: starting dose of 390 mj/cm2, for subjects with skin type IV: starting dose of 495 mj/cm2, for subjects with skin type V: starting dose of 525 mj/cm2, for subjects with skin type VI: starting dose of 600 mj/cm2. The dose will be increased by 15% with each treatment, as long as there are no side effects with treatment such as burning or redness.
3103105|NCT02107482|Sham Comparator|Levia sham/visible-light source|the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
3103106|NCT02107599|Experimental|Physician Readers|Physician readers will interpret Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to Florbetapir(18F) as part of this study.
3103107|NCT02107703|Experimental|Abemaciclib + Fulvestrant|150 milligrams (mg) Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
3103108|NCT02107703|Placebo Comparator|Placebo + Fulvestrant|Placebo will be supplied as capsules administered orally every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
3103109|NCT02107703|Experimental|Abemaciclib + Fulvestrant (Endocrine Naïve Cohort)|150 milligrams mg Abemaciclib given orally once every 12 hours in 28 day cycles. 500 mg fulvestrant administered as two 250-mg injections intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants may continue to receive treatment until discontinuation criteria are met.
3103110|NCT02107859|Experimental|Ataluren|Participants will receive ataluren suspension orally 3 times a day (TID), 10 milligrams/kilogram (mg/kg) at morning, 10 mg/kg at midday, and 20 mg/kg at evening (total daily dose 40 mg/kg) for 192 weeks.
3103111|NCT02107898|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
3103112|NCT02107898|Experimental|Alirocumab 75 mg/Up to 150 mg Q2W|"Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e.~≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD)~≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III"
3103113|NCT02108171|Active Comparator|dexmedetomidine|intranasal dexmedetomidine
3103114|NCT02108171|Placebo Comparator|placebo|intranasal saline
3103115|NCT02108223|Active Comparator|fix dose r-FSH (Gonal-f)|The patients who had normal ovarian response were included as the control group (Group 1). The dose of r-FSH (Gonal-f) was continued for the fix dose until the day of hCG in Group 1
3103116|NCT02108223|Active Comparator|r-LH supplementation to r-FSH|On day 7 of the stimulation, if at least six follicles between 6-10mm were present but there was no follicle over 10 mm on transvaginal ultrasound, E2 level was under 180 pg/ml, it has been considered that the patients had suboptimal response to the stimulation and were divided into Group 2. Group 2 received supplemental r-LH ( Lutropin alpha; Luveris, Merck Serono, France), 75IU/day to r-FSH (Gonal-f) treatment.
3103117|NCT02108223|Active Comparator|r-FSH (Gonal-f)|Group 3: Daily 75 IU/L r-FSH was added to r-FSH treatment until the end of ovarian stimulation.
3103118|NCT02108262|Experimental|CSL112 - low dose|CSL112 (low dose) is to be administered as an intravenous (IV) infusion once weekly for 4 consecutive weeks.
3103119|NCT02108262|Experimental|CSL112 - high dose|CSL112 (high dose) is to be administered as an IV infusion once weekly for 4 consecutive weeks.
3103120|NCT02108262|Placebo Comparator|Placebo|Placebo is to be administered as an IV infusion at the same frequency, volume and duration as either the low dose or high dose CSL112 infusion.
3103121|NCT02108288|Experimental|OPC-1085EL ophthalmic solution|Once daily
3103122|NCT02108288|Active Comparator|Carteolol long-acting ophthalmic solution|Once daily
3103123|NCT02108288|Active Comparator|Latanoprost ophthalmic solution|Once daily
3103124|NCT02108457||Proton subjects|
3103125|NCT02108457||IMRT subjects|
3103126|NCT02108522|Experimental|Multivirus Specific T cells|"Partially HLA-matched multivirus specific T cells (VSTs) will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team.~If after the first treatment there is persistent infection, there is an option to receive more treatments. These additional treatments might be with cells from the same donor or another donor whose cells are also thought to be a good match for the patient and effective against their virus. This second product will be administered at the same dose level 28 days after the initial infusion, and subsequent infusions should be at least 14 days apart."
3103127|NCT02108600|No Intervention|Standard of Care|Will continue usual immunosuppression and not receive any specific intervention.
3103128|NCT02108600|Experimental|Tocilizumab (TCZ) Group|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
3103130|NCT02108691|Experimental|Glycin max(L.) Merr. pell extract|
3103131|NCT02108691|Placebo Comparator|Placebo|
3103132|NCT02108821|Experimental|Fecal Microbiome Transplantation|Fecal Microbiome Transplantation will be done at the time of EGD and colonoscopy. A parent or sibling or a healthy relative will be tested for several infections like hepatitis, H. Pylori, HIV, syphilis, ova and parasites, culture and C.diff. They will fill out a donor questionnaire used for blood donors prior to the sample collection. After eligibility criteria have been met, appropriate consent has been obtained, and the screening labs have been assessed, the fecal transplant procedure will take place in the procedure center at Children's Hospital of Pittsburgh. Fresh stool sample will be obtained from the donor. The fecal sample will be prepared for transplantation in a designated area in the procedure center. Frequency: once. Duration: Approximately 1 hour
3103133|NCT02108912|Experimental|Traditional outpatient|Traditional outpatient physical therapy
3103134|NCT02108912|Experimental|ESTT outpatient|ESTT (early standardized task-specific training) in outpatient rehabilitation
3103135|NCT02108951|Experimental|Nilotinib|Nilotinib was administered orally at 300 mg BD at approximately 12 hour intervals which had to be taken without food. The capsules were to be swallowed whole with water and no food should have been consumed for at least 2 hours before and at least 1 hour after the dose was taken. Prior to the first dose of nilotinib, patients were required to have an imatinib or dasatinib washout period of at least 3 days. Therapy with nilotinib was to be continued for up to 24 months while on study.
3469115|NCT03889496|Other|Scheduled for (partial) pancreatectomy or Whipple procedure|I.v. injection with In-111-DTPA-exendin-4 and SPECT/CT scan
3469116|NCT03889392||polycystic kidney disease|Adult autosomal dominant polycystic kidney disease patients who received kidney transplantation at Asan Medical Center between 1994 and 2018
3103138|NCT02108977|Experimental|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
3103139|NCT02108977|Active Comparator|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
3103140|NCT02109029|Experimental|Insulin Peglispro (LY2605541)|Part A Cohort 1: (low dose) priming dose (PD) of 2.00 units (U), 0.92 U/hour (U/h) constant infusion of insulin peglispro Part A Cohort 1: (high dose) PD of 8.00 U, 4.50 U/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 1) PD of 4.00 U, 1.84/h constant IV infusion of insulin peglispro Part A Cohort 2: (intermediate dose 2) PD of 6.0 U, 2.76 U/h constant IV infusion of insulin peglispro Part B Insulin Peglispro: PD of 6.00 U, 2.76 constant IV infusion of insulin peglispro and a constant infusion of 6 pico moles per kilogram per minute (pmol/kg/min). IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
3103141|NCT02109029|Active Comparator|Human Insulin|Constant IV infusion ( 6 pico moles per kilogram perminute [pmol/kg/min]) of human insulin for up to 36 hours. IV infusion of sinistrin (250 mg/mL, SOC to achieve a steady state for up to 16 hours).
3103142|NCT02109042|Experimental|Blosozumab|Weekly SC injections of blosozumab for 6 weeks.
3103143|NCT02109107|Experimental|Erchonia EZ6 Laser|The Erchonia EZ6 Laser is a 6 headed scanner composed of 6 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices. It is a variable frequency, pulsed wave laser device.
3103144|NCT02109133|Experimental|Deep neuromuscular blockade|Deep neuromuscular blockade
3103145|NCT02109133|Active Comparator|moderate neuromuscular blockade|moderate neuromuscular blockade
3469117|NCT03889535|Active Comparator|Resin strip crowns|Current standard full coverage restoration provided for primary incisors. Please see intervention section for detailed description of technique.
3469118|NCT03889535|Experimental|Zirconia crowns|Experimental treatment under study. Zirconia crowns are an alternative restorative option. Please see intervention section for detailed description of technique.
3103146|NCT02109159|Experimental|emotional content|A short online video with emotional content, an interview with a postpartum hemorrhage survivor and her husband talking about their experience.
3103147|NCT02109159|Active Comparator|less emotional content|A short online video with less emotional content, the WOMAN trial coordinator talks about the experience of a postpartum hemorrhage survivor and her husband.
3103148|NCT02109172|Experimental|TD-4208 44 mcg twice daily|TD-4208 inhalation solution 44 mcg twice daily for 7 days
3103149|NCT02109172|Placebo Comparator|Placebo|Placebo inhalation solution twice daily for 7 days
3103150|NCT02109172|Experimental|TD-4208 175 mcg once daily|TD-4208 inhalation solution 175 mcg once daily, placebo once daily
3103151|NCT02109419||All participants|All participants, including control, mild cognitive impairment, and dementia.
3103152|NCT02109432|Other|Pedal Desk|"Participants will complete three 2-week conditions in the following order:~Self-directed Pedal Desk~Facilitated Pedal Desk~Facilitated Pedal Desk with Pedometer"
3103153|NCT02109445|Experimental|Phase 1|PF-03084014 in combination with gemcitabine and nab-paclitaxel
3103154|NCT02109445|Experimental|Phase 2 Arm A|PF-03084014 in combination with gemcitabine and nab-paclitaxel
3103155|NCT02109445|Active Comparator|Phase 2 Arm B|Gemcitabine plus nab-Paclitaxel
3103156|NCT02109458|Experimental|Assessing peripheral pulmonary nodules|To evaluate the feasibility and safety of a procedure path including convex Endobronchial Ultrasound (EBUS) lymph node sampling, navigation guided bronchoscopy (NB) and navigation guided transthoracic needle aspiration (N-TTNA).
3103157|NCT02109484|Experimental|Cohort A P2-VP8 30 mcg|Cohort A toddlers (24-35 mo) receiving P2-VP8 Subunit Vaccine (30 mcg)
3103158|NCT02109484|Placebo Comparator|Cohort A Placebo|Cohort A toddlers (24-35 mo)
3103159|NCT02109484|Experimental|Cohort A P2-VP8 60 mcg|Cohort A toddlers (24-35 mo) receiving high dose P2-VP8 Subunit Vaccine (60mcg)
3103160|NCT02109484|Experimental|Cohort B P2-VP8 10mcg|Cohort B infants receiving P2-VP8 Subunit Vaccine (10mcg)
3103161|NCT02109484|Placebo Comparator|Cohort B placebo|Cohort B infants aged 6 to < 8 weeks receiving placebo
3103162|NCT02109484|Experimental|Cohort B P2-VP8 30mcg|Cohort B infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (30mcg)
3103163|NCT02109484|Experimental|Cohort B1 P2-VP8 60mcg|Cohort B1 Infants aged 6 to < 8 weeks receiving P2-VP8 Subunit Vaccine (60mcg)
3103164|NCT02109484|Experimental|Cohort A P2-VP8 10mcg|Cohort A toddlers (24-35 mo) receiving P2VP8 Subunit Vaccine (10mcg)
3103165|NCT02109497|Other|Caffeine Dosing|Single dose of caffeine 100 mg administered
3103166|NCT02109562|Experimental|RBP-7000 90 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 90 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
3103167|NCT02109562|Experimental|RBP-7000 120 mg|Risperidone tablets given during the screening period to check for sensitivity. RBP-7000 administered as a 120 mg subcutaneous injection on Days 1 and 29 for a total of two injections.
3103168|NCT02109562|Placebo Comparator|Placebo|Risperidone tablets given during the screening period to check for sensitivity. Placebo administered by subcutaneous injection on Days 1 and 29 for a total of two injections.
3103169|NCT02109640|Experimental|Targinact|Oral Targinact 10-20mg bd following laparoscopic segmental colectomy
3103170|NCT02109640|Active Comparator|Oxycodone|Oral oxycodone 10-20mg bd following laparoscopic segmental colectomy
3103171|NCT02109731|Experimental|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
3103172|NCT02109939|Active Comparator|GeneSight Psychotropic Tested|Subjects being tested with GeneSight Psychotropic
3103173|NCT02109939|Placebo Comparator|Treatment As Usual|This group of subjects will not see their GeneSIght results or know whether or not they are in either arm until after week 12.
3103174|NCT02110095|Experimental|Picosure Laser System|Picosure Laser System for the treatment of unwanted tattoos
3103175|NCT02110108|Experimental|Revlite Laser System- Single Wavelength|Revlite Laser System- 1064nm wavelength will be used on half of the face.
3103176|NCT02110108|Experimental|Revlite Laser System- Dual Wavelength|Revlite Laser System- treatment will consist of 1064 nm and 532 nm wavelengths on half of the face.
3103177|NCT02110121|Experimental|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
3103178|NCT02110121|Experimental|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
3103179|NCT02110147|Experimental|Uridine Triacetate to Replace Uridine|Replacement therapy for oral uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. The starting dose of uridine triacetate will be 60 mg/kg/day which may be escalated to 300 mg/kg/day of oral uridine triacetate. The dose may be given once a day or as equally divided doses twice a day.
3103180|NCT02110225|Experimental|rhNGF 60µg/ml|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
3103181|NCT02110225|Experimental|rhNGF 180 µg/ml|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
3103182|NCT02110225|Placebo Comparator|Vehicle|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes.
3103183|NCT02110238|Active Comparator|Euflexxa|Euflexxa® (hyaluronic acid of bacterial origin)
3103184|NCT02110238|Experimental|Supartz|SUPARTZ® (hyaluronic acid of avian origin)
3103185|NCT02110264|Experimental|Vivitrol (XR-NTX)|50 participants will be randomized to the long-acting naltrexone condition (XR-NTX) which will include monthly injections of study drug.
3103186|NCT02110264|Experimental|XR-NTX+PN|50 participants will be randomized to receive long-acting naltrexone (XR-NTX) and will be assigned to a patient navigator (PN).
3103187|NCT02110264|Active Comparator|ETAU|50 participants will be randomized to the drug-education/treatment-as-usual group.
3103188|NCT02110381|Active Comparator|Device Guided Breathing/Combination Therapy|Participants will first do device guided breathing for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
3103189|NCT02110381|Active Comparator|Isometric Hand Grip/Combination Therapy|Participants will first do isometric hand grip exercises for 8 weeks, followed by 8 weeks of doing BOTH the device guided breathing AND the hand grip exercises. Participants will be given a home blood pressure monitor. Participants will measure blood pressure and heart rate at home for 2 weeks prior to starting any intervention and also during the 16 week of intervention.
3103190|NCT02110485|Experimental|Patient Activation Tool|Patients and their caregivers will receive the patient activation tool in addition to standard consultation
3103191|NCT02110485|No Intervention|Standard Consultation|Patients and their caregivers will receive standard consultation alone
3103192|NCT02110693|Other|Interviewer and tablet administration|All participants were administered the TAPS Tool via interviewer and tablet computer self-administration in the same session.
3103193|NCT02110706|Placebo Comparator|Placebo|The placebo group will receive a vehicle control infusion
3103194|NCT02110706|Experimental|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
3103195|NCT02110732|Active Comparator|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG 8-9 x 10 -9 pmy 2x2 for 3 weeks
3103196|NCT02110732|Placebo Comparator|Crystalline cellulose|Crystalline cellulose
3103197|NCT02110758||Pilot Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at pilot practice in southeastern Pennsylvania
3103198|NCT02110758||Comparison Practices Patient Survey Cohort|Patients with any active drug therapy treatment for cancer receiving care at comparison practice in southeastern Pennsylvania
3103199|NCT02110758||Pilot Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology pilot practice in southeastern Pennsylvania
3103200|NCT02110758||Comparison Practices Utilization Cohort|Patients with an evaluation & management claim attributed to a medical oncology comparison practice in southeastern Pennsylvania
3103201|NCT02110758||Pilot Practices Quality Measures Cohort|Patients with a new diagnosis of cancer in the past two years
3103202|NCT02110901|Active Comparator|PRT-201|PRT-201 administered at the time of radiocephalic fistula creation
3103203|NCT02110901|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.
3103204|NCT02111083|Active Comparator|Insulin Lispro A|Insulin Lispro A 20 units (U) of strength 200 units per milliliter (U/mL) (U-200)administered subcutaneously (SC) once in two of four study periods.(Two doses of test [T]).
3103205|NCT02111083|Experimental|Insulin Lispro B|Insulin Lispro B 20 units (U) of strength 100 U/mL (U-100) administered SC once in two of four study periods.(Two doses of reference [R]).
3103206|NCT02111096|Experimental|LY2409021|20 milligrams (mg) LY2409021 given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3103207|NCT02111096|Active Comparator|Sitagliptin|100 mg sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3103208|NCT02111096|Placebo Comparator|Placebo|Placebo matching LY2409021 and sitagliptin given orally once daily in the morning for 12 months (52 weeks). Participants remain on stable doses of metformin and sulfonylurea, as prescribed by their personal physician.
3103209|NCT02111174|Experimental|Scrambler Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
3103210|NCT02111174|Sham Comparator|Sham Therapy|The device is a cutaneous electrical stimulator that uses electrodes placed on the skin similar to an electrocardiogram (EKG) machine, feeling similar to a tingling or bee-sting like sensation during the therapy. The electrodes are placed in areas not thought to help relieve pain associated with chemotherapy-induced peripheral neuropathy.
3103211|NCT02111187|Active Comparator|LDE225 (Arm1)|Treatment arm (Arm 1) will receive LDE225 by mouth 800 mg daily for 4 weeks (+/- 3 days)
3103212|NCT02111187|No Intervention|Observation Arm (Arm2)|Observation Arm (Arm2) will receive no treatment prior to prostatectomy.
3103213|NCT02111200|Active Comparator|Sodium Benzoate arm|Sodium benzoate 5.5 g/m2/day divided into three equal doses per day (maximum dose 12 g/day) for 3 days
3103214|NCT02111200|Active Comparator|Sodium Phenylbutyrate arm|Sodium phenylbutyrate 7.15 g/m2/day divided into three equal doses per day (maximum dose of 20 g/day) for 3 days
3103215|NCT02111200|Active Comparator|Mix Arm|Sodium Phenylbutyrate 3.575 g/m2/day and Sodium Benzoate 2.75 g/m2/day will be given in three equal doses per day for 3 days
3103216|NCT02111213|Active Comparator|Promotora for physical activity|Weekly sessions with a volunteer promotora at a community center. A promotora is a trained, lay health worker. The promotora will provide guidance, advice and support to participants to encourage them to be more physically active.
3103217|NCT02111213|Experimental|Carmen system|Weekly sessions with the virtual advisor accessed through a computer located at a community center. Carmen is the virtual advisor and will provide guidance, advice and support to participants to encourage them to be more physically active.
3103218|NCT02111252|Experimental|TAK-850 0.5 mL|A single dose of 0.5 mL TAK-850 (15 µg of hemagglutinin [HA] antigen per strain) is injected into the deltoid muscle.
3103219|NCT02111369|Experimental|Propranolol/Botulinum|After baseline analysis, patient will be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times per day (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile. After second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
3469119|NCT03889379|Experimental|Effects of Albuterol on Immune Cell Composition|This is a single subject repeated measure experimental design with each participant acting as his/her own control.
3469120|NCT03889483|Other|NeuroCatch™ Platform Assessment|All participants will undergo two NeuroCatch™ Platform Assessments.
3103220|NCT02111447|Active Comparator|Sevoflurane, propofol, Nasal oxygen|After securing the IV, sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. A bolus of propofol will not be administered. Oxygen will be delivered via nasal prongs at 2 liters per minute. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min also after 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be administered if the child moves or if signs of light anesthesia are noticed. The propofol infusion may also be increased in response to light anesthesia.
3103221|NCT02111447|Active Comparator|Sevoflurane, Propofol, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane will be discontinued and a propofol infusion will be started at the dose of 300 mcg/kg/min depending on the child's age and neurologic status. Oxygen in air will be delivered via LMA. The infusion rate of propofol will be decreased to 250 after 15 min and then 200 mcg/kg/min after another 15 min. Supplemental IV boluses of Propofol (0.5 mg/kg) will be given if the child moves or exhibits signs of light anesthesia. The propofol infusion may also be increased in response to light anesthesia.
3103222|NCT02111447|Active Comparator|Sevoflurane, sevoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted and sevoflurane continued at 3% inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. The sevoflurane may be increased or decreased in 0.5% increments as needed.
3103223|NCT02111447|Active Comparator|Sevoflurane, isoflurane, LMA|After securing the IV, weight appropriate LMA will be inserted , sevoflurane will be discontinued and isoflurane will be administered at 2 % inspired concentration. Oxygen in air will be delivered via LMA at 2 lpm. Isoflurane may be increased or decreased in 0.5% increments as needed.
3103224|NCT02111564|Experimental|Rivaroxaban|Each patient will receive either 10 mg or 7.5 mg rivaroxaban tablet once daily orally (by mouth) for 45 days. The dosing will depend on a creatinine clearance at screening.
3103225|NCT02111564|Placebo Comparator|Placebo|Each patient will receive matching placebo tablet once daily orally (by mouth) for 45 days.
3103226|NCT02111577|Experimental|DCVAC/PCa with standard of care chemotherapy|Combination therapy with DCVAC/PCa and standard of care chemotherapy (docetaxel and prednisone)
3103227|NCT02111577|Placebo Comparator|Placebo with standard of care chemotherapy|Combination therapy with placebo and standard of care chemotherapy (docetaxel and prednisone) as comparator
3103228|NCT02111603|Other|Colesevelam|1875 mg of Colesevelam orally twice daily for 10 days
3103229|NCT02111746|Experimental|Exparel®|Patients in this group will receive will receive the study drug [bupivacaine liposomal injectable suspension (Exparel®)] and Patient Controlled Analgesia (PCA). Exparel® is an FDA-approved bupivacaine liposome injectable suspension produced by Pacira Pharmaceuticals.
3103230|NCT02111746|Active Comparator|Regular Bupivacaine|Patients in this group will receive will receive the standard regular bupivacaine hydrochloride (HCl) and PCA. Bupivacaine HCl is an FDA-approved injectable suspension. The standard non-liposomal bupivacaine will be from Hospira pharmaceuticals
3103231|NCT02111772|Experimental|Asthmatic subjects|Subjects with Asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus.
3103232|NCT02111772|Active Comparator|Without Asthma|Subjects without asthma whose cold and chest symptoms will be evaluated one week before and 4 weeks after an inoculation with rhinovirus
3103233|NCT02111785|Active Comparator|Burr Hole Craniostomy randomized|Group receiving burr hole craniostomy and drainage of chronic subdural hematoma
3103234|NCT02111785|Experimental|Dexamethasone randomized|Dexamethasone, tablet, initial dose 4mg q8h, total duration 15 days
3103235|NCT02111785|Other|Burr hole craniostomy observational|Observational cohort of patients selecting burr hole craniostomy
3103236|NCT02111785|Other|Dexamethasone observational|Observational cohort of patients treated with dexamethasone protocol
3103237|NCT02111798|Placebo Comparator|Placebo/Abstinence Initiation|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
3103238|NCT02111798|Active Comparator|Bupropion XL/Abstinence Initiation|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
3103239|NCT02111798|Placebo Comparator|Placebo/Relapse Prevention|In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
3103240|NCT02111798|Active Comparator|Bupropion XL/Relapse Prevention|In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide >/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.
3103241|NCT02111811|Experimental|Be Well At Work intervention + IC|CBT based intervention focused on work productivity plus integrated care as usual
3103242|NCT02111811|No Intervention|Integrated Care Only|usual care group (Behavioral Health lab care at the PVAMC)
3103243|NCT02111863|Experimental|Lymphocyte Depleting Prep Regimen|Patients will receive a lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by intravenous (IV) infusion of 4-1BB selected tumor infiltrating lymphocytes (TIL) plus IV aldesleukin.
3103244|NCT02111980|Experimental|RF Assure Scanning|The patient's CIED will be interrogated prior to the study to obtain a baseline reading. The patient will be asked to lie down on the RF Assure® Detection Mat with a sponge placed underneath his or her shoulder. The RF Assure® mat and wand will be activated to detect the sponge. The sponge will be removed from underneath the patient's shoulder, and the RF system will be re-activated to obtain a clear reading. The patient's CIED will be re-interrogated to determine if the RF Assure system caused any changes to the CIED parameters or function.
3103245|NCT02111993|Active Comparator|Standard Defibrillation Testing|Standard Defibrillation Threshold Testing is a procedure in which a low energy shock will be delivered to the heart to induce ventricular fibrillation (VF) followed by a rescue shock to restore sinus rhythm. Process is repeated after 5 minutes.
3103246|NCT02111993|Active Comparator|Upper Limit of VulnerabilityTesting|Upper Limit of Vulnerability Testing is a procedure in which four 18J shocks will be delivered at specified intervals. If VF is induced, then a 25 J rescue shock will be delivered.
3103247|NCT02112045|Experimental|Experimental: Granix and high dose melphalan (HDM)|"Granix on Day -7 through Day -2.~HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0"
3103248|NCT02112045|Active Comparator|Control: High dose melphalan (HDM)|"HDM intravenously (IV) on Day -2.~Autologous stem cell transplantation on Day 0."
3103249|NCT02112370|Placebo Comparator|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection.
3103250|NCT02112370|Experimental|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection.
3103251|NCT02112448|Active Comparator|Continuous infusion|Patients in this group will received morphine/midazolam drips at 0.3 mg/kg/hour each. They will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
3103252|NCT02112448|Active Comparator|As needed dosing|Patients in this arm will be given doses of morphine 0.05 mg/kg/dose every 2 hours as needed for pain score 4 or more. Midazolam will also be given as needed (0.05 mg/kg/dose every 1 hour)
3469121|NCT03889431|Experimental|Capsule group|Group one received iodine capsule
3103254|NCT02112838|Active Comparator|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
3103255|NCT02112838|Active Comparator|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
3103256|NCT02112838|Placebo Comparator|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
3103257|NCT02112877|Experimental|VICI Stent Implantation - Feasibility|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
3103258|NCT02112877|Experimental|VICI Stent Implantation - Pivotal|Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
3103259|NCT02112994|Experimental|Sebelipase Alfa|Pediatric and adult participants initiated IV treatment with sebelipase alfa at a dose of 1 mg/kg qow. Participants were considered for a dose adjustment at the discretion of the Investigator and in consultation with the Sponsor. Dose escalation to 3 mg/kg qow was considered if pre-defined dose-escalation criteria were met. If these criteria continued to be met, a subsequent dose escalation to 3 mg/kg every week (qw) was considered. Dose decreases as low as 0.35 mg/kg qow were permitted based upon evidence of intolerance to sebelipase alfa treatment. Participants who completed the 96-week treatment period were permitted to continue receiving sebelipase alfa in an expanded treatment period for up to 48 weeks, pending local drug availability and study participation status.
3103260|NCT02113007|Experimental|Rituximab plus Temozolomide|Rituximab: 375 mg/m2 IV, days 1, 3, and 5 Temozolomide: 150 mg/m2 PO, days 1-5
3103261|NCT02113124||Chronic brain injury|Individuals in this group have suffered a brain injury more than 2 years prior to study. Ages range from 21 to 70.
3103262|NCT02113124||Uninjured control|This group of individuals have no history of brain injury. Ages range between 21 and 70.
3103263|NCT02113189|Experimental|Walking program with ankle brace|This group will receive bilateral off-the-shelf ankle braces as well as a customized walking program.
3103264|NCT02113189|Experimental|Individualized walking program|This group will receive a customized walking program.
3103265|NCT02113189|Experimental|Walking program with custom braces|This group will receive bilateral custom-fabricated ankle braces as well as a customized walking program.
3103266|NCT02113241|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
3103267|NCT02113241|Placebo Comparator|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
3103268|NCT02113410|Experimental|Sit 'N' Fit Chair Yoga (SNFCY)|Willing and eligible subjects randomized to Sit 'N' Fit Chair Yoga attended twice-weekly 45-minute yoga sessions for 8 weeks, for a total of 16 sessions.
3103269|NCT02113410|Active Comparator|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
3103270|NCT02113436|Experimental|Fluticasone propionate (FP)/ Salmeterol xinafoate (SLM)|Subject will receive 1 or 2 inhalation of SLM 25mcg plus FP 50mcg twice daily in the first treatment period for 8 weeks and will continue to receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
3103271|NCT02113436|Active Comparator|Fluticasone propionate (FP)|Subject will receive 1 or 2 inhalation of FP 50mcg twice daily in the first treatment period for 8 weeks and will receive SLM 25mcg plus FP 50mcg one or two inhalation twice daily for 16 weeks in the second treatment period.
3103272|NCT02113449|Experimental|Treatment Group|Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day.
3103273|NCT02113579|Experimental|KOX|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste / Crest® Cavity Protection Regular and Experimental Mouth Rinse 12027-033"
3103274|NCT02113579|Placebo Comparator|PLA|"After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.~Fluoride Toothpaste/Crest® Cavity Protection Regular and Placebo Mouth Rinse"
3103275|NCT02113956|Experimental|Guy2Guy (G2G)|G2G is a 6-week HIV prevention program delivered daily via text messaging to 14-18 year old males who self-identify as gay, bisexual, and/or queer. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, G2Genie, which shares information about condoms, sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
3469122|NCT03889431|Experimental|Iodized salt group|Group two received iodized salt
3469123|NCT03889626|Experimental|Apatinib|In this arm, patients will receive a daily oral treatment with Apatinib 500mg.
3103276|NCT02113956|No Intervention|Healthy Lifestyle Control|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: STD information, nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 6-weeks in length (Week 6 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
3103277|NCT02114151|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|100 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
3103278|NCT02114164|Active Comparator|AirSeal System|This group receives the AirSeal System for intraoperative insufflation.
3103279|NCT02114164|Active Comparator|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
3103280|NCT02114177|Experimental|Arm 1 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
3103281|NCT02114177|Experimental|Arm 2 (Simeprevir/Sofosbuvir)|150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.
3103282|NCT02114203|Experimental|cohort 1 PF-04447943|
3103283|NCT02114203|Experimental|cohort 2 PF-04447943|
3103284|NCT02114203|Placebo Comparator|placebo comparator|
3103285|NCT02114203|Experimental|optional cohort of PF-04447943|
3103286|NCT02114216|Sham Comparator|control group|Subjects who do not show mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and do not complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3103287|NCT02114216|Active Comparator|ERD group|Subjects who have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and/or complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3103288|NCT02114216|Active Comparator|NERD group|Subjects who do not have mucosal breaks in the upper GI endoscopy consistent with reflux esophagitis and complain of GERD symptoms. Endoscopic mucosal biopsy was done for every subject.
3103289|NCT02114268|Experimental|MEDI8897 300 milligram (mg) Intravenous (IV)|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
3103290|NCT02114268|Experimental|MEDI8897 1000 mg IV|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
3103291|NCT02114268|Experimental|MEDI8897 3000 mg IV|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
3103292|NCT02114268|Experimental|MEDI8897 100 mg Intramuscular (IM)|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
3103293|NCT02114268|Experimental|MEDI8897 300 mg IM|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
3103294|NCT02114268|Placebo Comparator|Placebo|Participants received placebo on Day 1.
3103295|NCT02114307|Active Comparator|REVITIVE IX: actual device|Trial participants will receive the true Revitive IX device
3103296|NCT02114307|Sham Comparator|REVITIVE IX: sham device|Trial participants will receive a sham device
3103297|NCT02114385|Experimental|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3103298|NCT02114385|Active Comparator|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection in 3 dose regimen at Day 1, Month 2, and Month 6
3103299|NCT02114515|Other|Usual Care|"Hospital usual care~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge."
3103300|NCT02114515|Experimental|Usual Care + PArTNER|"Navigator intervention: (Community health worker, peer-led telephone support line, usual care)~Hospital usual care: Written discharge instructions provided to patients prior to hospital discharge.~Community health worker: The community health worker provides social support, literacy appropriate education, and acts as a conduit between the patient and the patient's medical team~Peer-led telephone support line: The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team."
3103301|NCT02114606|Experimental|EoE Patients|Patients who have been diagnosed with EoE as per recent guidelines will be enrolled. Samples will be obtained using the Cytosponge™ Cell Collection Device (Cytosponge) prior to participants' routine endoscopy with biopsy.
3103302|NCT02114684|Active Comparator|Moxifloxacin|"A Moxifloxacin-containing oral regimen of Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Moxifloxacin (M), substituting Moxifloxacin for Ethambutol, daily for 24 weeks, see information below.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks~RH(150,75mg), Z (500mg), M (400mg) Dosage and number of tablets dispensed is dependent on participants weight band."
3103303|NCT02114684|Active Comparator|Ethambutol|"An Ethambutol oral regimen of Isoniazid (H), Rifampicin(R), Pyrazinamide (Z), Ethambutol(E), daily for 24 weeks duration, substituting Ethambutol for Moxifloxacin.~Intensive phase 7 days a week for 8 weeks Continuation phase - 7 days a week for 16 weeks.See details below.~(150,75,400,275 mg) RHZE Dosage and number of tablets dispensed is dependent on participants weight band."
3469124|NCT03889626|Experimental|Capecitabine|In this arm , patients will receive capecitabine 1000mg/m2 twice for 14 days, and repeat every 3 weeks.
3469125|NCT03889626|No Intervention|Observation|In this arm, no additional treatment will be given, and patients will be followed up at regular time
3103306|NCT02114814|Experimental|Intervention group|Diabetes self-management and family support
3103307|NCT02114814|Active Comparator|Attention control group|General health information
3103308|NCT02114879|Active Comparator|Standard of Care Rehabilitation|
3103309|NCT02114879|Experimental|Enhanced Medical Rehabilitation|
3103310|NCT02114892|Experimental|Resveratrol|Resveratrol capsules, 500 mg, three times per day before meals during 90 days
3103311|NCT02114892|Placebo Comparator|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals during 90 days
3103312|NCT02114931|Experimental|ABP 501|Participants received ABP 501 40 mg subcutaneously (SC) every other week for up to 18 months.
3103313|NCT02115048|Active Comparator|Arm A|Continuous regimen of oral Letrozole 2.5 mg daily
3103314|NCT02115048|Experimental|Arm B|Continuous regimen of oral Letrozole 2.5 mg daily plus oral Afatinib 30 mg daily
3103315|NCT02115113|Experimental|Group A (Tacrolimus Elimination Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses were adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL. Tacrolimus withdrawal was completed by 6 months after transplant.
3103316|NCT02115113|Active Comparator|Group B (Tacrolimus Minimization Arm)|At study start, participants received an Everolimus starting dose of 1.0 mg twice daily in combination with Tacrolimus. Tacrolimus was administered as per center practice. Thereafter, Everolimus doses were adjusted to achieve Everolimus C-0h blood trough levels between 3-8 ng/mL by week 1 after drug initiation until 5 months after transplant. At 5 months after transplant, Everolimus doses continued to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL and Tacorlimus doses were adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
3103317|NCT02115139|Experimental|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles Whole-brain radiotherapy (WBRT) 30 Gy in 10 fractions (or radiobiological equivalent schedule, after Sponsor approval), starting between Cycle 1 Day 2 and Cycle 2 Day 1
3103318|NCT02115256|Active Comparator|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline
3103319|NCT02115256|Active Comparator|Intravenous Nitroglycerine|IV nitroglycerine 100 micrograms three minutes before beginning the procedure, then followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
3103320|NCT02115269||primary headaches|Adults taking IndoProCaf for acute treatment of their primary headache attacks (migraine and/or episodic tension-type headache) as per routine clinical practice
3103321|NCT02115282|Experimental|Arm A (exemestane, entinostat)|"Patients receive exemestane PO QD on days 1-28 and entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
3103322|NCT02115282|Placebo Comparator|Arm B (exemestane, placebo)|"Patients receive exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pre/perimenopausal female patients and all male patients also receive goserelin acetate SC on day 1."
3103323|NCT02115308|Other|Regadenoson|Regadenoson is a single-use, pre-filled syringe containing 0.4 mg/5 mL of regadenoson.
3103324|NCT02115321|Experimental|Part A: CP-B GZR 50 mg + EBR 50 mg|CP-B participants take GZR 50 mg + EBR 50 mg once daily (q.d.) by mouth for 12 weeks.
3103325|NCT02115321|Experimental|Part A: NC GZR 100 mg + EBR 50 mg|NC participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
3103326|NCT02115321|Experimental|Part B: CP-B GZR 100 mg + EBR 50 mg|CP-B participants take GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks.
3103327|NCT02115321|Experimental|Part C: CP-B GZR 50 mg or 100 mg + EBR 50 mg|CP-B participants take GZR 50 mg or GZR 100 mg + EBR 50 mg q.d. by mouth for 12 weeks (GZR dose chosen based on results of Part A CP-B arm).
3103328|NCT02115347|Experimental|Ertugliflozin 15 mg - Moderate Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3103329|NCT02115347|Other|Ertugliflozin 15 mg - Healthy Participants|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3103330|NCT02115347|Experimental|Ertugliflozin 15 mg - Mild Hepatic Impairment|Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
3103331|NCT02115373|Experimental|Phase 1b: Tepotinib 300 mg|
3103332|NCT02115373|Experimental|Phase 1b: Tepotinib 500 mg|
3103333|NCT02115373|Experimental|Phase 2: Tepotinib 500 mg|
3103334|NCT02115386|Experimental|Nilotinib|Dosage was 300 mg BID daily taken orally without food.
3103335|NCT02115542|Experimental|Regorafenib Monotherapy|Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
3103336|NCT02115581|Experimental|Coenzyme Q10|"Known cases of idiopathic dilated cardiomyopathy who received supplementation of coenzyme Q10 as a part of their medical regimen.~Dosage administered: 2 milligram/kilogram/day in 2 or 3 divided doses, these being increased to the maximum dose of 10 milligram/kilogram/day according to tolerance or the appearance of sideeffects."
3103337|NCT02115581|Placebo Comparator|Placebo|known cases of idiopathic dilated cardiomyopathy who received placebo
3103338|NCT02115607|Experimental|Definity infusion|Infusion of Definity (Perflutren Lipid Microspheres)
3103339|NCT02115633|Experimental|Walkasins ON then OFF|Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a 1 hour rest period they will be retested with Walkasins turned off.
3103340|NCT02115633|Experimental|Walkasins OFF then ON|Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a 1 hour rest period they will be retested with Walkasins turned on.
3103341|NCT02115646|Experimental|fractionated carbon dioxide laser|fractionated carbon dioxide laser
3103342|NCT02115750|Active Comparator|Enbrel (etanercept)|Enbrel 50mg weekly times 24 weeks.
3103343|NCT02115750|Experimental|CHS-0214|CHS-0214 50mg weekly times 24 weeks.
3103344|NCT02115815|Placebo Comparator|Placebo|Sterile saline for human use from commercial source, liquid
3103345|NCT02115815|Experimental|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
3103346|NCT02115815|Experimental|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 (20 mcg RSV sF with 2.5 mcg glucopyranosyl lipid A [GLA] + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3103347|NCT02115815|Experimental|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
3103348|NCT02115815|Experimental|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 (50 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3103349|NCT02115815|Experimental|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
3103350|NCT02115815|Experimental|MEDI7510 (80 mcg RSV sF)|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF with 2.5 mcg GLA + 2% weight per volume stable emulsion) by intramuscular injection on Day 1.
3103351|NCT02115828|Experimental|Vismodegib|Vismodegib Treatment arm will receive Vismodegib by mouth 150 mg daily up to 1 year.
3103352|NCT02115984|Experimental|Chemotherapy & Panagen|Panagen 5 mg tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the preparation immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
3103353|NCT02115984|Placebo Comparator|Chemotherapy & Placebo|Placebo tablet by mouth every 2-3 h (six times a day) for 18 days. Patients start to receive the placebo tablets immediately after the chemotherapy and take three tablets during 6 h, that is one tablet every 2 h. Then the patients stop taking the preparation and resume its administration after 42 h, that is, 48 h after the chemotherapy (Day 3) and continue its administration for 17 days (to Day 20 after the chemotherapy).
3103354|NCT02116205|Experimental|Vaccine + Placebo at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 1.0 mg placebo administration on Study Day 28.
3103355|NCT02116205|Experimental|Vaccine at 1.0 mg|1.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
3103356|NCT02116205|Experimental|Vaccine + Placebo at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 56 and 168. 2.0 mg placebo administration on Study Day 28.
3103357|NCT02116205|Experimental|Vaccine at 2.0 mg|2.0 mg HTNV/PUUV DNA vaccine IM-EP via TriGrid™ Delivery System (TDS) on Study Day 0, 28, 56 and 168.
3103358|NCT02116309|Active Comparator|Rectal Indomethacin only|Patients in this group will receive 20 ml of normal saline sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
3103359|NCT02116309|Active Comparator|Rectal Indomethacin plus papillary spray of Epinephrine|Patients in this group will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla and surrounding regions of edema, over a period of 1 minute using any ERCP cannulation catheter, at the end of procedure, just before the withdrawal of endoscope; followed by 100 mg of rectal indomethacin.
3103360|NCT02116322|Experimental|Pancreatic mass|Patients with pancreatic mass presenting for EUS-FNA
3103361|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 50 U|Placebo (normal saline) for onabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
3103362|NCT02116361|Experimental|onabotulinumtoxinA 50 U|OnabotulinumtoxinA 50 U injected into protocol-specified areas on Day 1.
3103363|NCT02116361|Placebo Comparator|Placebo for onabotulinumtoxinA 30 U|Placebo (normal saline) for onabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
3103364|NCT02116361|Experimental|onabotulinumtoxinA 30 U|OnabotulinumtoxinA 30 U injected into protocol-specified areas on Day 1.
3103365|NCT02116530|Experimental|Olanzapine + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3, 4 post chemotherapy)"
3103366|NCT02116530|Active Comparator|Placebo + Chemotherapy + Antiemetic treatment|"Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:~Ondansetron (8 mg orally or intravenously) or granisetron (1 mg intravenously or 2 mg orally) or palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (12 mg orally on the day of chemotherapy and 8 mg orally days 2, 3, 4 post chemotherapy), plus~Fosaprepitant (150 mg intravenously on the day of chemotherapy) or aprepitant (125 mg orally on the day of chemotherapy and 80 mg orally on days 2 and 3 post chemotherapy), plus~placebo"
3103367|NCT02116582|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once daily until they experienced an adverse event, disease progression, started new anti-cancer therapy, withdrew consent, or other protocol-specified criteria.
3103368|NCT02116608|Active Comparator|Group 1: Betadine|Apply locally as needed.
3103369|NCT02116608|Active Comparator|Group 2: Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
3103370|NCT02116608|Active Comparator|Group 3: Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
3103371|NCT02116621|Experimental|Trialist Intervention|Clinician and patient set up N-of-1 trial 4-12 weeks in length to compare two treatments for chronic pain. Patient uses Trialist smartphone app to monitor pain and associated side effects daily throughout length of N-of-1 trial. After trial ends, the patient reviews graphical displays of N-of-1 trial results with clinician.
3103372|NCT02116621|No Intervention|Control-Usual Care|Receive usual care from clinician for chronic pain, do not use Trialist smartphone app
3103373|NCT02116660|Experimental|Raltegravir plus Nevirapine plus Lamivudine|Raltegravir 400 mg oral twice daily for 96 weeks; plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
3103374|NCT02116660|Active Comparator|Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine|Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
3103375|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 1|(Part A): Patients receive talazoparib PO QD or BID on days 1-6 and temozolomide PO QD on days 2-6. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3103376|NCT02116777|Experimental|Treatment (talazoparib, temozolomide): Phase 2|(Part B): Relapse/Refractory EWS or PNET Patients receive MTD from Phase 1 portion of study. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3103377|NCT02116803|Experimental|dovitinib|Participants were given single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were given at the discretion of the investigator based on guidance provided in the protocol and investigative brochure (IB).
3103378|NCT02116803|Experimental|dovitinib + fulvestrant|Participants were given dovitinib and fulvestrant coadministration starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications were at the discretion of the investigator based on guidance provided in the protocol and IB.
3103379|NCT02116972|Experimental|FX006 16 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3103380|NCT02116972|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3103381|NCT02116972|Placebo Comparator|Placebo|Normal Saline Single 5 mL intra-articular (IA) injection
3103382|NCT02117024|Experimental|Viagenpumatucel-L Plus Metronomic Cyclophosphamide|Viagenpumatucel-L (HS-110) given as 1*10^7 cells for 12 weekly injections followed by injections every 9 weeks for up to 12 months or until discontinuation from study treatment, whichever occurs first, plus metronomic cyclophosphamide therapy for the first 12 weeks.
3103383|NCT02117024|Active Comparator|Chemotherapy Alone|Patients will be treated with a physician's choice regimen until progression.
3103384|NCT02117193|Placebo Comparator|Alcohol intake|1 g/kg of etanol combined. Beer without alcohol in the same volume will be used to placebo condition.
3103385|NCT02117193|Active Comparator|sleep deprivation|one night of sleep deprivation will be compared to 8h of normal sleep.
3103386|NCT02117310|Experimental|ICG|Angiography with administered ICG
3103387|NCT02117349|Experimental|Raplixa plus Gelfoam|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate target bleeding site (TBS). The treatment is topically applied using 1 of the following 3 methods:~A thin layer of Raplixa is sprinkled directly from the vial onto the TBS, followed by application of Gelfoam.~A thin layer of Raplixa is sprayed onto the TBS using the RaplixaSpray device, followed by application of Gelfoam.~Raplixa is applied onto moistened Gelfoam which is then applied to the TBS.~Manual pressure is applied over the treatments using sterile gauze. The amount of Raplixa and Gelfoam used is at the discretion of the investigator, within the maximum of two 1 gram (g) vials of Raplixa that are permitted for each participant.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute time-to-hemostasis (TTH) evaluation."
3103388|NCT02117349|Other|Gelfoam Only|"During a single predefined surgical procedure, participants receive the assigned treatment on an appropriate TBS. Gelfoam is cut to the appropriate size and applied topically, according to the manufacturer's package insert, followed by manual pressure using sterile gauze.~Thrombin-containing hemostats included in standard of care at the site are permitted as rescue therapy after the 5-minute TTH evaluation, if necessary."
3103389|NCT02117414|Experimental|MRI Group|Subjects randomized to the MRI group will undergo a series of MRI scans at the MRI visit (9-12 weeks post-implant).
3103390|NCT02117414|Sham Comparator|Control Group|Subjects randomized to the Control group will wait for 1 hour without having a series of MRI scans at the waiting period visit (9-12 weeks post-implant).
3103391|NCT02117427|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
3103392|NCT02117427|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
3103393|NCT02117427|Experimental|Group C|MDGN201 TARGTEPO secreting EPO (55-65 IU/Kg/day)
3103394|NCT02117479|Experimental|Ruxolitinib plus capecitabine|
3103395|NCT02117479|Active Comparator|Placebo plus capecitabine|
3103396|NCT02117544|Other|New MF, then AOAMF|Lotrafilcon B multifocal contact lenses (new), followed by lotrafilcon B multifocal contact lenses. Each product worn bilaterally (in both eyes) for about 1 hour.
3103397|NCT02117544|Other|AOAMF, then New MF|Lotrafilcon B multifocal contact lenses, followed by lotrafilcon B multifocal contact lenses (new). Each product worn bilaterally (in both eyes) for about 1 hour.
3103398|NCT02117570|Experimental|High dose of C. difficile vaccine|
3103399|NCT02117570|Experimental|Low dose of C. difficile vaccine|
3103400|NCT02117570|Placebo Comparator|Placebo|
3103401|NCT02117648|Experimental|Abemaciclib Alone Period 1|50 mg single oral dose of Abemaciclib was administered in Period 1 Day 1.
3103402|NCT02117648|Experimental|Abemaciclib + Clarithromycin Period 2|Clarithromycin 500 milligram (mg) orally twice daily for 12 days. Single oral dose of Abemaciclib 50 mg on Period 2 Day 5. Clarithromycin dosing continued for 7 days following the single dose of Abemaciclib.
3103403|NCT02117648|Experimental|Abemaciclib Safety Extension|After completing Period 2, eligible participants continued to receive 200 mg Abemaciclib every 12 hours (Q12H) on a 28-day cycle in a safety-extension phase until discontinuation criteria were met.
3103404|NCT02117687|Active Comparator|OPTIVE FUSION™|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
3103405|NCT02117687|Active Comparator|VISMED® Multi|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
3103406|NCT02117713|Experimental|LUM001 (Maralixibat)|Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
3103407|NCT02117934|Experimental|HEPLISAV|0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
3103408|NCT02117934|Active Comparator|Engerix-B|1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
3103409|NCT02117999|Experimental|Cross-linking with iontophoresis|Transepithelial cross-linking by using iontophoresis to administer riboflavin into the corneal stroma
3103410|NCT02117999|Active Comparator|Standard corneal cross-linking|Standard corneal cross-linking includes de-epithelialization and stromal soaking by applying drops of riboflavin
3103411|NCT02118012|Active Comparator|Chlorcyclizine and RBV|Chlorcyclizine HCl and Ribavirin
3103412|NCT02118012|Active Comparator|Chlorcyclizine HCl only|Chlorcyclizine HCl only
3103413|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 3 mg/kg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 3 mg/kg every 2 weeks (Q2W) for up to 12 months.
3103414|NCT02118337|Experimental|MEDI0680 0.1 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.1 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
3103415|NCT02118337|Experimental|MEDI0680 0.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 0.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
3103416|NCT02118337|Experimental|MEDI0680 2.5 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 2.5 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
3103417|NCT02118337|Experimental|MEDI0680 10 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 10 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
3103418|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 10 mg|Participants in dose-escalation phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 10 mg/kg Q2W for up to 12 months.
3103419|NCT02118337|Experimental|MEDI0680 20 mg/kg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
3103420|NCT02118337|Experimental|MEDI0680 20 mg/kg + Durvalumab 750 mg|Participants in dose-expansion phase will receive IV infusion of MEDI0680 20 mg/kg and durvalumab 750 mg/kg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
3103421|NCT02118337|Active Comparator|Nivolumab 240 mg|Participants in dose-expansion phase will receive IV infusion of nivolumab 240 mg Q2W until unacceptable toxicity, confirmed disease progression, development of other reason for treatment discontinuation, or for a maximum of 2 years, whichever occurred first.
3103422|NCT02118428|Experimental|Mirasol|Transfusions with Mirasol-treated whole blood
3103423|NCT02118428|Active Comparator|Control|Transfusions with untreated whole blood
3103424|NCT02118441|Active Comparator|direct palpation|Radial artery catheter insertion will be conducted by direct palpation and use of anatomic knowledge by the Anesthesiologist.
3103425|NCT02118441|Active Comparator|Ultrasound|"Radial artery catheter insertion will be conducted by ultrasound guidance. A Sono-site ilook 25 Ultrasound (Sono-site, Inc., Bothell, WA, USA) with a 10-5 MHz linear array ultrasound transducer will be used.~At the discretion on the Anesthesiologist, an out-of-plane (i.e. needle plane at right angles to ultrasound plane) will be used. Colour flow doppler may also be used to identify the artery if necessary."
3103426|NCT02118597||Triple Combination Therapy|Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
3103427|NCT02118610|Experimental|l-tetrahydropalmatine|l-tetrahydropalmatine (30 mg BID)
3103428|NCT02118610|Placebo Comparator|Sugar Pill|
3103429|NCT02118714|Experimental|Atrasentan|Atrasentan 0.75 mg administered orally once daily (QD) for 26 weeks
3103430|NCT02118766|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3103431|NCT02118766|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
3103432|NCT02118792|Experimental|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%, applied twice daily for up to 28 days
3103433|NCT02118792|Placebo Comparator|Matching vehicle control|Matching vehicle control, applied twice daily for up to 28 days
3103434|NCT02118831|Active Comparator|Aflibercept Blood Sample Collection|Blood samples will be collected from patients receiving aflibercept following the first and third dose of standard care therapy.
3103435|NCT02118831|Active Comparator|Bevacizumab Blood Sample Collection|Blood samples will be collected from patients receiving bevacizumab following the first and third dose of standard care therapy.
3103436|NCT02118831|Active Comparator|Ranibizumab Blood Sample Collection|Blood samples will be collected from patients receiving ranibizumab following the first and third dose of standard care therapy.
3103437|NCT02118896|Experimental|1: FK506E (MR4)|Single open arm of FK506E (MR4). Since this was an extension study for many studies, generally the dose given at enrollment was to be continued. The investigator was permitted to adjust the subject's dose and modify the MR4 dose regimen as deemed necessary to minimize Adverse Events (AEs) and maintain effective immunosuppression. MR4 capsules were taken orally, once daily in the morning. MR4 capsules were to be swallowed with fluid (preferably water) on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal. MR4 was supplied as 0.5 mg, 1 mg and 5 mg capsules in amber glass bottles or in blister packs.
3103438|NCT02118961|Experimental|BK1301|
3103439|NCT02118961|Active Comparator|DT toxoid|
3103440|NCT02119026|Active Comparator|A: XELIRI + BEV Followed by XELOX + BEV|"capecitabine and irinotecan (XELIRI) plus bevacizumab (AVASTIN; BEV)~Capecitabine : 800mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on day 1 q3w combined with irinotecan 200mg/m2 iv. d 1 q3w . Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression irinotecan will be replaced by oxaliplatin (arm A). Bevacizumab will be continued."
3103441|NCT02119026|Active Comparator|B: XELOX + BEV followed by XELIRI + BEV|"capecitabine and oxaliplatin (XELOX) plus bevacizumab (Avastin; BEV)~Arm B:~Capecitabine: 1000mg/m2 bid d1-14, bevacizumab 7,5 mg/kg given on d1 q3w combined with oxaliplatin 130mg/m2 iv. d 1 q3w Bevacizumab (7.5 mg/kg q3w) ± Capecitabine (1000 mg/m2 bid, days 1-14 q3w) maintenance~At disease progression oxaliplatin will be replaced by irinotecan (arm B). Bevacizumab will be continued."
3103442|NCT02119104||Prevenar (13v)|
3103443|NCT02119156|Experimental|Treatment Holiday Group|Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy.
3103444|NCT02119156|Active Comparator|Control Group|Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks.
3103445|NCT02119156|No Intervention|Long-Term Discontinuation Group|Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks.
3103446|NCT02119260|Experimental|Cohort 1|Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).
3103447|NCT02119260|Experimental|Cohort 2|Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.
3103448|NCT02119260|Experimental|Cohort 3|Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.
3103449|NCT02119260|Experimental|Cohort 4|Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.
3103450|NCT02119260|Experimental|Cohort 5|Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.
3103451|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (62.5mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation UMEC (62.5mcg) via DPI once-daily in the morning for 12 weeks.
3103452|NCT02119286|Experimental|FF/VI 100/25 mcg + UMEC (125mcg)|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of UMEC (125mcg) via a DPI once-daily in the morning for 12 weeks.
3103453|NCT02119286|Experimental|FF/VI 100/25 mcg + Placebo|Subjects received one inhalation of FF/VI 100/25 mcg via DPI followed by one inhalation of matching placebo via a DPI once-daily in the morning for 12 weeks.
3103454|NCT02119299|Experimental|SMART device|Use of Sensor Monitored Alimentary Restriction Therapy (SMART) device
3103455|NCT02119325|Experimental|Test|Fibre rich Health Food Drink packed as 30g individual sachet, administered as a single serve in 200 mL of luke warm water
3103456|NCT02119325|Placebo Comparator|Placebo|No Fibre Health Food Drink packed as 25g individual sachet, administered as single serve in 200 mL of luke warm water
3103457|NCT02119442|Other|Transcatheter Valve Implantation|Intervention, Transcatheter Valve Implantation with Melody or Sapien bioprosthetic valve Standard of care intervention.
3103458|NCT02119455|Experimental|Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment in conjunction with vibration therapy (daily use of OrthoAccel Aura device for 20 minutes/day) during the study period.
3103459|NCT02119455|No Intervention|No Vibration Device+Fixed Appliance Tx|Male and female subjects will randomly assigned to this group to receive fixed appliance orthodontic treatment only and no vibration treatment.
3103460|NCT02119468|Experimental|Treatment (3mg MLN9708)|Patients receive 3mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3103461|NCT02119468|Experimental|Treatment (4mg MLN9708)|Patients receive 4mg ixazomib citrate (MLN9708) orally on days 1, 8, and 15; dexamethasone orally on days 1, 8, 15, and 22; and pomalidomide orally on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3103462|NCT02119650|Experimental|Ruxolitinib plus Pemetrexed/Cisplatin|
3103463|NCT02119650|Active Comparator|Placebo plus Pemetrexed/Cisplatin|
3103464|NCT02119663|Experimental|Ruxolitinib plus capecitabine|
3103465|NCT02119663|Active Comparator|Placebo plus capecitabine|
3103466|NCT02119676|Experimental|Ruxolitinib plus regorafenib|
3103467|NCT02119676|Active Comparator|Placebo plus regorafenib|
3103468|NCT02119819|Experimental|10 mg LY2944876|"10 milligrams (mg) LY2944876 given subcutaneously (SC) once weekly for 24 weeks.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
3103469|NCT02119819|Experimental|15 mg LY2944876|15 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
3103470|NCT02119819|Experimental|30 mg LY2944876|30 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
3103471|NCT02119819|Experimental|50 mg LY2944876|50 mg LY2944876 given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
3103472|NCT02119819|Experimental|Exenatide extended-release|2 mg exenatide extended-release given SC once weekly for 24 weeks. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry.
3103473|NCT02119819|Placebo Comparator|Placebo|"Placebo for LY2944876 and Exenatide given SC once weekly for 12 weeks. Participants assigned to placebo will have no injections during the second 12 weeks of the study.~Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry."
3103474|NCT02119871|Experimental|Bilateral Open Pleurae|Bilateral open pleurae and usage of right pulmonary vein drainage
3103475|NCT02119871|Active Comparator|Right pleura open|Opening of right pleura and usage of left ventricular apical drainage.
3103476|NCT02119936|Experimental|Heart Rate Variability Biofeedback Tool|Intervention: Participants will be taught how to use the Heart Rate Variability Biofeedback tool (emWave 2) as a mechanism to reduce stress and anxiety, then use the tool, coupled with deep breathing exercises, to visualize their stress reduction.
3103477|NCT02120001|Experimental|ETT cleaning maneuver|Patients randomized to the treatment group will undergo an ETT cleaning maneuver with endOclear three times a day (every 8 hours) for the whole intubation period in addition to the standard of care.
3103478|NCT02120001|No Intervention|Standard of care|In the protocol no intervention is planned for the control group, which will therefore be treated with blind suctioning as per caregiver clinical decision.
3103479|NCT02120027|Experimental|Ibodutant 10 mg|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will continue on ibodutant 10 mg for additional 28 weeks of treatment via mock-re-randomisation at week 25 .
3103480|NCT02120027|Placebo Comparator|Placebo|Oral tablet to be given once daily for 24 weeks of treatment. Patients randomised to the placebo arm will be re-randomised at week 25 in a 1:1 ratio to ibodutant or placebo for additional 28 weeks of treatment.
3103481|NCT02120157|Experimental|Haploidentical BMT with PTCy for acute leukemias and MDS|"Patients with AML and MDS:~Days -6 through -3: Busulfan q 5-6h IV q24h x 4 days~Days -2 and -1: Cyclophosphamide 50mg/kg/day IV x 2 days+ Mesna 40 mg/kg/day IV~For patients with ALL and lymphoblastic lymphoma:~Days -5 through -4: Cyclophosphamide 50mg/kg/day IV q24h x 2 days+Mesna 40 mg/kg/day IV~Days -3 through -1: TBI 200 Centigray (cGy) twice a day for 3 days~All patients Day 0: Infuse unmanipulated bone marrow~Day +3 and +4: Cyclophosphamide 50 mg/kg/day IV + Mesna 40 mg/kg IBW/day IV~Day +5: Begin tacrolimus 0.015mg/kg IBW/dose IV over 4 hours q 12h and mycophenolate mofetil (MMF)15mg/kg po/IV tid with maximum daily dose 3 gm/day~Day +30: Assess chimerism and disease status in bone marrow~Day +35: Discontinue MMF~Day +60: Assess chimerism and disease status in bone marrow~Day 180: Discontinue tacrolimus"
3103482|NCT02120261|Experimental|TPI with Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
3103483|NCT02120261|Active Comparator|TPI with Lidocaine & Triamcinolone Acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
3103484|NCT02120287|Experimental|BZ-SRS with Bevacizumab|"All patients will receive Border Zone Stereotactic Radiosurgery (BZ-SRS) and additionally receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by 10 mg/kg/day every 14 days until progression.~One to 14 days before BZ- SRS procedure, patients at centers with MRS experience will undergo standard brain MRI /MRS"
3103485|NCT02120300|Experimental|LDV/SOF GT 1 or 4|Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.
3103486|NCT02120300|Experimental|SOF+RBV 12 wks GT 2|Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.
3103487|NCT02120300|Experimental|SOF+RBV 24 wks GT 3|Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.
3103488|NCT02120352|Experimental|GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks (Q8W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subject will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subject will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 900 mg IM. Week 4 only - GSK744 LA 600 mg IM (second loading dose, no TMC278).Week 8 - GSK744 LA 600 mg IM + TMC278 LA 900 mg IM every 8 weeks for 96 weeks.
3103489|NCT02120352|Experimental|GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks (Q4W)|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive following IM doses: Day 1 only - GSK744 LA 800 mg (loading dose delivered as two 400 mg IM injections) + TMC278 LA 600 mg IM. Week 4 - GSK744 LA 400 mg IM + TMC278 LA 600 mg IM every 4 weeks for 96 weeks
3103490|NCT02120352|Active Comparator|Oral Control Arm|In the Induction Period of 20 weeks, subjects will receive an oral regimen of GSK744 30 mg once daily plus ABC/3TC 600/300 mg once daily. In the last 4 weeks of the Induction Period subjects will also receive RPV 25 mg tablet once daily. In the Maintenance Period, subjects will receive an oral regimen of 30 mg of GSK744 and ABC/3TC once daily for 96 weeks (or 104 weeks if going on to the Extension Period)
3103491|NCT02120417|Experimental|Treatment A - Capecitabine and ruxolitinib|
3103492|NCT02120417|Active Comparator|Treatment B - Capecitabine and placebo|
3103493|NCT02120443|Experimental|Non-Infiltrated Tissue|The ivWatch Model 400 monitored a common peripheral IV site over a 24 hour observation period.
3103494|NCT02120456|Experimental|LEO 43204|Open-label, dose-escalation, 2-day treatment
3103495|NCT02120456|Experimental|LEO 43204 Dose 0.1%|LEO 43204 dose 0.1% once daily for two consecutive days
3103496|NCT02120456|Experimental|LEO 43204 Dose 0.075%|LEO 43204 dose 0.075% once daily for two days
3103497|NCT02120456|Placebo Comparator|Placebo|Placebo once daily for two days
3103498|NCT02120625||Lumbar MB RFN|Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
3103499|NCT02120664|Experimental|Amyloid Negative Subjects|Approximately 10 cognitively normal young subjects will receive a single i.v. bolus injection of approximately 370 megabecquerel (MBq) (10 millicurie [mCi]) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
3103500|NCT02120664|Experimental|Amyloid Positive Subjects|Approximately 25 subjects with a range of amyloid density comprised of subjects clinically diagnosed with Alzheimer's Disease (AD) and subjects at risk for elevated amyloid density will receive a single i.v. bolus injection of approximately 370 MBq (10 mCi) florbetapir (18F) and a single i.v. bolus injection of approximately 555 MBq (15 mCi) 11C-PiB.
3103501|NCT02120716|Experimental|Health Check-Up of Expectant Moms|Participants receive computer delivered intervention (Health Check-up for Expectant Moms)
3103502|NCT02120716|No Intervention|Time and attention matched control group|Participants will be presented a brief series of videos of television shows, with subsequent ratings of subjective preference
3103503|NCT02120781|Experimental|Azficel-T (autologous fibroblasts)|Azficel-T will be injected into the vocal fold(s) three times at two week intervals.
3103504|NCT02120781|Placebo Comparator|Control|Sterile saline will be injected into the vocal fold(s) three times at two week intervals.
3103505|NCT02120794|Experimental|530G insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
3103506|NCT02120833|Active Comparator|EPI|
3103507|NCT02120833|Experimental|NEE|
3103508|NCT02120898|Experimental|Generic Imiquimod Cream 2.5%|Generic imiquimod cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
3103509|NCT02120898|Active Comparator|Zyclara® (Imiquimod) Cream 2.5%|Zyclara® (imiquimod) cream 2.5% will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
3103510|NCT02120898|Placebo Comparator|Vehicle Cream|Vehicle cream will be applied once daily approximately 1 to 2 hours before bedtime to the skin of the treatment area (either full face [excluding the ears] or balding scalp) for two, 2-week treatment cycles separated by a 2-week no-treatment period. Participants will apply test article for 14 consecutive days for each treatment cycle.
3103511|NCT02120924|Active Comparator|Finacea|Finacea® (azelaic acid) Gel, 15% (Intendis)
3103512|NCT02120924|Experimental|Azelaic Acid|Azelaic Acid, 15% topical gel (Watson Laboratories, Inc.)
3103513|NCT02120924|Placebo Comparator|Vehicle Gel|Gel Vehicle of the test product (Watson Laboratories, Inc.)
3103514|NCT02120950|Experimental|Aflibercept + Sham PDT|Participants received 2 milligram (mg) Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus sham photodynamic therapy (only in subjects qualifying for rescue therapy)
3103515|NCT02120950|Experimental|Aflibercept + Active PDT|Participants received 2 mg Intravitreal aflibercept injection (IAI) (Eylea, VEGF Trap-Eye, BAY86-5321) every month for the first 3 months (run-in period). At Week 12, subjects were randomized to receive Aflibercept injection plus active photodynamic therapy (only in subjects qualifying for rescue therapy)
3103516|NCT02121002|Experimental|Diclofenac Sodium Topical Gel, 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
3103517|NCT02121002|Active Comparator|Voltaren Topical Gel, 1%|Voltaren Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
3103518|NCT02121002|Placebo Comparator|Vehicle Diclofenac Sodium Topical Gel|Vehicle Diclofenac Sodium Topical Gel. 4 gm, 4 times a day for 4 weeks
3103519|NCT02121041|No Intervention|Usual Care|Participants in the usual care arm will have 2 ABPM sessions during the study, but ABPM will not be used to make a diagnosis or dictate anti-hypertensive treatment. Any recommendations for anti-hypertensive treatment will be made only via regular clinical care.
3103520|NCT02121041|Active Comparator|ABPM Guided|Participants in the ABPM-guided arm will undergo 3 ABPM sessions. Results of ABPM will be used to make diagnoses and dictate anti-hypertensive treatment as applicable. Anti-hypertensive medications may include: Amlodipine, Chlorthalidone and/or Losartan.
3103521|NCT02121067|Experimental|LNG-IUS placed at 2 weeks postpartum|Enrolled women will have the LNG-IUS placed at two-weeks (14-20 days) postpartum
3103522|NCT02121210|Experimental|Sarilumab 150 mg q2w|Sarilumab 150 mg subcutaneous (SC) injection every two weeks (q2w) for 24 weeks.
3103523|NCT02121210|Experimental|Sarilumab 200 mg q2w|Sarilumab 200 mg SC injection q2w for 24 weeks.
3103524|NCT02121262|Other|Laser Photocoagulation|Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
3103525|NCT02121262|Experimental|Dexamethasone|Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.
3103526|NCT02121301|Experimental|Low Dose SkQ1|Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
3103527|NCT02121301|Experimental|High Dose SkQ1|Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
3103528|NCT02121301|Placebo Comparator|Placebo (vehicle)|Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days
3103529|NCT02121392|Sham Comparator|Epidural Catheter without Adductor Canal Nerve Block Catheter|Patients randomized to the sham catheter will have a sham catheter placed on the skin and obscured with an opaque dressing and attached to a functional pump which will not be turned on.
3103530|NCT02121392|Experimental|Epidural Catheter with Adductor Canal Nerve Block Catheter|Patients will receive a continuous adductor canal block placed under ultrasound guidance under the supervision of an attending physician who is fellowship trained.
3103531|NCT02121418|Experimental|Treatment (decitabine, cytarabine)|Patients receive decitabine IV daily on days 1-10 and cytarabine IV QD on days 1-7. Treatment repeats every 28-35 days for 2 courses in the absence of disease progression or unacceptable toxicity. After course 3, patients achieving remission will receive 1-2 more courses of therapy at the same dose. Patients in remission with significant side effects will receive decitabine and cytarabine at decreased doses. Patients not achieving remission will not receive any more treatment.
3103532|NCT02121483|Experimental|empagliflozin high dose|Patient to receive a high dose of empagliflozin
3103533|NCT02121483|Experimental|empagliflozin medium dose|Patient to receive a medium dose of empagliflozin
3103534|NCT02121483|Experimental|empagliflozin low dose|Patient to receive a low dose of empagliflozin
3103535|NCT02121509|Experimental|FDC first, fasted|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fasted condition
3103536|NCT02121509|Experimental|Single tablets first, fasted|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fasted condition
3103537|NCT02121509|Experimental|FDC first, fed|Linagliptin/Metformin ER FDC followed by single tablets of linagliptin and metformin ER, fed condition
3103538|NCT02121509|Experimental|Single tablets first, fed|single tablets of linagliptin and metformin ER followed by Linagliptin/Metformin ER FDC, fed condition
3103539|NCT02121522|Experimental|BI 144807|twice daily
3103540|NCT02121535|Experimental|T80/A5/H12.5 mg FDC|A Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination (FDC) tablet
3103541|NCT02121535|Active Comparator|T80/A5 mg FDC+H12.5 mg mono|A Telmisartan 80 mg/ Amlodipine 5 mg fixed dose combination (FDC) tablet and a Hydrochlorothiazide 12.5 mg tablet
3103542|NCT02121756|Experimental|Dipyridamole|ARM A: Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
3103543|NCT02121756|Active Comparator|Placebo then Dipyridamole|ARM B: Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
3103544|NCT02121795|Experimental|F/TAF + 3rd Agent|Participants will receive F/TAF (200/25 mg or 200/10 mg) plus FTC/TDF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks. Dosing of F/TAF will be dependent on the third agent of the participants' pre-existing treatment regimen.
3103545|NCT02121795|Active Comparator|FTC/TDF + 3rd Agent|Participants will receive FTC/TDF plus F/TAF placebo while remaining on an allowed third antiretroviral agent of the participant's pre-existing treatment regimen, for 96 weeks.
3103546|NCT02121808|Experimental|Supine|NIPPV and Tidal volume
3103547|NCT02121808|Experimental|Beach-chair (Back : 25 deg)|NIPPV and Tidal volume
3103548|NCT02121808|Experimental|Proclive (Global 25 deg)|NIPPV and Tidal volume
3103549|NCT02121834|Experimental|LY3050258|Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg.
3103550|NCT02121834|Placebo Comparator|Placebo|Daily dose of placebo matching LY3050258 for 28 days.
3103551|NCT02121847|Experimental|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily and carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
3103552|NCT02121860|Experimental|Chil-Pugh Class A|All subjects with mild hepatic impairment received a single 50 mg oral dose of IDN-6556
3103553|NCT02121860|Experimental|Chil-Pugh Class B|All subjects with moderate hepatic impairment received a single 50 mg oral dose of IDN-6556
3103554|NCT02121860|Experimental|Chil-Pugh Class C|All subjects with severe hepatic impairment received a single 50 mg oral dose of IDN-6556
3103555|NCT02121860|Experimental|Normal Hepatic Function|All healthy volunteers subjects received a single 50 mg oral dose of IDN-6556
3103556|NCT02121912|Experimental|FPH Pilairo Q CPAP mask|The Sleep Technician will fit the FPH Pilairo Q CPAP mask to the participant.
3103557|NCT02121912|Active Comparator|Any other market released nasal or nasal-pillow CPAP mask|The Sleep Technologist will fit the participant with any market released nasal or nasal-pillow CPAP mask
3103558|NCT02122146|Experimental|PF-06664178|Experimental
3103559|NCT02122341|Experimental|BackStop|Patients randomized to the Experimental arm will receive the BackStop gel during their ureteroscopic lithotripsy to prevent retrograde migration of stones or stone fragments.
3103560|NCT02122341|No Intervention|Control|Patients randomized to the control group will not use any devices to prevent retrograde migration of stones and stone fragments during their ureteroscopic lithotripsy.
3103561|NCT02122380|Experimental|Sitagliptin, then Placebo|Sitagliptin 100 mg by mouth daily for 30 days followed by Placebo daily for 30 days
3103562|NCT02122380|Experimental|Placebo, then Sitagliptin|Placebo daily for 30 days followed by Sitagliptin 100 mg daily for 30 days
3103563|NCT02122406||Patients RA-BIO|Patients with rheumatoid arthritis treated with biological drugs (infliximab, adalimumab, etanercept, abatacept, tocilizumab, golimumab, certolizumab, rituximab)
3103564|NCT02122445|Experimental|Low Back Pain|Lower body exercises before and after the application of Cramer Sports Motion tape
3103565|NCT02122471|Experimental|Plecanatide 3.0 mg|Plecanatide tablets 3.0 mg QD for 12 weeks
3103566|NCT02122471|Placebo Comparator|Placebo|Matching placebo tablets QD for 12 weeks
3103567|NCT02122471|Experimental|Plecanatide 6.0 mg|Plecanatide tablets 6.0 mg QD for 12 weeks
3103568|NCT02122549|Experimental|HWD1000|Subjects using HWD1000
3103569|NCT02122770|Experimental|MLN4924 + Fluconazole|"Part A: MLN4924, 8 milligram per square meter (mg/m^2), intravenously, once on Days 1 and 8; and fluconazole, 400 milligram (mg), tablets, orally, once on Day 4, and 200 mg, once daily on Days 5-10.~Part B: MLN4924, at a dose previously deemed tolerable, given on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, Clinicaltrials.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
3469126|NCT03889314|Experimental|Rosuvastatin 20mg|Each participant will receive a 3 month randomly allocated supply of this medication preceded by a 7 day wash-out period.
3469127|NCT03889314|Placebo Comparator|Placebo|
3469128|NCT03889314|No Intervention|No Treatment|7 day wash-out period between months
3103570|NCT02122770|Experimental|MLN4924 + Itraconazole|"Part A: MLN4924, 8-mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A (safety lead-in step): MLN4924, 15mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part A: MLN4924, 20mg/m^2, intravenously, once on Days 1 and 8; and itraconazole, 200 mg, oral solution, once daily on Days 4-10.~Part B: MLN4924, at a dose previously deemed tolerable given, on Days 1, 3, and 5 of each 21-day Cycle (Study C15010, ClinicalTrails.gov Identifier # NCT01862328) in combination with docetaxel or carboplatin + paclitaxel at standard dose regimen on Day 1 of each 21-day Cycle."
3103571|NCT02122783|Experimental|Conventional then Experimental brace resistance|Participants received the Default intervention for a period of a month, were evaluated in the lab and then the novel intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
3103572|NCT02122783|Experimental|Experimental then Conventional brace resistance|Participants received the the novel elastomer to provide brace support intervention for a period of a month, were evaluated in the lab and then the conventional intervention was administered for use for the next month. There was a small period (few hours in the lab) where the subject was transitioned to the second intervention.
3103573|NCT02122796|Experimental|Acupuncture|Two sessions of acupuncture, at least twelve hours apart, post-mastectomy.
3103574|NCT02122796|No Intervention|Standard of Care|Standard of care post-mastectomy.
3103575|NCT02122887|No Intervention|control group|no intervention for 3 months
3103576|NCT02122887|Experimental|experimental group|Peace-Building Intervention Process- The intervention process consists of eight sessions and adheres to a manualized protocol that we developed. Each session lasts 120 minutes.
3103577|NCT02122952|Experimental|Cohort 1|6.7 X 10^13 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=3)
3103578|NCT02122952|Experimental|Cohort 2|2.0 X 10^14 vg/kg of AVXS-101 delivered one-time through a venous catheter inserted into a peripheral vein (n=12)
3103579|NCT02123017|Experimental|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams of crystalline lactulose x three doses
3103580|NCT02123017|Experimental|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams of crystalline lactulose x three doses
3103581|NCT02123017|Experimental|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams of crystalline lactulose x three doses
3103582|NCT02123134|Placebo Comparator|Placebo|Participants received placebo administered in 0.2 mL subcutaneous (SC) injections, up to 10 milliliters (mL) per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3103583|NCT02123134|Experimental|ATX-101 deoxycholic acid injection|Participants received deoxycholic acid 2 mg/cm^2 administered in 0.2 mL SC injections, up to 10 mL per treatment session at intervals of approximately 1 month for up to a maximum of 6 treatments.
3103584|NCT02123251|Experimental|Financial Incentives Group|Participants (159) in the Incentive Group will: 1) continue to receive usual care; 2) are eligible to receive financial incentives based on completion of recommended ADA benchmarks and achievement of goals that are founded on evidence based guidelines for diabetes; and 3) be compensated for completion of surveys.
3103585|NCT02123251|No Intervention|Control Group|Participants (161) in the Control Group will continue to receive usual care and be compensated for the completion of surveys only. They will not receive financial incentives.
3103586|NCT02123329|Active Comparator|Control arm|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
3103587|NCT02123329|Experimental|Intervention arm|Participants assigned to the intervention arm will participate in a face-to-face 4-session program at the pharmacy delivered by the study pharmacist at 2-4-week intervals over 8 weeks in addition to nicotine replacement therapy. The sessions will be set at a date and time that is convenient for both the pharmacist and the participant. The pharmacist will deliver the program at a time different from his or her pharmacy duty regular time.
3103588|NCT02123446|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3103589|NCT02123446|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3103590|NCT02123459|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods
3103591|NCT02123459|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods
3103592|NCT02123472|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Italy by Facta administered once orally in one of two study periods.
3103593|NCT02123472|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3103594|NCT02123485|Experimental|low frequency rTMS|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation, administered with 2 sessions each week
3103595|NCT02123485|Sham Comparator|Sham-rTMS|Sham right prefrontal rTMS 2 times a week
3103596|NCT02123511|Experimental|Arm I (acetylcysteine)|Patients receive acetylcysteine oral rinse and gargle or swish for 60 seconds then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
3103597|NCT02123511|Placebo Comparator|Arm II (placebo)|Patients receive a placebo oral rinse and gargle or swish for 60 seconds and then spit 5 times per day beginning within 3 days of the initiation of radiotherapy to 14 days following completion of radiotherapy.
3103598|NCT02123576|Experimental|Treatment|Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR <10 for 90 days in addition to standard AMO therapy
3103599|NCT02123576|Placebo Comparator|Placebo|This is a standard placebo pill.
3103600|NCT02123745|Experimental|Infiltrated Tissue|The ivWatch Model 400 monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
3103601|NCT02123797||Multidisciplinary Clinic Patients|: 150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients
3103602|NCT02123797||Serial Care Patients|150 multidisciplinary clinic patients matched 1:2 with 300 serial care patients = 450 patients Since Baptist Health Care System manages >800 new cases each year, 300 of which are expected to be seen in multidisciplinary clinic, in practice, we conservatively expect to be able to recruit 150 cases from multidisciplinary clinic and 300 matched serial care controls (1:2 match) in 18 months.
3103603|NCT02123797||Multidisciplinary Caregivers|Consenting caregivers of consented multidisciplinary clinic patients (patients seen by multiple specialists at a single appointment time).
3103604|NCT02123797||Serial Care Caregivers|Consenting caregivers of consented serial care patients (patients who receive the current system of linear, sequential, referral-based care delivery).
3103605|NCT02123797||Clinical Providers|Clinical providers who referred at least 5 patients to the multidisciplinary program and consented to the study.
3103606|NCT02123849|Experimental|Arm I (continuous aspirin)|Participants receive aspirin PO QD for 12 weeks.
3103607|NCT02123849|Experimental|Arm II (intermittent aspirin)|Participants receive placebo PO QD during weeks 1, 3, 5, 7, 9, and 11 and aspirin PO QD during weeks 2, 4, 6, 8, 10, and 12.
3103608|NCT02123966|Experimental|Topical Sirolimus + Steroid|A four week supply of topical sirolimus will be dispensed. The treatment instructions will be to rinse and spit (NOT swallow) with one teaspoon (5 mL) of sirolimus solution 0.1mg/mL, combined with one teaspoon (5 mL) of steroid solution (dexamethasone 0.1%, clobetasol 0.05%, or budesonide 0.03%, based on the ongoing topical steroid prescription at the time of study enrollment) four times a day for 5 minutes at a time, and not to eat or drink for 15 minutes afterwards.
3103609|NCT02124018||Post-MI patients|"Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.~ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS"
3103610|NCT02124044|Experimental|HIV/HCV GT-1b, 24 wks ASV/DCV|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
3103611|NCT02124044|Experimental|HIV/HCV GT-1a/1b, 12 wks ASV/DCV with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
3103612|NCT02124083|Experimental|Vorinostat|Trial participants were treated with Vorinostat (3 days on/4 days off regimen) to limit toxicity. Subjects were initially dosed with 200 mg (two 100 mg capsules) by mouth daily for three months, followed by dose escalation to 400 mg (four 100 mg capsules) by mouth daily for three months.
3103613|NCT02124122|Experimental|Lactobacillus|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period that corresponds to a dose of the closely related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic. The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid found in the original BioGaia strain (L. reuteri ATCC 55730).
3103614|NCT02124122|Placebo Comparator|Placebo|Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm, Sweden).
3103615|NCT02124161|Other|13vPnC+SIIV/Placebo|
3103616|NCT02124161|Other|Placebo+SIIV/13vPnC|
3103617|NCT02124265|Experimental|Ceralyte 90|Ceralyte® will be administered during the first 24-hours post-burn. Fluid requirements will be calculated according to the Parkland Formula with 50% administered during the first 8 hours and the second 50% administered over the next 16 hours. During the first 2 hours IV fluids will be started at the Parkland goal minus 250cc, which will be administered using Ceralyte via oral, nasogastric (NG), or dobhoff tube. ORT and IV fluids will be monitored with additional doses given hourly. Urine output will be monitored hourly and gastric residuals will be monitored every 2 hours, with adjustments made as needed to ensure adequate fluid resuscitation.
3103618|NCT02124304|Experimental|Cervical Pain|Thera-Band elastic and manual resistance neck exercises for neck strengthening
3103619|NCT02124304|Experimental|Healthy|Thera-Band elastic and manual resistance neck exercises for neck strengthening
3103620|NCT02124460|No Intervention|Enhanced Primary Care|"We will provide current best practice to the control arm. Patients with a BMI greater than or equal to the 85th percentile will be flagged in the electronic health record. Clinicians are also provided with clinical decision support tools for pediatric weight management. We will encourage providers to schedule a follow up visit for weight management or make a referral to Harvard Vanguard Medical Associates nutritionists for children in this arm. We will also provide this group with a community resource guide and educational text messages."
3103621|NCT02124460|Experimental|Health Coaching|The intervention for this study will consist of the same best practices received by the enhanced primary care group well as the following three elements: visits with a health coach, connection to community resources and an interactive text messaging program.
3103622|NCT02124512|Experimental|Arm 1 Rifaximin SSD|Subjects randomized to this arm of the study will receive 80 mg per day Rifaximin SSD
3103623|NCT02124512|Placebo Comparator|Arm 2 Placebo|Placebo
3103624|NCT02124564|Experimental|Lacosamide|Open-label, single-arm
3103625|NCT02124603||single group|Patients undergone cataract surgery
3103626|NCT02124707|Experimental|Carboplatin, Paclitaxel and Cetuximab|A 6 week course of weekly carboplatin, paclitaxel, and cetuximab will be administered to 38 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Once protocol therapy is complete, cetuximab may be continued if the patient and physician agree. Within 3 weeks of the end of protocol therapy, response will be assessed, and if the patient has achieved at least stable disease, the treating physician may continue to treat with weekly cetuximab at their discretion until disease progression. Patients will be followed for a maximum of 3 years after the end of the 6 week treatment phase.
3103627|NCT02124746|Experimental|Cohort 1|Participants previously enrolled in Study CCL09191E will receive momelotinib for approximately 4 years.
3103628|NCT02124746|Experimental|Cohort 2|Participants previously enrolled in Study YM387-II-02 will receive momelotinib for approximately 4 years.
3469129|NCT03889561|Experimental|Improved Water Access, Promotion, and SSB taxes|Intervention parks will receive installation of water stations, multicultural water promotion campaign, and SSB taxes
3469130|NCT03889561|No Intervention|Control|SSB taxes
3103629|NCT02124746|Experimental|Cohort 3|"Participants previously enrolled in Study GS-US-354-0101 will receive momelotinib for up to 4 years.~Cohort 3 was closed and all enrolled participants were discontinued from this study because parent Study GS-US-354-0101 was terminated."
3103630|NCT02124746|Experimental|Cohort 4|Participants previously enrolled in Study GS-US-352-1672 will receive momelotinib for approximately 4 years.
3103631|NCT02124759|Placebo Comparator|Placebo|Placebo: maltodextrin, 6 g three times a day
3103632|NCT02124759|Active Comparator|Sevelamer|Sevelamer: (1.6 g sevelamer + 4.4 g maltodextrin three times a day)
3103633|NCT02124759|Active Comparator|Synbiotic|Synbiotic: 5g Oligofructose + 4x1010 Bifidobacterium longum CFU 3x daily during diet
3103634|NCT02124772|Experimental|Part A - TMT 0.0125 mg/kg/day|Participants treated with trametinib 0.0125 mg/kg/day
3103635|NCT02124772|Experimental|Part A - TMT 0.025 mg/kg/day|Participants treated with trametinib 0.025 mg/kg/day
3103636|NCT02124772|Experimental|Part A - TMT 0.032 mg/kg/day|Participants under 6 years of age treated with trametinib 0.032 mg/kg/day
3103637|NCT02124772|Experimental|Part A - TMT 0.04 mg/kg/day|Participants treated with trametinib 0.04 mg/kg/day
3103638|NCT02124772|Experimental|Part B - Neuroblastoma|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
3103639|NCT02124772|Experimental|Part B - LGG fusion|Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day
3103640|NCT02124772|Experimental|Part B - NF-1 with PN|Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day
3103641|NCT02124772|Experimental|Part B - BRAF V600 mutant solid tumor|Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day
3103642|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 50% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for <12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)
3103643|NCT02124772|Experimental|Part C - TMT 0.025 mg/kg/day + 100% DRB RP2D|Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
3103644|NCT02124772|Experimental|Part C - TMT 0.032 mg/kg/day + 100% DRB RP2D|Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)
3103645|NCT02124772|Experimental|Part D - LGG|Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
3103646|NCT02124772|Experimental|Part D - LCH|Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for < 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for <12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)
3103647|NCT02124798|Experimental|Single arm|Subjects will self-administer belimumab SC into thigh or abdomen using the autoinjector device for 8 weekly doses; 4 of the doses will be administered under observation in the clinic and 4 of the doses will be administered outside the clinic and without observation
3103648|NCT02124811|Experimental|High CRP|Subjects with a High Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
3103649|NCT02124811|Experimental|Low CRP|Subjects with a Low Baseline CRP will receive Minocycline. During the first week, subjects will receive one 100 mg capsule daily. On weeks 2-12, the subject will receive two 100 mg capsules at bedtime. The blinded psychiatrist (blinded to CRP status) will be allowed to reduce the dose if the subject complains of any side effect. Pending tolerability, the subject will have 200 mg per day.
3103650|NCT02124863|Experimental|Intrapulmonary Percussive Ventilation|number of refluxes during 20 min of IPV ( rate : 300/min, p = 10cmH2O) at least 120 min after feeding
3103651|NCT02124889|Experimental|Weekly surveys|Subjects will take the multivitamin, and will also receive weekly Internet surveys asking them questions about the multivitamin treatment.
3103652|NCT02124889|No Intervention|No Survey|Subjects will take the multivitamin.
3103653|NCT02125279|Experimental|Calcitriol ointment|
3103654|NCT02125292|Experimental|Mesalamine (Vanilla Yogurt)|One 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
3103655|NCT02125292|Experimental|Mesalamine (Applesauce)|One 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
3103656|NCT02125292|Experimental|Mesalamine (Dosing Cup)|One 500mg capsule contents emptied into a dosing cup and taken with water
3103657|NCT02125331||PDM-SuperSTAT|PDM-SuperSTAT Arm (minimum of 55 evaluable patients): GE DINAMAP® SuperSTAT algorithm delivered by the PDM acquisition module connected to the CARESCAPE Monitor B650
3103658|NCT02125331||PSM-Datex-Ohmeda|PSM-Datex-Ohmeda Arm (minimum of 45 evaluable patients): Datex-Ohmeda delivered by the PSM acquisition module connected to the CARESCAPE Monitor B650
3103659|NCT02125604|Experimental|Dimethyl Fumarate|Dimethyl fumarate administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter for a total of 12 weeks.
3103660|NCT02125721|Experimental|CBTD Patients|Part 1: patients will stop taking CBTDs for seven days and perform a 24-hour urine collection on day 7 Part 2: patients will take their usual CBTD, either tiopronin or d-penicillamine, 1g per day for 7 days, taken as 500 mg twice a day Part 3: patients will take a total of 2g of tiopronin or D-penicillamine daily for 7 days Part 4: patients will take a total of 3g/d of tiopronin or D-penicillamine, also for a 7 day period
3103661|NCT02125734|Experimental|Treatment sequence 1|QVA149 from day 1 to day 28 and tiotropium from day 29 to day 56
3103662|NCT02125734|Experimental|Treatment sequence 2|Tiotropium from day 1 to day 28 and QVA149 from day 29 to day 56
3103663|NCT02125838|Active Comparator|Group ETT|Group endotracheal tube In the endotracheal tube group for women no. 7-7.5 tube will use. ETT:Rüschelit, Teleflex Medical Sdn. Bhd. Malaysia. Ref:112482
3103664|NCT02125838|Experimental|Group LMS|Laryngeal mask airway-supreme Group In the LMS group for <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
3103665|NCT02125877|Active Comparator|Deferasirox dispersible tablet (DFX-DT)|Iron chelation naïve participants received DFX-DT 20 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 5 to 10 mg/kg/day, with a maximum dose of 40 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose.
3103666|NCT02125877|Experimental|Deferasirox film-coated tablet (DFX-FCT)|Participants received DFX-FCT 14 mg/kg/day once daily orally from weeks 1 - 4. After week 4, the dose could be adjusted by +/- 3.5 to 7 mg/kg/day, with a maximum dose of 28 mg/kg/day. Iron chelation pre-treated participants were supposed to start on a dose that was equivalent to their pre-washout dose
3103667|NCT02126306|Placebo Comparator|Placebo|Normal saline administered orally daily as a placebo
3103668|NCT02126306|Active Comparator|Beta Glucosylceramide|Beta glucosylceramide administered orally daily
3103669|NCT02126319|Experimental|Cognitive Affective Preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
3103670|NCT02126319|Active Comparator|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
3103671|NCT02126670|Placebo Comparator|ACT01 plus Comp01|ACT01 Cream in combination with Comp01 Cream, once daily, 29 days
3103672|NCT02126670|Active Comparator|ACT01 plus Comp02|ACT01 Cream in combination with Comp02 Cream, once daily, 29 days
3103673|NCT02126670|Active Comparator|ACT01 plus Comp03|ACT01 Cream in combination with Comp03 Cream, once daily, 29 days
3103674|NCT02126670|Other|ACT01 plus Comp04|ACT01 Cream in combination with Comp04 Cream, once daily, 29 days
3103675|NCT02126748|Experimental|Intrapulmonary Percussive Ventilation|20 min of IPV administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
3103676|NCT02126748|Active Comparator|Assisted Autogenic Drainage|20 min of AAD administered to the patient inhalation 4ml hypertonic saline 3% 3x/day
3103677|NCT02126748|No Intervention|control|20 min of bouncing administered tot the patient inhalation 4ml hypertonic saline 3% 3x/day
3103678|NCT02126826|Placebo Comparator|Placebo to BI 1026706|Multiple Rising Doses Placebo to BI 1026706
3103679|NCT02126826|Experimental|BI 1026706|Multiple Rising Doses BI 1026706
3103680|NCT02126839|Placebo Comparator|Placebo MDPI QID|Placebo multidose dry powder inhaler (MDPI) administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 3 weeks.
3103681|NCT02126839|Experimental|Albuterol MDPI 180 mcg QID|Albuterol multidose dry powder inhaler (MDPI) 90 mcg/inhalation administered as 2 inhalations QID (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for a total daily dose of 720 mcgs for 3 weeks.
3103682|NCT02126969|Experimental|Chemotherapy plus Radiation Therapy|Low dose fractionated radiation - 80cGy with chemotherapy
3103683|NCT02126969|Active Comparator|Chemotherapy without Radiation|Chemotherapy only
3103684|NCT02127125|Placebo Comparator|Type2 Diabetes Mellitus - Placebo|Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)
3103685|NCT02127125|Placebo Comparator|Obese with NGT - Placebo|Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)
3103686|NCT02127125|Placebo Comparator|Lean with NGT -Placebo|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)
3103687|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Synbiotic|Type 2 Diabetic subjects will receive synbiotic
3103688|NCT02127125|Active Comparator|Type2 Diabetes Mellitus - Sevelamer|Type 2 Diabetic subjects will receive sevelamer
3103689|NCT02127125|Active Comparator|Obese with NGT - Synbiotic|Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic
3103690|NCT02127125|Active Comparator|Obese with NGT - Sevelamer|Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
3103691|NCT02127125|Active Comparator|Lean with NGT - Synbiotic|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic
3103692|NCT02127125|Active Comparator|Lean with NGT - Sevelamer|Lean (BMI< 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer
3103693|NCT02127281|Active Comparator|Prevena|Prevena NPWT system will be used immediately following surgery and continue postoperatively until hospital discharge (expected average of 4 days).
3103694|NCT02127281|No Intervention|Control|A standard of care sterile wound dressing will be placed.
3103695|NCT02127567|Experimental|Online writing tool|Participants will be provided the corresponding CONSORT item(s), key elements from the explanation and elaboration of the CONSORT 2010 and NPT extension along with examples of good reporting
3103696|NCT02127567|Other|writing with no specific support.|The control intervention will only consist of the title of the domain and a large text box where the participant will be asked to describe this part of the study for their study protocol. The participant will also have the option to indicate any important or necessary information that is not available in the provided study protocol.
3103697|NCT02127632|Active Comparator|Group ETT (endo tracheal tube)|Group ETT (Endotracheal tube Group). In the ETT group for women no. 7-7.5 tube will use. ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
3103698|NCT02127632|Experimental|Group LM-S(Laryngeal mask supreme Group)|Experimental: Group LM-S Group LM-S (Laryngeal mask supreme Group) For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) will insert.
3103699|NCT02127710|Experimental|AZD6094 600 mg daily continuously|All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.
3103700|NCT02127723|Experimental|Macrolane|All subjects will receive hyaluronic acid injection (Macrolane VRF30)
3103701|NCT02127892|Other|unrelated BM with T cell depletion|Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
3103702|NCT02127892|Other|unrelated cord blood|Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
3103703|NCT02127892|Other|haplo BM with T cell depletion|If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
3103704|NCT02127892|Other|unrelated PBSC with T cell depletion|The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
3103705|NCT02127931|Experimental|ADHD group played Game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
3103706|NCT02127931|Active Comparator|Control group played game|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administer to probands with ADHD and age, gender matched controls without ADHD. The game was played on Sifteo cubes.
3103707|NCT02127970|Experimental|Single-Dose Dalbavancin|Single-dose of dalbavancin 1500 mg intravenous (IV) infusion over 30 minutes on Day 1 followed by dalbavancin-matching placebo IV infusion over 30 minutes on Day 8 for participants with creatinine clearance (CrCl) ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin dose was 1000 mg.
3103708|NCT02127970|Experimental|Two-Dose Dalbavancin|Two-dose regimen of dalbavancin 1000 mg IV infusion over 30 minutes on Day 1 followed by 500 mg IV infusion over 30 minutes on Day 8 for participants with CrCl ≥30 mL/min or with CrCl <30 mL/min who were receiving regular hemodialysis or peritoneal dialysis. For participants with CrCl <30 mL/min who were not receiving regular hemodialysis or peritoneal dialysis, the dalbavancin doses were 750 mg on Day 1 and 375 mg on Day 8.
3103709|NCT02128074|Experimental|KRX-0502|KRX-0502 (ferric citrate)
3103710|NCT02128217|Experimental|Cohort 1: SOF+weight-based RBV for 12 wks|Participants in Cohort 1 were assigned Sofosbuvir (SOF)+weight-based ribavirin (RBV) for 12 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
3103711|NCT02128217|Experimental|Cohort 2: LDV/SOF for 8 wks|Participants in Cohort 2 were assigned Ledipasvir/Sofosbuvir for 8 weeks. Follow-up visits occurred through to 24 weeks after the end of treatment.
3103712|NCT02128230|Experimental|Total Therapy 5b|Induction, optional bridging, first transplant, optional bridging, inter-therapy, optional bridging, second transplant, optional bridging, consolidation, maintenance
3103713|NCT02128269|Experimental|ALXN1007- Open label study|ALXN1007
3103714|NCT02128490|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3103715|NCT02128490|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3103716|NCT02128490|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3103717|NCT02128490|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3103718|NCT02128490|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3103719|NCT02128542|Experimental|Sofosbuvir+RBV 12 weeks|Participants will receive sofosbuvir+RBV for 12 weeks.
3103720|NCT02128724|Experimental|BKM120 plus radiotherapy|Three cohorts of patients will be treated with escalating doses of oral buparlisib. The doses will be 50mg, 80mg and 100mg, once daily. Patients will be treated with buparlisib for a total of fourteen days. One week after commencing buparlisib, patients will start palliative radiotherapy treatment. Radiotherapy treatment will be delivered as 20Gy in 5 fractions over a one week period. There will be an expansion cohort at the MTD. Patients in an optional fourth cohort will take buparlisib for 4 weeks at the MTD.
3103721|NCT02128763|Experimental|Omega-3 supplements|Total 2000 mg EPA and 1000 mg DHA per day taken in 5 gelcaps
3103722|NCT02128763|Placebo Comparator|Placebo|Olive oil-5 gelcaps per day
3103723|NCT02128828|Experimental|cenicriviroc|cenicriviroc 50 mg tablets, number of tablets adjusted for other antiretroviral medications or other drugs, given once daily
3103724|NCT02128867|Experimental|Assisted Autogenic Drainage (AAD)|airway clearance technique for infants :Assisted Autogenic Drainage
3103725|NCT02128867|Experimental|bouncing and AAD|airway clearance technique for infants : bouncing combined with AAD
3103726|NCT02128867|Experimental|bouncing|bouncing . intervention to relax the infant
3103727|NCT02128919|Experimental|Active tDCS|tDCS 2 ma for 20 minutes with anode at DLPFC once a day for 5 days
3103728|NCT02128919|Sham Comparator|Sham tDCS|tDCS 2 ma for 40 seconds with anode at DLPFC for 5 days
3103729|NCT02128932|Experimental|Semaglutide 0.5 mg/week|
3103730|NCT02128932|Experimental|Semaglutide 1.0 mg/week|
3103731|NCT02128932|Active Comparator|Insulin glargine|
3103732|NCT02128997|Experimental|Closed Incision Wound vacuum (Prevena)|Closed incision wound vacuum (Prevena)
3103733|NCT02128997|No Intervention|Routine Wound Care|This arm includes patients having a cesarean section with routine wound care
3103734|NCT02129062|Experimental|Treatment (ibrutinib)|Ibrutinib 560 mg orally daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3103735|NCT02129075|Experimental|Arm I (CDX-301, CDX-1401, poly-ICLC)|Patients receive recombinant Flt3 ligand (CDX-301) SC on days -7 to -1, 1-3, and 22-28 of cycle 1 and only on days 1-3 of cycle 2. Patients also receive CDX-1401 SC or ID on day 1 of each cycle and poly-ICLC SC on days 1-2 of each cycle. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
3103736|NCT02129075|Active Comparator|Arm II (CDX-1401, poly-ICLC)|Patients receive CDX-1401 and poly-ICLC as in Arm I. Treatment repeats every 28 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
3103737|NCT02129192|Experimental|T80/A5/H12.5 mg FDC|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
3103738|NCT02129192|Active Comparator|T80/H12.5 FDC + A5 mono|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule
3103739|NCT02129205|Experimental|PF-06650808|
3103740|NCT02129348|Active Comparator|Lithium Treatment Group|"The patient will be started on lithium 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on lithium blood level. Blood will be drawn at each study visit. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
3103741|NCT02129348|Placebo Comparator|Placebo Group|"The patient will be started on placebo 150mg/day, with subsequent dose titration to 300mg/day at the 2-week visit, 450mg/day at the 4-week visit, and 600mg/day (maximum daily dose) if tolerated and based on sham lithium blood level. Blood will be drawn for sham lithium levels at weeks 2, 4, 6, 8, and 12. This upward dose titration will occur only if clinically indicated (absence of response at lower doses without intolerable side effects).~Patients who develop side effects, e.g., tremor, falls, will have their dose reduced."
3103742|NCT02129426|Experimental|Dexmedetomidine and Ketamine|Subjects will already be getting Dexmedetomidine and Ketamine for their routine care.
3103743|NCT02129426|Active Comparator|Dexmedetomidine and Midazolam|Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
3103744|NCT02129478|Experimental|Olanzapine|
3103745|NCT02129556|Experimental|MK-3475 with trastuzumab (single arm)|"Phase Ib: MK-3475 at dose of 2 mg/kg or 10 mg/kg (i.v.), or a fall-back dose of 1 mg/kg, together with trastuzumab 6mg/kg by (i.v.) once every 3 weeks.~Phase II: MK-3475 at a flat dose of 200mg (i.v.) together with trastuzumab 6mg/kg (i.v.) once every 3 weeks until progression, lack of tolerability, or 24 months of treatment.~A dose of 8mg/kg trastuzumab will be used in cycle 1 if prior treatment with trastuzumab was stopped more than 3 months before."
3103746|NCT02129608|Active Comparator|LLLT|Low Level Laser Therapy (LLLT) once a week for 12 weeks
3103747|NCT02129608|Active Comparator|Lorcaserin|locarserin monotherapy - 10 mg, twice daily for 12 weeks
3103748|NCT02129608|Active Comparator|LLLT and Lorcaserin|LLLT once a week for 12 weeks and 10 mg of Lorcaserin twice daily for 12 weeks
3103749|NCT02129660|Experimental|Dose 1 of glycopyrrolate, 2.0% QD|glycopyrrolate Topical Wipes
3103750|NCT02129660|Experimental|Dose 2 of glycopyrrolate, 3.0% QD|glycopyrrolate Topical Wipes
3103751|NCT02129660|Active Comparator|Dose 1 of glycopyrronium, 2.5% QD|glycopyrronium Topical Wipes
3103752|NCT02129660|Active Comparator|Dose 2 of glycopyrronium, 3.75% QD|glycopyrronium Topical Wipes
3103753|NCT02129660|Placebo Comparator|Vehicle|Vehicle Topical Wipes
3103754|NCT02129725|Experimental|sildenafil citrate|In the parent study, subjects are randomized to sildenafil 25 mg tid.
3103755|NCT02129725|Placebo Comparator|placebo oral capsule|In the parent study, subjects are randomized to matching placebo
3103756|NCT02129777|Experimental|Blinded period: Namilumab 300 mg + namilumab 150 mg|Namilumab 300 mg (2 separate injections of 150 mg), subcutaneous injection, on Day 1, followed by namilumab 150 mg subcutaneous injection, on Days 15, 43 and 71.
3103757|NCT02129777|Experimental|Blinded period: Namilumab 160 mg + namilumab 80 mg|Namilumab 160 mg (2 separate injections of 80 mg), subcutaneous injection, on Day 1, followed by namilumab 80 mg subcutaneous injection, on Days 15, 43 and 71.
3103758|NCT02129777|Experimental|Blinded period: Namilumab 100 mg + namilumab 50 mg|Namilumab 100 mg (2 separate injections of 50 mg), subcutaneous injection, on Day 1, followed by namilumab 50 mg subcutaneous injection, on Days 15, 43 and 71.
3103759|NCT02129777|Experimental|Blinded period: Namilumab 40 mg + namilumab 20 mg|Namilumab 40 mg (2 separate injections of 20 mg), subcutaneous injection, on Day 1, followed by namilumab 20 mg subcutaneous injection, on Days 15, 43 and 71.
3103760|NCT02129777|Placebo Comparator|Blinded period: Placebo|Placebo (2 separate injections), subcutaneous injection, on Day 1, followed by placebo, subcutaneous injection, on Days 15, 43 and 71.
3103761|NCT02129777|Experimental|Open label: Namilumab 80 mg|Namilumab 80 mg subcutaneous injection, at Week 0 and every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
3103762|NCT02129777|Experimental|Open label: Namilumab 150 mg|Namilumab 150 mg, subcutaneous injection, from Week 8 and then every 4 weeks thereafter up to 52 weeks (active extension period) - if appropriate on the basis of treatment response.
3103763|NCT02129803|Experimental|Experimental Therapy|High-Flow, 20 LPM (via Optiflow cannula) Heated (34C) Humidified Air
3103764|NCT02129803|Placebo Comparator|Control Therapy (Low Flow)|Low FLow, 5 LPM (via Optiflow cannula) Room Temperature (23-26C) Ambient Air
3103765|NCT02130024|Experimental|Ranibizumab 0.5 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
3103766|NCT02130024|Active Comparator|Aflibercept 2.0 mg|3 monthly loading doses (Baseline, Week 4, and Week 8), followed by an individualised treatment and evaluation regimen according to disease activity [treat and extend]
3103767|NCT02130063|Experimental|iron isomaltoside 1000 (Monofer®)|iron isomaltoside 1000 (Monofer®)
3103768|NCT02130063|Active Comparator|iron sucrose (Venofer®)|iron sucrose (Venofer®)
3103769|NCT02130193|Experimental|Part A|Subjects will receive 50 mg danirixin twice daily (BID) orally for 14 days. If the exposure to danirixin is lower than expected, after 14 days of dosing, then the dose may be increased to 75 mg BID for Part B.
3103770|NCT02130193|Experimental|Part B|Subjects will be randomized to receive either danirixin BID or placebo BID treatment along with standard care of treatment for 52 weeks. Subjects completing Part A and meeting the eligibility criteria for Part B could also be randomized in Part B.
3103771|NCT02130258|Other|>30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
3103772|NCT02130258|Other|<30% Pain Relief|All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.
3103773|NCT02130284|Experimental|Predictive Low Glucose Management (PLGM)|To evaluate the safety of the Predictive Low Glucose Management feature in insulin pump algorithm with the Enlite 3 Sensor
3103774|NCT02130297|Active Comparator|Group 1 - day 1|Group 1 will receive laser therapy to half of the scar the day of the excision.
3103775|NCT02130297|Active Comparator|Group 2 - day 14|Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.
3103776|NCT02130297|Active Comparator|Group 3 - week 9|Group 3 will receive laser treatment to half the scar at the 9 week postop visit.
3103777|NCT02130427|Other|Lung Imaging|Weekly 3D/4D CT scans during radiation therapy. MRI may be used in addition to or instead of CT depending on the location of the tumor and the decision of the treating physician.
3103778|NCT02130557|Experimental|Bosutinib|Bosutinib, 400 mg, oral administration once a day
3103779|NCT02130557|Active Comparator|Imatinib|Imatinib, 400 mg, oral administration once a day
3103780|NCT02130570|Experimental|Multi-Model Intensive Discharge Program|Multi-Model Intensive Discharge Program
3103781|NCT02130570|No Intervention|Usual Care|Usual Care
3103782|NCT02130583|Experimental|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
3103783|NCT02130583|Active Comparator|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
3103784|NCT02130635|Experimental|Part A: GSK2269557 1000 MCG|Subjects will receive 2 inhalations (2 x GSK2269557 500 mcg = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103785|NCT02130635|Placebo Comparator|Part A: PLACEBO|Subjects will receive 2 inhalations of placebo once daily for 14 consecutive days
3103786|NCT02130635|Experimental|Part B: GSK2269557 100 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 100 mcg and 3 x Placebo = total dose of 100 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103787|NCT02130635|Experimental|Part B: GSK2269557 200 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 200 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103788|NCT02130635|Experimental|Part B: GSK2269557 500 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg and 3 x Placebo = total dose of 500 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days, once daily for 14 consecutive days
3103789|NCT02130635|Experimental|Part B: GSK2269557 700 MCG|Subjects will receive 4 inhalations (1 x GSK2269557 500 mcg, 2 x GSK2269557 100 mcg and 1 x Placebo = total dose of 700 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103790|NCT02130635|Experimental|Part B: GSK2269557 1000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 1000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103791|NCT02130635|Experimental|Part B: GSK2269557 2000 MCG|Subjects will receive 4 inhalations (2 x GSK2269557 100 mcg and 2 x Placebo = total dose of 2000 mcg GSK2269557) 30 seconds apart, once daily for 14 consecutive days
3103792|NCT02130635|Placebo Comparator|Part B: PLACEBO|Subjects will receive 4 inhalations of placebo once daily for 14 consecutive days
3103793|NCT02130687|Active Comparator|Amlodipine|Subjects in this arm will receive calcium channel blocker therapy with amlodipine 5mg daily for 3 days then 10mg daily for 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3103794|NCT02130687|Experimental|Ramipril|Subjects will receive ACE-inhibitor therapy with ramipril 5mg daily for 3 days, followed by 10mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3103795|NCT02130687|Active Comparator|Valsartan|Subjects will receive ARB therapy with valsartan 160mg daily for 3 days, followed by 320mg daily for the remaining 15 weeks. After 4 weeks of treatment, subjects will receive three different 1 week concurrent interventions, in a cross-over fashion, separated by a 4 week washout. The interventions will be: placebo + placebo, sitagliptin + placebo, sitagliptin + aprepitant.
3103796|NCT02130765|No Intervention|Drug with ICD/CRT-D|Implantable cardioverter defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) with routine drug therapy
3103797|NCT02130765|Active Comparator|Cardiac catheter ablation with ICD/CRT-D|Cardiac catheter ablation with ICD/CRT-D with routine drug therapy
3103798|NCT02130986|Experimental|Procalcitonin (PCT) group|Procalcitonin (PCT) level; Results of procalcitonin level to treating clinician; Provide procalcitonin guideline to treating clinician; Telephone Visit at Day 15 and Day 30
3103799|NCT02130986|Active Comparator|Usual Care group|Telephone Visit at Day 15 and Day 30
3103800|NCT02130999|Experimental|Sequence A|"Single oral dose of tasimelteon 20 mg on Day 1~Single I.V. dose of tasimelteon 2 mg on Day 6"
3103801|NCT02130999|Experimental|Sequence B|"Single I.V. dose of tasimelteon 2 mg on Day 1~Single oral dose of tasimelteon 20 mg on Day 6"
3103802|NCT02131064|Active Comparator|Trastuzumab (TCH) + Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) (loading dose) and 420 mg (maintenance dose) intravenous (IV) infusion followed by trastuzumab 8 milligrams per kilogram (mg/kg) (loading dose) and 6 mg/kg (maintenance dose) IV infusion followed by docetaxel 75 milligrams per square meter (mg/m^2) IV infusion and carboplatin at a dose to achieve an area under the curve (AUC) of 6 milligrams per milliliter* minute (mg/mL*min) IV infusion every 3 weeks (q3w) for 6 cycles in neoadjuvant period. Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w for rest of the cycles (12 cycles) in adjuvant period (up to a total of 18 cycles).
3103803|NCT02131064|Experimental|Trastuzumab Emtansine (T-DM1) + Pertuzumab|Participants will receive pertuzumab 840 mg (loading dose) and 420 mg (maintenance dose) IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion q3w for a total of 18 cycles (6 cycles of neoadjuvant period and 12 cycles of adjuvant period).
3103804|NCT02131129|Experimental|rTMS|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
3103805|NCT02131129|Sham Comparator|Sham|The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
3103806|NCT02131233|Experimental|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily plus placebo to raltegravir 1 tablet orally twice daily plus TRUVADA™ orally once daily for 96 weeks
3103807|NCT02131233|Active Comparator|Raltegravir|Raltegravir 400 mg tablet orally twice daily plus placebo to reformulated raltegravir 2 tablets orally once daily plus TRUVADA™ orally once daily for 96 weeks
3103808|NCT02131259||Afatinib|
3103809|NCT02131272|Experimental|Insulin detemir and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
3103810|NCT02131272|Active Comparator|Insulin NPH and diet/exercise|Current OADs i.e. metformin or other OADs are continued unchanged
3103811|NCT02131311|Experimental|pessary|disposable, single-use pessary
3103812|NCT02131324|Active Comparator|Clobetasol Propionate Cream, 0.05%|applied twice a day for 15 days
3103813|NCT02131324|Experimental|DFD06 Cream|applied twice a day for 15 days
3103814|NCT02131402|Experimental|enfilcon A / omafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3103815|NCT02131402|Active Comparator|enfilcon A / ocufilcon D|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3103816|NCT02131402|Active Comparator|enfilcon A / methafilcon A|Participants wear a pair of lenses, with a test lens in one eye and a control lens in the contra lateral eye. After approximately 1 hour of lens wear, the lenses will be removed and the next pair will be inserted. This will be repeated for a total of three pairs of lenses.
3103817|NCT02131532|Experimental|Psychological intervention|"This is a brief psychological intervention which targets patients' mood, their beliefs about their ability to overcome fatigue, and the scheduling of daily activities, with an aim to increase physical activities in daily life and finally reduce the level of fatigue.~Each participant will meet a therapist in six face-to-face sessions. Each session will be about one hour and be two weeks apart. During the sessions, the participant will discuss with the therapist their problems related to fatigue and work through an intervention manual to learn skills to overcome these problems."
3103818|NCT02131636|Experimental|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
3103819|NCT02131636|Placebo Comparator|Vehicle|Vehicle to AGN-199201 applied to the face once daily for 29 days.
3103820|NCT02131662|Experimental|VPR 4 mg|
3103821|NCT02131662|Experimental|VPR 2 mg|
3103822|NCT02131662|Experimental|VPR 1 mg|
3103823|NCT02131662|Experimental|VPR 0.5 mg|
3103824|NCT02131662|Placebo Comparator|Placebo|
3103825|NCT02131766|Experimental|USS Virginia Closed Loop Control|"The subject will be admitted to the research house/hotel and will be discharged after 5 nights. The subject will be trained on DiAs and on how to respond to the system's alerts. The DiAs will be initiated by 11:00 PM and will be discontinued before breakfast. The staff will be monitoring the subject remotely. The subject will need to remain within a 30 miles of the research house/hotel during the day and return by 6:00 PM.~A limited number of UVA and UPadova subjects will be asked to wear the DiAs at home for 5 days at the conclusion of research house admission."
3103826|NCT02131766|Placebo Comparator|Sensor Augmented Pump Therapy|The subject will wear the continuous glucose monitor with the study insulin pump for a full 7 day period (approximately 7 consecutive 24 hour periods). The subject will follow their usual regimen. The subject will be asked to use the bolus calculator function on your insulin pump and enter the carbohydrate information that you eat during the week.
3103827|NCT02132117|Experimental|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 29 days.
3103828|NCT02132117|Placebo Comparator|Vehicle|Vehicle to Oxymetazoline HCL Cream applied to the face once daily for 29 days.
3103829|NCT02132130|Experimental|CGF166 dose 20 uL|single dose volume #1
3103830|NCT02132130|Experimental|CGF166 dose 30 and 40 uL|single dose volume #2
3103831|NCT02132130|Experimental|CGF166 dose 40 uL|single dose volume #3
3103832|NCT02132130|Experimental|CGF166 dose 60 uL|single dose volume #4
3103833|NCT02132130|Experimental|CFG166 dose 30 uL|Single dose volume #5
3103834|NCT02132169|Experimental|AC-170 0.24%|
3103835|NCT02132169|Placebo Comparator|AC-170 0%|
3103836|NCT02132195|Active Comparator|Adrenocorticotropic hormone (ACTH)|"Patients will receive ACTH twice weekly subcutaneously The initial dosing will be based on body surface area (BSA): 80 IU/1.73 m2~The patients will receive the initial dose for 6 months. At 6 months, the dose will be reduced by 50%. Patients who have side effects may have the dose reduced by 50% during the initial 6 months. A second dose reduction would still occur at 6 months (25% of initial dose)."
3103837|NCT02132195|No Intervention|No treatment|Patients in this treatment arm will receive no treatment to prevent relapses of nephrotic syndrome. A relapse, if it occurs, will be treated with prednisone and the patient will leave the no treatment arm of the study.
3103838|NCT02132195|Active Comparator|Rescue therapy|There is an option for the patient in no-treatment arm to elect to be placed in the active treatment arm of the trial (rescue therapy).
3103839|NCT02132247|Experimental|Flector Patch|Flector Patch is a transdermal delivery system containing 180 mg of diclofenac hydroxyethylpyrrolidine. The patch will be used twice-a-day for up to two weeks, or until pain resolution, whichever comes first.
3103840|NCT02132312|Experimental|OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3103841|NCT02132312|Active Comparator|Phenylephrine HCl|Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
3103842|NCT02132468|Experimental|fosbretabulin tromethamine|Fosbretabulin 90 mg/vial; 60 mg/m2, IV infusion over 10 minutes; 1x/wk; three 3-week cycles
3103843|NCT02132520|No Intervention|Control|Subjects receiving standard-of-care physical therapy only.
3103844|NCT02132520|Sham Comparator|Sham rTMS + Real BCI Training|Subjects will receive sham rTMS followed by real BCI training.
3103845|NCT02132520|Active Comparator|Real rTMS + Real BCI Training|Subjects will receive real rTMS followed by real BCI training.
3103846|NCT02132533|Experimental|Nifedipine|Women with preterm labor will receive nifedipine.
3103847|NCT02132533|Experimental|Placebo|Women with preterm labor will receive placebo.
3103848|NCT02132572||Natrelle BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
3103849|NCT02132598|Experimental|Cabozantinib (XL184)|"Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events.~Treatment cycles are 4 weeks in duration"
3103851|NCT02132637|Experimental|Insulin Peglispro|Standard dose of insulin peglispro administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin peglispro administered once, SQ on day 3 of the inpatient stay.
3103852|NCT02132637|Experimental|Insulin Glargine|Standard dose of insulin glargine administered subcutaneously (SQ) once daily for 4 weeks in one of two study periods. Double dose of insulin glargine administered once, SQ on day 3 of the inpatient stay.
3103853|NCT02132650|Experimental|ACC|Rehabilitation of walking using accurate (ACC) walking tasks
3103854|NCT02132650|Active Comparator|SS|Rehabilitation of walking using typical steady state (SS) walking
3103855|NCT02132676||Active treatment|All those scheduled for a Shared Medical Appointment (SMA), regardless of whether the Peer to Peer (P2P) program was offered.
3103856|NCT02132676||Usual Care|The randomly selected sample of those not offered participation in a Shared Medical Appointment (SMA).
3103857|NCT02132754|Experimental|MK-4166 0.0015 mg|Participant received 0.0015 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103858|NCT02132754|Experimental|MK-4166 0.0045 mg|Participant received 0.0045 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103859|NCT02132754|Experimental|MK-4166 0.014 mg|Participant received 0.014 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103860|NCT02132754|Experimental|MK-4166 0.04 mg|Participant received 0.04 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103861|NCT02132754|Experimental|MK-4166 0.12 mg|Participant received 0.12 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103862|NCT02132754|Experimental|MK-4166 0.37 mg|Participant received 0.37 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103863|NCT02132754|Experimental|MK-4166 1.1 mg|Participant received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103864|NCT02132754|Experimental|MK-4166 3.3 mg|Participant received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103865|NCT02132754|Experimental|MK-4166 10 mg|Participant received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103866|NCT02132754|Experimental|MK-4166 30 mg|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103867|NCT02132754|Experimental|MK-4166 42 mg|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103868|NCT02132754|Experimental|MK-4166 59 mg|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103869|NCT02132754|Experimental|MK-4166 82 mg|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103870|NCT02132754|Experimental|MK-4166 120 mg|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103871|NCT02132754|Experimental|MK-4166 170 mg|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103872|NCT02132754|Experimental|MK-4166 240 mg|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103873|NCT02132754|Experimental|MK-4166 340 mg|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103874|NCT02132754|Experimental|MK-4166 480 mg|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103875|NCT02132754|Experimental|MK-4166 670 mg|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103876|NCT02132754|Experimental|MK-4166 900 mg|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles.
3103877|NCT02132754|Experimental|MK-4166 1.1 mg + Pembro|Participants received 1.1 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103878|NCT02132754|Experimental|MK-4166 3.3 mg + Pembro|Participants received 3.3 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103879|NCT02132754|Experimental|MK-4166 10 mg + Pembro|Participants received 10 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103880|NCT02132754|Experimental|MK-4166 30 mg + Pembro|Participants received 30 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103881|NCT02132754|Experimental|MK-4166 42 mg + Pembro|Participants received 42 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103882|NCT02132754|Experimental|MK-4166 59 mg + Pembro|Participants received 59 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103883|NCT02132754|Experimental|MK-4166 82 mg + Pembro|Participants received 82 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103884|NCT02132754|Experimental|MK-4166 120 mg + Pembro|Participants received 120 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103885|NCT02132754|Experimental|MK-4166 170 mg + Pembro|Participants received 170 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103886|NCT02132754|Experimental|MK-4166 240 mg + Pembro|Participants received 240 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103887|NCT02132754|Experimental|MK-4166 340 mg + Pembro|Participants received 340 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103888|NCT02132754|Experimental|MK-4166 480 mg + Pembro|Participants received 480 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103889|NCT02132754|Experimental|MK-4166 670 mg + Pembro|Participants received 670 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103890|NCT02132754|Experimental|MK-4166 900 mg + Pembro|Participants received 900 mg MK-4166 IV on Day 1 of each 21-day cycle for up to 4 cycles plus pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
3103891|NCT02132767|Active Comparator|Rhythm control|"Rhythm Control in post-operative AF~Amiodarone and/or DC-cardioversion~Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started~DC-Cardioversion - frequency and duration determined by medical professional as medically needed"
3103892|NCT02132767|Active Comparator|Rate control|"Rate Control in post-operative AF~Beta-blocker and/or Calcium channel blockers and/or Digoxin~Dose, frequency and duration determined by medical professional as medically needed"
3103893|NCT02132832|Experimental|Buspirone|Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
3103894|NCT02132832|Placebo Comparator|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
3103895|NCT02132910|Experimental|RESTORE Intervention|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about yourself, your pain and your current medication use.~For the first four weeks you will receive twice-weekly, individualized, hour-long RESTORE sessions from a specially trained RESTORE instructor.~For the next four weeks, you will receive weekly, individualized, hour-long RESTORE sessions from a RESTORE instructor.~At weeks four and eight, you will repeat the assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavioral health."
3103896|NCT02132910|No Intervention|Control Group 2|"First you will receive an initial assessment of pain, physical function, and behavioral health. You will be asked to take a computer questionnaire, perform so simple physical assessments, and answer questions about yourself, your pain and your current medication use.~You will be contacted once a week for eight weeks by phone or email to answer questions about your pain level.~At weeks four and eight, you will repeat the assessment of pain, physical function and behavioral health. You will be asked to take a computer questionnaire, perform some simple physical assessments, and answer questions about pain and medication use.~At three and six months, you will be contacted by telephone or email to answer questionnaires about pain, physical function, and behavior health."
3103897|NCT02132936|Experimental|LEO 90100|LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks
3103898|NCT02132936|Placebo Comparator|Aerosol foam vehicle|Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks
3103899|NCT02132936|Active Comparator|Calcipotriol BDP gel|Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks
3103900|NCT02132936|Placebo Comparator|Gel vehicle|Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks
3132633|NCT03441984|Experimental|Subjects with treatment sequence DEF|The subjects in Part 2 of the study, will receive a single dose of treatment D= Adult DTG (50 mg, 1 conventional tablet) and adult 3TC (300 mg, 1 conventional tablet) administered as direct-to-mouth, in TP1; treatment E= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as a dispersion and taken immediately in TP2; and treatment F= Pediatric DTG/3TC (DTG 5 mg/3TC 30 mg, 10 dispersible tablets) administered as direct-to-mouth in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3103901|NCT02132949|Experimental|Cohort A: ddAC, Paclitaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with dose-dense doxorubicin and cyclophosphamide (ddAC), with administration of doxorubicin 60 milligrams per square meter (mg/m^2) intravenously (IV) once every 2 weeks (q2w) and cyclophosphamide 600mg/m^2 IV q2w for 4 cycles, followed by paclitaxel 80mg/m^2 IV once weekly (qw) for 12 weeks. Pertuzumab (840 milligrams [mg] IV loading dose then 420mg IV q3w) and trastuzumab (8 milligrams per kilogram [mg/kg] IV loading dose then 4mg/kg IV q3w) were administered along with paclitaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
3103902|NCT02132949|Experimental|Cohort B: FEC, Docetaxel, Pertuzumab, Trastuzumab|Participants received neoadjuvant treatment with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC), with administration of 5-fluorouracil 500mg/m^2 intravenously (IV) q3w, epirubicin 100mg/m^2 IV q3w, and cyclophosphamide 600mg/m^2 IV q3w for 4 cycles, followed by docetaxel (with starting dose of 75mg/m^2 in Cycle 5, then 100mg/m^2 for Cycles 6-8) q3w for 4 cycles. Pertuzumab (840 mg IV loading dose then 420mg IV q3w) and trastuzumab (8 mg/kg IV loading dose then 4mg/kg IV q3w) were given along with doectaxel for 4 cycles (8 cycles of chemotherapy in total prior to surgery). Following surgery, participants received adjuvant treatment with pertuzumab and trastuzumab IV q3w (up to 13 cycles), for a total of 17 cycles of pertuzumab and trastuzumab therapy during the study. Radiotherapy and adjuvant hormonal therapy were also given as clinically indicated. Following treatment completion/discontinuation, participants were followed for safety and efficacy for up to 5 years.
3103903|NCT02133001|Experimental|Esketamine|Esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks. Dose may be reduced to 56 mg per day based on Investigator's discretion.
3103904|NCT02133001|Placebo Comparator|Placebo|Matching Placebo solution will be administered by intranasal route using nasal spray pump as two times a week, for 4 weeks.
3103905|NCT02133066|Active Comparator|US-Assisted site marking for Lumbar Punctures (LP)|Mindray M7 Ultrasound marking
3103906|NCT02133066|Placebo Comparator|Routine lumbar puncture|"These patients will receive no ultrasound-assisted site marking prior to lumbar puncture; The patients will simply have a standard-of-care spinal tap performed by the clinician"
3103907|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 4wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC with SOF 400mg once daily (q.d.) by mouth for 4 weeks (n=30 planned).
3103908|NCT02133131|Experimental|GT1:NC Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=30 planned).
3103909|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 6wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 6 weeks (n=20 planned).
3103910|NCT02133131|Experimental|GT1:C Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=20 planned).
3103911|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 8wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 8 weeks (n=15 planned).
3103912|NCT02133131|Experimental|GT3:NC Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=15 planned).
3103913|NCT02133131|Experimental|GT3:C Grazoprevir/Elbasvir+SOF 12wk|Participants took grazoprevir/elbasvir (100mg/50mg) FDC + SOF 400mg q.d. by mouth for 12 weeks (n=10 planned).
3103914|NCT02133235|Active Comparator|conventional|insertion of endobronchial blocker and auscultation, fiberoptic confirmation and reposition
3103915|NCT02133235|Experimental|auscultation|insertion endobronchial blocker by auscultation without conventional bronchoscopic reposition
3103916|NCT02133352|Experimental|Ranolazine|Ranolazine- initiated at 500mg twice daily and increased to 1000mg twice daily as tolerated after 2wks; the tolerated dose will be used for the remainder of the Treatment Period.
3103917|NCT02133508||NSCLC Participants|Participants with advanced non-small cell lung cancer (NSCLC), treated in second-line with erlotinib, presenting wild-type, not tested or unknown Epidermal Growth Factor Receptor (EGFR) status, and with stable disease at the first revaluation after start of erlotinib therapy.
3103918|NCT02133664|Experimental|lipoic acid and omega-3 fatty acids|lipoic acid and omega-3 fatty acids
3103919|NCT02133664|Placebo Comparator|placebo|placebo oil and placebo lipoic acid
3103920|NCT02133742|Experimental|Dose finding phase and dose expansion phase|To test the maximum tolerated dose of MK-3475 at 2 mg/kg every three weeks intravenous infusion in combination with approved axitinib dose
3103921|NCT02133781|Experimental|Age 8-17 years (identical twins )|Participants will be randomized to receive either Fluzone® 2009-2010 Formula or FluMist® 2009-2010 Formula
3103922|NCT02133781|Experimental|Age 18-30 years (non-twins)|Participants will be receive Fluzone® 2009-2010 Formula
3103923|NCT02133781|Experimental|Age >70 years (non-twins)|Participants will receive Fluzone® 2009-2010 Formula
3103924|NCT02134015|Experimental|Placebo + erlotinib|Placebo infusion every 3 weeks and oral erlotinib 150 mg/day
3103925|NCT02134015|Experimental|Patritumab + erlotinib|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day
3103926|NCT02134028|Experimental|dupilumab treatment|"For participants coming from the DRI12544 study: dupilumab loading dose subcutaneous (SC) on Day 1, followed by 1* Dose every 2 weeks added to current controller medications.~For participants coming from other studies: dupilumab 1 * Dose SC every 2 weeks added to current controller medications."
3103927|NCT02134119|Experimental|Echinacea-based dietary supplement|Echinacea-based dietary supplement 8,000mg/day or 16,000mg/day by mouth for 35-days
3103928|NCT02134119|Placebo Comparator|Sugar pill|Placebo given 8,000mg/day by mouth
3103929|NCT02134184|Experimental|CMV negative group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3103930|NCT02134184|Experimental|CMV positive group|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3103931|NCT02134184|Experimental|Recent CMV Converters|Participants will receive Fluzone® 2012-2013 Formula NDC No 498281-012-50
3103932|NCT02134210|Active Comparator|Enbrel (etanercept)|Enbrel 50mg twice weekly times 12 weeks
3103933|NCT02134210|Experimental|CHS-0214|CHS-0214 50mg twice weekly times 12 weeks
3103934|NCT02134314|Experimental|C1-Inhibitor (Berinert) (Human) (C1INH)|35 patients will receive C1 esterase inhibitor in addition to standard of care immunosuppressive therapy.
3103935|NCT02134314|Placebo Comparator|Normal Saline|35 patients will receive placebo in addition to standard of care immunosuppressive therapy.
3103936|NCT02134353|Experimental|Experimental arm A|Active treatment. Inhaled Mannitol
3103937|NCT02134353|Placebo Comparator|Arm B - Control|Arm B
3103938|NCT02134522|Experimental|C-PAP intervention|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
3103939|NCT02134587|Other|Subjects post educational intervention|Multifaceted educational intervention in pharmacovigilance
3469131|NCT03889587|Experimental|Innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibula bone flaps. In simultaneous innervated group, neurorrhaphy between the ilioinguinal nerve or fibula flap nerve with inferior alveolar nerve or great auricular nerve will be performed.~Intervention: Procedure: Innervation"
3103941|NCT02134756|Experimental|NutraStem Active|Daily supplementation with NutraStem Active; 2 capsules per day for 28 days
3103942|NCT02134756|Placebo Comparator|Placebo|Daily supplementation with placebo; 2 capsules per day for 28 days
3103943|NCT02134925|Experimental|Arm I (MUC1 peptide-poly-ILCLC adjuvant vaccine)|Participants receive MUC1 peptide-poly-ICLC adjuvant vaccine SC in weeks 0, 2 and 10 and a booster injection in week 53.
3103944|NCT02134925|Placebo Comparator|Arm II (saline)|Participants receive saline SC in weeks 0, 2, and 10 and a booster injection in week 53.
3103945|NCT02134951|Experimental|ketamine|IV infusion of ketamine 0.23mg/kg bolus over 1 minutes followed by 0.58 mg/kg/hr over 30 minutes then 0.29mg/kg/hr over 64 minutes
3103946|NCT02134951|Placebo Comparator|Placebo|Placebo group will receive normal saline
3103947|NCT02134977||Leuprorelin Acetate|Subcutaneous administration of leuprorelin acetate 11.25 mg once every 12 weeks
3103948|NCT02135016|Experimental|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
3103949|NCT02135016|Experimental|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
3103950|NCT02135016|Placebo Comparator|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
3469132|NCT03889587|Active Comparator|Non-innervation|"Patients with segmental defects of mandible sized 5 to 12 cm long will be reconstructed using microsurgical iliac or fibular bone flaps. In traditional noninnervated group, neurorrhaphy will not be performed.~Intervention: Procedure: Non-innervation"
3103954|NCT02135094|Experimental|Active ultrasound therapy device|Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity
3103955|NCT02135094|Placebo Comparator|Placebo ultrasound therapy device|Patients apply the Sam Ultrasonic Diathermy Device for 4 hours on days when their trapezius muscle pain score is at least a 3 on a scale of 0-10 (NRS). The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
3103956|NCT02135107|Experimental|Arm A|
3103957|NCT02135107|Experimental|Arm B|
3103958|NCT02135107|Experimental|Arm C|
3103959|NCT02135107|Experimental|Arm D|
3103960|NCT02135146|Active Comparator|Plasmalyte 3ml/kg/hr group|
3103961|NCT02135146|Active Comparator|Plasmalyte 6ml/kg/hr group|
3103962|NCT02135432|Experimental|Ivacaftor (VX-770)|twice a day administration of Ivacaftor: 150mg
3103963|NCT02135432|Placebo Comparator|Placebo|matching placebo
3103964|NCT02135445|Experimental|TAK-385|TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks. Each participant may have one upward dose adjustment of 40 mg for efficacy and/or one downward dose adjustment of 40 mg for safety during the study.
3103965|NCT02135445|Active Comparator|Degarelix|Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks.
3103966|NCT02135614|Experimental|Presatovir|Participants will receive a single dose of presatovir.
3103967|NCT02135614|Placebo Comparator|Presatovir placebo|Participants will receive a single dose of presatovir placebo.
3103968|NCT02135653||Feasibility Phase: Eischens Yoga Group|
3103969|NCT02135653||Phase II: Eischens Yoga Group|
3103970|NCT02135692|Experimental|Mepolizumab 100 mg|All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.
3103971|NCT02135848|Experimental|GSK1278863|Study Drug
3103972|NCT02135848|Placebo Comparator|Placebo|Placebo
3103973|NCT02135861|Experimental|Healthy volunteers|All subjects will undergo MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 Tesla (T) system.
3103974|NCT02135861|Experimental|Heart failure patients|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system.
3103975|NCT02135861|Experimental|Acute decompensated heart failure|All subjects will undergo DCE-MRI scanning conducted by experienced radiographers and radiologists in the nominated scanning sites, using a 1.5 T system
3103976|NCT02135900|Experimental|Heliox|Heliox which is a mix of oxygen and helium gase will be administered through a face mask during part of the sleep study.
3103977|NCT02136004|Experimental|Closer VSS|Rex Medical Closer Vascular Sealing System to close femoral arteriotomy
3103982|NCT02136238|Active Comparator|Prosthetic hand 1 (Hosmer 5XA)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 1
3103983|NCT02136238|Active Comparator|Prosthetic hand 2 (TRS Grip 3)|This arm of the study included unilateral transradial amputees who who were assessed while using prosthetic hand 2
3103984|NCT02136238|No Intervention|Non-amputee controls|This was an observational arm including non-amputees who were assessed as non-impaired control subjects. There are no interventions in this observational arm of the study.
3103985|NCT02136420|Experimental|Tilt perception, Training, placebo|placebo
3103986|NCT02136420|Placebo Comparator|Tilt perception, No training, placebo|subject does test with no hypergravity training and placebo drug only
3103987|NCT02136420|Experimental|Tilt perception, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3103988|NCT02136420|Experimental|Tilt perception,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment. No hypergravity training
3103989|NCT02136420|Experimental|Manual Control, Training, placebo|placebo
3103990|NCT02136420|Placebo Comparator|Manual Control, No training, placebo|subject does test with no hyper gravity training and placebo drug only
3103991|NCT02136420|Experimental|Manual Control, Training, promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3103992|NCT02136420|Experimental|Manual Control,No training,promethazine|promethazine 25 mg, one time 120 minutes prior to experiment
3103993|NCT02136420|Experimental|Perceptual thresholds,drug then placebo|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with promethazine then once with placebo, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
3103994|NCT02136420|Experimental|Perceptual thresholds,placebo then drug|"Subjects undergo perceptual motion threshold tests to determine the smallest motion they can reliably sense for yaw rotation, interaural translation and roll tilt. Each subject is tested twice, once with placebo then once with promethazine, separated by >4 days.~This arm corresponds to results published in Diaz-Artiles et al 2017."
3103995|NCT02136498|Active Comparator|mHealth self-help + varenicline|Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.
3103996|NCT02136498|Experimental|mHealth MyMAP program + varenicline|Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects & secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.
3103997|NCT02136576|Active Comparator|Sensodyne|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3103998|NCT02136576|Active Comparator|Crest Cavity Protection & MI Paste Plus|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3103999|NCT02136576|Active Comparator|Clinpro 5000|There are no specific characteristics for inclusion in this group. Enrollment will be determined randomly.
3104000|NCT02136680|Active Comparator|Patients at Intervention Site|Staff receives CASA Education
3104001|NCT02136680|No Intervention|Patients at CONTROL site|Staff does not receive CASA Education
3104002|NCT02136914|Experimental|ADS-5102|ADS-5102 (amantadine HCl extended release)
3104003|NCT02136914|Placebo Comparator|Placebo|Placebo
3104004|NCT02137226|Experimental|BI 695501|one injection every 2 weeks for 48 weeks (25 injections in total)
3104005|NCT02137226|Active Comparator|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
3469133|NCT03889327|Experimental|Cognitive Feedback and Psychoeducation (CFP)|Participants assigned to the cognitive feedback and psychoeducation (CFP) treatment group will watch a brief video integrating both neuropsychological test feedback and psychoeducation. The computerized intervention will cover MS disease-related information, define objective cognition, explain neuropsychological assessment, and inform patients of their cognitive test performance outcomes. The CFP intervention will also define and explain perceived cognition and subjective measures of cognition, and compare objective performance on neuropsychological tests to a subjective measure of perceived cognition. The intervention will also discuss emotion, attention, and misattribution related to PCI. The proposed intervention will incorporate expert testimony on MS disease course and related symptomology and interpretations of neuropsychological test performance.
3104008|NCT02137369|Active Comparator|SSRI|Escitalopram, pill form, 20mg-40mg, daily, for 12 weeks or Sertraline, pill form, 50 - 150 mg, daily for 12 weeks
3104009|NCT02137369|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) CBT will include 16 1-hour sessions provided over 12 weeks.
3104010|NCT02137382|Experimental|Creon N, then Creon®|Subjects first received Creon N for 5 days. After a washout period of 3 to 14 days, they received Creon® for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
3104011|NCT02137382|Experimental|Creon® , then Creon N|Subjects first received Creon® for 5 days. After a washout period of 3 to 14 days, they received Creon N for 5 days. The Investigator calculated the total number of capsules per day needed to treat the subject with 8000 to <10000 lipase units per kg body weight and day, Capsules of both Creon N and Creon® contain 25000 lipase units.
3104012|NCT02137447|Experimental|Negative Pressure Wound Therapy|"After the completion of the operation, incisional skin closure was performed using sutures or staples and the wound was then covered with the Negative Pressure Wound therapy Prevena Incision Management System (Kinetic Concepts Inc) as per the manufacturer's instructions of use. Continuous negative pressure was applied at 125 mm Hg.~For inpatients, wounds were assessed every 48 hours by inspection and palpation. The dressing was not routinely removed, but the surrounding skin was assessed for cellulitis. The NPWT dressing was removed between post-operative day 5 and 7"
3104013|NCT02137486||sequential ballooning|include BMS or DES
3104014|NCT02137486||final kissing ballooning|include BMS or DES
3104015|NCT02137499|Active Comparator|Healthy subjects|Healthy subjects, free from vascular disease
3104016|NCT02137499|Experimental|Superficial venous insufficiency|Clinically symptomatic and ultrasound evidence of superficial venous insufficiency
3104017|NCT02137499|Experimental|Deep venous insufficiency|Clinically symptomatic and ultrasound evidence of deep venous insufficiency
3104018|NCT02137499|Experimental|Deep venous obstruction|Clinically symptomatic and ultrasound evidence of deep venous obstruction
3104019|NCT02137512|Experimental|Closed-Loop Control System|Use of an investigational control-to-range automated insulin management (artificial pancreas) system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes in the home environment.
3104020|NCT02137512|Active Comparator|Sensor-Augmented Pump (SAP)|Use of a study-assigned commercial continuous glucose monitoring (CGM) system and commercial insulin pump
3104021|NCT02137538|Active Comparator|Letrozole|Letrozole 2.5 mg daily
3104022|NCT02137538|Active Comparator|Anastrozole|Anastrozole 1 mg daily
3104023|NCT02137603|Experimental|Fast track|Patients discharged home the same day following appendectomy
3104024|NCT02137603|No Intervention|Admission|Patients are admitted to the inpatient unit following appendectomy for suppurative appendicitis and treated per the current standard of care.
3104025|NCT02137772|Experimental|Letermovir|Letermovir oral or intravenous (IV) formulation was administered once daily for up to 14 weeks, beginning up to Day 28 days post-transplant. The dose was 240 mg once daily for participants receiving concomitant cyclosporin A and 480 mg once daily for participants not receiving cyclosporin A. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
3104026|NCT02137772|Placebo Comparator|Placebo|Placebo oral or IV formulation was administered once daily for up to 14 weeks, beginning up to Day 28 post-transplant. The number of placebo tablets was to mimic that for letermovir administration according to the concomitant cyclosporin A status. Intravenous infusion was administered only to participants who are unable to swallow tablets or who have a condition that may interfere with absorption of the tablets.
3104027|NCT02137785|Experimental|ALA|
3104028|NCT02137785|Placebo Comparator|Vehicle|
3104029|NCT02137837|Placebo Comparator|Arm 1: fulvestrant + everolimus placebo + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral placebo daily for both everolimus and anastrozole. This treatment regimen will continue until disease progression or toxicity.
3104030|NCT02137837|Experimental|Arm 2: fulvestrant + everolimus + anastrozole placebo|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive an oral everolimus and an oral placebo for anastrozole daily. This treatment regimen will continue until disease progression or toxicity.
3104031|NCT02137837|Experimental|Arm 3: fulvestrant + everolimus + anastrozole|Patients receive an injection of fulvestrant in each buttock on Days 1 &15 for Cycle 1 and then Day 1 only for subsequent cycles. Patients also receive everolimus and anastrozole by mouth daily. This treatment regimen will continue until disease progression or toxicity.
3104032|NCT02138006|Experimental|Intensive insulin treatment|Intensive insulin treatment
3104033|NCT02138006|Active Comparator|Standard insulin treatment|Standard insulin treatment
3104034|NCT02138097||Glitazones|
3104035|NCT02138097||Linagliptin|
3104036|NCT02138097||Meglitinides|
3104037|NCT02138097||Metformin|
3104038|NCT02138097||Non-insulin injectables|
3104039|NCT02138097||Saxagliptin|
3104040|NCT02138097||Sitagliptin|
3104041|NCT02138097||Sulfonylurea|
3104042|NCT02138110|Experimental|Neuro-Spinal Scaffold|Implantation of a Neuro-Spinal Scaffold into the epicenter of the post-irrigation contusion cavity during open spine surgery
3104043|NCT02138136|Experimental|Lubiprostone|"Participants receive lubiprostone twice daily~Participants must have completed the entire 12-week treatment period during the preceding study. Those who received 12 mcg twice daily (BID) continued to receive 12 mcg, those who received 24 mcg BID continued with that dose.Those of the placebo arm in the previous study weighing less than 50 kg received 12 mcg BID and over 50 kg received 24 mcg BID during this study."
3104044|NCT02138214|Experimental|Arm I (no CND)|Patients undergo total thyroidectomy alone.
3104045|NCT02138214|Experimental|Arm II (CND)|Patients undergo total thyroidectomy with ipsilateral prophylactic CND.
3104046|NCT02138214|Active Comparator|Arm III (SOC)|Patients who are not eligible for randomization into Arm I or Arm II, Standard of Care (SOC) group. No specific trial intervention, treated as per patient and physician preference
3104047|NCT02138227|Active Comparator|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills.
3104048|NCT02138227|Active Comparator|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
3104049|NCT02138240|Experimental|Social network intervention|"Individuals will be recruited and trained to be Peer Educators who will participate in group sessions and then communicate this information with members of participant's social network (Sidekick) and work to make changes to reduce intake of sugar-sweetened beverages. Peer Educators will participate in 6 core group sessions over a 6-week period as well as 3 additional booster sessions over the subsequent 3 months after completing the core curriculum. All sessions will be delivered by a facilitator and assistant facilitator using a guide."
3104050|NCT02138253|Experimental|IDN-6556|IDN-6556 25 mg BID
3104051|NCT02138253|Placebo Comparator|Placebo|Placebo BID
3104052|NCT02138461||bimatoprost|These patients take bimatoprost topically for glaucoma.
3104053|NCT02138461||latanoprost group|These patients take latanoprost topically for glaucoma.
3132634|NCT03441984|Experimental|Subjects with treatment sequence EFD|The subjects in Part 2 of the study, will receive a single dose respectively of treatment E in TP1, treatment F in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3104054|NCT02138578|Experimental|Randomized SBRT|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Stereotactic Body Radiation Therapy (SBRT) will receive SBRT delivered in fractions of 20 Gy, approximately every other day, for a total of three treatments. If the target is deemed too close to organs at risk, 5 fractions of up to 10 Gy per fraction will be prescribed.
3104055|NCT02138578|Active Comparator|Randomized RFA|Patients who meet eligibility criteria (unilateral primary renal cell carcinoma less than 4 cm in greatest diameter) and are randomized to Radiofrequency Ablation (RFA) will receive RFA.
3104056|NCT02138578|Active Comparator|Non-Randomized SBRT|Patients with renal cell carcinoma's greater than or equal to 4 cm in diameter, and up to 8 cm in diameter, may be placed in the non-randomized stereotactic body radiation therapy arm. Patients with tumors not amenable to RFA, those with metastatic disease, and those who elect a noninvasive means of treatment will also be eligible to receive treatment in the non-randomized SBRT cohort.
3104057|NCT02138747|Experimental|AB: Mirabegron/Tolterodine ER|In the treatment sequence AB participants received 25 mg of mirabegron (Myrbetriq) oral controlled absorption system (OCAS) modified-release tablets and 4 mg of placebo-to-match (PTM) tolterodine ER (Detrol LA) orally once a day during period 1. In the period 2, participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
3104058|NCT02138747|Experimental|BA: Tolterodine ER /Mirabegron|In the treatment sequence BA participants received 4 mg of tolterodine ER and 25 mg of PTM mirabegron (OCAS) modified-release tablets orally once a day during period 1. In the period 2, participants received 25 mg of mirabegron and 4 mg of PTM tolterodine ER orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron or mirabegron PTM was increased to 50 mg for the remainder of the treatment period.
3104059|NCT02138747|Experimental|AA: Mirabegron/Mirabegron|In treatment sequence AA participants received 25 mg of mirabegron and PTM tolterodine ER 4 mg capsules during period 1 and 2 orally once a day. Four weeks after the start of each 8-week treatment period, 25 mg of mirabegron was increased to 50 mg for the remainder of the treatment period.
3104060|NCT02138747|Experimental|BB: Tolterodine ER /Tolterodine ER|Participants received 4 mg of tolterodine ER and PTM mirabegron 25 mg OCAS modified-release tablets orally once a day during period 1 and period 2.
3104061|NCT02138786|Experimental|selinexor|"oral tablets~10 mg & 25 mg (bottled); or~20 mg (blister pack)"
3104062|NCT02138825|Experimental|Riociguat (Adempas, BAY63-2521)|In the main study treatment phase participants received Riociguat titrated to optimal dose within range of 0.5 mg TID (3 times a day) to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded sham titration phase of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
3104063|NCT02138825|Placebo Comparator|Placebo|In the main study treatment phase participants received sham titration within range of 0.5 mg TID to 2.5 mg TID for 10 weeks followed by maintenance period of 16 weeks. This phase was followed by a long-term extension phase, which included a blinded titration phase to optimal dose of Riociguat of 10 weeks followed by an open-label extension phase. During the open-label extension phase participants were to be treated with Riociguat until commercial access in the indication of PH associated with IIP or until an agreed time point is defined with the individual country, local regulatory authority and the Sponsor's global team.
3104064|NCT02138838|Active Comparator|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
3104065|NCT02138838|Experimental|Cinacalcet|In addition to standard of care participants received cinacalcet at a starting dose (based on dry body weight) of 0.20 mg/kg administered once a day by mouth. Dose adjustments and withholding were based on ionized calcium levels, plasma iPTH, and corrected calcium levels.
3104066|NCT02138890|Experimental|APS injection|Autologous Protein Solution
3104067|NCT02138890|Placebo Comparator|Control|Saline
3104068|NCT02138916|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3104069|NCT02138916|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3104070|NCT02138916|Placebo Comparator|Placebo|Placebo administered subcutaneously
3104071|NCT02139007|Active Comparator|Continuation Arm|Alendronate continuation arm
3104072|NCT02139007|Active Comparator|Discontinuation Arm|Alendronate discontinuation arm
3104073|NCT02139046|Active Comparator|Febuxostat IR 40 mg|Febuxostat Immediate Release (IR) 40 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day (for participants with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min) or every other day (if eGFR ≥ 15 - ≤ 59 mL/min), or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3104074|NCT02139046|Active Comparator|Febuxostat IR 80 mg|Febuxostat IR 80 mg over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3104075|NCT02139046|Experimental|Febuxostat XR 40 mg|Febuxostat Extended Release (XR) 40 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3104076|NCT02139046|Experimental|Febuxostat XR 80 mg|Febuxostat XR 80 mg over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3104077|NCT02139046|Placebo Comparator|Placebo|Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every day or every other day, or, alternatively, if colchicine is not tolerated and the subject's eGFR is ≥ 50 mL/min, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months.
3104078|NCT02139124|Placebo Comparator|Placebo|Placebo Arm
3104079|NCT02139124|Experimental|PRC-063 25 mg|PRC-063 25 mg
3104080|NCT02139124|Active Comparator|PRC-063 45 mg|PRC-063 45 mg
3104081|NCT02139124|Active Comparator|PRC-063 70 mg|PRC-063 70 mg
3104082|NCT02139124|Active Comparator|PRC-063 100 mg|PRC-063 100 mg
3104083|NCT02139137|Experimental|High Interference Control Condition|Computerized training program requiring participants to repeatedly practice controlling interference on a cognitive task
3104084|NCT02139137|Active Comparator|Low Interference Control Condition|Computerized training program requiring participants to minimally practice controlling interference on a cognitive task
3104085|NCT02139176|Active Comparator|Patient referral|Women are given an invitation to give to a male partner inviting them to come to the clinic for important pregnancy information
3104086|NCT02139176|Experimental|contract referral|Same as control. However, if the male partner does not present, a community worker will trace the partner in the community.
3104087|NCT02139228|Experimental|Hib CRM197|"Subjects treated with 3 doses of CRM 197 -conjugate Haemophilus influenzae type b vaccine (study vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
3104088|NCT02139228|Active Comparator|Hib TT|"Subjects treated with 3 doses of Tetanus Toxoid-conjugate Haemophilus influenzae type b vaccine (comparator vaccine): 2 doses given one month apart during study V37_07 (NCT01044316) and a booster dose of the same vaccine six months after, during study V37_07E1 (NCT01226953).~No vaccine was administered during this trial"
3104089|NCT02139280|Active Comparator|Arm 2: Cyclophosphamide 3 gms/m(2)|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).
3104090|NCT02139280|Experimental|Arm 1: 1.5 gms/m(2) Cyclophosphamide|Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).
3104091|NCT02139306|Experimental|Ataluren (PTC124®)|Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
3104092|NCT02139306|Placebo Comparator|Placebo|Participants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.
3104093|NCT02139358|Experimental|Dose Escalation / Phase II Treatment|Single arm, non-randomized, open label phase I/II multisite Simon two stage minimax trial. Gemcitabine plus trastuzumab and pertuzumab.
3104094|NCT02139540|Other|N2O/Placebo|First session: Nitrous oxide Second session: placebo
3104095|NCT02139540|Other|Placebo/N2O|First session: Placebo Second session: Nitrous Oxide
3104096|NCT02139592||brentuximab vedotin (recombinant) Intravenous infusion|Intravenous infusion of 1.8 mg/kg (body weight) of brentuximab vedotin (recombinant) administered once every three weeks
3104097|NCT02139644|Experimental|FS MDPI 100 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3104098|NCT02139644|Experimental|FS MDPI 50 / 12.5 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg (for a total daily dose of 100 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3104099|NCT02139644|Experimental|Fp MDPI 100 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg for a total daily dose of 200 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3104100|NCT02139644|Experimental|Fp MDPI 50 mcg|"Patients took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 50 mcg for a total daily dose of 100 mcg for 12 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3104101|NCT02139644|Placebo Comparator|Placebo MDPI|"The placebo multidose dry powder inhaler was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart).~Albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3104102|NCT02139800|Active Comparator|Control Arm-Standard of care|Control Arm-Respiratory support using Standard of Care positive-end expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O compared to Sustained Inflation intervention
3104103|NCT02139800|Experimental|Sustained Intervention|Administer delivery room respiratory support using a Sustained Inflation (SI) intervention and expiratory pressure/continuous positive airway pressure (PEEP/CPAP) of 5-7 cm H2O
3104104|NCT02139826|Experimental|IX-01 Capsule while Fasting|Singe oral dose of 800 milligrams of IX-01 as a capsule, while fasting, in 1 of 3 treatment periods
3104105|NCT02139826|Experimental|IX-01 Aqueous Dispersion while Fasting|Single oral dose of 800 milligrams IX-01 as an aqueous dispersion, while fasting in 1 of 3 treatment periods
3104106|NCT02139826|Experimental|IX-01 Capsule after Food|Single oral dose of 800 milligrams IX-01 as a capsule, after food, in 1 of 3 treatment periods
3104107|NCT02139878|Experimental|Wild blueberry juice|240 ml wild blueberry juice
3104108|NCT02139878|Placebo Comparator|Placebo wild blueberry juice|240 ml placebo wild blueberry juice
3104109|NCT02139943|Experimental|Canagliflozin 100 mg|Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
3104110|NCT02139943|Experimental|Canagliflozin 300 mg|Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
3104111|NCT02139943|Placebo Comparator|Placebo|Each participant will receive matching placebo once daily for 18 weeks
3104112|NCT02139969||GreenLight XPS Laser System|Treatment of BPH in men using the GreenLight XPS Laser System and the MoXy fiber
3104113|NCT02139982|Other|group MC(phase 1)|specific nerve block:musculocutaneous nerve block
3104114|NCT02139982|Other|group UL( phase 1)|specific nerve block:ulnar nerve block
3104115|NCT02139982|Other|group RA (phase 1)|specific nerve block:radial nerve block
3104116|NCT02139982|Other|group ME (phase 1)|specific nerve block:median nerve block
3104117|NCT02139982|Experimental|group A(phase 2)|30ml ropivacaine 0.125%
3104118|NCT02139982|Experimental|group B(phase 2)|30ml ropivacaine 0.2%
3104119|NCT02139982|Experimental|group C(phase 2)|30ml ropivacaine 0.25%
3104120|NCT02139982|Experimental|group D(phase 2)|30ml ropivacaine 0.375%
3104121|NCT02139982|Experimental|group E(phase 2)|30ml ropivacaine 0.5%
3104122|NCT02139982|Experimental|group F(phase 2)|30ml ropivacaine 0.75%
3104123|NCT02140060|Experimental|TravA/Brinz|Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3104124|NCT02140060|Experimental|TravB/Brinz|Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3104125|NCT02140060|Experimental|TravC/Brinz|Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3104126|NCT02140060|Active Comparator|AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks
3104127|NCT02140060|Active Comparator|TRAV Z|Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3104128|NCT02140060|Active Comparator|TRAV Z + AZOPT|Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks
3104129|NCT02140164|Experimental|Minocycline|Oral administration of minocycline
3104130|NCT02140372|Experimental|Volunteer group|Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later
3104131|NCT02140411|Experimental|Ranibizumab|Ranibizumab treatment
3104132|NCT02140567||Syncope Prediction|All enrolled patients that performed the tilt table test
3104133|NCT02140593|Placebo Comparator|Standard neuromuscular blockade|Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment decided by the attending anesthetist combined with saline infusion (placebo).
3104134|NCT02140593|Active Comparator|Deep neuromuscular blockade|Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level post tetanic count (PTC) of 0-1 combined with bolus saline (placebo) mimicking standard treatment.
3104135|NCT02140645||Linagliptin1|T2DM patients initiating Linagliptin (DPP-4 comparison)
3104136|NCT02140645||Other DPP4|T2DM patients initiating a non-linagliptin DPP-4 inhibitor
3104137|NCT02140645||Linagliptin2|T2DM patients initiating Linagliptin (glitizaone comparison)
3104138|NCT02140645||Glitazones|T2DM patients initiating Thiazolidinediones (glitazones)
3104139|NCT02140645||Sulfonylurea|T2DM patients initiating any medication in the Sulfonylurea class
3104140|NCT02140645||Linagliptin3|T2DM patients initiating Linagliptin (Sulfonylurea comparison)
3104141|NCT02140762|Experimental|MenABCWY|Subjects received one dose of MenABCWY vaccine at day 1 and a second dose after 2 months
3104142|NCT02140762|Active Comparator|Placebo/MenACWY|Subjects received one dose of placebo at day 1 and one dose of MenACWY vaccine after 2 months
3104143|NCT02140775|Experimental|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
3104144|NCT02140775|Active Comparator|Supportive Counseling|Supportive Counseling sessions will follow the same schedule and the Behavioral Activation Counseling, meeting for one hour every two weeks. The content of the sessions will be guided by the participant. The counselor will provide an accepting environment for the participant to explore his/her feelings about these topics.
3104145|NCT02140957|Experimental|Educational Intervention|Parents in this arm received a 5 minute educational intervention on bottle cessation plus standard nutritional counseling.
3104146|NCT02140957|Placebo Comparator|Control|Parents in this arm received a placebo which consisted of standard nutritional counseling alone.
3104147|NCT02140970|Experimental|Liquid ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
3104148|NCT02140970|Placebo Comparator|Liquid placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
3104149|NCT02141204|Experimental|HRV Liq Group|Subjects aged 6 to 10 weeks at the time of first vaccination, who received two oral doses of Liquid Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
3104150|NCT02141204|Active Comparator|HRV Lyo Group|Subjects aged 6 to 10 weeks at the time of first vaccination who received two oral doses of Lyophilized Human Rotavirus Vaccine (HRV) according to a two-dose schedule, at Day 1 and Month 1.
3104151|NCT02141217|Active Comparator|Amoxicillin/clavulanate|Amoxicillin/ clavulanate 1 g bd for for at least 5 days upto seven days depending on treament response
3104152|NCT02141217|Active Comparator|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon treatment response
3104153|NCT02141295|Experimental|Part 1 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose of 2000 milligram (mg) as intravenous (IV) infusion; oxaliplatin at a dose of 85 mg per meter-squared (mg/m^2) as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3104154|NCT02141295|Experimental|Part 1 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during induction as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3104155|NCT02141295|Active Comparator|Part 2 (Induction): Bevacizumab + mFOLFOX-6|Participants will receive bevacizumab at a dose of 5 milligram per kilogram (mg/kg) as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3104156|NCT02141295|Experimental|Part 2 (Induction): Vanucizumab + mFOLFOX-6|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; oxaliplatin at a dose of 85 mg/m^2 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks for up to 8 cycles (approximately 4 months).
3104157|NCT02141295|Active Comparator|Part 2 (Maintenance): Bevacizumab + 5-FU + Folinic acid|Participants will receive bevacizumab at a dose of 5 mg/kg as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3104158|NCT02141295|Experimental|Part 2 (Maintenance): Vanucizumab + 5-FU + Folinic acid|Participants will receive vanucizumab at a dose confirmed during part 1 as IV infusion; folinic acid at a dose of 400 mg/m^2 as IV infusion; and 5-FU at a dose of 400 mg/m^2 as starting IV bolus followed by 2400 mg/m^2 as IV infusion every 2 weeks until disease progression, unacceptable toxicities, consent withdrawal or Investigator's decision for a maximum of 24 months.
3104159|NCT02141360|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3104160|NCT02141360|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3104161|NCT02141399|Experimental|ALKS 5461|
3104162|NCT02141451|Experimental|INCB7839 100 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
3104163|NCT02141451|Experimental|INCB7839 200 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
3104164|NCT02141451|Experimental|INCB7839 300 mg (Phase I)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
3104165|NCT02141451|Experimental|INCB7839 (Phase II)|Rituximab will be given after day +28 re-staging and again 1 and 7 weeks later, followed by INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab Rituximab: Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later INCB7839: INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
3104166|NCT02141490|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|Ferumoxytol +MRI
3104167|NCT02141516|Experimental|Group A|Complement deficiency
3104168|NCT02141516|Experimental|Group B|asplenia/splenic dysfunction
3104169|NCT02141516|Active Comparator|Group C|age-matched healthy controls
3104170|NCT02141555|Active Comparator|Vaginal misoprostol|Participants will insert four misoprostol tablets (total of 800 micrograms) deeply into the vagina with their fingers.
3104171|NCT02141555|Experimental|Buccal Misoprostol|Participants will place two tablets of misoprostol between their gum and cheek on each side (total 800 micrograms), then swish and swallow the remnants after 30 minutes.
3104172|NCT02141581|Experimental|Group A Fluzone® (IM)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone®, administered intramuscularly (IM)~2011-2012, 2012-2013 or 2013-2014 Fluzone was used as appropriate for the current year of study"
3104173|NCT02141581|Experimental|Group B Fluzone® Intradermal (ID)|"Participants in this group will be randomized to the trivalent inactivated influenza vaccine (TIV), Fluzone® Intradermal, administered intradermally (ID)~2011-2012, 2012-2013 or 2013-2014 Fluzone Intradermal was used as appropriate for the current year of study"
3104174|NCT02141581|Experimental|Group C 2011-2012 FluMist®|"Participants in this group will be randomized to 2011-2012 live attenuated influenza vaccine, FluMist®, administered intranasally.~FluMist was only used in the first year of study."
3104175|NCT02141620|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo.
3104176|NCT02141620|Experimental|n-Acetylcysteine|Subjects will be maintained on oral n-acetylcysteine.
3104177|NCT02141633|Experimental|smokers|participants with smoking history ( > 10 pack/year) will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
3104178|NCT02141633|Experimental|non-smokers|healthy life-time non smokers will be enrolled and perform airway blood flow and echocardiogram before and 15 minutes after albuterol inhalation
3104179|NCT02141659|Experimental|Part A Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
3104180|NCT02141659|Experimental|Part A Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
3104181|NCT02141659|Experimental|Part A Cohort 3: TAK-385 320 mg + TAK-385 160 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 160 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
3104182|NCT02141659|Experimental|Part A Cohort 4: TAK-385 360 mg + TAK-385 120 mg|TAK-385 360 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 28.
3104183|NCT02141659|Experimental|Part B Cohort 1: TAK-385 320 mg + TAK-385 80 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 80 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
3104184|NCT02141659|Experimental|Part B Cohort 2: TAK-385 320 mg + TAK-385 120 mg|TAK-385 320 mg loading dose, tablet, orally, once on Day 1, followed by TAK-385 120 mg maintenance dose, tablet, orally, once daily through Days 2 to 672.
3104185|NCT02141672|Experimental|Voclosporin Low Dose|Voclosporin, oral, 23.7 mg BID
3104186|NCT02141672|Experimental|Voclosporin High Dose|Voclosporin, oral 23.7 mg BID until Week 2, then voclosporin, oral, 39.5 mg BID
3104187|NCT02141672|Placebo Comparator|Placebo|"Low dose: Voclosporin placebo, oral, 3 capsules BID~High dose: Voclosporin placebo, oral, 3 capsules BID until Week 2 then voclosporin placebo, oral, 5 capsules BID"
3104188|NCT02141854|Experimental|FS MDPI 200 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
3104189|NCT02141854|Experimental|FS MDPI 100 / 12.5 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.
3104190|NCT02141854|Experimental|Fp MDPI 200 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.
3104191|NCT02141854|Experimental|Fp MDPI 100 mcg|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.
3104192|NCT02141854|Placebo Comparator|Placebo MDPI|Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.
3104193|NCT02141867||Noncardiac surgical patients|Noncardiac surgery patients 16 years or older undergoing inpatient surgery
3104194|NCT02141984||Patients with Polyarticular JIA or ERA|Patients with polyarticular juvenile idiopathic arthritis (JIA) or enthesitis-related arthritis (ERA)
3104195|NCT02141997|Active Comparator|Adalimumab 40 mg EOW|Adalimumab 40 mg every other week (EOW) for 11 weeks.
3104196|NCT02141997|Experimental|ABT-122 60 mg EOW|ABT-122 60 mg every other week (EOW) for 11 weeks.
3104197|NCT02141997|Experimental|ABT-122 120 mg EOW|ABT-122 120 mg every other week (EOW) for 11 weeks.
3104198|NCT02141997|Experimental|ABT-122 120 mg EW|ABT-122 120 mg every week (EW) for 11 weeks.
3104199|NCT02142049|Experimental|Part 1: Dose Level 1|Ibrutinib 560 mg PO + DA-EPOCH-R
3104200|NCT02142049|Experimental|Part 1: Dose Level 2|Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R
3104201|NCT02142049|Experimental|Part 1: Dose Level 3|Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R
3104202|NCT02142049|Experimental|Part 1: Dose Level 4|Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
3104203|NCT02142049|Experimental|Part 2: RP2D|Recommended Phase 2 Dose(RP2D): Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R
3104204|NCT02142153|Experimental|F901318 0.25 mg/kg|Single intravenous infusion over 4 hours
3104205|NCT02142153|Placebo Comparator|0.25 mg/kg placebo|Single intravenous infusion over 4 hours
3104206|NCT02142153|Experimental|F901318 0.75 mg/kg|Single intravenous infusion over 4 hours
3104207|NCT02142153|Placebo Comparator|Placebo 0.75 mg/kg|Single intravenous infusion over 4 hours
3104208|NCT02142153|Experimental|F901318 1.5 mg/kg|Single intravenous infusion over 4 hours
3104209|NCT02142153|Placebo Comparator|Placebo 1.5 mg/kg|Single intravenous infusion over 4 hours
3104210|NCT02142153|Experimental|F901318 mg/kg|Single intravenous infusion over 4 hours
3104211|NCT02142153|Placebo Comparator|Placebo 3 mg/kg|Single intravenous infusion over 4 hours
3104212|NCT02142153|Experimental|F901318 5 mg/kg|Single intravenous infusion over 4 hours
3104213|NCT02142153|Placebo Comparator|Placebo 5 mg/kg|Single intravenous infusion over 4 hours
3104214|NCT02142283|Experimental|Trevo Thrombectomy Procedure|Trevo Thrombectomy Procedure and Medical Management
3104215|NCT02142283|Active Comparator|Medical Management|Medical Management
3104216|NCT02142361|Active Comparator|Omafilcon A/Enfilcon A|Subject's habitual hydrogel toric lenses Omafilcon A will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3104217|NCT02142361|Active Comparator|Ocufilcon D/Enfilcon A|Subject's habitual hydrogel toric lenses Ocufilcon D will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3104218|NCT02142361|Active Comparator|Methafilcon B/ Enfilcon A|Subject's habitual hydrogel toric lenses Methafilcon B will be evaluated at the first visit and then re-fitted with a pair of Enfilcon A lenses.
3132635|NCT03441984|Experimental|Subjects with treatment sequence FDE|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment D in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3132636|NCT03441984|Experimental|Subjects with treatment sequence DFE|The subjects in Part 2 of the study, will receive a single dose of treatment D in TP1, treatment F in TP2 and treatment E in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3104219|NCT02142387|Active Comparator|New DA-BLS training program|A one-hour training course that includes a 30-minute video-based self-instruction (VSI) training session, a short role-play, and a debriefing. The video consists of a bystander CPR simulation with dispatcher instructions using the trainee's own phone and practice session following demonstration by a simulated layperson. After watching the video clip, all trainees are divided into two groups and conduct a role-play as dispatchers and laypersons for 15 minutes. Finally, there is a 15-minute debriefing session with several assignments. The HEROS program focuses on cooperation with a dispatcher, from recognition of cardiac arrest to performing DA-CPR, with hands-on practice so that laypersons can provide bystander CPR immediately in a real situation. Moreover, the HEROS program emphasizes practice for providing the correct address of the scene and switching to speakerphone mode, especially for the elderly.
3104220|NCT02142387|No Intervention|Current Basic Life Support (BLS) training program|A one-hour training program that was developed by the Korea Center for Disease Control and Prevention (CDC) and it was based on the American Heart Association (AHA) guideline (http://www.cdc.go.kr/board.es?mid=a20503050000&bid=0021&tag=&act=view&list_no=127655). The program consists of a 30-minute VSI, and a 30-minute practice debriefing session. It focuses on detailed techniques for performing high-quality chest compressions including the correct hands and body position of the bystanders.
3104221|NCT02142504|Experimental|GI.1/GII.4 15/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|Intramuscular (IM) norovirus bivalent virus like particle (VLP) vaccine (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3104222|NCT02142504|Experimental|GI.1/GII.4 50/50 μg - MPL 50 μg + GI.1/GII.4 15/15 μg (no MPL)|IM norovirus bivalent VLP vaccine (50 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP) adjuvanted with 50 µg monophosphoryl lipid A (MPL) and 500 µg aluminum hydroxide, on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3104223|NCT02142504|Placebo Comparator|Saline Placebo + GI.1/GII.4 15/15 μg (No MPL)|IM saline placebo on Day 1, followed by IM norovirus bivalent VLP vaccine (15 µg of GI.1 norovirus VLP and 15 µg GII.4 norovirus VLP ) adjuvanted with 500 µg aluminum hydroxide (no MPL), on Day 365.
3104224|NCT02142608|Experimental|BR55|All patients received BR55 as a single intravenous injection at the dose of 0.03 mL/kg...
3104225|NCT02142712|Active Comparator|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
3104226|NCT02142712|Active Comparator|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
3104227|NCT02142712|Experimental|Dextromethorphan|"Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care.~If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration."
3104228|NCT02142712|Experimental|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
3104229|NCT02142738|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles.
3104230|NCT02142738|Active Comparator|Paclitaxel+Carboplatin|Participants receive paclitaxel 200 mg/m^2 and carboplatin Area Under the Curve (AUC) 5 or 6, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for participants with non-squamous histologies for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3104231|NCT02142738|Active Comparator|Pemetrexed+Carboplatin|Participants receive pemetrexed 500 mg/m^2 and carboplatin AUC 5 or 6, IV infusion on Day 1 of each 21-day cycle for 4-6 cycles; participants with non-squamous histologies may then receive pemetrexed 500 mg/m^2 on Day 1 of each 21-day cycle as maintenance therapy for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3104232|NCT02142738|Active Comparator|Pemetrexed+Cisplatin|Participants receive pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 Q3W maintenance for the remainder of the study or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3104233|NCT02142738|Active Comparator|Gemcitabine+Carboplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and carboplatin AUC 5 or 6, administered as IV infusion on Day 1 of a 21-day cycle, for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3104234|NCT02142738|Active Comparator|Gemcitabine+Cisplatin|Participants receive gemcitabine 1250 mg/m^2, administered as IV infusion on Days 1 and 8 of each 21-day cycle and cisplatin 75 mg/m^2, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles or until documented PD or participant discontinuation. If PD occurs, participants may be able to receive pembrolizumab Q3W in a second course of treatment.
3104235|NCT02142894||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
3104236|NCT02143024|Experimental|Family-based depression intervention|The family-focused component will consist of up to up to 10 joint (i.e. older man alone and/or with family members) sessions that will cover specific topics related to family support of men's depression care provided by a clinic-based social worker
3104237|NCT02143024|Active Comparator|Usual care plus educational materials|Control subjects will receive usual care in the clinic enhanced by a single depression psychoeducation session.
3104238|NCT02143063|Active Comparator|standard care|standard care
3104239|NCT02143063|Active Comparator|standard care plus traditional contingency managment|prize contingency management on a traditional twice weekly schedule for cocaine abstinence
3104240|NCT02143063|Experimental|standard care plus variable interval contingency management|prize contingency management on a variable interval schedule for cocaine abstinence
3104241|NCT02143102||Training set|Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.
3104242|NCT02143102||Testing set|Data from subjects in the testing set will be used to assess the study endpoints.
3104243|NCT02143141|Active Comparator|duramorph|duramorph 150 mcg administered spinally with placebo capsules administered by mouth every 6 hours x 4 doses during first 24 hours
3104244|NCT02143141|Experimental|no duramorph|no duramorph is administered spinally for surgery; subjects receive acetaminophen 1 G orally x 4 doses during first 24 hours postoperatively
3104245|NCT02143310|Experimental|EVP|Subject who use the EVP for up to 2 years
3104246|NCT02143583||AllerT 100 μg|patients having received AllerT at a first dose of 50 μg and 4 maintenance doses of 100 μg in study AN004T
3104247|NCT02143583||AllerT 50 μg|patients having received AllerT at a first dose of 25 μg and 4 maintenance doses of 50 μg in study AN004T
3104248|NCT02143583||Placebo|Patients having received Placebo (i.e., adjuvant alone) delivered in the same manner as AllerT in study AN004T
3104249|NCT02143648|Experimental|nalbuphine HCl ER 60mg|nalbuphine HCl ER tablets 60 mg BID
3104250|NCT02143648|Experimental|nalbuphine HCl ER 120mg|nalbuphine HCl ER tablets 120 mg BID
3104251|NCT02143648|Placebo Comparator|Sugar pill|Placebo tablets BID
3104252|NCT02143713|Experimental|Elagolix 150 mg QD|Participants received elagolix 150 mg tablets once a day (QD) for 6 months.
3104253|NCT02143713|Experimental|Elagolix 200 mg BID|Participants received elagolix 200 mg tablets twice a day (BID) for 6 months.
3104254|NCT02143778|Experimental|Compensated cirrhotic patients|A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
3104255|NCT02143843|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new 13 mg Bimatoprost Ocular Insert and used continuously for another 6 months.
3104256|NCT02143947|Experimental|Full Contact Orthosis|Full Contact Orthosis
3104257|NCT02143947|Experimental|Maximal Arch Subtalar Stabilization|Maximal Arch Subtalar Stabilization Orthoses
3104258|NCT02143973|Experimental|nalbuphine HCl ER|nalbuphine HCl ER titrated from a dose of 30 mg QD to 120 BID for up to 3 weeks based on tolerability and efficacy, then maintained for an additional 21 weeks. Total duration of 24 weeks.
3104259|NCT02144012|Experimental|Arm A: Trastuzumab emtansine|Participants will be administered trastuzumab emtansine once every three weeks (Q3W). Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
3104260|NCT02144012|Active Comparator|Arm B: Trastuzumab + Docetaxel|Participants will be administered trastuzumab plus docetaxel Q3W. Participants may remain on study treatment until investigator assessed disease progression, unacceptable toxicity, or Sponsor study termination occurs, whichever occurs first.
3104261|NCT02144077|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
3104262|NCT02144077|Active Comparator|methyl-aminolevulinate|Topical application of Metvix creme containing 160 mg/g methyl-aminolevulinate. Application of a 1 mm thick layer covering each lesion and 0.5 to 1 cm of surrounding margin.
3104263|NCT02144220|Experimental|Virtual care visit|One-time virtual care visit for Parkinson disease.
3104264|NCT02144233|Experimental|Occlusal adjustment therapy|Occlusal adjustment therapy consists of the elimination of premature tooth contacts during retruded jaw closure, and the reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance). A resin-composite, placed mainly in the canine tooth, can be used to increases the flatter lateral guidance on the habitual chewing side; overcorrection is expected to compensate for a masticatory preference on the opposite side to the handedness.
3104265|NCT02144233|Placebo Comparator|Placebo occlusal adjustment therapy|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
3104266|NCT02144259|Active Comparator|DMPA group|Subjects randomized to receive DepoProvera(DMPA) immediately post-partum.
3104267|NCT02144259|Active Comparator|Implanon group|Subjects randomized to receive Implanon immediately post-partum.
3104268|NCT02144259|No Intervention|Control group|Subjects selecting their own method of contraception or no contraception.
3104269|NCT02144285|Experimental|LY3113593 IV (Part A)|Single dose of LY3113593 administered intravenous (IV) at a minimum of six dose levels
3104270|NCT02144285|Placebo Comparator|Placebo IV (Part A)|Single dose of placebo matching LY3113593 administered IV
3104271|NCT02144285|Experimental|LY3113593 SC (Part A)|Single dose of LY3113593 administered subcutaneous (SC)
3104272|NCT02144285|Placebo Comparator|Placebo SC (Part A)|Single dose of placebo matching LY3113593 administered SC
3104273|NCT02144285|Experimental|LY3113593 IV (Part B)|Single dose of LY3113593 administered IV
3104274|NCT02144285|Placebo Comparator|Placebo IV (Part B)|Single dose of placebo matching LY3113593 administered IV
3104275|NCT02144337|Experimental|Intervention group|Steps To Active Kids (STAK) programme (6 weeks) includes: StreetDance DVD designed to be completed at home (4 weeks in total). A dance routine is taught over 4 weeks with new elements introduced each day. Activity diary aims to encourage children to record daily activities in a logbook and to educate children about physical activity. Step counter: Children are given a pedometer and encouraged to record steps in the activity diary and to set personal goals to increase their steps. Weekly group activity sessions for 4 - 6 weeks. Involve a circuit of activity stations varying in intensity. The group sessions are designed to be fun and non-competitive. Children can record their scores at each station and monitor their own progress.
3104276|NCT02144337|No Intervention|Control group|Control group. Children in the Control group are asked to continue normal daily activities.
3104277|NCT02144519|Experimental|Immediate Intervention|Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
3104278|NCT02144519|Experimental|Delayed Intervention|Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.
3104279|NCT02144597|Active Comparator|2-week LCD and Roux-en-Y gastric bypass (RYGB)|A 2-week liquid formula low-calorie diet (LCD) will be administered for 2 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
3104280|NCT02144597|Active Comparator|6-week LCD|A 6-week liquid formula low-calorie diet (LCD) will be administered for 6 weeks prior to Roux-en-Y gastric bypass. The diet will provide 800kcal per day in the form of powdered milkshakes and soups
3104281|NCT02144597|Other|Control diet|1000 calorie diet
3104282|NCT02144610|Experimental|Gene Therapy HGF Plasmid (AMG0001)|Randomized subjects will receive 4 sets of intramuscular (IM) injections of HGF plasmid two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
3104283|NCT02144610|Placebo Comparator|Placebo|Randomized subjects will receive 4 sets of intramuscular (IM) injections of matching placebo two weeks apart starting at Day 0 and again at Month 3 (first cycle) and at Month 9 and again at Month 12 (second cycle) in muscles of the affected lower limb.
3104284|NCT02144675|Experimental|Arm I (choline magnesium trisalicylate and chemotherapy)|Patients receive choline magnesium trisalicylate PO every 8 hours on days 0-7, idarubicin IV on days 1-3, and cytarabine IV continuously on days 1-7.
3104285|NCT02144675|Active Comparator|Arm II (chemotherapy)|Patients receive idarubicin IV on days 1- 3 and cytarabine IV continuously on days 1-7.
3104286|NCT02144701|Experimental|Lactobacillus rhamnosus GG|Patients receive Lactobacillus rhamnosus GG PO QD for 1 year.
3104287|NCT02144701|No Intervention|No intervention|Patients receive no intervention.
3104288|NCT02144714|Experimental|SB5|SB5, single dose of 40 mg via subcutaneous injection (study drug)
3104289|NCT02144714|Active Comparator|EU sourced Humira®|EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
3104290|NCT02144714|Active Comparator|US sourced Humira®|US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)
3104291|NCT02145026|Experimental|Epoetin Beta|Participants will receive epoetin beta at an initial dose of 30,000 International Units (IU) per week administered subcutaneously (SC). Response will be firstly evaluated at Week 4 and the subsequent dose will be based on the response: if hemoglobin level reaches greater than or equal to (>/=)12 grams per deciliter (g/dL) at any time, epoetin beta will be discontinued until hemoglobin levels are less than or equal to (</=) 10 g/dL; if the hemoglobin level increases less than (<) 1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 60,000 IU per week epoetin beta will be administered SC until Week 12; if the hemoglobin level increases >/=1 g/dL from screening level and hemoglobin level ˂12 g/dL, a 30,000 IU per week epoetin beta will be continued until Week 12.
3104292|NCT02145039|Experimental|Haploidentical stem cell transplant|This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen consists of fludarabine, cyclophosphamide and low dose total body irradiation (TBI).
3104293|NCT02145078|Experimental|Treatment (chemotherapy regimen)|Patients receive 1 of 4 chemotherapy regimens at the discretion of the primary oncologist following institutional guidelines, including cisplatin, carboplatin, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. After course 2, patients may continue treatment off-study at the discretion of the treating physician.
3104294|NCT02145156|Experimental|Tailored intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
3104295|NCT02145156|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
3104296|NCT02145156|Other|Usual Care|Intervention: survey-only. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
3104297|NCT02145182|Experimental|Active|Eculizumab was administered by intravenous (IV) infusion over 25-45 minutes (min) for 2 doses (on the day of transplant then 18-24 hours [h] later).
3104298|NCT02145182|Placebo Comparator|Placebo|Placebo was administered by IV infusion over 25-45 min for 2 doses (on the day of transplant then 18-24 h later).
3104299|NCT02145247|Active Comparator|Normal adult women|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
3104300|NCT02145247|Active Comparator|Women with PCOS|"Images of the both ovaries will be obtained using vaginal ultrasound and the number, size, and spatial arrangement of ovarian follicles will be noted for both ovaries in each subject.~On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~Blood samples will be obtained at T = -0.5, 0, and +24 hours.~Blood sample will be used for DNA testing to identify genes that may be associated with androgen production.~One to two weeks after hCG stimulation testing each subject will come to the CTRI for an Oral Glucose Tolerance Test (OGTT). Each subject will ingest 75 gm of a glucose solution and blood samples will be obtained at 0, 15, 30, 60, 120 and 180 minutes after the glucose load."
3104301|NCT02145299|Experimental|TruePath CTO Device|"The TruePath™ CTO Device (Boston Scientific Corporation, Natick, MA) is a new solution for intraluminal treatment of chronic total occlusions (CTO). It is the longest available crossing device (165 cm), and has a diamond-coated distal tip that can rotate at 13,000 rpm. Its profile is similar to a 0.018 guidewire, and includes a shapeable distal tip allowing 1:1 torque response. In addition, it provides audio and visual navigation during CTO crossing."
3104302|NCT02145299|Active Comparator|CROSSER CTO Device|"The CrosserTM CTO Recanalization Catheter (Crosser system) (Bard Peripheral Vascular Inc. Tempe, AZ, USA), which serves as a control in this investigation, gained U.S. FDA approval for peripheral indications in 2011. The device is similar in both design and indications to the TruePath device, with the exception that the Crosser system uses vibrational angioplasty to achieve CTO crossing."
3104304|NCT02145429|Experimental|problem solving therapy + Behavioral Treatment of Insomnia|Problem Solving Therapy + Brief Behavioral Treatment of Insomnia as needed
3104305|NCT02145429|No Intervention|Enhanced Usual Care|Care as usual with scheduled assessments of clinical status
3104306|NCT02145468|Experimental|Losmapimod|Losmapimod 7.5 mg twice daily oral tablet
3104307|NCT02145468|Placebo Comparator|Placebo|Placebo twice daily oral tablet
3104308|NCT02145676|Experimental|onabotulinumtoxinA 500U|OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.
3104309|NCT02145676|Experimental|onabotulinumtoxinA 300U|OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.
3104310|NCT02145676|Placebo Comparator|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
3104311|NCT02145754|Active Comparator|MKP media versus BSK-H media|one half of skin specimen obtained from erythema migrans patients was cultivated for Borrelia burgdorferi sensu lato in MKP media and the other half in BSK-H media
3104312|NCT02146001|Active Comparator|Moderate-to-vigorous activity group|This group will target achieving the current recommendations for physical activity in older adults. This is 150 minutes of moderate-to-vigorous activity per week.
3104313|NCT02146001|Experimental|Reducing sedentary behavior group|This group will target a 60 minute per day reduction in sedentary behavior using an objective activity monitor.
3104314|NCT02146105|Experimental|Yoga For Knee Osteoarthritis|An tailored arthritis-specific yoga program for women with knee osteoarthritis with the aim of increasing leg strength and alleviating knee pain related to the disease.
3104315|NCT02146131|Active Comparator|Standard FB with fluoroscopy|Administration of moderate or deep sedation, introduction of standard adult bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Localization of the lesion using fluoroscopy followed by the acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Evaluation of acquired samples for pathology. Performance of a portable chest X-ray to look for pneumothorax (PTX).
3104316|NCT02146131|Active Comparator|R-EBUS with ultrathin bronchoscope|"Administration of moderate or deep sedation, introduction of ultrathin bronchoscope into the airway. Following application of topical anesthesia on vocal cord, trachea, bronchoscope is advanced distally under direct visualization. Attempt to definitively locate the lesion with mechanical R-EBUS probe.~Acquisition of pathologic and cytologic specimens using standard bronchial brush and standard transbronchial biopsy forceps. Performance of a portable chest X-ray to look for PTX."
3104317|NCT02146248|Experimental|HSG Studies|"Women will be given combined oral contraceptives and Depo-medroxyprogesterone acetate (DepoProvera®).~2 HSG studies will be done prior to hormonal treatment, 1 after the pill treatment, and depending on whether the tubes appear patent, 1 more after the depoProvera treatment, and a final HSG after another 2 weeks on the pill."
3104318|NCT02146274||Ischemic Stroke Patients|Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.
3104319|NCT02146326|Active Comparator|Motivational Interviewing-Mental Health Staff|
3104320|NCT02146326|Active Comparator|BREATHE-Mental Health Staff|
3104321|NCT02146326|Active Comparator|Motivational Interviewing-Clients|
3104322|NCT02146326|Active Comparator|BREATHE-Clients|
3104323|NCT02146352|Experimental|Treatment|AXIOS Stent with Electrocautery Enhanced Delivery System
3104324|NCT02146365||PATH-wSP 300 µg + Booster|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
3104325|NCT02146365||PATH-wSP 300 µg Only|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received 300 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 300 µg PATH-wSP 8 weeks later.
3104326|NCT02146365||PATH-wSP 600 µg + Booster|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP plus the two booster vaccines (Synflorix and Pentavac) followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
3104327|NCT02146365||PATH-wSP 600 µg Only|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received 600 µg PATH-wSP and 2 saline injections followed by a 2nd injection of 600 µg PATH-wSP 8 weeks later.
3104328|NCT02146365||Booster Only (300 µg)|Toddlers who enrolled in Cohort 1 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
3104329|NCT02146365||Booster Only (600 µg)|Toddlers who enrolled in Cohort 2 of Study VAC-010 and received one saline injection and the two booster vaccines (Synflorix and Pentavac) followed by a 2nd saline injection 8 weeks later.
3104330|NCT02146365||No Intervention (300 µg)|Toddlers who enrolled during Cohort 1 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
3104331|NCT02146365||No Intervention (600 µg)|Toddlers who enrolled during Cohort 2 who did not participate in Study VAC-010 and did not receive either PATH-wSP or either of the booster vaccines (Pentavac or Synflorix).
3104332|NCT02146430|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
3104333|NCT02146430|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
3104334|NCT02146430|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3104335|NCT02146430|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
3104336|NCT02146482|No Intervention|Control|Did not receive an intervention during the active portion of the study (i.e. 12 weeks). After the active portion of the study, this group was given a sit-stand computer workstation.
3104337|NCT02146482|Experimental|Sit-stand computer workstation|Given a sit-stand computer workstation to use at their place of work
3104338|NCT02146599||Pseudophakic|
3104339|NCT02146833|Experimental|Selinexor Dosing Regimen 1|80 mg twice weekly for 4 weeks (8 doses per 28-day cycle)
3104340|NCT02146833|Experimental|Selinexor Dosing Regimen 2|80 mg once weekly for 4 weeks (4 doses per 28-day cycle)
3104341|NCT02146833|Experimental|Selinexor Dosing Regimen 3|60 mg twice weekly for 2 weeks, then 1 week off (4 doses per 21-day cycle)
3104342|NCT02147067|Experimental|Ranolazine|Ranolazine 1,000 mg twice daily
3104343|NCT02147067|Placebo Comparator|Placebo|Placebo twice daily
3104344|NCT02147093|Other|Control (sphere) /Test (multi-focal)|Subjects were first fitted with Control lens (sphere) and a pair of reading glasses for one week. Subjects were then fitted with the Test lens (multi-focal) for one week.
3104345|NCT02147093|Other|Test (sphere) /Control (multi-focal)|Subjects were first fitted with the Test lens (multi-focal) for one week. Subjects were then fitted with Control lens (sphere) and a pair of reading glasses for one week.
3104346|NCT02147132|Experimental|Order 1|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
3104347|NCT02147132|Experimental|Order 2|Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
3104348|NCT02147132|Experimental|Order 3|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
3104349|NCT02147132|Experimental|Order 4|Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
3104350|NCT02147158|Experimental|UPA 5 mg:Placebo|Ulipristal Acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
3104351|NCT02147158|Experimental|UPA 10 mg:Placebo|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 2.
3104352|NCT02147158|Experimental|UPA 5 mg:UPA 5 mg|UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
3104353|NCT02147158|Experimental|UPA 10 mg:UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily in both Treatment Course 1 and Treatment Course 2. There was a 2 menses drug-free interval in between courses.
3104354|NCT02147158|Experimental|Placebo:UPA 5 mg|Matching placebo tablets (5 mg and 10 mg) orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
3104355|NCT02147158|Experimental|Placebo:UPA 10 mg|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks in Treatment Course 1; followed by a 2 menses drug-free interval; followed by UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks in Treatment Course 2.
3104356|NCT02147184||SSRI Group|Participants within one month of starting an SSRI
3104357|NCT02147184||Unmedicated Group|No treatment with SSRIs
3104358|NCT02147197|Experimental|UPA 5 mg|Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
3104359|NCT02147197|Experimental|UPA 10 mg|UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
3104360|NCT02147197|Placebo Comparator|Placebo|Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.
3104361|NCT02147288|Experimental|Breast Recon with acellular dermal matrix (ADM) on NPWT|
3104362|NCT02147288|Experimental|Lipoabdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the lipoabdominoplasty patients enrolled in this arm.
3104363|NCT02147288|Experimental|Abdominoplasty on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the abdominoplasty patients enrolled in this arm.
3104364|NCT02147288|Experimental|Ventral Hernia Repair (VHR) on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the VHR patients enrolled in this arm.
3104365|NCT02147288|Experimental|Panniculectomy on NPWT|The Smith&Nephew Renasys*GO device connected to non-compressible drains will be applied to the panniculectomy patients enrolled in this arm.
3104366|NCT02147288|No Intervention|Breast Recon with ADM on Jackson-Pratt (JP) Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3104367|NCT02147288|No Intervention|Abdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3104368|NCT02147288|No Intervention|Lipoabdominoplasty on JP Drains|Standard of Care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3104369|NCT02147288|No Intervention|Ventral Hernia Repair (VHR) on JP Drains|Standard of Care
3104370|NCT02147288|No Intervention|Panniculectomy on JP Drains|Standard of care. The Jackson-Pratt (JP) drain is used following surgery to collect bodily fluids from the surgical site.
3104371|NCT02147301|Experimental|DEB-TACE|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first"
3104372|NCT02147353|Active Comparator|Sinecatechins 15% Ointment & Cryotherapy|Cryotherapy and then Sinecatechins 15% Ointment 1 week later.
3104373|NCT02147353|Placebo Comparator|Cryotherapy Alone|Cryotherapy will be standardized in all subjects and for all treated lesions: EGW lesions will be treated with 2 sprays, 5 seconds each, with a 5 second interval. All subjects will be treated with the same cryo-spray regimen.
3104374|NCT02147522|Experimental|A Helping Hand (AHH)|Participants receive DHS-PCMH usual care from their respective county health clinic providers plus the AHH intervention provided by study promotoras. AHH intervention includes 6 weekly in-person or via-telephone intervention sessions followed by 3 monthly telephone booster sessions aimed at reducing the burden and strain on patients, families, and care providers by assessing, enhancing, and facilitating patient depression and co-morbid illness self-care management, and activating patient communication with clinic medical providers.
3104375|NCT02147522|No Intervention|Usual Care (UC)|"Participants receive DHS Patient Centered Medical Home (PCMH) clinic team usual care from their respective county health clinic providers.~PCMH model has available DHS medical providers and social workers for depression care and refer patients when indicated to community mental health clinics. Problem-Solving Therapy (PST) is available in some of participating clinics."
3104376|NCT02147561|Experimental|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
3104377|NCT02147587|Experimental|Tofacitinib 5 mg BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
3104378|NCT02147587|Placebo Comparator|Placebo tofacitinib BID (oral) (70 subjects)|Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.
3104379|NCT02147613|Experimental|High intensity interval training|High intensity interval training - 3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
3104380|NCT02147613|Active Comparator|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
3104381|NCT02147626|Active Comparator|Information and Screening Group|Intervention: The patient website will include the American Heart Association (AHA) Class I Lifestyle recommendations (translated to an 8th grade reading level and with a link to the publication), a link to the online National Institutes of Health (NIH) Dietary Approaches to Stop Hypertension (DASH) website, and the NIH smoking cessation website
3104382|NCT02147626|Experimental|HH4M Intervention Arm|Intervention: The HH4M patient website will include information and tools. These resources are customized to help new mothers achieve the AHA Class I Lifestyle recommendations for women with a history of preeclampsia.
3104383|NCT02147691|Experimental|Azelaic acid 15%, Brimonidine 0.33 % Gel|"Azelaic acid 15% to the face each AM followed 30 minutes later by Brimonidine 0.33%~Azelaic acid 15% to the face each PM"
3104384|NCT02147691|Active Comparator|Brimonidine 0.33% Gel|Brimonidine 0.33% Gel
3104385|NCT02147769||Preterm infants monitored with NIRS|All infants enrolled in the study will be monitored with cerebral near-infrared spectroscopy (NIRS monitoring) to measure cerebral oxygenation levels in the first 96 hours of life. Mean arterial blood pressure will simultaneously be monitored.
3104386|NCT02147899|Experimental|SYM-1219 Low Dose|Administered orally
3104387|NCT02147899|Experimental|SYM-1219 High Dose|Administered orally
3104388|NCT02147899|Placebo Comparator|Placebo|Administered orally
3104389|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (625mg BID)|Starting dose of 625mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
3104390|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M +ve (500mg BID)|Starting dose of 500mg rociletinib, taken orally twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
3104391|NCT02147990|Experimental|Rociletinib Mono-Therapy, T790M -ve (500mg BID)|Starting dose of 500mg rociletinib, taken twice daily, with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Tablets should be swallowed whole. Treatment with rociletinib is continuous and each cycle will comprise of 28 days.
3104392|NCT02148107|Experimental|BI 691751 Dose 1|multiple dose given over 14 days
3104393|NCT02148107|Experimental|BI 691751 Dose 2|multiple dose given over 14 days
3104394|NCT02148107|Experimental|BI 691751 Dose 3|multiple dose given over 14 days
3104395|NCT02148107|Experimental|BI 691751 Dose 4|multiple dose given over 14 days
3104396|NCT02148107|Experimental|BI 691751 Dose 5|multiple dose given over 14 days
3104397|NCT02148107|Experimental|BI 691751 Dose 6|multiple dose given over 14 days
3104398|NCT02148107|Placebo Comparator|Placebo|Placebo
3104400|NCT02148211||Exposed cohort|Pregnant women, vaccinated with any of the 4 GSK seasonal Inactivated Influenza Vaccine(s) (GSK sIIVs): Fluarix/ FluLaval/Fluarix Quadrivalent /FluLaval Quadrivalent during pregnancy or within 28 days preceding conception.
3104401|NCT02148250|Experimental|100 Syringe Units, then 200|Participants randomized to first receive 100 syringe units of U-500 regular insulin, then 200 units
3104402|NCT02148250|Experimental|200 Syringe Units, then 100|Participants randomized to first receive 200 syringe units of U-500 regular insulin, then 100 units
3104403|NCT02148302|Experimental|Harvesting Device (CelluTome©)|"open-label trial designed to evaluate the safety and effectiveness of Epidermal grafting plus multi-layer compression therapy versus multi-layer compression alone in the healing of venous leg ulcers.~Epidermal grafting will be applied up to three times in the treatment arm: at day zero, week 4 and week 8.~A run-in period of two weeks followed by twelve weeks of active treatment"
3104404|NCT02148302|No Intervention|Control: SOC alone|The Standard of Care therapy in this study is multi-layer compression therapy. A number of compression bandaging systems are commercially available. The trial will utilize Coban-2 (3M, Minneapolis, MN).
3104405|NCT02148445|Active Comparator|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
3104406|NCT02148445|Experimental|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
3104407|NCT02148523|Experimental|Weekly Adherence Report|Adherence report to subject every 7 days.
3104408|NCT02148523|Experimental|Weekly Adherence Peer-Comparison Report|Adherence report to subject every 7 days with tailored comparison messages based on subject's adherence.
3104409|NCT02148523|Other|Usual Care|Usual care with GlowCap.
3104410|NCT02148588|Experimental|Pain testing|"Completion of NPSI questionnaire~Sensory mapping of the affected limb~Quantitative Sensory Testing~Patients will have a peripheral nerve blockade"
3104411|NCT02148718|Experimental|Adalimumab|Participants received adalimumab for 12 weeks (160 mg at Week 0; 80 mg at week 2; then adalimumab 40 mg every other week starting at Week 4).
3104412|NCT02148809|Experimental|Blood Volume Analysis, Fluid|Preop I-131 is given and the BVA is performed, 6 hours after surgery the same procedure will be done to compare the TBV at both points
3104413|NCT02148835|Active Comparator|Triomeg|Sausage: Triomeg
3104414|NCT02148835|Placebo Comparator|Control sausage|Sausage: Control
3104415|NCT02148874||Flu Shot|pregnant women receive a seasonal influenza virus vaccination
3104416|NCT02148952|Experimental|Intervention Health Facility|WHO Safe Childbirth Checklist Program
3104417|NCT02148952|No Intervention|Control Health Facility|Matched control facilities providing comparison for intervention facilities
3104418|NCT02149108|Experimental|Nintedanib (BIBF 1120) + BSC|
3104419|NCT02149108|Placebo Comparator|Placebo + BSC|
3104420|NCT02149173|Experimental|Diagnostic (F-18 FES PET/CT)|Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.
3104421|NCT02149199|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
3104422|NCT02149199|Active Comparator|"terbutaline as needed+placebo Pulmicort bid"|terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid
3104423|NCT02149199|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
3104424|NCT02149264|Experimental|Testosterone gel (FE 999303)|Subjects received at least one dose of testosterone gel (23 mg), which was further titrated, if needed (upto three doses [69 mg]), based on serum testosterone concentrations. Testosterone gel was delivered using an applicator to the contralateral shoulder/upper arm.
3104425|NCT02149290||Trends-equipped LifeVest 4000|Subjects using the LifeVest 4000 modified to collect Trends data
3104426|NCT02149303||Dabigatran|
3104427|NCT02149342|Experimental|HAL cream and MAL cream|0.2% HAL (Hexvix, Photocure) mixed with Unguentum M (Allmiral) and MAL (Metvix, Galderma) used in a randomized split-face design
3104428|NCT02149420|Experimental|VAY736 3 mg/kg|single dose iv of VAY736 at a dose of 3mg/kg
3104429|NCT02149420|Experimental|VAY736 10 mg/kg|single dose iv of VAY736 at a dose of 10mg/kg
3104430|NCT02149420|Placebo Comparator|Placebo|single dose iv of Placebo. At Week 24 patients were offered to receive open label VAY736 10 mg/kg.
3104431|NCT02149524|Active Comparator|Herceptin (trastuzumab)|Intravenous administration
3104432|NCT02149524|Experimental|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
3104433|NCT02149810|Experimental|Automatic Self Transcending Meditation and Treatment as Usual|Participants in the ASTM group will undergo ASTM training in groups of four .This involves participating in four, 90-120 minutes sessions each of four consecutive days. This will be followed by once weekly 45-60 minute follow up sessions for 12 weeks. In addition participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period (24 weeks). Participants will be asked to log practice frequency and any other noteworthy observations in the log sheet provided to them.
3104434|NCT02149810|No Intervention|Treatment as Usual|Participants randomized to control arm (TAU) will continue to receive their treatment as usual including antidepressant medications and/or psychotherapy
3104435|NCT02149836|Experimental|ezogabine|Ezogabine dosage plan to 900mg and then tapered down
3104436|NCT02149875|Experimental|Dl-3-n-butylphthalide|Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
3104437|NCT02149875|Experimental|Cerebrolysin|Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
3104438|NCT02149875|Placebo Comparator|Placebo|Intravenous infusion of 100 ml saline intravenous q.d. for 10 days
3104439|NCT02150044|Experimental|Tympanostomy tube|Performance and safety of tympanostomy tube delivery system
3104440|NCT02150057|No Intervention|Control Group|This group receives no experimental bracing intervention in the study.
3104441|NCT02150057|Active Comparator|Experimental Group|This group will receive the Breg Fusion Osteoarthritis Knee Unloading Brace to wear for a determined amount of time per study protocol for the treatment of osteoarthritis pain.
3104442|NCT02150109|Experimental|Persons With Diabetes|Untrained subjects WITH Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
3104443|NCT02150109|Experimental|Persons With and Without Diabetes|Untrained subjects WITH/WITHOUT Diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System).
3104444|NCT02150213|Experimental|BGG492|This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to > 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day
3104445|NCT02150343|Experimental|HMD-SPIRE Treatment 1|4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
3104446|NCT02150343|Experimental|HDM-SPIRE Treatment 2|4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart
3104447|NCT02150343|Experimental|HDM-SPIRE Treatment 3|4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart
3104448|NCT02150343|Placebo Comparator|Placebo|8 x placebo 4 weeks apart
3104449|NCT02150460|Experimental|One-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15 International Units (IU)/ml into the inferior medial orbital compartment
3104450|NCT02150460|Active Comparator|Two-site peribulbar injection|Injection of a mixture of lidocaine 2% + adrenaline 0.125mg/ml + hyaluronidase 15IU/ml into the infero-temporal and supero-nasal orbital compartments
3104451|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus placebo HFA|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of placebo HFA) for 24 total puffs, cumulative dose of 540 mcg levalbuterol tartrate HFA inhalation aerosol
3104452|NCT02150499|Experimental|levalbuterol tartrate HFA inhalation aerosol plus levalbuterol|Three doses. Each dose comprised of 8 puffs (4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff plus 4 puffs of levalbuterol tartrate HFA inhalation aerosol 45 mcg/puff) for 24 total puffs, cumulative dose of 1080 mcg levalbuterol tartrate HFA inhalation aerosol.
3104453|NCT02150759|Experimental|Dexmedetomidine-ketamine|Dexmedetomidine-ketamine group
3104454|NCT02150759|Active Comparator|Dexmedetomidine-fentanyl|Dexmedetomidine-fentanyl group
3104455|NCT02150837||5 & 2 & 2 Plan|MWCC members who used the Medifast 5 & 2 & 2 Meal Replacement Plan for weight loss.
3104456|NCT02150837||4 & 2 & 1 Plan|MWCC members who used the Medifast 4 & 2 & 1 Meal Replacement Plan for weight loss.
3104457|NCT02150954|Active Comparator|foley bulb induction with low dose pitocin|Subjects in this arm will receive a standard infusion protocol of pitocin starting at 1 milliunit/minute (mius/min) and increasing 2 milliunits per minute every 30 minutes.
3104458|NCT02150954|Active Comparator|foley bulb with standard incremental pitocin infusion protocol|Subjects in this arm will receive a fixed low dose pitocin infusion protocol of 2 mius/min.
3104459|NCT02151058|Other|Negative Control, 035000513007|Colgate® Regular Cavity Protection
3104460|NCT02151058|Experimental|Experimental Mouth Rinse, 19545-118|
3104461|NCT02151058|Active Comparator|Active Comparator: Mouth Rinse 037000089872|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint
3104462|NCT02151110|Placebo Comparator|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
3104463|NCT02151110|Experimental|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
3104464|NCT02151110|Experimental|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
3104465|NCT02151110|Experimental|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
3104466|NCT02151110|Experimental|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
3104467|NCT02151110|Experimental|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
3104468|NCT02151110|Experimental|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
3104469|NCT02151110|Experimental|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
3104470|NCT02151149|Other|Arm A: nab-Paclitaxel and Carboplatin (Every 21 days)|nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion over 30 minutes on Days 1, 8, and 15 and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of every 21-day treatment cycle
3104471|NCT02151149|Other|Arm B: nab-Paclitaxel and Carboplatin (Every 28 days)|nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1, 8, and 15 of each 21-day treatment followed by one-week break and Carboplatin AUC = 6 mg*min/mL IV following nab-paclitaxel infusion on Day 1 of each 21-day treatment followed by one-week break
3104472|NCT02151253|Experimental|Armodafinil First, Then Placebo|"During double-blind treatment subjects took armodafinil for 4 weeks before crossing over to placebo for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
3104473|NCT02151253|Placebo Comparator|Placebo First, Then Armodafinil|"During double-blind treatment subjects took placebo for 4 weeks before crossing over to armodafinil for 4 weeks. Pill is taken once daily, before 8 am.~Armodafinil/placebo was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects."
3104474|NCT02151266|Experimental|Exercise and Cognitive retraining|Aerobic exercise; Computerized cognitive retraining program; Heart failure education; Home visits; telephone follow-up.
3104475|NCT02151266|Experimental|Exercise only|Each participant will be provided with an individualized target heart rate (THR)zone based on treadmill results. Under the supervision of a research nurse, participants will begin the walking sessions at 60% of THR and increase to 70% by week 5. Participants will walk a minimum of 5 times per week for a duration of 30 minutes.
3104476|NCT02151266|Sham Comparator|Stretching and Flexibility|Stretching and flexibility movements; heart failure education; home visits; telephone follow-up.
3104477|NCT02151331|Experimental|REP + EF|Replication Effective Programs (REP) augmented with External Facilitation (EF)
3104478|NCT02151331|Experimental|REP + EF/IF|Replicating Effective Programs (REP) augmented with External and Internal Facilitation (EF + IF)
3132637|NCT03441984|Experimental|Subjects with treatment sequence EDF|The subjects in Part 2 of the study, will receive a single dose of treatment E in TP1, treatment D in TP2 and treatment F in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3104480|NCT02151448|Experimental|vaccine + chemokine modulatory regimen|Week 1 (at recovery from surgery; ≥ 6 weeks post-surgery)-Priming Vaccine dose; no chemokine modulation; 1 day: αDC1 vaccine; Oral celecoxib, 200 mg, before & after treatment on day of vaccination; Weeks 2-3 -Rest; Week 4 (target) - Booster C1; Mon: αDC1 vaccine;Tues - Fri: Systemic Chemokine Modulation Regimen. Oral celecoxib, 200 mg, BID on vaccination days & CKM. Celecoxib will be dced after CKM on Fri. Rintatolimod only administered on Wed & Fri.; Week 5-7 -Rest; Week 8 (target) -Booster C2; Monday: αDC1 vaccine. Oral celecoxib, 200 mg, BID on days of vaccination and CKM. Tues - Fri:Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Celecoxib will be dced after CKM on Fri.; Week 9-11 -Rest; Week 12 (target) -Booster C3; Monday: αDC1 vaccine. Tues-Fri: Systemic Chemokine Modulation Regimen. Rintatolimod only administered on Wed & Fri. Oral celecoxib, 200 mg, BID, given on days of vaccination and CKM. Celecoxib will be discontinued after CKM on Fri.
3104481|NCT02151461|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
3104482|NCT02151461|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
3104483|NCT02151461|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
3104484|NCT02151461|Experimental|Metformin Monotherapy|3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
3104485|NCT02151487||Ropivacaine|Ropivacaine 0.5% 25 ml alone for supraclavicular block
3104486|NCT02151487||Ropivacaine and dexamethasone|25 ml 0.5% ropivacaine + 4 mg dexamethasone
3104487|NCT02151487||Ropivacaine and clonidine|25 ml 0.5% ropivacaine + 100 mcg clonidine
3104488|NCT02151487||Ropivacaine, dexamethasone and clonidine|25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
3104489|NCT02151526|Experimental|LentiGlobin BB305 Drug Product|Following myeloablative conditioning with IV busulfan for 4 consecutive days (dose may be adjusted as per protocol) and subsequent daily monitoring of busulfan levels for confirmation of adequate washout, a single dose cluster of differentiation (CD) 34+ cells/kg LentiGlobin BB305 Drug Product was administered to participants by IV infusion.
3104490|NCT02151591|Experimental|Integrated Counseling for Tobacco and Alcohol (INT)|Integrated counseling for smoking and alcohol entails weekly counseling for 12-weeks targeting both behaviors. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
3104491|NCT02151591|Other|Standard Care for Primary Presenting Concern (SC)|Standard care (SC) for primary presenting concern only. For those presenting with the primary concern of tobacco, standard care will involve weekly smoking counseling alone for 12-weeks. For those presenting with the primary concern of alcohol, standard care will involve weekly alcohol counseling alone. Participants in this condition will also receive 12 weeks of varenicline (Chantix).
3104492|NCT02151643|Experimental|Group 1 - PT20 400 mg tid|"PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3104493|NCT02151643|Experimental|Group 2 - PT20 800 mg tid|"PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3104494|NCT02151643|Experimental|Group 3 - PT20 1600 mg tid|"PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3104495|NCT02151643|Experimental|Group 4 - PT20 3200 mg tid|"PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3104496|NCT02151643|Placebo Comparator|Group 5 - Placebo tid|"Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study"
3104497|NCT02151682|Active Comparator|Morphine prolonged-release (Part 1)|"10 milligram (mg) or 30 mg tablets were taken orally twice daily. Starting doses varied from 10 to 40 mg morphine PR twice daily depending on participant's weight; if necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 200 mg per day."
3104498|NCT02151682|Experimental|Tapentadol prolonged-release (Part 1)|"25 mg or 100 mg tablets were taken orally twice daily. Starting doses varied from 25 to 100 mg tapentadol PR twice daily depending on participant's weight. If necessary, doses were gradually increased up to a maximum dose defined per weight group.~The highest dose defined for participants weighing 55 kg and more was 500 mg per day."
3104499|NCT02151682|Experimental|Tapentadol in Part 2 after Tapentadol or Morphine in Part 1|Participants on tapentadol PR in Part 1 of the study continued on the current dose of tapentadol PR in Part 2 and if necessary could modify their tapentadol PR dosage. Participants who were randomized to morphine PR in Part 1 of the study were rotated to tapentadol PR in Part 2 with 70 percent of their current morphine equivalent dose or lower. The dosage could be increased gradually up to approximately 4.5 mg/kg body weight tapentadol PR twice daily.
3104500|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 1|Participants who completed tapentadol PR in Part 1 of the study or discontinued tapentadol treatment early in Part 1 could continue directly in the observation period in Part 2 for up to 12 months (with standard-of-care treatment if needed).
3104501|NCT02151682|No Intervention|Observation Period after Morphine in Part 1|Participants who completed morphine PR treatment in Part 1 of the study or discontinued early from morphine treatment in Part 1 could continue directly in the observation period in Part 2 (with standard-of-care treatment if needed).
3104502|NCT02151682|No Intervention|Observation Period after Tapentadol in Part 2|Participants who completed tapentadol PR or morphine PR treatment in Part 1 of the study could enter the Observation Period for up to 12 months (with standard-of-care treatment if needed) after they had discontinued from tapentadol PR treatment in Part 2.
3104503|NCT02151773||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 milliliter (mL) of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
3104504|NCT02151786||Thirty milligrams of lansoprazole|Thirty milligrams of lansoprazole is mixed in physiological saline (JP) or 5 percent (%) glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 milliliter (mL) of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
3104505|NCT02151851|Experimental|Certolizumab Pegol + Methotrexate|"Subjects will receive loading doses of CZP 400 mg (200 mg / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then CZP 200 mg (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
3104506|NCT02151851|Placebo Comparator|Placebo + Methotrexate|"Subjects will receive Placebo (1mL / prefilled syringe [PFS], ie, 2 injections) at Baseline, and Weeks 2 and 4; then Placebo (1 injection) Q2W until Week 22.~All subjects will continue their treatment on Methotrexate (MTX), with or without folic acid, at the same dose and route of administration as at entry (unless there is a need to reduce the dose for reasons of toxicity, minimum dose permitted 10 mg per week)."
3104507|NCT02151877|Experimental|Nitric oxide on CPB|neonates receiving inhaled NO into the cardiopulmonary bypass circuit during cardiac surgery
3104508|NCT02151877|Placebo Comparator|control|neonates not receiving inhaled NO into the cardiopulmonary bypass
3104509|NCT02151903|Experimental|DI-Leu16-IL2 1.0 mg/m^2|Participants will receive DI-Leu16-IL2 1.0 milligrams per square meter (mg/m^2) subcutaneously (SC) for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
3104510|NCT02151903|Experimental|DI-Leu16-IL2 2.0 mg/m^2|Participants will receive DI-Leu16-IL2 2.0 mg/m^2 SC for 3 consecutive days every 3 weeks (21-day cycle). Participants will continue to receive therapy through the duration of the study as long as they will have clinical benefit and will not experience any untoward side effects.
3104511|NCT02151981|Experimental|Osimertinib|Osimertinib 80 mg, orally, once daily
3104512|NCT02151981|Active Comparator|Platinum-based doublet chemotherapy|pemetrexed 500mg/m2 + carboplatin AUC5 or pemetrexed 500mg/m2 + cisplatin 75mg/m2
3104513|NCT02151994|Experimental|BIA 5-1058|BIA 5-1058 (5, 25 and 100 mg) tablets
3104514|NCT02151994|Placebo Comparator|Placebo|tablets, visually matching active medication
3104515|NCT02152007|Experimental|Split-body 1% sirolimus cream (TD201 1%)|This is a split-body design. Subjects will self-administer 1% topical sirolimus cream or placebo cream (no drug, vehicle control) on the plantar surface of each foot. At least one foot will be treated with topical sirolimus at some time during the study. Application will be one time daily for a total of 26 weeks. There will be an additional follow-up visit 3 months after the last application of study drug. The total duration of the study is 39 weeks.
3104516|NCT02152085|Experimental|Narrow pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 0.4 ms.
3104517|NCT02152085|Experimental|Wide pulse|Six-week treatment of electrical stimulation applied to the calf muscles with stimulus pulses that last 1 ms.
3104518|NCT02152137|Experimental|efatutazone dihydrochloride, paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 and efatutazone dihydrochloride PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3104519|NCT02152163|Active Comparator|IV Ibuprofen 800 mg|IV Ibuprofen 800 mg
3104520|NCT02152163|Placebo Comparator|IV Saline|IV Saline
3104521|NCT02152345|Experimental|Belatacept Immunosuppression|Renal transplant recipients will receive steroids (Methylprednisolone), rATG, Belatacept and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
3104522|NCT02152345|Active Comparator|Standard Immunosuppression (Tacrolimus)|Renal transplant recipients will receive standard immunosuppressive therapy, including steroids (Methylprednisolone), rATG, Tacrolimus and Mycophenolate. Subjects will be followed for primary endpoint to Day 7 and Month 3 after transplantation and secondary endpoints of kidney function and patient and graft survival up to month 36 after transplantation.
3104523|NCT02152371|Experimental|Dulaglutide + Insulin Glargine|1.5 milligrams (mg) dulaglutide administered subcutaneously (SQ) once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
3104524|NCT02152371|Placebo Comparator|Placebo + Insulin Glargine|Placebo administered SQ once weekly for 28 weeks. Titrated insulin glargine administered SQ once daily for 28 weeks. Participants who are taking metformin should remain on stable doses.
3104525|NCT02152384|Experimental|Insulin peglispro (LY2605541, with Insulin Lispro)|Insulin peglispro (LY2605541) once daily subcutaneous (SC) injection at bedtime. Insulin lispro given SC prandially or as bolus as required
3104526|NCT02152384|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine once daily SC injection at bedtime. Insulin lispro given SC prandially or as a bolus as required
3104527|NCT02152540|Experimental|ACTIVE rTMS|Those receiving experimental treatment will receive 20 sessions of rTMS. The treatment will be delivered by trained medical personnel.
3104528|NCT02152540|Placebo Comparator|Sham rTMS|Those receiving the sham rTMS will receive 20 sessions of sham rTMS. The treatment will be delivered by trained medical personnel.
3104529|NCT02152605|Experimental|Umeclidinium/Vilanterol 62.5/25 mcg once daily|The subjects will receive UMEC/VI 62.5/25 mcg, administered as one inhalation once-daily in the morning via a dry powder inhaler (DPI)
3104530|NCT02152605|Placebo Comparator|Placebo once daily|The subjects will receive placebo, administered as one inhalation once-daily in the morning via a DPI
3104531|NCT02152631|Experimental|Abemaciclib|200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).
3104532|NCT02152631|Active Comparator|Erlotinib|150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).
3104533|NCT02152696|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
3104534|NCT02152696|Active Comparator|Uterine evacuation with MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
3104535|NCT02152696|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
3104536|NCT02152761|Experimental|bimagrumab 700 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab high dose administered via intravenous infusion starting Day 1 until Week 20
3104537|NCT02152761|Experimental|bimagrumab 210 mg|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria were treated with the bimagrumab medium dose administered via intravenous infusion starting Day 1 until Week 20
3104538|NCT02152761|Placebo Comparator|placebo|Approximately 70 patients who met all inclusion criteria and none of the exclusion criteria received matching placbo administered via intravenous infusion starting Day 1 until Week 20
3104539|NCT02152761|Experimental|Bimagrumab 70 mg|Approximately 35 patients who met all inclusion criteria and none of the exclusion criteria were treated with bimagrumad low dose administered via intravenous infusion starting Day 1 until Week 20
3104540|NCT02152826|Experimental|potassium oxalate gel|Professional application
3104541|NCT02152826|Active Comparator|Potassium oxalate liquid|Professional application
3104542|NCT02153073||Omega-3 fatty acid ethyl esters 2 g|Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals
3104543|NCT02153086||Ramelteon 8 mg Tablets|
3104544|NCT02153099|Experimental|Cohort 1: TAK-058 15 mg|TAK-058 15 mg, 100 mL oral solution, once on Day 1.
3104545|NCT02153099|Experimental|Cohort 2: TAK-058 30 mg|TAK-058 30 mg, 100 mL oral solution, once on Day 1.
3104546|NCT02153099|Experimental|Cohort 3: TAK-058 45 mg|TAK-058 45 mg, 100 mL oral solution, once on Day 1.
3104547|NCT02153099|Experimental|Cohort 4: TAK-058 5 mg|TAK-058 5 mg, 100 mL oral solution, once on Day 1.
3104548|NCT02153099|Experimental|Cohort 5: TAK-058 75 mg|TAK-058 75 mg, 100 mL oral solution, once on Day 1.
3104549|NCT02153099|Experimental|Cohort 6: TAK-058 150 mg|TAK-058 150 mg, 100 mL oral solution, once on Day 1.
3104550|NCT02153099|Placebo Comparator|Cohort 1-6: Placebo|TAK-058 placebo-matching, 100 mL oral solution, once on Day 1.
3104551|NCT02153112|Experimental|Cohort 1, Group 1: 1 Dose|Children 4 to <9 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent virus-like particle (VLP) vaccine, intramuscularly (IM) and 500 µg aluminum hydroxide on Day 1, followed by placebo matching norovirus bivalent VLP vaccine IM on Day 29.
3104552|NCT02153112|Experimental|Cohort 1, Group 1: 2 Doses|Children 4 to <9 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide IM on Days 1 and 29.
3104553|NCT02153112|Experimental|Cohort 1, Group 2: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 29.
3104554|NCT02153112|Experimental|Cohort 1, Group 2: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
3104555|NCT02153112|Experimental|Cohort 1, Group 2a: 1 Dose|Children 1 to <4 years of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
3104556|NCT02153112|Experimental|Cohort 1, Group 2a: 2 Doses|Children 1 to <4 years of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
3104557|NCT02153112|Experimental|Cohort 1, Group 3: 1 Dose|Toddlers 6 months to <1 year of age received one dose of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Day 1, followed by placebo matching norovirus bivalent VLP vaccine, IM on Day 29.
3104558|NCT02153112|Experimental|Cohort 1, Group 3: 2 Doses|Toddlers 6 months to <1 year of age will receive 2 doses either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 29.
3104559|NCT02153112|Experimental|Cohort 2, Group 4: 2 Doses|Infants 6 weeks to <6 months of age received 2 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) formulations of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1 and 56, followed by placebo-matching norovirus bivalent VLP vaccine, IM on Day 112.
3104560|NCT02153112|Experimental|Cohort 2, Group 4: 3 Doses|Infants 6 weeks to <6 months of age received 3 doses of either of the 4 formulations (15 µg of GI.1 norovirus VLP and 15 µg GII.4/GI.1/GII.4 (15 μg/50 μg)/GI.1/GII.4 (50 μg/50 μg) or GI.1/GII.4 (50 μg/150 μg) of the norovirus bivalent VLP vaccine and 500 µg aluminum hydroxide, IM on Days 1, 56 and 112.
3104561|NCT02153346|Other|Arm 1|Intervention 1 & 2 are associated with Arm 1. All patients enrolled in the study will possibly receive both the valuation of lost productivity and work productivity and activity impairment questionnaires, which are outside of the patient's usual care.
3104562|NCT02153359|Experimental|Air cleaner then sham air cleaner|A High Efficiency Particulate Air Cleaner (HEPA) intervention will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the experimental arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the sham comparator arm.
3104563|NCT02153359|Sham Comparator|Sham air cleaner then air cleaner|A sham air cleaner will be placed in the participant's home for one month. During the last week of the month, health assessments will be conducted, which include in-home health questionnaires, symptom-, and activity- diaries/recalls, blood, and hand-held spirometry. Participants will also be asked to wear a light backpack with air monitoring devices during the course of the day during the last week in order to measure participants' exposures to pollutants. Finally, at the end of the month, participants will be asked to report to the Johns Hopkins outpatient endoscopy suite for bronchoscopy, during which airway sampling will occur under conscious sedation. For the participants who started in the sham comparator arm, after this one month intervention period, they will then enter a wash-out period where no intervention or outcome measures are undertaken for at least one month prior to cross-over to the experimental arm.
3104564|NCT02153398|Experimental|Group 1: D961H sachet 10 mg|Age: ≥1 year Weight: <20 kg
3104565|NCT02153398|Experimental|Group 2: D961H capsule 10mg|Age: ≥1 year to 11years Weight: ≥20 kg
3104566|NCT02153398|Experimental|Group 3: D961H capsule 20 mg|Age: ≥1 year to 11years Weight: ≥20 kg
3104567|NCT02153398|Experimental|Group 4: D961H capsule 10 mg|Age: 12 to 14 years Weight: ≥20 kg
3104568|NCT02153398|Experimental|Group 5: D961H capsule 20 mg|Age: 12 to 14 years Weight: ≥20 kg
3104569|NCT02153476|Experimental|2.0mg of ALG-1001|2.0mg of ALG-1001
3104570|NCT02153476|Placebo Comparator|Intravitreal injection in 0.05cc balanced salt solution.|Balanced Salt Solution
3104571|NCT02153489|Experimental|Aclidinium bromide|Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
3104572|NCT02153489|Placebo Comparator|Placebo|Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
3104573|NCT02153528|Active Comparator|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
3104574|NCT02153528|Experimental|double rimfampicin|2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
3104575|NCT02153632|Experimental|240mg amantadine HCl ER tablets|amantadine HCl ER, 240 mg tablets, once daily, 22 weeks
3104576|NCT02153632|Experimental|320mg amantadine HCl ER tablets|amantadine HCl ER, 320 mg tablets, once daily, 22 weeks
3104577|NCT02153632|Placebo Comparator|Placebo Tablets for Amantadine|Placebo, tablets, once daily, 26 weeks.
3104578|NCT02153645|Experimental|240mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 240mg daily for 12 weeks post two week titration phase.
3104579|NCT02153645|Experimental|320mg Amantadine HCl ER tablets|Amantadine HCl ER Tablets 320mg daily for 12 weeks post a two week dose titration phase.
3104580|NCT02153645|Placebo Comparator|Placebo tablets|Placebo Tablets matching Amantadine HCl ER Tablets taken daily for 16 weeks.
3104581|NCT02153671|Experimental|Primed with H5N2|Subjects who received A(H5N1) inactivated influenza vaccine as well as primed with H5N2 live attenuated influenza vaccine approximately 1.5 years before
3104582|NCT02153671|Active Comparator|Did not receive A(H5N2)|Subjects who received A(H5N1) inactivated influenza vaccine and did not receive A(H5N2) live attenuated influenza vaccine in a previous study.
3104583|NCT02153710|Experimental|Phonomotor therapy|Experimental group
3104584|NCT02153710|Active Comparator|Semantic Feature Analysis therapy|Current standard of care therapy
3104585|NCT02153723|Experimental|Copaxone|"Dose escalation:~Study drug will be administered once a week for 4 weeks, twice a week for 4 weeks and daily for 24 weeks. Drug is administered as a subcutaneous injection."
3104586|NCT02153736|No Intervention|Usual Care Group|This group of subjects will receive usual care provided in the medial system and community.
3104587|NCT02153736|Experimental|SPEEDI Intervention|This group will receive and parent and physical therapy provided intervention to increase the infants opportunities for play which will enhance development.
3104588|NCT02153788|Active Comparator|temazepam|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to temazepam will be given temazepam 15 mg for 12 weeks.
3104589|NCT02153788|Placebo Comparator|Placebo|After screening, all subjects meeting entry criteria will be placed on the same single blind study drug treatment, asked to complete a daily sleep diary, and return one week later. After one week subjects randomized to placebo will be given placebo for 12 weeks.
3104590|NCT02153827|Experimental|Eccentric External rotator training|Eccentric Shoulder External Rotators along with scapular retraction and posterior shoulder stretching exercises.
3104591|NCT02153827|Sham Comparator|General shoulder exercise|General shoulder exercise protocol of active flexion, abduction, scapular retraction and posterior shoulder stretching exercises.
3104592|NCT02153905|Experimental|Phase 1 - Dose Escalation/De-Escalation|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
3104593|NCT02153905|Experimental|Phase II - Maximum Tolerated Dose|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MAGE-A3- A1 transduced peripheral blood lymphocytes (PBL) + high-dose aldesleukin
3104594|NCT02153918|Experimental|Vaccine Plus Booster Shots|PROSTVAC-V/TRICOM followed by PROSTVAC-F/ TRICOM boost monthly until radical prostatectomy or off therapy PROSTVAC
3104595|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Placebo|Experimental treatment with placebo capsules identical in appearance to the experimental colchicine preparation
3104596|NCT02153983|Experimental|Obese Adults with Metabolic Syndrome Randomized to Colchicine|Experimental treatment with colchicine capsules identical in appearance to the experimental placebo preparation
3104597|NCT02153983|Experimental|Diet-controlled Type 2 Diabetes Adults Assigned to Colchicine|Participants with Diet-controlled Type 2 Diabetes who were assigned to Open-label treatment with colchicine. These participants were not randomized and were not part of the randomized controlled trial.
3104598|NCT02153983|No Intervention|Evaluation Only Non-obese Adults|Participants without obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
3104599|NCT02153983|No Intervention|Evaluation Only Obese Adults Not Randomized|Participants with obesity seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort. These participants were found not eligible for randomization.
3104600|NCT02153983|No Intervention|Evaluation Only Adults with Type 2 Diabetes|Participants with Diet-controlled Type 2 Diabetes seen only for the evaluation component of the study. Such participants are a control group for cross-sectional analyses of baseline data from the experimental cohort.
3104601|NCT02154048|Active Comparator|ropivacaine + dexamethasone|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an IV preservative-free dexamethasone 8 mg injection.
3104602|NCT02154048|Placebo Comparator|ropivacaine + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with 1:400,000 epinephrine and an intravenous (IV) normal saline placebo injection.
3104603|NCT02154048|Active Comparator|ropivacaine + dexamethasone + placebo|This group will be comprised of 20 subjects who will receive an ultrasound-guided supraclavicular brachial plexus block with 30ml of ropivacaine 0.5% with both 1:400,000 epinephrine and preservative-free dexamethasone 8mg and an IV normal saline placebo injection.
3104604|NCT02154061|Experimental|IIV Flu Vaccine with Antibiotics|This arm will receive antibiotics prior and after IIV administration.
3104605|NCT02154061|Active Comparator|IIV Flu Vaccine|This arm will not take antibiotics in conjunction with IIV.
3104606|NCT02154139||leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks
3104607|NCT02154243|Experimental|Midodrine|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV<15 will be given oral midodrine, 10 mg, once.
3104608|NCT02154243|Experimental|Intravenous fluid bolus|Patients who are diagnosed with orthostatic hypotension at their first physical therapy session and have an SVV>=15 will be given intravenous fluid bolus, 15 cc/kg, once.
3104609|NCT02154243|No Intervention|Control (no intervention)|Patients who are NOT diagnosed with orthostatic hypotension at their first physical therapy session will be given the interventions.
3104610|NCT02154347|Experimental|KAD-1229/KAD-1229|Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
3104611|NCT02154347|Other|Placebo/KAD-1229|Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.
3104612|NCT02154386|Experimental|8-10 week healing group|dental implant placed (and bone core biopsy harvested) 8-10 weeks after tooth extraction/grafting
3104613|NCT02154386|Active Comparator|18-20 week healing group|dental implant placed (and bone core biopsy harvested) 18-20 weeks after tooth extraction/grafting
3104614|NCT02154425|Experimental|Pharmacokinetic samples|"Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose if Q2W dosing), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).~Included are mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label."
3104615|NCT02154477|Active Comparator|diabetes|All patient will receive insulin at one visit and saline at another visit
3104616|NCT02154477|Active Comparator|control|All patient will receive insulin at one visit and saline at another visit
3104617|NCT02154581|Active Comparator|Type 1 implant and thin biotype|In this group, immediate implant placement (SLActive implant) is performed in patients with thin tissue biotype. In addition to implant placement bone grafting of the void between the implant and the fresh extraction socket, bone grafting the buccal aspect of the buccal plate (overcontouring) and soft tissue grafting (connective tissue) are performed.
3104618|NCT02154581|Active Comparator|Type 1 implant and thick biotype|In this group, immediate implant placement (SLActive implant) is performed including bone grafting of the void between the implant and the fresh extraction socket.
3104619|NCT02154672||BRCA2 Carriers|All men identified to have a BRCA2 mutation as part of the Yale Cancer Genetic Counseling Program will be approached and offered participation in the study via our program newsletter, BRCA listserv, Facebook page and a targeted mailing
3104620|NCT02154763|Placebo Comparator|Intraperitoneal Normal Saline|Intraperitoneal Normal Saline: 100mL (Milliliter) normal saline administered as in intervention arm
3132638|NCT03441984|Experimental|Subjects with treatment sequence FED|The subjects in Part 2 of the study, will receive a single dose of treatment F in TP1, treatment E in TP2 and treatment D in TP3. Each treatment will be followed by a wash-out period of 7-days minus 4 hours.
3104621|NCT02154763|Experimental|Intraperitoneal ropivacaine|The abdomen will be entered and trocars placed in the usual manner. Using a standard suction/irrigation device and tubing, 200mg of Ropivacaine (0.2% Ropivacaine in 100mL Normal Saline) will be instilled into the abdomen at the start of the case, prior to dissection as follows. Under direct visualization, 50mL (Milliliter) (of the 100mL) will be infused over the esophageal hiatus. The remaining 50mL will be infused throughout the abdomen. The infusion line will then be flushed with 30mL (Milliliter) of Normal Saline to ensure the entire treatment dose is delivered, and no Ropivacaine remains in the tubing. The remainder of the surgery will proceed as usual.
3104622|NCT02154906|Active Comparator|DFDBA|DFDBA used to graft intrabony defect
3104623|NCT02154906|Experimental|autologous platelet rich fibrin|autologous platelet rich fibrin used to graft intrabony defect
3104624|NCT02155010|Experimental|Dexmedetomidine|IV dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
3104625|NCT02155010|Active Comparator|Dexmedetomidine with heavy bupivacaine|IV dexmedetomidine infusion after intrathecal injection of heavy bupivacaine
3104626|NCT02155101|Active Comparator|ART with 2 NRTIs plus LPV/r (or ATV/r)|2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus either lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
3104627|NCT02155101|Experimental|Darunavir|"Dosage form: Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side."
3104628|NCT02155257|Active Comparator|Modafinil|Modafinil 200 mg will be administered orally one time
3104629|NCT02155257|Placebo Comparator|Placebo|A placebo will be administered orally one time
3104630|NCT02155257|Active Comparator|Gabapentin|Gabapentin 900 mg will be administered orally one time
3104631|NCT02155283|Other|Treatment Continuous Passive Motion|Single-arm; 3-week treatment plan using Kyrobak compared to baseline (before treatment)
3104632|NCT02155309|Experimental|Scopolamine|0.2 mg intranasal scopolamine, single dose
3104633|NCT02155309|Placebo Comparator|Placebo|placebo intranasal (0.1 mg per nostril), single dose
3104634|NCT02155322|Experimental|PEG-IFN|6.0 μg/kg/week subcutaneous administration during the Induction Phase of 8 weeks followed by a dose of 3.0 μg/kg/week subcutaneous administration in the Maintenance Period (Week 8 to Month 12)
3104635|NCT02155335|Experimental|Prefilled Syringe→Smartject™ Device|Golimumab 50 mg supplied in a prefilled syringe administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied in the Smartject 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab).
3104636|NCT02155335|Experimental|Smartject™ Device→ Prefilled Syringe|Golimumab 50 mg supplied in a Smartject administered 2 times (once by the treating physician and then by the participant under the supervision of the treating physician). Participant is then administered Golimumab 50 mg supplied a prefilled syringe 2 times, first by the physician and then by the participant. Participants receive a total of 200 mg of golimumbab.
3104637|NCT02155465|Experimental|Ruxolitinib and Erlotinib|"Phase I The study will follow a standard 3+3 dose escalation trial design. Three to six patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (21 days) before a dose escalation decision is made.~Phase II Once the MTD has been determined, patients will be enrolled in the phase 2 portion of the single-arm, two-stage, open-label study to determine efficacy of erlotinib and ruxolitinib. Patients will receive erlotinib and ruxolitinib at the MTD established in the phase I portion. The patient take their previous dose of erlotinib if it is less than 150mg daily."
3104638|NCT02155543|Experimental|Cohort 1: AGN-223575 Form A/Vehicle|One drop of AGN-223575 Formulation A in the study eye and one drop of AGN-223575 vehicle in the other eye on day 1, followed by one drop of AGN-223575 Formulation A twice daily in the study eye and 1 drop of AGN-223575 vehicle in the other eye twice daily for 6 days.
3104639|NCT02155543|Experimental|Cohort 2: AGN-223575 Formulation A BID|One drop of AGN-223575 Formulation A in both eyes on day 1, followed by one drop of AGN-223575 Formulation A twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation A in both eyes on day 15.
3104640|NCT02155543|Experimental|Cohort 3: AGN-223575 Formulation B BID|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
3104641|NCT02155543|Experimental|Cohort 4: AGN-223575 Formulation C BID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
3104642|NCT02155543|Placebo Comparator|AGN-223575 Vehicle BID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle twice daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
3104643|NCT02155543|Experimental|Cohort 5: AGN-223575 Formulation C TID|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C three times daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
3104644|NCT02155543|Placebo Comparator|AGN-223575 Vehicle TID|One drop of AGN-223575 vehicle in both eyes on day 1, followed by one drop of AGN-223575 vehicle three times daily in both eyes for 13 days, and a single drop of AGN-223575 vehicle in both eyes on day 15.
3104645|NCT02155608|Experimental|Active eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Positive responders will be invited to participate in a 12-month open extension.
3104646|NCT02155608|Sham Comparator|Sham eTNS|Following screening and determination of eligibility, participants at baseline are randomized to receive 4 weeks nightly treatment with active or sham eTNS, followed by one week ongoing blinded assessment following treatment discontinuation. Following double-blind phase, interested participants randomized to sham have an option for a 4-week open TNS trial. Positive responders will be invited to participate in a 12-month open extension.
3132639|NCT03442036|Active Comparator|Through-the-Needle Technique|"Perineural catheters are inserted through a straight hollow-bore needle.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
3104647|NCT02155647|Experimental|Part A: Avelumab|Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
3104648|NCT02155647|Experimental|Part B: Avelumab|Participants received Avelumab as first-line treatment for metastatic or distally recurrent MCC at a dose of 10 mg/kg as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
3104649|NCT02155660|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3104650|NCT02155660|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3104651|NCT02155660|Experimental|Benralizumab Arm C|Benralizumab administered subcutaneously
3104652|NCT02155660|Placebo Comparator|Placebo|Placebo administered subcutaneously
3104653|NCT02155712|Active Comparator|Triathlon Tritanium Knee|Cases are enrolled in the Cohort 1 (cementless) until a total of 356 cases receive the Triathlon Tritanium Tibial Baseplate, Triathlon Tritanium Patella, Triathlon CR or PS Beaded Femur with PA and the Triathlon Tibial Insert. All components in this cohort must used in a cementless application.
3104654|NCT02155712|Active Comparator|Triathlon Knee|Enrollment in Cohort 2 (cemented) will begin upon completion of enrollment into the Cohort 1 (cementless), and will continue until a total of 144 cases receive the Triathlon Tibial Tray, Triathlon Patella, Triathlon CR or PS Femur and Triathlon Tibial Insert. All components in this cohort must be used in a cemented application.
3104655|NCT02155725|Experimental|Human Fibrinogen concentrate|2 vials (200ml) / 3g intravenous
3104656|NCT02155725|Placebo Comparator|Placebo|2 vials (200ml)
3104657|NCT02155738|Placebo Comparator|Placebo|100 cc of normal saline administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
3104658|NCT02155738|Experimental|IV Acetaminophen|100 cc of Acetaminophen (1000mg/100mL) administered intravenously 10-30 minutes prior to anesthesia induction on the day of surgery.
3104659|NCT02155829|Experimental|Riluzole|"Weeks 1 and 2: Riluzole 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Riluzole 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
3104660|NCT02155829|Placebo Comparator|Placebo|"Weeks 1 and 2: Placebo 50 mg tablet by mouth every 12 hours (100 mg/day) for 2-weeks~Weeks 3 to 8 (optional dose increase): 2 Placebo 50 mg tablets by mouth every 12 hours (200 mg/day) for 6-weeks"
3104661|NCT02155881|Experimental|Ciclesonide 200 mcg|Ciclesonide 200 mcg nasal spray, 2 actuations (sprays) per nostril (50 mcg ciclesonide/actuation), daily, for 2 weeks.
3104662|NCT02155881|Placebo Comparator|Placebo|Ciclesonide placebo-matching nasal spray, 2 actuations (sprays) per nostril, daily, for 2 weeks.
3104663|NCT02155985|Active Comparator|Aspirin 300 mg + aspirin 100 mg placebo|At week 0, participants were prescribed aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
3104664|NCT02155985|Active Comparator|Aspirin 100 mg + aspirin 300 mg placebo|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study product tablets to allow for a 4-week washout period.
3104665|NCT02155985|Placebo Comparator|Aspirin 300 mg + aspirin 100 mg placebos|At week 0, participants were prescribed a placebo for aspirin 300 mg (one tablet) and placebo for aspirin 100 mg (one tablet) once daily. At week 12, participants were to stop both study products tablets to allow for a 4-week washout period.
3104666|NCT02156076|Placebo Comparator|Arm A: Placebo (Matching with BMS-919373)|Placebo (Matching with BMS-919373) 0 mg tablets orally once daily for approximately 28 Days
3104667|NCT02156076|Experimental|Arm B: BMS-919373|BMS-919373 3 mg tablets orally once daily for approximately 28 days
3104668|NCT02156076|Experimental|Arm C: BMS-919373|BMS-919373 5 mg tablets orally once daily for approximately 28 days
3104669|NCT02156076|Experimental|Arm D: BMS-919373|BMS-919373 12 mg tablets orally once daily for approximately 28 days
3104670|NCT02156154|Placebo Comparator|Intravenous 0.9% sodium chloride|0.9% sodium chloride infusion will be initiated before the surgical incision with 100 ml and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
3104671|NCT02156154|Experimental|Intravenous Acetaminophen|Acetaminophen infusion will be initiated before the surgical incision with 1 g and repeated every 6 hours for the earlier of 48 postoperative hours of hospital discharge.
3104672|NCT02156167|Experimental|CP810 and Codacs™Test System|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
3104673|NCT02156258||Diagnostic Cases|Collection of cases that were scheduled for biopsy (BI-RADS 4 or 5) using Full Field Digital Mammography (FFDM) Mammography and Digital Breast Tomosynthesis (DBT) Mammography
3104674|NCT02156258||Recall Cases|Collection of Imaging Recall Cases (were scheduled for additional imaging due an assessment of BI-RADS 0) using FFDM Mammography and DBT Mammography
3104675|NCT02156258||Screening Cases|Collection of cases who underwent routine screening mammography using FFDM Mammography and DBT Mammography
3104676|NCT02156271|Active Comparator|ramelteon|Subjects will take ramelteon 8mg one time daily 30 minutes before bedtime with approximately 8 ounces of water. Subjects have a 2 out of 3 chance of receiving ramelteon.
3104677|NCT02156271|Placebo Comparator|placebo|15 subjects will be randomized to receive the placebo
3104678|NCT02156466|Experimental|MSB0010841 30 mg|
3104679|NCT02156466|Experimental|MSB0010841 60 mg|
3104680|NCT02156466|Experimental|MSB0010841 120 mg|
3104681|NCT02156466|Experimental|MSB0010841 240 mg|
3104682|NCT02156466|Placebo Comparator|Placebo|
3104683|NCT02156492|Experimental|Evacetrapib Single|Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
3104684|NCT02156492|Experimental|Evacetrapib Multiple|Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.
3104685|NCT02156492|Active Comparator|Simvastatin|Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.
3104686|NCT02156492|Experimental|Evacetrapib and Simvastatin|Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.
3104687|NCT02156492|Active Comparator|Atorvastatin|Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
3104688|NCT02156492|Experimental|Evacetrapib and Atorvastatin|Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.
3104689|NCT02156674|Experimental|Naglazyme®|weekly Naglazyme® infusion for 2 years
3104690|NCT02156687|Active Comparator|Cololast, Inc. Restorell Y mesh|Y mesh
3104691|NCT02156687|Active Comparator|Coloplast, Inc. Restorelle Dual flat mesh|Dual flat mesh
3104692|NCT02156804|Experimental|Nivolumab (BMS-936558)|Nivolumab (BMS-936558) Intravenous solution every 2 weeks
3104693|NCT02156908|Experimental|D-serine|D-serine
3104694|NCT02157103|Experimental|Bevacizumab|Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
3104695|NCT02157168|No Intervention|Control Group|Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker. Those not invited will constitute the usual care control group.
3104696|NCT02157168|Other|Intervention Group|"Each month all newly enrolled female health plan members will have an equal chance of being randomly picked by the health plan (according to a randomization scheme provided by the study team) to be invited to contact and work with a Community health worker in the intervention group.~The intervention group will be made up of two sub groups. The group of individuals who accept the invitation to participate (IG1) in the intervention and receive it, and those randomized to the intervention group but who reject the opportunity to participate (IG2)."
3104697|NCT02157298|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
3104698|NCT02157298|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo
3104699|NCT02157376|Experimental|Esomeprazole active treatment|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
3104700|NCT02157376|Active Comparator|Cimetidine active treatment|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
3104701|NCT02157506|Experimental|CXL-1427 Starting Dose|The Starting dose of CXL-1427 in the dose escalation arms will be 3mcg/kg/min
3104702|NCT02157506|Experimental|CXL-1427 Dose Level 2|The Second Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3104703|NCT02157506|Experimental|CXL-1427 Dose Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3104704|NCT02157506|Experimental|CXL-1427 Dos Level 3|The Third Dose level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3104705|NCT02157506|Experimental|CXL-1427 Dose Level 4|The forth level of CXL-1427 will be evaluated in the Dose Escalation Arm of the study as determined by the independent dose escalation committee
3104706|NCT02157506|Experimental|Expansion Cohort 1|Up to 16 Patients will be enrolled across 1 or more of the previously evaluated Dose escalation Levels as determined by the independent dose escalation committee
3104707|NCT02157506|Placebo Comparator|Placebo for Dose Escalation and Expansion Cohort|Each Dose escalation Arm of the study will have a placebo group in a 2:1 ratio to active treatment for the first 3 patients enrolled and 4:1 to active treatment in the remaining 5 patients so that the overall randomization ratio in each Dose escalation arm will be 3:1 active to placebo. In the expansion Cohort of the study, the ratio of patients randomized to receive a 6-hour infusion of active CXL-1427 or placebo will be 3:1
3104708|NCT02157519|Experimental|Mobile Application Intervention|Participants in the intervention group will receive the mobile application for improving symptoms and adherence to oral chemotherapy along with their standard oncology care. The proposed elements of the mobile application include the following: 1) specification of an oral chemotherapy treatment plan; 2) weekly collection of patient-reported symptoms and medication adherence; and 3) delivery of real-time, tailored feedback to patients as well as immediate transmission of survey results to oncology clinicians.
3104709|NCT02157519|No Intervention|Standard Oncology Care|Participants in the control group will receive standard oncology care only.
3104710|NCT02157623|Experimental|Red Light PDT and Blue Light PDT|The tumor clearance with one side treated with Levulan and Red light PDT, and the contralateral side treated with Blue light PDT.
3104711|NCT02157779|Experimental|Cognitive Behavioral Intervention (CBI)|12 weekly individual sessions consisting of psychoeducation, and cognitive and behavioral anger management strategies
3104712|NCT02157779|Active Comparator|Supportive Intervention (SI)|12 weekly individual sessions consisting of psychoeducation, problem-solving strategies, and support
3104713|NCT02157883|Experimental|AZD9291 alone, AZD9291+itraconozole|Sequential treatments of AZD9291 alone followed by AZD9291+itraconazole, with a washout period in between.
3104714|NCT02157909|Experimental|AOA Modified|Lotrafilcon B sphere modified design contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
3104715|NCT02157909|Active Comparator|AOA|Lotrafilcon B sphere contact lenses worn at least 8 hours per day, 5 days per week on a daily wear basis for 7 days.
3104716|NCT02157935|Active Comparator|Symbicort pMDI|Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
3104717|NCT02157935|Active Comparator|Formoterol Turbuhaler|Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
3104718|NCT02157948|Active Comparator|Denosumab CP2|Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
3104719|NCT02157948|Experimental|Denosumab CP4|Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
3132640|NCT03442036|Experimental|Suture-Method Technique|"Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve.~The perineural catheter will then be used to infuse local anesthetic directly onto the nerve to provide postoperative pain control."
3132641|NCT03442296|Experimental|Immediate Treatment Group|Immediate treatment with Baltimore HEARS intervention
3104720|NCT02158039|Experimental|Pancreatic Cyst Ethanol Injection|EUS-guided lavage of a pancreatic cyst with ethanol solution. The ethanol solution was diluted to 80% using normal saline. Final solution also contained 1% lidocaine except in patients allergic to local anesthetics. The ethanol solution was injected into pancreatic cysts at a volume equal to 90% of the aspirated cyst volume. In subjects undergoing re-treatment of a cyst, ethanol was diluted to 90% using normal saline, and injected in a volume equal to 100% of the aspirated cyst volume.
3104721|NCT02158091|Experimental|IPI-145|"Phase I-Dose escalation will occur using a standard 3-3 dose escalation beginning in dose level 1 with dose cohorts and escalation.~Each treatment cycle lasts 28 days (except cycle 1, which is 35 days) during which time IPI-145 will be taken twice daily. The study begins with 1 week of IPI-145 monotherapy.~Fludarabine, cyclophosphamide, rituximab (iFCR) - FCR will subsequently be introduced after 1 week and administered at standard dosing for up to 6 cycles, with dose reductions permitted. IPI-145 will be continued through the course of chemotherapy and for up to 2 years maintenance after completing chemotherapy Phase II - 20 additional patients treated with IPI-145 at the Recommended Phase II Dose (RP2D) + fludarabine, cyclophosphamide, rituximab (FCR) with standard dosing."
3104722|NCT02158247||Conventional group, Touch and Read group|
3104723|NCT02158273|Active Comparator|TRICOR (fenofibrate)|
3104724|NCT02158273|Placebo Comparator|Sugar Pill|
3104725|NCT02158364||Live attenuated measles/rubella combined vaccine|Live attenuated measles/rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain) is dissolved in 0.7 mL of accompanying reconstitution fluid (water for injection [Japanese Pharmacopoeia]), and a 0.5-mL portion is typically administered subcutaneously as a single dose.
3104726|NCT02158442|Experimental|Treatment Group|The Treatment Group received intravenous Timentin prior to their PILP procedure.
3104727|NCT02158442|Active Comparator|Control Group|The Control Group received standard dosings of intravenous Timentin plus other standard care.
3104728|NCT02158494|Experimental|Neurostimulation|Balance and gait training using neurostimulation modulation. 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
3104729|NCT02158494|Sham Comparator|Minimally perceivable stimulation|Balance and gait training using non-zero, minimally perceivable stimulation (sham device). 2-week in lab training (ITP), (2 in-lab training sessions and 1 home training session daily) followed by 12 weeks of training at home (HTP) (3 home training sessions daily), and a 12-week withdrawal period (no training).
3104730|NCT02158520|Experimental|Arm A (bevacizumab and nab-paclitaxel)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm B within 2-4 weeks.
3104731|NCT02158520|Experimental|Arm B (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing progressive disease may cross-over to Arm A within 2-4 weeks.
3104732|NCT02158533|Experimental|High Dose|
3104733|NCT02158533|Experimental|Low Dose|
3104734|NCT02158533|Placebo Comparator|Placebo|
3104735|NCT02158546|Experimental|ALKS 5461|
3104736|NCT02158546|Placebo Comparator|Placebo|
3104737|NCT02158572|Experimental|AG200-15|AG200-15 is a transdermal delivery system designed to deliver daily hormone exposure of ethinyl estradiol (EE) and levonorgestrel (LNG)
3104738|NCT02158663|Active Comparator|Right slow prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
3104739|NCT02158663|Active Comparator|Right fast prefrontal rTMS|Repetitive Transcranial Magnetic Stimulation
3104740|NCT02158728||ICD indicated subjects|"Subjects indicated for implantable cardioverter defibrillator (ICD)/ cardiac resynchronization therapy defibrillator (CRT-D) implant, ICD/CRT-D change-out, or indicated for an ICD/CRT-D and undergoing ablation or electrophysiology (EP) study (including Non-Invasive ElectroPhysiology Study [NIPS]).~Enrolled subjects are prepared for the indicated procedure as per investigational center's standard practice. The investigator will determine the best methodology for inducing or simulating SVT within the indicated procedure. Data is recorded by a data acquisition recording system. Recording should begin just before the indicated procedure and continue until completion of the procedure.The recorded data are collected."
3104741|NCT02158806|Experimental|Aspirin|150 mg capsule once daily for up to 24 weeks
3104742|NCT02158806|Placebo Comparator|Inert capsule|Matching capsule once daily for up to 24 weeks
3104743|NCT02158884|Other|IDEO brace|IDEO brace
3104744|NCT02158936|Experimental|Eltrombopag|Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
3104745|NCT02158936|Placebo Comparator|Placebo|Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
3104746|NCT02158949|Experimental|mROAD|1 week of twice daily text messages modeled after SBIRT interventions
3104747|NCT02158949|No Intervention|Usual Care|Usual care in ED
3104748|NCT02158975|Experimental|MLN9708|MLN9708 4mg by mouth weekly (days 1, 8, 15) every 28 days.
3132642|NCT03442296|Placebo Comparator|Delayed Treatment Group|3-month delayed treatment with Baltimore HEARS intervention
3104749|NCT02159053|Experimental|Secukinumab 150 mg s.c. with loading|Secukinumab 150 mg at Baseline, Weeks 1, 2, and 3, followed by dosing every four weeks starting at Week 4.
3104750|NCT02159053|Experimental|Secukinumab 150 mg s.c. without loading|Secukinumab 150 mg at Baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2, and 3.
3104751|NCT02159053|Placebo Comparator|Placebo|Placebo at Baseline, Weeks 1, 2, 3, 4, 8, and 12, followed by dosing with Secukinumab 150 mg every four weeks starting at Week 16.
3104752|NCT02159079|No Intervention|Usual Care|Patients in the usual care arm will be managed exclusively by their treating clinician without input from study personnel.
3104753|NCT02159079|Experimental|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
3104754|NCT02159118|Active Comparator|Manual bone marrow aspiration and biopsy procedure|Manual bone marrow aspiration and biopsy device
3104755|NCT02159118|Active Comparator|Powered bone marrow aspiration and biopsy procedure|Powered bone marrow aspiration and biopsy device
3104756|NCT02159183|Experimental|Standard Plus ESTA STL Roxolid implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
3104757|NCT02159183|Active Comparator|Standard Plus STL implant|This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
3104758|NCT02159352|Experimental|Group 1: Daclatasvir and Darunavir/Ritonavir|"Treatment A: Daclatasvir oral tablet on specific days~Treatment B: Daclatasvir tablet and Darunavir Tablet/Ritonavir capsule orally on specific days"
3104759|NCT02159352|Experimental|Group 2: Daclatasvir and Lopinavir/Ritonavir|"Treatment C: Daclatasvir oral tablet on specific days~Treatment D: Daclatasvir tablet and Lopinavir/Ritonavir tablet orally on specific days"
3104760|NCT02159365|Experimental|Elotuzumab + Lenalidomide/Dexamethasone|Elotuzumab 10 mg/kg solution intravenously weekly in cycle 1 and 2, then every other week, Lenalidomide 25 mg tablet by mouth Days 1-21 of each cycle / Dexamethasone 40 mg tablet by mouth / solution intravenously weekly until progression or discontinuation of Elotuzumab
3104761|NCT02159469|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
3104762|NCT02159482|Experimental|interferon-alfa-2a|Starting within 6 months after completion of the dendritic cell vaccine, a dose of interferon alfa-2a will be administered subcutaneously in the skin of the arm, thigh or abdomen every other day for a total of 6 injections.
3104763|NCT02159521|Experimental|EkoSonic® Endovascular System|Thrombolytic infusion (Alteplase), at an infusion rate of 0.5-1.0 milligrams/hour (mg/hr) will be delivered to the participants with chronic lower extremity venous obstruction after DVT and PTS through the EkoSonic® Endovascular System for at least 12 hours and overnight as needed up to a maximum of 48 hrs. The alteplase dose could be adjusted per investigator discretion, but not to be exceeded 1 mg/hr or a total dose of 48 mg.
3104764|NCT02159547|Active Comparator|Dexketoprofen|50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
3104765|NCT02159547|Placebo Comparator|normal slaline|50 ml normal saline
3104766|NCT02159703|Experimental|Single Arm Phase 2|
3104767|NCT02159729|Placebo Comparator|Placebo|Participants treated with placebo in previous ATX-101 studies
3104768|NCT02159729|Experimental|ATX-101 (1 mg/cm^2)|Participants treated with ATX-101 (1 mg/cm^2) in previous phase 2 studies
3104769|NCT02159729|Experimental|ATX-101 (2 mg/cm^2)|Participants treated with ATX-101 (2 mg/cm^2) in previous phase 2 studies
3104770|NCT02159729|Experimental|ATX-101 (4 mg/cm^2)|Participants treated with ATX-101 (4 mg/cm^2) in previous phase 2 studies
3104771|NCT02159768|Experimental|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
3104772|NCT02159807|Active Comparator|1.25 mg Bupivacaine|1.25mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
3104773|NCT02159807|Active Comparator|1.66 mg Bupivacaine|1.66mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
3104774|NCT02159807|Active Comparator|2.5 mg Bupivacaine|2.5mg of bupivacaine dose with 20 mcg of fentanyl was injected in the spinal portion of the anesthetic
3104775|NCT02159859|Experimental|Ertapenem|Subjects with end stage renal disease (ESRD) who undergo hemodialysis three times a week and without infection will be administered one gram of ertapenem once over five minutes through infusion access after a hemodialysis session, and will have blood drawn at time 0, 0.5, 1, 2, 6, and 12 hours after the ertapenem administration and once prior to the next hemodialysis session
3104776|NCT02159872|Experimental|Omacetaxine|Omacetaxine 1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle. Participant may continue taking the study drug for up to 24 cycles of treatment.
3104777|NCT02159898|Experimental|EndoMAXX Endoluminal Valve Technology (EVT)|EndoMAXX Endoluminal Valve Technology (EVT) Fully Covered Esophageal Stent with Valve
3104778|NCT02159898|Active Comparator|EndoMAXX|EndoMAXX Fully Covered Esophageal Stent
3104779|NCT02159950|Experimental|Arm I (sipuleucel-T)|Patients receive sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
3104780|NCT02159950|Experimental|Arm II (tasquinimod, sipuleucel-T)|Patients receive tasquinimod PO QD beginning on day -14 and sipuleucel-T IV over 60 minutes on day 4. Treatment repeats every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients continue on tasquinimod treatment after day 42 until disease progression.
3104781|NCT02159976|Active Comparator|Sequential therapy|pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)
3104782|NCT02159976|Experimental|Modified bismuth quadruple therapy|pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)
3104783|NCT02160002|Active Comparator|Lower Weight (1600 grams)|Weaning from an incubator at a lower weight (1600 grams)
3104784|NCT02160002|Active Comparator|Higher Weight (1800 grams)|Weaning from an incubator at a higher weight (1800 grams)
3104785|NCT02160041|Experimental|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
3104786|NCT02160145|Experimental|Tolvaptan|Tolvaptan (OPC-41061)
3104787|NCT02160145|Placebo Comparator|Placebo|Placebo
3104788|NCT02160288|Active Comparator|Botulinum Toxin-A|Patients will receive Botulinum Toxin-A (Botox) injected in the puborectalis muscle and external anal sphincter. We will use 100 units of Botox, a dose with a good safety profile that has been proven to work in previous studies performed in adults.
3104789|NCT02160288|Placebo Comparator|Normal saline|Patients will receive normal saline (placebo) injected in the puborectalis muscle and external anal sphincter.
3104790|NCT02160314|Placebo Comparator|pad|absorbent pad control
3104791|NCT02160314|Experimental|pessary|disposable, single-use pessary
3104792|NCT02160535|Experimental|Treatment with OnabotulinumtoxinA|OnabotulinumtoxinA
3104793|NCT02160626|Placebo Comparator|A-101 Vehicle|A-101 Vehicle (placebo) Topical Solution
3104794|NCT02160626|Active Comparator|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
3104795|NCT02160626|Active Comparator|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
3104796|NCT02160730|Experimental|R-roscovitine|• R-roscovitine 400 mg oral administration twice daily for 4 days every week for total of 4 weeks.
3104797|NCT02160782|Experimental|LUM001 (Maralixibat)|"LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid [sBA] level and ItchRO[Obs] score) and safety assessment.~Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat."
3104798|NCT02160782|Placebo Comparator|Placebo|Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)
3104799|NCT02160808|Active Comparator|Secretin|Stimulate pancreatic secretion
3104800|NCT02160808|Placebo Comparator|Saline|Placebo should not stimulate the pancreas to release its fluids
3104801|NCT02160847|Experimental|DRIVE program|Participants in the experimental group will receive the DRIVE curriculum (15 sessions) via weekly sessions conducted in their home by a DRIVE provider.
3104802|NCT02160847|No Intervention|Control Group|"The parents in the control group will be mailed information on nutrition, physical activity, and parent-child interactions. Information on nutrition will include guidelines provided by the MyPlate website (http://www.choosemyplate.gov/preschoolers.html) in addition to information on proper nutrition and suggest levels of physical activity for preschoolers. Lastly, parents will be provided with the free publication, Adventures in Parenting: How responding, Preventing, Monitoring, Mentoring, and Modeling Can Help You Be A Successful Parent, authored by National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. Information covered in this document includes effective parenting strategies for children at specific ages."
3104803|NCT02160873|Experimental|chocolate milk|In this arm, subjects receive chocolate milk
3104804|NCT02160873|Placebo Comparator|flavor-matched placebo|In this arm, subjects receive a flavor-matched placebo
3104805|NCT02160899|Placebo Comparator|Cohort A: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3104806|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
3104807|NCT02160899|Experimental|Cohort A: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
3104808|NCT02160899|Placebo Comparator|Cohort B: Placebo|Participants will receive placebo (normal saline) subcutaneously on Days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
3104809|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx < 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
3104810|NCT02160899|Experimental|Cohort B: ISIS-APO(a)Rx >= 2000 mg|Participants will receive ISIS-APO(a)Rx subcutaneously: 100 mg on Days 1, 8, 15, and 22; 200 mg on Days 29, 36, 43, and 50 unless down-titrated; and 300 mg on Days 57, 64, 71, and 78 unless down-titrated.
3104811|NCT02160977|Experimental|QS-TKA|patients underwent minimally invasive surgery quadriceps sparing total knee arthroplasty (MIS-QS TKA)
3104812|NCT02160977|Active Comparator|MIS-TKA|patients underwent minimally invasive surgery total knee arthroplasty (MIS TKA)
3104813|NCT02160990|Experimental|Exenatide|Participants randomized to this arm received 5 mcg exenatide subcutaneously twice daily for 30 days.
3104814|NCT02160990|Placebo Comparator|Placebo|Participants randomized to this arm received placebo subcutaneously twice daily for 30 days.
3104815|NCT02161133|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
3104816|NCT02161133|Active Comparator|Health Education|Health education provides didactic information about Gulf War Illness
3104817|NCT02161146|Experimental|AGN-229666|One drop of AGN-229666 in each eye on Days 1 and 15.
3104818|NCT02161146|Placebo Comparator|Vehicle|One drop of Vehicle to AGN-229666 in each eye on Days 1 and 15.
3104819|NCT02161146|Active Comparator|Olopatadine|One drop of olopatadine in each eye on Days 1 and 15.
3104820|NCT02161146|Other|AGN-229666/Olopatadine|One drop of AGN-229666 in one eye and one drop of olopatadine in the other eye on Days 1 and 15.
3104821|NCT02161146|Other|AGN-229666/Vehicle|One drop of AGN-229666 in one eye and one drop of Vehicle to AGN-229666 in the other eye on Days 1 and 15.
3104822|NCT02161185|Other|USL261|
3104823|NCT02161406|Active Comparator|Abatacept|125 mg SC abatacept vs SC placebo administered weekly for 12 months, with a 24-week open-label extension
3104824|NCT02161406|Placebo Comparator|Placebo|125mg Placebo
3104825|NCT02161458|Experimental|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3104826|NCT02161458|Placebo Comparator|Placebo (sugar pill)|30 cognitively normal adults aged 60-85 will receive placebo for 2 weeks (upward titration as: 10mg for 5 days, then 20mg for 9 days) or 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 2 or 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3104827|NCT02161458|Experimental|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 5 days; then 30 mg for 46 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3104828|NCT02161458|Experimental|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20mg for 8 weeks (upward titration as: 10mg for 5 days, then 20mg for 51 days); and amyloid beta levels in the CSF will be measured at baseline (before drug administration) and after 8 weeks of study drug (active or placebo). Participants will taper off medication following the 2nd CSF measurement.
3104829|NCT02161484|Experimental|Continuous Lumbar Plexus Block with Parasacral Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected."
3104830|NCT02161484|Active Comparator|Lumbar Plexus Nerve Block|"Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.~No sham/placebo parasacral (sciatic) blocks will be performed in this group."
3104831|NCT02161536|Experimental|Motus CleanC System|Colonoscopy with Motus CleanC Syetem - Device Rev 2.0 ,enrolled under protocol Rev 3.0
3104832|NCT02161536|Experimental|Motus Cleansing System Rev 2.5|Colonoscopy with MCS Rev 2.5,enrolled under protocol Rev 4.0
3104833|NCT02161536|Experimental|Motus Cleansing System Rev 3.0|Colonoscopy with MCS Rev 3.0,enrolled under protocol Rev 5.0
3104834|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.0|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.0 , enrolled under protocol Rev 1.0
3104835|NCT02161549||Colonoscopy with MotusGi CleanUp System Rev 1.5|subjects indicated for colonoscopy procedure with CleanUp System Rev 1.5 , enrolled under protocol Rev 2.0
3104836|NCT02161562|Experimental|omalizumab 150mg|Participants received 150mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period (at 150mg or 300mg) may have been implemented based on protocol-defined assessment criteria.
3104837|NCT02161562|Experimental|omalizumab 300mg|Participants received 300mg omalizumab every 4 weeks during the initial dosing phase (24 weeks). A second dosing period may have been implemented based on protocol-defined assessment criteria.
3104838|NCT02161575|Experimental|Ranibizumab|All patients received 3 monthly intraveal injections of 0.5mg ranibizumab followed by monthly injections of ranibizumab 0.5mg for a further 3 months on a prn (as required) basis, as determined by the study doctor.
3104839|NCT02161705|Experimental|Ropivacaine Group|Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
3104840|NCT02161705|Placebo Comparator|Saline Group|Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.
3104841|NCT02161718|Experimental|Samidorphan + olanzapine (ALKS 3831)|Active study drug
3104842|NCT02161718|Placebo Comparator|Placebo + olanzapine|
3104843|NCT02161731|Active Comparator|Warfarin|15 milligram (mg) warfarin administered as a single oral dose on Day 1
3104844|NCT02161731|Experimental|Evacetrapib + Warfarin|Evacetrapib administered once daily (QD), orally, for 16 days with 15 mg warfarin co-administered once orally on Day 17
3104845|NCT02161757|Experimental|Tralokinumab Dose Regimen 1|Tralokinumab subcutaneous injection
3104846|NCT02161757|Placebo Comparator|Placebo Dose Regimen 1|Placebo subcutaneous injection
3104847|NCT02161757|Experimental|Tralokinumab Dose Regimen 2|Tralokinumab subcutaneous injection
3104848|NCT02161757|Placebo Comparator|Placebo Dose Regimen 2|Placebo subcutaneous injection
3104849|NCT02162433|Active Comparator|1. Awake extubation/dexmedetomidine|Awake extubation receiving dexmedetomidine.
3104850|NCT02162433|Placebo Comparator|2. Awake extubation/placebo|Awake extubation receiving placebo (normal saline).
3104851|NCT02162433|Active Comparator|3.Deep extubation/dexmedetomidine|Deep extubation receiving dexmedetomidine.
3104852|NCT02162433|Placebo Comparator|4. Deep extubation/placebo|Deep extubation receiving placebo (normal saline).
3104853|NCT02162446|Experimental|68Ga-OPS202|Satoreotide trizoxetan will be administered in two sequentially ascending peptide doses
3132643|NCT03442569|Experimental|Open-label, single arm, Phase II|Nivolumab and ipilimumab with panitumumab
3104854|NCT02162576|Other|Propeller Health intervention group|All participants attached the Propeller sensor to their SABA medications and tracked the time and location of use for up to 13 months, to capture seasonal variation in medication use, symptoms and environmental triggers. The first 30-day run-in period served as a control period to assess levels of asthma control and SABA use; subject actuations were tracked, but participants and physicians did not receive their data or feedback. After the run-in period, participants received the full intervention for 12 months (see intervention for description).
3104855|NCT02162667|Experimental|CT-P6|
3104856|NCT02162667|Active Comparator|Trastuzumab|
3104857|NCT02162680|Active Comparator|lidocaine|1% lidocaine intradermal injection
3104858|NCT02162680|Active Comparator|bacteriostatic normal saline (BNS)|bacteriostatic normal saline (BNS) injection
3104859|NCT02162680|No Intervention|no local anesthetic|usual care practice of no local anesthetic administration
3104860|NCT02162719|Experimental|Ipatasertib + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
3104861|NCT02162719|Placebo Comparator|Placebo + Paclitaxel|Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
3104862|NCT02162758|Experimental|Dexlansoprazole 60 milligram (mg) QD|Dexlansoprazole 60 mg, delayed-release capsules, orally, QD and dexlansoprazole 60 mg placebo-matching capsules, orally, once daily for up to 12 months.
3104863|NCT02162758|Experimental|Dexlansoprazole 60 mg BID|Dexlansoprazole 60 mg, delayed-release capsules, orally, BID for up to 12 months.
3104864|NCT02162771|Experimental|CT-P10|"Patient treated with CT-P10 (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with CT-P10 (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
3104865|NCT02162771|Active Comparator|Rituxan|"Patient treated with Rituxan (375 mg/m2 IV) in combination with cyclophosphamide (750 mg/m2 IV), vincristine (1.4 mg/m2 [max 2 mg] IV), and prednisone 40 mg/m2 orally) up to 8 cycles every 3 weeks during the Core Study Period.~Patients having responses during Core Study Period treated with Rituxan (375 mg/m2 IV) monotherapy up to 12 cycles every 2 months during the Maintenance Study Period."
3104866|NCT02162862|Other|Behavioral Counseling|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I). This treatment phase focuses on treating insomnia, a nighttime component of sleep disturbance delivered in 1:1 sessions which can be completed in person or by phone, except for initial session.
3104867|NCT02162862|Other|Behavioral counseling + bupropion-SR|Brief Behavioral Therapy for Sleep Disruption in IBD (BBTS-I) plus bupropion-SR (bupropion-Sustained Release). 8-week trial of bupropion-SR (target dose: 200-300 mg/day). bup-SR, a noradrenergic dopaminergic reuptake inhibitor (NDRI). NDRI has been shown to improve fatigue and rapid eye movement-sleep (REM) in medically ill populations.
3104868|NCT02162862|No Intervention|Healthy Control|The healthy control group includes individuals who are free of physical and psychiatric illness between the ages of 15-30.
3104869|NCT02162992||SLE and Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
3104870|NCT02162992||SLE without Anti-Ro antibodies Group|Patients with SLE visited in the rheumatology outpatient's area. No intervention (only observational)
3104871|NCT02163057|Other|Cohort 1: Surgery Cohort|Participants received up to two doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart before surgery and up to three doses of INO-3112 immunotherapy 3 weeks (± 3 days) apart after surgery for a total of no more than four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device.
3104872|NCT02163057|Other|Cohort 2: Chemoradiation|Participants received four doses of INO-3112 immunotherapy delivered IM followed by EP with CELLECTRA™-5P device 3 weeks (± 3 days) apart beginning approximately 2 to 6 months after chemoradiation therapy.
3104873|NCT02163226|Experimental|Hypofractionated Radiation Therapy|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row. Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
3104874|NCT02163226|Active Comparator|One Radiation Therapy Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV). Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
3104875|NCT02163395|Other|FullCeram implant|Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm
3104876|NCT02163421|Experimental|Vedolizumab SC 54 mg|Vedolizumab SC, once on Day 1.
3104877|NCT02163421|Experimental|Vedolizumab SC 108 mg|Vedolizumab SC, once on Day 1.
3104878|NCT02163421|Experimental|Vedolizumab SC 160 mg|Vedolizumab SC, once on Day 1.
3104879|NCT02163421|Active Comparator|Vedolizumab IV 300 mg|Vedolizumab IV, once on Day 1.
3104880|NCT02163434|Experimental|gabapentin|1800-2400mg/day divided tid or qid, orally.
3104881|NCT02163434|Experimental|metoclopramide|45-60mg/day divided tid or qid, orally
3104882|NCT02163447|Active Comparator|3 dose SP pregnancy / 3 monthly DP infancy|"Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3132644|NCT03442595||Cases|patients with uncontrolled type 2 diabetes mellitus that participate in the MedStar Diabetes Pathway
3104883|NCT02163447|Active Comparator|3 dose DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3104884|NCT02163447|Active Comparator|3 dose DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age."
3104885|NCT02163447|Active Comparator|monthly DP pregnancy / 3 monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug."
3104886|NCT02163447|Active Comparator|monthly DP pregnancy / monthly DP infancy|"Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.~Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age."
3104887|NCT02163486|Active Comparator|Group U (UNIQUE)|Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
3104888|NCT02163486|Experimental|Group I (I-GEL ): Group I-GEL|Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For > 90 kg no.5. I-GEL
3104889|NCT02163499|Experimental|Sodium Zirconium Cyclosilicate|
3104890|NCT02163538|Active Comparator|articulating Enseal|This group of women undergoing total laparoscopic hysterectomy is randomized to the the articulating Enseal energy device.
3104891|NCT02163538|Active Comparator|Ligasure device|This group of women undergoing hysterectomy is randomized to the Ligasure energy device.
3104892|NCT02163577|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W). Dose was determined by the participant's weight and prescribed dose by their study doctor.
3104893|NCT02163577|Experimental|Burosumab Q4W Then Q2W|Burosumab SC injections every 4 weeks (Q4W). Dose was determined by the participant's weight and prescribed dose by their study doctor. Participants in Q4W were to switch to Q2W beginning with Week 64 dosing.
3104894|NCT02163759|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3104895|NCT02163759|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
3104896|NCT02163759|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3104897|NCT02163811|Experimental|VETPALS|VETPALS is a five session course utilizing adult learning methods to teach self-management for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA Puget Sound clinician in conjunction with a peer facilitator (Veteran with limb loss).
3104898|NCT02163811|Active Comparator|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
3104899|NCT02163824|Active Comparator|KPI-121 0.25% QID|KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3104900|NCT02163824|Active Comparator|KPI-121 1.0% BID|KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3104901|NCT02163824|Placebo Comparator|Vehicle of KPI-121 0.25%|Vehicle of KPI-121 0.25% Ophthalmic Suspension dosed 4 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3104902|NCT02163824|Placebo Comparator|Vehicle of KPI-121 1.0%|Vehicle of KPI-121 1.0% Ophthalmic Suspension dosed 2 times daily for 14 days after routine, uncomplicated surgery for cataract removal and intraocular lens implant.
3104903|NCT02163837|Experimental|rifaximine|
3104904|NCT02163902|Experimental|ATX-101|Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.
3104905|NCT02163902|Placebo Comparator|Placebo|Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.
3104906|NCT02163915|Experimental|Cohort 1: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally once on Days 1-7.
3104907|NCT02163915|Experimental|Cohort 2: TAK-137 2 mg|TAK-137 2 mg, tablets, orally once on Days 1-7.
3104908|NCT02163915|Experimental|Cohort 3: TAK-137 5 mg|TAK-137 5 mg, tablets, orally once on Days 1-7.
3104909|NCT02163915|Experimental|Cohort 4: TAK-137 10 mg|TAK-137 10 mg, tablets, orally once on Days 1-7.
3104910|NCT02163915|Experimental|Cohort 5: TAK-137 TBD|TAK-137, tablets, orally once on Days 1-7. Dose to be determined from data collected in Cohorts 1-3.
3104911|NCT02163915|Experimental|Cohorts 1-5: Placebo|TAK-137 placebo-matching tablets, orally, once on Days 1-7.
3104912|NCT02163967|Other|Dose sequence: Sham, Low, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -1 milliamp stimulation intensity, Day 3 - 2milliamp stimulation intensity
3104913|NCT02163967|Other|Dose sequence: Sham, High, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- Sham stimulation; Day 2 -2 milliamp stimulation intensity, Day 3 - 1milliamp stimulation intensity
3104914|NCT02163967|Other|Dose sequence: Low, Sham, High|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 -Sham stimulation; Day 3 - 2milliamp stimulation intensity
3104915|NCT02163967|Other|Dose sequence: Low, High, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 1milliamp stimulation intensity; Day 2 - 2milliamp stimulation intensity; Day 3 - Sham stimulation
3104916|NCT02163967|Other|Dose sequence: High, Sham, Low|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - Sham stimulation; Day 3 - 1 milliamp stimulation intensity
3104917|NCT02163967|Other|Dose sequence: High, Low, Sham|Cranial Electrical Stimulation with Fisher-Wallace Stimulator (Model FW100) for 20 minutes on 3 separate days. Day 1- 2 milliamp stimulation intensity; Day 2 - 1 milliamp stimulation intensity; Day 3 - Sham stimulation
3104918|NCT02163993|Experimental|5mg Galcanezumab|5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period.
3104919|NCT02163993|Experimental|50mg Galcanezumab|50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3104920|NCT02163993|Experimental|120mg Galcanezumab|120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3104921|NCT02163993|Experimental|300mg Galcanezumab|300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period.
3104922|NCT02163993|Placebo Comparator|Placebo|Placebo given as SQ injections once every 28 days during a 12 week treatment period.
3104923|NCT02164240|Experimental|Sunitinib alternated with Regorafenib|The treatment cycle is defined as 28 days. Treatment consists of 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each cycle. The starting dose level is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage and recommended phase II dose is determined. An alternative scheme of 4-week cycles of the same regimen but with 21 days of dosing followed by 7 days of rest will be studied in case of toxicities during d 22-28 of the starting 4-weeks continuous cycles. Tumor assessments performed at baseline and after every two dosing cycles to assess response. Toxicity monitored throughout the study.
3104924|NCT02164318|No Intervention|Control group|Standard of care
3104925|NCT02164318|Experimental|Handgrip training group|Perform isometric handgrip exercises for 15 minutes twice per day for a total of 30 minutes
3104926|NCT02164318|Experimental|Nitroglycerin ointment group|Apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
3104927|NCT02164318|Experimental|Combined handgrip training /Nitroglycerin ointment group|Perform isometric handgrip exercises for 15 minutes twice each day for a total of 30 minutes and apply 15mg of nitroglycerin ointment to the back of the hand of the surgical arm nightly
3104928|NCT02164383|Experimental|Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention? Nicotine patch plus behavioral cessation counseling with access to Mobile Games."
3104929|NCT02164383|Experimental|No Mobile Games|"This arm of the project will address the following question:~How effective is the following intervention:~Nicotine patch plus behavioral cessation counseling without access to Mobile Games."
3104930|NCT02164396|Active Comparator|Spectacles Lens|Participant will discontinue soft contact lens wear and wear spectacles only. Spectacle lens refers to the habitual prescription glasses that the participant arrives to the testing center with; they are NOT prescribed or given to the participant by the investigator as part of the study protocol.
3104931|NCT02164396|Active Comparator|Habitual Soft Contact Lens|Participant will continue to wear their habitual soft contact lenses. Habitual lenses are the contact lenses used by the subjects prior to participating in the clinical trial. Various types/brands are used by subjects prior to participation.
3104932|NCT02164396|Experimental|Test Lens|Participants will be dispensed senofilcon A or narafilcon A depending on their habitual modality (reusable or daily disposable)
3104933|NCT02164422|Experimental|Guanfacine 3mg/day|Guanfacine 3mg/day
3104934|NCT02164422|Experimental|Guanfacine 1.5mg/day|Guanfacine 1.5mg/day
3104935|NCT02164422|Placebo Comparator|Placebo|Placebo
3104936|NCT02164513|Experimental|fluticasone furoate/umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg QD (morning) for a period of 52 weeks via DPI
3104937|NCT02164513|Experimental|fluticasone furoate/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive FF/VI 100 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI)
3104938|NCT02164513|Experimental|umeclidinium bromide/vilanterol|Eligible Subjects completing 2-weeks run-in period will receive UMEC/VI 62.5 mcg/25 mcg QD (morning) for a treatment period of 52 weeks via DPI
3104939|NCT02164539|Experimental|Treatment Phase A|Eligible subjects will enter a 4-week run-in period and will receive fluticasone propionate/salmeterol. Subjects will then be randomized to receive fluticasone furoate 100 mcg, fluticasone furoate/umeclidinium bromide 100/15.6 mcg, fluticasone furoate/umeclidinium bromide 100/62.5 mcg, fluticasone furoate/umeclidinium bromide 100/125 mcg, fluticasone furoate/umeclidinium bromide 100/250 mcg, or fluticasone furoate/vilanterol 100/25 mcg, respectively for 4 weeks
3104940|NCT02164539|Experimental|Treatment Phase B|Subjects completing Treatment Phase A will be randomized to receive either fluticasone furoate/umeclidinium bromide100/250 mcg or fluticasone furoate/umeclidinium bromide/vilanterol 100/250/25 mcg for 1 week.
3104941|NCT02164539|Experimental|Treatment Phase C|Subjects completing Treatment Phase B will be randomized to receive either the same treatment as in Treatment Phase B, or the same treatment minus the umeclidinium bromide component, for 1 week.
3104942|NCT02164721|Other|CRT-D (Defibrillator)|Implantation of a three-lead CRT-D (Defibrillator) in all registered patients
3104943|NCT02164864|Experimental|Dabigatran Etexilate 110mg|Patient to receive Dabigatran Etexilate 110mg twice a day (BID)
3104944|NCT02164864|Experimental|Dabigatran Etexilate 150mg|Patient to receive Dabigatran Etexilate 150mg twice a day (BID)
3104945|NCT02164864|Active Comparator|Warfarin|Warfarin doses to maintain INR
3104946|NCT02164916|Active Comparator|Arm I (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV and irinotecan hydrochloride IV on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross over to Arm II.
3104947|NCT02164916|Experimental|Arm II (cetuximab, irinotecan hydrochloride, vemurafenib)|Patients receive cetuximab and irinotecan hydrochloride as in Arm I and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3104948|NCT02164929|Active Comparator|Paravertebral block|Bilateral PVB will be placed between T7-T10 interspaces preoperatively. Patients will be in a sitting position which allows easy identification of landmarks, and the patients are often more comfortable. Ultrasound will be used to identify the paravertebral space. At the appropriate dermatome under aseptic precautions, the needle (22-gauge, 8-10-cm short beveled spinal needle) will inserted 2.5-3 cm lateral to the most cephalad aspect of the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process 3 of the vertebra below at a variable depth (2-4 cm). A 10 mL ropivacaine 0.25% will be injected at both T7 and T9 levels on each side (40 mL in total).
3104949|NCT02164929|Active Comparator|TAP block|Bilateral posterior and subcostal TAP blocks guided by ultrasound will be performed in the preoperative holding area. A total of 80 mL ropivacaine 0.25% (4 injections, 20 mL per injection) will be injected evenly upon identification of the appropriate planes. In the event the placement of block is uncomfortable for the patients, it will be performed after induction of anesthesia. This approach is currently practiced in the OR. Extent and degree of anesthetic blockage will be measured using a 5-point sensation scale following the procedure at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).
3104950|NCT02164929|Active Comparator|Epidural|"An epidural catheter will be inserted between T8-10 in the preoperative holding area, and a test dose of 1.5% lidocaine with 1:200,000 epinephrine will be given. Extent and degree of anesthetic blockage will be measured using a 5-point sensation following the procedure and postoperatively at 4 areas on the anterior abdominal wall (above and below the umbilicus bilaterally).~A bolus does of epidural hydromorphone (400-800 mcg) will be given preoperatively. An infusion of bupivacaine 0.25% at 4-6 ml/hour will be commenced before incision, and if tolerated, continued throughout surgery. Adjustments that may be required secondary to specific patient hemodynamic status will be left to the discretion of the individual anesthesiologist and guided by the specific patient requirements."
3104951|NCT02164929|Active Comparator|No block (PCA alone)|Premedication with midazolam up to 2 mg. General anesthesia is induced with propofol 1-2.5 mg/kg. Dexamethasone 4 mg IV will be administered after induction of anesthesia. Anesthesia will be maintained with sevoflurane to keep a bispectral index of between 40-60. Neuromuscular blocking drug and reversal agent of choice may be used. Local infiltration with 10 mL of plain ropivacaine 0.25% will be administered at the surgical incision site at the end of surgery. Acetaminophen 1g IV will be administered following induction of anesthesia will be administered at the end of the procedure
3104952|NCT02164981|Active Comparator|Drug - Drug|Phase 1 - intravenous sodium nitroprusside Phase 2 - intravenous sodium nitroprusside
3104953|NCT02164981|Other|Placebo - Drug|Phase 1 - intravenous dextrose Phase 2 - intravenous sodium nitroprusside
3104954|NCT02164981|Placebo Comparator|Placebo - Placebo|Phase 1 - intravenous dextrose Phase 2 - intravenous dextrose
3104955|NCT02165111|Experimental|Onabotulinumtoxin A|"One hand of each patient will be randomly selected for injection of Botulinum Toxin A (Onabotulinumtoxin A, 20 units/mL).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (10 units each=0.5mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (5 units each= 0.25mL each). Total treatment dose of Botulinum Toxin A will not exceed 50 units per hand."
3104956|NCT02165111|Placebo Comparator|Placebo|"One hand of each patient will be randomly selected for injection of sterile saline solution (placebo).~Injections are performed using a 30 gauge insulin syringe through the dorsal surface in seven locations: adjacent to the 2nd, 3rd, and 4th common digital arteries through the web spaces (0.5 mL each), and the radial side of the index finger metacarpal head, the ulnar side of the small finger metacarpal head, and each side of the thumb metacarpal head (0.25 mL each)."
3104957|NCT02165124|Experimental|Intervention/Bariatric Embolization|
3104958|NCT02165202|Active Comparator|Rilpivirine|Arm 1: Participants randomized to the active arm will receive rilpivirine 25 mg capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of TMC278 LA, 1200 mg dose, at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion 1200 mg of TMC278 LA will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
3104959|NCT02165202|Placebo Comparator|Placebo|Arm 2: Participants randomized to the placebo arm will receive placebo capsules once daily for four weeks to be taken orally with a meal. Participants will then receive IM injections of saline (0.9% NaCI) at eight week intervals (at Weeks 4, 12, 20, 28, 36 and 44). On each dosing occasion placebo will be delivered in two, 2 mL injections, one in each gluteus maximus muscle. All participants will receive a total of six doses (12 IM injections).
3104963|NCT02165384|Experimental|Hummingbird TTS|Ear tube placement with the Hummingbird TTS
3104964|NCT02165397|Experimental|Randomized Study (Ibrutinib + Rituximab)|Ibrutinib: 420 mg (3 capsules x 140 mg) orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 intravenous (IV) per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
3104965|NCT02165397|Experimental|Randomized Study (Placebo + Rituximab)|Placebo: 3 capsules of placebo orally administered daily beginning from Day 1. Rituximab: 375 mg/m^2 IV per package insert weekly for four consecutive weeks, followed by a second four-weekly rituximab course after a three-month interval.
3104966|NCT02165397|Experimental|Open-Label Substudy (Ibrutinib)|Ibrutinib: 420 mg (3 capsules) orally administered daily beginning from Day 1.
3104967|NCT02165462||Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task
3104968|NCT02165605|Experimental|HylaCare|HylaCare cream Each patient will be randomized blindly as to whether the study serum will be applied to the medial or lateral portion of the treated breast, using the nipple as the dividing line. The product and placebo will also be applied to the contra-lateral breast in the same fashion, as a further control. The study drug and placebo will be applied three (3) times daily, but not within 4 hours prior to radiation treatment.
3104969|NCT02165605|Placebo Comparator|Placebo|The patient is her own control.
3104970|NCT02165722|Experimental|Intervention: Toolkit|4 Pillars Toolkit
3104971|NCT02165722|No Intervention|No Intervention: Standard practice|11 Clinical Practices [control sites]
3104972|NCT02165735|Experimental|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification patient concerns and patient behavioral rehearsal for asking about these concerns.
3104973|NCT02165735|Experimental|Usual Care|Usual care for HIV
3104974|NCT02165761|Active Comparator|GORE® Hybrid Vascular Graft|GORE® Hybrid Vascular Graft
3104975|NCT02165761|Other|Non-heparin bonded synthetic graft|Non-heparin bonded synthetic graft
3104976|NCT02165826|Experimental|Roflumilast 500 μg once daily|Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3104977|NCT02165826|Experimental|Roflumilast 500 μg every other day|Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3104978|NCT02165826|Experimental|Roflumilast 250 μg once daily|Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
3104979|NCT02165839|Active Comparator|Healthy Eating Education Learning (HEAL)|Control group.
3104980|NCT02165839|Experimental|Brief Behavioral Therapy for Insomnia (BBT-I)|
3104981|NCT02165904|Experimental|Autologous Mesenchymal Bone Marrow Cell|All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow Cell
3104982|NCT02166047|Placebo Comparator|Placebo 4 Weeks (Cohort A)|Placebo tablet once a week for 4 weeks
3104983|NCT02166047|Experimental|Vesatolimod 1 mg 4 Weeks (Cohort A)|Vesatolimod 1 mg tablet once a week for 4 weeks
3104984|NCT02166047|Experimental|Vesatolimod 2 mg 4 Weeks (Cohort A)|Vesatolimod 2 mg tablet once a week for 4 weeks
3104985|NCT02166047|Experimental|Vesatolimod 4 mg 4 Weeks (Cohort A)|Vesatolimod 4 mg tablet once a week for 4 weeks
3104986|NCT02166047|Placebo Comparator|Placebo 8 Weeks (Cohort B)|Placebo tablet once a week for 8 weeks
3104987|NCT02166047|Experimental|Vesatolimod 1 mg 8 Weeks (Cohort B)|Vesatolimod 1 mg tablet once a week for 8 weeks
3104988|NCT02166047|Experimental|Vesatolimod 2 mg 8 Weeks (Cohort B)|Vesatolimod 2 mg tablet once a week for 8 weeks
3104989|NCT02166047|Experimental|Vesatolimod 4 mg 8 Weeks (Cohort B)|Vesatolimod 4 mg tablet once a week for 8 weeks
3104990|NCT02166047|Placebo Comparator|Placebo 12 Weeks (Cohort C)|Placebo tablet once a week for 12 weeks
3104991|NCT02166047|Experimental|Vesatolimod 1 mg 12 Weeks (Cohort C)|Vesatolimod 1 mg tablet once a week for 12 weeks
3104992|NCT02166047|Experimental|Vesatolimod 2 mg 12 Weeks (Cohort C)|Vesatolimod 2 mg tablet once a week for 12 weeks
3104993|NCT02166047|Experimental|Vesatolimod 4 mg 12 Weeks (Cohort C)|Vesatolimod 4 mg tablet once a week for 12 weeks
3104994|NCT02166333|Active Comparator|200 IU/d|200 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3104995|NCT02166333|Active Comparator|1000 IU/d|1000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3104996|NCT02166333|Active Comparator|2000 IU/d|2000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3104997|NCT02166333|Active Comparator|4000 IU/d|4000 IU/d cholecalciferol (vitamin D3) tablets that can be swallowed or consumed sublingually
3104998|NCT02166346|Experimental|Dalfampridine then Placebo|All subjects were randomized for the first double-blinded 8-week part of the study to the dalfampridine group. Then subjects were crossed over to the placebo arm for another 8 weeks.
3104999|NCT02166346|Experimental|Placebo the Dalfampridine|All subjects were randomized for the first double-blinded 8-week part of the study to the placebo arm. Then subjects were crossed over to the dalfampridine arm for another 8 weeks.
3105000|NCT02166476|Experimental|Meropenem-Vaborbactam|Meropenem-vaborbactam (meropenem 2 grams [g] plus vaborbactam 2 g), infused in 250 milliliters (mL) normal saline, administered intravenously (IV) over 3 hours, every 8 hours (q8h), with 100 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-milligram (mg) dose every 24 hours (q24h) after a minimum of 15 doses of IV meropenem-vaborbactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
3105001|NCT02166476|Active Comparator|Piperacillin-Tazobactam|Piperacillin-tazobactam (piperacillin 4 g plus tazobactam 0.5 g), infused in 100 mL normal saline, administered IV over 30 minutes, q8h, with 250 mL saline administered over 30 minutes q8h. Levofloxacin tablets administered orally as a 500-mg dose q24h after a minimum of 15 doses of IV piperacillin-tazobactam plus saline, if clinically indicated. Total treatment was 10 days, unless a participant had baseline bacteremia where up to 14 days of therapy could be administered IV.
3105002|NCT02166606||Pacemaker/Lead implant|"All enrolled subjects will receive an ImageReady Magnet Resonant (MR) Conditional Pacing System and the treatment assignment will be based on an all-comers consecutive basis."
3105003|NCT02166697||Oral administration of 4-8 mg of candesartan cilexetil|Oral administration of 4-8 milligram (mg) of candesartan cilexetil once daily (increased up to 12 mg, as necessary)
3105004|NCT02167035|Active Comparator|Combigan Two Times Daily (BID)|Combigan 0.2%/0.5% one drop Two Times Daily (BID)
3105005|NCT02167035|Active Comparator|Simbrinza Three Times Daily (TID)|Simbrinza 1/0.2% one drop Three Times Daily (TID)
3105006|NCT02167074|Active Comparator|25G FNA needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
3105007|NCT02167074|Active Comparator|20G ProCore FNB needle|Patients referred for EUS-guided tissue acquisition of a pancreatic mass, lymph node, or other submucosal or undefined mass (non-pancreatic).
3105008|NCT02167139|Experimental|SB5 (proposed biosimilar to adalimumab)|SB5 40 mg every other week via subcutaneous injection
3105009|NCT02167139|Active Comparator|Humira (adalimumab)|Humira 40 mg every other week via subcutaneous injection
3105010|NCT02167204|Experimental|Diagnostic (18F-FLT PET/CT)|Patients undergo 18F-FLT PET/CT at baseline (pre-therapy), mid-therapy, completion of therapy, and 1 year after completion of therapy or time of suspected recurrence.
3105011|NCT02167217|Experimental|Oral Prednisolone|Oral Prednisolone 5mg/kg/ day on two consecutive days, Friday and Saturday with breakfast
3105012|NCT02167256|Experimental|AZD0530 100mg daily|Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of <100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
3105013|NCT02167256|Placebo Comparator|AZD0530 Placebo|50% of patients will receive placebo treatment for the duration of the study,
3105014|NCT02167451|Experimental|Maraviroc|Maraviroc administration will start on day -3 and will end on day +30 after stell cell transplant, making the total number of days of drug administration 34 days. Maraviroc will be administered twice daily orally or via enteral tube. Dosing of Maraviroc will be based on body surface area (starting with 100mg twice a day for BSA of 0.2 and up to 300mg twice a day for BSA greater than 1.73).
3105015|NCT02167594|Experimental|PSP Subjects|Amyloid negative subjects with PSP receiving a flortaucipir PET scan at baseline and at 9 months.
3105016|NCT02167594|Experimental|CBD subjects|Amyloid negative subjects with CBD receiving a flortaucipir PET scan at baseline and at 9 months.
3105017|NCT02167594|Experimental|Healthy volunteers|Healthy volunteers receiving a flortaucipir PET scan at baseline.
3105018|NCT02167815|Active Comparator|Standard care|standard care ( such as alginate, hydrofiber or other treatment)
3105019|NCT02167815|Experimental|Intervention ( Mepilex XT)|
3105020|NCT02167867|Experimental|Lay End Users|Employees of the test sites (that were fitness centers or spas) who were provided with a User's Manual to operate the ZERONA Z6 to administer 6 40-minute evenly spaced treatments over 2 consecutive weeks to the front and back of the waist, hips and thighs of one Treatment Subject.
3105021|NCT02167867|Experimental|Treatment Subject Group|Treatment subjects received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
3105022|NCT02167893||Subcutaneous administration of leuprorelin acetate|Subcutaneous administration of leuprorelin acetate once every 12 weeks as daily medicinal practice.
3105023|NCT02168062|Active Comparator|Arm I (standard of care)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM and visit their health care provider every 3 months for 12 months. Patients will be referred to a nutrition, exercise, and symptom management service upon patient request or if deemed necessary by a healthcare provider. Patients may cross-over to Arm II after 12 months.
3105024|NCT02168062|Experimental|Arm II (STAND clinic)|Patients receive leuprolide acetate SC or IM, goserelin acetate SC, or triptorelin pamoate IM every 3 months for 12 months. Patients also review educational modules discussing various aspects of anti-androgen therapy and management of side effects and meet one-to-one with a licensed exercise trainer, registered dietician, and symptom management service to receive individualized counseling monthly for 12 months.
3105025|NCT02168101|Experimental|MLN9708 - 2.3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 2.3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
3105026|NCT02168101|Experimental|MLN9708 - 3 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 3 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
3105027|NCT02168101|Experimental|MLN9708 - 4 mg|Patients will be enrolled between Days 45 and 120 after allogeneic transplant and will receive a weekly dose of 4 mg of MLN9708 on Days 1, 8, and 15 of each 28-day cycle for 6 cycles.
3105028|NCT02168153|Active Comparator|Chiropractic Manipulative Therapy|Participants will complete questionnaires and biomechanical assessments, and additionally receive CMT treatment.
3105029|NCT02168153|Placebo Comparator|Wait-List Control Group|Participants will complete questionnaires and biomechanical assessments
3105030|NCT02168309|Other|Labetalol|Labetalol 200mg PO BID starting dose
3105031|NCT02168309|Other|Nifedipine|Nifedpine XL starting at dose 30mg PO daily
3105032|NCT02168361|Active Comparator|Standard|Pegylated Interferon Alfa-2b (1.5 ugm/kg/week subcutaneously) plus ribavirin (1000-1200 mg daily orally) plus sofosbuvir (400 mg daily) for 12 weeks
3105033|NCT02168361|Experimental|Simeprevir + Sofosbuvir|(SIM-SOF) which is Simeprevir + Sofosbuvir for 12 weeks
3105034|NCT02168387|Active Comparator|continuous high frequency oscillator (CHFO)|Subjects randomized to receive therapy with the CHFO will receive a 20 minute treatment every 6 hours for 48 hours.
3105035|NCT02168387|Active Comparator|medication|Subjects randomized to receive the medications will receive acetylcysteine and dornase alfa, two medications frequently used in the treatment of atelectasis. The medications will alternate every 6 hours for 48 hours.
3105036|NCT02168439|Experimental|Dexmedetomidine|Intranasal Dexmedetomidine 2 micrograms/kilogram once
3105037|NCT02168439|Experimental|Midazolam|Intranasal Midazolam 0.4 milligram/kilogram
3105038|NCT02168478|Experimental|Patch Test Group|"All subjects are patched with the following: 1.Neo-Synalar Cream 2.Sodium Lauryl Sulfate and 3. Saline.~Test material is applied to the absorbent pad and allowed to remain in direct skin contact for a period of 48 hours."
3105039|NCT02168491|Experimental|Intervention group|10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide
3105040|NCT02168660|Active Comparator|Control Group|Standard vitamin D3 dose as per IOM (Institute of Medicine) recommendations; actual dose will be 5000 IU per week, which is just slightly higher than the IOM recommendation of 600 IU per day. Length of time proposed to be 4 months at 5000 IU D3 per week. End of study measures at 4 months to be HOMA-IR, BMI Z score, 25-OHD level.
3105041|NCT02168660|Experimental|Low-Normal Group|Initial D3 dose will be 30,000 IU per week; at 6 week intervals serum D3 levels will be checked, and dose adjustments made to reach target 25-OHD level of between 30-50 ng/mL (inclusive). Once within target, D3 dose will be continued for 4 months, and end of study measurements done (HOMA-IR, BMI Z score, 25-OHD level).
3105042|NCT02168660|Experimental|High-Normal Group|Initial D3 dose will be 60,000 IU/week; at 6 week intervals 25-OHD levels will be done, and dose adjustments made to achieve target level of 40-60 ng/mL (inclusive). Once within target range, D3 dose will be continued for 4 months, and end of study measures obtained (HOMA-IR, BMI Z score, 25-OHD level).
3105043|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort 0|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort 0: Refametinib 30mg twice daily (b.i.d) + Regorafenib 80mg once daily (q.d), 3 weeks on/1 week off.
3105044|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1: Refametinib 20mg b.i.d + Regorafenib 80mg q.d, 3 weeks on/1 week off.
3105045|NCT02168777|Experimental|Ph1b-Refametinib/Regorafenib Cohort -1a|Phase 1b part of study: Participants received different doses of Refametinib and Regorafenib combination therapy to determine recommended Phase 2 dose (RP2D) via dose-escalation. Cohort -1a: Refametinib 20mg b.i.d + Regorafenib 120mg q.d, 3 weeks on/1 week off.
3105046|NCT02168803|Experimental|Evacetrapib: Single Dose|Single oral dose of evacetrapib on Day 1
3105047|NCT02168803|Experimental|Evacetrapib: Multiple Dose 12 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 12 consecutive weeks
3105048|NCT02168803|Experimental|Evacetrapib: Multiple Dose 24 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 24 consecutive weeks
3105049|NCT02168803|Experimental|Evacetrapib: Multiple Dose 52 Weeks|Evacetrapib administered orally once daily beginning on Day 8 for 52 consecutive weeks
3105050|NCT02168816|Active Comparator|Midfoot|Individuals with an infection on the midfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3105051|NCT02168816|Active Comparator|Hindfoot|Individuals with an infection on the hindfoot are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3105052|NCT02168816|Active Comparator|Toe|Individuals with an infection on the toe are randomized to an intravenous antibacterial agent or an oral antibacterial agent.
3105053|NCT02168842|Active Comparator|Isradipine|Oral capsule of up to 5 mg of isradipine taken twice daily for 36 months.
3105054|NCT02168842|Placebo Comparator|Placebo (for Isradipine)|Oral capsule taken twice daily for 36 months.
3105055|NCT02168855|Active Comparator|Active nicotine gum|
3105056|NCT02168855|Placebo Comparator|Inactive gum|
3105057|NCT02168933|Experimental|active excimer laser|308 nm excimer laser treatment: treatment with the laser by a dose protocol with increasing output.
3105058|NCT02168933|Sham Comparator|Sham excimer laser|Sham 308 nm excimer laser treatment: laser dose was administered with a cap that blocks all active UV passing through the device, therefore is a placebo, but because the procedure is the same, maintains a blind.
3105059|NCT02168946|Experimental|Vabomere|Vabomere (meropenem 2g plus vaborbactam 2g) IV q8h, for up to 14 days
3105060|NCT02168946|Active Comparator|Best Available Therapy|Subjects will receive Best Available Therapy (IV antibiotics)
3105061|NCT02169115|Experimental|Omalizumab 150mg|
3105062|NCT02169115|Experimental|Omalizumab 300mg|
3105063|NCT02169115|Placebo Comparator|Placebo|
3105064|NCT02169219|Experimental|Glucocorticoids and Rituximab|This is a single-arm trial. All patients receive both rituximab and glucocorticoids. The protocol calls for the discontinuation of prednisone within two months of the baseline visit.
3105065|NCT02169271|Experimental|Arm I (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO QD for 12 months.
3105066|NCT02169271|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 12 months.
3105067|NCT02169284|Experimental|Group I (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
3105068|NCT02169284|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD on days 1, 8, and 15. Patients then undergo TURBT or cystectomy on day 16.
3105069|NCT02169336|Experimental|DEX-IN 35mcg|DEX-IN 35mcg every 6 hours for 48 hours. DEX-IN 35mcg PRN for up to 3 additional days.
3105070|NCT02169336|Experimental|DEX-IN 50mcg|DEX-IN 50mcg every 6 hours for 48 hours. DEX-IN 50mcg PRN for up to 3 additional days.
3105071|NCT02169336|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours. IN Placebo PRN for up to 3 additional days.
3105072|NCT02169414|Experimental|BIA 9-1067 5 mg|1 capsule of 5 mg + 2 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3105073|NCT02169414|Experimental|BIA 9-1067 15 mg|3 capsules of 5 mg for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3105074|NCT02169414|Experimental|BIA 9-1067 50 mg|2 capsules of BIA 9-1067 25 mg + 1 capsule of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3105075|NCT02169414|Placebo Comparator|Placebo|3 capsules of placebo for 18 days levodopa/carbidopa 100/25 mg was administered on Day 11 levodopa/benserazide 100/25 mg was administered on Day 18.
3105076|NCT02169427|Experimental|Opicapone (OPC)|100 mg OPC
3105077|NCT02169440|Experimental|Group 1|Period 1: BIA 9-1067 + warfarin Period 2: warfarin
3105078|NCT02169440|Active Comparator|Group 2|Period 1: warfarin Period 2: BIA 9-1067 + warfarin
3105079|NCT02169453|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3105080|NCT02169453|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3105081|NCT02169453|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Sinemet® CR 100/25 (Single-dose of controlled-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® CR 100/25.)"
3105082|NCT02169453|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Subjects were to attend four treatment periods and were to receive a different dose of BIA 9-1067 (25 mg, 50 mg and 100 mg) or placebo during each of these treatment periods."
3105083|NCT02169466|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3105084|NCT02169466|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3105085|NCT02169466|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3105086|NCT02169466|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9-1067/Placebo was to be administered concomitantly with the dose of Madopar® HBS (Single-dose of controlled-release levodopa/benserazide 100/25 mg: 1 capsule of Madopar® HBS.)"
3105087|NCT02169479|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3105088|NCT02169479|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3105089|NCT02169479|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3105090|NCT02169479|Experimental|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~BIA 9- 067/Placebo was to be administered concomitantly with the a single-dose of immediate-release levodopa/carbidopa 100/25 mg: 1 tablet of Sinemet® 100/25"
3105091|NCT02169505|Experimental|Brentuximab Vedotin|"Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles."
3105092|NCT02169674|Active Comparator|10-11 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
3105093|NCT02169674|Active Comparator|15-16 Year-olds|Recombinant hepatitis B virus vaccine (EngerixB, GlaxoSmithKline Vaccines)
3105094|NCT02169739|No Intervention|Medical therapy only|Intensive standard medical secondary prevention stroke treatment as per the recommendations of the American Heart Association/American Stroke Association national guidelines.
3105095|NCT02169739|Active Comparator|Ischemic Preconditioning + Medical|Patients will receive treatment with Cell Aegis remote ischemic preconditioning device once or twice daily for one year. The procedure will consist of up to four 5-minute cycles of bilateral upper extremity ischemia separated by five minutes of reperfusion. Patients will also receive intensive standard medical secondary prevention stroke treatment as per the American Heart Association/American Stroke Association national guidelines.
3105096|NCT02169791|Experimental|Haploidentical Transplant|All patients will receive a haploidentical donor transplant using a conditioning regimen of Fludarabine (Flu), cyclophosphamide (cy) and total body irradiation (TBI) followed by MLN9708.
3105097|NCT02169869|Experimental|Immediate postplacental IUD insertion|Women randomized to the immediate postplacental IUD group will receive their IUD within 60 minutes of placental delivery.
3105098|NCT02169869|Active Comparator|6 weeks postpartum IUD insertion|Subjects who are randomized for IUD insertion at their postpartum visit will be assisted in scheduling a postpartum visit and IUD placement with their usual obstetrical care provider.
3105099|NCT02169895|Experimental|Group 1|"Period 1: BIA 9-1067 25 mg Period 2: BIA 9-1067 50 mg Period 3: BIA 9-1067 100 mg Period 4: Placebo~Every period with concomitant single oral administration of Prolopa® 100-25"
3105100|NCT02169895|Experimental|Group 2|"Period 1: BIA 9-1067 50 mg Period 2: BIA 9-1067 100 mg Period 3: Placebo Period 4: BIA 9-1067 25 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3105101|NCT02169895|Experimental|Group 3|"Period 1: BIA 9-1067 100 mg Period 2: Placebo Period 3: BIA 9-1067 25 mg Period 4: BIA 9-1067 50 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3105102|NCT02169895|Active Comparator|Group 4|"Period 1: Placebo Period 2: BIA 9-1067 25 mg Period 3: BIA 9-1067 50 mg Period 4: BIA 9-1067 100 mg~Every period with concomitant single oral administration of Prolopa® 100-25"
3105103|NCT02170025|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
3105104|NCT02170025|Experimental|Placebo|Participants received matching placebo tid.
3105105|NCT02170051|Experimental|CBSST-CCT|Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training
3105106|NCT02170051|Active Comparator|Goal-focused supportive contact|Goal-focused supportive contact
3105107|NCT02170064|Experimental|Group 1 (2-6 yrs)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 1 (2-6 years), oral suspension 50 mg/mL was used. The dose was to be rounded to the nearest 25 mg unit."
3105108|NCT02170064|Experimental|Group 2 (7-11 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
3105109|NCT02170064|Experimental|Group 3 (12-17 years)|"At the end of the baseline phase, patients meeting the final selection criteria were admitted to three consecutive 4-week treatment periods in which they received Eslicarbazepine acetate once-daily at the following dosage regimens: 5 mg/kg/day in the first 4 weeks, 15 mg/kg/day in weeks 5-8 and 30 mg/kg/day or 1800 mg/day, whichever less, in weeks 9-12. After the last treatment period, dose was down-titrated during a 2-week period or patient continued receiving Eslicarbazepine acetate (compassionate use) if both parent(s)/guardian(s)/patient and his/her physician agreed this was in the best patient's interest.~For Group 2 (7-11 years) and Group 3 (12-17 years), Eslicarbazepine acetate strengths 200 mg, 400 mg, 600 mg and 800 mg tablets might be used. The dose was to be rounded to the nearest 100 mg unit. Half tablets might be used for dosage adjustment (tablets were scored)."
3105110|NCT02170077|Experimental|ODG - once-daily group|BIA 2-093 once-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
3105111|NCT02170077|Experimental|TDG - twice-daily group|BIA 2-093 twice-daily; Daily doses of BIA 2-093 were increased at four-weekly periods (400 mg, 800 mg and 1200 mg).
3105112|NCT02170077|Placebo Comparator|PLG - placebo group|placebo
3105113|NCT02170207||30 mg of lansoprazole|30 mg of lansoprazole is mixed in physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by drip infusion or dissolved in 20 mL of physiological saline (JP) or 5% glucose solution for injection (JP) and administered twice daily by direct slow intravenous injection.
3105114|NCT02170220|Experimental|Vortioxetine 5 mg: Normal Hepatic Function Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
3105115|NCT02170220|Experimental|Vortioxetine 5 mg: Severe Hepatic Impairment Cohort|Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
3105116|NCT02170363|Experimental|HeartMate 3|Left Ventricular Assist System (LVAS) to be used on Subjects with advanced refractory left ventricular heart failure
3105117|NCT02170376|Experimental|Group 1|Placebo once-daily for 11 days 200 mg entacapone concomitantly with levodopa/carbidopa on Day 12
3105118|NCT02170376|Experimental|Group 2|25 mg BIA 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
3105119|NCT02170376|Experimental|Group 3|50 mg 9-1067 once-daily for 11 days Placebo concomitantly with levodopa/carbidopa on Day 12
3105120|NCT02170376|Experimental|Group 4|75 mg 9-1067 once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
3105121|NCT02170376|Placebo Comparator|Group 5|placebo once-daily for 11 days placebo concomitantly with levodopa/carbidopa on Day 12
3105122|NCT02170389|Experimental|Treatment (AGS-003 immunotherapy, nephrectomy)|Patients receive 3 injections of renal cell carcinoma/cluster of CD40L RNA-transfected autologous dendritic cell vaccine AGS-003 ID once every 7 days during weeks 6-8 in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy on week 10.
3105123|NCT02170519|Experimental|Phase 2: Inhaled Iloprost continuous|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized continuously at a dose of 5-30mcg/hour for as long as the attending physician deems it necessary to deliver vasodilator therapy."
3132645|NCT03442595||Matched controls|patients with uncontrolled type 2 diabetes that match the cases on 5 criteria and received standard of care diabetes management with a MedStar provider
3105124|NCT02170519|Experimental|Phase 1: Inhaled Iloprost 3 doses|"Each subject will have a stable dose of INO therapy as established by the attending physicians for at least one hour. Initial baseline data collection will then be made.~A 20 mcg dose of Iloprost will be given initially. During this treatment there will be a nitric oxide titration to 0. Iloprost will be aerosolized three different times on hour apart. Thirty minutes after the last iloprost dose, INO will be added back at the previous (baseline) dose."
3105125|NCT02170532|Active Comparator|levalbuterol + saline in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml saline in a breath actuated nebulizer
3105126|NCT02170532|Active Comparator|levalbuterol + ipratroprium in a breath actuated nebulizer|0.5 ml. levalbuterol + 0.5ml ipratroprium in a breath actuated nebulizer
3105127|NCT02170532|Active Comparator|levalbuterol MDI 2 puffs|levalbuterol metered dose inhaler 2 puffs
3105128|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max without pause 2 puffs|levalbuterol MDI + aerochamber max without pause 2 puffs
3105129|NCT02170532|Active Comparator|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs|levalbuterol MDI + aerochamber max with 2 second pause 2 puffs
3105130|NCT02170649|Experimental|Single Group|the volunteers received a single 800 mg BIA 2-093 following either a standard high fat content breakfast or 10 hours of fasting. Fed and fasting periods were separated by a washout period
3105131|NCT02170662|Active Comparator|Active drug|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
3105132|NCT02170662|Active Comparator|Placebo|During Part I of the study, subjects will be randomized in a blinded fashion to either placebo (vehicle that does not contain active drug) or topical bimatoprost to apply to the scalp target area every day for 16 weeks. After a 10 day washout period, each group will be crossed over to the alternate topical preparation (Part II) to apply for 16 weeks.
3105133|NCT02170688|Active Comparator|Fixed dose|50 subjects will receive contrast media based on a fixed dose. Each will receive 125 mL of Isovue 370 (370 mg of iodine/mL) administered at 4 mL/sec (1.48 gmI/sec for 31.25 sec).
3105134|NCT02170688|Active Comparator|Total body weight|25 subjects will receive contrast media dose based on the total body weight. Total body weight will be determined. Both men and women will receive contrast media at a dose of 0.7 gmI/kg (1.78 mL of Isovue 370/kg) or 0.30 gmI/lb (0.81 mL of Isovue 370/lb). The injection rate will be 0.058 mL/sec/kg (0.026 mL/sec/lb).
3105135|NCT02170688|Active Comparator|Calculated lean body weight|"25 subjects will receive contrast media dose based on the calculated lean body weight. Total body weight and height will be determined. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
3105136|NCT02170688|Active Comparator|Measured lean body weight|"50 subjects will receive contrast media dose based on the measured lean body weight. Lean body weight will be determined using the Tanita body composition/analyzer scales. From this data the lean body weight will be calculated.~Men will receive a dose of 0.86 gmI / kg LBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb LBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg LBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb LBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg)."
3105137|NCT02170688|Active Comparator|Estimated lean body (eLBW) weight|25 subjects will receive contrast media dose based on the estimated lean body (eLBW) weight. Estimated lean body weight will be determined by using a unique software program which measures the sum of the posterior to anterior attenuation from the digital scout radiograph (abbreviated as sqrt PA) obtained during the standard planning scan of the abdominal/pelvic CT. Men will receive a dose of 0.86 gmI / kg eLBW (2.32 mL of Isovue 370/kg at 0.074 mL/sec/kg) or 0.39 gmI/lb eLBW (1.05 mL of Isovue 370/lb at 0.034 mL/sec/lb). Women will receive a dose of 0.92 gmI/kg eLBW (2.49 mL of Isovue 370/kg at 0.080 mL/sec/kg) or 0.42 gmI/lb eLBW (1.13 mL of Isovue 370/kg at 0.036 mL/sec/kg).
3105138|NCT02170727|Experimental|Arm 1 : DCV/ASV/BMS-791325|DCV 30 mg (as the free base) / Asunaprevir (ASV) 200 mg / BMS-791325 75 mg FDC tablet orally twice daily for 12 weeks
3105139|NCT02170779|Experimental|A Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
3105140|NCT02170779|Other|B Usual care|2 visits: baseline and given usual treatment of brochure for stretching, outcome measures
3105141|NCT02170870|Experimental|Healthy Controls Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
3105142|NCT02170870|Placebo Comparator|Healthy Controls Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
3105143|NCT02170870|Experimental|Diabetics Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
3105144|NCT02170870|Placebo Comparator|Diabetics Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
3105145|NCT02170870|Experimental|Functional Dyspepsia Exendin 9-39|"Exendin 9-39 was administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).~Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml)."
3105146|NCT02170870|Placebo Comparator|Functional Dyspepsia Placebo|Normal saline infusion was prepared to match the appearance of Exendin 9-39. Lipid infusion 66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
3105147|NCT02171065|Sham Comparator|Guideline Directed Medical Therapy|Guideline Directed Medical Therapy
3105148|NCT02171065|Active Comparator|ABSORB BVS + Guideline Directed Medical Therapy|ABSORB BVS + Guideline Directed Medical Therapy
3105149|NCT02171130|Experimental|Nasal glucagon|3 mg nasal glucagon powder delivered using a nasal powder dosing device.
3105150|NCT02171195|Experimental|Group 1 (20 mg)|
3105151|NCT02171195|Experimental|Group 2 (50 mg)|
3105152|NCT02171195|Experimental|Group 3 (100 mg)|
3105153|NCT02171195|Experimental|Group 4 (200 mg)|
3105154|NCT02171195|Experimental|Group 5 (400 mg)|
3105155|NCT02171195|Experimental|Group 6 (600 mg)|
3105156|NCT02171195|Experimental|Group 7 (900 mg)|
3105157|NCT02171195|Experimental|Group 8 (1200 mg)|
3105158|NCT02171234|Experimental|Group 1- 200 mg b.i.d. (twice daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3105159|NCT02171234|Experimental|Group 2 - 400 mg b.i.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3105160|NCT02171234|Experimental|Group 3- 800 mg o.d. (once daily)|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3105161|NCT02171234|Experimental|Group 4 - either 800 mg b.i.d or 1200 mg o.d.|BIA 2-093 200mg with 200 ml potable water. Identical placebo administered as oral tablets.
3105162|NCT02171247|Active Comparator|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
3105163|NCT02171247|Active Comparator|Visipaque 320|Standard protocol is Visipaque 320.
3105164|NCT02171260|Experimental|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle. A cycle of therapy is considered to be 21 days. The starting dose for eribulin mesylate will be at 1.1 milligram per square meter (mg/m^2) (Dose Level 1), which is approximately 80% of the adult MTD, and will be escalated up to no more than 2.2 mg/m^2.
3105165|NCT02171429|Placebo Comparator|Placebo|Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3105166|NCT02171429|Active Comparator|Adalimumab|Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.
3105167|NCT02171429|Experimental|Etrolizumab|Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.
3105168|NCT02171611|Experimental|Dabigatran etexilate pellets|
3105169|NCT02171611|Experimental|Dabigatran etexilate powder|
3105170|NCT02171611|Active Comparator|Dabigatran etexilate capsule|
3105171|NCT02171819|Experimental|IVACFLU-A/H5N1, 7.5 mcg|IVACFLU-A/H5N1, 7.5 mcg HA per dose
3105172|NCT02171819|Experimental|IVACFLU-A/H5N1, 15 mcg|IVACFLU-A/H5N1, 15 mcg HA per dose.
3105173|NCT02171819|Placebo Comparator|Placebo|Phosphate buffered saline
3105174|NCT02172040|Experimental|Amlodipine+Celecoxib|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
3105175|NCT02172040|Active Comparator|Amlodipine+Placebo|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
3105176|NCT02172040|Placebo Comparator|Placebo+Celecoxib|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule once a day for two weeks
3105177|NCT02172040|Sham Comparator|Placebo+Placebo|Matched placebo capsule for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
3105178|NCT02172625|Placebo Comparator|Placebo Group|Corn starch and food coloring is the placebo comparator. Each subject will ingest 675 mg (1 pill) per day of the placebo comparator
3105179|NCT02172625|Experimental|Protandim Dietary Supplement|Each subject will ingest 675 mg per day (1 pill) of Protandim for about 90 days. Each pill contains 5 botanicals (Bacopa extract 150 mg, milk thistle 225mg, ashwagandha 150 mg, green tea 75 mg, turmeric 75 mg).
3105180|NCT02172664|Active Comparator|Adhese Universal with self etch enamel etching|patients will receive one restoration on randomly selected study tooth utilizing the self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent) with no separate enamel etching
3105181|NCT02172664|Experimental|selective etch protocol followed by Adhese Universal|patients will receive one restoration on randomly selected study tooth utilizing a 37% phosphoric acid solution followed by application of self-etch universal adhesive (Adhese Universal, Ivoclar Vivadent)
3105182|NCT02172742|Experimental|BIA 2-093|"BIA 2-093 1200 mg (2 tablets 600 mg) ESL, Eslicarbazepine acetate~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
3105183|NCT02172742|Placebo Comparator|Placebo|"Placebo (2 tablets matching BIA 2-093 600 mg tablets) PLC, Placebo~Concomitantly with a dose of digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day)."
3105184|NCT02172755|Experimental|Elderly subjects|14 Elderly subjects aged 65 years or more; During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
3105185|NCT02172755|Experimental|Young subjects|16 young subjects aged between 18 and 40 years During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
3105186|NCT02172820|Experimental|Financial incentives|Participants receive financial incentives for completing exercise sessions.
3105187|NCT02172820|No Intervention|Control|Participants receive an equal amount of clinical contact but no financial incentives for completing exercise visits.
3105188|NCT02172911|Experimental|Cohort I: INO-3112: Curative Intent|Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
3105189|NCT02172911|Experimental|Cohort II: INO-3112: Salvage Therapy|Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.
3105190|NCT02172950|Experimental|Previously treated patients (PTPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule for the subject based upon the subject's pharmacokinetic (PK) profile, rVIII-SingleChain PK data, previous FVIII treatment regimen, and bleeding phenotype, if available.
3105191|NCT02172950|Experimental|Previously untreated patients (PUPs)|The investigator will assign subjects to either prophylaxis or on-demand treatment regimens for rVIII-SingleChain by intravenous injection. The investigator will determine the rVIII-SingleChain dose and dosing schedule at their discretion, taking into consideration the World Federation of Hemophilia (WFH) guidelines, the type of bleeding episode, location of the bleeding, subject's age, and other disease characteristics.
3105192|NCT02173054|Placebo Comparator|Adapalene gel|"Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face"
3105193|NCT02173054|Placebo Comparator|Adapalene gel with placebo moisturizer|"Morning~Wash face by prepared facial foam and dry their face~Apply placebo cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply placebo cream all over the face"
3105194|NCT02173054|Active Comparator|Adapalene gel with Eucerin|"Morning~Wash face by prepared facial foam and dry their face~Apply Eucerin cream all over the face~Evening~Wash face by prepared facial foam and dry your face~Apply adapalene gel all over the face~Apply Eucerin cream all over the face"
3105195|NCT02173158|Experimental|lomitapide|Maximum tolerated dose of lomitapide (up to 60mg/day) in addition to existing lipid lowering therapy including plasmapheresis or lipid apheresis.
3105196|NCT02173379|Experimental|Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System
3105197|NCT02173379|Active Comparator|XIENCE|Subjects receiving XIENCE V, XIENCE PRIME, or XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) and XIENCE ProX (outside of the US only)
3105198|NCT02173392|Experimental|Brodalumab (single 1.5mL pre-filled syringe)|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using a single 1.5mL pre-filled syringe injection
3105199|NCT02173392|Experimental|Brodalumab (2 pre-filled syringes [1.0mL + 0.5mL])|A single 210 mg subcutaneous (SC) dose of Brodalumab administered using 2 (1.0mL + 0.5mL) pre-filled syringe injections
3105200|NCT02173522|Experimental|Prostate artery embolization (PAE)|10 patients will receive prostate artery embolization (PAE) prior to robot-assisted laparoscopic radical prostatectomy (RALRP).
3105201|NCT02173522|No Intervention|Control|10 patients, matched to PAE patients by risk score, will receive RALRP without PAE. RALRP without PAE is the current standard of care treatment for prostate cancer at the Sylvester Comprehensive Cancer Center.
3105202|NCT02173535|Experimental|etafilcon test contact lens Variant AP|
3105203|NCT02173535|Experimental|etafilcon test contact lens Variant JG|
3105204|NCT02173535|Experimental|etafilcon test contact lens Variant CS|
3105205|NCT02173535|Experimental|etafilcon test contact lens Variant VC|
3105206|NCT02173535|Experimental|etafilcon test contact lens Variant LA|
3105207|NCT02173548|Active Comparator|Anakinra|Anakinra 100 mg given subcutaneously once daily for 12 weeks
3105208|NCT02173548|Placebo Comparator|Placebo|Matching Placebo
3105209|NCT02173704|Experimental|Bexsero + Routine Group|Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
3105210|NCT02173704|Active Comparator|Routine Group|Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.
3105211|NCT02173769||Adults with COPD|
3105212|NCT02174198|Experimental|BioOss Collagen|Intervention: BioOss Collagen at the time of implant placement
3105213|NCT02174198|No Intervention|No Bone Graft|No placement of BioOss at the time of implant placement
3105214|NCT02174276|Active Comparator|TDF 48 weeks|Participants will receive TDF for 48 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
3105215|NCT02174276|Experimental|TDF plus GS-4774 2 YU|Participants will receive TDF plus GS-4774 2 yeast units (YU) for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
3105216|NCT02174276|Experimental|TDF plus GS-4774 10 YU|Participants will receive TDF plus GS-4774 10 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
3105217|NCT02174276|Experimental|TDF plus GS-4774 40 YU|Participants will receive TDF plus GS-4774 40 YU for 20 weeks. After Week 20, GS-4774 will be discontinued and participants will continue on TDF for an additional 28 weeks. After Week 48, participants will have the option to continue receiving TDF for up to 144 weeks.
3105218|NCT02174419|Experimental|nalbuphine HCl ER 90mg|nalbuphine HCl ER tablets 90 mg BID
3105219|NCT02174419|Experimental|nalbuphine HCl ER 180 mg|nalbuphine HCl ER tablets 180 mg BID
3105220|NCT02174419|Placebo Comparator|Sugar pill|Placebo tablets BID
3105221|NCT02174432|Experimental|nalbuphine HCl ER|nalbuphine HCl ER
3105222|NCT02174510|Experimental|20mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3105223|NCT02174510|Experimental|40mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3105224|NCT02174510|Experimental|80mg lurasidone|single oral lurasidone in 30 minutes after beginning of the over 350 kcal breakfast on day 1.The subjects will be follow up on day 8 to 11.
3105225|NCT02174523|Experimental|40mg lurasidone|Single oral administration of 40 mg study drug lurasidone after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg study drug lurasidone, once daily between Day 4 and Day 8.
3105226|NCT02174523|Placebo Comparator|placebo|Single oral administration of 40 mg study drug placebo after the over 350 kcal breakfast on Day 1. Administration was suspended on Days 2 and 3. Continuous oral administration of 40 mg placebo, once daily between Day 4 and Day 8.
3132646|NCT03442699|Experimental|Cognitive Behavioral Therapy|Participants will receive up to 10 daily sessions of cognitive behavioral therapy (depending on length of stay), for about an hour each day. During this time the therapist will work to develop a crisis response plan and build coping skills to prevent future suicidal thoughts and behaviors.
3105227|NCT02174562|Experimental|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
3105228|NCT02174562|Placebo Comparator|Enhanced Usual Care|Usual care enhanced with education and controls for attention
3105229|NCT02174627|Experimental|Roxadustat|
3105230|NCT02174627|Placebo Comparator|Placebo|
3105231|NCT02174731|Experimental|Roxadustat|
3105232|NCT02174731|Active Comparator|Epoetin alfa|
3105233|NCT02174848|Experimental|Deferiprone|All patients will receive deferiprone oral solution.
3105234|NCT02174861|Experimental|Erenumab|Participants received erenumab 70 mg once a month (QM) or 140 mg QM by subcutaneous injection for up to 52 weeks.
3105235|NCT02174913|Active Comparator|bispectral index/TCI propofol/fentanyl|Bispectral index guides the target controlled infusion of propofol by keeping BIS 40-60 throughout operation. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
3105236|NCT02174913|Placebo Comparator|clinical signs/TCI propofol/fentanyl|Clinical signs (heart rate, blood pressure and movement) guide target controlled infusion(TCI) of propofol. Fentanyl is used for analgesia and atracurium is used for tracheal intubation.
3105237|NCT02175121|Placebo Comparator|Treatment A- Placebo|
3105238|NCT02175121|Experimental|Treatment B- PF-06291874|
3105239|NCT02175121|Experimental|Treatment C- PF-06291874|
3105240|NCT02175121|Experimental|Treatment D- PF-06291874|
3105241|NCT02175121|Experimental|Treatment E- PF-06291874|
3105242|NCT02175199|Experimental|AIR OPTIX COLORS|Lotrafilcon B contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days.
3105243|NCT02175199|Active Comparator|FreshLook COLORBLENDS|Phemfilcon A contact lenses with color printing worn bilaterally in a daily wear modality 5 days/week, 8 hours/day for 30 days with a 2-week replacement.
3105244|NCT02175212|Experimental|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
3105245|NCT02175212|Active Comparator|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~High dose conformal radiotherapy"
3105246|NCT02175225|Experimental|Deferoxamine Mesylate|Deferoxamine Mesylate (32 mg/kg/day) given by an intravenous infusion for 3 consecutive days
3105247|NCT02175225|Placebo Comparator|Normal Saline|Normal saline (0.9% sodium chloride) given by intravenous infusion for 3 consecutive days
3105248|NCT02175277|Experimental|Darbepoetin Alfa|Participants received darbepoetin alfa for up to 73 weeks or until progression to acute myeloid leukemia (AML), whichever occurred first.
3105249|NCT02175368|Experimental|Adhese One F Upgrade|Adhese One F Upgrade (AOFU) is administered after phosphoric acid etching (etch-and-rinse protocol).
3105250|NCT02175472|Active Comparator|Spectramax light therapy device|Light therapy device which emits a specific bandwidth combination and intensity of light.
3105251|NCT02175472|Sham Comparator|Control light device|Light therapy device, identical in appearance and operation to the Spectramax device, except that it produces a different bandwidth and intensity, which is not believed to produce a therapeutic response.
3105252|NCT02175641|Experimental|Peer-led Group Lifestyle Balance|Group-based behavioral healthy lifestyle program
3105253|NCT02175641|Active Comparator|Usual Care Services|Usual wellness and health care services offered to clients at the two supportive housing agencies.
3105254|NCT02175745|Experimental|Diagnostic (FDOPA-PET/CT or PET/MRI)|Patients receive 18F-fluoro-dihydroxyphenylalanine (18F-FDOPA) intravenously (IV) and then undergo positron emission tomography / computed tomography (PET/CT) or PET/magnetic resonance imaging (PET/MRI) scans 10 to 30 minutes later.
3105255|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 12 to < 18 years of age with genotype (GT) 2 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
3105256|NCT02175758|Experimental|12 to < 18 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 12 to < 18 years of age with genotype 3 HCV infection weighing ≥ 45 kg will receive SOF (1 x 400 mg tablet, 4 x 100 mg tablets, or 8 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
3105257|NCT02175758|Experimental|6 to < 12 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 6 to < 12 years of age with genotype 2 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 12 weeks.
3105258|NCT02175758|Experimental|6 to <12 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 6 to < 12 years of age with genotype 3 HCV infection weighing ≥ 17 kg and < 45 kg will receive SOF (2 x 100 mg tablets or 4 x 50 mg oral granules based on swallowability assessment during screening) plus RBV (up to 1400 mg) for 24 weeks.
3105259|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 12 Weeks (GT 2)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 12 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 12 weeks.
3105260|NCT02175758|Experimental|3 to < 6 Years Old, SOF+RBV 24 Weeks (GT 3)|Participants between 3 to < 6 years of age with genotype 2 HCV infection weighing ≥ 17kg will receive SOF (4 x 50 mg oral granules) plus RBV (up to 1400 mg) for 24 weeks and those weighing < 17 kg will receive SOF (3 x 50 mg oral granules) + RBV (up to 1400 mg) for 24 weeks.
3105261|NCT02175771|Experimental|Fp MDPI 100 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg Fp for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105262|NCT02175771|Active Comparator|FLOVENT HFA 110 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 440 mcg Fp for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105263|NCT02175771|Experimental|Fp MDPI 200 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg Fp for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105264|NCT02175771|Active Comparator|FLOVENT HFA 220 mcg|"Participants took 2 inhalations using a hydrofluoroalkane (HFA) inhaler twice a day of fluticasone propionate (Fp) for a total daily dose of 880 mcg Fp for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid (ICS) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105265|NCT02175771|Experimental|FS MDPI 100/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 100/12.5 mcg for a total daily dose of 200/25 mcg FS for 26 weeks. This was the mid-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105266|NCT02175771|Active Comparator|ADVAIR DISKUS 250/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 250/50 mcg for a total daily dose of 500/100 mcg FS for 26 weeks. This was the mid-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105267|NCT02175771|Experimental|FS MDPI 200/12.5 mcg|"Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate/salmeterol (FS) 200/12.5 mcg for a total daily dose of 400/25 mcg FS for 26 weeks. This was the high-strength experimental intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105268|NCT02175771|Active Comparator|ADVAIR DISKUS 500/50 mcg|"Participants took 1 inhalation of a dry-powder formulation twice a day of fluticasone propionate/salmeterol (FS) 500/50 mcg for a total daily dose of 1000/100 mcg FS for 26 weeks. This was the high-strength active comparator intervention in the inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) cohort.~Albuterol/salbutamol HFA metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication."
3105269|NCT02175966|Experimental|Arm 1: DCV/ASV/BMS-791325+Sofosbuvir|"Initial Therapy:~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 4 weeks~Sofosbuvir 400 mg tablet once daily orally for 4 weeks"
3105270|NCT02175966|Experimental|Arm 2: DCV/ASV/BMS-791325 + Sofosbuvir|"Initial Therapy~Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 6 weeks~Sofosbuvir 400 mg tablet once daily orally for 6 weeks"
3105271|NCT02175966|Experimental|Rescue Therapy: Arm 1:DCV/ASV/BMS-791325+RBV±PegIFNα-2a|"Daclatasvir/Asunaprevir/BMS-791325 [30 mg (as the free base)/200 mg/75 mg (as the free base)] film coated Fixed Dose Combination tablet twice daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~With or without Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
3105272|NCT02175966|Other|Rescue Therapy: Arm 2: Sofosbuvir + RBV + PegIFNα-2a|"Sofosbuvir 400 mg tablet once daily orally for 12 weeks~Ribavirin 200 mg tablets twice daily (1000 or 1200 mg per day based on weight) orally for 12 weeks~Peginterferon α-2a 180 µg solution for injection subcutaneously once weekly for 12 weeks"
3105273|NCT02175979|Placebo Comparator|standard|standard of care
3105274|NCT02175979|Experimental|enriched enteral nutrition|enriched enteral tube feeding 1.5ml/ minute perioperative
3105275|NCT02176005|Active Comparator|Moxifloxacin|Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
3105276|NCT02176005|Experimental|moxifloxacin + DAV132|Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
3105277|NCT02176005|Experimental|DAV132|DAV132 oral, 7.5g x3/day for 7 days
3105278|NCT02176005|Placebo Comparator|Negative control|Negative control: 7.5g x3/day for 7 days
3105279|NCT02176018|Active Comparator|Nuedexta|One capsule will be taken (dextromethorphan HB and quinidine sulfate, 20 mg/10 mg) daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
3105280|NCT02176018|Placebo Comparator|Placebo|One capsule will be taken of placebo to match daily for seven days. On the eight day and for the remainder of the study 2 capsule will be taken twice a day. Medication will be taking daily for a total of 3 months.
3105281|NCT02176031|Experimental|Natalizumab|"Natalizumab-~(Day 0 and 28) Fixed dose Intravenous infusion over one hour. 2 hours observation completion of the infusion~At 4 weeks, if there has been less than a complete response participants can be treated with a second dose of natalizumab.~If participants have no response after one dose, they will be not be given a second dose.~Participants who receive a second dose of natalizumab will be evaluated for response at day 56 after first treatment dose administered.~Participants will be assessed for response to therapy with natalizumab at day +28, day +56, day +100, day + 180, and day +365.~Commercial supplies of Methylprednisolone (or equivalent steroid) will be utilized. The formulation, preparation and route of administration will be as per package insert"
3105282|NCT02176083|Experimental|Intervention|Text message management prompts: YBCS will receive text message prompts on how to manage hot flashes and vaginal dryness
3105283|NCT02176083|No Intervention|Control|Control YBCS will not receive text message prompts on managing hot flashes and vaginal dryness
3105284|NCT02176226|Experimental|8-Week Single Arm Field Trial|Use of IntelliCare program for 8 weeks.
3105285|NCT02176291|Experimental|Buprenorphine|Buprenorphine
3105286|NCT02176291|Placebo Comparator|Placebo|Placebo
3105287|NCT02176343|Experimental|ReSTOR Toric +2.5|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL previously implanted during cataract surgery
3105288|NCT02176356|Other|All Participants|JUVÉDERM® ULTRA XC and/or JUVÉDERM® ULTRA PLUS XC and/or JUVÉDERM® VOLUMA® XC injection into facial areas, volume as determined by the investigator on Day 1 with additional treatment at Day 14 if applicable. LATISSE® 1 drop applied to upper eyelid at the base of the eyelashes once daily in the evening for 17 weeks beginning on Day 1. BOTOX® Cosmetic 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas at Month 3.
3105289|NCT02176382|Active Comparator|Standard dose teriparatide|teriparatide daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
3105290|NCT02176382|Active Comparator|High dose teriparatide|teriparatide alternate dose daily subcutaneous injection (months 0-9) plus denosumab subcutaneous injection every 6 months (months 3-15) followed by zoledronic acid at month 15
3105291|NCT02176408|Experimental|Behavioral Activation plus Exercise|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the exercise intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
3105292|NCT02176408|Active Comparator|Behavioral Activation plus Stretching|"Six weekly 60-minute sessions plus three 60-minute biweekly booster sessions of behavioral activation treatment~Six weekly 30-minute sessions of the stretching intervention (with this intervention incorporated into the 60 minutes of the biweekly booster sessions)"
3105293|NCT02176421|Experimental|VOLBELLA® with lidocaine|Infra-orbital skin depressions injected with VOLBELLA® with lidocaine.
3105294|NCT02176486|Experimental|Cohort A: Ixazomib 0.5 milligram (mg)|Ixazomib 0.5 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
3105295|NCT02176486|Experimental|Cohort B: Ixazomib 2 mg|Ixazomib 2 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
3105296|NCT02176486|Experimental|Cohort C: Ixazomib 3 mg|Ixazomib 3 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
3105297|NCT02176486|Experimental|Cohort D: Ixazomib 4 mg|Ixazomib 4 mg, capsules, orally, once, on Day 1, 8 and 15 in 28-day cycles, Cycles 1 through 3.
3105298|NCT02176486|Placebo Comparator|Cohorts A through D: Placebo|Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in 28-day cycle, Cycles 1 through 3.
3105299|NCT02176525|Experimental|BI 207127 in patients with cirrhosis|multiple rising doses
3105300|NCT02176525|Experimental|BI 207127 in patients without cirrhosis|multiple rising doses
3105301|NCT02176525|Placebo Comparator|Placebo in patients without cirrhosis|
3105302|NCT02176642|Active Comparator|Oxybutynin plus PTNS|Oxybutynin extended release (blinded tablet) 5mg by mouth daily for 6 weeks, Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
3105303|NCT02176642|Placebo Comparator|Placebo plus PTNS|Placebo (blinded tablet) taken daily for 6 weeks. Posterior Tibial Nerve Stimulation utilizing the Urgent PC neuromodulation system administered weekly in the office setting for a total of 6 weeks.
3105304|NCT02176655|Active Comparator|VVD-101|One sumatriptan succinate 12.5 mg combined with acetylsalicylic acid 325 mg (VVD-101) capsule taken after the onset of a delayed alcohol induced headache.
3105305|NCT02176655|Placebo Comparator|Placebo|One placebo capsule to match taken after the onset of a delayed alcohol induced headache.
3105306|NCT02176837|Experimental|Sodium Nitrite|One dose cohort is planned, 64 nmol/min/kg sodium nitrite (0.1325 mg/hour/kg; 0.0442 ml/hour/kg at a concentration of 3mg/ml).
3105307|NCT02176928|Active Comparator|AutoPAP|PAP treatment will be delivered for four months by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
3105308|NCT02176928|Sham Comparator|Sham PAP|Sham PAP treatment will be delivered for four months by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events.
3105309|NCT02177032|Experimental|4-sites, 1-week without HRIG|"PCEC rabies vaccine, administered ID according to the 4-sites, 1-week regimen"
3105310|NCT02177032|Experimental|4-sites, 1-week with HRIG|"PCEC rabies vaccine, administered ID to adults, according to the 4-sites, 1-week regimen plus HRIG"
3105311|NCT02177032|Active Comparator|2-sites, TRC without HRIG|"PCEC rabies vaccine, administered ID according to the 2-sites, TRC regimen"
3105312|NCT02177032|Active Comparator|2-sites, TRC with HRIG|"PCEC rabies vaccine, administered ID to adults , according to the 2-sites, TRC regimen plus HRIG"
3105313|NCT02177123|Experimental|InnFocus MicroShunt Surgery|InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)
3105314|NCT02177136|Experimental|1.5 mg OCA titrating to 3 mg OCA|Participants randomized to 1.5 mg OCA took 1.5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 3 mg OCA daily for an additional 12 weeks.
3105315|NCT02177136|Experimental|5 mg OCA titrating to 10 mg OCA|Participants randomized to 5 mg OCA took 5 mg OCA daily for 12 weeks during the DB phase. If tolerated, the dose was increased to 10 mg OCA daily for an additional 12 weeks.
3105316|NCT02177136|Experimental|Placebo|Participants randomized to placebo took placebo for 24 weeks during the DB phase.
3105317|NCT02177136|Experimental|LTSE OCA Total|Following completion of the DB phase, participants were asked to reconfirm their consent for participation in the LTSE phase (planned as a further 24 months) beginning at 5 or 10 mg OCA, based on the last treatment received during the DB phase. Doses up to 10 mg daily were evaluated. All participants received open-label OCA during the LTSE phase of the study.
3105318|NCT02177201|Sham Comparator|Group 1|intravenous administration of 10 ml/kg/h 0.9% saline solution
3105319|NCT02177201|Active Comparator|Group 2|intravenous administration of 20 ml/kg/h 0.9% saline solution
3105320|NCT02177786|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 mg for 48 weeks.
3105321|NCT02177786|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 48 weeks.
3105322|NCT02177786|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 48 weeks.
3105323|NCT02177786|Placebo Comparator|Placebo to match selonsertib|Participants will receive placebo to match selonsertib for 48 weeks.
3105324|NCT02177812|Experimental|Dose Escalation Phase (Part 1)|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
3105325|NCT02177812|Experimental|Expansion Phase (Part 2)|Once the MTD and/or RP2D has been determined in Part 1, an expansion cohort of up to 30 subjects will be enrolled in order to characterize the clinical activity and safety profile of the RP2D. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, or withdrawal of consent.
3105326|NCT02177838|Experimental|Treatment (cetuximab, cisplatin, EBRT)|Patients receive cetuximab IV over 60-120 minutes for 3 weeks. Patients then undergo EBRT over 6-7 weeks. Patients achieving response continue weekly doses of cetuximab until radiation therapy is completed. Patients unable to achieve response or progression receive cisplatin IV over 1-2 hours on days 1, 22, and 43 of radiation therapy.
3105327|NCT02177942|Experimental|Test beverage powder|30 grams of cereal beverage powder with protein and added micronutrients will be made up to 100 mL drink using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
3105328|NCT02177942|Active Comparator|Control beverage powder|30 grams of cereal beverage powder with low protein and no added micronutrients will be made up to 100 mL using luke warm water. Subjects will be administered two doses of the drink (100 mL each) everyday
3105329|NCT02178059|Experimental|Bricanyl Turbuhaler M3|0.4 mg terbutaline sulphate (delivered dose) per inhalation
3105330|NCT02178059|Active Comparator|Bricanyl Turbuhaler M2|0.5 mg terbutaline sulphate (metered dose) per inhalation
3105331|NCT02178241|Experimental|Treatment (eribulin mesylate and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3105332|NCT02178358|Experimental|150 milligram (mg) Galunisertib Monotherapy|150 mg galunisertib administered orally, twice daily (BID) for 14 days followed by 14 days with no study drug (28 days cycle).
3105333|NCT02178358|Experimental|150 mg Galunisertib + 400 mg Sorafenib Therapy|"150 mg galunisertib administered orally, BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
3105334|NCT02178358|Placebo Comparator|400 mg Sorafenib + Placebo Therapy|"Placebo administered orally BID for 14 days followed by 14 days with no study drug (28 days cycle).~400 mg sorafenib administered orally BID for 28 days."
3105335|NCT02178475||Chemotherapy + Pegfilgrastim|Patients with non-Hodgkin's lymphoma or breast cancer being treated with a permitted standard-dose chemotherapy regimen with a high FN risk (> 20%) and who had pegfilgrastim prophylaxis initiated in the first cycle of chemotherapy.
3105336|NCT02178540|Other|Open label|one dose (4 capsules) of placebo
3105337|NCT02178553|Active Comparator|Epidural|In the epidural catheter (TEC) group, a thoracic epidural catheter will be placed at the level of T6-T8 and advanced 5 cm into the epidural space and a 3 ml test dose of lidocaine 1.5% will be administered before the induction of general anesthesia. Patients will be excluded from the study if the catheter cannot be placed. A bolus dose of 0.5 mg hydromorphone plus 4.5 ml 0.125% bupivacaine will be administered before surgical incision. An epidural infusion of 0.075% bupivacaine and 10 mcg/ml hydromorphone, prepared by the hospital pharmacy, will be started intraoperatively at a rate of 5 ml/hr.
3105338|NCT02178553|Active Comparator|Intercostal bupivicaine (Exparel)|In the intercostal block (ICB) group, liposomal bupivacaine 1.3% (4 ml) will injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and one interspace above and below. In addition, liposomal bupivacaine 1.3 % (4 ml) will be injected at each of the chest tube exit sites. Thus, a total of 20 ml liposomal bupivacaine 1.3% (260 mg) will be administered.
3105339|NCT02178592|Experimental|Dolutegravir|Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52
3105340|NCT02178592|Active Comparator|Efavirenz|Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.
3105341|NCT02178696|Experimental|Known Placebo First|"This arm gets a placebo that they know is a placebo (called inactive), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called active medication (which is also actually a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa or alternative as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
3105342|NCT02178696|Experimental|"Active (blinded) Placebo first group"|"This arm gets a placebo that they don't know is a placebo (called Active), then has 2 scans performed (FMRI and PET), then a 2-3 day washout, and then gets a so-called inactive medication (which participants know is a placebo), and another pair of scans. Following these, participants receive 10 weeks of open-label antidepressant administration (Celexa as explained in intervention description). First line antidepressant will be Celexa unless not clinically indicated."
3105343|NCT02178709|Experimental|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle~5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
3105344|NCT02178722|Experimental|Phase 1: MK-3475 + INCB024360|Phase 1: MK-3475 + INCB024360 25 mg twice a day (BID) as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
3105345|NCT02178722|Experimental|Phase 2: MK-3475 + INCB024360|(recommended phase 2 dose)
3105346|NCT02178787||Type 2 diabetes mellitus|Head-up tilt, vasoreactivity, standing up.
3105347|NCT02178787||Non-diabetic controls|Head-up tilt, vasoreactivity, standing up.
3105348|NCT02178800|Experimental|Group 1: GSK1265744|Participants in Cohorts 1 and 2 will receive one GSK1265744 tablet orally every day from study entry through Week 4. They will then receive an injection of GSK1265744-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
3105349|NCT02178800|Placebo Comparator|Group 2: Placebo|Participants in Cohorts 1 and 2 will receive one placebo tablet orally every day from study entry through Week 4. They will then receive an injection of placebo-at Weeks 5, 17, and 29 for participants in Cohort 1 and at Weeks 5, 9, 17, 25, and 33 for participants in Cohort 2.
3105350|NCT02178956|Experimental|BBI608 plus Paclitaxel|
3105351|NCT02178956|Placebo Comparator|Placebo plus Paclitaxel|
3105352|NCT02178995|No Intervention|Healthy Controls|"Healthy controls completed the same neurocognitive batteries and neuropsychiatric questionnaires as individuals with epilepsy, but were not exposed to study medication.~Healthy controls were included primarily for use in the open-label comparison. They did not receive blinded medication during the 'double-blind' portion and their data was not used in the 'double-blind' comparison. In order to control for test/re-test variables, they completed testing during the 'double-blind' portion, so that they completed testing an equivalent number of times to the epilepsy patients in the 'open-label' portion."
3105353|NCT02178995|Experimental|Participants With Epilepsy (Open-label)|Following the final randomized visit, interested participants were prescribed 10mg of methylphenidate twice daily, increased to 20mg of methylphenidate twice daily as tolerated. After a four week treatment trial, their scores on the batteries and questionnaires were again assessed.
3105354|NCT02178995|Experimental|10mg, 20mg, Then Placebo (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105355|NCT02178995|Experimental|10mg, Placebo, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105356|NCT02178995|Experimental|Placebo, 20mg, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105357|NCT02178995|Experimental|Placebo, 10mg, Then 20mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105358|NCT02178995|Experimental|20mg, Placebo, Then 10mg (Double-blind)|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105359|NCT02178995|Experimental|20mg, 10mg, Then Placebo - Double-blind|"Participants received three single doses in randomized order of blinded medication, either a placebo, 20mg of methylphenidate, or 10mg of methylphenidate, and completed cognitive testing and neuropsychiatric questionnaires. This single-dose phase was followed by an open-label 4-week treatment trial of methylphenidate.~Methylphenidate: Participants with epilepsy first received blinded, single-dose capsules which contained either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate. At each visit, they received one capsule and then completed the neurocognitive batteries and neuropsychiatric questionnaires. There was no medication administered between visits during this time."
3105360|NCT02178995|Experimental|40mg, 20mg, Then Placebo (One Participant)|This study was originally intended to use 40mg, 20mg, and placebo doses rather than 20mg, 10mg, and placebo. This individual developed tachycardia (see adverse events) on the 40mg dose, and was withdrawn from the double-blind portion as a result. We removed the 40mg doses from this study and replaced them with 10mg doses. No other participant received a 40mg dose. This participant rejoined the open-label portion after consultation with his PCP due to significant perceived benefit from the MPH dose.
3105361|NCT02179047||stable angina, biomarker|patients with stable angina who received coronary angiography.
3105362|NCT02179047||placebo|healthy subject
3105363|NCT02179177|Active Comparator|Apixaban|Active drug Apixaban 2.5mg taken by mouth twice a day
3105364|NCT02179177|Placebo Comparator|Placebo|Sugar pills that look like Apixaban that will be taken by mouth twice a day
3105365|NCT02179190|Experimental|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
3105366|NCT02179398|Experimental|Lab-score group|"Patients assessed through the Lab-score determination only: Lab-score ≥3 used as the sole marker for the detection of serious bacterial infection.~(WBC and band counts blinded to the physician in charge of the patient)"
3105367|NCT02179398|Active Comparator|Control group|"Patients assessed through the following classically admitted biomarkers for the detection of serious bacterial infection: WBC count, band count and CRP determination.~(PCT and thus Lab-score blinded to the physician in charge of the patient)."
3105368|NCT02179424|Experimental|Health talk + Workshop + Booklet + SMS|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
3105369|NCT02179424|Experimental|Face-to-face counseling + Booklet + SMS|Face to Face counseling (Motivational intervention) + Booklet + SMS
3105370|NCT02179424|Experimental|Phone counseling + Health talk + Booklet + SMS|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
3105371|NCT02179424|Experimental|Phone counseling + Booklet + SMS|Phone counseling (Motivational intervention) + booklet + SMS
3105372|NCT02179515|Experimental|modified vaccinia Ankara (MVA)-brachyury-TRICOM vaccine|Three cohorts will receive modified vaccinia Ankara (MVA)-brachyury-B7-1, ICAM-1 (Intercellular Adhesion Molecule 1), and LFA-3 (lymphocyte function-associated antigen 3) TRICOM vaccine administered subcutaneously as either 1, 2, or 4 injections of study drug at monthly (28 days +/4 days) intervals for 3 months. Patients with stable disease may continue to receive vaccine for up to 6 monthly doses.
3105373|NCT02179671|Experimental|Gefitinib with a Seq. Switch to a MEDI4736|Gefitinib once daily followed by MEDI4736
3105374|NCT02179671|Experimental|AZD9291 with a Seq. Switch to a MEDI4736|AZD9291 once daily followed by MEDI4736
3105375|NCT02179671|Experimental|Selumetinib+Docetaxel with a Seq. Switch to a MEDI4736|Selumetinib twice daily + docetaxel, followed by MEDI4736
3105376|NCT02179671|Experimental|Tremelimumab with a Seq. Switch to a MEDI4736|Tremelimumab every 4 weeks followed by MEDI4736
3105377|NCT02179788|Experimental|Standard care plus metformin|67% of stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day and to take the assigned study drug.
3105378|NCT02179788|Placebo Comparator|Standard Care plus placebo|"33% of Stage 2 eligible mothers will be randomly allocated to this arm. Mothers will be instructed to thoroughly empty their breasts at least 8 times per day (Standard Care) and to take the assigned study drug. The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
3105379|NCT02179892|Active Comparator|Group 1-Exparel|Bupivacaine Extended-Release Liposome Injection (Exparel)will be administered via TAP block procedure
3105380|NCT02179892|Active Comparator|Group 2-Bupivacaine and Dexamethasone IV|Bupivacaine and Dexamethasone Injection will be administered via TAP block procedure.
3105381|NCT02179918|Experimental|PF-05082566 +MK-3475|PF-05082566 +MK-3475
3105382|NCT02180061|Experimental|Advanced Cutaneous Melanoma|Participants with advanced cutaneous melanoma received pembrolizumab, 2 mg/kg, intravenously (IV) over 30 minutes on Day 1 of each 3-week dosing cycle (Q3W).
3105383|NCT02180061|Experimental|Advanced Mucosal Melanoma|Participants with advanced mucosal melanoma received pembrolizumab, 2 mg/kg, IV over 30 minutes on Day 1 Q3W.
3105384|NCT02180100|Experimental|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
3105385|NCT02180100|Active Comparator|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
3105386|NCT02180165|Experimental|Cohort 1: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
3105387|NCT02180165|Active Comparator|Cohort 1: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
3105388|NCT02180165|Experimental|Cohort 2: Posaconazole|300 mg posaconazole oral tablet (or 300 mg intravenous (IV) solution) twice on Day 1, followed by 300 mg oral tablet or IV solution once daily for up to 84 days
3105389|NCT02180165|Active Comparator|Cohort 2: Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
3105392|NCT02180230|Other|Shorty implants|Brånemark System Mk III Shorty and/or NobelSpeedy Shorty
3105393|NCT02180438|Experimental|Open label prospective single arm study of Stribild|
3105394|NCT02180646|Active Comparator|High Carb then High Protein Breakfast|A high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat) followed by a 7-day washout period, and then 7 days of eating a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat).
3105395|NCT02180646|Active Comparator|High Protein then High Carb Breakfast|A high protein breakfast - 500 kcal followed by a 7-day washout period, and then 7 days of eating a high carbohydrate breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
3105396|NCT02180659|Experimental|buprenorphine implants + placebo tablets|Four 80 mg Probuphine implants + daily SL placebo tablets
3105397|NCT02180659|Active Comparator|buprenorphine tablets + placebo implants|Daily SL BPN tablets (≤8 mg/daily) + four placebo implants
3105398|NCT02180672|Active Comparator|Nasal steroids|Participants randomly assigned to this study arm will receive a 3-month course of nasal steroids (nasal fluticasone).
3105399|NCT02180672|Placebo Comparator|Placebo|Participants randomly assigned to this study arm will receive a 3-month course of placebo nasal spray (saline).
3105401|NCT02180828|Experimental|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
3105402|NCT02180828|Active Comparator|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
3105403|NCT02180867|Experimental|Regimen A (pazopanib, chemoradiation)|See Regimen A Detailed Description.
3105404|NCT02180867|Experimental|Regimen B (chemoradiation)|See Regimen B Detailed Description.
3105405|NCT02180867|Experimental|Regimen C (pazopanib, radiation therapy)|"INDUCTION PHASE: Patients receive pazopanib PO QD on weeks 1-9. Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: Patients receive pazopanib PO QD on weeks 13-25. If applicable, patients undergo additional radiation therapy at week 13."
3105406|NCT02180867|Experimental|Regimen D (radiation therapy)|"INDUCTION PHASE: Patients undergo radiation therapy on weeks 1-7.~SURGERY: Patients undergo surgery on week 10.~CONTINUATION PHASE: If applicable, patients undergo additional radiation therapy at week 13."
3105407|NCT02180893|Experimental|Paravertebral block|Patient receiving a PVB prior to robotic mitral valve surgery
3105408|NCT02180893|Placebo Comparator|No block|Patients who did not receive PVB
3105409|NCT02181075|Experimental|Part I|"All participants in Part I received:~Pre-LTLD Biopsy of Target Liver Tumour ThermoDox® (LTLD) Post-LTLD Biopsy of Target Liver Tumour Focused Ultrasound of Target Liver Tumour Thermometry of Target Tumour Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour~Part I of the study was designed to identify optimal focused ultrasound (FUS) exposure parameters for a range of tumour locations within the liver, using real-time thermometry data from an implanted thermometry device (a thermistor or thermocouple). Plasma and biopsy samples of the target liver tumour were taken pre-LTLD, post-LTLD and post-LTLD+FUS."
3105410|NCT02181075|Experimental|Part II|"All participants in Part II received:~ThermoDox® (LTLD) Focused Ultrasound of Target Liver Tumour Post-LTLD Biopsy of Target Liver Tumour~Following a minimum of 5 Part I cases, and subject to Trial Management Group approval, Part II of the study was opened to run in parallel to Part I. Part II did not require implantation of a thermometry device, and instead used predictions from Part I data to set the FUS parameters. Targeted drug delivery in Part II thus proceeded completely non-invasively, and this part of the study was designed to more closely reflect how the therapy might be implemented in routine clinical practice. Plasma samples were taken pre-LTLD, post-LTLD and post-LTLD+FUS. Biopsy samples of the target liver tumour were taken only post-LTLD+FUS."
3105411|NCT02181127|Active Comparator|Glucagon-only Bionic Pancreas (active)|Glucagon-only Bionic Pancreas will deliver glucagon during 7 of the 14 days. The order of the glucagon days will be randomized in blocks of 2, with no more than 2 days in a row of glucagon.
3105412|NCT02181127|Placebo Comparator|Glucagon-only Bionic Pancreas (placebo)|Glucagon-only Bionic Pancreas will deliver placebo during 7 of the 14 days. The order of the placebo days will be randomized in blocks of 2, with no more than 2 days in a row of placebo.
3105413|NCT02181140|Other|EUS guided FNA and fine needle punction|punction of endosonographically identified space-occupying process with aspirating fine needle and pro core fine needle in a randomized order
3105414|NCT02181231|Experimental|venlafaxine plus buprenorphine|Drug: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
3105415|NCT02181231|Placebo Comparator|venlafaxine XR plus placebo|Drug: venlafaxine XR plus placebo Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks. 2 MRI sessions may occur before and during randomization.
3105416|NCT02181296|Active Comparator|High concentration group|0.2% ropivacaine
3105417|NCT02181296|Active Comparator|Lower concentration group|0.1% ropivacaine
3105418|NCT02181387|Active Comparator|acetaminophen|1000 mg every 6 hours during labor up to maximum 3 doses
3105419|NCT02181387|Placebo Comparator|placebo|placebo capsule identical to the acetaminophen capsule will be administered every 6 hours to a maximum of 4 doses
3105420|NCT02181400|Active Comparator|NIR Laser Treatment 25 miiliwatts (mW)/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 25 milliwats(mW)/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3105421|NCT02181400|Active Comparator|NIR laser treatment 100mW/cm2 dose|The Ellex Integre NIR Laser dose of 100 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3105422|NCT02181400|Active Comparator|NIR laser treatment 200mW/cm2 dose|The Ellex Integre NIR (near Infrared Light) Laser dose of 200 mW/cm2 for 90 seconds for 12 treatments at 2 to 3 day intervals over 5 weeks.
3105423|NCT02181413|Experimental|Ixazomib Citrate|Ixazomib citrate 3 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib citrate 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 until progressive disease (PD), unacceptable toxicity, or discontinuation for alternate reasons. Participants who have had any dose reductions due to adverse events (AEs) would not be dose escalated.
3105424|NCT02181413|Placebo Comparator|Placebo|Ixazomib citrate placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 26 until PD, unacceptable toxicity, or discontinuation for alternate reasons.
3105425|NCT02181426|Placebo Comparator|0 mg of Ketorolac|participant receives 0 mg of Ketorolac
3105426|NCT02181426|Active Comparator|7.5 mg of Ketorolac|participant receives 7.5 mg of Ketorolac
3105427|NCT02181426|Active Comparator|15 mg Ketorolac|participant receives 15 mg of Ketorolac
3105428|NCT02181426|Active Comparator|30 mg Ketorolac|participant receives 30mg of Ketorolac
3105429|NCT02181504|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3105430|NCT02181504|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3105431|NCT02181504|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
3105432|NCT02181517|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3105433|NCT02181517|Experimental|abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4 and 8, followed by a sham procedure at weeks 12 and 16.
3105434|NCT02181517|Active Comparator|ranibizumab 0.5 mg|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
3105435|NCT02181530||OZURDEX®|Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.
3105436|NCT02181556|Experimental|FOLFIRI + Aflibercept|FOLFIRI and aflibercept (4 mg/m²) each 14 days until progression of disease
3105437|NCT02181634|Experimental|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel 125 mg/m² IV and Gemcitabine 1000 mg/m² on days 1, 8 and 15 every 28 days until progression or unacceptable toxicity.
3105438|NCT02181673|Placebo Comparator|Treatment Group 1: Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20. At Week 24, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Week 24, 28 and thereafter every 8 weeks up to Week 52.
3105439|NCT02181673|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants will receive a placebo infusion to maintain the blind.
3105440|NCT02181738|Experimental|Nivolumab (Cohort A, B, C and D)|"Cohort (A, B, C): Nivolumab: Specified dose on specified days~Cohort (D): Nivolumab: Specified dose on specified days + Doxorubicin: Specified dose on specified days + Vinblastine: Specified dose on specified days + Dacarbazine: Specified dose on specified days"
3105441|NCT02181803|Experimental|Part 1 Panel A & B MK-8189 Monotherapy 2-40 mg: Schizophrenic|Participants with schizophrenia will receive monotherapy of MK-8189 in escalating doses starting at 2 mg once daily (QD) up to 40 mg QD, depending on safety and tolerability
3105442|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 2-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 2 mg QD up to 20 mg QD, depending on safety and tolerability
3105443|NCT02181803|Experimental|Part 2 Panel C MK-8189 Add-on Therapy 4-20 mg: Schizophrenic|Participants with schizophrenia will receive add-on therapy of MK-8189 in escalating doses starting at 4 mg QD up to 20 mg QD, depending on safety and tolerability
3105444|NCT02181803|Experimental|Part 3 Panel D MK-8189 Monotherapy 2-16 mg: Healthy|Healthy participants will receive monotherapy of MK-8189 in escalating doses starting at 2 mg QD up to 16 mg QD, depending on safety and tolerability
3105445|NCT02181803|Placebo Comparator|Part 1 Panel A & B Placebo Monotherapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 monotherapy
3105446|NCT02181803|Placebo Comparator|Part 2 Panel C Placebo Add-on Therapy: Schizophrenic|Participants with schizophrenia will receive dose-matched placebo to MK-8189 add-on therapy
3105447|NCT02181803|Placebo Comparator|Part 3 Panel D Placebo Monotherapy: Healthy|Healthy participants will receive dose-matched placebo to MK-8189 monotherapy
3105448|NCT02181816||Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets (20 mg/2.5 mg or 20 mg/5 mg), orally, once daily for up to 12 months. Participants will receive interventions as part of routine medical care.
3105449|NCT02181829|Experimental|Whole Lung IMRT|This is a single institution study involving patients with synovial sarcoma who have completed all standard therapy (e.g. surgery +/- radiation to the primary site) +/- any adjuvant chemotherapy. The sequence and types of therapy offered prior to WLI will likely vary based on primary tumor site, tumor resectability, extent of metastatic disease, performance status, and comorbidity. Each patient's therapy will be determined by the disease management team irrespective of participation on this protocol.
3105450|NCT02181842||Pioglitazone|Pioglitazone 15-30 mg, tablet, orally, once daily for up to 48 weeks before or after breakfast (the dose can be adjusted; however, the maximum daily dose should not exceed 45 mg).
3105451|NCT02182115|Active Comparator|standard of care|Surgeon's routine for preoperative showering.
3105452|NCT02182115|Experimental|antiseptic bundle|"Patients to use study bundle for 5 days prior to scheduled surgery with the following medications to use at home.~Chlorhexidine gluconate soap applied for bathing daily.~Chlorhexidine gluconate mouthrinse used to rinse mouth twice daily.~Nasal mupirocin to applied inside nostrils twice daily."
3105453|NCT02182440|Placebo Comparator|Placebo|1 hour IV infusion once daily for 3 days
3105454|NCT02182440|Experimental|0.4 mg/kg (250 U/kg) recAP|1 hour IV infusion once daily for 3 days
3105455|NCT02182440|Experimental|0.8 mg/kg (500 U/kg) recAP|1 hour IV infusion once daily for 3 days
3105456|NCT02182440|Experimental|1.6 mg/kg (1000 U/kg) recAP|1 hour IV infusion once daily for 3 days
3105457|NCT02182492|Experimental|Glucocorticoid|Fluticasone propionate nasal spray
3105458|NCT02182492|Experimental|Clarithromycin|Clarithromycin tablet
3105459|NCT02182804|Experimental|Study|probe-based confocal laser endomicroscopy narrow band imaging with magnification
3105460|NCT02182830|Experimental|Empagliflozin|starting dose 10mg; forced titration after 4 weeks 25mg dose
3105461|NCT02182830|Placebo Comparator|Placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
3105462|NCT02182843|Experimental|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
3105463|NCT02182895|Experimental|Saxagliptin group|DPP4 inhibitor therapy group will receive saxagliptin 2.5 to 5 mg daily in addition to correctional sliding scale insulin therapy before each meal and bedtime.
3105464|NCT02182895|No Intervention|Standard therapy group|Standard therapy group will receive basal-bolus insulin starting at a dose of 0.5 units/kg/day; given half as insulin glargine and half as insulin aspart. In addition, the standard therapy group will receive the correctional sliding scale insulin therapy before each meal and bedtime.
3105465|NCT02182947|Experimental|Endoscopy Imaging|Wireless-video capsule endoscopy (WCE) compared to the findings of MRE magnetic resonance enterography in same group of patients.
3105466|NCT02182973||DHM|Infants identified with neonatal abstinence syndrome requiring pharmacologic management and who will not be fed own mother's milk
3105467|NCT02182999|Placebo Comparator|NaCl 0,9%|Continuous wound infiltration NaCl 0,9% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
3105468|NCT02182999|Active Comparator|Ropivacaine|Continuous wound infiltration with Ropivacaine 0,2% 2 ml/h for first 24 postoperative hours by wound infiltration catheter (InfiltraLong-Katheter 19G x 420mm; Pajunk Medizintechnologie GmbH)
3105469|NCT02183519|Experimental|Healthy older adults|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
3105470|NCT02183519|Experimental|Parkinson's disease|All participants will receive reflex and voluntary cough testing. This will include coughing on command (voluntary cough) and coughing in response to capsaicin (reflex cough). This data will me measured to determine the strength of the cough (from both voluntary and reflex cough) and cough sensitivity (reflex cough only). Following baseline reflex and voluntary cough assessment, the participants will be cued to cough long and hard during both reflex and voluntary cough tasks. These data will help the investigators understand the baseline characteristics of voluntary and reflex cough, whether older adults can modify the magnitude of their cough response with verbal and visual cues.
3105471|NCT02183675|Experimental|T/A/H|Telmisartan/Amlodipine/HCTZ fixed-dose combination
3105472|NCT02183675|Active Comparator|T/A|Telmisartan/Amlodipine fixed-dose combination
3105473|NCT02183675|Active Comparator|T/H|Telmisartan/HCTZ fixed-dose combination
3105474|NCT02183792|Experimental|Tolvaptan|Tolvaptan 30-60mg once daily (with rescue loop diuretic or metolazone)
3105475|NCT02183792|Active Comparator|Furosemide|Furosemide continuous infusion 5mg/h with option to titrate (with rescue metolazone)
3105476|NCT02184143|Experimental|CBPT intervention|CBPT program consisting of weekly phone calls.
3105477|NCT02184143|Active Comparator|Education intervention|Education program consisting of weekly phone calls.
3105478|NCT02184169|Experimental|HLHS|Patients undergoing palliative repair.
3105479|NCT02184169|Active Comparator|TGA|Surgical repair of TGA.
3105480|NCT02184195|Experimental|Olaparib|Olaparib tablets po. 300 mg twice daily
3105481|NCT02184195|Placebo Comparator|Placebo|Placebo tablets twice daily
3105482|NCT02184208||Device utlization following extubation|
3105483|NCT02184208||Pulmonary mechanics|
3105484|NCT02184442|Experimental|TAVR - SAPIEN XT|TAVR (transaortic valve replacement) with SAPIEN XT
3105485|NCT02184442|Active Comparator|TAVR - SAPIEN|TAVR (transaortic valve replacement) with SAPIEN is the control arm
3105486|NCT02184455|Experimental|DermGEN Decellularized Dermal Matrix|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
3105487|NCT02184494|Experimental|Blood Lactate Response in PD|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in a PD population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3105488|NCT02184494|Experimental|Blood Lactate Response in MS|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in an MS population. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3105489|NCT02184494|Experimental|Blood Lactate Responses in Controls|This arm involves performing 5 sets of 1-minute squats with 1 minute of rest between each, and a finger prick before, after, and 10 minutes after the exercise in healthy, older adults. One set of the squats will be performed on a whole body vibration plate (pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)), and one on the ground.
3105490|NCT02184572|Experimental|INV_MMR|Subjects receive 1 dose of the study vaccine Priorix co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
3105491|NCT02184572|Active Comparator|COM_MMR|Subjects receive 1 dose of the licensed vaccine M-M-R II or M-M-R VaxPro Lot 1 or Lot 2 co-administered with Varivax and Havrix vaccines at Day 0. Subjects recruited in the US also receive Prevnar 13 at Day 0.
3105492|NCT02184611|Experimental|Umeclidinium bromide|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive UMEC Inhalation Powder 62.5 mcg OD over a period of 24 weeks
3105493|NCT02184611|Placebo Comparator|Placebo|Subjects meeting the eligibility criteria will complete a 7 to 14 day run-in period and will be randomized to receive matching placebo of UMEC Inhalation Powder OD over a period of 24 weeks
3105494|NCT02184624|Experimental|Sub-Study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler.
3105495|NCT02184624|Experimental|Sub-Study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI inhaler or use MDI inhaler first and then ELLIPTA inhaler.
3105496|NCT02184624|Experimental|Sub-Study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA.
3105497|NCT02184624|Experimental|Sub-Study 4|Subjects will be randomized to either use ELLIPTA inhaler first and then HANDIHALER inhaler or use HANDIHALER inhaler first and then ELLIPTA inhaler.
3105498|NCT02184624|Experimental|Sub-Study 5|Subjects will be randomized to either use ELLIPTA inhaler first and then BREEZEHALER inhaler or use BREEZEHALER inhaler first and then ELLIPTA inhaler.
3105499|NCT02184988|Experimental|Botulinum neurotoxin, Type A|DWP-450 (Botulinum purified neurotoxin, Type A) Injection
3105500|NCT02185014|Other|Adalimumab|Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.
3105501|NCT02185040|Experimental|CC-220 0.3mg Every Other Day (QOD)|Part 1: CC-220 0.3mg capsules by mouth every other day (QOD)
3105502|NCT02185040|Experimental|CC-220 0.3mg Every Day (QD)|"Part 1: CC-220 0.3mg capsules by mouth every day (QD)~ATEP: CC-220 0.3 mg capsules by mouth every day (QD)"
3105503|NCT02185040|Experimental|CC-220 0.6mg/0.3mg alternating dose QD|"Part 1: CC-220 0.6 mg and 0.3mg capsules PO on alternating days~ATEP:CC-220 0.6 mg and 0.3 mg capsules PO on alternating days"
3105504|NCT02185040|Experimental|CC-220 0.6mg QD|Part 1: CC-220 0.6mg capsules by mouth QD
3105505|NCT02185040|Placebo Comparator|Placebo QD|Part 1: Identically matching placebo capsules PO QD
3105506|NCT02185053|Experimental|CPC-201|
3105507|NCT02185105|Experimental|comfilcon A MTO|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
3105508|NCT02185105|Active Comparator|comfilcon A|Subjects will be randomized to receive either the Test or Control lens as a matched pair at each visit per a predetermined randomization schedule.
3105509|NCT02185131|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
3105510|NCT02185131|Active Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
3105511|NCT02185183|Experimental|AlequelTM|AlequelTM
3105512|NCT02185339|Experimental|dNMB group|For patients randomized to the dNMB group, intravenous infusion of 0.6 mg/kg/h rocuronium will be administered 10 minutes after the administration of intubation dose or after the return of post-tetanic count (PTC), whichever comes first. Then, the infusion rate will be titrated according to PTC (target to keep PTC between 1 to 2). Infusion rate will be increased or be reduced at a rate of 0.1 mg/kg/h if PTC is > or < than 1-2 to maintain deep muscle relaxation throughout the surgery. Neuromuscular monitoring will be carried out by monitoring the adductor pollicis muscle in response to ulnar nerve stimulation. A dose of sugammadex (4 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
3105513|NCT02185339|Active Comparator|mNMB group|For patients randomized to the mNMB group, intravenous infusion of 0.2 mg/kg/h rocuronium will be administered 30 minutes after the administration of intubation dose or after the appearance of train-of-four (TOF) count >2, whichever comes first. Then, the infusion rate will be titrated according to TOF (target to keep TOF between 1 to 2). Infusion rate will be increased or reduced at a rate of 0.1 mg/kg/h if TOF is > or < than 1-2. A dose of sugammadex (2 mg/kg) will be administered at the end of the surgery. Patients will be extubated when the train of four ratio is ≥0.9.
3105514|NCT02185404|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
3105515|NCT02185521|Experimental|visible HII - patient assessment|"Clinical team from study unit will observe the Hemodynamic Instability Index created by the HIRBA 2.0 system for individual subjects randomized into HII group arm.~If the HII value will cross the threshold, indicative of hemodynamic deterioration, subject from the study arm will receive intervention: clinical assessment."
3105516|NCT02185534|Experimental|European clopidogrel tablets, 75 mg|Treatment A: a single oral dose of clopidogrel 75 mg film-coated tablet (Zyllt, KRKA - test)
3105517|NCT02185534|Active Comparator|Japanese clopidogrel tablets, 75 mg|Treatment B: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Brystol-Myer Squibb,Sanofi-Aventis, reference)
3105518|NCT02185534|Active Comparator|US clopidogrel tablets, 75 mg|Treatment C: a single oral dose of clopidogrel 75 mg film-coated tablet (Plavix®, Sanofi-Aventis, reference)
3105519|NCT02185729|Active Comparator|Healthy Volunteer|Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat)
3105520|NCT02185794|Placebo Comparator|Placebo (GT 1a, Cohort 1)|Participants with genotype (GT) 1a HCV infection will receive placebo once daily for 3 days under fasted conditions.
3105521|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
3105522|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
3105523|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 1a, Cohort 1)|Participants with GT 1a HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
3105524|NCT02185794|Placebo Comparator|Placebo (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive placebo once daily for 3 days under fasted conditions.
3105525|NCT02185794|Experimental|Voxilaprevir 50 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 50 mg once daily for 3 days under fasted conditions.
3105526|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
3105527|NCT02185794|Experimental|Voxilaprevir 300 mg (GT 3, Cohort 2)|Participants with GT 3 HCV infection will receive voxilaprevir 300 mg once daily for 3 days under fasted conditions.
3105528|NCT02185794|Placebo Comparator|Placebo (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive placebo once daily for 3 days under fasted conditions.
3105529|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 2, Cohort 3)|Participants with GT 2 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
3105530|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 4, Cohort 4)|Participants with GT 4 HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
3105531|NCT02185794|Experimental|Voxilaprevir 100 mg (GT 1b, Cohort 5)|Participants with GT 1b HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fasted conditions.
3105532|NCT02185794|Experimental|Voxilaprevir 100 mg Fed (GT 3a, Cohort 6)|Participants with GT 3a HCV infection will receive voxilaprevir 100 mg once daily for 3 days under fed conditions.
3105533|NCT02185794|Experimental|Voxilaprevir 600 mg (Cohorts 7-9)|Participants with genotypes 1a, 1b, 2, 3, or 4 HCV infection will receive voxilaprevir up to 600 mg under fasted or fed conditions for 3 days.
3105534|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 1, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 after moderate fat meal and voxilaprevir 100 mg plus sofosbuvir (SOF)/velpatasvir (VEL) (400/100 mg) fixed-dose combination (FDC)on Days 2 and 3 after either a light or moderate-fat meal.
3105535|NCT02185794|Experimental|Voxilaprevir 100 mg + SOF/VEL 400/100 mg (Group 2, Cohort 10)|Participants with any GT HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal.
3105536|NCT02186015|Experimental|Cholecalciferol|All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
3105537|NCT02186015|No Intervention|Vitamin D sufficient|All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.
3105538|NCT02186171|Experimental|Romosozumab|Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months.
3105539|NCT02186171|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections once a month for 12 months.
3105540|NCT02186210|Experimental|prewarming|prewarming during induction of anesthesia
3105541|NCT02186210|No Intervention|control|no prewarming during induction of anesthesia
3105542|NCT02186223|Experimental|The Angel® Catheter|All eligible subjects will receive an Angel® Catheter.
3105543|NCT02186301|Active Comparator|Erlotinib Mono-Therapy|
3105544|NCT02186301|Experimental|Rociletinib Mono-Therapy|
3105545|NCT02186509|Experimental|Alisertib, fractionated stereotactic radiosurgery|"CONCURRENT PHASE: Patients undergo fractionated stereotactic radiosurgery QD every weekday for 10 days and receive alisertib PO BID concurrently with radiation therapy for 10 days.~MAINTENANCE PHASE: Patients receive alisertib PO BID on days 1-7. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity."
3105546|NCT02186561|Experimental|Pipeline™ Embolization Device|treatment with Pipeline™ Embolization Device
3105547|NCT02186587|Other|ConforMIS|Subjects who receive a ConforMIS custom total knee implant.
3105548|NCT02186652|Other|Pantoprazole|
3105549|NCT02186665|Experimental|calcitriol ointment|calcitriol 3 mcg/g ointment
3105550|NCT02186665|Placebo Comparator|placebo|placebo comparator
3105551|NCT02186795||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management with one to four multimodal oral pain medications (acetaminophen, celecoxib, oxycodone ER, gabapentin, pregabalin) administered preoperatively or in the first 48 hours postoperatively.
3105552|NCT02186795||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
3105553|NCT02186808|Other|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
3105554|NCT02186821|Experimental|Ceritinib 750 mg|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally, once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days with no breaks between dosing cycles.
3105555|NCT02186834|Experimental|Selinexor, Liposomal Doxorubicin and Dexamethasone|"Combination Therapy: Phase I Dose Escalation followed by Phase 2 treatment at Recommended Phase 2 Dose (RP2D).~After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg along with dexamethasone for 1 day. One week later, patients will receive weekly selinexor at a starting dose from 60 mg once a week to 80 mg twice a week in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone 40 mg orally weekly."
3105556|NCT02186847|Active Comparator|Chemoradiation|60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3105557|NCT02186847|Experimental|Metformin + Chemoradiation|Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin
3105558|NCT02186873|Experimental|Treatment Group 1: Placebo then Golimumab|Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
3105559|NCT02186873|Experimental|Treatment Group 2: Golimumab|Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.
3105560|NCT02186938|No Intervention|Usual Care|Arterial line (radial, femoral, dorsalis pedis, or brachial), central line for access when needed, intubation vs tracheostomy, general anesthesia. We currently use stroke-volume variability monitoring (FloTrac) in all patients using the arterial line placed for blood pressure monitoring.
3105561|NCT02186938|Experimental|Treatment|The study will use a treatment algorithm for patients in the treatment group. This algorithm will aim to maintain a near-normal blood pressure and use goal directed therapy to achieve this. Currently the standard of care is to use IV fluid exclusively in these patients and anesthesia providers everywhere have been challenging that treatment plan. Our algorithm has an iterative approach assessing volume status, cardiac output and vascular tone in order, with interventions specified for each. Individual treatments have been proven safe and effective in this population, we believe this sequence may be the best current management system. By avoiding excessive fluid administration we expect to decrease ICU length of stay due to the comorbidities caused (pulmonary edema, bowl edema, glycocalyx damage).
3105562|NCT02187016|Experimental|AirFloss + BreathRx|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with BreathRx rinse once a day.
3105563|NCT02187016|Experimental|AirFloss + Listerine|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device with Listerine Cool Mint rinse once a day.
3105564|NCT02187016|Experimental|Dental Floss|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute. Subjects used interproximal cleaning device once a day.
3105565|NCT02187016|Active Comparator|Manual Toothbrush|Device: Subjects brushed with a ADA Reference Manual Toothbrush once a day for 1 minute
3105566|NCT02187029|Experimental|PF-06743649 dose level 1 (Cohort 1)|
3105567|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 1)|
3105568|NCT02187029|Experimental|PF-06743649 dose level 2 (Cohort 2)|
3105569|NCT02187029|Placebo Comparator|Placebo for PF-06743649 (Cohort 2)|
3105570|NCT02187042||All patients|Metastatic and/or advanced renal cell carcinoma patients treated with sunitinib in first line and followed by standard care plus call center
3105571|NCT02187055|Experimental|Tofacitinib 5 mg twice daily with methotrexate|
3105572|NCT02187055|Experimental|Tofacitinib 5 mg twice daily monotherapy|
3105573|NCT02187055|Active Comparator|Adalimumab with methotrexate|
3105574|NCT02187159|Experimental|DS-5565 QD|Participants take one each of placebo tablet and capsule in the morning, and one DS-5565 tablet once daily (QD) with a placebo capsule in the evening
3105575|NCT02187159|Experimental|DS-5565 BID|Participants take one DS-5565 tablet and one placebo capsule, twice daily (BID)
3105576|NCT02187159|Active Comparator|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3105577|NCT02187159|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule BID
3105578|NCT02187172|Active Comparator|Ustekinumab (Stelara)|Ustekinumab (Stelara) subcutaneous injection 45mg (if person's weight is 100kg or less) or 90mg (if person's weight is greater than 100kg) at day 0 and week 4 followed by every 12-week dosing thereafter. Patient will receive total of 52 weeks of ustekinumab (12 weeks during RCT phase, 40 weeks post RCT phase). The end of study is at Week 52 for this arm.
3105579|NCT02187172|Placebo Comparator|Placebo|Placebo subcutaneous injection will be given according to the same dose and schedule as the active comparator until week 12 (end of RCT phase). At week 12, ustekinumab will be administered according according to the same injection schedule as the active comparator arm for 52 weeks. Patient will receive total of 52 weeks of ustekinumab (0 weeks during RCT phase, 52 weeks post RCT phase). The end of study is at Week 64 for this arm.
3105580|NCT02187471|Placebo Comparator|Placebo|Participants take one each of placebo tablet and capsule, twice daily (BID)
3105581|NCT02187471|Other|Pregabalin|Participants take one pregabalin capsule and one placebo tablet BID
3105582|NCT02187471|Experimental|DS-5565 15 mg QD|Participants take one each of placebo tablet and capsule in the morning and one placebo capsule in the evening with one DS-5565 tablet once daily (QD)
3105583|NCT02187471|Experimental|DS-5565 15 mg BID|Participants take one placebo capsule with one DS-5565 tablet BID
3105584|NCT02187744|Experimental|PF-05280014|
3105585|NCT02187744|Active Comparator|Herceptin®|
3105586|NCT02187783|Experimental|LEE011|LEE011 600 mg (hard gelatin capsules) was administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle was defined as 28 days.
3105587|NCT02187809|Experimental|Clobazam|A maximum of 2.0 mg/kg/day (maximum 80 mg/day) twice daily (BID); clobazam oral suspension (2.5 mg/mL) or clobazam scored tablets (10 mg), orally
3105588|NCT02187861|Experimental|Chemotherapy-Containing Cohort:Safety Run-In (Venetoclax + BR)|Participants will receive venetoclax no more than 600 milligrams (mg) orally once daily continuously along with rituximab 375 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Day 1 of 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of the 28-day cycle. Safety run-in will continue until first 9 participants complete the safety observation window of 28 days. Participants will continue receiving the same treatment as decided for Arm B.
3105589|NCT02187861|Experimental|Chemotherapy-Free Cohort: Arm A (Venetoclax + Rituximab)|Participants will receive venetoclax 800 mg orally once daily for 1 year along with rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15, 22 of Cycle 1 and Day 1 of Cycles 4, 6, 8, 10, and 12. Each cycle will be of 28 days.
3105590|NCT02187861|Experimental|Chemotherapy-Containing Cohort: Arm B (Venetoclax + BR)|Participants will receive venetoclax at doses decided from safety run-in orally once daily continuously for 1 year along with rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
3105591|NCT02187861|Active Comparator|Chemotherapy-Containing Cohort: Arm C (BR)|Participants will receive rituximab 375 mg/m^2 IV infusion on Day 1 of each 28-day cycle and bendamustine 90 mg/m^2 IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
3105592|NCT02187887|Experimental|Personalized normative feedback|Intervention participants receive feedback correcting their misperceptions of the drinking behavior and attitudes of fellow veterans
3105593|NCT02187887|No Intervention|Control|Control participants receive feedback correcting their misperceptions of the video game playing behavior and attitudes of fellow veterans
3105594|NCT02188160|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% ophthalmic suspension dosed QID for 28 days in subjects with dry eye disease
3105595|NCT02188160|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for 28 days in subjects with dry eye disease
3105596|NCT02188303|Placebo Comparator|Placebo (Single Dose, Cohorts 1-3)|Single dose of placebo matching LY2944876 administered subcutaneous (SC) on Day 1
3105597|NCT02188303|Experimental|LY2944876 (Single Dose, Cohorts 1-3)|Single dose of 10 milligrams (mg) of LY2944876 administered SC on Day 1
3105598|NCT02188303|Placebo Comparator|Placebo (Multiple Dose, Cohort 4)|Placebo matching LY2944876 administered once daily SC on Days 1-7
3105599|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 4)|40 mg LY2944876 administered once daily SC on Days 1-7
3105600|NCT02188303|Placebo Comparator|Placebo (Multiple, Cohort 5)|Placebo matching LY2944876 administered once daily SC on Days 1, 4, 6, 8, 10 and 12
3105601|NCT02188303|Experimental|LY2944876 (Multiple Dose, Cohort 5, Titrated)|LY2944876 in titrated doses of 15 mg on Day 1, 30 mg on Day 4, up to 60 mg on Day 6, and up to 80 mg on Days 8, 10 and 12 administered once daily SC
3105602|NCT02188459|Active Comparator|Bupropion|Bupropion 150 mg BID, PO for 10 weeks
3105603|NCT02188459|Placebo Comparator|Placebo|Placebo BID, PO for 10 weeks. The formulation appears identical to the bupropion capsules.
3132647|NCT03442725|Experimental|Severely decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
3105604|NCT02188485|Experimental|ENGAGE: a social engagement intervention|ENGAGE is a brief psychotherapy that specifically targets increased social engagement and activity. The study will use the ENGAGE manual developed by Drs. Alexopoulos, Arean and their colleagues, focusing on increased engagement in activities that allow subjects to be social (targeting thwarted belongingness) or contribute to the well-being of others (targeting perceived burdensomeness).
3105605|NCT02188485|No Intervention|Care-as-Usual|Care as usual in primary care with study assessments.
3105606|NCT02188576|Experimental|high dose TXA|"High dose TXA is the intervention.~A higher dose of tranexamic acid will be given to this arm as follows:~50 mg/kg loading dose and 5 mg/kg/h infusion"
3105607|NCT02188576|Experimental|Low Dose TXA|"Low dose TXA is the intervention.~A lower dose of TXa will be given as follows:~10 mg/kg loading dose and 5 mg/kg/h infusion"
3105608|NCT02188589|Experimental|Nasal implant group|Bilateral or unilateral INEX nasal implants
3105609|NCT02188719|Experimental|Cohort 1 - Treg-supportive IS only|3 subjects (Cohort 1a) at site 1 (UCSF) and 3 subjects (Cohort 1b) from site 2 (Mayo Rochester) will receive Treg-Supportive immunosuppression (IS) regimen and will not receive Donor-Alloantigen-Reactive T Regulatory Cells (darTregs). Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3105610|NCT02188719|Experimental|Cohort 2 - darTreg infusion,50 million(range 25 to 60 million)|At least 3 subjects will receive a single infusion of 50 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3105611|NCT02188719|Experimental|Cohort 3 - darTreg infusion,200 million(range100-240 million)|At least 3 subjects will receive a single infusion dose of 200 million darTregs. Progression from one cohort to the next will depend on the cumulative incidence of sentinel adverse events.
3105612|NCT02188719|Experimental|Cohort 4 - darTreg infusion,800 million(range 400-960 million)|Six subjects will receive a single infusion of 800 million darTregs.
3105613|NCT02188784|Active Comparator|Polysaccharide iron complex 150 mg|oral Fe polysaccharide 150mg twice daily for 16 weeks
3105614|NCT02188784|Placebo Comparator|Placebo (for Polysaccharide Iron Complex 150 mg)|Oral placebo twice a day for 16 weeks
3105615|NCT02188849|Experimental|Creatine|Creatine 5 g/ day
3105616|NCT02188849|Placebo Comparator|Placebo|Maltodextrin 5 g/day to be dissolved in water
3105617|NCT02189122|Active Comparator|Group 1:Aspirin/placebo|Group 1 will be randomized to the order in which they receive rapid-release aspirin (ASA), 81 mg), ASA 162.5 mg, and identical-appearing placebo for 5 days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
3105618|NCT02189122|Active Comparator|Group 2:NHP-544C/placebo|Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
3105619|NCT02189161|Experimental|Radiofrequency Ablation|circumferential radiofrequency ablation (RFA) to the anal canal
3105620|NCT02189213|Active Comparator|Sertraline|Sertraline will be administered PO to treat anxiety disorders in children and adolescents. he following dosing schedules will be used: Sertraline will be titrated from 25mg once a day orally up to 200mg once a day orally, for 12 weeks. The titration will stop at the dose in which the participant shows a full response to the medication or experiences side effects that will inhibit titration.
3105621|NCT02189213|No Intervention|Control|There will be no intervention in this arm.
3105622|NCT02189252|Active Comparator|E4:L4|Crossover Sequence
3105623|NCT02189252|Active Comparator|L4:E4|Crossover Sequence
3105624|NCT02189252|Active Comparator|E2:L4|Crossover Sequence
3105625|NCT02189252|Active Comparator|L4:E2|Crossover Sequence
3105626|NCT02189317|Experimental|Exparel|This arm will receive Exparel
3105627|NCT02189317|No Intervention|Control|
3105628|NCT02189382|Experimental|Potassium Oxalate Gel|Self Applied
3105629|NCT02189382|Other|Water|Self Applied
3105630|NCT02189473|Experimental|5 x 4 Gy in 1 week|radiotherapy with 5 x 4 Gy in 1 week (5 x 4 Gy per week)
3105631|NCT02189473|Active Comparator|10 x 3 Gy in 2 weeks|radiotherapy with 10 x 3 Gy in 2 weeks (5 x 3 Gy per week)
3105632|NCT02189629|Experimental|CD5789 (trifarotene) cream|
3105633|NCT02189668|Experimental|Non-operative Management|Non-operative management with antibiotics only Zosyn (Piperacillin/Tazobactam) and then Augmentin unless penicillin allergic Cipro/Flagyl if penicillin allergic
3105634|NCT02189668|No Intervention|Surgery|Usual care with urgent appendectomy
3105635|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to one hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
3105636|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to one hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
3105637|NCT02189759|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
3105638|NCT02189759|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
3105639|NCT02189837|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
3105640|NCT02189837|Active Comparator|Atorvastatin|Participants received placebo subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
3105641|NCT02189837|Experimental|Evolocumab|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and placebo tablets once a day for up to 8 weeks.
3105642|NCT02189837|Experimental|Evolocumab and Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once every 2 weeks on days 1, 15, 29 and 43 and 80 mg atorvastatin orally once a day for up to 8 weeks.
3105643|NCT02189850|Experimental|BLI800 - Dose 1|BLI800 oral solution
3105644|NCT02189850|Experimental|BLI800 - Dose 2|BLI800 oral solution
3105645|NCT02189863|Other|AOAMV, then AOAMF|Lotrafilcon B MV contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses worn for 2 weeks in Period 2
3105646|NCT02189863|Other|AOAMF, then AOAMV|Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
3105647|NCT02189889|Active Comparator|EPO and Feraheme|Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
3105648|NCT02189889|No Intervention|Control|The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.
3105649|NCT02189915|Experimental|Creatine monohydrate|
3105650|NCT02189941|Experimental|Deferiprone sustained-release (fed)|A single 1000 mg dose of deferiprone sustained-release following a high fat high calorie breakfast.
3105651|NCT02189941|Experimental|Deferiprone sustained-release (fasting)|A single 1000 mg dose of deferiprone sustained-release under fasting conditions.
3105652|NCT02189941|Active Comparator|Deferiprone immediate-release (fasting)|A single 1000 mg dose of Deferiprone immediate-release under fasting conditions.
3105653|NCT02189954|Active Comparator|Group Routine Care|The placement according to the manufacturer's instructions.
3105654|NCT02189954|Experimental|Group Pressure Limiting|Cuff inner pressure was held below 44 mmHg
3105655|NCT02190045|Experimental|Wii-Fit program|Wii-Fit exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
3105656|NCT02190045|Placebo Comparator|Cognitive remediation program|Cognitive remediation exercises will be adminstered for 45 minutes 3 days a week for 8 weeks
3105657|NCT02190279|Experimental|Suspected Localized Prostate Cancer|Patients with known localized prostate cancer with a soft tissue lesion at least 6mm or greater.
3105658|NCT02190279|Experimental|Biochemical Recurrence|Patients with biochemical prostate cancer relapse after definitive treatment
3105659|NCT02190279|Experimental|Known Metastatic Disease|Patients with identifiable metastatic disease on a conventional imaging modality. If only soft tissue metastasis, one lesion must measure 6mm or greater. Patients must have confirmation of prostate cancer prior to investigational imaging.
3105660|NCT02190435|Experimental|ADAPT|Patients that receive intramedullary nail fixation with use of the Stryker ADAPT computer-assisted navigation system
3105661|NCT02190435|Active Comparator|Control|Patients that receive conventional technique intramedullary nail fixation without use of the Stryker ADAPT computer-assisted navigation system
3105662|NCT02190552||EmboTrap® Revascularization Device|The EmboTrap® Revascularization Device is the investigational device
3105663|NCT02190591|No Intervention|Pillow and Wedge|Receiving standard care for positioning during labor using pillows and wedges
3105664|NCT02190591|Experimental|Peanut Labor Ball|Use of the peanut labor ball within 30 minutes after epidural placement
3105665|NCT02190604|Experimental|Part 1 Cohort 1: QBW251|Single dose of QBW251 10 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105666|NCT02190604|Experimental|Part 1 Cohort 2: QBW251|Single dose of QBW251 25 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105667|NCT02190604|Experimental|Part 1 Cohort 3: QBW251|Single dose of QBW251 75 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105668|NCT02190604|Experimental|Part 1 Cohort 4: QBW251|Single dose of QBW251 150 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105669|NCT02190604|Experimental|Part 1 Cohort 5: QBW251|Single dose of QBW251 300 mg in healthy volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105670|NCT02190604|Experimental|Part 1 Cohort 6: QBW251|Single dose of QBW251 500 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105671|NCT02190604|Experimental|Part 1 Cohort 6: QBW251(fed)|Single dose of QBW251 500 mg (fed). single dose with food for a preliminary assessment of the effect of food on the absorption of QBW251 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105672|NCT02190604|Experimental|Part 1 Cohort 7: QBW251|Single dose of QBW251 750 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105673|NCT02190604|Experimental|Part 1 Cohort 8: QBW251|Single dose of QBW251 1000 mg in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105674|NCT02190604|Placebo Comparator|Part 1 Placebo|Placebo to QBW251 in all cohorts of part 1 in Healthy Volunteers. Each treatment period was comprised of a baseline period (Day -1), an inpatient dosing period (Days 1 to 3), three follow-up visits (Days 4, 5, and 8), and one end-of-treatment-period evaluation performed 14 days after the dose of study drug (Day 15).
3105675|NCT02190604|Experimental|Part 2 Cohort 1: QBW251|Multiple doses of QBW25 150 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105676|NCT02190604|Experimental|Part 2 Cohort 2: QBW251|Multiple doses of QBW251 400 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105677|NCT02190604|Experimental|Part 2 Cohort 3: QBW251|Multiple doses of QBW251 750 mg qd in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105678|NCT02190604|Experimental|Part 2 Cohort 4: QBW251|Multiple doses of QBW251 450 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105679|NCT02190604|Experimental|Part 2 Cohort 5: QBW251|Multiple doses of QBW251 750 mg bid in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105680|NCT02190604|Placebo Comparator|Part 2 Placebo|Placebo to QBW251 in all cohorts of part 2 in Healthy Volunteers. 14-day treatment period, follow-up study visits (Days 18, 22 and 29) and one End-of-Study evaluation (Day 36).
3105681|NCT02190604|Experimental|Part 3 Cohort 1: QBW251|150 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3105682|NCT02190604|Experimental|Part 3 Cohort 2: QBW251|450 mg b.i.d. Multiple doses. Patients having a class III, IV, V, or VI mutation on one allele and any other CFTR mutation on the other allele in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3105683|NCT02190604|Experimental|Part 3 Cohort 3: QBW251|450 mg b.i.d. Multiple doses. Patients who are homozygous for the F508del mutation in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3105684|NCT02190604|Placebo Comparator|Part 3 Placebo|Placebo to QBW251 in all cohorts of part 3 in patients. treatment period (Day 1 to Day 14) with study visits on Days 1, 4, 7 and 14 with follow-up visits on Days 15, 28 and 42.
3105686|NCT02190747|Experimental|Palovarotene dose level 1 (Cohort 1)|Doses of palovarotene in dose level 1 are 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days.
3105687|NCT02190747|Experimental|Palovarotene dose level 2 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 2 are 10 mg palovarotene once daily, followed by 5 mg once daily for 28 days.
3105688|NCT02190747|Experimental|Palovarotene dose level 3 (Cohort 2)|Weight-adjusted doses of palovarotene in dose level 3 are 5 mg palovarotene once daily, followed by 2.5 mg once daily for 28 days.
3105689|NCT02190747|Placebo Comparator|Sugar pill|The placebo comparator will be taken once daily for the same duration as the palovarotene dose groups in both Cohorts 1 and 2.
3105690|NCT02190903|Active Comparator|General endotracheal anesthesia|Standard care general endotracheal anesthesia
3105691|NCT02190903|Active Comparator|Regional (spinal) anesthesia|Standard care spinal anesthesia
3105692|NCT02191033|Experimental|Text messaging|Smoking counseling, nicotine patch, text messaging
3105693|NCT02191033|Active Comparator|Standard of care|Smoking counseling, nicotine patch
3105694|NCT02191046|Active Comparator|syringe 20 ml|nasal irrigation with syringe by using buffer hypertonic saline about 100-240 ml until no nasal discharge
3105695|NCT02191046|Experimental|squeezable bottle|nasal irrigation with squeezable bottle by using buffer hypertonic saline about 100-240 ml until no nasal discharge
3105696|NCT02191137|Experimental|Riociguat 0.5mg to 2.5 mg|Single arm, open label
3105697|NCT02191267|Experimental|Presumed CTE Group|Interventions administered to the Presumed CTE Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans, and Genetic Analysis for Genetic Risk Score for Tau.
3105698|NCT02191267|Experimental|Control Group|Interventions administered to the Control Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, and MRI/MRS Scans.
3105699|NCT02191267|Experimental|AD Dementia Group|Interventions administered to the AD Dementia Group include: [F-18]-T807 PET Scan, [F18]-Florbetapir PET Scan, MRI/MRS Scans
3105700|NCT02191397|Experimental|Bupropion Treatment Arm|Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.
3132648|NCT03442725|Active Comparator|Normal renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
3105701|NCT02191397|Active Comparator|Escitalopram Treatment Arm|Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.
3105702|NCT02191579|Active Comparator|BOTOX®|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks for up to 3 treatments.
3105703|NCT02191579|Active Comparator|Topiramate|Topiramate starting at a daily oral dose of 25 mg/day titrated up to a maximum dose of 100 mg/day for 36 weeks. Participants who discontinue topiramate are eligible to receive treatment with BOTOX®.
3105704|NCT02191605|Experimental|electronic SBIRT (eSBIRT)|Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting.
3105705|NCT02191605|Experimental|Tailored texting|Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support.
3105706|NCT02191605|Experimental|eSBIRT & texting|Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms.
3105707|NCT02191605|No Intervention|Assessment only|Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
3105708|NCT02191605|No Intervention|Screening only|Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
3105709|NCT02191618|Other|WEB Aneurysm Embolization Device|"The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.~The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant."
3105710|NCT02191865|Experimental|Mild liver impairment|Patients with mild hepatic impaired function (Child-Pugh A)
3105711|NCT02191865|Experimental|Moderate liver impairment|Patients with moderate hepatic impaired function (Child-Pugh B)
3105712|NCT02191865|Experimental|Healthy volunteers|Healthy control subjects
3105713|NCT02192099|Experimental|Rapastinel (225 mg/450 mg IV administration) prefilled syringe|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
3105714|NCT02192190|Placebo Comparator|Placebo|Placebo capsule orally, once daily for approximately 16 weeks. Placebo subcutaneous (SC) once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3105715|NCT02192190|Active Comparator|Celecoxib + Placebo|Celecoxib 200 milligram (mg) capsule orally once daily for approximately 16 weeks. Placebo SC once every 4 weeks for 16 weeks (Treatment period = 16 weeks).
3105716|NCT02192190|Experimental|LY2951742 5 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 5 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
3105717|NCT02192190|Experimental|LY2951742 50 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 50 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
3105718|NCT02192190|Experimental|LY2951742 120 mg + Placebo|Placebo capsule orally, once daily for approximately 16 weeks. SC injections of 120 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
3105719|NCT02192190|Experimental|LY2951742 300 mg + Placebo|Placebo capsule orally, once daily for 16 weeks. SC injections of 300 mg LY2951742 once every 4 weeks for 8 weeks followed by placebo SC once every 4 weeks for 8 weeks (Treatment period = 16 weeks).
3105720|NCT02192307|Experimental|potassium oxalate gel|Professional application
3105721|NCT02192307|Active Comparator|Potassium oxalate liquid|Professional application
3105722|NCT02192541|Experimental|Ganetespib and Ziv-Aflibercept|Ganetespib was administered intravenously, over 1 hour, weekly, on days 1, 8, and 15 of each 28-day cycle. Ziv-aflibercept was administered intravenously, over 1 hour, every 2 weeks, on days 1 and 15 of each 28-day cycle. Ganetespib was started at a dose level of 100 mg/m^2 + ziv-aflibercept at 3 mg/kg or 4 mg/kg.
3105723|NCT02192606|Active Comparator|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy
3105724|NCT02192606|Active Comparator|3D laparoscopy|The Storz 3D Laparoscopy System is the intervention we are studying at the time of the total laparoscopic hysterectomy.
3105725|NCT02192684|Active Comparator|pioglitazone|pioglitazone 45 mg, oral, daily
3105726|NCT02192684|Placebo Comparator|placebo|Placebo, one pill daily
3105727|NCT02192814|Experimental|Lacosamide (LCM)|"On Day - 1, LCM oral tablets were administered in accordance with each subject's LCM dosage regimen in EP0009 (NCT01832038). The oral tablets were taken from EP0009 supply.~During the Treatment Period, subjects received a 30-minute infusion of intravenous (iv) LCM twice daily, once in the morning and once in the evening, for 5 days.~The daily dose of iv LCM was the same as the subject's daily dose of oral LCM in EP0009 (200 - 400 mg/day)."
3105728|NCT02192879|Active Comparator|Thoracic Epidural|
3105729|NCT02192879|Active Comparator|Continuous Paravertebral Catheter|
3105730|NCT02192879|Active Comparator|Patient-Controlled Analgesia|
3105731|NCT02192905|Experimental|Behavioral Weight Loss + Habit|Participants will receive 8 week of an online-delivered weight loss intervention adapted from the Diabetes Prevention Program Lifestyle Intervention and will use the Habit mobile app during the study.
3105732|NCT02192970|Experimental|Bevacizumab|Pars plana vitrectomy will be performed in the typical manner. After laser retinopexy and prior to air-gas exchange, intravitreal bevacizumab will be administered through the trocar. Either perfluoropropane (C3F8) or sulfur hexafluoride (SF6) gas will then be administered for long-term retinal tamponade and the vitrectomy ports closed in the usual manner.
3105733|NCT02192970|No Intervention|Chart review|Review records over the past 5 years of patients who underwent vitrectomy for retinal detachment repair to found out the percentage of those who had re-detachment of the retina within 6 months after surgery.
3105734|NCT02193074|Experimental|nusinersen|
3105735|NCT02193074|Sham Comparator|Sham procedure|
3105736|NCT02193087|Active Comparator|Group A: TDV Liquid + Placebo|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1, and TDV Liquid Formulation placebo-matching solution, subcutaneous injection, once on Day 90 (Month 3).
3105737|NCT02193087|Active Comparator|Group B: TDV Liquid|TDV Liquid Formulation 1, diluted 1:5 with vaccine diluent, subcutaneous injection on Day 1 and Day 90 (Month 3).
3105738|NCT02193087|Experimental|Group C: TDV Liquid|TDV Liquid Formulation 2, subcutaneous injection on Day 1 and Day 90 (Month 3).
3105739|NCT02193087|Experimental|Group D: TDV Lyophilized|TDV Lyophilized Formulation reconstituted with water, subcutaneous injection on Day 1 and Day 90 (Month 3).
3105740|NCT02193152|Experimental|Treatment: Pazopanib|"Pazopanib 800 mg daily should be taken orally without food at least one hour before or two hours after a meal.~One cycle of pazopanib is 28 days."
3105741|NCT02193165|Active Comparator|Regimen 1|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash
3105742|NCT02193165|Active Comparator|Regimen 2|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
3105743|NCT02193165|Placebo Comparator|Regimen 3 - Control group|fluoride toothpaste + fluoride Mouthwash
3105744|NCT02193178|Experimental|comfilcon A toric|Participants are habitual toric lens wearers and will be fitted with comfilcon A toric lenses.
3105745|NCT02193347|Experimental|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of a peptide that spans the mutated region of IDH1R132H (Isocitrate Dehydrogenase 1). The peptide is administered with GM-CSF (Granulocyte Macrophage Colony Stimulating Factor) mixed with Montanide ISA 51.
3105746|NCT02193490|Active Comparator|DNase|DNase 0.1% eye drops four times a day for 8 weeks
3105747|NCT02193490|Placebo Comparator|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
3105748|NCT02193776|Experimental|DS-TB: J(loading dose/t.i.w.)PaZ|Subjects with DS-TB. J(loading dose/t.i.w.)PaZ: Bedaquiline 400mg once daily Days 1-14, 200mg three times per week Days 15-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3105749|NCT02193776|Experimental|DS-TB: J(200mg)PaZ|Subjects with DS-TB. J(200mg)PaZ: Bedaquiline 200mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3105750|NCT02193776|Experimental|MDR-TB: J(200mg)MPaZ|Subjects with MDR-TB. J(200mg)MPaZ: Bedaquiline 200mg once daily Days 1-56; plus moxifloxacin 400mg once daily Days 1-56; plus PA-824 200mg once daily Days 1-56; plus pyrazinamide 1500mg once daily Days 1-56.
3105751|NCT02193776|Active Comparator|DS-TB: HRZE|Subjects with DS-TB. HRZE tablets (Isoniazid 75mg plus rifampicin 150mg plus pyrazinamide 400mg plus ethambutol 275mg combination tablets) dosed once daily Days 1-56 per the Subject's weight as follows: 30-37kg: 2 tablets; 38-54kg: 3 tablets; 55-70kg: 4 tablets; 71kg and over: 5 tablets.
3105752|NCT02193815|Experimental|One Arm|Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
3105753|NCT02193828|Experimental|AA4500 0.25 mg|Collagenase clostridium histolyticum, single 0.25 mg injection
3105754|NCT02193828|Experimental|AA4500 0.40 mg|Collagenase clostridium histolyticum, single 0.40 mg injection
3105755|NCT02193828|Experimental|AA4500 0.60 mg|Collagenase clostridium histolyticum, single 0.60 mg injection
3105756|NCT02193828|Placebo Comparator|Placebo|Placebo, single 0.25 mg, 0.40 mg, or 0.60 mg injection
3469134|NCT03889327|Active Comparator|Healthy Eating Habits (HEH)|The control group, healthy eating habits (HEH) group, will watch a brief psychoeducational video of same length in time as the treatment group. The control intervention will include information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The proposed control intervention will include expert testimony from a nutritionist and expert dietician.
3105758|NCT02193880|Other|Alpha-beta depleted T-cell infusion|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
3105759|NCT02194062|Active Comparator|fluticasone nasal spray|Group one will be prescribed fluticasone nasal spray ( to use 2-50 mcg sprays to each nostril two times per day)
3105760|NCT02194062|Active Comparator|budesonide respule in head upright|Group two will be prescribed budesonide respules (0.5 mg/2mL) to instill into each nostril in the upright position two times per day
3105761|NCT02194062|Active Comparator|budesonide head forward|Group three will be prescribed budesonide respules (0.5 mg/2mL) to use instill into each nostril in the head forward position two times per day with their head angled downwards by having their head lean forward off the side of a bed.
3105762|NCT02194088|Experimental|Pain medication: diclofenac and atropine|Diclofenac and Atropine combination drug Provided PO. This is a novel combination. Diclofenac 100mg + Atropine 1.2 mg in one single dose
3105763|NCT02194088|Placebo Comparator|placebo|Placebo capsules will be delivered in same number as the medication
3105764|NCT02194439||hematopoietic stem cell transplant|procedure
3105765|NCT02194465|Experimental|6 milligrams (mg) LY2623091|6 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3105766|NCT02194465|Experimental|13 mg LY2623091|13 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3105767|NCT02194465|Experimental|24.5 mg LY2623091|24.5 mg LY2623091 with placebo for blinding administered orally once daily for 4 weeks.
3105768|NCT02194465|Experimental|13 mg LY2623091 + 20 mg tadalafil|13 mg LY2623091 and 20 mg of tadalafil with placebo for blinding administered orally once daily for 4 weeks.
3105769|NCT02194465|Experimental|20 mg tadalafil|20 mg tadalafil with placebo for blinding administered orally once daily for 4 weeks.
3105770|NCT02194465|Active Comparator|Spironolactone|25 mg titrated to 50 mg as tolerated of spironolactone (open label) administered orally once daily for 4 weeks.
3105771|NCT02194465|Placebo Comparator|Placebo|Placebo for blinding administered orally once daily for 4 weeks.
3105772|NCT02194621|Experimental|Total Flavor Option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 1 ingredient - Total Flavor Option 1
3105773|NCT02194621|Experimental|Total Flavor Option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM (oral malodor) complex 2 ingredient. Total Flavor Option 2
3105774|NCT02194621|Placebo Comparator|Crest Toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste (currently marketed)
3105775|NCT02194699|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
3105776|NCT02194699|Placebo Comparator|Placebo|Placebo subcutaneous injection
3105777|NCT02194933|Experimental|Brexpiprazole 2 mg|Brexpiprazole 2 mg/day, once daily dose, tablet, orally
3105778|NCT02194933|Experimental|Brexpiprazole 4 mg|Brexpiprazole 4 mg/day, once daily dose, tablet, orally
3105779|NCT02194985|Experimental|Migalastat HCl 150 mg|Migalastat HCl 150 milligram (mg).
3105780|NCT02194998|Experimental|Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
3105781|NCT02194998|Experimental|Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took an INI-based (RAL or DTG) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
3105782|NCT02194998|Experimental|Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 24 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
3105783|NCT02194998|Experimental|Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks]|Participants took a PI-based (DRV or ATV) ART regimen for HIV-1 and received the following medications for 12 weeks: paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), dasabuvir (DSV), and ribavirin (RBV) (RBV for all participants (version 1) and only for participants with HCV genotype 1a (version 2)).
3105784|NCT02195011|Experimental|Cohort 1: Regorafenib/SIR-Spheres/Regorafenib|"Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.~Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration."
3105785|NCT02195011|Experimental|Cohort 2: SIR-Spheres/Regorafenib|"SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.~SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle."
3105786|NCT02195232|Experimental|Cohort A - Isoquercetin|"-- Cohort A: 500 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
3105787|NCT02195232|Experimental|Cohort B - Isoquercetin|"--Cohort B: 1000 mg, Once daily, 28 days~- For both cohorts A and B, lower extremity ultrasound will be performed at 56 days. Baseline D-dimer and correlative labs will be drawn at Day 1 and at 56 days. Patients will be followed for survival after completion of 56 days."
3105788|NCT02195310|Experimental|Prevena™ Incision Management System|Subjects will receive sternal wound treatment in the operating room using Prevena™ Incision Management System according to the intended use
3105789|NCT02195310|Active Comparator|Conventional sterile wound dressings|Subjects will receive standard conventional wound therapy (SCWT) placed in the operating room, defined as using conventional sterile wound dressings (gauze).
3105790|NCT02195349|Experimental|Healthy Subjects (no DTH)|One subject will be dosed with GSK2831781 (0.0003 mg/kg) and one with placebo. Depending on the safety data obtained for 28 days post dose along with the available PK data, a dose escalation may be done to the next planned dose (0.0015 , 0.0075, 0.04, 0.15 mg/kg). In case safety findings are noted then the cohort may be expanded to a maximum cohort size of 6:3 (GSK2831781: placebo) or the escalation will be stopped.
3105791|NCT02195349|Experimental|Healthy Subjects (DTH)|Sentinel subjects (one dosed with GSK2831781 (0.0003 mg/kg) and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 1 placebo subject will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). After reviewing the safety data for 28 days the healthy subjects (DTH) will be escalated to the planned dose of GSK2831781 (0.0075, 0.04, 0.15 mg/kg) in 6:3 ratio with placebo.
3132649|NCT03442725|Experimental|Mildly decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
3132650|NCT03442725|Experimental|Moderately decreased renal function group|Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
3105792|NCT02195349|Experimental|Subjects with Psoriasis|Sentinel subjects (one dosed with GSK2831781 and one with placebo) will be used in the cohort. Following a review of safety data up to 48 hours post dose, an additional 5 active (GSK2831781) and 2 placebo subjects will be dosed (no more than 2 subjects per day with dosing separated by at least 1 hour). All subsequent cohorts do not require stratification for pre-existing ADAs. After reviewing the safety data for 28 days for minimum of 8 out of 9 subjects within the cohort and all subjects have completed dosing and the inpatient monitoring until Day 4, the subjects with psoriasis will be escalated to the planned dose of GSK2831781 (1.5 and 5 mg/kg) in 6:3 ratio with placebo.
3105793|NCT02195414|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
3105794|NCT02195427|Experimental|TEOSYAL RHA Global Action/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Global Action into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3105795|NCT02195427|Experimental|TEOSYAL RHA Deep Lines/Juvederm Ultra XC|Split-face injection of TEOSYAL® RHA Deep Lines into one NLF and Juvederm® Ultra XC into the contralateral NLF (n=75). Up to 3.0 mL injected per NLF (mid-dermis to deep-dermis). Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3469135|NCT03889639|Experimental|Cohort 1: SAR442168 5 mg Then Placebo|Participants received SAR442168 5 milligrams (mg), orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3469136|NCT03889639|Experimental|Cohort 1: SAR442168 15 mg Then Placebo|Participants received SAR442168 15 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3105798|NCT02195518|Experimental|Tenofovir Disoproxil Fumarate|All enrolled subjects will receive open label TDF at a dose of 300 milligram (mg) orally once daily during the study period.
3105799|NCT02195531|Active Comparator|Treatment|Participants will receive education and feedback tailored to the psychological profile of the receiving participant.
3105800|NCT02195531|Active Comparator|Control Group|Participants will receive education inconsistent with their profile.
3105801|NCT02195531|No Intervention|Standard of care|Participants will not receive education or feedback.
3105802|NCT02195583|Experimental|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
3105803|NCT02195583|Experimental|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
3105804|NCT02195583|Experimental|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
3105805|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
3105806|NCT02195583|Experimental|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
3105807|NCT02195583|Placebo Comparator|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
3105808|NCT02195622|Other|Lumenis VersaCut Morcellator|Lumenis VersaCut Morcellator will be utilized for prostate tissue morcellation
3105809|NCT02195622|Other|Wolf Piranha Morcellator|Wolf Piranha Morcellator will be utilized for prostate tissue morcellation
3105810|NCT02195687|Experimental|botulinum toxin type A|24U botulinum toxin Type A (BOTOX®) total dose injected into bilateral Crow's Feet Line areas on Day 1.
3105811|NCT02195687|Placebo Comparator|placebo|Placebo (Normal Saline) injected into bilateral Crow's Feet Line areas on Day 1.
3105812|NCT02195700|Experimental|SD-809|SD-809 tablets taken twice daily for 12 weeks.
3105813|NCT02195700|Placebo Comparator|Sugar Pill|Placebo tablets taken twice daily for 12 weeks.
3105814|NCT02195713||Test- Accuryn Urine Output Monitor|Accuryn Anti-airlock Drainage System was attached to the Foley catheter and urine output / drainage line pressure was monitored.
3105815|NCT02195713||Control- Critcore Urine Output Monitor|A commercially available urine output monitor (Criticore, Bard Medical) was attached to the Foley catheter and urine output / drainage line pressure was monitored.
3105816|NCT02195869|Experimental|Phase 1b: Dose Level 1|Subjects receive daily dose of 420 mg of Ibrutinib capsules
3105817|NCT02195869|Experimental|Phase 1b: Dose Level 2|Subjects receive daily dose of 280 mg of Ibrutinib capsules
3105818|NCT02195869|Experimental|Phase 1b: Dose Level 3|Subjects receive daily dose of 140 mg of Ibrutinib capsules
3105819|NCT02195869|Experimental|Phase 2|Subjects receive daily dose of recommended phase 2 dose
3105820|NCT02195895|Experimental|Alendronate, Calcium, Vitamin D|"Drug: Weekly oral alendronate 70 mg for 12 months~Supplements: 1000 mg Calcium and 1000 IU Vitamin D daily for 12 months"
3105821|NCT02195921|Experimental|Single point CV12|"choose single point:Zhongwan(CV12).Zhongwan(CV12):On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line.Manipulating until achieving a de Qi sensation,then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
3469137|NCT03889639|Experimental|Cohort 1: SAR442168 30 mg Then Placebo|Participants received SAR442168 30 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3469138|NCT03889639|Experimental|Cohort 1: SAR442168 60 mg Then Placebo|Participants received SAR442168 60 mg, orally once daily for first 12 weeks then crossed over to matching placebo orally once daily for 4 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3105822|NCT02195921|Experimental|Single point ST36|"choose another single point Zusanli（ST36）.Zusanli(ST36):On the anterior aspect of the leg, on the line connecting ST35 with ST41, 3 B-cun inferior to ST35，located on the tibialis anterior muscle..Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
3105823|NCT02195921|Experimental|ST36+CV12 acupoints|"Choose both Zusanli(ST36) and Zhongwan（CV12）.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatmeat is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days. Received routine antiemetic treatment."
3105824|NCT02195921|Active Comparator|only antiemetics|The control group will receive standard antiemetics alone. Standard antiemetics for all groups are based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days. If nausea and/or vomiting is persistent and failed to respond to the antiemetic treatment , based on the experience of each clinician, the other advanced 5-HT3 antagonist or a neurokinin 1 antagonist(NK-1) will be chosen.
3105825|NCT02195986|Experimental|Estradiol Vaginal Cream|Estradiol Vaginal Cream, 0.01%, administered once daily for 7 days.
3105826|NCT02195986|Active Comparator|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream, administered once daily for 7 days.
3105827|NCT02195986|Placebo Comparator|Placebo Vaginal Cream|Placebo Vaginal Cream, administered once daily for 7 days.
3105828|NCT02196038|Other|Attention Control|Usual care group with bi-weekly contact from study staff
3105829|NCT02196038|Active Comparator|multi-domain rehabilitation intervention|Individual, tailored, progressive, physical function rehabilitation intervention
3105830|NCT02196077|Experimental|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3105831|NCT02196077|Experimental|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3105832|NCT02196077|Experimental|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
3105833|NCT02196077|Experimental|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
3105834|NCT02196077|Experimental|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
3105835|NCT02196168|Experimental|Arm I (WEE1 inhibitor MK-1775, cisplatin)|Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.
3105836|NCT02196168|Active Comparator|Arm II (placebo, cisplatin)|Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.
3105837|NCT02196259|Experimental|Initial MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3105838|NCT02196259|Experimental|Initial hospital|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3105839|NCT02196259|Experimental|Depression MRI|The subject will receive intravenous ketamine anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
3105840|NCT02196324|Active Comparator|serlopitant 5 mg tablets|serlopitant 5 mg tablets
3105841|NCT02196324|Placebo Comparator|Placebo tablets|Placebo tablets
3105842|NCT02196506|Experimental|Brexpiprazole + ADT|Brexpiprazole + ADT
3105843|NCT02196506|Placebo Comparator|Placebo + ADT|Placebo + ADT
3105844|NCT02196558|Experimental|E6011, 100 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase).100 mg group will receive E6011 subcutaneously, 1 ml. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
3105845|NCT02196558|Experimental|E6011, 200 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks upto 10 weeks (treatment phase). 200 mg group will receive E6011 subcutaneously, 1 ml each at two sites. If a subject intends to continue administrations; the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension phase).
3105846|NCT02196558|Experimental|E6011, 400 mg Arm|E6011 will be administered repeatedly, subcutaneously at Week 0, 1, 2, followed by every 2 weeks up to 10 weeks (treatment phase). 400 mg group will receive E6011 subcutaneously, 1 ml each at four sites or 2 ml each at two sites. If a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase).
3105847|NCT02196675||VATS wedge resection or lobectomy|Single arm study Intervention: Device: Endocutter
3105848|NCT02196688|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3105849|NCT02196688|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3105850|NCT02196701|Experimental|Adalimumab Plus Methotrexate|Participants received 40 mg adalimumab every other week and methotrexate, between 7.5 and 25 mg/week at the discretion of the Investigator, for 24 weeks.
3105851|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
3105852|NCT02196714|Experimental|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
3105853|NCT02196714|Experimental|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
3105854|NCT02196714|Experimental|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
3105855|NCT02196766|Active Comparator|Bioclean First Care EX combo, then Aosept Clearcare combo|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the Aosept Clearcare / comfilcon A combination.
3105856|NCT02196766|Active Comparator|Aosept Clearcare combo, then Bioclean First Care EX combo|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the Bioclean First Care EX / comfilcon A combination.
3105857|NCT02196831|Experimental|Tesamorelin|tesamorelin 2mg subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
3105858|NCT02196831|Placebo Comparator|Placebo|placebo subcutaneously daily x 12 months double-blind phase. At the end of 12 months, subjects enter open-label tesamorelin treatment phase for 6 months.
3105859|NCT02196857|Experimental|Azacytidine + Sorafenib|Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously.
3105860|NCT02196922|Active Comparator|Standard of Care|Patients in the control group will receive standard of care at a Heart Failure clinic (primary and cardiac care as reimbursed by Medicare or sliding scale/uncompensated care). Standard of care patients will be contacted on a weekly basis in order to maintain comparable frequency of contact.
3105861|NCT02196922|Experimental|Telehealth Self Management (TSM)|TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
3105862|NCT02197065|Experimental|Atorvastatin|Atorvastatin 40mg daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
3105863|NCT02197065|Placebo Comparator|Sugar pill|Sugar pill (placebo) daily starting at least 4 hours prior to hip fracture surgery, or 4 days prior to hip or knee arthroplasty, and continued until postoperative day 45.
3105864|NCT02197078||Glitazones|
3105865|NCT02197078||Linagliptin|
3105866|NCT02197078||Sulfonylurea|
3105867|NCT02197078||Within-class comparators|
3105868|NCT02197130|Experimental|20 mg PF-02545920 BID|20 mg PF-02545920 BID
3105869|NCT02197130|Experimental|5 mg PF-02545920 BID|5 mg PF-02545920 BID
3105870|NCT02197130|Placebo Comparator|Placebo BID|Matching placebo
3105871|NCT02197234|Experimental|AZD9291 and simvastatin|Sequential treatments of simvastatin alone followed by AZD9291 alone, followed by simvastatin + AZD9291.
3105872|NCT02197247|Experimental|Rifampicin and AZD9291|Sequential treatments of AZD9291 alone followed by AZD9291 +rifampicin, followed by AZD9291 alone.
3105873|NCT02197273|Active Comparator|Standard of care analgesia|"Total Hip Arthroplasty (THA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine~Injection into capsular tissue after placement of the acetabular component:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Knee Arthroplasty (TKA):~All patients will receive a spinal anesthetic using Fentanyl and Bupivacaine All patients will receive an adductor canal block of 0.25% Bupivacaine w/epinephrine 30cc~Injection into posterior capsule of the knee:~0.5% Bupivacaine 15 cc 40 mg Solumedrol 10 mg Morphine 20 cc Saline~Total Shoulder Arthroplasty (TSA):~All patients will receive a standard interscalene block with bupivacaine followed by indwelling catheter insertion with ropivacaine infusion to be left in place for two days."
3105874|NCT02197273|Experimental|Liposomal bupivacaine|"THA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Anterior capsule Inferior capsule Posterior capsule Short external rotator Gluteus maximus Subcutaneous tissue~TKA:~Standard of care analgesia, PLUS 266 mg of liposomal bupivacaine. Posterior knee capsule Anterior femoral periosteum Anterior tibial periosteum Subcutaneous tissue Pericapsular meniscal tissue~TSA:~All patients will receive a standard interscalene block with bupivacaine PLUS 266 mg of liposomal bupivacaine.~Posterior capsule Rotator cuff Subscapularis Humeral periosteum Subcutaneous tissue Deltopectoral muscle"
3105875|NCT02197377|Active Comparator|Group LMA Unique|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
3105876|NCT02197377|Experimental|Group LMA Supreme|The supraglottic airway devices were deflated fully before insertion. Size 4 LMA was used for those with a weight of 50-70 kg and size 5 LMA for those between 70-100 kg. After insertion, each device was inflated with a hand-held airway manometer (Rusch, Germany) to an intracuff pressure of 60 cm H2O.The oropharyngeal leak pressure was determined by transiently stopping ventilation and closing the adjustable pressure-limiting valve with a fresh gas flow of 3 L/min until airway pressure reached a steady state and a voice of leakage was heard. The airway pressure was not allowed to exceed 40 cm H2O.
3105877|NCT02197416|Experimental|dabigatran etexilate|
3105878|NCT02197455|Experimental|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
3105879|NCT02197481|Active Comparator|Clamp-Crushing technique|liver transection during hepatectomy by the routine clamp-crushing technical without BiClamp forceps assisted
3105880|NCT02197481|Experimental|BiClamp forceps hepatectomy|The BiClamp forceps, a reusable bipolar sealing instrument for use in open surgery, was uniformly employed in all patients randomized to BiClamp forcep hepatectomy group in the present study.
3105881|NCT02197520|Experimental|Insulin Peglispro (with Insulin Lispro)|Insulin peglispro, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
3105882|NCT02197520|Active Comparator|Insulin Glargine (with Insulin Lispro)|Insulin glargine, a once daily subcutaneous(SC) injection at bedtime for 5 weeks
3105883|NCT02197572|Experimental|Sapanisertib|Sapanisertib starting dose of 40 mg, capsules, orally, once, on Day 1, Cycle 1 (28 days cycle) followed by sapanisertib 30 mg, capsules, orally, once weekly (QW) starting on Cycle 1, Day 8 based on safety and tolerability and as per investigator's discretion up to disease progression, unacceptable sapanisertib-related toxicity, withdrawal of consent, or for up to 12 months (whichever occurred first).
3105884|NCT02197767|Experimental|rituximab|rituximab 1000 mg infusion two weeks apart for a total of two infusions. Retreated with identical rituximab 1000 mg infusion two weeks apart at six months after the first infusion for a grand total of four infusions.
3105885|NCT02197806|Experimental|AGN-199201|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3105886|NCT02197806|Experimental|AGN-190584|1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3105887|NCT02197806|Experimental|AGN-199201 + AGN-190584 in One Eye|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.
3105888|NCT02197806|Experimental|AGN-199201 + AGN-190584 in Both Eyes|1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.
3105889|NCT02197897|Experimental|Tamoxifen|As a single-arm study (single group assignment), Tamoxifen citrate will be given to all patients at a 20mg/day dose for 12 weeks using a marker-lesion study design.
3105890|NCT02198040|Experimental|Manual Therapy group|The treatment of this group consisted of two sessions per week, one hour each. We used joint traction, passive muscles stretching and Proprioceptive Neuromuscular Facilitation
3105891|NCT02198040|Experimental|Educational group|The treatment had education and home daily exercises for the improvement of the range of motion, biceps strength, perimeter of arm and the perception of pain in patients with haemophilia and arthropathy of the elbow.
3105892|NCT02198040|No Intervention|Control group|The control group did not receive any intervention. The patients in this group were assessed by the same reviewers (blinded to the study conditions) and under the same conditions, that patients in the experimental groups.
3105893|NCT02198235|Active Comparator|Control NB + IV Dex + IV Bup|IV Dexamethasone (4 mg) + IV Buprenorphine (150 mcg)
3105894|NCT02198235|Active Comparator|Control NB + IV Dex|IV Dexamethasone (4 mg)
3105895|NCT02198235|Experimental|NB with Dex + Bup in block.|Dexamethasone (4 mg) Buprenorphine (150 mcg)
3105896|NCT02198430||Patients|Patients with haemophilia recruited for multidisciplinary assessment of the main physical, functional and psychosocial variables.
3105897|NCT02198430||Control group|Children without hemophilia
3105898|NCT02198651|Experimental|Adalimumab 40 mg eow|40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
3105899|NCT02198651|Active Comparator|Adalimumab Tapering|40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
3105900|NCT02198651|Placebo Comparator|Adalimumab Withdrawal Arm|Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
3105901|NCT02198651|Experimental|Adalimumab 40 mg eow Rescue Arm|40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
3105902|NCT02198664|Experimental|ARC001 placebo group|Subjects who received placebo in study ARC001.
3105903|NCT02198664|Experimental|ARC001 AR101 group|Subjects who received AR101 and tolerated up to 300 mg peanut protein (443 mg cumulative) in the DBPCFC at the end of study ARC001.
3105907|NCT02198963|Experimental|Hypochlorous acid Solution 106 mg/L|Occlusive patches will be used to apply approximately 0.02 mL of the Test Product RUT058-60 to abraded and non-abraded sites on the skin in the scapular region of each subject's back.
3105908|NCT02198963|Active Comparator|0.1% (w/v) Sodium Lauryl Sulfate|Occlusive patches will be used to apply approximately 0.02 mL of the Positive Control (0.1% Sodium Lauryl Sulfate) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
3105909|NCT02198963|Placebo Comparator|0.9% Physiological Saline, USP|Occlusive patches will be used to apply approximately 0.02 mL of the Negative Control (0.9% Physiological Saline, USP) to abraded and non-abraded sites on the skin in the scapular region of each subject's back, once daily for 21 days.
3105910|NCT02199028|Experimental|Hyaluronidase, Then Control|"Participants assigned to active treatment arm (Hylenex) for weeks 1 and 3.~On weeks 1 and 3 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyaluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.~On weeks 2 and 4 (control weeks) no Hyaluronidase was administered."
3105911|NCT02199028|Experimental|Control, Then Hyaluronidase|"Participants were first assigned to the control arm. They received active treatment (Hyaluronidase) on weeks 2 and 4.~On weeks 1 and 3 (control weeks) no Hyaluronidase was administered.~On weeks 2 and 4 (Hyaluronidase weeks) subjects injected 1 milliliter (ml) Hyluronidase (150 units/ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear."
3105912|NCT02199041|Experimental|Treatment|"Interventions: cyclophosphamide, thiotepa, fludarabine, melphalan, mesna, granulocyte colony-stimulating factor (G-CSF), mycophenolate mofetil, tacrolimus, methylprednisolone, total lymphoid irradiation, and lymphocyte infusions.~Cells for infusion are prepared using the CliniMACS System."
3105913|NCT02199080|Other|Atrial fibrillation|D-dimer assay before ablation of atrial fibrillation
3105914|NCT02199197|Experimental|Radium Ra 223 Dichloride and Enzalutamide|Radium Ra 223 Dichloride and Enzalutamide administered concurrently for 6 28-day cycles.
3105915|NCT02199197|Active Comparator|Enzalutamide alone|Enzalutamide administered as a single agent for 6 28-day cycles.
3105916|NCT02199314|Experimental|desflurane MEP's|Transcranial motor evoked potentials are obtained under total intravenous anesthesia (TIVA) and again after desflurane at 3%, for at least 5 minutes.at two different time points. Each subject is his/her own control
3105917|NCT02199496|Experimental|Cohort 1: Ustekinumab-Single-dose Phase 1, Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously then re-enrolled into the multi-dose phase. In multi-dose phase, subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
3105918|NCT02199496|Experimental|Cohort 2: Ustekinumab-Multi-dose Phase 2|Subjects given an induction dose of 270 mg Stelara (ustekinumab) subcutaneously followed by every 8 week maintenance doses of 90 mg Stelara (ustekinumab) subcutaneously at week 8, week 16, week 24, week 32, and week 40
3105919|NCT02199574|Experimental|EXPAREL|Single administration of EXPAREL 133 mg (10 mL).
3105920|NCT02199652|Placebo Comparator|placebo|placebo pill
3105921|NCT02199652|Experimental|prazosin|prazosin pill
3105922|NCT02199691|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.
3105923|NCT02199691|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.
3105924|NCT02199691|Experimental|Group 3: MenACYW Conjugate Vaccine+Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
3105925|NCT02199691|Active Comparator|Group 4: Tdap+HPV|Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.
3105926|NCT02199717||Boys with Hemophilia|Accelerometer use for 1 week.
3105927|NCT02199743|Active Comparator|Lurasidone|Lurasidone 40mg po qhs with food x 1 week; Lurasidone 80mg po qhs with food x 3 weeks
3105928|NCT02199743|Active Comparator|Haloperidol|Haloperidol 4mg po qhs with food x 1 week; Haloperidol 8mg po qhs with food x 3 weeks.
3105929|NCT02199743|Active Comparator|Perphenazine|Perphenazine 16mg po qhs with food x 1 week; Perphenazine 32mg po qhs with food x 3 weeks.
3105930|NCT02199795|Experimental|CCNMES|Contralaterally Controlled Neuromuscular Electrical Stimulation (CCNMES): CCNMES uses electrical stimulation to move the weaker ankle up and down. The user will control the stimulation using the other (stronger) ankle. A special sock is worn on the stronger ankle. When the stronger ankle is moved, a signal is sent from a sensor on the sock to the electrical stimulator. The stimulator then sends stimulation to the weaker ankle which causes it to move. Sound and light cues coming from the stimulator will tell the user when to move the stronger ankle and when to relax.
3105931|NCT02199795|Active Comparator|Cyclic NMES|Cyclic Neuromuscular Electrical Stimulation (NMES) uses automatic, repetitive electrical stimulation to stimulate the muscles in order to move the weaker ankle up and down.
3105932|NCT02199964|Experimental|Cyclosporin 0.05% emulsion|used in the eye 4 times a day
3105933|NCT02199964|Active Comparator|Endura Refresh, Artificial Tears|Over the Counter artificial tears used in the eye 4 times a day
3105934|NCT02200055|Experimental|Bioimpedance Assessment|"The only group will be those patients having major intra-abdominal surgical procedures.~Each patient involved in the study will be evaluated with a bioimpedance monitor ('Bodystat Quadscan 4000') to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
3105935|NCT02200211|Experimental|Binocular Treatment|Binocular computer game play 1 hour per day, 7 days per week (minimum of 4 days per week)
3105936|NCT02200211|Active Comparator|Patching Treatment|Patching 2 hours per day, 7 days per week
3105937|NCT02200445|Experimental|Interleukin-2|"Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).~Each subject will receive an 8-week course of once-daily, subcutaneously administered IL-2. There will be three dose cohorts. Each subject will be recruited into a single dose cohort and receive a single dose level of IL-2 throughout the study.~The dose levels will be as follows:~Cohort 1: 0.3x10^6 IU/m^2/day.~Cohort 2: 1.0x10^6 IU/m^2/day.~Cohort 3: 1.5x10^6 IU/m^2/day.~Up to 6 subjects will be recruited to each dose cohort.~Once the maximum tolerated dose has been identified, a further 10 subjects will receive IL-2 at the maximum tolerated dose."
3105938|NCT02200458|Experimental|VeinViewer|Vascular imaging technology will be used to visualize peripheral vasculature.
3105939|NCT02200510|Other|Self-Management Group|Self-management intervention for Adolescents with SCD - 6 week self-management group
3105940|NCT02200510|Other|Patient Portal|Patient Portal Intervention for Adolescents with SCD - 6 week individual patient portal intervention
3105941|NCT02200523|Experimental|SARA electrode|new electrode
3105942|NCT02200523|Active Comparator|Gold cup|gold standard
3105943|NCT02200536|Experimental|Test|Infant oral health promotion package
3105944|NCT02200536|Active Comparator|Control 1|Infant oral health pamphlet
3105945|NCT02200536|No Intervention|Control 2|
3105946|NCT02200614|Experimental|Darolutamide (BAY1841788)|Participants received Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equal to a total daily dose of 1200 mg.
3105947|NCT02200614|Placebo Comparator|Placebo|Participants received matching placebo 2 tablets twice daily with food.
3469139|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 5 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 5 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3469140|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 15 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 15 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3105950|NCT02201056|Experimental|Cohort 1: TAK-935 15 mg|TAK-935 15 mg solution, orally, once, on Day 1.
3105951|NCT02201056|Experimental|Cohort 2: TAK-935 50 mg|TAK-935 50 mg solution, orally, once, on Day 1.
3105952|NCT02201056|Experimental|Cohort 3: TAK-935 200 mg|TAK-935 200 mg solution, orally, once, on Day 1.
3105953|NCT02201056|Experimental|Cohort 4: TAK-935 600 mg|TAK-935 600 mg solution, orally, once, on Day 1.
3105954|NCT02201056|Experimental|Cohort 5: TAK-935 900 mg|TAK-935 900 mg solution, orally, once, on Day 1.
3105955|NCT02201056|Experimental|Cohort 6: TAK-935 1350 mg|TAK-935 1350 mg solution, orally, once, on Day 1.
3105956|NCT02201056|Placebo Comparator|Cohorts 1-6: Placebo|TAK-935 placebo-matching solution, orally, once, on Day 1.
3105957|NCT02201108|Placebo Comparator|Placebo|Matching placebo tablets
3105958|NCT02201108|Experimental|Teriflunomide|Teriflunomide oral tablet, three dosages (3.5, 7 or 14 mg) to reach 14 mg adult equivalent
3105959|NCT02201212|Experimental|Everolimus|"Everolimus~Fixed doses orally once a day per each 28 day cycle~Participants will stay on study as long as they do not progress for a maximum of 24 months.~Tumor assessments will be performed after every 2 cycles for as long as they are on study."
3105960|NCT02201251|Experimental|Topiramate|Topiramate weight based dosing for participants 2 to less than (<) 10 years of age not to exceed 350 mg/day (milligram per day), as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
3105961|NCT02201251|Active Comparator|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 milligram per kilogram per day (mg/kg/day), as tolerated. The maximum recommended daily dosage is 3,000 milligram (mg).
3105962|NCT02201277|Experimental|Denali|Denali IVC Filter
3105963|NCT02201277|Experimental|Option|Option Elite IVC Filter
3105964|NCT02201290|Experimental|Eltrombopag|Eligible subject will be allocated to 1 of 3 age-defined cohorts. Cohort 1: between 12 and 17 years old, Cohort 2: between 6 and 11 years old, and Cohort 3: between 1 and 5 years old. For Cohorts 1 and 2, eltrombopag tablets will be administered, however, subjects in Cohort 2 may use eltrombopag powder for oral suspension (Eltrombopag PfOS) if they have difficulty swallowing tablets and are receiving a dose of eltrombopag of < 40 mg. For Cohort 3, either eltrombopag tablets or PfOS will be administered.
3105965|NCT02201329|Experimental|A|Volasertib escalating doses + azacitidine
3105966|NCT02201394|Experimental|Loading dose|Patients with stable CVD given a single ticagrelor loading dose and aspirin loading dose
3105967|NCT02201394|Experimental|Maintenance dose|Patients with stable CVD given ticagrelor maintenance dose and aspirin maintenance dose for one week.
3105968|NCT02201420|Experimental|Tc 99m tilmanocept|Subjects who are enrolled and will receive 50 micrograms tilmanocept radiolabeled with 2 millicuries of Tc 99m and undergo serial SPECT or SPECT/CT imaging.
3105969|NCT02201446||ARDS patients|Eighty-one patients were enrolled consecutively over a two-year time period (2014-2015) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 16 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
3105970|NCT02201446||Healthy volunteers|Fifty-eight healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
3105971|NCT02201524|Experimental|Cohort 1|200mg of PF-04965842 twice daily
3105972|NCT02201524|Experimental|Cohort 2|400mg of PF-04965842 once daily
3105973|NCT02201524|Experimental|Cohort 3|200mg of PF-04965842 once daily
3105974|NCT02201524|Placebo Comparator|Cohort 4|Placebo comparator daily
3105975|NCT02201771|Active Comparator|Aspirin|aspirin 100mg tablet by mouth daily for 12 months
3105976|NCT02201771|Experimental|Ticagrelor plus Aspirin|ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months
3105977|NCT02201771|Experimental|Ticagrelor|ticagrelor 90mg tablet by mouth twice daily for 12 months
3105978|NCT02201784|Active Comparator|Levobupivacaine 0.5%|intrathecal administration of 15 mg of Levobupivacaine 0.5%
3105979|NCT02201784|Active Comparator|Ropivacaine 0.75%|intrathecal administration of 22.5 mg of Ropivacaine 0.75%
3105980|NCT02201901|Experimental|SOF/VEL 12 weeks|Participants will receive SOF/VEL FDC for 12 weeks.
3105981|NCT02201901|Experimental|SOF/VEL+RBV 12 weeks|Participants will receive SOF/VEL FDC plus RBV for 12 weeks.
3105982|NCT02201901|Experimental|SOF/VEL 24 weeks|Participants will receive SOF/VEL FDC for 24 weeks.
3105983|NCT02201940|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3105984|NCT02201940|Placebo Comparator|Placebo|SOF/VEL placebo for 12 weeks
3105985|NCT02201953|Experimental|SOF/VEL 12 Weeks|SOF/VEL FDC for 12 weeks
3105986|NCT02201953|Experimental|SOF+RBV 24 Weeks|SOF+RBV for 24 weeks
3105987|NCT02202031|Experimental|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3105988|NCT02202031|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3105989|NCT02202109|Active Comparator|CHWs facilitated Self-Sampling|CHW and Self-sampling for Cervical Cancer. Home visit, self-sampler, collection of test
3105990|NCT02202109|Active Comparator|Mailed Self-Sampler|Mailed Self Sampler. Self sampler is mailed to participant; follow up by phone
3105991|NCT02202135|Experimental|Ceftaroline fosamil|Patients will receive 600 mg of ceftaroline fosamil administered as a 120-minute intravenous infusion very 8 hours. Each dose will be infused in a volume of 250 mL over 120-minutes followed by aztreonam placebo in a volume of 100 mL infused over 30 minutes every 8 hours. In addition vancomycin placebo will be given in a volume of 250 mL infused over 120 minutes every 12 hours. Doses will be adjusted according to the patient's renal function.
3105992|NCT02202135|Active Comparator|Vancomycin plus aztreonam|Patients will receive combination of vancomycin plus aztreonam. Dose of vancomycin will be based on the patient's actual weight and will receive intravenous vancomycin every 12 hours with each dose infused over 120-minutes. Aztreonam dose will be 1 gram intravenously in a volume of 100 mL infused over 30 minutes every 8 hours. In addition, ceftaroline fosamil placebo will be given in a volume of 250 mL infused over 120 minutes every 8 hours. Doses adjusted according to patients renal function
3105993|NCT02202161|Experimental|GSK2330672 10 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 10 mg BID for 14 days.
3105994|NCT02202161|Experimental|GSK2330672 20 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 20 mg BID for 14 days.
3105995|NCT02202161|Experimental|GSK2330672 30 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 30 mg BID for 14 days.
3105996|NCT02202161|Experimental|GSK2330672 90 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by GSK2330672 90 mg BID for 14 days.
3105997|NCT02202161|Placebo Comparator|GSK2330672-matched placebo|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by matching placebo (of GSK2330672) BID for 14 days.
3105998|NCT02202161|Active Comparator|Sitagliptin 50 mg|Subjects will receive metformin 850 mg BID for 13-15 days during the run in period followed by Sitagliptin 50 mg BID for 14 days. In this study, sitagliptin 50 mg BID will be provided as open-label (unblinded) study treatment.
3105999|NCT02202252|Experimental|Single drain|"Insertion of a single drain: A negative pressure drain will be inserted below the lower flap directing to the axilla in the single drain group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
3106000|NCT02202252|Experimental|Double drain|"Insertion of double drains: Two negative pressure drains will be inserted into the axilla and below the lower flap in the double drains group.~Ultrasonography after removal of the drains: One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography."
3106001|NCT02202317|Experimental|Y90 Based PET/CT Scan|
3469141|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 30 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 30 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3469142|NCT03889639|Experimental|Cohort 2: Placebo Then SAR442168 60 mg|Participants received placebo matching to SAR442168 tablets, orally once daily for first 4 weeks then crossed over to SAR442168 60 mg orally once daily for 12 weeks during the 16 weeks treatment period. To maintain the blinding, each participant was given a total of 4 tablets daily, either of SAR442168 or SAR442168 and placebo, to achieve the specified daily dose of SAR442168.
3469143|NCT03889548|Experimental|Mental Imagery|
3469144|NCT03889548|No Intervention|Control|
3106008|NCT02202499|Active Comparator|Extended Varenicline + Facilitated Extinction|Extended Varenicline plus Facilitated Extinction (EV+FE). Participants in the EV+FE condition will receive varenicline for a 4-week run-in period while continuing to smoke. In addition, the EV+FE condition will receive counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided. All groups will undergo periodic laboratory assessments and surveys.
3106009|NCT02202499|Active Comparator|Standard Varenicline (SV)|Participants in the Standard Varenicline (SV) condition will receive varenicline for the usual 1-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
3106010|NCT02202499|Active Comparator|Extended Varenicline (EV)|Participants in the Extended Varenicline (EV) condition will receive varenicline for a 4-week run-in period while continuing to smoke. All groups will undergo periodic laboratory assessments and surveys.
3106011|NCT02202538|Experimental|Indego|Indego
3106012|NCT02202551|Experimental|ADS-5102|amantadine HCl extended release
3106013|NCT02202616|Other|ULTIBRO BREEZHALER|Patients diagnosed with chronic obstructive pulmonary disorder (COPD) who are symptomatic (CAT score over 10) and who are treated with Tiotropium (SPIRIVA HANDALER) or Fluticasone propionate/Salmeterol- ADVAIR DISKUS (FDC).
3106014|NCT02202746|Experimental|Cohort A: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
3106015|NCT02202746|Experimental|Cohort B: Lucitanib (CO-3810) 15 mg daily|15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
3106016|NCT02202746|Experimental|Cohort C: Lucitanib (CO-3810) 10 mg daily|10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
3106017|NCT02202759|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 14 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
3106018|NCT02202785|Experimental|MLN0264 1.8 mg/kg|MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.
3106019|NCT02202837||Etanercept First|Adult patients with RA who receive etanercept as first biologic, according to prevailing Belgian reimbursement criteria
3106020|NCT02202837||Etanercept second|Adult patients who receive etanercept as second biologic, according to prevailing Belgian reimbursement criteria
3106021|NCT02202850||Etanercept First|Adults patients with AS receiving Etanercept as first biologic, according to prevailing reimbursement criteria in Belgium
3106022|NCT02202850||Etanercept second|Adults patients with AS receiving Etanercept as second biologic, according to prevailing reimbursement criteria in Belgium
3106023|NCT02202980|Experimental|LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1)|Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
3106024|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2)|Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
3106025|NCT02202980|Experimental|LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1)|Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
3106026|NCT02202980|Experimental|LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2)|Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
3106027|NCT02202980|Experimental|LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1)|Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
3106028|NCT02202980|Experimental|LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2)|Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
3106029|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 4)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
3106030|NCT02202980|Experimental|SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1)|Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
3106031|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2)|Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
3106032|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3)|Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
3106033|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4)|Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
3106034|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5)|Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
3106035|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
3106036|NCT02202980|Experimental|SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7)|Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
3106037|NCT02202980|Experimental|SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8)|Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.
3106038|NCT02203019|Active Comparator|Propofol|Propofol will be administered for sedation.
3106039|NCT02203019|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered for sedation
3106040|NCT02203032|Experimental|Open-label ustekinumab|
3106041|NCT02203032|Experimental|Double-blind guselkumab|
3106042|NCT02203032|Experimental|Double-blind ustekinumab|
3106043|NCT02203071||MSP with BioCartilage|Patients receiving marrow stimulating procedure with BioCartilage adjunct.
3106044|NCT02203071||MSP without BioCartilage|Patients receiving marrow stimulating procedure without BioCartilage.
3106045|NCT02203149|Experimental|Part 1 Grazoprevir 50 mg + Elbasvir|Non-cirrhotic participants take 50 mg grazoprevir in combination with 50 mg elbasvir by mouth (p.o.) once daily (q.d.) for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
3106046|NCT02203149|Experimental|Part 1 Grazoprevir 100 mg + Elbasvir|Non-cirrhotic participants take 100 mg grazoprevir in combination with 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 1 and are followed-up for 24 weeks during the open-label period of Part 1.
3106047|NCT02203149|Experimental|Part 2 Non-cirrhotic Immediate: Grazoprevir + Elbasvir|Non-cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2 and are followed-up for 24 weeks during the open-label period of Part 2.
3106048|NCT02203149|Placebo Comparator|Part 2 Non-cirrhotic Deferred: Placebo► Grazoprevir + Elbasvir|Non-cirrhotic participants take dose-matched placebo p.o. q.d. for 12 weeks during the blinded period of Part 2 followed by a 4-week follow-up. Afterwards, participants take grazoprevir (50 mg or 100 mg dose selected from Part I) and 50 mg elbasvir p.o. q.d. for 12 weeks and are followed-up for 24 weeks during the open-label period of Part 2.
3106049|NCT02203149|Experimental|Part 2 Cirrhotic: Grazoprevir + Elbasvir|Cirrhotic participants take grazoprevir (50 mg or 100 mg dose selected from Part 1) and 50 mg elbasvir p.o. q.d. for 12 weeks during the blinded period of Part 2, and are followed-up for 24 weeks during the open-label period of Part 2.
3106050|NCT02203162|Experimental|cough reflex sensitivity|electronic cigarette exposure
3106051|NCT02203331|Placebo Comparator|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3106052|NCT02203331|Experimental|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3106053|NCT02203331|Experimental|Anastrozole 300 µg/d + Levonorgestrel|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3106054|NCT02203331|Experimental|Anastrozole 600 µg/d + Levonorgestrel|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3106055|NCT02203331|Experimental|Anastrozole 1050 µg/d + Levonorgestrel|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
3106056|NCT02203331|Active Comparator|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
3106057|NCT02203357|Active Comparator|20μg, 0-1-6|117 young adults were administered with 20μg of hepatitis B vaccine according to the 0-1-6 mon schedule.
3106058|NCT02203357|Experimental|60μg, 0-1|112 young adults were administered with 60μg of hepatitis B vaccine according to the 0-1 mon schedule.
3106059|NCT02203357|Experimental|60μg, 0-2|125 young adults were administered with 60μg of hepatitis B vaccine according to the 0-2 mon schedule.
3106060|NCT02203565|Experimental|Supportive care (Dakin's solution, radiation therapy)|Patients apply Dakin's solution topically daily over 10 minutes within 60 minutes of radiation therapy for up to 6 weeks.
3106061|NCT02203578|Experimental|Supportive care (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3106062|NCT02203591|Experimental|3M CHG/IPA Prep C|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3106063|NCT02203591|Experimental|3M CHG/IPA Prep CH|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3106064|NCT02203591|Active Comparator|ChloraPrep|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3106065|NCT02203591|Placebo Comparator|Normal Saline|Apply topically for 30 seconds to the abdominal region or 2 minutes to the inguinal region, and allow to dry for 3 minutes.
3106066|NCT02203630|Active Comparator|Phenylephrine|Phenylephrine will be administered as the primary vasopressor for the treatment of septic shock
3106067|NCT02203630|Active Comparator|Norepinephrine|Norepinephrine will be administered as the primary vasopressor for the treatment of septic shock
3106068|NCT02203721|Experimental|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|Bilaterally implanted with TECNIS Symfony Extended Range of Vision Intraocular Lens, Model ZXR00
3106069|NCT02203721|Active Comparator|TECNIS Monofocal IOL, Model ZCB00|Bilaterally implanted with TECNIS Monofocal Intraocular Lens, Model ZCB00
3106070|NCT02203747||Pseudophakic implanted with toric IOL|Subjects bilaterally implanted with toric IOL
3106071|NCT02203747||Pseudophakic implanted with non-toric IOL|Subjects bilaterally implanted with non-toric IOL
3106072|NCT02203786|Active Comparator|Haloperidol|"Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
3106073|NCT02203786|Active Comparator|Fluphenazine|"Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine.~Response measured to 15 min session of a commercial slot machine game."
3106074|NCT02203838|Experimental|RBP-7000 - 120-mg dose|RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.
3106075|NCT02203851|Experimental|Risankizumab 90 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 continued to receive open-label (OL) risankizumab 90 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
3106076|NCT02203851|Experimental|Risankizumab 180 mg|Participants entered the study receiving risankizumab 90 mg by subcutaneous (SC) injection and had achieved <90% improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 12 switched to open-label (OL) risankizumab 180 mg by SC injection at Week 12 and every 12 weeks for approximately 4 years from the first dose in either the lead-in or extension study.
3106077|NCT02203916|Experimental|Azilsartan Medoxomil 40 mg|Azilsartan medoxomil 40 mg, tablets, orally, once daily for 6 weeks.
3106078|NCT02203916|Experimental|Azilsartan Medoxomil 80 mg|Azilsartan medoxomil 80 mg, tablets, orally, once daily for 6 weeks.
3106079|NCT02203916|Placebo Comparator|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for 6 weeks.
3106080|NCT02204007|Experimental|3D imaging, surrogate bone model|3D imaging & surrogate bone model
3106081|NCT02204007|No Intervention|Standard of Care Preoperative Imaging|Patients receiving standard of care preoperative planning prior to total hip arthroplasty.
3106082|NCT02204124|Active Comparator|Control Group|In the control group, scissors, ligatures, clips and sutures will be used for dissection and hemostasis as necessary.
3106083|NCT02204124|Experimental|Thunderbeat™|-In the Thunderbeat™ group, dissection and hemostasis of vessels will be performed using the Thunderbeat™ device (Olympus, Japan).
3106084|NCT02204150|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
3106085|NCT02204176|Sham Comparator|Exercise info only|"Participants in the exercise information only group will engage in a group discussion with the principal investigator to discuss what constitutes regular physical activity and benefits of exercise and basic tips on the activity itself. Guidelines for prescribing suggested exercises will be based on recommendations from the U.S. Department of Health and Human Services (USDHHS, 2008) as well as risks associated with exercise and how they can be reduced."
3106086|NCT02204176|Experimental|Exercise info + implementation intentions|"Participants in the exercise information plus implementation intentions group will engage in a group discussion with the principal investigator to discuss all of the components from the exercise information only approach, but with more emphasis on how to create implementation intentions. Discussions will revolve around possible barriers to exercise plans and how to overcome/address those barriers by making specific plans of when and where to exercise, along with designating which types of exercises they will perform and for how long (or how many repetitions)."
3106087|NCT02204176|Experimental|Exercise info + implementation intentions + industriousness|"Participants in the exercise information plus implementation intentions plus industriousness training group will engage in a group discussion with the principal investigator to discuss all of the components from the second approach as well as include findings linking industriousness and exercise behavior. Participants will be directed to think about and generate solutions to how they can become more industrious and monitor their efforts despite the difficulties they may face and relate these solutions to help them engage in more exercise behavior."
3106088|NCT02204293|Experimental|Canakinumab|Participants received canakinumab 4 mg/kg up to a maximum of 300 mg subcutaneous (SC) injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive same dose of canakinumab in Part II for Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
3106089|NCT02204293|Placebo Comparator|Placebo|Participants received placebo, SC injection, once in morning on Day 0, Weeks 4, 8, and 12 in Part I of the core study. Participants with response (change in DAS score > 1.2 at Week 12) continued to receive placebo at Weeks 12, 16, and 20. Non-responders (who had change in DAS score ≤ 1.2) were unblinded to receive canakinumab 4 mg/kg (up to 300 mg maximum), SC injection, at Weeks 12, 16, and 20. Participants who had remission (change in DAS score > 1.2 and no signs of systemic activity for adult-onset Still's disease at Week 20) entered Long-term extension (LTE) phase and received same dose of canakinumab at Weeks 24 and 28, which was down titrated to 2 mg/kg if applicable from Week 28 up to Month 27.
3106090|NCT02204319|Experimental|Cold Laser Treatment|Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
3106091|NCT02204371|Experimental|Part A- Dose Escalation phase|Part A will be an open label, dose-escalation study in which 4 cohorts of approximately 6 subjects will receive increasing doses of pazopanib for a maximum of 12 weeks. The dose in the first cohort will be 50mg per day and the maximum dose in a cohort will be 400 mg per day. Dose escalation will not occur if the predefined safety stopping criteria are met or at least 4 subjects in a cohort have demonstrated efficacy. Cohort 4 receiving 400 mg dosing schedule may involve cycles of up to 3 weeks of active treatment, followed by up to 3 weeks wash-out (instead of 12 weeks continuous dosing). Decision will be based on safety data obtained from lower doses
3106092|NCT02204371|Experimental|Part B-Dose Optimization phase|If efficacy is demonstrated in Part A with an acceptable safety profile, Part B will be initiated to further define the optimal dose(s) including dose duration/schedule and to provide further support for the proof of mechanism. Approximately 15 subjects will participate and will be randomised to active or placebo in a ratio of 3:2. This part of the study will be double-blind
3106093|NCT02204410|Experimental|Omega-3 Fatty Acids and Stimulant Treatment|Participants will receive open-label treatment with Omega-3 Fatty Acids. All participants must also be treated with a stable dose of a traditional ADHD medication at the time of enrollment.
3106094|NCT02204449|Experimental|Cardiac Rehabilitation Peer Mentorship|Trained cardiac rehabilitation (CR) peer mentors will visit cardiac inpatients in the hospital to provide patients with information on CR. During this visit the CR mentors will discuss the benefits of CR, stress the importance of getting a referral, and arrange a time to call the patient/participant at home to find out about their CR progress. One week post-discharge the peer mentor will mail a card to the patient to remind them of the planned call. Two weeks post-discharge the peer mentor will call the patient at home to determine if they were referred and if they are planning to attend CR. If any barriers are stated by patient the peer mentors will work with the patient to develop possible solutions. Patients can request up to two additional phone calls from the mentors.
3106095|NCT02204449|No Intervention|Usual Care|Cardiac inpatients will not be visited by the cardiac rehabilitation (CR) peer mentor. They will instead receive usual care involving care from health care providers (i.e. nurses and doctors) as well as allied health professionals such as physiotherapists. In addition, some may be visited by general volunteer cardiac mentors.
3106096|NCT02204566|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI Imaging system.
3106097|NCT02204579|Experimental|NPSP795|intravenous
3106098|NCT02204657|Active Comparator|Continuous Glucose Monitoring System|Patients in this arm will receive Continuous Glucose Monitoring System (CGMS) at 28,32 and 36 weeks of gestation and their insulin titrated according to the CGMS results.
3106099|NCT02204657|No Intervention|Control|Patients in this arm will not receive any Continuous Glucose Monitoring System( CGMS) and the insulin titration will be made based on their fingerstick sugar readings.
3106100|NCT02204748||DePuy Attune PS FB TKA|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system implanted by a single surgeon at least three months post-operative.
3106101|NCT02204761|Experimental|Treatment|Proton beam radiation therapy
3106102|NCT02204917|Experimental|Comparative performance of ceVUS & VCUG|Contrast enhanced Voiding Urosonography (ceVUS) will be performed with the intravesical administration of 0.1%-0.5% OPTISON / normal saline solution. The exact OPTISON dose (ml) that will be adjusted according to the age-related bladder filling capacity with a dose (ml) range from 0.3 mL in newborns to 3 mL in 18 year-old children. Voiding Cystourethrography (VCUG) exam will be subsequently performed using the same bladder catheter with intravesical administration of the x-ray contrast agent.
3106103|NCT02204982|Experimental|Duvelisib + Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
3106104|NCT02204982|Placebo Comparator|Placebo + Rituximab|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules.~Rituximab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
3106105|NCT02205177|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
3106106|NCT02205177|Experimental|Minimal Contact w/ Anxiety Coach (MC-AC)|In this condition the therapist will meet with the patient and primary care giver for an initial 50-minute, face-to-face session to provide a tutorial on the use of Anxiety Coach. The therapist is expected to review the patient's progress via the web-based portal and communicate with the patient electronically at least once per week for a total of at least 6 and up to 12 weeks of intervention. Therapists will be allowed 2 additional face-to-face sessions if necessary and still remain in protocol.
3106107|NCT02205307|Experimental|PINPOINT or SPY Elite|A low anterior resection will be performed according to the surgeon's standard practice with the addition of intraoperative imaging using PINPOINT near infrared fluorescence imaging or SPY Elite intraoperative imaging to assess colon and rectal tissue perfusion
3106108|NCT02205307|No Intervention|STANDARD|A low anterior resection will be performed according to the surgeon's standard practice
3106109|NCT02205333|Experimental|MEDI6469 6 mg/kg|Participants received MEDI6469 6 milligram/kilogram (mg/kg) as a single intravenous (IV) administration on Day 1
3106110|NCT02205333|Experimental|MEDI6469 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1
3106111|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 3 mg/k|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 3 mg/kg as IV administration on Day 1 then every 4 weeks (Q4W) for 6 doses, after which every 12 weeks (Q12W) for 2 doses or until PD
3106112|NCT02205333|Experimental|MEDI6469 2 mg/kg+Tremelimumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus tremelimumab 10 mg/kg as IV administration on Day 1 then Q4W for 6 doses after which Q12W for 2 doses or until progression of disease (PD)
3106113|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 3 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 3 mg/kg as IV administration on Day 1 then every 2 weeks (Q2W) for 12 months or until PD
3106114|NCT02205333|Experimental|MEDI6469 2 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 2 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
3106115|NCT02205333|Experimental|MEDI6469 10 mg/kg+Durvalumab 10 mg/kg|Participants received MEDI6469 10 mg/kg as a single IV administration on Day 1 plus durvalumab 10 mg/kg as IV administration on Day 1, then Q2W for 12 months or until PD
3106116|NCT02205333|Experimental|MEDI6469 2 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 2 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed complete response (CR) plus 1 cycle, or PD plus rituximab 375 mg/m^2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
3106117|NCT02205333|Experimental|MEDI6469 10 mg/kg+Rituximab 375 mg/m^2|Participants received MEDI6469 10 mg/kg as a repeat IV administration on Day 3 then Q4W for 11 doses, or until confirmed CR plus 1 cycle, or PD plus rituximab 375 mg/m2 as IV administration on Days 1, 8, and 29; then Q4W for 10 doses, or until confirmed CR plus 1 cycle, or PD
3106118|NCT02205476|Experimental|Group 1|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 1 = 4 doses).
3106119|NCT02205476|Experimental|Group 2|The number of doses each subject receives will be consistent with number received in protocol B5301001 (Group 2 = 3 doses).
3106120|NCT02205801|Active Comparator|superficial cervical block, active|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.25% Marcaine.
3106121|NCT02205801|Placebo Comparator|local wound infiltration, placebo|After induction of general anesthesia the surgeon will perform local wound infiltration using 0.9% Saline.
3106122|NCT02205801|Active Comparator|local wound infiltration, active|After induction of general anesthesia the surgeon will perform a local wound infiltration using 0.25% Marcaine.
3106123|NCT02205801|Placebo Comparator|superficial cervical block, placebo|After induction of general anesthesia the surgeon will perform a bilateral superficial cervical plexus block using 0.9% saline.
3106124|NCT02205814|Experimental|Fasitibant low dose|Drug: solution for intra-articular injection
3106125|NCT02205814|Experimental|Fasitibant intermediate dose|Drug: solution for intra-articular injection
3106126|NCT02205814|Experimental|Fasitibant high dose|Drug: solution for intra-articular injection
3106127|NCT02205814|Placebo Comparator|PLACEBO|Drug: solution for intra-articular injection
3106128|NCT02205983|Experimental|2 mg hydromophone|Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
3106129|NCT02205983|Experimental|4 mg hydromphone|Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
3106130|NCT02205983|Experimental|1000 mg acetaminophen|Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
3106131|NCT02205983|Placebo Comparator|Dextrose|Healthy adult volunteers will recieve Dextrose (placebo).
3106132|NCT02206061|Experimental|School-Based Asthma Care for Teens (SB-ACT)|"SB-ACT consists of 2 components: Motivational Interviewing (MI) and Directly Observed Therapy (DOT) For the first 6-8 weeks, the teen will visit the school nurse to receive a daily dose of preventive asthma medication as directly observed therapy (DOT). The purpose of DOT is to establish a relationship with the nurse, learn proper medication technique, and experience potential benefits of consistent preventive therapy.~The second component, Motivational Interviewing (MI) counseling , will start 4-6 weeks after the start of DOT. A counselor will conduct 3 in-person MI sessions with the teen at school to enhance the teen's motivation to adhere to their asthma treatment plan. The 3 sessions consist of an initial 40 minute counseling session (4-6 weeks after start of DOT), and two 30 minute follow-up sessions 2 and 6 weeks later. This component consists of an evidence-based self-management program to help the teen begin to transition to independence with preventive medication use."
3106133|NCT02206061|Active Comparator|Directly Observed Therapy|For the first 6-8 weeks after enrollment, the teen will visit the school nurse once a day to receive a daily dose of preventive asthma medication as directly observed therapy (DOT).
3106134|NCT02206061|Active Comparator|Asthma Education|Asthma educators will provide an in-school asthma education program that will match the time and attention of the MI counseling portion of the primary intervention. Each teen will receive three 1-on-1 educational sessions at school, and sessions will cover 3 main topics: 1) lung physiology and asthma basics, 2) triggers, symptoms, and warning signs, and 3) medications and self-advocacy.
3106135|NCT02206152|Placebo Comparator|Placebo|Normal Saline IV infusion given during a controlled hyperinsulinemic hypoglycemic insulin clamp
3106136|NCT02206152|Experimental|Treatment with N-Acetyl Cysteine|N-acetyl cysteine IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
3106137|NCT02206217|No Intervention|Single vision spectacle lens|Single vision lens with power for correcting distance refraction.
3106138|NCT02206217|Experimental|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus at the same time.
3106139|NCT02206607|Experimental|PF-04937319 IR MST|Reference formulation
3106140|NCT02206607|Experimental|PF-04937319 MR 1|Test MR #1
3106141|NCT02206607|Experimental|PF-04937319 MR 2|Test MR #2
3106142|NCT02206607|Experimental|PF-04937319 MR 3|Test MR #3
3106143|NCT02206620|Experimental|Donepezil|Donepezil 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
3106144|NCT02206620|Placebo Comparator|Placebo|Placebo 5 mg per day for week 1-3 or 12-14. 10 mg/day for weeks 4-6 or 14-18, if tolerated.
3106145|NCT02206685|Active Comparator|Treatment group|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes.
3106146|NCT02206685|Placebo Comparator|Control Group|The control group will receive a 20 ml normal saline placebo infusion over 10 minutes
3106147|NCT02206776|Placebo Comparator|Midazolam|A single dose of intranasal midazolam up to 4 mg
3106148|NCT02206776|Experimental|Ketamine|A single dose of intranasal ketamine up to 50 mg
3106149|NCT02206828||1 GROUP|Only 1 group not predetermined
3106150|NCT02207088|Experimental|3-DAA (Direct Acting Antivirals) with or without RBV|3-DAA (ombitasvir/paritaprevir/ritonavir 25 mg/150 mg/100 mg once daily [QD] and dasabuvir 250 mg twice daily [BID]) with or without ribavirin (RBV; dosed divided twice a day) for 12 or 24 weeks
3106151|NCT02207231|Experimental|Group I|Participants received Guselkumab 100 milligram (mg) at Weeks 0, 4, and 12 and every 8 weeks (q8w) thereafter through Week 252, placebo for guselkumab at Week 16, and placebo for adalimumab (two 0.8 milliliter [mL] injections) at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, and 5, and every 2 weeks (q2w) thereafter through Week 47.
3106152|NCT02207231|Placebo Comparator|Group II|Participants received Placebo for guselkumab at Weeks 0, 4, and 12, and placebo for adalimumab (two 0.8 mL injections) at Week 0, followed by one 0.8 mL injection at Weeks 1, 3, and 5, and q2w through Week 15. At Week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20 and q8w thereafter through Week 252, as well as placebo for adalimumab at Weeks 17, 19, 21, and 23, and q2w thereafter through Week 47.
3106153|NCT02207231|Active Comparator|Group III|Participants received Adalimumab 80 mg at Week 0 (two 40 mg [0.8 mL] injections) and 40 mg at Weeks 1, 3, 5, and q2w thereafter through Week 47, placebo for guselkumab at Weeks 0, 4, 12, 16, and 20, and q8w thereafter through Week 44 and guselkumab 100 mg at Weeks 52, 60, and q8w thereafter through Week 252.
3106154|NCT02207244|Experimental|Group I|Participants will receive guselkumab 100 milligram (mg) at Weeks 0, 4, 12 and 20. Starting at Week 28, participants will receive guselkumab 100 mg or placebo through Week 72 depending upon randomized treatment group and PASI response. Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending upon randomized treatment group and PASI response. Placebo for adalimumab [two 0.8 milliliter (mL) injections] at Week 0 followed by one 0.8 mL injection at Weeks 1, 3, 5, and every 2 week (q2w) through Week 23 to maintain the blind. All participants will receive guselkumab q8w starting at Week 76 through Week 252.
3106155|NCT02207244|Placebo Comparator|Group II|Participants will receive placebo for guselkumab at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response. Placebo for adalimumab (two 0.8 mL injections) at week 0, followed by one 0.8 mL injection at weeks 1, 3, and 5, and q2w through week 23. At week 16, placebo participants will cross over to receive guselkumab 100 mg at Weeks 16 and 20, starting at week 28, participants will continue to receive guselkumab 100 mg or placebo through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
3106156|NCT02207244|Active Comparator|Group III|Participants will receive adalimumab 80 mg (two 40 mg [0.8 mL] injections) at Week 0 followed by adalimumab 40 mg at weeks 1, 3, 5, and q2w through week 23 and placebo for guselkumab at weeks 0, 4, 12, 16, and 20. Participants will receive guselkumab or placebo starting at week 28 through week 72 depending upon PASI response. All participants will received guselkumab q8w starting at Week 76 through Week 252.
3106157|NCT02207322|No Intervention|Standard transplant care|"Patient Enrollment and Caregiver Enrollment (within 72 hours of hospital)~-- Complete baseline data collection, and registration~Patient Randomization~Standard transplant oncology care~-- Palliative care consults only upon request~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
3106158|NCT02207322|Experimental|transplant with early palliative care|"Standard transplant oncology care with early palliative care~Patient Enrollment and Caregiver Enrollment (within 72 hours of patient enrollment)~--Complete baseline data collection, and registration Intervention description: Inpatient palliative care intervention description: 1st visit within 72 hours of randomization, At least twice weekly follow up visits~Longitudinal Data Collection (patient & family caregivers)~Week-2 of hospitalization~3-months, and 6-months post HSCT"
3106159|NCT02207374|Experimental|Semaglutide 0.5 mg|
3106160|NCT02207374|Experimental|Semaglutide 1.0 mg|
3106161|NCT02207374|Active Comparator|One additional OAD + pre-trial treatment|The type and dosage of the additional OAD will be selected by the investigators according to the approved Japanese labelling including drug combinations and contraindications. One of DPP-4 inhibitor (dipeptidyl peptidase-4), SU (sulfonylurea), glinide, biguanide, α-GI (α-glucosidase inhibitor)or TZD (thiazolidinediones) will be selected as the additional OAD. For the subjects treated with OAD monotherapy as pre-trial treatment, the type and dosage of the additional OAD with a different mechanism of action from the pre-trial OAD should be chosen.
3106162|NCT02207400|Experimental|Experimental Dentifrice|Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
3106163|NCT02207400|Active Comparator|Reference Dentifrice|Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
3106164|NCT02207413|Experimental|Influsplit Tetra_IP Adult Group|Subjects in the Influsplit Tetra_IP group aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by investigational process (IP) at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm.
3106165|NCT02207413|Active Comparator|Influsplit Tetra_LP Adult Group|Subjects in the Influsplit Tetra_LP aged between 18 to 49 years received 1 dose of Influsplit Tetra™ vaccine produced by currently licensed process (LP) at Day 0. Influsplit Tetra™ vaccine produced by currently LP was administered intramuscularly in the deltoid region of left or non-dominant arm.
3106166|NCT02207413|Experimental|Influsplit Tetra_IP 3-17y Group|Subjects in the Influsplit Tetra_IP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by IP at Day 0. Influsplit Tetra™ vaccine produced by IP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
3106167|NCT02207413|Active Comparator|Influsplit Tetra_LP 3-17y Group|Subjects in the Influsplit Tetra_LP group aged between 3 years to <9 years received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Subjects aged 9-17 years received only 1 dose of Influsplit Tetra™ vaccine produced by LP at Day 0. Influsplit Tetra™ vaccine produced by LP was administered intramuscularly in the deltoid region of left or non-dominant arm (Day 0) and in the deltoid region of right or dominant arm (Day 28).
3106168|NCT02207413|Experimental|Influsplit Tetra_IP 6-35m Group|Subjects in the Influsplit Tetra_IP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by investigational process (IP). Influsplit Tetra™ vaccine produced by IP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
3106169|NCT02207413|Active Comparator|Influsplit Tetra_LP 6-35m Group|Subjects in the Influsplit Tetra_LP group aged between 6 months to 35 months received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Influsplit Tetra™ vaccine produced by licensed process (LP). Influsplit Tetra™ vaccine produced by LP was administered intramuscularly the anterolateral region of left thigh for subjects below 12 months of age and in the deltoid region of left or non-dominant arm in subjects ≥ 12 months of age (Day 0) and in the anterolateral region of right thigh for subjects below 12 months of age and in the deltoid region of right or dominant arm in subjects ≥ 12 months of age (Day 28).
3106170|NCT02207478|Experimental|ENB-GS-TBLB-X-ray Group|The guide sheath(GS) is introduced into the lesion via Electromagnetic Navigation System. The locatable guide(LG) and GS are confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained with fluoroscopic guidance.
3106171|NCT02207478|Active Comparator|GS-TBLB-X-ray group|The GS is introduced into the lesion via the working channel of a bronchoscope with radiographic fluoroscopy. Once the location of the lesion is identified by fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
3106172|NCT02207491|Experimental|AR-13324 Ophthalmic Solution 0.02% & Placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3106173|NCT02207491|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
3106174|NCT02207530|Experimental|MEDI4736|MEDI4736 monotherapy
3106175|NCT02207556|Experimental|Doxycycline|Doxycycline will be administered at dose of 100mg orally twice daily for 1 year.
3106176|NCT02207569|Experimental|CoreValve Evolut R TAVR system|"The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
3106177|NCT02207608|Active Comparator|BCG alone (Immucist®)|Group A receive BCG (Immucist® 81 mg, Sanofi-Aventis Group) alone
3106178|NCT02207608|Experimental|Hyaluronic acid|Group B receive BCG and HA 40 mg (Cystistat, Mylan, Pittsburgh, PA, U.S.A.).
3106179|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3106180|NCT02207621|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3106181|NCT02207621|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3106182|NCT02207634|Placebo Comparator|Placebo|Participants received placebo subcutaneous injections either once every 2 weeks (Q2W) or once a month (QM) according to their own preference. Participants continued with their background statin therapy during the course of the study.
3106183|NCT02207634|Experimental|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference. Participants continued with their background statin therapy during the course of the study.
3106184|NCT02207725|Experimental|Andexanet|Andexanet (antidote)
3106185|NCT02207725|Placebo Comparator|Placebo|Placebo
3106186|NCT02207803|Experimental|Intervention|Experimental Transition Assistance Program
3106187|NCT02207803|No Intervention|Control|Control
3106188|NCT02207816|Experimental|GSK257049 Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on a 0-1-2-month schedule, and a booster dose of GSK257049 malaria vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); left deltoid (GSK257049 booster dose); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
3106189|NCT02207816|Active Comparator|GSK257049 Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of GSK257049 malaria vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: in the anterolateral left thigh (GSK257049 vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
3106190|NCT02207816|Active Comparator|VeroRab/Menjugate Comparator Group|Male or female infants (between and including 6 to 12 weeks of age)/children (between and including 5 to 17 months of age) received 3 doses of VeroRab vaccine (children subgroup) or Menjugate vaccine (co-administered with Polio Sabin and Tritanrix HepB/Hib vaccines, for the infants subgroup) on 0-1-2-month schedule, and a booster dose of Menjugate vaccine (co-administered with Polio Sabin, for the infants subgroup) at Month 20 during the primary study MALARIA-055 PRI (NCT00866619). Vaccines were administered intramuscularly: left deltoid (VeroRab vaccine and Menjugate vaccine); anterolateral right thigh (Tritanrix HepB/Hib vaccine); orally: Polio Sabin vaccine. No vaccination was administered during this study.
3106191|NCT02207829|Experimental|Umeclidinium 62.5 mcg + placebo|Subjects will receive UMEC Inhalation Powder 62.5 mcg once daily via nDPI plus placebo once daily via HANDIHALER inhaler for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
3106192|NCT02207829|Active Comparator|Tiotropium 18mcg + placebo|Subjects will receive Tiotropium 18 mcg once daily via HANDIHALER inhaler plus placebo once daily via nDPI for 12 weeks (24 weeks in Germany). Subjects will be instructed to take one inhalation each morning from both the nDPI and the HANDIHALER inhaler
3106193|NCT02207907|Experimental|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
3106194|NCT02207907|Active Comparator|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
3106195|NCT02207946|Experimental|200 Units incobotulinumtoxinA (Xeomin)|Single injection cycle, total dose of up to 200 Units, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
3106196|NCT02207946|Placebo Comparator|Placebo|Single injection cycle, intramuscular injection into muscles of wrist (mandatory) and shoulder and/or elbow (both optional).
3106197|NCT02207972|Active Comparator|Use of Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
3106198|NCT02207972|Active Comparator|No ultrasound used|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started Infusion 12 ml/hr of 0.0625% Bupivacaine and Fentanyl 2mcg/ml
3106199|NCT02208037|Experimental|Tacrolimus/Methotrexate/Bortezomib|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Bortezomib.
3106200|NCT02208037|Experimental|Tacrolimus/Methotrexate/Maraviroc|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Methotrexate, and Maraviroc.
3106201|NCT02208037|Experimental|Tacrolimus/MMF/Cyclophosphamide|Participants will receive specified dosage of three different GVHD prophylaxis agents: Tacrolimus, Mycophenolate Mofetil (MMF), and Cyclophosphamide.
3106202|NCT02208050|Other|Group 1|Patients will be randomised to a 8 week treatment period with the active drug followed by a 2 week washout period before an 8 week treatment period with placebo.
3106203|NCT02208050|Other|Group 2|Patients will be randomised to a 8 week treatment period with the placebo, followed by a 2 week washout period and a further 8 week treatment period with the active drug.
3106204|NCT02208063|Experimental|Telavancin|7.5 mg/kg administered intravenously once every 24 hours daily over 60 minutes
3106205|NCT02208063|Active Comparator|Standard of care|Vancomycin, Daptomycin, synthetic penicillin or Cefazolin
3106206|NCT02208089|Experimental|TransPRKCXL|Simultaneous combined transepithelial photorefractive keratectomy (TransPRK) and corneal collagen cross-linking (CXL)
3106207|NCT02208089|Active Comparator|CXL only|Corneal collagen cross-linking (CXL) using the same protocol without transepithelial photorefractive keratectomy
3106208|NCT02208297|Experimental|Loteprednol Etabonate Gel (BID)|Loteprednol Etabonate Gel 0.38% administered two times daily (BID)
3106209|NCT02208297|Placebo Comparator|Vehicle Gel (BID)|Vehicle gel administered two times daily (BID)
3106210|NCT02208310|Active Comparator|Low Dose Vitamin D|Patients will be given 400 IU cholecalciferol once daily for 30 days. <-THIS IS THE Active Comparator Intervention. To maintain the blind, a random few will be given another round at the 30 day mark. For patients who enroll in the summer, a random few will again receive 400 IU cholecalciferol in March.
3106211|NCT02208310|Experimental|High Dose Vitamin D|Patients will be given cholecalciferol 10,000 IU daily for 30 days. <-THIS IS THE INTERVENTION. At that point, if their vitamin D levels remain below 50 ng/ml, the 30 day course will be repeated. For patients who enroll in the summer, levels will be rechecked in March and if <50 ng/ml, a 30 day course will be administered.
3106212|NCT02208349|Experimental|Video Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
3106213|NCT02208349|Active Comparator|Direct Laryngoscopy|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
3106214|NCT02208466|Experimental|Active rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of active low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of active low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
3106215|NCT02208466|Experimental|Sham rTMS/active fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of active fluoxetine by mouth daily.
3106216|NCT02208466|Experimental|Sham rTMS/placebo fluoxetine|Subjects in this arm will undergo 10 daily sessions over 15 days of sham low-frequency rTMS with each session lasting 20 minutes. This will be followed by 8 weekly sessions of sham low-frequency rTMS with each session lasting 20 minutes. Additionally, during this time beginning with enrollment, subjects will also be taking 20mg of placebo fluoxetine by mouth daily.
3106217|NCT02208843|Experimental|Afatinib|Afatinib tablet once daily until progression
3106218|NCT02208999||Neurostimulator Precision|Patients implanted or reimplanted with the neurostimulator Precision
3106219|NCT02209064|Other|EpiAccess|EpiAccess will be used to gain access to the normal, non-distended pericardial space in subjects presenting with the need for pericardial access as determined by the patient's physician.
3106220|NCT02209181|Experimental|JNJ-10450232 250 mg|
3106221|NCT02209181|Experimental|JNJ-10450232 1000 mg|
3106222|NCT02209181|Placebo Comparator|Placebo|
3106223|NCT02209181|Active Comparator|Acetaminophen 1000 mg|
3106224|NCT02209259|Experimental|Intervention Group 1|The first intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing the standard PCS.
3106225|NCT02209259|Experimental|Intervention Group 2|The second intervention group will be comprised of patients who will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS) after completing a positively-adjusted version of the PCS.
3106226|NCT02209259|Experimental|Control|The third group (the control arm) will complete PROMIS Upper Extremity Function, pain intensity, PROMIS depression, and the Positive affect negative affect scale (PANAS).
3106227|NCT02209272|Experimental|bacteriostatic saline|for ultrasound guided hip joint injection local anesthesia
3106228|NCT02209272|Active Comparator|buffered lidocaine|for ultrasound guided hip joint injection local anesthesia
3106229|NCT02209454|Other|Enantyum® oral solution|25mg DKP.TRIS oral solution
3106230|NCT02209454|Other|Keral® tablet|25mg DKP.TRIS tablet
3106231|NCT02209506|Experimental|Cohort 1A: MLN3126 100 mg Non-Japanese Participants|MLN3126 100 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3106232|NCT02209506|Experimental|Cohort 2A: MLN3126 300 mg Non-Japanese Participants|MLN3126 300 mg, administered orally as tablets, orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3106233|NCT02209506|Experimental|Cohort 3A: MLN3126 800 mg Non-Japanese Participants|MLN3126 800 mg, administered orally as tablets once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3106234|NCT02209506|Experimental|Cohort 4A: MLN3126 TBD Non-Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3A. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3106235|NCT02209506|Experimental|Cohorts 1A - 4A: Matched Placebo Non-Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, non-Japanese participants.
3106236|NCT02209506|Experimental|Cohort 1B: MLN3126 100 mg Japanese Participants|MLN3126 100 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 though 15) in healthy, Japanese participants.
3106237|NCT02209506|Experimental|Cohort 2B: MLN3126 300 mg Japanese Participants|MLN3126 300 mg, administered orally as tablets, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
3106238|NCT02209506|Experimental|Cohort 3B: MLN3126 800 mg Japanese Participants|MLN3126 800 mg, tablets, orally, once on Day 1, followed by a 7 day washout period, followed by MLN3126 800 mg, tablets, orally, once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
3106239|NCT02209506|Experimental|Cohort 4B: MLN3126 TBD Japanese Participants|The MLN3126 dose for this Cohort will be determined based on data collected from Cohort 3B. MLN3126, tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily administration for 7 days (Days 9 through 15) in healthy, Japanese participants.
3106240|NCT02209506|Experimental|Cohorts 1B - 4B: Matched Placebo Japanese Participants|MLN3126 placebo-matching tablets, administered orally, once on Day 1, followed by a 7 day washout period, followed by once daily for 7 days (Days 9 through 15) in healthy, Japanese participants.
3106241|NCT02209519|Experimental|Metronidazole|Male Partner: metronidazole 500 mg PO BID x 7days Female Partner: metronidazole 500 mg PO BID x 7days
3106242|NCT02209519|Placebo Comparator|Placebo|Male Partner: one tablet PO BID for 7 days Female Partner: metronidazole 500 mg PO BID x 7days
3106243|NCT02209532|Active Comparator|Blue - PINPOINT|The cervix will be injected 4 times with a 1ml solution of 1% Isosulfan blue followed by injection 4 times of 1 ml of 1.25 mg/ml solution of ICG. LN mapping with Blue dye will be performed until the investigator identifies all blue nodes or determines that blue nodes cannot be identified. Once complete, the Investigator will begin mapping with PINPOINT until all 'ICG' nodes are identified or the investigator determines that 'ICG' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
3106244|NCT02209532|Active Comparator|PINPOINT - Blue|The cervix will be injected 4 times with 1 ml of a 1.25 mg/ml solution of ICG followed by injection 4 times of a 1 ml solution of 1% Isosulfan blue. LN mapping with PINPOINT will be performed until the investigator identifies all 'ICG' nodes or determines that 'ICG' nodes cannot be identified. Once complete, the Investigator will begin mapping with Blue dye until all 'blue' nodes are identified or the investigator determines that 'blue' nodes cannot be identified. Once mapping with both Blue dye and PINPOINT have been completed and documented, LNs identified with Blue dye or PINPOINT will be excised.
3106245|NCT02209597|Experimental|StudyArm|"Subjects will be studied for 28 weeks in a sequential cross-over study: a~Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics)."
3106246|NCT02209610|Other|Patients With Heart Failure: Neuromuscular Abnormalities|Patients with Heart Failure
3106247|NCT02209610|Other|Health Control Subjects and Neuromuscular Function|Health Control Subjects
3106248|NCT02209766|Experimental|D5884|D5884 capsule, Per oral(po)
3106249|NCT02209766|Placebo Comparator|Placebo|Placebo capsule, po
3106250|NCT02209948|Experimental|Temozolomide|Those patients will take 6 additional Temozolomide cycles
3106251|NCT02209948|No Intervention|Without treatment|
3106252|NCT02210000|Placebo Comparator|Placebo|Subjects will receive camicinal matching placebo orally once daily (QD) from Day 1 to Day 84
3106253|NCT02210000|Experimental|Camicinal 25mg|Subjects will receive camicinal 25 mg orally QD from Day 1 to Day 84
3106254|NCT02210039|Experimental|SECM Probe Imaging|SECM probe will be guided to a pre-determined length in the esophagus and spiral imaging will be performed using the SECM Imaging System.
3106255|NCT02210052|Experimental|Radiofrequency neurotomy subjects|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
3106256|NCT02210065|Experimental|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
3106257|NCT02210091|Experimental|<6 years old|
3106258|NCT02210091|Experimental|≥6 to <12 years|
3106259|NCT02210195|Active Comparator|Experimental: aprepitant 125 mg/day|125 mg aprepitant daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3106260|NCT02210195|Placebo Comparator|Placebo 125mg/d|Matched placebo pill given daily for 8 weeks given in conjunction with 8 weeks of manual-guided behavioral counseling.
3106261|NCT02210208|Experimental|Mepitel® Ag|A dressing device used for surgical burn wounds with skin graft.
3106262|NCT02210208|Experimental|Mepilex® Transfer Ag|Donor site dressing device in the very same patient.
3106263|NCT02210247|Active Comparator|Cohort 1|Cohort 1 will receive a single dose of EXPAREL 266 mg on Day 1. No additional dose will be given.
3106264|NCT02210247|Active Comparator|Cohort 2|Cohort 2 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 4 at 72 hours.
3106265|NCT02210247|Active Comparator|Cohort 3|Cohort 3 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 3 at 48 hours.
3106266|NCT02210247|Active Comparator|Cohort 4|Cohort 4 will receive a dose of EXPAREL 266 mg on Day 1 and a second dose of EXPAREL 266 mg on Day 2 at 24 hours.
3106267|NCT02210247|Active Comparator|Cohort 5|Cohort 5 will receive a single dose of EXPAREL 266 mg on Day 1 followed immediately by a second dose of EXPAREL 266 mg (total of 532 mg/40 mL).
3106268|NCT02210286|Experimental|Magtein|All participants will orally take a total of 1800 mg/day for 60 days. Oral administration includes two pills 2 hours before bed time and one pill in the morning, each pill containing 600 mg of MgT-1219.
3106269|NCT02210689|Experimental|test product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.)
3106270|NCT02210689|Active Comparator|reference product|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing approximately 100 mg of Clindesse® (clindamycin phosphate vaginal cream 2% ) (Ther-Rx™)
3106271|NCT02210689|Placebo Comparator|placebo|One single-dose, pre-filled disposable applicator delivering approximately 5 g of cream containing vehicle of the test product (Watson Laboratories, Inc.)
3106272|NCT02210780|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
3106273|NCT02210780|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
3106274|NCT02211014|Experimental|Cohort 1|Acalabrutinib 100 mg twice daily (bid) continuously
3106275|NCT02211014|Experimental|Cohort 2|Acalabrutinib 100 mg bid continuously and 40 mg dexamethasone once weekly
3106276|NCT02211261|Experimental|Cohort 1-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3106277|NCT02211261|Experimental|Cohort 2-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3106278|NCT02211261|Experimental|Cohort 3-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3106279|NCT02211261|Experimental|Cohort 4-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3106280|NCT02211261|Experimental|Cohort 5-PF-06293620 or placebo|Single Ascending Dose PF-06293620 or placebo
3106281|NCT02211261|Experimental|Cohort 6-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3106282|NCT02211261|Experimental|Cohort 7 PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3106283|NCT02211261|Experimental|Cohort 8-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3106284|NCT02211261|Experimental|Cohort 9-PF-06293620 or placebo|Multiple Ascending Dose PF-06293620 or placebo
3106285|NCT02211313|Active Comparator|Ureteral stent - soft, 6 French|Subjects randomized to soft stent, size 6 French
3106286|NCT02211313|Active Comparator|Ureteral stent - hydrophobic, 6 French|Subjects randomized to hydrophobic stent, size 6 French
3106287|NCT02211456|Experimental|Participants|Having an ablation procedure with access to the left side of the heart
3106288|NCT02211495|Active Comparator|No device|Treated with best medical therapy
3106289|NCT02211495|Experimental|Device|As well as receiving best medical therapy, these people will be given the geko device to wear on their affected leg. They will wear it for 4 hours per day, 5 days a week.
3106290|NCT02211534|Active Comparator|Pulsed Electromagnetic Field Device|Pulsed Electromagnetic Field therapy device; self-administered at home twice daily for 30 minutes.
3106291|NCT02211534|Sham Comparator|Sham Pulsed Electromagnetic Field Device|Inactive Pulsed Electromagnetic Field Therapy device; self-administered at home twice daily for 30 minutes.
3106292|NCT02211638||Candesartan Cilexetil tablets (2 to 12 mg)|Candesartan Cilexetil tablets (2 to 12 mg), orally, once daily for up to 3 months
3106293|NCT02212028|Experimental|Prasugrel crush|Prasugrel 60mg loading dose as crushed tablets
3106294|NCT02212028|Active Comparator|Prasugrel tablets|Prasugrel 60 mg loading dose as whole tablets
3106295|NCT02212106|Experimental|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3106296|NCT02212106|Active Comparator|Comparator Quadrivalent Influenza Virus Vaccine|The comparator vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season.
3106297|NCT02212197|Experimental|CAM2032 3.75 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 3.75 mg on Days 0, 28 and 56.
3106298|NCT02212197|Experimental|CAM2032 7.5 mg|Single subcutaneous buttock injections of CAM2032 (leuprolide acetate FluidCrystal® injection depot) 7.5 mg on Days 0, 28 and 56.
3106299|NCT02212197|Active Comparator|Eligard 7.5 mg|Single subcutaneous buttock injections of Eligard® (leuprolide acetate) 7.5 mg on Days 0, 28 and 56.
3106300|NCT02212301|Active Comparator|senofilcon A / lotrafilcon B|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens and then wore the lotrafilcon B contact lens.
3106301|NCT02212301|Active Comparator|lotrafilon B/ senofilcon A|Subjects were randomized to one of two lens wear sequences. Subjects randomized to this sequence first wore the lotrafilcon B contact lens and then wore the senofilcon A contact lens
3106302|NCT02212379|Experimental|raltegravir and etravirine|
3106303|NCT02212457|Experimental|rMenB_0_2 Group|Subjects received two injections of Bexsero vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
3106304|NCT02212457|Experimental|ABCWY_ 0_2 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 2, Havrix vaccine at Visit Month 6 and Visit Month 12 and saline placebo at Visit Month 1.
3106305|NCT02212457|Experimental|ABCWY_0_1 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 1, Havrix vaccine at Visit Month 2 and Visit Month 12 and saline placebo at Visit Month 6.
3106306|NCT02212457|Experimental|ABCWY_0_6 Group|Subjects received MenABCWY vaccine at Visit Month 0 and Visit Month 6, Havrix vaccine at Visit Month 1 and Visit Month 12 and saline placebo at Visit Month 2.
3106307|NCT02212457|Experimental|ABCWY_0_11 Group|Subjects received MenABCWY vaccine at Visit Month 1 and Visit Month 12, Havrix vaccine at Visit Month 0 and Visit Month 6 and saline placebo at Visit Month 2.
3106308|NCT02212457|Experimental|ABCWY_0_2_6 Group|Subjects received MenABCWY vaccine at Visit Month 0, Visit Month 2 and Visit Month 6 and Havrix vaccine at Visit Month 1 and Visit Month 12.
3106309|NCT02212587|Experimental|TOBI Podhaler|
3106310|NCT02212678|Experimental|N-acetylcysteine|Subjects will be provided 6000 mg/day of N-acetylcysteine (capsule) to be divided into 2 equal daily doses and taken orally for approximately 28 days
3106311|NCT02212730|Experimental|Neoadjuvant Pembrolizumab + RCC Resection|Participants received pembrolizumab, 200 mg intravenously (IV) once every 3-week cycle for up to 2 cycles followed by standard of care (SOC) renal cell carcinoma (RCC) surgical resection; and then received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled after Protocol Amendment 04.
3106312|NCT02212730|Experimental|RCC Resection|Participants received SOC renal cell carcinoma (RCC) surgical resection; and then may have received post-resection pembrolizumab 200 mg IV once every 3 week cycle for up to approximately 1 year (17 cycles). Post-resection pembrolizumab was only administered to participants who enrolled under Protocol Amendment 04.
3106313|NCT02212834||Mammograms|Surveillance mammograms in women with a personal history of breast cancer
3106314|NCT02212834||Breast MRI|Surveillance breast Magnetic Resonance Imaging (MRI) in women with a personal history of breast cancer
3106315|NCT02212977|Active Comparator|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
3106316|NCT02212977|Experimental|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
3106317|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
3106318|NCT02213042|Active Comparator|Trastuzumab in HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of HER2 Enriched, Trastuzumab (loading dose of 8 mg/kg followed by the maintenance dose of 6 mg/kg IV q3weekly) along with chemotherapy of the investigator's choice or Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly along with chemotherapy of the investigators choice. Subjects randomized to this arm and hormone receptor positive received an aromatase inhibitor at the discretion of the investigator.
3106319|NCT02213042|Active Comparator|Lapatinib 1000mg + Trastuzumab in Non- HER2 Enriched|In subjects with HER2-overexpressing MBC with a molecular subtype of Non- HER2 Enriched (luminal A, luminal B or Basal type), Lapatinib 1000mg once daily orally along with Trastuzumab (loading dose of 8 milligram/ kilogram (mg/kg) followed by the maintenance dose of 6 mg/kg Intravenous (IV) Every 3 weeks (q3weekly)) or Lapatinib 1000 milligram (mg) once daily orally along with Weekly Trastuzumab (loading dose of 4 mg/kg) followed by maintenance dose of 2 mg/kg IV weekly. For subjects who were hormone receptor positive, an aromatase inhibitor of the investigator's choice was required.
3106320|NCT02213055|Experimental|LICEMD|Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment.
3106321|NCT02213055|Active Comparator|Standard Head lice product|Parents/guardians who do not agree to use the investigational product and choose a standard head lice treatment will be asked to participate in the comparison arm of the study.
3106322|NCT02213068|Experimental|belatacept + MPA|"subjects continue MPA per SOC, receive bimonthly infusions of belatacept while gradually reducing and then discontinuing tacrolimus:~Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 40-60% of the previous dose Day 21 (~ 3 weeks into study): 20-30% of the previous dose Day 30 (about 1 month): discontinue~MPA: administered according to SOC"
3106323|NCT02213068|Active Comparator|belatacept + Low-Dose Tac|"Belatacept: 5 mg/kg IV on Day 1, 15, 29, 43, and 57 post-conversion, then monthly thereafter.~Tacrolimus tapered over one month as follows:~Days 1- 14: SOC administration Day 15 (~ 2 weeks into study): 10% of the previous dose Day 21 (~ 3 weeks into study): 20% of the previous dose Day 30 (~ 1 month into study): 20% of the previous dose Target trough level ≤ 5 mg per ml of tacrolimus thereafter."
3106324|NCT02213068|Other|Tacrolimus + MPA standard treatment regimen|"Standard of Care treatment regimen:~Tacrolimus: administered orally twice daily (BID) The total initial dose of Tacrolimus is given at 0.1 mg/kg in two divided doses to achieve a stable 12-hour trough level of 8 - 12 ng/mL on Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.~MPA: dosed orally per package insert beginning on the day of transplantation. Methylprednisolone as sodium succinate is administered as 500 mg IV, 250 mg IV, 125 mg IV, on Days 0, 1, and 2 without corticosteroid taper.~MPA dose adjustments for gastrointestinal side effects or leukopenia will be made at the discretion of the investigator."
3106325|NCT02213094|Experimental|Nicotinamide 500 mg|Nicotinamide 500 mg by mouth each morning until delivery or 14 days, whichever occurs first.
3106326|NCT02213094|Experimental|Nicotinamide 1000 mg|Nicotinamide 1000 mg by mouth each morning until delivery or 14 days, whichever occurs first.
3106327|NCT02213133|Experimental|Cohort 1: Head and Neck-SCC|Participants with advanced squamous cell carcinoma (SCC) of head and neck, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 milligram (mg) selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets less than [<] 100*10^9 per litre [/L]), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
3106328|NCT02213133|Experimental|Cohort 2: Lungs-SCC|Participants with advanced SCC of lungs, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
3106329|NCT02213133|Experimental|Cohort 3: Esophagus-SCC|Participants with advanced SCC of esophagus, who had relapsed or had metastasis following chemotherapy, received a fixed dose of 60 mg selinexor oral tablets twice weekly on Days 1 and 3 of a 28-day cycle (8 doses in 4 weeks) until disease progression or development of unacceptable toxicities. After completion of Cycle 2, for participants with absence of any grade 2 toxicity and thrombocytopenia (platelets <100*10^9/L), dose may be increased to 80 mg selinexor oral tablets twice weekly as assessed by investigator in a 28-day cycle until disease progression or development of unacceptable toxicities.
3106330|NCT02213198|Experimental|Engagement Focused Care|Engagement Focused Care which includes all components of standard treatment plus both group Access intake process with its flexibility of scheduling and the SDM intervention
3106331|NCT02213198|Active Comparator|Standard Care|Standard Care includes individual intake appointments which are traditional in outpatient service and all services of the clinic including counseling, access to a prescriber, care coordination, and access to home visits.
3106332|NCT02213250|Experimental|BeneFIX|
3106333|NCT02213263|Experimental|PF-05280586|
3106334|NCT02213263|Active Comparator|MabThera®|
3106335|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)|"For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score >10, high microsatellite instability, tumor mutation burden >15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab."
3106336|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (HER2 amplified)|HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
3106337|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EFGR amplified)|EGFR amplified. These patients received ABT-806.
3106338|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)|FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
3106339|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)|MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
3106340|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (EGFR expressing)|EGFR expressing. These patients received standard cytotherapy plus ABT 806.
3106341|NCT02213289|Experimental|ITT-PTS: Personalized Treatment Strategy (All negative)|All negative. These patients received standard cytotherapy plus Ramucirumab.
3106342|NCT02213289|Other|Non-ITT: Standard Therapy|Patients without monoclonal antibodies available received standard cytotherapy.
3106343|NCT02213380|Other|group GA|General anesthesia
3106344|NCT02213380|Other|group RA|Regional anesthesia
3106345|NCT02213458|Experimental|Navigated Care|Comprehensive longitudinal continuing care program
3106346|NCT02213458|No Intervention|Survey of Care|Control group that will undergo the same regular assessments as patients enrolled in Navigated Care
3106347|NCT02213510|Experimental|Zip Surgical Skin Closure device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
3106348|NCT02213510|Active Comparator|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
3106349|NCT02213666||Intracardiac and Transesophageal Echocardiography|Imaging of the right atrial appendage and left atrial appendage with ICE and TEE
3106350|NCT02213900|Experimental|Haloperidol|Randomized patients will receive 0.5mg Haloperidol immediately after surgery and Q8H following the initial dose for a total of 4 days.
3106351|NCT02213900|Placebo Comparator|Placebo|Randomized patients will receive a placebo solution immediately after surgery and Q8H following for a total of 4 days.
3106352|NCT02213926|Experimental|ACP-196 (acalabrutinib) Regimen 1|ACP-196 (acalabrutinib) Regimen 1
3106353|NCT02214017|Active Comparator|Standard care|Diabetic patients attended usual procedure in the outpatient clinic with regular visits
3106354|NCT02214017|Experimental|Telemedicine group|After initial check-up in the outpatient dept. medical treatment, control of blood glucose, blood pressure, lipids, and education was executed via videotelephone in the telemedicine group. A videotelephone, TandBerg E20, in the telemedicine group was delivered and serviced by the Danish Tele Company, TDC.
3106355|NCT02214121|Other|Ticagrelor Dose 1a + Dose 2a|Part A: Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week repeated dosing Part B: Ticagrelor or placebo 4 weeks repeated dosing.
3106356|NCT02214121|Other|Ticagrelor Dose 1b + Dose 2b|Part A: Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week repeated dosing. Part B: Ticagrelor or placebo 4 weeks repeated dosing.
3106357|NCT02214147|Experimental|Alisertib: Normal Hepatic Function|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN.
3106358|NCT02214147|Experimental|Alisertib: Moderate Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin > 1.5-3 x ULN and any ALT level.
3106359|NCT02214147|Experimental|Alisertib: Severe Hepatic Impairment|Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin > 3 x ULN and any ALT level.
3106360|NCT02214186|No Intervention|Liberal Fluid therapy|The liberal group will receive 1500 mL of crystalloid solution during the cesarean section. This is the non-intervention arm once that 1500 ml of crystalloid is the amount usually used during caesarean.
3106361|NCT02214186|Active Comparator|Restrictive Fluid Therapy|The restrictive group will receive 250 mL of crystalloid solution during cesarean section.
3106362|NCT02214212|Active Comparator|Red Light (RL)|"Intervention/Device:~This patient group will receive 30 minutes of red light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
3106363|NCT02214212|Experimental|Bright White Light (BWL)|"Intervention/Device:~This patient group will receive 30 minutes of bright white light daily for a period of 10 days in the morning. Identical baseline and outcome testing will be completed for both arms."
3106364|NCT02214225|Experimental|Quadrivalent Influenza Vaccine (QIV)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3106365|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-1)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
3106366|NCT02214225|Active Comparator|Trivalent Influenza Vaccine (TIV-2)|The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).
3106367|NCT02214238|Active Comparator|Market released PAP device|Use of a market released PAP device
3106368|NCT02214238|Experimental|Modified PAP device|Us of the modified PAP device
3106369|NCT02214277|Experimental|Test Arm|
3106370|NCT02214277|Active Comparator|Control Arm|
3106371|NCT02214277|Other|Safety Arm|
3106372|NCT02214290|Active Comparator|Caffeine|200 mg caffeine tablet produced by CVS Pharmacy, USA
3106373|NCT02214290|Placebo Comparator|Placebo|Placebo pill produced by NOW FOODS, USA
3106374|NCT02214290|Experimental|L-citrulline|L-citrulline capsule (750 mg) provided by NOW FOODS
3106375|NCT02214420|Active Comparator|SMV+SOF|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)
3106376|NCT02214420|Active Comparator|SMV+SOF+RBV|IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day
3106377|NCT02214615|Active Comparator|Carbamazepine|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce. After 2 weeks of steady dose drug will be tapered down every 3 days.
3106378|NCT02214615|Placebo Comparator|Placebo|Administered in gradual doses from 200 mg twice a day increasing to no more than 800 mg twice a day if symptoms do not reduce to match dosing with carbamazepine. After 2 weeks of steady dose drug will be tapered down every 3 days.
3106379|NCT02214628|Experimental|Fovista® plus anti-VEGF Simultaneous|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Simultaneous regimen followed by quarterly administration."
3106380|NCT02214628|Experimental|Fovista® plus anti-VEGF Pre-Treatment|"Subjects will be administered Fovista® (anti-PDGF BB) plus anti-VEGF as a Pre-Treatment regimen followed by quarterly administration."
3106381|NCT02215070|Experimental|Pasireotide + Preparatory Regimen|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Preparatory regimen will be given 4 days before stem cell transplant.
3469145|NCT03889600|Experimental|REDD-CAT Recipient|The nurse care manager will incorporate the administration of the REDD-CAT to the patient as part of the standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
3469146|NCT03889301|Experimental|E-E Video|Watch E-E video that incorporates health and educational messages
3106384|NCT02215161|Experimental|Treatment (selinexor)|Patients receive selinexor PO on days 1 and 3 of weeks 1-3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3106385|NCT02215200|Experimental|Anti-Thymocyte Globulin (ATG) and Placebo|"Anti-Thymocyte Globulin (ATG)/Placebo: Anti-Thymocyte Globulin (ATG) will be administered at a dose of 2.5mg/kg as two divided IV infusions of 0.5mg/kg and 2mg/kg. First dose (0.5mg/kg) will be infused over a minimum of 12 hours, and the second dose (2mg/kg) over a minimum of 8 hours. The second dose should be given no less than 12 and no more than 24 hours after the previous dose.~Placebo(for GCSF) treatment will begin 6 hours after completion of the ATG. Placebo will be given subcutaneously every 2 weeks for a total of 6 doses"
3106386|NCT02215200|Experimental|ATG plus Granulocyte colony stimulating factor (GCSF)|"Granulocyte colony stimulating factor (GCSF) is supplied in 0.6 mL prefilled syringes for subcutaneous injection. Each syringe contains 6 mg GCSF (based on protein weight), in a sterile, clear, colorless, preservative-free solution (pH 4.0) containing acetate (0.35 mg), sorbitol (30.0 mg), polysorbate 20 (0.02 mg), and sodium (0.02 mg) in water for injection, U.S. Pharmacopeial Convention (USP). The standard 6mg dose will be given with the exception of subjects who weigh less than 45 kg.~GCSF treatment will begin 6 hours after completion of the ATG / Placebo. GCSF will be given subcutaneously every 2 weeks for a total of 6 doses"
3106387|NCT02215200|Placebo Comparator|Placebo|Placebo for ATG will be administered by IV infusion in 2 doses. Placebo for GCSF will be administered subcutaneously every 2 weeks for a total of 6 doses
3106388|NCT02215252|Experimental|PF-05089771|
3106389|NCT02215252|Experimental|Placebo|
3106390|NCT02215252|Experimental|Pregabalin|
3469147|NCT03889301|Active Comparator|Discussion|Structured discussion about depression and anxiety
3469148|NCT03889262|Active Comparator|Control Group|Participants in this group will receive only Neurodevelopmental therapy (NDT) based rehabilitation for 45 minutes in each session, twice a week, during 8 weeks, 16 sessions in total. Number of participants in this group is anticipated to be 20.
3106391|NCT02215252|Experimental|PF-05089771 + Pregabalin|
3106392|NCT02215369|Experimental|VenaCure EVLT 400 µm fiber Procedure Kit|Only one limb can be treated and included in this study; however, multiple IPV's within the study limb may be treated. All IPV's treated will be followed according to the study schedule.
3106393|NCT02215616|Placebo Comparator|Placebo|Participants will receive 3 capsules of matching laquinimod placebo, orally once daily for 52 weeks.
3106394|NCT02215616|Experimental|Laquinimod 0.5 mg|Participants will receive 1 capsule of laquinimod 0.5 milligrams (mg) and 2 capsules of matching placebo, orally once daily for 52 weeks.
3106395|NCT02215616|Experimental|Laquinimod 1.0 mg|Participants will receive 2 capsule of laquinimod 0.5 mg (total 1.0 mg laquinimod) and 1 capsule of matching placebo, orally once daily for 52 weeks.
3106396|NCT02215616|Experimental|Laquinimod 1.5 mg|"Participants will receive 3 capsules of laquinimod 0.5 mg (total 1.5 mg laquinimod), orally once daily.~Note: The treatment of this high dose arm was discontinued as of 10 January 2016."
3106397|NCT02215954|Experimental|Treatment arm [1]: FE 999169|One sachet on the day before colonoscopy, and another sachet on the day of colonoscopy
3106398|NCT02215954|Experimental|Treatment arm [2]: FE 999169|Two sachets on the day before colonoscopy
3106399|NCT02215954|Active Comparator|Treatment arm [3]: Niflec|One to two pack(s) on the day of colonoscopy
3106400|NCT02215967|Experimental|Multiple Myeloma|Dose Escalation with 5 dose levels based on the patients actual bodyweight
3106401|NCT02216071|Active Comparator|Ciprodex®, RLD|Ciprodex®, Otic Suspension, Twice daily for 7 days
3106402|NCT02216071|Experimental|EXL CDOS|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension, Otic Suspension, Twice daily for 7 days
3106403|NCT02216097|Experimental|Treatment|
3106404|NCT02216097|Placebo Comparator|Placebo|
3106405|NCT02216123|Experimental|Tafenoquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Tafenoquine 300mg (2×TQ 150 mg) will be given as a single oral dose on Day 1 or Day 2. Primaquine matching placebo will be given OD orally beginning on Day 1 or Day 2 and continue for 14 days total dosing. All subjects will be followed-up till 180 days.
3106406|NCT02216123|Experimental|Primaquine+ Chloroquine|All subjects will receive one of two formulations of CQ from Days 1 to 3 (600 mg [2×CQ 300 mg] on Day 1, 600 mg on Day 2 and 300 mg on Day 3, each once daily [OD] orally; OR, 620 mg [4×CQ 155 mg] on Day 1, 620 mg on Day 2 and 310 mg on Day 3, each once daily [OD] orally). Primaquine 15mg will be given OD orally beginning on Day 1 or Day 2 and continue for 14 total dosing. Tafenoquine matching placebo will be given as a single oral dose on Day 1 or Day 2. All subjects will be followed-up till 180 days.
3106407|NCT02216136||Breast Conservation Cohort|Breast Conservation group (Group A) with newly diagnosed breast cancer who decide to proceed with lumpectomy and radiation treatment.
3106408|NCT02216136||Mastectomy and Reconstruction Cohort|Mastectomy and Reconstruction group (Group B): This group will have mastectomy with immediate reconstruction (defined as reconstruction process starting at time of initial mastectomy surgery). They may or may not require chemotherapy and radiation depending on their cancer staging as well as multiple steps of their breast reconstruction.
3106409|NCT02216136||Mastectomy Only Cohort|Mastectomy Only Cohort: This group will have mastectomy without reconstruction. They may or may not require chemotherapy and radiation.
3106410|NCT02216214|Placebo Comparator|Placebo|Participants received placebo to match mirabegron at an initial dose of 25 mg and may have been increased to 50 mg of matching placebo based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
3106411|NCT02216214|Experimental|Mirabegron|Participants received mirabegron at an initial dose of 25 mg and may have been increased to 50 mg mirabegron after 4 weeks or 8 weeks based on individual participant efficacy, tolerability and investigator discretion. Once a participant had increased dose, they remained on that dose for the remainder of the study unless there were safety reasons that required discontinuation of study drug.
3106412|NCT02216357|Active Comparator|Ifetroban, Oral Capsule|Ifetroban, Oral Capsule; 200 mg per dose (four - 50 mg capsules), once per day on Study Days 1, 2, and 3.
3106413|NCT02216357|Placebo Comparator|Placebo, Oral Capsule|Placebo, Oral Capsule; matching capsules for oral ifetroban dosing, four capsules once per day on Study Days 1, 2, and 3.
3106414|NCT02216422|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir with RBV|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) co-administered with weight-based Ribavirin (RBV; twice daily) for 12 weeks
3106415|NCT02216526|Experimental|Cetaphil® Restoraderm|Cetaphil® Restoraderm Body Wash, once daily for 8 weeks and Cetaphil® Restoraderm Body Moisturizer, twice daily for 8 weeks
3106416|NCT02216526|Experimental|Excipial|Excipial Kids Body Wash, once daily for 8 weeks and Excipial U Lipolotio (4% urea), twice daily for 8 weeks
3106417|NCT02216526|No Intervention|Standard skin care|Usual skin care routine of the nursing home resident
3106418|NCT02216591|Experimental|Active Cognitive Training (ACT)|The ACT group will complete 12 individual sessions across 6-10 weeks. Sessions will utilize four commercially available memory-training programs from PSSCogRehab 2012, published by Psychological Software Service. The four programs used will be: (1) Sequence recall of digits - auditory (SRD-A), (2) Sequenced Recall Reversed Digits - Auditory (SRRD-A), (3) Sequenced Recall of Words - Visual (SRW-V), and (4) Verbal memory - categorizing (VM-C). In each training session, participants will complete each of the four memory training programs twice.
3106419|NCT02216591|Sham Comparator|Control (CON)|The CON group will also complete 12 total sessions across 6-10 weeks. The same four computer programs from PSSCogRehab 2012, published by Psychological Software Service, will be used in the control group sessions. However, the control program will identify the correct responses to participants, such that they do not need to engage their working memory to answer the questions correctly.
3469149|NCT03889262|Active Comparator|Study Group|After 16 sessions (8 weeks) of only Neurodevelopmental therapy (NDT) based rehabilitation, simulated hippotherapy treatment will be added to rehabilitation program of the same participants. Their NDT treatment will be reduced to 25 minutes whereas hippotherapy will be applied for 20 minutes in each session, 2 sessions a week, 8 weeks in total.
3106420|NCT02216773|Active Comparator|Portal vein embolization (PVE)|"Patients allocated to the PVE group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their portal vein embolized radiologically once their pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 4 weeks after the completion of the PVE. At this point, they will be listed to receive their definitive surgical hepatectomy."
3106421|NCT02216773|Experimental|Radiofrequency assisted liver partition and ligation (RALPP)|"Patients allocated to the RALPP group will receive pre-intervention blood tests and a contrast enhanced CT scan of the abdomen. They will then have their right portal vein surgically ligated followed by radiofrequency ablation in situ splitting of the liver. Certain patients may additionally have a tumourectomy or wedge resection of the left liver lobe if clinically indicated. The RALPP procedure will occur once the patient's pre-intervention investigations have been completed and reviewed by the clinical team.~Post-intervention investigations (blood tests and CT scan) will take place 2 weeks after the completion of the RALPP. At this point, they will be listed to receive their definitive surgical hepatectomy."
3106422|NCT02216812|Experimental|500 mg vitamin C|Arm will take 1 pill of 500 mg vitamin C per day for 6 weeks
3106423|NCT02216812|Placebo Comparator|Placebo|Arm will take 1 placebo pill per day for 6 weeks
3106424|NCT02216851|Experimental|Restylane Perlane|Single injection of Restylane Perlane in nasal dorsum and/or nasal root
3106425|NCT02216851|No Intervention|No-treatment control|No-treatment control group do not receive any treatment during the main study period
3106426|NCT02217280|Experimental|Injection with Gadolinium|This group of patients identified by the PI as having cervical radiculopathy will receive gadolinium (the intervention) in their epidural cervical injection along with steroid (DepoMedrol). There is no control group in this study.
3106427|NCT02217332|Experimental|dexpramipexole|dexpramipexole 150 mg BID
3106428|NCT02217410|Experimental|Regimen A|CFZ533 administered with the contemporary standard of care (SoC) consists of concentration-controlled tacrolimus (Tac), combined with mycophenolate mofetil (MMF) and corticosteroids (CS).
3106429|NCT02217410|Experimental|Regimen B|CFZ533 administered with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction
3106430|NCT02217410|Active Comparator|Regimen C|Standard of care (SoC) [concentration-controlled tacrolimus (Tac) combined with mycophenolate mofetil (MMF) and corticosteroids (CS) with anti-IL2 induction]
3106431|NCT02217436|Experimental|iPad|iPad with age-appropriate applications, videos, and music
3106432|NCT02217436|Active Comparator|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
3106433|NCT02217475|Experimental|Cenicriviroc (CVC) 150mg/CVC 150 mg|CVC 150 mg tablet in Years 1 and 2.
3106434|NCT02217475|Experimental|Placebo/CVC 150 mg|Placebo-matching CVC tablet in Year 1 then CVC 150 mg tablet in Year 2.
3106435|NCT02217475|Placebo Comparator|Placebo/Placebo|Placebo-matching cenicriviroc (CVC) tablet in Years 1 and 2.
3106436|NCT02217501|Experimental|DAPT - clinically indicated duration+12m|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration plus an additional 12 months
3106437|NCT02217501|Active Comparator|DAPT - clinically indicated duration|Clopidogrel 75 mg daily and Acetylsalicylic acid (ASA) 75-100 mg daily for clinically indicated duration with a minimum of 30 days
3106438|NCT02217527|Experimental|JNJ Active Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
3106439|NCT02217527|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
3106440|NCT02217566|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) orally once daily along with prednisone 5 mg orally once daily and androgen deprivation therapy (ADT) as per Investigator's discretion until prostate-specific Antigen (PSA) progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
3106441|NCT02217618|Experimental|LY2409021|Single oral dose of 20 milligrams (mg) LY2409021.
3106442|NCT02217800|Other|Saline, then DG3173, then octreotide|Interventions: saline, DG3173 and octreotide. Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
3106443|NCT02217878|Active Comparator|Morphine|morphine sulfate 5 mg IV followed by 180 mg loading dose of ticagrelor
3106444|NCT02217878|Placebo Comparator|Placebo|sodium chloride 0,9% 5 mg IV followed by 180 mg loading dose of ticagrelor
3106445|NCT02217904|Experimental|Islatravir 1 mg|Single oral dose of islatravir 1 mg
3106446|NCT02217904|Experimental|Islatravir 2 mg|Single oral dose of islatravir 2 mg
3106447|NCT02217904|Experimental|Islatravir 10 mg|Single oral dose of islatravir 10 mg
3106448|NCT02217904|Experimental|Islatravir 30 mg|Single oral dose of islatravir 30 mg
3106449|NCT02217904|Experimental|Islatravir 0.5 mg|Single oral dose of islatravir 0.5 mg
3106450|NCT02217904|Experimental|Islatravir 0.25 mg|Single oral dose of islatravir 0.25 mg
3106451|NCT02217904|Experimental|Islatravir 30 mg Extended Observation|Single oral dose of 30 mg islatravir administered following >8 hour fast. Participants will be closely monitored for viral load for up to approximately 21 days prior to starting standard of care ART.
3106452|NCT02217982|No Intervention|Control Group|Patients randomized to the standard therapy arm will be instructed to follow the normal dosing regimen for DMF with a food bolus of their choice prior to dosing. If severe symptoms (MAGIS >6.5) are noted at any time post randomization in any MAGIS category, crossover to the treatment arm will be allowed. Both groups will be asked to rate their GI symptoms over the past 24 hours using the MAGIS scale once daily.
3106453|NCT02217982|Active Comparator|Treatment Arm|Patients who are randomized to the treatment arm will be instructed to take 125 mg simethicone and one tablespoon of a high fat food (peanut butter)10 minutes prior to each DMF dose. If the average MAGIS score is greater than 3.5 in the diarrhea category they will also be instructed to take 2 mg loperamide three times daily.
3106454|NCT02218008|Experimental|High Dose|
3106455|NCT02218008|Experimental|Low Dose|
3106456|NCT02218008|Placebo Comparator|Placebo|
3106457|NCT02218164|Experimental|Capecitabine or 5-FU with Pegylated Interferon alpha-2b|"Participants will start the Capecitabine pills on day 1 thru day 14 and be off for 7 days (day 15-day 21).~Participants will receive 5-FU days 1-4 of each 21 day cycle.~Participants will receive the Interferon alpha-2b injection weekly every week. The three week period is referred to as one cycle.~After three cycles, new imaging studies will be performed that will measure how the disease is responding to treatment. Participants whose disease is stable or improved will undergo an additional 3 cycles of therapy and the imaging studies will be repeated. Again, participants whose disease is stable or improved will undergo a final 3 cycles of treatment (a total 27 weeks of treatment)."
3106458|NCT02218190|Experimental|Alvimopan|Alvimopan 12mg once orally two hours prior to surgery and then 2 mg orally twice a day until post-operative day (POD) seven.
3106459|NCT02218190|Placebo Comparator|Placebo - Sugar Pill|Placebo Sugar Pill orally two hours prior to surgery and then one sugar pill orally twice a day until post-operative day (POD) seven
3106460|NCT02218203|Placebo Comparator|Placebo- 0mg/kg Lido|Placebo in combination with 0mg/kg LBM lidocaine
3106461|NCT02218203|Experimental|Placebo - 1mg/kg Lido|Placebo in combination with 1mg/kg LBM lidocaine
3106462|NCT02218203|Experimental|Placebo - 2mg/kg Lido|Placebo in combination with 2mg/kg LBM lidocaine
3106463|NCT02218203|Experimental|Placebo - 4mg/kg Lido|Placebo in combination with 4mg/kg LBM lidocaine
3106464|NCT02218203|Experimental|Low Dose Dex - 0mg/kg Lido|Low dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3106465|NCT02218203|Experimental|Low Dose Dex - 1mg/kg Lido|Low dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3106466|NCT02218203|Experimental|Low Dose Dex - 2mg/kg Lido|Low dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3106467|NCT02218203|Experimental|Low Dose Dex - 4mg/kg Lido|Low dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3106468|NCT02218203|Experimental|Medium Dose Dex - 0mg/kg Lido|Medium dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3106469|NCT02218203|Experimental|Medium Dose Dex - 1mg/kg Lido|Medium dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3106470|NCT02218203|Experimental|Medium Dose Dex - 2mg/kg Lido|Medium dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3106471|NCT02218203|Experimental|Medium Dose Dex - 4mg/kg Lido|Medium dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3106472|NCT02218203|Experimental|High Dose Dex - 0mg/kg Lido|High dose dextromethorphan in combination with 0mg/kg LBM lidocaine
3106473|NCT02218203|Experimental|High Dose Dex - 1mg/kg Lido|High dose dextromethorphan in combination with 1mg/kg LBM lidocaine
3106474|NCT02218203|Experimental|High Dose Dex - 2mg/kg Lido|High dose dextromethorphan in combination with 2mg/kg LBM lidocaine
3106475|NCT02218203|Experimental|High Dose Dex - 4mg/kg Lido|High dose dextromethorphan in combination with 4mg/kg LBM lidocaine
3106476|NCT02218216|Experimental|Experimental: Diagnostic mTBI|MRI Diagnostic of subjects with mild Tramatic Brain Injury (mTBI)
3106477|NCT02218216|Placebo Comparator|Experimental: Diagnostic Non mTBI|MRI Diagnostic of Non injured subjects that are closely matched to mTBI
3106478|NCT02218242|Experimental|Ultrasound|Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.
3106479|NCT02218268||Pre-meal bolus then No meal bolus|"A meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
3106480|NCT02218268||No meal bolus then Pre-meal bolus|"A meal replacement drink (Boost) will be given but the subject will not receive a meal bolus. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring.~Then 3 months later meal replacement drink (Boost) and bolus of rapid insulin will be given to this group. Glucose will be monitored with a finger prick before they drink the meal replacement, 1 hour later and finally 2 hours after drinking the meal replacement. Stiffness of the blood vessel of the wrist will be determined using radial tonometry and will be done at the same time as the glucose monitoring"
3106481|NCT02218307|Active Comparator|Mupirocin|topical antibiotic
3106482|NCT02218307|Placebo Comparator|Placebo|Placebo control for mupirocin
3106483|NCT02218320||Group A|Ten HIV-infected adults will be in Group A and take the HIV medication raltegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
3106484|NCT02218320||Group B|Ten HIV-infected adults will be in Group B and take the HIV medication dolutegravir in combination with tenofovir and emtricitabine as their provider-prescribed antiretroviral regimen.
3106485|NCT02218372|Experimental|Fidaxomicin|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
3106486|NCT02218372|Active Comparator|Vancomycin|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days. Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
3106487|NCT02218424|Experimental|Magnesium|Intravenous magnesium. After IV placed intraoperatively, a bolus dose of magnesium 30 mg/kg is given over 15 minutes, followed by a continuous infusion of magnesium at 10 mg/kg/hr until the completion of the procedure.
3106488|NCT02218424|Placebo Comparator|Placebo infusion|Intravenous normal saline will be given as placebo. An equal amount of volume normal saline will be given intravenously as the control group.
3106489|NCT02218463|Active Comparator|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
3106490|NCT02218463|Active Comparator|Estradiol Cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
3106491|NCT02218489|Placebo Comparator|Vehicle|Vehicle (placebo) dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
3106492|NCT02218489|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for up to 30 days in subjects with inflammatory meibomian gland disease
3106493|NCT02218541|Other|abutment margin 0.5 mm subgingival|when fabricating an abutment to support the crown, the margin will be placed 0.5 mm below the gumline
3106494|NCT02218541|Other|abutment margin 1.5 mm subgingival|when fabricating the abutment to support the crown, the margin will be placed 1.5 mm below the gumline
3469150|NCT03889652||Cataract group|"Group 1 includes patients who are planned for cataract extraction without any other preexisting retinal or optic nerve pathology that may affect the RNFL thickness.~OCT (investigation) before and after cataract extraction"
3106497|NCT02218736|Experimental|CERC-501|Oral dosing of 10 mg CERC-501 (formerly known as LY2456302) administered daily for 8 weeks
3106498|NCT02218736|Placebo Comparator|Placebo|Oral daily administration of 10 mg placebo for 8 weeks
3106499|NCT02219009|Experimental|MIND1 System|
3106500|NCT02219048|Placebo Comparator|Placebo|Matched blinded placebo
3106501|NCT02219048|Experimental|PF-03715455|PF-03715455
3106502|NCT02219087|Experimental|Liposomal Bupivacaine|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Liposomal bupivacaine (diluted to 60mL): 20mL into the posterior pocket, 20mL into the lateral, and 20mL into the medial, including all deep and superficial tissues of these areas.
3106503|NCT02219087|Active Comparator|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
3106504|NCT02219256|Experimental|Cohort 1: TAK-079 0.0003 mg/kg|TAK-079 0.0003 mg/kg, infusion, intravenously, once.
3106505|NCT02219256|Experimental|Cohort 2-9: TAK-079 TBD|TAK-079, infusion, intravenously or subcutaneously, once. Dose to be determined from data collected in previous IV or SC Cohort(s)
3106506|NCT02219256|Placebo Comparator|Placebo to TAK-079|Placebo to TAK-079, infusion, intravenously or subcutaneously, once.
3106507|NCT02219282|Active Comparator|Group Dentulous|Laryngeal Mask Unique insertion
3106508|NCT02219282|Experimental|Group Edentulous|Laryngeal Mask Unique insertion
3106509|NCT02219308|Experimental|Paracervical Block (PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives paracervical block of 18 mL 1% buffered Lidocaine. Provider then places IUD."
3106510|NCT02219308|Sham Comparator|No Paracervical Block (Sham PCB)|"Subject receives 2 mL 1% buffered Lidocaine anesthetic at anterior lip of cervix, where tenaculum will be placed.~Subject then receives Sham paracervical block with capped needle. Provider then places IUD."
3106511|NCT02219321|Active Comparator|Lidocaine infusion|A continuous intravenous infusion of lidocaine
3106512|NCT02219321|Placebo Comparator|Saline infusion|A continuous intravenous infusion of saline
3106513|NCT02219334|Experimental|NoseFrida|If randomized to the NoseFrida group, the NoseFrida/filters will be given along with educational instruction of its use to the parents of patients admitted with bronchiolitis. The NoseFrida will be used by the parent to suction the nares of their infants/toddlers.
3106514|NCT02219334|No Intervention|NeoSucker|The NeoSucker (used for nasal suctioning) is part of the current standard of care for patients with bronchiolitis. The NeoSucker is used for removing nasal secretions by a nurse or respiratory therapist. The NeoSucker is a plastic tube which is used to suction the secretions. The bedside nurse will continue to use the NeoSucker as needed. NoseFrida will not be used for this sub group of patients.
3106515|NCT02219438|Experimental|RIGHT side BOLUS and left side basal|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours
3106516|NCT02219438|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral adductor canal catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 8 hours. For the left catheter, the ropivacaine was administered as hourly bolus doses of 8 mL each a total of 8 times: one at time point zero and 1 on the hour for the following 7 hours.
3106517|NCT02219464|Active Comparator|Nasopharyngeal catheter|Patients in this arm will receive oxygen supplementation through the use of a Nasopharyngeal catheter. Sedation will be standardized to ensure consistency between groups.
3106518|NCT02219464|Other|Nasal Cannula|Patients will receive oxygen supplementation through the use of a traditional nasal cannula. Sedation will be standardized to ensure consistency between groups.
3106519|NCT02219477|Experimental|Group 1: GT1B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) + ribavirin (RBV) for 12 weeks in hepatitis C virus (HCV) genotype (GT) 1b-infected participants
3106520|NCT02219477|Experimental|Group 2: GT1 Non-B|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + dasabuvir 250 mg BID + RBV for 24 weeks in HCV GT1non-b (including GT1a)-infected participants
3106521|NCT02219477|Experimental|Group 3: GT4|ombitasvir/paritaprevir/ritonavir 25/150/100 mg QD + RBV for 24 weeks in HCV GT4-infected participants
3106522|NCT02219503|Experimental|Ombitasvir/Paritaprevir/Ritonavir plus Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir (25/150/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 12 weeks
3106523|NCT02219516|Experimental|Cohort 1: Mild renal impairment|RDEA3170 15 mg once daily fasted
3106524|NCT02219516|Experimental|Cohort 2: Moderate renal impairment|RDEA3170 15 mg once daily fasted
3106525|NCT02219516|Experimental|Cohort 3: Severe renal impairment|RDEA3170 15 mg once daily fasted
3106526|NCT02219516|Experimental|Cohort 4: Control subjects with normal renal function|RDEA3170 15 mg once daily fasted
3106527|NCT02219685|Experimental|LDV/SOF|Participants will receive LDV/SOF FDC for 12 weeks.
3106528|NCT02219685|Placebo Comparator|Placebo|Participants will receive LDV/SOF placebo for 12 weeks.
3106529|NCT02219685|Experimental|Open-Label Treatment Phase|Following Posttreatment Week 4, participants in the placebo group will be offered open-label treatment with LDV/SOF FDC for 12 weeks.
3106530|NCT02219815|No Intervention|Standard Care|Patients in the standard care group will receive care as is currently delivered to patients awaiting cardiac surgery at each site. At present, patients are advised to rest and participate in very light intensity physical activity while awaiting surgery. At 1-2 weeks prior to their scheduled surgical date, the patient attends a single three hour cardiac pre-assessment with a nurse practitioner and cardiac anesthesiologist. In addition, a cardiac nurse counsels each patient on healthy behaviors (e.g. smoking cessation, diet, exercise).
3106531|NCT02219815|Experimental|Prehab Intervention|Patients in the Prehab group will receive, in addition to the standard of care, an eight-week comprehensive exercise therapy and education program at a community-based CR facility. Patients will be asked to complete at least two sessions of supervised, structured exercise class plus have the option to attend one additional exercise class per week for eight-weeks, with progression to a moderate to high-intensity interval program based on the supervised assessment of the patient's capabilities. Prehab participants will also attend four education sessions on topics such as risk factor reduction, medication use, cardiovascular physiology, smoking cessation, healthy eating, exercise, and stress management and promotion of self-managed care.
3106532|NCT02219932|Experimental|Fampridine 10 mg BID|Prolonged-release fampridine 10 mg twice daily (BID) for up to 24 weeks
3106533|NCT02219932|Placebo Comparator|Placebo|Matched placebo 10 mg BID for up to 24 weeks
3106534|NCT02219997|Experimental|ACRYSOF IQ IOL|ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
3106535|NCT02219997|Active Comparator|Clear IOL|Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
3106536|NCT02220205|Active Comparator|PelvicSim|Participants randomized to this arm practice IUD insertion on the PelvicSim for 30 minutes.
3106537|NCT02220205|Placebo Comparator|Manufacturer model|Participants randomized to this arm practice IUD insertion on models provided by the IUD manufacturer for 30 minutes.
3106538|NCT02220712|Experimental|Drug: OPC-14597 IMD|
3106539|NCT02220725|Experimental|Andexanet 800mg bolus (Part I)|Andexanet (antidote) - 800 mg bolus
3106540|NCT02220725|Experimental|Andexanet 800mg + 960mg (Part II)|800 mg bolus + 960 mg infusion (8 mg/min)
3106541|NCT02220764|Experimental|Tooth-supported|Long-span tooth-supported zirconia based fixed dental prostheses
3106542|NCT02220764|Active Comparator|Implant-supported|Long-span implant-supported zirconia based fixed dental prostheses
3106543|NCT02220855|Experimental|BKM120|BKM120, 100mg capsule for oral use, taken once daily for two or more months for a maximum of one year. Each cycle is 28 days.
3469151|NCT03889652||Combined cataract and glaucoma group|Group 2 includes patients who are diagnosed with POAG controlled on medical treatment and have cataract and planned for cataract extraction only OCT is done before and after cataract extraction
3469152|NCT03889366|Experimental|NXP001 Oral Capsule|
3106546|NCT02220907|Experimental|Teneligliptin/Canagliflozin|Patients receive Teneligliptin and Canagliflozin once daily for 52 weeks.
3106547|NCT02220920|Experimental|Canagliflozin (TA-7284) ＋insulin|
3106548|NCT02220920|Placebo Comparator|Placebo＋insulin|
3106549|NCT02220998|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
3106550|NCT02220998|Experimental|SOF+RBV|SOF+RBV for 12 weeks
3469153|NCT03889366|Experimental|NXP001 Oral Suspension|
3469154|NCT03889366|Active Comparator|Emend®|
3106553|NCT02221219|Placebo Comparator|immediate cord clamp & placebo IV solution|This Arm will receive immediate clamp of umbilical cord at birth, and an intravenous delivery of placebo drug solution (diluent for active drug, indomethacin) within the first 12hrs of life.
3106554|NCT02221219|Experimental|delay cord clamp & placebo IV solution|A delay in cord clamp for 45 seconds will be instituted in the delivery room. Placebo drug solution will be administered within 12hrs post-birth.
3106555|NCT02221219|Active Comparator|immediate cord clamp & indomethacin IV|Umbilical cord will be clamped immediately at birth. Indomethacin will be administered IV, starting within 12hrs of life (0.1mg/kg every 24 hrs for three total doses.This intervention is considered 'standard care' at many Neonatology medical facilities. The dose of indomethacin has been shown to be effective in reducing brain bleeds in preterm infants (although there are also data showing safety concerns).
3469155|NCT03889613|Experimental|all patients|All enrolled patients- prospective observation (all patients are followed using videocapsule)
3469156|NCT03889353|Experimental|BCI sessions|up to 3 test sessions (Day-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (Day 1-Day 5 and Day 8-Day 12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
3469157|NCT03888924|Experimental|BCG treated patients|a single dose of Bacille Calmette-Guerin vaccine
3469158|NCT03888924|Placebo Comparator|Placebo treated patients|a single dose of placebo.
3469159|NCT03889041||Caregivers of children with EA-TEF|Caregivers of children with esophageal atresia and tracheoesophageal fistula will be included in the study.
3106556|NCT02221219|Experimental|indomethacin iv & delayed cord clamp|A delay in cord clamp of 45 seconds will be instituted in the delivery room. In addition, indomethacin will be administered iv (initiated within 12hrs of life), 0.1mg/kg every 24 hrs for three total doses.
3106557|NCT02221284||Alogliptin|Alogliptin 25 milligram (mg), tablets, orally, once daily, up to 12 months, along with an insulin preparations, with a rapid-acting insulin secretagogue (Glinide), with a SGLT-2 inhibitor, or the other diabetic drugs within 3 months prior to the start of alogliptin treatment or during the alogliptin treatment period in routine medical care.
3106558|NCT02221349|Other|oxalate liquid & gel plus SnF2 paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Stannous fluoride paste, self applied
3106559|NCT02221349|Other|oxalate liquid & gel plus NaF paste|Potassium oxalate liquid, professionally applied Potassium oxalate gel, self applied Sodium fluoride paste, self applied
3106560|NCT02221557|Experimental|New alloplastic bone graft material|
3106561|NCT02221648|Placebo Comparator|Placebo|Subjects will be randomization to receive injections with either the study drug (abobotulinumtoxinA) or the placebo group. The subjects will be blinded to which intervention they will receive.
3106562|NCT02221648|Active Comparator|AbobotulinumtoxinA Treatment|Subjects will be randomized to receive intervention injections with the study drug arbobotulinumtoxinA.
3106563|NCT02221674|Experimental|Tapentadol|Tapentadol 4 mg/mL immediate release oral solution, single dose post-operatively.
3106564|NCT02221739|Experimental|Ipilimumab + radiotherapy|Patients receive ipilimumab (Ipi) 3mg/kg i.v. over 90 minutes, within 24 hours of starting radiotherapy (RT) to the biopsied lesion, 6 Gy x5, later changed to 9.5 Gy x3 (conformally or by intensity modulated RT (IMRT) with image guidance to maximally spare normal tissue). Ipilimumab is repeated on days 22, 43 (for patients who consent to the first biopsy), and 64. Repeat biopsy is performed between day 22-29, and patients are re-imaged between day 81-88 and evaluated for response (defined as an objective response by irRC of the measurable metastatic sites outside the radiation field).
3106565|NCT02221869|Experimental|Xyrem|Active Xyrem at a dose ≤9 g/night
3106566|NCT02221869|Placebo Comparator|Xyrem Placebo|Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
3106567|NCT02221882|Experimental|LY3164530|LY3164530 in escalating dose cohorts given intravenously (IV) once on Days 1 and 15 or on Days 1, 8, 15, and 22 of a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3106568|NCT02221947|Active Comparator|Bryostatin 1|single dose of 25 μg/m2 bryostatin, intravenous infusion over 1 hour
3106569|NCT02221947|Placebo Comparator|placebo|single dose of placebo, intravenous infusion over 1 hour
3106570|NCT02222129|Active Comparator|Bupivacaine|Surgical site infiltration of 0.25% bupivacaine.
3106571|NCT02222129|Experimental|Liposomal bupivacaine|Surgical site infiltration of liposomal bupivacaine.
3106572|NCT02222181|Experimental|Pharmacotherapy follow-up|patients with Alzheimer's disease
3106573|NCT02222207|Experimental|Regorafenib [A]|Part A: Patients will receive Regorafenib eye drops
3106574|NCT02222207|Experimental|Regorafenib [B1]|Part B: Regorafenib eye drops dose 1; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106575|NCT02222207|Experimental|Regorafenib [B2]|Part B: Regorafenib eye drops dose 2; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106576|NCT02222207|Experimental|Regorafenib [B3]|Part B: Regorafenib eye drops dose 3; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106577|NCT02222207|Experimental|Regorafenib [B4]|Part B: Regorafenib eye drops dose 4; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106578|NCT02222207|Experimental|Regorafenib [B5]|Part B: Regorafenib eye drops dose 5; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106579|NCT02222207|Experimental|Regorafenib [B6]|Part B: Regorafenib eye drops dose 6; plus sham IVT (Intravitreal therapy) once every 4 weeks
3106580|NCT02222207|Active Comparator|Ranibizumab|Ranibizumab IVT once every 4 weeks; plus placebo eye drops to match the regorafenib eye drop regimens
3106581|NCT02222246|Experimental|Patient Specific dose of Morphine Sulfate or Hydromorphone|A patient-specific analgesic protocol for use in the ED to manage VOC crises. Following randomization, a patient's healthcare team will develop a specific analgesic protocol for use during future ED visits for VOC occurring during the study period (up to 5 visits). Treatment protocols will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous). Dosage and frequency will be based on a patient's prior treatment history.
3106582|NCT02222246|Active Comparator|Standard dose of Morphine Sulfate or Hydromorphone|A standardized analgesic protocol (based on recent NHLBI recommendations) for use in the ED to manage VOC crises. Treatment protocol will include either morphine sulfate or hydromorphone (delivered intravenous or sub-cutaneous), with dosage based on weight. Repeat doses of opioids may be administered every 20-30 minutes as needed, although dosage will be maintained or provided at no more than 25% above the initial dose.
3106583|NCT02222337|Active Comparator|Nueva Vida Intervention|Nueva Vida Intervention consists of 8 sessions of a skills-building group held twice a month for 4 months. Latina survivors and their caregivers arrive at the group together, separate into different rooms to learn the coping and communication skills, and then join together for discussion of the topic.
3106584|NCT02222337|No Intervention|Usual Care|Usual care as provided by each of our 4 community-based organization partners. Usual care can include but is not limited to support groups, patient navigation, individual, couple or family therapy.
3106585|NCT02222493|Experimental|PF-06438179|
3106586|NCT02222493|Active Comparator|Infliximab|
3106587|NCT02222558|Experimental|Period 1: Single Dose|Period 1: Each study subject will receive an escalating single dose of TSX-002 (60, 90, 120, 180, 240 mg), with a minimum 3 day wash-out between each of the 5 escalating doses. After completing the 240 mg dose, a 7 day wash-out period will occur prior to Period 2.
3106588|NCT02222558|Experimental|Period 2: Two Times Daily Dosing 90 mg|Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days.
3106589|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3106590|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 90 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3106591|NCT02222558|Experimental|Period 3: Two Times Daily Dosing 180 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted two times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3106592|NCT02222558|Experimental|Period 3: Three Times Daily Dosing 120 mg|"Period 2: Each study subject dose is 90 mg twice daily of TSX-002, fasted for 17 days. On Day 15, a serum Testosterone level will be drawn and used to dose titrate and randomized to BID or TID (as eligible). The TSX-002 dose will be down or up titrated.~Period 3: Begins Day 18 with the first adjusted TSX-002 dose administered fasted three times daily. The Testosterone level on Day 22 will be used to perform the final, TSX-002 dose adjustment."
3106593|NCT02222610|Experimental|Cohort A|"Subject's will receive monthly treatment of an intravitreal injection of 0.5 mg ranibizumab for 48 weeks.~Starting at week 52, subject's will enter a treat & extend regime, if a subject achieves a dry macula. For a macula to be considered dry persistent or recurrent fluid must be resolved on spectral domain (SD)-optical coherence tomography (OCT). The interval between injections will not exceed 12 weeks. After a subject is extended beyond 4-weeks & develops recurrent disease activity, the eye is treated & the treatment interval for the next visit is reduced by 1 week, compared to the previous treatment interval. The interval between treatments will be reduced by 1-week intervals until a dry macula is again established. Once a dry macula is again achieved, the interval between visits will be extended by 1-week intervals again."
3106594|NCT02222610|Experimental|Cohort B|"Subject's receive monthly treatment of IVT of 0.5 mg ranibizumab for 48 weeks. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia based on 120° or greater wide field angiography. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
3106595|NCT02222610|Experimental|Cohort C|"Subject's will receive 3 consecutive monthly doses of IVT 0.5 mg ranibizumab followed by PRN treatment with 0.5 mg ranibizumab intravitreal injection. 1 week after the initial dose of IVT ranibizumab, the subject will have peripheral targeted-retinal photocoagulation (TRP) to areas of peripheral retinal ischemia. After the first session of TRP, subjects will have a repeat wide field angiogram at 12 weeks & 24 weeks & will receive additional TRP as needed (PRN) to areas of peripheral retinal ischemia.~Starting at week 52, subject's will enter a treat & extend regime as described in cohort A."
3106596|NCT02222688|Experimental|Cirmtuzumab 0.015 - 0.03 mg/kg|Cohort 1: Cirmtuzumab 0.015 mg/kg for two 14-day cycles followed by cirmtuzumab 0.03 mg/kg for two 14-day cycles via intravenous (IV) infusion
3106597|NCT02222688|Experimental|Cirmtuzumab 0.06 - 0.12 - 0.24 mg/kg|Cohort 2: Cirmtuzumab 0.06 mg/kg for one 14-day cycle, followed by cirmtuzumab 0.12 mg/kg for one 14-day cycle, followed by 0.24 mg/kg for two 14-day cycles via IV infusion
3106598|NCT02222688|Experimental|Cirmtuzumab 0.5 - 1.0 mg/kg|Cohort 3: Cirmtuzumab 0.5 mg/kg for one 14-day cycle, followed by cirmtuzumab 1.0 mg/kg for three 14-day cycles via IV infusion
3106599|NCT02222688|Experimental|Cirmtuzumab 2.0 - 4.0 mg/kg|Cohort 4: Cirmtuzumab 2.0 mg/kg for two 14-day cycles, followed by cirmtuzumab 4.0 mg/kg for two 14-day cycles via IV infusion
3106600|NCT02222688|Experimental|Cirmtuzumab 8 mg/kg|Cohort 5: Cirmtuzumab 8 mg/kg for four 14-day cycles via IV infusion
3106601|NCT02222688|Experimental|Cirmtuzumab 16 mg/kg|Cohort 6: Cirmtuzumab 16 mg/kg for four 14-day cycles (or maximum 2000 mg) via IV infusion
3106602|NCT02222688|Experimental|Cirmtuzumab 20 mg/kg|Cohort 7: Cirmtuzumab 20 mg/kg for four 14-day cycles (or maximum 2000 mg)
3106603|NCT02222714|Active Comparator|120 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3106604|NCT02222714|Active Comparator|240 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3106605|NCT02222714|Active Comparator|360 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3106606|NCT02222714|Active Comparator|540 µg/kg of 3K3A-APC|3K3A-APC, q12h for up to 5 doses
3106607|NCT02222714|Placebo Comparator|Placebo|Matching placebo, q12h for up to 5 doses
3106608|NCT02222818|Other|Group A: CAFR first|Subjects randomized to Group A will receive CAFR first, then cross over to CAFRPlus.
3106609|NCT02222818|Other|Group B: CAFRPlus first|Subjects randomized to Group B will receive CAFRPlus first, then cross over to CAFR.
3106610|NCT02222870|Experimental|Fluzone Study Group 1|Participants at 6 months to < 36 months age at enrollment
3106611|NCT02222870|Experimental|Fluzone Study Group 2|Participants at 3 years to < 9 years of age at enrollment
3106612|NCT02222896|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3106613|NCT02222896|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3106614|NCT02222896|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3106615|NCT02222922|Experimental|PF-06647020 Q3W|Investigational drug infused over 60 minutes once every 21 days.
3106616|NCT02222922|Experimental|Drug-drug interaction (DDI)|PF-06647020 combined with fluconazole
3106617|NCT02222922|Experimental|PF-06647020 Q2W|Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
3106618|NCT02222922|Experimental|PF-06647020 combined with Avelumab|PF-06647020 combined with Avelumab administered by infusion
3106619|NCT02223065|Experimental|Treatment A|Single oral dose of saxagliptin tablet coadministered with dapagliflozin tablet
3106620|NCT02223065|Experimental|Treatment B|Single oral dose of FDC (fixed-dose combination) tablet
3106621|NCT02223260|Experimental|dabigatran|open label arm with dabigatran oral liquid formulation as single dose
3106622|NCT02223338|Active Comparator|Ciprofloxacin|"Ciprofloxacin:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These patients must have been instructed to use post-injection topical ciprofloxacin 0.3% 4x daily for 3 days. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
3106623|NCT02223338|Active Comparator|Standard Aseptic Technique|"Standard Aseptic Technique:~Patients with choroidal neovascularization due to wet age-related macular degeneration or any other cause, clinically significant macular edema or cystoid macular edema over age 18 who have been treated with at least 3 monthly intravitreal injections of an anti-Vascular Endothelial Growth Factor (anti-VEGF) agent in the last 6 months. These injections must have been given with povidone-iodine only applied to the injection site and conjunctival fornix prior to injection, but no post-injection antibiotics were given. On the visit of their next injection, a conjunctival swab will be taken in the inferior fornix prior to instillation of any ophthalmic drops."
3106624|NCT02223351|Other|400mg ASP2151|400mg ASP2151 alone followed by 400mg ASP2151 + 600mg ritonavir
3106625|NCT02223351|Other|1200mg ASP2151|1200mg ASP2151 alone followed by 1200mg ASP2151 + 600mg ritonavir
3106626|NCT02223364|Active Comparator|Peripheral Nerve Block (PNB)|This group received a continuous femoral nerve block and a single injection sciatic nerve block consisting of the following: Peripheral nerve blocks with Bupivacaine.
3106627|NCT02223364|Active Comparator|Ropivacaine (PAI-R)|This group received intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
3106628|NCT02223364|Active Comparator|Liposomal Bupivacaine (PAI-L)|This group received Intra articular injection with liposomal bupivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Following the current, standardized practice for periarticular infiltration, approximately 30 - 40 mL of solution was injected into the posterior capsule just prior to cementing the implants in place and 40 - 50 mL of solution injected into the medial and lateral retinaculum while the cement was hardening and prior to deflation of the tourniquet. The remaining volume of approximately 40 mL was injected into the quadriceps tendon and subcutaneous tissue prior to skin closure.
3106629|NCT02223390|Experimental|Mental health treatment|The experimental condition, ImpACT, was developed in the pilot phase of the study. The intervention will be 4 sessions of individual psychological treatment related to stress, coping, and HIV adherence, followed by three group sessions. Sessions will follow an intervention manual and be delivered by a psychiatric nurse (or equivalent nonspecialist in mental health) who is supervised by a trained clinical psychologist.
3106630|NCT02223390|No Intervention|Standard of Care|Participants in standard of care will receive the three-session adherence counseling delivered in the clinic, along with referrals for trauma treatment.
3106631|NCT02223429|Experimental|OT + placebo|The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
3106632|NCT02223429|Experimental|AVP + placebo|The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
3106633|NCT02223455|Placebo Comparator|Single Hand Hygiene Sign|Wards/units in this arm of the study will have the same hand hygiene sign posted by the hand sanitizer dispensers outside each patient room. The sign will not change.
3106634|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Monthly|Intervention: Hand Hygiene Signs Changed Monthly Hand hygiene signs will be changed monthly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
3106635|NCT02223455|Active Comparator|Hand Hygiene Signs Changed Weekly|Intervention: Hand Hygiene Signs Changed Weekly Hand hygiene signs will be changed weekly on wards/units randomized to this arm of the study. Signs will be posted by the hand hygiene sanitizer outside each patient room.
3106636|NCT02223520|Active Comparator|Mupirocin and Chlorhexidine|Participants will apply 2% intranasal mupirocin twice a day for five days and cleanse with 2% chlorhexidine cloths once a day for five days.
3106637|NCT02223520|Placebo Comparator|Placebo ointment and placebo cloths|Participants will apply 2% petrolatum intranasal placebo ointment twice a day for five days and cleanse with 2% non-medicated soap placebo cloths once a day for five days.
3106638|NCT02223546||healthy subject|healthy subject, every 3 hour measurement
3106639|NCT02223637||Exposure group|"Pregnant women who were exposed to~≥1 dose of Menveo vaccine within 28 days prior to conception or at any time during pregnancy were included."
3106640|NCT02223650|Experimental|Overminus Treatment|2.50D overminus spectacles
3106641|NCT02223650|Active Comparator|Non-overminus Treatment|spectacles without overminus or no spectacles
3106642|NCT02223689|Experimental|Skin Affix|Surgical adhesive
3106643|NCT02223702|Active Comparator|amoxicillin+metronidazole|amoxicillin+metronidazole group received a combination of 500 mg of amoxicillin and 500 mg metronidazole three times per day for 7 days.
3106644|NCT02223702|Experimental|moxifloxacin|The moxifloxacin group received 400 mg moxifloxacin, once in a day for 7 days.
3106645|NCT02223715||CDI|
3106646|NCT02223754|Active Comparator|lotrafilcon B / etafilcon A|Subject randomized to this sequence will first be dispensed the lotrafilcon B contact lens and then the etafilcon A contact lens.
3106647|NCT02223754|Experimental|etafilcon A / lotrafilcon B|Subject randomized to this sequence will first be dispensed the etafilcon A contact lens and then the lotrafilcon B contact lens.
3106648|NCT02223793|Experimental|No information on high risk factor levels but lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline. However, they will receive general information on how to lower risk factor levels in 8 weeks
3106649|NCT02223793|Experimental|No information on high risk factor levels nor lifestyle advice|In this arm, participants will not be informed about their measured levels of the different cardiovascular risk factors, nor receiving lifestyle advices at baseline
3106650|NCT02223793|Experimental|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will not be informed about their measured levels of the different cardiovascular risk factors at baseline, and receive general information on how to lower risk factor levels in 8 weeks
3106651|NCT02223858|Experimental|Positive Activities (PA)|Positive Activities (PA) Program
3106652|NCT02223858|Active Comparator|Attention Control (AC)|Attention Control (AC) Program
3106653|NCT02223871|Experimental|ACT-451840 500 mg|All the participants were infected with Plasmodium falciparum parasites (malaria) using malaria-infected human erythrocytes. When the parasitemia reached 1000 counts/mL, all the participants received 500 mg of ACT-451840 as a single oral dose. Compulsory commencement of treatment with Riamet® (artemether-lumefantrine) to ensure complete clearance of any gametocytes, occurred 16 days after ACT-451840 administration (or earlier if required) for all participants. Primaquine was to be administered as a single dose only in participants for whom gametocytes were still identified after administration of Riamet® rescue medication
3106654|NCT02224053|Experimental|AZD9291 and omeprazole|Sequential treatments of AZD9291 + omeprazole followed by AZD9291 alone, with a washout period in between.
3106655|NCT02224157|Experimental|"Symbicort as needed+placebo Pulmicort bid"|Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid
3106656|NCT02224157|Active Comparator|"Pulmicort bid + terbutaline as needed"|Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'
3106657|NCT02224274|Active Comparator|Clopidogrel|These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.
3106658|NCT02224274|Experimental|Ticagrelor|These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.
3106659|NCT02224313|No Intervention|1.Premenopausal women|No treatment
3106660|NCT02224313|Experimental|2.Postmenopausal women with hormones|"Oral hormone therapy will be given to women in this group. Daily dose of oral estradiol 1 mg will be given the first 14 days after enrollment. Then a daily dose of oral estradiol 1 mg and progesterone 100 mg for 14 days will be given during the following 14 days."
3106661|NCT02224404|Experimental|Fast Gelling Dressing|
3106662|NCT02224482|No Intervention|Control|Print materials
3106663|NCT02224482|Active Comparator|Intervention Group|PROGRESS
3106664|NCT02224508||Opioid Risk Reduction Initiative|Opioid risk reduction initiative for chronic opioid therapy patients implemented in Group Health integrated group practice clinics.
3106665|NCT02224508||Usual Care|Usual care for management of chronic opioid therapy patients implemented in Group Health network care settings.
3106666|NCT02224560|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3106667|NCT02224560|Experimental|GWP42003-P 10 mg/kg/day Dose|Participants received GWP42003-P 10 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 10 mg/kg/day over 7 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3106668|NCT02224560|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD) volume matched to 1 of the 2 dose levels (10 or 20 mg/kg/day) administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 7 to 11 days according to the matched IMP group (7 or 11 days for the 10 or 20 mg/kg/day GWP42003-P groups, respectively) and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.
3106669|NCT02224612|Active Comparator|Children 4-5 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
3106670|NCT02224612|Active Comparator|Children 6-9 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
3106671|NCT02224612|Active Comparator|Children 10-12 yrs|"Medline Pediatric Face Mask KC Childs Face Mask~Comparison of Medline Pediatric Face Masks and KC Childs Mask which are both single use disposable masks. Each mask (two in total) were worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment."
3106672|NCT02224625|Experimental|2% CHG Cloth|Chlorhexidine Gluconate 2%
3106673|NCT02224625|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3106674|NCT02224625|Active Comparator|DynaHex (2% CHG)|Chlorhexidine Gluconate 2% solution
3106675|NCT02224625|Sham Comparator|Saline|0.9% sodium chloride
3106676|NCT02224625|Active Comparator|Sodium Lauryl Sulfate (SLS)|Sodium lauryl sulfate to produce mild irritation as a positive control
3106677|NCT02224638|Active Comparator|TheraHoney HD|Honey product
3106678|NCT02224638|Active Comparator|SkinTegrity|Skin moisturizer
3106679|NCT02224664|Experimental|Cohort 3|Titration of PF-06649751 up to 5 mg QD
3106680|NCT02224664|Experimental|Cohort 4|Titration of PF-06649751 up to 15 mg QD
3106681|NCT02224664|Experimental|Cohort 5|Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
3106682|NCT02224664|Experimental|Cohort 6|Titration of PF-0649751 up to 25 mg QD
3106683|NCT02224690|Experimental|GWP42003-P 20 mg/kg/day Dose|Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3106684|NCT02224690|Placebo Comparator|Placebo|Participants received placebo (0 mg/mL CBD), volume matched to the 20 mg/kg/day dose, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
3106685|NCT02224703|Experimental|10 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/milliliter [mL] cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 10 mg/kg/day dose was defined as 50% of the 20 mg/kg/day dose.
3106686|NCT02224703|Experimental|20 mg/kg/day GWP42003-P|GWP42003-P oral solution (100 mg/mL cannabidiol in sesame oil with anhydrous ethanol with added sweetener [sucralose] and strawberry flavoring). The 20 mg/kg/day dose was recommended by the DSMC after assessment of safety and pharmacokinetic data from Part A of study GWEP1332 (NCT02091206).
3106687|NCT02224703|Placebo Comparator|Placebo Control|Excipients only. Participants were pooled from 2 placebo cohorts, half receiving 10 mg/kg/day dose-volume equivalent and half receiving 20 mg/kg/day dose-volume equivalent.
3106688|NCT02224729|Experimental|Bendamustine, Bortezomib, Dexamethasone (Standard)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2; bortezomib SC on days 1, 8, 15, and 22; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 35 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than a VGPR or with more than 10% bone marrow plasmacytosis may receive 2 additional courses.
3106689|NCT02224755|Experimental|HeartMate 3 LVAS (HM3 LVAS)|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
3106690|NCT02224755|Active Comparator|HeartMate II LVAS|Evaluation of the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure.
3106691|NCT02224820|Experimental|Intravenous IdeS|One or two doses of IdeS in ascending doses
3106692|NCT02224846|Experimental|2.5 mg/5 mg tadalafil|2.5 mg tadalafil orally once daily for 3 months (Period 1) and then 5 mg tadalafil orally once daily for 21 months (Period 2).
3106693|NCT02224846|Experimental|5 mg tadalafil|5 mg tadalafil orally once daily for 24 months (Period 1 and Period 2).
3106694|NCT02225080||Duragen Secure|Have undergone a neurosurgical procedure where DuraGen® Secure has been implanted
3106695|NCT02225106|Experimental|Open label methylphenidate treatment|Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily.
3106696|NCT02225132|Experimental|1|This is a one arm, open-label, non- randomized pilot study to evaluate the effect of algorithm- based HU dosing on the HbF response, the ability to titrate each patient to the MTD of HU, acute complications, and organ function in patients with HbSS.
3106697|NCT02225223|Other|No previous Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
3106698|NCT02225223|Other|Failed/Refuse further Radiation Therapy|Targeted radio-frequency ablation using the STAR™ Tumor Ablation System and vertebral augmentation using the StabiliT® Vertebral Augmentation System.
3106699|NCT02225353|Experimental|Progesterone Cervical Pessary 6.3 g|90 pregnant women with Progesterone Cervical Pessary
3106700|NCT02225353|Experimental|Progesterone Cervical Pessary 7.7 g|90 pregnant women with Progesterone Cervical Pessary
3106701|NCT02225353|Active Comparator|Progesterone 200 mg vaginal capsules|90 pregnant women using Progesterone 200 mg vaginal capsules daily
3106702|NCT02225587|Experimental|Group 1: Prevnar 13™ → Pneumovax™ 23 → Placebo|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Pneumovax™ 23 0.5 mL intramuscular injection at Week 8, and Placebo 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
3106703|NCT02225587|Placebo Comparator|Group 2: Prevnar 13™ → Placebo → Pneumovax™ 23|Prevnar 13™ 0.5 mL intramuscular injection on Day 1, Placebo 0.5 mL intramuscular injection at Week 8, and Pneumovax™ 23 0.5 mL intramuscular injection at Week 26. Injections are to be administered in alternating limbs, if possible.
3106704|NCT02225665|Experimental|Cohort 1|
3106705|NCT02225665|Experimental|Cohort 2|
3106706|NCT02225743||Joint Arthroplasty|Participants undergoing joint replacement
3106707|NCT02225860|Active Comparator|Diet and Water adjustment|Reduction in dietary salt and protein intake
3106708|NCT02225860|No Intervention|Control|Continue with usual diet
3106709|NCT02225925|Experimental|Dynamic dosimetry brachytherapy|Cohort treated with dynamic dosimetry brachytherapy
3106710|NCT02226003|Experimental|Ertugliflozin 5 mg and Sitagliptin 100 mg|Ertugliflozin, 5 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks. Placebo to ertugliflozin, 10 mg, administered orally, once daily for 26 weeks.
3106711|NCT02226003|Experimental|Ertugliflozin 15 mg and Sitagliptin 100 mg|Ertugliflozin, 15 mg, administered orally, once daily for 26 weeks. Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
3106712|NCT02226003|Placebo Comparator|Placebo to Ertugliflozin and Placebo to Sitagliptin|Placebo to ertugliflozin, 5 mg and 10 mg, administered orally, once daily for 26 weeks. Placebo to sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
3106713|NCT02226120|Experimental|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
3106714|NCT02226159|Active Comparator|Lidocaine|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc normal saline
3106715|NCT02226159|Experimental|Lidocaine with Dexamethasone|Cervical transforaminal injection: 1.0 cc Lidocaine 1.0% with 1.0 cc of Dexamethasone (10 mg/cc)
3106716|NCT02226172|Experimental|Arm A|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
3106717|NCT02226172|Placebo Comparator|Arm B|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
3106718|NCT02226198|Active Comparator|Rosuvastatin|6-week treatment period, and after crossover finished a 12-week efficacy maintenance phase for all patients
3106719|NCT02226198|Placebo Comparator|Placebo|6 weeks treatment during crossover
3106720|NCT02226549|Experimental|LDV/SOF+VDV|Participants will receive LDV/SOF+VDV for 8 weeks.
3106721|NCT02226549|Experimental|LDV/SOF+VDV+RBV|Participants will receive LDV/SOF+VDV+RBV for 8 weeks.
3106722|NCT02226562|Experimental|Potassium nitrate and sodium fluoride|3.0% weight by weight (w/w) potassium nitrate mouthwash with 0.02% sodium fluoride
3106723|NCT02226562|Other|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as sodium monofluorophosphate (SMFP)
3106724|NCT02226653|Experimental|Evacetrapib (reference)|Single oral dose of 1 tablet of evacetrapib on Day 1 of up to three of five periods
3106725|NCT02226653|Experimental|Evacetrapib (test)|Single oral dose of 2 tablets of evacetrapib on Day 1 of up to three of five periods
3106726|NCT02226796|Active Comparator|Prime Condition|The primed (PRIME) condition is an intervention that will consist of presentation of a-tDCS for 20 minutes to the dorsolateral prefrontal cortex prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
3106727|NCT02226796|Active Comparator|Non-Prime Condition/Control|The non-primed (NON-PRIME) condition, or sham controlled, is an intervention that will consist of presentation of sham tDCS to the dorsolateral prefrontal cortex for 20 minutes prior to 40 minutes of behavioral naming treatment, while the subject sits comfortably in a chair.
3106728|NCT02226965|Experimental|PNT2258|"PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle. Treatment may continue unless there is disease progression or the occurrence of unacceptable toxicity for a total of 8 induction cycles of therapy. Subjects with CR/CMR, PR/PMR or SD/NMR at the end-of-cycle 8 scan then receive ongoing PNT2258 therapy at a dose of 100 mg/m2 on days 1-4 of a 28 day cycle until progressive disease, the occurrence of unacceptable toxicity, non-compliance, voluntary withdrawal or if in the opinion of the investigator the subject is no longer benefiting from exposure to PNT2258."
3106729|NCT02227108|Experimental|Moxetumomab Pasudotox 40 mcg/kg|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
3106730|NCT02227121|Experimental|VT/VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and defibrillation will be carried out as the invention in all subjects undergoing study procedures.
3106731|NCT02227147|Experimental|rhNGF 20 µg/ml|rhNGF 20 µg/ml eye drops solution, formulation containing anti-oxidant
3106732|NCT02227147|Placebo Comparator|Placebo|Vehicle: formulation containing anti-oxidant
3106736|NCT02227238|Experimental|DTG arm|Subjects will receive one oral tablet of 50 mg DTG once daily plus two NRTIs selected by the investigator
3106737|NCT02227238|Active Comparator|LPV/RTV arm|Subjects will receive four oral tablets of200/50 mg LPV/RTV once daily or two oral tablets of 200/50 mg LPV/RTV twice daily plus two NRTIs selected by the investigator
3106738|NCT02227316|Experimental|Intravenous Ibuprofen|Ibuprofen 800mg IV piggyback and Saline IVP q 6 hours x 4 during uterine fibroid embolization
3106739|NCT02227316|Experimental|Intravenous acetaminophen|Acetaminophen 1 gram IV piggyback and Saline IVP q6 hours x 4 during uterine fibroid embolization
3106740|NCT02227316|Experimental|IV ibuprofen/IV acetaminophen|Ibuprofen 800 mg/ Acetaminophen 1 gram IV piggyback and Saline IVP 6 hours x 4 during uterine fibroid embolization
3106741|NCT02227316|Active Comparator|Intravenous placebo/Intravenous placebo|Saline/Saline IV piggyback and IVP Ketorolac 30 mg q6 hours x 4 during uterine fibroid embolization
3106742|NCT02227329|Experimental|Ethanol Lock and Normal Saline|All patients randomized to the ELT group will receive 3ml of 70% ethanol and saline flush.
3106743|NCT02227329|Active Comparator|Heparin and Normal Saline|All patients randomized to this group will receive Heparin lock + saline infusion (current standard of care).
3106744|NCT02227368|Experimental|Ticagrelor|26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
3106745|NCT02227368|Active Comparator|Aspirin|26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
3106746|NCT02227446|Experimental|Vancomycin Antibotic Powder|"Participants in the treatment group will receive the study intervention of a maximum dose of 1000mg of Vancomycin antibiotic powder in their wound bed, which is placed right before wound closure. Vancomycin antibiotic powder may be combined with normal saline as per clinical practice at the participating institution.~In addition, participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection."
3106747|NCT02227446|No Intervention|Standard of Care|Participants in this group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection. Participants in this group will not receive local Vancomycin antibiotic powder.
3106748|NCT02227485|Active Comparator|Chlorhexidine (0.2%)|Chlorhexidine (0.2%) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
3106749|NCT02227485|Experimental|Punica granatum Pleniflora mouth rinse|Punica granatum Pleniflora (Golnaar) mouth rinse, 10 ml for 2 minutes every night for 2 weeks and tooth bleaching (one time) after using mouth rinse.
3106750|NCT02227667|Experimental|Patients with Advanced Colorectal Cancer|This will be a Simon two-stage design, single arm, phase II study. All subjects will receive MEDI4736 via IV infusion. Subjects will continue treatment for 12 months, or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reasons to discontinue treatment occur. Following the 12-month treatment period, subjects without evidence for progressive disease or other reason to discontinue treatment will be monitored without further treatment. Upon evidence of PD (with or without confirmation according to RECIST 1.1) during the monitoring period, administration of MEDI4736 may resume at the Q2W schedule, for up to another 12 months. The same treatment guidelines followed during the initial 12-month treatment period will be followed during the retreatment period, including the same dose and frequency of treatments and the same schedule of assessments.
3106751|NCT02227693|Experimental|avatrombopag 20-mg|20 mg avatrombopag (1 x 20 mg tablet and 2 x 20 mg matching placebo tablets) once daily on Days 1 through 5
3106752|NCT02227693|Experimental|avatrombopag 40-mg|40 mg avatrombopag (2 x 20 mg tablets and 1 x 20 mg matching placebo tablet) once daily on Days 1 through 5
3106753|NCT02227693|Experimental|avatrombopag 60-mg|60 mg avatrombopag (3 x 20 mg tablets) once daily on Days 1 through 5
3106754|NCT02227693|Placebo Comparator|placebo l|Placebo (3 x 20-mg matching placebo tablets) once daily on Days 1 through 5
3106755|NCT02227706|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
3106756|NCT02227706|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3106757|NCT02227758||implanted chronic migraine patients|Patients diagnosed with chronic migraine, failed 3 or more preventative drugs, with at least moderate disability, and implanted with a St. Jude Medical Conformité Européenne approved implantable neurostimulation system
3106758|NCT02227784|Experimental|Atorvastatin + Evacetrapib|Atorvastatin 40 milligrams (mg) orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus evacetrapib 130 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3106759|NCT02227784|Active Comparator|Atorvastatin 80 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 80 mg orally with placebo for blinding once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3106760|NCT02227784|Active Comparator|Atorvastatin + Ezetimibe|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg plus ezetimibe 10 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3106761|NCT02227784|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg orally once daily for 28 days during lead in period. Atorvastatin 40 mg with placebo for blinding orally once daily for 90 days. Open label extension (atorvastatin 40 mg plus evacetrapib 130 mg) is available for compliant participants.
3106762|NCT02227810|Experimental|electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle for 20 min/session, twice daily for 10 days
3106763|NCT02227810|Sham Comparator|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
3106764|NCT02227836|Experimental|Allergy Patch Testing APT|"Patient will undergo APT testing per the following protocol:~2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.~Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits~The patches will be removed at 48 hours, and results read at 72 and 120 hours after application~Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
3106765|NCT02227849|Experimental|Canagliflozin (TA-7284) ＋GLP-1 analogue|
3106766|NCT02227862|Experimental|Mylan's Insulin Glargine|Receive Mylan's Insulin Glargine plus insulin lispro.
3106767|NCT02227862|Active Comparator|Lantus®|Receive Lantus® plus insulin lispro
3106768|NCT02227875|Experimental|Mylan's insulin Glargine|receive Mylan's insulin Glargine
3106769|NCT02227875|Active Comparator|Lantus®|receive Lantus®
3106770|NCT02228096|Experimental|tisagenlecleucel (CTL019)|Pediatric patients with relapsed/refractory B-cell ALL
3106771|NCT02228174|Experimental|Subjects Treated with Sonata|Intervention: Intrauterine Ultrasound-Guided Radiofreq. Ablation System or the Sonata, which is a sonography guided transcervical ablation device intended for treatment of symptomatic uterine fibroids. Subjects with symptomatic uterine fibroids and heavy menstrual bleeding who met the study population selection criteria received treatment with Sonata.
3106772|NCT02228395|Experimental|Cohort 1|Participants received 1 single dose of placebo, PF-04958242 0.6 mg, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
3106773|NCT02228395|Experimental|Cohort 2|Participants received 1 single dose of PF-04958242 0.35 mg, placebo, and PF-04958242 0.8 mg orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
3106774|NCT02228395|Experimental|Cohort 3|Participants received 1 single dose of PF-04958242 0.35 mg, PF-04958242 0.6 mg, and placebo orally during 3 periods, respectively. There was at least a 10-day washout period between each dosing.
3106775|NCT02228408|Experimental|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35mg-3x/day ISD/HY 40 mg/75 mg-3x/day"
3106776|NCT02228408|Active Comparator|Placebo|Placebo will be administered Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
3106777|NCT02228460|Experimental|GZ/SAR402671|GZ/SAR402671 15 milligram (mg) once daily orally for 26 weeks.
3106778|NCT02228499||Asthma|children with asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
3106779|NCT02228499||Controls|Children with no history of asthma who were in middle school for the 2013-2014 school year will take surveys on health and quality of life
3106780|NCT02228564|Experimental|LIFESTREAM™|This is a single arm study. All subjects receive percutaneous transluminal angioplasty (PTA) and implantation of the LIFESTREAM™ covered stent.
3106781|NCT02228590|Other|APL-130277|open label baseline comparison
3106782|NCT02228681|Experimental|Everolimus and Letrozole|Everolimus 10 mg daily and Letrozole 2.5 mg PO daily
3106783|NCT02228681|Active Comparator|Hormonal Therapy|Tamoxifen 20 mg PO BID; on alternating weeks (even numbered) weeks, Medroxyprogesterone Acetate 200 mg PO daily with Tamoxifen 20 mg PO BID
3106784|NCT02228720|Experimental|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
3106785|NCT02228824|Experimental|Very low nicotine content cigarettes|
3106786|NCT02228824|Active Comparator|Normal nicotine content cigarettes|
3106787|NCT02228967|No Intervention|Usual Care|Those participants assigned to the usual care control group will be given a brochure on safe drinking limits, will be reminded of the 6-month follow-up, and thanked for their time.
3106788|NCT02228967|Active Comparator|SBIRT|"Those assigned to the SBIRT intervention group will receive 1 of 3 tracks:~Brief Intervention (BI) for At Risk Individuals (scores lower than 15) - Brief motivational intervention with feedback related to their use and change strategies.~Brief Treatment (BT) for High Risk Individuals (scores of 16-19) - Brief Intervention on site and be offered 6 individual confidential sessions with a civilian Brief Treatment Counselor over the phone.~Referral to Treatment (RT) for Severe Risk Individuals (scores of 20-40) - Brief Intervention on site and will be given a list of services where they may self-refer for further assessment and support."
3106789|NCT02228980|Experimental|Subjects aged 6 to 35 months (Group 1)|Participants aged 6 months to 35 months will receive two 0.25 mL doses of SP Shz TIV given 28 days apart.
3106790|NCT02228980|Experimental|Subjects aged 3 to 17 years (Group 2)|Participants aged 3 years to 17 years will receive a single 0.5 mL dose of SP Shz TIV
3106791|NCT02228980|Experimental|Subjects aged 18 to 60 years (Group 3)|Participants aged 18 years to 60 years will receive a single 0.5 mL dose of SP Shz TIV
3106792|NCT02228980|Experimental|Subjects aged 61 years or older (Group 4)|Participants aged 61 years or older will receive a single 0.5 mL dose of SP Shz TIV
3106793|NCT02229214|Experimental|VI-0521 (Qsymia)|"Days 1-3: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 4-6: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 7-9: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 10-28: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
3106794|NCT02229214|Placebo Comparator|Sugar pill|Days 1-28: Placebo
3106795|NCT02229227|Experimental|Albiglutide + Insulin Glargine Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will receive Albiglutide 30 milligrams (mg) weekly subcutaneous (SC) injection and insulin lispro dose will be downtitrated to half that used in the standardization period. At Week 4, Albiglutide will be uptitrated to 50 mg weekly SC injection and insulin lispro will be stopped for the remainder of the treatment Period. Insulin lispro may be re-introduced after Week 8 according to pre-defined hyperglycemia thresholds. Insulin will be adjusted according to protocol-defined insulin titration algorithms
3106796|NCT02229227|Experimental|Insulin Glargine + Insulin Lispro Arm|During standardization period, subjects will transit from basal bolus regimen received during screening period to insulin glargine plus insulin lispro. During treatment period, subject will continue with the same doses as at the end of the standardization period and doses will be adjusted according to protocol-defined insulin titration algorithms
3106797|NCT02229318|Experimental|FruitiVits|Daily administration of FruitiVits dietary supplement
3106798|NCT02229383|Experimental|Exenatide|Exenatide 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
3106799|NCT02229383|Placebo Comparator|Placebo|Placebo 2 mg 1 time per week + titrated basal insulin glargine with or without metformin
3106800|NCT02229396|Experimental|Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg|
3106801|NCT02229396|Experimental|Exenatide Once Weekly 2 mg Alone|
3106802|NCT02229396|Active Comparator|Dapagliflozin Once Daily 10 mg Alone|
3106803|NCT02229461|Experimental|IR ASA co-administered with naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg once daily (qd) in parallel with naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106804|NCT02229461|Experimental|IR ASA 30 min after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106805|NCT02229461|Experimental|IR ASA 8 hours after naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 8 hours after naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106806|NCT02229461|Active Comparator|IR ASA only|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106807|NCT02229461|Experimental|IR ASA 30 min before naproxen sodium|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes before naproxen sodium (Aleve, BAY117031) 220 mg qd for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106808|NCT02229461|Experimental|IR ASA 30 min after first dose of naproxen sodium bid|Confirmed eligible participants were randomized to be administered immediate release acetylsalicylic acid (IR ASA, Aspirin, BAYE4465) 81 mg qd 30 minutes after first dose of naproxen sodium (Aleve, BAY117031) 220 mg, followed by second dose of naproxen sodium 220 mg 12 hours after first dose, for 10 consecutive days. A 3-day IR ASA 81 mg qd Run-Out period was followed.
3106809|NCT02229474|Experimental|CST intervention|"We will use a two-group stepped-wedge design. Group 1 will receive the intervention immediately. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. We will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location."
3106810|NCT02229474|No Intervention|Group 2|and group 2 will have their intervention delayed until after the end of the group 1 intervention. This will also allow group 2 to act as controls for group 1 and allow further analysis as a controlled trial, during secondary analysis.
3106811|NCT02229487|Active Comparator|Normal Sleepers|Prediabetes patients with normal sleep duration (7-8 hours/ night) as measured objectively
3106812|NCT02229487|Experimental|Short Sleepers|Prediabetes patients with short sleep duration (<6 hours/night) as measured objectively
3106813|NCT02229513|No Intervention|Control|Normal cesarean technique.
3106814|NCT02229513|Experimental|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
3106815|NCT02229539|Experimental|doxepin rinse|"Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
3106816|NCT02229539|Active Comparator|DLA (diphenhydramine, lidocaine and antacid) rinse|"Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.~Patients will complete the Oral Symptoms booklet per the protocol."
3106817|NCT02229539|Placebo Comparator|placebo rinse|"Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.~Patients will complete the Oral Symptoms booklet per the protocol."
3106818|NCT02229552|Other|Baseline Cohort|Children completed body weight and other measures at baseline, 1-year follow up and 2-year follow up measurement periods.
3106819|NCT02229851|Experimental|NNC0195-0092 (somapacitan)|
3106820|NCT02229851|Active Comparator|Daily hGH|
3106821|NCT02229851|Placebo Comparator|Placebo|Switch to NNC0195-0092 (somapacitan) treatment in the extension period.
3106822|NCT02229864|Experimental|Coronary artery stenting: Absorb BVS|Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS)
3106823|NCT02230085||CPAP therapy|
3106824|NCT02230306|Experimental|Cobimetinib in Combination with Vemurafenib|"Vemurafenib (960 mg twice a day) will be taken on Days 1 - 28 of each 28-day treatment cycle. The first dose of vemurafenib should be taken in the morning, and the second dose should be taken in the evening. Vemurafenib can be taken with or without a meal and should be taken with a glass of water.~Cobimetinib (60 mg once a day) will be taken on Days 1 - 21 of each 28-day treatment cycle. The cobimetinib tablet should be taken at approximately the same time each day in the morning with the vemurafenib dose, but no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal and should never be chewed, cut, or crushed and should be taken with a glass of water."
3106825|NCT02230332|Experimental|Alendronate|Alendronate in 10mg capsules taken once daily
3106826|NCT02230332|Placebo Comparator|Placebo|Placebo capsule taken once daily
3106827|NCT02230384|Experimental|Active JNJ Drug|200 mg (100 mg b.i.d.) Active JNJ Drug used to assess quitting for one week, as part of crossover design. This JNJ experimental compound has NO name, just a company number.
3106828|NCT02230384|Experimental|Placebo Pill|Placebo pill used for one week quit attempt, as part of crossover design.
3106829|NCT02230527|Active Comparator|Clopidogrel|Clopidogrel 75mg by mouth daily
3106830|NCT02230527|Experimental|Ticagrelor|Ticagrelor 90mg by mouth twice daily
3106831|NCT02230540|Experimental|Sequence A|"Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product A in different positions. Measurement of residual urine at different positions."
3106832|NCT02230540|Experimental|Sequence B|"Based on results from sequence A, sequence B may or may not be initiated.~Catheterization with SelfCath (comparator) followed by measurement of residual urine.~Then catheterization with Product B in different positions. Measurement of residual urine at different positions."
3106833|NCT02230566|Experimental|Group A: 4 mg/kg UX003|4 mg/kg UX003 QOW through Week 46
3106834|NCT02230566|Experimental|Group B: 8 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 8 weeks followed by 4 mg/kg UX003 QOW through Week 46
3106835|NCT02230566|Experimental|Group C: 16 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 16 weeks followed by 4 mg/kg UX003 QOW through Week 46
3106836|NCT02230566|Experimental|Group D: 24 Weeks Placebo then 4 mg/kg UX003|Placebo QOW for the first 24 weeks followed by 4 mg/kg UX003 QOW through Week 46
3106837|NCT02230579|Experimental|Cohort SAD1 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
3106838|NCT02230579|Experimental|Cohort SAD2 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
3106839|NCT02230579|Experimental|Cohort SAD3 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
3106840|NCT02230579|Experimental|Cohort SAD4 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
3106841|NCT02230579|Experimental|Cohort SAD5 Fasted|Five fasted cohorts will receive a single, ascending dose of MMV390048. The starting dose will be 5mg. Cohort SAD6 will receive a single dose in a fed state
3106842|NCT02230579|Experimental|Cohort SAD6 Fed|Cohort SAD6, reusing volunteers from one of the previous cohorts, will receive a single dose in a fed state to evaluate the effect of food on the pharmacokinetics and tolerability
3106843|NCT02230670|Experimental|IDN-6556|25 mg BID of IDN-6556
3106844|NCT02230670|Placebo Comparator|Placebo|Placebo BID
3106845|NCT02230683|Experimental|IDN-6556 - Overall population|Overall evaluable population treated with IDN-6556 25 mg twice daily
3106846|NCT02230683|Experimental|IDN-6556 - Subgroup with Baseline HVPG < 12 mmHg|Subgroup for patients with Baseline HVPG < 12 mmHg that have been treated with IDN-6556 25 mg twice daily
3106847|NCT02230683|Experimental|IDN-6556 - Subgroup Baseline HVPG ≥ 12 mmHg|Subgroup for patients with Baseline HVPG ≥ 12 mmHg that have been treated with IDN-6556 25 mg twice daily
3106848|NCT02230696|Experimental|Test Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Perrigo
3106849|NCT02230696|Active Comparator|Reference Product|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray - Meda
3106850|NCT02230696|Placebo Comparator|Placebo Product|Placebo nasal spray
3106851|NCT02230761|Experimental|XOPH5 Ointment|XOPH5 Ointment is the investigational drug to be studied.
3106852|NCT02230761|Placebo Comparator|Placebo Ointment|Placebo is an ointment that matches XOPH5 Ointment but lacks the active ingredient.
3106853|NCT02230904|Experimental|Treatment Arm A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1)
3106854|NCT02230904|Experimental|Treatment Arm B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 hours reference product PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 hours, test product PR 2.3.1)
3106855|NCT02230956|Experimental|OnabotulinumtoxinA 400 U|OnabotulinumtoxinA 400 U injection into the intra-articular space of the study knee on Day 1.
3106856|NCT02230956|Experimental|OnabotulinumtoxinA 200 U|OnabotulinumtoxinA 200 U injection into the intra-articular space of the study knee on Day 1.
3106857|NCT02230956|Placebo Comparator|Placebo|Placebo (Normal Saline) injection into the intra-articular space of the study knee on Day 1.
3106858|NCT02230995|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
3106859|NCT02230995|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
3106860|NCT02231086|Active Comparator|Standard adjuvant systemic chemotherapy|Standard adjuvant systemic chemotherapy according to the Dutch colon cancer guideline, using a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) schedule. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
3106861|NCT02231086|Experimental|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC will be performed simultaneously with primary tumor resection, or as a staged procedure (<10 days or 5-8 weeks postoperatively). The chemotherapy during oxaliplatin-HIPEC consists of an intravenous phase with leucovorin 20 mg/m2 (maximum 40 mg) and 5-fluorouracil 400 mg/m2 (maximum 800 mg) and an intraperitoneal phase with oxaliplatin 460 mg/m2 (maximal 920 mg). Standard adjuvant systemic chemotherapy according to the national guideline will be given within 3 weeks from HIPEC. Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively.
3106862|NCT02231164|Placebo Comparator|Docetaxel and placebo|patients to receive backbone chemotherapy and placebo
3106863|NCT02231164|Experimental|Docetaxel and Nintedanib|patients to receive backbone chemotherapy and nintedanib
3106864|NCT02231177|Experimental|BI 1744 CL/Tiotropium FDC|
3106865|NCT02231177|Active Comparator|BI 1744 CL|
3106866|NCT02231177|Active Comparator|Tiotropium|
3106867|NCT02231580|Experimental|BN82451B|BN82451B capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
3106868|NCT02231580|Placebo Comparator|Placebo|Placebo capsule: Up to 3 dose levels (40, 60 or 80 mg) twice daily administered orally.
3106869|NCT02231749|Experimental|Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg|Nivolumab 3 mg/kg combined with Ipilimumab 1 mg/kg solutions intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solutions intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3106870|NCT02231749|Active Comparator|Arm B: Sunitinib 50 mg|"Sunitinib 50 mg capsules by mouth once daily for 4 weeks then 2 weeks off, continuously until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~After completion of final analysis eligible participants may switch from receiving Sunitinib to receiving Nivolumab 3 mg/kg IV combined with Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then Nivolumab 240mg flat dose IV every 2 weeks"
3106872|NCT02231918|Experimental|MIRAPEX® - low|
3106873|NCT02231918|Experimental|MIRAPEX® - medium|
3106874|NCT02231918|Experimental|MIRAPEX® - high|
3106875|NCT02232009|Other|3.0 T Neonatal Scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
3106876|NCT02232022|Experimental|NonCryptogenic Ischemic Stroke Patients|Patients with non-cryptogenic ischemic stroke will be enrolled within 10 days of stroke onset
3106877|NCT02232061|Experimental|Fingolimod|Fingolimod 0.5mg/day tablets taken orally.
3106878|NCT02232074|Experimental|Patient navigation enhanced with legal support|In addition to receiving standard navigation, patients will be connected with a Patient Navigator who is partnered with a lawyer from Medical-Legal Partnership to provide personalized assistance with regard to social-legal barriers.
3106879|NCT02232074|No Intervention|Standard patient navigation|These patients will receive standard patient navigation which will work to ensure that services are coordinated amongst medical personnel, while also addressing patients' needs.
3106880|NCT02232087|Experimental|test product A|salmeterol and fluticasone propionate, 2 puffs
3106881|NCT02232087|Active Comparator|reference product D|salmeterol and fluticasone propionate, 2 puffs
3106882|NCT02232087|Experimental|test product B|salmeterol and fluticasone propionate, 6 puffs
3106883|NCT02232087|Active Comparator|reference product E|salmeterol and fluticasone propionate, 6 puffs
3106884|NCT02232087|Experimental|test product C|salmeterol and fluticasone propionate, 12 puffs
3106885|NCT02232087|Active Comparator|reference product F|salmeterol and fluticasone propionate, 12 puffs
3106886|NCT02232126|No Intervention|Usual Care|
3106887|NCT02232126|Experimental|Intervention|
3106888|NCT02232178|Experimental|2 100mg Xaracoll implants|Bupivacaine HCl implant
3106889|NCT02232178|Experimental|3 100mg Xaracoll implants|Bupivacaine HCl implant
3106890|NCT02232178|Active Comparator|150mg Bupivacaine HCl injection|Bupivacaine HCl
3106891|NCT02232243|Experimental|Initial: Hydroxychloroquine 400mg HCQ|These initial 3 patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
3106892|NCT02232243|Experimental|Secondary: Hydroxychloroquine 800mg HCQ|Based on data analysis from the initial patients, these patients received 400mg hydroxychloroquine (HCQ) twice daily (800mg/day total) for 14 days prior to surgery.
3106893|NCT02232243|Experimental|Tertiary: Hydroxychloroquine 400mg HCQ|Based on data from the primary and secondary groups, patients received 200mg hydroxychloroquine (HCQ) twice daily (400mg/day total) for 14 days prior to surgery.
3106894|NCT02232282|Sham Comparator|Minimal Acupuncture|"Fifteen (15) will be allocated in the control sham/minimal acupuncture + standard medical treatments of IC. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture."
3106895|NCT02232282|Active Comparator|Standard acupuncture treatment|Fifteen (15) will be allocated in the standard acupuncture treatment + medical management of IC. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
3106896|NCT02232425|Experimental|Drug: IX-01|Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity
3106897|NCT02232425|Placebo Comparator|Placebo|Two to four capsules administered orally, 1-6 hours prior to sexual activity
3106898|NCT02232698|Experimental|Sensor Based Glucose Monitoring System|Standard sensing system use for 6 months.
3106899|NCT02232698|Active Comparator|Standard Blood Glucose Monitoring|Subjects randomised to the control group will be given blood glucose meters for monitoring for the 6 months study duration.
3106900|NCT02232802|Experimental|Enoxaparin Sodium Chemi|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
3106901|NCT02232802|Experimental|Clexane|Enoxaparin Sodium Chemi and Clexane will be administered to healthy subjects. Each subject will receive each treatment over two separate treatment periods under fasting conditions.
3106902|NCT02232893|Experimental|Daikenchuto (TU-100)|Daikenchuto (TU-100) 5g TID (15g/day)
3106903|NCT02232893|Placebo Comparator|Placebo|Placebo TID
3106904|NCT02232984||All study patients|All study patients will be implanted with a Boston Scientific (BSC) quadripolar Cardiac Resynchronization Therapy (CRT-D) and a currently approved quadripolar left ventricular lead. At the pre-discharge visit, multiple vectors will be tested in order to assess their respective performance.
3106905|NCT02233101|Active Comparator|Oral Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
3106906|NCT02233101|Active Comparator|Intravenous Tranexamic Acid|Patients will receive either oral or intravenous Tranexamic Acid
3106907|NCT02233296|Experimental|Group A|Dosing Sequence: Administration of lasmiditan 200 mg in fed state in Dosing Period 1 followed by administration of lasmiditan 200 mg in fasted state in Dosing Period 2
3106908|NCT02233296|Experimental|Group B|Dosing Sequence: Administration of lasmiditan 200 mg in fasted state in Dosing Period 1 followed by administration in lasmiditan 200 mg fed state in Dosing Period 2.
3106909|NCT02233309||Monitoring of pressures during caudal anesthesia|"Patients receiving caudal anesthesia as standard of care for a surgical procedure.~Our study adds a monitoring line to the needle for the caudal. The caudal itself is not part of the study."
3106910|NCT02233413|Sham Comparator|Non-active LLLT helmet application|A helmet containing near infrared LED's (LLLT helmet) will be applied to the head, however, the LEDs will not be turned on / activated.
3106911|NCT02233413|Active Comparator|Active LLLT helmet application|A helmet containing near infrared LEDs (LLLT helmet) will be applied and the LEDs will be turned on/activated
3106912|NCT02233478|Active Comparator|Pomegranate Juice|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3106913|NCT02233478|Active Comparator|Soybean Flour Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3106914|NCT02233478|Active Comparator|Soy Isolate Protein|Subjects will be asked to take a dietary supplement on the day of intervention. Prior to intervention, subjects will be asked to avoid high-polyphenol foods, certain vitamins, minerals, herbs and dietary supplements for 4 days, dietary instruction will be provided. Blood samples will be taken at screen for safety labs. On study days 5, 13 and 21 a spot urine will be collected and a 7 hr serial blood draw will be performed at 0 hr, 30 min, 1 hr, 2 hr, 3 hr, 4 hr and 6 hr. Subjects will be provided with a light lunch with foods low in polyphenols. Subjects will only be able to eat the foods provided on the intervention days. Subjects will be asked to drink 32oz of water during the 7-hr period. Subjects will also be asked to collect all of their urines for 24 hrs, 2 consecutive days.
3106915|NCT02233517|Experimental|Cognitive Behavioral Therapy|"Cognitive-Behavioral Therapy for Anger and Aggression in Combat Veterans with PTSD (CBT-A) is a 12-week manualized group treatment protocol that is grounded in up-to-date research, and that specifically addresses the Energy and Drive Functions, Attention Functions, Emotion Functions, and Thought Functions that are hypothesized to underlie the limitations to Activities and Participation associated with PTSD-related anger and aggression. Each session lasts 90 minutes. The first session orients participants to the structure and philosophy of the program, provides a historical overview of PTSD, and introduces the concept of the survival mode of functioning (Chemtob et al., 1997). The remaining 11 sessions follow a standard format: 1) practice relaxation training (15-20 minutes); 2) review homework, introduce new material, and engage in group activities focused on implementing new skills and behaviors (70-80 minutes); and 3) review problems or concerns of group members."
3106916|NCT02233517|Active Comparator|Present Centered Therapy|"Present Centered Therapy (PCT) is an active, manualized treatment comparison condition for psychotherapy trials. PCT is designed to control for nonspecific factors of therapy such as contact with a trained therapist, rationale for treatment, and instillation of expectancy for therapeutic gains. The therapeutic approach was drawn from Yalom's group therapy model, which utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now. Previous large-scale randomized clinical trials of Veterans with PTSD have found reduced PTSD symptoms in the PCT comparison condition (Schnurr et al., 2003), and a survey of practice patterns within the VA suggests that similar present-focused approaches are routinely employed by VA mental health providers (Rosen et al., 2004). Consistent with recommendations in the PCT manual, training will emphasize the approach rather than specific interventions."
3106917|NCT02233530|Experimental|CST intervention|"Outcomes at baseline will be compared with those immediately post intervention and at four weeks post-intervention.~In accordance with the CST manual protocol, patients will be allocated to groups to ensure a spread of abilities and ensure inclusivity. No group contains only one individual of a particular religion or gender, such that they may feel left out. The investigators will allocate patients to groups to avoid excessive travel to the group meeting place, participants may be allocated to a group based on their geographical location. Individuals will be allocated to groups based on religion, gender and geographical location."
3106918|NCT02233543|Experimental|First QVA149 (indacaterol/glycopyrronium), then Placebo|Participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
3106919|NCT02233543|Experimental|First Placebo, then QVA149 (indacaterol/glycopyrronium)|Participants received 4 weeks of placebo once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day followed by 2 weeks washout. Then participants received 4 weeks of QVA149 85/43 μg delivered dose once daily in the morning between 08:00 and 11:00 AM at approximately the same time every day.
3106920|NCT02233647|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3106921|NCT02233647|Experimental|Phendimetrazine Dose 1|"Subjects will be maintained on the low phendimetrazine dose. Cocaine will be administered acutely during low dose phendimetrazine maintenance.~Placebo will be administered acutely during low dose phendimetrazine maintenance."
3106922|NCT02233647|Experimental|Phendimetrazine Dose 2|"Subjects will be maintained on the intermediate phendimetrazine dose. Cocaine will be administered acutely during intermediate dose phendimetrazine maintenance.~Placebo will be administered acutely during intermediate dose phendimetrazine maintenance."
3106923|NCT02233647|Experimental|Phendimetrazine Dose 3|"Subjects will be maintained on the high phendimetrazine dose. Cocaine will be administered acutely during high dose phendimetrazine maintenance.~Placebo will be administered acutely during high dose phendimetrazine maintenance."
3106924|NCT02233738|Experimental|Group Motivational Interviewing (GMI)|Group Motivational Interviewing (GMI) participants will receive four structured, back-to-back, 90-min sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
3106925|NCT02233738|Active Comparator|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to Group Motivational Interviewing (GMI) (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
3106926|NCT02233751|Experimental|Testosterone enanthate auto-injector - 50 mg|Testosterone enanthate auto-injector - 50 mg (SC injection)
3106927|NCT02233751|Experimental|Testosterone enanthate auto-injector - 200 mg|Testosterone enanthate auto-injector- 200 mg (SC injection)
3106928|NCT02233803|Experimental|Sequence 1: BFF 400/12mcg to BFF 320/9mcg|Subjects will receive Regimen A in Treatment Period 1 followed by Regimen B in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
3106929|NCT02233803|Experimental|Sequence 2: BFF 320/9mcg to BFF 400/12mcg|Subjects will receive Regimen B in Treatment Period 1 followed by Regimen A in Treatment Period 2. The treatment periods will be separated by a wash out period of 4 weeks. Regimen A: Subjects will be instructed to take each morning and evening, 1 inhalation from a single capsule containing BFF (400/12 mcg) by single capsule inhaler. Regimen B: Subjects will be instructed to take each morning and evening,1 inhalation from BFF (320/9 mcg) TURBUHALER inhaler.
3106930|NCT02233842||Tobacco Use in Cancer Pts & Survivors|Cognitive testing (e.g. participant interview) of tobacco use in patients (pts) who have cancer and who have survived cancer.
3106931|NCT02233946|Experimental|screening w/ computer brief intervention|screening with computer-facilitated brief intervention
3106932|NCT02233946|No Intervention|Screening with Treatment as Usual|Screening with Treatment as Usual
3106933|NCT02233985|Active Comparator|Nebulized 0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
3106934|NCT02233985|Experimental|Nebulized 3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
3106935|NCT02233998|Active Comparator|Mouth Rinse 1|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3106936|NCT02233998|Active Comparator|Mouth Rinse 2|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3106937|NCT02233998|Placebo Comparator|Mouth Rinse 3|After brushing in your normal manner, rinse full strength twice a day with 20 mL for 30 seconds.
3106938|NCT02234063|Experimental|Immediate Genetic Testing|Participants randomized to intervention will receive the APOL1 genetic test upon study enrollment.
3106939|NCT02234063|No Intervention|Control- Delayed Testing|Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
3106940|NCT02234115|Experimental|Leuprolide Mesylate 50mg|All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.
3106941|NCT02234128|Experimental|EVLP Double Lung Group|Toronto EVLP System™ administered to double lungs.
3106942|NCT02234128|Experimental|EVLP Single Lung Group|Toronto EVLP System™ administered to single lungs.
3106943|NCT02234128|No Intervention|Control Group|Those patients receiving a single or double lung via conventional transplant.
3106944|NCT02234141|Experimental|Selonsertib 2 mg|Participants will receive selonsertib 2 milligrams (mg) for 24 weeks and may continue on this dose during the long-term treatment phase.
3106945|NCT02234141|Experimental|Selonsertib 6 mg|Participants will receive selonsertib 6 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
3106946|NCT02234141|Experimental|Selonsertib 18 mg|Participants will receive selonsertib 18 mg for 24 weeks and may continue on this dose during the long-term treatment phase.
3106947|NCT02234141|Experimental|Placebo|Participants will receive selonsertib placebo for 24 weeks, and may then be rerandomized 1:1:1 to selonsertib 2, 6, or 18 mg during the long-term treatment phase.
3106948|NCT02234180|Experimental|Arm I (regorafenib)|Within 6-12 weeks after surgery, patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3106949|NCT02234180|Placebo Comparator|Arm II (placebo)|Within 6-12 weeks after surgery, patients receive placebo PO QD on days 1-21. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3106950|NCT02234284|Experimental|Health Coaching|Patients randomized to the health coaching intervention would work with a trained health coach who would provide patient education self-management support, use action planning to help patient make changes to reach goals, as well as help coordinate patient care between the primary care provider and pulmonary specialist, identify gaps in care, and help patient access needed services
3106951|NCT02234284|No Intervention|Usual care|Usual care was chosen as the comparison group to provide maximum generalizability of the study, as usual care is the practical alternative for the target population. Usual care includes patient education classes, smoking cessation classes, psychosocial medicine and nutritional counseling.
3106952|NCT02234310|Experimental|Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc)|Participants received rFIXFc intravenous (IV) injection as follows: Prophylactic treatment regimen: started with rFIXFc 50 International Units per kilogram (IU/kg) weekly until a participant reached at least 50 exposure days (ED=24-hour period in which greater than or equal to (>=1) injection/dose of rFIXFc was given) to rFIXFc, withdrawal from study or end of study. Adjustments to dose and dosing interval was based on incremental recovery, subsequent Factor IX (FIX) levels, physical activity, bleeding pattern, in accordance with local standards of care for prophylactic regimen (PR). Treatment with episodic (on demand) regimen can be initiated before PR at investigators discretion. Episodic (On demand; optional): rFIXFc at individual doses based on participant's clinical condition, type and severity of bleeding event until PR.
3106953|NCT02234323|Experimental|rFVIIIFc|Participants were to receive rFVIIIFc as follows- Prophylaxis regimen (PR): rFVIIIFc 25-80 international units per kilogram (IU/kg), at 3- to 5-day intervals until participant reached greater than or equal to (>=) 50 exposure days (ED: 24-hour period in which >=1 injection/dose of rFVIIIFc was given), or study withdrawal/end of study. Adjustments to dose/dosing interval was done as needed by investigator; Treatment with an optional ER (Episodic regimen) can be initiated before PR at investigators discretion; ITI: rFVIIIFc 200 IU/kg, daily for participants who, after exposure to rFVIIIFc, had positive high titer inhibitor (>=5.00 Bethesda Units per milliliter [BU/mL]) or positive low titer inhibitor (>=0.60 and <5.00 BU/mL) and had poorly controlled bleeding despite increased rFVIIIFc doses, or required bypassing agent to treat bleeding.
3106954|NCT02234362|Experimental|open-label vortioxetine|flexible-dose vortioxetine of 5-20 mg depending on tolerability
3106955|NCT02234427|Experimental|Aspirin|
3106956|NCT02234479|Active Comparator|Hydrophor (Group A)|Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
3106957|NCT02234479|Experimental|MediHoney (Group B)|Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.
3106958|NCT02234570|Experimental|Group 1|N=8 subjects receive single oral dose 0.5mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3106959|NCT02234570|Experimental|Group 2|N=8 subjects receive single oral dose 1mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3106960|NCT02234570|Experimental|Group 3|N=8 subjects receive single oral dose 3mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3106961|NCT02234570|Experimental|Group 4|N=8 subjects receive single oral dose 7.5mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3106962|NCT02234570|Experimental|Group 5|N=8 subjects receive single oral dose 15mg/kg of oxfendazole; N= 2 subjects receive single oral dose placebo
3106963|NCT02234570|Experimental|Group 6|N=8 subjects receive single oral dose 30mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3106964|NCT02234570|Experimental|Group 7|N=8 subjects receive single oral dose 60mg/kg of oxfendazole; N=2 subjects receive single oral dose placebo
3106965|NCT02234583|Experimental|DS-5565|Participants receive 15 mg DS-5565 administered once or twice daily. Each participant's dose can be titrated up or down based on the investigator's decision. Analysis will be based on the dose modality at the time of data collection.
3106966|NCT02234596|Experimental|Nintedanib|
3106967|NCT02234622|Experimental|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
3106968|NCT02234622|Active Comparator|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity walking with didactics about wellness topics.
3106969|NCT02234713|Experimental|Behavioural Intervention/Feedback|The behavioral interventionist will contact the patient and parent by email and telephone to schedule a telephone call to review the downloaded adherence information and discuss barriers experienced by the patient/parent using a standard script. The behavioral feedback will be administered three times: at 1-, 2- and 3-months post-baseline.
3106970|NCT02234713|Active Comparator|Video Attention Control|The patients in this arm of the study will be emailed a link to an educational video about Pediatric MS and therapy for MS at three time points: 1-, 2-, and 3-months post-baseline.
3106971|NCT02234752|Experimental|Galantamine ER, Memantine XR|Week 1, Galantamine ER 8 mg HS & Memantine XR 7 mg HS Week 2, Galantamine ER 16 mg HS & Memantine XR 14 mg HS Weeks 3-6, Galantamine ER 24 mg HS & Memantine XR 21 mg HS
3469160|NCT03888872|Experimental|Group I|Group I (Study): will consist of 20 patients with diabetic neuropathy and will receive High tone power therapy in addition to selected physical therapy program (Wobble board training, AROM exercises for both UL & LL, gentle manual stretching exercises for both UL & LL and graduated gait training). for 10 sessions every other day, each session for 1.45 hours (60 minutes for HiTop and 45 minutes for selected physical therapy program).
3106974|NCT02235064|Experimental|Sertraline|Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
3106975|NCT02235064|Placebo Comparator|Placebo|Identical appearing capsule daily containing color-matched cellulose only
3106976|NCT02235077|Active Comparator|Spironolactone|Spironolactone 25mg or 100 mg orally, once daily while in the hospital for 96 hours
3106977|NCT02235077|Placebo Comparator|Placebo|Placebo 25mg or 100mg orally, once daily while in the hospital for 96 hours
3106978|NCT02235285|Experimental|breast augmentation,reoperation|A retrospective chart review was performed to examine a total of 162 patients received the same brand of implants for primary breast augmentation under sedative anesthesia (propofol infusion) in a single surgeon's practice.
3106979|NCT02235298|Experimental|Dapagliflozin and Metformin Group|Participants in this group will receive Dapagliflozin in addition to Metformin for 6 months.
3106980|NCT02235298|Active Comparator|Metformin and Placebo Group|Participants in this group will receive Metformin and Placebo for 6 months.
3106981|NCT02235311|Active Comparator|Pantoprazole twice daily|Pantoprazole 40mg orally twice daily x 8 weeks after acute management of UGIB
3106982|NCT02235311|Active Comparator|Pantoprazole once daily|Pantoprazole 40mg orally once daily x 8 weeks after acute management of UGIB
3106983|NCT02235454|Other|Glaucoma arm|Consecutive patients with glaucoma will undergo non-invasive OCT imaging
3106984|NCT02235493||Retrospective Case Only|
3106985|NCT02235831|Experimental|DACP MF|DACP MF worn first, followed by DACP and DACP MF (Low Add) as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF will be worn bilaterally (in both eyes).
3106986|NCT02235831|Active Comparator|DACP|DACP worn first, followed by DACP MF and DACP MF (Low Add), as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP worn as monovision (distance correction in one eye and near correction in the other eye).
3106987|NCT02235831|Active Comparator|DACP MF (Low Add)|DACP MF (Low Add) worn first, followed by DACP and DACP MF, as randomized. Lenses worn for 5±1 days, 6 hours per day, in a daily wear daily disposable modality. DACP MF (Low Add) worn bilaterally (in both eyes).
3106988|NCT02235870|Active Comparator|Treatment Group|In accordance with the randomization assignment, treatment arm subjects will receive a 6-month course of Balloon therapy with a nutrition and lifestyle program. Balloon treatment consists of placement of 3 balloons Obalon Intragastric Balloons in the first 3 months of therapy.
3106989|NCT02235870|Sham Comparator|Control Group|Control arm subjects will receive a single 6-month course of sham device therapy with a nutrition and lifestyle program. Sham treatment consists of placement of 3 shams in the first 3 months of therapy.
3106990|NCT02235987|Other|Octreotide, then ascending DG3173|Interventions: octreotide and DG3173. Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
3106991|NCT02236130|Active Comparator|General|General Anesthesia only
3106992|NCT02236130|Experimental|Regional|General Anesthesia combined with regional block
3106993|NCT02236338|Active Comparator|Radiofrequency Ablation|"Device: ClosureFAST radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
3106994|NCT02236338|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent greater saphenous vein, using this device."
3106995|NCT02236520|Active Comparator|Spironolactone|50 mg capsule of Spironolactone administered orally 1 per day for 8 weeks
3106996|NCT02236520|Active Comparator|Chlorthalidone|25 mg capsule of Chlorthalidone administered orally 1 per day for 8 weeks
3106997|NCT02236520|Active Comparator|Diet|diet of 6 g salt per day for 8 weeks
3106998|NCT02236520|Placebo Comparator|Placebo|placebo capsule administered orally 1 per day for 8 weeks
3106999|NCT02236559|Active Comparator|Noninvasive positive pressure ventilation|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
3107000|NCT02236559|Experimental|High flow therapy|"Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%."
3107001|NCT02236598|Experimental|K+ supplementation|K-supplement- Klor-Con® M10 is an immediately dispersing extended-release oral dosage form of potassium chloride containing 750 mg of microencapsulated potassium chloride, United States Pharmacopeia (USP) equivalent to 10 milliequivalent (mEq) of potassium in a tablet. Participants will be instructed to take two 10 mEq tablets twice daily in a blinded encapsulated form, for 3 months
3107002|NCT02236598|Experimental|Placebo|"Placebo - An inert powdered placebo will be identically encapsulated as the Klor-Con intervention tablets to maintain blinding. Participants will be instructed to take two tablets twice daily in a blinded encapsulated form, for 3 months~Subjects will be instructed to take the pills"
3107003|NCT02236611|Experimental|Umeclidinium 62.5 mcg|Randomized subjects will receive umeclidinium inhalation powder 62.5 mcg, once daily over a period of 12 weeks via a nDPI. Subjects will be instructed to take one dose each morning.
3107004|NCT02236611|Experimental|Glycopyrronium 44 mcg|Randomized subjects will receive glycopyrronium 44 mcg, once daily over a period of 12 weeks via a BREEZHALER inhaler. Subjects will be instructed to take one dose each morning.
3107005|NCT02236767|Experimental|rTMS Treatment|NeuroStar Transcranial Magnetic Stimulation Therapy System
3469161|NCT03888872|Experimental|Group II|Group II (Control): will consist of 20 patients with diabetic neuropathy and will receive selected physical therapy program only same as group I. For 10 sessions every other day, each session for 45 minutes.
3107006|NCT02236988|Experimental|Group 1|"Participants received the following 4 treatments, given in 4 possible sequences (ADBC, BACD, CBDA, and DCAB) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) B) A single oral dose 75 mg apremilast tablet prototype MR 1 C) A single oral dose 75 mg apremilast tablet prototype MR 2 D) A single oral dose 75 mg apremilast capsule prototype MR 3"
3107007|NCT02236988|Experimental|Group 2|"Participants received the following 4 treatments, given in 4 possible sequences (AGEF, EAFG, FEGA, and GFAE) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) E) A single oral dose 75 mg apremilast capsule prototype MR 4 F) A single oral dose 75 mg apremilast capsule prototype MR 5 G) A single oral dose 75 mg apremilast capsule prototype MR 6"
3107008|NCT02236988|Experimental|Group 3|"Participants received the following 3 treatments, given in 6 possible sequences (AIJ, IJA, JAI, AJI, IAJ, or JIA) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) I) A single oral dose 80 mg apremilast capsule prototype MR 8 J) A single oral dose 80 mg apremilast capsule prototype MR 9"
3107009|NCT02236988|Experimental|Group 4|"Participants received the following 5 treatments, given in 10 possible sequences (ALOMN, LMANO, MNLOA, NOMAL, OANLM, NMOLA, ONAML, AOLNM, LAMON, or MLNAO) with 7 to 10 days between each treatment:~A) Two oral doses of 30 mg apremilast immediate release tablets 12 hours apart (reference formulation) L) A single oral dose 80 mg apremilast capsule prototype MR 11 M) A single oral dose 80 mg apremilast capsule prototype MR 12 N) A single oral dose 80 mg apremilast capsule prototype MR 13 O) A single oral dose 80 mg apremilast capsule prototype MR 14"
3107010|NCT02237001|Experimental|Treatment|Suture-based meniscal repair
3107011|NCT02237092|Experimental|Measurement of IAP|The data obtained are in inches of water column were translated in millimeters of mercury.
3107012|NCT02237118|Active Comparator|Mepitel One|Pain on dressing removal, by VAS
3107013|NCT02237118|Active Comparator|UrgoTul|Pain on removal by VAS
3107014|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 1)|Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
3107015|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 2)|Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
3107016|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 3)|Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
3107017|NCT02237157|Other|Gemcitabine, Local Delivery (Dose 4)|Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
3107018|NCT02237196|Experimental|AMG 157+Cat Immunotherapy|"AMG 157 will be administered every four weeks.~Cat immunotherapy will be administered weekly."
3107019|NCT02237196|Active Comparator|AMG 157 Placebo+Cat Immunotherapy|"Placebo for AMG 157 of similar appearance will be administered every four weeks.~Cat immunotherapy will be administered weekly."
3107020|NCT02237196|Experimental|AMG 157+Cat Immunotherapy Placebo|"AMG 157 will be administered every four weeks.~Placebo for Cat immunotherapy will be administered weekly."
3107021|NCT02237196|Placebo Comparator|Placebo-Placebo|"Placebo for AMG 157 will be administered every four weeks.~Placebo for cat immunotherapy will be administered weekly."
3107022|NCT02237417|Other|Healthy Control|
3107023|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group A)|
3107024|NCT02237417|Active Comparator|Individuals with Schizophrenia (Group B)|
3107025|NCT02237898|Experimental|MoMba Contingency Management|Study will provide access to the web-based MoMba Live Long application & Sensodrone™ carbon-monoxide sensor for purposes of researching the acceptability of the smartphone application, operating and functioning of it, and providing remote contingency management for smoking cessation to postpartum women.
3107026|NCT02237898|Active Comparator|Office contingency management|Traditional contingency management with financial incentives delivered in-person in the office for smoking cessation to postpartum women
3107027|NCT02237911|Experimental|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
3107028|NCT02237911|Active Comparator|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
3107029|NCT02237911|No Intervention|Wait-listed usual medical care|Wait-listed usual medical care - no intervention provided by study.
3107030|NCT02237950|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3107031|NCT02237950|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3107032|NCT02237989|Active Comparator|paracetamol|The 1st group includes 19 patients given 1500mg/day paracetamol for three months
3107033|NCT02237989|Experimental|native collagen type 2 + paracetamol|The 2nd group consists of 20 patients given 1500mg/day paracetamol and 10mg/day native collagen type 2 for three months
3107034|NCT02238028|Experimental|Wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
3107035|NCT02238028|No Intervention|Not wear respirator|The recruited healthy subjects were randomly allocated into two groups.In each intervention, one group wore the high-efficiency respirator as much as possible for continuous 48hr and the other group behaved as usual. After a three-week interval, the two groups exchanged their roles in wearing the respirator or not. The same protocol on the measurements of health indicators and ambient air pollution was applied in the 1st intervention and 2nd intervention period.
3469162|NCT03888950|Experimental|early research PET-CT|The patient will undergo an early research PET-CT after 2 cycles of anti-PD1 (PET1) between the baseline PET-CT and the PET-CT at 3 months of initiation of treatment
3107036|NCT02238067||Chronic Renal Anemia Participants|Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
3107037|NCT02238080||Methoxy Polyethylene Glycol-Epoetin Beta|Participants with anemia and CKD who are on dialysis therapy, and who initiate erythropoiesis-stimulating agent (ESA) treatment with methoxy polyethylene glycol-epoetin beta or who are on stable methoxy polyethylene glycol-epoetin beta maintenance therapy, will be treated according to the usual standard of care and current best practice guidelines, and will be observed during the study period.
3107038|NCT02238379|Experimental|Oxytocin|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
3107039|NCT02238379|Placebo Comparator|Placebo|Each participant will receive both the oxytocin nasal spray in one visit AND the placebo nasal spray in another visit (randomized) in this design.
3107040|NCT02238483|Experimental|AZD7624|Active treatment
3107041|NCT02238483|Placebo Comparator|Placebo|Placebo Comparator
3107042|NCT02238626|Placebo Comparator|Placebo (for MN-166)|Sugar pill manufactured for MN-166 10 mg tablets plus 50 mg riluzole by mouth twice daily for 6 months.
3107043|NCT02238626|Experimental|MN-166|MN-166 10 mg tablets (up to 60 mg/day) by mouth 2-3 times a day plus 50 mg riluzole 2 times a day by mouth for 6 months.
3107044|NCT02238782|Experimental|selumetinib 75mg single dose|3 capsules of 25 mg administered orally
3107045|NCT02238847|Active Comparator|WallFlex Biliary RX Fully Covered Stent System|"Patients in this group will receive a fully covered study SEMS (self-expanding metal stent)~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
3107046|NCT02238847|Active Comparator|WallFlex Biliary RX Uncovered Stent System|"Patients in this group will receive an uncovered study SEMS (self-expanding metal stent).~Reintervention can occur with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System"
3107047|NCT02238925|Experimental|CPX-351|"Single Arm Study (Patients may receive up to 2 Inductions and 4 Consolidations):~Induction 1: CPX-351 will be given intravenously at 100units/m2 on days 1, 3, and 5 over a 90 minute infusion.~Induction 2: CPX-351 will be given intravenously at 100units/m2 on days 1 and 3 over a 90 minute infusion.~Consolidations 1-4: CPX-351 will be given intravenously at 65units/m2 on days 1 and 3 over a 90 minute infusion."
3107048|NCT02238977|Active Comparator|Fluoxetine|Fluoxetine up to 20 mg orally daily for 12 weeks. Flexible dosing between a minimum of 10 mg daily and 20 mg daily as tolerated.
3107049|NCT02238977|Experimental|Bupropion|Bupropion sustained release (SR) 150 mg orally twice per week
3107050|NCT02239094|Other|Lurasidone (Latuda)|All study participants will receive open-label Latuda.
3107051|NCT02239120|Experimental|dabigatran etexilate 110 or 150 mg|Patients will be assigned Dabigatran 150 mg b.i.d. (unless they are 75 years or older, or have a Creatinine Clearance (CrCl) of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive Dabigatran 110 mg b.i.d.). All patients in this arm will also receive ASA placebo (q.d.)
3107052|NCT02239120|Active Comparator|ASA 100 mg|All patients will receive blinded ASA 100 mg q.d. and dabigatran placebo 150 mg b.i.d. (unless they are 75 years or older, or have a CrCl of greater than or equal to 30 to less than 50ml/min (or experience GI bleed during trial), in which case they will receive placebo Dabigatran 110 mg b.i.d
3107053|NCT02239224|Experimental|Cohort 1: ATYR1940 0.3 mg/kg|Participants will receive ATYR1940 0.3 milligrams/kilograms (mg/kg) intravenous (IV) infusion once weekly for 4 weeks.
3107054|NCT02239224|Experimental|Cohort 2: ATYR1940 1.0 mg/kg|Participants will receive ATYR1940 1.0 mg/kg IV infusion once weekly for 4 weeks.
3107055|NCT02239224|Experimental|Cohort 3: ATYR1940 3.0 mg/kg|Participants will receive ATYR1940 3.0 mg/kg IV infusion once weekly for 12 weeks.
3107056|NCT02239224|Placebo Comparator|Placebo|Participants will receive placebo matched to ATYR1940 IV infusion once weekly for 4 weeks in Cohorts 1 and 2 and for 12 weeks in Cohort 3.
3107057|NCT02239263|Experimental|N6 Input Processing Features|
3107058|NCT02239289|Experimental|Biofeedback|Subjects will be provided with four sessions of supervised biofeedback training
3107059|NCT02239328||Lung Cancer, Esophageal Cancer|Lung Cancer and Esophageal Cancer patients will complete the online PROMIS survey. No treatment intervention will be performed.
3107060|NCT02239380|Experimental|Lorazepam|Lorazepam intravenous formulation
3107061|NCT02239510|Active Comparator|Senna|1 capsule (50 mg) Senna daily for 12 weeks
3107062|NCT02239510|Active Comparator|Linzess|1 capsule (145 mcg) once daily for 12 weeks
3107063|NCT02239536|Experimental|Hot snare polypectomy|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy technique
3107064|NCT02239536|Experimental|Hot snare polypectomy(saline injection)|Intervention: Procedure: removal of eligible polyps using hot snare polypectomy after saline injection technique
3107065|NCT02239562|Experimental|SAD sPIF 0.1|single ascending dose (SAD) 3 patients with normal liver function tests (LFTs) and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Single subcutaneous (SQ) dose 0.1 mg/kg sPIF or Placebo Day 1
3107066|NCT02239562|Experimental|SAD sPIF 0.5|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: single SQ dose 0.5 mg/kg sPIF or Placebo Day 1
3107067|NCT02239562|Experimental|SAD sPIF 1.0|single ascending dose (SAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) as follows: Cohort 3: single SQ dose 1.0 mg/kg sPIF or Placebo Day 1
3107068|NCT02239562|Experimental|MAD sPIF 0.1|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ (one time) 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.1 mg/kg sPIF or Placebo Days 1-5
3107069|NCT02239562|Experimental|MAD sPIF 0.5|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 0.5 mg/kg sPIF or Placebo Days 1-5
3469163|NCT03889054|No Intervention|Control|Current clinical management
3107070|NCT02239562|Experimental|MAD sPIF 1.0|multiple ascending dose (MAD) 3 patients with normal LFTs and 3 patients with abnormal LFTs randomized in a 2:1 ratio (active drug:placebo) to multiple doses of sPIF SQ 1X day for 5 consecutive days (Days 1 to 5) Cohort 1: SQ 1.0 mg/kg sPIF or Placebo Days 1-5
3107071|NCT02239601|Experimental|Physical Therapy|4 Physical therapy treatment sessions provided prior to chemotherapy and a home program to continue throughout the trial.
3107072|NCT02239640||Medtronic NV market-released device|Patients experiencing an acute ischemic stroke due to a large vessel occlusion treated with a Medtronic Neurovascular market-released neurothrombectomy device.
3107073|NCT02239679|Experimental|ALA X3|Cryotherapy followed by 3 aminolevulinic acid + blue light (BLU-U) treatments
3107074|NCT02239679|Placebo Comparator|VEH|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving cryotherapy and 2 or 3 subsequent Topical Solution Vehicle + BLU-U treatments. Subjects receiving VEH will be considered a single treatment group.
3107075|NCT02239679|Experimental|ALA X2|Cryotherapy followed by 2 aminolevulinic acid + BLU-U treatments
3107076|NCT02239692|Active Comparator|PICOPREP day-before dosing schedule|Both doses administered the day before colonoscopy.
3107077|NCT02239692|Experimental|PICOPREP tailored dosing schedule|First dose one day before colonoscopy or on the day of colonoscopy, dependent on the planned time for colonoscopy, and second dose on the day of colonoscopy.
3107078|NCT02239744|Experimental|True air purification|One group of subjects used an intervention of true air purifiers placed in the center of the room.
3107079|NCT02239744|Sham Comparator|Sham air purification|This group of subjects used an intervention of sham air purifiers under the same conditions with true purifiers with the only difference being removal of the filter gauze in the sham purifiers.
3107080|NCT02239770|Placebo Comparator|0 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one placebo nicotine film.
3107081|NCT02239770|Experimental|2 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 2 mg nicotine film.
3107082|NCT02239770|Experimental|4 mg Nicotine Film|In Part 1, 4 participants will be allocated to this arm and receive one 4 mg nicotine film.
3107083|NCT02239770|Placebo Comparator|0, 0, 0, 0mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 0, 0, 0, 0 mg.
3107084|NCT02239770|Experimental|2, 2, 2, 2mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 2, 2, 2, 2 mg.
3107085|NCT02239770|Experimental|4, 4, 0, 4mg Nicotine Film Regimen|In Part 2, 4 participants will be allocated to this arm and receive one nicotine film every 3 hours (for a total of 4 films over 12 hours) in the following order: 4, 4, 0, 4 mg.
3107086|NCT02239939|Experimental|Vest + Diet|All participants will undergo a 22 week dietary weight loss. In addition, participants will be asked to wear a weighted vest for >10 hours a day. Weight in the vest is adjusted to match weight lost during the intervention.
3107087|NCT02239939|Active Comparator|No Vest + Diet|All participants will undergo a 22 week dietary weight loss intervention. Participants in this group will be asked not to change their daily habits other than adherence to the diet protocol.
3107088|NCT02239978||Parkinsons disease|Individuals with Parkinsons disease
3107089|NCT02239978||Control|Age-matched healthy adults
3107090|NCT02240030|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
3107091|NCT02240030|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 3 months duration
3107092|NCT02240030|Placebo Comparator|Placebo|Capsules of inhalation-grade lactose used up to 5 times/day for OFF episodes for 3 months duration.
3107093|NCT02240108|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
3107094|NCT02240108|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
3107095|NCT02240121|Experimental|Rifaximin EIR 800 mg|Participants will receive rifaximin EIR 400 milligrams (mg) tablets orally twice daily for 52 weeks.
3107096|NCT02240121|Placebo Comparator|Placebo|Participants will receive placebo matching to rifaximin EIR tablets orally twice daily for 52 weeks.
3107097|NCT02240186|Experimental|Prosthetic knee joints|Each subject will be tested using their current Non-Microprocessor Knee (NMPK) , fit and tested with a Microprocessor Knee (MPK), and then tested again with their NMPK, e.g. A-B-A design.
3107098|NCT02240329|Other|Individuals with TBI|Individuals who have sustained a traumatic brain injury during the previous five years. Will have the following tests performed: Neuropsychological Testing and Measures of TBI severity; Cough and respiratory measures (including Maximum Respiratory Pressures); and Capsaicin cough sensitivity testing.
3107099|NCT02240368||Group 1|Children age between 1 month to 12 months
3107100|NCT02240368||Group 2|Children age between 13 months and 36 months
3107101|NCT02240368||Group 3|Children age between 37 months to 144 months
3107102|NCT02240589|Experimental|Memantine|24 weeks of memantine with accelerated titration, beginning within 48 hours of injury.
3107103|NCT02240589|Placebo Comparator|Placebo|24 weeks of placebo matched to memantine formulation, beginning within 48 hours of injury.
3107104|NCT02240628|Active Comparator|Propofol-Lidocaine mixture|All patients from both groups will receive a Synera Patch. Patients in this group will receive Propofol mixed with Lidocaine. Pain will be evaluated during the Propofol injection by both a blinded observer and a blinded anesthesia member.
3107105|NCT02240628|Placebo Comparator|Propofol -Saline mixture|All patients from both groups will receive a Synera Patch. Patienst in this group will receive Propofol mixed with Saline. Pain will be evaluated on Propofol injection by both a blinded observer and a blinded anesthesia member.
3107106|NCT02240654||Dabigatran etexilate|
3107107|NCT02240667||Subjects with atrial fibrillation|
3107108|NCT02240680|Experimental|linagliptin 5 mg|patient to receive a tablet of linagliptin 5 mg each day
3107109|NCT02240680|Placebo Comparator|placebo|patient to receive a tablet of placebo matching linagliptin 5 mg
3107110|NCT02240693|Experimental|BI 409306 dose 1|
3107111|NCT02240693|Experimental|BI 409306 dose 2|
3107112|NCT02240693|Experimental|BI 409306 dose 3|
3107113|NCT02240693|Experimental|BI 409306 dose 4|
3107114|NCT02240693|Placebo Comparator|Placebo|
3107115|NCT02240706|Active Comparator|Arm B|Best Supportive Care Alone
3107116|NCT02240706|Experimental|Arm A|BI 836858 plus Best Supportive Care
3107117|NCT02240810||PLATINUM Diversity (Overall)|PLATINUM Diversity (Overall) population. Test device is Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System (CSS)
3107118|NCT02241486|Experimental|Sublingual Fentanyl Spray|Examine the efficacy and safety of sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement) in patients with burn injury.
3107119|NCT02241512|Experimental|Ibuprofen|Single dose IV Ibuprofen at a dose of 10mg/kg (max: 800mg).
3107120|NCT02241512|Placebo Comparator|Placebo|Single dose IV normal saline
3107121|NCT02241655|Experimental|EEG guided protocol|Participants will have a pragmatic EEG-guided anesthetic protocol during their surgery. Practitioners will modify administration of anesthesia in an attempt to limit the occurrence of EEG burst suppression or persistent suppression.
3107122|NCT02241655|No Intervention|Control Arm|Participants will have the standard anesthetic protocol.
3107123|NCT02241720|Experimental|Regorafenib treatment|
3107124|NCT02241733|Active Comparator|exercise|Patients will exercise for 12 weeks and then participate in an adherence program
3107125|NCT02241733|Experimental|exercise plus breathing retraining|Patients will exercise plus breathing retraining for 12 weeks and then participate in an adherence program
3107126|NCT02241785|Experimental|natalizumab|natalizumab 300 mg intravenously (IV) every 4 weeks
3107127|NCT02241889|Active Comparator|Standard Insulin Pump Therapy|Subjects will undergo 21 hour study with exercise using Insulin pump therapy and managing their blood glucose as they normally would.
3107128|NCT02241889|Experimental|Closed-loop without adjustment|Subjects will undergo 21 study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will not be annouced to the controller and no adjustments to insulin and glucagon delivery will be made.
3107129|NCT02241889|Experimental|Closed-loop with adjustment|Subjects will undergo 21 hour study using the Closed-loop Artificial Pancreas Controller to manage blood sugar. Exercise will be annouced to the controller and adjustments to insulin and glucagon delivery will be made.
3107130|NCT02241967|Experimental|tDCS Full Dose|4 active treatments
3107131|NCT02241967|Experimental|tDCS Half Dose|2 active treatments
3107132|NCT02241967|Experimental|tDCS Minimal dose|1 active treatment
3107133|NCT02241967|Sham Comparator|Sham tDCS|no active treatments
3107134|NCT02242019|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
3107135|NCT02242045|Experimental|Idelalisib|Participants with iNHL or CLL will receive idelalisib until the earliest of the following: unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anticancer or experimental therapy, investigator discretion, or idelalisib discontinuation.
3107136|NCT02242201|Active Comparator|PNB Bupivacaine|Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
3107137|NCT02242201|Active Comparator|PAI Ropivacaine|Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
3107138|NCT02242201|Active Comparator|PAI liposomal bupivacaine|Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.
3107139|NCT02242305|Experimental|Hyoscine Butylbromide - Tablet|
3107140|NCT02242305|Active Comparator|Hyoscine Butylbromide - Capsule|
3107141|NCT02242487|Experimental|CVT-301 Low Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
3107142|NCT02242487|Experimental|CVT-301 High Dose|Capsules of levodopa inhalational powder used up to 5 times/day for OFF episodes for 12 months duration
3107143|NCT02242630|Active Comparator|Methylprednisolone, 20 mg|Methylprednisolone, 20 mg, will be injected
3107144|NCT02242630|Active Comparator|Methylprednisolone, 40 mg|Methylprednisolone, 40 mg, will be injected
3107145|NCT02242630|Active Comparator|Triamcinolone, 20 mg|Triamcinolone, 20 mg, will be injected
3107146|NCT02242630|Active Comparator|Triamcinolone, 40 mg|Triamcinolone, 40 mg, will be injected
3107147|NCT02242643|Experimental|FluLaval™ Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of FluLaval™ Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
3107148|NCT02242643|Active Comparator|Fluzone® Quadrivalent Group|"Subjects in this group received 1 dose (primed subjects) at Day 0 and 2 doses (unprimed subjects) at Days 0 and 28 of Fluzone® Quadrivalent vaccine.~The vaccine was administered intramuscularly into the anterolateral region of the thigh (subjects below 12 months of age) or in the deltoid muscle of the non-dominant arm (subjects ≥12 months of age)."
3107149|NCT02242903|Experimental|LY3079514|Single dose of LY3079514 administered intravenous (IV) or subcutaneous (SC) during a single occasion
3107150|NCT02242903|Placebo Comparator|Placebo|Single dose of placebo matching LY3079514 administered IV infusion or SC injection during a single occasion.
3107151|NCT02242942|Experimental|Safety Run-in Obinutuzumab + Venetoclax|Subjects received obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles comprised of 28 days.
3107152|NCT02242942|Experimental|Obinutuzumab + Chlorambucil|Participants will receive obinutuzumab for 6 cycles and chlorambucil for 12 cycles. Cycles will comprise 28 days.
3107153|NCT02242942|Experimental|Obinutuzumab + Venetoclax|Participants will receive obinutuzumab for 6 cycles and venetoclax for 12 cycles. Cycles will comprise 28 days.
3107154|NCT02242981|Experimental|LY2623091|Single oral dose of LY2623091
3107155|NCT02242994|Experimental|Dynavox Maestro and Experimental App|Receives both Experimental App and Dynavox Maestro to communicate. Each participant will receive both devices. Order of device received is randomly assigned.
3107156|NCT02243007|Experimental|Folfirinox-ARM A|"Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel~Treatment will be administered on an outpatient basis and will include intravenous administration of the FOLFIRINOX regimen on predetermined days.~After completion of FOLFIRINOX all patients without progressive disease will proceed with radiation therapy with the standard dose of capecitabine.~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
3107157|NCT02243007|Experimental|Gemcitabine/nab-Paclitaxel- Arm B|"Treatment will be administered on an outpatient basis. Upon registration patients will be randomized to Arm A (FOLFIRINOX) or Arm B (Gemcitabine/nab-Paclitaxel).~Intravenous administration of the Gemcitabine/Nab-paclitaxel regimen on predetermined days of each 28 day treatment cycle (unless a delay is mandated by toxicity criteria). A cycle of Gemcitabine/Nab-paclitaxel will constitute a 28 day treatment period.~After Gemcitabine/Nab-paclitaxel, all patients without progressive disease will proceed to radiation therapy with the standard dose of capecitabine~Between 2 and 4 weeks after radiation is complete, patients will proceed for surgical resection of pancreatic cancer"
3107158|NCT02243020|Experimental|Vagus Nerve Stimulation (VNS) + Rehabilitation (1)|This group receives vagus nerve stimulation during rehabilitation. VNS and rehabilitation are the interventions.
3107159|NCT02243020|Active Comparator|Vagus Nerve Stim (VNS) + Rehabilitation (2) - Comparator|This group receives rehabilitation and VNS, but the VNS is different than given in the other group (rehabilitation is the only true intervention in this group). It may not be as effective as the other group's settings. Both groups receive the same amount of rehabilitation.
3107160|NCT02243046|Placebo Comparator|Control toothpaste|1450 ppm Fluoride toothpaste
3107161|NCT02243046|Experimental|Experimental toothpaste|1450 ppm sodium fluoride toothpaste with a zinc base
3107162|NCT02243046|Active Comparator|Active comparator|1450 ppm sodium fluoride/triclosan toothpaste
3107163|NCT02243176|Experimental|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocated to this arm.
3107164|NCT02243176|Active Comparator|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose. An estimated total of 480 patients (240 per treatment arm) will be randomized in a 1:1 ratio to the active treatment arm and the active comparator arm. So estimated 240 patients will be allocalted to this arm.
3107165|NCT02243202|Experimental|Canagliflozin + Phentermine|300 mg capsule of Canagliflozin along with 15 mg capsule of Phentermine, taken once daily, orally for 26 weeks.
3107166|NCT02243202|Experimental|Canagliflozin + Placebo (Phentermine)|300 mg capsule of Canagliflozin along with matching placebo to Phentermine, taken once daily, orally for 26 weeks.
3107167|NCT02243202|Experimental|Phentermine + Placebo (Canagliflozin)|15 mg capsule of Phentermine along with matching placebo to Canagliflozin, taken once daily, orally for 26 weeks.
3107168|NCT02243202|Placebo Comparator|Placebo|Matching placebo to Canagliflozin and Phentermine, taken once daily, orally for 26 weeks.
3107169|NCT02243280|Experimental|Arm A|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1-infected participants without cirrhosis
3107170|NCT02243280|Experimental|Arm B|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1- infected participants without cirrhosis
3107171|NCT02243280|Experimental|Arm C|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
3107172|NCT02243280|Experimental|Arm D|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 8 weeks in HCV genotype 1-infected participants without cirrhosis (never opened - Sponsor decision)
3107173|NCT02243280|Experimental|Arm E|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3107174|NCT02243280|Experimental|Arm F|ABT-493 200 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 1- infected participants with compensated cirrhosis
3107175|NCT02243280|Experimental|Arm G|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD + ribavirin (RBV) 800 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3107176|NCT02243280|Experimental|Arm H|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 1-infected participants with compensated cirrhosis (never opened - Sponsor decision)
3107177|NCT02243280|Experimental|Arm I|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis
3107178|NCT02243280|Experimental|Arm J|ABT-493 200 mg once daily (QD) + ABT-530 40 mg QD for 12 weeks in HCV genotype 4-, 5-, and 6-infected participants without cirrhosis (never opened - Sponsor decision)
3107179|NCT02243280|Experimental|Arm K|ABT-493 300 mg once daily (QD) + ABT-530 120 mg QD for 8 weeks in HCV genotype 1- infected participants without cirrhosis
3107180|NCT02243293|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 2 (GT2) -infected treatment naïve and treatment experienced participants without cirrhosis.
3107181|NCT02243293|Experimental|Arm B|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107182|NCT02243293|Experimental|Arm C|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided twice daily (BID) for 12 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107183|NCT02243293|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV genotype 3 (GT3) -infected treatment naïve and treatment experienced participants without cirrhosis.
3107184|NCT02243293|Experimental|Arm E|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107185|NCT02243293|Experimental|Arm F|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and weight-based ribavirin (RBV) divided BID for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107186|NCT02243293|Experimental|Arm G|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107187|NCT02243293|Experimental|Arm H|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107188|NCT02243293|Experimental|Arm I|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (40 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107189|NCT02243293|Experimental|Arm J|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT2 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107190|NCT02243293|Experimental|Arm K|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and treatment experienced participants without cirrhosis.
3107191|NCT02243293|Experimental|Arm L|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in HCV GT3 -infected treatment naïve and for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3107192|NCT02243293|Experimental|Arm M|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
3107193|NCT02243293|Experimental|Arm N|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD and ribavirin (RBV) (800 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis.
3107194|NCT02243293|Experimental|Arm O|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in HCV GT3 -infected treatment naïve participants with compensated cirrhosis and for 16 weeks in HCV GT3 -infected treatment-experienced participants with compensated cirrhosis.
3107195|NCT02243293|Experimental|Arm P|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD and RBV (800 mg) QD for 12 weeks in HCV GT3-infected treatment naïve and treatment-experienced participants with compensated cirrhosis.
3107196|NCT02243293|Experimental|Arm Q1|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment naïve participants with cirrhosis.
3107197|NCT02243293|Experimental|Arm Q2|ABT-493/ ABT-530 (300 mg/ 120mg ) once daily (QD) for 12 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3107198|NCT02243293|Experimental|Arm R1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants without cirrhosis.
3107199|NCT02243293|Experimental|Arm R2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 16 weeks in HCV GT3 -infected treatment experienced participants with cirrhosis.
3107200|NCT02243293|Experimental|Arm S1|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT2 infected treatment naïve and treatment experienced participants without cirrhosis.
3107201|NCT02243293|Experimental|Arm S2|ABT-493/ ABT-530 (300 mg/ 120 mg) QD for 8 weeks in HCV GT4-6 infected treatment naïve and treatment experienced participants without cirrhosis.
3469164|NCT03889054|Active Comparator|Structured health education program|Patient will be referred to a specific consultation to carry out this intervention.
3469165|NCT03888989|Other|Study Phase|Participants will be given the current year's quadrivalent inactivated influenza vaccine (IIV)
3107204|NCT02243371|Experimental|Arm A: CY/ GVAX/ CRS-207/ nivolumab|
3107205|NCT02243371|Experimental|Arm B: CY/ GVAX/ CRS-207|
3107206|NCT02243527|Experimental|Inspiratory Muscle Training|
3107207|NCT02243527|Sham Comparator|Sham-Control Inspiratory Muscle Training|Inspiratory muscle training at a low intensity meant to elicit no physiological changes.
3107208|NCT02243579|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years (6 months for patients achieving CR) in the absence of disease progression or unacceptable toxicity.
3107209|NCT02243605|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3107210|NCT02243865|Experimental|Chordate S200 + control module (CT100), active|Chordate System S200 giving Kinetic Oscillation Stimulation Treatment for 15 minutes in each nostril
3107211|NCT02243865|Placebo Comparator|Chordate S200 + control module (CT100), placebo|Chordate System S200 giving Kinetic Oscillation Stimulation in placebo mode. Non-inflated and non-vibrating treatment
3107212|NCT02243943|Experimental|Sugammadex|Subjects in this arm will be reversed with sugammadex 2-4 mg/kg
3107213|NCT02243943|Active Comparator|neostigmine|subjects in this arm will be reversed with neostigmine 1.0-2.5 mg and atropine 0.5-1.0mg
3107214|NCT02244424|Experimental|Tools for Teen Moms Intervention Group|Tools for Teen Moms intervention group will receive daily challenges focusing on: 1) Maternal-Infant Feeding Interaction; and 2) Feeding Practices Challenges. The challenges will cycle through a pre-determined schedule where they are automatically updated each day at midnight. Participants will have a 24-hour period to complete each challenge. The intervention will provide a new daily challenge over six weeks, a time frame selected to provide participants with enough opportunities to form the habit of visiting the website daily. Participants will continue to receive usual MIHP care during the intervention.
3107215|NCT02244424|No Intervention|MIHP standard care|MIHP care consists of voluntary home visits: one week postpartum, at six weeks, and six months, and on-going as needed provided by a RN, licensed social worker, RD, infant mental health specialist and/or paraprofessional. Content includes a flexible plan of care with visits based on identified domains for both the mother and the infant.
3107216|NCT02244580|Experimental|MammaTyper™|MammaTyper™ kit will be used tio assess tumor material of patients enrolled into the FinHer trial.
3107217|NCT02244619|Active Comparator|Oral acetaminophen|Subjects receive 2 capsules each containing Tylenol 500 mg caplets. The test article administration will be initiated 60 minutes (± 15 minutes) prior to the scheduled surgery start time.
3107218|NCT02244619|Active Comparator|IV acetaminophen|Subjects receive Ofirmev 1000 mg in 100 ml Normal Saline IV infusion. The test article will be given perioperatively at the discretion of the attending anesthesiologist.
3107219|NCT02244840|Experimental|Electronic bidet and sitz bath|Electronic bidet for 3 minutes and sitz bath for 3 minutes, at another day, for each subject
3107220|NCT02244918|Active Comparator|Counseling|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions.
3107221|NCT02244918|Experimental|Counseling Plus NRT|Participants will go to smoking cessation counseling over 12 weeks. They will be asked to participated in 5 total counseling sessions. In addition to counseling, participants in this group will also take 12 weeks of a nicotine replacement therapy(NRT) (like the patch, gum or lozenge) of their choice.
3107222|NCT02244957|Active Comparator|Bi-level positive airway pressure (BPAP)|Bi-level positive airway pressure (BPAP)
3107223|NCT02244957|Active Comparator|Nocturnal oxygen|Nocturnal oxygen
3107224|NCT02244996|Experimental|Lycium Barbarum|Daily Lycium Barbarum dosage: 10g of granules for 12 months
3107225|NCT02244996|Placebo Comparator|Placebo|Placebo
3107226|NCT02245217|Experimental|PET/CT Imaging arm|
3107229|NCT02245360|Experimental|Grass tablet 75,000 SQ-T|Grass tablet 75,000 Standardized Quality units Tablet (SQ-T)
3107230|NCT02245360|Placebo Comparator|Placebo|Placebo
3107231|NCT02245412|Experimental|ALXN1007 10 mg/kg once weekly|Cohort 1, the first dosing cohort, received 10 mg/kg ALXN1007 IV once weekly for 8 weeks.
3107232|NCT02245412|Experimental|ALXN1007 20 mg/kg once weekly|Cohort 2 received 20 mg/kg ALXN1007 IV once weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
3107233|NCT02245412|Experimental|ALXN1007 20 mg/kg twice weekly|Cohort 3 received 20 mg/kg ALXN1007 IV twice weekly for 8 weeks. For the first 2 participants enrolled, the first ALXN1007 dose was not to be administered on the same day and a safety and tolerability review was to take place after the second (and prior to the third) ALXN1007 dose for each participant. If the ALXN1007 dose was determined to be sufficiently tolerated by the participant, dosing was to continue for that participant. For any other participants enrolled in the dosing cohort, participants were not to proceed to the third ALXN1007 dose prior to the completion of the safety and tolerability review (of the first 2 doses) for the first 2 participants.
3107234|NCT02245516|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|KPI-121 0.25% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
3107235|NCT02245516|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|KPI-121 1.0% Ophthalmic Suspension dosed QID for 4 weeks in subjects with Retinal Vein Occlusion or Diabetic Macular Edema
3107236|NCT02245568|Experimental|LMTM|
3107237|NCT02245620|Experimental|Elamipretide|Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
3107238|NCT02245620|Placebo Comparator|Placebo|Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
3107239|NCT02245672|Experimental|MGR001|MGR001 administered two times per day by inhalation throughout the study
3107240|NCT02245672|Active Comparator|Advair Diskus|Advair Diskus administered two times per day by inhalation throughout the study
3107241|NCT02245672|Placebo Comparator|Placebo|Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study
3107242|NCT02245737|Experimental|Lanabecestat 20 milligrams (mg)|Lanabecestat 20 mg given orally once daily for 104 weeks.
3107243|NCT02245737|Experimental|Lanabecestat 50 mg|Lanabecestat 50 mg given orally once daily for 104 weeks.
3107244|NCT02245737|Placebo Comparator|Placebo|Placebo given orally once daily for 104 weeks.
3107245|NCT02245815|Experimental|use probiotics boucardii|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
3107246|NCT02245815|Experimental|use probiotics Multi-species|was administered the probiotic 1x10⁹ colonies forming units per day for 3 weeks
3107247|NCT02246010|Experimental|Lactose-free milk|Lactose- free milk formula (Similac LF®) and anti-diarrheic diet for 7 days.
3107248|NCT02246010|No Intervention|Regular infant milk|Regular infant milk formula and anti-diarrheic diet for 7 days.
3107249|NCT02246062|No Intervention|Control group|in which the relative receive only conventional verbal information one day before the procedure at ward.
3107250|NCT02246062|Active Comparator|info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery at ward.
3107251|NCT02246062|Active Comparator|smartphone group|in which the relative received only conventional verbal information one day before the procedure and the child received smartphone application immediately before entering the operating room
3107252|NCT02246062|Active Comparator|smartphone and info group|in which the relative, in addition to conventional verbal information, received a leaflet containing information about the anesthetic procedure one day before the surgery and the child received smartphone application immediately before entering the operating room.
3107253|NCT02246166|Experimental|Test tablet|Tablet containing Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets (II) (Paracetamol 500mg, pseudoephedrine 30mg, chlorpheniramine 2mg and dextromethorphan 15mg).
3107254|NCT02246166|Placebo Comparator|Placebo|Matching placebo tablet
3107255|NCT02246218|Experimental|RAVICTI|RAVICTI Oral Liquid should be administered just prior to breastfeeding or intake of formula or food. The recommended dosing regimen is 3-6 times per day depending on feeding schedule and at the discretion of the Investigator.
3107256|NCT02246309|Experimental|Embryoscope Time Lapse System|All embryos from patients randomized to this arm will be cultured in the Embryoscope culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
3107257|NCT02246309|Active Comparator|Standard Embryo Culture|All embryos from patients randomized to this arm will be cultured in the standard embryo culture system from the time of insemination until the time of transfer on day 3. All staff interaction with the embryos or with maintenance or supervision of the system will be timed.
3107258|NCT02246413|Experimental|RAINBOW Intervention Program|An integrated intervention program for helping to improve mood and weight in adults who may be at risk for diabetes and heart disease.
3107259|NCT02246413|No Intervention|Usual Care|Usual Care.
3107260|NCT02246439|Experimental|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
3107261|NCT02246439|Placebo Comparator|Placebo|Placebo
3107262|NCT02246478|Placebo Comparator|Placebo|
3107263|NCT02246478|Active Comparator|TAS-205 low dose|
3107264|NCT02246478|Active Comparator|TAS-205 middle dose|
3107265|NCT02246478|Active Comparator|TAS-205 high dose|
3107266|NCT02246582|Other|Group A|Subjects underwent FST at 30 mins, 50 hrs and 146 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
3107267|NCT02246582|Other|Group B|Subjects underwent FST at 14 hrs, 62 hrs and 158 hrs from Enlite 3 Sensors connected to GST3C, GST4C Transmitter, and GSR
3107268|NCT02246608|Active Comparator|Routine NPWT Standard of Care|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, standard of care dressing will be placed.
3107269|NCT02246608|Experimental|NPWT Standard of Care plus Oasis wound product|Prior to applying and activating the Negative Pressure Wound Treatment (NPWT) pump, Oasis wound product will be applied in addition to standard of care dressing.
3469166|NCT03888846|Other|Colchicine|Colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
3469167|NCT03888846|Experimental|Topical Pentoxifylline Gel and Colchicine|Topical Pentoxifylline Gel administration in addition to the colchicine therapy as part of supportive care routinely offered in Behcet's Clinic-Istanbul
3107272|NCT02246647||Healthy volunteers|Permeability measurement: Ingestion of saccharides {mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
3107273|NCT02246647||IBS-C|Permeability measurement: Ingestion of saccharides (mannitol (regular, 12C) 100 mg, lactulose 1 g and labelled (13C mannitol) 100 mg} in 250ml of water Esophagogastroduodenoscopy Flexible sigmoidoscopy
3107274|NCT02246660|Active Comparator|Resveratrol - 500 mg/day|The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
3107275|NCT02246660|Active Comparator|Resveratrol - 125 mg/day|The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
3107276|NCT02246660|Placebo Comparator|Placebo|Placebo will be taken orally for 6 months.
3107277|NCT02246673|Experimental|RDEA3170 10 mg|Once daily (qd) with febuxostat 40mg (qd) for 7 days, and with febuxostat 80 mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3107278|NCT02246673|Experimental|RDEA3170 15 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3107279|NCT02246673|Experimental|RDEA3170 5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3107280|NCT02246673|Experimental|RDEA3170 2.5 mg|Once daily with febuxostat 40mg (qd) for 7 days and with febuxostat 80mg (qd) for 7 days; febuxostat 40 mg (qd) only for 7 days, and febuxostat 80 mg (qd) only for 7 days.
3107281|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) and 1 drop placebo in the morning (AM) in both eyes (OU)
3107282|NCT02246764|Experimental|AR-13324 Ophthalmic Solution 0.02% BID|1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3107283|NCT02246764|Active Comparator|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop Timolol maleate twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)
3107284|NCT02246777|Experimental|Ex-PRESS|Ex-PRESS® Glaucoma Filtration Device, Model P50PL, implanted in the anterior chamber of the study eye during glaucoma surgery intended for the lifetime of the patient
3107285|NCT02246998|Experimental|STB+iohexol|Participants will receive STB+iohexol for 24 weeks.
3107286|NCT02246998|Experimental|RTV+ATV+TVD+iohexol|Participants will receive RTV+ATV+TVD+iohexol for 24 weeks.
3107287|NCT02246998|Experimental|ATR+iohexol|Participants will receive ATR+iohexol for 24 weeks.
3107288|NCT02246998|Experimental|RTV+ATV+ABC/3TC+iohexol|Participants will receive RTV+ATV+ABC/3TC+iohexol for 24 weeks.
3107289|NCT02247011|Other|fracture group|Fracture group included participants with new fractures during the 5 year follow-up visit. Fracture consists of non-vertebral fracture and vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
3107290|NCT02247011|Other|non-fracture group|Fracture group included participants without new fractures during the 5 year follow-up visit. Fracture consists of vertebral fracture and non-vertebral fracture, which were investigated by questionnaire survey and lateral radiographs, respectively.
3107291|NCT02247063|Sham Comparator|Placebo|The subjects in the placebo arm will participate in 5 daily M1 High-Definition Transcranial Direct Current Stimulation (HD-tDCS) sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Current will be applied only for 30 seconds - this is a reliable method of sham stimulation (Gandiga et al., 2006) as sensations arising from tDCS treatment occur only at the beginning of application.
3107292|NCT02247063|Experimental|Experimental|The subjects in the experimental arm will participate in 5 daily sessions. During each session, a modular EEG recording cap will be placed on the subject's head and the anodal electrode will be placed on the motor cortex contralateral to the worst TMD pain side (C3). Then 2mA of transcranial direct current stimulation will be applied for 20 minutes.
3469168|NCT03888963|Experimental|PRF|
3469169|NCT03888963|Sham Comparator|SHAM|
3107293|NCT02247193|Experimental|Botulinum Toxin|Injection of botulinum toxin into cleft lip at time of surgical repair.
3107294|NCT02247193|Placebo Comparator|Saline|Injection of normal saline into cleft lip at time of surgical repair.
3107295|NCT02247245|Placebo Comparator|Placebo|Subjects are given a placebo capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
3107296|NCT02247245|Active Comparator|Ivabradine|Subjects are given an ivabradine capsule (double-blinded) to take 90 minutes prior to the cardiopulmonary exercise test.
3107297|NCT02247245|Experimental|Atrial fibrillation|Subjects are (double blind) randomised to either a low base pacing rate (30) or a standard base rate (60), with rate adaptive algortithms switched on.
3107298|NCT02247336|Experimental|Immediate|Patients will complete a family health history platform at enrollment
3107299|NCT02247336|Active Comparator|Delayed|Patients will complete a family health history platform 12 months following enrollment
3107300|NCT02247401|Active Comparator|Arm A|ABT-450/r/ABT-267 (paritaprevir/ritonavir/ombitasvir; 2 direct acting antiviral agent [DAA]) plus Ribavirin (RBV) for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants without cirrhosis.
3107301|NCT02247401|Active Comparator|Arm B|ABT-450/r/ABT-267 plus RBV for 12 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
3107302|NCT02247401|Active Comparator|Arm C|ABT-450/r/ABT-267 plus RBV for 24 weeks in treatment-naïve and treatment-experienced (with pegylated interferon and ribavirin) participants with compensated cirrhosis.
3107303|NCT02247440|Experimental|PegINF-ribavirin|"Peg-interferon + ribavirin under HIV physician supervision Peg-interferon alpha 2-b initial dosing is 1.5 micrograms/kg (subcutaneous injection) once a week~Ribavirin initial dosing in the morning and in the evening:~For genotypes 2, 3: ribavirin 400 mg (i.e. 800 mg daily).~For genotypes 1, 4, 5 and 6:~800 mg/day, if bodyweight <65 kg,~1000 mg/day, if bodyweight between 66-80 kg,~1200 mg/day, if bodyweight between 81-105 kg,~1400 mg/day, if bodyweight >105 kg.~Duration: 48 weeks"
3107304|NCT02247466|Active Comparator|Group A - Saline, assesment, rocuronium and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of saline (placebo) 6mL (TOF 100%) the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. After administration of rocuronium 0.6 mg/kg when TOF=0 the surgical workspace is assessed again
3107305|NCT02247466|Active Comparator|Group B - Rocuronium, assesment, sugammadex and assesment|Intervention after intubation and placement of trocars without NMB. Bolus of rocuronium 0.6 mg/kg when TOF=0 the surgeon assesses the surgical workspace with pneumoperitoneum 12 mmHg. Three minutes after administration of sugammadex (TOF 100%) the surgical workspace is assessed again
3107306|NCT02247479|Experimental|Lampalizumab Once in Every 4 Weeks (Q4W)|Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
3107307|NCT02247479|Experimental|Lampalizumab Once in Every 6 Weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
3107308|NCT02247479|Sham Comparator|Sham Comparator|Participants will receive sham comparator Q4W or Q6W for 96 weeks.
3107309|NCT02247531|Experimental|Lampalizumab once in every 4 weeks (Q4W)|Participants will receive 10 mg (milligrams) dose of lampalizumab by intravitreal injection, Q4W, starting at the Day 1 visit for approximately 92 weeks.
3107310|NCT02247531|Experimental|Lampalizumab once in every 6 weeks (Q6W)|Participants will receive 10 mg dose of lampalizumab by intravitreal injection, Q6W, starting at the Day 1 visit for approximately 90 weeks.
3107311|NCT02247531|Sham Comparator|Sham Comparator|Participants will receive sham comparator, Q4W, starting at the Day 1 visit for approximately 92 weeks or Q6W, starting at the Day 1 visit for approximately 90 weeks.
3107312|NCT02247739|Experimental|rhC1INH twice weekly|rhC1INH administered twice weekly
3107313|NCT02247739|Experimental|rhC1INH once weekly|rhC1INH administered once weekly
3107314|NCT02247739|Placebo Comparator|Placebo (Saline) twice weekly|Placebo (Saline) administered twice weekly
3107315|NCT02247765|Experimental|Arterial Line|CO-Oximetry value obtained as a comparator. Obtained during motion conditions.
3107316|NCT02247765|Experimental|Motion|The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.
3107317|NCT02247804|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained release (SR) 15 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107318|NCT02247804|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107319|NCT02247804|Active Comparator|Timolol 0.5%|Study Eye and Non-Study Eye: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107320|NCT02247960|Active Comparator|Ciprofloxacin|Antibiotic
3107321|NCT02247960|No Intervention|No Antibiotic|No Antibiotic
3107322|NCT02248103|Experimental|periosteal pedicle graft|autogenous marginal periosteal pedicle graft harvested by partial thickness periodontal flap.
3107323|NCT02248103|Active Comparator|Bioresorbable collagen membrane|Equine Achilles tendon collagen barrier membrane
3107324|NCT02248246|Other|Colectomy with Harmonic ACE®+7 Shears|Laparoscopic colectomy with Harmonic ACE®+7 Shears for dissection and vessel transection
3107325|NCT02248285|Experimental|Intervention|FilmArray™ GI Panel testing will be standard of care and provided at no cost. Additional testing may be ordered at the discretion of the clinician.
3107326|NCT02248285|No Intervention|Pre-intervention|Testing will be at the discretion of the clinician using standard laboratory tests, and specimens will be collected as appropriate for these methods.
3469170|NCT03889145|Active Comparator|Telmisartan, Amlodipine|
3469171|NCT03889145|Active Comparator|Hydrochlorothiazide|
3107327|NCT02248480|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 12 weeks administered orally once daily. Tapering week doses of 40 mg for three days and 20 mg for four days.
3107328|NCT02248480|Placebo Comparator|Placebo|Placebo administered orally once a day for 15 weeks.
3107329|NCT02248558|Active Comparator|Conventional video|This arm will receive a one-minute conventional video promoting HIV test uptake.
3107330|NCT02248558|Experimental|Crowdsourced video|This arm will receive a one-minute crowdsourced video promoting HIV test uptake.
3107331|NCT02248636|Experimental|Real discontinuation|This group is tapered off their previous cholinesterase inhibitor medication.
3107332|NCT02248636|Sham Comparator|Sham discontinuation|This group receives their previous cholinesterase inhibitor medication, but in in placebo form.
3107333|NCT02248649|Experimental|Physical Activity|Structured walking program
3107334|NCT02248649|Active Comparator|Control|Health education attention control
3107335|NCT02248662||Surveillance, Epidemiology, and End Results (SEER) Database|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER) with a diagnosis of ductal carcinoma in situ (DCIS) between 1990 and 2011 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
3107336|NCT02248662||Surveillance, Epidemiology, and End Results (SEER)-Medicare|Data were obtained for women in Surveillance, Epidemiology, and End Results (SEER)-Medicare with a ductal carcinoma in situ (DCIS) diagnosis between 1991 and 2009 who had not undergone radiotherapy for DCIS and experienced a subsequent breast cancer or DCIS diagnosis.
3107337|NCT02248675|Experimental|CBT-I + TAU|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions as an adjunctive treatment to treatment as usual (TAU).
3107338|NCT02248675|Active Comparator|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
3107339|NCT02248714|Experimental|Study arm|Use Glucerna SR as a meal replacement at breakfast meal in the study group, meanwhile patients receive diabetes diet management (Each subject will be individually instructed by a dedicating dietitian how to implement the daily diabetes diet before starting the study.)
3107340|NCT02248714|No Intervention|Control arm|Patients only receive diabetes diet management according to the instruction of dedicating dietitian on how to implement the daily diabetes diet.
3107341|NCT02248727|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
3107342|NCT02248727|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens and who are refitted with somofilcon A lens
3107343|NCT02248766|Active Comparator|enfilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
3107344|NCT02248766|Experimental|somofilcon A|All participants are habitual wearers of enfilcon A lens who are refitted with somofilcon A lens
3107345|NCT02248818|Experimental|AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 6 subjects will receive AZD8108
3107346|NCT02248818|Placebo Comparator|Placebo to match AZD8108|Subjects will participate in 1 of 7 groups and receive single or multiple doses of AZD8108 or matching placebo. In each group 2 subjects will receive matching placebo
3107347|NCT02248857|No Intervention|Usual Care|Employ the current standard of care. No intervention.
3107348|NCT02248857|Experimental|UMS strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.~Prescription instructions will be adapted to UMS to establish four standard time intervals for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with content from a patient's perspective and following health literacy best practices.~A list of their current medications each corresponding to a set of instructions and a checkbox for morning, noon, evening, and bedtime medicine to help patients visually depict when to take their medicines."
3107349|NCT02248857|Experimental|UMS strategy + SMS texting reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
3107350|NCT02248922|Experimental|Tobramycin ALL|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)twice a day (BID) 28days on / 28 days off
3107351|NCT02248961|Experimental|Kanarb (Fimasartan)|88 subjects will receive Kanarb (Fimasartan), manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, tablets 60/120 mg for 12 weeks
3107352|NCT02248961|Active Comparator|Cozaar® (Losartan)|88 subjects will receive Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg for 12 weeks
3107353|NCT02248974|Active Comparator|LVAD Decision Aid|Decision aid presented to subjects was developed from patient and clinician feedback to increase patient knowledge on the risks, benefits, misconceptions or mispredictions regarding LVADs to help patients make an informed decision on accepting or declining LVAD placement.
3107354|NCT02248974|No Intervention|No LVAD Decision Aid|The standard education processis institution-specific and unstandardized. The education consists of viewing education pamphlets that are created by device manufacturers. The traditional informed consent process may also include viewing and manipulating the actual device and meeting a patient with a device already implanted. Additionally, the LVAD coordinator describes the device and answers any questions LVAD candidates have.
3107355|NCT02249052|Active Comparator|AA4500|single injection of 0.58 mg study drug
3107356|NCT02249052|Placebo Comparator|Placebo|single injection of placebo
3107357|NCT02249065|Experimental|Mirvaso Gel|Brimonidine topical gel, 0.33%
3469172|NCT03889145|Experimental|Telmisartan, Amlodipine, Hydrochlorothiazide|
3469173|NCT03889106||Lassa fever|
3469174|NCT03889236|Experimental|Fasting mimicking diet|5-day Fasting mimicking diet Prolon. In total 3 cycles of the FMD in three months.
3107358|NCT02249091|Experimental|Cohort 1 / Selinexor 40 mg/m^2 in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m² continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a dose of 40 mg/m^2 twice weekly orally starting on day 2 (total of 8 doses per induction cycle)."
3107359|NCT02249091|Experimental|Cohort 2 / Selinexor 60 mg flat dose in combination with cytarabine and idarubicin|"All enrolled patients are treated with cytarabine at a dose of 100 mg/m^2 continuous infusion (day 1-7) and idarubicin at a dose of 10 mg/m^2 iv (day 1,3,5) every 4 weeks and selinexor for up to 2 induction cycles. If a second cycle is applied idarubicin is only given on day 1 and 3.~Selinexor is administered at a flat dose of 60 mg twice weekly orally in weeks 1-3 of a 4-week cycle starting on day 2 (total of 6 doses per induction cycle)."
3107360|NCT02249104|Experimental|Acne treatment|"Adapalene/benzoyl peroxide gel, 0.1%/2.5%, once daily~Cetaphil Acne Regimen:~Cetaphil® DermaControl™ Moisturizer SPF 30, once daily and additionally 15 minutes prior to participation in outdoor sports if more than 2 hours elapsed since morning application~Cetaphil® DermaControl™ Foam Wash, at least twice daily"
3107361|NCT02249143|Active Comparator|CPAP and room air|Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
3107362|NCT02249143|No Intervention|Room air|Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
3107363|NCT02249182|Experimental|12 to < 18 Years Old|"Participants between 12 to < 18 years of age weighing ≥ 45 kg will receive LDV/SOF FDC (90/400 mg tablet or 4 x 22.5 mg/100 mg tablets or 8 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV genotypes (GT) 1, 4, 5, or 6 treatment-naive (TN) with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 treatment-experienced (TE) without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
3107364|NCT02249182|Experimental|6 to < 12 Years Old|"Participants between 6 to < 12 years of age weighing ≥ 17 kg and < 45 kg will receive LDV/SOF FDC (45/200 mg as 2 x 22.5/100 mg tablets or 4 x 11.25/50 mg granules based on swallowability assessment during screening).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
3107365|NCT02249182|Experimental|3 to < 6 Years Old|"Participants between 3 to < 6 years of age weighing ≥ 17 kg will receive LDV/SOF FDC (45/200 mg granules as 4 x 11.25/50 mg packets) and participants weighing < 17 kg will receive LDV/SOF FDC (33.75/150 mg oral granules as 3 x 11.25/50 mg packets).~Treatment duration will be dependent on HCV genotype, prior treatment experience, cirrhosis status, and country of enrollment.~United Kingdom:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 3 TE with or without cirrhosis = LDV/SOF+RBV 24 weeks~United States/Australia/New Zealand:~HCV GT 1, 4, 5, or 6 TN with or without cirrhosis = LDV/SOF 12 weeks~HCV GT 1, 4, 5, or 6 TE without cirrhosis = LDV/SOF 12 weeks~HCV GT 1 TE with cirrhosis = LDV/SOF 24 weeks~HCV GT 4, 5, or 6 TE with cirrhosis = LDV/SOF 12 weeks"
3107366|NCT02249585|Experimental|CS|Patients who receive laparoscopic colon surgery under Trendelenberg position with conventional neuromuscular blockade and standard abdominal pressure.
3107367|NCT02249585|Experimental|DS|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and standard abdominal pressure.
3107368|NCT02249585|Experimental|DL|Patients who receive laparoscopic colon surgery under Trendelenberg position with deep neuromuscular blockade and low abdominal pressure.
3107369|NCT02249728|Experimental|Absolute Bioavailability|IV PBT2 microtracer and oral PBT2 single dose
3107370|NCT02249728|Experimental|Radiolabelled AME|oral 14C PBT2
3107371|NCT02249767|Active Comparator|Generic Tretinoin|Treatment of acne once daily over 12 weeks
3107372|NCT02249767|Active Comparator|Brand Tretinoin|Treatment of Acne once daily over 12 weeks
3107373|NCT02249767|Placebo Comparator|Placebo Vehicle|Treatment of acne once daily over 12 weeks
3107374|NCT02249793||Study group|Healthy volunteers
3107375|NCT02249819|Experimental|anodal tDCS, then sham tDCS|Participants received 1 single 20 min session of anodal tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of sham tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
3107376|NCT02249819|Experimental|sham tDCS, then anodal tDCS|Participants received 1 single 20 min session of sham tDCS + computerized naming therapy. Following a 1 week washout period, they received 1 single 20 min session of anodal tDCS + computerized aphasia therapy. Sequence of stimulation conditions was randomized across participants.
3107377|NCT02249832|Experimental|seated robot-assisted ankle therapy|All participants received eighteen 1 hour sessions (3x/week for 6 weeks) of seated robot-assisted ankle training with the MIT anklebot. Upon analysis, subjects were stratified based on average admission gait speed on the 10 Meter Walk Test at comfortable pace according to clinically established gait speed performance groups: low (<0.4m/sec), moderate (0.4m/sec-0.8m/sec) and high (>0.8m/sec) functioning.
3107378|NCT02249949|Experimental|efatutazone dihydrochloride|Patients receive efatutazone dihydrochloride PO BID continuously. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3107379|NCT02250092|Active Comparator|tDCS/CIMT|Intervention Group will receive 20 minutes of 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
3107380|NCT02250092|Placebo Comparator|tDCS sham/CIMT|Placebo Group will receive 20 minutes of sham 1.0 mA tDCS to the contralesional hemisphere concurrent with CIMT.
3107381|NCT02250183|Other|Medihoney & Santyl|Each patient will receive both interventions simultaneously, but on non-contiguous parts of the body that each consist of partial thickness burn injuries of similar depth. For example, if a patient presents with bilateral second-degree burns to the lower extremities, one leg will be treated with MEDIHONEY® GEL with Active leptospermum honey dressing, while the other leg will be treated with SANTYL® ointment dressing. MEDIHONEY® is the target treatment for this study, while SANTYL® is standard care.
3107382|NCT02250274|Other|LAIV 2014-15|Will receive LAIV this year. Includes 5-8 year olds and approximately half of the 9-17 year olds. Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, all ages.
3107383|NCT02250274|Other|IIV 2014-15|Will receive IIV this year. Includes only 9-17 year olds (unless shortages of LAIV encountered). Prior history includes vaccine failures, vaccinated/uninfected and unvaccinated/uninfected last year. PBMC available for those who were infected last year, only 9-17 year olds.
3107384|NCT02250326|Experimental|Combination arm: nab-paclitaxel and CC-486|Subjects in the combination arm will receive nab-paclitaxel 100 mg^/m2 intravenous (IV) infusion over 30 minutes on Days 8 and 15 and CC-486 200 mg orally daily (QD) on Days 1 to14 of each 21-day treatment cycle
3107385|NCT02250326|Experimental|Monotherapy arm: nab-paclitaxel IV infusion|Subjects in the monotherapy arm will receive nab-Paclitaxel 100 mg/m^2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day treatment cycle
3107386|NCT02250326|Experimental|Nab-paclitaxel and Durvalumab combination|subjects in the nab-Paclitaxel/durvalumab combination arm will receive nab-Paclitaxel 100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and durvalumab 1125 mg IV infusion over approximately 1 hour on Day 15 of each 21-day treatment cycle
3107387|NCT02250417|Experimental|Wave Surface, Then Non Wave Surface|Subjects sleep first for a whole night in the sleep laboratory with the Wave sleep surface. They then return to the sleep laboratory and sleep without the Wave sleep surface.
3107388|NCT02250417|Experimental|Non Wave Surface, Then Wave Surface|Subjects sleep first for a whole night in the sleep laboratory without the Wave sleep surface. They then return to the sleep laboratory and sleep with the Wave sleep surface.
3107389|NCT02250443|Experimental|BYM338|BYM338 Group
3107390|NCT02250521|Experimental|McGrath Mac intubations|All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The liquid crystal display (LCD) monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist.
3107391|NCT02250612|Experimental|SYL040012 (bamosiran) 0.375% eye drops|1 drop in each eye once daily for 28 consecutive days
3107392|NCT02250612|Experimental|SYL040012 (bamosiran) 0.750% eye drops|1 drop in each eye once daily for 28 consecutive days
3107393|NCT02250612|Experimental|SYL040012 (bamosiran) 1.125% eye drops|1 drop in each eye once daily for 28 consecutive days
3107394|NCT02250612|Experimental|SYL040012 (bamosiran) 1.5% eye drops|1 drop in each eye once daily for 28 consecutive days
3107395|NCT02250612|Active Comparator|Timolol maleate 0.5% ophthalmic solution|1 drop in each eye twice daily for 28 consecutive days
3107396|NCT02250651|Experimental|Bimatoprost SR 15 μg|Study Eye: bimatoprost sustained-release (SR) 15 micrograms (μg) administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107397|NCT02250651|Experimental|Bimatoprost SR 10 μg|Study Eye: bimatoprost SR 10 μg administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol vehicle administered once in the morning and once in the evening for up to 20 months. Non-Study Eye: sham administration on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107398|NCT02250651|Active Comparator|Timolol 0.5%: Comparator|Both Eyes: sham administered on Day 1 (Period 1), Week 16 (Period 2), and Week 32 (Period 3); timolol 0.5% administered once in the morning and once in the evening for up to 20 months.
3107399|NCT02250703|Active Comparator|Midazolam|In M group, patients will be given oral midazolam 0.5mg/kg upto maximum dose of 15mg (5mg/ml parenteral preparation) mixed with flavored syrup as premedication
3107400|NCT02250703|Experimental|Dexmedetomidine|In D group, patients will be given intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg prepared from 100mcg/ml parenteral preparation (Hospira R) . The drug will be administered using a intranasal mucosal administration device (LMA MAD NasalTM).
3107401|NCT02250807|Experimental|Simeprevir and Sofosbuvir|Subjects will receive oral capsule of Simeprevir 150 milligram (mg) along with oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
3107402|NCT02251236|Other|Stribild Arm|Stribild Arm is for participants taking Stribild at the time of study entry. Participants taking Stribild at the time of study entry will switch to Genvoya before the second PK.
3107403|NCT02251236|Other|Genvoya Arm|Genvoya Arm is for participants already taking Genvoya at the time of study entry. Participants taking Genvoya at the time of study entry will continue Genvoya for the second PK.
3107404|NCT02251236|Other|Untreated Arm|Untreated Arm is for participants who are not taking ART at the time of study entry. Participants will start Stribild at entry and switch to Genvoya before the second PK.
3107405|NCT02251275|Experimental|Tolvaptan|"Tolvaptan was self-administered orally as split-dose regimens. The dose regimens used in this trial were 15/15 milligram (mg), 30/15 mg, 45/15 mg, 60/30 mg, or 90/30 mg. Starting doses were dependent upon the participant's previous trial as follows:~Trial 156-13-210: initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability.~Trial 156-08-271: retained the last dose level of tolvaptan received in the trial (45/15 mg, 60/30 mg, or 90/30 mg) and started at that same dose in Trial 156-13-211.~Other Trials (156-04-251 and 156-09-290): initiated on tolvaptan at a split-dose of 45/15 mg with upward titration every 3 to 4 days to 60/30 mg or 90/30 mg per day according to tolerability."
3107406|NCT02251379|Experimental|ECS + Medication Group|"The Environmental Control Strategy (Home Environmental Intervention) plus inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)"
3107407|NCT02251379|Active Comparator|Medication Group Alone|inhaled corticosteroids or inhaled corticosteroids plus long-acting beta agonist. (Flovent Diskus or Advair diskus)
3107408|NCT02251496|Active Comparator|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
3107409|NCT02251496|Active Comparator|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
3107410|NCT02251548|Experimental|Ibrutinib|"- Ibrutinib-~Oral, daily during each cycle~fludarabine-administered at standard dosing for up to 6 cycles~cyclophosphamide-administered at standard dosing for up to 6 cycles~rituximab-administered at standard dosing for up to 6 cycles"
3107411|NCT02251561|Experimental|FID 109182|Senofilcon A contact lens pre-soaked in FID 109182 worn in the right or left eye as randomized for 2 hours
3107412|NCT02251561|Active Comparator|Opti-Free Plus|Senofilcon A contact lens pre-soaked in Opti-Free Plus worn in the fellow eye for 2 hours
3107413|NCT02251613|Experimental|Olopatadine (right or left, randomized)|Olopatadine HCl ophthalmic solution, 0.1%, 1 drop in the right or left eye as randomized
3107414|NCT02251613|Active Comparator|Epinastine (fellow eye)|Epinastine HCl ophthalmic solution, 0.05%, 1 drop in the in the fellow eye
3107415|NCT02251652|Active Comparator|Combination Therapy|Cryotherapy followed by Ingenol Mebutate Gel
3107416|NCT02251652|Active Comparator|Cryotherapy Alone|Cryotherapy only
3107417|NCT02251717|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF FDC for 12 weeks.
3107418|NCT02251717|Experimental|LDV/SOF 24 wk|Participants will receive LDV/SOF FDC for 24 weeks.
3107419|NCT02251743|Experimental|Neurofeedback treatment|The intended treatment is downtraining of theta power and uptraining of beta power for 38 treatments of active NF.
3107420|NCT02251743|Placebo Comparator|Sham neurofeedback treatment|"Participants assigned to sham and their trainers will be fed EEG data from pre-recorded files (recorded during live clinical NF) rather than from the participant's live signal. In order to prevent unblinding of experienced NF trainers/technicians, artifacts from the participant's EMG and EOG are blended into the pre-recorded EEG so that the trainer controlling the feedback cannot differentiate between live and simulated data. To insure trainer/technician blindness, the pre-recorded EEG will be 38 consecutive EEGs from the same age-matched clinical case so that EEGs of the sham group will also show training progress over successive sessions, like real NF."
3107421|NCT02251886|Active Comparator|Moxibustion in primiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in primiparae
3107422|NCT02251886|Active Comparator|Moxibustion in multiparae|Moxibustion added to the acupuncture point Bl 67 for 15-20 minutes daily from week 32 to 36 in multiparae
3107423|NCT02251886|No Intervention|Control primiparae|No intervention. Routine control schedule for primiparae with midwife
3107424|NCT02251886|No Intervention|Control multiparae|No intervention. Routine control schedule for multiparae with midwife
3107425|NCT02251912|Experimental|Active|Intranasal oxytocin doses 2-3 times/day for 12 weeks
3107426|NCT02251912|Placebo Comparator|Control|Intranasal placebo doses 2-3 times/day for 12 weeks
3107427|NCT02251938|Experimental|DE-109 Sirolimus|DE-109 440 μg
3107428|NCT02251990|Experimental|Immediate Treatment Group (ITG): Grazoprevir/Elbasvir|Participants receive a grazoprevir/elbasvir FDC tablet once daily (q.d.) by mouth during a 12-week Active Treatment period (Week 1 to Week 12) and are followed-up for 24 weeks to Week 36.
3107429|NCT02251990|Placebo Comparator|Deferred Treatment Group (DTG): Placebo > Grazoprevir/Elbasvir|Participants receive a placebo tablet q.d. by mouth for 12 weeks (placebo treatment period). After a 4-week Follow-Up period, participants receive open-label grazoprevir/elbasvir FDC during a 12-week Active Treatment period (Week 16 to Week 28). Participants are then followed-up for 24 weeks to Week 52.
3107430|NCT02252016|Experimental|Immediate Treatment|Participants will take grazoprevir 100 mg + elbasvir 50 mg once daily during the 12-week treatment period and then will be monitored for safety during a 24-week follow-up period.
3107431|NCT02252016|Placebo Comparator|Deferred Treatment|Participants will take placebo tablets once daily during the 12-week treatment period and will then be monitored for safety during a 4-week follow-up period. Participants will then begin open-label treatment with grazoprevir 100 mg + elbasvir 50 mg for a 12-week treatment period and will then be monitored for safety during a 24-week follow-up period.
3107432|NCT02252042|Experimental|Pembroliziumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
3107433|NCT02252042|Active Comparator|Active Comparator|Participants receive methotrexate 40 mg/m^2 IV (may be escalated to 60 mg/m^2 maximum dose) on Days 1, 8, and 15 of each 3-week cycle; or docetaxel 75 mg/m^2 IV on Day 1 of each 3- week cycle; or cetuximab 400 mg/m^2 IV loading dose on Day 1 and 250 mg/m^2 IV on Days 8 and 15 of Cycle 1, followed by cetuximab 250 mg/m^2 on Days 1, 8, and 15 of each subsequent 3-week cycle.
3107434|NCT02252068|Other|I-CBT feasibility pilot|Open trial of I-CBT
3107435|NCT02252068|Experimental|I-CBT randomized trial|I-CBT in randomized trial.
3107436|NCT02252068|Active Comparator|IDC randomized trial|Comparison condition (Individualized Drug Counseling) in randomized trial.
3107437|NCT02252081|Active Comparator|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
3107438|NCT02252081|Placebo Comparator|Placebo|placebo pill(s) orally per day for 16 weeks
3107439|NCT02252133|Other|DT1, then 1DAVTE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
3107440|NCT02252133|Other|1DAVTE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 7 days on a daily wear, daily disposable basis.
3107441|NCT02252146|Experimental|IMO-8400|IMO-8400 0.3 mg/kg twice weekly, 0.6 mg/kg twice weekly, or 1.2 mg/kg twice weekly
3469175|NCT03889236|Experimental|Food supplement|4 capsules a day of the food supplement Endocalyx for 3 months.
3469176|NCT03889236|Placebo Comparator|Placebo|4 capsules a day of the placebo for 3 months.
3107444|NCT02252211|Experimental|DS-8895a|Patients received infusions with DS-8895a on Days 1, 8, 22, and 36. Infusions on Days 1 and 36 were trace labelled with ^89Zr (^89Zr-Df-DS-8895a). The Day 1 dose was 0.2 mg/kg, followed by subsequent doses calculated based on individual patient body weight and dosing cohort assignment.
3107445|NCT02252354|Experimental|Part 1: [14C]-TAK-385|[14C]-TAK-385 80 mg, solution, orally, once on Day 1.
3107446|NCT02252354|Experimental|Part 2: TAK-385 + [14C]-TAK-385 IV|TAK-385 80 mg, tablets, orally, and [14C]-TAK-385 80 μg, infusion, intravenous once on Day 1.
3107447|NCT02252406|Experimental|Ranolazine|Ranolazine would start with 500 mg BID and be force titrated to 1 gram po BID after 3 weeks. Down titration would only be allowed for side effects. This would be on top of all standard medical therapy.
3107448|NCT02252406|Placebo Comparator|Placebo|Placebo arm would start with 500 mg matching placebo tablet BID and be force titrated to 1 gram matching placebo tablet twice a day after 3 weeks. Down titration would only be allowed for side effects (if reported). This would be on top of all standard medical therapy.
3107449|NCT02252445|Active Comparator|Propofol|Propofol will be administered as the anesthetic maintenance agent.
3107450|NCT02252445|Experimental|Sevoflurane|Sevoflurane will be administered as the anesthetic maintenance agent.
3107451|NCT02252536|Placebo Comparator|Sugar Pill|Matching placebo, sugar pill
3107452|NCT02252536|Active Comparator|Gabapentin Enacarbil|600 mg Gabapentin Enacarbil (Horizant)
3107453|NCT02252562|No Intervention|Standard practice|Usual intraoperative hand hygiene (standard wall mounted devices and machine and/or cart based dispensers)
3107454|NCT02252562|Experimental|Personal hand hygiene device|Intraoperative use of personalized body worn alcohol dispensers incorporating a novel wireless tracking system [(SAGE Products Inc., Cary, Il),
3107455|NCT02252588|Experimental|Chlorhexidine|Oral Rinse
3107456|NCT02252588|Placebo Comparator|Placebo|Oral Rinse
3107457|NCT02252666|Experimental|Neuromodulation Rehabilitation|Balance, posture and gait activities; therapeutic exercise for isolated muscle control; transfer training; and relaxation training using neurostimulation modulation. 2-week in lab intervention training, training at home and periodic return for follow-up testing and instruction on the next phase of the intervention.
3107458|NCT02252718||Children 1-18 months of age|Children aged between 1 month and 18 months admitted to the Department of Pediatrics The Medical University of Warsaw
3107459|NCT02252939|Experimental|Patients with Trapeziometacarpal (TMC) Arthrosis|Patients presenting to the Orthopaedic Hand Service not seeking care for TMC Arthrosis
3107460|NCT02252965|Active Comparator|Metformin IR|
3107461|NCT02252965|Experimental|Metformin XR|
3107462|NCT02253147|Experimental|Left side TEOSYAL® RHA Ultra Deep, Right side Perlane-L®|Split-face injection of TEOSYAL® RHA Ultra Deep into the left Naso Labial Folds (NLFs) and Perlane-L® into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3107463|NCT02253147|Experimental|Left side Perlane-L®, Right side TEOSYAL® RHA Ultra Deep|Split-face injection of Perlane-L® into the left Naso Labial Folds (NLFs) and TEOSYAL® RHA Ultra Deep into the right NLF (n=120). Up to 3.0 mL injected per NLF. Touch-up treatment provided at 2 weeks (up to 3.0 mL per NLF).
3107464|NCT02253160|Experimental|Spectra Optia CMNC first, then COBE Spectra MNC|Spectra Optia CMNC collection procedure followed by COBE Spectra MNC collection procedure.
3107465|NCT02253160|Experimental|COBE Spectra MNC first, then Spectra Optia CMNC|COBE Spectra MNC collection procedure followed by Spectra Optia CMNC collection procedure.
3107466|NCT02253173|Experimental|Estradiol 4mcg Vaginal Softgel Capsule|Estradiol 4mcg Vaginal Softgel Capsule
3107467|NCT02253173|Experimental|Estradiol 10mcg Vaginal Softgel Capsule|Estradiol 10mcg Vaginal Softgel Capsule
3107468|NCT02253173|Experimental|Estradiol 25mcg Vaginal Softgel Capsule|Estradiol 25mcg Vaginal Softgel Capsule
3107469|NCT02253173|Placebo Comparator|Placebo Vaginal Softgel Capsule|Placebo Vaginal Softgel Capsule
3107470|NCT02253316|Experimental|Consolidation: Ixazomib, Lenalidomide, & Dexamethasone|Consolidation therapy will begin between Day 80 and Day 120 following ASCT and will consist of four 28-day cycles of IRD (ixazomib, lenalidomide, & dexamethasone). Barring dose modifications for toxicity, 4 mg of ixazomib and 40 mg of dexamethasone will be administered on Days 1, 8, and 15, and 55 mg of lenalidomide will be administered on daily on Days 1-21.
3107471|NCT02253316|Experimental|Maintenance Arm 1: Ixazomib|Ixazomib will be administered on Days 1, 8, and 15 of a 28-day cycle at a starting dose of 4 mg until patient progresses or experiences an unacceptable toxicity.
3107472|NCT02253316|Experimental|Maintenance Arm 2: Lenalidomide|Lenalidomide will be administered daily continuously for a 28-day cycle at a starting dose of 10 mg. If lenalidomide is tolerated well (i.e. no dose modification required) during the first three cycles, lenalidomide dose will be increased to 15 mg daily and will continue until patient progresses or experiences an unacceptable toxicity.
3107473|NCT02253433|Experimental|Enhanced Clinic Care|This arm receives enhanced in-clinic care only.
3469177|NCT03888859|Experimental|Intravenous (i.v.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intravenous (IV) infusion
3469178|NCT03888859|Experimental|Intra-hepatic artery (i.a.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intra-hepatic artery (IA) infusion
3469179|NCT03888859|Experimental|Intratumoral Injections (i.t.) arm|autologous ET1402L1-ARTEMIS™2 T cells administered by intratumoral injections (i.t.) infusion
3469180|NCT03889132||Premenopausal women with obesity|
3469181|NCT03889132||Postmenopausal women with obesity|
3469182|NCT03889132||Men with obesity|
3469183|NCT03889132||Premenopausal women without obesity|
3469184|NCT03889132||Postmenopausal women without obesity|
3469185|NCT03889132||Men without obesity|
3469186|NCT03889184|Experimental|rehabilitating meals-on-wheels service|the intervention group will for 8 weeks receive a rehabilitating meals-on-wheels service
3469187|NCT03889184|No Intervention|Usual care|the control group will receive usual care
3107474|NCT02253433|Experimental|Enhanced Clinic Care + Home Intervention|This arm receives the enhanced in-clinic care intervention, as well as a home-based intervention.
3107475|NCT02253537||Symptomatic|Patients with bacteriologically confirmed and untreated TB disease tested with CST001 assay.
3107476|NCT02253654|Experimental|Epoetin alfa Alternative Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.
3107477|NCT02253654|Active Comparator|Epoetin alfa USPI Titration|Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.
3107478|NCT02253992|Experimental|Dose Escalation and Cohort expansion: Urelumab + Nivolumab|"Nivolumab followed by Urelumab~Nivolumab every 2 weeks up to 12 cycles and Urelumab every 4 weeks up to 6 cycles"
3107479|NCT02254252|Active Comparator|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
3107480|NCT02254252|Active Comparator|Nicorandil|nicorandil (10mg tablets, two times a day) + standard treatment (an anti-platelet agent, a beta-blocker, an angiotensin converting enzyme inhibitor, and a 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor)
3107481|NCT02254265|Experimental|OTX-101 0.05%|OTX-101 0.05% ophthalmic solution 1 drop in both eyes BID for 84 days
3107482|NCT02254265|Experimental|OTX-101 0.09%|OTX-101 0.09% ophthalmic solution 1 drop in both eyes BID for 84 days
3107483|NCT02254265|Placebo Comparator|Vehicle|Vehicle of OTX-101 ophthalmic solution 1 drop in both eyes BID for 84 days
3107484|NCT02254278|Experimental|IMRT 6 weeks + cisplatin|IMRT 6 weeks with concurrent cisplatin
3107485|NCT02254278|Experimental|IMRT 5 weeks|IMRT 5 weeks
3107486|NCT02254291|Experimental|Semaglutide 0.5 mg|
3107487|NCT02254291|Experimental|Semaglutide 1.0 mg|
3107488|NCT02254291|Active Comparator|Sitagliptin 100 mg|
3107489|NCT02254304|Experimental|Rebif in Relapsing Multiple Sclerosis (RMS) Subjects|
3107490|NCT02254304|Experimental|Rebif in Clinically Isolated Syndromes (CIS) Subjects|
3107491|NCT02254408|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3107492|NCT02254408|Placebo Comparator|Placebo|Participants will receive placebo on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3107493|NCT02254421|Experimental|Presatovir|Participants will receive presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3107494|NCT02254421|Placebo Comparator|Placebo|Participants will receive placebo to match presatovir on Days 1, 5, 9, 13, and 17, with follow-up visits through Day 28, and may continue in an optional extended monitoring phase with visits through Day 56.
3107495|NCT02254460|Experimental|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
3107496|NCT02254460|Placebo Comparator|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
3107497|NCT02254473|Experimental|Wedge Insert|Patients will receive a wedge insert
3107498|NCT02254473|Placebo Comparator|Flat insert|Patients will receive a flat insert
3107499|NCT02254486|Experimental|NER1006, 2-Day Split-Dosing|NER1006:2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
3107500|NCT02254486|Active Comparator|Trisulfate Solution, 2-Day Split-Dosing|Trisulfate Solution 2-Day Split-Dosing Regimen (to commence in the evening of the day before the colonoscopy)
3107501|NCT02254551|Experimental|LDE225 Plus Bortezomib|"Lead-In Portion: The lead-in portion of this study will investigate the safety and tolerability, and determine the MTD of LDE225, in combination with bortezomib in this patient population.~Expansion Portion: Eligible patients will receive LDE225 orally once daily for 21 days with the dose-level determined in the lead-in portion of the study. Eligible patients will also receive a standard regimen of bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 of each 21 day cycle.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
3107502|NCT02254681|Experimental|Treatment|Four three-week treatment cycles. Gemcitabine (1000 gm/m^2) and cisplatin (25 mg/m^2) administered on days one and eight of each cycle. Whole liver and portal lymph node basin low dose radiotherapy on days one, two, eight, and nine of each cycle.
3107503|NCT02254772|Experimental|Treatment|Patients receive TLR9 agonist SD-101 via intratumoral injections; ipilimumab via intratumoral injection; and undergo radiation therapy on days 1 and 2.
3107504|NCT02255032|Experimental|4 mg CLS-TA|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
3107505|NCT02255032|Experimental|0.8 mg CLS-TA|Single unilateral, suprachoroidal injection of 8 mg/mL (0.8 mg in 100 µL) of CLS-TA
3107506|NCT02255097|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
3107507|NCT02255110|Experimental|TH-302 and doxorubicin|
3107508|NCT02255149|Experimental|Bone/Mesh|Allograft and Titanium mesh will be used to grow jaw bone vertically.
3107509|NCT02255175|Experimental|Perimenopausal women, depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
3469188|NCT03889210|Active Comparator|HVMN ketone drink|HVMN ketone drink will be given in a total volume of 100 ml.
3107510|NCT02255175|Active Comparator|Perimenopausal women, non-depressed|Participants will receive transdermal estradiol (100μg/day) for 3 weeks. Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
3107511|NCT02255279|Experimental|aTIV|aTIV is a trivalent influenza virus vaccine, adjuvanted with MF59C.
3107512|NCT02255279|Active Comparator|TIV|TIV is trivalent influenza vaccine licensed in Mexico.
3107513|NCT02255357|Placebo Comparator|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
3107514|NCT02255357|Active Comparator|Intranasal Syntocinon|Intranasal Oxytocin 24 IU per day.
3107515|NCT02255422|Experimental|omaveloxolone Capsules 2.5 mg and 5 mg|omaveloxolone (RTA 408) Capsules, 2.5 mg taken orally once daily for 2 weeks, then 5 mg taken orally once daily for 10 weeks
3107516|NCT02255422|Experimental|omaveloxolone Capsules 10 mg|omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 12 weeks
3107517|NCT02255422|Placebo Comparator|Placebo Capsules|Placebo capsules taken orally once daily for 12 weeks
3107518|NCT02255422|Experimental|omaveloxolone Capsules 20 mg|omaveloxolone (RTA 408) Capsules, 20 mg taken orally once daily for 12 weeks.
3107519|NCT02255422|Experimental|omaveloxolone Capsules 40 mg|omaveloxolone (RTA 408) Capsules, 40 mg taken orally once daily for 12 weeks.
3107520|NCT02255422|Experimental|omaveloxolone Capsules 80 mg|omaveloxolone (RTA 408) Capsules, 80 mg taken orally once daily for 12 weeks.
3107521|NCT02255422|Experimental|omaveloxolone Capsules 160 mg|omaveloxolone (RTA 408) Capsules, 160 mg taken orally once daily for 12 weeks.
3107522|NCT02255461|Experimental|Treatment (palbociclib isethionate)|Patients receive palbociclib isethionate PO QD on days 1-21. Treatment repeats every 4 weeks for 26 courses in the absence of disease progression or unacceptable toxicity.
3107523|NCT02255474|Active Comparator|Biofinity|Soft spherical contact lens
3107524|NCT02255474|Experimental|Biofinity Multifocal D +1.50 add|"The Biofinity Multifocal D with a +1.50 add is a soft bifocal contact lens that has a medium reading power"
3107525|NCT02255474|Experimental|Biofinity Multifocal D +2.50 add|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power"
3107526|NCT02255500|Experimental|Bupivacaine FNB + EXPAREL Infiltration|Femoral nerve block with bupivacaine HCl 0.5% with epinephrine 1:200,000 within 2 hours of the surgical procedure. Infiltration of EXPAREL 266 mg just prior to wound closure.
3107527|NCT02255513|Experimental|HLD200|"HLD200 (methylphenidate hydrochloride) 20, 40, 60, 80, or 100 mg capsules~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to continue their HLD200 treatment over an one week double-blind, placebo-controlled phase. HLD200 was administered orally, once daily each evening."
3107528|NCT02255513|Placebo Comparator|Placebo|"Placebo capsules (dose matched to HLD200 capsules)~Subjects were allowed to titrate to their optimal HLD200 dose during a 6 week open-label, treatment optimization phase before being randomized to receive placebo treatment over a one week double-blind, placebo-controlled phase. Treatments were administered orally, once daily each evening."
3107529|NCT02255552|Experimental|Treated Group|Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
3107530|NCT02255552|No Intervention|Untreated Group|Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.
3107531|NCT02255565|Experimental|Very Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a very low dose level for 6 weeks.
3107532|NCT02255565|Experimental|Low Dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a low dose level for 6 weeks.
3107533|NCT02255565|Experimental|Moderate dose Quillivant XR|Patients in this treatment arm are given Quillivant XR (a liquid medication) to treat ADHD at a moderate dose level for 6 weeks.
3107534|NCT02255604|Active Comparator|intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015."
3107535|NCT02255604|Placebo Comparator|3 intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of alk 225 Phleum Pratense 10,000 standard quantity units/ml.~Patients receive 3 injection in total. 3 injection in the spring 2014 with one month interval. In in the spring 2015 patients will have a placebo injection."
3107536|NCT02255604|Sham Comparator|no intralymphatic immune therapy|"Lymphnodes in the groin are identified with ultrasound. Under ultrasound guide they are injected with 0,1 ml of isotone saline.~Patients receive 4 injection in total. 3 injection in the spring 2014 with one month interval and 1 injection in the spring 2015. All injections are with isotone saline as placebo control."
3107537|NCT02255656|Experimental|Alemtuzumab|All Participants who completed the study CAMMS03409 (extension study of CAMMS223 [NCT00050778], CAMMS323 [NCT00530348], or CAMMS324 [NCT00548405]) and received alemtuzumab within 48 months prior to enrollment were included in this LPS13649 study. Participants received alemtuzumab, intravenous infusion of 12 milligram per day (mg/day) for 3 consecutive days, at the study investigators' discretion; and at least 12 months after the prior treatment course in the current study (LPS13649).
3107538|NCT02255760|Experimental|MEDI3902 - Dose 1|Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
3107539|NCT02255760|Experimental|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
3107540|NCT02255760|Experimental|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
3107541|NCT02255760|Experimental|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
3107542|NCT02255760|Placebo Comparator|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
3107543|NCT02255981|Experimental|Acupuncture group|"Acupuncture and massage Therapy of Traditional Chinese Medicine (acupuncture and Massage) for 24 months~."
3107544|NCT02256072|Experimental|Plan Your Lifespan Website|Participants in the intervention arm will navigate the Plan Your Lifespan website, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. The Plan Your Lifespan tool is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
3107545|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. Our attention control group will control for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention website.
3107546|NCT02256111|Experimental|ENZ+ADT+Usual care|The usual care arm will receive treatment with enzalutamide with androgen deprivation therapy, with no supervised exercise training.
3107547|NCT02256111|Experimental|ENZ+ADT+Exercise|The ENZ+ADT+Exercise arm will receive treatment with enzalutamide plus androgen deprivation therapy along with supervised exercise training.
3107548|NCT02256189|Other|Sitagliptin first, then placebo|Sitagliptin treatment for four weeks, then washout for four weeks, then placebo for four weeks
3107549|NCT02256189|Other|Placebo first, then sitagliptin|Placebo for four weeks, then washout for four weeks, then sitagliptin for four weeks
3107550|NCT02256267|Experimental|LY2835219|Single oral dose of LY2835219
3107551|NCT02256267|Experimental|LY2835219 + Rifampin|Single oral dose of LY2835219 with rifampin orally, once daily for 14 days
3107552|NCT02256345|Active Comparator|KNO3 active comparator|KNO3 will be given at a dose of 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
3107553|NCT02256345|Placebo Comparator|KCl placebo comparator|KCl will be used as a placebo and will be given as 6 mmol twice daily for the first week, increasing to 6 mmol three times daily for the second week if well tolerated
3107554|NCT02256358|Active Comparator|Midazolam|Intravenous 0.1 mg/kg midazolam was administered to the patients as premedication drug before entering operating room.
3107555|NCT02256358|Experimental|Ketamine|Intravenous 1 mg/kg ketamine was administered to the patients as premedication drug before entering operating room.
3107556|NCT02256384|Experimental|Respiratory Acoustic Monitoring|All participants will wear the respiratory acoustic monitoring device.
3107557|NCT02256436|Active Comparator|Control|Participants receive paclitaxel 175 mg/m^2 intravenously (IV) or docetaxel 75 mg/m^2 IV or vinflunine 320 mg/m^2 IV, on Day 1 of each 3-week cycle (Q3W). Eligible participants who experience disease progression may be able to switch over to receive pembrolizumab 200 mg Q3W for up to 35 treatment administrations (up to approximately 2 years).
3107558|NCT02256436|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg IV on Day 1 Q3W. Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to approximately 1 additional year).
3107559|NCT02256488|Experimental|TIVc-Lot A|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot A
3107560|NCT02256488|Experimental|TIVc-Lot B|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot B
3107561|NCT02256488|Experimental|TIVc-Lot C|Subjects 18 to ≤ 49 years of age who received one vaccination with an investigational vaccine TIVc from Lot C
3107562|NCT02256488|Active Comparator|TIVf|Subjects 18 to ≤ 49 years of age who received one vaccination of Control vaccine TIVf
3107563|NCT02256540|Placebo Comparator|Placebo patch - placebo tablets|Postmenopausal women will be given a placebo patch to wear two days prior to exercise visit and a placebo tablet to take the morning of the exercise visit.
3107564|NCT02256540|Experimental|Placebo patch - Resveratrol tablets|Postmenopausal women will be given a placebo patch to wear for two days prior to the exercise visit and a resveratrol tablet (dosed at 250mg) to take the morning of the exercise visit.
3107565|NCT02256540|Active Comparator|Climara patch - placebo tablets|Postmenopausal women will be given a transdermal estrogen patch to wear (0.05mg/day) for two days prior to the exercise visit and a placebo tablet to take the morning of the exercise visit.
3107566|NCT02256553|Experimental|MK-3641+ MK-7243|Participants receive one MK-7243 tablet, SL QD in the evening for 14 days during Period I; one MK-3641 tablet, SL QD in the morning and one MK-7243 tablet, SL QD in the evening for 14 days during Period II; and one MK-3641 tablet, SL QD, and one MK-7243 tablet, SL QD, within 5 minutes of each other for 14 days during Period III.
3469189|NCT03889210|Placebo Comparator|Placebo|Placebo will be given in a total volume of 100 ml.
3469190|NCT03889119|Active Comparator|Elekta Versa HD|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Elekta machines, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
3469191|NCT03889119|Other|Agility Systems|This study seeks to investigate biochemical failure rates for patients treated with SBRT utilizing Agility Systems, as well as obtain quality of life data and assess the intrafraction motion in approximately 15 patients for 5 years following SBRT.
3469192|NCT03889015|Active Comparator|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
3469193|NCT03889015|Experimental|probiotic yogurt|Probiotics are live microorganisms that confer oral health benefits by adhering to the oral mucosa and surface of teeth as a part of the biofilm thus preventing the adhesion, colonization, and proliferation of cariogenic bacteria inhibiting the formation of pathogenic plaque
3107574|NCT02256839||non TB infection|Group tested with CST_001
3107575|NCT02256839||low exposure risk|Group tested with CST_001
3107576|NCT02256891|Experimental|Double Row|Double Row
3107577|NCT02256891|Experimental|Double Row with PRFM|Double Row with PRFM
3107578|NCT02256917|Experimental|Human-cl rhFVIII|
3107579|NCT02256969|Other|Meibomian Gland Probing plus lubricant|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Lubricant: GenTeal PM Night-Time Ointment (Alcon), a sterile ophthalmic lubricant that is commonly used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks with the following regimen: twice daily for 2 weeks and then once daily for 2 weeks."
3107580|NCT02256969|Other|Sham Meibomian Gland Probing plus lubricant|"Sham Meibomian Gland Probing: The patient's the lid margin was touched with the probes without actual probing occurring.~Lubricant: GenTeal PM Night-Time Ointment, ophthalmic lubricant used to relieve symptoms in patients with dry eye disease, was applied topically to both eyes for 4 weeks: twice daily for 2 weeks and then once daily for 2 weeks."
3107581|NCT02256969|Active Comparator|Meibomian Gland Probing plus Blephamide|"Meibomian Gland Probing: Stainless steel probes were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were probed with a 1-mm probe followed by a 2-mm probe for all glands.~Blephamide: is a combination of an antibiotic and an anti-inflammatory agent commonly used to treat various ocular conditions. Blephamide was applied topically to both eyes for 4 weeks with a regimen of: twice daily for 2 weeks and then once daily for 2 weeks."
3107582|NCT02256982|Experimental|Resectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~-- Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to surgery~Additional care as recommended; may include additional cycles of GEM + CDDP on a 21 day cycle and/or post-op radiation as recommended by treating medical oncologist and radiation oncologist"
3107583|NCT02256982|Experimental|Unresectable Disease|"Consent and Registration~3 cycles of gemcitabine + cisplatin~Evaluate for surgery* (weeks 10-15)~Patients who are eligible for surgery at restaging will receive surgery; patients not eligible for surgery at restaging will receive radiation therapy.~Proceed to radiation therapy with protons or photons, determined by available resources~Additional cycles of GEM + CDDP on a 21 day cycle as recommended by treating medical oncologist"
3107584|NCT02257177|Active Comparator|0.15 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 0.15mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107585|NCT02257177|Active Comparator|1.5 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 1.5mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107586|NCT02257177|Active Comparator|3 mg TD139 (Part 1)|4 Healthy Subjects are administered a single dose of 3mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107587|NCT02257177|Active Comparator|10 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 10mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107588|NCT02257177|Active Comparator|20 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 20mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107589|NCT02257177|Active Comparator|50 mg TD139 Part 1|4 Healthy Subjects are administered a single dose of 50mg TD139 inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107590|NCT02257177|Placebo Comparator|Placebo Part 1|12 Healthy Subjects are administered placebo inhaled as a dry powder in a fasted state. Each cohort will include a dose leader volunteer to be dosed a day before the rest of the cohort, followed by the remaining 3 subjects who will be dosed approximately 24 hours later.
3107591|NCT02257177|Active Comparator|0.3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 0.3mg TD139 once daily for 14 days inhaled as a dry powder.
3107592|NCT02257177|Active Comparator|3 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 3mg TD139 once daily for 14 days inhaled as a dry powder.
3107593|NCT02257177|Active Comparator|10 mg TD139 Part 2|5 Patients with IPF are administered a single dose of 10mg TD139 once daily for 14 days inhaled as a dry powder.
3107594|NCT02257177|Placebo Comparator|Placebo Part 2|9 Patients with IPF are administered placebo inhaled as a dry powder.
3107595|NCT02257372|Experimental|UMEC (62.5 mcg)|Participants will self-administer blinded UMEC (62.5 mcg) each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment.
3107596|NCT02257372|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI over a treatment period of 12 weeks. Participants will receive open labeled ICS/LABA medication through out duration of the treatment period as background treatment
3107597|NCT02257385|Experimental|UMEC/VI arm|Participants will be instructed to self-administer one dose each morning of UMEC/VI Inhalation Powder 62.5/25 mcg once daily via ELLIPTA DPI, placebo once daily via HANDIHALER inhaler and placebo once daily via BREEZHALER inhaler
3107598|NCT02257385|Placebo Comparator|Tiotropium + Indacaterol arm|Participants will be instructed to self-administer one dose each morning of Tiotropium bromide 18 mcg once daily via HANDIHALER inhaler, Indacaterol 150 mcg once daily via BREEZHALER inhaler and placebo once daily via ELLIPTA DPI
3107599|NCT02257489|Experimental|50 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (50 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3107600|NCT02257489|Experimental|100 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3107601|NCT02257489|Experimental|200 mg single dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, single injection, intramuscularly
3107602|NCT02257489|Experimental|100 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (100 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3107603|NCT02257489|Experimental|200 mg multiple dose|8 subjects in total; 6 subjects to received ACE-083 (200 mg) and 2 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3107604|NCT02257489|Experimental|100 mg (multiple dose)|9 subjects in total; 6 subjects to received ACE-083 (100 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3107605|NCT02257489|Experimental|150 mg multiple dose|9 subjects in total; 6 subjects to received ACE-083 (150 mg) and 3 subjects to receive placebo, two injections 3 weeks apart, intramuscularly
3107606|NCT02257528|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
3107607|NCT02257541|Experimental|BGJ398 With Imatinib Mesylate|BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
3107608|NCT02257632|Experimental|Group 1|6 monthly intravitreal injections of 0.5 mg ranibizumab
3107609|NCT02257632|Experimental|Group 2|3 monthly intravitreal injections of 2 mg aflibercept followed by 3 monthly intravitreal injections of 0.5 mg ranibizumab
3107610|NCT02257684|Experimental|Pegcrisantaspase|
3107611|NCT02257736|Experimental|Group 1: AAP and apalutamide|Participants will receive apalutamide 240 milligram (mg) (4*60 mg tablets) and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily, until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the Open-Label Extension (OLE) or Long-Term Extension (LTE) phase (AAP + open label apalutamide or AAP alone).
3107612|NCT02257736|Placebo Comparator|Group 2: AAP and Placebo|Participants will receive matching Placebo of apalutamide and abiraterone acetate (AA) 1000 mg (4*250 mg tablets) once daily on an empty stomach and 5 mg prednisone (P), AAP, twice daily until disease progression, unacceptable toxicity or end of treatment, whichever occurs first. After unblinding participants will be offered further treatment as defined in the OLE or LTE phase (AAP + open label apalutamide or AAP alone).
3107616|NCT02257957|Experimental|Platelet -Rich Plasma (PRP)|15 patients with diagnosis of severe dry eye will receive PRP injection at day 0, 30,60 and 90
3107617|NCT02257957|Active Comparator|Standard Care|15 patients with diagnosis of severe dry eye will receive standard of care treatment and will be revised at day 0, 30,60,90
3107618|NCT02257970|Experimental|Part 1: Exploratory Group|"Ketoprofen 225-300 mgs daily, taken orally~Ketoprofen-exploratory group: 225-300 mgs daily for four to six months"
3107619|NCT02257970|Experimental|Part 2: Open-label Group|"Ketoprofen 225 mg daily, taken orally~Open-label group: 75 mgs, three times daily, for four months"
3107620|NCT02257970|Placebo Comparator|Part 3: Placebo Group|"Participants randomized to receive placebo: placebo, three times daily, taken orally~Placebo: 1 capsule, three times daily, for four months"
3107621|NCT02257970|Active Comparator|Part 3: Ketoprofen Group|"Participants randomized to receive active medication: ketoprofen 75 mgs., three times daily, taken orally~Ketoprofen: 1 capsule, three times daily, for four months"
3107622|NCT02258074|Experimental|Lanthanum carbonate + nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3107623|NCT02258074|Placebo Comparator|Lanthanum carbonate + nicotinamide placebo|Two lanthanum carbonate 500 mg capsules by mouth with each meal (3000 mg) for 12 months. One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months.
3107624|NCT02258074|Active Comparator|Lanthanum carbonate placebo and nicotinamide|One nicotinamide 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3107625|NCT02258074|Placebo Comparator|Lanthanum carbonate placebo and nicotinamide placebo|One Placebo (for nicotinamide) 750 mg capsule by mouth twice daily (1500 mg) for 12 months. Two Placebo (for lanthanum carbonate) 500 mg capsules by mouth with each meal (3000 mg) for 12 months.
3107626|NCT02258139|Experimental|Study Group 1|1st overnight visit with no contact lens; 2nd overnight visit randomized to either left or right eye for B&L Investigational Contact Lens
3107627|NCT02258152|Placebo Comparator|Placebo|
3107628|NCT02258152|Experimental|SYN120|
3107629|NCT02258217|Experimental|Single arm|Acthar 80 units subcutaneously for five consecutive days.
3107630|NCT02258256|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device
3107631|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
3107632|NCT02258334|Experimental|Fluzone® Intradermal vaccine Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of Fluzone® Intradermal vaccine
3107633|NCT02258334|Experimental|Fluzone® Quadrivalent vaccine Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® Quadrivalent vaccine
3107634|NCT02258334|Experimental|Fluzone® High-Dose vaccine Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of Fluzone® High-Dose vaccine
3107635|NCT02258373|Experimental|CGM Only|"Participants will be instructed to check the blood glucose with the standard study BGM for calibration of the CGM and for specific circumstances that are specified in the protocol. This group will make management decisions based on the CGM glucose value without a BGM confirmation measurement as long as the participant is confident that the CGM glucose value is not erroneous.~In addition, participants will be instructed to make a BGM measurement on the blinded study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia and a standard BGM measurement has not been made. The participant may be asked to make post-prandial blinded BGM measurements at selected times."
3107636|NCT02258373|Active Comparator|CGM+BGM|Participants will be instructed to perform BGM measurements for sensor calibration according to Dexcom specifications and measure the blood glucose whenever a diabetes management decision is made. A BGM measurement is to be made on the study BGM before going to bed, whenever an insulin bolus is given and when treating or attempting to prevent hypoglycemia. Additional BGM measurements can be made on the study BGM at any time that the participant desires.
3107637|NCT02258412|Active Comparator|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day.
3107638|NCT02258412|Active Comparator|hand antiseptic with CHG and alcohol|Hand antiseptic is applied by dispensing 1 pump into hands, spreading over the hands up to the wrist, and rubbing until dry. Hand antiseptic will be used twice approximately 15-30 minutes apart on one day.
3107639|NCT02258464|Experimental|Radium 223 dichloride|Participants treated with a single hormonal agent as background therapy received 50 kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) of Radium 223 dichloride intravenously for a maximum of 6 cycles at intervals of 4 weeks
3107640|NCT02258464|Placebo Comparator|Placebo|Participants treated with a single hormonal agent as background therapy received isotonic saline (0.9% sodium chloride solution for injection) intravenously for a maximum of 6 cycles at intervals of 4 weeks
3107641|NCT02258477|Active Comparator|Sequence 1 (D-B-A-C)|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
3107642|NCT02258477|Active Comparator|Sequence 2 (A-D-C-B)|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
3107643|NCT02258477|Active Comparator|Sequence 3 (C-A-B-D)|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
3107644|NCT02258477|Active Comparator|Sequence 4 (B-C-D-A)|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
3107645|NCT02258529|Experimental|Idelalisib + rituximab|Idelalisib + rituximab for up to 104 weeks
3107648|NCT02258659|Experimental|Group A (radiation therapy alone)|Patients undergo radiation therapy once daily for weeks.
3107649|NCT02258659|Experimental|Group B (combination chemotherapy, low-dose radiation therapy)|Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive low-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3107650|NCT02258659|Experimental|Group C (combination chemotherapy, high-dose radiation)|"Patients receive hydroxyurea PO BID on days 0-5, fluorouracil IV continuously on days 1-5, and paclitaxel IV over 60 minutes on day 1. Patients also receive standard-dose radiation therapy BID on days 1-5. Treatment repeats every 14 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.*~*NOTE: At the discretion of the PI, patients may receive cisplatin IV over 1-3 hours every 3 weeks during radiation therapy instead of paclitaxel and undergo daily radiation therapy."
3107651|NCT02259010|Experimental|Part A: Alisertib 30 mg+Itraconazole; Part B: Alisertib 50 mg|All participants were to complete Part A prior to Part B. Part A: Alisertib 30 mg, tablets, orally, on Days 1 and 10 plus itraconazole, 200 mg, oral solution, once daily on Days 5 to 13. Part A and B were separated by a washout period of at least 10 days (and up to 4 weeks). Part B: Alisertib 50 mg, tablets, orally, twice daily, for 7 days in 21-day cycles until disease progression or unacceptable toxicity (up to 16 cycles).
3107652|NCT02259088|Experimental|Ranibizumab (RFB002)|3 initial intravitreal injections to the study eye at Day 1, Month 1 and Month 2, followed by as-needed intravitreal injections of ranibizumab 0.5 mg guided by VA stabilization, plus sham laser
3107653|NCT02259088|Active Comparator|Laser|Laser photocoagulation applied to the study eye at Day 1, followed by active laser photocoagulation at intervals no shorter than 3 months apart, plus sham injections
3107654|NCT02259114|Experimental|Continuous Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-21 of each 21-day cycle. Starting dose for dose escalation is 80 mg.
3107655|NCT02259114|Experimental|Days 1-7 Dosing Regimen|Participants receive birabresib capsules once daily in a fasted state in the morning on Days 1-7 of each 21-day cycle. Starting dose for dose escalation is 100 mg.
3107656|NCT02259231|Experimental|Omaveloxolone 5 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, Dose1 taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
3107657|NCT02259231|Experimental|Omaveloxolone 10 mg & ipilimumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus ipilimumab (3 mg/kg) administered at weeks 1, 4, 7, and 10.
3107658|NCT02259231|Experimental|Omaveloxolone 5 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 5 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3107659|NCT02259231|Experimental|Omaveloxolone 10 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 10 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3107660|NCT02259231|Experimental|Omaveloxolone 20 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 20 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3107661|NCT02259231|Experimental|Omaveloxolone 100 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 100 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3107662|NCT02259231|Experimental|Omaveloxolone 150 mg & nivolumab|Omaveloxolone (RTA 408) capsules, 150 mg taken orally once daily for 168 weeks, plus nivolumab (240 mg) administered every two weeks as clinically indicated.
3107663|NCT02259348|Experimental|Participants|Participants undergo a conditioning regimen with cyclophosphamide, fludarabine, aldesleukin (interleukin-2), natural killer cell therapy, anti-thymocyte globulin, rituximab, thiotepa, and melphalan prior to transplantation of T-cell depleted HPC transplant on day 0 and CD45RA-depleted HPC transplant on day 1. Beginning Day 6 post-transplant, patients receive G-CSF daily until ANC recovers to normal level.
3107664|NCT02259400|Active Comparator|NSIPPV group|The NSIPPV is a conventional modality of mechanical ventilation delivered by the nasal ventilator device Giulia (Ginevri, Rome, Italy), that in noninvasive modality detects the inspiratory effort by means of a pneumotachograph, equipped with a fixed orifice (2 mm in diameter for LBW infants), positioned proximally to the nasal interface. Short bi-nasal prongs (NIV set, Ginevri, Rome, Italy), with different size according to infants'weight, will be used as interface.
3107665|NCT02259400|Active Comparator|BiPAP group|The BiPAP is a modality of noninvasive respiratory support that provides two alternate different levels of CPAP in which the babies can breath spontaneously. The BiPAP will be delivered by the Infant Flow-driver device (Infant Flow System, Vyasis Corp,Yorba Linda, California (CA),USA) and bi-nasal prongs as interface (Vyasis Corp,Yorba Linda, CA,USA) with different size according to infants' weight.
3107666|NCT02259582|Placebo Comparator|Arm 1 Pem, carbo, placebo x 4 cycles|Pemetrexed (500 mg/m2),carboplatin (area under the concentration-time curve of 6 mg/mL x min) once every 21 days X 4 cycles, pemetrexed maintenance and placebo starting at Day 84
3107667|NCT02259582|Active Comparator|Arm 2 Pem, carbo x 4 cycles, one course of dem|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, one course of demcizumab 5mg/kg, maintenance pemetrexed + placebo starting on Day 84
3107668|NCT02259582|Active Comparator|Arm 3 pem, carbo, dem x 4 cycles, dem retreatment|Pemetrexed (500 mg/m2), carboplatin (area under the concentration-time curve of 6 mg/mL x min) x 4 cycles, maintenance pemetrexed starting on Day 84. 2 courses of demcizumab 5 mg/kg
3107669|NCT02259608|Experimental|BCG vaccine SSI|Healthy volunteers are vaccinated with yBCG. Blood will be drawn before and at several timepoints after vaccination. Cytokine production before vaccination will be used as reference to compare later timepoints with.
3107670|NCT02259699|Experimental|Decision Aid (PCOA)|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
3107671|NCT02259699|No Intervention|UC (Standard care)|Standard pamphlets will be given to patients to educate them about IV and IV/IP therapies.
3107672|NCT02260154||Post-cholecystectomy gastrointestinal spasms|Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day
3107673|NCT02260180|Active Comparator|A-101 40%|A-101 40% Topical Solution
3107674|NCT02260180|Active Comparator|A-101 32.5%|A-101 32.5% Topical Solution
3107675|NCT02260180|Placebo Comparator|A-101 Vehicle Topical Solution|A-101 0% Topical Solution (vehicle)
3107676|NCT02260258|Experimental|Rocuronium|"Patients will receive a bolus dose of 1 mg/kg, then a continuous intravenous (IV) infusion as per standard intensive care unit practice.~Of note, protocol allows for use of cistatracurium in place of rocuronium for either reasons of drug-shortage or clinical conditions (if institutional preferences for dose adjustment in liver or renal insufficiency arise)."
3107677|NCT02260258|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
3107678|NCT02260388|Experimental|Nortriptyline|Nortriptyline - 25 mg daily for 1 week at bedtime, then 50 mg daily at bedtime for 1 week, then 75 mg daily at bedtime for the remainder of the study.
3107679|NCT02260388|Experimental|Duloxetine|Duloxetine - 20 mg daily for 1 week, then 40 mg daily for 1 week, then 60 mg daily for the remainder of the study.
3107680|NCT02260388|Experimental|Pregabalin|Pregabalin - 100 mg at bedtime for 1 week, then 100 mg 2 times per day for 1 week, then 100 mg 3 times per day for the remainder of the study.
3107681|NCT02260388|Experimental|Mexiletine|Mexiletine - 200 mg at bedtime for 1 week, then 200 mg 2 times per day for 1 week, then 200 mg 3 times per day for the remainder of the study.
3107682|NCT02260401|Experimental|Individualized report|Each patient in this group will receive an individualized report with their own outcome data (pain and function) during the first year of the LESS trial. They will receive these reports at 18 months.
3107683|NCT02260401|No Intervention|Individualized Reports after 24 months|Patients in this group will receive the individualized report, but will not receive it until after the conclusion of the study at 24 months. They will serve as the control group.
3107684|NCT02260440|Experimental|Pembrolizumab and Azacitidine Arm|"9 cycles~Pembrolizumab will be given at 200 mg every 21 days.~Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days."
3107685|NCT02260492|Experimental|OT329 Solis|OT329 Solis (twice daily inhalation throughout the study)
3107686|NCT02260492|Active Comparator|Advair Diskus|Advair Diskus (twice daily inhalation throughout the study)
3107687|NCT02260492|Placebo Comparator|Placebo|Placebo (twice daily inhalation throughout the study)
3107688|NCT02260531|Experimental|Cohort 1 - Cabozantinib, Trastuzumab for HER2+|"HER2-positive~Cabozantinib- orally administered daily per treatment cycle, 60 mg per day~Trastuzumab- IV administered once per cycle, 8 mg/kg IV loading dose followed by 6 mg/kg IV Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
3107689|NCT02260531|Experimental|Cohort 2 - Cabozantinib for ER+ and/or PR+|"Hormone receptor-positive (ER+ and/or PR+)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
3107690|NCT02260531|Experimental|Cohort 3 - Cabozantinib for ER-, PR-, HER2-|"Triple negative (ER-, PR-, HER2-)~- Cabozantinib- orally administered daily per treatment cycle, 60 mg per day Cycle duration equals 3 weeks. Patients are treated indefinitely based on unacceptable toxicity, disease progression, or withdrawal for other reasons."
3107691|NCT02260622|Active Comparator|clopidogrel plus aspirin|Clopidogrel 75 mg daily X 90 days plus ASA 81 mg daily
3107692|NCT02260622|Experimental|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg BID X 90 days plus ASA 81 mg daily
3107693|NCT02260635|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
3107694|NCT02260635|Placebo Comparator|Placebo|Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.
3107695|NCT02260648|Experimental|Evacetrapib|130 milligrams (mg) evacetrapib and 10 mg atorvastatin administered PO once a day for 12 weeks.
3107696|NCT02260648|Active Comparator|Ezetimibe|10 mg ezetimibe and 10 mg atorvastatin administered PO once a day for 12 weeks as a reference arm.
3107697|NCT02260648|Placebo Comparator|Placebo|Placebo and 10 mg atorvastatin administered PO once a day for 12 weeks.
3107698|NCT02260791|Experimental|FKB327|Patients will receive FKB327 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
3107699|NCT02260791|Active Comparator|Humira®|Patients will receive Humira® 40 mg every other week by subcutaneous injection. The treatment period will continue for 22 weeks.
3107700|NCT02260804|Experimental|CT-P10|CT-P10, intervention 375mg/m2, intravenous, 4 cycles in induction period and additional 12 cycles in maintenance period
3107701|NCT02260804|Active Comparator|Rituxan|Rituxan, 375mg/m2 intravenous, 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
3107702|NCT02260817|Experimental|Expanded Access for 11C-Choline|"The key objective of this study is to provide expanded access to this drug product as currently defined under the reference listed drug as an investigational drug in geographical service areas where 11C-choline injection is not available.~Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. Patient data obtained in this arm of the study will not be further analyzed beyond that need for clinical diagnosis."
3107703|NCT02260817|Experimental|11C-Choline Comparison of Modalities|"11C-choline injection is approved for use in conjunction with both CT and MR imaging modalities. This arm will attempt to determine which modality is most efficacious and under which conditions.~Patients entered into the study will undergo imaging using GE's Trimodality Imaging System that combines PET, CT, and MR techniques to provide PET/CT and PET/MR fused images"
3107704|NCT02260882|Experimental|Revaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who received an initial vaccination at least 5 years prior
3107705|NCT02260882|Experimental|Primary Vaccination Group|0.5 mL intramuscular injection (deltoid or lateral mid-thigh) of PNEUMOVAX™ 23 vaccine on Day 1 for participants who have never received PNEUMOVAX™ 23 vaccination
3107706|NCT02260921|Experimental|iovera° Treatment|Treatment with the iovera° device administered by a trained investigator to treat knee pain.
3107707|NCT02260921|Sham Comparator|Sham Treatment|Sham Treatment (similar device with no active therapeutic treatment) administered by a trained investigator to treat knee pain.
3107708|NCT02260934|Active Comparator|Rituximab/Cyclophosphamide (RC)|Prednisone taper to 10 mg/day by week 12 and continue prednisone 10 mg/day to week 96.
3107709|NCT02260934|Experimental|Rituximab/Cyclophosphamide/Belimumab (RCB)|"Belimumab (10 mg/kg IV) at weeks 4, 6, 8, and every 4 weeks to week 48.~Prednisone taper to 10 mg/day by week 12, and continue prednisone 10 mg/day to week 96."
3107710|NCT02260986|Experimental|Placebo qw|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.
3107711|NCT02260986|Experimental|Dupilumab 300 mg q2w|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.
3107712|NCT02260986|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.
3107713|NCT02261428|Experimental|Catheter Tiemann|We tested the ability of Tiemman catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
3107714|NCT02261428|Active Comparator|Suction catheter|We tested the ability of suction catheter to access trachea and aspirate bronchial secretions, measuring number of attempts and time required for the intervention
3107715|NCT02261467|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3107716|NCT02261467|Placebo Comparator|Placebo followed by OnabotulinumtoxinA in Period 2|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria in Period 2, the subject will receive up to 2 open-label treatments with onabotulinumtoxinA into the protocol-specified areas.
3107717|NCT02261493|Experimental|OnabotulinumtoxinA Dose A|OnabotulinumtoxinA Dose A injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3107718|NCT02261493|Experimental|OnabotulinumtoxinA Dose B|OnabotulinumtoxinA Dose B injected into the protocol-specified areas on Day 1. Subjects will receive at least 1 and up to 3 treatments.
3107719|NCT02261493|Placebo Comparator|Placebo followed by OnabotulinumtoxinA Dose A|Placebo (normal saline) injected into the protocol-specified areas on Day 1. If the subject meets the re-treatment criteria, the subject will receive up to 2 treatments with onabotulinumtoxinA Dose A into the protocol-specified areas.
3107720|NCT02261597||Insomnia Disorder|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among participants with a clinical diagnosis of insomnia disorder.
3107721|NCT02261597||Healthy Control|Testing reactivity of stress-related systems to repeated exposure to the cold pressor test (hand immersion into ice-cold water) among healthy participants without a diagnosis of insomnia disorder.
3107722|NCT02261714|Experimental|TG01/GM-CSF and Gemcitabine|
3107723|NCT02261727|Placebo Comparator|Placebo|Placebo theophylline, one tablet twice daily, and Placebo prednisone, one tablet once daily
3107724|NCT02261727|Active Comparator|Low-dose theophylline arm|Theophylline 100 mg twice daily
3107725|NCT02261727|Active Comparator|Theophylline and Prednisone arm|Theophylline 100 mg twice daily plus prednisone 5 mg once daily
3107726|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 1|Ganetespib 100 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3107727|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase Ib Dose Level 2|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3107728|NCT02261805|Experimental|Ganetespib and doxorubicin - Phase II Expansion|Ganetespib 150 mg/m2 IV on days 1 and 8 of a 21-day cycle Doxorubicin 50 mg/m2 IV on day 1 of a 21-day cycle
3107729|NCT02261818|Other|Meetings with peer mentors|Peer mentors who have experience of depression are trained and supervised to provide social support to older adults to relieve depression. They will provide active listening, empathy, work on a patient-derived goal, psychoeducation and connection to both clinical and community resources.
3107730|NCT02261948|Active Comparator|Levosimendan|Levosimendan must be diluted before the administration (500 ml of glucose). The intravenous infusion may be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
3107731|NCT02261948|Placebo Comparator|Placebo|Placebo must be diluted before the administration (500 ml of glucose). The intravenous infusion may' be administered either by the peripheral or central. The dose and duration of therapy should be decided according to the patient's clinical condition and response to the drug. Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min. A low infusion bolus (6 mcg / kg) is recommended for patients who have a concomitant intravenous treatment with vasodilators or inotropic. The patient's response should be evaluated during the infusion bolus or within 30 to 60 minutes and a dose adjustment based on clinical response.
3107732|NCT02261961|Experimental|Nutritional Supplement|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
3107733|NCT02261961|Placebo Comparator|Placebo|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
3107734|NCT02261974|Active Comparator|Active Viveve Treatment|Intervention in the active arm will be with the Viveve System using 90 Joules/cm2 active treatment with radiofrequency energy in the vaginal introitus
3107735|NCT02261974|Placebo Comparator|Sham Viveve Treatment|Intervention in the sham arm will be with the Viveve System using ≤1 Joule/cm2 sham treatment with radiofrequency energy in the vaginal introitus
3107736|NCT02262039|Active Comparator|Conventional Pressure|Conventional Insufflation with 15mmHg target pressure
3107737|NCT02262039|Experimental|Low Pressure (VTI)|Valveless recirculating insufflation (VTI) with 10mmHg target pressure
3107738|NCT02262078|Placebo Comparator|Placebo (Saline)|Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
3107739|NCT02262078|Experimental|Sodium Nitrite|Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer
3107740|NCT02262130|Experimental|Omalizumab|Omalizumab 300 mg W0, W4 and W8
3107741|NCT02262260|Experimental|Ranibizumab labeled regime arm|Ranibizumab (Anti VEGF) 0.5mg treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month
3107742|NCT02262260|Experimental|Ranibizumab wait and Extend regime arm|Ranibizumab (Anti VEGF) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
3107743|NCT02262364|Experimental|NStride APS|Subjects will receive an intra-articular injection of APS.
3107744|NCT02262377|Experimental|Integrative Medicine Group Visits|9-week integrative medicine group visit that meets 1 time per week for 2.5 hours followed by a 3 month Web based curriculum and final group meeting
3107745|NCT02262377|No Intervention|Standard of Care|primary care visits, which include medications and advice
3107746|NCT02262507|Experimental|Device wearing|All subjects who meet the study criteria and volunteer to participate will be included in the study. Subjects will undergo repeat oto-acoustic measures both wearing the device and not wearing the device. The intervention will be the auto-acoustic measurement - taken while wearing the collar and then again when not wearing the collar.
3107747|NCT02262728|Experimental|Panel 1|Participants with Child-Pugh score <7 with evidence of portal hypertension (confirmed by presence of esophageal varices or hepatic venous pressure gradient [HVPG] greater than or equal to 10 millimeter of mercury [mm Hg]) will receive simeprevir (150 milligram [mg] capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
3107748|NCT02262728|Experimental|Panel 2|Participants with Child-Pugh score 7 to 9 (extremes included) will receive simeprevir (150 mg capsule), daclatasvir (60 mg tablet) and sofosbuvir (400 mg tablet) orally once daily for 12 weeks.
3107749|NCT02262754|Experimental|PF-06372865|Daily BID dosing for 4 weeks
3107750|NCT02262754|Placebo Comparator|Placebo|Daily BID dosing for 4 weeks
3107751|NCT02262754|Active Comparator|Naproxen|Daily BID dosing for 4 weeks
3107752|NCT02263014||Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide to have contralateral prophylactic mastectomy (CPM) along with scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after the surgery is completed.
3107753|NCT02263014||No Contralateral Prophylactic Mastectomy (CPM) Group|Group of women who decide not to have contralateral prophylactic mastectomy (CPM) performed during scheduled mastectomy. Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, and 12 months after unilateral mastectomy or breast conserving surgery is completed.
3107754|NCT02263040|Experimental|High Dose Fluzone|Fluzone High-Dose® Licensed for use in the USA in persons ≥ 65 years of age as a single dose of 0.5 mL containing 60μg hemagglutinin per virus strain
3107755|NCT02263040|Active Comparator|Fluzone (standard dose)|Fluzone ® Licensed for the prevention of influenza as a single dose of 0.5 mL containing 15μg hemagglutinin per virus strain for adults
3107756|NCT02263079|Experimental|Peg-IFN-Alfa-2A + Lamivudine or Entecavir|Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
3107757|NCT02263079|No Intervention|Untreated Control Participants|Untreated control participants will be observed up to 80 weeks.
3107758|NCT02263079|Experimental|Peg-INF-Alfa-2A Monotherapy|Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
3107759|NCT02263118|Experimental|Uni-directional SMS|Participants in this group received breastfeeding promoting messages based on the MAMA (http://www.mobilemamaalliance.org/) breastfeeding database. Individuals could only receive text messages.
3107760|NCT02263118|Experimental|Virtual communities|Participants were made part of virtual communities in which could exchange about infant's health as groups, via SMS, following the SHM Foundation's (http://www.shmfoundation.org/) m-health methodology.
3107761|NCT02263118|Experimental|Hybrid setup|Participants were made part of virtual communities in which they could exchange about infant's health as groups, via SMS. Additionally, a health professional was included in the virtual community.
3107762|NCT02263118|Experimental|Control group|Individuals were given a feature phone (simple mobile phone)
3107763|NCT02263131|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
3107764|NCT02263131|Active Comparator|TIV PFS|VAXIGRIP Prefilled Syringe INJ.
3107765|NCT02263326|Experimental|dolutegravir plus lamivudine|dolutegravir 50 mg plus lamivudine 300 mg once daily
3107766|NCT02263326|Active Comparator|Continue current ART regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
3107767|NCT02263547|Other|teriflunomide elimination with colestipol|
3107768|NCT02263833||Overall Participants|Participants not previously on erythropoietin-stimulating agent (ESA) therapy and participants on ESA therapy who were switched to Mircera
3107769|NCT02263911|Experimental|Baricitinib Test Treatment 1 (T1)|Single oral dose of 2 × 4 milligram (mg) baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
3107770|NCT02263911|Experimental|Baricitinib Reference Treatment 1 (R1)|Single oral dose of 1 × 8 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
3107771|NCT02263911|Experimental|Baricitinib Test Treatment 2 (T2)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet fasted on Day 1 in one of five periods.
3107772|NCT02263911|Experimental|Baricitinib Reference Treatment 2 (R2)|Single oral dose of 1 × 4 mg baricitinib Phase 2 tablet fasted on Day 1 in one of five periods.
3107773|NCT02263911|Experimental|Baricitinib Test Treatment 2 with Meal (T2F)|Single oral dose of 1 × 4 mg baricitinib commercial formulation tablet after food intake on Day 1 in one of five periods.
3107774|NCT02264249||Split dose colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - split dose - ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)
3107775|NCT02264249||Evening before colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Evening before (4L, 2L or miralax bowel preparation)
3107776|NCT02264249||Same day prep colonoscopy preparation|Esophagogastroduodenoscopy and colonoscopy - Same day prep (4L volume or 2L volume or Miralax bowel preparation)
3107777|NCT02264353|Experimental|Donepezil|Sleep data with Donepezil given
3107778|NCT02264353|Placebo Comparator|Placebo|Sleep data with Placebo given
3107779|NCT02264574|Experimental|IBR + OB|Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.
3107780|NCT02264574|Experimental|CLB + OB|"Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.~Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity."
3107781|NCT02264639|Experimental|Cohort 1|First Dose 25mg, Repeated Dose 5 mg/day
3107782|NCT02264639|Experimental|Cohort 2|First Dose 50 mg, Repeated Dose 30 mg/day
3107783|NCT02264639|Experimental|Cohort 3|Repeated Dose 180 mg/day
3107784|NCT02264639|Experimental|Cohort 4|Repeated Dose 270 mg/day
3107785|NCT02264821|Experimental|ropivacaine infiltration|ropivacaine 2 mg/ml bolus 15 ml continuous 10 ml/h wound infusion and intrathecal saline
3107786|NCT02264821|Experimental|rachi morphine|100 µg intrathecal morphine and saline infiltration
3107787|NCT02264821|Placebo Comparator|placebo|intrathecal saline and saline infiltration
3107788|NCT02264977|Experimental|Branched TAG® Device|Treatment with the GORE® TAG® Thoracic Branch Endoprosthesis
3107789|NCT02264990|Experimental|Veliparib + Carboplatin + Paclitaxel|"Participants received 120 mg veliparib twice a day (BID) on Days -2 to 5 (7 days), carboplatin at an area under the curve (AUC) of 6 mg/mL*min on Day 1 and paclitaxel 200 mg/m² on Day 1 of each 21-day cycle for a maximum of 6 cycles.~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
3107790|NCT02264990|Active Comparator|Investigator's Choice Chemotherapy|"Participants received Investigator's choice of standard doublet chemotherapy consisting of 1 of the following 3 options, administered on Day 1 of each 21-day cycle for a maximum of 6 cycles:~Carboplatin AUC 6 mg/mL*min + paclitaxel 200 mg/m²~Cisplatin 75 mg/m² + pemetrexed 500 mg/m²~Carboplatin AUC 6 or AUC 5 mg/mL*min + pemetrexed 500 mg/m²~After completion of up to 6 cycles, optional maintenance pemetrexed was administered as 500 mg/m² on Day 1 of each 21-day cycle until toxicity required cessation of therapy, or radiographic progression occurred."
3107791|NCT02265224|Experimental|Test - Reference|N-acetylcysteine (NAC) 600 mg uncoated tablet (single dose) followed by NAC 600 mg film-coated tablet (single dose)
3107792|NCT02265224|Active Comparator|Reference - Test|N-acetylcysteine (NAC) 600 mg film-coated tablet (single dose) followed by NAC 600 mg uncoated tablet (single dose)
3107793|NCT02265237|Experimental|Arm A|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 12 weeks for genotype 4 treatment-naïve or treatment-experienced with IFN/RBV.
3107794|NCT02265237|Experimental|Arm B|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 16 weeks for genotype 4 treatment-naive or treatment-experienced with IFN/RBV.
3107795|NCT02265237|Experimental|Arm C|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 treatment-naive and treatment-experienced with IFN/RBV.
3107796|NCT02265237|Experimental|Arm D|Ombitasvir/paritaprevir/ritonavir (25/150/100 mg) and Ribavirin dosed for 24 weeks for genotype 4 SOF/pegIFN/RBV or SOF/RBV treatment-experienced.
3107797|NCT02265341|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3107798|NCT02265510|Experimental|Phase 1a: INCB052793 Monotherapy|
3107799|NCT02265510|Experimental|Phase 1b: INCB052793 Combination Therapy|
3107800|NCT02265510|Experimental|Phase 2: INCB052793 and itacitinib Combination Therapy|
3107801|NCT02265705|Experimental|Baricitinib|"4 milligrams (mg) baricitinib administered orally once a day for 52 weeks. Participants with renal impairment will receive 2 mg baricitinib orally once a day for 52 weeks.~Participants will continue to take background methotrexate (MTX) therapy throughout study. Other background therapies, including non-steroidal anti-inflammatory drugs (NSAIDs) and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
3107802|NCT02265705|Placebo Comparator|Placebo|"Placebo administered orally once a day through week 24. At week 24, participants will be given 4 mg or 2 mg (participants with renal impairment) baricitinib orally once a day through Week 52.~Participants will continue to take background MTX therapy throughout study. Other background therapies, including NSAIDs and low dose oral corticosteroids, are permitted during the study for participants who are on stable doses of these treatments at baseline."
3107803|NCT02265744|Experimental|Experimental:Arm A: BMS-931699|12.5mg subcutaneous (SC) injection Weekly dosing
3107804|NCT02265744|Experimental|Experimental:Arm B: BMS-931699|12.5mg SC injection Every other Week dosing
3107805|NCT02265744|Experimental|Experimental:Arm C: BMS-931699|5mg SC injection Every other Week dosing
3107806|NCT02265744|Experimental|Experimental:Arm D: BMS-931699|1.25mg SC injection Every other Week dosing
3107807|NCT02265744|Placebo Comparator|Placebo Comparator: Arm E: Placebo matching BMS-931699|0mg SC injection Weekly dosing
3107808|NCT02265783|Other|Nellcor USB Pulse Oximeter Monitor Interface Cable Sensor Test|
3107809|NCT02265796|Active Comparator|Ranolazine|"Ranolazine 500 mg tablets~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3107810|NCT02265796|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3107811|NCT02265848|Active Comparator|Treatment group A|Subjects assigned to treatment group A will begin the 7 week study with high frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the low frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
3107812|NCT02265848|Active Comparator|Treatment group B|Subjects assigned to treatment group B will begin the 7 week study with low frequency stimulation for first 3 weeks of the study. After first 3 weeks, subject will return to clinic to turn off the SCS device, and will start 7-10 days of wash off period. At the end of the wash off period, subject will return to clinic and have the SCS device turned on to have it programmed to deliver the high frequency stimulation for the next 3 weeks. At the end of the 7th week, the subject will return for final end of treatment visit for conclusion of the study.
3107813|NCT02265913|Experimental|Test Product|acyclovir cream
3107814|NCT02265913|Active Comparator|Reference Product|acyclovir cream
3107815|NCT02265913|Placebo Comparator|Placebo Product|Placebo cream
3107816|NCT02265952|Experimental|Open-label|Open-label REGN1500
3107817|NCT02265965|Experimental|Intravenous Nitroglycerin|Subjects will receive IV nitroglycerin at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
3107818|NCT02265965|No Intervention|Intravenous Saline|Subjects will receive IV saline at the time of Hysterotomy. Infusion will be stopped once neonate is delivered
3107819|NCT02266004|Experimental|tDCS+ LT|Transcranial direct current stimulation(tDCS) plus locomotor training (LT) 3x per week for 3 consecutive weeks.
3107820|NCT02266108|Experimental|ESTIMA intervention|This group is randomized to receive the ESTIMA intervention and will be followed for 12 months for follow-up.
3107821|NCT02266108|Other|Wait-list control|This group will receive standard of care (education as well as referrals to testing and treatment). After 12 months of follow-up, this group will receive the ESTIMA intervention.
3107822|NCT02266147|Experimental|SD-101 in combination with low-dose radiation|"PART 1~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29~PART 2~Cycle 1: Required~Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1~COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29~COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29~Cycle 2: Optional~Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181~COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209~COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209"
3107823|NCT02266225|Experimental|Lifestyle-integrated functional exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
3107824|NCT02266277|Active Comparator|Arm 1: E-portal message with IVR call|Patients identified as e-portal users will receive an e-portal message with IVR call
3107825|NCT02266277|Active Comparator|Arm 2: E-portal message with no IVR call|Patients identified as e-portal users will receive an e-portal message only
3107826|NCT02266277|Active Comparator|Arm 3: No e-portal message with IVR call|Patients identified as e-portal users will receive an IVR call only
3107827|NCT02266277|No Intervention|Arm 4: No E-portal message with no IVR call|Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
3107828|NCT02266277|Active Comparator|Arm 5: IVR call|Patients identified as non e-portal users will receive an IVR call only
3107829|NCT02266277|No Intervention|Arm 6: No IVR call|Patients identified as non e-portal users will not receive any outreach
3107830|NCT02266381|Other|US-guided group|Patients in US-guided group undergo MPCNL using only US-guided renal access.
3107831|NCT02266381|Other|Fluoroscopy-guided group|Patients in Fluoroscopy-guided group undergo MPCNL using only fluoroscopy-guided renal access.
3107832|NCT02266381|Other|Combined-guided group|Patients in Combined-guided group undergo MPCNL using US combined with fluoroscopy-guided renal access.
3107833|NCT02266433|Active Comparator|Arm Receiving Dexamethasone Injection|"Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Dexamethasone will be administered as a peritendinous soft tissue injection of 1 mL of dexamethasone sodium phosphate (4mg/mL) and 0.5 mL (5mg) of 1% lidocaine~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
3107834|NCT02266433|Experimental|Arm Receiving Ketorolac Injection|"Ketorolac will be administered as a peritendinous soft tissue injection of 1 mL of ketorolac (30mg/mL) and 0.5 mL (5mg) of 1% lidocaine.~Patients will be followed at the initial office visit, 4-weeks, 8-weeks, 12-weeks, and 6 months post injection to determine clinical response. A second injection can be given only once if the patient desires due to no clinical response at the 4 or 8-week follow-up."
3107835|NCT02266472|Experimental|Fixed dose combination|Single dose empagliflozin/metformin
3107836|NCT02266472|Active Comparator|Single tablets combination|single doses empagliflozin and metformin
3107837|NCT02266576|Active Comparator|Standard Diabetes Prevention Program (DPP)|Participants receive Standard DPP over the course of 20 weeks.
3107838|NCT02266576|Experimental|Enhanced DPP|Participants receive Standard DPP plus Enhanced DPP over the course of 20 weeks.
3107839|NCT02266706|Experimental|Cohort 1: ≥12 to <18 years TOL/TAZ 1000/500 mg FDC|Participants ≥12 to <18 years of age received a single dose of ceftolozane/tazobactam (TOL/TAZ) 1000/500 mg FDC as a 60-minute infusion on Day 1.
3107840|NCT02266706|Experimental|Cohort 2: ≥7 to <12 years TOL/TAZ 18/9 mg/kg|Participants ≥7 to <12 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1.
3107841|NCT02266706|Experimental|Cohort 3: ≥2 to <7 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥2 to <7 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
3107842|NCT02266706|Experimental|Cohort 4: ≥3 months to <2 years TOL/TAZ 18/9 or 30/15 mg/kg|Participants ≥3 months to <2 years of age received a single dose of TOL/TAZ 18/9 mg/kg as a 60-minute infusion on Day 1. Participants in this cohort enrolled after interim analysis for Cohort 3 received TOL/TAZ 30/15 mg/kg.
3107843|NCT02266706|Experimental|Cohort 5: birth to <3 months TOL/TAZ 20/10 mg/kg|Participants from birth (>32 weeks gestation, 7 days postnatal) to <3 months of age received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 mg/kg was changed to TOL/TAZ 20/10.
3107844|NCT02266706|Experimental|Cohort 6: birth to <3 months TOL/TAZ 12/6 or 20/10 mg/kg|Participants from birth (≤32 weeks gestation, 7 days postnatal) to <3 months of age with creatinine clearance =20 - 49 mL/min/1.73 m^2 received a single dose of TOL/TAZ 12/6 mg/kg as a 60-minute infusion on Day 1; participants with creatinine clearance ≥50 mL/min/1.73 m^2 received a single dose of TOL/TAZ 20/10 mg/kg as a 60-minute infusion on Day 1. After interim analysis for Cohort 4, the original regimen of TOL/TAZ 12/6 was changed to TOL/TAZ 20/10 mg/kg for participants with creatinine clearance ≥50 mL/min/1.73 m^2.
3107845|NCT02266810|Experimental|PROPEL Mini Sinus Implant|Propel Mini placed in frontal sinus opening following ESS
3107846|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 1|Sinus Surgery only: cohort 1: ESS with standard post-operative care.
3107847|NCT02266810|Experimental|PROPEL Nova Sinus Implant|Propel Nova placed in frontal sinus opening following ESS
3107848|NCT02266810|Active Comparator|Sinus Surgery alone: cohort 2|Sinus Surgery only: cohort 2: ESS with standard post-operative care.
3107849|NCT02266875|Experimental|Hypertonic Saline|"Patients will receive nebulized hypertonic (3%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
3107850|NCT02266875|Active Comparator|Standard Saline|"Patients will receive standard saline (0.9%) saline along with standard 2.5 mg. albuterol treatments once every 6 hours for 24 hour, with allowance for PRN (as needed use).~Dyspnea will be assessed prior to treatment and at completion of the 24 hour period using the Modified Borg Dyspnea Scale."
3107851|NCT02266888|Experimental|Rituximab Induction|Rituximab (Rituxan®) Induction Therapy Plus Standard of Care Immunosuppression (thymoglobulin induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
3107852|NCT02266888|Placebo Comparator|Placebo Induction|Placebo Induction Therapy Plus Standard of Care Immunosuppression (Thymoglobulin® induction, tacrolimus or equivalent, mycophenolate mofetil (MMF) or equivalent, and steroids)
3107853|NCT02267083|Experimental|GPX-150|GPX-150 for Injection, 265 mg/m2, every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity, or subject withdrawal.
3107854|NCT02267135|Experimental|Secukinumab|Eligible patients will receive secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 20 inclusive
3107855|NCT02267135|Placebo Comparator|Placebo|Eligible patients will receive placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8. Prior to taking the Week 12 dose, the patient will be assessed for response to treatment using the Psoriasis Scalp Severity Index (PSSI). If the subject is a responder, the subject will continue on placebo dosing weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20. Subjects who are not responders will be switched to treatment with secukinumab 300 mg and will dose once weekly at Weeks 12, 13, 14, 15 and 16 and then after four weeks at Week 20.
3107856|NCT02267187|Experimental|Fat Graftting|For the purpose of this study the fat grafting procedure is a research procedure. It is very important to note that this research procedure is not an experimental procedure. Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is known as a filler providing an accurate means to restoring facial soft tissue structure.
3107857|NCT02267226|Experimental|Octafibrin|
3107858|NCT02267278|Experimental|Ruxolitinib + Pracinostat|"Ruxolitinib starting dose 15 mg orally twice/day in 28-day cycle (dose assigned based on platelet count, if low platelet count gradual up-titration from a starting dose of 5 mg) - given alone for first 3 months, then Pracinostat added at starting dose 60 mg orally once/day for 3 alternating days every 3 weeks starting Day 1 of Cycle 4.~Dose of Ruxolitinib may be increased or decreased prior to initiation of Pracinostat. Quality of Life Questionnaire."
3107859|NCT02267317|Active Comparator|Obese Group-D5W|Obese subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
3107860|NCT02267317|Active Comparator|Obese Group - Eritoran|Obese subjects receive IV administration of Eritoran 12 mg every 12 hours
3107861|NCT02267317|Active Comparator|Diabetes (T2DM) Group - D5W|T2DM subjects receive IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours
3107862|NCT02267317|Active Comparator|Diabetes (T2DM) Group - Eritoran|T2DM subjects receive IV administration of Eritoran 12 mg every 12 hours
3107863|NCT02267356|Experimental|Low dose 12-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
3107864|NCT02267356|Experimental|Low dose 24-week|2 VT-1161 150mg tablets and 2 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
3107865|NCT02267356|Experimental|High dose 12-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 10 weeks, followed by 4 placebo tablets once weekly for 12 weeks
3107866|NCT02267356|Experimental|High dose 24-week|4 VT-1161 150mg tablets once daily for 2 weeks, then once weekly for 22 weeks
3107867|NCT02267356|Placebo Comparator|Placebo|4 placebo tablets once daily for 2 weeks, then once weekly for 22 weeks
3107868|NCT02267382|Experimental|VT-1161 Low-dose 3-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
3107869|NCT02267382|Experimental|VT-1161 Low-dose 6-month|1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
3107870|NCT02267382|Experimental|VT-1161 High-dose 3-month|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
3107871|NCT02267382|Experimental|VT-1161 High-dose 24-week|2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
3107872|NCT02267382|Placebo Comparator|Placebo|2 placebo tablets once daily for 7 days, then once weekly for 23 weeks
3107873|NCT02267447||Derivation cohort|Eligible respondents to the combined 2001, 2003 and 2005 Canadian Community Health Surveys, conducted by Statistics Canada.
3107874|NCT02267447||Validation cohort|Eligible respondents to the 2007 and 2009 Canadian Community Health Surveys.
3107875|NCT02267538|Experimental|Dex group|The intervention drug (dexmedetomidine hydrochloride for injection) will be administered during a period from before anesthesia induction until the end of mechanical ventilation after surgery.
3107876|NCT02267538|Placebo Comparator|Placebo group|The placebo drug (normal saline, i.e., 0.9% sodium chloride for injection) will be administered in the same way and rate for a same duration as that in the Dex group.
3107877|NCT02267577|Experimental|Healthy Adults Volunteers|Men and women over the age of 18 will have their blood pressure measured with both the Sphygmo: Automatic Blood Pressure Monitor device and the GE Dinamap ProCare automatic blood pressure monitor.
3107878|NCT02267603|Experimental|Treatment (pembrolizumab)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression* or unacceptable toxicity.~* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years."
3107879|NCT02267629|Experimental|Experimental:Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13) infusion followed by assessments daily for a week, and weekly for a week.
3107880|NCT02267746|Active Comparator|Fabior™(tazarotene)|Reference listed drug: Fabior™ 0.1% foam (Stiefel)
3107881|NCT02267746|Experimental|Tazarotene|Tazarotene 0/1% foam (Actavis)
3107882|NCT02267746|Placebo Comparator|Vehicle foam|Foam vehicle of the test product (Actavis)
3107883|NCT02267772|Experimental|IV Acetaminophen|IV acetaminophen for pain control
3107884|NCT02267772|Active Comparator|IV morphine|IV morphine for pain control
3107885|NCT02267811|Experimental|Fixed Orthodontic Treatment with OrthoPulse™|Subjects assigned to this group receive orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
3107886|NCT02267811|Experimental|Fixed Orthodontic Treatment|Subjects assigned to this group receive orthodontic treatment with no OrthoPulse™ treatment.
3107887|NCT02267824|Experimental|Extraoral OrthoPulse® PBM|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily extraoral OrthoPulse® photobiomudulation (PBM) treatments.
3107888|NCT02267824|Other|Orthodontic Treatment (Control)|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment, only.
3107889|NCT02267837|Experimental|OrthoPulse™|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
3107890|NCT02267837|No Intervention|Control|Subjects assigned to this group receive full mouth fixed orthodontic appliance treatment only, and no OrthoPulse™ treatments.
3107891|NCT02267850|Experimental|OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with receiving daily OrthoPulse™ treatments.
3107892|NCT02267850|Sham Comparator|Sham-Control OrthoPulse™|Subjects assigned to this group receive fixed orthodontic appliance treatment in conjunction with carrying out daily non-functional OrthoPulse™ treatments (untreated control).
3107893|NCT02268045|Experimental|RTXM83|Active Ingredient: Rituximab (Biosimilar)
3107894|NCT02268045|Active Comparator|MabThera|Active Ingredient: Rituximab
3107895|NCT02268058|Active Comparator|tx 1: acetaminophen and education|"Patient took routinely acetaminophen every 4 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
3107896|NCT02268058|Active Comparator|Tx 2: ibuprofen and education|"Patient took routinely ibuprofen every 6 hours when awake for a 72 hour period and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency department."
3107897|NCT02268058|Active Comparator|Tx 3: ibuprofen/acetaminophen/education|"Patient took routinely ibuprofen (Q6H) and acetaminophen (Q4H) for when awake for 72 hours post concussion and documented their headaches for a week.~Patient and family received standard education on concussion management in the Emergency Department."
3107898|NCT02268058|No Intervention|Tx 4: no routine meds and education|"Patient was advised to manage headaches as they typically would. There was no instruction given for the routine administration of either ibuprofen or acetaminophen.~The Patient and family received standard education in the ER department and diarized their headaches and medications they took for a one week period."
3107899|NCT02268084|Sham Comparator|Sham Stimulation|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase only) using a sham device. Sham device mimics the same noise and sensation of active treatment.
3107900|NCT02268084|Active Comparator|Active sTMS|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 2 weeks (double blind phase) and 2 additional weeks for all subjects (open label) with Synchronized Transcranial Magnetic Stimulation (sTMS), using an active device.
3107901|NCT02268175|Experimental|ARM 1|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle~Enzalutamide- Once daily at prespecified dose, orally~Abiraterone Acetate- Once daily at prespecified dose, orally~Prednisone-Once daily at prespecified dose, orally~Leuprolide Acetate-Intermuscular injection at prespecified dose and duration"
3107902|NCT02268175|Experimental|ARM 2|"Participants will be randomized in a 2:1 ratio to neoadjuvant treatment (ARM 1) or (ARM 2).~Participants will receive the assigned study treatment per cycle.~Enzalutamide- once daily at prespecified dose, orally~Leuprolide Acetate- Intermuscular injection at prespecified dose and duration"
3107903|NCT02268214|Experimental|Arm A: Dapagliflozin|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
3107904|NCT02268214|Experimental|Arm B: Dapagliflozin|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
3107905|NCT02268214|Placebo Comparator|Arm C: Placebo for Dapagliflozin|Placebo tablet orally, once daily for 52 weeks
3107906|NCT02268396|Experimental|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003
3107907|NCT02268500|Active Comparator|Standard dose influenza vaccine|Standard dose (45ug) influenza vaccine will be administered intramuscularly
3107908|NCT02268500|Active Comparator|High dose influenza vaccine|High dose (180ug) influenza vaccine will be administered intramuscularly
3107909|NCT02268526|Experimental|Cohort 1: CSJ148|Cohort 1: CSJ148 IV q 4weeks
3107910|NCT02268526|Experimental|Cohort 2: CSJ148|Cohort 2: CSJ148 IV q 4weeks
3107911|NCT02268526|Placebo Comparator|Cohort 2: Placebo|Cohort 2: Placebo IV q 4weeks
3107912|NCT02268786|Experimental|Group A|Intent to transfer single euploid embryo based on NGS testing (VeriSeq™ PGS) of biopsied blastocysts
3107913|NCT02268786|No Intervention|Group B|Intent to transfer single embryo based on morphological assessment according to the Gardner scoring system (no PGS)
3107914|NCT02268812||Ziconotide|"No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.~IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice."
3107915|NCT02268851|Experimental|CLL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
3107916|NCT02268851|Experimental|MCL|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each Cycle = 28 days~TGR-1202 (oral): Starting on Day 1 administered daily.~Ibrutinib (oral): Starting on Day 1 administered daily."
3107917|NCT02268864|Experimental|Simeprevir + Daclatasvir|Participants who have Hepatitis C virus (HCV) genotype 1b infection with advanced fibrosis or compensated cirrhosis (METAVIR F3/F4) will receive simeprevir 150 milligram (mg) capsule and daclatasvir 60 mg tablet orally once daily for 12 or 24 weeks.
3107918|NCT02268877|Experimental|Emergency Medicine Physician Ultrasound|Patients will receive an ultrasound performed by a credentialed emergency medicine attending or resident. The ultrasound will be transabdominal, transvaginal, or both. The intervention is the personnel who performs the ultrasound.
3107919|NCT02268877|Active Comparator|Radiology Tech Ultrasound|Patients will receive an ultrasound performed by a credentialed radiology department technician. The ultrasound will be transabdominal, transvaginal, or both. This is standard-of-care.
3107920|NCT02268942|Experimental|HeartWare HVAD via Thoracotomy|HeartWare HVAD implanted via thoracotomy
3107921|NCT02268955|Placebo Comparator|Control Group: Adults age 18-55 years|Saline-only control group
3107922|NCT02268955|Active Comparator|IV Ibuprofen: Adults age 18-55 years|Patients receiving intravenous ibuprofen therapy
3107923|NCT02268994|Experimental|KRX-0502 (ferric citrate)|1 g of KRX-0502 (ferric citrate) containing approximately 210 mg of ferric iron
3107924|NCT02268994|Placebo Comparator|Placebo|Matching Placebo
3107925|NCT02269098|Experimental|Intervention|"Diabetes survival skills self-management education; plus diabetes medication management using medication algorithm by diabetes educator supervised by endocrinologist, plus health system naviagation.~Metformin, sulfonylureas and basal insulin were included in the algorithm. Survival skills DSME included: BG meter instruction if the patient did not already have a meter or confirmation of self-BG monitoring technique if they did; instructions on how to self-inject insulin if prescribed; and information on BG targets, signs and treatment of hypoglycemia and hyperglycemia, basic nutrition information and when to call the doctor or go to the ED."
3107926|NCT02269098|No Intervention|Control|Usual ED care was provided to controls. Hyperglycemia was treated with rapid acting insulin and with IV hydration, if indicated. DM medications were added and/or doses were adjusted at the discretion of the ED physician and prescriptions provided. Insulin, however, was not prescribed as a new medication due to staff concerns regarding post-discharge hypoglycemia and lack of certainty of timely medical follow-up. Follow-up with primary care was recommended.
3107927|NCT02269124|No Intervention|Conventional Measures Only|In arm 1, the child will utilize conventional measures for management of unilateral hearing loss, such as FM system and preferential seating in the classroom. While two basic types of FM systems exist, personal and sound field, subjects in our study will utilize a personal FM system, worn at the ear-level. This will increase the likelihood that the child will receive amplification in all classes, and will help to standardize this intervention. The HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm via Redcap. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals.
3107928|NCT02269124|Experimental|Conventional Measures + Hearing Aid|In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
3107929|NCT02269163|Active Comparator|Gammargard, Gammaplex, Gamunex, or Octogam Treatment Period|Subjects who enroll in the study while on Gammargard, Gammaplex, Gamunex, or Octogam IGIV Product and need to wait for the scheduled start of Prometic IGIV (10%) treatment will continue on their usual dose and treatment cycle with Gammargard, Gammaplex, Gamunex, or Octogam IVIG Product during this period.
3107930|NCT02269163|Experimental|Prometic IGIV 10% Treatment Period|Subjects will receive Prometic Immune Globulin Intravenous 10%
3107931|NCT02269241|Experimental|LF111 (drospirenone)|single treatment arm receives LF111
3107932|NCT02269423|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3107933|NCT02269423|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3107934|NCT02269423|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in one deltoid and a 1-mL intramuscular injection of placebo in the contralateral deltoid on Day 0.
3107935|NCT02269423|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in each deltoid on Day 0.
3107936|NCT02269475|Experimental|MEDI3250|MEDI3250 Nasal Spray
3107937|NCT02269475|Placebo Comparator|Placebo|Placebo Nasal spray
3107938|NCT02269488|Experimental|MEDI3250|MEDI3250 Nasal spray
3107939|NCT02269631|Experimental|Legume diet group|Meals will include approximately 1 ½ cups of cooked legumes, such as pinto, baked and navy beans as part of your 2 daily main dishes (lunch and dinner) and additional foods and snacks, preferably from the recommended healthy foods list. The smartpill will be administered at the end of the study.
3107940|NCT02269631|Active Comparator|Control diet group|Meals will be healthy, typical American foods (without legumes) for 2 daily main dishes and additional foods and snacks, preferably from the recommended healthy foods list.The smartpill will be administered at the end of the study.
3107941|NCT02269657||Subject Cohort|Two bi-planar full spinal X-rays will be taken using the EOS® imaging system with subjects standing in two different positions. The first x-ray will be taken while the subject's hands and forearms in front of them on the wall vertically. A second image will be taken while the subject's knuckles loosely placed on ipsi-lateral clavicles. A pressure mat will record the magnitude of pressure under the subjects' feet during each set of images. A third set of pressure mat recordings will be obtained while the subject is in a natural standing position with both arms hanging on either side (no x-ray images will be taking in this position).
3107942|NCT02269709|Experimental|ARFI Ultrasound|This study uses ultrasound scanning with acoustic radiation force impulse shear wave velocity imaging to measure pediatric liver fibrosis. Patients will be children who have had the Fontan operation. This is a non-invasive scan that uses sound waves to create images.
3107943|NCT02269787|Experimental|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one 15-minute telephone call per week for 12 weeks.
3107944|NCT02269787|No Intervention|Usual Care|Patients in the usual care condition will receive the care they would receive in the absence of a research project.
3469194|NCT03889223|Active Comparator|The LDF neuraxial positioning technique|In the LDF neuraxial positioning technique, fifty participants were planned to lay down the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist. Volunteers jaw touch to chest and legs in abdominal flexion with hands are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
3107947|NCT02269943|Experimental|CC-486|CC-486 will be administered orally every day on Days 1-14 of a 21 day cycle at a dose of 300 mg. The first 6 participants of Asian-Pacific ethnicity will receive a starting dose of 200 mg. If there are no safety concerns, the 300 mg dose will be administered to all subsequent participants of Asian-Pacific ethnicity.
3107948|NCT02270060|Experimental|Music Therapy Group|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
3107949|NCT02270060|Active Comparator|Music Listening Group|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
3107950|NCT02270060|No Intervention|Control Group|Patient receives standard care and waits in treatment room/bay for twenty minutes.
3107951|NCT02270242|Active Comparator|Aspirin + Ticagrelor|enteric coated aspirin 81mg-100mg daily p.o. for 12 months and ticagrelor 90mg tablet bid for 12 months
3107952|NCT02270242|Placebo Comparator|Placebo + Ticagrelor|placebo pill daily p.o. for 12 months - match for enteric coated aspirin 81mg-100mg and ticagrelor 90mg tablet bid for 12 months
3107953|NCT02270255|Sham Comparator|Control group|Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
3107954|NCT02270255|Experimental|Sup Hypogastric Nerve block group|Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
3107955|NCT02270515|Experimental|PCMH-KD dialysis care|Dialysis care team is expanded to include a primary care doctor, nurse coordinator, community health worker, and pharmacist. Enrolled patients are observed for an initial baseline period receiving care under the usual dialysis care model called the 'usual dialysis care phase'.
3107956|NCT02270645|Experimental|Treatment: 595/1064 multiplex laser|"Subjects in the treatment arm will receive 3 treatments using the 595/1064 multiplex laser spaced by a four week interval (+/- 3 days), administered in an outpatient clinic setting. If a subject in the treatment arm has multiple BCCs satisfying inclusion criteria, all BCCs will be treated.~Four weeks (+/- 3 days) after the last treatment (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
3107957|NCT02270645|No Intervention|Control|"Subjects in the control arm will receive 3 regular study visits spaced 4 weeks (+/- 3 days) apart. If a subject in the control arm has multiple BCCs satisfying inclusion criteria, all BCCs will not be treated.~Four weeks (+/- 3 days) after the last (Day 84) both treatment and control patients will be assessed for final clinical appearance, measurement, and evaluation of the lesion by a dermatologist.~Subjects will also undergo deep excisional biopsy encompassing the entire lesion to determine residual tumor cell presence. If histologic examination of the tissue reveals residual BCC, then the subject will receive standard of treatment."
3107958|NCT02270671|Placebo Comparator|Placebo|The placebo protocol consists of 160 trials (120 angry-neutral face pair and 40 neutral-neutral face pair presentations). In this condition, angry-face location, probe location and actor are fully counterbalanced in presentation. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
3107959|NCT02270671|Experimental|Intervention|The attention bias modification training (ABMT) protocol consists of 160 trials (120 angry-neutral face pair presentations and 40 neutral-neutral face pair presentations). In the ABM condition, the target-probe appears at the neutral-face locations in all angry-neutral trials. A short break is delivered every 40 trials (1 block). An accuracy of 70% or above for each block is necessary to continue training. The task takes 7 minutes.
3107960|NCT02270736|Experimental|Double-blind MP: Placebo (Age 6 to 17 Years)|Participants will receive placebo via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks. Volumes will be matched to the volumes of NT 201 (incobotulinumtoxinA; Xeomin) injected in the experimental arm.
3107961|NCT02270736|Experimental|Double-blind, MP: NT 201 (Age 6 to 17 Years)|Participants will receive NT 201 (up to 2.5 Units per kilogram [U/kg] body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
3107962|NCT02270736|Experimental|Open-label, MP: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands in one injection session on Day 1 (Visit 2) of the MP, followed by an observation period of 16 weeks.
3107963|NCT02270736|Experimental|OLEX: NT 201 (Age 6 to 17 Years)|"Participants will receive NT 201 (up to 2.5 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total). This arm will consist of participants who will participate in MP arms Double-blind, MP: placebo (age 6 to 17 years) and Double-blind, MP: NT 201 (age 6 to 17 years)."
3107964|NCT02270736|Experimental|OLEX: NT 201 (Age 2 to 5 Years)|Participants will receive NT 201 (about 1.5-2 U/kg body weight) via bilateral intraglandular injection into the parotid and submandibular glands on Day 1 of second (Visit 6), third (Visit 10), and fourth (Visit 14) injection cycle of the OLEX, followed by an observation period of 16 weeks each (48 weeks in total).
3107965|NCT02270944|Experimental|Liquid GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of liquid GBS trivalent vaccine
3107966|NCT02270944|Active Comparator|Lyophilized GBS trivalent vaccine|Healthy non-pregnant women aged 18-40 years that received a single dose of lyophilized GBS trivalent vaccine
3107967|NCT02270957|Active Comparator|Abatacept|Patients receive Abatacept 125 mg subcutaneously weekly for six months. An optional continuation up until 12 months is allowed. Background immune suppressants are withdrawn at the beginning of the study and the option of depomedrol up to 320 mg total (in divided doses) is allowed at any time up through the visit 2 months after study medication is started. After this additional rescue is allowed with any standard of care treatment and/or open label abatacept (since patients are blinded) but this additional rescue will define non-response in the primary endpoint at six months.
3107968|NCT02270957|Placebo Comparator|Placebo|Patients receive placebo instead of Abatacept in a double blind fashion. Otherwise participation is the same, including that at the time of treatment failure they may elect any standard of care treatment and/or to begin taking open label abatacept but this rescue will define non-response in the primary endpoint at six months.
3107969|NCT02270983|Experimental|Linaclotide 145 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3107970|NCT02270983|Experimental|Linaclotide 290 micrograms|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3107971|NCT02270983|Experimental|Placebo|Oral capsule, taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center after at least a 2-hour fast.
3107972|NCT02271217|Placebo Comparator|Placebo|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3107973|NCT02271217|Active Comparator|dalfampridine-ER 7.5 mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3107974|NCT02271217|Active Comparator|dalfampridine-ER 10mg|Subjects randomized 1:1:1 to receive either dalfampridine-ER 7.5mg, dalfampridine-ER 10mg, or matching placebo tablets taken twice daily 12 hours apart.
3107975|NCT02271386|Experimental|Intervention|Clinicians in the intervention arm will receive the three-part intervention (Supporting Practice for ADHD, or SPA) which includes: education about ADHD management and communication training, collaborative consultation, and performance feedback, for the first 8 months of the study.
3107976|NCT02271386|Other|Control|Clinicians in the control arm will receive no intervention for the first 8 months of the study, then will receive the full SPA intervention for the last 8 months of the study.
3107977|NCT02271425|Experimental|Evacetrapib Tablet + Evacetrapib Intravenous|A single oral dose of 130 milligrams (mg) evacetrapib tablet + a single intravenous (IV) dose of 175 micrograms (μg)[¹³C₈] evacetrapib administered over a 4 hour infusion.
3107978|NCT02271451|Experimental|Q collar|subjects wearing the q collar
3107979|NCT02271451|No Intervention|Control|subjects not wearing the Q collar
3107980|NCT02271477|No Intervention|Wild-Type|The setting is standard spinal anesthesia and corresponds to our first arm of the study, used as the control sample and statistical reference. During the induction phase, the patient is fitted with non-invasive blood pressure monitoring, three-lead ECG, pulse-oximetry and peripheral intravenous device. Data and vital signs are recorded and an infusion of crystalloid (NaCl 0.9% or Ringer's acetate) is given during the procedure until the beginning of the operation. Total amount of fluid is also recorded before and after the spinal anesthesia.
3107981|NCT02271477|Experimental|Echocardiography|In addition to the current clinical standard, a Trans-Thoracic Echocardiography is performed before spinal anesthesia, with the aim of assessing the patient's volume status; the exam is performed to assess size and collapsing of the Inferior Vena Cava during breathing cycle. According to different pre-established parameters13, the patient is defined as fluid-responsive or unresponsive. If the patient is not responsive, investigators proceed to spinal anesthesia; otherwise they proceed to administration of crystalloid bolus (500 ml of NaCl 0.9% or Hartmann's solution). The patient may receive another bolus so as to reach a non-responsive pattern for echocardiographic evaluation.
3107982|NCT02271529|Experimental|Drug Eluting Stent|Zilver® Paclitaxel(PTX)® Drug-Eluting Peripheral Stent
3107983|NCT02271698|Active Comparator|Dexamethasone 6mg|Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3107984|NCT02271698|Active Comparator|Dexamethasone 12mg|Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3107985|NCT02271698|Active Comparator|Dexamethasone 24mg|Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3107986|NCT02271698|Placebo Comparator|Placebo|Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
3107987|NCT02271854|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1% applied four times daily
3107988|NCT02271854|Placebo Comparator|Placebo|Placebo gel applied four times daily
3107989|NCT02271880|Active Comparator|Medication as usual|Medication as typically prescribed by physician.
3107990|NCT02271880|Active Comparator|Medication as usual + STAR|Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence
3107991|NCT02271906|Experimental|BIBW 2992|BIBW 2992 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
3107992|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 2.5 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
3107993|NCT02271945|Experimental|MEDI-551 12 mg/kg and MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13 (each cycle of 28 days) and IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
3107994|NCT02271984|Experimental|Treatment A: MSC2499550A|MSC2499550A: 20 milligram per kilogram (mg/kg) under fed condition
3107995|NCT02271984|Experimental|Treatment B: Cysticide|Cysticide® 40 mg/kg under fed condition
3107996|NCT02271984|Experimental|Treatment C: MSC2499550A|C1:MSC2499550A :10 mg/kg under fed condition C2:MSC2499550A : 30 mg/kg under fed condition
3107997|NCT02271984|Experimental|Treatment D: MSC2499550A|MSC2499550A 20 mg/kg under fasting condition
3107998|NCT02271984|Experimental|Treatment E: MSC2499550A|MSC2499550A: 20 mg/kg directly disintegrated in mouth under fed condition
3107999|NCT02272244|Active Comparator|Standard|SI Group participants will be mailed a set of standard materials. The materials will include a letter from the participant's primary care practice encouraging selection and performance of either (1) colonoscopy screening, or (2) stool blood test (SBT) screening. Accompanying the letter will be instructions for arranging a colonoscopy appointment and instructions for completing an enclosed immunochemical SBT kit. Print materials and contacts will be provided, in both English and Spanish, after the baseline survey. At 45 days following random assignment that encourages screening.
3108000|NCT02272244|Experimental|Decision Support & Navigation|DSNI Group will be mailed print materials, including a letter from the practice on CRC screening, an informational booklet, and instructions for arranging a colonoscopy appointment and for completing an enclosed immunochemical SBT kit. All materials will be provided in both English and Spanish. Within 7 days after this mailing, participants will receive a telephone call from a trained bilingual study navigator. Following the call, the navigator will enter the participant's screening plan into the participant's electronic medical record, send the participant a letter describing the screening plan, and send the participant's primary care provider a copy of that same letter. At 45 days following random assignment, research staff will send participants a reminder letter encouraging the participant's preferred test. At 6 months after randomization, the navigator will send the provider and their office manager a participant CRC screening status report.
3108001|NCT02272413|Experimental|BI 695502|
3108002|NCT02272413|Active Comparator|Avastin|
3108003|NCT02272634|Experimental|Treatment A|Multiple oral YPL-001 80 mg doses (1 x 80 mg tablet + 1 x 1 YPL-001 80 mg matching placebo tablet) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
3108004|NCT02272634|Experimental|Treatment B|Multiple oral YPL-001 160 mg doses (2 x 80 mg tablets) are administered approximately every 12 hours under fasting conditions for 55 consecutive days.
3108005|NCT02272634|Placebo Comparator|Treatment C|Multiple oral matching placebo (2 x 1 YPL-001 80 mg matching placebo tablets) will be administered approximately every 12 hours under fasting conditions for 55 consecutive days.
3108006|NCT02272686|Experimental|Ibrutinib|Ibrutinib started at a daily dose of 560 mg by mouth daily for up to 3 years.
3108007|NCT02272725|Placebo Comparator|Placebo|tasteless and inert tablets
3108008|NCT02272725|Active Comparator|Ibuprofen|Each tablet containing 400mg of ibuprofen
3108009|NCT02272777|Active Comparator|Imatinib|Eligible patients from imatinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in imatinib 400 mg daily arm received imatinib daily dose of 300 mg, 400 mg or 600 mg all at once every day.
3108010|NCT02272777|Experimental|Nilotinib|Eligible patients from nilotinib arm in core study CAMN107ECN02 were enrolled into imatinib arm in this study. Patients in nilotinib arm received 300 mg BID by mouth each morning and evening approximately 12 hours apart, or 400 mg QD.
3108011|NCT02272790|Experimental|Arm A (adavosertib + gemcitabine)|Adavosertib (175 mg PO) will be taken on Days 1-2, 8-9, and 15-16. Gemcitabine 800 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
3108012|NCT02272790|Experimental|Arm B (adavosertib + paclitaxel)|Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days weekly (Days 1-3, 8-10, and 15-17). Weekly paclitaxel 80 mg/m² IV will be administered according to institutional standards on Day 1, 8, and 15 of each 28 day cycle.
3108013|NCT02272790|Experimental|Arm C/C2 (adavosertib + carboplatin)|"Arm C: Five doses of adavosertib (225 mg PO BID) will be taken in approximate 12 hour intervals over 2.5 days (Days 1-3). Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21-Day cycle.~Arm C2: Five doses of adavosertib (225 mg PO BID) 2.5 days per dosing week (QW), on Weeks 1 (D1-3), 2 (D8-10) and 3 (D15-17), or on Weeks 1 (D1-3) and 2 (D8-10) ( 2 weeks on followed by 1 week off.) Carboplatin AUC 5 IV will be administered according to institutional standards on Day 1 of each 21 day cycle."
3108014|NCT02272790|Experimental|Arm D (adavosertib + PLD)|Five doses of adavosertib (175 mg or 225 mg) will be taken in approximate 12 hour intervals over 2.5 days (Days 1, 2, and 3) of each 28-day cycle. PLD will administered IV on Day 1 of each cycle.
3108015|NCT02272803|Experimental|Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Biological: Elotuzumab (BMS-901608)~Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug~Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug"
3108016|NCT02272803|Active Comparator|Arm B: Lenalidomide + Dexamethasone|"Drug: Lenalidomide~Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug~Drug: Dexamethasone~Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
3108017|NCT02272816|Experimental|Carboplatin AUC-10|
3108018|NCT02272842|Experimental|Vitamin B12|A paste containing vitamin B12 2µg per 10 mL administered every day. The paste also contains 1 RDA of several other vitamins. The paste is produced by Compact (Norway / India)
3108019|NCT02272842|Placebo Comparator|Placebo|A paste containing no vitamin administered every day. The paste also contains 1 RDA of several vitamins, but no vitamin B12. The paste is produced by Compact (Norway / India)
3108020|NCT02272985|Other|CBF change during hemodialysis|[15O]H2O PET-CT scan and NIRS (Invos)
3108021|NCT02273037|Placebo Comparator|Pinard horn|Pinard horn (current practice) used to monitor the fetal heart rate in labour in this arm of the study.
3108022|NCT02273037|Experimental|Fetal heart rate Doppler|Doppler used to monitor the fetal heart rate in labour in this arm of the study.
3108023|NCT02273050|Experimental|Saxagliptin 5 mg + Metformin (500 mg with titration)|Saxagliptin 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3108024|NCT02273050|Active Comparator|Saxagliptin 5 mg + Placebo|Saxagliptin 5 mg once daily and Placebo 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3108025|NCT02273050|Active Comparator|Metformin (500 mg with titration) + Placebo|Placebo 5 mg once daily and metformin 500 mg once daily, then titrate. Acarbose will be used as rescue medication as needed.
3108026|NCT02273063|Experimental|Transcranial Magnetic Stimulation|Stimulation at pulse frequency of 5Hz delivered over L DLPFC. Intensity: 120% of Motor Threshold, 5 Sec Train, 14 Sec Inter-Train Interval, Frequency: 5Hz, Total Pulses: 3000/session. Sessions delivered once/day on weekdays for up to 40 sessions.
3108027|NCT02273115|Active Comparator|Nulliparous - Foley only|Nulliparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
3108028|NCT02273115|Active Comparator|Nulliparous - Foley and oxytocin|Nulliparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
3108029|NCT02273115|Active Comparator|Multi(primi)parous - Foley only|Multiparous and primiparous women randomized to receive Foley only treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. No additional ripening agents or oxytocin will be administered while the Foley is in place. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol after Foley removal.
3108030|NCT02273115|Active Comparator|Multi(primi)parous - Foley and oxytocin|Multiparous and primiparous women randomized to receive Foley and oxytocin treatment will have a 20 French latex or silicone Foley catheter placed by the provider in the method they are most comfortable (direct visualization or indirectly). Balloons will have the ability to accommodate up to 80 ml of fluid to avoid rupture. The Foley balloon with be instilled with 60 ml of saline. The end of the catheter is then taped to the medial aspect of the patient's thigh on tension. If spontaneous expulsion has not occurred, the Foley will be removed after 12 hours. Oxytocin will be administered per Christiana Care protocol immediately after Foley placement.
3108031|NCT02273141|Experimental|NER1006, Day Before-Only Dosing|NER1006 1-Day Day Before-Only Split-Dosing Regimen (to commence on the evening of the day before colonoscopy).
3108032|NCT02273141|Active Comparator|SP+MS, Day Before-Only Dosing|SP+MS 1-Day Day Before-Only Split-Dosing Regimen (to commence on the morning of the day before colonoscopy).
3108033|NCT02273167|Experimental|NER1006, 2-Day Split-Dosing|NER1006: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
3108034|NCT02273167|Experimental|NER1006,1-Day Morning Split-Dosing|NER1006: 1-Day Morning Split-Dosing Regimen (to commence in the morning of the day of colonoscopy).
3108035|NCT02273167|Active Comparator|MOVIPREP, 2-Day Split-Dosing|MOVIPREP®: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy).
3108036|NCT02273180|Experimental|SAR342434|SAR342434 before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
3108037|NCT02273180|Active Comparator|Humalog|Humalog before meals intake on top of QD Insulin Glargine, up to Week 52.
3108038|NCT02273206|Active Comparator|Prevention Care Management for Cancer Screening|The Care Manager will focus on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening.
3108039|NCT02273206|Experimental|Prevention Care Management for Depression and Cancer Screening|"The Care Manager will provide depression care management and motivational support (supportive counseling) and act as a critical link between primary care, mental health care provider, and the patients, helping to develop and implement a treatment plan.~In addition, the Care Manager will work with participants on cancer screening, providing education, patient navigation, and motivational support to overcome screening barriers and form favorable attitudes towards screening."
3108040|NCT02273310|Experimental|Families Taking Control|Families participate in a 1 day Problem-Solving Skills training for disease management intervention
3108041|NCT02273310|No Intervention|Delayed Intervention Control|Families are given the opportunity to complete the Problem-solving Skills training for disease management intervention after assessment time 2.
3108042|NCT02273323|Experimental|Tea|Black tea
3108043|NCT02273323|Placebo Comparator|Placebo|Placebo
3108044|NCT02273596|Experimental|ALXN1840|"Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period."
3108045|NCT02273726|Experimental|Roxadustat|Participants will receive roxadustat tablets, administered orally 3 times weekly (TIW). Initial roxadustat dose will be based on the participant's average prescribed erythropoietin stimulating agent (ESA) dose in the 4 weeks (if on epoetin or darbepoetin or 8 weeks (if on Mircera®) prior to randomization. Dose adjustments will be permitted to maintain a hemoglobin (Hb) level of approximately 11 grams (g)/deciliter (dL). The maximum roxadustat dose is 3.0 milligrams (mg)/kilogram (kg) per dose or 400 mg per administration (whichever is lower).
3108046|NCT02273726|Active Comparator|Epoetin Alfa|Participants on hemodialysis (HD) will receive epoetin alfa, administered intravenously (IV) TIW and participants on home HD or peritoneal dialysis (PD) will receive epoetin alfa, administered subcutaneously (SC). Initial epoetin alfa dose will be based on the participant's average weekly prescribed ESA dose in 4 weeks prior to randomization if on epoetin or darbepoetin, and average monthly (4-week) prescribed ESA dose in 8 weeks prior to randomization if on Mircera®. In case of a change in route of administration from SC to IV (TIW), the initial dose of IV epoetin alfa will be determined by the investigator per local standard of care (SOC). Dose adjustments will follow the recommendations as per the approved country-specific product label (United States Package Insert [USPI] or Summary of Product Characteristics [SmPC]) or local SOC.
3108047|NCT02273739|Experimental|Enasidenib|During the dose escalation phase, consented eligible participants will be enrolled into sequential cohorts of increasing doses of enasidenib.The starting dose for this study is 100 mg administered every 24 hours,
3108048|NCT02273908||Pregabalin|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
3108049|NCT02273908||Usual care|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
3108050|NCT02273960|Experimental|Arm A: BMS-986004|BMS-986004 solution intravenously (IV) as specified
3108051|NCT02273960|Experimental|Arm B: BMS-986004|BMS-986004 solution intravenously as specified
3108052|NCT02273960|Experimental|Arm C: BMS-986004|BMS-986004 solution intravenously as specified
3108053|NCT02273960|Experimental|Arm D: BMS-986004|BMS-986004 solution intravenously as specified
3108054|NCT02273973|Placebo Comparator|Letrozole + Placebo|Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
3108055|NCT02273973|Experimental|Letrozole + Taselisib|Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
3108056|NCT02274038|Experimental|All patients will be enrolled in a single arm of the study|All patients enrolled in the study will receive three 18F-thymidine (FLT) PET/CT scans at the following timepoints: before therapy, on the day of starting pemetrexed therapy (within 24 hours of starting pemetrexed) and at 2-4 weeks of starting pemetrexed therapy.
3108057|NCT02274311|Experimental|Clomiphene citrate|Patients receiving clomiphene citrate
3108058|NCT02274493|Experimental|Robotic Harvest of the LD Muscles|Surgical harvesting of the Latissimus Dorsi (LD) Muscles using da Vinci® robotic surgical system in participants undergoing LD muscle flap harvest procedures in conjunction with breast, scalp, upper extremity and lower extremity reconstructive surgery procedures.
3108059|NCT02274558|Experimental|NBI-98854 40 mg|NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
3108060|NCT02274558|Experimental|NBI-98854 80 mg|Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
3108061|NCT02274558|Experimental|Placebo|Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
3108062|NCT02274649|Experimental|Intervention|Intervention group receiving one-to-one peer mentoring
3108063|NCT02274649|Active Comparator|Control|Control group receiving general peer support
3108064|NCT02274675|Experimental|Robot group|Receive 0.5 hour of robot-assisted therapy for wrist and forearm and 1.5 hours of daily standard rehabilitation therapy
3108065|NCT02274688|No Intervention|Enhanced Usual Care - Nurse Notification of Patient Concerns|Randomized and will be blindly assessed.
3108066|NCT02274688|Experimental|Patient-centered care transition|"Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.~Randomized and will be blindly assessed."
3108067|NCT02274766|Experimental|ADS-5102 (amantadine HCl extended release)|ADS-5102 (amantadine HCl extended release)
3108068|NCT02274766|Placebo Comparator|Placebo|Placebo
3108069|NCT02274792|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice a week (BIW) for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
3108070|NCT02274844|Experimental|Peer Coaching|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching.
3108071|NCT02274844|No Intervention|Usual Care|At enrollment, the investigators will provide an educational DVD on general health and wellness topics including vaccination, cancer screening, osteoporosis and other topics not related to diabetes care. There will be no peer storytelling on these DVDs.
3108072|NCT02274857|Active Comparator|Standard PVI Ablation|Standard catheter ablation including pulmonary vein isolation (PVI) procedure for the treatment of persistent AF.
3108073|NCT02274857|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by standard catheter ablation including PVI.
3108074|NCT02274870|Experimental|Liposome Bupivacaine,|Liposome Bupivacaine 266mg, Knee Infiltration
3108075|NCT02274870|Active Comparator|Bupivacaine HCl|Bupivacaine HCl Continuous Femoral Nerve Block (CFNB), bolus and continuous for 48 hrs)
3108076|NCT02274948|Active Comparator|Metformin|8-10.99 year old children received metformin. Initially children given 250mg of metformin daily for a week and increased to 250mg twice daily for a week and then to 500 mg twice daily there after. 11-16 year old children received 500mg of metformin daily initially for one week which increased to 500mg twice daily for a week and then to 1g twice daily. The medication was continued for 12 months.
3108077|NCT02274948|Placebo Comparator|Placebo|"A placebo tablet which is physically similar to metformin tablets will be given in a similar manner as described above.~Metformin and placebo is manufactured by the State Pharmaceutical Manufacturing Corporation (SPMC)"
3108078|NCT02275026|Experimental|Functional magnetic resonance imaging|Magnetic resonance images will be acquired on a 3 Tesla scanner (Skyra, Siemens, Erlangen, Germany) with a 20 channel receiver coil.
3108079|NCT02275052|Experimental|UMEC/VI 62.5/25mcg|Participants will self-administer blinded UMEC/VI (62.5 mcg/25 mcg) each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days.
3108080|NCT02275052|Experimental|Placebo|Participants will self-administer blinded placebo each morning (once daily) as one inhalation from the double-blind DPI in one of the 2 treatment periods of 12 weeks. The treatment periods will be separated by a wash out period of 12-17 days
3108081|NCT02275065|Experimental|Bictegravir 5 mg|Bictegravir 5 mg (1 × 5 mg tablet) for 10 days
3108082|NCT02275065|Experimental|Bictegravir 25 mg|Bictegravir 25 mg (1 × 25 mg tablet) for 10 days
3108083|NCT02275065|Experimental|Bictegravir 50 mg|Bictegravir 50 mg (2 × 25 mg tablets) for 10 days
3108084|NCT02275065|Experimental|Bictegravir 100 mg|Bictegravir 100 mg (1 × 100 mg tablet) for 10 days
3108085|NCT02275065|Placebo Comparator|Placebo|Placebo matched to bictegravir tablet for 10 days
3108086|NCT02275117|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
3108087|NCT02275117|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
3108088|NCT02275117|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
3108089|NCT02275117|Experimental|ALD403 Dose Level 4|ALD403 Dose Level 4 (IV)
3108090|NCT02275117|Placebo Comparator|Placebo|Placebo (IV)
3108091|NCT02275156|Experimental|Evolocumab|Participants received a single 140 mg dose of evolocumab subcutaneously on Day 1.
3108092|NCT02275338|Experimental|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
3108093|NCT02275364|Experimental|Test nasal strip|Marketed Nasal Strip to be applied for up to two hours, and during the third scanning session for approximately 20 minutes.
3108094|NCT02275364|Placebo Comparator|Placebo nasal strip|Placebo nasal strip to be applied for up to two hours in either of the first two scans only.
3108095|NCT02275546|Experimental|Applicator→No Applicator (manual)|Treatment period 1: Participants will use applicator to insert vaginal ring. Treatment period 2: Participants will manually insert vaginal ring using fingers only.
3108096|NCT02275546|Experimental|No applicator (manual)→Applicator|Treatment period 1: Participants will manually insert vaginal ring using fingers only. Treatment period 2: Participants will use applicator to insert vaginal ring.
3108097|NCT02275611|Active Comparator|Intranasal oxytocin spray (Syntocinon Spray)|TID inpatient; BID outpatient for 12 wks
3108098|NCT02275611|Placebo Comparator|Intranasal Placebo Spray|TID inpatient; BID outpatient for 12 wks
3108099|NCT02275767|Experimental|Combination 50% cortical/50% cancellous FDBA|Ridge preservation with Combination 50% cortical/50% cancellous freeze-dried bone allograft (FDBA)
3108100|NCT02275767|Active Comparator|100% cortical FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
3108101|NCT02275767|Active Comparator|100% cancellous FDBA|Ridge preservation with 100% cortical freeze-dried bone allograft (FDBA)
3108102|NCT02275780|Experimental|Doravirine 100 mg|Double-blind Doravirine 100 mg administered orally (p.o.) once daily (q.d.) + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks in the Base Study. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
3108103|NCT02275780|Active Comparator|Darunavir 800 mg and Ritonavir 100 mg|Double-blind Darunavir 800 mg and Ritonavir 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for 96 weeks. Eligible participants may continue in Study Extension 1 with open-label Doravirine 100 mg administered p.o., q.d. + investigator selected TRUVADA™ or EPZICOM™/KIVEXA™ administered p.o., q.d. for an additional 96 weeks. Eligible participants may continue to receive the same treatment regimen in Study Extension 2 until doravirine becomes locally available, or for an additional 96 weeks, whichever comes first.
3108104|NCT02275819|No Intervention|control|Will not receive intervention with exercise
3108105|NCT02275819|Active Comparator|Intervention group|2 groups will receive 2 different types of therapy (exercise or Inspiratory Muscle Therapy)
3108106|NCT02275923|Experimental|Diagnostic|'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions.
3108107|NCT02276027|Experimental|BYL719 350 mg QD|Patient's tumor must have molecular alteration of the PIK3CA gene.
3108108|NCT02276027|Experimental|INC280 400 mg BID tab/600 mg BID cap|Patient's tumor must have molecular alteration of the c-MET gene.
3108109|NCT02276027|Experimental|LDK378 750 mg QD|Patient's tumor must have ALK or ROS1 gene rearrangement.
3108110|NCT02276027|Experimental|MEK162 45 mg BID|Patient's tumor must have KRAS, NRAS or BRAF mutation.
3108111|NCT02276040||Exparel|Participants will receive Exparel (periarticular bupivicaine and liposomal bupivicaine).
3108112|NCT02276053||BTRE patients|Patients with brain tumor-related epilepsy (BTRE) routinely treated with lacosamide as add on to one or two baseline anti-epileptic drugs.
3108113|NCT02276222|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
3108114|NCT02276222|Active Comparator|Spiriva 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
3108115|NCT02276274|Experimental|Fasted dosing followed by fed dosing|Oral administration
3108116|NCT02276274|Experimental|Fed dosing followed by fasted dosing|Oral administration
3108117|NCT02276482|Experimental|Tedizolid Phosphate|Tedizolid Phosphate IV and/or oral 200 mg once per day for 6 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
3108118|NCT02276482|Active Comparator|Antibiotic comparator drug|IV and/or oral antibiotic comparator drug for 10 days. Participants with gram-negative wound infection may receive aztreonam (IV) and/or metronidazole (IV or oral).
3108119|NCT02276547|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
3108120|NCT02276612|Experimental|E/C/F/TAF|"Treatment-experienced participants will receive open-label E/C/F/TAF for up to 48 weeks.~After completion of 48 weeks of treatment, all eligible participants will be given the option to participate in an open-label extension phase to receive E/C/F/TAF until a) the participant turns 18 years old and E/C/F/TAF is commercially available for use in adults in the country the participant is enrolled, or b) E/C/F/TAF becomes commercially available for use in the participant's current age group in the country the participant is enrolled, or c) E/C/F/TAF becomes accessible to participants through an access program, or d) Gilead Sciences elects to terminate development of E/C/F/TAF in the applicable country."
3108121|NCT02276638||18-28 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
3108122|NCT02276638||29-80 years old Non-pathologic|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
3108123|NCT02276638||29-80 years old pathological|Device: Specular Microscope Nidek CEM-530 Device: Specular Microscope Konan CELLCHEK XL
3108124|NCT02276807|Experimental|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques. Emphasis is placed upon understanding the individuals values and increasing the number of pleasurable activities aligned with the individuals values.
3108125|NCT02276807|Active Comparator|Usual Care|This is the usual care condition, where participants often times will be provided with brief treatment in primary care that can take many forms.
3108126|NCT02276872|Experimental|Cohort 1 (Transitioning from Parental)|Transitioned from IV or SC Remodulin to oral treprostinil
3108127|NCT02276872|Experimental|Cohort 2 (Transitioning from Inhaled)|Transitioned from inhaled prostacyclin to oral treprostinil
3108128|NCT02276872|Experimental|Cohort 3 (Add-on to Current PAH Therapy)|Treated with oral treprostinil as a de novo add-on to current PAH therapy
3108129|NCT02276963|Experimental|Ublituximab Plus Glucocorticoids|Ublituximab 450 mg intravenously once on day 1, plus glucocorticoids 1000 mg intravenously daily on days 1-5
3108130|NCT02277054|Experimental|Collagen-MPC cornea substitute|Collagen-phosphorylcholine (collagen-MPC) cornea substitute transplantation using anterior lamellar keratoplasty technique.
3108131|NCT02277093|Experimental|Pacritinib|"Pacritinib is an oral drug which will be taken on an outpatient basis daily on a 28-day cycle at a dose of 200 mg twice a day (BID)~Pacritinib should be take at approximately the same times every day with a glass of water, with or without food"
3108135|NCT02277249|Other|Transvaginal digoxin|Transvaginal administration of digoxin for inducing fetal death prior to second-trimester abortion
3108136|NCT02277249|Other|Transabdominal digoxin|Transabdominal administration of digoxin for inducing fetal death prior to second-trimester abortion
3132651|NCT03442777|Experimental|Study Arm 1 (on top of standard of care)|"Allevyn® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith & Nephew (Allevyn® brand)."
3469195|NCT03889223|Experimental|The SCF neuraxial positioning technique|In the SCF neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 7-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 15 weeks.
3108138|NCT02277548|Experimental|Lyrica at 300 mg per day|
3108139|NCT02277548|Placebo Comparator|Placebo|
3108140|NCT02277626|Experimental|Randomized Crossover to ElectroFlo|Experimental: ElectroFlo 5000, then VEST Patients are randomized to a sequence of ElectroFlo 5000 on one visit and during the second visit, they cross-over to the Vest system.
3108141|NCT02277626|Experimental|Randomized Crossover to Vest|Experimental: VEST, then ElectroFlo 5000 Patients are randomized to a sequence of Vest system on one visit and during the second visit, they cross-over to the ElectroFlo 5000.
3108142|NCT02277639|Experimental|Bone Marrow Failure Syndrome|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
3108143|NCT02277639|Experimental|Immunodeficiency / Dysregulation|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells. Reduced intensity conditioning will include Busulfan, Fludarbine, Cyclophosphamide followed by stem cell infusion.
3108144|NCT02277665|Active Comparator|CUD Treatment Only|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD
3108145|NCT02277665|Experimental|CUD and Tobacco Treatment|12 Week Behavioral Treatment that included weekly computer-assisted counseling and contingency management for CUD, and behavioral counseling and nicotine replacement therapy (NRT) for tobacco
3108146|NCT02277691|Experimental|TAK-536TCH|"For 4 weeks during the run-in period, one tablet of TAK-536CCB (as TAK-536/AML, 20 mg/5 mg, respectively) orally, once daily, before or after breakfast.~For 48 weeks during 52 weeks of the treatment period, one tablet of TAK-536TCH (as TAK-536/AML/HCTZ, 20 mg/5 mg/12.5 mg, respectively) orally, once daily, before or after breakfast. For the remaining 4 weeks of the treatment period, one tablet each of TAK-536CCB and HCTZ 12.5 mg orally, once daily, before or after breakfast."
3108147|NCT02277743|Experimental|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
3108148|NCT02277743|Experimental|Dupilumab 300 mg once weekly (qw)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3108149|NCT02277743|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3108150|NCT02277769|Placebo Comparator|Placebo|Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection once weekly (qw) from Week 1 to Week 15.
3108151|NCT02277769|Experimental|Dupilumab 300 mg every 2 weeks (q2w)|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a placebo alternating with single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3108152|NCT02277769|Experimental|Dupilumab 300 mg qw|Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 15.
3108153|NCT02277925|Active Comparator|Gore-Tex permanent suture|Participants in this arm will receive Gore-Tex permanent suture
3108154|NCT02277925|Experimental|PDS delayed absorbable suture|Participants in this arm will receive 2-0 PDS delayed absorbable suture
3108155|NCT02277990|Active Comparator|TYRX™ envelope|The Medtronic TYRX™ Absorbable Antibacterial Envelope is an absorbable sterile prosthesis designed to hold a pacemaker pulse generator or defibrillator to create a stable environment when implanted in the body. The purpose of the absorbable coating is to act as a carrier for the antimicrobial agents.
3108156|NCT02277990|No Intervention|Control|No TYRX™ envelope, bare CIED
3108157|NCT02278003|Experimental|children going under sedation with propofol|"Children who will undergo sedation as part of their clinical management and give them a memory encoding task during propofol infusion to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of propofol.~measure the amnesic effects of propofol."
3108158|NCT02278003|Active Comparator|children not going under sedation|A control group of children of similar age and undergoing similar minor therapeutic procedures will be recruited to perform memory.
3469196|NCT03888911|Experimental|High dose IQP-LU-104 (5120mg)|High dose treatment group
3469197|NCT03888911|Experimental|Low dose IQP-LU-104 (2560mg)|Low dose treatment group
3108161|NCT02278146|Experimental|1) Stress urinary incontinence|Stress urinary incontinence. Diagnosed with urinary stress incontinence and treated with the ParaPatch System
3108162|NCT02278146|Experimental|2) Overactive bladder|Overactive bladder. Diagnosed with overactive bladder syndrome and treated with the ParaPatch System
3108163|NCT02278237|Experimental|VME Group|Pre and post VME education group. The Intervention is the use of the virtual education module rather than the interpersonal educational strategy.
3469198|NCT03888911|Placebo Comparator|Placebo|Placebo group
3469199|NCT03889080||SCN9A-group|Patients with SCN9A-associated small fiber neuropathy
3469200|NCT03889080||Skin biopsy|Patients with SFN confirmed with a decreased intra-epidermal nerve fiber density (IENFD)
3469201|NCT03889080||Control|Age- and gender-matched healthy controls
3469202|NCT03888898|Active Comparator|N95 Filtering Facepiece Respirator|control fit testing
3469203|NCT03888898|Experimental|Elastomeric Respirator|experimental rapid conversion fit testing and competency evaluations
3108164|NCT02278263|Placebo Comparator|Control|Application of 20ml of normal saline (NaCl 0.9%) topically after implantation of prosthesis and left to sit for two minutes, excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
3108165|NCT02278263|Experimental|Topical|Application of 1.5g in 20ml tranexamic acid topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; application of 15ml of normal saline intravenously at the same time prior to release of tourniquet.
3108166|NCT02278263|Experimental|Systemic|Application of 20ml of normal saline topically after implantation of prosthesis with excess carefully suctioned followed by standard closure with no drains; Application of tranexamic acid intravenously (1.5g/15ml) at the same time prior to release of tourniquet
3108167|NCT02278289|Active Comparator|ultrasound therapy group|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
3108168|NCT02278289|Active Comparator|paraffin therapy group|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
3108169|NCT02278328|Experimental|A. Placebo then 15mg then 30mg|"Subjects will receive a single dose of placebo on week 1, 15 mg of STX209 on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
3108170|NCT02278328|Experimental|B. 15mg then placebo then 30mg|"Subjects will receive a single dose of 15 mg of STX209 on week 1, placebo on week 2 and 30 mg of STX209 on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
3108171|NCT02278328|Experimental|C. 15mg then 30mg then placebo|"Subjects will receive a single dose of 15 mg of STX209 on week 1, 30 mg of STX209 on week 2 and placebo on week 3.~Subjects will receive STX209 via oral disintegrating tablets, administered in individual 15mg tablets."
3108172|NCT02278341|Experimental|Roxadustat|Participants received roxadustat three times a week (TIW) for at least 52 weeks up to a maximum of 104 weeks. Participants received initial dose of roxadustat in doses of 100 mg, 150 mg or 200 mg, according to the average weekly dose of epoetin or darbepoetin alfa prior to randomization. Participants' roxadustat dosage was adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps were as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300, and 400 mg. Oral iron treatment of 200 mg was allowed for supplementation to support erythropoiesis. Treatment with intravenous iron was allowed only if certain protocol criteria were met.
3108173|NCT02278341|Active Comparator|ESA (Erythropoiesis Stimulating Agent) treatment|Participants received epoetin alfa once weekly, twice weekly or TIW and darbepoetin alfa once a week or once every other week. Participants were treated for at least 52 weeks up to a maximum of 104 weeks. Treatment dosage was adjusted according to the pre-specified rule of keeping the participant's Hb levels between 10.0 to 12.0 g/dL. Participants were not allowed to switch from the epoetin alfa to darbepoetin alfa or vice versa.
3108174|NCT02278354|Experimental|Active Professional Fighters|Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
3108175|NCT02278354|Experimental|Retired Professional Fighters|Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
3108176|NCT02278367|Experimental|Flortaucipir PET Scans|
3108177|NCT02278471|No Intervention|Usual Care|Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
3108178|NCT02278471|Experimental|Polypill|"The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily."
3108179|NCT02278484|Other|Balloon Sinus Dilation|
3108180|NCT02278562|Active Comparator|anakinra|100 mg of Anakinra in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
3108181|NCT02278562|Active Comparator|actos|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and 30 mg of Actos in capsules administered orally 1 capsule per day for 3 months
3108182|NCT02278562|Placebo Comparator|placebo 1 and 2|Normal saline (placebo) in syringes administered subcutaneously 3 times a week for 3 months and lactose (placebo) in capsules administered orally 1 capsule per day for 3 months
3108183|NCT02278614|Experimental|T2347|T2347: fixed combination Latanoprost 0.005% + Timolol 0.5% unpreserved eye drops
3108184|NCT02278614|Active Comparator|Xalacom|Xalacom®: Latanoprost 0.005% + Timolol 0.5% preserved eye drops
3108185|NCT02278640|Other|Harmonic ACE®+7 Shears|Single Arm study using Harmonic ACE for dissection and transection in Hysterectomy
3108186|NCT02278783|Experimental|Regorafenib Treatment arm, all patients|
3108187|NCT02278939|Experimental|Fit and Trim group|This groups will start with the Filipinos Fit and Trim Weight Loss Program mobile phone based (smartphone) intervention with social networking for 3 months, a pedometer/accelerometer, access to a study private Facebook virtual social networking group, and and 4 in-person intervention session with individually tailored goals for physical activity, diet, and weight. At 3months, the Fit and Trim group will transition to a maintenance phase for 3 months, receive one in-person session for maintenance support (at 4.5 months) and complete the study at month 6.
3108188|NCT02278939|Active Comparator|Pedometer only group|This group will start with the pedometer/accelerometer only to monitor/ track their physical activity step-counts for the initial 3 months. In addition, subjects will receive an educational materials on Hepatitis B and Tuberculosis. At 3 months the pedometer only group will transition to receive the Filipinos Fit and Trim Weight Loss Program intervention (as previously described) for the next 3 months and complete the study at month 6.
3132652|NCT03442777|Experimental|Study Arm 2 (on top of standard of care)|"Mepilex® brand silicone adhesive multilayer foam dressings~Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand)."
3108189|NCT02279043|Experimental|Intervention|IUC users and non-IUC user participants randomized to the intervention arm will take part in small intervention groups in an online community called Birth Control Connect for twelve days. There will be up to 35 intervention groups with 9 members each. Non-IUC users in these groups will receive the intervention of Interaction with users of IUC and non-IUC users in the context of the online community. About 50% of participants in intervention groups will be current IUC users, and 50% will not be current IUC users. We will measure the attitudes and behaviors of those who do not have IUC before and after the intervention, considering social exposure to IUC users as a possible predictor of changes in knowledge, attitude and behavior.
3108190|NCT02279043|Placebo Comparator|Control|Participants randomized to the control arm will take part in Birth Control Connect control groups identical to those in the intervention arm, except no participants in the control arm will be current IUC users. Therefore, participants in the control arm will have interaction with non-IUC users only. We will measure these participants' attitudes and behavior related to IUC use before and after the twelve-day study period, and compare results to those of participants in the intervention arm. There will be up to 35 control groups of 9 members each.
3108191|NCT02279043|No Intervention|IUC users|IUC users will be recruited to populate intervention groups. Interaction with IUC users will be the intervention for non-IUC users randomized to the intervention arm. IUC users will receive no intervention.
3108192|NCT02279082|Experimental|DFN-02|DFN-02 to be taken during migraine attack
3108193|NCT02279108|Experimental|double detection Indocyanine + isotope|intradermal injection of 2.5 milligrams of indocyanine green and 20 MBq of technetium 99 before breast surgery
3108194|NCT02279108|Active Comparator|isotope detection alone|intradermal injection of 20 MBq of technetium 99 before breast surgery
3108195|NCT02279160|Experimental|APD811|Multiple dose titration to maximum tolerated dose.
3108196|NCT02279160|Placebo Comparator|Placebo|Multiple dose titration to maximum tolerated dose.
3108197|NCT02279173|Experimental|Romiplostim|Participants received romiplostim administered weekly by subcutaneous injection for up to 3 years. The starting dose was 1 µg/kg titrated in 1 µg/kg increments up to a maximum of 10 µg/kg to reach a target platelet count ≥ 50 x 10⁹/L.
3108198|NCT02279407|Placebo Comparator|placebo|
3108199|NCT02279407|Experimental|Omega-3 carboxylic acids 4g / day|
3108200|NCT02279407|Experimental|Dapagliflozin, 10mg / day|
3108201|NCT02279407|Experimental|Omega-3 carboxylic acids 4g/day+Dapagliflozin 10mg/day|
3108202|NCT02279420|Other|Essential Study Sham Cross-over|Device: g-Cath EZ™ Suture Anchor Delivery Catheter This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
3108203|NCT02279498|Experimental|Liprotamase|Individually-optimized dose to be administered orally
3108204|NCT02279498|Active Comparator|porcine (pig) PERT|Individually-optimized dose to be administered orally
3108205|NCT02279524|Experimental|Aramchol 600mg|One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
3108206|NCT02279524|Experimental|Aramchol 400mg|One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
3108207|NCT02279524|Placebo Comparator|Placebo|Two tablet of Aramchol matching placebo.
3108208|NCT02279641|Experimental|Sequence A|RDEA3170 qd (once daily), RDEA3170 + allopurinol qd, allopurinol qd
3108209|NCT02279641|Experimental|Sequence B|allopurinol qd, RDEA3170 + allopurinol qd, RDEA3170 qd
3108210|NCT02279667|Experimental|Group A|"st period - 16 mL oral suspension 50 mg/mL~nd period - Four 200 mg tablets~rd period - One 800 mg tablet"
3108211|NCT02279667|Experimental|Group B|"st period - One 800 mg tablet~nd period - 16 mL oral suspension 50 mg/mL~rd period - Four 200 mg tablets"
3108212|NCT02279667|Experimental|Group C|"st period - Four 200 mg tablets~nd period - One 800 mg tablet~rd period - 16 mL oral suspension 50 mg/mL"
3108213|NCT02279719|Experimental|BBI608 and Sorafenib|
3108214|NCT02279719|Experimental|BBI503 and Sorafenib|
3108215|NCT02279719|Active Comparator|Sorafenib|
3108216|NCT02279732|Experimental|Arm 1: Carboplatin + Paclitaxel + Ipilimumab|"Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by modified WHO (mWHO)~Carboplatin Area Under the Curve (AUC6) IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Ipilimumab 10 mg/kg IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
3108217|NCT02279732|Experimental|Arm 2: Carboplatin + Paclitaxel + Placebo|"Carboplatin AUC6 IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Paclitaxel 175 mg/m² IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO~Placebo IV Solution Every 3 weeks during induction and every 12 weeks during maintenance until disease progression declared by mWHO"
3108218|NCT02279862|Experimental|Arm 1: Ipilimumab 3 mg/kg|Ipilimumab 3 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
3108219|NCT02279862|Experimental|Arm 2: Ipilimumab 10 mg/kg|Ipilimumab 10 mg/kg injection intravenously every 3 weeks for 4 doses in Induction phase. Subjects that are eligible to receive Ipilimumab in the Maintenance phase will be dosed every 12 weeks for a maximum of 3 years since the first induction dose
3108220|NCT02280044|Experimental|rifaximin|Subjects receiving rifaximin prophylaxis will be challenged with C. jejuni
3108221|NCT02280044|Placebo Comparator|placebo|Subjects receiving placebo will be challenged with C. jejuni
3108222|NCT02280096|Active Comparator|4-aminopyridine treatment|4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
3108223|NCT02280096|Placebo Comparator|Placebo|Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.
3108224|NCT02280122||gen. mod. to sev. chronic periodontitis|"Sites with probing pocket depths (PPD) ≥ 3.5 mm~Attachment loss (PAL-V) ≥ 3 mm > 30% of sites~no Intervention provided"
3108225|NCT02280122||periodontally healthy|"PPD ≤ 3 mm~PAL-V ≤ 2 mm at < 30% of sites~BOP < 20%~No radiographically detectable bone loss: distance cemento-enamel junction to provided~no Intervention but aMMP-8 test"
3108226|NCT02280187||Spine Fusion with InductOs|Patient had spinal fusion surgery with InductOs between 1st January 2011 and 31st December 2012
3108227|NCT02280200|Experimental|AFO to improve outcomes|Patients completed graded treadmill testing, followed by 12 weeks of unstructured community-based walking using the AFO ad libitum
3108228|NCT02280200|No Intervention|Historical Controls|Historical PAD control group (n = 10) received upfront advice to walk at home with no intervention
3108229|NCT02280226|Experimental|Deliberate Apnea Group|Subjects undergo maximum apnea.
3108230|NCT02280291|Active Comparator|Ankle Single Shot Block (SSB)|
3108231|NCT02280291|Experimental|Ankle OnQ (Continuos Sedation OnQ Pump)|
3108232|NCT02280291|Experimental|DR SSB|
3108233|NCT02280291|Experimental|DR OnQ|
3108234|NCT02280304|Experimental|Inner Resources for Veterans (IRV) mindfulness and mantra|Complete a mindfulness and mantra therapy
3108235|NCT02280304|Active Comparator|Essential Skills therapy|Learn symptoms of mTBI and PTSD, coping skills
3108236|NCT02280317|Experimental|Cohort 1: 0.5 mg/kg|VAL201-001 Sub-cutaneous injection. 0.5 mg/kg
3108237|NCT02280317|Experimental|Cohort 2: 1 mg/kg|VAL201-001 Sub-cutaneous injection. 1.0 mg/kg
3108238|NCT02280317|Experimental|Cohort 3: 2 mg/kg|VAL201-001 Sub-cutaneous injection. 2.0 mg/kg
3108239|NCT02280317|Experimental|Cohort 4: 4 mg/kg|VAL201-001 Sub-cutaneous injection. 4.0 mg/kg
3108240|NCT02280317|Experimental|Cohort 5: up to 8 mg/kg|VAL201-001 Sub-cutaneous injection. 8.0 mg/kg; potential to escalate to 16 mg/kg after 3 cycles according to clinician decision Flexibility of dosing enabled under protocol.
3108241|NCT02280408|Experimental|3x10^6 plaque-forming units (pfu) Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0 and Day 28.
3108242|NCT02280408|Experimental|2x10^7 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0 and Day 28.
3108243|NCT02280408|Experimental|1x10^8 pfu Vaccine Cohort|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0 and Day 28.
3108244|NCT02280408|Placebo Comparator|Placebo Cohort|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0 and Day 28.
3108245|NCT02280421|Other|ASP2151 400mg|ASP2151 400mg + 100mg ciclosporin
3108246|NCT02280421|Other|ASP2151 1200mg|ASP2151 1200mg + 100mg ciclosporin
3108247|NCT02280473|Experimental|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3108248|NCT02280473|Active Comparator|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
3108249|NCT02280655|Active Comparator|Storage-aged red blood cells (saRBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with older stored red blood cells (RBCs) units. The units had been stored for greater than 21 days.
3108250|NCT02280655|Active Comparator|Fresh red blood cells (RBCs)|Subjects with cardiovascular disease (CVD) received a transfusion with fresh red blood cells (RBCs) units. The units had been stored for less than 14 days.
3108251|NCT02280811|Experimental|T Cell Receptor Immunotherapy|patients will receive cyclophosphamide and fludarabine followed by infusion of the human papilloma virus (HPV) E6 T cell receptor (TCR), followed by high dose aldesleukin
3108252|NCT02280863|Experimental|Adult Cohort|Medtronic Hybrid Closed-Loop System will be used by adults for five days in open-loop (sensor augmented pump) and five days in closed-loop. The first 8 Adults use the Android Platform.
3108253|NCT02280863|Experimental|Adolescent Cohort|Medtronic Hybrid Closed-Loop System will be used by adolescents for four days in open-loop (sensor augmented pump) and four days in closed-loop.
3469204|NCT03888885|Experimental|Sport Education Group|Participants participated in the required physical education lessons which were delivered in a season of sport education model for 10 lessons.
3469205|NCT03888885|No Intervention|Control Group|Participants received no intervention treatment. They were asked to attend in normal physical education classes for the same period of time.
3108256|NCT02281136|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
3108257|NCT02281318|Experimental|Mepolizumab SC|Participants will receive Mepolizumab 100 mg subcutaneously (SC) into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
3108258|NCT02281318|Placebo Comparator|Placebo SC|Participants will receive placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks (total of 6 doses) along with their respective standard care of treatment
3108259|NCT02281344|Experimental|Cohort 1|Cohort 1 will receive a single dose of 20mg MMV390048.
3108260|NCT02281357|Experimental|Tralokinumab|Tralokinumab subcutaneous injection
3108261|NCT02281357|Placebo Comparator|Placebo|Placebo subcutaneous injection
3108262|NCT02281409|Experimental|Phase I: Mogamulizumab (KW-0761)|Patients will be enrolled to receive a weekly intravenous (IV) dose of KW-0761 ranging from 0.5 mg/kg to 10.0 mg/kg as feasible starting on Day 1 for 4 weeks. In the absence of toxicity or progression of disease, patients may continue receiving KW-0761 for up to 12 months. Subsequent treatment courses will consist of an infusion every other week. Following end of treatment or treatment completion date, a 24-week short term follow-up (STFU) period of observation will begin.
3469206|NCT03889067|Experimental|Combination of Challenge Agents|"Wild-Type Quailes Strain Salmonella Typhi: Quailes Typhoid toxin knock out strain in a 1:1 ratio at a dose of 1-5 x 10^4CFU~All participants will receive the same intervention in a given group for challenge (dose reduction may occur for later participants depending on the results from the first six participants)"
3108263|NCT02281409|Experimental|Phase II: Mogamulizumab (KW-0761)|Phase II of the study will enroll a total of 48 subjects, 16 patients in 3 tumor-specific expansion cohorts each treated at the RP2D (MTD, or highest dose tested in Phase I part of trial).
3108264|NCT02281422|Other|Group 1 normal renal function|normal renal function (creatinine clearance > 80 mL/min)
3108265|NCT02281422|Other|Group 2 mild renal impairment|mild renal impairment (creatinine clearance 50-80 mL/min)
3108266|NCT02281422|Other|Group 3 moderate renal impairment|moderate renal impairment (creatinine clearance 30-50 mL/min)
3108267|NCT02281422|Other|Group 4 severe renal impairment|severe renal impairment (creatinine clearance <30 mL/min)
3108268|NCT02281422|Other|Group 5 end stage renal disease|end stage renal disease, requiring haemodialysis (ESRD)
3108269|NCT02281448|Other|Treatment sequence A|oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days followed by washout and 3 days of oral single-dose contraceptive
3108270|NCT02281448|Other|Treatment sequence B|oral single-dose of a contraceptive for 3 days after pre-treatment with an oral once daily dose of 1200 mg of BIA 2-093 plus single-dose of a contraceptive for 15 days
3108271|NCT02281500|Experimental|Single|Human Plasma-Derived Fibrinogen Concentrate Grifols (FIB Grifols)
3108272|NCT02281526|Other|Subjects with moderate hepatic impairment|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
3108273|NCT02281526|Other|subjects - healthy controls|This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
3108274|NCT02281552|Experimental|tofacitinib modified release tablet|
3108275|NCT02281552|Active Comparator|tofacitinib immediate release tablet|
3108276|NCT02281591|Experimental|eslicarbazepine acetate|900mg of eslicarbazepine acetate (ESL, BIA 2-093)
3108277|NCT02281591|Active Comparator|S-licarbazepine R-licarbazepine|450 mg of S-licarbazepine plus 450 mg of R-licarbazepine
3108278|NCT02281591|Active Comparator|S-licarbazepine|450 mg of S-licarbazepine
3108279|NCT02281591|Active Comparator|R-licarbazepine|450 mg of Rlicarbazepine
3108280|NCT02281760|Experimental|Combination therapy with dabrafenib and trametinib in patients with ECD|Patients with Erdheim Chester Disease (ECD) and BRAFV600E mutation received combination therapy with dabrafenib, a BRAFV600E inhibitor 150mg orally every twelve hours, and trametinib, an inhibitor of MEK, downstream of BRAF, 2mg orally daily.
3108281|NCT02281773|Experimental|dose 1|
3108282|NCT02281773|Experimental|dose 2|
3108283|NCT02281773|Experimental|dose 3|
3108284|NCT02281773|Experimental|dose 4|
3108285|NCT02281773|Placebo Comparator|placebo|
3108286|NCT02281851||Supplemented|The group consists of well-trained cyclists who habitually consume vitamin/antioxidant supplements for a period longer than 6 months
3108287|NCT02281851||Non-supplemented|The group consists of well-trained cyclists who do not consume vitamin/antioxidant supplements
3469207|NCT03888651||Observational (questionnaires, quality of life assessment)|Patients complete questionnaires and quality of life assessments over 10-15 minutes at pre-surgery, after-surgery, at discharge, within 2-3 weeks after surgery, and within 90 days after surgery.
3108289|NCT02282111|Active Comparator|EUS-CNB|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that the procedure terminated.
3108290|NCT02282111|Active Comparator|SINK|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
3108291|NCT02282163|Experimental|Lumason|All patients were administered, Lumason (sulphur hexafluoride lipid-type A microspheres) an ultrasound contrast agent as a single 0.03 mL/kg bolus injection during echocardiography.
3108292|NCT02282293|Active Comparator|Daily TS + Monthly DP pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregancy, TS will be given to women at a dose of 960mg once daily.
3108293|NCT02282293|Placebo Comparator|Daily TS + DP Placebo pregnancy|Women will be given DP placebo (3 tabs, given once a day for 3 consecutive days) every 4 weeks during pregnancy. During pregnancy, TS will be given to women at a dose of 960mg once daily.
3108294|NCT02282514|Experimental|Hematopoietic Stem Cell Transplantation|The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.
3108295|NCT02282527|Other|Treatment Sequence 1|Subjects were treated first with Liquid Alpha₁-PI and then treated with Prolastin-C
3108296|NCT02282527|Other|Treatment Sequence 2|Subjects were treated first with Prolastin-C and then treated with Liquid Alpha₁-PI
3108297|NCT02282605|Experimental|XF-73 2.0 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris, twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.6mg XF-73 per naris/1.2mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3108298|NCT02282605|Experimental|XF-73 0.5 mg/g nasal gel|0.3mL (nominal 300 microgram) XF-73 nasal gel will be applied to each naris twice daily for two days. Each dose will be 0.3mL per naris/0.6mL per dose delivering 0.15mg XF-73 per naris/0.3mg XF-73 per dose. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3108299|NCT02282605|Placebo Comparator|Placebo nasal gel|0.3mL nasal gel will be applied to each naris twice daily for two days. Prior to each morning dose, subjects will use chlorhexidine gluconate 2% body and face cloths.
3108300|NCT02282631|Experimental|Intervention group school|School where the incentive scheme will be run.
3108301|NCT02282631|No Intervention|Control group school|School with no intervention; ongoing advice on active school travel.
3108302|NCT02282722|Active Comparator|Usual informed consent|Study participant will receive usual, standard-of-care informed consent for chemotherapy materials.
3108303|NCT02282722|Experimental|Investigational informed consent|Study participant will receive investigational informed consent for chemotherapy materials that were developed by the study team.
3108304|NCT02282813|Experimental|CTAP101 Capsules alone|CTAP101 Capsules 30 or 60 mcg daily for up to 26 weeks
3108305|NCT02282813|Experimental|CTAP101 Capsules +calcitriol|CTAP101 Capsules 60 mcg +calcitriol daily for 14 weeks
3108306|NCT02282813|Experimental|CTAP101 Capsules +doxercalciferol|CTAP101 Capsules 60 mcg +doxercalciferol daily for 14 weeks
3108307|NCT02282813|Experimental|CTAP101 Capsules +paricalcitol|CTAP101 Capsules 60 mcg +paricalcitol daily for 14 weeks
3108308|NCT02282904|Experimental|CGD Recipient|CGD patients that will undergo haplo transplantation with post-transplant cyclophosphamide as described
3108309|NCT02282930|Experimental|ACTH Gel|Injected does of 80 units subcutaneously twice weekly for 6 months.
3108310|NCT02282982||Infants at high-risk of serious RSV illness|Infants who received immunoprophylaxis during the RSV season
3108311|NCT02283268|Experimental|Recombinant von Willebrand Factor (rVWF)|Surgery participants treated with Recombinant von Willebrand Factor (rVWF)
3108312|NCT02283294|Experimental|Apixaban|Apixaban twice a day for 180 days with drug initiation day 0-3 (TIA), day 3-5(small stroke) or day 7- 9 (medium stroke) respectively
3108313|NCT02283294|Active Comparator|Warfarin|standard of care warfarin starting at day 7±5 (TIA) or day 14 ±5 (small to medium ischemic stroke).
3108314|NCT02283333|Experimental|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
3108315|NCT02283333|Active Comparator|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
3108316|NCT02283411|Other|Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
3108317|NCT02283528|Experimental|Hybrid|Placement of Hybrid arch bars for open or closed reduction of mandible fractures
3108318|NCT02283528|Active Comparator|Erich|Placement of Erich archbars for open or closed reduction of mandible fractures
3108319|NCT02283658|Experimental|Treatment (everolimus and letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3108320|NCT02283749|Experimental|Xofigo|Xofigo, 50 kBq/kg body weight, will be administered in the nuclear medicine department as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles.
3108321|NCT02283762|Experimental|Riociguat|Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
3108322|NCT02283762|Placebo Comparator|Placebo|Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
3108323|NCT02283788|Experimental|Treatment Sequence ABCD|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3108324|NCT02283788|Experimental|Treatment Sequence BDAC|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3108325|NCT02283788|Experimental|Treatment Sequence CADB|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3108326|NCT02283788|Experimental|Treatment Sequence DCBA|A - BIA 2-093 1200 mg once daily × 5 days B - BIA 2-093 2400 mg once daily × 5 days C - Moxifloxacin 400 mg × 1 dose D - placebo once daily × 5 days
3108327|NCT02283814|Experimental|Group A BIA 2-093 + Topamax|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 100 mg (morning) + 100mg (evening) for two consecutive days~Treatment 4: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200 mg for fifteen consecutive days"
3108328|NCT02283814|Experimental|Group B BIA 2-093 + Topamax|"Pre-treatment: 100 mg once daily dose of TPM administered for two consecutive days;~Pre-treatment 2: 100 mg twice daily dose of TPM administered for two consecutive days;~Treatment: 200 mg once daily dose of TPM administered for four consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 600 mg and TPM 200 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and TPM 200mg for seventeen consecutive days"
3108329|NCT02283827|Experimental|Group A BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 1: 600 mg ESL Day 3 to 8: Treatment 1: 1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ 100 mg PHT Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
3108330|NCT02283827|Experimental|Group B BIA 2-093 + Phenytoin (PHT)|Day 1 to 2: Pre-treatment 2: 100 mg PHT Day 3 to 8: Treatment 2: 300 mg PHT Day 9 to 10: Treatment 2 + Pre-treatment 1: 300 mg PHT + 600 mg ESL Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + 300 mg PHT
3108331|NCT02283840|Experimental|Cohort A1:BIA 2-093 400 mg|"One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF)"
3108332|NCT02283840|Experimental|Cohort A2:BIA 2-093 400 mg|One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 400 mg tablet (To-Be-Marketed Formulation, TBM)
3108333|NCT02283840|Experimental|Cohort B1:BIA 2-093 600 mg|"One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF)"
3108334|NCT02283840|Experimental|Cohort B2:BIA 2-093 600 mg|One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 600 mg tablet (To-Be-Marketed Formulation, TBM)
3108335|NCT02283840|Experimental|Cohort C1:BIA 2-093 800 mg|"One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)~One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF)"
3108336|NCT02283840|Experimental|Cohort C2:BIA 2-093 800 mg|One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (Clinical Trial Formulation, CTF) One Eslicarbazepine acetate (BIA 2-093) 800 mg tablet (To-Be-Marketed Formulation, TBM)
3108337|NCT02284009|Experimental|Albiglutide|Approximately 51 subjects will be assigned to albiglutide 30 mg weekly (with treatment-masked increase to 50 mg weekly at Week 6) + background insulin. The starting dose of albiglutide will be 30 mg once weekly and will be increased at Week 6 to 50 mg, once weekly, if the 30-mg weekly dose is tolerated.
3108338|NCT02284009|Experimental|Placebo|Approximately 17 subjects will be assigned to albiglutide matching placebo + background insulin
3108339|NCT02284126|Experimental|Topical Vancomycin|Treatment group, receive 2 g topical vancomycin hydrochloride (1 g applied as powder, 1 g mixed with sterile solution and applied as paste) at the time of closure, in addition to the standard of care for wound prophylaxis
3108340|NCT02284126|No Intervention|Standard of Care|Control group, receive standard of care only
3108341|NCT02284178|Experimental|Enhanced oral suction|Deep oropharyngeal suction with catheter
3108342|NCT02284178|Sham Comparator|Usual Care Oral Suction|Oropharyngeal suction with suction swab
3108343|NCT02284243|Experimental|DEX-IN 50mcg|DEX-IN (Intranasal dexmedetomidine) 50mcg every 6 hours for 48 hours.
3108344|NCT02284243|Placebo Comparator|IN Placebo|IN Placebo every 6 hours for 48 hours.
3108345|NCT02284347|Experimental|NuVent™|Revision patients treated with NuVent™
3108346|NCT02284386|Experimental|Bupivacaine SNB + EXPAREL Infiltration|Spinal block with bupivacaine HCl 7.5 mg/mL. Local infiltration of EXPAREL 266 mg.
3108347|NCT02284399||IDTFK Group Post NIPT - (January 2012-June 2014)|Pregnant women who present to participating centers between January 2012-June 2014, after the release of non-invasive prenatal testing (NIPT), who are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
3108348|NCT02284399||IDTFK Group pre-NIPT (January 2010-July 2010)|A control group of pregnant women, prior to the release of non-invasive prenatal testing (NIPT), who present to participating centers between January 2010-June 2010 and are undergoing invasive prenatal diagnostic testing for fetal karyotype (IDTFK).
3108349|NCT02284464|Active Comparator|Steroids, tacrolimus and mycophenolate|Normal treatment arm
3108350|NCT02284464|Experimental|Tacrolimus and mycophenolate|Normal treatment for first 90 days, then steroid withdrawal carrying on with the other drugs
3108351|NCT02284516|Experimental|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
3108352|NCT02284516|Placebo Comparator|Placebo|Placebo to match active treatment, BID for 84 days
3108353|NCT02284555|Experimental|Mupirocin 2% nasal Ointment|Mupirocin (Bactroban 2% nasal ointment) will be administered twice daily for 5 days in accordance with the Summary of Product Characteristics (SmPC).
3108354|NCT02284568|Placebo Comparator|Placebo|once daily oral dose
3108355|NCT02284568|Experimental|Laquinimod 0.6 mg|1 capsule containing 0.6 mg laquinimod and 2 capsules containing placebo were administered orally once daily for at least 48 weeks.
3108356|NCT02284568|Experimental|Laquinimod 1.5 mg|3 capsules containing 0.5 mg laquinimod were administered orally once daily for at least 48 weeks. However this arm was discontinued as of 01 January 2016 and no participants reached the 48 week timeframe.
3108357|NCT02284828|Experimental|Group 1 BIA 2-093|A single dose of oral ESL 900 mg was followed by consecutive 7-day periods of: Placebo, ESL 800 mg, and ESL 1200 mg.
3108358|NCT02284854|Experimental|Group A|Day 1 to Day 8 - BIA 2-093 800 mg Day 9 to Day 14 - BIA 2-093 800 mg + CBZ 200 mg Day 15 to Day 22 - BIA 2-093 800 mg + CBZ 400 mg Day 23 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
3108359|NCT02284854|Experimental|Group B|Day 1 to Day 8 - CBZ 200 mg Day 9 to Day 14 - CBZ 400 mg Day 15 to Day 29 - CBZ 400 mg twice-daily Day 30 to Day 35 - BIA 2-093 800 mg + CBZ 400 mg twice-daily
3108360|NCT02284867||Preterm labor|Patients who has threatened preterm labor and will receive tocolysis and these patients will either not respond to tocolysis and delivered preterm or will respond to tocolysis and will deliver at term .
3108361|NCT02284867||Term labor|Patient delivered vaginally at term with no history of having tocolysis for preterm labor at the current pregnancy .
3108362|NCT02284880|Experimental|Group 1 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);
3108363|NCT02284880|Experimental|Group 2 BIA 2-093|Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).
3108364|NCT02284893|Experimental|A1:Saxagliptin / Placebo + Dapagliflozin / Placebo|Saxagliptin 5 mg and matching placebo 0 mg (once daily) plus Dapagliflozin 10 mg and matching placebo 0 mg (once daily)
3108365|NCT02284893|Experimental|A2: Sitagliptin / placebo|Sitagliptin 100 mg and matching placebo 0 mg (once daily)
3108366|NCT02285010|Placebo Comparator|Placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery.
3108367|NCT02285010|Active Comparator|Pregabalin|Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
3108368|NCT02285023||CU-Q2oL|"Evaluation by the Urticaria Activity Score (UAS7)~Fill the DLQI and CU-Q2oL questionnaire"
3108369|NCT02285062|Experimental|R2-CHOP|Lenalidomide plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
3108370|NCT02285062|Active Comparator|R-CHOP|Placebo plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
3108371|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 1)|Participants between 12 to < 18 years of age and ≥ 35 kg in body weight will switch their current 2-NRTI containing regimen to F/TAF (200/25 mg for unboosted 3rd agent and 200/10 mg for boosted 3rd agent) while continuing on their 3rd ARV agent for 48 weeks.
3108372|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part A)|Participants between 6 to < 12 years of age and ≥ 25 kg in body weight must be on a boosted protease inhibitor (PI) as their 3rd ARV agent and will switch their current 2-NRTI regimen to F/TAF 200/25 mg while continuing on their boosted PI for 48 weeks.
3108373|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part A)|Participants between 2 to < 12 years of age and between 17 kg to < 25 kg in body weight must be on a boosted protocol specified 3rd ARV agent and will switch their current 2-NRTI containing regimen to F/TAF 120/15 mg while continuing their 3rd ARV agent for 48 weeks.
3108374|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part A)|Participants between 2 to < 6 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
3108375|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part A)|Participants between 1 month to < 2 years of age will receive F/TAF plus a 3rd ARV agent through 48 weeks.
3108376|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 1, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3108377|NCT02285114|Experimental|F/TAF+3rd ARV agent (Cohort 2, Group 2, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3108378|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 3, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3108379|NCT02285114|Experimental|FTC/TAF+3rd ARV agent (Cohort 4, Part B)|Screening will be initiated for Part B following confirmation of TAF dose in Part A. Approximately 10 additional total participants will be enrolled across all Part B cohorts and will receive F/TAF while continuing their 3rd ARV agent through 48 weeks.
3108380|NCT02285114|Experimental|FTC/TAF +3rd ARV agent (Extension Phase)|After completion of 48 weeks, all participants will be given the option to participate in an extension phase of the study. Gilead will provide F/TAF until a) the participant turns 18 and F/TAF is commercially available for use in adults in the country in which the participant is enrolled or, b) F/TAF becomes commercially available for pediatric use in the country in which the participant is enrolled or, c) Gilead Sciences elects to terminate development of F/TAF in the applicable country.
3108381|NCT02285153|Experimental|Acetylsalicylic acid lysinate|100mg Acetylsalicylic Acid
3108382|NCT02285153|Placebo Comparator|0.9% sodium-chloride solution|0.9% sodium-chloride solution
3108383|NCT02285283|Placebo Comparator|Placebo|2 capsules by mouth twice a day for 24 weeks
3108384|NCT02285283|Active Comparator|Itraconazole|Two 100mg capsules by mouth twice a day for 24 weeks
3108385|NCT02285361||GIOTRIF|
3108386|NCT02285634|Experimental|Oxymetazoline 0.05%|Oxymetazoline 0.05%
3108387|NCT02285634|Experimental|Phenylephrine 0.25%|Phenylephrine 0.25%
3108388|NCT02285634|Experimental|Lidocaine 1% plus epinephrine 1:100,000|Lidocaine 1% plus epinephrine 1:100,000
3108389|NCT02285634|Placebo Comparator|Bacteriostatic 0.9% sodium chloride (NaCL)|Bacteriostatic 0.9% NaCL
3108390|NCT02285777|Experimental|MenABCWY Group|Subjects who received 2 doses of MenABCWY vaccine in the parent study and a 3rd dose of MenABCWY vaccine in the current study.
3108391|NCT02285777|Active Comparator|MenACWY Group|Subjects who received 1 dose of placebo and 1 dose of MenACWY vaccine in the parent study and 1 dose of placebo in the current study.
3108392|NCT02285855|Experimental|Stereotactic body Radiotherapy (SBRT) + Metformin|Participants randomized to Metformin treatment receive Metformin for 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Metformin administered at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week. SBRTdelivered per standard of care practice.
3108393|NCT02285855|Placebo Comparator|Stereotactic Body Radiotherapy (SBRT) + Placebo|Participants randomized to placebo treatment 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day. SBRT delivered per standard of care practice.
3108394|NCT02285907|Experimental|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
3108395|NCT02285907|Experimental|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
3108396|NCT02285907|Experimental|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
3108397|NCT02285907|Experimental|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
3108398|NCT02285920|Active Comparator|Spironolactone 12.5 mg|Participants will initiate treatment at 12.5 mg daily and continue at this dose for 36 weeks.
3108399|NCT02285920|Active Comparator|Spironolactone 25 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for a total treatment time of 36 weeks.
3108400|NCT02285920|Active Comparator|Spironolactone 50 mg|Participants will initiate treatment at 12.5 mg daily for 2 weeks at which time the dose will be increased to 25 mg daily for 2 weeks, and increased to 50 mg daily for a total treatment time of 36 weeks.
3108401|NCT02285920|Placebo Comparator|Placebo|Participants will be treated with placebo for 36 weeks.
3108402|NCT02285998|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
3108403|NCT02285998|Active Comparator|Inactivated Influenza Vaccine|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
3108404|NCT02286102|Experimental|OrthoPAT|Patients in the experimental group will receive OrthoPAT drains, which will be used to collect and retransfuse postoperative blood loss. Drains will be removed after 48 hours.
3108405|NCT02286102|Active Comparator|Constavac|Patients identified as active comparator will receive standard Constavac drains, which will be removed after 48 hours.
3108406|NCT02286193||Patients presenting to Community Resource Specialist (CRS)|Primary care patients who are referred or self-refer to the CRS for education and linkage to community resources that can help support health goals
3108407|NCT02286466|Active Comparator|Health Education Program|The presence and usage of Health Education Program.
3108408|NCT02286466|Experimental|CBT Mobile Application|The presence and usage of a CBT Mobile Application.
3108409|NCT02286518|Experimental|Cohort 1A: TAK-114 10 mg|Orally, once only.
3108410|NCT02286518|Experimental|Cohort 1B: TAK-114 10 mg|Orally, once
3108411|NCT02286518|Experimental|Cohort 2A: TAK-114 20 mg|Orally, once
3108412|NCT02286518|Experimental|Cohort 2B: TAK-114 20 mg|Orally, once
3108413|NCT02286518|Experimental|Cohort 3A: TAK-114 50 mg|Orally, once
3108414|NCT02286518|Experimental|Cohort 3B: TAK-114 50 mg|Orally, once
3108415|NCT02286518|Experimental|Cohort 4a: TAK-114 20 mg|Period 1: Single-dose administration in a fasting state Period 2: Single-dose administration 30 minutes after breakfast
3108416|NCT02286518|Experimental|Cohort 4b: TAK-114 20 mg|Period 1: Single-dose administration 30 minutes after breakfast Period 2: Single-dose administration in a fasting state
3108417|NCT02286518|Experimental|Cohort 5A: TAK-114 20 mg|Orally, Twice daily, 10 days
3108418|NCT02286518|Experimental|Cohort 5B: TAK-114 20 mg|Orally, Twice daily, 10 days
3108419|NCT02286518|Experimental|Cohort 6A: TAK-114 50 mg|Orally, Twice daily, 10 days
3108420|NCT02286518|Experimental|Cohort 6B: TAK-114 50 mg|Orally, Twice daily, 10 days
3108421|NCT02286518|Placebo Comparator|Cohort 1A, 2A, 3A: TAK-114 placebo|Cohort 1A, 2A, 3A: Orally, once
3108422|NCT02286518|Placebo Comparator|Cohort 5A: TAK-114 placebo|Cohort 5A: Orally, Twice daily, 10 days
3108423|NCT02286518|Placebo Comparator|Cohort 6A: TAK-114 placebo|Cohort 6A: Orally, Twice daily, 10 days
3108424|NCT02286713|Active Comparator|Patient Decision Aid|Decision Aid study materials including video mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
3108425|NCT02286713|Active Comparator|Standard Educational Information|Study materials including education booklet mailed to participant with 1-week, 3-month, and 6-month Follow-up Assessments
3108426|NCT02286726|Experimental|Arm I (lower-dose (50 units/m^2) CPX-351)|Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5 of a 28-day course. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
3108427|NCT02286726|Experimental|Arm II (intermediate-dose (75 units/m^2) CPX-351)|Patients receive intermediate-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
3108428|NCT02286726|Experimental|Arm III (standard-dose (100 units/m^2) CPX-351)|Patients receive standard-dose liposomal cytarabine-daunorubicin CPX-351 IV over 90 minutes on days 1, 3, and 5. Patients with persistent disease may receive a second course with treatment on days 1 and 3.
3108429|NCT02286843|Experimental|HER2-targeted PET/CT|Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
3108430|NCT02286895|Active Comparator|Group A (without rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg).
3108431|NCT02286895|Experimental|Group B (with rotavirus vaccine)|Group A will receive measles vaccine (MV), yellow fever vaccine (YFV), and meningitis conjugate vaccine (PsA-TT-5μg) plus one oral dose of pentavalent rotavirus vaccine (PRV).
3108432|NCT02286921|Experimental|Arm A: Testosterone cypionate or testosterone enanthate|Patients on BAT will receive testosterone cypionate or testosterone enanthate administered as an intramuscular injection. A dose of 400 mg of either agent will be injected intramuscularly (IM) every 28 days.
3108433|NCT02286921|Experimental|Arm B: Enzalutamide|Patients randomized to enzalutamide will be prescribed enzalutamide 40 mg tablets and instructed to take 4 tablets per day orally for 28 days/cycle.
3108434|NCT02286947|Experimental|Eteplirsen 30 mg/kg|Participants will receive eteplirsen 30 mg/kg/week intravenous (IV) infusions, weekly, for up to 96 weeks.
3108435|NCT02286960|Active Comparator|Steroid|Prednizone pills. 4 day course 2 x 20mg per day.
3108436|NCT02286960|Placebo Comparator|Placebo|Lactose Pills. 4 day course 2 x 20mg per day.
3108437|NCT02287038|Active Comparator|Atomoxetine 80mg|Atomoxetine (fixed dose of 80mg), a non-stimulant medication, FDA approve for treatment of ADHD. The active drug will be applied in first phase in group one and in second phase in group two
3108438|NCT02287038|Placebo Comparator|Placebo|A pharmaceutically inert substance, which will be given to group one in their second phase and group tow in first phase.
3108439|NCT02287350|Experimental|diclofenac potassium oral solution|5 mg/mL, liquid form, weight-based dosing, every 6 hours, for up to 4 days.
3108440|NCT02287376|Experimental|Diclofenac Potassium|Diclofenac Potassium for Oral Solution 50 mg
3108441|NCT02287402|Experimental|AO-128 0.6 mg|One AO-128 0.2 mg tablet was taken orally 3 times a day before meals.
3108442|NCT02287415|Experimental|Group 1|Phase A: Warfarin Phase B: Warfarin + BIA 2-093 (ESL) Phase C: Warfarin
3108443|NCT02287467|Experimental|Arm A: hIVIG|Participants will receive a single infusion of intravenous hyperimmune immunoglobulin (hIVIG), administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
3108444|NCT02287467|Placebo Comparator|Arm B: Placebo|Participants will receive a single infusion of placebo for hIVIG, administered over approximately 2 hours on Day 0. Participants will also receive SOC treatment for the flu.
3108447|NCT02287584|Placebo Comparator|DSP-5423P Placebo|Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
3108448|NCT02287584|Experimental|DSP-5423P 40mg|Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
3108449|NCT02287584|Experimental|DSP-5423P 80mg|Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
3108450|NCT02287584|Experimental|DSP-5423P Placebo-to-Flex|Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
3108451|NCT02287584|Experimental|DSP-5423P Active-to-Flex|Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
3108452|NCT02287623|Experimental|liposomal bupivacaine TAP|Patients will receive a TAP block with liposomal bupivacaine
3108453|NCT02287623|Active Comparator|bupivacaine TAP|Patients will receive a TAP block with bupivacaine
3108454|NCT02287675|Active Comparator|Lymphoseek|Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.
3108455|NCT02287675|Active Comparator|Sulfur Colloid|"Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:~In adults, to assist in the:~localization of lymph nodes draining a primary tumor in patients with~breast cancer or malignant melanoma when used with a hand-held gamma counter.~evaluation of peritoneovenous (LeVeen) shunt patency in adults."
3108456|NCT02287688||Exposure group|Subjects aged 2-23 months who received at least one dose of the MenACWY-CRM vaccine at a Kaiser Permanente Southern California (KPSC) facility while enrolled as a KPSC health plan member.
3108457|NCT02287779|Experimental|SHP626|9/12 subjects -1x daily dose of 20mg for 12 days 9/12 subjects-1x daily dose of 40mg for 12 days 9/12 subjects-1x daily dose of 80mg for 12 days 9/12 subjects-1x daily dose of 120mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-1x daily dose of 160mg for 12 days or dose lower than 80mg for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD) for 12 days 9/12 subjects-2x daily dose of SHP626 (dose TBD; lower or higher than cohort 6) for 12 days 9/12 subjects-1x or 2x daily dose of SHP626 in an escalating titration (doses TBD). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days 9/12 subjects will take a 1x or 2x daily dose of SHP626 in escalating titration (doses TBD; lower or higher dose than cohort 8). Initial 3 days of SHP626 followed by an increased dose of SHP626 for 3 days and finally a further increase in dose of SHP626 for 6 days
3108458|NCT02287779|Placebo Comparator|Placebo|Three subjects per cohort will take a matched placebo
3108459|NCT02287818|Placebo Comparator|Placebo|Placebo plus Febuxostat
3108460|NCT02287818|Experimental|AC-201|AC-201 CR tablet plus Febuxostat
3108461|NCT02287883||Patients at high PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with high implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
3108462|NCT02287883||Patients at low PAE clinic|"Patients with diabetes or cardiovascular disease receiving care within two Accountable Care Organizations (ACOs) at clinics with low implementation of patient activation and engagement activities.~Observational: Patient Activation and Engagement (PAE)"
3132653|NCT03442777|No Intervention|Study Arm 3 (standard of care)|"Patients at risk for pressure ulcer category II, III, IV, Unstageable, and Deep Tissue Injury (DTI) development will receive standard pressure ulcer prevention strategies (as described in the hospital protocol) which include ongoing risk assessment, regular repositioning and skin care.~No silicone adhesive multilayer foam dressings will be applied on the skin sites of interest for this trial (sacrum, heel right/left, greater trochanter right/left)."
3108463|NCT02287896|Experimental|Roledumab Open-label IM|"- Planned antenatal prophylaxis: A single dose of 300 µg IM of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IM anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IM postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
3108464|NCT02287896|Experimental|Roledumab Open-label IV|"- Planned antenatal prophylaxis: A single dose of 300 µg IV of Roledumab at 28 or 29 weeks of gestation.~- Antenatal prophylaxis following sensitizing events: One or more dose(s) of 300μg IV anti-RhD antibodies (Rhophylac or Roledumab) based on the Kleihauer-test as soon as possible and no later than 72 hours after event occurrence.~- Postnatal prophylaxis: Roledumab should be administered to the mother as soon as possible within 72 hours of delivery of an RhD positive infant.~The postnatal dose must still be given even when antenatal prophylaxis has been administered.~Before Roledumab 300μg IV postnatal administration, a Kleihauer-Betke test will be performed on maternal blood sample taken no earlier than 30 min after delivery in order to determine the volume of foetomaternal hemorrhage (FMH)."
3108465|NCT02287909|Experimental|A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3108466|NCT02287909|Experimental|B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3108467|NCT02287909|Experimental|C) clopidogrel 75mg MD 24 hours after last MD of ticagrelor|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3108468|NCT02287909|Active Comparator|D) continue ticagrelor MD 90mg twice daily|Patients will be randomized (1:1:1:1) into one of the four following groups: A) clopidogrel 600 mg LD 24 hours after last MD of ticagrelor, followed by 75mg daily MD; B) clopidogrel 600 mg LD 12 hours after last MD of ticagrelor, followed by 75mg daily MD; C) clopidogrel 75mg daily MD 24 hours after last MD of ticagrelor; D) continue ticagrelor MD 90mg twice daily
3108469|NCT02287922|Experimental|ALX-0061 150 mg q4w|ALX-0061 150 mg every 4 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
3108470|NCT02287922|Experimental|ALX-0061 150 mg q2w|ALX-0061 150 mg every 2 weeks from baseline through Week 12 + placebo every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
3108471|NCT02287922|Experimental|ALX-0061 225 mg q2w|ALX-0061 225 mg every 2 weeks from baseline through Week 12. The last injection with study drug was administered at the Week 10 visit.
3108472|NCT02287922|Active Comparator|TCZ 162 mg q1w or q2w|Open-label TCZ. Injections were to be performed q1w or q2w depending on the approved label per region (last injection was administered at Week 10 or Week 11, depending on the dose regimen).
3108473|NCT02288091|Experimental|Open-label|Subjects will receive oral inosine daily.
3108474|NCT02288156|Active Comparator|0.1mM|
3108475|NCT02288156|Experimental|0.01mM|
3108476|NCT02288156|Experimental|0.001mM|
3108477|NCT02288156|Placebo Comparator|Placebo|
3108478|NCT02288182|Experimental|Straumann VivOss|Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of > 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and < 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
3108479|NCT02288182|Active Comparator|Geistlich Bio-Oss|The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.
3108480|NCT02288273|Experimental|Bydureon|Once weekly injected exenatide
3108481|NCT02288273|Placebo Comparator|Placebo|Placebo comparator
3108482|NCT02288312|Experimental|BIA 2-093 800 mg fasting|Tablets 800 mg. Administration:Oral.
3108483|NCT02288312|Experimental|BIA 2-093 800 mg fed|Tablets 800 mg. Administration:Oral.
3108484|NCT02288312|Experimental|BIA 2-093 400 mg|Tablets 2 x 400 mg. Administration:Oral.
3108485|NCT02288325|Experimental|Open-Label FETZIMA®|FETZIMA® (levomilnacipran extended release [ER]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
3108486|NCT02288325|Placebo Comparator|Double-Blind Placebo|Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
3108487|NCT02288325|Experimental|Double-Blind FETZIMA®|FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
3108488|NCT02288364|Active Comparator|1% Lidocaine|1% Lidocaine alone.
3108489|NCT02288364|Active Comparator|1% Lidocaine plus sodium bicarbonate|1% Lidocaine plus 8.4% sodium bicarbonate
3108490|NCT02288377|Experimental|lanreotide|In this arm, patients will receive lanreotide 120 mg every 28 days until disease progression
3108491|NCT02288377|Placebo Comparator|placebo|In this arm, patients will receive placebo every 28 days until disease progression
3108492|NCT02288559|Experimental|Lampalizumab: Open-label Safety Run-In|Participants will receive 10 milligrams (mg) lampalizumab intravitreally Q2W during the safety run-in period.
3108493|NCT02288559|Experimental|Q2W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q2W during the 24-week treatment period.
3108494|NCT02288559|Experimental|Q4W Lampalizumab: Randomized Treatment|Participants will receive 10 mg dose of lampalizumab intravitreally Q4W during the 24-week treatment period.
3108495|NCT02288559|Sham Comparator|Sham: Randomized Treatment|Participants randomized to control arms will receive sham injections, that mimics intravitreal injection of lampalizumab.
3108496|NCT02288819|Experimental|Loop diuretic downtitration|Scheduled downtitration of maintenance loop diuretic dose while monitoring weight
3108497|NCT02289079|Experimental|liposomal bupivacaine TAP|these patients receive a subcostal TAP with liposomal bupivacaine
3108498|NCT02289079|Active Comparator|bupivacaine TAP|These patients receive a subcostal TAP with bupivacaine
3108499|NCT02289105|Experimental|Mandatory active choice|The mandatory active choice group will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
3108500|NCT02289105|No Intervention|Control|Participants in the control group will be presented an AD form only and will be encouraged to complete, and submit the form without having to declare the choice of completing or declining the AD.
3108501|NCT02289157|Experimental|Negative Pressure Wound Therapy|After standard cesarean section completed patients will have Prevena negative pressure wound therapy system placed.
3108502|NCT02289157|No Intervention|Standard dressing|After standard cesarean section completed patients will have standard dressing placed.
3108503|NCT02289222|Experimental|Pomalidomide, Dexamethasone & MK-3475|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
3108504|NCT02289352|Experimental|brimonidine 0.33% gel|Brimonidine Topical Gel, 0.33%, 30 gram fill (Watson Laboratories, Inc., USA)
3108505|NCT02289352|Active Comparator|Mirvaso gel|Mirvaso® (brimonidine) topical gel, 0.33% (Galderma Laboratories, L.P., USA)
3108506|NCT02289352|Placebo Comparator|Placebo|Topical gel base only (Watson Laboratories Inc., USA)
3108507|NCT02289417|Experimental|Apremilast 30 mg PO BID|"Apremilast 30 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks:~Participants who achieve at least a 20% decrease from baseline in the total Mayo score (TMS) will continue to receive apremilast 30 mg BID for an additional 40 weeks. (Wk 52)~Participants who do not achieve at least a 20% decrease from baseline in the TMS will receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the Extension Phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
3108508|NCT02289417|Experimental|Apremilast 40 mg PO BID|"Apremilast 40 mg by mouth (PO) twice a day (BID) for 12 weeks~After 12 weeks, participants assigned to the 40 mg BID dose of apremilast at baseline will continue to receive apremilast 40 mg BID for an additional 40 weeks (Wk 52)~After 52 weeks, participants who are eligible for the extension Phase will continue to receive apremilast 40 mg BID for an additional 52 weeks (Wk 104)"
3108509|NCT02289417|Placebo Comparator|Placebo BID|"Identically matching placebo by mouth (PO) twice a day (BID) for 12 weeks. After 12 weeks all participants randomized to placebo at baseline will be re-randomized to receive apremilast 30 mg or 40 mg BID for an additional 40 weeks (Wk 52)~After Wk 52, participants who are eligible for the extension phase will continue to receive the same dose of apremilast assigned at Wk 12 (30 mg BID or 40 mg BID) for an additional 52 weeks (Wk 104)"
3108510|NCT02289456|Experimental|nab-Paclitaxel|"nab-Paclitaxel 100 mg/m2 intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle~• Carboplatin AUC = 5 mg*min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion."
3108511|NCT02289469|Experimental|PictureRx|PictureRx medication history platform
3108512|NCT02289469|No Intervention|Usual care|Usual medication history process
3108513|NCT02289690|Experimental|Phase 1: Veliparib + Carboplatin + Etoposide|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of veliparib in combination with carboplatin/etoposide for up to four 21-day cycles.~Participants without evidence of disease progression will continue on veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity."
3108514|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Veliparib|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by veliparib monotherapy at 400 mg BID continuous dosing (21-day cycles) until disease progression or unacceptable toxicity.
3108515|NCT02289690|Experimental|Phase 2: Veliparib + Carboplatin + Etoposide -> Placebo|Participants will receive veliparib 240 mg in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
3108516|NCT02289690|Active Comparator|Phase 2: Placebo + Carboplatin + Etoposide -> Placebo|Participants will receive placebo in combination with carboplatin/etoposide for four to six 21-day cycles followed by placebo monotherapy continuous dosing (21-day cycles) until disease progression or unacceptable toxicity occurs.
3108517|NCT02289729||All Participants|Levodopa/carbidopa intestinal gel (LCIG) prescribed in the usual manner, in accordance with the terms of the local marketing authorization, for participants with advanced Parkinson's disease with motor fluctuation not well responding to conventional therapies.
3108518|NCT02289742|Other|Arm1: Presbyopes|Nelfilcon A contact lenses (multifocal and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
3108519|NCT02289742|Other|Arm2: Astigmats|Nelfilcon A contact lenses (toric and sphere) worn as randomized in a crossover design during Periods 1 and 2, with nelfilcon A sphere contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 12 hours.
3108520|NCT02289755|Experimental|ALLN-177|"Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days."
3108521|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1|Participants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
3108522|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
3108523|NCT02289820|Experimental|MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3|Participants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
3108524|NCT02289820|Experimental|MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4|Participants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
3108525|NCT02289820|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
3108526|NCT02289833|Experimental|Cohort IHC2+|Participants with HER2 IHC2-positive (IHC 2+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
3108527|NCT02289833|Experimental|Cohort IHC3+|Participants with HER2 IHC3-positive (IHC 3+) locally advanced or metastatic NSCLC, who had received at least one prior platinum-based chemotherapy regimen, will receive trastuzumab emtansine.
3108528|NCT02289898|Experimental|Abraxane® and gemcitabine plus placebo|Abraxane® and gemcitabine plus placebo (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
3108529|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab plus placebo|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus placebo (3 cycles) and then Abraxane® and gemcitabine until disease progression
3108530|NCT02289898|Experimental|Abraxane® and gemcitabine plus demcizumab|Abraxane® and gemcitabine plus demcizumab (3 cycles), Abraxane® and gemcitabine (3 cycles), Abraxane® and gemcitabine plus demcizumab (3 cycles) and then Abraxane® and gemcitabine until disease progression
3108531|NCT02289950|Experimental|Farletuzumab|All participants will receive a loading dose for the first 2 weeks of 10 milligram per kilogram (mg/kg) farletuzumab, followed by 5 mg/kg weekly farletuzumab administered intravenously (IV).
3108532|NCT02289950|Placebo Comparator|Placebo|All subjects will receive placebo weekly, administered intravenously (IV).
3108533|NCT02289963|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) subcutaneous (SC) injection every 2 weeks (Q2W) added to stable Lipid-Modifying Therapy (LMT) for 24 weeks.
3108534|NCT02289963|Placebo Comparator|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg SC injection Q2W added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3108535|NCT02289989|Active Comparator|Standard: Hydrocortisone 1% ointment|Intervention: hydrocortisone 1% ointment will be applied to one patient's forearm
3108536|NCT02289989|Experimental|Experimental: oregano extract cream|Intervention: Oregano extract cream for mild to moderate atopic dermatitis will be applied to the other patient's forearm
3108537|NCT02290028|Other|Sentus QP left ventricular lead|Subjects consented and implanted with a Sentus QP left ventricular lead.
3108538|NCT02290106|Experimental|Pitavastatin|pitavastatin 4mg daily by mouth for 6 months
3108539|NCT02290106|Placebo Comparator|Placebo|Identical placebo 4mg by mouth daily for 6 months
3108540|NCT02290184|Experimental|Intervention - PilAm Go4Health Program|In the first 3 months this groups will start with the PilAm Go4Health Weight-loss Program lifestyle intervention. After 3 months this group will transition to a 3-month maintenance phase where they will continue to maintain the physical activity and healthy eating behaviors learned in the PilAm Go4Health Weight-loss Program lifestyle intervention and will complete the study for a total of 6 months.
3108541|NCT02290184|Active Comparator|Active control - pedometer only|In the first 3 months this groups will start with a pedometer only. After 3 months, this group will transition to receive the PilAm Go4Health Weight-loss Program lifestyle intervention for the next 3 month and will complete the study for a total of 6 months
3108542|NCT02290223|Experimental|Patient Activation Group Intervention|The experimental procedure is a behavioral based treatment model, plus usual care which is is determined by patients' individual providers, according to practice guidelines related to specific conditions.
3108543|NCT02290223|No Intervention|Usual Care|Usual care is determined by patients' individual providers, according to practice guidelines related to specific conditions.
3108544|NCT02290340|Placebo Comparator|Placebo|Participants will receive placebo intramuscularly.
3108545|NCT02290340|Experimental|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
3108546|NCT02290340|Experimental|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
3108547|NCT02290340|Experimental|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
3108548|NCT02290405||Primary Insomnia (PI)|PI sufferers enrolled will meet Research Diagnostic Criteria for insomnia disorder, score > 14 on the Insomnia Severity Index, report insomnia for > 3 months, have sleep difficulties > 3 nights per week, score < 3 on the Epworth Sleepiness Scale (ESS), score > 40 on the Hyperarousal Scale10 and report an inability to nap in the daytime.
3108549|NCT02290405||Normal Sleepers (NS)|The normal sleepers enrolled will report general satisfaction with sleep and no sleep/wake complaints, score < 10 on the ESS, score < 35 on the Hyperarousal Scale10, and deny a practice of routine daytime napping.
3108551|NCT02290444|Experimental|Cognitively Relapsing Patients|For individuals experiencing cognitive relapses/exacerbations, 5ml/80 IU of Adrenocorticotropic Hormone will be administered through either subcutaneous or intramuscular self-injection (selected by the patient) for 5-days.
3108552|NCT02290444|No Intervention|Stable Multiple Sclerosis Patients|Individuals whose Multiple Sclerosis is currently in a stable state (not currently or recently exacerbating) are age-matched with relapsing MS patients. There is no intervention for individuals with MS whose are currently in a stable state.
3108553|NCT02290509|Experimental|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine containing 4 x 45µg (180µg total) of each recombinant hemagglutinin (rHA) derived from influenza A/H1N1 and A/H3N2 and two lineages of influenza B viruses identified for the season in which the trial is conducted in a total volume of 0.5 mL
3108554|NCT02290509|Active Comparator|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of vaccine contains 4 x 15µg (60µg total) of HA derived from the same influenza A/H1N1 and A/H3N2 and influenza B strains in a total volume of 0.5mL.
3108555|NCT02290574|Experimental|Thermo-radio-chemotherapy arm|Hyperthermia with concurrent chemo-radiation therapy
3108556|NCT02290613|Experimental|Ambrisentan Verum|Study medication will be ambrisentan 10 mg (starting with 5 mg in the beginning of the study and then up-titrated to 10 mg/day).
3108557|NCT02290613|Placebo Comparator|Placebo|Placebo tablet
3108558|NCT02290691|Experimental|Needle- Free|Subjects will receive a single 0.5mL injection of inactivated influenza vaccine in the deltoid region on Day 0.
3108559|NCT02290691|Active Comparator|Needle and Syringe|Subjects will receive a single 0.5mL injection of inactivated Influenza Vaccine in the deltoid region on Day 0.
3108560|NCT02290821|Experimental|diclofenac sodium gel 1%|diclofenac sodium gel 1%
3108561|NCT02290821|Placebo Comparator|Placebo|Placebo
3108562|NCT02290873|Experimental|Remimazolam|"Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
3108563|NCT02290873|Placebo Comparator|Placebo|"Inactive control arm~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
3108564|NCT02290873|Active Comparator|Midazolam|"Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.~*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill~Fentanyl pre-treatment: 50 μg (or less for elderly/disabled subjects) and 25 μg top-up doses"
3108565|NCT02290925|Experimental|Kothala Himbutu biscuit|A biscuit containing Kothala Himbutu (Salacia reticulata) extract. This biscuit is available in the supermarkets. Four biscuits twice a day for 3 months.
3108566|NCT02290925|Placebo Comparator|placebo biscuit|An identical biscuit without the herbal extract from Kothala Himbutu (Salacia reticulate)
3108567|NCT02291016|Active Comparator|Formoterol via DPI then Formoterol via nebulizer|"Group A: Received Formoterol 12 µg via DPI and placebo via nebulizer at treatment visit #1, and Formoterol 20 µg (solution form) via nebulizer and placebo via DPI at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
3108568|NCT02291016|Active Comparator|Formoterol via nebulizer then Formoterol via DPI|"Group B: Received Formoterol 20 µg (solution form) via nebulizer and placebo via a DPI at treatment visit #1, and Formoterol 12 µg via a DPI with placebo via nebulizer at treatment visit 2.~Placebo: The placebo used will be sterile, preservative free, normal saline for nebulizer inhalation and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2."
3108569|NCT02291029|Experimental|CFZ533 active- Cohort 2|multiple doses of CFZ533 intravenous infusion
3108570|NCT02291029|Placebo Comparator|CFZ533 placebo- Cohort 2|multiple doses of placebo intravenous infusion
3108571|NCT02291029|Experimental|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
3108572|NCT02291029|Placebo Comparator|CFZ533 placebo - Cohort 1|multiple doses of placebo s.c. injection
3108573|NCT02291029|Experimental|CFZ533 Treatment Arm 1 - Cohort 3|multiple doses of CFZ533 s.c. injection
3108574|NCT02291029|Experimental|CFZ533 Treatment Arm 2 - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
3108575|NCT02291133|Experimental|Electrochemotherapy treatment|
3108576|NCT02291237|Experimental|Eleclazine|Eleclazine 30 mg single loading dose followed by 3 mg daily maintenance dose up until Week 12, then 6 mg daily maintenance dose from Week 12 at least Week 24, followed by eleclazine 6 mg in an open-label extension period.
3108577|NCT02291237|Experimental|Placebo|Placebo to match eleclazine until at least Week 24, followed by active eleclazine 6 mg in an open-label extension period.
3108578|NCT02291289|Experimental|Cohort 1: 5-FU/LV,cetuximab,vemurafenib|Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) will receive 1600-2400 milligrams per square meter (mg/m^2) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m^2 cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.
3108579|NCT02291289|Experimental|Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab|Participants with BRAFwt will receive fluoropyrimidine (1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.
3108580|NCT02291289|Experimental|Cohort 3: capecitabine,trastuzumab,pertuzumab|Participants with human epidermal growth factor receptor 2 positive (HER2+) will receive 1000 mg/m^2 twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.
3108581|NCT02291289|Experimental|Cohort 4: Cobimetinib,atezolizumab|Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) will receive 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.
3108582|NCT02291289|Active Comparator|Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
3108583|NCT02291289|Active Comparator|Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
3108584|NCT02291289|Active Comparator|Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
3108585|NCT02291289|Active Comparator|Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab|Per Investigator discretion, participants will receive fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.
3108586|NCT02291289|Other|Cohort 1: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
3108587|NCT02291289|Other|Cohort 2: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
3108588|NCT02291289|Other|Cohort 3: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
3108589|NCT02291289|Other|Cohort 4: Induction Treatment|All participants will receive either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab.
3108590|NCT02291302|Active Comparator|Environmental Intervention|Active Classroom air purifiers and school integrated pest management environmental intervention
3108591|NCT02291302|Placebo Comparator|Sham and Control (control)|Sham air purifiers and no school integrated pest management environmental intervention
3108592|NCT02291302|Placebo Comparator|Active Air Purifier and Control|Active air purifiers and no school integrated pest management environmental intervention
3108593|NCT02291302|Sham Comparator|Sham and Inegrated Pest|Sham air purifiers and active school integrated pest management
3108594|NCT02291419|Experimental|ticagrelor|ticagrelor 90mg bid
3108595|NCT02291419|Active Comparator|aspirin|Patients in the aspirin arm will receive aspirin 81 mg daily orally
3108596|NCT02291432|Experimental|AMDC-USR|Cell treatment
3108597|NCT02291510|Experimental|500 mg Met DR BID|Two doses of 500 mg metformin delayed-release
3108598|NCT02291510|Experimental|1000 mg Met DR BID|Two doses of 1000 mg metformin delayed-release
3108599|NCT02291510|Active Comparator|1000 mg Met IR BID|Two doses of 1000 mg metformin immediate-release
3108600|NCT02291510|Active Comparator|2000 mg Met XR QD|Single dose of 2000 mg metformin extended-release
3108601|NCT02291549|Experimental|Treatment|"In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses~Mometasone furoate nasal spray (200mcg) once daily"
3108602|NCT02291549|Sham Comparator|Control|"In-office bilateral sham procedure~Mometasone furoate nasal spray (200mcg) once daily"
3108603|NCT02291601|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3108604|NCT02291601|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3108605|NCT02291601|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3108606|NCT02291614|Experimental|AMG 211 200 μg/day for 7/14 Days|In cycle 1 participants receive 200 µg/day AMG 211 administered as a continuous intravenous infusion (cIV) infusion at a constant flow rate for 7 days followed by a 3-week treatment-free interval. In cycle 2 and thereafter, participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108607|NCT02291614|Experimental|AMG 211 200 μg/day for 14 Days|Participants receive 200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108608|NCT02291614|Experimental|AMG 211 400 μg/day for 14 Days|Participants receive 400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108609|NCT02291614|Experimental|AMG 211 800 μg/day for 14 Days|Participants receive 800 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108610|NCT02291614|Experimental|AMG 211 1600 μg/day for 14 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108611|NCT02291614|Experimental|AMG 211 1600 µg/day for 28 Days|Participants receive 1600 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
3108612|NCT02291614|Experimental|AMG 211 3200 µg/day for 14 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108613|NCT02291614|Experimental|AMG 211 3200 µg/day for 28 Days|Participants receive 3200 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
3108614|NCT02291614|Experimental|AMG 211 6400 µg/day for 14 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 14 days followed by a 2-week treatment-free interval.
3108615|NCT02291614|Experimental|AMG 211 6400 µg/day for 28 Days|Participants receive 6400 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
3108616|NCT02291614|Experimental|AMG 211 12,800 µg/day for 28 Days|Participants receive 12,800 µg/day AMG 211 administered as a cIV infusion for 28 days followed by a 2-week treatment-free interval.
3108617|NCT02291679|Experimental|72 μg linaclotide|72 μg oral linaclotide, once daily for 12 weeks
3108618|NCT02291679|Experimental|145 μg linaclotide|145 μg oral linaclotide, once daily for 12 weeks
3108619|NCT02291679|Placebo Comparator|Placebo|matching placebo, once daily for 12 weeks
3108620|NCT02291718|Active Comparator|Isovue 300 75mL|Isovue 300 75mL injected 120 kVp 250 mAs
3108621|NCT02291718|Active Comparator|Isovue 370 75mL|Isovue 370 75mL injected 100 kVp 240 mAs
3108622|NCT02291718|Active Comparator|Isovue 370 60mL|Isovue 370 60mL injected 100 kVp 240 mAs
3108623|NCT02291861|Placebo Comparator|Placebo|Placebo tablets taken twice daily for 12 weeks.
3108624|NCT02291861|Experimental|SD-809 12 mg/day|SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
3108625|NCT02291861|Experimental|SD-809 24 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
3108626|NCT02291861|Experimental|SD-809 36 mg/day|SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.
3108627|NCT02291913|Experimental|everolimus|Everolimus will be administered at a dose of 10 mg PO daily combined with any one of the following anti-estrogen therapies on which the patient most recently progressed (tamoxifen, fulvestrant, anastrozole, letrozole, exemestane, toremifine, or LHRH agonists in conjunction with anti-estrogen therapy). Anti-estrogen therapy will be administered at the US Food and Drug Administration (FDA) prescribed doses.
3108628|NCT02292082|Active Comparator|Peri-Articular Injections only|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Surgeon will perform the periarticular injections:~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 1.20 ml 0.25% bupivacaine~Intravenous sedation with midazolam and propofol."
3108629|NCT02292082|Experimental|Peri-Articular Injections and Adductor Canal Block|"Intra-Operatively~Spinal anesthetic with 0.5% bupivacaine (10 or 12.5)~Adductor canal block technique:~Supine position, after IV sedation~Ultrasound guided with linear transducer 8 MHz. Chiba needle, 22 G / 4 inches~Femoral artery will be identified in the adductor canal deep to the Sartorius muscle~15 cc of Bupivacaine 0.25% with 2 mg of Preservative free Dexamethasone~Local anesthetic will be delivered periarterial between 12 and 6 o'clock~Intravenous sedation with midazolam and propofol.~First deep injection prior to cementation Bupivacaine 0.5% with epinephrine, 30cc Morphine, 8 mg/ml, 1 cc Methylprednisolone, 40 mg/ml, 1 ml Cefazolin, 500 mg in 10 ml Normal saline, 22cc~Second superficial injection prior to closure. 20 ml 0.25% bupivacaine"
3108630|NCT02292186|Experimental|Revusiran (ALN-TTRSC)|
3108631|NCT02292212|Experimental|Single arm|The dialyzer will be changed from conventional one to ViE-21 for 36 sessions for all the enrolled subjects.
3108632|NCT02292433|Experimental|PF-04937319|PF-04937319 Split dose
3108633|NCT02292433|Placebo Comparator|Placebo|Placebo split dose
3108634|NCT02292446|Experimental|All patients|All patients will receive ruxolitinib at a starting dose of 10 mg twice daily which could be titrated to most appropriate dose. Dose was not to exceed 25 mg bid nor be less than 5 mg once a day
3108635|NCT02292537|Experimental|Nusinersen|Nusinersen 12 mg solution via intrathecal (IT) injection on Days 1, 29, 85 and 274.
3108636|NCT02292537|Sham Comparator|Sham procedure|Sham comparator on Days 1, 29, 85 and 274.
3108637|NCT02292654|Experimental|Olipudase alfa|Participants received intravenous (IV) infusion of olipudase alfa once every 2 weeks (Q2W) for 64 weeks. Each participant underwent a dose escalation according to the following paradigm: 0.03, 0.1, 0.3, 0.3, 0.6, 0.6, 1.0, 2.0, 3.0 milligram per kilogram (mg/kg). Three (3) mg/kg was the target maintenance dose, which was maintained for the remaining duration of 64 treatment weeks.
3108638|NCT02292719|Experimental|Arm A (genotype [GT]3, noncirrhotic)|Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) 25/150/100 mg once daily (QD) and sofosbuvir (SOF) 400 mg QD for 12 weeks.
3108639|NCT02292719|Experimental|Arm B (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and ribavirin (RBV; weight-based 1,000 mg or 1,200 mg daily divided twice daily [BID]) for 12 weeks.
3108640|NCT02292719|Experimental|Arm C (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight- based 1,000 mg or 1,200 mg daily divided BID) for 8 weeks.
3108641|NCT02292719|Experimental|Arm D (GT2, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 6 weeks.
3108642|NCT02292719|Experimental|Arm E (GT3, cirrhotic)|OBV/PTV/r (25/150/100) mg QD with SOF (400 mg QD) and RBV (weight-based 1,000 mg or 1,200 mg daily divided BID) for 12 weeks.
3108643|NCT02292719|Experimental|Arm F (GT3, noncirrhotic)|OBV/PTV/r (25/150/100) mg QD and SOF (400 mg QD) for 12 weeks.
3108644|NCT02292758|Experimental|Arm I (cetuximab, bevacizumab, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, bevacizumab IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3108645|NCT02292758|Active Comparator|Arm II (cetuximab, placebo, irinotecan)|Patients receive cetuximab IV over 90-120 minutes, placebo IV over 30-90 minutes, and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3108646|NCT02292771|Experimental|Retosiban + Atosiban Placebo|Participants will receive retosiban 6 milligrams (mg) intravenous (IV) loading dose over 5 minutes, followed by a 6mg/hour continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, investigators will administer another 6mg IV loading dose and increase the infusion rate to 12 mg/hour for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for the atosiban loading (bolus) dose and continuous infusion to ensure blinding.
3108647|NCT02292771|Active Comparator|Atosiban + Retosiban Placebo|Participants will receive atosiban in 3 successive stages: an initial bolus dose (6.75 mg) over 1 minute, immediately followed by a continuous infusion at 18 mg/hour for 3 hours, followed by a 6 mg/hour infusion for the remainder of the 48-hour treatment period. Participants will also receive placebo infusion matched for retosiban loading (bolus) dose and continuous infusion to ensure blinding.
3108648|NCT02292784|Placebo Comparator|Placebo (200719 study)|All infants and children born to women who received the placebo (0.9 percent sodium chloride infusion matched for retosiban volume, intravenous [IV] loading dose over 5 minutes and continuous infusion rate including dose increase in participants with an inadequate response any time after first hour of treatment) in 200719 study. Current study will not require any medical interventions or study visits to an investigational site.
3108649|NCT02292784|Experimental|Retosiban (200719 and 200721 study)|All infants and children born to women who received retosiban (6 milligram [mg] IV loading dose of retosiban over 5 minutes followed by a 6 mg per hour continuous infusion of retosiban over 48 hours. Participants with an inadequate response any time after first hour of treatment were administered another 6 mg retosiban loading dose followed by 12 mg per hour continuous infusion for remainder of 48-hour treatment period) in 200719 study or 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
3108650|NCT02292784|Active Comparator|Atosiban (200721 study)|All infants and children born to women who received atosiban (in 3 successive stages; an initial bolus dose of 6.75 mg using atosiban 6.75 mg per 0.9 milliliter [mL] solution for injection, followed by continuous high dose infusion at 18 mg per hour for 3 hours, then a lower 6 mg per hour infusion for the remainder of the 48-hour using the atosiban 37.5 mg per 5 mL concentrate for solution) in 200721 study. Current study will not require any medical interventions or study visits to an investigational site.
3108651|NCT02292849|Experimental|Peer to Peer|These individuals will receive a standard mental health referral to a community agency and in addition meet with a trained peer coach for 12 weekly meetings.
3108652|NCT02292849|Active Comparator|Referral|These individuals will receive a standard mental health referral to a community agency.
3108653|NCT02292927|No Intervention|Pre-intervention|Patients treated as standard before intervention
3108654|NCT02292927|Active Comparator|Post-intervention arm = Prehabilitation|Introduction of rehabilitation program
3108655|NCT02293044|Experimental|Crest® Sensi-Stop™ Strips|Self Applied
3108656|NCT02293096|Experimental|Metoprolol succinate, CYP2D6 Genotyping, CYP2D6 Phenotyping|"The parent study will integrate covariates to predict metoprolol effectiveness for SBP decline of 10%. All patients will receive metoprolol. The following covariates will be used to predict metoprolol effectiveness: clinical variables (Age, sex, race/ethnicity, co-medications, and BMI) CYP2D6 genotype, CYP2D6 phenotype, and metabolomic factors.~metoprolol succinate~Genotyping: CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete.~CYP2D6 Phenotyping: Phenotype can be discordant from what is predicted by genotype. CYP2D6 henotyping using dextromethorphan will be used. Investigators will be blind to the patient blood pressure outcome for this intervention."
3108657|NCT02293395|Active Comparator|Stratum 1/ASA|Acetylsalicylic acid (ASA) 100 milligram (mg) enteric-coated tablet once daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3108658|NCT02293395|Experimental|Stratum 1/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with clopidogrel 75 mg once daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3108659|NCT02293395|Active Comparator|Stratum 2/ASA|ASA 100 mg enteric-coated tablet once daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3108660|NCT02293395|Experimental|Stratum 2/Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally along with ticagrelor 90 mg twice daily orally, up to either 180 days after randomization of the last enrolled participant in the study or Day 360, whichever occurs earlier.
3108661|NCT02293460|Experimental|I10E Arm|
3108662|NCT02293499|Active Comparator|Peer Led Asthma Self-Management|Peer-led asthma self-management for adolescents : PLASMA will be implemented in small groups at a camp setting where paired peer-leaders will facilitate learning activities.Paired peer leaders will share and coordinate the responsibilities of facilitating group activities. Training content includes: Day 1: Asthma basics and prevention; Day 2: Asthma monitoring and management; Day 3: Communication/ psychosocial issue management/leadership training/hands-on practice in simulated peer-led group settings (role-play)
3108663|NCT02293499|Active Comparator|Adult Led Asthma Self-Management|The adult led asthma self-management will take place within 2 weeks of the peer-led camp to minimize the history effect. Two healthcare professionals will attend peer-leader training sessions to become familiar with the program content, then lead instructional activities. As in PLASMA, adult leaders will base their instruction on the program manual to ensure comparable program content. Adult leaders will adopt mainly a didactic format and skill demonstration.
3108664|NCT02293512|Experimental|Coping Effectiveness Training|Coping Effectiveness Training (CET) is provided in a 3-session intervention to facilitate coping strategies among individuals with tinnitus. The CET psychoeducational intervention teaches coping skills to increase understanding of stress and coping with tinnitus, and to help individuals better know how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
3108665|NCT02293512|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy (CBT) is provided in a 3-session psychoeducational intervention to reduce negative affectivity triggered by tinnitus. CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
3108666|NCT02293512|Active Comparator|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is provided in a 3-session psychoeducational intervention to decrease resistance to tinnitus and increase committed action based on values, despite having tinnitus.
3108667|NCT02293512|No Intervention|Wait-list control group|Wait-list control group involves no intervention. This is a 'usual care' group.
3108668|NCT02293538|Experimental|FID 114657|FID 114657 eye drops (10 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
3108669|NCT02293538|Active Comparator|Saline Control|Saline control eye drops (15 ml), 1-2 drops instilled in each eye 10 minutes prior to inserting a new pair of habitual contact lenses and after removing them, daily for 2 weeks.
3108670|NCT02293798|Experimental|SERI|Subjects receiving SERI for mastopexy
3108671|NCT02293837|Experimental|Tocilizumab (TCZ) + SOC|Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥30 kg) or 10.0 mg/kg (body weight <30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
3108672|NCT02293837|Placebo Comparator|Tocilizumab Placebo Group + SOC|Subjects will receive IV infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])
3108673|NCT02293863|Experimental|A: MHAA4549A 3600 mg + Oseltamivir|Participants will receive a single low IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
3108674|NCT02293863|Experimental|B: MHAA4549A 8400 mg + Oseltamivir|Participants will receive a single high IV dose of MHAA4549A on Day 1 and standard oseltamivir therapy for minimum of 5 days.
3108675|NCT02293863|Placebo Comparator|C: Placebo + Oseltamivir|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1 and standard oseltamivir therapy (75 or 150 mg BID) for minimum of 5 days.
3108676|NCT02293902|Experimental|Sarilumab 150 mg/150 mg|Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either tender joint count [TJC] or swollen joint count [SJC], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3108677|NCT02293902|Experimental|Sarilumab 200 mg/200 mg|Sarilumab 200 mg SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3108678|NCT02293902|Placebo Comparator|Placebo/Sarilumab 150 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 150 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3108679|NCT02293902|Placebo Comparator|Placebo/Sarilumab 200 mg|Placebo (for sarilumab) SC injection q2w in combination with MTX and folic acid in double-blind period up to Week 24 followed by a single-blind period in which participants were switched and received sarilumab 200 mg SC injection q2w in combination with MTX and folic acid up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits [at least 4 weeks apart] in either TJC or SJC, or with any other clear lack of efficacy based on Investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
3108680|NCT02293993|Experimental|Cohort1|SGI-110 36mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3108681|NCT02293993|Experimental|Cohort2|SGI-110 60mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3108682|NCT02293993|Experimental|Cohort3|SGI-110 90mg/m2 will be administered subcutaneously once daily for 5 consecutive days (Day 1 to Day 5), followed by a 23-day non-dosing period (Day 6 to Day 28).
3108683|NCT02293993|Experimental|Cohort4|SGI-110 60mg/m2 will be administered subcutaneously once daily for 10 days (Day 1 to Day 5 and Day 8 to Day 12 with dosing, Day 6 and 7 with non-dosing), followed by a 16-day non-dosing period (Day 13 to Day 28).
3108684|NCT02294019|Experimental|Ibuprofen caplet arm|
3108685|NCT02294058|Active Comparator|Interferon beta-1a|Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
3108686|NCT02294058|Experimental|Ozanimod 0.5 mg|Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
3108687|NCT02294058|Experimental|Ozanimod 1 mg|Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
3108688|NCT02294175|Active Comparator|Larval Debridement Therapy|Larval debridement therapy intervention (Biobags) filled with sterile green bottle fly maggots (larvae) placed in open, chronic lower extremity or diabetic foot ulcer once every 4 days for total of 2 applications over the 8 day study period.
3108689|NCT02294175|Active Comparator|Sharp Debridement Therapy|Bedside sharp debridement therapy as a comparator performed by wound care clinician once every 7 days in a chronic lower extremity or diabetic foot ulcer for a total of 2 sharp debridements over the 8 day study period.
3108690|NCT02294227|Experimental|Secukinumab 150 mg|Secukinumab 150 mg s.c. with loading: Secukinumab 150 mg at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3108691|NCT02294227|Experimental|Secukinumab 150 mg No load|Secukinumab 150 mg s.c. without loading: Secukinumab 150 mg at baseline, followed by dosing every four weeks starting at Week 4, with Placebo at Weeks 1, 2 and 3. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3132654|NCT03442829|Experimental|Sweet food consumption|Sweet breakfasts. Participants are asked to consume a sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
3108692|NCT02294227|Placebo Comparator|Placebo|Placebo to Secukinumab at Baseline, Weeks 1, 2 and 3, followed by dosing every four weeks starting at Week 4 until Week 16/24, depending on patients responder status. From Week 16/24, patients were switched to Secukinumab 150 mg every four weeks. After primary outcome evaluation, approval and implementation of Amendment 2 Secukinumab dose may have been escalated to 300 mg as judged appropriate by the investigator
3108693|NCT02294253|Experimental|Buprenorphine/naloxone stabilization|Participants who have initially failed outpatient induction onto XR-NTX will receive buprenorphine/naloxone (BUP) on a weekly basis that they will take daily,
3108694|NCT02294318|Active Comparator|Motivational Interviewing (MI)|Participants will engage in a 30-minute Motivational Interviewing session with the study counselor to discuss participant's drug and alcohol use, its implications for their health, and the possibility of drug and alcohol use reduction. This counseling session is intended to help people reduce their drug and alcohol use if they wish. In the counseling session, participants describe the pros and cons of their drug and alcohol use and whether it might be important to quit using drugs and drinking alcohol. Open discussion of the pros (what they like about drug use and drinking) and cons (what they don't like) can help people think about reducing drug and alcohol use in a more complete way than they might have before. This arm will be compared to the HealthCall+Motivational Interviewing arm.
3108695|NCT02294318|Experimental|HealthCall+Motivational Interviewing|The HealthCall+Motivational Interviewing arm will investigate whether the addition of HealthCall, a smartphone application designed to keep track of the participant's drug and alcohol use and other health-related behaviors through short daily use, will help participants reduce their substance use more than Motivational Interviewing alone. Participants will receive the same 30-minute Motivational Interviewing session as described in the MI arm. After the session, participants will be introduced to HealthCall and will be asked to use the app daily over the next 30 days. Each use lasts 2-3 minutes and can be done anywhere on the phone in the U.S. The purpose of daily HealthCall use is to help participants keep track of their drug and alcohol use.
3108696|NCT02294396|Experimental|Mirabegron + Solifenacin|Participants received mirabegron 50 mg and solifenacin 5 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of solifenacin 10 mg, if the treatment was not effective.
3108697|NCT02294396|Experimental|Mirabegron + Propiverine|Participants received mirabegron 50 mg and propiverine 20 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of propiverine 40 mg, if the treatment was not effective.
3108698|NCT02294396|Experimental|Mirabegron + Imidafenacin|Participants received mirabegron 50 mg and imidafenacin 0.2 mg once daily after breakfast orally for 8 weeks. In the next 44 weeks, participants continued to receive mirabegron 50 mg, but received an increased dose of imidafenacin 0.4 mg, if the treatment was not effective.
3108699|NCT02294396|Experimental|Mirabegron + Tolterodine|Participants received mirabegron 50 mg and tolterodine 4 mg once daily after breakfast orally for 52 weeks.
3108700|NCT02294461|Experimental|Enzalutamide|Participants received 160 mg of enzalutamide orally once a day until Prostate-Specific Antigen (PSA) progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
3108701|NCT02294461|Experimental|Placebo|Participants received matching placebo orally once a day until PSA progression and radiographic disease progression were centrally confirmed and 1 of the following 2 events became applicable to the participants: (1) initiation of cytotoxic chemotherapy or (2) initiation of an investigational agent for treatment of prostate cancer.
3108702|NCT02294474|Experimental|SAR342434|SAR342434 100 Unit/mL (U/mL) before meals intake on top of once daily (QD) Insulin Glargine, up to Week 26.
3108703|NCT02294474|Active Comparator|Humalog|Humalog 100 U/mL before meals intake on top of QD Insulin Glargine, up to Week 26.
3108704|NCT02294604|Experimental|Group R|Waterless surgical hand rub formulation containing 61% ethyl alcochol, 1% chlorhexidine and moisturizers
3108705|NCT02294604|Active Comparator|Group I|Traditional scrub formation with 10 % povidone-iodine
3108706|NCT02294604|Active Comparator|Group C|Traditional scrub formation with 4% chlorhexidine
3108707|NCT02294630|Active Comparator|Dose Schedule I|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:1
3108708|NCT02294630|Active Comparator|Dose Schedule II|Surfactant dose to be administered as aerosol - 100 mg phospholipid/kg. Surfactant Dilution 1:2
3108709|NCT02294630|Active Comparator|Dose Schedule III|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:1
3108710|NCT02294630|Active Comparator|Dose Schedule IV|Surfactant dose to be administered as aerosol - 200 mg phospholipid/kg. Surfactant Dilution 1:2
3108711|NCT02294682|Experimental|GSK2140944 1500 mg|Subjects will receive single oral dose of GSK2140944 1500 mg.
3108712|NCT02294682|Experimental|GSK2140944 3000 mg|Subjects will receive single oral dose of GSK2140944 3000 mg.
3108713|NCT02294734|Experimental|GSK2269557 repeat dose|Participants will receive 2 inhalation of GSK2269557 dry powder once daily via DISKUS™ 'device' (DISKUS is a trademark of the GSK group of companies)
3108714|NCT02294734|Placebo Comparator|Matching placebo repeat dose|Participants will receive 2 inhalation matching placebo dry powder once daily via DISKUS 'device'
3108715|NCT02294773|Active Comparator|Day Of|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day the home ovulation predictor kit first turns positive.
3108716|NCT02294773|Active Comparator|Day After|This group takes either clomiphene or letrozole on cycle days 3-7 and then receives intrauterine insemination on the day after the home ovulation predictor kit first turns positive.
3108717|NCT02294786|Experimental|Octreotide treatment|Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
3108718|NCT02294786|Experimental|No Octreotide treatment|Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment
3108719|NCT02295020|Active Comparator|Standard Treatment Only|Group A will receive standard treatment only such as NSAIDs and injections
3108720|NCT02295020|Experimental|Standard Treatment plus Bioskin Ten-7|Group B will receive standard treatment such as NSAIDs and injections and the Bioskin Ten-7 knee brace.
3108721|NCT02295280|Active Comparator|Metoclopramide IV & Diphenhydramine IV|Intravenous (IV) access will be obtained and administration of 10mg Metoclopramide IV and 25mg Diphenhydramine IV Group A
3108722|NCT02295280|Active Comparator|Codeine|Group B (control group) will receive standard treatment consisting of a codeine 30mg tablet.
3108723|NCT02295553|Experimental|Ketamine 0 mg/kg|Ketamine dose will be 0 mg/kg. Propofol dose for the first patient will be 4 mg/kg. Doses for the subsequent patients will increase or decrease by 1.6 mg/kg using the Dixon Up and Down method.
3108724|NCT02295553|Experimental|Ketamine 0.25 mg/kg|Ketamine dose will be 0.25 mg/kg. Propofol dose for the first patient will be 3 mg/kg. Doses for the subsequent patients will increase or decrease by 1.2 mg/kg using the Dixon Up and Down method.
3108725|NCT02295553|Experimental|Ketamine 0.5 mg/kg|Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
3108726|NCT02295553|Experimental|Ketamine 1.0 mg/kg|Ketamine dose will be 1.0 mg/kg. Propofol dose for the first patient will be 2 mg/kg. Doses for the subsequent patients will increase or decrease by 0.4 mg/kg using the Dixon Up and Down method.
3108727|NCT02295644|Experimental|A: 0.4 Watts/Sq cm 50% Duty cycle|0.4 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 (MegaHertz) MHz, 5 minutes
3108728|NCT02295644|Experimental|B: 0.4 Watts/Sq cm 100% Duty cycle|0.4 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3108729|NCT02295644|Experimental|C: 0.8 Watts/Sq cm 50% Duty cycle|0.8 Watts/Sq cm 50% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3108730|NCT02295644|Experimental|D: 0.8 Watts/Sq cm 100% Duty cycle|0.8 Watts/Sq cm 100% Duty cycle Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1 MHz, 5 minutes
3108731|NCT02295735|Experimental|Mepilex® Border|If a patient is assigned to the intervention group the dressings Mepilex® Border Sacrum and Mepilex® Border Heel will be applied onto the respective intact skin areas in addition to standard pressure ulcer prevention
3108732|NCT02295735|No Intervention|Control|Standard pressure ulcer prevention according to hospital standard
3108733|NCT02295774|Placebo Comparator|Group A|Biopsy samples collected during standard white light colonoscopy.
3108734|NCT02295774|Active Comparator|Group B|Subjects who have had samples collected during a Group A colonoscopy, who require a second colonoscopy within 2 weeks. Prior to this second colonoscopy the subjects take Methylene Blue MMX tablets. Biopsies collected are compared to their previous group A colonoscopy for histone gamma H2AX activity.
3108735|NCT02295995|Experimental|Physical Activity|Participants randomized to this arm will be enrolled in a 12-week physical activity program.
3108736|NCT02295995|No Intervention|Usual Care Wait-List|Participants randomized to this arm will continue to receive usual care services for PTSD through the Veterans Health Administration (VHA) for 12 weeks after which time they will be offered the physical activity program for 12 weeks.
3108737|NCT02296099|Experimental|Liposomal Bupivacaine|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. If randomized to liposomal bupivacaine, the standard 20 milliliter (ml) vial (266mg dose) will be diluted with 10ml of preservative-free, sterile normal saline (0.9%) for injection to a reconstituted volume of 30ml. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have the 30ml dilutional volume injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
3108738|NCT02296099|Placebo Comparator|Saline Placebo|The placement of the retropublic sling will be placed in routine fashion under general anesthesia. At the completion of the procedure, and at least 20 minutes after the injection of 30ml lidocaine with epinephrine (routine for the surgical procedure), those subjects in the saline placebo arm will receive 30ml normal saline injected. 10ml will be injected into the vaginal epithelium in the mid-urethral area and 10ml will be injected into each of the trocar paths through the suprapubic incisions bilaterally. An aspiration and moving needle technique will be employed.
3108739|NCT02296112|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3108740|NCT02296125|Experimental|AZD9291+ placebo|AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
3108741|NCT02296125|Active Comparator|Standard of Care + placebo AZD9291|"Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
3108742|NCT02296138|Experimental|tiotropium + olodaterol high dose|Once daily 2 puffs solution for inhalation Respimat
3108743|NCT02296138|Active Comparator|tiotropium|Once daily 2 puffs solution for inhalation Respimat
3108744|NCT02296164||MF-CTCL Patients receiving Valchlor|Patients will undergo clinical assessments and receive standard medical care, as determined by the patients' physician, in the real world setting. With the exception of protocol-required patient completed questionnaires for symptoms and Quality Of Life.
3108745|NCT02296190|Experimental|Etripamil|1 dose of Etripamil via 4 intranasal applications at time 0 (140 mg, 105 mg, 70 mg, or 35 mg)
3108746|NCT02296190|Placebo Comparator|Placebo|1 dose of placebo via 4 intranasal applications at time 0
3108747|NCT02296242|Experimental|BVD-523|
3108748|NCT02296320|Active Comparator|MEDI4893 5000 mg|Participants will receive a single intravenous (IV) dose of MEDI4893 5000 milligrams (mg) on Day 1 of the study.
3108749|NCT02296320|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
3108750|NCT02296320|Active Comparator|MEDI4893 2000 mg|Participants will receive a single IV dose of MEDI4893 2000 mg on Day 1 of the study.
3108751|NCT02296346|Active Comparator|Corticosteroid arm|Patients will receive 1 gram of IV SoluMedrol over 1 hour, once every month for 12 months.
3108752|NCT02296346|Experimental|Extracorporeal Photopheresis|"Patient will receive an Extracorporeal Photopheresis treatment at a set frequency over the course of 1 year. The treatment takes about 2-3 hours per session to complete. The treatment schedule is as follows:~ECP will be administered according to the following schedule:~Study Arm: Weeks 1-8: 3 times per week Weeks 9-16: Twice per week Weeks 17-36: Treatment on two consecutive days every 2 weeks (or optionally, one treatment per week) Weeks 37-43: Once every 2 weeks Weeks 44-52: Once every 4 Weeks"
3108753|NCT02296424|Experimental|Canakinumab Dose Reduction|All patients received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 1 in Part II of the study: Canakinumab was administered at a reduced dose (2 mg/kg every 4 weeks). If the patient continued to maintain inactive disease for 24 additional weeks, canakinumab was administered at 1mg/kg every 4 weeks. If the patient continued to maintain inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
3108754|NCT02296424|Experimental|Canakinumab Dose Interval Prolongation|All participants received canakinumab 4mg/kg (300 mg max) every 4 weeks in Part I of the study. Patients eligible for Part II of the study were randomized to one of two treatment arms. This is Treatment Arm 2 in Part II of the study: Canakinumab dose interval was prolonged to a regimen of 4mg/kg every 8 weeks. If the patient continued to be stable with inactive disease for 24 additional weeks, canakinumab dose interval was prolonged to a regimen of 4mg/kg every 12 weeks. If the patient was clinically stable with inactive disease for another 24 additional weeks, canakinumab treatment was discontinued.
3108755|NCT02296476|Experimental|Birabresib 80 mg|Participants received 80 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3108756|NCT02296476|Experimental|Birabresib 120 mg|Participants received 120 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3108757|NCT02296476|Experimental|Birabresib 160 mg|Participants received 160 mg of oral birabresib administered once daily (in a fasted state) every day in a 28-day cycle for up to 6 cycles.
3108758|NCT02296502||Autism Spectrum Disorder (DSM IV & 5)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in both DSM-IV and DSM-5
3108759|NCT02296502||Autism Spectrum Disorder (DSM 5 only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-5 but not DSM-IV
3108760|NCT02296502||Autism Spectrum Disorder (DSM IV only)|All children and adolescents seen for autism diagnostic evaluations at the study sites who meet diagnostic criteria for ASD in DSM-IV but not DSM-5
3108761|NCT02296502||Non-Autism Spectrum Disorder|All children and adolescents seen for autism diagnostic evaluations at the study sites who do not meet diagnostic criteria for ASD.
3108762|NCT02296775|Experimental|DRL_RI|
3108763|NCT02296775|Active Comparator|Rituxan|
3108764|NCT02296775|Active Comparator|MabThera|
3108765|NCT02296840|Experimental|Ibuprofen|After undergoing adenotonsillectomy, patients who are randomized into the test intervention arm will receive ibuprofen (10mg/kg/day every 6-8 hours) after surgery.
3108766|NCT02296840|Active Comparator|Hydrocodone-acetaminophen (Control)|After undergoing adenotonsillectomy, patients who are randomized into the control intervention will receive hydrocodone-acetaminophen (0.15mg/kg/day every 4-6 hours).
3108767|NCT02296853|Experimental|Severe Hepatic Impairment Group|Participants with severe hepatic impairment will receive a single oral dose of TAF 25 mg on Day 1.
3108768|NCT02296853|Active Comparator|Matched Normal Hepatic Function Group|Participants with normal hepatic function will receive a single oral dose of TAF 25 mg on Day 1.
3108769|NCT02296892|Experimental|Remimazolam|"Double-blind Remimazolam arm: 5 mg iv for sedation induction, and 2.5 mg iv top-ups for sedation maintenance.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3108770|NCT02296892|Placebo Comparator|Placebo|"Double-blind placebo arm as inactive control~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3108771|NCT02296892|Active Comparator|Midazolam|"Open-label Midazolam arm: 1.75 mg* iv for sedation induction and 1.0 mg* iv for sedation maintenance. *1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3108772|NCT02296931|Active Comparator|Healthy Adults|Phase 1 will be an initial validation of the clinical performance of the device delivering only standard IV saline to 10 stable women.
3108773|NCT02296931|Experimental|Pre-eclamptic pregnant women|In Phase 2, the device will deliver MgSO4 to up to 40 women presenting with symptoms of pre-eclampsia.
3108774|NCT02297100|Experimental|Botox upper aspect trigone|Subjects in the experimental cohort will receive a one time dose of 100 units of Onabotulinumtoxin A diluted in 10 mL of preservative free normal saline and injected in 1.0 mL boluses in a set pattern across the upper aspect of the trigone of the urinary bladder.
3108775|NCT02297100|Active Comparator|botox periphery of trigone|Each group will receive a total of 100 units of botox spread out among 10 separate injections. Subjects in the control group will have 10 injections made about the periphery of the trigone. The control cohort will receive a one time dose of Onabotulinumtoxin A using the same dilution and number of boluses, but boluses will be administered at random sites on the posterior bladder wall (excluding the trigone).
3108776|NCT02297308||SoloPath Sheath|The study focuses on subjects that underwent TAVI with a SoloPath Sheath used for femoral vascualar access
3108777|NCT02297412|Experimental|Arm I (minocycline hydrochloride)|Patients receive minocycline hydrochloride PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3108778|NCT02297412|Placebo Comparator|Arm II (placebo)|Patients receive a placebo PO BID on days 1-7. Treatment repeats every 7 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3108779|NCT02297438|Experimental|Palbociclib + Letrozole|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously)
3108780|NCT02297438|Active Comparator|Placebo + Letrozole|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
3108781|NCT02297503|Experimental|Azzalure alone as single treatment|Azzalure alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
3108782|NCT02297503|Experimental|Filler alone as single treatment|HA filler alone as single treatment at initial treatment followed by two combined treatments with Azzalure, HA filler and Skinboosters at Month 6 and Month 12.
3108783|NCT02297516|Experimental|Azzalure/Dysport as single treatment|Azzalure/Dysport as single treatment at initial treatment
3108784|NCT02297516|Experimental|Filler as single treatment|Filler as single treatment at initial treatment
3108785|NCT02297815||Broad-spectrum antibiotics|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Broad-spectrum antibiotics.
3108786|NCT02297815||Narrow-spectrum|Children diagnosed with an acute respiratory tract infections (ARTI) and prescribed Narrow-spectrum antibiotics.
3108787|NCT02297841|Experimental|Human Repeat Insult Patch Test|Approximately 0.2ml of each intervention (Experimental: Novel lubricant Miami Fragrance, Experimental: Novel lubricant Miami no Fragrance, KY Liquid lubricant, Astroglide Gel lubricant) was applied to an occlusive patch and applied to participant's back.
3108788|NCT02298023|Experimental|Mesenchymal stem cell group|Received allogenic adipose tissue-derived adult mesenchymal stem cells (10million cells) in fibrin glue scaffold.
3108789|NCT02298023|Active Comparator|Active control (fibrin glue) group|Received fibrin glue and normal saline.
3108790|NCT02298023|Placebo Comparator|Control (normal saline )group|Received only normal saline.
3108791|NCT02298179|Experimental|RSV F 45 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with no adjuvant.
3108792|NCT02298179|Experimental|RSV F 45 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with aluminum hydroxide adjuvant.
3108793|NCT02298179|Experimental|RSV F 45 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the low dose RSV F subunit vaccine [45 μg], with MF59 adjuvant.
3108794|NCT02298179|Placebo Comparator|Placebo 1 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 1.
3108795|NCT02298179|Experimental|RSV F 90 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with no adjuvant.
3108796|NCT02298179|Experimental|RSV F 90 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with aluminum hydroxide adjuvant.
3108797|NCT02298179|Experimental|RSV F 90 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the medium dose RSV F subunit vaccine [90 μg], with MF59 adjuvant.
3108798|NCT02298179|Placebo Comparator|Placebo 2 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 2.
3108799|NCT02298179|Experimental|RSV F 135 No Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with no adjuvant.
3108800|NCT02298179|Experimental|RSV F 135 Alum Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with aluminum hydroxide adjuvant.
3108801|NCT02298179|Experimental|RSV F 135 MF59 Adj Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of the high dose RSV F subunit vaccine [135 μg], with MF59 adjuvant.
3108802|NCT02298179|Placebo Comparator|Placebo 3 Group|Healthy female and male subjects, 18 to 45 years of age, who received two doses of an intramuscular injection of saline solution. Subjects were enrolled in a stepwise dosage escalation manner into one of the three cohorts (Cohort 1: low dosage of RSV F subunit vaccine [45 μg], Cohort 2: middle dosage of RSV F subunit vaccine [90 μg], and Cohort 3: high dosage of RSV F subunit vaccine [135 μg]). This placebo group belongs to Cohort 3.
3108803|NCT02298192|Experimental|Once weekly titration|
3108804|NCT02298192|Experimental|Twice weekly titration|
3108805|NCT02298322|Experimental|CoolSculpting Treatment|The intervention is the CoolSculpting System.
3108806|NCT02298361||Intervention patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were used
3108807|NCT02298361||Within-clinic comparison patients|Community Health Centers that implemented health insurance outreach IT tools: active patients on whom tools were not used
3108808|NCT02298361||Control clinic comparison patients|Matched Community Health Centers that did not implement health insurance outreach IT tools: active patients
3108809|NCT02298491|Experimental|H.P. Acthar Gel|
3108810|NCT02298803|Other|Holter and Glucose monitoring|In this study the interventions will be the simultaneous monitoring of glucose and QT interval via a subcutaneous continuous glucose monitor and a Hoter monitor, respectively.
3108811|NCT02298842|Active Comparator|Platelets Stored in Plasma|Platelets stored in Plasma
3108812|NCT02298842|Experimental|Test Platelets Stored in InterSol|Platelets stored in InterSol
3108813|NCT02298868|Experimental|Treatment|All patients will be administered a standing dose of Baclofen initially at 5 mg three times a day for the first week and then increased to 10 mg three times a day for the next 3 weeks with a tapering dose the final week, a total of 5 weeks of therapy.
3108814|NCT02298933|Experimental|Eculizumab|1200 mg IV infusion over 30-40 min
3108815|NCT02298946|Experimental|DL1 - CTX, SBRTx1 day, & AMP-224|Dose Level 1 (DL1) Cyclophosphamide (CTX) 200mg/m(2) intravenous (IV) on day 0. Stereotactic body radiation therapy (SBRT) 8 (gray)Gy x 1 day on day 0, AMP-224 10mg/kg on day 1 then every (q)14 days for a total of 6 doses
3108816|NCT02298946|Experimental|DL2 - CTX, SBRTx3 days, and AMP-224|Dose Level 2 (DL2) CTX 200mg/m(2) IV on day 0, SBRT 8Gy x 3 day on days -2, -1, and 0. AMP-224 10mg/kg on day 1 then q14 days.
3108817|NCT02299050|Other|Cycloset|"Drug - Cycloset Cycloset 2.4 -3.2 mg/day~Other Names:~Bromocriptine Mesylate Quick Release"
3108818|NCT02299076|Other|Usual care with minimal incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, and receive compensation for enrolling and completing a survey at the end of the study.
3108819|NCT02299076|Active Comparator|Usual care with BE incentives|Participants in this arm receive usual care from the Pro-Change smoking cessation program, the chance to win money based on their behavior (behavioral economics incentives), and receive compensation for enrolling and completing a survey at the end of the study.
3108820|NCT02299089|Experimental|CAM2029 10 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
3108821|NCT02299089|Experimental|CAM2029 20 mg (NET)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
3108822|NCT02299089|Experimental|CAM2029 10 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks
3108823|NCT02299089|Experimental|CAM2029 20 mg (Acromegaly)|CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly
3108824|NCT02299141|Experimental|Nintedanib|-Nintedanib will be administered orally at a dose of 200 mg twice daily during each 28 day cycle
3108825|NCT02299167|Experimental|Saddle block|The dose of bupivacaine given to each patient was determined by the response of the previously tested patient using a modified Dixon's up-and-down method
3108826|NCT02299258|Active Comparator|Tailored stents MTN-WE-20/100-A|The distal portion of the GOO tailored stents was semi-spherical, with a length of 20 mm, and a diameter of 28 mm. The middle segment had a diameter of 20 mm. The overall length of the stents was 100 mm. Both the middle part and the bottom of the proximal cup segment, and a part of the proximal funnel segment, were covered by a polyethylene membrane.
3108827|NCT02299258|Experimental|Standard stents MTN-CG-s-20/100|Standard uncovered stents were used in the control group. The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
3108828|NCT02299297|Experimental|Tofacitinib|Tofacitinib will be self-administered for 6 months, with the option to extend treatment up to an additional 6 months at the discretion of the principal investigator. Patients will then be followed for 6 months off the drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment.
3108829|NCT02299336|Other|PRN (pro re nata)|2 mg intravitreal aflibercept (Eylea) PRN, focal laser administered based on pre-specified criteria, 104 weeks
3108830|NCT02299349|Experimental|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
3108831|NCT02299349|Active Comparator|concentrated multi drug injection|concentrated multi drug periarticular injection
3108832|NCT02299375|Experimental|Losmapimod 15 mg|Subjects with COPD will receive losmapimod 15 mg tablets orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of inhaled corticosteroid (ICS). Salbutamol metered dose inhaler (MDI) will be provided as a rescue medication.
3108833|NCT02299375|Experimental|Placebo|Subjects with COPD will receive placebo orally, twice daily, approximately 12 hours apart and within 30 minutes after meals with a full glass of water for the duration of the treatment period in addition to standard of care, stratified according to whether a center collects sputum or not and current use of ICS. Salbutamol MDI will be provided as a rescue medication.
3108834|NCT02299388|Active Comparator|Liraglutide|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
3108835|NCT02299388|Placebo Comparator|Placebo|All subjects will be advised a low sodium diet. This will be a placebo controlled, double blind and randomized trial of effects of Liraglutide on systolic BP control. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval. Each subject will be asked to keep a log of activities throughout the day.
3108836|NCT02299427|Experimental|dog safety|2 weeks of regular use of website on child dog safety developed for this research
3108837|NCT02299427|Active Comparator|transportation safety|2 weeks of regular use of publicly-available website on child transportation safety
3108838|NCT02299479|Experimental|Intervention|Volunteers will wear a Dexcom G4 Platinum CGM device as well as an activity monitor. Data will be uploaded to study investigators on a regular basis, and recommendations will be made to adjust insulin dosing based upon analysis of these data.
3108839|NCT02299570|Active Comparator|Group A|Two enemas of RBX2660 (microbiota suspension) administered 7 days apart
3108840|NCT02299570|Placebo Comparator|Group B|Two enemas of placebo administered 7 days apart
3108841|NCT02299570|Active Comparator|Group C|1 enema of RBX2660 (microbiota suspension) and 1 enema of placebo administered 7 days apart
3108842|NCT02299635|Experimental|PF-03084014|PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
3108843|NCT02299791|Active Comparator|Early Intervention|6 study clinics received the ALL intervention starting 6/1/11
3108844|NCT02299791|Active Comparator|Late implementation|5 study clinics received the ALL intervention starting 6/1/12
3108845|NCT02299869|Other|Group 1 - Verde (Competitor-control) vs. Green (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3108846|NCT02299869|Other|Group 2 - Cinza (Competitor-control) vs. Grey (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3108847|NCT02299869|Other|Group 3 - Esmeralda (Competitor-control) vs. Jade (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3108848|NCT02299869|Other|Group 4 - Azul (Competitor-control) vs. Blue (CVI-test)|Each subject was randomized to wear the test and control lenses contralaterally.
3108849|NCT02300025|Experimental|Cohort 1: Normal function|
3108850|NCT02300025|Experimental|Cohort 2: Mild Hepatic Impairment|
3108851|NCT02300025|Experimental|Cohort 3: Moderate Hepatic Impairment|
3108852|NCT02300025|Experimental|Cohort 4: Severe Hepatic Impairment|
3108853|NCT02300077|Active Comparator|Control|Control (Intra-operative administration of opioids, other than methadone)
3108854|NCT02300077|Active Comparator|Treatment methadone 0.1 mg/kg|methadone 0.1 mg/kg
3108855|NCT02300077|Active Comparator|Treatment methadone 0.15 mg/kg|
3108856|NCT02300103|Experimental|SOF/VEL+RBV|Participants will receive SOF/VEL fixed dose combination (FDC) and RBV for 24 weeks.
3108857|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design)~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks"
3108858|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks then 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks."
3108859|NCT02300129|Experimental|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~Application of 1g of CD07805/47 0.5% Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of Placebo Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
3108860|NCT02300129|Experimental|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~Application of 1g of Placebo Gel on full face on Day 1 (cross-over design) and 500mg on a half-face (split-face design) on Day 3.~Application of 500mg of CD07805/47 0.5% Gel on a half-face (split-face design) on Day 3 and 1g on full face on Day 5 (cross-over design).~Period 2 (cross-over design):~Application of 1g of Placebo Gel on full face once daily 7 days per week for 2 weeks then 1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks."
3108861|NCT02300220|Active Comparator|Ciprofloxacin|500 mg, twice daily for 1 week (oral).
3108862|NCT02300220|Placebo Comparator|Placebo|one capsule, twice daily for 1 week.
3108863|NCT02300259|Experimental|LY2623091 (Group 1)|LY2623091 administered orally once on Day 1 of Period 1.
3108864|NCT02300259|Experimental|Itraconazole + LY2623091 (Group 1)|200 mg itraconazole administered orally twice daily on Day 1 of Period 2 and once daily on Days 2 - 20 of Period 2. Single oral dose of LY2623091 coadministered on Day 6 of Period 2.
3108865|NCT02300259|Experimental|Simvastatin (Group 2)|20 mg simvastatin administered orally once daily on Day 1.
3108866|NCT02300259|Experimental|LY2623091 + Simvastatin (Group 2)|LY2623091 administered orally once daily on Days 3 - 13. Single oral dose of 20 mg simvastatin coadministered on Day 12.
3108867|NCT02300259|Experimental|Tadalafil (Group 3)|5 mg tadalafil administered on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
3108868|NCT02300259|Experimental|Tadalafil + LY2623091 (Group 3)|LY2623091 administered orally once daily on Day 1 up to Day 15 of Period 2. 5 mg tadalafil co-administered once daily on Day 10 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
3108869|NCT02300259|Experimental|LY2623091 (Group 4)|LY2623091 administered orally once on Day 1 of Period 1. Arm is contingent on interim results from Groups 1 and 2.
3108870|NCT02300259|Experimental|Diltiazem + LY2623091 (Group 4)|240 mg diltiazem administered once daily on Days 1 to 13 of Period 2. Single oral dose of LY2623091 coadministered on Day 4 of Period 2. Arm is contingent on interim results from Groups 1 and 2.
3108871|NCT02300285|Experimental|CGM Protocol|Subjects will receive continuous glucose monitoring and caregivers will be able to view continuous glucose measurements.
3108872|NCT02300285|Placebo Comparator|Standard of Care|Subjects will receive continuous glucose monitoring but caregivers will not be able to view continuous glucose measurements.
3108873|NCT02300298|Experimental|Nintedanib plus Docetaxel|patients to receive backbone chemotherapy and nintedanib
3108874|NCT02300311|Experimental|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
3108875|NCT02300311|Placebo Comparator|placebo|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
3108876|NCT02300545|Experimental|Pazopanib|Pazopanib will be started at a dose of 200 mg BID for four days, then escalated to a dose of 400 mg BID for four days, then escalated once more to a dose of 800 mg QD for the duration of participation (or until dose reduction, if necessary). Pazopanib should be taken orally without food at least one hour before or two hours after a meal. One cycle of pazopanib is 28 days.
3108877|NCT02300558|Experimental|Eleclazine (Single-blind treatment phase)|Eleclazine and/or eleclazine placebo up to Week 24
3108878|NCT02300558|Experimental|Open-label Extension Phase|Eligible participants will continue to receive open-label eleclazine until this drug is commercially available for the treatment of patients with LQT3, or until Gilead terminates development of eleclazine for the treatment of patients with LQT3, or the investigator deems it no longer in the participant's best interest.
3108879|NCT02300610|Experimental|Dose Escalation|Dose Escalation: Begin with Level 1 dose of enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).
3108880|NCT02300610|Experimental|Dose Expansion|Dose Expansion: Enzalutamide at recommended dose level with standard doses of cisplatin and gemcitabine.
3108881|NCT02300727|Active Comparator|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
3108882|NCT02300727|Experimental|Curcumin|Curcumin (BCM-95) administered by ingested mouth rinse three times per day. Subjects will be in this arm at the previously determine maximum tolerated dose (MTD).
3108883|NCT02300727|Other|Curcumin-MTD|"Curcumin (BCM-95) administered by ingested mouth rinse. A total of 12-15 subjects will be in this arm to determine maximum tolerated dose (MTD).~There will be 3 participant at each of 4 does levels (0.33g, 1g, 2g, 3g) per rinse, three times daily for 4-6 weeks. (additional 3 subjects if a dose-limiting toxicity occurs)"
3108884|NCT02300987|Active Comparator|LEE011|600 mg daily dosing days 1-21 of a 28 day cycle
3108885|NCT02300987|Placebo Comparator|Placebo Arm|600 mg daily dosing days 1-21 of a 28 day cycle
3108886|NCT02301039|Experimental|Soft tissue sarcoma|Patients with the following types of soft tissue sarcoma: leiomyosarcoma, poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma/MFH, MPNST and synovial sarcoma). Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
3108887|NCT02301039|Experimental|Bone sarcoma|Patients with the following types of bone sarcoma: Ewing sarcoma, osteosarcoma, and chondrosarcoma [de-differentiated or mesenchymal]. Pembrolizumab will be administered at 200 mg intravenously every 3 weeks
3108888|NCT02301039|Experimental|Expansion|Patients with the following types of soft tissue sarcoma: poorly differentiated/de-differentiated liposarcoma, high grade pleomorphic undifferentiated sarcoma. Pembrolizumab was administered at 200 mg intravenously every 3 weeks
3108889|NCT02301143|Experimental|nab-Paclitaxel plus Gemcitabine|"nab-Paclitaxel 125 mg/m2 intravenous (IV) infusion over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000 mg/m2 IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle Subjects who complete 6 cycles of nab-paclitaxel and gemcitabine without disease progression or unacceptable toxicities, the Investigator will then determine the best option for the subject.~Continuation of nab-paclitaxel and gemcitabine therapy to disease progression or unacceptable toxicity OR~Chemoradiation therapy consisting of the concurrent use of capecitabine or gemcitabine with radiation according to institutional practice OR~Surgical intervention"
3108890|NCT02301169|Active Comparator|T4P1001|
3108891|NCT02301169|Sham Comparator|Placebo|
3108892|NCT02301299||Community-based Stroke Awareness Program|Neighborhoods in the south side of Chicago surrounding a primary stroke center hospital will be targeted for a community-partnered stroke awareness and action educational campaign. To assess the effectiveness of this intervention, the investigators will monitor early hospital arrival and EMS use for stroke over a 60-month period comparing performance at the primary stroke center hospital using an interrupted time-series analysis.
3108893|NCT02301364|Experimental|Buparlisib (BKM120)|This is an open-label, phase II trial of the pan-PI3K inhibitor buparlisib (BKM120) for patients with recurrent or refractory primary central nervous lymphoma (PCNSL) and recurrent or refractory secondary central nervous lymphoma (SCNSL).
3108894|NCT02301377|Active Comparator|Intervention Group|Participants will receive a Spiro PD personal spirometer that will allow them to measure their lung function at home and provide medication reminders. Participants will be instructed to use the device to check their lung function once a week. They will also be asked to use the medication reminder feature of their device daily. Participants in this group will receive a telephone call once a week from the research team to review lung function results and answer questions. All participants need to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. Participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed.
3108895|NCT02301377|No Intervention|Control|Participants will be asked to fill out a quality of life questionnaire at the time of enrollment and at the end of the study. All participants will be asked to come to their quarterly clinic visits with their pediatric pulmonologist where their height, weight, body mass index, lung function and frequency of hospitalizations will be assessed. All participants will be asked to sign a release form so their pharmacies can be contacted for prescription refill data to monitor adherence over the course of the study.
3108896|NCT02301390|Active Comparator|Amiodarone only|The control group will receive amiodarone only.
3108897|NCT02301390|Experimental|Amiodarone + Catheter Ablation|The experimental group will receive amiodarone plus catheter VT ablation.
3108898|NCT02301403|Active Comparator|Modern Usual Care|Participants assigned to the M-UC will receive 8 weeks of nicotine patch, a single brief, in-person counseling session, a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), and will be signed up for either the QUITNOW app or the Web Coach (both provided by Alere Wellbeing, the vendor that provides the WTQL services).
3108899|NCT02301403|Experimental|Abstinence-Optimized Cessation Treatment|There are 5 intervention components to include in the AOCT package: 1) Preparation Nicotine Mini-Lozenges; 2) 26-week postquit Combination NRT (nicotine patch + nicotine mini-lozenges); 3) Intensive In-Person Cessation Counseling; 4) Extended Maintenance Counseling Calls; and 5) Automated Adherence Calls.
3108900|NCT02301416|Experimental|Phentermine/topiramate|All subjects enrolled in the study will be placed on the study medication.
3108901|NCT02301416|No Intervention|Historical Control|Historical controls who had sleeve gastrectomy during the same time frame without phentermine/topiramate treatment
3108902|NCT02301429|Experimental|Model 20105|Receiving the model 20105 Lead
3108903|NCT02301546|Experimental|experimental cognitive training|Participants will use experimental computerized cognitive training exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks.
3108904|NCT02301546|Active Comparator|control cognitive exercises|Participants will use control computerized cognitive activities, 1 hour per day, 3 - 5 days per week, for 13 weeks.
3108905|NCT02301624|Experimental|Eculizumab/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with eculizumab in Study ECU-MG-301 were administered eculizumab (4 vials/1200 milligrams [mg]) on Day 1 and Week 2 and placebo (4 vials/0 mg) at Weeks 1 and 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
3108906|NCT02301624|Experimental|Placebo/Eculizumab|"Blind Induction Phase: Participants who had received blinded treatment with placebo in Study ECU-MG-301 were administered eculizumab/placebo (3 vials/900 mg, plus 1 vial/0 mg, respectively) on Day 1 and Weeks 1 through 3.~Open-Label Maintenance Phase: Participants received open-label eculizumab (4 vials/1200 mg) every 2 weeks starting at Week 4 and continued throughout the study.~Eculizumab 1200 mg was administered for up to 4 years in this extension study."
3108907|NCT02301793|Experimental|Contemporary Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based contemporary interactive format.~Intervention: Nurse education in contemporary format"
3108908|NCT02301793|Active Comparator|Traditional Education Format|"Nurses in this arm received education about venous thromboembolism (VTE) in a web-based traditional linear PowerPoint format with voice over.~Intervention: Nurse education in traditional format"
3108909|NCT02301897|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the off drug interval (ODI).
3108910|NCT02301897|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
3108911|NCT02301897|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12 mg, orally, once daily for 18 weeks (Treatment Course 1) and repeated for an additional 18 weeks (Treatment Course 2) following the ODI.
3108912|NCT02301936|Experimental|LDV/SOF 12 weeks|Treatment-naive or treatment-experienced participants without cirrhosis will receive LDV/SOF for 12 weeks.
3108913|NCT02301936|Experimental|LDV/SOF 24 weeks|Treatment-experienced participants with cirrhosis will receive LDV/SOF for 24 weeks.
3108914|NCT02301975|Experimental|Fluticasone Furoate/Vilanterol 100/25 mcg|FF/VI 100/25 mcg by inhalation OD (PM) via ELLIPTA plus placebo by inhalation BD (AM and PM) via ACCUHALER/DISKUS for 24 weeks.
3108915|NCT02301975|Experimental|Fluticasone Propionate/Salmeterol 250/50 mcg|FP/Salmeterol 250/50 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
3108916|NCT02301975|Experimental|Fluticasone Propionate 250 mcg|FP 250 mcg by inhalation BD (AM and PM) via ACCUHALER/DISKUS plus placebo by inhalation OD (PM) via ELLIPTA for 24 weeks.
3108917|NCT02301988|Experimental|Ipatasertib + Paclitaxel|Participants will receive ipatasertib orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel intravenous (IV) infusion every week (QW) for 3 cycles (12 total doses).
3108918|NCT02301988|Placebo Comparator|Placebo + Paclitaxel|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles and paclitaxel IV infusion QW for 3 cycles (12 total doses).
3108919|NCT02302066|Experimental|Group 1 (TDV 2-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 91. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 365.
3108920|NCT02302066|Experimental|Group 2 (TDV 1-Dose)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Day 1. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 91 and 365.
3108921|NCT02302066|Experimental|Group 3 (TDV 1-Dose + Booster)|Takeda's tetravalent dengue vaccine candidate (TDV), 0.5 mL, subcutaneous injection on Days 1 and 365. Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Day 91.
3108922|NCT02302066|Placebo Comparator|Group 4 (Placebo Control)|Placebo-matching vaccine, 0.5 mL, subcutaneous injection on Days 1, 91 and 365.
3108923|NCT02302092|Experimental|Flomoxef|Flomoxef, 2g, injection, intravenously, twice daily (every 12 hours), for up to 12 days.
3108924|NCT02302092|Active Comparator|Cefepime|Cefepime, 1g, injection, intravenously, twice daily (every 12 hours) for up to 14 days.
3108925|NCT02302157|Experimental|AST-OPC1|Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point
3108926|NCT02302222|Active Comparator|Standard of Care|dry sterile dressing/gauze and steristrips
3108927|NCT02302222|Experimental|Customizable|Prevena Customizable Dressing with ActiV.A.C. Therapy Unit
3108928|NCT02302339|Experimental|Glembatumumab vedotin|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle.
3108929|NCT02302339|Experimental|Glembatumumab vedotin and varlilumab|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Varlilumab administered as an intravenous infusion on Day 1 of cycles 1, 2, 4, 6, 8 and 10.
3108930|NCT02302339|Experimental|Glembatumumab vedotin and PD-1 targeted checkpoint inhibitor|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. Nivolumab OR pembrolizumab administered according to institutional standard of care.
3108931|NCT02302339|Experimental|Glembatumumab vedotin and CDX-301|glembatumumab vedotin administered as an intravenous infusion on Day 1 of each 21 day cycle. CDX-301 is injected once a day for five days before cycles 1 and 2.
3108932|NCT02302716|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or neutral protamine hagedorn (NPH) QD will begin the study at their current dose SC. Participants will self titrate LY2963016 based on fasting blood glucose (FBG). Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will continue oral antihyperglycemic medication (OAM).
3108933|NCT02302716|Active Comparator|LANTUS®|Insulin naive participants started on 10 U LANTUS® given SC QD for 24 weeks. Participants entering the study on LANTUS®, insulin detemir or NPH QD will be started at the same dose SC. Participants entering on insulin detemir or NPH twice a day will be started at 80% of the total daily dose SC. Participants will self titrate LANTUS® based on FBG. Participants will continue OAM.
3108934|NCT02302807|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants will receive atezolizumab as long as they continue to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.
3108935|NCT02302807|Active Comparator|Arm B: Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)|Participants randomized to the chemotherapy arm will receive vinflunine, paclitaxel, or docetaxel per the investigator's choice. Vinflunine 320 milligrams per square meter (mg/m^2), paclitaxel 175 mg/m^2, or docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.
3108936|NCT02302846|Experimental|Ixazomib|Participants receive 4 mg oral dose of Ixazomib on Days 1, 8 and 15 of each 28-day cycle.
3108937|NCT02303041|Experimental|BCC Smoothened inhibitor-naive|Participants with locally advanced or metastatic basal cell carcinoma (BCC) and naive to treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
3108938|NCT02303041|Experimental|BCC refractory or relapsed after Smoothened inhibitor|Participants with locally advanced or metastatic basal cell carcinoma (BCC) that is refractory or relapsed after treatment with Smoothened inhibitors receive sonidegib and buparlisib in repeating 28-day cycles in the absence of disease progression or unacceptable toxicity.
3108939|NCT02303093||Octagam|Patient receiving Octagam 5% or 10% IVIG
3108940|NCT02303093||Panzyga|Patient receiving panzyga
3108941|NCT02303184|Experimental|4 mg CLS-TA + IVT aflibercept|Single unilateral, suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA following a 2 mg intravitreal injection of aflibercept
3108942|NCT02303184|Active Comparator|sham + IVT aflibercept|Single unilateral, suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
3108943|NCT02303262|Experimental|Mocetinostat and gemcitabine|For each 21-day cycle, gemcitabine is administered on days 5 and 12 and mocetinostat is administered 3 days a week.
3108944|NCT02303548|Experimental|1 (Sodium bicarbonate)|Sodium bicarbonate 50cc (50mEq) intravenous injection over 2 min
3108945|NCT02303548|Placebo Comparator|2 (Normal saline)|Normal saline 50cc intravenous injection over 2 min
3108946|NCT02303574|Experimental|AZD7986, single and mulltiple doses|In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution
3108947|NCT02303574|Placebo Comparator|Placebo, single and multiple doses|In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution
3108948|NCT02303704|Active Comparator|multiport antegrade cardioplegia|Patients who received multiport antegrade cardioplegia and continuous controlled warm blood perfusion through vein grafts.
3108949|NCT02303704|Active Comparator|Aortic root antegrade cardioplegia|Patients who underwent routine conventional CABG with antegrade aortic root cardioplegia without warm blood perfusion
3108950|NCT02303743|Active Comparator|Smart Phone Application (SPA) Group|Patients assigned to SPA group were instructed on how to free-download the application onto their smartphone. Each patient enters the date and time of his colonoscopy and timed alerts appeared on the phone to alert the patient of the next step in bowel preparation. In addition to the alerts, the app assists in bowel preparation by explaining the procedure, providing tips, examples of low fiber diet, and displaying pictures of preparation quality and educational video to explain how to prepare the purgative solution.Finally, the patient can obtain a checklist to confirm all steps.
3108951|NCT02303743|Active Comparator|Control Group|Written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution
3108952|NCT02303977|Experimental|Gemcitabine + Paciltaxel|All patients were treated intravenously with albumin-bound paclitaxel at 100 mg/m2 plus gemcitabine at 1000 mg/m2 on days 1 and 8 of each three-week cycle.
3108953|NCT02303990|Experimental|Single arm|Hypofractionated RT and Pembro
3108954|NCT02304159|Experimental|Group A - 16 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 16 weeks
3108955|NCT02304159|Active Comparator|Group B - 24 weeks|Combination of sofosbuvir 400 mg daily, ribavirin 1000-1200 mg daily (weight based) and daclatasvir 60 mg daily for 24 weeks
3108956|NCT02304367|Experimental|Burosumab|Participants received burosumab at a starting dose of 0.3 mg/kg administered subcutaneously (SC) every 4 weeks (Q4W). Doses may have been titrated up to a maximum of 2.0 mg/kg every 2 weeks (Q2W) in order to achieve fasting peak serum phosphorus levels within the target range of 2.5 to 4.0 mg/dL.
3108957|NCT02304432|Experimental|Open label DCS|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule for 8 weeks.
3108958|NCT02304432|Experimental|DCS or placebo|Randomized to DCS or placebo. Participants underwent double-blind placebo-controlled exposures to DCS for 6 weeks or placebo for 6 weeks. One participant received exposure to DCS for 6 weeks and then received placebo dosing for 6 weeks. The other participant received exposure to placebo dosing for 6 weeks and then DCS for 6 weeks.
3108959|NCT02304432|Experimental|Second open label DCS|Both participants received second open label exposures to D-cycloserine (seromycin), 50 mg/d capsule for 24 weeks.
3108960|NCT02304484|Experimental|Evolocumab|Participants received 420 mg evolocumab once a month for up to 2 years.
3108961|NCT02304705|Placebo Comparator|Placebo|Placebo three times per day, orally
3108962|NCT02304705|Active Comparator|Sildenafil|Sildenafil 20 mg three times per day, orally
3108963|NCT02304757|Experimental|99Tc-MDP|15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
3108964|NCT02304757|Active Comparator|Fosamax|70mg po every week for 12 months.
3108965|NCT02304926|Experimental|Simvastatin|Hyperlipidemic patients received simvastatin (40 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
3108966|NCT02304926|Experimental|Ezetimibe|Hyperlipidemic patients received ezetimibe (10 mg/day) for 4 weeks, after they were administered combined therapy (simvastatin, 40 mg/day plus ezetimibe,10 mg/day) for an additional 4-week period. Lipid profile, lipoprotein subfractions of LDL and HDL, inflammatory, oxidative stress and endothelial function parameters were evaluated.
3108967|NCT02305017|Experimental|Period 1 OPC + Paracetamol; Period 2 OPC|Period 1 BIA 9-1067 (Opicapone, OPC) + Paracetamol; Period 2 BIA 9-1067 (Opicapone, OPC)
3108968|NCT02305017|Experimental|Period 1 OPC; Period 2 OPC+ Paracetamol|Period 1 BIA 9-1067 (Opicapone, OPC) Period 2 BIA 9-1067 (Opicapone, OPC) + Paracetamol;
3108969|NCT02305238|Experimental|2 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
3108970|NCT02305238|Experimental|4 Weeks adjustment|Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
3108971|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 1|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108972|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 1|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108973|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 1|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: CM Formulation Period 2: TBM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108974|NCT02305277|Experimental|BIA 9-1067 5 mg Sequence 2|"volunteers received a single oral dose of 5 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108975|NCT02305277|Experimental|BIA 9-1067 25 mg Sequence 2|"volunteers received a single oral dose of 25 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108976|NCT02305277|Experimental|BIA 9-1067 50 mg Sequence 2|"volunteers received a single oral dose of 50 mg BIA 9-1067: Period 1: TBM Formulation Period 2: CM Formulation~CM - clinical micronized TBM - to-be-marketed"
3108977|NCT02305316|Experimental|BIA 9-1067 non-micronized - micronized|Each subject was orally administered with 50 mg OPC non-micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC micronized
3108978|NCT02305316|Experimental|BIA 9-1067 micronized - non-micronized|Each subject was orally administered 50 mg OPC micronized followed by a washout period of 14 days. After washout period each subject was orally administered with 50 mg OPC non-micronized
3108979|NCT02305329|Experimental|Group 1 BIA 9-1067 25 mg|Period 1 - 5x5 mg OPC Period 2 - 1x25 mg OPC
3108980|NCT02305329|Experimental|Group 2 BIA 9-1067 25 mg|Period 1 - 1x25 mg OPC Period 2 - 5x5 mg OPC
3108981|NCT02305329|Experimental|Group 1 BIA 9-1067 50 mg|Period 1 - 2x25 mg OPC Period 2 - 1x50 mg OPC
3108982|NCT02305329|Experimental|Group 2 BIA 9-1067 50 mg|Period 1 - 1x50 mg OPC Period 2 - 2x25 mg OPC
3108983|NCT02305381|Experimental|Semaglutide 0.5 mg/Week|
3108984|NCT02305381|Experimental|Semaglutide 1.0 mg/Week|
3108985|NCT02305381|Placebo Comparator|Semaglutide Placebo 0.5 mg/Week|
3108986|NCT02305381|Placebo Comparator|Semaglutide Placebo 1.0 mg/Week|
3108987|NCT02305446|Experimental|rMenB+OMV NZ|Subjects who received two doses of rMenB+OMV NZ according to a 0, 2-month schedule
3108988|NCT02305563|Experimental|Ulocuplumab + low dose Cytarabine|Ulocuplumab + low dose Cytarabine (LDAC) Phase 1 (escalation cohort) - closed for enrollment
3108989|NCT02305563|Experimental|Ulocuplumab Dose A + low dose Cytarabine|Ulocuplumab Dose A + low dose Cytarabine Phase 2 (expansion cohort)
3108990|NCT02305563|Experimental|Ulocuplumab Dose B + low dose Cytarabine|Ulocuplumab Dose B + low dose Cytarabine Phase 2 (expansion cohort)
3108991|NCT02305563|Other|low dose Cytarabine only|Low Dose Cytarabine only Phase 2 (expansion cohort)
3108992|NCT02305758|Experimental|Veliparib + modified FOLFIRI ± bevacizumab|Dosing of oral veliparib (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Modified FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle.
3108993|NCT02305758|Placebo Comparator|Placebo + FOLFIRI ± bevacizumab|Dosing of oral placebo (200 mg) began 2 days prior to the start of FOLFIRI and continued twice a day (BID) for a total of 7 consecutive days. At the discretion of the Investigator, bevacizumab (5 mg/kg) could be administered intravenously (IV) immediately preceding FOLFIRI. Standard FOLFIRI was administered as irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) immediately followed by fluorouracil 2400 mg/m^2 (46-hour continuous infusion ± 4 hours) on Day 1 of each 14-day cycle.
3108994|NCT02305797|Experimental|EDG004|EDG004 - Extended release lorazepam capsules
3108995|NCT02305797|Placebo Comparator|Placebo|Placebo
3108996|NCT02305849|Experimental|Peficitinib 100 mg|Participants received 100 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
3108997|NCT02305849|Experimental|Peficitinib 150 mg|Participants received 150 mg tablet of peficitinib orally once daily in combination with MTX for a period of 52 weeks.
3108998|NCT02305849|Placebo Comparator|Placebo|Participants who received placebo matching to peficitinib 100 mg or 150 mg orally once daily in combination with MTX until week 12 or 28 were switched to receive 100 mg or 150 mg tablet of peficitinib orally once daily in combination with MTX from week 12 or 28 to week 52.
3108999|NCT02305888|Experimental|LEO 43204, 0.018% once daily for 3 days|
3109000|NCT02305888|Experimental|LEO 43204, 0.037% once daily for 3 days|
3109001|NCT02305888|Experimental|LEO 43204, 0.1% once daily for 3 days|
3109002|NCT02306265|Other|DBT and FFDM|Subjects will undergo 2D breast imaging with full-field digital mammography (FFDM) device (active comparator) and 3D breast imaging with digital breast tomosynthesis (DBT) device (experimental).
3109003|NCT02306694|Experimental|Open label|Everyone receives Advate (antihemophilic factor) on Day 1 and 3.
3109004|NCT02306759|Experimental|Treatment|Ketamine 0.3mg/kg intravenous piggyback (IVPB) in 50ml NS over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
3109005|NCT02306759|Placebo Comparator|Placebo|Normal saline 50ml intravenous piggyback (IVPB) over 15 minutes Morphine 0.1mg/kg intravenous push (IVP) PRN at designated intervals
3109006|NCT02306850|Experimental|Pembrolizumab|Open-label non-randomized trial. All subjects will receive active drug (pembrolizumab).
3109007|NCT02306928||Piperacillin pharmacokinetics|Patients with suspected septic shock who are treated with piperacillin/tazobactam.
3109008|NCT02307123||HEMS treated patients|Patients whose airways were secured by the HEMS physician.
3109009|NCT02307266|Experimental|Standard of care + supplementary education|Subjects will receive supplementary patient educational material in addition to standard-of-care instructions.
3109010|NCT02307266|Experimental|Standard of care|Subjects will receive standard-of-care instructions only.
3109011|NCT02307266|Experimental|Standard of care + additional visits|Subjects will receive standard-of-care instructions, and two additional clinical visits.
3109012|NCT02307318|Other|SoftSeal Hemostatic Pad|This is a single arm study. All patients received the SoftSeal hemostatic pad for compression following elective or urgent coronary angiogram.
3109013|NCT02307370|Experimental|Turbo-Elite Atherectomy|
3109014|NCT02307513|Experimental|Placebo / Apremilast|Participants randomized to this arm will receive placebo tablets twice daily by mouth for the first twelve weeks followed by 52 weeks of 30 mg apremilast tablets twice daily by mouth.
3109015|NCT02307513|Experimental|Apremilast|Participants randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
3109016|NCT02307526|Experimental|Spinal Cord Injury|After being transferred onto a tilt table, subject with complete SCI will lie in a rested, supine position in which the study drug, pyridostigmine bromide (60 mg) will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
3109017|NCT02307552|Experimental|All patients|All patients in the study will receive a scan of their prostate with the novel UreScan machine. All scans will be evaluated in their accuracy of detecting cancer loci within the prostate as compared to histopathological reviews of the prostate post robotic prostatectomy.
3109018|NCT02307682|Experimental|Brolucizumab 3 mg|Single intravitreal (IVT) injection of brolucizumab ophthalmic solution administered as a 3 mg/50 microliter (μL) dose at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
3109019|NCT02307682|Experimental|Brolucizumab 6 mg|Single IVT injection of brolucizumab ophthalmic solution administered as a 6 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit
3109020|NCT02307682|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution administered as a 2 mg/50 μL dose at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
3109021|NCT02307838|Other|Phase 2 CFTY720D2201 (NCT02307838) participants|CFTY720D2201E2 participants did not receive any protocol specified treatment. The original D2201 study sites, who agreed to participate in this study, were required to locate their participants who were randomized in D2201 and asked them to return for a 10 year assessment, regardless of current treatment status.
3109022|NCT02307916|Experimental|FGF-2|FGF-2 given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
3109023|NCT02307916|Placebo Comparator|Placebo|Equal concentration of saline is given a minimum of 1 and maximum of 3 times within, approximately, 60 days.
3109024|NCT02308007|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
3109025|NCT02308007|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
3109026|NCT02308007|Active Comparator|Terconazole/metronidazole vaginal gel|One applicator full at bedtime
3109027|NCT02308020|Experimental|Part A Abemaciclib: HR+, HER2+ Breast Cancer|Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3109028|NCT02308020|Experimental|Part B Abemaciclib: HR+, HER2- Breast Cancer|"Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET).~Participants may continue to receive treatment until discontinuation criteria are met."
3132655|NCT03442829|Active Comparator|Non-sweet food consumption|Non-sweet breakfasts. Participants are asked to consume a non-sweet breakfast every day for three weeks (excepting on three days when outcomes will be assessed (days 0, 7 and 21, day 21 reported). All foods will be provided.
3132656|NCT03442868|Experimental|High frequency rTMS|High frequency rTMS will be applied to different neural loci based on the randomized sessions.
3132657|NCT03442933|Active Comparator|Road Cycling first, then Mountain Biking|First Intervention (3 hours: Road cycling), followed by a 7 days washout, and the second Intervention (3 hours: Mountain Biking).
3109029|NCT02308020|Experimental|Part C Abemaciclib: Surgical Resection|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3109030|NCT02308020|Experimental|Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3109031|NCT02308020|Experimental|Part E Abemaciclib: Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3109032|NCT02308020|Experimental|Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma|Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3109033|NCT02308033|Active Comparator|Metronidazole vaginal gel|One applicator full at bedtime
3109034|NCT02308033|Placebo Comparator|Gel vehicle|One applicator full at bedtime
3109035|NCT02308046|Active Comparator|Terconazole vaginal gel|One applicator full at bedtime
3109036|NCT02308046|Placebo Comparator|Gel vehicle|One applicator full at bedtime
3109037|NCT02308124|Experimental|Midodrine|Start midodrine 2.5mg bid, and then dose up to 5mg bid after one month if necessary.
3109038|NCT02308124|Experimental|Pyridostigmine|Start Pyridostigmine 30mg bid, and then dose up to 60mg bid after one month if necessary.
3109039|NCT02308124|Experimental|Midodrine + Pyridostigmine|Start midodrine 2.5mg bid+ Pyridostigmine 30mg bid, and then dose up to midodrine 5mg bid+ Pyridostigmine 60mg bid after one month if necessary.
3109040|NCT02308163|Placebo Comparator|Placebo|Participants were assigned to receive placebo to peficitinib once a day until week 12.
3109041|NCT02308163|Experimental|Peficitinib 100 mg|Participants were assigned to receive peficitinib 100 mg/day for 52 weeks.
3109042|NCT02308163|Experimental|Peficitinib 150 mg|Participants were assigned to receive peficitinib 150 mg/day for 52 weeks.
3109043|NCT02308163|Active Comparator|Etanercept|Participants were administered 50 mg of subcutaneous etanercept once weekly for 52 weeks.
3109044|NCT02308189|Active Comparator|Exercise|Low load resistance exercise training
3109045|NCT02308189|Experimental|Exercise with blood flow restriction|Low load resistance exercise training with blood flow restriction
3109046|NCT02308228|Experimental|Metformin|Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.
3109047|NCT02308228|Placebo Comparator|Placebo, Sugar Pill|Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.
3109048|NCT02308371|Experimental|Prospective|Patients in this arm will have fluid given based on standard clinical data (blood pressure, heart rate, lactate level, urine output) in addition to information provided by automated pulse pressure variation (PPV). PPV will be followed for first 48 hours after recruitment to the study. Fluid (normal saline, albumin 5%, hetastarch per the clinician preference) will be given in 5cc/kg increments for PPV> 13 (in addition to standard clinical data) until PPV < 13.
3109049|NCT02308371|No Intervention|Retrospective|Patients in this arm were previously admitted to the PICU and were given fluid based on standard clinical data. PPV was not used to guide therapy in this group of patients.
3109050|NCT02308501|Active Comparator|Lastacaft ®|One drop Lastacaft ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
3109051|NCT02308501|Placebo Comparator|Tears Naturale ®|One drop Tears Naturale ® in right eye or left eye based on randomization list once on Day 1 and once on Day 2
3109052|NCT02308540|Experimental|Adult SIILPCV10|Single dose of SIILPCV10 on day 0
3109053|NCT02308540|Active Comparator|Adult Pneumovax 23|Single dose of Pneumovax 23 on day 0
3109054|NCT02308540|Experimental|Toddler SIILPCV10|Single dose of SIILPCV10 on day 0
3109055|NCT02308540|Active Comparator|Toddler Prevenar 13|Single dose of Prevenar 13 on day 0
3109056|NCT02308540|Experimental|Infants SIIL PCV10|A three-dose series of SIILPCV10 on day 0, day 28, and day 56
3109057|NCT02308540|Active Comparator|Infants Prevenar 13|A three-dose series of Prevenar 13 on day 0, day 28, and day 56
3109058|NCT02308540|Experimental|Infant Booster Dose SIILPCV 10|One dose of SIILPCV 10 at 9 months of age
3109059|NCT02308540|Active Comparator|Infant Booster Dose Prevenar 13|One dose of SIILPCV 10 at 9 months of age
3109060|NCT02308696|Experimental|Peer-to-peer support (non-randomized)|225 older adults that are currently receiving peer-to-peer support
3109061|NCT02308696|Active Comparator|Standard Services (non-randomized)|225 older adults will continue receiving standard community services
3109062|NCT02308748|Active Comparator|Dofetilide|Dofetilide alone arm
3109063|NCT02308748|Active Comparator|Dofetilide + Mexiletine|Dofetilide combined with mexiletine
3109064|NCT02308748|Active Comparator|Dofetilide + Lidocaine|Dofetilide combined with lidocaine
3109065|NCT02308748|Active Comparator|Moxifloxacin + Diltiazem|Moxifloxacin with and without diltiazem.
3109066|NCT02308748|Placebo Comparator|Placebo|Placebo (#2 gelcap and intravenous saline)
3109067|NCT02309099|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
3109068|NCT02309112|Experimental|Yoga Group A: Minimum Exposure|The minimum-exposure yoga package, this intervention included 45-minutes of contact time with a trained yoga professional. In Week 1, this session included a 30-minute introductory session focussing on pranayama (breathing techniques), as well as a brief introduction to available community-based and online yoga to encourage a safe home-based practice (15-minutes). Financial subsidy, compensation or special promotion of any particular yoga was not provided. Participants were invited to stay for a social discussion following the yoga class.
3109069|NCT02309112|Experimental|Yoga Group B: Medium Exposure|The medium-exposure yoga package, this intervention included the components of Group A, with an additional 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were then invited to stay and ask questions following the yoga class. A pre-paid online yoga membership to http://www.myyogaonline.com was offered for the duration of the study (Weeks 1 to 4). In addition to this, one 120-minute workshop to further develop yoga pranayama, dhyana and asana training was administered by an expert instructor during Week 2 or 3.
3109070|NCT02309112|Experimental|Yoga Group C: Maximum Exposure|The maximum-dose yoga package, this intervention includes the components of Group A, with the same 30-minute orientation and safety training of how to practice yoga dhyana (meditation techniques) and asana (physical postures) in Week 1. Participants were invited to stay and ask questions following the yoga class. As in Group B, a pre-paid online yoga membership to http://www.myyogaonline.com was also provided for the duration of the study (Weeks 1 to 4). Participants were then invited to attend three 60-minute yoga group classes led by an expert yoga instructor per week (Weeks 1 to 4). These yoga sessions were held in a clinical setting in proximity to their treatment location and delivered at no cost to the patient.
3109071|NCT02309138|Active Comparator|3 hour 100 gm OGTT (CC Criteria)|Gestational diabetes screening with fasting 3 hour 100 gm. Receive a fasting 3 hour 100 gram oral glucose tolerance test and are diagnosed based on the Carpenter Coustan Criteria: a 50 gm Glucose tolerance test of >130 + fasting 3 hour 100 gram oral glucose tolerance test with two or more values greater than the following diagnostic threshold: Fasting 95, 1-hour 180, 2-hour 155, or 3 hour 140 mg/dL . A positive criteria will be diagnostic for gestational diabetes.
3109072|NCT02309138|Active Comparator|2 hr 75 gm OGTT (IADPSG Criteria)|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gm oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
3109073|NCT02309294|Experimental|Healthy Subject|Occlusive patches applied each day for 14 days for each intervention (Experimental: Novel lubricant Miami w/ fragrance, Experimental: Novel lubricant Miami no fragrance, KY Liquid lubricant, Astroglide Gel lubricant, Wet Platinum lubricant).
3109074|NCT02309359|Placebo Comparator|Placebo q2w + MTX|Placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
3109075|NCT02309359|Experimental|ALX-0061 75 mg q4w + MTX|ALX-0061 75 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
3109076|NCT02309359|Experimental|ALX-0061 150 mg q4w + MTX|ALX-0061 150 mg every 4 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
3109077|NCT02309359|Experimental|ALX-0061 150 mg q2w + MTX|ALX-0061 150 mg every 2 weeks + placebo every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24. The last study drug administration was at the Week 22 visit.
3109078|NCT02309359|Experimental|ALX-0061 225 mg q2w + MTX|"ALX-0061 225 mg every 2 weeks + MTX (at a stable dose and route) from baseline through Week 24.~The last study drug administration was at the Week 22 visit."
3109079|NCT02309372|Experimental|Cognitive Behavioral Therapy (CBT)|Those assigned to the CBT arm will undergo therapy with the Beating the Blues (BtB) computerized intervention.
3109080|NCT02309372|No Intervention|Usual Care|No specific depression care will be provided through this study for those assigned to this arm. However, the participant's caregiver may choose to provide depression treatment outside of this trial.
3109081|NCT02309411|Experimental|Rivaroxaban|Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily
3109082|NCT02309489|Experimental|Intervention|"Receive standard maternity care~Woman and partner attend one extra couple counselling session during pregnancy (A)~Partner attends one group education session for men (B)~Partner participates in pre-discharge consultation (C)"
3109083|NCT02309489|No Intervention|Control|"Receive standard maternity care~No active encouragement of partner involvement, no extra sessions offered"
3109084|NCT02309515|Experimental|Arm I (lenalidomide, pneumococcal 13-valent conjugate vaccine)|Patients receive lenalidomide PO QD on days 1-42 and pneumococcal 13-valent conjugate vaccine IM on day 15.
3109085|NCT02309515|Active Comparator|Arm II (pneumococcal 13-valent conjugate vaccine)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.
3109086|NCT02309723|Experimental|Positive beta amyloid findings|Beta amyloid imaging results indicated a positive finding.
3109087|NCT02309723|Experimental|Negative beta amyloid findings|Beta amyloid imaging results indicated a negative finding.
3109088|NCT02309723|No Intervention|No beta amyloid information|
3109089|NCT02309944|Active Comparator|Standard Wound Closure|Standard surgical closure of the fascia and skin.
3109090|NCT02309944|Experimental|Negative Pressure Wound Therapy|Standard surgical closure as used by the standard of care group plus placement of the Prevena™ Incision Management System over the closed incision.
3109091|NCT02310100|Experimental|TactiCath Quartz|TactiCath Quartz treatment
3109092|NCT02310126|Active Comparator|etafilcon A(sphere)/etafilcon A(multi-focal)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (sphere) contact lens first and then the etafilcon A (multi-focal) contact lens second.
3109093|NCT02310126|Active Comparator|etafilcon A(multi-focal)/etafilcon A(sphere)|Subjects were randomized to one of two lens wear sequences. subjects randomized to this sequence received etafilcon A (multi-focal) contact lens first and then the etafilcon A (sphere) contact lens second.
3109094|NCT02310568|Experimental|PF 06372865 2.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for 4 weeks (Stage 1), followed by placebo 2 times daily for 4 weeks (Stage 2).
3109095|NCT02310568|Experimental|PF 06372865 7.5 mg BID then placebo.|PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 1), followed by placebo (2 times daily) for 4 weeks (Stage 2).
3109096|NCT02310568|Experimental|Placebo then PF 06372865 2.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for 4 weeks
3109097|NCT02310568|Experimental|Placebo then PF 06372865 7.5 mg BID.|Placebo 2 times daily for 4 weeks (Stage 1), followed by PF 06372865 2.5 mg tablet 2 times daily for one week, then PF 06372865 7.5 mg tablet 2 times daily for 3 weeks (Stage 2).
3109098|NCT02310568|Placebo Comparator|Placebo followed by placebo.|Placebo 2 times daily for 4 weeks (Stage 1) followed by Placebo 2 times daily for 4 weeks (Stage 2).
3109099|NCT02310581|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual spray three times daily (TID) and placebo-matching buprenorphine sublingual spray once daily (QD) for two days.
3109100|NCT02310581|Experimental|Buprenorphine 1.0 mg BID|Participants received buprenorphine 1.0 mg sublingual spray twice daily (BID) and placebo-matching buprenorphine sublingual spray BID for two days.
3109101|NCT02310581|Experimental|Buprenorphine 1.0 mg TID|Participants received buprenorphine 1.0 mg sublingual spray TID and placebo-matching buprenorphine sublingual spray QD for two days.
3109102|NCT02310581|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray four times daily for two days.
3109103|NCT02310646|Active Comparator|Treatment group 1|Day 1 to 7: LEO 90100 aerosol foam Day 8 to 14: Daivobet® gel
3109104|NCT02310646|Active Comparator|Treatment group 2|Day 1 to 7: Daivobet® gel Day 8 to 14: LEO 90100 aerosol foam
3109105|NCT02310672|Experimental|Macitentan|All patients take open-label macitentan 10mg o.d.
3109106|NCT02310750|Experimental|PF-06700841 Oral Solution/Suspension|
3109107|NCT02310750|Experimental|PF-06700841 Tablet|
3109108|NCT02310750|Placebo Comparator|Placebo|Oral placebo comparator for the healthy subject single and multiple ascending dose periods, and the psoriasis multiple dose period. No placebo used for the bioavailability investigation.
3109109|NCT02310763|Experimental|PF-06252616|3 dose levels (5mg/kg, 20mg/kg and 40 mg/kg) of IV infused PF-06252616 will be investigated within each subject
3109110|NCT02310763|Placebo Comparator|Placebo|Matching Placebo
3109111|NCT02310776|Other|Automated & Handheld breast US exams|"Automated breast ultrasound exam: 3D supine automated breast ultrasound scanner.~Handheld breast ultrasound exam: High-resolution handheld breast ultrasound."
3109112|NCT02310789|Experimental|Ivacaftor|Participants will receive ivacaftor orally for 3 days, followed by 35 days off drug. Participants will repeat this cycle then receive ivacaftor for 3 additional days. For sweat testing, participants will receive β-adrenergic cocktail to stimulated sweating, at both 1% stimulation strength and full stimulation strength. Each participant will also receive pilocarpine nitrate 5% administered by Macroduct sweat stimulator device. Sweat stimulation testing will be done on- and off-ivacaftor.
3109113|NCT02310906|Experimental|Part 1: SRP-4053|Patients will receive SRP-4053 (golodirsen) intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
3109114|NCT02310906|Placebo Comparator|Part 1: Placebo|Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.
3109115|NCT02310906|Experimental|Part 2: SRP-4053|All eligible patients from Part 1, as well as new patients, will receive SRP-4053 (golodirsen) 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.
3109116|NCT02310906|No Intervention|Part 2: Untreated Group|Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144. The untreated patients are not considered as control group.
3109117|NCT02311153|Active Comparator|Endotracheal intubation|Endotracheal intubation for airway management and ventilation during sinonasal surgical procedure
3109118|NCT02311153|Experimental|Laryngeal mask airway|Laryngeal mask for airway management and ventilation during sinonasal surgical procedure
3109119|NCT02311309||control|Patients with either transfusion with pre ordered packed red blood cells or hemoglobin concentration > 8 g/dL.
3109120|NCT02311309||unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or hemoglobin concentration < 8 g/dL.
3109121|NCT02311361|Experimental|Durvalumab + 8 Gray (Gy) in 1 fraction|Cohort 1/Dose Level A1 Durvalumab + 8 Gray (Gy) in 1 fraction
3109122|NCT02311361|Experimental|Durvalumab +5 Gy in 5 fractions|Cohort 2/Dose Level A2 Durvalumab +5 Gy in 5 fractions
3109123|NCT02311361|Experimental|Tremelimumab + 8 Gy in 1 fraction|Cohort 3/Dose Level B1 (was removed with Amendment A) Tremelimumab + 8 Gy in 1 fraction
3109124|NCT02311361|Experimental|Tremelimumab + 5 Gy in 5 fractions|Cohort 4/Dose Level B2 (was removed with Amendment A) Tremelimumab + 5 Gy in 5 fractions
3109125|NCT02311361|Experimental|Durvalumab +Tremelimumab + 8 Gy in 1 fraction|Cohort C/ Dose Level C1 Durvalumab +Tremelimumab + 8 Gy in 1 fraction
3109126|NCT02311361|Experimental|Durvalumab +Tremelimumab +5 Gy in 5 fractions|Cohort C/Dose Level C2 Durvalumab +Tremelimumab +5 Gy in 5 fractions
3109127|NCT02311478|Experimental|T380A Copper IUD|All participants will receive a T380A copper intrauterine device when enrolled. They can continue using the device for as long as they wish. The study will be completed when 6 months of prospective bleeding data has been collected.
3109128|NCT02311881|Experimental|Paracetamol 2000 mg twice daily (BID)|Participants will be instructed to take two active paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3132658|NCT03442933|Active Comparator|Mountain Biking first, then Road Cycling|First Intervention (3 hours: Mountain Biking), followed by a 7 days washout, and the second Intervention (3 hours: Road cycling).
3109129|NCT02311881|Active Comparator|Paracetamol 1330 mg thrice daily (TID)|Participants will be instructed to take two active paracetamol 665 mg SR tablets orally thrice daily (with 6-8 hours between adjacent doses) and two placebo to match paracetamol 1000 mg SR tablets orally twice daily (with 10-12 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3109130|NCT02311881|Placebo Comparator|Placebo|Participants will be instructed to take two placebo to match paracetamol 1000 mg SR tablets twice daily (with 10-12 hours between adjacent doses) and two placebo to match paracetamol 665 mg SR tablets thrice daily (with 6-8 hours between adjacent doses) orally with approximately 8 ounces (~ 240 mL) of water/dose for 12 weeks.
3109131|NCT02311894|Experimental|Somatropin|Children will receive daily SC injections of somatropin at a dose of up to 0.043 milligrams per kilogram per day (mg/kg/day) for 1 year.
3109132|NCT02311907|Experimental|Arm I (glutathione, carboplatin)|Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
3109133|NCT02311907|Placebo Comparator|Arm II (placebo, paclitaxel)|Patients receive placebo IV over 15 minutes, paclitaxel* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
3109134|NCT02311933|Experimental|Arm I (z-endoxifen hydrochloride)|Patients receive z-endoxifen hydrochloride PO on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3109135|NCT02311933|Experimental|Arm II (tamoxifen citrate)|Patients receive tamoxifen citrate PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression and bone metastases may cross over to Arm I and receive z-endoxifen hydrochloride starting no later than 28 days after documentation of disease progression.
3109136|NCT02311972|Active Comparator|Control - Standard of Care|Infants in the standard of care group will receive no study interventions other than study recorded axillary temperatures on admission, and at 1, 4, 8 and 24 hours. Infants will receive standard delivery room stabilization and NICU stabilization. Infants in the control group will receive a feeding tube as standard of care, and the standard issue feeding tube used in the Intensive Care Nursery does not have the capability to record or display esophageal temperatures. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age for each infant in both groups on a data sheet at the bedside. These data will be entered into a RedCap data base created for the study.
3109137|NCT02311972|Active Comparator|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|The nurse will insert an InnerSense temperature sensor/feeding tube per normal standards as soon after birth as possible, during delivery room stabilization. Nurses will record an axillary temperature upon admission to the NICU, and at 1, 4, 8 and 24 hours of age. The InnerSense tube will be attached to the infant's bedside monitor to continuously display esophageal temperatures. The tube will stay in place until the infant is 24 hours of age. Central body temperature will be displayed continuously for care-providers in the delivery room, through transport from the birthing center to the NICU and through stabilization. Infants will have a thermistor placed on the abdominal skin with standard skin tape once admitted in the NICU. This thermistor will be attached to a Squirrel SQ2010 (Grant Instruments) temperature monitor/data logger to collect abdominal temperatures every minute for the first 24 hours of life. All temperatures entered into the study database.
3109138|NCT02312063|Experimental|Sitagliptin|Sitagliptin 50 mg a day for 16 weeks
3109139|NCT02312063|Active Comparator|Glimepiride|Glimepiride 0.5 mg a day for 16 weeks
3109140|NCT02312154|Experimental|treated side (Restylane vital)|"We injected staabilized hyaluronic acid (HA)-based gel of nonanimal origin on the left side of face.~(We performed split face study)"
3109141|NCT02312154|No Intervention|untreated side (control)|We did nothing on the right side of face and we compared the results on same participants
3109142|NCT02312206|Experimental|NEOD001|24 mg/kg (maximum dose of 2500 mg) of NEOD001 administered once every 28 days.
3109143|NCT02312206|Placebo Comparator|Placebo|Placebo will be administered as a 250 mL bag of normal saline once every 28 days.
3109144|NCT02312219||Low Dose Methotrexate|Subjects will take 1 mg folic acid once daily plus 5 mg methotrexate (MTX) . If clinically stable at the week 1 visit, the dose of MTX will be increased to 10 mg once weekly through week 12. For subjects who remain clinically stable on 10 mg MTX or placebo through the week 12 visit, the dose of MTX will be increased to 15 mg once weekly through week 24. If the subject does not meet the criteria for dose escalation at the week 1 or 12 study visit, then the subject will remain on his/her current dose until the next study visit at which time he/she will be re-evaluated for dose escalation.
3109145|NCT02312219||Placebo|Subjects will take 1 mg folic acid once daily plus placebo once weekly. If clinically stable at weeks 1 and 12, the number of placebo tablets will be increased in a manner matching those on the MTX.
3109146|NCT02312258|Experimental|Placebo|Ixazomib placebo-matching capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib placebo-matching capsules, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
3109147|NCT02312258|Placebo Comparator|Ixazomib|Ixazomib 3 mg, capsule, orally, once on Days 1, 8 and 15 in a 28-day cycle for Cycles 1 through 4. Ixazomib 3 or 4 mg, capsules, orally, once, on Days 1, 8 and 15 in a 28-day cycle for Cycles 5 through 26 (Up to data cut-off 12 August 2019).
3109148|NCT02312310|Placebo Comparator|F 0 mg|daily consumption of capsules containing 0 mg cocoa flavanol for 12 weeks
3109149|NCT02312310|Active Comparator|F 260 mg|"daily consumption of capsules containing 260 mg* cocoa flavanol for 12 weeks~*see note in Record Log regarding the change in the method of assessment of cocoa flavanol content of the capsules"
3109150|NCT02312310|Active Comparator|F 510 mg|daily consumption of capsules containing 510 mg cocoa flavanol for 12 weeks
3109151|NCT02312310|Active Comparator|F 770 mg|daily consumption of capsules containing 770 mg cocoa flavanol for 12 weeks
3109152|NCT02312622|Experimental|Cohort A - Pegylated Irinotecan to treat NSCLC|Patients with non-small cell lung carinoma (NSCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3109153|NCT02312622|Experimental|Cohort B - Pegylated Irinotecan to treat SCLC|Patients with small cell lung carinoma (SCLC) will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3109154|NCT02312622|Experimental|Cohort C - Pegylated Irinotecan to treat mBC|Patients with metastatic breast cancer (MBC) to brain will receive pegylated irinotecan intravenously (IV) over 90 minutes every 21 days in the absence of disease progression or unacceptable toxicity.
3109155|NCT02312687|Experimental|KRN23|KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.
3109156|NCT02312713|Active Comparator|Standard Physical Therapy|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
3109157|NCT02312713|Experimental|Internet Based Exercise Training|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
3109158|NCT02312713|No Intervention|Wait list control|no intervention
3109159|NCT02312726||Epidural group|Participants who elect to have an epidural anesthesia during labor, delivery and postplacental IUD insertion
3109160|NCT02312726||Non Epidural group|Participants who elect not to have epidural anesthesia during labor, delivery and postplacental IUD insertion
3109161|NCT02312739|Active Comparator|Vicodin, Lorazepam and Oxygen|"Patients in this group will receive the Standard Oral Pain Medications consisting of Vicodin and Lorazepam, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Oxygen via scented mask will also given.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
3109162|NCT02312739|Experimental|Placebo pills and Nitrous Oxide|"Patients in this group will receive two placebo pills, as well as intramuscular ketorolac at least 30 minutes prior to the procedure. Nitrous oxide will be administered during the procedure via scented mask.~All participants randomized to this group will undergo in-office transcervical sterilization (Essure® procedure ) using standard technique."
3109163|NCT02312765|Experimental|Intervention|Study participants will receive a tablet computer with the AirCare system.
3109164|NCT02312765|No Intervention|Control|Standard care
3109165|NCT02312856|Experimental|PulseRider aneurysm|Endovascular treatment of intracranial aneurysms
3109166|NCT02312882|Experimental|Tofacitinib|Participants will receive tofacitinib for 3 months.
3109167|NCT02312934|Experimental|Transdermal Nicotine|"Nicotine will be delivered by a transdermal patch delivery system for topical application. Each patch will contain approximately 1.75mg nicotine/cm2, and releases 7, and 14mg of nicotine, respectively, over 24 hours. Patches will be applied for 16 hours per day. Participants will be titrated over the course of the 6-week treatment period in order to avoid initial side effects as follows:~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
3109168|NCT02312934|Placebo Comparator|Placebo|"Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.~Week 1: ½ 7 mg patch per day, Week 2: 7 mg patch per day, Weeks 3-4: ¾ 14 mg patch per day, Weeks 5-6: 14 mg per day, Weeks 7-8: Treatment withdrawal"
3109169|NCT02312986|Experimental|Fecal microbiota transplantation|Subjects will receive 150mL of fecal microbiota product via enema.
3109170|NCT02313155|Experimental|TAK-850 0.5 mL (subcutaneous)|Single subcutaneous injection of TAK-850
3109171|NCT02313155|Experimental|TAK-850 0.5 mL (Intramuscular)|Single intramuscular injection of TAK-850
3109172|NCT02313233|Experimental|Umooze|Tablet oral dosage. Astragalus radix Extracts 480 mg+ Soy extracts 20 mg
3109173|NCT02313233|Placebo Comparator|Placebo|Cornstarch.
3109174|NCT02313454|Experimental|Intranasal Application|Intranasal Tear Neurostimulator device, intranasal application for approximately 3 minutes on Day 0 when the participant experienced an Ocular Discomfort Score (ODS) ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
3109175|NCT02313454|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device, extranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥3 at 2 or more consecutive time points in at least one eye during CAE exposure.
3109176|NCT02313506|Active Comparator|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT. These three components of the intervention will be delivered to the participants in Month 1. At the end of the education session, the PT will help participants set personal activity goals. In Month 1, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute weekly phone calls and progressively modify their activities. In Month 2, they will continue using the Fitbit and have access to a PT via email as needed, but no weekly phone calls.
3109177|NCT02313506|Placebo Comparator|Delayed Intervention Group|Same intervention with a 1 month delay: The full intervention will be initiated in Month 2 with a brief education session, use of Fitbit Flex, and counselling by a physiotherapist. The trial will conclude at the end of Month 2.
3109178|NCT02313558|Experimental|Dentifrice Containing Ilex Rotunda Thunb|use the dentifrice containing Ilex Rotunda Thunb to brush teeth twice daily for 12 weeks
3109179|NCT02313558|Placebo Comparator|control dentifrice|use the control dentifrice to brush teeth twice daily for 12 weeks
3109180|NCT02313597|Placebo Comparator|SETON|Silk suture will be used as SETON
3109181|NCT02313597|Experimental|VAAFT|Video assisted anal fistula treatment
3109182|NCT02313675|Experimental|IV tylenol|One time intra-operative IV acetaminophen administration
3109183|NCT02313675|Experimental|IV toradol|One time intra-operative IV ketorolac thromethamine administration
3109184|NCT02313675|Experimental|IV tylenol/toradol combination|One time intra-operative IV combination of acetaminophen/ketorolac administration
3109185|NCT02313675|Placebo Comparator|saline|One time intra-operative 50ml IV normal saline administration
3109186|NCT02313766|No Intervention|spontaneous breathing (SB)|"preoxygenation through a face mask firmly applied and connected to the anaesthesia machine delivering a fresh gas flow of 12 l min-1. The inspired O2 concentration was set at 100%.~End of preoxygenation FEO2=90%"
3109187|NCT02313766|Experimental|positive pressure ventilation (PPV)|"PPV : positive pressure ventilation : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) without PEEP.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=0 cmH2O End of preoxygenation FEO2=90%"
3109188|NCT02313766|Experimental|PPV + PEEP|"PEEP : PPV + PEEP : preoxygenation with noninvasive positive inspiratory pressure ventilation (12 cmH2O) with PEEP at 6 cmH2O.~Preoxygenation through a face mask firmly applied and connected to the anaesthesia machine - non invasive inspiratory ventilation mode - inspiratory trigger sensitivity was set at -2 l min-1, the adjustable pressure limiting valve was opened, and maximal airway pressure was limited at 18 cmH2O - PEEP=6 cmH2O End of preoxygenation FEO2=90%"
3109189|NCT02313909|Experimental|Rivaroxaban|Rivaroxaban 15 mg orally once daily
3109190|NCT02313909|Active Comparator|Aspirin|Aspirin 100 mg orally once daily
3109191|NCT02314000|Active Comparator|SCS starting with supra-perception|Precision or Precision Spectra Spinal Cord Stimulator System programmed at supra-perception followed by sub-perception SCS
3109192|NCT02314000|Experimental|SCS starting with sub-perception amplitude|Precision or Precision Spectra Spinal Cord Stimulator System programmed at sub-perception followed by supra-perception SCS
3109193|NCT02314026|Experimental|Suspected NASH|13C-Octanoate, 13C-Methacetin
3109194|NCT02314052|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
3109195|NCT02314104|Active Comparator|Treatment TAP, placebo local injection|Treatment TAP block was 30 mL 0.5% ropivacaine bilaterally. Placebo local injection was 2 mL of 0.9% normal saline at each port site.
3109196|NCT02314104|Active Comparator|Placebo TAP, treatment local injection|Placebo TAP was 30 mL of 0.9% normal saline bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
3109197|NCT02314104|Active Comparator|Treatment TAP, treatment local injection|Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally. Treatment local injection was 2 mL of 0.5% ropivacaine at each port site.
3109198|NCT02314117|Experimental|Ramucirumab + Cisplatin + Capecitabine|8 milligrams/kilogram (mg/kg) ramucirumab given intravenously (IV) on days 1 and 8 in combination with 80 mg/square meter (m^2) cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day fluorouracil (5-FU) IV on days 1 to 5 of each 21-day cycle.
3109199|NCT02314117|Active Comparator|Placebo + Cisplatin + Capecitabine|Placebo for blinding given IV on days 1 and 8 in combination with 80 mg/m^2 cisplatin given IV on day 1 of each 21-day cycle (for up to 6 cycles) and 1000 mg/m^2 capecitabine given orally twice a day on days 1 through 14. Participants that were unable to take capecitabine will be given 800 mg/m^2/day 5-FU IV on days 1 to 5 of each 21-day cycle.
3109200|NCT02314143|Experimental|Dabrafenib followed by combination therapy|Eligible subjects will receive dabrafenib 150 milligrams (mg) twice a day (BID) continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
3109201|NCT02314143|Experimental|Trametinib followed by combination therapy|Eligible subjects will receive trametinib 2 mg per day continuously during 8 weeks of monotherapy treatment followed by the combination of trametinib 2 mg once daily with dabrafenib 150 mg BID until disease progression, death or unacceptable toxicity.
3109202|NCT02314143|Experimental|Combination therapy|Eligible subjects will receive trametinib 2 mg per day plus dabrafenib 150 mg BID continuously until disease progression, death or unacceptable toxicity.
3109203|NCT02314247|Experimental|Selinexor|60 mg dose (equivalent to ~35 mg/m²)
3109204|NCT02314260||Labour Induction|80 primigravidas undergoing bishop score calculation, trans-vaginal ultrasound assessment of cervical length &, Modified bishop score calculation, then induction of labour at our hospital.
3109205|NCT02314403|Experimental|Combined Bone Marrow and Kidney Transplantation|Recipients will receive a conditioning regimen that starts with Rituximab on day -7 (and days -2, 5, 12), Whole Body Irradiation 1.5 Gy x2 on study days -6 and -5, followed by ATG on Days -2, -1, 0. Belatacept 10mg/kg on Days 0, 3, 10, 17, 24, 38, 52. Thymic irradiation (7 Gy) will be given on study day -1, and combined renal and bone marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be administered on study days -1 through 60, and then tapered if weaning criteria are met.
3109206|NCT02314520|Active Comparator|PICC|Patients randomly assigned to receive a peripherally inserted central catheter and they will be monitored for either having a complication or no complication.
3109207|NCT02314520|Active Comparator|CVC|Patients randomly assigned to receive a centrally inserted central catheter and they will be monitored for either having a complication or no complication.
3109208|NCT02314546|Placebo Comparator|Saline placebo|saline placebo
3109209|NCT02314546|Active Comparator|Nasal Midazolam only|Nasal Midazolam only - Patients received 0.2 mg/kg of intranasal midazolam
3109210|NCT02314546|Active Comparator|Midazolam and Xylocaine|Midazolam Plus Xylocaine - Patients received 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam
3109211|NCT02314598||No treatment|
3109212|NCT02314637|Experimental|Teneligliptin|Teneligliptin for 52 weeks
3109213|NCT02314637|Experimental|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
3109214|NCT02314689|Experimental|IV citrulline|IV citrulline 20 mg/kg bolus with dose escalation of 10 mg/kg to target citrulline concentration of 100 µmol/L with a maximum dose of 60 mg/kg.
3109215|NCT02314728|Active Comparator|Misoprostol|Those randomized to the prostaglandin arm will receive PGE1 (misoprostol) in a dose of 25mcg placed vaginally every 4 hours as per hospital protocol.
3109216|NCT02314728|Active Comparator|Oxytocin Alone|Those randomized to the oxytocin arm will receive infusion of oxytocin, which will then be titrated per hospital protocol or until adequate contractions.
3109217|NCT02314780|Experimental|Heme arginate (high dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 3 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
3109218|NCT02314780|Experimental|Heme arginate (low dose)|24 hours prior to the planned surgical aortic valve replacement, heme arginate at a dose of 1 mg/kg diluted to 110ml with 0.9% sodium chloride was administered at a single intravenous infusion using an infusion pump.
3109219|NCT02314780|Placebo Comparator|Placebo|24 hours prior to the planned surgical aortic valve replacement, subjects received a single intravenous infusion of an equivalent volume of 0.9% sodium chloride solution.
3469208|NCT03888820|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
3469209|NCT03888820|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL applied to low back, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the low back from the lower ribs to the SI joint and iliac crests. The participant will wait 15 minutes, rate the pain in their low back.
3469210|NCT03888677|Active Comparator|Standard|Standard FEC (F600, E60, C600) every 3rd week.
3469211|NCT03888677|Experimental|Tailored|Tailored FEC (F600, E75-90, C900-1200) every 3rd week.
3469212|NCT03888677|Active Comparator|Registered|Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.
3109230|NCT02314936|Experimental|Litesse powder containing 12 g polydextrose|12 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3109231|NCT02314936|Experimental|Litesse powder containing 8 g polydextrose|8 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3109232|NCT02314936|Experimental|Litesse powder containing 4 g polydextrose|4 g of polydextrose, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3109233|NCT02314936|Placebo Comparator|Placebo|Maltodextrin, 1 sachet of powder mixed with water taken daily with breakfast for 2 weeks
3109234|NCT02315170|Experimental|intraocular injection guide|novel intraocular injection guide is a long, tubular structure consisting of a non-moldable material with a single internal opening. There is a 2x2 square hole located at the bottom of the device where the needle exits the guide and enters the eye
3109235|NCT02315170|Active Comparator|standard lid speculum|Standard wire eyelid speculum
3109236|NCT02315352|Experimental|Period 1 and 2|A-B or B-A where A: L-PZQ ODT (MSC 2499550A) put on tongue; B: Rac-PZQ ODT (MSC1028703A) put on the tongue
3109237|NCT02315352|Experimental|Period 3, 4 and 5|C-D-E; C-E-D; D-E-C; D-C-E; E-C-D; E-D-C where C: L-PZQ ODT (MSC 2499550A) dispersed in water; D: Rac-PZQ ODT (MSC1028703A) dispersed in water; E: Cesol® 150 mg crushed in water
3109238|NCT02315430|Experimental|Treatment (cabozantinib-s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3109239|NCT02315534|Experimental|Arm A|Patients for whom surgery is recommended as part of treatment for recurrent Glioblastoma.
3109240|NCT02315534|Experimental|Arm B|Patients for whom surgery is not recommended as part of the treatment for recurrent Glioblastoma.
3109241|NCT02315560|Experimental|Tibial Nerve Stimulation|The subject/parents will be instructed to record a night-time voiding log specifying the number of incontinent episodes per night. This log is included in the Institutional Review Board application. Subjects/parents will fill out the log for a two week period prior to foot stimulation to determine a baseline average of nocturnal enuresis episodes, during the two week foot stimulation period to measure any acute effect on nocturnal enuresis episodes and finally during the two weeks after stimulation to evaluate any post-stimulation residual benefit
3109242|NCT02315625|Experimental|1/ Arm 1 Sunitinib|Sunitinib
3109243|NCT02315625|Experimental|2/ Arm 2 Everolimus|Everolimus
3109244|NCT02315664|Experimental|Immediate Intervention Group|Education session, Fitbit Flex, and remote coaching by a PT: These three components of the intervention will be delivered to the participants in Month 1 and 2. At the end of the education session, the PT will help participants set personal activity goals. In Month 1 and 2, participants will use the Fitbit Flex. The PT will review the progress with participants via 20-minute bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will keep the Fitbit and continue to use it with access to a PT via email as needed. In addition, they will receive a monthly e-newsletter about arthritis research that is not related to physical activity.
3109245|NCT02315664|Experimental|Delayed Intervention Group|Same intervention with a 2 month delay: The Delayed Intervention Group (control group) will receive the same monthly e-newsletter in Months 1-2. The full intervention will be initiated in Month 3 with a brief education session, use of Fitbit Flex, and counseling by a physiotherapist. In Month 4, they will continue the intervention without the PT phone calls. Participants will keep the Fitbit for Month 5-6, and have email access to PT as needed.
3109246|NCT02315703|Experimental|Group 1|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + HIV type 1 Clade C glycoprotein 140 drug product (gp140 DP) vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
3109247|NCT02315703|Experimental|Group 2|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
3109248|NCT02315703|Experimental|Group 3|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + placebo injection at Week 24 and 48.
3109249|NCT02315703|Experimental|Group 4|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by modified Vaccinia Ankara (MVA)-Mosaic vaccine + gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant at Week 24 and 48.
3109250|NCT02315703|Experimental|Group 5|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + gp140 DP vaccine containing 50 mcg of total protein mixed with adjuvant at Week 24 and 48.
3109251|NCT02315703|Experimental|Group 6|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by MVA-Mosaic vaccine + placebo injection at Week 24 and 48.
3109252|NCT02315703|Experimental|Group 7|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by gp140 DP vaccine containing 250 mcg of total protein mixed with adjuvant + placebo injection at Week 24 and 48.
3109253|NCT02315703|Placebo Comparator|Group 8|Participants will receive 1 placebo injection at Week 0 and 12; followed by 2 placebo injections at Week 24 and 48.
3109254|NCT02315755||Study cohort|Metastatic renal cell carcinoma patients under 3rd line targeted therapy following 1st line interferon alpha and 2nd line TKI. All patients will be ≥ 18 years old and have signed the informed consent document.
3109255|NCT02315872|Experimental|ACTH|The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.
3109256|NCT02315872|Placebo Comparator|Placebo|Placebo will be given subcutaneously twice weekly for 28 weeks.
3109257|NCT02315989|Other|safety|proton therapy
3109258|NCT02316002|Experimental|Pembrolizumab|Pembrolizumab 200 mg every 3 weeks
3109259|NCT02316171|Experimental|CVA21|CVA21 was administered by intravesical instillation at one of three (3) ascending dose levels or schedules.
3109260|NCT02316171|Experimental|CVA21/Mitomycin C|Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
3109261|NCT02316223|Experimental|Clinic-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at the office/clinic. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
3109262|NCT02316223|Active Comparator|Home-based care coordination|The ACC and CHW programs for asthma CC/SMS will have the same objectives and provide the same general services at participant's home. The ACC and CHW programs were developed from existing, successfully operating programs at the participating sites, and in the East Harlem and South Bronx communities.
3109263|NCT02316223|No Intervention|Usual care|Clinician-centric strategy and EMR-based clinician decision support
3109264|NCT02316353|Experimental|C1-INH - low-volume dose|A low-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
3109265|NCT02316353|Experimental|C1-INH - medium-volume dose|A medium-volume dose of C1-INH will be administered subcutaneously twice a week for up to 52 weeks (up to 146 weeks extension period).
3109266|NCT02316366|Experimental|Warm fluid|Patients in this arm of the study receive intravenous saline warmed to 37.5 degrees Celsius by Astoflo Plus fluid warmer
3109267|NCT02316366|No Intervention|Room temperature Fluid|Patients receive intravenous saline at room temperature (22-24 degrees Celsius)
3109268|NCT02316470|Active Comparator|VLA84 75 mcg (microgram) w/o Alum|VLA84 75 mcg w/o Alum consists of 0.75 mL (milliliters) VLA84 w/o Alum and 0.75 mL Placebo Vaccination Days: 0, 7 and 28 each with two injections
3109269|NCT02316470|Active Comparator|VLA84 200 mcg w/o Alum|VLA84 200 mcg w/o Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 w/o Alum Vaccination Days: 0, 7 and 28 each with two injections
3109270|NCT02316470|Active Comparator|VLA84 200 mcg with Alum|VLA84 200 mcg with Alum consists of 2 injections each with 1.0 mL (milliliters) VLA84 with Alum Vaccination Days: 0, 7 and 28 each with two injections
3109271|NCT02316470|Placebo Comparator|Placebo|Placebo consists of 2 injections each with 1.0 mL PBS (Phosphate Buffered Saline) Vaccination Days: 0, 7 and 28 each with two injections
3109272|NCT02316548|No Intervention|No Radiation Therapy|Patients do not receive radiation therapy (RT).
3109273|NCT02316548|Experimental|Intensity-modulated radiation therapy (IMRT)|Postoperative adjuvant intensity-modulated radiation therapy (IMRT).
3109274|NCT02316613||All Participants|Participants with histologically confirmed, refractory/relapsed cluster of differentiation-20 (CD20) positive follicular non-Hodgkin's lymphoma (grade IIII), whatever the first-line treatment was (chemotherapy and/or immunotherapy and/or radio-immunoconjugate and/or radiochemotherapy), and eligible for salvage treatment were observed for approximately 6 years. All participants received at least one cycle of rituximab (MabThera) during maintenance therapy or observation period.
3109275|NCT02316678||anti-TNF - no intervention|Patients who are new users of anti-TNF therapy
3109276|NCT02316678||Corticosteroids - no intervention|Patients initiating corticosteroids
3109277|NCT02316717|Experimental|Treatment Arm A|IMM-124E, 600 mg three times daily, orally plus matching placebo
3109278|NCT02316717|Experimental|Treatment Arm B|IMM-124E, 1200 mg three times daily, orally
3109279|NCT02316717|Placebo Comparator|Treatment Arm C|Matching placebo, three times daily, orally
3109280|NCT02316769|Active Comparator|King Vision Video Laryngoscope|Patient intubated with the King Vision Video Laryngoscope
3109281|NCT02316769|Active Comparator|McGrath MAC Video Laryngoscope|Patient intubated with the McGrath MAC Video Laryngoscope
3109282|NCT02316847|Experimental|diazepam nasal spray (Adults)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
3109283|NCT02316847|Experimental|Diazepam Nasal Spray (Adolescents)|One dose of diazepam nasal spray is two intranasal sprays; one in each nostril using a nasal spray device. The dose is administered while the subject is sitting up or lying down.
3109284|NCT02317016|Experimental|AZD9291 and rosuvastatin|Sequential treatments of rosuvastatin alone followed by AZD9291 alone, followed by rosuvastatin + AZD9291.
3469213|NCT03888690|Active Comparator|With and then without VR|Virtual Reality with standardized procedures for first intervention, Standardized procedures for second intervention, without VR.
3109285|NCT02317042|Active Comparator|Standard ST Mode|"Participants underwent the first PSG study (Titration Night 1) on ST Mode ( prior to going on AutoEPAP iVAPS or Fixed EPAP iVAPS) whilst receiving their standard NIV therapy through the clinical trial device Juno. During this mode the participant's current NIV settings were reviewed and re-titrated to deliver optimal therapy."
3109286|NCT02317042|Experimental|AutoEPAP iVAPS|"Participants underwent a PSG study on the AutoEPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
3109287|NCT02317042|Active Comparator|Fixed EPAP iVAPS|"Participants underwent a PSG study on the Fixed EPAP iVAPS mode on either Night 2 or Night 3 according to their computer generated randomisation.~Participants were randomised (1:1) according to a computer-generated randomised list (Microsoft Excel 2010) to receive 'AutoEPAP iVAPS' or 'FixedEPAP iVAPS' therapy mode first."
3109288|NCT02317432|Experimental|CBT + InVEST exercise|10 sessions of individual CBT plus 36 sessions of InVEST group exercise, provided over a 12-week intervention period.
3109289|NCT02317432|Active Comparator|Enhanced Usual Care|Usual care, as accessed through the community-based organization, plus written material from the NIH on depression, anxiety, and physical health for elders.
3109290|NCT02317510|Active Comparator|group 1|Laparoscopic cholecystectomy in General Anesthesia
3109291|NCT02317510|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anesthesia (Spino epidural).
3109292|NCT02317549|Experimental|Tranexemic Acid|Daily a total of 700 mL of LB1148 solution containing 7.5 g of tranexemic acid will be administered orally or via NG/OG/NJ/ND/PEG tube
3109293|NCT02317549|Placebo Comparator|Placebo|Daily a total of 700 mL of Placebo solution will be administered orally or via NG/OG/NJ/ND/PEG tube
3109294|NCT02317562|Experimental|I10E Arm|
3109295|NCT02317575|Experimental|Part A: LY900014 Test A|Test Formulation A. Single dose of LY900014 administered subcutaneously (SC) in one of five periods.
3109296|NCT02317575|Experimental|Part A:Insulin Lispro|Reference formulation. 15 U insulin lispro administered SC in one of five periods.
3109297|NCT02317575|Experimental|Part A: LY900014 Test B|Test Formulation B. Single dose LY900014 administered subcutaneously (SC) in one of five periods.
3109298|NCT02317575|Experimental|Part A: LY900014 Test C|Test Formulation C. Single dose LY900014administered subcutaneously (SC) in one of five periods.
3109299|NCT02317575|Experimental|Part A: LY900014 Test D|Test Formulation D. Single dose LY900014administered subcutaneously (SC) in one of five periods.
3109300|NCT02317575|Experimental|Part B: LY900014|Test formulation selected from Part A. Single dose of LY900014 administered SC in one of four periods.
3109301|NCT02317614|Experimental|SteadyRx|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. In addition, they will be given Smartphones loaded with the SteadyRx intervention.
3109302|NCT02317614|No Intervention|Usual Care|This group will be assessed at monthly intervals. They will receive their usual care at their regular providers. They will not receive a Smartphone or the SteadyRx adherence intervention.
3109303|NCT02317627|Experimental|Cohort 1|KD025 400 mg QD PO for 12 weeks
3109304|NCT02317627|Experimental|Cohort 2|KD025 200 mg BID PO for 12 weeks
3109305|NCT02317627|Experimental|Cohort 3|KD025 400 mg BID PO for 12 weeks
3109306|NCT02317692|Active Comparator|Standard ADHD parent training|8 sessions of evidence-based parent training plus school intervention
3109307|NCT02317692|Experimental|Culturally-modified ADHD parent training|8 sessions of culturally-modified parent training plus school intervention
3109308|NCT02317744|Experimental|Naltrexone/ Bupropion combination|50 mg naltrexone and 300 mg bupropion per day for 3 months
3109309|NCT02317744|Placebo Comparator|Pill placebo|Daily placebo medication for 3 months
3109310|NCT02317809|Experimental|First Liquid Pergoveris, Then Freeze-dried Pergoveris|
3109311|NCT02317809|Experimental|First Freeze-dried Pergoveris, Then Liquid Pergoveris|
3109312|NCT02318095|Other|Chemotherapy/radiation/surgery|This is a single arm prospective study. All eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel, followed by hypofractionated radiation therapy followed by surgical resection. Subjects may receive adjuvant chemotherapy post surgical resection at the clinical discretion of the medical oncologist.
3109313|NCT02318134|Experimental|FMT group|In the FMT group, participants received 200 mL fresh donor feces for twice (once every two days) via a nasoduodenal tube.
3109314|NCT02318134|Placebo Comparator|Control group|In the control group, participants received 200 mL normal saline for twice (once every two days) via a nasoduodenal tube.
3109315|NCT02318277|Experimental|MEDI4736 + INCB024360|MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
3109316|NCT02318303|Placebo Comparator|GSP 301 Placebo NS|
3109317|NCT02318303|Experimental|GSP 301-1 NS (QD)|
3109318|NCT02318303|Experimental|GSP 301-2 NS (BID)|
3109319|NCT02318303|Active Comparator|Olopatadine HCl-1 NS (QD)|
3109320|NCT02318303|Active Comparator|Olopatadine HCl-2 NS (BID)|
3109321|NCT02318303|Active Comparator|Mometasone Furoate-1 NS (QD)|
3109322|NCT02318303|Active Comparator|Mometasone Furoate-2 NS (BID)|
3469214|NCT03888690|Active Comparator|Without and then with VR|Standardized procedures without VR for first intervention, Virtual Reality with standardized procedures for second intervention.
3109326|NCT02318368|Experimental|Ficlatuzumab plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with 20 mg/kg Ficlatuzumab administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
3109327|NCT02318368|Active Comparator|Placebo plus erlotinib|150 mg Erlotinib orally once daily starting on Day 1 of Cycle 1 with Placebo administered intravenously once every 2 weeks on Day 1 and Day 15 of each 28 day cycle.
3109328|NCT02318602|Experimental|Infants|"Participants 1 to<2 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose, milligrams per kilograms per day (mg/kg/day), will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3109329|NCT02318602|Experimental|Children|"Participants 2 to <12 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3109330|NCT02318602|Experimental|Adolescents|"Participants 12 to <17 years of age. Participants who completed INS011-14-029 initiated this study on the dose with which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant. The maximum daily dose was 40 mg/kg/day.~Participants who enrolled from INS011-15-054 continued treatment with the dose at which they were being treated previously, and dose modifications were made at the Investigator's discretion if tolerability or efficacy issues were observed for a particular participant.~The total daily dose (mg/kg/day) will be evenly split between morning and evening doses (12 hours apart). If tolerability issues arise, the participant's dose may be changed at the investigator's discretion."
3109331|NCT02318667|Experimental|Golimumab treatment|Golimumab 200 mg initially administered by subcutaneous (SC) injection at Week 0, followed by 100 mg at Week 2 and then 50 mg or 100 mg every 4 weeks (per prescribing information) up to 16 weeks.
3109332|NCT02318693|Experimental|Sitagliptin 50 mg|Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.
3109333|NCT02318693|Active Comparator|Glibenclamide 2.50 mg TDD|Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.
3109334|NCT02318706|Placebo Comparator|placebo|placebo group (14 weeks)
3109335|NCT02318706|Experimental|DS-5565 15mg|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3109336|NCT02318706|Experimental|DS-5565 20 mg group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
3109337|NCT02318706|Experimental|DS-5565 30 mg group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3109338|NCT02318719|Placebo Comparator|Placebo|Placebo (14-weeks)
3109339|NCT02318719|Experimental|DS-5565 15 mg Group|DS-5565 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3109340|NCT02318719|Experimental|DS-5565 20 mg Group|DS-5565 20 mg, oral administration, Treatment period; 1-week titration and 13-weeks fixed dose
3109341|NCT02318719|Experimental|DS-5565 30 mg Group|DS-5565 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3109342|NCT02318797|Active Comparator|Patient Self-Directed Care|See intervention description
3109343|NCT02318797|Active Comparator|Provider-Supported Integrated Care|See intervention description
3109344|NCT02318940|Other|Landmark method|"installation of Central venous catheter In this arm the catheter will be installed under the usual method guided by anatomical landmarks.~access will be through the femoral vein only"
3109345|NCT02318940|Active Comparator|Ultrasound method|installation of Central venous catheter This arm of the catheter is installed using real-time ultrasound. Access will be through the femoral vein only
3109346|NCT02318979|Experimental|Running|Participants will run on an instrumented treadmill at one speed using three different prostheses.
3109347|NCT02318979|Experimental|Sprinting|Participants will run on an instrumented treadmill at a range of speeds from a jogging speed up to top speed.
3109348|NCT02318992|Active Comparator|Fecal Microbiota_Fresh|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% sodium chloride (NaCl) in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was used within 2 hours of preparation (Fresh).
3109349|NCT02318992|Active Comparator|Fecal Microbiota_Frozen|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was kept at -80 degrees Celsius (C) freezer labeled with identity (ID) and expiration date which was 6 months after preparation day (Frozen).
3109350|NCT02318992|Active Comparator|Fecal Microbiota_Lyophilized|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 1500 milliliters (mL) (1:10 dilution) sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (250mL) was starting lyophilization process within 30 minutes after completion of stool filtration (Lyophilized). Lyophilized microbiota products were kept at 4 degrees celsius (C) and were used within 6 months after preparation day.
3109351|NCT02319031|Active Comparator|Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
3109352|NCT02319031|Active Comparator|Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)|Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing
3109353|NCT02319044|Experimental|MEDI4736|MEDI4736 monotherapy
3109354|NCT02319044|Experimental|Tremelimumab|Tremelimumab monotherapy
3109355|NCT02319044|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
3109356|NCT02319148|Experimental|Treatment B|Treatment B subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of itraconazole (200 mg once daily).
3109357|NCT02319148|Experimental|Treatment C|Treatment C subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of diltiazem (240 mg once daily).
3109358|NCT02319148|Experimental|Treatment D|Treatment D subjects receive single dose administration of 20 mg PF-00489791 and multiple dose administration of verapamil (240 mg once daily).
3109359|NCT02319174|Experimental|Sphygmo|All subjects will have blood pressure measured by both the research device (Sphygmo) and the commercially available device. All clinical decisions will be made using measurements from the commercially available device.
3109360|NCT02319304|Other|Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX|"Part I:~FOLFOX: combination of drugs administered in a specific sequence as prescribed below.~Oxaliplatin: 85 mg/m2 intravenously (IV) over 2 hours~Leucovorin: 200 mg/m2 IV bolus over 2 hours~5-FU: 400 mg/m2 IV bolus over 5-15 minutes, then 2,400 mg/m2 continuous IV infusion over 46-48 hours~Part II:~Low dose fractionated radiation therapy (LDFRT) Intensity-modulated, bone marrow sparing, whole pelvic radiation therapy 40 cGy fractions twice per day delivered at least 4-6 hours apart on the first 2 days of each chemotherapy cycle for a total of 6 cycles"
3109361|NCT02319317|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
3109362|NCT02319317|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
3109363|NCT02319369|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules
3109364|NCT02319369|Experimental|Part 1A, Milademetan with 5-azacytidine (AZA)|Participants receive milademetan in combination with 5-azacytidine (AZA), with different dose schedules
3109365|NCT02319369|Experimental|Part 2, Cohort 1|Participants with refractory or relapsed acute myelogenous leukemia (AML) receive the recommended dose for Part 2 of milademetan or milademetan with5-azacytidine (AZA)
3109366|NCT02319369|Experimental|Part 2, Cohort 2|Participants with newly diagnosed acute myelogenous leukemia (AML) unfit for intensive chemotherapy receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
3109367|NCT02319369|Experimental|Part 2, Cohort 3|Participants with high-risk myelodysplastic syndrome (MDS) receive the recommended dose for Part 2 of milademetan or milademetan with 5-azacytidine (AZA)
3109368|NCT02319486|Experimental|CEV with/without carboplatin|CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
3109369|NCT02319525|Experimental|Computerized patient decision-aid|A computerized decision-aid showing benefits and harms of medications in words patients prefer
3109370|NCT02319525|Active Comparator|Usual care (lupus pamphlet)|A handout/pamphlet from a non-profit organization on lupus and lupus medications (American College of Rheumatology [ACR])
3109371|NCT02319642|Experimental|Certolizumab Pegol (CZP)|"Those subjects from either treatment group in RA0044 (NCT02151851) who fail to achieve an ACR20 response in RA0044 (NCT02151851) at Week 12, which is confirmed at Week 14. These subjects are withdrawn from RA0044 (NCT02151851) at Week 16 of that study, and that assessment will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 400 mg sc at Weeks 0, 2, and 4 followed by CZP 200 mg sc Q2W.~Subjects from either treatment group in RA0044 (NCT02151851) who completed RA0044 (NCT02151851) through Week 24. The Week 24 assessment in RA0044 (NCT02151851) will also be the Entry assessment for this Extension study. In this OLE study, these subjects will receive CZP 200 mg sc Q2W."
3109372|NCT02319668|Experimental|Test product|Mouthwash containing 0.2% w/v Chlorhexidine digluconate
3109373|NCT02319668|Placebo Comparator|Control|Sodium fluoride toothpaste (Aquafresh Mild & Minty)
3109374|NCT02319759|Experimental|Guselkumab|Participants will receive guselkumab 100 milligram (mg) subcutaneous injection (injected under the skin by way of a needle) at Weeks 0, 4, 12, 20, 28, 36, and 44, and placebo for guselkumab at Week 24 to maintain the blind. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
3109375|NCT02319759|Experimental|Placebo|Participants will receive placebo for guselkumab at Weeks 0, 4, 12, and 20, and guselkumab 100 mg subcutaneous injection at Weeks 24, 28, 36, and 44. Participants who enter early escape at Week 16 will switch to open label therapy with ustekinumab 45 mg or 90 mg at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
3109376|NCT02319824|Experimental|Treatment (radiation and NY-ESO-1-specific T cells)|Patients undergo palliative radiation therapy at the discretion of the treating radiation oncologist. Patients then receive NY-ESO-1-specific T cells IV over 60 minutes 2-3 days after completion of radiation therapy.
3109377|NCT02319967|No Intervention|Enhanced usual care|Inhaler technique education and distribution of spacers to all participants.
3109378|NCT02319967|Experimental|ED-only|Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.
3109379|NCT02319967|Experimental|ED-plus-home|"Inhaler technique education and distribution of spacers to all participants. Structured patient-centered ED discharge template (CAPE) to be completed by ED coordinator.~Home visits by a community health worker (CHW)."
3109380|NCT02320058|Experimental|Nivolumab and Ipilimumab|"Induction Phase: Nivolumab + Ipilimumab infusion intravenously~Maintenance Phase: Nivolumab infusion intravenously"
3109381|NCT02320123|Experimental|Patients - intervention|For the intervention arm of the study, patients will be invited to view the educational DVD explaining end-of-life care options and meet with a lay health advisor for discussion.
3109382|NCT02320123|No Intervention|Patients - Control|Patients will receive usual care (nor view the DVD or meet with the lay health advisor).
3109383|NCT02320149|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
3109384|NCT02320149|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
3109385|NCT02320175|No Intervention|Pre-intervention|Before implementation of Patient and Family Centered I-PASS.
3109386|NCT02320175|Experimental|Post-intervention|After implementation of Patient and Family Centered I-PASS.
3109387|NCT02320214|Experimental|Miami w/ frag Personal lubricant|Healthy subjects use Novel lubricant Miami w/ frag Personal lubricant at least 4 times per week for 2 weeks.
3109388|NCT02320227|Experimental|Miami w/o frag Personal lubricant|Healthy subjects use Miami w/o frag Personal lubricant at least 4 times per week for 2 weeks
3109389|NCT02320253|Active Comparator|Medical Nutrition Therapy (MNT)|Participants in this arm will meet with a dietitian at their respective Health Center, not with a study dietitian. The participant and dietitian will decide how frequently to meet and create an individualized treatment plan. The participant's health insurance will be billed for these dietitian visit(s) and the participant is responsible for any copay(s) or deductible(s) associated with the visit(s).
3109390|NCT02320253|Experimental|In Person Group (IP)|Participants enrolled to the IP arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
3109391|NCT02320253|Experimental|Telephone Conference Call Group (TCC)|Participants enrolled in the TCC arm will meet weekly for 14 weeks, biweekly for 10 weeks, and then monthly for the next 18 months. Each session will be led, over-the-phone, by a study dietitian that has been assigned to that specific health center and will last 1.5 hours. Participants will be allowed to have one-on-one sessions with their dietitian throughout the first two years, twice in the first year and three times in the second year.
3109392|NCT02320396|Experimental|Desloratadine|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded desloratadine (one 5 mg tablet) orally (PO) once daily (QD) in the morning for 2 weeks during the Treatment Period.
3109393|NCT02320396|Placebo Comparator|Placebo|After a 1-week single-blinded placebo run-in during which SAR symptoms are confirmed (Confirmation of Symptom Period), participants receive double-blinded placebo (one tablet) PO QD in the morning for 2 weeks during the Treatment Period.
3109394|NCT02320487|Experimental|Obinutuzumab + Bendamustine (BG)|Participants received obinutuzumab + bendamustine (BG) induction therapy in 28-day cycles for 6 cycles.
3109395|NCT02320695|Placebo Comparator|Saline|0.9% Sodium Chloride Saline Solution (0.3 cc)
3109396|NCT02320695|Placebo Comparator|Isopropyl Alcohol|70% Isopropyl Alcohol (0.3 cc)
3109397|NCT02320695|Experimental|Pain Relieving Cream|Neosporin® Plus Pain Relieving Cream formula with pH balance technology (0.3 cc)
3109398|NCT02320695|Experimental|Antibiotic/Pain Relieving Ointment|Neosporin® Complete First Aid Antibiotic/Pain Relieving Ointment (0.3 cc)
3109399|NCT02320695|Experimental|Original Ointment|Neosporin® Original Ointment (0.3 cc)
3109400|NCT02320695|Experimental|Pain Relief Ointment|Neosporin® Plus Pain relief Ointment (0.3 cc)
3109401|NCT02320721|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
3109402|NCT02320721|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily up to Week 26 on top of stable non-insulin antihyperglycemic therapy.
3109403|NCT02320812|Experimental|Treated subjects|human retinal progenitor cells
3109404|NCT02320838|Experimental|5 KHz|"Transcutaneous application of 5 KHz current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
3109405|NCT02320838|Experimental|TENS|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 110 Hz and pulse width 200 microseconds"
3109406|NCT02320838|Sham Comparator|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
3109407|NCT02320903|Experimental|Use of VillageWhere App Prototype|In this single-arm study design, all enrolled caregivers and teens will use the VillageWhere App Prototype that has been developed for this study. They are requested to use it as often as they would like throughout the duration of the trial. The app is designed to be used several times throughout each day.
3109408|NCT02321098|Experimental|Investigator blinded Loceryl NL+ Cosmetic varnish|Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails
3109409|NCT02321098|Experimental|Investigator blinded Loceryl NL alone|Loceryl NL once/week for 12 weeks on right or left foot toenails
3109410|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Saline|IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour
3109411|NCT02321111|Active Comparator|D5W (5% Dextrose in water) + Intralipid|IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour
3109412|NCT02321111|Active Comparator|Eritoran + Intralipid|IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour
3109413|NCT02321319|Experimental|Hydromorphone HCl ER Tablets|Participants receive Hydromorphone HCl ER Tablets (4-16 mg, based on standard conversion ratios for common opioids)
3109414|NCT02321436|Active Comparator|Treatment group|Dysport® 500U intramuscular injection
3109415|NCT02321436|Placebo Comparator|Placebo Group|Placebo intramuscular injection
3109416|NCT02321462|Experimental|Eziclen|
3109417|NCT02321462|Active Comparator|Fortrans®|
3109418|NCT02321514|Experimental|Tendyne Mitral Valve System|Patients will undergo transcatheter mitral valve replacement
3132659|NCT03443024|Experimental|125 milligrams (mg) Lebrikizumab - Every 4 Weeks (Q4W)|"125 mg Lebrikizumab administered subcutaneously (SC) once Q4W.~Baseline: Loading dose 250 mg Lebrikizumab SC (two injections SC 1-milliliter (mL) of 125 mg/mL Lebrikizumab and 1-mL placebo).~Week 2: Four 1-mL SC injections placebo.~Weeks 4, 8, 12: 125 mg SC Lebrikizumab and 1-mL SC placebo.~Weeks 6, 10, 14: Two 1-mL SC placebo."
3109419|NCT02321527|Experimental|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™). Ultrasound images and videos of tumor and lymph nodes in underarm area taken. Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery. Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
3109420|NCT02321748|Other|Montelukast|10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
3109421|NCT02321748|Other|ASP2151|10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
3109422|NCT02321800|Experimental|Cefiderocol|Participants received 2 g cefiderocol by intravenous injection once every 8 hours for 7 to 14 days.
3109423|NCT02321800|Active Comparator|Imipenem/cilastatin|Participants received 1 g each of imipenem/cilastatin by intravenous injection once every 8 hours for 7 to 14 days.
3109424|NCT02321930|Other|tofacitinib 5mg po bid|Open label with tofacitinib 5mg po bid
3109425|NCT02322021|Experimental|MCI/Prodromal Cohort: Low Dose|A low dose of E2609 will be assessed.
3109426|NCT02322021|Experimental|MCI/Prodromal Cohort: Middle Dose|A middle dose of E2609 will be assessed.
3109427|NCT02322021|Experimental|MCI/Prodromal Cohort: High Dose|A high dose of E2609 will be assessed.
3109428|NCT02322021|Placebo Comparator|MCI/Prodromal Cohort: Placebo|
3109429|NCT02322021|Experimental|Mild to Moderate AD Cohort: Low Dose|A low dose of E2609 will be assessed.
3109430|NCT02322021|Experimental|Mild to Moderate AD Cohort: High Dose|A high dose of E2609 will be assessed.
3109431|NCT02322021|Placebo Comparator|Mild to Moderate AD Cohort: Placebo|
3109432|NCT02322021|Experimental|Mild to Moderate AD cohort: Middle Dose|A middle dose of E2609 will be assessed.
3109433|NCT02322047|Experimental|Praz/Nal|"Prazosin and Naltrexone.~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
3109434|NCT02322047|Active Comparator|Praz/Pl|"Prazosin and Placebo (Naltrexone)~Prazosin will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
3109435|NCT02322047|Active Comparator|Nal/Pl|"Naltrexone and Placebo (Prazosin)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
3109436|NCT02322047|Placebo Comparator|Pl/Pl|"Placebo (Prazosin) and Placebo (Naltrexone)~Prazosin Placebo will be taken following this titration schedule:~Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM Days 15-42: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM~Naltrexone Placebo will be taken from day 1 to day 42 at 9 PM. Dose: 50 mg."
3109437|NCT02322125|Experimental|ReWalk training|ReWalk exoskeleton training: 1.5 hr/day, 4 days/week, for 12-14 weeks (approximately 50 training sessions). Participants will progress through the following: sit-to-stand, stand-to-sit, standing balance and weight shift, walking on smooth ground, stopping, turning while walking, walking on rough ground, ascending and descending slopes, ascending and descending steps and curbs.
3109438|NCT02322190|No Intervention|Investigator chosen second line therapy|Investigator chosen second line therapy
3109439|NCT02322190|Experimental|Second line therapy + Extracorporeal Photopheresis|Second line therapy in addition to Extracorporeal Photopheresis (ECP)
3109440|NCT02322216|Experimental|PATADAY|Olopatadine hydrochloride ophthalmic solution 0.2% in the morning and olopatadine 0.2% vehicle in the evening, 1 drop in each eye for 14 days
3109441|NCT02322216|Active Comparator|PATANOL|Olopatadine hydrochloride ophthalmic solution 0.1%, 1 drop in each eye in the morning and evening, for 14 days
3109442|NCT02322229|Experimental|Ocriplasmin|Ocriplasmin 0.125 mg in a 0.1 mL volume administered as a single dose by intravitreal (IVT) injection
3109443|NCT02322242|Active Comparator|Perineural Dexamethasone|ISB performed with local anesthetic (ropivacaine 0.5%) and perinerual dexamethasone (4mg)
3109444|NCT02322242|Other|Systemic Dexamethasone|ISB with local anesthetic alone (ropivacaine 0.5%) alone and intravenous dexamethasone (4mg)
3109445|NCT02322281|Experimental|Rociletinib Monotherapy (500 mg BID)|Daily oral rociletinib at 500 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
3109446|NCT02322281|Experimental|Rociletinib Monotherapy (625 mg BID)|Daily oral rociletinib at 625 mg BID with 8 oz (240 mL) of water and with a meal or within 30 minutes after a meal. Treatment with rociletinib is continuous and each cycle will comprise of 21 days.
3109447|NCT02322281|Active Comparator|Pemetrexed or gemcitabine or paclitaxel or docetaxel|"Pemetrexed~500 mg/m2 pemetrexed given intravenously on Day 1 of each 21-day cycle.~Gemcitabine~1250 mg/m2 gemcitabine given intravenously on Day 1 and 8 of each 21-day cycle.~Docetaxel~75 mg/m2 docetaxel (60 mg/m2 for patients residing in East-Asian territories) given intravenously on Day 1 of each 21-day cycle.~or 35 mg/m2 docetaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle.~Paclitaxel~80 mg/m2 paclitaxel given intravenously on a weekly basis as part of a continuous 21-day cycle; i.e. dosing will be on Days 1, 8, and 15 of each 21-day cycle."
3109448|NCT02322320|Active Comparator|Tandem Auto Transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
3109449|NCT02322320|Active Comparator|RVD Consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
3109450|NCT02322320|Active Comparator|Lenalidomide Maintenance|Initial autologous transplant followed by lenalidomide maintenance
3109451|NCT02322333|Active Comparator|MLD10|Subjects randomized to MLD10 will be dispensed a 28 day supply of magnesium L-lactate dehydrate for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
3109452|NCT02322333|Placebo Comparator|Placebo|Subjects randomized to placebo will be dispensed a 28 day supply of matching placebo for daily treatment. A total of 120 caplets will be given each time at Visit 2, 3, and 4. Additional overage will be given to account for the 3 day window. Subjects will be instructed to take two caplets of study medication BID (twice a day) at about the same time each day. Subjects will be instructed regarding storage requirements and will be asked to return all used/partially used/unused medication containers at the next office visit.
3109453|NCT02322411|Active Comparator|Compensatory|This group will receive standard swallowing intervention, which is identified by the SLP as appropriate to treat the patient's dysphagia and is common clinical practice. Their therapy may include: 1) modifying their foods and fluids; 2) changing their posture when they eat or drink; or 3) having them eat more slowly or in a quiet environment to make swallowing easier and safer. These compensatory approaches will ensure safety while swallowing foods and fluids. Range of motion, vocal exercises, and other oromotor exercises, such as the Shaker Exercise, as well as any other potential strengthening regimens for swallowing or speech will be delayed until subjects have completed participation.
3109454|NCT02322411|Experimental|I-PRO + compensatory|The Device-Facilitated Isometric Progressive Resistance Oropharyngeal (D-F I-PRO) intervention will be completed using the SwallowSTRONG® device. Tongue press exercises consist of pressing the tongue against the sensors located along the hard palate. Isometric exercises will focus on the anterior and posterior sensor. Subjects will take the SwallowStrong® device home with them and will complete 20 repetitions of the exercise (10 repetitions at the front sensor; 10 repetitions at the back sensor), three times per day on three days per week for twelve weeks.
3109455|NCT02322528|Other|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.
3109456|NCT02322710|Active Comparator|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
3109457|NCT02322710|Active Comparator|Urgotul|Sterile, hydrocolloid dressing, that consists of a polyester fabric coated with hydrocolloid particles and vaseline
3109458|NCT02322749|Experimental|Treatment A|AZD6244 blue reference capsules (3 x 25 mg) administered orally
3109459|NCT02322749|Experimental|Treatment B|AZD6244 blue capsules (3 x 25 mg) Variant 1 (free base variant) administered orally
3109460|NCT02322749|Experimental|Treatment C|AZD6244 blue capsules (3 x 25 mg) Variant 2 (vitamin E polyethylene glycol succinate [TPGS] variant) administered orally
3109461|NCT02322775|Experimental|Arm A|Benralizumab administered subcutaneously every 4 weeks
3109462|NCT02322775|Experimental|Arm B|Placebo administered subcutaneously every 4 weeks
3109463|NCT02322788|Active Comparator|Bricanyl Turbuhaler M2, Active|Terbutaline sulphate powder for inhalation, 0.5 mg terbutaline per inhalation
3109464|NCT02322788|Active Comparator|Bricanyl Turbuhaler M3, Active|Terbutaline sulphate powder for inhalation, 0.4 mg terbutaline per inhalation
3109465|NCT02322788|Placebo Comparator|Turbuhaler M2, Placebo|Placebo powder for inhalation
3109466|NCT02322788|Placebo Comparator|Turbuhaler M3, Placebo|Placebo powder for inhalation
3109467|NCT02322814|Experimental|Cohort I: Cobimetinib, Paclitaxel|Participants will receive a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3109468|NCT02322814|Placebo Comparator|Cohort I: Placebo, Paclitaxel|Participants will receive a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3109469|NCT02322814|Experimental|Cohort II:Cobimetinib,Paclitaxel,Atezolizumab|Participants will receive cobimetinib plus paclitaxel plus atezolizumab in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3109470|NCT02322814|Experimental|Cohort III: Cobimetinib, Nab-Paclitaxel, Atezolizumab|Participants will receive cobimetinib plus nab-paclitaxel plus atezolizumab until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.
3109471|NCT02322866|Experimental|Sarecycline|Sarecycline tablets, 1.5 milligram(mg)/kilogram(kg)/day, taken orally once daily for 12 weeks.
3109472|NCT02322866|Placebo Comparator|Placebo|Placebo-matching sarecycline tablets, taken orally once daily for 12 weeks.
3109473|NCT02322879|Experimental|Acetaminophen first, then Acetaminophen + Propylene Glycol|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks.~The total study time is 6 weeks."
3109474|NCT02322879|Experimental|Acetaminophen + Propylene Glycol first, then Acetaminophen|"Subjects in this arm will receive 4 grams of solid acetaminophen formulation in addition to 70 mg/kg/day of liquid propylene glycol for two weeks, followed by a two week wash out period.~Then, subjects will receive 4 grams of solid acetaminophen formulation for two weeks.~The total study time is 6 weeks."
3109475|NCT02322892|Placebo Comparator|Control Arm|50 mL normal saline solution
3109476|NCT02322892|Experimental|Thiamine|200 mg thiamine in 50 mL normal saline solution
3109477|NCT02323048|Experimental|Paired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3109478|NCT02323048|Experimental|Paired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3109479|NCT02323048|Experimental|Paired no reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3109480|NCT02323048|Experimental|Unpaired, high reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3109481|NCT02323048|Experimental|Unpaired, low reward|All participants will be administered methamphetamine (20mg) and placebo. All subjects received methamphetamine (20 mg) on two conditioning sessions and placebo on the other two sessions, administered under double-blind conditions.
3109482|NCT02323113|Experimental|Phase 1b: TAK-659|TAK-659 tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage of TAK-659 may increase in 20 mg increments using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
3109483|NCT02323113|Experimental|Phase 2: TAK-659|TAK-659, tablets taken orally, once daily or twice daily on Days 1-28 in a 28 day cycle, for up to 12 cycles or until disease progression. Dosage for this phase will be determined from results of Phase 1b MTD/RP2D.
3109484|NCT02323126|Experimental|Nivolumab and EGF816|Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.
3109485|NCT02323126|Experimental|Nivolumab and INC280|Arm 2 (INC280 + nivolumab) is open and enrolling as planned.
3109486|NCT02323204|Experimental|Psychological First Aid|Link for Injured Kids, a form of psychological first aid
3109487|NCT02323204|Active Comparator|Trauma Education|"Educational materials, So you've been in an accident provided to parents."
3109488|NCT02323217|Experimental|Healthy Volunteers|
3109489|NCT02323334|Placebo Comparator|Part A Cohort 1 Sequence1: 0.1mg, 1.6mg, Placcebo; 15mg|"Part A Cohort 1 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg LY3202626 Period 2: 1.6mg LY3202626 Period 3: 15 mg placebo (PBO) Period 4: 15mg LY3202626."
3109490|NCT02323334|Experimental|Part A Cohort 1 Sequence 2: 0.1mg, PBO, 15mg, 15mg|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.1mg Period 2: PBO Period 3: 15mg LY3202626 Period 4: 15mg LY3202626."
3109491|NCT02323334|Experimental|Part A Cohort 1 Sequence 3: PBO, 1.6mg, 15mg, Placebo|"Part A Cohort 1 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: PBO Period 2: 1.6mg LY3202626 Period 3: 15mg LY3202626 Period 4: PBO."
3109492|NCT02323334|Experimental|Part A Cohort 2 Sequence 1:0.4mg, 5mg, PBO, 0.4mg/Itraconazole|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg LY3202626 Period 3: 45mg, PBO Period 4: 0.4mg LY3202626/200mg Itraconazole."
3109493|NCT02323334|Experimental|Part A Cohort 2 Sequence 2: 0.4mg, PBO, 45mg. 0.4mg/Itra|"Part A Cohort 2 involved healthy participants and comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg LY3202626 Period 2: 5mg, PBO Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
3109494|NCT02323334|Experimental|Part A Cohort 2 Sequence 3:PBO, 5mg, 45mg,0.4mg/200mg Itra|"Part A Cohort 2 involved healthy participants and was comprised of 4 treatment periods with a washout period of approximately 14 days between doses.~Period 1: 0.4mg, PBO Period 2: 5mg LY3202626 Period 3: 45mg LY3202626 Period 4: 0.4mg LY3202626/200mg Itraconazole."
3109495|NCT02323334|Experimental|Part A Cohort 3 Sequence 1: Food Effect Fed/Fasted|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose of 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fed 2: Fasted.
3109496|NCT02323334|Experimental|Part A Cohort 3 Sequence 2: Food Effect Fasted/Fed|Part A Cohort 3 involved healthy participants and was comprised of two treatment periods with a washout period of approximately 14 days between doses. Single dose 10mg LY3202626 given PO in Period 1 and 2. Period 1: Fasted 2: Fed.
3109497|NCT02323334|Experimental|Part B Cohort 4: 1.6mg|Part B Cohort 4 involved healthy participants and was comprised of one period. Single dose of 1.6mg LY3202626 given PO in Period 1. Dose determined by Part A.
3109498|NCT02323334|Experimental|Part B Cohort 5: 10mg|Part B Cohort 5 involved healthy participants and was comprised of one period. Single dose of 10mg LY3202626 given PO in Period 1. Dose determined by Part A.
3109499|NCT02323334|Experimental|Part B Cohort 6: 26mg|Part B Cohort 6 involved healthy participants and was comprised of one period. Single dose of 26mg LY3202626 given PO in Period 1. Dose determined by Part A.
3109500|NCT02323334|Placebo Comparator|Part B Cohort 4, 5, 6: Placebo Comparator|Part B Cohort 4,5,6 involved healthy participants and was comprised of one period. Single dose of PBO given PO in Period 1.
3109501|NCT02323334|Experimental|Part C Cohort 7: 1mg|Part C Cohort 7 involved healthy participants and was comprised of one period. 1mg LY3202626 given PO once daily for 14 days. Dose determined by Part B.
3109502|NCT02323334|Experimental|Part C Cohort 8: 6mg|Part C Cohort 8 involved healthy participants and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
3109503|NCT02323334|Experimental|Part C Cohort 9: 26mg|Part C Cohort 9 included healthy participants and was comprised of one period. 26mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
3109504|NCT02323334|Placebo Comparator|Part C Cohort 7, 8 ,9: Placebo Comparator|Part C Cohort 7,8,9 involved healthy participants and was comprised of one period. Placebo given PO once daily for 14 days.
3109505|NCT02323334|Experimental|Part D Cohort 10: 6mg|Part D Cohort 10 involved participants with Alzheimer's disease and was comprised of one period. 6mg LY3202626 was given PO once daily for 14 days. Dose determined by Part B.
3109506|NCT02323646|Placebo Comparator|Placebo|Following the baseline assessment no treatment period, matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
3109507|NCT02323646|Experimental|Telapristone Acetate 6 mg|Following the baseline assessment no treatment period, telapristone acetate 6 milligrams (mg), vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
3109508|NCT02323646|Experimental|Telapristone Acetate 12 mg|Following the baseline assessment no treatment period, telapristone acetate 12mg, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
3109509|NCT02323854|Other|Ablation and Surgical Resection|Ablation of lung tumor; followed by surgical resection of the ablation zone.
3109510|NCT02324049|Experimental|SBC-103|"Part A (Initial therapy): Participants received SBC-103, 0.3, 1.0, or 3.0 mg/kg QOW for 24 weeks, followed by a ≥ 4-week treatment break. Participants enrolled in the lowest dosage first.~Part B: Participants were escalated to the next highest dose that was considered safe (1.0 or 3.0 mg/kg QOW) for ≥ 8 weeks. Participants who received doses of 0.3 mg/kg in Part A were considered for a second dose escalation to 3.0 mg/kg at any time during Part B provided that they tolerated at least 2 doses of 1.0 mg/kg in Part B. Participants who received and tolerated at least 4 doses of SBC-103 QOW at 3.0 mg/kg were considered for participation in Part C.~Part C: Participants received SBC-103 5.0 or 10.0 mg/kg administered IV QOW. Dosing in Part C began at the 5.0 mg/kg dose level. The decision to begin dosing the first participant at 10.0 mg/kg was based on the review of safety data at 5.0 mg/kg."
3109511|NCT02324075|Experimental|Behavior change|Behavior change messaging with facilitating hardware
3109512|NCT02324075|No Intervention|Control Arm|Standard habits and practices
3109513|NCT02324153|Experimental|Treatment|Ramelteon 8 mg oral dose Riboflavin 100 mg (preoperative first dose only)
3109514|NCT02324153|Placebo Comparator|Placebo|Capsule Shells filled with microcrystalline cellulose Riboflavin 100 mg (preoperative first dose only - if received as an outpatient)
3109515|NCT02324205|Experimental|DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.
3109516|NCT02324270|Active Comparator|Diclofenac epolamine|Flector® (Diclofenac Epolamine Topical Patch 1.3%) (Pfizer)
3109517|NCT02324270|Experimental|generic diclofenac epolamine patch|Generic Diclofenac Epolamine Topical Patch 1.3% (Watson Laboratories, Inc.)
3109518|NCT02324270|Placebo Comparator|Placebo|Placebo patch of the test product (Watson Laboratories, Inc.); Identical in appearance and formulated as the test product, omitting the active ingredient, diclofenac epolamine
3109519|NCT02324335|Placebo Comparator|Placebo Comparator Oral Rinse|Water for Injection
3109520|NCT02324335|Active Comparator|Active Comparator Oral Rinse|Brilacidin 3 mg/mL in Water for Injection
3109521|NCT02324361|Experimental|Facebook group|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for Facebook posts on a private study Facebook group.~Participating parents/guardians will have access to all features of the secret study Facebook group (e.g., create and view postings, comment and like existing posts and view user names of other members of the group (existing study participants and staff) for the duration of the study.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
3109522|NCT02324361|Experimental|Text messaging|"The intervention consists of evidence-based information on healthy family routines and parenting strategies adapted for 140-character text messages.~The automated text-messaging algorithm consists of the delivery of two types of text messages: 1-way messages, in which participating parents/guardians will receive a piece of education or motivation on the dimension topic that they're being coached on and 2-way messages, in which participants are able to respond to an educational message containing a number response prompt that will provide them with personalized feedback regarding a dimension they are being coached on.~All index children will be provided with a Physical Activity Monitor to wear during waking hours for the duration of the study."
3109523|NCT02324465|Active Comparator|King Vision Video Laryngoscope|The patient would be randomized to intubation via use of the King Vision VL
3109524|NCT02324465|Active Comparator|Glidescope Video Laryngoscope|The patient would be randomized to intubation via use of the Glidescope VL
3109525|NCT02324504|Experimental|Placement with C3 Wave Tip System|Subjects will have their central catheters placed with the addition of the FDA approved C3 Wave ECG-Based PICC Tip Confirmation System to the standard institution protocol. The system will assist with location of the catheter tip in real-time, during the procedure.
3109526|NCT02324543|Experimental|Dose level 1 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/twice daily (BID)~Cisplatin - 15 mg/m^2~Irinotecan - 20 mg/m^2"
3109527|NCT02324543|Experimental|Dose Level 2 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 40 mg/m^2"
3109528|NCT02324543|Experimental|Dose Level 3 - Phase 1|"Gemcitabine - 400 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 15 mg/m^2~Irinotecan - 60 mg/m^2"
3109529|NCT02324543|Experimental|Dose Level 1a - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
3109530|NCT02324543|Experimental|Dose level 1b - Phase 1|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 40 mg/m^2"
3109531|NCT02324543|Experimental|Phase 2|"Gemcitabine - 500 mg/m^2~Taxotere - 20 mg/m^2~Xeloda - 500 mg/BID~Cisplatin - 20 mg/m^2~Irinotecan - 20 mg/m^2"
3109532|NCT02324569|Experimental|Treatment Group I|One tablet of SYR-472 100 mg orally once weekly before breakfast
3109533|NCT02324569|Experimental|Treatment Group II|One tablet of SYR-472 100 mg orally or one placebo tablet orally once weekly before breakfast
3109534|NCT02324660|Other|screening test|all consecutive patients admitted to our hospital for ACS and current/former smokers will be screened according our protocol with PEF and RHSQ. Patients will be blinded to result of both tests. Indipendently to results, all included patients will receive spirometry (50-70 days after inclusion) to assess the presence or not of COPD (primary outcome).
3109535|NCT02324673|Experimental|Low Dose Cannabidiol Oral Solution [10 mg/kg/day]|Low Dose [10 milligrams/kilogram/day (mg/kg/day)] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 5 mg/kg in the morning on Day 1 followed by total dose of 10 mg/kg/day (5 mg/kg in the morning and 5 mg/kg in the evening) on Days 4 to 10.
3109536|NCT02324673|Experimental|Mid Dose Cannabidiol Oral Solution [20 mg/kg/day]|Mid Dose [20 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 10 mg/kg in the morning on Day 1 followed by total dose of 20 mg/kg/day (10 mg/kg in the morning and 10 mg/kg in the evening) on Days 4 to 10.
3109537|NCT02324673|Experimental|High Dose Cannabidiol Oral Solution [40 mg/kg/day]|High Dose [40 mg/kg/day] oral solution containing pharmaceutical grade cannabidiol (nonplant-based). Starting dose of 20 mg/kg in the morning on Day 1 followed by total dose of 40 mg/kg/day (20 mg/kg in the morning and 20 mg/kg in the evening) on Days 4 to 10.
3109538|NCT02324699|Experimental|Prednisone co-inductive therapy|Prednisone 40 mg/day starting at week 0 for 2 weeks, tapered by 10 mg weekly to achieve 0 mg by end of week 5
3109539|NCT02324699|Placebo Comparator|Placebo|Identical placebo taper
3109541|NCT02324842|Active Comparator|Canagliflozin|canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects
3109542|NCT02324842|Active Comparator|liraglutide|liraglutide, 1.2 mg/day, increased to 1.8 mg/day after week two if tolerated without side effects
3109543|NCT02324842|Active Comparator|canagliflozin plus liraglutide|canagliflozin, 100 mg/day, plus liraglutide, 1.2 mg/day, increased to 300 mg/day and 1.8 mg/day, respectively at week two, if tolerated without side effects
3109544|NCT02324920|Experimental|DDD+CLS|The pacemaker will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON.
3109545|NCT02324920|Placebo Comparator|ODO|The pacemaker will be programmed in ODO mode.
3109546|NCT02324972|Experimental|AQX-1125|1 x AQX-1125 Capsule daily
3109547|NCT02324972|Placebo Comparator|Placebo|1 x placebo capsule daily
3109548|NCT02325219|Experimental|Group 1|Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.
3109549|NCT02325219|Experimental|Group 2|Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.
3109550|NCT02325219|Experimental|Group 3|Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.
3109551|NCT02325401|Experimental|Metformin with Chemoradiation|Metformin administered orally daily to start one week prior to Cisplatin and Radiation Therapy. Metformin dose is escalating.
3109552|NCT02325414|Experimental|Zol|Intravenous infusion of zoledronic acid (zol) 5 mg at baseline.
3109553|NCT02325414|Experimental|Placebo|Intravenous infusion of placebo at baseline.
3109554|NCT02325518|Experimental|BRI/TIM|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
3109555|NCT02325518|Active Comparator|DOR/TIM|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.
3109556|NCT02325687|Experimental|Treated OSA (CPAP-compliant)|"Treated OSA patients will have previously been diagnosed with OSA, and are currently CPAP-compliant. CPAP compliance is defined by daily use of a CPAP machine for at least 4 hours. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
3109557|NCT02325687|Experimental|Untreated OSA (non-CPAP-compliant)|"Patients in the untreated OSA group will have previously been diagnosed with OSA, but for some reason do not use a CPAP machine every night. We will determine if patients are CPAP-compliant by looking at their medical records and pre-operative assessments, as well as directly verifying compliance with the patient.~Intervention: Lumbar Puncture (Standard-of-Care)"
3109558|NCT02325687|Experimental|Control (No suspicion of OSA)|"Patients in the control group will not have previously been diagnosed with OSA, and are currently not at high risk. We will determine overall risk for OSA using the STOP-BANG questionnaire. Patients with a STOP-BANG score <3 are considered to have minimal risk for OSA and will be included in the control group.~Intervention: Lumbar Puncture (Standard-of-Care)"
3109559|NCT02325713|Experimental|Sequence A-B-C1-D1|
3109560|NCT02325713|Experimental|Sequence A-B-C1-D2|
3109561|NCT02325713|Experimental|Sequence A-B-C2-D1|
3109562|NCT02325713|Experimental|Sequence A-B-C2-D2|
3109563|NCT02325713|Experimental|Sequence A-B-D1-C1|
3109564|NCT02325713|Experimental|Sequence A-B-D2-C1|
3109565|NCT02325713|Experimental|Sequence A-B-D1-C2|
3109566|NCT02325713|Experimental|Sequence A-B-D2-C2|
3109567|NCT02325713|Experimental|Sequence B-A-C1-D1|
3109568|NCT02325713|Experimental|Sequence B-A-C1-D2|
3109569|NCT02325713|Experimental|Sequence B-A-C2-D1|
3109570|NCT02325713|Experimental|Sequence B-A-C2-D2|
3109571|NCT02325713|Experimental|Sequence B-A-D1-C1|
3109572|NCT02325713|Experimental|Sequence B-A-D2-C1|
3109573|NCT02325713|Experimental|Sequence B-A-D1-C2|
3109574|NCT02325713|Experimental|Sequence B-A-D2-C2|
3109575|NCT02325739|Experimental|Phase I: FGF401 50 mg fasted|Participants received single agent FGF401 50 mg while fasted
3109576|NCT02325739|Experimental|Phase I: FGF401 80 mg fasted|Participants received single agent FGF401 80 mg while fasted
3109577|NCT02325739|Experimental|Phase I: FGF401 80 mg fed|Participants received single agent FGF401 80 mg while fed
3109578|NCT02325739|Experimental|Phase I: FGF401 120 mg fasted|Participants received single agent FGF401 120 mg while fasted
3109579|NCT02325739|Experimental|Phase I: FGF401 120 mg fed|Participants received single agent FGF401 120 mg while fed
3109580|NCT02325739|Experimental|Phase I: FGF401 150 mg fasted|Participants received single agent FGF401 150 mg while fasted
3109581|NCT02325739|Experimental|Phase I: FGF401 80 mg + PDR001 300 mg|Participants received FGF401 80 mg in combination with PDR001 300 mg while fasted
3109582|NCT02325739|Experimental|Phase I: FGF401 120 mg + PDR001 300 mg|Participants received FGF401 120 mg in combination with PDR001 300 mg while fasted
3109583|NCT02325739|Experimental|Phase II: Group 1 - FGF401 120 mg QD|Group 1 was comprised of HCC participants from Asian countries who received single agent FGF401 120 mg QD while fasted
3109584|NCT02325739|Experimental|Phase II: Group 2 - FGF401 120 mg QD|Group 2 was comprised of HCC participants from non-Asian countries who took single agent FGF401 120 mg QD while fasted
3109585|NCT02325739|Experimental|Phase II: Group 3 - FGF401 120 mg QD|Group 3 was comprised of participants with other solid malignancies regardless of geography who took single agent FGF401 120 mg QD while fasted
3109586|NCT02325791|Experimental|Part A: Suptavumab 30 mg/kg|
3109587|NCT02325791|Experimental|Part B: Placebo Matched to Suptavumab|
3109588|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg- 1 Dose|
3109589|NCT02325791|Experimental|Part B: Suptavumab 30 mg/kg - 2 Doses|
3109590|NCT02325856|Active Comparator|Study group|Dry weight determined by performing Bioimpedance Spectroscopy (intervention is the performance of this tool)
3109591|NCT02325856|Placebo Comparator|Control group|Dry weight determined by clinical symptoms
3109592|NCT02326025|Experimental|Part A|"Doxorubicin Alone: On Cycle 1, Day 1, participants received 75 milligram/square meter (mg/m2) of doxorubicin intravenously (IV).~Olaratumab Alone: On Cycle 1, Day 10, participants received 15 milligram/kilogram (mg/kg) of olaratumab IV.~Olaratumab + Doxorubicin: For Cycles 2 to 8, participants received 15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, IV and 75 mg/m2 of doxorubicin IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onward, until discontinuation criteria are met."
3109593|NCT02326025|Experimental|Part B|"Doxorubicin Alone: On Cycle 1, Day 1, participants received doxorubicin 75 mg/m2 IV~Olaratumab Alone: On Cycle 1, Day 10, participants received 20 mg/kg of olaratumab IV.~Olaratumab + Doxorubicin:~For Cycle 2, participants received 20 mg of olaratumab on Days 1 and 8 of each 21-day cycle, IV. On Day 1 of Cycle 2, doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~For Cycles 3 - 8, Day 1 and 8, olaratumab 15 mg/kg was administered and on Day 1 doxorubicin 75 mg/m2 was administered IV immediately following the completion of the olaratumab infusion.~Participants continued to receive olaratumab monotherapy (on days 1 and 8 of each cycle) for Cycle 9 onwards, until discontinuation criteria are met."
3109594|NCT02326220|Experimental|Placebo Q2W (Double Blind Period)|Placebo (for alirocumab) subcutaneous (SC) injection Q2W up to Week 16.
3109595|NCT02326220|Experimental|Alirocumab 150 mg Q2W (Double Blind Period)|Alirocumab 150 mg SC injection Q2W up to Week 16.
3109596|NCT02326220|Experimental|Alirocumab 150 Q2W (Open Label Treatment Period)|Alirocumab 150 mg SC injection Q2W starting from Week 18 up to Week 76.
3109597|NCT02326233|Experimental|Pen of SB5|Pen of SB5, single-dose of 40 mg via subcutaneous injection (study drug)
3109598|NCT02326233|Active Comparator|PFS of SB5|PFS of SB5, single-dose of 40 mg via subcutaneous injection (reference drug)
3109599|NCT02326272|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
3109600|NCT02326272|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
3109601|NCT02326272|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
3109602|NCT02326298|Experimental|CZP 200 mg|"CZP 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~Treatment received from Week 16-48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 200 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to unblinded CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W.~Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Depending on PASI50 or PASI75 responses at Week 60 or a later time point, subjects may switch to CZP 400 mg Q2W or withdraw from the study."
3109603|NCT02326298|Experimental|CZP 400 mg|"CZP 400 mg every two weeks (Q2W) through Week 14.~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16 continue to receive CZP 400 mg Q2W.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension (OLE) Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W.~Subjects who achieve a PASI75 response during the OLE Phase may switch to CZP 200 mg Q2W."
3109604|NCT02326298|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~Treatment received from Week 16 - 48 is based on initial treatment and response to treatment:~PASI50 responders at Week 16, who do not achieve a PASI75 response at Week 16 receive CZP 400 mg at Weeks 16, 18 and 20 (loading doses) followed by CZP 200 mg Q2W starting at Week 22.~PASI75 responders at Week 16 continue to receive Placebo.~PASI50 non-responders at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~PASI50 non-responders at Week 32 or a later time point will be withdrawn from the study.~Subjects who complete the Maintenance Period (with PASI50 response at Week 48) enter the Open-label Extension Period on CZP 200 mg Q2W. Week 48 completers in the escape arm continue to receive CZP 400 mg Q2W or may switch to CZP 200 mg Q2W."
3109605|NCT02326363|Experimental|Mindfulness Based Relapse Prevention (MBRP):|The Introductory session provides an orientation to the intervention, basic mindfulness techniques and general description of group sessions. Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of mindfulness meditation (MM) practices such as breath meditation, urge surfing, walking or movement meditation.
3109606|NCT02326363|Active Comparator|Twelve-Step Facilitation Intervention (TSF)|"The Introductory session covers the 12-Step view of addiction and therapy overview. The manual, originally developed for individual sessions, has been adapted for group delivery. The eight selected sessions include four topics chosen by the manual developers as core topics and four elective topics. The intervention involves helping participants understand and incorporate core principles of 12-Step approaches while encouraging active participation in 12-Step meetings and related activities. The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
3109607|NCT02326467|Experimental|Chlorhexidine gluconate bath|All subjects will receive a bath twice a week with 2% CHG bathing cloths. The baths will be followed by blood sampling for CHG levels prior to initiation of baths and every Friday for the duration of study participation. The study team will monitor the infant's skin for evidence of untoward lesions prior to the first bath and every 12 hours during the course of the study. CHG blood levels will be monitored for associated adverse events and accumulation.
3109608|NCT02326597|Active Comparator|Standard Practice|Participants will receive education regarding treatment consideration from their healthcare provider/team as per standard practice (usual care).
3109609|NCT02326597|Experimental|Standard Practice + Decision Aid|Participants will receive standard of care teaching and discussion in addition to web-based decision aid tool access.
3109610|NCT02326649||CHD patients undergoing cardiac MRI without sedation|
3109611|NCT02326805|Experimental|Arm I (rilimogene-galvacirepvec)|Patients receive rilimogene-galvacirepvec SC at baseline and on days 14, 28, 56, 84, 112, and 140.
3109612|NCT02326805|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140.
3109613|NCT02326844|Experimental|Ovarian Cancer Patients|Ovarian cancer patients with germline breast cancer mutation (gBRCAm) who have progressed on prior poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
3109614|NCT02326883|Experimental|Care Management|The Care Management intervention will last up to a year and includes routine outreach to assess ongoing risk of suicide attempt, and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
3109615|NCT02326883|Experimental|Skills Training|The Skills Training intervention will last up to a year and uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
3109616|NCT02326883|Active Comparator|Usual Care|Those assigned to the Usual Care group will not be approached or contacted.
3109617|NCT02326974|Experimental|T-DM1 and Pertuzumab|T-DM1 3.6 mg per kg of body weight via IV every 3 weeks for 6 doses and Pertuzumab loading dose of 840 mg via IV on Cycle 1 Day 1 followed by maintenance dose of 420 mg via IV every 3 weeks for 6 doses. Excision of tumor/mastectomy of biopsy residual tumor within 42 days of the last cycle of therapy.
3109618|NCT02327013|Experimental|vortioxetine 10 mg tablet|"In Stage 1, patients will receive vortioxetine 10mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 10mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3109619|NCT02327013|Experimental|vortioxetine 20 mg tablet|"In Stage 1, patients will receive vortioxetine 20mg/day for 6 weeks.~In Stage 2, patients who received vortioxetine 20mg/day in Stage 1 will continue on the same treatment for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3109620|NCT02327013|Placebo Comparator|Placebo tablet|"In Stage 1, the patients will receive placebo for 6 weeks.~In Stage 2, placebo responders will continue on placebo for additionally 6 weeks. Placebo non-responders will be re-randomized to placebo, or vortioxetine 10 or 20mg/day for additionally 6 weeks."
3109621|NCT02327052||Chagas disease|The study comprised 58 subjects with Chagas disease, confirmed by two positive serologic tests.
3109622|NCT02327117|Experimental|Tranexamic acid|
3109623|NCT02327117|Placebo Comparator|Normal Saline|
3109624|NCT02327130|Experimental|Exhaled Breath|Exhaled breath samples will be collected 6 times per day and blood samples will be collected once per day for 7 days. Subjects will be followed for an additional 3 days. We will use the Isomark Canary™ to determine the BDV of breath samples collected during this study. Analysis results of these samples will be combined with data that is abstracted from the subjects' medical records.
3109625|NCT02327143|Experimental|200 mg LY2835219|200 mg LY2835219 administered orally on day 1.
3109626|NCT02327143|Experimental|0.4 mg ¹³C₈-LY2835219|0.4 mg ¹³C₈-LY2835219 given intravenously (IV) for 15 minutes, starting approximately 6 hours after the oral dose.
3109627|NCT02327169|Experimental|MLN2480 + MLN0128|Dose Escalation Phase: MLN2480 100 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and MLN0128 2 mg, capsules, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles.
3109628|NCT02327169|Experimental|MLN2480 + Alisertib|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and alisertib 30-40 mg, tablets, orally, twice daily (BID) on protocol specified days of a 28-day cycle for up to 12 cycles. The doses of MLN2480 and alisertib were modified during this phase based on tolerability during each 28-day cycle.
3109629|NCT02327169|Experimental|MLN2480 + Paclitaxel|Dose Escalation Phase: MLN2480 100-200 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 milligram per square meter (mg/m^2), intravenous (IV) infusion, once weekly (QW) for 3 weeks in each 28-day cycle for up to 12 cycles or MLN2480 400-600 mg tablets, orally, QW on protocol specified days of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg/m^2, IV infusion, QW for 3 weeks in each 28-day cycle for up to 12 cycles The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in paclitaxel dose was based on the standard of care.
3109630|NCT02327169|Experimental|MLN2480 + Cetuximab|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and cetuximab administered intravenously at a loading dose of 400 mg/m^2 (cycle 1 Day 1), then at 250 mg/m^2 QW on Days 8, 15, and 22 of cycle 1 and Days 1, 8, 15, and 22 in each additional 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in cetuximab dose was based on the standard of care.
3109631|NCT02327169|Experimental|ML2480 + Irinotecan|Dose Escalation Phase: MLN2480 400-600 mg, tablets, orally, once on protocol specified days of a 28-day cycle for up to 12 cycles, and irinotecan 180 mg/m^2, IV infusion over 90 minutes, every other week (Q2W) for 2 weeks in each 28-day cycle for up to 12 cycles. The dose of MLN2480 was modified during this phase based on tolerability during each 28-day cycle. Any changes in irinotecan dose was based on the standard of care.
3109632|NCT02327169|Experimental|MLN2480 600 mg + Paclitaxel 80 mg (Dose Expansion Phase)|Dose Expansion Phase: MLN2480 600 mg, tablets, orally, once per week on Days 2, 9, 16 and 23 of a 28-day cycle for up to 12 cycles, and paclitaxel 80 mg, capsules, orally, once on 1, 8, and 15 of a 28-day cycle for up to 12 cycles.
3109633|NCT02327260|Experimental|Video + MI for CR|This group receives the educational video and an MI session for CR participation.
3109634|NCT02327260|Experimental|MI for medication adherence|This group receives an MI session for taking prescribed cardioprotective medications.
3109635|NCT02327260|No Intervention|Control group (standard care)|The control group receives standard care while hospitalized.
3109636|NCT02327325|Experimental|Physical Activity Only|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
3109637|NCT02327325|Experimental|Physical Activity + Cognitive Behavioral Therapy|12-week combined home-based physical activity and cognitive behavioral program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive physical activity program including stretching, strengthening and aerobic activity. Cognitive behavioral component includes training in multiple skills for managing pain.
3109638|NCT02327325|No Intervention|Wait List Control Group|Will receive the physical activity only or physical activity + cognitive behavioral therapy (based on participant choice) after completing all follow-up assessments.
3109639|NCT02327351|Experimental|TCR alfa beta depletion|TCR alfa beta depleted graft, infusion. The leukapheresis product will undergo TCR alfa beta depletion following the standardized protocol.
3109640|NCT02327429|Experimental|A Chinese menu plan for type 2 diabetes|All participants will be in the intervention arm for this pilot study
3109641|NCT02327741|Experimental|plavix long term|taking plavix more than 12 months
3109642|NCT02327741|Active Comparator|plavix short term|taking plavix less than 12 months
3109644|NCT02328027|Experimental|99mTc-rhAnnexin V-128, i.v.|Patients will receive 2 administrations of the 99mTc-rhAnnexin V-128 medical imaging agent: one at Day 1 and the other at Day 42.
3109645|NCT02328040|Placebo Comparator|Part A|Placebo and Insulin monotherapy via CL
3109646|NCT02328040|Active Comparator|Part B|Sitagliptin and insulin/novolog via CL
3109647|NCT02328105|Experimental|Carboplatin + Abraxane|Carboplatin (AUC = 6; on Day 1) plus Abraxane (nab-paclitaxel; 100 mg/m^2; Days 1, 8, 15) for 6 21-day cycles. Treatment was discontinued if: disease progression, unacceptable toxicity, withdrawn consent, or completion of treatment
3109648|NCT02328326|Experimental|CO-IMPACT|patient and supporter (dyad) receive one coaching session on action planning, communicating with providers, navigation skills and support skills; preparation by phone before patients' primary care visits; after-visit summaries by mail; and biweekly automated phone calls to prompt action on new patient health concerns
3109649|NCT02328326|Active Comparator|PACT|patient and their health supporter (dyad) will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
3109650|NCT02328404|Active Comparator|vitamin D3 (Biodal 50,000 IU)|50,000 IU Vitamin D3 tablet given orally once weekly for 3 months
3109651|NCT02328404|Placebo Comparator|placebo|Placebo tablet given orally once weekly for 3 months
3109652|NCT02328547|Experimental|FMT capsules|Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
3109653|NCT02328547|Placebo Comparator|Placebo capsules|Intervention: Placebo capsules that do not contain donor stool or any active drug, prepared by OpenBiome, Medford, MA. 25 placebo capsules will be taken on three consecutive days.
3109654|NCT02328755|Experimental|peg-IFN-α|"peg-IFN-α will be administered prior to HCT (Hematopoietic Cell Transplant) and at three subsequent time points post HCT. (Maximum of 4 doses) It will be administered by subcutaneous injection every 14 days beginning with dose level 1.~Dose Level -1 - 45mcg Dose Level 1 - 90mcg Dose Level 2 - 180 mcg"
3109655|NCT02328807|Experimental|Radio-Frequency Ablation (RFA)|Focal Prostate Radio-Frequency Ablation (RFA). Focal bipolar RFA followed by clinical follow-up visits at 6 weeks, 3 months and 6 months.
3109656|NCT02328937|Active Comparator|etafilcon A/lotrafilcon B/comfilcon A|Subjects that were randomized to receive the etafilcon A lens 1st, the lotrafilcon B lens 2nd and the comfilcon A lens 3rd.
3109657|NCT02328937|Active Comparator|etafilcon A/comfilcon A/lotrafilcon B|Subjects that were randomized to receive the etafilcon A lens 1st, the comfilcon A lens 2nd and the lotrafilcon B lens 3rd.
3109658|NCT02328937|Active Comparator|comfilcon A/etafilcon A/lotrafilcon B|Subjects that were randomized to receive the comfilcon A lens 1st, the etafilcon A lens 2nd and the lotrafilcon B lens 3rd.
3109659|NCT02328937|Active Comparator|comfilcon A/lotrafilcon B/etafilcon A|Subjects that were randomized to receive the comfilcon A lens 1st, the lotrafilcon B lens 2nd and the etafilcon A lens 3rd.
3109660|NCT02328937|Active Comparator|lotrafilcon B/etafilcon A/comfilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the etafilcon A lens 2nd and the comfilcon A lens 3rd.
3109661|NCT02328937|Active Comparator|lotrafilcon B/comfilcon A/etafilcon A|Subjects that were randomized to receive the lotrafilcon B lens 1st, the comfilcon A lens 2nd and the etafilcon A lens 3rd.
3109662|NCT02329015|Experimental|Health and Wellness program|Behavioral intervention
3109663|NCT02329015|Active Comparator|Physical Education Class|Behavioral intervention
3109664|NCT02329223|Experimental|Omalizumab 300 mg|Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
3109665|NCT02329223|Experimental|Omalizumab 150 mg|Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
3109666|NCT02329223|Placebo Comparator|Placebo|Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.
3109667|NCT02329431|Experimental|activation curriculum|Psycho-social curriculum teaching activation skills
3109668|NCT02329431|Active Comparator|support group|Parent-directed support group
3109669|NCT02329587|Experimental|ERP plus tDCS|ERP plus anodal tDCS of right inferior frontal gyrus
3109670|NCT02329587|Active Comparator|ERP plus sham tDCS|ERP plus sham tDCS of right inferior frontal gyrus
3109671|NCT02329600|No Intervention|control subjects|10 systemically healthy control subjects taking no medication.
3109672|NCT02329600|Active Comparator|OLP and corticosteroid|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month.
3109673|NCT02329600|Experimental|OLP and corticosteroid and green tea|15 Patients who were previously diagnosed with oral lichen planus presented in acute exacerbation were treated with both topical corticosteroids; Triamcinolone acetonide (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month in addition to green tea tablets 200 mg (Green tea extract 5:1, El Obour For Modern Pharmaceutical Industries) as one tablet a day also for one month.
3109674|NCT02329730|Experimental|the healthy subjects|The healthy subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
3109675|NCT02329730|Experimental|the first part of tuberculosis subjects|The first part kind of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time , or 20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative only one time .Right arm inject ESAT6-CFP10 and left arm inject tuberculin purified protein derivative. Two drugs must be use in the same subjects.
3109676|NCT02329730|Experimental|the second part of tuberculosis subjects|The second part of tuberculosis subjects inject 1μg/ml ESAT6-CFP10 and placebo only one time , or 5μg/ml ESAT6-CFP10 and placebo only one time , or 10μg/ml ESAT6-CFP10 and placebo only one time , or 20μg/ml ESAT6-CFP10 and placebo only one time .Right arm inject ESAT6-CFP10 and left arm inject placebo. Two drugs must be use in the same subjects.
3109677|NCT02329743|Experimental|RX-10045 0.05% nanomicellar solution|topical eye drops
3109678|NCT02329743|Experimental|RX-10045 0.1% nanomicellar solution|topical eye drops
3109679|NCT02329743|Placebo Comparator|Vehicle|topical eye drops
3109680|NCT02329964|Experimental|R-S group|"Rocuronium-Sugammadex group~Induction of anesthesia : 1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent : Rocuronium 1mg/kg~After endotracheal intubation : normal saline(0.025 ml/kg)~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Rocuronium 0.15mg/kg~Relaxant agent reversal. at the the end of surgery : sugammadex 2mg/kg"
3109681|NCT02329964|Active Comparator|S-C-N group|"Succinylcholine-Cisatracurium-Neostigmine group~Induction of anesthesia :1% propofol 1.5-2.5 mg/kg with fentanyl 1.5 mcg/kg~Muscle relaxant agent :Succinylcholine 1mg/kg~After endotracheal intubation : Cisatracurium 0.08mg/kg~Additive dose, for ensuring that neuromuscular blockade remains below T2 during surgery : Succinylcholine 10mg~Relaxant agent reversal at the appearance of second TOF twitch (T2) : Neostigmine 0.2mg/kg with atropine 10 mcg/kg (for preventing side effects of neostigmine)"
3132660|NCT03443024|Experimental|250 mg Lebrikizumab - Q4W|"250 mg Lebrikizumab administered SC once Q4W.~Baseline: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 2: Four 1-mL SC injections of placebo.~Weeks 4, 8, 12: 250 mg (two 1-mL injections of 125 mg/mL Lebrikizumab).~Weeks 6, 10, 14: Two 1-mL injections of placebo."
3109682|NCT02330055|Active Comparator|Forty-five degrees elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will elevate the patients upper body to 45 degree prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
3109683|NCT02330055|Placebo Comparator|Non-elevated upper body position|"If the patient is randomized in this study arm after enrollment, the investigators will flatten the patients upper body to a supine position prior to sleeping. The patient will wear a pulseoximeter (WristOx Model 3150) during the night. The investigators will collect the SpO2 and pulse rate with this device and then quantify desaturation events.~The investigators will ask the patient to fill out a questionnaire, which includes the P-SAP score, the STOP-BANG score, the Epworth Sleepiness Scale and the self-reported pain."
3109684|NCT02330081|Experimental|Mirasol|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subjects stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subjects untreated fresh whole blood."
3109685|NCT02330094|Experimental|Gabapentin|Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
3109686|NCT02330094|Placebo Comparator|Control|Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
3109687|NCT02330172|Active Comparator|rocuronium 0.45 - neostigmine|"when anesthetic induction, inrocuronium 0.45 mg/kg will be administered for muscle relaxation.~When the end of operation, a injection of neostigmine or sugammadex will be administered."
3109688|NCT02330172|Active Comparator|rocuronium 0.9 - sugammadex|"When anesthetic induction, rocuronium 0.9 mg/kg will be injected to rocuronium 0.9 - sugammadex group for muscle relaxation.~When the end of operation,, a injection of neostigmine or sugammadex be administered."
3109689|NCT02330276|Experimental|10 mg (+)-epicatechin|4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
3109690|NCT02330276|Experimental|30 mg (+)-epicatechin|4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
3109691|NCT02330276|Experimental|100 mg (+)-epicatechin|4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
3109692|NCT02330341|Experimental|Artemisia Dracunculus|Artemisia Dracunculus extract, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
3109693|NCT02330341|Placebo Comparator|Placebo|Calcined magnesia, 2 capsules of 500 mg, two times per day before breakfast and dinner during 90 days
3109694|NCT02330523|Active Comparator|allograft + x-link collagen membrane|Demineralized freeze-dried allograft + x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
3109695|NCT02330523|Active Comparator|xenograft + non-x-link collagen|Xenograft + non-x-linked collagen membrane will be used for guided bone regeneration of dehiscence buccal defects post extraction.
3109696|NCT02330549|Experimental|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food for up to 24 weeks.
3109697|NCT02330549|Placebo Comparator|Placebo|Placebo-matching CVC, administered orally once daily and taken every morning with food for up to 24 weeks.
3109698|NCT02330588|Experimental|Eat It! (Injunctive Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
3109699|NCT02330588|Experimental|Eat It! (Normative Feedback)|Parents are presented with two questions about portion size and sugar-sweetened beverages; answers are contrasted with normative feedback (i.e., referent data from Canadian children).
3109700|NCT02330588|Experimental|Move It! (Injunctive Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with injunctive feedback (i.e., Canadian guidelines).
3109701|NCT02330588|Experimental|Move It! (Normative Feedback)|Parents are presented with two questions about screen time and moderate-to-vigorous physical activity (MVPA); answers are contrasted with normative feedback (i.e., referent data from Canadian children).
3109702|NCT02330588|Placebo Comparator|eHealth Control|Parents randomly assigned to the control arm will include information on children's lifestyle behaviors only (no intervention questions).
3109703|NCT02330627|Experimental|Positive Valence System Treatment|10 one-hour individual sessions comprised of psychoeducation and positive activity interventions designed to increase positive emotions, cognitions, and behaviors.
3109704|NCT02330627|No Intervention|Delayed Treatment (Waitlist)|
3109705|NCT02330978|Experimental|MSC transplantion|One group of glaucomatous patients will receive 10(6) autologous bone marrow-derived mesenchymal stem cells transplantation into their worst eyes, through an unique intravitreal injections, under anesthesia.
3109706|NCT02331095|Active Comparator|Anticoagulation|Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
3109707|NCT02331095|Experimental|Atorvastatin + anticoagulation|In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment
3109708|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age 18-55.
3109709|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age <56|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age 18-55.
3109710|NCT02331108|Active Comparator|propofol, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction with 2.2 mg/kg propofol. Age 18-55.
3109711|NCT02331108|Active Comparator|propofol with phenylephrine, age <56|The intervention will be the randomized selection of anesthetic induction technique to intravenous induction 2.2 mg/kg propofol immediately preceded by 160 mcg intravenous phenylephrine. Age 18-55.
3109712|NCT02331108|Active Comparator|sevoflurane in 100% oxygen, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 100% oxygen and temperatures will be recorded per protocol. Age >55.
3109713|NCT02331108|Active Comparator|sevoflurane in 50% nitrous, age >55|The intervention will be the randomized selection of anesthetic induction technique to sevoflurane in 50% oxygen and 50% nitrous oxide. Age >55.
3109714|NCT02331368|Experimental|Anti-PD-1 (MK-3475)|"Standard Treatment:~High-dose Melphalan and autologous stem cell transplantation with post-transplant maintenance of Lenalidomide.~Study Treatment:~200 mg/day of MK-3475 administered every 3 weeks, starting day +14 post-transplant for a total of 9 doses."
3109715|NCT02331394|Experimental|Chinese herbs formula: Shu Yu Wan|All participants will be offered the choice of taking the CH formula in capsules or sachets in addition to standard care. This study will use the Shu Yu Wan formula which comprises 23 different herbs and is based on the best evidence in the literature of use of CH in lung cancer.
3109716|NCT02331407|Experimental|Robot arm rehabilitation therapy|Arm training using the ReoGo robotic device, 3 times a week for 3 weeks.
3109717|NCT02331446|No Intervention|Control|The control group will be oriented to maintain their normal activity and habits and will not receive the intervention.
3109718|NCT02331446|Experimental|90 minutes per week|The group of 90 minutes per week will do three sessions of 30 minutes per week of concurrent training, which consists on 15 minutes of aerobic exercise and 15 minutes of strength training.
3109719|NCT02331446|Experimental|150 minutes per week|The group of 150 minutes will do three sessions of 50 minutes per week, which consists on 25 minutes of aerobic exercise and 25 minutes of strength training.
3109720|NCT02331446|Experimental|210 minutes per week|The group pf 210 minutes per week will do three sessions of 70 minutes per week, which consists on 35 minutes of aerobic exercise and 35 minutes of strength training.
3109721|NCT02331589|Active Comparator|Korea Red Ginseng (KRG)|KRG capsule (3,000 mg/day) for 3 weeks
3109722|NCT02331589|Placebo Comparator|Placebo (for KRG)|placebo (for KRG) for 3 weeks
3109723|NCT02331680|Experimental|OPC-41061 15mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 24 week.
3109724|NCT02331680|Experimental|OPC-41061 30mg/day|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. OPC-41061 at 15 mg/day will be administered for 1 week and then OPC-41061 30 mg/day for 23 weeks
3109725|NCT02331680|Placebo Comparator|Placebo|Will be orally administered once daily after breakfast on all days on which subjects do not undergo dialysis. Placebo will be administered for 24 week.
3109726|NCT02331940|Active Comparator|Handihaler|Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
3109727|NCT02331940|Active Comparator|Respimat|Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
3109728|NCT02331992|Experimental|Positive airway pressure adherence program|Participants will be enrolled in the automated adherence program and will receive supportive messages while they use CPAP as prescribed by their healthcare provider. These messages are designed to aid the participant towards therapy adherence.
3109729|NCT02332239|Experimental|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored CBT-based text-message program"
3109730|NCT02332239|Placebo Comparator|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
3109731|NCT02332291|Active Comparator|Blinded Escitalopram / Open-Label Bupropion|8 weeks of blinded escitalopram, followed by 8 weeks of open-label bupropion xl for nonremitters
3109732|NCT02332291|Placebo Comparator|Blinded Placebo / Open-Label Bupropion|8 weeks of blinded placebo, followed by 8 weeks of open-label bupropion xl for nonremitters.
3109733|NCT02332590|Active Comparator|Adalimumab 40 mg|Adalimumab 40 mg subcutaneous (SC) injection in combination with placebo for sarilumab every 2 weeks (q2w) for 24 weeks during randomized treatment period. The dosing frequency of adalimumab may be adjusted to 40 mg every week (qw) dosing in case of participants with inadequate response (<20% improvement from baseline tender joint count [TJC] and swollen joint count [SJC] for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
3109734|NCT02332590|Experimental|Sarilumab 200 mg|Sarilumab 200 mg SC injection in combination with placebo for adalimumab q2w for 24 weeks during randomized treatment period. The dosing frequency of placebo for adalimumab may be adjusted to qw dosing in case of participants with inadequate response (<20% improvement from baseline TJC and SJC for 2 consecutive visits) at or after Week 16 until Week 23. Participants completed 24 weeks treatment period had the option to continue in open-label treatment period and received sarilumab 200 mg q2w until commercial availability of sarilumab in the country or maximum of 276 weeks.
3109735|NCT02332707|Experimental|A1: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3109736|NCT02332707|Experimental|A2: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3109737|NCT02332707|Experimental|A3: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3109738|NCT02332707|Experimental|A4: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3109739|NCT02332707|Experimental|A5: GT1 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3109740|NCT02332707|Experimental|A6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.
3109741|NCT02332707|Experimental|B7: GT2 NC GZR+UPR+EBR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.
3109742|NCT02332707|Experimental|A8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3109743|NCT02332707|Experimental|B9: GT1 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3109744|NCT02332707|Experimental|B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
3109745|NCT02332707|Experimental|B11: GT2 NC GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3109746|NCT02332707|Experimental|B12: GT1 C GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3109747|NCT02332707|Experimental|B13: GT1 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3109748|NCT02332707|Experimental|B14: GT2 C GZR+UPR+RZR (12 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.
3109749|NCT02332707|Experimental|B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.
3109750|NCT02332707|Experimental|B16: GT2 C GZR+UPR+RZR (16 weeks)|In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.
3109751|NCT02332707|Experimental|B6: GT1 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3109752|NCT02332707|Experimental|B8: GT2 NC GZR+UPR+RZR (8 weeks)|In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.
3109753|NCT02332720|Experimental|A1: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3109754|NCT02332720|Experimental|A2: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (300 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3109755|NCT02332720|Experimental|A3: GT3 NC TN Grazoprevir+Uprifosbuvir+Elbasvir (8 weeks)|In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + elbasvir (50 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3109756|NCT02332720|Experimental|A4/B4: GT3 NC TN Grazoprevir+Uprifosbuvir+Ruzasvir (8 weeks)|Participants will be randomized to either Part A or Part B. In Part A, HCV GT3-infected NC TN participants will take grazoprevir (100 mg) + uprifosbuvir (450 mg) + ruzasvir (60 mg) q.d. by mouth for 8 weeks. In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks. Part A participants who relapsed following completion of therapy were offered the option of retreatment with 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. and RBV (weight-based dosing) b.i.d. by mouth for 16 weeks during Part C.
3109757|NCT02332720|Experimental|B5: GT3 NC TN MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
3109758|NCT02332720|Experimental|B6: GT3 NC TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109759|NCT02332720|Experimental|B7: GT3 NC TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3109760|NCT02332720|Experimental|B8: GT3 NC TE MK-3682B (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
3109761|NCT02332720|Experimental|B9: GT3 NC TE MK-3682B + RBV (8 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 8 weeks.
3109762|NCT02332720|Experimental|B10: GT3 NC TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109763|NCT02332720|Experimental|B11: GT3 NC TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682 FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3109764|NCT02332720|Experimental|B12: GT3 NC TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected NC TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3109765|NCT02332720|Experimental|B13: GT3 C TN MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109766|NCT02332720|Experimental|B14: GT3 C TN MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3109767|NCT02332720|Experimental|B15: GT3 C TN MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3109768|NCT02332720|Experimental|B16: GT3 C TE MK-3682B (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109769|NCT02332720|Experimental|B17: GT3 C TE MK-3682B + RBV (12 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 12 weeks.
3109770|NCT02332720|Experimental|B18: GT3 C TE MK-3682B (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 16 weeks.
3109771|NCT02332720|Experimental|B19: GT3 C TE MK-3682B + RBV (16 weeks)|In Part B, HCV GT3-infected C TE participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d., and RBV (weight-based dosing) b.i.d., by mouth for 16 weeks.
3109772|NCT02332720|Experimental|B20: GT4 NC TN MK-3682B (8 weeks)|In Part B, HCV GT4-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 8 weeks.
3109773|NCT02332720|Experimental|B21: GT5 NC TN MK-3682B (12 weeks)|In Part B, HCV GT5-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109774|NCT02332720|Experimental|B22: GT6 NC TN MK-3682B (12 weeks)|In Part B, HCV GT6-infected NC TN participants will take 2 MK-3682B FDC tablets (each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg) q.d. by mouth for 12 weeks.
3109775|NCT02332798|Experimental|PF-04958242 0.25 mg|All participants who received PF-04958242 0.25 milligram (mg) twice daily (BID) for 14 consecutive days with the last dose occurring in the morning on Day 14.
3109776|NCT02332798|Experimental|PF-04958242 0.475 mg|All participants who received PF-04958242 0.475 mg BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
3109777|NCT02332798|Placebo Comparator|Matching Placebo|All participants who received placebo BID for 14 consecutive days with the last dose occurring in the morning on Day 14.
3109778|NCT02332824|Placebo Comparator|Placebo|"TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109779|NCT02332824|Experimental|TAK-272 5 mg|"TAK-272 5 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109780|NCT02332824|Experimental|TAK-272 20 mg|"TAK-272 20 mg one tablet, TAK-272 placebo 3 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109781|NCT02332824|Experimental|TAK-272 40 mg|"TAK-272 20 mg 2 tablets, TAK-272 placebo 2 tablets, and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109782|NCT02332824|Experimental|TAK-272 80 mg|"TAK-272 20 mg 4 tablets and Candesartan cilexetil placebo one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109783|NCT02332824|Active Comparator|Candesartan cilexetil 8 mg|"TAK-272 placebo 4 tablets and Candesartan cilexetil 8 mg one tablet, orally, once daily for up to 12 weeks.~Participants were administered TAK-272 placebo 4 tablets and Candesartan cilexetil placebo one tablet for 4 weeks (Week -4 to 0) in placebo run-in period and follow-up period (Week 12-14)."
3109784|NCT02332863|Active Comparator|Back-loaded needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G back-loaded needle. CRFs will be used to record data for primary and secondary endpoints.
3109785|NCT02332863|Experimental|Preloaded Needle|The patients will undergo Linear EUS and have fiducial marker placement via a traditional 22G preloaded needle. CRFs will be used to record data for primary and secondary endpoints.
3109786|NCT02332876|Experimental|Exercise Intervention|This arm will receive a 12-week individually tailored phone and email-based exercise program.
3109787|NCT02332876|Active Comparator|Wellness Waitlist Control|This arm will receive emails on the same schedule as the exercise arm, that cover a variety of health and wellness topics. At the end of the 12 weeks, participants will be able to start the exercise program.
3109788|NCT02332889|Experimental|Decitabine/Vaccine Therapy|Biological/Vaccine: Vaccine (autologous dendritic cells) and Drug: Decitabine and Hiltonol
3109789|NCT02332902|Experimental|Intervention|This is a single arm intervention using Everolimus
3109790|NCT02332915|Experimental|SPT - Intense First|Participants will receive intense application in the first phase of treatment, followed by the non intense application of treatment.
3109791|NCT02332915|Experimental|SPT - Traditional First|"Participants will receive non intense, traditional application of treatment in the first phase of treatment, followed by the intense application of treatment."
3109792|NCT02333045|Experimental|Truvada qd|Women will be assigned at random Truvada 1 tablet PO daily
3109793|NCT02333045|Experimental|Maraviroc 300 qd|Women will be assigned at random Maraviroc 300 mg PO daily
3109794|NCT02333071|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
3109795|NCT02333071|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
3109796|NCT02333331|Experimental|BYM338 70 mg|BYM338 70 mg intravenous infusion
3109797|NCT02333331|Experimental|BYM338 210 mg|BYM338 210 mg intravenous infusion
3109798|NCT02333331|Experimental|BYM338 700 mg|BYM338 700 mg intravenous infusion
3109799|NCT02333331|Placebo Comparator|Placebo|Placebo intravenous infusion
3109800|NCT02333383||Participants with Ankylosing Spondylitis|Adalimumab 40 mg every other week by subcutaneous (SC) injection for 52 weeks
3109801|NCT02333487|Experimental|Lu AF35700 (Group D1)|Up to 3 PET scans, besides baseline scan, using [11C]-NNC 112 tracer to detect D1 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
3109802|NCT02333487|Experimental|Lu AF35700 (Group D2)|Up to 3 PET scans, besides baseline scan, using [11C]-Raclopride to detect D2 dopamine receptor occupancy before and after multiple oral dosing of Lu AF35700
3109803|NCT02333487|Experimental|Lu AF35700 (Group 5-HT6)|Up to 3 PET scans, besides baseline scan, using [11C]- Lu AE60157 tracer to detect 5-HT6 (5-hydroxytryptamine-6) receptor occupancy before and after multiple oral dosing of Lu AF35700
3109804|NCT02333630|Experimental|AsthmaCare intervention|Participants randomized to this arm will have the AsthmaCare app downloaded to their mobile device at time of study recruitment. They will have access to AsthmaCare indefinitely after enrollment.
3109805|NCT02333630|Active Comparator|Control group|Participants randomized to this arm will receive a link to a website containing asthma education videos and information. They will be able to access this link at their discretion.
3109806|NCT02334059|Active Comparator|Ketamine|Ketamine: 0.5 mg/kg IV dose
3109807|NCT02334059|Active Comparator|Ketamine plus magnesium|Ketamine plus magnesium group: 0.5 mg/kg IV dose as well as Magnesium 2 grams IV
3109808|NCT02334059|Placebo Comparator|Placebo|Placebo (normal saline)
3109809|NCT02334215|Experimental|Methadone plus Patient Navigation|Participants will begin methadone treatment during detention and will have a patient navigator for up to 3 months post-release from detention.
3109810|NCT02334215|Experimental|Methadone|Participants will begin methadone during detention.
3109811|NCT02334215|Active Comparator|Enhanced Treatment as Usual|Participants will receive opioid detoxification during detention, as well as drug abuse education, overdose prevention education, and referral to drug abuse treatment and overdose prevention services in the community.
3109812|NCT02334267|Active Comparator|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of NaturaLyte for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
3109813|NCT02334267|Active Comparator|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using acid dialysate concentrations of GranuFlo for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
3109814|NCT02334306|Experimental|MEDI5872 210 mg|Participants will receive a fixed SC dose of 210 mg MEDI5872 every week (QW) from Days 1 to 15 and then every 2 weeks (Q2W) from Days 29 to 85 in double-blind period. In open-label period, participants will continue dosing of MEDI5872 210mg Q2W from Days 99 to 183 and will receive an additional dose of blinded placebo on Day 106.
3109815|NCT02334306|Placebo Comparator|Placebo/MEDI5872 210 mg|Participants will receive a SC dose of placebo matching with MEDI5872 QW on Days 1, 8, and 15 and then Q2W from Days 29 to 85 in double-blind period. In open-label period, participants will receive a fixed SC dose of 210 mg MEDI5872 QW (Days 99 to 113) and Q2W (Days 127 to 183) in open-label period.
3109816|NCT02334358||YVOIRE Classic s|Treatment with YVOIRE Classic s
3109817|NCT02334384|Experimental|Antimicrobial TheraGauze|Antimicrobial TheraGauze (i.e. tobramycin impregnated TheraGauze) will be used as a wound packing after incision and drainage of skin abscess (i.e. furunculosis). Antimicrobial TheraGauze will be administered once.
3109818|NCT02334384|No Intervention|Standard of care - standard wound packing|In this control arm the subject will receive standard of care with standard wound packing. The ED physician will have the choice to use plain cotton wick or iodoform wick. Standard wound packing will be administered once.
3109819|NCT02334423|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
3109820|NCT02334423|Placebo Comparator|Placebo|0.9 % sterile, unpreserved saline
3109821|NCT02334436|Experimental|Botulinum toxin, Type A|Botulinum toxin, Type A
3109822|NCT02334436|Placebo Comparator|Placebo|0.9% sterile, unpreserved saline
3109823|NCT02334527|Other|Palbociclib Single Arm trial|Palbociclib
3109824|NCT02334683|Experimental|Electrophysiologic guidance|Electrophysiologic guidance, using electrical stimulation
3109825|NCT02334683|Active Comparator|Ultrasound guidance|Ultrasound guidance,using sound waves through a wand directed towards the targeted muscles.
3109826|NCT02334748|Experimental|canakinumab|Patients will continue the same dose as their last dose administered in the study CACZ885G2301E1, CACZ885N2301 or CACZ885G2306. For all indications, the maximum canakinumab dose is 4 mg/kg or 300 mg for patients ≥ 40 kg. Ilaris® dosage may be adjusted (or interrupted) according to the clinical response and to investigators judgment.
3109827|NCT02334787|Experimental|0.3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned0.3% OPA-15406 ointment assessed until 48 hours postdose.
3109828|NCT02334787|Experimental|1% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1% OPA-15406 ointment assessed until 48 hours postdose.
3109829|NCT02334787|Experimental|3% OPA-15406 in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3% OPA-15406 ointment assessed until 48 hours postdose.
3109830|NCT02334787|Placebo Comparator|Placebo in a single administration period|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned placebo ointment assessed until 48 hours postdose.
3109831|NCT02334787|Experimental|0.3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3109832|NCT02334787|Experimental|1% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3109833|NCT02334787|Experimental|3% OPA-15406 in the multiple administration period|In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
3109834|NCT02334787|Experimental|Placebo in the multiple administration period|In the multiple administration period, same subjects were treated with assigned OPA-15406 ointment placebo twice daily for 14 days and assessed until 48 hours post dose.
3109835|NCT02334800|Experimental|Healthy Volunteers|Cohort of Healthy Volunteers
3109836|NCT02334800|Experimental|Mild Hepatic Impairment|Cohort of mild hepatic impairment subjects meeting the criteria for Child-Pugh Class A
3109837|NCT02334800|Experimental|Moderate Hepatic Impairment|Cohort of moderate hepatic impairment subjects meeting the criteria for Child-Pugh Class B
3109838|NCT02334800|Experimental|Severe Hepatic Impairment|Cohort of severe hepatic impairment subjects meeting the criteria for Child-Pugh Class C
3109839|NCT02334813|Active Comparator|Arm A: daily prednisone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm A prednisone is continued at 1 mg/kg/d for a second week. If platelets increase to ≥50/nl, its dose is reduced to <25 mg/d by week 14 and <7.5 mg/d by week 20 according to a step-wise reduction scheme provided in the protocol. In patients without response after 2 weeks of treatment, the prednisone dose is increased to 2 mg/kg/d for another 2 weeks, then tapered as described above.
3109840|NCT02334813|Active Comparator|Arm B: pulsed dexamethasone|During the first week of treatment patients in both arms receive prednisone at 1 mg/kg/d. In arm B patients subsequently receive six 21-day courses of pulsed dexamethasone (0.6 mg/kg/d, days 1-4).
3109841|NCT02334982|Experimental|Cohort 1: TAK-137 2 mg|TAK-137 2 mg, tablets, orally, once on Day 1.
3109842|NCT02334982|Experimental|Cohort 2: TAK-137 5 mg|TAK-137 5 mg, tablets, orally, once on Day 1.
3109843|NCT02334982|Experimental|Cohort 3: TAK-137 10 mg|TAK-137 10 mg, tablets, orally, once on Day 1.
3109844|NCT02334982|Experimental|Cohort 4: TAK-137 5 mg Food Effect|TAK-137 5 mg, tablets, orally, under fasted conditions, once on Day 1 of Period 1, followed by 14 days of follow-up, followed by TAK-137 5 mg, tablets, orally, under fed conditions, once on Day 1 of Period 2.
3109845|NCT02334982|Experimental|Cohort 5: TAK-137 0.5 mg|TAK-137 0.5 mg, tablets, orally, once on Day 1.
3109846|NCT02334982|Experimental|Cohort 6: TAK-137 20 mg|TAK-137 20 mg, tablets, orally, once on Day 1.
3109847|NCT02334982|Placebo Comparator|Cohorts 1-6: Placebo|TAK-137 placebo-matching tablets, orally, once on Day 1.
3109848|NCT02335125|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both TBI and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, medication, and psychotherapy elements.
3109849|NCT02335125|No Intervention|Usual Care|Only standard care practices will be administered to this arm.
3109850|NCT02335216||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3109851|NCT02335229||Axium DRG Neurostimulator|All eligible subjects recruited and treated with the Axium Neurostimulator
3109852|NCT02335294|Experimental|TRV130|
3109853|NCT02335294|Active Comparator|Morphine|
3109854|NCT02335294|Placebo Comparator|Placebo|
3109855|NCT02335346|Experimental|Duloxetine|Duloxetine 20 milligram (mg) for first week, 40 mg for second week and 60 mg for next 48 weeks administered orally once daily. During tapering period, dose of 40 mg for one week and then 20 mg for the last week.
3109856|NCT02335424|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg intravenous (IV) on Day 1 of each 3-week cycle for up to 24 months.
3109857|NCT02335450|Experimental|Single Arm|All five participants in the study will receive this intervention. The participants will be visited in their homes by a physical therapist once a week. The physical therapist will use a coaching technique called motivational interviewing to help the participant develop personal physical activity goals. The participant will discuss their physical activity challenges, and with the help of the physical therapist the participant will set up personal physical activity goals for the following week. The participant will be given a wristband physical activity monitor to wear during the day for four weeks to track their progress in meeting their activity goals.
3109858|NCT02335489||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3109859|NCT02335502||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3109860|NCT02335658|Experimental|DSP-5423P|Percutaneous
3109861|NCT02335710||Smith & Nephew Journey II BCS TKA|Subjects must be implanted with a Smith & Nephew Journey II bi-cruciate stabilizing (BCS) total knee arthroplasty (TKA) implanted by Dr. Harold Cates
3109862|NCT02335710||Normal knee|Subjects must have a healthy, functioning knee with no osteoarthritis or knee pathologies
3109863|NCT02335905|Experimental|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour). The dose may vary with age.
3109864|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 56 mg/m²|"Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109865|NCT02335983|Experimental|RRMM Dose-evaluation: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109866|NCT02335983|Experimental|RRMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109867|NCT02335983|Experimental|NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²|"Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109868|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 70 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109869|NCT02335983|Experimental|NDMM Dose-expansion: Carfilzomib 56 mg/m²|"Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death.~Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8."
3109870|NCT02336074|Active Comparator|Control|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total)
3109871|NCT02336074|Experimental|Intervention|Combination Antiretroviral Therapy (cART) preferably including raltegravir prescribed at week 0 for the duration of the study up to post-randomisation week 18 (42 weeks in total) Plus ChAdV63.HIVconsv prime (post-randomisation week 00) and MVA.HIVconsv boost (post randomisation week 08 day 1) vaccines; followed by a 28-day course of vorinostat (10 doses in total).
3109872|NCT02336165|Experimental|Cohort A|Subjects with newly diagnosed unmethylated MGMT GBM receive durvalumab (10 mg/kg Q2W) + standard radiotherapy.
3109873|NCT02336165|Experimental|Cohort B|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) as monotherapy.
3109874|NCT02336165|Experimental|Cohort B2|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (10 mg/kg Q2W).
3109875|NCT02336165|Experimental|Cohort B3|Bevacizumab-naïve subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + bevacizumab (3 mg/kg Q2W).
3109876|NCT02336165|Experimental|Cohort C|Bevacizumab-refractory subjects with recurrent GBM receive durvalumab (10 mg/kg Q2W) + continued bevacizumab (10 mg/kg Q2W).
3109877|NCT02336178|Experimental|Benefix|This is a single arm study. Subjects will be treated with Benefix by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
3109878|NCT02336282|Active Comparator|tDCS on Day 1|"On day one, participants will be randomized to receive the transcranial Direct Current Stimulation (tDCS) intervention. On day two, participants receive sham intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~In the second phase of the trial, participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive assessment will be conducted pre- and post-intervention using remote assessment."
3109879|NCT02336282|Active Comparator|tDCS on Day 2|"On day one, participants will be randomized to receive sham intervention. On day two, participants receive the transcranial Direct Current Stimulation (tDCS) intervention.~On both days 1 and 2, within two hours of completing the intervention, participants will complete cognitive assessment.~The second phase of the trial will be conducted the same as for participants in the tDCS on Day 1 arm. Participants will be evaluated over 5 weeks using a mobile tDCS device and Brain Games Stimulation twice per week. Within two hours of completing each tDCS session, participants will complete 20 minutes of cognitive training using a mobile application installed on an iPad. Cognitive testing will be conducted pre- and post-intervention using remote assessment."
3109880|NCT02336360|Experimental|Urine Analysis|Urine will be collected from subjects administered flortaucipir in an Avid-sponsored study to determine the amount of radioactivity excreted in urine.
3109881|NCT02336373|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.
3109882|NCT02336438|No Intervention|Baseline Phase (Control)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) and scheduled blood draws over 3 hours."
3109883|NCT02336438|Experimental|Treatment Phase (Glucomannan)|"iPro CGM device will be worn for next 5 days. The subjects will maintain a diet history and will be given a One Touch glucometer and strips to check their blood glucose at home four times a day for next five days and log this onto the System Patient Log (included).~Subjects will undergo MMTT, which includes consumption of a standard meal (Boost) + 5 grams of Glucomannan soluble fiber powder and scheduled blood draws over 3 hours.~For the next five days subjects will take the following amounts of Glucomannan soluble fiber (provided by the investigator) three times a day with meals."
3109884|NCT02336451|Experimental|Arm 1 (PrALKi=Y, PrBRad=Y)|Participants with metastases in the brain without evidence of leptomeningeal carcinomatosis (LC), previously treated with radiation to the brain and with prior exposure to an Anaplastic lymphoma kinase inhibitor (ALK-I). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
3109885|NCT02336451|Experimental|Arm 2 (PrALKi=Y, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain but with prior exposure to an ALK-I. Previous treatment with ALK-I other than crizotinib was not allowed in this arm 2 as of protocol amendment 3 and had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
3109886|NCT02336451|Experimental|Arm 3 (PrALKi=N, PrBRad=Y)|Participants with metastases in the brain without evidence of LC, previously treated with radiation to the brain but with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
3109887|NCT02336451|Experimental|Arm 4 (PrALKi=N, PrBRad=N)|Participants with metastases in the brain without evidence of LC, previously untreated with radiation to the brain and with no prior exposure to an ALK-I. Participants in this arm had to present with active brain lesion defined as a lesion free of any local treatment (like stereotactic radiosurgery or whole brain radiation).
3109888|NCT02336451|Experimental|Arm 5 (LepDis)|Participants had LC with or without evidence of active lesion at the baseline Gadolinium-enhanced brain magnetic resonance imaging (MRI). Previous treatment with ALK-I other than crizotinib was not allowed in this arm as of protocol amendment 3.
3109889|NCT02336555|Experimental|MK-8291 → Placebo|In Treatment Period 1, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
3109890|NCT02336555|Experimental|Placebo → MK-8291|In Treatment Period 1, participants were orally administered Placebo once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. After Treatment Period 1, participants were to undergo a minimum of a 7-day Washout Period, which was followed by Treatment Period 2. In Treatment Period 2, participants were orally administered 10 mg MK-8291 once daily on Days 1 and 2, twice daily on Days 3 to 27, and once daily on Day 28 of the period. (Total duration of treatment: up to approximately 63 days)
3109891|NCT02336594|Experimental|Sequence ABCD|2.5 mg x 4 tablets qd (once daily) fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat.
3109892|NCT02336594|Experimental|Sequence BACD|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed low-fat, 10 mg tablet qd fed high-fat
3109893|NCT02336594|Experimental|Sequence ABDC|2.5 x 4 mg tablets qd fasted, 10 mg tablet qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
3109894|NCT02336594|Experimental|Sequence BADC|10 mg tablet qd fasted, 2.5 mg x 4 tablets qd fasted, 10 mg tablet qd fed high-fat, 10 mg tablet qd fed low-fat
3109895|NCT02336607|Experimental|Felodipine tablet (Plendil)|
3109896|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|
3109897|NCT02336607|Active Comparator|Felodipine tablets (Plendil)+Lisinopril (Zestril)|
3109898|NCT02336607|Active Comparator|Felodipine tablet (Plendil)+Hydrochlorothiazide|
3109899|NCT02336737|Experimental|SiennaXP injection|"Single injection of SiennaXP in addition to comparator single dose of radioisotope (Technetium Tc99m Sulfur Colloid) and single dose of isosulfan blue dye.~Lymph node localization using the SentiMag handheld intraoperative localization system in addition to localization with standard of care handheld gamma probe."
3109900|NCT02336815|Experimental|Part 1|Participants with quad-exposed, double-class-refractory (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, but not an anti-CD38 mab) and penta-exposed, triple-class-refractory multiple myeloma (MM) (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mAb daratumumab) received, two dosing schedules (1) Selinexor 80 milligrams (mg) plus low-dose dexamethasone 20 mg (Sd) twice-weekly on Days 1 and 3 for 3 weeks of each 4-week cycle (2) Selinexor 80 mg plus low-dose dexamethasone 20 mg (Sd) twice-weekly continuously in 4-week cycles; until disease progression, death, or unacceptable toxicity (maximum duration of approximately 13 months).
3109901|NCT02336815|Experimental|Part 2|Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, Selinexor 80 mg post oral (PO) plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).
3109902|NCT02336958|Active Comparator|ropivacaine|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml ropivacaine 0.75%.
3109903|NCT02336958|Placebo Comparator|saline|Ultrasound guided intermediate cervical plexus block: 20ml ropivacaine 0.75%. Ultrasound guided perivascular/pericarotidal infiltration: 5ml saline 0.9%.
3109904|NCT02337062|Experimental|APD421 + standard anti-emetic|Single dose of IV APD421
3109905|NCT02337062|Placebo Comparator|Placebo + standard anti-emetic|Single dose of IV placebo
3109906|NCT02337218|Active Comparator|SENSUS Pain Management System|Electrical stimulation device worn on the leg delivering a dose of 50 volts.
3109907|NCT02337218|Sham Comparator|SENSUS Pain Management System - Sham|Electrical stimulation device worn on the leg and programmed to deliver no stimulation.
3109908|NCT02337361|Experimental|e-SBI|Single session, Electronic SBI for risky alcohol use
3109909|NCT02337361|No Intervention|Control|Treatment as usual with only assessment
3109910|NCT02337387|Experimental|Blosozumab Formulation A|Part A. Blosozumab administered as 2 subcutaneous (SC) injections in week 1 followed by once weekly (QW) injections SC in weeks 2 to 6, followed by six week follow-up period.
3109911|NCT02337387|Experimental|Blosozumab Formulation B|Part A. Blosozumab administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3109912|NCT02337387|Placebo Comparator|Placebo|Part A. Placebo administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3109913|NCT02337387|Experimental|Blosozumab (Part B)|Part B. Blosozumab formulation determined by Part A administered as 2 SC injections in week 1 followed by QW injections SC in weeks 2 to 6, followed by six week follow-up period.
3109914|NCT02337465|Experimental|Diagnostic (KV-CBCT, ultrasound-guided radiation therapy)|Patients undergo 3-Dimensional Ultrasound-Guided Radiation Therapy prior to and during radiation therapy. Patients also undergo kilo-voltage Cone-Beam Computed Tomography prior to radiation therapy.
3109915|NCT02337478|Experimental|Treatment (vincristine sulfate liposome)|Patients receive vincristine sulfate liposome via injection on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3109916|NCT02337491|Experimental|Cohort A Safety Lead-In: Pembrolizumab (DL 0) + Bevacizumab|"Pembrolizumab (Dose Level 0): 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3109917|NCT02337491|Experimental|Cohort A: Pembrolizumab + Bevacizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle Bevacizumab: 10 mg/kg administered Intravenously on days 1, 15 and 29 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3109918|NCT02337491|Experimental|Cohort B: Pembrolizumab|"Pembrolizumab: 200 mg administered intravenously on days 1 and 22 of each 42 day cycle~Participants were treated until disease progression or unacceptable toxicity up to 16 cycles."
3109919|NCT02337517|Experimental|Supportive care (vismodegib)|Patients receive vismodegib PO daily, every other day, every three days, or twice weekly for 6-12 months in the absence of disease progression or unacceptable toxicity.
3109920|NCT02337530|Active Comparator|Arm A|"Selumetinib: 75mg/ bid PO given on days 2-19 Pemetrexed: 500mg/m^2 & Cisplatin or Carboplatin*: AUC6: 75mg/m^2 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3109921|NCT02337530|Active Comparator|Arm B|"Selumetinib: 75mg/ bid PO given on days 1-21 (continuous) Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC 6 given on day 1 Schedule = q 21 days~**Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3109922|NCT02337530|Active Comparator|Arm C|"Selumetinib: NOT GIVEN Pemetrexed: 500mg/m^2 & Cisplatin*: 75mg/m^2 or carboplatin AUC6 given on day 1 Schedule = q 21 days~*Must be specified at time of randomization. Patients who start on treatment with cisplatin may switch to carboplatin only after discussion with CCTG"
3109923|NCT02337725|Experimental|TVP-1012 1 mg|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of TVP-1012 1 mg orally, once daily before or after breakfast.
3109924|NCT02337725|Placebo Comparator|Placebo|For 2 weeks during the run-in period, one tablet of placebo orally, once daily before or after breakfast, followed by 26 weeks during the treatment period, one tablet of placebo orally, once daily before or after breakfast.
3109925|NCT02337738|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
3109926|NCT02337738|Experimental|TVP-1012 0.5mg|TVP-1012 0.5 mg once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
3109927|NCT02337738|Placebo Comparator|Placebo|One placebo tablet once daily orally, before or after breakfast, concomitantly with levodopa tablet for 26 weeks as treatment period after 2 weeks of run-in period.
3109928|NCT02337751|Experimental|TVP-1012 1mg Group|TVP-1012 (1 mg/day) once daily, either before or after breakfast.
3109929|NCT02337764|Experimental|TVP-1012 1mg|TVP-1012 1 mg once daily orally, either before or after breakfast, concomitantly with levodopa tablet for 52 weeks as treatment period after 2 weeks of run-in period.
3109930|NCT02337829|Experimental|Arm A|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
3109931|NCT02337829|Experimental|Arm B|Subjects will be randomized to receive 1 of 2 dosing regimens: 1) acalabrutinib, dose A once daily; or 2) acalabrutinib, dose B twice daily.
3109932|NCT02337907|Placebo Comparator|Placebo comparator|
3109933|NCT02337907|Experimental|BI 409306 dose 1|
3109934|NCT02337907|Experimental|BI 409306 dose 2|
3109935|NCT02337907|Experimental|BI 409306 dose 3|
3109936|NCT02337907|Active Comparator|Active Comparator Donepezil|
3109937|NCT02337907|Experimental|BI 409306 dose 4|
3109938|NCT02337933|Experimental|Ursolic acid|Ursolic acid capsules, 150 mg, once a day before breakfast during 12 weeks
3109939|NCT02337933|Placebo Comparator|Placebo|Calcined magnesia capsules, 150 mg, once a day before breakfast during 12 weeks
3109940|NCT02337946|Active Comparator|Group A|Panitumumab (Pmab) 6 mg/kg, intravenous drip infusion (DIV), at Day 1, oxaliplatin (OXA) 85 mg/m^2, DIV, at Day 1, levofolinate (l LV) 200 mg/m^2, DIV, at Day 1, fluorouracil (5-FU) 400 mg/m^2, intravenous (IV) at Day 1, 5-FU 2400 mg/m^2, continuous intravenous infusion (CIV), at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
3109941|NCT02337946|Experimental|Group B|Pmab 6 mg/kg, DIV, at Day 1, OXA 85 mg/m^2, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 1 through cycle 6 as protocol treatment 1 followed by Pmab 6 mg/kg, DIV, at Day 1, l LV 200 mg/m^2, DIV, at Day 1, 5-FU 400 mg/m^2, IV, at Day 1, 5-FU 2400 mg/m^2, CIV, at Day 2 once every two weeks from cycle 7 until progressive disease or intolerance.
3109942|NCT02337959|Experimental|Predicate & Invest.-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
3109943|NCT02337959|Experimental|Predicate & Invest.-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
3109944|NCT02337959|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using the both the GoS and the CsI investigational detectors.
3109945|NCT02338076|Experimental|Interventional arm|petrolatum application under occlusion
3109946|NCT02338193|Experimental|DAPA/MET Extended Release (XR)|Dapagliflozin plus metformin XR- 5 mg/1000 mg with meal for 4 weeks DAPA/MET XR- 5mg/1000 mg BID final dose for 20 weeks
3109947|NCT02338193|Active Comparator|Dapaglifloxin|Dapagliflozin- 10 mg once daily before first meal for 24 weeks
3109948|NCT02338193|Active Comparator|Metformin XR|Metformin XR with 500 mg once a day for 2 weeks, followed by 500 mg twice a day for 2 weeks, followed by 500 mg in the morning (AM), 1000 mg in the evening ( PM) for 2 weeks, with 1000 mg twice a day as the final dose for 20 weeks
3109949|NCT02338336|Placebo Comparator|Placebo|Placebo
3109950|NCT02338336|Experimental|Nowarta110 3 drops|Nowarta110 3 drops administration
3109951|NCT02338336|Experimental|Nowarta110 6 drops|Nowarta110 6 drops administration
3109952|NCT02338336|Experimental|Nowarta110 10 drops|Nowarta110 10 drops administration
3109953|NCT02338362|Active Comparator|Fluticasone|10 participants will be asked to use fluticasone propionate 250 µg metered-dose inhaler 1 puff twice-daily for 6 weeks.
3109954|NCT02338362|Placebo Comparator|Saline placebo|10 participants will be asked to use a saline placebo metered-dose inhaler 1 puff twice-daily for 6 weeks.
3109955|NCT02338492|Experimental|Photodynamic Bone Stabilization System|Photodynamic Bone Stabilization System (PBSS) is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone
3109956|NCT02338713|Experimental|Noncarbonated Water + Calcichew D3|Noncarbonated water 200 milliliter (mL), orally, once daily on Days 1, 2 and 3 in period 1 (dummy treatment period) followed by Calcichew D3 500 milligram (mg)/1000 international units (IU) (Calcium 500 mg, chewable tablets and vitamin D3 1000 IU, chewable tablets), orally, once daily on Days 4, 5 and 6 in period 2 (study treatment period) of 6 days treatment period.
3109957|NCT02338843|Experimental|LJPC-501 (angiotensin II)|Treatment arm
3109958|NCT02338843|Placebo Comparator|Placebo (0.9% sodium chloride solution)|Placebo arm
3109959|NCT02338882|Experimental|Bi flex M multifocal intraocular lens|Subjects implanted bilaterally with the Bi flex M multifocal intraocular lens
3109960|NCT02338882|Active Comparator|Bi flex 1.8 monofocal intraocular|Subjects implanted bilaterally with the Bi flex 1.8 monofocal intraocular lens
3109961|NCT02338960|Experimental|Bremelanotide (BMT/BMT)|"(Main Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 24 weeks~(OLE Study) Subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
3109962|NCT02338960|Placebo Comparator|Placebo (PBO/BMT)|"(Main Study) PBO administered SC on an as-desired basis for 24 weeks~(OLE Study) subjects will self-administer a fixed dose (1.75 mg) of bremelanotide (BMT) subcutaneously (SC) via auto-injector on an as needed basis with no more than 1 dose taken every 24 hours for 52 weeks"
3109963|NCT02338973|Experimental|Interferon Gamma-1b|Topical interferon (IFN) gamma-1b, 112 µg dose, administered in study eye daily for two weeks
3109964|NCT02338999|Experimental|Pioglitazone, then placebo|Treatment with pioglitazone up to 45 mg orally daily for three months. Followed by a two-month washout period before cross over to placebo orally daily for three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
3109965|NCT02338999|Experimental|Placebo, then Pioglitazone|Treatment with placebo orally daily for three months. Followed by a two-month washout period before cross over to pioglitazone up to 45 mg daily orally for an additional three months. A randomly selected subset of subjects underwent optional FDG-PET/CT for measurement of inflammatory activity in the blood vessels.
3109966|NCT02339038|Other|Standard of Care|Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months
3109967|NCT02339155|Experimental|Anthrax Vaccine Adsorbed|Subjects will be administered subcutaneous (SC) 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks).
3109968|NCT02339155|Experimental|AVA + Raxibacumab|Subjects will be administered SC 0.5 mL AVA doses on Days 1, 15, and 29 (0, 2, and 4 weeks), with the first AVA dose administered immediately after completion of a single intravenous (IV) infusion 40 milligram (mg)/kilogram (kg) raxibacumab dose. Subjects will be premedicated with 25-50 mg of diphenhydramine up to 1 hour prior to the raxibacumab infusion to reduce the risk of infusion reactions.
3109969|NCT02339246|Active Comparator|Prograf vs Envarsus XR vs Astagraf XL|Prograft capsules Twice daily for 7 days, followed by Envarsus XR tablets once daily for 7 days followed by Astagraf XL capsules once daily for 7 days.
3109970|NCT02339246|Active Comparator|Prograf vs Astagraf XL vs Envarsus XR|Prograf capsules twice daily for 7 days followed by Astagraf XL capsules once daily for 7 days followed by Envarsus XR tablets once daily.
3109971|NCT02339285|Experimental|tACS (alpha)|10 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (alpha) device.
3109972|NCT02339285|Experimental|tACS (gamma)|40 Hz tACS with a peak-to-peak amplitude of 2 milliamps (mA) for 40 minutes. Uses tACS (gamma) device.
3109973|NCT02339285|Sham Comparator|Sham stimulation|Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation. Uses tACS (alpha) device.
3109974|NCT02339389||ventilation during labor analgesia|We are simply measuring ventilation changes that occur following labor analgesia.
3109975|NCT02339415|Active Comparator|Treatment|Edoxaban 30mg daily
3109976|NCT02339415|Placebo Comparator|Placebo|Matching Placebo
3109977|NCT02339506|Active Comparator|Cosyntropin|Subjects will receive cosyntropin infusion at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
3109978|NCT02339506|Placebo Comparator|Normal saline (Placebo)|Subjects will receive normal saline infusion for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
3109979|NCT02339545||All Enrolled Subjects|All subjects will receive Coronary Flow Reserve (CFR) measurements post successful orbital atherectomy treatment and stenting.
3109980|NCT02339558|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over approximately 60 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3109981|NCT02339584|Experimental|Brinz/Brim|Vehicle solution, 1 drop, followed by Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) twice daily (BID) for 3 months
3109982|NCT02339584|Active Comparator|Brinz+Brim|Brimonidine 2 mg/mL eye drops, solution, 1 drop, followed by Brinzolamide 10 mg/mL eye drops, suspension, 1 drop, administered at least 5 minutes apart in the treated eye(s) BID for 3 months
3109983|NCT02339831|Active Comparator|active motion device|An active motion device (CAM) known as a CAMOPED was given after surgery. The device was used for 3 sessions of 20 minutes for 3 weeks.
3109984|NCT02339831|Active Comparator|CPM passive motion device|A continuous passive motion device (CPM) given after surgery. The device bends and moved the knee passively. It was used for 4 hours daily for 3 weeks.
3109985|NCT02339909|Active Comparator|Control|"The intervention for the Control group consists of the standard invitation letter from the Screening service. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3109986|NCT02339909|Experimental|Fixed Incentive|"The intervention for the fixed incentive group consists of the standard invitation letter from the Screening service, with additional text offering a fixed financial incentive (£10) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3109987|NCT02339909|Experimental|Probabilistic Incentive|"The intervention for the probabilistic incentive group consists of the standard invitation letter from the Screening service, with additional text offering a probabilistic financial incentive (entry into a lottery offering at least a 1 in 100 chance to win £1000) if they attend screening. (The trial is testing the impact of the different invitation letters on the primary outcome of screening attendance.)"
3109988|NCT02340000|Active Comparator|standard dose|amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
3109989|NCT02340000|Experimental|high dose|Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days
3109990|NCT02340078|Active Comparator|HA IDF II|cross-linked HA filler
3109991|NCT02340078|Experimental|HA IDF II plus|cross-linked HA filler with lidocaine
3109992|NCT02340091|Experimental|HA IDF plus|cross-linked HA filler with lidocaine
3109993|NCT02340091|Active Comparator|HA IDF|cross-linked HA filler without lidocaine
3109994|NCT02340104|Experimental|Baricitinib|Single oral dose of baricitinib and single intravenous (IV) infusion of [^13C4D3^15N]-baricitinib over 1.5 hours.
3109995|NCT02340156|Experimental|SGT-53 with Temozolomide|SGT-53, at 3.6 mg DNA/infusion, will be administered twice weekly in a 28 day cycle starting on Day 1 (cycle 1), Day 29 (cycle 2) and Day 57 (cycle 3). Temozolomide (TMZ) will be administered by mouth daily on days 9-13 of each cycle. Patients who are responding to treatment may receive three additional cycles of SGT-53/TMZ therapy or continue on TMZ alone at investigator's discretion. Surgical resection of recurrent or progressive tumor for tumor analysis is an optional procedure. In these individuals SGT-53, at 3.6 mg DNA/infusion, will be administered twice (on days -1 and -3) in the week prior to surgery. Surgical resection is Day 0. 14-21 days post operatively and having recovered from the effects of surgery, the patients will then start cyclical TMZ with SGT-53 as described above.
3469215|NCT03888807|Experimental|Biofreeze|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees.
3109998|NCT02340299|Experimental|nHFOV|"Immediately after extubation, nHFOV is provided via binasal prongs. Ventilator settings: Frequency set at 10 Hz, I:E ratio 33:66, amplitude 20 cm H2O, Pmean 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum amplitude 30 cm H2O, minimum frequency 9 Hz, maximum Pmean 8 cm H2O.~For infants in the nHFOV-group who fail nHFOV (see definition below), but do not need immediate reintubation, a non-invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
3109999|NCT02340299|Active Comparator|nCPAP|"Immediately after extubation, nCPAP is provided via binasal prongs. Ventilator settings: CPAP level set at 8 cm H2O, flow 7 l/min. Set FiO2 to maintain SpO2 at 90-94%.~The weaning process is left to the discretion of the attending physician. Maximum CPAP level 8 cm H2O, maximum flow 8 l/min.~For infants in the nCPAP-group who fail nCPAP (see definition below), but do not need immediate reintubation, Rescue-nHFOV via binasal prongs may be provided. The decision to attempt Rescue-nHFOV and the ventilator settings used are at the discretion of the attending clinician."
3110000|NCT02340338|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 100 ng
3110001|NCT02340338|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 300 ng
3110002|NCT02340338|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 1 µg
3110003|NCT02340338|Experimental|Dose Group 4|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
3110004|NCT02340338|Experimental|Dose Group 5|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
3110005|NCT02340338|Experimental|Dose Group 6|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
3110006|NCT02340338|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
3110007|NCT02340520|Experimental|thophylline and roflumilast|Theophylline for one week, followed by the addition of Roflumilast for a further one week.
3110008|NCT02340663|Experimental|SOVA bite splint|SOVA Bite splint: Over-the-counter, heat-and-mold bite splint. Investigators evaluate subject self-fabrication, and evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
3110009|NCT02340663|Active Comparator|Michigan Bite Splint|Michigan bite splint: Gold standard, custom acrylic bite splint made for subjects. Investigators evaluate fit. Subjects wear splint nightly for one week. Polysomnographic data obtained from one night during the week. Subjects continue to wear splint for 3 months, dairy kept of nightly wear. Polysomnographic data obtained from one night at the end of three months.
3110010|NCT02340676|Experimental|ECP plus IL-2|"Extracorporeal Photopheresis (ECP) standard-of-care~Daily subcutaneous (SC) interleukin-2 (IL-2) (Proleukin®) during predetermined weeks of treatment cycle"
3110011|NCT02340715||MRI for treatment planning or follow up|MRI for treatment planning for radiation therapy or those who have completed treatment and are receiving follow up care.
3110012|NCT02340767|No Intervention|No Device Clinicians|The clinicians will not receive any additional training.
3110013|NCT02340767|Experimental|Spectra Device Clinicians|The clinicians in the Spectra Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
3110014|NCT02340767|Experimental|DIAGNOdent Device Practitioners|The clinicians in the DIAGNOdent Device Arm will be trained to the device according to the manufacturers' usual care for training. The training will consist of viewing the manufacturer's instructions for the device. Training will also consist of clinicians familiarizing themselves with the device through unsupervised clinical use with patients.
3110015|NCT02340780|Experimental|Buparlisib|100mg daily orally every 28 days
3110016|NCT02340806|Experimental|High rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 300 mL/h in the high-rate bolus group.
3110017|NCT02340806|Experimental|Low rate bolus (CADD-Solis pump)|Labor analgesia will be maintained using timed-intermittent boluses of local anesthetic with PCEA using the CADD-Solis pump. The bolus rate will be 100 mL/h in the low-rate bolus group.
3110018|NCT02340819|Experimental|Arm 1|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
3110019|NCT02340949|Experimental|mFOLFOX6 + Aflibercept|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~- Aflibercept, will be administered intravenously (I.V.) at doses of 4 mg/Kg on Day 1 every 14 days. Aflibercept will be supplied to sites by the study Sponsor as 4 ml vials at a concentration of 25 mg/ml.~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
3110020|NCT02340949|Active Comparator|mFOLFOX6|"- mFOLFOX-6 scheme: 5-Fluoruracil [5-FU], oxaliplatin and leucovorin will be administered intravenously once every 14 days according to mFOLFOX-6 scheme:~Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL and leucovorin 200 mg/m² IV, both over two hours, followed by 5-FU 400 mg/m² IV bolus and a 46 h infusion of 5-FU 2400 mg/m².~Treatment will continue until six cycles are administered unless unacceptable toxicity or progression occurs."
3110021|NCT02340962|Experimental|Group I|200 mg TG-2349 (2 capsules) + Interferon or Peg-interferon + Ribavirin
3110022|NCT02340962|Experimental|Group II|400 mg TG-2349 (4 capsules) + Interferon or Peg-interferon + Ribavirin
3110023|NCT02340975|Experimental|Phase 1b-M20 mg/kg (Q4W) + T 1 mg/kg (Q4W) Fw M10 mg/kg (Q2W)|Participants in second-line therapy with gastric or gastroesophageal junction (GEJ) adenocarcinoma will receive intravenous (IV) infusion of 20 mg/kg MEDI4736 every 4 weeks (Q4W) for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
3110024|NCT02340975|Experimental|Phase 2 Arm A-(M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
3110025|NCT02340975|Experimental|Phase 2 Arm B-M10 mg/kg (Q2W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg MEDI4736 Q2W for 12 months (up to 26 doses).
3110026|NCT02340975|Experimental|Phase 2 Arm C-T10 mg/kg (Q4W)|Participants in second-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 10 mg/kg tremelimumab Q4W for 7 doses and then Q12W for 2 doses for 12 months (for a total of up to 9 doses).
3110027|NCT02340975|Experimental|Phase 2 Arm D-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
3110028|NCT02340975|Experimental|Phase 2 Arm E-M20 mg/kg (Q4W) + T1 mg/kg Fw M10 mg/kg (Q2W)|Participants in second and third-line therapy with metastatic or recurrent gastric or GEJ adenocarcinoma and a positive IFN-γ gene expression signature will receive IV infusion of 20 mg/kg MEDI4736 Q4W for 4 months (up to 4 doses) in combination with IV 1 mg/kg tremelimumab Q4W for 4 months (up to 4 doses in total). Thereafter, participants will receive MEDI4736 monotherapy (10 mg/kg) every 2 weeks (Q2W) to complete a total of 12 months of therapy (up to 18 additional doses).
3110029|NCT02341144|Active Comparator|Pre-op percutaneous rectus sheath block|ultrasound-guided, percutaneous rectus sheath block with ropivacaine by a qualified anesthesiologist
3110030|NCT02341144|Active Comparator|Intra-operative rectus sheath block|rectus sheath block with ropivacaine under direct visualization by the attending surgeon
3110031|NCT02341417|Experimental|Cinacalcet|"Participants received cinacalcet daily for 24 weeks in this extension study. For participants who received standard of care (SOC) in parent study 20130356, the starting dose was 0.20 mg/kg/day. For participants who received SOC and cinacalcet in parent study 20130356 or 20110100 the starting dose was either the same as the last dose received in the parent study or 0.20 mg/kg/day if the last dose of cinacalcet in the parent study was received > 14 days before day 1 of this study.~Dose adjustments and withholding were based on weekly assessments of ionized calcium as well as plasma intact parathyroid hormone (iPTH) and corrected serum calcium levels assessed monthly."
3110032|NCT02341456|Experimental|AZD1775|AZD1775 will be administered orally as a single dose on Day 1 Cycle 0. Following a 5±2 days washout period, AZD1775 (5 doses BID over 2.5 days) will be taken in combination with paclitaxel and carboplatin in each 21-day cycle for 6 cycles. Following 6 cycles of combination treatment, patients may continue on AZD1775 monotherapy (5 doses BID Day 1 to Day 2.5 in each 21-day cycle) at the investigator's discretion.
3110033|NCT02341456|Experimental|Paclitaxel|Commercially available paclitaxel will be administered at a dosage of 175 mg/m2 as a 3-hour IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles.
3110034|NCT02341456|Experimental|Carboplatin|Following the paclitaxel infusion, carboplatin will be administered at a dose of AUC 5 as an IV infusion on Cycle Day 1 of a 21-day cycle for 6 cycles. According to the Cancer Therapy Evaluation Program Information Letter Regarding the AUC Based Dosing of Carboplatin, the maximum carboplatin dose should not exceed the target AUC (mg*min/mL)*150 mL/min, but it may be less (Ivy et al 2010). For this study, the maximum dose of carboplatin cannot exceed a total dose of 750 mg.
3110035|NCT02341482|Experimental|PF-04958242 and itraconazole|"PF-04958242 will be provided in a capsule. Participants will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.~Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17)."
3110036|NCT02341599|Experimental|Group A: Healthy|Healthy participants with normal renal function (Stage 1: eGFR ≥90 mL/min/1.73m^2).
3110037|NCT02341599|Experimental|Group B: Mild RI|Participants with mild RI (Stage 2: eGFR ≥60 to <90 mL/min/1.73m^2).
3110038|NCT02341599|Experimental|Group C: Moderate RI|Participants with moderate RI (Stage 3: eGFR ≥30 to <60 mL/min/1.73m^2).
3110039|NCT02341599|Experimental|Group D: Severe RI|Participants with severe RI (Stage 4: eGFR <30 mL/min/1.73m^2) not receiving HD.
3110040|NCT02341599|Experimental|Group E: ESRD-HD|Participants with ESRD who are receiving HD for at least 3 months preceding the initial dose in this study (Stage 5).
3110041|NCT02341859|Active Comparator|stenfilcon A and delefilcon A|Participants randomized wear the stenfilcon A and the delefilcon A contralaterally.
3110042|NCT02341859|Active Comparator|stenfilcon A and narafilcon A|Participants randomized wear the stenfilcon A and the narafilcon A contralaterally
3110043|NCT02342015|Experimental|Atorvastatin|Atorvastatin 40 mg/day for three months
3110044|NCT02342171|Experimental|Convalescent Plasma|Convalescent Plasma: 400-500 mL from two donors (2 x 200-250 ml) and 10mL/kg for small adults and children <45kg
3110045|NCT02342171|No Intervention|standard care|The control arm will consist of historical controls having being treated with standard of care
3110046|NCT02342197|Active Comparator|Minidose long protocol|Half dose of GnRH agonist (Decapeptyl 0.05) was started in the midluteal phase and Gn's was started from the second day of the cycle.
3110047|NCT02342197|Active Comparator|Microdose flare protocol|Half the dose of GnRH agonist (Decapeptyl 0.05) was started on the second day of the cycle together with Gn's
3110048|NCT02342223|Experimental|Voluma|"Subjects will be screened for severity on their HIV facial lipoatrophy according to the Carruthers Lipoatrophy Severity Scale (CLSS), and will receive subcutaneous injections of Voluma in the affected facial areas with the 'smile and fill' technique (Jagdeo 2014) based on Carruthers scoring scale.~Subjects with Carruthers Score level 2 will receive total of 2-6 syringes of Voluma.~Subjects with Carruthers Score level 3 will receive total of 4-8 syringes of Voluma.~Subjects with Carruthers Score level 4 will receive total of 6-12 syringes of Voluma.~All subjects will receive one Voluma treatment at initial time = 0 and may be eligible for touchup treatment, if necessary, at 2 weeks post-initial treatment."
3110049|NCT02342288|Experimental|Head raised 10 degrees|Head raised 10 degrees from neutral position using Gardner Wells tongs
3110050|NCT02342288|Active Comparator|Head in neutral position|Head in neutral position
3110051|NCT02342314|Experimental|LY3143753 (Part A)|Single subcutaneous (SC) injection of ascending doses of LY3143753 on Day 1
3110052|NCT02342314|Experimental|LY3185643 (Part B)|Single SC injection of ascending doses of LY3185643 on Day 1
3110053|NCT02342314|Placebo Comparator|Placebo (Part A)|Single SC injection of normal saline on Day 1
3110054|NCT02342314|Active Comparator|rGlucagon (Part B)|Single SC injection on Day 1
3110055|NCT02342314|Placebo Comparator|Placebo (Part B)|Single SC injection of normal saline on Day 1
3110056|NCT02342327|Other|Continue smoking menthol cigarettes|Menthol cigarette smokers continue to smoke menthol cigarettes for a four week period before attempting to quit smoking
3110057|NCT02342327|Other|Switch to non-menthol cigarettes|Menthol cigarette smokers switch to non-menthol cigarettes for a four week period before attempting to quit smoking
3110058|NCT02342379|Experimental|Bevacizumab and TH-302|Patients will be treated with combination of bevacizumab and TH-302.
3110059|NCT02342418|Active Comparator|Morbidly obese|The morbidly obese (BMI ≥ 40 kg/m2) arm will be recruited first. Each morbidly obese subject will be matched to a non-obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
3110060|NCT02342418|Active Comparator|Non-obese|Each non-obese subject will be matched to a morbidly obese subject (BMI 18.5-29.9 kg/m2) based on age (± 5 years), sex, and ideal body weight (± 4.6 kg, i.e. ± 5 cm in height). Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
3110061|NCT02342535|Other|Physical activity intervention|"Participants will attend bi weekly exercise classes for a total of 16 weeks, led by certified, and trained instructors.~The participant's children between the ages of 6 and 14 years will participate in the martial arts class with the mothers."
3110062|NCT02342548|Experimental|20 mg BID PF-02545920 non-titrated|Subjects who received 20 mg BID in completed study A8241021 will continue to receive 20 mg BID PF-02545920
3110063|NCT02342548|Experimental|20mg BID PF-02545920 titrated|Subjects who received either Placebo or 5mg BID of PF-02545920 in completed study A8241021 will be titrated up to 20 mg with 5mg increment per week, over 4 weeks (5mg increment/wk)
3110064|NCT02342561|Experimental|Intervention knees (Drape side)|One knee of the patient is randomly selected to be drape with an Ioban 2 incision drape.
3110065|NCT02342561|No Intervention|Control knees (no-drape side)|The knee that is not drape is left uncovered during the intervention.
3110066|NCT02342639|Experimental|Rifaximin|Participants will receive a 10-day course of Rifaximin.
3110067|NCT02342639|Placebo Comparator|Placebo|Participants will receive a 10-day course of placebo.
3110068|NCT02342678|Experimental|Yoga Therapy Group|Participants will take part in twice weekly group yoga classes focusing on selected Iyengar-based yoga techniques as well as practice study-specific yoga techniques at home for at least one hour per week for a total of 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing yoga exercises for at least an hour per week.
3110069|NCT02342678|Experimental|Physical Conditioning Group|Patricipants will take part in twice weekly group physical conditioning classes and practice stretching exercises at least one hour per week at home for 12 weeks. During a 12-week post-treatment follow-up period, participants will also be encouraged to continue practicing stretching exercises for at least an hour per week.
3110070|NCT02342704|Experimental|natalizumab|Open-label natalizumab 300 mg IV every 4 weeks (Q4W)
3110071|NCT02342704|Active Comparator|fingolimod|Open-label fingolimod 0.5 mg once daily orally
3110072|NCT02342743|Experimental|Active|Daily trigeminal nerve stimulation session of 20 minutes with CEFALY
3110073|NCT02342886|Experimental|MDR-TB|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg for 26 weeks.
3110074|NCT02342886|Active Comparator|DS-TB (HRZE), HR|"26 consecutive weeks to DS-TB subjects only, as follows:~HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination) Weeks 1-8 with daily dose per the subjects weight~HR (Rifampicin plus isoniazid combination tablets) Weeks 9 - 26 with daily dose per the subjects weight~Daily dose per the subjects weight as follows: 30-39kg: 2 tablets; 40-54kg: 3 tablets; 55 - 70kg: 4 tablets; 71kg and over: 5 tablets."
3110075|NCT02342886|Experimental|DS-TB PA-824 200mg 26 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once daily for 26 weeks
3110076|NCT02342886|Experimental|DS-TB PA-824 200mg 17 weeks|moxifloxacin 400 mg + PA-824 200 mg + pyrazinamide 1500 mg orally once a day for 17 weeks
3110077|NCT02342886|Experimental|DS-TB PA-824 100mg 17 weeks|moxifloxacin 400 mg + PA-824 100 mg + pyrazinamide 1500 mg orally once daily for 17 weeks
3110078|NCT02343003|Experimental|Cooled radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
3110079|NCT02343003|Active Comparator|Corticosteroid injection|Corticosteroid injections will be administered to study subjects' knees to reduce knee pain
3110080|NCT02343081|Active Comparator|Temodal|Temozolomide (Schering-Plough) 200 mg/m2, single oral dose.
3110081|NCT02343081|Experimental|Dralitem|Temozolomide (Monte Verde S.A.) 200 mg/m2, single oral dose
3110082|NCT02343276|Placebo Comparator|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
3110083|NCT02343276|Experimental|Intervention|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
3110084|NCT02343380|Experimental|morning-first|calorimetric exam after a standard meal
3110085|NCT02343380|Experimental|evening-first|calorimetric exam after a standard meal
3110086|NCT02343406|Experimental|ABT-414/temozolomide|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks in combination with temozolomide (TMZ) to adult participants
3110087|NCT02343406|Experimental|ABT-414_adult|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to adult participants
3110088|NCT02343406|Active Comparator|Control_lomustine|Adult participants relapsing during temozolomide (TMZ) treatment or within the first 16 weeks after the first day of the last TMZ cycle received lomustine on Day 1 of every 42-day treatment period until one of the treatment withdrawal criteria was met, up to a maximum of 1 year.
3110089|NCT02343406|Active Comparator|Control_ temozolomide|Adult participants relapsing 16 weeks or more after the first day of the last temozolomide (TMZ) cycle received TMZ on Day 1 to Day 5 for the first 28-day cycle, with dose escalation in subsequent cycles in case of adequate tolerance and treatment continuing until one of the treatment withdrawal criteria was met.
3110090|NCT02343406|Experimental|ABT-414_ pediatric|Depatuxizumab mafodotin (ABT-414) administered once every 2 weeks to pediatric participants. Temozolomide (TMZ) was only allowed for pediatric participants if its use was in accordance with local clinical practice, and was not considered an investigational product for the study (unless this was a local requirement).
3110091|NCT02343458|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3110092|NCT02343458|Experimental|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3110093|NCT02343458|Experimental|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
3110094|NCT02343458|Placebo Comparator|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
3110095|NCT02343549|Experimental|Planned RT + TMZ + BEV + NovoTTF100A Device|Best standard of care radiation therapy (RT, 2 Gy given daily 5 days per week), temozolomide (TMZ, 75 mg/m2 administered daily), and bevacizumab (BEV, 10 mg/kg administered every 2 weeks as an IV infusion) for 6 weeks. After completion of chemoradiation, NovoTTF100A system was initiated, to be worn on average 18 hours or more a day for up to 12 months. The patients also continued with maintenance TMZ/BEV.
3110096|NCT02343575|Experimental|Valproic Acid|"Start:~VPA PO/NGT 500 mg BID~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS~Rescue at all stages: HAL IV 2-5 mg Q4hr PRN"
3110097|NCT02343575|Placebo Comparator|Placebo|"Placebo: PO/NGT BID~Rescue: HAL IV 2-5 mg Q4hr PRN"
3110098|NCT02343627|Experimental|NVXT Solution|NVXT Solution once daily for 60 days
3110099|NCT02343627|Placebo Comparator|Vehicle of test product|Vehicle of test product, once daily for 60 days
3110100|NCT02343939|Experimental|Entospletinib + daunorubicin + cytarabine (Group A)|"Dose Escalation: Entospletinib up to 400 mg for 14 days and then entospletinib up to 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles.~Dose Expansion: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with daunorubicin and cytarabine for up to two 14-day cycles. Some participants will have the option to receive post-induction therapy with entospletinib 400 mg in combination with cytarabine/cytosine arabinoside (ARA-C). Participants may receive maintenance therapy with 28-day cycles of entospletinib 400 mg for up to twelve 28-day cycles, if the participant is not eligible for stem cell transplant."
3110101|NCT02343939|Experimental|Entospletinib + decitabine (Group B)|"Dose Escalation: Entospletinib 400 mg for 14 days and then entospletinib 400 mg in combination with decitabine for 10 days beginning on Day 1 of every 28-day cycle (at least 2 cycles of induction therapy but no more than 4 cycles). Participants who are intolerant of decitabine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles.~Dose Expansion: Entospletinib 400 mg for 14 days for the safety run-in participants or Entospletinib 400 mg for 5 days for the randomization participants. Then entospletinib 400 mg in combination with decitabine or azacitidine (at least 2 cycles of induction therapy but no more than 4 cycles). Some participants will have the option to receive maintenance therapy with entospletinib in combination with decitabine or azacitidine. Participants who are intolerant of decitabine or azacitidine may switch to entospletinib monotherapy maintenance at any time after completing the first 2 cycles."
3110102|NCT02343939|Experimental|Entospletinib (Group C)|"Dose Escalation: Entospletinib up to 800 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the study protocol.~Dose Expansion: Entospletinib 400 mg for 28-day cycles until the participant meets criteria for study treatment discontinuation per the protocol."
3110103|NCT02344004|No Intervention|Multi-drug Regimen|Participants received their already prescribed anti-mycobacterial regimen (based on the 2007 American Thoracic Society/Infectious Diseases Society of America [ATS/IDSA] Guidelines)
3110104|NCT02344004|Experimental|LAI + Multi-drug Regimen|"Participants received LAI 590 mg QD in addition to their already prescribed anti-mycobacterial regimen (based on the 2007 ATS/IDSA Guidelines)~LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes"
3110105|NCT02344225|Active Comparator|Caffeine+Saline IV+Saline drops|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose) plus placebo saline IV (1 ml/kg followed by 0.25 ml/kg) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Caffeine is the intervention
3110106|NCT02344225|Experimental|Caffeine+Ibp IV+Saline drops|Caffeine citrate as described in group 1, plus Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days plus sterile normal saline (one drop two times a day) for 14 days (n=40); Ibuprofen is the intervention
3110107|NCT02344225|Experimental|Caffeine+Saline+Ketorolac drops|Caffeine citrate plus saline IV placebo as described in group 1, and Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days (n=40); Ketorolac is the intervention
3110108|NCT02344238|Other|Standard Capsules|Receive standard capsules (no ID cap technology) with compliance measured by self-report, pill count, and riboflavin measurement.
3110109|NCT02344238|Other|ID Capsules without Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap.
3110110|NCT02344238|Other|ID Capsules with Prompts|Receive ID capsules, with compliance measured by self-report, pill count, riboflavin measurement, and data collected by the ID Cap. This arm will also receive prompts (reminder calls and/or text messages) to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
3110111|NCT02344251|Other|Group 1|Adherence measured by MEMS Cap
3110112|NCT02344251|Other|Group 2|Adherence measured by ID-Cap technology.
3110113|NCT02344316|Active Comparator|Melatonin|Group randomized to melatonin 3 mg orally nightly
3110114|NCT02344316|Placebo Comparator|Placebo|Group randomized to placebo orally nightly
3110115|NCT02344342|Experimental|Health Buddy Web Management system|Patients randomized to the telemonitoring intervention will be assigned to use the Bosch Health Buddy Web management system.
3110116|NCT02344342|Experimental|Flexible Diuretic Regimen|Patients randomized into the Flexible Diuretic Regimen intervention will have a diuretic regimen specified by specific weight ranges.
3110117|NCT02344407|Experimental|2|ChAd3-EBO Z
3110118|NCT02344407|Experimental|3|VSVG-ZEBOV
3110119|NCT02344407|Placebo Comparator|1|Placebo (Saline)
3110120|NCT02344576|No Intervention|Control: Usual Care|Patients and caregivers will receive the current usual education and consent process for DT LVAD at each hospital. This often means viewing consent forms and industry materials.
3110121|NCT02344576|Experimental|DT LVAD Decision Support Intervention|In the intervention phase of the study, patients and caregivers will receive the new decision support intervention, which consists primarily of decision aid materials about DT LVAD. The standard consent process will also still take place, but will be supplemented with additional decision support.
3110122|NCT02344628|Active Comparator|AZT30|Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
3110123|NCT02344628|Experimental|AZT20|Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
3110124|NCT02344745|Placebo Comparator|Control|Distilled water
3110125|NCT02344745|Experimental|Lavender|Lavandula angustifolia essential oil (Aura Cacia)
3110126|NCT02345031|Active Comparator|AUT00063 (600 mg capsules)|3 capsules of 200 mg of the investigational drug AUT00063, to take orally once daily with food for 4 weeks
3110127|NCT02345031|Placebo Comparator|(AUT00063 placebo capsules)|3 capsules of placebo, to take orally once daily with food for 4 weeks
3110128|NCT02345070|Placebo Comparator|Placebo qw|Participants received one injection of placebo (matched to SAR156597) subcutaneously once every week (qw) for 52 weeks.
3110129|NCT02345070|Experimental|SAR156597 200 mg q2w|Participants received one injection of SAR156597 200 mg subcutaneously once every 2 weeks (q2w) alternating with placebo (matched to SAR156597) for 52 weeks.
3110130|NCT02345070|Experimental|SAR156597 200 mg qw|Participants received one injection of SAR156597 200 mg subcutaneously qw for 52 weeks.
3110131|NCT02345161|Experimental|FF/UMEC/VI (100 mcg/62.5 mcg/25 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive FF/UMEC/VI (100mcg/62.5mcg/25mcg) via the ELLIPTA DPI and placebo via reservoir inhaler.
3110132|NCT02345161|Experimental|Budesonide/formoterol (400 mcg/12 mcg)|Each subject will inhale once from their ELLIPTA DPI and once from the reservoir inhaler in the morning and once from the reservoir inhaler in the evening, for 24 weeks (or 52 weeks for subjects participating in the extension part of the study). Subjects will receive Budesonide/formoterol (400mcg/12mcg) via reservoir inhaler and placebo via the ELLIPTA DPI.
3110133|NCT02345226|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus EFV/FTC/TDF placebo for at least 96 weeks.
3110134|NCT02345226|Active Comparator|EFV/FTC/TDF|EFV/FTC/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
3110135|NCT02345226|Experimental|Open Label Extension Phase|After the Week 96 visit, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead elects to discontinue the study, whichever occurs first.
3110136|NCT02345252|Experimental|FTC/RPV/TAF|FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
3110137|NCT02345252|Active Comparator|FTC/RPV/TDF|FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
3110138|NCT02345252|Experimental|Open Label Extension Phase|After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.
3110139|NCT02345330|Experimental|Tavokinogene Telseplasmid (tavo) Electroporation (EP)|Participants received tavo intratumorally followed immediately by electroporation (EP) on Days 1, 8, and 15 in a 6-week cycle for up to 9 cycles.
3110140|NCT02345434|No Intervention|No informative letter|This is the control arm and it involves no contact with the prescriber
3110141|NCT02345434|Experimental|Informative letter|This is the treatment arm; prescribers in this arm receive an informative letter (called a comparative billing report or peer activity report)
3110142|NCT02345486|Active Comparator|0.9% sodium chloride|Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
3110143|NCT02345486|Active Comparator|Physiologically balanced fluid|Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission.
3110144|NCT02345512|Other|Falls|Wearing of Lycra splinting garment
3110145|NCT02345642|Active Comparator|10 Healthy Patients without THA|The 10 test subjects of this study arm will be healthy volunteers of various ages that are willing to have the efficacy of pneumatic compression tested on them.
3110146|NCT02345642|Experimental|10 Patients with THA on Post-Op Day 2|The 10 test subjects of this study arm will be primary THR patients of Dr. Westrich that have undergone uncomplicated THR surgery in which they are allowed to be full weight bearing by or before post-op day 2.
3110147|NCT02345720|Experimental|etafilcon - PVP (multi-focal)|The investigational soft contact lenses will be worn in a daily wear modality for 30 days over the course of the study.
3110148|NCT02345811|Experimental|Sapphire|Participants were randomized to wear the Sapphire lens pair for two weeks during the cross over study.
3110149|NCT02345811|Active Comparator|senofilcon A|Participants were randomized to wear the senofilcon A lens pair for two weeks during the cross over study.
3110150|NCT02345889|Active Comparator|FUSE® Colonoscopy|A FUSE® system with 3 HD (high-definition) monitors will be used to perform the colonoscopy
3110151|NCT02345889|Active Comparator|Colonoscopy with EndoCuff™|An EndoCuff™ distal attachment will be placed at the distal end of a standard colonoscope
3110152|NCT02345889|Active Comparator|Colonoscopy with EndoRings™|An EndoRings™ distal attachment will be placed at the distal end of a standard colonoscope
3110153|NCT02345889|Active Comparator|Standard Colonoscopy|A standard colonoscope will be used to complete the procedure
3110154|NCT02346136|Experimental|Tai Chi|This arm will receive a 6-month Tai Chi training intervention. Tai Chi training will include gentle dynamic stretching and strengthening, slow integrated movements, efficient posture, heightened body awareness and inner focus, active relaxation of body and mind, mindful diaphragmatic breathing, and healing imagery and intention. Participants will be asked to complete two formal group classes each week for at least 6 months, led by senior Tai Chi instructors. Additionally, participants will be given practice Digital Versatile Disc (DVD), DVD players if necessary, and instructions for daily home practice a minimum of 20 minutes on 3 non-class days each week.
3110155|NCT02346136|Active Comparator|Educational Control|This arm will receive a 6-month educational control intervention. Participants will attend monthly educational group sessions within a common area of each housing facility. Sessions will be led by research personnel and include material from Patient Education Forms (PEFs) produced by the American Geriatric Society. Sessions will be semi-structured and contain approximately 30 minutes of lecture and 30 minutes of group discussion.
3110156|NCT02346240|Experimental|CZP 200 mg|"Certolizumab Pegol (CZP) subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by CZP 200 mg every two weeks (Q2W) from Week 6 to Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to receive either CZP 200 mg Q2W or CZP 400 mg every 4 weeks (Q4W; with Placebo administered on alternate dosing weeks to maintain the blind) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3110157|NCT02346240|Experimental|CZP 400 mg|"Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W) through Week 14.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to CZP 200 mg Q2W or CZP 400 mg Q2W or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3110158|NCT02346240|Active Comparator|Etanercept|"Etanercept (ETN) subcutaneous (sc) injection 50 mg twice weekly through Week 12.~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 will be re-randomized to either Certolizumab Pegol (loading dose of 400 mg at Weeks 16, 18, and 20 followed by 200 mg Q2W) or Placebo Q2W.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3110159|NCT02346240|Placebo Comparator|Placebo|"Placebo subcutaneous (sc) injection every two weeks (Q2W).~The treatment received from Week 16 to Week 48 is based on initial treatment and response to treatment at Week 16:~Subjects with a PASI75 response at Week 16 continue to receive blinded Placebo.~Subjects who do not achieve a PASI75 response at Week 16 will be removed from blinded study medication and escape to CZP 400 mg Q2W. Subjects who receive unblinded CZP 400 mg Q2W for 16 weeks and do not achieve a PASI50 response will be withdrawn from the study.~Subjects can enter a 96-week open-label extension period after completing the Maintenance Period and receive CZP under certain conditions."
3110160|NCT02346370|Experimental|PEGPH20 + Docetaxel|PEGylated recombinant human hyaluronidase PH20 (PEGPH20) (1.6, 3.0, or 2.2 micrograms per kilogram (ug/kg)) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m^2)) was administered on Day 2 of each 21-day cycle.
3110161|NCT02346383|Active Comparator|program 1|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3110162|NCT02346383|Active Comparator|program 2|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3110163|NCT02346383|Active Comparator|program 3|preset program - epidural and peripheral lead to cover pain Randomized selection of epidural and/or peripheral lead programs from 3 possible programs
3110164|NCT02346461|Active Comparator|Cohort A|6 subjects on Cohort A will receive oral ManNAc 3 g twice daily (6 g/day) for 7 days and, if safe, continue on 6 g twice daily (12 g/day) for the remainder of the study.
3110165|NCT02346461|Active Comparator|Cohort B|6 subjects on Cohort B will receive oral ManNAc 6 g twice daily (12 g/day) for the duration of the study.
3110166|NCT02346643||Treated Subjects|All subjects recruited and treated with the Axium neurostimulator
3110167|NCT02346708|Experimental|Real TMS|TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease.52, 123 Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.
3110168|NCT02346708|Sham Comparator|Sham TMS|Sham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.
3110169|NCT02346721|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3132661|NCT03443024|Experimental|250 mg Lebrikizumab - Every 2 Weeks (Q2W)|"250 mg Lebrikizumab administered SC once Q2W.~Baseline and Week 2: Loading dose of 500 mg (four 1-mL SC injections of 125 mg/mL Lebrikizumab).~Week 4, 6, 8, 10, 12, 14: 250 mg (two 1-mL SC injections of 125 mg/mL Lebrikizumab)."
3110170|NCT02346903|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, ranging from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. The patients will be asked follow-up questions concerning their experiences with chest pain in the past and their tolerance of spicy foods. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion."
3110171|NCT02346916|Other|Cardiac Catheterization Patients|"Subjects will undergo the cutaneous capsaicin test at the time of the study visit. A one inch ribbon of Capzasin-HP Cream (0.1%) will be applied to the skin on the forearm of the non-dominant arm. Subjects will be asked to assign a numerical score to the maximum intensity of any cutaneous discomfort experienced during the subsequent 30 minutes, from 0 (no discomfort) to 10 (the worst discomfort imaginable). The cream will then be removed by washing the affected arm with cold water. Efforts will then be made to examine the association between the pain score documented in response to the cutaneous capsaicin test with the pain score obtained during coronary balloon occlusion. This method should allow an individual's subjective sensitivity to the TRPV1-mediated noxious stimulus of myocardial ischemia to be compared with his/her sensitivity to the TRPV1-mediated noxious stimulus of cutaneous capsaicin in extra-cardiac tissues."
3110172|NCT02347072|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3110173|NCT02347072|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
3110174|NCT02347072|Active Comparator|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
3110175|NCT02347085|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3110176|NCT02347085|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
3110177|NCT02347098|Experimental|intensive LDL-lowering therapy (ILLT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to LDL-apheresis and an oral daily dose of 40-80mg of Atorvastatin or equivalent.
3110178|NCT02347098|Active Comparator|standard statin monotherapy (SMT)|Patient of acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is randomized to an oral daily dose of 40-80mg of Atorvastatin or equivalent without LDL-apheresis
3110179|NCT02347124|Active Comparator|Usual Care Control|Standard tobacco quitline counseling program and materials + attention-matched text messaging.
3110180|NCT02347124|Experimental|Enhanced Intervention|Standard tobacco quitline counseling program and materials + multi-modal oral health promotion program .
3110181|NCT02347176|Placebo Comparator|Placebo|Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
3110182|NCT02347176|Experimental|Tralokinumab Dose 1|Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3110183|NCT02347176|Experimental|Tralokinumab Dose 2|Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3110184|NCT02347176|Experimental|Tralokinumab Dose 3|Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
3110185|NCT02347189|Other|Melody TPV PB1016|
3110186|NCT02347332|Experimental|Vinflunine plus methotrexate|vinflunine IV 280 mg/m² Day 1 plus methotrexate IV 30 mg/m² Day 1 and Day 8 every 3 weeks
3110187|NCT02347332|Active Comparator|Methotrexate|methotrexate IV 40 mg/m² Day 1, 8 and 15 every 3 weeks
3110188|NCT02347345|Active Comparator|Active injection drug use (IDU)|In active IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
3110189|NCT02347345|Active Comparator|Former injection drug use (former IDU)|In former IDU, Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill orally daily x 12 weeks
3110190|NCT02347345|No Intervention|Healthy volunteers|HIV, HCV and HBV negative, never injected drugs, no recreational drugs for at least 2 years (does not include marijuana) and negative urine screen for opiates at the screening visit.
3110191|NCT02347410|Other|Investigation Group|This is a single-arm investigation. All subjects were treated with the SIFS device filled with bone graft. Posterior fixation required.
3110192|NCT02347488|Experimental|ETT holder and bite guard|Participants will have endotracheal tubes secured with tape prior to having surgery, which is the current standard of care. Following the traction test and measurement of displacement, participants will have endotracheal tubes secured with a combined Haider ETT Tube Holder and Bite Guard.
3110193|NCT02347605|Experimental|Nicotine lozenge 4 mg prior to cue exposure|Nicotine lozenge is used 15 minutes prior to smoking cue exposure
3110194|NCT02347605|Placebo Comparator|Placebo lozenge prior to cue exposure|Placebo lozenge is used 15 minutes prior to smoking cue exposure
3110195|NCT02347605|Other|Control condition: Lozenge after cue exposure|Lozenge is used immediately after smoking cue exposure
3110196|NCT02347631|Experimental|Alcon DAILIES TOTAL1, and ACUVUE TruEye|Intervention: Soft Contact Lens - Daily Disposable Name - Alcon Dailies Total 1 Material - Delefilcon A Water Content - 33% Oxygen Permeability - 140 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 156 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm Manner of Wear - Daily Disposables Wearing Time - 2 months
3110197|NCT02347631|Active Comparator|ACUVUE TruEye and Alcon Dailies Total 1|Intervention: Soft Contact Lens - Daily Disposable Name - Acuvue TruEye Material - Narafilcon A Water Content - 46% Oxygen Permeability - 100 x10-11 (cm2/sec)(mL O2/mL mmHg) Oxygen Transmissibility - 118 x10-9 (cm/sec)(mL O2/mL mmHg) Base Curve - 8.5mm & 9.0mm Manner of Wear - Daily Disposables Wearing Time - 2 months
3110198|NCT02347657|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA tablet administered orally in the evening up to Week 24.
3110199|NCT02347657|Experimental|VX-661/IVA|VX-661 100 mg plus IVA 150 mg FDC tablet administered orally in the morning and IVA 150 mg tablet administered orally in the evening up to Week 24.
3110200|NCT02347761|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3110201|NCT02347761|Experimental|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3110202|NCT02347761|Placebo Comparator|Placebo BID eFlow (CS) nebulizer|Placebo twice daily (BID) eFlow (R) Closed System (CR) nebulizer
3110203|NCT02347774|Experimental|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg Twice Daily (BID) via e-Flow (R) Closed System (CS) nebulizer
3110204|NCT02347774|Experimental|SUN-101 25 mcg BID e-Flow (CS) nebulizer|SUN-101 25 mcg (BID) via e-Flow (R) Closed System (CS) nebulizer
3110205|NCT02347774|Placebo Comparator|Placebo BID Eflow (CS) nebulizer|Placebo (BID) via e-Flow (R) Closed System (CS) nebulizer
3110206|NCT02347787|Placebo Comparator|Usual clinician support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the usual clinician support arm will receive usual care in accordance with guidelines at each site.
3110207|NCT02347787|Experimental|CHW support|Prior to randomization, patients in this arm will already have set a chronic disease management goal with their primary care provider (who will have received training in collaborative goal-setting). After randomization, patients in the CHW arm will receive the IMPaCT intervention.
3110208|NCT02347813|Other|Delayed Intervention|After enrollment, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care. Then they will begin the pioglitazone regimen for 24 more weeks, during which time skin cancer tumors will be observed and appropriately treated as per standard of care.
3110209|NCT02347813|Other|Immediate Intervention|Subjects will begin the 24 week pioglitazone regimen immediately after enrollment, during which time skin cancer tumors will be observed and appropriately treated as per standard of care. After 24 weeks of drug, subjects will be observed for 24 weeks for skin cancer tumors. Tumors will be appropriately treated as per standard of care.
3110210|NCT02347917|Experimental|BBI608 puls pemetrexed and cisplatin|
3110211|NCT02348008|Experimental|Arm A - Phase 1b Dose Escalation Cohort|"Cohort 1 will consist of 3-6 patients who will receive MK-3475 200mg and bevacizumab 10mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~Cohort 2 will consist of 3-9 patients who will receive MK-3475 200mg and bevacizumab 15mg on day 1 of the 21-day cycle. The drugs are administered 15-30 minutes apart in separate intravenous infusions.~If none of the 3 subjects experience a dose limiting toxicity (DLT) during the first cycle of therapy, an additional 3 subjects will be enrolled at dose level 2. If all three subjects in dose level 2 complete the first cycle of therapy without DLT, 3 more subjects will be enrolled to ensure only 0-1 of 6 subjects have a DLT. There will be no further escalation beyond dose level 2."
3110212|NCT02348008|Other|Arm B - Phase II Investigational Treatment|The maximum safe dose of MK-3475 in combination bevacizumab (as determined in the phase 1b cohort) will be given on day 1 of each 21 day cycle.
3110213|NCT02348203|Experimental|Arm I (aspirin, zileuton)|Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
3110214|NCT02348203|Placebo Comparator|Arm II (double placebo)|Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
3110215|NCT02348216|Experimental|Axicabtagene Ciloleucel|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, axicabtagene ciloleucel.
3110216|NCT02348359|Experimental|50 mg of X-82 plus ivt anti-VEGF prn|Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3110217|NCT02348359|Experimental|100 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3110218|NCT02348359|Experimental|200 mg of X-82 plus ivt anti-VEGF prn|Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3110219|NCT02348359|Placebo Comparator|Placebo plus ivt anti-VEGF prn|Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
3110220|NCT02348385||Healthy Tobacco Smokers|There is only one arm to the study. All subjects will receive amphetamine
3110221|NCT02348385||Healthy Nonsmokers|There is only one arm to the study. All subjects will receive amphetamine
3110222|NCT02348489|Experimental|SGI-110 (guadecitabine)|Guadecitabine 60 mg/m^2 administered subcutaneously (SC) daily for 5 days (Days 1-5) in 28-day cycles.
3110223|NCT02348489|Active Comparator|Treatment Choice|One of the following treatment regimens: 20 mg cytarabine administered subcutaneously (SC) twice daily (BID) on Days 1-10 every 28 days; 20 mg/m^2 decitabine given as a 1-hour intravenous (IV) infusion daily on Days 1-5 every 28 days; or 75 mg/m^2 azacitidine given IV or SC daily on Days 1-7 every 28 days.
3110224|NCT02348593|Active Comparator|75 mg of JZP-110|Once Daily Dosing
3110225|NCT02348593|Active Comparator|150 mg JZP-110|Once Daily Dosing
3110226|NCT02348593|Active Comparator|300 mg of JZP-110|Once Daily Dosing
3110227|NCT02348593|Placebo Comparator|Placebo|Once Daily Dosing
3110228|NCT02348606|Active Comparator|37.5 mg of JZP-110|Once Daily Dosing
3110229|NCT02348606|Active Comparator|75 mg of JZP-110|Once Daily Dosing
3110230|NCT02348606|Active Comparator|150 mg of JZP-110|Once Daily Dosing
3110231|NCT02348606|Active Comparator|300 mg of JZP-110|Once Daily Dosing
3110232|NCT02348606|Active Comparator|Placebo|Once Daily Dosing
3110233|NCT02348619|Active Comparator|75, 150, 300 mg of JZP-110|Once Daily Dosing
3110234|NCT02348619|Active Comparator|Placebo|Once Daily Dosing
3110235|NCT02348632|Other|75 mg - 300 mg of JZP-110|Once Daily Dosing
3110236|NCT02348658|Other|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
3110237|NCT02348658|Other|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
3110238|NCT02348684||Radiation therapy groups|Risk groups based on dosimetric radiation parameters.
3110239|NCT02348723|Experimental|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
3110240|NCT02348723|Active Comparator|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR) between 2.0 - 3.0
3110241|NCT02348775|Experimental|GlyNAC|HIV infected subjects will be studied before and after taking oral glycine and n-acetylcysteine for 3 months
3110242|NCT02348840|Experimental|mHealth midwives|Midwives will receive access to mHealth technology immediately and use it for 12 months
3110243|NCT02348840|Active Comparator|mHealth midwives - control|Midwives will not have access to mHealth technology for the first six months, and then will receive the technology for the remaining six months.
3110244|NCT02348840|Active Comparator|Pregnant Women|Pregnant women may or may not receive mHealth technology, based on the collaborating midwife they are assigned.
3110245|NCT02348918|Active Comparator|Luminate 1.0mg group|Stage 1- Luminate 1.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3110246|NCT02348918|Active Comparator|Luminate 2.0mg group|Stage 1 -Luminate 2.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week 20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3110247|NCT02348918|Active Comparator|Luminate 3.0mg group|Stage 1- Luminate 3.0 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Luminate injection at week20 for a total of at least 3 and no more than 4 Luminate injections. Sham injections will be performed at weeks 12 and 16 and may also be performed at week 20 if prn Luminate is not required; sham laser treatment will be administered at baseline and at 16 weeks.
3110248|NCT02348918|Active Comparator|Avastin® group|Stage 1- Avastin 1.25 mg intravitreal injection administered at baseline (Day 0), 4 weeks and 8 weeks with prn Avastin injection at weeks 12, 16, or 20 for a total of at least 3 and up to 6 Avastin injections. Sham injections may be performed at weeks 12, 16, and 20 if prn Avastin is not required.
3110249|NCT02348918|Active Comparator|Avastin then Luminate 1.0 mg IVT + sham injection|Stage 2 - Week 0 (Baseline): Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 1.0 mg IVT + sham injection Weeks 12 and 16: Sham IVT
3110250|NCT02348918|Active Comparator|Avastin then Luminate 0.5 mg IVT + sham injection|Stage 2- Week 0 (Baseline); Avastin 1.25 mg IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + sham injection Weeks 12 and 16: Sham IVT
3110251|NCT02348918|Active Comparator|Sham then Luminate 1.0 mg + Avastin 1.25 mg IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Luminate 1.0 mg + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
3110252|NCT02348918|Active Comparator|Sham then Luminate 0.5 mg IVT + Avastin 1.25 mg IVT|Stage 2 : Week 0: Sham IVT Weeks 1, 4 and 8: Luminate 0.5 mg IVT + Avastin 1.25 mg IVT Weeks 12 and 16: Sham IVT
3110253|NCT02348918|Active Comparator|Avastin 1.25 mg + Sham IVT|Stage 2 : Week 0 (Baseline): Sham IVT Weeks 1, 4 and 8: Avastin 1.25 mg + Sham IVT Weeks 12 and 16: Avastin PRN
3110254|NCT02349048|Experimental|Arm A|Chronic hepatitis C virus (HCV) genotype 1 infected participants with early stages of liver fibrosis, will receive Simeprevir (SMV) 150 milligram (mg), Daclatasvir (DCV) 60 mg and Sofosbuvir (SOF) 400 mg once daily for 6 weeks.
3110255|NCT02349048|Experimental|Arm B|Chronic HCV genotype 1 infected participants with cirrhosis, will receive SMV 150 mg, DCV 60 mg and SOF 400 mg once daily for 8 weeks.
3110256|NCT02349061|Experimental|Ustekinumab plus Concomitant Medication|Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
3110257|NCT02349061|Experimental|Placebo followed by Ustekinumab plus Concomitant Medication|Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
3110258|NCT02349152|Experimental|Remifentanil group|Half of subjects enrolled will be randomized to the remifentanil group
3110259|NCT02349152|Active Comparator|Fentanyl group|Half of subjects enrolled will be randomized to the fentanyl group
3110260|NCT02349178|Experimental|Bridging Arm|Days 1-5 Receive 20 mg/m2 IV Clofarabine (CLOLAR) over 2 hours followed by 100 mg/m2 IV Etoposide (VP-16, Etopophos) over 2 hours followed by 300 mg/m2 IV Cyclophosphamide (Cytoxan, CTX) as a 30-60 minute infusion
3110261|NCT02349295|Experimental|Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)|Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
3132662|NCT03443024|Placebo Comparator|Group 4 - Placebo|"Placebo administered SC once Q2W.~Baseline and Week 2: Four 1-mL SC injections of placebo.~Week 4, 6, 8, 10, 12, 14: Two 1-mL SC injections of placebo."
3110262|NCT02349295|Experimental|Ixekizumab 80 mg Q4W|Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
3110263|NCT02349295|Placebo Comparator|Placebo|Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
3110264|NCT02349360|Active Comparator|Probiotic|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
3110265|NCT02349360|Placebo Comparator|Placebo|Encapsulated starch placebo administered for 8 weeks
3110266|NCT02349412|Experimental|Arm 1|Patients receive early palliative care and standard oncology care. Patients and family caregivers will be asked to complete quality-of-life questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years.
3110267|NCT02349412|Experimental|Arm 2|Patients receive standard oncology care. Patient and family caregiver will be asked to complete self-report questionnaires at weeks 6, 12, and 24. Survival follow-up will be every 4 months from week 24 until death or up to 3 years. Palliative care visit only upon request from attending oncologist(s) or patient/family.
3110268|NCT02349425|Experimental|Cohort 1: Gefapixant>Placebo|50, 100, 150, and 200 mg gefapixant twice daily (BID) for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
3110269|NCT02349425|Experimental|Cohort 1: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 50, 100, 150, and 200 mg BID for 4 days each in Period 2. For Cohort 1, there was a 3 to 7 day washout period between treatment periods.
3110270|NCT02349425|Experimental|Cohort 2: Gefapixant>Placebo|Gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 1 and placebo BID for 16 days in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
3110271|NCT02349425|Experimental|Cohort 2: Placebo>Gefapixant|Placebo BID for 16 days in Period 1 and gefapixant 7.5, 15, 30, and 50 mg BID for 4 days each in Period 2. For Cohort 2, there was a 14 to 21 day washout period between treatment periods.
3110272|NCT02349438|Experimental|senofilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
3110273|NCT02349438|Active Comparator|lotrafilcon A|The lenses will be worn for 2 hours in both eyes, and not dispensed
3110274|NCT02349451|Active Comparator|Adalimumab|Double-blind adalimumab 40 mg administered every other week (EOW) for 12 weeks
3110275|NCT02349451|Placebo Comparator|Placebo|Double-blind placebo administered every week (EW) for 12 weeks
3110276|NCT02349451|Experimental|ABT-122 120 mg|Double-blind ABT-122 120 mg administered EW for 12 weeks
3110277|NCT02349451|Experimental|ABT-122 240 mg|Double-blind ABT-122 240 mg administered EW for 12 weeks
3110278|NCT02349477|Experimental|Gabapentin|Gabapentin up to 1200 mg per day in 3 divided doses
3110279|NCT02349477|Placebo Comparator|placebo|matching placebo
3110280|NCT02349542|Experimental|Liposomal bupivacaine|Patients will receive liposomal bupivacaine following simultaneous bilateral total knee arthroplasty.
3110281|NCT02349633|Experimental|Cohort 1|Cohort 1 will be initiated (current dose 200 mg)
3110282|NCT02349633|Experimental|Cohort 2A|Cohort 2A will evaluate PF-06747775 200 mg by mouth (PO) daily (QD) in combination with palbociclib continuous PO QD dosing in 21-day cycles. The starting dose (DL1) for palbociclib will be 100 mg PO daily. Dose finding will follow mTPI method with adjustments using DLT rate.
3110283|NCT02349633|Experimental|Cohort 2B|Cohort 2B will be initiated once the RP2D of the PF-06747775 and palbociclib combination is determined.
3110284|NCT02349633|Experimental|Cohort 3|Cohort 3 combination is PF-06747775 200 mg PO QD and avelumab 10 mg/kg IV Q2W in 28-day (4-week) cycles. Dose finding will follow the mTPI design. Once RP2D of PF-06747775 in combination with avelumab is determined, the Dose Expansion Phase will be opened.
3110285|NCT02349646||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
3110286|NCT02349685|Experimental|14 day bismuth based quadruple therapy (PBMT) group|Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
3110287|NCT02349685|Experimental|14 day Moxifloxacin containing triple therapy (MEA) group|PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.
3110288|NCT02349685|Active Comparator|14 day tailored therapy group|based on H. pylori culture and antimicrobial sensitivity, select the 2nd rescue regimen between 14 days of bismuth-based quadruple therapy or 14 days moxifloxacin-containing triple therapy according to antibiotics susceptibility.
3110289|NCT02349711|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3110290|NCT02349711|Experimental|Probiotic mixture|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3110291|NCT02350127|Experimental|Immediate Start|The Immediate Start group will participate in the Preventing Loss of Independence through Exercise (PLIE) group movement program for 1 hour, 2-3 days/week, for 4 months. After the intervention has been completed, they will be encouraged to maintain PLIE activities on their own for the next 4 months.
3110292|NCT02350127|Active Comparator|Delayed Start|Study participants who are randomized to the Delayed Start control group will be placed on a waitlist and will be encouraged to continue participating in their usual activities at the adult day center or in their community setting for 4 months. After the 4-month waitlist period ends, they will participate in the PLIE program for 1 hour, 2-3 days/week, for 4 months.
3110293|NCT02350309|Experimental|Lemborexant 5 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 5 mg within 5 minutes before bedtime.
3110294|NCT02350309|Experimental|Lemborexant 10 mg|Participants will receive a single, oral tablet formulation dose of lemborexant 10 mg within 5 minutes before bedtime.
3110295|NCT02350309|Placebo Comparator|Lemborexant-matched Placebo|Participants will receive a single, oral tablet formulation dose of lemborexant-matched placebo within 5 minutes before bedtime.
3110296|NCT02350309|Active Comparator|Flurazepam 30 mg|Participants will receive a single, oral capsule formulation dose of flurazepam 30 mg within 5 minutes before bedtime.
3110297|NCT02350478|Active Comparator|Linagliptin|The subjects will receive Linagliptin 5mg (licensed dose for treatment of type 2 diabetes) .
3110298|NCT02350478|Placebo Comparator|Placebo|The subjects will receive placebo.
3110299|NCT02350569|Experimental|LDV/SOF|Participants with genotype 1 or 4 HCV who are undergoing liver transplant will receive one dose of LDV/SOF prior to the transplant and then will receive LDV/SOF once daily for 4 weeks following the transplant.
3110300|NCT02350647|Experimental|HEALICOIL Regenesorb|Suture anchor for rotator cuff repair
3110301|NCT02350647|Active Comparator|Twinfix Ultra HA|Suture anchor for rotator cuff repair
3110302|NCT02350660|Experimental|Cow's milk for alpha-gal allergics|daily consumption of cow's milk
3110303|NCT02350660|Experimental|Peanut powder|peanut oral immunotherapy
3110304|NCT02350816|Active Comparator|HGT-1410 Q2W in Study HGT-SAN-093 randomized to HGT-1410 Q2W|"Patients in Group 1 will continue HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 50, with a cumulative treatment period of up to 42 months (168 weeks) . HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).~HGT-SAN-093 = NCT02060526"
3110305|NCT02350816|Active Comparator|HGT-1410 Q4W in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 2 will continue HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 52, with a cumulative treatment period of up to 42 months (168 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3110306|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q2W|Patients in Group 3A will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 2 weeks (Q2W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3110307|NCT02350816|Active Comparator|no-treatment in Study HGT-SAN-093 randomized to HGT-1410 Q4W|Patients in Group 3B will receive an IDDD following informed consent and will be randomized in a 1:1 allocation ratio to begin HGT-1410 treatment at a dose of 45 mg administered every 4 weeks (Q4W) starting at Week 0 of the extension study, with a cumulative treatment period of up to 30 months (120 weeks). HGT-1410 will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
3110308|NCT02350998|Experimental|OTO-201|6 mg OTO-201 administered trans-tympanostomy tube
3110309|NCT02351037|Experimental|Ibrutinib Monotherapy Cohort|Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.
3110310|NCT02351037|Experimental|Ibrutinib + LD-AraC Combination Cohort|Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
3110311|NCT02351037|Experimental|Ibrutinib+Azacitidine Combination Cohort|Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).
3110312|NCT02351115|Experimental|Sequence BEADC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
3110313|NCT02351115|Experimental|Sequence CDAEB|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
3110314|NCT02351115|Experimental|Sequence DEBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
3110315|NCT02351115|Experimental|Sequence EDBAC|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
3110316|NCT02351115|Experimental|Sequence CABED|A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 mg, D= Inhaled Alprazolam 2 mg, E=Placebo
3110317|NCT02351167|Active Comparator|Combination NRT and Counseling|Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
3110318|NCT02351167|Active Comparator|Varenicline (Chantix) and Counseling|Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.
3110319|NCT02351167|Placebo Comparator|Placebo Medicine and Counseling|Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.
3110320|NCT02351258|Experimental|Usual Care only, then Usual Care + 70% Isopropyl Alcohol|Usual care for central line while patients are at home and then switch to usual care plus 70% isopropyl alcohol after washout.
3110321|NCT02351258|Experimental|Usual Care + 70% Isopropyl Alcohol, then Usual Care only|Use of 70% isopropyl alcohol embedded caps on central lines in addition to usual care of central line in the home setting and then switch to usual care only after washout.
3110322|NCT02351271|Experimental|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
3110323|NCT02351271|Active Comparator|Manual capsulorhexis&lens fragmentation|The Conventional group acts as a control group with conventional capsulorhexis and ultrasound phacoemulsification
3110324|NCT02351349|Experimental|multidisciplinary intervention|Due to the problem of randomization, the study became a before and after assessment in the one group that completed the 12 week exercise program and received nutritional support
3110325|NCT02351349|No Intervention|Non adherence|Those who were offered the program but did not complete the prescription
3110326|NCT02351505|Experimental|Treatment (selinexor)|Patients receive selinexor PO twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3110327|NCT02351700|Active Comparator|IV Caldolor (ibuprofen)|Intravenous (IV) Caldolor (ibuprofen) (800mg every 8 hours) initiated during surgery and oral acetaminophen 1000mg every 6 hours initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
3110328|NCT02351700|Placebo Comparator|standard treatment group|IV placebo will be initiated during surgery and oral acetaminophen 1000mg every 6 hours will be initiated post-operatively and continued for the duration of the hospital stay (an expected average stay of 2 days) or 48 hours, whichever comes first. Breakthrough pain will be treated with rescue narcotics (IV morphine 2-4mg every 2 hours and oral oxycodone 5-15mg every 4 hours immediately post-operatively through discharge, an expected average stay of 2 days). Hydromorphone (IV 0.5-2mg every 2 hours and oral 2-4mg every 4 hours) will be used in patients with morphine or oxycodone allergy or intolerance.
3110329|NCT02351739|Other|Pembrolizumab|Arm 1: pembrolizumab monotherapy
3110330|NCT02351739|Other|ACP-196 in combination with pembrolizumab|Arm 2: ACP-196 in combination with pembrolizumab
3110331|NCT02351817|Experimental|Baseline - Test A - Test B|"Three period investigation. First each subject tests baseline product, then Test A and finally Test B.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
3110332|NCT02351817|Experimental|Baseline - Test B - Test A|"First each subject tests baseline product, then Test B and finally Test A.~Baseline product: the subject's usual product~Test A: A newly developed 1-piece, open ostomy appliance for collecting feces~Test B: A newly developed 1-piece, open ostomy appliance for collecting feces"
3110333|NCT02351934|Experimental|Furosemide + Enhanced Recovery after Surgery (ERAS)|Furosemide 10 mg IV on post-operative day #1 and/or 2, plus ERAS, as described in other arm.
3110334|NCT02351934|Active Comparator|Enhanced Recovery after Surgery (ERAS)|ERAS included administration of celecoxib and gabapentin in the pre-operative setting, single-injection intrathecal analgesic administration immediately prior to induction of general anesthesia, post-operative administration of scheduled acetaminophen and nonsteroidal anti-inflammatory drug (NSAID) or tramadol, and discontinuation of IV fluids by 0800 on postoperative day (POD) 1. Intraoperative fluid administration was dependent on the individual anesthesia provider with no unified commitment to either zero balance or goal-directed fluid therapy. Fluid status was determined based on patient weight. Patients were weighed preoperatively and daily post-operatively using either a bed scale or a unit-based scale.
3110335|NCT02351960|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once daily for up to 4 weeks to participants with non-erosive reflux disease (NERD).
3110336|NCT02351960|Experimental|Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules orally, once daily for up to 8 weeks to participants with erosive esophagitis (EE).
3110337|NCT02352090|Experimental|Synthetic estrogen + progestin|Ethinyl estradiol / dienogest
3110338|NCT02352090|Experimental|Natural estrogen + progestin|Estradiol valerate / dienogest
3110339|NCT02352090|Active Comparator|Progestin-Only|Dienogest
3110340|NCT02352103|Active Comparator|Control arm|Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System
3110341|NCT02352103|Experimental|Treatment arm|Retzius sparing radical prostatectomy da Vinci Surgical System
3110342|NCT02352259|Experimental|Electrochemotherapy|
3110343|NCT02352298|Experimental|Dario Blood Glucose Monitoring System|Blood obtained via fingerstick and blood glucose level is tested on the Dario Blood Glucose Monitoring System
3110344|NCT02352298|Active Comparator|YSI STAT|Blood obtained via fingerstick and blood glucose level is tested on the YSI STAT for comparison to the results obtained with the Dario Blood Glucose Monitoring System
3110345|NCT02352363|Experimental|CVT-301|Capsules of Levodopa Inhalational Powder (LIP) used up to 5 times per day for OFF episodes, for up to 54 weeks duration.
3110346|NCT02352363|Other|Observational Cohort|Standard of care. Patients in both the CVT-301 treatment group and the observational cohort will be managed with their standard PD treatment throughout the study.
3110347|NCT02352493|Active Comparator|ALN-CC5|
3110348|NCT02352493|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3110349|NCT02352779|Experimental|Arm I (low-dose omega-3 fatty acid)|Patients receive low-dose omega-3 fatty acid supplementation PO BID and placebo PO BID for 6 weeks.
3110350|NCT02352779|Experimental|Arm II (high-dose omega-3 fatty acid)|Patients receive high-dose omega-3 fatty acid supplementation PO BID for 6 weeks.
3110351|NCT02352779|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO BID for 6 weeks.
3132663|NCT03443063|Experimental|Group 1: Severe Renal Impairment|Participants with severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 milliliters per minute (mL/min/1.73 square meter [m^2]) and not on dialysis) will receive a single dose of 10 milligrams (mg) lemborexant (oral tablet) in the morning after an overnight fast.
3110352|NCT02352831|Experimental|Phase I (tosedostat + capecitabine)|"The phase I study will be conducted in the standard 6-patient-per-cohort dose de-escalation fashion.~Tosedostat by mouth daily Days 1-21 of each 21-day cycle. Dose Level 0 (starting dose) = 120 mg PO daily and Dose Level -1 = 60 mg PO daily. All 6 patients in the Phase 1 received 120 mg starting dose of tosedostat.~Capecitabine 1000 mg/m^2 by mouth BID Days 1-14 of each 21-day cycle~Fresh tissue biopsy: Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain."
3110353|NCT02352831|Experimental|Phase II (tosedostat + capecitabine)|"Tosedostat (dose determined by Phase I portion of study) by mouth daily Days 1-21 of each 21-day cycle~Capecitabine by mouth BID Days 1-14 of each 21-day cycle"
3110354|NCT02352844|Experimental|Arm 1 (everolimus)|Everolimus is an oral drug which will be administered on an outpatient basis at a dose of 10 mg daily on a 28-day cycle.
3110355|NCT02352922|Experimental|Liposomal Bupivacaine|extended-release bupivacaine (EXPAREL)
3110356|NCT02352922|Active Comparator|Bupivacaine HCl|short-acting bupivacaine
3110357|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study A|MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.
3110358|NCT02352948|Active Comparator|Standard of Care in Sub-study A|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.
3110359|NCT02352948|Experimental|MEDI4736 (durvalumab) + tremelimumab in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3110360|NCT02352948|Active Comparator|Standard of Care in Sub-study B|Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.
3110361|NCT02352948|Experimental|MEDI4736 (durvalumab) monotherapy in Sub-study B|MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3110362|NCT02352948|Experimental|tremelimumab in Sub-study B|tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.
3110363|NCT02352974|Experimental|GAD-Alum+Vitamin D|"GAD-Alum (Diamyd) injected into Lymph Nodes Dosage and interval: One injection of 4 µg Diamyd will be administered into the lymph nodes at three occasions, with one month intervals~Vitamin D (Calciferol) in oral solution. Dosage and interval: 2000 IU daily for 120 days"
3110364|NCT02353091|No Intervention|APD Control Group|Comprised 13 children diagnosed with APD and acts as a control without using any form of intervention.
3110365|NCT02353091|Experimental|APD Intervention Group|Comprised 13 children diagnosed with APD and received the Remote Microphone Hearing AId intervention at the start of the study, after baseline testing, and used for 6 months.
3110366|NCT02353169|Experimental|Dexmedetomidine 0.25mcg/kg|0.25mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3110367|NCT02353169|Experimental|Dexmedetomidine 0.5mcg/kg|0.5mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3110368|NCT02353169|Experimental|Dexmedetomidine 0.75mcg/kg|0.75mcg/kg dexmedetomidine diluted with normal saline in a 10mL syringe, administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3110369|NCT02353169|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting 3 minutes after induction of anesthesia.
3110370|NCT02353299|Active Comparator|Silenor 6 mg (DXP-4H)|Silenor 6 mg single nightime dose- 4 hour post dose arousability and cognitive assessments
3110371|NCT02353299|Placebo Comparator|Placebo (PBO-4H)|placebo single nightime dose -4 hour post dose arousability and cognitive assessments
3110372|NCT02353299|Active Comparator|Zolpidem 10 mg (ZOL-1.5H)|zolpidem 10 mg single nightime dose - 1.5 hour arousability and cognitive assessments
3110373|NCT02353299|Placebo Comparator|Placebo (PBO-1.5H)|placebo single nightime dose -1.5 hour arousability and cognitive assessments
3110374|NCT02353442|Placebo Comparator|Control group|"This group will perform during 4 weeks:~placebo ultrasound during 5min ;~scapular squeezing in the sitting position (3x10repetitions);~upper trapezius stretching (in sitting position, 3x30s and 30s of rest)."
3110375|NCT02353442|Active Comparator|Experimental group|"This group will perform during 4 weeks:~posterior shoulder mobilizations during 5min (mobilizations during 30s and 30s of rest);~external rotators strengthening in sidelying positions with load (3x10repetitions);~posterior capsule stretching (sleeper stretch in sidelying position, 3x30s and 30s of rest)."
3110376|NCT02353754|Active Comparator|Standard of Care|Subjects in Group 1 (Standard of Care) will receive intrathecal morphine injection (e.g., Duramorph®) 0.2 mg in conjunction with the single-shot spinal anesthesia. No TAP block will be administered.
3110377|NCT02353754|Experimental|EXPAREL/TAP|Subjects in Group 2 will receive a bilateral TAP infiltration with a single 20 mL dose of EXPAREL 266 mg expanded in volume with 20 mL of normal saline for a total volume of 40 mL (20 mL infiltrated on each side of the abdomen).
3110378|NCT02353780|Active Comparator|Different TNF inhibitor|The participant will be prescribed any TNF antagonist in this arm. The treating rheumatologist selects the TNF antagonist and the appropriate options for that therapy.
3110379|NCT02353780|Active Comparator|Abatacept|The participant will be prescribed abatacept in this arm. The treating rheumatologist selects the appropriate options for that therapy.
3110380|NCT02353780|Active Comparator|Tocilizumab|The participant will be prescribed tocilizumab. The treating rheumatologist selects the appropriate options for that therapy.
3110381|NCT02353806|Experimental|Pregnant women taking amlodipine|Women already taking amlodipine besylate 5 mg for treatment of chronic hypertension in pregnancy who plan to breastfeed postpartum will be assigned to the single experimental arm.
3110382|NCT02353832|Other|No Arm|Study did not have Arm(s)
3110383|NCT02353871|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
3110384|NCT02353871|Placebo Comparator|Placebo|Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
3110385|NCT02354092|Sham Comparator|Sham Group|"This non-intervention group will receive the sham paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~Sham Paracervical Block done with capped spinal needle~osmotic dilators placed in the usual fashion~postprocedural assessment"
3110386|NCT02354092|Experimental|Paracervical Block Group|"This intervention group will receive the paracervical block. This intervention will include~Preprocedural pain control: 800 mg Ibuprofen prior to dilator placement~Local anesthetic for tenaculum placement~18 ml 1% buffered lidocaine Paracervical Block~osmotic dilators placed in the usual fashion~postprocedural assessment"
3110387|NCT02354144|Experimental|Carrageenan-based gel|"The intervention to be administered is:~a commercially available gel that contains carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the placebo gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
3110388|NCT02354144|Placebo Comparator|Control gel|"The intervention to be administered is:~a commercially available gel that does not contain carrageenan.~water-based, latex-condom compatible, clear, odourless, tasteless, and have similar viscosity as the carrageenan-containing gel.~also packaged in a similar plastic bottle with a disk cap that can be operated with one finger, and must be applied prior to anal intercourse during the entire study period. Around 15 ml of the personal lubricant will be dispensed into the hand and applied directly to the genital, anal, and condom surfaces prior to and as needed during anal sex. When sexual activity ceases, the water-based formulation of the gel allows it to be easily removed with lukewarm water."
3110389|NCT02354222|Experimental|Teneligliptin + Canagliflozin|Patients receive Teneligliptin for 24 weeks in combination with Canagliflozin.
3110390|NCT02354222|Placebo Comparator|Placebo + Canagliflozin|Patients receive placebo for 24 weeks in combination with Canagliflozin.
3110391|NCT02354235|Experimental|Canagliflozin + Teneligliptin|Patients receive Canagliflozin for 24 weeks in combination with Teneligliptin.
3110392|NCT02354235|Placebo Comparator|Placebo + Teneligliptin|Patients receive placebo for 24 weeks in combination with Teneligliptin.
3110393|NCT02354339|Experimental|Irvingia gabonensis|Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
3110394|NCT02354339|Placebo Comparator|Placebo|Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
3110395|NCT02354352|Active Comparator|Eplerenone|Eplerenone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Inspra. Eplerenone is a potassium-sparing diuretic.
3110396|NCT02354352|Active Comparator|Spironolactone|Spironolactone is an aldosterone antagonist used as an adjunct in the management of chronic heart failure. It is marketed under the trade name Aldactone. Spironolactone is a potassium-sparing diuretic.
3110397|NCT02354378||Children undergoing sedation with Dexmedetomidine|Children who will undergo sedation for MRI will be given a memory encoding task during dexmedetomidine bolus induction to measure the effects of sedation. The mere task of naming a picture will encode that picture into memory. When the anesthesia has worn off (at approximately 1 hour later), children will be given a memory recognition task to measure the amnesic effects of dexmedetomidine.
3110398|NCT02354378||Children not undergoing sedation|A control group of children of similar age scheduled for MRI will be recruited to perform memory recognition testing.
3110399|NCT02354417|Experimental|ProHema-CB|"All subjects will receive treatment with ProHema-CB (ex-vivo modulated human cord blood cells) transplant.~ProHema-CB (the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 also referred to as FT1050) will be prepared and administered in one of two formulations, based upon subject weight:~For subjects > 35 kg, ProHema-CB will be administered as 150 mL product in a blood bag via gravity infusion. It will be infused at 10 mL to 15 mL per minute, for a total infusion time of 10 to 15 min.~For subject's ≤ 35 kg, ProHema-CB will be administered as a 50 mL product in a syringe via syringe pump.o It will be infused at 5 mL/kg per hour for a total infusion time of up to ~1 hour."
3110400|NCT02354443|Experimental|ProHema-CB|ProHema-CB represents Ex Vivo Modulated Human Cord Blood Cells. Each subject will receive one administration of ProHema-CB unit transplant.
3110401|NCT02354482||Diverse, high-risk patient populations|
3110402|NCT02354508|Experimental|Pasireotide LAR|Patients who qualify for the core phase of the study will be treated with pasireotide LAR 40 mg initially. Patients not achieving biochemical control can be up-titrated to pasireotide LAR 60 mg.
3110403|NCT02354534|Experimental|50 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3110404|NCT02354534|Experimental|200 mg Artesunate suppositories, 1 cycle|Subjects enrolled in this cohort will receive 1 five day cycle of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3110405|NCT02354534|Experimental|200 mg Artesunate suppositories,2 cycles|Subjects enrolled in this cohort will receive 2 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3110406|NCT02354534|Experimental|200 mg Artesunate suppositories,3 cycles|Subjects enrolled in this cohort will receive 3 five day cycles of Artesunate suppositories prior to therapeutic resection of their lesion (if clinically indicated).
3110407|NCT02354586|Experimental|Niraparib|
3110408|NCT02354599|Experimental|Cohort 1: MT203 80 mg|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110409|NCT02354599|Placebo Comparator|Cohort 1: MT203 80 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 80 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110410|NCT02354599|Experimental|Cohort 2: MT203 150 mg|Six Japanese participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110411|NCT02354599|Placebo Comparator|Cohort 2: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110412|NCT02354599|Experimental|Cohort 3: MT203 300 mg|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110413|NCT02354599|Placebo Comparator|Cohort 3: MT203 300 mg matching placebo|Six Japanese participants will be randomized to receive a single dose of MT203 300 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110414|NCT02354599|Experimental|Cohort 4: MT203 150 mg|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously.
3110415|NCT02354599|Placebo Comparator|Cohort 4: MT203 150 mg matching placebo|Six Caucasian participants will be randomized to receive a single dose of MT203 150 mg and 2 participants will be randomized to receive matched placebo subcutaneously
3110416|NCT02354690|Experimental|A|7 days before tumor harvest, patients will begin taking vemurafenib until admission for lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine, followed by TIL infusion and interleukin-2.
3110417|NCT02354781|Experimental|Experimental|The vector will be delivered to both limbs via multiple, direct intramuscular injections of rAAV1.CMV.huFollistin344; the number of injections per muscle will depend on the size of the patient. A total dose of 2.4E12 vg/kg (1.2E12vg/kg/limb) will be delivered to the lower limbs of 6 DMD subjects
3110418|NCT02354833|Experimental|Phenylephrine|A continuous phenylephrine infusion at 0.1 mcg/kg/min
3110419|NCT02354833|Experimental|Norepinephrine|A continuous norepinephrine infusion at 0.05 mcg/kg/min
3110420|NCT02354859|Active Comparator|5 day of infusion of gallium nitrate|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device () using an ambulatory infusion pump infused over 24 hours for 5 sequential days.
3110421|NCT02354859|Placebo Comparator|5 day of infusion of normal saline|Placebo with be dispensed as 1,000 milliliters of 0.9% sodium chloride to match the reconstitution volume of the IV Ga
3110422|NCT02354924|Experimental|Visco soft contact lens|Olifilcon A, Daily wear, monthly disposable soft contact lens
3110423|NCT02354924|Active Comparator|Biofinity soft contact lens|Comfilcon A, Daily wear, monthly disposable soft contact lens
3110424|NCT02354976|Placebo Comparator|Placebo|
3110425|NCT02354976|Experimental|Omega-3 carboxylic acids 4g / day|
3110426|NCT02354976|Active Comparator|Fenofibrate 200mg|
3110427|NCT02355028|Experimental|LHA510|LHA510 ophthalmic suspension administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
3110428|NCT02355028|Placebo Comparator|Vehicle|LHA510 vehicle administered topically in the study eye as specified in the protocol for 84 days, with ranibizumab ophthalmic solution for IVT injection as standard of care rescue therapy.
3110429|NCT02355067|Experimental|Social Media Format|Social Media Intervention for women with postpartum depression (PPD) symptoms
3110430|NCT02355067|Active Comparator|In-Person Format|Traditional In-Person Intervention for Women with postpartum depression (PPD)
3110431|NCT02355158|Experimental|Active|Clonidine hydrochloride topical gel, 0.1%
3110432|NCT02355210|Placebo Comparator|Placebo|5 g lactose given as a placebo
3110433|NCT02355210|Experimental|Probiotic 1|Bifidobacteria adolescentis BD1, 10^9
3110434|NCT02355210|Experimental|Probiotic 2|Bifidobacteria animalis subsp. lactis BB-12, 10^9
3110435|NCT02355210|Experimental|Prebiotic|galactooligosaccaride, 5 g
3110436|NCT02355210|Experimental|Synbiotic 1|galacto-oligosaccharide (5 g) and Bifidobacteria adolescentis BD1 (10^9)
3110437|NCT02355210|Experimental|Synbiotic 2|galacto-oligosaccharide (5 g) and Bifidobacteria animalis subsp. lactis BB-12 (10^9)
3110438|NCT02355275|Experimental|Home Exercise Program|
3110439|NCT02355665|Experimental|Nicotine|Nicotine Spray
3110440|NCT02355665|Placebo Comparator|Placebo|Placebo to match Nicotine spray
3110441|NCT02355691|Experimental|PREVENA Group|Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.
3110442|NCT02355691|No Intervention|Standard group|Patients will be treated with the standard absorptive dressing following total hip arthroplasty.
3110443|NCT02355743|Experimental|rtPA lock therapy Recipients|rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks
3110444|NCT02355821|Experimental|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID
3110445|NCT02355821|Active Comparator|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID
3110446|NCT02355886|Experimental|Arm I (gabapentin)|Patients receive gabapentin PO TID for 48 hours after surgery.
3110447|NCT02355886|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO TID for 48 hours after surgery.
3110448|NCT02355977|Active Comparator|surface and root planning|surface and root planning is performed in a single-visit, one-stage, full mouth pattern using periodontal ultrasonic scaler (Satelec, Mérignac, France)
3110449|NCT02355977|Active Comparator|locally delivered minocycline|Locally delivered minocycline is administered directly into the periodontal pocket up to the gingival margin of the selected teeth
3110450|NCT02355977|Experimental|surface and root planning+minocycline|surface and root planning+locally delivered minocycline is the combined administration of both surface and root planning and locally delivered minocycline.
3110451|NCT02356003|Experimental|Low frequency rTMS|Eleven children (7-12 years of age) with Tourette syndrome will be undergo low frequency repetitive transcranial magnetic stimulation (5 times a week for three weeks).
3110452|NCT02356107|Experimental|Open label treatment with 5-HTP and Creatine|
3110453|NCT02356198|Active Comparator|TAP block (EXPAREL)|After induction of anesthesia, the patients will receive a single injection with 133 mg of EXPAREL in the transversus abdominis plane (TAP), on each side, suspended in 20 milliliters (mL) of injectable saline.
3110454|NCT02356198|Active Comparator|Intrathecal opioid (IT)|single injection intrathecal hydromorphone analgesia given preoperatively
3110455|NCT02356211|Experimental|Treatment|Geriatric Multifactorial Falls Assessment Clinic
3110456|NCT02356211|No Intervention|Control|Geriatric Evaluation and Management Service (GEM)
3110457|NCT02356471|Experimental|Supportive care (consumer-based activity monitor)|Patients wear Fitbit Zip (portable pedometer device) to track physical activity for 7 days before undergoing surgery and for 21 more days after undergoing surgery.
3110458|NCT02356484||Major abdominal surgery cohort|In this surgical cohort, 4 inflammatory markers were measured: albumin, procalcitonin, CRP and lactate levels
3110459|NCT02356562|Experimental|3-DAA with or without SOF and RBV|3-DAA (ombitasvir/paritaprevir/ritonavir once daily [QD] and dasabuvir twice daily [BID]) with and without sofosbuvir (SOF) QD and with or without ribavirin (RBV) BID for 12 or 24 weeks
3110460|NCT02356575|Active Comparator|Acupuncture Group|In the acupuncture group, patients will receive ten treatments of acupuncture over eight weeks.
3110461|NCT02356575|Active Comparator|CBT-I Group|In the CBT-I group, patients will receive seven sessions of CBT-I over eight weeks.
3110462|NCT02356588|Experimental|Sufentanil Tablet 30 mcg|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
3110463|NCT02356588|Placebo Comparator|Placebo Tablet|A stratified randomization will be applied in this study with sex as a stratification factor. Patients who meet all inclusion and none of the exclusion criteria at screening, and following surgery, will be randomly assigned at a 2:1 ratio to treatment with ST 30 mcg or PT within one of two groups (male or female) at each study center. Patients may receive a dose of study medication no more frequently than once per hour. The study may last up to 48 hours.
3110464|NCT02356692|Experimental|enfilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
3110465|NCT02356692|Active Comparator|senofilcon A|participants randomized to wear the Enfilcon A (test) lens in one eye and Senofilcon A (control) lens in the other eye.
3110466|NCT02356705|Placebo Comparator|Saline Placebo|Control patients will receive intranasal saline
3110467|NCT02356705|Active Comparator|Nasal Midazolam Only|Patients will receive 0.2 mg/kg of intranasal midazolam
3110468|NCT02356705|Active Comparator|Midazolam Plus Xylocaine|Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
3110469|NCT02356783|Other|Interlaminar|"Approach for lumbar epidural steroid injection for this arm will be interlaminar.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
3110470|NCT02356783|Other|Transforaminal|"Approach for lumbar epidural steroid injection for this arm will be transforaminal.~We will be implementing a wireless pedometer to each of the 15 patients in this group to measure our primary and secondary outcomes."
3110471|NCT02356887|Experimental|sitting position|The volunteers were kept comfortable in the sitting position. The cricoid cartilage (representing the C6 level) was used as a landmark. A horizontal straight line drawn across the volunteer's neck at the cricoid level and intersecting the IJV on both sides of the neck marked the initial scanning points. The second scanning point was along the IJV at the highest accessible point on the neck. Internal jugular vein cross-sectional area and blood velocity were measured using 2D ultrasound and Doppler (Philips CX50, Andover, MA, USA), respectively, with a 12-3 MHz transducer (Philips L12-3, Andover, MA, USA)
3110472|NCT02356900|Experimental|Hyperoxic, Hyperbaric|Hyperoxic hyperbaric interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis at 1.4 ATA of oxygen in a hyperbaric chamber.
3110473|NCT02356900|Sham Comparator|Normoxic, Normobaric|Normoxic, normobaric, interval exercise training Six sessions of 30 min.of High-intensity interval training completed on a 3-times a week basis.
3110474|NCT02357043|Experimental|Dario Blood Glucose Monitoring System|Subject will be requested to follow the device instructions and perform his/her own finger-stick test using the Dario Glucose Monitoring System (BGMS).
3110475|NCT02357134|Experimental|Arm I (high-flow oxygen)|Patients receive high-flow oxygen via nasal prongs during a structured stationary bicycle exercise session.
3110476|NCT02357134|Experimental|Arm II (high-flow air)|Patients receive high-flow air via nasal prongs during a structured stationary bicycle exercise session
3110477|NCT02357134|Active Comparator|Arm III (low-flow oxygen)|Patients receive low-flow oxygen via a nasal cannula during a structured stationary bicycle exercise session.
3110478|NCT02357134|Active Comparator|Arm IV (low-flow air)|Patients receive low-flow air via a nasal cannula during a structured stationary bicycle exercise session.
3110479|NCT02357147|Experimental|Arm 1|"Combination Phase - Amatuximab + Pemetrexed and Cisplatin~Maintenance Phase - Amatuximab"
3110480|NCT02357147|Experimental|Arm 2|"Combination Phase - Placebo + Pemetrexed and Cisplatin~Maintenance Phase - Placebo"
3110481|NCT02357173|Active Comparator|cigarette group|This group (1/3 of the sample) will not receive electronic cigarettes to sample and will continue smoking their regular cigarettes as much or as little as they would like.
3110482|NCT02357173|Experimental|electronic cigarette|This group (2/3 of the sample) will be given electronic cigarettes for a 3-week period, to use as much or as little as they would like.
3110483|NCT02357264||pre-eclampsia|Ultrasound of Pregnant Females 18+ with pre-Eclampsia
3110484|NCT02357264||No pre-eclampsia.|Ultrasound of Pregnant Females 18+ with no pre-eclampsia
3110485|NCT02357290|Experimental|Open-label Treatment with NAC|"12-week, open-label treatment with NAC. Subjects will be treated with the following dose:~Subjects ages 5-12:~Week 1: 900mg po daily Weeks 2+: 900mg po QAM, 900mg po QPM~Subjects ages 13-17:~Week 1: 900mg po daily Weeks 2-3: 900mg po QAM, 900mg po QPM Weeks 4+: 1800mg po QAM, 900mg po QPM~In Weeks 3-12 for subjects ages 13-17, we will encourage twice per day dosing, but we will permit daily dosing if needed for adherence."
3110486|NCT02357342|Experimental|Sirolimus|Intravitreal Sirolimus
3110487|NCT02357342|Active Comparator|Standard of Care intravitreal anti-VEGF|anti-VEGF intravitreal injections
3110488|NCT02357368|Experimental|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at 150 mg by intramuscular (IM) injection at week 3 of study enrollment and repeated at week 15.
3110489|NCT02357368|Experimental|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant will be placed at study week 3.
3110490|NCT02357368|Experimental|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3.
3110491|NCT02357368|Experimental|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3.
3110492|NCT02357394|Experimental|Device: Arabin Pessary|Participants randomized to this group will receive the pessary.
3110493|NCT02357394|No Intervention|Standard of Care|Patients randomized to the control group will receive standard of care for their condition. This includes surveillance of cervical length, vaginal progesterone, and emergency cerclage.
3110494|NCT02357420|Experimental|Relamorelin 10 μg|Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
3110495|NCT02357420|Experimental|Relamorelin 30 μg|Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
3110496|NCT02357420|Experimental|Relamorelin 100 μg|Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
3110497|NCT02357420|Placebo Comparator|Placebo|Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.
3110498|NCT02357459|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
3110499|NCT02357459|Placebo Comparator|Normal Saline|Single 5 mL intra-articular (IA) injection
3110500|NCT02357459|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection TCA IR 40 mg: Immediate-release formulation
3110501|NCT02357485|Experimental|Treatment arm|Single injection of ADSC
3110502|NCT02357576|Experimental|Reduced Lipid|Subjects will receive a minimized dose (1 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
3110503|NCT02357576|Active Comparator|Standard Lipid|Subjects will receive the standard dose (up to 3 g/kg/day) of the soybean-based lipid component of parenteral nutrition.
3110504|NCT02357706|Active Comparator|Group 1|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 1) will use APAP A on the first night of the evaluation, and APAP B on the second night.
3110505|NCT02357706|Active Comparator|Group 2|Patients will be randomised to either Group 1 or Group 2. Patients in this group (group 2) will use APAP B on the first night of the evaluation and APAP A on the second night.
3110506|NCT02357758|Active Comparator|Antibiotic Prophylaxis|Patients with RUTI receiving Septra (Trimethoprim dose 2mg/kg) or nitrofurantoin (dose 2 mg/kg) as determined by clinician.
3110507|NCT02357758|No Intervention|Healthy Population|Healthy population
3110508|NCT02357758|No Intervention|Clinical Observation|Patients experiencing RUTI that do not require antibiotic prophylaxis as determined by clinician.
3110509|NCT02357810|Experimental|Treatment (pazopanib hydrochloride, topotecan hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and topotecan hydrochloride PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3110510|NCT02357836|Other|Itraconazole|600 mg twice daily for 10-14 days
3110511|NCT02357901|Experimental|RBP-6000 300mg/100mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given RBP-6000 300 mg injections on Days 1 and 29. Injections 3-6 are separated by 28 days (Day 57-Day 141) and contain RBP-6000 100 mg.~In addition, participants received individual drug counseling (IDC) at least once a week."
3110512|NCT02357901|Experimental|RBP-6000 300mg/300mg|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six RBP-6000 300 mg injections on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
3110513|NCT02357901|Placebo Comparator|Placebo Matching 300 mg/100 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given placebo injections on Days 1 and 29 (matching the RBP-6000 300 mg dose volume). Injections 3-6 are separated by 28 days (Day 57-Day 141) and also contain placebo (matching the RBP-6000 100 mg volume).~In addition, participants received individual drug counseling (IDC) at least once a week."
3110514|NCT02357901|Placebo Comparator|Placebo Matching 300 mg RBP-6000|"During the Run-In Period, participants are inducted onto SUBOXONE sublingual film (SL) followed by a 4- to 11-day SUBOXONE sublingual film open-label run-in dose-adjustment period to achieve buprenorphine dosages ranging from 8 to 24 mg according to the SUBOXONE sublingual film prescribing information. Participants are then randomized. As of protocol Amendment 2 (21 August 2015) SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.~Participants in this treatment arm are given six placebo injections (volume-matched to RBP-6000 300 mg dose) on Days 1 to 141 with injections separated by 28 days.~In addition, participants received individual drug counseling (IDC) at least once a week."
3110515|NCT02357940|Experimental|Adult Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
3110516|NCT02357940|Experimental|Baby (infants, toddlers, young children) Tolerance Assessment|Apply thin layer of experimental product to the affected skin areas at least 2 times per day and massage gently into skin
3110517|NCT02357979|Experimental|Laser & Fluoride|In the split mouth design the molar on one side of the mouth receives the intervention CO2 9.3 μm short pulsed laser treatment and fluoride varnish (experimental side) in the occlusal fissure areas.
3110518|NCT02357979|Active Comparator|Fluoride alone|In the split mouth design this arm (this side in the mouth - the contralateral tooth to the experimental site in the same jaw) will receive only fluoride varnish treatment. In the split mouth design this opposite side of the jaw is functioning as control.
3110519|NCT02358031|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months.
3110520|NCT02358031|Experimental|Pembrolizumab + Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 24 months; plus cisplatin 100 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
3110521|NCT02358031|Active Comparator|Cetuximab + Chemotherapy (Control)|Participants receive cetuximab on Day 1 at a dose of 400 mg/m^2 IV, and then 250 mg/m^2 IV on Day 1 of each subsequent week until disease progression or unacceptable toxicity; plus cisplatin 100 mg/m^2 IV or carboplatin AUC 5 IV (Investigator's choice) on Day 1 of each 3-week cycle (6 cycle maximum for platinum-based therapy); plus 5-FU 1000 mg/m^2/day IV continuous from Day 1-4 of each 3-week cycle (6 cycle maximum).
3110522|NCT02358044|Experimental|Grazoprevir + Elbasvir|Participants receive a fixed-dose combination (FDC) tablet of 100 mg grazoprevir and 50 mg elbasvir for 12 weeks, followed by 24 weeks of follow-up.
3110523|NCT02358044|Active Comparator|SOF + PR|Participants receive SOF (400 mg) combined with PegIntron (1.5 mcg/kg) plus RBV (1000-1200 mg weight-based dose) for 12 weeks, followed by 24 weeks of follow-up.
3110524|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or ultraviolet therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from primary care practitioners or dermatologists, just as they would in the real world.
3110525|NCT02358135|Experimental|CCH Model|The intervention arm will be the collaborative connected health (CCH) model, which purports to increase access to specialists and improve outcomes. Specifically, CCH offers multiple modalities for patients and primary care providers (PCPs) to access dermatologists online directly and asynchronously. CCH also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, PCPs, and dermatologists.
3110526|NCT02358343|Active Comparator|Engagement Interview|Subjects will be randomly assigned to engagement interview or a control visit.Trained CBT therapists at each of the three sites will conduct the engagement interview. The session will be aimed at improving the acceptance of the diagnosis of depression by patients and treatment for the same.
3110527|NCT02358343|No Intervention|Control Visit|Subjects will be randomly assigned to engagement interview or a control visit. Individuals assigned to control visit will be scheduled for a follow-up discussion with a member of the research team. During this session, they will be informed of the diagnosis of major depression or dysthymia, the options for treatment available through the clinical trial, and alternatives should they decline participation in the clinical trial.
3110528|NCT02358343|Active Comparator|Cognitive Behavioral Therapy|"The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization.~Individuals will undergo 10 CBT sessions of 60 minutes each, by a trained therapist in the dialysis facility (8 weekly sessions; then every other week x 2). The CBT will be administered while the patient is undergoing HD; however, alternative arrangements will be made upon individual patient's preferences."
3110529|NCT02358343|Active Comparator|Antidepressant Drug Therapy|The subjects will be randomly assigned to individual CBT or sertraline drug therapy using block randomization. Anti-Depressant Drug Therapy will be delivered with sertraline, a selective serotonin reuptake inhibitor, and the dose will be titrated using the Measurement Based Care Protocol.
3110530|NCT02358343|No Intervention|Observational Cohort|Subjects who (1) are not willing to participate in the clinical trial and (2) do not find any treatment acceptable outside the clinical trial will be invited to participate in the prospective observational cohort for serial assessment of depressive symptoms.These subjects will only undergo assessment of severity of depressive symptoms at weeks 0, 6, and 12 using QIDS-C.
3110531|NCT02358369|Experimental|13 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 13 mg Bimatoprost Ocular Insert in each eye (OU) for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops to each eye twice a day (BID) for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
3110532|NCT02358369|Experimental|2.2 mg Bimatoprost Ocular Insert|Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 2.2 mg Bimatoprost Ocular Insert in each eye for 12 weeks. Note: participants also self-administered placebo ophthalmic eye drops in each eye twice a day for the first 6 weeks. After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks.
3110533|NCT02358369|Active Comparator|Timolol 0.5%|"Washout + Placebo Ocular Insert in each eye for 4 to 6 weeks, followed by 0.5% timolol ophthalmic solution in each eye for 6 weeks. Note: participants simultaneously wore placebo ocular inserts for 12 weeks.~After 12 weeks, 13 mg Bimatoprost Ocular Insert in each eye for an additional 12 weeks."
3110534|NCT02358473|Experimental|mogamulizumab + docetaxel|"Mogamulizumab will be given as monotherapy in a 4-week run-in period. Subjects will then receive up to 6 cycles of mogamulizumab in combination with docetaxel at appropriate intervals.~Subjects may then continue to receive mogamulizumab, at the same dose administered in Cycle 1, once every 3 weeks as monotherapy."
3110535|NCT02358603|Experimental|Case group|At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
3110536|NCT02358603|Placebo Comparator|Control group|Each subject of the control group will do the same test and examination with the subjects in the case group.
3110537|NCT02358668|Experimental|BTI320 4 grams|three times daily, oral for 16 weeks
3110538|NCT02358668|Experimental|BTI320 8 grams|three times daily, oral for 16 weeks
3110539|NCT02358668|Placebo Comparator|BTI320 matching placebo|2 tablets three times daily, oral for 16 weeks
3110540|NCT02358863|Experimental|Chemotherapy|"Standard chemotherapy doublet based on molecular testing using one of the following interventions:~Modified FOLFOX6 Docetaxel/Capecitabine Cisplatin/Irinotecan Cisplatin/Docetaxel IRI/EPI EPI/Docetaxel Irinotecan/Docetaxel Docetaxel"
3110541|NCT02358889|Experimental|hI-con1|Patients will receive monthly intravitreal hI-con1 as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3110542|NCT02358889|Experimental|hI-con1 + ranibizumab|Patients will receive monthly intravitreal hI-con1 in combination with intravitreal ranibizumab for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3110543|NCT02358889|Active Comparator|ranibizumab|Patients will receive monthly intravitreal ranibizumab as monotherapy (plus sham injection) for the first 2 months followed by monthly treatment for 3 months, as needed, according to protocol criteria.
3110544|NCT02359006|Active Comparator|minocycline|200mg minocycline
3110545|NCT02359006|Placebo Comparator|Placebo|Sugar pill
3110546|NCT02359019|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3110547|NCT02359045|Experimental|Part 1: Treatment A-B-C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1), D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fasted condition.
3110548|NCT02359045|Experimental|Part 2: Treatment A-B/C-D|Subjects received a single dose of D1400147 (Treatment A: Omega-3-carboxylic acids 2000 mg uncoated capsules), D14000136 (Treatment B: Omega-3-carboxylic acids 2000 mg coated capsules coat 1) or D14000137 (Treatment C: Omega-3-carboxylic acids 2000 mg coated capsules coat 2) and Epanova® (Treatment D: Epanova capsules 1000 mg) under fed condition.
3110549|NCT02359058|Other|Ramucirumab + Capecitabine + Cisplatin|Ramucirumab (8 milligram per kilogram (mg/kg) given intravenously (IV) on days 1 and 8 in combination with 1000 mg/square meter (m^2) capecitabine given orally twice a day on days 1 through 14 and 80 mg/m^2 cisplatin given IV on day 1 of each 21 day cycle (up to 6 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3110550|NCT02359058|Other|Ramucirumab + S-1 + Cisplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 of 21 day in combination with 40 mg/m^2 tegafur/gimeracil/oteracil (S-1) given orally twice a day on days 1 through 21 and 60 mg/m^2 cisplatin given IV on day 8 of each 35 day cycle (up to 8 cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3110551|NCT02359058|Other|Ramucirumab + S-1 + Oxaliplatin|Ramucirumab 8 mg/kg given IV on days 1 and 8 in combination with 40 mg/m^2 S-1 given orally twice a day on days 1 through 14 and 100 mg/m^2 oxaliplatin given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3110552|NCT02359110|Experimental|Drug 1|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
3110553|NCT02359110|Placebo Comparator|Drug 2|Patients will receive Methylcellulose based placebo tab less than 1 hour before surgery.
3110554|NCT02359305||IV Acetaminophen|Acetaminophen administered by intravenous infusion.
3110555|NCT02359305||Rectal Acetaminophen|Acetaminophen administered by rectal suppository.
3110556|NCT02359435|Experimental|Reverse hybrid therapy|pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg and amoxicillin 1 g for another 5 days; with all drugs given twice daily
3110557|NCT02359435|Active Comparator|Standard triple therapy|pantoprazole 40 mg, clarithromycin 500 mg, and amoxicillin 1 g for 12 days; with all drugs given twice daily
3110558|NCT02359552|Placebo Comparator|Placebo|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
3110559|NCT02359552|Active Comparator|Rasagiline|"Subjects will be randomized in 1:1 ratio to receive Rasagiline or the matching placebo 24-week double blind treatment.~Subjects will take one 0.5 mg Rasagiline tablet or the matching placebo once a day on Baseline (Day 1) through Week 4. The dose will be titrated up to one 1 mg tablet or the matching placebo once a day starting on Week 5 until the Week 28 (end of treatment visit)."
3110560|NCT02359851|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
3110561|NCT02359877|Experimental|BCD-054|Pegylated interferon beta 1a Single doses - 60 mcg, SC/IM Single doses - 120 mcg, SC/IM Single doses - 240 mcg, SC/IM Single doses - 360 mcg, SC/IM Multiple doses - 180 mcg, SC/IM
3110562|NCT02359877|Active Comparator|Rebif|interferon beta 1a 44 mcg, SC, 3 times a week for 2 weeks
3110563|NCT02359877|Active Comparator|Avonex|interferon beta 1a 30 mcg, IM, once a week for 2 weeks
3110564|NCT02359890|Experimental|Treatment Group|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH® SF family of contact force sensing catheters (study device)
3110565|NCT02359903|Experimental|BCD-055 group|BCD-055 (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
3110566|NCT02359903|Active Comparator|Remicade group|Remicade (infliximab) at a dose of 5 mg/kg, administered as a slow intravenous infusion, which will be performed on week 0, 2, 6, 14 and 22
3110567|NCT02359916||A|Snacks sold under equal pricing, no delays
3110568|NCT02359916||B|Healthier snacks sold at 25% or $0.25 discount, no delays
3110569|NCT02359916||C|Less healthy snacks sold at equal pricing with delays
3110570|NCT02359916||D|Healthy snacks sold at 25% or $0.25 discount, plus delays on less healthy snacks
3110571|NCT02359916||E|Less healthy snacks sold at 25% or $0.25 higher price, no delays
3110572|NCT02359916||F|Less healthy snacks sold at 25% or $0.25 higher price, plus delays
3110573|NCT02359916||G|Snacks sold under equal pricing, no delays
3110574|NCT02359955|Experimental|Zero-Degree Teeth, then Anatomic Teeth|edentulous patients who were first treated with zero-degree teeth complete denture, then with anatomic teeth complete denture
3110575|NCT02359955|Experimental|Anatomic Teeth, then Zero-Degree Teeth|edentulous patients who were first treated with anatomic teeth complete denture, the with zero degree teeth complete denture
3110576|NCT02360124|Placebo Comparator|control|instructions on oral hygiene (OHI) tailored to the individual's condition will be given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) will be provided. The OHI and provision of toothpaste will be repeated at 6-month intervals. In addition, distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) will be painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.
3110577|NCT02360124|Experimental|silver diammine fluoride|the subjects will receive the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution will be painted onto the exposed tooth root surfaces. This treatment will be repeated after 12 and 24 months.
3110578|NCT02360124|Active Comparator|silver diammine fluoride and KI|the subjects will receive the same treatment as those provided to subjects in the control group except that a 38% SDF solution instead of the placebo solution will be painted onto the exposed tooth root surfaces and followed by painting of a saturated potassium iodide solution. This treatment will be repeated after 12 and 24 months.
3110579|NCT02360215|Experimental|WBRT + Memantine|Whole brain radiation therapy (WBRT) and memantine
3110580|NCT02360215|Experimental|HA-WBRT/IMRT+ Memantine|Whole brain radiation therapy with hippocampal avoidance (HA-WBRT) using intensity modulated radiation therapy (IMRT) and memantine
3110581|NCT02360228|Experimental|tACS (alpha)|20 participants: 10Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily
3110582|NCT02360228|Experimental|tDCS|20 participants: 2mA stimulation for 20 minutes twice daily
3110583|NCT02360228|Sham Comparator|Sham stimulation|20 participants: Will include 10 seconds of ramp in to 1 minutes of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily.
3110584|NCT02360280|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
3110585|NCT02360280|Active Comparator|Single ketamine infusion preceded by 5 midazolam infusions|Single infusion of 0.5 mg/Kg of ketamine hydrochloride solution preceded by midazolam 0.045 mg/kg over 2 weeks.
3110586|NCT02360293|Experimental|Stay Strong w/coaching|participants in the Stay Strong w/coaching (Experimental) arm are provided a wearable device, scale, telephone coaching, tailored push notifications, personalized goals, and enhanced online/app support.
3110587|NCT02360293|Active Comparator|Stay Strong|participants in the Stay Strong (active comparison) arm will only be provided a wearable device with standard online/app support.
3110588|NCT02360319|Active Comparator|Clinician's Choice|Prescribers are not limited in the choice of treatment they can administer to their clients to alleviate the symptoms of schizophrenia. Any FDA approved antipsychotic agent can be used. Clients in the study wil be followed for 2 years
3110589|NCT02360319|Experimental|Aripiprazole Once Monthly|Aripiprazole long acting injectable formulation, 400mg per dose is to be administered once monthly. Clients in the study will be followed for 2 years
3110590|NCT02360371|Placebo Comparator|Placebo (oral)|Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.
3110591|NCT02360371|Experimental|Hydromorphone (oral) 2mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
3110592|NCT02360371|Experimental|Hydromorphone (oral) 4mg|Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.
3110593|NCT02360371|Experimental|Hydromorphone (oral) 8mg|Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.
3110594|NCT02360397|Experimental|Ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
3110595|NCT02360475|Experimental|RSV vaccine formulation 1 Group|Subjects in this group will receive a single dose of formulation 1 of the RSV vaccine
3110596|NCT02360475|Experimental|RSV vaccine formulation 2 Group|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
3110597|NCT02360475|Experimental|RSV vaccine formulation 3 Group|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
3110598|NCT02360475|Active Comparator|Boostrix Group|Subjects in this group will receive a single dose of Boostrix
3110599|NCT02360488|Experimental|Telerehabilitation Therapy|The Telerehabilitation arm of this study will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During half of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
3110600|NCT02360488|Active Comparator|In-Clinic Therapy|The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
3110601|NCT02360605|Active Comparator|automated telephone reminder arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions. Patients will receive reminders to complete their FIT screening kits by an automated call.
3110602|NCT02360605|Active Comparator|prevention coordinator arm|Patients will receive Health literacy appropriate education and demonstration of FIT kits with simplified instructions.Patients will receive reminders to complete their FIT screening kits by a prevention coordinator.
3110603|NCT02360631|Experimental|Chantix (varenicline)|Participants will receive 1mg pills to take twice a day for 12 weeks.
3110604|NCT02360631|Placebo Comparator|Placebo|Participants will receive a placebo pill to take twice a day for 12 weeks.
3110605|NCT02360774|Experimental|Canagliflozin|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
3110606|NCT02360774|Placebo Comparator|Placebo|Subjects will be randomized (1:1) to treatment with canagliflozin 300mg or placebo once daily for 18 weeks.
3110607|NCT02360995|Active Comparator|Total Toothpaste|Triclosan/fluoride toothpaste
3110608|NCT02360995|Active Comparator|Toothpaste + Mouthwash|Stannous fluoride toothpaste & cetylpyridinium chloride Mouthwash
3110609|NCT02360995|Placebo Comparator|Control group|fluoride toothpaste +fluoride mouthwash
3110610|NCT02361216|Experimental|Ingenol mebutate gel|Treatment once daily for 3 days
3110611|NCT02361216|Placebo Comparator|Vehicle|Treatment once daily for 3 days
3110612|NCT02361307|Placebo Comparator|conventional ADL training|The control group receive the conventional ADL training programme
3110613|NCT02361307|Active Comparator|seamless ADL training|The experimental group receive the seamless ADL training programme which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training.
3110614|NCT02361476|Experimental|Intervention|Clonidine : injection og 3 micg/kg IV during the operation.
3110615|NCT02361476|Placebo Comparator|Placebo|Placebo : injection og equal amount of NaCl IV during the operation.
3110616|NCT02361736|Sham Comparator|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
3110617|NCT02361736|Experimental|Hydroxyethyl Starch|6% Hydroxyethyl Starch (HES) is intravenously administrated at a dose of 7.5ml/ kg in the first hour of surgery, and then, Lactate Ringers' is administrated to the patient until the end of the surgery
3110618|NCT02361762|Experimental|Training|Computerized executive control training
3110619|NCT02361762|No Intervention|Waitlist|The waitlist group will not initially receive the training program. At the end of the study, the waitlist group will be offered training if it is efficacious.
3110620|NCT02362048|Experimental|Experimental: Arm 1|ACP-196 alone
3110621|NCT02362048|Experimental|Experimental: Arm 2|ACP-196 in combination with pembrolizumab
3110622|NCT02362191|Experimental|Single Session tACS Across Menstrual Cycle|Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.
3110623|NCT02362269|Active Comparator|Control Group|The control group will receive 2500 IU of vitamin D3 daily.
3110624|NCT02362269|Experimental|Dosing Algorithm Group|The dosing algorithm group will initially receive 1000, 2500, or 4000 IU of vitamin D3 daily based on the baseline 25(OH)D. This group's dosing may be adjusted at the 3-month visit.
3110625|NCT02362282|Active Comparator|Gait plus cognitive training|Rehabilitation of walking/gait, combined with rehabilitation of cognitive function
3110626|NCT02362282|Active Comparator|Gait plus arm training|Rehabilitation of walking/gait, combined with rehabilitation of arm function
3110627|NCT02362321|Experimental|Dexamethasone|Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
3110628|NCT02362321|Placebo Comparator|Control|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
3110629|NCT02362360|Experimental|Coloplast Test Product then Comparator|The subject first tests the Coloplast Test Product and then tests the Comparator
3110630|NCT02362360|Experimental|Comparator then Coloplast Test Product|The subject first tests the Comparator and then tests the Coloplast Test Product.
3110631|NCT02362373|Other|levonorgestrel IUS|all women in the study underwent placement of the levonorgestrel IUS in an open-label fashion, outcomes were compared before and after placement.
3110632|NCT02362412|Experimental|FK949E 50 MG / FK949E 150 MG|Participants who received the 50 mg tablet once daily during Treatment Period II (8 weeks) and 150 mg tablet once daily during Treatment Period III (8 weeks).
3110633|NCT02362412|Experimental|FK949E 150 MG / FK949E 50 MG|Participants who received the 150 mg tablet once daily during Treatment Period II (8 weeks) and 50 mg tablet once daily during Treatment Period III (8 weeks).
3110634|NCT02362425|Active Comparator|RYR1-RM Patients Administered N-acetylcysteine|N-acetylcysteine
3110635|NCT02362425|Placebo Comparator|RYR1-RM Patients Administered Placebo|Placebo
3110636|NCT02362425|No Intervention|Healthy Volunteers|Healthy volunteers who had physical exam, study biomarker, Near Infrared Spectroscopy (NIRS) testing and muscle ultrasound only, in one visit.
3110637|NCT02362503|Experimental|A1: BMS-663068|Phase 1: BMS-663068 600 mg tablets orally twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3110638|NCT02362503|Active Comparator|B1: Placebo + BMS-663068|Phase 1: Placebo twice daily for 8 days. Phase 2: BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3110639|NCT02362503|Experimental|BMS-663068|BMS-663068 600 mg tablets orally twice daily for 48 weeks or longer.
3110640|NCT02362594|Experimental|Pembrolizumab|In Part 1, participants receive pembrolizumab 200 mg intravenously (IV) as post-surgery therapy every 3 weeks (Q3W) for up to 1 year. During Part 2, participants with documented recurrence may receive optional re-treatment with pembrolizumab Q3W for up to 2 years or disease progression.
3110641|NCT02362594|Placebo Comparator|Placebo|In Part 1, participants receive placebo IV as post-surgery therapy Q3W. During Part 2, participants with documented recurrence who received placebo in Part 1 may receive optional treatment with pembrolizumab Q3W for up to 2 years or disease progression.
3110642|NCT02362646|Experimental|MPC Intramyocardial Injection|Intramyocardial injections of 150 million MPCs
3110643|NCT02362646|Sham Comparator|Control Solution|Intramyocardial injections of 50% Alpha-MEM/42.5% ProFreeze NAO Freezing Medium/7.5% DMSO
3110644|NCT02362672|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
3110645|NCT02362672|Placebo Comparator|Placebo|Placebo to match NKTR-181 twice daily (BID) tablets
3110646|NCT02362724|Experimental|Sapphire|Subjects randomized to the experimental contact lens over the study duration
3110647|NCT02362724|Active Comparator|Pearl|Subjects randomized to the active comparator contact lens over the study duration
3110648|NCT02362789|Experimental|Secukinumab|300 mg secukinumab (administered as two injections of 150 mg each) at Weeks 16, 20, 24, and 28
3110649|NCT02362789|Placebo Comparator|Placebo|Inactive ingredients administered as a matching placebo at Weeks 16, 20, 24, and 28
3110650|NCT02363010|Active Comparator|Standard Behavior Therapy for Weight Loss|Eighteen months of standard, group-based behavioral treatment for weight loss and weight loss maintenance.
3110651|NCT02363010|Experimental|Behavior Therapy for Weight Loss with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of standard, group-based behavioral treatment for weight loss and weight loss maintenance with a larger emphasis on physical activity goals.
3110652|NCT02363010|Experimental|Acceptance-based Behavior Therapy with PA emphasis|Six months of standard, group-based behavioral treatment for weight loss and weight loss maintenance, followed by 12 months of group-based behavior therapy with acceptance-based strategies, and a larger emphasis on physical activity goals.
3110653|NCT02363270|Active Comparator|IV Push Group|Ketamine medication given via IV Push. IV Push is the intervention.
3110654|NCT02363270|Active Comparator|IV Drip Group|Ketamine medication given via IV Drip. IV Drip is the intervention.
3110655|NCT02363283|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes every 3 weeks in the absence of disease progression or unacceptable toxicity.
3110656|NCT02363322|Active Comparator|A/Current Standard of Care Alone|A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
3110657|NCT02363322|Experimental|B/Current Standard of Care Plus ZMapp|"B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.~ZMapp 50mg/kg IV administered every third day for 3 infusions."
3110658|NCT02363439|Experimental|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg 2xwk|Subcutaneous injection of IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly per Protocol 8400-401
3110659|NCT02363478|Experimental|buspirone|4-weeks buspirone administration (20mg) in patients with SSc and esophageal involvement
3110660|NCT02363621|Active Comparator|Ranibizumab 0.3 Intravitreal injection|Intravitreal injection of Ranibizumab 0.3 mg once
3110661|NCT02363621|Active Comparator|Aflibercept 2.0 mg intravitreal injection|Intravitreal Aflibercept 2.0 mg once
3110662|NCT02363686|Other|FEES & Bedside Swallow Evaluation (BSE)|Subjects will receive a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), followed by a speech language pathologist (SLP) performing a bedside swallowing evaluation (BSE).
3110663|NCT02363738|Experimental|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation
3110664|NCT02363738|Placebo Comparator|Saline (Placebo)|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency.
3110665|NCT02363803|Placebo Comparator|Normal saline infusion then lidocaine infusion|Intravenous infusion of normal saline over a 40 minute period. second intervention: Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period.
3110666|NCT02363803|Active Comparator|Lidocaine infusion, then normal saline infusion|Intravenous infusion of lidocaine [5mg/kg] over a 40 minute period. second intervention: Intravenous infusion of normal saline over a 40 minute period.
3110667|NCT02363933|Experimental|Perampanel + Current Anti-Epileptic Drug|Primary glioma patients will receive perampanel along with their current AED for a total of 20 weeks. Perampanel will be titrated from 2 mg in weeks 1 and 2 and up to 8 mg daily by week 5 if well tolerated by the patient. They will then receive a maintenance dose of 8 mg per day through 16 weeks. After 16 weeks, subjects will be tapered off perampanel over a 4 week period.
3110668|NCT02363946|Experimental|Part A: 0.38 mg/kg|Single dose administration of ARC-AAT intravenous (IV) injection, 0.38 mg/kg in healthy volunteers
3110669|NCT02363946|Experimental|Part A: 1.0 mg/kg|Single dose administration of ARC-AAT IV injection, 1.0 mg/kg in healthy volunteers
3110670|NCT02363946|Experimental|Part A: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in healthy volunteers
3110671|NCT02363946|Experimental|Part A: 3.0 mg/kg|Single dose administration of ARC-AAT IV injection, 3.0 mg/kg in healthy volunteers
3110672|NCT02363946|Experimental|Part A: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in healthy volunteers
3110673|NCT02363946|Experimental|Part A: 5.0 mg/kg|Single dose administration of ARC-AAT IV injection, 5.0 mg/kg in healthy volunteers
3110674|NCT02363946|Experimental|Part A: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in healthy volunteers
3110675|NCT02363946|Experimental|Part A: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in healthy volunteers
3110676|NCT02363946|Experimental|Part A: 8.0 mg/kg|Single dose administration of ARC-AAT IV injection, 8.0 mg/kg in healthy volunteers
3110677|NCT02363946|Placebo Comparator|Part A: Placebo|Single dose administration of 0.9% normal saline IV injection in healthy volunteers
3110678|NCT02363946|Experimental|Part B: 2.0 mg/kg|Single dose administration of ARC-AAT IV injection, 2.0 mg/kg in participants with AATD
3110679|NCT02363946|Experimental|Part B: 4.0 mg/kg|Single dose administration of ARC-AAT IV injection, 4.0 mg/kg in participants with AATD
3110680|NCT02363946|Experimental|Part B: 6.0 mg/kg|Single dose administration of ARC-AAT IV injection, 6.0 mg/kg in participants with AATD
3110681|NCT02363946|Experimental|Part B: 7.0 mg/kg|Single dose administration of ARC-AAT IV injection, 7.0 mg/kg in participants with AATD
3110682|NCT02363946|Placebo Comparator|Part B: Placebo|Single dose administration of 0.9% normal saline IV injection in participants with AATD
3132664|NCT03443063|Experimental|Group 2: Normal Renal Function|Participants with normal renal function (eGFR ≥90 mL/min/1.73 m^2) demographically matched to participants in Group 1 will receive a single dose of 10 mg lemborexant (oral tablet) in the morning after an overnight fast.
3132665|NCT03443414|Experimental|0.75 mg RPL554|
3110683|NCT02363959|Experimental|Hyperbaric Oxygen, Airway Biopsy|"The hyperbaric oxygen therapy (HBOT) will be performed with the standard HBOT protocol used at Duke for the treatment of compromised grafts and flaps. This is 2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at atmospheric pressure of 2 (2 ATA) once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.~During standard bronchoscopies, an endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure."
3110684|NCT02363959|Other|No Hyperbaric Oxygen, Airway Biopsy|No hyperbaric oxygen therapy administered, but lung biopsy still completed during standard post-lung transplant bronchoscopies. An endobronchial biopsy of the airway epithelium will be performed. Biopsy will add roughly 3 minutes total to each procedure.
3110685|NCT02363972|Experimental|Ellipsys Vascular Access Catheter|ESRD patients who require and qualify for creation of a surgical AV fistula will be offered the opportunity to participate in this study for a less invasive way of creating an AV fistula.
3110686|NCT02363998|Other|Open Label Lofexidine|During this open-label study, subjects will be given the option to receive lofexidine tablets for 7 days and up to 14 days if requested.
3110687|NCT02364037|Other|Phase 1: Enhanced Care|Women in Phase 1 of the prospective study will receive the CHOICE Project structured contraceptive counseling in addition to usual care by their health care provider. Contraceptive coverage will be by the usual mechanism such as insurance or financial assistance programs.
3110688|NCT02364037|Other|Phase 2: Complete CHOICE|Women in Phase 2 of the prospective study (Complete CHOICE) will receive the CHOICE Project structured contraceptive counseling. Immediately prior to the start of Phase 2, health care providers in participating health centers will undergo a contraceptive education session with a focus on evidence-based guideline for LARC provision and same-day insertion. Participating women will receive cost support for IUDs and implants if she chooses either as her contraceptive method and does not have appropriate insurance coverage.
3110689|NCT02364076|Experimental|Pembrolizumab and Epacadostat|Pembrolizumab 200 mg intravenously every 3 weeks Epacadostat 100mg by mouth taken daily
3110690|NCT02364180|Other|Electromyography|Subjects taking pyridostigmine bromide for more than 6 weeks for a condition other than myasthenia gravis were observed with Electromyography (EMG)
3110691|NCT02364271||Not low risk for MACE in 30 days|"Patients with not low risk of major adverse cardiac events within 30 days Patients with TIMI>0 or mHEART>2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
3110692|NCT02364271||Low risk for MACE in 30 days|"Patients with low risk of major adverse cardiac events within 30 days~Patients with TIMI=0 and mHEART<=2~Routine blood test for hs-cTnT and Thrombolysis in myocardial infarction (TIMI) score were performed on study patients~Protocol amendment:~In October 2014, mHEART score of the study patients was determined retrospectively"
3110693|NCT02364336|Experimental|HBeAg positive|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg and HBeAg positivity
3110694|NCT02364336|Experimental|HBeAg negative|Patients who have been treated with one or more nucleos(t)ides for at least 192 weeks who have known serum HBsAg positivity and HBeAg negativity
3110695|NCT02364388|Active Comparator|Imagio IUS gray-scale ultrasound|Imagio gray-scale ultrasound
3110696|NCT02364388|Other|Imagio OA/US|Imagio OA/US (opto-acoustic+gray-scale ultrasound)
3110697|NCT02364570|Active Comparator|Oral Glucose Tolerance Test|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (100 g). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3110698|NCT02364570|Experimental|Glucose with Whole Eggs|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 1.5 whole eggs (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3110699|NCT02364570|Experimental|Glucose with Egg Whites|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 7 egg whites (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3110700|NCT02364570|Experimental|Glucose with Egg Yolks|We will perform fasting measurements of flow-mediated dilation (FMD) using ultrasound, and draw a blood sample, prior to administration of the test meal. Following these baseline measurements, participants will ingest glucose (75 g) with 2 egg yolks (cooked). FMD will be performed intermittently post-ingestion at 30, 60, 90, 120, 150, and 180 minutes. Blood samples will be collected at 0 min (immediately prior to eating) and at 30, 60, 90, 120, 150, and 180 minutes following the ingestion of the meal. After each blood sample is obtained, the catheter will be flushed with saline in order to prevent the formation of clots and to minimize the likelihood of having to insert a needle again. Subjects will remain supine in a comfortable position for the entire duration of the test.
3110701|NCT02364700|Experimental|interventional group|This is a single group, interventional pilot study. All participants will receive 6-week hand training on the HOH device.
3110702|NCT02364778||Provisional stenting strategy|Patients with stable coronary artery disease with angiographic main vessel lesion not involving side branch (SB) in whom provisional stenting strategy is planned.
3110703|NCT02364947|Experimental|Nalmefene hydrochloride 10 mg|
3110704|NCT02364947|Experimental|Nalmefene hydrochloride 20 mg|
3110705|NCT02364947|Placebo Comparator|Placebo|
3110706|NCT02364999|Experimental|Bevacizumab-Pfizer|Bevacizumab-Pfizer plus paclitaxel and carboplatin
3110707|NCT02364999|Active Comparator|Bevacizumab-EU|Bevacizumab-EU plus paclitaxel and carboplatin
3110708|NCT02365064|Active Comparator|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.
3110709|NCT02365064|Experimental|Adaptive Servo-Ventilation|Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.
3110710|NCT02365285|Experimental|Galantamine 16 mg then placebo|Galantamine 16 mg po one time dose then placebo on 2nd visit
3110711|NCT02365285|Placebo Comparator|Placebo then Galantamine 16 mg|Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit
3110712|NCT02365298|Experimental|etafilcon A|Worn in a daily disposable modality
3110713|NCT02365298|Active Comparator|nelfilcon A|Worn in a daily disposable modality
3110714|NCT02365480|Experimental|Arm I (berberine chloride)|Patients receive berberine chloride PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
3110715|NCT02365480|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO TID for 90 days in the absence of disease progression or unacceptable toxicity.
3110716|NCT02365506|Experimental|Eleclazine 24 mg + Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1 and 4, eleclazine 24 mg on Day 2 and eleclazine 48 mg on Day 3.
3110717|NCT02365506|Experimental|Eleclazine 48 mg + Placebo|Participants will receive placebo to match eleclazine on Days 1, 2 and 4, and eleclazine 48 mg on Day 3.
3110718|NCT02365506|Placebo Comparator|Placebo|Participants will receive placebo to match eleclazine on Days 1 to 4.
3110719|NCT02365519|Experimental|LME636|LME636 ophthalmic solution, 1 drop (approx. 40 µL; 2.4 mg) administered topically in each eye 3 times a day (TID) for 6 weeks
3110720|NCT02365519|Placebo Comparator|Vehicle|LME636 Vehicle, 1 drop administered topically in each eye TID for 6 weeks
3110721|NCT02365558|Experimental|Evacetrapib|Single oral dose of evacetrapib administered alone on Day 1 of Period 1.
3110722|NCT02365558|Experimental|Omeprazole + Evacetrapib|"In Period 2, participants will receive 40 mg oral dose of Omeprazole once daily (QD) on Days 8 through 20.~Evacetrapib will be co-administered once, orally on Day 14."
3110723|NCT02365584|Experimental|Standard care and Lanreotide Autogel|Standard care according to site clinical practice and Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
3110724|NCT02365584|No Intervention|Standard care|Standard care according to site clinical practice.
3110725|NCT02365636|Experimental|TV-45070 4%|TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
3110726|NCT02365636|Experimental|TV-45070 8%|TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
3110727|NCT02365636|Placebo Comparator|Placebo|Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.
3110728|NCT02365714|Other|Treatment-Radiation|CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
3110729|NCT02365870|Active Comparator|rotigotine|rotigotine transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
3110730|NCT02365870|Placebo Comparator|placebo|placebo transdermal patch 2mg to 6mg daily per 24 hour patch for 8 weeks
3110731|NCT02365961|Experimental|FI Block|Fascia iliaca block consisting of up to 60 mL of 0.35% ropivicaine at a dose of 3 mg/kg (with adjuvants of 100 mcg clonidine [per 60 mL] and epinephrine 1:400,000)
3110732|NCT02365961|Active Comparator|Local Injection|Local anesthetic in the hip joint consisting of 30cc of 0.5% Noropin
3110733|NCT02366091|Experimental|Methotrexate|Methotrexate 15 mg weekly by mouth and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
3110734|NCT02366091|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth and placebo for methotrexate 1 tablet weekly by mouth and folate 1 mg by mouth daily
3110735|NCT02366091|Experimental|Methotrexate & Colchicine|Methotrexate 15 mg by mouth weekly and colchicine 0.6 mg by mouth daily and folate 1 mg by mouth daily
3110736|NCT02366091|Experimental|Placebo|Placebo for methotrexate 1 tablet by mouth weekly and placebo for colchicine 1 tablet by mouth daily and folate 1 mg by mouth daily
3110737|NCT02366130|Experimental|Ra-223 dichloride + Denosumab|"Ra-223 dichloride 55 kBq/kg administered as a bolus intravenous (IV) injection (over 1 minute) through a secure in-dwelling catheter on day 1 of the study and then every four weeks thereafter for 6 cycles.~Denosumab 120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.~A single hormonal agent (ie, Tamoxifen or Aromatase Inhibitor or Fulvestrant) administered daily while on study. Physician to decide what type of hormone therapy participant will receive."
3110738|NCT02366143|Experimental|Arm A (Atezolizumab+Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
3132666|NCT03443414|Experimental|1.5 mg RPL554|
3132667|NCT03443414|Experimental|3 mg RPL554|
3132668|NCT03443414|Experimental|6 mg RPL554|
3132669|NCT03443414|Placebo Comparator|Placebo|
3110739|NCT02366143|Experimental|Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)|Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.
3110740|NCT02366143|Active Comparator|Arm C (Bevacizumab+Paclitaxel+Carboplatin)|Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.
3110741|NCT02366195|Experimental|Talimogene Laherparepvec|Talimogene laherparepvec was administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 21 days after the initial dose and every 14 days thereafter. Participants were treated with talimogene laherparepvec until they achieved a complete response, all injectable tumors had disappeared, clinically significant (resulting in clinical deterioration or requiring change of therapy) disease progression beyond 6 months of treatment, per modified World Health Organization (WHO) response criteria, or intolerance of study treatment, whichever occurred first.
3110742|NCT02366312|Experimental|vismodegib|The 150-mg vismodegib drug product is a hard gelatin capsule formulation for oral administration. This study involves one year of treatment with Erivedge (150 mg/day) plus two years of follow-up.
3110743|NCT02366403|Experimental|SKY|a standardized meditation program
3110744|NCT02366403|Active Comparator|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
3110745|NCT02366468|Experimental|Discretion of the investigator (DI)|ranibizumab 0.5 mg, after initial monthly treatment until maximum BCVA and no signs or no further change of disease activity, the investigator treated patients at their own discretion. There were no strict recommendations for retreatment or scheduling of upcoming visits.
3110746|NCT02366468|Active Comparator|Pro re nata (PRN)|ranibizumab 0.5 mg, after initial monthly therapy until maximum BCVA and no signs or no further improvement of disease activity, patients were monitored every month and retreated if any signs of disease activity occurred
3110747|NCT02366611|Experimental|Transcranial Direct Current Stimulation (tDCS)|tDCS is a method of non-invasive brain stimulation that is based on the application of a weak direct current to the head that flows between two relatively large electrodes-anode and cathode. tDCS offers a unique analgesic modality of central pain neuromodulation by altering the activity of key sensory and motor cortical structures. Participants in this arm will undergo 20 tDCS sessions, tDCS in clinic and remotely supervised tDCS, and 2mA of transcranial direct current stimulation will be applied for 20 minutes.
3110748|NCT02366611|No Intervention|Chemoradiotherapy Standard of Care|The control group will consist of patients receiving the Standard of care and no neuromodulation.
3110749|NCT02366637|Placebo Comparator|Placebo|Double blind placebo for PF-03715455
3110750|NCT02366637|Experimental|PF-03715455|
3110751|NCT02366663|Experimental|Arm I (ZBEAM)|Patients receive rituximab IV on days -21 and -14, and 90-yttrium ibritumomab tiuxetan IV on day -14. Patients also receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
3110752|NCT02366663|Active Comparator|Arm II (BEAM)|Patients receive BEAM comprising carmustine IV over 4 hours on day -6; cytarabine IV over 2 hours BID on days -5 to -2; etoposide IV over 1 hour BID or QD on days -5 to -2; and melphalan IV on day -1. Patients then undergo autologous hematopoietic stem cell transplant on day 0.
3110753|NCT02366689|Active Comparator|Toothpaste|Triclosan/fluoride toothpaste
3110754|NCT02366689|Active Comparator|Toothpaste + mouthwash|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash
3110755|NCT02366689|Placebo Comparator|Fluoride only Toothpaste + mouthwash|Fluoride only toothpaste + Fluoride only Mouthwash
3110756|NCT02366767|Experimental|automatic closed-loop insulin delivery|The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
3110757|NCT02366767|Active Comparator|Control|The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
3110758|NCT02366845|Active Comparator|Clinician Chosen Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. The total dose will be determined by the physician's judgment which is the current standard of care. The physician chosen dose will be utilized but physician will be unaware of which dosing strategy has been utilized.~INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component, crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
3110759|NCT02366845|Experimental|Algorithm Dosing|"Admitted University of Colorado Hospital or Denver Health bleeding patients with chronic liver disease determined to receive fresh frozen plasma (FFP) for clinical indications as determined by hospital clinician. This group will receive plasma doses based on the study dosing algorithm table.~A pre-transfusion INR (before transfusion) and a target post-transfusion INR (after transfusion) will be used to determine dose of FFP. The study table will reveal the dose in (ml/kg) of FFP to be transfused. INR measurements will be performed before (pre) and after (post) transfusion of plasma has been administered. Primary and secondary outcome measures will be collected. No other transfused blood component,crystalloid or colloidal fluid will be infused between the first and second INR studies except plasma."
3110760|NCT02366871|Experimental|Oral apixaban|Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
3110761|NCT02366871|Active Comparator|Subcutaneous enoxaparin|Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
3110762|NCT02366910|Experimental|omafilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3110763|NCT02366910|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3110764|NCT02366923|Experimental|stenfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3110765|NCT02366923|Active Comparator|delefilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye (contra lateral design).
3110766|NCT02366936|Experimental|Use of Tortle midliner|This study will be an interventional, longitudinal study of 30 preterm infants using the Tortle Midliner.
3110767|NCT02367014|Experimental|Low Dose|elamipretide 0.01 mg/kg/hr infused for 2 hours for 5 days
3110768|NCT02367014|Experimental|Intermediate dose|elamipretide 0.10 mg/kg/hr infused for 2 hours for 5 days
3110769|NCT02367014|Experimental|High dose|elamipretide 0.25 mg/kg/hr infused for 2 hours for 5 days
3110770|NCT02367014|Placebo Comparator|Placebo|In each cohort, subjects received either IV elamipretide given once daily for 2 hours for 5 days or matching placebo.
3110771|NCT02367066|Experimental|AR-C165395XX + placebo|1st period AR-C165395XX 2nd period placebo
3110772|NCT02367066|Placebo Comparator|Placebo + AR-C165395XX|1st period Placebo for AR-C165395XX 2nd period AR-C165395XX
3110773|NCT02367105|Active Comparator|Testosterone plus Lifestyle Therapy|Testosterone replacement in combination with behavioral diet to induce ~10% weight loss + supervised aerobic and exercise training
3110774|NCT02367105|Placebo Comparator|Placebo plus Lifestyle Therapy|Placebo in combination with behavioral diet to induce ~10% weight loss and supervised aerobic and exercise training
3110775|NCT02367131||Jardiance|
3110776|NCT02367352|Experimental|Cohort 1 (Dose Escalation Phase)|Alisertib 15 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in a 28-day cycle until disease progression or unacceptable toxicity (Up to 22 Cycles).
3110777|NCT02367352|Experimental|Cohort 2 (Dose Escalation Phase)|Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
3110778|NCT02367352|Experimental|Dose Expansion Cohort|Alisertib, MTD/RP2D determined in Dose Escalation Phase, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m^2, IV on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity.
3110779|NCT02367391|Experimental|Motivational Text Messages|
3110780|NCT02367391|Sham Comparator|Control|
3110781|NCT02367430|Experimental|Critical Time Intervention for Hoarding Disorder|Patients with Hoarding Disorder received CTI Model
3110782|NCT02367456|Experimental|Arm A|MDS patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
3110783|NCT02367456|Experimental|Arm B|AML patients: PF-04449913 (Glasdegib) 100 mg + Azacitidine 75 mg/m2
3110784|NCT02367521|Experimental|LFR rTMS|Investigators propose to deliver 1200 pulses daily at 110% Motor threshold for 4 weeks using four trains of 300 pulses daily separated by an intertrain interval of 60 seconds.
3110785|NCT02367521|Placebo Comparator|Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
3110786|NCT02367599|Active Comparator|Vitamin D Supplement + PrEP|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks in addition to their PrEP provided through the main study.
3110787|NCT02367599|No Intervention|PrEP Only|Subjects not enrolled into this sub-study will continue receiving PrEP through the main study. Subjects taking unsupplemented PrEP may still be used as matched controls to sub-study subjects.
3110788|NCT02367729|Experimental|Neurostimulator|Auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
3110789|NCT02367729|Sham Comparator|Sham Neurostimulator|Inactive auricular neurostimulator treatment x 5 days each week for 4 consecutive weeks
3110790|NCT02367781|Experimental|Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)|Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.
3110791|NCT02367781|Active Comparator|Arm B (Nab-Paclitaxel+Carboplatin)|Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.
3110792|NCT02367794|Experimental|Arm A: Atezolizumab + Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab, paclitaxel, and carboplatin will be administered on Day 1 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
3132670|NCT03443427|Experimental|Schedule 0-2-6 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 181 (Month 6) and one dose of placebo at Day 361 (Month 12).
3110793|NCT02367794|Experimental|Arm B: Atezolizumab + Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; atezolizumab and carboplatin will be administered on Day 1 of each 21-day cycle. Nab-Paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: atezolizumab, then nab-paclitaxel, then carboplatin. Participants who experience no further clinical benefit at any time during the induction phase will discontinue all study treatments. In the absence of the above criteria, after the 4- or 6-cycle induction phase, participants will begin maintenance therapy with atezolizumab. Atezolizumab will be continued as long as there is a clinical benefit to the participant.
3110794|NCT02367794|Active Comparator|Arm C: Nab-Paclitaxel + Carboplatin|The induction phase of the study will consist of four or six cycles; carboplatin will be administered on Day 1 of each 21-day cycle, nab-paclitaxel will be administered on Days 1, 8, and 15 of each 21-day cycle. The Day 1 order of drug administration is as follows: nab-paclitaxel, then carboplatin. Participants who experience disease progression at any time during the induction phase will discontinue all study treatment. In the maintenance phase, participants will receive best supportive care.
3110795|NCT02367820|Experimental|NKTR-181|NKTR-181 twice daily (BID) tablets
3110796|NCT02367833|Experimental|Combined Oral Contraceptives (COC)|Apri (or generic equivalent - Reclipsen) (30µg/d EE, 150 µg/d desogestrel) is a monophasic dosing regimen of 21 active and 7 placebo pills. On Day 1 of the Intervention, participants in the COC group will begin taking the COC pill. Each participant in this group will ingest active pills from the first pack each day for the first 21 days. Pills ingested on days 22 through 28 are placebo pills. A second pill pack will begin on day 29 and pills with active ingredients will be ingested from the second pack each day for days 29-49. On day 50, the participants will immediately begin a 3rd pill pack, if the post-study testing is still occurring, and will ingest a pill with active ingredients from the third pack for days 50-56 (or for as long as the post-study testing is occurring).
3110797|NCT02367833|Experimental|Transdermal Contraceptive (TDC)|Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock. The patch will be changed once weekly on the same day each week for weeks 1-3 (days 1-21, removed on day 22) and weeks 5-8 (days 29-56). Week 4 (days 22-28) will be a patch-free week. As soon as the post-study testing is complete, subjects will remove the patch.
3110798|NCT02367833|Experimental|Contraceptive Vaginal Ring (CVR)|Participants in the CVR group (NuvaRing - 15µg/d EE/120µg/d etonogestrel) will insert a vaginal ring into the vagina on Day 1 of the intervention. The vaginal ring will be removed and discarded after 3 weeks of continuous use (days 1-21 of continuous use and removed on day 22). There will be one week (days 22-28) that will be ring-free. A new ring will be inserted for days 29-49. On day 50, the second ring will be removed, and a third ring will be immediately inserted into the vagina (if the post-study testing is still occurring). The third ring will remain in the vagina for the last week of the post-study period (days 50-56). As soon as the post-study testing is complete, subjects will remove the ring.
3110799|NCT02367833|No Intervention|Control Group|The Control group will complete all procedures with the exception of contraceptive therapy.
3110800|NCT02367859|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID every 12 hours plus trametinib daily PO for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients whose disease is judged to be not amenable to resection will continue dabrafenib and trametinib indefinitely as long as there has not been tumor progression.
3110801|NCT02367872|Active Comparator|Participants with normal renal function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 milligram (mg)
3110802|NCT02367872|Experimental|Participants with mild renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110803|NCT02367872|Experimental|Participants with moderate renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110804|NCT02367872|Experimental|Participants with severe renal impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110805|NCT02367872|Experimental|Hemodialysis participants: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110806|NCT02367872|Active Comparator|Participants with normal hepatic function: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110807|NCT02367872|Experimental|Participants with mild hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110808|NCT02367872|Experimental|Participants with moderate hepatic impairment: TAK-272 40 mg|Fasted single oral administration of TAK-272 40 mg
3110809|NCT02367885|Experimental|TAK-850 0.5 mL injection (13-19 years of age)|Single intramuscular injection of TAK-850 0.5 mL in participants aged 13-19 years
3110810|NCT02367885|Experimental|TAK-850 0.5 mL injection (3-12 years of age)|Two intramuscular injections of TAK-850 0.5 mL in participants aged 3-12 years old.
3110811|NCT02367885|Experimental|TAK-850 0.25 mL injection (6-35 months of age)|Two intramuscular injections of TAK-850 0.25 mL in participants aged 6-35 months old.
3110812|NCT02367911|Experimental|Active Arm|122-0551 Foam, topically applied twice daily for two weeks
3110813|NCT02367911|Placebo Comparator|Vehicle Arm|Vehicle Foam, topically applied twice daily for two weeks
3110814|NCT02368093|Experimental|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide; Detosiv Slow Release® (60mg per tablet, Lotus Pharmaceutical Company, Taipei, Taiwan), 120mg per day with once daily dose taken after breakfast]
3110815|NCT02368093|Placebo Comparator|Placebo|placebo pills with the same appearance as Detosiv tablets.
3110816|NCT02368210|Experimental|122-0551 Foam|122-0511 Foam, topically applied twice daily
3110817|NCT02368210|Placebo Comparator|Vehicle Foam|Vehicle Foam, topically applied twice daily
3110818|NCT02368314|Experimental|BCD-080|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of BCD-080 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery.
3110819|NCT02368314|Active Comparator|Clexane|Sodium enoxaparine 40 mg (4 000 anti-Xa IU / 0,4 ml) at pre-filled syringe. Administration of Clexane 30 mg (0,3 ml) every 12 hours during 14 days after surgery for preventing venous thromboembolic complications after surgery/
3132671|NCT03443427|Experimental|Schedule 0-2-12 Group|Subjects between, and including, 40 and 80 years of age at the time of the first vaccination, receiving three doses of the GSK3277511A investigational vaccine at Day 1 (Month 0), Day 61 (Month 2) and Day 361 (Month 12) and one dose of placebo at Day 181 (Month 6).
3110820|NCT02368431|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
3110821|NCT02368431|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
3110822|NCT02368457|Experimental|Pentoxifylline and Tocopherol|Drug: pentoxifylline with tocopherol Combination of pentoxifylline and tocopherol during a minimum of 6 months and a maximum of 24 months.
3110823|NCT02368457|No Intervention|CONTROL|No drug treatment
3110824|NCT02368691|Experimental|GTx-024|GTx-024 capsules, 18 mg PO once-daily for up to 12 months
3110825|NCT02368886|Experimental|Arm A1 (lower-dose regorafenib, pre-emptive clobetasol)|Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib.
3110826|NCT02368886|Experimental|Arm A2 (lower-dose regorafenib, reactive clobetasol)|Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
3110827|NCT02368886|Experimental|Arm B1 (standard dose regorafenib, pre-emptive clobetasol)|Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
3110828|NCT02368886|Experimental|Arm B2 (standard dose regorafenib, reactive clobetasol)|Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
3110829|NCT02369068|Experimental|Onabotulinumtoxin A|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 200u of onabotulinumtoxin A and saline injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~An injection of 30 cc of ropivicaine (5cc/6 sites) will be used, followed by a mixture of 200 u of Onabotulinumtoxin A and 6 cc of saline (1cc/injection site)."
3110830|NCT02369068|Active Comparator|Kenalog|"Intervention is a one time 30 cc intravaginal injection totaling a dose of 40mg/cc of Kenalog (triamcinolone) and ropivicaine 0.5% (29cc) injected throughout the pelvic floor at 1, 3, 5, 7, 9 and 11 o'clock sites/locations.~A mixture of 40mg/1 cc of triamcinolone (40 mg) and 29cc of ropivicaine 0.5% (5cc/6 sites) will be used, followed by 6 cc of saline (1cc/injection site)."
3110831|NCT02369159|Experimental|Peramivir (IV)|"Subjects randomized to peramivir will receive an age appropriate single dose, diluted to a maximum volume of 100 mL in normal saline, administered as a short intravenous infusion over a minimum of 15 minutes.~Subjects ≥12 years will receive a dose of 600 mg.~Subjects <12 years will receive a dose of 12 mg/kg (to a maximum dose of 600 mg).~Subjects < 6 months will receive a dose of 8 mg/kg."
3110832|NCT02369159|Active Comparator|Oseltamivir|"Subjects randomized to oral oseltamivir will receive an age appropriate dose twice daily for 5 days.~Subjects ≥ 13 years will receive a 75mg dose administered as a capsule or oral suspension (twice daily for 5 days).~Subjects < 13 years of age will receive a weight-based dose administered as a capsule or oral suspension (twice daily for 5 days)."
3110833|NCT02369172|Other|Bupropion + ASP2151|400 mg ASP2151 followed by 150 mg Bupropion
3110834|NCT02369211|Experimental|Intravenous acetaminophen|Patient receives 1g intravenous acetaminophen after the incision
3110835|NCT02369211|Placebo Comparator|Placebo|Patient receives saline injection instead of the study drug
3110836|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Adult Group|Subjects aged 18-60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3110837|NCT02369341|Experimental|Fluarix Tetra (Southern Hemisphere) Elderly Group|Subjects aged >60 years received 1 dose of Fluarix™ Tetra (Southern Hemisphere) vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
3110838|NCT02369484|Other|Afatinib|Afatinib 40 mg p.o./day until tumour progression or lack of tolerability
3110839|NCT02369510|Experimental|Low-dose epinephrine|100micrograms of epinephrine group
3110840|NCT02369510|Experimental|High-dose epinephrine|200micrograms of epinephrine group
3110841|NCT02369510|Placebo Comparator|No epinephrine|0.2ml saline
3110842|NCT02369536|Active Comparator|nutraceutical mixture|Lifestyle counseling plus three month administration of nutraceutical mixture (2 soft gelatin capsules of 800 mg per day)
3110843|NCT02369536|Placebo Comparator|placebo|Lifestyle counseling plus three month administration of placebo formulation (2 soft gelatin capsules of 800 mg per day)
3110844|NCT02369796|Experimental|TAK-448 3 µg once weekly|TAK-448 3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3110845|NCT02369796|Experimental|TAK-448 1 µg once weekly|TAK-448 1 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3110846|NCT02369796|Experimental|TAK-448 0.3 µg once weekly|TAK-448 0.3 µg, subcutaneous injection, once weekly on Days 1, 8, 15 and 22.
3110847|NCT02369796|Experimental|TAK-448 0.3 µg twice weekly|TAK-448 0.3 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
3110848|NCT02369796|Experimental|TAK-448 0.1 µg twice weekly|TAK-448 0.1 µg, subcutaneous injection, twice weekly on Days 1, 4, 8, 11, 15, 18, 22, and 25.
3110849|NCT02369835|Experimental|Arm I (modified Dakin's solution)|Participants apply modified Dakin's solution (0.005% to 0.010%) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
3110850|NCT02369835|Placebo Comparator|Arm II (placebo)|Participants apply placebo solution (saline) topically to the skin of the arm up to 3 hours in advance of each radiation treatment.
3110851|NCT02369848|Experimental|Lithoplasty Treatment|Shockwave Lithoplasty System
3110852|NCT02369874|Experimental|MEDI4736|MEDI4736 monotherapy
3110853|NCT02369874|Experimental|MEDI4736 + Tremelimumab|MEDI4736 + tremelimumab combination therapy
3110854|NCT02369874|Active Comparator|Standard of Care|Standard of Care
3132672|NCT03443713|Experimental|Aerobic exercise|Subjects in this arm will complete aerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
3132673|NCT03443713|Experimental|Anaerobic exercise|Subjects in this arm will complete anaerobic exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
3110855|NCT02369900|Active Comparator|Esmolol infusion|"Esmolol infusion for 24 hours. Esmolol will be titrated to a heart rate of 80 - 94 per minute, starting at 10mcg/kg/min and subsequently increasing every 20 minutes in increments of 10 mcg/kg/min (or slower at the discretion of the team) until target is achieved. The maximum allowed dose will be 300mcg/kg/min.~Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs"
3110856|NCT02369900|Placebo Comparator|Standard care, Saline|Standard care (no esmolol). Patients, irrespective of treatment group, will be managed at the discretion of the clinical team. BIDMC has internal guidelines for the management of septic shock which reflect the most recent 2012 Surviving Sepsis Campaign guidelines and are incorporated into the care of patients with septic shock in the ICUs
3110857|NCT02370004|Experimental|Resistive Flexibility and Strength Training|Each subject will undergo Resistive Flexibility and Strength Training (RFST) with a trained practitioner.
3110858|NCT02370043|Experimental|KQ-791|Escalating doses of KQ-791, starting at 15 milligrams
3110859|NCT02370043|Experimental|KQ-791 (after meal)|Single dose of KQ-791 in capsule form, after a meal
3110860|NCT02370043|Placebo Comparator|Placebo|Single dose of placebo matching KQ-791 dose
3110861|NCT02370056|Experimental|3D Visualization|"3-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using 3D Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons.Effect of using 3D Laparoscopic Surgical Video System on operative outcomes will be evaluated."
3110862|NCT02370056|Active Comparator|2D Visualization|"2-dimensional visualization: In this group, total laparoscopic abdominal colectomy will be performed for patients diagnosed with ulcerative colitis by using conventional Laparoscopic Surgical Video System.~This group will be consisted of 27 patients, 9 colectomies performed by 3 surgeons and outcomes will be evaluated."
3110863|NCT02370095|Active Comparator|Treprostinil inhalation solution|Treprostinil will be randomized 2:1 to placebo. Treprostinil (6 mcg per breath) will be administered every 4 hours. The dose will increase from 6 to12 breaths (maximum 72 mcg) over the first 20 hours, maintained for 7 days, and tapered down over 3 days.
3110864|NCT02370095|Placebo Comparator|Placebo|Placebo administration will be administered as above for the active arm
3110865|NCT02370121|Placebo Comparator|Placebo|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
3110866|NCT02370121|Experimental|Gymnema Sylvestre|600 mg dose per day. Two capsules of 300 mg, one in the morning with the first meal and the other at dinner during 90 days.
3110867|NCT02370160|Experimental|DT2219ARL|A recombinant bispecific antibody-targeted toxin.
3110868|NCT02370238|Experimental|paclitaxel+reparixin|"paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + reparixin oral tablets 1200 mg t.i.d.~continuing from D 1 to Day 21 of 28-day cycle"
3110869|NCT02370238|Active Comparator|paclitaxel+placebo|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15) + placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
3110870|NCT02370251|Experimental|Omegaven|Children will receive Omegaven at a maximum of 1 g/kg/day upon enrollment in this arm.
3110871|NCT02370368|Experimental|Dance Group|"Training: participants will engage in dance training with the Xbox Kinect 360 using the Just Dance 2014 disc.~Duration : 45 minutes per session. Frequency: three times per week for six weeks."
3110872|NCT02370368|Active Comparator|Ladder Drills|Intervention: Agility ladder drill training. Duration: 45 minutes per session. Frequency: three times per week for six weeks
3110873|NCT02370394|Experimental|ROSE Program|Participants received a 35-40-minute intervention on the Tablet PC and an in-person 10-15-minute booster session conducted by interventionists within a month after the intervention. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
3110874|NCT02370394|No Intervention|Control Condition|Control Condition consisted of a series of questions regarding television show preferences and then viewed a brief series of videos of popular entertainers/shows, with subsequent requests for ratings of subjective preference. Participants in this condition completed a baseline assessment as well as a follow-up assessment 3 months later.
3110875|NCT02370407|Experimental|Laparoscopic simulator|20 study participants will be randomized to perform peg transfer task on a laparoscopic simulator 10 times (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA).
3110876|NCT02370407|Experimental|Mimic da Vinci robotic simulator|20 study participants will be randomized to perform peg board 1 exercise 10 times on a Mimic da Vinci robotic simulator (Mimic da Vinci Simulator, Intuitive Surgical, Sunnyvale, CA).
3110877|NCT02370420|Experimental|Unique application of PRP|Patients will be applied a unique application of platelet-rich plasma for knee osteoarthritis, and will be given rehabilitation exercises at home
3110878|NCT02370420|Active Comparator|Triple application of PRP|Patients will be applied a triple application of platelet-rich plasma for knee osteoarthritis, with a interval of two weeks between each, and will be given rehabilitation exercises at home
3110879|NCT02370498|Experimental|Pembrolizumab|Participants receive 200 mg intravenous (IV) pembrolizumab on Day 1 of each 21-day cycle, for up to 35 administrations (approximately 2 years).
3110880|NCT02370498|Active Comparator|Paclitaxel|Participants receive 80 mg/m^2 IV paclitaxel on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
3110881|NCT02370511|Experimental|Native mitral valve with severe MAC|Patients with symptomatic severe calcific native mitral valve disease with severe mitral annular calcification who have extremely high surgical risk for standard surgical mitral valve replacement, will undergo transcatheter mitral valve replacement.
3110882|NCT02370511|Experimental|Valve-in-Ring|Patients with symptomatic failing surgical rings resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (valve-in-ring).
3110883|NCT02370511|Experimental|Valve-in-Valve|Patients with symptomatic failing surgical bioprostheses resulting in severe mitral regurgitation or stenosis will undergo transcatheter mitral valve replacement (Valve-in-valve).
3110884|NCT02370537|Experimental|Sequence AB|A single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 7.
3110885|NCT02370537|Experimental|Sequence BA|A single dose of OMACOR® 4 g (administered as 4 x 1 g capsules) at Visit 4, followed by 10 to 14 days washout, followed by a single dose of EPANOVA® 4 g (administered as 4 x 1 g capsules) at Visit 7.
3110886|NCT02370602|Experimental|Pilot Cohort: [^11C]T-773 + TAK-063|[^11C]T-773 <8 μg; 400MBq ± 10%, intravenous (IV), once on Days 1 and 2 prior to PET scans and TAK-063 30 mg or 1000 mg, tablets, orally, once on Day 2 and after PET scan #2 and prior to PET scan #3 and [^11C]T-773 IV after TAK-063 and prior to PET scan #3 on Day 2.
3110887|NCT02370602|Experimental|Main Cohort: TAK-063 + [^11C]T-773|TAK-063 3 to 100 mg, tablets, orally, once, on Day 1, and [^11C]T-773 <8 μg; 400MBq ± 10%, intravenously (IV), prior to PET scans, twice on Day 1 (before and after administration of TAK-063) and once on Day 2 .
3110888|NCT02370615|Experimental|Cohort 1: TAK-272 + Itraconazole|TAK-272 40 mg, tablet, orally, once on Day 1 and 10, followed by Itraconazole 200 mg, solution, orally, twice on Day 4, further followed by Itraconazole 200 mg, solution, orally, once from Day 5 to 12.
3110889|NCT02370615|Experimental|Cohort 2: Midazolam + Digoxin + TAK-272|Midazolam 2 mg, syrup, and Digoxin 0.25 mg, tablet, orally, once on Day 1 and 7, followed by TAK-272 80 mg, tablet, orally, once from Day 3 to 8.
3110890|NCT02370641|Active Comparator|urolithin excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
3110891|NCT02370641|Active Comparator|non excretors|The excretor status will be determined by analysis for urolithin A glucuronide in 24 hour urine after one dose of POMx. A blood sample and stool sample will be obtained before administering the extract.
3110892|NCT02370667|Experimental|Biomechanical Exercise (BE)|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks at a local yoga studio taught by a certified yoga instructor. Four class times will be offered per week. These classes will include a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes will include clinical mobility; muscle and fat volumes, and cartilage morphology using MRI; pain; isometric leg strength; cardiovascular fitness; and gait analysis.
3110893|NCT02370667|Active Comparator|Traditional Exercise (TE)|The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
3110894|NCT02370667|Other|Meditation Control (M)|The participants in this arm will be asked to attend 3 meditation classes per week for 12 weeks taught by a certified yoga instructor with a specialization in meditation. This will take place at an alternate yoga studio to avoid contamination. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the control group will be offered a free exercise pass following completion of the study.
3110895|NCT02370693|Active Comparator|bortezomib plus mycophenolate mofetil|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
3110896|NCT02370693|Placebo Comparator|Placebo plus mycophenolate mofetil|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month and mycophenolate mofetil 1.5 g orally twice daily for 24 weeks
3110897|NCT02370784|Active Comparator|Active Drug|atorvastatin 40 mg once daily for sixteen weeks
3110898|NCT02370784|Placebo Comparator|Placebo control|receive a placebo of similar appearance once daily for sixteen weeks
3110899|NCT02370810|Experimental|experimental group|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
3110900|NCT02370810|Other|weekly check-in group with delayed treatment|will complete weekly measures and commence the treatment once the experimental group completes the intervention
3110901|NCT02370914|Experimental|Suspected Concussive Event (SCE)|When a subject is suspected of a concussion, a Nautilus NeuroWaveTM System recording is obtained from the subject and the recording is evaluated by a Jan Medical concussion algorithm. The subject is declared concussed or not per the algorithm. This is compared to a SCAT test.
3110902|NCT02370914|Experimental|Control|All subjects at the start of study have a baseline recording using the Nautilus NeuroWaveTM System. These subjects are enrolled into the study as non-concussed and these recordings serve as control recordings. Additionally, some subjects from this cohort will be recorded again at the end of the study to obtain end of season recordings. These results are compared to a SCAT test.
3110903|NCT02371187|Experimental|Dapagliflozin|The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3110904|NCT02371187|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3110905|NCT02371252|No Intervention|Original alendronate (Fosamax)|The patients will be given the brand alendronate (Fosamax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
3110906|NCT02371252|Active Comparator|Generic alendronate (Bonmax)|The patients will be given the generic alendronate (Bonmax®) (70 mg) 1 tablet once a week orally for 1 year after enrollment. In addition, calcium and vitamin D supplementation will be given to all patients.
3110907|NCT02371356||Depressed, Medication only|Screen positive for depression and use only antidepressants during pregnancy
3110908|NCT02371356||Depressed, Psychotherapy only|Screen positive for depression and receive psychotherapy only.
3110909|NCT02371356||Depressed, Medication & Psychotherapy|Screen positive for depression and receive both antidepressants and psychotherapy.
3110910|NCT02371356||Depressed, untreated|Screen positive for depression and receive no treatment.
3110911|NCT02371356||Not depressed|Screen negative for depression and receive no treatment.
3110912|NCT02371369|Experimental|Part 1 - Pexidartinib|Participants received blinded treatment of pexidartinib,1000 mg (5 capsules per day ) for 2 weeks, then 800 mg (4 capsules per day) for 22 weeks
3110913|NCT02371369|Placebo Comparator|Part 1 - Placebo|Participants received blinded treatment of matching placebo (5 capsules per day) for 2 weeks, then matching placebo (4 capsules per day) for 22 weeks
3110914|NCT02371369|Experimental|Part 2 - All Pexidartinib|Participants received pexidartinib in Part 1 and in Part 2 at their prescribed dose
3110915|NCT02371369|Experimental|Part 2 - Placebo-Pexidartinib|Participants received placebo in Part 1 and pexidartinib in Part 2 at their prescribed dose
3110916|NCT02371616|Experimental|Test dentifrice|Test dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium flouride
3110917|NCT02371616|Active Comparator|Comparator dentifrice|Comparator dentifrice containing 5% w/w calcium sodium phosphosilicate and 1426 ppm fluoride as sodium monofluorophosphate
3110918|NCT02371629|Experimental|NVA237 Twice daily|Patients randomized to this arm received an NVA237 22 μg capsule in the morning and evening for 26 weeks. All participants received salbutamol as rescue medicine.
3110919|NCT02371629|Experimental|NVA237 Once daily|Patients randomized to this arm received an NVA237 44 μg capsule in the morning and a placebo capsule in the evening for 26 weeks. All participants received salbutamol as rescue medicine.
3110920|NCT02371668|Placebo Comparator|Placebo|Placebo, 5% dextrose (D-glucose) water
3110921|NCT02371668|Experimental|CR6261|CR6261, Investigational monoclonal antibody against influenza A viruses
3110922|NCT02371746|Experimental|Cohort 1|ENV515-1 and ENV515-3 implants in Study Eye for 28 days
3110923|NCT02371746|Experimental|Cohort 2|Two ENV515-3 implants in Study Eye for 12 months with optional 6 month and 3 month extensions (total of 21 months)
3110924|NCT02371746|Experimental|Cohort 3|One or two ENV515-3-2 implants in Study Eye with optional 6 months and additional 6 month extension (total of 24 months)
3110925|NCT02371759|Experimental|Diabetics: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
3110926|NCT02371759|Experimental|Diabetics: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
3110927|NCT02371759|Active Comparator|Diabetics: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
3110928|NCT02371759|Active Comparator|Diabetics: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
3110929|NCT02371759|Experimental|Healthy: L+C maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for maxillary infiltration anesthesia
3110930|NCT02371759|Experimental|Healthy: L+C mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + clonidine (15 mcg/ml) for mandibular block anesthesia
3110931|NCT02371759|Active Comparator|Healthy: L+E maxillary anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%)+ epinephrine (1:80.000) for maxillary infiltration anesthesia
3110932|NCT02371759|Active Comparator|Healthy: L+E mandibular anesthesia|Single dose intraoral local anesthesia with 2ml lidocaine (2%) + epinephrine (1:80.000) for mandibular block anesthesia
3110933|NCT02371785|Experimental|CorPath 200 System|CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
3110934|NCT02371850|Experimental|Nicoderm patch first, then Aveva patch|Each subject gets two procedure days with heating applied for one hour at hours 4 and hour 8 after the application of the Nicoderm CQ nicotine patch, then followed by two procedure days with heating applied for one hour at hours 4 and hour 8, after the application of the Aveva nicotine patch (total of four Procedure days)
3110935|NCT02371876|Experimental|Users of the Monitoring System|Untrained subjects with diabetes used the ONYX PLUS Investigational Blood Glucose Monitoring System.
3110936|NCT02371889|Experimental|Topiramate + Medical Management|Topiramate 200 mg/day orally in two divided doses. Dose will be titrated upward over a six-week period, maintained for 6 weeks, then tapered over 6 days + Medical Management sessions for 15-25 minutes per study visit
3110937|NCT02371889|Placebo Comparator|Placebo Pill + Medical Management|Inactive placebo with dosing schedule matched to intervention group + Medical Management sessions for 15-25 minutes per study visit
3110938|NCT02371980|Experimental|Open-label: Vortioxetine 10 mg|Vortioxetine 10 mg, capsules, orally, once, daily (QD) up to 8 weeks. Participants who achieved response (defined as a ≥50% reduction in Montgomery Asberg Depression Rating Scale (MADRS) total score from Baseline) continued to receive vortioxetine 10 mg, capsules, orally, QD for up to Week 16 (stabilization period) in the Open-label Period.
3110939|NCT02371980|Placebo Comparator|Double-blind: Placebo|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine placebo-matching capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
3110940|NCT02371980|Experimental|Double-blind: Vortioxetine 5 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 5 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
3110941|NCT02371980|Experimental|Double-blind: Vortioxetine 10 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 10 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
3110942|NCT02371980|Placebo Comparator|Double-blind: Vortioxetine 20 mg|Following Open-label Period, participants who achieved remission criteria (defined as MADRS total score ≤12 at Weeks 14 and 16) were randomized to receive vortioxetine 20 mg, capsules, orally, QD from Week 17 up to Week 44 in the Double-blind Period.
3110943|NCT02372006|Experimental|afatinib|dose escalation
3110944|NCT02372058|Other|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
3110945|NCT02372071|Other|BiliCare|Two measurements with the BiliCare device
3110946|NCT02372097|Experimental|Group A|Participants in group A will be orally administered 2 tablets of SYR-472 25 mg in period 1 and 1 tablet of SYR-472 50 mg tablet in period 2, both in a single dose under fasting conditions in the morning.
3110947|NCT02372097|Experimental|Group B|Participants in group B will be orally administered 1 tablet of SYR-472 50 mg in period 1 and 2 tablets of SYR-472 25 mg tablets in period 2, both in a single dose under fasting conditions in the morning.
3110948|NCT02372136|Experimental|Individualized and Optimized Nutrition|Individualized nutrition Optimized nutrition
3110949|NCT02372136|Other|Optimized Nutrition|Optimized nutrition
3110950|NCT02372253|Experimental|Verapamil|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral verapamil for 12 months. The initial dose of verapamil will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The verapamil tablets will be encapsulated to match the placebo capsules
3110951|NCT02372253|Placebo Comparator|Placebo|13-26 subjects with Type 1 Diabetes meeting the inclusion criteria will be randomly assigned to receive daily oral placebo for 12 months. The initial dose of placebo will be 120 mg daily, and this will be advanced if tolerated to a maximum dose of 360 mg daily. The placebo tablets will be encapsulated to match the verapamil capsules
3110952|NCT02372344|Experimental|Fasting|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered at the end of a 10-hour fast.
3110953|NCT02372344|Experimental|Before meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered before consumption of a low calorie, low-fat breakfast (within 30 minutes before starting food intake).
3110954|NCT02372344|Experimental|After meal|Each subject will receive a single oral dose of 4 g AZD0585 on Day 1 of Visits 2, 3, and 4. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
3110955|NCT02372383|Experimental|Fasting|"Subjects with CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3110956|NCT02372383|Experimental|Food/Enzymes|"Subjects with CF will be given the antimycobacterial drugs with a standardized meal plus a typical meal-dose of pancreatic enzymes (Pancrelipase).~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3110957|NCT02372383|Active Comparator|Healthy Controls|"Healthy subjects without CF will be given the antimycobacterial drugs in the fasting state, without supplemental pancreatic enzymes~Rifampin 10mg/kg oral once daily (max 600mg, round to closest 150mg)~Ethambutol 15mg/kg oral once daily (max 2500mg, round to nearest 100mg)~Azithromycin 10mg/kg oral once daily (max 500mg, rounded to the nearest 250mg)~Blood will be drawn at time points 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 12 hours post dose"
3110958|NCT02372396|Experimental|Compassion Meditation|Compassion Meditation delivered in 10 2-hour group treatment sessions.
3110959|NCT02372396|Active Comparator|Relaxation|Relaxation delivered in 10 2-hour group treatment sessions.
3110960|NCT02372682||Test|"Any pediatric patient (0-18 years of age) with known liver disease in whom a liver biopsy is to be performed as standard of care to assess the degree of fibrosis will also undergo an abdominal ultrasound to evaluate the liver.~Underlying diagnoses include but are not limited to biliary atresia, congenital fibrosis-cholestasis, Alagille syndrome, Caroli's disease, choledochal cyst, alpha-1-antitrypsin deficiency, progressive familial intrahepatic cholestasis (PFIC), viral hepatitis, glycogenosis, fructosemia, Wilson disease, cystic fibrosis, autosomal recessive polycystic kidney disease (ARPCKD), mesenterico-caval shunt, post liver transplant, and nonalcoholic steatohepatitis (NASH)."
3110961|NCT02372682||Control|Any pediatric patient (0-18 years of age) undergoing evaluation with an abdominal ultrasound as standard of care for evaluation for a diagnosis other than liver disease and in whom the US shows a normal liver, gallbladder, pancreas, spleen, and biliary tree will then be asked to enroll in the research study by undergoing shear wave elastography.
3110962|NCT02372799|Experimental|Vilazodone|Vilazodone tablets, 5mg, 10mg and 20mg. Oral administration, once per day.
3110963|NCT02372799|Placebo Comparator|Placebo|Dose-matched placebo tablets or capsules, oral administration, once per day.
3110964|NCT02372799|Active Comparator|Fluoxetine|Fluoxetine capsules, 10mg and 20 mg. Oral administration, once per day.
3110965|NCT02373098|Experimental|FTY720|
3110966|NCT02373098|No Intervention|Healthy volunteers|Healthy volunteers with no intervention or drug administered.
3110967|NCT02373124|Experimental|open-label|52 minute infusion of NMDA antagonist
3110968|NCT02373137|Other|DSAEK|Type of corneal transplant; Tissue grafts will be cut to the right thickness using a microkeratome prepared at the eye bank per standard eye bank protocol (about 60-90 microns thick). A 4 mm corneal incision will be used, with Endoserter as the means of inserting the graft, an FDA approved device for this purpose.
3110969|NCT02373137|Other|DMEK|Type of corneal transplant; Endothelial grafts will be pre-peeled at the eyebank (70%). In the operating room the remaining 30% will be peeled, and the endothelium will be stained with trypan blue. A 3.5 mm corneal incision will be used and the graft will be inserted with a modified jones tube injector. The tap technique will be used to position the graft.
3110970|NCT02373202|Experimental|Sarilumab 150 mg q2w + DMARDs|Participants received sarilumab 150 mg, subcutaneous (SC) injection, once every two weeks (q2w) along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
3110971|NCT02373202|Experimental|Sarilumab 200 mg q2w + DMARDs|Participants received sarilumab 200 mg, SC injection, q2w along with non-MTX DMARDs (sulfasalazine, leflunomide, bucillamine, tacrolimus, and/or mizoribine) for up to 52 weeks.
3110972|NCT02373202|Experimental|Sarilumab 150 mg q2w|Participants received sarilumab 150 mg, SC injection, q2w for up to 52 weeks.
3110973|NCT02373202|Experimental|Sarilumab 200 mg q2w|Participants received sarilumab 200 mg, SC injection, q2w for up to 52 weeks.
3110974|NCT02373371|Experimental|Daylight|Metvix® (160mg/g) and Photodynamic Therapy Daylight One session at baseline
3110975|NCT02373371|Active Comparator|Conventional treatment|Metvix® (160mg/g) and Photodynamic Therapy Blue light One session at baseline
3110976|NCT02373813|Experimental|Open Label Run-In: Etanercept plus Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 24 weeks. Participants also receive folic acid as standard of care.
3110977|NCT02373813|Experimental|Double-Blind Treatment: Methotrexate Monotherapy|"Oral methotrexate 10 to 25 mg weekly plus placebo for etanercept for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
3110978|NCT02373813|Experimental|Double-Blind Treatment: Etanercept Monotherapy|"Etanercept 50 mg weekly by subcutaneous injection plus placebo for methotrexate for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will initiate rescue treatment with etanercept 50 mg QW plus methotrexate (10 to 25 mg)."
3110979|NCT02373813|Experimental|Double-Blind Treatment: Etanercept plus Methotrexate|"Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 10 to 25 mg weekly for 48 weeks. Participants also receive folic acid as standard of care.~After randomization, a participant experiencing protocol-defined disease worsening will continue on the assigned treatments (as rescue treatment)."
3110980|NCT02374060|Active Comparator|Periocular triamcinolone 40mg|"Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3110981|NCT02374060|Active Comparator|Intravitreal triamcinolone 4mg|"(preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0~Second injection permitted at Week 8 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3110982|NCT02374060|Active Comparator|Dexamethasoneintravitreal implant|"Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0~Second injection permitted at Week 12 IF:~Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;~IOP of ≤21 or mm Hg and treatment with ≤3 IOP-lowering agents;"
3110983|NCT02374099|Experimental|CC-486 and fulvestrant|CC-486 300 mg by mouth (PO) daily on days 1-21 of each 28 day cycle and fulvestrant 500mg by intramuscular (IM) injection on Days 1 and 15 of cycle 1 and day 1 of each subsequent cycle every 28 days.
3110984|NCT02374099|Experimental|Fulvestrant|Fulvestrant will be administered by intramuscular injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
3110985|NCT02374138|Active Comparator|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
3110986|NCT02374138|Experimental|Intervention|Parental stress management in addition to IMPACT DC intervention of guideline-based clinical care, education, and short-term care coordination.
3110987|NCT02374164|Experimental|Treatment Sequence ABC|Febuxostat extended release (XR) 80 mg, capsules, orally, once on Day 1 of Period 1 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
3110988|NCT02374164|Experimental|Treatment Sequence BCA|Febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a 10-hour fast, followed by a 7-day washout period, followed by Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 3 after a high-fat meal.
3110989|NCT02374164|Experimental|Treatment Sequence CAB|Febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 1 after a 10-hour fast, followed by a 7-day washout period, followed by febuxostat XR 80 mg, capsules, orally, once on Day 1 of Period 2 after a high-fat meal, followed by a 7-day washout period, followed by febuxostat XR 40 mg, capsules, orally, once on Day 1 of Period 3 after a 10-hour fast.
3110990|NCT02374255|Experimental|GoC intervention|Oncologists trained using OncoTalk to have Goals of Care discussions.
3110991|NCT02374255|No Intervention|Usual Care|
3110992|NCT02374307|Experimental|Exercise and education|This group performs a 12-week individual tailored home exercise programme in accordance with the manual of Otago exercise programme. Physiotherapists visit the participants 5 times during the 12 weeks (at week 1,2,4,8 and 10) to prescribe and progress exercises. Motivational conversations on telephone are performed the weeks when no visits are scheduled. Additionally, the participants receive information on the first visit which will focus on motivation, importance of adherence and effectiveness of falls prevention. The participants are expected to do exercises on their own, and in that way perform exercises 3 times weekly. If safe, the participant are provided with a walking plan and be encouraged to walk twice weekly.
3110993|NCT02374307|No Intervention|Control|The control group performs activities as usual.
3110994|NCT02374398|Active Comparator|Tranexamic Acid|TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes
3110995|NCT02374398|Active Comparator|Aquamantys System|The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts
3132674|NCT03443713|Experimental|High intensity interval exercise|Subjects in this arm will complete high intensity interval exercise at home and at OHSU for the study. Subjects will use a Dexcom G6 CGM.
3110996|NCT02374398|Active Comparator|TXA plus Aquamantys|"TXA will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The TXA dose will be 20mg/kg to be administered as a bolus over 20 minutes.~The Aquamantys system will be used as indicated by orthopedic surgeon intraoperative. Local temperatures under 100°C are sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels. Simultaneous RF power and saline delivery. Power settings from 20-200 watts."
3110997|NCT02374398|Placebo Comparator|Control|Saline will be provided ready-to-use as IV infusion with instructions written by the pharmacy department. The saline dose will be administered as a bolus over 20 minutes
3110998|NCT02374463|Experimental|Multimodality Balance Intervention (MMBI)|Multimodality Balance Intervention (MMBI)
3110999|NCT02374463|Active Comparator|Tai Chi|Tai Chi Intervention
3111000|NCT02374593|Experimental|Targeted dosing|Patients in this arm will receive targeted levothyroxine dosing based on thyroid anatomy on ultrasound as follows: 10 mcg/kg for normal gland, 12 mcg/kg for ectopic gland, 15 mcg/kg for athyreosis.
3111001|NCT02374671|Experimental|Implantation-Non-Randomized|Subjects are not participants in the randomized sub-study. VisAbility micro inserts surgically implanted in the eye(s) after enrollment and meeting inclusion/exclusion criteria.
3111002|NCT02374671|Experimental|Implantation-Randomized|Subjects are participants in the randomized sub-study. Subjects were randomized to the Immediate Treatment group. VisAbility micro inserts surgically implanted in the eyes. Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria.
3111003|NCT02374671|No Intervention|Deferred Implantation-Randomized|Subjects are participants in the randomized sub-study after enrollment and meeting inclusion/exclusion criteria. Subjects were randomized to the Deferred Treatment group are observed for 6 months. Upon completion of the observation follow-up, subjects can opt to have VisAbility micro inserts surgically implanted in the eye(s) and become part of the overall study experimental group.
3111004|NCT02374918|Experimental|mTBI wavelength-1 bright light|30 minutes daily light exposure for 6 weeks
3111005|NCT02374918|Placebo Comparator|mTBI wavelength-2 bright light|30 minutes daily light exposure for 6 weeks
3111006|NCT02374918|Experimental|HC wavelength-1 bright light|30 minutes of light exposure
3111007|NCT02374918|Placebo Comparator|HC wavelength-2 bright light|30 minutes of light exposure
3111008|NCT02374957|Active Comparator|Cilostazol|Administer Cilostazol100 mg twice daily for 90 days.
3111009|NCT02374957|No Intervention|Control|No Cilostazol
3111010|NCT02375347|Experimental|Chickpea Enhanced Diet|Fed an enhanced Chickpea diet over a short term period (Chickpea Enhanced Diet Short Term)
3111011|NCT02375373||Observational Chickpea Diet|Observed long-term to study legume intake and GI health (Observational Chickpea Diet)
3111012|NCT02375672|Experimental|Pembrolizumab (MK-3475) + mFOLFOX6|"Following the safety run-in cohort:~mFOLFOX6 Treatment D1 and D15 (every 2 weeks); Pembrolizumab (MK-3475) IV over 30 minutes (every 3 weeks)"
3111013|NCT02375698|Experimental|Gr 1 H56:IC31 5/500|5ug H56 + 500 ug IC31
3111014|NCT02375698|Placebo Comparator|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
3111015|NCT02375724|Experimental|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg twice daily by inhalation
3111016|NCT02375724|Placebo Comparator|Placebo|placebo twice daily by inhalation
3111017|NCT02375971|Experimental|Ranibizumab 0.2 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
3111018|NCT02375971|Experimental|Ranibizumab 0.1 mg|1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
3111019|NCT02375971|Active Comparator|Laser therapy|Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
3111020|NCT02375984|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro either as part of this treatment protocol or the JWCI procurement protocol. TIL from these cultures will be assessed for tumor-reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day X 2 days IV) and fludarabine (25 mg/m2/day IV X 5 days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 109 tumor-reactive lymphocytes (TIL) followed by high-dose intravenous IL-2 (600-720,000 IU/kg/dose every 8 hours for up to 12 doses).
3111021|NCT02376010|Active Comparator|rivaroxaban|rivaroxaban will be given to this cohort, once daily orally (15 or 20 mg, depending on GFR)
3111022|NCT02376010|Active Comparator|warfarin|warfarin orally once a day, titrated to INR of 2-3
3111023|NCT02376166|Experimental|Metformin|850 mg PO once daily for 4 weeks
3111024|NCT02376179||Cuffed ETT|Pediatric patients intubated with a cuffed endotracheal tube for adenotonsillectomy.
3111025|NCT02376257|Active Comparator|250 mg DCS|Baseline assessment (week 1), two weekly sessions when 250mg DCS is administered, and final week (week 4) when retention is assessed.
3111026|NCT02376257|Active Comparator|100 mg modafinil|Baseline assessment (week 1), two weekly sessions when 100 mg modafinil is administered, and final week (week 4) when retention is assessed.
3111027|NCT02376257|Placebo Comparator|Placebo|Baseline assessment (week 1), two weekly sessions when placebo is administered, and final week (week 4) when retention is assessed.
3111028|NCT02376283|Other|STEMI prasugrel|Patients with diabetes mellitus admitted with STEMI who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel Loading (60mg) and maintenance (10mg per day).
3111029|NCT02376283|Other|STEMI clopidogrel|Patients admitted with STEMI over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
3111030|NCT02376283|Other|NSTEMI clopidogrel|Patients admitted with NSTEMI/UA over the age of 75 or under 60 Kg receiving clopidogrel loading (600 mg) and then maintenance (75mg per day).
3111031|NCT02376283|Other|Patients with NSTEMI|who are under 75 years of age and greater than 60Kg in weight receiving Prasugrel loading (60mg) however: - i. After sample collection patients treated with intracoronary stent placement on the same day as loading will receive prasugrel maintenance dose (10mg per day) as per licensing agreement for prasugrel ii. After sample collection patients who are not stented after loading will receive clopidogrel maintenance dose (75mg per day).
3111032|NCT02376283|Other|Patients admitted with STEMI receiving ticagrelor loading|Patients admitted with STEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day)
3111033|NCT02376283|Other|Patients Admitted with NSTEMI receiving ticagrelor loading|Patients Admitted with NSTEMI receiving ticagrelor loading (180 mg) and then maintenance (90mg bd per day).
3111034|NCT02376361|Active Comparator|Surveillance Group|Monthly blood flow surveillance by ultrasound dilution technique and standard of care.
3111035|NCT02376361|No Intervention|Control Group|Control group will receive standard monitoring (standard care).
3111036|NCT02376530|No Intervention|Usual shopping|No change in condition.
3111037|NCT02376530|Experimental|Nutrient profiling|Nutrient profiling system will be present during shopping session.
3111038|NCT02376530|Experimental|Price change|Price changes will be present during shopping session.
3111039|NCT02376530|Experimental|Nutrient profiling and price change|Nutrient profiling system and price changes will be present during shopping session.
3111040|NCT02376790|Active Comparator|Methotrexate Monotherapy|Participants received oral methotrexate 20 mg weekly plus placebo to etanercept subcutaneous injection once a week for 48 weeks.
3111041|NCT02376790|Experimental|Etanercept Monotherapy|Participants received etanercept 50 mg weekly by subcutaneous injection plus oral placebo to methotrexate for 48 weeks.
3111042|NCT02376790|Experimental|Methotrexate + Etanercept|Participants received etanercept 50 mg a week by subcutaneous injection plus oral methotrexate 20 mg weekly for 48 weeks.
3111043|NCT02376998|Experimental|Valiant™ endoluminal procedure|Data from early and long term complications following endoluminal stent-graft placement for thoracic endovascular aortic repair (TEVAR) procedure (Valiant™ endoluminal procedure) will be collected.
3111044|NCT02377063|Other|pressed juice 6 bottles|Subjects will consume pressed juice daily for 3 days.
3111045|NCT02377349|Experimental|dTpa Group|This group will consist of pregnant women who will receive a single dose of Boostrix™ at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of the placebo post-delivery (within 72 hours).
3111046|NCT02377349|Placebo Comparator|Control Group|This group will consist of pregnant women who will receive a single dose of placebo at 27-36 weeks (i.e. completed 27 weeks until 36 weeks) of gestation (Visit 1) and will receive a dose of Boostrix™ post-delivery (within 72 hours).
3111047|NCT02377362|Experimental|GLWL-01, Part A|Escalating dose in at least 2 of 3 periods, starting at 10 milligrams (mg)
3111048|NCT02377362|Placebo Comparator|Placebo, Part A|Escalating dose of placebo to match GLWL-01, in 1 period
3111049|NCT02377362|Experimental|GLWL-01, Part B|Multiple ascending daily doses of GLWL-01 at up to six dose levels, based on Part A
3111050|NCT02377362|Placebo Comparator|Placebo, Part B|Multiple daily doses of placebo to match GLWL-01
3111051|NCT02377362|Experimental|GLWL-01, Part C|Multiple daily doses of GLWL-01 at level based upon Part B
3111052|NCT02377362|Placebo Comparator|Placebo, Part C|Multiple daily doses of placebo to match GLWL-01
3111053|NCT02377427|Experimental|Mepolizumab 40 mg in Part A and B|Participants with bodyweight < 40 kg will receive 0.4 milliliter (mL) of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
3111054|NCT02377427|Experimental|Mepolizumab 100 mg in Part A and B|Participants with bodyweight >= 40 kg will receive 1.0 mL of reconstituted mepolizumab subcutaneously, in upper arm or thigh.
3111055|NCT02377466|Experimental|Retosiban|Retosiban treatment will be administered as a 6 mg IV loading dose over 5 minutes followed by a 6 milligram per hour (mg/hour) continuous infusion over 48 hours. For subjects with an inadequate response after the first hour of treatment, another 6 mg loading dose will be administered and infusion rate will be increased to 12 mg/hour for the remainder of the 48 hour treatment period. The retosiban dosing regimen will require adjustment in subjects treated concomitantly with drugs that are strong Cytochrome 3A4 inhibitors or inducers.
3111056|NCT02377466|Placebo Comparator|Placebo|The placebo control will be a normal saline (0.9% sodium chloride [NaCl]) infusion matched for the loading dose and continuous infusion rates, including a dose increase in subjects with an inadequate response after the first hour of treatment.
3111057|NCT02377674|Experimental|Vascular Graft, Model COR-VG-001|A surgically implanted vascular graft for pediatric patients undergoing extracardiac total cavopulmonary connection.
3111058|NCT02377700|Experimental|Xeltis Vascular Patch, Model COR-VP-001|Patients implanted with the vascular patch during staged bidirectional cava-pulmonary anastomosis.
3111059|NCT02377752|Experimental|Part A cohort 1: Olaratumab+Doxorubicin|"15 milligram per kilogram (mg/kg) of olaratumab administered intravenously (IV) on Day 1 and Day 8, and 25 milligram per square meter (mg/m2) of doxorubicin administered IV on Day 1, Day 2, and Day 3 every 21-day cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met~."
3111060|NCT02377752|Experimental|Part A cohort 2: Olaratumab+Doxorubicin|15 mg/kg of olaratumab administered IV on Day 1 and Day 8, and 75 mg/m2 of doxorubicin administered IV on Day 1 every 21 day-cycle for up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3111061|NCT02377752|Experimental|Part A cohort 3 Olaratumab + Doxorubicin|20 mg/kg loading dose of olaratumab administered IV on Day 1 and Day 8 in Cycle 1, followed by 15 mg/kg IV on Day 1 and Day 8 in subsequent cycles, and 75 mg/m2 of doxorubicin administered IV on Day 1 of every 21 day-cycle up to 6 cycles or until the cumulative dose of doxorubicin reached 500 mg/m2, whichever came later, followed by 15 mg/kg of olaratumab IV monotherapy on Day 1 and Day 8 in subsequent cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3111062|NCT02377752|Experimental|Part B: Olaratumab|15 mg/kg olaratumab administered IV on Day 1 and Day 8 of every 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3111063|NCT02377817|Experimental|PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
3111064|NCT02377817|Sham Comparator|Sham PrenaBelt on First Sleep Test Night|Participants will be randomized to treatment order: sham PrenaBelt on first night, then PrenaBelt on second night, or vice versa. This will avoid the potential impact of changes to sleep across the two nights resulting from familiarization with the polysomnography equipment, which could bias the results.
3111065|NCT02377921|Experimental|Aceneuramic Acid Extended-Release (Ace-ER)|Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.
3111066|NCT02377921|Placebo Comparator|Placebo|Matching placebo TID for 48 weeks.
3111067|NCT02377947||Patients with cirrhosis (grade 3 & 4 per west haven cr.)|Patients with cirrhosis having grade 3 or grade 4 (West Haven Criteria) hepatic encephalopathy who were treated with Lactulose retention enema
3111068|NCT02377986|Experimental|Experimental: BIT+In-home Decluttering|Patients who have not received the BIT workshop through our previous study (IRB 6681) will receive BIT+in-home decluttering practice.
3111069|NCT02378025|Experimental|Yoga Group|Postures, meditation, breathing exercises
3111070|NCT02378025|Active Comparator|Pain Management Wellness Group|Behavioral medicine
3111071|NCT02378038|Experimental|PNT2258|PNT2258 will be administered at 120 mg/m2 on days 1-5 of a 21-day cycle for 8 induction cycles followed by continuation phase therapy at a dose of 100 mg/m2 on days 1-4 of a 28-day cycle.
3111072|NCT02378207|Experimental|Group 1 H4:IC31|15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3111073|NCT02378207|Experimental|Group 2 H56:IC31|5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3111074|NCT02378207|Active Comparator|Group 3 BCG (2-8 x 105 CFU)|Administered IM as 0.1 mL in either deltoid muscle at Day 0.
3111075|NCT02378207|Placebo Comparator|Group 4 Control Sodium Chloride 0.9%|Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
3111076|NCT02378220|No Intervention|"Controls (not tested)"|Treatment as usual (e.g. review of potential drug-drug interactions via Lexicomp Online)
3111077|NCT02378220|Active Comparator|"Intervention (tested)"|"Patients in the tested group will receive pharmacogenetic testing via YouScript® Personalized Prescribing System. The study pharmacist will review drug-drug interactions (DDI), drug-gene interactions (DGI), and drug-drug-gene interactions (DDGI) using YouScript® to provide drug therapy recommendations to prescribers."
3111078|NCT02378402||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
3111079|NCT02378402||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=50%. Proton (1H-) magnetic resonance (MR) spectroscopy.
3111080|NCT02378402||Control group|Age- and gender-matched healthy volunteers recruited as normal control group. Proton (1H-) magnetic resonance (MR) spectroscopy.
3111081|NCT02378480|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
3111082|NCT02378480|Active Comparator|Linezolid|Linezolid IV; Linezolid tablets
3111083|NCT02378506|Experimental|ETN 50mg QW|
3111084|NCT02378662|Experimental|Group A|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
3111085|NCT02378662|Experimental|Group B|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
3111086|NCT02378714|Placebo Comparator|Standard treatment + placebo varenicline|Standard behavioral smoking cessation treatment plus placebo varenicline
3111087|NCT02378714|Experimental|BASC + placebo varenicline|Behavioral activation for smoking cessation plus placebo varenicline
3111088|NCT02378714|Active Comparator|Standard treatment + active varenicline|Standard behavioral smoking cessation treatment plus active varenicline
3111089|NCT02378714|Experimental|BASC + active varenicline|Behavioral activation for smoking cessation plus active varenicline
3111090|NCT02378753|Experimental|rVSVΔG-ZEBOV (immediate vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units)
3111091|NCT02378753|Experimental|rVSVΔG-ZEBOV (deferred vaccination)|One intramuscular (deltoid) injection of rVSVΔG-ZEBOV (2 x 10^7 plaque forming units) in participants randomized to receive deferred vaccination (18-24 weeks after enrollment).
3111092|NCT02378844|Active Comparator|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
3111093|NCT02378844|Sham Comparator|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
3111094|NCT02378883|Other|AVM treatment|Apollo™ Onyx™ Delivery Micro Catheter
3111095|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
3111096|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, without cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, without cirrhosis)
3111097|NCT02378935|Experimental|VOX+SOF/VEL 6 wk, TN, with cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
3111098|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|VOX + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
3111099|NCT02378935|Experimental|VOX+SOF/VEL+RBV 8 wk, TN, with cirrhosis|VOX + SOF/VEL+RBV for 8 weeks (treatment naive, with cirrhosis)
3111100|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 8 weeks (direct-acting antiviral experienced (DAA-E), without cirrhosis)
3111101|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, without cirrhosis|VOX + SOF/VEL for 12 weeks (direct-acting antiviral experienced, without cirrhosis)
3111102|NCT02378935|Experimental|VOX+SOF/VEL 8 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (direct-acting antiviral experienced, with cirrhosis)
3111103|NCT02378935|Experimental|VOX+SOF/VEL 12 wk, DAA-E, with cirrhosis|GS-9857 + SOF/VEL for 12 weeks (direct-acting antiviral experienced, with cirrhosis)
3111104|NCT02378935|Experimental|VOX+SOF/VEL 12 wk (GS-US-338-1121)|VOX + SOF/VEL for 12 weeks (participants who were previously enrolled in GS-US-338-1121 phase 1b study)
3111105|NCT02378961|Experimental|VOX+SOF/VEL 6 wk, TN, without cirrhosis|VOX + SOF/VEL for 6 weeks (treatment naive (TN), without cirrhosis)
3111106|NCT02378961|Experimental|GS-9857+SOF/VEL 6 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 6 weeks (treatment naive, with cirrhosis)
3111107|NCT02378961|Experimental|VOX+SOF/VEL 8 wk, TN, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment naive, with cirrhosis)
3111108|NCT02378961|Experimental|VOX+SOF/VEL 8 wk,TE, without cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced (TE), without cirrhosis)
3111109|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, without cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
3111110|NCT02378961|Experimental|GS-9857+SOF/VEL 8 wk, TE, with cirrhosis|GS-9857 + SOF/VEL for 8 weeks (treatment experienced, with cirrhosis)
3111111|NCT02378961|Experimental|VOX+SOF/VEL 12 wk, TE, with cirrhosis|VOX + SOF/VEL for 12 weeks (treatment experienced, without cirrhosis)
3111112|NCT02379052|Experimental|Dupilumab 300 mg QW|Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
3111113|NCT02379052|Experimental|Placebo|Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.
3111114|NCT02379078|Experimental|Shared decision-making aid|"At study start (step 1: provider-directed intervention phase): Online shared decision-making aid, 1-page provider enabler, provider training video made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): Online shared decision-making aid, 1-page patient enabler, patient training video also made available to patients (in addition to health care providers)"
3111115|NCT02379078|Placebo Comparator|Generic hard-copy diabetes resources|"At study start (step 1: Provider-directed intervention phase): A hard copy of the executive summary of the CDA CPG and postcard outlining online resources made available to health care providers~At 6 months (step 2: provider- and patient-directed phase): A CDA patient education pamphlet regarding diabetes self-management also made available to patients~In addition, provider- and patient-directed guideline dissemination tools (not incorporating SDM) will also be publicly accessible from the CDA website."
3111116|NCT02379091|Placebo Comparator|Placebo|Namilumab placebo-matching, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
3111117|NCT02379091|Experimental|Namilumab 20 mg/mL|Namilumab 20 mg/mL, subcutaneous (SC) injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
3111118|NCT02379091|Experimental|Namilumab 80 mg/mL|Namilumab 80 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant entered an open-label period and received namilumab 150 mg/mL, SC injection, every 4 Weeks up to Week 24. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
3111119|NCT02379091|Experimental|Namilumab 150 mg/mL|Namilumab 150 mg/mL, SC injection, once on Days 1, 15, 43, 71 and every 4 weeks for 12 Weeks. Participants were assessed for response (a 20% improvement from Baseline in both swollen and tender joint counts). If the participant was a responder, the current treatment continued every 4 weeks up to Week 24. If the participant was a non-responder, the participant was discontinued from the study. All participants were on a stable dose of methotrexate tablets (15-25 mg weekly) and folic acid (at least 5 mg/week) orally throughout the duration of the study.
3111120|NCT02379117||Crohn's Disease Patients|Patients with a diagnosis of Crohn's disease fitting the studies inclusion & exclusion criteria.
3111121|NCT02379117||Healthy Volunteers|For healthy volunteers the studies exclusion criteria apply.
3111122|NCT02379195|Experimental|A|"All patients receive the same treatment.~All patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy are administered on day 0 to day 5.~Interleukin-2 are administered in an i.v. continuous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days~Subcutaneous injections of peginterferon alpha 2b are administered three time (day -2, day 7 and day 14)"
3111123|NCT02379221|Experimental|Injectable / Topical|Half of the face is injected with local anesthesia (lidocaine-epinephrine), the other half is treated with topical anesthesia (topicaine gel) per randomize method.
3111124|NCT02379247|Experimental|Dose level 1 BYL-719/alpelisib (250mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 250mg daily on day 1-28~Nab-paclitaxel: 100mg/m2 IV days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3111125|NCT02379247|Experimental|Dose level 2 BYL-719 (alpelisib) (300mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 300mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3111126|NCT02379247|Experimental|Dose level 3 BYL-719 (alpelisib) (350mg)+Nab-paclitaxel|"BYL-719 (alpelisib): 350mg by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3111127|NCT02379247|Experimental|BYL-719 (alpelisib) Dose Expansion|"BYL-719 (alpelisib): RP2D from Phase I by mouth daily on day 1-28 of each 28 day cycle~Nab-paclitaxel: 100mg/m2 given IV on days 1, 8, 15 of each 28 day cycle (Window for Nab-paclitaxel is +/- 1 day)"
3111128|NCT02379273|Experimental|Hybrid L24 pivotal study subjects|Subjects implanted with the Nucleus Hybrid L24 Implant as part of the pivotal IDE study and who still have the device implanted will continue to be followed for 5 years post activation
3111129|NCT02379442|Experimental|1|Target dose of 2 times 106 MSC/kg for up to 12 doses
3111130|NCT02379637|Experimental|A N-acetylcysteine|N-acetylcysteine
3111131|NCT02379637|Placebo Comparator|B Placebo|Placebo
3111132|NCT02379728|Experimental|PrenaBelt|"Participants will be instructed to use the PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3111133|NCT02379728|Experimental|PrenaBelt with Body Position Sensor|"Participants will be instructed to use the PrenaBelt (with integrated body position sensor (BPS)) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3111134|NCT02379728|Sham Comparator|Control|"Participants will be instructed to use the sham-PrenaBelt nightly for the remainder of their pregnancy in addition to receiving the local standard of care.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3111135|NCT02379728|Sham Comparator|Control with Body Position Sensor (BPS)|"Participants will be instructed to use the sham-PrenaBelt (with integrated BPS) nightly for the remainder of their pregnancy in addition to receiving the local standard of care. The BPS will be securely integrated into a small pocket on the sham-PrenaBelt. The BPS is not expected to affect body position or sleep.~Participants will be followed by study personnel through the remainder of pregnancy and delivery."
3111136|NCT02379858|Experimental|Alvimopan (Entereg)|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
3111137|NCT02379858|Placebo Comparator|Suger Pill (Control)|Placebo, 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
3111138|NCT02379923|Experimental|Crossing of Coronary Artery CTO|This is a single arm intent to treat study. A subject is considered enrolled when the subject has given informed consent and meets all inclusion and exclusion criteria, including angiographic inclusion and exclusion criteria, which includes an attempt to cross the target lesion with an investigational device (ASAHI PTCA Guidewire or ASAHI Corsair Microcatheter). Clinical evaluation up to hospital discharge is conducted on all enrolled subjects. The purpose of the clinical follow-up is to determine if the subject has experienced or is experiencing any adverse events
3111139|NCT02380183|Experimental|Intervention|Civco needle guidance device will be used while the nerve block is performed.
3111140|NCT02380183|No Intervention|Standard of Care|Needle guidance device will not be used while nerve block is performed; nerve block is performed by hand alone.
3111141|NCT02380248|Experimental|Systane|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops, 1 drop QID in each eye for 90 days
3111142|NCT02380261|Experimental|Systane|Systane® Lid Wipes, 1 per eyelid, used once and discarded after each use, for 21 days
3111143|NCT02380287|Experimental|Cohort no.1|This cohort includes just one subject who will receive the maximum safe starting dose of BCD-085 (0.05 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
3111144|NCT02380287|Experimental|Cohort no.2|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.05 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3."
3111145|NCT02380287|Experimental|Cohort no.3|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4."
3111146|NCT02380287|Experimental|Cohort no.4|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 0.825 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5."
3111147|NCT02380287|Experimental|Cohort no.5|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6."
3111148|NCT02380287|Experimental|Cohort no.6|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 1.75 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7."
3111149|NCT02380287|Experimental|Cohort no.7|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 2.25 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 8 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 8."
3111150|NCT02380287|Experimental|Cohort no.8|"This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-085 at a dose of 3.0 mg/kg.~If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level."
3111151|NCT02380612|Experimental|All Participants (within patient control)|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3111152|NCT02380677|Experimental|Schedule 1 Cohort 1|CRLX301 7.5 mg/m2 IV given every 3 weeks
3111153|NCT02380677|Experimental|Schedule 1 Cohort 2|CRLX301 15 mg/m2 IV given every 3 weeks
3111154|NCT02380677|Experimental|Schedule 1 Cohort 3|CRLX301 30 mg/m2 IV given every 3 weeks
3111155|NCT02380677|Experimental|Schedule 1 Cohort 4|CRLX301 60 mg/m2 IV given every 3 weeks
3111156|NCT02380677|Experimental|Schedule 1 Cohort 5|CRLX301 75 mg/m2 IV given every 3 weeks
3111157|NCT02380677|Experimental|Schedule 1 Cohort 6|CRLX301 90 mg/m2 IV given every 3 weeks
3111158|NCT02380677|Experimental|Schedule 2 Cohort 1|CRLX301 25 mg/m2 IV given weekly
3111159|NCT02380677|Experimental|Schedule 2 Cohort 2|CRLX301 35 mg/m2 IV given weekly
3111160|NCT02380677|Experimental|Schedule 2 Cohort 3|CRLX301 45 mg/m2 IV given weekly
3111161|NCT02380677|Experimental|Schedule 2 Cohort 4|CRLX301 54 mg/m2 IV given weekly
3111162|NCT02380677|Experimental|Schedule 2 Cohort 5|CRLX301 54 mg/m2 given weekly for 3 weeks with 1 week off
3111163|NCT02380677|Experimental|Phase 2a expansion cohort|CRLX301 75mg/m2 IV given every 3 weeks
3111164|NCT02380690|Experimental|Peer Coach Assignment|Veteran participants will be assigned to a peer coach, who delivered self-management instruction one-on-one over a 6-month period.
3111165|NCT02380690|No Intervention|Control|"Veteran participants will attend a 2-hour class in pain basics and pain self-management. Veterans will aso be given a set of pamphlets related to pain self-management."
3111166|NCT02380703|Experimental|Aggression Prevention Training (APT)|APT will use active learning tools, including didactics, role-playing, and multimedia (eg, books and DVDs) to educate and provide skill training for the caregiver. The 6-8 modules in the intervention will include 4 core modules that address 4 main aggression risk factors: a) recognizing pain, b) treating pain, c) increasing pleasant activities, and d) improving patient-caregiver communication. Caregivers can select 2 to 3 additional elective sessions; elective selection is guided by the needs of the dyad to further enhance skills related to these core topics. Sessions will take place in the patient's home.
3111167|NCT02380703|Placebo Comparator|Enhanced Usual Primary Care (EU-PC)|EU-PC provides the patient and caregiver educational materials on pain, notifies the primary care provider of the PWD's level of pain and depression, and provides 8 weekly supportive telephone calls to caregivers.
3111168|NCT02380742|Experimental|lidocaine-prilocaine|4 mL of lidocaine-prilocaine cream
3111169|NCT02380742|Placebo Comparator|Placebo|4 mL of placebo cream
3111170|NCT02380859|Active Comparator|Prism adaptation|Patients will undergo twice daily adaptation to upward shifts in vision. Participants will be provided with goggles fitted with prismatic lenses that shift vision upward by 25 dioptres (about 17 degrees). While wearing the lenses, participants point to two 10cm-diameter visual targets positioned one above the other (about 20cm apart) on a wall, returning their pointing arm to their chest between each pointing movement. Participants make 50 pointing movements, as fast and as accurately as possible. Such a procedure induces a downward sensorimotor adaptation of pointing movements. Participants undergo this training twice a day (morning and evening) for two weeks in a self-guided fashion.
3111171|NCT02380859|Sham Comparator|Sham adaptation|Participants undergo the same treatment protocol as described in the active comparator arm, with the exception that they wear goggles fitted with neutral lenses that do not induce sensorimotor adaptation.
3111172|NCT02381015|Experimental|Genetic Risk Score: Number Format|Genetic Risk Score: Number Format Subjects receive genetic risk scores in a number format.
3111173|NCT02381015|Experimental|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Subjects receive genetic risk scores in a number and pictograph format.
3111174|NCT02381015|Experimental|Family History: Number Format|Family History: Number Format Subjects receive family history risk in a number format.
3111175|NCT02381015|Experimental|Family History: Number + Pictograph|Family History: Number + Pictograph Subjects receive family history risk in a number and pictograph format.
3111176|NCT02381288|Experimental|TAK-448 0.1 mcg|TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.
3111177|NCT02381288|Experimental|TAK-448 0.3 mcg|TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.
3111178|NCT02381288|Experimental|TAK-448 1.0 mcg|TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.
3111179|NCT02381288|Placebo Comparator|Placebo|TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.
3111180|NCT02381392|Experimental|AV400|The nurse will use the Accuvein AV400 to assist with intravenous access. If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter without using the device. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400.
3111181|NCT02381392|No Intervention|Standard|The nurse will use the standard technique for intravenous access (not using the Accuvein AV400). If the nurse cannot place the catheter after 2 tries (two needle sticks into the skin) then the nurse will attempt to put in the catheter with the help of the Accuvein AV400. While the nurse is putting in the catheter, a member of the study team will record the number of tries, the type of catheter and where the catheter is successfully put in. Afterwards the parent and nurse will be surveyed on their satisfaction and the nurse will be asked specific questions about using the AV400 if they crossed over to the AV400 after two failures.
3111182|NCT02381418|Experimental|1|"Trivalent influenza subunit vaccine Influvac. 3x 15mcg Hemagglutinin Antigen (HA) per 0.5 ml,trivalent one injection at Day 1 "
3111183|NCT02381652|Experimental|Cingal/Cingal|Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
3111184|NCT02381652|Experimental|Cingal/Monovisc|Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
3111185|NCT02381652|Experimental|Cingal/Saline|Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.
3111186|NCT02381678||Subjects implanted with Perimount Heart Valve|Only one group was set for this study, including all enrolled subjects who implanted with Perimount Heart Valve during 2001 to 2007
3111187|NCT02381795|Experimental|Nasal Carbon Dioxide|0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
3111188|NCT02382016|Experimental|Investigational treatment|Macitentan film-coated tablet 10 mg once daily.
3111189|NCT02382016|Placebo Comparator|Placebo|Matching placebo tablet once daily.
3111190|NCT02382133|Other|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
3111191|NCT02382276|Experimental|Nalmefene hydrochloride 20 mg|As-needed; tablets, orally
3111192|NCT02382640|Experimental|Sequence 1: ABDC|Experimental: Sequence 1: ABDC Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and 20 mL Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL (hereafter referred as Maalox) or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 1 (A), followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 2 (B), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 3 (D), followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 4 (C).
3111193|NCT02382640|Experimental|Sequence 2: DACB|Experimental: Sequence 2: DACB Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 3, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 4.
3111194|NCT02382640|Experimental|Sequence 3: CDBA|Febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 2, followed by a 7-day washout period, followed by Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox or equivalent), on Day 1 of Period 3, followed by a 7-day washout period, followed by Febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 4.
3111195|NCT02382640|Experimental|Sequence 4: BCAD|Maalox or equivalent, orally, once, after a 9-hour fast, and febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast (1 hour after Maalox), on Day 1 of Period 1, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after an 11-hour fast (1 hour after febuxostat), on Day 1 of Period 2, followed by a 7-day washout period, followed by febuxostat 80 mg extended-release (XR) capsule, orally, once, after a 10-hour fast, and Maalox or equivalent, orally, once, after a 10-hour fast, on Day 1 of Period 3, followed by a 7-day washout period, followed by febuxostat 80 mg XR capsule, orally, once, after a 10-hour fast, on Day 1 of Period 4.
3111196|NCT02382744|Experimental|Ultrasound Guidance|Saphenous nerve block placed using ultrasound guidance alone
3111197|NCT02382744|Experimental|Ultrasound Guidance + nerve stimulation|Saphenous nerve block placed using ultrasound guidance and nerve stimulation
3111198|NCT02382796|Experimental|Dacomitinib|3 dose strengths (45 mg, 30 mg, and 15 mg), continuous oral daily dosing
3111199|NCT02382848|Active Comparator|Prazosin, Then Placebo|Participants first received Prazosin. A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily. After a washout period, they then receive Placebo
3111200|NCT02382848|Placebo Comparator|Placebo, Then Prazosin|Participants first received Placebo (matching Prazosin) for a 3 consecutive week period during the 7 week study period. After a washout period, they then received Prazosin. The starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
3111201|NCT02382913|Experimental|Group 1|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: low dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3111202|NCT02382913|Experimental|Group 2|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: medium dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart.
3111203|NCT02382913|Experimental|Group 3|Subjects received acellular pertussis (aP) vaccine with different antigen dose formulations: high dose of PT, FHA, PRN, followed by one fixed dose of diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) administered one month apart
3111204|NCT02382913|Experimental|Group 4|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, low dose of D (diphteria) toxoid, fixed dose of T (tetanus) toxoid, followed by one administration of saline solution one month apart.
3111205|NCT02382913|Experimental|Group 5|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3111206|NCT02382913|Experimental|Group 6|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, low dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3111207|NCT02382913|Experimental|Group 7|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: low dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3111208|NCT02382913|Experimental|Group 8|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: medium dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart
3111209|NCT02382913|Experimental|Group 9|Subjects received tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) with different antigen dose formulations: high dose of PT, FHA, PRN, double dose of D toxoid, fixed dose of T toxoid, followed by one administration of saline solution one month apart.
3111210|NCT02382913|Active Comparator|Group 10|Subject received one dose of a licensed TdaP booster vaccine (containing 8 μg each of PT, FHA and 2.5 μg of PRN antigens and 2.5 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid) followed by one administration of saline solution one month apart
3111211|NCT02382939|Experimental|somapacitan|
3111212|NCT02382939|Active Comparator|hGH (somatropin)|
3111213|NCT02382991|Other|NMPK-3C60|D0 + 30 days: evaluation with the non-microprocessor knee. D1 + 90 days: evaluation with the 3C60 knee.
3111214|NCT02382991|Other|3C60-NMPK|"D0 + 90 days: evaluation with the 3C60 knee. A period of 10 days of wash out. D1 + 30 days: evaluation with the non-microprocessor knee."
3111215|NCT02383017|Experimental|Shroom Tech Sport|Shroom Tech Sport is a multi-ingredient performance supplement taken, in pill form, prior to work outs to enhance workout performance.
3111216|NCT02383017|Placebo Comparator|Placebo|The placebo is a calorie matched sugar pill that will be taken in the same fashion as the STS pill.
3111217|NCT02383043|Experimental|Active Treatment|Cocaine choice during d-amphetamine maintenance
3111218|NCT02383043|Placebo Comparator|Placebo Treatment|Cocaine choice during placebo maintenance
3111219|NCT02383056|Sham Comparator|Sham Group (Group 1)|This group will receive 4 sessions of Omnilux sham light, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
3111220|NCT02383056|Experimental|Treatment group (Group 2)|This group will receive 4 treatment sessions with Omnilux 633nm LED, starting 1 week after the surgery. Frequency: 1 session every week (+/- 3 days), for 4 weeks. Session duration: 20 minutes
3111221|NCT02383173|Active Comparator|Basic Implementation Approach|Basic approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
3111222|NCT02383173|Experimental|Enhanced Implementation Approach|Enhanced approach to implementing a Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams
3111223|NCT02383355|Experimental|Switch group|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy for 10 weeks
3111224|NCT02383355|Active Comparator|Continuation group|Individuals in the continuation group will continue the regimen, which consists of antiretroviral therapy as indicated in the inclusion criteria
3111225|NCT02383420|Experimental|Predicate & Invest-GOS|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the GOS investigational detector.
3111226|NCT02383420|Experimental|Predicate & Invest-CsI|Radiation - Each subject will receive one x-ray using the predicate detector and one x-ray using the CsI investigational detector.
3111227|NCT02383420|Experimental|Predicate & Invest.-Cadavers GOS & CsI|Radiation - Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
3111228|NCT02383472|Experimental|MedX Health Console model 1100|The treatment group will receive LED treatments over 6 weeks, 3 times per week, totaling 18 visits. All treatments will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
3111229|NCT02383472|Placebo Comparator|MedX Health Console model 1100-placebo|Subjects enrolled in the placebo group will be on the same schedule as the treatment group. The placebo group will receive LED placebo over 6 weeks, 3 times per week, totaling 18 visits. All placebo patients will take place at Boston Children's Hospital. The cluster heads are applied to frontal, parietal, and temporal areas. Each cluster head is applied to the forehead/scalp areas for up to 10 minutes. There will be two 10-minute LED/placebo treatment periods per visit, each with different cluster head placements on the head/scalp.
3111230|NCT02383576||Bevacizumab|Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
3111231|NCT02383576||Bevacizumab and Capecitabine|Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.
3111232|NCT02383589|Active Comparator|Mycophenolate Mofetil (MMF)|Participants will receive MMF orally twice daily (every 12 hours, Q12H) from Day 1 to Week 52. Participants will also receive rituximab matching placebo by intravenous (IV) infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met.
3111233|NCT02383589|Experimental|Rituximab (RTX)|Participants will receive rituximab by IV infusion on Days 1 and 15 with repeat administration on Days 168 and 182 provided specific safety criteria have been met. Participants will also receive MMF matching placebo orally twice daily Q12H from Day 1 to Week 52.
3111234|NCT02383667||Patients with Electrocardiograms|"Any patient within the hospital either for procedure or for admission will be screened. Patients will be simultaneously be hooked up to two ambulatory Holter monitors for the period of time to be not less than one hour.~One holter will use standard electrodes in a standard electrode distribution. The second holter will use dry electrodes in a derived; data will be collected for 1-6 hours. After the data is collected the Holters will be removed and the data will be downloaded into the reading software to be scanned."
3111235|NCT02383706||Subjects|Pregnant women, BMI greater than or equal to 40 undergo questionnaires, physical exam, and ApneaLink Air, at home, overnight polysomnography study.
3111236|NCT02383719|Experimental|Oro-nasal mask|All patients are included in this arm. Patients in this group receive the experimental oro-nasal mask during non-invasive ventilation
3111237|NCT02383758|Experimental|Treatment Program|Pediatric subjects with autistic spectrum disorder will begin treatment immediately. The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, subjects will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
3111238|NCT02383758|Active Comparator|Waitlist Control|Pediatric subjects with autistic spectrum disorder will wait for 8 weeks and then be offered treatment at that time.The treatment program will consist of 10 appointments of up to 4 hours each, over a 14 day period, followed by 4 weekly 1-hour follow-up visits. During each appointment, participants will be guided to sit on the toilet. If the participant has a continent urination they will be provided with praise and remain on the toilet. If a participant has a continent bowel movement they will be provided with enthusiastic praise along with positive reinforcement and they will be allowed to leave the bathroom. A continent bowel movement will end that day's appointment. If necessary, glycerin suppositories, bisacodyl suppositories, and/or senna may be used to aid in the bowl movement.
3111239|NCT02383862|Experimental|Feedback Group|Patients whose clinician received baseline PROMIS symptom scores at the time of their clinic visit
3111240|NCT02383862|No Intervention|Control Group|Patients whose clinician did not receive baseline PROMIS symptom scores at the time of their clinic visit
3111241|NCT02383940|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 12 weeks.
3111242|NCT02383940|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets), once daily, orally, before the first meal of the day for 12 weeks.
3111243|NCT02383966|Experimental|Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil|
3111244|NCT02383966|Active Comparator|Cisplatin/Carboplatin + 5-Flurouracil|
3111245|NCT02384044|Active Comparator|Crest® Sensi-Stop™ Strips|Professionally Applied
3111246|NCT02384044|Active Comparator|Colgate® Sensitivity Relief Pen|Professionally Applied
3111247|NCT02384070|Experimental|Group 1|Received upstream aspirin plus clopidogrel with no intra-procedural anticoagulation for the FFR calculation with a saline bolus and drip used for placebo anticoagulation during the procedure to blind the operator
3111248|NCT02384070|Active Comparator|Group 2|Received upstream aspirin and clopidogrel plus intra-procedural anticoagulation with bivalirudin for FFR calculation
3111249|NCT02384070|Experimental|Group 3|Received only upstream single anti-platelet therapy with aspirin plus intra-procedural anticoagulation for the FFR calculation with bivalirudin
3111250|NCT02384096|Active Comparator|Conventional Programming, then Advanced Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received conventional single source programming followed by Precision Spectra SCS System advanced programming.
3111251|NCT02384096|Active Comparator|Advanced Programming, then Conventional Programming|Precision Spectra SCS System with CoverEdge Surgical Lead or more than 2 percutaneous leads. Subjects first received Precision Spectra SCS System advanced programming followed by conventional single source programming.
3111252|NCT02384200|Experimental|Antibiotic|"1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily starting 1 week prior to planned kidney stone surgery (PCNL).~In addition, each patient receives a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin."
3111253|NCT02384200|Active Comparator|No preoperative oral antibiotics|Each patient does receive a a dose of ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 60 minutes of surgery start time. Patients with penicillin allergy will receive vancomycin IV (1 g) instead of ampicillin and patients with gentamicin/aminoglycoside allergy will receive ceftriaxone IV (2 g) instead of gentamicin.
3111254|NCT02384382|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
3111255|NCT02384395|Experimental|DTG/3TC/ABC FDC|Dolutegravir (DTG 50 mg), abacavir sulfate (ABC 600 mg) and lamivudine (3TC 300 mg) formulated in a single tablet fixed dose combination (FDC) (DTG/ABC/3TC, GSK2619619), administered orally, once daily
3111256|NCT02384460|Experimental|SD-101-6.0 cream|SD-101-6.0 cream applied topically, once a day to the entire body for a period of 90 days
3111257|NCT02384460|Placebo Comparator|Placebo (SD-101-0.0) cream|SD-101-0.0 (placebo) cream applied topically, once a day to the entire body for a period of 90 days
3111258|NCT02384538|Placebo Comparator|Placebo|Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.
3111259|NCT02384538|Experimental|ABT-981|ABT-981 200 mg every two weeks (Q2W) for 24 weeks.
3111260|NCT02384941|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tables, orally for 24 weeks followed by a 28 week extension period.
3111261|NCT02384941|Experimental|Sotagliflozin 200 milligrams (mg)|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), orally, for 24 weeks followed by a 28 week extension period.
3111262|NCT02384941|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), orally, for 24 weeks followed by a 28 week extension period.
3469216|NCT03888807|Sham Comparator|Placebo|The Biofreeze® gel will contain 3.5% menthol while the placebo will be the same formula with menthol removed and a menthol fragrance added so it is non-distinguishable from the real Biofreeze® gel. The dose of both gels will be 5 mL per knee, which is consistent with previous studies who reported a treatment effect for topical gels containing menthol (1 mL of gel for every 200 cm2 of surface area). The treatment will be applied by the investigator using a gloved hand and syringe containing 5mL of gel. The gel will be applied to the anterior and posterior knee from superior patella to the quadriceps insertion over a period of 5 seconds. The participant will wait 15 minutes, rate the pain in their knees
3469217|NCT03888781||With Left Ventricular Remodeling|By Echocardiography
3111265|NCT02385084|Experimental|Part A: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of three study periods.
3111266|NCT02385084|Experimental|Part A: LY2409021 Tablet Pre-commercial|Single oral dose of LY2409021 tablet (pre-commercial formulation) in one of three study periods.
3111267|NCT02385084|Experimental|Part A: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of three study periods.
3111268|NCT02385084|Experimental|Part B: LY2409021 Capsule|Single oral dose of LY2409021 capsule in one of two study periods.
3111269|NCT02385084|Experimental|Part B: LY2409021 Tablet Commercial|Single oral dose of LY2409021 tablet (commercial formulation) in one of two study periods.
3111270|NCT02385097|Experimental|Chloroprocaine HCl 2% (20 mg/mL)|Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
3111271|NCT02385097|Active Comparator|Ropivacaine 0.75% (7.5 mg/mL)|Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
3111272|NCT02385240|Experimental|Test product|Brimonidine Topical Gel, 0.33 percent
3111273|NCT02385240|Active Comparator|Reference Product|Brimonidine Topical Gel, 0.33 percent (Reference)
3111274|NCT02385240|Placebo Comparator|Placebo gel|Placebo
3111275|NCT02385318|Experimental|Test Product|Ingenol Mebutate
3111276|NCT02385318|Active Comparator|Reference product|Ingenol Mebutate
3111277|NCT02385318|Placebo Comparator|Placebo product|Placebo gel
3111278|NCT02385526||Group A|Vagus Nerve Stimulation Therapy Standard Titration
3111279|NCT02385526||Group B|Vagus Nerve Stimulation Therapy Alternate Titration 1
3111280|NCT02385526||Group C|Vagus Nerve Stimulation Therapy Alternate Titration 2
3111281|NCT02385669|Experimental|6MHP and ipilimumab|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 43, 64, and 85. All peptide vaccines are administered intradermally and subcutaneously.~Ipilimumab will be administered in accord with the official prescribing information: 3 mg/kg intravenously once every 3 weeks, for 4 doses. Ipilimumab will be administered on days 1, 22, 43, and 64."
3111282|NCT02385708|Active Comparator|Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery
3111283|NCT02385708|Active Comparator|Treatment Arm|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
3111284|NCT02385799|Placebo Comparator|Sertraline Liquid Placebo|The placebo will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid placebo once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid placebo once per day for a period of six months.
3469218|NCT03888781||Without Left Ventricular Remodeling|By Echocardiography
3469219|NCT03888768|Active Comparator|ProPBM|Pre-operative: patient will be screened for iron deficiency and anemia and administered IV monofer Intra-operative:IV tranexamic Acid 1gm will be administered at the beginning of surgery and blood transfusion triggered by Allowable blood loss Post-operative: IV Iron monofer will be given to those with estimated blood loss >1L and subsequent post operative follow up till 6month
3469220|NCT03888768|No Intervention|Standard Care|patient will received standard hospital practise
3469221|NCT03888703|Experimental|Treatment|
3469222|NCT03888703|No Intervention|Control|
3111285|NCT02385799|Active Comparator|Sertraline Active Medication|Liquid sertraline (20 mg/cc) will be dosed in an age depended manner. Participants aged 2-3 years of age will be given 2.5 mg of liquid sertraline once per day for a period of six months. Participants aged 4 years to 6 years will be given 5 mg of liquid sertraline once per day for a period of six months.
3111286|NCT02386098|Experimental|Arm 1: BMS-955176 + ATV + RTV + DTG|BMS-955176 at 120 mg tablet per day + Atazanavir boosted with ritonavir (ATV/r) 300/100 mg tablets per day + DTG 50 mg tablet per day, orally
3111287|NCT02386098|Other|Arm 2: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
3111288|NCT02386098|Experimental|Arm 3: BMS-955176 + ATV + DTG|BMS-955176 at 120 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
3111289|NCT02386098|Experimental|Arm 4: BMS-955176 + ATV + DTG|BMS-955176 at 180 mg tablet per day + ATV at 400 mg tablet per day + DTG at 50 mg tablet per day, orally
3111290|NCT02386098|Other|Arm 5: TDF + ATV + RTV + DTG|TDF 300 mg tablet per day + ATV/r at 300/100 mg tablets per day + DTG 50 mg per day, orally
3111291|NCT02386189|No Intervention|Usual Care|Veterans randomized to usual care will not receive any training on using their patient portal(s) to access and share information. They will be contacted via phone and/or secure messaging to remind him/her to take the VA or non-VA provider packet to their appointment. At the conclusion of the study, Veterans assigned to usual care will be provided the training information on the VA health summary for their own reference.
3111292|NCT02386189|Active Comparator|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
3111293|NCT02386319|Active Comparator|Melatonin|"Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery."
3111294|NCT02386319|Placebo Comparator|Placebo|Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
3111295|NCT02386605|Experimental|Treatment|Motivational Interviewing Treatment group
3111296|NCT02386605|Active Comparator|Control|Relaxation Skills Training group
3111297|NCT02386995||BIS and Entropy monitoring|Depth of anesthesia monitoring (BIS and entropy) are compared with standard clinical monitoring in patients with deep brain stimulators inserted at internalization whilst they are having a general anesthesia.
3111298|NCT02387008|Active Comparator|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
3111299|NCT02387008|Active Comparator|GUIDOR® membrane alone|horizontal bone augmentation with synthetic GUIDOR® membrane
3111300|NCT02387008|Active Comparator|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
3111301|NCT02387164|Experimental|Alum-GAD, Vitamin D3|Two doses à 20 microgram of subcutaneous alum-GAD (Diamyd), 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years.
3111302|NCT02387164|Placebo Comparator|Placebo, Vitamin D3|Two doses of subcutaneous placebo, 30 Days apart. Vitamin D 2000 U/Daily with start 30 days before the first injection of Diamyd. Vitamin D treatment will continue throughout the whole study period of 5 years
3111303|NCT02387216|Experimental|Arm A: Experimental Arm|MM-121 in combination with Docetaxel
3111304|NCT02387216|Active Comparator|Arm B: Comparator Arm|Docetaxel alone
3111305|NCT02387268|Experimental|CleanC|Standard colonoscopy procedure using the CleanC system
3111306|NCT02387294|Experimental|Age group 1: children (3-11 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: Half dose of a single dose (0.25 ml) vaccine, administered intramuscularly."
3111307|NCT02387294|Experimental|Age group 2: adolescents (12-18 years)|"Intervention: Vaccination with Fluval AB Novo suspension for injection.~Dosage: A single dose (0.5 ml) vaccine, administered intramuscularly."
3111308|NCT02387359|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
3111309|NCT02387359|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
3111310|NCT02387359|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
3111311|NCT02387372|Experimental|Mechanically Ventilated|"Participants with proven or suspected pneumonia, undergoing mechanical ventilation will receive 4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Those with Creatinine clearance (CLCR) > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Those with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Those with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
3111312|NCT02387372|Experimental|Critically Ill|Critically ill participants with CLCR ≥180 mL/min (as calculated by the Cockcroft-Gault equation) will receive a single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion.
3111313|NCT02387476|Experimental|FRESCA mask first night|"FRESCA mask first night (experimental device) | CPAP second night (active comparator)"
3111314|NCT02387476|Experimental|CPAP Mask first night|"CPAP Mask first night (active comparator)| FRESCA mask second night (experimental device)"
3111315|NCT02387502|Experimental|Intubation with Macintosh laryngoscope|40 patients were intubated with Macintosh laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3111316|NCT02387502|Active Comparator|Intubation with MacCoy laryngoscope|40 patients were intubated with MacCoy laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3111317|NCT02387502|Active Comparator|Intubation with Airtraq laryngoscope|40 patients were intubated with Airtraq laryngoscope after simulating difficult laryngoscopy using rigid neck collar.
3111318|NCT02387554|Experimental|HGP0904+HGP0608+HGP1405|amlodipine + losartan + chlorthalidone
3111319|NCT02387554|Active Comparator|HGP0904|amlodipine
3111320|NCT02387554|Active Comparator|HGP0608|losartan
3111321|NCT02387554|Active Comparator|HGP1405|chlorthalidone
3111322|NCT02387580|Active Comparator|Regimen A: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3111323|NCT02387580|Experimental|Regimen B: OZ439 Prototype 1 and PQP - 110mL|800 mg OZ439 Prototype 1 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3111324|NCT02387580|Experimental|Regimen C: OZ439 Prototype 3 and PQP - 110mL|800 mg OZ439 Prototype 3 granules (oral suspension 60 mL volume and 50 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3111325|NCT02387580|Active Comparator|Regimen D: OZ439 + TPGS and PQP|800 mg OZ439 + TPGS granules (oral suspension 240 mL volume and 100 mL rinse volume) and 960 mg (3 × 320 mg) PQP tablets
3111326|NCT02387580|Experimental|Regimen E: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
3111327|NCT02387580|Experimental|Regimen F: OZ439 Prototype 1 or 3 and PQP - XmL|800 mg OZ439 Prototype 1 or 3 granules (oral suspension and rinse volume to be determined) and 960 mg (3 × 320 mg) PQP tablets
3111328|NCT02387710|Active Comparator|Tiagabine|Tiagabine PO 12 mg before sleep
3111329|NCT02387710|Placebo Comparator|Placebo|Placebo PO before sleep
3111330|NCT02387749|Experimental|mesenchymal stem cells|The BM aspirate will be diluted at 6:1 ratio with phosphate buffer saline with 2 ml EDTA (30 ml BM aspirate+ 5 ml PBS/EDTA buffer).MNCs will be separated under aseptic conditions using a Ficoll. Hypaque desity gradient by centrifugation at 1800 rpm for 20 min then the MNCs will be plated in 40 ml(αMEM), serum free media; mesencult(MSCs culture),penicillin (100 U/ml),streptomycin(10 mg/ml),0.5 ml amphotericin B(all from Gibco BRL) and 10 ng/ml basic fibroblast growth factor (b-FGF)(R&D system, Minneapolis, MN) and will be incubated at 370 c in a humidified atmosphere containing 5% CO2 .after one day ,nonadherent cells will be cultured in the presence of Mesenchymal media for 3 weeks changed every week. After reaching 80% confluence the MSCs will be placed in 10 ml saline and infused IV.
3111331|NCT02387762|Experimental|ACP-196 + Methotrexate|Oral acalabrutinib 15 mg QD plus a stable dose of methotrexate (MTX) between 7.5 mg and 25 mg per week
3111332|NCT02387762|Placebo Comparator|Placebo + Methotrexate|Oral placebo QD plus a stable dose of MTX between 7.5 mg and 25 mg per week
3111333|NCT02387801|Experimental|Ixekizumab Dosing Q2W|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q2W) every 2 weeks through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 44.
3111334|NCT02387801|Experimental|Ixekizumab Dosing Q4W|160 mg ixekizumab given as two SC injections at week 0 followed by 80 mg ixekizumab given as a single SC injection once (Q4W) every 4 weeks through week 44.
3111335|NCT02387814|Experimental|Abemaciclib: Normal Hepatic Function|Single dose of Abemaciclib administered orally on Day 1 to participants with normal hepatic function.
3111336|NCT02387814|Experimental|Abemaciclib: Mild Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with mild hepatic impairment.
3111337|NCT02387814|Experimental|Abemaciclib: Moderate Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with moderate hepatic impairment.
3111338|NCT02387814|Experimental|Abemaciclib: Severe Hepatic Impairment|Single dose of Abemaciclib administered orally on Day 1 to participants with severe hepatic impairment.
3111339|NCT02387840|Experimental|NF1-associated Optic Pathway Glioma (OPG)|Patients with neurofibromatosis type 1 (NF1) associated OPG will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111340|NCT02387840|Experimental|NF1 without brain tumor|Patients with NF1 without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111341|NCT02387840|Experimental|Without NF1 and with brain tumor exposed to therapy|Patients without NF1 and with low grade gliomas exposed to therapy will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111342|NCT02387840|Experimental|Without NF1 and with untreated low grade brain tumors|Patients without NF1 and with untreated low grade gliomas will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111343|NCT02387840|Experimental|Without NF1 and without brain tumors|Patients without NF1 and without brain tumor will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111344|NCT02387840|Experimental|Brain tumors of assorted pathology|Patients with brain tumors of assorted pathologies will be imaged by magnetic resonance imaging and magnetic resonance fingerprinting
3111345|NCT02387853|Experimental|LEO 90100|
3111346|NCT02387957|Experimental|Fovista® plus bevacizumab|Fovista® 1.5 mg intravitreal injection + bevacizumab 1.25 mg intravitreal injection
3111347|NCT02387957|Experimental|Fovista® plus ranibizumab|Fovista® 1.5 mg intravitreal injection + 0.5 mg ranibizumab intravitreal injection
3111348|NCT02387957|Experimental|Fovista® plus aflibercept|Fovista® 1.5 mg intravitreal injection + 2.0 mg aflibercept intravitreal injection
3111349|NCT02387970|Active Comparator|Immediate provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant at the same day as implant surgery
3111350|NCT02387970|Active Comparator|Delayed provisionalization|Individuals will receive temporary dental crowns supported by NobelParallel CC implant 3 months after implant surgery
3111351|NCT02387983|Experimental|Posaconazole|Posaconazole 300 mg tablet (3 x 100 mg tablets) once every 12 hours on Day 1 and once-daily on Days 2 to 28
3111352|NCT02387996|Experimental|Nivolumab|Nivolumab intravenous infusion as specified
3111353|NCT02388074|Experimental|CyPath® Assay of Deep-Lung Sputum Sample|Deep-lung sputum was obtained from healthy individuals who had no known lung disease, was labeled with TCPP and evaluated to detect red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples.
3111354|NCT02388165|Active Comparator|SA4Ag|Staphylococcus aureus 4-antigen Vaccine
3111355|NCT02388165|Placebo Comparator|Placebo|Diluent (sterile water) for Placebo
3111356|NCT02388191|Experimental|Naproxen sodium|550 mg naproxen sodium
3111357|NCT02388191|Placebo Comparator|Placebo|Placebo
3469223|NCT03888664|Experimental|FRDA patients treated with gIFN|1st 2 weeks: gIFN 100 ugr/three times a week From the 3rd week: gIFN 200 ugr three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
3111358|NCT02388269|Active Comparator|gammaCore®-G|"The user/operator applies the gammaCore®-G device to the skin on the right side and left side of the neck. The 2 stimulations should be performed on the same side of the neck before stimulating the other side. This is also applies with the doses increase in the open label phase. The user applies conductive gel to the stimulation surfaces to maintain an uninterrupted conductive path from the stimulation surfaces to the skin.~The device is capable of delivering multiple patient treatments (doses). Each dose consists of 90 seconds of stimulation; for each dose, the device is active for 120 seconds before automatically stopping stimulation.The extra 30 seconds allows ."
3111359|NCT02388269|Sham Comparator|gammaCore®-G sham|"The sham device is a hand-held portable device that appears identical to the gammaCore®-G, in look, weight, visual and audible feedback, user application and control. It passes a low frequency (0.1 Hz) biphasic DC signal into the tissue, which can be felt as a tingling sensation but does not stimulate the vagus nerve or cause muscle contraction. Similar to the active device, the sensation becomes more pronounced as the amplitude is increased, until it is uncomfortable, at which point the amplitude is decreased slightly until tolerable.~Like the active device, the sham device is a multi-use device capable programmed to deliver up to 150, 90-second treatments with a 30-second margin for set-up and operator adjustment of the stimulation intensity."
3111360|NCT02388295|Experimental|AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
3111361|NCT02388295|Placebo Comparator|Placebo to match AZD3241|Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.
3111362|NCT02388321|Experimental|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
3111363|NCT02388321|Active Comparator|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
3111364|NCT02388347|Placebo Comparator|Placebo|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
3111365|NCT02388347|Experimental|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
3111366|NCT02388347|Experimental|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
3111367|NCT02388347|Experimental|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
3111368|NCT02388347|Experimental|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
3111369|NCT02388386|Experimental|PROTEUS-SENSOR|The current study is a prospective interventional design with a single experimental arm. The intervention consists of two components: an edible sensor and a wearable receiver health monitor.
3111370|NCT02388568|Active Comparator|Lorcaserin plus Lifestyle Modification|
3111371|NCT02388568|Placebo Comparator|Placebo plus Lifestyle Modification|
3111372|NCT02388633||Plasmapharesis|Patients undergoing apheresis for elevated LDL. Patients will undergo contrast ultrasound perfusion imaging at rest and during forearm exercise at before and immediately after apheresis.
3111373|NCT02388646|Active Comparator|Exercise Only|Home exercise program.
3111374|NCT02388646|Active Comparator|Brace Only|Reaction Web brace.
3111375|NCT02388646|Active Comparator|Bracing + Exercises|Reaction Web brace and home exercises.
3111376|NCT02388724|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg, tablet, orally, once daily and lansoprazole placebo-matching capsule, orally, once daily for up to 8 weeks.
3111377|NCT02388724|Active Comparator|Lansoprazole 30 mg|Lansoprazole 30 mg, capsule, orally, once daily and vonoprazan placebo-matching tablet, orally, once daily for up to 8 weeks.
3111378|NCT02388737|Experimental|Vonoprazan 10 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
3111379|NCT02388737|Experimental|Vonoprazan 20 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing"
3111380|NCT02388737|Active Comparator|Lansoprazole 15 mg|"Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE.~Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing."
3111381|NCT02388763|Other|MyDay, then 1DAVTE|Stenfilcon A contact lenses, followed by narafilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
3111382|NCT02388763|Other|1DAVTE, then MyDay|Narafilcon A contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
3111383|NCT02388815|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
3111384|NCT02388880|Experimental|ITPR|Use of the ITPR for 240 minutes.
3111385|NCT02388906|Experimental|Ipilimumab and Placebo matching Nivolumab|
3111386|NCT02388906|Experimental|Nivolumab and Placebo matching Ipilimumab|
3132438|NCT03426995|Experimental|GSK3358699, Part C|The dose level for the first cohort in Part C will be decided following completion of Part A of the study for GSK3358699. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive GSK3358699, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
3111387|NCT02388932|Experimental|Treatment (SBRT)|"Participants undergo Stereotactic Body Radiation Therapy in 5 fractions at least 40 hours apart over 10-18 days.~Three dose levels: 40Gy and 45Gy all in 5 fractions. Each initial dose level will have 6 participants allocated to them. All participants are assessed at their 3 month post SBRT visit for Dose-Limiting Toxicities (DLTs). If ≤1 participant experiences a DLT, participants will be enrolled at the next dose level. If ≥3 participants experience a DLT, further accrual will be permanently halted and the study stopped. If 2 participants experience a DLT, then an additional 6 participants will be enrolled at the same dose level. In this setting, if ≤ 3/12 participants have a DLT, participants will be enrolled at the next dose level. If ≥ 4/12 participants have a DLT, further accrual will be permanently halted and the study stopped and 35 Gy will not be recommended as safe.~The dosing strategy for the 2nd (45Gy) cohort will be identical to the first."
3111388|NCT02388997|Active Comparator|Mild asthmatics treated with omalizumab|Subjects with mild asthma will be treated with omalizumab for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. Omalizumab will be given subcutaneously every 2 to 4 weeks according to the manufacturer's recommendations.
3111389|NCT02388997|Placebo Comparator|Mild asthmatics treated with placebo medication|Subjects with mild asthma will be treated with placebo medication for 8 weeks before and for 3 weeks after an experimental challenge with rhinovirus. The placebo mediation will consist of the same diluent used for suspending the omalizumab without omalizumab added.
3111390|NCT02389088|No Intervention|Phase I|"9 PCOS women will be studied. On study day one, r-FSH will be administered I.V. at a dose of 150 IU (FSH stimulation test). Blood samples will be obtained before and after FSH administration. After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month.~The FSH stimulation test will be repeated, as described above, at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
3111391|NCT02389088|Active Comparator|Phase II|"Women that participated in Phase I will be studied again after a washout of 2 months. On study day one, an FSH stimulation test will be performed as described above.~After the FSH stimulation test, each subject will receive an I.M. injection of Lupron 3.75 mg. This dose has a duration effect of one month. Four weeks after administration of Lupron, each subject will receive Letrozole 5mg for 14 days. The FSH stimulation test will be repeated at 5 weeks (early resumption of ovarian function) and 6 weeks (moderate resumption of ovarian function)."
3111392|NCT02389101|Experimental|Lymphoma|Newly diagnosed lymphoma, all subtypes allowed
3111393|NCT02389361|Experimental|Group Z|Postoperative Analgesia with Zaldiar
3111394|NCT02389361|Active Comparator|Group PT|Postoperative Analgesia with Paracetamol-Tramadol
3111395|NCT02389374|Other|chloroquine primaquine 14days|P.vivax malaria patients receiving chloroquine and primaquine 14days as per guidelines
3111396|NCT02389374|Other|artemether-lumefantrine primaquine 1day|P.falciparum malaria patients receiving artemether-lumefantrine combination and primaquine 1day as per guidelines
3111397|NCT02389374|Other|artemether-lumefantrine primaquine 14days|mixed malaria infection receiving artemether-lumefantrine combination and primaquine 14days as per guidelines
3111398|NCT02389452|Experimental|Synvisc-One|Single 6 mL IA injection of Synvisc-One (48 mg of cross-linked hylan polymer) at Day 0 (Initial Treatment). Participants received repeat injection based on physician's discretion of safety and efficacy (no major safety concerns and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) A1 subscore [measurement of pain while walking on flat surface] between 40-80 mm, measured on a 0-100 mm scale with 0 represents no pain and 100 represents worst possible pain) at Week 26, 39 or 52 (Repeat treatment).
3111399|NCT02389621|Experimental|Lusutrombopag|Lusutrombopag 3 mg once daily for up to 7 days.
3111400|NCT02389621|Placebo Comparator|Placebo|Placebo once daily for up to 7 days.
3111401|NCT02389725|Active Comparator|disposable elastic tourniquet|
3111402|NCT02389725|Active Comparator|manual blood pressure cuff|manual blood pressure cuff inflated to 150 milliliters mercury (mmHg)
3111403|NCT02389738|Experimental|BBB disruption with regadenoson|"This is an exploratory (pilot) study to assess whether Regadenoson can disrupt the BBB, change the barrier permeability, to enhance the temozolomide delivery to brain.~Five evaluable patients will be studied in this trial. The sample size justification is not based on statistical rationale but clinical affordability. If the investigators detect ≥ 50% increase in temozolomide brain interstitium concentrations after Regadenoson, then the investigators will consider future studies evaluating additional patients."
3111404|NCT02389764|Experimental|BIBF 1120|Initial dose of BIBF 1120 is 200 mg twice daily orally for a 28 day cycle. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit.
3111405|NCT02389816|Placebo Comparator|Placebo|Placebo tablets, orally, once daily for up to Week 8
3111406|NCT02389816|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 8
3111407|NCT02389816|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg tablets, orally, once daily for up to Week 1 followed by vortioxetine 20 mg tablets, orally, once daily for up to Week 8
3111408|NCT02389829|Active Comparator|Hydromorphone|Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
3111409|NCT02389829|Active Comparator|Prochlorperazine|"Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour."
3111410|NCT02389881|Experimental|Cohort 1 Non-elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3111411|NCT02389881|Experimental|Cohort 2 Non-elderly Healthy: TAK-058 75 mg|TAK-058 75 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3111412|NCT02389881|Experimental|Cohort 3 Non-elderly Healthy: TAK-058 150 mg|TAK-058 150 mg solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3111413|NCT02389881|Experimental|Cohort 4 Elderly Healthy: TAK-058 25 mg|TAK-058 25 mg solution, orally, once daily on Day 1 and Days 4 through 10, in elderly healthy participants.
3111414|NCT02389881|Placebo Comparator|Cohort 5 Non-elderly Healthy: TAK-058 300 mg|TAK-058 300 mg solution, orally, once daily on Day 1, in non-elderly healthy participants.
3111415|NCT02389881|Placebo Comparator|Cohorts 1, 2, 3 and 5 Non-elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10 (Cohorts 1, 2 and 3), or TAK-058 placebo-matching solution, orally, once on Day 1 (Cohort 5), in non-elderly healthy participants.
3111416|NCT02389881|Placebo Comparator|Cohort 4 Elderly Healthy: Placebo|TAK-058 placebo-matching solution, orally, once daily on Day 1 and Days 4 through 10, in non-elderly healthy participants.
3111417|NCT02389894|Active Comparator|Embol-X Embolic Protection Device|The surgeon may use either the EMBOL-X® Access Device/Aortic Cannula or a standard cannula with the EMBOL-X® filter deployed through a separate introducer sheath.
3111418|NCT02389894|Active Comparator|CardioGard Cannula|The Cardiogard embolic protection device is a curved tip 24-French aortic perfusion cannula.
3111419|NCT02389894|No Intervention|Standard Cannula|Patients in this arm will receive the standard of care surgical procedure using a cannula of the surgeon's choosing.
3111420|NCT02389946|Experimental|Orsiro sirolimus coronary stent system|Intervention with a Orsiro DES.
3111421|NCT02389946|Active Comparator|Xience everolimus coronary stent system|Intervention with a Xience DES.
3111422|NCT02389959|Experimental|Bevacizumab|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
3111423|NCT02389959|Placebo Comparator|Saline Control|The Stanford Hospital Investigational Pharmacy will perform all randomization, drug storage and management, as well as mixing and packaging for double-blinded injection of bevacizumab or saline control. Patients will undergo standard-of-care bipolar electrocautery of nasal telangiectasias in the Stanford Surgery Center operating room. At the time of electrocautery, patients will receive intranasal injection of either study drug or saline control. The surgeon performing the injection will be blinded to whether injection is composed of bevacizumab or saline control. The saline control placebo will be mixed by the Stanford Hospital Pharmacy to a total dose of 4mL in order to be identical in quantity and appearance to the mixed doses of bevacizumab, and 2mL will be injected into each side of the nose. Injections will be performed according to the standardized four-point injection protocol (0.5mL/site) based on the vascular anatomy of the nose published in 2012 by Dheyauldeen et al.
3111424|NCT02389998|Experimental|Placebo|Arm 1: Subjects take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary for a period of three weeks. Subjects will also have access to hyoscyamine as a rescue medication.
3111425|NCT02389998|Other|No Treatment|Arm 2: Subjects receive no treatment but have access to hyoscyamine as a rescue medication.
3111426|NCT02390050|Active Comparator|Bexagliflozin tablets, 5 mg|Bexagliflozin tablets, 5 mg, once daily by mouth before breakfast
3111427|NCT02390050|Active Comparator|Bexagliflozin tablets, 10 mg|Bexagliflozin tablets, 10 mg, once daily by mouth before breakfast
3111428|NCT02390050|Active Comparator|Bexagliflozin tablets, 20 mg|Bexagliflozin tablets, 20 mg, once daily by mouth before breakfast
3111429|NCT02390050|Placebo Comparator|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, once daily by mouth before breakfast
3111430|NCT02390076|Active Comparator|Left active LLLT|Active LLLT targeting the left forehead Attention Bias Modification Left low level light therapy
3111431|NCT02390076|Active Comparator|Right active LLLT|Active LLLT targeting the right forehead Attention Bias Modification Right low level light therapy
3111432|NCT02390076|Sham Comparator|Sham LLLT|Sham LLLT targeting the right forehead Attention Bias Modification Sham low level light therapy
3111433|NCT02390167|Experimental|Persons With Diabetes|Untrained Subjects WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System).
3111434|NCT02390219|Experimental|Lumacaftor/Ivacaftor combination|Lumacaftor 400 milligram (mg) and ivacaftor 250 mg combination tablet orally twice daily for 24 weeks.
3111435|NCT02390557|No Intervention|Control - Standard Practice|Standard measures of quality at baseline. No intervention reports sent to providers
3111436|NCT02390557|Experimental|Survey|Persons with Disabilities Quality Survey.PDQS Survey Reports Intervention.reports sent to providers of OneCare enrollees
3111437|NCT02390557|Experimental|YESHealth|Arm 3: YESHealth Reports and PDQS Survey Reports sent to providers of OneCare enrollees
3111438|NCT02390791|Experimental|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
3111439|NCT02390791|Active Comparator|treatment as usual standard portal|Standard version of myADHDportal.com web software
3111440|NCT02390908|Experimental|Site 1 Immediate PLUS intervention|Site 1 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
3111441|NCT02390908|Active Comparator|Wait-list PLUS condition|Received the PLUS intervention at 12 months post baseline
3111442|NCT02390908|Experimental|Site 2 Immediate PLUS intervention|Site 2 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
3111443|NCT02390908|Experimental|Site 3 Immediate PLUS intervention|Site 3 Immediate delivery of the PLUS intervention (Six sessions of Motivational Interviewing and Cognitive Behavioral Skills Training)
3111444|NCT02391038|Experimental|MLN0264|"Phase 1: MLN0264 1.2 milligram per kilogram (mg/kg) starting dose, Intravenous (IV), on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage of MLN0264 will be increased to 1.5 mg/kg then 1.8 mg/kg using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or recommended Phase 2 Dose (RP2D).~Phase 2: MLN0264, IV, on Day 1 of 3 week cycles, for up to 1 year or until disease progression or unacceptable toxicity. Dosage for this phase will be determined from results of Phase 1 MTD/RP2D."
3111445|NCT02391116|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib (Aliqopa, BAY80-6946) solution for IV infusion (test drug/investigational medicinal product)
3111446|NCT02391311|Active Comparator|Sham tDCS + Cognitive Remediation|Subjects in the sham arm will be administered sham transcranial direct current stimulation (tDCS) (i.e., tDCS will be administered for 30 seconds and then will automatically turn off). Sham group will have identical intervention of engagement in 10 1-hour computerized cognitive remediation therapy sessions during sham tDCS as with the active tDCS condition.
3111447|NCT02391311|Experimental|Active tDCS + Cognitive Remediation|Subjects in the active arm will be administered active transcranial direct current stimulation (tDCS) (i.e., 2.0 mA tDCS will be administered for 20 minutes and then will automatically turn off). Active group will have identical intervention engagement in 10 1-hour computerized cognitive remediation therapy sessions during active tDCS as with the sham tDCS condition.
3111448|NCT02391337|Active Comparator|Beta-blocker|In Group B, oral bisoprolol will be commenced at either 1.25mg, 2.5mg or 5mg according to the treatment schedule and uptitrated, as required, to 15mg daily. Recommended additional therapy in this arm includes diltiazem. Use of digoxin is explicitly discouraged but will not terminate participation in the study. If intolerance to bisoprolol occurs, investigators will be advised to try an alternate beta-blocker of their choosing (typically carvedilol, nebivolol, or metoprolol) at equivalent dosage.
3111449|NCT02391337|Active Comparator|Digoxin|In Group A, the maintenance dose of oral digoxin will be either 62.5mcg or 125mcg according to the pre-defined treatment schedule and uptitrated, as required, to 250mcg daily. A single loading dose of four tablets (250 or 500mcg according to target maintenance dose) will be prescribed in digoxin-naïve participants, where necessary. Recommended additional therapy in this arm includes the calcium-channel blocker diltiazem. Use of beta-blockers is explicitly discouraged but will not terminate participation in the study.
3111450|NCT02391350|Active Comparator|Usual Care|Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
3111451|NCT02391350|Experimental|Early Intervention|Patients will receive education and re-assurance in the same manner as the usual care group and will receive physical therapy during the initial 4 weeks following enrollment. Physical therapy will be based on evidence and prior research evaluating a centralizing treatment program for patients with LBP and sciatica. The first physical therapy session will be scheduled within 3 days after enrollment and 6-8 sessions will be administered in the first 4 weeks. Each session will include a brief assessment, treatment with centralizing exercises and spinal mobilizations. Mechanical traction is an optional component. Patients will be provided handouts and instructed to perform assigned exercises at home every 4-5 hours on days between sessions.
3111452|NCT02391363|Experimental|Calmer Life|Cognitive behavior treatment for anxiety
3111453|NCT02391363|Active Comparator|Enhanced Community Care|Enhanced information and referral services for mental health and basic needs
3111454|NCT02391545|Experimental|Duvelisib and Rituximab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
3111455|NCT02391545|Experimental|Duvelisib and Obinutuzumab|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles.~Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26."
3111456|NCT02391584|Experimental|XprESS|Balloon dilation of the Eustachian tube
3111457|NCT02391584|Other|Control|Continued medical management
3111458|NCT02391701|Experimental|Diet group|Diet program 1 day a month for 3 months in 120-minute diet sessions + Freely they receive AD food: vegetables, cheese, olive oil, mussels and wine.
3111459|NCT02391701|No Intervention|Control|No intervention
3111460|NCT02391714|Placebo Comparator|Oxygen (Placebo)|"100% oxygen will be administered via disposable scented nasal masks 2 minutes before, throughout and 3-5 minutes after procedure.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
3111461|NCT02391714|Experimental|Nitrous Oxide (NO)|"Nitrous Oxide in a fixed dose ratio of 50% nitrous/50% oxygen will be administered via disposable scented nasal masks 2 minutes before and throughout the procedure; 100% oxygen will be given after the procedure for 3-5 minutes.~If you are randomized to this group, you will undergo the IUD insertion (including Povidone-Iodine or Chlorhexidine swab) using standard technique."
3111462|NCT02391961|Experimental|dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
3111463|NCT02391961|Placebo Comparator|placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo. Within the trial, each patient serves as his own control.
3111464|NCT02391987|Active Comparator|Tele-Monitoring|Tele-monitoring and health coaching in addition to standard health care
3111465|NCT02391987|No Intervention|Standard Care|Standard care is defined as Heart Failure (HF) care based on current American College of Cardiology (ACC) and American Heart Association (AHA) HF guidelines implemented and orchestrated by a cardiologist and support staff at the participating institution.
3111466|NCT02392000|Experimental|WatchPAT and CBT-i Coach mobile app|Individuals use the WatchPAT sleep monitor and the CBT-i Coach app to self-manage insomnia
3111467|NCT02392104|Experimental|Intervention Arm|All patients in the study will be in the intervention arm.
3111468|NCT02392195||Single arm; Non-interventional|A convenience sample of 10-15 infants born at term gestation, that are </= 6 months of age with significant DP (defined as head flattening requiring helmet therapy) and no major health issues will be recruited into this phase 1 descriptive pilot study
3111469|NCT02392208|Other|Telavancin Before Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin before their normally scheduled hemodialysis session.
3111470|NCT02392208|Other|Telavancin After Hemodialysis|Stage 5 Chronic Kidney Disease patients receive a single dose of telavancin immediately after their normally scheduled hemodialysis session.
3111471|NCT02392234|Experimental|VX-661/Ivacaftor combination|
3111472|NCT02392234|Experimental|Ivacaftor monotherapy|
3111473|NCT02392234|Placebo Comparator|Placebo|
3111474|NCT02392247||Cardiac Surgery Patients|Single cohort of 50 consecutive cardiac surgery patients undergoing cardiopulmonary bypass. The study compares output of two technologies for determination of point of care coagulation function: thromboelastography (TEG; current care option) and the new technology Sonic Estimation of Elasticity via Resonance (SEER) Sonorheometry
3111475|NCT02392286|Active Comparator|Weight-based|Corticosteroid dose weight-based at equivalent to 1mg/kg prednisone daily.
3111476|NCT02392286|Active Comparator|Fixed dose|Corticosteroid dose fixed at equivalent to 40mg prednisone daily.
3111477|NCT02392351|Experimental|Renal Denervation|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator (Vessix Renal Denervation System).
3111478|NCT02392351|Sham Comparator|Masked Procedure|Percutaneous renal angiography
3111479|NCT02392403|Experimental|Nucleus CI532 cochlear implant|
3111480|NCT02392481||Healthy subjects|
3111481|NCT02392481||Mild asthma|
3111482|NCT02392481||Moderate asthma|
3111483|NCT02392481||Severe asthma|
3111484|NCT02392494|Experimental|MK-1075 100 mg (Panel A)|HCV-infected participants receive a single 100 mg dose of MK-1075.
3111485|NCT02392494|Experimental|MK-1075 200 mg (Panel B)|HCV-infected participants receive a single 200 mg dose of MK-1075.
3111486|NCT02392494|Experimental|MK-1075 400 mg (Panel C)|HCV-infected participants receive a single 400 mg dose of MK-1075.
3111487|NCT02392494|Experimental|MK-1075 800 mg (Panel D)|HCV-infected participants receive a single 800 mg dose of MK-1075.
3111488|NCT02392507|Experimental|Necitumumab + Nab-Paclitaxel + Carboplatin|"Induction: Necitumumab administered intravenously (IV) at 800 milligram (mg) on day 1 and 8 of each cycle (3 week cycles); nab-paclitaxel administered IV at 100 milligram per square meter (mg/m²) on day 1, 8 and 15 of each cycle; carboplatin administered IV at a concentration of AUC (area under curve) 6 milligram per milliliter over time (mg*min/mL) on day 1 of each cycle, for a maximum of 4 cycles.~Maintenance: Necitumumab administered IV at 800 mg on day 1 and 8 of each cycle; nab-paclitaxel administered IV at 100mg/m² on day 1 and 8 of each cycle (3 week cycles).~Participants may continue to receive treatment until discontinuation criteria are met."
3111489|NCT02392559|Placebo Comparator|Placebo|Matching subcutaneous injection every 4 weeks (QM)
3111490|NCT02392559|Experimental|EvoMab 420 mg QM|Evolocumab subcutaneous injection QM
3111491|NCT02392611|Experimental|Monotherapy: Alobresib 0.6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 0.6 mg to determine the MTD.
3111492|NCT02392611|Experimental|Monotherapy: Alobresib 1.4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 1.4 mg to determine the MTD.
3111493|NCT02392611|Experimental|Monotherapy: Alobresib 2 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 2 mg to determine the MTD.
3111494|NCT02392611|Experimental|Monotherapy: Alobresib 3 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 3 mg to determine the MTD.
3111495|NCT02392611|Experimental|Monotherapy: Alobresib 4 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 4 mg to determine the MTD.
3111496|NCT02392611|Experimental|Monotherapy: Alobresib 6 mg|Participants with advanced solid tumors and lymphomas who have failed or are intolerant to standard therapy or for whom no standard therapy exists, will receive alobresib at a dose of 6 mg to determine the MTD.
3111497|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Exemestane|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with exemestane 25 mg.
3111498|NCT02392611|Experimental|Combination Therapy: Alobresib 2 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 2 mg in combination with fulvestrant 500 mg.
3111499|NCT02392611|Experimental|Combination Therapy: Alobresib 3 mg + Fulvestrant|Participants with advanced stage estrogen receptor positive breast cancer for whom no standard curative therapy exists, will receive alobresib at a dose of 3 mg in combination with fulvestrant 500 mg.
3111500|NCT02392624|Experimental|Omalizumab|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive omalizumab treatment at 300 mg SC Q4W for next 24 weeks (up to Week 48). Participants randomized to omalizumab may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
3111501|NCT02392624|Placebo Comparator|Placebo|Participants will receive open-label omalizumab treatment at 300 mg SC Q4W for 24 weeks. After 24 weeks open-label treatment, eligible participants will be randomized to receive placebo SC Q4W for next 24 weeks (up to Week 48). Participants randomized to placebo may, at the discretion of the investigator, be transitioned from blinded study drug to open-label omalizumab at 300 mg SC Q4W if they experience clinically significant worsening in their CIU (as judged by the investigator). Participants who are transitioned to open-label omalizumab will continue to receive open-label omalizumab as study drug until Week 48.
3111502|NCT02392767|Active Comparator|Verum|2 times 2 tablets a day for 4 weeks.
3111503|NCT02392767|Placebo Comparator|Placebo|2 times 2 tablets a day which cornstarch. Tablets look identical like verum tablets.
3111504|NCT02392806|Active Comparator|BabiPlus, Respiralogics|Infants randomized to the BabiPlus device will be extubated to BabiPlus Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the B&B Bubbler device for 24 hours
3111505|NCT02392806|Active Comparator|B&B Bubbler, B&B medical Technologies|Infants randomized to the B&B Bubbler device will be extubated to B&B Bubbler Bubble CPAP device and after 72 hours, if the infant has remained extubated, will be crossed-over to the BabiPlus device for 24 hours
3111506|NCT02393209|Experimental|TAK-117 200 mg + Docetaxel (36 mg/m^2)|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).
3111507|NCT02393209|Experimental|TAK-117 300 mg + Docetaxel 36 mg/m^2|TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).
3111508|NCT02393209|Experimental|Phase 2 - TAK-117 + Docetaxel 36 mg/m^2|TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m^2 IV infusion on Days 1 and 8 of a 21-day cycle.
3111509|NCT02393209|Experimental|Phase 2 - Docetaxel 75 mg/m^2|Docetaxel 75 mg/m^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.
3111510|NCT02393339|Active Comparator|study group|Study group will receive syrup paracetamol (15 mg/kg) 15 min before the dental treatment
3111511|NCT02393339|Placebo Comparator|controll group|Control group will receive placebo syrup, designed to mimic paracetamol syrup, similar in color and viscosity, 15 min before dental treatment.
3111512|NCT02393378|Experimental|Adalimumab 40 mg|Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
3111513|NCT02393378|Active Comparator|Namilumab 150 mg|Namilumab 150*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.
3111514|NCT02393417|Experimental|Cohort 1|0.3 mL of CANDIN administered intralesionally in the largest common wart
3111515|NCT02393417|Experimental|Cohort 2|0.5 mL of CANDIN administered intralesionally in the largest common wart
3111516|NCT02393417|Experimental|Cohort 3|0.3 mL of CANDIN administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
3111517|NCT02393417|Placebo Comparator|Pooled Placebo|0.3 mL or 0.5 mL administered intralesionally in the largest common wart, or 0.3 mL administered intralesionally in up to 4 warts at the same visit (up to 1.2 mL total injected volume)
3111518|NCT02393547|Experimental|Varenicline + Lorcaserin|Open label all subjects receive both Varenicline and Lorcaserin
3111519|NCT02393677|Placebo Comparator|Ropivacaine|amide local anesthetic
3111520|NCT02393677|Active Comparator|Ropivacaine with Dexmedetomidine|combination of amide local anaesthetic and alpha2 agonist
3111521|NCT02393690|Experimental|Arm I (selumetinib, iodine I-131)|Patients receive selumetinib PO BID starting on week 1, day 1 and continuing through 2 days after iodine I 131 therapy has been administered. Approximately 3 weeks after beginning treatment with selumetinib, patients receive iodine I-131 PO.
3111522|NCT02393690|Active Comparator|Arm II (placebo, iodine I-131)|Patients receive placebo PO BID starting on week 1, day 1 and continuing through 2 days after iodine I-131 therapy has been administered. Approximately 3 weeks after beginning treatment with placebo, patients receive iodine I-131 PO.
3111523|NCT02393755|Experimental|Treatment (capecitabine, nintedanib)|Patients received capecitabine PO BID (every 12 hours) on days 1-14 and nintedanib PO BID (every 12 hours) on days 1-21. Courses repeated every 21 days in the absence of disease progression or unacceptable toxicity.
3111524|NCT02393755|Experimental|Treatment (capecitabine , nintendanib)|Patients receive the highest safe dose of the combination of nintedanib and capcitabine.
3111525|NCT02393859|Active Comparator|High Risk Consolidation 3 (HC3) Chemotherapy|One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m^2/day intravenous [IV] on Days 1-6), vincrisitne (1.5 mg/m^2/day IV on Days 1 and 6), daunorubicin (30 mg/m^2 IV over 24 hours on Day 5), methotrexate (1 g/m^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m^2 IV for 1 hour on Days 2-4), and pegylated [PEG]-asparaginase (1000 U/m^2 IV for 2 hours or intramuscularly [IM] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m^2 IV or IM every 48 hours for a total of 6 doses).
3111526|NCT02393859|Experimental|Blinatumomab|15 μg/m^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
3111527|NCT02393950|Experimental|Drug: ODM-106|Oral capsules dosage 2-800mg once daily for one day
3111528|NCT02393950|Placebo Comparator|Drug: Placebo|Oral capsules given once daily for one day
3111529|NCT02394275|Experimental|Single arm:|Eligible patients with receive intervention: frozen fecal microbiota transplantation (FMT), kept at -20 oC and will be thawed prior to administration. Patients on antibiotic to control CDI will discontinue antibiotic 24 hours prior to FMT.
3111530|NCT02394340|Experimental|Luliconazole Cream 1%|Participants will receive 1 oral capsule of omeprazole 40 milligrams (mg) on Day 1 and Day 8. Participants will also receive luliconazole cream 1% to cover the entire affected surface areas and adjacent areas once daily in the morning on Day 2 (24 hours after initial omeprazole dosing) through Day 8.
3111531|NCT02394457|Experimental|Intravenous Cosyntropin Group A|Cosyntropin 500 mcg in 1000cc Normal Saline
3111532|NCT02394457|Active Comparator|Epidural Blood Patch Group B|Epidural Blood Patch and I000cc Normal Saline
3111534|NCT02394561|Experimental|Cw6-positive AIN457 300 mg|Stratified to Cw6 positive cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
3111535|NCT02394561|Experimental|Cw6-negative AIN457 300 mg|Stratified to Cw6 negative cohort. Investigators and patients were blinded to Cw6 results. All patients were treated according to an induction regimen of two injections of secukinumab 150 mg a week for five weeks starting at baseline (week 0), followed by a maintenance period of two injections per month. At week 16, patients achieving PASI 50 response were eligible to continue on secukinumab for an additional 8 weeks in CORE. Eligible patients with at least a PASI 75 response were included in the extension phase, up to 72 weeks
3111536|NCT02394600|Experimental|Grastek®|48 participants will receive Grastek® once per day for 120 days. Grastek® is a standardized sublingual immunotherapy (SLIT) tablet containing 2800 BAU of standardized allergen extract from Timothy grass (Phleum pretense). This SLIT product is approved by Health Canada and the Food and Drug Administration (FDA) for the treatment of grass-pollen induced allergic rhinoconjunctivitis (AR) in Canada and the United States respectively.
3111537|NCT02394600|Placebo Comparator|Placebo|48 participants will receive placebo once per day for 120 days.
3111538|NCT02394730|Experimental|vorapaxar|2.5mg of vorapaxar po qd
3111539|NCT02394730|Placebo Comparator|Placebo|sugar pill po qd
3111540|NCT02394756|Experimental|Marketed Soft Contact Lens (Test)|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3111541|NCT02394756|Active Comparator|AIR OPTIX® AQUA|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3111542|NCT02394756|Active Comparator|Biofinity®|Subjects will be randomized to wear each of three contact lens types (Marketed Soft Contact lens, AIR OPTIX® AQUA, or Biofinity®) for a 4-week period with each lens type.
3111543|NCT02394769|Placebo Comparator|Placebo (For Aspirin)|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose, once daily, until the final visit. Duration not to exceed 12 weeks.
3111544|NCT02394769|Active Comparator|Low Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (81 mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
3111545|NCT02394769|Active Comparator|Standard Dose Aspirin|The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy (start of randomization). Participants will be expected to take one capsule orally at the blinded dose (325mg/d), once daily, until the final visit. Duration not to exceed 12 weeks.
3111546|NCT02394808|Experimental|Test Lens 1|senofilcon A (Approved contact lens material)
3111547|NCT02394808|Active Comparator|Test Lens 2|lotrafilcon B (Approved contact lens material)
3111548|NCT02394912|Experimental|Single-arm|
3111549|NCT02394925|Experimental|Multifocal Test Contact Lens|Subjects will wear the test lenses at least six hours per day, at least five days per week
3111550|NCT02394951|Experimental|Pregabalin|Pregabalin administered for 4 weeks, titrated to highest tolerated dose up to 600 mg/day.
3111551|NCT02394951|Placebo Comparator|Placebo|Identical, matching inactive substance administered for 4 weeks following the same dosing regimen.
3111552|NCT02395042|Placebo Comparator|LiRIS Placebo, LiRIS Placebo (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period (Tx 1): Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 10 and then removed and a second matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 14 and removed on Day 28. Treatment 2 Period (Tx 2): optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and removed on Day 14.
3111553|NCT02395042|Experimental|LiRIS®, LiRIS® (Tx 1)/LiRIS® (Tx 2)|Treatment 1 Period: LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 then removed and a second LiRIS® 400 mg inserted into the bladder on Day 14 and removed on Day 28. Treatment 2 Period: optional LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 0 and then removed on Day 14.
3111554|NCT02395042|Experimental|LiRIS Placebo, LiRIS® (Tx 1)/ LiRIS® (Tx 2)|Treatment 1 Period: Matching placebo device to the LiRIS inserted into the bladder by cystoscopy on Day 0 and then removed and LiRIS® (continuous release of lidocaine) 400 mg inserted into the bladder by cystoscopy on Day 14 then removed on Day 28. Treatment 2 Period: optional LiRIS® 400 mg inserted into the bladder by cystoscopy on Day 0 then removed on Day 14.
3111555|NCT02395055|Experimental|BCD-057 group|BCD-057 (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
3111556|NCT02395055|Active Comparator|Humira group|Humira (adalimumab) at a dose of 40 mg, administered as a single subcutaneous injection, which will be performed on week 0.
3111557|NCT02395081|Placebo Comparator|600 IU|Women will receive prenatal vitamins containing 600 IU of Vitamin D.
3111558|NCT02395081|Experimental|2000 IU|Women will receive prenatal vitamins containing 2000 IU of Vitamin D.
3111559|NCT02395081|Experimental|4000 IU|Women will receive prenatal vitamins containing 4000 IU of Vitamin D.
3111560|NCT02395133|Placebo Comparator|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW) from Week 1 (Day 1) to Week 36.
3111561|NCT02395133|Experimental|Dupilumab 300 mg Q8W|Subcutaneous injection of Dupilumab 300 milligram (mg) alternatively with placebo (matched to Dupilumab) was administered once every eight week (Q8W) from Week 1 to Week 36.
3111562|NCT02395133|Experimental|Dupilumab 300 mg Q4W|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every four week (Q4W) from Week 1 to Week 36.
3111563|NCT02395133|Experimental|Dupilumab 300 mg Q2W/QW|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered once every week (QW) or twice a week (Q2W) from Week 1 to Week 36.
3111564|NCT02395172|Experimental|Avelumab|
3111565|NCT02395172|Active Comparator|Docetaxel|
3111566|NCT02395185|Experimental|Milk|Milk bottle administration
3111567|NCT02395185|Experimental|Water|Water bottle administration
3111568|NCT02395185|Experimental|Sucrose|Sucrose bottle administration
3111569|NCT02395302|Experimental|Dual Action Pneumatic Compression|Dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an alternating current (AC) outlet.
3111570|NCT02395471|Experimental|Patient wth Barrett's|Subjects presenting for routine endoscopic BE surveillance examinations
3111571|NCT02395471|Experimental|Patients with GERD|Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
3111572|NCT02395536|Experimental|In office Outside walls of hospital|Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.
3111573|NCT02395536|Other|Traditional Hospital Setting|Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.
3111574|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group A)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
3111575|NCT02395627|Experimental|Pembrolizumab Cycle 2 (Group B)|Tamoxifen: 20 mg daily orally (starting at Cycle 1) Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 2)
3111576|NCT02395627|Experimental|Pembrolizumab Cycle 1 (Group C)|Vorinostat: 400 mg 5 days every 7 orally (starting at Cycle 1) Pembrolizumab: 200 mg every 3 weeks intravenously (starting at Cycle 1)
3111577|NCT02395653|Experimental|SSEC Fentanyl|SSEC fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation.
3111579|NCT02395692|Experimental|Treatment (methoxyamine, temozolomide)|Patients receive methoxyamine PO QD and temozolomide PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3111580|NCT02395822|Experimental|Preparative Regimen and SubQ rHuIL-15|"Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion"
3111581|NCT02395978|Experimental|Part I: 1 PDC-1421 Capsule|1 PDC-1421 Capsule TID, p.o. after meal for 28 days
3111582|NCT02395978|Experimental|Part I: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 28 days
3111583|NCT02395978|Experimental|Part II: 2 PDC-1421 Capsule|2 PDC-1421 Capsule TID, p.o. after meal for 42 days
3111584|NCT02395978|Experimental|Part II: 1 PDC-1421 Capsule plus 1 placebo|1 PDC-1421 Capsule plus 1 placebo TID, p.o. after meal for 42 days
3111585|NCT02395978|Placebo Comparator|Part II: 2 placebo|2 placebo TID, p.o. after meal for 42 days
3111586|NCT02395991||Observe1|Patients who are referred to MR unit for hepatocyte-specific contrast (gadoxetic acid) enhanced liver magnetic resonance imaging (MRI)
3111587|NCT02396147|Experimental|Arm 1: T2-A + T4B-B + T4B-C|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation B Regimen B (T4B-B) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation B Regimen C (T4B-C) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was a 10-day washout period between each dose.
3111588|NCT02396147|Experimental|Arm 2: T2-A + T4C-D + T4C-E|T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
3111589|NCT02396160|Active Comparator|Treatment|2 capsules per day of the herbal formula (Urox®) with each capsule containing 420mg of a concentrated proprietary blend of extracts of Crateva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root
3111590|NCT02396160|Placebo Comparator|Placebo|identical placebo vegetarian capsule containing color-matched cellulose
3111591|NCT02396212|Experimental|Canakinumab|All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.
3111592|NCT02396251|Experimental|HA experimental|HA experimental only
3111593|NCT02396251|Active Comparator|HA comparator|HA experimental + HA comparator
3111594|NCT02396316|Experimental|Aflibercept|Aflibercept 2 mg Intravitreal (IVT) injection group
3111595|NCT02396316|Sham Comparator|Sham Injection|Sham injection group
3111596|NCT02396381|Experimental|THS 2.2|Ad libitum use of THS 2.2
3111597|NCT02396381|Active Comparator|CC|Ad libitum use of CC
3111598|NCT02396420|Experimental|Treatment arm|Patients will receive prostate artery embolization (PAE) with Embosphere Microspheres.
3111599|NCT02396511|Experimental|TRC105 and Bevacizumab|TRC105 weekly intravenous infusion bevacizumab every 2 weeks intravenous infusion
3111600|NCT02396537|Experimental|Intranasal Lidocaine|Patient to receive 4% lidocaine intranasally prior to midazolam
3111601|NCT02396537|Placebo Comparator|Intranasal 0.9% saline|Patient to receive 0.9% Saline intranasally prior to midazolam
3111602|NCT02396732|Experimental|Low Molecular Weight Heparin (LMWH) + Aspirin (ASA)|Group will get both enoxaparin (standard of care) and aspirin (intervention) after consent up to Intensive Care Unit (ICU) discharge.
3111603|NCT02396732|Active Comparator|Low Molecular Weight Heparin (LMWH) Alone|Group will get only enoxaparin (standard of care) after consent up to Intensive Care Unit (ICU) discharge.
3111604|NCT02396745|Experimental|TECR & ECM|Subjects undergoing TECR with ECM placement Intervention is Trans-oral Endoscopic circumferential resection (TECR) with placement of extra-cellular matrix (ECM)
3111605|NCT02396758|Experimental|APT/2 Hours-r-tPA/2 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 2 mg/hour [hr]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
3111606|NCT02396758|Experimental|APT/4 Hours-r-tPA/1 mg/hr/Catheter|A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
3111607|NCT02396758|Experimental|APT/6 Hours-r-tPA/1 mg/hr/Catheter|A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
3111608|NCT02396758|Experimental|APT/6 Hours-r-tPA/2 mg/hr/Catheter|A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
3111609|NCT02396849|Experimental|Continuous Positive Airway Pressure (CPAP)|Use of a CPAP machine for at least 5 days per week for 28 days
3111610|NCT02396849|Sham Comparator|Continuous Positive Airway Pressure (CPAP) Sham|Use of a sham CPAP machine for at least 5 days per week for 28 days
3111611|NCT02396953|Experimental|lanreotide PRF|One single dose of lanreotide PRF (via subcutaneous injection) either 180mg or 270mg or 360mg.
3111612|NCT02397057|Active Comparator|Injectafer|Two doses of Injectafer 750 mg undiluted dose at 100 mg/minute given 5 days apart for a total of 1500 mgs.
3111613|NCT02397057|Placebo Comparator|Normal Saline|IV Placebo (15ml of Normal Saline) IV push at 2ml/minute
3111614|NCT02397096|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a non nucleoside reverse transcriptase inhibitor (NNRTI) (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will switch on Day 1 to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 48 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
3111615|NCT02397096|Active Comparator|Delayed Switch to Doravirine, Tenofovir, Lamivudine|Participants receiving continuous antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2 NRTIs for >=6 months with undetectable HIV-1 RNA will continue on this therapy until Week 24, at which time they will switch to doravirine, tenofovir, lamivudine single tablet by mouth once daily for 24 weeks in the Base Study and, optionally, for up to an additional 6 years in the Study Extensions
3111616|NCT02397122|Experimental|PRF+CAF+CTG|platelet-rich fibrin + coronally advanced flap + connective tissue graft
3111617|NCT02397122|Active Comparator|CAF+CTG|coronally advanced flap + connective tissue graft
3111618|NCT02397265|Experimental|Bihormonal closed loop|Bi-hormonal closed loop pump will be used in the exercise and mixed meal substudies
3111619|NCT02397265|Active Comparator|Standard opened loop pump|Standard opened loop pump will be used in the exercise and mixed meal substudies
3111620|NCT02397265|Placebo Comparator|Insulin only|Insulin only closed loop
3111621|NCT02397278|Active Comparator|Platelet rich plasma (PRP)|Patients will receive three PRP injections into the symptomatic knee; they will also be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
3111622|NCT02397278|No Intervention|Conventional therapy|Patients will be fitted with a hinged brace locked in extension, with weight bearing as tolerated and crutches for those with pain upon weight bear, complete rest from impact activities with progression to weight bearing as tolerated for 6 weeks, and then followed according to the Sports Medicine department's protocol for OCD.
3111623|NCT02397291|Placebo Comparator|Part 1: Measurements of maternal and fetal concentrations|"At the time of the elective cesarean section, a blood sample of 0.5 ml will be obtained from a maternal heated hand vein at the time the umbilical cord is clamped. Then, the umbilical cord will be doubly clamped to isolate a segment. The umbilical artery and vein will be sampled for 0.5 ml of blood. There are no stable isotopes infused. Heating the maternal hand vein allows it to be arterialized. These patients are separate from those required for the stable isotope studies listed below."
3111624|NCT02397291|Active Comparator|Part 2: Stable Isotope Studies|Prior to the elective cesarean section, 2 samples from the patient's heated hand vein are obtained to establish a baseline for the compounds. Next, a primed constant infusion containing the stable isotopes of mannose and myoinositol is begun in a peripheral IV of the mother. This is continued approximately 2 hours until the Cesarean section is complete and the umbilical cord samples are obtained. An additional 3 samples are obtained from the patient's heated hand vein: 1 at the start of the cesarean section, 1 at the time the fetus is delivered, and 1 at the time the umbilical cord samples are obtained.
3111625|NCT02397408|Experimental|Diagnostic 11C- and 18F-choline PET/MR imaging|Patients are given 370 megabecquerel (MBq) 11C-Choline (11C) intravenously and 3 MBq/kg 18F-Choline (18F) intravenously prior to a whole-body PET/MR imaging
3111626|NCT02397447|Experimental|Momordica charantia|Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days
3111627|NCT02397447|Placebo Comparator|Placebo|Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days
3111628|NCT02397460|Experimental|Gefapixant 50 mg|Gefapixant 50 mg (1 tablet) administered as a single dose
3111629|NCT02397460|Experimental|Gefapixant 300 mg|Gefapixant 300 mg (6 tablets) administered as a single dose
3111630|NCT02397460|Placebo Comparator|Placebo|Placebo-matching tablets administered as a single dose
3111631|NCT02397473|Experimental|Galcanezumab 300mg|Galcanezumab 300mg administered subcutaneously (SC) every 30 days during an 8 week treatment period.
3111632|NCT02397473|Placebo Comparator|Placebo|Placebo administered SC every 30 days during an 8 week treatment period.
3111633|NCT02397564|Experimental|1|Enroll 20 patients for nonsurgical treatment of surgical scars. Half of each scar will be treated with the Er:YAG laser on the traditional ablative setting and the other half of the scar will receive Er:YAG treatment with the fractional ablative setting. The patients will receive 3 treatments at monthly intervals. They will follow up at 1 and 2 months after the treatment.
3111634|NCT02397694|Experimental|BIC + F/TAF|"Participants will receive BIC + F/TAF FDC + DTG placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
3111635|NCT02397694|Active Comparator|DTG + F/TAF|"Participants will receive DTG + F/TAF FDC + BIC placebo for 48 weeks.~Following Week 48, participants will continue to take their blinded treatment and attend visits every 12 weeks until treatment assignments have been unblinded. Participants will return for an unblinding visit and be given the option to participate in an open-label rollover extension and receive B/F/TAF until it becomes commercially available, or until Gilead Sciences elects to terminate the development of BIC/F/TAF."
3111636|NCT02397694|Experimental|Open Label Extension Phase|After Week 48 participants continued to take their randomized study drug and attended visits every 12 weeks until treatment assignments were unblinded, at which point all participants returned for an unblinding visit and were given the option to participate in an open-label rollover extension to receive an FDC containing B/F/TAF.
3111637|NCT02397707|Experimental|Moderate Hepatic Impaired|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
3111638|NCT02397707|Experimental|Severe Hepatic Impaired|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of voxilaprevir on Day 1.
3111639|NCT02397785|Experimental|ApexM Device|InControl Medical created a line of products FDA approved for urinary incontinence and fecal incontinence (10). These devices are non-implanted, customizable, battery-operated vaginal probes made of medical grade silicon and provide electrical stimulation to the pelvic floor. One of the devices, ApexM™ provides electrical stimulation at frequencies alternating between 13 Hz and 50 Hz and allows the clinician to adjust the intensity as well as the duration of the electrical stimulation. The investigators propose the use of low power electrical stimulation for the treatment of pain in patients diagnosed with CPP. The electrical stimulation is delivered using ApexM™, adjusting the power to a sensory threshold to prevent muscle contraction.
3111640|NCT02397785|Sham Comparator|Sham Device|"Subjects in the control arm will use a sham ApexM device. The original ApexM device will be modified to disable its electrical stimulation functionality. Otherwise, the devices are indistinguishable and possess identical dimensions. Although the sham device can be powered on, the circuitry will be disconnected so that electrical stimulation is disabled."
3111641|NCT02397837|Experimental|Pramipexole|Pramipexole, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
3111642|NCT02397837|Placebo Comparator|Placebo|Placebo, by mouth. Dosing will be initiated at 0.25 mg on night one, followed by 0.25 mg twice-a-day day two onward, and increased every week to a target of 4.5 mg/day for the 12-week duration of the study.
3111643|NCT02397889|Experimental|Experimental ketamine group|This arm will receive 0.5mg/kg repeated dose ketamine (6 infusions, 3 per week for 2 weeks).
3111644|NCT02397889|Active Comparator|Active control midazolam group|This arm will receive 0.045mg/kg repeated dose midazolam (6 infusions, 3 per week for 2 weeks).
3111645|NCT02397915|Experimental|Fluticasone Furoate|Subjects will receive a single dose of intranasal FF (total dose of 110 mcg) as 2 sprays per nostril / 4 sprays in total.
3111646|NCT02397915|Experimental|Mometasone Furoate|Subjects will receive a single dose of intranasal MF (total dose of 200 mcg) nasal spray as 2 sprays per nostril / 4 sprays in total.
3111647|NCT02397954|Experimental|Zimura + Anti-VEGF|Subjects will receive monthly intravitreous injections of Zimura in combination with either Lucentis, Avastin or Eylea.
3111648|NCT02398188|Experimental|LIPO-202|Experimental arm
3111649|NCT02398188|Placebo Comparator|Placebo|Placebo comparator
3111650|NCT02398227|Experimental|HOPE|Cognitive Behavioral Treatment Program for PTSD
3111651|NCT02398227|Active Comparator|PCT|Present Centered Therapy for PTSD
3111652|NCT02398409|Experimental|ANSWERS-VA|"8 week telephone intervention with nurse case manager using Acquiring New Skills While Enhancing Remaining Strengths (ANSWERS)"
3111653|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
3111654|NCT02399085|Experimental|Treatment (MOR00208, lenalidomide)|"MOR00208 Fc-Optimized Anti-CD19 Antibody, intravenous Infusion, weekly (Cycle 1-3) to bi-weekly (Cycle 4 onwards), 4 week cycles, until disease progression or unacceptable toxicity or discontinuation due to any other reason.~Lenalidomide (Revlimid®), PO, daily, 4 week cycles, lenalidomide is used 3 of the 4 weeks. Up to 12 cycles in the absence of disease progression or unacceptable toxicity."
3111655|NCT02399163|Experimental|Placebo dentifrice/Fluoride rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride
3111656|NCT02399163|Placebo Comparator|Placebo dentifrice/No rinse|Twice daily brushing with a non-fluoride (placebo) toothpaste
3111657|NCT02399163|Active Comparator|Fluoride dentifrice/No rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride
3111658|NCT02399163|Experimental|Fluoride dentifrice/Fluoride rinse|Twice daily brushing with a fluoride toothpaste containing 1150 ppm of fluoride as sodium fluoride, followed by once daily rinsing (post night time brushing) with a fluoride mouthwash containing 220 ppm of fluoride as sodium fluoride.
3111659|NCT02399228|Experimental|0.25% EISO Mouth Rinse|"A mouth rinse containing 0.25% East Indian sandalwood oil (EISO), a candidate botanical drug substance. The rinse will be used three times a day for up to ten weeks. The material will not be ingested but used to swish, gargle and spit."
3111660|NCT02399254||Pulmonary Rehabilitation|Chronic Obstructive Pulmonary Disease (COPD) patients following pulmonary rehabilitation
3111661|NCT02399345|Experimental|Ombitasvir/Paritaprevir/r, Dasabuvir, and SOF plus RBV|Ombitasvir/paritaprevir/ritonavir (ombitasvir/paritaprevir/r) (25 mg/150 mg/100 mg once daily) with dasabuvir (250 mg twice daily) and sofosbuvir (SOF) (400 mg once daily), plus weight-based ribavirin (RBV) (dosed 1,000 or 1,200 mg daily divided twice a day) for 6 weeks.
3111662|NCT02399475|Experimental|Levothyroxine First|Participants will start on the thyroid hormone Levothyroxine prior to crossing over to Liothyronine
3111663|NCT02399475|Experimental|Liothyronine First|Participants will start on the thyroid hormone Liothyronine prior to crossing over to Levothyroxine
3111664|NCT02399917|Experimental|Phase 1b Lead-in Cohort 1|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 1.0 mg/kg"
3111665|NCT02399917|Experimental|Phase 1b Lead-in Cohort 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
3111666|NCT02399917|Experimental|Phase 2|"Patients receive azacitidine SC or IV over 1 hour as determined by the treating physician on days 1-7 and lirilumab IV over 60 minutes on day 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~5-Azacitidine 75mg/m^2 Lirilumab 3.0 mg/kg"
3111667|NCT02400073|Experimental|AutoSet for Her PAP device|Patients in this study will use the AutoSet for Her: A new AutoSetting Positive Airway Pressure (PAP) device designed specifically to treat female OSA
3111668|NCT02400307|Experimental|Severe Renal Impairment|Participants with severe renal impairment and matched healthy controls will receive a single dose of bictegravir.
3111669|NCT02400307|Experimental|Moderate Renal Impairment|Participants with moderate renal impairment and matched healthy controls will receive a single dose of bictegravir.
3111670|NCT02400307|Experimental|Mild Renal Impairment|Participants with mild renal impairment and matched healthy controls will receive a single dose of bictegravir.
3111671|NCT02400333|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
3111672|NCT02400333|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
3111673|NCT02400333|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
3111674|NCT02400333|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
3111675|NCT02400346|Experimental|Adjunct brexpiprazole|All patients continue their current antidepressant treatment (ADT) and receive brexpiprazole in addition
3111676|NCT02400437|Experimental|IDR|"- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity~Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.~Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase~Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase~Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase"
3111677|NCT02400463|Experimental|Ruxolitinib|"Ruxolitinib 15 mg by mouth twice daily.~For patients unable to ingest tablets, ruxolitinib suspended in water may be administered through a nasogastric (NG) or percutaneous endoscopy gastrostomy (PEG) tube."
3111678|NCT02400580|Experimental|Intravenous IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
3111679|NCT02400580|Placebo Comparator|Normal Saline|The patients in the placebo arm will receive normal saline.
3111680|NCT02400710|Experimental|Clinician-Supported PTSD Coach|Four 20-minute sessions (2 in-person, 2 by phone) focused on instructions for use, setting symptom reductions goals, and assigning specific PTSD Coach activities (i.e., assessments, management strategies, psycho-educational readings) for the participant to complete on their own.
3111681|NCT02400710|Active Comparator|Self-Managed PTSD Coach|One in-person 10-minute session that provides instructions on how to use the PTSD Coach app.
3111682|NCT02400736|Experimental|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) competitive employment: IPS assists participants to enter into competitive jobs; 2) eligibility based on client choice, i.e. zero exclusion; 3) integration of IPS and treatment team, i.e. the PACT; 4) patient-centered job match for competitive employment; 5) personalized benefits counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) rapid job search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) job development: IPS specialists build an employer network based on Veterans' interests; 8) time-unlimited and individualized support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
3111683|NCT02400736|Active Comparator|Treatment as Usual Vocational Rehabilitation/Transitional Work (TAU-VR)|Treatment as Usual Vocational Rehabilitation includes pre-vocational counseling, Community Based Supported Employment, or most commonly Transitional Work assignments (TW) which involves 1) time-limited set-aside work experiences: short-term transitional work experiences in a brokered or set-aside work setting; 2) no strict entrance criteria other than general medical clearance; 3) limited integration of TW and clinical Services; 4) not patient-centered: TW jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) personalized benefits counseling; 6) limited job search: TW specialists provide variable and limited guidance for competitive job search; 7) no job development: TW specialists do not engage in community based job development; 8) time limited: The TW specialist does not provide long-term follow-up after the first job is obtained.
3111684|NCT02400749|Experimental|Apremilast|Patients will receive Apremilast until week 32.
3111685|NCT02400749|Placebo Comparator|Placebo followed by Apremilast|Patients will receive Placebo until week 16 and then receive Apremilast until week 32
3111686|NCT02400905|Experimental|BioMimics 3D Vascular Stent|Implantation of BioMimics 3D nitinol stent using the BioMimics 3D Vascular Stent System
3111687|NCT02400996||Pancreatic Endocrine Neoplasms|We did an observational analysis from a prospectively maintained database of patients who underwent pancreatic surgery for neoplasms of the pancreas at Sir Ganga Ram Hospital, New Delhi, India from 1995 to 2013 and using pathological reports and preoperative CT scan as gold standard, we identified 40 patients with PENs.
3111688|NCT02401022|Active Comparator|AZD8529 low dose|1.5 mg
3111689|NCT02401022|Active Comparator|AZD8529 high dose|40mg
3111690|NCT02401048|Experimental|Phase 1b/ 2: Follicular lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
3111691|NCT02401048|Experimental|Phase 1b/ 2: Diffuse large B-cell lymphoma expansion cohort|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 explored in cohort 1 and followed a 6+3 dose de-escalation design. Phase 2 used the phase 1b starting dose.
3111692|NCT02401230|Active Comparator|Rectal Gel Lubricant|Subjects will insert 5 mL of lubricant in rectum for seven consecutive days
3111693|NCT02401230|Active Comparator|Truvada|Subjects will take one Truvada tablet orally for seven consecutive days
3111694|NCT02401230|Active Comparator|Rectal Gel Lubricant + Truvada|Subjects will insert 5 mL of lubricant in rectum and take one Truvada tablet orally for seven consecutive days
3111695|NCT02401256|Experimental|CYP2B6|"This is a fixed-order, open label prospective cohort study to determine: a) the contribution of CYP2B6 autoinhibition/autoinduction processes to variable CYP2B6 activity and efavirenz exposure; b) the impact of CYP2B6 genetic variants on these processes; and c) drug interactions that ensue.~Included drugs:~Efavirenz (600mg) - The volunteers will receive it in two of three inpatient visits and also during 17 days at home~Bupropion (100mg), Montelukast (10mg) and Rosuvastatin (5mg) - These drugs will be administrated on 3 occasions (at the begging each inpatient visit of Phase 1, 2 and 4)."
3111696|NCT02401412|Other|Test Ostomy Barrier|The test product is a new Hollister ostomy barrier.
3111697|NCT02401412|Other|Control Ostomy Barrier|The control product is a currently marketed Hollister ostomy barrier.
3111698|NCT02401464|Experimental|Dry syrup formulation (Group a)|One pack of the dry syrup formulation of TAK-536, containing 10 milligram (mg) of TAK-536, will be orally administered with water (200 milliliter [mL]) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3111699|NCT02401464|Experimental|Dry syrup formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the dry syrup formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3111700|NCT02401464|Experimental|Granule formulation (Group a)|One pack of the granule formulation of TAK-536, containing 10 mg of TAK-536,will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3111701|NCT02401464|Experimental|Granule formulation (Group b)|One 10 mg tablet of TAK-536 will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 1 and, after a washout period of 6 days or more, one pack of the granule formulation of TAK-536, containing 10 mg of TAK-536, will be orally administered with water (200 mL) at breakfast to fasting participants who have fasted for 10 hours or longer since the night prior to the administration of study medication in Period 2.
3111702|NCT02401529|Experimental|IV dexamethasone and oral Prednisolone|Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
3111703|NCT02401529|Active Comparator|Placebo|Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
3111704|NCT02401542|Active Comparator|Vofatamab plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of vofatamab, 25 mg/kg, on day one of each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing with vofatamab and docetaxel will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor."
3111705|NCT02401542|Placebo Comparator|Placebo plus docetaxel|"IV infusion of docetaxel, 75 mg/m2, followed by IV infusion of placebo on day one of each 21-day cycle.~One additional IV infusion of placebo given on Day 8 of Cycle 1. Dosing of docetaxel and placebo will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination. Docetaxel treatment beyond 12 cycles of therapy may be considered at the discretion of the treating investigator and Medical Monitor"
3111706|NCT02401542|Experimental|Vofatamab|"IV infusion vofatamab, 25 mg/kg on day one each 21-day cycle. One additional IV infusion of vofatamab (25 mg/kg) given on Day 8 of Cycle 1.~Dosing of vofatamab will continue in each patient until disease progression, unacceptable toxicity, death, or study exit, including withdrawal of patient consent or study termination."
3111707|NCT02401555||Known HIV1 positives|Individuals known to the HIV1 positive tested with Geenius HIV1/2 Supplemental Assay
3111708|NCT02401555||Known AIDS|Individuals known to meet diagnostic criteria for AIDS tested with Geenius HIV1/2 Supplemental Assay
3111709|NCT02401555||Low risk (negatives)|Individuals at low risk for HIV infection tested with Geenius HIV1/2 Supplemental Assay
3111710|NCT02401672|Active Comparator|Active TMS|Repetitive TMS pulse stimulation
3111711|NCT02401672|Sham Comparator|Sham TMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
3111712|NCT02402062|Experimental|TH-302 + Sunitinib|TH-302 + Sunitinib. Single arm Study.
3111713|NCT02402127|Other|TruEye, MyDay, clariti 1day|Narafilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally (in both eyes) for 1 day (16 hours).
3111714|NCT02402127|Other|TruEye, clariti 1day, MyDay|Narafilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3111715|NCT02402127|Other|MyDay, TruEye, clariti 1day|Stenfilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and somofilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3111716|NCT02402127|Other|MyDay, clariti 1day, TruEye|Stenfilcon A contact lenses in Period 1, followed by somofilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3111717|NCT02402127|Other|Clariti 1day, TruEye, MyDay|Somofilcon A contact lenses in Period 1, followed by narafilcon A contact lenses in Period 2 and stenfilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3111718|NCT02402127|Other|Clariti 1day, MyDay, TruEye|Somofilcon A contact lenses in Period 1, followed by stenfilcon A contact lenses in Period 2 and narafilcon A contact lenses in Period 3. Each product worn bilaterally for 1 day (16 hours).
3111719|NCT02402153|Other|Sydvestjysk Hospital|Investigation of EEG recording with the Hyposafe device
3111720|NCT02402166|Experimental|Single Arm|There are 4 periods in this study: 1)screening and washout; 2) Dose Optimization; 3) Dose Maintenance; 4) Safety Follow-up. SPD489 will be used to treat all subjects.
3111721|NCT02402218|Active Comparator|Usual Care|Participants receive standard of care for Hepatitis C in the clinic.
3111722|NCT02402218|Experimental|Usual care plus peer-mentors|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be asked to interact with a peer-mentor who is someone who has been cured of their HCV infection.
3111723|NCT02402218|Experimental|Usual care plus incentives|In addition to receiving standard of care for HCV in the clinic, this is an investigational strategy in which participants assigned to this group will be given incentives after completing certain goals during the course of the study.
3111724|NCT02402296|Active Comparator|Group II (test group)|Included those patients who received a systemic β-1,3/1,6-D-glucan (100 mg capsule) once/ day for 40 days after scaling and root planing.
3111725|NCT02402296|Placebo Comparator|Group I (control group)|Was assigned for patients who had scaling and root planing and empty capsules filled with carbohydrates (placebo) for 40 days.
3111726|NCT02402322|Active Comparator|Non-scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone when they required it.
3111727|NCT02402322|Experimental|Scheduled support|Participants received an Web-based cognitive behavioral treatment for Panic Disorder with the support of a therapist via phone weekly.
3111728|NCT02402322|No Intervention|Waiting list|Participants in a waiting list.
3111729|NCT02402452|Experimental|Normal Renal Function|Participants will receive a single dose of voxilaprevir on Day 1.
3111730|NCT02402452|Experimental|Severe Renal Impairment|Participants will receive a single dose of voxilaprevir on Day 1.
3111731|NCT02402764|Experimental|Selinexor Treatment|"Screening period (which may last up to 28 days), followed by Selinexor treatment for qualified participants.~During the treatment period, participants will undergo physical examination every 2 weeks until Cycle 6 Day 1 (C6D1), and then every 4 weeks and assessment of tumor response every 8 weeks.~Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo a final visit (end of treatment visit)."
3111732|NCT02402881|Experimental|Intervention|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
3111733|NCT02402881|No Intervention|Control|Patients will receive only the standard practices of care
3111734|NCT02402907|Experimental|CHG cloth|2% chlorhexidine gluconate (CHG) cloth
3111735|NCT02402907|Placebo Comparator|Placebo cloth|A fragrance free cleansing cloth
3111736|NCT02402933|Experimental|Nasal Glucagon|A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.
3111737|NCT02403180|Other|DACP MF, then PROCLEAR 1D MF|DACP MF (nelfilcon A) multifocal contact lenses worn in Period 1, followed by PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
3111738|NCT02403180|Other|PROCLEAR 1D MF, then DACP MF|PROCLEAR 1D MF (omafilcon A) multifocal contact lenses worn in Period 1, followed by DACP MF (nelfilcon A) multifocal contact lenses worn in Period 2. Both products were worn bilaterally (in both eyes) for 5 ±1 days in a daily wear, daily disposable modality.
3111739|NCT02403206|Experimental|Laser|Femtosecond laser assisted capsulotomy and corneal incision performed during cataract surgery
3111740|NCT02403206|Active Comparator|Manual|Continuous curvilinear capsulorhexis performed during cataract surgery
3111741|NCT02403271|Experimental|Phase 1b|In the Phase 1b (safety portion) of the study, a starting dose of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 will be explored and will follow a 6+3 dose de-escalation design and will include a sentinel participant which will have a 3-day observation period prior to dosing of subsequent participants. Participants with one of the following three tumor types will be eligible for enrollment: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma).
3111742|NCT02403271|Experimental|Phase 2|Participants with one of three solid tumor types (Stage III/IV) will be enrolled in the Phase 2 portion of this protocol: NSCLC (adenocarcinoma and squamous-cell carcinoma), Breast cancer (triple-negative and HER2-positive cancer), and Pancreatic cancer (adenocarcinoma) and treated at the R2PD of ibrutinib and durvalumab determined in Phase 1b. An interim analysis will be performed to evaluate the response and the safety profile, and the study may be discontinued based on the interim efficacy and/or safety results.
3111743|NCT02403479|Experimental|Saline then Silver Colloid|Each participant uses 6 weeks of Saline first (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of silver colloid (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks)
3111744|NCT02403479|Experimental|Silver Colloid then Saline|Each participant uses 6 weeks of Silver Colloid first (Dose= 6.7mcg silver daily; Frequency= 2 sprays twice daily; Route= Topical intra-nasal spray; Duration= 6 weeks) followed by 6 weeks of saline (Frequency= 2 sprays twice daily; Route= topical intra-nasal spray; Duration= 6 weeks).
3111745|NCT02403622|Experimental|Intervention: Fecal Microbiota Preparation|"Open label single arm Dosage form: Screened human donor stool, sourced from human-derived microbes generated by healthy, screened donors.~Route of administration: either colonoscopic/sigmoidoscopic FMT or retention enema FMT Dosing Regimen: 250 mL x 1 dose. In the event of a clinical non-response, a repeat single 250 mL dose will occur from a different donor"
3111746|NCT02403635|Other|Midazolam + ASP2151|400 mg ASP2151 followed by 7.5 mg midazolam
3111747|NCT02403674|Experimental|Doravirine, Tenofovir, Lamivudine|Treatment-naive HIV-infected participants will receive doravirine, tenofovir, lamivudine, a single-tablet FDC containing doravirine 100 mg + lamivudine 300 mg + tenofovir disoproxil fumarate 300 mg, q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to ATRIPLA™ q.d. by mouth for 96 weeks in order to maintain blinding.
3111748|NCT02403674|Active Comparator|ATRIPLA™|Treatment-naive HIV-infected participants will receive ATRIPLA™, a single-tablet FDC containing efavirenz 600 mg + emtricitabine 200 mg + tenofovir disoproxil fumarate 300 mg (equivalent to 245 mg tenofovir disoproxil), q.d. by mouth for 96 weeks. Participants will also take 1 placebo tablet matched to doravirine, tenofovir, lamivudine q.d. by mouth for 96 weeks in order to maintain blinding.
3111749|NCT02403778|Active Comparator|Ipilimumab|Arm A (No VESANOIDTherapy) will receive the standard of care treatment with ipilimumab only, receiving the standard 4 doses of either 3 or 10 mg/kg ipilimumab every 3 weeks.
3111750|NCT02403778|Experimental|VESANOID|Arm B (VESANOID Therapy) will receive the standard 4 doses of either 3 or 10 mg/kg ipilimumab every three weeks plus the supplemental treatment of 150 mg/m2 of VESANOID orally for 3 days surrounding each dose of ipilimumab (day -1, day 0, day +1) for a total of 12 days of VESANOID treatment.
3111751|NCT02403817|Experimental|Eye Movement Game Control|Cognitive Training Eye Motor Training
3111752|NCT02403817|Active Comparator|Hand Movement Game Control|Cognitive Training Hand Motor Training
3111753|NCT02403830|Experimental|Methylnaltrexone|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
3111754|NCT02403830|Placebo Comparator|Placebo|Patients will be randomly assigned in a 1:1 fashion to receive either i.v methylnaltrexone or placebo (0.9% sodium chloride iv injection). Methylnaltrexone, at a dose of 0.3 mg/Kg, will be administered diluted with 5 ml of normal saline as a single i.v. bolus over 1 minute followed by morphine (5-mg intravenous bolus). Then patients will receive iv morphine and a loading dose of ticagrelor.
3111755|NCT02403895|Experimental|Open-label AZD2014|Open-label AZD2014 given twice daily 3 days on, 4 days off during weekly paclitaxel
3111756|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (three)|Treatment with three initial sessions
3111757|NCT02403986|Experimental|R. Vital Skinboosters Lidocaine (two)|Treatment with two initial sessions
3111758|NCT02403999|Experimental|Test shampoo|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3111759|NCT02403999|Experimental|Test bath foam|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3111760|NCT02403999|Experimental|Test head to toe Wash|Participants' will be instructed to use the test product as per the label instructions for a minimum of twice per week for 2 weeks.
3111761|NCT02404025|Experimental|Eltrombopag+rabbit ATG/CsA arm|Subjects received rabbit ATG diluted by 500 mL of saline or 5% glucose injection at a dose of 2.5 to 3.75 mg per kilogram (kg) per day for 5 days as a slow intravenous infusion over 6 hours. CsA was administered at a dose of 3 mg per kg twice a day from day 0. The dose level was adjusted based on the monitoring of blood level or renal function. Eltrombopag was initiated on day 14 and it could be delayed up to 2 weeks if the subject had infection, serum sickness, or other adverse events. Eltrombopag wasadministered orally once a day at fasting at an initial dose of 75 mg, and the dose adjusted every 2 weeks according to the platelet count. Eltrombopag and CsA were continued until Week 26.After Week 26, eligible subjects received eltrombopag; and CsA was tapered or maintained as per the investigator's discretion.
3111762|NCT02404103|Active Comparator|Flunisolide 160 mcg per day|Patients will receive inhaled Flunisolide HFA 80 mcg twice per day for a total of 160 mcg per day over the 6 week study period
3111763|NCT02404103|Active Comparator|Flunisolide 320 mcg per day|Patients will receive inhaled Flunisolide HFA 160 mcg twice per day for a total of 320 mcg per day over the 6 week study period
3111764|NCT02404168|Active Comparator|lamotrigine brand tablet1|lamotrigine tablet Lamictal
3111765|NCT02404168|Experimental|lamotrigine generic tablet1|lamotrigine tablet Teva
3111766|NCT02404168|Active Comparator|lamotrigine brand tablet2|lamotrigine tablet Lamictal
3111767|NCT02404168|Experimental|lamotrigine generic tablet2|lamotrigine tablet Teva
3111768|NCT02404220|Experimental|ENTO 200 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): Entospletinib (ENTO) 200 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 200 mg twice daily continuously in combination with vincristine (VCR) 0.5 mg intravenously (IV) on Days 1, 8, 15, and 22 of each cycle; dexamethasone (DEX) 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and central nervous system (CNS) prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a complete remission (CR) received stem cell transplant (SCT) (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a partial response [PR]) after induction were offered maintenance therapy with ENTO 200 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
3132675|NCT03444090|Experimental|Insertion/withdrawal colon polypectomy|For participants assigned in the experimental group, the colon is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both insertion and withdrawal phases.Colon polypectomy for polyp size <10 mm will be performed when they are identified during insertion and withdrawal of the colonoscope. Colon polypectomy for polyp size >10 mm will be performed only during withdrawal of the scope.
3111769|NCT02404220|Experimental|ENTO 400 mg + VCR 0.5 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 0.5 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
3111770|NCT02404220|Experimental|ENTO 400 mg + VCR 1.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 1.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
3111771|NCT02404220|Experimental|ENTO 400 mg + VCR 2.0 mg|"Monotherapy Lead-In (Day -7 to Day -1): ENTO 400 mg tablet orally twice daily as a single agent.~Induction (two 28-day cycles): ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg IV on Days 1, 8, 15, and 22 of each cycle; DEX 20 mg twice daily orally on Days 8-11 and Days 22-25 (Cycle 1) and on Days 1-4 and Days 15-18 (Cycle 2); and CNS prophylaxis per institutional standards on Day 28 of each cycle.~Maintenance (up to 36, 28-day cycles): Participants who achieved a CR received SCT (if eligible) per investigator's discretion; others who obtained clinical benefit (ie, at least a PR) after induction were offered maintenance therapy with ENTO 400 mg twice daily continuously in combination with VCR 2.0 mg on Day 1 of each cycle and DEX (20 mg daily or 10 mg twice daily) on Days 1-4 and Days 15-18 of each cycle."
3111772|NCT02404285|Placebo Comparator|Vehicle|"Subjects will be treated with once daily vehicle and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
3111773|NCT02404285|Active Comparator|NAG (Next Science Acne Gel)|"Subjects will be treated with once daily NAG and will attend screening, randomization, 2,4,8 and 12 week visits. The following will be assessed:~Lesions will be counted and right, left and forward facing photographs will be taken~Investigator Global Assessment~Acne Quality of Life Questionnaire~Treatment Area Assessment by Investigator"
3111774|NCT02404311|Active Comparator|Part A, Group 1: Vaccine|ALVAC-HIV at months 0 and 1, and ALVAC-HIV + bivalent subtype C gp120/MF59 at months 3, 6, and 12
3111775|NCT02404311|Placebo Comparator|Part A, Group 2: Placebo|Placebo for ALVAC-HIV at months 0 and 1, and placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at months 3, 6, and 12
3111776|NCT02404311|Active Comparator|Part B, Group 1a: Vaccine|Participants originally in Part A Group 1 (Vaccine) receive ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
3111777|NCT02404311|Active Comparator|Part B, Group 1b: Vaccine + Placebo|Participants originally in Part A Group 1 (Vaccine) receive placebo for ALVAC-HIV + bivalent subtype C gp120/MF59 at month 30
3111778|NCT02404311|Placebo Comparator|Part B, Group 2: Placebo|Participants originally in Part A Group 2 (Placebo) receive placebo for ALVAC-HIV + placebo for bivalent subtype C gp120/MF59 at month 30
3111779|NCT02404350|Experimental|Secukinumab 150 mg load (Group 1)|"Secukinumab 150 mg sc injection every week for 4 weeks followed by Secukinumab 150 mg every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks until week 100"
3111780|NCT02404350|Experimental|Secukinumab 150 mg no load (Group 2)|"Secukinumab 150 mg sc injection every 4 weeks until week 100~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
3111781|NCT02404350|Experimental|Secukinumab 300 mg load (Group 3)|Secukinumab 300 mg sc injection every week for 4 weeks followed by Secukinumab 300 mg every 4 weeks until week 100
3111782|NCT02404350|Placebo Comparator|Placebo arm 1 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders will be switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
3111783|NCT02404350|Placebo Comparator|Placebo arm 2 (Group 4)|"Placebo to Secukinumab sc injection every week for 4 weeks followed by placebo to Secukinumab every 4 weeks until week 16. Non-responders were switched to Secukinumab either 150 or 300 mg sc injection every four weeks until week 100. Responders at week 16 continued receiving placebo until week 24, then were switched to secukinumab 150 or 300 mg sc injection every 4 weeks until week 100. PLEASE NOTE: Placebo arms 1 and 2 belong to the same placebo group (group 4)~Beginning at Week 52, for subjects whose signs and symptoms were not fully controlled, and who the investigator believed may improve further with an increase in dose, may have had the secukinumab dose increased to 300mg s.c. every 4 weeks."
3111784|NCT02404389|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications
3111785|NCT02404389|Experimental|LFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications
3111786|NCT02404389|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications
3111787|NCT02404389|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications
3111788|NCT02404389|Active Comparator|Aldara|Aldara cream 3 applications per week
3111789|NCT02404441|Other|patients with solid tumors|Phase I Dose escalation cohorts
3111790|NCT02404441|Other|Selected tumor types|Phase II expansion: Selected tumor types: melanoma, NSCLC, triple negative breast cancer, anaplastic thyroid cancer
3111791|NCT02404493|Active Comparator|EpiCeram Skin Barrier Emulsion|Marketed. Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin.
3111792|NCT02404493|Experimental|1% Colloidal Oatmeal Balm|Not Yet Marketed. Apply in a thin layer to the affected skin areas at least once at night or more if needed (anytime), and massage gently into the skin.
3111793|NCT02404532|Experimental|1|
3111794|NCT02404610|Experimental|Moderate Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of moderate sedation. Moderate procedural sedation is a specific term referring to procedural sedation with a target depth of moderate.
3111795|NCT02404610|Experimental|Deep Procedural Sedation|Subjects will undergo procedural sedation for an indicated urgent medical procedure with a target sedation level of deep sedation. Deep procedural sedation is a specific term referring to procedural sedation with a target depth of deep.
3111796|NCT02404649|Active Comparator|Bone Augmention|Two implant designs in a Sinus Bone Augmentation Procedure. Sinus bone augmentation with Puros Cortico-Cancellous Particulate Allograft (70% Cortico and 30% Cancelleous) (Zimmer Dental- Carlsbad, CA, USA)- one implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the initial insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
3111797|NCT02404649|Active Comparator|Sinus elevation only|Two implant designs in a Sinus Floor Elevation Procedure. Placement of two dental implants as mentioned above in sinus bone augmentation by sinus elevation procedure, blood clot and CopiOs Pericardium Membrane (Zimmer Dental- Carlsbad, CA, USA) only. One implant will be TMDI (Zimmer Dental- Carlsbad, CA, USA) and the second will be Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA). Implant stability will be determined by the insertion torque and RFV values at time of implant placement and after 1 month of healing on a monthly basis up until 12 months post implant placement.
3111798|NCT02404792|Active Comparator|HIV-uninfected|HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
3111799|NCT02404792|Experimental|HIV-infected|HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.
3111800|NCT02404805|Experimental|Sequence 1a|Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.
3111801|NCT02404805|Experimental|Sequence 1b|Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.
3111802|NCT02404805|Experimental|Sequence 2a|Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.
3111803|NCT02404805|Experimental|Sequence 2b|Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.
3111804|NCT02404805|Experimental|Sequence 3a|Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.
3111805|NCT02404805|Experimental|Sequence 3b|Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.
3111806|NCT02405091|Experimental|Dose Group 1|Fixed dose of NBI-98854 administered once daily for 48 weeks
3111807|NCT02405091|Experimental|Dose Group 2|Fixed dose of NBI-98854 administered once daily up to 48 weeks
3111808|NCT02405325|Experimental|Physical Activity|The program will be run by peer Leaders and senior center staff with the support of UCSD staff. Participants will work towards a 2000 increase in daily steps through self-paced incidental walking and peer led group walks.
3111809|NCT02405325|No Intervention|Usual Care|Measurement at baseline, 6, 12, 18 and 24 months only with a health related event at each time point.
3111810|NCT02405390|Experimental|Video Laryngoscopy|Some patients will be intubated with a video laryngoscope 'Storz C-Mac® laryngoscope'
3111811|NCT02405390|Active Comparator|Direct Laryngoscopy|Some patients will be intubated with a direct (conventional) laryngoscope
3111812|NCT02405442|Experimental|Andecaliximab 150 mg Every 2 Weeks|Double-Blind Phase: Participants will receive 1 single-use prefilled syringe (PFS) of andecaliximab 150 mg and matching placebo coadministered at Weeks 0, 2, 4, and 6 and 2 single-use PFS of placebo coadministered at Weeks 1, 3, 5, and 7. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
3111813|NCT02405442|Experimental|Andecaliximab 150 mg Weekly|Double-Blind Phase: Participants will receive 1 single-use PFS of andecaliximab 150 mg and matching placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
3111814|NCT02405442|Experimental|Andecaliximab 300 mg Weekly|Double-Blind Phase: Participants will receive 2 single-use PFS of andecaliximab 150 mg coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for an additional 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
3132676|NCT03444090|Active Comparator|Withdrawal colon polypectomy|For participants assigned in the control group, deliberate mucosa inspection and colon polypectomy will be performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum.
3111815|NCT02405442|Placebo Comparator|Placebo|Double-Blind Phase: Participants will receive 2 single-use PFS of placebo coadministered weekly for 8 weeks. Open-Label Phase: Participants will be eligible to enroll in the Open-Label Phase to receive andecaliximab 150 mg weekly for 44 weeks. Extended Treatment Phase: Participants who complete Week 52 assessments will be eligible to enter into the Extended Treatment Phase to continue treatment with andecaliximab 150 mg for an additional 156 weeks.
3111816|NCT02405780|Experimental|FKB327|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
3111817|NCT02405780|Active Comparator|Humira®|Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
3111818|NCT02405962|Placebo Comparator|Control group|Parents of children with asthma will receive one session of asthma educational talk as the usual care, plus three weekly sessions of telephone calls to assess the child's asthma symptoms
3111819|NCT02405962|Experimental|ACT group|Parents of children with asthma will receive four sessions of group-based ACT intervention integrated with asthma education (its content will be the same as that of the Control Group).
3111820|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 10 mg|Participants will continue with their current treatment regimen (10 milligram [mg] of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 10 milligram (mg) of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3111821|NCT02406027|Experimental|Double-blind Treatment Phase: JNJ-54861911, 25 mg|Participants will continue with their current treatment regimen (25 mg of JNJ-54861911) established in the parent study of JNJ-54861911. Participants will receive 25 mg of JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3111822|NCT02406027|Placebo Comparator|Double-blind Treatment Phase: Placebo|Participants will continue with their current treatment regimen established in the parent study of JNJ-54861911. Participants will receive placebo matching to JNJ-54861911 orally, once daily from Day 1 up Week 52 in the DB treatment phase.
3111823|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 5 mg|Participants who were receiving JNJ-54861911, 10 mg and placebo in the DB treatment phase, will receive the 5 mg JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in Open-label phase.
3111824|NCT02406027|Active Comparator|Open-label Phase: JNJ-54861911, 25 mg|Participants who were receiving JNJ-54861911, 25 mg in the DB treatment phase, will continue to receive the same regimen in open-label treatment phase. Participants who were receiving placebo in the DB treatment phase will be randomly assigned to receive 25 mg of JNJ-54861911 once daily up to end of treatment visit (until registration of JNJ-54861911 or any safety issue) in the open-label treatment phase.
3111825|NCT02406248|Experimental|single arm|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
3111826|NCT02406261|Experimental|Cohort A|"500 microgram (mcg) midazolam, single oral dose on Days 1, 17, and 35;~20 mg simvastatin, single oral dose on Days 2 and 36;~250 microgram (mcg) midazolam, intravenous (IV) on Days 3 and 37;~50 mg lanabecestat, single oral dose on Day 4;~50 mg lanabecestat, single oral dose, Days 10 to 37"
3111827|NCT02406261|Experimental|Cohort B|"5 mg donepezil, single oral dose on Day 1, Period 1;~50 mg lanabecestat, single oral dose Days 1 to 43, Period 2;~5 mg donepezil, single oral dose on Day 28, Period 2"
3111828|NCT02406443|Experimental|Experimental arm|sitagliptin (DPP-4 inhibitor) oral tablet (100 mg); Januvia; administered once daily for 28 days
3111829|NCT02406443|Placebo Comparator|Placebo arm|placebo (no medicinal ingredients) oral tablet (100 mg); administered once daily for 28 days
3111830|NCT02406495|Experimental|filcon IV 1 and ocufilcon D|Habitual wearers of filcon IV 1 sphere lenses refitted with asphere ocufilcon D lenses.
3111831|NCT02406573|Experimental|Crest® Sensi-Stop™ Strips|Professionally Applied
3111832|NCT02406586|Experimental|Salsalate|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one salsalate 750 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two salsalate 750 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3111833|NCT02406586|Experimental|Carvedilol|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one carvedilol 3.125 mg tablet twice daily for two weeks. If the subject has no side effects, the dose will be increased to two carvedilol 3.125 mg tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3111834|NCT02406586|Placebo Comparator|Placebo|Obese, normotensive, healthy subjects will receive an intravenous (IV) administration of Intralipid 20% for 24 hours, and then one placebo tablet twice daily for two weeks. The dose will be increased to two placebo tablets twice daily for the remaining four weeks. The subjects will then receive another 24-hour IV administration of Intralipid 20% at the 6-week point.
3111835|NCT02406612|Experimental|X-Seal 6F Vascular Closure Device|The X-Seal 6F Vascular Closure device will be used to achieve hemostasis in both diagnostic and interventional procedures using up to a 6F procedure sheath.
3111836|NCT02406651|Experimental|F-652 and systemic coritcosteroids|Subjects will be dosed once a week for four weeks with Recombinant Human Interleukin-22 IgG2-Fc (F-652). Dosing will be concurrent with systemic corticosteroids.
3111837|NCT02406677|Experimental|Copayment Intervention Arm|Sites in the intervention arm will provide patients with a study voucher card to offset any patient copayments or medication card for the filling of any prescriptions of clopidogrel or ticagrelor.
3111838|NCT02406677|No Intervention|Usual Care Arm|For hospitals randomized to the control arm, all patients receive usual care and no study intervention is performed.
3111839|NCT02406742|Experimental|CC-122 Single Agent|An intrasubject dose escalation design was selected to determine the safety of single agent CC-122 (Arm A) in order to reach an optimal, clinically active dose and to mitigate the risk of early tumor flare reactions, based on earlier experience with lenalidomide monotherapy in CLL.
3111840|NCT02406742|Experimental|CC-122 in combination with ibrutinib|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and ibrutinib to determine the NTD, MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee. The RP2D of the combination may be evaluated in ibrutinib-naïve and high-risk CLL patients in the dose expansion phase to continue to evalute safety and efficacy.
3111841|NCT02406742|Experimental|CC-122 in combination with obinutuzumab|Ascending fixed dose cohorts evaluated in a 3 + 3 dose-finding design will be used to determine the safety and tolerability of the combination of CC-122 and obinutuzumab to determine the , MTD, and Recommended Phase 2 Dose (RP2D). An intrasubject dose escalation cohort may also be evaluated at the discretion of the Safety Review Committee.. The RP2D of the combination may be evaluated in CLL patients who failed a B-cell receptor pathway inhibitor or venetoclax in the dose expansion phase to continue to evalute safety and efficacy.
3111842|NCT02406859|Experimental|Anorectal Manometry|Part 1 [Anorectal Manometry]: Fifty SCI subjects and 15 AB subjects will undergo anorectal manometry and a baseline assessment of level of constipation or frequency of fecal incontinence (FI). Additional 10 able-bodied subjects will be enrolled to serve as controls. The 10 Question Bowel Survey and Incontinence Scale will be administered.
3111843|NCT02406859|Experimental|Bowel Biofeedback Training|Part 2 [Bowel Biofeedback]: A subgroup of 20 subjects who participated in the first arm of the study (Anorectal Motility) and report either constipation or fecal incontinence will be asked to participate in 12 weeks of twice weekly, biofeedback training. The biofeedback training will consist of in-lab exercises that are paired with a visual feedback. Anorectal manometry and bowel surveys will be repeated after the training session to assess the effects of bowel biofeedback on anorectal function.
3111844|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in VSG|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing vertical sleeve gastrectomy
3111845|NCT02406885|Active Comparator|APB study: Apixaban Pharmacokinetics in RYGB|To determine the durability or change in pharmacokinetics and pharmacodynamics of apixaban in patients with a body mass index (BMI) of 35 kg/m2 or greater pre vs. post surgery for patients undergoing Roux-en Y gastric bypass.
3111846|NCT02406937|Experimental|Feihe New Formula|Oral intake of Feihe new formula with hydrolyzed protein supplied by Arla Foods Ingredients.
3111847|NCT02406937|Active Comparator|Feihe Stage 1 Formula|Oral intake of Feihe stage 1 formula
3111848|NCT02406937|Placebo Comparator|Breast Feeding|Oral intake of breast milk
3111849|NCT02407041|Experimental|GR-MD-02|active arm
3111850|NCT02407054|Experimental|Part A: 200 mg LY3023414 BID + 160 mg of Enzalutamide QD|Participants received 200 milligrams (mg) LY3023414 orally twice daily (BID) during the initial week to assess pharmacokinetics (PK). Thereafter, participants received 200 mg of LY3023414 BID in combination with 160 mg of enzalutamide QD beginning Cycle 1 Day 1. A treatment cycle was defined as 28 days.
3111851|NCT02407054|Experimental|Part B: 200 mg LY3023414 BID + 160 mg Enzalutamide QD|Participants received 200 mg LY3023414 orally BID in combination with 160 mg enzalutamide orally once daily (QD).
3111852|NCT02407054|Active Comparator|Part B: Placebo + 160 mg Enzalutamide QD|Participants received placebo in combination with 160 mg enzalutamide QD.
3111853|NCT02407132|Active Comparator|Standard DSME|Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
3111854|NCT02407132|Experimental|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
3111855|NCT02407223|Placebo Comparator|Group 1: Placebo|Participants will receive placebo subcutaneously (SC) at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 milligram (mg) SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88. NOTE: Intervention Description should have no more than 800 characters.
3111856|NCT02407223|Experimental|Group 2: Ustekinumab 45 milligram (mg)|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
3111857|NCT02407223|Experimental|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
3111858|NCT02407236|Placebo Comparator|Induction Study - Placebo Intravenous (IV)|Participants will be randomized to receive single dose of placebo as Intravenous (IV: into the vein) infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study, but will not be randomized.
3111859|NCT02407236|Experimental|Induction Study - Ustekinumab 130 milligram (mg) IV|Participants will be randomized to receive single dose of ustekinumab 130 mg as IV infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
3111860|NCT02407236|Experimental|Induction Study - Ustekinumab 6 mg/kg IV|Participants will be randomized to receive ustekinumab approximating 6 mg/kg of body weight, as intravenous infusion at Week 0. Participants with clinical response at Week 8 will be eligible to enter the Maintenance study and will be randomized.
3111861|NCT02407236|Other|Induction Study- Placebo- Nonresponsders at Week 8|Participants without clinical response to placebo at Week 8 will receive a single IV infusion of ustekinumab approximating 6mg/kg along with matching subcutaneous (SC) placebo (to maintain the blind). Participants in clinical response at Week 16 will be eligible to enter Maintenance study and will be randomized.
3111862|NCT02407236|Other|Induction study-Ustekinumab Nonresponders at Week 8|Participants without clinical response to ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 will receive a single dose of ustekinumab 90 mg subcutaneously along with matching placebo intravenously (to maintain the blind). Participants in clinical response at Week 16 (that is, delayed responders) will be eligible to enter Maintenance study, but will not be randomized.
3111863|NCT02407236|Placebo Comparator|Maintenance Study - Placebo Subcutaneous (SC)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.
3111864|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 12 weeks|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 12 weeks, beginning Week 0 of Maintenance study through Week 44.
3111865|NCT02407236|Experimental|Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w)|Participants in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab will be randomized to receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44.
3111866|NCT02407236|Other|Maintenance Study - Placebo IV - Responder - Placebo SC|Participants in clinical response to Induction treatment with IV Placebo will receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
3111867|NCT02407236|Other|Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w|Participants without clinical response to induction treatment ustekinumab (130 mg or 6 mg/kg [IV]) at Week 8 but in clinical response at Week 16 after receiving Induction Ustekinumab at week 8 (delayed responders) will receive ustekinumab 90 mg subcutaneously every 8 weeks, beginning Week 0 of Maintenance study through Week 44. Participants are not randomized.
3111868|NCT02407457|Active Comparator|AFX EVAR AAA Graft System|Subjects randomized to receive the Endologix AFX Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
3111869|NCT02407457|Active Comparator|FDA Approved EVAR AAA Graft Systems|Subjects randomized to receive the comparator AAA Endovascular Graft System for implantation to repair Abdominal Aortic Aneurysm via femoral access.
3111870|NCT02407704|Experimental|Aerobic Exercise + Venlafaxine XR|"Venlafaxine (Effexor) Extended-Release (XR) comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Exercise will include walking on a treadmill 1 hour 3 times/week for 12 weeks. Heart rate will be closely monitored during sessions. The intensity of the exercise will start at 50% of the age-based maximum for the first week and then increase and be maintained at 60-70% of the age-based maximum for the remainder of the intervention.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
3111871|NCT02407704|Active Comparator|Venlafaxine XR Only|"Venlafaxine (Effexor) XR comes in capsule form and is taken by mouth. Target dose will be 150mg/d, with a maximum dose of 300mg/d (response dependent) for a minimum of 12 weeks.~Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. This will be administered in pill form (2mg or less per 24 hours)."
3111872|NCT02407756|Experimental|Cohort 1|Cohort 1 will receive dupilumab dosing regimen 1
3111873|NCT02407756|Experimental|Cohort 2|Cohort 2 will receive dupilumab dosing regimen 2
3111874|NCT02407990|Experimental|BGB-A317 Phase 1A|
3111875|NCT02407990|Experimental|BGB-A317 Phase 1B|
3111876|NCT02408016|Experimental|Arm I, Stage I (T lymphocytes, cyclophosphamide, IL-2)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on days 0 and 14, cyclophosphamide IV on days 11 and 12, and aldesleukin SC BID for 14 days. Patients who have received radiation to the chest/lung tissue may receive gene-transduced T lymphocytes 90 days after completion of radiation.
3111877|NCT02408016|Experimental|Arm I, Stage II (T lymphocytes, cyclophosphamide, IL-2)|Patients receive cyclophosphamide IV on days -3 and -2, autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV on day 0, and aldesleukin SC BID for 14 days.
3111878|NCT02408016|Experimental|Arm II (T lymphocytes, IL-2, surgery)|Patients receive autologous WT1-TCRc4 gene-transduced CD8-positive Tcm/Tn lymphocytes IV between 24-96 hours after the last dose of chemotherapy and receive aldesleukin SC BID for 14 days. Patients then undergo surgery within 3-4 weeks after the T-cell infusion.
3111879|NCT02408068|Active Comparator|Chronocort : fed|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and receive a high fat, high calorie breakfast on the morning of Day 1. Thirty minutes after the start of the breakfast they will receive 20mg of modified release hydrocortisone with 200 millilitres of water, and no further food for 4 hours, water will be allowed from 1 hour after the food. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken starting prior to the dose and then over 24 hours (29 samples).
3111880|NCT02408068|Active Comparator|Immediate release hydrocortisone: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg immediate release hydrocortisone with 200 millilitres of water on the morning of Day 1. Water will be allowed 1hr after the study drug, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00 and 18:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
3111881|NCT02408068|Active Comparator|Chronocort: fasted|Volunteers will be admitted, take dexamethasone at 22.00hrs, fast overnight, and take 20mg modified release hydrocortisone with 200millilitres of water on the morning of Day 1. Water will be allowed 1hr after the dose, but no food for at least 4hrs post dose. Further dexamethasone doses will be given at 06:00, 12:00, 18:00 and 22:00 hours on Day 1. One baseline pharmacokinetics (PK) sample will be taken prior to the dose, and then afterwards for over a 12 hour period (16 samples)
3111882|NCT02408120|Active Comparator|Insulin Aspart for BG > 140 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >140 mg/dL.
3111883|NCT02408120|Active Comparator|Insulin Aspart for BG > 260 mg/dL|Subjects will consist of hospitalized patients with type 2 diabetes and be randomized to receive insulin glargine once daily and insulin aspart divided in three equal doses before meals. Supplemental insulin aspart will be given before meals and at bedtime to subjects with blood glucose (BG) levels >260 mg/dL.
3111884|NCT02408198|Experimental|Immediate therapy|Therapy will be delivered for a period of 6 weeks immediately after randomisation
3111885|NCT02408198|No Intervention|Delayed therapy|Therapy will be delayed until 10 weeks following randomisation, and then delivered over a 6 week period
3111886|NCT02408263||Total Hip Replacement (THR) and Total Knee Replacement (TKR)|25 patients receiving a THR and 25 patients receiving aTKR. The investigators are using Skin Conductance Algesimeter (SCA) to measure pain by analyzing changes in skin conductance.
3111887|NCT02408315|Placebo Comparator|misoprostol/placebo using buccal|Randomized for buccal route of administration/ placebo
3111888|NCT02408315|Placebo Comparator|misoprostol/placebo using vaginal|Randomized for vaginal route of administration/ placebo
3111889|NCT02408445|Experimental|Testosterone treatment|Testosterone cypionate (200 mg/ml) intramuscular injection
3111890|NCT02408445|No Intervention|No treatment|Subjects will not receive any testosterone during the study period.
3111891|NCT02408484|Experimental|Octafibrin|Plasma-derived fibrinogen concentrate
3111892|NCT02408523|Experimental|Lacosamide|"Lacosamide 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400 mg/day for adult subjects and pediatric subjects >= 50 kg.~Lacosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30 kg.)~Lasosamide oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30 kg to < 50 kg.)"
3111893|NCT02408523|Placebo Comparator|Placebo|"Placebo 50 mg tablets: starting with 100 mg/day at Week 1. Weekly increase in steps of 50 mg or 100 mg/day are allowed. Maximal dose 400mg/day for adult subjects and pediatric subjects >= 50kg.~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 12 mg/kg/day for pediatric subjects < 30kg.)~Placebo oral solution 10 mg/ml: starting with 2 mg/kg/day, titrations steps (1 mg/kg/day to 2 mg/kg/day; maximal dose 8 mg/kg/day for pediatric subjects 30kg to < 50kg.)"
3111894|NCT02408692|Active Comparator|Normal BMI ECx1|5 normal weight women (BMI<25 kg/m2) taking 1.5mg LNG
3111895|NCT02408692|Active Comparator|Obese BMI ECx1|5 obese women (BMI >30 kg/m2) taking 1.5mg LNG
3111896|NCT02408692|Active Comparator|Obese BMI ECx2|5 obese women (BMI >30 kg/m2) taking 3mg LNG
3111897|NCT02408796|Experimental|OTO-201|6 mg OTO-201
3111898|NCT02408965|Experimental|methergine|Methergine group 0.2 mg of methylergonovine maleate single injection when manual cervical dilation begins the day before the procedure
3111899|NCT02408965|Placebo Comparator|saline placebo|Placebo group saline single injection when manual cervical dilation begins the day before the procedure
3111900|NCT02409277|Experimental|Standard e-AT Intervention|Patients in Standard e-AT or standard intervention group will receive a daily (if a participant forgets to complete his/her weekly assessment) email and text reminders with a link to the e-AT website to help patient/parent participants to comply with their weekly assessment of patient's level of asthma control. Note: patient/parent participants are required to complete their asthma control assessment 1x/week. The e-AT is now set up to send a weekly reminder to participants with a link to the website. If a participant does not complete an assessment within a week of the last assessment, the reminder will be sent daily until the patient/parent complies and the system resets to weekly.
3111901|NCT02409277|Experimental|Intensive e-AT Intervention|Participants in the intensive e-AT or adherence support intervention will receive everything as those in Standard Intervention. In addition, they will see a progress bar display, which adds 25 points each time they complete an assessment. When this bar reaches 100 points, a pop-up message with fireworks will appear to congratulate them about the milestone. The progress bar resets to zero after it reaches 100 points. Participants will also see a leader board allowing them to compare themselves with the 5 best users to increase compliance.
3111902|NCT02409277|No Intervention|Usual Care (Non-Randomized Cohort)|Both arms (Intensive and standard e-AT interventions) will be compared to each other as well as to a non-randomized cohort who did not receive the e-AT interventions. These non-randomized cohort will be matched 2:1 to each randomized individuals.
3111903|NCT02409329|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence and targeted to address other self-care behaviors) for 12 months.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3111904|NCT02409329|Experimental|REACH + FAMS|"In addition to the REACH text messages tailored to user's individual barriers to adherence, participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months. After six months, participants in this arm will receive REACH text messages only.~All participants will also receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3111905|NCT02409329|Active Comparator|Helpline and A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, receive quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3111906|NCT02409342|Active Comparator|(Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)|Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
3111907|NCT02409342|Experimental|Atezolizumab|Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
3111909|NCT02409459|Experimental|Injectafer|15 mg/kg up to 750 mg undiluted blinded dose of IV Injectafer (ferric carboxymaltose) at 100 mg/minute
3111910|NCT02409459|Placebo Comparator|Placebo|15 cc of Normal Saline IV push at 2 ml/minute
3111911|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
3111912|NCT02409667|Experimental|Secukinumab 300mg in PASI 90 responders (longer intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 6 weeks.
3111913|NCT02409667|Experimental|Secukinumab 300mg in PASI 75-90 responders (every 4 weeks)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks will be treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 4 weeks.
3111914|NCT02409667|Active Comparator|Secukinumab 300mg in PASI 75-90 responders (shorter intervals)|Participants with moderate to severe plaque psoriasis who had reached PASI 75 to <90 response after 24 weeks of treatment with secukinumab 300 mg subcutanous (s.c.) every 4 weeks were treated with Secukinumab 300 mg subcutanous (s.c.) from week 24 until Week 52 every 2 weeks.
3111915|NCT02409680|Active Comparator|Intervention Arm|Women will be randomized equally to receive daily low dose aspirin (LDA) [also known as acetylsalicylic acid (ASA)] of 81 mg beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
3111916|NCT02409680|Placebo Comparator|Placebo Arm|Women will be randomized equally to receive an identical appearing placebo beginning between 6 0/7 weeks and 13 6/7 weeks GA and continuing until 36 0/7 weeks GA or delivery.
3111917|NCT02409719|Active Comparator|Control - Verbal information and Booklet|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given.
3111918|NCT02409719|Experimental|Study - Verbal information, Booklet & Schedule.|Verbal information will be provided in order to explain how the patient should perform physical rehabilitation exercises. Furthermore, an illustrative booklet with representative exercises will be given. Also, an illustrative daily schedule to mark on the exact day in which the exercise was performed
3111919|NCT02409732|Experimental|PDT|PDT with aminolevulinic acid hydrochloride (HCl) and blue light to the affected area of the lips every six weeks for up to three treatments
3111920|NCT02409784|Experimental|Ketogenic diet|"Pre/Post TEP study with a 4 days ketogenic diet (KD).~Interventions 1: Pre-KD = Participants did a TEP before starting the 4-day diet~Intervention 2: Post-KD = Participants did a TEP after completing the 4-day diet"
3111921|NCT02409914||POLYCYSTIC OVARY SYNDROME (PCOS)|FDG PET scan,T1-weight MRI and blood were obtained for each participant
3111922|NCT02409927|Other|Healthy participant|Each participant undergo 7 metabolic day, separate by at least 3 days, where they received a different dietary supplement on each day: control (no supplement), MCT oil 10g, MCT oil 20g, MCT oil 30g (provided from pure MCT oil), MCT homogenate 10g, MCT homogenate 20g, MCT homogenate 30g (provided by a 10% MCT homogenate emulsion)
3111923|NCT02410018|Experimental|Cohort 1 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 week post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
3111924|NCT02410018|Experimental|Cohort 2 - Uterine Artery Embolization|"Women treated with OCL 503 proceeding to hysterectomy 1 month post embolization.~OCL 503 will be administered by catheter to the uterine artery(ies) to achieve blood flow stasis."
3111925|NCT02410161|Experimental|4 week ALA treatment|Participants will receive the alpha-linolenic acid-rich supplement (1000mg 4 times par day) for 4 weeks
3111926|NCT02410200|Experimental|BG00012|Oral BG00012 120 mg twice daily (BID) for the first 7 days followed by 240 mg BID for 24 weeks.
3111927|NCT02410213|Experimental|Ferric Carboxymaltose (FCM)|FCM at 7.5 mg/kg or 15 mg/kg to a maximum single dose of 750 mg iron, whichever is smaller
3111928|NCT02410252|Experimental|iThermonitor|Participants are asked to use the iThermonitor device for two weeks to monitor their temperature. Participants are asked to wear the device for as many hours as they can but at a minimum to wear while sleeping.
3111929|NCT02410278|Experimental|DMF plus montelukast|DMF as described in the United States Prescribing Information (USPI) plus 10mg montelukast tablet once daily according to the prevailing product label (Singulair)
3111930|NCT02410278|Experimental|DMF plus placebo|DMF as described in the USPI plus matched placebo
3111931|NCT02410291|Experimental|Experimental group|Patients will receive the standard are to prepare them for their planning CT scan. They will be presented with the flyer that will be developed based on information about the importance of rectal and bladder preparation that is currently provided to patients and will also watch a youtube video on how to prepare for their CT simulation appointment. A few days before the CT planning appointment, patients in this group will be called by the radiation therapist or RA, reminding them about the rectal preparation for the appointment. Each patient will also be reminded to watch the instructional video on YouTube. Patients will be asked not to share the video link with other patients during the study.
3111932|NCT02410291|No Intervention|Control group|Patients in this group will receive the standard care to prepare them for their planning CT scan. They will be presented with the flyer at the consultation. A few days before the CT appointment, patients in this group will also be called and reminded about the required preparations, but will not be told about the video. In addition to the statistics about patient preparedness collected by the radiation therapist conducting the CT scan and stored and secured in an OCC Pinnacle planning system, we will also evaluate: patients' satisfaction with the preparation instructions, their knowledge (knowledge questionnaire) about the video content and importance of understanding the rectal emptying procedures, and radiation therapists' satisfaction with patients' rectal preparation.
3111933|NCT02410343|Placebo Comparator|Placebo|Placebo was injected subcutaneously once weekly on the same day and time for 24 weeks. To maintain the blind, placebo could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 to match the effect of dose titration.
3111934|NCT02410343|Experimental|TV-1106|TV-1106 was injected subcutaneously once weekly on the same day and time for 24 weeks. A common starting dose was 5.0 mg. Doses could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
3111935|NCT02410382|Placebo Comparator|Arm 1 Placebo|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
3111936|NCT02410382|Active Comparator|Arm 2 Dexamethasone|Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days
3111937|NCT02410629|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
3111938|NCT02410629|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
3111939|NCT02410707|Experimental|Nitrous Oxide Arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
3111940|NCT02410772|Active Comparator|Regimen 1|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
3111941|NCT02410772|Experimental|Regimen 2|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg"
3111942|NCT02410772|Experimental|Regimen 3|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin~All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg"
3111943|NCT02410798|Experimental|TransLoc electrode|Electrode placement
3111944|NCT02410811||Age Stratum A|"Age 6 to 13.99 years~Cardiac magnetic resonance imaging (CMR)"
3111945|NCT02410811||Age Stratum B|"Age 14 to 20.99 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
3111946|NCT02410811||Age Stratum C|"Age ≥21 years~Detectible and quantifiable TRJV with reported value~Cardiac magnetic resonance imaging (CMR)"
3111947|NCT02410811||Age Stratum D|"Age ≥6 years.~Current use of disease-modifying therapy [hydroxyurea, chronic transfusions, or both (given concurrently, sequentially, or both)] that was initiated at <3 years of age, and for which there has been no interruption of therapy for >6 consecutive months since the initiation of disease-modifying therapy.~Cardiac magnetic resonance imaging (CMR)"
3111948|NCT02410824|Experimental|stenfilcon A toric lens|Participants were randomized to wear stenfilcon A toric lens for one week during the cross over study.
3111949|NCT02410824|Active Comparator|etafilcon A toric lens|Participants were randomized to wear etafilcon A toric lens for one week during the cross over study.
3111950|NCT02410967|Experimental|Attention Bias Modification|Attention Bias Modification is a computer-based attention training program.
3111951|NCT02410967|Placebo Comparator|Placebo Attention Task|The Placebo Attention Task uses the same computer-based format and stimuli as the Attention Bias Modification Task, but does not train attention toward or away from stimuli.
3111952|NCT02411084|Experimental|BEGEDINA® (Begelomab)|BEGEDINA® (Begelomab) (murine monoclonal antibody against CD26). Dose is 2.7 mg/m2/day i.v. infusion for 5 consecutive days (Study Days 1, 2, 3, 4, 5) and then single dose on each of Study Days 10, 14, 17, 21, 24 and 28, for a total of 11 doses. BEGEDINA® is supplied as 1 mg/mL concentrate for solution for infusion in vials of 6 mL (5.4 mg of active substance) for reconstitution. The total volume to be administered should be further diluted in 100 mL of 0.9% sodium chloride solution for injection prior to administration. The infusion lasts 60 minutes. Subjects are eligible for a single treatment for flare after study Day 28
3111953|NCT02411084|Active Comparator|Conventional Second-line Treatment|Subjects in the conventional treatment arm will receive a second line treatment, which is to be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center. Currently no treatments for this life-threatening disease have been approved in either the USA or Europe. The recommendations of the American Society for Blood and Marrow Transplantation (ASBMT) confirm that no treatment for acute steroid-refractory GvHD can be considered gold standard in terms of TRM or survival as results remain unsatisfactory and this approach has been agreed by the FDA and the EMA.
3111954|NCT02411110|Experimental|LiRIS® (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment Period 1: continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
3111955|NCT02411110|Other|LiRIS Placebo (Treatment Period 1)/LiRIS® (Treatment Period 2)|Treatment period 1: Matching placebo device to LiRIS inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 1. Treatment Period 2: optional continuous release of lidocaine inserted into the bladder by cystoscopy on Day 0 and removed on Day 14 of Period 2.
3111956|NCT02411201|Experimental|DOTAREM|
3111957|NCT02411292|Experimental|Enoxaparin metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
3111958|NCT02411396||Patients With SCD|Patients treated for uncomplicated VOC in ICs and EDs.
3111959|NCT02411448|Experimental|Ramucirumab + Erlotinib|"Part A: 10 milligrams per kilogram (mg/kg) ramucirumab administered every 2 weeks intravenously (IV) in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met.~Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally. Participants may continue to receive treatment until discontinuation criteria are met."
3111960|NCT02411448|Placebo Comparator|Placebo + Erlotinib|"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.~Participants may continue to receive treatment until discontinuation criteria are met."
3111961|NCT02411448|Experimental|Ramucirumab + Gefitinib or Osimertinib|"Part C: 10 mg/kg ramucirumab administered every 2 weeks intravenously (IV) + 250 mg Gefitinib or 80 mg Osimertinib daily orally.~Ramucirumab and gefitinib administered during period 1.~Ramucirumab and osimertinib administered during period 2."
3111962|NCT02411461||Pseudohypoparathyroidism type 1a|Study group
3111963|NCT02411461||Healthy siblings|Control group
3111964|NCT02411461||Obese patients|Control group
3111965|NCT02411539|Experimental|Arm A: VRC01 followed by placebo|Participants received an infusion of VRC01 at Day 0 and Week 3 and an infusion of placebo (normal saline) at Weeks 6 and 9.
3111966|NCT02411539|Experimental|Arm B: placebo followed by VRC01|Participants received an infusion of placebo (normal saline) at Day 0 and Week 3 and an infusion of VRC01 at Weeks 6 and 9.
3111967|NCT02411565|Active Comparator|Fermented Wheat Germ Extract (FWGE)|FWGE administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
3111968|NCT02411565|Placebo Comparator|Placebo Administration|Placebo administration 2 - 4 weeks prior to planned surgery, + Quality of Life (QoL) Surveys: FACT-O.
3111969|NCT02411578|Experimental|G-Pen Mini™ (glucagon injection)|"Participants are to check blood glucose (BG) with study meter once their continuous glucose monitor (CGM) reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using mini-dose glucagon for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
3111970|NCT02411578|Active Comparator|Glucose Tabs|"Participants are to check their blood glucose (BG) with study meter once their continuous glucose meter reads <70 mg/dl or they experience symptoms. Participants will be instructed to treat using oral glucose tablets for certain phases/periods when BG is 40 to 69 mg/dl (considered a non-severe hypoglycemic event).~For every event, participant will check BG with meter 3 times and treat according to protocol instructions based on BG measurement."
3111971|NCT02411591|Experimental|Necitumumab + Abemaciclib|"Cohort 1 Part A: Necitumumab 800 mg administered intravenously (IV) on Days 1 and 8, followed by abemaciclib 100 mg given orally every 12 hours on Days 1 to 21. (21 day cycles.) Treatment may continue until discontinuation criterion is met.~Cohort 2 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Cohort 3 Part A: Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 200 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met.~Part B (expansion cohort): Necitumumab 800 mg administered IV on Days 1 and 8, followed by abemaciclib 150 mg given orally every 12 hours on Days 1 to 21. Treatment may continue until discontinuation criterion is met."
3111972|NCT02411747|Experimental|Testing+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training with knowledge of a test afterwards, max. time cap 1h45min. 15 minutes of testing with a expert in the procedure. Total max time: 2 hours.
3111973|NCT02411747|Active Comparator|Oral lecture+endoscopic simulation training|Endoscopic training in flexible cystoscopy by directed self-regulated training, max. time cap 1h45min after a 15 minute oral theoretical lecture by a expert in the procedure. Total max. time: 2 hours.
3111974|NCT02411916|Experimental|intervention cases|patient receiving misoprostol
3111975|NCT02411916|No Intervention|controls|patients not receiving misoprostol
3111976|NCT02411929|Experimental|Ertugliflozin|Period 1: Oral dose of 15 mg unlabeled ertugliflozin + intravenous (IV) dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. The 14^C IV dose will be administered as an infusion over approximately 5 minutes starting at 55 minutes after the unlabeled oral dose. → Period 2: Oral dose 15 mg unlabeled ertugliflozin + oral dose of 100 µg 14^C-labeled ertugliflozin containing approximately 400 nCi 14^C. Both the unlabeled and 14^C-ertugliflozin will be administered at the same time (no more than 5 minutes apart). Dosing in Periods 1 and 2 will be separated by a washout of at least 11 days.
3111977|NCT02412098|Experimental|Moderate Hepatic Impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3111978|NCT02412098|Experimental|Severe Hepatic Impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3111979|NCT02412098|Experimental|Mild Hepatic Impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3111980|NCT02412111|Experimental|Ivacaftor (Run-in Period)|Ivacaftor 150 milligram (mg) tablet orally every 12 hours for 4 weeks.
3111981|NCT02412111|Experimental|VX-661 + Ivacaftor (Active comparator period)|VX-661 100 mg and ivacaftor 150 mg fixed-dose combination tablet orally once daily in the morning and ivacaftor 150 mg tablet orally once daily in the evening for 8 weeks.
3111982|NCT02412111|Active Comparator|Ivacaftor monotherapy (Active comparator period)|Ivacaftor 150 mg tablet orally every 12 hours as monotherapy for 8 weeks.
3111983|NCT02412228|Experimental|Ixazomib Regimen|"Cycle 1: Ixazomib: 4mg/day 1, 8, 15, Cyclophosphamide: 50 mg/day continuous daily, Dexamethasone: 20 mg/day 1, 8, 15 Cycles 2-6: Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18, Cyclophosphamide: 50 mg/day continuous, daily, Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
3111984|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 1b Adult Population|Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
3111985|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Phase 1b Pediatric Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
3111986|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Phase 2 Adult Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
3111987|NCT02412306|Experimental|Blinatumomab 9-28 µg/day Adult Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose for adults was 9 µg/day for the first week of cycle 1, escalated to 28 µg/day starting from Week 2 and all cycles thereafter.
3111988|NCT02412306|Experimental|Blinatumomab 5-15 µg/m^2/day Pediatric Expansion Population|Participants received blinatumomab by CIV infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. For pediatric participants the initial dose was 5 µg/m²/day for the first week of cycle 1, escalated to 15 µg/m²/day starting from week 2 and all cycles thereafter.
3111989|NCT02412371|Experimental|Phase 1: Veliparib + Carboplatin + Paclitaxel + Radiotherapy|"Participants in Phase 1 will be sequentially assigned to ascending dose levels of 60 mg, 80 mg, 120 mg, 200 mg, and 240 mg of twice daily (BID) veliparib in combination with carboplatin at an area under the concentration-time curve (AUC) 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
3111990|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Veliparib|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of veliparib 120 mg or 240 mg BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
3111991|NCT02412371|Experimental|Phase 2: Veliparib + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive veliparib at the recommended phase 2 dose determined in Phase 1 in combination with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
3111992|NCT02412371|Active Comparator|Phase 2: Placebo + CRT -> Paclitaxel/Carboplatin/Placebo|"Participants will receive placebo to veliparib with carboplatin at an AUC 2 mg/mL/min and paclitaxel 45 mg/m² once a week plus thoracic radiotherapy for 7 weeks.~After completion of concurrent chemoradiotherapy participants will receive up to 2 cycles of consolidation therapy consisting of placebo to veliparib BID, carboplatin AUC 6 mg/mL/min and paclitaxel 200 mg/m² administered on Day 1 of each 21-day cycle."
3111993|NCT02412436|Experimental|Arm A: Depot medroxyprogesterone acetate|At study entry/week 0, participants received depot medroxyprogesterone acetate (DMPA) 150 mg administered intramuscularly as a single dose and co-administered with rifampicin (RIF) and efavirenz (EFV).
3111994|NCT02412488|Experimental|Out of CathLab setting|Out of cathlab insertion
3111995|NCT02412501|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System 2.0 mm Stent
3111996|NCT02412631|Placebo Comparator|Varenicline plus placebo|Subjects will receive open label varenicline (12 weeks) plus a placebo for lorcaserin (24 weeks)
3111997|NCT02412631|Experimental|Varenicline plus lorcaserin|Subjects will receive open label varenicline (12 weeks) plus lorcaserin (24 weeks)
3111998|NCT02412644|Active Comparator|Apremilast + apremilast|apremilast 30mg bid for 12 weeks.followed by apremilast 30 mg bid for 24 weeks
3111999|NCT02412644|Placebo Comparator|apremilast + placebo|apremilast 30mg bid for 12 weeks followed by placebo bid for 24 weeks
3112000|NCT02412657|Experimental|Dexamethasone 10 mg intravenous|Dexamethasone 10 mg diluted with Normal Saline 17,5 mL i.v. (20 mL total) injected slowly during 30 seconds immediately after performing interscalene brachial plexus block
3112001|NCT02412657|Experimental|Dexamethasone 4 mg intravenous|Dexamethasone 4 mg diluted with Normal Saline 19 mL i.v. (20 mL total) injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
3112002|NCT02412657|Placebo Comparator|Normal Saline 20 mL intravenous|Normal saline 20 mL injected slowly during 30 seconds, immediately after performing interscalene brachial plexus block
3112003|NCT02412670|Experimental|Arm A (methotrexate, vinblastine, doxorubicin, cisplatin)|Patients receive methotrexate IV over 2-3 minutes, vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV over 4 hours on day 1. Pegfilgrastim at 6 mg is given once 24-48 hours after completion of chemotherapy. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
3112004|NCT02412670|Experimental|Arm B (gemcitabine, carboplatin)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients without metastatic disease undergo nephroureterectomy and lymph node dissection 21-60 days after completion of chemotherapy.
3112005|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 3 mg|Following Pharmacokinetic (PK) - Run in Period, sapanisertib 3 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, starting from Cycle 2 for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
3112006|NCT02412722|Experimental|Single-Agent QD Arm: Sapanisertib 4 mg|Following PK Run-In Period, sapanisertib 4 mg milled capsules, orally, once, daily in a 28-day Cycle, under fasted conditions, for up to 13 cycles.
3112007|NCT02412722|Experimental|Combination Arm: Sapanisertib 4 mg + Paclitaxel 80 mg/m^2|Sapanisertib 4 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 12 cycles, and paclitaxel 80 mg/m^2, intravenously (IV), on Days 1, 8, and 15 in 28-day Cycle, for up to 6 cycles.
3112008|NCT02412722|Experimental|Combination Arm: Sapanisertib 6 mg + Paclitaxel 80 mg/m^2|Sapanisertib 6 mg milled capsules, orally, once, for 3 consecutive days following each paclitaxel administration (Days 2-4, 9-11, 16-18, and 23-25) in a 28-day Cycle, under fasted conditions, for up to 9 cycles, and paclitaxel 80 mg/m^2, IV, on Days 1, 8, and 15 in 28-day Cycle, for up to 9 cycles. The dose of sapanisertib was modified based on safety and tolerability during each 28-day cycle.
3112009|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 20 mg|Sapanisertib 20 mg, capsules milled API, QW in a 28-day Cycle, for up to 6 cycles.
3112010|NCT02412722|Experimental|Single-Agent QW Arm: Sapanisertib 30 mg|Sapanisertib 30 mg, capsules, milled API, QW in a 28-day Cycle, for up to 10 cycles.
3112011|NCT02412761|Active Comparator|Amlodipine, then HCTZ, then Lisinopril|Participants first received amlodipine once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112012|NCT02412761|Active Comparator|Amlodipine, then Lisinopril, then HCTZ|Participants first received amlodipine once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112013|NCT02412761|Active Comparator|HCTZ, then Amlodipine, then Lisinopril|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then lisinopril once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112014|NCT02412761|Active Comparator|HCTZ, then Lisinopril, then Amlodipine|Participants first received hydrochlorothiazide (HCTZ) once daily for 2 weeks, then crossed over to lisinopril once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112015|NCT02412761|Active Comparator|Lisinopril, then Amlodipine, then HCTZ|Participants first received lisinopril once daily for 2 weeks, then crossed over to amlodipine once daily for 2 weeks, then hydrochlorothiazide (HCTZ) once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112016|NCT02412761|Active Comparator|Lisinopril, then HCTZ, then Amlodipine|Participants first received lisinopril once daily for 2 weeks, then crossed over to hydrochlorothiazide (HCTZ) once daily for 2 weeks, then amlodipine once daily for 2 weeks. Subsequent treatments varied depending on individual patient response.
3112017|NCT02412852|Placebo Comparator|Placebo|One placebo tablet administered twice daily for 12 weeks.
3112018|NCT02412852|Active Comparator|40 mg TV1001sr|One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
3112019|NCT02412852|Placebo Comparator|Placebo (2)|Two placebo tablets administered twice daily for 12 weeks.
3112020|NCT02412852|Active Comparator|80 mg TV1001sr|Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
3112021|NCT02412878|Experimental|Once-weekly Carfilzomib 20/70 mg/m² + Dexamethasone|"Participants received carfilzomib administered by intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle (20 mg/m² on day 1 of cycle 1 and 70 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
3112022|NCT02412878|Experimental|Twice-weekly Carfilzomib 20/27 mg/m² + Dexamethasone|"Participants received carfilzomib administered by IV infusion on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle (20 mg/m² on days 1 and 2 of cycle 1 and 27 mg/m² thereafter).~Participants also received 40 mg dexamethasone IV or orally on days 1, 8, 15 and 22 for the first 8 cycles; starting with cycle 9, dexamethasone was administered only on days 1, 8, and 15."
3112023|NCT02412956|No Intervention|Control|pamphlet
3112024|NCT02412956|Experimental|Intervention (text)|SmokefreeMOM text messaging program
3112025|NCT02412956|Experimental|Intervention Plus (text+quitline)|SmokefreeMOM text messaging program + state quitline
3112026|NCT02412982|No Intervention|Serum anti-Xa >= 0.1 IU/mL|Patients with serum anti-Xa level >= 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
3112027|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 40 mg q12h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 40 mg every 12 hours. If repeat steady state trough anti-Xa is subtherapeutic, dose will be increased to enoxaparin 50 mg every 12 hours.
3112028|NCT02412982|Active Comparator|Anti-Xa <0.1 IU/mL:enoxaparin 30 mg q8h|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours who then receive enoxaparin 30 mg every eight hours
3112029|NCT02412982|No Intervention|Serum anti-Xa < 0.1 IU/mL|Patients with serum anti-Xa level < 0.1 IU/mL after third dose of enoxaparin 30 mg every 12 hours
3112030|NCT02413008|Experimental|0.005% estriol vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3112031|NCT02413008|Placebo Comparator|placebo vaginal gel|Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3112032|NCT02413034|Placebo Comparator|Control group|no antibiotic prophylaxis group
3112033|NCT02413034|Active Comparator|Study group cefazolin|Classical antibiotic prophylaxis
3112034|NCT02413151|Experimental|Exercise Training Program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods.
3112035|NCT02413151|Active Comparator|Control|Regular lifestyle
3112036|NCT02413203|Experimental|Celecoxib|Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.
3112037|NCT02413203|Placebo Comparator|Placebo|Oral administration of a single placebo pill.
3112038|NCT02413229|Experimental|DSXS1411|DSXS applied once a day for a total of 28 days.
3112039|NCT02413229|Placebo Comparator|Placebo|Placebo (vehicle) applied once a day for a total of 28 days.
3112040|NCT02413255|Placebo Comparator|Part 1 Cohort 1-9: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1.
3112041|NCT02413255|Experimental|Part 1 Cohort 1: TAK-020 0.1 mg|TAK-020 0.1 mg, solution, orally once on Day 1.
3112042|NCT02413255|Experimental|Part 1 Cohort 2: TAK-020 0.5 mg|TAK-020 0.5 mg, solution, orally, once on Day 1 following review of safety, tolerability and pharmacokinetic (PK) data from Cohort 1.
3112043|NCT02413255|Experimental|Part 1 Cohort 3: TAK-020 2.5 mg|TAK-020 2.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 2.
3112044|NCT02413255|Experimental|Part 1 Cohort 4: TAK-020 4.4 mg|TAK-020 4.4 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 3.
3112045|NCT02413255|Experimental|Part 1 Cohort 5: TAK-020 8.8 mg|TAK-020 8.8 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 4.
3112046|NCT02413255|Experimental|Part 1 Cohort 6: TAK-020 17.5 mg|TAK-020 17.5 mg, solution, orally once on Day 1 following review of safety, tolerability and PK data from Cohort 5.
3112047|NCT02413255|Experimental|Part 1 Cohort 7: TAK-020 35 mg|TAK-020 35 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 6.
3112048|NCT02413255|Experimental|Part 1 Cohort 8: TAK-020 70 mg|TAK-020 70 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 7.
3112049|NCT02413255|Experimental|Part 1 Cohort 9: TAK-020 105 mg|TAK-020 105 mg, solution, orally once on Day 1. TAK-020 dose will be determined based on review of safety, tolerability and PK data from Cohort 8.
3112050|NCT02413255|Placebo Comparator|Part 2 Cohort 1-6: Placebo|TAK-020 placebo-matching solution, orally, once on Day 1 and Days 3 to 9.
3112051|NCT02413255|Experimental|Part 2 Cohort 1: TAK-020 3.75 mg|TAK-020 3.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose are determined based on data from Part 1 of the study.
3112052|NCT02413255|Experimental|Part 2 Cohort 2: TAK-020 5.75 mg|TAK-020 5.75 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 1 in Part 2.
3112053|NCT02413255|Experimental|Part 2 Cohort 3: TAK-020 13 mg|TAK-020 13 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 2 in Part 2.
3112054|NCT02413255|Experimental|Part 2 Cohort 4: TAK-020 25 mg|TAK-020 25 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose will be determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 3 in Part 2.
3112055|NCT02413255|Experimental|Part 2 Cohort 5: TAK-020 45 mg|TAK-020 45 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 4 in Part 2.
3112056|NCT02413255|Experimental|Part 2 Cohort 6: TAK-020 60 mg|TAK-020 60 mg, solution, orally once on Day 1 and Days 3-9. TAK-020 dose was determined based on data from Part 1 and review of safety, tolerability and PK data from Cohort 5 in Part 2.
3112057|NCT02413294|Experimental|Bright Light Intervention|Before the bright light intervention is initiated (and during the intervention), participants will wear two wrist bands which measure sleep quality and activity levels- the Fitbit and actigraphy watches. These will be worn for two weeks to assess individuals' baseline levels of sleep quality and will continue to be worn during the intervention. Following the baseline period, the re-timer glasses will be introduced and worn for a period of 30 to 50 minutes a day for two weeks.
3112058|NCT02413320|Active Comparator|Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide|Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
3112059|NCT02413320|Active Comparator|Carboplatin + Docetaxel|Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
3112060|NCT02413333|Other|Clear Care Plus, then PeroxiClear|Clear Care Plus contact lens solution in Period 1, followed by PeroxiClear contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
3112061|NCT02413333|Other|PeroxiClear, then Clear Care Plus|PeroxiClear contact lens solution in Period 1, followed by Clear Care Plus contact lens solution in Period 2. Each product used daily per packaging instructions with participant's habitual silicone hydrogel contact lenses for approximately 30 cleaning cycles.
3112062|NCT02413346|Experimental|Placebo/Sarecycline|Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
3112063|NCT02413346|Experimental|Sarecycline/Sarecycline|Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).
3112064|NCT02413372|Experimental|Treatment Group A: BMS-986036|Administered as specified on specified days
3112065|NCT02413372|Experimental|Treatment Group B: BMS-986036|Administered as specified on specified days
3112066|NCT02413372|Placebo Comparator|Treatment Group C: Placebo|Administered as specified on specified days
3112067|NCT02413398|Experimental|Dapagliflozin|10 mg Tablets, Oral, Once daily, 24 weeks
3112068|NCT02413398|Placebo Comparator|Placebo|Matching placebo to Dapagliflozin 10 mg tablet. Oral, Once daily, 24 weeks
3112069|NCT02413463|Active Comparator|Augmented recession|The medial rectus muscle will be exposed and hooked through a limbal approach. The muscle will then be secured with 6-0 polyglactin sutures. The medial rectus muscles will then be recessed using standard tables with the surgical dose targeting the average of the largest and smallest angles
3112070|NCT02413463|Active Comparator|Faden|Medial rectus muscle recession will be performed as described above with the surgical dose targeting the smallest pre-operative angle. The muscle will then fixated to the sclera using 6/0 polyester sutures placed in a mattress like with the anterior and the posterior sutures passing through both the edge of muscle and the sclera 12 mm and 14 mm from the muscle insertion, respectively.
3112071|NCT02413489|Experimental|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
3112072|NCT02413580|Experimental|IGIV-C Treatment|In this arm, subjects with myasthenia gravis exacerbations were treated with an IV dose of 2 g/kg of IGIV-C, which was administered over 2 consecutive days at a dose of 1 g/kg per day.
3112073|NCT02413593|Experimental|LDV/SOF+RBV|LDV/SOF FDC plus RBV for 12 weeks
3112074|NCT02413684|Other|Asthma Patients|Patient engagement toolkit
3112075|NCT02413879|Experimental|Treatment Group|All study subjects will be treated using the CleanCision device.
3112076|NCT02413918|Experimental|Open Label iloperidone|open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
3112077|NCT02413996|Experimental|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS) in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
3112078|NCT02413996|Active Comparator|traditional rehabilitation|exercise therapy through a traditional rehabilitation training in addition to a knee continuous passive motion device ( Kinetec® continuous passive motion ( CPM )) and functional activities (e.g.,stairs, walking)
3112079|NCT02414204|Active Comparator|Sildenafil|20 mg twice a day orally
3112080|NCT02414204|Placebo Comparator|Placebo|Placebo twice a day orally
3112081|NCT02414243|Experimental|New Amino Acid formula|New Amino-Acid based Infant Formula
3112082|NCT02414243|Active Comparator|Control formula|Commercially available Amino Acid Formula
3112083|NCT02414633||Humira|Subjects with Psoriatic Arthritis taking adalimumab under conditions of daily clinical practice.
3112084|NCT02414828|Placebo Comparator|Placebo|Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3112085|NCT02414828|Experimental|AERAS-402 3 x 10^8 vp|AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3112086|NCT02414828|Experimental|AERAS-402 3 x 10^9 vp|AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3112087|NCT02414828|Experimental|AERAS-402 3 x 10^10 vp|AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.
3112088|NCT02414841|Active Comparator|Vonapanitase|Vonapanitase administered at the time of radiocephalic fistula creation
3112089|NCT02414841|Placebo Comparator|Placebo|Placebo administered at the time of radiocephalic fistula creation
3112090|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 200 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 200 mg) as a loading dose on Day 1 (Week 0), followed by a single injection every 2 weeks (q2w) from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3112091|NCT02414854|Experimental|Dupilumab 200 mg q2w|2 subcutaneous injections of Dupilumab 200 mg (for a total of 400 mg) as a loading dose on Day 1 (Week 0), followed by a single 200 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3112092|NCT02414854|Placebo Comparator|Placebo (for Dupilumab 300 mg) q2w|2 subcutaneous injections of matched Placebo (for Dupilumab 300 mg) as a loading dose on Day 1 (Week 0), followed by a single injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3112093|NCT02414854|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1 (Week 0), followed by a single 300 mg injection q2w from Week 2 to Week 50 in combination with stable ICS and up to 2 other controller medicines . Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3112094|NCT02414932|Experimental|Ketamine|Ketamine (ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland)) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered. Infusions will be discontinued by the Anaesthetist if there are persisting haemodynamic changes (i.e. heart rate >110/minute or systolic/diastolic blood pressure (BP) >180/100 or >20% increase above pre-infusion BP for more than 15 minutes) that do not respond to beta-blocker therapy.
3112095|NCT02414932|Active Comparator|Midazolam|Midazolam (0.045 mg/kg; Roche Products Ireland Ltd) will be made up as a 50 ml colourless saline solution and administered as a slow infusion over 40 minutes using an intravenous infusion pump. A course of up to four once-weekly infusions will be administered.
3112096|NCT02414958|Experimental|Empagliflozin low dose|Empagliflozin tablets once daily
3112097|NCT02414958|Experimental|Empagliflozin high dose|Empagliflozin tablets once daily
3112098|NCT02414958|Placebo Comparator|Placebo|Placebo tablets matching empagliflozin once daily
3112099|NCT02415127|Experimental|Interferon γ-1b|Approximately 45 participants will receive subcutaneous (SC) doses of ACTIMMUNE® 3 times a week (TIW) for a total of 26 weeks.
3112100|NCT02415127|Placebo Comparator|Placebo|Approximately 45 participants will receive SC doses of placebo TIW for a total of 26 weeks.
3112101|NCT02415244||Age 0 - 18|TEE visualization of the spinal cords in patients age between 0 - 18
3112102|NCT02415244||Age 18 plus|TEE visualization of the spinal cords in patients age 18 or greater
3112103|NCT02415400|Active Comparator|Apixaban|5 mg or 2.5 mg Apixaban tablets orally twice per day
3112104|NCT02415400|Active Comparator|Vitamin K Antagonist|VKA tablets orally once daily
3112105|NCT02415400|Placebo Comparator|Acetylsalicylic acid film coated tablet|81 mg Acetylsalicylic acid film coated tablet orally once daily
3112106|NCT02415400|Placebo Comparator|Placebo matching Acetylsalicylic acid film coated tablet|Placebo matching Acetylsalicylic acid film coated tablet once daily
3112107|NCT02415439|Experimental|VBP15- 0.1 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
3112108|NCT02415439|Experimental|VBP15- 0.3 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
3112109|NCT02415439|Experimental|VBP15- 1.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
3112110|NCT02415439|Experimental|VBP15- 3.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
3112111|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fasting SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
3112112|NCT02415439|Experimental|VBP15- 8.0 mg/kg Fed SAD|Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
3112113|NCT02415439|Experimental|VBP15- 20.0 mg/kg SAD|Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
3112114|NCT02415439|Placebo Comparator|Placebo - SAD|Subjects were orally administered a placebo under fasted conditions.
3112115|NCT02415439|Experimental|VBP15- 1.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
3112116|NCT02415439|Experimental|VBP15- 3.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
3112117|NCT02415439|Experimental|VBP15- 9.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
3112118|NCT02415439|Experimental|VBP15- 20.0 mg/kg 14 Day MAD|Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
3112119|NCT02415439|Placebo Comparator|Placebo MAD|Subjects were orally administered placebo for 14 days under fasted conditions.
3112120|NCT02415556|Experimental|Type 2 Diabetes Mellitus - Insulin|40 IU of regular human insulin once daily over 24 weeks
3112121|NCT02415556|Placebo Comparator|Type 2 Diabetes Mellitus - Placebo|Intranasal sterile saline once daily over 24 weeks
3112122|NCT02415556|Experimental|Control - Insulin|40 IU of regular human insulin once daily over 24 weeks
3112123|NCT02415556|Placebo Comparator|Control - Placebo|Intranasal sterile saline once daily over 24 weeks
3112124|NCT02415595|Experimental|Arm 1: BMS-955176 60 mg + TDF/FTC|BMS-955176 at 60 mg active dose per day + BMS-955176 placebo matching 120 mg + efavirenz (EFV) placebo matching 600 mg + tenofovir/emtricitabine (TDF/FTC) 300/200 mg per day, orally
3112125|NCT02415595|Experimental|Arm 2: BMS-955176 120 mg + TDF/FTC|BMS-955176 placebo matching 60 mg + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC 300/200mg per day, orally
3112126|NCT02415595|Experimental|Arm 3: BMS-955176 180 mg + TDF/FTC|BMS-955176 at 60mg active dose per day + BMS-955176 at 120mg active dose per day + EFV placebo matching 600mg + TDF/FTC at 300/200mg per day, orally
3112127|NCT02415595|Active Comparator|Arm 4: EFV + TDF/FTC|BMS-955176 placebo matching 60mg + BMS-955176 placebo matching 120mg + EFV at 600mg per day + TDF/FTC 300/200mg per day
3112128|NCT02415608|Experimental|Ibrutinib 420 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
3112129|NCT02415608|Experimental|Ibrutinib 560 mg/day|Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles
3112130|NCT02415842||H1N1_AS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42.
3112131|NCT02415842||H1N1_NAS Group|Subjects 19-40 years of age (in H1N1 cohort of primary completed study -Q-PAN H1N1-019 (113536) (A/California/07/2009)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and TIV at Day 42
3112132|NCT02415842||H5N1_AS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21
3112133|NCT02415842||H5N1_NAS Group|Subjects 18-49 years of age (in H5N1 cohort of primary completed study CC-PAN H5N1-001 (114371)(A/Indonesia/5/2005 RG)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21.
3112134|NCT02415842||H9N2_AS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed study Q-PAN H9N2-001 (116358) (A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered adjuvanted (AS03A) pandemic vaccine with 3.75 µg HA (hemagglutinin) at Days 0 and 21 and saline placebo at Day 182.
3112135|NCT02415842||H9N2_NAS Group|Subjects 18-64 years of age (in H9N2 cohort of primary completed studyQ-PAN H9N2-001 (116358)(A/chicken/Hong Kong/G9/1997 NIBRG-91)) who were administered unadjuvanted pandemic vaccine with 15 µg HA (hemagglutinin) at Days 0 and 21 and with saline placebo at Day 182.
3112136|NCT02415842||DQIV_NAS Group|Subjects 18-≤39 years of age (in D-QIV cohort of primary completed study FLU D-QIV-015 (201251) (A/Christchurch/16/2010 (H1N1)pdm09, A/Texas/50/2012 (H3N2), B/Massachusetts/02/2012, B/Brisbane/60/2008)) who were administered 15 µg HA (no AS) of each of 4 strains (total 60 µg HA) at Day 0.
3112137|NCT02415842||QPAN_C Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered 3.8 µg A/Indonesia/5/05 (H5N1) with AS03A on Day 0; phosphate buffer saline (PBS) preserved with 20 ppm thimerosal on Day 182; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Day 549.
3112138|NCT02415842||QPAN5_G Group|Subjects 18-40 years of age (in Q-PAN cohort of primary completed study Q-PAN-005 (110624)) who were administered PBS preserved with 20 ppm thimerosal on Day 0; 3.8 µg A/turkey/Turkey/1/05 (H5N1) with AS03A on Days 182 and 549.
3112139|NCT02415842||H5N1_VT Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed study H5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received two administrations of the adjuvanted (AS03A) pandemic influenza vaccine (3.8 µg) containing the Vietnam (VT) strain at Day 0 and Month 12.
3112140|NCT02415842||H5N1_IN Group|Subjects 18-60 years of age (in H5N1 cohort of primary completed studyH5N1-012 (107495) A/Vietnam/1194/2004-like or A/Indonesia/05/2005-like) who received one administration(3.8 µg) of the adjuvanted (AS03A) pandemic influenza vaccine containing the Vietnam (VT) strain at Day 0 and one administration(3.8 µg) of the adjuvanted (AS03A) pandemic vaccine containing the Indonesia (IN) strain at Month 12.
3112141|NCT02415842||H5N1_PAS Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered adjuvanted (AS03B) pandemic vaccine with 1.9 µg HA (hemagglutinin) at Days 0 and 21.
3112142|NCT02415842||H5N1_PCN Group|Subjects 6-35 months of age (in H5N1 cohort of primary completed study Q-PAN H5N1-AS03-021 (114464)(A/Indonesia/5/2005 RG)) who were administered placebo at Days 0 and 21.
3112143|NCT02415959|Experimental|Creon IR low dose|Creon IR 300 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 30,000 lipase units)
3112144|NCT02415959|Experimental|Creon IR medium dose|Creon IR 1,200 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 120,000 lipase units)
3112145|NCT02415959|Experimental|Creon IR high dose|Creon IR 2,400 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 240,000 lipase units)
3112146|NCT02415959|Experimental|Creon IR maximum dose|Creon IR 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
3112147|NCT02415959|Active Comparator|Creon® (DR/GR)|Creon® (DR/GR) 4,000 Ph. Eur. U lipase/g fat/day, proportionally administered five times daily (during 3 meals and 2 snacks) for 6 to 7 days (target total daily dose of 400,000 lipase units)
3112148|NCT02415998||TEE|
3112149|NCT02416011|No Intervention|Assessment Only (ASSESS)|Participants in this condition will not receive any intervention materials. They will participate solely in the repeated assessments. Including this comparison condition controls for the effect of repeated assessments and allows for the most meaningful evaluation of the efficacy effect size as well as the cost-effectiveness of the eTARGET intervention. This condition will also be the primary source of data for the secondary surveillance aim regarding naturalistic changes in smoking and e-cigarette use over time.
3112150|NCT02416011|Active Comparator|Generic Self-Help (GENERIC)|This will allow us to evaluate our novel self-help intervention for e-cigarette users (our If you Vape booklets) against a matched non-targeted intervention that has demonstrated efficacy for cigarette smokers in general. Such a comparison controls for the possibility that e-cigarette users are sufficiently primed to quit smoking and that even a generic, non-targeted intervention would be effective. This possibility will be directly tested by comparing this condition against both the ASSESS and eTARGET conditions in terms of clinical outcomes and cost-effectiveness.
3112151|NCT02416011|Experimental|Targeted Self-Help (eTARGET)|Participants in this condition will receive the intervention created as the product of Study I.
3112152|NCT02416102|Active Comparator|Healthy non-smokers|10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
3112153|NCT02416102|Experimental|Smokers without COPD|10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
3112154|NCT02416102|Experimental|Ex-smokers with COPD|10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
3112155|NCT02416180|Experimental|SERETIDE EVOHALER|Subjects will switch from their current usual maintenance treatment of SERETIDE via DISKUS Inhaler to an equivalent dose of SERETIDE via the MDI (EVOHALER) at Visit 1. Subjects will use the MDI as 2 inhalations twice daily for approximately 14 days. Subjects will revert back to using SERETIDE DISKUS Inhaler again from Visit 2 (after 14 days) starting with the next scheduled dose.
3112156|NCT02416193|Experimental|High Dose|50,000 IU cholecalciferol once weekly for three months
3112157|NCT02416193|Active Comparator|Low Dose|5,000 IU cholecalciferol once weekly for three months
3112158|NCT02416453|Experimental|Group 1|Participants will receive intramuscular (IM) injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 29.
3112159|NCT02416453|Experimental|Group 2|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 57.
3112160|NCT02416453|Experimental|Group 3|Participants will receive IM injection of Ad26.ZEBOV/Placebo on Day 1 followed by IM injection of MVA-BN-Filo/Placebo on Day 85.
3112161|NCT02416622|Experimental|Groups 1A and 1B|Subjects at least 18 y/o treated with a lower dose of rAAV2tYF-CB-hRS1 study drug.
3112162|NCT02416622|Experimental|Groups 2 and 2A|Subjects at least 6 y/o treated with a middle dose of rAAV2tYF-CB-hRS1 study drug.
3112163|NCT02416622|Experimental|Group 3|Subjects at least 18 y/o treated with a higher dose of rAAV2tYF-CB-hRS1 study drug.
3112164|NCT02416622|Experimental|Group 4|Subjects at least 6 y/o treated with a maximum tolerated dose of rAAV2tYF-CB-hRS1 study drug determined for Groups 1A, 1B, 2 and 3.
3112165|NCT02416713|Placebo Comparator|Education Only (Control)|The Cellcontrol DriveID device will run completely in the background with no observable changes to cellphone functions while driving. During Week Four, participants will be presented educational materials on the dangers of distracted driving.
3112166|NCT02416713|Experimental|Opt-in Blocking|Participants will have to initiate Cellcontrol DriveID device when entering the vehicle; the blocking settings will be pre-set to block all calls and text messages when the car is in motion.
3112167|NCT02416713|Experimental|Opt-out Blocking|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion.
3112168|NCT02416713|Experimental|Opt-out Blocking with Notification|Cellcontrol DriveID device will automatically turn on when the teen begins driving and will be pre-set to block all calls and text messages when the car is in motion. If a participant overrides the blocking function, an email will be sent to a parent/guardian.
3112169|NCT02416791|Active Comparator|Active tDCS + robotic therapy + physical therapy|"Active tDCS (transcranial direct current stimulation) will be applied prior to the robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
3112170|NCT02416791|Active Comparator|sham tDCS + robotic therapy + physical therapy|"Sham tDCS (transcranial direct current stimulation) will be applied prior to robotic training. After robot training, the patient will receive physical therapy for 40 minutes.~Number of treatment sessions: 18 (3 times a week, for 6 weeks)."
3112171|NCT02416791|Experimental|sham tDCS + physical therapy + occupational therapy|Sham tDCS (transcranial direct current stimulation) will be applied prior to conventional therapy (40 minutes of physical therapy and 40 minutes of occupational therapy) Number of treatment sessions: 18 (3 times a week, for 6 weeks).
3112172|NCT02416908|Experimental|Phase I Schedule A (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, and 12 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3112173|NCT02416908|Experimental|Phase I Schedule B (selinexor)|"Selinexor will be dosed on Days 1, 5, 10, 12, 17, and 19 of the 28-day cycle. All doses will be 60 mg each PO.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3112174|NCT02416908|Experimental|Phase II (selinexor)|"Selinexor will be given at the schedule as determined in Phase 1.~Single agent selinexor maintenance may be given at 60 mg on Days 1, 8, 15, and 22 (4 doses per 28 day cycle).~Cladribine will be given 5 mg/m^2/day IV once daily on Days 4-8.~G-CSF will be given 300 mcg SC once daily on Days 3-8.~Cytarabine will be given 2000 mg/m^2/day IV once daily on Days 4-8.~Bone marrow biopsy will be performed at baseline, Day 3, at time of hematopoietic recovery, and as clinically indicated to assess treatment response."
3112175|NCT02416934|Experimental|Treatment 1; Dexamethasone|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
3112176|NCT02416934|Placebo Comparator|Treatment 0; Saline placebo|"Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive 0.3 mg/kg of intravenous dexamethasone within one hour of the incision, then 0.15 mg/kg every eight hours for two doses. This dosage is approximately 20 mg, 10 mg, and 10 mg of dexamethasone. Patients in the control(saline) group will receive a similar volume of saline on the same schedule for three doses."
3112177|NCT02416973|Other|Sham of Provant|Sham of Provant
3112178|NCT02416973|Other|Active Treatment|Active Provant Treatment
3112179|NCT02416973|Other|Active Treatment with alternative settings|Active Provant Treatment with alternative settings
3112180|NCT02417064|Experimental|Intranasal Esketamine 84mg plus Oral Antidepressant|As part of an initial titration, participants will self-administer 56 milligrams (mg) of esketamine intranasally on Day 1, and then 84 mg from Day 4 onwards, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112181|NCT02417064|Experimental|Esketamine 56 mg plus Oral Antidepressant|Starting from Day 1, participants will self-administer 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112182|NCT02417064|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (i.e, duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112183|NCT02417129|Experimental|BI 695500|375 mg/m2; One intravenous infusion once a week for 4 weeks
3112184|NCT02417129|Active Comparator|Rituximab (US reference product)|375 mg/m2; One intravenous infusion once a week for 4 weeks
3112185|NCT02417142|Experimental|Experimental|Exenatide 2mg subcutaneous injection, once weekly
3112186|NCT02417142|Placebo Comparator|Placebo|Placebo
3112187|NCT02417233|No Intervention|Standard of Care|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime) only. This group will not receive any additional engagement to care intervention.
3112188|NCT02417233|Active Comparator|SMS text message|"Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also automated bi-weekly check-in text messages that will trigger a phone call from clinic staff if the participant reports not being well."
3112189|NCT02417233|Active Comparator|SMS text message + Peer Navigation|Participants are administered baseline, 6 month, and 12 month questionnaires and provided with the study incentive (mobile phone airtime). In addition, they receive automated bi-weekly behavioral text messages aimed at improving health and reducing transmission risk and also bi-weekly contact from an HIV-positive peer who provides personalized support and with health or other service systems navigation assistance.
3112190|NCT02417246|Active Comparator|Study Sequence A|Start with brand name metoprolol ER, switch to Generic B metoprolol, switch back to brand name metoprolol ER, then switch to Generic A metoprolol
3112191|NCT02417246|Active Comparator|Study Sequence B|Start with brand name metoprolol ER, switch to Generic A metoprolol, switch back to brand name metoprolol ER, then switch to Generic B metoprolol.
3112192|NCT02417376|Active Comparator|Experimental|"Periodontal intervention in the form of scaling and root planing by:~ultrasonic piezoelectric scaler (frequency of 28-36 KHz) and~gracey curets (set of 7 instruments number 1-14) to remove supra and subgingival calculus on teeth, is completed in two appointments of 45 to 60 min, within 24 hours"
3112193|NCT02417376|No Intervention|Control|No periodontal intervention in any form.
3112194|NCT02417441|Experimental|Early Embryo Viability Assessment + Morphological Grading|Embryos of subjects randomized in this group were assessed using Early Embryo Viability Assessment (Eeva) System and morphological grading to identify optimal embryos for transfer.
3112195|NCT02417441|No Intervention|Morphological Grading|Embryos of subjects randomized in this group were assessed only using morphological grading to identify optimal embryos for transfer.
3112196|NCT02417532|Experimental|Rehabilitation using REX|Exercises using Rex mobility assist device
3112197|NCT02417753|Experimental|AZD9150 in People with Malignant Ascites|AZD9150 over a 28 day cycle
3112198|NCT02417831|Active Comparator|tamsulosin capsules|
3112199|NCT02417831|Active Comparator|tamsulosin HCl capsules|
3112200|NCT02417844|Active Comparator|Tamsulosin HCl|
3112201|NCT02417844|Active Comparator|Tamsulosin|
3112202|NCT02417935|Experimental|Duloxetine|20 milligrams (mg) duloxetine orally once a day (QD) for one week and then 40 mg duloxetine orally QD for 3 weeks. Duloxetine dosage may be increased up to 60 mg QD at week 4 or week 8. Placebo will be given with duloxetine for blinding. Dosage will be tapered down during the final week of the study.
3112203|NCT02417935|Active Comparator|Pregabalin|150 mg pregabalin orally twice a day (BID) for 1 week and then 300 mg pregabalin orally BID for 3 weeks. Pregabalin dosage may be increased up to 450 mg BID at week 4 or 8, and increased up to 600 mg BID at week 8. Placebo will be given with pregabalin for blinding. Dosage will be tapered down during the final week of the study.
3112204|NCT02417961|Experimental|Benralizumab 30 mg|Benralizumab administered subcutaneously every 4 weeks
3112205|NCT02418000|Experimental|E6201 240 mg/m^2 IV weekly|E6201 240 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
3112206|NCT02418000|Experimental|E6201 320 mg/m^2 IV weekly|E6201 320 mg/m^2 administered IV over 2 hours once weekly, on Days 1, 8, 15, and 22, repeated every 28 days (= 1 cycle)
3112207|NCT02418000|Experimental|E6201 160 mg/m^2 IV twice weekly|E6201 160 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
3112208|NCT02418000|Experimental|E6201 240 mg/m^2 IV twice weekly|E6201 240 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22 and 25, repeated every 28 days (= 1 cycle)
3112209|NCT02418000|Experimental|E6201 320 mg/m^2 IV twice weekly|E6201 320 mg/m^2 administered IV over 2 hours twice weekly, on Days 1, 4, 8, 11, 15, 18, 22, and 25, repeated every 28 days (= 1 cycle)
3112210|NCT02418026|No Intervention|Control|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from general care
3112211|NCT02418026|Experimental|Hypnosis|women who attended the obstetrics department for a scheduled or unplanned cesarean section and who benefited from a hypnosis session during the surgery in addition to general care
3112212|NCT02418156||Single Arm|Subjects undergoing femoral arterial reconstruction using CorMatrix ECM for vascular repair.
3112213|NCT02418182|Placebo Comparator|Control|Control group participants will receive unlabelled 2 non-active placebo tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
3112214|NCT02418182|Experimental|Experimental|Experimental group participants will receive 2 acetaminophen 500mg tablets approximately 1 hour prior to transvaginal oocyte retrieval procedure.
3112215|NCT02418312|Active Comparator|histamine-2 receptor antagonist group|famotidine 40mg qd for 6 months.
3112216|NCT02418312|Placebo Comparator|placebo group|placebo for 6 months.
3112217|NCT02418455|Experimental|UX003|UX003 4 mg/kg every other week (QOW). Initial treatment period 48 weeks. Continuation period up to 240 weeks.
3112218|NCT02418468|Experimental|Placebo|Matching placebo indacaterol capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3112219|NCT02418468|Experimental|Indacaterol 150 mcg|Indacaterol 150 mcg capsules for inhalation once daily delivered via the Novartis single dose dry power inhaler (SDDPI) (Onbrez® Breezhaler®)
3112220|NCT02418546|Active Comparator|In-Person Nutritional Counseling|Participants in the in-person nutritional counseling arm will meet with a Registered Dietitian at every clinic visit and will also receive regular phone calls to monitor weight and food intake. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level.
3112221|NCT02418546|Experimental|E-Health App for Nutritional Counseling|Participants randomized to the e-Health App arm with receive nutritional counseling using the e-Health Application. Participants will enter weights at home and complete electronic food records using the App. Participants' individual dietary needs will be calculated using baseline calorie consumption, weight history, disease status and current activity level. Participants will receive these calorie recommendations through the Application.
3112222|NCT02418546|No Intervention|Standard Care|Participants are allowed to receive all usual treatments and medications. Participation in other research studies is allowed.
3112223|NCT02418585|Experimental|Intranasal Esketamine plus oral antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112224|NCT02418585|Active Comparator|Placebo plus oral antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112225|NCT02418676|Experimental|Gel with HPβCD-I complex|A quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3112226|NCT02418676|Active Comparator|Gel with insulin|A quantity of 5 grams of gel with insulin was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3112227|NCT02418676|Placebo Comparator|Control gel|A quantity of 5 grams of gel without active was placed on the pressure ulcer, previously cleaned with saline, and covered with sterile gauze and a transparent film.
3112228|NCT02418754|Experimental|REGN2176-3 (1 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
3112229|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg)|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
3112230|NCT02418754|Experimental|Intravitreal Aflibercept Injection (IAI) 2 mg|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
3112231|NCT02418754|Experimental|REGN2176-3 (3 mg: 2 mg) to IAI 2 mg|Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
3112232|NCT02418754|Experimental|IAI 2 mg to REGN2176-3 (3 mg:2 mg)|IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.
3112233|NCT02418819|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
3112234|NCT02418819|Experimental|PF-06412562 9mg|PF-06412562 9mg BID
3112235|NCT02418819|Experimental|PF-06412562 45mg|PF-06412562 45mg BID
3112236|NCT02418819|Placebo Comparator|Placebo|Placebo BID
3112237|NCT02418845|Experimental|SYM-1219|Administered orally
3112238|NCT02418845|Placebo Comparator|Placebo|Administered orally
3112239|NCT02418910||bipolar outpatients|Patients with Bipolar Disorder in any clinical state
3112240|NCT02418949|Experimental|Cyproheptadine + AMP|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
3112241|NCT02418949|Placebo Comparator|Placebo for Cyproheptadine + Stretching|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
3112242|NCT02418949|Active Comparator|Cyproheptadine + Stretching|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of passive cyclical stretching treatment (1 hour sessions 3x/week). Each session will involve 20 min of stretching followed by 10 minutes of rest.~Dose will be titrated down to zero in the 2 weeks following treatment."
3112243|NCT02418949|Active Comparator|Placebo for Cyproheptadine + AMP|"Placebo for Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Chronic dose will be maintained throughout the 6 weeks of Active movement practice (AMP) treatment (1 hour sessions 3x/week). Dose will be titrated down to zero in the 2 weeks following treatment."
3112244|NCT02419001|Experimental|Period 1 - Treatment Sequence AB|"Treatment Sequence AB:~Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
3112245|NCT02419001|Experimental|Period 1 - Treatment Sequence AC|"Period 1: Ceftriaxone 1 g infused IV over 30 minutes~[Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion]"
3112246|NCT02419001|Experimental|Period 2 - Treatment Sequence AB|"Treatment Sequence AB:~[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg (1 x 75 mg capsule) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
3112247|NCT02419001|Experimental|Period 2 - Treatment Sequence AC|"[Period 1: Ceftriaxone 1 g infused IV over 30 minutes]~Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg (2 x 75 mg capsules) orally administered 30 minutes before and 5.5 hours after the start of the ceftriaxone infusion"
3112248|NCT02419313|Active Comparator|Placebo, then Xeomin|Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
3112249|NCT02419313|Active Comparator|Xeomin, then Placebo|Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.
3112250|NCT02419469|Experimental|Augmented BFM Therapy + Ofatumumab or Rituximab|Participants receive the study drugs in Induction, Consolidation, and Maintenance Courses.
3112251|NCT02419508|Experimental|SIMBRINZA + PGA|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
3112252|NCT02419508|Other|Vehicle + PGA|Brinz/brim vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00) plus designated prostaglandin analogue, 1 drop instilled in each eye once per day in the evening for 42 days
3112253|NCT02419521|Other|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Stent System
3112254|NCT02419547|Other|Anesthesia Induction|Patients undergoing ventricular tachycardia ablation will undergo programmed stimulation (PS) with minimal sedation (Versed, Fentanyl), with intravenous agents (propofol) , and finally with volatile inhalational agent (sevoflurane).
3112255|NCT02419573|Active Comparator|Endotracheal Intubation|The insertion of a plastic breathing tube through the mouth and into the trachea.
3112256|NCT02419573|Active Comparator|Laryngeal Tube (King)|Insertion of a supraglottic airway (SGA)
3112257|NCT02419612|Experimental|Saxagliptin 5 mg/ dapagliflozin 10mg or Placebo|Saxagliptin 5 mg /dapagliflozin 10 mg Placebo once a day orally
3112258|NCT02419612|Experimental|Glimepiride or Placebo|Glimepiride or placebo 1mg or 2mg or 3mg or 4mg or 6mg once a day orally
3112259|NCT02419690|No Intervention|Usual Care|The current standard of care in the clinic is a preventive care physical examination every 1-2 years and/or treatment for presenting medical conditions. The frequency and content of reproductive health is not standardized between clinicians, but it is expected that all clinicians will address sexuality during routine visits. Additionally, sexually active teens are encouraged to have urine screening tests for chlamydia, gonorrhea and pregnancy as indicated. Teens may also see a reproductive health educator at the clinic as well. Available contraceptive methods are oral contraceptive pills, contraceptive patches, Depo-Provera, diaphragms, condoms, implants and intrauterine devices (IUDs).
3112260|NCT02419690|Active Comparator|text message intervention|Subjects in the intervention arm will receive usual care plus text messages that have been developed to promote overall teen sexual health.
3112261|NCT02419755|Experimental|Stratum 1: Myeloid Malignancies|Participants receive cytarabine, bortezomib, vorinostat, methotrexate, hydrocortisone, mitoxantrone as described in the Detailed Study Description.
3112262|NCT02419755|Experimental|Stratum 2: ALL and MLM|Participants in Stratum 2 [Acute Lymphoid Leukemia (ALL) and Mixed Lineage Malignancies (MLM)] receive mitoxantrone, PEG-L-Asparaginase (or Erwinia L-asparaginase), dexamethasone, bortezomib, vorinostat, cytarabine, methotrexate, hydrocortisone, mercaptopurine, and doxorubicin as described in the Detailed Study Description.
3112263|NCT02419807|Experimental|Diagnostic (indocyanine green, 99mTc-labeled radiotracer)|Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.
3112264|NCT02419924|Experimental|Experimental|Pelvic floor support device to treat refractory constipation.
3112265|NCT02419937|Active Comparator|Tocilizumab|Blinded subjects will be randomized to tocilizumab 162 mg subcutaneously once.
3112266|NCT02419937|Placebo Comparator|Placebo|Blinded subjects will be randomized to placebo
3112267|NCT02420015|Experimental|iCOMMIT|The components of the intervention include 1) behavioral therapy in the form of mobile contingency management (mCM) designed to increase early abstinent rates; 2) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; 3) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation; 4) a smart-phone based relapse prevention application (the Stay Quit Coach) that is populated during the counseling sessions; and 5) SMS text messaging reminders to increase medication adherence.
3112268|NCT02420015|Active Comparator|Control Group|The components of the intervention include 1) pharmacotherapy for smoking cessation [including nicotine replacement therapy (NRT) and bupropion]; and 2) four sessions of guideline based cognitive-behavioral smoking cessation counseling designed to increased coping skills specific to smoking cessation.
3112269|NCT02420041|Active Comparator|Fluoroscopic Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of sacroiliac joint (SIJ) dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group A : Fluoroscopy will be used to Guide Needle Placement to inject Steroid into joint. Then complete the multidimensional pain inventory (MPI) and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PGIC), numerical rating scale (NRS), and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
3112270|NCT02420041|Experimental|Ultrasound Guidance|Patients referred to the Naval Medical Center-San Diego Pain Medicine Clinic. Need a history and physical showing objective findings of SIJ dysfunction. If the patient meets inclusion / exclusion criteria, they will be presented with the study. After accepting and being consented, they will then be scheduled. The day of the appointment they will be randomised to Group A or B. In Group B Ultrasound will be used to Guide Needle Placement to inject steroid into joint. Then complete the MPI and rate their pain on the NRS from 0-11. After procedure, they will rate their pain from 0-10 in the recovery area and then be discharged to home. They will complete an MPI, Patient Global Impression of Change (PIGC), NRS, and adverse events questionnaire 1-2 weeks post-procedure and 3 months post-procedure.
3112271|NCT02420093|Experimental|Experimental Group|"The experimental group will use the Pelvis Support Assembly per US Patent number US 8,857,906 B2, in the seat of their work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting."
3112272|NCT02420093|No Intervention|Control Group|"The control group will not use the Pelvis Support Assembly per US Patent number US 8,857,906 B2 but will continue in their current sitting arrangement during the same 3 week interval"
3112273|NCT02420210|Experimental|Treatment (bendamustine, obinutuzumab, dexamethasone)|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2, obinutuzumab IV over 4 hours on days 1 or 2, 8, and 15 (on both days 1 and 2 in course 1 only), dexamethasone PO daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3112274|NCT02420223|Experimental|Propranolol|Patient's randomized to the Propranolol arm will be starting 7 days prior to transplant and continuing through 28 days post-transplant. Propranolol will start at 20mg twice daily and will be titrated to 40mg twice daily as tolerated. Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for up to 7 total weeks for patient's on the Propranolol arm.
3112275|NCT02420223|No Intervention|Control Arm|Both groups will come back to the hospital weekly in order to assess items such as patient's level of anxiety, depression, your adherence, and also to monitor for side effects. The patient's will complete questionnaires during your visit. These will take approximately 15 minutes to complete. This will continue for 6 total weeks for patient's on the control arm.
3112276|NCT02420262|Experimental|IDegLira|
3112277|NCT02420262|Active Comparator|IGlar plus IAsp|
3112278|NCT02420327|Experimental|Placebo patch and placebo capsule|On the double-placebo test day, participants receive a placebo patch and a placebo capsule.
3112279|NCT02420327|Experimental|Nicotine patch and placebo capsule|On the nicotine test day, participants receive a nicotine patch (7 mg/24 hrs) and a placebo capsule.
3112280|NCT02420327|Experimental|Placebo patch and galantamine capsule|On the galantamine test day, participants receive a placebo patch and a capsule containing 4 mg of galantamine.
3112281|NCT02420327|Experimental|Nicotine patch and galantamine capsule|On the nicotine + galantamine test day, participants receive a nicotine patch (7 mg/24 hrs) and a capsule containing 4 mg of galantamine.
3112282|NCT02420353|Active Comparator|Somatropin|Somatropin of rDNA origin
3112283|NCT02420353|Placebo Comparator|Placebo|A placebo vehicle that contains somatropin diluent but no active hormone.
3112284|NCT02420379|Experimental|Open-Label|Approximately 20 patients will receive weekly infusions of eteplirsen 30 mg/kg .
3112285|NCT02420379|No Intervention|Control Group|Approximately 20 patients with DMD not amenable to exon 51 skipping will be observed for 96 weeks.
3112286|NCT02420639|Experimental|Intervention|The placement of the Esophageal Cooling Device will follow standard recommendations as per Instructions for Use. The Esophageal Cooling Device will be connected to the appropriate console (Meditherm III, Blanketrol II, or Blanketrol III).
3112287|NCT02420691|Experimental|Treatment (ribociclib)|Patients receive ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112288|NCT02420821|Experimental|Atezolizumab + Bevacizumab|Participants will receive both atezolizumab and bevacizumab until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
3112289|NCT02420821|Active Comparator|Sunitinib|Participants will receive sunitinib until loss of clinical benefit, unacceptable toxicity or symptomatic deterioration attributed to disease progression, withdrawal of consent, or death, whichever occurs first.
3112290|NCT02420873|Experimental|Cohort 1: CD56 Expressing Hematological Malignancies|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3112291|NCT02420873|Experimental|Cohort 2: Myelofibrosis|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3112292|NCT02420873|Experimental|Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm|Lorvotuzumab mertansine (IMGN901) administered intravenously at a dose of 100 mg/m2 on Day 1 and 8 of a 21-day cycle.
3112293|NCT02420951|Experimental|Injection|Will receive injection of 30ml of .5% bupivacaine solution prior to catheter removal
3112294|NCT02420951|Active Comparator|No Injection|Will not receive injection of bupivacaine prior to catheter removal
3112295|NCT02421055||Group 1|Roux-en-Y Gastric Bypass
3112296|NCT02421055||Group 2|Sleeve Gastrectomy
3112297|NCT02421094|Active Comparator|GR-MD-02|Active
3112298|NCT02421094|Placebo Comparator|Placebo|Placebo
3112299|NCT02421120|Experimental|Ceftolozane/Tazobactam|Ceftolozane/Tazobactam 3 grams every 8 hours intravenously for 4-6 doses
3112300|NCT02421146|Sham Comparator|Sham tDCS - Healthy Controls|The sham group session will contain 20 minute sessions of transcranial direct current stimulatio , but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
3112301|NCT02421146|Active Comparator|tDCS - Healthy Controls|will receive real transcranial direct current stimulation. Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
3112302|NCT02421146|Sham Comparator|Sham tDCS - Patients|The sham group session will contain 20 minute sessions of transcranial direct current stimulation as well, but only the first minute will be with 2mA, then unbeknownst to the subject, the unblinded research assistant will turn off the stimulation.
3112303|NCT02421146|Active Comparator|tDCS - Patients|will receive real transcranial direct current stimulation . Real tDCS stimulation will involve ten 20 minute stimulations daily (at 2 mA anode over the left DLPFC while cathode over the right suborbital region) on 5 weekdays of two consecutive weeks
3112304|NCT02421172|Experimental|Period 1: CJM112 High Dose|Period 1: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
3112305|NCT02421172|Placebo Comparator|Period 1: Placebo|Period 1: Placebo subcutaneously (s.c.) weekly for 5 doses followed by bi-weekly for 5 doses for a total of 10 doses
3112306|NCT02421172|Placebo Comparator|Period 2: CJM112 High Dose (Period 1) / Placebo (Period 2)|Period 2: Placebo subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on CJM112 High Dose in Period 1
3112307|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 Low Dose (Period 2)|Period 2: CJM112 Low Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
3112308|NCT02421172|Experimental|Period 2: Placebo (Period 1)/CJM112 High Dose (Period 2)|Period 2: CJM112 High Dose subcutaneously (s.c.) weekly for 5 doses then bi-weekly for 5 doses for a total of 10 doses this group.This group was on Placebo in Period 1
3112309|NCT02421211|Experimental|Panel 1|Participants will receive Simeprevir (SMV) 150 milligram (mg) capsule (Treatment A) along with Sofosbuvir (SOF) 400 mg tablet, orally, once daily (Treatment C) from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with fixed dose combination (FDC) tablet of 90 mg Ledipasvir (LDV)/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 70.
3112310|NCT02421211|Experimental|Panel 2|Participants will receive FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 1 until Day 14 followed by SMV 150 mg capsule (Treatment A) along with FDC tablet of 90 mg LDV/400 mg SOF (Treatment B), orally, once daily from Day 15 until Day 56.
3112311|NCT02421224|Active Comparator|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
3112312|NCT02421224|Experimental|Deposits|Same as Usual Care, plus participants will have to deposit a certain amount of their own money as an incentive to quit smoking. Participants will be able to make additional voluntary deposits above the minimum amount. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
3112313|NCT02421224|Experimental|Small Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
3112314|NCT02421224|Experimental|Large Individual Bonus|Same as Usual Care, plus each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
3112315|NCT02421224|Experimental|Team Bonus|Same as Usual Care, plus each participant will be randomly assigned one teammate to provide social support during the quit attempt. If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
3112316|NCT02421224|Experimental|Deposits plus Small Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Small Individual Bonus group.
3112317|NCT02421224|Experimental|Deposits plus Large Individual Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will follow the protocol for the monetary bonus as described for the Large Individual Bonus group.
3112318|NCT02421224|Experimental|Deposits plus Teammate|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group and will be randomly assigned one other participant to serve as a teammate who provides social support during the quit attempt.
3112319|NCT02421224|Experimental|Deposits plus Team Bonus|Same as Usual Care, plus the participant will follow the protocol for deposits as described for the Deposits group, will be randomly assigned a teammate, and will follow the protocol for the monetary bonus as described for the Team Bonus group.
3112320|NCT02421354|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks for 8 doses and then once every 12 weeks thereafter. Treatment may continue for up to 4 years in the absence of disease progression or unacceptable toxicity.
3112321|NCT02421419|Active Comparator|Corticosteroid alone (CS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable
3112322|NCT02421419|Active Comparator|Corticosteroid/Lidocaine (CSL) Group|1 cc dexamethasone sodium phosphate (4 mg/ml) injectable and 1 cc 1% Xylocaine (lidocaine) injectable
3112323|NCT02421419|Active Comparator|Corticosteroid/Saline (CSS) Group|1 cc dexamethasone sodium phosphate (4mg/ml) injectable and 1 cc 0.9% injectable Sodium Chloride (saline)
3112324|NCT02421510|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
3112325|NCT02421510|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 milligram (mg) (one 200 mg tablet and one placebo tablet), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
3112326|NCT02421510|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally, before the first meal of the day for 24 weeks followed by a 28-week extension period.
3112327|NCT02421588|Experimental|Arm A|lurbinectedin (PM01183)
3112328|NCT02421588|Active Comparator|Arm B|"pegylated liposomal doxorubicin~OR~topotecan"
3112329|NCT02421601|Experimental|SI-6603|SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
3112330|NCT02421666|Experimental|behavioral PNMI|eligible patients received patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care.
3112331|NCT02421666|No Intervention|control|eligible chronic HBV patients received standard care
3112332|NCT02421757|Experimental|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
3112333|NCT02421757|Placebo Comparator|Sham Device|Sham Device
3112334|NCT02421887|Active Comparator|Antioxidant Supplement|Tablet: Vitamin C, 500 mg; Vitamin D3, 1000 IU; Vitamin E, 400 IU; Folic Acid 1000 mcg; Zinc, 20 mg; Selenium 200 mcg; Lycopene, 10 mg; Capsule: Vitamin D3, 1000 IU, L-Carnitine, 1000 mg
3112335|NCT02421887|Placebo Comparator|Placebo|
3112336|NCT02421939|Experimental|Gilteritinib|Participants received 120 mg dose (3 tablets of 40 mg) orally once a day in continuous 28-day cycles, at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants met one of the treatment discontinuation criteria.
3112337|NCT02421939|Active Comparator|Salvage Chemotherapy|Participants received chemotherapy in 28-day cycles. Participants on Low-Dose Cytarabine (LoDAC) received 20 mg of cytarabine twice daily by subcutaneous (SC) or intravenous (IV) injection for 10 days. Participants on azacitidine received 75 mg/m^2 daily by SC or IV injection for 7 days. Participants on LoDAC or azacitidine treatment continued until they met discontinuation criteria. Participants on MEC chemotherapy received mitoxantrone 8 mg/m^2 daily by IV for 5 days, etoposide 100 mg/m^2 daily by IV for 5 days and cytarabine 1000 mg/m^2 daily by IV for 5 days (days 1-5). Participants on FLAG-IDA chemotherapy received G-CSF 300 μg/m^2 daily by SC/IV for 5 days (days 1-5), fludarabine 30 mg/m^2 daily by IV for 5 days (days 2-6), cytarabine 2000 mg/m^2 daily by IV for 5 days (days 2-6) and idarubicin 10 mg/m^2 daily by IV for 3 days (days 2-4). Participants receiving MEC or FLAG-IDA received 1 cycle of therapy and were assessed for response on or after day 15.
3112338|NCT02421952||Single Cohort|All subjects will be asked to assess their pain and nausea using the visual analogue scales (VAS), the modified faces scale and the BARF scale as described below in the preoperative and postoperative areas.
3112339|NCT02422186|Experimental|Intranasal Esketamine plus Oral Antidepressant|Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112340|NCT02422186|Active Comparator|Placebo plus Oral Antidepressant|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase using the same titration as Esketamine. In addition participants will simultaneously initiate a new, open-label oral antidepressant (Duloxetine, Escitalopram, Sertraline, or Venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.
3112341|NCT02422264|Experimental|dTpa Group|This group will consist of infants born to mothers belonging to the dTpa Group in study 116945 [DTPA (BOOSTRIX)-047] i.e. who received a single dose of BoostrixTM during pregnancy and a dose of placebo immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
3112342|NCT02422264|Active Comparator|Control Group|This group will consist of infants born to mothers belonging to the Control group in study 116945 [DTPA (BOOSTRIX)-047], i.e. who received a single dose of placebo during pregnancy and a dose of BoostrixTM immediately post-delivery. All infants in this group will receive Infanrix hexaTM co-administered with Prevenar 13®.
3112343|NCT02422290|Experimental|Adolescents and young adults with OCD|All participants will be receive the intravenous ketamine infusion.
3112344|NCT02422446|Experimental|EPA arm|EPA arm will receive 4 grams per day of EPA (icosapent ethyl) taken twice a day
3112345|NCT02422446|No Intervention|Control|Control group will not receive EPA
3112346|NCT02422511|Active Comparator|Well Baby Family History Only|Parents of newborns in well-baby units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
3112347|NCT02422511|Experimental|Well Baby Family History + Exome Sequencing|Parents of newborns in well-baby units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
3112348|NCT02422511|Active Comparator|ICU Baby Family History Only|Parents of newborns in intensive care units receive an Annotated Family History Report only. Active Comparator: Standard of Care Only: Family History report only
3112349|NCT02422511|Experimental|ICU Baby Family History + Exome Sequencing|Parents of newborns in intensive care units receive a Genome Report and an Annotated Family History Report. Main Study Experimental: Genome Report and Family History report
3469224|NCT03888508|Experimental|SIT plus standard therapy|Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses such as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home Sensory integration kit will be prepared which consists of varying textures from soft to hard items (wool, jute, sand paper, velvet), picture cards, sensory brush, elastic band(Thera tube) and also usage of other home based items such as swings, sofa/bed, textured board, black board, wet chalks and paint. Each session would take approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 d Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving as a standard therapy
3469225|NCT03888508|No Intervention|Standard therapy alone|Standard therapy -Conventional physiotherapy, occupational,behavioural intervention and pharmacotherapy that they are already receiving
3112354|NCT02422940|Active Comparator|dalfampridine-ER 7.5 mg|"Dalfampridine-ER 7.5 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
3112355|NCT02422940|Active Comparator|dalfampridine-ER 10 mg|"Dalfampridine-ER 10 mg tablets taken orally twice daily, approximately 12 hours apart.~Subjects who received active treatment in the antecedent core study will retain the dose assignment to which they were initially randomized (7.5 mg or 10 mg dalfampridine-ER tablets). Subjects who received placebo in the core study will be randomly assigned to receive 7.5 mg or 10 mg dalfampridine-ER tablets in this extension study."
3112356|NCT02423109|Experimental|fanfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
3112357|NCT02423109|Active Comparator|enfilcon A|Each subject randomized to wear either the test or control as a matched pair and cross over to the second matched pair.
3112358|NCT02423122|Experimental|VX-745 dose 1|Active Group 1: VX-745 40 mg twice daily
3112359|NCT02423122|Experimental|VX-745 dose 2|Active Group 2: VX-745 125 mg twice daily
3112360|NCT02423200|Experimental|VX-745 dose level 1|Active Group 1: VX-745 dose level 1 twice daily
3112361|NCT02423200|Experimental|VX-745 dose level 2|Active Group 1: VX-745 dose level 2 twice daily
3112362|NCT02423291|Experimental|Vial for IV infusion|This is a single-arm, open-label, multicenter, Phase 2 clinical trial to evaluate the efficacy and safety of Brentuximab vedotin as a single agent in patients with relapsed or refractory PMLBCL who have previously received a first line of treatment with chemotherapy or immunotherapy.20 patients will be treated in this study and All patients will receive 1.8 mg/kg Brentuximab vedotin administered as a single outpatient IV infusion on Day 1 of each 21-day treatment cycle. Patients may continue on study treatment until disease progression or unacceptable toxicity. Patients who achieve stable disease or better as assessed by investigator should receive a minimum of 8, but no more than 16 cycles of study treatment.
3112363|NCT02423317|Active Comparator|Intubation with Miller's blade|After induction and muscle paralysis, Miller's blade was introduced in the patient's mouth. After visualization of vocal cord, patient was intubated with appropriate sized tracheal tube.
3112364|NCT02423317|Experimental|Intubation with Airtraq laryngoscope|After induction and muscle paralysis, Airtraq laryngoscope's blade was introduced in the patient's mouth. After visualization of vocal cord as a reflected image in the viewfinder of the device, patient was intubated with appropriate sized tracheal tube.
3112365|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 1) Phase 1b|50 milligrams (mg) Galunisertib administered orally once daily (QD) on Day 1 through Day 14 of each 4-week cycle in combination with 3 milligrams per kilogram (3 mg/kg) nivolumab given intravenously (IV), every 2 weeks (Q2W), (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
3112366|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 2) Phase 1b|50 mg Galunisertib administered orally twice daily (BID) on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
3112367|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 3) Phase 1b|80 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
3112368|NCT02423343|Experimental|Galunisertib + Nivolumab (Cohort 4) Phase 1b|150 mg Galunisertib administered orally BID on Day 1 through Day 14 of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W,(Day 1 and Day 15). Participants may continue to receive study drug until discontinuation criteria are met.
3112369|NCT02423343|Experimental|Galunisertib + Nivolumab - Non-small Cell Lung Cancer (NSCLC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3112370|NCT02423343|Experimental|Galunisertib + Nivolumab - Hepatocellular Carcinoma (HCC) Phase 2|150 mg Galunisertib administered orally BID for the first 14 days of each 4-week cycle in combination with 3 mg/kg nivolumab given IV, Q2W, (Day 1 and Day 15) of each 4-week cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3112371|NCT02423408|Experimental|TNX-201|4 X 35 mg capsules to be taken when qualifying tension-type headache occurs
3112372|NCT02423408|Placebo Comparator|Placebo|4 X placebo capsules to be taken when qualifying tension-type headache occurs
3112373|NCT02423447|Active Comparator|Electro-Flo Arm|The patients were randomized to a series of airway clearance sessions with Electro-Flo on Day 1 and G5 on Day 2.
3112374|NCT02423447|Active Comparator|G5 Arm|The patients were randomized to a series of airway clearance sessions with G5 on Day 1 and Electro-Flo on Day 2.
3112375|NCT02423577|Experimental|FF-3 dry powder|FF-3
3112376|NCT02423577|Placebo Comparator|Placebo|
3112377|NCT02423798|Other|Open-label, single-sample design|"The trial has an open label design with a glucose sensor intervention. Only 1 sensor system is used in the trial (no comparator).~As all subjects will receive identical devices and undergo the same experimental procedures, no randomization will be performed. Furthermore, neither subjects nor clinical staff will be blinded to the sensor readings, as knowing the sensor glucose readings will not affect the accuracy endpoint."
3112378|NCT02423980|Experimental|Glucagon|1 mg G-Pen™ (glucagon injection) first, followed by 0.5 mg
3112379|NCT02423993|Experimental|SAP + Group Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) in group using specialised structured education program. CGM will be used for self monitoring of blood glucose permanently within 4 month.
3112380|NCT02423993|Active Comparator|SAP + Standard Education|Patients will be transferred from MDI to sensor-augmented pump (SAP) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
3112381|NCT02423993|Experimental|CSII + Group Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) using specialised structured education program.
3112382|NCT02423993|Active Comparator|CSII + Standard Education|Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
3112383|NCT02424097|Experimental|MI Paste & MI Varnish|MI past will be applied by the patient every night; MI varnish will be applied every three months in the office
3112384|NCT02424097|Active Comparator|Standard of Care|Subjects will use at home regal toothpaste every night and F-mouth rinse as recommended
3112385|NCT02424149|No Intervention|Control|No preoperative phenazopyridine
3112386|NCT02424149|Experimental|Phenazopyridine|Preoperative phenazopyridine
3112387|NCT02424175|Experimental|Patients with PSC|This is an open label study. All patients enrolled will receive a fecal microbiota transplantation.
3112388|NCT02424253|Experimental|ZPL-3893787|30 mg ZPL-3893787 orally once daily for 8 weeks.
3112389|NCT02424253|Placebo Comparator|Placebo|1 capsule orally once daily for 8 weeks.
3112390|NCT02424344|Experimental|Aclidinium Bromide/Formoterol Fumarate FDC 400/12μg|8 weeks, double blind treatment period
3112391|NCT02424344|Placebo Comparator|Placebo to Aclidinium/Formoterol|8 weeks, double blind treatment period
3112392|NCT02424357|Experimental|5% povidone iodine ophthalmic solution|patient received 1 drop of 5% povidone-iodine instilled over the adjustable suture noose in addition to routine antibiotic/steroid ointment to operated eye at surgery completion
3112393|NCT02424357|Active Comparator|no povidone-iodine ophthalmic solution|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
3112394|NCT02424383|Experimental|PTA (Lutonix® 035 DCB Catheter)|Treatment with the Lutonix 035 DCB will be per the investigational site's standard of care and adhering to the IFU.
3112395|NCT02424526|Active Comparator|high-intensity group|Children will engage in home-based treadmill training 5 days/week, twice daily for 10-20 min for 6 weeks
3112396|NCT02424526|Active Comparator|low-intensity group|Children will engage in home-based treadmill training 2 days/week, once daily for 10-20 minutes for 6 weeks
3112397|NCT02424539|Experimental|FFNS 55 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing either FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 55 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
3112398|NCT02424539|Experimental|FFNS 110 mcg Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.
3112399|NCT02424539|Placebo Comparator|Placebo Arm|Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing only placebo. Subject's on their own or with assistance from parent/guardian will administer one intranasal spray of placebo, from Device A and Device B, once daily into each nostril in the morning for 4 Weeks.
3112400|NCT02424578|Experimental|Diclofenac Capsules low dose|Diclofenac Capsules low dose three times daily for up to three days
3112401|NCT02424578|Experimental|Diclofenac Capsules high dose|Diclofenac Capsules high dose three times daily for up to three days
3112402|NCT02424591|Active Comparator|Ketamine|ketamine group will be infused after intubation and terminated at the start of skin closure
3112403|NCT02424591|Placebo Comparator|Placebo|placebo group will have standard of care rather than ketamine infusion
3112404|NCT02424630|Experimental|ISB with SSNB|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL ropivacaine.
3112405|NCT02424630|Placebo Comparator|ISB alone|During arthroscopic rotator cuff repair, ultrasound-guided ISB was performed preemptively with 7.5 mL ropivacaine immediately after general anesthesia was induced. And at the end of surgery, arthroscopy-guided SSNB was performed with 10 mL normal saline.
3112406|NCT02424734|Experimental|Ceftaroline Fosamil|Ceftaroline Fosamil
3112407|NCT02424799|Experimental|Part A: Dose group 1|Subjects will be treated topically with 0.5 % GSK2646264 cream and placebo cream on an area of approximately 12 x 3 centimetre (cm) on the volar aspect of the arm which approximates to 0.2% total body surface area (BSA), on each arm. On Day 2 and Day 3 subjects will receive active treatment and placebo on the same arms as on Day 1, with the percentage BSA being 1% on Day 2 and 5% on Day 3.
3112408|NCT02424799|Experimental|Part A: Dose group 2|Subjects will be treated topically with 1 % GSK2646264 cream and placebo cream on the morning and evening of Day 1 starting at the final % BSA dosed at Day 3 in group 1 which is anticipated to be 5%. In dose group 2, the starting BSA will increase to 10% at Day 3 and then 20% by Day 5. Administration of the evening (PM) dose will be dependent on the data from Part A Dose group 1.
3112409|NCT02424799|Experimental|Part B|Cold urticaria subjects will receive treatment to 4 defined areas (right and left arms and legs). Subjects will be treated with maximum tolerated strength of GSK2646264 cream (0.5% or 1%) and placebo cream in morning or in morning and evening to 2 specified areas of ~5% BSA on the subject's legs for the CU assessment and to 2 specified areas of 0.2% BSA on the volar aspect of the arm. The maximum tolerated strength and evening dosing will be dependent on the data from the Part A
3112410|NCT02424799|Experimental|Part C|Chronic spontaneous urticaria subjects will be treated with the maximum tolerated strength of GSK2646264 cream from Part A (0.5% or 1%) and placebo cream onto defined areas (right and left arms and, legs and front torso) from Days 1 to 7. The total % BSA for an individual subject will be decided by the investigator prior to randomization. The maximum % BSA and the frequency of dosing will be decided after part A of the study.
3112411|NCT02424968|Experimental|Infusion of Allogeneic CD8+ Memory T-cells|All participants receive allogeneic CD8+ memory T-cells 30 to 60 days after standard non-myeloablative allogeneic hematopoietic cell transplant (aHCT).
3112412|NCT02425098|Experimental|High-dose Tetravalent Dengue Vaccine (HD-TDV)|High-dose Tetravalent Dengue Vaccine [HD-TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
3112413|NCT02425098|Experimental|Tetravalent Dengue Vaccine (TDV)|Tetravalent Dengue Vaccine [TDV], 0.5 mL, subcutaneous injection on Day 1. TDV comprised one molecularly-characterized and cloned TDV-2 live attenuated dengue virus strain and three recombinant live attenuated dengue virus strains: TDV-1, TDV-3 and TDV-4. TDV contained 2*10^4 plaque forming units (PFU), 5*10^3 PFU, 1*10^5 PFU, and 3*10^5 PFU of TDV-1, TDV-2, TDV-3 and TDV-4 respectively.
3112414|NCT02425111|Experimental|Vedolizumab 300 mg|Part A: Vedolizumab 300 mg, intravenously (IV), once on Day 1 and Weeks 2, 6, 14 and 22, followed by Part B: Vedolizumab 300 mg, intravenously (IV), once at Weeks 30, 38, and 46.
3112415|NCT02425306|Experimental|Arm A:6MHP + Montanide ISA-51|Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
3112416|NCT02425306|Experimental|Arm B:6MHP + Montanide ISA-51 + Cyclophosphamide|"Part 1: 200 mcg of 6MHP emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
3112417|NCT02425306|Experimental|Arm C:6MHP + polyICLC + Montanide ISA-51|Part 1: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78.
3112418|NCT02425306|Experimental|Arm D:6MHP + polyICLC + Montanide ISA-51 + Cyclophosphamide|"Parts 1 and 2: 200 mcg of 6MHP plus 1 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered on 1, 8, 15, 36, 57 and 78. Cyclophosphamide (50 mg) will be taken orally once a day for 7 days followed by a 7 day rest period. This will be repeated for 5 cycles. Cycles will begin on the following days:~Day -6 (Cycle 1)~Day 8 (Cycle 2)~Day 22 (Cycle 3)~Day 36 (Cycle 4)~Day 50 (Cycle 5)"
3112419|NCT02425449|Experimental|01 mg/kg|Succinylcholine 0.1 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3112420|NCT02425449|Experimental|0.15 mg/kg|Succinylcholine 0.15 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3112421|NCT02425449|Experimental|0.2 mg/kg|Succinylcholine 0.2 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3112422|NCT02425449|Experimental|0.25 mg/kg|Succinylcholine 0.25 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3112423|NCT02425449|Experimental|0.3 mg/kg|Succinylcholine 0.3 mg/kg will be administered and TOF ratio measured before and after the administration until stable
3112424|NCT02425644|Experimental|Ponesimod|Subjects to receive 20 mg ponesimod
3112425|NCT02425644|Active Comparator|Teriflunomide|Subjects to receive 14 mg teriflunomide
3112426|NCT02425826|Experimental|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
3112427|NCT02425826|Placebo Comparator|Placebo|Placebo tablets BID during Weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 36 weeks (from week 16 to week 52)
3112428|NCT02425891|Experimental|Atezolizumab Plus Nab-Paclitaxel|Participants assigned to atezolizumab plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
3112429|NCT02425891|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel received both agents until disease progression or unacceptable toxicity.
3112430|NCT02425956|Experimental|MRI imaging of liver|GE Optima/Discovery® MRI imaging data of the liver and surrounding tissues will be acquired using 1.5T and 3.0T GE Healthcare (GEHC) IDEAL IQ scans and commercially available 1.5T MRI scans conducted according to the FerriScan®
3112431|NCT02426086|Experimental|Imetelstat 4.7 mg/kg|
3112432|NCT02426086|Experimental|Imetelstat 9.4 mg/kg|
3112433|NCT02426125|Experimental|Ramucirumab + Docetaxel|Ramucirumab (10 milligram/kilogram [mg/kg]) intravenously (IV) plus docetaxel (75 milligram/square meter [mg/m²]) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3112434|NCT02426125|Placebo Comparator|Placebo + Docetaxel|Placebo IV plus docetaxel (75 mg/m²) IV in 21 day cycles. Participants may continue to receive treatment until discontinuation criteria are met.
3112435|NCT02426138|Experimental|Med. Tailored Meal Delivery, Usual Care + Choose Myplate|Participants will receive 12 weeks of medically tailored meal delivery, comprising approximately half of their weekly caloric intake and consisting of foods prepared under the supervision of a registered dietitian to be compatible with a diabetes diet. They will also receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
3112436|NCT02426138|Active Comparator|Usual Care + Choose Myplate, Med. Tailored Meal Delivery|Participants will receive usual diabetes care and a Choose MyPlate healthy eating brochure for 12 weeks.
3112437|NCT02426476|Experimental|active HRVB training|Heart rate variability biofeedback training
3112438|NCT02426476|Sham Comparator|sham HRVB training|passive relaxation
3112439|NCT02426541|Experimental|Dapagliflozin|Dapagliflozin Once Daily 10 mg
3112440|NCT02426541|Placebo Comparator|Placebo|Matching placebo for Dapagliflozin Once Daily 10 mg
3112441|NCT02426580|Experimental|Intervention with wechat group|The wechat model will provide information of protein, calcium, phosphorus and sodium intake, which were suggested by the current KDIGO/ KDOQI guideline.
3112442|NCT02426580|No Intervention|Controlled group|Only conventional education every 3 months during routing clinical visit
3112443|NCT02426658|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality-of-Life Assessment and Laboratory Biomarker Analysis.
3112444|NCT02426749|Active Comparator|Active Coil|Participants of this arm will receive active rTMS intervention (treatment).
3112445|NCT02426749|Sham Comparator|Sham|Participants of this arm will receive sham rTMS intervention (treatment).
3112446|NCT02426918|Experimental|Debio 1450 320/480 mg|After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).
3112447|NCT02426918|Experimental|Debio 1450 160/240 mg|After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.
3112448|NCT02426918|Placebo Comparator|Placebo|After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.
3112449|NCT02427100|No Intervention|Control Group|Control participants will be paid for assessments. They will receive study newsletters and a pedometer with advice after the final follow-up visit.
3112450|NCT02427100|Active Comparator|Intervention Group|Intervention participants will receive 4 weekly newsletters, a pedometer with walking advice, and twice daily fruit/vegetable snacks during weekdays.
3112451|NCT02427399|No Intervention|Usual care / opportunistic screening|This group will not be contacted by the study team in any way and will receive the general standard of care at Fenway. Patient charts are reviewed by the provider and medical team shortly before a scheduled visit to determine if the patient is due for a Pap, and if so, the patient is offered a Pap during the visit or the chance to schedule one for another date. Any proactive outreach occurs infrequently and at an ad-hoc basis, but should any proactive outreach occur, the study team will not interfere.
3112452|NCT02427399|Experimental|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests. If the patient does not contact Fenway within 1 month to schedule an appointment, an additional letter will be sent at 1 month, and similarly again at 2 months. These letters will be the same, except that letters two and three will mention that previous attempts have been made at contact. Based on best practices in the literature, the letters will be signed by the patient's primary care provider.
3112453|NCT02427399|Experimental|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders. The email will be sent from the provider's email account. The email will have an informational sheet attached or included in the body of the email. The emails will be sent through MyFenway, the secure, Health Insurance Portability and Accountability Act (HIPAA)-compliant patient contact system at Fenway.
3112454|NCT02427399|Experimental|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. As per HIPAA regulations, if the patient does not answer, a voicemail will be left saying that a Fenway representative has called and request that the patient calls back, but a reason will not be given. Some, but not all of the information contained in the info sheet will be provided during the call (see phone script). The script used is consistent with the scripts used currently for patient outreach. A voicemail will still count as one outreach attempt out of three. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
3112455|NCT02427399|Experimental|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called. If a patient randomly selected for this group does not have an email listed, she will receive one letter and two phone calls.
3112456|NCT02427477|Experimental|senofilcon A/ delefilcon A/ senofilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the senofilcon A contact lens, then wore the delefilcon A contact lens second and then wore the senofilcon A contact lens third.
3112457|NCT02427477|Active Comparator|delefilcon A/senofilcon A/ delfilcon A|Subjects were randomized to one two lens wear sequences. Subjects randomized to this sequence first wore the delefilcon A contact lens then wore the senofilcon A contact lens second and then wore the Control lens delefilcon A contact lens third.
3112458|NCT02427568|Placebo Comparator|Placebo with therapy|Inactive placebo administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by (optional) inactive placebo supplemental dose.
3112459|NCT02427568|Active Comparator|MDMA-assisted therapy (125 mg)|125 mg 3,4-methylenedioxymethamphetamine (MDMA) administered on 2 blinded experimental sessions scheduled 2 to 4 weeks apart. Initial dose possibly followed 1.5 to 2.5 hours later by a (optional) supplemental dose of 62.5 mg MDMA.
3469226|NCT03888521|Experimental|Resound Relief|All participants are in the same group, and receive the same intervention - use of the Resound Relief smartphone app for 6 months
3469227|NCT03888573|Active Comparator|Stretch|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms.
3112460|NCT02427607|Experimental|Perampanel|Participants started the study with the dose that they were receiving at the end of their participation in the previously participated Study E2007-G000-332 (Study 332) [NCT02307578]. Doses of perampanel were allowed to be adjusted based on clinical judgment. A minimum perampanel dose of 2 milligram (mg) per day was required to continue in the study. The maximum daily dose of perampanel permitted was 12 mg per day.
3112461|NCT02427646|Experimental|ET BoNT-A treatment|ET participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
3112462|NCT02427646|Experimental|PD tremor BoNT-A treatment|PD participants treated with kinematic-guided BoNT-A injections over 6 injection cycles
3112463|NCT02427672|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal bilateral transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the dorsolateral prefrontal cortex bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 1mA will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
3112464|NCT02427672|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
3112465|NCT02427737|Experimental|Comfort Talk® Training|In the experimental group, MRI personnel is trained to use Comfort Talk® to help patients who are claustrophobic, anxious, and/or cannot lie still to complete their tests at the onset of the MRI scan.
3112466|NCT02427737|No Intervention|Control|MRI sites not trained in Comfort Talk®.
3112467|NCT02427750|Experimental|Trivalent Influenza Vaccine|One injection of Agrippal®
3112468|NCT02427802|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112469|NCT02427802|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112470|NCT02427802|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112471|NCT02427841|Experimental|Treatment (chemotherapy, chemoradiation therapy, surgery)|"PRE-OPERATIVE (NEOADJUVANT) CHEMOTHERAPY: Patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo IG-IMRT 5 days a week for 28 fractions and receive fluorouracil IV continuously on days 1-7 for 6 weeks.~SURGICAL RESECTION: Patients undergo surgery 4-10 weeks after the last dose of chemoradiation.~POST-OPERATIVE (ADUJUVANT) CHEMOTHERAPY: Beginning within 8-12 weeks after surgery, patients receive nab-paclitaxel IV over 30 minutes and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 4 additional courses in the absence of disease progression or unacceptable toxicity."
3112472|NCT02427958|Experimental|Leuprorelin|Participants with body weight greater than or equal to (>=) 20 kilogram (kg) will receive the recommended dose of leuprorelin 3.75 milligram (mg), injection, subcutaneously, once every 4 weeks for 96 weeks. Participants with body weight less than (<) 20 kg will receive leuprorelin 1.88 mg, injection, subcutaneously, once every 4 weeks for 96 weeks.
3112473|NCT02427984||Metal on Metal (MoM)|Patients wearing MoM hip prosthesis
3112474|NCT02427984||Ceramic on Ceramic (CoC)|Patients wearing CoC hip prosthesis
3112475|NCT02427984||Controls|Patients free from hip devices
3112476|NCT02428192|Experimental|Cohort A (nivolumab - closed to accrual on 21-Oct-2015)|Patients receive nivolumab IV over approximately 60 minutes once every 2 weeks for up to 46 doses in the absence of disease progression or unacceptable toxicity.
3112477|NCT02428192|Experimental|Cohort B (nivolumab and Ipilimumab)|Patients receive nivolumab IV over approximately 60 minutes followed by a saline flush and ipilimumab IV over 90 minutes. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3112478|NCT02428296|Experimental|Patients with PIK3CA gene mutation treated with Sirolimus|This is a single-arm, non-randomized, open-label study for the treatment of segmental overgrowth disorders (somatic PIK3CA gene mutation) with Sirolimus in thirty-nine patients.
3112479|NCT02428309|Experimental|Low Dose Treg Cohort|3-6 participants will receive a single infusion of 1 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3112480|NCT02428309|Experimental|Medium Dose Treg Cohort|Sequential dose escalation, 3-6 subjects will receive a single infusion of 4 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3112481|NCT02428309|Experimental|High Dose Treg Cohort|Sequential dose escalation, 3-6 participants will receive a single infusion of 16 x 10^ 8 autologous polyclonal Tregs (ex vivo selected and expanded)
3112482|NCT02428413|Active Comparator|Standard oxygen mask|Standard face mask to provide supplemental oxygen
3112483|NCT02428413|Active Comparator|ISO-Gard Mask|Face mask to scavenge waste anesthetic gases from patient during recovery from general anesthesia and to provide supplemental oxygen.
3112484|NCT02428478|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
3112485|NCT02428478|Active Comparator|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
3112486|NCT02428595|Experimental|Treatment|Eclipse™ System
3112487|NCT02428608|Experimental|Botulinum toxin, Tyoe A|DWP-450 (Botulinum toxin, Type A)
3112488|NCT02428699|Experimental|Test|30mL Test contains 10%w/w cod oil + 10%w/w cod liver oil in an emulsion formulation
3112489|NCT02428699|Active Comparator|Control|5.8mL of cod liver oil in a free flowing non-emulsified formulation
3112490|NCT02428855|Experimental|Dasatinib|"Patients with advanced intrahepatic cholangiocarcinoma who have either IDH1 or IDH2 mutations and have received at least one prior platinum containing regimen~Dasatinib, oral, daily, predetermined dosage per cycle~Radiologic Response Assessment every 2 cycles"
3112491|NCT02429115|Experimental|Face-to-face peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
3112492|NCT02429115|Experimental|Online peer mentoring|Will receive 6 months of face-to-face peer mentoring by a trained peer mentor.
3112493|NCT02429115|No Intervention|Control|Will not receive peer mentoring.
3112494|NCT02429258|Experimental|Farxiga with metformin or insulin|Farxiga with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
3112495|NCT02429258|Placebo Comparator|Placebo with metformin or insulin|Placebo with metformin (>/=1500mg/day) or insulin (>/=30 units/day) and up to 2 OAD medications
3112496|NCT02429310|No Intervention|Supervised Exercise Only|This is the cohort of patients with Intermittent Claudication that will receive standard care of a supervised exercise programme only.
3112497|NCT02429310|Experimental|NMES + Supervised Exercise|This cohort of patients with Intermittent Claudication will receive the standard care of supervised exercise plus the use of a Revitive IX neuromuscular electrical stimulation device (Intervention) as per the protocol. The adjunctive benefit of the latter intervention compared to standard treatment alone will then be assessed.
3112498|NCT02429427|Experimental|Celecoxib|Patients in this arm will receive 400mg of celecoxib once daily. In addition, Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
3112499|NCT02429427|Placebo Comparator|Placebo|Patients in this arm will receive 2 tablets once daily. In addition Hormone Receptor (+) patients will receive endocrine treatment according to local practice.
3112500|NCT02429778|Experimental|BREATHE|4 weeks DVD-delivered relaxation intervention program called breathe. The experimental intervention includes progressive muscle relaxation, diaphragmatic breathing, and home practice of the skills. Following the 4 weeks of treatment, participants will be asked to continue to practice at home for 4 weeks.
3112501|NCT02429778|No Intervention|Wait List|8 week wait list period. Participants assigned to wait list will have the opportunity to receive BREATHE arm after 8 weeks if interested.
3469228|NCT03888573|Active Comparator|Traction|Patients within Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
3112504|NCT02429856|Active Comparator|PCS|SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
3112505|NCT02429856|Active Comparator|PCR|SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
3112506|NCT02429869|Experimental|Everolimus|
3112507|NCT02429934|Active Comparator|Abatacept also known as Orencia also known as CTLA4Ig|32 SLE patients to be treated with subcutaneous abatacept 125mg sq once a week for 16 weeks.
3112508|NCT02429934|Placebo Comparator|Placebo|32 SLE patients to be treated with subcutaneous placebo once a week for 16 weeks. Injection will be vehicle injected subcutaneously once a week for 16 weeks
3112509|NCT02430090|Experimental|Levobupivacaine|"Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.~Injection Surgical anaesthesia~Adult: Epidural block: 50-100 mg (10-20 ml) of a 0.5% solution or 75-150 mg (10-20 ml) of a 0.75% solution. Caesarean section: 75-150 mg (15-30 ml) of a 0.5% solution. Spinal block: 15 mg (3 ml) of a 0.5% solution. Max: 150 mg/dose; 400 mg/day. Injection Peripheral nerve block~Read more: http://www.ndrugs.com/?s=levobupivacaine#ixzz3Xvp0iS5T"
3112510|NCT02430090|Experimental|Levobupivacaine + fentanyl|"Fentanyl - Used for: Producing anesthesia for surgery and treating pain before, during, and after surgery.Fentanyl is a narcotic (opioid) analgesic. It works in the brain and nervous system to cause anesthesia and decrease pain.~Indications:~Adult: PO Breakthrough cancer pain As a loz: Initially, 200 mcg over 15 minutes for an episode of breakthrough pain; may repeat once after 15 minutes if needed. Not more than 4 unit doses/day. IV Adjunct to general anesth Patients w/ spontaneous resp: Initial: 50-200 mcg, w/ supplements of 50 mcg. Patients w/ assisted ventilation: Initial: 300-3,500 mcg (up to 50 mcg/kg), w/ supplements of 100-200 mcg depending on response.~Read more: http://www.ndrugs.com/?s=fentanyl#ixzz3XvpAcULL"
3112511|NCT02430090|Experimental|Levobupivacaine + sufentanil|"Sufentanil is a synthetic opioid analgesic. Sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation.~Maintenance: Additional doses of 0.5-10 mcg/kg may be given if needed. Max (total dose): 30 mcg/kg. Post-op pain Initial: 30-60 mcg. Additional doses of up to 25 mcg may be given at intervals of ≥1 hr if needed. Epidural Pain relief during labour and delivery W/ bupivacaine: 10-15 mcg w/ or w/o epinephrine. May repeat dose twice at intervals of ≥1 hr till delivery. Max (total dose): 30 mcg.~Read more: http://www.ndrugs.com/?s=sufentanil#ixzz3XvqVyLzx"
3112512|NCT02430311|Experimental|Cohort 1|Treat 15 patients, single dose olaparib 300mg followed by multiple dose olaparib 300mg twice a day
3112513|NCT02430311|Experimental|Cohort 2|Treat 15 patients, single dose olaparib 100mg followed by multiple dose olaparib 100 mg twice a day and then in combination with paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle)
3112514|NCT02430337|Experimental|Technology-Assisted SafeCare|A modified version of SafeCare, using a tablet and online program to complete a portion of the session
3112515|NCT02430337|Active Comparator|SafeCare-as-usual|SafeCare as it is usually delivered
3112516|NCT02430389|Experimental|Remifentanil|Intravenous bolus of 10 mL of remifentanil (0.7 mcg/kg based on ideal body weight) will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
3112517|NCT02430389|Placebo Comparator|Normal Saline|Intravenous bolus of 10 mL normal saline from study syringe will be given ninety seconds before head pinning as well as an intravenous bolus of propofol (0.7 mg/kg).
3112518|NCT02430480|Experimental|1/Arm 1- Enzalutamide and Goserelin|Patients will have an multi-parametric magnetic resonance imaging (mpMRI) guided biopsy, then receive enzalutamide and goserelin subcutaneous (SC) treatment for 6 months followed by a second mpMRI examination.
3112519|NCT02430818|Experimental|Ketamine|Ketamine is a dissociative agent that is thought to modulate pain by binding to NMDA receptors. Participants assigned to the ketamine arm will be given 0.4 mg/kg IV of ketamine (40 mg maximum).
3112520|NCT02430818|Experimental|Morphine|Morphine is an opioid that acts on opioidergic receptors to modulate pain. Participants in the opioid arm will receive 0.1 mg/kg IV of morphine (10 mg maximum).
3112521|NCT02430870|Experimental|Part 1 Cohort 1: TAK-648 0.35 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 1 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3112522|NCT02430870|Experimental|Part 1 Cohort 2: TAK-648 0.80 mg|Participants with T2DM on a stable dose of metformin in study Part 1, Cohort 2 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3112523|NCT02430870|Placebo Comparator|Part 1: Placebo Cohort 1-2|Participants with T2DM on a stable dose of metformin in study Part 1 received placebo-matching TAK-648, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by once daily (QD) doses starting on Day 4 and continuing through Day 17 (14 days).
3112524|NCT02430870|Experimental|Part 2 Cohort 1: TAK-648 0.05 mg|Healthy participants of Japanese descent in study Part 2, Cohort 1 received TAK-648 0.05 mg, solution , orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3112525|NCT02430870|Experimental|Part 2 Cohort 2: TAK-648 0.15 mg|Healthy participants of Japanese descent in study Part 2, Cohort 2 received TAK-648 0.15 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3112526|NCT02430870|Experimental|Part 2 Cohort 3: TAK-648 0.35 mg|Healthy participants of Japanese descent in study Part 2, Cohort 3 received TAK-648 0.35 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3112527|NCT02430870|Experimental|Part 2 Cohort 4: TAK-648 0.80 mg|Healthy participants of Japanese descent in study Part 2, Cohort 4 received TAK-648 0.80 mg, solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3112528|NCT02430870|Placebo Comparator|Part 2: Placebo Cohort 1-4|Healthy participants of Japanese descent in study Part 2, received TAK-648 placebo-matching solution, orally, single dose on Day 1, no drug administration on Days 2 to 3, followed by multiple QD doses starting on Day 4 and continuing through Day 10 (7 days).
3112529|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle QD|Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
3112530|NCT02431052|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle BID|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
3112531|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 4.0% QD|Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
3112532|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% QD|Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
3112533|NCT02431052|Experimental|Olumacostat Glasaretil Gel, 7.5% BID|Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
3469229|NCT03888729|Experimental|HCV treatment-naïve participants|HCV-infected individuals naïve to DAA therapy regimen; in this group we consider also HCV-infected individuals who have failed interferon-based therapy. Sofosbubir/velpatasvir (SOF/VEL) will be administered once daily for 12 weeks to eligible HCV treatment-naïve participants.
3469230|NCT03888729|Experimental|HCV treatment-experienced participants|HCV treatment-experienced participants, i.e.HCV-infected individuals with a history of virologic failure to SOF/LDV or other DAA-containing regimen. Sofosbubir/velpatasvir /voxilaprevir (SOF/VEL/VOX) will be administered once daily for 12 weeks to eligible HCV treatment-experienced participants
3112536|NCT02431260|Experimental|INCB054329 Monotherapy|
3112537|NCT02431273|Experimental|TDF (Single IVR)|"All subjects will be asked to wear Single (TDF) IVRs for 7 days."
3112538|NCT02431273|Experimental|TDF-FTC (Dual IVR)|"If the TDF IVR is determined as safe, study participants will be asked to replace it with Dual (TDF-FTC) IVRs for 7 days. There will be follow-up visit between removal of a single IVR and replacing it with a dual IVR."
3112539|NCT02431273|Experimental|TDF-FTC-MVC (Triple IVR)|"If the TDF-FTC IVR is determined as safe, study participants will be asked to replace them with Triple (TDF-FTC-MVC) IVRs for 7 days. There will be follow-up visit between removal of a dual IVR and replacing it with a triple IVR."
3112540|NCT02431364|Placebo Comparator|Placebo|Participants received matched placebo tablets to verdinexor tablets orally once daily on Days 1 and 3.
3112541|NCT02431364|Experimental|Verdinexor 5 mg|Participants received verdinexor 5 milligrams (mg) (2 tablets of 2.5 mg each) orally once daily on Days 1 and 3.
3112542|NCT02431364|Experimental|Verdinexor 10 mg|Participants received verdinexor 10 mg tablet orally once daily on Days 1 and 3.
3112543|NCT02431364|Experimental|Verdinexor 20 mg|Participants received verdinexor 20 mg tablet (2 tablets of 10 mg each) orally once daily on Days 1 and 3.
3112544|NCT02431364|Experimental|Verdinexor 40 mg|Participants received verdinexor 40 mg tablet (4 tablets of 10 mg each) orally once daily on Days 1 and 3.
3112545|NCT02431455|Active Comparator|Incentive Spirometry|Incentive spirometry 10 times per hour while awake
3112546|NCT02431455|Experimental|No Incentive Spirometry|No incentive spirometer provided
3112547|NCT02431468|Experimental|Bryostatin 1 20ug|Bryostatin 20 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
3112548|NCT02431468|Experimental|Bryostatin 1 40ug|Bryostatin 40 micrograms administered IV over 45 minutes every other week after 2 initial loading doses of 48 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
3112549|NCT02431468|Placebo Comparator|Placebo|Placebo administered IV over 45 minutes every other week after 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.
3112550|NCT02431533|Experimental|Probiotic PX0612|PX0612 is a probiotic contained in a veggie capsule.
3112551|NCT02431533|Placebo Comparator|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
3112552|NCT02431559|Experimental|Phase 1, Dose Level 0a|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (3 mg/kg Q2W [equivalent to 450 mg Q4W] IV on Days 3 and 17 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Days 3 and 17 of Cycles 4-12.
3112553|NCT02431559|Experimental|Phase 1, Dose Level 0b|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.0 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
3112554|NCT02431559|Experimental|Phase 1, Dose Level +1|Subjects received PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment. Prior to removal of motolimod from the study, subjects received motolimod (2.5 mg/m^2 SC) on Days 3, 10, and 17 of Cycles 1-3 and Day 3 of Cycles 4-12.
3112555|NCT02431559|Experimental|Phase 2|Subjects received the MTD determined in Phase 1 (Dose Level +1), comprising PLD (40 mg/m^2 IV on Day 1 of every cycle) + durvalumab (1500 mg Q4W IV on Day 3 of every cycle) for up to 12 continuous 28-day cycles (Core Study), with extended durvalumab monotherapy permitted for subjects tolerating and benefiting from treatment.
3112556|NCT02431572|Experimental|Metastatic Melanoma to the Brain (Cohort A)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
3112557|NCT02431572|Experimental|Primary Brain Tumor (Cohort B)|"Assess Inflammation (PBR PET)~Immunotherapy~Assess Inflammation (PBR PET)"
3112558|NCT02431572|Experimental|Primary Brain Tumor (Cohort C)|"Chemoradiation~Assess inflammation (PBR PET)~Follow Patients"
3112559|NCT02431598|Active Comparator|Eovist (gadoxetate disodium)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3112560|NCT02431598|Active Comparator|Dotarem (gadoterate dimeglumine)|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3112561|NCT02431598|Active Comparator|Saline|While in the MRI scanner, the subject will receive a clinical dose of Eovist, Dotarem, or normal saline. Each subject will receive all three, in random order, blinded to which agent is received in a given instance.
3112562|NCT02431637|Experimental|Piperaquine Phosphate after infected blood malaria challenge|Volunteers will receive a dose of 480 mg piperaquine phosphate (PQP) approx. 7 days after a challenge with P. falciparum infected red blood cells. The effects of PQP on gametocyte carriage (assessed by PCR) and infectivity to mosquitos after direct and indirect feeding on blood from volunteers will be assessed.
3112563|NCT02431650|Experimental|OZ439|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~In the first cohort 500 mg OZ439 will be administered as a single dose. Doses used in subsequent cohort(s) will be determined following a review of observed safety and pharmacodynamic drug effects."
3112564|NCT02431650|Active Comparator|Primaquine|"Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. when PCR quantification of all participants is ≥ 5,000 parasites/mL, they will receive a single dose of 480 mg of piperaquine phosphate to clear blood stage parasitemia. When gametocytemia is at the peak (approximately 15 days after administration of piperaquine), participants will be randomised to receive either OZ439 or a control group (primaquine treatment).~Primaquine is a positive control for OZ439, to be administered 15 mg as a single dose."
3112565|NCT02431676|Active Comparator|Self-Directed|In this group, the study staff will meet with you once at the beginning of the study to give you written information about weight management.
3112566|NCT02431676|Experimental|Coach Directed Behavioral Weight Loss|The Remote Lifestyle Coaching intervention is based on the Call Center Directed intervention to help you loss weight
3112567|NCT02431676|Experimental|Metformin|This group will be given the study drug called Metformin. Metformin comes in tablet form that you take with meals
3469231|NCT03888534|Experimental|Ixazomib|Ixazomib, injection, intravenously, once on Days 1, 4, 8, and 11 in a single 29-day treatment cycle in combination with multiagent reinduction therapy. Participants >= 1 year will receive the starting dose of 1.0 milligram per square meter (mg/m^2) and <1 year will receive the starting dose of 0.03 milligram per kilogram (mg/kg). The dose escalation phase will determine the MTD or RP2D of Ixazomib. Dose of Ixazomib will be escalated based on the observed safety and tolerability data.
3469232|NCT03888833||Veno arterial extracorporeal membrane oxygenation|
3469233|NCT03888586|Experimental|Dry Needling|Participants were administered trigger point dry kneedling technique 6 times for 1 month, once every 5 days. The subject was positioned prone and the arm position was slightly changed related with the muscle. After the skin inspection it was cleaned with the alcohol. .
3469234|NCT03888586|Experimental|Deep Friction Massage|Deep friction massage was applied transversely unlike the superficial massage and sufﬁciently deep to the ﬁber direction of affected connective tissue to maintain the mobility. Totally 6 sessions were administered twice a week for 3 weeks.
3469235|NCT03888456|Experimental|study|participants will receive a single touch intervention based on osteopathic assessment and treatment
3469236|NCT03888456|Sham Comparator|Control|participants will receive a single touch sham intervention mimicking the intervention
3469237|NCT03888430||Standard Oxygen|preoxygenation methods : Standard Oxygen
3469238|NCT03888430||High flow Oxygen|preoxygenation methods : High flow Oxygen
3112574|NCT02431741|Experimental|Mepilex Transfer Ag|Non controlled investigation
3112575|NCT02431754|Experimental|Tadalafil|"5 milligrams (mg) tadalafil administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
3112576|NCT02431754|Placebo Comparator|Placebo|"Placebo administered once daily orally for 8 weeks in one of two treatment periods.~0.2 mg tamulosin once daily or 4 mg silodosin twice daily.~Participants will remain on stable dose of alpha1 blocker through both treatment periods."
3112577|NCT02431793|No Intervention|Usual Care|Employ the standard of care, no intervention
3112578|NCT02431793|Experimental|EMC2 strategy|"Patients of providers randomized to EMC2 arm will received educational tool from the ED to support the understanding and safe use of opioids.~A single-page medication information sheet with content from a patients perspective and following health literacy best practices.~Prescribing instructions will be adapted to the Universal Medication Scheduled Take-Wait-Stop regimen for both the prescribing and dispensing of the medicine. This format uses simplified text and numeric characters to detail dose.~Provider counseling prompts: The providers for patients in this arm will be prompted to encourage counseling both in the ED and at follow-up time points. These prompts include: 1) An automated prompt to the ED physician upon signing the order; 2) an automated message to the PCP (if an in-system PCP) notifying them of the ED visit, new prescription, and counseling request; and 3) a request for the pharmacist to counsel patient printed automatically on the prescription."
3112579|NCT02431793|Experimental|EMC2 strategy + SMS Text Reminders|In addition to the EMC2 Strategy Arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
3112580|NCT02431806|Placebo Comparator|Placebo|Participants received 2 dose matched over-encapsulated placebo capsules, once daily, orally during the Double-blind Treatment Period up to 8 weeks followed by a 1 week Taper-down Period if applicable as determined by the investigator.
3112581|NCT02431806|Experimental|Levomilnacipran 40 mg|Participants received over-encapsulated levomilnacipran extended release (ER) 40 mg/day capsules orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Days 3-7 and 40 mg/day on Week 2 through Week 8 during the Double-Blind Treatment Period, followed by a 1-week Double-Blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
3112582|NCT02431806|Experimental|Levomilnacipran 80 mg|Participants received over-encapsulated levomilnacipran ER two 40 mg/day capsules (80 mg/day) orally starting at a dose of 10 mg/day on Day 1-2, 20 mg/day on Day 3-4, 40 mg/day on Day 5-7 and 80 mg/day on Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule the first week and during the taper-down period to maintain the blind.
3112583|NCT02431806|Active Comparator|Fluoxetine 20 mg|Participants received over-encapsulated fluoxetine 20 mg/day tablets orally starting at a dose of 10 mg/day in Week 1 and 20 mg/day in Week 2 through Week 8 during the Double-blind Treatment Period, followed by a 1-week Double-blind Taper-down Period if applicable as determined by the investigator. Participants received 1 dose matched placebo capsule each day to maintain the blind.
3112584|NCT02432040|Experimental|Atorvastatin|Atorvastatin 40 mg once a day at night Patients asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
3112585|NCT02432040|Placebo Comparator|Placebo|Placebo tablets But patients are still asked to apply Betamethasone valerate 0.1% ointment twice a day, 3 weeks on, 1 week off, at the most
3112586|NCT02432105|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
3112587|NCT02432105|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
3112588|NCT02432105|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
3112589|NCT02432144|Experimental|UX003|4 mg/kg UX003 every other week (QOW)
3112590|NCT02432183||Football players|Football players of the first grade of high school are recruited from the topsportschool in Leuven.
3112591|NCT02432183||Basketball players|Basketball players of the first grade of high school are recruited from the topsportschool in Leuven.
3112592|NCT02432183||Swimmers|Swimmers of the first grade of high school are recruited from the future team of the Flemish Swimming Federation
3112593|NCT02432183||Control group|Age-matched controls are recruited (exercising at a recreational level, >4 hours).
3112594|NCT02432196|Experimental|Harpoon Medical TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
3112595|NCT02432209|Active Comparator|Intensive Lifestyle Mod. Intervention|The intensive lifestyle modification intervention will consist of caloric restriction (consumption of approximately 1200-1500 kcal/d), use of an over-the-counter weight loss medication (Alli, which is brand name Orlistat, a gastric lipase inhibitor that limits gut fat absorption), and moderate physical activity (goal of reaching 10,000 steps a day). The pretreatment intervention will last 16 weeks and is designed to promote a weight loss of approximately 7% of total body weight.
3112596|NCT02432209|Placebo Comparator|Standard Lifestyle Intervention|Women in the standard lifestyle intervention (standard) will receive publicly available written materials that promote engagement in moderate physical activity with target of 10,000 steps a day. Detailed instruction of physical activity will not be provided.
3469239|NCT03888430||Non invasive ventilation|preoxygenation methods : Non invasive ventilation
3469240|NCT03888443||uCP children|15 Children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol twice separated from 2 to 4 weeks
3469241|NCT03888443||uCP children with botulinum toxin injections|5 children aged from 6 to 17 with unilateral spastic Cerebral Palsy and a sufficient level of manipulation will realize the bimanual protocol three times
3112597|NCT02432235|Experimental|3 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (3 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
3112598|NCT02432235|Experimental|5 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (5 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 4 cycles.
3112599|NCT02432235|Experimental|8 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (8 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
3112600|NCT02432235|Experimental|13 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (13 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 15 cycles.
3112601|NCT02432235|Experimental|20 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (20 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 3 cycles.
3112602|NCT02432235|Experimental|30 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (30 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
3112603|NCT02432235|Experimental|45 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (45 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 10 cycles.
3112604|NCT02432235|Experimental|60 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (60 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 8 cycles.
3112605|NCT02432235|Experimental|80 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (80 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 7 cycles.
3112606|NCT02432235|Experimental|100 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (100 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 5 cycles.
3112607|NCT02432235|Experimental|150 μg/kg|Participants received an intravenous (IV) infusion of camidanlumab tesirine (150 μg/kg) on Day 1 of each 3-week treatment cycle, for a maximum of 2 cycles.
3112608|NCT02432235|Experimental|300 μg/kg|A single participant received by error an intravenous (IV) infusion of camidanlumab tesirine (300 μg/kg) on Day 1 of Cycle 1 (planned dose was 30 μg/kg). Dosing in the subsequent cycles was 30 μg/kg (for 2 more cycles).
3112609|NCT02432274|Experimental|Cohort 1: Single-Agent Dose-Finding|Children and adolescents with relapsed or refractory solid malignant tumors.
3112610|NCT02432274|Experimental|Cohort 2A: Single-agent Expansion (DTC)|Children and adolescents with 131 iodine-refractory DTC.
3112611|NCT02432274|Experimental|Cohort 2B: Single-agent Expansion (Osteosarcoma)|Participants with relapsed or refractory osteosarcoma.
3112612|NCT02432274|Experimental|Cohort 3A: Combination Dose-finding|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
3112613|NCT02432274|Experimental|Cohort 3B: Combination Expansion|Participants with relapsed or refractory osteosarcoma will receive lenvatinib in combination with ifosfamide and etoposide.
3112614|NCT02432287|Experimental|Metformin|Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism.
3112615|NCT02432287|Experimental|Placebo|Placebo
3112616|NCT02432300|Experimental|Intervention|Treatment sessions with a virtual treatment program called Emotion Builder
3112617|NCT02432456|Placebo Comparator|Placebo Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a placebo (NaCl) infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
3112618|NCT02432456|Experimental|Ketamine Infusion|"Subjects in this arm will receive the institutional standard of care for rib fractures along with a ketamine infusion.~All patients will undergo Intercostal Nerve Blockade with administration of scheduled medications including acetaminophen, ibuprofen, pantoprazole, and methocarbamol. All subjects will receive adjunct opioids."
3112619|NCT02432703|Experimental|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
3112620|NCT02432703|Placebo Comparator|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
3112621|NCT02432716|Experimental|Insulin (glulisine), then Placebo|Participants first receive one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril). After a washout period of 2 weeks, they then received one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril).
3112622|NCT02432716|Experimental|Placebo, then Insulin (glulisine)|Participants first receive one dose of placebo, Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril). After a washout period of 2 weeks, they then received one dose of Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril).
3112623|NCT02432729||Study population|"Adult smokers who are willing to quit smoking within the next 30 days at the Screening Visit will be asked to continuously quit smoking for 1 year.~Smokers who are not continuously abstinent from smoking or any nicotine/tobacco containing product from the actual quit date will be discontinued from the study."
3112624|NCT02432742|Experimental|Restylane Perlane|Single injection and optional touch up injection with Restylane Perlane in NLF
3112625|NCT02432742|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
3112626|NCT02433080|Active Comparator|Shape-Up following cancer treatment|"In addition to usual care, cancer survivors in the intervention group will participate in a behaviour change programme, called Shape-Up following cancer treatment: a self-help programme on eating well and being active. Participants will be allocated to groups of eight to ten. These groups will meet every week for eight weeks and each session will last approximately 90 minutes. The programme focuses on strategies for improving diet and physical activity in a self-help and peer education format. Each week, one participant will volunteer to present a new concept (e.g. regular eating, being active, eating a balanced diet, keep an eye on portion sizes, and manage internal and external triggers, and understanding food labeling) to the rest of the group."
3469242|NCT03888443||healthy volunteers (TDC children)|20 children aged from 6 to 17 (healthy volunteers) will realize the bimanual protocol once
3469243|NCT03888196|Experimental|Intervention Group|500 mg/day of Panax Ginseng. 2 weeks treatment
3469244|NCT03888196|Placebo Comparator|Control Group|500 mg/day of Celulose. 2 weeks treatment
3112627|NCT02433080|No Intervention|Control intervention|"Participants in the control group will be offered usual care until the 24-week follow-up. Quantifying usual care is challenging, but preliminary qualitative work suggested that most survivors do not received any unsolicited advice about healthy eating and physical activity from their health care professionals after treatment.~During the course of their participation in the trial, participants will be contacted only for the assessments. After the completion of the 24-week follow-up, participants will receive the booklet Healthy living after cancer; a brief self-help manual produced by the World Cancer Research Fund. Providing only this information aims to match the currently offered usual care as accurately as possible but also meet ethical standards."
3112628|NCT02433288|Other|Active app|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
3112629|NCT02433288|Other|Control app|a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
3112630|NCT02433340|Experimental|ABT-122 120 mg EOW|All subjects receive open-label ABT-122 120 mg EOW subcutaneously, with the first dose administered at the last visit of Study M12-963 randomized controlled trial.
3112631|NCT02433366||Patients|
3112632|NCT02433366||Physicians|
3112633|NCT02433379|Experimental|Single Arm|Subjects implanted with an EMBLEM S-ICD with rate zones set at 200 bpm and 250 bpm per protocol.
3112634|NCT02433483|Experimental|Myeloid Malignancies|"Includes participants with AML and MDS. Participants receive chemotherapy based on diagnosis followed by infusion of donor HPC-A.~Participants with CNS disease receive weekly age-adjusted intrathecal triples therapy until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).~Interventions:~Cycle 1: cytarabine, HPC-A donor infusion~Cycle 2: Participants who have at least a partial response to Cycle 1 are eligible to receive Cycle 2: cytarabine, HPC-A infusion"
3112635|NCT02433496||Physician coaching|This group includes 4 intervention primary care clinics that are part of the University of Wisconsin's Department of Family Medicine. These clinics will receive an organizational coaching intervention that includes in-person site visits and phone/email communication. Each participating clinic will designate one primary care physician to act as a clinic lead in working with the coach to coordinate an initial site visit (during project month 13, July 2015), a follow-up site visit (month 15, October, 2015), and communicating with the coach throughout the 6-month follow-up period via phone and email.
3112636|NCT02433496||Control Group|This group includes 4 control primary care clinics that will not receive any intervention. A de-identified dataset will be created to examine differences in outcome variables between intervention and control clinics.
3112637|NCT02433665|Active Comparator|Fixed dose|100 of the first 200 subjects will be randomized to a fixed dose of contrast material.
3112638|NCT02433665|Active Comparator|Customized dose|100 of the first 200 subjects will be randomized to a customized dose of contrast material based on the experimental algorithm. The second group of 300 subjects will receive a customized dose of contrast material based on the experimental algorithm.
3112639|NCT02433678|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
3112640|NCT02433678|Active Comparator|Dapagliflozin|10 mg daily for the 12 weeks
3112641|NCT02433834|Experimental|GP MDI 28.8 μg|GP MDI (PT001) 28.8 μg
3112642|NCT02433834|Experimental|GP MDI 14.4 μg|GP MDI (PT001) 14.4 μg
3112643|NCT02433834|Experimental|GP MDI 7.2 μg|GP MDI (PT001) 7.2 μg
3112644|NCT02433834|Experimental|GP MDI 3.6 μg per|GP MDI (PT001) 3.6 μg
3112645|NCT02433834|Experimental|GP MDI 1.9 μg|GP MDI (PT001) 1.9 μg
3112646|NCT02433834|Placebo Comparator|Placebo|Placebo
3112647|NCT02433834|Active Comparator|Serevent® Diskus® 50 μg per inhalation|Serevent® Diskus® 50 μg per inhalation
3112648|NCT02433977|Experimental|Conjugated Linolenic Acid + NOx|"This is a single arm study~Conjugated Linolenic Acid (CLA)- daily oral dose 3 g/day~Sodium Nitrate- Capsules for daily oral administration at the dose of 1 g (2 x 500 mg)~Sodium Nitrite- Capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)"
3112649|NCT02434081|Experimental|Chemo-radiotherapy with concurrent nivolumab|4 doses of nivolumab 360mg concurrently with standard chemo-radiotherapy, followed by 480mg for up to 1 year from start of nivolumab treatment.
3112650|NCT02434328|Experimental|Brolucizumab 6 mg|Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit
3112651|NCT02434328|Active Comparator|Aflibercept 2 mg|Single IVT injection of aflibercept ophthalmic solution at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
3469245|NCT03888378|Active Comparator|0.3% Topical Minocycline Ointment|Topical administration of 0.3% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
3112653|NCT02434471|No Intervention|Breath hold Liver Acquisition with Volume Acquisition (LAVA)|Subjects will undergo abdominal MRI with LAVA with conventional breath holds (typically four or more breath holds) per standard of care.
3112654|NCT02434471|Active Comparator|Respiratory-triggered T1w DISCO LAVA|The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
3112655|NCT02434497|Experimental|Single Arm|One treatment period for all patients (<1 year and 10 months), with the possibility to up-titrate dose to 40 mg of rosuvastatin for non-Asian patients.
3112656|NCT02434523|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler)
3112657|NCT02434523|Placebo Comparator|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
3112658|NCT02434770|Experimental|BBIBP bOPV Lot 1|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 1, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
3469246|NCT03888378|Active Comparator|1% Topical Minocycline Ointment|Topical administration of 1% Topical Minocycline Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
3112659|NCT02434770|Experimental|BBIBP bOPV Lot 2|Infants received 2 drops of liquid bivalent oral polio vaccine (bOPV) manufactured by BBIBP, Lot 2, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
3112660|NCT02434770|Active Comparator|BioFarma bOPV|Infants received 2 drops of WHO prequalified liquid bivalent oral polio vaccine manufactured by BioFarma, administered directly into the mouth in the first two weeks of life, and at 6, 10, and 14 weeks of age.
3112661|NCT02434939|Experimental|Low dose ketamine|Low dose ketamine 1mg/kg given as an IV infusion via syringe pump over 10 minutes. Maximum of 2 doses to be given during study period that will last 2 hours.
3112662|NCT02434939|Active Comparator|Morphine|Morphine 0.1mg/kg given as an IV infusion via a syringe pump over 10 minutes. Maximum of 2 doses to be given during the study period that will last 2 hours.
3112663|NCT02435069|No Intervention|Pre-operative Baseline Phase|Baseline data including frequency and severity of fecal soiling and frequency and severity of abdominal pain were collected for a minimum of 2 weeks prior to surgical construction of the ACE stoma. Baseline stool calprotectin and serum electrolytes were collected in the baseline phase prior to initiation of the preoperative bowel prep. Pre-operative data served as the control.
3112664|NCT02435069|Experimental|Dose Response - NS and USP Glycerin - First Intervention|Initial flush used NS or USP Glycerin randomized to treatment sequence. The starting volume and administration frequency for NS was 10mL/kg and glycerin 20 mL administered every other day. The NS dose was titrated in 10 mL increments to achieve continence so as not to exceed 500 mL daily for a child under five years of age and 1000 mL daily for a child over 5 years of age. USP Glycerin was titrated in 5 mL increments so as not to exceed 50 mL daily. For side effects greater than Wong Bailey Faces Pain Rating Scale (WBFPRS) level 4, NS was decreased by 2.5 mL/kg to the lowest dose of 5 mL/kg daily. USP Glycerin was decreased in 5 mL increments to the lowest dose of 5 mL daily. If the maximum dose did not result in continence, if the dose necessary to minimize side effects resulted in fecal soiling, or if there were side effects greater than WBFPRS level 4 at the lowest dose of administration, the child was be trialed on the alternate therapy and then dropped from the study.
3112665|NCT02435069|Experimental|NS and USP Glycerin - Effectiveness - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they achieved continence on optimal dosing with minimal side effects.This arm evaluated the long term effectiveness of NS and glycerin at optimal dose and administration frequency for 4 weeks and served as comparison between flush solutions. The study concluded with the child being placed back on 2 weeks of the initial flush in the randomized sequence.
3112666|NCT02435277|Experimental|Low Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
3112667|NCT02435277|Experimental|Mid Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
3112668|NCT02435277|Experimental|High Metformin|3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
3112669|NCT02435277|Active Comparator|Metformin Monotherapy|3 Capsules BID each containing 283.3 mg of metformin BID (1,700 mg/Day) at Day 14.
3112670|NCT02435381|Placebo Comparator|Placebo|Participants will receive placebo from days 2- 4.
3112671|NCT02435381|Active Comparator|Carisbamate|Participants will receive carisbamate 600mg qd from days 2- 4.
3112672|NCT02435433|Experimental|Ramucirumab|8 milligrams per kilogram (mg/kg) ramucirumab administered as an intravenous (IV) injection on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3112673|NCT02435433|Placebo Comparator|Placebo|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
3112674|NCT02435433|Experimental|Open Label Ramucirumab|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3112675|NCT02435433|Experimental|Ramucirumab ME2 Cohort|8 mg/kg ramucirumab administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.
3112676|NCT02435433|Placebo Comparator|Placebo ME2 Cohort|"Placebo administered IV on day 1 of each 14 day cycle. Participants may continue treatment until discontinuation criteria are met.~Participants still on treatment at the time of study completion may have the option to crossover to the ramucirumab arm."
3112677|NCT02435511|No Intervention|Control arm|The control group will receive usual care, no HealtheRx.
3112678|NCT02435511|Experimental|Intervention arm|The intervention arm will receive the intervention, a HealtheRx, which includes a list of resources in their community tailored to their health needs.
3112679|NCT02435524|Experimental|A&T Intervention Communes|
3112680|NCT02435524|No Intervention|Control Communes|
3112681|NCT02435680|Experimental|Arm 1: MCS110+carboplatin+gemcitabine|MCS110+carboplatin+gemcitabine
3112682|NCT02435680|Active Comparator|Arm 2: carboplatin+gemcitabine|carboplatin+gemcitabine
3112683|NCT02435706|Experimental|Flapless immediate implant placement group|Flapless placement of immediate implant and temporary crown
3112684|NCT02435706|Active Comparator|Flap assisted immediate implant placement group|Flap elevation prior to placement of immediate implant and temporary crown
3112685|NCT02435836|Experimental|Aripiprazole|All subjects began open-label treatment with 30 mg aripiprazole on the first day of participation in the current trial. Once a subject stabilized at the 30 mg per day dose, the investigator could adjust the dose within the range of 10 to 30 mg per day as needed (throughout this long-term trial), to manage AEs.
3112686|NCT02435849|Experimental|Single dose of CTL019|Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).
3112687|NCT02435901|Experimental|Reduced Intensity Regimen|Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients <10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients > 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.
3112688|NCT02435914|Experimental|AGN-223575 Dose A|1 drop of AGN-223575 Dose A ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose A ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3112689|NCT02435914|Experimental|AGN-223575 Dose B|1 drop of AGN-223575 Dose B ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose B ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3112690|NCT02435914|Experimental|AGN-223575 Dose C|1 drop of AGN-223575 Dose C ophthalmic solution administered in each eye twice daily for 14 day followed by either 1 drop of AGN-223575 Dose C ophthalmic solution or 1 drop of vehicle to AGN-223575 in each eye once daily for 7 days.
3112691|NCT02435914|Placebo Comparator|AGN-223575 Vehicle|1 drop of Vehicle to AGN-223575 ophthalmic solution administered in each eye twice daily for 14 day followed by 1 drop of vehicle to AGN-223575 ophthalmic solution in each eye once daily for 7 days.
3112692|NCT02435966|Experimental|Manual therapy + Dry needling|Manual therapy + Dry needling: 2 sessions, after a 7 days interval
3112693|NCT02435966|Other|Manual therapy + Sham Dry needling|Manual therapy + Sham Dry needling: after a 7 days interval
3112694|NCT02435966|No Intervention|Untreated control|Natural history of the condition
3112695|NCT02435992|Experimental|RPC1063 (Ozanimod)|1mg, daily oral administration during Induction and Maintenance periods.
3112696|NCT02435992|Placebo Comparator|Placebo|Daily oral administration during Induction and Maintenance periods.
3112697|NCT02436005|Experimental|Phenacite|Subjects will be randomized to wear the Phenacite contact lenses binocularly.
3112698|NCT02436005|Active Comparator|comfilcon A|Subjects will be randomized to wear the comfilcon A contact lenses binocularly.
3112699|NCT02436031|Active Comparator|Desipramine First, Placebo Second|Desipramine 200 mg administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then placebo-matching desipramine administered 2 hours before normal sleep time on second study night.
3112700|NCT02436031|Experimental|Placebo First, Desipramine Second|Placebo-matching desipramine administered 2 hours before normal sleep time on first study night, then a 1-week non-treatment period, then desipramine administered 2 hours before normal sleep time on second study night.
3112701|NCT02436135|Experimental|Cohort A, Idelalisib + Ruxolitinib|Idelalisib 50 mg once daily in participants receiving ruxolitinib.
3112702|NCT02436135|Experimental|Cohort B, Idelalisib + Ruxolitinib|Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
3112703|NCT02436135|Experimental|Cohort C, Idelalisib + Ruxolitinib|Idelalisib 150 mg once daily in participants receiving ruxolitinib.
3112704|NCT02436135|Experimental|Cohort D, Idelalisib + Ruxolitinib|Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
3112705|NCT02436200|Experimental|Intervention|Patients receiving neuromuscular electrical stimulation.
3112706|NCT02436239|Experimental|Vilazodone|
3112707|NCT02436304|Experimental|EXE844 for 7 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops, twice daily (BID) in each ear for 7 days after Tympanostomy Tube Insertion
3112708|NCT02436304|Experimental|EXE844 for 3 Days + Tubes|EXE844 Sterile Otic Suspension, 0.3%, ototopical, 4 drops BID in each ear for 3 days after Tympanostomy Tube Insertion
3112709|NCT02436304|Active Comparator|Tubes Only|Bilateral myringotomy and tympanostomy tube insertion
3112710|NCT02436330|Experimental|Exergaming and Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting of exergaming combined with didactic teaching.
3112711|NCT02436330|Active Comparator|Didactic health teaching|Participation of child and parent/guardian in 6 months of weight management programming consisting only of didactic teaching.
3112712|NCT02436356|Active Comparator|Distal Radius Fracture Operative Group|Fracture group patients will undergo DXA and MRI scans, along with Osteoprobe indentation.
3112713|NCT02436356|Active Comparator|Healthy Volunteers (Non Fracture Group)|Healthy volunteers will undergo DXA and MRI scans.
3112714|NCT02436356|Active Comparator|Distal Radius Fracture Non-operative Group|Fracture group patients will undergo DXA and MRI scans, but will not undergo Osteoprobe indentation.
3112715|NCT02436408|Experimental|Vismodegib|150mg taken orally once daily
3112716|NCT02436577|Experimental|Sequence ABC|Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3
3112717|NCT02436577|Experimental|Sequence BCA|Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3
3112718|NCT02436577|Experimental|Sequence CAB|Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3
3112719|NCT02436577|Experimental|Sequence ACB|Treatment A in Period 1, Treatment C in Period 2 and Treatment B in Period 3
3112720|NCT02436577|Experimental|Sequence BAC|Treatment B in Period 1, Treatment A in Period 2 and Treatment C in Period 3
3112721|NCT02436577|Experimental|Sequence CBA|Treatment C in Period 1, Treatment B in Period 2 and Treatment A in Period 3
3112722|NCT02436668|Active Comparator|Ibrutinib|"Ibrutinib daily in combination with:~Nab-paclitaxel and gemcitabine"
3112723|NCT02436668|Placebo Comparator|Placebo|"Placebo daily in combination with:~Nab-paclitaxel and gemcitabine"
3112724|NCT02436681|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of hiatal hernias.
3112725|NCT02436759|Experimental|RVL-1201|RVL-1201 Ophthalmic Solution 0.1% 1 drop per eye QD for 6 weeks
3112726|NCT02436759|Placebo Comparator|RVL-1201 Vehicle Placebo|RVL-1201 Ophthalmic Solution vehicle (placebo) 1 drop per eye QD for 6 weeks
3112727|NCT02436811|Experimental|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
3469247|NCT03888378|Placebo Comparator|Topical Vehicle Ointment|Topical administration of Topical Vehicle Ointment. Regimen: Apply BID (twice daily), morning and evening to eyelid margin
3469248|NCT03888625|Active Comparator|Group A: Conventional ILM peeling|peeling with complete removal of the internal limiting membrane (ILM)
3112728|NCT02436811|Experimental|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
3112729|NCT02436811|Experimental|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
3112730|NCT02436876|Experimental|Cohort 1|Single, intra-wound local administration of MBN-101; dosage = 0.5 µg/cm2; randomized 3:1 with placebo
3112731|NCT02436876|Experimental|Cohort 2|Single, intra-wound local administration of MBN-101; dosage = 1.5 µg/cm2; randomized 3:1 with placebo
3112732|NCT02436876|Experimental|Cohort 3|Single, intra-wound local administration of MBN-101; dosage = 5.0 µg/cm2; randomized 3:1 with placebo
3112733|NCT02436889|Experimental|Mirabegron|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with Mirabegron (25mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day (Mirabegron 50mg).
3112734|NCT02436889|Active Comparator|Tolterodine Tartrate|Participants will be instructed to take one tablet and 1 capsule (total of 2) of blinded study medication once a day, orally, for 8 weeks. They will start with tolterodine tartrate (4 mg) dose of study medication and will have the option of dose escalation to 2 tablets and 2 capsules (total of 4) per day tolterodine tartrate 4 mg + identical placebo.
3112735|NCT02436915|Experimental|Real tDCS|"The real tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation (tDCS) targeting left prefrontal cortex at a target current intensity of 1.5 mA."
3112736|NCT02436915|Sham Comparator|Sham tDCS|"The sham tDCS intervention will consist of 10 daily 20-minute sessions of transcranial direct current stimulation with same montage as the real tDCS, except current will only be applied for the first 60 seconds of each session."
3112737|NCT02437084|Other|Individuals without diabetes eligible to receive statin therapy|Eligible participants will receive 40 mg of atorvastatin
3112738|NCT02437162|Placebo Comparator|Group 1 (Placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
3112739|NCT02437162|Experimental|Group 2 (Ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3112740|NCT02437162|Experimental|Group 3 (Ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3112741|NCT02437188|Experimental|ACT plus TAU|"Participants randomized to receive ACT will be scheduled to attend a 1-day training session before their preoperative clinic visit. The intervention will incorporate both experiential learning and didactic content, will include a summary of the main concepts at the end of the day, and a manual of the main concepts will be sent home with participants so they can practice the exercises prior to and after surgery. Participants will also receive an individualized phone call booster intervention 2 weeks after surgery to address any issues and reinforce the information that was given during the workshop. This will be done to facilitate the participant's use of the skills during the postoperative period."
3112742|NCT02437188|No Intervention|TAU|Current pre-surgery treatment includes a nurse-led patient education class covering the post-operative course and what to expect for pain control and recovery. Patients may be taking analgesia (i.e. opioids and/or non-opioids) preoperatively for a chronic pain condition and are prescribed analgesics, sedatives and/ or anxiolytics immediately prior to surgery. Intraoperatively, regional (i.e., spinal and femoral) anesthesia and analgesia is given and patients receive opioids, non-opioids, anticonvulsants and/or anxiolytics during the immediate postoperative period. Other pain treatments may be used, such as cryotherapy, music therapy, relaxation, imagery, etc. Patients are sent home with analgesia (often a combination medication of an opioid and acetaminophen) for breakthrough pain.
3112743|NCT02437253|Experimental|Adalimumab first, then Placebo|Participants first received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks. Participants then received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks.
3112744|NCT02437253|Experimental|Placebo first, then Adalimumab|Participants first received Placebo saline subQ (volume matching Adalimumab 20 mg or 40 mg subQ) every other week for 16 weeks. Participants then received Adalimumab 20 mg subQ every other week (weight 15 to <30 kg) or 40 mg subQ every other week (weight ≥30 kg) for 16 weeks.
3112745|NCT02437305|Experimental|ABCDEs of Melanoma Skin Cancer|"A modified melanoma educational intervention that uses the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation but also incorporates the nomenclature melanoma skin cancer; indicates that melanoma is relevant for everyone regardless of race and ethnicity; includes images of melanoma on ethnic skin; informs people of the likelihood of melanoma developing in acral, subungual and mucosal surfaces; and provides guidance on self-skin examinations."
3112746|NCT02437305|Active Comparator|ABCDEs of Melanoma|"A conventional melanoma educational intervention using the ABCDEs of Melanoma pamphlet from the Skin Cancer Foundation."
3469249|NCT03888625|Active Comparator|GroupB: Inverted ILM Peeling|the inverted ILM peeling technique, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
3469250|NCT03888248|Active Comparator|Exercises|Daily muscle-strengthening exercises
3112749|NCT02437344|Experimental|CI-581aa|CI-581aa will be administered 24 hours after last opioid use, and followed by naltrexone dosing
3112750|NCT02437383|Active Comparator|Propranolol ER|Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
3112751|NCT02437383|Placebo Comparator|Placebo|Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).
3112752|NCT02437487|Experimental|SER-109|SER 109 (1 × 108 SporQs)
3112753|NCT02437487|Placebo Comparator|Placebo|Placebo
3112754|NCT02437513||NewBreez|"The study group is composed only of patients who have already opted to receive the NewBreez device as part of their routine care from their physician.~Patients who have the device implanted, and consent to be part of the 12 week observational study, will be enrolled and have standard clinical parameters measured over the 12 week period as well as complete quality of life assessments in the form of patient questionnaires."
3112755|NCT02437669|Experimental|Intranasal hydromorphone|Hydromorphone, intranasal. 2 mg/mL concentration. Initial dose: 0.03 mg/kg, maximum single dose 4 mg. Rescue dose: 0.015 mg/kg, maximum single dose 2 mg.
3112756|NCT02437864|No Intervention|Baseline Group|Airway management (intubation) undertaken immediately after anesthetic induction, without simultaneous supplemental oxygen via nasal cannula.
3112757|NCT02437864|Experimental|With-Cannula Group|Airway management (intubation) undertaken immediately after anesthetic induction, with simultaneous supplemental oxygen via nasal cannula.
3112758|NCT02437890|Placebo Comparator|Placebo|"Two s.c. injections with placebo every 2 weeks (q2w).~***~Placebo was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to the placebo group received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
3112759|NCT02437890|Experimental|ALX-0061 75 mg q4w|"ALX-0061 75 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 75 mg q4w received 2 s.c. injections q2w:~Syringe A with placebo (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe B with placebo (0.5 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46."
3112760|NCT02437890|Experimental|ALX-0061 150 mg q4w|"ALX-0061 150 mg every 4 weeks (q4w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q4w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q4w at Day 1, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44, and syringe A with placebo (1 mL) q4w at Weeks 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 42, and 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
3112761|NCT02437890|Experimental|ALX-0061 150 mg q2w|"ALX-0061 150 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) and placebo were supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 150 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with placebo (0.5 mL) q2w starting at Day 1, up to and including Week 46."
3112762|NCT02437890|Experimental|ALX-0061 225 mg q2w|"ALX-0061 225 mg every 2 weeks (q2w).~***~Vobarilizumab (ALX-0061) was supplied as a sterile liquid for s.c. injection at a volume of 0.5 mL and 1.0 mL in pre-filled single-use syringes. To maintain the blind, subjects randomly assigned to ALX-0061 225 mg q2w received 2 s.c. injections q2w:~Syringe A with ALX-0061 (1 mL) q2w starting at Day 1, up to and including Week 46.~Syringe B with ALX-0061 (0.5 mL) q2w starting at Day 1, up to and including Week 46."
3112763|NCT02437903|Other|JUVÉDERM VOLUMA™ XC|Subjects will be injected with JUVÉDERM VOLUMA™ XC to their right and left facial temporal regions at the baseline visit.
3112764|NCT02438137|Active Comparator|Dimethyl Fumarate (Tecfidera®) capsules|The starting dose for dimethyl fumarate (Tecfidera®, http://www.tecfidera.com/pdfs/full-prescribing-information.pdf) is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day, though slower dose escalations are possible to increase tolerability, if necessary. Participants randomized to dimethyl fumarate will be instructed to take this medication twice a day with breakfast and dinner for a period of 4 months.
3112765|NCT02438137|Placebo Comparator|Placebo|The placebo is an inert product that looks like a pill and is identical to dimethyl fumarate capsules, but it contains no medicine. Participants randomized to placebo will be instructed to take placebo twice a day with breakfast and dinner for a period of 4 months.
3112766|NCT02438280|Experimental|Active Vibration|Use of Active Vibration (AcceleDent device) 20 minutes each day during treatment with aligners
3112767|NCT02438280|Active Comparator|Sham Vibration|Use of Sham Vibration (Sham AcceleDent device) 20 minutes each day during treatment with aligners
3112768|NCT02438371|Active Comparator|Nifedipine|Participants will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours.
3112769|NCT02438371|Active Comparator|Nifedipine plus Indomethacin|Participants will receive will receive nifedipine 10 mg orally every 20 minutes for 3 doses, then nifedipine 10 mg every 6 hours for a total of 48 hours, as well as indomethacin 100 mg orally, then indomethacin 50 mg orally every 6 hours for a total of 48 hours.
3112770|NCT02438384|No Intervention|Usual care|Pts will receive education and follow-up based on judgment of emergency provider.
3112771|NCT02438384|Experimental|Video|Patients will watch 10 minute educational video
3469251|NCT03888248|Experimental|Whole-body vibration + exercises|Home-based whole-body vibration therapy plus daily muscle-strengthening exercises
3112772|NCT02438384|Experimental|Video plus Phone Follow-up|Patients will watch 10 minute educational video and receive phone call follow-up at 3 days to assess pain symptoms. Patients with a pain score of 4 or more will receive another call with advice from a geriatric pain specialist.
3112773|NCT02438423|Experimental|IIV delivered by MN patch by study staff|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch administered by study staff
3112774|NCT02438423|Active Comparator|IIV delivered IM by study staff|Inactivated influenza vaccine (IIV) delivered by intramuscular (IM) injection administered by study staff
3112775|NCT02438423|Experimental|IIV delivered by MN patch by subject|Inactivated influenza vaccine (IIV) delivered by microneedle (MN) patch self-administered by subject
3112776|NCT02438423|Placebo Comparator|Placebo MN patch by study staff|Placebo delivered by microneedle patch administered by study staff
3112777|NCT02438475|Active Comparator|Mynx Vascular Closure System|Where subjects will have venous hemostasis attempted to be achieved using the Mynx Vascular Closure system alone
3112778|NCT02438475|Other|Manual Compression|Where patients will have venous hemostasis attempted to be achieved using manual compression alone
3112779|NCT02438540|Experimental|metformin & acupuncture|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and acupuncture treatment including electro body acupuncture and Auricular acupuncture for 30 minutes, 10 times, every other day, for 3 weeks.
3112780|NCT02438540|Placebo Comparator|metformin & placebo|Metformin 500 mg (one/two/three times per day), to control their diabetes during the period of this study as previously, and placebo acupuncture treatment, needling not in right acupoints and EA machine was switched off during 30 minutes of therapeutic time. For ear acupuncture was just used sticky layers without seeds. All placebo treatment used for 30 minutes, 10 times, every other day, for 3 weeks.
3112781|NCT02438722|Experimental|Arm I (afatinib dimaleate, cetuximab)|Patients receive afatinib dimaleate PO QD on days 1-28 and cetuximab IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112782|NCT02438722|Active Comparator|Arm II (afatinib dimaleate)|Patients receive afatinib dimaleate as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112783|NCT02438787|Placebo Comparator|Group 1 (placebo)|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 24 all participants (with the exception of participants who qualified for early escape [EE]) will be re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52. Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.
3112784|NCT02438787|Experimental|Group 2 (ustekinumab 45 mg)|Ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3112785|NCT02438787|Experimental|Group 3 (ustekinumab 90 mg)|Ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52. At Week 24, participants will receive placebo SC injection to maintain the blind. Participants who meet EE criteria (<10% improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.
3112786|NCT02438813||All Enrolled Participants|All enrolled participants who signed informed consent whether or not they elected to receive treatment as per standard of care in clinical practice for submental fat (SMF). Treatments for SMF included: ATX1-101, Surgical Procedures, Laser Liposuction, Energy Devices or Other Treatments.
3112787|NCT02438826|Experimental|Galcanezumab 300 mg|"Double-Blind Treatment Phase: Participants received galcanezumab 300 mg once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
3112788|NCT02438826|Placebo Comparator|Placebo|"Double-Blind Treatment Phase: Participants received placebo once a month by subcutaneous (SC) injection for 3 months.~Open-Label Treatment Phase: Participants received 300 mg galcanezumab by subcutaneous injections every 30 days, for up to a total of 12 administrations."
3112789|NCT02439138|Experimental|GS-1101|"After the screening procedures confirms eligibility to participate in the research study. Treatment will be administered on an outpatient basis.~-- Idelalisib (GS-11-01) orally, predetermined dose twice daily per cycle for up to 6 cycles. After this initial 6 month period, for Cycles 7 and beyond, Idelalisib will be administered once a day until disease progression."
3112790|NCT02439164|Experimental|Glioma group|Patients in this group will be administered sedatives (midazolam or propofol or dexmedetomidine) titrating to mild sedation.
3112791|NCT02439164|Active Comparator|non-neurosurgical group|patients in this group will be administered the same sedative midazolam as compared glioma group, and titrate to mild sedation.
3112792|NCT02439281|Active Comparator|Ropivacaine Group|Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
3112793|NCT02439281|Experimental|Ropivacaine/ Clonidine Group|Ropivacaine/ Clonidine Group will receive ropivacaine 0.5% (10 ml) and clonidine (2mcg/kg) injected bilaterally in the posterior rectus sheath, at the umbilicus location.
3112794|NCT02439320|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match 200 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3112795|NCT02439320|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match 100 mg tablet). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3112796|NCT02439320|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match lasmiditan 100 mg and lasmiditan 200 mg. One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed within 24 hours.
3112797|NCT02439749|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
3112798|NCT02439749|Sham Comparator|Sham Procedure|Renal angiography
3112799|NCT02439814|Experimental|Pregnenolone|
3112800|NCT02439814|Placebo Comparator|Placebo|
3112801|NCT02439879|Active Comparator|alpha lipoic acid treatment|After a decrease in the total symptoms score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks 600 mg orally once a day of alpha lipoic acid
3112802|NCT02439879|No Intervention|alpha lipoic acid withdrawal|After a decrease in the total symptoms Score >3 points with 600 mg orally tid of alpha lipoic acid for 4 weeks patients were randomized to recieve for 16 weeks no treatment
3112803|NCT02440022|Experimental|Lutonix DCB|Percutaneous transluminal angiography (PTA) will be performed using the Lutonix AV drug coated balloon.
3112804|NCT02440022|Active Comparator|Standard Balloon Angioplasty Catheter|Percutaneous transluminal angiography (PTA) will be performed using a commercially available uncoated PTA balloon. Balloons with an external wire support, cutting/scoring component or other similar modifications are not permitted. Multiple balloons, inflations and/or prolonged inflation may be used.
3112805|NCT02440139|No Intervention|Arm 1|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.
3112806|NCT02440139|Active Comparator|Arm 2|Participating radiologists will perform clinical reading on ~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.
3112807|NCT02440178|Experimental|micafungin prophylaxis|Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count > 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.
3112808|NCT02440204|Active Comparator|Remifentanil 1.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3112809|NCT02440204|Active Comparator|Remifentanil 1.5 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3112810|NCT02440204|Active Comparator|Remifentanil 2.0 mcg/kg|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
3112811|NCT02440308|Experimental|68Ga-DOTA-Bombesin PET/MRI|Patients receive 68Ga-DOTA-Bombesin IV and then undergo PET/MRI approximately 1 hour later.
3112812|NCT02440334|Experimental|Contrast Ultrasound Reccurence Screening|Patients scheduled for MRI/CT follow up of a renal cancer previously treated by cryoablation therapy who will also undergo a contrast-enhanced ultrasound exam. This is a one-time imaging study and contrast ultrasound exams will be compared to the clinically scheduled MRI/CT.
3112813|NCT02440425|Experimental|Combination Therapy|Combination Therapy: Pembrolizumab (experimental use) and Paclitaxel (standard use). All trial treatments will be administered on an outpatient basis. One cycle equals 21 days. The first cycle is 28 days with Pembrolizumab given on day 8 in order to determine paclitaxel tolerance.
3112814|NCT02440451|Experimental|Neurofeedback using BCI|16 (13 + 3 in case of dropoffs) ASD subjects
3112815|NCT02440568|Experimental|Cohort 1: Omacetaxine at Dose level at 0.625mg/m^2|Patients will receive Omacetaxine at Dose level 0.625mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
3112816|NCT02440568|Experimental|Cohort 2: Omacetaxine at Dose level at 1.25mg/m^|Patients will receive Omacetaxine at Dose level 1.25mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
3112817|NCT02440568|Experimental|Cohort 3: Omacetaxine at Dose level at 2.0mg/m^|Patients will receive Omacetaxine at Dose level 2.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
3112818|NCT02440568|Experimental|Cohort 4: Omacetaxine at Dose level at 3.0mg/m^|Patients will receive Omacetaxine at Dose level 3.0mg/m^2, Cytarabine and Idarubicin as part of the treatment plan. Study participants will follow in outpatient clinic at least every 2 months for a total of 6 months. A final study visit will occur 6 months (+/-1 week) after the last dose of Omacetaxine. This visit will end study participation unless there is ongoing toxicity that is at least possibly related to study treatment. In this case, the patient will be followed as medically appropriate until resolution or stabilization of the adverse event.
3132677|NCT03444155|Active Comparator|Natural Panmol-B-Complex first, then synthetic Vitamin B-complex|Participants first received a Natural Vitamin B-complex, i.e., Panmol-B-Complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
3112819|NCT02440594|Experimental|Enhanced Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
3112820|NCT02440594|Active Comparator|Standard Care High-Symptom AD/AX|Patients newly prescribed an antidepressant or anxiolytic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
3112821|NCT02440594|Experimental|Enhanced Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Enhanced BHL Program Services, which for this group include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Monitoring via a one-time BHP follow-up call with the enrollee after 6 weeks to discuss continuing versus discontinuing the medication.
3112822|NCT02440594|Active Comparator|Standard Monitoring Low-Symptom AD/AX/AP|Patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who report low baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
3112823|NCT02440594|Experimental|Enhanced Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Enhanced BHL Program Services, which include the: 1) Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues, and 2) Enhanced Care Management Module - Care Management services with a BHP.
3112824|NCT02440594|Active Comparator|Standard Care High-Symptom AP|Patients newly prescribed an antipsychotic who report significant baseline symptoms receive Standard BHL Program Services, which include the Standard Clinical Monitoring Module - evidence-based care consisting of up to 4 brief (5-10 minutes), structured assessments following the Core/baseline assessment. Interviews are conducted over the telephone by the Health Technician/BHP and take place during the initial 12 weeks of pharmaceutical treatment (e.g., 2, 6, 9, and 12 weeks), and monitor adherence, side effects, and treatment response. A progress report is provided to the prescribing clinician after each interview to help in treatment planning and to alert the clinician of special issues.
3112825|NCT02440594|Experimental|Caregiver TEP Intervention|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Enhanced BHL Program Services which include: 1) a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services, and 2) the Telehealth Education Program (TEP) - BHPs provide manual and workbook-guided psychoeducation, support, and skills training.
3112826|NCT02440594|Active Comparator|Caregiver Control|Caregivers of patients newly prescribed an antidepressant, anxiolytic, or antipsychotic who cannot participate due to cognitive impairment and meet criteria for dementia receive Standard BHL Program Services, which include a baseline clinical assessment of caregiver and care recipient factors (e.g., level of disability, burden, safety concerns) and contact information for local community services
3112827|NCT02440633|Experimental|14C-OPS-2071|Suspension containing 50 mg of 14C-OPS-2071
3112828|NCT02440659||Hemodialysis (HD)|Patients who have chronic kidney disease (CKD) and are currently on hemodialysis.
3112829|NCT02440659||Peritoneal Dialysis (PD)|Patients who have chronic kidney disease (CKD) and are currently on peritoneal dialysis.
3112830|NCT02440789|Experimental|Sirolimus|
3112831|NCT02441062|Other|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study. Subjects may receive a second 68Ga-DOTATOC PET/CT for restaging after therapy 12-36 months following the first scan.
3112832|NCT02441114|Experimental|Inhalation of HCP0910 and HGP1011|"Single, twice and triple inhalation of HCP0910 and HGP1011 (open-label, single-arm, dose-escalation) at period 1, 2, and 3, respectively.~The periods were separated with a washout period of 14 days."
3112833|NCT02441179|Experimental|Acute Intermittent Hypoxia Arm|AIH protocol: it consists of 15, 90-second hypoxic episodes (FiO2=0.09) interspersed with 15, 90-second normoxic intervals (FiO2=0.21) for a total time of 45 minutes. This protocol will be repeated every day for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks. After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
3112834|NCT02441179|Placebo Comparator|Normoxia Arm|Sham protocol: it consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.After this AIH protocol, patients will received body weight-assisted treadmill training (BWSTT) for 45 minutes.
3112835|NCT02441218|Experimental|Ivabradine|
3112836|NCT02441218|Placebo Comparator|Placebo|
3112837|NCT02441283|No Intervention|HCV-infected Participants|Hepatitis C virus (HCV)-infected participants who received ABT-493 and/or ABT-530 in prior Phase 2 or 3 clinical studies with these agents for the treatment of chronic HCV and were not retreated prior to entering this study. No AbbVie study drug was administered in this study.
3112838|NCT02441309|Experimental|A. Mifamurtide only|"Treatment Weeks 1-6 (post 1st biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Mifamurtide 2mg/m2, IV infusion, twice/week, with each infusion given at least 3 days apart, for 6 weeks.~Treatment Weeks 13-36:~Mifamurtide 2mg/m2, IV infusion, once/week."
3112839|NCT02441309|Experimental|B. Ifosfamide (Followed by Mifamurtide)|"Treatment Weeks 1-6: Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days as per local practice. Repeated every 21 days for 2 cycles (3 weeks=1 cycle).~Treatment Weeks 7-12 (post 2nd biopsy/resection): Day 1 of 21: Ifosfamide 12-15g/m2 IV infused over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle). Ifosfamide administered as per local practice, including concurrent dosing with mesna. Plus mifamurtide 2mg/m2, IV infusion, twice/week. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-18: Mifamurtide 2mg/m2, IV infusion, twice/week. Treatment Weeks 19-42: Mifamurtide 2mg/m2, IV infusion, once/week."
3112840|NCT02441309|Experimental|C. Ifosfamide + Mifamurtide|"Treatment Weeks 1-6:~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks=1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, each given at least 3 days apart, for 6 weeks.~Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 7-12 (post 2nd biopsy/resection):~Day 1 of 21: Ifosfamide 12-15g/m2 IV infusion over 4-5 days once every 21 days for two cycles (3 weeks = 1 cycle).~Plus Mifamurtide 2mg/m2, IV infusion, twice per week, given at least 3 days apart, for 6 weeks. Ifosfamide infusion started 24 hours prior to mifamurtide. Mifamurtide given on day 2 and either day 5 or day 6.~Treatment Weeks 13-36: Mifamurtide 2mg/m2, IV infusion, once/week."
3112841|NCT02441517|Experimental|Enzalutamide|Participants received 160 mg enzalutamide orally once daily until radiographic or clinical progression, or unacceptable toxicity.
3112842|NCT02441946|Experimental|Abemaciclib + Anastrozole|"Abemaciclib (150 milligrams [mg]) was given orally every 12 hours (Q12H) plus anastrozole (1 mg) orally once daily (QD) for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
3112843|NCT02441946|Experimental|Abemaciclib|"Abemaciclib (150 mg) was given orally Q12H for 2 weeks. Loperamide was given as a prophylaxis for 4 weeks and then at physician discretion.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Total treatment duration was 16 weeks."
3112844|NCT02441946|Active Comparator|Anastrozole|"Anastrozole (1 mg) is given orally QD for 2 weeks.~All participants received abemaciclib (150 mg) orally Q12H plus anastrozole (1 mg) QD for an additional 14 weeks. Loperamide was given as a prophylaxis for the first 2 weeks of the combination treatment and then at physician discretion. Total treatment duration was 16 weeks."
3112845|NCT02442206|Experimental|Treatment sequence 1|QVA149 from day 1 to day 15 followed by Placebo from day 29 to day 43
3112846|NCT02442206|Experimental|Treatment sequence 2|Placebo from day 1 to day 15 followed by QVA149 from day 29 to day 43
3112847|NCT02442271|Experimental|3-DAA ± RBV|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks.
3112848|NCT02442284|Experimental|3-DAA ± RBV for 12 or 24 weeks|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on genotype and presence of cirrhosis.
3112849|NCT02442310|Experimental|Delayed release, fed conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
3112850|NCT02442310|Experimental|Delayed release, fasting conditions|A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
3112851|NCT02442310|Experimental|Delayed release half-tablets|A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
3112852|NCT02442310|Active Comparator|Oral solution, fasting conditions|A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
3112853|NCT02442336|Experimental|My Journey AHead|Several internet modules will be developed to address mouth and swallowing concerns, oral care, healthy eating, speech problems, coping with cancer, pain management, and physical therapy.
3112854|NCT02442622|Active Comparator|Occupational therapy|Traditional therapy for de Quervain's Tenosynovitis
3112855|NCT02442622|Experimental|Occupational therapy with ASTYM|Traditional therapy for de Quervain's Tenosynovitis plus ASTYM
3112856|NCT02442687|Active Comparator|A|JKB 121, 5 mg twice daily
3112857|NCT02442687|Active Comparator|B|JKB 121, 10 mg twice daily
3112858|NCT02442687|Placebo Comparator|C|Identical appearing placebo
3112859|NCT02442700|Experimental|Treatment sequence A, B|Treatment visits were seperated by a 2-week washout period. Treatment A = administration pitavastatin for 12 weeks; Treatment B = administration placebo for 12 weeks
3112860|NCT02442700|Experimental|Treatment sequence B, A|Treatment visits were seperated by a 2-week washout period. Treatment B = adminstration placebo for 12 weeks; Treatment A = adminstration pitavastatin for 12 weeks
3112861|NCT02442804|Experimental|Stroke - POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
3112862|NCT02442804|Placebo Comparator|Stroke - Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
3112863|NCT02442830|Experimental|Early Video Capsule Endoscopy|The intervention for subjects in this arm will be to have a video capsule deployed as soon as possible after presentation to the emergency department. Information from the video capsule will be obtained and reviewed to determine location of bleeding. Once that information has been obtained a decision will be made on which endoscopic test is most pertinent in finding and treating the source of bleeding.
3112864|NCT02442830|No Intervention|Standard of Care Workup Group|"In this arm, patients will receive standard of care workup for non-hematemesis gastrointestinal bleeding. This could include upper endoscopy, colonoscopy, and additional capsule or small bowel enteroscopy depending on the subject's presentation and the results of the workup performed by the gastroenterology team. For patients requiring a video capsule endoscopy as part of standard of care workup the patients will be given the same Olympus video capsule that is used in the Early Capsule group."
3112865|NCT02442856|Experimental|Intervention|We will measure dCA with both TCD and DCS during acute changes in mean arterial pressure using thigh cuff deflation techniques in vascular risk factor subjects. Measurements will be compared between TCD and DCS in order to validate DCS as a tool to measure dCA in this population.
3112866|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 CAMS|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
3112867|NCT02442869|Experimental|Stage 1 TAU plus Stage 2 DBT|"Treatment as usual [TAU] -- the treatment typically provided by the counselor for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
3112868|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 CAMS|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Additional Collaborative Assessment and Management of Suicidality (CAMS) for 4-16 weeks"
3112869|NCT02442869|Experimental|Stage 1 CAMS plus Stage 2 DBT|"Collaborative Assessment and Management of Suicidality (CAMS) for 4-8 weeks~If participant is responding, treatment ends. Participants who don't respond are then re-randomized to~Dialectical Behavioral Therapy (DBT) for 4-16 weeks"
3112870|NCT02443103|Experimental|Guanabenz|
3112871|NCT02443155|Experimental|NNC0114-0006 + Liraglutide|
3112872|NCT02443155|Experimental|NNC0114-0006 + Placebo|
3112873|NCT02443155|Active Comparator|Liraglutide + Placebo|
3112874|NCT02443155|Placebo Comparator|Placebo|
3112875|NCT02443298|Experimental|Risankizumab|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe with 90 milligram/ milliliter (mg/mL) risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
3112876|NCT02443298|Placebo Comparator|Placebo|Patients received subcutaneous injection of 1 milliliter (mL) prefilled syringe consisting of matching placebo to risankizumab once every 4 weeks (weeks 0, 4, 8, 12, 16, 20).
3112877|NCT02443337|Experimental|LY3023414 + Necitumumab|200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.
3112878|NCT02443402|Experimental|Sitagliptin|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take sitagliptin. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
3112879|NCT02443402|Placebo Comparator|Placebo|Subjects undergoing cardiac surgery with no history of diabetes and with normal blood glucose (BG) will be randomized to take a placebo. Subjects with stress hyperglycemia (defined as a BG >180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
3112880|NCT02443519|Experimental|MBCT for Migraine|In this arm, participants will receive 8 weeks of the manualized treatment Mindfulness Based Cognitive Therapy (MBCT; Day & Thorn). Participants will attend weekly 75-90 minute individual sessions for eight weeks. At each weekly session one of eight broad topics are addressed and discussed (Automatic-Pilot, Dealing with Barriers, Mindfulness of Breath, Staying Present, Allowing/Letting Be, Cognitive Restructuring, Self Care, Application to Headache Pain). Homework is assigned each week, and participants are expected to develop a daily formal mindfulness practice (body scan meditation, seated meditation, breathing meditation, etc). Participants are provided with a course manual, reading materials, and audio recordings to facilitate meditation practice.
3112881|NCT02443519|No Intervention|Wait List/Treatment as Usual|Patients will continue with standard care. Patients will be offered MBCT after the primary endpoint.
3112882|NCT02443688|Experimental|50 mg CTX-4430|Once daily oral capsule for 48 weeks
3112883|NCT02443688|Experimental|100 mg CTX-4430|Once daily oral capsule for 48 weeks
3112884|NCT02443688|Placebo Comparator|Matching Placebo|Once daily oral capsule for 48 weeks
3112885|NCT02443740|Experimental|Single Ascending Dose-1 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
3112886|NCT02443740|Experimental|Single Ascending Dose-2 (Part A)|Single ascending doses of BIIB118 administered to healthy volunteers in a cross over study design
3112887|NCT02443740|Experimental|Single Dose Cerebrospinal Fluid (Part B)|Single maximum dose from Part A of BIIB118 administered to healthy volunteers to assess the PK of BIIB118 in CSF
3112888|NCT02443792|Experimental|Unicirc with tissue adhesive|Unicirc under topical anesthetic w/ cyanoacrylate wound sealing
3112889|NCT02443792|Active Comparator|Open Surgical|Open surgical circumcision under local anesthetic with suturing
3112890|NCT02443805|Active Comparator|300 IR|300 IR tablet of HDM Allergen Extracts
3112891|NCT02443805|Placebo Comparator|Placebo|Placebo tablet
3112892|NCT02443883|Experimental|Ramucirumab Regimen 1|Standard dose of 8 milligram per kilogram (mg/kg) ramucirumab given intravenously (IV) on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
3112893|NCT02443883|Experimental|Ramucirumab Regimen 2|Experimental dose of 12 mg/kg ramucirumab given IV on day 1 and day 15 of each cycle (28-day cycle) until discontinuation criteria are met.
3112894|NCT02443883|Experimental|Ramucirumab Regimen 3|Experimental dose of 6 mg/kg ramucirumab given IV on day 1, 8, 15 and 22 of each cycle (28-day cycle) until discontinuation criteria are met.
3112895|NCT02443883|Experimental|Ramucirumab Regimen 4|Experimental dose of 8 mg/kg ramucirumab given IV on day 1 and day 8 of each cycle (21-day cycle) until discontinuation criteria are met.
3112896|NCT02444143|Active Comparator|IBW|tacrolimus extended release 0.15 mg/kg/day based on Ideal Body Weight (IBW)
3112897|NCT02444143|Experimental|ABW|tacrolimus extended release 0.15 mg/kg/day based on adjusted Body Weight (aBW)
3112898|NCT02444182|Experimental|Probiotics|participants will receive a lozenge containing mixture of probiotic bacteria BB-12 and LGG
3112899|NCT02444182|Placebo Comparator|Control - No probiotics|Participants will receive a control lozenge containing no probiotics. all lozenges are sugar-free; sweetened by xylitol (0.5 g xylitol per piece)
3112900|NCT02444234|Experimental|Tedizolid PO|Tedizolid phophate 200mg tablet
3112901|NCT02444234|Experimental|Tedizolid IV|Tedizolid phophate 200mg IV
3112902|NCT02444533|Active Comparator|Liposomal Bupivacaine|Patient will receive liposomal bupivacaine in the tonsillar fossae after tonsillectomy
3112903|NCT02444533|No Intervention|No treatment|Patient will not be given any medications in the tonsillar fossae after tonsillectomy
3112904|NCT02444663|Active Comparator|Clinician Valgus|Clinician performed fluoroscopic valgus and varus stress X-rays
3112905|NCT02444663|Active Comparator|Clinician Varus|Clinician performed fluoroscopic varus stress X-rays
3112906|NCT02444663|Experimental|Device Valgus - 0 Newton force|Device performed fluoroscopic valgus stress X-rays - 0 Newton force
3112907|NCT02444663|Experimental|Device Valgus - 10 Newton force|Device performed fluoroscopic valgus stress X-rays - 10 Newton force
3112908|NCT02444663|Experimental|Device Valgus - 20 Newton force|Device performed fluoroscopic valgus stress X-rays - 20 Newton force
3112909|NCT02444663|Experimental|Device Valgus - 30 Newton force|Device performed fluoroscopic valgus stress X-rays - 30 Newton force
3112910|NCT02444663|Experimental|Device Varus - 0 Newton force|Device performed fluoroscopic varus stress X-rays - 0 Newton force
3112911|NCT02444663|Experimental|Device Varus - 10 Newton force|Device performed fluoroscopic varus stress X-rays - 10 Newton force
3112912|NCT02444663|Experimental|Device Varus - 20 Newton force|Device performed fluoroscopic varus stress X-rays - 20 Newton force
3112913|NCT02444663|Experimental|Device Varus - 30 Newton force|Device performed fluoroscopic varus stress X-rays - 30 Newton force
3112914|NCT02444715|Active Comparator|Standard care (SC)|
3112915|NCT02444715|Experimental|Interventional care (IC)|
3112916|NCT02444793|Experimental|PF-05082566 + KW-0761|During Parts 1 & 2 Mogamulizumab and PF-05082566 will be administered at appropriate intervals. Part 1: PF-05082566 dose escalation; increased doses of PF-05082566 IV are administered with mogamulizumab IV. Part 2: patients will be treated with the maximum tolerated dose established in Phase 1 for the combination.
3112917|NCT02444936|Active Comparator|ZOSTAVAX|ZOSTAVAX shingles vaccine Zoster vaccine live Single 0.65mL subcutaneous injection
3112918|NCT02444936|No Intervention|Control|There is no drug given in this arm.
3112919|NCT02444988|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
3112920|NCT02444988|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
3112921|NCT02445014|Experimental|MGH SECM Imaging Capsule|Subject will swallow the SECM imaging capsule and images will be acquired using the SECM Imaging system.
3112922|NCT02445027|Experimental|MGH OCT Imaging Capsule|Subject will swallow the OCT capsule and images will be acquired using the OCT Imaging system.
3112923|NCT02445196|Experimental|PTSD Coach|Subjects assigned to this condition receive information about how to download the research app, PTSD Explorer. This research version of PTSD Coach functions exactly the same, however we have the ability to track individual usage of the app. The app contains contains psycho-education about PTSD and the management of symptoms of PTSD along with activities and techniques to address symptoms. Subjects are told to use the app as much or as little as they want over the next three months.
3112924|NCT02445196|Active Comparator|Waitlist Control|"Subjects assigned to this condition are told: You have been randomly assigned to Group 2, the group that does not use the app.~Following their completion of the post-intervention assessment at 3 months, they are told how to access to the publicly available PTSD Coach app in the Apple App Store or Android Play Store, just so that they are made aware of the resources available to them."
3112925|NCT02445287|Experimental|Predicate & Invest.- Cadavers 2D & 3D|Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
3112926|NCT02445287|Experimental|Investigational - Human Subjects 3D|Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.
3112927|NCT02445326|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3112928|NCT02445326|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3112929|NCT02445573|Active Comparator|EA group|
3112930|NCT02445573|Placebo Comparator|Sham EA group|
3112931|NCT02445586|Experimental|Pertuzumab in Combination with Trastuzumab and Docetaxel|Participants will receive pertuzumab in combination with trastuzumab and docetaxel every 3 weeks until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
3112932|NCT02445625|Experimental|BCI to train joint attention in ASD|We are using Brain Computer Interfaces implemented by EEG in 16 ASD subjects
3112933|NCT02445794|Experimental|RT001, oral, 1.8 g/day|RT001, oral, 1.8 g QD for 28 days or matching comparator
3112934|NCT02445794|Experimental|RT001, oral, 9 g/day|RT001, oral, 4.5 g BID for 28 days or matching comparator
3112935|NCT02445807|Experimental|DFD-06 cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3112936|NCT02445807|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3112937|NCT02445859|Active Comparator|Standard regimen|Cefuroxime 1.5grams pre-operatively Repeated every 4 hours
3112938|NCT02445859|Experimental|Interventional regimen|Cefuroxime continuous infusion targeting 64mg/l serum concentrations.
3112939|NCT02445911|Experimental|KQ-791 Dose 1|Single loading dose on day 1, followed by single doses on days 8, 15, 22, 29
3112940|NCT02445911|Experimental|KQ-791 Dose 2|Single loading dose on day 1, followed by a daily dose for 28 days
3112941|NCT02445911|Experimental|KQ-791 Dose 3|Single loading dose on day 1 or days 1-2, followed by a daily dose for 28 days
3112942|NCT02445911|Placebo Comparator|Placebo|Multiple ascending doses matching KQ-791 dose
3112943|NCT02445963|Active Comparator|10 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3112944|NCT02445963|Active Comparator|50 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3112945|NCT02445963|Active Comparator|250 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3112946|NCT02445963|Active Comparator|500 μg S. flexneri 2a Invaplex|10 subjects vaccinated on days 0, 14, 28
3112947|NCT02446015|Experimental|Systane Ultra QID|SYSTANE® ULTRA lubricant eye drops,1 drop in each eye, 4 times per day (QID) for 28 days
3112948|NCT02446015|Active Comparator|Systane Ultra PRN|SYSTANE® ULTRA lubricant eye drops, 1 drop in each eye, as needed (PRN) for 28 days
3112949|NCT02446171|Experimental|Treatments A-D-B-C sequence|Treatment A in Period 1, Treatment D in Period 2, Treatment B in Period 3 and Treatment C in Period 4
3112950|NCT02446171|Experimental|Treatments B-A-C-D sequence|Treatment B in Period 1, Treatment A in Period 2, Treatment C in Period 3 and Treatment D in Period 4
3112951|NCT02446171|Experimental|Treatments C-B-D-A sequence|Treatment C in Period 1, Treatment B in Period 2, Treatment D in Period 3 and Treatment A in Period 4
3112952|NCT02446171|Experimental|Treatments D-C-A-B sequence|Treatment D in Period 1, Treatment C in Period 2, Treatment A in Period 3 and Treatment B in Period 4
3112953|NCT02446223|Experimental|Active|
3112954|NCT02446314|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
3112955|NCT02446314|Experimental|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine + 2.5 mg L-Glutathione + 250 mg placebo powder, once daily, in a 2-hard capsule regimen
3112956|NCT02446314|Experimental|Wild Blueberry Powder - 900 mg|Formulation containing containing 450 mg wild blueberry powder + 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
3112957|NCT02446314|Experimental|Wild Blueberry extract 100mg|Formulation containing containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
3112958|NCT02446418|Experimental|Fluticasone Furoate/Vilanterol|Subjects will receive FF/VI 92 micrograms (mcg)/22 mcg or FF/VI 184 mcg/22 mcg as decided by the investigator QD via ELLIPTA DPI for 24 weeks.
3112959|NCT02446418|Active Comparator|FP/S OR BUD/F|Subjects will receive FP/S (250 mcg/50 mcg or 500 mcg/50mcg) twice daily via DISKUS or BUD /F (200 mcg/6mcg or 400 mcg/12mcg one or two inhalations) twice daily via TURBUHALER DPI as decided by the investigator for 24 weeks.
3112960|NCT02446483|Experimental|Group A|Thirty subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in treatment period 2.
3112961|NCT02446483|Experimental|Group B|Thirty subjects will receive a single oral dose of PARIET 20 mg DR tabs under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of idiazole 20mg DR tabs under fasting condition in treatment period 2.
3112962|NCT02446496|Experimental|Group A|Subjects will receive a single oral dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 2
3112963|NCT02446496|Experimental|Group B|Subjects will receive a single oral dose of cefadroxil tablet manufactured by NP under fasting condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of cefadroxil tablet manufactured by GSK under fasting condition in treatment period 2
3112964|NCT02446600|Active Comparator|Arm I (platinum-based chemotherapy)|"REGIMEN I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity.~REGIMEN II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 for at least 4 cycles in the absence of disease progression or unacceptable toxicity.~REGIMEN III: Patients receive pegylated liposomal doxorubicin hydrochloride IV and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for at least 4 cycles in the absence of disease progression or unacceptable toxicity."
3112965|NCT02446600|Experimental|Arm II (olaparib)|Patients receive olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112966|NCT02446600|Experimental|Arm III (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3112967|NCT02446613|Other|Nasal allergen challenge|Subjects do not receive study medication in this study 204509. Subjects who carried from study TL7116958 treatment group GSK2245035 will undergo NAC with pollen allergen extract.
3112968|NCT02446691|Experimental|MenACWY Group|Healthy male and female infants approximately 2 months (55-89 days) of age on the day of consent, who will receive 4 doses of the GSK MenACWY Conjugate Vaccine, administered intramuscularly at 2,4,6 ad 12 months of age.
3112969|NCT02446717|Experimental|Arm A|ABT-493 (200 mg) once daily (QD) co-administered with ABT-530 (80 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3112970|NCT02446717|Experimental|Arm B|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD plus ribavirin (RBV) for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3112971|NCT02446717|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 12 weeks in chronic HCV genotype 1- infected participants without cirrhosis.
3112972|NCT02446717|Experimental|Arm D|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks in HCV genotypes 1- or 4-6- infected participants with or without cirrhosis.
3112973|NCT02446717|Experimental|Arm E|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 16 weeks in HCV genotype 1- or 4-6- infected participants with or without cirrhosis.
3112974|NCT02446743|Experimental|Group 3B|Subjects who received a third dose booster of rMenB+OMV NZ at 4 to 7.5 years after the last dose received during studies V72P10 (NCT00661713) or V72_41(NCT0142384), and had blood collected at baseline and at 3, 7 and 30 days after the third dose booster.
3112975|NCT02446743|Active Comparator|Group B_0_1|Subjects who received two doses of rMenB+OMV NZ at a 0 and 1 month schedule and had blood collected at baseline, 30 days after the first dose and 3 or 7, and 30 days after the second dose.
3112976|NCT02446769|Experimental|AVAPS-AE Non-invasive ventilation therapy|Participants will be initiated on AVAPS-AE therapy (intervention arm) for 60 days. AVAPS-AE is a mode of therapy (Philips Respironics Inc, Monroeville, Pa) with potential advantages over the currently established modes of non-invasive positive pressure ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated adjustable Inspiratory Positive Airway Pressure (IPAP) setting to maintain target ventilation with a settable rate of change), Auto Expiratory Positive Airway Pressure (EPAP) and Auto Back up Rate.
3112977|NCT02446769|No Intervention|Standard of Care Group|Evaluation and treatment of the participant's sleep disordered breathing will be per their participant's health care provider's usual care pathway.
3112978|NCT02446847|Experimental|Group A: 3BNC117 IV + ART Interruption|Two intravenous infusions of 3BNC117 (30 mg/kg) at day 0 and day 21, with interruption of antiretroviral treatment (ART) at day 2.
3112979|NCT02446847|Experimental|Group B: 3BNC117 IV + ART interruption|Four intravenous infusions of 3BNC117 (30 mg/kg) at day 0, day 14, day 28, and day 42 with interruption of antiretroviral treatment (ART) at day 2.
3112980|NCT02446886|Active Comparator|One Time Treatment|"MS patients enrolled in this study will be randomized into:~Intervention for Group A: 80 units/day ACTH (H.P. Acthar®)for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.)"
3112981|NCT02446886|Experimental|Monthly Treatments|Intervention for Group B: 80 units/day ACTH (H.P. Acthar®) for 3-5 days (The dose could be adjusted based on the individual needs of the patients up to 80-120 units daily for 2-3 weeks.), followed by monthly 80 units/day ACTH for 3 days for 12 months of treatment.
3112982|NCT02446899|Experimental|Anifrolumab|Anifrolumab 300 mg intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
3112983|NCT02446899|Placebo Comparator|Placebo|Placebo intravenous infusion (IV) administered every 4 weeks for a total of 13 doses.
3112984|NCT02446912|Experimental|Anifrolumab - higher dose|Anifrolumab
3112985|NCT02446912|Placebo Comparator|Placebo|Placebo
3112986|NCT02446912|Experimental|Anifrolumab - lower dose|Anifrolumab
3112987|NCT02446990|Experimental|Ivabradine|
3112988|NCT02446990|Placebo Comparator|Placebo|
3112989|NCT02447003|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants will be administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
3112990|NCT02447003|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants will be administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~ 2 years).
3112991|NCT02447029|Experimental|Active Comparator|Drug: vaginal 2% Xylocaine
3112992|NCT02447029|Other|standard lidocaine paracervical block|standard lidocaine paracervical block
3112993|NCT02447081||Subjects implanted with Amulet Device|All subjects who receive the Amulet device will be followed.
3112995|NCT02447172|Experimental|Gentamicin sponge group|Topical Gentamicin Collagen Sponge: Up to four collagen sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base) administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112996|NCT02447172|Placebo Comparator|Placebo sponge group|Matching placebo collagen sponge administered daily, with systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112997|NCT02447172|No Intervention|No sponge group|Systemic antibiotic therapy and standard ulcer care (gentamicin-sponge group) for up to 28 days.
3112998|NCT02447250|Experimental|Single Arm: varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning after 14 days of age and at 28w0d to 33w6d corrected gestational age. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a single dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
3112999|NCT02447302|Experimental|Etrasimod Low Dose|Oral, low dose, daily for 12 Weeks
3113000|NCT02447302|Experimental|Etrasimod High Dose|Oral, high dose, daily for 12 weeks
3113001|NCT02447302|Placebo Comparator|Placebo|Oral, placebo, daily for 12 weeks.
3113002|NCT02447328|Experimental|Single Arm|Faslodex treated in the study
3113003|NCT02447432|Experimental|10Pn_4d Group|Subjects received 10Pn-PD-DIT, in its investigational 4-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
3113004|NCT02447432|Active Comparator|10Pn Group|Subjects received 10Pn-PD-DIT, in its licensed 1-dose presentation (4 doses in total with each single dose injected at Study Months 0, 1, 3 and 8), co administered with DTPw-HBV/Hib vaccine (3 doses injected at Study Months 0, 1 and 2).
3113005|NCT02447458|Experimental|Cohort 1: MLN3126 300 mg|MLN3126 300 mg tablets, orally, fasting, once on Day 1.
3113006|NCT02447458|Experimental|Cohort 2: MLN3126 600 mg|MLN3126 600 mg tablets, orally, fasting, once on Day 1.
3113007|NCT02447458|Experimental|Cohort 3: MLN3126 1000 mg|MLN3126 1000 mg tablets, orally, fasting, once on Day 1. Participants returned to the clinic then received MLN3126 1000 mg tablets, orally, fed (30 minutes after the start of a high-fat breakfast), once on Day 1.
3113008|NCT02447458|Experimental|Cohort 4: MLN3126 1500 mg|MLN3126 1500 mg administered orally as tablets, once on Day 1.
3113009|NCT02447458|Experimental|Cohort 5: MLN3126 2000 mg|MLN3126 2000 mg tablets, orally, fasting, once on Day 1.
3113010|NCT02447458|Experimental|Cohort 6|Did not take place due to termination of the study.
3113011|NCT02447458|Placebo Comparator|Placebo: Cohort 1-6|Placebo-matching MLN3126 tablets, orally, once on Day 1.
3113012|NCT02447497|Experimental|3M CHG/IPA - Abdominal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
3113013|NCT02447497|Placebo Comparator|Normal Saline - Abdominal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
3113014|NCT02447497|Experimental|3M CHG/IPA - Inguinal Region|Apply Chlorhexidine (CHG) 2% / Isopropyl alcohol (IPA) 70% for 30 seconds and allow to dry for 3 minutes.
3113015|NCT02447497|Placebo Comparator|Normal Saline - Inguinal Region|Apply 0.9% sodium chloride with applicator for 30 seconds and allow to dry for 3 minutes.
3113016|NCT02447575|Other|MDI use Evaluation|"All subjects took 2 or more puffs of the placebo metered dose inhaler (MDI), attaching the Cognita electronic flowmeter to show measurements during the MDI use.~The inhaler technique is also evaluated by study staff prior to an education demonstration."
3113017|NCT02447718|Active Comparator|Experimental|Children who were diagnosed with ALL at ≥1 year of age, and are within 6-8 months of completing chemotherapy will receive 1 dose each of: Prevnar®13 and Pediacel® vaccines, followed by 1 dose of Pneumovax® 23 given 2 months after PCV13.
3113018|NCT02447718|No Intervention|Healthy Control|Children 3-18 years of age who are not immunocompromised age-matched to cases from Group 1.
3113019|NCT02447744|Experimental|Mindfulness group|This arm receives an 8-week mindfulness based behavioral intervention program.
3113020|NCT02447744|Other|Waitlist control group|This arm waits while the mindfulness group receives their intervention, and then receives the mindfulness based intervention after their waiting period.
3113021|NCT02447848|Experimental|sufentanil sublingual tablet 30 mcg|Patients may be administered one tablet every 60 minutes as needed during the study period
3113022|NCT02447926|Other|Leaukapheresis of End Stage Liver Disease Patients|Leukapheresis. All subjects will receive the same treatment arm.
3113023|NCT02447952|Experimental|Pilot and Core Study Phase|During Pilot phase,subjects will attend clinic at least once to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (home monitoring). During 48 week Core Study, subjects will attend 5 clinic visits to perform gold standard measures of function (ALS Functional Rating Scale-Revised and Forced Vital Capacity) and perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visits (home monitoring). In between clinic visits, subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period
3113024|NCT02447991|Placebo Comparator|Placebo|During the Treatment Phase, three placebo capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
3113025|NCT02447991|Experimental|Rizatriptan|During the Treatment Phase, three Rizatriptan capsules will be administered to each subject. One capsule will be taken during one acute episode, until three episodes are treated with the study drug.
3113026|NCT02448043|Other|Right Hand Bimatoprost 0.01% drops, Left Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the right hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the left hand digits two times per day for 30 days."
3113027|NCT02448043|Other|Left Hand Bimatoprost 0.01% drops, Right Hand Placebo|"Bimatoprost 0.01% drops placed on the proximal nail folds of the left hand digits two times per day for 30 days.~Saline solution drops placed on the proximal nail folds of the right hand digits two times per day for 30 days."
3113028|NCT02448303|Experimental|Arm 1|pembrolizumab
3113029|NCT02448303|Experimental|Arm 2|acalabrutinib plus pembrolizumab
3113030|NCT02448368|Experimental|Treatment A|RDEA3170, 5 mg (FN24), administered in the fasted state.
3113031|NCT02448368|Experimental|Treatment B|RDEA3170, 5 mg (FN24), administered in the fed state (high-fat, high-calorie meal).
3113032|NCT02448368|Experimental|Treatment C|RDEA3170, 10 mg (FN25), administered in the fasted state.
3113033|NCT02448368|Experimental|Treatment D|RDEA3170, 10 mg (FN25), administered in the fed state (high-fat, high-calorie meal).
3113034|NCT02448368|Experimental|Treatment E|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
3113035|NCT02448368|Experimental|Treatment I|RDEA3170, 10 mg (FN26), administered in the fasted state.
3113036|NCT02448368|Experimental|Treatment J|RDEA3170, 10 mg (FN26), administered in the fed state (high-fat, high-calorie meal).
3113037|NCT02448368|Experimental|Treatment K|RDEA3170, 2.5 mg (FN17), administered as 10 mg (4 × 2.5 mg), in the fasted state.
3113038|NCT02448446|Active Comparator|Diabetic macular edema treatment group (Group 1)|Treatment using intravitreal ranibizumab 0.3mg based on the DRCR protocol I 4:2:7 strategy based on the presence of macular edema.
3113039|NCT02448446|Active Comparator|Diabetic macular edema and lipid treatment group (Group 2)|Continued treatment with intravitreal ranibizumab 0.3mg until, not only the macular edema is resolved, but also until the lipid exudate is resolved.
3113040|NCT02448537|Experimental|PM01183 and Doxorubicin|"Anthracycline-naïve patients will receive combination of PM01183 and Doxorubicin per cycle.~PM01183 predetermined dose daily via IV per cycle~Doxorubicin predetermined dose daily via IV per cycle"
3113041|NCT02448537|Experimental|PM01183 and Gemcitabine|"Prior anthracycline exposure and without prior gemcitabine exposure~PM01183 predetermined dose given twice via IV per cycle~Gemcitabine predetermined dose given twice via IV per cycle"
3113042|NCT02448537|Experimental|Single Agent PM01183|"Patients who have received at least both prior anthracycline and prior gemcitabine~-PM01183 predetermined dose once via IV per cycle"
3113043|NCT02448563|Experimental|Intervention|Weekly, in-person, support groups providing nutrition and physical activity education
3113044|NCT02448563|No Intervention|Control|Standard of care - one counseling visit with a study dietitian
3113045|NCT02448641|Experimental|SB623 Implant (2.5M)|2.5 million SB623 cells
3113046|NCT02448641|Experimental|SB623 Implant (5.0M)|5 million SB623 cells
3113047|NCT02448641|Sham Comparator|Sham Control|Sham surgery
3113048|NCT02448654|Active Comparator|Tolcapone|100mg tolcapone three times a day for 7 days then 100mg once a day on day 8
3113049|NCT02448654|Placebo Comparator|Sugar Pill|Sugar pill
3113050|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 75 µg/kg|75 µg/kg treatment regimen for 3 months
3113051|NCT02448680|Active Comparator|Coagulation Factor VIIa (Recombinant): 225 µg/kg|225 µg/kg treatment regimen for 3 months
3113052|NCT02448706|Active Comparator|Hearing Aid Fitting Order A|High level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
3113053|NCT02448706|Active Comparator|Hearing Aid Fitting Order B|Low level of signal manipulation for 6 weeks, followed by a low level of signal manipulation for 6 weeks.
3113054|NCT02448719|Experimental|Cohort 1-active|Single oral administration of TAK-792 30 milligram (mg) in Japanese participants
3113055|NCT02448719|Placebo Comparator|Cohort 1-placebo|Single oral administration of TAK-792 30 mg placebo in Japanese participants
3113056|NCT02448719|Experimental|Cohort 2-active|Single oral administration of TAK-792 100 mg in Japanese participants
3113057|NCT02448719|Placebo Comparator|Cohort 2-placebo|Single oral administration of TAK-792 100 mg placebo in Japanese participants
3113058|NCT02448719|Experimental|Cohort 3-active|Single oral administration of TAK-792 250 mg in Japanese participants
3113059|NCT02448719|Placebo Comparator|Cohort 3-placebo|Single oral administration of TAK-792 250 mg placebo in Japanese participants
3113060|NCT02448719|Experimental|Cohort 4-active|Single oral administration of TAK-792 500 mg in Japanese and Caucasian participants
3113061|NCT02448719|Placebo Comparator|Cohort 4-placebo|Single oral administration of TAK-792 500 mg placebo in Japanese and Caucasian participants
3113062|NCT02448719|Experimental|Cohort 5-active|Single oral administration of TAK-792 750 mg in Japanese and Caucasian participants
3113063|NCT02448719|Placebo Comparator|Cohort 5-placebo|Single oral administration of TAK-792 750 mg placebo in Japanese and Caucasian participants
3113064|NCT02448719|Experimental|Cohort 6-active|Single oral administration of TAK-792 1250 mg in Japanese and Caucasian participants
3113065|NCT02448719|Placebo Comparator|Cohort 6-placebo|Single oral administration of TAK-792 1250 mg placebo in Japanese and Caucasian participants
3113066|NCT02448771|Experimental|Palbociclib in Combination with Bazedoxifene|"Palbociclib 125 mg Oral on days 1-21 per cycle Bazedoxifene 40 mg Oral on days 1-28 per cycle~One cycle is 28 days."
3113067|NCT02448810|Experimental|Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS)|Subjects stratified according to their mutation status.
3113068|NCT02448810|Experimental|Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt)|Subjects stratified according to their mutation status.
3113069|NCT02448810|Experimental|Part 2: Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
3113070|NCT02448810|Experimental|Part 2: Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.
3113071|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS or NRAS mutated|Subjects stratified according to their mutation status.
3113072|NCT02448810|Active Comparator|Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor|Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.
3113073|NCT02448862||Elderly patients|Patients aged over 70 who had used fentanyl based IV-PCA for postoperative pain.
3113074|NCT02448862||Young adults|Patients aged 20 to 39 who had used fentanyl based IV-PCA for postoperative pain.
3113075|NCT02448875|Active Comparator|CyPass|CyPass Micro-Stent without adjunct viscoelastic implanted in the study eye
3113076|NCT02448875|Experimental|CyPass30|CyPass Micro-Stent implantation followed by targeted delivery of 30 μl ophthalmic viscoelastic
3113077|NCT02448875|Experimental|CyPass60|CyPass Micro-Stent implantation followed by targeted delivery of 60 μl ophthalmic viscoelastic
3113078|NCT02448914|Experimental|TRIGEL first, then Duodopa|"First Intervention (Day 1): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Second Intervention (Day 2): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
3469252|NCT03888495|Experimental|Gender socialization (GS)|Gender socialization workshops raised awareness on gender, its social construction and inequality, notions of masculinity and femininity, division of labor, access and control over resources. The workshop also included skill-building sessions on effective communication and negotiation and relationship building.
3113079|NCT02448914|Experimental|Duodopa first, then TRIGEL|"First Intervention (Day 1): Duodopa, intestinal gel (20 mg/mL levodopa and 5 mg/mL carbidopa monohydrate).~Second Intervention (Day 2): TRIGEL, intestinal gel (20 mg/mL levodopa, 5 mg/mL carbidopa monohydrate, and 20 mg/mL entacapone).~Both TRIGEL and Duodopa treatment consists of 3 individually adjusted and pre-defined doses: a morning dose, a continuous 14 h infusion, and extra bolus doses (if required).~All TRIGEL doses correspond to 80% of the pre-study individually optimised doses of Duodopa. All Duodopa doses correspond to 100% of the pre-study individually optimized doses of Duodopa.~Administration is done through duodenal or upper jejunal infusion via the patient's permanently inserted gastrojejunostomy tube by means of an ambulatory infusion pump."
3113080|NCT02449018|Experimental|QBW251|QBW251 will be provided to participants during 70 days
3113081|NCT02449018|Placebo Comparator|Placebo|Placebo will be provided to participants during 70 days
3113082|NCT02449044|Experimental|Tolvaptan|Enrolled subjects began treatment with 15 mg tolvaptan QD. A titration between target doses of 15 mg, 30 mg, or 60 mg of trial medication was based on the subject's change in serum sodium concentration and clinical tolerance of the trial medication.
3113083|NCT02449174|Active Comparator|Frozen Microbiota|Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was kept at -80C labeled with ID and expiration date which was 6 months after preparation. Intervention - Frozen Microbiota will be delivered via enema
3113084|NCT02449174|Active Comparator|Lyophilized Microbiota|Lyophilized Microbiota_Donor stool (greater than 150 grams) was collected <4 hours prior to the procedure and then mixed in a homogenizer with 750mL, 1:5 dilution sterilized 0.9% NaCl in a large sterilized suction canister until a smooth consistency was reached. The suspension was filtered using a coffee filter twice. The microbiota suspension (750mL) was starting lyophilization process within 30 minutes after completion of stool filtration. Lyophilized microbiota products were kept at 4C and were used within 6 months after preparation. Intervention - Lyophilized Microbiota will be delivered orally
3113085|NCT02449291|Experimental|APD421 standard|Single (standard) dose IV APD421
3113086|NCT02449291|Experimental|APD421 high|Single (high) dose IV APD421
3113087|NCT02449291|Placebo Comparator|Placebo|Single IV placebo
3113088|NCT02449356|Experimental|prone position endotracheal tube(PPT)|the subjects of this arm are given the prone ventilation endotracheal tube which contains fixed device, fixed rope.
3113089|NCT02449356|No Intervention|traditional endotracheal tube(TT)|the subjects of this arm are given the routine endotracheal tube.
3113090|NCT02449434||Severe Tooth Wear|"Severe tooth wear with a BEWE score of 12 and at least one score of 3 in three quadrants Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
3113091|NCT02449434||Without Tooth Wear|"BEWE score of 10 or lower and no score of 3 on any surface of any tooth (clinically classified as no or mild erosive tooth wear) Adult 18 years or older No missing anterior teeth Minimum of at 10 teeth in the upper and 10 teeth in the lower jaw No anterior crowns/ bridges or implants Written consent to the study~There was no intervention - just a questionnaire for each group"
3113092|NCT02449473|Experimental|Tralokinumab Dose Regimen|Tralokinumab Subcutaneous Injection
3113093|NCT02449473|Placebo Comparator|Placebo Dose Regimen|Placebo Subcutaneous Injection
3113094|NCT02449798|Experimental|"AccuCath 2.25 BC Intravascular Catheter"|"Use of AccuCath 2.25 BC peripheral IV device for difficult IV access in emergency room patients who have had 2 previous attempts, identified as difficult IV access from patient history or non-palpable, non-visible veins."
3113095|NCT02449889|Experimental|HP-hCG IM|highly purified human chorionic gonadotropin, intramuscularly (IM)
3113096|NCT02449889|Experimental|HP-hCG SC|highly purified human chorionic gonadotropin, subcutaneously (SC)
3113097|NCT02449889|Active Comparator|rhCG|recombinant human chorionic gonadotropin
3113098|NCT02449902|Active Comparator|Treatment 1|Estradiol 10 μg vaginal softgel capsule
3113099|NCT02449902|Placebo Comparator|Treatment 2|Placebo vaginal softgel capsule
3113100|NCT02449915|Experimental|Bupivacaine Arm|Those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
3113101|NCT02449915|Placebo Comparator|Placebo Arm|Those subjects in the placebo arm will have 30 mL sterile normal saline injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected into the port site wounds in the abdomen (5 sites, 4 mL per incision).
3469253|NCT03888495|Experimental|GS + Financial literacy (FL)|Financial literacy workshops promoted knowledge and skills in budgeting, financial planning and accessing and using financial services and income generating activities.
3113104|NCT02450383|Active Comparator|Control|Autologous subepithelial connective tissue graft
3113105|NCT02450383|Experimental|Experimental|Acellular Dermal Matrix
3113106|NCT02450487|Experimental|Interventional group|100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control after lower third molar surgery
3113107|NCT02450526|Experimental|AbobotulinumtoxinA|Dysport, 50 Units, divided into five injections into the glabellar area. Administered in double blind fashion at cycle 1 followed by up to 4 cycles Dysport, 50 Units administered with an interval period depending on response, no less than 12 weeks between each treatment cycle.
3113108|NCT02450526|Active Comparator|OnabotulinumtoxinA|Botox will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
3113109|NCT02450526|Placebo Comparator|AbobotulinumtoxinA Placebo|Dysport placebo will be administered in treatment cycle 1 only. On Day 1, 50 Units, divided into five injections into the glabellar area.
3113110|NCT02450526|Placebo Comparator|OnabotulinumtoxinA Placebo|Botox placebo will be administered in treatment cycle 1 only. On Day 1, 20 Units, divided into five injections into the glabellar area.
3113111|NCT02450539|Experimental|Abemaciclib|200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3113112|NCT02450539|Active Comparator|Docetaxel|75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3113113|NCT02450552|Experimental|Oral ezogabine 600 mg/day|
3113114|NCT02450552|Experimental|Oral ezogabine 900 mg/day|
3113115|NCT02450552|Placebo Comparator|Placebo|
3113116|NCT02450578|Experimental|Cohort 1a: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -1, sporozoite inoculum Day 0
3113117|NCT02450578|Active Comparator|Cohort 1b: Malarone, sporozoite inoculum|Malarone daily for 9 days from Day -1 to Day 7, sporozoite inoculum Day 0
3113118|NCT02450578|Experimental|Cohort 2: DSM265/placebo, sporozoite inoculum|DSM265 400mg / placebo Day -7, sporozoite inoculum Day 0
3113119|NCT02450578|Experimental|Cohort 3: DSM265 / placebo, sporozoite inoculum (Optional)|DSM265 400mg / placebo Day -X, sporozoite inoculum Day 0
3113120|NCT02450747|Experimental|Multifocal Test Contact Lens|Subjects will wear the etafilcon A Multifocal test lens in a daily wear modality.
3113121|NCT02450799|Experimental|AcrySof IOL|Acrylic IOL, prior implantation (1994-2000) in one or both eyes
3113122|NCT02450799|Active Comparator|Silicone IOL|Silicone IOL, prior implantation (1994-2000) in one or both eyes
3113123|NCT02450799|Active Comparator|PMMA IOL|PMMA IOL, prior implantation (1994-2000) in one or both eyes
3113124|NCT02450903|Experimental|LDK378 (Ceritinib)|Participants who received LDK378 750mg once daily on a 28 day cycle.
3113125|NCT02451007|Experimental|A (lurbinectedin)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
3113126|NCT02451124|Experimental|Screening: non-endoscopic inflatable balloon for the esophagus|Patients undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus over 30-60 minutes followed by a standard esophagogastroduodenoscopy. Questionnaire administration will provide self-reported data on patient experiences. laboratory biomarker analysis of biopsy will confirm diagnosis.
3113127|NCT02451137|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 units per millilitre [U/mL]) subcutaneous (SC) injection once daily up to Month 12, with or without available participant support program.
3113128|NCT02451137|Active Comparator|Standard of Care|Lantus® (Insulin glargine, 100 U/mL) SC injection administered once daily; or Levemir® (Insulin detemir) SC injection administered either once or twice daily up to Month 12, with or without available participant support program.
3113129|NCT02451150|Experimental|Azilsartan 5 mg|Weight <50 kg: azilsartan 5 mg, tablets, orally, once, after breakfast on Day 1.
3113130|NCT02451150|Experimental|Azilsartan 10 mg|Weight ≥50 kg: azilsartan 10 mg, tablets, orally, once, after breakfast on Day 1.
3113131|NCT02451202|Experimental|Deep Neuromuscular Blockade arm|"After initial doses of 0.6 mg Rocuronium, a continuous infusion can be initiated to maintain 0 responses to train-of-four (TOF) stimulation or 1-2 responses to Post-Tetanic Count (PTC) (Deep NMB). The pump rate will vary and depends on the PTC value. The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required PTC value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthetist. Deep NMB should be maintained throughout the operation.~The infusion of Rocuronium will be discontinued and Sugammadex will be given 4 mg/kg at the end of surgery, which is from deep NMB (PTC = 1-2)."
3113132|NCT02451202|Active Comparator|Moderate Neuromuscular Blockade arm|"After evidence of early spontaneous recovery (< 10% of control T1) from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain 1 to 2 responses to train-of-four stimulation (Moderate NMB). The initial pump rate will be set at 0.5 mg/kg per hour. In case of a deviation from the required TOF value the pump rate can be increased or decreased. This was left to the discretion of the attending anaesthesiologist. Moderate paralysis should be maintained throughout an operation.~At the end of surgery, the infusion of Rocuronium will be discontinued and Sugammadex 2 mg/kg via bolus injections]will be administered at least reappearance of T2."
3113133|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months|Participants aged 6 to 35 months received 2 doses of 0.25 mL QIV (2016-2017 NH formulation) intramuscularly, 1 injection each at Day 0 and 28.
3113134|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years|Participants aged 3 to 8 years received 2 doses of 0.5 mL QIV (2016 SH formulation) intramuscularly, 1 injection each at Day 0 and 28.
3113135|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 3: 9 to 17 Years|Participants aged 9 to 17 years received 1 dose of 0.5 mL QIV (2015-2016 NH formulation) intramuscularly, at Day 0.
3113136|NCT02451358|Experimental|Quadrivalent Influenza Vaccine Group 4: >=18 Years|Participants aged >=18 years received 1 dose of 0.5 mL QIV (2015 SH formulation) intramuscularly, at Day 0.
3113137|NCT02451488|Experimental|GM-CSF|Patients will be treated with 14 days of GM-CSF self-administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on the day of enrollment. Patients will be instructed in the self-administration of GM-CSF and after they have demonstrated competency with the procedure, they will self-administer the treatment at home. Patients will undergo surgery within 1 day to 5 days after cessation of the GM-CSF therapy.
3113138|NCT02451488|Other|Standard of Care|no neo-adjuvant therapy prior to surgical intervention
3113139|NCT02451514|Experimental|MenABCWY+OMV Group|Subjects who received 2 doses of MenABCWY+OMV vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received a booster dose of MenABCWY+OMV vaccine in the current study at Day 1.
3113140|NCT02451514|Experimental|MenACWY Group|Subjects who received MenACWY vaccine in the parent study V102_02 (NCT01210885) and received no subsequent meningococcal vaccines, received 2 doses of MenABCWY+OMV vaccine, one month apart (Day 1 and Day 31), in the current study.
3113141|NCT02451514|Experimental|Naive Group|Subjects similar in age to subjects in the MenABCWY+OMV and MenACWY groups, who had not previously received any meningococcal vaccine and who received 2 doses of MenABCWY+OMV vaccine, 1 month apart (Day 1 and Day 31), in the current study.
3469254|NCT03888495|Experimental|GS + FL + Family planning|Family planning counseling was provided to couples by family planning providers from nearby facilities. Couples were encouraged to seek services in facilities of their choice. A voucher system provided financial support for the poorest couples.
3113142|NCT02451670|Experimental|Prioritized Clinical Decision Support|Patients receiving care in clinics randomized to the intervention arm of the study and their primary care providers were presented with patient-specific written advice as to prioritized treatment and lifestyle changes that could reduce their cardiovascular risk, prompted by an electronic health record-based alert during their primary care visit.
3113143|NCT02451670|No Intervention|Usual Care|Patients receiving care in clinics randomized to the usual care arm of the study and their providers were not presented with the prioritized clinical decision support.
3113144|NCT02451696|Experimental|Treated Subjects|This group will be treated with everolimus 7-28 days prior to surgery
3113145|NCT02451696|No Intervention|Reference Subjects|This group will be enrolled as reference subjects, and will be undergoing routine surgery as part of standard of care treatment. No intervention will be provided to these subjects as part of the study.
3113146|NCT02451839||Crohn's Disease|Participants with Crohn's disease. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
3113147|NCT02451839||Rheumatoid Arthritis|Participants with rheumatoid arthritis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
3113148|NCT02451839||Psoriasis|Participants with psoriasis. All participants will receive at least 3 months of treatment with adalimumab. Adalimumab was prescribed by the physician under usual and customary practice and according to the approved adalimumab New Zealand Datasheet.
3113149|NCT02451917|Experimental|Glargine insulin|This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin. At the end of the study, all data acquired during the use of insulin glargine, regardless of the sequence were grouped as glargine.
3113150|NCT02451917|Active Comparator|NPH insulin|"This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.~At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH."
3113151|NCT02451930|Experimental|Necitumumab + Pembrolizumab|"Part A Cohort 1: 600 mg Necitumumab + 200 mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 600 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in participants with Stage IV NSCLC (all histologies).~Part A Cohort 2, Part B and Part C: 800mg Necitumumab + 200mg Pembrolizumab:~Participants received 200 mg pembrolizumab absolute dose by intravenous (IV) infusion on Day 1 of 21 days cycles followed by 800 mg necitumumab absolute dose by IV infusion on Days 1 and 8 of 21 days cycles in Part A cohort 2 participants with any histology, Part B and C participants with Stage IV NSCLC of squamous and nonsquamous histology.~Part C were Japan participants. Part C were Japan participants."
3113152|NCT02451943|Experimental|Doxorubicin + Olaratumab|75 milligrams per meter squared (mg/m^2) doxorubicin administered intravenously (IV) on day 1 of each 21-day cycle for 8 cycles plus 20 milligrams per kilogram (mg/kg) dose of olaratumab administered IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab administered IV on day 1 and day 8 of cycles 2-8. Beginning with cycle 9, 15 mg/kg olaratumab administered IV on day 1 and day 8 of each subsequent 21-day cycle until documented progressive disease (PD) or discontinuation for any other reason.
3113153|NCT02451943|Placebo Comparator|Doxorubicin + Placebo|75 mg/m^2 doxorubicin administered IV on day 1 of each 21-day cycle for 8 cycles plus placebo (equivalent volume) administered IV on day 1 and day 8 for 8 cycles. Beginning with cycle 9, placebo (equivalent volume) administered on days 1 and 8 of each subsequent 21-day cycle until PD or discontinuation for any other reason.
3113154|NCT02451995|Experimental|Ripple Mapping guided AT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to diagnose the mechanism of AT and guide ablation
3113155|NCT02451995|Active Comparator|Local activation Time Mapping AT Ablation|Standard activation mapping will be used to guide ablation.
3113156|NCT02452034|Experimental|3.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 3.5 mg/kg by intravenous (IV) solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by powder for oral suspension (PFS) for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3113157|NCT02452034|Experimental|4.5 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3113158|NCT02452034|Experimental|3.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 3.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 3.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3113159|NCT02452034|Experimental|4.5 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 4.5 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 4.5 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3113160|NCT02452034|Experimental|6 mg/kg POS (2<7 years old)|Children 2 to less than 7 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3113161|NCT02452034|Experimental|6 mg/kg POS (7-17 years old)|Children 7 to 17 years of age will receive POS at 6 mg/kg by IV solution twice on Day 1, then once daily on Days 2-10. This will be followed by treatment with 6 mg/kg POS once daily by PFS for a minimum of 10 days; or, if they are unwilling or unable to tolerate POS PFS, continued treatment with POS IV.
3469255|NCT03888495|No Intervention|Control|Couples were interviewed at baseline, and will be interviewed at endline.
3469256|NCT03888313||Patients participating in the pretreatment group consultation|Patients who chosse to participate in a group consultation (with other patients also in the process of undergoing surgery for colorectal cancer).
3113162|NCT02452047|Experimental|Group 1: Imipenem+Cilastatin/Relebactam|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours and placebo for colistimethate sodium IV infusion once every 12 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3113163|NCT02452047|Active Comparator|Group 2: Colistimethate sodium + Imipenem+Cilastatin|Participants will be stratified by infection type (HABP/VABP, cIAI, and cUTI) and randomized to receive colistimethate sodium IV infusion once every 12 hours and imipenem+cilastatin IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3113164|NCT02452047|Experimental|Group 3: Imipenem+Cilastatin/Relebactam|Participants with documented imipenem-resistant and colistin-resistant bacterial infections may be eligible to receive open-label imipenem+cilastatin/relebactam IV infusion once every 6 hours for 5 to 21 days for cIAI and cUTI or for 7 to 21 days for HABP or VABP. Treatment durations >21 days may be approved by the Sponsor for participants requiring longer treatment duration.
3113165|NCT02452060|Placebo Comparator|treatment/placebo|saline infusion
3113166|NCT02452060|Experimental|treatment|ketamine (0.4mg/kg)
3113167|NCT02452190|Experimental|Reslizumab|Reslizumab
3113168|NCT02452190|Placebo Comparator|Placebo|Matching Placebo
3113169|NCT02452320|Placebo Comparator|Control|Subjects randomized into the control group will not receive study medication, they will receive a placebo administered at the same schedule as the active drug in the other arm.
3113170|NCT02452320|Active Comparator|Randomized|Subjects randomized into the active treatment group will receive intravenous acetaminophen
3113171|NCT02452346|Experimental|All Patients|Tosedostat 120 mg PO once daily will be administered.
3113172|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 1)|"Open-label, sequential PLX3397 dose escalation with a fixed dose of pembrolizumab in approximately 24 patients with advanced solid tumors.~(Enrollment complete- 33 enrolled)"
3113173|NCT02452424|Experimental|PLX3397 and Pembrolizumab (Part 2)|"Extension cohort at the RP2D of PLX3397 in combination with pembrolizumab in approximately 376 patients with advanced solid tumors~(Enrollment Complete- 45 enrolled)"
3113174|NCT02452463|Experimental|Arm I (nintedanib)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3113175|NCT02452463|Placebo Comparator|Arm II (placebo)|Beginning 4-8 weeks after completion of radiation therapy, patients receive placebo capsules PO BID on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3113176|NCT02452463|Experimental|Arm III (nintedanib, durvalumab)|Beginning 4-8 weeks after completion of radiation therapy, patients receive nintedanib PO BID on days 1-28 and standard of care durvalumab IV over 60 minutes on days 1 and 15. Treatment with nintedanib repeats every 28 days for up to 6 cycles and treatment with durvalumab repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3113177|NCT02452476|Experimental|CHF5633|Single dose within 24 hours from birth
3113178|NCT02452476|Active Comparator|Poractant alfa|Single dose within 24 hours from birth
3113179|NCT02452528|Experimental|ARC-520|"Intravenous administration of 1.0 mg/kg ARC-520 once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of study drug."
3113180|NCT02452528|Placebo Comparator|Placebo|"Intravenous administration of normal saline (0.9%) once every 4 weeks for 3 total doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day), taken throughout the study.~Pretreatment with diphenhydramine 50 mg 2 hours (±30 minutes) prior to administration of placebo."
3113181|NCT02452554|Experimental|Treatment (lorvotuzumab mertansine)|Patients receive lorvotuzumab mertansine IV over 1-1.5 hours on days 1 and 8. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3113182|NCT02452762|Experimental|Enteral Loading Arm|Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)
3113183|NCT02452762|Placebo Comparator|Placebo Arm|Patients will receive a placebo solution equivalent in volume to the dose of cholecalciferol administered to patients in the enteral loading arm.
3113184|NCT02452866|Experimental|SYM-1219|All pateints recieved single dose SYM-1219 Containing 2 Grams of Secnidazole
3113185|NCT02452892|Sham Comparator|LFMS Sham|For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered. Low field magnetic stimulation (no magnetic field for sham) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3113186|NCT02452892|Active Comparator|LFMS 20 minutes|LFMS 20 minutes + Sham 40 min.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3113187|NCT02452892|Active Comparator|LFMS 60 minutes|LFMS 60 minutes.Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3113188|NCT02452892|Other|LFMS 120 min|Week 2 subjects may be re-randomized to receive LFMS 120 minutes. Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS.
3113189|NCT02452931|Experimental|Assigned Intervention|Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.
3113190|NCT02452944|Experimental|US-IFI group|"ultrasound-guided obturator nerve block with interfascial injection approach group (US-IFI; experimental group)~The stimulating needle without nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles, another 5mL of LA was injected.~After that, the needle was reinserted to the same spots attached with nerve stimulator at 1.0 mA. If adductor muscle twitching was shown, another 5mL of LA was injected, and it was documented as 'fail'."
3113191|NCT02452944|Active Comparator|US-NS group|ultrasound-guided obturator nerve block with nerve stimulating approach group (US-NS; control group) The stimulating needle attached to a nerve stimulator advanced via an ultrasound to position the needle tip on the fascia between adductor longus and adductor brevis muscles. The nerve stimulator was then turned on, and the stimulation current started at 0.5 mA. If adductor muscle twitching was observed on the sonogram even at the stimulation current 0.3mA, 10mL of local anesthetics were slowly injected. The needle was reinserted to position the needle tip on the fascia between adductor brevis and adductor magnus muscles. The stimulation current started at 0.5 mA. If adductor muscle twitching was visualized on the sonogram even at 0.3mA, another 5mL of LA was injected.
3113192|NCT02453048|Experimental|BPZE1 - 10,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3113193|NCT02453048|Experimental|BPZE1 - 100,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3113194|NCT02453048|Experimental|BPZE1 - 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 or Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3113195|NCT02453048|Experimental|BPZE1 - High Antibody 1,000,000,000 cfu|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
3113196|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
3113197|NCT02453191|Experimental|Treatment|"Talimogene Laherparepvec in combination with radiotherapy~Talimogene Laherparepvec Dose Levels:~• Initial dose for all = talimogene laherparepvec up to 4.0 mL of 106 PFU/mL"
3113198|NCT02453256|Placebo Comparator|Double-Blind Placebo|Participants will receive double-blind matching placebo from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
3113199|NCT02453256|Experimental|Double-Blind Tocilizumab|Participants will receive double-blind tocilizumab from Baseline to Week 47. Participants may then receive open-label tocilizumab from Weeks 48 to 96.
3113200|NCT02453282|Experimental|Monotherapy|PD-L1 monoclonal Antibody monotherapy.
3113201|NCT02453282|Experimental|Combination Therapy|PD-L1+Tremelimumab combination therapy
3113202|NCT02453282|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
3113203|NCT02453321|Active Comparator|Cont. Femoral Block - Low Dose Group|Arm is named by the intervention the group receives. Continuous Femoral Block - Low Dose. The Block/catheter is placed about 5cm below groin at ultrasonographic apex of femoral triangle. Rate of 2ml/hr of bupivacaine 0.0625% until morning of POD#2.
3113204|NCT02453321|Experimental|Cont. Femoral Block - Higher Dose|Place the CPNB in same manner as low-dose group, but rate will be 4ml/hr. Hypothesis is that this group may experience better pain control, but likely will have more dense motor blockade of thigh and less participation in physical therapy
3113205|NCT02453321|Experimental|Continuous Adductor Canal|Placed at mid-thigh in proximal adductor canal near femoral artery with a bupivacaine infusion rate of 4ml/hr. Hypothesis is that this group may experience less motor blockade of thigh but may have more pain than the femoral nerve groups.
3113206|NCT02453334|Experimental|Injectafer|2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.
3113207|NCT02453334|Placebo Comparator|Normal Saline|Normal saline administered as an infusion of no more than 250mL infused over 15 minutes.
3113208|NCT02453347|Experimental|CES Therapy|All participants will complete CES treatment over the course of four weeks. Assessments will take place at baseline and at post-test four weeks later.
3113209|NCT02453360|Experimental|5 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3113210|NCT02453360|Experimental|10 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3113211|NCT02453360|Experimental|20 ml|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
3113212|NCT02453386|Experimental|Tozadenant 60 mg BID|"During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3113213|NCT02453386|Experimental|Tozadenant 120 mg BID|"During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3113214|NCT02453386|Placebo Comparator|Placebo BID|"During Part A, patients took two (2) tablets of placebo, by mouth BID for a total of four (4) tablets per day.~Upon completion of Part A, all patients will begin dosing with open label tozadenant in Part B."
3113215|NCT02453555|Active Comparator|Linagliptin|patient to receive 5 mg linagliptin once daily
3113216|NCT02453555|Experimental|Empagliflozin + linagliptin low dose|patient to receive one tablet once daily
3113217|NCT02453555|Experimental|Empagliflozin + linagliptin high dose|patient to receive one tablet once daily
3113218|NCT02453555|Placebo Comparator|Linagliptin placebo|
3113219|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin high dose placebo|
3113220|NCT02453555|Placebo Comparator|Empagliflozin + linagliptin low dose placebo|
3113221|NCT02453581|Experimental|OZ439 100mg|OZ439 100mg Powder for Oral Suspension
3113222|NCT02453581|Experimental|OZ439 200mg|OZ439 200mg Powder for Oral Suspension
3113223|NCT02453581|Experimental|OZ439 500mg|OZ439 500mg Powder for Oral Suspension
3113224|NCT02453672|Experimental|SB8|SB8, single dose of 3 mg/kg, IV infusion
3113225|NCT02453672|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion
3113226|NCT02453672|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 3 mg/kg, IV infusion
3113227|NCT02453685|Experimental|BIAsp|
3113228|NCT02453685|Active Comparator|IGlar + IAsp|
3113229|NCT02453711|Experimental|Sema 0.05 mg|Dose 0.05 mg
3113230|NCT02453711|Experimental|Sema 0.1 mg|Dose 0.05 or 0.1 mg with dose escalation every fourth week
3113231|NCT02453711|Experimental|Sema 0.2 mg|Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week
3113232|NCT02453711|Experimental|Sema 0.3 mg|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week
3113233|NCT02453711|Experimental|Sema 0.4 mg|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week
3113234|NCT02453711|Experimental|Sema 0.3 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week
3113235|NCT02453711|Experimental|Sema 0.4 mg (fast dose escalation)|Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week
3113236|NCT02453711|Active Comparator|Lira 3.0 mg|Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week
3113237|NCT02453711|Placebo Comparator|Placebo Sema 0.05 mg|Placebo arm matching active arm Sema 0.05 mg
3113238|NCT02453711|Placebo Comparator|Placebo Sema 0.1 mg|Placebo arm matching active arm Sema 0.1 mg
3113239|NCT02453711|Placebo Comparator|Placebo Sema 0.2 mg|Placebo arm matching active arm Sema 0.2 mg
3113240|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg|Placebo arm matching active arm Sema 0.3 mg
3113241|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg|Placebo arm matching active arm Sema 0.4 mg
3113242|NCT02453711|Placebo Comparator|Placebo Sema 0.3 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)
3113243|NCT02453711|Placebo Comparator|Placebo Sema 0.4 mg (fast dose escalation)|Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)
3113244|NCT02453711|Placebo Comparator|Placebo Lira 3.0 mg|Placebo arm matching active arm Lira 3.0 mg
3113245|NCT02453750|Experimental|Hypersaline and Bronchodilator Response|After the subject has performed post-bronchodilator spirometry, they will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer.
3113246|NCT02453841|Active Comparator|FESS|Patients undergoing functional endoscopic sinus surgery and receiving oxymetazoline as part of their surgery.
3113247|NCT02453841|Active Comparator|Turbinates|Patients undergoing turbinate reduction surgery and receiving oxymetazoline as part of their surgery.
3113248|NCT02453841|Active Comparator|Adenoidectomy|Patients undergoing an adenoidectomy and receiving oxymetazoline as part of their surgery.
3113249|NCT02454075|Experimental|Eligible patients|The dose will be 100 mg YF476 once daily. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.
3113250|NCT02454101|Other|cord milking|milking of the umbilical cord 5 times toward the neonate
3113251|NCT02454101|Other|delayed cord clamping|delayed cord clamping for 120 seconds
3113252|NCT02454127|Active Comparator|Atkins Diet|Atkins Diet (dietary counseling)
3113253|NCT02454127|Active Comparator|Zone Diet|Zone Diet (dietary counseling)
3113254|NCT02454127|Active Comparator|Weight Watchers Diet|Weight Watchers Diet (dietary counseling)
3113255|NCT02454127|Active Comparator|Ornish Diet|Ornish Diet (dietary counseling)
3113256|NCT02454153|Active Comparator|REMStar Positive Airway Pressure|Positive pressure therapy is the standard of care for managing obstructive sleep apnea.
3113257|NCT02454153|Other|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
3113258|NCT02454179|Experimental|Arm 1|pembrolizumab
3113259|NCT02454179|Experimental|Arm 2|acalabrutinib in combination with pembrolizumab
3113260|NCT02454283|Experimental|Vanoxerine HCl|Vanoxerine HCl, 400 mg (2 x 200 mg capsules), orally, single dose
3113261|NCT02454283|Placebo Comparator|Placebo|identically matching placebo capsules, orally, single-dose
3113262|NCT02454296|Active Comparator|Paracervical Block with lidocaine|A paracervical block will be done prior to the placement of laminaria with 1% lidocaine and sodium bicarbonate.
3113263|NCT02454296|Sham Comparator|Sham paracervical block|A sham block will be done prior to the placement of laminaria using a capped needle
3113264|NCT02454478|Experimental|Lenvatinib plus Everolimus|
3113265|NCT02454530||Cancer patients treated with Nivestim®|
3113266|NCT02454608|Experimental|Treatment|Verapamil HCl, capsules for oral administration, 80mg, TID, for 8 weeks
3113267|NCT02454608|Placebo Comparator|Control|Placebo, capsules for oral administration, TID, for 8 weeks
3113268|NCT02454608|Experimental|Open Label|Verapamil HCl, capsules for oral administration, 80mg, TID, for 1 year
3113269|NCT02454959|Experimental|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
3113270|NCT02454959|Experimental|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
3113271|NCT02454972|Experimental|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion
3113272|NCT02455050|Other|New Eye Drop Formulation then Systane®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
3113273|NCT02455050|Other|Systane® then New Eye Drop Formulation|1 to 2 drops of Systane® Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
3113274|NCT02455050|Other|Genteal® then New Eye Drop Formulation|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks followed 1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks.
3113275|NCT02455050|Other|New Eye Drop Formulation then Genteal®|1 to 2 drops of New Eye Drop Formulation (carboxymethylcellulose sodium based eye drops) in each eye as needed at least 2 times daily for 2 weeks followed by 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye as needed at least 2 times daily for 2 weeks.
3113276|NCT02455076|Active Comparator|Exenatide inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3113277|NCT02455076|Active Comparator|Exenatide plus glargine insulin inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide twice daily and glargine once daily. Glargine insulin will be given once daily at the same time. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3113278|NCT02455076|Active Comparator|Basal bolus regimen inpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive the Basal Bolus Regimen with Glargine and Rapid-Acting Insulin Analogs. Patients treated with insulin previously will receive 80% of total home daily insulin dose as the basal bolus. Half of the total daily dose will be given as glargine and half as rapid-acting insulin analogs. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3113279|NCT02455076|Active Comparator|Exenatide outpatient|Patients with Type 2 Diabetes treated with diet, oral antidiabetic drugs, or with low-dose insulin will receive exenatide (Byetta®) twice daily. Supplemental (correction) doses of rapid-acting insulin analogs will be given for blood glucose levels > 140 mg/dL per the sliding scale.
3113280|NCT02455076|Active Comparator|Insulin Only|Patients with Type 2 Diabetes will be treated with Insulin only
3113281|NCT02455167|Experimental|HCV positive group|A single arm study of 'Simeprivir (SMV), Sofosbuvir (SOF) and Ribavirin (RBV) in an HCV positive population.
3113282|NCT02455336|Experimental|Fenofibrate|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months
3113283|NCT02455336|Other|No Intervention|Subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive no therapy for 4 months
3113284|NCT02455388|Experimental|Low, then high added sugar diet|Participants will consume a low added sugar (5% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a high added sugar (25% total energy) diet for 7 consecutive days.
3113285|NCT02455388|Experimental|High, then low added sugar diet|Participants will consume a high added sugar (25% total energy) diet for 7 consecutive days. After a 4-week washout period, participants will then consume a low added sugar (5% total energy) diet for 7 consecutive days
3113286|NCT02455388|No Intervention|Dietary recall and fingerstick|Participants will complete 4 in-person 24-hr dietary recalls and 2 fingerstick blood samples at Visit 1 and 3 within 3 weeks.
3113287|NCT02455453|Experimental|Diagnostic FFNP-PET/CT Scan|"(2) 18F-FFNP-PET/CT scans~First one prior to estradiol challenge test~Second one immediately following one day of estradiol challenge test~(1) FDG-PET/CT scan at screening~The estradiol challenge test will consist of administering a total of 6 mg of estradiol dosed orally as three 2 mg tablets with each tablet being administered approximately 8 hours apart and within a 24 hour period. This estradiol medication will be provided to the patient by the study."
3113288|NCT02455518|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
3113289|NCT02455518|Active Comparator|Hydrocodone/acetaminophen|Hydrocodone/acetaminophen (5 mg/300 mg)
3113290|NCT02455518|Active Comparator|Codeine/acetaminophen|Codeine/acetaminophen (30 mg/300 mg)
3113291|NCT02455518|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/1000 mg)
3113292|NCT02455557|Experimental|Treatment (SurVaxM, temozolomide)|Patients receive the first priming dose of SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC within 7-28 days after completion of chemoradiation. Treatment repeats every 2 weeks for a total of 4 doses in the vaccine priming phase and then every 12 weeks during the adjuvant phase in the absence of disease progression or unacceptable toxicity. Patients also receive standard adjuvant temozolomide PO or IV on days 1-5. Treatment repeats every 28 days for 6 courses or more (at the discretion of the investigator) in the absence of disease progression or unacceptable toxicity. Patients may then receive maintenance SVN53-67/M57-KLH peptide vaccine in emulsion with montanide ISA 51 SC and sargramostim SC every 12 weeks in the absence of disease progression or unacceptable toxicity.
3113293|NCT02456103|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/grams (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 96 weeks.
3113294|NCT02456636|Active Comparator|Fee-for-Service Model (FFS, In clinic individual visits)|Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
3113295|NCT02456636|Active Comparator|Patient Centered Medical Home (PCMH, In clinic group visits)|Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
3113296|NCT02456636|Active Comparator|Disease Management (DM, Phone group visits)|Participants will take part in group weight-management counseling by telephone.
3113297|NCT02456662|Placebo Comparator|Placebo|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive placebo tablet 30 minutes prior to taking 200mg PO doxycycline
3113298|NCT02456662|Active Comparator|Ondansetron|160 Patients will randomly be assigned, using sealed numbered opaque envelopes to receive 8mg ondansetron tablet 30 minutes prior to taking 200mg PO doxycycline
3113299|NCT02456727|Active Comparator|Individual Acupuncture|Participants will be treated weekly with individual acupuncture treatment sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
3113300|NCT02456727|Active Comparator|Group/Community Acupuncture|Participants will be treated weekly with group acupuncture treatments sessions for 12 consecutive weeks. Quality of life assessments will be taken at intervals during treatment and post-treatment.
3469257|NCT03888287|Experimental|Retrospective Phase|150 patients with Parkinson disease before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
3113301|NCT02456740|Placebo Comparator|Placebo|Participants received placebo once a month (QM) by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3113302|NCT02456740|Experimental|Erenumab 70 mg QM|Participants received erenumab 70 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3113303|NCT02456740|Experimental|Erenumab 140 mg QM|Participants received erenumab 140 mg QM by subcutaneous injection on day 1 and weeks 4, 8, 12, 16, and 20 in the 24-week double-blind treatment phase. At week 24, participants were re-randomized to receive either erenumab 70 mg or erenumab 140 mg, administered QM at weeks 24, 28, 32, 36, 40, 44, and 48, with actual dose blinded.
3113304|NCT02456896|No Intervention|Healthy control|Twenty five (25) age and sex matched healthy individuals will serve as the control group. Control subjects will be evaluated at baseline only.
3113305|NCT02456896|Experimental|Oxcarbazepine|Twenty five (25) patients of bipolar mania will be prescribed oxcarbazepine for 4 weeks.
3113306|NCT02456909|Experimental|Cues|The PCA pump will be programmed to provide a cue to the end of the lockout period.
3113307|NCT02456909|Placebo Comparator|No Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period (current standard of care).
3113308|NCT02457065|Experimental|Receive Plaque|"Treatment~Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators gave the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors."
3113309|NCT02457065|No Intervention|Do Not Receive Plaque|"Control~No Melanoma Survivor plaque: After the patients enrolled in the study and completed the initial survey, the investigators did not give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors or any other intervention."
3113310|NCT02457182|Experimental|Mindfulness-based Stress Reduction|Mindfulness-based Stress Reduction (MBSR)
3113311|NCT02457182|Placebo Comparator|Usual Care|Usual medical therapy
3113312|NCT02457195|Experimental|Admnistration of granisetron|Preoperative administration of granisetron transdemal patch
3113313|NCT02457247|Experimental|Test Group 1: Sequence AB|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) [A], chewable tablets, orally, twice, daily, on Days 1 through 14, followed by Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3) [B], chewable tablets, orally, twice, daily, on Days 15 through 28.
3113314|NCT02457247|Experimental|Test Group 1: Sequence BA|Adcal-D3 (Calcium 600 mg / 400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 1 through 14, followed by, Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3), chewable tablets, orally, twice, daily, on Days 15 through 28.
3113315|NCT02457247|Experimental|Test Group 2: Sequence CD|Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3) [C], chewable tablets, orally, once, daily, on Days 1 through 14, followed by Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3) [D], chewable tablets, orally, once, daily, on Days 15 through 28.
3113316|NCT02457247|Experimental|Test Group 2: Sequence DC|Kalcipos-D (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 1 through 14, followed by, Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3), chewable tablets, orally, once, daily, on Days 15 through 28.
3113317|NCT02457260|Experimental|Healthy control|10 healthy adults, age 70 or older to receive 14 Nitrogen (14N) sodium nitrite, 40 mg tid
3113318|NCT02457260|Experimental|HFpEF|10 adults with heart failure and preserved ejection fraction age 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
3113319|NCT02457260|Experimental|HFrEF|10 adults with heart failure and reduced ejection fraction aged 70 or older to receive 14N sodium nitrite, 20 or 40 mg tid depending on dose stratification for safety
3113320|NCT02457325|Experimental|Surgery With 2% Articaine first, then Surgery With 4%Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne)
3113321|NCT02457325|Experimental|Surgery With 4%Articaine first, then Surgery With 2% Articaine|First Intervention (1 day - third molar surgery with infiltration of one cartridge of 4% articaíne), Washout (1-2 months), and Second Intervention (1 day - third molar surgery with infiltration of one cartridge of 2% articaíne)
3113322|NCT02457403|Experimental|ROTEM|Transfusion guided by ROTEM during OLT
3113323|NCT02457403|Active Comparator|Conventional|Transfusion guided by conventional labs
3113324|NCT02457520|Experimental|Single treatment arm|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
3113325|NCT02457546|Experimental|EVICEL Fibrin Sealant|EVICEL is a human plasma-derived fibrin sealant composed of two components - thrombin and fibrinogen
3113326|NCT02457546|Active Comparator|Hydrogel sealant|The sealant is composed of two solutions, a polyethylene glycol (PEG) ester solution and a trilysine amine solution
3113327|NCT02457611|Experimental|LDV/SOF|LDV/SOF FDC for 6 weeks
3113328|NCT02457637||Acute-on-Chronic Liver Disease Inpatient|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients; and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT>3NL(normal level),AST>3NL or TB>2NL within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection gastrointestinal bleeding or jaundice(TB>5NL)within 1 month before enrollment)].~Standary therapy"
3113329|NCT02457728|Experimental|Inguinal herniation|In patients with bilateral herniations it should be explored if one glue device (LiquiBandFix8) for mesh fixation and closure of peritoneum is sufficient.
3113330|NCT02457793|Experimental|Not assigned|One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.
3113331|NCT02457793|Experimental|COB 20 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3113332|NCT02457793|Experimental|COB 40 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3113333|NCT02457793|Experimental|COB 80 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3113334|NCT02457793|Experimental|COB 80 mg + GDC 400 mg|Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.
3113335|NCT02457793|Experimental|COB 100 mg + GDC 200 mg|Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.
3113336|NCT02457819|Experimental|Dasotraline|Dasotraline 2, 4, 6 mg
3113337|NCT02457897|Experimental|Patients with insulin receptor mutation|
3113338|NCT02457910|Experimental|Taselisib 2 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
3113339|NCT02457910|Active Comparator|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib
3113340|NCT02457910|Experimental|Taselisib 4 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
3113341|NCT02457910|Experimental|Taselisib 6 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
3113342|NCT02457910|Experimental|Taselisib 8 mg|Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
3113343|NCT02457910|Experimental|Enzalutamide + Taselisib|Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3113344|NCT02457910|Experimental|Cross-Over|Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD
3113345|NCT02458092|Experimental|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant|50 µg of FMP010 antigen in 0.5 mL AS01B adjuvant given intramuscularly in the deltoid muscle of the non-dominant arm.
3113346|NCT02458092|Experimental|Rabies Vaccine Rabipur|Rabies Vaccine Rabipur given intramuscularly in the deltoid muscle of the non-dominant arm.
3113347|NCT02458235|Experimental|Azacitidine/donor lymphocyte infusion|Patients will be stratified according to risk categories (low, standard and high), defined by GVHD status, mixed versus full donor chimerism, and positive versus negative Minimal Residual Disease (MRD) results. Patients will receive up to 7 cycles of low-dose azacitidine (40mg/m2 IV/SC daily x 4 days) at 6 weekly intervals, except for low risk ALL patients who may not receive treatment after withdrawal of immunosuppression. Standard risk patients will receive an additional 6 cycles of azacitidine alone. High risk patients will receive an additional 6 cycles of azacitidine plus escalating DLI.
3113348|NCT02458287|Experimental|Bococizumab 150mg|Bococizumab 150mg autoinjector (pre-filled pen)
3113349|NCT02458287|Experimental|Bococizumab 75mg|Bococizumab 75mg autoinjector (pre-filled pen)
3113350|NCT02458287|Placebo Comparator|Bococizumab 150mg placebo|Bococizumab 150mg placebo autoinjector (pre-filled pen)
3113351|NCT02458287|Placebo Comparator|Bococizumab 75mg placebo|Bococizumab 75mg autoinjector (pre-filled pen)
3113352|NCT02458352|Other|Standard dose CT, Ultra-low dose CT|Standard dose non-contrast enhanced CT (clinically indicated) and Ultra low dose non-contrast enhanced CT (as part of the trial)
3113353|NCT02458365|Experimental|Teen Choices|Teen Choices: A Program for Healthy Nonviolent Relationships
3113354|NCT02458365|Other|Comparison|Health In Motion
3113355|NCT02458469|Active Comparator|Buspirone|This drug will be taken for two week period
3113356|NCT02458469|Active Comparator|Trazodone|This drug will be taken for two week period
3113357|NCT02458469|Placebo Comparator|Placebo|A placebo pill will be taken at bed time for two week period
3113358|NCT02458638|Experimental|Atezolizumab|The dose of atezolizumab in this study will be 1200 milligrams (mg) administered by intravenous (IV) infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3113359|NCT02458690|Experimental|eIMPACT|eIMPACT is a 12-month, modernized, collaborative, stepped care intervention consisting of (1) computerized and telephonic cognitive-behavioral therapy for depression and (2) select antidepressant medications included in an algorithm optimized for cardiovascular disease risk reduction. It is a collaborative care intervention in which a multidisciplinary team delivers established depression treatments consistent with patient preference. It uses a stepped, flexible, treat-to-target approach that modernizes the IMPACT intervention by harnessing technology to minimize staff and space requirements. Interventions are Beating the Blues, Problem Solving Treatment in Primary Care, and select FDA-approved antidepressants. The treatment team consists of a depression clinical specialist, a supervising MD with expertise in primary care and IMPACT, and the patients' primary care providers.
3113360|NCT02458690|Active Comparator|Usual Care|Patients and their primary care providers are informed of the depressive disorder diagnosis, and follow-up is encouraged. There are no restrictions on the care received. The Eskenazi Health primary care clinics utilize a team care approach, with PCPs supported by embedded behavioral health clinicians and affiliated psychiatrists.
3469258|NCT03888287|Experimental|Prospective Phase-Watch Rx system|150 patients after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program who are also assigned to a WatchRx system
3113361|NCT02458768|Experimental|IVF-M HP Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
3113362|NCT02458768|Active Comparator|Menopur® Inj.|"administration was initiated on the mean menstrual cycle day (MCD) 2 or 3 and made by subcutaneous injection.~Although the recommended initial dose of Investigational Product (IP) was 225 IU, adjustment was allowed according to the patient's individual response based on the monitoring (blood estradiol (E2) concentration and ultrasonography results)."
3113363|NCT02459080|Active Comparator|TD-4208-1|88 mcg
3113364|NCT02459080|Active Comparator|TD-4208-2|175 mcg
3113365|NCT02459080|Placebo Comparator|Placebo|Placebo
3113366|NCT02459093|Experimental|poliglecaprone 25 suture|Subcuticular skin approximation with poliglecaprone 25 suture at cesarean birth surgery
3113367|NCT02459093|Experimental|polyglactin 910 suture|Subcuticular skin approximation with polyglactin 910 suture at cesarean birth surgery
3113368|NCT02459119|Experimental|Regorafenib|Regorafenib will be administered orally to all patients on study. The drug will be taken once a day for 3 of every 4 week cycle (3 weeks on/1 week off). The dose is 120 mg once daily for the first cycle, then 160 mg once daily from the second cycle if no significant Regorafenib-associated toxicities occur during the first cycle. Drug dosage may be modified if toxicities occur. Patients will undergo up to 4 cycles of treatment and may continue on additional at the discretion of the investigator.
3113369|NCT02459197|Active Comparator|T4P1001|
3113370|NCT02459197|Sham Comparator|Placebo|
3113371|NCT02459262|Active Comparator|GBS-NN Vaccine|GBS-NN vaccine administered either adsorbed to Alhydrogel® or alone.
3113372|NCT02459262|Placebo Comparator|Sterile dilution buffer with Alhydrogel|The placebo will contain either Alhydrogel® or buffer alone.
3113373|NCT02459275|Experimental|PEP uP Protocol|Participants will receive the PEP uP protocol with the pro motility agent. The intervention will be provided until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
3113374|NCT02459275|No Intervention|Standard of Care|Standard formula polymeric tube feeds started at a rate of 20 ml/hour. Gastric residual volume (GRV) will be checked every 4 hours. GRV is reinfused to the patient each time it is checked. GRV threshold is 200-500 ml. If the patient is tolerating tube feeds as determined by measuring the GRV, the rate is advanced by 20 ml/hour every 4 hours up to the goal rate. Participants will be followed until the tube feeds are stopped or patient is fed meals orally and will be tracked until hospital discharge or 60 days which ever occur first.
3113375|NCT02459418|Experimental|Afolia - US Gonal-f® (Sequence A) Arm|During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive treatment sequence: (Sequence A): Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
3113376|NCT02459418|Active Comparator|US Gonal-f® - Afolia (Sequence B) Arm:|During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive treatment sequence (Sequence B): Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27
3113377|NCT02459587|Experimental|Crisis Line Facilitation (CLF)|Crisis Line Facilitation
3113378|NCT02459587|Placebo Comparator|Enhanced Usual Care (EUC)|Enhanced Usual Care
3113379|NCT02459665|No Intervention|Group 1|Negative control group: After initial treatment for BV/TV, no intervention.
3113380|NCT02459665|Other|Group 2|Positive control group: After initial treatment for BV/TV, metronidazole pills (500 mg) twice per week for 2 months.
3113381|NCT02459665|Active Comparator|Group 3|After initial treatment for BV/TV, Ecologic Femi+ vaginal capsule (a vaginal probiotic) once per day for 5 days immediately after the initial treatment followed by thrice weekly for two months.
3113382|NCT02459665|Active Comparator|Group 4|After initial treatment for BV/TV, Gynophilus LP vaginal tablet (a vaginal probiotic) once every 4 days for two months.
3113383|NCT02459795|Experimental|Test product|Ingenol Mebutate (Perrigo)
3113384|NCT02459795|Active Comparator|Reference product|Ingenol Mebutate (Reference)
3113385|NCT02459795|Placebo Comparator|Placebo product|Placebo gel
3113386|NCT02459899|Placebo Comparator|Placebo|Two placebo-matching sotagliflozin tablets, once daily, orally for 12 weeks.
3113387|NCT02459899|Experimental|Sotagliflozin 75 mg|Sotagliflozin 75 mg (one 75 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
3113388|NCT02459899|Experimental|Sotagliflozin 200 mg|Sotagliflozin 200 mg (one 200 mg tablet and one placebo tablet), once daily, orally for 12 weeks.
3113389|NCT02459899|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 mg (two 200 mg tablets), once daily, orally for 12 weeks.
3113390|NCT02459951||clenched fist|Adult participants with upper limb hemiparesis secondary to stroke and greater than 12 months duration. Medical determination that .botulinum toxin injections are indicated for treatment of spasticity.
3113391|NCT02459964|Experimental|Fentanyl Nasal Spray|"Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
3113392|NCT02459964|Active Comparator|Hydromorphone Hydrochloride|"Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).~Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study."
3113393|NCT02460159|Experimental|EZ 10 mg/Atorva 10 mg FDC|one EZ 10 mg/Atorva 10 mg fixed-dose combination (FDC) tablet orally with food once daily for 52 weeks.
3113394|NCT02460159|Experimental|EZ 10 mg/Atorva 20 mg FDC|one EZ 10 mg/Atorva 20 mg fixed -dose combination (FDC) tablet orally with food once daily for 52 weeks.
3113395|NCT02460172|Active Comparator|Zip Surgical Skin Closure|Subject will be randomized to receive one knee (right or left) closed with Zip Surgical Skin Closure and the other knee closed with steel staples.
3113396|NCT02460172|Active Comparator|Steel Staples|Subject will be randomized to receive one knee (right or left) closed with steel staples and the other knee closed with Zip Surgical Skin Closure.
3113397|NCT02460198|Experimental|Cohort A - Pembrolizumab 200 mg|Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 52 cycles (up to approximately 4 years).
3113398|NCT02460198|Experimental|Cohort B - Pembrolizumab 200 mg|Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants receive pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 52 cycles (up to approximately 4 years).
3113399|NCT02460263|Placebo Comparator|In-Center|Staff administered treatments in-center using the device
3113400|NCT02460263|Experimental|In-Home|Patient administered treatments in-home using the device
3113401|NCT02460380|Active Comparator|Vitamin D3|Women allocated to vitamin D3 group received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
3113402|NCT02460380|Placebo Comparator|Placebo|Women in the placebo group received once capsule of placebo once weekly for eight weeks.
3113403|NCT02460458||Type 3 Von Willebrand's Disease (VWD3)|Patients with diagnosis of Type 3 Von Willebrand's Disease
3113404|NCT02460562|Active Comparator|PMMA resin|A denture base will be made with PMMA resin as a standard material.
3113405|NCT02460562|Experimental|PMMA resin & S-PRG filler|A denture base will be made from PMMA resin & S-PRG filler for subject to wear.
3113406|NCT02460575|Experimental|Lactobacillus|Active Product: Description Lactobacillus reuteri 17938 suspended in sunflower oil, medium chain triglyceride oil, silicone dioxide. Total viable count of L. reuteri 17938 1 x 108 CFU/5 drops.
3113407|NCT02460575|Placebo Comparator|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
3113408|NCT02460666|Experimental|Tai-Chi Chih Classes|Participants will engage in 12 weekly 60 minute Tai-Chi-Chih classes.
3113409|NCT02460666|Active Comparator|Health Education and Wellness Classes|Participants will engage in 12 weekly 60 minute Health Education and Wellness classes.
3113410|NCT02460679|Experimental|EPI-589|Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues.
3113411|NCT02460822|Experimental|MyChemoCare|Participants will receive access to the the MyChemoCare iPad application, which allows them to track cancer and chemotherapy related symptoms daily, and suggests strategies that may help the participant deal with these symptoms. While using the application, high symptom severity scores will be reported to the participant's medical team, who may intervene to help relieve the symptom. Participants will also be contacted if they have not checked in for 48 hours to make sure they are coping well with their chemotherapy regimen.
3113412|NCT02460978|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg tablet orally, once daily for 52 weeks
3113413|NCT02460978|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg tablet orally, once daily for 52 weeks
3113414|NCT02460978|Placebo Comparator|Placebo|Placebo tablet orally, once daily for 52 weeks
3113415|NCT02460991|Experimental|DEB-TACE|ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments can be repeated every 4-8 weeks until complete tumor response is achieved.
3113416|NCT02460991|Active Comparator|Sorafenib|200 mg Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
3113417|NCT02461134|Experimental|Ponesimod|Study treatment consists of 3 consecutive periods: 5 mg ponesimod treatment period (including up-titration), 10 mg treatment period (including up-titration) and a 20 mg treatment period.
3113418|NCT02461160|Placebo Comparator|SRD Cohorts 1-3: Placebo|TAK-915 placebo-matching suspension, orally, once on Day 1.
3113419|NCT02461160|Experimental|SRD Cohort 1 TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1.
3113420|NCT02461160|Experimental|SRD Cohort 2: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1.
3113421|NCT02461160|Experimental|SRD Cohort 3: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1.
3113422|NCT02461160|Placebo Comparator|MRD Cohorts 4-6|TAK-915 placebo-matching suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 placebo-matching suspension, orally, once on Days 8 to 14.
3113423|NCT02461160|Experimental|MRD Cohort 4: TAK-915 30 mg|TAK-915 30 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 30 mg suspension, orally, once on Days 8 to 14.
3113424|NCT02461160|Experimental|MRD Cohort 5: TAK-915 100 mg|TAK-915 100 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 100 mg suspension, orally, once on Days 8 to 14.
3113425|NCT02461160|Experimental|MRD Cohort 6: TAK-915 200 mg|TAK-915 200 mg suspension, orally, once on Day 1, followed by a 7-day washout period, followed by TAK-915 200 mg suspension, orally, once on Days 8 to 14.
3113426|NCT02461160|Experimental|DDI Cohort 7: TAK-915 + Midazolam 2 mg|Midazolam 2 mg suspension, orally, once on Day 1, followed by TAK-915 100 mg, suspension, orally, once on Day 3, followed by a 7-day washout period, followed by TAK-915 100 mg, suspension, orally, once, daily on Days 10 to 16 and Midazolam 2 mg solution, orally, once, on Day 16 (within 15 minutes after last dose of TAK-915).
3113427|NCT02461160|Experimental|BA/FE Cohort 8 Group 1: A,B,C|Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1, followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3. Each period was separated out by a 6 to 14-day washout period.
3113428|NCT02461160|Experimental|BA/FE Cohort 9 Group 1: B,C,A|Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2, followed by Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1. Each period was separated out by a 6 to 14-day washout period.
3113429|NCT02461160|Experimental|BA/FE Cohort 10 Group 1: C,A,B|Regimen C: TAK-915 50 mg, tablet, orally under fed conditions once on Day 1 of Period 3 followed by Regimen A: TAK-915 50 mg, suspension, orally, under fasted conditions once on Day 1 of Period 1 followed by Regimen B: TAK-915 50 mg, tablet, orally, under fasted conditions once on Day 1 of Period 2. Each period was separated out by a 6 to 14-day washout period.
3113430|NCT02461160|Experimental|ESSD Cohort 11: TAK-915 50 mg|TAK-915 50 mg, suspension, orally, under fasted conditions, once on Day 1 in participants aged 65 to 75 years.
3113431|NCT02461290||Combination Therapy|Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.
3113432|NCT02461433|Experimental|Prevena|After surgery this group will receive the Prevena device (negative pressure wound therapy).
3113433|NCT02461433|Active Comparator|Standard dressing|After surgery this group will receive standard of care dressings on their surgical wound.
3113434|NCT02461563|Experimental|GT1: 200 mg MK-1075|Fasted GT1 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113435|NCT02461563|Experimental|GT1: 400 mg MK-1075|Fasted GT1 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113436|NCT02461563|Experimental|GT1: 800 mg MK-1075|Fasted GT1 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113437|NCT02461563|Experimental|GT3: 200 mg MK-1075|Fasted GT3 participants are administered 200 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113438|NCT02461563|Experimental|GT3: 400 mg MK-1075|Fasted GT3 participants are administered 400 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113439|NCT02461563|Experimental|GT3: 800 mg MK-1075|Fasted GT3 participants are administered 800 mg MK-1075 in tablet form, orally, once daily for 7 consecutive days
3113440|NCT02461589|Experimental|Semaglutide 0.05 mg/day|
3113441|NCT02461589|Active Comparator|Liraglutide 0.3 mg/day|
3113442|NCT02461589|Placebo Comparator|Placebo 50 µL|
3113443|NCT02461589|Experimental|Semaglutide 0.05/0.1 mg/day|
3113444|NCT02461589|Active Comparator|Liraglutide 0.3/0.6 mg/day|
3113445|NCT02461589|Placebo Comparator|Placebo 50/100 µL|
3113446|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2 mg/day|
3113447|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2 mg/day|
3113448|NCT02461589|Placebo Comparator|Placebo 50/100/200 µL|
3113449|NCT02461589|Experimental|Semaglutide 0.05/0.1/0.2/0.3 mg/day|
3113450|NCT02461589|Active Comparator|Liraglutide 0.3/0.6/1.2/1.8 mg/day|
3113451|NCT02461589|Placebo Comparator|Placebo 50/100/200/300 µL|
3113452|NCT02461589|Experimental|Semaglutide flexible escalation from 0.05 mg/day to 0.3 mg/day|
3113453|NCT02461628|Experimental|Malaria RDT & conditional voucher|In the intervention arm, trained community health volunteers (CHVs) will offer eligible household members a free malaria rapid diagnostic test (RDT) and a voucher allowing the purchase of a qualified artemisinin combination therapy (ACT) at a reduced fixed price in the retail sector conditional on a positive test.
3113454|NCT02461628|No Intervention|Comparison Arm|Individuals in the comparison arm will only receive standard community health volunteer (CHV) visits.
3113455|NCT02461693|Experimental|Caffeine|One-time treatment with 200mg caffeine pill
3113456|NCT02461693|Placebo Comparator|Placebo|One-time treatment with lactose-based placebo pill
3113457|NCT02461745|Active Comparator|Genotype 1a|Study participants with chronic Hepatitis C Genotype 1A receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) and RBV (ribavirin tablets) for 12 weeks.
3113458|NCT02461745|Active Comparator|Genotype 1b|Study participants with chronic Hepatitis C Genotype 1B receiving VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) for 12 weeks.
3113459|NCT02461758|Other|Control Group|A group of 20 healthy individuals without IBD, other chronic diseases, or immunosuppressive therapy will be enrolled. All healthy individuals will receive standard dose influenza vaccine SDIV.
3113460|NCT02461758|Other|Vedolizumab Group + standard dose influenza vaccine (SDIV)|A group of 20 patients who are currently on vedolizumab. All individuals in this group will receive SDIV
3113461|NCT02461758|Other|High dose influenza vaccine (HDIV)|"This arm will be a double blind randomized controlled trial of High dose influenza vaccine (HDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
3113462|NCT02461758|Other|Standard dose influenza vaccine (SDIV)|"This arm will be a double blind randomized controlled trial of standard dose influenza vaccine (SDIV) for IBD patients on TNF monotherapy.~40 patients will be enrolled and randomized in a 5:3 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme."
3113463|NCT02461771|Experimental|Pegcetacoplan Cohort 1|4 mg of pegcetacoplan 100 μL IVT injection
3113464|NCT02461771|Experimental|Pegcetacoplan Cohort 2|10 mg of pegcetacoplan 100 μL IVT injection
3113465|NCT02461771|Experimental|Pegcetacoplan Cohort 3|20 mg of pegcetacoplan 100 μL IVT injection
3113466|NCT02461966|Other|Hepatocellular carcinoma (HCC)|Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC)
3113467|NCT02461966|Other|20 cirrhotic patients|Estimation of serum aflatoxin level in 20 patients with liver cirrhosis
3113468|NCT02461966|Other|Control group|Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study
3113469|NCT02461992|Experimental|Intravenous infusion of Xyntha|observation arm
3113470|NCT02462057|No Intervention|Control Arm|This arm will represent current practice. This group will receive no contact from the research team. They may receive information regarding the benefit from the Vitality marketing team during the intervention period and can enroll in the benefit at any time during the study period.
3113471|NCT02462057|Active Comparator|Diabetes-specific|This group will receive a message which simply cites the two specific benefits of the eating more healthy foods for individuals with diabetes. This message contains a link to start the enrolment process.
3469259|NCT03888287|Experimental|Retrospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist before completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
3113472|NCT02462057|Active Comparator|Experience of another member|This group will receive a message that includes a quote from the perspective of a Vitality member with diabetes who uses the HealthyFood benefit. Given the need to standardise message content across study arms, the quote was written by the study team and not an actual member. The quote emphasizes the positive impact the benefit has had for the member-both the financial benefit, as well as the two specific diabetes health benefits.
3113473|NCT02462057|Active Comparator|Input from a diabetes expert|This group will receive a message that includes a quote from a South African physician who specializes in diabetes. The quote emphasises the financial benefit and the two specific diabetes health benefits of the HealthyFood program included in the other messages. It concludes with the doctor's recommendation of the benefit for all individuals with diabetes.
3113474|NCT02462057|Active Comparator|Enhanced active choice|"This group will receive a message whose first portion is identical to those in the diabetes-specific message group. The second portion of the message differs in that instead of just asking recipients to click on the provided link if interested, the message asks people to choose and click on one of following possible responses:~Yes! I want to active the HealthyFood benefit and get up to 25% cash back on the healthy food I buy at Pick n Pay or Woolworths~No, I'd prefer not to activate and continue paying full price for my healthy food purchases"
3113475|NCT02462070|Experimental|IDP-118 Lotion|Lotion
3113476|NCT02462070|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
3113477|NCT02462083|Experimental|IDP-118 Lotion|IDP-118 lotion (halobetasol propionate 0.01%, tazarotene 0.045%) will be applied topically on the affected area once daily for 8 weeks and then as needed once daily for up to 1 year.
3113478|NCT02462122|Experimental|IDP-118 Lotion|Lotion
3113479|NCT02462122|Active Comparator|IDP-118 Vehicle Lotion|Vehicle Lotion
3113480|NCT02462148|Experimental|4 mg Perineural Dexamethasone Group|4 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
3113481|NCT02462148|Experimental|1 mg Perineural Dexamethasone Group|1 mg of dexamethasone will be included in the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. No systemic dexamethasone will be given.
3113482|NCT02462148|Placebo Comparator|Placebo Group|This group will receive only the saphenous nerve block mixture including 20 ml of 0.25% bupivacaine with 1:400,000 epinephrine. Dexamethasone will not be administered to this group systemically or perineural.
3113483|NCT02462291|Experimental|Experimental group (TR)|A group of 80 patients with AD will perform a program of EET for 2 hours a day, 5 days a week for a total of 6 months.
3113484|NCT02462291|No Intervention|Control group (CTRL)|A group of 80 patients with AD will be treated with the standard therapy.
3113485|NCT02462382|Active Comparator|Ropivacaine infusion|270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
3113486|NCT02462382|Placebo Comparator|Saline infusion|270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
3113487|NCT02462473|Experimental|Cohort 1|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in this cohort at a given site have completed their study participation.
3113488|NCT02462473|Experimental|Cohort 2|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will be provided to the clinician as they become available.
3113489|NCT02462473|Experimental|Cohort 3|Participants will receive treatment as usual (TAU) which include one or more of the 5 antipsychotic medications (aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) for 12 weeks as determined by the treating clinician and the antipsychotic medication plasma level (AMPL) results will not be available to the clinicians until all participants in cohorts 2 and 3 at a given site have completed participation in the active assessment phase.
3113490|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 8, followed by injections every 8 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
3113491|NCT02462486|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, and Week 12, followed by injections every 12 weeks through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
3113492|NCT02462486|Active Comparator|Ranibizumab (rQ4)|Ranibizumab (Lucentis®) was administered to the study eye by intravitreal injection every 4 weeks from Day 1 through Week 96.
3113493|NCT02462720|Experimental|Varithena®, then Radiofrequency Ablation|Varithena (polidocanol injectable foam) supplied as polidocanol solution 180 mg/18 mL (10 mg/mL) to be activated before use. Once activated, Varithena is a white injectable foam delivering a 1% polidocanol solution. Each milliliter of Varithena injectable foam contains 1.3 mg of polidocanol. Up to 5 mL per injection or 15 mL per treatment session could be used. This was followed by RFA treatment.
3113494|NCT02462720|Active Comparator|Radiofrequency ablation then Varithena|RFA procedures were conducted in accordance with the physician's standard of care and according to the manufacturer's instructions for use. This was followed by treatment with Varithena.
3113495|NCT02462759|Experimental|Nusinersen|Administered by intrathecal injection.
3113496|NCT02462759|Sham Comparator|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
3113497|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q8)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
3113498|NCT02462928|Experimental|Abicipar Pegol 2 mg (2Q12)|Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.
3113499|NCT02462928|Active Comparator|Ranibizumab 0.5 mg (rQ4)|Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.
3113500|NCT02462967|Active Comparator|2 mg/kg GR MD 02|GR MD 02 in a dose of 2 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
3113501|NCT02462967|Active Comparator|8 mg/kg GR MD 02|GR MD 02 in a dose of 8 mg/kg lean body mass administered every other week over a 52 week period for a total of 26 infusions
3113502|NCT02462967|Placebo Comparator|Placebo|Phosphate buffered saline solution administered every other week over a 52 week period for a total of 26 infusions
3113503|NCT02463032|Experimental|GTx-024 9 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 9 mg
3113504|NCT02463032|Experimental|GTx-024 18 mg|Drug: GTx-024 GTx-024 softgel capsules will be administered once daily to a total dose of 18 mg
3113505|NCT02463071|Experimental|AZD0585 2g group|AZD0585 1g × 2 capsules and AZD0585 placebo 1g × 2 capsules once daily
3113506|NCT02463071|Experimental|AZD0585 4g group|AZD0585 1g × 4 capsules once daily
3113507|NCT02463071|Placebo Comparator|Placebo control group|AZD0585 placebo 1g × 4 capsules once daily
3113508|NCT02463097|Experimental|Study Arm|All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm
3113509|NCT02463227|Experimental|VRC01|Participants received an IV infusion of 40 mg/kg of VRC01 on study days 0, 21, and 42.
3113510|NCT02463331|Active Comparator|chloroquine plus prednisone|Chloroquine diphosphate 250mg/day associated to prednisone in variable doses
3113511|NCT02463331|Experimental|azathioprine plus prednisone|azathioprine in variable doses (50-150mg/day) associated to prednisone in variable doses
3113512|NCT02463357|Experimental|Quercetin|Quercetin: 500mg pill, twice daily for 5 days
3113513|NCT02463357|Experimental|Nifedipine+Methazolamide|Nifedipine extended release: 30mg pill, twice daily for 5 days; Methazolamide: 125mg pill, twice daily for 5 days
3113514|NCT02463357|Experimental|Metformin|Metformin: 500mg pill, once daily for 2 days, then 500mg twice daily at altitude (3 days)
3113515|NCT02463357|Placebo Comparator|Placebo|Sugar pill manufactured to look like all other investigational products
3113516|NCT02463357|Experimental|Nitrite|Nitrite: 20mg pill, three times daily for 5 days
3113517|NCT02463409|Experimental|Theophylline|Patients will receive a 24 hour continuous infusion of intravenous theophylline.
3113518|NCT02463487|Active Comparator|Cardinal Pro + Irrigation (NPWTi)|Negative Pressure Wound Therapy with Irrigation: Quantum™ +Simultaneous Irrigation (NPWTi) - Negative Pressure Wound Therapy with Prontosan® Intervention is receiving the Cardinal Vac with Irrigation
3113519|NCT02463487|Active Comparator|Cardinal Pro (NPWT) Therapy|Negative Pressure Wound Therapy without Irrigation: Quantum™ (NPWT) -Negative Pressure Wound Therapy (without Prontosan®) Intervention is receiving the Cardinal Vac without Irrigation
3113520|NCT02463799|Experimental|sipuleucel-T and radium 223 combination|"Radium-223 will be administered by intravenous injection over 1 minute at 50kbq (1.35 microcurie) per kg body weight per standard of care every 4 weeks at weeks 0, 4, 8, 12, 16, and 20~Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10"
3113521|NCT02463799|Active Comparator|sipuleucel-T alone|Sipuleucel-T will be administered intravenously per standard of care every 2 weeks at weeks 6, 8, and 10
3113522|NCT02463981|Experimental|neurofeedback training|Neurofeedback training group receives neurofeedback from their own anterior insula.
3113523|NCT02463981|Sham Comparator|sham control|Sham control group receives sham neurofeedback from a large control brain region.
3113524|NCT02464033|Experimental|A|All patients will from Day 1 receive 2 000 IU vitamin D per os per day during 15 months, and from Days 1-90 receive etanercept (Enbrel) injected subcutaneously 0.8 mg/kg body weight (max 50 mg) once a week, and receive 2 subcutaneous injections of 20 μg Diamyd in a prime-and-boost regimen on Days 30 and 60.
3113525|NCT02464059|Experimental|Vitamin D3|Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks
3113526|NCT02464163|Experimental|Panblok 30µg in 2% SE|30µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3113527|NCT02464163|Experimental|Panblok 15µg in 2% SE|15µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3113528|NCT02464163|Experimental|Panblok 7.5µg in 2% SE|7.5µg recombinant hemagglutinin in a 2% oil-in-water stable emulsion (rHA adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3113529|NCT02464163|Experimental|Panblok 30µg (No Adjuvant)|30µg recombinant hemagglutinin (no adjuvant). 0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle
3113530|NCT02464176|Experimental|4 mg dexamethasone group|Following lumbar plexus nerve block administration using bupivacaine and epinephrine, 4 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
3113531|NCT02464176|Experimental|8 mg dexamethasone group|Following peripheral nerve block using bupivacaine and epinephrine administration, 8 mg of systemic dexamethasone will be administered to this group intravenously. The volume given intravenously will be identical for all groups.
3113532|NCT02464176|Placebo Comparator|Control Group|Normal saline will be used as a placebo control group given at the same time and in the same manner as the experimental groups following peripheral nerve block administration. The volume given intravenously will be identical for all groups.
3113533|NCT02464449|Experimental|AI CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT FU based on what patient reports and what other similar patients report. Stepped care model.
3113534|NCT02464449|Active Comparator|Standard telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
3113535|NCT02464540|Active Comparator|Light-cured resin cement|Laminate veneers luted using light-cured resin cement
3113536|NCT02464540|Active Comparator|Light-cured flowable composite|Laminate veneers luted using light-cured flowable composite
3113537|NCT02464657|Experimental|Ph 1 Nivolumab (1mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 1 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
3113538|NCT02464657|Experimental|Ph 1 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase I dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
3113539|NCT02464657|Experimental|Ph 2 Nivolumab (3 mg) + Idarubicin + Cytarabine|"Phase II dose of Nivolumab 3 mg/kg by vein on Day 24 of a 28 day cycle. Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.~Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.~Phase I and Phase II dose of Solumedrol 50 mg or Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle."
3113540|NCT02464917|Experimental|Supplemental oxygen|Subjects in this arm will receive 10L/min via simple facemask
3113541|NCT02464917|No Intervention|Room air|This control arm will receive no supplemental oxygen
3113542|NCT02465034|Active Comparator|Subcortical stroke|Subjects with subcortical stroke in the chronic phase of recovery with mild-moderate impairment of arm function will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol. The subjects will also undergo median nerve stimulation.
3113543|NCT02465034|Active Comparator|Healthy Control|Healthy individuals will undergo noninvasive targeting of cortical locations by stereotactic neuronavigation using Transcranial Magnetic Stimulation (TMS), median nerve stimulation and arm motor function assessments. A paired associative stimulation (PAS) protocol using noninvasive stimulation will also be used which will be one of the following, a traditional or a corticocortical or a sham paired associative stimulation protocol.
3113544|NCT02465073|Active Comparator|NXTSC|This group will receive the NXTSC gel only. The NXTSC wound gel and its active agents are applied on the wound bed. A synthetic microfiber dressing will be applied to the surface of the wound. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. ( NXTSC).
3113545|NCT02465073|Active Comparator|NXTSC plus SOC|This group will receive the NXTSC wound gel plus Standard of Care. The NXTSC wound gel is applied to the wound bed. Local wound management will consist of diagnosing the wound biofilm and providing specific measures to suppress the wound biofilm to allow host healing. Determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site.( Next Science Wound Gel, plus standard of care).
3113546|NCT02465073|Active Comparator|SOC|This group will receive Standard of Care only. The Standard of Care is based on wound management intervention to remove wound slough by frequent debridement. Moist interactive wound care with multiple strategies to suppress biofilm is instituted. Determine the effect on wound treatment outcomes using standard of care treatment
3113547|NCT02465099|Active Comparator|Electrocautery Dissection (ED)|Patients meeting the study criteria, scheduled to undergo posterior spinal fusion (PSF) using monopolar electrocautery and metal Cobb elevator (considered the current standard) for soft tissue dissection and removal from vertebral surfaces.
3113548|NCT02465099|Experimental|Ultrasonic Dissection (UD)|Patients meeting the study criteria, scheduled to undergo PSF using ultrasonic dissection and metal Cobb elevator for soft tissue dissection and removal from vertebral surfaces.
3113549|NCT02465203|Other|Follow up from feeder studies|Follow up arm
3113550|NCT02465216|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and low dose of adjuvant.
3113551|NCT02465216|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. High dose of antigen and low dose of adjuvant.
3113552|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine|Two intramuscular injections of ID93 + GLA-SE at Days 0 and 56. Low dose of antigen and high dose of adjuvant. Placebo injection at Day 28 to maintain blind with the 3 dose arm.
3113553|NCT02465216|Placebo Comparator|Placebo|Two intramuscular injections of normal saline at Days 0 and 56, or Days 0, 28, and 56.
3113554|NCT02465216|Experimental|2 mcg ID93 + 5 mcg GLA-SE Vaccine 3 doses|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of adjuvant.
3113555|NCT02465372|Experimental|CSPAP|Schools in this arm will receive the Comprehensive School Physical Activity Program training.
3113556|NCT02465372|No Intervention|Control|Standard practice.
3113557|NCT02465437|Experimental|JBT-101 5 mg/20 mg bid|JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.
3113558|NCT02465437|Experimental|JBT-101 20 mg/20 mg bid|JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.
3113559|NCT02465437|Experimental|JBT-101 20 mg bid/20 mg bid|JBT-101 20 mg bid on Days 1-84.
3113560|NCT02465437|Placebo Comparator|Placebo|Placebo bid on Days 1-84.
3113561|NCT02465437|Experimental|Part B Open-label|JBT-101 20 mg bid on Days 1-364
3113562|NCT02465450|Experimental|JBT101 (lenabasum) 1 mg|JBT-101 1 mg once a day on Days 1-28
3113563|NCT02465450|Experimental|JBT-101 (lenabasum) 5 mg|JBT-101 5 mg once a day on Days 1-28
3113564|NCT02465450|Placebo Comparator|Placebo|Placebo once a day on Days 1-28.
3113565|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg QD|JBT-101 20 mg once a day on Days 29-84.
3113566|NCT02465450|Experimental|JBT-101 (lenabasum) 20 mg BID|JBT-101 20 mg twice daily on Days 29-84.
3113567|NCT02465450|Placebo Comparator|Placebo BID|Placebo twice daily on Days 29-84.
3113568|NCT02465463|Experimental|FMT arm|Patients in the experimental arm with undergo a fecal microbiota transplant (FMT) after finishing a course of antibiotics.
3113569|NCT02465463|No Intervention|Control|Patients in the non-interventional group will not receive a FMT but will be followed over the course of 6 months to assess for recurrence of C.difficile.
3113570|NCT02465489|Experimental|ER, fasting conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fasting conditions
3113571|NCT02465489|Experimental|ER, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation administered under fed conditions
3113572|NCT02465489|Experimental|ER half-tablets, fed conditions|A single 1000 mg dose of deferiprone extended release tablet formulation (one 1000 mg tablet divided in two) administered under fed conditions
3113573|NCT02465489|Active Comparator|IR, fasting conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fasting conditions
3113574|NCT02465489|Active Comparator|IR, fed conditions|A single 1000 mg dose of deferiprone immediate release tablet formulation administered under fed conditions
3113575|NCT02465515|Experimental|Albiglutide|Albiglutide once weekly by subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed. Albiglutide will be administered in addition to standard therapy for diabetes and cardiovascular health.
3113576|NCT02465515|Placebo Comparator|Placebo|Placebo once weekly by subcutaneous injection. Placebo will be administered in addition to standard therapy for diabetes and cardiovascular health.
3113577|NCT02465528|Experimental|Inflammatory myofibroblastic tumor (IMT)|Patients diagnosed with IMT with a confirmed translocation involving the ALK gene
3113578|NCT02465528|Experimental|Anaplastic large cell lymphoma (ALCL)|Patients with a diagnosis of ALCL histologically or cytologically confirmed to be ALK-positive
3113579|NCT02465528|Experimental|Glioblastoma (GBM)|Patients with GBM with a translocation involving the ALK gene
3113580|NCT02465528|Experimental|Any other ALK-positive tumor|Patients with any other ALK-positive tumor. Patients in this arm included adenocarcinoma (n= 2), sarcoma (1) and other (2).
3113581|NCT02465567|Experimental|BGF (PT010) MDI 320/14.4/9.6 μg|BGF MDI 320/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
3113582|NCT02465567|Experimental|BGF (PT010) MDI 160/14.4/9.6 μg|BGF MDI 160/14.4/9.6 μg, Budesonide, Glycopyrronium, Formoterol Fumarate Aerosol (PT010, BGF metered dose inhaler [MDI])
3113583|NCT02465567|Experimental|BFF (PT009) MDI 320/9.6 μg|BFF MDI 320/9.6 μg Budesonide, Formoterol Fumarate Aerosol Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT009)
3113584|NCT02465567|Experimental|GFF (PT003) MDI 14.4/9.6 μg|GFF MDI 14.4/9.6 μg Glycopyrronium, Formoterol Fumarate Aerosol Budesonide and Formoterol Fumarate Inhalation Aerosol (PT003)
3113585|NCT02465632|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|apply a thin layer of gel to the face
3113586|NCT02465632|Active Comparator|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|apply a thin layer of the gel to the face
3113587|NCT02465632|Placebo Comparator|Placebo topical gel|apply a thin layer of the gel to the face
3113588|NCT02465866|Experimental|Treatment A: CL-108 (Fasted)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fasted condition
3113589|NCT02465866|Experimental|Treatment B: CL-108 (Fed)|CL-108 single dose tablet (7.5 mg/325 mg/12.5 mg) by mouth under fed condition
3113590|NCT02465866|Active Comparator|Treatment C: Vicoprofen, Ultracet and Phenergan (Fasted)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fasted condition
3113591|NCT02465866|Active Comparator|Treatment D: Vicoprofen, Ultracet and Phenergan (Fed)|Vicoprofen 7.5 mg/200 mg + Ultracet 37.5 mg/325 mg + Phenergan 12.5 mg single dose tablets by mouth under fed condition
3113592|NCT02465931|Other|Comparison Condition|Paper and pencil informed consent
3113593|NCT02465931|Experimental|Intervention condition|Digital informed consent tool
3113594|NCT02466009|Experimental|Regorafenib|"120 mg qd, 3 weeks on/1 week off (each cycle is 28 days)~Three 40 mg tablets should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (< 30% fat) breakfast."
3113595|NCT02466087|Experimental|Mg Cl|500mg Mg Cl per day for 6 weeks
3113596|NCT02466087|No Intervention|Control|No intervention
3113597|NCT02466126|Experimental|bCBT/Direct Referral|A brief cognitive behavioral therapy intervention that offers 6 active- treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to maintain changes.
3113598|NCT02466126|No Intervention|Enhanced Usual Care (EUC)|Participants are provided with educational information on depression and will be encouraged to seek additional depression care options through their primary care providers.
3113599|NCT02466230|Experimental|Active rTMS|Subjects in the active rTMS arm will receive daily active repetitive transcranial magnetic stimulation (rTMS) treatments for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system will be administered. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
3113600|NCT02466386|Experimental|SPD489|Participants will receive 5 milligrams (mg) of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached within 52 weeks.
3113601|NCT02466399|Experimental|POLAT-001|Latanoprost liposome ophthalmic injection
3113602|NCT02466399|Active Comparator|Latanoprost ophthalmic solution|latanoprost ophthalmic solution 0.005%
3113603|NCT02466412|Active Comparator|CHTP 1.1 M then mCC|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of CHTP 1.1 M)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of mCC)."
3113604|NCT02466412|Active Comparator|mCC then CHTP 1.1 M|"Each subject will follow the below study design:~Day -1 = Wash-out (1 day)~Day 1 = 1st intervention (single product use of mCC)~Day 2 = Wash-out~Day 3 = 2nd intervention (single product use of CHTP 1.1 M)."
3113605|NCT02466425|Experimental|SHP465|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
3113606|NCT02466425|Placebo Comparator|Placebo|Subjects will receive SHP465 (12.5mg and 25mg capsules) or matching placebo. Subjects will take 1 capsule daily throughout the study at approximately 7:00am (+/- 2 hours)
3113607|NCT02466516|Experimental|SEL 6 mg|Selonsertib (SEL) 6 mg for 24 weeks.
3113608|NCT02466516|Experimental|SEL 18 mg|SEL 18 mg for 24 weeks.
3113609|NCT02466516|Experimental|SEL 6 mg+SIM 125 mg|SEL 6 mg plus SIM 125 mg for 24 weeks.
3113610|NCT02466516|Experimental|SEL 18 mg+SIM 125 mg|SEL 18 mg plus SIM 125 mg for 24 weeks.
3113611|NCT02466516|Experimental|SIM 125 mg|SIM 125 mg for 24 weeks.
3113612|NCT02466555|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
3113613|NCT02466646|Active Comparator|Full-mouth Disinfection IPT|Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
3113614|NCT02466646|Experimental|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
3113615|NCT02466646|Experimental|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
3113616|NCT02466659|Experimental|CIAO Therapy|Intervention with wearing 3-hour daily CIAO therapy glasses
3113617|NCT02466659|No Intervention|Observation|To observe as one kind of standard care for IXT.
3113618|NCT02466958|Active Comparator|levomilnacipran (FETZIMA)|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
3113619|NCT02466958|Placebo Comparator|Placebo|All eligible subjects will be randomized to levomilnacipran or placebo group using a computer-generated random assignment scheme, which assigned subjects in a 1:1 ratio to each group. Randomization will be done prior to subject's being assigned to the groups.
3113620|NCT02467075|Active Comparator|Iopamidol 300 (Contrast)|Subjects scheduled for a clinical CT will be randomized to receive weight-based low-osmolality iodinated contrast with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
3113621|NCT02467075|Placebo Comparator|Placebo (Normal Saline)|Subjects scheduled for a standard of care CT will be randomized to receive weight-based normal saline instead of contrast material with the CT. All subjects will receive a minimum of 1 mL/kg/hr of isotonic volume expansion for at least three hours before and three hours after the CT.
3113622|NCT02467166|Experimental|Circa™ Probe|The Circa™ Probe will be used during the RFCA to monitor esophageal temperature. Following ablation, the esophagoscopy will be performed to examine the esophagus for resulting thermal lesions.
3113623|NCT02467179|Active Comparator|Manual Catheter Manipulation|25 subjects will be randomized to this arm. Manual catheter ablation of the cavo-tricuspid isthmus will be performed.
3113624|NCT02467179|Experimental|Amigo™ Robotic Catheter Manipulation|25 subjects will be randomized to this arm. Robotic catheter ablation of the cavo-tricuspid isthmus with the Amigo Catheter System will be performed.
3113625|NCT02467192|Experimental|Low dose CT|All patients will have Thoracic CT scan
3113626|NCT02467270|Experimental|Cohort A: Ponatinib 45 mg|Ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
3113627|NCT02467270|Experimental|Cohort B: Ponatinib 30 mg|Ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS up to data cut-off: 31 May 2020. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
3113628|NCT02467270|Experimental|Cohort C: Ponatinib 15 mg|Participants received ponatinib 15 mg orally once daily up to data cut-off: 31 May 2020 in each 28 day Cycle.
3113629|NCT02467387|Experimental|Experimental: Human (aMBMC)|Intervention: One time intravenous infusion of 1.5 million (aMBMC) per kg administered at approximately 2mL/min. Maximum dose as for 100kg subject or 150 million cells for any subject 100kg or more.
3113630|NCT02467387|Placebo Comparator|Placebo:Lactated Ringer's Solution (LRS)|Intervention: One time intravenous infusion of 1.5mL/kg Lactated Ringer's Solution (LRS) administered at a constant rate of approximately 2mL/min.
3113631|NCT02467465|Experimental|Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises.
3113632|NCT02467465|Experimental|Invasive Physical therapy modalities|Manual therapy techniques aimed to relaxed gastrocnemius and soleus muscles tone, movilizations, stretching and home exercises. Previously, DN will be applied in gastrocnemius and soleus muscles.
3113633|NCT02467491|Other|Physical Activity group|All the participants enrolled in the study will be part of the physical activity group in which they will perform a scheduled exercise program for 4 weeks using a new physical activity technology called Jintronix.
3113634|NCT02467504|Active Comparator|Experimental|hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
3113635|NCT02467504|Placebo Comparator|Placebo Comparator|hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
3113636|NCT02467621|Experimental|Proton pump inhibitor (PPI)|Pantoprazole 40 mg
3113637|NCT02467621|Placebo Comparator|Normal saline|Saline (0.9%)
3113638|NCT02467777|Active Comparator|Forced Air|Bair Hugger
3113639|NCT02467777|Active Comparator|Conductive Warming|VitaHeat
3113640|NCT02467842|Experimental|NBP607-QIV|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0
3113641|NCT02467842|Active Comparator|NBP607-Y|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0
3113642|NCT02467842|Active Comparator|NBP607-V|Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0
3113643|NCT02468154|Experimental|splint|Splint is placed under the cast of children affected by spasticity who have to keep the heel unloaded.
3113644|NCT02468154|Active Comparator|standard care|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
3113645|NCT02468193|Experimental|Osilodrostat|Patients in this arm took the study drug, osilodrostat.
3113646|NCT02468414|Experimental|MDGN201 TARGTEPO secreting EPO|MDGN201 TARGTEPO secreting EPO
3113647|NCT02468557|Experimental|Idelalisib 150 mg|Participants were administered with idelalisib (IDL) 150 mg tablets orally, twice daily (morning and evening) for 8 weeks.
3113648|NCT02468557|Experimental|Idelalisib + nab-paclitaxel|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + nab-paclitaxel.
3113649|NCT02468557|Experimental|Idelalisib + mFOLFOX6|Participants will receive escalating doses of idelalisib at a dose level of up to 150mg + mFOLFOX6.
3113650|NCT02468648|Experimental|Combination of sofosbuvir and GS-5816|Combination of sofosbuvir and GS-5816 agent into a single pill will be used.
3113651|NCT02468674|Other|Follow-up (arm 1)|Patients in Population I received 6 doses of bimagrumab 70 mg, 210 mg, 700 mg or placebo - one approximately every four weeks - over a 20-week period providing drug exposure for a total of 24 weeks.
3113652|NCT02468674|No Intervention|Follow-up (arm 2)|Patients in Population II received either bimagrumab 700 mg or placebo in the core study and did not receive any investigational treatment in the extension study.
3113653|NCT02468700|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3113654|NCT02468700|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3113655|NCT02468804|Experimental|Parkinson's Disease Subjects, (rTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3113656|NCT02468804|Experimental|Control Subjects (rTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3113657|NCT02468804|Sham Comparator|Parkinson's Disease Subjects, (sTMS)|The PD subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3113658|NCT02468804|Sham Comparator|Control Subjects (sTMS)|The control subjects will be randomized, and on a separate day receive a course of either real (rTMS) or sham TMS. Twenty minutes after this treatment subjects will again perform the same working memory task (at 9am to control for fatigue and diurnal effects) while having MEG data recorded
3113659|NCT02468830|Experimental|Mirabegron|Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. Patients with significantly bothersome S/E on antimuscarinics will also be included.
3113660|NCT02468934|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 2 Smartpatch Leads placed in their leg that underwent total knee replacement, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
3113661|NCT02469038|Experimental|AccuCath catheter|We use the AccuCath catheter with ultrasound guidance for IV access for patients in the experimental group.
3113662|NCT02469038|Active Comparator|Control|We will use ultrasound-guided conventional IV for patients in the control group.
3113663|NCT02469064|Experimental|Respiratory Muscle Training|Experimental group receives as additional treatment respiratory muscle training.
3113664|NCT02469064|Active Comparator|Conventional physical therapy|Conventional Cardiopulmonary Physical Therapy
3113665|NCT02469077|Experimental|6 week aerobic exercise intervention|Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
3113666|NCT02469077|Active Comparator|Normal exercise (control)|Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
3113667|NCT02469090|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3113668|NCT02469090|Placebo Comparator|Placebo|Matching placebo for APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3113669|NCT02469116|Experimental|Arm 1: (docetaxel, carboplatin, pegylated G-CSF)|"Docetaxel intravenously over 1 hour followed by carboplatin intravenously over 30 minutes-1 hour on day 1 every 21 days for maximum of 6 cycles~Pegylated G-CSF on day 2 every 21 days for maximum of 6 cycles"
3113670|NCT02469168|Experimental|ReCell|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3113671|NCT02469168|Active Comparator|Control|Allocation of treatments (Recell vs Control) to the INTEGRA™ Meshed Bilayer Wound Matrix (MBWM). Each patient serves as their own control. Their study treatment area will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3113672|NCT02469246|Experimental|F/TAF (Double-Blind)|"F/TAF + ABC/3TC placebo + allowed 3rd antiretroviral (ARV) agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
3113673|NCT02469246|Active Comparator|ABC/3TC (Double-Blind)|"ABC/3TC + F/TAF placebo + allowed 3rd ARV agent for 96 weeks~After Week 96, participants will continue to take their blinded study drug and attend visits every 12 weeks until treatment assignments have been unblinded."
3113674|NCT02469246|Experimental|Open-Label F/TAF|After the unblinding visit, in countries where F/TAF FDC is not commercially available, participants (except in certain countries such as the UK) will be given the option to receive open-label F/TAF (200/10 mg or 200/25 mg) FDC and attend study visits every 12 weeks until it becomes commercially available, or until Gilead terminates the study in that country.
3113675|NCT02469298|Experimental|Danirixin + Oseltamivir matching placebo|Subjects will receive 75 mg oral Danirixin twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
3113676|NCT02469298|Placebo Comparator|Danirixin matching placebo + Oseltamivir matching placebo|Subjects will receive Danirixin matching placebo twice daily with Oseltamivir matching placebo twice daily for a total of ten doses over five days
3113677|NCT02469298|Experimental|Danirixin + Oseltamivir|Subjects will receive 75 mg oral Danirixin twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
3113678|NCT02469298|Active Comparator|Danirixin matching placebo + Oseltamivir|Subjects will receive Danirixin matching placebo twice daily with 75 mg Oseltamivir twice daily for a total of ten doses over five days
3113679|NCT02469389|Experimental|Engaging in Community Roles and Experiences (ENCoRE)|Engaging in Community Roles and Experiences (ENCoRE) includes evidence-based psychosocial treatment strategies to target the affective-motivational deficits, negative expectancies, and behavioral skills deficits that are central to the maintenance of negative symptoms. Behavioral strategies include motivational enhancement, psychoeducation, cognitive therapy, and social skills training.
3113680|NCT02469389|Active Comparator|Health & Wellness (H&W)|Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application. Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions), 8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1session).
3113681|NCT02469597|Experimental|Single Dose of Furosemide|Furosemide 1 dose
3113682|NCT02469597|Placebo Comparator|Placebo|Normal saline 1 dose
3113683|NCT02469610|Experimental|study|In the study group the surgeon will perform an intercostal Bupivacaine block of 100ml over five intercostal spaces which include the operation cuts. The block will be done in the beginning of the surgery right after the insertion of the video camera to the pleural space.
3113684|NCT02469610|Other|control|In the control group the surgeon will perform the same intercostal block at the end of the surgery just before closing the operation cuts. this approach is used today in our department.
3113685|NCT02469623|Experimental|Dipole Density Mapping|
3113686|NCT02469701|Experimental|Nivolumab with ablation|"3mg/kg IV over 60 minutes on Day 1 +/- 3 days every 2 weeks until progression for a maximum of 2 years.~Either cryoablation or thermal ablation may be performed as per standard institutional policies.~As of amendment # 7 submitted to sites November 17, 2017, the dosing for Nivolumab per the FDA guidance was amended to a flat dose of 240mg IV Q2 weeks. As of amendment #8 sent to sites February 22, 2017 the dose of Nivolumab was updated to 3 mg/kg with a maximum dose of 240 mg for patients with weights that would correlate to exceed that dose instead of a flat dose secondary to the standard institutional practice and the FDA guidance ."
3113687|NCT02469714|Experimental|Peer Navigator Intervention|Integrated care with a peer navigator to be provided for one year, where data will be collected at baseline, 4, 8 and 12 months.
3113688|NCT02469714|No Intervention|Controlled|Integrated care without a peer navigator, where data will be collected at baseline, 4, 8 and 12 months
3113689|NCT02469857|Experimental|AB103 0.5 mg/kg|AB103 0.5 mg/kg, IV, single dose
3113690|NCT02469857|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, IV, single dose
3113691|NCT02469870|Experimental|Autism Parent Trainer (APT)|Practiced Routines was a facilitated program. It was organized into four modules that included a total of seven videos ranging from 3-13 minutes each. The topics overlapped with those in the TR program, but included more explicit information on function-based strategies, as well as mindfulness practice. Participants were assigned six fillable forms, and provided supplemental data collection tools. Additional resources focused on mindfulness and PBS within family routines. Eighteen brief guided audio meditations were available to participants via the Practiced MindTM mobile application. The meditations focused on bringing the parents' awareness to both internal and external experiences and helping them act intentionally.
3113692|NCT02469870|Active Comparator|Teaching Routines (Control|Teaching Routines was entirely self-directed. The program included eight modules with videos for each ranging 3 - 5 minutes in duration. The topics were antecedent-behavior-consequence method, creating task analyses, antecedent-based strategies, communication, reinforcement, teaching methods, and overcoming obstacles. Participants were assigned six activities using fillable forms and provided additional resources including examples, a glossary of terms, and a list of websites. No feedback was given to the parents apart from the automated completion responses. The participants were given access to the TR LMS for the duration of the study, but post and follow-up assessments were completed at 6 and 10 weeks (i.e., same as the PR condition).
3113693|NCT02469896|Placebo Comparator|Placebo|8 subjects will receive matching IV placebo every 4 weeks for 3 months.
3113694|NCT02469896|Active Comparator|Active drug|14 subjects will receive 8mg/kg of IV tocilizumab every 4 weeks for 3 months.
3113695|NCT02469961|Experimental|dexmedetomidine|Participants will receive an interscalene block and be sedated with dexmedetomidine
3113696|NCT02469961|Active Comparator|Propofol|Participants will receive an interscalene block and be sedated with propofol
3113697|NCT02470091|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1 (days 1, 8, and 15 of course 1 only). Treatment repeats every 4 weeks (28 days) for up to 24 months or 26 courses, whichever occurs first, in the absence of disease progression or unacceptable toxicity.
3113698|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 10 mg|Methylphenidate Hydrochloride Extended Release Capsules, 10 mg. Active drug, administered once
3113699|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 15 mg|Methylphenidate Hydrochloride Extended Release Capsules, 15 mg. Active drug, administered once
3113700|NCT02470234|Experimental|Methylphenidate HCl ER Capsules, 20 mg|Methylphenidate Hydrochloride Extended Release Capsules, 20 mg. Active drug, administered once
3113701|NCT02470312||CRT|Patients who are undergoing CRT implantation utilizing MediGuide system and tools
3113702|NCT02470312||EP|Patients who are undergoing ablation procedures for Atrial Fibrillation, Atrial Flutter, and Ventricular Tachycardia utilizing MediGuide system and tools
3113703|NCT02470390|Active Comparator|Nasal fentanyl|"nasal fentanyl, 200 μg, administered as one 100 μg spray (100 μL) to each nostril; both completed within one minute.~Will be administered on either study day 1 or 3 per protocol and randomization."
3113704|NCT02470390|Active Comparator|Sub-Lingual fentanyl|"sublingual fentanyl, 200 μg, administered as a single spray (100 μL) under the tongue.~Will be administered on either study day 1 or 3 per protocol and randomization."
3113705|NCT02470390|Active Comparator|IV fentanyl|"IV fentanyl, 100 μg in 2 mL administered as an intravenous injection over 1-3 minutes.~Will be administered on study day 5 per protocol."
3113706|NCT02470403|Experimental|Part 1: LIK066 150 mg once daily (qd)|LIK066 150 mg qd within 15 minutes before starting lunch
3113707|NCT02470403|Placebo Comparator|Part 1: Placebo once daily|Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
3113708|NCT02470403|Experimental|Part 2: LIK066 75 mg twice daily (bid)|LIK066 75 mg bid before breakfast and dinner
3113709|NCT02470403|Experimental|Part 2: LIK066 50 mg three times daily (tid)|LIK066 50 mg tid before all 3 meals;
3113710|NCT02470403|Placebo Comparator|Part 2: Placebo three times daily|Matching placebo tablets tid before meals.
3113711|NCT02470429|Experimental|SYSTANE HYDRATION|SYSTANE HYDRATION lubricant eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
3113712|NCT02470429|Active Comparator|Hyabak 0.15%|Hyabak 0.15% eye drops, 1 drop 4 times per day (QID) in each eye for 42 days
3113713|NCT02470494|Experimental|Sound amplificatoin via EarLens CHD|Sound amplification provided via the EarLens CHD for subjects with hearing impairment.
3113714|NCT02470585|Active Comparator|Placebo + Carboplatin + Paclitaxel -> Placebo|Participants will receive placebo to veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
3113715|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Placebo|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by placebo monotherapy continuous dosing for an additional thirty 21-day cycles.
3113716|NCT02470585|Experimental|Veliparib + Carboplatin + Paclitaxel -> Veliparib|Participants will receive 150 mg veliparib orally twice a day in combination with carboplatin/paclitaxel for six 21-day cycles followed by 300/400 mg veliparib monotherapy orally twice a day for an additional thirty 21-day cycles.
3113717|NCT02470741|Experimental|Letrozole|Oral letrozole 2.5mg/day
3113718|NCT02470741|Placebo Comparator|Placebo and Letrozole|Intermittent oral letrozole 2.5mg/day for 2 months and an identical placebo capsule for 4 months
3113719|NCT02470754|Active Comparator|EC Block1/TC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Electronic Cigarettes only for Study Block #1, then crossover to Tobacco Cigarettes only for Study Block #2.
3113720|NCT02470754|Active Comparator|TC Block 1/EC Block 2|Participants will be randomized into one of two groups. In this group, participants will be assigned to Tobacco Cigarettes only for Study Block #1, then crossover to Electronic Cigarettes only for Study Block #2.
3113721|NCT02470806|Experimental|PICO System|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
3113722|NCT02470806|Active Comparator|tNPWT System|Traditional NPWT (tNPWT) from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
3113723|NCT02470910|Experimental|Magnetic resonance imaging|MRI examination after intraprostatic fiducial markers have been placed and prior to beginning radiotherapy
3113724|NCT02470949|Experimental|Low Social Status|Low Social Status Condition in Monopoly Game.
3113725|NCT02470949|Experimental|High Social Status|High Social Status Condition in Monopoly Game
3113726|NCT02471014||Obese Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
3113727|NCT02471014||Normal Individuals|Participants in this group will receive one 0.5mL Pneumovax23 intramuscular vaccine at baseline, four questionnaires administered at baseline, and one 50mL blood draw at baseline and one 50mL blood draw up to 6 weeks later.
3113728|NCT02471144|Experimental|Secukinumab low dose|Secukinumab
3113729|NCT02471144|Experimental|Secukinumab high dose|Secukinumab
3113730|NCT02471144|Placebo Comparator|Placebo|Placebo
3113731|NCT02471144|Active Comparator|Etanercept Comparator|Etanercept
3113732|NCT02471183|Experimental|Selexipag, Open Label|"Subjects on inhaled treprostinil treatment participate in a 16-week main treatment period including down-titration of treprostinil to end of Week 8 and parallel up-titration of selexipag to the maximum tolerated dose (MTD) up to Week 12, for each individual patient but not above 1600 mcg twice daily.~From Week 12 up to Week 16, patients continue selexipag at their individual MTD. Patients could continue the study drug selexipag during the extended treatment period from Week 16 until commercial availability of selexipag."
3113733|NCT02471313|Experimental|[18F] FMISO PET scan|Patients with primary hepatic malignancy who underwent [18F] FMISO PET Scan following transarterial chemoembolization (TACE) procedure
3113734|NCT02471326|Experimental|HIV Positive Subjects|VRC-HIVMAB060-00-AB (VRC01) given in HIV-infected Adults (age 18-65 years) on cART with suppressed viremia
3113735|NCT02471404|Active Comparator|Dapagliflozin+metformin|Dapagliflozin + saxagliptin placebo + glimepiride placebo + metformin
3113736|NCT02471404|Active Comparator|Dapagliflozin+saxagliptin+metformin|Dapagliflozin + saxagliptin + glimepiride placebo+ metformin
3113737|NCT02471404|Active Comparator|Glimepiride+metformin|Glimepiride + dapagliflozin placebo + saxagliptin placebo + metformin
3113738|NCT02471521|Experimental|Neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed with after rocuronium administration in children while continuous gastric auscultation and abdominal sonography are performed.
3113739|NCT02471521|Active Comparator|Non-neuromuscular blocker|During induction of anesthesia, mask ventilation by pressure controlled ventilation is performed without rocuronium in children while continuous gastric auscultation and abdominal sonography are performed.
3113740|NCT02471586|Active Comparator|Coronary PCI guided by IVUS|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with IVUS guidance according to local standard practice. IVUS imaging is required pre and post stent implantation.~At the end of the procedure, a final IVUS imaging run must be performed.~After the final IVUS run, a blinded OCT imaging run shall be performed to document final stent dimensions and results."
3113741|NCT02471586|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
3113742|NCT02471586|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
3113743|NCT02471651|Active Comparator|Implant|Subjects randomized to dexamethasone intravitreal implant (0.7mg) will receive the initial treatment at Month 3 (visit 4) and Month 6 (visit 7) and are eligible to receive one additional dose at Month 9 (visit 10), Month 10 (visit 11) or Month 11 (visit 12) for persistent or recurrent macular edema documented on SDOCT. If dexamethasone intravitreal implant (0.7mg) is administered at Month 10 (visit 11) or Month 11 (visit 12) an additional safety study visit will be required at one to two months following Month 12 (visit 13). The investigator can withhold treatment with dexamethasone intravitreal implant (0.7mg) beginning at Month 9 if there is complete resolution of diabetic macular edema document on SDOCT.
3113744|NCT02471651|Active Comparator|Intravitreal anti-VEGF injection|Subjects randomized to continue on anti-vegf therapy will receive intravitreal anti-vegf injections at Month 3 (visit 4) Month 4 (visit 5) and Month 5 (visit 6). Beginning at Month 6 (visit 7), subjects who have received 6 intravitreal anti-vegf injections and continue to present with persistent diabetic macular edema defined as less than 10% reduction or any increase in CST compared to baseline values and CST is greater than 300 microns, will receive dexamethasone intravitreal implant (0.7mg) at Month 6 (visit 7) and Month 9 (visit 10). The follow-up period for all subjects will continue through 12 months from the baseline study visit.
3113745|NCT02471716|Experimental|Phase 1 FPA008 Dose Escalation|IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose or lower dose that provide adequate PK exposure and biologic activity with tolerability.
3113746|NCT02471716|Experimental|Phase 2 FPA008 Dose Expansion|IV infusion; once MTD and/or RD has been determined in Phase 1, expansion cohorts of approximately 30 patients (each cohort) with PVNS or dt-TGCT will be enrolled to characterize clinical activity and safety profile of the RD. Treatment is planned to continue for up to 24 weeks or 56 weeks.
3113747|NCT02471755|Active Comparator|Electro-acupuncture Group|
3113748|NCT02471755|Placebo Comparator|Sham Electro-acupuncture Group|
3113749|NCT02472145|Experimental|Decitabine plus Talacotuzumab|"Part A: For Cycle 1 of Part A, participants will receive talacotuzumab on Day 1. Starting from Cycle 2 of Part A, participants may receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle.~Part B Arm 1: Participants will receive decitabine on Day 1, 2, 3, 4, and 5, and talacotuzumab on Day 8 and 22 of a 28-day cycle."
3113750|NCT02472145|Active Comparator|Decitabine|Participants in Part B Arm 2 will receive decitabine on Day 1,2, 3, 4 and 5 of a 28-day cycle.
3113751|NCT02472223|Active Comparator|Betadine 5%|One time in-office administration (4-5 drops) of Betadine 5% limited to 2 minutes, followed by saline lavage.
3113752|NCT02472223|Placebo Comparator|Artificial Tears|One time in-office administration (4-5 drops) of artificial tears limited to 2 minutes, followed by saline lavage.
3113753|NCT02472262|Experimental|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3113754|NCT02472262|Experimental|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3113755|NCT02472262|Active Comparator|Corn Soy Flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
3113756|NCT02472314|Experimental|Liposomal Bupivacaine A|One time injection of 1.3% Liposomal Bupivacaine during shoulder arthroplasty
3113757|NCT02472314|Active Comparator|CISB control for A|Peripheral nerve block (CISB) with 0.125% bupivacaine during shoulder arthroplasty .
3113758|NCT02472314|Experimental|Liposomal Bupivacaine B|One time injection of 1.3% Liposomal Bupivacaine during Humerus Fracture Fixation
3113759|NCT02472314|Active Comparator|CISB control for B|Peripheral nerve block (CISB) with 0.125% bupivacaine during fracture fixation
3113760|NCT02472353|Active Comparator|Standard of Care|Patients will receive standard of care for their breast cancer with no metformin during their treatment with doxorubicin.
3113761|NCT02472353|Experimental|Metformin + Standard of Care|Patients will receive metformin during their treatment with doxorubicin for their breast cancer.
3113762|NCT02472366|Other|laser|laser with or without prior history of intraocular corticosteroid therapy
3113763|NCT02472366|Other|laser and anti-VEGF|laser and anti-VEGF therapy with or without prior history of intraocular corticosteroid therapy
3113764|NCT02472405|Active Comparator|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3113765|NCT02472405|Active Comparator|595/1064nm Multiplex Laser|One third of the scar will be treated with 595/1064nm Multiplex laser for 3 weeks (1 treatment session per week). A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3113766|NCT02472405|No Intervention|Control|One third of the scar will be left untreated for the duration of the study. A blinded observer will evaluate each third of the scar 4 weeks after the last treatment session using the POSAS system.
3113767|NCT02472457|Placebo Comparator|Free Diet|No dietary restrictions
3113768|NCT02472457|Active Comparator|Crohn Disease Exclusion Diet|The CDED is a palatable diet that excludes foods suspected to have a role in intestinal inflammation.
3113769|NCT02472522|Placebo Comparator|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
3113770|NCT02472522|Experimental|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with addition of Dexmedetomidine 1 micrograms/kg to with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
3113771|NCT02472652|Other|Abilify Maintena|Subjects will be switched to Abilify Maintena (Aripiprazole) LAI monthly doses of 400mg, 300mg, 200mg or 160mg and have their sexual functioning reevaluated over a 3 month period to determine if there is any significant sexual functioning improvement.
3113772|NCT02472730|Experimental|Cap Assisted Colonoscopy|The distal attachment cap is affixed to the colonoscope before every colonoscopy in this arm.
3113773|NCT02472730|No Intervention|Standard Colonoscopy|Standard colonoscopy without the distal attachment cap is performed in this arm.
3113774|NCT02472756||Follicular Lymphoma Participants|Previously treated adult participants with relapsed/refractory FL will receive rituximab in combination with chemotherapy regimen. All treatments prescribed during the observation period will be at the treating physician's discretion. Participants will be followed up for safety and efficacy evaluation in accordance with routine practice, up to 30 months.
3113775|NCT02472795|Experimental|Cenerimod 0.5 mg (Part A)|Participants will receive cenerimod 0.5 mg capsules orally once daily for 12 weeks.
3113776|NCT02472795|Experimental|Cenerimod 1 mg (Part A)|Participants will receive cenerimod 1 mg capsules orally once daily for 12 weeks.
3113777|NCT02472795|Experimental|Cenerimod 2 mg (Part A)|Participants will receive cenerimod 2 mg capsules orally once daily for 12 weeks.
3113778|NCT02472795|Experimental|Cenerimod 4 mg (Part B)|Participants will received cenerimod 4 mg capsules orally once daily for 12 weeks. This treatment arm will start after all patients in Part A have completed 4 weeks of placebo, 0.5 mg, 1 mg and 2 mg cenerimod treatment.
3113779|NCT02472795|Placebo Comparator|Matching placebo (Part A and B)|Capsules of matching placebo taken orally once daily for 12 weeks.
3113780|NCT02472847|Placebo Comparator|Placebo|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning.
3113781|NCT02472847|Active Comparator|Dronabinol|In a randomized, double-blind, placebo-controlled, between-subjects design, the investigators will couple a standard Pavlovian fear extinction paradigm in fMRI with an acute pharmacological challenge with oral dronabinol (synthetic THC) or placebo 2 hours prior to extinction learning in healthy adult volunteers and test extinction retention and maintenance 24 hours and 1 week later, respectively, after extinction learning
3113782|NCT02472886|Experimental|LDV/SOF|Treatment-naive participants with genotype 1 HCV infection without cirrhosis will receive LDV/SOF FDC for 8 weeks.
3113783|NCT02472886|Experimental|LDV/SOF Coinfected with HIV-1|Treatment-naive participants with genotype 1 HCV infection without cirrhosis and who are coinfected with HIV-1 will receive LDV/SOF FDC for 8 weeks.
3113784|NCT02472886|Experimental|LDV/SOF+RBV Retreatment|Participants with genotype 1 or 3 HCV infection who failed to achieve SVR12 in Gilead Study GS-US-334-0119 will receive LDV/SOF FDC + RBV for 12 weeks.
3113785|NCT02472964|Active Comparator|Herceptin© + Taxane|"Part 1: Herceptin© (trastuzumab) intravenously+ paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to Herceptin© (trastuzumab) alone once every 3 weeks until DP or subject withdrawal ."
3113786|NCT02472964|Experimental|MYL- 1401O + Taxane|"Part 1:MYL-1401O Intravenously + paclitaxel 80 mg/m2 weekly intravenously or docetaxel 75 mg/m2 intravenously once every three weeks (investigators choice) for 8 cycles then evaluate for primary endpoint.~Part 2: If SD or PR, CR at cycle 9 (week 24) proceed to MYL-1401O alone once every 3 weeks until DP or subject withdrawal."
3113787|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (SCLC)|Small cell lung cancer (SCLC)
3113788|NCT02472977|Active Comparator|BMS-936564 (Ulocuplumab) + Nivolumab, Tumor type arm (PAC)|Pancreatic cancer (PAC)
3113789|NCT02473250|Experimental|Bipolar depressed|Bipolar depressed subjects will have neuroimaging and treatment with fluoxetine in combination with a mood stabilizer (valproate)
3113790|NCT02473289|Experimental|Sirukumab 50 milligram (mg)|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
3113791|NCT02473289|Placebo Comparator|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
3113792|NCT02473367|Experimental|Raltegravir Pre- and 4 Period Sequence|Starting five days prior to Period 1 participants will be treated with 1200 mg raltegravir, once daily for five days. In Period 1 participants will be treated with 1200 raltegravir alone; this is followed by Period 2 where participants will be treated with 1200 mg raltegravir and TUMS concomitantly; this is followed by Period 3 where participants will be treated with 1200 mg raltegravir and 12 hours later with Leader Antacid; followed by Period 4 where participants will be treated with 1200 mg raltegravir and 12 hours later with TUMS. The wait between Periods is 2-7 days.
3113793|NCT02473393|Experimental|OPS-2071 50mg/day|OPS-2071 50 mg/day：25 mg tablet administered orally twice daily
3113794|NCT02473393|Experimental|OPS-2071 100 mg/day|OPS-2071 100 mg/day：50 mg tablet administered orally twice daily
3113795|NCT02473393|Experimental|OPS-2071 200 mg/day|OPS-2071 200 mg/day：100 mg tablet administered orally twice daily
3113796|NCT02473393|Experimental|OPS-2071 400 mg/day|OPS-2071 400 mg/day：100 mg two tablets administered orally twice daily
3113797|NCT02473471|Experimental|MOP side|Three small holes in cortical bone can be created by Miniscrews.Before application of the MOPs, Patient will be asked to wash their mouth twice by chlorhexidine for 1 minute. Local anesthesia will be given (2% lidocaine with 1:100,000 epinephrine). Microosteoperforation (MOPs) will be performed distal to canine.
3113798|NCT02473471|No Intervention|control side|No intervention in the other side of maxilla (control side)
3113799|NCT02473510|Experimental|Trivalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3113800|NCT02473510|Placebo Comparator|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
3113801|NCT02473614|Experimental|Music Glove|Music Glove is a glove with sensors attached to the tips of all 5 fingers. The glove is connected to a software musical program like guitar hero. Participants will follow the rhythm or musical notes of the songs and move their fingers accordingly. Participants are reinforced with biofeedback that includes visual and auditory cues when the correct sequences are achieved.
3113802|NCT02473614|Active Comparator|Conventional Hand Exercise Program|Conventional Hand Exercise Program includes range of motion exercises, strengthening exercises, coordinating exercises of the hand and fingers. This exercise program is designed by an occupational therapist and is a general exercise program that a stroke patient will receive when he/she is being discharged from the hospital.
3113803|NCT02473640|Experimental|150 mg SYN-004|There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.
3113804|NCT02473718|Experimental|Fluid minimization group|Patients in the fluid minimization arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ. A fluid challenge in the form of a leg raise or infusion of 250 mL of crystalloid over 5 minutes will then be performed and the parameters repeated. The patient will be judged to be fluid responsive or nonresponsive based on the changes in the parameters. Fluid nonresponsive patients will receive the intervention of the fluid minimization protocol by concentrating continuous infusions, discontinuing maintenance fluids, and minimizing carrier fluids. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance.
3113805|NCT02473718|No Intervention|Usual care group|Patients in the usual care arm will have daily fluid intake and output, baseline central venous pressure, mean arterial pressure, central venous oxygen saturation, pulse pressure variation, and inferior vena cava diameters during inspiration and expiration recorded by a dedicated research fellow. Patients who are intubated will also have corrected flow time, stroke volume, cardiac output, and cardiac index recorded via CardioQ.
3113806|NCT02473783|Experimental|Treatment Group|The subjects with major depressive disorder who are screened into this study were scheduled for T1-weighted MRI (MRI examination results within 6 months before study are acceptable) prior to the visit of SPECT scans to confirm the absence of organic lesion in the brain and to co-register with SPECT images for the delineation of brain anatomical locations. After the screening visit, eligible subjects received I-123-ADAM SPECT before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. The subjects were observed until no clinically significant adverse events at the drug administration visits before being dismissed.
3113807|NCT02473913|Experimental|Milk Thistle|Each subject will have a 6 week treatment phase with milk thistle.
3113808|NCT02473913|Placebo Comparator|Placebo|6 week placebo phase before or after milk thistle phase depending on randomization.
3113809|NCT02473952|Experimental|IGIV-C|"IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified.~An initial loading dose of 2 g/kg of body weight will be administered at Baseline (Week 0, Visit 1) followed by maintenance doses of 1 g/kg of body weight administered every third week through Week 21 (Visit 8)."
3113810|NCT02473952|Placebo Comparator|Placebo|Placebo: Sterile 0.9% sodium chloride injection or equivalent. Placebo will be infused at the Baseline/Week 0 Visit (Visit 1) using the same volume as would be required for the IGIV-C loading dose. Subsequent placebo maintenance doses will be matched in volume to the IGIV-C maintenance doses and administered every third week until Week 21 (Visit 8).
3113811|NCT02473965|Experimental|IGIV-C|An IGIV-C loading dose of 2 g/kg and maintenance dose of 1 g/kg will be administered in CS dependent subjects with MG.
3113812|NCT02473965|Placebo Comparator|Placebo|0.9% sodium chloride injection, USP or equivalent
3113813|NCT02474069|Active Comparator|Secukinumab Interval Shortening|
3113814|NCT02474069|Active Comparator|Secukinumab 4-weekly|
3113815|NCT02474082|Experimental|Secukinumab|Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
3113816|NCT02474082|Active Comparator|Fumaric acid (initial and maintenance therapy)|Participants were daily self-administered with fumaric acid derivatives initial and maintenance therapy in dosetitrated scheme as per protocol. Dose was up-titrated weekly (1 tablet/day) until objective was achieved or until tapering was required or until the maximum dose of 2 tablets each at morning, noon and evening was reached, whichever occurred earlier.
3113817|NCT02474199|Experimental|darTregs|Donor Alloantigen Reactive Tregs (darTregs). Participants will receive a target dose of 400X10^6 darTregs (range 300-500 x10^6) infused intravenously (IV) over an approximate 20-30 minute interval
3113818|NCT02474355|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
3113819|NCT02474407|Experimental|diazepam nasal spray (DZNS)|One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
3113820|NCT02474407|Active Comparator|diazepam rectal gel (DRG)|A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.
3113821|NCT02474498|Active Comparator|EMD alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland) and after the flap will be repositioned.
3113822|NCT02474498|Active Comparator|βTCP/HA alone|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
3113823|NCT02474498|Active Comparator|EMD + βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland). Immediately after debridement, EMD will be applied on the root surfaces. The remaining part of the material in the seringe will be then mixed with the bone substitute on a sterile dappen. This mixture will be used to completely fill the defect (EMD + βTCP/HA).
3113824|NCT02474589|Active Comparator|Active|600 mg tecovirimat capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
3113825|NCT02474589|Placebo Comparator|Placebo|matching placebo capsules BID to assess safety and tolerability and pharmacokinetics of the anit-orthopoxvirus compound Tecovirimat when administered orally in healthy subjects
3113826|NCT02474901|Active Comparator|QLAIV, HIV-infected|QLAIV administered to HIV-infected individuals 2 to 25 yoa
3113827|NCT02474901|Active Comparator|QLAIV, HIV-uninfected|QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
3113828|NCT02475031|Placebo Comparator|Placebo Group (TAP-S)|(TAP-S) - the On-Q reservoir will be filled with saline and set to infuse at rate of 10 ml/hr through the TAP catheter
3113829|NCT02475031|Active Comparator|Active Group (TAP-C)|(TAP-C) - The On-Q reservoir will be filled with 0.2% ropivacaine and set to infuse at rate of 10 ml/hr through the TAP catheter
3113830|NCT02475070|Active Comparator|Vildagliptin first|Treatment with vildagliptin 50mg twice daily for two weeks followed by four weeks washout and then treatment with dapagliflozin 10mg once daily for two weeks
3113831|NCT02475070|Active Comparator|Dapagliflozin first|Treatment with dapagliflozin 10 mg once daily for two weeks followed by four weeks washout and then treatment with vildagliptin 50 mg twice daily for two weeks
3113832|NCT02475265|Experimental|estradiol 0.045mg/levonorgestrel 0.015mg|6 months of estradiol 0.045mg/levonorgestrel 0.015mg (once weekly patch).
3113833|NCT02475278|Experimental|NoV Vaccine|Norovirus GI.1/GII.4 bivalent Virus-Like Particle (VLP) vaccine (NoV Vaccine) (15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum hydroxide), intramuscular (IM) injection, once on Day 1.
3113834|NCT02475369|Other|PES, Then Placebo|Participants first received Pancreatic Enzyme Supplementation (PES) for 10 days. PES taken 6 times daily with gluten free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received placebo tablets (matching PES treatment) 6 times daily for 10 days.
3113835|NCT02475369|Other|Placebo, Then PES|Participants first received placebo tablets (matching PES) for 10 days. Placebo was taken 6 times daily with gluten-free meals and snacks. To facilitate duodenal digestion Omeprazole (20 mg/QD) was co-administered. After a washout period of 1 week, they then received PES tablets six times daily for 10 days.
3113836|NCT02475395|Experimental|Donor/Tester Subjects|Male subjects use the TRAK device to attain a measurement of sperm concentration from their semen specimen
3113837|NCT02475395|Experimental|Tester Only Subjects|Male or female subjects use the TRAK device to attain a measurement of sperm concentration from another donor's semen specimen.
3113838|NCT02475564|Placebo Comparator|placebo|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 1 pill of placebo (starch)
3113839|NCT02475564|Experimental|resveratrol|Patients will take once a day a monophasic pill (ethinylestradiol + levonorgestrel) continuously for 42 days with 40mg of resveratrol
3113840|NCT02475629|Experimental|Open-Label Ibalizumab plus OBR|2000 mg intravenous ibalizumab (loading dose) on Day 7 followed in 14 days (on Day 21) by 800 mg intravenous ibalizumab administered once every two weeks, plus an Optimized Background Regimen (OBR) beginning on Day 14.
3113841|NCT02475655|Experimental|Arm A: Ruxolitinib|Participants received ruxolitinib twice a day for 5 weeks. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
3113842|NCT02475655|No Intervention|Arm B: No Study Treatment|Participants did not receive any study treatment. Participants were required to remain on ART regimen (not provided by the study) for the duration of the study.
3113843|NCT02475733|Experimental|CAZ-AVI and metronidazole|CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion
3113844|NCT02475733|Active Comparator|Meropenem|administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
3113845|NCT02475837|Active Comparator|Vorapaxar intervention|"This arm will receive the study drug: Vorapaxar sulfate.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
3113846|NCT02475837|Placebo Comparator|Placebo intervention|"This arm will receive the matching placebo.~The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm)."
3113847|NCT02475850|Other|Fall prevention standard of care|"An evidence-based patient-centered intervention that will combine elements of a multifactorial, risk factor-based, standardly-tailored fall prevention strategy developed at Yale, practice guidelines offered by the CDC's STEADI toolbox and the joint American Geriatrics Society/British Geriatrics Society guidelines, and ACOVE practice change approach"
3113848|NCT02475850|Other|Control|Usual fall prevention care
3113849|NCT02475954|Active Comparator|TH-CBT + Standard Care|Cognitive-behavioral therapy delivered via telehealth with a focus on decreasing depressive symptoms in Parkinson's Disease (PD).
3113850|NCT02475954|Other|Standard Care|VA standard care depression in Parkinson's Disease (PD)
3113851|NCT02475980||Adolescent girls|Adolescent post-menarchal girls ages 13-18 with Medicaid insurance presenting to a pediatric emergency department for a non-emergent complaint who receive comprehensive contraception counseling
3113852|NCT02476006|Experimental|Alirocumab|Participants received Alirocumab 150 milligram (mg) subcutaneously (SC) once every two weeks (Q2W) or 75 mg SC Q2W added to stable LMT up to a maximum of 120 weeks. Alirocumab dose was either up-titrated from 75 to 150 mg Q2W or down-titrated from 150 to 75 mg Q2W, based on Investigator judgment and treatment response.
3113853|NCT02476032|Experimental|Prof applied oxalate|Subjects will be randomized to either receive the Prof applied oxalate Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank. The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3113854|NCT02476032|Active Comparator|Self-applied oxalate|Participants randomized to the Active Comparator Group will have the following intervention: Intervention: self-applied oxalate (Crest Sensi-Stop strip Procter & Gamble™), which contains 3% dipotassium oxalate desensitizing gel. The strip will be placed by the participant, following the manufacturer's directions. The strip will be left in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3113855|NCT02476032|Sham Comparator|Prof applied placebo|Subjects will be randomized to either receive the Prof applied placebo Crest Sensi-Stop strip (Procter & Gamble™). The oxalate strip contains 3% dipotassium oxalate desensitizing gel. The placebo strip is blank (sham). The strips will be placed by a licensed dental professional and will be in place for 10 minutes. Subjects will be instructed to not rinse their mouth, drink, eat or brush their teeth for 30 minutes after completion of the treatment.
3113856|NCT02476175|Experimental|Add-on Mirabegron|Experimental: Add-on Mirabegron Patients without symptom improvement or with partial response under intensive behavioural protocol and medical therapy (at least 2 different antimuscarinic agents) will be recruited. They will keep the antimuscarinic and Mirabegron will be added (dual therapy).
3113857|NCT02476201|Experimental|MPP ON|To activate the Multipoint Pacing (MPP) feature to ON in all patients
3113858|NCT02476357|Active Comparator|Harmonic|Harmonic Scalpel (HS; Ethicon Endo-Surgery, Cincinnati, OH)
3113859|NCT02476357|Active Comparator|Control|Monopolar scalpel and ligature
3113860|NCT02476422|Experimental|Dilcofenac potassium + placebo to Ibuprofen|Single dose of diclofenac potassium 50 mg soft gelatin capsule was given once patient developed moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to ibuprofen 400 mg tablet was also given to patient in order to maintain double dummy method.
3113861|NCT02476422|Active Comparator|Ibuprofen + placebo to diclofenac potassium|Single dose of ibuprofen 400 mg tablet was given once patient develops moderate to severe pain post the extraction of two ipsilateral third molar teeth. Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule was also given to patient in order to maintain double dummy method.
3113862|NCT02476448|Active Comparator|Normal Saline|Infused into the bladder to allow for visualization of bladder walls and urine jets.
3113863|NCT02476448|Experimental|Dextrose 10%|Infused into the bladder to allow for visualization of bladder walls and colored urine jets.
3113864|NCT02476448|Experimental|Phenazopyridine|Will be administered (orally) preoperatively and will be evaluated for its colorization properties during cystoscopy.
3113865|NCT02476448|Experimental|Sodium Fluorescein|Will be administered (intravenously) prior to the cystoscopy and will be evaluated for its colorization properties during cystoscopy.
3113866|NCT02476565|Experimental|LMA-Supreme supraglottic device|The LMA-Supreme is a single-use disposable supraglottic airway that utilizes an inflatable cuff
3113867|NCT02476565|Active Comparator|I-gel supraglottic device|The I-gel is an alternative supraglottic device made from thermoplastic elastomer which provides the seal over the airway versus an inflatable cuff.
3113868|NCT02476578|Experimental|Intervention Email|An email is sent, alerting the primary care providers about low values of BMI, HbA1c% or cholesterol and advising to consider appropriate dietary and medical revision.
3113869|NCT02476578|No Intervention|Control|No email is sent.
3113870|NCT02476617|Experimental|Ombitasvir/paritaprevir/ritonavir + dasabuvir + RBV|Ombitasvir/paritaprevir/ritonavir (25 mg/150 mg/100 mg once daily [QD]) + dasabuvir (250 mg twice daily [BID]) + weight based Ribavirin (RBV; dosed 1,000 or 1,200 mg daily divided BID)
3113871|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Healthy (Sequence A)|Healthy participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3113872|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Healthy (Sequence B)|Healthy participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3113873|NCT02476890|Experimental|Placebo then gefapixant 100 mg/Chronic Cough (Sequence A)|Chronic Cough participants in Sequence A received a single dose of placebo in treatment Period 1 then a single dose of gefapixant 100 mg in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3113874|NCT02476890|Experimental|Gefapixant 100 mg then placebo/Chronic Cough (Sequence B)|Chronic Cough participants in Sequence B received a single dose of gefapixant 100 mg in treatment Period 1 then a single dose of placebo in treatment Period 2. There was a minimum 48-hr washout between Periods 1 & 2.
3113875|NCT02476916|Experimental|AG-348 50 mg BID|Participants with PK deficiency received AG-348, 50 milligrams (mg), as initial dose, twice daily (BID) for the Core Period (Week 24).
3113876|NCT02476916|Experimental|AG-348 300 mg BID|Participants with PK deficiency received AG-348, 300 mg, as initial dose, BID for the Core Period (Week 24).
3113877|NCT02476968|Other|Olaparib|Open Label Drug
3113878|NCT02477020|Experimental|TAK-063 20 mg|TAK-063 20 mg, tablets, orally, once daily for up to 6 weeks. Dose may be titrated down to 10 mg/day, if intolerable.
3113879|NCT02477020|Placebo Comparator|Placebo|TAK-063 matching-placebo tablets, orally, once daily for up to 6 weeks.
3113880|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone Dose Escalation|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: 70 mg/m^2, 80mg/m^2, or 90 mg/m^2 given on days 1 and 2"
3113881|NCT02477215|Experimental|MLN9708, Bendamustine and Dexamethasone MTD|"Ixazomib 4 mg, days 1, 8, 15.~Dexamethasone 40 mg oral weekly.~Bendamustine dose levels: MTD given on days 1 and 2"
3113882|NCT02477319||Part A|"Cohort 1: Healthy Controls~Cohort 2: Partial CFTR function CF (class IV/V)~Cohort 3: Absent CFTR function CF (Class I/II)"
3113883|NCT02477319||Part B|CF patients who are homozygous for the F508del
3113884|NCT02477332|Experimental|QGE031 24 mg s.c. q4w|ligelizumab 24 mg injection subcutaneous every 4 weeks
3113885|NCT02477332|Experimental|QGE031 72 mg s.c. q4w|ligelizumab 72 mg injection subcutaneous every 4 weeks
3113886|NCT02477332|Experimental|QGE031 240 mg s.c. q4w|ligelizumab 240 mg injection subcutaneous every 4 weeks
3113887|NCT02477332|Active Comparator|Omalizumab 300 mg s.c. q4w|omalizumab 300 mg injection subcutaneous every 4 weeks
3113888|NCT02477332|Placebo Comparator|Placebo s.c. q4w|placebo injection subcutaneous every 4 weeks
3113889|NCT02477332|Experimental|QGE031 120 mg s.c. s.d.|ligelizumab 120 mg injection subcutaneous single dose
3113890|NCT02477358|Experimental|PRF Treated|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
3113891|NCT02477358|No Intervention|Control|Subjects will be randomized to either receive either left tooth platelet rich fibrin; right tooth implant alone, OR right tooth platelet rich fibrin; left tooth implant alone. Following treatment each tooth is replaced and splinted to the adjacent teeth. Teeth are followed for 3 months and then tested for vitality before extracting and examining histologically.
3113892|NCT02477423|Active Comparator|Randomized & Blinded - Receiving Antibiotics|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive routine ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
3113893|NCT02477423|Placebo Comparator|Randomized & Blinded - Receiving Placebo|The infants within this arm of the study meet the inclusion criteria as being low risk. They will be randomized to receive placebo (saline) in place of ampicillin and gentamicin for the initial 48 hours of their life as a routine rule-out sepsis. Stool samples will be collected throughout hospitalization and at 18 months of life.
3113894|NCT02477527|Experimental|Stribild|Patients to be changed from Atripla to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil and observed for changes in sleep patterns / sleep disturbances.
3113895|NCT02477553|Experimental|Quantitative|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
3113896|NCT02477553|Active Comparator|Verbal|"Subjects view:~A computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy and stool testing. Includes excerpts from a video from the American Cancer Society.~Computer-based presentation providing verbal information regarding (a) the lifetime average probability of getting and dying from CRC, (b) the reduction in morbidity and mortality provided by colonoscopy and stool tests, (c) the sensitivity of colonoscopy and stool tests for finding cancer, (d) the false negative values of colonoscopy and stool tests for finding cancer, (e) the risk of heavy bleeding or colon injury from colonoscopy, and (f) the chance of having a positive stool test."
3113897|NCT02477605|Experimental|27-gauge pak|CONSTELLATION® 27-gauge combined surgical pak used during vitrectomy surgery
3113898|NCT02477605|Active Comparator|23-gauge pak|CONSTELLATION® 23-gauge combined surgical pak used during vitrectomy surgery
3113899|NCT02477618|Active Comparator|SAGE-547|Intravenous
3113900|NCT02477618|Placebo Comparator|Placebo|Intravenous
3113901|NCT02477670|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
3113902|NCT02477670|Experimental|AVP-786|AVP-786 dose 2 capsules administered twice a day over a 12-week period
3113903|NCT02477709|Experimental|Gefapixant|Gefapixant oral tablets (150 mg) administered as a single dose
3113904|NCT02477800|Experimental|Low Dose|Monthly intravenous (IV) infusion
3113905|NCT02477800|Experimental|High Dose|Monthly intravenous (IV) infusion
3113906|NCT02477839|Experimental|Lacosamide|Lacosamide syrup 8 mg/kg/day to 12 mg/kg/day
3113907|NCT02477839|Placebo Comparator|Placebo|Matching placebo syrup
3113908|NCT02478164|Experimental|Ponatinib|Drug will be administered once daily per cycle through oral ingestion.
3113909|NCT02478359|No Intervention|Standard Care|Standard care patients received their routine care from Kaiser Permanente Southern California and had access to all health services in accordance with their health plan
3113910|NCT02478359|Experimental|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
3113911|NCT02478372|Active Comparator|Patient Controlled Epidural (PCEA)|A lumbar epidural was sited using a side-directed technique towards the side of surgery following establishment of the spinal blockade. Following the completion of the operation, patients received 4ml of 0.25% levobupivacaine prior to leaving the operating room. Thereafter they were connected to a PCEA pump (McKinley 545) with no background infusion. Patients could self-medicate with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes to control their pain until the following morning (post-operative day one) when it was stopped. Nurse-administered rescue top-ups of 4ml of 0.25% levobupivacaine were available for insufficient analgesia. The epidural catheter was removed on the morning of post-operative day two (POD2).
3113912|NCT02478372|Experimental|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine. 50ml injected following bone preparation prior to implant cementation perpendicular to the posterior femur through the posterior joint capsule in 10ml aliquots. 30ml proximal to the suprapatellar pouch down to the femur.100ml spread into subcutaneous tissues including; collateral and cruciate ligaments, fatty and connective tissue on the anterior aspect of the incision. A 16 gauge epidural catheter inserted via a medial portal, 20ml was injected via the catheter following closure of wound. Post-operatively, patients received boluses of 40ml ropivacaine 0.2% via the catheter using a mechanical McKinley 595 pump 4 hours after leaving theatre, at 22:00 and 08:00 on post-operative day one.
3113913|NCT02478398|Experimental|Short ragweed pollen allergen extract|Participants receive one sublingual tablet containing 12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U), once daily (QD) for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
3113914|NCT02478398|Placebo Comparator|Placebo|Participants receive one placebo sublingual tablet, QD for up to 35 weeks. Participants may use study-provided rescue medication(s) as needed to treat rhinoconjunctivitis symptoms.
3113915|NCT02478463|Experimental|Cabotegravir|Subject will receive CAB 30 mg tablet once daily oral dose for 28 days (4 weeks) followed by a washout period of 14 to 42 days. After the washout, subject will receive a single dose of CAB LA 600 mg IM to gluteal region.
3113916|NCT02478489|Experimental|Extended-release injectable naltrexone (XR-NTX)|Monthly XR-NTX (380 mg) Subjects randomized to XR-NTX will receive one intramuscular gluteal injection (in accordance with the FDA approved label/package insert) of 380 mg of NTX for extended-release injectable suspension at study entry (in the hospital) and 1, and 2 months later (outpatient in the primary care clinic), alternating buttocks.
3113917|NCT02478489|Active Comparator|Oral naltrexone (PO-NTX)|Daily PO-NTX (50 mg, up to 100 mg if heavy drinking continues) Subjects randomized to PO-NTX will receive a study prescription (first one in the hospital)(fillable only at the medical center research pharmacy and prepared by the research pharmacist) for a 1-month supply of oral NTX to be taken once daily- 25 mg a day for 3 days, then 50 mg a day. If the subject has a prior history of taking PO-NTX and tolerating it well, the participant may be started at 50 mg. The dose may be increased to 100 mg daily for any participant who continues to have heavy drinking.
3113918|NCT02478580|Experimental|Nuvigil|A single oral dose of Nuvigil at 150mg dose in preoperative area
3113919|NCT02478580|Placebo Comparator|Placebo|A single oral placebo will be given in preoperative area
3113920|NCT02478632|Active Comparator|CAR|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).
3113921|NCT02478632|Experimental|DTG 50 mg + RPV 25 mg|Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)
3113922|NCT02478671|Experimental|TR Band|Each subject will have a Terumo TR Band applied to the wrist with MRI scans done at differing band pressure levels. The diameter of the radial artery will be measured at each level of band compression.
3113923|NCT02479139|Placebo Comparator|Vehicle|Vehicle for botulinum toxin Type A topical liniment (ANT-1207) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113924|NCT02479139|Experimental|ANT-1207 Dose 1|Botulinum toxin Type A topical liniment (ANT-1207) Dose 1 (lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113925|NCT02479139|Experimental|ANT-1207 Dose 2|Botulinum toxin Type A topical liniment (ANT-1207) Dose 2 (second lowest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113926|NCT02479139|Experimental|ANT-1207 Dose 3|Botulinum toxin Type A topical liniment (ANT-1207) Dose 3 (mid-level dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113927|NCT02479139|Experimental|ANT-1207 Dose 4|Botulinum toxin Type A topical liniment (ANT-1207) Dose 4 (second highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113928|NCT02479139|Experimental|ANT-1207 Dose 5|Botulinum toxin Type A topical liniment (ANT-1207) Dose 5 (highest dose) applied topically in a volume of 12 drops per axilla (armpit) once on Day 0.
3113929|NCT02479412|Experimental|Sequence 1|Placebo once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
3113930|NCT02479412|Experimental|Sequence 2|Placebo once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
3113931|NCT02479412|Experimental|Sequence 3|Placebo once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
3113932|NCT02479412|Experimental|Sequence 4|58 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 800 µg AZD7594 once daily for 14 days in Period 3
3113933|NCT02479412|Experimental|Sequence 6|250 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 58 µg AZD7594 once daily for 14 days in Period 3
3113934|NCT02479412|Experimental|Sequence 8|800 µg AZD7594 once daily for 14 days in Period 1, Placebo once daily for 14 days in Period 2 and 250 µg AZD7594 once daily for 14 days in Period 3
3113935|NCT02479412|Experimental|Sequence 5|58 µg AZD7594 once daily for 14 days in Period 1, 800 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3113936|NCT02479412|Experimental|Sequence 7|250 µg AZD7594 once daily for 14 days in Period 1, 58 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3113937|NCT02479412|Experimental|Sequence 9|800 µg AZD7594 once daily for 14 days in Period 1, 250 µg AZD7594 once daily for 14 days in Period 2 and Placebo once daily for 14 days in Period 3
3113938|NCT02479763|No Intervention|Conventional loss-of-resistance|
3113939|NCT02479763|Experimental|Waveform-confirmed loss-of-resistance|
3113940|NCT02479802|Experimental|Albumin|Plasma exchange with Albumin
3113941|NCT02479880|Other|Tenofovir DF + increased bone/renal monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.
3113942|NCT02479880|Other|Tenofovir DF + prespecified bone monitoring|Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.
3113943|NCT02480010|Experimental|Pertuzumab 1050 mg (Cohort B)|Participants in Cohort B will receive 1050 mg pertuzumab via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
3113944|NCT02480010|Experimental|Pertuzumab 420 mg (Cohort A)|Participants in Cohort A will receive an IV loading dose of 840 milligrams (mg) pertuzumab followed by 420 mg via IV infusion on Day 1 of each 3-week cycle. At the end of 3 treatment cycles, response will be evaluated to determine whether additional participants will be enrolled for treatment. If a second stage of enrollment occurs, participants may continue treatment until disease progression or unacceptable toxicity.
3113945|NCT02480114|Active Comparator|Arm I Standard of Care|Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
3113946|NCT02480114|Experimental|Arm II Standard of Care Plus Gabapentin|Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.
3113947|NCT02480153|Experimental|PF-06410293|
3113948|NCT02480153|Active Comparator|Adalimumab|
3113949|NCT02480166|Experimental|8 weeks SOF/LED|Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
3113950|NCT02480166|Experimental|12 weeks SOF/LED|Patients that are either treatment experienced or are cirrhotic will be assigned to 12 weeks of treatment with fixed-dose combination sofosbuvir (400 mg) and ledipasvir (90 mg) daily.
3113951|NCT02480439|Experimental|TAK-648 Sequence ABC|Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 3.
3113952|NCT02480439|Experimental|TAK-648 Sequence BCA|Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, 30 minutes after a high fat meal, once on Day 1 of Period 3.
3113953|NCT02480439|Experimental|TAK-648 Sequence CAB|Regimen C TAK-648 0.3 mg, solution, orally, in fasted state, once on Day 1 of Period 1, followed by at least 7 day washout period, followed by Regimen A TAK-648 0.3 mg, tablet, orally, after a high fat meal, once on Day 1 of Period 2, followed by at least 7 day washout period, followed by Regimen B TAK-648 0.3 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.
3113954|NCT02480582|Experimental|Almond, then No Food, then Cheese Savouries|Participants first received a mid-morning snack of almonds (0.9g/kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g/kg).
3113955|NCT02480582|Experimental|Cheese Savouries then Almond, then No Food|Participants first received a mid-morning snack of cheese savouries (0.9g/kg). After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received no food.
3113956|NCT02480582|Experimental|No Food, then Cheese Savouries, then Almond|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of almonds (0.9g/kg).
3113957|NCT02480582|Experimental|Cheese Savouries, then No Food, then Almond|Participants first received a mid-morning snack of cheese savouries (0.9g\kg). After a washout period of 5 days, they then received no food. Finally, after another washout period participants received a mid-morning snack of almonds (0.9g\kg).
3113958|NCT02480582|Experimental|Almond, then Cheese Savouries, then No Food|Participants first received a mid-morning snack of almonds (0.9g\kg). After a washout period of 5 days, they then received a mid-morning snack of cheese savouries (0.9g\kg). Finally, after another washout period participants received no food.
3113959|NCT02480582|Experimental|No Food, then Almond, then Cheese Savouries|Participants first received no food. After a washout period of 5 days, they then received a mid-morning snack of almonds (0.9g/kg). Finally, after another washout period participants received a mid-morning snack of cheese savouries (0.9g\kg).
3113960|NCT02480621|No Intervention|Control|Standard of care: Open Reduction Internal Fixation with no injection of pain medications around the affected ankle.
3113961|NCT02480621|Experimental|Liposomal Bupivacaine with Bupivacaine|Intra-operatively, patients receive a local injection of liposomal bupivacaine with bupivacaine around the affected ankle.
3113962|NCT02480712|Experimental|SOF/VEL|Participants will receive SOF/VEL for 12 weeks
3113963|NCT02480764|Experimental|Azilsartan medoxomil 40 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 40 mg tablets, orally, once daily, azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
3113964|NCT02480764|Experimental|Azilsartan medoxomil 80 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: azilsartan medoxomil 80 mg tablets, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for up to 8 weeks.
3113965|NCT02480764|Active Comparator|Valsartan 160 mg|Run-in Period: azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and valsartan two 80 mg placebo-matching capsules, orally, once daily, for 2 weeks prior to the start of the treatment period. Treatment Period: valsartan two 80 mg capsules, orally, once daily, azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily, and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily, for up to 8 weeks.
3113966|NCT02480998|Experimental|IL-YANG Flu Vaccine QIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
3113967|NCT02480998|Active Comparator|IL-YANG Flu Vaccine TIV 0.5mL|A single 0.5mL dose administrated as an intramuscular injection.
3113968|NCT02481050|Experimental|Eribulin Mesylate|Participants with metastatic HER2-negative breast cancer previously treated with 2 to 5 chemotherapy regimens.
3113969|NCT02481141|Active Comparator|5-ALA-SFC|"Study product administration will be as follows:~Beginning Week 0: 1 capsule of 50mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 2: 1 capsule of 75mg 5-ALA-SFC twice per day for 2 weeks Beginning Week 4: 1 capsule of 100mg 5-ALA-SFC twice per day for 8 weeks"
3113970|NCT02481141|Placebo Comparator|Placebo|"Study matching placebo administration will be as follows:~Beginning Week 0: 1 capsule twice per day for 2 weeks Beginning Week 2: 1 capsule twice per day for 2 weeks Beginning Week 4: 1 capsule twice per day for 8 weeks"
3113971|NCT02481206|Experimental|Wearable Cardioverter Defibrillator|End Stage Renal Disease (ESRD) patients beginning hemodialysis will use a Wearable Cardioverter Defibrillator for six months
3113972|NCT02481206|No Intervention|Conventional Treatment|Conventional Treatment
3113973|NCT02481219|Active Comparator|Bowel preparation regimen -Control|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of polyethylene glycol (PEG) on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution Drug: 10mg Bisacodyl suppository."
3113974|NCT02481219|Experimental|Bowel preparation regimen-Test|"Regimen includes administration of:~Drug: 4 Senna tablets 2 days before the procedure, Drug: 2-liters of PEG on the evening before the procedure Drug: 2-liters of PEG on the morning of the procedure, Drug:10mg Metoclopramide or 250 mg Erythromycin Drug: 2 SUPREP oral sulfate solution with Gastrografin Drug: 10mg Bisacodyl suppository."
3113975|NCT02481258|Experimental|Ataciguat (HMR1766)|200mg taken daily for 12 months
3113976|NCT02481258|Placebo Comparator|Matching Placebo|Taken Daily for 12 months
3113977|NCT02481297|Experimental|Cohort 1: Refractory/Relapsed After Prior Therapy|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
3113978|NCT02481297|Experimental|Cohort 2: Untreated with High-rRisk mMolecular Features|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22), then with start of each course. Lirilumab 3 mg/kg by vein given on Day 1 of each cycle. Rituximab given for the first 12 cycles and Lirilumab continues for up to 24 cycles. Each cycle is 4 weeks.
3113979|NCT02481375|Experimental|Multiple micronutrients with iron|"Multiple micronutrient formulations were based on the UNICEF/WHO/UNU standard formulation for pregnant and lactating women (UNIMMAP) with increased iron (from 30 mg to 60 mg elemental iron) for comparability to the iron only group (60 mg). This formulation has 15 micronutrients including iron.~Women will receive the multiple micronutrient with iron for 12 weeks."
3113980|NCT02481375|Active Comparator|Multiple micronutrients without iron|"This formulation has the 14 micronutrients included in the UNIMMAP formulation, but does not include iron.~Women will receive the multiple micronutrient without iron for 12 weeks."
3113981|NCT02481375|Active Comparator|Iron only|"This formulation only has 60 mg elemental iron.~Women will receive iron for 12 weeks."
3113982|NCT02481375|Placebo Comparator|Placebo|"This formulation is a placebo.~Women will receive a placebo for 12 weeks."
3113983|NCT02481440|Experimental|hUC-MSC Transplantation|Repeated intrathecal administrations of 1x10E6 human umbilical cord mesenchymal stem cells per kg in subjects with spinal cord injury with an interval of one month between each administration
3113984|NCT02481505|Experimental|3 mL Chloroprocaine HCl 1%|Patients in D1 group will receive a single dose of 3 mL Chloroprocaine HCl 1% (corresponding to 30 mg chloroprocaine HCl)
3113985|NCT02481505|Experimental|4 mL Chloroprocaine HCl 1%|Patients in D2 group will receive a single dose of 4 mL Chloroprocaine HCl 1% (corresponding to 40 mg chloroprocaine HCl)
3113986|NCT02481505|Experimental|5 mL Chloroprocaine HCl 1%|Patients in D3 group will receive a single dose of 5 mL Chloroprocaine HCl 1% (corresponding to 50 mg chloroprocaine HCl)
3113987|NCT02481557|Experimental|Oxalate Salt Solution|Professionally applied
3113988|NCT02481557|No Intervention|No Treatment|No Treatment
3113989|NCT02481596|Experimental|REACH + FAMS|"Participants will receive FAMS components (monthly phone coaching and text messages supporting a goal set in coaching, plus the option to invite a family member/support person to receive text messages) for six months.~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3113990|NCT02481596|Experimental|REACH|"Participants will receive REACH text messages (individual-focused text messaging tailored to user's individual barriers to adherence, messages assessing medication adherence with feedback, and targeted to address other self-care behaviors).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3113991|NCT02481596|Active Comparator|Helpline & A1c results|"Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment and physician monitoring).~All participants will receive text messages advising how to access their study A1c test results, quarterly newsletters on healthy living with diabetes, and have access to a Helpline for study- and diabetes medication-related questions."
3113992|NCT02481713|Experimental|MI condition|motivational interview condition
3113993|NCT02481713|Sham Comparator|CI condition|learning style interview condition
3113994|NCT02481830|Experimental|Arm A Nivolumab|Nivolumab intravenous infusion as specified
3113995|NCT02481830|Active Comparator|Arm B Chemotherapy Topotecan|Topotecan as specified
3113996|NCT02481830|Active Comparator|Arm B Chemotherapy Amrubicin|Amrubicin intravenous infusion as specified (upon investigator's choice, where locally approved for 2nd line SCLC treatment)
3113997|NCT02481869|Active Comparator|Arthrocentesis/PRP|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the PRP will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of PRP. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of PRP, just an aspiration of both injured and uninjured ankles."
3113998|NCT02481869|Placebo Comparator|Arthrocentesis/Saline|"At the time of surgery, the participant will have both injured and uninjured ankles cleaned with surgical soap. An needle will be placed into the injured ankle joint and synovial fluid will be drawn out of the ankle and collected into a syringe. Using the same needle, the Saline will be delivered into the same arthrocentesis needle.~Next the uninjured ankle will have the same procedure as the injured ankle, except there will be no injection of Saline. There will only be a aspiration of synovial fluid from the uninjured ankle joint using a different clean needle.~Another aspiration of the synovial fluid will be done at the time of the second surgery in the same manner as before, except there will be no injection of Saline, just an aspiration of both injured and uninjured ankles."
3113999|NCT02481934|Experimental|NKAE cells infusion + chemotherapy|Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).
3114000|NCT02481947|Experimental|BLI400 Laxative|21 gm BLI400 powder
3114001|NCT02481947|Active Comparator|Lubiprostone|24 mcg capsule bid
3114002|NCT02482025|No Intervention|Usual care|Usual care delivered at VA Boston
3114003|NCT02482025|Active Comparator|SMMRT|Receives Usual Care PLUS SMMRT Intervention
3114004|NCT02482129|Experimental|LME636|LME636 60 mg/mL ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 1 week (Week 3) and 1 week of masked Vehicle administration (Week 4)
3114005|NCT02482129|Active Comparator|Dexamethasone|Dexamethasone 0.1% ophthalmic solution, maximum drop frequency administered for 2 weeks, followed by a tapering for 2 weeks (Weeks 3 and 4)
3114006|NCT02482233|Experimental|ENDD|"6-week supply of disposable NJOY ENDDs (e-cigarettes)~the number of e-cigarettes will be determined by equating the number of e-cigarettes to the number of cigarettes smoked per day (1 pack per day = 2 e-cigarettes per day = 14 e-cigarettes/week)~veterans will be given detailed instructions for use and also instructed to start with the high nicotine content (4.5%) strength for three weeks, then decrease to the low nicotine content (2.4%) for two weeks, then switch to nicotine-free for the final week~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
3114007|NCT02482233|Active Comparator|NRT (NicoDerm CQ)|"A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d.~Both groups will receive:~i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery"
3114008|NCT02482298|Experimental|Dose A|
3114009|NCT02482298|Experimental|Dose B|
3114010|NCT02482298|Placebo Comparator|Placebo|
3114011|NCT02482428|Experimental|LFX453 0.1% NMC|LFX453 0.1% nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
3114012|NCT02482428|Experimental|LLFX453 0.15% LCC|LFX453 0.15% liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
3114013|NCT02482428|Placebo Comparator|Vehicle to NMC|Vehicle to nanomedicinal cream (NMC) Twice daily applications for a maximum of 12 weeks
3114014|NCT02482428|Placebo Comparator|Vehicle to LCC|Vehicle to liquid crystal cream (LCC) Twice daily applications for a maximum of 12 weeks
3114015|NCT02482428|Active Comparator|Aldara|Aldara 5% cream 3 applications per week for a maximum of 16 weeks
3114016|NCT02482571|Experimental|Mild Hypoxia|Subjects are exposed to an intervention that controls the composition of breathed air by using a gas blender (RespirAct). Subjects undergo MRI and MRS while breathing air with both normal oxygen concentration (normoxia) and reduced oxygen concentration (mild hypoxia).
3114017|NCT02482610|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114018|NCT02482610|Experimental|Glucose with Whole Fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114019|NCT02482610|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114020|NCT02482675|Active Comparator|Glucose|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114021|NCT02482675|Experimental|Glucose with Non-fat Milk|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114022|NCT02482675|Experimental|Glucose with Whey Protein Isolate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114023|NCT02482675|Experimental|Glucose with Sodium Caseinate|This study day will last approximately three hours and will be separated from the other arms by four days for men and one month for women.
3114024|NCT02482805|Experimental|Power Posing|Individuals hold two, 1-minute postures associated with dominance and high power prior to exposure therapy.
3114025|NCT02482805|Experimental|Submissive Posing|Individuals hold two, 1-minute postures associated with submissiveness and low power prior to exposure therapy.
3114026|NCT02482805|Experimental|Rest|Individuals rest (no postures) for 2 minutes prior to exposure therapy.
3114027|NCT02482870|Active Comparator|Macintosh|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a Macintosh laryngoscope.
3114028|NCT02482870|Active Comparator|KingVision|Patients scheduled for general anesthesia during the period from January 2014 to June 2014. Each patient has been intubated with a King Vision video laryngoscope.
3114029|NCT02482935|Experimental|Abemaciclib High Fat Meal|Abemaciclib capsules administered once orally in the fed state.
3114030|NCT02482935|Experimental|Abemaciclib Fasted|Abemaciclib capsules administered once orally in the fasted state.
3114031|NCT02483000|Experimental|Treatment (PRIT)|"B9E9-FP INFUSION: Patients receive B9E9-fusion protein IV over a minimum of 2 hours on day -17.~CLEARING AGENT INFUSION: Patients receive clearing agent IV over a minimum of 30 minutes on day -15.~RADIOBIOTIN INFUSION: Patients receive indium In 111-DOTA-biotin IV and yttrium Y 90 DOTA-biotin IV over 2-5 minutes on day -14.~BEAM CHEMOTHERAPY: Patients receive BEAM chemotherapy comprising carmustine IV over 3 hours on day -7; etoposide IV over 2 hours BID and cytarabine IV over 4 hours BID on days -6 to -3; and melphalan IV over 30 minutes on day -2.~STEM CELL INFUSION: Patients undergo autologous PBSCT on day 0 per standard of care."
3114032|NCT02483416||group 1|Group without 'remote additional personalised nurse-led follow-up: patients will receive the healthcare given routinely by their medical team
3114033|NCT02483416||group 2|Group with 'remote additional personalised nurse-led follow-up: patients will receive telephone calls from a nurse in addition to the healthcare given routinely by their medical team
3114034|NCT02483520|Experimental|Intervention FamTechCare|This group will submit videos and receive weekly feed back after review by dementia care experts for managing challenging care situations. The intervention is weekly individualized feedback based on video data (FamTechCare).
3114035|NCT02483520|Placebo Comparator|Control and Delayed FamTechCare|This group will submit videos and will receive weekly feedback from a nurse based on their verbal communication until the end of their participation. At the end of the study, they will receive feedback based on submitted videos from dementia care experts (delayed FamTechCare).
3114036|NCT02483572|Experimental|Functional Communication Training|Participants assigned to this condition will receive treatment immediately after assignment. The investigators will implement functional communication training (FCT) to teach the participant an appropriate request response, known as a functional communication response or FCR. FCT training will continue until the participant emits independent FCRs in at least 90% of the 30-s intervals and until destructive behavior decreases by 90% (relative to pre-treatment baseline) for two consecutive sessions.
3114037|NCT02483572|No Intervention|Waitlist-Control Condition|Participants assigned to the waitlist-control condition will not immediately receive services. These participants will be paired with an FCT-condition participant such that the no-treatment duration for these participants is yoked to the amount of time their respective FCT-condition participants receive services (e.g., most treatment last approximately 4 months, or 16 weeks); if Participant A finishes treatment in 16 weeks, Participant B will not receive treatment for at least 16 weeks for comparative measures). After the wait period, these participants will then receive the same services as those assigned to the immediate treatment (FCT Condition).
3114038|NCT02483585|Placebo Comparator|Placebo|Participants received placebo on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. At week 12 participants began treatment with erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
3114039|NCT02483585|Experimental|Erenumab|Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
3114040|NCT02483611|Experimental|Group M|"Magnesium Sulfate. In this group, the patients received magnesium sulfate 40 mg/Kg as a bolus and 20 mg/kg/h by continuous IV infusion during surgery.~After the bolus of magnesium sulfate, 0.15 mg/kg of cisatracurium was infused over 5 seconds."
3114041|NCT02483611|Experimental|Group ML|"Magnesium Sulfate plus Lidocaine. In this group, the patients received 40 mg/kg of Magnesium Sulfate plus 3 mg kg-1 lidocaine as a bolus and 20 mg/kg/h and 3 mg/kg/h, respectively, by infusion continuously during the surgery.~After the bolus of magnesium sulfate and lidocaine, 0.15 mg/kg of cisatracurium was infused over 5 seconds"
3114042|NCT02483611|Placebo Comparator|Group C|"Isotonic Solution. In this group, the patients received the volume of isotonic solution equivalent to the volume of solution infused into experimental groups.~After the bolus of the isotonic solution , 0.15 mg/kg of cisatracurium was infused over 5 seconds"
3114043|NCT02483676|Experimental|Treadmill+anklebot|This group will receive gait training on a treadmill while wearing the anklebot with the adaptive control system.
3114044|NCT02483676|Active Comparator|Treadmill only|This group will receive gait training on a treadmill, without use of the anklebot.
3114045|NCT02483975|Experimental|FF 50 mcg|Subjects will receive by oral inhalation FF 50 mcg once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
3114046|NCT02483975|Placebo Comparator|Placebo|Subjects will receive by oral inhalation placebo once daily in the morning via ELLIPTA for 42 days. Subjects will continue to receive oral montelukast once daily in the evening and may use albuterol/salbutamol inhalation aerosol as needed.
3114047|NCT02484092|Experimental|SPK-9001|Single intravenous (i.v.) infusion of SPK-9001 [an adeno-associated viral (AAV) vector with human factor IX gene] Intervention: Gene Therapy / Gene Transfer
3114048|NCT02484443|Experimental|Treatment (sargramostim and dinutuximab)|Patients receive sargramostim SC QD on days 1-14 and dinutuximab IV over 10 hours on days 4-7 (dinutuximab infusion may be extended up to a total of 20 hours per day for anticipated toxicities). Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
3114049|NCT02484547|Experimental|Low Dose|Monthly intravenous (IV) infusions
3114050|NCT02484547|Experimental|High Dose|Monthly intravenous (IV) infusions
3114051|NCT02484651|No Intervention|Standard Group|Standard Clinical Practice Group - standard neuromuscular block, with a standard rocuronium dose for intubation (0.6 mg/kg). If required, the reversal of neuromuscular block is performed with neostigmine.
3114052|NCT02484651|Experimental|Deep NMB group|Deep Neuromuscular Block group - with a standard rocuronium dose for intubation (0.6 mg/kg), followed by a constant infusion of rocuronium (10-15 ug/kg/min) to guarantee a PTC less or equal to 2 on the TOF monitor (PTC is evaluated every 5 minutes). The reversal of neuromuscular block is performed with Sugammadex (4 mg/kg).
3114053|NCT02484690|Active Comparator|Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)|Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
3114054|NCT02484690|Experimental|Arm B: Faricimab, 1.5 mg Q4W|Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
3114055|NCT02484690|Experimental|Arm C: Faricimab, 6 mg Q4W|Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
3114056|NCT02484690|Experimental|Arm D: Faricimab, 6 mg Every 4-8 weeks|Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
3114057|NCT02484690|Experimental|Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W|Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
3114058|NCT02484729|Experimental|AZD9977 oral suspension, single doses|In Part A up to 10 cohorts with single ascending doses with AZD9977 as oral suspension. In Part B AZD9977 as oral suspension in IntelliCap® capsule
3114059|NCT02484729|Placebo Comparator|Placebo, oral suspension, single doses|In Part A up to 10 cohorts with single doses with matching placebo to AZD9977
3114060|NCT02484729|Experimental|AZD9977, oral solution, single dose|In Part B, of oral solution of AZD9977 will be used as reference
3114061|NCT02484807||Bosentan + Sildenafil|Combination treatment with Bosentan + Sildenafil at baseline
3114062|NCT02484807||Bosentan + Tadalafil|Combination treatment with Bosentan + Tadalafil at baseline
3114063|NCT02484807||Ambrisentan + Sildenafil|Combination treatment with Ambrisentan + Sildenafil at baseline
3114064|NCT02484807||Ambrisentan + Tadalafil|Combination treatment with Ambrisentan + Tadalafil at baseline
3114065|NCT02484807||Macitentan + Sildenafil|Combination treatment with Macitentan + Sildenafil at baseline
3114066|NCT02484807||Macitentan + Tadalafil|Combination treatment with Macitentan + Tadalafil at baseline
3114067|NCT02484859|Active Comparator|remifentanil|Following an intravenous bolus dose of 0.5 µg/kg remifentanil administered just before the induction of anaesthesia, patients will receive an intravenous infusion of remifentanil at a dose of 0.25-0.5 µg/kg/min throughout the surgery. The rate of infusion will be adjusted to maintain a mean blood pressure within %70-80 of the baseline value. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
3114068|NCT02484859|Active Comparator|tramadol + metoprolol|Just before the induction of anaesthesia, an intravenous infusion of 1 mg/kg of tramadol in 100 ml isotonic fluid will be started. The infusion will be completed in 30 minutes using a perfusor. Additionally, following the administration of the neuromuscular blocking agent, 0.1 mg/kg of intravenous metoprolol will be administered within 5 minutes.
3114069|NCT02484898||SEEQ™ MCT/ECM System|SEEQ™ MCT/ECM monitoring for the detection of non-lethal cardiac arrhythmias.
3114070|NCT02484911|Experimental|Olanzapine regimen|Olanzapine in combination with aprepitant ,palonosetron and dexamethasone.
3114071|NCT02484911|Other|Control regimen|Aprepitant in combination with palonosetron and dexamethasone
3114072|NCT02485158|Experimental|AMP, ALC, THC or Placebo 1|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
3114073|NCT02485158|Experimental|AMP, ALC, THC or Placebo 2|All healthy adult volunteers attended 6 sessions in which they received 20mg AMP, 0.8g/kg ALC, and 7.5mg THC, alternating with three placebo sessions.
3114074|NCT02485301|Experimental|Group EBO-Z|The subjects in the Group EBO-Z will receive the vaccine at Day 0 of the study
3114075|NCT02485301|Placebo Comparator|Group Placebo/ EBO-Z|The subjects in the Group Placebo/ EBO-Z will receive a placebo at Day 0 (as a control) and will receive the investigational ChAd3-EBO-Z vaccine at Month 6
3114076|NCT02485353|Other|Vosaroxin and Cytarabine|
3114077|NCT02485483||VADERA I|RA participants without a concurrent history of depression and who have not received psychotherapy, antidepressants, or inpatient psychiatric treatment in the 3 months before baseline (T0) will be asked to complete the World Health Organization Five Well-Being Index (WHO-5), Patient Health Questionnaire-9 (PHQ-9) and Beck Depression Inventory (2nd edition) (BDI-II) questionnaires and a subsequent structured interview using Montgomery-Åsberg Depression Rating Scale (MADRS) at 2 time-points (T0 and T1 [12 ± 2 weeks]) with a 10-14 week interval between assessments.
3114078|NCT02485483||VADERA II|All RA participants who are able to complete the PHQ-9 and BDI-II questionnaires, and have been scheduled for a RA consultation at one of the participating clinics will be eligible for participation.
3114079|NCT02485561|Active Comparator|Information only|INTERVENTION: Information about colon cancer and screening tests from sources such as the Centers for Disease Control and Prevention Screen for Life campaign.
3114080|NCT02485561|Experimental|Screener Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for colon cancer
3114081|NCT02485561|Experimental|Survivor Narrative|INTERVENTION: Information + Personal Narrative from someone who was screened for, and diagnosed with, colon cancer
3469260|NCT03888287|Experimental|Prospective Phase - Clinicians|346 clinicians, including physician's assistant, advanced practice nurses, staff nurses, nurse educators, case managers, dietitians pharmacists physical therapist and occupational therapist after completion of the Parkinson's Disease Inpatient Clinical Knowledge and Management Program.
3469261|NCT03888326|Experimental|Robotic Rehabilitation plus 1x1 anodal tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to 20 minutes, 2mA anodal tDCS (Soterix 1x1 tDCS) over the ipsilesional sensory cortex during the first 20 minutes of each robotic session. Current is ramped up to 2mA over 30 seconds and ramped back down over 30 seconds at the end of the 20 minutes.
3114084|NCT02485704|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
3114085|NCT02485704|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad (vehicle). Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
3114086|NCT02485717|Experimental|Natroba (spinosad)|spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours
3114087|NCT02485717|Placebo Comparator|Placebo|placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.
3114088|NCT02485834|Active Comparator|Arm A - surgery, chemotherapy and radiation therapy|Patients undergo surgery within 42 days of completion of pre-registration chemotherapy. Beginning within 49 days of surgery, patients receive 5-FU IV continuously and capecitabine PO BID on days 1-7, and undergo 3D-CRT or IMRT QD on days 1-5. Treatment continues for 5 weeks in the absence of disease progression or unacceptable toxicity.
3114089|NCT02485834|Experimental|Arm B - surgery, chemotherapy and FDG-PET|Beginning within 28 days of day 1 of pre-registration chemotherapy, patients receive docetaxel IV and irinotecan IV on days 1 and 8. Treatment repeats every 3 weeks for 2 courses. Beginning within 42 days of completion of docetaxel and irinotecan, patients undergo surgery. Patients also undergo FDG-PET within 14 days of planned surgery. Beginning within 60 days after surgery, patients receive 3 additional courses of docetaxel and irinotecan hydrochloride courses in the absence of disease progression or unacceptable toxicity.
3114090|NCT02485912|Active Comparator|Group 1|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. Both vaccinations are administered in the same arm.
3114091|NCT02485912|Active Comparator|Group 2|ChAd3-EBO Z (2.5 - 3.7 x 10^10 vp) and MVA-EBO Z (1.0 x 10^8 pfu) 7 days later. The MVA-EBO Z is administered in the opposite arm to the ChAd3-EBO Z.
3114092|NCT02485925|Experimental|Treatment group|THERMOCOOL® SMARTTOUCH™
3114093|NCT02485964|Other|Blood Draw Only|One time blood draw at time of consent; No treatment
3114094|NCT02486016|Experimental|Duragesic Reference Fentanyl TDS|Each volunteer participates in two procedure days using the Duragesic reference (RLD) fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
3114095|NCT02486016|Active Comparator|Apotex Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Apotex generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
3114096|NCT02486016|Active Comparator|Mylan Generic Fentanyl TDS|Each volunteer participates in two procedure days using the Mylan generic fentanyl TDS with heating applied for one hour at hour 11 and hour 18, respectively.
3114097|NCT02486211|Placebo Comparator|Placebo|Placebo medication administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
3114098|NCT02486211|Experimental|Amantadine|100mg Amantadine administered at 0600 and 1200 via mouth, gastric tube or duo-tube.
3114099|NCT02486263|Experimental|Study|Treated with omeprazole. This group of subjects will have prescribed restricted feeding volumes, monitored feeding duration time and positioning restrictions
3114100|NCT02486263|Other|Conventional|Treated with omeprazole. This group of subjects will receive the current standard treatment for Gastro-esophageal reflux disease (GERD) which includes use of acid suppressive medication with no restrictions of the feeding volume, duration or positioning.
3114101|NCT02486302||Observation Group|
3114102|NCT02486328|Other|Group MM|2 mg midazolam and 20mg meperidine given intravenously and additional 1-2mg midazolam and 20mg meperidine (wtih a maximum total of 5 mg midazolam and 50 mg meperidine) given when FPS greater than 3
3114103|NCT02486328|Other|Group RP|100 mcg/kg/min propofol infusion and 1 mcg/kg remifentanil bolus administered and additional 0,5 mcg/kg remifentanil bolus given when FPS greater than 3
3114104|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 1|Participants with HCV GT1b without cirrhosis received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75 mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label.
3114105|NCT02486406|Experimental|Adult tablet, 12-17 yr, Part 2|Participants with HCV GT1b received the adult 3-DAA (OBV/PTV/RTV and DSV) regimen: two 12.5 mg ombitasvir /75mg paritaprevir /50 mg ritonavir tablets taken orally every morning (QD) and one dasabuvir 250 mg tablet taken orally twice a day (BID) for 12 weeks. Participants with HCV GT1a without cirrhosis received 12-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT1a with compensated cirrhosis received 24-week treatment with the adult 3-DAA regimen and ribavirin 200 mg tablets were administered orally per local label. Participants with HCV GT4 received 12-week treatment with the OBV/PTV/RTV formulation and ribavirin 200 mg tablets were administered orally per local label.
3114106|NCT02486406|Experimental|Mini tablet, 9-11 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
3114107|NCT02486406|Experimental|Mini tablet, 3-8 yr, Part 1|Participants with HCV GT1b without cirrhosis were to receive the mini-tablet 3-DAA (OBV, PTV, RTV, and DSV) regimen for 12 weeks: ombitasvir 0.3 mg, paritaprevir 1.0 mg, and ritonavir 1.0 mg mini-tablets administered orally QD based on body weight and dasabuvir taken orally BID as 3.08 mg mini-tablets based on body weight. Participants with HCV GT1a without cirrhosis received 12-week treatment with the mini-tablet 3-DAA regimen and ribavirin was provided as a 40 mg/mL oral solution and administered per local label.
3114108|NCT02486588|No Intervention|Control--no weekly message|10% cash back level, no weekly message, and the standard monthly message
3114109|NCT02486588|Experimental|General Weekly Message|10% cash back, general weekly message, standard monthly message
3114110|NCT02486588|Experimental|Personalized Weekly Message|10 % cash back, personalized weekly message, standard monthly message
3114111|NCT02486588|Experimental|25 percent cash back|25% cash back, personal weekly message, standard monthly message
3114112|NCT02486588|Experimental|Standard monthly message|10%+15% cash back, personal weekly message, standard monthly message
3114113|NCT02486588|Experimental|Unbundled monthly message|10%+15% cash back, personal weekly message, unbundled monthly message
3114114|NCT02486627|Experimental|Plazomicin|Patients received 15 milligrams per kilogram (mg/kg) plazomicin as an intravenous (IV) infusion once daily followed by matching placebo infusions 8 and 16 hours later. After a minimum of 4 days of IV plazomicin, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
3114115|NCT02486627|Active Comparator|Meropenem|Patients received 1.0 g meropenem as an IV infusion every 8 hours (q8h). After a minimum of 4 days of IV meropenem, patients could switch to 250 or 500 mg oral levofloxacin for a total duration of 7 to 10 days (IV plus oral).
3114116|NCT02486653|Experimental|Tamsulosin|
3114117|NCT02486653|Placebo Comparator|Placebo|
3114118|NCT02486692|Experimental|Phase II- Experimental Group|Participants were provided with instructions and a web link for accessing the AboutFace website after the baseline assessment.
3114119|NCT02486692|No Intervention|Phase II- Usual Care Group|Participants were provided with instructions and a web link for accessing some online PTSD education materials after the baseline assessment.
3114120|NCT02486757|Experimental|Interventional|estradiol 50 mcg transdermal patch x 7 days oral micronized progesterone 0.5 mg/kg/dose TID x 7 days
3114121|NCT02486796|Active Comparator|Immediate and Continuous Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 1 Day 1 of their prescribed neoadjuvant chemotherapy.
3114122|NCT02486796|Active Comparator|Delayed Dosing|Subjects will be dosed with Reishi mushroom extract, Coenzyme Q10 and Melatonin beginning with Cycle 3 Day 1 of their prescribed neoadjuvant chemotherapy.
3114123|NCT02486939|Experimental|CHS-0214|CHS-0214 50 mg weekly
3114124|NCT02486952||Diffuse Large B-Cell Lymphoma (DLBCL)|Participants, who were not treated previously for DLBCL, will receive rituximab (MabThera) in combination with Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) or CHOP-like chemotherapy at the treating physician's discretion and according to package labeling, within approved indication and local approval status of respective drugs. Participants will be followed up for safety and efficacy in accordance with routine practice until progression of disease, unacceptable toxicity, withdrawal of consent or death from any reason.
3114125|NCT02487030|Experimental|LDV/SOF 8 wk TN (Cohort 1, Group 1)|LDV/SOF for 8 weeks (treatment-naive (TN))
3114126|NCT02487030|Experimental|LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)|LDV/SOF+RBV for 8 weeks (treatment-naive)
3114127|NCT02487030|Experimental|LDV/SOF 12 wk TN (Cohort 1, Group 3)|LDV/SOF for 12 weeks (treatment-naive)
3114128|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)|LDV/SOF+RBV for 12 weeks (treatment-naive)
3114129|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 2)|Treatment-experienced (TE) participants who completed treatment in Gilead sponsored study GS-US-334-0138 or in Cohort 1 of this study and did not achieve SVR12 will receive LDV/SOF+RBV for 12 weeks.
3114130|NCT02487030|Experimental|LDV/SOF 12 wk TE (Cohort 3, Group 1)|LDV/SOF for 12 weeks (treatment-experienced)
3114131|NCT02487030|Experimental|LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)|LDV/SOF+RBV for 12 weeks (treatment-experienced)
3114132|NCT02487199|Experimental|HCV GT1a (3-DAA)|Participants with hepatitis C virus (HCV) genotype 1a (GT1a) infection received 3-direct-acting antiviral agent (3-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3114133|NCT02487199|Experimental|HCV GT4 (2-DAA)|Participants with hepatitis C virus (HCV) genotype 4 (GT4) infection received 2-direct-acting antiviral agent (2-DAA: ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) for 12 weeks.
3114134|NCT02487225|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
3114135|NCT02487225|Placebo Comparator|Placebo|Placebo 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects to receive up to a maximum of 9 doses.
3114136|NCT02487303|Active Comparator|Acetaminophen Intravenous|(group 1) 1 gram IV acetaminophen every 8 hours for three doses
3114137|NCT02487303|Active Comparator|Acetaminophen Oral|(group 2) 1 gram oral acetaminophen every 8 hours for three doses
3114138|NCT02487303|No Intervention|No acetaminophen|(group 3) no acetaminophen
3114139|NCT02487446|Experimental|First QVA149, then Umeclidinium/vilanterol|Participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks. Then after 3 weeks washout, participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks.
3114140|NCT02487446|Experimental|First Umeclidinium/vilanterol, then QVA149|Participants received Umeclidinium/vilanterol 62.5/25 ug via inhalation once daily for 12 weeks. Then after 3 weeks washout, participants received QVA149 27.5/12.5 ug via inhalation twice daily (b.i.d.) for 12 weeks.
3114141|NCT02487472||HZ cohort|All patients ≥ 50 years old with a HZ diagnosis (as the primary diagnoses and no earlier case of HZ) during approximately 6 months inclusion period will be included in the HZ cohort, until total study target is achieved.
3114142|NCT02487485|Experimental|ketamine + sirolimus (placebo at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg orally. After two weeks, they will recieve another infusion of ketamine, and a single dose of placebo.
3114143|NCT02487485|Placebo Comparator|ketamine + placebo (sirolimus at time 2)|Participants will be treated twice with ketamine 0.5 mg/kg infused over 40 minutes, combined with a single dose of sirolimus 6 mg placebo. After two weeks, they will recieve another infusion of ketamine, and a single dose of sirolimus 6 mg.
3114144|NCT02487498|Experimental|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
3114145|NCT02487498|Experimental|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
3114146|NCT02487563|Experimental|Experimental Group 1|Decitabine in combination with rhTPO.
3114147|NCT02487563|Experimental|Experimental Group 2|Decitabine
3114148|NCT02487563|Active Comparator|Control Group|Conventional treatment except decitabine.
3114149|NCT02487771|Placebo Comparator|Placebo Capsule|
3114150|NCT02487771|Experimental|DHA Capsule|
3114151|NCT02487810|Experimental|Intuitive|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
3114152|NCT02487810|Experimental|Deliberative|Patients in each arm will be asked all of the same questions. The only difference between the arms will be the instructions regarding how and when to answer the series of hypothetical questions regarding medical interventions. The instructions will be designed to influence patients to think either intuitively or deliberatively about the questions regarding life-sustaining interventions.
3114153|NCT02487966|Experimental|Active tDCS and Active Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of active Mirror Therapy.
3114154|NCT02487966|Experimental|Active tDCS and sham Mirror Therapy|Subjects will receive 20 minutes of active tDCS, while receiving 15 minutes of sham Mirror Therapy.
3114155|NCT02487966|Experimental|Sham tDCS and active Mirror Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of active Mirror Therapy.
3114156|NCT02487966|Sham Comparator|Sham tDCS and sham Mirrory Therapy|Subjects will receive 20 minutes of sham tDCS, while receiving 15 minutes of sham Mirror Therapy.
3114157|NCT02487979|Experimental|Treatment (glembatumumab vedotin)|Patients receive glembatumumab vedotin IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3114158|NCT02488005|Experimental|Small Bowel Ultrasound|Subjects will receive a small bowel ultrasound to measure bowel wall thickness at Week 0 and Week 14
3114159|NCT02488018|Experimental|Provision of experimental honeys|Eight experimental monofloral honeys and reference glucose
3114160|NCT02488070|Experimental|Diagnostic (68Ga-PSMA PET/CT or PET/MRI)|Patients receive gallium Ga 68-labeled PSMA ligand Glu-urea-Lys(Ahx) IV and then undergo PET/CT or PET/MRI approximately 45-60 minutes later.
3114161|NCT02488109|Active Comparator|Higher Calorie Refeeding Protocol|Participants in this arm will receive a higher calorie meal-based refeeding treatment plan in hospital.
3114162|NCT02488109|Active Comparator|Lower Calorie Refeeding Protocol|Participants in this arm will receive a lower calorie meal-based refeeding treatment plan in hospital.
3114163|NCT02488239||CRT-P indicated patients|Planned to be implanted with a 3-lead CRT-P system and connected to the remote data collection through the Latitude® system
3114164|NCT02488317|Other|Intervention arm|These patients will receive the decision aid tool. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
3114165|NCT02488317|No Intervention|Control arm|These patients will not receive the decision aid tool and will be asked to test their knowledge without it. Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
3114166|NCT02488330|Experimental|Control and/or Onartuzumab treatment|Participants will receive treatment with either the control treatment (erlotinib, bevacizumab) and/or onartuzumab-based study treatment (as during their P-trial) until progression of disease, unacceptable treatment related toxicity, withdrawal of consent, or death (whichever occurs first). All participants will continue on the same dose and schedule of control treatment as specified in their respective P-trial. The dose of onartuzumab will be calculated based on the participant's weight at the screening visit for the E-trial.
3114167|NCT02488681|Experimental|Micra Pacemaker Implant|Micra Pacemaker Implant
3114168|NCT02488824|Experimental|Warm Temperature Exposure in Tetraplegia|Subjects are persons with higher-level spinal cord injury, levels C3 to T4, and ASIA Impairment Scale (AIS) level A and B, ages 18-68 years. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
3114169|NCT02488824|Active Comparator|Warm Temperature Exposure in Able-Bodied|Subjects are able-bodied controls matched with participants with tetraplegia for age and gender. Procedure is exposure to warm temperature (95 degrees Fahrenheit) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance
3114170|NCT02488915|Experimental|EmboTrap® Revascularization Device|Mechanical Thrombectomy with EmboTrap
3114171|NCT02488980|Experimental|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 once a week for 24 weeks.
3114172|NCT02488980|Active Comparator|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 once a week for 24 weeks.
3114173|NCT02488980|Placebo Comparator|Placebo|Placebo
3114174|NCT02489045|Experimental|SHAPE measurement|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
3114175|NCT02489110|Experimental|Webnovela|Caregivers will watch the Webnovela and read related information. The Webnovela is a short online Telenovela in Spanish, specifically designed for Hispanic caregivers on how to cope with dementia caregiving. A DVD will be available to participants without Internet access.
3114176|NCT02489110|Active Comparator|Control|Caregivers will be directed to existing web sites, such as NIA Alzheimer's and Dementia Resources in Spanish. Participants will receive related materials in Spanish language.
3114177|NCT02489123|Experimental|Treatment (enzalutamide)|Patients receive enzalutamide PO QD. Courses 1-3 repeat every 4 weeks (28 days) and subsequent courses repeat every 12 weeks (84 days) in the absence of disease progression or unacceptable toxicity.
3114178|NCT02489227|Active Comparator|Humira (adalimumab)|Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
3114179|NCT02489227|Experimental|CHS-1420|CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
3114180|NCT02489279|Experimental|Active - SAC|Behavioral learning by using the Sustained Attention Control (SAC) Method's mobile software to increase sustained attention skills and self-awareness of attention control.
3114181|NCT02489279|Active Comparator|Control - Scrabble|"Behavioral learning using the mobile software game Scrabble to exercise word processing and executive control functions."
3114182|NCT02489344|Experimental|GZ/SAR402671|Participants received GZ/SAR402671 15 milligrams (mg) once daily orally for 30 months in this extension study (LTS14116).
3114183|NCT02489357|Experimental|Treatment (pembrolizumab, cryosurgery)|Patients receive standard of care degarelix SC once a month for 8 months. Within 1 month of receiving degarelix, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Within 3 days of receiving pembrolizumab, patients undergo whole gland cryoablation of the prostate.
3114184|NCT02489422|Experimental|Group I (Yoga Skills Training)|Patients participate in YST consisting of four 30 minute in-person yoga sessions at weeks 2, 4, 6, and 8 that instructs skills to enhance mindfulness and promote relaxation, through instruction of awareness, movement, breathing practices, and meditation.
3114185|NCT02489422|Active Comparator|Group II (Attention Control)|Patients participate in four 30 minute in-person sessions of supportive conversation at weeks 2, 4, 6, 8.
3114186|NCT02489500|Active Comparator|melphalan|Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion
3114187|NCT02489500|Experimental|melphalan + Bortezomib|Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion
3114188|NCT02489630|Experimental|Ketamine|0.1 mg/kg ketamine + opiate analgesic
3114189|NCT02489630|Placebo Comparator|Placebo|0.1 mL/kg normal saline + opiate analgesic
3114190|NCT02489734|Experimental|low concentration (LC)|low concentration group
3114191|NCT02489734|Experimental|high concentration (HC)|high concentration group
3114192|NCT02489773||Group 1|HbA1c values ranged from 7.5% to 12% (or higher)
3114193|NCT02489773||Group 2|HbA1c values <7.5%
3114194|NCT02489799|Active Comparator|Intervention|Advance care planning video
3114195|NCT02489799|Placebo Comparator|Control|Control video - no advance care planning content
3114196|NCT02489968|Experimental|empagliflozin 10 mg + linagliptin 5 mg|patient to receive a tablet containing low dose empagliflozin and linagliptin once daily
3114197|NCT02489968|Experimental|empagliflozin 10 mg|patient to receive a tablet containing low dose empagliflozin once daily
3114198|NCT02489968|Experimental|empagliflozin 25 mg + linagliptin 5 mg|patient to receive a tablet containing high dose empagliflozin and linagliptin once daily
3114199|NCT02489968|Experimental|empagliflozin 25 mg|patients to receive a tablet containing high dose empagliflozin once daily
3114200|NCT02489981||Spiriva|Patients with severe persistent asthma
3114201|NCT02490293|Experimental|Group A (cephalosporin)|"During the period of hospitalization, intake of active drug ('pacetin', 2nd generation cephalosporin). 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
3114202|NCT02490293|Placebo Comparator|Group B (placebo)|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
3114203|NCT02490371|Experimental|(1) rTMS- PT Ex Group|"1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse (20 minutes) at 90% resting motor threshold (rMT) will conduct for 10 consecutive sessions (5 days per week for 2 weeks) and immediately followed by 30- minutes structured physiotherapy upper limb training.~After the 10 sessions of brain stimulation, the 30-minute structured physiotherapy upper limb training program will continue for another 12 weeks (2 sessions per week)"
3114204|NCT02490371|Placebo Comparator|(2) Placebo- PT Ex Group|"placebo stimulation over contra-lesional M1 region will be conducted for 10 consecutive sessions (5 sessions per week for 2 weeks) of and immediately followed by 30- minutes of structured physiotherapy upper limb training.~Then, the structured physiotherapy upper limb training will continue for another 12 weeks (2 sessions per week)."
3469262|NCT03888326|Sham Comparator|Robotic Rehabilitation plus sham tDCS|Receive 10 days of 1hr robotic rehabilitation with the KINARM Exoskeleton, in addition to sham anodal tDCS over the ipsilesional sensory cortex. Current is ramped up to 2mA over 30 seconds and immediately ramped back down over 30 seconds. This is repeated after 20 minutes.
3114205|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 100 mg/m^2 (Level 3)|Docetaxel will be administered via intravenous (IV) infusion on Day 1 of each 3-week cycle at a dose of 100 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114206|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 60 mg/m^2 (Level 1)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 60 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114207|NCT02490475|Experimental|RhuMab 2C4 + Docetaxel 75 mg/m^2 (Level 2)|Docetaxel will be administered via IV infusion on Day 1 of each 3-week cycle at a dose of 75 mg/m^2 per day, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 420-mg IV infusion. For Cycle 1 only, rhuMab 2C4 administration will be delayed to Day 2 with an initial 840-mg loading dose. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114208|NCT02490631|No Intervention|Control Arm|Standard of care pre-operative cleansing with soap and water the night before and morning of surgery
3114209|NCT02490631|Experimental|Intervention Arm|2% chlorhexidine gluconate cloths the night before and morning of surgery
3114210|NCT02490670|Experimental|Cephalexin (Reference)|Cephalexin manufactured in Mexico by Eli Lilly administered once orally in one of two study periods.
3114211|NCT02490670|Active Comparator|Cephalexin (Test)|Cephalexin manufactured in Brasil by Antibioticos do Brasil Ltda administered once orally in one of two study periods.
3114212|NCT02490878|Experimental|bevacizumab + corticosteroids|"The patient will receive bevacizumab 10 mg/kg IV given on days 1 and 15 of a 28 day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be treated as per treating MD."
3114213|NCT02490878|Experimental|placebo + corticosteroids|"The patient will receive placebo 0.9% NaCl volume equal to bevacizumab volume added to 100 mL bag of 0.9% NaCl delivered IV given on days 1 and 15 of a 28-day cycle for 4 cycles. Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as tolerated, under the management of the treating MD. If patients deteriorate while tapering, dexamethasone will be increased up to a maximum of 16 mg per day, as per treating MD, to manage symptoms.~Patients who meet the criteria for clinical progression will be allowed to receive bevacizumab according to the protocol."
3114214|NCT02491073||Eslicarbazepine acetate treated|
3114215|NCT02491073||Non-Eslicarbazepine acetate treated|
3114216|NCT02491359|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over approximately 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3114217|NCT02491437|Experimental|Dydrogesterone tablets 3x10 mg|Dydrogesterone tablets 3x10 mg
3114218|NCT02491437|Experimental|Crinone 8% intravaginal progesterone gel 90 mg|Crinone 8% intravaginal progesterone gel 90 mg
3114219|NCT02491463|Experimental|GSK3389245A_LD GROUP|Subjects in this group will receive 2 doses, one month apart of the GSK3389245A vaccine low dose
3114220|NCT02491463|Experimental|GSK3389245A_HD GROUP|Subjects in this group will receive 2 doses, one month apart, of the GSK3389245A vaccine high dose
3114221|NCT02491463|Active Comparator|Bexsero Group|Subjects in this group will receive 2 doses, one month apart, of Bexsero
3114222|NCT02491463|Placebo Comparator|Placebo Group|Subjects in this group will receive 2 doses, one month apart, of placebo
3114223|NCT02491671|Experimental|Experimental group|Experimental group: At the end of lung resection, lung sutures and 1.5 cm of lung parenchyma on each side will be covered by Hemopatch. No additional measures for preventing air leak will be indicated. In the case of massive air leak in spite of the use of Hemopatch, each surgeon will decide on the indication of additional sutures of tissue plasties. These cases will be accounted for failures on an intention to treat basis.
3114224|NCT02491671|Other|Control group|Control group: The standard preventive measures will be followed in each center, including reinforcement of sutures, pleural tents, suturing pericardial or subcutaneous fat
3114225|NCT02491684|Placebo Comparator|Placebo (matching)|Placebo, once daily inhalation for 14 days
3114226|NCT02491684|Experimental|Interferon beta-1a|Interferon beta-1a, 24 μg (metered dose) once daily inhalation for 14 days
3114227|NCT02491788|Experimental|Drug|10 mg of suvorexant 30 minutes prior to daytime sleep opportunity
3114228|NCT02491788|Placebo Comparator|Placebo|Placebo pill 30 minutes prior to daytime sleep opportunity
3114229|NCT02491892|Experimental|Pertuzumab 1050 mg|Participants will not receive a loading dose, but will receive pertuzumab 1050 milligrams (mg) via intravenous (IV) infusion every 3 weeks until unacceptable toxicity or disease progression.
3114230|NCT02491892|Experimental|Pertuzumab 420 mg|Participants will receive a loading dose of 840 mg via IV infusion at the first infusion of pertuzumab, followed by a maintenance dose of 420 mg every 3 weeks until unacceptable toxicity or disease progression.
3114231|NCT02491944|Experimental|Bioavailability of AZD9291|To assess the absolute bioavailability of a single oral dose of AZD9291 with respect to an intravenous microdose of [14C]AZD9291
3114232|NCT02492100|Experimental|Multi-modality sexual dysfunction intervention|"- Patients in remission > 6 months after allogeneic bone marrow transplant~Patient Enrollment and Baseline Data Collection~First Intervention Visit:~Comprehensive assessment of sexual dysfunction~Normalization & Education~Therapeutic interventions~Referral to Sexual Health Clinic if applicable~Follow-Up Intervention Visit --- Referral to Sexual Health Clinic if applicable"
3114233|NCT02492165|Experimental|Age 9 Months through 4 Years Group|Participants age 9 Months through 4 Years old at enrollment
3114234|NCT02492165|Experimental|Age 5 Years through 11 Years Group|Participants age 5 Years through 11 Years old at enrollment
3114235|NCT02492165|Experimental|Age 12 Years through 17 Years Group|Participants age 12 Years through 17 Years old at enrollment
3114236|NCT02492165|Experimental|Age 18 Years through 60 Years Group|Participants age 18 Years through 60 Years old at enrollment
3114237|NCT02492451|Active Comparator|Endometrial Injury|Endometrial injury in luteal phase of preceding IUI cycle
3114238|NCT02492451|Active Comparator|Luteal Phase Support|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
3114239|NCT02492451|No Intervention|Control group|Only IUI
3114240|NCT02492750|Experimental|Arm A (lenalidomide, dexamethasone, anakinra)|Patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Patients also receive anakinra SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3114241|NCT02492750|Active Comparator|Arm B (lenalidomide, dexamethasone, placebo)|Patients receive lenalidomide and dexamethasone as in Arm A. Patients also receive placebo SC on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3114242|NCT02492763|Experimental|MK-8521 300 μg|Participants receive double-blind MK-8521 300 μg daily (QD), subcutaneously, over 12 weeks.
3114243|NCT02492763|Experimental|MK-8521 180 μg|Participants receive double-blind MK-8521 180 μg QD, subcutaneously, over 12 weeks.
3114244|NCT02492763|Placebo Comparator|Placebo|Participants receive matching double-blind placebo, QD over 12 weeks.
3114245|NCT02492763|Active Comparator|Liraglutide 1.8 mg|Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.
3114246|NCT02492802||posaconazole-group|patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection
3114247|NCT02492841|Experimental|Mineral trioxide aggregate (MTA)|Mineral trioxide aggregate Root canal repair material
3114248|NCT02492841|Active Comparator|Calcium hydroxide|-material for pulp capping
3114249|NCT02492841|Experimental|Biodentine|Is a calcium-silicate based materia root perforations, apexification, resorptive lesions, and retrograde filling material in endodontic surgery, pulp capping
3114250|NCT02492854|Active Comparator|Standard Sterile Gauze Dressings|In this arm, pts. will be randomized to receive standard sterile gauze dressing post-operatively.
3114251|NCT02492854|Experimental|PICO Negative Pressure Dressings|In this arm, pts. will be randomized to receive PICO single-use negative pressure dressings.
3114252|NCT02492958|Experimental|SA4Ag|Staphylococcus aureus 4-antigen vaccine
3114253|NCT02492958|Placebo Comparator|Placebo|a lyophile match to the vaccine, consisting of excipients of SA4Ag formulation minus the active ingredients
3114254|NCT02492984|Experimental|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
3114255|NCT02492997|Experimental|Treatment Group|Group treated with the active Venus Versa octipolar applicator and the glycerine gel.
3114256|NCT02492997|Sham Comparator|Control Group|Group treated with the inactive Venus Versa octipolar applicator and the glycerine gel.
3114257|NCT02493036|Experimental|High Dose SYN-010|42-mg SYN-010
3114258|NCT02493062|Experimental|single-arm study|This single-arm study is described by women who have undergone prenatal fetal open (uterus was opened to perform a fetal intervention/surgery) surgery and cesarean section delivery. These women will undergo sonohysterogram.
3114259|NCT02493088||Antisocial personality|Individuals Diagnosed with Antisocial Personality Disorder
3114260|NCT02493127|Experimental|Standard PCS|Grip strength measurements and completes standard PCS
3114261|NCT02493127|Experimental|Positive PCS|Grip strength measurements and completes positively adjusted PCS
3114262|NCT02493257|Experimental|intranasal capsaicin|The capsaicin solution will be prepared by using the formula previously reported by Van Rijswijk et al; (0.1mmol/l) diluted in ethanol and 0.9% normal saline (19). Using the mucosal atomizer device (MAD), 0.8 milliliters (mL) will be delivered to each nasal cavity for a total of 24.4 ug per nasal cavity. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
3114263|NCT02493257|Placebo Comparator|Vehicle solution|100 μL of 1% ethanol in 0.9% saline solution. 5 consecutive applications of capsaicin or placebo will be administered intranasally, with 1 hour between each application.
3114264|NCT02493361|Experimental|Treatment|Pembrolizumab: 200 mg IV, Day 1 of each cycle pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle
3114265|NCT02493452|Active Comparator|3.0 mg plecanatide|Plecanatide 3.0 mg dosed daily for 12 weeks
3114266|NCT02493452|Active Comparator|6.0 mg plecanatide|Plecanatide 6.0 mg dosed daily for 12 weeks
3114267|NCT02493452|Active Comparator|Matching placebo|Placebo dosed daily for 12 weeks
3114268|NCT02493517|Experimental|Lanreotide Autogel® 60mg, 90mg and 120mg|Lanreotide Autogel 90mg from day 1 to week 13, 1 injection every 4 weeks (4 in total), titrated to 60mg, 90mg, or 120mg at week 17, then from week 17 to week 29 each group receives 1 injection every 4 weeks (4 in total/group).
3114269|NCT02493517|Active Comparator|Lanreotide 40mg PR (Lanreotide Acetate for Injection )|Lanreotide PR 40mg from day 1 to week 15, 1 injection every 10 days, then at dose titration (week 16) injection frequency will either remain at 10 days or increase to 14 days or decrease to 7 days up until week 30 or 31.
3114270|NCT02493608|Active Comparator|scalpel group|Scalpel is the device used to make abdominal wall incision in this group of patient.
3114271|NCT02493608|Active Comparator|Diathermy group|In this study group, abdominal wall incisions are made with diathermy which is a electrosurgical instrument.
3114272|NCT02493621||Lumbar plexus|Patients received a preoperative lumbar plexus nerve block (20 ml, ropivacaine 0.5%) for postoperative pain management.
3114273|NCT02493621||Lumbar Epidural|Patients received a lumbar epidural preoperatively for postoperative pain management. Epidural infusions of ropivacaine 0.2% were initiated intraoperatively, administered until the morning of postoperative day 1, and titrated to patient comfort.
3114274|NCT02493660|Experimental|InSpace implantation|Arthroscopic InSpace (Sub-acromial tissue spacer system) implantation
3114275|NCT02493660|Active Comparator|Tendon Repair|Arthroscopic partial repair of rotator cuff
3114276|NCT02493712|Experimental|High dose|High dose, twice a day for 6 weeks.
3114277|NCT02493712|Placebo Comparator|Placebo: C|Placebo, twice a day
3114278|NCT02493712|Experimental|Low dose|Low dose, twice a day for 6 weeks
3114279|NCT02493751|Experimental|Dose finding phase and dose expansion phase.|To test the maximum tolerated dose of avelumab (MSB0010718C) in combination with axitinib (AG-013736)
3114280|NCT02493764|Experimental|IMI/REL|Imipenem 500 mg + relebactam 250 mg + cilastatin 500 mg as a FDC administered intravenously (IV) every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
3114281|NCT02493764|Active Comparator|PIP/TAZ|Piperacillin 4000 mg + tazobactam 500 mg as a FDC administered IV every 6 hours for a minimum of 7 days, up to 14 days. At study entry open label linezolid 600 mg will also be administered by IV every 12 hours for up to 14 days.
3114282|NCT02493777|Experimental|HLD200 (methylphenidate)|The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 1-week prior to testing.
3114283|NCT02493777|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following open-label treatment optimization, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 1-week prior to testing.
3114284|NCT02493855|Experimental|Arm A: Ribavirin Full Dose for Last 10 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) for 12 weeks and weight-based ribavirin (1000 mg or 1200 mg split BID) for the last 10 weeks.
3114285|NCT02493855|Experimental|Arm B: Ribavirin Full Dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and weight-based ribavirin (1000 mg or 1200 mg split BID) for 12 weeks.
3114286|NCT02493855|Experimental|Arm C: Ribavirin Low-dose for 12 Weeks|Participants received ombitasvir/ABT-450/ritonavir 25 mg/150 mg/100 mg once daily (QD) + dasabuvir 250 mg twice daily (BID) and 600 mg ribavirin once daily for 12 weeks.
3114287|NCT02493868|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Direct-entry participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Open-label Induction Phase. Participants will initiate a new oral antidepressant on Day 1 of this phase. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to esketamine will self-administer intranasal esketamine (same dose) once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
3114288|NCT02493868|Experimental|Placebo Plus Oral Antidepressant|Optimization Phase: Transferred-entry participants will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase. Maintenance Phase: Direct-entry and transferred-entry participants assigned to intranasal placebo will self-administer intranasal placebo once weekly or once every other week based on depressive symptoms. Participants continue same oral antidepressant treatment from induction phase.
3114289|NCT02493946|Experimental|BTX-A-HAC NG|Clostridium Botulinum Toxin Type A (BTX A HAC NG), total treatment volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. A total of 50 Units of BTX-A-HAC NG will be injected/ cycle.
3114290|NCT02493946|Placebo Comparator|Placebo|The total placebo volume 0.25mL will be divided into 5 injections (0.05mL per injections) injected in 5 pre-defined sites across the glabellar region. Administered in Cycle 1 of the double blind phase only.
3114291|NCT02494076|Experimental|EzPAP|Patients randomized to the EzPAP arm will receive first-line therapies and PEP therapy via EzPAP. All patients will receive 4 cycles with 12 breaths per cycle. 4 cycles is considered one time administration.
3114292|NCT02494076|Sham Comparator|Standard care|Patients randomized to the control arm will receive first-line therapies and standard therapy.
3114293|NCT02494102|Placebo Comparator|Placebo|Administered Placebo day of surgery immediately prior to general anesthesia and surgery
3114294|NCT02494102|Active Comparator|Intervention|Administered Modafinil 200mg day of surgery prior to general anesthesia and surgery
3114295|NCT02494180|Placebo Comparator|A: intravenous fentanyl, midazolam|group A will be given intravenous 0.1mg fentanyl and 5mg midazolam prior oocyte retrieval
3114296|NCT02494180|Placebo Comparator|B: intravenous pethidine, diazepam|group B will be given intravenous 25mg pethidine, 5mg diazepam prior oocyte retrieval
3114297|NCT02494297||Cyproterone Acetate and Ethinyl Estradiol|Users of Diane 35 (EE/CPA, BAY86-5264)
3114298|NCT02494323|Experimental|Functional Electrical Stimulation|Dual channel stimulation of the peroneal nerve to improve dropfoot
3114299|NCT02494336|Active Comparator|Trans-incisional rectus sheath block|rectus sheath block under direct visualization through the umbilical incision by the attending surgeon
3114300|NCT02494336|Active Comparator|Laparoscopic guided rectus sheath block|rectus sheath block under direct laparoscopic visualization by the attending surgeon
3114301|NCT02494401|Active Comparator|Internet-based self-management program|Internet-based self-management program Patients randomized to active treatment intervention will be assigned to the Internet program. The site will be accessed via secured website. The modules will be presented 1-2 per week and will be moderated by a researcher with expertise in moderating Discussion Boards.
3114302|NCT02494401|Other|Education book group|Educational book group. Participants in the control group will receive a copy of The Scleroderma Book: A Guide for Patients and Families, by Dr. Maureen Mayes.
3469263|NCT03888326|No Intervention|Standard of Care Rehabilitation|No additional therapy/treatment provided. The individual continues with their normal daily routine
3114303|NCT02494518|Active Comparator|Forced Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
3114304|NCT02494518|Active Comparator|Voluntary Exercise & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling on a recumbent stationary bike at your self-selected speed~45 minutes of upper extremity repetitive arm exercises"
3114305|NCT02494518|Active Comparator|Stroke Education & Upper Extremity Repetitive Task Practice|"Participants will perform the following:~45 minutes of stroke education~45 minutes of upper extremity repetitive arm exercises"
3114306|NCT02494583|Experimental|Pembrolizumab Monotherapy (Pembro Mono)|Participants receive pembrolizumab 200 mg, intravenously (IV) on Day 1 of each 3-week cycle (Q3W)
3114307|NCT02494583|Experimental|Pembrolizumab + SOC Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 twice a day (BID) on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
3114308|NCT02494583|Placebo Comparator|Placebo + SOC Chemotherapy (SOC)|Participants receive placebo IV Q3W plus cisplatin 80 mg/m^2 Q3W plus 5-FU 800 mg/m^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m^2 BID on Days 1-14 Q3W may be substituted for 5-FU per local guidelines.
3114309|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1000 mg/m^2 (Level 2)|Participants will receive a single 1000-mg/m^2 dose of oral (PO) capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1000 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114310|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 1250 mg/m^2 (Level 3)|Participants will receive a single 1250-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 1250 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114311|NCT02494596|Experimental|RhuMab 2C4 + Capecitabine 825 mg/m^2 (Level 1)|Participants will receive a single 825-mg/m^2 dose of PO capecitabine on Day -7 for pretreatment assessment. Capecitabine will then be administered on Days 1 to 14 of each 3-week cycle at a dose of 825 mg/m^2 twice daily, and rhuMab 2C4 will be given on Day 1 of each 3-week cycle as a fixed-dose 1050-mg IV infusion. The incidence of DLTs will be used to guide intrapatient dose modification, as well as subsequent enrollment.
3114312|NCT02494713|Other|ADT + chemotherapy|Patients will be treated with 4 monthly injections of degarelix along with two 8-week cycles of chemotherapy (doxorubicin and ketoconazole, weeks 1, 3, 5 and docetaxel and estramustine, weeks 2, 4, 6). Each cycle of chemotherapy will consist of 6 weeks of chemotherapy and 2 weeks of rest. In the absence of toxicity or disease progression, patients will receive 2 cycles of treatment prior to radical prostatectomy.
3114313|NCT02494778|Experimental|Pridopidine|The mode of administration is oral. Capsules will be swallowed whole with water. One capsule should be taken in the morning and 1 in the afternoon, 7 to 10 hours after the morning dose. Study drug can be taken irrespective of meals.
3114314|NCT02494817|Placebo Comparator|Control group|Couples assigned to the control group will be directed to the website that only has the following: 1) module about learning about effective HIV prevention strategies, 2) sexual health resource center, and 3) a link to download a corresponding smartphone app that will include the sexual health resource center.
3114315|NCT02494817|Active Comparator|Intervention group|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
3114316|NCT02495025|Experimental|Telephone-based screening|Families randomized to the intervention arm will be connected with 211 Los Angeles for completion of developmental screening over the phone. Screening will consist of three structured, validated, parent-report tools: the Parental Evaluation of Developmental Status (PEDS), the PEDS Developmental Milestones (PEDS:DM), and the Modified Checklist for Autism in Toddlers (M-CHAT). If any developmental or behavioral concerns are present, the care coordinator at 211 Los Angeles will make appropriate referrals for developmental evaluation and intervention services. A copy of the care plan generated from 211 will be sent to the child's primary care provider and included in the medical record.
3114317|NCT02495025|No Intervention|Usual care|Children randomized to the control group will report for their well-child care visits as scheduled, and will receive clinic-based developmental screening and care coordination. Any developmental or behavioral concerns will be directed to the child's pediatrician, as is the current clinical recommendation.
3114318|NCT02495038|No Intervention|Intubating dose, Group I|"combined ED95 rocuronium and ED95 cisatracurium~ED95, dose causing on average 95% suppression of neuromuscular response."
3114319|NCT02495038|Experimental|10% reduction of combination of Esmeron® and Nimbex®, Group S|This arm reduced 10% of combined ED95 rocuronium and ED95 cisatracurium
3114320|NCT02495038|Experimental|20% reduction of combination of Esmeron® and Nimbex®, Group L|This arm reduced 20% of combined ED95 rocuronium and ED95 cisatracurium
3114321|NCT02495103|Experimental|Phase I Component - Vandetanib|Phase I Component
3114322|NCT02495103|Experimental|Phase II Component- Vandetanib/Metformin|Phase II Component
3114323|NCT02495168|Experimental|Generic Budesonide/Formoterol Fumarate Dihydrate|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
3114324|NCT02495168|Active Comparator|Symbicort (Budesonide/Formoterol Fumarate Dihydrate)|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a Symbicort budesonide/formoterol fumarate dihydrate (80 μg/4.5 μg) pMDI for up to 50 days.
3114325|NCT02495168|Placebo Comparator|Placebo|After a 2-week Run-in Period of administering 2 inhalations twice daily via a generic placebo pMDI device, participants will administer 2 inhalations twice daily via a generic placebo pMDI for up to 50 days.
3114326|NCT02495233|Experimental|Gilteritinib 120mg + Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
3114327|NCT02495233|Experimental|Gilteritinib 80mg+ Erlotinib 150mg|Gilteritinib was administered in combination with erlotinib orally once daily.
3114328|NCT02495259|Experimental|ZU-bend stylet with GlideScope technique|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the ZU-bend with the GlideScope technique of a double lumen endobronchial tube (DLT) placement as part of the anesthesia procedure prior to surgery.
3114329|NCT02495259|Active Comparator|GlideScope with the GlideRite stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the GlideScope with the GlideRite stylet for placement of a double lumen endobronchial tube (DLT) as part of the anesthesia procedure prior to surgery.
3114330|NCT02495259|Active Comparator|Macintosh blade and a regular DLT stylet|Subjects scheduled for thoracic surgery in which the surgeon requests lung isolation will undergo laryngoscopy and intubation using the direct laryngoscopy technique with the Macintosh blade and a regular double lumen endobronchial tube (DLT) stylet as part of the anesthesia procedure prior to surgery.
3114331|NCT02495389|Experimental|Mirabegron|Participants received mirabegron (Myrbetriq) daily for 12 weeks
3114332|NCT02495454|Experimental|Ga101-miniCHOP|"6 courses of GA101-miniCHOP regimen and 2 additional infusions of GA101, every 21 days (for a total of 6 courses of miniCHOP and 10 infusions of GA101).~GA101-miniCHOP regimen:~Cycle 1 GA101: 1000 mg day 1, day 8 and day 15, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Cycles 2-6 GA101: 1000 mg day 1, iv Cyclophosphamide: 400 mg/mq, day 1, iv Doxorubicin: 25 mg/mq, day 1, iv Vincristine: 1 mg, day 1, iv Prednisone: 40 mg/mq, days 1-5, os~Two additional infusions of GA101: 1000 mg day 1, iv, every 21 days."
3114333|NCT02495467|Experimental|MED Placebo then MED2005|Participants first receive MED Placebo to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
3114334|NCT02495467|Experimental|MED2005 then MED Placebo|Participants first receive MED2005 (0.2% glyceryl trinitrate gel) to be used at least 4 times during a 4 week period. Following a 1-week treatment-free cross-over period participants receive MED Placebo to be used at least 4 times during a 4 week period. Treatments are provided in single unit dose aluminium tubes packed in boxes of 5. Each tube will contain sufficient gel to apply a pea sized amount (approximately 300 mg).
3114335|NCT02495623|Active Comparator|Low Dose|21 mg SYN-010
3114336|NCT02495623|Active Comparator|High Dose|42 mg SYN-010
3114337|NCT02495623|Placebo Comparator|Placebo|Placebo
3114338|NCT02495779|Experimental|Intervention|Given emtricitabine/tenofovir for 2-3 weeks. Brief CBT-based counseling to promote PrEP adherence
3114339|NCT02495831|Experimental|Diclofenac sodium|Diclofenac sodium 50 mg oral tablets, single dose
3114340|NCT02495831|Active Comparator|Diclofenac sodium and safinamide|Diclofenac sodium 50 mg oral tablets, single dose, and safinamide 200 mg oral tablets, single dose
3114341|NCT02495844|Experimental|UCB0942|UCB0942/UCB0942
3114342|NCT02495844|Placebo Comparator|Placebo|Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).
3114343|NCT02495857|Experimental|Hyaluronate Injectable Viscosupplement|Hyaluronate Injectable Viscosupplement (1% sodium hyaluronate). IA injection to the knee once weekly for 3 weeks
3114344|NCT02495857|Active Comparator|Euflexxa IA injection|Euflexxa IA injection to the knee once weekly for 3 weeks
3114345|NCT02495857|Placebo Comparator|Placebo|Placebo (normal saline). IA injection to the knee once weekly for 3 weeks
3114346|NCT02495883|Other|Essential Tremor Group|Patients will be randomized to start in one of two treatment arms: 1) 50ml of 40% ethanol or 2) Propranolol SR 60-120mg. In patients who receive ethanol first, they will return for a second visit when they will receive Propranolol, and vice versa. Ethanol will be administered to participants diagnosed with Essential Tremor during the study visit, whereas patients receiving Propranolol SR will be administered daily over an estimated period of two weeks prior to the fMRI visit.
3114347|NCT02495883|No Intervention|Health Volunteer Group|Healthy Volunteers will receive no interventions.
3114348|NCT02495948|Other|AOA then ULTRA|Lotrafilcon B contact lenses worn first, followed by samfilcon A contact lenses. Each product worn bilaterally (in both eyes) for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
3114349|NCT02495948|Other|ULTRA then AOA|Samfilcon A contact lenses worn first, followed by lotrafilcon B contact lenses. Each product worn bilaterally for a minimum of 5 days/week, 8 hours/day for 30 days in a daily wear modality.
3114350|NCT02496000|Placebo Comparator|Placebo Comparator|three identical capsules containing placebo
3114351|NCT02496000|Experimental|ORMD-0801 Dose 1|three identical capsules, as follows: capsule #1: one half of Dose 1 capsule #2: one half of Dose 1 capsule #3: placebo
3114352|NCT02496000|Experimental|ORMD-0801 Dose 2 = 1.5 * Dose 1|three identical capsules, as follows: capsule #1, 2, and 3: one half of Dose 1
3114353|NCT02496091||ATLANTIS Abutment|The investigational product (ATLANTIS abutment) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
3469264|NCT03888547|Experimental|OT-HAWP|"The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules:~Week 1: Sleep Hygiene Week 2: Fatigue Management Week 3: Cancer-related cognitive impairments Week 4: Stress Management Each session will last 1.5 hours (45 minutes of group education and 45 minutes of individual modifications and strategy recommendations."
3114354|NCT02496221|Experimental|Albiglutide / Placebo or Placebo / Albiglutide|In treatment period 1, subjects will receive Albiglutide 50 mg or Placebo subcutaneously (SC) after fasting overnight for at least 10 hours according to randomization schedule on Day 1. Subject will also receive CCK (Kinevac) infusion intravenously for a period of 50 minutes after fasting overnight for at least 10 hours on Day 4. After washout period of a minimum of 42 days in treatment period 2, subjects will receive same treatment according to randomization schedule in a cross-over fashion
3114355|NCT02496533|No Intervention|No Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before and after imaging. The anxiety VAS will be repeated after the imaging procedure. Subjects in this arm will not receive the hand massage prior to the imaging procedure.
3114356|NCT02496533|Experimental|Hand Massage|Subjects in this arm will complete rate their anxiety by visual analog scale (VAS). Blood pressure, pulse and respiration will be recorded before massage, after massage but before imaging, and after imaging.The subjects will receive hand massage prior to the imaging procedure. The anxiety VAS will be repeated after the imaging procedure.
3114357|NCT02496702|Experimental|Training|"The intervention is done in the form of groups of 4-5 participants per set of tiles, with 2-3 set of tiles at a time. As more set can be used it is possible to make groups of more people. The training will consist of 1.5-3 minutes of training (depending on the game) on tiles and the rest while the other 2-3 participants train (4-6 minutes of break). Then the participants will train for 1.5-3 minutes again until each participant have received a total of 13 minutes of training.~The intervention will be done 2 times a week for 12 weeks, each session lasting 1 hour and each participant receiving 13 minutes of training each time (see training plan)."
3114358|NCT02496702|No Intervention|Control|No training.
3114359|NCT02496767|Placebo Comparator|Group 1 - Placebo|Day 1 through Week 48: 2 placebo tablets twice daily
3114360|NCT02496767|Experimental|Group 2 - 250 mg tirasemtiv|Day 1 through Week 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM
3114361|NCT02496767|Experimental|Group 3 - 375 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the PM; Weeks 3 through 48: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
3114362|NCT02496767|Experimental|Group 4 - 500 mg tirasemtiv|Day 1 through Week 2: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in PM; Weeks 3 and 4: 1 tablet of tirasemtiv (125 mg) and 1 tablet of matching placebo in the AM and 2 tablets of tirasemtiv (250 mg) in the PM; Weeks 5 through 48: 2 tablets of tirasemtiv (250 mg) in the AM and 2 tablets of tirasemtiv (250 mg) in the PM
3114363|NCT02496884|Experimental|M-CKD DS-5565 7.5 mg BID|Patients with moderate chronic kidney disease (M-CKD) randomized to receive DS-5565 BID during the treatment period.
3114364|NCT02496884|Experimental|S-CKD DS-5565 7.5 mg QD|Fibromyalgia patients with severe chronic kidney disease (S-CKD) randomized to receive a DS-5565 7.5 mg tablet once per day (QD), and a placebo tablet (no drug) QD, for a total of 7.5 mg DS-5565
3114365|NCT02496884|Placebo Comparator|M-CKD Placebo|Patients with M-CKD randomized to receive placebo twice daily (BID) during the treatment period.
3114366|NCT02496884|Placebo Comparator|S-CKD Placebo|Patients with S-CKD randomized to receive placebo once daily (QD) during the treatment period.
3114367|NCT02497001|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg ex-actuator|BGF MDI 320/14.4/9.6 μg,Budesonide, Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
3114368|NCT02497001|Experimental|GFF MDI (PT003) 14.4/9.6 μg ex-actuator|GFF MDI 14.4/9.6 μg ex-actuator Glycopyrronium, Formoterol Fumarate Inhalation Aerosol
3114369|NCT02497001|Experimental|BFF MDI (PT009) 320/9.6 μg ex-actuator|BFF MDI 320/9.6 μg, Budesonide, Formoterol Fumarate Inhalation Aerosol
3114370|NCT02497001|Active Comparator|Symbicort|Symbicort® Turbuhaler® (TBH) Inhalation Powder 200/6 μg
3114371|NCT02497040|Experimental|bupivacaine,levobupivacaine|20 ml of 0.5% bupivacaine 20 ml of 0.5% levobupivacaine
3114372|NCT02497040|Active Comparator|levobupivacaine|20 ml of 0.5% levobupivacaine saline as a placebo
3114373|NCT02497040|Active Comparator|bupivacaine|20 ml of 0.5% bupivacaine saline as a placebo
3114374|NCT02497235|Experimental|TAK-935|A single dose of TAK-935 600 milligram (mg), oral solution on Day 1 as a starting dose and up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]MNI-792 with a mass of up to 5 microgram (mcg), injection intravenously (IV), prior to each PET imaging at Baseline, 45 minutes and 10 hours post-TAK-935 dose. Subsequent dose of TAK-935 oral solution and timing of PET imaging will be based on safety, tolerability and occupancy data from previous level participants.
3114375|NCT02497287|Experimental|Intranasal Esketamine plus oral antidepressant|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg). Participants greater than or equal to (>=) 65 will start at a dose of 28 mg on Day 1. Direct-entry participants will initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1; transferred-entry participants will continue the same oral antidepressant from ESKETINTRD3005. Optimization/Maintenance Phase: Participants will self-administer esketamine (56mg or 84mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) intranasally once per week for 4 weeks; transferred entry responder subjects from ESKETINTRD3005 will start at a dose of 28 mg in the first week. All participants will continue their same oral antidepressant during this phase.
3114376|NCT02497391|Experimental|Evacetrapib Reference (R)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
3114377|NCT02497391|Experimental|Evacetrapib Test 1 (T1)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
3114378|NCT02497391|Experimental|Evacetrapib Test 2 (T2)|Single oral dose of 130 mg evacetrapib tablet given one time during one study period.
3114379|NCT02497404|Experimental|5 Azacytidine|Patients will be given a five day course of subcutaneous 5-azacytidine, followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor.
3469265|NCT03888404||Underlying Cohort|"The study will recruit and follow a prospective cohort of women at risk of pregnancy for one year."
3114380|NCT02497469|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 milligram (mg), infusion, intravenously over 30 minutes on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46. Adalimumab placebo-matching injection, subcutaneously on Day 1, Week 2, and every 2 weeks thereafter up to Week 50.
3114381|NCT02497469|Active Comparator|Adalimumab SC 160/80/40 mg|Adalimumab 160 mg, injection, subcutaneously on Day 1, adalimumab 80 mg, injection, subcutaneously at Week 2, then adalimumab 40 mg, injection, subcutaneously every 2 weeks thereafter up to Week 50. Vedolizumab placebo-matching infusion, intravenously on Day 1 and Weeks 2, 6, 14, 22, 30, 38, and 46.
3114382|NCT02497612|Experimental|Ferroquine (up to 400 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the body weight (BW), participants received orally a single dose of ferroquine (FQ) capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of artefenomel (OZ439) (maximum dose up to 800 milligrams [mg]) oral suspension as follows: BW greater than or equal to (>=) 35 kilograms (kg): FQ 400 mg + OZ439 800 mg; BW >=24 kg to less than (<) 35 kg: FQ 300 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 200 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 150 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 100 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 75 mg + OZ439 150 mg.
3114383|NCT02497612|Experimental|Ferroquine (up to 600 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 600 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 450 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 300 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 225 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 150 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 115 mg + OZ439 150 mg.
3114384|NCT02497612|Experimental|Ferroquine (up to 900 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 900 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 675 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 450 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 335 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 225 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 170 mg + OZ439 150 mg.
3114385|NCT02497612|Experimental|Ferroquine (up to 1200 mg) + Artefenomel (up to 800 mg)|On Day 0, based on the BW, participants received orally a single dose of FQ capsules or oral suspension (along with matching placebo, as applicable to maintain blinding) and a single dose of OZ439 (maximum dose up to 800 mg) oral suspension as follows: BW >= 35 kg: FQ 1200 mg + OZ439 800 mg; BW >=24 kg to <35 kg: FQ 900 mg + OZ439 600 mg; BW >=15 kg to <24 kg: FQ 600 mg + OZ439 400 mg; BW >=10 kg to <15 kg: FQ 450 mg + OZ439 300 mg; BW >=7 kg to <10 kg: FQ 300 mg + OZ439 200 mg; >=5 kg to <7kg: FQ 225 mg + OZ439 150 mg.
3114386|NCT02497755|Experimental|Mobile app|Participants will install an app on their smartphone to add to their treatment for depression and/or anxiety.
3114387|NCT02497781|Experimental|ceftazidime-avibactam (CAZ-AVI)|CAZ-AVI to be administered every 8 hours as a 2-hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function)
3114388|NCT02497781|Active Comparator|Cefepime|Patients randomised to receive cefepime should receive the dose, schedule and infusion duration as recommended in the local prescribing information or as prescribed by the investigator. The maximum dose of cefepime in any single infusion should not exceed 2000 mg
3114389|NCT02497937|Experimental|GSK2798745 and Placebo|Each subject will be randomized to receive GSK2798745 2.4 milligrams (mg) and Placebo once daily for 7 days, each in one of the two treatment periods. Two treatment periods will be separated by a 14-day washout period.
3114390|NCT02497976|Active Comparator|Group 1: Experimental|Biological: Certolizumab pegol (Cimzia) 400 mg loading dose given subcutaneously at week 0, 2, and 4 followed by a maintenance dose at week 8
3114391|NCT02497976|Placebo Comparator|Group 2: Placebo Comparator|Placebo: given subcutaneously at week 0, 2, 4, and week 8
3114392|NCT02498067|Experimental|Intervention|Participants will complete a 10-15 minute questionnaire . After completing the questionnaire, a research assistant (RA) will provide a brief orientation to the rPlan app and use the rPlan app for up to 15 minutes. After viewing rPlan, participants will be asked a series of questions regarding the app's usability, helpfulness, and content appropriateness (10 min). The participant will also be given an STI test.
3114393|NCT02498236|Experimental|Oxytocin 6-84 IU|Subjects will be randomly assigned to one of eight doses of intranasal oxytocin.
3114394|NCT02498236|Placebo Comparator|Placebo|Subjects will be administered intranasal placebo using the same spray volume as experimental condition
3114395|NCT02498418|Experimental|Generic Rifaximin 200 mg Tablets|Participants will receive a generic rifaximin 200 mg tablet 3 times daily orally for 3 days.
3114396|NCT02498418|Active Comparator|Xifaxan 200 mg Tablets|Participants will receive a xifaxan 200 mg tablet 3 times daily orally for 3 days.
3114397|NCT02498418|Placebo Comparator|Placebo|Participants will receive a rifaximin placebo tablet 3 times daily orally for 3 days.
3114398|NCT02498483|Experimental|Acetaminophen Arm|Acetaminophen 15 mg/kg PO solution administered via syringe one time immediately post circumcision.
3114399|NCT02498483|No Intervention|Non-treatment Arm|Routine circumcision without acetaminophen.
3114400|NCT02498522|Experimental|metformin arm|83 patients will continue metformin until end of 1st trimester (14 weeks gestation)
3114401|NCT02498522|Placebo Comparator|control arm|83 patients will stop metformin at diagnosis of pregnancy ( 5-6 weeks gestation)
3114402|NCT02498600|Active Comparator|Group I (nivolumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
3114403|NCT02498600|Experimental|Group II (nivolumab, ipilimumab)|"INDUCTION: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes. Treatment repeats every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive nivolumab IV over 30 minutes every 2 weeks. Treatment repeats every 4 weeks for up to 21 cycles in the absence of disease progression or unacceptable toxicity."
3114404|NCT02498652|Experimental|RDEA3170 2.5 mg, 7.5 mg and 15 mg|RDEA3170 2.5 mg, 7.5 mg and 15 mg once daily (qd) in combination with allopurinol 300 mg (qd and twice daily (bid))
3114405|NCT02498652|Experimental|RDEA3170 5 mg, 10 mg and 20 mg|RDEA3170 5 mg, 10 mg 20 mg qd in combination with allopurinol 300 mg (qd and bid)
3114406|NCT02498678|No Intervention|control group|After verifying the absence of sevoflurane through the gas analyzer, TOF monitor mode starts with stimuli every 12 to 15 seconds. After 1 minute (min) stimulation, calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
3114407|NCT02498678|Experimental|tetanus group|After verifying the absence of sevoflurane through the gas analyzer, a 50-Hz tetanic stimulation will be applied for 5 s and followed after 1 min by TOF stimulation every 15 s. After 1 minute (min) calibration and supramaximal stimulation will be ensured by the built-in calibration function (CAL 2) of the TOF-Watch®. The stability of the response will be documented by at least 2 to 5 min [< 5% variation in the first response (T1) in the TOF]. Monitoring of neuromuscular junction will be held until recovery of the TOF ratio to 0.9 (90%), an expected average of 60 minutes.
3114408|NCT02498769|Experimental|Epicardial Botulinum|After instituting cardiopulmonary bypass (CPB), botulinum toxin injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 50U (1mL) of botulinum toxin (OnabotulinumtoxinA, Botox®). After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
3114409|NCT02498769|Placebo Comparator|Epicardial Placebo|After instituting cardiopulmonary bypass (CPB), placebo (normal saline) injections will be performed by the surgeon as follows: Using a standard sterile insulin syringe with a 27g needle, surgeons will inject each of the epicardial fat pads with 1mL of normal saline. After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge.
3114410|NCT02498821|Other|Standard of Care (Chest X-ray)|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using standard of care (Chest X-ray).
3114411|NCT02498821|Other|Sherlock 3CG® TCS|Correct placement of the Peripherally Inserted Central Catheter (PICC) will be confirmed using Sherlock 3CG® TCS magnetic tracking PICC placement and ECG-based tip confirmation.
3114412|NCT02498834|Experimental|Educational Video and Question Prompt List|Parents and adolescents in this group will watch a short educational video in English or Spanish on an iPad about the importance of encouraging adolescents to ask questions and to be involved during their pediatric asthma visits to improve their self-management skills. Also, the adolescents in this group will be handed a question prompt list to complete, which will be collected after the medical visit.
3114413|NCT02498834|No Intervention|Control group|Standard of care will be used
3114414|NCT02499029|Experimental|N-Acetylcysteine|Eligible participants were randomized to either NAC (2400 mg/day) or placebo for 8 weeks. The starting dose of NAC was 1200 mg twice daily (2400 mg/day). All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance.
3114415|NCT02499029|Placebo Comparator|Placebo|Identical appearing placebo capsules were dispensed. All NAC and placebo capsules contained riboflavin 25 mg, which was used as a biomarker for medication compliance. Study medications (USP-grade NAC and matched placebo capsules) dispensed to participants by the medical clinician or study staff. Treatment assignment followed a pre-arranged randomization scheme and was carried out by study personnel at the pharmacy (i.e., personnel not involved in clinical management of participants to preserve the double-blind design).
3114416|NCT02499081|Experimental|Ixazomib|Ixazomib 4.0 mg given on days 1, 8 15, 22 of a 28 day cycle maximum of 6 cycles.
3114417|NCT02499120|Experimental|Palbociclib plus Cetuximab|Palbociclib, 125 mg, orally once daily (QD) with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
3114418|NCT02499120|Active Comparator|Placebo plus Cetuximab|Placebo orally QD with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle; in combination with Cetuximab, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
3114419|NCT02499146|Experimental|Cohort 1|Combination therapy of palbociclib and letrozole
3114420|NCT02499159|Experimental|Exparel|Liposomal Bupivicaine (Exparel) - 266 mg, 20 mL total, diluted at surgeon's discretion, Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
3114421|NCT02499159|Active Comparator|0.25% standard bupivicaine|Bupivicaine - 0.25%, 20 mL total. Two doses of 10 mL each, into two separate incisions, delivered via 22 gauge needle.
3114422|NCT02499172|Experimental|Cohort 1|Cohort 1: Women who were pregnant and received at least one dose of ShancholTM during the mass OCV vaccination campaign.
3114423|NCT02499172|No Intervention|Cohort 2|Cohort 2: Women who received at least one dose and who became pregnant after the mass vaccination campaign; hence their fetuses were not exposed to the vaccine.
3114424|NCT02499172|No Intervention|Cohort 3|Cohort 3: Women who were pregnant in Chikwawa District at the time of the vaccination campaign in Nsanje District, but who did not receive the vaccine during the campaign.
3114425|NCT02499172|No Intervention|Cohort 4|Cohort 4: Women who become pregnant in Chikwawa District after the vaccination campaign in Nsanje District, and who did not receive the vaccine during the campaign.
3114426|NCT02499263||Participants with Ulcerative Colitis (UC)|Adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg every other week per the Korean label in participants with active moderate-to-severe UC.
3114427|NCT02499328|Experimental|Part A1: AZD9150 / MEDI4736|Patients allocated in cohort of arm A1 (AZD9150/MEDI4736 will be evaluated for DLT until an MTD is achieved.
3114428|NCT02499328|Experimental|Part A2: AZD5069 / MEDI4736|Patients allocated in cohort of arm A2 (AZD5069/MEDI4736 will be evaluated for DLT until an MTD is achieved.
3114429|NCT02499328|Experimental|Part B1:AZD9150+MEDI4736:PDL1 pretreated|Patients in arm B1 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3114430|NCT02499328|Experimental|Part B2:AZD5069+MEDI4736:PDL1 pretreated|Patients in arm B2 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3114431|NCT02499328|Experimental|Part B3: AZD9150+MED4736:naiive 2L|Patients in arm B3 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3114432|NCT02499328|Experimental|Part B4:AZD5069+MEDI4736:naiive patients|Patients in arm B4 will be evaluated for efficacy until disease progression and then followed-up for safety and survival.
3114433|NCT02499328|Experimental|Part B5: AZD9150 in naiive patients|Patients in arm B5 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
3114434|NCT02499328|Experimental|Part B6:AZD5069 in naiive patients|Patients in arm B6 will be evaluated for efficacy until disease progression and then allowed to receive additional MEDI4736 and followed for safety and survival
3114435|NCT02499328|Experimental|Part A3: AZD5069/MEDI4736|Patients allocated in cohort of arm A3 (AZD5069/MEDI4736) will be evaluated for DLT and viability as alternate dosing option for Phase 2 studies
3114436|NCT02499328|Experimental|Part A4: AZD9150/Treme/MEDI4736|Patients allocated in cohort of arm A4 (AZD9150/treme/MEDI4736) will be evaluated for DLT and MTD
3114437|NCT02499328|Experimental|Part A5: AZD5069/Treme/MEDI4736|Patients allocated in cohort of arm A5 (AZD5069/treme/MEDI4736) will be evaluated for DLT and MTD.
3114438|NCT02499328|Experimental|Part A6: AZD9150/MEDI4736|Patients allocated in cohort of arm A6 (AZD9150/MEDI4736) will be evaluated for safety, PK and PD.
3114439|NCT02499328|Experimental|Part A7: AZD5069/MEDI4736|Patients allocated in cohort of arm A7 (AZD5069/MEDI4736) will be evaluated for safety, PK and PD.
3114440|NCT02499328|Experimental|Part B7: AZD9150+MEDI4736: naiive 1L|Patients in Arm B7 will be evaluated for efficacy until disease progression and then followed up for safety and survival
3114441|NCT02499328|Experimental|Part B8: AZD9150 (every other week)+MEDI4736: naive 1L|Patients in Arm B8 will be evaluated for efficacy until disease progression and then followed up for safety and survival
3114442|NCT02499380||Treatment|Patients treated with PneumRx Coil System
3114443|NCT02499406|Other|Skills group|Dialectical behavior therapy skills group
3114444|NCT02499497|Placebo Comparator|Placebo|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
3114445|NCT02499497|Active Comparator|LY2452473 Dose 1|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
3114446|NCT02499497|Active Comparator|LY2452473 Dose 2|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1 or LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
3114447|NCT02499497|Active Comparator|LY2452473 Dose 3|Subjects who meet the eligibility criteria, will be randomized, to either placebo, LY SARM Dose 1, LY SARM Dose 2 or LY SARM Dose 3 daily, oral per cycle.
3114448|NCT02499575|Active Comparator|Regional Block|Group A patients will receive only a pre-operative adductor canal block with 10 mL 0.5% ropivacaine plus a popliteal block with 30 mL 0.5% ropivacaine (total block 40 mL/200 mg).
3114449|NCT02499575|Experimental|Regional Block Plus Exparel|Group B patients will receive the standard of care pre-operative adductor and popliteal block as described (40 mL/200 mg of 0.5% ropivacaine) in addition to a postoperative pericapsular injection of Exparel using 106 mg (8 mL, equivalent to 120 mg bupivacaine HCl), per the same total dose as provided in manufacturer recommendations.
3114450|NCT02499692|Experimental|SYNERGYTM Coronary Stent System|Device:SYNERGY MONORAIL Everolimus-Eluting Platinum Chromium Coronary Stent System
3114451|NCT02499770|Experimental|trilaciclib + carboplatin/etoposide|All patients in part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3114452|NCT02499770|Experimental|trilaciclib/placebo + carboplatin/etoposide|All patients enrolled in part 2 will be randomized to receive either trilaciclib (G1T28) or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3114453|NCT02499783|Experimental|Placebo Induction Regimen|"Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6.~Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24."
3114454|NCT02499783|Experimental|Adalimumab Induction Regimen|"Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6.~Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24."
3469266|NCT03888404||Pregnancy Match Cohort, Pregnant Group|Women from the Underlying Cohort who become pregnant will be transferred into the Pregnancy Match Cohort to be followed for two years.
3469267|NCT03888404||Pregnancy Match Cohort, Not Pregnant Group|The study will also follow a comparison cohort of non-pregnant women from the Underlying Cohort, frequency matched to the pregnant participants on Desire to Avoid Pregnancy score and time at risk of pregnancy.
3114457|NCT02499952|Experimental|Experimental Arm|Pembrolizumab
3114458|NCT02500043|Experimental|TAS-102+BSC|Participants received 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice daily (BID) for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until a discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
3114459|NCT02500043|Experimental|Placebo+BSC|Participants received 35 mg/m^2 of matching placebo for TAS-102 tablets orally BID for 5 days per week (i.e., from Days 1 to 5 and Days 8 to 12) for 2 weeks followed by 14 days rest in each 28-day cycle along with BSC until discontinuation criterion (participant withdrawal, disease progression, irreversible treatment-related Grade 4 non-hematologic event, physician's decision, pregnancy or death) was met.
3114460|NCT02500056|Active Comparator|OM group|Optilene LP mesh
3114461|NCT02500056|Active Comparator|UM group|Ultrapro mesh
3114462|NCT02500368|Experimental|silicone hydrogel lens (test)|Participants were randomized to wear silicone hydrogel lens (test) for 1 week during the cross over study.
3114463|NCT02500368|Active Comparator|enfilcon A lens (control)|Participants were randomized to wear enfilcon A lens (control) for 1 week during the cross over study.
3114464|NCT02500537|Experimental|Abdominal Procedures|"Abdominal procedures may include, but are not limited to, laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and biliopancreatic diversion, as well as hepatic and pancreatic resection.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
3114465|NCT02500537|Experimental|Thoracic Procedures|"Thoracic procedures may include, but are not limited to wedge resection and lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures.~Device: Endo GIA™ Reinforced Reload with Tri-Staple™ Technology"
3114466|NCT02500550|Experimental|ATIR101|
3114467|NCT02500602|Experimental|Doxazosin|Participants randomly assigned to receive doxazosin (target dose of 16 mg/day). Doxazosin will be initiated at 1 mg/day for the first week, 2mg/day for the second week, 4mg/day for the third week, 8mg/day for the fourth week, and then increase to 16 mg/day for the remaining eight weeks (as tolerated). Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
3114468|NCT02500602|Placebo Comparator|Placebo|Participants randomly assigned to placebo. Research staff administered the study medication at the weekly visits, and participants were given take-home doses of the medication to self-administer on the days in between study visits.
3114469|NCT02500628|Experimental|Fibromyalgia|Fibromyalgia (subgroups: opioid responsive, opioid resistant, opioid intolerant) Metformin 500 mg orally in the morning
3114470|NCT02500628|Experimental|Antipsychotic use|Antipsychotic use (subgroups: no side effects, dyskinesia, weight gain) Metformin 500 mg orally in the morning
3114471|NCT02500641|Experimental|Febuxostat 80/120 mg/day|"Febuxostat 80/120 mg film coated tablets.The initial daily dose is 80 mg given orally. In case a patient has serum urate level 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained during the study treatment period.~To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg quaque die (QD ) or in case of colchicine intolerance, Naproxen 550 mg bis in die (BID) with Omeprazole (20-40 mg once daily), if indicated to be used."
3114472|NCT02500641|Active Comparator|Allopurinol 100 up to 600 mg/day|"Allopurinol 100/300 mg tablets.The initial daily allopurinol dose is 100 mg given orally, to be escalated of 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl.~The maximum dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg daily.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD or in case of colchicine intolerance, Naproxen 550 mg BID with Omeprazole (20-40 mg once daily), if indicated to be used."
3114473|NCT02500706|Experimental|Mealtime faster-acting insulin aspart and insulin degludec|
3114474|NCT02500706|Active Comparator|Mealtime NovoRapid® and insulin degludec|
3114475|NCT02500706|Experimental|Postmeal faster-acting insulin aspart and insulin degludec|
3114476|NCT02500719|Experimental|Healthy Participants|A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
3114477|NCT02500719|Experimental|PTSD Participants|A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.
3114478|NCT02500732|Placebo Comparator|Placebo|Placebo capsule to be given the night before the study tilt, and the morning of the study tilt test.
3114479|NCT02500732|Active Comparator|Atomoxetine|Atomoxetine 40mg PO to be given the night before the study tilt, and the morning of the study tilt test.
3114480|NCT02500758|Experimental|Parachlorometaxylenol|Reducing bacterial load after preoperative surgical scrubbing using 3% PCMX. Both hands have been prepared by preparatory handwash.
3114481|NCT02500758|Active Comparator|Clorhexidine digluconate|Reducing bacterial load after preoperative surgical scrubbing using 4% CHG. Both hands have been prepared by preparatory handwash.
3114482|NCT02500797|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress after 10 weeks on single agent nivolumab may elect to cross over to Arm II.
3114483|NCT02500797|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 30 minutes every 2 weeks. Cycles repeat every 42 days for up to 108 weeks in the absence of disease progression or unacceptable toxicity. Patients who progress by imaging during the first 12 weeks of therapy may continue treatment, at the discretion of the patient and treating investigator.
3114484|NCT02500836|Experimental|Cocaine HCI 4% Topical Solution|Cocaine HCl 4% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded, then the diagnostic procedure or surgery proceeds along with safety monitoring for at least 90 minutes after removal of the pledget(s). The subject will be followed for safety for seven days. The total number of pledgets used, and the amount of Cocaine HCl 4% topical solution used (1 mL per pledget) will be recorded.
3469268|NCT03888339|Active Comparator|Control group - Commercially available high abutments|Commercially available 2.5mm high abutments
3469269|NCT03888339|Experimental|Test group - Modified shape abutments|Modified shape 2.5mm high abutments (imitating the shape of 0.5mm short abutments)
3114485|NCT02500836|Experimental|Cocaine HCI 10% Topical Solution|Cocaine HCl 10% Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. If a pain score of 0 (zero) is recorded the application then proceed with the diagnostic procedure or surgery along with safety monitoring for at least 90 minutes post removal of pledgets, and, the subject will be followed for safety for at least seven days post solution application. The total number of pledgets used, and the amount of Cocaine HCl 10% topical solution used (1 mL per pledget) will be recorded.
3114486|NCT02500836|Placebo Comparator|Placebo Topical Solution|Placebo Topical Solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s), then the nasal site is tested with a Von Frey (or equivalent) filament (Size 5.88, about 60 grams of force) to determine and record whether the subject has a pain score of 0 (zero) (0 = No Pain, 10 = Unbearable pain) after treatment application compared to the Von Frey filament test right before treatment application. The subject will then exit the treatment portion of the trial and be followed for safety for seven days . The total number of pledgets used, and the amount of placebo solution used (1 mL per pledget) will be recorded. After a minimum of 90 minutes from the time of study drug pledget removal, the subjects may have their surgery or diagnostic procedure, and the treatment reverts to standard anesthetic management (e.g. application of lidocaine, tetracaine, bupivicaine or other suitable products at the discretion of the investigator).
3114487|NCT02500979|Experimental|Pramlintide acetate & regular insulin|Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL
3114488|NCT02500979|Placebo Comparator|Placebo and regular insulin|Placebo is similar sterile solution without pramlintide.
3114489|NCT02501135||Femoral Nerve Blocks|Patients who receive ropivacaine or bupivacaine during femoral nerve block.
3114490|NCT02501161|Experimental|Insulin degludec/liraglutide QD + OAD(s)|
3114491|NCT02501161|Active Comparator|insulin glargine QD + OAD(s)|
3114492|NCT02501265|Active Comparator|Varenicline Standard Protocol|Participant choses Varenicline-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Varenicline. Consistent with Varenicline Standard Treatment, 1 week prior to the TQD the participant will switch to active Varenicline and placebo Bupropion. Participant will continue active Varenicline and placebo Bupropion to 12 weeks post-TQD.
3114493|NCT02501265|Active Comparator|Nicotine Patch Standard Protocol|Participant choses Nicotine patch-based treatment and is then randomized to Standard Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts placebo Nicotine Patch. One week prior to TQD, participant will start placebo Bupropion. Consistent with Nicotine Patch Standard Treatment, participant will start active Nicotine Patch on TQD. Participant will continue active Nicotine Patch and placebo Bupropion to 12 weeks post-TQD.
3114494|NCT02501265|Experimental|Varenicline Adaptive Protocol|Participant chooses Varenicline treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Varenicline. Two weeks prior to TQD, cigarettes smoked per day is assessed. If the number of cigarettes smoked per day is reduced by >50%, the participant is considered a Varenicline responder, and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Varenicline non-responder and starts active Bupropion 1 week prior to TQD. Varenicline responders will continue active Varenicline and placebo Bupropion to 12 weeks post TQD. Varenicline non-responders will continue active Varenicline and active Bupropion to 12 weeks post TQD.
3114495|NCT02501265|Experimental|Nicotine Patch Adaptive Protocol|Participant choses Nicotine treatment and is randomized to Adaptive Treatment arm (N=75). Four weeks prior to target quit date (TQD), participant starts active Nicotine Patches. Two weeks prior to TQD, cigarettes smoked per day is assessed. If cigarettes smoked per day is reduced by >50%, the participant is considered a Nicotine Patch responder and starts placebo Bupropion 1 week prior to the TQD. If the participant DOES NOT reduce cigarettes smoked per day by >50%, the participant is considered a Nicotine Patch non-responder and starts active Bupropion 1 week prior to the TQD. Nicotine Patch responders will continue active Nicotine Patches and placebo Bupropion to 12 weeks post TQD. Nicotine Patch non-responders will continue active Nicotine Patches and Bupropion to 12 weeks post TQD.
3114496|NCT02501473|Experimental|Part 1: Local Radiation + G100 5μg/tumor|Part 1: Local radiation and G100 [glucopyranosyl lipid A stable emulsion, GLA-SE] at 5μg/tumor administered intratumorally (IT) into accessible tumors for up to 8 weeks.
3114497|NCT02501473|Experimental|Part 1: Local Radiation + G100 10μg/tumor|Part 1: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
3114498|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks.
3114499|NCT02501473|Experimental|Part 2: Local Radiation + G100 10μg/tumor+Pembrolizumab 200mg|Part 2: Local radiation and G100 at 10μg/tumor administered IT into accessible tumors for up to 8 weeks; pembrolizumab 200mg intravenously (IV) administered every 3 weeks (Q3W) IV for up to 2 years.
3114500|NCT02501473|Experimental|Part 2: Local Radiation, G100 20 μg/tumor in Large Tumors|Part 2: Local radiation and G100 at 20 μg/tumor administered IT into accessible large tumors [injectable lymphoma mass(es) ≥ 4 cm in total size] for up to 8 weeks.
3114501|NCT02501473|Experimental|Part 3: Local Radiation + G100 20μg/tumor|Part 3: Local radiation and G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks.
3114502|NCT02501473|Experimental|Part 4: G100 20μg/tumor and pembrolizumab 200mg|Part 4: G100 at 20μg/tumor administered IT into accessible tumors for up to 8 weeks and pembrolizumab 200mg IV and administered Q3W for up to 2 years.
3114503|NCT02501473|Experimental|Part 5: G100 + Rituximab 375mg/m^2|Part 5: G100 at 20, 40, 60, or 80μg/tumor administered IT for up to 6 weeks and rituximab administered as an IV infusion at 375mg/m^2 on Day 0 and then QW for up to 3 weeks.
3114504|NCT02501538|Experimental|Transcutaneous O2 device|Continuous diffusion of oxygen (CDO) (topical oxygen) therapy, which will be administered using a portable device.
3114505|NCT02501590||study|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
3114506|NCT02501590||control|"After the parents sign an informed consent form, they will fill out a demographic questionnaire. Than if the Beery VMI test was not yet administered, it would be performed, as well as the Developmental Coordination Disorder Questionnaire (DCD-Q). Surface electromyography electrodes will be placed on the Upper Trapezius, Extensor Carpi Radialis, and Biceps brachii of the child's dominant hand.~The subject will perform 4 copying tasks and 2 tracing tasks on a tablet placed once on a horizontal surface (while sitting) and once on a vertical surface (while standing)."
3114507|NCT02501629|Experimental|Reslizumab 110 mg|Reslizumab was administered by subcutaneous injection (sc) in a dosage of 110 mg (1.0 mL) every 4 weeks for a total of six doses.
3114508|NCT02501629|Placebo Comparator|Placebo|Matching placebo was administered by subcutaneous injection (sc) 1.0 mL every 4 weeks for a total of six doses.
3114509|NCT02501642|Experimental|Concussion Coach group|"After informed consent and randomization, participants will complete baseline study measures and will receive an iPod touch® with the Concussion Coach Explorer version"
3114510|NCT02501642|Other|Treatment as usual|Treatment as usual
3114511|NCT02501811|Experimental|Mesenchymal Stem Cells (MSC)|Target dose of 150 million MSCs
3114512|NCT02501811|Experimental|c-kit+ cells|Target dose of 5 million c-kit+ cells
3114513|NCT02501811|Experimental|Combination Cells (MSC and c-kit+ cells)|Target dose of 150 million MSCs and 5 million c-kit+ cells
3114514|NCT02501811|Placebo Comparator|Placebo (Plasmalyte A)|Plasmalyte A
3114515|NCT02501902|Experimental|Palbociclib + Nab-Paclitaxel|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle. Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
3114516|NCT02501928|Experimental|Fesoterodine PR 4 mg|Fesoterodine PR 4 mg for 28 or 40 weeks in open-label treatment period
3114517|NCT02501928|Experimental|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg for 28 or 40 weeks in open-label treatment period
3114518|NCT02501928|Experimental|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg for 28 weeks in open-label treatment period
3114519|NCT02501928|Experimental|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg for 28 weeks in open-label treatment period
3114520|NCT02502019|Experimental|HEMOBLAST|All subjects will have the investigational device implanted
3114521|NCT02502071|Experimental|Sodium Bicarbonate|All participants will receive 2 doses of 1950mg Sodium Bicarbonate
3114522|NCT02502097|Experimental|Gefapixant>Placebo Pre-Amendment 3|Gefapixant 50 mg twice daily (BID) for 10 days, then 150 mg BID for 4 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
3114523|NCT02502097|Experimental|Placebo>Gefapixant Pre-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 10 days, then 150 mg for 4 days in Period 2
3114524|NCT02502097|Experimental|Gefapixant>Placebo Post-Amendment 3|Gefapixant 50 mg twice daily (BID) for 14 days in Period 1, followed by a 14-21 day washout period, then placebo BID for 14 days in Period 2
3114525|NCT02502097|Experimental|Placebo>Gefapixant Post-Amendment 3|Placebo BID for 14 days in Period 1, followed by a 14-21 day washout period, then gefapixant 50 mg BID for 14 days in Period 2
3114526|NCT02502149|Experimental|rFVIIIFc (15K scale) 1000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc (15K scale) 1000 IU vial at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 1000 IU vial.
3114527|NCT02502149|Experimental|rFVIIIFc (15K scale) 6000 IU vial|Single injection of rFVIIIFc (current 2K scale) followed by 2 single injections of rFVIIIFc high strength vial (15K scale) at PK2 and PK3 timepoints. Participants will be on prophylaxis regimen along with treatment for bleeding episodes for 26 weeks of treatment period using the rFVIIIFc (15K scale) 6000 IU vial.
3114528|NCT02502461|Sham Comparator|standard care|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
3114529|NCT02502461|Active Comparator|cuff palpation|Intervention: Subject intubated in routine fashion by the attending anesthesiologist with cuffed endotracheal tube; endotracheal tube cuff inflated; inflated cuff palpated and depth adjusted accordingly; tube taped in place; depth measured bronchoscopically; patient asked to rate soreness of throat on verbal response scale when awake postoperatively.
3114530|NCT02502487|Placebo Comparator|Tetracaine gel group|Dorsal penile nerve block with saline and tetracaine gel into urethra before rigid cystoscopy
3114531|NCT02502487|Experimental|Dorsal penile nerve block group|Dorsal penile nerve block with ropivacaine and plain lubricating gel into urethra before rigid cystoscopy
3114532|NCT02502487|Experimental|Combination group|Dorsal penile nerve block with ropivacaine and tetracaine gel into urethra before rigid cystoscopy
3114533|NCT02502526|Experimental|CVS with 45° Balanced Tip|Centurion® Vision System, 45° Balanced Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3114534|NCT02502526|Active Comparator|CVS with 45° MFK Tip|Centurion® Vision System, 45° MFK Tip used with INTREPID® Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3114535|NCT02502526|Active Comparator|IVS with 45° MFK Tip|lnfiniti® Vision System, 45° MFK Tip used with Ultra Infusion Sleeve in one time routine surgical procedure followed by 3 months (+/- 14 days) of post-operative follow-up
3469270|NCT03888222|Placebo Comparator|Placebo|"Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) capsule orally once daily for 3 months (90 days)."
3114536|NCT02502734|Experimental|Sequence 1: Fluticasone furoate 50 μg and then placebo|Subjects will receive oral inhalation of FF 50 μg administered via ELLIPTA, once daily (OD) for 14 days +/- 4 days in Period 1 followed by oral inhalation of placebo administered via ELLIPTA, OD for 14 days +/- 4 days in Period 2. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
3114537|NCT02502734|Experimental|Sequence 2: Placebo and then fluticasone furoate 50 μg|Subjects will receive oral inhalation of placebo administered via ELLIPTA OD for 14 days +/- 4 days in Period 1 followed by receive oral inhalation of FF 50 μg administered via ELLIPTA, OD for 14 days +/- 4 days. The two treatment periods will be separated by a two-week wash-out period. Additionally all subjects will be provided salbutamol inhaler to be used for symptomatic relief of asthma symptoms during both the run-in and treatment periods as needed.
3114538|NCT02502864|Experimental|Standard of Care + Surveys|Standard of Care Docetaxel and Cyclophosphamide (TC) Chemotherapy + Surveys. TC Regimen with Function Assessment of Cancer Therapy (FACT) Surveys. All participants will receive TC for cycle 1 with subsequent cycles repeated every 3 weeks for a total of 4 cycles. All initial dosing will be based on actual body weight and height. Participants will receive up to 4 doses of chemotherapy. Following their 4th dose of chemotherapy, or the last dose of chemotherapy in which blood level monitoring was performed, participants will be assessed for side effects from the chemotherapy and complete their final written 53 question survey about their quality of life.
3114539|NCT02503085|Experimental|Nurofen for Children® (fasted)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fasted condition
3114540|NCT02503085|Experimental|Nurofen for Children® (fed)|Nurofen for Children® suspension 400 mg/20 mL single-oral dose under fed condition
3114541|NCT02503085|Active Comparator|Algifor Dolo Junior® (fasted)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fasted condition
3114542|NCT02503085|Active Comparator|Algifor Dolo Junior® (fed)|Algifor Dolo Junior® suspension 400 mg/20 mL single-oral dose under fed condition
3114543|NCT02503202|Experimental|V920 Consistency Lot A|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
3114544|NCT02503202|Experimental|V920 Consistency Lot B|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
3114545|NCT02503202|Experimental|V920 Consistency Lot C|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
3114546|NCT02503202|Experimental|V920 High-dose Lot|Participants received a 1.0 mL intramuscular injection of V920 on Day 1
3114547|NCT02503202|Placebo Comparator|Placebo to V920|Participants received a 1.0 mL intramuscular injection of placebo on Day 1
3114548|NCT02503215|Experimental|Compression Stockings|Patients will wear graduated lower limb compression stockings for a week. The investigators will evaluate if such procedure will cause better sleep performance
3114549|NCT02503254|Experimental|CHTP 1.0|Ad libitum use of the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) for 5 days in confinement
3114550|NCT02503254|Active Comparator|Conventional cigarette (CC)|Ad libitum use of subject's own preferred brand of CC for 5 days in confinement
3114551|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL Monthly for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every month for 12 consecutive months.
3114552|NCT02503332|Experimental|Pegcetacoplan 15 mg/100 µL EOM for 12 months|A single dose of 15 mg pegcetacoplan/100 µL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month (EOM) for 12 consecutive months.
3114553|NCT02503332|Sham Comparator|Sham Monthly for 12 months|Subjects will receive a Sham procedure every month for 12 consecutive months.
3114554|NCT02503332|Sham Comparator|Sham EOM for 12 months|Subjects will receive a Sham procedure every other month (EOM) for 12 consecutive months.
3114555|NCT02503410|Active Comparator|Usual care|Subjects receive physical therapy for low back pain as typically prescribed in the clinic.
3114556|NCT02503410|Experimental|Interactive gaming|Subjects participate in an intervention combining usual care and home-based exercises using the Valedo system.
3114557|NCT02503501|Experimental|Insulin Glulisine|Insulin Glulisine 20 IU (0.1ml/10 units in each nostril) per intranasal dose, 2 times per day for 6 months
3114558|NCT02503501|Placebo Comparator|Placebo|Saline 20 IU (0.1 ml in each nostril) per intranasal dose, 2 times per day for 6 months
3114559|NCT02503540|Other|Aflibercept|Monthly aflibercept for 6 months and then every other month for 6 months.
3114560|NCT02503735|Other|12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)|10 patients with hepatitis C (HCV) and HCV-associated CKD that will receive 12 weeks treatment with Sofosbuvir/Ledipasvir (400mg/90mg)
3114561|NCT02503787|Other|Open label treatment|Spinal Cord Stimulation (SCS)
3114562|NCT02503852|Experimental|Fat + High Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 1,000,000 ADRC prepared with the Celution System per square centimeter of scalp.
3114563|NCT02503852|Experimental|Fat + Low Dose ADRC|Kerastem Therapy includes micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System + 500,000 ADRC prepared with the Celution System per square centimeter of scalp.
3114564|NCT02503852|Active Comparator|Fat Alone|Micro-liposuction followed by subcutaneous scalp injection of purified adipose prepared with the Puregraft System per square centimeter of scalp.
3114565|NCT02503852|Placebo Comparator|No Fat Control|Micro-liposuction followed by subcutaneous scalp injection of normal saline per square centimeter of scalp.
3114566|NCT02503865|Active Comparator|Conventional Patient group|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin
3114567|NCT02503865|Experimental|"Analimentary detoxication Weight loss"|Vegetables and salt diet
3114568|NCT02503865|No Intervention|Healthy people|64 healthy people
3114569|NCT02503982|Experimental|Solid Organ Transplanted children|Intervention: treatment with prophylactic oral valganciclovir with a fixed dose of 17 mg/kg once daily for prophylaxis, and stratified dose reductions for impaired renal function. Max dose was 900 mg.
3114570|NCT02504073||PT's working in stroke in NW-Switzerland|"54 Physiotherapists (PT's) working in north-west Switzerland (at Bruderholzspital, RehaB Basel, Klinik Tschugg, Reha Rheinfelden, RehaClinic Zurzach) are asked to analyse videos of 6 hemiplegic patients when walking. They are asked to write down their main observations, the major problem and hypotheses about how this major problem is produced.~There is no intervention."
3114571|NCT02504216|Experimental|Rivaroxaban|Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)
3114572|NCT02504216|Placebo Comparator|Placebo|Rivaroxaban-placebo orally twice daily
3114573|NCT02504268|Experimental|Combination Therapy: Abatacept + Methotrexate|Abatacept 125 mg subcutaneous injection once per week + Methotrexate at least 15mg per week tablet or capsule orally once per week
3114574|NCT02504268|Active Comparator|Methotrexate treatment|Methotrexate at least 15mg per week tablet or capsule orally
3114575|NCT02504268|Placebo Comparator|Abatacept Placebo|Placebo for Abatacept subcutaneous injection once per week
3114576|NCT02504268|Placebo Comparator|Methotrexate Placebo|Placebo to match Methotrexate capsule orally once per week
3114577|NCT02504294|Other|Epoetin Hospira|Epoetin Hospira Arm
3114578|NCT02504294|Other|Standard of Care|Standard of care arm
3114579|NCT02504320|Experimental|Treatment Sequence ABDC|Febuxostat XR 80 mg capsule Formulation 1 (F1), orally, once on Day 1 of Period 1 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 2 (F2), orally, once on Day 1 of Period 2 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 4 (F4), orally, once on Day 1 of Period 3 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule Formulation 3 (F3), orally, once on Day 1 of Period 4 (C).
3114580|NCT02504320|Experimental|Treatment Sequence DACB|Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 1 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1 orally, once on Day 1 of Period 2 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 3 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 4 (B).
3114581|NCT02504320|Experimental|Treatment Sequence CDBA|Febuxostat XR 80 mg capsule F3, orally, once on Day 1 of Period 1 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4 orally, once on Day 1 of Period 2 (D), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 3 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 4 (A).
3114582|NCT02504320|Experimental|Treatment Sequence BCAD|Febuxostat XR 80 mg capsule F2, orally, once on Day 1 of Period 1 (B), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F3 orally, once on Day 1 of Period 2 (C), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F1, orally, once on Day 1 of Period 3 (A), followed by at least a 7-day washout period, followed by Febuxostat XR 80 mg capsule F4, orally, once on Day 1 of Period 4 (D).
3114583|NCT02504424|Experimental|AeroForm Tissue Expander|AeroForm Tissue Expansion inflation with carbon dioxide by remote control
3114584|NCT02504502|Experimental|Enhanced genomic report|routine clinical care for return of results per whole genome sequencing study with enhanced genetic test results report developed through phase 1 and 2 of this study
3114585|NCT02504502|Other|Control with delayed access|routine clinical care for return of results per whole genome sequencing study and no intervention through three months. This arm will crossover to receipt of enhanced report upon completion of baseline and 3 month post-baseline followup surveys. Participants in this arm will complete a third survey at 3 months post receipt of enhanced report
3114586|NCT02504541|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate 50 mg / 75 mg / 100 mg administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.
3114587|NCT02504554|Experimental|Oral Group|This group will receive all treatments orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
3114588|NCT02504554|Experimental|Rectal Group|This group will receive some treatments rectally and some orally. The treatments include a combination of Vancomycin, MoviPrep, Prilosec, and human fecal material; processed, frozen.
3114589|NCT02504619|Experimental|CordIn|Transplantation of CordIn
3114590|NCT02504645|Active Comparator|IPP-201101 200-mcg plus SOC|Patients randomly assigned to IPP-201101 will be administered a dosage of 200 mcg subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
3114591|NCT02504645|Placebo Comparator|PLACEBO plus SOC|Patients randomly assigned to placebo will be administered placebo subcutaneously (sc) every 4 weeks for 48 weeks (a total of 13 doses will be administered).
3114592|NCT02504671|Experimental|GSK3196165, Dose 1 + MTX and Folic acid|Subject will receive GSK3196165 Dose 1 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114593|NCT02504671|Experimental|GSK3196165, Dose 2 + MTX and folic acid|Subject will receive GSK3196165 Dose 2 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114594|NCT02504671|Experimental|GSK3196165, Dose 3 + MTX and folic acid|Subject will receive GSK3196165 Dose 3 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114595|NCT02504671|Experimental|GSK3196165, Dose 4 + MTX and folic acid|Subject will receive GSK3196165 Dose 4 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114596|NCT02504671|Experimental|GSK3196165, Dose 5 + MTX and folic acid|Subject will receive GSK3196165 Dose 5 (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114597|NCT02504671|Placebo Comparator|Placebo + MTX and folic acid|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (at a dose between 15-25 mg/week) and folic acid >=5 mg/week.
3114598|NCT02504723|Experimental|Cyanoacrylate injection plus carvedilol|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
3114599|NCT02504723|Active Comparator|Cyanoacrylate injection|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
3114600|NCT02504775|Experimental|Tylenol® Caplets, then Mejoral® 500 Tablets|Participants will first receive one tablet [500 milligram (mg) of paracetamol] of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
3114601|NCT02504775|Experimental|Mejoral® 500 Tablets, then Tylenol® Caplets|Participants will first receive one tablet (500 mg of paracetamol) of Mejoral® 500 tablets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting. After a washout period of 72 h, they then will receive one tablet (500 mg of paracetamol) of Tylenol® Caplets, orally with 250 mL of water at room temperature, in a single dose, under minimum 10 h fasting.
3114602|NCT02504827|Experimental|IV Ceftazidime/Avibactam|Ceftazidime/avibactam 2.5gm IV q8h for 3 doses
3114603|NCT02504892|Experimental|Birt-Hogg-Dube Syndrome|Birt-Hogg-Dube Syndrome (BHD)-associated renal tumors
3114604|NCT02504892|Experimental|Sporadic chromophobe renal tumors|Sporadic chromophobe renal tumors
3114605|NCT02504931|Experimental|Sertraline|"Subjects will receive a fixed dose of 150 mg sertraline per day. Sertraline dose will be gradually increased by giving sertraline subjects capsules filled with 50 mg for the first three days and then capsules filled with 100 mg for 4 days before beginning the 150 mg per day in the second week. After completing the study Visit 12, subjects will be given an additional two week supply of medicine to gradually taper down so as to minimize any withdrawal discomfort.~Subjects in the Sertraline arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
3114606|NCT02504931|Placebo Comparator|Placebo|"Matching placebo capsules will be filled with corn starch only on the same schedule as the Sertraline.~Subjects in the Placebo arm also will receive COPE therapy (Concurrent Treatment with Prolonged Exposure)which involves 12 sessions of manualized cognitive and behavioral therapy including exposure therapy for PTSD."
3114607|NCT02505269|Experimental|Brentuximab Vedotin|"The following procedures will take place during study visits beginning after the screening procedures:~- Participants will receive combination therapy:~Brentuximab Vedotin intravenously on predetermined days per cycle~Adriamycin intravenously on predetermined days per cycle~Dacarbazine intravenously on predetermined days per cycle"
3114608|NCT02505334|Experimental|Liraglutide 1.8 mg|The total trial duration for the 1.8 mg/day treatment arm will be approximately 67 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week main treatment period, a safety extension period of 26 weeks and a follow-up visit.
3114609|NCT02505334|Active Comparator|Liraglutide 0.9 mg|The total trial duration for the 0.9 mg/day treatment arm will be approximately 41 weeks, consisting of 2 weeks screening period, a 12 weeks run-in period, a 26-week treatment period, and a follow-up visit.
3114610|NCT02505425|Experimental|Active Intervention|"Behavioral: behavioral support~Usual HF Care + ENABLE CHF-PC"
3114611|NCT02505425|Active Comparator|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
3114612|NCT02505542|Other|Open-label Certolizumab Pegol|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 to Week 48 (Part A). Subjects in sustained remission at Week 48 are eligible for randomization into Part B.
3114613|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 2 weeks (Q2W) from Week 48 onwards.
3114614|NCT02505542|Experimental|Double-blind Certolizumab Pegol 200 mg Q4W|"Certolizumab Pegol (CZP) 200 mg subcutaneous (sc) every 4 weeks (Q4W) from Week 48 onwards.~At visits where CZP is not received, subjects receive one injection of Placebo to maintain the study blind."
3114615|NCT02505542|Placebo Comparator|Placebo|One placebo injection is administered every 2 weeks from Week 48 onwards.
3114616|NCT02505542|Other|Placebo to CZP 200 mg Q2W escape|Subjects randomized to Placebo who meet flare criteria receive CZP 400 mg subcutaneous (sc) every 2 weeks (Q2W) for the first 3 visits after flare has been confirmed. After that, CZP 200 mg is given every 2 weeks in open-label fashion.
3114617|NCT02505542|Other|CZP 200 mg Q4W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q4W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
3114618|NCT02505542|Other|CZP 200 mg Q2W to CZP 200 mg Q2W escape|Subjects randomized to CZP 200 mg Q2W who meet flare criteria receive CZP 200 mg subcutaneous (sc) every 2 weeks (Q2W) for all visits after flare has been confirmed. At the first 3 visits after flare has been confirmed, subjects receive one injection of 200 mg CZP and one injection of Placebo to maintain the study blind.
3114619|NCT02505867|Experimental|Device - ASV Therapy|Participants are provided with Adaptive Servo Ventilation (ASV) device during inpatient hospitalization or shortly after discharge.
3114620|NCT02505867|No Intervention|Control|No device provided
3114621|NCT02505919|Experimental|Treatment|AQUABEAM System
3114622|NCT02505919|Active Comparator|Control|Transurethral Resection of the Prostate (TURP)
3114623|NCT02505945|Active Comparator|Control Arm|Double-dose PPI [Omeprazole 20 mg BID (twice a day)]
3114624|NCT02505945|Active Comparator|Treatment Arm|LINX Reflux Management System
3114625|NCT02506036|Active Comparator|Control then Social Cognitive Training|Patients assigned to this arm will first receive a control therapy on a laptop followed by the Brain HQ social-cognitive training.
3114626|NCT02506036|Experimental|Social Cognitive Training then Control|Patients assigned to this arm will first receive the Brain HQ social-cognitive training and then undergo a control therapy.
3114627|NCT02506114|Experimental|Arm A: PROSTVAC-V/F|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36.
3114628|NCT02506114|Experimental|Arm B: Ipilimumab Monotherapy|Ipilimumab: 3 mg/kg; intravenously; Days 1 and 21.
3114629|NCT02506114|Experimental|Arm C: Combined PROSTVAC-V/F + Ipilimumab|PROSTVAC-V: 2 x 10^8pfu; subcutaneous; Day 1. PROSTVAC-F: 1 x 10^9pfu; subcutaneous; Days 15, and 36. Ipilimumab: 3 mg/kg; intravenously; Days 15 and 36.
3114630|NCT02506257|Experimental|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3114631|NCT02506257|Experimental|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3114632|NCT02506257|Experimental|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3114633|NCT02506257|Placebo Comparator|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
3114634|NCT02506309|Experimental|SIS single incision sling|SIS - Innovative fixation single incision sling A third generation of the Mid-urethral slings inserted through a SIS single incision sling (SIS) to treat female stress urinary incontinence (SUI).
3114635|NCT02506309|Active Comparator|TOT trans obturator tape/sling|TOT - inside-out trans-obturator tape/sling Trans-obturator slings (TOT) now represent a gold standard in the treatment of female stress urinary incontinence (SUI).
3114636|NCT02506634||Participants with upper gastrointestinal symptoms|Participants are stratified at baseline based on their main upper gastrointestinal symptoms and then evaluated for GERD using different methods (i.e., reflux esophagitis on endoscopy or positive acid exposure time (AET) on reflux monitoring). Patients would then be given Esomeprazole MUPS（ Multiple Unit Pellet System）20 mg bid for evaluating the ability of the PPI Test for GERD. According to the guidelines, the duraion of PPI treatment was 4 weeks and 8 weeks for endoscopy negative patients and patients has reflux esophagitis, respectively.
3114637|NCT02506660|Active Comparator|Intravenous dexamethasone|Patients will receive 1 cc (1 mg) dexamethasone intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc saline.
3114638|NCT02506660|Experimental|Perineural dexamethasone|Patients will receive 1 cc saline intravenously and a block containing 15 cc bupivacaine 0.5% and 1 cc (1 mg) dexamethasone.
3114639|NCT02506673|Active Comparator|Sedation only with skin conductance monitor|Patients will receive traditional sedation with 2 mg of midazolam on arrival in the OR. Patients in this group will wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
3114640|NCT02506673|Experimental|Sedation & audiovisual aids with skin conductance monitor|Prior to surgery, patients will be asked to wear audiovisual equipment (Zeiss, Cinema ProMED) in the holding area. Patients in this group will also receive 2 mg of midazolam on arrival in OR. Patients in this group will also wear the skin conductance monitor to measure changes in levels of sympathetic discharge.
3114641|NCT02506816||Olaparib|Drug exposure has a limited duration 28 (+/- 5) days.
3114642|NCT02506868|Experimental|BCD-066|Patients in this arm will receive weekly subcutaneous injections of BCD-066 (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
3114643|NCT02506868|Active Comparator|Aranesp|Patients in this arm will receive weekly subcutaneous injections of Aranesp (darbepoetin alfa) with dose level titration to maintain target hemoglobin level (100 - 120 g/l) for 52 weeks
3114644|NCT02506881|Experimental|BCD-066 → Aranesp - subcutaneous|Volunteers in this group initially will receive a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
3114645|NCT02506881|Experimental|Aranesp → BCD-066 - subcutaneous|Volunteers in this group initially will receive a single sc injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single sc injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
3114646|NCT02506881|Experimental|BCD-066 → Aranesp - intravenous|Volunteers in this group initially will receive a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg.
3114647|NCT02506881|Experimental|Aranesp → BCD-066 - intravenous|Volunteers in this group initially will receive a single iv injection of the reference drug Aranesp® (darbepoetin alfa) at a dose of 1 µg/kg (on Day 1) and then, after at least 25 days, a single iv injection of the study drug BCD-066 (darbepoetin alfa) at a dose of 1 µg/kg.
3114648|NCT02507011|Experimental|Carvedilol First|Crossover Design: Participants receive Carvedilol first and placebo second
3114649|NCT02507011|Placebo Comparator|Placebo First|Crossover Design: Participants receive placebo first and Carvedilol second
3114650|NCT02507219|Placebo Comparator|Placebo|Subjects will receive one dose of placebo (sugar pill) at one of the three testing sessions . Placebo capsules will be produced in the same manner as the ibuprofen by a local compounding pharmacy in Tulsa, OK.
3114651|NCT02507219|Active Comparator|Ibuprofen, 200mg|Subjects will receive one oral dose of 200mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
3114652|NCT02507219|Active Comparator|Ibuprofen, 600mg|Subjects will receive one oral dose of 600mg at one of the three testing sessions. Ibuprofen capsules will be produced by a local compounding pharmacy in Tulsa, OK.
3114653|NCT02507297|Experimental|PAP Group|Positive airway pressure (PAP) delivered through an auto-titrating machine, to be used nightly
3114654|NCT02507297|No Intervention|TAU Group|Treatment as usual through obstetrics
3114655|NCT02507349|Active Comparator|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
3114656|NCT02507349|Active Comparator|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
3114657|NCT02507375|Experimental|Cohort 1|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 100 mg orally (PO).
3114658|NCT02507375|Experimental|Cohort 2|Participants will receive IV infusion of pertuzumab at a loading dose of 840 mg on Day 1, followed by a dose of 420 mg every 3 weeks. Erlotinib will be administered daily, at a dose level of 150 mg orally (PO).
3114659|NCT02507388|Experimental|Brolucizumab 3 mg|Brolucizumab 3 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
3114660|NCT02507388|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/50 μL administered as an intravitreal injection 3 times at 4-week intervals with follow-up for 84 days from the initial injection
3114661|NCT02507752||Rituximab|Participants who are receiving 1000 milligrams (mg) intravenous (IV) infusion of rituximab on Day 1 and Day 15 as part of standard of care of the treating site will be included in this observational study.
3114662|NCT02508077|Experimental|Treatment (panitumumab and FOLFIRI)|Patients receive panitumumab IV over 30-90 minutes, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium PO, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3114663|NCT02508103|Experimental|Oxytocin, then Placebo|"Participants were randomized to receive Intransal Oxytocin for late luteal phase administration during one menstrual cycle, then received Intranasal Placebo for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
3114664|NCT02508103|Experimental|Placebo, then Oxytocin|"Participants were randomized to receive Intranasal Placebo for late luteal phase administration during one menstrual cycle, then received Intransal Oxytocin for late luteal phase administration of a subsequent menstrual cycle.~Intranasal Oxytocin spray (40 IU, 3x/day) for 4-5 days; Intranasal Placebo spray (3x/day) for 4-5 days"
3114665|NCT02508116|Experimental|CYP2C19 Genotype guided|Prospective CYP2C19 genotyping to decide antiplatelet therapy.
3114666|NCT02508116|No Intervention|Control group|Antiplatelet therapy will be decided based on usual care
3114667|NCT02508194|Active Comparator|Placebo + Inactivated Influenza Vaccine (IIV)|Participants received a single intramuscular (IM) injection of placebo (matched with MEDI7510) in one arm and single IM injection of (IIV) in the contralateral arm.
3114668|NCT02508194|Experimental|MEDI7510 + IIV|Participants received a single IM injection of MEDI7510 in one arm and single IM injection of IIV in the contralateral arm.
3114669|NCT02508207|Placebo Comparator|Placebo|Participants received placebo matched to tezacaftor (TEZ)/ivacaftor (IVA) fixed dose combination (FDC) tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 29 days.
3114670|NCT02508207|Experimental|TEZ/IVA|Participants received 100 milligram (mg) TEZ/150 mg IVA FDC tablet orally once daily in the morning followed by 150 mg IVA tablet orally once daily in the evening for 29 days.
3114671|NCT02508259|Active Comparator|Suramin|20 mg/kg suramin in 50 ml of saline by intravenous infusion over 30 minutes
3114672|NCT02508259|Placebo Comparator|Saline|50 ml of saline by intravenous infusion over 30 minutes
3114673|NCT02508389|Experimental|Low Dose GC4419: 30mg/day|30 mg GC4419/day prior to IMRT
3114674|NCT02508389|Experimental|High Dose GC4419: 90mg/day|90 mg GC4419/day prior to IMRT
3114675|NCT02508389|Placebo Comparator|Placebo|Placebo daily, prior to IMRT
3114676|NCT02508428|Active Comparator|Crosslinked Marathon polyethylene|The crosslinked Marathon polyethylene liners used for the primary total hip replacements in this study were treated with 5 Mrad (50 kGy) of gamma irradiation to induce crosslinking and then heated above the melting temperature (150 degrees Celsius) to eliminate free radicals. This manufacturing process was designed to improve the polyethylene's resistance to wear through increased crosslinking and eliminate free radicals that render it susceptible to oxidative degradation. These liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. These liners did not have had free radicals at the time of implantation and did not incorporate antioxidants.
3114677|NCT02508428|Active Comparator|Noncrosslinked Enduron polyethylene|The standard, noncrosslinked Enduron polyethylene liners used for the primary total hip replacements in this study were manufactured from the same polyethylene resin as the crosslinked Marathon liners but never irradiated. Like the Marathon components, these liners were machined and terminally sterilized with gas plasma, a noncrosslinking chemical surface treatment. Based on the manufacturing methods, these liners would not have had free radicals at the time of implantation and did not incorporate antioxidants.
3114678|NCT02508480|Experimental|Photovoice|Participants in this arm will attend a 10-week peer-led Photovoice program conducted in group format.
3114679|NCT02508480|Active Comparator|Enhanced Control|Participants in this arm will attend a 60-minute peer-led group discussion on stigma and discrimination, and be eligible to participate in the 10-week Photovoice program after completing all study assessments.
3114680|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 30 mg QD|"Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3114681|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 60 mg QD|"Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3114682|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 90 mg QD|"Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3114683|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 135 mg QD|"Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3469271|NCT03888222|Active Comparator|100 mg of Bosutinib|Thirty (30) participants will be recruited and randomized into 2 groups (arms) (1:1) .Fifteen (15) patients in group 2 will receive the 100 mg of Bosutinib one (1) capsule orally once daily for 3 months (90 days).
3114684|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 200 mg QD|"Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. ."
3114685|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 300 mg QD|"Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
3114686|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 400 mg QD|"Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation.~Patients that received at least one dose of avapritinib were included in the Part 2 analysis."
3114687|NCT02508532|Experimental|Part 1 Avapritinib (formerly BLU-285) 600 mg QD|"Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3114688|NCT02508532|Experimental|Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD|"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.~Patients received avapritinib in continuous 28 day cycles until discontinuation."
3114689|NCT02508636|Experimental|Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy|"Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months.~Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks."
3114690|NCT02508649|Placebo Comparator|Placebo|
3114691|NCT02508649|Experimental|Selepressin 1|Starting dose 1.7 ng/kg/min
3114692|NCT02508649|Experimental|Selepressin 2|Starting dose 2.5 ng/kg/min
3114693|NCT02508649|Experimental|Selepressin 3|Starting dose 3.5 ng/kg/min
3114694|NCT02508649|Experimental|Selepressin 4|"Starting dose 5.0 ng/kg/min~The highest dosing regimen of selepressin was not investigated in the trial as the desired primary outcome for selepressin 3 arm was not achieved, and the trial was terminated for futility."
3114695|NCT02508701|Other|Altruistic inside-dorm|"Altruistic & personal message with direct recommendation and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm and provides a direct recommendation to get the vaccine"
3114696|NCT02508701|Other|Generic inside-dorm|"Generic message and access to the vaccine on-site~The intervention is a message asking students to get the vaccine that tell students the vaccine is available in the dorm but provides no recommendation"
3114697|NCT02508701|Other|Generic outside-dorm|"Generic message and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the health center but provides no recommendation"
3114698|NCT02508701|Other|Altruistic outside-dorm|"Altruistic & personal message with direct recommendation and off-site access to the vaccine~The intervention is a message asking students to get the vaccine that tell students the vaccine is available at the student health center and provides a direct appeal to get the vaccine"
3114699|NCT02508935|Experimental|XARTEMIS XR|All participants received XARTEMIS XR
3114700|NCT02509026|Experimental|Etanercept|etanercept 50 mg QW
3114701|NCT02509065|Active Comparator|Usual Care|Comparator week to all closed-loop control, utilizing usual diabetes care and the subject's own insulin pump.
3114702|NCT02509065|Experimental|145 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 145 mg/dl and using only an insulin pump.
3114703|NCT02509065|Experimental|130 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl and using only an insulin pump. This arm is for subjects with type 1 diabetes only. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3114704|NCT02509065|Experimental|130 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 130 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3114705|NCT02509065|Experimental|115 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 115 mg/dl using both an insulin and a glucagon pump.
3114706|NCT02509065|Experimental|100 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 100 mg/dl using both an insulin and a glucagon pump.
3114707|NCT02509065|Experimental|110 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl and using only an insulin pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3114708|NCT02509065|Experimental|110 mg/dl Set Point - bihormonal|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 110 mg/dl using both an insulin and a glucagon pump. This arm is double blinded; neither the subject nor the study team know if it is insulin only or bihormonal.
3114709|NCT02509065|Experimental|120 mg/dl Set Point - insulin only|Automated blood glucose control via a closed-loop bionic pancreas device targeting a blood glucose level of 120 mg/dl and using only an insulin pump.
3114710|NCT02509078|Active Comparator|Early Neuromuscular Blockade (NMB)|Patients will receive cisatracurium besylate for the first 48 hours of the trial.
3114711|NCT02509078|No Intervention|Control: No Routine Early NMB|Use of non-study NMB will be discouraged.
3114712|NCT02509117|Experimental|Single Ascending Dose Cross-over|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
3114713|NCT02509117|Experimental|Multiple Ascending Dose PF-06751979|Multiple dose administration to Healthy Subjects in parallel cohorts(PF-06751979)
3114714|NCT02509117|Placebo Comparator|Multiple Ascending Dose Placebo|Multiple dose administration to Healthy Subjects in parallel cohorts(Placebo)
3114715|NCT02509117|Experimental|Multiple Dose Elderly PF-06751979|Multiple dose administration to Healthy Elderly Subjects (PF-06751979)
3114716|NCT02509117|Placebo Comparator|Multiple Dose Elderly Placebo|Multiple dose administration to Healthy Elderly Subjects (Placebo)
3114717|NCT02509156|Experimental|Allo-MSCs|Target dose of 100 million allo-MSCs
3114718|NCT02509156|Placebo Comparator|Placebo|Buminate solution
3114719|NCT02509481|Active Comparator|Single MDA|Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
3114720|NCT02509481|Experimental|Repeated MDA|Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.
3114721|NCT02509585|Experimental|Tc99m tilmanocept|2 mCi (74 MBq), 50 ug of Tc99M tilmanocept single administration
3114722|NCT02509624|Experimental|Moderate hepatic impairment (Cohort 1)|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
3114723|NCT02509624|Experimental|Severe hepatic impairment (Cohort 2)|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
3114724|NCT02509624|Experimental|Mild hepatic impairment (Cohort 3)|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of selonsertib on Day 1.
3114725|NCT02509767|Experimental|Self-Administration|Subjects who are randomized to self-administration will be taught self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA sc) by a clinic nurse or other qualified personnel using instructions based on the packaging insert. If willing, subjects will then self-administer DMPA sc under supervision. Subjects who are able to correctly self-administer DMPA sc as assessed by the supervising nurse and who are interested in continued home self-administration will then be provided medication (3 doses of DMPA sc), a self-administration kit (includes alcohol swabs, cotton pads, bandages, mini sharps disposal container), and instructions to do so for the subsequent 3 injections indicating the appropriate dates for injection. All subjects will receive reminders when their next injection is due.
3114726|NCT02509767|Other|Clinic Administration (Standard Care)|Subjects who are randomized to clinic administration will receive subcutaneous depot medroxyprogesterone acetate (DMPA sc) injection administered by a clinic nurse or other qualified personnel and receive standard care. They will be instructed to make an appointment to return to the clinic as usual to receive subsequent injections every 12-14 weeks. All subjects will receive reminders when their next injection is due.
3114727|NCT02509936|Active Comparator|Standard of Care Arm|In this arm enrolled children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement.
3114728|NCT02509936|Experimental|Home-based Education|In the intervention arm, children will receive the national standard of care for growth support, which includes growth monitoring, a food ration, and a multiple micronutrient powder supplement. In addition, they will receive monthly home visits from a community health promoter who will provide detailed dietary assessments and individualized dietary coaching and education to parents.
3114729|NCT02510001|Experimental|Dose Escalation Phase Cohort 1 Dose level 1|Crizotinib 250mg OD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3114730|NCT02510001|Experimental|Dose Escalation Phase Cohort 2 Dose level 2|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 2mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3114731|NCT02510001|Experimental|Dose Escalation Phase Cohort 3 Dose level 3|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 4mg BD Run in Day -7 to Cycle 1 Day 1, then Day 1-21 every 28 day cycle
3114732|NCT02510001|Experimental|Dose Escalation Phase Cohort 4 Dose level 4|Crizotinib 200mg BD Days 1-28 continuously PD-0325901 8mg BD Run in Day -7 to Cycle 1 Day1, then Day 1-21 every 28 day cycle
3114733|NCT02510001|Experimental|Dose Escalation Phase Cohort 7 Dose level 5|Binimetinib 30mg BD continuous administration or Days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
3114734|NCT02510001|Experimental|Dose Escalation Phase Cohort 13 Dose level 5a|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days. PF-02341066 250mg OD continuous administration
3114735|NCT02510001|Experimental|Dose Expansion Phase|Binimetinib 30mg BD interval dose administration Days 1-21 every 28 days PF-02341066 (Crizotinib) 250mg OD Days 1-28 continuously Dosage determined following the recommended Phase II dose identification in the dose escalation phase.
3114736|NCT02510001|Experimental|Dose Escalation Phase Cohort 12 Dose level 5 (Interval dosing)|Binimetinib 30mg BD interval dose administration days 1-21 every 28 days. PF-02341066 200mg BD continuous administration
3114737|NCT02510014|Experimental|Roll-over Subjects|Subjects who completed RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 6 months in the Treatment period.
3114738|NCT02510014|Experimental|De Novo Subjects|Subjects who did not participate in RB-US-13-0001 received SUBOXONE sublingual film during the Run-In period, followed by an initial open-label injection of 300 mg RBP-6000. Participants continued with monthly injections of either 300 mg or 100 mg (based on judgement of the Investigator) for a total of 12 months in the Treatment period.
3114739|NCT02510040||Convergence insufficiency|Eligible adults with convergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3114740|NCT02510040||Divergence insufficiency|Eligible adults with divergence insufficiency can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3114741|NCT02510040||Small-angle hypertropia|Eligible adults with small-angle hypertropia can be treated with prism, orthoptic exercises, eye muscle surgery, or botox injection, per the investigator's usual clinical practice.
3114742|NCT02510144|Active Comparator|Chlorhexidine|A preoperative Chlorhexidine gluconate solution 4.0% (i.e Hibiclens)
3114743|NCT02510144|Experimental|Benzoyl Peroxide|A preoperative 5% benzoyl peroxide wash prep (i.e. Brevoxyl-4 and Brevoxyl-8)
3114744|NCT02510664|Experimental|Intervention|There is no control/comparator group for this pilot study - all participants receive the intervention
3114745|NCT02510794|Experimental|Port Delivery System with Ranibizumab 10mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 10-mg/mL ,approximately 0.2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 10-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
3114746|NCT02510794|Experimental|Port Delivery System with Ranibizumab 40mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 40-mg/mL, approximately 0.8 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 40-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
3114747|NCT02510794|Experimental|Port Delivery System with Ranibizumab 100mg/mL|Participants had the Implant (prefilled with approximately 20 μL of 100-mg/mL, approximately 2 mg dose, of ranibizumab) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Starting at the Month 1 visit, participants were evaluated monthly for the need for Implant refill with the 100-mg/mL formulation of ranibizumab according to their randomization as per protocol-specified refill criteria.
3114748|NCT02510794|Active Comparator|Intravitreal Injection with Ranibizumab 0.5mg|Participants received ranibizumab 0.5 mg monthly ITV injections of 10 mg/mL formulation at Day 1 and every month thereafter.
3114749|NCT02510820|Active Comparator|Synergi / comfilcon A|Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study.
3114750|NCT02510820|Active Comparator|Biotrue / comfilcon A|Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study.
3114751|NCT02511106|Experimental|AZD9291|AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
3114752|NCT02511106|Placebo Comparator|Placebo AZD9291|Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
3114753|NCT02511184|Experimental|Dose finding and dose expansion phases|Find and expand the maximum tolerated dose of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks.
3114754|NCT02511236|Experimental|Group Cognitive Behavioral Therapy|Participants may receive 8 group cognitive behavioral therapy (CBT) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
3114755|NCT02511236|Active Comparator|General Health Education|Participants may receive group general health education (GHE) sessions and eight weeks of transdermal nicotine patches (TNP) [21mg (4 weeks), 14mg (2 weeks), and 7mg (2 weeks)].
3114756|NCT02511379|Experimental|Systane Balance|Propylene Glycol 0.6% eye drops, 1 drop QID (with the last dose of each day at bedtime) in each eye for 90 days
3114757|NCT02511431|Experimental|Group 1|Lonafarnib/Ritonavir at 50 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3114758|NCT02511431|Experimental|Group 2|Lonafarnib/Ritonavir at 75 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3114759|NCT02511431|Experimental|Group 3|Lonafarnib/Ritonavir at 100 mg/100 mg daily for 24 weeks followed by 24 weeks of off therapy follow-up.
3114760|NCT02511431|Experimental|Group 4|Placebo for 12 weeks then Lonafarnib/Ritonavir at 50 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3114761|NCT02511431|Experimental|Group 5|Placebo for 12 weeks then Lonafarnib/Ritonavir at 75 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3114762|NCT02511431|Experimental|Group 6|Placebo for 12 weeks then Lonafarnib/Ritonavir at 100 mg/100 mg daily for 12 weeks followed by 24 weeks of off therapy follow-up.
3114763|NCT02511535|Experimental|Allergic patients|Allergic patients receive TBE booster vaccination
3114764|NCT02511535|Experimental|Allergic patients with de-sensitization treatment|Allergic patients with de-sensitization treatment receive TBE booster vaccination
3114765|NCT02511535|Active Comparator|Healthy controls|Healthy controls receive TBE booster vaccination
3114766|NCT02511561|Experimental|0.1 mL OTO-201|Ciprofloxacin
3114767|NCT02511561|Experimental|0.2 mL OTO-201|Ciprofloxacin
3114768|NCT02511561|Experimental|0.4 mL OTO-201|Ciprofloxacin
3114769|NCT02511587|Active Comparator|intra muscular application|intra muscular application of FSME-Immune vaccination
3114770|NCT02511587|Experimental|subcutaneous application|subcutaneous application of FSME-Immune vaccination
3114771|NCT02511678|Experimental|Cryoablation|All participants will have one cryoablation procedure on one painful metastatic lesion involving bone using a Galil Medical cryoablation system and needles within 14 days of screening. In the case of participants with multiple metastatic lesions involving bone, the most painful lesion is to be selected for cryoablation. If treatment could not be completed within 14 days of screening, the participant will be re-screened using the inclusion and exclusion criteria. Participant preparation, anesthesia, intra-operative monitoring, and postoperative management for the study cryoablation procedure will be identical to those for standard cryoablation treatment routinely performed at the clinical centers that participated in this study and will be at the discretion of the Investigators.
3114772|NCT02511717|Sham Comparator|Sham|Transcutaneous stimulation in a location and with settings not relation to the bladder nerves, 3x/week for 30 minutes for 12 weeks
3114773|NCT02511717|Active Comparator|Transcutaneous nerve stimulation|Transcutaneous stimulation of the bladder nerves, 3x/week for 30 minutes for 12 weeks
3114774|NCT02511730|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
3114775|NCT02511730|Active Comparator|FFDM Alone|Breast Images with FFDM alone
3469272|NCT03888300|Experimental|Patient Group|Patients with obstructive pulmonary diseases receiving standard physiotherapy treatment
3469273|NCT03888183|Placebo Comparator|salt solution without 0.15% HA|
3469274|NCT03888183|Active Comparator|preservative-free 0.15% HA|
3114776|NCT02511782|Experimental|Acute Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop acute graft versus host disease. Skin cell samples will be collected using the D-SQUAME Skin Sampling Discs. The first baseline skin sample will be obtained prior to the preparative regimen for stem cell transplant. Samples will be collected weekly after stem cell infusion until 8 weeks, if acute GVHD does not develop. If acute GVHD does develop, weekly samples will continue to be collected until resolution of acute GVHD or development of chronic GVHD, whichever occurs first. Blood samples will be collected at these same time points.
3114777|NCT02511782|Experimental|Chronic Graft versus Host Disease|This study arm includes patients who undergo allogeneic hematopoietic cell transplantation at CCHMC and develop chronic graft versus host disease. Skin cell samples will be collected weekly for 4 weeks using the D-SQUAME Skin Sampling Discs. Blood samples will be collected at these same time points.
3114778|NCT02511782|Active Comparator|Healthy Controls|This study arm includes healthy age matched controls as comparisons to study participants who develop graft versus host disease. These controls may be either healthy age matched siblings of patients who develop acute graft versus host disease or healthy age matched siblings of patients that are seen in the bone marrow transplant, oncology, or hematology clinics. A one-time single skin cell sample will be collected using a D-SQUAME Skin Sampling Disc. Blood samples will not be collected from the healthy controls.
3114779|NCT02512042|Experimental|Brinzolamide 1% Ophthalmic suspension|Brinzolamide Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Indoco Remedies, Ltd for Watson Pharma Pvt. Ltd
3114780|NCT02512042|Active Comparator|Azopt® 1% Ophthalmic suspension|Azopt® (Contains Brinzolamide) Pharmaceutical dosage form: Ophthalmic suspension Strength: 1% Manufactured by: Alcon Laboratories, Inc
3114781|NCT02512068|Experimental|Trelagliptin 25 mg|Trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period I + II)
3114782|NCT02512068|Experimental|Placebo and Trelagliptin 25 mg|Placebo tablet, orally, once weekly before breakfast for up to Week 12 (Period I), followed by trelagliptin 25 mg tablet, orally, once weekly before breakfast for up to Week 52 (Period II)
3114783|NCT02512224||Parenteral nutrition|investigators selected participants aged 20 years or older who had undergoneparenteral nutrition by central venous port insertion between April 1, 2012, and March 31, 2013.
3114784|NCT02512224||Enteral nutrition|investigators selected participants aged 20 years or older who had undergone enteral nutrition by percutaneous endoscopic gastrostomy, percutaneous transesophageal gastrotubing, or ileostomy between April 1, 2012, and March 31, 2013.
3114785|NCT02512276|Experimental|Telepharmacist intervention|Patients diagnosed with diabetes, hypertension, or hyperlipidemia exhibiting sub-optimal adherence to their medications [defined as combined (average of averages) proportion of days covered (PDC) < 80%] who also have poor or worsening disease control.
3114786|NCT02512276|No Intervention|Usual care|Patients randomized to this arm will receive usual care.
3114787|NCT02512302|Experimental|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
3114788|NCT02512302|Experimental|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
3114789|NCT02512302|Active Comparator|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
3114790|NCT02512302|Active Comparator|Seebri® Breezhaler® with activated charcoal|: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
3114791|NCT02512302|Active Comparator|: Glycopyrrolate Injection|50 mcg glycopyrrolate via IV infusion
3114792|NCT02512393|Experimental|Active tDCS|This group will receive five daily sessions of 2mA, 20 minutes of Transcranial Direct Current Stimulation (tDCS). The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, and gait speed, Assessment of conditioned pain modulation, and Blood test.
3114793|NCT02512393|Sham Comparator|Sham tDCS|This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
3114794|NCT02512419|Experimental|Text-Enhanced Physical Activity Intervention Arm|The Spanish-language PA intervention is based on Social Cognitive Theory (SCT) and Transtheoretical Model (TTM), and emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals).
3114795|NCT02512419|Active Comparator|Health Education Control Arm|The health education control arm will receive the publicly available NHBLI Spanish-language booklets on heart-healthy behaviors for Latinos, which include information on PA, diet, and stress management.
3114796|NCT02512510|Active Comparator|TD-4208-1|88 mcg
3114797|NCT02512510|Active Comparator|TD-4208-2|175 mcg
3114798|NCT02512510|Placebo Comparator|Placebo|Placebo
3114799|NCT02512575|Experimental|AZD9567 oral suspension|"In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).~In Part B: one cohort with a single dose"
3114800|NCT02512575|Placebo Comparator|Placebo|Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.
3469275|NCT03888157||Liraglutide|Patients with type 2 diabetes in Iran are to receive Victoza® for 26 weeks.
3469276|NCT03888209|Experimental|Anodal tDCS|Patients will receive 20min anodal tDCS
3469277|NCT03888209|Sham Comparator|Sham tDCS|Patients will receive 20 minutes of Sham anodal tDCS
3114801|NCT02512575|Experimental|Prednisolone capsules|"Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.~Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved."
3114802|NCT02512679|Other|Cyclophosphamide Dose Level 1|"Cyclophosphamide given by Intravenous (IV) at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level.~Drug to be given in combination of Busulfan, Campath and Fludarabine"
3114803|NCT02512679|Other|Cyclophosphamide Dose Level 2|Cyclophosphamide given by intravenous (IV) at a total dose of 70 mg/kg (divided in two doses) given once a day for two days in combination with Busulfan, Campath and Fludarabine.
3114804|NCT02512679|Other|Cyclophosphamide Dose Level 3|Cyclophosphamide given by intravenous (IV) at total does of 35 mg/kg as a one time dose in combination with Busulfan, Fludarabine and Campath
3114805|NCT02512679|Other|Cyclophosphamide Dose Level 4|No cyclophosphamide given with Busulfan, Fludarabine and Campath
3114806|NCT02512783|Active Comparator|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
3114807|NCT02512783|Placebo Comparator|Normal Saline|Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
3114808|NCT02512809|Experimental|Isoflurane Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with isoflurane.
3114809|NCT02512809|Experimental|Dexmedetomidine/remifentanil Arm|Pediatric patients, aged 0-5 years, diagnosed with hydrocephalus undergoing a surgical (non-bedside) shunting procedure with general anesthesia. Pts will receive a standardized general anesthetic with dexmedetomidine and remifentanil infusions..
3114810|NCT02512809|No Intervention|MRI Control Arm|Otherwise healthy pediatric patients, aged 0-5 years, undergoing MRI with general anesthesia for evaluation of non-neurologic disease. Patients will receive a standardized general anesthetic with isoflurane.
3114811|NCT02512861|Active Comparator|Bupivacaine|Bupivacaine as a parasternal nerve block following pediatric cardiothoracic surgery
3114812|NCT02512861|Placebo Comparator|Placebo|Normal Saline
3114813|NCT02512874|Other|Pulmonary Rehabilitation|One arm study - all participants will go to pulmonary rehabilitation, received questionnaires, Dual-energy X-ray absorptiometry (DEXA) scans, Dynamometer and gait speed tests and activity measured through an activity monitor.
3114814|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 1 (12 to 14 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 12 to 14 years of age.
3114815|NCT02512900|Experimental|MEDI9929, 140 mg, Cohort 2 (15 to 17 years)|On Day 1, one MEDI9929 subcutaneous injection of 70 mg was given into the anterior aspect of one thigh immediately followed by the second injection of 70 mg into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants with 15 to 17 years of age.
3114816|NCT02512965|Active Comparator|Standard Conventional Radiotherapy|Standard Conventional Radiotherapy (CRT) 20 Gy in 5 fractions
3114817|NCT02512965|Experimental|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy (SBRT) 24 Gy in 2 fractions
3114818|NCT02513095|Experimental|Ryanodex|Ryanodex (dantrolene sodium) for injectable suspension administered as an IV bolus, in addition to standard of care (SOC) treatment.
3114819|NCT02513095|No Intervention|Standard of Care only (SOC)|Standard of Care (SOC) treatment only, consisting of body cooling and supportive measures implemented immediately.
3114820|NCT02513121|Active Comparator|Dietary modification|Low free sugar diet
3114821|NCT02513121|No Intervention|Observational Arm|Standard of care
3114822|NCT02513160|Experimental|Beclomethasone dipropionate BAI 320|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3114823|NCT02513160|Experimental|Beclomethasone dipropionate BAI 640|"Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) at 640 mcg/day (80 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3114824|NCT02513160|Active Comparator|Beclomethasone dipropionate MDI 320|"Beclomethasone dipropionate Metered Dose Inhaler (MDI) 320 mcg/day (40 mcg/inhalation, 4 inhalations twice daily)~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3114825|NCT02513160|Placebo Comparator|Placebo|"Pooled breath-actuated inhaler (BAI) or metered-dose inhaler (MDI) placebo groups. Participants were instructed to take 4 inhalations twice daily for 6 weeks.~Albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent was supplied by the sponsor for use as rescue medication during the run-in and double-blind study periods."
3114826|NCT02513212|Other|oxalate liquid, SnF2 paste, manual toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Manual toothbrush
3114827|NCT02513212|Other|oxalate liquid, SnF2 paste, power toothbrush|Potassium oxalate liquid, professionally applied Stannous fluoride paste, self applied Power toothbrush
3114828|NCT02513446|Experimental|BI 1026706|Single dose
3114829|NCT02513446|Experimental|BI 1026706 + Itraconazole|7 days of itraconazole treatment combined with a single dose of 1026706 on day 4
3114830|NCT02513459|Experimental|Risankizumab|Maintenance treatment with risankizumab 180 mg administered subcutaneously (SC) every 8 weeks (q8w) from Visit 2 through the end of trial (EOT) visit. Participants who re-gained their clinical response following the re-induction treatment could continue with maintenance treatment beginning at Visit 5.
3469278|NCT03888170||Non-pregnant|Women aged 18-45 years old undergoing elective hysterectomy (either vaginal, laparoscopic, or open routes) for benign indications.
3114831|NCT02513472|Experimental|Eribulin Mesylate + Pembrolizumab|Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting.
3114832|NCT02513498|Experimental|Treatment (ixazomib citrate)|Patients receive ixazomib citrate PO once weekly on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response, partial response, or stable disease may receive an additional 6 courses of ixazomib citrate.
3114833|NCT02513550|Experimental|80 mg Ixekizumab Q2W|160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.
3114834|NCT02513550|Experimental|80 mg Ixekizumab Q4W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.
3114835|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
3114836|NCT02513550|Experimental|80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.
3114837|NCT02513550|Experimental|80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.
3114838|NCT02513550|Experimental|80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort|160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.
3114839|NCT02513641|Experimental|Moderate Hypoxia|2-weeks of nightly exposure (7-12 hrs per night) to moderate hypoxia (~2,400 meters) using the Hypoxico Altitude Training Systems device.
3114840|NCT02513719||XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Coronary Stent
3114841|NCT02513732||XIENCE Xpedition 2.25 mm stent arm|Patients receiving XIENCE Xpedition 2.25 mm stent
3114842|NCT02513745|Active Comparator|Conventional|Surgeon's standard of care prior to getting VERION. Spherical power will be selected using the surgeon's preferred formula (Haigis, Holladay 2, Holladay, or other) and biometry method (IOL Master, Lenstar). Astigmatism correction will be planned using the surgeon's preferred keratometry method and calculator/nomogram to determine toric power and corneal incisions (i.e. Alcon toric calculator, Holladay toric calculator, Abbott Medical Optics (AMO) LRI calculator, etc). At time of surgery, axis of placement will be marked using blue ink marks. Corneal incisions will be made manually.
3114843|NCT02513745|Active Comparator|Refractive Cataract Suite (Verion + ORA)|Digital Surgical Planning and Positioning Tools + ORA System with VerifEye or VerifEye +. Spherical power of the IOL will be selected using the Verion Planner with the surgeon's preferred formula with an optimized A-constant (Haigis, Holladay 2, Holladay, or other). Both toric lenses and corneal incisions will be calculated with the Verion Planner using the Verion Reference Unit keratometry and white to white measurements, and Lenstar biometry. The VERION Digital Markers L and M will be used for axis of placement and confirmed using ORA System with VerifEye or VerifEye +.
3114844|NCT02513771|Active Comparator|Sitagliptin Arm|Sitagliptin (Januvia) 100 mg one tablet daily p.o. for 16 weeks, followed by a 4-week post-treatment follow-up.
3114845|NCT02513771|Placebo Comparator|Placebo Arm|Placebo for sitagliptin one tablet daily p.o.for 16 weeks, followed by a 4-week post-treatment follow-up.
3114846|NCT02513823|Experimental|Intervention|2,000 IU of vitamin D given to African American women for 10 weeks
3114847|NCT02513940|Experimental|Testosterone - progesterone - placebo|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days
3114848|NCT02513940|Experimental|Testosterone - placebo - progesterone|Subjects received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo ( 2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
3114849|NCT02513940|Experimental|Progesterone - testosterone - placebo|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days
3114850|NCT02513940|Experimental|Progesterone - placebo - testosterone|Subjects received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal placebo gel once daily every morning for 7 days and oral placebo (2 capsules) once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
3114851|NCT02513940|Experimental|Placebo - testosterone - progesterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days.
3114852|NCT02513940|Experimental|Placebo - progesterone - testosterone|Subjects received transdermal placebo gel once daily every morning for 7 days and oral placebo once daily every morning x 7 days. After a washout period of at least 13 days, they then received oral progesterone 400 mg (2 x 200 mg capsules) once every evening for 7 days and transdermal placebo gel once daily every morning for 7 days. After a washout period of at least 13 days, they then received transdermal testosterone gel 1% 100 mg once daily in the morning and two (2) oral placebo capsules x 7 days.
3114853|NCT02514044|Experimental|Dexedrine+sham tDCS+speech therapy|10 mg Dexedrine and speech therapy for 10 days
3114854|NCT02514044|Experimental|active tDCS+placebo+speech therapy|1.5 mA anodal tDCS and speech therapy for 10 days
3114855|NCT02514044|Experimental|Dexedrine+tDCS+speech therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 10 days
3114856|NCT02514044|Experimental|sham stimulation+placebo+speech therapy|Sham stimulation, placebo and speech therapy for 10 days
3114857|NCT02514044|Experimental|Dexedrine+tDCS+Speech Therapy|10 mg Dexedrine, 1.5 mA anodal tDCS, and speech therapy for 1 day
3114858|NCT02514044|Experimental|placebo+tDCS+Speech Therapy|1.5 mA anodal tDCS, and speech therapy for 1 day
3114859|NCT02514070|Experimental|EPA-rich fish oil arm then DHA-rich fish oil arm|Subjects randomized to the EPA-rich fish oil arm will take the equivalent to 3g of EPA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the DHA-rich capsule arm
3114860|NCT02514070|Experimental|DHA-rich fish oil arm then EPA-rich fish oil arm|Subjects randomized to the DHA-rich fish oil arm will take the equivalent to 3g of DHA /day (12 gel capsules/day) for 6 more or less 1 weeks and cross-over to the EPA-rich capsule arm
3469279|NCT03888170||Pregnant|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age.
3114862|NCT02514122|Experimental|Ketamine|Participants will receive subcutaneous ketamine (1mg/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg.
3114863|NCT02514122|Placebo Comparator|Saline|Participants will receive subcutaneous saline (0.02cc/kg) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
3114864|NCT02514174|Experimental|Afatinib|afatinib starting at 30 mg daily dose
3114865|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.2 μg/d)|
3114866|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.4 μg/d)|
3114867|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (0.8 μg/d)|
3114868|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (1.6 μg/d)|
3114869|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (3.2 μg/d)|
3114870|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (6.5 μg/d)|
3114871|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (13 μg/d)|
3114872|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (25 μg/d)|
3114873|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (50 μg/d)|
3114874|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (100 μg/d)|
3114875|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (200 μg/d)|
3114876|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (400 μg/d)|
3114877|NCT02514239|Experimental|Intravenous Infusion of BI 836909 (800 μg/d)|
3114878|NCT02514473|Experimental|LUM/IVA|Fixed-dose combination with lumacaftor (LUM) 200 mg every 12 hours (q12h)/ ivacaftor (IVA) 250 mg q12h
3114879|NCT02514473|Placebo Comparator|Placebo|Matching placebo q12h
3114880|NCT02514551|Experimental|12mg/kg Ramucirumab + 80 mg/m² Paclitaxel|12 milligram per kilogram (mg/kg) ramucirumab administered intravenously (IV) on day 1 and day 15 (28 day cycles) in combination with 80 milligram per square meter (mg/m²) paclitaxel administered IV on day 1, day 8 and day 15.
3114881|NCT02514551|Active Comparator|8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel|8 mg/kg ramucirumab administered IV on day 1 and day 15 (28 day cycles) in combination with 80 mg/m² paclitaxel administered IV on day 1, day 8 and day 15.
3114882|NCT02514577|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
3114883|NCT02514577|Active Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
3114884|NCT02514746|Experimental|Live Attenuated JE SA-14-14-2 Vaccine (CD-JEV)|Participants previously vaccinated with CD-JEV will receive a booster dose of live, attenuated Japanese encephalitis SA-14-14-2 vaccine four years after initial vaccination.
3114885|NCT02514772|Experimental|GP2013 - proposed biosimilar rituximab|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration, two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
3114886|NCT02514772|Active Comparator|Originator rituximab - Rituxan ® or MabThera ®|10 mg/mL in 500 mg (50 mL) single-use vials. For i.v. administration two 500 mg vials (1000 mg of active molecule) of concentrate are diluted in 0.9% NaCl solution and infused i.v. The treatment course consists of 2 i.v. infusions 2 weeks apart (at Day 1 and Day 14).
3114887|NCT02514824|Experimental|Dose Level 1: MLN01283 3 mg (Phase 1)|"Phase 1 dose level 1 participants receive MLN01283 3 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
3114888|NCT02514824|Experimental|Dose Level 2: MLN01283 4 mg (Phase 1)|"Phase 1 dose level 2 participants receive MLN01283 4 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
3114889|NCT02514824|Experimental|Dose Level 3: MLN01283 5 mg (Phase 1)|"Phase 1 dose level 3 participants receive MLN01283 5 mg orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
3114890|NCT02514824|Experimental|MLN01283 RP2D (Phase 2)|"Phase 2 participants receive MLN01283 at the recommended phase 2 dose (RP2D) orally once daily of a 28 day cycle.~Participants are treated indefinitely until disease progression, unacceptable toxicity or withdrawal for other reasons."
3114891|NCT02514889|Active Comparator|Calorie-counting|Intervention protocol adapted from Diabetes Prevention Program lifestyle change intervention.
3114892|NCT02514889|Experimental|MyPlate|Intervention protocol adapted from Dietary Approaches to Stop Hypertension dietary pattern.
3114893|NCT02515045|Active Comparator|TriMoxiVanc|The formulation containing triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin used as an injection at the end of the uneventful phacoemulsification procedure. The compounded Tri-Moxy-Vanco will be delivered into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
3114894|NCT02515045|Active Comparator|TriMoxiVanc + Ilevro|Nepafenac ophthalmic suspension 0.3% will be started 3 days prior to surgery QD and continue QD for 4 weeks after surgery. The compounded Tri-Moxy-Vanco will be injected into the vitreous cavity using a transzonular approach after IOL implantation before removal of the OVD.
3114895|NCT02515045|Active Comparator|Control|"Moxifloxacin HCl 0.1%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Nepafenac ophthalmic suspension 0.3% : 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued."
3114896|NCT02515058|Experimental|PUROS (Non-Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Non-Freeze-Dried cancellous bone allograft (PUROS)
3114897|NCT02515058|Active Comparator|FDBA (Freeze-Dried bone allograft)|Ridge preservation bone grafting surgery with Freeze-Dried cancellous bone allograft (FDBA)
3114898|NCT02515097|Experimental|IDP-122 Lotion|Participants will apply IDP-122 Lotion (halobetasol propionate [HP] 0.01%) topically once daily for 8 weeks.
3114899|NCT02515097|Placebo Comparator|IDP-122 Vehicle Lotion|Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
3114900|NCT02515253|Experimental|Prescription group|Participants in this group will receive the standard care for benign breast pain sufferers (administered by the Queen Alexandra Hospital in Portsmouth) and will also attend the Department of Sport and Exercise Science at the University of Portsmouth for an individual bra prescription. Participants will be prescribed an appropriate bra to wear over an eight week intervention period.
3114901|NCT02515253|Other|Standard care group|Participants in this group will receive the standard care for benign breast pain sufferers administered by the Queen Alexandra Hospital in Portsmouth.
3114902|NCT02515279||Participants With Hepatitis C|All participants were treated with Peginterferon alfa-2a+Ribavirin (Pegasys/Copegus) according to the summary of product characteristics and to the investigator's discretion. The daily recommended dose for Pegasys, for the treatment of chronic Hepatitis C, was 180 micrograms once weekly by subcutaneous administration. Copegus was administered orally in doses according to the physician's decision (depending on the participant's weight and genotype). All participants were observed for 12 months.
3114903|NCT02515305|Experimental|Test product|
3114904|NCT02515305|Active Comparator|Reference product|
3114905|NCT02515305|Placebo Comparator|Placebo product|
3114906|NCT02515331|Experimental|LHW090 100 mg|LHW090 100 mg once daily for 28 days
3114907|NCT02515331|Experimental|LHW090 200 mg|LHW090 200 mg once daily for 28 days
3114908|NCT02515331|Placebo Comparator|Placebo|Matching placebo to LHW090 oral dose for 28 days
3114909|NCT02515630|Experimental|Momelotinib|MMB for 24 weeks (± 7 days)
3114910|NCT02515656|Experimental|POLYGYNAX®|Name : POLYGYNAX® Active components : nystatin 100 000 IU + neomycin sulphate 35 000 IU + polymyxin B sulphate 35 000 IU Dosage : 1 capsule intravaginally per day (administered at bedtime lying down) 12 vaginal soft capsules
3114911|NCT02515656|Active Comparator|miconazole + placebo|Name : GYNODAKTARIN® Active components : miconazole nitrate 400 mg Dosage : 1 capsule intravaginally per day (administered at bedtime, lying down) 3 vaginal soft capsules followed by 9 placebo vaginal soft capsules
3114912|NCT02515669|Active Comparator|RO7239361|RO7239361 subcutaneous injections on specified days
3114913|NCT02515669|Placebo Comparator|Placebo|Placebo subcutaneous injections on specified days
3114914|NCT02515825||AMBIENCE|CADence System testing followed by coronary angiogram
3114915|NCT02515825||AMBIENCE plus R&R Substudy|CADence System testing for repeatibility and reproducibility (4x by 2 operators) followed by coronary angiogram
3114916|NCT02515890|Experimental|Dexmedetomidine Only|All subjects receive saline (control), followed by a dexmedetomidine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3114917|NCT02515890|Experimental|Midazolam Only|Subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3114918|NCT02515890|Experimental|Ketamine Only|All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.
3114919|NCT02515890|Experimental|Saline/Midazolam/Saline/Ketamine|"All subjects receive saline (control), followed by midazolam infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by ketamine infusion."
3114920|NCT02515890|Experimental|Saline/Ketamine/Saline/Midazolam|"All subjects receive saline (control), followed by ketamine infusion. They also experience intermittent experimental pain delivered by peripheral nerve stimulation.~Subjects then returned at least 1 week later for another set of experimental sessions with the same design, however the saline was followed by midazolam infusion."
3114921|NCT02515942|Experimental|CLG561|CLG561 10 mg, one IVT injection every 28 days for a total of 12 injections
3114922|NCT02515942|Experimental|CLG561+LFG316|CLG561 5mg + LFG316 5 mg, one IVT injection every 28 days for a total of 12 injections
3114923|NCT02515942|Sham Comparator|Sham Injection|One sham injection every 28 days for total of 12 sham injections
3114924|NCT02515994|Experimental|senofilcon C|JJVCI investigational contact lens daily wear replacement.
3114925|NCT02515994|Active Comparator|comfilcon A|Marketed contact lens daily wear replacement.
3114926|NCT02516046|Experimental|Flortaucipir PET Scan|
3114927|NCT02516098|Active Comparator|Hyoscine butylbromide SCT|
3114928|NCT02516098|Experimental|Hyoscine butylbromide|
3114929|NCT02516150|Experimental|Glucagon with Ethanol|Volunteers will receive an infusion of IV ethanol that will increase their BAC (blood alcohol content) to 0.1. Once their BAC has stabilized at 0.1%, 50 micrograms of glucagon will be administered via subcutaneous injection.
3114930|NCT02516150|Active Comparator|Glucagon without Ethanol|Volunteers will not receive an infusion of IV ethanol at this visit. 50 micrograms of glucagon will be administered via subcutaneous injection.
3114931|NCT02516163|Other|Shapematch Cutting Guides|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
3114932|NCT02516202|Active Comparator|Vagifem|"One hundred participants will be randomized into the Vagifem® 'active' arm. These women will receive a bottle of Vagifem® tablets (estradiol 10 mcg). One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.~Vagifem® tablets contain 10.3 mcg of estradiol hemihydrate equivalent to 10 mcg of estradiol. The excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate. Vagifem® comes as a small white film-coated tablet. The coating is made of hypromellose and polyethylene glycol.~A placebo gel visually similar to Replens composed of inert hydroxyethylcellulose gel (pH adjusted) applied every 3 days over entire 12 weeks."
3114933|NCT02516202|Active Comparator|Replens|"One hundred participants will be randomized into the Replens® 'active' arm. These women will receive a tube containing Replens® vaginal gel, with 2.5 gm applied vaginally every 3 days over 12 weeks.~Replens® is a bioadhesive polycarbophil-based moisturizing vaginal gel containing; purified water (vehicle humectant), glycerin (moisturizer), mineral oil (as a moisturizer), polycarbophil and carbomer homopolymer type B (allow the product to stick to the vaginal wall), hydrogenated palm oil glyceride (moisturizer), sorbic acid (preservative, antimicrobial), methylparaben, sodium hydroxide (adjusts pH of product so it is suitable for vaginal use).~A placebo tablet visually identical to Vagifem® is inserted daily for 2 weeks, then 2 days/week for remaining 10 weeks."
3114934|NCT02516202|Placebo Comparator|Placebo|"One hundred participants will be randomized into the 'placebo' arm of the study. This arm is comprised of two placebo preparations; placebo tablet and placebo gel applied on the same schedule as 'active' arms.~The placebo tablet coating and excipient ingredients will be the same as are used for Vagifem®; the coating is made of hypromellose and polyethylene glycol and the excipient (inactive) ingredients are hypromellose, lactose monohydrate, maize starch, and magnesium stearate.~Placebo gel. The product is an inert hydroxyethylcellulose gel (pH adjusted)."
3469280|NCT03888170||Pregnant with hypertension|Pregnant women aged 18-45 undergoing cesarean section at or beyond 34 weeks gestational age with pregnancy complicate by chronic hypertension, gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, or superimposed preeclampsia.
3469281|NCT03888261|Active Comparator|Active Intervention:|Mind-body intervention (incl. Relaxation Response Resiliency Program & the Open and Calm Program)
3114938|NCT02516306|Experimental|EV06 Ophthalmic Solution|EV06 Ophthalmic Solution: Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
3114939|NCT02516306|Placebo Comparator|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution (EV06 vehicle): Day 1 - 7 one drop twice per day in one eye; Day 8 - 91 one drop twice per day in both eyes.
3114940|NCT02516332|Experimental|Supervised Aerobic Exercise|Patients will exercise three times per week, under medical supervision, at a level of 70-85% of their VO2peak as determined at the time of their baseline exercise stress test. Patients' exercise will consist of 10 minutes of gradual warm-up exercises followed by 35 minutes of continuous walking, biking, or jogging, and 5 minutes of cool down exercises for a total a 50 minutes per session. Patients will be instructed to monitor their radial pulses and will be checked at least three times per session to ensure that they are within their prescribed exercise training ranges.
3114941|NCT02516332|Experimental|Lexapro|Treatment in the medication will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service. The investigators will use the SSRI escitalopram (Lexapro), which has received FDA approval for the treatment of anxiety, in 5 mg capsules. Medication will be dispensed as capsules of escitalopram in individually coded bottles. Medication adherence will be assessed using pill count at each study visit. Patients will visit face-to-face with a study psychiatrist at week 0 (baseline), week 1, week 2, week 4, week 8, and week 12 with phone encounters at weeks 3 and 6. The psychiatrist will make all medication adjustments based primarily upon Spielberger Anxiety Scores. Depending on symptoms, daily escitalopram doses will be titrated to 10 mg after week 2 and to 15 mg or placebo equivalent at week 3 if patients show no change or only minimal improvement.
3114942|NCT02516332|Placebo Comparator|Placebo|Treatment in the medication and placebo pill arms will be supervised by a study psychiatrist. Drug dispensing will be done by licensed pharmacists at the Duke Investigational Pharmacy Service, who have extensive experience in clinical trials. Medication will be taken once daily in the morning but can be switched to once daily in the evening if deemed necessary. Placebo medication administration will follow the same protocol as outlined for Lexapro.
3114943|NCT02516410|Experimental|VX-661/IVA|VX-661 100 milligram (mg) plus IVA 150 mg fixed dose combination (FDC) tablet administered orally in the morning and IVA 150 mg film-coated tablet administered orally in the evening up to Week 12.
3114944|NCT02516410|Placebo Comparator|Placebo|Placebo matched to VX-661 plus IVA FDC tablet administered orally in the morning and placebo matched to IVA film-coated tablet administered orally in the evening up to Week 12.
3114945|NCT02516592|Experimental|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. Capsules for inhalation
3114946|NCT02516592|Active Comparator|salmeterol/fluticasone 50/500 micrograms|salmeterol/fluticasone 50/500 micrograms b.i.d. Dry inhalation powder
3114947|NCT02516605|Experimental|LJN452|
3114948|NCT02516605|Placebo Comparator|Placebo|
3114949|NCT02516982||Screening - Scrolling layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~All questions will be presented on a single screen. This means that participants will have to scroll vertically in order to answer all the questions."
3114950|NCT02516982||Screening - Paging layout|"Participants will be asked to complete a survey consisting of three sections using an iPad Air tablet:~Section 1: Demographic information survey~Section 2: Whooley questions~Section 3: Edinburgh Postnatal Depression Scale~Only one question will be presented at any given time. This means that participants will have to navigate through multiple pages in order to answer all the questions."
3114951|NCT02516982||Retrospective plus momentary assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of 6 consecutive days, once a month for 6 months. During the 6 assessment days, participants will be required to complete the Edinburgh Postnatal Depression Scale, 5 momentary questions on a 5-point pictorial scale, and 2 contextual questions.
3114952|NCT02516982||Retrospective assessment|Participants in this group will be asked to download and install an app onto their own smartphones. After that, they will be asked to complete a sampling protocol consisting of one day a month for 6 months. The assessment days will consist of a single administration of the Edinburgh Postnatal Depression Scale.
3114953|NCT02517021|Experimental|Pro-netupitant/Palonosetron plus Dexamethasone|Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3114954|NCT02517021|Active Comparator|Netupitant/Palonosetron plus Dexamethasone|Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle
3114955|NCT02517047|Experimental|CareTRx Device|Subject will receive CareTRx device for rescue inhaler as well as the application downloaded to their Android phone. The device will track when the rescue inhaler is administered. The information will then be loaded to phone app.
3114956|NCT02517268|Active Comparator|Standard 7-Day Pathway|Patients follow the standard 7-day pathway following pancreaticoduodenectomy
3114957|NCT02517268|Experimental|Accelerated 5-Day Pathway|Patients follow the Whipple accelerated 5-day pathway following pancreaticoduodenectomy. The accelerated pathway includes more rapidly leaving the ICU setting, early mobilization and enhanced physical therapy, multimodal pain control, dietary modifications, and increased and standardized phone contact by a nurse practitioner during the first week following hospital discharge.
3114958|NCT02517463||Pre-ovulatory|Ulipristal acetate 30 mg single oral dose
3114959|NCT02517463||Post-ovulatory|Ulipristal acetate 30 mg single oral dose
3114960|NCT02517515|Experimental|Double-blind 3-DAA|Double-blind 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3114961|NCT02517515|Experimental|Double-blind Placebo Followed by Open-label 3-DAA|Double-blind placebo for 12 weeks, followed by open-label 3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) for 12 weeks.
3114962|NCT02517528|Experimental|ABT-450/r/ABT-267 + ABT-333 + Ribavirin|ABT-450/r/ABT-267 once daily + ABT-333 twice daily + weight-based RBV divided twice daily for 12 weeks
3114963|NCT02517541|Experimental|Test period|The arm consists of a two-week baseline period where subjects apply their own product and a 12 weeks test period where the subjects apply the intervention (SenSura Mio Convex Soft)
3114964|NCT02517567|Other|Sequence 1|Delefilcon A, then narafilcon A, then somofilcon A, then no lens wear. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3114965|NCT02517567|Other|Sequence 2|Narafilcon A, then no lens wear, then delefilcon A, then somofilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3114966|NCT02517567|Other|Sequence 3|Somofilcon A, then delefilcon A, then no lens wear, then narafilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3114967|NCT02517567|Other|Sequence 4|No lens wear, then somofilcon A, then narafilcon A, then delefilcon A. Each contact lens product was worn for 8 hours. The 'No Lens wear' treatment was evaluated over an 8 hour period.
3114968|NCT02517580|Experimental|Vitamin K2 (MK7)|Vitamin K2 (MK7) 360 mcg/day PO once daily for 8 weeks
3114969|NCT02517658|Active Comparator|Standard Discharge Teaching|Parents will receive standard discharge teaching from the nurse prior to discharge.
3114970|NCT02517658|Experimental|Video w/ post exam immediately after video|Parents will watch the video and then take the post test immediately after watching the video.
3114971|NCT02517658|Experimental|Video w/ post exam after discharge teaching|Parents will watch the video but wait to take the post exam until after the discharge instructions are given by the nurse prior to discharge.
3114972|NCT02517866|Experimental|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of <140/85 mmHg at Week 6.
3114973|NCT02517905|Experimental|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
3114974|NCT02517905|Placebo Comparator|Placebo|10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration
3114975|NCT02517996|Experimental|1% Lidocaine|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters 1% lidocaine after anesthesia induction.
3114976|NCT02517996|Placebo Comparator|Normal Saline|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
3114977|NCT02518048|Active Comparator|LEO 90100 Aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g (LEO 90100 Aerosol foam)
3114978|NCT02518048|Active Comparator|Betesil® 2.25 mg|Betamethasone (as valerate). Each 7.5 cm x 10 cm medicated plaster contains: 2.250 mg of betamethasone valerate (corresponding to 1.845 mg of betamethasone).(Betesil® )
3114979|NCT02518113|Experimental|LY3039478 + Dexamethasone (Adult)|"Part A: 50 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~75 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~100 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~125 mg LY3039478 administered orally three times per week (TIW) and 24 mg dexamethasone administered orally on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression."
3114980|NCT02518113|Experimental|LY3039478 + Dexamethasone (Pediatric)|"Part B: LY3039478 administered orally TIW at escalating doses and dexamethasone administered orally twice a day (BID) on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Part B of the study."
3114981|NCT02518113|Experimental|Phase 2: LY3039478 + Dexamethasone|"LY3039478 administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
3114982|NCT02518113|Placebo Comparator|Phase 2: Placebo + Dexamethasone|"Placebo administered orally TIW and dexamethasone administered orally BID on days 1-5 every other week during 28 day cycles. Participants receiving benefit may continue until disease progression.~There were no participants enrolled to Phase 2 of the study."
3114983|NCT02518139|Experimental|TD-4208-1|88 mcg
3114984|NCT02518139|Experimental|TD-4208-2|175 mcg
3114985|NCT02518139|Active Comparator|Tiotropium|18 mcg
3114986|NCT02518191|Experimental|GnRHa group|Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
3114987|NCT02518191|No Intervention|None GnRHa group|Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.
3114988|NCT02518230|Other|Neurally Adjusted Ventilatory Assist|Subject will be randomized to NAVA ventilation. Intervention is mechanical ventilation with Neurally Adjusted Ventilatory Assist for 12 hours.
3114989|NCT02518230|Other|Synchronized Interm. Mandatory Assist|Subject will be randomized to SIMV(PC)PS ventilation. Intervention is mechanical ventilation with Synchronized Intermittent Mandatory Assist with Pressure Support for 12 hours.
3114990|NCT02518464|Experimental|Ticagrelor 90 mg twice per day|Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.
3114991|NCT02518490|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
3114992|NCT02518490|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens on one eye and control lens on one eye.
3114993|NCT02518620|Experimental|ALX-0061 150 mg q2w (+ MTX)|
3114994|NCT02518685|Experimental|TransPyloric Shuttle (TPS)|TransPyloric Shuttle plus Lifestyle Counseling
3114995|NCT02518685|Sham Comparator|Control|Sham procedure plus Lifestyle Counseling
3114996|NCT02518919|No Intervention|Standard|Patients will receive intravenous ketamine (1-2mg/kg)
3114997|NCT02518919|Experimental|Child Life Intervention|Child life therapist will comfort the child during all painful procedures(including IV insertion) and during sedation
3114998|NCT02518919|Experimental|Music Listening|Patients will listen to music of their choice using headphones during sedation
3114999|NCT02518971|Experimental|tamsulosin|0.4 mg daily for five days pre-op through post-op day one (seven total)
3115000|NCT02518971|Placebo Comparator|placebo|One capsule daily for five days pre-op through post-op day one (seven total)
3115001|NCT02518997|Experimental|All enrolled infants|All participants will have Parental Reading Aloud at the prescribed intervals while being monitored for cardio-respiratory stability.
3115002|NCT02519023|Experimental|TAP-Block with liposomal bupivacaine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side. In the same arm the surgeon infiltration into the incision will consist of 10 ml of normal saline per port site, 5 ml prior to incision and 5 ml prior to closure at each port site.
3115003|NCT02519023|Active Comparator|Surgical infiltration with bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
3115004|NCT02519036|Experimental|ISIS 443139 10 mg|Participants received ISIS 443139, 10 milligrams (mg), by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115005|NCT02519036|Experimental|ISIS 443139 30 mg|Participants received ISIS 443139, 30 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115006|NCT02519036|Experimental|ISIS 443139 60 mg|Participants received ISIS 443139, 60 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115007|NCT02519036|Experimental|ISIS 443139 90 mg|Participants received ISIS 443139, 90 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115008|NCT02519036|Experimental|ISIS 443139 120 mg|Participants received ISIS 443139, 120 mg, by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115009|NCT02519036|Placebo Comparator|Placebo|Participants received placebo, by intrathecal injection, on Study Days 1, 29, 57, and 85.
3115010|NCT02519231|Active Comparator|Treatment|This study arm includes naproxen as potential treatment for heavy or prolonged bleeding or dysmenorrhea may provide useful preliminary data for a larger, adequately powered placebo-controlled comparative trial testing additional promising treatments, such as tranexamic acid.
3115011|NCT02519231|Placebo Comparator|placebo|This study arm includes capsules that are exactly like the active treatment medication (naproxen), but there is no active treatment medication in these tablets.
3115012|NCT02519244|Experimental|Robot-assisted rehabilitation|Subjects will participate in individualized locomotion training sessions using wearable lower limb exoskeleton, Ekso®. Each training session will last up to 60 minutes, 5 days per week for 3 weeks, for a total of 15 sessions. During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit.
3115013|NCT02519387|Experimental|Buprenorphine Transdermal Patch|Buprenorphrine transdermal patch 5mg/10mg, every 7 days, for 3 months
3115014|NCT02519491|Active Comparator|Modified Allen's Test|The Modified Allen's Test to assess radial and ulnar patency.
3115015|NCT02519491|Active Comparator|Iphone assessment|iPhone assessment of radial and ulnar patency.
3469282|NCT03888261|No Intervention|No Intervention|No intervention (Study participants will receive routine clinical practice)
3115016|NCT02519504||Duarte galactosemia|Pediatric subjects with Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
3115017|NCT02519504||Control|Pediatric subjects without Duarte galactosemia will undergo direct assessments of cognitive skills (memory, executive function, and auditory processing), communication processes (speech and language), physical development (including motor skills, coordination, and occurrence of tremors), and social-emotional development.
3115018|NCT02519595|Experimental|ketamine IV 1 mg/kg|Intervention: A blinded dose of 1mg/kg IV ketamine is administered to patients
3115019|NCT02519595|Experimental|Ketamine IV 1.5 mg/kg|Intervention: A blinded dose of 1.5mg/kg IV ketamine is administered to patients
3115020|NCT02519595|Experimental|Ketamine IV 2 mg/kg|Intervention: A blinded dose of 2 mg/kg IV ketamine is administered to patients
3115021|NCT02519621|Active Comparator|NPWT PRO without irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage
3115022|NCT02519621|Active Comparator|NPWT PRO with Irrigation|Cardinal Health NPWT PRO system (K143016) continuous/intermittent vacuum-assisted drainage with simultaneous delivery of topical wound treatment solutions and suspensions over the wound bed (saline irrigant).
3115023|NCT02519621|Active Comparator|KCI Ulta NPWT|KCI Ulta NPWT without irrigation.
3115024|NCT02519842|Experimental|Fosaprepitant Regimen Cycle 1|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) administered intravenously (IV) on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3115025|NCT02519842|Placebo Comparator|Control Regimen Cycle 1|Participants received a single dose of matched placebo for fosaprepitant IV on Day 1 prior to chemotherapy plus ondansetron IV on Day 1 prior to chemotherapy and at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy. Participants may have also received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3115026|NCT02519842|Experimental|Fosaprepitant Regimen Cycles 2-6|Participants received a single dose of fosaprepitant 150 mg (or age-based adjustment) IV on Day 1 prior to chemotherapy plus a 5-hydroxytryptamine 3 (5-HT3) antagonist on Day 1 prior to chemotherapy and per product label or standard of care. Participants may also have received dexamethasone IV at investigator's discretion on day(s) of chemotherapy and up to 24 hours after chemotherapy.
3115027|NCT02519855|Experimental|Concomitant Vaccination|ZOSTAVAX™ concomitantly with influenza vaccine on Day 1, placebo to ZOSTAVAX™ at Week 4
3115028|NCT02519855|Experimental|Nonconcomitant Vaccination|Influenza vaccine and placebo to ZOSTAVAX™ on Day 1, ZOSTAVAX™ at Week 4
3115029|NCT02520011|Experimental|ACM (Stage 1 / Stage 2)|A: alvocidib, 30 mg/m2 as a 30 minute intravenous (IV) bolus followed by 60 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3; C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 6-8; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3115030|NCT02520011|Active Comparator|CM (Stage 2)|C: cytarabine (ara-c), 2 gm/m2 by continuous IV infusion over 72 hours on Days 1-3; M: mitoxantrone (mitoxantrone hydrochloride), 40 mg/m2 by IV infusion over 1-2 hours starting 12 hours after completing cytarabine
3115031|NCT02520089|Active Comparator|Bone autograft|The investigator it will obtain bone autograft of iliac crest ipsilateral of each patient. And apply into the pseudoarthrosis focus at the moment of the fixation with a locking compression plates.
3115032|NCT02520089|Experimental|platelet rich plasma plus Bone autograft|Other group of patients it will be extracted 40 mL of peripheric blood sample, and processed with a double-centrifugation technique to obtain 5 mL of platelet rich plasma, and collocated into the focus of pseudoarthrosis after standard fixation with locking compression plates and Bone Autograft of Iliac Crest.
3115033|NCT02520284|Experimental|Andecaliximab Every 2 Weeks|Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
3115034|NCT02520284|Experimental|Andecaliximab Weekly|Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
3115035|NCT02520284|Placebo Comparator|Placebo|Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
3115036|NCT02520310|Experimental|AVJ-514|The AVJ-514 system
3115037|NCT02520388|Experimental|HLD200 (methylphenidate)|"Experimental: HLD200 (methylphenidate)~The investigational drug for this study is HLD200 MPH MR capsules comprised of the active pharmaceutical ingredient (MPH) in a dual-coated drug-layered core. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind HLD200 to be taken once daily during the evening for a period of 3-weeks prior to testing."
3115038|NCT02520388|Placebo Comparator|Placebo|Placebo capsules will be composed of microcrystalline cellulose beads in place of MPH containing beads found in the HLD200 capsules. Following a minimum 72-hour washout, subjects will be randomized (1:1) to double-blind placebo to be taken once daily during the evening for a period of 3-weeks prior to testing.
3115039|NCT02520414|Experimental|Symphion®|Patients treated in-office with Symphion® Bipolar Hysteroscopic Tissue Resection System.
3115040|NCT02520518|Experimental|Dapagliflozin: ad libitum dietary intake|Daily oral administration of dapagliflozin with ad libitum dietary intake. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3115041|NCT02520518|Experimental|Dapagliflozin: weight maintenance|Daily oral administration of dapagliflozin with supplemented dietary intake to achieve weight maintenance. The dose of dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
3115042|NCT02520518|Placebo Comparator|Placebo: ad libitum dietary intake|Daily oral administration of a placebo with ad-libitum dietary intake. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3115043|NCT02520518|Placebo Comparator|Placebo: dietary restriction|Daily oral administration of a placebo plus dietary restriction such that weight loss is matched to participants in Arm 1. Matching placebo for dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
3115044|NCT02520531|Active Comparator|Scorpio PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio PS Total Knee Replacement.
3115045|NCT02520531|Active Comparator|Scorpio NRG PS|Patients on the waiting list for a total knee prosthesis who fulfil the inclusion and exclusion criteria will be asked to participate in this study and are randomized to receive the Scorpio NRG PS Total Knee Replacement.
3115046|NCT02521181|Experimental|Lower Dose Sodium Bicarbonate|Participants will receive oral 0.5 milliequivalents (mEq)/kg-lean body weight (LBW)/day of sodium bicarbonate. Half of the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3115047|NCT02521181|Experimental|Higher Dose Sodium Bicarbonate|Participants will receive 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3115048|NCT02521181|Placebo Comparator|Placebo|Participants will take the same number of placebo capsules as if they were assigned to receive either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of sodium bicarbonate. Half the total daily dose is taken in the morning and the other half is taken in the evening. (If the number of capsules is an odd number, the greater number of capsules will be taken in the morning.)
3115049|NCT02521259||low Bispectral index (BIS) group|BIS range under 40
3115050|NCT02521259||normal BIS group|BIS range from 40 to 60
3115051|NCT02521376|Experimental|Cohort 1 (Moderate Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
3115052|NCT02521376|Experimental|Cohort 2 (Severe Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
3115053|NCT02521376|Experimental|Cohort 3 (Mild Hepatic Impairment)|Entospletinib administered twice daily on Days 1-4, and 1 morning dose only on Day 5.
3115054|NCT02521766|Experimental|All HMIOL Cohort|HMIOL implantation with or without optic exchange
3115055|NCT02521766|Experimental|Cohort 1|HMIOL implantation with no optic exchange
3115056|NCT02521766|Experimental|Cohort 2|HMIOL implantation with optic exchange
3115057|NCT02521766|Other|Fellow Eye|IOL implantation per standard of care
3115058|NCT02521792|Experimental|Palovarotene|The protocol is open only to the subjects who completed Clementia Study PVO-1A-202. Eligible subjects will receive a weight-based equivalent dose of palovarotene 10 mg once daily for 14 days, followed by 5 mg once daily for 28 days. Should treatment be extended beyond 6 weeks, a weight-based equivalent dose of 5 mg will be administered in 2-week increments.
3115059|NCT02521870|Experimental|Dose Escalation Phase 1b|Determine the maximum tolerated dose (MTD) of escalating doses of SD-101(1) administered in combination with pembrolizumab in patients with melanoma (anti-PD-1/L1 therapy naïve and experienced patients with progressive disease).
3115060|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 1)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
3115061|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 2)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent or metastatic melanoma.
3115062|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 3)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
3115063|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 4)|Determine the safety and efficacy of SD-101(2) and pembrolizumab in anti-PD-1/L1 therapy progressing patients with recurrent head and neck squamous cell carcinoma.
3115064|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 5)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent or metastatic melanoma.
3115065|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 6)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy naïve patients with recurrent head and neck squamous cell carcinoma.
3115066|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 7)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent head and neck squamous cell carcinoma.
3115067|NCT02521870|Experimental|Dose Expansion Phase 2 (Cohort 8)|Determine the safety and efficacy of SD-101(3) and pembrolizumab in anti-PD-1/L1 therapy refractory or resistant patients with recurrent or metastatic melanoma.
3115068|NCT02521948|Experimental|MANTA Vascular Closure Device|The MANTA device, developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
3115069|NCT02521974|Experimental|SABIN monovalent OPV2 vaccine|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid
3115070|NCT02522104|Experimental|Normal-renal function|Normal-renal function: 90 ≤ GFR ≤ 130 mL/min/1.73m2 in women or 140 mL/min/1.73m2 in men
3115071|NCT02522104|Experimental|Glomerular hyperfiltration|Glomerular renal hyperfiltration: GFR > 130 mL/min/1.73m2 in women and GFR > 140 mL/min/1.73m2 in men.
3115072|NCT02522104|Experimental|Moderate renal failure|Moderate renal failure: 30 ≤ GFR ≤ 60 mL/min/1.73m2
3115073|NCT02522286|No Intervention|Usual Care|Standard clinical care in primary care offices
3115074|NCT02522286|Experimental|Ask 3 Questions|Patients using 3 questions to their physicians when making medical decisions during the office visit.
3115075|NCT02522286|Experimental|Open Communication|This arm has three components: (1) Patients, physicians, and medical assistants watching a video aimed at encouraging open communication; (2) Patients fill out a Visit Companion Booklet about what are the most important issues they want to discuss with their physicians, record their next steps, and teach back on their next steps; (3) physicians receiving communication coaching from a Standardized Patient Instructor on patient-centered communication.
3115076|NCT02522286|Experimental|Ask 3 Questions + Open Communication|A combination of both the Ask 3 and Open Communication arms.
3115077|NCT02522299|Experimental|GSK2269557 1000 microgram (mcg)|Subjects will receive 2 inhalations of GSK2269557 (30 seconds apart, 2 x 500 mcg, total dose of 1000 mcg) once daily for 84 consecutive days via DISKUS™ device.
3115078|NCT02522299|Placebo Comparator|Placebo via DISKUS|Subjects will receive 2 inhalations of placebo once daily for 84 days via DISKUS device.
3115079|NCT02522299|Experimental|GSK2269557 700 mcg|Subjects will receive 2 inhalations of GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
3115080|NCT02522299|Placebo Comparator|Placebo via ELLIPTA|Subjects will receive Placebo once daily for 84 consecutive days via ELLIPTA.
3115081|NCT02522325|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo, administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3115082|NCT02522325|Experimental|Phendimetrazine|Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3115083|NCT02522377|Experimental|Ketamine Infusions|Subjects who are randomized to be on this group will receive a standard dose of ketamine interleaved with Electroconvulsive Treatments.
3115084|NCT02522377|Active Comparator|Midazolam|Subjects who are randomized to be on this group will receive midazolam infusions interleaved with Electroconvulsive Treatments.
3115085|NCT02522403|Active Comparator|Rehabilitation|The investigators will be apply laser acupuncture for the rehabilitation of the wrist and hand of the patients, with the laser device in an off position, plus exercise of wrist flexion, extension, cubital and radial deviation, pronation and supination of the forearm. The investigators will be use ten different acupuncture points for treat this patients.
3115086|NCT02522403|Experimental|Low Lever Laser acupuncture|The investigators will utilize an low level laser therapy device apply into each acupuncture point. Ten acupuncture points will be used. Each acupuncture point will be irradiated for 30 seconds at 8,000 Hz.
3115087|NCT02522442|Experimental|Auto BiLevel Group|Auto Bilevel; auto-titrating bilevel positive airway pressure device with pressure flexing used as experimental treatment for obstructive sleep apnea
3115088|NCT02522442|Active Comparator|CPAP Group|CPAP; continuous positive airway pressure used as comparator treatment for obstructive sleep apnea
3115089|NCT02522481|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
3115090|NCT02522494|Active Comparator|Intervention|Patients randomized to the intervention will view the video
3115091|NCT02522494|Other|Pamphlet alone|Patients randomized to the pamphlet alone will only receive the pamphlet
3115092|NCT02522624|Experimental|Decision Aid (DA)|The decision aid (DA) will be provided to participants randomized to the experimental/intervention group.
3115093|NCT02522624|No Intervention|Control|Participants randomized to the control group will receive usual care. They will be directed to the healthcare.gov website and asked to follow the prompts to view and select (if applicable) a health insurance plan.
3115094|NCT02522715|Experimental|Treatment (cabazitaxel, enzalutamide)|Patients receive cabazitaxel IV over 1 hour on day 1 and enzalutamide PO QD on days 1-21 (days 2-21 of cycle 1). Patients also receive prednisone PO BID as standard of care with cabazitaxel. Cycles repeat every 21 days for 6-10 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue enzalutamide PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity.
3115095|NCT02522728|Active Comparator|Triathlon CR|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
3115096|NCT02522728|Active Comparator|Triathlon PS|Triathlon Cruciate Retaining (CR) versus Triathlon Posterior Stabilized (PS): During knee prosthesis surgery the surgeon many times need to make a judgement on if to keep a defect anatomical structure or if to replace it with knee prosthesis with a design that allows for adjustment of this defect. This study is aimed to evaluate which prosthetic choice to be made in respect of stability, long-term results and patient outcome.
3115097|NCT02522767|Experimental|Mesalamine|4 g extended release granules (sachet)
3115098|NCT02522767|Placebo Comparator|Placebo|Matching placebo
3115099|NCT02522780|Experimental|Mesalamine|Mesalamine 2 g extended release granules (sachet), administered orally once daily (QD) for 6 months.
3115100|NCT02522780|Placebo Comparator|Placebo|Placebo matched to mesalamine extended release granules (sachet), administered orally QD for 6 months.
3115101|NCT02522845|Active Comparator|Compression|Patients randomised to this group will be asked to wear Class II compression stockings for 1 week
3115102|NCT02522845|No Intervention|No Compression|Patients randomised to this group will not be provided with any compression
3115103|NCT02522884|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections.
3469283|NCT03888144|Active Comparator|Oxycodone group|Patients randomized to 20 pills of 5 mg oxycodone by mouth every 6 hours as needed for pain after ureteroscopy.
3115104|NCT02523196|Other|(HVPG) and HepQuant-SHUNT (HQ-Shunt)|"Successful Hepatic Venous Pressure Gradiant (HVPG) testing is required prior to administration of the HepQuant-SHUNT test.~Comparison of Disease Severity Index (DSI) from HQ-SHUNT with HVPG in identifying patients with cirrhosis and patients with varices."
3115105|NCT02523235|Active Comparator|proximal catheter insertion|"Adductor canal catheters: Inserted as described by Jæger et al., 2013: …we performed an ultrasound survey at the medial part of the thigh, halfway between the superior anterior iliac spine and the [superior border of the] patella. In a short axis view, we identified the femoral artery underneath the sartorius muscle, with the vein just inferior and the saphenous nerve just lateral to the artery.~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle will be inserted to intersect the sciatic nerve 6-7 cm proximal to the mark on the skin (therefore, proximal to the sciatic bifurcation) and injection with saline used to ensure subepimyseal spread."
3115106|NCT02523235|Experimental|distal catheter insertion|"Adductor canal catheters: Inserted as described by Manickam et al. 2009~Popliteal catheters: Using an ultrasound, the bifurcation of the sciatic nerve will be identified in short axis and marked at a point immediately distal at which point the two main branches of the sciatic nerve are separate and a hypoechoic area can be viewed between the two. This level will be marked on the skin. The needle tip will be inserted into the hypoechoic area between the two branches of the sciatic nerve immediately distal to the sciatic nerve bifurcation between the paraneurium and epineurium (the subparaneural space/compartment). As described by Tran et al, An adequate position was defined as the presence of circular expansion of the paraneural sheath... Once circular expansion was obtained, we injected."
3115107|NCT02523586||Oxygen administration|Via Simple Mask, Via Non-rebreather, Via OxyMask, Via Anesthesia Mask (head strap and J-R circuit), Via Room Air
3115108|NCT02523599|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
3115109|NCT02523599|Placebo Comparator|Placebo|3 placebo implants
3115110|NCT02523690|Experimental|Intervention|Lorcaserin will be administered as a single dose on day 1 and day 3 to participants in this arm.
3115111|NCT02523690|Placebo Comparator|Control|Placebo will be administered as a single dose on day 1 and day 3 to participants in this arm.
3115112|NCT02523924|Experimental|18F-DCFPyL PET/CT|Men with an elevated PSA following radical prostatectomy imaged with 18F-DCFPyL PET/CT
3115113|NCT02524054|Experimental|Aerosol furosemide Study 2a|Subjects will inhale 40mg of furosemide aerosol over the course of 10-15 min. This will be a single, unblinded administration.
3115114|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm F|Inhalation of furosemide aerosol one one day then placebo saline aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
3115115|NCT02524054|Experimental|Aerosol furosemide Study 2b Arm S|Inhalation of saline aerosol one one day then furosemide aerosol on another day. Baseline measurement 15 min; Inhalation over the course of 10-15 min.; outcome measurement 15 min. Watch for adverse effects 2 hours.
3115116|NCT02524106|Experimental|Bococizumab|150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
3115117|NCT02524106|Placebo Comparator|Placebo|150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
3115118|NCT02524119|Experimental|LEE001 with Chemoembolization|A total of 40 patients will be enrolled and undergo chemoembolization. Patients will receive LEE011 (600 mg PO once daily, 3 weeks on/1 week off) on Day 1 with chemoembolization. Patients can receive a total of 4 chemoembolization treatments within 6 month following first treatment as needed to treat initial HCC lesion.
3115119|NCT02524145|Active Comparator|Healthy Seniors|"Fifteen healthy senior volunteers > 60 years of age. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins. All control subjects will have a Body Mass Index (BMI) <30, with exercise histories of less than 3 days per week of aerobic exercise.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3115120|NCT02524145|Experimental|HFpEF|"Patients with HFpEF will provide data from their cardiologist or primary care physician that confirm the following: a) signs and symptoms of heart failure; b) an ejection fraction > 0.50; and c) objective evidence of diastolic dysfunction.~Intervention: Static handgrip and Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3115121|NCT02524145|Active Comparator|Healthy Young|"Fifteen volunteers <45 yrs will be enrolled. Subjects will be healthy with no chronic medical problems and on no cardiac medications except for statins and have BMI <30.~Intervention: Autonomic Blockade (Dexmedetomidine, Glycopyrrolate, Isoproterenol)"
3115122|NCT02524158|Experimental|Yoga|The yoga intervention will consist of 2x weekly, 60-minute Hatha Yoga classes for 12 weeks, geared toward a CLBP population. Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
3115123|NCT02524158|No Intervention|Delayed Treatment Control - Usual Care|Participants randomly assigned to this arm are allowed to continue all existing treatments. Participants and their primary care physician are asked to not change treatments unless medically necessary. participants are asked to not do yoga for 6 months. They are given free yoga and a yoga mat after 6 months.
3115124|NCT02524288|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3115125|NCT02524418|Other|Cholangiopancreatoscopy|A standard of care Endoscopic Retrograde Cholangiopancreatoscopy (ERCP) will be performed using the Spyglass DS. The clinical outcomes will be collected and analyzed.
3115126|NCT02524561|Active Comparator|CEE pill, active progesterone|Conjugated equine estrogens 0.45 mg/day, placebo patch, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
3115127|NCT02524561|Active Comparator|estradiol patch, active progesterone|Transdermal estradiol, 50 mcg/day, placebo tablet, Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
3115128|NCT02524561|Placebo Comparator|placebo|Placebo tablet, placebo patch, placebo progesterone
3115129|NCT02524665|Experimental|MAXCLARITY II|MAXCLARITY II Foam Cleanser (2.5% BPO) plus Foam Treatment (2.5% BPO) and (0.5% Salicylic Acid) Toner Foam. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3115130|NCT02524665|Active Comparator|MURAD|MURADClarifying Cleanser (1.5% SA) plus Exfoliating Acne Treatment Gel (1% SA) and Skin Perfecting Lotion. Available over the counter. Each subject applies both arms (MAXCLARITY II and MURAD) simultaneously for the entire duration of the study (8 weeks), each arm to be applied to one side of the face only (split-face study) according to randomization.
3115131|NCT02524730|Other|Scorpio NRG CR Total Knee System|Primary total knee replacement
3115132|NCT02524769|Other|conjugated estrogen|All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.
3115133|NCT02524847|Experimental|Methoxsalen with ECP|Participants receive methoxsalen 20 µg/ml in conjunction with ECP procedure three times per week for Weeks 1 to 4, and two times per week for Weeks 5 to 12.
3115134|NCT02524977|Active Comparator|Educational Intervention Only|"Educational Intervention Only - Educational package was delivered as 2 didactic noon-conferences on atrial fibrillation with a review of up-to-date anticoagulation guidelines for stroke prevention, and distribution of educational materials. Physicians delivering the noon conference series at all of the general internal medicine and primary care practice sites included 3 stroke neurologists, 2 cardiologists, and a general internist (PI) who were co-investigators in this study. Internists who were faculty at the University of Cincinnati and Internal Medicine residents also had an opportunity to participate in the first of the noon conferences in a special Department of Medicine Grand Rounds delivered by the PI.~All practices (intervention and control groups) received the educational package focused on physicians, and clinical and non-clinical staff who would be involved in this QI process."
3115135|NCT02524977|Experimental|Educational Intervention plus Decision Support|Educational Intervention plus Decision Support - Physicians in the intervention arm received a practice-level and physician-level summary report via a secure web site designed for patients with treatment recommendations that were discordant with current therapy, along with an explanation for the recommendation, the gain or loss in QALYs predicted by the decision model and the current 2014 ACC/AHA/HRS guidelines. Providers were also reminded of upcoming visits for patients being seen within the next week so they could review their reports and use them in discussions with their patients.
3115136|NCT02525055|Experimental|Infectious titre 1|6 participants aged 18 to 45 were inoculated with 1mL containing 2.8 x 10*3 TCID50 of virus
3115137|NCT02525055|Experimental|Infectious titre 2|6 participants aged 18 to 45 were inoculated with 1mL containing 2.5 x 10*4 TCID50 of virus
3115138|NCT02525055|Experimental|Infectious titre 3|6 participants aged 18 to 45 were inoculated with 1mL containing 3.6 x 10*5 TCID50 of virus
3115139|NCT02525055|Experimental|Infectious titre 4|6 participants aged 18 to 45 were inoculated with 1mL containing 4.7 x 10*6 TCID50 of virus
3115140|NCT02525055|Experimental|Infectious titre 5 (age 18 to 45 y)|6 participants aged 18 to 45 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
3115141|NCT02525055|Experimental|Infectious titre 5 (age 46 to 64 y)|16 participants aged 46 to 64 were inoculated with 1mL containing 3.5 x 10*5 TCID50 of virus.
3115142|NCT02525094|Experimental|MEDI9929 280 mg|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
3115143|NCT02525094|Placebo Comparator|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
3115144|NCT02525133|Experimental|XaraColl|3 XaraColl Bupivacaine Implants each containing 100 mg of bupivacaine hydrochloride, for a 300 mg total dose
3115145|NCT02525133|Placebo Comparator|Placebo|3 placebo implants
3115146|NCT02525263|Experimental|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
3115147|NCT02525471|Experimental|RNS60|"Following screening visit to determine eligibility, enrolled subjects will undergo the baseline visit within 6 weeks where the first intravenous (IV) infusion of study medication, RNS60, will be administered. Study medication for inhalation use will be dispensed at this time, and again at weeks 7 and 15. Subjects will continue once a week follow ups to receive RNS60 by IV infusion, continuing inhalation use the remaining 6 days per week, for 23 weeks total. Additionally, eligible subjects will undergo PET imaging at baseline and again between weeks 18 and 23.~In addition, upon nearing completion of the core study, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug, following the optional extension phase schedule of activities."
3115148|NCT02525523|Experimental|Alicaforsen|Alicaforsen enema, 240mg once daily for 6 weeks
3115149|NCT02525523|Placebo Comparator|Placebo|Placebo enema, once daily for 6 weeks
3115150|NCT02525536|Experimental|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 milligram/kilogram (mg/kg), 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3115151|NCT02525536|Experimental|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3115152|NCT02525536|Experimental|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, 60-minute infusion, intravenously once weekly on Days 1, 8, 15 and 22 and thereafter once weekly starting from Day 36 (Week 6) until intolerance to investigational product, progressive disease, consent withdrawn, or lost to follow-up (up to approximately 249 weeks).
3115153|NCT02525549|Experimental|Test product|Adapalene and Benzoyl Peroxide Gel
3115154|NCT02525549|Active Comparator|Reference product|Adapalene and Benzoyl Peroxide Gel (Reference)
3115155|NCT02525549|Placebo Comparator|Placebo product|Placebo gel
3115156|NCT02525575|Experimental|Project Life Force Group Treatment|"Project Life Force Clinical Intervention: is a manualized, weekly 90-minute group treatment lasting 3 months coinciding with the time frame for enhanced monitoring of Veterans identified as high-risk. The use of Dialectical Behavior Therapy skills in PLF differs from other DBT interventions in that it focuses primarily on emotion regulation (ER), distress tolerance and interpersonal effectiveness in the specific context of implementing a safety plan. Mindfulness is not covered. PLF is augmented with additional skill modules on strengthening friendships and education pertaining to suicide risk, suicide means restriction and suicide prevention mobile Apps."
3115157|NCT02525588|Active Comparator|Conventional polyethylene inlay nitrogen/vacuum-packed (N2Vac)|Conventional UHMWPE inlay in a Triathlon Condyle Stabilizing (CS) fixed bearing total knee prosthesis
3115158|NCT02525588|Active Comparator|Highly cross-linked polyethylene (X3)|X3 highly cross-linked polyethylene inlay in a Triathlon CS fixed bearing total knee prosthesis
3115159|NCT02525627|Active Comparator|Trident cup, X3 inserts, 28 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
3115160|NCT02525627|Active Comparator|Trident cup, X3 inserts, 40 mm head|Equality of 5 year wear in the 28mm and the 40mm metal femoral head sizes. Trident cup in combination with Symax stem or Accolade TMZF stem.
3115161|NCT02525653|Experimental|Albumin-Bound Paclitaxel and Gemcitabine|During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.
3115162|NCT02525718|Placebo Comparator|Placebo|Subjects will be randomly selected to receive saline (placebo), administered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery.
3115163|NCT02525718|Active Comparator|0.25 % bupivacaine w/ epinephrine & 4mg dexamethasone|"Subjects will be randomly selected to receive selective block with a local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone. The injection will be performed in certain locations of the breast area to cover the intercostal nerves supplying the breast tissue.~Subjects will be randomly selected to receive the local anesthetic solution containing 0.25 % bupivacaine (2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasoneadministered to the breast area to cover the intercostal nerves supplying the breast tissue during surgery."
3115164|NCT02525744|Experimental|LY900014 7.5 Units (U)|Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods.
3115165|NCT02525744|Active Comparator|Insulin Lispro|Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods.
3115166|NCT02525744|Experimental|LY900014 15 U|Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods.
3115167|NCT02525744|Experimental|LY900014 30 U|Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.
3115168|NCT02525861|Experimental|Cohort I: GLASSIA (High-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the high end within) at 60 milligrams per kilogram (mg/kg) BW active A1PI protein administered at a rate of 0.2 milliliters per kilogram of body weight per minute (ml/kg/min) for 25 weeks (25 planned infusions) via an IV administration.
3115169|NCT02525861|Experimental|Cohort II: GLASSIA (Low-end)|Participants will receive weekly IV infusions of GLASSIA (lot with particle loads representing the low end within the normal range) at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 ml/kg/min for 25 weeks (25 planned infusions) via an IV administration.
3115170|NCT02525874|Experimental|dimethyl fumarate|120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
3115171|NCT02526160|Experimental|Burosumab 1 mg/kg|Burosumab 1 mg/kg administered subcutaneously (SC) every 4 weeks, for the duration of the study.
3115172|NCT02526160|Placebo Comparator|Placebo|Placebo administered SC every 4 weeks through Week 24, followed by burosumab 1 mg/kg, for the duration of the study.
3115173|NCT02526212|Experimental|G-BMT, Buprenorphine|This arm will receive the G-BMT intervention, which will include group visits where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. The G-BMT intervention will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
3115174|NCT02526212|Active Comparator|Treatment as usual, Buprenorphine|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
3115175|NCT02526277|Active Comparator|MMF07 Foot Massager device|Participants randomized to the MMF07 Foot Massager device arm will be provided the MMF07 Foot Massager device and instructed to set this device at setting 3, then increase or decrease the setting to their desired level of comfort, to be used for 30 minutes at bedtime.
3115176|NCT02526277|Active Comparator|Heat therapy|Participants randomized to heat therapy will be provided an electric heating pad and will be instructed to use this pad at a medium setting for 30 minutes at bedtime.
3115177|NCT02526277|Active Comparator|MMF07 Foot Massager device and heat therapy|Participants randomized to both the MMF07 Foot Massager device and heat therapy will be provided both the MMF07 Foot Massager device and electric heating pad. Participants will be instructed to set the MMF07 Foot Massager device at setting 3, then increase or decrease the setting to their desired level of comfort. They will also be instructed to use the electric heating pad at a medium setting at the same time for 30 minutes at bedtime.
3115178|NCT02526277|No Intervention|No treatment|Participants receiving no intervention will be asked to not alter their nighttime routine.
3115179|NCT02526290|Experimental|Active - Device|The Oculeve Intranasal Lacrimal Neurostimulator will be administered two to ten times per day for up to three minutes per administration.
3115180|NCT02526524|Experimental|600 mg Met DR qAM|600 mg metformin delayed-release once daily in the morning
3115181|NCT02526524|Experimental|900 mg Met DR qAM|900 mg metformin delayed-release once daily in the morning
3115182|NCT02526524|Experimental|1200 mg Met DR qAM|1200 mg metformin delayed-release once daily in the morning
3115183|NCT02526524|Experimental|1500 mg Met DR qAM|1500 mg metformin delayed-release once daily in the morning
3115184|NCT02526524|Placebo Comparator|Placebo-1|placebo match for 600 and 1200 mg Met DR qAM treatment groups
3115185|NCT02526524|Placebo Comparator|Placebo-2|placebo match for 900 and 1500 mg Met DR qAM treatment groups
3115186|NCT02526524|Active Comparator|2000 mg Met IR|1000 mg metformin immediate-release twice daily
3115187|NCT02526550|Experimental|Imojev|Live attenuated chimeric Japanese Encephalitis vaccine, 0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh and Simultaneous administration of Inactivated Hepatitis A vaccine, 0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
3115188|NCT02526654|Experimental|Glaucoma Subjects|Subjects with glaucoma were recruited based on characteristic glaucomatous disc damage and visual field changes. They will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
3115189|NCT02526654|Experimental|Healthy Controls|Subjects that do not have glaucoma and are recruited for testing will perform visual field with Heidelberg Edge Perimeter and Octopus visual field. Optical Coherence Tomography will image the retinal nerve fiber layer.
3115190|NCT02526667|Experimental|Chlorhexidine Gluconate Cloth|2% CHG, single application
3115191|NCT02526667|Placebo Comparator|Vehicle Cloth|Excipients on cloth
3115192|NCT02526667|Active Comparator|Active Chlorhexidine gluconate solution|Dynahex 2% CHG
3115193|NCT02526680|Experimental|Glaucoma Subjects|27 glaucoma subjects will be given the OrCam low vision aid device to use for 1 month.
3115194|NCT02526693|Other|Glaucoma Patients|Glaucoma patients recruited from Wills Eye Hospital Glaucoma Service will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
3115195|NCT02526693|Other|Healthy Controls|Healthy subjects with no eye diseases recruited from Wills Eye Hospital Glaucoma Service staff, family and friends will be tested with the relative afferent pupillary defect test (RAPDx) Pupillometer. The noninvasive RAPDx measures the pupils response during light stimulation.
3115196|NCT02527148|Active Comparator|OtisMed® ShapeMatch® with Triathlon|Participants randomised to the Intervention Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System and OtisMed® ShapeMatch® Technology with the goal of kinematic alignment (re-aligning the limb to its pre-disease kinematic alignment).
3115197|NCT02527148|Active Comparator|Stryker Precision Knee Navigation|Participants randomised to the Control Group will undergo Total Knee Replacement (TKR) with the Stryker Triathlon® Total Knee System guided by Stryker Precision Knee Navigation with the goal of neutral alignment to the mechanical axis. This is the standard method for TKR with Triathlon® Knee System and this group will serve as a control reference for the intervention group.
3115198|NCT02527161|Other|ShapeMatch Cutting Guides with Triathlon|"The ShapeMatch® Cutting Guides are intended to be used as patient-specific surgical instrumentation to assist in the positioning of knee arthroplasty components intra-operatively and in guiding the marking of bone before cutting.~They are intended for single use only."
3115199|NCT02527265|Experimental|Afrezza (Technosphere Insulin)|"Individualized dose of Afrezza (Technosphere Insulin) for each patient at each meal (breakfast, lunch, and dinner) for 30 days.~During the trial, all patients will receive multiple injections of basal long acting insulin, in general at bedtime every day."
3115200|NCT02527343|Experimental|Placebo/Volanesorsen|"Randomized Period: Volanesorsen-matching placebo as SC, QW for Weeks 1-52. Participants who received volanesorsen-matching placebo in RT period and not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen-matching placebo in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Weeks 105-156). Participants not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
3115201|NCT02527343|Experimental|Volanesorsen|"Randomized Period: 300 mg of volanesorsen as SC, QW for Weeks 1-52. Participants who received 300 mg of volanesorsen in RT period and did not enter in OLE period went straight to 13-week PT follow-up period. Dose adjustment based on monitoring rules were allowed.~OLE Period: Participants who received volanesorsen in RT period and completed RT period, were to receive 300 mg of volanesorsen as SC QW for 52 weeks (Weeks 53-104) in OLE period. Dose adjustment based on monitoring rules were allowed. After Week 104, participants had option of continuing treatment with 300 mg of volanesorsen as SC injection for up to additional 52 weeks (Week 105-156). Participants who were not entered in option for additional 52 weeks of dosing in OLE PT period went straight to 13-week PT follow-up period after completion of first 52 weeks (Weeks 53-104) of OLE. Participants entered in OLE PT period went straight to 13-week PT follow-up period after completion of Week 156 of OLE."
3115202|NCT02527421|Experimental|DFD01 Spray Group 1|DFD01 spray, twice daily, 15 days
3115203|NCT02527421|Experimental|DFD01 Spray Group 2|DFD01 spray, twice daily, 29 days
3115204|NCT02527434|Experimental|treme mono to be sequenced to MEDI4736 mono or combination|tremelimumab monotherapy, with the option for eligible patients to be sequenced to MEDI4736 monotherapy or MEDI4736 + tremelimumab combination therapy after progressive disease (PD)
3115205|NCT02527512|Active Comparator|Povidone-Iodine|"0.35% povidone-iodine (Betadine)"
3115206|NCT02527512|Active Comparator|Normal Saline|Sterile sodium chloride (NaCl) solution
3115207|NCT02527681|Experimental|Ceftobiprole|Ceftobiprole medocaril is the water-soluble prodrug of ceftobiprole, an advanced-generation cephalosporin developed for intravenous administration. Ceftobiprole is characterized by potent, broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative pathogens.
3469284|NCT03888144|Experimental|Ketorolac group|Patients randomized to 20 pills of 10 mg ketorolac by mouth every 6 hours as needed for pain after ureteroscopy.
3115208|NCT02527694|Experimental|Flexible EMS Stretcher Cart Group|Patients in this group will be transported on the new flexible EMS stretcher cart and receive mechanical CPR during transport to the hospital. The intervention will be given during elevator transport (if applicable) as well as in the moving ambulance.
3115209|NCT02527694|No Intervention|Standard Stretcher Cart Group|Patients in this group will be transported on the standard stretcher cart and receive manual CPR during transport to the hospital. The resuscitation protocol will follow the current standard protocol used by the EMS providers.
3115210|NCT02528188|Active Comparator|NSAID|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
3115211|NCT02528188|Experimental|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac ER) twice daily for 56 weeks
3115212|NCT02528188|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for NSAID (naproxen, celecoxib or diclofenac) twice daily for 56 weeks
3115213|NCT02528214|Placebo Comparator|Placebo q2w|2 subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1, followed by a single injection every 2 weeks (q2w) for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable inhaled corticosteroid (ICS). OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3115214|NCT02528214|Experimental|Dupilumab 300 mg q2w|2 subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection q2w for 24 weeks in combination with OCS - (prednisone or prednisolone) and stable ICS. OCS dose was reduced according to a predetermined titration schedule every 4 weeks until Week 20. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication.
3115215|NCT02528253|Placebo Comparator|Placebo to Week 16; tanezumab 5 mg SC|
3115216|NCT02528253|Placebo Comparator|Placebo to Week 16, tanezumab 10 mg SC|
3115217|NCT02528253|Experimental|Tanezumab 5 mg SC|
3115218|NCT02528253|Experimental|Tanezumab 10 mg SC|
3115219|NCT02528253|Active Comparator|Tramadol PR oral|
3115220|NCT02528305|Experimental|High-intensity Interval Training (HIT)|6 week control period with no intervention then 6 weeks of twice weekly HIT
3115221|NCT02528318|Experimental|50 mg/kg|"Lucinactant for inhalation 50 mg total phospholipids (TPL)/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
3115222|NCT02528318|Experimental|75 mg/kg|"Lucinactant for inhalation 75 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
3115223|NCT02528318|Experimental|100 mg/kg|"Lucinactant for inhalation 100 mg TPL/kg with nCPAP~1 repeat dose allowed if repeat dosing criteria are met."
3115224|NCT02528318|Experimental|150 mg/kg|"Lucinactant for inhalation 150 mg TPL/kg with nCPAP~1 repeat dose will be allowed if repeat dosing criteria are met."
3115225|NCT02528318|Active Comparator|nCPAP alone|nCPAP therapy alone
3115226|NCT02528331|Experimental|rTMS and Cognitive Behavior Therapy|
3115227|NCT02528357|Experimental|Part 1A: GSK3174998 Monotherapy- Dose escalation|Participants will receive GSK3174998 intravenously (IV) (dose range 0.003 to 10.0 milligram per kilogram [mg/kg]) every 3 weeks (Q3W) for up to 2 years or 35 cycles, whichever comes first.
3115228|NCT02528357|Experimental|Part 2A: GSK3174998+ pembrolizumab - Dose escalation|Participants will receive GSK3174998 IV (dose range 0.003 to 10.0 mg/kg) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for up to 2 years or 35 cycles, whichever comes first.
3115229|NCT02528357|Experimental|Part 2B: GSK3174998+ pembrolizumab - Cohort expansion|Participants will receive GSK3174998 IV (at one dose level shown to be tolerable in dose escalation of part 2A) Q3W for up to 2 years or 35 cycles, whichever comes first + Pembrolizumab 200 mg IV Q3W for 2 years or 35 cycles, whichever comes first.
3115230|NCT02528370|Experimental|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
3115231|NCT02528370|No Intervention|No telEPOC / Usual Care|"The control group follows the usual care protocol in our health system. That includes periodic control by their primary and respiratory specialist. They receive non-structured information/education about COPD and follow a programmed control agenda depending on the severity of the disease every 4-6 months.~Generally speaking the differences between the two cohorts were the educational structured program and the telemonitoring control."
3115232|NCT02528409|Placebo Comparator|Placebo|10 milligrams per day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
3115233|NCT02528409|Experimental|Vortioxetine|10 milligrams per day day for the first week and 10 milligrams per day for the final taper week 20 milligrams per day for 10 weeks between taper periods.
3469285|NCT03888118|Experimental|Study Group|A four-week rehabilitation program (Monday to Friday) involving the hour of individual ankle therapy and one hour therapy on the Luna EMG device.
3115235|NCT02528643|Experimental|Enzalutamide|Participants received enzalutamide 160 mg once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
3115236|NCT02528643|Placebo Comparator|Placebo|Participants received placebo once daily until disease progression, unacceptable toxicity, or any other discontinuation criterion was met.
3115237|NCT02528721|Experimental|Initial Diagnosis Subjects|Patients with clinical indication for H.pylori infection
3115238|NCT02528721|Experimental|Post Therapy Subjects|Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
3115239|NCT02528786|Other|All Participants|Participants who received namilumab previously in M1-1188-002-EM (PRIORA, [NCT01317797]) will have blood samples collected on Day 1.
3469286|NCT03888118|No Intervention|Control group|A four-week rehabilitation program (Monday to Friday) involving two hours of individual ankle therapy.
3469287|NCT03887923|Experimental|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
3115240|NCT02528942|Experimental|Radiation therapy|The functional avoidance radiation therapy plan will be delivered using a standard course of radiation treatment on a linear accelerator. Patients will receive daily radiation treatment for 15-35 days.
3115241|NCT02529072|Experimental|Group I|Patients will receive nivolumab 3 mg/kg IV every 2 weeks for 8 weeks followed by surgery. Following resection, nivolumab and DC vaccine will be administered every 2 weeks (± 1) for a total of 3 vaccines, followed by biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
3115242|NCT02529072|Experimental|Group II|Patients will initially receive the fourth cycle of nivolumab then receive nivolumab 3 mg/kg IV and DC vaccine every 2 weeks for a total of 3 vaccines, and then surgery. Subsequent to surgery, the patient will resume biweekly treatment with nivolumab and monthly DC vaccinations for a total of 5 more vaccines. Patients will continue to receive nivolumab every 2 weeks until progression.
3115243|NCT02529137||Surgical pathology cases|Cases will be selected from the sites Laboratory Information Systems using the in- and exclusion criteria.
3115244|NCT02529488|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
3115245|NCT02529553|Experimental|LY3076226|"Part A (dose escalation in advanced cancer): LY3076226 administered intravenously (IV) on day 1 of each 21 day cycle.~Part B (dose expansion in advanced urothelial carcinoma): LY3076226 administered IV on day 1 of each 21 day cycle."
3115246|NCT02529995|Experimental|AZD9291 40 mg|Cohort 1: 40 mg once daily
3115247|NCT02529995|Experimental|AZD9291 80 mg|Cohort 2: 80 mg once daily
3115248|NCT02530125|Experimental|Treatment (pidilizumab)|Patients receive pidilizumab IV over approximately 5 hours on day 1. Treatment repeats every 42 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3115249|NCT02530151|Experimental|Morphine with Clonidine|11 mL intra-articular injection of 10 mg morphine and 100 mcg clonidine in .9% NaCl solution at conclusion of hip arthroscopy procedure
3115250|NCT02530151|Placebo Comparator|Normal Saline|11 mL intra-articular injection of .9% NaCl solution at conclusion of hip arthroscopy procedure
3115251|NCT02530242|Other|End-tidal Carbon Monoxide Subjects|Children between 1-18 years old with Sickle Cell Anemia
3115252|NCT02530242|Other|End-tidal Carbon Monoxide Controls|Healthy children age matched with subjects.
3115253|NCT02530281|Experimental|glycopyrronium|glycopyrronium Topical Wipes
3115254|NCT02530281|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
3115255|NCT02530294|Experimental|glycopyrronium|glycopyrronium Topical Wipes
3115256|NCT02530294|Placebo Comparator|Vehicle|glycopyrronium Topical Wipes, Vehicle
3115257|NCT02530385|Experimental|FMT|Active FMT capsules
3115258|NCT02530385|Placebo Comparator|Placebo|Placebo capsules
3115259|NCT02530450||Group 1|Initially blinded to continuous glucose monitoring (CGM) data after 1st use Not blinded to continuous glucose monitoring data after 2nd and 3rd use
3115260|NCT02530450||Group 2|Never blinded to continuous glucose monitoring (CGM) data
3115261|NCT02530476|Experimental|Phase I Group 1 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle."
3115262|NCT02530476|Experimental|Cohort 1 (FLT3-ITD inhibitor failure cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
3115263|NCT02530476|Experimental|Cohort 2 (FLT3-ITD inhibitor naive cohort)|"Cohort includes those with FLT3-ITD and -D835 mutated relapsed/refractory AML who have failed therapy with up to two prior salvage regimens.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
3115264|NCT02530476|Experimental|Phase I Group 2 Selinexor + Sorafenib|"Cohort includes those with FLT3-ITD and -D835 mutated participants with relapsed/refractory AML, including participants who may have been previously exposed to one or more FLT3-inhibitors.~Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle. Phase I Group 2 received Selinexor 80 mg by mouth twice weekly for a 28 day cycle."
3115265|NCT02530515|Experimental|Treatment (ex vivo autologous lymph node lymphocytes)|Patients receive infusion of ex vivo-activated autologous lymph node lymphocytes IV over 10-30 minutes on day 0.
3115266|NCT02530528|Experimental|2% CHG 1 min|single administration, 1 min application time
3115267|NCT02530528|Experimental|2% CHG 2 min|single administration, 2 min application time
3115268|NCT02530528|Experimental|2% CHG 3 min|single administration, 3 min application time
3115269|NCT02530528|Active Comparator|Comparator 2% CHG|Single administration, Marketed CHG
3115270|NCT02530541|Experimental|CHG 1 min|1 min application time
3115271|NCT02530541|Experimental|CHG 2 min|2 min application time
3115272|NCT02530541|Active Comparator|Comparator CHG|Marketed CHG
3115273|NCT02530554|Experimental|CHG Cloth|3 min application time
3115274|NCT02530554|Active Comparator|Comparator CHG|Marketed 2% CHG
3115275|NCT02530619|Experimental|Treatment (alisertib)|Patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3115276|NCT02530671|Active Comparator|Manual toothbrush|ADA reference manual toothbrush
3115277|NCT02530671|Experimental|Power toothbrush|Multi-directional power toothbrush
3115278|NCT02530905|Placebo Comparator|Placebo (double-blind dose titration)|Participants with genotypically confirmed Duchenne muscular dystrophy (DMD) characterized by deletions amenable to exon 45 skipping will receive placebo-matching to casimersen intravenous (IV) infusions, once weekly over approximately 12 weeks in the double-blind period.
3469288|NCT03888131|Experimental|CHF 1535 100/6 µg pMDI|2 inhalations BID Total Daily Dose = 400/24µg
3469289|NCT03888131|Active Comparator|Symbicort® Turbohaler®|2 inhalations BID Total Daily Dose = 640/18µg
3115279|NCT02530905|Experimental|SRP-4045 (double-blind dose titration)|Participants with genotypically confirmed DMD characterized by deletions amenable to exon 45 skipping will receive weekly IV infusions of casimersen at four escalating dose levels, each for at least 2 weeks: 4 milligrams per kilograms (mg/kg) during Week 1 to Week 2, followed by 10 mg/kg during Week 3 to Week 4, followed by 20 mg/kg during Week 5 to Week 6, followed by 30 mg/kg beginning at Week 7 and continue over approximately Week 12 in the double-blind period.
3115280|NCT02530905|Experimental|SRP-4045 (open label extension period)|All participants who completed double blind period will be enrolled to receive casimersen 30 mg/kg once weekly, for up to Week 144 in the open label extension period.
3115281|NCT02530996|Experimental|Placebo before BH4|Six SSc received oral placebo 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral BH4 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
3115282|NCT02530996|Experimental|BH4 before Placebo|Six SSc received oral BH4 10 mg/kg and had flow mediated dilatation measured. After a five day washout they crossed over to oral placebo 10 mg/kg and had flow mediated dilatation measured. Blood samples were obtained from these SSc patients and assessed for oxidative stress.
3115283|NCT02531022|Active Comparator|Control|Participants will be given standard exercise recommendations that are given to all patients based on the federal guidelines. They will monitor their step counts using a wearable device and receive daily feedback.
3115284|NCT02531022|Experimental|Intervention|Participants will be given a wearable device to monitor daily step counts with automated daily feedback on goal attainment via text message or email. A baseline step count will be calculated for each participant (weeks 1-2) and then they will be given a daily step goal with an increase of 15 percentage point each week during the 8-week ramp-up period (weeks 3-10) with a maximum goal of 10,000 steps. Then they'll be asked to maintain that step count (maintenance period). During the ramp-up and maintenance period they'll have a financial incentive of $14 allocated each week and $2 taken away each day the goal is not achieved. They'll be followed up for 8 weeks without incentives
3115285|NCT02531035|Placebo Comparator|Placebo|Two placebo-matching to sotagliflozin tablets daily, orally, before the first meal of the day for 24 weeks.
3115286|NCT02531035|Experimental|Sotagliflozin 400 mg|Sotagliflozin 400 milligram (mg) (two 200 mg tablets) once daily, orally, before the first meal of the day for 24 weeks.
3115287|NCT02531113|Experimental|RPC1063 (Ozanimod)|
3115288|NCT02531321|Experimental|Ritonavir|Participants taking antiretroviral regimens including ritonavir-boosted protease inhibitors will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
3115289|NCT02531321|Active Comparator|Control|Participants taking antiretroviral regimens known not to interact with oral contraceptives will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days.
3115290|NCT02531373|Experimental|Adult: V114 Medium Dose|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 on Day 1.
3115291|NCT02531373|Experimental|Adult: V114 High Dose|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 on Day 1.
3115292|NCT02531373|Experimental|Adult: V114 Medium Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein on Day 1.
3115293|NCT02531373|Experimental|Adult: V114 High Dose with Alternative Carrier Protein|Adult participants will receive a single 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein on Day 1.
3115294|NCT02531373|Experimental|Infant: V114 Medium Dose|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 at 2, 4, 6, and 12 to 15 months of age.
3115295|NCT02531373|Experimental|Infant: V114 High Dose|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 at 2, 4, 6, and 12 to 15 months of age.
3115296|NCT02531373|Experimental|Infant: V114 Medium Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of medium-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
3115297|NCT02531373|Experimental|Infant: V114 High Dose with Alternative Carrier Protein|Infant participants will receive a 0.5 mL intramuscular injection of high-dose V114 with alternative carrier protein at 2, 4, 6, and 12 to 15 months of age.
3115298|NCT02531373|Active Comparator|Infant: Prevnar 13™|Infant participants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age.
3115299|NCT02531438|Experimental|Omadacycline|Omadacycline IV; Omadacycline tablets
3115300|NCT02531438|Active Comparator|Moxifloxacin|Moxifloxacin IV; Moxifloxacin tablets
3115301|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (6-month taper)|Subjects will receive blinded sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3115302|NCT02531633|Experimental|Part A: Sirukumab, Dose 1+prednisone (3-month taper)|Subjects will receive blinded sirukumab 100 mg SC q2w for 52 weeks plus a pre-specified maximum of 3-month oral prednisone taper regimen.
3115303|NCT02531633|Experimental|Part A: Sirukumab, Dose 2+prednisone (6-month taper)|Subjects will receive blinded sirukumab 50 mg SC every 4 weeks (q4w) for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3115304|NCT02531633|Placebo Comparator|Part A:Placebo to match sirutkumab+prednisone (6-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 6-month oral prednisone taper regimen.
3115305|NCT02531633|Placebo Comparator|Part A:Placebo to match sirukumab+prednisone (12-month taper)|Subjects will receive blinded placebo to match sirutkumab q2w for 52 weeks plus a pre-specified maximum of 12-month oral prednisone taper regimen.
3115306|NCT02531633|Experimental|Part B:Open-label sirukumab 100 mg SC (if applicable)|Subjects completing Part A will receive open label 100 mg SC q2w for a maximum of 52 weeks based on remission status and disease activity at the primary 52-week endpoint or prednisone tapering status of subject during Part A. Methotrexate will be provided to subjects, alone or in addition to sirukumab treatment during Part B, based on the discretion of the investigator.
3115307|NCT02531646|Experimental|Predicate & Invest. DE - Human Subjects|Radiation -Thirty to forty (30-40) patients will receive a DR standard of care chest exam using the DRX Plus detector and a DE exam. Each DE patient exam includes high energy and low energy image exposures using the investigational device. These images are used by the DE console software to generate additional DE images (e.g. bone and soft tissue).
3115308|NCT02531646|Experimental|Predicate & Invest. DT - Human Subjects|Radiation - Fifteen to twenty (15-20) patients will receive a DR standard of care chest exam using the DRX Plus detector, and a DT exam. Each DT patient exam includes a scout image (chest PA) and a DT scan using the investigational DT SW. The DT scan is used by the DT console software to generate tomographic images.
3115309|NCT02531646|Experimental|Predicate & Invest. DT - Phantom Images|Radiation - Eleven (11) phantoms of various anatomy will be imaged with linear tomography (LT) as predicate and DT for investigational.
3115310|NCT02531698|Experimental|Bivalent rLP2086|Bivalent rLP2086 (containing 60 μg each of a purified subfamily A and subfamily B rLP2086 protein, adsorbed to aluminum in a sterile buffered isotonic suspension) in a 0.5-mL dose for injection.
3115311|NCT02531698|Other|Licensed pediatric hepatitis A vaccine|
3115312|NCT02531802|Experimental|Adult: ETVAX (Full)|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) added to bicarbonate buffer solution administered orally on Day 0 and 14
3115313|NCT02531802|Experimental|Adult: ETVAX (Full) + 10 ug dmLT|Adult arm (18-45 year olds) receiving the full dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) with 10 ug dmLT added to bicarbonate buffer solution administered orally on Day 0 and 14
3115314|NCT02531802|Placebo Comparator|Adult: Placebo|Adult arm (18-45 year olds) receiving a placebo on days 0 and 14
3115315|NCT02531802|Experimental|24-59 months: ETVAX (1/4)|24-59 month old children receiving a quarter adult dose (2.5 x 10^10 inactivated E. coli bacteria) of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
3115316|NCT02531802|Experimental|24-59 months: ETVAX (1/2)|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115317|NCT02531802|Experimental|24-59 months: ETVAX (full)|24-59 month old children receiving a full adult dose of ETVAX vaccine (10^11 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115318|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 2.5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115319|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 5 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115320|NCT02531802|Experimental|24-59 months: ETVAX (1/2) + 10 ug dmLT|24-59 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 10 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115321|NCT02531802|Placebo Comparator|24-59 months: Placebo|24-59 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
3115322|NCT02531802|Experimental|12-23 months: ETVAX (1/4)|12-23 month old children receiving a quarter adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115323|NCT02531802|Experimental|12-23 months: ETVAX (1/2)|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115324|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 2.5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115325|NCT02531802|Experimental|12-23 months: ETVAX (1/2) + 5 ug dmLT|12-23 month old children receiving a half adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115326|NCT02531802|Placebo Comparator|12-23 months: Placebo|12-23 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
3115327|NCT02531802|Experimental|6-11 months: ETVAX (1/8)|6-11 month old children receiving an eighth of an adult dose of ETVAX vaccine in bicarbonate buffer solution administered orally on Day 0 and 14
3115328|NCT02531802|Experimental|6-11 months: ETVAX (1/4)|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115329|NCT02531802|Experimental|6-11 months: ETVAX (1/2)|6-11 month old children receiving a half of an adult dose of ETVAX vaccine (5 x 10^10 inactivated E. coli bacteria) in bicarbonate buffer solution administered orally on Day 0 and 14
3115330|NCT02531802|Experimental|6-11 months: ETVAX (1/4) + 2.5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 2.5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115331|NCT02531802|Experimental|6-11 month olds: ETVAX (1/4) + 5 ug dmLT|6-11 month old children receiving a quarter of an adult dose of ETVAX vaccine (2.5 x 10^10 inactivated E. coli bacteria) plus 5 ug dmLT in bicarbonate buffer solution administered orally on Day 0 and 14
3115332|NCT02531802|Placebo Comparator|6-11 month olds: Placebo|6-11 month old children receiving a placebo of bicarbonate buffer solution administered orally on Day 0 and 14
3115333|NCT02531867|Experimental|Asfotase Alfa|Patients will receive asfotase alfa by subcutaneous injection. Asfotase alfa will be administered at either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week depending on investigator's discretion.
3115334|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Duragesic (192 h), Mylan (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained 0-192 h
3115335|NCT02531971|Active Comparator|Fentanyl citrate (36 h), Mylan (192 h), Duragesic (192 h)|Volunteers received a single-dose of 100 µg fentanyl citrate infusion (Study Session I) and blood samples obtained 0-36 h, washout at least one week, then wore a Mylan fentanyl TDDS (25 µg/h) for 72 h (Study Session II) and blood samples obtained 0-192 h, washout at least one week, then wore a Duragesic® fentanyl TDDS (25 µg/h) for 72 h (Study Session III) and blood samples obtained for 0-192 h
3115336|NCT02532010|Active Comparator|Arm A: Pacritinib and Decitabine|Arm A: Each cycle: Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
3115337|NCT02532010|Active Comparator|Arm B: Pacritinib and Cytarabine|Arm B: Each cycle: Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
3115338|NCT02532036|Experimental|Starter Group|Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
3115339|NCT02532036|Experimental|Group A|Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
3115340|NCT02532036|Experimental|Group B|Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
3115341|NCT02532179|Experimental|Mouse Allergenic Extract|Participants will receive escalating doses of glycerinated mouse allergenic extract administered via the subcutaneous route up to a Maximum Study Dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol.
3115342|NCT02532283|Experimental|JNJ-63623872 plus Oseltamivir|Participants will be administered JNJ-63623872 600 milligram (mg) tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
3115343|NCT02532283|Experimental|Placebo plus Oseltamivir|Participants will be administered placebo tablets and oseltamivir 75 mg capsules orally twice daily for 7 days.
3115344|NCT02532374|Experimental|Nicorette® inhalator then P3L|Each subject will use the Nicorette® inhalator (15 mg) on Visit 3, and then use the P3L aerosol at nicotine dose levels of approximately 50 µg/puff, 80 µg/puff and 150 µg/puff on Visits 4, 5 and 6, respectively.
3115345|NCT02532465|Active Comparator|Air-Q|The Air-Q is composed of an airway tube that connects to an elliptical mask with a cuff which is inserted through the patient's mouth, down the windpipe, and once deployed forms an airtight seal on top the glottis (unlike tracheal tubes which pass through the glottis) allowing a secure airway to be managed by a health care provider.
3115346|NCT02532465|Experimental|i-gel|The i-gel is designed to create a non-inflatable anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures whilst avoiding the compression trauma that can occur with inflatable supraglottic airway devices.
3115347|NCT02532517|Experimental|Enterprise|
3115348|NCT02532543|Active Comparator|Group A- Allograft, Membrane|Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
3115349|NCT02532543|Active Comparator|Group B- Alloplast, Membrane|Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
3115350|NCT02532543|Active Comparator|Group C- Xenograft, Membrane|OsteoGraf/N-300 , Symbios OsteoShield Collagen Resorbable Membrane
3115351|NCT02532543|Active Comparator|Group D- Membrane|Symbios OsteoShield Collagen Resorbable Membrane
3115352|NCT02532556|Experimental|1|Stimulation of muscle in this order: vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius
3115353|NCT02532556|Experimental|2|Stimulation of muscle in this order: rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials
3115354|NCT02532556|Experimental|3|Stimulation of muscle in this order: vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris
3115355|NCT02532556|Experimental|4|Stimulation of muscle in this order: tibialis anterior, peroneus longus, and the medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis
3115356|NCT02532556|Experimental|5|Stimulation of muscle in this order: peroneus longus, medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior
3115357|NCT02532556|Experimental|6|Stimulation of muscle in this order: medial head gastrocnemius, lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus
3115358|NCT02532556|Experimental|7|Stimulation of muscle in this order: lateral head gastrocnemius, vastus medials, rectus femoris, vastus lateralis, tibialis anterior, peroneus longus, medial head gastrocnemius,
3115359|NCT02532647|Experimental|Remimazolam|"Remimazolam 2.5 - 5.0 mg initially, followed by 1.25 - 2.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3115360|NCT02532647|Active Comparator|Midazolam|"Midazolam 1.0 mg initially, followed by 0.5 mg top-up doses as required to maintain sedation.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3115361|NCT02532647|Placebo Comparator|Placebo|"Placebo administered in double-blind manner.~Fentanyl pre-treatment: 25-50 μg (or less for elderly/disabled subjects), and 25 μg top-up doses"
3115362|NCT02532764|Experimental|QR-010|QR-010 administered via inhalation either as a single dose or three times weekly for four weeks.
3115363|NCT02532764|Placebo Comparator|Placebo|Placebo (normal saline) administered via inhalation either as a single dose or three times weekly for four weeks.
3115364|NCT02532855|Experimental|Sitagliptin|Participants receive sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 5 mg once daily for 4 weeks followed by sitagliptin 100 mg once daily plus matching placebo for dapagliflozin 10 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
3115365|NCT02532855|Active Comparator|Dapagliflozin|Participants receive dapagliflozin 5 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 4 weeks followed by dapagliflozin 10 mg once daily plus matching placebo for sitagliptin 100 mg once daily for 20 weeks. Participants continue pre-study metformin (at least 1500 mg daily) alone or in combination with a sulfonylurea agent (at a dose of ≥ 50% maximum labeled dose in the country of the investigational site) throughout the duration of the study.
3115366|NCT02532933|Active Comparator|Medialized Dome Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with a medialized dome component geometry
3115367|NCT02532933|Active Comparator|Anatomic Patella|Subjects with total knee arthroplasty using the DePuy Synthes Attune Posterior Stabilized Rotating Platform including patella resurfacing with an anatomic component geometry
3115368|NCT02532972|Experimental|Cochlear Implant surgery|All subjects will be part of a single arm involving placement of the Med-El MAESTRO Cochlear Implant with Flex 28 electrode array
3115369|NCT02532998|Experimental|Treatment Sequence 1|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115370|NCT02532998|Experimental|Treatment Sequence 2|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115371|NCT02532998|Experimental|Treatment Sequence 3|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115372|NCT02532998|Experimental|Treatment Sequence 4|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115373|NCT02532998|Experimental|Treatment Sequence 5|Period 1: fludrocortisone + eplerenone + AZD9977 Period 2: fludrocortisone + eplerenone + AZD9977 Placebo Period 3: fludrocortisone + AZD9977 Placebo Period 4: fludrocortisone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115374|NCT02532998|Experimental|Treatment Sequence 6|Period 1: fludrocortisone + AZD9977 Placebo Period 2: fludrocortisone + eplerenone + AZD9977 Period 3: fludrocortisone + AZD9977 Period 4: fludrocortisone + eplerenone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115375|NCT02532998|Experimental|Treatment Sequence 7|Period 1: fludrocortisone + AZD9977 Period 2: fludrocortisone + AZD9977 Placebo Period 3: fludrocortisone + eplerenone + AZD9977 Placebo Period 4: fludrocortisone + eplerenone + AZD9977 Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115376|NCT02532998|Experimental|Treatment Sequence 8|Period 1: fludrocortisone + eplerenone + AZD9977 Placebo Period 2: fludrocortisone + AZD9977 Period 3: fludrocortisone + eplerenone + AZD9977 Period 4: fludrocortisone + AZD9977 Placebo Period 5: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment Period 6: fludrocortisone + eplerenone and/or AZD9977 or AZD9977 Placebo treatment
3115377|NCT02533063|Active Comparator|Combination Treatment|"In the loading + vibration group (intervention group), subjects will be seated in the VibeTech One system and vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
3115378|NCT02533063|Sham Comparator|Sham Treatment|"In the loading only group (control group) participants will be seated in the vibration device (VibeTech One) and will experience loading of their leg muscles through the device."
3115379|NCT02533089|Experimental|KT intervention|Multifaceted KT strategy employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
3115380|NCT02533089|No Intervention|Control|Control sites will receive no intervention, with LHW training left to the discretion of the health centers TB focus LHW. Control sites will not have access to the point of care tool.
3115381|NCT02533167|Experimental|skin to skin|skin to skin initiated on all consented CS while in the operating room
3115382|NCT02533180|Other|Immunosuppression withdrawal (ISW)|Gradual immunosuppression withdrawal according to the protocol defined algorithm
3115383|NCT02533375|Experimental|Participants receiving adalimumab|80 mg at Week 0 by subcutaneous (SC) injection, followed by 40 mg every other week (eow) on and after Week 2 until Week 50. Dose escalation to 80 mg eow was allowed for participants who did not have adequate response on or after Week 8.
3115384|NCT02533401|Experimental|Rituximab + Fludarabine + Cyclophosphamide|Participants will receive rituximab (375 milligrams per meter-squared [mg/m^2] intravenously [IV]) on Cycle 1 Day 1, followed by fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) for Days 2 to 4 of Cycle 1. Then rituximab (500 mg/m^2 IV) will be administered on Day 1 of Cycles 2 to 6, followed by IV fludarabine (25 mg/m^2 once daily IV) and cyclophosphamide (250 mg/m^2 once daily IV) on Days 1 to 3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length, and the overall duration of treatment will be approximately 6 months.
3115385|NCT02533427|Experimental|SOF/VEL/VOX + VOX|"Part A: Participants without a documented history of taking norgestimate/ethinyl estradiol for at least one menstrual cycle will receive norgestimate/ethinyl estradiol. Participants with a documented history of taking norgestimate/ethinyl estradiol may enroll directly into Part B of the study.~Part B: Participants will continue taking norgestimate/ethinyl estradiol for the remainder of the study and will receive SOF/VEL/VOX FDC plus VOX."
3115386|NCT02533453|Experimental|Bydureon|exenatide once weekly
3115387|NCT02533466|Experimental|Test Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
3115388|NCT02533466|Placebo Comparator|Reference Product|Subjects will apply a full ribbon of dentifrice and brush their teeth for 1 timed minute using a wetted toothbrush, swish the resulting slurry around the mouth for 30 seconds making sure it contacts the selected teeth, spit out slurry and rinse mouth for 10 seconds with water.
3115389|NCT02533505|Active Comparator|Symbicort pressurized Metered Dose Inhaler (pMDI)|Symbicort pressurized Metered Dose Inhaler (pMDI)
3115390|NCT02533505|Placebo Comparator|Placebo of reference drug|Placebo of reference drug
3115391|NCT02533570|Experimental|Brentuximab vedotin|4 dose groups
3115392|NCT02533570|Placebo Comparator|Placebo|Matching placebo
3115393|NCT02533674|Experimental|gemcitabine plus PM060184|
3115394|NCT02533726|Experimental|Treatment - Optimal Turning|All patients will have a sensor applied. Patients within this arm will receive care from nurses who have access to a User Dashboard that provides visual advisories for patient turning, based on data obtained from a wearable patient sensor (Leaf Healthcare, Inc.).
3115395|NCT02533726|Active Comparator|Control - Standard Care|All patients will have a sensor applied. Patients within this arm will receive care from nurses who DO NOT have access to a User Dashboard that provides visual advisories for patient turning. Instead, these patients will receive standard care practices, patient turning initiated by nurses as necessary.
3115396|NCT02533921|Other|Standard of Care|Usual care as in including both a Primary Care Physician (PCP) and neurologist.
3115397|NCT02533921|Active Comparator|Interdisciplinary outpatient palliative care|Usual care augmented by an outpatient interdisciplinary palliative care team.
3115398|NCT02533934|Experimental|Treatment with Sofosbuvir based HCV Therapy|Prospective and retrospective treatment for HCV
3115399|NCT02533999|Experimental|Surgical Instrument|"PEAK® Plasma Surgery System [PEAK PlasmaBlade® TnA Tonsil and Adenoid Tissue Dissection Device] (Medtronic, Inc) is a marketed device. The PEAK® system generates plasma, an electrically conductive cloud produced when radiofrequency energy contacting tissue and the tissue breaks down. The system was designed to have the precision of a scalpel, minimal bleeding as with electrosurgery, but reduced collateral thermal tissue damage. The PEAK® Plasma System setting will be standardized for tonsils, to 2 for coagulation and 1 for cutting; and for adenoids, to 7 for coagulation, and 7 for cutting."
3115400|NCT02533999|Active Comparator|Electrosurgery|Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
3115401|NCT02534129|Experimental|Single Arm|Radiation field is divided into two sections, one treated with Difinsa53 and the other with Aquaphor
3115402|NCT02534285|Sham Comparator|Control|Patients of the control group receive a Sham hearing protection with no effect on noise attenuation.
3115403|NCT02534285|Active Comparator|Intervention|Patients of the Intervention group receive a Hearing protection with a noise attenuation of 20-45 decibel.
3115404|NCT02534324||High SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge < 180 mmHg
3115405|NCT02534324||Severely high SBP+antihypertensive meds|Patients with pre-discharge systolic blood pressure at discharge >= 180 mmHg
3115406|NCT02534350|Experimental|Presatovir|Presatovir 200 mg (4 x 50 mg) on Day 1, followed by 100 mg (2 x 50 mg) from Day 2 to Day 14
3115407|NCT02534350|Placebo Comparator|Placebo|Placebo tablets for a total of 14 days
3115408|NCT02534493|Experimental|Carpal Tunnel Medical Device (CTMD)|Carpal Tunnel Tissue Manipulation Device (CTMD)
3115409|NCT02534883|Active Comparator|Group 1|Group 1 will received 200ug of misoprostol, to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery (a total of 400ug of misoprostol).
3115410|NCT02534883|Placebo Comparator|Group 2|Group 2 will received placebo (empty gelatin capsule), to be placed into the posterior vaginal fornix 12 hours and 2 hours before their scheduled surgery.
3115411|NCT02534896|Experimental|Treatment 1: Sunpharma1505 (Low dose) and Placebo|
3115412|NCT02534896|Experimental|Treatment II: Sunpharma1505 (High Dose) and Placebo|
3115413|NCT02534896|Active Comparator|Treatment III: Reference1505 and Placebo|
3115414|NCT02534935|Experimental|rLP2086 vaccine|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
3115415|NCT02534935|Active Comparator|Control|"Arm stratified by age:~≥12 to <18 months and ≥18 to <24 months"
3115416|NCT02535000|Experimental|Group C (control)|subjects who will receive one capsule of placebo before the surgery and being repeated the next day
3115417|NCT02535000|Active Comparator|Group D (duloxetine)|subjects who will receive one capsule of duloxetine 60 mg before the surgery and being repeated the next day
3115418|NCT02535026||Breast Cancer Participants|Breast tissue samples from female participants with a breast cancer diagnosis that undergo an anatomopathological examination of surgical specimens and/or core needle biopsies will be considered for analysis in this study.
3115419|NCT02535065|Experimental|Endovascular Graft|The Zenith Low Profile AAA Endovascular Graft and ancillary components
3115420|NCT02535364|Experimental|JCAR015 (CD19-targeted CAR T cells)|JCAR015 was administered as two intravenous (IV) infusions separated by 14 to 28 days.
3115421|NCT02535416|Experimental|ARC-520 Cohort 1|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine
3115422|NCT02535416|Experimental|ARC-520 Cohort 2A|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine
3115423|NCT02535416|Experimental|ARC-520 Cohort 2|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine
3115424|NCT02535416|Experimental|ARC-520 Cohort 3|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine
3115425|NCT02535416|Experimental|ARC-520 Cohort 4|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine
3115426|NCT02535416|Experimental|ARC-520 Cohort 5|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine
3115427|NCT02535416|Experimental|ARC-520 Cohort 6|Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine
3115428|NCT02535416|Experimental|ARC-520 Cohort 7|Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine
3115429|NCT02535416|Experimental|ARC-520 Cohort 8|Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
3115430|NCT02535481|Experimental|Epidermal Graft|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
3115431|NCT02535481|Experimental|Split Thickness Skin Graft|Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.
3115432|NCT02535572|Experimental|FEAST|Patients will receive the FEAST form of ECT
3115433|NCT02535572|Active Comparator|RUL UB|Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)
3115434|NCT02535611|Active Comparator|Memantine|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive 20 mg/d(2 tab 5mg BID) memantine for 7 days and then 10mg/d(1 tab 5mg BID) memantine for 21 days.
3115435|NCT02535611|Placebo Comparator|Placebo|Patients with ischemic stroke in middle cerebral artery (MCA) territory who will receive placebo(2 tab BID) for 7 days and continue placebo(1 tab BID) for 21 days.
3115436|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 2x8mg 1st; 3x8mg 2nd, 1x16mg 3rd|Two 8 mg ORAMED capsules containing insulin then 3X8mg ORAMED capsules containing insulin, second study then 1X16mg ORAMED capsules containing insulin, third study
3115437|NCT02535715|Experimental|ORAMED ORMD-0801 capsules- 3x8mg 1st, 1x16mg 2nd, 2x8mg 3rd|Three 8mg ORAMED capsules containing insulin then 1X16mg ORAMED capsules containing insulin, second study then 2X8mg ORAMED capsules containing insulin, third study
3115438|NCT02535715|Experimental|ORAMED ORMD-0801 capsules-1x16mg 1st, 2x8mg 2nd, 3x8mg 3rd|One 16mg ORAMED capsule containing insulin then 2X8mg ORAMED capsule containing insulin, second study then 3X8mg ORAMED capsule containing insulin, third study
3115439|NCT02535741|Other|Triathlon CR Total Knee System|Primary total knee replacement
3115440|NCT02535806|Experimental|Treatment Arm|"Velcade will be given IV push on days 1,4,8 and 11 at a dose of 1.3 mg/m2/dose. At least 72 hours must have relapsed between doses.~IT Methotrexate (CNS Negative patients only) on days 1 and 8; age based dosing IT Methotrexate/Hydrocortisone/AraC (CNS positive patients only) on days 1, 8, 15 and 22; age based dosing.~Dexamethasone: Days 1-5 and 15-19; 10mg/m2/dose PO BID. Mitoxantrone: Days 1 and 2; 10mg/m2/dose Vincristine: days 1, 8, 15, and 22 at 1.5 mg/m2 (Maximum dose 2 mg) PEG-asparaginase: Days 3 and 17, 2500 IU/m2/dose"
3115441|NCT02535949|Experimental|Tranexamic Acid 2 Gram|One time dose IV TXA 2 Grams given over 10 minutes within 2 hours of initial injury
3115442|NCT02535949|Experimental|Tranexamic Acid 4 Gram|One time dose IV TXA 4 Grams given over 10 minutes within 2 hours of initial injury
3115443|NCT02535949|Placebo Comparator|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
3115444|NCT02536040|Experimental|38% diamine silver fluoride|Topical application of 38% diammine silver fluoride to active cavity
3115445|NCT02536040|Placebo Comparator|Water|Topical application of fluoride free water to active cavity
3115446|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 1|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3115447|NCT02536105|Placebo Comparator|Placebo|During the double-blind period, in one of the 4 study weeks, the study participant will take a blinded placebo instead of one of the the 3 active comparators.
3115448|NCT02536105|Active Comparator|Methylphenidate HCl ER tablets 2|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3115449|NCT02536105|Active Comparator|Methylphenidate HCl ER for suspension|During the open-label optimization phase, one of the methylphenidate hydrochloride extended-release products will be titrated at weekly intervals of 18mg increments until an optimal dose is achieved or a maximum of 72mg per day is reached. During the double-blind phase, participants will receive blinded treatment each week. The dose of each methylphenidate hydrochloride extended-release product will be determined by the optimized dose during the open-label optimization phase
3115450|NCT02536196|Experimental|Intervention|Embolic Protection with transcatheter aortic valve implantation (TAVI)
3115451|NCT02536196|Active Comparator|Control Arm|Transcatheter aortic valve implantation (TAVI) without embolic protection
3115452|NCT02536248|Experimental|Sitagliptin first, then Placebo|"Sitagliptin 100 mg/d for 6 weeks~Wash-out 14 days~Placebo for 6 weeks"
3115453|NCT02536248|Placebo Comparator|Placebo first, then Sitagliptin|"Placebo for 6 weeks~Wash-out 14 days~Sitagliptin 100 mg/d for 6 weeks"
3115454|NCT02536313|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
3115455|NCT02536313|Experimental|SOF/VEL/VOX + RBV|SOF/VEL/VOX + RBV for 12 weeks
3469290|NCT03887793|Experimental|VACs intervention|Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI. Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
3115457|NCT02536404|Experimental|Etrasimod 2 mg|
3115458|NCT02536404|Active Comparator|Placebo|
3115459|NCT02536508|Experimental|BGF MDI (PT010) 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) (PT010, BGF MDI)
3115460|NCT02536508|Experimental|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate (GFF) metered dose inhaler (MDI) (PT003, GFF MDI)
3115461|NCT02536508|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate (BFF) metered dose inhaler (MDI) (PT009, BFF MDI)
3115462|NCT02536664||First-line Stratum|Participants who were untreated and decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
3115463|NCT02536664||Relapsed/Refractory Stratum|Participants who relapsed after treatment with chemotherapeutic regimens with or without Rituximab and were decided by the treating physician to be treated with Rituximab for the CD 20-positive follicular lymphoma condition.
3115464|NCT02536781|Placebo Comparator|Placebol|Placebo
3115465|NCT02536781|Active Comparator|Anthocynin|Anthocyanin
3469291|NCT03887793|No Intervention|Wait list control|Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
3115466|NCT02536794|Experimental|Treatment (MEDI4736, tremelimumab)|Patients receive anti-B7H1 monoclonal antibody MEDI4736 IV over 1 hour and tremelimumab IV over 1 hour on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Four weeks after the last combination dose, patients continue to receive anti-B7H1 monoclonal antibody MEDI4736 every 2 weeks for up to 18 additional doses in the absence of disease progression or unacceptable toxicity. Patients achieving PD or clinical benefit (CR, PR, or SD) may be retreated with anti-B7H1 monoclonal antibody MEDI4736 for an additional 52 weeks.
3115467|NCT02536833|Experimental|0.03 mg SM04690|Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension
3115468|NCT02536833|Experimental|0.07 mg SM04690|Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension
3115469|NCT02536833|Experimental|0.23 mg SM04690|Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension
3115470|NCT02536833|Placebo Comparator|Placebo|Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline
3115471|NCT02536846|Experimental|Second Generation Antipsychotic Drug|Olanzapine; a single 2.5 mg dose PO daily followed by 5 mg dose PO daily for 14 days
3115472|NCT02536963||PVS Screening and reference examination|All enrolled participants will be screened with the Pediatric Vision Scanner (PVS screening) during a well-child visit to compare whether the results of the PVS match the results of the regular eye examination performed during the well-visit. They will then receive a reference examination performed by a fellowship-trained pediatric ophthalmologist. Results will be compared with PVS screening results.
3115473|NCT02536976|Experimental|Active treatment|mirabegron
3115474|NCT02536976|Placebo Comparator|Placebo|Matching placebo
3115475|NCT02537015|Experimental|13 mg Bimatoprost Ocular Insert|13 mg Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new 13 mg Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
3115476|NCT02537431|Experimental|Open-Label Burosumab Q4W|1.0 mg/kg burosumab monthly (Q4W), calculated based on baseline weight and up to a maximum dose of 90 mg.
3115477|NCT02537444|Experimental|Regimen 1|Drug: acalabrutinib monotherapy
3115478|NCT02537444|Experimental|Regimen 2|Drug: Combination of acalabrutinib and pembrolizumab
3115479|NCT02537522|Experimental|Test/Control - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 8.5 BC in right eye and Contact Lenses with 9.0 BC in left eye in a contralateral manner.
3115480|NCT02537522|Experimental|Control/Test - Phase 1|Over visits 1 and 2, subject will wear Contact Lenses with 9.0 BC in right eye and Contact Lenses with 8.5 BC in left eye in a contralateral manner.
3115481|NCT02537522|Experimental|Test/Control - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 9.0 BC at Period 1 and Contact Lenses with 8.5 BC at Period 2 in a bilateral manner.
3115482|NCT02537522|Experimental|Control/Test - Phase 2|During Phase 2, subjects will wear a pair of Contact Lenses with 8.5 BC at Period 1 and Contact Lenses with 9.0 BC at Period 2 in a bilateral manner.
3115483|NCT02537574|Experimental|NTX/BUP|Oral naltrexone + sublingual buprenorphine
3115484|NCT02537574|Active Comparator|NTX/PBO-B|Oral naltrexone + sublingual placebo
3115485|NCT02537574|Placebo Comparator|PBO-N/PBO-B|Oral placebo naltrexone + sublingual placebo buprenorphine
3115486|NCT02537717|Experimental|Sapphire lens|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
3115487|NCT02537717|Active Comparator|enfilcon A|Each subject will be randomized to wear the test lens in one eye and control lens in the other eye. Both test and control lenses will be used in a daily wear modality for one month.
3115488|NCT02537730|Active Comparator|Bioclean MPS VII / comfilcon A combination|Participants were randomized to the Bioclean MPS VII / comfilcon A combination for one week during the cross over study.
3115489|NCT02537730|Active Comparator|Aosept Clearcare / comfilcon A combination|Participants were randomized to the Aosept Clearcare / comfilcon A combination for one week during the cross over study.
3115490|NCT02537873|Experimental|Arm 1: Lorcaserin and Cocaine IV|"Lorcaserin 10 mg administered orally once daily for 6 days then increasing to twice daily for 3 days.~Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12."
3115491|NCT02537873|Placebo Comparator|Arm 2: Placebo Comparator and Cocaine IV|Dextrose placebo in gelatin capsule identical to experimental drug. Cocaine IV (intravenous) administered in ascending doses of 0, 10, 20, 40 mg on study days 1, 2, 6 and 12.
3115492|NCT02537951|Experimental|AFI intensity in healthy volunteers|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope
3115493|NCT02537951|Active Comparator|negative control 1: lidocaine/prilocaine|10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1hour after application of lidocaine/prilocaine creme (negative control 1)
3115494|NCT02537951|Active Comparator|negative control 2: 8% capsaicin|-10 healthy volunteers, on whose 3rd fingertips AFI intensity is measured through an AFI microscope, 1week after application of an 8% capsaicin patch (negative control 2)
3115495|NCT02538016|Other|Tolvaptan|
3115496|NCT02538029|Experimental|Dual Task Group|This group will complete an exercise intervention that involves performing dual tasking activities (simultaneously performing 2 things at once). This group will exercise 3x/wk for 8 weeks.
3115497|NCT02538029|Active Comparator|Single Task Group|This group will complete an exercise intervention that involves performing single task activities. The participant will perform motor tasks and cognitive tasks individually. This group will exercise 3x/wk for 8 weeks.
3115498|NCT02538042|Experimental|MCE+|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
3115499|NCT02538042|Other|MCE- (Control)|Three weeks prior to the target quit date, participants will switch to smoking very low nicotine content cigarettes and wear a 21 mg/d nicotine patch. During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes. Following the quit date, participants will quit smoking and wear the nicotine patch for 10 weeks.
3115500|NCT02538094|Sham Comparator|Sham Stimulation First|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS first and then Anodal Stimulation second.
3115501|NCT02538094|Experimental|Anodal Stimulation First|Transcranial direct current stimulation using Anodal stimulation first over the area of interest and then Sham Stimulation second.
3115502|NCT02538107||Kidney Transplant Participants|Participants with kidney transplant and a chronic kidney disease who were receiving methoxy polyethylene glycol epoetin beta (Mircera) as part of their medical care.
3115503|NCT02538341|Active Comparator|Zostavax (Zoster Vaccine Live)|Zostavax (zoster vaccine live) is used to prevent herpes zoster (HZ) virus (shingles) in people age 50 and older. Patients randomized to this arm will receive active herpes zoster (HZ) vaccine. It is administered as a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
3115504|NCT02538341|Placebo Comparator|Placebo Normal Saline|Saline injection: patients randomized to this arm will receive a single 0.65 mL dose subcutaneously in the deltoid region of the upper arm.
3115505|NCT02538354|Experimental|Riboflavin supplementation in quiescent disease|Group 1 (n=42) will consist of patients with disease in remission (quiescent disease).
3115506|NCT02538354|Experimental|Riboflavin supplementation in active disease|Group 2 (n=42) will consist of patients with active disease.
3115507|NCT02538419|Active Comparator|CPAP + Peer Support|"Participants randomized to this arm will receive support from a 'CPAP Peer Leader', delivered as part of a group of other participants as well as targeted one-on-one support throughout the study.~All participants will receive CPAP in addition to this intervention."
3115508|NCT02538419|Active Comparator|CPAP + Individual Education|"Participants randomized to this arm will receive individual support and education from a trained investigator.~All participants will receive CPAP in addition to this intervention."
3115509|NCT02538471|Experimental|Arm 1 - Study Drug & Radiation therapy|"Study Drug: Enrolled patients will receive 300 mg/day of LY2157299. LY2157299 will be administered as an oral drug tablet.~The study drug will be administered orally on a 28-day cycle (1 cycle=28 days), every 2 weeks, or 14 days on / 14 days off. Blood samples will be obtained at baseline, and weeks 2, 6 and 15 for immune monitoring.~Radiation therapy : Patients will receive Radiation therapy to a metastatic site at a dose of 7.5 Gy, given consecutively on days 1, 3 and 5, during Week 1 of their treatment."
3115510|NCT02538510|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO QD or via PEG on days 1-5 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3115511|NCT02538523|Active Comparator|Erchonia FX-635|The Erchonia FX-635 is made up of 3 independent 17 milliWatts (mW), 635 nanometer (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
3115512|NCT02538523|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia FX-635 but does not emit any therapeutic light.
3115513|NCT02538614|Experimental|Phase 1b: Idelalisib + BI 836826|Participants will receive escalating dose of idelalisib at dose levels, 50 mg, 100 mg, and 150 mg + BI 836826 10 mg on Day 8, 50 mg on Day 9 and Day 15, and 100 mg on Day 22, every 2 weeks through Week 18, and every 4 weeks through Week 46. 2 dose combinations (highRP2D and lowRP2D) will be determined for further evaluations in Phase 2.
3115514|NCT02538614|Experimental|Phase 2 Idelalisib + BI 836826|Participants will be randomly assigned to receive 1 of the 2 dose combinations selected from Phase 1b.
3115515|NCT02538666|Experimental|Nivolumab monotherapy|Nivolumab intravenous fusion
3115516|NCT02538666|Experimental|Nivolumab and ipilimumab combination therapy|Nivolumab and ipilimumab intravenous fusion
3115517|NCT02538666|Placebo Comparator|Placebo|Placebo
3115518|NCT02538679|Placebo Comparator|PLACEBO|No TAP block performed
3115519|NCT02538679|Experimental|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
3115520|NCT02538679|Experimental|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
3115521|NCT02538783|No Intervention|Control|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. No financial incentive other than for the midpoint and end of study surveys will be given.
3115522|NCT02538783|Experimental|Escalating lottery|Participants will receive weekly tips and weekly feedback for months 1-6 and will be observed without intervention in Phase II (months 7-12). The weekly feedback will pertain to whether or not the participant met his/her goal of weighing at least 6/7 days. The weekly tips will give information and suggestions on how to make it easier to weigh-in most days of the week. In addition to the incentives for midpoint and end of study surveys, participants who meet their weekly goal (weighing in 6 of 7 days) will be eligible for the weekly lottery during the first 6 months of the study. The expected weekly winning for the lottery is $3.55 in week 1 and this expected value will increase by $0.43 per week for each week the participant achieves their goal of weighing 6/7 days. All incentive earnings will be paid out on a monthly basis.
3115523|NCT02538900|Experimental|Group 1|Low-intensity, self-paced walking exercise. Home based exercise.
3115524|NCT02538900|Experimental|Group 2|Standard high intensity, ischemic pain-inducing walking exercise. Home based exercise.
3115525|NCT02538900|Active Comparator|Group 3|Non-exercising attention control group. Contact with staff at same frequency as exercise groups, but staff deliver information on health not related to exercise.
3115526|NCT02538965|Experimental|Lenalidomide|Lenalidomide API will administered at a starting dose of 2 mg/kg/day. Lenalidomide will be provided as either a capsule (2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg) or as an oral suspension (10mg/mL).
3115527|NCT02539108|Experimental|Study Group 1|Participants at 6 months to < 36 months age at enrollment
3115528|NCT02539108|Experimental|Study Group 2|Participants at 3 years to < 9 years age at enrollment
3115529|NCT02539134|Experimental|Part 1, Cohort 1: TAK-935 100 mg QD|TAK-935 100 milligram (mg), solution, orally, once daily (QD) or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3115530|NCT02539134|Experimental|Part 1, Cohort 2: TAK-935 300 mg QD|TAK-935 300 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3115531|NCT02539134|Experimental|Part 1, Cohort 3: TAK-935 300 mg BID|TAK-935 300 mg, solution, orally, twice daily (BID) or TAK-935 placebo-matching solution, orally, BID for up to 10 days.
3115532|NCT02539134|Experimental|Part 1, Cohort 4: TAK-935 600 mg QD|TAK-935 600 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 10 days.
3115533|NCT02539134|Experimental|Part 1, Cohort 5: TAK-935 400 mg QD|TAK-935 400 mg, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3115534|NCT02539134|Experimental|Part 2, Cohort 6: TAK-935 Dose 1|TAK-935 first decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3115535|NCT02539134|Experimental|Part 2, Cohort 7: TAK-935 Dose 2|TAK-935 second decided dose as determined from other TAK-935 trials and Cohorts 1 to 4 of Part 1, solution, orally, QD or TAK-935 placebo-matching solution, orally, QD for up to 14 days.
3115536|NCT02539225|Experimental|S-1/Oxaliplatin + Ramucirumab|"(Part A) Ramucirumab intravenously (IV) on day 1 and day 8 along with S-1 by mouth (PO) on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3115537|NCT02539225|Active Comparator|S-1/Oxaliplatin + Placebo|"(Part A) Placebo IV on day 1 and day 8 along with S-1 PO on days 1-14 and oxaliplatin IV on day 1 of each 21 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met then move to Part B.~(Part B) Ramucirumab IV on day 1 and day 15 along with paclitaxel IV on day 1, 8, and 15 of each 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met."
3115538|NCT02539342|Experimental|Caphosol Arm|Caphosol Arm: Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day from the start of chemotherapy until 7 days after the completion of chemotherapy AND until the ANC is >500 after count recovery OR until the the symptoms or oral mucositis resolve, whichever occurs last. Patients will also complete a study diary to record symptoms of oral mucositis.
3115539|NCT02539342|Active Comparator|Control Arm|Control Arm: Subjects randomized to the Control Arm will use Biotene 4 times per day. They will also complete a study diary to record doses and any symptoms of oral mucositis. This will begin at the start of chemotherapy until for 7 days AND until ANC >500 after nadir or oral mucositis resolves (whichever occurs later)
3115540|NCT02539368||CT-P13|biosimilar infliximab
3115541|NCT02539368||Remicade|infliximab
3115542|NCT02539459|Experimental|Treatment (everolimus)|Patients will take 10 mg (1 tablet) of everolimus each day for 4 months
3115543|NCT02539511|Experimental|CI-581a+MET|Administration of CI-581a during wk 2 at 0.71 mg/kg in the context of a 5 wk course of MET
3115544|NCT02539511|Active Comparator|CI-581b+MET|Administration of CI-581b during wk 2 at 0.025 mg/kg in the context of a 5 wk course of MET
3115545|NCT02539563|Active Comparator|peanut ball|the peanut shaped birthing ball after labor analgesia will be utilized
3115546|NCT02539563|No Intervention|no peanut ball|the peanut shaped birthing ball will not be utilized during labor
3115547|NCT02539654|Experimental|EXE844|EXE844 Sterile Otic Suspension, 0.3%, single ototopical dose (4 drops) in each ear following tympanostomy tube insertion
3115548|NCT02539797|Experimental|tDCS anodal stimulation|anodal stimulation
3115549|NCT02539797|Active Comparator|tDCS cathodal stimulation|cathodal stimulation
3115550|NCT02539797|Sham Comparator|Sham stimulation|Sham stimulation. Termination of electrical stimulation following 30 seconds
3115551|NCT02539992|Active Comparator|Triathlon® CR/Kinematic Alignment|Receive the Triathlon® Cruciate Retaining Total Knee System (Triathlon® CR) in a procedure using patient-specific cutting guides to reproduce the natural kinematic alignment of the knee.
3115552|NCT02539992|Active Comparator|Triathlon® CR/Neutral Overall Limb Alignment|Receive the Triathlon® CR device in a procedure using patient-specific cutting guides modified to provide neutral overall limb alignment of the knee.
3115553|NCT02539992|Active Comparator|Triathlon® CR/Conventional Limb Alignment|Receive the Triathlon® CR device in a procedure using traditional instrumentation intended to achieve a neutral overall limb alignment of the knee.
3115554|NCT02540083|Experimental|Experimental: DBT and FFDM|Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT).
3115555|NCT02540161|Experimental|non-bevacizumab failures - 18 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
3115556|NCT02540161|Experimental|bevacizumab failures - 18 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
3115557|NCT02540161|Experimental|non-bevacizumab failures - 24 mg/kg|Non-bevacizumab failure (either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen) will receive Sym004 intravenously every two weeks.
3115558|NCT02540161|Experimental|bevacizumab failures - 24 mg/kg|Prior progression on a bevacizumab-containing regimen (defined as having progressed/grown through bevacizumab by RANO criteria within 2 months of prior bevacizumab treatment) will receive Sym004 intravenously every two weeks.
3115559|NCT02540213||MIRCERA Ready-To-Use-Syringe|Participants will use MIRCERA ready-to-use-syringes (methoxy polyethylene glycol epoetin beta 0.6 micrograms per kilogram [mcg/kg]) every 2 weeks (q2w) up to 9 months
3115560|NCT02540226|Active Comparator|Intravenous tranexamic acid|Patients will receive 1g tranexamic acid in 100mL solution intravenously in the operating room before inflation of the tourniquet. They will again receive the same IV solution in the post-anesthesia care unit, approximately 3 hours after the first solution was given. They will also receive a 75cc topical saline solution approximately 5 minutes before the tourniquet is released.
3115561|NCT02540226|Experimental|Topical tranexamic acid|Patients will receive 3g tranexamic acid in 75mL solution topically in the operating room, approximately 5 minutes before the tourniquet is released. It will sit for 5 minutes before the solution is suctioned off by the surgeon. They will also receive 2 intravenous saline solutions: one in the operating room before inflation of the tourniquet, and one in the post-anesthesia care unit 3 hours after the first solution was given.
3115562|NCT02540265|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
3115563|NCT02540265|Experimental|N1539 60mg|N1539 (Intravenous meloxicam) 60mg every 24 hours for up to 3 doses.
3115564|NCT02540265|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
3115565|NCT02540291|Experimental|E7046|Participants with tumor types that harbor high levels of myeloid infiltrate based on the Cancer Genome Atlas (TCGA).
3115566|NCT02540356|Experimental|Single-Route Arm|BAX69 administered weekly by intraperitoneal (IP) infusion only
3115567|NCT02540356|Experimental|Double-Route Arm|BAX69 administered weekly by intravenous (IV) infusion + intraperitoneal (IP) infusion
3115568|NCT02540447|Experimental|Purge|"The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold custodiol (4°C solution, Portal vein (PV) was completely anastomosed and the right hepatic vein (RHV) was anastomosed with the recipient hepatic vein apart from last suture that was left for drainage of the liver graft contents of the preservative solution into the peritoneal cavity using portal blood after portal declamping based on the graft volume and suctioned through an external sucker, then completed the RHV anastomosis."
3115569|NCT02540447|No Intervention|No Purge|The donor surgical team excised the right liver lobe (without inclusion of the middle hepatic vein) and preserved it on the back table with cold Custodiol (4°C solution, Both portal vein and RHV were completely anastomosed prior to portal declamping and the graft preservative contents were washed into the systemic circulation by the portal blood at portal declamping.
3115570|NCT02540538|Active Comparator|HB vaccine naive - HBVaxPro|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBVaxPro-10ug at day 0, 30, and 180.
3115571|NCT02540538|Experimental|HB vaccine naive - HBAI20|Subjects have never been vaccinated with a Hepatitis B vaccine. Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180.
3115572|NCT02540538|Experimental|Non-responders - HBAI20|"Subjects have been vaccinated 6 times with a Hepatitis B vaccine without developing a protective immune response, measured as anti Hepatitis B surface antigen antibodies, superior to 10mIU/ml.~Subjects are vaccinated with Hepatitis B vaccine HBAI20 at day 0 and 30, and Hepatitis B vaccine HBVaxPro-10ug at day 180."
3115573|NCT02540629|No Intervention|Before intervention|The before intervention group will include patients from January, 2013 through December, 2014, as to refer to the historic control population who did not receive any of study interventions.
3115574|NCT02540629|Experimental|After intervention|The main study phase was planned to begin in January, 2016 through December, 2017, for a total of two years. Patients during the main study phase will have received one or more study interventions as applicable. However, because we could not continue our project in 2017, we changed after period. We included implementation period (2015) in after period. Therefore, final after period begins in January 2015 to December 2016.
3115575|NCT02540668|Experimental|Warfarin|Single oral dose of 15 mg warfarin on Day 1.
3115576|NCT02540668|Experimental|Lanabecestat + Warfarin|Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22.
3115577|NCT02540772|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
3115578|NCT02540772|No Intervention|No treatment|Patients in the control group only performed the baselines.
3115579|NCT02540850||CRC group|stage 0-IV CRC subjects
3115580|NCT02540850||precancerous disease group|subjects with adenoma or polyps
3115581|NCT02540850||other disease group|subjects with other bowel diseases, other cancers, and subjects with no evidence of disease
3115582|NCT02540954|Experimental|Aflibercept extended dosing|Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).
3115583|NCT02540954|Active Comparator|Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)|Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.
3115584|NCT02540993|Experimental|Finerenone (BAY94-8862)|Participants received finerenone 10 mg or 20 mg once daily in addition to standard of care therapy
3115585|NCT02540993|Placebo Comparator|Placebo|Participants received matching placebo once daily in addition to standard of care therapy
3115586|NCT02541409|Active Comparator|SOF+PEG+RBV|Sofosbuvir (400mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) + Ribavirin (800mg/daily) for 12 weeks
3115587|NCT02541409|Active Comparator|SOF+RBV|Sofosbuvir (400mg/daily) + Ribavirin (800mg/daily) for 24 weeks
3115588|NCT02541422|Active Comparator|NAC group|Patients receiving NAC after drinking to breathalyzer value 0.1
3115589|NCT02541422|Placebo Comparator|Placebo group|Patients receiving placebo after drinking to breathalyzer value 0.1
3469292|NCT03888014||Treatment group|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
3115590|NCT02541565|Experimental|Treatment (pembrolizumab, combination chemotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and prednisone PO on days 1-5. Patients also receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 2 of course 1 and on day 1 of subsequent courses. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3115591|NCT02541604|Experimental|Atezolizumab|Participants received intravenous (IV) infusion of atezolizumab (maximum 1200 milligrams [mg]) on Day 1 of each 21-day cycle.
3115592|NCT02541669|Experimental|TAK-491 40 mg (Open Label)|TAK-491 40 milligram (mg), tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
3115593|NCT02541669|Experimental|TAK-491 80 mg (Open-label)|TAK-491 80 mg, tablet, orally, once daily on Day 1 and Days 4 to 10 as an open-label treatment.
3115594|NCT02541669|Experimental|TAK-491 40 mg (Double-blind)|TAK-491 40 mg, tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
3115595|NCT02541669|Experimental|TAK-491 80 mg (Double-blind)|TAK-491 80 mg, tablet, orally, once daily and TAK-491 40 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10 in double-blind manner.
3115596|NCT02541669|Placebo Comparator|Placebo|TAK-491 40 mg placebo-matching tablet, orally, once daily and TAK-491 80 mg placebo-matching tablet, orally, once daily on Day 1 and Days 4 to 10.
3115597|NCT02541812|Experimental|Patients|Ten sessions of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in patients with obsessive compulsive disorder
3115598|NCT02541812|Active Comparator|Healthy Control Subjects|One session of 1Hz repetitive Transcranial Magnetic Stimulation of the dorsal anterior cingulate cortex in healthy control individuals
3115599|NCT02541864|Experimental|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
3115600|NCT02541864|Active Comparator|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
3115601|NCT02541903|Experimental|Gilotrif|Gilotrif will be administered orally at 40 mg dosage once daily. Continuous administration of 4 weeks is considered one cycle. Therapy will continue until progression of the disease or severe toxicities. Labs will be monitored with routine blood collections every cycle and a CT scan will be done every two cycles (8 weeks).
3115602|NCT02541942|Other|Collection of specimen|
3115603|NCT02542046||Barium|Patients who received barium sulfate oral contrast for abdominopelvic CT
3115604|NCT02542046||diatrizoate|Patients who received diatrizoate oral contrast for abdominopelvic CT
3115605|NCT02542046||iohexol|Patients who received iohexol oral contrast for abdominopelvic CT
3115606|NCT02542072|Active Comparator|comfilcon A|Participants were randomized to wear the comfilcon A lens pair for one month during the cross over study.
3115607|NCT02542072|Active Comparator|samfilcon A|Participants were randomized to wear the samfilcon A lens pair for one month during the cross over study.
3115608|NCT02542150|Experimental|acetate arm|IV acetate given during magnetic resonance scan
3115609|NCT02542150|Experimental|alcohol arm|jello shots given before magnetic resonance scan
3115610|NCT02542267|Other|Gore VIABAHN Endoprosthesis|Gore VIABAHN Endoprosthesis deployed to treat failed non-covered stent(s) in the Superficial Femoral Artery
3115611|NCT02542280|Experimental|endometrial injury|Endometrial injury during ovarian stimulation combined with intrauterine insemination.
3115612|NCT02542280|Active Comparator|no endometrial injury|Ovarian stimulation combined with intrauterine insemination.
3115613|NCT02542397|Experimental|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
3115614|NCT02542410|Active Comparator|Control|Norethindrone acetate 5 mg po daily x 6 months
3115615|NCT02542410|Experimental|Experimental|cabergoline 0.5 mg PO twice weekly x 6 months
3115616|NCT02542462|Active Comparator|Rotarix® alone|monovalent rotavirus vaccine (Rotarix®, RV1)
3115617|NCT02542462|Active Comparator|Rotarix®,with other routine vaccines|monovalent rotavirus vaccine (Rotarix®, RV1), plus additional immunizations
3115618|NCT02542462|Active Comparator|RotaTeq®, alone|pentavalent rotavirus vaccine (RotaTeq®, RV5)
3115619|NCT02542462|Active Comparator|RotaTeq®,with other routine vaccines|pentavalent rotavirus vaccine (RotaTeq®,RV5) plus additional immunizations
3115620|NCT02542605|Other|PACAP-38 Challenge Agent|In Part A, 4 cohorts of 2 to 5 participants sequentially received an intravenous infusion of 10 picomol/kilogram/minute (pmol/kg/minute) PACAP-38 for 2.5, 5, 7.5 and 10 minutes each in order to determine the dose for Part B.
3115621|NCT02542605|Placebo Comparator|Placebo|Participants were randomized to receive matching erenumab placebo by intravenous administration over 30 minutes on day 1. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
3115622|NCT02542605|Experimental|Erenumab|Participants were randomized to receive 140 milligrams (mg) erenumab by intravenous administration over 30 minutes on day 1 in Part B. On day 8 participants were administered the dose of PACAP-38 determined from Part A of the study (100 pmol/kg) and were followed up for 11 weeks.
3115623|NCT02542631|Experimental|Bolus Insulin Patch (Calibra Finesse)|Use of the wearable patch to deliver meal-related bolus insulin dose
3115624|NCT02542631|Active Comparator|Insulin Pen (Novo-Nordisk FlexPen®)|Use of the pen device to deliver meal-related bolus insulin dose
3115625|NCT02542761|Experimental|CFPF first, then FPF|After a 4 week acclimation period, subjects were studied on their current carbon fiber composite foot (CFPF), followed by another 4 week acclimation period, then studied on the study provided fiberglass composite foot (FPF).
3115626|NCT02542761|Experimental|FPF first, then CFPF|After a 4 week acclimation period, subjects were studied on the study provided fiberglass composite foot (FPF), followed by another 4 week acclimation period, then studied on their current carbon fiber composite foot (CFPF).
3115627|NCT02542865|Experimental|Test Group|Fortified malt based food (27 grams) made up in 150 mL lukewarm water administered twice daily
3115628|NCT02542865|No Intervention|Control Group|No treatment was administered
3469293|NCT03888092|Experimental|Z650 , Single-arm|Z650 will be administered daily, at dose of 350 mg orally
3115629|NCT02542943|Experimental|Experimental Oral Rinse1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3115630|NCT02542943|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3115631|NCT02542943|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3115632|NCT02543203|Active Comparator|A/C - Reconnect, Then Coconut Oil Comparator|"Participants randomized to treatment order A/C, received Reconnect for 3-months each day, morning and evening. After a washout period of one-month, they received the Coconut Oil Comparator morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
3115633|NCT02543203|Sham Comparator|C/A - Coconut oil Blend, Then Reconnect|"Participants randomized to treatment order C/A received the Coconut Oil Comparator for 3-months each day, morning and evening. After a washout period of one-month, they received Reconnect morning and evening for 3-months.~AM: Children received a topical application of one drop of oil to the back of the neck and 1 drop to the feet.~PM: Children received the oil blend by the aromatic method as it was diffused throughout their bedrooms while they slept. Each bottle has an orifice that allows the oil to be expelled drop by drop the evening dose was 8-12 drops added to the diffuser."
3115634|NCT02543294|Experimental|Anthracycline Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3115635|NCT02543294|Experimental|Herceptin Treatment Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3115636|NCT02543294|Experimental|Combination of Treatments Group|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30. Electrocardiogram performed at baseline. Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30. Telephone follow-up by study staff at months 3 and 5.
3115637|NCT02543346|Other|cetirizine hydrochloride|
3115638|NCT02543346|Placebo Comparator|placebo|
3115639|NCT02543398|Other|Ridge preservation|"The molar extraction socket is grafted with FDA approved materials, which includes a bone graft material derived from human donors (enCore®, Osteogenics biomedical, Lubbock, TX) and a membrane (like a thin sheet of paper) covering the grafted extraction socket. The membrane used will need to be removed at a later point since it is non-resorbable (it will not dissolve by itself). This membrane is made of dense polytetrafluoroethylene (dPTFE) (Cytoplast™, Osteogenics biomedical, Lubbock, TX). The procedure is called Ridge preservation"
3115640|NCT02543398|Other|No ridge preservation|"The molar extraction socket is left to heal by itself without any grafting material or membrane, i.e. Spontaneous Healing (No ridge preservation is performed)"
3115641|NCT02543437|Other|Trident Acetabular X3 Insert|28mm, 32mm and 36mm liner
3115642|NCT02543528|Experimental|etafilcon A (1-Day) and etafilcon A (Reusable)|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3115643|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 1|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3115644|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 2|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3115645|NCT02543528|Experimental|etafilcon A (1-Day) and Investigational Lens 3|Prior to randomization, all subjects will participate in a 2-week contact lens adaptation period wearing etafilcon A (1-Day). Subjects will then be randomized to one of four experimental contact lenses to be worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
3115646|NCT02543554||Pre-intervention group|mechanically ventilated patients before implementation of ED lung protective ventilation
3115647|NCT02543554||Intervention group|mechanically ventilated patients after implementation of ED lung protective ventilation
3115648|NCT02543658|Experimental|Neostigmine|Intramuscular injection of neostigmine on the basis of conventional conservative treatment
3115649|NCT02543658|Other|Conservative treatment|Intragastric administration of paraffin oil, 50ml,once every 8 hours；gastrointestinal decompression with nasogastric tube and rectal tub; lycerin enema promotes defecation; patients with ascites undergo percutaneous puncture drainage. Other conservative medical treatment recommended by the guidelines.
3115650|NCT02543723|Active Comparator|Nurse Coach Intervention|The nurse coach conducted an initial assessment with the participant and identified specific adherence strategies tailored to the participant's needs. The educational strategies include information about the patient's cancer treatment and expected outcomes; clear instructions about medication dosing schedule; what to do if a dose is missed or delayed; medication side effects and/or potential drug interactions; and review of cancer health literacy infographics. The behavioral skills and affective support strategies include coping strategies for side effects, skills for fitting medication regimen into daily routine, identifying a support network, communication skills for interacting with providers, and facilitating a positive perception for effective self-management experience. Patients received weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period.
3115651|NCT02543723|No Intervention|Control|Patients received standard of care.
3115652|NCT02543801|Active Comparator|Hip Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
3115653|NCT02543801|Active Comparator|Hip Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
3115654|NCT02543801|Active Comparator|Knee Cohort Liposomal Bupivacaine|Liposomal bupivacaine Bupivacaine Clonidine Epinephrine Ketorolac
3115655|NCT02543801|Active Comparator|Knee Cohort Ropivacaine|Ropivacaine Clonidine Epinephrine Ketorolac
3115656|NCT02543840|Experimental|Implementation Facilitation|Implementation Facilitation consists of the Center for Disease Control's Replicating Effective Programs, plus External Facilitation. The intervention lasts 6 months followed by a 6-month step-down period.
3115657|NCT02543840|Placebo Comparator|Educational Materials|Dissemination of available materials explaining the Collaborative Chronic Care Model and implementation tools. Sites randomized to delay initiation of facilitation will have these materials plus technical assistance for 4 or 8 months prior to full implementation facilitation.
3115658|NCT02543892|Experimental|Adult 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
3115659|NCT02543892|Placebo Comparator|Adult Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
3115660|NCT02543892|Experimental|Adult 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
3115661|NCT02543892|Placebo Comparator|Adult Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
3115662|NCT02543892|Experimental|Toddler 0.6mg PATH-wSP|Two 0.6 mg doses of PATH-wSP with a 28 day interval between doses
3115663|NCT02543892|Placebo Comparator|Toddler Placebo Low Dose|Two injections of normal saline with a 28 day interval between injections
3115664|NCT02543892|Experimental|Toddler 1.0 mg PATH-wSP|Two 1 mg doses of PATH-wSP with a 28 day interval between doses
3115665|NCT02543892|Placebo Comparator|Toddler Placebo High Dose|Two injections of normal saline with a 28 day interval between injections
3115666|NCT02543918|Experimental|Ixekizumab + Boostrix® + Pneumovax®23|"Ixekizumab administered once by subcutaneous injection (SQ) at week 0 and once at week 2.~Boostrix® and Pneumovax®23 administered once by intramuscular (IM) injection into opposing arms at week 2."
3115667|NCT02543918|Other|Boostrix® + Pneumovax®23|Boostrix® and Pneumovax®23 administered once by IM injection into opposing arms at week 2.
3115668|NCT02544074||eSAGE score of 10|Participants who score a 10 on the eSAGE. Interventions include neuropsychological testing.
3115669|NCT02544074||eSAGE score of 11|Participants who score an 11 on the eSAGE. Interventions include neuropsychological testing.
3115670|NCT02544074||eSAGE score of 12|Participants who score a 12 on the eSAGE. Interventions include neuropsychological testing.
3115671|NCT02544074||eSAGE score of 13|Participants who score a 13 on the eSAGE. Interventions include neuropsychological testing.
3115672|NCT02544074||eSAGE score of 14|Participants who score a 14 on the eSAGE. Interventions include neuropsychological testing.
3115673|NCT02544074||eSAGE score of 15|Participants who score a 15 on the eSAGE. Interventions include neuropsychological testing.
3115674|NCT02544074||eSAGE score of 16|Participants who score a 16 on the eSAGE. Interventions include neuropsychological testing.
3115675|NCT02544074||eSAGE score of 17|Participants who score a 17 on the eSAGE. Interventions include neuropsychological testing.
3115676|NCT02544074||eSAGE score of 18|Participants who score a 18 on the eSAGE. Interventions include neuropsychological testing.
3115677|NCT02544074||eSAGE score of 19|Participants who score a 19 on the eSAGE. Interventions include neuropsychological testing.
3115678|NCT02544074||eSAGE score of 20|Participants who score a 20 on the eSAGE. Interventions include neuropsychological testing.
3115679|NCT02544074||eSAGE score of 21|Participants who score a 21 on the eSAGE. Interventions include neuropsychological testing.
3115680|NCT02544074||eSAGE score of 22|Participants who score a 22 on the eSAGE. Interventions include neuropsychological testing.
3115681|NCT02544074||eSAGE score of 9|Participants who score a 9 on the eSAGE. Interventions include neuropsychological testing.
3115682|NCT02544074||eSAGE score of 8|Participants who score an 8 on the eSAGE. Interventions include neuropsychological testing.
3115683|NCT02544074||eSAGE score of 6|Participants who score a 6 on the eSAGE. Interventions include neuropsychological testing.
3115684|NCT02544074||eSAGE score of 7|Participants who score a 7 on the eSAGE. Interventions include neuropsychological testing.
3115685|NCT02544074||eSAGE score of 5|Participants who score a 5 on the eSAGE. Interventions include neuropsychological testing.
3115686|NCT02544074||eSAGE score of 4|Participants who score a 4 on the eSAGE. Interventions include neuropsychological testing.
3115687|NCT02544074||eSAGE score of 3|Participants who score a 3 on the eSAGE. Interventions include neuropsychological testing.
3115688|NCT02544074||eSAGE score of 2|Participants who score a 2 on the eSAGE. Interventions include neuropsychological testing.
3115689|NCT02544113|Experimental|Thymo|Subjects randomized to the (Delay CNI) group will be treated with Thymoglobulin® (total dose of 4.5 mg/kg) administered in three doses; (each dose being 1.5 mg/kg - administered Day 0 [after transplant], Day 2, and Day 4 post transplant), along with CNI delay for 10 days. CNI will be initiated on postoperative (post-transplant) Day 10. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
3115690|NCT02544113|Placebo Comparator|Control|Subjects randomized to the (Early CNI) group (Control group) will receive no antibody therapy for induction and will start CNI therapy on postoperative (post-transplant) Day 2. Subjects will also receive a maintenance immunosuppression regimen of corticosteroids and MMF in accordance with the standard practice at each clinical center.
3115691|NCT02544152|Experimental|Lubiprostone|Participants receive 8 mcg lubiprostone capsules twice daily (BID)
3115692|NCT02544152|Placebo Comparator|Placebo|Participants receive 0 mcg capsules BID
3115693|NCT02544217|Experimental|Single Escalating|2 alternating groups receiving escalating single doses of active/placebo
3115694|NCT02544217|Experimental|Multiple Escalating|3 multiple escalating groups, receiving active/placebo
3115695|NCT02544321|Active Comparator|Bromocriptine QR|4 weeks of investigational drug Bromocriptine QR
3115696|NCT02544321|Placebo Comparator|Placebo|4 weeks of placebo
3115697|NCT02544451|Experimental|Treatment Period 1: LUM/IVA to LUM/IVA|
3115698|NCT02544451|Experimental|Treatment Period 1: Placebo (PBO) to LUM/IVA|
3115699|NCT02544451|No Intervention|Treatment Period 1: Observational Cohort|
3115700|NCT02544451|Experimental|Treatment Period 2: LUM/IVA|
3115701|NCT02544607|Experimental|Ketamine + MRI|All eligible participants will receive open label ketamine and undergo Magnetic Resonance Imaging (MRI).
3115702|NCT02544633|Experimental|Arm 1|MGCD265 in patients with MET activating mutations in tumor tissue
3115703|NCT02544633|Experimental|Arm 2|MGCD265 in patients with MET gene amplifications in tumor tissue
3115704|NCT02544633|Experimental|Arm 3|MGCD265 in patients with MET activating mutations in blood (circulating tumor DNA)
3115705|NCT02544633|Experimental|Arm 4|MGCD265 in patients with MET gene amplifications in blood (circulating tumor DNA)
3115706|NCT02544763|Experimental|25 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
3115707|NCT02544763|Experimental|50 mg/kg/day GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening).
3115708|NCT02544763|Placebo Comparator|Placebo|Placebo oral solution matching 100 mg/mL GWP42003-P.
3115709|NCT02544984|Placebo Comparator|placebo|The control group will be provided with a placebo medication of similar taste, color, texture, and consistency as the study medication, and will be dispensed once a day on Monday, Wednesday, and Friday.
3115710|NCT02544984|Experimental|azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will be not be adjusted if a new weight is obtained during the trial period.
3115711|NCT02545075|Experimental|Ipilimumab|Intravenously (IV) 3 mg/kg every 3 weeks (at week 1,4,7,10) and thereafter (q3w/4 doses) at the time of progression
3115712|NCT02545075|Experimental|Dacarbazine|IV solution 250 mg/m2 (Day 1-5, every 3weeks/at week 1, 4, 7, 10,13,16,19,22)
3115713|NCT02545270|Experimental|Group 1: 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation after surgery is completed.
3115714|NCT02545270|Experimental|Group 2: 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation after surgery is completed.
3115715|NCT02545270|Experimental|Group 3: 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make three video-recordings (lasting 20-30 seconds) under different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation after surgery is completed.
3469294|NCT03887832|Experimental|SBSI intervention|Mothers is this arm will download the SMBI intervention app onto their smartphone. They will be shown a video from the app and how to share videos with others. After hospital discharge, mothers will receive a weekly media package (video, associated prompt(s), and activity) via the SMBI for six months.
3469295|NCT03887832|Active Comparator|Infant standard of care|Mothers in this arm will receive the standard of care for newborn and infants including education and a list of resources.
3115718|NCT02545322|Experimental|Adaptive Radiotherapy|"Follow-up CT scans during week 3 and week 5 of Treatment~Image-guided adaptive Radiotherapy arm:~Follow-up CT scans are performed on a conventional CT-simulator. Deformable Image Registration between the planning-CT and the follow-up CT (fCT) is done using a dedicated Software package. Delineations for target volumes and organs at risk are transferred to the fCT based on the Deformation vector fields calculated during deformable Image registration. Volumetric changes in target volumes and organs-at-risk are assessed. The initial treatment plan is transferred to the fCT scan. Dosimetric consequences of morphologic changes are analysed with the Focus on target dose coverage for the planning target volume. Adaption and plan re-optimisation are performed."
3115719|NCT02545504|Experimental|Andecaliximab|Andecaliximab plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by andecaliximab plus LV+5-FU during subsequent cycles
3115720|NCT02545504|Placebo Comparator|Placebo|Placebo plus mFOLFOX6 (LV+5-FU+OXA) during Cycles 1-6, followed by placebo plus LV+5-FU during subsequent cycles
3115721|NCT02545543|Experimental|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season).
3115722|NCT02545543|Active Comparator|Comparator Quadrivalent Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2015/2016 influenza season.
3115723|NCT02545608|Experimental|Restylane Vital in both hands|Open group used to develop a proper use of injection technique for Restylane Vital
3115724|NCT02545608|Other|Restylane Vital and No treatment|Split-hand design: Restylane Vital in one hand and initially no treatment in the other hand
3115725|NCT02545868|Experimental|Group A: OCR + Vaccines|Participants will receive dual infusion of OCR 300 milligrams (mg) on Day 1 and then on Day 15, and then participants will further receive immunization course (TT-containing adsorbed vaccine, 23-PPV either unboosted or boosted with 13-PCV, influenza vaccine, and repeated administration with KLH) at 12 weeks post-OCR treatment until Week 24. Participants who complete the 24-week immunization study period will have the option for retreatment with a single infusion of 600 mg OCR on Day 169 and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
3469296|NCT03887845||Open gastrointestinal surgery|All patients enrolled in this group would undergo open gastric and colorectal resection surgery.
3469297|NCT03887845||Laparoscopic gastrointestinal surgery|All patients enrolled in this group would undergo laparoscopic gastric and colorectal resection surgery.
3469298|NCT03887949|Active Comparator|VCV|Volume controlled ventilation
3469299|NCT03887949|Active Comparator|PCV|Pressure controlled ventilation
3469300|NCT03887949|Experimental|PCV-VG|Pressure controlled ventilation with volume guarantee
3469301|NCT03888040|Experimental|Blood Flow Restriction Training|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training with blood flow restriction.
3115726|NCT02545868|Other|Group B: Vaccines (Optional OCR in Extension)|Participants will receive immunizations (TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH) on Day 1 until Week 12 of the immunization period. Participants who complete the 12-week immunization study period will have the option to receive two single infusions of OCR 300 mg, on Day 84 and Day 98, and subsequent single infusions (600 mg OCR) at intervals of 24 weeks. Participants who have received one or more infusions of OCR will enter the 48-week safety follow-up period.
3115727|NCT02545907|Experimental|KTD treatment|"Participants in the escalation phase will receive carfilzomib (K), thalidomide (T), and dexamethasone (D) in combination. The dose of thalidomide will be 50mg/day. The dose of dexamethasone will be 20mg on Day 1, 8, and 15. Carfilzomib will be administered on Day 1, 8, and 15, but the level of carfilzomib delivered with depend on the cohort allocation. The dose of carfilzomib may be:~Level -1 - 27mg/m2~Level 0 - 36mg/m2~Level 1 - 45mg/m2~Level 2 - 56mg/m2~Participants will receive up to six cycles of treatment. Following determination of the maximum tolerated dose and recommended dose, the trial will be opened to an expansion phase where participants will receive the RD of carfilzomib, along with thalidomide and dexamethasone, using the schedule outlined above."
3115728|NCT02545933|Experimental|DAPT plus vorapaxar|Aspirin plus prasugrel or ticagrelor plus vorapaxar 2.5mg od
3115729|NCT02545933|Experimental|Prasugrel/ticagrelor plus vorapaxar|Prasugrel or ticagrelor plus vorapaxar 2.5mg od
3115730|NCT02545933|Active Comparator|DAPT|Aspirin in addition to prasugrel or ticagrelor
3115731|NCT02546193|Experimental|Outpatient Foley catheter (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the outpatient Foley catheter group (RCT design) or (B) chose the outpatient Foley catheter group (Modified Prospective study design).~Participants underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exams the evening before their scheduled induction in the Family Birth Center. A Foley catheter was placed for cervical ripening. After fetal monitoring, they were dismissed to home, to return to the Family Birth Center in the morning for continuation of their labor inductions in the inpatient setting."
3115732|NCT02546193|Active Comparator|Inpatient usual care (Randomized & Prospective)|"This arm reflects enrolled women who were (A) randomized to the inpatient usual care group (RCT design) or (B) chose the inpatient usual care group (Modified Prospective study design). No participants in the modified Prospective study design were accrued due to screen failure.~Participants presented to the Family Birth Center in the evening for their scheduled induction of labor. They underwent basic history review, fetal nonstress testing, ultrasound for presentation and amniotic fluid index, and cervical exam. Cervical ripening commenced with either a Foley catheter or vaginal misoprostol per the discretion of the managing obstetric team. They remained in the inpatient setting throughout their entire labor induction course."
3115733|NCT02546323|Experimental|Rosuvastatin|20 mg tablets, Daily oral dose
3115734|NCT02546323|Placebo Comparator|Placebo|Matching placebo tablets
3115735|NCT02546362|Experimental|Cefaly active device|12 weeks of treatment using Cefaly twice a day (treatment session of 20 minutes)
3115736|NCT02546375||Chronic Myeloid Leukaemia|Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
3115737|NCT02546388|Experimental|Indium-111 Pentreotide (OctreoScan)|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Indium-111 Pentreotide (OctreoScan). The imaging protocol will consist of imaging at 4 and 24 hours after OctreoScan injection.
3115738|NCT02546388|Experimental|Gallium-68 DOTATATE|Patients with biopsy-proven extra-cardiac sarcoidosis OR atypical findings on FDG PET and MRI without previous biopsy will be recruited to receive an injection of the FDA-approved radiotracer Gallium-68 DOTATATE. The imaging protocol will consist of imaging 1 hour after injection for DOTATATE.
3115739|NCT02546544|Other|Linsitinib|Linsitinib is to be taken orally once a day on days 1-3, 8-10 and 15-17 on a 21 day cycle. The starting dose is 600 mg
3115740|NCT02546570|Experimental|Healthy adult controls (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3115741|NCT02546570|Experimental|Adults with PTSD (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3115742|NCT02546570|Experimental|Trauma-exposed/no-PTSD adults (18-55)|Drug: oxytocin and placebo nasal spray (within-subjects design, blinded and counterbalanced for two lab sessions); dosage=24 international units (IU). Participant inserts nasal spray container 1cm into nostril at angle of 45 degrees and sprays. Will wait 15 seconds then repeat administration to other nostril (alternating between nostrils). Participants will receive 6 puffs in total (3 in each nostril).
3115743|NCT02546609|Experimental|Leu Met Sil 0.5mg|Leu-Met-Sil 0.5: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 0.5 mg of sildenafil.
3115744|NCT02546609|Experimental|Leu Met Sil 1.0mg|Leu-Met-Sil 1.0: 3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 500 mg metformin and 1.0 mg of sildenafil.
3115745|NCT02546609|Placebo Comparator|Placebo|Placebo: 3 capsules BID containing 99% Avicel PH302 and 1% magnesium stearate (w/w)
3115746|NCT02546765|Experimental|IV acetaminophen & IV propofol|"20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU~1g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
3115747|NCT02546765|Experimental|IV acetaminophen & IV dexmedetomidine|"A loading infusion of 0.5 - 1 µg/kg given over 10 minutes will be administered. After the loading infusion, a maintenance infusion of 0.1-1.4 µg/kg/hr will be initiated.~1 g IV acetaminophen every 6 hours for 48 hours during the first 2 days postoperatively"
3115748|NCT02546765|Active Comparator|IV propofol & placebo|20-100 µg/kg/min IV propofol given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl.
3115749|NCT02546765|Active Comparator|IV dexmedetomidine & placebo|0.1-1.0 µg/kg/hour IV dexmedetomidine given for 4-6 hours before the patients are woken up in the ICU Volume of the placebo (saline) will match that of i.v. acetaminophen at 100ml 0.9% NaCl.
3115750|NCT02546856|Active Comparator|Heart Failure (HF) cardiologist up-titration|Active Comparator:Cardiologist decides dosage with nursing clinical and educational support.
3115751|NCT02546856|Experimental|HF nurse up-titration|Intervention: The cardiologist prescribes drugs and, driven by protocol, the HF nurse implements the up-titration.
3115752|NCT02546986|Experimental|CC-486 plus Pembrolizumab|In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days.
3115753|NCT02546986|Experimental|Pembrolizumab plus Placebo|In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.
3115754|NCT02547012|Experimental|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
3115755|NCT02547012|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
3115756|NCT02547038|Experimental|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
3115757|NCT02547038|Active Comparator|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
3115758|NCT02547064|Active Comparator|90 degree|The ETT with the 90° angle stylet was bent at a point 8 cm from its distal end.
3115759|NCT02547064|Experimental|70 degree|The ETT was bent by 70° at a point 6 cm from its distal end and the proximal portion of the ETT was formed as the shape of the GL blade until the point of the handle.
3115760|NCT02547220|Experimental|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
3115761|NCT02547220|Placebo Comparator|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
3115762|NCT02547233|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3115763|NCT02547233|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3115764|NCT02547363|Experimental|LEO 43204|Treatment once daily for 3 days
3115765|NCT02547363|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3115766|NCT02547428|Experimental|CTN SR First, Then Placebo|Participants received CTN SR tablets starting at a dose of 100 or 200 milligrams (mg) on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 1. The dose was decreased based on safety and tolerability based on Investigator's discretion, followed by a washout Period of 1 week followed by matching-placebo for up to 3 weeks in Period 2. The most common total daily dose (TDD) was 400 mg/day.
3115767|NCT02547428|Experimental|Placebo First, Then CTN SR|Participants received matching-placebo for up to 3 weeks in Period 1, followed by a washout Period of 1 week, followed by CTN SR tablets starting at a dose of 100 or 200 mg on Day 1. Dose was up titrated up to 800 mg daily dose for up to 3 weeks in Period 2. The dose was decreased based on safety and tolerability based on Investigator's discretion. The most common TDD was 400 mg/day.
3115768|NCT02547454||CKD participants treated with Mircera|Participants with CKD received Mircera, as per routine clinical practice and was followed for approximately 36 months.
3115769|NCT02547623|Active Comparator|dexamethasone depot|dexamethasone depot 517 mcg
3115770|NCT02547623|Active Comparator|standard of care|prednisolone drops 1%
3115771|NCT02547649|Experimental|V114 Formulation A|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation A on Day 1
3115772|NCT02547649|Experimental|V114 Formulation B|Participants receive a single 0.5 mL intramuscular injection of V114 Formulation B on Day 1
3115773|NCT02547649|Active Comparator|Prevnar 13®|Participants receive a single 0.5 mL intramuscular injection of Prevnar 13® on Day 1
3115774|NCT02547714|Experimental|Secukinumab (AIN457) 300 mg|Participants received secukinumab 300 mg subcutaneously (s.c.) (two 150 mg injections) on Day 1 and at Weeks 1, 2, 3, 4, 8 and 12.
3115775|NCT02547766|Experimental|Anakinra Arm|All patients in this arm receive Anakinra in a pre-post design. That is, outcome markers are measured, the intervention (Anakinra) is applied, and the outcome markers are measured again at various intervals to determine effect.
3115776|NCT02547779|Active Comparator|0.9% Saline|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
3115777|NCT02547779|Active Comparator|Physiologically-balanced|Patients in an ICU block randomized to physiologically-balanced isotonic fluid will receive Plasma-Lyte© A or Lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
3115778|NCT02547922|Experimental|Anifrolumab - Lower Dose|Anifrolumab - Lower Dose
3115779|NCT02547922|Experimental|Anifrolumab - Higher Dose|Anifrolumab - Higher Dose
3115780|NCT02547922|Placebo Comparator|Placebo|Placebo IV Q4W plus SOC
3115781|NCT02547935|Experimental|Dapagliflozin 10mg|Tablets administered orally once daily for 24 weeks
3115782|NCT02547935|Experimental|Dapagliflozin 10mg + Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks
3115783|NCT02547935|Placebo Comparator|Placebo|Tablets administered orally once daily for 24 weeks
3115784|NCT02547974|Experimental|GSK3277513A F1 Group|Subjects, 18 - 40 years, receiving two doses of the non adjuvanted GSK Biologicals' NTHi Mcat investigational vaccine (GSK3277513A ) containing formulation 1 (F1) of PD, PE-PilA and UspA2 during Step 1 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3115785|NCT02547974|Experimental|GSK3277513A F2 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 2 (F2) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3115786|NCT02547974|Experimental|GSK3277513A F3 Group|Subjects, 50 - 70 years, receiving two doses of the GSK Biologicals' NTHi-Mcat investigational vaccine(GSK3277513A) containing formulation 3 (F3) (adjuvanted) of PD, PE-PilA and UspA2 during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3115787|NCT02547974|Placebo Comparator|Placebo Group|Subjects, 18 - 40 years, receiving two doses of placebo (saline solution) during Step 1 of the study and subjects, 50 - 70 years, receiving two doses of placebo (saline solution) during Step 2 of the study. Intramuscular injection should be done in the deltoid of the non-dominant arm. In case it is not possible to inject in the non dominant arm, an injection in the dominant arm may be performed.
3115788|NCT02547987|Experimental|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV on Day 1 of each 21 day cycle for 6 cycles
3115789|NCT02548078|Experimental|GSK3390107A+Nimenrix Group|Subjects in the GSK3390107A+Nimenrix Group received the investigational GSK3390107A vaccine at the Day 0 visit and Nimenrix at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
3115790|NCT02548078|Experimental|Nimenrix+GSK3390107A Group|Subjects in the Nimenrix +GSK3390107A Group received Nimenrix at the Day 0 visit and the investigational GSK3390107A vaccine at the Month 6 visit, intramuscularly into the deltoid region, or thigh region for smaller children.
3115791|NCT02548143|Experimental|Coagulation Factor VIIa (Recombinant)|A dose of 75 μg/kg (minor surgery or invasive procedure) or 200 μg/kg (major surgery or major invasive procedure) of LR769 will be administered as an initial intravenous (IV) bolus dose of LR769 within ≤2 minutes before the surgical incision or start of the invasive procedure. For both minor and major procedures, the initial dose will be followed by repeated administration of 75 µg/kg of LR769 every 2 hours (±5 minutes) for the first 48 hours after completion of the procedure and then as per the dosing schedules in the protocol for major or minor surgeries or invasive procedures. The minimum duration of LR769 treatment for major procedures will be 5 days, and for minor procedures 2 days except for certain procedures that may not require this duration of treatment.
3115792|NCT02548156|Other|Test dentifrice|1.5g (± 0.05g) of Test dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
3115793|NCT02548156|Other|Reference dentifrice|1.5g (± 0.05g) of Reference dentifrice followed by 10mL of de-ionised water rinse, then 10 mL water rinse
3115794|NCT02548156|Other|Comparator dentifrice|1.5g (± 0.05g) of Comparator dentifrice followed by 10mL of de-ionised water rinse, then 10 mL orange juice rinse
3115795|NCT02548312|Experimental|Review 1- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
3115796|NCT02548312|Experimental|Review 1- competing interest statement 2|Variations of financial competing interest statements.
3115797|NCT02548312|Experimental|Review 1- competing interest statement 3|Variations of financial competing interest statements.
3115798|NCT02548312|Experimental|Review 1- competing interest statement 4|Variations of financial competing interest statements.
3115799|NCT02548312|Experimental|Review 2- competing interest statement 1|Variations of financial competing interest statements. There will be a statement that the authors have no competing interests.
3115800|NCT02548312|Experimental|Review 2- competing interest statement 2|Variations of financial competing interest statements.
3115801|NCT02548312|Experimental|Review 2- competing interest statement 3|Variations of financial competing interest statements.
3115802|NCT02548312|Experimental|Review 2- competing interest statement 4|Variations of financial competing interest statements.
3115803|NCT02548455|Experimental|Treatment|Subjects implanted with the Quartet 1457Q LV lead
3115804|NCT02548585|Placebo Comparator|Placebo|Participants will receive placebo (matched to either 100 micrograms [mcg], or 150 mcg or 200 mcg or 300 mcg of MEDI0382) subcutaneously (SC) once daily from Day 1 to Day 7 (Cohort 1); or Day 1 to Day 11 (Cohort 2); or Day 1 to Day 15 (Cohort 3); or Day 1 to Day 41 (Cohort 4); or Day 1 to Day 22 (Cohort 5); or Day 1 to Day 17 (Cohort 6).
3115805|NCT02548585|Experimental|Cohort 1: MEDI0382 100 mcg|Participants will receive MEDI0382 100 mcg SC once daily from Day 1 to Day 7.
3115806|NCT02548585|Experimental|Cohort 2: MEDI0382 150 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4) and thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 7 days (Day 5 to Day 11).
3115807|NCT02548585|Experimental|Cohort 3: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 7 days (Day 9 to Day 15).
3115808|NCT02548585|Experimental|Cohort 4: MEDI0382 200 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 4 days (Day 1 to Day 4); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 4 days (Day 5 to Day 8); followed by second up titrated dose of MEDI0382 200 mcg SC once daily for 4 days (Day 9 to Day 12), then a further MEDI0382 200 mcg SC once daily for 28 days (Day 13 to Day 40) at home-dosing; followed by MEDI0382 200 mcg SC once daily for 1 day in hospital (Day 41).
3115809|NCT02548585|Experimental|Cohort 5: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 150 mcg SC once daily for 5 days (Day 6 to Day 10); then a second up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 11 to Day 15); followed by third up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 16 to Day 22).
3115810|NCT02548585|Experimental|Cohort 6: MEDI0382 300 mcg|Participants will receive MEDI0382 100 mcg SC once daily for at least 5 days (Day 1 to Day 5); thereafter, an up titrated dose of MEDI0382 200 mcg SC once daily for 5 days (Day 6 to Day 10); followed by a second up titrated dose of MEDI0382 300 mcg SC once daily for 7 days (Day 11 to Day 17).
3115811|NCT02548650|Experimental|Patients with diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
3115812|NCT02548650|Active Comparator|Patients without diabetes|Triple therapy (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days.
3115813|NCT02548728|Experimental|Oxytocin|Self administration three times on the first day, then twice daily treatment with intranasal oxytocin spray for 4 days.
3115814|NCT02548728|Placebo Comparator|Placebo|Self administration three times on the first day, then twice daily treatment with intranasal spray that does not contain oxytocin for 4 days.
3115815|NCT02548754|Experimental|Active|Patients will receive 1 hour of active low level tragus stimulation daily for 6 months
3115816|NCT02548754|Sham Comparator|Sham|Patients will receive 1 hour of sham low level tragus stimulation daily for 6 months
3115817|NCT02548910|Experimental|Phlebotomy|For patients randomized to phlebotomy, the intervention will consist of the standard of care (low CVP surgery), plus whole blood phlebotomy. Blood will be collected in citrated whole blood collection bag.
3115818|NCT02548910|No Intervention|Control|Standard of care (low CVP surgery). In this arm, standard anesthesia will be maintained.
3115819|NCT02548962|Experimental|Phase 1: Dose Finding|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
3115820|NCT02548962|Experimental|Phase 2: Treatment Arm A|Ibrutinib PO+ Pomalidomide PO+ Dexamethasone PO
3115821|NCT02548962|Experimental|Phase 2: Treatment Arm B|Placebo PO+ Pomalidomide PO+ Dexamethasone PO
3115822|NCT02549014|Experimental|Panel A: MK-1064 5 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 5 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115823|NCT02549014|Experimental|Panel B: MK-1064 10 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 10 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115824|NCT02549014|Experimental|Panel A: MK-1064 25 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 25 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115825|NCT02549014|Experimental|Panel B: MK-1064 50 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 50 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115826|NCT02549014|Experimental|Panel A: MK-1064 100 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 100 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115827|NCT02549014|Experimental|Panel B: MK-1064 150 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 150 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115828|NCT02549014|Experimental|Panel A: MK-1064 200 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 200 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115829|NCT02549014|Experimental|Panel B: MK-1064 250 mg|Within each of up to 4 treatment periods, 6 participants were randomly assigned to receive single oral doses of MK-1064 250 mg in a fasted state. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115830|NCT02549014|Experimental|Panel A: MK-1064 25 mg (Fed)|In Period 5, participants received a single MK-1064 dose of 25 mg administered in the evening following a standard high-fat breakfast.
3115831|NCT02549014|Experimental|Panel B: MK-1064 50 mg (Night)|In Period 5, participants received a single MK-1064 dose of 50 mg administered in the evening after a 4-hour fast.
3115832|NCT02549014|Placebo Comparator|Panels A & B: Placebo|Within each of up to 5 treatment periods, 2 participants were randomly assigned to receive single oral doses of matching placebo in a fasted stated. There was to be a minimum 7-day washout between treatment periods for any given participant.
3115833|NCT02549027|Experimental|Sequence (MK-1064): 50 mg→250 mg→Placebo→120 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 50 mg MK-1064, Period 2 - single dose of 250 mg MK-1064, Period 3 - single dose of placebo, Period 4 - single dose of 120 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3115834|NCT02549027|Experimental|Sequence (MK-1064): Placebo→50 mg→120 mg→250 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of placebo, Period 2 - single dose of 50 mg MK-1064, Period 3 - single dose of 120 mg MK-1064, Period 4 - single dose of 250 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3115835|NCT02549027|Experimental|Sequence (MK-1064): 120 mg→Placebo→250 mg→50 mg|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 120 mg MK-1064, Period 2 - single dose of placebo, Period 3 - single dose of 250 mg MK-1064, Period 4 - single dose of 50 mg MK-1064. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3115836|NCT02549027|Experimental|Sequence (MK-1064): 250 mg→120 mg→50 mg→Placebo|For overall study population, 5 participants each were to be allocated to one of 4 sequences. In this sequence, participants received the following: Period 1 - single dose of 250 mg MK-1064, Period 2 - single dose of 120 mg MK-1064, Period 3 - single dose of 50 mg MK-1064, Period 4 - single dose of placebo. Participants completing the first 4 periods also were to receive the following: Period 5 - single dose of 20 mg MK-6096 or placebo, in an 18:2 ratio for overall study population, according to separate allocation. There was a minimum 7-day washout between doses.
3115837|NCT02549040|Experimental|Doravirine fixed sequence treatment|After a minimum 10 hour overnight fast, participants received a single oral dose during each of 5 periods. During Period 1, participants received Treatment B: Doravirine Type 1 dose (150 mg tablet [40% drug loaded granule]). During Period 2, participants received Treatment A: Doravirine 100 mg film coated tablet. During Period 3, participants received Treatment C: Doravirine Type 2 dose (150 mg tablet [30% drug loaded granule]). During Period 4, participants received Treatment D: Doravirine Type 3 dose (150 mg tablet [50% drug loaded granule]. During Period 5, participants received Treatment E: Doravirine Type 4 dose (100 mg tablet [30% drug loaded granule]). Each period was separated by a 14 day washout.
3115838|NCT02549092|Active Comparator|Optimized Medical Treatment (OMT)|"Participants randomized to continue OMT remain on their current optimized regimen. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose (after NJ and/or PEG-J placement), in order to transition to commercially available LCIG."
3115839|NCT02549092|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|"Participants randomized to LCIG at an individually optimized dose (after NJ and/or PEG-J placement), in accordance with the LCIG approved product label for countries participating in the study. During the 26-week treatment phase, changes to anti-PD and NMS medications are to remain stable and can only be made if medically indicated.~The total daily dose of LCIG was composed of 3 components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. The continuous infusion is expected to run over a period of 16 consecutive hours each day.~Eligible participants may elect to enter an extension/transition follow-up period to receive an individually optimized LCIG dose, in order to transition to commercially available LCIG."
3115840|NCT02549196|Experimental|Cohort 1|Donepezil 20mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
3115841|NCT02549196|Experimental|Cohort 2|Donepezil 20mg/day upward dose titration of 20mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
3115842|NCT02549196|Experimental|Cohort 1b|Donepezil 10mg/day upward dose titration of 10mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 60mg/day with solifenacin 15 or 20mg/day.
3115843|NCT02549196|Experimental|Cohort 3c|Donepezil 10mg/day upward dose titration of 5mg at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) of 40mg/day with solifenacin 15mg/day.
3115844|NCT02549209|Experimental|Investigational Treatment|"Subjects with no prior therapy:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 175mg/m2~Carboplatin administered at an AUC of 6~Subjects with prior external beam radiation therapy (XRT) and/or platinum-based chemotherapy must initiate paclitaxel and carboplatin at a reduced dose:~Pembrolizumab administered at 200 mg~Paclitaxel administered at 135mg/m2~Carboplatin administered at an AUC of 5"
3115845|NCT02549287|Experimental|SafeCare|SafeCare, an evidence-based home visiting program
3115846|NCT02549287|Active Comparator|Supportive Case Management|Child welfare services as usual
3115847|NCT02549339|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3115848|NCT02549339|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3115849|NCT02549352|Experimental|LEO 43204 gel|Treatment once daily for 3 days
3115850|NCT02549352|Placebo Comparator|Vehicle gel|Treatment once daily for 3 days
3115851|NCT02549365|Experimental|Intervention|Administration of Live attenuated influenza vaccine (LAIV) as per national guidance. Surveillance thereafter through nasal swabbing in the event of influenza-like illness.
3115852|NCT02549365|Other|Controls|Surveillance in siblings of participants in the Intervention arm, through nasal swabbing in the event of influenza-like illness, irrespective of their vaccination status.
3115853|NCT02549508|Experimental|AutoCPAP with SensAwake On, then SenAwake Off|Participants will start AutoCPAP treatment with SensAwake on for 4 weeks. After 4 weeks, the will cross over to SensAwake off for another 4 weeks.
3115854|NCT02549508|Experimental|AutoCPAP with SensAwake Off, then SensAwake On|Participants will start AutoCPAP treatment with SensAwake Off for 4 weeks. After 4 weeks, the will cross over to SensAwake On for another 4 weeks.
3115855|NCT02549573|Active Comparator|Apokyn treatment before physical therapy|"APOKYN treatment before the PT Intervention Visit. Subjects in the APO+ group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit."
3115856|NCT02549573|Other|Apokyn treatment withheld before physical therapy|"APOKYN treatment withheld before the PT Intervention Visit. Subjects in the APO- group will not take carbidopa/levodopa and APOKYN for at least 3 hours before or during the PT Intervention Visit. No rescue therapy will be allowed during the PT. Intervention Visit. If the PT Intervention Visit needs to be stopped early, the Physical Therapist will record this along with a reason for the discontinuation."
3115857|NCT02549859|Experimental|Deep Brain Stimulation (DBS)|All patients were treated and assessed under three conditions (60 Hz DBS, 130 Hz DBS and no DBS) at Visit 1 (V1), were then treated with 60 Hz DBS for at least 6 months (14.5 months on average), and were finally reassessed during a second visit (V2) under the same three conditions as V1. The order of treatment/assessment under the three conditions was randomized at each visit.
3115858|NCT02550106|Experimental|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
3469302|NCT03888040|Experimental|Resistance Training Only|This leg will then perform low-load resistance training (30% of 1-RM) including 3 sets of 15 knee extensions performed as fast as possible while seated upright in a knee extension weight machine. Sets will be interspersed with 30 seconds rest. This leg will always perform the training without blood flow restriction.
3115859|NCT02550132|Experimental|Participants|All volunteers will participate in an experimental session. Participants will be delivered four different spinal manipulations (SMT) at T7 with a rate of force application of about 2200 Newtons/seconds and a preload force of 25 Newtons (N). SMTs will differed in their time to peak force (ms) and peak force (N), respectively fixed as follow for each applied SMT: (1)57 ms / 150 N, (2)80 ms / 200 N, (3)102 ms / 250 N and (4)125 ms / 300 N.
3115860|NCT02550197|Experimental|QIV Group|Subjects will receive one dose of the Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016 formulation
3115861|NCT02550197|Active Comparator|TIV Group|Subjects will receive one dose of the Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation
3115862|NCT02550210|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
3115863|NCT02550288|Active Comparator|Ezetimibe 10 mg|1 ezetimide 10 mg tablet, 2 atorvastatin 10 mg placebo capsules orally once daily for 12 weeks.
3115864|NCT02550288|Active Comparator|Atorvastatin 10 mg|1 atorvastatin 10 mg capsule, 1 ezetimide 10 mg placebo tablet, and 1 atorvastatin 10 mg placebo capsule orally once daily for 12 weeks.
3115865|NCT02550288|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg capsules and 1 ezetimide 10 mg placebo tablet orally, once daily for 12 weeks.
3115866|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|1 Ezetimibe 10 mg tablet, 1 atorvastatin 10 mg capsule and 1 atorvastatin 10 mg placebo capsule orally, once daily for 12 weeks
3115867|NCT02550288|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|1 Ezetimibe 10 mg tablet and 2 atorvastatin 10 mg capsules orally, once daily for 12 weeks
3115868|NCT02550652|Experimental|Obinutuzumab|Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
3115869|NCT02550652|Placebo Comparator|Placebo|Participants will receive placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose will be up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, may use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants may receive 750-1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants will receive 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.
3115870|NCT02550743|Experimental|Dose 1|BYL719, capectabine and radiation Dose BYL719: 200mg/day
3115871|NCT02550743|Experimental|Dose 2|BYL719, capectabine and radiation Dose BYL719: 250mg/day
3115872|NCT02550743|Experimental|Dose 3|BYL719, capectabine and radiation Dose BYL719: 300mg/day
3115873|NCT02550743|Experimental|Dose -1|BYL719, capectabine and radiation Dose BYL719: 150mg/day
3115874|NCT02550795|Placebo Comparator|Control|administration of 0.9% normal saline 10ml
3115875|NCT02550795|Active Comparator|Dexmedetomidine|administration of 0.5ug/kg of dexmedetomidine (5ml)
3115876|NCT02550795|Active Comparator|Dexmedetomidine and dexamethasone|administration of 0.5 ug/kg of dexmedetomidine and dexamethasone 5mg (total 5ml)
3115877|NCT02550873|Experimental|PRM-151 10mg / kg|Dosing Every 4 Weeks
3115878|NCT02550873|Placebo Comparator|Placebo|Dosing Every 4 weeks
3115879|NCT02550938|Experimental|7 Aligner Cohort weartime 1|Seven Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
3115880|NCT02550938|Experimental|7 Aligner Cohort weartime 2|Seven Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
3115881|NCT02550938|Experimental|12 aligner cohort weartime 1|Twelve Aligner cohort will change aligners at a designated interval Invisalign is the intervention.
3115882|NCT02550938|Experimental|12 aligner cohort weartime 2|Twelve Aligner cohort will change aligners at a modified interval Invisalign is the intervention.
3115883|NCT02551055|Experimental|MLN1117 300 mg + Alisertib|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
3115884|NCT02551055|Experimental|MLN1117 600 mg + Alisertib|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; 22, 23, and 24) and 4 days off per week and alisertib 40 mg, tablets, orally, twice daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15,16, and 17) and 4 days off per week on Weeks 1-3, and 1 week off in 28-day treatment cycles until PD or unacceptable toxicity.
3115885|NCT02551055|Experimental|MLN1117 300 mg + Paclitaxel|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
3115886|NCT02551055|Experimental|MLN1117 600 mg + Paclitaxel|MLN1117 600 mg, tablets, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, 18; 23, 24, and 25) and 4 days off per week and paclitaxel 80 mg/m^2, infusion, intravenously, once weekly on (Days 1, 8, and 15) and 1 week off, in 28-day treatment cycles until PD or unacceptable toxicity.
3115887|NCT02551055|Experimental|MLN1117 300 mg + TAK-659|MLN1117 300 mg, tablets, orally, once daily for 3 days on (Days 1, 2, 3; 8, 9, 10; 15, 16, 17; and 22, 23, and 24) and 4 days off per week and TAK-659 100 mg (as determined in study C34001 [NCT02000934]), tablets, orally, once daily, in 28-day treatment cycles until progressive disease (PD) or unacceptable toxicity.
3115888|NCT02551055|Experimental|MLN1117 200 mg + Docetaxel|MLN1117 200 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
3115889|NCT02551055|Experimental|MLN1117 300 mg + Docetaxel|MLN1117 300 mg, orally, once daily for 3 days on (Days 2, 3, 4; 9, 10, 11; 16, 17, and 18) and 4 days off per week and docetaxel 75 mg/m^2, infusion, intravenously, on Day 1 once every 3 weeks in 21-day treatment cycles until PD or unacceptable toxicity.
3115890|NCT02551094|Active Comparator|colchicine|0.5 mg tablet of colchicine taken once a day
3115891|NCT02551094|Placebo Comparator|colchicine placebo|0.5 mg tablet of placebo taken once a day
3115892|NCT02551159|Experimental|Monotherapy|MEDI4736 monotherapy.
3115893|NCT02551159|Experimental|Combination Therapy|MEDI4736+Tremelimumab combination therapy
3115894|NCT02551159|Active Comparator|Standard of Care|Standard of Care treatment
3115895|NCT02551224|Experimental|Breezhaler, then Ellipta|Half of the patients will be assigned to first receive a single dose of placebo via the Breezhaler® followed by a single dose of placebo via the Ellipta® inhalation device. The evaluation questionnaires after using each device.
3115896|NCT02551224|Experimental|Ellipta, then Breezhaler|Half of the patients will be assigned to first receive a single dose of placebo via the Ellipta® followed by a single dose of placebo via the Breezhaler® inhalation device. The evaluation questionnaires after using each device.
3115897|NCT02551432|Experimental|Paclitaxel pembrolizumab|"PD-L1 Induction phase : Paclitaxel 175 mg/m2, Day 1 q 3weeks, intravenous,~Post Induction treatment phase: Paclitaxel 175 mg/m2, Day 1 q 3weeks (maximum up to total 6 cycles) + pembrolizumab 200 mg D1 q 3 weeks, intravenous,~Maintenance phase: pembrolizumab 200 mg D1 q 3 weeks, intravenous till PD or unacceptable toxicity"
3115898|NCT02551653|Experimental|[11C]-GSK2256098|Subjects will receive single IV bolus injection of [11C]-GSK2256098 over about 30 seconds. Each unit dose will contain up to 500 millibecquerel (MBq) of [11C]-GSK2256098 with maximum [11C]-GSK2256098 mass <=10 microgram (mcg).
3115899|NCT02551666|Active Comparator|Tai Chi exercise intervention|Participants will perform 30-minute Tai Chi sessions (Yang Short form) 3 times a week for 4 weeks.
3115900|NCT02551666|Experimental|Balance recovery training|Participants will practice balance recovery on a modified treadmill for approximately 30-minutes per session, 3 sessions a week for 4 weeks.
3115901|NCT02551692|Placebo Comparator|NRT|
3115902|NCT02551692|Placebo Comparator|VAR|
3115903|NCT02551692|Placebo Comparator|PLAC|
3115904|NCT02551718|Experimental|Treatment (chemosensitivity testing, chemotherapy)|Leukemia cells purified from blood or bone marrow samples are analyzed for sensitivity to individual drugs and drug combination and by next generation sequencing.
3115905|NCT02551731|Experimental|Cannabidiol Oral Solution: 20 or 40 mg/kg/day BID|The dose of Cannabidiol Oral Solution will begin at 20 mg/kg/day [10 mg/kg twice per day (BID)], will be adjusted at any time if the investigator feels the safety or well-being of the participant is at risk, and will be titrated up or down according to protocol-stipulated parameters and at the investigator's discretion after Day 14 to enhance efficacy. Dose will not exceed 40 mg/kg/day.
3115906|NCT02551744|Active Comparator|proton pump inhibitor group|Pantoprazole Tab 40mg qd for 6 monthrs.
3115907|NCT02551744|Experimental|histamine-2 receptor antagonist group|famotidine Tab 40 mg qd for 6 months.
3115908|NCT02551757|Experimental|Active-CPAP|Patients assigned to active-CPAP were treated with auto-titrating CPAP, where an auto-titrator adjusted the delivered pressure between 4 to 20 cm of water to eliminate obstructive events for a goal apnea-hypopnea index less than or equal to 5.
3115909|NCT02551757|Sham Comparator|Sham-CPAP|The sham-CPAP device in our study was designed to entail no risks beyond those with standard CPAP and provide a high level of blinding. The sham-CPAP device is an auto-titrating CPAP with an internal flow restrictor and a modified elbow attached to the nasal mask. The elbow modification creates a larger than standard air leak that serves to prevent any chances of carbon dioxide rebreathing and delivers a pressure at the mask in¬terface of roughly 0.75 to 1 cm water. The elbow modification is not noticeable when the device is fully assembled to avoid the possibility of unblinding patients, providers, or study personnel. The elbow modification could only be used on standard nasal masks; consequently full facemasks and nasal pillows were excluded for patients in both active and sham-CPAP.
3115910|NCT02551770|Active Comparator|Test (with Emdogain)|Scaling and root planing with Emdogain
3115911|NCT02551770|Other|Control (without Emdogain)|Scaling and root planing without Emdogain
3115912|NCT02551809|Experimental|3 priming doses followed by 4 boosters|Subjects will receive 7 doses of UB-311.
3115913|NCT02551809|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311 and 2 doses of placebo.
3115914|NCT02551809|Placebo Comparator|Placebo|Subjects will receive 7 doses of placebo.
3115915|NCT02551822|Active Comparator|Cycling|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to on-off cycles (on 16 seconds, off 8 seconds). This means the devices are not continuously on. Rather they are on a cycling program."
3115916|NCT02551822|Active Comparator|Continuous|"Sacral neuromodulator devices (implanted pulse generator) will be programmed to be on continuously. This means the devices are continuously on. They are on a continuous program."
3115917|NCT02551874|Experimental|Saxagliptin/Dapagliflozin/Metformin|Oral route. Saxagliptin/Dapa adminsitered once daily for 24 weeks at a dose of 5 mg Saxagliptin and 10 mg Dapagliflozin
3115918|NCT02551874|Active Comparator|Insulin Glargine, Lantos/Metformin|Insulin glargine administered once a day with starting dose of 0.2 Unit per kg or 10 units.
3115919|NCT02551887|No Intervention|Usual Care|Usual Care Only
3115920|NCT02551887|Active Comparator|Automated Reminder|Reminder
3115921|NCT02551887|Experimental|Automated Reminder Plus Script|Provider sees both reminder and script.
3115922|NCT02552121|Experimental|Tisotumab vedotin (HuMax-TF-ADC)|
3115923|NCT02552147|Experimental|Transdermal nicotine first, placebo last|Subject will receive transdermal nicotine 7 mg daily for 7 days, placebo patch for 7 days, then placebo patch for a final 7 days.
3115924|NCT02552147|Experimental|Transdermal placebo first, nicotine last|Subject will receive transdermal placebo daily for 7 days, placebo patch for another 7 days, then transdermal nicotine 7 mg daily for a final 7 days.
3115925|NCT02552212|Experimental|Certolizumab Pegol 200 mg Q2W|Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
3115926|NCT02552212|Placebo Comparator|Placebo|Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.
3115927|NCT02552225|Experimental|amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
3115928|NCT02552225|Placebo Comparator|placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
3115929|NCT02552238|Experimental|Lumason|Lumason (sulfur hexafluoride lipid-type A microspheres) 2 mL IV injection
3115930|NCT02552303|Active Comparator|CBT for Insomnia (CBTI) + Armodafinil|CBT-I with Armodafinil (active medication)
3115931|NCT02552303|Placebo Comparator|CBTI + Placebo|Cognitive Behavioral Therapy for Insomnia with Placebo medication
3115932|NCT02552303|Active Comparator|Armodafinil|Medication (armodafinil) only, without CBTI.
3115933|NCT02552303|Placebo Comparator|Placebo|Placebo only, without CBTI.
3115934|NCT02552316|Other|NB-UVB Phototherapy|NB-UVB phototherapy is a therapy which uses ultraviolet B (UVB) light directed at the skin. This type of light therapy is given through the use of phototherapy booths which contain fluorescent tubes that emit UVB light. Booths used for phototherapy look similar to commercial tanning booths. NB-UVB phototherapy affects psoriasis by causing changes to the cells of the skin and producing a local effect by reducing the number of certain types of skin cells which have an impact on psoriasis formation.
3115935|NCT02552355|Experimental|Metformin/Carbohydrate|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin.
3115936|NCT02552355|Placebo Comparator|Placebo/Carbohydrate|Daily oral administration of matching placebo with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of matching placebo will begin as one tablet for the first week and will increase by one tablet/day/week until reaching 4 tablets by week 4. Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo.
3115937|NCT02552355|Active Comparator|Metformin/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin
3115938|NCT02552355|Active Comparator|Placebo/Protein|Daily oral administration of Metformin with a 12-week exercise training program consisting of 3 days per week of aerobic exercise training. The dose of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week. Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.
3115939|NCT02552368|Experimental|IpsiHand|IpsiHand is a device which includes a robotic glove that you wear on your hand and a headset that you wear on your head. The headset picks up your thoughts and sends them to the robotic glove, to control opening and closing of your hand.
3115940|NCT02552732|Experimental|NHF with or without Oxygen|NHF with or without oxygen will be delivered to COPD patients using myAIRVO™ 2 for 30 days post hospital discharge
3115941|NCT02552810|Active Comparator|Plasma of Argon|Abutment cleaning by plasma of Argon protocol .
3115942|NCT02552810|Active Comparator|Steam clean|Abutment cleaning by steam clean device.
3115943|NCT02552888|Experimental|treatment|Immediate release sodium nitrite 40 mg by mouth twice per day and Isoquercetin 225 mg by mouth once per day.
3115944|NCT02552888|Placebo Comparator|Placebos|identical placebos.
3115945|NCT02552966|Experimental|UESAD|Upper Esophageal Sphincter Assist Device
3115946|NCT02553135|Experimental|Injection of AAV2-REP1|Injection of AAV-REP1, 1.00x10e11 vg, subretinal injection of total volume of 100 μL.
3115947|NCT02553317|Experimental|Caplacizumab|Caplacizumab 10 mg once daily
3115948|NCT02553317|Placebo Comparator|Placebo|Placebo once daily
3115949|NCT02553330|Experimental|Ruxolitinib Phosphate Cream|"Part A: Open-label treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks;~Part B: Double-blind treatment is 24 weeks, an optional open-label treatment extension is 24 weeks if eligible, and follow-up is an additional 12 weeks."
3115950|NCT02553330|Placebo Comparator|Placebo Cream|Part B: Double-blind treatment is 24 weeks (and/or treatment with Ruxolitinib Phosphate Cream if eligible) and follow-up is an additional 12 weeks.
3115951|NCT02553395|Experimental|Phenacite contact lens|Study Test Contact Lens
3115952|NCT02553395|Active Comparator|comfilcon A contact lens|Control Contact Lens
3115953|NCT02553421|Experimental|Pilot|A non-alarming ivWatch device will monitor the IV sites of these subjects. The goal of this small pilot study is to give clinicians an opportunity to perform the protocol and operate the ivWatch device and to give researchers the ability to make adjustments prior to starting the subsequent non-alarming group.
3115954|NCT02553421|Experimental|Non-alarming|150 patients will be enrolled in the non-alarming group. The ivWatch device will monitor the IV sites but will not issue infiltration notifications.
3115955|NCT02553421|Experimental|Alarming|150 patients will be enrolled in the alarming group. The IV sites will be monitored with the ivWatch Model 400 infiltration notifications enabled.
3115956|NCT02553499|Experimental|MK-1248|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 170 mg MK-1248) via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 4 cycles (up to ~3 months).
3115957|NCT02553499|Experimental|MK-1248 + Pembrolizumab|Participants received escalating doses of MK-1248 at assigned dose (dose range: 0.12 mg to 60 mg MK-1248) via IV infusion on Day 1 of each 21-day cycle for a maximum of 4 cycles (up to ~3 months) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~24 months).
3469303|NCT03887975|Active Comparator|Percentage of force in monoplane occlusion|Different occlusal scheme evaluation using tscan
3469304|NCT03887975|Active Comparator|Percentage of force in lingualized occlusion|Different occlusal scheme evaluation using tscan
3115958|NCT02553538|Experimental|Patient Navigation Intervention|Participants randomized to the intervention arm were transferred to a navigator roster within the TopCare application for the 8-month study period. Navigators utilized TopCare to track these participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
3115959|NCT02553538|No Intervention|Standard of Care - No Intervention|Participants randomized to the control arm received usual care within TopCare, which meant that clinicians and staff could elect to send the participant a reminder letter about their overdue cancer screening exams, reach out to schedule overdue exams, or document appropriate reasons for deferral or exclusion.
3115960|NCT02553629|Active Comparator|moderate neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a train of four of 1 - 2 twitches
3115961|NCT02553629|Experimental|deep neuromuscular block|rocuronium 0.1-0.6 mg/kg aimed at a post tetanic count of 1 - 2 twitches
3115962|NCT02553746|Experimental|Ultrasound|
3115963|NCT02553746|Active Comparator|Landmarks|
3115964|NCT02553772|Experimental|OM3 Tear|Carboxymethylcellulose based eye drop [Omega-3 (OM3) Tear] administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
3115965|NCT02553772|Active Comparator|REFRESH OPTIVE® ADVANCED|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
3115966|NCT02553798|Experimental|Glycopyrronium|Glycopyrronium Topical Wipes
3115967|NCT02553915|Placebo Comparator|Placebo|Soybean oil placebo capsules, 4 capsules daily for 12 weeks
3115968|NCT02553915|Experimental|EPA 1 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 1 daily (plus 3 placebo capsules) for 12 weeks
3115969|NCT02553915|Experimental|EPA 2 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 2 daily (plus 2 placebo capsules) for 12 weeks
3115970|NCT02553915|Experimental|EPA 4 g/day|Eicosapentaenoic acid (EPA) 1000 mg capsules, 4 daily for 12 weeks
3115971|NCT02553928|Experimental|Memantine (once daily)|Memantine 20 mg once daily, tablets, orally AND Placebo tablets once daily, orally
3115972|NCT02553928|Experimental|Memantine (twice daily)|Memantine 10 mg twice daily, tablets, orally AND Placebo tablets twice daily, orally
3115973|NCT02554019|Experimental|BT063|50 mg BT063 administered by intravenous (IV) infusion 8 times
3115974|NCT02554019|Placebo Comparator|Placebo|Placebo administered by IV infusion 8 times
3115975|NCT02554279|Experimental|menotropin|menotropins for injection
3115976|NCT02554279|Active Comparator|recombinant FSH|
3115977|NCT02554435|Active Comparator|Pedometer|All participants will be given 5 A's counseling and a digital pedometer (Digi-walker CW-700/701, YAMAX, San Antonio, TX). Participants will be asked to log their daily steps measured by the pedometer in an activity diary.
3115978|NCT02554435|Experimental|Electronic Activity Monitor (EAM)|"All participants will be given an EAM (UP24 by Jawbone, San Francisco, CA) and the corresponding UP24 application (app) on their smart device. In addition to monitoring activity, the app allows for social comparison and social interaction. Participants will friend other participants to utilize these features."
3115979|NCT02554474|Active Comparator|Immediate Group|Time spent in Moderate/Vigorous Physical Activity (MVPA) was measured with a SenseWear Mini sensor over a 7-day period. The mean time was calculated in bouted MVPA per day. A bout is defined as >= 10 consecutive minutes or more at the level of >= 3 METs (i.e., the lower bound of MVPA), with allowance for interruption of up to two minutes below the threshold.
3115980|NCT02554474|Placebo Comparator|Delay Group|Time spent in sedentary activity was measured with a SenseWear Mini sensor over a 7-day period. The mean daily time spent in sedentary activity was calculated with an energy expenditure of <=1.5 METs, occurring in bouts of >= 20 minutes during waking hours.
3115981|NCT02554513|Active Comparator|EPG Tx|An articulatory-kinematic treatment in conjunction with visual biofeedback specifically tongue to palate contact to improve speech production
3115982|NCT02554513|Active Comparator|Sound Production Treatment (SPT)|An articulatory-kinematic treatment that uses integral stimulation to improve speech production.
3115983|NCT02554682|Other|Sexual Health|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to sexual health at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
3115984|NCT02554682|Other|Alcohol Prevention|Parents of teens between the ages of 14 and 15 will review psychoeducational workbooks related to alcohol prevention at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 4 to 5 months post baseline we will collect data to assess the efficacy of the study materials.
3115985|NCT02554682|No Intervention|Sexual Health & Alcohol Control Group|Parents of teens between the ages of 14 and 15 will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 4 to 5 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from both the sexual health and alcohol prevention groups.
3115986|NCT02554682|Other|Teen Driving|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will review psychoeducational workbooks related to teen driving at a well-child visit appointment with the primary care giver (baseline); 2 weeks after baseline they will received a follow-up phone call and health coaching session to review the materials and ask questions; and then at 6 months post baseline we will collect data to assess the effectiveness of the study materials.
3115987|NCT02554682|No Intervention|Teen Driving Control|Parents of teens between the ages of 16 and 17 who are planning on having the medical certification for the permit application completed and plan on taking their driving permit test in the next 8 weeks will receive their usual care at their well-child visit appointment with their primary care giver (baseline) and then at 6 months post baseline we will collect data. At the end of the post data collection, the control group will get all of the study materials from the teen driving group.
3469305|NCT03887689|Experimental|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
3469306|NCT03887897|Active Comparator|Airtraq|Airtraq laryngoscope
3115988|NCT02554721|Experimental|Group 1 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Acetylsalicylic acid 100 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Acetylsalicylic acid 100mg once daily for 1 week (Days 22-28)
3115989|NCT02554721|Experimental|Group 2 (CYP2C19 Wild Type)|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3115990|NCT02554721|Experimental|Group 3 (CYP2C19 heterozygous (*1/*2) )|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3115991|NCT02554721|Experimental|Group 4 (CYP2C19 homozygous (*2/*2))|Trial period A: Cilostazol 100 mg twice daily for 1 week (Days 1-7) Trial period B: Wash out period (Days 8-14) Trial period C: Clopidogrel 75 mg once daily for 1 week (Days 15-21) Trial period D: Cilostazol 100 mg twice daily and Clopidogrel 75 mg once daily for 1 week (Days 22-28)
3115992|NCT02554760|Experimental|All Study Participants|This is a split body study in which all subjects will receive bilateral flank treatment with CoolSculpting. The investigator will determine one flank for treatment using the CoolCore applicator without an accessory for a duration of 60 minutes at a protocol-defined temperature. The contralateral flank will be treated with the standard CoolCore Applicator using an applicator accessory, the Crown Cooling Insert (CCI) at a protocol-defined temperature for a duration of up to 45 minutes. All enrolled subjects receive identical treatments; the investigator will use alternate subject numbers to balance which flank to treat with and without the CoolCore applicator accessory, such that all even subject numbers will receive treatment using the Standard CoolCore on the right flank and odd subject numbers will receive the same treatment on the left flank.
3115993|NCT02554786|Experimental|QMF149 150/160 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/160 μg was delivered once daily (o.d) via Concept1 inhaler in the evening.
3115994|NCT02554786|Experimental|QMF149 150/320 µg|QMF149 (Indacaterol acetate/Mometasone furoate) 150/320 μg was delivered o.d via Concept1 inhaler in the evening.
3115995|NCT02554786|Active Comparator|MF 400 µg|Mometasone furoate (MF) 400 μg was delivered o.d via Twisthaler® in the evening
3115996|NCT02554786|Active Comparator|Salmeterol /fluticasone 50/500 μg|Salmeterol xinafoate/fluticasone propionate 50/500 μg was delivered twice daily (in the morning and in the evening) via Accuhaler®.
3115997|NCT02554786|Active Comparator|MF 800 μg|MF 800 μg of total daily dose (400 μg twice daily, in the morning and in the evening) was delivered via Twisthaler®.
3115998|NCT02554799|Experimental|40 mg MMV390048 tablet formulation A fasted|40 mg MMV390048 tablet formulation A, in fasted state
3115999|NCT02554799|Experimental|40 mg MMV390048 tablet formulation B fasted|40 mg MMV390048 tablet formulation B fasted
3116000|NCT02554799|Experimental|40 mg MMV390048 formulation A or B, with milk or fasted|Optional cohort: 40 mg of MMV390048 in the formulation that has been shown to have the most favourable PK profile, taken with milk or in the fed state.
3116001|NCT02554877|Placebo Comparator|Placebo|
3116002|NCT02554877|Experimental|PF-06291874, 30 mg|
3116003|NCT02554877|Experimental|PF-06291874, 60 mg|
3116004|NCT02554877|Experimental|PF-06291874, 100 mg|
3116005|NCT02554890|Experimental|sacubitril/valsartan (LCZ696)|"Initial dose for patients randomized to sacubitril/valsartan (LCZ696) was determined by the blood pressure at the time of randomization. Study treatment was titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg bid (Dose Level 3). Titration was based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active sacubitril and valsartan and one tablet of enalapril matching placebo pack)."
3116006|NCT02554890|Active Comparator|Enalapril|"Initial dose for patients randomized to enalapril were determined by the blood pressure at the time of randomization. Study treatment were titrated to the target dose of enalapril 10 mg bid. Titration were based on blood pressure at the time of the visit. Dose adjustments were only allowed if indicated per protocol defined safety and tolerability criteria and investigator judgement.~Patients were required to take a total of two tablets twice daily (one tablet of active enalapril, second from sacubitril and valsartan matching placebo pack)"
3116007|NCT02554903|Experimental|Macitentan 10 mg po|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
3116008|NCT02554903|Placebo Comparator|Placebo sugar pill|Approximately 78 adult subjects with PH post-LVAD implantation will be randomized (1:1) to receive either macitentan 10 mg, or matching placebo, once daily orally.
3116009|NCT02554929|Experimental|Taming Sneaky Fears Group|An 11 week (introduction plus 10 week) manualized treatment protocol utilizing cognitive behavioral strategies specifically developed for children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
3116010|NCT02554929|Active Comparator|Parent Psychoeducation and Child Socialization Group|An 11 week (introduction plus 10 week) manualized treatment protocol focusing on parent psychoeducation and child socialization in children 4 to 7 years of age with social anxiety disorder and/or selective mutism. Parent and child groups run separately but concurrently.
3116011|NCT02554981|Experimental|RESTASIS®|1 drop of RESTASIS® ophthalmic emulsion instilled in each eye twice a day for 6 months.
3116012|NCT02555098|Experimental|Sapphire contact lenses|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
3116013|NCT02555098|Active Comparator|senofilcon A|Each subject randomized to wear either the Investigational lenses (test) or senofilcon A contact lenses (control) as a matched pair and cross over to the second matched pair.
3116014|NCT02555215|Experimental|dimethyl fumarate|Participants will receive 120 mg capsule(s) taken orally.
3116015|NCT02555228|Experimental|Simethicone premedication|Liquid simethicone (1ml volume) in 5mls of water
3116016|NCT02555228|Placebo Comparator|Placebo|Just 5 mls of water
3469307|NCT03887897|Active Comparator|Macintosh|Macintosh laryngoscope
3116017|NCT02555306|Experimental|Low Dose DE-122|Single intravitreal injection of DE-122 Low Dose Injectable Solution
3116018|NCT02555306|Experimental|Medium-Low Dose DE-122|Single intravitreal injection of DE-122 Medium-Low Dose Injectable Solution
3116019|NCT02555306|Experimental|Medium-High Dose DE-122|Single intravitreal injection of DE-122 Medium-High Dose Injectable Solution
3116020|NCT02555306|Experimental|High Dose DE-122|Single intravitreal injection of DE-122 High Dose Injectable Solution
3116021|NCT02555371|Experimental|Arm Mepolizumab 100 mg|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). Subjects will receive mepolizumab (100 mg SC) every 4 weeks throughout study
3116022|NCT02555371|Placebo Comparator|Arm Placebo|There will be 4 parts during the study. Part A will be Variable Open-Label Run-in (maximum up to 132 weeks). Part B- Fixed Open-Label Run-In (4 Weeks to 8 weeks). Part C will be randomized double-blind treatment period (Up to 52 weeks) and in case of clinically significant asthma exacerbation, optional open label switch Part D (Up to 52 weeks post randomization). During Part A, B and D, subjects will receive open label mepolizumab (100 mg SC) every 4 weeks and during Part C, subjects will receive placebo SC every 4 weeks.
3116023|NCT02555449|Experimental|[¹⁴C]-LY3202626|Single oral dose of LY3202626 containing 100 micro curies of radioactivity
3116024|NCT02555618|Experimental|TAK-850|A single dose of 0.5 mL TAK-850 (15 μg of hemagglutinin [HA] antigen per strain) is injected subcutaneously into the upper arm.
3116025|NCT02555618|Active Comparator|Influenza HA Vaccine|A single dose of the 0.5 mL influenza HA vaccine (15 μg of HA antigen per strain) is injected subcutaneously into the upper arm.
3116026|NCT02555631|Experimental|lifestyle intervention|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
3469308|NCT03887884|Experimental|CVT-301|Single inhaled dose of CVT-301 84 mg
3469309|NCT03887884|Active Comparator|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
3116029|NCT02555683|Experimental|QAW039 150 mg|QAW039 150 mg once daily
3116030|NCT02555683|Experimental|QAW039 450 mg|QAW039 450 mg once daily
3116031|NCT02555683|Placebo Comparator|Placebo|Placebo once daily
3116032|NCT02555722|Experimental|fanfilcon A (test)|Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
3116033|NCT02555722|Active Comparator|enfilcon A (control)|Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
3116034|NCT02555878|Experimental|Rivaroxaban|Participants will be administered rivaroxaban 10 milligram (mg) tablet orally once daily for 180 days.
3116035|NCT02555878|Experimental|Placebo|Participants will be administered matching placebo tablet orally once daily for 180 days.
3116036|NCT02556112|Active Comparator|Group Lifestyle Balance|Participants receive the Group Lifestyle Balance intervention as per the standard curriculum
3116037|NCT02556112|Active Comparator|Better Body Better Life|Participants receive the Better Body Better Life intervention as per the standard curriculum
3116038|NCT02556112|Active Comparator|Fitness Improvement Program|Participants take the Fitness Improvement Program on-line
3116039|NCT02556138|Experimental|Orbera Intragastric Balloon|All subjects will be receiving the ORBERA Intragastric Balloon
3116040|NCT02556177|Active Comparator|mTBI patient group (Segment 1)|"1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit~Patients in the acute period following recent diagnosis of mild traumatic brain injury (mTBI)"
3116041|NCT02556177|Active Comparator|non-TBI patients (Segment 2)|Control subjects with no recent mild traumatic brain injury. 1.5T or 3.0T MRI brain scanning with research sequences at 3 to 4 intervals in the acute period, with psychological cognitive evaluations at each MR visit
3116042|NCT02556203|Experimental|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were treated with Rivaroxaban (10mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, ASA was discontinued and rivaroxaban (10mg once-daily) was to be continued alone. In the event of NOAF (New Onset of Atrial Fibrillation), subjects should be switched to rivaroxaban (20/15mg once-daily) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and rivaroxaban (20/15mg once-daily) was to be continued alone.
3116043|NCT02556203|Active Comparator|Antiplatelet|Subjects were treated with clopidogrel (75mg once-daily) and ASA (75-100mg once-daily) within first 90 days after randomization. After 90 days, clopidogrel was discontinued and ASA (75-100mg once-daily) was to be continued alone. In the event of NOAF, subjects should start treatment of open-label VKA to target INR 2 to 3 (according to guidelines) and ASA (75-100mg once-daily) within first 90 days. After 90 days, ASA was discontinued and VKA was to be continued alone.
3116044|NCT02556255|Experimental|B-Laser™ Atherectomy Catheter|Percutaneous Transluminal Angioplasty (PTA) for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD), that the atherectomy part of the PTA will include an experimental atherectomy catheter, B-Laser™.
3116045|NCT02556307||Peginterferon alfa-2a + Ribavirin|
3116046|NCT02556333|Experimental|FTC/TAF|Emtricitabine 200mg/tenofovir alafenamide 25mg (FTC/TAF) tablet to be given orally once daily to be added to a failing regimen for 10 days. If HIV RNA decline by >= 0.5 log copies/mL, patient will continue on FTC/TAF with a new antiretroviral regimen for 48 weeks. If < 0.5 log copies/mL decline, patient will be taken off FTC/TAF.
3116047|NCT02556554|No Intervention|Routine Care|Standard of Care in the Pregnancy and Women's Health clinic.
3116048|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system|An intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy.
3116049|NCT02556554|Active Comparator|Dexcom G4 Platinum CGM system with Share™|A treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™ remote monitoring capabilities during pregnancy.
3116050|NCT02556606|Experimental|Ketamine 0.10 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
3116051|NCT02556606|Experimental|Ketamine 0.25 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
3116052|NCT02556606|Experimental|Ketamine 0.50 mg/kg|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
3116053|NCT02556606|Active Comparator|Midazolam 0.03 mg/kg|randomly assigned to a single 40 min infusion of either MID 0.03mg/Kg
3116054|NCT02556632|Experimental|Arm I (curcumin-based gel)|Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3116055|NCT02556632|Experimental|Arm II (HPR Plus)|Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3116056|NCT02556632|Placebo Comparator|Arm III (placebo gel)|Patients apply placebo gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.
3116057|NCT02556736|Experimental|Group 1|Single intravitreal injection of RST-001
3116058|NCT02556775||Alternative Product Arm|Participant stops HYQVIA treatment (if the participant is still treated) and a licensed human normal immunoglobulin other than HYQVIA for intravenous (IV) or subcutaneous (SC) infusion or an alternative treatment will be administered, as determined by the physician.
3116059|NCT02556775||HYQVIA Arm|Participant continues to receive HYQVIA (Immune Globulin (Human) 10% with recombinant human hyaluronidase (rHuPH20)), according to her treatment regimen.
3116060|NCT02556788|Experimental|CD5789 (Trifarotene) 50µg/g Cream|CD5789 (trifarotene) 50µg/g Cream
3116061|NCT02556788|Placebo Comparator|Placebo Cream|Placebo Cream
3116062|NCT02556801|Placebo Comparator|SUBLIVAC FIX Phleum Prat. 0 AUN/ml|42 subjects received placebo (SUBLIVAC FIX Phleum Pratense 0 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3116063|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 10,000 AUN/ml|42 subjects received SUBLIVAC FIX Phleum Pratense 10,000 AUN/ml) sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3116064|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 40,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 40,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3116065|NCT02556801|Experimental|SUBLIVAC FIX Phleum Prat. 80,000 AUN/ml|40 subjects received SUBLIVAC FIX Phleum Pratense 80,000 AUN/ml sublingually. Subjects will start with one drop and add one drop each consecutive day until the maintenance dose of 5 drops per day is reached. Next treatment at maintenance dose is continued during 10 months.
3116066|NCT02556918|Experimental|Sitagliptin|"Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
3116067|NCT02556918|Placebo Comparator|Placebo|"Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.~Interventions:~Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)"
3116068|NCT02557035|Experimental|I.V. palonosetron infusion plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3116069|NCT02557035|Active Comparator|I.V. palonosetron bolus plus dexamethasone|Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
3116070|NCT02557100|Experimental|Treatment A|Abatacept Single Blind Treatment Period
3116071|NCT02557100|Active Comparator|Treatment B|Adalimumab Single Blind Treatment Period
3116072|NCT02557100|Active Comparator|Treatment C|Abatacept Cumulative Treatment Period
3469310|NCT03887702|Experimental|Group A (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD immediately or within 42 days after initial dose of chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
3116076|NCT02557178|Experimental|Activity Monitor plus Health Coaching|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen. Participants in the intervention condition (wearing the Actigraph) will also receive supportive health coaching to encourage them to exercise.
3116077|NCT02557178|No Intervention|Control|Device: Actigraph Participants will wear the device daily during weeks 1, 9, and 17. Daily steps and activity will be measured. It will identify if they complete a prescribed exercise regimen.
3116078|NCT02557399|Experimental|Duac® fixed dose combination gel|Subjects will use Duac® fixed dose combination gel (clindamycin phosphate 1.2% and benzoyl peroxide 3%) with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) for 12 weeks.
3116079|NCT02557399|Active Comparator|Combination therapy: ADA 0.1% gel + CLDM 1% gel|Subjects will use combination therapy of ADA 0.1% gel with quantity sufficient to cover entire face (including the forehead, nose, cheeks and chin) once daily in the evening (at bedtime) and subjects will also apply CLDM 1% gel twice daily, once in the morning and once in the evening (at bedtime) for 12 weeks. The CLDM 1% gel should apply subsequent to the application of ADA 0.1% gel in the evening. The CLDM 1% gel should be applied to ILs only.
3116080|NCT02557516|Experimental|Phase 1 Level 1 - 1 mg/kg|In phase 1, Monalizumab given at the first dose level of 1 mg/kg.
3116081|NCT02557516|Experimental|Phase 1 Level 2 - 2 mg/kg|In phase 1, Monalizumab given at the second dose level of 2 mg/kg.
3116082|NCT02557516|Experimental|Phase 1 Level 3 - 4 mg/kg|In phase 1, Monalizumab given at the third dose level of 4 mg/kg.
3116083|NCT02557516|Experimental|Phase 2 RP2D - 2 mg/kg|In phase 2, Monalizumab given at the Recommended Phase 2 Dose (RP2D) of 2 mg/kg, selected by a safety committee.
3116084|NCT02557646||Pegasys + Copegus|Treatment naive participants with confirmed chronic hepatitis C who are started on combined Pegasys-Copegus treatment in accordance with current guidelines and SPCs, and whose treatment has been approved by the Interferon Committee.
3116085|NCT02557698|Experimental|Balneum oil bath|Balneum oil bath, bathing every other day for four weeks
3116086|NCT02557698|No Intervention|standard skin cleanser|Usual skin cleanser (non-oil containing), bathing or showering every other day for four weeks
3116087|NCT02558231|Experimental|Triple oral combination treatment|Macitentan, tadalafil, and selexipag
3116088|NCT02558231|Placebo Comparator|Dual oral combination treatment|Macitentan, tadalafil, and placebo
3116089|NCT02558296|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
3116090|NCT02558296|Placebo Comparator|Placebo tablets|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
3116091|NCT02558374|Experimental|AR-13324 Ophthalmic Solution 0.02% & placebo|1 drop AR-13324 in the evening (PM) & 1 drop placebo in the morning (AM) in both eyes (OU)
3116092|NCT02558374|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop twice daily (BID) in the morning (AM) & evening (PM) in both eyes (OU)
3116093|NCT02558400|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005% ophthalmic solution
3116094|NCT02558400|Active Comparator|AR-13324 Ophthalmic Solution 0.02%|Netarsudil 0.02% ophthalmic solution
3116095|NCT02558400|Active Comparator|Latanoprost Ophthalmic Solution 0.005%|Latanoprost 0.005% ophthalmic solution
3116096|NCT02558790|Experimental|L-Threonic Acid Magnesium Salt (L-TAMS)|Subjects received open label L-Threonic acid Magnesium salt for 12 weeks. Subjects took MMFS202 (6-hour release) and MMFS302 (12-hour release) by mouth each day, up to three times a day.
3116097|NCT02558829|Experimental|GHST Sequence A|1st Macimorelin-GHST, 2nd Insulin Tolerance Test
3116098|NCT02558829|Experimental|GHST Sequence B|1st Insulin Tolerance Test, 2nd Macimorelin-GHST
3116099|NCT02558894|Experimental|MEDI4736 monotherapy|MEDI4736 via IV infusion.
3116100|NCT02558894|Experimental|tremelimumab+MEDI4736|MEDI4736+tremelimumab via IV infusion.
3116101|NCT02559115|Experimental|PET/CT imaging with 68Ga-RM2|The intervention is the administration of a single dose of 150-200 MBq 68Ga-RM2 (mass <= 30 μg) for imaging purposes. This will be followed by a 30-40 min PET/CT study after a waiting period of 60 min (+/- 10 min). Prior clinical experience suggests that imaging can be performed within 1 hour post injection (27, 28). MR imaging and prostatectomy will be performed as standard of care at MSKCC.
3116102|NCT02559206|Experimental|30 μg linaclotide DR1 and placebo|
3116103|NCT02559206|Experimental|100 μg linaclotide DR1 and placebo|
3116104|NCT02559206|Experimental|300 μg linaclotide DR1 and placebo|
3116105|NCT02559206|Experimental|30 μg linaclotide DR2 and placebo|
3116106|NCT02559206|Experimental|100 μg linaclotide DR2 and placebo|
3116107|NCT02559206|Experimental|300 μg linaclotide DR2 and placebo|
3116108|NCT02559206|Experimental|290 μg linaclotide IR and placebo|
3116109|NCT02559206|Placebo Comparator|Placebo|
3116110|NCT02559310|Experimental|Lefamulin|Intravenous lefamulin with potential step-down to oral lefamulin
3116111|NCT02559310|Active Comparator|Moxifloxacin +/- Linezolid|Intravenous moxifloxacin with potential step-down to oral moxifloxacin +/- linezolid
3116112|NCT02559414|No Intervention|Control|This arm of 10 subjects will be assigned randomly via a computer generated treatment sequence, and then be given no antiplatelet medication.
3116113|NCT02559414|Active Comparator|Aspirin|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given aspirin.
3116114|NCT02559414|Active Comparator|Clopidogrel|This arm of 20 subjects will be assigned randomly via a computer generated treatment sequence, and then be given clopidogrel.
3116115|NCT02559505|Experimental|6-12 months Seasonal IIV|Children 6 - 12 months of age vaccinated with seasonal IIV
3116116|NCT02559505|Experimental|3-12 months natural infection|Children 3-12 months of age presenting with natural influenza infection
3116117|NCT02559505|Experimental|13-35 months Seasonal IIV|Children 13-35 months of age vaccinated with seasonal IIV
3116118|NCT02559505|Experimental|13-35 months natural infection|Children 13-35 months of age presenting with natural influenza infection
3116119|NCT02559505|Experimental|3-5 years Seasonal IIV|Children 3-5 years of age vaccinated with seasonal IIV
3116120|NCT02559505|Experimental|3-5 years natural infection|Children 3-5 years of age presenting with natural influenza infection
3116121|NCT02559505|Experimental|6-8 years Seasonal IIV|Children 6-8 years of age vaccinated with seasonal IIV
3116122|NCT02559505|Experimental|6-8 years natural infection|Children 6-8 years of age presenting with natural influenza infection
3116123|NCT02559570|Placebo Comparator|Placebo|Participants aged 6 to 11 or 12 to 17 years received matching placebo linaclotide (LIN), 30 minutes before evening meal, once daily for 4 weeks. Administered as liquid oral solution for participants 6 to 11 years of age and solid oral capsule or liquid oral solution for participants 12 to 17 years of age.
3116124|NCT02559570|Experimental|LIN Dose A (9 ug or 18 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 9 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 18 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
3116125|NCT02559570|Experimental|LIN Dose B (18 ug or 36 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 18 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 36 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
3116126|NCT02559570|Experimental|LIN Dose C (36 ug or 72 ug)|Participants aged 6 to 11 years with weight 18 to <35 kg received LIN 36 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 6 to 11 years with weight ≥35 kg received LIN 72 ug, oral solution, 30 minutes before evening meal, once daily for 4 weeks. Participants aged 12 to 17 years received LIN 72 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
3116127|NCT02559570|Experimental|LIN 145 µg|Participants aged 12 to 17 years received LIN 145 ug, oral solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
3116128|NCT02559622|Experimental|300 mg secukinumab|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
3116129|NCT02559622|Experimental|150 mg secukinumab|150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
3116130|NCT02559622|Other|Placebo followed by 300 mg secukinumab|Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)
3116131|NCT02559622|Other|Placebo followed by 150 mg secukinumab|Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)
3116132|NCT02559687|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks (Q3W) for up to 35 treatments (approximately 2 years)
3116133|NCT02559713|Experimental|Vedolizumab 300 milligram (mg)|Vedolizumab 300 mg, IV infusion over 30-minutes, single dose on Day 1.
3116134|NCT02559817|Experimental|Linaclotide Dose A|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose A: 18 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose A: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose A: 36 micrograms solid oral capsule in children 12-17 years of age"
3116135|NCT02559817|Experimental|Linaclotide Dose B|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose B: 36 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose B: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose B: 72 micrograms solid oral capsule in children 12-17 years of age"
3116136|NCT02559817|Experimental|Linaclotide Dose C|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Dose C: 72 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight 18 to <35 kg~Dose C: 145 micrograms liquid oral solution or solid oral capsule in children 7-11 years of age with weight ≥ 35 kg~Dose C: 145 micrograms solid oral capsule in children 12-17 years of age"
3116137|NCT02559817|Experimental|Linaclotide Approved Adult Dose|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast.~Approved Adult Dose: 290 micrograms solid oral capsule in children 12-17 years of age"
3116138|NCT02559817|Placebo Comparator|Matching Placebo|"Taken once daily each morning at least 30 minutes before breakfast, with the exception of the first Treatment Period dose which will be taken at the study center, after at least a 2-hour fast~Placebo liquid oral solution or placebo solid oral capsule in children 7-11 years of age~Placebo solid oral capsule in children 12-17 years of age"
3116139|NCT02559895|Experimental|ALD403 Dose Level 1|ALD403 Dose Level 1 (IV)
3116140|NCT02559895|Experimental|ALD403 Dose Level 2|ALD403 Dose Level 2 (IV)
3116141|NCT02559895|Experimental|ALD403 Dose Level 3|ALD403 Dose Level 3 (IV)
3116142|NCT02559895|Placebo Comparator|Placebo|Placebo (IV)
3116143|NCT02560012|Other|Personalized therapy|"Subjects will receive one of the four first-line therapy agents based on their tumor's profile. The first-line agents are sunitinib, temsirolimus, sorafenib, or pazopanib. These are all routine drugs for RCC treatment and will be given at their approved doses and dosing schedules.~Upon disease progression, subject's tumor(s) will be biopsied again to create another tumor profile. The second-line agents are everolimus or axitinib. Both of these are routine drugs for RCC treatment and will be given at their approved doses and dosing schedules."
3116144|NCT02560025|Experimental|Alisertib / MLN8237|"Participants will initially receive 7+3 induction chemotherapy, consisting of cytarabine and concurrent idarubicin (or daunorubicin if appropriate). Oral alisertib, at 30mg twice daily, will begin on day 8, and will continue for 7 days. During induction, patients with residual disease at day 14 may have re-induction with 5+2 chemotherapy, but will not receive additional dosing of alisertib at that time. Following count recovery after induction, if patients proceed to consolidative cycles of therapy with cytarabine, they will receive alisertib at day 6 following conclusion of cytarabine administration. Upon count recovery following consolidation, alisertib will be resumed for 7 days, followed by 14 days off, and will be continued as 21-day cycles of maintenance, for up to 12 cycles."
3116145|NCT02560038|Experimental|Combination chemotherapy|Combination chemotherapy consisting of gemcitabine and cisplatin plus paclitaxel on a 21-day cycle.
3116146|NCT02560051|Active Comparator|Definitive local therapy|3 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 12 months ADT (degarelix)
3116147|NCT02560051|Active Comparator|Nodal only/Low-volume bone|4 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 18 months ADT (degarelix)
3116148|NCT02560051|Active Comparator|High volume/no prior tx|5 cycles of chemotherapy (doxorubicin, ketoconazole, docetaxel and estramustine) + 24 months ADT (degarelix)
3116149|NCT02560324|Experimental|Ramelteon|"The study will be performed using 8mg of ramelteon, which is currently marketed for the treatment of sleep problems. The proposed study follows the typical dosing regimen for ramelteon (8mg once a day) for 5 days during each quit assessment period.~Ramelteon will be purchased and packaged into blister packs by the Investigational Drug Service (IDS) at the University of Pennsylvania. In accordance with FDA recommendations, subjects will be instructed to take study medication within 30 min prior to going to bed and avoid taking study medication with or immediately after a high fat meal."
3116150|NCT02560324|Placebo Comparator|Placebo|"5-day placebo-controlled medication period.~Placebo ingredients will be purchased, encapsulated, and packaged into blister packs by the IDS at UPenn. Both active medication and placebo will look identical.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take ramelteon during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by ramelteon during the second medication period."
3116151|NCT02560389|Placebo Comparator|Placebo|Placebo administered in pill form once by mouth
3116152|NCT02560389|Active Comparator|100mg L-DOPA|100mg levodopa administered in pill form once by mouth
3116153|NCT02560389|Active Comparator|200mg L-DOPA|200mg levodopa administered in pill form once by mouth
3116154|NCT02560493|No Intervention|Control Condition|Participants randomly assigned to the control condition will be asked to continue their usual physical activity habits and will not interact with the intervention staff.
3116155|NCT02560493|Experimental|Exergaming Condition|Participants randomly assigned to the exergaming condition will participate in a 6 month exergaming intervention.
3116156|NCT02560558|Experimental|Belatacept 8-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.
3116157|NCT02560558|Active Comparator|Belatacept 4-weekly|Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.
3116158|NCT02560584|Experimental|Cysview arm|"In this single-arm trial, Cystoscopy in white light followed by blue light (BL) is performed in all applicable patients during 2 study visits; Visit 2 (Surveillance) and Visit 3 (Operating room procedure)~All patients receive instillation of 100 mg hexaminolevulinate hydrochloride as intravesical solution (50 mL) in the bladder prior to cystoscopy. Retention time: 1-3 hours.~Surveillance cystoscopy is performed with the investigational device KARL STORZ D-Light C PDD Flexible Videoscope System"
3116159|NCT02560753|Experimental|T3D-959 3mg|Nine subjects will take 3mg by mouth once daily for two weeks, with or without food.
3116160|NCT02560753|Experimental|T3D-959 10mg|Nine subjects will take 10mg by mouth once daily for two weeks, with or without food.
3116161|NCT02560753|Experimental|T3D-959 30mg|Nine subjects will take 30mg by mouth once daily for two weeks, with or without food.
3116162|NCT02560753|Experimental|T3D-959 90mg|Nine subjects will take 90mg by mouth once daily for two weeks, with or without food.
3116163|NCT02560779|Experimental|Carotuximab (TRC105) and Sorafenib|Carotuximab (TRC105) in combination with standard dose Sorafenib.
3116164|NCT02560922|Experimental|Pain Coping Skills Training|This group will take part in an 11-week pain coping skills training (CST) intervention.
3116165|NCT02560922|No Intervention|Wait list Control|The other group will be the wait list group and will receive the pain CST program after completing all follow-up study measures.
3116166|NCT02561000|Experimental|PZ-128 0.3 mg/kg|PZ-128, 0.3 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3116167|NCT02561000|Experimental|PZ-128 0.5 mg/kg|PZ-128, 0.5 mg/kg, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3116168|NCT02561000|Placebo Comparator|Placebo|Placebo, in 250 cc 5% dextrose, single dose, 2-hour intravenous infusion
3116169|NCT02561078|Experimental|Human regular U-500 insulin administered by CSII|Human regular U-500 insulin administered by CSII and titrated based on blood glucose readings for 26 weeks with a 2-week MDI lead-in.
3116170|NCT02561078|Active Comparator|Human regular U-500 insulin administered by MDI|Human regular U-500 insulin administered subcutaneously (SC) by MDI three times a day and titrated based on blood glucose readings for 26 weeks.
3116171|NCT02561130|Experimental|Intervention|Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise
3116172|NCT02561130|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
3116173|NCT02561156|Experimental|Part 1 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 milligram (mg), tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3116174|NCT02561156|Experimental|Part 1 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3116175|NCT02561156|Experimental|Part 1 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3116176|NCT02561156|Experimental|Part 1 Cohort 4: TAK-653 5.0 mg|TAK-653 5.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3116177|NCT02561156|Experimental|Part 1 Cohort 5: TAK-653 9.0 mg|TAK-653 9.0 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours.
3116178|NCT02561156|Experimental|Part 1 Cohort 6: TAK- 653 18 mg|TAK-653 18 mg, tablet, orally, once on Day 1 or TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation to be decided (TBD) based on safety, tolerability, and available PK and pharmacodynamics (PD) data from previous cohorts.
3116179|NCT02561156|Experimental|Part 1 Additional Cohorts: TAK- 653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1. TAK-653 or placebo will be administered after an overnight fast of approximately at least 10 hours. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3116180|NCT02561156|Experimental|Part 2 Cohort 1: TAK-653 0.3 mg|TAK-653 0.3 mg, tablet, orally, once on Day 1, and once daily (QD) from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3116181|NCT02561156|Experimental|Part 2 Cohort 2: TAK-653 1.0 mg|TAK-653 1.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3116182|NCT02561156|Experimental|Part 2 Cohort 3: TAK-653 3.0 mg|TAK-653 3.0 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18.
3116183|NCT02561156|Experimental|Part 2 Cohort 4: TAK-653 6 mg|TAK-653 6 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3116184|NCT02561156|Experimental|Part 2 Cohort 5: TAK-653 9 mg|TAK-653 9 mg, tablet, orally, once on Day 1, and QD from Days 6 to 18 or placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3116185|NCT02561156|Experimental|Part 2 Additional Cohorts: TAK-653 Placebo|TAK-653 placebo-matching tablet, orally, once on Day 1 and QD from Days 6 to 18. Dose escalation TBD based on safety, tolerability, and available PK and PD data from previous cohorts.
3116186|NCT02561195|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
3116187|NCT02561195|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
3116188|NCT02561195|Placebo Comparator|Placebo (accelerated schedule)|
3116189|NCT02561195|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
3116190|NCT02561195|Experimental|High-Dose C. difficile Vaccine (non-accelerated schedule)|
3116191|NCT02561195|Placebo Comparator|Placebo (non-accelerated schedule)|
3116192|NCT02561221|Experimental|Lifestyle Counseling|Patients in the Lifestyle Counseling Arm attended weekly (16 in-person) sessions in the first six months, followed by monthly sessions for the remaining 18 months. The behavioral intervention was delivered by a trained health coach embedded in the primary care clinic. Primary Care Practitioners in the experimental arm received a series of webinars on obesity science to help them manage and treat patients with obesity.
3116193|NCT02561221|No Intervention|Usual Care|Patients assigned to the usual care arm continued to interact with their Primary Care Practitioners according to their usual schedule, and received a series of newsletters on topics of interest, including importance of sleep for health, brain and memory health, goal setting, smoking cessation, etc. Primary Care Practitioners in the usual care arm received a webinar describing the current Centers for Medicare and Medicaid (CMS) approach to reimbursing for obesity treatment, and a reminder informational brochure was sent to the Primary Care Practitioners each year.
3116194|NCT02561247|Experimental|Prismaflex HF20 CRRT|Patients included in this arm will be treated for a minimum period of 20 of the first 24 hours and up to 72 hours with each Prismaflex® HF 20 Set with BUN, creatinine and bicarbonate being measured for statistical analysis at 12 hour intervals during CRRT treatment.
3116195|NCT02561273|Experimental|Treatment (combination chemotherapy, lenalidomide)|"Patients receive cyclophosphamide IV, doxorubicin hydrochloride IV and vincristine sulfate IV on day 1, etoposide IV over 30-60 minutes on days 1-3, prednisone PO on days 1-5, and lenalidomide PO on days 1-10. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients responding after 6 courses of treatment may then undergo an autologous stem cell transplant or receive maintenance lenalidomide at the discretion of the physician or patient choice as follows:~TRANSPLANT: Patients undergo autologous stem cell transplant per standard of care.~MAINTENANCE LENALIDOMIDE: Patients receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3116196|NCT02561299|Experimental|OA with adjunctive DCB angioplasty|Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty
3116197|NCT02561299|Active Comparator|DCB angioplasty|014 Drug Coated Balloon angioplasty
3116198|NCT02561338|Experimental|HMS5552 dose 1|75mgQD oral administration
3116199|NCT02561338|Experimental|HMS5552 dose 2|100mgQD oral administration
3116200|NCT02561338|Experimental|HMS5552 dose 3|50mgBID oral administration
3116201|NCT02561338|Experimental|HMS5552 dose 4|75mgBID oral administration
3116202|NCT02561338|Placebo Comparator|Placebo|Placebo, BID/QD oral administration
3116203|NCT02561455|Experimental|Gilteritinib 40 mg|Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
3116204|NCT02561455|Experimental|Gilteritinib 80 mg|Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
3116205|NCT02561455|Experimental|Gilteritinib 120 mg|Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
3116206|NCT02561455|Experimental|Gilteritinib 200 mg|Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.
3116207|NCT02561481|Active Comparator|Sulforaphane|"Sulforaphane (SF) will be administered once a day orally in an approximate dose of 1 µmol/lb (2.2 kg µmol/kg) body weight. Each SF tablet will contain 125 mg broccoli seed powder (equivalent to ~ 15 µmol SF). The total dose per day will depend on participants' body weight:~30-50 lb: 3 tablets (45 µmol/day) 50-70 lb: 4 tablets (60 µmol/day) 70-90 lb: 6 tablets (90 µmol/day) 90-110 lb: 7 tablets (105 µmol/day) 110-130 lb: 8 tablets (120 µmol/day)~For pilot study, all participants (n=10) will receive SF for 14 days. For main clinical trial, 25 participants will randomly receive SF for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo to sulforaphane arm will take place, and all participants will receive SF from 15-30 weeks."
3116208|NCT02561481|Placebo Comparator|Placebo|"Placebo tablets identical in size and similar in appearance to the active tablets will be used. Number of placebo tablets will be equivalent to the active tablets depending on participants' body weight.~For the main clinical trial, 25 participants will be randomly allocated to receive placebo for 15 weeks (phase 1). During phase 2, a single-arm crossover from placebo arm to sulforaphane arm will take place, and all participants will receive sulforaphane from 15-30 weeks."
3116209|NCT02561572|Experimental|Intervention|Acupuncture at the Yintang point for 30 minutes.
3116210|NCT02561572|No Intervention|Control|No intervention for 30 minutes.
3116211|NCT02561585|Experimental|LEO 124249|LEO 124249 ointment 30 mg/g twice daily
3116212|NCT02561585|Placebo Comparator|Vehicle|LEO 124249 ointment vehicle twice daily
3116213|NCT02561702|Experimental|Mexiletine first/placebo second|Participants will receive 150 mg of mexiletine by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of placebo (240 mg of lactose powder) taken by mouth 3 times daily
3116214|NCT02561702|Experimental|placebo first/mexiletine second|Participants will receive placebo (240 mg of lactose powder) taken by mouth 3 times daily for 5-7 days followed by 7 day washout period and 5-7 days of 150 mg of mexiletine by mouth 3 times daily
3116215|NCT02561806|Active Comparator|Ustekinumab|45 mg ustekinumab given as SC injection for participants ≤100 kilograms (kg) and 90 mg SC injection for participants >100 kg at Week 0, 4, 16, 28, and 40. Placebo for ixekizumab injections will be used for blinding.
3116216|NCT02561806|Experimental|Ixekizumab|160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline followed by 80 mg ixekizumab given as a single SC injection once every 2 weeks from week 2 through week 12. After week 12 participants will receive 80 mg ixekizumab every 4 weeks through week 52.Placebo for ustekinumab injections will be used for blinding.
3116217|NCT02561832|Experimental|Arm 1|Part A: ascending doses of olaparib in combination with carboplatin will be administered to investigate safety and tolerability and to define the MTD and/or RD for part B. Patients will be treated with this combination up to cycle 4, after cycle 4 they can continue with combination or monotherapy (carboplatin or olaparib). Cohorts will be started sequentially, based on SRC recommendation. Part B will start after MTD/RD identification in part A. Patients will receive olaparib and carboplatin combination for first 4 cycles (21 days per cycle), at the dose, frequency and schedule recommended from Part A. This will be followed by another 4 cycles of standard cancer therapy consisting of anthracycline and cyclophosphamide regimen. Total of 8 treatment cycles will be given before final surgery
3116218|NCT02561897|Experimental|Edoxaban|Edoxaban 30 or 60 mg
3116219|NCT02561897|Active Comparator|Warfarin|Warfarin 1 -1 0 mg
3469311|NCT03887702|Experimental|Group B (TAF, TDF, entecavir)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD after HBV reactivation during chemotherapy. Treatment continues for up to 6 months after the last dose of chemotherapy or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
3469312|NCT03887702|Experimental|Group C (TAF, TDF, entecavir, usual care)|Patients receive TAF PO QD or TDF PO QD or entecavir PO QD at the discretion of the physician during usual care. Treatment continues for up to 6 months after discontinuation of usual care or a maximum of 24 months in the absence of disease progression or unacceptable toxicity.
3469313|NCT03887650|Experimental|Liposomal Bupivacaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
3469314|NCT03887650|Active Comparator|Bupivacaine 0.5% with Adjuncts|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
3469315|NCT03888053|Active Comparator|BB-101 Treatment Arm|BB-101 liquid formulation concentration of 2 µg/mL or 20 µg/mL will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
3469316|NCT03888053|Placebo Comparator|Placebo Arm|Placebo will be applied on the target lower leg or foot ulcer once a day for 4 consecutive weeks.
3469317|NCT03887754|Active Comparator|The Hyperbaric oxygen therapy group|This group consists of twenty autistic children received forty sessions of HBOT, the time of the session is one hour. The sessions were done at pressure 1.5 ATA (atmosphere absolute) and with 100% oxygen concentration, either in multiplace or monoplace chamber. The number of sessions per week allowed is five sessions per week, all participants were required to complete forty sessions within two months. After six months from the last session, another forty sessions would be taken in the same manner
3116229|NCT02562066|Experimental|amifampridine phosphate -placebo|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive amifampridine in Period I and then crossed over to receive placebo in Period II. Each randomized treatment period is 7 days in duration and is separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
3116230|NCT02562066|Experimental|placebo - amifampridine phosphate|Each patient will participate in an open-label unblinded drug escalation/treatment run-in phase for up to 4 weeks until stable dose and frequency of amifampridine phosphate is achieved for 7 days. After this phase, half of the subjects will be randomized to receive placebo in Period I and then crossed over to receive amifampridine in Period II. Each randomized treatment period is 7 days in duration and separated by a re-stabilization period of approximately two weeks where the subject will be returned to the stable dose administered at the end of the open-label run-in period. Dosing will be between 20 - 80 mg per day and frequency will be between 2-4 times per day.
3116232|NCT02562482|Experimental|Group 1: VRC-CHKVLP059-00-VP 20 mcg|Group 1 subjects were randomized to receive two intramuscular (IM) injections of CHIKV VLP vaccine (VRC-CHKVLP059-00-VP) at Day 0 and Day 28 (+14 days) at a dose of 20 micrograms (mcg).
3116233|NCT02562482|Placebo Comparator|Group 2: Placebo (VRC-PBSPLA043-00-VP)|Group 2 subjects were randomized to receive two intramuscular (IM) injections of Phosphate Buffered Saline (VRC-PBSPLA043-00-VP) placebo at Day 0 and Day 28 (+14 days).
3116234|NCT02562521|Experimental|Smoking Cessation Treatment|The intervention will consist of Contingency management (CM) in conjunction with effective first line pharmacotherapy (dual nicotine replacement therapy [NRT] or varenicline) and brief counseling to rapidly induce cessation and to maintain abstinence long term. Pharmacotherapy will be flexible. Participants will also be given the option of receiving additional behavioral support by being referred to the CT Quitline and using text or mobile phone apps for quitting.
3116235|NCT02562521|No Intervention|Delayed Treatment Control|Participants in this arm will be offered the Smoking Cessation Treatment 6 weeks later
3116236|NCT02562755|Experimental|Pexa-Vec followed by Sorafenib|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 1e9 pfu at day 1 and weeks 2 and 4, followed by sorafenib at Week 6.
3116237|NCT02562755|Active Comparator|Sorafenib|Sorafenib (400 mg twice daily) begins on Day 1.
3116238|NCT02562898|Experimental|Dose escalation for safety and toxicity|All patients in phase Ib dosing escalation with extended safety and toxicity cohorts will start treatment with daily dosing of ibrutinib concurrently with standard doses of gemcitabine and nab-paclitaxel. Ibrutinib (560 mg/day, 840 mg/day, or 420 and 280 mg/day if de-escalation is necessary) will be started on day 1. Approximately patients 15-30 will be enrolled in escalation and extended safety cohort.
3116239|NCT02562898|Experimental|Immune Response cohort|Subjects who are assigned to the Immune Response Cohort will have a biopsy before starting ibrutinib-only therapy. They will then receive ibrutinib for 7 days and have a second biopsy after completing the ibrutinib-only therapy, before starting the combination of chemotherapy with ibrutinib. Approximately 20 patients will be enrolled in this arm.
3116240|NCT02562924|Active Comparator|Budesonide rinse group|"1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
3116241|NCT02562924|Experimental|MEDIHONEY® rinse alone group|"Days 0-7: Same as 1a;~Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182."
3116242|NCT02562924|Experimental|MEDIHONEY® and budesonide rinse group|"Days 0-7: Same as 1a.;~Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.~After day 91:~i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.~ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.~Reevaluate at day 119:~In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.~In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182."
3116243|NCT02562989|Experimental|Part 1, Healthy Young Participants|Healthy young participants received a single intravenous (IV) dose of ~185 megabecquerel (MBq) [18F]MK-6240 in Part 1 of the study
3116244|NCT02562989|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants received a single IV dose of ~160 MBq [18F]MK-6240, in Part 2 of the study
3116245|NCT02562989|Experimental|Part 2, AD and Amnestic MCI Elderly Participants|AD and amnestic MCI participants received up to two IV doses of ~160 MBq [18F]MK-6240 in Part 2 of the study
3116246|NCT02563028|Experimental|SightSaver Visual Stimulator|A SightSaver Visual Stimulator mask will be applied during surgery. Baseline VEPs will be recorded prior to prone positioning. At the end of surgery, after supine positioning, the SightSaver Visual Stimulator mask will be removed and discarded.
3116247|NCT02563067|Experimental|QAW039 150 mg|QAW039 150 mg once daily
3116248|NCT02563067|Experimental|QAW039 450 mg|QAW039 450 mg once daily
3116249|NCT02563067|Placebo Comparator|Placebo|Placebo once daily
3116250|NCT02563093|Experimental|Study Group 1|Adults 18 to < 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
3116251|NCT02563093|Experimental|Study Group 2|Adults 18 to < 65 years of age randomly assigned to receive an intradermal injection of one dose of Fluzone Intradermal Quadrivalent vaccine
3116252|NCT02563093|Experimental|Study Group 3|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone Quadrivalent vaccine
3116253|NCT02563093|Experimental|Study Group 4|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of Fluzone High-Dose vaccine
3116254|NCT02563106|Experimental|SYN-004|SYN-004 150 mg
3116255|NCT02563106|Placebo Comparator|Placebo|Matching placebo
3116256|NCT02563496|Experimental|Tafenoquine 50 mg|Subjects with weight band of >=5 to <=10 kilogram (kg) will receive 50 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
3116257|NCT02563496|Experimental|Tafenoquine 100 mg|Subjects with weight band of >10 to <=20 kg will receive 100 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
3116258|NCT02563496|Experimental|Tafenoquine 150 mg|Subjects with weight band of >10 to <=20 kg will receive 150 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
3116259|NCT02563496|Experimental|Tafenoquine 200 mg|Subjects with weight band of >20 to <=35 kg will receive 200 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
3116260|NCT02563496|Experimental|Tafenoquine 300 mg|Subjects with weight band of >35 kg will receive 300 mg tafenoquine on Day 1. Subject may receive CQ per local/national guidelines.
3116261|NCT02563548|Experimental|GAC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory locally advanced or metastatic gastric adenocarcinoma (GAC) will receive PEGPH20 1.6 micrograms/kilogram (µg/kg) or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 milligrams/kilogram (mg/kg) every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory locally advanced or metastatic GAC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 60 weeks).
3116262|NCT02563548|Experimental|NSCLC: PEGPH20 1.6 µg/kg/2.2 µg/kg + Pembrolizumab|Dose escalation part: Participants with relapsed/refractory Stage IIIB or IV non-small cell lung cancer (NSCLC) will receive PEGPH20 1.6 µg/kg or 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle (i.e. 3 doses/cycle) and pembrolizumab 2 mg/kg every 21 days on Day 1 of each cycle (i.e. 1 dose/cycle), 4-6 hours after the completion of PEGPH20 administration. Dose expansion part: Participants with relapsed/refractory Stage IIIB or IV NSCLC will receive PEGPH20 2.2 µg/kg on Day 1, Day 8 and Day 15 of each 21-day cycle and pembrolizumab 200 mg on Day 1 of each cycle, 4-6 hours after the completion of PEGPH20 administration. Treatment in both phases of the study will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity (maximum exposure: 46 weeks).
3116263|NCT02563561|Experimental|1 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
3116264|NCT02563561|Experimental|2 Dose Apaziquone|Participants were randomized to receive first dose of 4 mg of apaziquone by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of 4 mg of apaziquone by intravesical administration via an indwelling catheter on Day 15 (±5 days).
3116265|NCT02563561|Placebo Comparator|Placebo|Participants were randomized to receive first dose of matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter. Followed by second dose of matching placebo by intravesical administration via an indwelling catheter on Day 15 (±5 days).
3116266|NCT02563808|Active Comparator|Standard Decision Aid|The brochure with standard information on surgery for early-stage breast cancer
3116267|NCT02563808|Experimental|Post-surgical Regret Decision Aid|The brochure that incorporates additional information on the rates of regret after surgical treatment of early-stage breast cancer.
3116268|NCT02563834|Experimental|Saline|Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
3116269|NCT02563834|Experimental|Insulin Clamp|Studies will be performed on a separate day under fasting conditions, using an insulin infusion to achieve steady state insulin/glucose clamp conditions. Studies will be performed on one day under fasting conditions, using a saline infusion. All subjects will receive infusions of radiolabeled acetate and radiolabeled thiapalmitate tracer (16-18-F-fluoro-4-thiapalmitate).
3116270|NCT02563860|Experimental|Open label|"Treatment with Lovastatin, dose escalating trial according to the following schedule:~10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks."
3116271|NCT02563899|Experimental|Umeclidinium|Subjects will receive umeclidinium once daily before bedtime for 14 days.
3116272|NCT02563899|Placebo Comparator|Vehicle|Subjects will receive vehicle once daily before bedtime for 14 days.
3116273|NCT02563990|Experimental|High Pressure|High pressure injection of Ropivacaine local anesthetic at greater than 20 psi
3116274|NCT02563990|Active Comparator|Low Pressure|Low pressure injection of Ropivacaine local anesthetic at less than 15 psi
3116275|NCT02564016|Active Comparator|Capped Epidural|Group 1 (control) will have the epidural catheter capped and left in place.
3116276|NCT02564016|Experimental|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
3116277|NCT02564029|Experimental|PF-06372865 dose level 1|17.5 milligram (mg) single dose
3116278|NCT02564029|Experimental|PF-06372865 dose level 2|52.5 mg single dose
3116279|NCT02564029|Placebo Comparator|Placebo|Single dose
3116280|NCT02564029|Active Comparator|Lorazepam|2mg single dose
3116281|NCT02564042|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116282|NCT02564042|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116283|NCT02564042|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116284|NCT02564042|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116285|NCT02564042|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116286|NCT02564042|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all psoriasis lesions (except on the scalp).
3116287|NCT02564055|Experimental|GSK2894512 1% cream twice daily|Subjects will apply a thin layer of GSK2894512 1% (10 milligram per gram [mg/g]) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116288|NCT02564055|Experimental|GSK2894512 1% cream once daily|Subjects will apply a thin layer of GSK2894512 1% (10 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116289|NCT02564055|Experimental|GSK2894512 0.5% cream twice daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116290|NCT02564055|Experimental|GSK2894512 0.5% cream once daily|Subjects will apply a thin layer of GSK2894512 0.5% (5 mg/g) topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116291|NCT02564055|Placebo Comparator|Vehicle cream twice daily|Subjects will apply a thin layer of vehicle topical cream twice daily (morning and evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116292|NCT02564055|Placebo Comparator|Vehicle cream once daily|Subjects will apply a thin layer of vehicle topical cream once daily (evening) for 12 weeks, to all atopic dermatitis lesions (except on the scalp).
3116293|NCT02564198|Experimental|Ramucirumab|"(Part A-Non-CNS Solid Tumors) Escalating doses of 8 milligrams per kilogram (mg/kg) or 12 mg/kg Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.~(Part B-CNS Tumors) Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle."
3116294|NCT02564211|Experimental|Ipragliflozin|Ipragliflozin one 50 mg tablet co-administered with one 50 mg sitagliptin once daily (QD) for 52 weeks in addition to diet and exercise therapy.
3116297|NCT02564354|Experimental|ΔF508 Homozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
3116298|NCT02564354|Experimental|ΔF508 Compound Heterozygous|QR-010 administered intranasally as an atomized liquid 10 mg (5 mg per nostril), 3 times weekly for 4 weeks.
3116299|NCT02564432||POP 10 patient cohort|This is an observational study
3116300|NCT02564471|Experimental|Chloroquine|Chloroquine Phosphate tablet for oral administration 500 mg chloroquine phosphate (equivalent to 300 mg base)
3116301|NCT02564471|Experimental|Atovaquone and Proguanil (Malarone)|"Malarone tablet for oral administration 250 mg atovaquone and 100 mg proguanil hydrochloride.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
3116302|NCT02564471|Experimental|Doxycycline|"Doxycycline hyclate tablet for oral administration, contains specially coated pellets of doxycycline hyclate equivalent to 100 mg of doxycycline.~RabAvert rabies vaccine, at least 2.5 IU of rabies antigen."
3116303|NCT02564471|Active Comparator|Rabies|RabAvert rabies vaccine, at least 2.5 IU of rabies antigen.
3116304|NCT02564497|Other|Process E Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process E
3116305|NCT02564497|Other|Process C Belatacept|Active Pharmaceutical Ingredient (API) of Belatacept manufactured by Process C
3116306|NCT02564718|Experimental|Arm 1|Rivaroxaban oral suspension from granules will be dosed according to body weight as oral 0.1% suspension (1 mg/mL)
3116307|NCT02564887|Other|Traditional Therapy Only|"Standard of care therapy for qualifying population (with opportunity to crossover and be assigned to the IOPI device if so desired after initial 8 week standard of care therapy completion."
3116308|NCT02564887|Experimental|Traditional Therapy with IOPI|Standard of care therapy plus the addition of the IOPI instrument
3116309|NCT02564900|Experimental|Part 1 Dose escalation|Part 1 is a dose escalation to identify the Maximum Tolerated dose (MTD) or the recommended phase 2 dose of DS-8201a guided by the modified continuous reassessment method using a Bayesian logistic regression model following escalation with overdose control principal.
3116310|NCT02564900|Experimental|Part 2 Dose expansion|Part 2 is a dose expansion to examine the safety and efficacy of DS-8201a and it is consist of multiple cohorts: in subjects with trastuzumab emtansine (T-DM1)-treated HER2 overexpressing breast cancer (Part 2a); trastuzumab-treated HER2 overexpressing gastric or gastroesophageal junction adenocarcinoma (Part 2b); HER2 low expressing breast cancer (Part 2c), HER2 expressing other solid malignant tumor (Part 2d); HER2 expressing breast cancer (Japan only; Part 2e)
3116311|NCT02564926|Experimental|Dapagliflozin|Dapagliflozin 10mg + Metformin 1000mg
3116312|NCT02564926|Active Comparator|Glimepiride|Glimepiriide 1-2mg + Metformin 1000mg
3116313|NCT02564952|Experimental|GWP42003-P|"Participants who transferred from the DB phase (NCT02565108) to the OLE (still blinded at that stage) tapered off their GWP42003-P or placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P to 20 mg/kg/day initially for the OLE; doses could then be adjusted up or down, dependent on investigator opinion, to a maximum of 30 mg/kg/day GWP42003-P.~Clobazam (CLB) was administered in line with the physician's preferred CLB dosing regimen for each participant."
3116314|NCT02565108|Experimental|GWP42003-P 20 mg/kg/Day Dose|"Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study."
3116315|NCT02565108|Placebo Comparator|Placebo|"Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.~All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study."
3116316|NCT02565147|Experimental|PPCI with Bivalirudin|Bivalirudin was administered as a bolus (0.75 mg/kg) and an infusion (1.75 mg/kg/h) for the duration of the PPCI and continued for the first 4 h after completion of the procedure.
3116317|NCT02565147|Active Comparator|PPCI with Heparin|UFH was administered as a bolus according to standard of care for completion of PPCI per site. An ACT ≥250 s at the end of the procedure was recommended.
3116318|NCT02565186|Experimental|Lasmiditan 100mg|Participants received oral dose of 100 milligrams (mg) Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond within 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
3116319|NCT02565186|Experimental|Lasmiditan 200mg|Participants received oral dose of 200mg Lasmiditan with in four hours of onset of migraine attack. If the migraine did not respond with in 2 hours after first dose or if responded and recurred then a second dose was permitted within 24 hours after first dose.
3116320|NCT02565381|Active Comparator|Control (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling"
3116321|NCT02565381|Experimental|Financial rewards (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Contingent financial rewards for smoking abstinence"
3116322|NCT02565381|Experimental|Text messaging (N=25)|"Transdermal nicotine patch~In-person smoking cessation counseling~Text messages to support smoking abstinence"
3116323|NCT02565485|No Intervention|Standard IV Preload|Patients in this arm will receive 500mL of Lactated Ringer's solution, which is the standard IV fluid preload used on Labor and Delivery at MetroHealth Medical Center
3116324|NCT02565485|Experimental|Volume Replacement IV Preload|Patients in this arm will receive 1500mL of Lactated Ringer's solution
3116325|NCT02565511|Experimental|Cohort I (CAD106)|CAD106 (450 µg) + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
3116326|NCT02565511|Placebo Comparator|Cohort I (CAD106 Placebo)|Placebo to CAD106 + Alum (450 µg) intra-muscular injection at Weeks 1, 7, 13 and every 13 weeks thereafter
3116327|NCT02565511|Experimental|Cohort II (CNP520)|CNP520 (50 mg) capsules taken orally once daily
3116328|NCT02565511|Placebo Comparator|Cohort II (CNP520 Placebo)|Matching Placebo to CNP520 capsules taken orally once daily
3116329|NCT02565576|Active Comparator|CFZ533|CFZ533
3116330|NCT02565576|Placebo Comparator|Placebo|Placebo
3116331|NCT02565615||Atorvastatin dose titration (single-arm)|Judged by investigators, patients in cardiology department who are using atorvastatin can be included into this study, if they are eligible. During the study, the dose can be titrated based on the judgement of investigator
3116332|NCT02565628|Experimental|PF-06669571|Once daily (QD) for 7 days
3116333|NCT02565628|Placebo Comparator|Placebo|QD for 7 days
3116334|NCT02565706|Active Comparator|WIC Fresh Start Program|Participants in this arm receive the Fresh Start program.
3116335|NCT02565706|Active Comparator|Existing Online Health Education|Participants in this arm receive existing online WIC health education.
3116336|NCT02565706|Experimental|WIC Fresh Start Program (FMNP)|Participants in this arm receive the Fresh Start program and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
3116337|NCT02565706|Active Comparator|Existing Online Health Education (FMNP)|Participants in this arm receive existing online WIC health education and WIC Farmers' Market Nutrition Program (FMNP) vouchers redeemable at farmers' markets.
3116338|NCT02565784|Experimental|Intradermal injection|Restylane and/or Perlane
3116339|NCT02565810|Experimental|SB5 40mg|
3116340|NCT02565901|Experimental|Arm I (sirolimus, docetaxel, carboplatin)|Patients receive docetaxel IV over 30-60 minutes and carboplatin IV over 30 minutes on day 1. Beginning in cycle 2 and continuing in subsequent cycles, patients also receive sirolimus PO on day -2. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
3116341|NCT02565901|Experimental|Arm II (sirolimus, docetaxel, carboplatin)|Patients receive sirolimus PO on day -2. Patients also receive docetaxel IV over 30-60 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 10 cycles in the absence of disease progression or unacceptable toxicity.
3116342|NCT02565914|Experimental|Part A: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
3116343|NCT02565914|Experimental|Part B: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
3116344|NCT02565914|Experimental|Part C: TEZ/IVA|TEZ 100 mg/IVA150 mg fixed dose tablet once daily in the morning and IVA150 mg mono tablet once daily in the evening.
3116345|NCT02566005|Active Comparator|misoprostol group|The women in the misoprostol only group will receive 25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist
3116346|NCT02566005|Active Comparator|misoprostol and foley bulb group|Women in the combination group will receive vaginal misoprostol per standard protocol. In addition, a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours. Oxytocin will be initiated in those patients who were not in labor after expulsion or removal of the catheter.
3116347|NCT02566031|Experimental|Indacaterol and glycopyrronium (QVA149)|QVA149 110/50 μg capsules for inhalation delivered once daily via single-dose dry powder inhaler (SDPPI) for 12 weeks
3116348|NCT02566031|Active Comparator|Tiotropium|Tiotropium 18 μg capsules for inhalation delivered once daily via HandiHaler® device for 12 weeks
3116349|NCT02566044|Experimental|CQBW276|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
3116350|NCT02566044|Placebo Comparator|Placebo|"Cohorts 1 and 2 will enroll 8 patients each (6:2 QBW276 and placebo, respectively).~Cohort 1: dose is 3 mg bid (6 mg daily) QBW276 or placebo for 7 days. Cohort 2: dose and frequency will be confirmed after cohort 1 is complete. The duration is 14 days.~Cohort 3: dose and frequency will be confirmed after cohort 2 is complete. The duration is approximately 4 months. Patients will be randomized to one of two treatment sequences: QBW276 in Period 1 and Placebo in Period 2 or Placebo in Period 1 and QBW276 in Period 2. Twenty four patients are required to complete cohort 3."
3116351|NCT02566083|Active Comparator|non-toric intraocular lens|non-toric approved intraocular lens
3116352|NCT02566083|Active Comparator|toric intraocular lens|approved toric intraocular lens
3116353|NCT02566109|Other|Fast MRI|All patients who agree to participate in this study will have a 10 minute fast MRI scan and Baseline and 6 month time periods. The fast MRI will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
3116354|NCT02566135|Active Comparator|Group-I|Tracheal intubation using I-gel and ventilating bougie insertion. In Group-I, following general anaesthesia I-gel is to be inserted, through it ventilating bougie is to be inserted then I-gel is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
3116355|NCT02566135|Active Comparator|Group-C|Tracheal intubation using C-LMA and ventilating bougie insertion. In Group-C, following general anaesthesia C-LMA is to be inserted, through it ventilating bougie is to be inserted then C-LMA is to be removed and endotracheal tube is to be railroaded over ventilating bougie. Then ventilating bougie is to be removed.
3116356|NCT02566239|Experimental|Shared Data|"Share activity data with care team.~Participants will have sensor technology installed in their home and caregivers will be provided with the data via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
3116357|NCT02566239|No Intervention|Non-shared Data|"Participants will have sensor technology installed in their home and caregivers will NOT have data provided via our caregiver tool.~This group will be newly enrolled as part of this study and randomized to either the shared data or non-shared data groups. Randomization will be stratified by continuing care retirement community site and include statistical balancing on demographic factors."
3116358|NCT02566265|Experimental|Fluzone High Dose Vaccine then Fluzone High Dose Booster|Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
3116359|NCT02566265|Active Comparator|Standard of Care|Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.
3116360|NCT02566317|Active Comparator|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace.
3116361|NCT02566317|Experimental|Stand & Move|Move intervention (A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace) plus the installation of a sit-stand workstation.
3116362|NCT02566369|Experimental|CD5789 (trifarotene) 50μg/g Cream|CD5789 (trifarotene) 50μg/g Cream
3116363|NCT02566369|Placebo Comparator|Placebo Cream|Placebo cream
3116364|NCT02566525|Experimental|CytoSorb Device|Standard of care plus treatment with CytSorb device installed on the CPB machine
3116365|NCT02566525|No Intervention|Control|Standard of care
3116366|NCT02566577|Active Comparator|Fresh RBC transfusion/Storage-aged RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of fresh blood (<10 days old) followed by a transfusion of packed RBC units of storage-aged (>21 days old) blood.
3116367|NCT02566577|Active Comparator|Storage-aged RBC transfusion/Fresh RBC transfusion|Subjects will receive a transfusion of packed red blood cell (RBC) units of storage-aged (>21 days old) blood followed by a transfusion of packed RBC units of fresh blood (<10 days old).
3116368|NCT02566590|Experimental|Control|Participants will complete bed rest but will receive a non-protein placebo supplement
3116369|NCT02566590|Experimental|NMES + PRO|Participants will receive daily treatment with neuromuscular electrical stimulation (NMES) and daily supplements of a protein drink.
3116370|NCT02566759|Experimental|Part 1, Cohort 1: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116371|NCT02566759|Experimental|Part 1, Cohort 2: TAK-831 250 mg|TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116372|NCT02566759|Experimental|Part 1, Cohort 3: TAK-831 500 mg|TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116373|NCT02566759|Experimental|Part 1, Cohort 4: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116374|NCT02566759|Experimental|Part 1, Cohort 5: TAK-831 750 mg|TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116375|NCT02566759|Experimental|Part 1, Cohort 6: TAK-831 10 mg|TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.
3116376|NCT02566759|Experimental|Part 2, Cohort 1: TAK-831 30 mg|TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
3116377|NCT02566759|Experimental|Part 2, Cohort 2: TAK-831 100 mg|TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
3116378|NCT02566759|Experimental|Part 2, Cohort 3: TAK-831 200 mg|TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
3116379|NCT02566759|Experimental|Part 2, Cohort 4: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.
3116380|NCT02566759|Experimental|Part 3, Cohort 1: TAK-831 400 mg|TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.
3116381|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
3116382|NCT02566759|Experimental|Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)|TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
3116383|NCT02566759|Experimental|Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)|TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.
3116384|NCT02566785|Experimental|Intervention Group|Those allocated to the intervention group will participate in a supervised group session exercise one time per week and be asked to exercise two more times per week at home.
3116385|NCT02566785|Other|Wait List Control Group|The wait list control group will not participate in the intervention and will be asked to continue their usual activity level during the first 12 weeks and will receive the multi-component balance intervention during weeks 12-24.
3116386|NCT02566889|Experimental|Dose Escalation Group|Participants must have completed: a) recommended infliximab induction dosing regimen of 5 milligram (mg)/kilogram (kg) at Weeks 0, 2, and 6, followed by at least 1 maintenance doses of 5 mg/kg every 8 weeks (q8wk); or b) induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk with clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose; d) must have lost clinical response, after first or subsequent q8wk maintenance dose of infliximab 5 mg/kg for participants who have completed the recommended infliximab induction dosing regimen or, after most recent (second or later) q8wk maintenance dose of infliximab 5 mg/kg for participants with an induction regimen with doses >6 mg/kg or with previous maintenance doses >6 mg/kg.
3116387|NCT02566889|Experimental|Reference Group|Participants must have completed: a) the recommended infliximab induction dosing regimen of 5 mg/kg at Weeks 0, 2, and 6, and have maintained a stable clinical response to infliximab after at least 1 maintenance doses of 5 mg/kg q8wk; or b) an induction regimen with doses >6 mg/kg and have received at least 2 maintenance doses of 5 mg/kg q8wk and have maintained clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose; or c) maintenance doses >6 mg/kg within the past 6 months and at least 2 maintenance doses of 5 mg/kg q8wk and have maintained a clinical response for at least 28 days after the most recent 5 mg/kg maintenance dose 5 mg/kg maintenance dose.
3116388|NCT02566902|Active Comparator|T-piece Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental T-piece Nebulizer (Hudson RCI® Micro Mist® nebulizer Teleflex Medical®, Research Triangle Park, NJ). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
3116389|NCT02566902|Experimental|Breath-Enhanced Nebulizer|"Pre-treatment spirometry measurement will be performed, intervention with a one time 5mg nebulized albuterol treatment will be administered with the experimental Breath-Enhanced Nebulizer (NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer Salter Labs®, Arvin, CA). Treatment will be administered over 10 minutes. Following this therapy, post-treatment spirometry measurement will be performed."
3116390|NCT02566993|Experimental|Experimental Arm|Lurbinectedin (PM01183) / Doxorubicin
3116391|NCT02566993|Active Comparator|Control Arm 1|CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))
3116392|NCT02566993|Active Comparator|Control Arm 2|Topotecan
3116393|NCT02567188||Cohort of CKD Participants|Pre-dialysis participants with CKD treated with MIRCERA according to the current standard of care and in line with the current local summary of product characteristics were observed for maximum of 12 months.
3116394|NCT02567227|Experimental|Cognitive Remediation|An individualized computerized cognitive remediation program.
3116395|NCT02567227|Active Comparator|Active control|Individualized computer based exposure and interactive health education classes.
3116396|NCT02567266|Experimental|Unified Protocol for Adolescents (UP-A)|Participants will be treated with the Unified Protocol for the Treatment of Emotional Disorders in Adolescence. Their clinicians will also receive feedback using the Youth Outcomes Questionnaire feedback system.
3116397|NCT02567266|Experimental|Treatment as Usual Plus (TAU+)|Participants will be treated by clinicians who receive feedback using the Youth Outcomes Questionnaire, but who otherwise use Treatment as Usual
3116398|NCT02567266|Active Comparator|Treatment as Usual (TAU)|Participants will receive Treatment as Usual provided at the study clinics.
3116399|NCT02567552|Experimental|Prolutex|Subcutaneous progesterone
3116400|NCT02567552|Active Comparator|Prontogest|Intramuscular progesterone
3116401|NCT02567656|Experimental|Single arm|RP6530 administered orally twice a day.
3116402|NCT02567708|Experimental|GSK2269557 and Placebo|Each subject will complete two treatment periods: GSK2269557 1000 mcg in one treatment period, and matching placebo in the other treatment period. Each treatment will be administered once daily for 28 days (+/- 2 days) via the DISKUS DPI. The treatment periods will be separated by a washout of at least 4 weeks.
3116403|NCT02567968|Placebo Comparator|Placebo|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
3116404|NCT02567968|Active Comparator|Caffeine|Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
3116405|NCT02568046|Experimental|Sym004 12 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level 1
3116406|NCT02568046|Experimental|Sym004 9 mg/kg + FOLFIRI|Phase 1b, Dose-Escalation: Dose Level -1
3116407|NCT02568046|Experimental|Sym004 (RP2D) + FOLFIRI|Phase 2a, Dose-Expansion: Sym004 in the RP2D in combination with FOLFIRI
3116408|NCT02568254|Active Comparator|Lens 1/ Lens 2/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (nesofilcon A) third.
3116409|NCT02568254|Active Comparator|Lens 1 / Lens 3 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 1 (etafilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 2 (nelfilcon A) third.
3116410|NCT02568254|Active Comparator|Lens 2/ Lens 3/ Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 3 (nesofilcon A) second and then wear Lens 1 (etafilcon A) third .
3116411|NCT02568254|Active Comparator|Lens 2 / Lens 1/ Lens 3|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 2 (nelfilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nesofilcon A) third. Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
3116412|NCT02568254|Active Comparator|Lens 3 / Lens 1 / Lens 2|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 1 (etafilcon A) second and then wear Lens 3 (nelfilcon A) third.
3116413|NCT02568254|Active Comparator|Lens 3 / Lens 2 / Lens 1|Each subject will be randomly assigned to one of six unique sequences. Subjects randomized to this sequence will first wear Lens 3 (nesofilcon A), then wear Lens 2 (nelfilcon A) second and then wear Lens 3 (etafilcon A) third.
3116414|NCT02568345|Experimental|sugammadex ED90|"Sequential design method up-and-down of the biased coin aimed to determine the minimum effective dose in 90% of patients (ED90).~The following doses were chosen: 2.0 mg/kg, 2.2 mg/kg, 2.4 mg/kg, 2.6 mg/kg, 2.8 mg/kg."
3116415|NCT02568384|Experimental|Users of Onyx BG Meter / App System|"Subjects with diabetes used the Onyx Blood Glucose (BG) Meter / App System at home. The enrollment goal for the intended use population:~40 to 70% of subjects will have type 1 diabetes~Not more than 30% of subjects will use an insulin pump"
3116416|NCT02568397|Experimental|Dabigatran Etexilate|Single dose of dabigatran etexilate administered orally.
3116417|NCT02568397|Experimental|Lanabecestat and Dabigatran Etexilate|Single dose of lanabecestat administered orally once daily on Days 3 to 21. Single doses of dabigatran etexilate administered orally on Days 16 and 20 during the lanabecestat dosing.
3116418|NCT02568475|Experimental|Decision aid|"Provision of Go to the Hospital or Stay Here?"
3116419|NCT02568475|No Intervention|No decision aid|Does not receive the decision aid.
3116420|NCT02568644|Experimental|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerols) and intravenous ketoprofen (100mg).
3116421|NCT02568644|Placebo Comparator|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose) and intravenous ketoprofen (100mg).
3116422|NCT02568683|Experimental|Dose Escalation: ENTO|Participants will be enrolled sequentially in a 3 + 3 dose escalation design to receive escalating dose of ENTO+VCR at dose levels 1 to 4 with the objective of defining the maximum tolerated dose (MTD) or recommended dose for the dose expansion stage. Following the determination of the MTD of the dose levels 1 to 4 (or concurrently with the opening of dose level 4), the safety of administering ENTO with VCR when administered as a 4-day prolonged continuous infusion may be evaluated in the continuous infusion dose escalation level (dose level C1) with the objective of investigating the schedule of dosing ENTO when administered with VCR as a continuous infusion.
3116423|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort A)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) may receive VCR+ENTO.
3116424|NCT02568683|Experimental|Dose Expansion: VCR+ENTO (Cohort B)|Based on the tolerability, safety, and efficacy data from the dose escalation phase, participants with relapsed or refractory B-cell NHL (non-DLBCL) may receive VCR+ENTO.
3116425|NCT02568852|Active Comparator|group 1|Laparoscopic cholecystectomy in general anaesthesia
3116426|NCT02568852|Active Comparator|group 2|Laparoscopic cholecystectomy in combined anaesthesia (Spino epidural).
3116427|NCT02569112|Active Comparator|cryolipolysis|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
3116428|NCT02569112|Experimental|cryolipolysis, multipolar RF, varipulse|Each patient is their own control and one side will have only a cryolipolysis treatment while the other side will have a cryolipolysis treatment plus multipolar radiofrequency and varipulse treatment.
3116429|NCT02569398|Experimental|Group 1|Participants will receive one atabecestat, 5 milligram (mg) tablet orally once daily up to 54 months.
3116430|NCT02569398|Experimental|Group 2|Participants will receive one atabecestat, 25 mg tablet orally once daily up to 54 months.
3116431|NCT02569398|Experimental|Group 3|Participants will receive one matching placebo tablet orally once daily up to 54 months.
3116432|NCT02569411|No Intervention|No Incentive|Those allocated to the control group will be contacted by email, mail, and phone, but will not receive a financial incentive
3116433|NCT02569411|Experimental|Incentive|Those allocated to the intervention group will be contacted by email, mail, and phone, and will be asked to provide the IPD from their RCT and they will be given a financial incentive.
3116434|NCT02569437|Experimental|Doxycycline|Doxycycline plus oral methylprednisolone and nasal saline sprays
3116435|NCT02569437|Placebo Comparator|Sugar pill|placebo pill plus oral methylprednisolone for three weeks. After this, maintenance therapy which includes nasal saline sprays and daily nasal steroid sprays.
3116436|NCT02569476|Experimental|Zanubrutinib and Obinutuzumab|In the dose-escalation part, dose levels and regimens were evaluated. In the indication-specific expansion cohorts, participants were assigned to different cohorts based on histology type.
3116437|NCT02569541|Experimental|CEM-102 (Sodium fusidate)|"1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy:~6 months of treatment; or~24 months of treatment (if continued on chronic suppressive therapy)"
3116438|NCT02569632|Experimental|Open Label: MenB-FHbp|Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)
3116439|NCT02569658|Experimental|Tranexamic Acid Group|Group will be administered 1 gram tranexamic acid IV bolus (10 ml solution) 10 minutes prior to incision.
3116440|NCT02569658|Placebo Comparator|Placebo Group|Group will be administered 10 ml normal saline placebo IV bolus 10 minutes prior to incision
3116441|NCT02569710|Experimental|Cohorts 1 and 2 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic Hepatitis C virus (HCV)-infected participants will receive AL-335 and Odalasvir (ODV) with Simeprevir (SMV) for 8 weeks.
3116442|NCT02569710|Experimental|Cohort 1b (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV for 8 weeks.
3116443|NCT02569710|Experimental|Cohort 3 (Without Cirrhosis) : AL-335+ODV+SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV for 6 weeks.
3116444|NCT02569710|Experimental|Cohort 4 (Without Cirrhosis) : AL-335+ODV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV up to 8 or 12 weeks.
3116445|NCT02569710|Experimental|Cohort 5 (Without Cirrhosis) : AL-335+ODV + SMV|Treatment-naïve non-cirrhotic HCV-infected participants will receive AL-335 and ODV with SMV up to 8 or 12 weeks.
3116446|NCT02569710|Experimental|Cohorts 6, 7, 8 and 12 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 8 weeks.
3116447|NCT02569710|Experimental|Cohorts 9, 10 and 11 (With Cirrhosis) : AL-335+ODV+SMV|Treatment naïve or treatment experienced HCV-infected participants with compensated cirrhosis will receive AL-335 and ODV with SMV for 12 weeks.
3116448|NCT02569710|Experimental|Cohorts 12 to 15: AL-335+ODV With/without SMV|Based on safety, pharmacokinetic (PK), and viral load data, the treatment duration (4 to 12 weeks) and dose levels (AL-335: 400-1,200 milligram [mg], ODV: 25-50 mg with/without SMV: 75-150 mg) may be changed for ongoing and future cohorts (up to 15) after obtaining agreement from the Sponsor and the Principal Investigator.
3116449|NCT02569723|Experimental|carbon C 14 oxaliplatin and oxaliplatin|Patients receive carbon C 14 oxaliplatin microdose IV over 120 minutes. Beginning not more than 4 weeks after the initial carbon C 14 oxaliplatin microdose administration, patients receive FOLFOX6 comprised of leucovorin calcium IV, fluorouracil IV over 2 hours (over 46-48 hours via ambulatory infusion pump on days 1 and 2), and oxaliplatin (contain carbon C 14 microdose course I only) IV over 2 hours on day 1.
3116450|NCT02569801|Active Comparator|Fulvestrant|Participants will receive 500 milligrams (mg) of fulvestrant as two intramuscular injections (250 mg each) on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
3116451|NCT02569801|Experimental|GDC-0810|Participants will receive three 200 mg tablets (total dose = 600 mg) of GDC-0810 orally once daily until disease progression, unmanageable toxicity, withdrawal of consent, exhaustion of GDC-0810 drug supply, or termination of study by the Sponsor.
3116452|NCT02569853|Experimental|DFN-11|DFN-11 active injection upon occurrence of migraine
3116453|NCT02569853|Placebo Comparator|Placebo|Placebo injection upon occurrence of migraine
3116454|NCT02569892|Experimental|Laser Arm|Participants receive treatment with sub-threshold macular laser photocoagulation
3116455|NCT02569892|Sham Comparator|Sham Laser Arm|Participants receive sham treatment with sub-threshold macular laser photocoagulation (with power setting at zero)
3116456|NCT02569996|Experimental|Rituximab|Participants will receive rituximab 375 milligrams per meter square (mg/m^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
3116457|NCT02570022|Experimental|Liposomal bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
3116458|NCT02570022|Active Comparator|Inter-scalene nerve block|Patients in this group received preoperative ultrasound guided inter-scalene nerve blocks by senior anesthesiologist using ropivicaine.
3116459|NCT02570074|Experimental|Fosfomycin - 3 doses QoD/7 doses QD|Fosfomycin given as a 3 gm dose, every other day for 3 doses, followed by 3 gm dose, once a day for 7 doses.
3116460|NCT02570074|Experimental|Fosfomycin - 7 doses QD/3 doses QoD|Fosfomycin given as a 3 gm dose, once a day for 7 doses, followed by 3 gm dose, every other day for 3 doses.
3116461|NCT02570126|Experimental|VAR_HSA_F Group|2 doses of Varilrix HSA-free vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
3116462|NCT02570126|Active Comparator|VAR Group|2 doses of Varilrix™ vaccine, one at Visit 1 (Day 0) and the other at Visit 2 (Day 42), will be given to the subjects in this group. The vaccine will be administered subcutaneously in the triceps region of the left arm
3116463|NCT02570139|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.
3116464|NCT02570139|Active Comparator|ConvaTec Sensi-Care Protective Barrier|Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.
3116465|NCT02570152|Experimental|AFI Group|Population living in randomly selected households in geographically-defined communities. Households including at least one member aged less than 18 years will be considered eligible if at least one adult (aged no more than 50 years) and one child (aged less than 18 years) consent (and assent if applicable) to participate in the study.
3116466|NCT02570165|Experimental|Batefenterol 37.5 mcg|Each subject will receive batefenterol 37.5 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116467|NCT02570165|Experimental|Batefenterol 75 mcg|Each subject will receive batefenterol 75 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116468|NCT02570165|Experimental|Batefenterol 150 mcg|Each subject will receive batefenterol 150 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116469|NCT02570165|Experimental|Batefenterol 300 mcg|Each subject will receive batefenterol 300 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116470|NCT02570165|Experimental|Batefenterol 600 mcg|Each subject will receive batefenterol 600 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116471|NCT02570165|Experimental|UMEC/VI 62.5/25 mcg|Each subject will receive UMEC/VI 62.5/25 mcg (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116472|NCT02570165|Experimental|Placebo|Each subject will receive placebo (1 actuation) once daily via DPI in the morning for 42 days of treatment period.
3116473|NCT02570295|Experimental|Swiss Army Physical Fitness Training|"Sport according to the new sport concept (Swiss Army Physical Fitness Training) of the Swiss Armed Forces"
3116474|NCT02570295|No Intervention|Traditional Sport Concept|Sport according to the traditional sport concept of the Swiss Armed Forces
3116475|NCT02570308|Experimental|Dose escalation|Dose escalation cohorts of the intra-patient escalation regimen.
3116476|NCT02570308|Experimental|Dose expansion|Dose expansion cohort with the recommended phase 2 dose of the intra-patient dose escalation regimen.
3116477|NCT02570425|Placebo Comparator|Spiromax followed by Turbohaler|Training on BF Spiromax followed by SYMBICORT Turbohaler
3116478|NCT02570425|Placebo Comparator|Turbohaler followed by Spiromax|Training on SYMBICORT Turbohaler followed by BF Spiromax
3116479|NCT02570711|Experimental|Regimen 1|ACP-196 and nab-paclitaxel and gemcitabine
3116480|NCT02570711|Experimental|Regimen 2|Nab-paclitaxel and gemcitabine
3116481|NCT02570750||Group 1: smokers patients group|smokers (more than 10 cigarettes per day)
3116482|NCT02570750||Group 2 : non-smokers patients group|Smoking status will be classified as current and never/former. Former smokers will be defined as those who had stopped smoking at least 1 year before being interviewed for this study
3116483|NCT02571049|Experimental|Sumatriptan 3 mg then 6 mg|DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections
3116484|NCT02571049|Experimental|Sumatriptan 6 mg then 3 mg|Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo
3116485|NCT02571075|Experimental|Group 1 - Receives auricular acupuncture|"Receives Battlefield Acupuncture (BFA) as soon a anesthesia is initiated and needles removed right before they are extubated and awakened."
3116486|NCT02571075|No Intervention|Group 2 don't receive anything|They do not receive any any acupuncture only standard of care.
3116487|NCT02571153|Placebo Comparator|Saline group|Normal saline 0.9% (5 mL)
3116488|NCT02571153|Experimental|Ketamine 0.2|ketamine 0.2 mg/kg (5 mL)
3116489|NCT02571153|Experimental|Ketamine 0.4|ketamine 0.4 mg/kg (5 mL)
3116490|NCT02571218|Active Comparator|mCPVA|"Subjects in the mCPVA arm will undergo intervention called modified circumferential pulmonary vein ablation, which is considered to be the standard ablation treatment for AF."
3116491|NCT02571218|Experimental|Substrate+mCPVA|Subjects in the Substrate+mCPVA arm will undergo intervention of substrate mapping and substrate-targeted ablation guided by the investigational device, followed by completion of modified circumferential pulmonary vein ablation.
3116492|NCT02571244|Experimental|Motivational Interview plus text message|Inside the hospital: All participants have received the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended treatment: Participants in this arm have received a telephone counseling session using a motivational interviewing approach and fifteen or eight days of text messages. The timing, duration, and content of the counseling session were consistent with guideline-based recommendations.
3116493|NCT02571244|No Intervention|Control Arm|Inside the hospital: All participants have receive the written materials. Patients with high tobacco dependence (Fagerstrom screening test score 5 or higher) have received also Nicotine Replacement Therapy (NRT). The written materials provided information on benefits of quitting and strategies for a successful quit plan, including information on relapse prevention. Post discharge extended care: None
3116494|NCT02571439|Experimental|Surgical TAP block|surgeon administered intraoperative TAP block using 0.5% ropivacaine
3116495|NCT02571439|Active Comparator|Conventional TAP block|Conventional, Anesthesiologist administered post-operative TAP block using 0.5% ropivacaine
3116496|NCT02571452|Experimental|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
3116497|NCT02571452|Active Comparator|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
3116498|NCT02571634|Other|Open label|Open label, no blinding, everyone receives Lazanda.
3116499|NCT02571777|Experimental|QVM149 150/50/160 µg o.d.|QVM149 150/50/160 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
3116500|NCT02571777|Experimental|QVM149 150/50/80 µg o.d.|QVM149 150/50/80 μg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device
3116501|NCT02571777|Active Comparator|QMF149 150/320 µg o.d.|QMF149 150/320 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
3116502|NCT02571777|Active Comparator|QMF149 150/160 µg o.d.|QMF149 150/160 μg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device
3116503|NCT02571777|Active Comparator|Salmeterol/fluticasone 50/500 μg b.i.d.|Salmeterol xinafoate /fluticasone propionate 50/500 μg twice daily (b.i.d.) delivered via Accuhaler®
3116504|NCT02571972|Experimental|Dorzolamide-timolol|"On enrollment, eligible patients will have visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan and will then receive the same intravitreal pharmacologic agent administered at prior visit.~Subsequent follow-up visits will be at an identical interval to pre-enrollment visit intervals (4, 5, or 6 week intervals) for the study duration.~Each subsequent visit will consist of visual acuity testing, intraocular pressure, dilated fundoscopic examination, SD-OCT scan, and intravitreal injection of same pharmacologic agent as prior visits~At study conclusion, mean central macular thickness, maximum subretinal fluid height, and maximum pigment epithelial detachment height will be measured over the study period for all patients"
3116505|NCT02572076|Experimental|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
3116506|NCT02572167|Experimental|Brentuximab Vedotin + Nivolumab|Brentuximab vedotin plus nivolumab
3116507|NCT02572388|Active Comparator|Group 1|10µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
3116508|NCT02572388|Active Comparator|Group 2|50µg of R21 on days 0, 28, and 56.
3116509|NCT02572388|Active Comparator|Group 3|50µg of R21 mixed with 50µg of Matrix-M on days 0, 28, and 56.
3116510|NCT02572388|Active Comparator|Group 4|2µg of R21 mixed with 50µg of Matrix-M
3116511|NCT02572401|Experimental|HIV Risk Reduction Only|STAND HIV Risk Reduction Intervention. Participants will not receive the Text Messaging Intervention.
3116512|NCT02572401|No Intervention|No-Intervention No-Text Message Control|Participants do not receive the STAND HIV Risk Reduction Intervention or the Text Messaging Intervention.
3116513|NCT02572401|Experimental|HIV Risk Reduction and Text Messaging|STAND HIV Risk Reduction Intervention and Text Messaging Intervention. Participants will receive the intervention and text messages.
3116514|NCT02572401|Experimental|Text Messaging Only|Text Messaging Intervention. Participants will receive the text messages but not the STAND HIV Risk Reduction Intervention.
3116515|NCT02572427|Experimental|Education for intubation skills|Interventions: Training for Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP); 7 minute excerpt from the NRP training video regarding intubation; cognitive instruction which consisted of equipment needed for intubation; hands on instruction using the Storz video laryngoscope with manikins in simulation lab.
3116516|NCT02572427|Active Comparator|No added education for intubation skills|Interventions: Training for Routine Pediatric Advanced Life Support (PALS) and Neonatal Resuscitation Program (NRP) training; no additional training for intubating newborns.
3116517|NCT02572570|Experimental|Posterior Composite Resin Restoration|Participants will receive two commercially available tooth-colored restorative materials used for direct restoration as per manufacturer's instructions.
3116518|NCT02572609|Experimental|Mucosolvan ® adult syrup|
3116519|NCT02572609|Experimental|Ambroxol hydrochloride soft pastille|
3116520|NCT02572752|Experimental|Treatment T (Test)|Nintedanib, 1 capsule, oral with 240 mL of water
3116521|NCT02572752|Experimental|Treatment R - 1 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
3116522|NCT02572752|Experimental|Treatment R - 2 (Reference)|Nintedanib, 2 capsules, oral with 240 mL of water
3116523|NCT02572817|Experimental|High-titer anti-influenza plasma|Participants received two intravenous infusions of high-titer anti-influenza plasma on Study Day 0.
3116524|NCT02572817|Active Comparator|Low-titer anti-influenza plasma|Participants received two intravenous infusions of low-titer anti-influenza plasma on Study Day 0.
3116525|NCT02573012|Experimental|Tocilizumab+prednisone (constant dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) or matching placebo orally for 24 weeks.
3116526|NCT02573012|Experimental|Tocilizumab+prednisone (tapering dose)|Participants will receive tocilizumab at a dose of 162 milligram (mg) once a week subcutaneously; and prednisone at a dose of 5 milligram per day (mg/day) with 1 mg decrements every 4 weeks or matching placebo orally for 24 weeks.
3116527|NCT02573155|Experimental|Sequence 1, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Dose 5
3116528|NCT02573155|Experimental|Sequence 2, Part 1|Period 1: Placebo Period 2: Dose 3 Period 3: Dose 5
3116529|NCT02573155|Experimental|Sequence 3, Part 1|Period 1: Dose 1 Period 2: Placebo Period 3: Dose 5
3116530|NCT02573155|Experimental|Sequence 4, Part 1|Period 1: Dose 1 Period 2: Dose 3 Period 3: Placebo
3116531|NCT02573155|Experimental|Sequence 5, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Dose 6
3116532|NCT02573155|Experimental|Sequence 6, Part 1|Period 1: Placebo Period 2: Dose 4 Period 3: Dose 6
3116533|NCT02573155|Experimental|Sequence 7, Part 1|Period 1: Dose 2 Period 2: Placebo Period 3: Dose 6
3116534|NCT02573155|Experimental|Sequence 8, Part 1|Period 1: Dose 2 Period 2: Dose 4 Period 3: Placebo
3116535|NCT02573155|Experimental|Sequence 1, Part 2|Period 1: Treatment A Period 2: Treatment B Period 3: Treatment E Period 4: Treatment C Period 5: Treatment D
3116536|NCT02573155|Experimental|Sequence 2, Part 2|Period 1: Treatment B Period 2: Treatment C Period 3: Treatment A Period 4: Treatment D Period 5: Treatment E
3116537|NCT02573155|Experimental|Sequence 3, Part 2|Period 1: Treatment C Period 2: Treatment D Period 3: Treatment B Period 4: Treatment E Period 5: Treatment A
3116538|NCT02573155|Experimental|Sequence 4, Part 2|Period 1: Treatment D Period 2: Treatment E Period 3: Treatment C Period 4: Treatment A Period 5: Treatment B
3116539|NCT02573155|Experimental|Sequence 5, Part 2|Period 1: Treatment E Period 2: Treatment A Period 3: Treatment D Period 4: Treatment B Period 5: Treatment C
3116540|NCT02573155|Experimental|Sequence 6, Part 2|Period 1: Treatment D Period 2: Treatment C Period 3: Treatment E Period 4: Treatment B Period 5: Treatment A
3116541|NCT02573155|Experimental|Sequence 7, Part 2|Period 1: Treatment E Period 2: Treatment D Period 3: Treatment A Period 4: Treatment C Period 5: Treatment B
3116542|NCT02573155|Experimental|Sequence 8, Part 2|Period 1: Treatment A Period 2: Treatment E Period 3: Treatment B Period 4: Treatment D Period 5: Treatment C
3116543|NCT02573155|Experimental|Sequence 9, Part 2|Period 1: Treatment B Period 2: Treatment A Period 3: Treatment C Period 4: Treatment E Period 5: Treatment D
3116544|NCT02573155|Experimental|Sequence 10, Part 2|Period 1: Treatment C Period 2: Treatment B Period 3: Treatment D Period 4: Treatment A Period 5: Treatment E
3116545|NCT02573181|Experimental|V114|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of V114 on Day 1.
3116546|NCT02573181|Active Comparator|Prevnar 13™|Participants (≥65 years of age) who were vaccinated previously (≥1 year ago) with 23-valent pneumococcal polysaccharide vaccine will receive a single 0.5 mL intramuscular injection of Prevnar 13™ on Day 1.
3116547|NCT02573233|Placebo Comparator|Placebo|Placebo (for dupilumab), 2 subcutaneous injections on Day 1 (Week 1) as a loading dose followed by a single injection q2w from Week 2 to Week 14, added to stable inhaled corticosteroid/ long-acting beta-agonist (ICS/LABA) therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3116548|NCT02573233|Experimental|Dupilumab|Dupilumab, 2 subcutaneous injections on Day 1 as a loading dose for a total of 600 mg, followed by a single 300 mg injection q2w from Week 2 to Week 14, added to stable ICS/LABA therapy. Salbutamol/albuterol or Levosalbutamol/levalbuterol was given as reliever medication.
3116549|NCT02573246|Experimental|Cognitive Restructuring+rTMS (left)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the left side of the brain and will partake in short term and long term follow up testing.
3116550|NCT02573246|Sham Comparator|Cognitive Restructuring + sham rTMS|Participants in this arm will receive cognitive restructuring alone as an active intervention and will partake in short term and long term follow up testing.
3116551|NCT02573246|Experimental|Cognitive Restructuring+rTMS (right)|Participants in this arm will be administered the neuromodulation enhanced cognitive restructuring intervention over the right side of the brain and will partake in short term and long term follow up testing.
3116552|NCT02573311|Experimental|men|
3116553|NCT02573350|Experimental|Delamanid 100 mg BID + OBR|Participants received Delamanid 100 milligrams (mg) (2x50 mg tablets), orally, twice daily (BID) along with at least 4 additional anti-TB medications per optimized background regimen (OBR) from Week 0 to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment.
3116554|NCT02573350|Experimental|Delamanid 200 mg BID + OBR|Participants received Delamanid 200 mg (4x50 mg tablets), orally, BID along with at least 4 additional anti-TB medications per OBR up to Week 26. Participants were administered OBR as directed by the given investigator based on WHO guidelines and clinical judgment. A participant might have been titrated to Delamanid 200 mg BID after an initial hospitalization of 2 weeks. Participants were grouped according to the longest duration of Delamanid dose administered during the study.
3116555|NCT02573402|Experimental|Transcutaneous Tibial Nerve Stimulation|Transcutaneous Tibial Nerve Stimulation (TTNS) applied to subjects for 2-week protocol.
3116556|NCT02573402|Sham Comparator|Control|Sham stimulation.
3116557|NCT02573467|Experimental|BYM338/bimagrumab 10 mg/kg|Participants received BYM338 10 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
3116558|NCT02573467|Experimental|BYM338/bimagrumab 3 mg/kg|Participants received BYM338 3 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
3116559|NCT02573467|Experimental|BYM338/bimagrumab 1 mg/kg|Participants received BYM338 1 mg/kg administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
3116560|NCT02573467|Placebo Comparator|Placebo|Participants received placebo administered via intravenous infusion every 4 weeks for up to a maximum of 8 months after which they entered a 6-month, treatment-free follow-up period.
3116561|NCT02573493|Experimental|Arm 1: nab-Paclitaxel and cisplatin (AP) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) and cisplatin (75 mg/m2 days 1 and 22) followed by primary tumor site (PTS) assessment~If complete response (CR)/partial response (PR), three more weeks of nab-paclitaxel and cisplatin followed by concurrent chemoradiation therapy (CRT)~If <PR, move directly to CRT if not surgical candidates.~CRT includes cisplatin which will begin 1 to 35 days after the completion of cycle 3. The first dose of cisplatin will be given during the initial 5 days of definitive radiation therapy, the second on approximately Day 22 of radiation, and the third on approximately Day 43 of radiation.~It is strongly recommended that intensity-modulated radiation therapy (IMRT) begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
3116562|NCT02573493|Experimental|Arm 2: nab-Paclitaxel (A) + CRT|"Six weeks of nab-paclitaxel (100 mg/m2/week) followed by primary tumor site (PTS) assessment~If CR/PR, three more weeks of nab-paclitaxel followed by CRT~If <PR, move directly to CRT if not surgical candidates.~CRT includes cetuximab and will begin 1 to 35 days after completion of cycle -Cetuximab will be started 7 days before starting definitive radiation therapy. The initial loading dose of cetuximab will be 400 mg/m^2. Subsequently, cetuximab will be given weekly at a dose of 250 mg/m^2 for seven additional doses concurrently with radiation therapy.~It is strongly recommended that IMRT begin within 21 to 42 days (no later than 56 days) after the start of cycle 3. The total dose will be 7000 cGy in 35 fractions of 200 cGy each over 7 weeks. A dose of 6300 cGy in 35 fractions is optional and may be delivered to areas considered to be an intermediate risk."
3116563|NCT02573493|Experimental|Arm 3: nab-Paclitaxel and cisplatin (AP) + modified CRT|"6 weeks of nab-paclitaxel and cisplatin (days 1 & 22) followed by primary tumor site assessment~If CR/PR, cycle 3 of induction then 42Gy radiation, 1 dose of cisplatin or 6 doses cetuximab~If SD/PD: undergo surgery if candidate followed by CRT with 42 Gy RT and abbreviated cisplatin or cetuximab or 70Gy RT and 3 cycles of cisplatin or 8 doses of cetuximab~CRT includes Cisplatin and will begin 1-35 days after the completion of Cycle 3 of induction. Cisplatin will be given as 1 dose during the initial 5 days of definitive radiation therapy~Strongly recommended that radiation therapy begin within 28-49 days (and no later than 56 days) after the start of Cycle 3. Intensity modulated radiation therapy is to be used exclusively for this study."
3116564|NCT02573779||Infants fed mother's own milk|Infants fed >50% mother's own milk with enteral feeding.
3116565|NCT02573779||Donor milk fed infants|Infants fed <50% mother's own milk (and thus >50% donor human milk) with enteral feeding.
3116566|NCT02573857|Experimental|DSM265 P. falciparum|Cohort 1: the efficacy of a single administration of 400 mg DSM265 for the clearance of asexual blood stages of P. falciparum will be determined. Activity of a second single dose of 400 mg DSM265 against gametocytes will be assessed in this cohort only if sexual stages are identified by PCR following the initial drug treatment.
3116567|NCT02573857|Experimental|OZ439 P. vivax|Cohort 2: subjects will be infected with P. vivax by IBSM, then treated with a single 200 mg dose OZ439. If recrudescence occurs following initial drug treatment with 200 mg OZ439, then affected participants who reach the treatment threshold will receive a single 400 mg dose of OZ439.
3116568|NCT02573857|Experimental|DSM265 P. vivax|Cohort 3: subjects will be infected with P. vivax by IBSM, then treated with a single 400 mg dose of DSM265
3116569|NCT02573870|Experimental|Batefenterol + Fluticasone Furoate|Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
3116570|NCT02573870|Placebo Comparator|Placebo|Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.
3116571|NCT02573883|Experimental|Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus previously treated with clobetasol propionate
3116572|NCT02573883|Active Comparator|No Prior Clobetasol Exposure|Patients with biopsy proven lichen sclerosus never previously treated with clobetasol propionate.
3116573|NCT02574078|Experimental|Group A Nivolumab|Opdivo specified dose on specified days
3116574|NCT02574078|Experimental|Group A Nivolumab + SOC maintenance therapy|"Opdivo/Bevacizumab specified dose on specified days~Opdivo/Pemetrexed specified dose on specified days"
3116575|NCT02574078|Active Comparator|Group A SOC maintenance therapy|"Bevacizumab specified dose on specified days~Pemetrexed specified dose on specified days"
3116576|NCT02574078|Experimental|Group B Nivolumab|Opdivo specified dose on specified days
3116577|NCT02574078|Other|Group B Best supportive care|Therapy directed against specific symptoms of disease, i.e., palliative radiation or palliative surgery
3116578|NCT02574078|Active Comparator|Group C Investigator's choice chemotherapy|"Carboplatin/nab-paclitaxel specified dose on specified days~Carboplatin/paclitaxel specified dose on specified days~Carboplatin/pemetrexed specified dose on specified days~Carboplatin/docetaxel specified dose on specified days~Carboplatin/gemcitabine specified dose on specified days~Paclitaxel specified dose on specified days~Docetaxel specified dose on specified days~Gemcitabine specified dose on specified days~Pemetrexed specified dose on specified days"
3116579|NCT02574078|Experimental|Group C Nivolumb|Opdivo specified dose on specified days
3116580|NCT02574078|Active Comparator|Group D Erlotinib|Erlotinib specified dose on specified days
3116581|NCT02574078|Experimental|Group D Nivolumab + Erlotinib|Opdivo/Erlotnib specified dose on specified days
3116582|NCT02574078|Experimental|Group E Nivolumab + Crizotinib|Opdivo/Crizotinib specified dose on specified days
3116583|NCT02574247|Experimental|Training|Participants in the Training arm will undergo 15 hours of computerized auditory training across 10 laboratory visits. Medial olivocochlear reflex function and speech perception abilities will be measured before, during, and after the training visits to examine the changes in the measurements across time.
3116584|NCT02574247|No Intervention|Control|Participants in the Control arm will undergo the same number of visits as the Training arm, but will not participate in computerized auditory training. Medial olivocochlear reflex function and speech perception abilities will be measured at each visit to establish the test-retest reliability of these measurements in the absence of any training.
3116585|NCT02574247|No Intervention|Speech Group|Participants in the Speech Group will undergo 1 visit. Medial olivocochlear reflex function and speech perception abilities will be measured at this visit to establish the correlation between these measures in the absence of any training.
3116586|NCT02574260|Experimental|Talimogene Laherparepvec|Participants received talimogene laherparepvec 10⁸ plaque forming units (PFU)/mL (up to 4 mL depending on tumor size) administered intratumorally every 2 weeks, on Day 1 and Day 15 of 28-day cycles until discontinuation criteria were met.
3116587|NCT02574312|Active Comparator|TKA with RUI|44 Subjects will receive TKA with RUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Reusable instruments (RUI).
3116588|NCT02574312|Experimental|TKA with SUI|44 Subjects will receive TKA with SUI per their study doctor's standard of care. These 44 subjects will receive the TKA using Single Use Instruments (SUI).
3469318|NCT03887754|Active Comparator|The Risperidone group|"This group consists of twenty autistic children received Risperidone (dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more) for eight months.~The medication schedule in the initial 2 months was based on the child's weight and clinical response. Adjusting the total daily dose according to response and/or adverse effects, at the end of these eight months of treatment we began the discontinuation phase. In this phase, gradual placebo substitution occurs. The discontinuation reduced the maintenance dose by 25% per week. Thus, the dose was 75% of the last week in the eight months for the first week, followed by 50% of the last week for the second week, 25% of the last week for the third week, and placebo only by the fourth week."
3469319|NCT03887754|Active Comparator|The HBOT and Risperidone group|This group consists of twenty autistic children received HBOT as the HBOT group in addition to Risperidone as the Risperidone group in the same manner and duration
3116591|NCT02574520|Placebo Comparator|Part 1|SABER-Bupivacaine and Saline Placebo
3116592|NCT02574520|Active Comparator|Part 2|SABER-Bupivacaine and Bupivacaine HCl
3116593|NCT02574598|Experimental|Docetaxel + MK-3475|"Docetaxel 75 mg/m2 every 3 weeks until progression of disease~MK-3475 (administered on day 8) 200mg every 3 until progression of disease"
3116594|NCT02574598|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 every 3 weeks until progression of disease followed by MK-3475 200mg every 3 until progression of disease
3116595|NCT02574637|Placebo Comparator|Placebo|Placebo-matching brazikumab intravenous (IV) infusion and subcutaneous (SC) injection at Weeks 0 and 4 followed by placebo-matching brazikumab SC injection at Weeks 8 and 12 in the induction phase and at Weeks 16, 20 and 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection every 4 weeks up to Week 48 in the open-label period.
3116596|NCT02574637|Experimental|Brazikumab High Dose|Brazikumab 700 mg, IV infusion and placebo-matching brazikumab, SC injection at Weeks 0 and 4 followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
3116597|NCT02574637|Experimental|Brazikumab High-Medium Dose|Brazikumab 280 mg, IV infusion and placebo-matching brazikumab, SC injection at Week 0 followed by brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 210 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 210 mg, SC injection every 4 weeks in the maintenance phase and open-label period up to Week 48.
3116598|NCT02574637|Experimental|Brazikumab Low-Medium Dose|Brazikumab 210 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 105 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 105 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 105 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
3116599|NCT02574637|Experimental|Brazikumab Low Dose|Brazikumab 70 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 0 followed by brazikumab 35 mg, SC injection and placebo-matching brazikumab, IV infusion at Week 4, followed by brazikumab 35 mg, SC injection at Weeks 8 and 12 in the induction phase. Participants received brazikumab 35 mg, SC injection every 4 weeks up to Week 24 in the maintenance phase. Participants received brazikumab 210 mg, SC injection, every 4 weeks up to Week 48 in the open-label period.
3116600|NCT02574832|Experimental|Spinal Lidocaine Administration|"Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg."
3116601|NCT02574845|Experimental|R (Reference) Rosuvastatin|1film-coated tablet as single dose, fasted
3116602|NCT02574845|Experimental|T1 (Test 1) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (10 mg) as single dose, fasted
3116603|NCT02574845|Experimental|T2 (Test 2) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (50 mg) as single dose, fasted
3116604|NCT02574845|Experimental|T3 (Test 3) Rosuvastatin + Metformin HCl|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Metformin HCl (500 mg) as single dose, fasted
3116605|NCT02574845|Experimental|T4 (Test 4) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (1 mg) as single dose, fasted
3116606|NCT02574845|Experimental|T5 (Test 5) Rosuvastatin + Furosemide|Rosuvastatin: 1 film-coated tablet as single dose (10 mg), fasted / Furosemide: (5 mg) as single dose, fasted
3116607|NCT02574858|Experimental|QRH-886620|The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (~100 µM concentration).
3116608|NCT02575079|Experimental|Parafilm|Pediatric patients undergoing hematopoietic stem cell transplant (HCT) with central venous catheters (CVCs) will have pre-cut, single-use sections of parafilm applied over the CVC hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC and routine CVC care will be continued, per institutional standard of practice, until the CVC is removed.
3116609|NCT02575079|No Intervention|Historical Cohort|Pediatric patients receiving hematopoietic cell transplantation in the 16 months preceding the study intervention. Data were obtained retrospectively through medical records for the purpose of comparing CLABSI rates among recipients of parafilm to a control group.
3116610|NCT02575300|Experimental|Ibrutinib Therapy|Ibrutinib Initial Dose 560 mg by mouth (PO) every day (QD)
3116611|NCT02575807|Experimental|Phase 1: CRS-207|"CRS-207 administered in 3-week cycles.~* CRS-207 (1 x 10e9 colony forming units [CFU]) administered by intravenous (IV) infusion. For Cycle 1 through Cycle 6, CRS-207 will be administered on Day 1 of each cycle. After 6 cycles, CRS-207 will be administered on Day 1 once every 6 weeks (every other cycle)."
3116612|NCT02575807|Experimental|Phase 1: CRS-207/IDO 100 mg|"CRS-207 administered in 3-week cycles, IDO administered twice daily (BID).~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (100 milligrams [mg]) administered by mouth (PO) BID, starting on Day 2 of the first CRS-207 treatment cycle."
3116613|NCT02575807|Experimental|Phase 1: CRS-207/IDO 300 mg|"CRS-207 administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 1 of each cycle. After 6 cycles, CRS-207 administered on Day 1 once every 6 weeks (every other cycle).~IDO (300 mg) administered PO BID, starting on Day 2 of the first CRS-207 treatment cycle."
3116614|NCT02575807|Experimental|Phase 2: CRS-207/Pembro/IDO|"CRS-207 and pembrolizumab (pembro) administered in 3-week cycles, IDO administered BID.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles.~IDO (300 mg) administered PO BID, starting on Day 3 of the first CRS-207 treatment cycle."
3116615|NCT02575807|Experimental|Phase 2: CRS-207/Pembro|"CRS-207 and pembro administered in 3-week cycles.~CRS-207 (1 x 10e9 CFU) administered by IV infusion. For Cycle 1 through Cycle 6, CRS-207 administered on Day 2 of each cycle. After 6 cycles, CRS-207 administered on Day 2 once every 6 weeks (every other cycle).~Pembro (200 mg) administered by IV infusion on Day 1 in 3-week cycles."
3116616|NCT02575833|Placebo Comparator|Placebo|Participants received a single dose of placebo administered by intravenous infusion on day 1.
3116617|NCT02575833|Experimental|Erenumab|Participants received a single dose of erenumab 140 mg administered by intravenous infusion on day 1.
3116618|NCT02575911|Experimental|LenSx|LASIK surgery in both eyes using LenSx® Femtosecond Laser System
3116619|NCT02575950|Experimental|LEO43204 0,018%|Experimental drug
3116620|NCT02575950|Placebo Comparator|Vehicle|Placebo
3116621|NCT02576041|Experimental|Placebo (run-in); Bilastine|At V0, the enrolled patient received the complete drug-kit and started a 7 (+3)-day wash-out period with placebo. At the end of the 7 (+3)-days of placebo-treatment period, patients repeated the F1-high speed simulator test at Visit V1, and afterwards initiated the 7 (+3)-day treatment period with active treatment (bilastine).
3116622|NCT02576054|Experimental|V501|0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
3116623|NCT02576067|Experimental|Low dose methotrexate|average dose of 15-20 mg po/weekly
3116624|NCT02576067|Placebo Comparator|Placebo|matching placebo
3116625|NCT02576145|Experimental|Group A (With Daclizumab Therapy)|Participants who were receiving a full course of 5 doses of daclizumab (1 milligram per kilogram [mg/kg]) with Day 1 vaccine administered immediately prior to the fifth dose.
3116626|NCT02576145|Active Comparator|Group B (Post Daclizumab Therapy)|Participants who completed a full course of daclizumab therapy in the previous 4 to 18 months.
3116627|NCT02576249|Active Comparator|Ropivacaine and Methylprednisolone|0.2% ropivacaine and methylprednisolone knee joint injection
3116628|NCT02576249|Experimental|Saline and Methylprednisolone|0.9% normal saline and methylprednisolone knee joint injection
3116629|NCT02576509|Experimental|Nivolumab|Nivolumab specified dose on specified days
3116630|NCT02576509|Active Comparator|Sorafenib|Sorafenib specified dose on specified days
3116631|NCT02576535|Experimental|Fractionated stereotactic radiosurgery|The radiation dose will be delivered by the standard, FDA approved Leksell gamma unit (Gamma knife; Elekta Instruments, Atlanta, GA). Treatment dose and volume will be determined using the Gamma Plan software provided with the unit (Elekta Instruments, Atlanta, GA).
3116632|NCT02576587|Other|Case (diagnosed with PAF)|"Cases. Patients with Paroxysmal Atrial Fibrillation who present to Electrophysiology Clinic at UHCMC and the Cleveland Clinic Foundation will be approached for recruitment in the study.~Cases found to have an apnea hypopnea index >=15 will be asked to continue in the study for 3 months wearing a Continuous Positive Airway Pressure (CPAP) machine."
3116633|NCT02576587|No Intervention|Controls|Controls. Patients without AF will be recruited from General Cardiology and Internal Medicine clinics (geographically similar to controls). Selection bias will be minimized as there are a broad range of reasons for patients to present to these clinics.
3116634|NCT02576639|Placebo Comparator|Placebo|Matching placebo to CNP520 was taken once daily (qd) orally for 13 weeks.
3116635|NCT02576639|Experimental|CNP520 2 mg|CNP520 2 mg was taken qd orally for 13 weeks.
3116636|NCT02576639|Experimental|CNP520 10 mg|CNP520 10 mg was taken qd orally for 13 weeks.
3116637|NCT02576639|Experimental|CNP520 35 mg|CNP520 35 mg was taken qd orally for 13 weeks.
3116638|NCT02576639|Experimental|CNP520 85 mg|CNP520 85 mg was taken qd orally for 13 weeks.
3116639|NCT02576652|Other|Osteoarthritis Participants|Participants previously treated with denosumab and planning to undergo total hip replacement (THR) received one cycle of tetracycline administered at either 250 mg four times a day or 500 mg twice a day for 3 days and one cycle of demeclocycline administered at either 150 mg four times a day or 300 mg twice a day for 3 days, ten days after last dose of tetracycline in cycle 1. THR surgery was performed 5 to 42 days after the last dose of demeclocycline.
3116640|NCT02576678|Experimental|Open label apremilast|"Apremilast doses of 10-mg, 20-mg or 30-mg tablets have been selected to determine the dose range in adolescents and children with moderate to severe plaque psoriasis. These pediatric dosages are expected to achieve exposures similar to those achieved in adult psoriasis and psoriatic arthritis (PsA) subjects treated with apremilast 30 mg orally twice daily (BID).~A staggered, stepwise approach by age range and weight (starting with older and heavier subjects) is considered appropriate for this first-time-in-children study. Doses for younger and lower body weight subjects will be adjusted based on safety and PK data from older and heavier subjects.~Subjects will be divided into 2 age groups with at least 16 subjects in each group. Dosing within and between groups will be staggered, based on PK data collected and on a minimum of 2 weeks of safety data."
3469320|NCT03887754|Placebo Comparator|The Control group|This group consists of twenty autistic children received placebo in the form of multivitamins
3469321|NCT03887871|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
3469322|NCT03887871|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
3116641|NCT02576899|Active Comparator|Stage 1b Study of ACT-PT vs. FFS|This study involves a randomized clinical trial study of Veteran smokers with PTSD and tobacco dependence randomized to one of two different types of psychosocial treatment: ACT-PT versus the American Lung Association's Freedom From Smoking Program [FFS]. This study has two primary aims: 1) Evaluate the relative feasibility and acceptability of the two interventions (including ease of recruitment, randomization proportion, staff and Veteran acceptance of the treatment, retention rates, treatment adherence, fidelity, ease of the assessment process), and 2) Evaluate the preliminary efficacy of ACT-PT vs. FFS with the primary outcomes of tobacco use, PTSD symptoms, health-related quality of life, and functional impairment.
3116642|NCT02576899|Placebo Comparator|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
3116643|NCT02576938|Experimental|Baricitinib|"Administered once daily in multiple oral dose cohorts for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
3116644|NCT02576938|Placebo Comparator|Placebo|"Administered orally once daily, for 16 weeks~(Triamcinolone 0.1% topical also permitted)"
3116645|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part A|Galcanezumab solution formulation in a prefilled syringe given SC once.
3116646|NCT02576951|Placebo Comparator|Placebo-Part A|Placebo in a prefilled syringe given SC once.
3116647|NCT02576951|Experimental|Galcanezumab Lyophilized Formulation-Part B|Galcanezumab lyophilized (freeze dried) formulation given SC once.
3116648|NCT02576951|Experimental|Galcanezumab Solution Formulation-Part B|Galcanezumab solution formulation in a prefilled syringe given SC once.
3116649|NCT02576977|Experimental|Pembrolizumab+Pomalidomide+Dexamethasone|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 every 3 weeks (Q3W) PLUS pomalidomide 4 mg orally (PO) on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
3116650|NCT02576977|Active Comparator|Pomalidomide+Dexamethasone|Participants receive pomalidomide 4 mg PO on Days 1 to 21 of each 28-day cycle PLUS dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle.
3116651|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)|Participants with rrPMBCL receive pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years).
3116652|NCT02576990|Experimental|Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)|Participants with rrRS receive pembrolizumab 200 mg Q3W, IV for each 3-week cycle for up to a maximum of 35 administrations (approximately 2 years). Effective with Protocol Amendment 04, enrollment into this cohort was closed.
3116653|NCT02577003|Experimental|Ipragliflozin + Sitagliptin|Ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
3116654|NCT02577003|Active Comparator|Placebo + Sitagliptin|Placebo to ipragliflozin once daily for 24 weeks in addition to sitagliptin, diet, and exercise.
3116655|NCT02577016|Experimental|Sitagliptin + Ipragliflozin|Sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
3116656|NCT02577016|Active Comparator|Placebo + Ipragliflozin|Placebo to sitagliptin, oral, once daily for 24 weeks plus ipragliflozin (base therapy), in addition to diet and exercise.
3116657|NCT02577029|Experimental|Cohort 1|"Treatment-naïve, hepatitis B e antigen (HBeAg)-positive participants with chronic hepatitis B (CHB) of any genotype administered ARC-520 (2 mg/kg intravenous [IV]) every 4 weeks for 48 weeks (13 doses)."
3116658|NCT02577029|Experimental|Cohort 2|Treatment-naïve, HBeAg-positive, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered peginterferon (PEG IFN) alpha 2a for 48 weeks starting Day 87.
3116659|NCT02577029|Experimental|Cohort 3|Treatment-naïve, HBeAg-negative, Genotype B participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
3116660|NCT02577029|Experimental|Cohort 4|Treatment-naïve, HBeAg-positive, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
3116661|NCT02577029|Experimental|Cohort 5|Treatment-naïve, HBeAg-negative, Genotype C participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
3116662|NCT02577029|Experimental|Cohort 6|Treatment-naïve, HBeAg-negative, Genotype D participants with CHB administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) concomitantly with daily orally administered ETV or TDF for approximately 60 weeks starting Day 1 and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 87.
3116663|NCT02577029|Experimental|Cohort 7|Treatment-naïve, HBeAg-negative or HBeAg-positive participants with hepatitis delta virus (HDV) administered ARC-520 (2 mg/kg increasing to 4 mg/kg or 4 mg/kg IV) every 4 weeks for 48 weeks (13 doses) and weekly subcutaneously administered PEG IFN alpha 2a for 48 weeks starting Day 15.
3116664|NCT02577029|Experimental|Cohort 8|Treatment-naïve, HBeAg-positive participants with CHB of any genotype administered ARC-520 (4 mg/kg IV) every 4 weeks for 48 weeks (13 doses).
3116665|NCT02577042|Experimental|Raltegravir + Atorvastatin|Switching the PI by raltegravir, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks
3116666|NCT02577042|Active Comparator|PI-based regimen + Atorvastatin|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks. After that, atorvastatin, 20mg/day, will be added for 48 weeks.
3116667|NCT02577107|Experimental|Ranibizumab 0.5 mg|Three monthly injections of 0.5mg Ranibizumab
3116668|NCT02577107|Active Comparator|Conbercept 0.5 mg|Three monthly injections of 0.5mg Conbercept
3116669|NCT02577146|Experimental|Study ultrasound|Study ultrasound with ureteral jet assessment will be obtained after CT diagnosis of ureteral calculus is made. Ureteral jet data will be documented and patients will be followed prospectively for 42 days for spontaneous stone passage or need for surgical intervention.
3116670|NCT02577315|Experimental|Test - Empagliflozin/Metformin|fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin, oral with 200 mL of water uder fed conditions
3116671|NCT02577315|Experimental|Reference - Empagliflozin + Metformin|free combination of 1 tablet of 25 mg Empagliflozin and 1 tablet of 1000 mg of Metformin, oral with 200 mL of water under fed conditions
3116672|NCT02577354|Experimental|Treatment|
3116673|NCT02577354|Experimental|Control|
3116674|NCT02577445||CSA patients without remedē system|For all patients diagnosed with CSA who will not move forward with remedē® system therapy, the intention is to obtain information on their alternate therapy, if any, and safety information, including all cause mortality and all cause hospitalizations during phone calls at 6, 12 and 24 months after enrollment.
3116675|NCT02577445||CSA patients with remedē system|"For all patients diagnosed with CSA and referred for implant / or have already been implanted with remedē system, information from the implant procedure will be collected.~Patients will be asked to complete quality of life questionnaires at baseline and during follow-up visits.~Patients will be evaluated at the time of therapy activation which may be followed by one or more titration visits. Patient follow-ups will be programmed at 6 and 12 months, and yearly, up to 5 years post-implant, until the last patients reach their 2-year follow-up.~Echocardiogram for patients with reduced ejection fraction (≤ 45%) and follow-up respiratory polygraphy are considered standard of care, however, to ensure sufficient data, related to the study objectives, are being collected, baseline and 12-months echocardiogram for a subgroup of patients and respiratory polygraphy at 12-month follow-up for all patients must be done when participating in this study:"
3116676|NCT02577510|Experimental|Nerve Stimulation- Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
3116677|NCT02577510|Experimental|Ultrasound guided Xylocaine injection|Anesthesia of the lateral femoral cutaneous nerve using local anesthetic will be randomly assigned on the right or left side to receive nerve stimulation-xylocaine or ultrasound guided -xylocaine injections in all patients. One patient will therefore have both nerve stimulation AND ultrasound guided injections, only the side of the injection will be randomly assigned to one of the two modalities. Once one technique has been used to freeze one side, the other side will be frozen using the other technique.
3116678|NCT02577601|Active Comparator|UPA Only|During the first treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10). Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
3116679|NCT02577601|No Intervention|Washout Cycle|The month following this first treatment month (washout-cycle),there will be no study visits during this menstrual cycle but there will be contact with study staff (1 or 2 times) by telephone or email to discuss any health changes that are experiencing.
3116680|NCT02577601|Active Comparator|UPA + COC|During the second treatment month, 1 dose of the study medication ulipristal acetate (UPA) will be given when the follicle is a certain size (approximately cycle day 10) and then 2 days later start birth control pills. Following this, there will be daily study visits for 7 days unless evidence of ovulation occurs earlier.
3116681|NCT02577640|Experimental|Dose Escalation (DE) Phase|Here a traditional 3+3 design will be used to determine the compliance, tolerability and dose limiting toxicities in this unique patient population. Dose escalation with soy bread will be continued until dose-limiting toxicities are observed in >33% of the participants or the daily target dose of 4 slices of bread [132 mg soy isoflavone] is reached.
3116682|NCT02577640|Experimental|Maximum Tolerated Dose (MTD) Phase|After the Phase I study has been completed, an additional 10 chronic pancreatitis patients will be treated at the best tolerated dose of soy bread for 4 weeks to further verify safety and toxicity.
3116683|NCT02577718|Experimental|Nitroglycerin-Citrate-Ethanol (NiCE)|Antimicrobial Nitroglycerin-Citrate-Ethanol catheter lock solution was administered for 2 hours then flushed
3116684|NCT02577822|Other|Short Stem Group|Short femoral stem
3116685|NCT02577822|Other|Long Stem Group|standard-length stem
3116686|NCT02577900|Experimental|Acticoat absorbent|Apply Acticoat absorbent onto the ulcer
3116687|NCT02577900|Active Comparator|Honey gel sheet|Apply Honey gel sheet onto the ulcer
3116688|NCT02577900|Other|Jelonet|Apply Jelonet onto the ulcer
3116689|NCT02577978|Other|Medacta Sphere|Ball-and-socket
3116690|NCT02577978|Other|Medacta PS|Cam-and-post
3116691|NCT02577991|No Intervention|Control group|No steroid
3116692|NCT02577991|Experimental|IV steroid|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
3116693|NCT02577991|Experimental|Local steroid|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
3116694|NCT02578186|Experimental|Diphenhydramine Hydrochloride|Diphenhydramine (50 mg) elixir taken when subjects had trouble falling asleep
3116695|NCT02578186|Placebo Comparator|Placebo|Placebo elixir taken when subjects had trouble falling asleep
3116696|NCT02578199|Experimental|motivational interviewing and nutrition|Motivational interviewing and nutritional counseling.
3116697|NCT02578238||Participants With Pediatric CD|Participants with pediatric CD who have been prescribed Humira® (adalimumab) by the treating physician.
3116698|NCT02578316|Experimental|Lenvatinib 24 mg|Participants with advanced solid tumors or lymphomas, who are unsuitable for, or had failed, existing therapies.
3116699|NCT02578680|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression.
3116700|NCT02578680|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. With Amendment 10 (effective date: 23-Dec-2019), all participants will discontinue saline placebo. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression.
3116701|NCT02578706|Active Comparator|Aspirin and placebo|At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
3116702|NCT02578706|Active Comparator|Clopidogrel and placebo|At week 0, participants will be administered clopidogrel 75 mg (one tablet) and placebo for aspirin 81 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
3116703|NCT02578706|Placebo Comparator|Placebos only|At week 0, participants will be administered placebo for aspirin 81 mg (one tablet) and placebo for clopidogrel 75mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
3116704|NCT02578732|Experimental|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
3116705|NCT02578745|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the PICO device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4.
3116706|NCT02578745|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
3116707|NCT02578862|Experimental|Total Intravenous|Intravenous propofol for maintenance of anesthesia
3116708|NCT02578862|Active Comparator|Inhaled Anesthetic|Inhaled volatile anesthetic for maintenance of anesthesia
3116709|NCT02578901|Active Comparator|Tranexamic Acid (TXA)|IV or PO administered after meeting inclusion/exclusion criteria
3116710|NCT02578901|Placebo Comparator|Placebo|IV Normal Saline or PO placebo pills administered after meeting inclusion/exclusion criteria
3116711|NCT02578940|Experimental|Single arm|Single intravenous administration of 18F-Fluciclovine for PET Scan
3116712|NCT02578992|Experimental|Head-lift Position|The patients' head was placed in the head-lift position(A 7 cm high pillow was set beneath the patients' head with head in neutral position) and then the patient was intubated with Trachway by single-handed chin lift technique
3116713|NCT02578992|No Intervention|Neutral Position|The patients' head was placed in the neutral position and then the patient was intubated with Trachway by single-handed chin lift technique
3116714|NCT02579057|Active Comparator|Furosemide Injection Solution, USP|Single dose determined by Investigator (maximum dose 160mg) administered intravenously by IV bolus over approximately 2 minutes (reference treatment)
3116715|NCT02579057|Experimental|Furosemide Injection Solution (SCP-101)|80 mg dose administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours (test treatment)
3116716|NCT02579135|Experimental|Project HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
3116717|NCT02579135|Other|Control: Project Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
3116718|NCT02579343|Experimental|Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants in this group will be treated twice weekly during their follow-up visits with micro-currents of electricity through auricular acupuncture.
3116719|NCT02579343|Sham Comparator|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
3116720|NCT02579382|Placebo Comparator|TDF + placebo|"Main Study Phase: Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily for up to 48 weeks + placebo administered orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
3116721|NCT02579382|Experimental|TDF + Vesatolimod 1 mg|"Main Study Phase:TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 1 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
3116722|NCT02579382|Experimental|TDF + Vesatolimod 2 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 2 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
3116723|NCT02579382|Experimental|TDF + Vesatolimod 4 mg|"Main Study Phase: TDF 300 mg tablets orally once daily for up to 48 weeks + vesatolimod 4 mg tablet orally once a week (every 7 days) for 12 doses.~Optional Treatment Extension Phase: At Week 48 participants had the option to continue TDF 300 mg tablets orally once daily up to Week 144."
3116724|NCT02579421|Active Comparator|Males - Progesterone|200 mg progesterone BID
3116725|NCT02579421|Placebo Comparator|Males - Placebo|placebo BID
3116726|NCT02579421|Active Comparator|Females - Progesterone|200 mg progesterone BID
3116727|NCT02579421|Placebo Comparator|Females - Placebo|placebo BID
3116728|NCT02579603|Experimental|Nintedanib|Nintedanib 150 mg bid
3116729|NCT02579603|Experimental|Nintedanib and Pirfenidone|Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid
3116730|NCT02579616|Experimental|24 mg Lenvatinib|Participants with unresectable BTC and disease progression or failure following one prior gemcitabine-based doublet chemotherapy regimen (combination of gemcitabine and cisplatin, or gemcitabine and other platinum agent/fluoropyrimidine agent).
3116731|NCT02579629|Active Comparator|Ropivacaine 0.1%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
3116732|NCT02579629|Experimental|Ropivacaine 0.2%|Subjects undergoing their first,second or third cesarean sections will receive a bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump for 3 days after the cesarean section.
3116733|NCT02579629|Active Comparator|Normal Saline|Subjects undergoing their first, second or third cesarean sections will receive a bolus dose of 8ml normal saline followed by an infusion of 8ml/hr of normal saline using the On-Q® elastomeric pump for 3 days after the cesarean section.
3116734|NCT02579759|Active Comparator|PXT3003 dose 1|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
3116735|NCT02579759|Active Comparator|PXT3003 dose 2|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
3116736|NCT02579759|Placebo Comparator|placebo|Oral solution, 5 ml b.i.d. (taken morning and evening with food) during 15 months
3116737|NCT02579772|Active Comparator|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC) pills
3116738|NCT02579772|Placebo Comparator|Placebo|Treatment with placebo pills
3116739|NCT02579811|Experimental|Axitinib|All subjects will be given axitinib on an individualized dosing schedule. Axitinib will be administered orally beginning with 5mg twice a day and can be escalated or reduced if specific grade 2 or greater toxicity develops. Axitinib will continue until progression. At progressive disease, dose escalation above current dose is allowed based on investigator discretion of clinical benefit. However, axitinib should be discontinued if a subject experiences a second RECIST progressive disease following dose escalation, patient intolerability, or at provider discretion.
3116740|NCT02579863|Experimental|Pembrolizumab + Lenalidomide + Dexamethasone|Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS lenalidomide 25 mg orally (PO) on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
3116741|NCT02579863|Active Comparator|Lenalidomide + Dexamethasone|Participants received lenalidomide 25 mg PO on Days 1 to 21 of each 21-day treatment cycle, and dexamethasone 40 mg PO on Days 1, 8, 15 and 22 of each 28-day cycle for up to 18 cycles.
3116742|NCT02579876|Active Comparator|Viaskin Milk 500 mcg|Viaskin patch containing milk protein. The patch is applied to the skin
3116743|NCT02579876|Placebo Comparator|Viaskin Placebo|Viaksin patch without any milk protein.
3116744|NCT02579915|Experimental|FaceAnxiety - Mental Habits|Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session. A FaceAnxiety Specialist facilitates program completion.
3116745|NCT02579915|Active Comparator|FaceAnxiety - Symptom Tracking|Treatment will consist of weekly self-assessment of anxiety and depression symptoms via on-line surveys. A FaceAnxiety Specialist will facilitate program completion.
3116746|NCT02579928|Experimental|Ketamine|Participants were randomly be assigned to receive a dose of 0.5 mg/kg of Ketamine (administered intravenously over 40 minutes with a maximum total dose allowed in this study will be 50mg).
3116747|NCT02579928|Experimental|Midazolam|Participants were randomly assigned to receive a dose of 0.045mg/kg of Midazolam (administered Intravenously over 40 minutes with a the maximum total dose allowed in this study of 4.5mg),
3116748|NCT02580058|Experimental|avelumab|Arm A: avelumab alone
3116749|NCT02580058|Experimental|avelumab plus pegylated liposomal doxorubicin (PLD)|Arm B: avelumab plus PLD
3116750|NCT02580058|Active Comparator|PLD|Arm C: PLD alone
3116751|NCT02580188|No Intervention|Moderate block|Maintenance dose of 0.15-0.3 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of train of four count 1-2 (moderate block). At the end of surgery neostigmine 50 ㎍/kg with glycopyrrolate 10 ㎍/kg are administered IV for reversal of neuromuscular block.
3116752|NCT02580188|Experimental|Deep block|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
3116753|NCT02580201|Experimental|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
3116754|NCT02580240|Placebo Comparator|Placebo|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
3116755|NCT02580240|Experimental|hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
3116756|NCT02580318|Experimental|all study participants|subjects consumed alcohol to a BrAC of 0.1 and then performed the following manipulations while using the breathalyzer: poor effort, hyperventilation (immediate), hyperventilation (after 5 minutes), hyperventilation (after 10 minutes), drinking water (immediate), drinking water (after 5 minutes)
3116757|NCT02580357|Sham Comparator|Low Level Laser therapy (LLLT) Sham|The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue. The applications were performed by a different operator (CAS) from the one who measured the study parameters. During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications.
3116758|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 60 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 60 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 60 J/cm2 and a time of 60 seconds (30 J/cm2 per point and an application time of 30 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
3116759|NCT02580357|Experimental|GaAlAs Laser therapy (LLLT) 30 J/cm²|The irradiation was performed with a GaAlAs diode laser that continuously emitted a wavelength of 660 nm with a power of 30 mW. The patients allocated for the group 30 received the following protocol for laser application: Two (2) points of irradiation were performed using a total energy density (fluence) of 30 J/cm2 and a time of 30 seconds (15 J/cm2 per point and an application time of 15 seconds per point). During irradiation, the tip of the laser probe was placed perpendicularly with slight contact on the area. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was repeated by six more applications performed every other day, with a total of 7 laser applications. The power of the equipment was calibrated prior to each application.
3116760|NCT02580591|Experimental|Empagliflozin low dose|
3116761|NCT02580591|Experimental|Empagliflozin high dose|
3116762|NCT02580591|Experimental|Empagliflozin medium dose|
3116763|NCT02580591|Placebo Comparator|Placebo|
3116764|NCT02580799||Breast Cancer Pathology Samples|Breast cancer pathology samples were evaluated for a period of 70 days.
3116765|NCT02580877|Experimental|67.5 mg oral insulin crystals daily|67.5 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given daily for six months
3116766|NCT02580877|Experimental|500mg oral insulin crystals every other week|500 mg oral insulin crystals in capsules (by mouth or sprinkled on food) given every other week for six months
3116767|NCT02581111|Experimental|Naloxone|Naloxone 8-mg IV given once after baseline ABG
3116768|NCT02581111|Sham Comparator|Placebo|Equivalent volume of saline given once
3116769|NCT02581137|Experimental|Prevention (extended-release metformin hydrochloride)|Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3116770|NCT02581163||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
3116771|NCT02581189||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
3116772|NCT02581202||HIV-1 infected participants|HIV-1-infected participants on any triple highly active antiretroviral therapy (HAART) with plasma HIV-1 ribonucleic acid (RNA) level < 50 copies/mL for at least 6 months (two consequently plasma HIV-1 RNA levels) transferred as medically appropriate to lopinavir with ritonavir plus lamivudine (LPV/r+3TC) as decided by the physician in the routine clinical settings. Or HIV-1 infected participants who were switched on the dual therapy (LPV/r+3TC) no more than 60 days prior to enrollment.
3116773|NCT02581345|Experimental|M923|Participants assigned to receive M923
3116774|NCT02581345|Active Comparator|Humira|Participants assigned to receive Humira
3116775|NCT02581345|Other|M923 and Humira|Participants assigned to receive M923 and Humira
3116776|NCT02581384|Experimental|Cohort 1 Dose Level 1 [Phase I]|Participants with Wilms tumors or other primary renal tumors. Stereotactic Body Radiotherapy (SBRT) Dose Levels for each target lesion are three 8 Gy fractions for 24 Gy total.
3116777|NCT02581384|Experimental|Cohort 1 Dose Level 2 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
3116778|NCT02581384|Experimental|Cohort 1 Dose Level 3 [Phase I]|Participants with Wilms tumors or other primary renal tumors. SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
3116779|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
3116780|NCT02581384|Experimental|Cohort 2 Dose Level 3 [Phase I]|Participants with Ewing sarcoma or rhabdomyosarcoma.SBRT Dose Levels for each target lesion are three 12 Gy fractions for 36 Gy total.
3116781|NCT02581384|Experimental|Cohort 2 Dose Level 2 [Phase II]|Participants with Ewing sarcoma or rhabdomyosarcoma. SBRT Dose Levels for each target lesion are three 10 Gy fractions for 30 Gy total.
3116782|NCT02581410|Experimental|GSK1437173A Group|Subjects ≥ 65 years of age who received Zostavax vaccine ≥ 5 years earlier and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
3116783|NCT02581410|Active Comparator|Control Group|Subjects ≥ 65 years of age who never received Zostavax vaccine and received 2 doses of the HZ/su vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
3116784|NCT02581475|Active Comparator|Group A|"Extending withdrawal time in the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then to the splenic flexure with an extended withdrawal time during colonoscopy.~From cecum to hepatic flexure, 1.5-2 min is required and 2.5-3 min is required from heptic flexure to splenic flexure."
3116785|NCT02581475|Experimental|Group B|Segmental examination twice of the proximal colon: After cecal intubation, the colonoscopy is withdrawn to the hepatic flexure and then the colonoscopy is intubated to the cecum again. The same procedure is performed in the colonic segment from hepatic flexure to splenic flexure. The withdrawal time in each colonic segment is similar to the group A.
3116786|NCT02581488|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks.
3116787|NCT02581488|Active Comparator|Product containing silver|Products containing silver will be applied per Investigator instructions and instructions for use/package insert for up to six weeks.
3116788|NCT02581839|Experimental|Eribulin Mesylate|The recommended starting dose of eribulin mesylate is 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
3116789|NCT02581865|Placebo Comparator|Placebo|Placebo administered once daily for 8 weeks
3116790|NCT02581865|Experimental|Dose Group 1|Fixed dose administered once daily for 8 weeks
3116791|NCT02581865|Experimental|Dose Group 2|Fixed dose administered once daily for 8 weeks
3116792|NCT02581891|Experimental|Early-start T&E / Arm 1|Early-start T&E arm: test group, early treatment individualization
3116793|NCT02581891|Active Comparator|Late-start T&E / Arm 2|Late-start T&E arm; per label, control group, treatment individualization after Year 1
3116794|NCT02581930|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3116795|NCT02581995|Experimental|Arm 1 / Quality of Life|Aflibercept treatment in subjects with diabetic macular edema (DME)
3116796|NCT02582151|Sham Comparator|Sham tibial nerve stimulation|Use of peripheral nerve stimulator in a location that will not actively stimulate the tibial nerve.
3116797|NCT02582151|Active Comparator|Tibial nerve stimulation|Transcutaneous peripheral nerve stimulator in a location that will actively stimulate the tibial nerve.
3116798|NCT02582216|Experimental|Open label|3D augmented reality
3116799|NCT02582242|Experimental|BIAsp 30 TID|
3116800|NCT02582242|Active Comparator|BIAsp 30 BID|
3116801|NCT02582255|Experimental|Sabin mOPV2 1 dose|IPV-vaccinated children to receive 1 dose of SABIN mOPV2 (Group 1)
3116802|NCT02582255|Experimental|SABIN mOPV2 2 doses|IPV-vaccinated children to receive 2 doses of SABIN mOPV2 (Group 2)
3116803|NCT02582515|Experimental|D-cycloserine + Habit Reversal Training|Participants randomly assigned to the D-cycloserine (DCS) condition will receive a single dose of DCS immediately prior to a single session of habit reversal training.
3116804|NCT02582515|Placebo Comparator|Placebo + Habit Reversal Training|Participants randomly assigned to the placebo condition will receive a single dose of placebo immediately prior to a single session of habit reversal training.
3116805|NCT02582632|Experimental|Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks
3116806|NCT02582658||Chronic infection of HCV GT1 or GT4|Participants with confirmed chronic hepatitis C genotype (GT) 1 or 4, receiving combination therapy with the interferon-free ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir +/- dasabuvir) ± Ribavirin (RBV) according to standard of care and in line with the current local label
3116807|NCT02582671||Participants with HCV genotype 1|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
3116808|NCT02582684|Experimental|Arm 1: DTG 50 mg + 3TC 300 mg|Dolutegravir 50mg and Lamivudine 300mg, orally daily
3116809|NCT02582814|Experimental|dapagliflozin 5mg + insulin|dapagliflozin tablet 5mg + adjustable insulin
3116810|NCT02582814|Experimental|dapagliflozin 10mg + insulin|dapagliflozin tablet 10mg + adjustable insulin
3116811|NCT02582840|Experimental|dapagliflozin 5mg|dapagliflozin tablet 5mg
3116812|NCT02582840|Experimental|dapagliflozin 10mg|dapagliflozin tablet 10mg
3116813|NCT02582840|Placebo Comparator|Placebo|dapagliflozin tablet 5mg placebo or 10 mg placebo
3116814|NCT02582866|Experimental|Lacosamide|"Lacosamide (LCM) will be administered orally twice daily from 200 mg/day to 600 mg/day (at approximately 12 hour intervals in the morning and in the evening) in 2 divided doses. Medication must not be chewed and must be swallowed with a sufficient amount of fluid. The investigator may maintain the subject's LCM dose, decrease the dose in decrements of 100 mg/day per week to a minimum dose of LCM 200 mg/day, or increase the dose in increments of 100 mg/day per week up to a maximum dose of LCM 600 mg/day.~Subjects stopping LCM should be tapered off LCM at recommended decreasing steps of 200 mg/day/week. A slower taper (eg, 100 mg/day/week) or faster taper is permitted, if medically necessary; however, the maximum duration of tapering should not exceed 6 weeks."
3116815|NCT02582970|Experimental|Bevacizumab + Chemotherapy|Participants will receive IV bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 2 weeks in combination with standard of care chemotherapy regimen (5-Fluorouracil/Irinotecan/Oxaliplatin) until disease progression or until termination of the study.
3116816|NCT02582983|Experimental|Enfuvirtide|Participants received Enfuvirtide 90 mg subcutaneously (SC) twice daily (BID).
3116817|NCT02583048|Experimental|Arm 1: Bedaquiline|"Participants received 400 mg of bedaquiline once a day for 2 weeks followed by 200 mg of bedaquiline three times a week for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
3116818|NCT02583048|Experimental|Arm 2: Delamanid|"Participants received 100 mg of delamanid twice a day for 24 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
3116819|NCT02583048|Experimental|Arm 3: Bedaquiline and Delamanid|"Participants received 400 mg of bedaquiline once a day and 100 mg of delamanid twice a day for 2 weeks. They then received 200 mg of bedaquiline three times a week and 100 mg of delamanid twice a day for 22 weeks.~Participants also received Multidrug Background Treatment (MBT) for TB.~For HIV-positive participants only, one 50 mg tablet of Dolutegravir was taken in combination with two NRTIs until study completion."
3116820|NCT02583230|Experimental|MedLink|For 8 weeks, the patient who is newly prescribed antidepressant medication will receive a mobile phone app (and a phone if they do not have a compatible Android phone) and a GSM enable pill bottle in order to provide and receive feedback regarding medication adherence.
3116821|NCT02583256|Experimental|aQIV/aQIV|Subjects previously vaccinated with aQIV followed one year later by aQIV
3116822|NCT02583256|Experimental|aQIV/QIV|Subjects previously vaccinated with aQIV followed one year later by QIV
3116823|NCT02583256|Experimental|QIV/aQIV|Subjects previously vaccinated with QIV followed one year later by aQIV
3116824|NCT02583256|Experimental|QIV/QIV|Subjects previously vaccinated with QIV followed one year later by QIV
3116825|NCT02583269|Experimental|Arm 1 (muscadine grape skin extract) 1 pill 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
3116826|NCT02583269|Experimental|Arm 2 (muscadine grape skin extract) 2 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
3116827|NCT02583269|Experimental|Arm 3 (muscadine grape skin extract) 3 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
3116828|NCT02583269|Experimental|Arm 4 (muscadine grape skin extract) 4 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
3116829|NCT02583269|Experimental|Arm 5 muscadine grape skin extract) 5 pills 2 times a day|Patients receive muscadine grape skin extract PO BID. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing benefit from muscadine grape skin extract may continue treatment in the absence of disease progression or unacceptable toxicity.
3116830|NCT02583360|Active Comparator|Study|Eligible subjects (study) will undergo diagnostic VFSS in combination with manometry, either concurrent or sequential. They will have parental choice of preferred feeding therapy.
3116831|NCT02583360|No Intervention|Control|Eligible subjects who had VFSS alone with provider recommendations from the same single center.
3116832|NCT02583399|Experimental|Ibuprofen|Ibuprofen, 10 mg/kg
3116833|NCT02583425|Experimental|DFN-11|DFN-11 Injection upon occurrence of migraine
3116834|NCT02583477|Experimental|MEDI4736 +nab-paclitaxel + gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
3116835|NCT02583477|Experimental|MEDI4736+AZD5069|MEDI4736 via IV infusion and oral AZD5069
3116836|NCT02584140|Other|AEGIS|All participants will be assigned to this arm of the study.
3116837|NCT02584257|Placebo Comparator|Placebo dose|Placebo dose: 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols and one actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
3116838|NCT02584257|Active Comparator|90 mcg ProAir HFA|90 mcg of ProAir HFA: 1 actuation each from ProAir HFA inhalation aerosol and the placebo ProAir HFA inhalation aerosol and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
3116839|NCT02584257|Active Comparator|180 mcg ProAir HFA|180 mcg of ProAir HFA: 1 actuation each from 2 different ProAir HFA inhalation aerosols and 1 actuation each from 2 different placebo Lupin albuterol HFA MDI inhalation aerosols
3116840|NCT02584257|Experimental|90 mcg Lupin albuterol HFA MDI|90 mcg of Lupin albuterol HFA MDI product: 1 actuation each from the Lupin albuterol HFA MDI inhalation aerosol and the placebo Lupin albuterol HFA MDI inhalation aerosol and 1 actuation each from 2 different placebo ProAir HFA inhalation aerosols
3116841|NCT02584257|Experimental|180 mcg Lupin albuterol HFA MDI|180 mcg of Lupin albuterol HFA MDI: 1 actuation each from 2 different Lupin albuterol HFA MDI inhalation aerosols and 1 actuation each from 2 different placebo ProAir HFA product inhalation aerosols
3116842|NCT02584452|Active Comparator|Continuous Adductor Canal Nerve Catheter|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal continuous nerve catheter using normal saline bolus followed by 1/8% bupivacaine infusion through catheter at 8cc/h.
3116843|NCT02584452|Active Comparator|Long Acting Single Bolus Adductor Canal Nerve Block|Ultrasound guided femoral nerve block with 20cc of 2% mepivacaine <20 minutes prior to in room time. Intraoperative patients will undergo initiation of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert this group will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine and 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve.
3132439|NCT03426995|Placebo Comparator|Placebo, Part C|The subjects in this cohort will receive a matching placebo to GSK3358699, Part C, as a single oral dose once daily for 14 consecutive days. The subjects in this arm will constitute 3 cohorts each (cohort 4 to 6), where the subjects will receive placebo, as one repeat dose treatment once daily for 14-consecutive days. Subjects will have control blisters induced on the forearm (0.2% cantharidin) on Day -10. On the Day 14 of each cohort, each subject will receive an intravenous in vivo LPS challenge at a dose not exceeding 0.75 nanogram per kilogram or an intravenous infusion of GM-CSF, in vivo as 60 microgram per meter^2. The administration of LPS or GM CSF will be followed by blister induction on forearm (0.2 % cantharidin).
3116844|NCT02584504|Experimental|Alirocumab 150 mg Q4W|Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)
3116845|NCT02584504|Experimental|Alirocumab 150 mg Q2W|In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
3116846|NCT02584504|Placebo Comparator|Placebo Q2W|In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
3116847|NCT02584608|Experimental|Treatment|ACTIMMUNE 50 µg/m2 subcutaneously three times per week (TIW) for 8 weeks
3116848|NCT02584660|Experimental|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.
3116849|NCT02584660|Experimental|local Standard-of-care|Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.
3116850|NCT02584673|Experimental|CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
3116851|NCT02584673|No Intervention|Control|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
3116852|NCT02584686|Experimental|(BTX) A Group|The treatment group will be injected intracavernously with a trimix solution for colour Doppler assessment, followed, on a separate day by 50 units of Botulinum toxin (BTX) A.
3116853|NCT02584686|Placebo Comparator|Saline Group|The control group, 12 patients, will be injected with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) during penile colour Doppler assessment followed on a separate day with a normal saline injection.
3116854|NCT02584725|Active Comparator|5 mg/kg/dose tranexamic acid|5 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
3116855|NCT02584725|Active Comparator|10 mg/kg/dose tranexamic acid|10 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
3116856|NCT02584725|Active Comparator|15 mg/kg/dose tranexamic acid|15 mg/kg tranexamic acid IV, administered twice, once 20 minutes prior to surgical incision and once at when surgical wound closure begins
3116857|NCT02584790|Other|Post radiotherapy 8 weeks NPC patient|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
3116858|NCT02584855|Experimental|Ixekizumab Open Label|Open-Label Treatment Period: Starting dose of 160 milligrams (mg) ixekizumab given as two subcutaneous (SC) injections at baseline (week 0) followed by 80 mg given as one SC injection every two weeks (Q2W) from week 2 to randomization (week 36 to 64).
3116859|NCT02584855|Experimental|Ixekizumab|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: 80 mg ixekizumab given as one SC injection Q2W from randomization to week 104 (or, early termination or relapse)."
3116860|NCT02584855|Placebo Comparator|Placebo|"Participants completed open label and met criteria for randomization to the double-blind Withdrawal Period.~Double-Blind Withdrawal Period: Placebo given as one SC injection Q2W any time from randomization to week 104 (or, early termination or relapse)"
3116861|NCT02584855|Experimental|IXE80Q2W Non-randomized|"Participants completed open label but did not meet criteria for randomization to the double-blind Withdrawal Period.~Participants continued to receive 80 mg given as one SC injection every two weeks during the double-blind withdrawal period."
3116862|NCT02584868|Experimental|Volulyte|Investigational drug: HES 130/0.4 (6%) in an isotonic electrolyte solution (brand name=Volulyte®)
3116863|NCT02584868|Active Comparator|Voluven|Control drug: HES 130/0.4 (6%) in sodium chloride 0.9% (brand name=Voluven®)
3116864|NCT02584959|Experimental|Experimental/Placebo|Subjects will be randomized to receive C1 Esterase Inhibitor in the 1st Treatment period and then switch to Placebo in the 2nd treatment period.
3116865|NCT02584959|Experimental|Placebo/Experimental|Subjects will be randomized to receive a placebo treatment in the 1st Treatment period and then switch to receive C1 Esterase Inhibitor in the 2nd treatment period.
3116866|NCT02584959|Experimental|Experimental/ Experimental|Subjects will be randomized and receive C1 Esterase Inhibitor in both 1st as well as the 2nd treatment period
3132440|NCT03427073|Experimental|Solid tumours|"Part 1 - Dose-escalation of ALM201 in patients with advanced solid tumours~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle. Escalating dose cohorts"
3116867|NCT02584998|No Intervention|Usual care|These patients will continue to receive the current practice at the Philadelphia VA Medical Center (VAMC) of offering screening during an office visit. Other interventions will be embedded within this existing program for a pragmatic approach. However, all participants in the trial, including those in usual care (UC), will receive follow-up of test results and navigation to diagnostic colonoscopy for positive FIT results.
3116868|NCT02584998|Active Comparator|Screening invitation-reminder|Participants will receive UC and also receive an invitation letter with information about CRC testing. The information will include lay-audience description of screening tests and symptoms that should prompt diagnostic work-up. The packet will have instructions to contact the study team if participants believe they are not eligible and to update the contact information on record. The letter will inform participants that a telephone reminder will follow in 4 weeks from invitation letter if screening is not completed. They will also receive notification of test results and navigation to colonoscopy, if needed. For the purposes of this intervention, Week 1 will be the week the invitation letter was sent (time zero).
3116869|NCT02584998|Active Comparator|Mailed-FIT|Participants randomized to Mailed-FIT will receive a mailed FIT pre-notification letter (plus a screening invitation) followed by the kit 1 week later. Participants will receive instructions to contact the study team if they believe they are not eligible and to update their contact information. They will be informed that a telephone reminder will follow 4 weeks from notification letter if screening is not completed. Participants who do not return their kit within 4 weeks after their pre-notification letter was mailed will receive a live telephone reminder, followed by 2 additional calls at the end of weeks 5 and 6, if needed. For the purposes of this intervention, Week 1 will be the week the pre-notification letter was sent (time zero).
3116870|NCT02585232|Active Comparator|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment - much like an interview guide - which then immediately shapes development of concrete action plans."
3116871|NCT02585232|Experimental|Care Consultation + Counseling (CC+C)|Care Consultation + Counseling (CC+C): is consistent with the original CC protocol in that the therapist partners with each dyad in a patient-centered way to prioritize unmet needs as identified during the CC initial assessment. Once this phase has been completed, typically within the first 2 sessions, the CC+C therapist will determine when to initiate counseling sessions targeting 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.). The counseling component of the CC+C intervention incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework.
3116872|NCT02585245||NRS2002 Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
3116873|NCT02585245||ThedaCare RD/RN Nutrition Risk Screen|Patients identified at HIgh, medium or Low Risk in Hospitalized patients. Determining accuracy of identifiying patients affected by malnutrition.
3116874|NCT02585700|Experimental|Vaccine|"0.5 mL of influenza vaccine, split, inactivated with 15 mcg of haemagglutination (HA) of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~X-181 reassortant of H1/A/California/7/2009~X-223A reassortant of H3/A/Texas/50/2012."
3116875|NCT02585700|Placebo Comparator|Placebo|0.5 mL of phosphate buffered saline
3116876|NCT02585713|Experimental|Arm I (apixaban)|Patients receive apixaban 10 mg PO BID on days 1-7 and lower-dose apixaban 5 mg PO BID on days 8-180.
3116877|NCT02585713|Experimental|Arm II (dalteparin)|Patients receive dalteparin 200 IU/kg/day SC QD on days 1-30 and lower-dose dalteparin 150 IU/kg/day SC QD on days 31-180.
3116878|NCT02585778|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to stable, maximally tolerated dose of statin therapy with or without other lipid-modifying therapy (LMT), insulin alone or with other antihyperglycemic drugs for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C levels ≥70 mg/dL (1.81 mmol/L) at Week 8.
3116879|NCT02585778|Placebo Comparator|Placebo Q2W|Placebo (for alirocumab) SC injection Q2W added to stable, maximally tolerated dose of statin therapy with or without other LMT, insulin alone or with other antihyperglycemic drugs for 24 weeks.
3116880|NCT02585843|Experimental|High-dose|Spironolactone 100mg: 100mg/day of spironolactone (2 capsules), PO (oral) for 7 days
3116881|NCT02585843|Active Comparator|Standard of Care|Spironolactone 25mg: 25mg/day of spironolactone, PO (oral)
3116882|NCT02585895|Experimental|Evolocumab|Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
3116883|NCT02585895|Active Comparator|Low Density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants continued apheresis at the same schedule, every week (QW) or every two weeks (Q2W), as prior to study entry, for the first 6 weeks. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
3116884|NCT02585934|Experimental|RVT-101|RVT-101 adjunct to 5 mg or 10 mg donepezil
3116885|NCT02585934|Placebo Comparator|Placebo|Placebo adjunct to 5 mg or 10 mg donepezil
3116886|NCT02585960|Experimental|Pharmacokinetic (PK) evaluation of BAX 855|Participants will first undergo an initial pharmacokinetic (PK) assessment. Following the PK assessment participants will be randomized to one of 2 dosing regimens.
3116887|NCT02585960|Experimental|FVIII trough target 1-3%|Standard treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 1-3%
3116888|NCT02585960|Experimental|FVIII trough target 8-12%|Intensified treatment arm - PK-guided dosing schedule to achieve a Factor VIII (FVIII) trough of 8-12%
3116889|NCT02585999|Other|Xulane|All participants using the Xulane contraceptive patch for 12 continuous weeks
3132441|NCT03427073|Experimental|Ovarian cancer|"Part 2 - Dose-expansion of ALM201 Maximum Tolerated Dose (MTD) in patients with advanced ovarian cancer~Daily dosing of ALM201 on Days 1-5, 8-12 and 15-19 of 21 day cycle at the MTD determined in Part 1"
3116890|NCT02586012|Experimental|TBW, LBM, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on IBW (Ideal Body Weight).
3116891|NCT02586012|Experimental|LBM, IBW, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on TBW (Total Body Weight).
3116892|NCT02586012|Experimental|IBW, TBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on IBW (Ideal Body Weight); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
3116893|NCT02586012|Experimental|TBW, IBW, LBM|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on TBW (Total Body Weight); Week 2, the dose will be based on IBW (Ideal Body Weight); and Week 3, the dose will be based on LBM (Lean Body Mass).
3116894|NCT02586012|Experimental|LBM, TBW, IBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on LBM (Lean Body Mass); Week 2, the dose will be based on TBW (Total Body Weight); and Week 3, the dose will be based on IBW (Ideal Body Weight).
3116895|NCT02586012|Experimental|IBW, LBM, TBW|Subjects will be randomized to receive rFVIII doses calculated by 3 separate methods over a 3 week period. Week 1, the dose will be based on, IBW (Ideal Body Weight); Week 2, the dose will be based on LBM (Lean Body Mass); and Week 3, the dose will be based on TBW (Total Body Weight).
3116896|NCT02586025|Experimental|Trastuzumab, Pertuzumab, Docetaxel|Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.
3116897|NCT02586025|Experimental|Trastuzumab, Placebo, Docetaxel|Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.
3116898|NCT02586064|Experimental|Interpersonal Psychotherapy for PTSD|Relationally-focused intervention addressing PTSD symptoms and relationship dysfunctions, 12 weekly sessions
3116899|NCT02586064|Active Comparator|Prolonged Exposure|Exposure based intervention including exposure to memories and avoided places and activities
3116900|NCT02586077|Experimental|Exparel|Patients will receive a single shot popliteal block (standard of care) and then undergo their standardized procedure. Patients will then receive 20cc Exparel and 10cc of normal saline at the conclusion of the case.
3116901|NCT02586155|Experimental|High-Intensity statin therapy+RVX000222|Daily dose 100 mg capsule b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
3116902|NCT02586155|Active Comparator|High-Intensity statin therapy+Placebo|Placebo (for RVX000222 100 mg capsule) b.i.d. with high-intensity statin therapy (atorvastatin or rosuvastatin)
3116903|NCT02586207|Experimental|Single Arm|Pembrolizumab + Cisplatin + Radiation
3116904|NCT02586233|Experimental|DS-1040b|Participants who will be randomized to receive intravenous (IV) infusion of DS-1040b ranging from 0.6 mg to 9.6 mg.
3116905|NCT02586233|Placebo Comparator|Placebo|Participants who will be randomized to receive intravenous (IV) infusion of placebo.
3116906|NCT02586415|Active Comparator|endovascular thrombectomy therapy|"Treatment with one or more thrombectomy devices (only the devices listed in this protocol are approved for use in DEFUSE 3) plus standard medical therapy for patients who have evidence of an ICA or MCA M1 occlusion and a Target Mismatch Profile.~Devices approved for use in DEFUSE 3:~Trevo Retriever~Solitaire™ FR Revascularization Device~Penumbra thrombectomy system~Covidien MindFrame Capture Revascularization Device"
3116907|NCT02586415|No Intervention|Medical Management|standard medical therapy alone
3116908|NCT02586493|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
3116909|NCT02586506|Experimental|Placebo ELLIPTA inhaler|Subjects will be provided the ELLIPTA inhaler, which is a molded plastic two-sided inhaler that holds two individual blister strips containing either lactose or a blend of lactose and magnesium stearate. Subjects will continue to use regular COPD medications throughout the study as per protocol.
3116910|NCT02586675|Experimental|Tamoxifen and Ribociclib with Goserelin|Phase I dose escalation followed by Phase Ib dose expansion. Tamoxifen and Ribociclib, with Goserelin added for premenopausal or peri-menopausal participants. Ribociclib: Capsules/Tablets for oral use 400 mg OR 600 mg Days 1-21 of each 28 day cycle or daily. Tamoxifen: Tablets for oral use 20 mg daily (all days of every cycle without interruption). Goserelin: Subcutaneous injection 3.6 mg Day 1 of each 28 day cycle.
3116911|NCT02586727|Active Comparator|six week dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, and then again every six weeks. Treatment will be given at each visit.
3116912|NCT02586727|Active Comparator|treat and extend dosing regimen arm|Patients will receive an intravitreal aflibercept injection the first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward. Patients with decreased radiation maculopathy by one grade or more will extend re-evaluation by two weeks. Patients with increased radiation maculopathy by one grade or more will have re-evaluation decreased by one week. Patients that show no maculopathy grade change will remain at the same re-evaluation interval.
3116913|NCT02586805|Experimental|DX-2930 300 mg every 2 weeks|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
3116914|NCT02586805|Experimental|DX-2930 300 mg every 4 weeks|300 mg DX-2930 administered every 4 weeks by subcutaneous injection
3116915|NCT02586805|Experimental|DX-2930 150 mg every 4 weeks|150 mg DX-2930 administered every 4 weeks by subcutaneous injection
3116916|NCT02586805|Placebo Comparator|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
3116917|NCT02586857|Experimental|Cohort 1|ACP-196 200 mg administered orally (PO) twice per day (BID)
3116918|NCT02586857|Experimental|Cohort 2|ACP-196 400mg administered orally (PO) once per day (QD).
3132442|NCT03427177|Experimental|Treatment|Participants randomized to the treatment arm of the study will be given the mychoice tool.
3116919|NCT02586896|Experimental|Strengths-based Case Management (SBCM)|The structure of SBCM follows the widely accepted functions of case management-assessment, planning, linking, monitoring and advocacy-and the theory-driven gestalt of the strengths perspective. Strengths-based principles include an emphasis on client strengths, teaching clients a method for setting and completing goals, and development of a strong working alliance.
3116920|NCT02586896|Active Comparator|Screening, Assessment and Referral (SAR)|Following randomization, participants in the SAR condition will be provided with minimal scripted feedback to let them know that their assessment indicates substance dependence, and given a recommendation to seek treatment.
3116921|NCT02586909|Experimental|RVT-101 35 mg tablets|once daily, oral tablets
3116922|NCT02586974|Experimental|Group H+WB|32 patients will receive warmed, humidified CO2 insufflation with the Humigard® device, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger®)
3116923|NCT02586974|No Intervention|Group WB|32 patients will receive standard CO2 insufflation, along with the hot air warming blanket used as a routine in our institution (forced air warming blanket at 38°C : Bear Hugger® and a standard insufflation with non-humidified, non-heated CO2)
3116924|NCT02587065|Experimental|peginterferon beta-1a|125 μg administered subcutaneously (SC) every 2 weeks
3116925|NCT02587117|Experimental|lycopene group|Lycopene- 4 mg capsule by mouth single dose per day for 2 months
3116926|NCT02587117|Active Comparator|Prednisolone group|Prednisolone- 40 mg capsule by mouth single dose per day for 2 months
3116927|NCT02587143|Active Comparator|Control|Alcohol -based spray as placebo will be administrated before arterial puncture.
3116928|NCT02587143|Experimental|Ethyl chloride|Ethyl choride will be administrated before arterial puncture.
3116929|NCT02587221|Experimental|aQIV|MF59-adjuvanted Quadrivalent Influenza Vaccine (aQIV)
3116930|NCT02587221|Placebo Comparator|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine
3116931|NCT02587234|Experimental|Active|2 hours of active peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
3116932|NCT02587234|Sham Comparator|Sham PNS|2 hours of sham peripheral nerve stimulation paired with 4 hours of intensive task-oriented upper extremity training
3116933|NCT02587351|Active Comparator|Metoprolol succinate|Metoprolol succinate extended release tablets (50 mg) starting dose followed by a dose titration procedure which will result in a final dose of 25mg (1/2 of one tablet daily), 50 mg, or 100 mg (two tablets daily).
3116934|NCT02587351|Placebo Comparator|Placebo|Matched placebo
3116935|NCT02587520|Experimental|Adolescents: SP0173 Formulation 1|Healthy participants aged 10-18 years received a single dose of the SP0173 Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap) vaccine.
3116936|NCT02587520|Experimental|Adolescents: SP0173 Formulation 2|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
3116937|NCT02587520|Experimental|Adolescents: SP0173 Formulation 3|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
3116938|NCT02587520|Experimental|Adolescents: SP0173 Formulation 4|Healthy participants aged 10-18 years received a single dose of the SP0173 Tdap vaccine.
3116939|NCT02587520|Active Comparator|Adolescents: Adacel®|Healthy participants aged 10-18 years received Adacel®.
3116940|NCT02587520|Active Comparator|Adolescents: Boostrix®|Healthy participants aged 10-18 years received Boostrix®.
3116941|NCT02587520|Experimental|Adults: SP0173 Formulation 1|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
3116942|NCT02587520|Experimental|Adults: SP0173 Formulation 2|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
3116943|NCT02587520|Experimental|Adults: SP0173 Formulation 3|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
3116944|NCT02587520|Experimental|Adults: SP0173 Formulation 4|Healthy participants aged 19-64 years received a single dose of the SP0173 Tdap vaccine.
3116945|NCT02587520|Active Comparator|Adults: Adacel®|Healthy participants aged 19-64 years received Adacel®.
3116946|NCT02587520|Active Comparator|Adults: Boostrix®|Healthy participants aged 19-64 years received Boostrix®.
3116947|NCT02587520|Experimental|Older Adults: SP0173 Formulation 1|Healthy participants aged greater than equal to (>=65) years received a single dose of the SP0173 Tdap vaccine.
3116948|NCT02587520|Experimental|Older Adults: SP0173 Formulation 2|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
3116949|NCT02587520|Experimental|Older Adults: SP0173 Formulation 3|Healthy participants aged >=65 years received a single dose of the SP0173 Tdap vaccine.
3116950|NCT02587520|Experimental|Older Adults: SP0173 Formulation 4|Healthy participants aged >= 65 years received a single dose of the SP0173 Tdap vaccine.
3116951|NCT02587520|Active Comparator|Older Adults: Adacel®|Healthy participants aged >=65 years received Adacel®.
3116952|NCT02587520|Active Comparator|Older Adults: Boostrix®|Healthy participants aged >=65 years received Boostrix®.
3116953|NCT02587819|Experimental|Treatment with BSCT|21 patients with BCC were treated with BSCT (anti-nf-P2X7) 10% Ointment topically applied twice daily for 28 consecutive days.
3116954|NCT02587962|Experimental|Birinapant in combination with pembrolizumab|Birinapant in combination with pembrolizumab
3116955|NCT02588092|Experimental|Part 1: ADCT-301 (dose escalation)|"Weekly administration - Participants will receive an IV infusion of ADCT-301, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-301, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
3116956|NCT02588092|Experimental|Part 2: ADCT-301 (dose expansion)|Participants will be assigned to receive the recommended dose and/or schedule of ADCT-301 as determined by the Dose Escalation Steering Committee.
3116957|NCT02588261|Experimental|ASP8273|Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
3116958|NCT02588261|Active Comparator|erlotinib or gefitinib|Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).
3116959|NCT02588339|Experimental|Panobinostat (PANO) Therapy|Participants will be treated with standard of care chemotherapy agents prior to their allogeneic hematopoietic cell transplant. For Graft Versus Host Disease (GVHD) prevention, participants will receive PANO, Sirolimus and Tacrolimus.
3116960|NCT02588573|Active Comparator|Etafilcon A (control)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
3116961|NCT02588573|Active Comparator|Somofilcon A (test)|Subjects in each of the habitual wearing groups will be randomized to wear either the test or control lens in either the left or right eye.
3116962|NCT02588586|Experimental|3BNC117 + ART Interruption|Four intravenous infusions of 3BNC117 (30mg/kg) at weeks 0, 12, 24 and 27, and antiretroviral treatment interruption (ART)at week 24.
3116963|NCT02588599|Experimental|Erchonia LUNULA|The Erchonia LUNULA emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
3116964|NCT02588612|Experimental|letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
3116965|NCT02588664|No Intervention|Usual Care|Participating hospitals randomized to the usual care group will provide their usual, post-acute stroke care to their patients.
3116966|NCT02588664|Active Comparator|COMPASS Intervention|Participating hospitals randomized to the intervention will change the structure and process for delivery of post-acute stroke care.
3116967|NCT02588833|Experimental|Cohort 1|180 mg pegcetacoplan/day
3116968|NCT02588833|Experimental|Cohort 2|270 mg pegcetacoplan/day
3116969|NCT02588872|Active Comparator|Hyaluronic Acid (HA)|Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
3116970|NCT02588872|Experimental|Platelet-rich Plasma (PRP)|Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
3116971|NCT02588976|Other|ACT measurements|ACT measurements by SONOCLOT Analyzer during cardiac surgery
3116972|NCT02589067|Experimental|Experimental|Randomized to 15mL 0.12% Chlorhexidine Gluconate oral rinse, to be used twice daily for 60 seconds for 7 days.
3116973|NCT02589067|Placebo Comparator|Placebo|Randomized to 15mL saline placebo oral rinse, to be used twice daily for 60 seconds for 7 days.
3116974|NCT02589171|Experimental|Neo Close Abdominal Closure|
3116975|NCT02589171|Active Comparator|Carter Thomason Device|
3116976|NCT02589405|Experimental|Benzaknen treatment regimen|Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
3116977|NCT02589626|Experimental|empagliflozin 10 mg|empagliflozin 10 mg tablet and placebo matching empagliflozin 25 mg tablet
3116978|NCT02589626|Experimental|empagliflozin 25 mg|empagliflozin 25 mg tablet and placebo matching empagliflozin 10 mg tablet
3116979|NCT02589639|Experimental|empagliflozin 10 mg|
3116980|NCT02589639|Experimental|empagliflozin 25 mg|
3116981|NCT02589639|Placebo Comparator|placebo|
3116982|NCT02589665|Experimental|50 mg Mirikizumab IV Q4W (Induction)|50 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period. Participants who do not have a clinical response may choose to participate in the unblinded study extension period.
3116983|NCT02589665|Experimental|200 mg Mirikizumab IV Q4W (induction)|"200 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
3116984|NCT02589665|Experimental|600 mg Mirikizumab IV Q4W (Induction)|"600 mg mirikizumab administered every 4 weeks (Q4W) intravenously (IV) during the induction period.~Participants who do not have a clinical response may choose to participate in the unblinded study extension period."
3116985|NCT02589665|Placebo Comparator|Placebo IV Q4W (Induction)|Placebo administered every 4 weeks (Q4W) intravenously (IV) during the induction period.
3116986|NCT02589665|Experimental|200 mg Mirikizumab SC Q4W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) Q4W during the maintenance period.
3116987|NCT02589665|Experimental|200 mg Mirikizumab SC Q12W (Maintenance)|Induction mirikizumab responders were re-randomized: 200 mg mirikizumab administered subcutaneously (SC) once every 12 weeks (Q12W) during the maintenance period.
3116988|NCT02589665|Placebo Comparator|Placebo SC Q4W (Maintenance)|Induction placebo responders: Placebo administered subcutaneously (SC) Q4W during the maintenance period.
3116989|NCT02589665|Experimental|600mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 600 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
3116990|NCT02589665|Experimental|1000mg Mirikizumab IV Q4W Extension Open-Label|Induction non-responders: 1000 mg mirikizumab administered intravenously (IV) once every 4 weeks (Q4W) during the Extension Open-Label.
3116991|NCT02589665|Experimental|200mg Mirikizumab SC Q4W Extension Open-Label|Extension Induction responders: 200 mg mirikizumab administered subcutaneously (SC) once every 4 weeks (Q4W) during the Extension Open-Label
3116992|NCT02589808|Experimental|Full TTE|Full echocardiogram.
3116993|NCT02589808|Experimental|VScan|Handheld echocardiogram.
3116994|NCT02589847|Experimental|RBX2660 Open-label|RBX2660 (microbiota suspension)
3116995|NCT02589847|Other|Historical control antibiotics|Retrospective Historical Control with standard of care
3116996|NCT02589977|Other|normal participants|"No cardiovascular abnormalities or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
3116997|NCT02589977|Other|hypertensive participants|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
3116998|NCT02589977|Other|HFpEF patients|"No history of coronary artery disease or diabetes. Estimated glomerular filtration rate (eGFR) >60.~Studies: Echocardiography for left ventricular function and LV diastolic performance; cardiac magnetic resonance (CMR) imaging using gadolinium for LV fibrosis and regadenoson for myocardial blood flow (MBF); positron-emission tomography (PET) using regadenoson for MBF and 11C-acetate for oxidative metabolism."
3116999|NCT02590003|Experimental|Platinum-based doublet chemotherapy|"Carboplatin AUC 5 30 minute infusion IV on day 1~Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle"
3117000|NCT02590003|Active Comparator|Single agent chemotherapy|-Nab-paclitaxel 100mg/mg2 30 minute infusion IV on days 1, 8 of a 21 day cycle
3117001|NCT02590354|Experimental|Treatment interruption|The ART treatment in patients with a very low viral reservoir will be interrupted.
3117002|NCT02590406|Active Comparator|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
3117003|NCT02590406|Experimental|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
3117004|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Open Label)|LINZESS® (linaclotide) 145 μg capsules, orally, once daily for up to 52 weeks for participants with CIC. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
3117005|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Open Label)|LINZESS® 290 μg capsules, orally, once daily for up to 52 weeks for participants with IBS-C. If an intolerable AE occurred participants could be randomized to the Double-blind Treatment Period.
3117006|NCT02590432|Experimental|LINZESS® 290 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 290 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
3117007|NCT02590432|Experimental|LINZESS® 145 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was reduced to Open Label 72 μg, if applicable.
3117008|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with IBS-C. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
3117009|NCT02590432|Experimental|LINZESS® 145 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 145 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was reduced to 72 μg, if applicable.
3117010|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Double Blind)|Following participation in the Open Label Treatment Period, LINZESS® 72 μg capsules, orally, once daily from double-blind randomization up to Week 52 for participants with CIC. If an intolerable AE occurred, dose was maintained at Open Label 72 μg, if applicable.
3117011|NCT02590432|Experimental|LINZESS® 72 μg (CIC, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with CIC.
3117012|NCT02590432|Experimental|LINZESS® 72 μg (IBS-C, Dose-reduced Open Label)|Following participation in the Double-blind Treatment Period, if an intolerable AE occurred, LINZESS® 72 μg capsules, orally, once daily up to Week 52 for participants with IBS-C.
3117013|NCT02590562||RA patients treated with routine clinical practice|Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)
3117014|NCT02590588|Experimental|Idelalisib|Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.
3117015|NCT02590939|Experimental|Active device|60 minutes of active external trigeminal nerve stimulation with a CEFALY Active device
3117016|NCT02590939|Sham Comparator|Sham device|60 minutes of placebo external trigeminal nerve stimulation with a CEFALY Placebo device
3117017|NCT02591056|Experimental|Erchonia Verju Laser + Green PRESS 8|All subjects receive 12 combination treatments over 6 weeks (two per week) with the Erchonia® Verju™ Laser and the Green PRESS 8 devices simultaneously.
3117018|NCT02591238|Placebo Comparator|non-smoker + placebo|non-smoker oral placebo
3117019|NCT02591238|Active Comparator|non-smoker + melatonin|non-smoker oral melatonin
3117020|NCT02591238|Placebo Comparator|smoker + placebo|smoker oral placebo
3117021|NCT02591238|Active Comparator|smoker + melatonin|smoker oral melatonin
3117022|NCT02591290|Experimental|Menactra® Vaccine|Participants received 2-dose series of the study vaccine with 8-week interval.
3117023|NCT02591511|Experimental|health-education app|Smart phone and pad is a stroke-related health education app intervention group
3117024|NCT02591511|Active Comparator|health education manuals|stroke-related health education manual control group
3117025|NCT02591537|Experimental|OxyGenesys Dissolved Oxygen Dressing|OxyGenesys Dissolved Oxygen Dressing will be applied.
3117026|NCT02591537|No Intervention|Standard Tegaderm Dressing|Tegaderm will be applied.
3117027|NCT02592018|Experimental|Secukinumab|All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.
3117028|NCT02592421|Active Comparator|Dapagliflozin|20 subjects will receive dapagliflozin 10mg
3117029|NCT02592421|Placebo Comparator|Placebo|10 subjects will receive placebo
3117030|NCT02592434|Experimental|CP-690,550|Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights
3117031|NCT02592434|Placebo Comparator|Placebo|Control arm: matching placebo tablets or solution for tofacitinib
3117032|NCT02592447|Experimental|Cognitive Behavior Therapy (CBT)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions.
3117033|NCT02592447|Other|Wait-List Control Condition (WLC)|Wait-List Control Condition (WLC) group will not receive therapy sessions and will continue usual care with their providers. This group will be offered the same cognitive behavior therapy as the group receiving the CBT-TTF intervention, after the 18 week study period.
3117034|NCT02592486|Active Comparator|Simultaneous administration group|The subjects receive injections of pneumococcal vaccine and influenza vaccine simultaneously. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016 season.
3117035|NCT02592486|Active Comparator|Sequential administration group|The subjects receive injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine. We use commercially available PPV23 (Pneumovax NP®, MSDKK, Tokyo, Japan) containing 25 μg each of 23 capsular polysaccharide types. We use Fluvic HA syringe® (Handai Biken Ltd, Osaka, Japan), quadrivalent influenza vaccine (0.5ml) of 2015/2016.
3117036|NCT02592629|Active Comparator|no topical or subcutaneous anesthetic|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine
3117037|NCT02592629|Active Comparator|subcutaneous lidocaine|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after 2 ml or 1% lidocaine by subcutaneous injection
3117038|NCT02592629|Active Comparator|topical ethyl chloride|Injection of 1 ml of 40 mg Kenalog combined with 4 ml of 1% lidocaine after applying ethyl chloride spray for 3 seconds
3117039|NCT02592655|Active Comparator|Pneumatic Tourniquet|All participants randomly allocated to receive all interventions. Pneumatic Tourniquet: The Automatic Tourniquet System (ATS) 1500 by Zimmer (formerly Aspen Labs) is a pneumatic tourniquet that is typically used in surgical settings, and is representative of best outcome under the ideal circumstances of a controlled environment. The 10 cm (4 inch) wide cylindrical cuff was used for all participants.
3117040|NCT02592655|Active Comparator|Windlass Tourniquet|Windlass Tourniquet with a 3.8 cm (1.5 inch) wide strap is representative of the typical use device in civilian prehospital and military combat environments. In accordance with current prehospital guidelines: If distal perfusion is observed after One Windlass Tourniquet is applied then a second windlass tourniquet will be applied immediately proximal to the first windlass tourniquet so that the participant has Two Windlass Tourniquets applied.
3117041|NCT02592655|Experimental|Tourniquet Tape 10 cm|Tourniquet Tape 10 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
3117042|NCT02592655|Experimental|Tourniquet Tape 5 cm|Tourniquet Tape 5 cm wide is a highly elastic transparent occlusive tape that is expected to create sufficient circumferential pressure to occlude arterial blood flow when tightly wrapped around a limb. The tape should be applied in mostly overlapping layers. The final wrap should be applied without tension to prevent the elastic tension from causing the tape to unwind itself.
3117043|NCT02592798|Experimental|Abatacept|"Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
3117044|NCT02592798|Placebo Comparator|Placebo|"Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period.~Open Label Period (OLE): Abatacept IV administered every 28 days"
3117045|NCT02592876|Experimental|19A+RICE|Denintuzumab mafodotin plus rituximab, ifosfamide, carboplatin, and etoposide
3117046|NCT02592876|Active Comparator|RICE|Rituximab, ifosfamide, carboplatin, and etoposide
3117047|NCT02593032|Experimental|Randomized Treatment|Patients in the treatment group will begin receiving their medications in pre-filled trays from Friendship Pharmacy. Patients will receive 5 trays on a monthly basis in order to accommodate a 30-day, insurance-reimbursed fill schedule.
3117048|NCT02593032|No Intervention|Control Arm|Patients in the control arm will receive usual care and can continue using their existing pharmacy.
3117049|NCT02593097|Experimental|Metformin first, then matching placebo|Subjects will be randomized into the Metformin group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with matching placebo for 12 weeks.
3117050|NCT02593097|Experimental|Matching placebo first, then Metformin|Subjects will be randomized into the matching placebo group, treated for 12 weeks with a 4 week washout period in between treatments, then treated with Metformin for 12 weeks.
3117051|NCT02593149|Experimental|Treatment|ClearGuard HD End Cap
3117052|NCT02593149|No Intervention|Control|Tego® connector with the CurosTM for Tego disinfecting port protector
3117053|NCT02593305|Experimental|Beetroot crystals (nitrate), then placebo|Participants will receive a nitrate rich beetroot powder (10g/day) for 4 weeks. After a washout period of 4 weeks, they will then receive the placebo (beetroot powder, no nitrate) for 4 weeks.
3117054|NCT02593305|Experimental|Placebo, then beetroot crystals (nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 4 weeks. After a 4 week washout period, they will receive the nitrate rich beetroot powder for 4 weeks.
3117055|NCT02593305|No Intervention|Young Comparison|Young control group, used for age-related comparisons. This group did not go through any intervention.
3117056|NCT02593318|Experimental|Part 1 - Oxaloacetate (OAA) 1 gram/day|Participants take 1 gram of OAA per day for period of 4 weeks
3117057|NCT02593318|Experimental|Part 2 - Oxaloacetate (OAA)2 gram/day|Participants take 2 grams of OAA per day for period of 4 weeks
3117058|NCT02593396|Placebo Comparator|placebo|Placebo BD
3117059|NCT02593396|Experimental|Active|Bupropion hydrochloride sustained-release 150mg BD
3117060|NCT02593539|Experimental|Participants recieving nemiralisib|
3117061|NCT02593630|Experimental|Unicirc circumcision|Unicirc circumcision under topical anaesthetic, wound sealing with cyanoacrylate tissue adhesive
3117062|NCT02593773|Experimental|interferon γ-1b|Subcutaneous (SC) doses of ACTIMMUNE® TIW for a total of 26 weeks.
3117063|NCT02593825|Experimental|START-Play intervention|Intervention incorporating cognitive factors and focusing on self-initiated movement toward achievement of skill in sitting and reaching to increase problem-solving skills, which will then improve overall developmental outcomes. Visits to home by physical therapist twice weekly with parent training, for 3 months.
3117064|NCT02593825|Active Comparator|Business as Usual|Early motor intervention provided as standard treatment in the home for infants with motor dysfunction who are just beginning to sit. Dosage and content of intervention may vary from infant to infant and geographically.
3117065|NCT02593864|Experimental|Variable-Stiffness Shoe|Subjects will wear a load-modifying variable-stiffness shoe for 6 months
3117066|NCT02593903|Experimental|Antibiotics Group|Patients randomized to this arm will receive prophylactic oral antibiotics following the surgery and catheter placement (Septra, 3 mg/kg/dose once daily), and will continue the medication for until the day before catheter removal 4-8 days post-operation.
3117067|NCT02593903|No Intervention|No Antibiotics Group|Patients randomized to this arm will receive regular clinical care without prophylactic antibiotics, including catheter placement/removal.
3117068|NCT02594098|Experimental|Secukinumab|Secukinumab (300 mg) via subcutaneous injection using 2 prefilled syringes
3117069|NCT02594098|Placebo Comparator|Placebo|Placebo via subcutaneous injection using 2 prefilled syringes
3117070|NCT02594111|Active Comparator|Colchicine|Colchicine 1.8 mg PO over 1 hour
3117071|NCT02594111|Placebo Comparator|Placebo|Matching placebo
3117072|NCT02594163|Experimental|Brentuximab Vedotin|Subjects randomized to the brentuximab vedotin arm will receive IV infusions of brentuximab vedotin followed by bendamustine on day 1, and rituximab followed by bendamustine on day 2 of each 21 day cycle.
3117073|NCT02594163|Active Comparator|Rituximab,Bendamustine control|Subjects randomized to the control arm will receive IV infusions of rituximab on day 1 or day 2 and bendamustine on both days 1 and 2 of each 21 day cycle.
3117074|NCT02594644|Experimental|10-minute Incubation with Microneedle Roller & Sham|10-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
3117075|NCT02594644|Experimental|20-minute Incubation with Microneedle Roller & Sham|20-minute topical aminolevulinic acid incubation group. Subjects randomized by binary randomization into each treatment group and undergo secondary binary randomization for microneedle roller treatment (vs. sham microneedle) to the right or left side of the face. Blue light therapy follows.
3117076|NCT02594826|Experimental|Culturally appropriate intervention|Culturally appropriate, church-based intervention focused on cervical cancer and navigation assistance.
3117077|NCT02594826|Active Comparator|General health education control|General health and cancer education on nutrition, regular check-ups, tobacco use, and cancer screening.
3117078|NCT02595008|Experimental|DSXS topical product|treatment with DSXS twice daily for 28 days
3117079|NCT02595073|Experimental|DSXS topical product|DSXS Active treatment
3117080|NCT02595073|Placebo Comparator|Placebo topical product|Placebo treatment
3117082|NCT02595398|Experimental|4mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 µL) of CLS-TA
3117083|NCT02595398|Sham Comparator|Sham Procedure|Matching suprachoroidal syringe with sham procedure
3117084|NCT02595437|Experimental|Triferic via IV and Hemodialysate|On study Day 1, patients will receive IV Triferic iron 0.07 mg/kg diluted in an appropriate amount of D5W administered as a 100 mL infusion into the venous return port of the blood lines during the time the patient is receiving dialysis.The rate of administration will be calculated as such that the entire amount will be administered over the course of the dialysis treatment. On study Day 3, Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.
3117085|NCT02595450||Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
3117086|NCT02595502|Active Comparator|Sequence 1: Test Control Test|Test/control/test using the Johnson & Johnson Vision Care (JJVC) Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each in between lenses for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
3117087|NCT02595502|Active Comparator|Sequence 2: Control Test Control|Control/test/control using the JJVC Marketed contact lens (test) and the Competitor Marketed contact lens (control). Lenses will be worn as daily wear, daily disposable on both eyes for approximately one week each for total study duration of approximately three weeks per subject. Subjects are required to wear the lenses at least five days for at least eight hours per day worn.
3132443|NCT03427177|No Intervention|Control|Participants randomized to the control arm of the study will be given existing literature from the NCI that describes clinical trials (standard information for newly diagnosed cancer patients).
3132444|NCT03427268|Experimental|PM060184|PM060184
3117088|NCT02595528|Experimental|AGN-199201 and AGN-190584 Vehicle|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
3117089|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose A|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose A, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
3117090|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose B|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose B, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
3117091|NCT02595528|Experimental|AGN-199201 and AGN-190584 Dose C|Participants will receive 5 different treatments as per protocol for 2 days each. Treatment 1: nondominant eye--1 drop AGN-199201 vehicle followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 2: nondominant eye--1 drop AGN-199201 Dose A followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 3: nondominant eye--1 drop AGN-199201 Dose B followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 4: nondominant eye--1 drop AGN-199201 Dose C followed by 1 drop AGN-190584 Dose C, dominant eye--2 drops AGN-190584 vehicle; Treatment 5: nondominant eye--1 drop fixed combination of AGN-199201 and AGN-190584 followed by 1 drop AGN-190584 vehicle, dominant eye--2 drops AGN-190584 vehicle.
3117092|NCT02595567|Other|ITPC|
3117093|NCT02595684|Experimental|Tadalafil|Tadalafil capsules
3117094|NCT02595684|Placebo Comparator|Placebo|Calcined magnesia capsules
3117095|NCT02595723|Experimental|Phenytoin, Then Megestrol|Participants first received pretreatment with Phenytoin 200 mg capsule twice/day for one day. Participants then received both Phenytoin (200 mg capsule twice/day) and liquid Megestrol (800 mg/day) for three consecutive days.
3117096|NCT02595723|Experimental|Placebo, Then Megestrol|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Megestrol (800 mg/day) for three consecutive days.
3117097|NCT02595723|Experimental|Placebo, Then Placebo|Participants first received pretreatment with Placebo (matching Phenytoin 200 mg capsule) twice/day for one day. Participants then received both Placebo (matching Phenytoin 200 mg capsule) twice/day and liquid Placebo (matching liquid Megestrol 800 mg/day) for three consecutive days.
3117098|NCT02595749|Experimental|Placebo then Intranasal Oxytocin (40 IU)|Participants received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
3117099|NCT02595749|Experimental|Intranasal Oxytocin (40 IU) then Placebo|Participants received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the first experimental session, which occurred on a single day. After a 72 hour washout period, they then received a single placebo nasal spray (consisting of 4ml sterile saline [Ocean Nasal Spray Solution]) during the second experimental session, which occurred on a single day. All nasal spray solutions were transferred into two, 2 ml intranasal atomizers and administered in four sprays to each nostril over the course of 10 minutes.
3117100|NCT02595970|Experimental|Secukinumab|Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.
3117101|NCT02595983|Experimental|All Patients|All patients who received at least 1 dose of revusiran (ALN-TTRSC)
3117102|NCT02596009|Experimental|Breezhaler®|Each patient was required to inhale via Breezhaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
3117103|NCT02596009|Other|Ellipta®|Each patient were required to inhale via Ellipta® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
3117104|NCT02596009|Other|Handihaler®|Each patient were required to inhale via Handihaler® in a randomized cross-over sequence. The randomization numbers were generated using 6 sequences: BEH, EHB, HBE, BHE, EBH, HEB (B: Breezhaler, E: Ellipta, H: Handihaler).
3117105|NCT02596022|Experimental|CI-581a|Administration of CI-581a followed 2 weeks later by CI-581b
3117106|NCT02596022|Active Comparator|CI-581b|Administration of CI-581b followed 2 weeks later by CI-581a
3117107|NCT02596035|Experimental|Nivolumab|Nivolumab dose as specified
3117108|NCT02596230||Patients with acute VTE|Patients will be enrolled for cross sectional characterization of baseline characteristics
3117109|NCT02596230||Dabigatran|Patients treated with dabigatran for acute VTE will be followed for one year
3117110|NCT02596230||vitamin K antagonist|Patients treated with VKA for acute VTE will be followed for one year
3117111|NCT02596321|Experimental|Mitizax ALK HDM tablet|Standardised allergen extract from the house dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae developmental unit, dose standard for ALK HDM tablets (12DU)
3117112|NCT02596321|Placebo Comparator|Placebo tablet|Placebo tablet
3117113|NCT02596451|Experimental|Diclofenac Sodium gel, 1%|apply gel to the target knee
3117114|NCT02596451|Active Comparator|Voltaren® Gel|apply gel to the target knee
3117115|NCT02596451|Placebo Comparator|Placebo|apply gel to the target knee
3117116|NCT02596620|Experimental|Sequential therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily, amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 5 days followed by esomeprazole (Nexium) (40 mg) twice daily, levofloxacin(Cravit)(500 mg), 1 tablet once daily and metronidazole (Flagyl)(250 mg) 2 tablets three times daily for 5 days
3117117|NCT02596620|Active Comparator|Triple therapy|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily; amoxicillin (Amolin)(500 mg) 2 tablets twice daily and levofloxacin(Cravit)(500 mg), 1 tablet once daily for 10 days
3117118|NCT02596711|Experimental|Health Education (HE) Group|Participants receive general health education and handouts. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Counselor discusses a health topic (such as sleep, nutrition, and exercise) and how it relates to participant and their smoking. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
3117119|NCT02596711|Experimental|Culturally Tailored Smoking Cessation (CTSC) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participant and counselor discuss how smoking and their culture may relate to each other. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
3117120|NCT02596711|Experimental|Culturally Tailored Smoking + Adherence Enhancement (AE) Group|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting. Participants attend 3 counseling sessions during the study. Each of these counseling sessions are audio recorded. Participants receive additional talks related to smoking cessation tailored to their culture. Participants receive 12 weeks of Nicotine Replacement Therapy (NRT).
3117121|NCT02596750|Active Comparator|Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with microneedle rollers that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
3117122|NCT02596750|Sham Comparator|Sham Microneedle Pretreatment|One ventral forearm is randomized to receive pretreatment with sham microneedle rollers (flat roller without any microneedles) that are 200 micrometers in length (Clinical Resolution Laboratories, Inc.). Then topical 4% lidocaine is applied and pain in assessed after a pain stimulus at the 2 min, 4 min, 10 min, and 30 min time points.
3117123|NCT02596854|Experimental|Neurological MRI|Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.
3117124|NCT02596867|Experimental|open label single arm, drug propanolol|all subjects will receive the experimental drug
3117125|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic 160 mg GED0301|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 160 mg QD for 4 weeks and placebo QD for 4 weeks, until the the Week 52 Visit
3117126|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by periodic GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by placebo QD for 4 weeks; followed by alternating GED-0301 40 mg QD for 4 weeks and placebo QD for 4 weeks, until the Week 52 Visit
3117127|NCT02596893|Experimental|GED0301 160mg x 12 weeks followed by continuous GED0301 40mg|GED-0301 160 mg once daily (QD) for 12 weeks; followed by continuous GED-0301 40 mg QD, until the Week 52 Visit
3117128|NCT02596893|Placebo Comparator|Placebo|Placebo once daily (QD) until the Week 52 Visit
3117129|NCT02596906|Experimental|tDCS+Training|This group will receive 20 minutes of tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks
3117130|NCT02596906|Sham Comparator|Sham tDCS+training|"This group will receive 20 minutes of sham tDCS, 8x over four weeks immediately followed by reasoning training 8x over four weeks."
3117131|NCT02596945||Peritoneal Dialysis participants|Participants who are on peritoneal dialysis and have been prescribed with methoxy polyethylene glycol were observed for a period of 9 months.
3117132|NCT02596958||Bevacizumab|Patients will receive six 3-weeks cycle of IV bevacizumab along with platinum-based chemotherapy, followed by maintenance therapy of bevacizumab until progression (approximately 7 months).
3117133|NCT02596971|Experimental|Atezo-G-Benda (Safety Run-In and Expansion Phases)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month [q2m]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
3117134|NCT02596971|Experimental|Atezo-G-CHOP (Safety Run-In Phase)|Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, obinutuzumab, and CHOP during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (q2m) for 24 months, during maintenance treatment.
3117135|NCT02596971|Experimental|Atezo-R-CHOP (Expansion Phase)|Participants with previously untreated DLBCL will receive rituximab and CHOP during Cycle 1 (21-day cycle) and atezolizumab, rituximab, and CHOP during Cycles 2-8 (atezolizumab and rituximab for 8 cycles and CHOP for either 6 or 8 cycles, as determined by the investigator), during induction treatment, followed by atezolizumab from Cycles 9-25 during consolidation treatment.
3117136|NCT02597049|Experimental|1.5 mg Dulaglutide|1.5 milligrams (mg) given subcutaneously (SC) once a week for 24 weeks.
3117137|NCT02597049|Experimental|0.75 mg Dulaglutide|0.75 mg dulaglutide given SC once a week for 24 weeks.
3117138|NCT02597049|Placebo Comparator|Placebo|Placebo given SC once a week for 24 weeks.
3117139|NCT02597062|Experimental|Carfilzomib plus cyclophosphamide plus dexamethasone|20 mg/m2 day 1 of first cycle then escalated to 70 mg/m2 for all subsequent doses) given on days 1, 8, and 15 of a 28 day cycle plus weekly oral dexamethasone (< 70 years, 40 mg; ≥ 70 years 20mg) and cyclophosphamide 300 mg/m2 capped at 500 mg
3117140|NCT02597101|Placebo Comparator|Placebo|5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day) and 60 mg placebo tablet twice daily
3117141|NCT02597101|Experimental|AZD9668|60 mg AZD9668 twice daily in addition to 5 mg saxagliptin, once a day, together with optimised (after titration) metformin (500-2000 mg/day)
3117142|NCT02597127|Experimental|ALN-PCSSC 200 mg (bi-annual dosing)|ALN-PCSSC 200 milligram (mg) SC administration once at Day 1
3117143|NCT02597127|Experimental|ALN-PCSSC 300 mg (bi-annual dosing)|ALN-PCSSC 300 mg SC administration once at Day 1
3117144|NCT02597127|Experimental|ALN-PCSSC 500 mg (bi-annual dosing)|ALN-PCSSC 500 mg SC administration once at Day 1
3117145|NCT02597127|Placebo Comparator|Normal Saline (bi-annual dosing)|Saline SC administration once at Day 1
3117146|NCT02597127|Experimental|ALN-PCSSC 100 mg (quarterly dosing)|ALN-PCSSC 100 mg SC administration twice at Day 1 and Day 90
3117147|NCT02597127|Experimental|ALN-PCSSC 200 mg (quarterly dosing)|ALN-PCSSC 200 mg SC administration twice at Day 1 and Day 90
3117148|NCT02597127|Experimental|ALN-PCSSC 300 mg (quarterly dosing)|ALN-PCSSC 300 mg SC administration twice at Day 1 and Day 90
3117149|NCT02597127|Placebo Comparator|Normal Saline (quarterly dosing)|Saline SC administration twice at Day 1 and Day 90
3117150|NCT02597452|Other|intelligent Breast Exam, iBE|Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.
3117151|NCT02597478|Experimental|Low-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving low-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. Low-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
3117152|NCT02597478|Experimental|High-Dose Fentanyl Spray Group|Questionnaires completed at baseline and at end of study visit. Participant performs Shuttle Walk Test before and after receiving high-dose Fentanyl sublingual spray. Four mental ability tests completed after each walk test. High-dose Fentanyl sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
3117153|NCT02597543|Experimental|Nonspecific allograft dysfunction|Patients with nonspecific allograft dysfunction will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
3117154|NCT02597543|Experimental|Normal graft function|Patients with normal graft function will undergo stress cardiac MRI with regadenoson in addition to performing late gadolinium enhancement and obtaining mean segmental T1 values of the heart.
3117155|NCT02597582|Active Comparator|Ligusure assisted neck dissection|"The study group patients were treated using the LigaSure vessel sealing system (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) for dissection and hemostasis throughout the whole procedures during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
3117156|NCT02597582|Other|Conventional neck dissection|"The control group patients were treated using conventional cold instrument dissection, monopolar electrocautery hemostasis, and suture ligation during neck dissection.~Participants were asked to take a Voren enteric-microencapsulated (Diclofenac 50 mg/capsule) capsule 3 times a day for pain relief postoperatively. An additional capsule before sleep was allowed if persistent pain was told by the patient. When intolerable pain was complained in spite of oral analgesic, pethidine (meperidine 50 mg/ampule) injection was prescribed every 6 hours."
3117157|NCT02597673|Active Comparator|Standard rehabilitation protocol|Home Exercise Program (HEP). All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. The HEP sessions provide the participant with a self-management framework for returning to duty following PFPS rehabilitation. The exercises are quadriceps strengthening exercises. These exercises consist of stretching exercises of the quadriceps and hamstring muscles and a combination of open chain and closed chain exercises. The combined open and closed chain exercises are active straight leg raises, quadriceps straightening, step up, and squats.
3117158|NCT02597673|Experimental|Self-Managed NMES Program|Neuromuscular electrical stimulation (NMES). This group will receive a portable battery-operated device, KneeHAB® XP (Bio-Medical Research, Galway, Ireland) with the thigh garment. NMES training will consist of 20-minute stimulation sessions performed concurrently with the HEP for 9 weeks; each 20-minute NMES session includes a 2-minute warm-up, a 15-minute work-out and a 3-minute cool down. NMES with the thigh garment will be used as the participant is performing the home exercises of stretching and combined open and closed chain exercises. Those in the NMES group will alternate HEP alone and NMES with HEP for a total of 62 sessions (31 sessions of NMES/HEP and 31 sessions HEP alone).
3117159|NCT02597673|Experimental|Self-Managed TENS Program|Transcutaneous electrical nerve stimulation (TENS). The TENS treatment groups will receive the battery-operated Kneehab® XP with lead wire TENS applicator system. The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks for a total of 31 TENS/HEP sessions and 31 HEP alone for a total of 62 sessions.
3117160|NCT02597673|Experimental|Combined NMES/TENS Program|The combined NMES/TENS treatment group will receive the Kneehab® XP with the conductive thigh garment and the lead wire TENS applicator. The same parameters for TENS and NMES will be used (described above). The NMES and the TENS protocol will be performed on alternating days. There will be a total of 31 NMES sessions with HEP and 31 TENS sessions with HEP for a total of 62 sessions.
3117161|NCT02597712|Experimental|Treatment|Patients will take 25 mg YF476 once daily for 12 weeks
3117162|NCT02597712|Placebo Comparator|YF476 Placebo|Patients will take matching placebo once daily for 12 weeks
3117163|NCT02597855||Type 1 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
3117164|NCT02597855||Type 2 polypoidal choroidal vasculopathy|Monthly intravitreal aflibercept injection for 3 months and 1 additional injection after 2 months. Indocyanine green angiography was used to classify the type of PCV and evaluate the polyp closure rate.
3117165|NCT02597907|Experimental|aprepitant plus palonosetron|aprepitant 80 mg palonosetron 0.075 mg
3117166|NCT02597907|Active Comparator|aprepitant plus ramosetron|aprepitant 80 mg ramosetron 0.3 mg
3117167|NCT02597920||Switch patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
3117168|NCT02597920||New AF patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
3117169|NCT02597933|Experimental|Nintedanib|patient receives capsules containing nintedanib twice a day
3117170|NCT02597933|Placebo Comparator|Placebo|patient receives capsules identical to those containing active drug
3117171|NCT02597946|Experimental|all patients|Part A: all enrolled patients will receive afatinib monotherapy. Part B: all eligible patients will receive afatinib combined with weekly paclitaxel.
3117172|NCT02598076|Active Comparator|control|Group will receive standard treatment for psychogenic non-epileptic seizures. They will undergo an initial clinic visit with a neuropsychiatrist and neurologists. They will not undergo any subsequent motivational interview. Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference.
3117173|NCT02598076|Experimental|MI|"Group will receive an initial clinic visit with a neuropsychiatrist and neurologists, identical to the initial clinic visit for the control group. In addition they will receive 1 session of motivational interviewing immediately following the initial clinic visit. These patients will be questioned using standardized motivational interviewing techniques by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.~Following the initial clinic visit, all subjects with ongoing seizures will either be scheduled for ongoing psychotherapy for treatment of PNES at Brigham and Women's Hospital or referred to a local psychotherapist according to their preference (identical treatment in control and MI arms)."
3117174|NCT02598089|Experimental|Trivalent Seasonal Influenza Vaccine|"0.5 mL of seasonal trivalent influenza vaccine with 15 mcg of HA of each of 3 strains:~NYMC BX-51B reassortant of B/Massachusetts/2/2012~NYMC X-179A reassortant of A/California/7/2009 (H1N1)~NYMC X-223A reassortant of H3/A/Texas/50/2012 (H3N2)"
3117175|NCT02598089|Placebo Comparator|Placebo|This is the placebo comparator: 0.5 mL of Phosphate Buffered Saline
3117176|NCT02598128|Experimental|RELiZORB|Treatment (RELiZORB)
3117177|NCT02598128|Placebo Comparator|Control|Placebo control
3117178|NCT02598193|Experimental|Pirfenidone+Nintedanib|Participants with IPF will receive pirfenidone at 1602-2403 milligrams per day (mg/day) dose and nintedanib at the 200-300 mg/day dose up to 24 weeks.
3117179|NCT02598297|Active Comparator|Ruxolitinib|Two tablets of ruxolitinib 5 mg were administered orally twice per day.
3117180|NCT02598297|Placebo Comparator|Ruxolitinib Placebo|Two tablets of 5mg placebo were administered orally twice per day.
3117181|NCT02598583|Experimental|Cohort 1|"Intravenous infusion of ALXN1210 as follows:~Induction phase: a) 400 milligrams (mg) on Day 1 and Day 8, 600 mg on Day 15; or b) 600 mg on Day 1, 600 mg on Day 15~Maintenance phase: the first 5 doses of 900 mg on Day 29 and every 4 weeks thereafter~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:~≥40 to <60 kilograms (kg): 3000 mg every 8 weeks~≥60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
3117182|NCT02598583|Experimental|Cohort 2|"Intravenous infusion of ALXN1210 as follows:~Induction phase: 600 mg on Day 1, 900 mg on Day 15~Maintenance phase: the first of 5 doses of 1800 mg on Day 29 and every 4 weeks thereafter~On Day 477, the dose and dosing interval for all participants changed to an every-8-week, weight-based regimen as follows:~≥40 to <60 kg: 3000 mg every 8 weeks~≥60 to <100 kg: 3300 mg every 8 weeks~≥100 kg: 3600 mg every 8 weeks"
3117183|NCT02598934|Experimental|Ibandronate Group 1|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 1 will receive a physician consultation after 4 months of treatment to review bone turnover test results.
3117184|NCT02598934|Experimental|Ibandronate Group 2|Participants will receive a 6-month regimen with oral ibandronate, 150 mg once monthly. Group 2 will not receive a physician consultation.
3117185|NCT02599129|Experimental|Secukinumab|300 mg subcutaneous injections
3117186|NCT02599129|Placebo Comparator|Placebo|matching placebo subcutaneous injections
3117187|NCT02599194|Experimental|18F-FSPG and 18F-FDG Intragroup Comparision|Participants sequentially receive radioimaging agents 18F-FSPG and 18F-FDG IV followed by PET/CT scan with 60 minutes.
3117188|NCT02599402|Experimental|Combination therapy: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab specified dose on specified days
3117189|NCT02599402|Experimental|Monotherapy: Nivolumab|Nivolumab specified dose on specified days
3117190|NCT02599441||Ankle fracture cases|
3117191|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Lirilumab|Lirilumab by vein over about 60 minutes 1 time each 28 day cycle.
3117192|NCT02599649|Experimental|Low or Intermediate-1 MDS Group - Nivolumab + Lirilumab|Nivolumab by vein over about 60 minutes every 2 weeks during Cycles 1-9. Lirilumab by vein over about 60 minutes 1 time each cycle. Cycle is 28 days.
3117193|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle.
3117194|NCT02599649|Experimental|High Risk MDS Group - Azacitidine + Lirilumab + Nivolumab|Azacitidine by vein over about 60 minutes on Days 1-7 of each 28 day cycle. Lirilumab by vein over about 60 minutes on Day 7 of each 28 day cycle. On Days 7 and 21 of Cycles 1-9 and then on Day 7 of Cycles 10 and beyond, Nivolumab by vein over about 60 minutes.
3117195|NCT02599766|Experimental|animal assisted therapy|"Standard therapy that is done in the presence and with integrating an animal."
3117196|NCT02599766|Active Comparator|standard therapy|"Standard therapy without the presence of an animal."
3117197|NCT02599961|Experimental|UX007|UX007 dosing targeted and/or maintained at 35% of total daily caloric intake.
3117198|NCT02600325|Experimental|Treatment group|Grazoprevir/elbasvir single tablet regimen (100/50mg)
3117199|NCT02600351|Experimental|LDV/SOF 12 weeks, without cirrhosis|LDV/SOF for 12 weeks
3117200|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, without cirrhosis|LDV/SOF + RBV for 12 weeks
3117201|NCT02600351|Experimental|LDV/SOF + RBV 12 weeks, with compensated cirrhosis|LDV/SOF + RBV for 12 weeks
3117202|NCT02600351|Experimental|LDV/SOF 24 weeks, with compensated cirrhosis|LDV/SOF for 24 weeks
3117203|NCT02600403||IOP between 22-32 mmHg|Forty four (44) patients with intraocular pressure between 22 and 32 millimeters (mmHg) of mercury will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
3117204|NCT02600403||IOP greater than 32 mmHg|Six (6) patients with intraocular pressure greater than 32 millimeters of mercury (mmHg) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
3117205|NCT02600403||IOP less than 22 mmHg|Eleven (11) patients with stable intraocular pressure (less than 22 millimeters of mercury (mmHg)) on ophthalmic solutions (eye drops) will undergo Optical Coherence Tomography (OCT); Visual Evoked Potential (VEP); and Humphrey Visual Field (HVF).
3117206|NCT02600559|Experimental|0.1 mL OTO-201|Ciprofloxacin
3117207|NCT02600611|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
3117208|NCT02600611|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
3117209|NCT02600637|Experimental|MBSR|Mindfulness-based Stress Reduction program
3117210|NCT02600637|Active Comparator|Education|Educational group program
3117211|NCT02600715|Experimental|Active B&O suppository of belladonna|Receive the B&O suppository (belladonna/morphine) 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
3117212|NCT02600715|Placebo Comparator|Placebo suppository|Receive a placebo suppository 40 minutes prior to Onabotulinumtoxin A (BoNT) injection procedure in conjunction with local analgesia.
3117213|NCT02600767|Other|Artemether-Lumefantrine|Three days of standard treatment. This is a standard combination therapy for the treatment of P. falciparum malaria.
3117214|NCT02600819|Experimental|E/C/F/TAF|Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
3117215|NCT02600819|Experimental|Open-Label Rollover Extension B/F/TAF|At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.
3117216|NCT02600845|Experimental|ACCU-CHEK|All participants will utilize ACCU-CHEK Connect Diabetes Management System containing three primary components: ACCU-CHEK Aviva Connect Blood Glucose Monitoring System intended to be used for the quantitative measurement of glucose, ACCU-CHEK Connect Diabetes Management App indicated as an aid in the treatment of diabetes, and ACCU-CHEK Connect Online Diabetes Management System indicated for use by persons with diabetes or by healthcare professionals in the home or in healthcare facilities.
3117217|NCT02600871|Experimental|Provodine|"Provodine patients will have standard care including incision and drainage. The contents of 1 packet of Provodine applied with a Q-tip to the walls and floor of the abscess cavity. The contents of a 2nd packet will be applied to the surrounding skin within 5 cm around the incision.~Provodine patients will return within 48-72 hours for a follow-up visit, have the packing removed and the contents of the packet reapplied to the abscess cavity and surrounding skin.~Provodine patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will wash their hands with soap and water, pat dry, and apply the contents of 1 packet of Provodine to dorsum and palmar aspects of hands and fingers and rub together for 1 minute. They will apply the contents of a 2nd packet to the abscess cavity, and a 3rd packet to the surrounding skin. They will be then rinse their hands with water, pat dry, and cover the wound with 4x4 gauze."
3117218|NCT02600871|Active Comparator|Standard Care|"Standard care patients will have standard care including incision and drainage.~Standard care patients will return within 48-72 hours for a follow-up visit and have the packing removed.~Standard care patients will be instructed to cleanse the abscess at home by soaking in water once a day and patting the wound dry. They will cover wound with 4x4 gauze and wash hands with soap and water for 1 minute."
3117219|NCT02600923|Experimental|Palbociclib + Letrozole|palbociclib and letrozole combination
3117220|NCT02601001|Placebo Comparator|Placebo|Participants received placebo tablets twice a day (BID) in dosing period 1 (days 1 to 8) and in dosing period 2 (days 20 to 27).
3117221|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 37.5 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 37.5 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 37.5 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
3117222|NCT02601001|Experimental|Omecamtiv mecarbil 25 mg / 50 mg|Participants received omecamtiv mecarbil 25 mg BID in dosing period 1 (days 1 to 8) and 25 mg or 50 mg BID in dosing period 2 (days 20 to 27) based on their day 8 predose omecamtiv mecarbil plasma concentration (Cpredose): If day 8 Cpredose was < 200 ng/mL, participants received 50 mg BID; if day 8 Cpredose was ≥ 200 ng/mL or a day 8 PK value was not available participants continued to receive 25 mg BID.
3117223|NCT02601027|Experimental|0.125% Bupivacaine|0.125% bupivacaine infusion via transversus abdominis plane (TAP) catheter
3117224|NCT02601027|Placebo Comparator|Placebo|Saline infusion (sham) via transversus abdominis plane (TAP) catheter.
3117225|NCT02601105|Placebo Comparator|Placebo Vehicle Cream|Lipoderm® base served as the placebo vehicle control to be applied every night to demarcated 10 x 10 cm area containing stretch marks on randomly assigned side of abdomen for 12 weeks.
3117226|NCT02601105|Experimental|Centella Asiatica Cream|An alcoholic extract of CA (verified by HPLC) mixed into a Lipoderm® base served as the treatment cream to be applied every night to demarcated 10 x 10 cm area containing stretch marks on the opposite side of the abdomen for 12 weeks.
3117227|NCT02601170|Experimental|PRP Group|single intra-articular injection of 2mL PRP (RegentKit-THT-1, RegenLab SA, Mont-sur-Lausanne, Switzerland)
3117228|NCT02601170|Active Comparator|HA Group|five weekly intra-articular injections of 2.5 mL of hyaluronate sodium (ARTZDispo, Seikagaku Corporation Japan).
3117231|NCT02601300|Experimental|GED-0301 160 mg once daily (QD)|Patients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
3117232|NCT02601313|Experimental|Axicabtagene ciloleucel/brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma (MCL) will receive conditioning chemotherapy (CTE) consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of axicabtagene ciloleucel at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg on Day 0 or brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 CAR T cells/kg, with a maximum dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 1 or brexucabtagene autoleucel at a targeted dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg, with a maximum dose of 0.5 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 2.
3117233|NCT02601469|Experimental|DSXS1503|administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
3117234|NCT02601560|Experimental|MEDI6012 24 mg IV|Participants received a single IV dose of 24 mg MEDI6012 on Day 1.
3117235|NCT02601560|Experimental|MEDI6012 80 mg IV|Participants received a single IV dose of 80 mg MEDI6012 on Day 1.
3117236|NCT02601560|Experimental|MEDI6012 240 mg IV|Participants received a single IV dose of 240 mg MEDI6012 on Day 1.
3117237|NCT02601560|Experimental|MEDI6012 800 mg IV|Participants received a single IV dose of 800 mg MEDI6012 on Day 1.
3117238|NCT02601560|Experimental|MEDI6012 80 mg SC|Participants received a single SC dose of 80 mg MEDI6012 on Day 1.
3117239|NCT02601560|Placebo Comparator|Placebo Intravenous (IV)|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
3117240|NCT02601560|Experimental|MEDI6012 600 mg SC|Participants received a single SC dose of 600 mg MEDI6012 on Day 1.
3117241|NCT02601560|Placebo Comparator|Placebo Subcutaneous (SC)|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
3117242|NCT02601573|Experimental|Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks|TN HCV GT3 participants will take 1 fixed-dose combination (FDC) tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg once-daily (q.d.) with RBV (200 mg capsules; weight-based dosing) twice-daily (b.i.d.) for 8 weeks.
3117243|NCT02601573|Experimental|Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks|TN HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
3117244|NCT02601573|Experimental|Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
3117245|NCT02601573|Experimental|Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.
3117246|NCT02601573|Experimental|Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks|TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.
3117247|NCT02601625|Experimental|Anifrolumab 300 mg SC injections|300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially
3117248|NCT02601625|Experimental|Anifrolumab 300 mg IV infusion|300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes
3117249|NCT02601625|Experimental|Anifrolumab 600 mg SC infusion|600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump
3117250|NCT02601625|Placebo Comparator|Placebo 300 mg SC injections|300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially
3117251|NCT02601625|Placebo Comparator|Placebo 300 mg IV infusion|300 mg single dose placebo delivered as an IV infusion over 30 minutes
3117252|NCT02601625|Placebo Comparator|Placebo 600mg SC infusion|600 mg single dose placebo delivered as 4 mL SC by infusion pump
3117253|NCT02601833|Experimental|Silver Diamine Fluoride|This arm will receive Silver Diamine Fluoride applied to their carious lesion, in lieu of restoration placement, with the goal of arresting caries.
3117254|NCT02601833|Active Comparator|Conventional Caries Management|Restorative dental care according to American Academy of Pediatric Dentistry guidelines. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
3117255|NCT02601976|Experimental|PegInterferon alfa-2a and Ribavirin|PegInterferon alfa-2a subcutaneously once weekly Ribavirin administered orally according to the body weight
3117256|NCT02602080||FA patients under popliteal block + spinal + sedation|Foot and ankle patients under popliteal block+ spinal+ sedation
3117257|NCT02602080||TSA patients under brachial plexus block + general (LMA)|Total shoulder arthroscopy patients under brachial plexus block + general (LMA)
3117258|NCT02602080||TSA patients under brachial plexus block + sedation|Total shoulder arthroplasty patients under brachial plexus block + sedation
3117259|NCT02602223|Experimental|Amnion chorion membrane|Amnion chorion membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the active comparator.
3117260|NCT02602223|Active Comparator|d-PTFE membrane|dense polytetrafluoroethylene membrane will be placed over bone graft after socket preservation on randomly assigned side of the mouth i.e., contra-lateral to the Experimental side
3117261|NCT02602496|Experimental|Control|3 servings of refined grains per day.
3117262|NCT02602496|Experimental|Fruits and Vegetables|5 servings of fruits and vegetable per day.
3117263|NCT02602496|Experimental|Whole Grain|3 servings of whole grains per day.
3117264|NCT02603107|Experimental|B/F/TAF|"Randomized Phase: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks, without regard to food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
3117265|NCT02603107|Experimental|Stay on Baseline Regimen (SBR)|"Randomized Phase: Participants remained on current antiretroviral (ARV) regimen consisting of ritonavir (RTV)-boosted or cobicistat (COBI)-boosted atazanavir (ATV) or darunavir (DRV), plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) for at least 48 weeks with food.~Extension Phase: After Week 48, participants in countries where B/F/TAF is not available will be given the option to receive B/F/TAF for up to 96 additional weeks or until the product becomes accessible to participants through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first."
3117266|NCT02603120|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 48 weeks
3117267|NCT02603120|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 48 weeks
3117268|NCT02603120|Experimental|Open-Label Phase|At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, participants in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.
3117269|NCT02603172|Experimental|Part A: Cohort 1|Subjects will receive a single dose of GSK3039294 (Dose level 1) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 2 on Day 15 (Period 2).
3117270|NCT02603172|Experimental|Part A: Cohort 2|Subjects will receive a single dose of GSK3039294 (Dose level 3) on Day 1 and will remain in-house until Day 4. Wash-out will take place from Day 5 to Day 14. Subjects will receive Dose level 4 on Day 15 (Period 2).
3117271|NCT02603172|Experimental|Part B: Cohort 3a|Subjects will receive repeat dosing of GSK3039294 for a total of 21 days. The dose will be escalated every week throughout the study duration. Subjects will first receive a low dose given once daily. After 7 days, if well tolerated, the total daily dose will be increased and, GSK3039294 will be given, for example, as twice daily dosing for 7 days. At the end of this 7 day period and if previous dosing was well tolerated, the dose will be increased to a maximum daily dose that will not exceed pre-clinical safety exposure limits. On Day 4 and 5 GSK3039294 will be administered under fasted and fed conditions, respectively, to investigate the food effect on the PK.
3117272|NCT02603172|Experimental|Part B: Cohort 3b|Subjects will be enrolled in Cohort 3b only if required for further investigation. Subjects will receive GSK3039294 for 21 consecutive days and more than one dose level or regimen may be investigated, for example on the first 10 days the dose may be administered thrice daily, and on the last 11 days may be administered twice daily.
3117273|NCT02603172|Experimental|Part C: Cohort 4|Subjects will receive repeat dosing of GSK3039294 at the predicted optimal clinical dose determined from Part B for a total of 21 days.
3117274|NCT02603211||Women with Breast Tumors|Women with breast tumors.
3117275|NCT02603393|Experimental|QVA149|
3117276|NCT02603393|Active Comparator|Tiotropium + salmeterol/fluticasone|
3117277|NCT02603419|Experimental|Lead-in phase-Cohort A|X1 mg IV every 2 weeks
3117278|NCT02603419|Experimental|Lead-in phase-Cohort B|X2 mg IV every 2 weeks
3117279|NCT02603419|Experimental|Lead-in phase-Cohort C|X3 mg IV every 3 weeks
3117280|NCT02603419|Experimental|Lead-in phase-Cohort D|X4 mg IV every 2 weeks
3117281|NCT02603419|Experimental|Lead-in phase-Cohort E|X5 mg IV every 2 weeks
3117282|NCT02603419|Experimental|Expansion phase|X1 mg IV every 2 weeks followed by X1 or X4 mg every 2 weeks
3117283|NCT02603432|Experimental|Arm A|Avelumab plus Best Supportive Care (BSC)
3117284|NCT02603432|Other|Arm B|"Best Supportive Care (BSC) alone~Following the planned interim analysis for this study, eligible patients in Arm B whose cancer has not worsened and are still in the watch and wait part of the study will be given the option to receive Avelumab plus BSC. Prior to this, Arm B patients received BSC alone. All patients who choose not to receive Avelumab will be discontinued."
3117285|NCT02603666|Other|Elastography|Fibroscan elastography device for evaluation of liver disease in CF patients.
3117286|NCT02603809|Placebo Comparator|Placebo|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received placebo orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117287|NCT02603809|Experimental|Aprocitentan 5 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117288|NCT02603809|Experimental|Aprocitentan 10 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 10 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117289|NCT02603809|Experimental|Aprocitentan 25 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 25 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117290|NCT02603809|Experimental|Aprocitentan 50 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received aprocitentan 50 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117291|NCT02603809|Active Comparator|Lisinopril 20 mg|After a 4 to 6-week single-blind placebo run-in period, participants will be randomized to received lisinopril 20 mg orally once daily in the morning for 8 weeks during the double-blind treatment period, followed by a 2-week single-blind placebo washout period, followed by a further two-week follow-up period.
3117292|NCT02603887|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3132445|NCT03427619|Experimental|OK432 (Picibanil)|There is no control in this study. All participants will receive the actual drug -OK432. With each injection they may receive 0.01 to 0.05mg/mL 6-12 weeks apart up to 4 injections total.
3117293|NCT02603926|Experimental|Allopregnanolone|Subjects will receive an intravenous infusion of Allopregnanolone at escalating doses of 2mg, 4mg, and 6mg once weekly over a three week period. The highest dose tolerated without sedation will be held stable for the remaining weekly infusions, for a total of 12 infusions.
3117294|NCT02603952|Placebo Comparator|Placebo + Oseltamivir 75 mg|Participants will receive a single intravenous (IV) infusion of placebo (matched to MEDI8852) on Day 1 and oseltamivir 75 milligrams (mg) capsules orally twice a day (BID) from Day 1 to Day 5.
3117295|NCT02603952|Experimental|MEDI8852 750 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 750 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
3117296|NCT02603952|Experimental|MEDI8852 3000 mg + Oseltamivir 75 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1 and oseltamivir 75 mg capsules orally BID from Day 1 to Day 5.
3117297|NCT02603952|Experimental|MEDI8852 3000 mg|Participants will receive a single IV infusion of MEDI8852 3000 mg on Day 1.
3117298|NCT02604017|Experimental|ABT-493/ABT-530 for 12 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3117299|NCT02604017|Experimental|ABT-493/ABT-530 for 8 weeks|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
3117300|NCT02604160|Experimental|LY3113593|Escalating doses of LY3113593 administered by intravenous (IV) infusion once every 4 weeks (Q4W) on (Day 1 and 29) in part A.
3117301|NCT02604160|Placebo Comparator|Placebo|0.9% saline, administered by intravenous (IV) infusion once Q4W (Day 1 and 29) in part A.
3117302|NCT02604173|Experimental|Budesonide|Budesonide inhaler as experimental treatment along with placebo pill.
3117303|NCT02604173|Active Comparator|Acetazolamide|Acetazolimide pill as active comparator along with sham inhaler.
3117304|NCT02604173|Sham Comparator|Control|Sham inhaler as control for budesonide inhaler along with placebo pill as control for acetazolamide comparator.
3117305|NCT02604199|Placebo Comparator|PBO Low Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
3117306|NCT02604199|Placebo Comparator|PBO High Dose|0.9% normal saline, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
3117307|NCT02604199|Experimental|ARC-520 Injection 1 mg/kg|Intravenous ARC-520 at 1.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
3117308|NCT02604199|Experimental|ARC-520 Injection 2 mg/kg|Intravenous ARC-520 at 2.0 mg/kg, once every 4 weeks for 4 doses plus daily oral entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg) throughout the study period
3117309|NCT02604212|Placebo Comparator|Placebo Low Dose Comparator|Placebo (low dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
3117310|NCT02604212|Placebo Comparator|Placebo High Dose Comparator|Placebo (high dose comparator) once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
3117311|NCT02604212|Experimental|ARC-520 1.0 mg/kg|Low dose (1.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
3117312|NCT02604212|Experimental|ARC-520 2.0 mg/kg|High dose (2.0 mg/kg) ARC-520 once every 4 weeks for 4 doses, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
3117313|NCT02604264|Active Comparator|ClearGuard HD end cap|Treatment
3117314|NCT02604264|No Intervention|Standard hemodialysis end cap|Control
3117315|NCT02604342|Experimental|Alectinib|Participants will receive oral alectinib at a dose of 600 milligrams (mg) twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
3117316|NCT02604342|Active Comparator|Premetrexed/Docetaxel|Participants will receive chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
3117317|NCT02604407|Experimental|SHP465 12.5 mg|Subjects will receive SHP465 12.5 mg
3117318|NCT02604407|Experimental|SHP465 37.5 mg|Subjects will receive SHP465 titrated up to 37.5 mg
3117319|NCT02604407|Placebo Comparator|Placebo|Subjects will receive matching placebo
3117320|NCT02604433|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Luspatercept, subcutaneous(ly) (SC) once every 21 days
3117321|NCT02604433|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
3117322|NCT02604550|Active Comparator|Femoral Nerve Block|Subjects undergoing anterior cruciate ligament (ACL) surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the femoral nerve. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
3117323|NCT02604550|Active Comparator|Adductor Canal Block|Subjects undergoing anterior cruciate ligament surgery will be randomized to receive 20 mL of ropivacaine 0.5% in the adductor canal. Subjects will also receive standard of care Percocet 7.5/325 and naprosyn following surgery.
3117324|NCT02604589|Placebo Comparator|PCA only|Procedure: Standard of care - Intravenous Patient Controlled Anesthesia (PCA) 0.1 mg hydromorphone hydrochloride, every 6 minutes. Boluses of 0.1 mg IV hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.
3117325|NCT02604589|Experimental|Bupivicaine 0.25% (LOW DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.25% 4 ml/hr total for dual chamber catheter."
3117326|NCT02604589|Experimental|Bupivicaine 0.5% (HIGH DOSE)|"Standard PCA infusion 0.1 mg hydromorphone hydrochloride, every 6 minutes. Bolus 0.1 mg hydromorphone for uncontrolled pain up to a maximum of 2.5 mg/hr.~Infusion catheter placement. Bupivacaine 0.5% 4 ml/hr total for dual chamber catheter."
3117327|NCT02604810|Active Comparator|IGIV-C 10%|IV dose of Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (Grifols)
3117328|NCT02604810|Experimental|IGSC 20%|Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (Grifols)
3117329|NCT02605122|Experimental|Solithromycin|Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
3117330|NCT02605122|Active Comparator|Standard of Care|Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.
3117331|NCT02605174|Experimental|Lasmiditan 50 milligram (mg)|Oral tablet. Lasmiditan 50 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
3117332|NCT02605174|Experimental|Lasmiditan 100 mg|Oral tablet. Lasmiditan 100 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
3117333|NCT02605174|Experimental|Lasmiditan 200 mg|Oral tablet. Lasmiditan 200 mg plus placebo (to match a lasmiditan dose). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
3117334|NCT02605174|Placebo Comparator|Placebo|Oral tablet. Placebo tablets match each of the lasmiditan doses (50 mg, 100 mg and 200 mg). One dose for acute treatment of migraine. Second dose for rescue or recurrence of migraine allowed between 2 and 24 hours.
3117335|NCT02605187|Active Comparator|No choice|No choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
3117336|NCT02605187|Experimental|Choice: low protocol|Choice given low dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
3117337|NCT02605187|Experimental|Choice: medium protocol|Choice given medium dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h
3117338|NCT02605187|Experimental|Choice: high protocol|Choice given high dose intrathecal morphine acetaminophen po q6h ibuprofen po q6h gabapentin po one time dose
3117339|NCT02605304|Experimental|Arm A: LDV/SOF + RBV|Ledipasvir/sofosbuvir + ribavirin for 12 weeks, followed by 24 weeks of post-treatment follow-up.
3117340|NCT02605304|Experimental|Arm B: LDV/SOF|Ledipasvir/sofosbuvir for 24 weeks, followed by 24 weeks of post-treatment follow-up.
3117341|NCT02605395|Experimental|Group A-Idiazole then Pariet|Subjects will receive a single oral dose of IDIAZOLE 20mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of PARIET 20 mg DR tabs under fed condition in treatment period 2.
3117342|NCT02605395|Experimental|Group B-Pariet then Idiazole|Subjects will receive a single oral dose of PARIET 20 mg DR tabs under fed condition in treatment period 1 followed by 7 days washout interval from the first study drug administration. After the washout interval the subjects will receive a single dose of Idiazole 20mg DR tabs under fed condition in treatment period 2.
3117343|NCT02605447|Experimental|SYNERGY stent + 3 month DAPT|Subject with implantation of at least one SYNERGY stent within the preceding 3 calendar days that takes the required dual antiplatelet therapy (3 months of P2Y12 inhibitor, 15 months of aspirin)
3117344|NCT02605642||CT-P13|biosimilar infliximab
3117345|NCT02605837|Experimental|Oral Budesonide Suspension (OBS)|Participants will receive Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
3117346|NCT02605837|Placebo Comparator|Placebo|Participants will receive oral dose of 10 ml of placebo matched with the experimental drug twice daily up to 16 weeks.
3117347|NCT02605863|Experimental|Intermediate Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
3117348|NCT02605863|Experimental|High Risk NMIBC|Enzalutamide 160mg by mouth daily for 12 months
3117349|NCT02605876|Experimental|Whole Body Vibration|Subjects will receive whole body vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
3117350|NCT02605876|Experimental|Local Muscle Vibration|Subjects will receive local muscle vibration (30Hz, 2g) applied continuously for 1 minute. This exposure will be repeated 6 times with 2 minutes of rest between exposures.
3117351|NCT02605876|No Intervention|Control|Subjects will perform the same procedures as the experimental groups with the exception that no vibratory stimulus will be applied.
3117352|NCT02605928|Experimental|BIP Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It measures bioimpedance and detects synovial fluid during inta-articular injection.
3117353|NCT02605954|Experimental|E/C/F/TAF|Participants will switch to E/C/F/TAF FDC and receive treatment for 48 weeks.
3117354|NCT02605954|Active Comparator|ABC/3TC+3rd Agent|"Participants will maintain prior regimen of ABC/3TC plus a third antiretroviral agent for 24 weeks followed by a delayed switch to E/C/F/TAF FDC.~Note: the prior regimen is determined by the participant's clinician (prior to entry into the study) and will consist of one of the third antiretroviral agents listed."
3117355|NCT02605967|Experimental|PDR001 - Investigational drug|anti-PD1 humanized monoclonal antibody
3117356|NCT02605967|Active Comparator|Chemotherapy|commonly used chemotherapy as per investigator's choice
3117357|NCT02605993|Experimental|Cohort 1|"During the Treatment Period, participants were administered ravulizumab 1400 milligram (mg) on Day 1, ravulizumab 1000 mg on Day 15 and Day 29, and then ravulizumab 1000 mg every 4 weeks for 7 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kilograms (kg), 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
3117358|NCT02605993|Experimental|Cohort 2|"During the Treatment Period, participants were administered ravulizumab 2000 mg on Day 1, ravulizumab 1600 mg on Day 22 and Day 43, and then ravulizumab 1600 mg every 6 weeks for 4 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
3132446|NCT03427892|Experimental|Brexpiprazole|Brexipiprazole will be taken orally beginning at 0.5 mg/day with an increase to 1 mg/day at week 1 and 2 mg/day at week 2. If reduction in mood symptoms does not occur, the dose will increase to 3 mg/day and 4 mg/day.
3132447|NCT03427931|Experimental|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data by wearing the device at home a minimum of 28 days but may continue for up to 3 months.
3117359|NCT02605993|Experimental|Cohort 3|"During the Treatment Period, participants were administered ravulizumab 1600 mg on Day 1 and Day 15, ravulizumab 2400 mg on Day 29, and then ravulizumab 2400 mg every 8 weeks for 3 doses.~In the Extension Period, participants initially continued to receive their dose. During the second year of the study, participants were administered weight-based doses of ravulizumab every 8 weeks for up to 5 years: 3000 mg for participants weighing 40 to less than 60 kg, 3300 mg for participants weighing 60 to less than 100 kg, and 3600 mg for participants weighing 100 kg or more."
3117360|NCT02605993|Experimental|Cohort 4|"During the Treatment Period, participants were administered ravulizumab 3000 mg on Day 1, ravulizumab 5400 mg on Day 29, and then ravulizumab 5400 mg every 12 weeks for 2 doses.~During the Extension Period, participants were administered ravulizumab 5400 mg every 12 weeks for up to 5 years."
3117361|NCT02606253|Active Comparator|Metolazone|Metolazone 5mg tablet orally twice daily for 48 hours.
3117362|NCT02606253|Experimental|Chlorothiazide|Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
3117363|NCT02606253|Experimental|Tolvaptan|Tolvaptan 30mg tablet orally once daily for 48 hours
3117364|NCT02606500|Experimental|Elonva 150 mcg|Elonva 150 mcg intramuscular daily obese
3117365|NCT02606500|Active Comparator|Elonva 100 mcg|Elonva 100 mcg intramuscular daily normal weight
3117366|NCT02606604|Experimental|FES Cycling|The intervention consists of electrical stimulation to five lower extremity muscle groups (quadricep, hamstring, anterior tibialis, gluteal, and gastrocnemius muscle groups) while cycling for 45 minutes, 3 times per week for 8 weeks. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed).
3117367|NCT02606604|Active Comparator|Cycling Only|The intervention consists of lower extremity cycling for 45 minutes, 3 times per week for 8 weeks. Electrical stimulation will not be applied to any muscles. Outcome measures will be collected at baseline, 4 weeks, 8 weeks and 4 weeks after training is completed.
3117368|NCT02606643|Active Comparator|Group 1 Catheter to slight traction|"For the Tension arm (research related), slight tension will be placed on the catheter, which will then be taped to the patient's inner thigh. The tension will be assessed and retaped as needed every 30 minutes by the research and/or the nursing staff.~Only slight tension will be applied to those catheters assign to the tension group. The catheter will be taped to the inner thigh so there is no sag in the catheter from the urethra to the tape. There is no method or device to measure the tension placed on these catheters, if the patient moves her leg it can lessen or increase the tension, these are known factors."
3117369|NCT02606643|Active Comparator|Group 2 Catheter to no traction|"Foley catheter to no traction placed as SOC No traction applied"
3117370|NCT02606708|Experimental|Accelerated intensity modulated radiation therapy (AIMRT)|All patients shall receive a total of 40.5 Gy to the entire breast in 2.7 Gy/fraction x 15 fractions, Monday to Friday for 3 weeks delivered prone in uniform daily doses through IMRT tangent fields. A concurrent boost to the original tumor bed of 0.50 Gy will be delivered.
3117371|NCT02606734|Other|Treatment Arm|All subjects enrolled in the trial will use the DyeVert System.
3117372|NCT02606838|Experimental|Persons with Diabetes|Untrained Persons with Diabetes used the Styx Lancing Device System to obtain fingerstick and Alternate Site palm capillary blood.
3117373|NCT02606877|Experimental|Treatment naïve|Treatment naïve to pirfenidone
3117374|NCT02606877|Experimental|Pirfenidone-treated|Treatment before with pirfenidone
3117375|NCT02606903|Experimental|BI 695501 prefilled syringe|
3117376|NCT02606903|Experimental|BI 695501 autoinjector|
3117377|NCT02607046|Experimental|Exercise|Exercise Training
3117378|NCT02607046|Experimental|NMES|Neuromuscular Electrical Stimulation
3117379|NCT02607124|Experimental|RB+ High Grade Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
3117380|NCT02607124|Experimental|Non-Biopsied Diffuse Instrinsic Pontine Glioma|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 600mg daily (DIPG); <21 yrs of age 350 mg/m2/day)
3117381|NCT02607228|Experimental|Alobresib Dose Escalation|Participants who have progressed on either abiraterone and/or enzalutamide will be enrolled to receive increasing doses of alobresib up to 9 mg to determine the MTD.
3117382|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Escalation|Following a two week lead-in with enzalutamide once daily, participants who have progressed on abiraterone will receive less than or equal to MTD of alobresib in combination with enzalutamide 160 mg once daily. Based on observed pharmacokinetics (PK) interaction, toxicity, and tolerability observed in the single agent dose escalation, the dose of alobresib may be increased.
3117383|NCT02607228|Experimental|Alobresib Dose Expansion (Group 1)|Participants will receive a dose less than or equal to MTD of alobresib (based on safety, pharmacodynamics (PD), and tolerability).
3117384|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 2)|Participants will receive a dose less than or equal to MTD of alobresib plus enzalutamide (based on safety, PD, and tolerability).
3117385|NCT02607228|Experimental|Alobresib + Enzalutamide Dose Expansion (Group 3)|Participants will receive alobresib plus enzalutamide (dose will be equivalent to the dose chosen for Group 2).
3117386|NCT02607254|Experimental|Pregabalin Treatment phase|All patients will be initially treated with pregabalin in a single blind fashion
3117387|NCT02607254|Experimental|Withdrawal phase|After finishing the treatment phase, some patients will be randomized to the placebo or continue on pregabalin for the 4 weeks of withdrawal phase.
3117388|NCT02607280|Experimental|DS-5565 group|DS-5565 15 mg (for moderate renal impairment) or 7.5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
3117389|NCT02607306|Experimental|Insulin degludec/liraglutide OD|
3117390|NCT02607306|Active Comparator|Insulin degludec OD|
3117391|NCT02607306|Active Comparator|Liraglutide OD|
3117392|NCT02607618|Experimental|iclaprim|iclaprim 80 mg intravenous every 12 hours
3117393|NCT02607618|Active Comparator|vancomycin|vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance
3117394|NCT02607735|Experimental|SOF/VEL/VOX (Primary Study)|SOF/VEL/VOX for 12 weeks
3117395|NCT02607735|Experimental|Placebo (Primary Study)|Placebo to match SOF/VEL/VOX for 12 weeks
3117396|NCT02607735|Experimental|SOF/VEL/VOX (Deferred Treatment Substudy)|SOF/VEL/VOX for 12 weeks for eligible participants initially randomized to receive placebo
3117397|NCT02607800|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
3117398|NCT02607800|Active Comparator|SOF/VEL 12 weeks|SOF/VEL tablet for 12 weeks
3117399|NCT02607865|Experimental|Semaglutide 3 mg|
3117400|NCT02607865|Experimental|Semaglutide 7 mg|
3117401|NCT02607865|Experimental|Semaglutide 14 mg|
3117402|NCT02607865|Active Comparator|Sitagliptin 100 mg|
3117403|NCT02607930|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + ABC/DTG/3TC placebo for at least 144 weeks
3117404|NCT02607930|Active Comparator|Blinded Phase: ABC/DTG/3TC|ABC/DTG/3TC + B/F/TAF placebo for at least 144 weeks
3117405|NCT02607930|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
3117406|NCT02607956|Experimental|Blinded Phase: B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for at least 144 weeks
3117407|NCT02607956|Active Comparator|Blinded Phase: DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for at least 144 weeks
3117408|NCT02607956|Experimental|Open-Label (OL) Phase|After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.
3117409|NCT02608099|Active Comparator|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
3117410|NCT02608099|Experimental|Uninterrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
3117411|NCT02608177|Experimental|Linagliptin/Glipizide|Arm receives 4 weeks of study drug linagliptin followed by 4 weeks of glipizide
3117412|NCT02608177|Experimental|Glipizide/Linagliptin|Arm receives 4 weeks of study drug glipizide followed by 4 weeks linagliptin
3117413|NCT02608229|Experimental|Dose De-escalation: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals).~BVD-523 at 600 mg twice daily on its own for two weeks before initiating Cycle 1 treatment with gemcitabine and nab-paclitaxel.~Nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes.~Gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes.~Mandatory biopsy at baseline and baseline at end of 2 week BVD-523 lead in."
3117414|NCT02608229|Experimental|Dose Expansion: BVD-523/Nab-paclitaxel/Gemcitabine|"Treatment will be given in a 28-day cycle.~First 2 patients enrolled: BVD-523 600 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 125 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 1000 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Remaining 6 patients enrolled: BVD-523 450 mg on a twice daily basis (at approximately 12-hour intervals), nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30-40 minutes, and gemcitabine 800 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle over the course of 30 minutes~Mandatory biopsy at baseline and at end of cycle 2 (if deemed safe for participant and feasible to obtain)"
3117415|NCT02608450|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
3117416|NCT02608450|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
3117417|NCT02608463|Other|Part A - Neuropathic Pain|Subjects with a score of ≥ 13 on the painDETECT Questionnaire (PDQ) will be assigned to the Neuropathic Pain group.
3117418|NCT02608463|Other|Part A - Non-Neuropathic Pain|Subjects with a score of ≥ 1 or ≤ 12 on the painDETECT Questionnaire (PDQ) will be assigned to the Non-Neuropathic Pain group.
3117419|NCT02608463|Other|Part A - Control|Subjects with a score of score = 0 on the painDETECT Questionnaire (PDQ) will be assigned to the Control group.
3117420|NCT02608463|Experimental|Part B - rTMS|Subjects from the Neuropathic Pain group will be invited to participate in the Part B rTMS group to receive repetitive transcranial magnetic stimulation (rTMS).
3117421|NCT02608476|Experimental|CB-03-01 cream|CB-03-01 cream, 1% applied twice daily for 12 weeks
3117422|NCT02608476|Placebo Comparator|Vehicle cream|Vehicle cream applied twice daily for 12 weeks
3117423|NCT02608489|Active Comparator|Diqufosol|3% Diquafosol Tetrasodium Ophthalmic Solution
3117424|NCT02608489|Placebo Comparator|Hyaluronate|0.1% Sodium Hyaluronate Ophthalmic Solution
3117425|NCT02608684|Experimental|Cisplatin+Gemcitabine+Pembrolizumab|"2 cycles of 750mg gemcitabine and 30mg cisplatin chemotherapy (standard of care) followed by 4 cycles of gemcitabine and cisplatin combined with pembrolizumab in 21-day treatment cycles followed by single-agent pembrolizumab maintenance therapy for up to 2 years of treatment (6 cycles combination treatment + 28 cycles maintenance).~Gemcitabine 750 mg/m2 every 3 weeks (Q3W) x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle Standard of care~Cisplatin 30 mg/m2 Q3W x 6 cycles IV infusion~-Day 1 and Day 8 of each 3 week cycle after gemcitabine Standard of care~Pembrolizumab 200 mg Q3W starting with cycle 3 IV infusion~-Day 1 of each 3 week cycle after gemcitabine and cisplatin Experimental"
3117426|NCT02608879|Experimental|OMDP Group|Subjects randomized to this group will attend weekly visits and receive a full dental cleaning, as well as have their gums/tongue cleaned by a dental professional. Subjects will also receive standard of care oral hygiene instructions.
3117427|NCT02608879|Other|Control Group|Subjects assigned to the control group will receive standard of care oral health instructions and will come for bi-weekly treatment visits where they will have their teeth cleaned (brushed) by a dental professional.
3117428|NCT02608892|Experimental|Intervention|BSweet2Babies video
3117429|NCT02608892|No Intervention|Control|Usual care
3117430|NCT02609100|Active Comparator|Video Capsule Endoscopy|Randomization arm one is to video capsule endoscopy (VCE) a non-invasive procedure in which a patient swallows a disposable 1.0 X 2.5 cm 'pill' containing a camera electronically linked to equipment outside the patient which records images as it passes from the esophagus through the entire tract and is excreted in feces. It images the small intestine in areas beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. Its greatest use is in identifying points of bleeding and ulcers.
3117431|NCT02609100|Active Comparator|Next Day Colonoscopy|Randomization arm two is to colonoscopy, a test that allows the doctor to look at the inner lining of the large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
3117432|NCT02609113|Active Comparator|Strong Magnetic Wristband|Magnetic wristband of 1,795 Gauss strength
3117433|NCT02609113|Placebo Comparator|Weaker Magnetic Wristband|Magnetic wristband of 5 Gauss strength.
3117434|NCT02609178|Experimental|FGP design (FGP, AVR)|use functional generated path to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
3117435|NCT02609178|No Intervention|conventional design (CON)|use conventional method to execute different occlusal surface designs of the artificial crown and evaluate its efficacy
3117436|NCT02609204|Experimental|Healthy Controls|Participants with normal eye exams and no history of eye diseases will best tested with Diopsys NOVA.
3117437|NCT02609308|Active Comparator|Short leg cast|The patients in this group will be immobilize with a short leg cast for 14 days, and later they will be able to do physical rehabilitation and will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
3117438|NCT02609308|Experimental|Platelet-rich plasma|In this group, the patients will be receive a single dose of autologous platelet-rich plasma, and will be immobilized with a short leg cast. Posteriorly, they will be evaluated with American Orthopedic Foot and Ankle Society´s Ankle Hindfoot scale and Foot and Ankle Disability Index.
3117439|NCT02609399|Experimental|Oseltamivir|Subjects randomized to the oral treatment arm will receive 5 days of oral oseltamivir.
3117440|NCT02609399|Experimental|Peramivir|Subjects randomized to the IV treatment group will receive 1 dose of IV peramivir.
3117443|NCT02609607|Placebo Comparator|Placebo|Every other day placement of a placebo rectal suppository for 4 weeks
3117444|NCT02609607|Experimental|Bisacodyl|Every other day placement of a bisacodyl 10 mg rectal suppository for 4 weeks
3117445|NCT02609633|Active Comparator|Control: Usual Care - Current Diabetes Management System (DMS)|Participants will perform self-monitoring of blood glucose (SMBG) for 6 months using the current DMS device. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the type 1 diabetes (T1D) regimen as needed.
3117446|NCT02609633|Experimental|Interventional: Accu-Chek® CONNECT DMS|Participants will receive training on Day 1 with the Accu-Chek® CONNECT DMS and will thereafter perform SMBG for 6 months. Follow-up office visits will be scheduled at Months 3 and 6 to review and discuss SMBG data and modify the T1D regimen as needed.
3117447|NCT02609659|Experimental|3-DAA + RBV 600 mg|3-DAA (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] and dasabuvir [250 mg twice daily]) plus RBV (ribavirin [600 mg once daily]) for 12 weeks.
3117448|NCT02609672|Experimental|Exercise|The participants in this arm were asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Four class times were offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
3117449|NCT02609672|Other|No Exercise|The participants in this arm were asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group were offered a free exercise pass following completion of the study. Measurements were obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
3117450|NCT02609841||Cardiac rhythm remote monitoring system|Subjects use non-invasive wearable BodyGuardian remote monitoring system throughout 12 days of study.
3117451|NCT02609984|Experimental|CMB305 (sequentially administered LV305 and G305)+Atezolizumab|Participants received CMB305 treatment in combination with 1200 mg/day atezolizumab administered by intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 2 years. CMB305 treatment consisted of 2 doses of LV305 administered intradermally (ID) on Days 0 and 14 followed every 2 weeks with alternating doses of G305 administered intramuscularly (IM) and LV305. LV305 was administered at a dose of 1×10^10 vector genomes and G305 at a dose of 5 mcg glucopyranosyl lipid A stable emulsion mixed with 250 mcg of NY ESO-1 protein.
3117452|NCT02609984|Active Comparator|Atezolizumab|Participants received 1200 mg/day atezolizumab by IV infusion Q3W for up to approximately 2 years.
3117453|NCT02610140|Experimental|BAY94-9343|Drug Anetumab ravtansine given Intravenously (IV)
3117454|NCT02610140|Active Comparator|Vinorelbine|Drug Vinorelbine given Intravenously
3117455|NCT02610231|Experimental|Istradefylline 20 mg or 40 mg|Treatment for 52 weeks
3117456|NCT02610634||Parkinson's disease|People with Parkinson's disease (≥ 50 years old) who do not have dementia (MoCA ≥ 21).
3117457|NCT02610634||Older Adults|Aged-matched older adults (≥ 50 years old) who are cognitively intact (MoCA ≥26).
3117458|NCT02610725|Other|Yoga class|A 30 minute online Hatha yoga video intervention will be administered to participants.Participants will only participate in one yoga class and complete follow-up questionnaires.
3117459|NCT02610777|Active Comparator|Azacitidine|Azacitidine 75 milligram per square meter (mg/m^2), intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles.
3117460|NCT02610777|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 mg/m^2, intravenously or subcutaneously, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+ or - 10) infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles.
3117461|NCT02610816|Active Comparator|1FED|1-food elimination diet: Participants eliminate milk from the diet in Phase 1
3117462|NCT02610816|Active Comparator|4FED|4-food elimination diet: Participants eliminate milk, egg, wheat, soy from the diet in Phase 1
3117463|NCT02610816|Other|1FED Non-Responders (4FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy from the diet in Phase 2
3117464|NCT02610816|Other|4FED Non-Responders (SGC)|Participants that fail to respond to 4FED in Phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily in Phase 2
3117465|NCT02610842|Experimental|Handbook group|"Patients will receive a home based program named Hands on - a hand care guide in Systemic Sclerosis which includes a handbook with instructions about the disease and hand exercises. Patients will be asked to follow the program instructions and carry out the exercises daily during the following 12 weeks."
3117466|NCT02610868|Experimental|MYOBLOC Injection|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.
3117467|NCT02610972||CLINICALLY CONFIRMED PREECLAMPSIA|Women clinically diagnosed with preeclampsia (severe, mild or superimposed) during pregnancy will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
3117468|NCT02610972||CLINICALLY HEALTHY|Women with a delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample in the postpartum period to determine the presence or absence of proteinuria using the Congo Red test GV-005.
3117469|NCT02611154|Experimental|Intranasal Testosterone|All participants will be receiving intranasal testosterone and will follow the same study procedures.
3117470|NCT02611362|Experimental|Intervention|"Subjects in the intervention group will each receive a smartphone with a data service plan as the active arm. The IMB Gaming Intervention is designed to improve information, motivation, and skills about adherence and HIV preventative behaviors throughout play. The mission of Viral Combat is: kill virus and build strength through taking medicine, learning HIV prevention information, and engaging with healthy characters in order to improve motivation and build skills. Participants will get a game graphic with a supportive message such as Missing you: Get in the Game to their phones. Throughout the gaming intervention subjects will continue routine clinical care visits and HIV testing in the PrEP clinic."
3117471|NCT02611362|No Intervention|Comparison|This condition will be matched with the IMB Gaming Intervention for appeal, time and attention. Subjects in COMP will each receive smartphones with the same data service plan as the active arm. Smartphones given to participants in COMP will have a stylistically similar non-PrEP, non-IMB game designed by Mission Critical Studios (Dr. Nano X: Incredible Voyage Inside The Body, http://www.youtube.com/watch?v=lyHzSZFzU1Q ). This is the same game that Viral Combat is being adapted from. Therefore, the iPhone game in COMP will have a look and feel that is very similar to our intervention game but without IMB, PrEP, and HIV prevention related content. Similar to the Intervention group, participants will have routine clinical care visits in the PrEP clinic (or more frequently if needed for urgent care).
3117472|NCT02611752|Experimental|CAM2038 q1w, 24 mg|CAM2038 q1w 24 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
3117473|NCT02611752|Experimental|CAM2038 q1w, 32 mg|CAM2038 q1w 32 mg will be administered on Day 0 and Day 7. Hydromorphone 0 mg (placebo), 6 mg and 18 mg will be subsequently administered during 4 challenge sessions on Days 1-3, 4-6, 8-10 and 11-13
3117474|NCT02611765|Experimental|Enhanced therapy|Benzathine penicillin G intramuscular 7.2 million units Three doses of 2.4 million units of intramuscular benzathine penicillin G administered weekly (a total of 7.2 million units)
3117475|NCT02611765|Active Comparator|Standard therapy|Benzathine penicillin G intramuscular 2.4 million units A single intramuscular injection of 2.4 million units of benzathine penicillin G
3117476|NCT02611778|Experimental|FYB201|FYB201 is provided as single use vials and will be administered by intra-vitreal injection.
3117477|NCT02611778|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection.
3117478|NCT02611817|Experimental|Vedolizumab SC 108 mg Maintenance Arm|"Open-label Induction: vedolizumab IV 300 milligram (mg), infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: vedolizumab SC 108 mg injection once every 2 weeks (Q2W) starting at Week 6 up to Week 50"
3117479|NCT02611817|Placebo Comparator|Placebo SC Maintenance Arm|"Open-label Induction: vedolizumab IV 300 mg, infusion at Week 0 (Day 1) and Week 2 (Day 15)~Double-blind Maintenance: matching placebo to vedolizumab SC injection Q2W starting at Week 6 up to Week 50"
3117480|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 108 mg SC|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab SC in maintenance phase. Vedolizumab SC, 108 mg, injection, Q2W and placebo-matching IV infusions, Q8W, starting at Week 6 up to approximately Week 50.
3117481|NCT02611830|Experimental|Maintenance Phase: Induction IV + Vedolizumab 300 mg IV|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive vedolizumab IV in maintenance phase. Vedolizumab 300 mg, IV infusion, Q8W and placebo-matching SC injection, Q2W starting at Week 6 up to approximately Week 50.
3117482|NCT02611830|Experimental|Maintenance Phase: Induction IV + Placebo|Participants received vedolizumab 300 mg IV infusion in open-label induction phase and achieved clinical response at Week 6 were randomized to receive placebo in maintenance phase. Placebo-matching subcutaneous (SC) injections, once every 2 weeks (Q2W) and placebo-matching IV infusions, once every 8 weeks (Q8W) starting at Week 6 up to approximately Week 50.
3117483|NCT02611882|Experimental|High-risk prostate cancer pre-prostatectomy (preRP) population|"Patients with high-risk prostate cancer pre-prostatectomy.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
3117484|NCT02611882|Experimental|Biochemical Recurrence (BCR)|"Patients with prostate cancer with biochemical recurrence~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
3117485|NCT02611882|Experimental|Castrate Resistant Prostate cancer (CRCP) population|"Patients with castrate resistant prostate cancer.~Patients receive Ga-68-HBED-CC-PSMA and then undergo PET/CT or PET/MRI approximately 55-70 minutes later."
3117486|NCT02612064|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
3117487|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
3117488|NCT02612077||Observational Chemotherapy/Bevacizumab|Observed patients receiving chemotherapy with concomitant bevacizumab
3117489|NCT02612155|Experimental|Intervention cell recipients|Experimental: infusions: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have autologous nucleated cord blood cells available for infusion will receive up to two infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
3117490|NCT02612155|Placebo Comparator|Placebo recipients|Control: infants with moderate to severe hypoxic ischemic encephalopathy, begin cooling, and have cord blood available for infusion will receive placebo (a mix of autologous cord blood red blood cells and plasma) infusions. Outcomes will be measured at 22-26 months by neurodevelopment assessment
3117491|NCT02612194|Experimental|Cohort 1|c-MET high (> 50%), RON null (0-9%)
3117492|NCT02612194|Experimental|Cohort 2|c-MET + (10-100%), RON + (10-100%)
3117493|NCT02612194|Experimental|Cohort 3|c-MET null (0-9%), RON + (10-100%)
3117494|NCT02612428|Experimental|ELAD System|This group will receive treatment with ELAD plus standard of care therapy.
3117495|NCT02612428|Other|Standard of Care (Control)|This group will receive standard of care therapy as defined in the protocol.
3117496|NCT02612610|Placebo Comparator|Placebo|Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
3117497|NCT02612610|Experimental|Gefapixant 7.5 mg|Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
3117498|NCT02612610|Experimental|Gefapixant 20 mg|Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
3117499|NCT02612610|Experimental|Gefapixant 50 mg|Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
3117500|NCT02612623|Experimental|Gefapixant 15 mg twice daily|Two 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
3117501|NCT02612623|Experimental|Gefapixant 30 mg twice daily|Four 7.5 mg gefapixant tablets administered by mouth twice daily for 8 weeks
3117502|NCT02612623|Experimental|Gefapixant 50 mg twice daily|One 50 mg gefapixant tablet administered by mouth twice daily for 8 weeks
3117503|NCT02612623|Experimental|Placebo to match gefapixant|Matching placebo tablets administered by mouth twice daily for 8 weeks
3117504|NCT02612688|Experimental|ACP Video Program|Facility asked to implement ACP Video Program
3117505|NCT02612688|No Intervention|Usual ACP procedures|Facility follows usual ACP procedures
3117506|NCT02612727|Experimental|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
3117507|NCT02612727|Active Comparator|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
3117508|NCT02612779|Experimental|Elotuzumab + Pomalidamide + Low Dose Dexamethasone (EPd)|patients will receive treatment with elotuzumab in combination with pomalidomide and low-dose dexamethasone. Patients are eligible to receive Nivolumab at progression.
3117509|NCT02612779|Experimental|Elotuzumab + Nivolumab (EN)|Patients will receive treatment with a combination of elotuzumab and nivolumab
3117510|NCT02612857|Placebo Comparator|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
3117511|NCT02612857|Experimental|IMO-8400 Dose Group 1|IMO-8400 Dose Group 1 subcutaneous injections once a week for 24 weeks.
3117512|NCT02612857|Experimental|IMO-8400 Dose Group 2|IMO-8400 Dose Group 2 subcutaneous injections once a week for 24 weeks.
3117513|NCT02612909|Placebo Comparator|Phase 2: Placebo|Subjects participating in Phase 2 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
3117514|NCT02612909|Active Comparator|Phase 2: Vaccine (15 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
3117515|NCT02612909|Active Comparator|Phase 2: Vaccine (30 mcg)|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (30 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
3117516|NCT02612909|Placebo Comparator|Phase 3: Placebo|Subjects participating in Phase 3 and assigned to receiving two injections of placebo administered intramuscularly as a single dose, separated by 21 days.
3117517|NCT02612909|Experimental|Phase 3: Vaccine|Subjects participating in Phase 2 and assigned to receiving two injections of IVACFLU-A/H5N1 vaccine (15 mcg concentration) administered intramuscularly as a single dose, separated by 21 days.
3117518|NCT02613117|Other|potassium oxalate gel|potassium oxalate gel self applied
3117519|NCT02613117|Other|oxalate liquid, SnF2 paste|Potassium oxalate liquid professionally applied, Stannous fluoride paste self applied
3117520|NCT02613169|Experimental|Isoniazid|Isoniazid (INH) ~10 mg/kg (7-15 mg/kg), will be administered once daily to infants in INH arm for 12 months.
3117521|NCT02613169|No Intervention|No Isoniazid|No INH will be administered to this arm.
3117522|NCT02613182|Experimental|Open Label|Open Label Study Drug NEOD001
3117523|NCT02613208||Participants With Metastatic Breast Cancer|Participants with metastatic breast cancer receiving bevacizumab in combination with paclitaxel, will be observed for treatment responses for up to 18 months from the start of treatment.
3117524|NCT02613221|Experimental|panitumumab + TAS-102 combination therapy|Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course).
3117525|NCT02613338||DePuy Attune PS FB knee system|Patients implanted with a DePuy Attune posterior stabilizing fixed bearing knee system
3117526|NCT02613364|Experimental|Arm I (behavioral intervention-yoga)|Patients undergo the YOCAS intervention comprising 18 specific physical postures and mindfulness exercises focused on breathing and meditation and meet with the yoga instructor over 75 minutes 2 times a week for 4 weeks.
3117527|NCT02613364|Experimental|Arm II (cognitive intervention-CBT-I)|Patients undergo CBT-I intervention comprising sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention delivered by a health professional over 90 minutes once a week for 8 weeks.
3117528|NCT02613364|Active Comparator|Arm III (educational intervention)|"Patients attend survivorship health education sessions over 75 minutes 2 times a week for 4 weeks based on the American Society of Clinical Oncology cancer survivorship educational recommendations delivered by a community health educator. Patients also receive a booklet entitled, Cancer Survivorship Next Steps for Patients and Their Families."
3117529|NCT02613403|Experimental|[Part A, Arm 1] Prior SOF/LDV Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
3117530|NCT02613403|Experimental|[Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of SOF/LDV receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
3117531|NCT02613403|Experimental|[Part A, Arm 3] Prior GZR/EBR Failure: MK-3682B + RBV|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily in combination with RBV twice daily for 16 weeks.
3117532|NCT02613403|Experimental|[Part A, Arm 4] Prior GZR/EBR Failure: MK-3682B|C or NC HCV GT1 participants previously failing a DAA regimen of GZR/EBR (MK-5172/MK-8742) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 24 weeks.
3117533|NCT02613403|Experimental|[Part B] Prior DAA (GT1-6) or SOF/PR (GT3) Failure: MK-3682B|C or NC HCV participants previously failing any all-oral DAA regimen (GT1-6) or SOF/PR regimen (GT 3 only) receive MK-3682B, an FDC of GZR (MK-5172 [50 mg]) + UPR (MK-3682 [225 mg]) + RZR (MK-8408 [30 mg]), administered as 2 tablets once daily for 16 weeks.
3117534|NCT02613481|Other|Poly-L-Lactic Acid (Sculptra) injection|Poly-L-Lactic Acid (Sculptra) injection for all enrolled subjects
3117535|NCT02613507|Experimental|Arm A: Nivolumab|Nivolumab Intravenous infusion specified dose on specified days
3117536|NCT02613507|Active Comparator|Arm B: Docetaxel|Docetaxel Intravenous infusion specified dose on specified days
3117537|NCT02613572|Experimental|alpha lipoic acid (ALA) 600mg once daily x 5 days|All 15 patients recruited to the Phase I part will take escalating doses of alpha lipoic acid (ALA) open label. Each enrolled subject will take 600 mg of oral ALA once daily with a meal for 5 days. If well-tolerated, each subject will then take 800 mg of oral ALA once daily with a meal for 5 additional days. If 800 mg of oral ALA is well-tolerated, then subjects will then take 1200 mg of oral ALA once daily with a meal for 5 days.
3117538|NCT02613572|Experimental|alpha lipoic acid 800mg|once daily with meal x 5 days
3117539|NCT02613572|Experimental|alpha lipoic acid 1200mg|once daily x 5 days
3117540|NCT02613572|Placebo Comparator|Placebo 600mg|All 50 subjects in Phase II will be double blinded and randomized to either placebo or ALA. Each will take one 600mg capsule of ALA (or placebo) once daily with a meal for 2 weeks and then increase to two 600 mg capsules of ALA (or placebo) once daily with a meal for the
3117541|NCT02613572|Experimental|ALA 600 mg|once daily with a meal for 2 weeks
3117542|NCT02613572|Placebo Comparator|Placebo 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
3117543|NCT02613572|Experimental|ALA 1200mg|Two 600mg capsules once daily with a meal for the entire remainder of the 18 month period of the study
3117544|NCT02613871|Experimental|LDV/SOF|LDV/SOF FDC for 12 weeks
3117545|NCT02613884|Experimental|Treatment|All patients with a 25OHD level <30 ng/dL will be given 250,000 IU D3 (cholecalciferol) orally at one point in time and during CF clinic.
3117546|NCT02613897|Active Comparator|DAPA/SAXA (dapagliflozin plus saxagliptin)|Dapagliflozin 10mg + Saxagliptin 5mg (plus standard of care treatment of metformin or metformin plus sulfonylurea).
3117547|NCT02613897|Active Comparator|DAPA (Dapagliflozin plus placebo)|Dapagliflozin 10mg + Placebo (plus standard of care treatment of metformin or metformin plus sulfonylurea).
3117548|NCT02613897|Placebo Comparator|PCB (Placebo plus placebo)|Placebo (for dapagliflozin) + placebo (for saxagliptin) (plus standard of care treatment of metformin or metformin plus sulfonylurea).
3117549|NCT02613910|Experimental|Ofatumumab|t the Baseline (Bln) and wk 4 visits, Subjects will receive 40mg ofatumumab sc (Oft) (as two 20mg sc inj) and as 1 Oft 20mg sc inj every 4 wks from wk 8 through wk 56. Subjects will return to clinic 4 wks after the last dose for a follow-up (f/u) visit (wk 60). Antihistamine 10 mg and Acetaminophen/paracetamol (A/P) 1 grams(g) will be given 1-2 hours(h) before and 4 h after each dose of Oft. A/P 1 g will be supplied for self administration if needed. Prednisone/Prednisolone dose will continue to be tapered during core study period (CSP) by 1 dose level every 2 wks to <= 10 mg/day from Bln through wk 60. Upon completion of the CSP, subjects will enter Individualized f/u Period, where subjects will monitored every 12 wks for a minimum of 1 yr and for up to 2 yr, until CD19+ B-LC or IgG recover to lower limit of normal (LLN) or to the subject's Bln value from Study OPV116910 (if <LLN) or if study withdrawal criteria are met or for a maximum of 2 yr after the last dose of Oft.
3132448|NCT03428100|Experimental|4 mg Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
3132449|NCT03428100|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
3117550|NCT02614066|Experimental|Phase 1: 2 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with relapsed or refractory B-precursor acute lymphoblastic leukemia (r/r B-ALL) will receive conditioning chemotherapy (fludarabine 25 mg/m^2 intravenously [IV] over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel (KTE-X19) chimeric antigen receptor (CAR) transduced autologous T cells at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
3117551|NCT02614066|Experimental|Phase 1: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 1 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
3117552|NCT02614066|Experimental|Phase 1: 0.5 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 0.5 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 0.5 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
3117553|NCT02614066|Experimental|Phase 2: 1 x 10^6 Anti-CD19 CAR T Cells/kg|Participants with r/r B-ALL will receive conditioning chemotherapy (fludarabine 25 mg/m^2 IV over 30 minutes on Day -4, Day -3, and Day -2 and cyclophosphamide 900 mg/m^2 IV over 60 minutes on Day -2) following a single IV infusion of brexucabtagene autoleucel CAR transduced autologous T cells at a target dose of 1 x 10^6 anti-CD19 CAR T cells/kg of body weight on Day 0. For participants weighing > 100 kg, a maximum flat dose of 1 x 10^8 anti-CD19 CAR T cells/kg of body weight will be administered.
3117554|NCT02614079|Experimental|DSSEP|DSSEP testing after SCS trial lead placement
3117555|NCT02614131|Experimental|LY2599666 (Part A)|LY2599666 given subcutaneously (SC) once.
3117556|NCT02614131|Placebo Comparator|Placebo (Part A)|Placebo matching LY2599666 given SC once.
3117557|NCT02614131|Experimental|LY2599666 (Part B)|LY2599666 given SC once weekly for 12 weeks (13 doses).
3117558|NCT02614131|Placebo Comparator|Placebo (Part B)|Placebo given SC once weekly for 12 weeks (13 doses).
3117559|NCT02614131|Experimental|Solanezumab (Part C)|Solanezumab given intravenously (IV) once weekly or once every 4 weeks for 12 weeks.
3117560|NCT02614131|Placebo Comparator|Placebo (Part C)|Placebo given IV once weekly or once every 4 weeks for 12 weeks.
3117561|NCT02614183|Experimental|Galcanezumab 120mg|Galcanezumab given by subcutaneous (SC) injection at 120mg dose once a month for 6 months. Participants received a loading dose of 240mg (2 injections of 120mg each) was administered at visit 3 only.
3117562|NCT02614183|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
3117563|NCT02614183|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
3117564|NCT02614196|Experimental|Galcanezumab 120mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
3117565|NCT02614196|Experimental|Galcanezumab 240mg|Galcanezumab 240mg given by SC injection once a month for 6 months.
3117566|NCT02614196|Placebo Comparator|Placebo|Placebo given by SC injection once a month for 6 months.
3117567|NCT02614196|Experimental|Galcanezumab 120mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
3117568|NCT02614196|Experimental|Galcanezumab 240mg Maximum Extended Enrollment Cohort|Galcanezumab 240mg given by SC injection once a month for 6 months.
3117569|NCT02614196|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo given by SC injection once a month for 6 months.
3117570|NCT02614222|Experimental|Peripheral Nerve Block with CAIG|The participants in this group (test group) will utilize the same procedure utilizing existing ultrasound equipment with the supplemental CAIG system.
3117571|NCT02614222|No Intervention|Peripheral Nerve Block without CAIG|The participants in the control group will receive the procedure with traditional ultrasound methods and equipment.
3117572|NCT02614261|Experimental|Galcanezumab 120 mg|"Galcanezumab 240 mg given as loading dose at first dosing visit followed by 120 mg once a month for 2 months by subcutaneous (SC) injection.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
3117573|NCT02614261|Experimental|Galcanezumab 240 mg|"Galcanezumab 240 mg given by SC injection once a month for 3 months.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
3117574|NCT02614261|Placebo Comparator|Placebo|"Placebo given by SC injection once a month for 3 months.~Participants may be eligible for optional open-label extension at the end of the double blind period with dose level 1 or dose level 2."
3117575|NCT02614274|Experimental|Nutraceutical joint health formulation|A Proprietary Blend
3117576|NCT02614287|Experimental|Galcanezumab 120 mg|Galcanezumab 240mg given as loading dose at first dosing visit followed by 120 mg given by subcutaneous (SC) injection once a month for up to 11 months by auto injector or pre-filled syringe.
3117577|NCT02614287|Experimental|Galcanezumab 240 mg|Galcanezumab 240 mg given by SC injection once a month for up to 12 months by auto injector or pre-filled syringe.
3117578|NCT02614469|Experimental|Group 1, Inosine with Food|Group 1 subjects will take inosine with food on day 1 after an overnight fast and will take a second dose of inosine without food on day 8 after an overnight fast.
3117579|NCT02614469|Experimental|Group 2, Inosine without Food|Group 2 subjects will take inosine without food on day 1 after an overnight fast and will take a second dose of inosine with food on day 8 after an overnight fast.
3117580|NCT02614547|Placebo Comparator|Placebo|Participants received infusion rates of placebo matched to SAGE-547.
3132450|NCT03428100|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily in combination with topical corticosteroids. Placebo administered orally to maintain the blind.
3117581|NCT02614547|Experimental|SAGE-547|Participants received a 4-hour dose titration of 30 micrograms per kilogram per hour (micrograms/kg/hr) (0 to 4 hours), then 60 micrograms/kg/hr (4 to 24 hours), then 90 micrograms/kg/hr (24 to 52 hours), followed by a taper to 60 micrograms/kg/hr (52 to 56 hours), and 30 micrograms/kg/hr (56 to 60 hours).
3117582|NCT02614560|Experimental|Pre-allo (before stem cell transplant)|Pre-allo reduced intensity chemotherapy vadastuximab talirine (melphalan and fludarabine)
3117583|NCT02614560|Experimental|Post-allo (after stem cell transplant)|Post-allo vadastuximab talirine
3117584|NCT02614690|Active Comparator|No split Cast of forearm fractures|"Patient will have a No split cast long arm cast applied after a closed reduction of forearm fractures. The cast will not be split. 20 patients will be randomized to this arm."
3117585|NCT02614690|Active Comparator|Univalve Split Cast of forearm fractures|"Patients will have a Univalve Split Cast long arm cast applied after undergoing closed reduction of of forearm fractures. This is a cast that is split on only one side of the cast. 20 patients will be randomized to this arm"
3117586|NCT02614690|Active Comparator|Bivalve Split Cast of forearm fractures|"Patients will have a Bivalve Split Cast long arm cast applied after they have undergone a closed reduction of of forearm fractures. This is a cast that will be split on both sides of the cast. 20 patients will be randomized to the bivalve split arm cast."
3117587|NCT02614703|Experimental|Chromoendoscopy using Acetic Acid 2.5%|Patient will have endoscopic examination of esophagus. Esophageal mucosa sprayed with 5cc solution of Acetic Acid 2.5% one time only. Esophageal mucosa examined again. Biopsies are obtained. Abnormal areas identified by Acetic Acid 2.5% will be submitted on separate containers for pathology review. If no abnormalities seen, random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
3117588|NCT02614703|Active Comparator|Standard random esophageal biopsies|Patient will have endoscopic examination of the esophagus. Esophageal mucosa will not be sprayed with Acetic Acid 2.5%. Random biopsies taken as per standard recommendations for Barrett's esophagus. Samples submitted for pathology review.
3117589|NCT02614729|Experimental|Energy Balance Comparison|"Participants will randomly consume 4 eucaloric diets for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy balance.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN); High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)"
3117590|NCT02614729|Experimental|Energy Restriction Comparison|"Participants will randomly consume 3 energy restriction diets (1250 kcal/day) for 7 consecutive days/treatment. Energy levels for all diets are established according to needs for energy restriction.~Interventions:~Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN); Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN); High Protein-Beef, Even Distribution (HP-BEEF-EVEN)"
3117591|NCT02614794|Experimental|Tucatinib in combination with capecitabine & trastuzumab|Tucatinib + capecitabine + trastuzumab
3117592|NCT02614794|Active Comparator|Placebo in combination with capecitabine & trastuzumab|Placebo + capecitabine + trastuzumab
3117593|NCT02614924|Other|Flexible fibre-optic scope|Randomly allocated to fibreoptic group
3117594|NCT02614924|Other|Pentax AWS videolaryngoscope|Randomly allocated Pentax AWS videolaryngoscope
3117595|NCT02615145||Genotype 1a (G1a) Participants|"Treatment-naïve or -experienced participants with confirmed chronic hepatitis C (CHC) genotype 1a (G1a, includes all GT1-participants except participants with GT1b or GT1b/4), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) + ribavirin (RBV) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
3117596|NCT02615145||Genotype 1b (G1b) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 1b (G1b; includes G1b/Genotype 4 [G4]), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir with dasabuvir (ABBVIE REGIMEN) according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
3117597|NCT02615145||Genotype 4 (G4) Participants|"Treatment-naïve or -experienced participants with confirmed CHC genotype 4 (G4; non-G1), receiving combination therapy with the interferon-free paritaprevir/ritonavir - ombitasvir (ABBVIE REGIMEN) + RBV according to standard of care and in line with the current local label.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
3117598|NCT02615158|Experimental|Maternal Physical Activity and Nutrition|A maternal intervention focusing on healthy diet and physical activity patterns for mothers.
3117599|NCT02615158|Experimental|Parenting|A toddler parenting intervention focusing on parenting, limit setting, and development strategies.
3117600|NCT02615158|Experimental|Child Safety|Attention control group. The parents received intervention to promote safety among toddlers.
3117601|NCT02615171|Active Comparator|Comprehensive Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
3117602|NCT02615171|Active Comparator|Simple Dietary Self-Monitoring|The intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
3117603|NCT02615249|Experimental|Metal Allergen Epicutaneous Patch|8 allergens were tested. Not all subjects tested each allergen. Section reports number of subjects with positive responses to each allergen.
3117604|NCT02615470|Experimental|Enhanced immunization delivery model|Pharmacist-technician pairs employed by community pharmacies that are assigned to this arm will receive a) immunization update training, b) training by immunization experts to enhance immunization delivery model and foster practice change at the beginning of 6-month and c) regular feedback and clinical support for the period of 6 months.
3117605|NCT02615470|Active Comparator|Immunization update|Pharmacist-technician pairs employed by community pharmacies that are assigned to the control arm will receive an immunization update training. They will not receive a training by immunization experts nor regular feedback and clinical support.
3117606|NCT02615509|Other|Imaging on experimental tomo device|"Women will have a bilateral two-view mammogram (a total of four images) with the Philips MicroDose Tomosynthesis system and a bilateral two-view mammogram (a total of four images) with an FFDM system. The order of this will be randomised.~After collecting the cases together with ground truth a readers study will be performed."
3117607|NCT02615535|Experimental|EEG neurofeedback-assisted meditation|EEG neurofeedback assisted meditation using the MUSE device and auditory feedback.
3117608|NCT02615535|Active Comparator|Non-EEG feedback-assisted meditation|Non-EEG neurofeedback assisted meditation. Subjects will have auditory instruction from the MUSE device without the EEG neurofeedback.
3117609|NCT02615717|Experimental|Attentional Bias Modification|In the ABM treatment condition, participants will have four 20-minute in-lab treatment conditions across two weeks. Within these Attention Bias Modification sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target will always appear in the location of the neutral word).
3117610|NCT02615717|Active Comparator|Attentional Control Condition|Participants will have four 20-minute in-lab treatment conditions across two weeks. Within the Attention Bias Modification control sessions, participants will be presented with a fixation cross for 500 ms. The fixation cross will then be replaced with a word pair consisting of either a threat/neutral pair or a neutral/neutral word for 500 ms, followed by a probe in the location of one of the two words (80% threat/neutral pairs, 20% neutral/neutral pairs; the target appears in the location of the neutral word in 50% of the trials. Complete Stroop and 3-back task, etc.
3117611|NCT02615743|Experimental|Intervention Group|Caregivers of intervention arm participants will receive daily text message reminders about asthma controller medication use, as well as an electronic monitoring device to track the participant's medication usage for 60 days following hospital discharge. At the end of 30 days, participants will be able to opt out of daily text messages if they choose. All caregivers of participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
3117612|NCT02615743|Other|Control Group|Caregivers of control arm participants will receive an electronic monitoring device to track their medication usage for 60 days following hospital discharge. At 30 days, caregivers of participants will be able to opt in to receive daily text message reminders about asthma medication use. Caregivers of all participants will also complete a 30-minute survey at the time of enrollment and 2 brief telephone followups at 30 and 60 days.
3117613|NCT02616029|Experimental|Part 1: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and without any other NRTI resistance mutation switched from their current human immunodeficiency virus (HIV) treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: lopinavir/ritonavir (LPV/r), atazanavir + ritonavir (ATV+RTV), atazanavir+cobicistat (ATV+COBI), darunavir + ritonavir (DRV+RTV), darunavir + cobicistat (DRV+COBI), fosamprenavir + ritonavir (FPV + RTV), saquinavir + ritonavir (SQV + RTV), atazanavir (ATV) (no booster) efavirenz (EFV), rilpivirine (RPV), nevirapine (NVP), etravirine (ETR), raltegravir (RAL) or dolutegravir (DTG)."
3117614|NCT02616029|Experimental|Part 2: E/C/F/TAF|"Participants with M184V and/or M184I mutations in reverse transcriptase and with or without 1 or 2 TAMs switched from their current HIV treatment regimen consisting of FTC/TDF or ABC/3TC plus a third antiretroviral agent to E/C/F/TAF (150/150/200/10 mg) FDC tablet orally once daily for 48 weeks.~Allowed third agents include: LPV/r, ATV+RTV, ATV+COBI, DRV+RTV, DRV+COBI, FPV + RTV, SQV + RTV, ATV (no booster) EFV, RPV, NVP, ETR, RAL or DTG."
3117615|NCT02616146|Experimental|ENG-E2 125 μg/300 μg|Participants will receive up to 13 cycles of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
3117616|NCT02616146|Active Comparator|LNG-EE 150 μg/30 μg|Participants will receive up to 13 cycles of LNG-EE 150 μg/30 μg. Each cycle will consist of one tablet per day for 21 days, followed a 7-day tablet-free interval.
3117617|NCT02616250|Experimental|Brimonidine 0.33% gel / CD07805/47 (Br) + Ivermectin 1% cream|"Half group will receive once-daily Br 0.33% gel in the morning and once-daily IVM 1% cream in the evening for 12 weeks.~Half group will receive once-daily Br vehicle gel in the morning for the first 4 weeks and once-daily Br 0.33% gel in the morning for the following 8 weeks and once-daily IVM 1% cream in the evening for 12 weeks."
3117618|NCT02616250|Placebo Comparator|CD07805/47 (Br) placebo gel + CD5024 (IVM) placebo cream|Subjects will receive once-daily Br vehicle gel in the morning and once-daily IVM vehicle cream in the evening for 12 weeks.
3117619|NCT02616380||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
3117620|NCT02616393|Experimental|Cohort A: Brain Metastases (BM)|Tesevatinib 300 mg orally (PO) once daily (QD) administered to subjects with NSCLC who had progressed with brain metastases (BM)
3117621|NCT02616393|Experimental|Cohort B: Leptomeningeal Metastases (LM)|Tesevatinib 300 mg PO QD administered to subjects with NSCLC who had progressed with leptomeningeal metastases (LM)
3117622|NCT02616393|Experimental|Cohort C: Brain Metastases at Initial Presentation (BM-IP)|Tesevatinib 300 mg PO QD administered NSCLC who presented initially with BM at initial presentation
3117623|NCT02616523|Active Comparator|dexmedetomidine|The investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
3117624|NCT02616523|Active Comparator|lidocaine|Lidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
3117625|NCT02616523|Placebo Comparator|placebo|The placebo group will receive intravenous infusion of normal saline only.
3117626|NCT02616601|Experimental|Generic Fluorouracil Cream|Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
3117627|NCT02616601|Active Comparator|Carac® (Fluorouracil) Cream|Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
3117628|NCT02616601|Placebo Comparator|Vehicle Cream|Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible. Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime. Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water. Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
3117629|NCT02616614|Active Comparator|Onexton gel|Clindamycin 1.2% and benzoyl peroxide 3.75% topical gel Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
3117630|NCT02616614|Experimental|Clindamycin/benzoyl peroxide gel|Generic clindamycin 1.2% and benzoyl peroxide 3.75% topical gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
3117631|NCT02616614|Placebo Comparator|Placebo|A vehicle gel. Applied a thin film of medication onto 6 areas of the face (chin, left cheek, right cheek, nose, left forehead, and right forehead) once daily
3117632|NCT02616783|Experimental|E/C/F/TAF|Participants will switch from tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) or 3TC plus a third agent to E/C/F/TAF and will receive treatment for 48 weeks.
3117633|NCT02616783|Active Comparator|Remain current regimen|Participants will remain on current TDF and FTC (or FTC/TDF) or 3TC plus continuing third agent.
3117634|NCT02616900|Experimental|eSight Eyewear|Main arm
3117635|NCT02617589|Experimental|Nivolumab + Radiotherapy Arm|Nivolumab IV infusion + Radiotherapy dose as specified
3117636|NCT02617589|Active Comparator|Temozolomide + Radiotherapy Arm|Temozolomide + Radiotherapy dose as specified
3117637|NCT02617628|Active Comparator|Before Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
3117638|NCT02617628|Active Comparator|After Re-entry|Extended Release Naltrexone, 380 mg injection, 1x monthly for 4 months
3117639|NCT02617667|Experimental|CyclASol Ophthalmic Solution 1|Cyclosporine A solution (dose-level 1) in vehicle
3117640|NCT02617667|Experimental|CyclASol Ophthalmic Solution 2|Cyclosporine A solution (dose-level 2) in vehicle
3117641|NCT02617667|Placebo Comparator|Placebo Ophthalmic Solution|Vehicle only
3117642|NCT02617667|Active Comparator|Restasis|Cyclosporine A 0.05% ophthalmic emulsion
3117643|NCT02617784|Experimental|Regimen A: Oseltamivir with HD|Participants will receive 30 milligrams (mg) of oseltamivir via oral suspension approximately 1 hour after alternating HD sessions. Sessions will occur three times per week within the 6.5-week study period, and participants will receive a total of 9 doses of oseltamivir.
3117644|NCT02617784|Experimental|Regimen B: Oseltamivir with CAPD|Participants will receive 30 mg of oseltamivir via oral suspension once weekly after dialysis exchange. CAPD sessions will occur four times every 24 hours, and participants will receive a total of 6 doses of oseltamivir within the 6-week study period.
3117645|NCT02617888|Active Comparator|CCTA Breast Shields|Within female subset, randomization to wearing bismuth breast shield.
3117646|NCT02617888|No Intervention|CCTA No Breast Shields|Within female subset, randomization to wearing no bismuth breast shield (standard of care).
3117647|NCT02617888|No Intervention|Observational Arm|Non-females undergoing CTA and subjects undergoing cardiac catheterization and nuclear medicine testing.
3117648|NCT02617901|Experimental|Recruited children|"Children aged below 16 years attending the Radiology Department for a left hand radiograph in order to assess bone age on the basis of clinical need. There will be one male and one female from each of five age groups (< 5 years; 5 to 7 years; 8 to 10 years; 11 to 13 years; 14 to 16 years).~Bone age will be assessed according to the Greulich & Pyle and TW3 methods by 3 observers on 2 separate occasions at least 4 weeks apart. Recruited children will have intervention in the form of a left hand DXA which will be anonymised and from which the same 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
3117649|NCT02618031|Other|Favorable CIS|Patients with a favorable CIS (fCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
3117650|NCT02618031|Experimental|Poor CIS|Patients with a poor CIS (pCIS) will receive endovascular treatment (EVT) and medical treatment consistent with national guidelines.
3117651|NCT02618187|Experimental|Weekly SER-287, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
3117652|NCT02618187|Placebo Comparator|Daily placebo, after Placebo Pre-Treat.|Placebo pre-treatment, followed by once daily placebo for 8 weeks
3117653|NCT02618187|Experimental|Daily SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks
3117654|NCT02618187|Experimental|Weekly SER-287, after Vanco. Pre-Treat.|Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks
3117655|NCT02618343|Experimental|ISOPROPYL ALCOHOL AROMATHERAPY|Prehospital patients complaining of nausea randomized into the IPA Arm.
3117656|NCT02618343|Active Comparator|Ondansetron|Prehospital patients complaining of nausea randomized into the ondansetron arm.
3117657|NCT02618382|Experimental|All subjects|Patients will undergo standard treatment of their chronic subdural hematoma with the addition of preoperative and postoperative oral tranexamic acid treatment. Patients will receive a dose of 1300mg orally three to four hours prior to surgery. They will then take 1300mg orally three times daily for three days or until discharge, whichever occurs first.
3117658|NCT02618512|Experimental|SBC-103|Patients were administered 1 mg/kg by IV infusion once every other week (qow) for at least 12 weeks. After evaluation of 12-week safety, tolerability, and pharmacodynamic data in individual patients, the dose was increased to 3 mg/kg qow. Infusions were to be at least 10 days apart and were administered every 14 days ±5 days.
3117659|NCT02618616|Experimental|ZPL-389|Each subject was given 30 mg ZPL-3893787 capsules, to be taken orally once daily (OD) for 12 weeks.
3117660|NCT02618616|Placebo Comparator|Placebo|Each subject was given 30 mg capsules of matching placebo, to be taken orally OD for 12 weeks.
3117661|NCT02618642|Active Comparator|Piler light + red filter|Group x: irradiation with a red filter (visible red radiation and infrared; 650-800 nm and 800-3900 nm, respectively) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
3117662|NCT02618642|Active Comparator|Piler light + blue filter|Group y: irradiation with a blue filter (blue radiation; 440-480 nm) time of phototherapy treatment: 10 minutes for one session 10 irradiations to the biceps brachii muscle
3117663|NCT02618642|Active Comparator|Piler light without a filter|Group v: irradiation without a filter (white radiation in the entire spectrum and near-infrared radiation; 480-3400 nm) one session lasted 10 minutes 10 irradiations to the biceps brachii muscle
3117664|NCT02618642|Placebo Comparator|placebo|Group z: placebo irradiation (without a filter, 3 min, distance: 100 cm). time of phototherapy treatment: 3 minutes for one session distance of 1meter 10 irradiations to the biceps brachii muscle
3117665|NCT02618759|Experimental|DSXS1505|To evaluate the therapeutic efficacy and safety of DSXS topical spray, 0.15%.
3117666|NCT02618759|Placebo Comparator|Placebo|Eligible patients will be randomized in a 1:1 ratio to Test or Placebo product.
3117667|NCT02618772|Placebo Comparator|Intranasal Saline|0.08ml/kg of saline to a maximum of 2ml intranasally with an atomizer MAD-300
3117668|NCT02618772|Active Comparator|Intranasal Midazolam|0.08ml/kg (0.4mg/kg of 5mg/ml IV solution) intranasal midazolam, to a maximum of 2ml (10mg), with an atomizer MAD-300
3117669|NCT02618915|Experimental|DTX101, Cohort 1|a single peripheral intravenous (IV) infusion of 1.6 x 10^12 genome copies (GC)/kg DTX101
3117670|NCT02618915|Experimental|DTX101, Cohort 2|a single peripheral IV infusion of 5.0 x 10^12 GC/kg DTX101
3117671|NCT02618928||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 8, 12, or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
3117672|NCT02618967|Experimental|AMG 570 - 7 mg|Participants will receive a single dose 7 mg dose of AMG 570 administered subcutaneously.
3117673|NCT02618967|Experimental|AMG 570 - 21 mg|Participants will receive a single 21 mg dose of AMG 570 administered subcutaneously.
3117674|NCT02618967|Experimental|AMG 570 - 70 mg|Participants will receive a single 70 mg dose of AMG 570 administered subcutaneously.
3117675|NCT02618967|Experimental|AMG 570 - 140 mg|Participants will receive a single 140 mg dose of AMG 570 administered subcutaneously.
3117676|NCT02618967|Experimental|AMG 570 - 210 mg|Participants will receive a single 210 mg dose of AMG 570 administered subcutaneously.
3117677|NCT02618967|Experimental|AMG 570 - 420 mg|Participants will receive a single 420 mg dose of AMG 570 administered subcutaneously.
3117678|NCT02618967|Experimental|AMG 570 - 700 mg|Participants will receive a single 700 mg dose of AMG 570 administered subcutaneously.
3117679|NCT02618967|Placebo Comparator|Placebo|Participants will receive a single dose of the matching AMG 570 placebo administered subcutaneously.
3117680|NCT02619175|Experimental|Perturbation-based balance training|"perturbation-based balance training while standing and walking on the BalanceTutor (MediTouch).~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
3117681|NCT02619175|Active Comparator|Weight shifting and gait training|"Balance and gait training without external perturbations. Voluntary weight shifting while standing on a computerized posturography (NeuroCom) and walking on a treadmill.~10-12 training sessions, 4-5 per week for 3 weeks. Each session will last 30 minutes."
3117682|NCT02619396|Active Comparator|"Group 20 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 1 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
3117683|NCT02619396|Active Comparator|"Group 40 W / LSI 4"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 2 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
3117684|NCT02619396|Active Comparator|"Group 20 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 3 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
3117685|NCT02619396|Active Comparator|"Group 40 W / LSI 5"|Patients elected to atrial fibrillation (AF) ablation and randomized to Combination 4 of radiofrequency (RF) power and Lesion Size Index (LSI) on left atrial (LA) posterior wall
3117686|NCT02619409|Placebo Comparator|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
3117687|NCT02619409|Active Comparator|EPI25 group|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
3117688|NCT02619409|Active Comparator|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc.
3117689|NCT02619409|Active Comparator|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075 cc, and sterile saline 0.025%.
3117690|NCT02619409|Active Comparator|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc
3117691|NCT02619591|Active Comparator|Ultrasound Imaging - Single View|Ultrasound performed on patient. A single view of each hemithorax with ultrasound was performed on patient
3117692|NCT02619591|Experimental|Ultrasound Imaging - Multiple Views|Ultrasound performed on patient. Multiple view of each hemithorax with ultrasound was performed on patient
3117693|NCT02619617|Experimental|SOM230 0.9mg|cohort 2
3117694|NCT02619617|Experimental|SOM230 1.5 mg|cohort 1
3117695|NCT02619799|Active Comparator|GROUP A(MAGNESIUM GROUP)|MAGNESIUM GROUP received 50 mg(0.1 ml) of intrathecal magnesium sulphate diluted to 1 ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
3117696|NCT02619799|Active Comparator|GROUP B(MIDAZOLAM GROUP)|MIDAZOLAM GROUP received 1mg(0.2ml) of intrathecal midazolam diluted to 1ml with 0.9% normal saline combined with 14-16 ml of epidural 0.75% ropivacaine as a part of combined spinal epidural technique at L2-L3/L3-L4 interspace.
3117697|NCT02620020|Experimental|Fasinumab 6 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 6 mg SC Q4W arm received fasinumab 12 mg SC on Day 1 (loading dose) and then 6 mg SC (planned maintenance dose) at Weeks 4, 8, and 12 for a total of 4 doses. Matching placebo was received via intravenous (IV) infusion Q8W on Day 1 and at Week 8.
3117698|NCT02620020|Experimental|Fasinumab 9 mg SC Q4W and Placebo IV Q8W|Participants randomized to the fasinumab 9 mg SC Q4W arm received 18 mg SC on day 1 (loading dose) and then 9 mg SC (planned maintenance dose) at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo IV Q8W was received on Day 1 and at Week 8.
3117699|NCT02620020|Experimental|Fasinumab 9 mg IV Q8W and Placebo SC Q4W|Participants randomized to the fasinumab 9 mg IV Q8W arm received IV infusions of fasinumab 9 mg on Day 1 and Week 8, for a total of 2 doses. Matching placebo SC Q4W was received on day 1 and at weeks 4, 8, and 12.
3117700|NCT02620020|Experimental|Placebo SC Q4W and Placebo IV Q8W|Participants randomized to the matching placebo subcutaneously (SC) every four weeks (Q4W) arm received SC placebo in a manner similar to the SC loading dose of the active groups (placebo loading dose) on Day 1 and then an SC injection of placebo at weeks 4, 8, and 12 for a total of 4 doses. Matching placebo intravenously (IV) every 8 weeks (Q8W) was received on Day 1 and at Week 8.
3117701|NCT02620384|Placebo Comparator|Experimental: Placebo|This group will receive all standard heart failure therapy and placebo pill.
3117702|NCT02620384|Active Comparator|Experimental: Metolazone|This group will receive all standard heart failure therapy with addition of metolazone.
3117703|NCT02620683|Active Comparator|Buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
3117704|NCT02620683|Active Comparator|Non-buffered Lidocaine|"In week One each subject would receive anesthetic to block the inferior alveolar and lingual N; Halstead or Gow-Gates techniques. No Buccal N. block. At least a week later injections would involve the alternate local anesthetic combination.~Venous blood samples would be drawn from the antecubital fossa 30min post oral injection and assayed for blood lidocaine levels"
3117705|NCT02620774|Experimental|Diabetic Wound Infection|Participants with a documented history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 8 hours.
3117706|NCT02620774|Active Comparator|Healthy Volunteer|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive at least 3 doses of intravenous ceftolozane/tazobactam 1.5g every 8 hours, followed by sampling of interstitial tissue fluid in the thigh by a microdialysis probe over 8 hours.
3117707|NCT02620787|Experimental|Diabetic Wound Infection|Participants with a documented medical history of Type 1 or Type 2 diabetes and a mild to moderate (Grade 2 or 3) wound infection of the lower limb will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
3117708|NCT02620787|Active Comparator|Healthy Volunteers|Participants will be male or female healthy adult volunteers with no significant medical or medication history. Participants will receive 3 to 6 doses of oral tedizolid 200mg once daily, followed by sampling of interstitial tissue fluid at the margin of the wound by a microdialysis probe over 24 hours following the last dose (e.g., 48-72 hours).
3117709|NCT02620878|Experimental|AP|"Experimental arm: A closed-loop control system (artificial pancreas) will be used during night and day for 72 hours (3 days) with the aim of automate insulin infusion by an insulin pump to control glucose level. AP is composed of a CGM device (Dexcom G4), an insulin pump (Accu Chek Spirit combo, Roche), and a model predictive control algorithm that is embedded in a smartphone and wirelessly linked to the CGM device and insulin pump. A remote monitoring will be ensured all the time the AP will be active and study team will be present in the camp.~Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence"
3117710|NCT02620878|Active Comparator|SAP|"Active Comparator: Sensor Augmented Pump (SAP teraphy : CGM + insulin pump) will be used for 72 hours during day and night (3 days).~Patients will be randomly assigned to receive either 3 days of SAP (Control) followed by 3 days of automated closed-loop insulin delivery (intervention), or the inverted sequence"
3117711|NCT02620904|Active Comparator|mifepristone|following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery
3117712|NCT02620904|Placebo Comparator|placebo pill|following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery
3117713|NCT02621034|Experimental|Control|K-file hand instrumentation
3117714|NCT02621034|Experimental|Reciproc|rotary reciprocating protocol
3117715|NCT02621034|Experimental|One shape|one shape continuous rotation protocol
3117716|NCT02621047|Experimental|Alectinib: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 milligrams (mg) on Day 1.
3117717|NCT02621047|Experimental|Alectinib: Severe Hepatic Impairment|Participants with severe hepatic impairment (based on Child-Pugh score) will receive alectinib at a single oral dose of 300 mg on Day 1.
3117718|NCT02621047|Experimental|Alectinib: Normal Hepatic Function|Participants with normal hepatic function will receive alectinib at a single oral dose of 300 mg on Day 1.
3117719|NCT02621060|Placebo Comparator|Placebo|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
3117720|NCT02621060|Experimental|Chlorogenic acid|1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
3117721|NCT02621073|Active Comparator|VeraFlo with Prontosan|V.A.C. VeraFlo™ Therapy, the only NPWT system with an instillation feature which allows solution to dwell in the wound for thorough contact with the wound bed. The solution being instilled is Prontosan: Unlike other antiseptics, the antimicrobial efficacy of Prontosan® is not impaired in human wound fluid, human tissue or by high loads of blood or albumin. Furthermore, Prontosan® blocks the microbial attachment to surfaces and has been shown to effectively remove biofilms in vitro and in vivo (Hubner et al 2010).
3117722|NCT02621073|Active Comparator|V.A.C Ulta System|The V.A.C.Ulta™ Therapy System is an integrated wound therapy system that provides NPWT (negative pressure wound therapy), without instillation.
3117725|NCT02621463|Experimental|Noninvasive Ventilation|Use of the Noninvasive Ventilator (V60, Philips). The ventilator mask will be placed on the patient's face according to their comfort using an elastomeric H-strap. CPAP of 8 cmH2O (pressure) will be the starting setting for the ventilator.
3117726|NCT02621606|Experimental|Part 1, Healthy Participants|Healthy participants receive a single intravenous (IV) dose of ~370 megabecquerel (MBq) [11C]MK-6884 in Part 1 of the study.
3117727|NCT02621606|Experimental|Part 2, Healthy Elderly Participants|Healthy elderly participants receive two separate IV doses of ~370 MBq [11C]MK-6884 in Part 2 of the study. Administration of the two doses is separated by at least 3 hours.
3117728|NCT02621606|Experimental|Part 3, Participants with AD|Participants with AD receive a single IV dose of ~370 MBq [11C]MK-6884 in Part 3 of the study.
3117729|NCT02621619|Experimental|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram IV acetaminophen in addition to 0.5 mg IV hydromorphone
3117730|NCT02621619|Placebo Comparator|Normal saline + 0.5 mg IV hydromorphone|100 ml normal saline placebo in addition to 0.5 mg IV hydromorphone
3117731|NCT02621892|Experimental|50mg BID|Tenapanor
3117732|NCT02621892|Placebo Comparator|Placebo|Placebo
3117733|NCT02621931|Placebo Comparator|Placebo|Matching Placebo
3117734|NCT02621931|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to the fremanezumab 675 mg/placebo/placebo treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
3117735|NCT02621931|Experimental|Fremanezumab 675/225/225 mg|Participants randomized to the fremanezumab 675/225/225 mg treatment arm received 675 mg of fremanezumab as 3 active injections (225 mg/1.5 mL) on Day 0 and 225 mg of fremanezumab as 1 active injection (225 mg/1.5 mL) on Days 28 and 56.
3117736|NCT02621983|Active Comparator|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
3117737|NCT02621983|Active Comparator|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
3117738|NCT02622074|Experimental|Cohort A: KNp / KAC|Participants receive pembrolizumab (K) 200 mg on Cycle 1 Day 1 followed by pembrolizumab 200 mg in Cycles 2-5 on Day 1 (once every 3 weeks; Q3W) PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (once each week; QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via intravenous (IV) infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117739|NCT02622074|Experimental|Cohort B: KNpCb (Regimen 1) / KAC|Participants first receive KNpCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 100 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at Area Under the Curve (AUC) 6 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117740|NCT02622074|Experimental|Cohort C: KNpCb (Regimen 2) / KAC|Participants first receive KNpCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117741|NCT02622074|Experimental|Cohort D: KNpCb (Regimen 3) / KAC|Participants first receive KNpCb Regimen 3 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS nab-paclitaxel (KNp) starting at 125 mg/m^2 in Cycles 2-5 on Days 1, 8 and 15 (QW) PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117742|NCT02622074|Experimental|Cohort E: KTCb (Regimen 1) / KAC|Participants first receive KTCb Regimen 1 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 (QW) PLUS carboplatin (Cb) starting at AUC 5 in Cycles 2-5 on Day 1 (Q3W). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117743|NCT02622074|Experimental|Cohort F: KTCb (Regimen 2) / KAC|Participants first receive KTCb Regimen 2 which consists of: pembrolizumab (K) 200 mg on Cycle 1 Day 1 PLUS paclitaxel (T) starting at 80mg/m^2 in Cycles 2-5 on Days 1, 8, and 15 PLUS carboplatin (Cb) starting at AUC 2 in Cycles 2-5 on Days 1, 8 and 15 (QW). This will be followed by pembrolizumab (K) 200 mg in Cycles 6-9 on Day 1 (Q3W) PLUS doxorubicin (A) 60 mg/m^2 in Cycles 6-9 on Day 1 (Q3W) PLUS cyclophosphamide (C) 600 mg/m^2 in Cycles 6-9 on Day 1 (Q3W). All treatments will be administered via IV infusion except for doxorubicin (A), which will be administered via IV injection. Each cycle is 21 days.
3117744|NCT02622113|Experimental|Canagliflozin (TA-7284) ＋insulin|
3117745|NCT02622178|Experimental|Healthy Subjects|42 Healthy subjects with intraocular pressure less than 22 millimeters of mercury (mmHg), normal appearing optic discs and retinal nerve fiber layer, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
3117746|NCT02622178|Experimental|Glaucoma Suspects|45 Glaucoma suspects with glaucomatous appearance optic discs and/or thin retinal nerve fiber layer in at least one eye, normal optical coherence technology (RNFL thickness) and normal visual field results in both eyes. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
3117747|NCT02622178|Experimental|Glaucoma Patients|49 Glaucoma patients with repeatable abnormal visual fields, glaucomatous optic disc appearance (those with cup to disc ratio greater than 0.7, rim thinning or Retinal Nerve Fiber Layer defects indicative of glaucoma) and/or repeatable intra-ocular pressure of 23 mmHg or higher, in at least one eye. Participants will have optical coherence tomography (OCT) and Diopsys visual evoked potential testing (VEP).
3117748|NCT02622191|Experimental|Open-angle glaucoma|Participants with primary open-angle glaucoma and an abnormal visual field defect in one eye. Spectral domain Optical Coherence Tomography will be obtained from the effected eye and fellow eye of each glaucoma patient.
3117749|NCT02622191|Experimental|Healthy Controls|Participants without glaucoma and no other eye diseases. Spectral domain Optical Coherence Tomography will be obtained from eyes of each healthy control.
3117750|NCT02622321|Experimental|Arm A: 1.5 mg/kg Emicizumab QW|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm A started to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 milligrams per kilogram (mg/kg) once a week (QW) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
3117751|NCT02622321|Active Comparator|Arm B (Control): No Prophylaxis, Then Emicizumab|Participants who were receiving episodic treatment with bypassing agents prior to study entry and were randomized to study Arm B continued with their prior episodic treatment regimen for the first 24 weeks of the study; they did not receive emicizumab prophylaxis during that time. After completing at least 24 weeks on study, participants in Arm B were allowed to switch to emicizumab prophylaxis (as described for Arm A) up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
3117752|NCT02622321|Experimental|Arm C: 1.5 mg/kg Emicizumab QW|Participants who were receiving prophylactic bypassing agents prior to study entry were enrolled in Arm C to receive prophylactic emicizumab. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
3117753|NCT02622321|Experimental|Arm D: 1.5 mg/kg Emicizumab QW|Participants who were either: 1) Receiving episodic bypassing agents prior to study entry but were unable to enroll in Arms A or B; or 2) Receiving bypassing agent prophylaxis prior to study entry but were unable to enroll in Arm C, were enrolled in Arm D to receive emicizumab prophylaxis. Emicizumab was administered at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg emicizumab QW SC up to the end of study. Participants continued to receive bypassing agent therapy to treat any breakthrough bleeds.
3117754|NCT02622568|Active Comparator|Cryotherapy and Veregen|Cryotherapy will be performed on the day of first clinic visit according to current standard of care in Children's Medical Center pediatric outpatient dermatology clinic, which consists of two freeze/thaw cycles for maximum of 10 seconds each. Sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Sinecathecins 15% ointment will be applied to verrucous lesions twice daily. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
3117755|NCT02622568|Experimental|Veregen only|Veregen ™or sinecathecins 15% ointment will be prescribed and initiated immediately following the day of first clinic visit. Veregen ™ or sinecathecins 15% ointment will be applied to verrucous lesions twice daily per current Children's Medical Center protocol. Follow-up clinical visits will be required at 0 weeks, 6 weeks, and 12 weeks. Clinical photos will be taken at each visit. Verrucae will be measured at each visit using a standard ruler. Outcome measures will be numerical reduction in diameter of verruca.
3117756|NCT02622724|Experimental|FP-1201-lyo 10 μg|"FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
3117757|NCT02622724|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection."
3117758|NCT02623218|Experimental|TBI-ACUP|This group will receive the standard of care plus acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
3117759|NCT02623218|Sham Comparator|TBI-SHAM|This group will receive the standard of care plus sham acupuncture treatments during the acute 10-day phase following a diagnosed TBI.
3117760|NCT02623218|Active Comparator|C-ACUP|This group of participants without TBI will receive one acupuncture treatment and serve as a healthy control group.
3117761|NCT02623218|Sham Comparator|C-SHAM|This group of participants will receive one sham acupuncture treatment and serve as a healthy sham comparator group.
3117762|NCT02623218|Active Comparator|C-EX|This group of participants without TBI will receive one acupuncture treatment following 30-60 minutes of aerobic exercise, and serve as a healthy control group.
3117763|NCT02623322|Experimental|MHAA4549A 3600 milligrams (mg)|Participants will receive single-dose MHAA4549A, 3600 mg, by intravenous (IV) administration.
3117764|NCT02623322|Experimental|MHAA4549A 8400 mg|Participants will receive single-dose MHAA4549A, 8400 mg, by IV administration.
3117765|NCT02623322|Placebo Comparator|Placebo|Participants will receive single-dose placebo by IV administration.
3117766|NCT02623335|Experimental|QPL (question prompt list) brochure|Patients were mailed the QPL (question prompt list) prior to their appointment with an enrolled surgeon.
3117767|NCT02623335|No Intervention|Usual care|The investigators observed that usual care included informed consent and a surgeon-directed deliberative phase in which surgeons presented their own evaluation of the trade-offs and goals of the proposed intervention.
3117768|NCT02623348|Experimental|pedometer|Patients will be given pedometers and instructions to increase physical activity based on pedometer output
3117769|NCT02623348|No Intervention|usual care|No intervention
3117770|NCT02623361|Placebo Comparator|Sham|
3117771|NCT02623361|Active Comparator|Fascia Iliaca Compartment Block|
3117772|NCT02623725|Experimental|CYD Dengue Vaccine Booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD64).
3117773|NCT02623725|Experimental|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in previous CYD dengue vaccine studies (CYD13 or CYD30), received an injection of placebo at Day 0 in this study (CYD64).
3117774|NCT02623803|Active Comparator|Treatment group|lidocaine infusion will be initiated at the time of anesthesia induction in the operating room. Dosage 1.5mg/kg/hour. Continuous infusion until patient meets discharge criteria in recovery room.
3117775|NCT02623803|Placebo Comparator|Control group|placebo infusion (D5W) will be initiated at the time of anesthesia induction in the operating room. Continuous infusion until patient meets discharge criteria in recovery room.
3117776|NCT02623829|Experimental|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered. The forehead will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml(2.5 units) and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml(5 units) each in addition to the lateral aspect of each corrugator with 0.05ml(2.5 units). The injections will be administered with a 30G needle perpendicular to the skin.
3117777|NCT02623829|Sham Comparator|Saline|1ml of normal saline will be injected with 12, evenly spaced and symmetrical aliquots of 0.05ml and the glabella will be injected at the nasal root and the medial aspect of the corrugators with 0.1ml each in addition to the lateral aspect of each corrugator with 0.05ml. The injections will be administered with a 30G needle perpendicular to the skin.
3117778|NCT02623855|Active Comparator|Park prescription|Park prescription, pedometry.
3117779|NCT02623855|Experimental|Park prescription and family outings|Park prescription, pedometry, case management and 3 weekly family outings.
3117780|NCT02624050|Active Comparator|Methohexital|Methohexital will be administered intravenously as a general anesthetic at a dosage of 1.5mg per kg of patient body weight.
3117781|NCT02624050|Active Comparator|Propofol|Propofol will be administered intravenously as a general anesthetic at a dosage of 2.5mg per kg of patient body weight.
3117782|NCT02624180|Experimental|Colchicine|Colchicine 0.6 mg daily by mouth
3117783|NCT02624180|Placebo Comparator|Placebo|Placebo for colchicine 1 tablet by mouth daily
3117784|NCT02624284|Sham Comparator|Sham dose|Participants in this arm will receive the sham transcranial direct current stimulation (tDCS) procedure. During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS.
3117785|NCT02624284|Experimental|1mA dose|Participants in this arm will receive the 1mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
3117786|NCT02624284|Experimental|2 mA dose|Participants in this arm will receive the 2 mA transcranial direct current stimulation (tDCS) procedure. A neuroConn DC-Stimulator Plus will apply a constant direct current (2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
3117787|NCT02624375|Experimental|10 persons over 70 years of age that received Zostavax|10 persons over 70 years of age that received Zostavax (single 0.65-mL dose subcutaneously in the deltoid region of the upper arm)
3117788|NCT02624492|Experimental|BI 836826-GemOx|
3117789|NCT02624492|Active Comparator|R-GemOx|
3117790|NCT02624687|Active Comparator|Intervention|These subjects will participate in a behavioral intervention that will focus on reducing sedentary behavior and improving self-management of pain. This will include an initial, in-person behavioral intervention and then monthly follow-up calls. In addition, subjects will receive a sit-stand desk attachment and a wrist-worn activity prompter to aid in sedentary behavior reduction.
3117791|NCT02624687|Placebo Comparator|Control|These subjects will receive no intervention.
3117792|NCT02624700|Experimental|A: Pemetrexed + Sorafenib|Pemetrexed 500 mg/m2 IV Day 1 + Sorafenib 400mg PO twice each day on Days 1-5 of each 14-day cycle
3117793|NCT02624700|Experimental|B: Pemetrexed + Sorafenib|Pemetrexed 375mg/m2 intravenously (IV) Day 1 + Sorafenib 200mg by mouth twice daily on days 1-5, every 21 days of each cycle.
3117794|NCT02624713|Other|Retrospective Random Controlled Research|"In the controlled retrospective follow up, (not random) 44 families participated with their 81 children and siblings. The intervention group included 18 families who participated in the Maccabi Active program (obesity treatment) in the years 2012-2013 in the northern district, with their 24 children (18 overweight children and 6 siblings). The control group included 26 families with their 57 children (27 children who had been overweight or obese in the years 2012-2013 when they were 8-14 years old and their 30 siblings). These families did not take part in a family based treatment for their overweight child. The parameters were measured at one set point time. All participants from both the control and research groups were evaluated at the follow-up and the data collected at follow-up is being reported collectively for the Retrospective Controlled Research branch."
3117795|NCT02624713|Other|The Prospective study|The Prospective study had only an intervention group (obesity treatment). Forty-two families took part in this study, with 78 children: 48 overweight children and 30 siblings . The parameters were measured in three different times. Before the program (time 1), at the end of the program (after 6 months - time 2) and 8 months after completing the program (time 3).
3117796|NCT02624791|Experimental|Lens sequence 1|"No contact lenses; 1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
3117797|NCT02624791|Experimental|Lens sequence 2|"No contact lenses; 1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
3117798|NCT02624791|Experimental|Lens sequence 3|"1-DAY ACUVUE® MOIST contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses"
3117799|NCT02624791|Experimental|Lens sequence 4|"1-DAY ACUVUE® MOIST contact lenses;~1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses"
3117800|NCT02624791|Experimental|Lens sequence 5|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses;~1-DAY ACUVUE® MOIST contact lenses; No contact lenses"
3117801|NCT02624791|Experimental|Lens sequence 6|"1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses; No contact lenses;~1-DAY ACUVUE® MOIST contact lenses"
3117802|NCT02624843|Experimental|Benzyl Alcohol Lotion 5%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
3117803|NCT02624843|Active Comparator|Ulesfia (Benzyl Alcohol Lotion 5%)|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
3117804|NCT02624843|Placebo Comparator|Vehicle Placebo Lotion 0%|Day 1- Sufficient to saturate hair and scalp for 10 min and then washed out. Day 8 -Sufficient to saturate hair and scalp for 10 min and then washed out.
3117805|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
3117806|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
3117807|NCT02624986|Experimental|DLBCL Non-Bridging: Idasanutlin 200 mg + Obinutuzumab 1000 mg|Participants with diffuse large B-cell lymphoma (DLBCL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 200 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
3117808|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 150 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 150 mg orally in combination with rituximab 375 milligrams per square meter of body surface area (mg/m^2) IV for 6 cycles (1 cycle = 28 days).
3117809|NCT02624986|Experimental|DLBCL Bridging: Idasanutlin 200 mg + Rituximab 375 mg/m^2|Participants with diffuse large B-cell lymphoma (DLBCL) in this bridging cohort received induction treatment with idasanutlin 200 mg orally in combination with rituximab 375 mg/m^2 IV for 6 cycles (1 cycle = 28 days).
3117810|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 100 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 100 milligrams (mg) orally in combination with a fixed dose of obinutuzumab 1000 mg intravenously (IV) for 6 cycles (1 cycle = 28 days).
3117811|NCT02624986|Experimental|FL Non-Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this non-bridging dose-escalation cohort received induction treatment with idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for 6 cycles (1 cycle = 28 days).
3117812|NCT02624986|Experimental|FL Bridging: Idasanutlin 150 mg + Obinutuzumab 1000 mg|Participants with follicular lymphoma (FL) in this bridging cohort received induction treatment with single-agent obinutuzumab 1000 mg IV for Cycle 1 and then idasanutlin 150 mg orally in combination with a fixed dose of obinutuzumab 1000 mg IV for Cycles 2-6 (1 cycle = 28 days).
3117813|NCT02625181|Experimental|PONV clinical decision support system|Automated recommendations on PONV prophylaxis provided to anesthesia providers through the anesthesia information management system and email.
3117814|NCT02625207|Experimental|Cohort 1|African-Americans with No CYP3A5*1 alleles (poor metabolizer)
3117815|NCT02625207|Experimental|Cohort 2|African-Americans with One CYP3A5*1 allele (intermediate metabolizer)
3117816|NCT02625207|Experimental|Cohort 3|African-Americans with Two CYP3A5*1 alleles (extensive metabolizer)
3117817|NCT02625207|Experimental|Cohort 4|Caucasians with No CYP3A5*1 alleles (poor metabolizer)
3117818|NCT02625220|Experimental|Prototype toric lens senofilcon A|Subjects will wear the senofilcon A prototype toric contact lens bilaterally for 6-8 days as a daily disposable modality.
3117819|NCT02625233|Experimental|senofilcon C|Vistakon Investigational Contact Lens (Test)
3117820|NCT02625233|Active Comparator|comfilcon A|Marketed Monthly Wear Contact Lens (Control)
3117821|NCT02625259|Experimental|Part 1: TAK-117 9*100 mg + TAK-117 3*300 mg|TAK-117900 milligram (mg), capsules, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, tablets, orally, once on Day 15.
3117822|NCT02625259|Experimental|Part 1: TAK-117 3*300 mg + TAK-117 9*100 mg|TAK-117 900 mg tablets, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 900 mg, capsules, orally, once on Day 15.
3117823|NCT02625259|Experimental|Part 2: TAK-117 Fasted + TAK-117 Fed|TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 15.
3117824|NCT02625259|Experimental|Part 2: TAK-117 Fed + TAK-117 Fasted|TAK-117 at the dose determined in Part 1, tablets, with a standard high-fat meal, orally, once on Day 1, followed by 2 weeks of washout, followed by TAK-117 at the dose determined in Part 1, tablets, in fasted condition, orally, once on Day 15.
3117825|NCT02625259|Experimental|Part 3: TAK-117 + Lansoprazole|TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 1, followed by lansoprazole 30 mg, tablets or capsules, once daily from Day 10 to Day 15, followed by TAK-117 at the dose determined in Part 1, tablets, orally, once on Day 15.
3117826|NCT02625298|Experimental|ProRoot MTA|Traumatized permanent teeth obturated with ProRoot MTA after root canal treatment
3117827|NCT02625298|Experimental|MTA+ Cercamed|Traumatized permanent teeth obturated with MTA+ Cerkamed after root canal treatment
3117828|NCT02625324|Experimental|Endovascular repair|Valiant Evo Thoracic Stent Graft System
3117829|NCT02625402|Experimental|Interactive decision aid|Group receiving brief interactive decision aid. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise
3117830|NCT02625402|Experimental|Video decision aid|Group receiving long video decision aids. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog
3117831|NCT02625428|Experimental|For Cause|For cause biopsies to evaluate a recent rise in serum creatinine.
3117832|NCT02625428|Experimental|Surveillance|Surveillance biopsies done after transplant mostly looking for subclinical rejection.
3117833|NCT02625545|Experimental|UroLift System procedure|All eligible,enrolled subjects will undergo a UroLift procedure
3117834|NCT02625571|Experimental|Intervention|
3117835|NCT02625610|Experimental|Chemotherapy + Best Supportive Care (BSC)|In Maintenance Phase, participants continued the same regimen of oxaliplatin-fluoropyrimidine doublet chemotherapy (oxaliplatin + 5FU/LV or oxaliplatin + capecitabine) as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation. Participants who were not deemed eligible to receive chemotherapy at the dose and schedule specified above received BSC alone once every 3 weeks. BSC was defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and was based on Investigator's discretion.
3117836|NCT02625610|Experimental|Avelumab|In Maintenance phase, participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligrams per kilogram (mg/kg) once every 2-week treatment cycle until progressive disease or unacceptable toxicity or discontinuation.
3117837|NCT02625623|Experimental|Physician choice chemotherapy+Best Supportive Care (BSC)|Participants received BSC plus physician's choice chemotherapy. Chemotherapy comprises of one of the following: paclitaxel at a dose of 80 milligram per meter square (mg/m^2) on Days 1, 8, and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity OR irinotecan at a dose of 150 mg/m^2 on Days 1 and 15 of a 4-week treatment cycle until confirmed progressive disease or unacceptable toxicity. Participants who are not deemed eligible to receive paclitaxel or irinotecan at the dose and schedule specified above receive BSC alone once every 3 weeks. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
3117838|NCT02625623|Active Comparator|Avelumab+BSC|Participants received avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with BSC. BSC is defined as treatment administered with the intent to maximize quality of life without a specific antineoplastic regimen and is based on investigator's discretion.
3117839|NCT02625844||Monopegylated Epoetin Beta|Health care personnel performing anemia management tasks for patients using monopegylated epoetin beta.
3117840|NCT02625844||Other Erythropoiesis Stimulating Agents (ESAs)|Health care personnel performing anemia management tasks for patients using other ESAs.
3117841|NCT02625909|Experimental|Drug: SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the short treatment duration arm (A) for 6 weeks.
3117842|NCT02625909|Experimental|Drug: SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg co-formulated tablet once daily will be given to participants who are randomised into the standard treatment duration arm (B) for 12 weeks.
3117843|NCT02625922|Experimental|Serelaxin followed by Placebo|On Day 1 of treatment period 1, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
3117844|NCT02625922|Experimental|Placebo followed by Serelaxin|On Day 1 of treatment period 1, matching placebo will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen The routine exercise assessment will commence at minute 120. In treatment period 2, on day 15 ± 1-day washout, Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen.
3117845|NCT02625974|Experimental|Nifurtimox 60 days / Arm 1|Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)
3117846|NCT02625974|Other|Nifurtimox 30 days / Arm 2|Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)
3132451|NCT03428100|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with topical corticosteroids.
3132452|NCT03428152||Hypo|The participants with a superior hypogastric block
3132453|NCT03428152||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retro-peritoneum is opened intraoperatively by the surgeon)
3117847|NCT02626000|Experimental|Talimogene Laherparepvec + Pembrolizumab|Talimogene laherparepvec is administered by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions at an initial dose of 10⁶ plaque-forming units (PFU) per mL on day 1 followed by a dose of 10⁸ PFU/mL 3 weeks after the initial dose and every 3 weeks (Q3W) thereafter. Pembrolizumab is administered by intravenous infusion at a dose of 200 mg Q3W after the initial dose. Participants are treated until complete response, no injectable lesions, confirmed disease progression, intolerance of study treatment, 24 months from the date of the first dose of talimogene laherparepvec, or end of study, whichever occurred first.
3117848|NCT02626026|Experimental|Cohort 1, Part A: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally once daily (QD) in the morning for 1 week.
3117849|NCT02626026|Placebo Comparator|Cohort 1, Part A: Placebo|Placebo to match tirabrutinib capsules orally QD in the morning for 1 week.
3117850|NCT02626026|Experimental|Cohort 2, Part A: Tirabrutinib 10 mg BID|Tirabrutinib 10 mg capsules orally twice daily (BID) (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
3117851|NCT02626026|Placebo Comparator|Cohort 2, Part A: Placebo|Placebo to match tirabrutinib capsules orally BID (morning and approximately 12 hours later) for 7 days. On Day 7, only morning dose was administered.
3117852|NCT02626026|Experimental|Part B: Tirabrutinib 20 mg QD|Tirabrutinib 20 mg capsules orally QD for 4 weeks.
3117853|NCT02626026|Placebo Comparator|Part B: Placebo|Placebo to match tirabrutinib capsules orally QD for 4 weeks.
3117854|NCT02626156|Experimental|Cooling gel pack|A cooling pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
3117855|NCT02626156|Active Comparator|Cooling cotton pack|A cooling cotton pack will be applied to affected leg or foot skin where an ulcer has recently healed for 30 minutes three times a week (preventive maintenance). Patients will self monitor skin temperature of affected skin daily to detect elevation and will cool the affected skin daily for 5 consecutive days (bolus) if the skin temperature becomes elevated 2°F above the baseline.
3117856|NCT02626182|Experimental|Sildenafil|Subjects will be randomized in a 3:1 (sildenafil:placebo) fashion. Subjects randomized to the treatment arm will receive sildenafil 20 mg p.o. t.i.d for 1 week followed by 40 mg p.o. t.i.d. for 11 weeks.
3117857|NCT02626182|Placebo Comparator|Placebo|Subjects randomized to the placebo arm will receive placebo p.o. t.i.d for 1 week followed by 2 placebo tablets p.o. t.i.d. for 11 weeks.
3117858|NCT02626611|Placebo Comparator|Placebo|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
3117859|NCT02626611|Active Comparator|Low Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
3117860|NCT02626611|Active Comparator|High Dose Food|Xolair will be administered in week 0 through 16 of the study. Starting at week 8, food doses will be serially increased, per protocol, to up to 2000 milligrams per food. At week 30, the cohort will be randomized into 3 groups (placebo, low dose food, and high dose food). Participants will continue on this dose for 6 weeks. The oat placebo food, will be compared to high dose (2000 milligrams or low dose 300 milligrams food immunotherapy). At week 36 a food challenge will be performed to assess study endpoints.
3117861|NCT02626780|Experimental|SVF Injection|Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
3117862|NCT02626819|Experimental|Arm 1: Receiving MOVE! Toward Your Goals|Receiving MOVE! Toward Your Goals intervention (MTG tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)
3117863|NCT02626819|Active Comparator|Arm 2: Receiving Enhanced Usual Care|Receiving Enhanced Usual Care (standard VA Health Living Messages handouts, potential support of weight management efforts from primary care provider)
3117864|NCT02626910||Second Life: People with disabilities|People with disabilities recruited from the virtual world, Second life.
3117865|NCT02626910||Second Life: People without disabilities|People without disabilities recruited from the virtual world, Second life.
3117866|NCT02626910||Second Life: Clinicians|Clinicians recruited from the virtual world, Second life.
3117867|NCT02626910||Urban group|People with and without disabilities recruited from an Urban setting.
3117868|NCT02627001|Experimental|NuMask Intraoral Airway Device|A United States Army Combat Medic uses a single hand technique to hold a Nu-Mask Intraoral Airway Device on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
3117869|NCT02627001|Active Comparator|Bag Valve Mask|A United States Army Combat Medic uses a single hand technique to hold a conventional bag valve mask on a cadaver while an Impact 731 ventilator delivers 10 standardized breaths with tidal volumes of 750 ml each.
3117870|NCT02627118|Experimental|Dialyzer Comparison|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR followed by 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H
3117871|NCT02627144||Advanced and/or Metastatic RCC participants|Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.
3117872|NCT02627495|Experimental|tDCS intervention (open label)|Subjects will undergo tDCS stimulation
3117873|NCT02627677|Experimental|Cohort A: Ponatinib 30 mg|Ponatinib 30 mg, tablets, orally, once daily (QD) until achievement of major molecular response (MMR) up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 42 months.
3117874|NCT02627677|Experimental|Cohort B: Ponatinib 15 mg|Ponatinib 15 mg, tablets, orally, QD until achievement of MMR up to 12 months. Once MMR was achieved, participants received reduced dose of ponatinib 15 mg orally once daily up to 45 months.
3117875|NCT02627677|Active Comparator|Cohort C: Nilotinib 400 mg|Nilotinib 400 mg, tablets, orally, twice daily up to approximately 42 months.
3117876|NCT02627794|Experimental|Silastic Silicone & Restora™ Steroid eluting spacer|"Silastic Silicone spacers are actively being used as the standard of care.~Restora™ Steroid eluting spacer (experimental).~Each nostril will receive one each of above spacers."
3117877|NCT02627924||Adalimumab|Participants diagnosed with rheumatoid arthritis who were prescribed adalimumab according to their physician's discretion and routine clinical practice.
3117878|NCT02627963|Experimental|Tivozanib hydrochloride|Patients randomized to this arm will receive the study drug, tivozanib hydrochloride.
3117879|NCT02627963|Active Comparator|Sorafenib|Patients randomized to this arm will receive the comparator drug, sorafenib.
3117880|NCT02628028|Experimental|Part A 5 mg LY3337641|Given once a day for 4 weeks.
3117881|NCT02628028|Experimental|Part A 10 mg LY3337641|Given once a day for 4 weeks.
3117882|NCT02628028|Experimental|Part A 30 mg LY3337641|Given once a day for 4 weeks.
3117883|NCT02628028|Placebo Comparator|Part A Placebo|Given once a day for 4 weeks.
3117884|NCT02628028|Experimental|Part B 5 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
3117885|NCT02628028|Experimental|Part B 10 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
3117886|NCT02628028|Experimental|Part B 30 mg LY3337641|Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
3117887|NCT02628028|Placebo Comparator|Part B Placebo|Given once a day for 12 weeks.
3117888|NCT02628093|Other|THUNDERBEAT|THUNDERBEAT energy device ( Olympus) will be used for dissection of tissue and ligation of vessels
3117889|NCT02628093|Other|LIGASURE|LIGASURE energy device will be used for dissection of tissue and ligation of vessels
3117890|NCT02628106|Experimental|Lipo-prostaglandin E1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days.
3117891|NCT02628223|Active Comparator|180 degrees|180 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
3117892|NCT02628223|Active Comparator|360 degrees|360 degrees of Selective Laser Trabeculoplasty using Neodymium:Yttrium Aluminum Garnet (YAG) laser
3117893|NCT02628236|Experimental|ALA|20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment
3117894|NCT02628418|Experimental|Gloreha Group|"The patients in the Gloreha Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation by Gloreha device"
3117895|NCT02628418|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific hand rehabilitation performed by physiotherapist"
3117896|NCT02628444|Experimental|STAGE-I Group 1: CYD Dengue Vaccine|Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).
3117897|NCT02628444|Experimental|STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)|Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).
3117898|NCT02628444|Experimental|STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)|Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).
3117899|NCT02628444|Experimental|STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)|Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
3117900|NCT02628444|Experimental|STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
3117901|NCT02628444|Experimental|STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).
3117902|NCT02628444|Experimental|STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)|Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
3117903|NCT02628444|Experimental|STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
3117904|NCT02628444|Experimental|STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)|Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).
3117905|NCT02628600|Experimental|Prior LAI + Multidrug Regimen|Participants in the prior Study INS-212 who received LAI+MDR. All participants in this safety extension study received LAI+MDR.
3117906|NCT02628600|Experimental|Prior Multidrug Regimen Alone|Participants in the prior Study INS-212 who received MDR alone. All participants in this safety extension study received LAI+MDR.
3132454|NCT03428230|Experimental|30 mg Paracetamol 3% (1 mL)|30 mg Paracetamol 3% (1 mL), solution for injection, single dose by intrathecal injection (IT)
3132455|NCT03428230|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3% (2 mL), solution for injection, single dose by intrathecal injection (IT)
3132456|NCT03428230|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3% (3 mL), solution for injection, single dose by intrathecal injection (IT)
3117907|NCT02628743|Experimental|Olesoxime|"Participants who have consented to the dose increase will receive 10 milligrams per kilogram (mg/kg) suspension twice a day (BID) either orally or via a naso-gastric or gastrostomy tube with breakfast and dinner, preferably at the same time of the day throughout the study. If the drug administration does not coincide with one of the scheduled meals, a snack should be taken prior to drug administration. Preferably there should be at least 10 hours between the morning and evening dose. The total dose in this study will not exceed 2000 mg.~Participants who do not consent to the dose increase will continue with the previous dosage and receive a dose of 10 mg/kg suspension once a day orally or via a naso-gastric or gastronomy tube with the main meal, preferably at the same time of the day."
3117908|NCT02628769|Experimental|Solithromycin|28 day treatment of 400 mg Solithromycin taken once a day.
3117909|NCT02628769|Placebo Comparator|Placebo|28 day treatment with placebo taken once per day.
3117910|NCT02628873|Experimental|Arm 1 (HyCoSy followed by HSG)|HyCoSy procedure followed by HSG procedure
3117911|NCT02628873|Experimental|Arm 2 (HSG followed by HyCoSy)|HSG procedure followed by HyCoSy procedure
3117912|NCT02628938|Experimental|Miswak extract mouth wash|50% mouthwash aqueous solution 5ml twice a day for 7 days
3117913|NCT02628938|Experimental|Miswak sticks|Sticks twice a day for 7 days
3117914|NCT02628938|Active Comparator|Chlorohexidine gluconate mouth wash|0.2% mouth wash aqueous solution (Oraxine ®) 5 ml twice a day for 7 days
3117915|NCT02628964|Active Comparator|4.5% e-cig|e-cigarettes with nicotine cartridges
3117916|NCT02628964|Placebo Comparator|0 mg e-cig|e-cigarettes with placebo cartridges (0mg).
3117917|NCT02629094|Experimental|Treatment|Intervention: Eplerenone will be administered for 6 months as follows: 25 mg once daily for 1 week and then 50 mg once daily for the remainder of the study.
3117918|NCT02629133|Experimental|SHE Program|"Participants received a 50 minute intervention on the computer immediately after their baseline assessment and a 15 minute booster session on the computer within 2 weeks after the intervention. There was also a 3 and 6 month follow-up after completion of the SHE program."
3117919|NCT02629133|No Intervention|Control Condition|Control condition consisted of a series of questions regarding television show preferences and viewing a brief series of videos of popular entertainers/shows, with subsequent requests for rating of subjective preference. Participants in this condition completed a baseline assessment as well as a television show booster and a follow-up assessment 3 and 6 months later.
3117920|NCT02629159|Placebo Comparator|Placebo followed by ABT-494|"Participants were to receive placebo to upadacitinib orally once daily (QD) and placebo to adalimumab by subcutaneous injection once every two weeks (eow) for up to 26 weeks. Participants who did not achieve a ≥ 20% improvement in tender joint count (TJC) and swollen joint count (SJC) at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26, all remaining participants were to be switched to 15 mg upadacitinib QD until Week 48 (end of Period 1).~Participants who complete Period 1 will continue to receive 15 mg upadacitinib orally QD for up to 5 years in Period 2."
3117921|NCT02629159|Active Comparator|Adalimumab|"Participants were to receive placebo to upadacitinib orally QD and 40 mg adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 15 mg upadacitinib orally QD. At Week 26 remaining participants who did not achieve low disease activity (defined as Clinical Disease Activity Index [CDAI] ≤ 10) were to be switched to 15 mg upadacitinib orally QD until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
3117922|NCT02629159|Experimental|Upadacitinib|"Participants were to receive 15 mg upadacitinib orally QD and placebo to adalimumab by subcutaneous injection eow for up to 48 weeks in Period 1. Participants who did not achieve a ≥ 20% improvement in TJC and SJC at Weeks 14, 18, or 22 compared to Baseline were to be switched to 40 mg adalimumab eow. At Week 26 remaining participants who did not achieve low disease activity (defined as CDAI ≤ 10) were to be switched to 40 mg adalimumab eow until Week 48.~Participants who complete Period 1 will continue to receive the same treatment assigned at the end of Period 1 (15 mg upadacitinib QD or 40 mg adalimumab eow) for up to 5 years in Period 2."
3117923|NCT02629354|Experimental|Ibuprofen and Caffeine|
3117924|NCT02629354|Active Comparator|Ibuprofen|
3117925|NCT02629822|Experimental|DOR/3TC/TDF|Treatment-naïve HIV-1 infected participants with NNRTI transmitted resistance-associated mutations were treated with open-label MK-1439A (DOR/3TC/TDF 100mg/300mg/300mg) as a FDC tablet taken once daily by mouth for 96 weeks in the Base Study. In addition, eligible participants continued to receive the same MK-1439A regimen from Week 96 to Week 192 during the Extension Study.
3117926|NCT02629861|Placebo Comparator|Placebo|Matching Placebo
3117927|NCT02629861|Experimental|Fremanezumab 675 mg/placebo/placebo|Participants randomized to receive fremanezumab 675 mg/placebo/placebo received 675 mg of fremanezumab as 3 injections (225 mg/1.5 mL) on Day 0, and placebo as a single 1.5-mL injection on Days 28 and 56.
3117928|NCT02629861|Experimental|Fremanezumab 225/225/225 mg|Participants randomized to receive fremanezumab 225/225/225 mg received 1 active injection (225 mg/1.5 mL) on Days 0, 28 and 56.
3117929|NCT02629965|Experimental|tiotropium + olodaterol|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
3117930|NCT02629965|Active Comparator|tiotropium|inhalation two puffs from the RESPIMAT inhaler, once a day, in the morning
3117931|NCT02629991|Experimental|Intranasal Oxytocin|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
3117932|NCT02629991|Placebo Comparator|Matched Placebo|Participants were instructed to take 16 IU/per day everyday (2 puffs per nostril, 4 IU each puff).
3117933|NCT02630017|Experimental|ADHD group|Adults with ADHD
3117934|NCT02630017|Experimental|non-ADHD group|Adults without ADHD
3117935|NCT02630030|Experimental|Ixazomib|Patients receive ixazomib PO 3 hours before surgery.
3117936|NCT02630186|Experimental|Single Arm Rociletinib and MPDL3280A|Specific doses of rociletinib, taken continuously BID, will be administered in combination with a fixed dose of MPDL3280A, given intravenously on Day 1 of each 21-day cycle.
3132457|NCT03428230|Placebo Comparator|Placebo, 0.9% saline solution|Placebo, 0.9% saline solution (1 mL, 2 mL or 3 mL), solution for injection, single dose by intrathecal injection (IT)
3117937|NCT02630251|Experimental|GSK2820151 arm|An accelerated dose escalation phase will be utilized in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD. Initially, one subject per dose cohort will be recruited (accelerated dose escalation phase) until the first instance of a >=Grade 2 drug related toxicity or dose-limiting toxicity (DLT). Further cohorts will be recruited in blocks of three subjects (3+3 dose escalation phase). Projected dose levels are 3 mg, 6 mg, 12 mg, 20 mg, 40 mg, 60 mg, 100 mg, 150 mg, 200 mg, and 300 mg. Additional subjects may be enrolled at previously cleared dose levels in order to obtain further data for PK and/or PD analysis. Once MTD is determined, additional subjects (18 subjects total at MTD) may be enrolled to collect additional safety data.
3117938|NCT02630316|Placebo Comparator|Placebo|Matching placebo inhaled using an ultrasonic nebulizer four times daily
3117939|NCT02630316|Active Comparator|Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily
3117940|NCT02630459|Placebo Comparator|Double Blind Treatment Phase (DBTP): Placebo|Participants received placebo by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
3117941|NCT02630459|Experimental|DBTP: Erenumab 28 mg QM|Participants received erenumab 28 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
3117942|NCT02630459|Experimental|DBTP: Erenumab 70 mg QM|Participants received erenumab 70 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
3117943|NCT02630459|Experimental|DBTP: Erenumab 140 mg QM|Participants received erenumab 140 mg by subcutaneous injection on day 1 and at weeks 4, 8, 12, 16, and 20 in the double-blind treatment phase.
3117944|NCT02630459|Experimental|Open-Label Treatment Phase (OLTP): Erenumab 70-140 mg QM|Participants received an erenumab dose of 70 and/or 140 mg QM SC (depending on the participant's visit completion status after Institutional Review Board [IRB] approval of Protocol Amendment 2) in the OLTP for a total of 76 weeks.
3117945|NCT02630459|Experimental|CHU Sub-Study: Two 70 mg/mL AI/pens|A subset of participants in the OLTP randomized to self administer erenumab via two 70 mg/mL autoinjector (AI)/pens on day 29 and day 57 of the CHU Sub-Study
3117946|NCT02630459|Experimental|CHU Sub-Study: One 140 mg/mL AI/pen|A subset of participants in the OLTP randomized to self administer erenumab via one 140 mg/mL AI/pen on day 29 and day 57 of the CHU Sub-Study
3117947|NCT02630563|Experimental|Mycophenolate Mofetil+Corticosteroids+Cyclosporine|Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.
3117948|NCT02630693|Active Comparator|Palbociclib (100mg)|Palbociclib 100mg PO daily plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
3117949|NCT02630693|Active Comparator|Palbociclib (125mg)|Palbociclib 125mg PO daily 3 out of 4 weeks plus Fulvestrant or Tamoxifen or another Aromatase Inhibitor at the standard doses/schedules
3117950|NCT02630706|Experimental|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
3117951|NCT02630706|Experimental|Ertugliflozin 15 mg|Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
3117952|NCT02630706|Placebo Comparator|Placebo|Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
3117953|NCT02630719|Active Comparator|Timolol eye drops|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
3117954|NCT02630719|Placebo Comparator|Artificial tears|All subjects received timolol eye drops or placebo (artificial tears) for two months then crossed over to the opposite medication for the final two months of the study.
3117955|NCT02630953|Active Comparator|Original Tailored Intervention|This existing empirically supported Spanish-language PA intervention, which is based on Social Cognitive Theory and the Transtheoretical Model (TTM), emphasizes behavioral strategies for increasing PA levels (goal-setting, self-monitoring, problem-solving barriers, increasing social support, self-rewards for meeting PA goals).
3117956|NCT02630953|Experimental|Enhanced Tailored Intervention|We designed the Enhanced Tailored Intervention to build upon our previous research in order to outperform the original tailored intervention, in a cost effective, theoretically guided and data driven manner with potential for dissemination. Participants in the Enhanced Tailored Intervention will receive an interactive technology based intervention that: 1) addresses important SCT constructs for increasing PA that were not significantly changed in the original parent trial (enjoyment/outcome expectations and social support) and 2) provides greater accountability and interactivity for self-monitoring (through text messages), as requested by participants in the original parent trial.
3117957|NCT02630966|Experimental|Group 1: Vedolizumab IV 300 mg + Placebo|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.
3117958|NCT02630966|Experimental|Group 2: Vedolizumab 300 mg|Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.
3117959|NCT02630992|Experimental|amoxicillin-clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/221.5 mg/5 mL; 28:1) administered prior to February 25, 2016 at 90/3.2 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 1) or administered as of February 25, 2016 at 80/2.85 mg/kg/day in two divided doses for 10 days; oral, liquid (formulation 2)
3117960|NCT02631057||Non-Valvular Atrial Fibrillation|
3117961|NCT02631057||acute ischemic stroke|
3117964|NCT02631525|Active Comparator|REM-PRO|Total intravenous anesthesia with remifentanil and propofol, target controlled infusion based on Minto's and Marsh's pharmacokinetic models.
3117965|NCT02631525|Active Comparator|REM-DES|Balanced anesthesia with remifentanil target controlled infusion based on Minto's pharmacokinetic model and desflurane.
3117966|NCT02631538|Placebo Comparator|Placebo|Subjects will receive belimumab placebo weekly subcutaneous injections to Week 52 and rituximab placebo infusions at Weeks 8 and 10.
3117967|NCT02631538|Experimental|Belimumab monotherapy|Subjects will receive 200 mg weekly subcutaneous injections of belimumab to Week 52 and placebo rituximab infusions at Weeks 8 and 10.
3117968|NCT02631538|Experimental|Belimumab and Rituximab co-administration therapy|Subjects will receive belimumab 200 mg SC weekly for 24 weeks followed by weekly placebo belimumab injections to Week 52 with rituximab 1000 mg intravenously at Weeks 8 and 10.
3117969|NCT02631538|Active Comparator|Rituximab monotherapy|Subjects will receive 1000 mg IV rituximab infusions at Weeks 8 and 10 and weekly subcutaneous injections of placebo belimumab to Week 52.
3117970|NCT02631551|Experimental|GSP 301 NS|
3117971|NCT02631551|Active Comparator|Olopatadine HCl NS|
3117972|NCT02631551|Active Comparator|Mometasone furoate NS|
3117973|NCT02631551|Placebo Comparator|GSP 301 Placebo NS|
3117974|NCT02631577|Experimental|Atezolizumab-G-lena 15mg|Participants were administered obinutuzumab, Atezolizumab, and 15 mg of Lenalidomide.
3117975|NCT02631577|Experimental|Atezolizumab-G-lena 20mg|Participants were administered obinutuzumab, Atezolizumab, and 20 mg of Lenalidomide.
3117976|NCT02631590|Experimental|Combination Therapy|Treatment Plan: Cisplatin (25 mg/m^2 ) + Gemcitabine (1000 mg/m^2) + copanlisib (60 mg) on days 1 and 8 with day 15 off to be administered on an every 21-days schedule.
3117977|NCT02631746|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for 46 courses in the absence of disease progression or unacceptable toxicity.
3117978|NCT02631772|Experimental|Late Cohort, Arm 1|Ledispasvir (LDV) and Sofosbuvir (SOF) monotherapy x 12 weeks
3117979|NCT02631772|Active Comparator|Late Cohort, Arm 2|Ledispasvir (LDV) and Sofosbuvir (SOF) +ribavirin x 12 weeks
3117982|NCT02631850|Active Comparator|Traditional CI Therapy|"Participants will receive a 35-hour dose of CI therapy. Treatment will consist of 35 therapist/client contact hours in the clinic, 10 weekdays, over 3 weeks. To promote carry-over of motor gains to daily activities, participants will complete: (1) a treatment contract, (2) daily self-report of arm use, and (3) problem-solving to overcome barriers to use of the more affected upper extremity. In addition, the client will agree to wear a padded restraint mitt on the less affected hand for the majority of waking hours to encourage use of the weaker hand for daily activities. Finally, the participant will agree to 30 minutes per day of individualized task-practice outside the clinic (in addition to training in the clinic) focused on functional activities catered towards accomplishing the person's therapeutic goals."
3117983|NCT02631850|Active Comparator|Gaming CI Therapy|15 hours of progressive massed motor practice will occur through in-home video game play over 15 consecutive weekdays. Participants will play the game during times of their choosing. The participant will wear an activity monitor biofeedback device for the majority of waking hours. As with traditional CI therapy, the client will agree to an additional 30 minutes per day of individualized task-practice. Five therapist/client contact hours will occur in the clinic on approximate treatment days 1, 3, 6, and 11 and will focus on treatment elements that cannot be readily addressed through the game, such as problem-solving to help the participant carry over motor gains to daily life.
3117984|NCT02631850|Active Comparator|Gaming CI Therapy with Additional Contact via Video Conference|This group will receive treatment that is identical to Group 2, but will receive an additional 2.6 hours video conference consultation throughout the treatment period.
3117985|NCT02631850|Active Comparator|Traditional Occupational Therapy/Physical Therapy|Five therapist/client contact hours will occur on approximate treatment days 1, 3, 6, and 11 (same schedule as gaming CI therapy). 1 hour progressive resistance exercise to establish and progress an upper extremity home exercise program, 2 hours of neuromuscular reeducation, and 2 hours functional practice on activities of daily living (ADLs) with verbal encouragement to use the more affected upper extremity to the largest extent possible. Home practice consists of strengthening exercises, designed to increase range of motion, prescribed twice daily. After completing their participation in the standard OT condition (6 months), participants will be crossed-over to a CI therapy gaming only condition. This condition will be identical to that described above, excluding therapist contact throughout the intervention. Rather, participants will receive a DVD explaining the intervention and guiding them through use of the system.
3117986|NCT02631876|Experimental|Mirvetuximab Soravtansine|Participants will receive mirvetuximab soravtansine at 6 milligrams/kilogram (mg/kg) adjusted ideal body weight (AIBW) administered intravenously (IV) on Day 1 of a 3 week cycle. Participants will continue to receive study drug until they experience progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (as assessed by the blinded independent review committee [BIRC]), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 86.9 weeks)
3117987|NCT02631876|Experimental|Investigator's Choice (IC) Chemotherapy|Participants will receive a dose of IC chemotherapeutic agent calculated using body surface area (BSA). Paclitaxel will be administered at 80 milligrams/square meter (mg/m^2) as a 1-hour IV infusion on Days 1, 8, 15, and 22 of a 4-week cycle; or topotecan will be administered at 4 mg/m^2 over 30 minutes on Days 1, 8, and 15 of a 4-week cycle. Alternatively, topotecan could be administered at 1.25 mg/m^2 over 30 minutes on Days 1 to 5 of a 3-week cycle; or pegylated liposomal doxorubicin will be administered at 40 mg/m^2 as a 1 mg/minute IV infusion on Day 1 of a 4-week cycle. After Cycle 1, if tolerated, pegylated liposomal doxorubicin could be administered as a 1-hour infusion. Participants will continue to receive study drug until they experience PD per RECIST version 1.1 (as assessed by BIRC), experience unacceptable toxicity, or withdraw consent, whichever comes first, or until the sponsor terminate the study. (Maximum exposure: 62.9 weeks)
3117988|NCT02631954|Experimental|TR Group|Test drug: Vorico Injection 200mg(Voriconazole) Wash out: 7 days Reference drug: Vfend® IV 200mg
3117989|NCT02631954|Experimental|RT group|Reference drug: Vfend® IV 200mg Wash out: 7 days Test drug: Vorico Injection 200mg(Voriconazole)
3117990|NCT02632110|Experimental|ALA 25 min 10 Milliwatts (mW)|ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3117991|NCT02632110|Experimental|MN + ALA 25 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3117992|NCT02632110|Experimental|ALA 25 min 20 mW|ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
3117993|NCT02632110|Experimental|MN + ALA 25 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 25 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
3117994|NCT02632110|Experimental|ALA 60 min 10 mW|ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3117995|NCT02632110|Experimental|MN + ALA 60 min 10 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3117996|NCT02632110|Experimental|ALA 60 min 20 mW|ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
3117997|NCT02632110|Experimental|MN + ALA 60 min 20 mW|Microneedle lesion preparation prior to ALA-PDT, 60 min incubation period, 20 mW/cm2 power density for 8 min 20 second light treatment.
3117998|NCT02632110|Placebo Comparator|VEH|Vehicle (VEH) PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3117999|NCT02632110|Placebo Comparator|MN + VEH|Microneedle lesion preparation prior to Vehicle PDT, 60 minute incubation period, 10 mW/cm2 power density for 16 min 40 second light treatment.
3118000|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part A)|Starting dose 25 mg/day, single ascending dose
3118001|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part A)|Single dose of AZD5718 amorphous suspension
3118002|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part A)|Single dose of AZD5718 amorphous suspension
3118003|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part A)|Single dose of AZD5718 amorphous suspension
3118004|NCT02632526|Experimental|AZD5718 amorphous form, treatment 5 (Part A)|Single dose of AZD5718 amorphous suspension
3118005|NCT02632526|Experimental|AZD5718 amorphous form, treatment 6 (Part A)|Single dose of AZD5718 amorphous suspension
3118006|NCT02632526|Experimental|AZD5718, crystalline form, treatment 7 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
3118007|NCT02632526|Experimental|AZD5718 crystalline form, treatment 8 (Part A)|Crystalline suspension (Part A), dosage lower than highest dose used with amorphous suspension, single ascending dose
3118008|NCT02632526|Experimental|AZD5718 amorphous form, treatment 1 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
3118009|NCT02632526|Experimental|AZD5718 amorphous form, treatment 2 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
3118010|NCT02632526|Experimental|AZD5718 amorphous form, treatment 3 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
3118011|NCT02632526|Experimental|AZD5718 amorphous form, treatment 4 (Part B)|Once or twice daily from Days 2 to 9 and single doses on Days 1 and 10, dosage TBD (Part A)
3118012|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 1 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
3118013|NCT02632526|Experimental|AZD5718 amorphous/crystalline form, repeat 2 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
3118014|NCT02632526|Experimental|AZD5718 amorphous/crystalline, repeat 3 (Part A)|Single dose of AZD5718 amorphous form (Part A) Crystalline form (Part A), dosage lower than highest dose used with amorphous form, single ascending dose
3118015|NCT02632526|Experimental|AZD5718 amorphous form, repeat 1 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
3118016|NCT02632526|Experimental|AZD5718 amorphous form, repeat 2 (Part B)|Twice daily dosing (Day 1 - 9) and once daily dosing (Day 10), dosage TBD (Part A)
3118017|NCT02632552|Experimental|Technology-assisted care transition arm|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
3118018|NCT02632552|Active Comparator|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
3118019|NCT02632747|Experimental|Sequence A|Empagliflozin followed by a wash-out followed by empagliflozin matching placebo on a background of open label ramipril.
3118020|NCT02632747|Experimental|Sequence B|Empagliflozin matching placebo followed a wash-out followed by empagliflozin on a background of open label ramipril.
3118021|NCT02632786|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
3118022|NCT02632786|Placebo Comparator|Placebo|Placebo
3118023|NCT02632812|Experimental|Rebamipide & Naproxen|Rebamipide 100 mg effervescent granules (oral) Twice daily (total dose = 200 mg) for 7 days
3118024|NCT02632812|Placebo Comparator|Placebo & Naproxen|Sugar pill manufactured to mimic Rebamipide 100 mg effervescent granules (oral) Twice daily for 7 days
3118025|NCT02632838|Experimental|the mHealth Group|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor on a daily basis at HOME and also will be asked to visit community health center once a week to receive the regular hypertension care for the 6-month period as usual.
3118026|NCT02632838|No Intervention|the Standard Follow-up Group|The standard follow-up group will receive regular hypertension care as usual which consists: nursing assessment, medication management, patient education, follow up and continuing care in the community health center
3118027|NCT02633020|Experimental|AMG 714|Participants were administered 8 mg/kg AMG 714 via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
3118028|NCT02633020|Placebo Comparator|Placebo|Participants were administered placebo via intravenous infusion on day 0, day 7 and every 2 weeks thereafter through week 10.
3118029|NCT02633046|Other|Acthar Gel|Acthar Gel, 1 mL (80 U) by subcutaneous injection (SC) 3x/week will be administered to all participants from Week 0 to 50. Tapering of dose to 1 mL SC 2x/week will be allowed for safety and/ tolerability issues. Once the dose is tapered to 1 mL SC 2x/week it must remain at this level. Participants unable to tolerate 1 mL SC 2x/week will be discontinued. All participants will have an End of Study/Early Termination Visit 4 weeks after discontinuing Investigational Medicinal Product (IMP).
3118030|NCT02633215|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
3118031|NCT02633215|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
3118032|NCT02633241|Other|Dexmedetomidine (bolus and infusion)-Propofol arm|Patients in this cohort will receive a combination of Dexmedetomidine 1mcg/kg and Propofol100mcg/kg/minute to accomplish an MRI examination.
3118033|NCT02633241|Other|Dexmedetomidine (bolus only)-Propofol arm|Patients in this cohort will receive dexmedetomidine 1mcg/kg over 5 minutes and then propofol 2-3mg/kg titrated bolus followed by 100mcg/kg/min infusion to accomplish MRI
3118034|NCT02633306|Experimental|Transcranial Magnetic Stimulation|transcranial magnetic stimulation
3118035|NCT02633358|Experimental|Therapeutic hypothermia group|Anti-inflammatory effect of therapeutic hypothermia. The hypothesis is anti-inflammatory effect triggered by IL-6 trans-signaling
3118036|NCT02633358|No Intervention|Control group|No therapeutic hypothermia for controlled data.
3118037|NCT02633371|Experimental|Oxybutynin|Oxybutynin 3% gel, 1 gram of product (56 mg oxybutynin) topically to each armpit daily for 4 weeks
3118038|NCT02633488|Placebo Comparator|Placebo|12 weeks of Placebo tablet 3 x daily
3118039|NCT02633488|Experimental|Metformin|12 weeks of Metformin tablet 850 mg 3 x daily
3118040|NCT02633501|Experimental|Subset 1 Arm 1|One of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
3118041|NCT02633501|Experimental|Subset 1 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the two doses of P03277 (0.05 or 0.1 mmol/kg)-enhanced MRI
3118042|NCT02633501|Experimental|Subset 2 Arm 1|One of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI then gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI
3118043|NCT02633501|Experimental|Subset 2 Arm 2|Gadobenate dimeglumine (0.1 mmol/kg)-enhanced MRI then one of the four doses of P03277 (0.025, 0.05, 0.1 or 0.2 mmol/kg)-enhanced MRI
3118044|NCT02633527|Placebo Comparator|Placebo|Placebo, qd, oral capsule
3118045|NCT02633527|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
3118046|NCT02633527|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
3118047|NCT02633527|Experimental|300mg SPN-812|300mg SPN-812, qd, oral capsule
3118048|NCT02633527|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
3118049|NCT02633735|Experimental|Appy CDS|The Appy-cds intervention is a point of care clinical decision support system designed to identify pediatric patients at risk for appendicitis using EHR and supplemental data. The intervention is administered to providers in this arm.
3118050|NCT02633735|No Intervention|Usual Care|
3118051|NCT02633787|Experimental|Study Group|Participants received a booster dose of Menactra vaccine approximately four years earlier
3118052|NCT02633800|Experimental|Patritumab|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
3118053|NCT02633800|Placebo Comparator|Placebo|All participants receive placebo with cetuximab plus platinum-based therapy (cisplatin or carboplatin)
3118054|NCT02633956|Experimental|5 mg Obeticholic Acid|5 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
3118055|NCT02633956|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
3118056|NCT02633956|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
3118057|NCT02633956|Placebo Comparator|Placebo|One tablet daily for the double-blind treatment period. 10 mg Atorvastatin titrating to 20mg.
3118058|NCT02634073|Experimental|Treatment A: Lamivudine 300 milligram(mg)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
3118059|NCT02634073|Experimental|Treatment B: Lamivudine 300 mg + Sorbitol 3.2 g (low dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
3118060|NCT02634073|Experimental|Treatment C: Lamivudine 300 mg + Sorbitol 10.2 g (medium dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
3118061|NCT02634073|Experimental|Treatment D: Lamivudine 300 mg + Sorbitol 13.4 g (high dose)|Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
3118062|NCT02634151|Placebo Comparator|Placebo|Participants on stable statin therapy received matching placebo orally, once daily for 12 weeks.
3118063|NCT02634151|Experimental|Gemcabene 600 mg|Participants on stable statin therapy received 600 milligrams (mg) of Gemcabene orally, once daily for 12 weeks.
3118064|NCT02634177|Active Comparator|Assay-guided treatment (AGT)|Assay results will be provided to the treating investigator, who will use the results to guide pharmacotherapy of the subject's MDD treatment.
3118065|NCT02634177|Placebo Comparator|Treatment-as-usual (TAU)|The treating investigator will treat subjects of the TAU group without the knowledge of the pharmacogenetic testing results.
3118066|NCT02634320|Other|Aripiprazole Lauroxil|Intramuscular (IM) injection
3118067|NCT02634333|Sham Comparator|Observation (Prompt Sham)|Sham injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. Deferred aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
3118068|NCT02634333|Experimental|Prompt aflibercept|Aflibercept injection in study eye at randomization and at visits at 1, 2, and 4 months and then every 4 months thereafter. More frequent aflibercept may be given if center-involved diabetic macular edema or proliferative diabetic retinopathy develops and deferred laser may subsequently be added to intravitreal aflibercept if certain criteria are met.
3118069|NCT02634346|Experimental|ALKS 3831|Administered as a coated bilayer tablet
3118070|NCT02634346|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
3118071|NCT02634346|Placebo Comparator|Placebo|Administered as a coated bilayer tablet
3118072|NCT02634580|Active Comparator|Ezetimibe (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
3118073|NCT02634580|Active Comparator|Ezetimibe (QM)|Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
3118074|NCT02634580|Experimental|Evolocumab Q2W|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 140 mg subcutaneously once every 2 weeks until week 48.
3118075|NCT02634580|Experimental|Evolocumab QM|Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for 12 weeks. From week 12 participants received open-label evolocumab 420 mg subcutaneously once a month until week 48.
3118076|NCT02634684|Active Comparator|dextroamphetamine|"Drug: Dexedrine, dextroamphetamine, d-amphetamine.~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
3118077|NCT02634684|Placebo Comparator|Placebo|"Drug: Dexedrine, dextroamphetamine, d-amphetamine~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week."
3118078|NCT02634788|Experimental|Buprenorphine 0.5 mg TID|Participants received buprenorphine 0.5 mg sublingual (under the tongue) spray three times daily (TID) for two days.
3118079|NCT02634788|Experimental|Buprenorphine 0.25 mg TID|Participants received buprenorphine 0.25 mg sublingual spray TID for two days.
3118080|NCT02634788|Experimental|Buprenorphine 0.125 mg TID|Participants received buprenorphine 0.125 mg sublingual spray TID for two days.
3118081|NCT02634788|Placebo Comparator|Placebo|Participants received placebo-matching buprenorphine sublingual spray TID for two days.
3118082|NCT02634801|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given as two subcutaneous injections (SC) followed by 80 mg ixekizumab given SC every 2 weeks until week 12 and then 80 mg ixekizumab given SC every 4 weeks until week 24.~Extension Period: At week 24, participants have the option to continue ixekizumab treatment for up to 36 weeks."
3118083|NCT02634801|Active Comparator|Fumaric Acid Esters|"Starting dose of 105 mg FAE given orally followed by 215 mg FAE given orally 1 to 3 times per day until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
3118084|NCT02634801|Active Comparator|Methotrexate|"7.5 mg starting dose up to 30 mg MTX given orally once a week until week 24.~Extension Period: At week 24, participants have the option to begin ixekizumab treatment for up to 36 weeks."
3118085|NCT02634814|Experimental|TENS and Therapeutic Exercise|Patients assigned to the TENS+Therapeutic Exercise (TE) group will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN), and 8 hours of TENS per day (150 pulses per second, 150 msec phase duration at a patient-perceived strong sensory intensity). Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
3118086|NCT02634814|Sham Comparator|Sham TENS and Therapeutic Exercise|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program."
3118087|NCT02634814|Active Comparator|Therapeutic Exercise Only|The role of the comparison group is to provide data on how traditional TE affects the outcome measures. The TE only group will allow us to assess how the addition of TENS to traditional TE will augment the effects of traditional TE. Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program.
3118088|NCT02634983|Experimental|QVA149 110/50 mcg then Matching placebo|Single daily dose of 110/50 μg QVA149 for 8-10 days.
3118089|NCT02634983|Placebo Comparator|Matching placebo then QVA149 110/50 mcg|Single daily dose of matching placebo for 8-10 days.
3118090|NCT02635035|Experimental|Lisdexamfetamine First|In this crossover study design, participants assigned to this group will receive Lisdexamfetamine first, then placebo second
3118091|NCT02635035|Experimental|Lisdexamfetamine Second|In this crossover study design, participants assigned to this group will receive placebo first, then Lisdexamfetamine second
3118092|NCT02635204|Experimental|DFD-06 Cream|DFD-06 Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3118093|NCT02635204|Placebo Comparator|Vehicle Cream|Vehicle Cream will be applied to subjects with moderate plaque psoriasis twice daily for 14 days.
3118094|NCT02635347|Experimental|Remote Ischemic Conditioning (RIC) group|Participants will receive RIC during transplant and the initial four post-transplant days. During transplant: first intervention after induction of anesthesia but before commencing surgery and the second at the conclusion of the procedure. After transplant: RIC applied daily during the first four consecutive postoperative days. Pneumatic tourniquet will be used to induce RIC
3118095|NCT02635386|Experimental|Exenatide once weekly (EQW )|EQW- 2 mg subcutaneous (SC) injection once every seven days for 24 weeks
3118096|NCT02635386|Experimental|Dapagliflozin (DAPA)|DAPA-10 mg oral pill once daily in am for 24 weeks
3118097|NCT02635386|Experimental|EQW plus DAPA|EQW- 2 mg SC injection once every seven days for 24 weeks DAPA-10 mg oral pill once daily in am daily for 24 weeks
3118098|NCT02635386|Experimental|Dapagliflozin plus Glucophage (MET ER)|Combination DAPA / MET ER-10 mg /2000 mg oral pill daily with food for 24 weeks
3118099|NCT02635386|Active Comparator|Phentermine /Topiramate (PHEN/ TPM) ER|Combination Phentermine /Topiramate ER -7.5 mg/46mg pill once daily in am for 24 weeks
3118100|NCT02635425|Experimental|7 eggs collection|Aspiration of 7 eggs only
3118101|NCT02635425|Active Comparator|Full eggs collection|Aspiration of all eggs
3118102|NCT02635542|Active Comparator|Group CIS|Continual neuromuscular blockade (standard therapy) during general anesthesia will be provided with cisatracurium (CIS), with 0.2mg/kg IV given as an initial dose and repeated dosing determined by neuromuscular blockade monitoring (peripheral nerve stimulator maintained at 1-2 twitches).
3118103|NCT02635542|Experimental|Group SUX|A single dose of neuromuscular blockade (experimental group) will be provided at the start of anesthesia with succinylcholine (SUX), with 1mg/kg IV given as an initial dose and no repeat dosing.
3118104|NCT02635646|Experimental|Family and interdisciplinary approach|Family and interdisciplinary approach: Patients in this group will receive a Family and interdisciplinary approach that includes nutritional, physical activity and psychological counseling + metformin 850mg twice at day for 12 months
3118105|NCT02635646|Active Comparator|individual approach|individual approach: Patients in this group will receive individual approach that includes nutritional and physical activity counseling + metformin 850mg twice at day for 12 months
3118106|NCT02635724|Experimental|Peramivir|Single dose 600 mg IV injection
3118107|NCT02635737|Experimental|Sentimark device placement|Sentimark device placed in women having mastectomy surgery
3118108|NCT02635828|Experimental|Triple therapy PONV prophylaxis|At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.
3118109|NCT02635880|Experimental|Investigational Enlighten Device|Laser treatment for removal of benign pigmented lesions (BPLs) with Nd:YAG dual-wavelength, dual-pulse duration laser.
3118110|NCT02635984|Placebo Comparator|Triplet Therapy Plus Placebo|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive placebo on all chemotherapy days and for three additional days post chemotherapy.
3118111|NCT02635984|Active Comparator|Triplet Therapy Plus Olanzapine|All subjects will receive standard triplet antiemetic therapy which consists of ondansetron and dexamethasone on each day of chemotherapy plus fosaprepitant 150 mg IV once per national guidelines for CINV prophylaxis. In addition to those antiemetics, subjects will receive olanzapine 10mg orally on all chemotherapy days and for three additional days post chemotherapy.
3118112|NCT02636049|Experimental|Treatment Period: 6 mg Triferic IV over 3 hours|Each subject will receive a single 6 mg dose of Triferic administered as a continuous intravenous infusion over 3 hours on Day 2. The Triferic IV dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 0.020 mg/mL. Administration of 300 mL IV at 100 mL/hr for 3 hours results in delivery of 6 mg of Triferic iron.
3118113|NCT02636049|Experimental|Treatment Period: 35 micrograms/kg IV push|Each subject will receive Triferic as 35 µg/kg body weight IV push over 30-60 seconds on Day 3. The Triferic IV push dosing solution will have been prepared by diluting Triferic from ampules (5.44 mg/mL) in an appropriate amount of D5W to a concentration of 35 µg Triferic iron/kg body weight per subject in 4.5 mL.
3118114|NCT02636361|Experimental|LY900014 Test B|Test formulation B: Single dose of LY900014 formulation administered subcutaneously (SC) in one of five periods
3118115|NCT02636361|Experimental|LY900014 Test A|Test formulation B: Single dose of LY900014 formulation administered SC in one of five periods
3118116|NCT02636361|Experimental|LY900014 Test C|Test formulation C: Single dose of LY900014 formulation administered SC in one of five periods
3118117|NCT02636361|Experimental|LY900014 Test D|Formulation D: Single dose of LY900014 formulation administered SC in one of five periods
3118118|NCT02636361|Active Comparator|Insulin Lispro|Reference formulation: Single dose of lispro administered SC in one of five periods
3118119|NCT02636595|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3118120|NCT02636608||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
3118121|NCT02636699|Experimental|Viaskin Peanut 250mcg|
3118122|NCT02636699|Placebo Comparator|Placebo|
3118123|NCT02636712||ImageReady™ MR Conditional Pacing System|"Subject must have the ImageReady™ System as their initial (de novo) pacing system implant~Subject has a Class I or II indication for implantation of a pacemaker according to the CSPE guidelines"
3118124|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Group|Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
3118125|NCT02636725|Experimental|Axitinib Plus Pembrolizumab Expansion Cohort|Expansion cohort for up to 10 additional patients with alveolar soft part sarcoma. Participants in this group will receive combination treatment of Axitinib plus Pembrolizumab for up to 2 years followed by monotherapy of Axitinib until withdrawal of consent, disease progression and/or unacceptable toxicity as assessed by treating physician, whichever occurs first.
3118126|NCT02636868|Experimental|Aerosolized lucinactant (low dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
3118127|NCT02636868|Experimental|Aerosolized lucinactant (high dose)|Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.
3118128|NCT02636868|Active Comparator|nasal CPAP|nCPAP alone
3118129|NCT02636907|Experimental|BI 695501|
3118130|NCT02637037|Experimental|Treatment A|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
3118131|NCT02637037|Active Comparator|Treatment B|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
3118132|NCT02637037|Experimental|Treatment C|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 5/500 mg dose
3118133|NCT02637037|Active Comparator|Treatment D|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 5/500 mg dose
3118134|NCT02637037|Experimental|Treatment E|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
3118135|NCT02637037|Active Comparator|Treatment F|Under fed conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
3118136|NCT02637037|Experimental|Treatment G|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR test drug (Mount Vernon) 10/1000 mg dose
3118137|NCT02637037|Active Comparator|Treatment H|Under fasted conditions, subjects will receive single doses of dapagliflozin/metformin XR reference drug (Humacao) 10/1000 mg dose
3118138|NCT02637063|Experimental|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
3118139|NCT02637063|Experimental|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
3118140|NCT02637063|Other|Usual care|No intervention beyond the participants' personal medical care.
3118141|NCT02637076|Experimental|narcolepsy with cataplexy|patients given single dose of Xyrem
3118142|NCT02637076|Experimental|healthy controls|healthy controls given a single dose of Xyrem
3118143|NCT02637141|Experimental|AMG 714 150 mg|Participants received 150 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
3118144|NCT02637141|Experimental|AMG 714 300 mg|Participants received 300 mg AMG 714 via subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
3118145|NCT02637141|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every 2 weeks for a total of 6 doses over 10 weeks from day 0. Participants received gluten-free cookies twice a day for the first 2 weeks and gluten-containing cookies twice a day from weeks 2 to 12 (gluten-challenge).
3118146|NCT02637232||Mirvaso® / Onreltea TM|
3118147|NCT02637323|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3118148|NCT02637323|Active Comparator|TCA IR 40 mg|Commercially available triamcinolone acetonide, single 1 mL intra-articular (IA) injection Immediate-release formulation
3118149|NCT02637427|Experimental|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg, range 10-20 cc/Kg, to a maximum of 5 units)
3118150|NCT02637427|No Intervention|No transfusion|No transfusions prior to the procedure
3118151|NCT02637557|Placebo Comparator|Control|Matching placebo twice daily
3118152|NCT02637557|Experimental|500 mg IW-3718|500 mg IW-3718 twice daily
3118153|NCT02637557|Experimental|1000 mg IW-3718|1000 mg IW-3718 twice daily
3118154|NCT02637557|Experimental|1500 mg IW-3718|1500 mg IW-3718 twice daily
3118155|NCT02637804|Active Comparator|stenfilcon A vs narafilcon A (Group 1)|Participants are randomized to wear either stenfilcon A lens pair or narafilcon A lens pair, bilaterally, for 1 week during the cross over study.
3118156|NCT02637804|Active Comparator|stenfilcon A vs delefilcon A (Group 2)|Participants are randomized to wear either stenfilcon A lens pair or delefilcon A lens pair, bilaterally, for 1 week during the cross over study.
3118157|NCT02637856|Experimental|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
3118158|NCT02637856|Experimental|Ocrelizumab (substudy)|Participants with no serious IRR throughout the main study will be eligible to enroll in an optional substudy and receive one additional shorter infusion of ocrelizumab at the Week 96 visit. Ocrelizumab will be administered IV as a single 600-mg dose at a shorter infusion rate (approximately 2 hours instead of 3.5 hours)
3118159|NCT02637895|Placebo Comparator|Placebo|Placebo pill once daily for 12 weeks of active treatment.
3118160|NCT02637895|Active Comparator|Vortioxetine|Vortioxetine pill 10mg once daily up to 4 weeks followed by 20mg once daily if tolerated for the rest of the study. Patients unable to tolerate the 20 mg/day dose may be reduced to 10 mg/day between weeks 4 and 8. The dose of study medication should remain stable for weeks 8-12.
3118161|NCT02637999|Experimental|MXB then PEG IFN|Myrcludex B 2mg daily for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 48 weeks
3118162|NCT02637999|Experimental|MXB + PEG IFN then PEG IFN|Myrcludex B 2mg daily and PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks, followed by PEG IFN alfa-2a 180 µg/0.5 mL weekly for 24 weeks
3118163|NCT02637999|Active Comparator|PEG IFN|PEG IFN alfa-2a 180 µg/0.5 mL once weekly for 48 weeks
3118164|NCT02638012|Experimental|HHT - Floseal|"Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity.~If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care)."
3118165|NCT02638051|Experimental|Study Group|Modulated Electro-Hyperthermia (mEHT): 150 Watt x 60 min/session every 2nd day for 4 weeks (14 sessions); TCM Herbal Decoction: Shi Pi Decoction administered orally twice a day (200 mL x 2) 30 min after breakfast and supper, for 4 weeks.
3118166|NCT02638051|Active Comparator|Control Group|IPCI: CDDP (30-60 mg) with 5FU (500-600 mg/sqm of body surface), both dissolved in 100 mL of normal saline, after abdominal paracentesis and catheterization with following closed drainage of the ascites up to small amount of remaining liquid. After IPCI, the catheter occluded. Administered biweekly during four weeks of the course, totally two times.
3118167|NCT02638103|Experimental|TEV-48125 225 mg Monthly: New/Placebo Rollover Participants|Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
3118168|NCT02638103|Experimental|TEV-48125 225 mg Monthly: Active Rollover Participants|Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
3118169|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants|Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
3118170|NCT02638103|Experimental|TEV-48125 675 mg Quarterly: Active Rollover Participants|Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).
3118171|NCT02638168|Active Comparator|Immediate Release Methylphenidate|With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
3118172|NCT02638168|Placebo Comparator|Placebo|inert placebo ingredient
3118173|NCT02638207|Experimental|0.5 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
3118174|NCT02638207|Experimental|1.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
3118175|NCT02638207|Experimental|2.0 g/kg NewGam|All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).
3118176|NCT02638259|Experimental|50mg GP2015|Group 1 will receive treatment with 50mg GP2015 by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response continue treatment with 50mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
3118177|NCT02638259|Active Comparator|50mg EU-authorized Enbrel|Group 2 will receive treatment with 50mg EU-authorized Enbrel by subcutaneous injection every week up to 24 weeks (Treatment Period 1) after which patients achieving at least a moderate clinical response will be switched to 50 mg GP2015 subcutaneous injection every week up to 48 weeks (Treatment Period 2).
3118178|NCT02638337|Experimental|Ospemifene|Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
3118179|NCT02638337|Placebo Comparator|Placebo|Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.
3118180|NCT02638493||HIV positive TDF/FTC|8 HIV positive men taking TDF/FTC as treatment
3118181|NCT02638493||HIV negative|8 HIV negative men taking TDF/FTC as pre-exposure prophylaxis
3118182|NCT02638493||HIV Positive TAF|8 HIV positive men taking TAF as treatment
3118183|NCT02638597|Experimental|Gemfibrozil|Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
3118184|NCT02638597|Other|Waitlist|Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
3118185|NCT02638623|Active Comparator|Drug Lactated Ringer|Covered two liters of body temperature warmed lactated ringer's in the immediate preoperative setting of subjects undergoing total knee or total hip replacement
3118186|NCT02638623|Placebo Comparator|Placebo|Covered empty bag with no hydration supplement
3118187|NCT02638948|Placebo Comparator|Placebo|Placebo + Methotrexate dose as specified
3118188|NCT02638948|Experimental|Dose Level 1|BMS-986142 at dose level 1+ Methotrexate as specified
3118189|NCT02638948|Experimental|Dose Level 2|BMS-986142 at dose level 2 + Methotrexate as specified
3118190|NCT02638974|Experimental|Medical Skin Camouflage|This arm will use medical skin camouflage for 6 weeks
3118191|NCT02638974|No Intervention|Wait List Control|This arm will receive medical skin camouflage at the end of the study
3118192|NCT02639052|Experimental|Botox|10 units of Botox intradermally injected into one forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
3118193|NCT02639052|Placebo Comparator|Saline|Saline vehicle intradermally injected into the other forearm. The subject is blinded to which forearm receives the Botox and which forearm receives the saline vehicle.
3118194|NCT02639182|Experimental|AGS-16C3F|Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
3118195|NCT02639182|Active Comparator|Axitinib|Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
3118196|NCT02639247|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
3118197|NCT02639247|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3118198|NCT02639286|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC)
3118199|NCT02639286|Experimental|ISIS 304801|300 mg of study drug administered via SC
3118200|NCT02639338|Experimental|SOF/VEL/VOX|SOF/VEL/VOX tablet for 8 weeks
3118201|NCT02639338|Experimental|SOF/VEL|SOF/VEL tablet for 12 weeks
3118202|NCT02639351|Experimental|LHD153R Formulation 1 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 12.5 ug of LHD153R.
3118203|NCT02639351|Experimental|LHD153R Formulation 2 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 25 ug of LHD153R.
3118204|NCT02639351|Experimental|LHD153R Formulation 3 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational MenC-CRM vaccine adjuvanted with 50 ug of LHD153R.
3118205|NCT02639351|Experimental|LHD153R Formulation 4 Group|Healthy subjects aged 18 to 45 years who received a single dose of investigational Meningococcal C-CRM conjugate vaccine (MenC-CRM) adjuvanted with 100 ug of LHD153R.
3118206|NCT02639351|Active Comparator|MenC Group|Healthy subjects aged 18 to 45 years who received a single dose of MenC-CRM vaccine.
3118207|NCT02639429|Experimental|Combined approach: Foley Balloon + Vaginal Misoprostol|These women will receive vaginal misoprostol per standard protocol at 25 micrograms every 4 hours. In addition, a 26 Fr-Foley balloon catheter will be inserted by routine clinical standards. The Foley will be inserted through the internal cervical os, filled with 60 mL of normal saline, and then pulled snugly against the internal os. The catheter of the Foley will be taped to the patient's inner thigh under gentle traction. If the Foley is unable to be placed, the patient will be reexamined in 1 hour and placement will be reattempted if Bishop's score is still 6 or less by the healthcare provider. When the Foley balloon had fallen out or had to be removed because 12 hours have passed since insertion as per protocol, further management of labor will be left at the discretion of the labor team.
3118208|NCT02639429|Active Comparator|Single approach: Vaginal Misoprostol only|These women will receive 25 micrograms of misoprostol per vagina every 4 hours. Once the cervix becomes favorable (Bishop score > 6), misoprostol administration will be discontinued. Further management will be left at the discretion of the labor team.
3118209|NCT02639494|Experimental|Self-Centering Guide Catheter|Subjects who provided written informed consent and an attempt is made to insert the Self-Centering Guide Catheter into the subject's femoral artery.
3118210|NCT02639559|Experimental|Arm 1: Donors|-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10^6 CD34+ cells/kg and at least ≥ 2 x 10^6 CD34+ cells/kg from the combined collections.
3118211|NCT02639559|Experimental|Arm 2: Recipients|-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0
3118212|NCT02639637|Other|Sitagliptin then Placebo|Subjects in this arm will receive sitagliptin 100 mg daily. After one week of treatment, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive placebo for one week followed by study day #2.
3118213|NCT02639637|Other|Placebo then Sitagliptin|Subjects in this arm will receive placebo for one week. After this, subjects will report for study day #1. During the study day subjects will be given intra-aterial neuropeptide Y and enalaprilat. A four week washout of medications will occur after the study day. Subjects will then receive 100 mg of sitagliptin daily for one week followed by study day #2.
3118214|NCT02639637|Placebo Comparator|Sitagliptin then Placebo: Valsartan|Subjects in this arm will receive sitagliptin 100 mg/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive placebo/d and valsartan 160 mg/d for one week followed by study day #2.
3118215|NCT02639637|Placebo Comparator|Placebo then Sitagliptin: Valsartan|Subjects in this arm will receive placebo/d for one week as well as valsartan 160 mg/d for one week. After this subjects will report for study day #1. During the study day, subjects will be given intra-arterial neuropeptide Y. A four week washout of medication will occur after the study day. Subjects will then receive sitagliptin 100mg/d and valsartan 160 mg/d for one week followed by study day #2.
3118216|NCT02639884|Experimental|Evaluation Group|All subjects will be enrolled into the evaluation group and will receive SedLine EEG and RRa monitoring
3118219|NCT02640053|Experimental|Arm I (topical cryotherapy, paclitaxel)|Patients apply bags filled with crushed ice to hands and feet for 15 minutes before, for 60 minutes during administration, and for 15 minutes after finishing administration of paclitaxel. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
3118220|NCT02640053|Active Comparator|Arm II (paclitaxel)|Patients receive paclitaxel IV over 60 minutes on weeks 1-12. Courses repeat once a week for 12 weeks in the absence of disease progression or unacceptable toxicity.
3118221|NCT02640157|Experimental|Arm A|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3118222|NCT02640157|Active Comparator|Arm B|Sofosbuvir 400 mg once daily (QD) co-administered with daclatasvir 60 mg QD for 12 weeks.
3118223|NCT02640157|Experimental|Arm C|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.
3118224|NCT02640235|Experimental|CELSTAT|Oxidized cellulose strip (CELSTAT), Single-use treatment, Intraoperative, direct application to target bleeding site
3118225|NCT02640235|Active Comparator|Surgicel Original|Oxidized regenerated cellulose strip (Surgicel Original), Single-use treatment, Intraoperative, direct application to target bleeding site
3118226|NCT02640404|Experimental|Menactra® Vaccine (9 to 23 Months)|Participants (infants and toddlers) received 2-dose series of study vaccine with 3-month interval (first dose at Day 0 and second dose 3 months after dose 1).
3118227|NCT02640404|Experimental|Menactra® Vaccine (2 to 55 Years)|Participants (children, adolescents and adults) received 1 dose of study vaccine at Day 0.
3118228|NCT02640482|Experimental|Arm A DB Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (double-blind [DB] treatment period)
3118229|NCT02640482|Experimental|Arm B DB Placebo|Placebo for ABT-493/ABT-530 QD for 12 weeks (DB treatment period)
3118230|NCT02640482|Experimental|Arm B OL Active Drug|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks (open-label [OL] treatment period)
3118231|NCT02640547||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
3118232|NCT02640612|Experimental|BI 695501|
3118234|NCT02640716|Active Comparator|training group|Intervention: Multi-domain adaptive internet-based training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. 5 x 30 minutes per week, for 7 weeks.
3118235|NCT02640716|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
3118236|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 Monotherapy|Arm will be comprised of [14C]AZD2014 followed by AZD2014 Monotherapy
3118237|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Fulvestrant|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Fulvestrant
3118238|NCT02640755|Experimental|[14C]AZD2014 followed by AZD2014 + Paclitaxel|Arm will be comprised of [14C]AZD2014 followed by AZD2014 + Paclitaxel
3118239|NCT02640807|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
3118240|NCT02640807|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
3118241|NCT02640807|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
3118242|NCT02641067|Experimental|Severe Renal Impairment|Participants with severe renal impairment receive a single oral dose of 100 mg doravirine
3118243|NCT02641067|Experimental|Healthy Matched Control|Healthy participants matched for age and weight receive a single oral dose of 100 mg doravirine
3118244|NCT02641080|Active Comparator|Aspirin|Participants randomized to aspirin alone will be advised to take a 325mg per day as their outpatient DVT/PE prophylaxis.
3118245|NCT02641080|Active Comparator|Aspirin with portable Compression Device|Participants randomized to the compression device group are asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an 325mg aspirin per day as their outpatient DVT/PE prophylaxis.
3118246|NCT02641249|No Intervention|No vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
3118247|NCT02641249|Experimental|Vibration|In the same subject cardiorespiratory parameters - heart rate, respiratory rate and oxygen saturation were compared during the procedure (vibration) and without procedure (no vibration). The same subject had both control and treatment periods.
3118248|NCT02641353|Experimental|Treatment A: Apremilast 30 mg Tablet - Fasted|A single oral dose of 30 mg apremilast tablet after an overnight fast.
3118249|NCT02641353|Experimental|Treatment B: Apremilast 30 mg Oral Suspension - Fasted|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after an overnight fast.
3118250|NCT02641353|Experimental|Treatment C - Apremilast 30 mg Oral Suspension - Fed|A single oral dose of 30 mg apremilast oral suspension formulation (6 mL) after a high-fat meal.
3118251|NCT02641379|Experimental|PEG-IFN 24 weeks|Participants will receive PEG-IFN (180 microgram [mcg]), subcutaneously (sc), once weekly for 24 weeks and Ribavirin 1000-1200 milligram per day (mg/day) (<75 kilogram (kg); >75 kg) for 24 weeks.
3118252|NCT02641379|Experimental|PEG-IFN 24/72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 24; if patient is still HCV RNA positive. Treatment will be stopped if participant is HCV RNA negative at week 24 -treatment with PEG-IFN (180 mcg), sc, once weekly and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) till week 72
3118253|NCT02641379|Experimental|PEG-IFN 48 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 48 weeks and Ribavirin 1000-1200 mg/day (<75kg; >75 kg) for 48 weeks.
3118254|NCT02641379|Experimental|PEG-IFN 72 weeks|Participants will receive PEG-IFN (180 mcg), sc, once weekly for 72 weeks and Ribavirin 1000-1200 mg/day (<75 kg; > 75 kg) for 72 weeks.
3118255|NCT02641392|Experimental|GED-0301 (160 mg) followed by Placebo intermittent 160 mg|GED-0301 160 mg once daily (QD) for 12 weeks, followed by alternating Placebo (PBO) QD for 4 weeks with GED 0301 160 mg QD for 4 weeks, up to 208 weeks, if the subject previously received Placebo in the prior GED-0301 Study
3118256|NCT02641392|Experimental|Intermittent GED-0301 160 mg and placebo|Alternating GED-0301 160 mg once daily (QD) for 4 weeks with placebo (PBO) QD for 4 weeks, up to 208 weeks, depending on previous response in the prior GED-0301 study
3118257|NCT02641392|Experimental|Intermittent placebo and GED-0301 40 mg|Alternating PBO once daily (QD) for 4 weeks with GED-0301 40 mg QD for 4 weeks with, up to 208 weeks, depending on previous response in the prior GED-0301 study
3118258|NCT02641392|Experimental|Continuous GED-0301 40 mg|GED-0301 40 mg once daily (QD) for up to 208 weeks
3118259|NCT02641392|Experimental|Intermittent placebo and GED-0301 160 mg|Alternating PBO QD for 4 weeks with GED-0301 160 mg QD for 4 weeks, through Week 208
3118260|NCT02641522|Experimental|Post-Infusion|Single infusion of siltuximab (11 mg/kg)
3118261|NCT02641561|Placebo Comparator|A (NS+Placebo)|Normal Saline (intravenous during procedure) + Placebo (100mg suppository per rectum prior to procedure )
3118262|NCT02641561|Active Comparator|B (NS+IND)|Normal Saline (intravenous during procedure) + Indomethacin (100mg suppository per rectum prior to procedure )
3118263|NCT02641561|Active Comparator|C (LR+Placebo)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Placebo (100mg suppository per rectum prior to procedure)
3118264|NCT02641561|Experimental|D (LR+IND)|Lactated ringer's solution (1 Liter, intravenous prior to procedure) + Indomethacin (100mg suppository per rectum prior to procedure)
3118265|NCT02641587|Experimental|CHTP 1.2|Ad libitum use of the CHTP 1.2
3118266|NCT02641587|Active Comparator|CC|Ad libitum use of subject's own preferred non-menthol brand of CC
3118267|NCT02641691|Experimental|Arm 1: Radiation/Oxaliplatin/Leucovorin/5-FU|"Radiotherapy will consist of five fractions, delivered once daily, to a total dose of 25Gy at 5 Gy per fraction.~An optional concomitant boost may be delivered to the primary tumor of 1-2 Gy per day (30-35 Gy to tumor total). If a boost is given then the maximum allowed dose to small bowel is 25 Gy.~Chemotherapy should begin two weeks (9-12 working days) after completion of radiotherapy.~Oxaliplatin will be given intravenous (IV) over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~Leucovorin will be given IV over 2 hours on Day 1 every 14 days for a maximum of 8 cycles.~5-FU bolus will given IV push on Day 1 every 14 days for a maximum of 8 cycles.~5-FU infusion will be given continuous IV on Day 1 over 46 hours every 14 days for a maximum of 8 cycles~Alternatively, capecitabine/oxaliplatin (CAPE PO 1000 mg/m2 BID days 1-14 Q21 days, oxaliplatin IV 130 mg/m2 IV Q21 days on day 1) x 5 cycles over 15 weeks may be administered instead of FOLFOX"
3118268|NCT02641730|Experimental|Group 1|Participants will receive guselkumab 200 milligram (mg) at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, and two syringes of placebo at Week 16 to maintain the blind.
3118269|NCT02641730|Experimental|Group 2|Participants will receive a syringe of guselkumab 100 mg and a syringe of placebo for guselkumab at Week 0, 4, 12 and every 8 weeks thereafter through Week 60, two syringes of placebo at Week 16 to maintain the blind.
3118270|NCT02641730|Experimental|Group 3|Participants will receive two syringes of placebo at Week 0, 4 and 12. At Week 16, placebo participants will be randomized in a 1:1 ratio to guselkumab mg arm (Group 3a) or 100 mg arm (Group 3b). Group 3a participants will receive guselkumab 200 mg at Week 16, 20 and every 8 weeks thereafter through Week 60. Group 3b participants will receive guselkumab 100 mg and a syringe of placebo at Week 16, 20 and every 8 weeks thereafter through Week 60.
3118271|NCT02641834|Experimental|Veg Group|Group that starts with the Vegetarian diet
3118272|NCT02641834|Active Comparator|Med group|Group that starts with the Mediterranean diet
3118273|NCT02641912|Experimental|Experimental Mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
3118274|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
3118275|NCT02642042|Experimental|Treatment (trametinib, docetaxel)|Patients receive trametinib PO on days 1-21. Patients also receive docetaxel IV on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3118276|NCT02642159|Experimental|Alirocumab 75 mg Q2W/Up to 150 mg Q2W|Alirocumab 75 mg subcutaneous (SC) injection every 2 weeks (Q2W) added to insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without other lipid modifying therapy (LMT) for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when non-high-density lipoprotein cholesterol (non-HDL-C) levels >=100 mg/dL (2.59 mmol/L) at Week 8.
3118277|NCT02642159|Active Comparator|Usual Care|Participants on usual care continued on insulin or other antihyperglycemic drugs, stable maximally tolerated dose of statin therapy without additional LMT or with either ezetimibe, fenofibrate, omega-3 fatty acids or nicotinic acid as per Investigator's judgment for 24 weeks.
3118278|NCT02642237|Experimental|LPS-Fluenz|Healthy volunteers administered intravenously with endotoxin, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
3118279|NCT02642237|Placebo Comparator|Placebo-Fluenz|Healthy volunteers administered intravenously with placebo, followed by an intranasal inoculation with Fluenz, a live-attenuated influenza vaccin
3118280|NCT02642393|Experimental|Inosine|Inosine will be dosed by titrating the number of capsules taken daily to achieve an elevation of serum urate to trough levels of 7.1 to 8.0 mg/dL.
3118281|NCT02642393|Placebo Comparator|Placebo|Placebo will be dosed to match the capsule titrations of the inosine group.
3118282|NCT02642432|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3118283|NCT02642536|Active Comparator|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
3118284|NCT02642536|Active Comparator|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
3118285|NCT02642614|Experimental|BI 1026706 low dose|
3118286|NCT02642614|Experimental|BI 1026706 medium|
3118287|NCT02642614|Experimental|BI 1026706 high dose|
3118288|NCT02642614|Placebo Comparator|Placebo|
3118289|NCT02642627|Experimental|Bellafill Injections|Correctable acne scars will be individually identified and only scars that the Investigator determines to be correctable will receive study treatment. All eligible scars within the treatment area will be treated. Bellafill will be injected using a standard tunneling technique whereby the filler is injected in a retrograde manner utilizing several passes until the scar reaches a desired level of correction. A touch-up treatment is allowed if additional treatment is required to achieve optimal correction.
3118290|NCT02642653|Active Comparator|Lovastatin and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with study medication Lovastatin.
3118291|NCT02642653|Placebo Comparator|Placebo and PILI|Subjects will receive the Parent Implemented Language Intervention (PILI) in combination with placebo.
3118292|NCT02642679|Experimental|Opticell Ag|Opticell Ag covered with a transparent occlusive dressing (Tegaderm) with evenly distributed perforations which permit a controlled leakage into a layer of cotton gauze pads placed directly over the Opticell Ag and occlusive dressing combination.
3118293|NCT02642952||Open-graft group|Patients treated for abdominal aortic aneurysm with open graft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
3118294|NCT02642952||Endograft group|Patients treated for abdominal aortic aneurysm with endograft will be measured for central hemodynamics and arterial stiffness by non-invasive methods.
3118295|NCT02642965|Experimental|Treatment (CPX-351 and FLAG)|"COURSE 1: Patients receive cytarabine IT on day 0 and at day 28-30 or up to 7 days prior to day 1 of course 2, and liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5. Patients with CNS1 receive no further CNS-directed therapy in course 1. Patients with CNS2 disease may receive additional 4-6 doses of cytarabine IT twice weekly starting 48 hours after the third dose of liposome-encapsulated daunorubicin-cytarabine until CNS is clear at the discretion of the investigator. Patients meeting criteria for CR, CRp, and CRi may proceed to course 2.~COURSE 2: Patients receive filgrastim on days 1-5 and then on day 15 until blood count recovery, and fludarabine phosphate IV over 30 minutes and high-dose cytarabine IV over 1-3 hours QD on days 1-5."
3118296|NCT02642991|Experimental|Phenacite Test lens then comfilcon A control lens|Participants were randomized to wear Phenacite test lens for one week then cross-over to wear comfilcon A control lens for one week.
3118297|NCT02642991|Active Comparator|Comfilcon A control lens then Phenacite test Lens|Participants were randomized to wear comfilcon A control lens for one week then cross over to Phenacite test lens for one week.
3118298|NCT02643004|Active Comparator|Senofilcon A|Participants were randomized to wear senofilcon A lens pair for one week during the crossover study.
3118299|NCT02643004|Active Comparator|Stenfilcon A|Participants were randomized to wear stenfilcon A lens pair for one week during the crossover study.
3118300|NCT02643082|Experimental|GFF MDI, 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3118301|NCT02643082|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI)
3118302|NCT02643095|Experimental|Lens fitting/evaluation|This study will be done with subjects who already habitually wear scleral contact lenses. The study lens is made with a material that is already widely available and has a new design. It will be fit by the investigators and will be assessed and at one week and 1 month.
3118303|NCT02643225||pregnant women with gestational diabetes|case group
3118304|NCT02643225||non diabetic pregnant women|control group
3118305|NCT02643251|Experimental|Clonidine Hydrochloride Topical Gel,0.1%|Clonidine Hydrochloride Topical Gel,0.1%
3118306|NCT02643251|Placebo Comparator|Clonidine Hydrochloride Gel Comparator|Clonidine Hydrochloride Gel Comparator
3118307|NCT02643355|Experimental|Standard of Care - Olanzapine|Drug of interest in the study - Olanzapine
3118308|NCT02643355|Active Comparator|Standard of Care - Clonidine|Standard of care - clonidine
3118309|NCT02643394|Active Comparator|Oral Acetaminophen|Oral Acetaminophen 1-hour before surgery
3118310|NCT02643394|Active Comparator|Intravenous Acetaminophen|Intravenous Acetaminophen within 1-hour prior to anesthetic emergence
3118311|NCT02643459|No Intervention|Conventional|no suPAR measurement. Standard care.
3118312|NCT02643459|Experimental|suPAR|suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR. Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention. A possible intervention depends on the clinical situation.
3118313|NCT02643472|Other|Care Notebook|Parents of infants who were discharged from the Children's National NICU will be randomized to receive enhanced usual care by provision of a NICU care resource notebook. Parents will be notified about group assignment prior to discharge. Stratification will occur according to birth weight.
3118314|NCT02643472|Experimental|Care Notebook + Parent Navigator|Parents of infants who were discharged from the Children's National NICU will be randomized to receive a care notebook + Parent Navigation. Parents will be notified about group assignment prior to discharge. Stratification will occur according to the birth weight.
3118315|NCT02643615|Experimental|VEP under TIVA|Patients undergoing prone spine surgery will receive an anesthesia regimen using propofol (TIVA) for maintenance
3118316|NCT02643615|Experimental|VEP under balanced anesthesia|Patients undergoing prone spine surgery will receive an anesthesia regimen using Desflurane as part of balanced general anesthesia
3118317|NCT02643628|Experimental|Microneedling Only|All eligible scars within the treatment areas on each side of the face will receive microneedling treatment. The device will be rolled in a horizontal direction with medium pressure. After every roll, the device will be lifted and positioned a few millimeters inferior to the previous starting point. Rolling will be repeated until the entire skin area has been treated. The device will then be reoriented vertically and rolling will be repeated in a vertical direction.
3118318|NCT02643628|Experimental|Microneedling followed by Bellafill treatment|Subjects undergo microneedling as described for the Microneedling Only group. Then at Week 12, all eligible scars within the treatment areas on each side of the face will be treated with Bellafill (injected using a standard tunneling technique). A touch-up treatment is allowed at Month 1 after initial treatment, if additional treatment is required to achieve optimal correction.
3118319|NCT02643693|Experimental|P3L Product use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
3118320|NCT02643693|Experimental|VUSE Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
3118321|NCT02643693|Experimental|CC Product Use|Subject product use was randomly assigned for each ad libitum use session, following a sequence of product exposure comprised of the three products (P3L, VUSE, and CC).
3118322|NCT02643849|Experimental|Spanner|
3118323|NCT02643862|Active Comparator|xolair|Pts will be randomized to receive xolair at a 3 active:1 placebo ratio
3118324|NCT02643862|Placebo Comparator|Placebo|This is a placebo that looks similar to Xolair and is given as a subcutaneous shot, just like Xolair
3118325|NCT02643875|Sham Comparator|Ortho-k lens with normal compression factor|The eye wears ortho-k lens with normal compression factor to achieve plano (+/- 0.25D) correction.
3118326|NCT02643875|Active Comparator|Ortho-k lenses with increased compression factor|The eye wears ortho-k lenses with increased compression factor to achieve 1 diopter (+/- 0.25D) over correction.
3118327|NCT02643979|Experimental|Ketofol and Propofol|This arm receives a 50mg dose of Ketamine mixed with 100mg of Propofol at the start of their upper endoscopy.
3118328|NCT02643979|Active Comparator|Propofol only|This arm receives 100mg of Propofol mixed with 1mL of saline at the start of the upper gastrointestinal endoscopy.
3118329|NCT02644096|No Intervention|conventional treatment|After surgery, patients with total hip replacement are only seen once 3 months after surgery, and they have no further contact with the hospital.
3118330|NCT02644096|Other|Intervention|counselling and support after discharge from hospital
3118331|NCT02644109|Experimental|Phytosterols|"Milk powder: subjects will be instructed to consume 22 g/day of the product, with 0.65 g of esterified phytosterols (0.39 g of free equivalent sterols). The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day with 1.3 grs of esterified phytosterols (0.78 g of free equivalent phytosterols). Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
3118332|NCT02644109|Placebo Comparator|Placebo|"Milk powder: subjects will be instructed to consume 22 g/day of the product, without phytosterols. The product will be reconstituted with 200 ml of water at time of consumption, preferably at breakfast or tea time. The total amount of product will be provided at the beginning of the study (day 1), together with instructions, material for preparation, and storage.~Drinking yoghurt: the daily volume consumed will be 90 ml/day without phytosterols. Subjects will be instructed to consume this beverage with main meal (not later than 15 min after it. The product should be kept refrigerated. Products will be distributed to subjects on a weekly basis."
3118333|NCT02644122|Experimental|SF1126|SF1126 1110 mg/m2 administered intravenously (IV) twice per week (separated by at least three days) for the first four treatment cycles (28 days) and then once weekly for subsequent cycles.
3118334|NCT02644278|Experimental|VX-984 120 mg + PLD 40 mg/m^2|
3118335|NCT02644278|Experimental|VX-984 240 mg + PLD 40 mg/m^2|
3118336|NCT02644278|Experimental|VX-984 480 mg + PLD 40 mg/m^2|
3118337|NCT02644278|Experimental|VX-984 720 mg + PLD 40 mg/m^2|
3118338|NCT02644343|Experimental|Remote Programming Group|"Subjects will undergo remote programming of Nucleus cochlear implants via Custom Sound software using an online interactive meeting platform.~The intervention is the programming of the cochlear implant, the experimental aspect is the remote delivery method."
3118339|NCT02644356|Experimental|Online CE/CME course|Participant in taking the three course modules and completing pre- and post-course data collection.
3118340|NCT02644668|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive a placebo suspension twice daily for 8 weeks.
3118341|NCT02644668|Experimental|Reldesemtiv 150 mg twice daily|Patient randomized to this treatment arm will receive reldesemtiv suspension at a dose of 150 mg, twice daily for 8 weeks.
3118342|NCT02644668|Experimental|Reldesemtiv 450 mg twice daily|Patients randomized to this treatment arm will receive reldesemtiv suspension at a dose of 450 mg, twice daily for 8 weeks.
3118343|NCT02645019||Cuffed ETT|Airway secured using a cuffed endotracheal tube.
3118344|NCT02645019||LMA 2|Airway secured using a size 2 laryngeal mask airway.
3118345|NCT02645019||LMA 2.5|Airway secured using a size 2.5 laryngeal mask airway.
3118346|NCT02645019||LMA 3|Airway secured using a size 3 laryngeal mask airway.
3118347|NCT02645019||LMA 4|Airway secured using a size 4 laryngeal mask airway.
3118348|NCT02645123|Experimental|Spinal mobilization|The individuals of the group received 5 treatments in total for 10 minutes that included: posterior to anterior spinal accessory mobilization passive physiological inter vertebral rotation The above was applied to the level that the MRI showed disc degeneration
3118349|NCT02645123|Sham Comparator|Sham Treatment|The investigator touched the skin overlying the low back statically for 10 minutes
3118350|NCT02645123|Active Comparator|Classic Physiotherapy|This group received static hamstring stretch for 5 minutes, TENS (2 channels biphasic pulse, 90Hz, 100μs pulse width) for 20 minutes and 15 minutes of Swedish type massage (effleurage, petrissage, kneading)
3118351|NCT02645253|Experimental|Cohort 1|AZD7594 inhalation powder (200 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
3118352|NCT02645253|Experimental|Cohort 2|AZD7594 inhalation powder (400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
3118353|NCT02645253|Experimental|Cohort 3|1600 μg AZD7594 inhalation powder (4 x 400 μg) or AZD7594 placebo inhalation powder via multi-dose dry powder inhaler (DPI)
3118354|NCT02645253|Experimental|Cohort 4|400 μg AZD7594 pressurized inhalation suspension (2 x 200 μg inhalations) or placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
3118355|NCT02645409|Experimental|Partial nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for partial nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
3118356|NCT02645409|Experimental|Radical nephrectomy|OTL38 will be given approximately 2 hours before surgery. Intraoperative fluorescent imaging will utilized in parallel with standard operating procedures for radical nephrectomy. Photographs of the surgery field and tumor (ex-vivo) will be taken under normal light and fluorescent light.
3118357|NCT02645617|Experimental|Varnish|Dental varnish containing povidone iodine and sodium fluoride
3118358|NCT02645760|Active Comparator|Core stabilization exercise|7-weeks of core stabilization exercise
3118359|NCT02645760|Active Comparator|conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
3118360|NCT02646124|Experimental|Diazepam|Naproxen +Diazepam
3118361|NCT02646124|Active Comparator|Placebo|Naproxen + Placebo
3118362|NCT02646332|Experimental|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
3118363|NCT02646332|Active Comparator|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
3118364|NCT02646371|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
3118365|NCT02646371|Placebo Comparator|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
3118366|NCT02646423|Experimental|Prior CD Decision App (PCDDA)|Women who are randomized to PCDDA will be provided access to a tablet which they can use to view the Prior CD Decision App at their own pace. The research assistant will print a summary of the participant's predicted likelihood of a vaginal delivery (VBAC) if she undergoes a trial of labor (TOLAC), as well as her answers to the values clarification exercises, that she can review and share with whomever she chooses, including her provider.
3118367|NCT02646423|No Intervention|Usual Care - No App|Women randomized to the Usual Care - No App group will simply continue with usual care.
3118368|NCT02646449|Active Comparator|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
3118369|NCT02646449|Placebo Comparator|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
3118370|NCT02646566|Experimental|APD421 standard|Single (standard) dose IV APD421
3118371|NCT02646566|Experimental|APD421 high|Single (high) dose IV APD421
3118372|NCT02646566|Placebo Comparator|Placebo|Single IV placebo
3118373|NCT02646618|Active Comparator|Get Social|"Get Social participants will receive a weight loss intervention in a protected Twitter group. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet."
3118374|NCT02646618|Active Comparator|Traditional|Participants will attend weight loss groups weekly for 8 weeks, then biweekly for 16 weeks, then monthly between months 6 and 12. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
3118375|NCT02646761|Experimental|Rehabilitation with InterACTION|After total knee arthroplasty, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
3118376|NCT02646761|Other|Standard Physical Therapy|After total knee arthroplasty, subjects will undergo standard of care physical therapy 2 times per week with standard home exercise program.
3118377|NCT02646826|Placebo Comparator|Placebo|Subjects are treated with placebo tablets.
3118378|NCT02646826|Experimental|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol.
3118379|NCT02646826|Experimental|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol.
3118380|NCT02646826|Experimental|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol.
3118381|NCT02646891|Placebo Comparator|Adults: Placebo|Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
3118382|NCT02646891|Experimental|Adults: 30 µg P2-VP8|Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
3118383|NCT02646891|Experimental|Adults: 90 µg P2-VP8|Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
3118384|NCT02646891|Placebo Comparator|Toddlers: Placebo|Toddlers received one intramuscular injection of placebo on Day 0.
3118385|NCT02646891|Experimental|Toddlers: 30 µg P2-VP8|Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
3118386|NCT02646891|Experimental|Toddlers: 90 µg P2-VP8|Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
3118387|NCT02646891|Placebo Comparator|Infants: Placebo|Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
3118388|NCT02646891|Experimental|Infants: 15 µg P2-VP8|Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
3118389|NCT02646891|Experimental|Infants: 30 µg P2-VP8|Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
3118390|NCT02646891|Experimental|Infants: 90 µg P2-VP8|Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
3118391|NCT02646917|Active Comparator|SkinPen II|Three treatments using SkinPen II aesthetic microneedling device to each patient, with each treatment spaced one month apart.
3118392|NCT02646917|Active Comparator|SkinPen Precision|Three treatments using SkinPen Precision aesthetic microneedling device to each patient, with each treatment spaced one month apart.
3118393|NCT02647203|Experimental|High Fluoride Toothpaste|5,000 ppm fluoridated toothpaste, high concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
3118394|NCT02647203|Active Comparator|Standard Fluoride Toothpaste|1,450 ppm fluoridated toothpaste, low concentration. Self-administered fluoridated dentifrices. By the elderly subjects, twice per day Drug (including placebo)
3118395|NCT02647281|Experimental|Part 1: GSK3389404 10 mg|Subjects will receive a single dose of GSK3389404 10 mg by subcutaneous injection on Day 1 of Part 1.
3118396|NCT02647281|Placebo Comparator|Part 1: Placebo|Subjects will receive a single dose of subcutaneous (injection under the skin) injection of placebo matching with GSK3389404 10 milligram (mg) or 30 mg, or 60 mg or 120 mg.
3118397|NCT02647281|Experimental|Part 1: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection on Day 1 of Part 1.
3118398|NCT02647281|Experimental|Part 1: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection on Day 1 of Part 1.
3118399|NCT02647281|Experimental|Part 1: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection on Day 1 of Part 1.
3118400|NCT02647281|Experimental|Part 2: GSK3389404 30 mg|Subjects will receive a single dose of GSK3389404 30 mg by subcutaneous injection QW for 4 weeks in Part 2.
3118401|NCT02647281|Placebo Comparator|Part 2: Placebo|Subjects will receive a single dose of subcutaneous injection of placebo matching with GSK3389404 30 mg or 60 mg or 120 mg once weekly (QW) for 4 weeks in Part 2.
3118402|NCT02647281|Experimental|Part 2: GSK3389404 60 mg|Subjects will receive a single dose of GSK3389404 60 mg by subcutaneous injection QW for 4 weeks in Part 2.
3118403|NCT02647281|Experimental|Part 2: GSK3389404 120 mg|Subjects will receive a single dose of GSK3389404 120 mg by subcutaneous injection QW for 4 weeks in Part 2.
3118404|NCT02647320|Experimental|DS-8500a 25mg|One DS-8500a 25 mg tablet, 2 placebo tablets, and one placebo capsule in a once-daily oral dose
3118405|NCT02647320|Experimental|DS-8500a 50 mg|Two DS-8500a 25 mg tablets, 1 placebo tablet, and one placebo capsule in a once-daily oral dose
3118406|NCT02647320|Experimental|DS-8500a 75 mg|Three DS-8500a 25 mg tablets and one placebo capsule in a once-daily oral dose
3118407|NCT02647320|Placebo Comparator|Placebo|Three placebo tablets and one placebo capsule in a once-daily oral dose
3118408|NCT02647320|Active Comparator|Sitagliptin 100 mg|Three placebo tablets and one sitagliptin 100 mg over-capsule in a once-daily oral dose
3118409|NCT02647346|Experimental|Participant cohort|Participants with diabetes that each have a history of healed Diabetic Foot Ulcer (DFU) prior to enrollment.
3118410|NCT02647645|Active Comparator|Cognitive Training|Cognitive training Sham tDCS
3118411|NCT02647645|Experimental|Cognitive Training with tDCS|Cognitive training Active tDCS
3118412|NCT02647658|Experimental|GBC+PIPT|Guideline Based Care plus Psychologically Informed Physical Therapy (GBC+PIPT)
3118413|NCT02647658|Active Comparator|GBC|Guideline Based Care (GBC)
3118414|NCT02647788|Active Comparator|Acetaminophen/Ibuprofen|Group 1: Acetaminophen 650 mg; Ibuprofen 400 mg
3118415|NCT02647788|Active Comparator|Acetaminophen/Codeine|Group 2: Acetaminophen 300mg, Codeine 30 mg
3118416|NCT02647866|Experimental|KHK4083 Cohort 1|Subjects received one 1.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
3118417|NCT02647866|Experimental|KHK4083 Cohort 2|Subjects received one 3.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
3118418|NCT02647866|Experimental|KHK4083 Cohort 3|Subjects received one 10.0 mg/kg IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
3118419|NCT02647866|Experimental|KHK4083 Cohort 4|Subjects received one maximum tolerated dose (10.0 mg/kg) IV infusion treatment of KHK4083 every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48.
3118420|NCT02647866|Placebo Comparator|Placebo|Subjects received one IV infusion treatment of Placebo every two weeks from Week 0 to Week 10 of Induction Therapy. Subjects who chose to continue into extension therapy and were eligible received one IV infusion every 4 weeks (at the same dose as Induction Therapy) from Week 12 to Week 48. Subjects who participated in Open-Label Therapy received KHK4083 instead of placebo.
3118421|NCT02647905|Experimental|Accuracy assessment, CGMS|To determine accuracy of the Senseonics Continuous Glucose Monitoring System measurements through approximately 90 days post-insertion. Manipulation of glucose levels during multiple clinic days
3118422|NCT02647944|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
3118423|NCT02647944|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
3118424|NCT02648022|Experimental|Integrated Care|Consisted of brief mental health interventions and case management provided in a collaborative treatment environment.
3118425|NCT02648022|No Intervention|Usual Care|"The usual care group received standard of care required for HCV patients as currently performed in each clinic. All usual care patients were evaluated by their HCV Clinic treatment team, usually consisting of clinical nursing staff, the treating physician, and a clinic psychiatrist or psychologist"
3118426|NCT02648178|Active Comparator|HALO G6|HALO cigalike model
3118427|NCT02648178|Active Comparator|HALO Triton|HALO tank model
3118428|NCT02648204|Experimental|Semaglutide 0.5 mg/Week|
3118429|NCT02648204|Experimental|Semaglutide 1.0 mg/Week|
3118430|NCT02648204|Active Comparator|Dulaglutide 0.75 mg/Week|
3118431|NCT02648204|Active Comparator|Dulaglutide 1.5 mg/Week|
3118432|NCT02648217|Experimental|IDegAsp U100 BID|
3118433|NCT02648217|Active Comparator|BIAsp U100 BID|
3118434|NCT02648230|Experimental|Pressure wire and Microcatheter|All subjects enrolled will have both an FFR done measured by a pressure wire (PW) and then again by a microcatheter (MC).
3118435|NCT02648438|Experimental|Treatment sequence 1|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
3118436|NCT02648438|Experimental|Treatment sequence 2|Treatment Period 1:AZD7594 Solution for infusion (150 μg intravenous formulation) Treatment Period 2:AZD7594 Inhalation powder (400 μg) by dry powder inhaler (DPI) Device 1 (monodose inhaler) Treatment Period 3:AZD7594 Pressurized inhalation suspension (400 μg) by pressurized metered-dose inhaler (pMDI) Treatment Period 4:AZD7594 Oral suspension (1200 μg oral formulation)
3118437|NCT02648646|Experimental|Single Arm - Intervention|Receives Otago Exercise Programme and Walk with Ease
3118438|NCT02648698|Experimental|Antibiotic group|This group received antibiotic therapy
3118439|NCT02648698|No Intervention|Control group|This group did not receive antibiotic therapy
3118440|NCT02648880|Experimental|Exercise Group|Participants will complete an exercise program in addition to standard care. Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery. Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy. Exercise intensity, components, and time will be recorded for each exercise session. Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
3118441|NCT02648880|Active Comparator|Standard Care|Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
3118442|NCT02648919|Experimental|Noni 6,000 mg/day|Noni extract 6,000 mg/day (4 capsules with breakfast, 4 capsules with lunch and 4 capsules with dinner)
3118443|NCT02648932|Other|Haplo-Cord Search|If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.
3118444|NCT02648932|Other|Matched Unrelated Donor Search (MUD)|If subject meets the inclusion criteria and consents, will undergo a MUD transplant.
3118445|NCT02648971|Active Comparator|Single Portal Knee Arthroscopy|After randomization for each patient is complete, the website will document the name of the person who logged on to perform the randomization, the date and time of the log in, and the surgical group assignment for each patient. This randomization information will be forwarded to the operating room staff so that they can prepare for each study participant's surgical procedure. Patients in Group 1 will undergo knee arthroscopy using a single portal. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
3118446|NCT02648971|Active Comparator|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals. The details of the surgical procedure for each study participant will be documented on the IKDC Surgical Documentation Form. Study participants in each group will return for standard post-operative follow-up visits at one week, 30 days, and three months. They will return to the clinic at six months and one year for study visits.
3118447|NCT02649192|Active Comparator|Influenza Virus Vaccine Plus Vitamins A and D|Participants receive influenza virus vaccine and Vitamins A and D supplement on Day 0 and Day 28.
3118448|NCT02649192|Placebo Comparator|Influenza Virus Vaccine Plus Placebo|Participants receive influenza virus vaccine and matched placebo on Day 0 and Day 28.
3118449|NCT02649218|Experimental|Ligelizumab|QGE031 240 mg s.c. q4w x 13 treatments
3118450|NCT02649231|Experimental|Ketamine+Psychological Therapy|Ketamine with psychological therapy
3118451|NCT02649231|Active Comparator|Ketamine+Education|ketamine with alcohol education
3118452|NCT02649231|Active Comparator|Placebo+Psychological Therapy|placebo with psychological therapy
3118453|NCT02649231|Placebo Comparator|Placebo+Education|placebo with simple alcohol education
3118454|NCT02649322|Experimental|Group A|Participants in Group A will receive 0.25 mL of 1% plain lidocaine delivered by the J-tip injector at the regional block site prior to introduction of the needle for the nerve block procedure.
3118455|NCT02649322|Active Comparator|Group B|Participants in Group B will receive 2 mL of 1% plain lidocaine injected by syringe and 25 gauge needle at the regional block site prior to introduction of the needle for the nerve block procedure.
3118456|NCT02649439|Experimental|A/PROSTVAC treatment|PROSTVAC treatment for 6 months with an additional optional year of maintenance for eligible patients
3118457|NCT02649439|Experimental|B/ Delayed PROSTVAC treatment|Surveillance for 6 months followed by PROSTVAC treatment for 6 months with an additional year of maintenance for eligible patients
3118458|NCT02649556|Experimental|THS 2.2|Ad libitum use of THS 2.2
3118459|NCT02649556|Active Comparator|CC|Ad libitum use of CC
3118460|NCT02649608|Experimental|0.04 mg Lu AE04621|Patients having received a dose of 0.04 mg, independent of which Cohort they belong to.
3118461|NCT02649608|Experimental|0.08 mg Lu AE04621|Patients having received a dose of 0.08 mg, independent of which Cohort they belong to.
3118462|NCT02649608|Experimental|0.2 mg Lu AE04621|Patients having received a dose of 0.2 mg, independent of which Cohort they belong to.
3118463|NCT02649608|Experimental|0.4 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
3118464|NCT02649608|Experimental|0.6 mg Lu AE04621|Patients having received a dose of 0.6 mg, independent of which Cohort they belong to.
3118465|NCT02649608|Experimental|0.8 mg Lu AE04621|Patients having received a dose of 0.8 mg, independent of which Cohort they belong to.
3118466|NCT02649608|Experimental|1.0 mg Lu AE04621|Patients having received a dose of 1.0 mg, independent of which Cohort they belong to.
3118467|NCT02649608|Experimental|1.2 mg Lu AE04621|Patients having received a dose of 1.2 mg, independent of which Cohort they belong to.
3118468|NCT02649634|Experimental|Motivational Interviewing|Two 45-60 minute motivational interviewing sessions focusing on exploring and resolving ambivalence towards change.
3118469|NCT02649634|Active Comparator|Attention Control|Two 45-60 minute semi-structured interviews, acting as a pseudo-intervention, ascertaining information relevant to health history, weight history, diet history, as well as dietary and physical activity habits.
3118470|NCT02649842|Experimental|Extended Cylinder IOL|Approved toric intraocular lenses, Model ZCT450, ZCT525 or ZCT600
3118471|NCT02649894|Experimental|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)
3118472|NCT02649894|Active Comparator|Approved Uncoated PleurX Indwelling Pleural Catheter|Approved Uncoated PleurX Indwelling Pleural Catheter
3469323|NCT03887611||thyroid nodules|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of thyroid surgery or thyroid biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
3118475|NCT02650128|Experimental|Lithoplasty System|Shockwave Coronary Rx Lithoplasty® System is a lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement
3118476|NCT02650193|Experimental|HSP-130|"Cycle 0:~Regimen A: HSP 130, 3 mg, single SC injection in the deltoid region (n = 6) Regimen B: HSP 130, 6 mg, single SC injection in the deltoid region (n = 6)~Cycles 1-4:~Regimen B (n = 12): HSP 130, 6 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4.~Potential Regimen A (n = 12): 3 mg with background chemotherapy: Inclusion of this cohort will be based on assessment of comparability between Regimens A and B in Cycle 0 for ANC and CD34+ as defined above. If performed, this regimen will be HSP 130, 3 mg, single SC injection in the deltoid region, at least 24 hours after administration of chemotherapy in Cycle 1, Cycle 2, Cycle 3, and Cycle 4, as appropriate.~Conditional Regimen C (12 mg):This cohort will not be initiated until data from cycle 0 for 3 mg and 6 mg and Cycles 1-4 for 6 mg has been reviewed and analyzed."
3118477|NCT02650219||gaucher disease type 1|"Inclusion criteria:~Adult patients >= 18 years old~Gaucher disease type 1, proved by low betaglucosidase, with or without treatment~Patients must have read, understood and signed informed consent. intervention : genetic analyses"
3118478|NCT02650219||Control|healthy subjects intervention: genetic analyses
3118479|NCT02650284|Other|Bicompartmental Knee Replacement (BKR)|Receiving Restoris MCK Multicompartmental Knee System for Bicompartmental Knee Replacement (BKR). Surgery performed using Stryker's robotic-arm assisted surgery system Mako
3118480|NCT02650284|Other|Total Knee Replacement (TKR)|Receiving Stryker Triathlon Primary Total Knee System for Total Knee Replacement. Surgery performed using Stryker's robotic-arm assisted surgery system Mako
3118481|NCT02650440|Experimental|Novel Protocol|Progressive decrease of speed and guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.0 km/h.
3118482|NCT02650440|Experimental|Standard Protocol|Progressive increase of speed and decrease of guidance force on robotic gait training. Initial speed is 1.4 km/h and final speed is 1.9 km/h.
3118483|NCT02650466|Experimental|Nanopulse treatment|The study will be a single center, open label, non-randomized clinical trial that will provide efficacy data for the treatment of common warts by the Nanopulse system in terms of efficacy and cosmetic outcome with 1 - 4 application (treatment) sessions. All subjects will receive a minimum number of applications per discrete skin wart lesion. Up to 4 warts per subject will be treated with the Nanopulse device. The wart will be debulked to the point of pinpoint bleeding prior to the initial application. The subject will return after 1 week for an evaluation visit and at 4 weeks for a second treatment and 2 additional monthly treatments if warranted. If the subject is declared clinically clear at any of the application visits, they will be placed into follow up. The minimum number of treatments per wart is one and the maximum is 4. They will return at the 12 week point post last visit for final assessment and evaluation.
3118484|NCT02650856|Experimental|Group 1 Tranexamic acid|"A dosis of 2 gr of tranexamic acid (1000mg/10ml X-GEN pharmaceuticals inc.) diluted in 80ml of physiologic solution and will be divided in two applications.~First application: 40ml of the solution previously prepared is applied over the surgical site and it will be left for five minutes then drained out completely by suction.~Second application: The rest of 40ml of solution previously prepared is applied after placing the final TKR components (femoral, tibial and patellar), over the surgical site and leaving it without draining it by suction."
3118485|NCT02650856|Active Comparator|Group 2 Platelet rich plasma|"A final volumen of 16 ml of platelet rich plasma is obtained from the forearm vein of the patient and will be divided in two applications.~First application: 8 ml of PRP are applied over the surgical site and are left for five minutes then drained out completely by suction.~Second application: The rest of the 8 ml are applied after placing the final TKR cemented components (femoral, tibial and patellar), over the surgical site and leaving it without draining."
3118486|NCT02650895|Experimental|CD24Fc|Single dose of CD24Fc is administrated as intravenous infusion in one hour. There are 5 dose cohorts, 10mg, 30mg, 60mg, 120mg, 240mg. Each cohort has 6 subjects in CD24Fc and 2 subject in placebo.
3118487|NCT02650895|Placebo Comparator|Saline|Single dose of 100 ml normal saline is administrated as intravenous infusion in one hour.
3118488|NCT02650921|Experimental|Restylane Lyft with Lidocaine|
3118489|NCT02650921|No Intervention|No Intervention|
3118490|NCT02650999|Experimental|Pembrolizumab|Single arm, pembrolizumab 200mg IV every 3 weeks until progression/toxicity
3118491|NCT02651103||Posterior spinal fusion|Patients undergoing spinal fusion surgery
3118492|NCT02651116|Experimental|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
3118493|NCT02651116|Placebo Comparator|Placebo|10 mL of Placebo
3118494|NCT02651155|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
3118495|NCT02651155|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
3118496|NCT02651194|Experimental|ABT-493/ABT-530|ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3118497|NCT02651220|Experimental|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w|
3118498|NCT02651220|Active Comparator|Epiduo® Forte Gel 0.3%/2.5% w/w|
3118499|NCT02651220|Placebo Comparator|Placebo (vehicle) Topical Gel|
3118500|NCT02651259|Experimental|Cohort 1 (pregnant women enrolled in the second trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
3118501|NCT02651259|Experimental|Cohort 2 (pregnant women enrolled in the third trimester)|Participants received 12 directly observed once-weekly doses of RPT, INH, and pyridoxine (vitamin B6) at study entry and at 11 weekly follow-up visits.
3118502|NCT02651272|Experimental|macitentan|10mg macitentan tablets, taken once daily (QD), by mouth (PO), for the treatment period lasting 16 weeks.
3118503|NCT02651337|Experimental|Drainage with Alivio in-line Flusher|Volume of saline needed to drain CSF using the Alivio in-line Flusher historically compared with volume of saline needed to drain CSF using a standard syringe
3118504|NCT02651415|Experimental|Regorafenib and Perindopril|Phase II, open label, single arm trial of patient with refractory mCRC treated with regorafenib (10 mg/day) and perindopril (4 mg/day). There will be no stratification in this study.
3118505|NCT02651428|Experimental|Neutrolin arm|Neutrolin: Neutrolin will be added to the central venous catheter after dialysis as a lock solution
3118506|NCT02651428|Active Comparator|Heparin arm|Heparin: Heparin will be added to the central venous catheter after dialysis as a lock solution
3118507|NCT02651467|Experimental|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 1 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
3118508|NCT02651467|Experimental|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the experimental oral rinse 2 (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
3118509|NCT02651467|Placebo Comparator|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|Participants will apply a strip of standard fluoride toothpaste to cover the full head of the toothbrush and brush their teeth for one timed minute and expectorate. They will then rinse with 20ml of tap water (using the dosing cap provided) for 10 seconds and expectorate, then rinse with 10ml of the placebo oral rinse (using the second dosing cap provided) for one timed minute and expectorate. No further rinsing will be allowed. This regimen will be performed twice daily for 8 weeks.
3118510|NCT02651545||Relapsing MS patients|Thirty (30) relapsing MS patients new to teriflunomide therapy will be enrolled.
3118511|NCT02651545||Healthy Controls|A sample of 30 healthy control volunteers, matched on demographics with the treated group will be enrolled.
3118512|NCT02651584|Experimental|SL BPN/NX tabs + placebo SC injections|"SL BPN/NX: 2 mg/0.5 mg or 8 mg/2 mg BPN/naloxone tablets administered daily, at doses of 8 mg/2 mg to 32 mg/8 mg per day.~CAM2038 placebo: 0.16, 0.32, 0.48 and 0.64 mL SC injection administered once weekly or once monthly (matching volumes for CAM2038 q1w and near-matching volumes for CAM2038 q4w)."
3118513|NCT02651584|Experimental|CAM2038 SC injections + SL placebo tabs|"CAM2038 q1w: BPN FluidCrystal® SC injection depot for once weekly administration (50 mg/mL) at doses of 8, 16, 24 or 32 mg (BPN base) (0.16, 0.32, 0.48 or 0.64 mL SC injection).~CAM2038 q4w: BPN FluidCrystal® SC injection depot for once monthly administration (356 mg/mL) at doses of 64, 96, 128 or 160 mg (BPN base) (0.18, 0.27, 0.36 or 0.45 mL SC injection).~SL placebo: tablets matching 2 mg/0.5 mg and 8 mg/2 mg SL BPN doses, administered daily"
3118514|NCT02651688|Experimental|Enclomiphene 12.5 mg|Enclomiphene 12.5 milligram (mg) capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
3118515|NCT02651688|Experimental|Enclomiphene 25 mg|Enclomiphene 25 mg capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
3118516|NCT02651688|Placebo Comparator|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months. Participant followed a commercial diet plan and exercised with a personal trainer at least 3 times a week.
3118517|NCT02651987|Experimental|Lanreotide Autogel®|One subcutaneous (SC) injection of lanreotide Autogel® 120mg every 14 days until disease progression or death or unacceptable toxicity or tolerability.
3118518|NCT02652156|Active Comparator|Single Injection of Bupivacaine|Subjects will undergo post-operative pain relief treatment with a single injection of Bupivacaine, a local anesthetic injected into the transversus abdominis plane.
3118519|NCT02652156|Active Comparator|Single Injection of Exparel®|Subjects will undergo post-operative pain relief treatment with a single injection of Exparel®, a liposomal form of bupivacaine, into the transversus abdominis plane
3118520|NCT02652156|Active Comparator|Continuous infusion of Ropivacaine|Subjects will be treated with a continuous infusion of the local anesthetic Ropivacaine with the ON-Q® pump
3118521|NCT02652208|Active Comparator|Online decision aid|This group will receive the access to an online decision aid that covers the main treatment options for stable chest discomfort.
3118522|NCT02652208|Active Comparator|Video decision aid|This group will receive the DVD and booklet decision aid describing stable chest discomfort and the main treatment options including medical therapy and stents.
3118523|NCT02652221|Experimental|Study cohort|Acoustic Radiation Force Imaging
3118524|NCT02652260|Experimental|Immediate Switch to Doravirine, Tenofovir, Lamivudine|Participants on a baseline regimen of ATRIPLA™ for at least 12 weeks prior to screening will be switched to blinded doravirine, tenofovir, lamivudine orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for an additional 12 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 216 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 312 weeks.
3118525|NCT02652260|Experimental|Deferred Switch to Doravirine, Tenofovir, Lamivudine|Participants will continue on their ongoing ATRIPLA™ regimen orally, once daily for 12 weeks, followed by open-label doravirine, tenofovir, lamivudine orally, once daily for 24 weeks. Participants who meet eligibility criteria can enter study extension 1 to receive open-label doravirine, tenofovir, lamivudine for an additional 96 weeks. Participants who meet eligibility criteria can enter study extension 2 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 228 weeks. Participants who meet eligibility criteria can enter study extension 3 to receive open-label doravirine, tenofovir, lamivudine, with a maximum total duration of treatment of 324 weeks.
3118526|NCT02652390|Experimental|Methylprednisolone 80 mg|Local injection of 80 mg Methylprednisolone into the carpal tunnel
3118527|NCT02652390|Experimental|Methylprednisolone 40 mg|Local injection of 40 mg Methylprednisolone into the carpal tunnel
3118528|NCT02652390|Placebo Comparator|Placebo|Local injection of saline into the carpal tunnel
3118529|NCT02652416|Experimental|SRD part (low dose)|Chinese, Japanese both
3118530|NCT02652416|Experimental|SRD part (medium dose)|Chinese, Japanese both
3118531|NCT02652416|Experimental|SRD part (high dose)|Chinese, Japanese both
3118532|NCT02652416|Experimental|MD part (high dose)|Chinese, Japanese both
3118533|NCT02652416|Experimental|Placebo (SRD part)|placebo
3118534|NCT02652416|Placebo Comparator|Placebo (MD part)|placebo
3118535|NCT02652442|Experimental|Centrifugation Parameters|Three experiments were performed to identify optimal centrifugation parameters: (1) distance off-axis (3.5 vs 7 cm); (2) duration (1 min vs 3 mins); (3) schedule (daily vs biweekly). The comparisons were all within subjects; i.e., each subject was tested systematically for each centrifugation parameter under both conditions. The change in the outcome measure SVV (from pre- to post-off-axis rotation) for each condition (e.g., 3.5 vs 7 cm) within a parameter was compared.
3118536|NCT02652468|Experimental|Peripheral Blood Stem Cell Transplant|"PREPARATIVE REGIMEN: Participants receive fludarabine phosphate IV over approximately 30 minutes on days -5 to -2, and mesna IV over 24 hours and cyclophosphamide IV over approximately 2 hours on days -5 and -4. Participants also undergo total nodal irradiation on day -1.~TRANSPLANT: Participants undergo TCR alpha-beta/CD19 depleted hematopoietic stem cell transplant on day 0. If the graft contains less than 4 x 10^6 CD34+ cells/kg participant body weight (BW), patients may receive a second graft on day 1.~GVHD PROPHYLAXIS: Participants receive mycophenolate mofetil orally twice a day (PO BID) on days -1 to 30, tacrolimus PO or IV on days 2-180 with a taper beginning on day 90 (given only if graft TCR alpha-beta+ cell content is over 1 x 10^5 cells/kg ideal BW of the patient), and rituximab IV on day 2 (given only if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the participant)."
3118537|NCT02652481|Other|ImageReady MR Conditional Defibrillation System Group|"Prospective, non-randomized, confirmatory study.Subjects will initially be enrolled into Phase I to undergo a non-diagnostic study required MR Scan. Once Phase I is complete, subjects will be enrolled into Phase II where there is no requirement to undergo a non-diagnostic study required MR scan Up to 37 subjects will be used for an interim analysis. Of these subjects, the first 20 who undergo the study required MRI scan and complete the MRI + 1 Month Visit will be used for this analysis. The second cohort will consist of subjects who will receive the non-diagnostic study required MR scan until 137 CRT-D and 28 VR ( single chamber) ICD subjects undergo the study required MR scan (complete or incomplete).~De novo implants and existing implants may be enrolled in Phase I There will be a non-diagnostic study required MR scan (during the MRI visit) There will be a study required MRI visit and MRI + 1 month visit"
3118538|NCT02652624|Experimental|B/F/TAF|Participants will switch to B/F/TAF FDC and receive treatment for 48 weeks.
3118539|NCT02652624|Active Comparator|Baseline Regimen|Participants will remain on their baseline regimen of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF for 48 weeks.
3118540|NCT02652624|Experimental|Extension Phase|Following Week 48, participants in countries where B/F/TAF is not available may have the option to receive B/F/TAF for up to 48 additional weeks.
3118541|NCT02652767|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
3118542|NCT02652767|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
3118543|NCT02652780|Experimental|GS010-treated Eyes|Each participant will have one eye randomly selected to receive a single injection of GS010 and the other eye will receive a sham injection. GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
3118544|NCT02652780|Sham Comparator|Sham-treated Eyes|Each participant will have one eye randomly selected to receive GS010 and the other eye will receive a sham injection. Eyes receiving sham injection will undergo the same preparatory procedures as eyes receiving GS010 injection, including pupillary dilation, topical anti-infection and topical anesthetic procedures. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.
3469324|NCT03887910|Experimental|Enhanced Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and referrals and developmental toys.
3118546|NCT02653144|Experimental|dexmedetomidine and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml + 75mcg of dexmedetomidine
3118547|NCT02653144|Experimental|dexamethasone and ropivacaine group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with. Ropivacaine 0.5% 20ml + 4mg dexamethasone
3118548|NCT02653144|Active Comparator|ropivacaine only group|In this group, participants will undergo pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation with Ropivacaine 0.5% 20ml (acting as control)
3118549|NCT02653170|No Intervention|Usual Care|Patients in this group will receive the hospitals' usual transitional care approach.
3118550|NCT02653170|Experimental|SCM|"One intervention is provided:~1. SCM (Stroke Case manager): a trained social worker who provides in-home case management services."
3118551|NCT02653170|Experimental|SCM and VSSP|"Two interventions are provided:~SCM (Stroke Case manager): a trained social worker who provides in-home case management services. Plus:~VSSP (Virtual Stroke Support Portal): Access and training in the use of the VSSP: a purpose-built, online, patient-centered information and support resource."
3118552|NCT02653183|Active Comparator|Device Aquacel Surgical|"Aquacel Surgical is a sterile, one piece post-operative dressing from Convatec.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
3118553|NCT02653183|Experimental|Device Mepilex Border Post-Op|"Post-operative all-in-one self-adherent soft silicone coated foam dressing.~Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
3118554|NCT02653300|Experimental|Oral Insulin|treatment
3118555|NCT02653326|Experimental|Telerehabilitation|In addition to routine care, patients in this arm will receive a telerehabilitation strategy comprised by a portable EKG monitor and a smartphone application.
3118556|NCT02653326|Active Comparator|Routine Care|Patients allocated to routine care will receive care as enforced by current practice guidelines. This care included nutritional counseling, depression screening, drug therapy for the management of comorbidities and physical exercise without telemonitoring.
3118557|NCT02653391|Experimental|Elamipretide 1.0% Ophthalmic Solution Part A (Cohort 1)|Part A Each subject will receive one drop of elamipretide 1.0% ophthalmic solution BID in the randomly selected study eye (Cohort 1).
3118558|NCT02653391|Experimental|Elamipretide 3.0% Ophthalmic Solution Part B (Cohort 2)|Part B Each subject will receive one drop of elamipretide 3.0% ophthalmic solution BID in both the right and left study eyes (Cohort 2).
3118559|NCT02653391|Placebo Comparator|Placebo A|Part A: Each subject will receive one drop of vehicle solution BID in the paired eye of the randomly selected study eye (Cohort 1).
3118560|NCT02653391|Placebo Comparator|Part B Placebo|Part B Each subject will receive one drop of vehicle solution BID in both the right and left study eyes (Cohort 2).
3118561|NCT02653417|Experimental|Regimen 1|RAD1901 5 mg/day
3118562|NCT02653417|Experimental|Regimen 2|RAD1901 10 mg/day
3118563|NCT02653417|Experimental|Regimen 3|RAD1901 20 mg/day
3118564|NCT02653417|Placebo Comparator|Regimen 4|Placebo
3118565|NCT02653456|Experimental|RA-308 Excimer Laser and DABRA Catheter|Treatment with the RA-308 excimer laser and DABRA catheter to treat chronic total occlusions that cannot be crossed with standard guidewires. The catheter and laser are a system, and cannot be used separately.
3118566|NCT02653560|Experimental|Potassium magnesium Citrate (KMgCit) arm|Potassium magnesium citrate will be prepared by mixing potassium citrate, magnesium citrate and/or citric acid by Meta Pharm Development. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day for 4 weeks
3118567|NCT02653560|Experimental|Potassium citrate arm|A special sachet formulation containing 20 meq K/sachet will be made for the study by Meta Pharm Development. The contents of a sachet will be added to 250 ml water and drunk with breakfast and dinner, to deliver 40 meq K (as citrate) per day during the Potassium Citrate Phase for 4 weeks.
3118568|NCT02653560|Experimental|Potassium chloride arm|Potassium chloride will contain 20 meq KCl per sachet. During the Potassium Chloride Phase, subjects will dissolve the content of each sachet in 250 ml water and ingest it with breakfast and again with dinner, to deliver 40 meq K (as chloride) per day for 4 weeks
3118569|NCT02653560|Placebo Comparator|Placebo|Placebo will comprise microcrystalline cellulose, equivalent in volume in each sachet as other test products. During the Placebo Phase, subjects will dissolve the entire content of a sachet in 250 ml water and drink it with breakfast and again with dinner for 4 weeks.
3118570|NCT02653625|Experimental|Cenicriviroc 150 mg|One tablet of Cenicriviroc 150 mg once daily with food in the morning for 24 weeks.
3118571|NCT02653664|Experimental|Condition #1: PsychoEducation (ED)|Condition #1 will include 8 90-minute group sessions that will educate the subject about chronic pain, discuss the impact of pain, and inform the subject of different ways to manage it in hopes of decreasing pain and its impact on the subject's life. Participants in this condition will be given pre-recorded audio recordings of the content of the sessions to listen to.
3118572|NCT02653664|Experimental|Condition #2:Self-Hypnosis Training (HYP)|In condition #2, the facilitator will perform a standard hypnotic short induction followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the clinician read a standardized hypnotic script that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
3118573|NCT02653664|Experimental|Condition #3: Mindfulness Meditation (MM)|In condition #3, the facilitator will teach participants Vipassana meditation, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. Time will also be devoted to problem solving around any difficulties with MM practice.
3118574|NCT02653768|Experimental|STEP-KOA|This is a stepped exercise program. It begins with an internet-based exercise training program (STEP 1). After three months, participants are assessed to see if they have achieved clinically meaningful improvement in key osteoarthritis outcomes. If so, they remain at STEP 1. If not, they move on to STEP 2, which adds telephone-based coaching. Participants are assessed again three months later. Those that still have not achieved clinically relevant improvement move on to STEP 3, which adds a series of in-person physical therapy visits.
3118575|NCT02653768|Active Comparator|Arthritis Education (AE)|"Participants in the AE control group will receive low literacy educational materials via mail every two weeks. Because STEP-KOA is a multi-component intervention, with participants receiving different numbers of Steps, it is not possible to implement a control condition that will mirror the exact intervention dose received by all participants in the STEP-KOA group. However, AE will achieve the goal of providing an active, OA-related control condition."
3118576|NCT02653872|Experimental|AZD7986 (alone) Treatment period 1|AZD7986 (15 mg/mL) 25 mg dosage administered alone
3118577|NCT02653872|Active Comparator|Verapamil (with AZD7986) Treatment period 2|Daily administration of verapamil (240 mg, extended release formulation) on Days 1 to 10 plus administration of single dose AZD7986 (25 mg) on Day 5
3118578|NCT02653872|Active Comparator|Itraconazole (with AZD7986) Treatment Period 3|Itraconazole (200 mg, oral solution formulation 10 mg/mL) administered twice on Day 1 and then daily Days 2 to 11 plus single dose AZD7986 (25 mg, tbc) on Day 6
3118579|NCT02653872|Active Comparator|Diltiazem (with AZD7986) Treatment period 3|Diltiazem (360 mg, extended release formulation) administered Days 1 to 13 plus single dose AZD7986 (25 mg) on Day 8
3118580|NCT02654002|Experimental|Cohort 1: Cilofexor 10 mg|Participants in fasted state will receive cilofexor 10 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
3118581|NCT02654002|Experimental|Cohort 2: Cilofexor 30 mg|Participants in fasted state will receive cilofexor 30 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 30 mg or placebo once daily from Day 7 to Day 20.
3118582|NCT02654002|Experimental|Cohort 3: Cilofexor 100 mg|Participants in fasted state will receive cilofexor 100 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo once daily from Day 7 to Day 20.
3118583|NCT02654002|Experimental|Cohort 4: Cilofexor 300 mg|Participants in fasted state will receive cilofexor 300 mg or placebo once on Day 1 followed by a 5-day washout period then receive cilofexor 300 mg or placebo once daily from Day 7 to Day 20.
3118584|NCT02654002|Experimental|Cohort 5: Cilofexor 100 mg|Participants in fed state will receive cilofexor 100 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 100 mg or placebo tablet, orally, once daily with food from Day 7 to Day 20.
3118585|NCT02654002|Experimental|Cohort 6: Cilofexor 50 mg|Participants in fed state will receive cilofexor 50 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 50 mg or placebo twice daily from Day 7 to Day 20.
3118586|NCT02654002|Experimental|Cohort 7: Cilofexor 15 mg|Participants in fed state will receive cilofexor 15 mg or placebo twice with food on Day 1 followed by a 5-day washout period then receive cilofexor 15 mg or placebo twice daily from Day 7 to Day 20.
3118587|NCT02654002|Experimental|Cohort 8: Cilofexor 10 mg|Participants in fed state will receive cilofexor 10 mg or placebo once with food on Day 1 followed by a 5-day washout period then receive cilofexor 10 mg or placebo once daily from Day 7 to Day 20.
3118588|NCT02654002|Experimental|Cohort 9: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
3118589|NCT02654002|Experimental|Cohort 10: Cilofexor|Participants will receive cilofexor up to 300 mg or placebo once daily in the evening on empty stomach.
3118590|NCT02654054|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/NETA) once daily (QD)
3118591|NCT02654054|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
3118592|NCT02654054|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
3118593|NCT02654132|Experimental|Elotuzumab Arm|"Biological:Elotuzumab (BMS-901608; HuLuc63)~Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~•Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Subjects > 75 years old:~•Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1&2) Day 1(Cycle 3 and Beyond)~•Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak"
3118594|NCT02654132|Active Comparator|Control Arm|"Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects > 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~Decadron~Dexamethasone Intensol~Dexpak~Taperpak"
3118595|NCT02654145|Experimental|Omalizumab switch to mepolizumab 100mg SC every 4 weeks|Subjects with severe eosinophilic asthma who are receiving omalizumab will enter a run-in period for a minimum of one week and a up to 4 weeks. Subjects will remain on their current maintenance therapy throughout the run-in period, including omalizumab. At Visit 2 (week 0) subjects will discontinue omalizumab treatment and will be switched to receiving mepolizumab 100 mg SC every 4 weeks for 28 weeks. Except for omalizumab, subjects will remain on their current maintenance therapy throughout the open-label treatment period. Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
3118596|NCT02654314|Experimental|Melatonin|5 mg Melatonin nightly, beginning within 24 hours of admission
3118597|NCT02654314|Placebo Comparator|Cellulose Microcrystylline|Blue capsule matching the melatonin arm
3118598|NCT02654483|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 56 days
3118599|NCT02654483|Placebo Comparator|Placebo|Placebo tablets to be taken daily by mouth for 56 days
3118600|NCT02654652|Experimental|Symbiotic|Patients will receive the symbiotic product LactoFos twice a day during seven days after surgical treatment. The intervention consists of giving twice a day a sachet of 6g of symbiotic diluted in 20mL of water via nasoenteric tube for seven days, totaling the administration of 14 sachets per intervention.
3118601|NCT02654652|Placebo Comparator|Maltodextrin|Patients will receive 6g of maltodextrin twice a day during seven days after surgical treatment.
3118602|NCT02654717|Experimental|DFD-07 cream|DFD-07 cream applied twice daily
3118603|NCT02654717|Placebo Comparator|Placebo cream|Placebo cream applied twice daily
3118604|NCT02654769|Active Comparator|Active Comparator Picato®|Picato® (ingenol mebutate) gel, 0.05% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
3118605|NCT02654769|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.05% [Test]
3118606|NCT02654769|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
3118607|NCT02654808|Active Comparator|Standard trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
3118608|NCT02654808|Active Comparator|Standard trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the standard trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
3118609|NCT02654808|Active Comparator|AirSeal trocar/ IAP 15 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 15 mmHg.
3118610|NCT02654808|Active Comparator|AirSeal trocar/ IAP 10 mmHg|Patients who are randomized into this arm will have their laparoscopic procedures performed with the AirSeal trocar insufflator at an intra-abdominal pressure (IAP) of 10 mmHg.
3118611|NCT02654860|Experimental|60 mg Paracetamol 3% (2 mL)|60 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
3118612|NCT02654860|Experimental|90 mg Paracetamol 3% (3 mL)|90 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
3118613|NCT02654860|Experimental|120 mg Paracetamol 3% (4mL)|120 mg Paracetamol 3%. Solution for injection, single administration by Intrathecal route.
3118614|NCT02654860|Placebo Comparator|Phase II Only: Saline solution 0.9%|Placebo, 0.9%. Solution for injection , single administration by route Intrathecal (2 mL, 3 mL and 4 mL) Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
3118615|NCT02654977|Experimental|Metreleptin|Metreleptin open-label
3118616|NCT02655016|Experimental|Participants receiving Niraparib|
3118617|NCT02655016|Placebo Comparator|Participants receiving Placebo|
3118618|NCT02655224|Experimental|Relugolix 40 mg|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix 40 mg, tablet, orally once daily before breakfast for 12 weeks.
3118619|NCT02655224|Placebo Comparator|Placebo|Relugolix placebo-matching tablet, orally, once daily before breakfast for 3 to 6 weeks in the run-in period, followed by relugolix placebo-matching tablet, orally once daily before breakfast for 12 weeks.
3118620|NCT02655237|Experimental|Relugolix 40 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by relugolix 40 mg, tablets, orally, once daily and leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 24 weeks in treatment period.
3118621|NCT02655237|Active Comparator|Leuprorelin 1.88 mg or 3.75 mg|Relugolix placebo matching tablets, orally, once daily along with leuprorelin acetate placebo matching injection, SC, once in 4 weeks for 3 to 6 weeks in run-in period followed by leuprorelin acetate 1.88 mg or 3.75 mg, injection, SC, once in 4 weeks and relugolix placebo matching tablets, orally, once daily for 24 weeks in treatment period.
3118622|NCT02655354|Experimental|Intervention|The intervention aims to prevent the development of chronic PTSD and depressive symptoms, alcohol use problems, and enduring physical disability in survivors of both traumatic brain injury(TBI) and non-TBI injuries. The intervention utilizes a computerized decision support tool to flexibly target these multiple conditions including and includes care management, motivational interviewing, cognitive behavioral therapy elements, psychotropic drugs, and psychotherapy elements.
3118623|NCT02655354|No Intervention|Usual Care|Enhanced standard care practices will be administered to this arm. This enhancement is sharing distressing emotional symptoms at recruitment with the attending nursing staff to address with patient subject.
3118624|NCT02655419|Experimental|ATM-AVI + Metronidazole|Aztreonam-avibactam + metronidazole
3469325|NCT03887910|Experimental|Intervention|Northwell Health Visits postnatal Nurse Practitioner home visitation program and developmental screening and parent guides only.
3469326|NCT03887910|No Intervention|Control|Usual care with developmental toys.
3469327|NCT03887858|Experimental|Reference/Test|"Period 1: Harnal-D Tab. 1T~Period 2: Chong Kun Dang Tamsulosin HCl Tab. 1T"
3118625|NCT02655510|Experimental|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients with MELD 11-20 will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg. After demonstrating absence of side effects in this group, patients in MELD 21-28 will follow the same dose escalation regiment as the MELD 11-20 group.
3118626|NCT02655653|Experimental|Epsilon-aminocaproic acid (EACA)|Epsilon-aminocaproic acid administered following anesthetic induction: EACA was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr.
3118627|NCT02655653|Experimental|Tranexamic acid (TA)|Tranexamic Acid administered following induction: TA was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion.
3118628|NCT02655666||Medtronic MiniMed Paradigm® REAL-Time System|Medtronic MiniMed Paradigm® REAL-Time System consisting of Paradigm 722 Insulin Pump (MMT-722), Medtronic MiniLink® REAL-Time Transmitter (MMT-7703) and Sof-Sensor® (MMT-7003) Glucose Sensor
3118629|NCT02655679|Experimental|VTP-38543 0.05%|VTP-38543 0.05% administered topically every 12 hours for 28 days.
3118630|NCT02655679|Experimental|VTP-38543 0.15%|VTP-38543 0.15% administered topically every 12 hours for 28 days.
3118631|NCT02655679|Placebo Comparator|Vehicle without Transcutol®P|Vehicle without Transcutol®P administered topically every 12 hours for 28 days.
3118632|NCT02655679|Experimental|VTP-38543 1%|VTP-38543 1% administered topically every 12 hours for 28 days.
3118633|NCT02655679|Placebo Comparator|Vehicle with Transcutol®P|Vehicle with Transcutol®P administered topically every 12 hours for 28 days.
3118634|NCT02655887|Experimental|VENOVO™ Venous Stent.|Implant of the VENOVO™ Venous Stent
3118635|NCT02656069|Other|G-Pen first, then Lilly Glucagon|A single 1 mg subcutaneous (SC) injection of G-Pen (glucagon injection) with a 7-28 day wash-out, followed by a single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin])
3118636|NCT02656069|Other|Lilly Glucagon first, then G-Pen|A single 1 mg SC injection of Lilly Glucagon (glucagon injection [rDNA origin]) with a 7-28 day wash-out, followed by a single 1 mg SC injection of G-Pen (glucagon injection)
3118637|NCT02656160|Placebo Comparator|Placebo|
3118638|NCT02656160|Active Comparator|Dalfampridine|
3118639|NCT02656173|Experimental|Mirabegron 50 mg|Participants who received mirabegron 50 mg once a day along with tamsulosin 0.2 mg for 12 weeks
3118640|NCT02656173|Experimental|Placebo|Participants who received matching placebo once a day along with tamsulosin 0.2 mg for 12 weeks.
3118641|NCT02656290|Experimental|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Pulmonary valve replacement
3118642|NCT02656329|Experimental|AdreView™|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection). Participants with AdreView™ Heart-to-Mediastinal ratio (H/M) <1.6 underwent Implantable Cardioverter Defibrillator (ICD) device implantation and H/M >= 1.6 continued to receive Guideline-Directed Optimal Medical Therapy (GDMT) according to clinical standard practice.
3118643|NCT02656329|Experimental|Standard of Care|Participants received 1 intravenous injection of 10 mCi (370 MBq) of AdreView™ (Iobenguane I-123 Injection) and underwent ICD implantation and were followed up in accordance with internationally accepted Heart Failure (HF) guidelines.
3118644|NCT02656420|Placebo Comparator|Placebos|Beverage (100 mL) containing pineapple juice, lime juice and water. Nightly for 10 days.
3118645|NCT02656420|Experimental|High Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (600 micromole) and sulforaphane-rich (40 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
3118646|NCT02656420|Experimental|Medium Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (300 micromole) and sulforaphane-rich (20 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
3118647|NCT02656420|Experimental|Low Dose Broccoli Sprout|Beverage (100 mL) containing glucoraphanin-rich (120 micromole) and sulforaphane-rich (8 micromole) broccoli sprout powder mixed in pineapple juice, lime juice and water. Nightly for 10 days.
3118648|NCT02656485|Experimental|Dose I|B244 Dose 1 (dose level [cells/mL] 20,000,000,000)
3118649|NCT02656485|Experimental|Dose II|B244 Dose 2 (dose level [cells/mL] 40,000,000,000)
3118650|NCT02656485|Experimental|Dose III|B244 Dose 3 (dose level [cells/mL] 80,000,000,000)
3118651|NCT02656485|Placebo Comparator|Placebo|Placebo to Match B244
3118652|NCT02656680|Experimental|FB+Friends|FB+Friends is a Facebook-delivered weight loss intervention. For this group, the study team continued to enroll participants through week 8.
3118653|NCT02656680|Active Comparator|FB Only|FB Only Facebook-delivered weight loss intervention including only study participants.
3118654|NCT02656693|Experimental|Online Program Only|Patients will use an online weight management program called BMIQ, with minimal additional support.
3118655|NCT02656693|Experimental|Combined Intervention|Patients will use an online weight management program called BMIQ, but will also receive additional monitoring and support from a population health manager who works with their primary care practices.
3118656|NCT02656693|No Intervention|Usual Care|Patients will continue receiving usual care but will also be mailed some general written information about weight management (very minimal intervention.)
3118657|NCT02656745|Experimental|Mobile Smoking Cessation Solution|Subjects download & use the mobile application.
3118658|NCT02656875|Experimental|TRV130|"For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.~For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval."
3118659|NCT02657031|Active Comparator|Control Arm|This arm uses standard of care treatment of prochlorperazine 10 mg IV along with diphenhydramine 25 mg IV plus Normal Sailine 500 cc bolus
3118660|NCT02657031|Experimental|Study Arm|This arm uses stud drug regime of Ketamine 0.3 mg/kg along with Ondansetron 4 mg IV plus Normal Saline 500 cc bolus.
3118661|NCT02657226||Intensive Monitoring of Renal Function|Urine output measurements recorded at least every 2 hours within the first 48 hours of ICU admission and serum creatinine measurements recorded daily for 3 days following ICU admission.
3118662|NCT02657226||Less-Intensive Monitoring of Renal Function|Urine output measurements with gaps of more than 3 hours recorded during the first 48 hours of ICU admission and fewer than 3 days of serum creatinine measurements after ICU admission.
3118663|NCT02657252|Active Comparator|Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
3118664|NCT02657252|Active Comparator|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
3118665|NCT02657369|Experimental|Lenvatinib|Participants will receive lenvatinib 24 milligrams (mg) (2 10-mg capsules and one 4-mg capsule) once daily by oral administration at approximately the same time each morning for up to approximately 24 months.
3118666|NCT02657408|Experimental|BI 1026706|
3118667|NCT02657408|Experimental|Placebo|
3469328|NCT03887858|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tamsulosin HCl Tab. 1T~Period 2: Harnal-D Tab. 1T"
3469329|NCT03887624|Experimental|Experimental group|Ethosuximide(2 weeks) + Escitalopram (4 weeks)
3118670|NCT02657538|Active Comparator|Near infrared transillumination|Near infrared transillumination is applied for initial enamel caries lesion detection.
3118671|NCT02657538|Active Comparator|Visual caries detection + BW|visual caries detection + bite wing radiography (BW): considered as gold standard in caries diagnostics.
3118672|NCT02657564|Other|Polyethylene glycol (PEG)|3-L polyethylene glycol (PEG) is provided for colonoscopy preparation. Patients receive blood tests for renal function and electrolytes before and after colonoscopy.
3118673|NCT02657629|Active Comparator|Continuous Feeding Regimen|Enteral feedings given as combination of continuous nocturnal feedings and intermittent bolus daytime feedings.
3118674|NCT02657629|Active Comparator|Intermittent Bolus Feeding Regimen|Enteral feedings given as intermittent bolus feedings for entire 24 hour period.
3118675|NCT02657889|Experimental|niraparib plus pembrolizumab|"Phase 1: Dose-escalation: ascending doses of niraparib up to 300mg/day orally (PO) on Days 1-21 and pembrolizumab 200mg intravenously (IV) on Day 1 of each 21-day cycle~Phase 2: niraparib (recommended Phase 2 dose) in combination with pembrolizumab 200mg IV on Day 1 of each 21-day cycle"
3118676|NCT02657915|Placebo Comparator|Placebo|This was a follow-up study, investigational product was administered in the previous study. Participants in the placebo arm have received at least 1 dose of placebo.
3118677|NCT02657915|Experimental|BIIB033 100mg/Kg|This was a follow-up study, investigational product was administered in the previous study. Participants in the BIIB033 arm have received at least 1 dose of 100 mg/kg BIIB033.
3118678|NCT02657928|Experimental|Treatment (ribociclib and letrozole)|Patients receive ribociclib PO daily and letrozole PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3118679|NCT02658019|Experimental|Pembrolizumab in Advanced HCC|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression and/or unacceptable toxicity, whichever occurs first.
3118680|NCT02658084|Experimental|Phase 1: T-DM1 + Vinorelbine|One cycle of Trastuzumab Emtansine (T-DM1)/Vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). The recommended (starting) dose of trastuzumab emtansine is 3.6 mg/kg given as an intravenous infusion on Day 1 of every 21-day cycle. The starting dose of Vinorelbine is 22.5 mg/m2 given as a direct intravenous push over 6-10 minutes on day 1 and day 8 of every 3-week (i.e. 21-day) cycle. Participants will be treated until documented disease progression or other criteria for discontinuation. Approximately 15 to 21 patients will be needed to establish the recommended phase II dose (RP2D).
3118681|NCT02658084|Experimental|Phase 2: T-DM1 + RP2D Vinorelbine|One cycle of trastuzumab emtansine (T-DM1)/vinorelbine combination treatment is defined as 21-days (i.e. 3 weeks). Participants will receive the recommended Phase 2 Dose (RPSD) of Vinorelbine with the fixed dose (3.6 mg/kg) of Trastuzumab Emtansine. Participants will be treated until documented disease progression or other criteria for discontinuation. Up to 35 patients will be treated at the RP2D (MTD) including 6 patients treated at RP2D in phase I.
3118682|NCT02658149|Experimental|Psoas Compartment Block|After exposure anesthetic (Ropivacaine with NaCl) is introduced directly into the iliopsoas muscle, where it then spreads to the lumbar plexus (the nerves responsible for sensation around the surgical site).
3118683|NCT02658149|Active Comparator|Periarticular Local Anesthetic|"An anesthetic cocktail of four drugs (ropivacaine, epinephrine, ketorolac tromethamine, morphine) is injected at five locations at the surgical site to the surrounding tissues."
3132458|NCT03428360|Experimental|Subjects with Epilepsy|Male or female subjects between the ages of 2 and 65 years who had an established diagnosis of epilepsy exhibited by motor seizures with clear alteration of awareness, and while on a regimen of anti-epileptic medication(s), still experienced bouts of seizures (frequent breakthrough seizures, eg, seizure clusters) and who, in the opinion of the Investigator, could need benzodiazepine intervention for seizure control at least 1 time a month on average. Subjects must have been on at least 1 concomitant anti-epileptic drug at screening.
3469330|NCT03887624|Placebo Comparator|Control group|Placebo(2 weeks)+Escitalopram(4 weeks)
3469331|NCT03887676|Active Comparator|Arbaclofen|
3469332|NCT03887676|Placebo Comparator|Placebo|
3469333|NCT03887637||Danoprevir Sodium triple therapy|"DNV(Danoprevir Sodium)/PegIFNα(Peginterferon α-2a)/RBV(Ribavirin) : (1) DNV : 100mg (one tablet) orally twice daily for 12 weeks. (2) PegIFNα: 180ug subcutaneous infection on abdomen or thigh once a week for 12 weeks. (3) RBV: 500mg (5 tablets) orally twice daily for 12 weeks in patients weighing less than 75kg; 600mg (6 tablets) orally twice daily for 12 weeks in patients weighing ≥75kg.~Dosing time: In the morning, participants will be instructed to take DNV and RBV with food or one hour after food. The drugs are not allowed to be cut or divided. The interval between DNV and RBV dosing time should be 12±2 hours."
3469334|NCT03887637||Sofosbuvir/ Velpatasvir therapy|Sofosbuvir/ Velpatasvir :500mg (two drugs in one tablet) orally once daily for 12 weeks.
3469335|NCT03887637||Ombitasvir/Paritaprevir therapy|Ombitasvir/Paritaprevir: Ombitasvir two tablets orally once daily for 12 weeks; Paritaprevir one tablet orally twice daily for 12 weeks.
3118684|NCT02658175|Experimental|Treatment-naïve Group|Treatment naïve group included combined group of ISIS 304801-CS7 (CS7-New) study participant and participant on placebo in index studies (ISIS 304801-CS6 [NCT02211209] and ISIS 304801-CS16 [NCT02300233]), were to receive 300 mg of volanesorsen as single SC once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following Week 52 visit, participants had option of participating in expanded access program or continuing treatment with 300 mg of volanesorsen as single SC once-weekly for up to additional 52 weeks (Weeks 53-104) and in France participants, up to additional 104 weeks for total of 156 weeks (Weeks 105 to Week 156) until expanded access program was approved and available in their country. Participants who were not participating in expanded access program were to enter 13-week post-treatment (PT) evaluation period and in France, participants not continuing treatment were to enter 26-week PT follow-up period.
3118685|NCT02658175|Experimental|CS6-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS6 (NCT02211209) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
3118686|NCT02658175|Experimental|CS16-Volanesorsen|Participants with FCS rolling over from the ISIS 304801-CS16 (NCT02300233) index study after receiving volanesorsen, were to receive 300 mg of volanesorsen as a single SC injection once weekly for Weeks 1-52 of this study. Participants were allowed dose adjustment/dose reduction based on monitoring rules. Following the Week 52 visit, participants had the option of participating in an expanded access program or continuing treatment with 300 mg of volanesorsen as a single SC injection once-weekly for up to an additional 52 weeks (Weeks 53-104) and in France participants, up to an additional 104 weeks for total of 156 weeks of treatment (Weeks 105 to Week 156) of this study until an expanded access program was approved and available in their country. Participants who were not participating in an expanded access program were to enter a 13-week post-treatment evaluation period and in France, participants not continuing treatment were to enter a 26-week post-treatment follow-up period.
3118687|NCT02658240|Active Comparator|Compartment Block|Fascia iliaca compartment block (FICB) with ropivacaine and epinephrine after surgery
3118688|NCT02658240|Active Comparator|Infiltration|Periarticular infiltration with ropivacaine and epinephrine prior to closing the incision
3118689|NCT02658448|Experimental|GTx-024 3 mg|GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.
3118690|NCT02658461||Trastuzumab IV Infusion|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via IV infusion.
3118691|NCT02658461||Trastuzumab SC Single-Use Injection Device|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC single-use injection device.
3118692|NCT02658461||Trastuzumab SC Vial/Syringe|Participants with HER2-positive EBC will be evaluated for the costs and other factors associated with health care utilization with the administration of trastuzumab via SC vial/syringe.
3118693|NCT02658487|Experimental|Treatment (vosaroxin, cytarabine)|Patients receive vosaroxin IV on days 1 and 4 and cytarabine IV continuously on days 1-7 (Induction I). Patients with residual leukemia and for whom a second course is indicated in the judgment of the investigator may undergo a second course of treatment (Induction II) 14-57 days after day 1 of Induction I.
3118694|NCT02658630|Experimental|Device: Robot + TTT Exercise|All participants will be enrolled in this group to receive the same 60 minute study intervention consisting of wrist and shoulder-elbow robot training and TTT arm exercises.
3118695|NCT02658734|Experimental|Trastuzumab emtansine|
3118696|NCT02658851|Experimental|J-Plasma|Enrolled participants will have their PLND performed using J-Plasma® for dissection and sealing of lymphatic channels.
3118697|NCT02658994|Experimental|THPP+|As part of THPP+, the intervention will continue from the 6th month postnatal through 36 months postnatal and so will consist of an additional 30 months of lower intensity services that are unique to THPP+. The THPP+ will also include additional group sessions to be held every other month for a total of 18 over the intervention duration. The content will be a continuation of the previous THPP sessions with continuing emphasis on self-care as well as the baby's health and development.
3118698|NCT02658994|Active Comparator|Enhanced Usual Care|Women in the control clusters who were depressed prenatally have been receiving Enhanced Usual Care (EUC). At the time of the screening, women, their Lady Health Workers, and their local primary health care facility were informed of the diagnosis, and women were given an information sheet about depression and how to access care. There are no new EUC protocols put in place post-partum as part of the THPP+.
3118699|NCT02659020|Experimental|Phase 1b: Cohort 1 - 15 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 15 milligrams per kilogram (mg/kg) on days 1, 8 plus gemcitabine 900 milligrams per meter square (mg/m^2) on days 1, 8 plus docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met.
3118700|NCT02659020|Experimental|Phase 1b: Cohort 2 overall - 20 mg/kg Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab 20 mg/kg on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met (cohort 2). Following a protocol amendment, additional participants were enrolled into this group to confirm the safety of the 20 mg/kg dose level prior to opening the Phase 2 (cohort 2 expansion).
3132459|NCT03428750|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
3132460|NCT03428750|Placebo Comparator|Placebo|
3132461|NCT03428815|Experimental|PCM liner|Willowwood Smart Temp Liner
3132462|NCT03428815|Active Comparator|regular liner|User's regular prescribed liner
3118701|NCT02659020|Experimental|Phase 2: Olaratumab + Gemcitabine + Docetaxel|Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
3118702|NCT02659020|Placebo Comparator|Phase 2: Placebo + Gemcitabine + Docetaxel|Participants received intravenous infusions of placebo on days 1, 8 in combination with gemcitabine 900 mg/m^2 on days 1, 8 and docetaxel 75 mg/m^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. This cohort is a combination of participants who never received olaratumab (olaratumab-naive) and who received commercially available olaratumab (olaratumab pre-treated) prior to enrollment.
3118703|NCT02659059|Experimental|Nivolumab+Ipilimumab|"Part 1~Specified Dose on Specified Days"
3118704|NCT02659059|Experimental|Nivolumab+Ipilimumab + 2 cycles Platinum Doublet Chemotherapy|"Part 2~Specified Dose on Specified Days"
3118705|NCT02659098|Experimental|Open-Label Safety Run-in Phase: Treatment Group|Participants will receive CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL). CNTO 2476 will be delivered using the custom-designed Delivery System.
3118706|NCT02659150|Other|Open-Label tocilizumab|tocilizumab will be given to rheumatoid arthritis patients at a dose of 162 mg subcutaneously a week
3118707|NCT02659501|Active Comparator|Bupivacaine with epinephrine injections|Patients in the control arm of the study will be treated intra-operatively with standard of care, 0.5% bupivacaine and epinephrine injection (1:200,000), with 50 mg delivered into each breast pocket to perform a field block of the breast pocket (see below). Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
3118708|NCT02659501|Experimental|Liposomal bupivacaine|Patients in the experimental arm of the study will be treated intra-operatively with 1.33% liposomal bupivacaine, with 133 mg delivered to perform a field block of each breast pocket. Postoperatively, these patients will be treated with standard postoperative pain control, including narcotics as needed, such as morphine sulfate and hydrocodone/acetaminophen, and muscle relaxants, such as diazepam.
3118709|NCT02659540|Experimental|Cohort A (Conventional RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a conventional total palliative dose of 30 Gy delivered over 2 weeks in 10 fractions of 3 Gy each.
3118710|NCT02659540|Experimental|Cohort B (Hypofractionated RT)|Subjects received concurrent ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) every 3 weeks for 4 doses (i.e., Weeks 1, 4, 7 and 10), followed by nivolumab monotherapy administered at a dose of 240 mg every 2 weeks through Week 18. Continued nivolumab monotherapy was permitted beyond Week 18 at the Investigator's discretion as either 240 mg every 2 weeks or 480 mg every 4 weeks starting at Week 20. Extracranial RT was initiated after the first dose and before the second dose of immunotherapy and was administered to a target lesion at a hypofractionated high-dose of 27 Gy delivered over 2 weeks in 3 fractions of 9 Gy each.
3118711|NCT02659631|Experimental|PF-06671008|
3118712|NCT02659709||Glaucoma Patients and Caregivers|Glaucoma patients and caregivers will complete a 20 item questionnaire providing demographic information, glaucoma eye drop compliance, interest in medication reminders, availability to smartphone, tablet and social media technology and interest in using a glaucoma application on social media.
3118713|NCT02659787|Active Comparator|Low dose buprenorphine|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
3118714|NCT02659787|Placebo Comparator|Placebo|Subjects all receive placebo, 0.2 mg buprenorphine in crossover design
3118715|NCT02659943|Experimental|LEVEL 1 - Participants Who Received 0.66x10^6 CAR T Cells Only|LEVEL 1 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells only
3118716|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 2-Participants Who Received - 0.66x10^6 CAR T Cells Foll/by 2x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 2 - participants who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 2x10^6 CAR T cells
3118717|NCT02659943|Experimental|LEVEL 1 Foll/by LEVEL 3 - Participants Who Received 0.66x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 1 followed by LEVEL 3 - participant who received - 0.66x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
3118718|NCT02659943|Experimental|LEVEL 2 - Participants Who Received 2x10^6 CAR T Cells Only|LEVEL 2 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells only
3118719|NCT02659943|Experimental|LEVEL 2 Followed by LEVEL 3-Participants Who Received 2x10^6 CAR T Cells Foll/by 6x10^6 CAR T Cells|LEVEL 2 followed by LEVEL 3 - participants who received - 2x10^6 Chimeric Antigen Receptor (CAR) T cells followed by 6x10^6 CAR T cells
3118720|NCT02659943|Experimental|LEVEL 3 - Participants Who Received 6x10^6 CAR T Cells Only|LEVEL 3 - participants who received - 6x10^6 Chimeric Antigen Receptor (CAR) T cells only
3118721|NCT02660112|Experimental|(+)-Epicatechin|Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks
3118722|NCT02660138|Experimental|600 U Dysport® Group|
3118723|NCT02660138|Placebo Comparator|600 U Dysport® Placebo Group|
3118724|NCT02660138|Experimental|800 U Dysport® Group|
3118725|NCT02660138|Placebo Comparator|800 U Dysport® Placebo Group|
3118726|NCT02660229|Experimental|Oxycodone Hydrochloride|Brand Name: OxyNorm® Generic name: Oxycodone hydrochloride
3118727|NCT02660229|Active Comparator|Morphine Sulphate|Brand name: BC Morphine sulfate Generic name: Morphine sulfate
3118728|NCT02660242|No Intervention|Control|No basal insulin adjustment, no carbohydrate intake (until glucose drops <70 mg/dL).
3118729|NCT02660242|Active Comparator|Basal insulin reduction|Basal insulin reduction to 50% five minutes before the start of exercise.
3132463|NCT03428997|Experimental|Lotion|Test sites were patched with the lotion F #13451-131.
3118730|NCT02660242|Active Comparator|Glucose Tabs|Dextrose tabs orally (20 grams) five minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
3118731|NCT02660242|Experimental|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) five minutes before the start of exercise (SQ-abdomen).
3118732|NCT02660359|Experimental|600 U Dysport® Group|
3118733|NCT02660359|Placebo Comparator|600 U Dysport® Placebo Group|
3118734|NCT02660359|Experimental|800 U Dysport® Group|
3118735|NCT02660359|Placebo Comparator|800 U Dysport® Placebo Group|
3118736|NCT02660489|Experimental|OC459 (CRTH2 antagonist)|OC459 50mg once daily for 5 weeks
3118737|NCT02660489|Placebo Comparator|Placebo|Placebo tablet once daily for 5 weeks
3118738|NCT02660580|Experimental|MSB11022 (Core Treatment Period)|Participants received MSB11022 subcutaneously at an initial dose of 80 milligram (mg) on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
3118739|NCT02660580|Active Comparator|EU-Humira|Participants received EU-Humira subcutaneously at an initial dose of 80 mg on Day 1 of Week 1 followed by 40 mg every other week starting at Week 2 up to and including Week 14 in Core Treatment Period.
3118740|NCT02660580|Experimental|MSB11022 (Extended Treatment Period)|Participants who had achieved PASI 50 and received MSB11022 during Core Treatment Period continued to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
3118741|NCT02660580|Active Comparator|EU-Humira/EU-Humira|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period and continued to receive EU-Humira subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 after re-randomization in extended treatment period.
3118742|NCT02660580|Experimental|EU-Humira/MSB11022|Participants who had achieved PASI 50 and received EU-Humira in Core Treatment Period were re-randomized to receive MSB11022 subcutaneously at dose of 40 mg every other week starting at Week 16 up to and including Week 50 in extended treatment period.
3118743|NCT02660788|Active Comparator|Control Arm|Mail
3118744|NCT02660788|Experimental|Family Physician Reminder Letter Arm|Mail
3118745|NCT02660801|Experimental|Spinal manipulation|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
3118746|NCT02660801|Experimental|Spinal mobilization|Twenty-six participants with chronic nonspecific back pain will participate in two experimental sessions. During the first session, each participant will received either a spinal manipulation of a spinal mobilization of their thoracic spine preceded and followed by the assessment of their thoracic spine stiffness. The second session (24 to 48h after) will be identical but with the other experimental condition (spinal manipulation or spinal mobilization).
3118747|NCT02660827|Experimental|Hybrid closed loop|All subjects will be wearing the MMT-670G insulin pump, using it with the closed loop algorithm
3118748|NCT02660853|Other|Severe Asthma|Patients under Steps 4/5 of Asthma Treatment - SIGN (Scottish Intercollegiate Guidelines Network) / BTS (British Thoracic Society) Guidelines
3118749|NCT02660918|Experimental|Treatment|Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.
3118750|NCT02660918|Placebo Comparator|Control|Women undergoing endometrial ablation that meet the eligibility criterial will receive an equal volume standardized paracervical injection of Normal Saline at the completion of the procedure.
3118751|NCT02660944|Experimental|RSLV-132|10 mg/kg RSLV-132
3118752|NCT02660944|Placebo Comparator|Placebo|Saline placebo
3118753|NCT02660983|Placebo Comparator|Double Blind Phase: Placebo|Participants will receive donepezil matching placebo, once daily in the evening during the double blind period.
3118754|NCT02660983|Experimental|Double Blind Phase: Donepezil|Participants will receive donepezil 5 milligram (mg), once daily in the evening during the titration phase and then the dose will be increased to 10 mg at Week 4 during the double blind period. During the maintenance period, dose reduction to 5 mg/day will be permitted only when 10 mg/day is intolerable due to adverse events.
3118755|NCT02660983|Experimental|Open-Label Extension Phase: Donepezil|All participants who will complete the double-blind phase and want to continue the study participation, can be enrolled in the 24-week open-label extension phase. In this phase, treatment will be initiated at 5 mg/day, and the dose will be maintained until Week 6 (Day 28-42). After assessing clinical response during the period by examination, the dose can be increased to 10 mg/day. Dose reduction (from 10 mg/day to 5 mg/day) will be permitted when the investigator judges it difficult to continue the 10 mg/day administration. It will be possible to increase the dose to 10 mg/day again.
3118756|NCT02661061|Experimental|Ketamine|Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
3118757|NCT02661061|Active Comparator|Midazolam|Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
3118758|NCT02661126|Experimental|Moderate RI Participants|Participants with an estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73m^2 to <60 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
3118759|NCT02661126|Experimental|Severe RI Participants|Participants with an eGFR of ≥15 mL/min/1.73m^2 to <30 mL/min/1.73m^2 take 2 MK-3682B FDC tablets on Day 1 after fasting for 10 hours.
3118760|NCT02661126|Experimental|Healthy Participants|Healthy participants (creatinine clearance [CLcr] ≥80 mL/min) take 2 MK-362B FDC tablets on Day 1 after fasting for 10 hours. Healthy participants are matched to RI participants based on mean age, body mass index (BMI) and gender.
3118761|NCT02661178|Experimental|emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
3118762|NCT02661178|Placebo Comparator|placebo of emodepside (BAY 44-4400)|Up to 10 cohorts with single ascending dose
3118763|NCT02661217|Other|Pre-discharge treatment initiation|Patients received first dose at any point after Randomization but no later than 12 h before discharge.
3118764|NCT02661217|Other|Post-discharge treatment initiation|Patients received first dose after discharge and up to 14 days thereafter.
3118765|NCT02661256|Active Comparator|on NCPAP|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS) while NCPAP was administered via a RAM cannula® (intervention). With the NCPAP turned on each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow), a total of 20 swallows were recorded. These swallows were termed on NCPAP swallows. The swallows were assessed in real time for any swallowing dysfunction."
3118766|NCT02661256|Active Comparator|Off NCPAP|"Immediately following the on NCPAP condition, an additional 20 swallows were recorded under VFSS with the NCPAP turned off (intervention). These swallows were termed off NCPAP swallows."
3118767|NCT02661490|Experimental|Arm 1: NoV Vaccine Formulation A _1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.
3118768|NCT02661490|Experimental|Arm 2: NoV Vaccine Formulation A _2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.
3118769|NCT02661490|Experimental|Arm 3: NoV Vaccine Formulation B_1-Dose|Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.
3118770|NCT02661490|Experimental|Arm 4: NoV Vaccine Formulation B_2-Dose|Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.
3118771|NCT02661490|Experimental|Arm 5: NoV Vaccine Formulation A_1-Dose|Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.
3118772|NCT02661594|Experimental|ABCD|A: APD421 5 mg followed by B: APD421 40 mg; C: Moxifloxacin 400 mg; D: Placebo.
3118773|NCT02661594|Experimental|BDAC|B: APD421 40 mg; D: Placebo. A: APD421 5 mg C: Moxifloxacin 400 mg;
3118774|NCT02661594|Experimental|CADB|C: Moxifloxacin 400 mg A: APD421 5 mg D: Placebo B: APD421 40 mg
3118775|NCT02661594|Active Comparator|DCBA|D: Placebo C: Moxifloxacin 400 mg B: APD421 40 mg A: APD421 5 mg
3118776|NCT02661737||YVOIRE volume s|Treatment with YVOIRE volume s
3118777|NCT02661815|Experimental|Phase 1 Expansion Cohort A|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
3118778|NCT02661815|Experimental|Phase 1 Expansion Cohort B|Paclitaxel 70mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
3118779|NCT02661815|Experimental|Phase 1 Expansion Cohort C|Paclitaxel 80mg/m2 weekly days 1, 8, and 15 of a 28-day cycle Bevacizumab 10mg/kg days 1 and 15 of a 28-day cycle Ricolinostat dosing as identified as the RP2D combination dose
3118780|NCT02661815|Experimental|Phase 1 Escalation Cohort|Ricolinostat with weekly paclitaxel dosed at 80 mg/m2 per week (3 out of 4 weeks).
3118781|NCT02661828|Active Comparator|Taper A Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a Two-Week Taper Regimen to discontinue their medication.
3118782|NCT02661828|Active Comparator|Taper B Regimen|Participants taking an antidepressant for at least four weeks and no longer wish to take the antidepressant medication will undergo a One-Week Taper Regimen to discontinue their medication.
3118783|NCT02662023|Experimental|RIGHT side BOLUS and left side basal|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later. For the left catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours
3118784|NCT02662023|Active Comparator|RIGHT side BASAL and left side bolus|Bilateral transversus abdominis catheters were inserted and ropivacaine 0.2% administered concurrently. For the right catheter, the ropivacaine was administered as a continuous basal infusion (8 mL/h) from time point zero for the following 6 hours. For the left catheter, the ropivacaine was administered as two separate bolus doses of 24 mL each: one at time point zero and one 3 hours later
3118785|NCT02662036|Active Comparator|Group 1: Bupivicaine|-TAP block of 30 cc of 0.25% bupivicaine
3118786|NCT02662036|Experimental|Group 2: Liposomal bupivacaine|-TAP block of 266 mg/30 cc liposomal bupivacaine
3118787|NCT02662244|Experimental|Yag Laser Treatment Of Basal Cell Carcinoma|Study participants will be treated with long-pulsed 1064 nm Nd:YAG laser at the investigator's discretion based on the clinical endpoint (slight contraction and greying of the skin surface), the tumor characteristics, and the patient's skin phototype.
3118788|NCT02662387|Active Comparator|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
3118789|NCT02662387|Experimental|HFNC and external nasal dilator (END)|high flow nasal cannula and external nasal dilator
3118790|NCT02662556|Experimental|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg
3118791|NCT02662569|Active Comparator|Atorvastatin (Q2W)|Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
3118792|NCT02662569|Active Comparator|Atorvastatin (QM)|Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
3118793|NCT02662569|Experimental|Evolocumab Q2W + Atorvastatin|Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
3118794|NCT02662569|Experimental|Evolocumab QM + Atorvastatin|Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.
3118795|NCT02662582|Experimental|CK-2127107 1000 mg, then placebo|Participants received CK-2127107 500 milligram (mg), orally, twice daily for 2 weeks in treatment period 1 followed by matching placebo orally, twice daily for 2 weeks in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
3132464|NCT03428997|Other|Negative Control|Test sites were patched with undosed occlusive patch.
3118796|NCT02662582|Experimental|Placebo, then CK-212710 1000 mg|Participants received matching placebo orally, twice daily for 2 weeks in treatment period 1 followed by CK-2127107 500 mg in treatment period 2. A washout period of 2 weeks was maintained between the two treatment periods.
3118797|NCT02662608|Experimental|Brontictuzumab|1.5 mg/Kg of Brontictuzumab single agent intravenously every three weeks.
3118798|NCT02662764|Experimental|Zalviso™ 15 mcg|Zalviso™(sufentanil sublingual tablet system) 15 mcg
3118799|NCT02663128|Experimental|Lanabecestat Reference Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
3118800|NCT02663128|Experimental|Lanabecestat Test Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
3118801|NCT02663128|Experimental|Lanabecestat Test Non Fasted|Lanabecestat: 50 mg administered once PO in each of 3 treatment periods.
3118802|NCT02663232||Metastatic melanoma|Participants with metastatic melanoma who attend their physicians during the 18-month recruitment period and have valid biological samples available for BRAF mutation testing will be included in the study. There will be no intervention in this study.
3118803|NCT02663453|Experimental|study group|multicomponent lipid emulsion composed of 30% soybean oil, 30% MCTs, 25% olive oil and 15% fish oil (SMOF lipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
3118804|NCT02663453|Active Comparator|control group|pure soybean oil lipid emulsion(intralipid) was administered at a dose of 1gm/kg/day within 24 hours after birth; lipid dosage was increased by an increment of 0.5gm/kg/day until the maximal dose of 3.5gm/kg/day was reached.The macronutrients and micronutrients were provided using the same products in both groups.
3469336|NCT03887637||Grazoprevir/elbasvir therapy|Grazoprevir/elbasvir: 150mg (two drugs in one tablet) orally once daily for 12 weeks.
3469337|NCT03887637||Daclatasvir/Asunaprevir therapy|Daclatasvir (60mg)one tablet once daily and Asunaprevir (100mg)one tablet twice daily for 24weeks
3469338|NCT03887637||Danoprevir Sodium/Sofosbuvir therapy|Danoprevir Sodium: 100mg (one tablet) orally twice daily for 12 weeks;Sofosbuvir:400mg (one tablet) orally once daily for 12 weeks.
3469339|NCT03887962|Experimental|Virtual Environment feedback|"Subjects will be instructed to walk on a treadmill, moving at a constant speed, following a virtual path displayed on a flat screen in front of them. In this group, the gait task may involve avoiding virtual obstacles on the screen in the path or stepping on targets as determined by the therapist."
3118809|NCT02663674|Placebo Comparator|Group 1|A single dose of Fluconazole placebo (2 capsules) administered orally once daily for 42 days starting on Day 1. N=500
3118810|NCT02663674|Experimental|Group 2|400 mg of Fluconazole (2 capsules of 200 mg) administered orally once daily for 42 days starting on Day 1. N=500
3118811|NCT02663687|Experimental|Treatment 1- 4|Treatment A: 9 Subjects will receive dose level I of SHP623 intravenously (IV). B: 9 Subjects will receive dose level I of SHP623 subcutaneously(SC).
3118812|NCT02663687|Placebo Comparator|Placebo|3 Subjects will receive placebo for each cohort
3118813|NCT02663817|Experimental|IMRT|Study participants being treated according to the standard of care with intensity modulated radiotherapy (IMRT). Several CT scans will be performed for each enrolled subject: one before the radiotherapy course for patient treatment planning purposes (as part of the standard of care), one during the radiotherapy treatment course (between fraction 10 and 20), and one at follow up visit or at least 6 weeks post-radiotherapy treatment (whichever comes first).
3118814|NCT02663882|Experimental|smoking-related self control task|self control practice - smoking related task
3118815|NCT02663882|Active Comparator|Non-smoking-related self control task|self control practice - non-smoking related task
3118816|NCT02663895|Experimental|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated for 12 months
3118817|NCT02664181|Experimental|Oral THU/decitabine + Nivolumab|Oral THU ~10 mg/kg, followed by oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days. This drug combination is administered with Nivolumab 3mg/kg IV Q2 weeks until progression
3118818|NCT02664181|Active Comparator|Nivolumab|Nivolumab 3mg/kg IV Q2 weeks until progression; This is the standard of care for patients with NSCLC who have progressed on prior chemotherapy.
3469340|NCT03887962|Active Comparator|Control|Subjects will be instructed to walk on a treadmill, moving at a constant speed. The flat screen will play random scenes from the virtual reality environment and thus control for attentional and non-movement related clues.
3118819|NCT02664220|Experimental|Povidone-iodine irrigation|
3118820|NCT02664220|Active Comparator|No irrigation|
3118821|NCT02664311|Placebo Comparator|Conventional Ventilation|Patients receiving conventional ventilation for the duration of this study
3118822|NCT02664311|Active Comparator|Jet Ventilation|Patients receiving Jet ventilation while under general anesthesia and during mapping and ablation in the left atrium
3118823|NCT02664363|Experimental|EGFRvIII CAR T cells|Dose escalation cohorts for 4 dose levels will be considered: #1: 4.5 x 10^6/kg, #2: 1.5 x 10^7/kg, #3: 4.5 x 10^7/kg, and #4: 1.5 x 10^8/kg. Starting at dose level 1, cohorts of 3-6 subjects will be accrued at each dose level.
3118824|NCT02664415|Experimental|VRC01|Participants will receive an intravenous (IV) infusion of 40 mg/kg of VRC01 at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
3118825|NCT02664415|Placebo Comparator|Placebo for VRC01|Participants will receive an IV infusion of placebo at Week 0 and every 3 weeks until Week 24 or until criteria for resumption of ART are met.
3118826|NCT02664532|Experimental|Miller group|In Miller group, no 3 Miller blade was used for laryngoscopy by paraglossal technique. While intubating, the endotracheal tube (ETT) was directed underneath the laryngoscope blade without allowing it to go lateral to the blade. The curvature of the ETT automatically brings the tip towards the vocal cords as it was advanced. After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
3469341|NCT03888079||Local anesthetic|Patients who chose local anesthesia for their surgery
3469342|NCT03888079||General anesthetic|Patients who chose general anesthesia for their surgery
3469343|NCT03887585|Experimental|Achilles tendon lengthening|Surgery of percutaneous Achilles tendon lengthening by triple hemisection
3118827|NCT02664532|Other|Macintosh group|In Macintosh group, the curved blade was introduced to lift the base of the epiglottis to visualize larynx and then trachea intubated conventionally.After successful endotracheal intubation, the ETT was attached to the circuit and anaesthesia continued as per plan.
3118828|NCT02664610|No Intervention|No text messages, hypertensive|Participants who have high blood pressure, who are randomized to health information (do not receive text messages).
3118829|NCT02664610|Experimental|Text messages, hypertensive|Participants who have high blood pressure, who are randomized to receive text messages.
3118830|NCT02664909|Experimental|Tranexamic Acid|Patients will receive 1 gram of topically applied tranexamic acid into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. 1 gram of tranexamic acid will be mixed with normal saline to a total volume of 50 cc, half of which will be delivered intra-articularly and half of which will be delivered in the subfascial space.
3118831|NCT02664909|Placebo Comparator|Placebo|Patients will receive 50 cc of topically applied normal saline into their surgical wound at the time of wound closure during their hip hemiarthroplasty surgery. Half of this 50 cc dose of normal saline will be delivered intra-articularly and half will be delivered in the subfascial space.
3118832|NCT02664922|Experimental|Sedation - Group 1|Sedation - monitored anesthesia with propofol.
3118833|NCT02664922|Experimental|Sedation - Group 2|Sedation - monitored anesthesia with ketamine + propofol
3118834|NCT02664922|Experimental|Sedation - Group 3|Sedation - monitored anesthesia with remifentanil + propofol
3118835|NCT02664922|Experimental|General Anesthesia - Group 1|General anesthesia (GA) with Sevoflurane + O2
3118836|NCT02664961|Experimental|TRC105 and/or bevacizumab|All subjects will begin by receiving single agent TRC105 weekly. In the case of a complete response to single agent TRC105, subjects will continue to receive single agent TRC105 for at least 3 months following complete response. In the case of a partial response (without a complete response) to single agent TRC105, bevacizumab every two weeks will be added. In the absence of a partial or complete response to single agent TRC105, subjects will receive single agent bevacizumab every two weeks. In the absence of a complete response to single agent bevacizumab, or for subjects who have documented disease progression on a prior bevacizumab containing regimen, subjects will receive TRC105 weekly and bevacizumab every two weeks.
3118837|NCT02664987||Patients receiving cancer pain treatment|
3118838|NCT02665052|Experimental|Home-Based BATRAC|Home-based BATRAC training will consist of 45 minutes of high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
3118839|NCT02665052|Experimental|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and rest periods followed by 15 minutes of therapist guided transition to task training (TTT).
3118840|NCT02665052|Placebo Comparator|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions. They will also receive weekly phone calls to record general activity level. After serving as a control, this group will be entered into their randomized active intervention group of either lab-based BATRAC + TTT training, or Lab-based Robot+ TTT.
3118841|NCT02665260|Active Comparator|Cantharidin with occlusion|Cantharidin 0.7% topical with occlusion
3118842|NCT02665260|Experimental|Cantharidin without occlusion|Cantharidin 0.7% topical without occlusion
3118843|NCT02665260|Placebo Comparator|Placebo with occlusion|Placebo topical with occlusion
3118844|NCT02665260|Placebo Comparator|Placebo without occlusion|Placebo topical without occlusion
3118845|NCT02665273|Experimental|Greater occipital nerve block|Bilateral greater occipital nerve block with 3cc of 0.5% bupivacaine, delivered using fan technique
3118846|NCT02665273|Sham Comparator|Sham|Bilateral intradermal injection of 0.5cc of 0.5% bupivacaine, delivered superficially to the area overlying the greater occipital nerve
3118847|NCT02665286|Placebo Comparator|Placebo|Naproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
3118848|NCT02665286|Active Comparator|Orphenadrine|Naproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
3118849|NCT02665286|Active Comparator|Methocarbamol|Naproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
3118850|NCT02665364|Experimental|IFNα-Kinoid|IFNα-Kinoid (IFN-K) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at W0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
3118851|NCT02665364|Placebo Comparator|Placebo|Placebo normal saline (0.9% Sodium Chloride) adjuvanted with ISA 51 VG via intramuscular injection. 1 administration of 240 μg at week (W)0, W1, W4 and 1 administration of 120 μg at month 3 (W12) and month 6 (W24) in addition to standard of care treatment.
3118852|NCT02665455|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
3118853|NCT02665468|Other|Arm 1: Supported Adoption Intervention (SAI)|Supported adoption intervention
3118854|NCT02665468|Active Comparator|Arm 2: General wellness information|General wellness information
3118855|NCT02665689|Active Comparator|Regular Glycemic Control|Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen. Patients randomized into this group will be controlled by their general practitioner or private diabetologist (usual care). The glycemic control (blood measurements of HbA1c) will be performed at trial site (Department of diabetology, endocrinology and nutritional medicine) every 3 months. The site will not influence or change the diabetes medication given by general physician and serves as an observer only to monitor the diabetic control.
3132465|NCT03429270|Experimental|Urodynamics Arm|
3132466|NCT03429348|No Intervention|No additional rehabilitation|No additional rehabilitation will be done
3118856|NCT02665689|Experimental|Intensified Glycemic Control|"Diabetic macular edema will be treated with 3 monthly ranibizumab (0,5mg) injections followed by PRN regimen.~Patients randomized into this group will be controlled at the trial site (Department of diabetology, endocrinology and nutritional medicine) during first year monthly, in the second study year every 3 months. The individual HbA1c will be targeted according to the general status reflecting other risk factors for the vasculopathy (e.g. BMI, smoking, blood pressure, lipid status). All effort will be done to reach the target blood pressure ≤ 140/90 mmHg and blood triglyceride level < 140 mg/dl: Further the patients will be educated to improve their eating habits in regard to reduce the carbohydrate intake."
3118857|NCT02665728|Experimental|BLI400|BLI400 Laxative
3118858|NCT02665741|Other|Control|Standard colonoscopy - no distal colonoscope attachment will be used in this arm
3118859|NCT02665741|Experimental|Olympus transparent cap|The Olympus transparent cap will be attached to the distal end of colonoscope prior to starting the procedure
3118860|NCT02665741|Experimental|Medivators Endocuff|The Medivators Endocuff will be attached to the distal end of colonoscope prior to starting the procedure
3118861|NCT02665975|Experimental|Experimental group: iCBT|CBT-based internet-intervention for tinnitus The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
3118862|NCT02665975|Active Comparator|Face-to-face clinical tinnitus care|Receive individual face-to-face tinnitus care, and follow-up appointments as required.
3118863|NCT02666352|Experimental|Moderate HI Participants|On Day 1, participants with moderate HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
3118864|NCT02666352|Experimental|Severe HI Participants|On Day 1, participants with severe HI will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
3118865|NCT02666352|Experimental|Healthy Participants|On Day 1, participants with normal hepatic function will receive a single oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast.
3118866|NCT02666430|Experimental|Mylan's insulin glargine|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
3118867|NCT02666430|Active Comparator|Lantus®|Patients will be administered either Mylan insulin glargine or Lantus® subcutaneously, once daily in combination with lispro and titrated based on blood glucose readings per standard of care for a total of thirty-six (36) weeks, split into three cycles of twelve (12) weeks each.
3118868|NCT02666508|Active Comparator|Plaque identifying toothpaste|A 30 day supply of daily syringes containing a plaque identifying toothpaste with targetol
3118869|NCT02666508|Active Comparator|Non-plaque identifying toothpaste|A 30 day supply of daily syringes containing an identical non plaque identifying toothpaste without targetol
3118870|NCT02666560|Active Comparator|Auditory cueing at self paced cadence|Participants performed a functional task with auditory cueing set at self paced cadence.
3118871|NCT02666560|Experimental|Cueing at 20% above self paced cadence|Participants performed a functional task with auditory cueing set at 20% above self paced cadence whilst performing a functional task.
3118872|NCT02666664|Experimental|ETC-1002|ETC-1002 180 mg/day
3118873|NCT02666664|Placebo Comparator|Placebo|Placebo control
3118874|NCT02666742|Experimental|DOAC (Direct Oral Anticoagulant)|Participants will be asked to take standard dose approved for stroke prophylaxis
3118875|NCT02666742|Active Comparator|Aspirin|Participants will be asked to take 81 milligrams by mouth once per day.
3118876|NCT02666846|Experimental|Cohort 1: TIB200 gel 10%|All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)
3118877|NCT02666846|Active Comparator|Cohort 1: Nurofen gel 10%|All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)
3118878|NCT02666846|Active Comparator|Cohort 1: Nurofen tablets|All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)
3118879|NCT02666846|Placebo Comparator|Cohort 1: TIB200 Placebo gel|All Cohort 1 Participants: TIB200 matching placebo gel
3118880|NCT02666846|Active Comparator|Cohort 2: DCF100 gel 2%|All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)
3118881|NCT02666846|Experimental|Cohort 2: DCF100 gel 4%|All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)
3118882|NCT02666846|Active Comparator|Cohort 2: Voltaren gel 2%|All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)
3118883|NCT02666846|Active Comparator|Cohort 2: Voltarol oral tablet|All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)
3118884|NCT02666846|Placebo Comparator|Cohort 2: DCF100 Placebo gel|All Cohort 2 Participants: DCF100 matching placebo gel
3118885|NCT02666846|Active Comparator|Cohort 3: SPR300 gel (15%:7%)|All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)
3118886|NCT02666846|Placebo Comparator|Cohort 3: SPR300 Placebo gel|All Cohort 3 Participants: SPR300 matching placebo gel
3118887|NCT02666950|Experimental|Arm B (cytarabine and WEE1 inhibitor AZD1775|Patients receive cytarabine and WEE1 inhibitor AZD1775 as in Arm A.
3118888|NCT02666950|Experimental|Arm C (WEE inhibitor AZD1775)|Patients receive WEE inhibitor AZD1775 PO daily on days 1-5, 8-12, 15-19, and 22-26.
3118889|NCT02667236|Active Comparator|A-101 Solution|A-101 Solution 40% administered once
3118890|NCT02667236|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
3118891|NCT02667275|Experimental|A-101 Solution|A-101 Solution 40% administered once
3118892|NCT02667275|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once
3118893|NCT02667288|Experimental|A-101 Solution|A-101 Solution 40% administered once
3132467|NCT03429348|Other|Sauna rehabilitation|An additional rehabilitation in a sauna will be done
3132468|NCT03429556|Placebo Comparator|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
3132469|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 1|Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.
3118894|NCT02667301|Experimental|EMG, TAS and tympanometry|"All treatments were performed by the same group of professionals. EMG needle administration by an ENT specialist with 30+ year experience, EMG recording by a neurologist with 20+ year experience. Tympanic cavity Air exchange Sensor (TAS) recording is done by an experienced technician. The following are done to all patients:~The patient is subjected to tympanometry test on the specific ear,~The patient is subjected to TAS test on the specific ear while sipping water and signals from ear and nasal cavity recorded,~The patient is hooked up to EMG instrument and TAS test equipment simultaneously and signals are recorded by both instruments for a duration of 150-300 seconds while the patient is at rest without sipping water. The patient is allowed to swallow during the test."
3118895|NCT02667392|Experimental|Biofeedback Group|Participants will wear a pressure-sensitive insole inside the shoe of their paretic limb. An auditory tone will sound when participants have provided sufficient load to active the pressure-sensitive in-sole.
3118896|NCT02667392|Active Comparator|Verbal Feedback Group|Participants will receive verbal feedback from a physical therapist regarding the amount of loading they are exerting on their paretic limb.
3118897|NCT02667457|Experimental|CAD Participants|Participants with asymptomatic or previously symptomatic with TIA only carotid atherosclerotic plaque with evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an intraveneous (IV) catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
3118898|NCT02667457|Experimental|Healthy Participants|Healthy participants with no significant carotid artery disease on carotid ultrasound, received a single intravenous bolus of 350 MBq ± 10 % of 99mTc-rhAnnexin V-128 via an IV catheter in an antecubital vein, followed by a saline flush on screening (Day 0).
3118899|NCT02667626|Experimental|SCPR Intervention|"Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.~Healthcare providers of young breast cancer participants randomized to the intervention arm will receive their patient's SCPR and access to the same additional web-based educational reproductive health information as their patient, including resource lists of helpful websites."
3118900|NCT02667626|Active Comparator|Control|"Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.~Healthcare providers of young breast cancer participants randomized to the waitlist control arm will receive access to the same web-based resources as their patient."
3118903|NCT02667704|Experimental|Nintedanib|
3118904|NCT02667704|Experimental|Bosentan|
3118905|NCT02667821|Experimental|Intervention group|Participants included in the experimental arm will be adults aged 18 years and older with chronic/recurrent neck pain Grade II who have been prescribed cervical manipulation for treatment of their condition. Each participant will undergo three separate test maneuvers consistent with prior work completed at the St. Joseph's Healthcare Hamilton Brain Body Institute. Each participant will begin with neutral cervical spine as a standard natural control, followed by block randomization between maximum voluntary rotation of the cervical spine and one cervical manipulation. Please see Intervention section for a detailed description.
3118906|NCT02667912|Experimental|Distal renal denervation|Endovascular denervation of segmental branches of renal artery
3118907|NCT02667912|Active Comparator|Conventional renal denervation|Endovascular denervation of main trunk of renal artery
3118908|NCT02667951|No Intervention|Control group|Caregivers received general information on dementia care and follow-up phone calls simply to maintain contact, but without any training for developing a behavioral problem-management plan and strategies.
3118909|NCT02667951|Experimental|Intervention group|Caregivers received solutions for managing behavioral problems, with referrals to community services and telephone consultation, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
3118910|NCT02668003|Experimental|Cognitive Behavioural Therapy|Brief Cognitive Behavioural Therapy delivered by telephone
3118911|NCT02668003|No Intervention|Treatment as usual|The group allocated to usual care will receive no additional intervention - this will reflect the fact there is no specific intervention provided to patients currently for the prevention of CWP. Participants in this group will receive usual care and there will be no restriction on what this can involve. CBT is not readily available within the NHS and is generally restricted to persons who have developed specific conditions rather than persons at risk of those conditions.
3118912|NCT02668185|Experimental|Active drug first|Baseline period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Washout period - 2 weeks Matched placebo orally bd - 2 weeks Monitoring period - 2 weeks
3118913|NCT02668185|Placebo Comparator|Placebo|Baseline period - 2 weeks Matched placebo orally bd - 2 weeks Washout period - 2 weeks NK3R antagonist - AZD4901 - 40mg bd - 4 weeks Monitoring period - 2 weeks
3118914|NCT02668198|Experimental|Endoscopic scar assessment|Using endoscope with high definition white light, high definition white light with near focus, narrow band imagining, and narrow band imaging with near focus.
3118915|NCT02668302|Experimental|Treatment|Bilateral in-office placement of a steroid-eluting sinus implant following ethmoidectomy in addition to post-op standard of care, including debridement, irrigation, and topical steroids
3118916|NCT02668302|Active Comparator|Control|Post-op standard of care, including debridement, irrigation, and topical steroids
3118917|NCT02668393|Other|Level 0|Nintedanib low dose with docetaxel
3118918|NCT02668393|Other|Level 1|Nintedanib medium dose with docetaxel
3118919|NCT02668393|Other|Level 2|Nintedanib high dose with docetaxel
3118920|NCT02668393|Other|Level 3|Nintedanib continuous high dose with docetaxel
3132470|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 2|Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.
3132471|NCT03429556|Experimental|Botulinum Neurotoxin Serotype E Dose 3|Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.
3118921|NCT02668432|Experimental|Partial Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive <4g IV or < 8g PO. The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
3118922|NCT02668432|Active Comparator|Full Load|All patients will receive a 150 mg intravenous (IV) bolus dose of amiodarone, followed immediately by a continuous infusion of 1 mg/min for the first six hours, with a recommended reduction to 0.5 mg/min subsequently. Conversion from IV to oral (PO) amiodarone will occur based on patient hemodynamic stability and physician/pharmacist discretion. Patients randomized to the partial load arm will receive (≥ 5g IV or ≥10g PO +/- 20%). The assigned total loading dose will include all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO amount (accounting for 50% bioavailability of PO versus IV amiodarone).
3118923|NCT02668640||Participants with RA receiving adalimumab|40 mg adalimumab via subcutaneous (SC) injection every other week (eow) for 24 weeks
3118924|NCT02668692|Experimental|LEO 80185 gel|
3118925|NCT02668692|Active Comparator|Dovobet ® ointment|
3118926|NCT02668783|Experimental|ENG-E2 125 μg/300 μg|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
3118927|NCT02668783|Placebo Comparator|Placebo|Participants will receive 4 cycles (or 6 cycles if also participating in the extension) of placebo. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
3118928|NCT02668822|Experimental|ENG 125 μg + E2 300 μg (MK-8342B)|Participants received up to 4 cycles of etonogestrel-17β estradiol (ENG-E2) at a daily dose of 125 μg/300 μg via vaginal ring. Each cycle consisted of 21 days of MK-8342B vaginal ring use followed by 7 ring-free days.
3118929|NCT02668822|Placebo Comparator|Placebo|Participants received up to 4 cycles of placebo via vaginal ring. Each cycle consisted of 21 days of placebo vaginal ring use followed by 7 ring-free days.
3118930|NCT02668952|Active Comparator|Normal Saline group|0.9% Normal Saline (0.9% Sodium Chloride) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients.
3118931|NCT02668952|Experimental|Isolyte group|Isolyte S (B Braun, Irvine CA) injection intravenously as needed. The amount administered (dosage, frequency, and duration) will be left to the clinical judgment of the attending physicians, and will follow usual patterns of use in cardiac surgery patients. Isolyte S is a prepackaged solution containing sodium chloride 0.53%, sodium gluconate 0.5%, sodium acetate trihydrate 0.37%, potassium chloride 0.037%, and magnesium chloride hexahydrate 0.03% w/v.
3118932|NCT02669017|Experimental|Part 1: ADCT-402 dose escalation|In Part 1 (dose escalation) participants will receive intravenous (IV) infusions of ADCT-402 at escalating doses, according to a 3+3 study design. Doses will be escalated from 15 µg/kg to 200 µg/kg on Day 1 of each cycle, with cycle lengths of 3 or 6 weeks.
3118933|NCT02669017|Experimental|Part 2: ADCT-402 dose expansion|"In Part 2 (expansion), participants will be assigned to the recommended dose level(s) and schedule(s) of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee.~Participants will receive intravenous (IV) infusions of ADCT-402 at either 120 μg/kg or 150 μg/kg on Day 1 of each 3 week cycle (Q3W)."
3118934|NCT02669043|Experimental|Ketamine|All participants receive open-label ketamine
3118935|NCT02669082|Experimental|Ramelteon 8 mg|Ramelteon 8 mg, tablet, orally, once daily at bedtime for 8 weeks.
3118936|NCT02669095|Experimental|Arm 1 (Test Lens)|Subjects will be dispensed the Investigational Contact Lenses (Test) to be worn as daily wear.
3118937|NCT02669095|Active Comparator|Arm 2 (Control Lens)|Subjects will be dispensed the Marketed Contact Lenses (Control) to be worn as daily wear.
3118938|NCT02669121|Placebo Comparator|Placebo|NoV placebo-matching 0.5 mL solution for injection, intramuscularly (IM), once, on Day 1.
3118939|NCT02669121|Experimental|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV GI.1/GII.4 bivalent virus-like particle (VLP) vaccine, 0.5 mL injection, intramuscularly (IM), once, on Day 1.
3118940|NCT02669264|Experimental|Part 1: ADCT-402 dose escalation|"Weekly administration - Participants will receive an intravenous (IV) infusion of ADCT-402, on Days 1, 8, and 15 of each 3-week (21-day) cycle.~3-week administration - Participants will receive an IV infusion of ADCT-402, on Day 1 of each 3-week (21-day) cycle.~The dose escalation will be conducted according to a 3+3 design."
3118941|NCT02669264|Experimental|Part 2: ADCT-402 expansion|All participants will be assigned to the recommended dose and/or schedule of ADCT-402 identified in Part 1 by the Dose Escalation Steering Committee
3118942|NCT02669329|Experimental|Upper arm treatment with vacuum applicator|Subjects with clearly visible fat sufficient for treatment received bilateral CoolSculpting treatments, 1 treatment on each arm.
3118943|NCT02669407|Experimental|Regional nerve anesthesia|Regional nerve anesthesia of splanchnic nerve
3118944|NCT02669433|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
3118945|NCT02669433|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
3118946|NCT02669433|Placebo Comparator|Placebo|Placebo
3118947|NCT02669615|Experimental|Melphalan HCl for injection (propylene glycol free)|Patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2. Blood samples for the pharmacokinetic (PK) evaluation of melphalan will be collected after melphalan dosing (day -2). Following one day of rest after the myeloablative Melphalan conditioning (day -1), patients will receive an autologous graft with a minimum cell dose of 2 × 106 CD34+ cells/kg of patient body weight (day 0).
3118948|NCT02669667|Experimental|Cohort 1|single dose of MEDI9314 or placebo
3118949|NCT02669667|Experimental|Cohort 2|single dose of MEDI9314 or placebo
3118950|NCT02669667|Experimental|Cohort 3|single dose of MEDI9314 or placebo
3118951|NCT02669667|Experimental|Cohort 4|single dose of MEDI9314 or placebo
3118952|NCT02669667|Experimental|Japanese Cohort|single dose of MEDI9314 or placebo
3118953|NCT02669667|Experimental|Cohort 5|single dose of MEDI9314 or placebo
3118954|NCT02669758|Experimental|ALKS 3831|Olanzapine + samidorphan; administered as a coated bilayer tablet.
3118955|NCT02669784|Active Comparator|Low Dose Contrast (40mL)|CTA of the chest: 40 mL of intravenous contrast at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
3118956|NCT02669784|Active Comparator|Low Dose Contrast (50mL)|CTA of the abdomen OR or CTA of the chest and abdomen or CTA of the abdomen and pelvis or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds. The Low Dose scan will then be compared to the standard of care high dose scan of the same area taken at a previous date.
3118957|NCT02669849|Placebo Comparator|Placebo|
3118958|NCT02669849|Experimental|VX-210|
3118959|NCT02669862|Experimental|A-101 Solution 40|A-101 Solution 40% administered once per week
3118960|NCT02669862|Experimental|A-101 Solution 45|A-101 Solution 45% administered once per week
3118961|NCT02669862|Placebo Comparator|Vehicle Solution|Vehicle Solution administered once per week
3118962|NCT02669914|Experimental|Cohort A: Non-small cell lung cancer w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
3118963|NCT02669914|Experimental|Cohort B: Epithelial origin solid tumors w/o corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
3118964|NCT02669914|Experimental|Cohort C: NSCLC or non-NSCLC w/corticosteroids|-MEDI4736 will be given to all patients > 30 kg actual body weight intravenously at a fixed dose 750 mg every 2 weeks over the course of 60 minutes on an outpatient basis on Days 1 and 15 of each 28-day cycle. Patients < 30 kg actual body weight will be dosed at 10 mg/kg every 2 weeks.
3118965|NCT02669940||Participants With Chronic Hepatitis C Genotype 1|Participants with confirmed chronic hepatitis C genotype 1 receiving combination therapy with paritaprevir/r - ombitasvir with or without dasabuvir ± RBV according to standard of care and in line with the current local label.
3118966|NCT02670083|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
3118967|NCT02670083|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
3118968|NCT02670122||Patients with non resectable HCC|DEB-TACE with doxorubicin eluting 100 µ microspheres
3118969|NCT02670330|Experimental|Experimental: SD-101-6.0 cream|All participants (or their caregivers) applied SD-101-6.0 cream topically once a day to the entire body for a period of up to 36 months.
3118970|NCT02670343|Experimental|Oral Testosterone Undecanoate|A single dose of oral testosterone undecanoate equivalent to 200 mg of testosterone in the form of two soft gelatin capsules containing 158 mg of testosterone undecanoate will be administered to each subject.
3118971|NCT02670382|Experimental|EPA intervention|Subjects randomized to receive 3000 mg EPA/day, provided as EPA 750 mg/capsule will be instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
3118972|NCT02670382|Experimental|DHA intervention|Subjects randomized to 3000 mg DHA/day provided as DHA 750 mg/capsule will instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals for 10 weeks.
3118973|NCT02670382|Placebo Comparator|Placebo|3000 mg high oleic acid sunflower oil/day; 750 mg high oleic acid sunflower oil/capsule; subjects instructed to take 2 capsules by mouth in the morning and 2 in the evening with meals during 4 week long lead-in phase.
3118974|NCT02670473|No Intervention|enfilcon A (habitual)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
3118975|NCT02670473|Experimental|fanfilcon A (test)|Participants are habitual wearers of enfilcon A lens and refitted with fanfilcon A lens.
3118976|NCT02670538|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligrams (mg) capsule, one per day, orally for 2 weeks increased to cariprazine 3.0 mg capsule, one per day orally beginning on Day 15 for 4 weeks.
3118977|NCT02670538|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day, orally for 6 weeks.
3118978|NCT02670538|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, matching placebo capsule, one per day, orally for 6 weeks.
3118979|NCT02670551|Placebo Comparator|Placebo|Following a 7 to 14 days screening/washout period, placebo-matching cariprazine capsule, one per day, orally for 6 weeks.
3118980|NCT02670551|Experimental|Cariprazine 1.5 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 milligram (mg) capsule, one per day, orally for 6 weeks.
3118981|NCT02670551|Experimental|Cariprazine 3.0 mg|Following a 7 to 14 days screening/washout period, cariprazine 1.5 mg capsule, one per day for 2 weeks followed by cariprazine 3.0 milligram (mg) capsule, one per day, orally beginning on Day 15 for 4 weeks.
3118982|NCT02670629|Active Comparator|Anatomic Closed Reduction + Short Cast|"Patients in this group were treated by performing a closed anatomic reduction under anesthesia by using sedatives and then placing the child in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was performing a closed anatomic reduction under anesthesia."
3118983|NCT02670629|Experimental|Partial reduction overriding position|"Patients in this group were only given oral medications, the fracture was not reduced, instead it was left with a partial reduction with overriding position placed in a short arm cast for 6 weeks. The follow up was done at week 1, 3, 6 and 10 with new X rays in each consult.~The intervention in this control group was not performing a closed anatomic reduction under anesthesia."
3118984|NCT02670811|Experimental|Intervention|Daily consumption of 150 mL of fermented milk with Lactococcus lactis for 8 weeks
3118985|NCT02670811|Placebo Comparator|Placebo|Daily consumption of 150 mL of artificially acidified milk
3118986|NCT02670915|Experimental|Meal-time faster-acting insulin aspart and insulin degludec|
3118987|NCT02670915|Active Comparator|Meal-time NovoRapid® (insulin aspart) and insulin degludec|
3118988|NCT02670915|Experimental|Post-meal faster-acting insulin aspart and insulin degludec|
3118989|NCT02670928|Active Comparator|Active group of patients|Active group of patients underwent program of active lifestyle management (healthy nutrition, physical exercises, psychological counselling and classes on diabetes) in first 12 weeks of the study.
3118990|NCT02670928|Experimental|Control group of patients|Control group pf patients were being monitored for the same criteria as active group but did not take part in the lifestyle change management program.
3118991|NCT02671032|Experimental|Implantation with Nucleus CI532 cochlear implant|All participants will receive the same treatment - Implantation with Nucleus CI532 cochlear implant.
3118992|NCT02671266|Experimental|Oxytocin, Then Placebo|Participants will first receive a nasal spray containing the hormone oxytocin (24 IU, 3 puffs per nostril). After a one-week washout period, participants will come back to the clinic and receive a placebo nasal spray (containing all of the same ingredients as the oxytocin spray minus the active oxytocin ingredient).
3118993|NCT02671266|Experimental|Placebo, Then Oxytocin|Participants will first receive a placebo nasal spray containing a matching formulation as the oxytocin spray (without the active oxytocin ingredient). After a one-week washout period, participants will come back to the clinic and receive an oxytocin nasal spray (24 IU, 3 puffs per nostril).
3118994|NCT02671500|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
3118995|NCT02671760|Experimental|Treatment|SM-1
3118996|NCT02671760|Active Comparator|Comparator|2-drug combination
3118997|NCT02671760|Placebo Comparator|Placebo|Placebo
3118998|NCT02672111|Experimental|CAM2038 q1w or q4w exposure to SL BPN/NX|"CAM2038 (buprenorphine FluidCrystal®)~Subjects previously exposed to SL BPN/NX who received CAM2038 q1w or q4w"
3118999|NCT02672111|Experimental|CAM2038 q1w or q4w new to BPN treatment|CAM2038 (buprenorphine FluidCrystal®) New to BPN Treatment who received CAM2038r q1w or q4w
3119000|NCT02672176|Sham Comparator|Usual Care-Chronic Disease Management|Usual Care through Chronic Disease Management: The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
3119001|NCT02672176|Active Comparator|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (2, 3). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org).
3119002|NCT02672423|Experimental|Abemaciclib Part A|Reference formulation (R) = 3 x 50 mg abemaciclib capsules, Test formulation (T150) = 150 mg abemaciclib tablet administered orally on Day 1 in each of 2 periods.
3119003|NCT02672423|Experimental|Abemaciclib Part B|R = 3 x 50 mg abemaciclib capsules, T150 = 150 mg abemaciclib tablet, Test Formulation 50 (T50) = 3 x 50 mg abemaciclib tablets administered orally on Day 1 in each of 3 periods.
3119004|NCT02672423|Experimental|Abemaciclib Part C|T150 Fed and T150 Fasted = 150 mg abemaciclib tablet with a high-fat meal (T150 Fed) and then without a high-fat meal (T150 Fasted) on Day 1 in each of 2 periods administered orally.
3119005|NCT02672514|Active Comparator|MiECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the minimally invasive extracorporeal circulation system (MiECC). MiECC has been developed based on the concept of a closed total CPB circuit. The basic elements are a centrifugal pump, a membrane oxygenator and an arterial filter. The priming volume compared to CECC could be reduced. The complete circuit is heparin-coated for maximizing the biocompatibility.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation."
3119006|NCT02672514|Active Comparator|CECC|"Coronary artery bypass grafting is used with the help of cardiopulmonary bypass (CPB). The technique used in this arm based on the conventional extracorporeal circulation system (CECC). The CECC is an opened circulation system. The basic elements are a membrane oxygenator, a centrifugal pump, an open perfusion system containing the venous hard shell cardiotomy reservoir and the arterial line filter.~CPB was performed under normothermic conditions of 36°C. Retrograde autologous priming was performed for all patients with stable hemodynamic circulation, leading to a reduction of the priming volume. The CECC flow was set as required in order to maintain a mean arterial pressure (MAP) between 50 and 75 mmHg."
3119007|NCT02672553|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
3119008|NCT02672553|Active Comparator|Stented Aortic Bioprostheses|Stented Aortic Bioprostheses
3119009|NCT02672852|Experimental|Risankizumab|Participants randomized at Baseline to receive double-blind (DB) risankizumab 150 mg by subcutaneous injection at Weeks 0 and 4 (Part A1).
3119010|NCT02672852|Placebo Comparator|Placebo|Participants randomized at Baseline to receive double-blind (DB) placebo by subcutaneous injection at Weeks 0 and 4 (Part A1).
3119011|NCT02673138|Active Comparator|Basal interruption|Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit
3119012|NCT02673138|Experimental|Basal interruption with canagliflozin|Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit
3119013|NCT02673203|Active Comparator|Lean Healthy Control|(BMI <25 kg/m2)
3119014|NCT02673203|Active Comparator|Obese non-diabetic subject|BMI > 30 kg/m2
3119015|NCT02673333|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
3119016|NCT02673372|Active Comparator|Morphine Group|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg.
3119017|NCT02673372|Experimental|Ketamine Group|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min)
3119018|NCT02673489|Experimental|Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)|Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
3119019|NCT02673515|Active Comparator|Alternate day fasting|"Subjects are requested to alternate fast for 4 weeks (alternate an ad libitum feed day with a 100% restriction fast day)."
3119020|NCT02673515|No Intervention|control group|control group
3119021|NCT02673541|Active Comparator|AXIOS™ stent|1. Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Repeat endoscopy will be performed for stent removal at or before 60 days at the discretion of the attending gastroenterologist
3119022|NCT02673541|Active Comparator|double pigtail stents|2. Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity. Necrosectomy will be performed at the discretion of the attending gastroenterologist. Routine repeat treating gastroenterologist for stent removal will not be necessary, but left to the discretion of the attending gastroenterologist.
3119023|NCT02673619|Experimental|Umeclidinium once daily (QD) 1.85%|Subjects will apply UMEC topically once daily (2microliter [µL]/centimeter [cm]^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days. Randomization will be 4:1 (UMEC 1.85%: vehicle)
3119024|NCT02673619|Placebo Comparator|Vehicle QD|subjects will apply vehicle topical once daily (2µL/cm^2) to both the hands (palm and fingers) using graduated syringe at night before bedtime for 28 days.
3119025|NCT02673918|Experimental|Part 1: Rehabilitation after surgery for breast cancer|Home-based upper-body rehabilitation with online support
3119026|NCT02673918|Experimental|Part 2: Rehabilitation after radiation for breast cancer|Home-based upper-body rehabilitation with online support
3119027|NCT02673944|Experimental|Peritron+|Patients will undergo a routine urodynamic evaluation, the Peritron+ will be used in conjunction with a water-based urodynamic catheter
3119028|NCT02674061|Experimental|Cohort A: Pembrolizumab|Participants in Cohort A received 0-2 prior lines of treatment for recurrent ovarian cancer (ROC; 1-3 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year).
3119029|NCT02674061|Experimental|Cohort B: Pembrolizumab|Participants in Cohort B received 3-5 prior lines of treatment for ROC (4-6 total prior lines including front-line treatment) and will be administered pembrolizumab at a dose of 200 mg via IV infusion on Day 1 of each 21-day cycle for up to 35 cycles (up to ~2 years). Qualified participants who complete 35 administrations of pembrolizumab but progress after discontinuation can initiate a second course of pembrolizumab 200 mg for up to 17 cycles (up to ~1 additional year)
3119030|NCT02674334|Active Comparator|NIRS Monitored Not Treated|Anesthesiologist blinded to Near Infrared Spectroscopy (NIRS)
3119031|NCT02674334|Active Comparator|NIRS Monitored and Treated|Anesthesiologist treats based on Near Infrared Spectroscopy (NIRS)
3119032|NCT02674386|Other|Cohort 1|long-term observational study of subjects from tanezumab parent study
3119033|NCT02674399|Experimental|JointStem|autologous adipose tissue derived mesenchymal stem cells (AdMSC)
3119034|NCT02674399|Active Comparator|Synvisc-One|hyaluronic acid
3119035|NCT02674412|Experimental|Buspirone then Placebo|Buspirone 10 mg PO TID for two weeks, followed by a washout period for two weeks and placebo for two weeks
3119036|NCT02674412|Experimental|Placebo then Buspirone|Placebo Tablet TID for two weeks, followed by a washout period for two weeks and Buspirone 10mg TID for two weeks.
3119037|NCT02674477|Experimental|Therapeutic Education System (TES)|Participants will have the opportunity to use the TES program while hospitalized, at specific, monitored times, and can also use it when discharged by using participant's specific login information. Participants can use it as much or as little as participants like. Participants will continue with treatment as usual during and after hospitalization, as well.
3119038|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
3119039|NCT02674568|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine administered intravenously on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for 2 cycles. An additional 2 cycles of rovalpituzumab tesirine (retreatment) was permitted for eligible participants.
3119040|NCT02674633|Active Comparator|AKL-T01 (EVO Multi)|AKL-T01, or EVO Multi, is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
3119041|NCT02674633|Active Comparator|AKL-T09 (EVO Words)|AKL-T09, or EVO Words, is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
3119042|NCT02674659|Experimental|Control group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program (aerobic training only)
3119043|NCT02674659|Experimental|Intervention group|Patients after coronary bypass surgery who undergo conventional cardiac rehabilitation program plus resistance training (aerobic and resistance training as well)
3119044|NCT02674854|Experimental|PG324 Ophthalmic Solution 0.02%/0.005%|Fixed combination of netarsudil 0.02%, latanoprost 0.005 % ophthalmic solution
3119045|NCT02674854|Active Comparator|Netarsudil (AR-13324) ophthalmic solution 0.02%|Netarsudil 0.02% ophthalmic solution
3119046|NCT02674854|Active Comparator|Latanoprost ophthalmic solution 0.005%|Latanoprost 0.005 % ophthalmic solution
3119047|NCT02675075||Veterans With ALS|This Cohort Study will admit all eligible, interested Veterans diagnosed with ALS who meet the inclusion criteria.
3119048|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab + 500 mg Fulvestrant|150 milligram (mg) abemaciclib given orally every 12 hours (Q12H) of a 21-day cycle; plus 8 milligram per kilogram (mg/kg) trastuzumab intravenous (IV) infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle; plus 500 mg fulvestrant intramuscularly (IM) on day 1, 15 and 29 and then once every 4 weeks thereafter.
3119049|NCT02675231|Experimental|150 mg Abemaciclib + 8 mg/kg Trastuzumab|150 mg abemaciclib given orally Q12H of a 21-day cycle; plus 8 mg/kg trastuzumab IV infusion on Day 1 of the cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle.
3119050|NCT02675231|Active Comparator|8 mg/kg Trastuzumab + Standard of Care Chemotherapy|8 mg/kg trastuzumab IV infusion on Day 1 of a 21-day cycle then a 6 mg/kg maintenance dose IV infusion on Day 1 of each subsequent cycle plus standard of care single agent chemotherapy of physician's choice administered according to product label
3119051|NCT02675426|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive Upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on Upadacitinib 15 mg once daily."
3119052|NCT02675426|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive Upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will continue on Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
3119053|NCT02675426|Experimental|Placebo and Upadacitinib 15 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 15 mg once daily."
3119054|NCT02675426|Experimental|Placebo and Upadacitinib 30 mg|"Period 1: Participants receive Placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 30 mg once daily until participants begin to receive Upadacitinib 15 mg once daily."
3119055|NCT02675517||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD)guidelines
3119056|NCT02675543|Experimental|Standard silicone oil|after vitreous removal, the vitreous chamber was filled with standard silicone oil (PDMS)
3119057|NCT02675543|Experimental|Heavy silicone oil|after vitreous removal, the vitreous chamber was filled with heavy silicone oil (Densiron 68)
3119058|NCT02675634|Experimental|Test A, Test B, Subjects own product|The subjects first test Coloplast Test A, followed by Coloplast Test B and finally Subjects own product
3119059|NCT02675634|Experimental|Test A, Subjects own product, Test B|The subjects first test Coloplast Test A, followed by Subjects own product, and finally Coloplast Test B
3119060|NCT02675634|Experimental|Test B, Test A, Subjects own product|The subjects first test Coloplast Test B, followed by Coloplast Test A and finally Subjects own product
3119061|NCT02675634|Experimental|Test B, Subjects own product, Test A|The subjects first test Coloplast Test B, followed by Subjects own product, and finally Coloplast Test A
3119062|NCT02675634|Experimental|Subjects own product, Test A, Test B|The subjects first test Subjects own product, followed by Test A, and finally Coloplast Test B
3119063|NCT02675634|Experimental|Subjects own product, Test B, Test A|The subjects first test Subjects own product, followed by Test B, and finally Coloplast Test A
3119065|NCT02675764|Experimental|Experimental|The experimental group receives the wrist subthreshold vibrotactile stimulation during therapy.
3119066|NCT02675764|Active Comparator|Placebo|"The control group will wear the vibration device with no vibration.~Both groups cannot feel the vibration since the vibration intensity is set below the perceptible level.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
3119067|NCT02675907|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
3119068|NCT02675907|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
3119069|NCT02675998|Experimental|3mg BID|Tenapanor, 3mg BID (6mg total)
3119070|NCT02675998|Experimental|10mg BID|Tenapanor, 10mg BID (20mg total)
3119071|NCT02675998|Experimental|Dose Titration|Tenapanor, patients start at 30mg BID and can down titrate weekly to 20, 15, 10, and 3mg BID, sequentially based on a GI tolerability question
3119072|NCT02675998|Placebo Comparator|Placebo|Placebo
3119073|NCT02676375|Other|Standard Monotherapy|Treatment as usual starting with one smoking cessation medication plus group therapy.
3119074|NCT02676375|Experimental|Combination Extended Treatment|Extended treatment with multiple standard medications plus group therapy.
3119075|NCT02676375|Experimental|Combination Extended Treatment + Home Visits/Calls|Extended treatment with multiple standard medications plus group therapy plus home visits.
3119076|NCT02676466|Experimental|Fish oil Active|This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.
3119077|NCT02676466|Placebo Comparator|Fish oil Placebo|This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.
3119078|NCT02676466|Active Comparator|Losartan Active|This group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.
3119079|NCT02676466|Placebo Comparator|Losartan Placebo|This group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan.
3119080|NCT02676466|Active Comparator|Fish oil Active + Losartan Active|"This group will receive both the Losartan and Omega-3 fish oil. Losartan will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months.~Omega-3 fish oil will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month."
3132472|NCT03430050|Active Comparator|Progesterone|Prometrium 200mg. Take one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
3119081|NCT02676466|Other|Fish oil Active + Losartan Placebo|"This group will receive the Omega-3 fish oil which will be administered at a dose of 1.4 grams per day for the first six months. Based on tolerability and inflammation level, dose may either continue at 1.4 grams per day or be increased to 2.8 grams per day for the remaining six month.~In addition, this group will receive a placebo which will be matching to the losartan. The placebo cellulose based capsule are obtained in 25 mg and 50 mg capsules. The shell capsules are cellulose based. Placebo and LO have identical shape, color, taste and weight. the doses will be administered at doses corresponding to the losartan."
3119082|NCT02676466|Other|Fish oil Placebo + Losartan Active|"This group will receive a placebo which will be matching to the Omega-3 fish oil. The placebo corn oil are obtained in gel caps and they have identical shape, color, taste and weight. The doses will be administered at doses corresponding to the Omega-3 fish oil.~In addition, this group will receive the Losartan which will be administered at a starting dose of 25 milligrams per day. Based on tolerability, losartan will continue at a dose of either 25 milligrams per day or 50 milligrams per day for the first six months. Based on continued tolerability and inflammation level, dose may either continue at 25 or 50 milligrams per day or be increased to 100 milligrams per day for the remaining six months."
3119083|NCT02676466|Other|Fish oil Placebo + Losartan Placebo|This group will receive a placebo which will be matching to both the omega-3 fish oil and losartan which will be administered at doses corresponding to doses administered for omega-3 fish oil and losartan throughout the 12 month study.
3119084|NCT02676778|Experimental|E7777|Participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) will receive 9 μg/kg/day of E7777, administered by intravenous drip infusion in 60 minutes (± 10 min) for Days 1 through 5 of each cycle in maximum of 8 cycles. Every cycle consists of 3 weeks.
3119085|NCT02676843|Experimental|18F-AV-1451|Subjects who are microtubule associated protein tau (MAPT) family carriers and non-carriers will receive 18F-AV-1451 by injection, and undergo a Positron Emission Tomography (PET) scan, which will then be qualitatively analyzed to examine tau deposition in the brain.
3119086|NCT02676882|Other|EnBrace HR for Prevention of Depressive Relapse (Group 1)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are not currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are not experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score </= 10.
3119087|NCT02676882|Other|EnBrace HR for Acute Treatment of Major Depression (Group 2)|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 weeks. Participants are currently in a depressive episode per the Mini International Neuropsychiatric Interview (MINI) and are experiencing clinically significant depression symptoms assessed using the Montgomery Asberg Depression Rating Scale (MADRS) with a score >/= 15.
3119088|NCT02676895|Experimental|1790GAHB 25 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 25 μg of S. sonnei.
3119089|NCT02676895|Experimental|1790GAHB 100 μg Group|Subjects who received 2 injections of 1790GAHB vaccine containing 100 μg of S. sonnei.
3119090|NCT02676895|Active Comparator|Control Group|Subjects who received one dose of Menveo vaccine and a second dose of Boostrix vaccine.
3119091|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119092|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119093|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part A)|"Cycle 1: Olaratumab 15 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 15 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119094|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119095|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119096|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part B)|"Cycle 1: Olaratumab 20 mg/kg was administered IV Days 1 and 8.~Cycle 2 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119097|NCT02677116|Experimental|Olaratumab + Doxorubicin (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 and doxorubicin administered IV on Days 1 and 2. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119098|NCT02677116|Experimental|Olaratumab + Vincristine + Irinotecan (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg and vincristine administered IV on Days 1 and 8. Irinotecan administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119099|NCT02677116|Experimental|Olaratumab + Ifosfamide (Part C)|"Cycle 1 and beyond: Olaratumab 20 mg/kg administered IV on Days 1 and 8 of each cycle. Ifosfamide administered IV on Days 1 through 5. Treatment will cease when discontinuation criterion is met.~All cycles are 21 days."
3119100|NCT02677220|Experimental|Surgical|Subjects to be implanted with the CI532 cochlear implant in one ear
3119101|NCT02677324|Experimental|ABT199|ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles
3132473|NCT03430050|Placebo Comparator|Placebo|Placebo. ake one pill in the evening on day 1 with water. Take one pill twice a day on days 2-4. Take one pill on morning day 5.
3119102|NCT02677428|Experimental|Remotely Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
3119103|NCT02677428|Active Comparator|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the Veterans Benefits Administration (VBA) website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
3119104|NCT02677493|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The QIV is included both B strain (Yamagata, Victoria).
3119105|NCT02677493|Active Comparator|IL-YANG Flu Vaccine Prefilled Syringe|This TIV is included the B/Yamagata strain, and it was approved for commercial sale by MFDS.
3119106|NCT02677493|Active Comparator|IL-YANG Trivalent Influenza Vaccine|This TIV is included the B/Victoria strain.
3119107|NCT02677623|Experimental|A- Pyridium|"Method of administration: oral~Dose: 200 mg PO with small sip of water~Known adverse events: yellow discoloration of skin or sclera, 1-10% central nervous system effects including headache and dizziness, GI effect of cramping, < 1% acute renal failure, methemoglobinemia, hemolytic anemia, hepatitis, rash, skin pigmentation, vertigo, stomach cramps~Contraindications: to be used in caution in patients with renal impairment Cr Cl < 50ml/minute and in patients who are receiving nitric oxide, prilocaine and sodium nitrite as it can cause methemoglobinemia"
3119108|NCT02677623|Experimental|B- Sodium Fluorescein|"Method of administration: intravenous~Dose: 25 mg~Known adverse events: nausea, vomiting, flushing or rash, hypersensitivity and anaphylactic reactions can occur following injection and immediate treatment with epinephrine should be available, skin and urine discoloration (urine may appear bright yellow for 24-36 hours), extravasation may cause skin sloughing, toxic neuritis and phlebitis, nausea, rare cardiac arrest and seizure,~Contraindications: use with caution in patients with history of hypersensitivity, allergies or asthma"
3119109|NCT02677623|Experimental|C- Mannitol|"Method of administration: irrigant during cystoscopy~Dose: 300cc during cystoscopy to visualize the ureters~Known adverse events: dysuria, polyuria, hyponatremia with excess absorption, potential increased risk of urinary tract infection~Contraindications when used as a genitourinary irrigation solution: anuria"
3119110|NCT02677623|Experimental|Control- Normal saline|"Method of administration: irrigant during cystoscopy~Dose: 300cc~Known adverse events: no known significant adverse events~Contraindications: none"
3119111|NCT02677701|Active Comparator|azithromycin|azithromycin 500mg tablet over-encapsulated to match placebo in appearance, taken by mouth thrice weekly for 6 weeks
3119112|NCT02677701|Placebo Comparator|placebo|encapsulated placebo taken by mouth thrice weekly for 6 weeks
3119113|NCT02677714|Experimental|Patients with breast cancer receiving chemotherapy|After reconstitution and radiolabeling, 99mTc-rhAnnexin V-128 was administered as a single intravenous bolus of 350 MBq +/- 10% at baseline, after the 2nd cycle, after the 4th cycle and 12 weeks after AC chemotherapy.
3119114|NCT02677740|Experimental|Inhibitory rTMS (1 Hz)|Subjects are exposed to a 20-min inhibitory rTMS intervention that transiently suppresses the excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
3119115|NCT02677740|Experimental|Excitatory rTMS (5 Hz)|Subjects are exposed to a 20-min excitatory rTMS intervention that transiently increases the net excitability of cortical structures beneath the site of stimulation. Subjects undergo MRI and MRS both before and right after the rTMS intervention.
3119116|NCT02677753|Active Comparator|Fluoroscopy guided PNE|Fluoroscopy will be utilized to assist with placement and/or confirm correct placement of lead wires.
3119117|NCT02677753|No Intervention|PNE without fluoroscopic guidance|No fluoroscopy will be used during or after the placement of the lead wires.
3119118|NCT02677766|Experimental|Intervention|Intervention of Occupational therapy consists of implementing plans of action focused on the occupational needs chosen by patients through COPM
3119119|NCT02677766|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
3119120|NCT02677779|Experimental|CO2 laser|Ulcer debridement with laser-CO2 (DEKA SmartXide2 c80-El.En, Florence Italy)
3119121|NCT02677779|Active Comparator|Traditional surgery|Ulcer debridement with traditional surgery
3119122|NCT02677844|Experimental|Abemaciclib|200 - 600 mg single increasing oral dose of abemaciclib on Day 1 of up to 3 study periods.
3119123|NCT02677844|Placebo Comparator|Placebo|Single oral dose of placebo on Day 1 of 1 study period.
3119124|NCT02677844|Active Comparator|Loperamide|Cohort 2, only. 8 mg Loperamide given orally once in 1 of 4 study periods.
3119125|NCT02677844|Experimental|Loperamide + Abemaciclib|Cohort 2, only. 8 mg Loperamide co-administered with abemaciclib given orally once in up to 1 of 4 study periods.
3119126|NCT02677844|Active Comparator|Loperamide + Placebo|Cohort 2, only. 8 mg Loperamide co-administered with placebo given orally once in up to 1 of 4 study periods.
3469344|NCT03887598||breast nodule|Those with one or more breast nodules, age 18 or older, upcoming FNAB or surgery and signed informed consent.Those without adverse effects on the test or threatening other candidates, such as mental illness, pregnancy, poor ultrasound image quality, history of breast surgery or breast biopsy, simple cystic nodules, calcification, excessive mass or too small, the S-DetectTM system can not identify the boundary of the tumor, the basic information is incomplete.
3119129|NCT02678000|Experimental|LHW090|"For Part 1, patients will receive 3 doses of LHW090 once daily with escalating doses every 4 days for a total 12 days of treatment.~For Part 2, patients will receive LHW090 once daily for 4 weeks."
3119130|NCT02678000|Placebo Comparator|Placebo|For Part 1, patients will receive matching placebo once daily for 12 days. For Part 2, patients will receive matching placebo once daily for 4 weeks.
3119131|NCT02678039|Experimental|Fluoroscopy|"Real-time fluoroscopic X-ray guidance to confirm placement of an epidural catheter in the spinal epidural space at the desired location.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
3119132|NCT02678039|Active Comparator|Traditional|"The traditional approach for placement of an epidural catheter is used with indirect indicators of placement including palpation of spine and 'loss-of-resistance' to fluid injection.~Following epidural catheter placement, 1/8% bupivacaine is infused at 4ml/hr into the epidural catheter during and after surgery for pain control."
3119133|NCT02678247|Active Comparator|NU-FlexSIV Socket|The Northwestern University Flexible Sub-Ischial Vacuum Socket is a novel socket design for transfemoral amputees.
3119134|NCT02678247|Active Comparator|IC Socket|The Ischial Containment Socket is the standard of care socket design for transfemoral amputees.
3119135|NCT02678286|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 3 doses.
3119136|NCT02678286|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 3 doses.
3119137|NCT02678390|Experimental|Healthy women|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
3119138|NCT02678390|Experimental|Women with prediabetes|"Arm: Evaluation of MCT, aerobic exercise alone and MCT+ aerobic exercise on glucose/ketone/lipid/insulin metabolism in 4-hour visits with repeated blood sampling.~Interventions:~A control day with no MCT and no aerobic exercise.~A 5 day consecutive MCT intake of 30 g/day.~30 minutes of aerobic exercise at 70% to 80% HRR of intensity.~A 5 day consecutive MCT intake of 30 g/day in combination with 30 minutes of aerobic exercise (70% to 80% HRR)/ day for the five days."
3119139|NCT02678416|Experimental|IV Acetaminophen|All participants receive IV acetaminophen as one of 4 interventions in random sequence
3119140|NCT02678416|Experimental|Oral Acetaminophen|All participants receive oral acetaminophen as one of 4 interventions in random sequence
3119141|NCT02678416|Experimental|Placebo|All participants receive placebo as one of 4 interventions in random sequence
3119142|NCT02678416|Experimental|Morphine|All participants receive morphine as one of 4 interventions in random sequence
3119143|NCT02678442|Active Comparator|FNB first, then FNA|In an endoscopic ultrasound-guided procedure, Shark Core Fine Needle Biopsy (FNB) will be performed first, followed by Fine Needle Aspiration (FNA).
3119144|NCT02678442|Active Comparator|FNA first, then FNB|In an endoscopic ultrasound-guided procedure, Fine Needle Aspiration (FNA) will be performed first, followed by Shark Core Fine Needle Biopsy (FNB).
3119145|NCT02678676||Pioglitazone|Participants who previously received pioglitazone in the PROactive study (NCT00174993).
3119146|NCT02678676||Placebo|Participants who previously received Pioglitazone-matching placebo in the PROactive study (NCT00174993).
3119147|NCT02678923|Experimental|MDCO-216|20 mg/kg of MDCO-216 administered intravenously (IV) as a 360 milliliter (mL) infusion over 2 hours on Days 1, 8, 15, 22, and 29
3119148|NCT02678923|Placebo Comparator|Placebo|360 mL of placebo (0.9% sodium chloride [NaCl] solution) infusion, IV, over 2 hours on Days 1, 8, 15, 22, and 29
3119149|NCT02679079|Placebo Comparator|Placebo|Administered once daily for 6 weeks
3119150|NCT02679079|Experimental|Dose Group 1|Administered once daily for 6 weeks
3119151|NCT02679079|Experimental|Dose Group 2|Administered once daily for 6 weeks
3119152|NCT02679222|Experimental|Supplementation|Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
3119153|NCT02679235|Experimental|Triheptanoin|Participant will undergo POST Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night) after a control PRE supplementation imaging protocol.
3119154|NCT02679274|Placebo Comparator|Placebo|Placebo injection (saline) to be received on weeks 0, 1, 4, 5, 8 and 9.
3119155|NCT02679274|Experimental|Testosterone|Testosterone Enanthate injections (25mg/injection females; 100mg/injection males) to be received on weeks 0, 1, 4, 5, 8 and 9.
3119156|NCT02679287|Experimental|Group A|"Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
3119157|NCT02679287|Experimental|Group B|"Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP~SAP=sensor-augmented pump only~USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight~USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control"
3119158|NCT02679469|Experimental|Nalmefene hydrochloride 10 mg|nalmefene 10 mg tablet
3119159|NCT02679573|Experimental|Delafloxacin|IV delafloxacin with potential to switch to oral delafloxacin
3119160|NCT02679573|Active Comparator|Moxifloxacin/Linezolid|IV moxifloxacin with potential to switch to oral moxifloxacin, and potential to switch moxifloxacin to IV linezolid for confirmed MRSA
3119161|NCT02679690|Experimental|Standard dietary sodium education|Standard dietary sodium education provided to patients with heart failure using voice over powerpoint presentation.
3119162|NCT02679690|Experimental|color-coded cue cards|The use of a color-coded cue cards to educate patients with heart failure on dietary sodium. The education regarding the use of the color-coded cue card was provided using a voice over powerpoint presentation.
3119163|NCT02679729|Experimental|Part A, Dose Level 1|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119164|NCT02679729|Experimental|Part A, Dose Level 2|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119165|NCT02679729|Experimental|Part A, Dose Level 3|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119166|NCT02679729|Experimental|Part A, Dose Level 4|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119167|NCT02679729|Experimental|Part A, Dose Level 5|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119168|NCT02679729|Experimental|Part A, Dose Level 6|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119169|NCT02679729|Experimental|Part A, Dose Level 7|Subjects will inhale single doses of AZD5634 or placebo under fasted conditions and will rinse his/her mouth with approximately 100 mL (up to 240 mL) of water which must be swallowed
3119170|NCT02679729|Experimental|Part B, Dose Level 1|Subjects will receive a single dose of IV AZD5634 and after a washout period of 14 days the same subjects will receive a single dose of inhaled AZD5634
3119171|NCT02679755|Experimental|Experimental arm|Palbociclib plus Letrozole
3119172|NCT02679807|Active Comparator|Bifidobacterium lactis Bl-04|2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
3119173|NCT02679807|Placebo Comparator|Placebo|sucrose
3119174|NCT02679911|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 12 weeks on all affected toenails of one foot
3119175|NCT02679911|Active Comparator|Ciclopirox NL|Ciclopirox NL 8% to be applied once daily for 12 weeks on all affected toenails of the opposite foot
3119176|NCT02679976|Experimental|Study Lens (etafilcon A) for Multifocal|All Subjects in this study will wear the same contact lenses. However subjects wil be stratified as Hyperopes or Myopes using a 1:1 allocation. The study lens will be worn for a period of approximately 4 hours to allow lenses to settle on the eyes.
3119177|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg hemagglutinin (HA) antigen stored long-term as monobulk inactivated
3119178|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (monobulk)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored long-term as monobulk MF59 adjuvant
3119179|NCT02680002|Experimental|7.5 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 7.5 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
3119180|NCT02680002|Experimental|15 mcg H5N1 (monobulk) Plus MF59 (vials)|Two 0.5-mL doses, given at Day 0 and 21 consisting of 15 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 vaccine and MF59 stored short-term in vials as MF59 adjuvant
3119181|NCT02680002|Experimental|90 mcg H5N1 (monobulk) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term as monobulk inactivated A/Vietnam/H5N1 antigen formulated and filled in 2015, administered without MF59
3119182|NCT02680002|Experimental|90 mcg H5N1 (vials) without MF59|Two 1.0-mL doses at Day 0 and 21 consisting of 90 mcg HA antigen stored long-term in vials as inactivated A/Vietnam/H5N1 vaccine, administered without MF59
3119183|NCT02680041|Experimental|18F-fluciclovine PET CT|Single intravenous administration of 18F-fluciclovine PET CT.
3119184|NCT02680054|Active Comparator|Arm 1 (usual treatment)|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given at the same time as the insulin for the carbohydrate content BEFORE the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
3119185|NCT02680054|Active Comparator|Arm 2|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given one hour after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
3119186|NCT02680054|Active Comparator|Arm 3|Insulin dose (insulin Aspart, NovoRapid) for the fat and protein in a high-fat, high-protein meal is given two hours after the meal. The dose is calculated on an individual basis according to the usual insulin to carbohydrate ratio for that child.
3119187|NCT02680145|Experimental|Preoperative Pessary Use|All patients will use a pessary for 1-4 weeks preoperatively to reparative surgery for pelvic organ prolapse
3119188|NCT02680158|Experimental|Sequence 1-Intranasal: Extranasal: Sham|Oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device, intranasal (control) application, for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119189|NCT02680158|Experimental|Sequence 2-Intranasal: Sham: Extranasal|Oculeve device, intranasal (test) application for approximately 3 minutes followed by sham device, intranasal (control) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119190|NCT02680158|Experimental|Sequence 3-Extranasal: Intranasal: Sham|Oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes, followed by sham device (control), intranasal application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119191|NCT02680158|Experimental|Sequence 4-Extranasal: Sham: Intranasal|Oculeve device, extranasal (control) application for approximately 3 minutes followed by sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119192|NCT02680158|Experimental|Sequence 5-Sham: Intranasal: Extranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119193|NCT02680158|Experimental|Sequence 6-Sham: Extranasal: Intranasal|Sham device (control), intranasal application for approximately 3 minutes followed by oculeve device, extranasal (control) application for approximately 3 minutes followed by oculeve device, intranasal (test) application for approximately 3 minutes followed by on Day 0. There was rest period of 60 minutes before proceeding to the next application.
3119194|NCT02680301|Other|Ointment Right/Cream Left|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on right side and 0.1% triamcinolone CREAM with wet-wrap dressing on left side of bilateral flare of atopic dermatitis twice daily as instructed.
3119195|NCT02680301|Other|Ointment Left/Cream Right|Pt. will use 0.1% triamcinolone OINTMENT with wet-wrap dressing on left side and 0.1% triamcinolone CREAM with wet-wrap dressing on right side of bilateral flare of atopic dermatitis twice daily as instructed.
3119196|NCT02680314|Active Comparator|Single Dose|single dose of misoprostol
3119197|NCT02680314|Active Comparator|Multiple Dose|multiple doses of misoprostol
3119198|NCT02680457|Active Comparator|Insulin Degludec - Insulin Glargine|Insulin Degludec 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Glargine 10 IU SC every 24 hours for 6 days
3119199|NCT02680457|Active Comparator|Insulin Glargine - Insulin Degludec|Insulin Glargine 10 IU SC every 24 hours for 6 days Washout for 14 days Insulin Degludec 10 IU SC every 24 hours for 6 days
3119200|NCT02680639|Active Comparator|optimal EPAP determination|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be automatically adjusted by the ventilator to find optimal EPAP that abolishes EFL. Peak-to-Peak pressure oscillations will be set at 2.5 cmH2O (centimeters of water)
3119201|NCT02680639|Experimental|Optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator the EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water)
3119202|NCT02680639|Experimental|Optimized EPAP w/ max peak-to-peak|On the BiPAP Synchrony ventilator EPAP (and IPAP) will be set at optimal pressure as determined by the Auto EPAP. Peak-to-Peak pressure oscillations will be set at 5 cmH2O (centimeters of water)
3119203|NCT02680639|Experimental|non-optimized EPAP w/ no peak-to-peak|On the BiPAP Synchrony ventilator EPAP will be set at 4 cmH2O and IPAP will be set at 10 cmH2O (centimeters of water). Peak-to-Peak pressure oscillations will be set at 0 cmH2O (centimeters of water).
3119204|NCT02680756|Experimental|Oral ferric iron compound|30 mg capsules to be taken orally twice a day for 52 weeks
3119205|NCT02680756|Active Comparator|Intravenous iron|Administered as per the local summary of product characteristics (SPC)
3119206|NCT02680834|Experimental|Dual Action Pneumatic Compression Device|ACTitouch dual action pneumatic compression system used daily during wakeful hours for up to 16 weeks.
3119207|NCT02680834|Active Comparator|Multi-layer bandaging|PROFORE or Coban 2 to be worn 24 hours daily for up to 16 weeks.
3119208|NCT02680847|Experimental|ALO-02|One arm, open label, active
3119209|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin
3119210|NCT02681094|Active Comparator|Dapagliflozin+Saxagliptin placebo+Metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Dapagliflozin and Saxagliptin Placebo
3119211|NCT02681094|Active Comparator|Saxagliptin+Dapagliflozin placebo+metformin|5 mg Tablets, Oral, Once daily, 24 weeks for Saxagliptin and Dapagliflozin placebo
3119212|NCT02681172|Experimental|Neuraceq (florbetaben 18F) PET scan|"A single dose of 300 Megabecquerels (8.1 millicuries) Neuraceq will be administered per subject.~The applied florbetaben radioactive dose will be ± 20%."
3119213|NCT02681458||Drug Users|Case group that consisted of drug users with fungal infections
3119214|NCT02681458||Non-drug Users|Control group that consisted of non drug users with fungal infections
3119215|NCT02681510|Experimental|Three drug intervention|varenicline, nicotine patch and nicotine lozenge for 12 weeks
3119216|NCT02681523|Experimental|Single arm study|3 x 3 weekly cycles at the recommended dose of eribulin as the ready to use solution, 1.23 mg/m2, administered intravenously over 2-5 minutes on days 1 and 8 of every 21 day cycle. This will then be followed by 9 weeks of AI treatment, to be followed again by 3 x 3 weekly cycles of eribulin and 9 weeks AI treatment. Patients will remain on treatment for up to 9 months, or until disease progression or unacceptable toxicities, whichever is sooner.
3119217|NCT02681614|Experimental|Uronav|"Participants will undergo a Uronav guided biopsy with Magnetic Resonance Imaging confirmation.~All biopsies will be completed in the outpatient setting in the ambulatory OR prior to routine prostate brachytherapy under general anesthesia."
3119218|NCT02681757|Active Comparator|Control- triple antibiotic ointment|triple antibiotic ointment (TAO) impregnated Adaptic gauze, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
3119219|NCT02681757|Experimental|Variable- mepitel Ag|mepitel Ag, kling or kerlex, cast padding, gypsoma plaster, soft cast material, and coban
3119220|NCT02681809|Experimental|Ocriplasmin 0.0625mg|
3119221|NCT02681809|Experimental|Ocriplasmin 0.125mg|
3119222|NCT02681809|Sham Comparator|Sham injection|
3119223|NCT02682030|Active Comparator|Treatment group A|Subjects randomized to group A will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device for home use. Subjects will be instructed to use the HFCC device 2-3 times per day for 15-30 minutes each. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
3132474|NCT03430206|No Intervention|Control|Control subjects will undergo their scheduled procedure and recovery with the usual care. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
3119224|NCT02682030|Active Comparator|Treatment group B- HFCC and Cough Assist|Subjects randomized to group B will be fitted for and issued a mechanical High Frequency Chest Compression Device (HFCC) device and will also be issued a cough assist device. Subjects will be instructed in the use of both devices. The HFCC device should be utilized 2-3 times per day for 15-30 minutes each followed by a session with the cough assist. Subjects will be instructed to keep a device usage, concomitant medication, and adverse event diary.
3119225|NCT02682056|Other|Single Study Arm|Children and adolescents with diabetes will have blood glucose levels tested using microneedle patches, intravenous (IV) catheter draw, and lancet.
3119226|NCT02682069|Experimental|All patients|There is one arm to this study and all patients will undergo the same procedures. The test of this technology is on a per wound basis where bacteria will fluoresce red and samples will be obtained from the discrete red locations. Microbiology results indicating the presence or absence of bacteria will be correlated to the fluorescence signal in the fluorescent images.
3119227|NCT02682264|Experimental|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) Cream, 1%, applied twice daily to whole face (about 1 gram) and affected areas of trunk (if applicable) for up to an additional 9 months. Over the course of the study, treatment on the face and/or trunk may be discontinued if/when acne clears and re-started if/when acne worsens, according to the assessment of the investigator for each respective treatment area.
3119228|NCT02682381|Experimental|0.025 mg/kg/day Teduglutide|0.025 milligrams per kilogram per day (mg/kg/day) of teduglutide for 24 weeks.
3119229|NCT02682381|Experimental|0.05 mg/kg/day Teduglutide|0.05 mg/kg/day of teduglutide for 24 weeks.
3119230|NCT02682381|Active Comparator|Standard of care|Observational cohort for the 24-week treatment period and 4 week follow-up. The subjects in the standard of care group will follow the same visit schedule as the randomized subjects.
3119231|NCT02682420|Other|endoAVF|
3119232|NCT02682498|Active Comparator|EXPAREL® Bupivacaine Liposome Suspension|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-Liposomal Bupivicaine will be administered at the end of the surgery. A new sustained-release local anesthetic solution (Bupivacaine Liposome Injectable Suspension) will be injected into the soft tissues around the join after surgery. Exparel is a novel-composition of bupivacine in which the drug is dissolved into liposomes which release it slowly over a period of 72 hours.
3119233|NCT02682498|Active Comparator|Standard periarticular joint injection|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
3119234|NCT02682563|Experimental|Dapagliflozin 10mg once daily|Once daily treatment with oral dapagliflozin (forxiga) 10mg for 12 consecutive weeks.
3119235|NCT02682563|Active Comparator|Gliclazide modified release 30mg once daily|Once daily treatment with oral gliclazide MR 30mg for 12 consecutive weeks.
3119236|NCT02682602||Diseased Hip|Subjects will have a diseased hip which requires replacement, which will be implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA.
3119237|NCT02682602||Normal Hip|Subjects will have a normal hip.
3119238|NCT02682602||Implanted Group|All subjects from the Diseased Hip group were implanted with either DePuy Synthes Summit/Pinnacle total hip arthroplasty (THA) or the Corail/Pinnacle THA
3119239|NCT02682784|Experimental|Oxytocin/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to oxytocin.
3119240|NCT02682784|Active Comparator|Placebo/Cocaine User|Individuals who meet criteria for cocaine use disorder and are randomized to placebo.
3119241|NCT02682784|Experimental|Oxytocin/Control|Healthy controls who are randomized to oxytocin.
3119242|NCT02682784|Active Comparator|Placebo/Control|Healthy controls who are randomized to placebo.
3119243|NCT02682823|Experimental|Caregivers|CGs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
3119244|NCT02682823|Experimental|Healthcare Professionals|HCPs will perform injection of SC tocilizumab to a subset of participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
3119245|NCT02682823|Experimental|RA Group 1 (Self-Administration)|Participants with RA will perform self-injection of SC tocilizumab with the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
3119246|NCT02682823|Other|RA Group 2 (Administration by CG)|CGs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Visit 1 (Day 0) will be conducted for administration training, while Visits 2 and 3 (Days 14 and 28) will be conducted for use/performance evaluation.
3119247|NCT02682823|Other|RA Group 3 (Administration by HCP)|HCPs will perform injection of SC tocilizumab to participants with RA using the AI-1000 G2 device. Because enrolled HCPs are to be professionally qualified to deliver SC injections, no administration training will be provided. Visit 1 (Day 0) will be performed by the study nurse. Visits 2 and 3 (Days 14 and 28) will be conducted by the HCP for use/performance evaluation.
3119248|NCT02683083|Experimental|[131I]-SGMIB Anti-HER2 VHH1|
3119249|NCT02683109|Experimental|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
3119250|NCT02683109|Active Comparator|Free combination tiotropium + olodaterol|
3119251|NCT02683161|Other|Open-label trial|All participants will attend approximately 6 study sessions pre-surgery and approximately 6 study sessions post-surgery, during which they will be provided three intervention components aimed at smoking cessation: a medication (varenicline) that has been FDA approved for smoking cessation, contingency management for biological evidence of nonsmoking, and behavioral counseling.
3119252|NCT02683174|Experimental|Single study arm|All enrolled patients will be fitted with a novel ambulatory patch (ZIO®Patch), which continuously records heartbeats for up to 14 days. Brain natriuretic peptide (BNP) and hs-troponin I at 0 and 3 hours post ED attendance
3469345|NCT03887559|Experimental|Intervention group|Group-based stabilization and skill-training combined with individual treatment.
3469346|NCT03887559|Active Comparator|controls|Individual treatment as usual only.
3119253|NCT02683187|Active Comparator|Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, Sitagliptin will be administered.
3119254|NCT02683187|Placebo Comparator|Non-Sitagliptin|The infusion procedures performed during study visits 2 and 3 are identical except that the oral medicine Sitagliptin will only be administered at one of the two visits, with order of Sitagliptin administration determined at random by study staff. In this arm, placebo will be administered
3119255|NCT02683421|Other|Cohort 1|Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
3119256|NCT02683421|Other|Cohort 2|Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
3119257|NCT02683421|Experimental|Cohort 3|RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
3119258|NCT02683421|Experimental|Cohort 4|RA group:200 mcg tilmanocept with 2 mCi Tc 99m
3119259|NCT02683525|Experimental|Sitagliptin|Sitagliptin 600 mg q 12 hours PO starting on Day -1 before transplant to be administered between 8:00 am and 10:00 am then given every 12 hours (total 32 doses) through day +14.
3119260|NCT02683577|Experimental|Telotristat etiprate 500 mg|1 single oral dose (2 x 250-mg tablets)
3119261|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg untrained|Patients receiving Handihaler who have not been trained (real-life use) for over 3 months on its use. Here the investigators want to see that if patients have on-going symptoms but are on Handihaler-Tiotropium 18mcg what is happening PRIOR to proper inhaler technique training - that is their 'real-life' use of the inhaler - to their lung function (large and small airways) and also symptoms or exercise limitation (determined by CAT score) will already be recorded as entry criteria
3119262|NCT02683668|Experimental|Handihaler-Tiotropium 18 mcg trained|Patients will be trained in their use of Handihaler-Tiotropium and asked to take 18 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER proper inhaler technique training on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score)
3119263|NCT02683668|Experimental|Respimat-Tiotropium 5 mcg trained|Patients will be switched to trained Respimat Tiotropium 5 mcg once daily for 14 days to see if their (i) airway lung function and or (ii) clinical symptoms improve. Here the investigators want to see what happens AFTER this efficient device Respimat (trained) compared to PREVIOUS device Handihaler (trained) on large and small airways lung function and also symptoms or exercise limitation (determined by CAT score). The investigators want to see if the properties of the Respimat device with deeper lung deposition (slow velocity and small particles) can improve small airway measures (and indeed large airway measures) that might also be related to an improvement in symptoms.
3119264|NCT02683707|Experimental|PCI without IV opiate|IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
3119265|NCT02683707|Active Comparator|PCI with IV opiate|IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
3119266|NCT02683746|Experimental|Albiglutide active LAI plus Placebo lyophilized DCC PI|Subjects will receive 30 milligrams (mg) of albiglutide liquid drug product via auto injector and matching placebo via lyophilized DCC pen injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
3119267|NCT02683746|Experimental|Albiglutide lyophilized DCC PI plus Placebo LAI|Subjects will receive 30mg of albiglutide lyophilized drug product via DCC pen injector and matching placebo via auto injector for 4 weeks. The dose will then be up-titrated to 50mg albiglutide for the remaining 22 weeks of the study. The study treatment will be administered once weekly by subcutaneous injection in the abdomen, thigh, or upper arm.
3119268|NCT02683772|Experimental|iVAPS with AutoEPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with AutoEPAP on the first night, and on iVAPS with manual EPAP on the second night.
3119269|NCT02683772|Active Comparator|iVAPS with manual EPAP|This is a crossover study. During overnight PSG, Astral device will be set using iVAPS with manual EPAP on the first night, and on iVAPS with AutoEPAP on the second night.
3119270|NCT02683785|Experimental|GSK3196165|Subjects will receive a total of 8 doses of GSK3196165 over a 12-week treatment period.
3119271|NCT02683785|Placebo Comparator|Placebo|Subjects will receive a total of 8 doses of placebo over a 12-week treatment period.
3119272|NCT02683876||Subjects with malodor|individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
3119273|NCT02683876||Healthy control|individuals not complaining of uncontrollable or unpredictable malodor episodes
3119274|NCT02683928|Experimental|GBR 830|Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
3119275|NCT02683928|Placebo Comparator|Placebo|Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.
3119276|NCT02683941|Experimental|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
3119277|NCT02683941|Placebo Comparator|Placebo|120mg every 28 days until disease progression, death, or unacceptable toxicity during the double-blind phase. The patient may enter open-label phase for treatment with Lanreotide.
3119278|NCT02683954||endometriosis|30 women with laparoscopically diagnosed endometriosis. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
3119279|NCT02683954||control|30 women without any laparoscopically detected pelvic endometriotic pathology. This group will be categorized into 3 sub-groups according to the BMI: i) Lean: BMI <25.0 kg/m2. ii) Overweight: BMI ≥25.0 kg/m2 but less than 30 kg/m2. iii) Obese: BMI ≥30 kg/m2.
3119280|NCT02684097|Active Comparator|Tralokinumab|Tralokinumab subcutaneous injection every two weeks for 24 weeks
3119281|NCT02684097|Placebo Comparator|Placebo|Saline subcutaneous injection every two weeks for 24 weeks.
3119282|NCT02684136|Experimental|suvorexant|9 nights of 20 mg suvorexant
3119283|NCT02684136|Placebo Comparator|placebo|9 nights placebo
3119284|NCT02684188|No Intervention|Standard hospital discharge services|Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
3119285|NCT02684188|Experimental|Enhanced rural discharge and transition|Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.
3119286|NCT02684279|Experimental|Dasotraline|4, 6, 8 mg flexibly dosed
3119287|NCT02684344|Experimental|Tamsulosin Group|"Subjects will receive:~0.4mg tamsulosin by mouth nightly for 3 doses prior to the day of surgery and for 2 doses following surgery~education about signs and symptoms of urinary retention"
3119288|NCT02684344|Active Comparator|Education Group|"Subjects will receive:~1) education about signs and symptoms of urinary retention"
3119289|NCT02684357|Placebo Comparator|Placebo (Part A)|Participants were randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119290|NCT02684357|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119291|NCT02684357|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119292|NCT02684370|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119293|NCT02684370|Active Comparator|Ustekinumab (Part A)|Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119294|NCT02684370|Experimental|Risankizumab (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3119295|NCT02684396|Experimental|Cohort 1: TAK-648 0.05 mg|TAK-648 0.05 mg, solution, orally, once on Day 1.
3119296|NCT02684396|Experimental|Cohort 2: TAK-648 0.15 mg|TAK-648 0.15 mg, solution, orally, once on Day 1.
3119297|NCT02684396|Experimental|Cohort 3: TAK-648 0.35 mg|TAK-648 0.35 mg, solution, orally, once on Day 1.
3119298|NCT02684396|Experimental|Cohort 4: TAK-648 0.7 mg|TAK-648 0.7 mg, solution, orally, once on Day 1.
3119299|NCT02684396|Experimental|Cohort 5: TAK-648 0.85 mg|TAK-648 0.85 mg, solution, orally, once on Day 1.
3119300|NCT02684396|Placebo Comparator|Cohort 1-5: Placebo|TAK-648 placebo-matching solution, orally, once on Day 1.
3119301|NCT02684435|Experimental|Perflutren lipid microsphere|Activate by shaking for 45 seconds using VIALMIX. Use activated product within 5 minutes. Infusion: The recommended infusion dose for activated perflutren is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute per P.I. approval
3119302|NCT02684591|Experimental|Aramchol 600 mg orally daily|"Total 600 mg Aramchol (200 mg/tablet and 400 mg/tablet) per day once a day orally for 12 weeks.~Intervention: Aramchol"
3119303|NCT02684591|Placebo Comparator|Placebo|Placebo in the form of a tablet; Two bottles will be given to patient and they will take two pills, once a day orally for 12 weeks.
3119304|NCT02684604||unexplained infertility patients|44 patients diagnosed to have unexplained infertility
3119305|NCT02684604||Fertile women|44 fertile women
3119306|NCT02684617|Experimental|rrCLL Cohort|Participants with refractory chronic lymphocytic leukemia (rrCLL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
3119307|NCT02684617|Experimental|rrMM Cohort|Participants with relapsed or refractory multiple myeloma (rrMM) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
3119308|NCT02684617|Experimental|rrDLBCL Cohort|Participants with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 7 mg/m^2 on Cycle 1 Day 1, and infusion of dinaciclib 10 mg/m^2 alone on Cycle 1 Day 8. Participants then received an infusion of pembrolizumab 200 mg followed by infusion of dinaciclib 14 mg/m^2 on Cycles 2-35 Day 1 and infusion of dinaciclib 14 mg/m^2 alone on Cycles 2-35 Day 8. Each cycle is 21 days.
3119309|NCT02684630|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
3119310|NCT02684630|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection, with or without other components, will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System).
3119311|NCT02684851|Placebo Comparator|Placebo|Inactive
3119312|NCT02684851|Active Comparator|Tranexamic|Tranexamic acid: anti-fibrinolytic agents
3119313|NCT02684942|Active Comparator|Meperidine,Fentanyl,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy.
3119314|NCT02684942|Active Comparator|Fentanyl,Meperidine,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and fourth fraction of brachytherapy. And injection fentanyl 1 umg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and third fraction of brachytherapy.
3119315|NCT02684942|Active Comparator|Meperidine,Meperidine,Fentanyl,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy.
3119316|NCT02684942|Active Comparator|Fentanyl,Fentanyl,Meperidine,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at third and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and second fraction.
3119317|NCT02684942|Active Comparator|Meperidine,Fentanyl,Fentanyl,Meperidine|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score more than 4 at second and third fraction of brachytherapy.
3119318|NCT02684942|Active Comparator|Fentanyl,Meperidine,Meperidine,Fentanyl|Injection meperidine 1 mg./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at second and third fractionof brachytherapy. And injection fentanyl 1 ug./kg. to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4 at first and fourth fraction of brachytherapy.
3119319|NCT02684981||Cohort A - VKA to Pradaxa switcher|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
3119320|NCT02684981||Cohort B - newly assigned to treatment|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
3119321|NCT02685007||Inpatients|Inpatients planned for laparoscopic surgery, in the field of gynecology, urology and visceral surgery will be documented from of surgery until date of discharge from hospital
3119322|NCT02685033|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was < 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.
3119323|NCT02685033|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
3119324|NCT02685072|Experimental|TNP + Progesterone|Transdermal Nicotine Patch + Progesterone (200 mgs BID)
3119325|NCT02685072|Placebo Comparator|TNP + Placebo|Transdermal Nicotine Patch + Placebo (for Progesterone)
3119326|NCT02685267|Active Comparator|Docetaxel/Prednisone|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout
3119327|NCT02685267|Active Comparator|Docetaxel/Prednisone + Enzalutamide|Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.
3119328|NCT02685293|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
3119329|NCT02685293|Placebo Comparator|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
3119330|NCT02685436|Other|omeprazole and domperidone|wheezy infants with GERD will receive 12 weeks of domperidone (0.2mg/kg/day t.d.s.) and omeprazole (10 mg/once/day).
3119331|NCT02685488|Active Comparator|Transcranial Ultrasound Power|Transcranial Ultrasound Power
3119332|NCT02685488|Sham Comparator|Transcranial Ultrasound Sham|Transcranial Ultrasound Sham. Unknown to both participants and experimenters, the ultrasound will not stimulate.
3119333|NCT02685566|Experimental|FFDM Plus DBT|Breast Images with FFDM and DBT
3119334|NCT02685566|Active Comparator|Full-Field Digital Mammography|Breast Images with FFDM alone
3119335|NCT02685826|Experimental|Cohort A: High risk, TNE|"High risk, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle"
3119336|NCT02685826|Experimental|Cohort B: >=65 years old, TNE|">= 65 years old, transplant non-eligible [TNE], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance [CrCl]) value on Days 1 to 21 of each 28-day treatment cycle~Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles"
3119337|NCT02685826|Experimental|Cohort C: High risk, Post-transplant|"High risk, post-transplant NDMM participants were administered the following as maintenance therapy:~Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle~Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle"
3119338|NCT02685956||Vela Sentosa SA HSV1/2 PCR Test|Male and female subjects of any age with sample collected from a lesion and submitted to a clinical laboratory for the purpose of testing for the presence of HSV1 or HSV2 and diagnosing HSV infection.
3132678|NCT03444155|Active Comparator|Synthetic Vitamin B-complex first, then Natural Panmol-B-Complex|Participants first received a Synthetic Vitamin B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks. After a wash-out period of 2 weeks, they then received a natural Vitamin B-complex, i.e., Panmol-B-complex - B1 (2.93 mg), B2 (3.98 mg), B3 (29.85 mg), B5 (10.95 mg), B6 (3.38 mg), B7 (0.108 mg), B9 (0.69 mg), B12 (8.85 µg) daily each morning for 6 weeks.The study finished after the second wash-out period for another 6 weeks.
3119339|NCT02685995|Active Comparator|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
3119340|NCT02685995|Active Comparator|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
3119341|NCT02686034|Active Comparator|gammaCore-S|Treatment of up to 5 migraine attacks with the Active gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
3119342|NCT02686034|Sham Comparator|gammaCore-S Sham|Treatment of up to 5 migraine attacks with the Sham gammaCore-S non-invasive vagus nerve stimulator device which delivers a mild electrical signal in the vicinity of the vagus nerve
3119343|NCT02686138|Experimental|50mg BID|Tenapanor, 50mg BID (100mg total)
3119344|NCT02686138|Placebo Comparator|Placebo|Placebo
3119345|NCT02686164|Experimental|Lenvatinib + midazolam|Participants with histologically confirmed unresectable or refractory solid tumors.
3119346|NCT02686437|Experimental|Increasing Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the lesser tubercle of the humerus. Over the course of the 4 weeks of care, the tension of the Intervention Group's tape will systemically increase based on the following timelines:~Week 1: 0% tension Week 2: 25% tension Week 3: 50% tension Week 4: 75% tension"
3119347|NCT02686437|Sham Comparator|Control Tension|"The kinesiology tape will be applied to the shoulder complex to influence proper activation of the rotator cuff muscles, specifically the supraspinatus and infraspinatus. The clinician applied the tape in an I strip from the vertebral border of the scapula to the greater tuberosity of the humerus. Over the course of the 4 weeks of care, the tension of the Control Group's tape will remain at 0% tension"
3119348|NCT02687035|Experimental|TAVR|Intermediate risk patients receiving transcatheter aortic valve replacement (TAVR)
3119349|NCT02687126|Other|Pediatric Cardiac Surgical Patients|Central Venous Catheterization
3119350|NCT02687139|Experimental|18F-DCFPyL PET/CT|
3119351|NCT02687191|Experimental|PF-05230907 (Cohort 1)|PF-05230907 IV bolus injection
3119352|NCT02687191|Experimental|PF-05230907 (Cohort 2)|PF-05230907 IV bolus injection
3119353|NCT02687191|Experimental|PF-05230907 (Cohort 3)|PF-05230907 IV bolus injection
3119354|NCT02687191|Experimental|PF-05230907 (Cohort 4)|PF-05230907 IV bolus injection
3119355|NCT02687191|Experimental|PF-05230907 (Cohort 5)|PF-05230907 IV bolus injection
3119356|NCT02687191|Experimental|PF-05230907 (Cohort 6)|PF-05230907 IV bolus injection
3119357|NCT02687191|Experimental|PF-05230907 (Cohort 7)|PF-05230907 IV bolus injection
3119358|NCT02687191|Experimental|PF-05230907 (Cohort 8)|PF-05230907 IV bolus injection
3119359|NCT02687191|Experimental|PF-05230907 (Cohort 9)|PF-05230907 IV bolus injection
3119360|NCT02687191|Experimental|PF-05230907 (Cohort 10)|PF-05230907 IV bolus injection
3119361|NCT02687191|Experimental|PF-05230907 (Cohort 11)|PF-05230907 IV bolus injection
3119362|NCT02687191|Experimental|PF-05230907 (Cohort 12)|PF-05230907 IV bolus injection
3119363|NCT02687191|Experimental|PF-05230907 (Cohort 13)|PF-05230907 IV bolus injection
3119364|NCT02687191|Experimental|PF-05230907 (Cohort 14)|PF-05230907 IV bolus injection
3119365|NCT02687191|Experimental|PF-05230907 (Cohort 15)|PF-05230907 IV bolus injection
3119366|NCT02687217|No Intervention|Group A: Control|Group A: Control- Received no supplemental oxygen throughout the surgery and received oxygen at 4l/min. in 2hrs postoperatively
3119367|NCT02687217|Experimental|Group B: Test|Group B: Test- Received hyperoxygenation more than or equal to 50% throughout the surgery and received oxygen at 6l/min. upto 2 hrs postoperatively.
3119368|NCT02687412|Experimental|Fast-track Surgery|Pre-operative: Assessment, counseling and education; preoperative nutritional drink up to 4 h prior to surgery, bowel preparation, only oral intestinal cleaner，antimicrobial prophylaxis and skin preparation; preoperative treatment with carbohydrates (patients without diabetes). Intraoperative : fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia; avoiding hypothermia keeping temperature at 36 ±0.5℃, antiemetics at end of anaesthesia. Post-operative : Postoperative glycaemic control; postoperative nausea and vomiting (PONV) control; early postoperative diet(3-6 h after surgery).
3119369|NCT02687412|Other|Traditional surgery|"pre-operative assessment：pre-operative fasting at least 8h, bowel preparation for traditional surgery, Antimicrobial prophylaxis and skin preparation or mechanical bowl until liquid stool Intraoperative: keeping the intra-operative lowtemperature at 34.7±0.6 degree centigrade.~Post-operative: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust"
3119370|NCT02687451|Experimental|Oxymorphone HCl Open-Label Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; open-label, single-dose, dose selection phase.
3119371|NCT02687451|Experimental|Oxymorphone HCl Multiple-Dose Phase|Oxymorphone HCl Immediate Release Oral Liquid and Oxymorphone HCl Injection; placebo controlled, randomized, double-blinded multiple-dose phase.
3119372|NCT02687451|Placebo Comparator|Placebo|Sodium Chloride 0.9% solution; comparator for multiple-dose phase.
3119373|NCT02687529||Low Risk|Tested with CST001
3119374|NCT02687529||Known Risk|Tested with CST001
3119375|NCT02687542|Placebo Comparator|Placebo|Placebo
3119376|NCT02687542|Experimental|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose level (1 mg QD)
3119377|NCT02687542|Experimental|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
3119378|NCT02687542|Experimental|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751 higher middle dose 2 (7 mg QD)
3119379|NCT02687542|Experimental|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
3119380|NCT02687815|Experimental|vitamin D3|Cholecalciferol (Vitamin D3) 4000 IU oral gel cap daily
3119381|NCT02687815|Placebo Comparator|placebo|placebo formulations will be in gel cap form and identical to the active drug
3119382|NCT02687919|Experimental|Modified Paleo Diet Intervention (MPDI)|Consumed a modified Paleo diet, described as nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
3119383|NCT02687919|No Intervention|Usual Care|Typical physician recommendations for MS.
3119384|NCT02688153|Active Comparator|EDWARDS INTUITY|EDWARDS INTUITY Valve System, Model 8300A
3119385|NCT02688153|Active Comparator|Stented aortic bioprostheses|Stented aortic bioprostheses
3119386|NCT02688192|Active Comparator|Arm I (Intervention)|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~Participate in a fitness program which includes:~8 group meetings of 90 minutes weekly~Behavioral internet based intervention engage in private social support messaging within the app and Facebook private groups and mobile app"
3119387|NCT02688192|Active Comparator|Arm II (Waitlist Control [WLC])|"Assessment including~Wear an electronic accelerometer~Quality of life assessment~Physical fitness evaluation~After waiting 6 months they will begin the fitness program as described in Arm I"
3119388|NCT02688218|Experimental|Aerobic First, Resistance Second|Subjects will complete three 15 minute periods of aerobic exercise, with 10 minute recovery between each period. This will be followed by 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises.
3119389|NCT02688218|Experimental|Resistance First, Aerobic Second|Subjects will complete 5-15 minute periods of up to 7 activities of daily living with an additional 20 minute period of resistance exercise, such as straight leg raises. This will be followed by three 15 minute periods of aerobic exercise, with 10 minute recovery between each period.
3119390|NCT02688387|Experimental|Part 1|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.
3119391|NCT02688387|Experimental|Part 2|Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.
3119392|NCT02688387|Experimental|Part 3|Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.
3119393|NCT02688556|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar ophthalmic solution
3119394|NCT02688556|Placebo Comparator|Vehicle|vehicle of OTX-101
3119395|NCT02688621|Active Comparator|Internet only|Participants will be required to attend a weekly Internet chat session with your group members and one of the behavioral weight control therapists. Participants will learn the principles of managing eating and exercise behaviors in weekly, hour-long chat sessions and by completing weekly lessons. Participants are asked to self-monitor foods and exercise through the use of a smartphone ap. Participants will wear a tracking device that monitors steps. All participants will be contacted via e-mail individually, by their group leader who will monitor their progress and offer advice and encouragement. Meetings are weekly for 24 weeks and monthly for 12 months.
3119396|NCT02688621|Experimental|Internet + Incentives|Participants are given the same intervention as described for the internet only group, with the exception that they will have the opportunity to earn financial incentives. Financial incentives will be based on participants weight loss, and compliance with certain weight loss behaviors including meeting exercise goals, self-monitoring foods consumed, and daily weighing and reporting.
3119397|NCT02688764|Experimental|PA21 (Velphoro®)|"PA21 (Velphoro®), chewable tablets 500 mg iron~PA21 (Velphoro®), chewable tablets 250 mg iron~PA21 (Velphoro®), powder for oral suspension 500 mg iron~PA21 (Velphoro®), powder for oral suspension 250 mg iron~PA21 (Velphoro®), powder for oral suspension 125 mg iron"
3119398|NCT02688764|Active Comparator|Calcium Acetate (Phoslyra®)|Calcium Acetate (Phoslyra®) - Oral Solution: 667 mg calcium acetate per 5 mL.
3119399|NCT02688829|Experimental|treatment group|Implantation of the rapamycin target-eluting coronary stent system (Firehawk)in patients with coronary heart disease.
3119400|NCT02688842|Experimental|treatment group|Implantation of the released specification (38mm) of FirehawkTM rapamycin target-eluting coronary stent systems
3119401|NCT02688868|Experimental|new specifications (Diameter 2.25mm)of Firehawk stent|Evaluation of new specifications (Diameter 2.25mm) of FirehawkTM in the treatment of coronary heart disease
3119402|NCT02688933|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
3119403|NCT02688933|Active Comparator|Lantus|Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
3119404|NCT02689063|Experimental|Maxigesic IV|intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
3119405|NCT02689063|Active Comparator|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
3119406|NCT02689063|Active Comparator|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
3119407|NCT02689063|Placebo Comparator|Placebo IV|Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
3119408|NCT02689076|Experimental|HIE Notification plus Care Coordination|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) plus post-hospital geriatric care transitions intervention
3119409|NCT02689076|Active Comparator|HIE Notification alone|VA provider notification of non-VA hospitalization via electronic health information exchange (HIE) followed by usual post-hospital care
3119410|NCT02689076|No Intervention|Usual Care (No HIE Notification and No Care Coordination)|Absence of VA provider notification of non-VA hospitalization via HIE plus Absence of post-hospital geriatric care transitions intervention [Usual Care]
3119411|NCT02689154|Experimental|W8Loss2Go App|Subjects will complete all stages of W8Loss2Go mHealth intervention.
3119412|NCT02689206|Experimental|GSK1278863 10 mg|Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
3119413|NCT02689206|Experimental|GSK1278863 15 mg|Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
3119414|NCT02689206|Experimental|GSK1278863 25 mg|Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
3119415|NCT02689206|Experimental|GSK1278863 30 mg|Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).
3119416|NCT02689206|Placebo Comparator|Placebo|Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).
3119417|NCT02689219|Experimental|CD30 positive|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
3119418|NCT02689219|Experimental|CD30 negative/unknown|Brentuximab vedotin, 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) will be administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
3119419|NCT02689804|Other|Normal-BMI|Women with normal BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
3119420|NCT02689804|Other|Obese-BMI|Women with obese BMI will receive the first emergency contraception (EC) dose and complete pharmacokinetics (PK) assessments; then return to the clinic after at least 8 days to receive the second study drug and complete the same assessments. The study drugs Levonorgestrel (LNG-EC) and Ulipristal Acetate (UPA-EC) will be given in random order.
3119421|NCT02689973|Experimental|Self-efficacy|The self-efficacy intervention protocol included following behavior change techniques (BCT; Michie et al., 2011): barrier identification, prompting focus on past success, and prompting self-talk. Applications of all BCT included references to self-efficacy beliefs. The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up).
3119422|NCT02689973|Experimental|Planning|"The following BCT were included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.~The intervention was integrated into health promotion-nutrition education program (8h). The intervention was applied twice (the baseline and 2-month follow-up)."
3119423|NCT02689973|Experimental|Combined planning+self-efficacy|This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
3119424|NCT02689973|Active Comparator|Education|The education group received extended physical activity education program. The physical activity education was integrated into health promotion-nutrition education program.The education program was applied twice (the baseline and 2-month follow-up).
3119425|NCT02690168||Healthy Men|
3119426|NCT02690181|Experimental|GBS NoAdj/GBS NoAdj|Subjects who had received unadjuvanted GBS Trivalent Vaccine in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119427|NCT02690181|Experimental|GBS Alum/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with alum adjuvant in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119428|NCT02690181|Experimental|GBS MF59 Full/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with full dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119429|NCT02690181|Experimental|GBS MF59 Half/GBS NoAdj|Subjects who had received GBS Trivalent Vaccine with half dose of MF59 in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119430|NCT02690181|Experimental|Placebo/GBS NoAdj|Subjects who had received placebo in parent study V98_06 (205468 - NCT01150123) and received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119431|NCT02690181|Experimental|Naive/GBS NoAdj|Healthy non-pregnant female subjects aged 22 through 46 years inclusive on the day of informed consent who had not received any GBS vaccine in the past and who received a single dose of unadjuvanted GBS Trivalent Vaccine in V98_06E1 (205421 - NCT02690181).
3119432|NCT02690194|Placebo Comparator|Placebo Group|"Pre-Placebo therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PLACEBO THERAPY SESSION~Post-Placebo therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
3119433|NCT02690194|Experimental|Experimental (Buddhify) Group|"Pre-Buddhify therapy~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~BUDDHIFY THERAPY SESSION~Post-Buddhify therapy/Pre-procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
3119434|NCT02690194|No Intervention|Control Group|"Pre-Procedure~Blood pressure, pulse, and respiration rate~State-Trait Anxiety Inventory~PROCEDURE~Post-procedure -Rate pain level of procedure"
3119435|NCT02690207|Experimental|HZ/su Group|Subjects received Herpes Zoster subunit vaccine, administered intramuscularly (IM) in the deltoid of the non-dominant arm
3119436|NCT02690558|Experimental|pembrolizumab, gemcitabine and cisplatin|There is one arm in this study. Subjects will receive Pembrolizumab 200mg IV on day 1 in combination with cisplatin 35mg/m2 and gemcitabine 1000mg/m2 on day 1 and day 8 every 3 weeks for 4 cycles over 12 weeks.
3119437|NCT02690649|Experimental|Health Messaging (Non-Procedural)|"PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use."
3119438|NCT02690649|No Intervention|No Health Messaging|"No PHR messaging of tailored health education pertinent to non-valvular atrial fibrillation and anticoagulant use.~Standard care, training on the use of MyChart and the AdhereTech smart pill bottle, medication adherence monitored with Surescripts e-prescribing software and AdhereTech smart pill bottle use"
3119439|NCT02690701|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by monthly dosing starting at Week 8 through Week 48 inclusive
3119440|NCT02690701|Placebo Comparator|Placebo then Secukinumab|"Eligible patients received placebo doses once weekly at Baseline, Weeks 1, 2, 3 and 4 followed by a dose after four weeks at Week 8.~Beginning with the Week 12 dose, participants were switched to treatment with secukinumab 300 mg and were dosed once weekly at Weeks 12, 13, 14, 15 and 16 followed by monthly dosing through Week 48 inclusive."
3119441|NCT02690714|Experimental|6.6 mg/kg Plasminogen (Human) Intravenous|6.6 mg/kg Plasminogen (Human) Intravenous given every 2 to 4 days by a 10- to 30-minute intravenous infusion
3119442|NCT02690727|Experimental|RP6530 in fast condition|A single dose of RP6530 following fast condition
3119443|NCT02690727|Experimental|RP6530 in fed condition|A single dose of RP6530 following fed condition
3119444|NCT02690935|Experimental|2LALERG|"Interleukin 1: 17 CH Interleukin 4: 17-27 CH Interleukin 5: 17 CH Interleukin 6: 17 CH Interleukin 10: 17 CH Interleukin 12: 9 CH Interleukin 13: 17 CH Tumor Necrosis Factor Alpha: 17 CH Transforming Growth Factor Beta: 5 CH Pulmo histaminum: 15 CH SNA-HLA-II: 18 CH~Impregnated on lactose saccharose globules (380 mg/capsule)"
3119445|NCT02690935|Placebo Comparator|Placebo|Non-impregnated lactose saccharose globules (380 mg/capsule)
3119446|NCT02690948|Experimental|Pembrolizumab Monotherapy|Participants who previously received vismodegib and subsequently progressed will receive pembrolizumab IV over 30 minutes on day 1. Cycles are every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3119447|NCT02690948|Experimental|Pembrolizumab plus Vismodegib Combination Therapy|Participants who have not progressed while receiving vismodegib will receive pembrolizumab IV over 30 minutes on day 1 and take vismodegib 150 mg by mouth daily. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3119448|NCT02690974|Other|LCZ696 (sacubitril / valsartan)|All patients were initiated on either LCZ696 at 24 mg sacubitril / 26 mg valsartan or LCZ696 at 49 mg sacubitril / 51 mg valsartan bid for 2-4 weeks and were up-titrated to the next higher dose for another 2 - 4 weeks as applicable.
3119449|NCT02691013|Placebo Comparator|Placebo|Patients will receive a Placebo tablet every evening.
3119450|NCT02691013|Active Comparator|Ramelteon|Patients will receive Ramelteon 8mg every evening.
3119451|NCT02691143|Experimental|Manipulation plus Tape|"The Tape Group will have TheraBand® Kinesiology Tape, an elastic therapeutic tape (ETT), applied immediately following cervical manipulation from a licensed chiropractor. The taping protocol will be applied by the investigator and consist of a Y strip applied at 25% tension running superior to inferior from the hair line to T1-2 and a horizontal I strip applied at 50% tension at the site of pain."
3119452|NCT02691143|No Intervention|Manipulation Only|The control group will receive manipulation from a licensed chiropractor only
3119453|NCT02691247|Experimental|CLBS03 Low Dose|A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution.
3119454|NCT02691247|Experimental|CLBS03 High Dose|A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution.
3119455|NCT02691247|Placebo Comparator|Placebo|A single infusion of placebo, consisting of the infusion solution only
3119456|NCT02691260|No Intervention|no incentives|Participants do not receive financial incentives.
3119457|NCT02691260|Active Comparator|incentives for dietary self-monitoring|Participants receive financial incentives for dietary self-monitoring.
3119458|NCT02691260|Active Comparator|incentives for interim weight loss|Participants receive financial incentives for interim weight loss.
3119459|NCT02691260|Experimental|incentives for both|Participants receive incentives for dietary self-monitoring and interim weight loss.
3119460|NCT02691416|Experimental|propofol postconditioning|1.2mg/L propofol
3119461|NCT02691416|Experimental|sevoflurane|0.5%-2% sevoflurane
3119462|NCT02691455|Active Comparator|Second Aqueous Shunt|"Second Aqueous Shunt~Either a Baerveldt Glaucoma Implant 350-mm2 BG101-350 or an Ahmed Model FP7 Flexible Plate must be used for all participants unless there is insufficient space, in which case a Baerveldt Glaucoma Implant 250-mm2 BG103-250 may be used."
3119463|NCT02691455|Active Comparator|Transscleral Cyclophotocoagulation|Transscleral Diode Laser Cyclophotocoagulation
3119464|NCT02691468|Active Comparator|PVC DLT|"After the induction of general anesthesia, a left sided PVC DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of PVC DLT is calculated from difference in tracheal distance between supine and lateral position."
3119465|NCT02691468|Active Comparator|silicon DLT|"After the induction of general anesthesia, a left sided silicon DLT was placed by the anesthesiologist using direct laryngoscopy. Tube position was confirmed with fiberotic bronchoscope.~The first set of measurements tracheal distance(from tracheal carina to proximal tip of DLT) and bronchial distance(from bronchial carina to distal tip of DLT) measured by bronchoscope is taken in supine position .~The second set of measurements is taken in lateral position after position change.~The displacement of silicon DLT is calculated from difference in tracheal distance between supine and lateral position."
3119466|NCT02691494|Placebo Comparator|Placebo|Placebo for both elagolix twice daily (BID) and norethindrone acetate (E2/ NETA) once daily (QD)
3119467|NCT02691494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
3119468|NCT02691494|Experimental|Elagolix + E2/NETA|Elagolix 300 mg BID and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
3119469|NCT02691507|Active Comparator|Positive Control|Marketed - EpiCeram(R) Skin Barrier Emulsion: Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin.
3119470|NCT02691507|Experimental|Experimental|Not Yet Marketed - 1% Colloidal Oatmeal Balm: Apply at least once per night or more if needed.
3119471|NCT02691572|Active Comparator|Wound Infiltration|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
3119472|NCT02691572|Experimental|Transversus abdominis plane block|Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.
3119473|NCT02691702|Experimental|Multiple Doses - Part A|Multiple ascending doses administered in the morning to healthy adult subjects in a parallel study design
3119474|NCT02691702|Experimental|Multiple Dose - Part B|Multiple ascending doses administered in the evening to healthy adult subjects in a parallel study design
3119475|NCT02691702|Experimental|Multiple Doses - Elderly|Multiple ascending doses administered to elderly subjects
3119476|NCT02691741|Experimental|TFNT00|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL, bilateral implantation
3119477|NCT02691741|Active Comparator|839MP|AT LISA® tri IOL, bilateral implantation
3119478|NCT02691936|Experimental|CO2 fractionated vaginal laser|Postmenopausal women will undergo treatment intravaginally with the fractional microablative CO2 laser system MonaLisa Touch vaginal laser protocol x 3 time points at baseline, 6 weeks and 3 months.
3119479|NCT02691936|Active Comparator|Estrogens, Conjugated (USP)|The women in the vaginal estrogen group will be prescribed and asked to administer the conjugated estrogen cream 0.5 g of cream equivalent to 0.625 mg of conjugated estrogen.
3119480|NCT02691962|Experimental|Xen Matrix AB|Subjects treated with Xen Matrix AB
3119481|NCT02692040|Experimental|12-24 mg (B1) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 24 mg."
3119482|NCT02692040|Experimental|6-10 mg (B2) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 10 mg."
3119483|NCT02692040|Experimental|5-16 mg (B3) dose of G3215|"G3215 multiple dose, subcutaneous injection:~5 doses over a 4 week treatment period at escalating doses to a max of 16 mg."
3119484|NCT02692040|Experimental|3.2mg (C) infusion pump dose of G3215|G3215 subcutaneous infusion over a 4 day treatment period at escalating doses to a max of 3.2 mg (with either the first or last day administering infusion of placebo [saline]).
3119485|NCT02692040|Placebo Comparator|Placebo (B) - saline|5 subcutaneous injections of 0.9% saline, over a 4 week treatment period
3119486|NCT02692040|Placebo Comparator|Placebo (A) - saline|Single subcutaneous injection of 0.9% saline
3119487|NCT02692040|Experimental|0.1 mg dose G3215 (A1)|0.1 mg G3215 single dose, subcutaneous injection
3119488|NCT02692040|Experimental|0.5 mg dose G3215 (A1)|0.5 mg G3215 single dose, subcutaneous injection
3119489|NCT02692040|Experimental|1.5 mg dose G3215 (A1)|1.5 mg G3215 single dose, subcutaneous injection
3119490|NCT02692040|Experimental|4 mg dose G3215 (A2) with varied formulation|4 mg G3215 single dose, subcutaneous injection
3119491|NCT02692040|Experimental|4 mg dose G3215 (A3) with varied formulation|4 mg G3215 single dose, subcutaneous injection
3119492|NCT02692040|Experimental|4 mg dose G3215 (A4) with varied formulation|4 mg G3215 single dose, subcutaneous injection
3119493|NCT02692040|Experimental|4 mg dose G3215 (A5) with varied formulation|4 mg G3215 single dose, subcutaneous injection
3119494|NCT02692040|Experimental|8 mg dose G3215 (A7)|8 mg G3215 single dose, subcutaneous injection
3119495|NCT02692040|Experimental|10 mg dose G3215 (A6)|10 mg G3215 single dose, subcutaneous injection
3119496|NCT02692040|Experimental|12 mg dose G3215 (A8)|12 mg G3215 single dose, subcutaneous injection
3119497|NCT02692040|Experimental|16 mg dose G3215 (A9)|16 mg G3215 single dose, subcutaneous injection
3119498|NCT02692040|Experimental|32 mg dose G3215 (A10)|32 mg G3215 single dose, subcutaneous injection
3119499|NCT02692040|Experimental|48 mg dose G3215 (A11)|48 mg G3215 single dose, subcutaneous injection
3119500|NCT02692209||FFDM Plus DBT|FFDM Plus DBT images are being evaluated as compared to FFDM alone
3119501|NCT02692209||Full Field Digital Mammography|Fujifilm FFDM alone images are being evaluated as compared to FFDM + DBT
3119502|NCT02692235|Experimental|carnitine|24 weeks l-carnitine-l-tartrate supplementation
3119503|NCT02692235|Placebo Comparator|placebo|24 weeks isonitrogenous supplementation
3119504|NCT02692391|Placebo Comparator|Placebo|6 doses, Q8hrs for a total period of 48 hours
3119505|NCT02692391|Active Comparator|Indomethacin suppository|Loading dose :100mg Maintenance dose: 50 mg, Q8hrs for a total period of 48 hours (5 doses)
3119506|NCT02692417|Experimental|Posterior Tibial Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
3119507|NCT02692417|Experimental|Dorsal Genital Nerve Stimulation Group|Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
3119508|NCT02692482|Experimental|polyurethane foam|Hydrocellular polyurethane foam multilayer dressing shaped for the sacral area
3119509|NCT02692482|Active Comparator|standard care|
3119510|NCT02692495||Body odor|individuals self-reporting recurrent episodes of uncontrollable body odor with or without halitosis
3119511|NCT02692495||Halitosis|individuals with extra-oral halitosis, not complaining of body odors
3119512|NCT02692560|Experimental|I-STAND|Participants randomly assigned to the I-STAND intervention group will receive 2 in-person health coaching sessions and 4 biweekly phone-based health coaching sessions. They will receive a wristband that gives a mild vibration after 20 minutes of inactivity and will be encouraged to stand if possible after each inactivity alert. Participants may also choose to receive biweekly email reminders in the weeks between coaching calls. They will also receive a workbook with content around reducing sitting time.
3119513|NCT02692560|Active Comparator|Healthy Living|Participants randomly assigned to the Healthy Living enhanced usual care control group will receive 1 in-person health coaching session and 5 biweekly check-in letters by mail. They will receive a workbook with general healthy living topics that are not expected to impact sitting time. All content is taken from Kaiser Permanente Washington's website and is available to all members. Participants will select topics of interest and review them on their own with no further health coaching.
3119514|NCT02692586|Experimental|FlowTriever System|
3119515|NCT02692703|Experimental|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir (300 mg/120 mg) coformulated once daily (QD) for 12 weeks.
3119516|NCT02692716|Experimental|Oral semaglutide|
3119517|NCT02692716|Placebo Comparator|Placebo|
3119518|NCT02692755|Experimental|Palbociclib + Letrozole or Fulvestrant|
3119519|NCT02692859|Experimental|Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.)|Hib conjugate vaccine
3119520|NCT02692859|Active Comparator|Vaccine (Walvax Biotechnology Co., LTD.)|Hib conjugate vaccine
3119521|NCT02693106|Experimental|Ketogenic potential|"Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated followed by a period of 4-hour with multiple blood sampling.~Intervention 1: Control; no supplement Intervention 2: 5 g of leucine Intervention 3: 3.6 g of butyrate Intervention 4: 7.2 g of butyrate Intervention 5: 5 g of octanoate Intervention 6: 10 g of octanoate Intervention 7: 1.95 g of carnitine Intervention 8: 65 g of butter fraction rich in MCT"
3119522|NCT02693119|Experimental|Group 1|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the left eye (OS) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
3119523|NCT02693119|Experimental|Group 2|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to the right eye (OD) and one drop of vehicle topical ophthalmic solution BID in the fellow eye
3119524|NCT02693119|Experimental|Group 3|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
3119525|NCT02693119|Experimental|OLE|One drop elamipretide (MTP-131) 1% topical ophthalmic solution BID applied to both eyes (OU).
3119526|NCT02693132|Experimental|Supervised (SUP-PA)|Weight loss intervention that focuses on supervised physical activity and involves an energy restricted diet. Physical activity will be supervised by trained staff.
3119527|NCT02693132|Experimental|Unsupervised (UNSUP-PA)|Weight loss intervention that focuses on unsupervised physical activity (identical dose to SUP-PA) and involves an energy restricted diet (identical diet to SUP-PA). Physical activity will be self-monitored but no activity tracker will be used as an intervention tool.
3119528|NCT02693132|Experimental|Step-based (STEP)|Weight loss intervention that focuses on unsupervised physical activity prescribed as steps/day and involves an energy restricted diet (identical diet to SUP-PA and UNSUP-PA). Physical activity will be self-monitored and a pedometer will be used to track steps/day.
3119529|NCT02693262|Experimental|CLS Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the CLS mode for 1 week.
3119530|NCT02693262|Active Comparator|Accelerometer Mode on Biotronik CRT-D|All 15 patients will be randomized to this group. Their device will be set in the accelerometer rate responsive mode for 1 week.
3119531|NCT02693418|Experimental|Acidform Gel, Group A|Administration of a single vaginal dose of Acidform gel (5 g)
3119532|NCT02693418|Experimental|Acidform Gel, Group B|Administration of a single vaginal dose of Acidform gel (4 g)
3119533|NCT02693418|Experimental|Acidform Gel, Group C|Administration of a single vaginal dose of Acidform gel (3 g)
3119534|NCT02693418|Placebo Comparator|Placebo Gel, Group D|Administration of a single dose of hydroxyethylcellulose (HEC) placebo gel (4 g)
3119535|NCT02693418|No Intervention|No intervention, Group E|No vaginal product administered
3119536|NCT02693691|Experimental|CardioMEMS HF System|Subjects will collect pulmonary artery pressure measurements daily which will be used by health care professionals to adjust cardiac medications.
3119537|NCT02693704|Experimental|Normal hearing|People showing no hearing loss (< 20 dB HL). Introduction of speech signal via the DAI of two hearing aids Phonak Naida IX SP.
3119538|NCT02693704|Experimental|Moderate hearing impaired|"Patients showing moderate hearing loss (40-60 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
3119539|NCT02693704|Experimental|Severe hearing impaired|"Patients showing severe hearing loss (60-80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
3469347|NCT03887572||Pre-intervention/control|20 older adult patients (age 65 or older) will be recruited over 3 months prior to implementation of the unit-based MOVIN intervention.
3119540|NCT02693704|Experimental|Profound hearing impaired|"Patients showing profound hearing loss (> 80 dB HL).~Introduction of speech signal via the DAI of two hearing aids among:~PhonakAudéo V-13 Phonak Baseo Q-P, Q-SP, Q-M13 Phonak Bolero Q-P, Q-SP, Q-M13, Boléro V-P, V-SP Phonak Naida Q-CRT, Q-SP, Q-UP Phonak Sky Q-RIC, Q-SP, Q-UP, Q-M13 Phonak Ambra microP, SP, M H20 Phonak Cassia microP, SP, M H20 Phonak Dalia microP, SP, M H20 Phonak Naida S SP, S UP, S CRT Phonak Solana microP, SP, M H20 Phonak Certéna micro, Art M, Art P, Art SP, Art micro Phonak Exélia micro, Art M, Art P, Art SP, Art micro Phonak Milo Plus micro, Plus SP, Plus UP Phonak Naida SP, SP Junior, UP, UP Junior Phonak Nios micro, S H20 Phonak Versata micro, Art M, Art P, Art SP, Art micro"
3119541|NCT02693834|Experimental|PLS AFO first then DA AFO|Participants will be assigned to practice with Posterior Leaf spring AFO for a week, then they will be assigned to practice with Double adjustable AFO for another week.
3119542|NCT02693834|Experimental|DA AFO first then PLS AFO|Participants will be assigned to practice with Double adjustable AFO for a week, then they will be assigned to practice with Posterior Leaf spring AFO for another week
3119543|NCT02694029|Active Comparator|ABC (Active Breathing Coordinator ), Then VRT|Active Breathing Coordinator to assist radiation therapy. This group will be administered 14 fractions with ABC-assisted DIBH, followed by 14 fractions with VRT-assisted DIBH
3119544|NCT02694029|Active Comparator|VisionRT (VRT), Then ABC|VisionRT-based deep inspiration breath-hold to assist radiation therapy. This group will be administered 14 fractions with VRT-assisted DIBH, followed by 14 fractions with ABC-assisted DIBH
3119545|NCT02694185|Experimental|Experimental Group|This group will undergo the intervention as described in the protocol
3119546|NCT02694185|No Intervention|Control Group|This group will not receive the intervention, they will receive usual care
3119547|NCT02694315||Induction of labor|200 women all are primigravida between 37-42 weeks gestation to whom induction of labor will be carried out in the casualty of Ain Shams University Maternity Hospital. All participants will have an assessment of the cervix by both Bishop score system and transvaginal measurement of cervical length.
3119548|NCT02694328|Experimental|ALKS 3831|Administered as a coated bilayer tablet
3119549|NCT02694328|Active Comparator|Olanzapine|Administered as a coated bilayer tablet
3119550|NCT02694523|Active Comparator|Adalimumab (Part A)|Participants randomized to receive double-blind (DB) adalimumab 80 mg by subcutaneous (SC) injection at Week 0, then 40 mg at Week 1 and every 2 weeks for 15 weeks (Part A).
3119551|NCT02694523|Experimental|Risankizumab (Part A)|Participants randomized to receive risankizumab at Weeks 0 and 4 (Part A).
3119552|NCT02694536|Experimental|Erlotinib + Gemcitabine|Participants will receive erlotinib in combination with standard of care chemotherapy (gemcitabine) until disease progression, unacceptable toxicity, or withdrawal for any reason.
3119553|NCT02694549|Experimental|CaveoVasc|
3119554|NCT02694562|Experimental|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg)
3119555|NCT02694601|Experimental|Ketonemia following caffeine intake|"Participants have to follow three sequential visits of four hours each, which included a breakfast with one of the doses (2.5 or 5 mg/kg) of the caffeine supplement or without any supplement (baseline) and repeated blood sampling in order to evaluate ketone concentrations.~Intervention 1: Control; no caffeine intake Intervention 2: Caffeine low dose (2.5 mg/kg of BW) Intervention 3: Caffeine high dose (5.0 mg/kg of MW)"
3119556|NCT02694718|Experimental|Capecitabine+Oxaliplatin|Eligible participants received capecitabine 1000 milligrams per square meter (mg/m^2) on Days 1-14, and 825 mg/m^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m^2/once a day (d) on Day 1 and 50 mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
3119557|NCT02694744|Experimental|Group 1 - Dosing Without Food|Patiromer dosing without food
3119558|NCT02694744|Active Comparator|Group 2 - Dosing With Food|Patiromer dosing with food
3119559|NCT02694835|Experimental|DT1 UV|Delefilcon A contact lenses with Ultraviolet (UV) Absorber worn bilaterally (in both eyes) for 9 hours
3119560|NCT02694835|Active Comparator|DT1|Delefilcon A contact lenses worn bilaterally for 9 hours
3119561|NCT02694978|Experimental|Ferumoxytol|Participants received an IV infusion of ferumoxytol 510 milligram (mg) diluted (17 milliliter [mL]) in 233 mL 0.9% sodium chloride injection, United States Pharmacopeia (USP) (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.020 g.
3119562|NCT02694978|Active Comparator|FCM|Participants received an IV infusion of FCM 750 mg diluted (15 mL) in 235 mL 0.9% sodium chloride injection, USP (normal saline) (final volume 250 mL) over at least 15 minutes with a second dose 7-8 days after the first dose, for a total cumulative dose of 1.500 g.
3119563|NCT02695290|Experimental|Afatinib|
3119564|NCT02695329|Active Comparator|Vanguard with KneeAlign 2|Having total knee arthroplasty surgery with the use of a navigation system KneeAlign 2.
3119565|NCT02695329|No Intervention|Vanguard without KneeAlign 2|Having total knee arthroplasty surgery with the use of conventional surgical instruments, and without a navigation system KneeAlign 2.
3119566|NCT02695420|Placebo Comparator|Placebo BID|Participants will receive placebo BID.
3119567|NCT02695420|Experimental|25 mg Omecamtiv Mecarbil BID|Participants will receive 25 mg omecamtiv mecarbil BID.
3119568|NCT02695420|Experimental|37.5 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
3119569|NCT02695420|Experimental|50 mg Omecamtiv Mecarbil BID Target Dose|Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.
3119570|NCT02695446|Other|Oral ER Minocycline - Up to 2mg/kg|Oral extended release minocycline - up to 2mg/kg once a day for 30 days.
3119571|NCT02695524|Active Comparator|Scapula-focused exercises|Side lying external rotation, prone horizontal abduction , Scapular punch, Knee Push, Full can, D1 Diagonal, three times a week, 8 weeks, 3x10 repetitions
3119572|NCT02695524|Experimental|Motor control exercises|Towel slide, Scapular Clock, PNF scapular, Inferior Glide modified, Scapular Orientation Exercise, protraction and retraction of scapula, three times a week, 8 weeks, 3x10 repetitions
3119573|NCT02695537|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
3119574|NCT02695628|Experimental|Diagnostic (18F-fluoromisonidazole, PET/CT, embolization)|Patients undergo transcatheter arterial embolization. Patients also receive 18F-fluoromisonidazole IV and undergo PET/CT scans 4 weeks prior to embolization treatment and in the 20 hours following completion of treatment.
3119575|NCT02695719|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
3119576|NCT02695719|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
3119577|NCT02696031|Experimental|Secukinumab, 150 mg Load (Core phase)|Secukinumab 150 mg s.c., pre-filled syringe (PFS) at baseline, Weeks 1, 2, and 3, followed by administration every four weeks starting at Week 4, Load, Core phase
3119578|NCT02696031|Experimental|Secukinumab, 150 mg No Load (Core phase)|Secukinumab 150 mg s.c. PFS at baseline, placebo at Weeks 1, 2, and 3, followed by secukinumab 150 mg PFS administration every four weeks starting at Week 4, No Load, Core phase
3119579|NCT02696031|Placebo Comparator|Placebo (Core phase)|Placebo s.c., PFS at baseline, Weeks 1, 2, 3, followed by administration every four weeks starting at Week 4, Core phase
3119580|NCT02696031|Experimental|Core Phase Responder 150 mg (Extension phase)|Core Phase Responder 150 mg blinded: secukinumab 150 mg s.c. PFS and placebo (1 mL) s.c. PFS every four weeks, in the Extension phase
3119581|NCT02696031|Experimental|Core Phase Responder 300 mg (Extension phase)|Core Phase Responder 300 mg blinded: 2 injections with secukinumab 150 mg s.c. PFS every four weeks, in the Extension phase
3119582|NCT02696031|Experimental|Core Phase Non-Responder 300 mg (Extension phase)|Core Phase Non-Responder 300 mg: 2 injections with secukinumab 150 mg s.c. PFS every four weeks open-label, in the Extension phase
3119583|NCT02696070|Other|Sham of Provant|Sham of Provant
3119584|NCT02696070|Other|Active Treatment|Active Provant Treatment
3119585|NCT02696083|Experimental|Active Treatment|
3119586|NCT02696200|Experimental|Subjects Wearing the Q Collar|Subjects wearing the Q collar throughout the football season
3119587|NCT02696200|No Intervention|Subjects Not Wearing the Q Collar|Control group of subjects not wearing the q collar
3119588|NCT02696291|Experimental|Cohort 1 - 30 mg|Subjects receiving UV-4B 30 mg oral solution or placebo
3119589|NCT02696291|Experimental|Cohort 2 - 75 mg|Subjects receiving UV-4B 75 mg oral solution or placebo
3119590|NCT02696291|Experimental|Cohort 3 - 150 mg|Subjects receiving UV-4B 150 mg oral solution or placebo
3119591|NCT02696291|Experimental|Cohort 4 - X mg (dose to be determined)|Subjects receiving UV-4B X mg (dose to be determined) oral solution or placebo
3119592|NCT02696291|Experimental|Cohort 5 - Y mg (dose to be determined)|Subjects receiving UV-4B Y mg (dose to be determined) oral solution or placebo
3119593|NCT02696317|Other|AO1D, then AO|Senofilcon A contact lenses with HydraLuxe™, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 10 days in a daily wear, daily disposable modality.
3119594|NCT02696317|Other|AO, then AO1D|Senofilcon A contact lenses, followed by senofilcon A contact lenses with HydraLuxe™. Each product worn bilaterally for 10 days in a daily wear, daily disposable modality.
3119595|NCT02696434|Active Comparator|PBO NTX + BUP|Placebo naltrexone + buprenorphine
3119596|NCT02696434|Experimental|NTX + BUP|Naltrexone + buprenorphine
3119597|NCT02696759|Other|Blood & Fecal Collection|Subjects receiving neoadjuvant chemotherapy for advanced breast cancer will be asked to complete questionnaires, provide two blood samples, and provide 2 fecal samples while receiving standard of care neoadjuvant chemotherapy
3119598|NCT02696785|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
3119599|NCT02696785|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
3119600|NCT02696785|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
3119601|NCT02696785|Active Comparator|Adalimumab|"Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52."
3119602|NCT02696798|Experimental|Q2W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52."
3119603|NCT02696798|Experimental|Q4W Ixekizumab|"Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52."
3119604|NCT02696798|Placebo Comparator|Placebo|"Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: Starting dose of 160 mg ixekizumab given SC at week 16 followed by 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52."
3119605|NCT02696850|Experimental|Budesonide|"The study intervention will be budesonide powder (0.5 mg/capsule). Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.~Each study bottle will contain 60 capsules of Budesonide and will be assigned with a number from 1-80."
3469348|NCT03887572||Post-intervention|20 older adult patients (age 65 or older) will be recruited over 3 months after MOVIN has been implemented on the unit for a period of 12-14 weeks.
3119606|NCT02696850|Placebo Comparator|Saline Alone|Each study bottle will contain 60 capsules of placebo, which is lactose monohydrate and will be supplied in clear plastic capsules identical to the budesonide capsules. Subjects will be required to dissolve the contents of two capsules into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily.
3119607|NCT02696902|Experimental|MEDI3902 500 mg|Participants will receive a single intravenous (IV) dose of 500 mg MEDI3902.
3119608|NCT02696902|Placebo Comparator|Placebo|Participants will receive a single IV dose of placebo matched to MEDI3902.
3119609|NCT02696902|Experimental|MEDI3902 1500 mg|Participants will receive a single IV dose of 1500 mg MEDI3902.
3119610|NCT02696967|Experimental|CLR325|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of CLR325 (i.v.) in double blind manner.
3119611|NCT02696967|Placebo Comparator|Placebo|Patients were assigned to one of the 2 treatment arms in fixed randomization ratio. Patients randomized to this arm received single dose of placebo (i.v.) in double blind manner.
3119612|NCT02697071|Placebo Comparator|Placebo Control|Patients will receive an equivalent volume of normal saline intravenously.
3119613|NCT02697071|Experimental|Ketamine|Patients will receive 0.2mg/kg ketamine intravenously over one minute.
3119614|NCT02697188|Experimental|Testosterone undecanoate|Period 2 - 200 mg T (as TU) QD Period 3 - 200 mg T (as TU) BID (100 mg/dose) Period 4 - 400 mg T (as TU) BID (200 mg/dose)
3119615|NCT02697188|Active Comparator|Testosterone enanthate|Period 1 - 400 mg T (as TE) QD Period 5 - 800 mg T (as TE) BID (400 mg/dose)
3119616|NCT02697214|Active Comparator|Apple Watch|Apple Watch heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device .
3119617|NCT02697214|Active Comparator|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
3119618|NCT02697214|Active Comparator|Mio Fuse|Mio Fuse heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
3119619|NCT02697214|Active Comparator|Basis Peak|Basis Peak heart rate monitoring device worn with standard ECG, Polar H7 chest monitor and one other wrist monitoring device.
3119620|NCT02697240|Experimental|Intravenous citrulline|Intravenous citrulline at a bolus dose over 5 minutes and then a continuous rate for the next 23 hours.
3119621|NCT02697292|Placebo Comparator|Placebo/Normal Saline Group|Subjects will receive placebo for 4 infusions. After completion of the blinded phase, subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
3119622|NCT02697292|Active Comparator|Intravenous Immunoglobulin (IVIG) (Gamunex-C) Group|Subjects will receive IVIG for 4 infusions. Subjects will maintain their stable dose of antiepileptic meds.
3119623|NCT02697435|Experimental|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain.
3119624|NCT02697435|Placebo Comparator|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
3119625|NCT02697591|Experimental|Phase 1: 20.0 Milligram Per Kilograms (mg/kg) Every 2 Weeks (Q2W)|Participants received IV infusion of study drug at a dose of 20.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119626|NCT02697591|Experimental|Phase 1: 0.03 mg/kg Q2W|Participants received intravenous (IV) infusion of study drug at a dose of 0.03 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119627|NCT02697591|Experimental|Phase 1: 0.1 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.1 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119628|NCT02697591|Experimental|Phase 1: 0.3 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 0.3 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119629|NCT02697591|Experimental|Phase 1: 1.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 1.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119630|NCT02697591|Experimental|Phase 1: 3.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 3.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119631|NCT02697591|Experimental|Phase 1: 5.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 5.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119632|NCT02697591|Experimental|Phase 1: 10.0 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 10.0 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119633|NCT02697591|Experimental|Phase 1: 400 mg/kg Every 4 Weeks (Q4W)|Participants received IV infusion of study drug at a dose of 400 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119634|NCT02697591|Experimental|Phase 2: 300 mg/kg Q2W|Participants received IV infusion of study drug at a dose of 300 mg/kg every Q2W starting on Day 1 of each cycle for up to 15 months.
3119635|NCT02697617|Placebo Comparator|Placebo Arm|Subject will be on placebo
3119636|NCT02697617|Active Comparator|Pioglitazone Arm|Subject will be on pioglitazone
3119637|NCT02697734|Experimental|osilodrostat Group|Participants in this arm were randomized to receive the study drug, osilodrostat followed after Week 12 by open-label osilodrostat at the starting dose (with a second dose titration)
3119638|NCT02697734|Placebo Comparator|osilodrostat Placebo Group|Participants in this arm were randomized to receive osilodrostat placebo followed after Week 12 by open-label osilodrostat at the starting dose (with a dose titration)
3119639|NCT02697773|Placebo Comparator|Placebo|placebo administered subcutaneously at day 0 and week 8
3119640|NCT02697773|Experimental|Tanezumab 2.5 mg|tanezumab 2.5 mg administered subcutaneously at day 0 and week 8
3119641|NCT02697773|Experimental|Tanezumab 2.5mg/5mg|tanezumab 2.5 mg administered subcutaneously at day 0 and tanezumab 5 mg administered subcutaneously at week 8
3119642|NCT02697890|Active Comparator|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|"Interventions:~Procedure: Ridge preservation procedure"
3119643|NCT02697890|Experimental|FDBA (MinerOss®) + Mucograft® seal|"Interventions:~Device: Mucograft® seal Procedure: Ridge preservation procedure"
3119644|NCT02697916|Active Comparator|ASA 81mg|aspirin 81mg
3119645|NCT02697916|Active Comparator|ASA 325mg|aspirin 325mg
3119646|NCT02698033||Low dose challenge passed|Individuals who tolerated without dose limiting symptoms the screening food challenge for a parent interventional trial
3119647|NCT02698176|Experimental|Birabresib 20 mg CRPC Cohort-Part A|Participants in the CRPC cohort in Part A of the study received birabresib 20 mg orally (PO), twice a day (BID), in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
3119648|NCT02698176|Experimental|Birabresib 20 mg NMC Cohort-Part A|Participants in the NMC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
3119649|NCT02698176|Experimental|Birabresib 20 mg TNBC Cohort-Part A|Participants in the TNBC cohort in Part A of the study received birabresib 20 mg PO, BID, in a fasted state for 21 consecutive days per cycle. Participants received birabresib in continuous cycles up to 24 months.
3119650|NCT02698176|Experimental|NMC Cohort-Part B|Participants (up to 30) in Part B will receive birabresib at one dose level below the dose currently being administered in Part A of the study. Once the recommended Phase 2 dose (RP2D) from Part A is established, participants in Part B will receive birabresib at the RP2D. Participants will continue receiving birabresib at an assigned/adjusted dose level for continuous cycles up to 24 months.
3119651|NCT02698189|Experimental|Birabresib 20 mg AML Cohort|Participants in the AML cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
3119652|NCT02698189|Experimental|Birabresib 20 mg DLBCL Cohort|Participants in the DLBCL cohort received 20 mg of birabresib as an oral capsule twice a day for 21 consecutive days per cycle (21-day cycle).
3119653|NCT02698215|Experimental|Varenicline plus Naltrexone|VAR (1 mg twice daily) + NTX (50 mg once daily)
3119654|NCT02698215|Placebo Comparator|Varenicline|VAR (1 mg twice daily)
3119655|NCT02698241|Other|Diagnostic & Medication Management|Enrolled subjects will be managed using integrated device diagnostics combined with a clinical medication plan.
3119656|NCT02698371|Active Comparator|FBDC-SE (G1; Control)|Futurabond DC (single dose blister) will be applied as thickness to the enamel/dentine and rub into the tooth surface for 20s; FBDC drying layer for at least 5s with an air syringe; This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20s.
3119657|NCT02698371|Active Comparator|FBDC-SE-EE (G2; Control )|Etch with 36% phosphoric acid, during 30s in enamel structures. Remove the 36% phosphoric acid with water during 1 minute. The remove of water excess will be done with weak air spray, not to dry the dentine completely. The dentine surface must slightly remain wet. Application of Futurabond DC (FBDC) as self-etch mode simultaneously in dentin and enamel, and the light-cured (LED light; 1000mW/cm2), during 20s.
3119658|NCT02698371|Other|FBU-ER (G3)|FuturabondU® (FBU) apply in enamel and dentin as etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15s in dentin and 30s in enamel) and then rinse with water for 1 min. Dry off excess moisture with a gentle stream of air. Activating FBU SingleDose. FBU adhesive will be homogeneously applied to all cavity surfaces and rub in for 20s using the Single Tim; This adhesive layer will be light-cured with a light emitting diode unit, with an intensity of 1000mW/cm2 during 20s.
3119659|NCT02698371|Other|FBU-SE (G4)|FuturabondU® (FBU) apply in enamel and dentin as SE mode. Activating FBU SingleDose. FBU adhesive will be homogeneously apply to all cavity surfaces and rub in for 20 s using the Single Tim; Dry off the adhesive layer with dry, oil-free air for at least 5 s in order to remove any solvents. This adhesive layer will be light-cured with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2, during 20 seconds.
3119660|NCT02698371|Other|ADU-ER (G5)|Adhese®Universal (ADU) apply by etch-and-rinse (ER) mode. Etching of the dental hard tissue phosphoric acid (15 seconds in dentin and 30 seconds in enamel); Etch agent rinse with water for 1 minute. Dry off excess moisture with a gentle stream of air. Keep dentin dry, do not over dry; Adhesive ADU will be scrubbed into the tooth surface (enamel and dentin) for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 10 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2 for 20s.
3119661|NCT02698371|Other|ADU-SE (G6)|Adhese®Universal (ADU)apply by self-etch (SE) mode. Starting with the enamel, thoroughly coat the tooth surfaces (enamel and dentin) to be treated with ADU; Adhesive will be scrubbed into the tooth surface for at least 20 seconds. Adhesive will be dispersed with compressed air until a glossy, immobile film layer results.Light-curing for 20 s with a light emitting diode unit (LED light), with an intensity of 1000mW/cm2.
3119662|NCT02698410|Experimental|Lanreotide (Autogel formulation) and Temozolomide|"Lanreotide ATG 120 mg every 28 days, deep subcutaneous injection for a maximum of 48 weeks, for a total number of 12 injections.~Temozolomide 250 mg hard capsules, for 5 consecutive days every 28 days, oral route, for a maximum of 48 weeks."
3119663|NCT02698423|Experimental|Cobas HPV DNA test|Women will be invited to perform HPV self-testing with the Cobas HPV DNA test at home.
3119664|NCT02698423|Active Comparator|Papanicolau test|Women will be invited to come to the hospital to undergo a Papanicolau test (Pap test), which will be performed by the clinician.
3119665|NCT02698436|Experimental|Acne Mask|"The light therapy acne device is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.~Other Names: Cleanser is marketed while the device is not marketed"
3119666|NCT02698436|Active Comparator|2.5% Benzoyl Peroxide Treatment|"Cleanser and 2.5% Benzoyl Peroxide Treatment Both the cleanser and the 2.5% Benzoyl Peroxide Treatment are applied twice daily, once in the morning and once in the evening.~Other names: Both products are marketed"
3119667|NCT02698475|Experimental|Ustekinumab Group|Participants will receive 1 of the following dose levels depending on their weight: participants weighing less than (<) 60 kg will receive Ustekinumab 0.75 milligram per kilogram (mg/kg); participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg; participants weighing >100 kg will receive ustekinumab 90 mg, at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants who enter the long-term extension (LTE) period will continue receiving ustekinumab every 12 weeks (q12w) beginning at Week 56 up to Week 248.
3119668|NCT02698566|Experimental|Ranibizumab PFS|Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
3119669|NCT02698735|Experimental|Gentamicin|Gentamicin antibiotic
3119670|NCT02698735|Placebo Comparator|Placebo|Vehicle control
3119671|NCT02698787|Experimental|Group 1|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 1 will be receiving the FAST (experimental) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 1 will be switched to the commercially available ACE (control) sound coding strategy.
3119672|NCT02698787|Experimental|Group 2|All patients will be receiving commercially available Cochlear™ Nucleus® CI24RE with Contour Advance™ Electrode or Cochlear™ Nucleus® CI512 cochlear implant with Contour Advance™ Electrode for this study. Group 2 will be the commercially available ACE (control) sound coding strategy at initial activation and use it for the first three months.At the three month interval subjects in Group 2 will be switched to the receiving intervention of the FAST (experimental) sound coding strategy. The experimental sound coding strategy will be used from 3-6 months post activation.
3119673|NCT02698800|Experimental|Blue blocking (BB)|Wearing of BB lenses.
3119674|NCT02698800|Placebo Comparator|Clear|Wearing of clear lenses
3119675|NCT02699099|Experimental|Coad group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
3119676|NCT02699099|Experimental|RTS,S group|Children randomized received Vitamin A at 6 months of age, SB257049 vaccine at 6, 7.5 and 9 months of age, and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 10.5 months of age. Subjects received a booster dose of SB257049 vaccine at 18 months post Dose 3 (i.e. at 27 months of age).
3119677|NCT02699099|Experimental|Control group|Children randomized received Vitamin A at 6 months of age and Yellow Fever (YF) vaccine and a combined measles and rubella vaccine at 9 months of age. These children received SB257049 vaccine at 10.5, 11.5 and 12.5 months of age plus a booster dose 17.5 months post Dose 3 (i.e. at 30 months of age).
3119678|NCT02699125|Experimental|Placebo, Guanfacine, Hydrochlorothyazide|Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
3119679|NCT02699125|Experimental|Placebo, Hydrochlorothyazide, Guanfacine|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.
3119680|NCT02699450|Active Comparator|Arm A: 0.3 mg Ranibizumab|Participants will receive 0.3 milligrams (mg) ranibizumab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
3119681|NCT02699450|Experimental|Arm B: 1.5 mg Faricimab|Participants will receive 1.5 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
3119682|NCT02699450|Experimental|Arm C: 6 mg Faricimab|Participants will receive 6 mg faricimab every fourth week up to Week 20, for a total of 6 administrations, followed by an observational period up to Week 36. If a participant meets pre-specified criteria the participant will receive a single dose of 0.3 mg ranibizumab and exit the study.
3119683|NCT02699463|Active Comparator|Continous Positive Airway Pressure|Participants in this group will use CPAP therapy, nightly, for the 3 month duration of the trial
3119684|NCT02699463|Placebo Comparator|Control Group|Participants will receive standard care (Sleep hygiene counseling) during the study.
3119685|NCT02699593|Experimental|Test / Control Sequence|Subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality.
3119686|NCT02699593|Active Comparator|Control / Test Sequence|Subjects will be dispensed the Control Contact Lens to wear for two weeks, to be worn in a daily wear modality, attending a follow-up visit in 12-17 days. At the follow-up visit, subjects will be dispensed the Test Contact Lens to wear for two weeks, to be worn in a daily wear modality.
3119687|NCT02699684|Other|AOHG, then AOA|Lotrafilcon B contact lenses with EOBO-41 worn first, followed by lotrafilcon B contact lenses worn second. Both products worn bilaterally (in both eyes) for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
3119688|NCT02699684|Other|AOA, then AOHG|Lotrafilcon B contact lenses worn first, followed by lotrafilcon B contact lenses with EOBO-41 worn second. Both products worn bilaterally for 30 days and removed nightly for care using a hydrogen peroxide-based lens care solution.
3119689|NCT02699749|Experimental|TAK-931|"TAK-931 30 mg, capsules, orally, QD or BID on Days 1-14 of each 21-day treatment cycle in dosing schedule A followed by dosing schedule B, C, D, E and F. In dosing schedules B through F, starting doses and dosing escalations will vary depending on the dosing data obtained from dosing in the previous schedule.~Dose escalation of TAK-931 will be based on evaluation of clinical safety and tolerability and guided by accumulating PK data. 3-4 dose cohorts are expected for each dosing schedule.~If the PK from the early cohorts support BID dosing, then study drug administration in subsequent cohorts may transition to a BID dosing schedule."
3119690|NCT02699866|Experimental|BLT Implant Ø 2.9 mm|The Straumann BLT Implants Ø 2.9 mm are available with a length of 10, 12 and 14 mm.
3119691|NCT02699892||Rheumatoid arthritis participants|Participants who were on rituximab for rheumatoid arthritis and who will continue receiving rituximab treatment (at the discretion of treating physician) according to previous approved indication will be observed for a period of 72 weeks.
3132679|NCT03444584|Experimental|MEDI0382|Participants will receive subcutaneous dose of MEDI0382 daily (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days) for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period.
3119692|NCT02699970||Selected features|"No intervention is administered to the selected features. They only need to be observed by the pathologist.~The features are part of tissue that is present on a slide. This slide is fully scanned and the digital image is than viewed by the pathologist who indicates if he can see the feature. By repeating the scan three times and having the pathologist view three times, the consistency of the feedback can be monitored. The consistency is a measure on how repeatable and reproducible the scanner is. To be very clear: the scanner does not do anything to the tissue. It only takes a digital 'photo' of the tissue. It is no treatment or intervention. It just takes a picture."
3119693|NCT02699983|Experimental|Group I (SparkPeople program)|"Participants receive one 30-minute session with the research assistant for training on how to use the SparkPeople website, and they may request additional training if needed.~Participants are instructed to self-monitor their diet at least weekly using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.~Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.~All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3, and 6 months."
3119694|NCT02699983|Active Comparator|Group II (wait list)|Participants receive the weight loss handout and a Fitbit activity monitoring device and proceed with their usual life. After 6 months, patients receive the SparkPeople treatment as in Group I. All participants answer survey questions on quality of life and social cognitive theory variables and undergo anthropometric measurements at baseline, 3 and 6 months.
3119695|NCT02699996|Experimental|self-management + peer mentoring|Participants complete the self-management + peer mentoring intervention comprising 5 online educational modules and 6 videoconference or phone calls with the peer mentor.
3119696|NCT02700165|Experimental|CoolSculpting with CoolMini|The treatments are designed to see if fat in the submandibular/submental area (chin), can be reduced using cryolipolysis.
3119697|NCT02700334|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
3119698|NCT02700334|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
3119699|NCT02700412|Experimental|Epidiolex 100 milligram/milliliter (mg/mL) oral solution|"Participants will receive a CBD starting dose of 5 mg/kg/day in twice daily dosing and titrate by 5 mg/kg/2 weeks up to 25 mg/kg/day. Additional increases in dosing, by 5 mg/kg/day up to a maximum of 50 mg/kg/day, may be instituted at the discretion of the treating Principle Investigator (PI).~If a subject experiences a clinically significant or dose limiting adverse event (AE) or severe adverse event (SAE) attributable to CBD, the investigator will determine if a dose reduction or taper is necessary (decreases will occur in 5 mg/kg/2 week increments or at a rate felt appropriate by the treating PI)."
3119700|NCT02700425|Active Comparator|His Bundle Pacing|Subjects will be randomized to the HB lead position with their cardiac resynchronization therapy (CRT) pacemaker. HB lead pacing will be performed with the Medtronic SelectSecure™, Model 3830 lead. Delivery of the lead utilizes a deflectable sheath, the Medtronic SelectSite™, Model C304. Both devices are FDA approved for the purpose of HB pacing. It is the only device available which is presently FDA approved for selective HB pacing.
3119701|NCT02700425|Active Comparator|Coronary Sinus Pacing|Subjects will be randomized to the CS lead position with their cardiac resynchronization therapy (CRT) pacemaker. CS lead and CRT device generator selected for implant will be left to the discretion of the operator. Only FDA approved CS leads and CRT generators will be utilized in the study. There are five present manufacturers of CS leads and CRT generators: Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude Medical.
3119702|NCT02700815|Experimental|Diclofenac and capsaicin|Fixed dose combination
3119703|NCT02700815|Active Comparator|Diclofenac|
3119704|NCT02700815|Active Comparator|Capsaicin|
3119705|NCT02700815|Placebo Comparator|Placebo|
3119706|NCT02700919|Experimental|Regimen 1|Drug: BCT197 Dose 1, Day 1 to Day 5
3119707|NCT02700919|Experimental|Regimen 2|Drug: BCT197 Dose 2, Day 1 to Day 5
3119708|NCT02700919|Placebo Comparator|Regimen 3|Placebo Day 1 to Day 5
3119709|NCT02700945|Active Comparator|Reveal LINQ™ Insertable Cardiac Monitor|Subjects randomized to the Reveal LINQ™ Insertable Cardiac Monitor arm will be continuously monitored via the inserted Reveal LINQ™ device.
3119710|NCT02700945|No Intervention|Control Arm|Subjects randomized to the control arm will be followed per site specific standard of care.
3119711|NCT02700984|Experimental|Cataract Surgery + CyPass|CyPass Micro-Stent implanted at the conclusion of cataract surgery (COMPASS trial)
3119712|NCT02700984|Active Comparator|Cataract Surgery Only|Cataract Surgery (COMPASS trial) with no CyPass Micro-Stent implantation
3119713|NCT02700997|Experimental|Vascular clip|Application of a clip to dissolvable sutures.
3119714|NCT02701049|Other|SO/GI Collection|Methods to collect SO/GI information in the ED
3119715|NCT02701062|Other|LAA Exclusion with AtriClip®|LAA Exclusion with AtriClip®: AtriClip® is used per label and is not experimental.
3119716|NCT02701062|Active Comparator|Medical Management|Medical Management: Standard of Care Oral Anticoagulation Therapy at the discretion of the Investigator.
3119717|NCT02701101|Other|Daily Skin Assessments (SoC and SEM Scanner Readings)|"The SEM Scanner 200 measures sub-epidermal moisture (SEM), which has been studied as an indicator of localized edema characteristic of pressure-induced tissue damage. Daily assessments were performed at the sacrum and both heels unless the anatomical location(s) were not assessable. Daily assessments included:~Risk Assessment (standard of care; Braden, Waterlow, or Norton)~Skin Assessment (standard of care visual skin assessments utilizing tactile and visual cues)~SEM Scanner readings (test variable in this study). Standard of care evaluations were conducted by individuals meeting the definition of Specialist specified in the study protocol whereas separate individuals meeting the definition of Generalist performed SEM Scanner 200 measurements. Specialists were blinded to the assessment by the Generalists, and vice versa."
3119718|NCT02701192||Coccygectomy Treatment|Patients undergoing coccygectomy surgical procedure.
3119719|NCT02701257|Active Comparator|iPhone bionic pancreas - Lilly glucagon|iPhone based bionic pancreas using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
3119720|NCT02701257|Experimental|iLet bionic pancreas - Lilly glucagon|iLet Bionic Pancreas using using insulin lispro and Lilly glucagon. These visits will be conducted separately from the infusion set sub-study visits.
3119721|NCT02701257|Experimental|iLet bionic pancreas - Xerisol glucagon|iLet Bionic Pancreas using using insulin lispro and Xeris Xerisol glucagon. These visits will be conducted separately from the infusion set sub-study visits.
3119722|NCT02701257|Experimental|iLet infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
3119723|NCT02701257|Active Comparator|Contact Detach infusion set|The infusion set sub-study will be testing just the experimental iLet infusion set in a crossover with the contact detach infusion set. These visits will be conducted separately from the iPhone and iLet bionic pancreas visits.
3119724|NCT02701270|Experimental|Experimental Dietary Fibre 1|
3119725|NCT02701270|Experimental|Experimental Dietary Fibre 2|
3119726|NCT02701270|Active Comparator|Polydextrose|
3119727|NCT02701270|Active Comparator|Dextrose control|
3119728|NCT02701283|Experimental|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of Aortic Stenosis with the Medtronic CoreValve System Transcatheter Aortic Valve Implantation (TAVI) device or the Medtronic Corevalve Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
3119729|NCT02701283|Active Comparator|Surgical Aortic Valve Replacement (SAVR)|Treatment of Aortic Stenosis with commercial Surgical Aortic Valve Replacement (SAVR)
3119730|NCT02701296|Experimental|Posterior capsular injection|Ultrasound guided posterior capsular injection of ropivacaine with epinephrine
3119731|NCT02701296|Active Comparator|Tibial nerve block|Ultrasound selective tibial nerve block of ropivacaine
3119732|NCT02701361|Active Comparator|Education group|A care condition in which an educational program relevant to critical illness is presented in a web-based format similar to the other arms. Telephone calls will be used to answer questions and assist with web content.
3119733|NCT02701361|Experimental|Standard mindfulness|Receives audiovisual mindfulness content via internet plus 1 call per week from a trained mindfulness expert.
3119734|NCT02701361|Experimental|Mobile mindfulness|Receives audiovisual mindfulness content via web-app. Will receive at least 1 call from a trained mindfulness expert, though up to 4 total calls based on symptoms / request.
3119735|NCT02701387|Experimental|AnyRidge Implant|Experimental implant (Megagen AnyRidge dental implant) placed in a healed edentulous site to replace a missing tooth.
3119736|NCT02701387|Active Comparator|EZ Plus Implant|Comparative implant (Megagen EZ Plus dental implant) placed in a healed edentulous site to replace a missing tooth.
3119737|NCT02701400|Experimental|Arm I (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients also receive durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving disease control may restart treatment upon evidence of progressive disease, with or without confirmation.
3119738|NCT02701400|Active Comparator|Arm II (RT, tremelimumab, durvalumab)|Patients undergo stereotactic body radiation therapy (SBRT) or hypofractionated radiation therapy daily for 5 days over 1 week or for 3 fractions every other day for 1 week and then receive the same treatment as in Arm I.
3119739|NCT02701413|Experimental|ApexM Device|The ApexM Device (InControl Medical) is a cylindrical inflatable instrument with electrodes on the dorsal and ventral sides. It is a battery operated, non-implanted device which will be inserted into the vagina and will stimulate the pelvic floor muscles. This device has been shown to be safe and effective for clinical use. Stimulation will alternate between 13 and 50Hz. The initial intensity will be set by the clinician at the patient's initial visit and will be increased in a standard fashion over the duration of the trial.
3119740|NCT02701413|Sham Comparator|Sham Device|The ApexM Device will be identical in every way but the electrical stimulation will be disabled. The device will still turn on and inflate to fit the contours of the vagina.
3119741|NCT02701556|Experimental|Bausch & Lomb (B&L) NNR06 Multi-Purpose Solution (MPS)|B & L investigational NNR06 used as a rub care regimen (Test)
3119742|NCT02701556|Active Comparator|COMPLETE MPS|B&L Multi-Purpose Solution as a rub care regimen (Control)
3119743|NCT02701582|Experimental|Goal Directed Therapy|Flotrack monitor is connected and based on what anesthesiologist sees and following study algorithm, anesthesiologist chooses: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
3119744|NCT02701582|Active Comparator|Control Group|FloTrac monitor is connected, but he anesthesiologist will not be able to see the monitor although the data will be collected and stored for analysis. Anesthesiologist will be given a study algorithm to follow for the duration of the surgery, and based on it will choose: Phenylephrine, Epinephrine , volume resuscitation (fluids, including normal saline, albumin, voluven and packed red blood cells) and no intervention.
3119745|NCT02701634|Experimental|ENTO|ENTO 400 mg or 200 mg tablet twice daily for 48 weeks
3119746|NCT02701634|Placebo Comparator|Placebo|Placebo to match tablet twice daily for 48 weeks
3119747|NCT02701647|Experimental|25Hz-TT|Participants will receive 4s train of 25-Hz rTMS pulses with 50s inter-train interval, with an intensity of 80% resting motor threshold (RMT). Participant will receive a total of 600 rTMS pulses in 6 minutes for each hemisphere and a total of 1200 pulses followed by 30 minutes of treadmill training.
3119748|NCT02701647|Experimental|1Hz-TT|Participants will receive a total of 600 1-Hz rTMS pulses in 10 minutes for each hemisphere and a total of 1200 pulses ,with an intensity of 80% RMT, followed by 30 minutes of treadmill training.
3119749|NCT02701647|Sham Comparator|Sham-TT|Sham rTMS will be applied over the same site as for real rTMS, however, with the cable of the coil disconnected. Another figure-of-eight coil using the same stimulation parameters (intensity, time, and frequency) as per 25Hz-TT group will be placed posterior to the subject's neck with the handle pointing backward to produce the same clicking sound effect. Sham rTMS will be followed by 30 minutes of treadmill training.
3119750|NCT02701764|Experimental|Pregabalin|Pregabalin 150 mg twice a day starting 1 day prior to LASIK and continuing for 14 days total.
3119751|NCT02701764|Placebo Comparator|Placebo|Placebo pill twice a day starting 1 day prior to LASIK and continuing for 14 days total.
3119752|NCT02701777|Active Comparator|STDP|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time.
3119753|NCT02701777|Active Comparator|STDP + Training|Paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined time. Motor training will follow paired stimulation.
3119754|NCT02701777|Active Comparator|Sham STDP + Training|Sham or fake paired stimulation will be given to the brain and to a peripheral nerve so that the messages are received at the spinal cord at predetermined times. Motor training will follow stimulation.
3119755|NCT02701868||Phase 1|Up to 40 individuals will be recruited to participate in focus groups at Pennington Biomedical Research Center. Approximately six focus groups (each with 5-10 participants) will be conducted at the Pennington Biomedical Demonstration Kitchen over the course of approximately 3 months.
3119756|NCT02701868||Phase 2|Up to 150 individuals who did not participate in Whoa Baby Phase 1 will be recruited to test the efficacy of the revised instructions on infant overfeeding in comparison with the instructions currently provided on the packaging.
3119757|NCT02701985|Placebo Comparator|Placebo|Matching-placebo capsules will be administered orally, 2 times a day, for up to 12 weeks.
3119758|NCT02701985|Experimental|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day, for up to 12 weeks.
3119759|NCT02702011|Experimental|empagliflozin low dose|
3119760|NCT02702011|Experimental|empagliflozin medium dose|
3119761|NCT02702011|Experimental|empagliflozin high dose|
3119762|NCT02702011|Placebo Comparator|placebo|
3119763|NCT02702193|Experimental|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers.
3119764|NCT02702193|No Intervention|TAU|Treatment as usual - the usual outpatient substance abuse or mental health services received by the mothers with no additional services provided by the study team.
3119765|NCT02702388|Experimental|24 mg Lenvatinib|Participants will receive 24 mg once daily (QD) as the starting dose. Dose reductions will occur in succession based on the previous dose level (24, 20, 14, 10, or 8 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
3119766|NCT02702388|Experimental|18 mg Lenvatinib|Participants will receive 18mg QD as the starting dose. Dose reductions will occur in succession based on the previous dose level (18,14, 10, 8, or 4 mg QD). To maintain blinded treatment assignment, participants will be administered study drug in the form of two 10-mg capsules and two 4-mg capsules containing either lenvatinib or placebo (total of 4 capsules) to be taken orally, at approximately the same time each morning and may be taken in a fasting state or following a meal.
3119767|NCT02702401|Experimental|Pembrolizumab+Best Supportive Care|Participants receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
3119768|NCT02702401|Placebo Comparator|Placebo+Best Supportive Care|Participants receive a placebo IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment PLUS BSC.
3119769|NCT02702518|Active Comparator|rhDNase I|rhDNase I 0.1% eye drops 4 times a day for 8 weeks
3119770|NCT02702518|Placebo Comparator|Vehicle|Drug vehicle eye drops 4 times a day for 8 weeks
3119771|NCT02702609|Experimental|Moldable beta-TCP grafting system|Device: easy-graft CLASSIC (beta-Tricalcium Phosphate)
3119772|NCT02702609|Active Comparator|Allograft|Device: Freeze-Dried Bone Allograft (FDBA) with collagen plug
3119773|NCT02702921|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's current standard of care stapler
3119774|NCT02702921|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
3119775|NCT02702999|Active Comparator|Routine third trimester care|Routine third trimester care with clinically-indicated ultrasound (control)
3119776|NCT02702999|Experimental|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
3119777|NCT02703259|Active Comparator|Gabapentin|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen, celecoxib, and gabapentin x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Gabapentin 600 mg (two capsules of gabapetin 300 mg); Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (two capsules of celecoxib 200 mg) = Total 3 tablets, 4 capsules"
3119778|NCT02703259|Placebo Comparator|Control|"As per the enhanced recovery after surgery protocol at our health institution, subject will receive oral medications prior to surgery including acetaminophen and celecoxib x 1 dose given preoperatively. The number of tablets and capsules will remain identical in both study arms. Medications given include:~Acetaminophen 975 mg (three tablets of acetaminophen 325 mg); Celecoxib 400 mg (four capsules of celecoxib 100 mg) = Total total 3 tablets, 4 capsules"
3119779|NCT02703311|Other|Cardioband procedure|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
3119780|NCT02703324|Experimental|LY900014|LY900014 delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
3119781|NCT02703324|Active Comparator|Insulin Lispro|Insulin lispro delivered via an insulin pump as a continuous infusion under the skin with intermittent bolus doses during meals for two 3-day periods
3119782|NCT02703337|Experimental|LY900014 (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
3119783|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
3119784|NCT02703337|Experimental|LY900014 (Part B)|Individualized doses of LY900014 administered by injection under the skin with each meal for 14 days
3119785|NCT02703337|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
3119786|NCT02703350|Experimental|LY900014 - Test (Part A)|Individualized doses of LY900014 administered by injection under the skin once in each of 3 periods
3119787|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part A)|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
3119788|NCT02703350|Experimental|LY900014 - Test (Part B)|Individualized doses of LY900014 administered by injection under the skin immediately before each meal for 14 days
3119789|NCT02703350|Active Comparator|Insulin Lispro - Reference (Part B)|Individualized doses of insulin lispro reference formulation administered by injection under the skin immediately before each meal for 14 days
3119790|NCT02703454|Experimental|FIRM-only|Subjects in this arm will be treated with FIRM-guided RF ablation without pulmonary vein isolation (PVI).
3119791|NCT02703454|Active Comparator|Conventional|Subjects in this arm will undergo conventional radio frequency (RF) ablation with confirmation of PVI.
3119792|NCT02703467||Healthy|Healthy subjects will have no significant medical history and no previous history of asthma or other serious illnesses. They should be non-smokers. The investigators willl measure spirometry and ensure that the values lie within the normal predicted range.
3119793|NCT02703467||Asthmatics|Patients diagnosed as having asthma will be recruited from Royal Brompton Hospital Asthma Clinics. These patients will have a range of severity of asthma ranging from mild-moderate to severe asthma patients. The diagnosis of asthma is ascertained as described in the inclusion criteria.
3119794|NCT02703532|Experimental|Stroke Survivors with CARE-CITE Carepartners|Stroke survivors with a carepartner randomized to the CARE-CITE intervention. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
3119795|NCT02703532|Experimental|CARE-CITE Education Program Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in online CARE-CITE education while their partner (stroke survivor) receives therapy.
3119796|NCT02703532|Active Comparator|Traditional Education Carepartners|Caregivers (someone who assists in the care of stroke survivors) will participate in traditional education while their partner (stroke survivor) receives therapy.
3119797|NCT02703532|Active Comparator|Stroke Survivors with Traditional Education Carepartners|Stroke survivors with a carepartner randomized to receive traditional education. Participants who have survived a stroke will receive constraint-induced movement therapy (CIMT) while their caregiver participates in an educational program.
3119798|NCT02703636|Other|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
3119799|NCT02703779|Active Comparator|Stem cell collection without in-vivo purging with Bortezomib|"Standard of Care Stem cell collection without in-vivo purging with Bortezomib. Standard of Care drugs Granulocyte colony-stimulating factor (G-CSF) +/- Mozobil (the latter if needed).~NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
3119800|NCT02703779|Experimental|Stem cell collection with in-vivo purging with Bortezomib|"Bortezomib will be given subcutaneously (SQ) at 1.3 mg/m2 on day -11 and day -8 followed by Granulocyte colony-stimulating factor (G-CSF) given SQ on day -4 thru day -1 and continued until the collection is completed. Mozobil will be given if needed.~There must be at least 72 hours between each dose of bortezomib. NOTE: Multiparametric Flow Cytometry to be performed on samples for BOTH groups A and B"
3119801|NCT02703909|Experimental|moderate NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate neuromuscular block (NMB) which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
3119802|NCT02703909|Active Comparator|moderate NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a moderate NMB which is defined as 2-3 twitches in the train of four on a neuromuscular junction monitor. The initial insufflation pressure for the laparoscopy will be 15 mm Hg pressure. This arm represents the usual operating conditions for this type of surgery at the University hospital.
3119803|NCT02703909|Experimental|deep NMB + 10 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 10 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
3119804|NCT02703909|Experimental|deep NMB + 15 mm IP|participants will be given the muscle relaxant, rocuronium, iv to obtain a deep NMB which is defined as 0-1 posttetanic counts on a neuromuscular junction monitor and the initial insufflating pressure will be 15 mm Hg. The initial insufflation pressure for the laparoscopy will be 10 mm Hg pressure.
3119805|NCT02703948|Other|Restylane Silk with Lidocaine|
3119806|NCT02703987|Experimental|Group I|Fermented infant milk formula
3119807|NCT02703987|Active Comparator|Group II|Non-fermented infant milk formula
3119808|NCT02704091|Active Comparator|Smecta|2 sachets, three times a day (TID), during 5 to 9 days
3119809|NCT02704091|Placebo Comparator|Smecta placebo|2 sachets of placebo, TID, during 5 to 9 days
3119810|NCT02704104|Experimental|AC5 Topical Hemostatic Device|The intervention in this arm is the application of a topical hemostatic agent (AC5) to a freshly excised skin lesion
3119811|NCT02704104|Placebo Comparator|Control|The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion
3119812|NCT02704143|Experimental|Combination of Cyberknife with S-1|Patients with locally advanced pancreatic cancer meeting all inclusion criteria will receive combination of Cyberknife with S-1.
3119813|NCT02704156|Experimental|SBRT plus Pembrolizumab and Trametinib|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
3119814|NCT02704156|Active Comparator|SBRT plus Gemcitabine|Patients with locally recurrent pancreatic cancer were randomly allocated to SBRT plus Pembrolizumab and Trametinib or SBRT plus Gemcitabine.
3119815|NCT02704689|Experimental|AccuLIF|
3119816|NCT02704702|Other|Sequence 1 (ABC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment C)~There will be a washout of at least 7 days between the each period."
3119817|NCT02704702|Other|Sequence 2 (ACB)|"Period 1(Treatment A) → Period 2(Treatment C) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
3119818|NCT02704702|Other|Sequence 3 (BAC)|"Period 1(Treatment A) → Period 2(Treatment B) → Period 3(Treatment 3)~There will be a washout of at least 7 days between the each period."
3119819|NCT02704702|Other|Sequence 4 (BCA)|"Period 1(Treatment B) → Period 2(Treatment C) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
3119820|NCT02704702|Other|Sequence 5 (CAB)|"Period 1(Treatment C) → Period 2(Treatment A) → Period 3(Treatment B)~There will be a washout of at least 7 days between the each period."
3119821|NCT02704702|Other|Sequence 6 (CBA)|"Period 1(Treatment C) → Period 2(Treatment B) → Period 3(Treatment A)~There will be a washout of at least 7 days between the each period."
3119822|NCT02705105|Experimental|Dose-Finding Cohort|"Cycle 1 Days 1, 8, 15, and 22: Dose Level 1 of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Dose Level 1 of Mogamulizumab + Nivolumab~If >1 patient has a DLT at first dose level, then the following cohort will be enrolled:~Cycle 1 Days 1, 8, 15, and 22: Optional Dose Level of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Optional Dose Level of Mogamulizumab + Nivolumab"
3119823|NCT02705105|Experimental|Expansion Cohort|"Cycle 1 Days 1, 8, 15, and 22: Maximum Tolerated Dose of Mogamulizumab + Nivolumab Subsequent Cycles Days 1 and 15: Maximum Tolerated Dose of Mogamulizumab + Nivolumab~Subjects will be separated further into cohorts by tumor type"
3119824|NCT02705352|Experimental|5-Fluorouracil|Antimetabolite will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
3119825|NCT02705352|Placebo Comparator|Normal saline|Normal saline will be injected 2 weeks after periocular reconstruction with full thickness skin graft. Injection will be repeated every 2 weeks for a total of up to 4 injections.
3119826|NCT02705365|Experimental|Patient Navigation|Patients assigned to the patient navigator (PN) arm will be sent a letter about the program with lung screening educational materials. The PN will educate eligible patients about lung screening, explore barriers to screening, coordinate scheduling an appointment with a provider, and possibly attend the visit with the patient. The PN will further coordinate scheduling the CT scan, help the patient obtain the test, and access any required follow-up. The PN will assess the patient's interest in quitting smoking and if so, offer and help to connect the smoker to existing cessation resources in the community and provide follow-up contacts to monitor adherence to treatments.
3119827|NCT02705365|Active Comparator|Usual Care|The control group will receive usual care during the 1-year study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results as well as smoking cessation guidance.
3119828|NCT02705586|Experimental|only one arm - open label study|2 hour video based mindfulness-based stress reduction class once a week for 10 weeks.
3119829|NCT02705625|Experimental|MIV-711:1|MIV-711 for a total of 26 w
3119830|NCT02705625|Experimental|MIV-711:2|MIV-711 for a total of 26 w
3119831|NCT02705625|Placebo Comparator|Placebo|Placebo for a total of 26 w
3119832|NCT02705716|Experimental|Test Dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste containing 0.454% weight by weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute.
3119833|NCT02705716|Placebo Comparator|Control Dentifrice|Participants will be instructed to apply a full brush head of toothpaste containing 0.76% sodium monofluorophosphate (1000ppm fluoride) to a dry toothbrush. Participants will then brush the whole mouth thoroughly for at least 1 minute.
3119834|NCT02705807|Experimental|FLOLAN arm|Subjects will receive the existing FLOLAN treatment (i.e., FLOLAN injection prepared with the currently marketed diluent) for a run-in period of a maximum of 4 weeks, the thermostable formulation of FLOLAN injection (i.e., FLOLAN injection prepared with the reformulated diluent) for a 4-week treatment period and there will be a one-week follow-up visit.
3119835|NCT02706041|Active Comparator|Definitive closure laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
3119836|NCT02706041|Other|Damage control laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
3119837|NCT02706249|Active Comparator|A: Standard Dose Enoxaparin|"Participants will receive Enoxaparin 40 mg subcutaneously once daily. On study Enoxaparin will be administered for up 14 days during hospitalization.~After the day 14 assessment, treatment arms will be un-blinded in order to appropriately schedule a bilateral lower extremity ultrasound for participants enrolled onto Arm A at day 17."
3119838|NCT02706249|Active Comparator|B: Weight Adjusted Enoxaparin|"Participants will receive Enoxaparin at 1mg/kg subcutaneously once daily with maximum dose of 100 mg daily. Participants who weigh more than 100kg will be capped at 100mg.~On study Enoxaparin will be administered for up 14 days during hospitalization."
3119839|NCT02706327|Experimental|CAD/CAM|8-week follow-up with CAD/CAM insole and home based exercise program
3119840|NCT02706327|Experimental|Semi-custom|8-week follow-up with semi-custom insole and home based exercise program
3119841|NCT02706327|Placebo Comparator|Control|8-week follow-up with placebo insole and home based exercise program
3119842|NCT02706483|Experimental|Plecanatide|Plecanatide 6.0 mg tablets
3119843|NCT02706717|Active Comparator|Visbiome Extra Strength|
3119844|NCT02706717|Placebo Comparator|Placebo for Visbiome Extra Strength|
3119845|NCT02706834|Experimental|Cohort 1, Sequence I|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119846|NCT02706834|Experimental|Cohort 1, Sequence II|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119847|NCT02706834|Experimental|Cohort 1, Sequence III|Non-Japanese participants. TAK-828 0.1 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119848|NCT02706834|Experimental|Cohort 1, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 0.5 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 15 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119849|NCT02706834|Experimental|Cohort 2, Sequence I|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119850|NCT02706834|Experimental|Cohort 2, Sequence II|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119851|NCT02706834|Experimental|Cohort 2, Sequence III|Non-Japanese participants. TAK-828 3 mg, oral solution, fasted (after an 8 hour fast) on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. Each period lasted 4 days with a 7-day washout period between periods.
3119852|NCT02706834|Experimental|Cohort 2, Sequence IV|Non-Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 50 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 200 mg, oral solution, fasted, on Day 1 of Period 3; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 4; followed by, TAK-828 100 mg, oral solution, fed (high-fat, high-calorie meal 30 minutes prior to administration of study drug), on Day 1 of Period 5. There was a 7-day washout period between each period. Each period lasted 4 days with a 7-day washout period between periods.
3119853|NCT02706834|Experimental|Cohort 3, Sequence I|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
3119854|NCT02706834|Experimental|Cohort 3, Sequence II|Japanese participants. TAK-828 15 mg, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, placebo-matching TAK-828, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
3119855|NCT02706834|Experimental|Cohort 3, Sequence III|Japanese participants. Placebo-matching TAK-828, oral solution, fasted (after an 8 hour fast), on Day 1 of Period 1; followed by, TAK-828 100 mg, oral solution, fasted, on Day 1 of Period 2; followed by, TAK-828 150 mg, oral solution, fasted, on Day 1 of Period 3. Each period lasted 4 days with a 7-day washout period between periods.
3119856|NCT02706847|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitinib 15 mg once daily for 24 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
3119857|NCT02706847|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitinib 30 mg once daily for 24 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
3119858|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 15 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily from Week 24 to Week 260."
3119859|NCT02706847|Placebo Comparator|Placebo / Upadacitnib 30 mg|"Period 1: Participants receive placebo once daily for 12 weeks followed by upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants continue on upadacitinib 30 mg once daily until implementation of Protocol Amendment 4, then participants begin to receive upadacitinib 15 mg once daily up to Week 260."
3119860|NCT02706873|Active Comparator|Methotrexate|"Period 1: Participants will receive placebo to upadacitinib once daily and methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on placebo to upadacitinib once daily and methotrexate once weekly until the study is unblinded, after which participants will receive open-label methotrexate up to Week 260."
3119861|NCT02706873|Experimental|Upadacitinib 7.5 mg (Japan-only)|"Period 1: Participants will receive upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 7.5 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 7.5 mg up to Week 260."
3119862|NCT02706873|Experimental|Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 15 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 15 mg up to Week 260."
3119863|NCT02706873|Experimental|Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily and placebo to methotrexate once weekly for 48 weeks.~Period 2: Participants will continue on upadacitinib 30 mg once daily and placebo to methotrexate once weekly until the study is unblinded, after which participants will receive open-label upadacitinib 30 mg once daily. After implementation of Protocol Amendment 6 participants will receive upadacitinib 15 mg once daily up to Week 260."
3119864|NCT02706886|Placebo Comparator|Part A: SAD: Placebo|A single dose of matching placebo will be administered subcutaneously (SC).
3119865|NCT02706886|Experimental|Part A: SAD: Lumasiran 0.3 mg/kg|A single dose of 0.3 mg/kg lumasiran will be administered SC.
3119866|NCT02706886|Experimental|Part A: SAD: Lumasiran 1.0 mg/kg|A single dose of 1.0 mg/kg lumasiran will be administered SC.
3119867|NCT02706886|Experimental|Part A: SAD: Lumasiran 3.0 mg/kg|A single dose of 3.0 mg/kg lumasiran will be administered SC.
3119868|NCT02706886|Experimental|Part A: SAD: Lumasiran 6.0 mg/kg|A single dose of 6.0 mg/kg lumasiran will be administered SC.
3119869|NCT02706886|Placebo Comparator|Part B: MAD: Placebo|Participants with primary hyperoxaluria type 1 (PH1) will be treated with placebo matching one of the lumasiran dosages in the lumasiran arms (one placebo participant for each lumasiran arm). At Day 85 these placebo treated participants will cross over to their respective Part B lumasiran arms in the Part B: MAD Study Day 85-End of Study Period and will then be treated with lumasiran. The estimated total time on study was up to 546 days.
3119870|NCT02706886|Experimental|Part B: MAD: Lumasiran 1.0 mg/kg qM|Participants with PH1 will be treated with 1.0 mg/kg lumasiran SC once monthly (qM) on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
3119871|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg qM|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC qM on Days 1, 29 and 57. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
3119872|NCT02706886|Experimental|Part B: MAD: Lumasiran 3.0 mg/kg q3M|Participants with PH1 will be treated with 3.0 mg/kg lumasiran SC once every three months (q3M) on Days 1 and 85. The estimated total time on study is up to 546 days. One participant from the Part B: MAD: Placebo arm will cross over to this lumasiran arm at Day 85. For this participant treatment with lumasiran starts at Day 85.
3119873|NCT02706899|Experimental|33A + azacitidine|Vadastuximab talirine plus azacitidine
3119874|NCT02706899|Active Comparator|Placebo + azacitidine|placebo plus azacitidine
3119875|NCT02706925|Experimental|BI 443651|
3119876|NCT02706925|Placebo Comparator|Placebo|
3119877|NCT02706938|Other|Head of bed elevation - Control|Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
3119878|NCT02706938|Other|Control - Head of bed elevation|Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
3119879|NCT02706951|Experimental|Upadacitinib 30 mg|"Period 1: Participants receive upadacitnib 30 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
3119880|NCT02706951|Experimental|Upadacitinib 15 mg|"Period 1: Participants receive upadacitnib 15 mg once daily and placebo to methotrexate once weekly for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
3119881|NCT02706951|Experimental|Methotrexate / Upadacitinib 30 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib once daily for 14 weeks.~Period 2: Participants receive upadacitinib 30 mg once daily until implementation of Protocol Amendment 5 when participants begin to receive upadacitinib 15 mg once daily up to Week 260."
3119882|NCT02706951|Experimental|Methotrexate / Upadacitinib 15 mg|"Period 1: Participants receive methotrexate once weekly and placebo to upadacitinib for 14 weeks.~Period 2: Participants receive upadacitinib 15 mg once daily up to Week 260."
3119883|NCT02707146|Experimental|Tablet in the waiting room|"Patients in the intervention arm will be met in the waiting room prior to their primary care visit and will use the Visit Planner tool application on the tablet"
3119884|NCT02707146|Active Comparator|Health Education Handout|Patients in the control arm will be met in the waiting room prior to their primary care visit and will be given an educational pamphlet on health lifestyle to review
3119885|NCT02707172|Experimental|Intervention|"Subject was first exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the intervention, handwashing with soap, by a standardized hand washing technique.~Then the subjects in this arms are crossover to receive placebo, handwashing with water only."
3119886|NCT02707172|Placebo Comparator|Placebo|"Subject was exposed to 1000 microgram of diethylhexyl phthalate on both hands, and was asked to perform the placebo, handwashing with water, by a standardized hand washing technique.~Then the subjects in this arms are crossover to perform the intervention, handwashing with soap."
3119887|NCT02707432|Experimental|Time 1 (T1) Intervention Group|"This group will be the first to receive the adapted intervention, Heart Matters (adapted from the PREMIER intervention). The intervention will be 12 months long."
3119888|NCT02707432|Experimental|Time 2 (T2) Intervention Group|"This delayed intervention group will receive the adapted intervention, Heart Matters, six months after the T1 Intervention group. The intervention will be 12 months long."
3119889|NCT02707523|Placebo Comparator|Control|Placebo controlled (normal saline) daily for 3 days
3119890|NCT02707523|Active Comparator|Azithromycin (10 mg/kg)|10 mg/kg IV Azithromycin daily for 3 days
3119891|NCT02707523|Active Comparator|Azithromycin (20 mg/kg)|20 mg/kg IV Azithromycin daily for 3 days
3119892|NCT02707601|Experimental|E/C/F/TAF + LDV/SOF|"Part 1: Participants will switch from 2 nucleoside reverse transcriptase inhibitors (NRTI) plus a third agent to E/C/F/TAF.~Part 2: After 8 weeks of E/C/F/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
3119893|NCT02707601|Experimental|F/R/TAF + LDV/SOF|"Part 1: Participants will switch from 2 NRTI plus a third agent to F/R/TAF.~Part 2: After 8 weeks of F/R/TAF treatment, the participants maintaining HIV-1 RNA < 50 copies/mL will start receiving LDV/SOF for 12 weeks and continue their HIV treatment until the end of the study."
3119894|NCT02707640|Placebo Comparator|Matching Placebo|
3119895|NCT02707640|Experimental|N-Acetylcysteine|
3119896|NCT02707640|Other|Pirfenidone|Background therapy
3119897|NCT02707757|Active Comparator|Iron sucrose|Iron sucrose 200mg for 5 doses
3119898|NCT02707757|Active Comparator|Neorecormon|Incremental increase in dose along following parameters: 1000-2000-3000-4000-6000-8000-12000
3119899|NCT02707770|Experimental|Ambulatory oxygen|Patient will use ambulatory oxygen during pulmonary rehabilitation programme (flow rate determined at the initial assessment to a maximum flow rate of 6 litres per minute)
3119900|NCT02707770|Placebo Comparator|Room air|Patient will breath on room air during pulmonary rehabilitation programme
3119901|NCT02707861|Experimental|Cohort 1|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~OR~2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial~Administered for 48 weeks, or until ibalizumab becomes commercially available"
3119902|NCT02707861|Experimental|Cohort 2|"IV ibalizumab (combined with optimized background regimen):~800 mg once every two weeks for qualifying patients who have never received ibalizumab~Administered for 48 weeks, or until ibalizumab becomes commercially available"
3119903|NCT02707952|Experimental|Arm A|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) once daily (QD) for 8 weeks in HCV genotype(GT)1 -infected, DAA treatment-naïve participants without cirrhosis.
3119904|NCT02707952|Active Comparator|Arm B|Ombitasvir (25 mg)/paritaprevir (150 mg)/ritonavir (100mg) (OBV/PTV/r) QD for 12 weeks in HCV GT1 infected, DAA treatment-naïve participants without cirrhosis.
3119905|NCT02707952|Experimental|Arm C|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120mg) QD for 12 weeks in HCV GT1- or GT2-infected participants with compensated cirrhosis, HCV GT3-, 4-, 5- and 6-infected participants (with compensated cirrhosis or without cirrhosis), HCV GT1- and GT2-infected participants who had failed prior DAA treatments (with compensated cirrhosis or without cirrhosis), and HCV GT1- or GT2-infected participants with severe renal impairment and compensated cirrhosis.
3119906|NCT02707952|Experimental|Arm D|ABT-493 (300 mg) once daily (QD) co-administered with ABT-530 (120 mg) QD for 8 weeks in GT1- or GT2-infected participants with severe renal impairment and without cirrhosis.
3119907|NCT02707965|Active Comparator|Sequence 1|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
3119908|NCT02707965|Active Comparator|Sequence 2|This is a crossover study with 4 treatment periods consisting of 2 Test periods(generic drug) and 2 Reference periods (brand name drug). Each treatment period lasts about 2 weeks, and patients will be randomized into one of the two sequences. All drugs are administered orally, and dosage will depend on a patient.
3119909|NCT02707991|No Intervention|Enhanced Usual Care|Usual clinic appointment process plus receipt of the Centers for Disease Control and Prevention (CDC) Hepatitis C Fact Sheet
3119910|NCT02707991|Experimental|Nurse Case Management|Nurse-initiated hepatitis C clinic referral, strengths-based education, patient navigation, appointment reminders, and care coordination of HIV/hepatitis C drug-drug interaction prevention
3119911|NCT02708095|Experimental|2 mg Baricitinib|Participants received 2 (milligrams) mg of Baricitinib tablet orally once a day for 24 weeks.
3119912|NCT02708095|Experimental|4 mg Baricitinib|Participants received 4 mg of Baricitinib tablet orally once a day for 24 weeks.
3119913|NCT02708095|Placebo Comparator|Placebo|Participants received Placebo orally once daily (QD) for 24 weeks.
3119914|NCT02708121|Experimental|Intervention arm|Participant receives intervention to motivate weight loss treatment initiation and access to weight loss treatment.
3119915|NCT02708121|Active Comparator|Comparator Arm|Participant receives access to weight loss treatment alone.
3119916|NCT02708186|Experimental|Nelotanserin|Nelotanserin 80 mg
3119917|NCT02708186|Placebo Comparator|Placebo|Placebo
3132475|NCT03430206|Experimental|Intervention|Treatment subjects will undergo the scheduled procedure, with the difference being that a high-flow nasal cannula will be applied prior to the start of the procedure and removed following the procedure's conclusion. While applied, the cannula will deliver high- flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 1-2L/kg/min with a maximum of 70L/min. Participants in the treatment arm will then proceed to the recovery area as usual. Following recovery from anesthesia, a brief questionnaire will be provided to applicable patients or their parents / guardians / representatives.
3119918|NCT02708212|Active Comparator|EGD-colonoscopy group|In this group, patients receiving an EGD followed by a colonoscopy during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to EGD and colonoscopy examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
3119919|NCT02708212|Active Comparator|Colonoscopy-EGD group|In this study group, patients receive a colonoscopy followed by an EGD during a same-day bidirectional endoscopy. Patients receive moderate conscious sedation with fentanyl and midazolam for the procedures. Colon polypectomy will be provided when colon polyps are found during a colonoscopy study. Gastric polypectomy will be provided when gastric polyps are found during an EGD study. Patients' heart rate, respiratory rate, blood pressure, and oxygen saturation will be recorded every 60 seconds during the endoscopic examinations. Patients' tolerability to colonoscopy and EGD examinations will be scaled by patients and endoscopists after the completion of the examinations. Aldrete scores are recorded15 minutes and 25 minutes after entering the recovery room. The recovery time will also be recorded.
3119920|NCT02708238|Experimental|Group A|All enrolled infants randomized to Group A will receive a standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized Lactobacillus Acidophilus (H122), administered at the dose of 1 ml twice a day of a commercially available solution
3119921|NCT02708238|Active Comparator|Group B|All enrolled infants randomized to Group B will receive Lactobacillus reuteri DSM 17938 administered at the dose of 108 colony-forming units (CFU)/day in 5 drops of a commercially available oil suspension
3119922|NCT02708238|Active Comparator|Group C|All enrolled infants randomized to Group C will receive simethicone, given at a dose of 60 mg in 15 drops two times per day of a commercially available solution
3119923|NCT02708277|Experimental|Group A|At the end of the procedure the surgery loop-shaped intrauterine contraceptive device (IUCD) was placed in the uterine cavity.
3119924|NCT02708277|Experimental|Group B|At the end of the procedure the surgery an intrauterine balloon (Cook Medical) was placed in the uterine cavity.
3119925|NCT02708290||Test arm|The test group included participants who completed more than one thousand exercises and made no more than one error per exercise.
3119926|NCT02708290||Control arm|The control group included the rest of participants. The test group participants were matched to the control group by age, gender, expressive language, receptive language, sociability, cognitive awareness, and health at the 1st evaluation.
3119927|NCT02708355|Experimental|Esomeprazole 20 mg once daily|Esomeprazole 20 mg administered orally in the morning and placebo administered orally in the evening
3119928|NCT02708355|Experimental|Esomeprazole 20 mg twice daily|Esomeprazole 20 mg administered orally in the morning and esomeprazole 20 mg administered orally in the evening
3119929|NCT02708355|Placebo Comparator|Placebo|Placebo administered orally in the morning and placebo administered orally in the evening
3119930|NCT02708433|Active Comparator|Buffered 1% lidocaine|"In week one each subject would receive either anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~In week two the alternate anesthetic would be administered.~Mandibular molar and canine tested for pulpal anesthesia"
3119931|NCT02708433|Active Comparator|Non-Buffered lidocaine|"In week two each subject would receive the alternate anesthetic (Buffered 1% lidocaine with 1/100,000 Epinephrine) or (Non-Buffered 2% lidocaine with 1/100,000 Epinephrine) to block the inferior alveolar, lingual, buccal nerves.~Mandibular molar and canine tested for pulpal anesthesia"
3119932|NCT02708485|No Intervention|Control group|No intervention
3119933|NCT02708485|Experimental|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
3119934|NCT02708498|Experimental|Kronoberg Educational Intervention|The educational intervention is provided to ten nursing homes.
3119935|NCT02708498|No Intervention|Skåne Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
3119936|NCT02708498|Experimental|Skåne Educational Intervention|The educational intervention is provided to ten nursing homes.
3119937|NCT02708498|No Intervention|Kronoberg Control|The control group consists of an equal number of nursing homes. This group receives no intervention.
3119938|NCT02708524|Experimental|Senofilcon C Wearers|Senofilcon C Wearers will wear the Senofilcon C Contact Lenses as daily wear for 30 (-2/+6) days.
3119939|NCT02708524|Active Comparator|Comfilcon A Wearers|Comfilcon A Wearers will wear the Comfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
3119940|NCT02708524|Active Comparator|Lotrafilcon B Wearers|Lotrafilcon B Wearers will wear the Lotrafilcon B Contact Lens as daily wear for 30 (-2/+6) days.
3119941|NCT02708524|Active Comparator|Samfilcon A Wearers|Samfilcon A Wearers will wear the Samfilcon A Contact Lens as daily wear for 30 (-2/+6) days.
3119942|NCT02708641|Experimental|AML patients|pembrolizumab 200 mg given IV once every three weeks
3119943|NCT02708745|Placebo Comparator|Placebo Arm|Parent participants will receive a placebo survey about their attitudes toward common child health topics before their child's health supervision visit.
3119944|NCT02708745|Experimental|Intervention Arm|Parent participants will also receive the intervention survey about their attitudes toward childhood vaccines before their child's health supervision visit.
3119945|NCT02708862|Experimental|Preoxygenation|All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 15 L/min for 3 min 3) Non-rebreather at 60 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
3119946|NCT02708966|Experimental|Gymnema Sylvestre|Patients with IGT
3119947|NCT02708966|Placebo Comparator|Placebo|Patients with IGT
3119948|NCT02709005|Experimental|5% Monolaurin Vaginal Gel|80 subjects will receive 5% Monolaurin Gel twice daily for three successive days for a total of 6 doses
3119949|NCT02709005|Placebo Comparator|Vehicle Placebo|40 subjects will receive placebo Gel twice daily for three successive days for a total of 6 doses
3119950|NCT02709018|Experimental|Losartan|Losartan flexibly dosed from 25-100 mg per day over 10 weeks
3119951|NCT02709018|Placebo Comparator|Placebo|Placebo flexibly dosed from 25-100 mg per day over 10 weeks
3119952|NCT02709096|Experimental|BPX-01, 1% Topical Gel|BPX-01, 1% Topical Gel; applied once daily to the face for four weeks.
3119953|NCT02709096|Placebo Comparator|BPX-01, Vehicle Gel|BPX-01, Vehicle Gel; applied once daily to the face for four weeks.
3119954|NCT02709109|Experimental|Sequence 1: VX-371 + Hypertonic Saline (HS), then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 milligram (mg)/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their cystic fibrosis (CF) standard of care.
3119955|NCT02709109|Experimental|Sequence 2: HS, then VX-371 + HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
3119956|NCT02709109|Experimental|Sequence 3: VX-371 + Placebo, then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
3119957|NCT02709109|Experimental|Sequence 4: Placebo, then VX-371 + Placebo|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 1 to Day 28) in treatment period 1 followed by a 28 days washout period (Day 29 to Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (Day 57 to Day 84) in treatment period 2. Participants also received a stable dose of 2 tablets of Orkambi (lumacaftor 400 mg/ivacaftor 250 mg) orally every 12 hours with fat-containing food throughout the study as part of their CF standard of care.
3119958|NCT02709330|Experimental|Lunasin regimen|"The Lunasin regimen consists of:~LunaRich X Capsules (12 capsules per day)~Reliv NOW - a mixture of 'vitamins, minerals and super-powered antioxidants' (3 scoops per day)~Pro-Vantage - a mixture of 'soy protein, medium chain triglycerides, creatine, CoQ10 and supercharged amino acids' (2 scoops per day)~It will be suggested that patients open the LunaRich X capsules and mix the contents of these as well as the other 2 ingredients in water to make a shake. If patients do not tolerate advancing to the next dosage, they will be asked to drop back to the highest dosage they could tolerate."
3119959|NCT02709330|Active Comparator|Historical controls|For each enrolled participant, matched historical controls will be identified from the PatientsLikeMe database. Participants will be matched according to their ALSFRS-R progression rate before they start on the Lunasin regimen (estimated by assuming their score was normal at 48 on the date of symptom onset).
3119960|NCT02709369|Experimental|Active HIRREM|This is a single site, single-arm, open-label, developmental study. Participants are recruited to receive eight to twenty sessions of High-resolution, relational, resonance-based electroencephalic mirroring (HIRREM), in addition to their usual care.
3119961|NCT02709486|Experimental|Low dose|Investigational product
3119962|NCT02709486|Experimental|High dose|Investigational product
3119963|NCT02709486|Placebo Comparator|Placebo|Investigational product
3119964|NCT02709538|Experimental|GSP 301 NS|
3119965|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 3.7|
3119966|NCT02709538|Placebo Comparator|GSP 301 Placebo NS pH 7.0|
3119967|NCT02709577|Experimental|EndoBarrier Gastrointestinal Liner|Subjects randomized and implanted with the EndoBarrier Gastrointestinal liner; subjects will be implanted for 24 weeks to 52 weeks and evaluated for study endpoints.
3119968|NCT02709577|Experimental|Sham: endoscopy and standard of care|Subjects randomized to sham arm received an upper GI examination and were evaluated for study endpoints.
3119969|NCT02709746|Experimental|Vortioxetine 10 mg/day|
3119970|NCT02709746|Experimental|Vortioxetine 20 mg/day|
3119971|NCT02709746|Active Comparator|Fluoxetine 20 mg/day,|
3119972|NCT02709746|Placebo Comparator|Placebo|
3119973|NCT02709785|Experimental|Group 1 SmartMouth|24 subjects with plaque and gingival inflammation
3119974|NCT02709785|Experimental|Group 2 Chlorhexidine|28 subjects with plaque and gingival inflammation
3119975|NCT02709785|Placebo Comparator|Group 3 Placebo|28 subjects with plaque and gingival inflammation
3119976|NCT02709889|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab tesirine 0.2-0.4 mg/kg administered intravenously on Day 1 of each 6-week cycle. Dexamethasone 8 mg administered orally twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6-week cycle.
3119977|NCT02710045|Active Comparator|MV at 9 months|"Measles Vaccine at 9 months of age. Measles Vaccine at 18 months of age. All vaccines given as per normal Gambia schedule until 9 months of age, including third dose of diphtheria-tetanus-whole cell pertussis (DTP3), hepatitis B vaccine (HBV) and oral polio vaccine (OPV) at four months of age.~At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age."
3132476|NCT03430245|Experimental|VelaShape III & UltraShape Power|VelaShape III treatment with radiofrequency, infrared and massage combined with UltraShape Power treatment, using pulsed, focused ultrasound treatment.
3119978|NCT02710045|Active Comparator|DTP + MV at 9 months|Measles Vaccine at 9 months of age. DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given a single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid, and i.m. DTP (Serum Institute of India Ltd.) in the thigh. Yellow fever vaccine (YF) and OPV administered at 11 months of age. Given a standard MV challenge at 18 months of age.
3119979|NCT02710045|Active Comparator|DTP at 9 months|DTP Vaccine at 9 months of age. Measles Vaccine at 18 months of age. DTP3 dose withheld and given HBV and OPV at four months of age. At 9 months of age given i.m. DTP (Serum Institute of India Ltd.) in the thigh. MV, OPV and YF administered at 11 months of age. Given a standard MV challenge at 18 months of age.
3119980|NCT02710071|Experimental|Placebo, Nebivolol, Hydrochlorothyazide|Sequence: Placebo, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks,Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
3119981|NCT02710071|Experimental|Placebo, Hydrochlorothyazide, Nebivolol|Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Nebivolol 5mg for 2 weeks followed by nebivolol 10 mg for 4 weeks.
3119982|NCT02710136|Experimental|Glycerinated CR Allergenic Extract|"Complete Arm Title: Glycerinated German Cockroach Allergenic Extract.~Cockroach sensitive subjects are exposed to cockroach nasal allergen (NAC) intranasally at at increasing doses per protocol. The NAC aim is pursuit of optimal dose range as determined by tolerability and eliciting a threshold of nasal symptoms."
3119983|NCT02710214|Experimental|Duavee|1 Tablet of 0.45mg conjugated estrogens/20 mg bazedoxifene daily for 8 weeks
3119984|NCT02710214|Placebo Comparator|Placebo|Placebo pill daily for 8 weeks.
3119985|NCT02710240|Experimental|ICG Arm|Subjects undergo indocyanine green injection within 72 hours prior to surgery. Permitting infusion time within 72 hours of operation is believed to be adequate for tissue glow/surgical visualization. Alternately, patients may receive 25 mg of indocyanine green during induction. Dose and time of administration will be determined by the neurosurgeon during surgical planning. This 25 mg dose of indocyanine green is similar to dosing for other intraoperative vascular visualization.
3119986|NCT02710292|Other|DT1, then TE|Delefilcon A contact lenses worn first, followed by narafilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
3119987|NCT02710292|Other|TE, then DT1|Narafilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product will be worn bilaterally (in both eyes) for at least 7 days in a daily disposable modality.
3119988|NCT02710422|Experimental|Arm 1 - Amniotic Membrane Placement|Participants who receive the human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
3119989|NCT02710422|Other|Arm 2 - No Amniotic Membrane Placement|Participants who do not receive human amniotic membrane placement after robotic assisted radical prostatectomy (RARP). Participants will also undergo PSA measurement and complete the EPIC 26 and Sexual History Inventory for Men (SHIM) psychosocial questionnaires at protocol-defined intervals.
3119990|NCT02710526|Experimental|32 mg CAM2038 weekly|Group 1, 32 mg of CAM2038 subcutaneous weekly injection at multiple injection sites
3119991|NCT02710526|Experimental|128 mg CAM2038 monthly injection|Group 2: 128 mg of CAM2038 subcutaneous monthly injection in the buttocks
3119992|NCT02710526|Experimental|160 mg CAM2038 monthly injection|Group 3: 24mg sublingual BPN for the first 7 days, and then 160 mg of CAM2038 subcutaneous monthly injection in the buttocks starting on Day 8.
3119993|NCT02710591|Experimental|Rimeporide|"Multiple oral doses of rimeporide ranging from 50 to 300 mg will be administered three times a day (TID) for a total of 4 weeks. 4 ascending dose levels will be studied sequentially in ascending order. Rimeporide is provided as hard gel 25 mg or 50 mg capsules.~Each patient will participate in only 1 dose cohort. 5 patients are expected to be recruited in each cohort through all participating sites."
3119994|NCT02710630|Active Comparator|Dabigatran etexilate capsule|
3119995|NCT02710630|Experimental|Dabigatran etexilate tablet A1|
3119996|NCT02710630|Experimental|Dabigatran etexilate tablet B1|
3119997|NCT02710630|Experimental|Dabigatran etexilate tablet C1|
3119998|NCT02710630|Experimental|Dabigatran etexilate tablet D1|
3119999|NCT02710630|Experimental|Dabigatran etexilate tablet E1|
3120000|NCT02710669|Experimental|(R)-propafenone|Single intravenous dose of (R)-propafenone (2mg/kg) infused over 10 minutes
3120001|NCT02710669|Active Comparator|(S)-Propafenone|Single intravenous dose of (S)-propafenone (2mg/kg) infused over 10 minutes
3120002|NCT02710669|Placebo Comparator|Placebo|Placebo (normal saline) is infused over 10 minutes
3120003|NCT02710890|Experimental|Lacosamide|Up to 2 age-based Cohorts with Cohort 1 including at least 40 subjects who are >=8 to <17 years. For Cohort 2 every attempt will be made to enroll 20 subjects >= 4 to < 8 years of age, 12 subjects >= 2 to < 4 years of age and 12 subjects >= 1 month to < 2 years of age. A Data Monitoring Committee (DMC) will review the safety and tolerability data for each Cohort to make the following recommendations: the progression of the current Cohort, including intravenous (iv) infusion durations to be evaluated, and progression to initiate enrollment in the next Cohort (Cohort 2).
3120004|NCT02710981|Active Comparator|Clomiphene citrate only|women with prior 5 ovulatory cycles of Clomiphene citrate induction, but without conception (clomiphene citrate failure), with thin endometrium (<8mm) in at least 3 cycles.
3120005|NCT02710981|Experimental|Sildenafil vaginal gel and Clomiphene|Women who did not conceive on the Clomiphene citrate only cycle (41 women) were given Clomiphene citrate 100 mg/ day starting from day of the cycle for 5 days, with the addition to sildenafil vaginal gel 5 gm twice daily starting from day 8 of the cycle until day of HCG injection.
3120006|NCT02711306|Experimental|GMN Diet|In the glucomannan noodle (GMN) diet, the participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks, with each serving of glucomannan noodles weighing up to 200 g with 2 g of glucomannan.
3120007|NCT02711306|Placebo Comparator|PN Diet|In the placebo noodle (PN) diet, the participants received the participants received the same amount of noodles without glucomannan.
3120008|NCT02711345|Experimental|Escalation|
3120009|NCT02711345|Experimental|Expansion Group 1|
3120010|NCT02711345|Experimental|Expansion Group 2|
3120011|NCT02711345|Experimental|Expansion Group 3|
3120012|NCT02711345|Experimental|Expansion Group 4|
3120013|NCT02711553|Experimental|8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
3120014|NCT02711553|Placebo Comparator|Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
3120015|NCT02711553|Experimental|80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
3120016|NCT02711553|Placebo Comparator|Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine|Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
3120017|NCT02711800|Experimental|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by Dr. Patrick Seed from the department of pediatrics. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The intervention duration is 30 days.
3120018|NCT02711839|Placebo Comparator|Control Group|Commercial diabetic formula
3120019|NCT02711839|Experimental|Treatment Group|White sweet potato formula
3120020|NCT02711956|Experimental|DE and DC - ZEN003694 in Combination with Enzalutamide|"Dose Escalation (DE) and Dose Confirmation (DC): ZEN003694 will be administered orally once daily with enzalutamide in 28-day cycles, enrolling mCRPC patients.~Two patient populations will be enrolled in DE and DC. Cohort A: Patients with prior progression on enzalutamide or apalutamide by PCWG2 criteria who were receiving a stable dose of enzalutamide at the time of study entry. Cohort B: Patients who were enzalutamide-naïve with prior progression on abiraterone by Prostate Cancer Working Group 2 (PCWG2) criteria."
3120021|NCT02711995|Experimental|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
3120022|NCT02711995|Active Comparator|Botulinum toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
3120023|NCT02712008|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram (mg):2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
3120024|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to week 12.
3120025|NCT02712008|Active Comparator|Aflibercept 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12.
3120026|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 16 and Q8 through Week 32.
3120027|NCT02712008|Experimental|REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at Week 20 and Q12 through Week 32.
3120028|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week16 and Q8 through Week 32.
3120029|NCT02712008|Experimental|Aflibercept 2 mg Q4 to Aflibercept 2 mg Q12|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI at Week 20 and Q12 through Week 32.
3120030|NCT02712008|Experimental|Aflibercept 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) at week 16 and Q8 through week 32.
3120031|NCT02712047|Experimental|Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg|Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
3120032|NCT02712047|Placebo Comparator|Placebo|Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
3120033|NCT02712320|Experimental|LMIS 50 mg|50 mg leuprolide mesylate administered subcutaneously, when given as two separate injections 6 months apart (Month 12 and Month 18 from the initiation of Protocol FP01C-13-001)
3120034|NCT02712333|Experimental|Air purifiers|Participants in this group received an intervention of true air purifiers placed in the center of the room.
3120035|NCT02712333|Sham Comparator|Control|Participants in this group received an intervention of sham air purifiers, which were under the same conditions as the true purifiers except the filter gauze in them were removed.
3120036|NCT02712359|Other|Havrix 1 dose_Year 8 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
3120037|NCT02712359|Other|Havrix 2 doses_Year 8 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 7 years and less than (<) 10 years between the administration of the last vaccine dose and the Persistence Visit at Year 8 and who participated in the Year 8 cross-sectional survey.
3120038|NCT02712359|Other|Havrix 1 dose_Year 10 Group|Subjects who received one dose of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
3120039|NCT02712359|Other|Havrix 2 doses_Year 10 Group|Subjects who received two doses of Havrix vaccine and with more than or equal to (≥) 10 years and less than (<) 13 years between the administration of the vaccine dose and the Persistence Visit at Year 10 and who participated in the Year 10 cross-sectional survey.
3120040|NCT02712398|Experimental|Phasix™ ST|Subjects treated with Phasix™ ST mesh
3120041|NCT02712424|Active Comparator|DAR-901|0.1 mL intradermal injection of 1 mg DAR-901
3120042|NCT02712424|Placebo Comparator|Placebo|0.1 mL intradermal injection of sterile saline for human use
3120043|NCT02712554|Experimental|Treatment A:CL-108 22.5mg/975mg/37.5mg|CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
3120044|NCT02712554|Experimental|Treatment B:CL-108 37.5mg/1625mg/62.5mg|CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
3120045|NCT02712554|Active Comparator|Treatment C:M366 22.5mg/975mg|M366 22.5 mg/975 mg tablet by mouth
3120046|NCT02712554|Active Comparator|Treatment D: M366 37.5mg/1625mg|M366 37.5 mg/1625 mg tablet by mouth
3120047|NCT02712554|Placebo Comparator|Treatment E: Placebo|Placebo 0 mg tablet by mouth
3120048|NCT02712788|Active Comparator|Milrinone|Milrinone will be administered intravenously at an initial rate of 0.75mCg/kg/min and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
3120049|NCT02712788|Placebo Comparator|Placebo|Placebo (Normal Saline) will be administered intravenously and titrated based on symptoms in addition to hyperdynamic therapy and angiographic therapy as indicated per institutional protocol.
3120050|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP)
3120051|NCT02712983|Experimental|Cohort A (3 capsules o.d.): TIP/PBO|Cohort A (3 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
3120052|NCT02712983|Placebo Comparator|Cohort A (3 capsules o.d.): PBO|Cohort A (3 capsules o.d.): Inhaled placebo (PBO)
3120053|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP)
3120054|NCT02712983|Experimental|Cohort B (5 capsules o.d.): TIP/PBO|Cohort B (5 capsules o.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
3120055|NCT02712983|Placebo Comparator|Cohort B (5 capsules o.d.): PBO|Cohort B (5 capsules o.d.): inhaled placebo (PBO)
3120056|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP)
3120057|NCT02712983|Experimental|Cohort C (4 capsules b.i.d.): TIP/PBO|Cohort C (4 capsules b.i.d.): Tobramycin inhalation powder (TIP) and inhaled placebo (PBO) cyclical
3120058|NCT02712983|Placebo Comparator|Cohort C (4 capsules b.i.d.): PBO|Cohort C (4 capsules b.i.d.): inhaled placebo (PBO)
3120059|NCT02712996|Active Comparator|Vyvanse|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
3120060|NCT02712996|Placebo Comparator|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
3120061|NCT02713178|Active Comparator|EXPAREL 133 mg|Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.
3120062|NCT02713178|Active Comparator|EXPAREL 266 mg|Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).
3120063|NCT02713178|Placebo Comparator|Placebo|Normal saline (20 mL).
3120064|NCT02713204|Experimental|REGN910-3 (3 mg: 2 mg)|Participants were administered intravitreal injection of REGN910-3 (3 milligram [mg]:2 mg) every 4 weeks (Q4) on Day 1, Week 4, and Week 8 for 3 initial doses followed by every Week 8 (Q8) dosing beginning at Week 16 up to Week 32.
3120065|NCT02713204|Experimental|REGN910-3 (6 mg:2 mg)|Participants were administered intravitreal injection of REGN910-3 (6 mg:2 mg) Q4 on Day 1, Week 4 and Week 8 for 3 initial doses. At Week 12, participants were re-randomized to receive REGN910-3 (6 mg:2 mg) Q8 or Q12 (beginning at Week 16 or Week 20) through Week 32.
3120066|NCT02713204|Experimental|Aflibercept (IAI) 2 mg|Participants were administered intravitreal injection of Aflibercept (IAI) 2 mg Q4 on Day 1, Week 4 and Week 8 for 3 initial doses up to Week 12. At Week 12, participants were re-randomized to receive IAI Q8 or Q12 (beginning at Week 16 or 20) or REGN910-3 (6 mg:2 mg) Q8 beginning at Week 16 through Week 32.
3120067|NCT02713230|Active Comparator|EXPAREL 133 mg|10 mL EXPAREL (bupivacaine liposome injectable suspension) expanded with 10 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
3120068|NCT02713230|Active Comparator|EXPAREL 266 mg|20 mL EXPAREL (bupivacaine liposome injectable suspension) as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
3120069|NCT02713230|Placebo Comparator|Placebo|20 mL normal saline as single-injection brachial plexus block (interscalene or supraclavicular) ≥1 h preoperatively
3120070|NCT02713243|Experimental|LJN452 followed by placebo|Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
3120071|NCT02713243|Experimental|Placebo followed by LJN452|Randomized patients in this arm will receive single oral dose of placebo daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of LJN452 daily for 14 days.
3120072|NCT02713256|Experimental|CFZ533 10mg/kg|CFZ533 intravenously over approximately one hour
3120073|NCT02713425|Experimental|Single Arm - Entertaining Video Game|The children in this study will have a single visit. During this visit they will be introduced to the game. The child will then interact with the game and after they have finished, they will be asked questions about their experience with the game. Parents will observe and provide their own feedback about the game.
3120074|NCT02713490|Active Comparator|EXPAREL|Single dose of EXPAREL 266 mg in 20 mL admixed with bupivacaine HCl 0.5% in 20 mL and expanded in volume with 80 mL normal saline (total volume of 120 mL).
3120075|NCT02713490|Active Comparator|Bupivacaine|Bupivacaine HCl 0.5% in 20 mL expanded in volume with 100 mL normal saline (total volume of 120 mL).
3120076|NCT02713529|Experimental|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
3120077|NCT02713542|Experimental|Autologous Conditioned Plasma (ACP)|3 Intra-articular (IA) injections at 1 week intervals
3120078|NCT02713542|Placebo Comparator|Normal Saline (NS)|3 NS Intra-articular (IA) injections at 1 week intervals
3120079|NCT02713594|Placebo Comparator|Control|Counseling from WTQL
3120080|NCT02713594|Experimental|Incentive|Counseling from WTQL; Financial incentive to participate
3120081|NCT02713659|Experimental|Early Literacy Promotion|Parents and children randomized to the Early Literacy Promotion arm.
3120082|NCT02713659|Active Comparator|Standard Literacy Promotion|Parents and children randomized to the Standard Literacy Promotion arm.
3120083|NCT02713698||Group 1 (≥18 years, BMI<35kg/m2)|Patients with 18 or more years presenting for inpatient nose and ear surgery.
3120084|NCT02713698||Group 2 (≥18 years, ≥35kg/m2)|Patients with 18 or more years presenting for inpatient bariatric surgery.
3120085|NCT02713698||Group 3 (≥65 years)|Patients with 65 or more years presenting for orthopaedic surgery.
3120086|NCT02713711|No Intervention|control group|The control group plaques did not receive any treatment.
3120087|NCT02713711|Experimental|phototherapy group|Twelve sessions of phototherapy (UV-B) applied on psoriatic plaques according to individual initial evaluation of Minimal Erythema Dose (MED).
3120088|NCT02713711|Experimental|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L) applied on psoriatic plaques.
3120089|NCT02713711|Experimental|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments on the same conditions described above applied on psoriatic plaques.
3120090|NCT02713789|Active Comparator|hMaxi-K|Single Treatment/ two escalating dose levels (8000 µg and 16,000 µg injection). In each dose level, 11 participants will receive hMaxi-K and 6 will receive placebo (only one injection per each participant)
3120091|NCT02713789|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single treatment dose levels (8000 µg and 16000 µg) by injection (only one injection per each participant)
3120092|NCT02713828|Experimental|Phase I: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Dose-Limiting Toxicity (DLT) evaluation period for determination of the appropriateness of dose-escalation will be through the end of the second treatment cycle.
3120093|NCT02713828|Experimental|Phase II: Glembatumumab Vedotin|Glembatumumab vedotin once every three weeks (q3w) by 90-minute intravenous (IV) infusion, until disease progression or intolerance. The Maximum Tolerated Dose (MTD) determined in Phase I will be used in Phase II.
3120094|NCT02713867|Active Comparator|Nivolumab 240 mg|Nivolumab 240 mg Every 2 Weeks
3120095|NCT02713867|Experimental|Nivolumab 480 mg|Nivolumab 480 mg Every 4 Weeks
3120096|NCT02714062|Placebo Comparator|Placebo|Days 1-56: Placebo
3120097|NCT02714062|Experimental|VI-0521 Mid Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-56: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)"
3120098|NCT02714062|Experimental|VI-0521 Top Dose|"Days 1-14: VI-0521 (Phentermine/Topiramate 3.75 mg/23 mg)~Days 15-28: VI-0521 (Phentermine/Topiramate 7.5 mg/46 mg)~Days 29-42: VI-0521 (Phentermine/Topiramate 11.25 mg/69 mg)~Days 43-56: VI-0521 (Phentermine/Topiramate 15 mg/92 mg)"
3120099|NCT02714153|Experimental|Bridge Occlusion Balloon|Bridge Balloon catheter is designed to be used for temporary vessel occlusion of the superior vena cava in applications including perioperative occlusion and emergency control of hemorrhage associated with vascular tears that may occur during lead extraction procedures.
3469349|NCT03887546|Experimental|Intervention group|"Intervention is administrated with Inspiratory Muscle Trainer. 20% maximum inspiratory pressure (MIP) during the first two weeks and 30% MIP after the second week.~12 weeks, 5 days/week, 15 minutes/day."
3469350|NCT03887546|Active Comparator|Control group|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day
3120103|NCT02714283||Non-CF bronchiectasis patients|Complete national 2006-2014 Medicare data from Part A, B and D will be obtained from CMS. We will use bronchiectasis ICD-9 codes 494.0 and 494.1 to identify patients with bronchiectasis within Medicare. From this identified bronchiectasis cohort, we will exclude patients with cystic fibrosis (ICD-9 codes 277.00-277.09), HIV infection (042), and a history of organ transplant (V42.0, V42.1, V42.6, V42.7, V42.8).
3120104|NCT02714400|Active Comparator|Venlafaxine|50mg of Venlafaxine before sleep
3120105|NCT02714400|Placebo Comparator|Placebo|One piece of placebo before sleep
3120106|NCT02714426|Active Comparator|Brain Health|In weeks 1 and 14, participants receive: Montreal Cognitive Assessment (MoCA), Wechsler Test of Adult Reading (WTAR), Functional Activities Questionnaire (FAQ), Older Americans Resources and Services (OARS) Complete Activities of Daily Living Scale, The Short Form (36) Health Survey (SF-36), Attention measures (Attention Network Test (ANT); Continuous Performance Test (CPT); Auditory Dual Task (ADT); Mind wandering; Cued Stroop), Positive and Negative Affect Scale (PANAS), Geriatric Depression Scale (GDS), Mindfulness Attention Awareness Scale (MAAS), Five Facet Mindfulness Questionnaire (FFMQ), Emotion Regulation Questionnaire (ERQ), State-Trait Anxiety Inventory (STAI), and Starkstein Apathy Scale (AS). In weeks 4-11, participants receive the Brain Health control instruction.
3120107|NCT02714426|Experimental|Mindfulness-inspired Treatment/Testing|"Participants receive all of the same measures as the active comparator Brain Health condition in Weeks 1-14. In weeks 4-11, participants receive Mindfulness Inspired Treatment"
3120108|NCT02714504|No Intervention|observational|No anti-mold prophylaxis given on the basis of results of baseline presence of skin lesions
3120109|NCT02714504|Experimental|Anti-mold prophylaxis|Anti-mold prophylaxis with either voriconazole or posaconazole for patients with baseline skin lesions in the extremities positive for Fusarium spp.
3120110|NCT02714569|Experimental|Part A: LY3202328 (LY)|Single ascending doses of 1 milligram (mg), 3 mg, 10 mg, 30 mg, 100 mg, 300mg, 600 mg LY3202328 orally while fasting, or 30 mg LY3202328 orally while fed in 4 periods.
3120111|NCT02714569|Placebo Comparator|Part A: Placebo|A single ascending dose of placebo orally, in 1 period while fasting, and up to one period while fed.
3120112|NCT02714569|Experimental|Part B: LY3202328 (LY)|A multiple ascending dose of 5 mg, 20 mg, 100 mg, and 300 mg LY3202328 at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
3120113|NCT02714569|Placebo Comparator|Part B: Placebo|A multiple ascending dose of placebo at up to 4 dose levels, orally, once daily for 29 days, while fasting and with a single dose of 10 mg statin (atorvastatin or simvastatin) one week prior to treatment and on Day 29.
3120114|NCT02714595|Experimental|Cefiderocol|Participants will receive cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
3120115|NCT02714595|Active Comparator|Best Available Therapy (BAT)|Best available therapy (BAT) will be chosen by the investigator and may include up to three antibacterial agents for carbapenem resistant Gram-negative bacteria, intravenously administered per country-specific guidelines for 7-14 days. Treatment could be extended to 21 days at the discretion of the investigator.
3120116|NCT02714868|Experimental|Project TEAM Intervention|Project TEAM is a manualized intervention co- facilitated by a disability advocate and a licensed professional. The intervention includes eight group sessions and two experiential learning field trips. In addition, young adults with disabilities serve as peer mentors on field trips and contact youth weekly to support attainment of goals. Project TEAM outcomes are to: increase youths' knowledge of environmental factors and modification strategies; reduce the impact of environmental barriers on participation; increase self-efficacy and self-determination; and increase participation in a personal activity goal in the area of education, employment, or community life.
3120117|NCT02714868|Active Comparator|Matched comparison|Youth with disabilities who are matched controls will receive their typical educational or therapeutic services. Youth will receive a stipend to participate in a preferred activity in the community; youth will document what they did and with whom they participated. Attempts to control for the impact of resources on participation and goal achievement.
3120118|NCT02715076|Experimental|Ambient Temp 19°C & Passive Insulation|Ambient Temperature 19°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
3120119|NCT02715076|Experimental|Ambient Temp 19°C & Forced-air Warming|Ambient Temperature 19°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
3120120|NCT02715076|Experimental|Ambient Temp 21°C & Passive Insulation|Ambient Temperature 21°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
3120121|NCT02715076|Experimental|Ambient Temp 21°C & Forced-air Warming|Ambient Temperature 21°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
3120122|NCT02715076|Experimental|Ambient Temp 23°C & Passive Insulation|Ambient Temperature 23°C and Passive Insulation: patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
3120123|NCT02715076|Experimental|Ambient Temp 23°C & Forced-air Warming|Ambient Temperature 23°C and Forced-air Warming: patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
3120124|NCT02715258|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will self-administer bexagliflozin tablets once daily for 24 weeks.
3120125|NCT02715258|Placebo Comparator|Placebo tablets|Each subject will self-administer placebo (inactive tablet) once daily for 24 weeks.
3120126|NCT02715700|Experimental|Maintenance Methadone and MK-1439|Participants maintained on a stable methadone regimen (20 to 200 mg once daily) for ≥14 days prior to Day 1 will continue to receive methadone maintenance once per day on Days 1 to 7. From Day 2 to 6, participants will also receive doravirine 100 mg once daily.
3120127|NCT02715726|Active Comparator|Ezetimibe 10 mg|Oral ezetimibe 10 mg capsule once daily with or without food for 24 weeks and subcutaneous placebo injection for alirocumab every 2 weeks (Q2W) for 22 weeks added to lipid modifying therapy (LMT).
3120128|NCT02715726|Experimental|Alirocumab 75 mg Q2W/up to 150 mg Q2W|Subcutaneous injection of alirocumab 75 mg Q2W and oral placebo capsule for ezetimibe once daily with or without food added to stable LMT for 24 weeks. Alirocumab dose up-titrated to 150 mg Q2W from Week 12 when LDL-C level was >=70 milligrams per deciliter (mg/dL) (1.81 millimoles per liter [mmol/L]) at Week 8.
3120129|NCT02715804|Experimental|PAG: PEGPH20 + nab-Paclitaxel + Gemcitabine|Participants will receive 3.0 micrograms/kilogram (μg/kg) PEGPH20 as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 milligrams/square meter (mg/m^2) nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
3120130|NCT02715804|Placebo Comparator|AG: Placebo + nab-Paclitaxel + Gemcitabine|Participants will receive placebo matching to PEGPH20 as an IV infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks [Week 4 of every cycle will be a rest week with no treatment]), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond in combination with 125 mg/m^2 nab-paclitaxel as an IV infusion and 1000 mg/m^2 gemcitabine as an IV infusion, once weekly for Weeks 1 to 3 of all treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, death, or withdrawal of consent.
3120131|NCT02716194|Experimental|Cohort 1 - Low dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
3120132|NCT02716194|Experimental|Cohort 2 - Medium dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
3120133|NCT02716194|Experimental|Cohort 3 - High dose|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 10 evaluable participants; Cohort 2: 10 evaluable participants; Cohort 3: 10 evaluable participants]. Participants will be recruited to the next dose level only after short-term safety has been reviewed and subject to approval by a Safety Review Committee at the preceding dose level.
3120134|NCT02716298|Active Comparator|fanfilcon A|Study participants are randomized to wear fanfilcon A lens during the crossover study
3120135|NCT02716298|Active Comparator|lotrafilcon B|Study participants are randomized to wear lotrafilcon B lens during the crossover study.
3120136|NCT02716324|Active Comparator|ADHD Portal|In this arm, the ADHD Portal was used alone as an electronic communication tool.The ADHD portal is considered standard of care at our institution for communicating information between clinicians, teachers, and parents.
3120137|NCT02716324|Experimental|ADHD Portal plus Care Manager (CM)|In this arm, the ADHD Portal was combined with the CM. Clinicians, teachers, and parents used the ADHD Portal as standard of care. In addition, clinicians, teachers, parents, and any external mental health providers interacted with a CM, who had access to information contained in the ADHD Portal.
3120138|NCT02716506||Symptomatic POP|POP surgery in year 2015
3120139|NCT02716584|Experimental|Physical exercise|Participants participate in brisk walking exercises.
3120140|NCT02716584|Active Comparator|Stretching exercise|Participants participate in non-aerobic, non-Yoga stretching exercises
3120141|NCT02716714|Active Comparator|ingenol mebutate gel 0.015%|Applied on face and scalp for three days.
3120142|NCT02716714|Active Comparator|ingenol mebutate gel 0.05%|Applied on trunk and extremities for two days.
3120143|NCT02716727|Active Comparator|Aquasil Ultra Cordless, Dentsply|Gingival displacement procedure that uses a pneumatic hand piece to inject the light body impression material into the gingival sulcus.
3120144|NCT02716727|Active Comparator|Ultrapak, Ultradent cord|The knitted cord is used for physical displacement of gingival tissue. Cord is placed in the gingival sulcus and left in place for at least 4 minutes to achieve gingival displacement.
3120145|NCT02716779|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants with chronic hepatitis C, genotype 1, received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
3120146|NCT02716779|Placebo Comparator|Placebo|Participants with chronic hepatitis C, genotype 1, received ribavirin matching placebo for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
3120147|NCT02716779|Experimental|Ribavirin|Participants with chronic hepatitis C, genotype 1, received ribavirin monotherapy for 6 weeks. Thereafter, all participants received combination therapy with PEG-IFN alfa-2a plus ribavirin for 12 weeks.
3120148|NCT02716805|Experimental|Cohort 1|"Subjects received Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
3120149|NCT02716805|Experimental|Cohort 2|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
3120150|NCT02716805|Experimental|Cohort 3|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Late post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Day 100 ± 10 days and Day 128 (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
3120151|NCT02716805|Experimental|Cohort 4|"Subjects were to receive Prevnar-13 on Day -33 ± 2 days, tremelimumab (75 mg) + durvalumab (1500 mg) on Day -31, leukopheresis on ~Day -10, melphalan (200 mg/m^2) on Day -2, ASCT on Day 0, and reinfusion of PBLs and tremelimumab (75 mg) on Day 3. Early post-ASCT treatment comprised Prevnar-13 on Days 30 and 60, tremelimumab (75 mg) + durvalumab (1500 mg) on Days 30 through 40 and Day 100 ± 10 days (Cycles 1 and 2), followed by up to 6 cycles of durvalumab (1500 mg) on Day 1 of Cycles 3 through 8."
3120152|NCT02716818|Experimental|Chronocort®|Chronocort® will be provided as 5mg, 10mg and 20mg capsules for oral administration. The starting dose for each subject will be based on the subjects previous glucocorticoid therapy dose and then dose titrated to effect.
3120153|NCT02716818|Active Comparator|standard glucocorticoid therapy|Subjects in this arm will continue previous oral glucocorticoid therapy titrated to effect.
3120154|NCT02716896|Active Comparator|Surgery (radical cystectomy)|In brief, radical cystectomy is the removal of the entire bladder, nearby lymph nodes (lymphadenectomy), part of the urethra, and nearby organs that may contain cancer cells. In men the prostate, the seminal vesicles, and part of the vas deferens are also removed. In women the cervix, the uterus, the ovaries, the fallopian tubes, and part of the vagina are also removed. Participants in this group may also undergo neoadjuvant chemotherapy prior to the surgery. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, Glomerular Filtration rate (GFR), participant's preference, and availability of chemotherapeutic regimen.
3120155|NCT02716896|Active Comparator|Radiation and Chemoradiation|Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
3120156|NCT02716987|Experimental|Set A: TAK-831 100 mg|TAK-831 100 milligram (mg), suspension, orally, once on Day 1 and up to 100 megabecquerel (MBq) of Positron Emission Tomography (PET) ligand PGM028299 labeled with [18F] ([18F]PGM299) with a maximal mass up to 12.5 microgram (mcg), injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
3120157|NCT02716987|Experimental|Set A: TAK-831 200 mg|TAK-831 200 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
3120158|NCT02716987|Experimental|Set A: TAK-831 250 mg|TAK-831 250 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
3120159|NCT02716987|Experimental|Set A: TAK-831 500 mg|TAK-831 500 mg, suspension, orally, once on Day 1 and up to 100 MBq of [18F]PGM299 with a maximal mass up to 12.5 mcg, injection, intravenously, prior to PET imaging at Baseline, 2 hours and 26 hours post-TAK-831 dose.
3120160|NCT02716987|Experimental|Set B: [18F]PGM299|[18F]PGM299 up to 100 MBq (with a maximal mass up to 12.5 mcg), injection, intravenously, prior to PET imaging on Days 1 and 10.
3120161|NCT02717195|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
3120162|NCT02717195|Experimental|Double-blind Treatment (DBT) Period, Lu AF35700 10 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
3120163|NCT02717195|Experimental|DBT Period, Lu AF35700 20 mg|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period, 10 weeks
3120164|NCT02717195|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC Period (based on criteria to which investigator and patient are blinded), will be randomly assigned (1:1:1) double-blind treatment in DBT Period,10 weeks. Patients in this arm will continue with same the treatment and dose as at last visit of PC Period
3120165|NCT02717273|Active Comparator|standard peri-operative antibiotics|The standard of care at the University of Virginia Medical Center for liver transplantation patients is a 3.375 gram dose of piperacillin / tazobactam (Zosyn®) at the time of induction of anesthesia, though this dose may be adjusted for renal insufficiency. This dose is repeated during the operation every six hours.
3120166|NCT02717273|Experimental|extended three-day course of antibiotics|"For those patients randomized to the study group, antibiotics will be started as per the usual intra-operative dosing regimen, then continued to provide coverage for 72 hours.~This is typically provided as additional doses of 3.375 grams of piperacillin / tazobactam (Zosyn®) every 8 hours for 3 total days (giving a total of 72 hours of antibiotic coverage), though this may be altered based on kidney function."
3120167|NCT02717494|Experimental|Arm 1A (PPV-23)|In Step 1, women in Arm 1A were administered a 0.5 milliliter (mL) dose of PPV-23 intramuscularly once.
3120168|NCT02717494|Experimental|Arm 1B (PCV-10)|In Step 1, women in Arm 1B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
3120169|NCT02717494|Placebo Comparator|Arm 1C (placebo)|In Step 1, women in Arm 1C were administered a 0.5 mL dose of 0.9 percent Sodium Chloride (NaCl) intramuscularly once.
3120170|NCT02717494|Experimental|Arm 2A (PPV-23)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2A were administered a 0.5 mL dose of PPV-23 intramuscularly once.
3120171|NCT02717494|Experimental|Arm 2B (PCV-10)|In Step 2, women who received placebo in step 1 that were randomized to Arm 2B were administered a 0.5 mL dose of PCV-10 intramuscularly once.
3120172|NCT02717494|Experimental|Step 3 (PCV-10)|In Step 3, women who received placebo in step 1 and failed entry into step 2 due to ongoing new pregnancy were administered a 0.5 mL dose of PCV-10 intramuscularly once.
3120173|NCT02717546||Group One|Distal Tibia Fracture repaired with Zimmer MotionLoc Screw
3120174|NCT02717754|Experimental|Oseltamivir 100 mg|Participants will receive 100 mg oseltamivir intravenous BID for 5 days.
3120175|NCT02717754|Experimental|Oseltamivir 200 mg|Participants will receive 200 mg oseltamivir intravenous BID for 5 days.
3120176|NCT02717754|Placebo Comparator|Placebo|Participants will receive oseltamivir matched placebo intravenous BID for 5 days.
3120177|NCT02718040|Experimental|Emervel Treatment Group|Eligible subjects received bilateral treatment of Nasolabial Folds (NLFs) and Marionette Lines (MLs) with Emervel Classic and/or Emervel Deep
3120178|NCT02718118|Experimental|1.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 1.5 mL (0.05 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
3120179|NCT02718118|Experimental|2.5 mL Reconstitution|Subjects treated with Dysport reconstituted at 2.5 mL (0.08 mL/injection) following the US on-label guidelines, with each subject receiving a single treatment session (50 units [U]) at the Day 1 visit.
3120180|NCT02718131|Active Comparator|INFUSE Bone Graft (BMP-2)|Children with NF1 and tibial pseudarthrosis who require surgery will have the INFUSE bone graft added to their surgical protocol. After a standard surgical approach of resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest; in addition, the INFUSE bone graft in the form of a collagen sponge will be wrapped around the tibia during the surgical process.
3120181|NCT02718131|Placebo Comparator|Control Group|Children with NF1 and tibial pseudarthrosis who require surgery will receive the standard surgical protocol only. This includes resection of abnormal pseudarthrotic tissue, placement of a rigid intramedullary rod (of the surgeon's choice) and placement of autogenous bone graft from the iliac crest.
3120182|NCT02718157|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
3120183|NCT02718248|Experimental|CHESS Mobile Health Group|The intervention will be six weekly one hour sessions of face-to-face problem solving therapy combined with the CHESS Mobile Health smart phone application (Comprehensive Health Enhancement Support System - CHESS). The CHESS Mobile Health smart phone application enables users to access relevant resources, create a support network and check in regularly with carers. The intervention will be delivered by Dr. Hatcher, a staff psychiatrist in Liaison Psychiatry at The Ottawa Hospital General Campus.
3120184|NCT02718326|Experimental|Dosing regimen 1|Participants will receive IVT aflibercept dosing regimen 1
3120185|NCT02718326|Experimental|Dosing regimen 2|Participants will receive IVT aflibercept dosing regimen 2
3120186|NCT02718326|Sham Comparator|Dosing regimen 3|Participants will receive matching sham injections
3120187|NCT02718417|Active Comparator|Arm A|Chemotherapy followed by observation
3120188|NCT02718417|Experimental|Arm B|Chemotherapy followed by avelumab in maintenance
3120189|NCT02718417|Experimental|Arm C|Chemotherapy in combination with avelumab followed by avelumab in maintenance
3120190|NCT02718625|Experimental|Santyl|Santyl collagenase ointment applied topically once per day for up to six weeks
3120191|NCT02718625|Active Comparator|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
3120192|NCT02718898|Experimental|Ixekizumab|"Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC.~Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40."
3120193|NCT02718898|Placebo Comparator|Placebo|"Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC.~Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40."
3120194|NCT02718963|Experimental|Control group|"control group(N=10): who does not have dysphagia symptom~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
3120195|NCT02718963|Experimental|Experimental group|"experimental group(N=10): who have dysphagia symptoms~apply Synchronized Electrical Stimulation Device~before apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function~during apply the synchronized electrical stimulation device, we will evaluate the high resolution manometry for evaluation of deglutition function"
3120196|NCT02719028|Placebo Comparator|Placebo|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
3120197|NCT02719028|Experimental|Antroquinonol 50 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
3120198|NCT02719028|Experimental|Antroquinonol 100 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
3120199|NCT02719028|Experimental|Antroquinonol 150 mg PO|Subjects with screening central laboratory with a diagnosis of primary hypercholesterolemia (nonfamilial) or mixed hyperlipidemia (TG between 150 mg/dL and 500 mg/dL, and cholesterol between 160 mg/dL and 250 mg/dL or LDL-C > 130 mg/dL ) who meet inclusion/exclusion criteria will be randomized to 4 groups patient will take (antroquinnonol 50mg or Placebo) 3 capsules once a day.
3120200|NCT02719158|Experimental|6 mg OTO-201|6 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.1 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
3120201|NCT02719158|Experimental|12 mg OTO-201|12 mg OTO-201 (sustained-release suspension of ciprofloxacin), single 0.2 mL supra-tympanostomy tube (STT) administration to the affected ear(s)
3120202|NCT02719158|Sham Comparator|Sham (empty syringe)|Sham (empty syringe), single 0.1 mL STT administration to the affected ear(s)
3120203|NCT02719171|Placebo Comparator|Placebo|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.
3120204|NCT02719171|Experimental|Risankizumab 150 mg Every 4 Weeks|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.
3120205|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0, 4, and 16|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.
3120206|NCT02719171|Experimental|Risankizumab 150 mg Weeks 0 and 12|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.
3120207|NCT02719171|Experimental|Risankizumab 75 mg Week 0|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.
3120208|NCT02719353|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
3120209|NCT02719353|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
3120210|NCT02719366|Experimental|comfilcon A Extended Range test lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
3120211|NCT02719366|Active Comparator|comfilcon A control lens|Subjects will be randomized to wear either the test or control pair of lens, then cross over to the alternate pair.
3120212|NCT02719535|Experimental|Corneal reshaping therapy|Subjects will be wearing corneal reshaping lenses for the correction of their myopia
3120213|NCT02719743|Active Comparator|H5N1 Formulation 1 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 1 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered intramuscularly (IM) in anterolateral thigh.
3120214|NCT02719743|Experimental|H5N1 Formulation 2 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 2 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
3120215|NCT02719743|Experimental|H5N1 Formulation 3 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 3 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
3120216|NCT02719743|Experimental|H5N1 Formulation 4 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 4 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
3120217|NCT02719743|Experimental|H5N1 Formulation 5 Group|Subjects received 2 primary doses (adjuvanted) at Days 0 and 21 of H5N1 vaccine Formulation 5 and a booster dose (unadjuvanted) at Day 385 of H5N1 vaccine (GSK1557484A). All doses were administered IM in anterolateral thigh.
3120218|NCT02719938|Experimental|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
3120219|NCT02719938|No Intervention|Control|Usual care.
3120220|NCT02720042|Experimental|Phasix™ Mesh|Patients treated with Phasix™ Mesh for hernia repair
3120221|NCT02720081|Experimental|MK-1029 150 mg + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 150 mg + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
3120222|NCT02720081|Placebo Comparator|MK-1029 Placebo + Montelukast 10 mg|Participants receive single-blind MK-1029 Matching-image Placebo + open-label Montelukast 10 mg for a 2 to 4 week run-in period while discontinuing or tapering off asthma controller medications. Participants receive double-blind MK-1029 Matching-image Placebo + Montelukast 10 mg for 6 weeks in the treatment period. Participants can use rescue medication during both periods as needed.
3120223|NCT02720107|Experimental|fingolimod|Patients did not receive any protocol specified treatment during this follow-up study. Patients remained on their current treatment regime (fingolimod), as determined by their regular treating physician (i.e. 0.5 mg fingolimod daily, single-arm).
3120224|NCT02720198|Active Comparator|Levomilnacipran|Levomilnacipran ER is switched from SSRI.
3120225|NCT02720198|Active Comparator|Quetiapine|Quetiapine XR is added in addition to current SSRI.
3120226|NCT02720224|Experimental|Estetrol|A single oral dose of 15 mg carbon 14 labelled estetrol ([14C]-estetrol), containing approximately 2.8 MBq (76 µCi) 14C
3120227|NCT02720484|Experimental|Treatment (Nivolumab)|Patients receive nivolumab IV over 30 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity.
3120228|NCT02720523|Experimental|Placebo / Upadacitinib 7.5 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive Upadacitinib 7.5 mg once daily for 248 weeks."
3120229|NCT02720523|Experimental|Placebo / Upadacitinib 15 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
3120230|NCT02720523|Experimental|Placebo / Upadacitinib 30 mg|"Period 1: Participants will receive placebo once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
3120231|NCT02720523|Experimental|Upadacitinib 7.5 mg / Upadacitinib 7.5 mg|"Period 1: Participants will receive upadacitinib 7.5 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 7.5 mg once daily for 248 weeks."
3120232|NCT02720523|Experimental|Upadacitinib 15 mg / Upadacitinib 15 mg|"Period 1: Participants will receive upadacitinib 15 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 15 mg once daily for 248 weeks."
3120233|NCT02720523|Experimental|Upadacitinib 30 mg / Upadacitinib 30 mg|"Period 1: Participants will receive upadacitinib 30 mg once daily for 12 weeks.~Period 2: Participants will receive upadacitinib 30 mg once daily until regulatory approval of RA indication in Japan at which point they will switch to receive upadacitinib 15 mg once daily. Participants will receive upadacitinib for 248 weeks."
3120234|NCT02720536|Experimental|Deferasirox|Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.
3120235|NCT02720627|Experimental|CB-03-01 cream, 1%|Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
3120236|NCT02720757||Spiolto Respimat|COPD patients requiring a fixed combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved Summary of Product Characteristics (SmPC) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines
3120237|NCT02720952|Experimental|Infacort|"Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).~The clinically-appropriate dose, based on standard individualised treatment, will be administered, given as a single dose orally. This will usually be equivalent to the previous day's dose."
3120238|NCT02721017|Experimental|Cryoanalgesia|Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure
3120239|NCT02721017|Active Comparator|Thoracic Epidural|Thoracic epidural (ropivicaine, fentanyl).
3120240|NCT02721147|Experimental|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
3120241|NCT02721147|Active Comparator|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
3120242|NCT02721251|Experimental|Exercise|16 week intervention, building up to 30-45 minutes of aerobic exercise 4 days per week, and 15 min of resistance exercise 2 days per week
3120243|NCT02721251|Experimental|Weight Loss|16 week intervention with a goal weight loss of 10%, accomplished with caloric and fat restriction, weekly sessions with a nutritionist, and some meal replacement
3120244|NCT02721251|Experimental|Exercise + Weight Loss|Combined components of the exercise and weight loss treatments
3120245|NCT02721355|Experimental|Food supplement GastimunHP|The subjects take food supplement containing specific IgY (GastimunHP) during treatment with routine medical regime
3120246|NCT02721355|No Intervention|Control|The subjects undergo the routine treatment regime without taking food supplement
3120247|NCT02721641|Experimental|Herceptin|Participants with stable disease and HER2-overexpressing metastatic or locally advanced cancer will receive expanded access to IV Herceptin until disease progression, unacceptable toxicity, death, or decision by the investigator or participant to discontinue treatment.
3120248|NCT02721875|Experimental|Volasertib monotherapy|
3120249|NCT02721875|Experimental|Volasertib + azacitidine combination|
3120250|NCT02721966|Experimental|AIN457 150mg|Secukinumab dose amount 1 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 1 sc injection every 4 weeks for remaining 44 weeks
3120251|NCT02721966|Experimental|AIN457 300mg|Secukinumab dose amount 2 sc injection weekly for 4 weeks followed by Secukinumab dosage amount 2 sc injection every 4 weeks for remaining 44 weeks
3120252|NCT02721966|Placebo Comparator|AIN457 Placebo|Placebo sc injection weekly for 4 weeks and at week 8, followed by Secukinumab 150 mg or 300 mg sc injection every 4 week for remaining 40 weeks.
3120253|NCT02721979|Experimental|Treatment (apalutamide)|Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
3120254|NCT02722044|Experimental|All Study Participants|All study participants to receive M923 administered via a subcutaneous auto-injector (AI)
3120255|NCT02722148|Experimental|Enrolled Patients|All enrolled subjects will receive a novel allergen-specific immune signature directed approach to dietary elimination therapy
3120256|NCT02722239|Experimental|T/R|Test product (T): a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release. Volunteers enrolled to group 1, on the first study period will take the study test product (Т), and on the second study period after wash out period of 7 days the volunteers will be given the Reference product (R)
3120257|NCT02722239|Experimental|R/T|Reference product (R): co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long). Volunteers from group 2 will be administered with the study drug in reverse order. It means that group 1 will take the study products in sequence T-R and group 2 in the sequence R-T.
3120258|NCT02722278|Experimental|Oral Testosterone Undecanoate|Approximately 135 subjects will receive oral TU treatment during the study for approximately 3.5 months. Subjects randomly assigned to the oral TU treatment group will begin treatment at a dose of 237 mg TU twice daily (BID).
3120259|NCT02722278|Active Comparator|Axiron Testosterone Topical Solution|Subjects randomly assigned to the Axiron treatment group will begin treatment at a dose of 60 mg every morning.
3120260|NCT02722304|Experimental|ARALAST NP 60 mg/kg|60 mg/kg body weight/week
3120261|NCT02722304|Experimental|ARALAST NP 120 mg/kg|120 mg/kg body weight/week
3120262|NCT02722304|Experimental|GLASSIA 60 mg/kg|60 mg/kg body weight/week
3120263|NCT02722304|Experimental|GLASSIA 120 mg/kg|120 mg/kg body weight/week
3120264|NCT02722304|Placebo Comparator|Placebo|Human Albumin 2%
3120265|NCT02722330|Experimental|Baha 5 SuperPower on Baha Attract System|"The device involves the following parts:~The sound processor unit, an actuator unit and a cable, the Sound Processor Magnet (SP Magnet) of the Baha Attract System, the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant, a snap coupling."
3120266|NCT02722408|Experimental|Gemcabene|Participants with homozygous familial hypercholesterolemia (HoFH) on stable lipid lowering therapy received 300 milligram (mg) of Gemcabene, orally once daily from day 1 to 28 followed by 600 mg of Gemcabene, orally once daily from day 29 to 56 followed by 900 mg of Gemcabene, orally once daily from day 57 to 84. Participants were followed until Day 112.
3120267|NCT02722499|Experimental|High Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the high frequency incentive structure
3120268|NCT02722499|Experimental|Moderate Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the moderate frequency incentive structure
3120269|NCT02722499|Experimental|Low Frequency Financial Incentive|This arm will receive telephone delivered diabetes education and skills training in combination with the low frequency incentive structure
3120270|NCT02722564|Experimental|all study participants|subject will self estimate breath alcohol content and their actual BrAC will be recorded as measured by the Alco Sensor IV after each beer ingested.
3120271|NCT02722837|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3120272|NCT02722928|No Intervention|Conventional 1:1 oxygen/air gas mixture|80 patients will receive ventilation during the surgery with a 1:1 oxygen / air gas mixture
3120273|NCT02722928|Experimental|Pure oxygen ventilation|Patients will receive controlled ventilation with a conventional 1:1 oxygen / air gas mixture (60% oxygen concentration) during the approach and tumor removal phases. Once tumor resection is completed and hemostasis started, this group of patients will be switched to ventilation with 100% (pure) oxygen concentration
3469351|NCT03887481|Experimental|Active HD-tDCS + Language/Cognitive Intervention(s) first|Participants will receive active HD-tDCS + Language/Cognitive Intervention(s) first and then receive Sham + Language/Cognitive Intervention(s) after a three-month washout period.
3120276|NCT02722967|Experimental|Aripiprazole + IEM|Subjects will receive an intervention consisting of a drug-device combination that consists of an aripiprazole tablet with a tiny sensor embedded within it referred to as an Ingestible Event Marker (IEM) . They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole(2, 5, 10, 15, 20, or 30 mg) + IEM once daily for the 8-week assessment period for this trial.
3120277|NCT02723006|Experimental|TAK-580 + nivolumab|TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
3120278|NCT02723006|Experimental|TAK-202 (plozalizumab) + nivolumab|TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
3120279|NCT02723006|Experimental|vedolizumab + nivolumab + ipilimumab|Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
3120280|NCT02723084|Experimental|Arm A|Co-formulated ABT-493/ABT-530 (300 mg/120 mg) administered once daily (QD) for 8 weeks in HCV genotype (GT) 2 -infected, DAA treatment-naïve participants without cirrhosis.
3120281|NCT02723084|Active Comparator|Arm B|sofosbuvir (400 mg) QD co-administered with weight based ribavirin (RBV) 600-1000 mg divided twice daily (BID) for 12 weeks in HCV GT2 -infected, DAA treatment-naïve participants without cirrhosis.
3120282|NCT02723175|Experimental|Sham tDCS Stimulation|"30 minutes of the sham transcranial Direct Current Stimulation~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
3120283|NCT02723175|Experimental|Anodal tDCS Stimulation of DLPFC|"30 minutes of the active transcranial Direct Current Stimulation (tDCS)~Transcranial Direct Current Stimulation: Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people."
3120284|NCT02723188|Sham Comparator|Sham|Sham electrical stimulation
3120285|NCT02723188|Experimental|DC: Direct current|Direct current electrical stimulation
3120286|NCT02723188|Experimental|AC: Alternating current|Alternating current electrical stimulation
3120287|NCT02723201|Experimental|Part-1, Period 1: TAK-020 17.5 mg Oral Solution|Single dose 17.5 milligram (mg), on Day 1, followed by 7 days of washout. Dose will be determined from TAK-020 single rising dose (SRD) trial.
3120288|NCT02723201|Experimental|Part-1, Period 2: TAK-020 17.5 mg Co-crystal Tablet (CCT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
3120289|NCT02723201|Experimental|Part-1, Period 3:TAK-020 17.5 mg Solid Dispersion Tablet (SDT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
3120290|NCT02723201|Experimental|Part-1, Period 4:TAK-020 17.5 mg Immediate Release Tablet(IRT)|Single oral dose 17.5 mg, on Day 1, followed by 7 days of washout. Dose will be the same as Part 1, Period 1.
3120291|NCT02723201|Experimental|Part 2, Period 1: TAK-020 25 mg CCT|Participants will be randomized to AB or BA crossover where A= Fasted, B =Fed. Sequence I: Single oral dose TAK-020 25 mg, Fasted (A), 7 days washout, single oral dose TAK-020 Fed (B) Sequence II: Single oral dose TAK-020 25 mg, Fed (B), 7 days washout, single oral dose TAK-020 Fasted (A) Dose will be determined from SRD trial and Part 1.
3120292|NCT02723201|Experimental|Part- 3 Cohort 1: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
3120293|NCT02723201|Experimental|Part 3 Cohort 2: TAK-020 Solid Formulation|Single oral dose on Day 1. Dose will be determined from SRD trial and Parts 1 and 2
3120294|NCT02723344|Experimental|L. reuteri|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
3120295|NCT02723344|Placebo Comparator|Sunflower and medium chain triglyceride oils|Sunflower and medium chain triglyceride oils
3120296|NCT02723591|Active Comparator|Tacrolimus, Extended Release (Astagraf XL®) Once Daily|Participants received tacrolimus extended release (Astagraf XL) at a starting dose of 0.15 milligram per kilogram (mg/kg), once daily, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 nanogram per milliliter (ng/mL) at all times during the study.
3120297|NCT02723591|Active Comparator|Tacrolimus, Immediate Release Twice Daily (BID)|Participants received tacrolimus immediate release as per the institutionally-derived protocol, BID, orally within 48 hours of transplantation (per the treating physician's discretion) for up to 1 year. Dose adjustments were allowed such that participants receiving tacrolimus maintained a minimal trough concentration of 6 ng/mL at all times during the study.
3120298|NCT02723630|Experimental|Sequence A:|Participants will receive one dose of Treatment 1 followed by one dose of Treatment 2, then one dose of Treatment 3
3120299|NCT02723630|Experimental|Sequence B|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 3, then one dose of Treatment 1
3120300|NCT02723630|Experimental|Sequence C|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 1, then one dose of Treatment 2
3120301|NCT02723630|Experimental|Sequence D|Participants will receive one dose of Treatment 3, followed by one dose of Treatment 2, then one dose of Treatment 1
3120302|NCT02723630|Experimental|Sequence E|Participants will receive one dose of Treatment 1, followed by one dose of Treatment 3, then one dose of Treatment 2
3120303|NCT02723630|Experimental|Sequence F|Participants will receive one dose of Treatment 2, followed by one dose of Treatment 1, then one dose of Treatment 3
3132477|NCT03430349|Experimental|Novel OPV2 Candidate 1|Participants received one vaccination with novel OPV2 candidate 1 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
3120304|NCT02723786|Experimental|GSK1070806 3 mg/kg IV|Subjects received a single dose of 3 milligram per kilogram (mg/kg) intravenous (IV) infusion of GSK1070806 administered prior to kidney allograft reperfusion. Subjects also received a combination immunosuppression comprized of basiliximab; mycophenolate mofetil (MMF) or aziothioprine; tacrolimus; and corticosteroids based on the clinical judgment of the investigator.
3120305|NCT02723916|Experimental|Intervention: ezParent Program|
3120306|NCT02723916|Active Comparator|Control: Health-e Kids App|
3120307|NCT02723929|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
3120308|NCT02723929|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
3120309|NCT02724020|Active Comparator|Arm A: Single-agent Everolimus 10 mg QD|Everolimus 10 mg capsules, orally, once daily in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to end of study).
3120310|NCT02724020|Experimental|Arm B: Single-agent MLN0128 30 mg QW|MLN0128 30 mg capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to end of study).
3120311|NCT02724020|Experimental|Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD|MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to end of study).
3120312|NCT02724033|Active Comparator|Group A|Group A - regional nerve block
3120313|NCT02724033|Active Comparator|Group B|Group B - antiemetic
3120314|NCT02724033|Active Comparator|Group C|Group C - block and antiemetic
3120315|NCT02724111|Experimental|deep neuromuscular blockade|This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade [NMB] (train-of-four [TOF] count 0, post-tetanic count [PTC] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
3120316|NCT02724111|Active Comparator|restricted neuromuscular blockade|This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade [NMB] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change [a prone position]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.
3120317|NCT02724423|Experimental|NRL-1 Ictal|During the ictal or peri-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
3120318|NCT02724423|Experimental|NRL-1 Inter-Ictal|During the inter-ictal setting, a single intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
3120319|NCT02724449|Experimental|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Film applied to areas of IAD
3120320|NCT02724462|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
3120321|NCT02724462|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smartphone smoking cessation app. Therapy description withheld to protect the integrity of the study.
3120322|NCT02724592|Experimental|intervention|intervention group, self assembling peptide P11-4 (Curodont™ Repair) and fluoride varnish (Duraphat®)
3120323|NCT02724592|Active Comparator|control|control group, only Fluoride varnish (Duraphat®)
3120324|NCT02724644|Experimental|EN3835 Active|EN3835 0.84 mg (Collagenase Clostridium Histolyticum). Each subject can receive up to three treatment sessions. Each treatment session will be separated by approximately 21 days.
3120325|NCT02724644|Placebo Comparator|EN3835 Placebo|Placebo
3120326|NCT02724787|Other|Open Trial|All Veterans will receive the same emotion regulation treatment titled, Manage Emotions to Reduce Aggression.
3120327|NCT02724800|Active Comparator|CBTI|CBTI consists of five in-person sessions within an eight week period. Topics covered include: sleep education, stimulus control, sleep restriction, relaxation strategies, cognitive therapy, and sleep hygiene.
3120328|NCT02724800|Active Comparator|BBTI|BBTI consists of one in-person session with three weekly follow-up sessions (in-person or phone) in a four week period. Topics covered include: sleep education, stimulus control, and sleep restriction.
3120329|NCT02724839|Experimental|Biweekly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place biweekly.
3120330|NCT02724839|Experimental|Monthly Arm|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place monthly.
3120331|NCT02724839|Experimental|Weekly|6 group nutrition sessions co-led by a peer and a content expert, Fitbit given to parent-child dyads during second session. Sessions took place weekly.
3120332|NCT02724878|Experimental|Bevacizumab And Atezolizumab Combination|"1200 mg of Atezolizumab intravenously x 3 weeks~15 mg/kg of Bevacizumab intravenously x 3 weeks.~One cycle will be 3 weeks in duration."
3120333|NCT02724956|Experimental|Ambu AuraGain|"SGAD placement using Ambu AuraGain~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
3132478|NCT03430349|Experimental|Novel OPV2 Candidate 2|Participants received one vaccination with novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3120334|NCT02724956|Experimental|Teleflex LMA Protector|"SGAD placement using the Teleflex LMA Protector~Lubricate airway tube of SGAD & pass the aScope through until visualization of the carina.~Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.~Pass ETT tube down the insertion cord of the Ambu aScope & verify placement.~Inflate cuff and remove aScope."
3120335|NCT02725008|Active Comparator|Control|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and a second dose of 0.6 milligrams per kilogram up to 16 milligrams to take 24 hours after ED visit
3120336|NCT02725008|Experimental|Investigational|Patients are given one dose of oral dexamethasone 0.6 milligrams per kilogram up to 16 milligrams in the ED and placebo to be taken 24 hours after ED visit
3120337|NCT02725268|Experimental|Paclitaxel 80 mg/m^2|Paclitaxel 80 milligrams per square meter (mg/m^2), IV, weekly on Days 1, 8, and 15 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 13 weeks).
3120338|NCT02725268|Experimental|Paclitaxel 80 mg/m^2 + Sapanisertib 4 mg|Paclitaxel 80 mg/m^2, IV, weekly on Days 1, 8, and 15 of a 28-day cycle along with sapanisertib 4 milligrams (mg), capsule, orally on Days 2-4, 9-11, 16-18, and 23-25 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 20 weeks).
3120339|NCT02725268|Experimental|Sapanisertib 30 mg|Sapanisertib 30 mg, capsule, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 6 weeks).
3120340|NCT02725268|Experimental|Sapanisertib 4 mg + MLN1117 200 mg|Sapanisertib 4 mg, capsule, orally and MLN1117 200 mg, capsule, orally on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day cycle until disease progression, unacceptable toxicity, or withdraw consent (the median exposure was up to approximately 8 weeks).
3120341|NCT02725411|Active Comparator|Celecoxib|Subcutaneous injection of placebo for tanezumab every 8 weeks plus oral celecoxib 100 mg twice daily for 56 weeks
3120342|NCT02725411|Experimental|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
3120343|NCT02725411|Experimental|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks plus oral placebo for celecoxib twice daily for 56 weeks
3120344|NCT02725476|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 12 infusions
3120345|NCT02725515|Experimental|XmAb5871|XmAb5871 administered by IV infusion for up to a total of 16 infusions
3120346|NCT02725515|Placebo Comparator|Placebo|Placebo to match XmA5871 administered by IV infusion for up to a total of 16 infusions
3120347|NCT02725593|Experimental|Dapagliflozin|
3120348|NCT02725593|Placebo Comparator|Dapagliflozin placebo|
3120349|NCT02725645|Experimental|Healthy school children|elementary school children will be presented with different backpack loading conditions
3120350|NCT02725710|Active Comparator|Group 1: Placebo|Usual perioperative pain management protocol PLUS placebo orally 1-2 hour prior to procedure.
3120351|NCT02725710|Active Comparator|Group 2: Gabapentin|Usual perioperative pain management protocol PLUS 600mg Gabapentin administered orally 1-2 hour prior to procedure.
3120352|NCT02725788|Experimental|New PIV Dressing|Bordered, notched dressing that covers, secures peripheral intravenous (PIV) catheter
3120353|NCT02725788|Other|Standard PIV Dressing|Film,adhesive dressing that covers, secures peripheral intravenous (PIV) catheter and used with a medical grade tape
3120354|NCT02725801|Active Comparator|one-port|intervention is placement of one-port tissue expander at time of reconstruction
3120355|NCT02725801|Active Comparator|two-port|intervention is placement of two-port tissue expander at time of reconstruction
3120356|NCT02725866||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablet; 1000 or 1200 mg divided twice a day) up to 24 weeks
3120357|NCT02726022||Chronic Hepatitis C Participants|Participants with chronic hepatitis C, who were under treatment with peg-interferon alfa-2a and ribavirin for four weeks, will be observed up to 24 weeks after end of treatment (EOT) (up to 72 weeks). Peg-interferon alfa-2a and ribavirin will be administered as per treating physician discretion and according to summary of product characteristics.
3120358|NCT02726074|Experimental|Perampanel 12 mg|During the Titration Period, participants will receive perampanel 2 milligrams per day (mg/day) and be up-titrated in no less than 2-week intervals in increments of 2 mg up to 12 mg according to the investigator's judgment. Upon entering the Maintenance Period, participants will receive the last dose they achieved at the end of the Titration Period and will continue receiving this dose once daily for the remainder of the study.
3120359|NCT02726113|Active Comparator|Intervention: Cholecalciferol|vitamin D3 (cholecalciferol) supplementation at 4000 IU daily for approximately two months prior to surgery (prostatectomy).
3120360|NCT02726113|Placebo Comparator|Placebo|softgel (containing no active ingredient) daily for approximately two months prior to surgery (prostatectomy).
3120361|NCT02726178|Experimental|Advil® Pediatric drops for infants|"Oral ibuprofen (Advil® Pediatric drops for infants less than 3 months of age; Wyeth-Ayerst 40 mg/ml, DIN 2242522), at a dosage of 5 mg/kg/dose.~The drug was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
3120362|NCT02726178|Placebo Comparator|Control|"Oral placebo: composed of sodium stearate 0.25g + lactose 0.5g + 15 ml of simple syrup, with a measured osmolarity of about 750 mosml/kg.~The drug (or placebo) was administered 30 minutes prior to immunization, and then at 8 and 16 hours following the immunization for a total of 3 doses."
3120363|NCT02726451|Placebo Comparator|Basic Skin Care|Subjects use a basic skin care regimen.
3120364|NCT02726451|Active Comparator|Active Skin Care|Subjects use the Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products in additional to a basic skin care regiment.
3120365|NCT02726542|Experimental|Growth hormone|Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.
3120366|NCT02726542|No Intervention|No treatment|(no study treatment - observation only)
3132479|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 45mg|Strength of each tablet is 15mg
3132480|NCT03430856|Experimental|Insulin Tregopil (IN-105) - 30mg|Strength of each tablet is 15mg
3120367|NCT02726620|Experimental|Hypotension decision support|"The intervention period. Several decision support elements are implemented to notify anesthesia providers: attending anesthesiologists and in-room anesthesia providers of intraoperative hypotension (threshold of a mean arterial pressure below 60 mmHg). Two types of decision support will be implemented: near real-time decision support and feedback emails.~Near real-time decision support elements will notify the anesthesia providers of a blood pressure drop below the threshold and display the associated increased risk of acute kidney injury. The notification is presented through the pager system for attending anesthesiologists and through the anesthesia information management system for the in-room anesthesia provider.~All providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension that is associated with an increased risk of organ injury due to organ ischemia."
3120368|NCT02726620|Active Comparator|Usual care group|The 'before' period - or historic control group - during which no decision support for intraoperative hypotension was being used, also known as 'usual care'. This is the three year period prior to the intervention period (the 'Intraoperative hypotension decision support' arm).
3120369|NCT02726789|Experimental|Experimental|Patients either treatment naive or with HBV DNA controlled with entecavir receive REP 2139-Ca in combination with pegylated interferon. Only patients receiving entecavir at enrollment continue to receive entecavir during treatment in the study.
3120370|NCT02726945|Experimental|Low Dose SVF|This group of subjects will receive a low dose of SVF for treatment of knee OA.
3120371|NCT02726945|Experimental|High Dose|This group of subjects will receive a high dose of SVF for treatment of knee OA.
3120372|NCT02726945|Placebo Comparator|Placebo|This group of subjects will receive a placebo with no SVF Cells for treatment of knee OA.
3120373|NCT02726971|Experimental|Low dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral one red tablet daily for 11 days and oral one yellow tablet in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
3120374|NCT02726971|Active Comparator|High dose of oestrogen|"Patients in this group will build artificial cycle by Femoston.(oral three red tablets daily for 11 days and oral two yellow tablets in the next 10 days). This process will last for 3 months after the surgery.~P.S.1.A red tablet contains 2mg estradiol. 2.A yellow tablet contains 2mg estradiol and 10mg dydrogesterone."
3120375|NCT02727192|Active Comparator|PAP-therapy (CPAP or ASV)|Patients are randomized to either intervention Group: Positive airway pressure therapy (PAP-therapy) or Control. Patients in the intervention arm will be treated with PAP-therapy (Continous Positive Airway Pressure (CPAP) or Adaptive Servo Ventilation (ASV).
3120376|NCT02727192|No Intervention|Control group|No sleep apnea treatment
3120377|NCT02727322|Active Comparator|Nitrofurantoin|Receives once daily nitrofurantoin 100mg
3120378|NCT02727322|Placebo Comparator|Placebo|Receives matching placebo
3120379|NCT02727660|Experimental|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3120380|NCT02727660|Experimental|BFF MDI (PT009) 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol - 80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3120381|NCT02727660|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate Inhalation Aerosol - 4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3120382|NCT02727699|Experimental|Xanamem™|Oral Xanamem™ capsules 10mg, to be administered once daily
3120383|NCT02727699|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily
3120384|NCT02727751|Experimental|50mg BID|Tenapanor, 50 mg BID (100 mg total)
3120385|NCT02727777|Experimental|Aggressive Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Aggressive NHL: Diffuse Large B Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Transformed Large Cell Lymphoma, and Follicular Lymphoma (FL) grade 3b Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
3120386|NCT02727777|Experimental|Indolent Non-Hodgkin Lymphoma (NHL) - TAK228|"Phase II - Indolent NHL: Follicular Lymphoma (FL) grade 1-3a, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL) Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
3120387|NCT02727777|Experimental|Hodgkin Lymphoma - TAK228|"Phase II - Hodgkin Lymphoma Group~Participants take TAK-228 1 time every day of a 28 day cycle.~Treatment continues until progression of disease occurs, or a maximum of 12 months of treatment.~Participant checks blood sugar every day before TAK-228 dose."
3120388|NCT02727816|Experimental|filcon IV I (BC 8.6) / ocufilcon D (pair one)|Participants were randomized to a test and control lens for each pair in a contralateral design.
3120389|NCT02727816|Experimental|filcon IV I (BC 8.7) / ocufilcon D (pair two)|Participants were randomized to a test and control lens for each pair in a contralateral design.
3120390|NCT02727816|Experimental|methafilcon A (BC 8.6) / ocufilcon D (pair three)|Participants were randomized to a test and control lens for each pair in a contralateral design.
3120391|NCT02727816|Experimental|methafilcon A (BC 8.7) / somofilcon A (pair four)|Participants were randomized to a test and control lens for each pair in a contralateral design.
3120392|NCT02727842|Experimental|Treatment group|All patients will receive the CP950 Sound Processor and be part of the treatment group for one month which is programmed via the wireless programming pod
3120393|NCT02727894||Screening Group|CRC diagnosed by screening was defined as cancer diagnosed by primary screening colonoscopy, or colonoscopy after a positive immunochemical based faecal occult blood test i(FOBT) in patients without symptoms invited to examination according to the national screening programme policy
3120394|NCT02727894||Non-screening Group|Symptomatic CRC was defined as cancer diagnosed in symptomatic patients.
3120395|NCT02728089|Experimental|MK-7625A|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion every 8 hours for 7 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
3132481|NCT03430856|Active Comparator|Insulin Aspart|Pre-filled pen: 100 U/L
3120396|NCT02728102|Experimental|Lenalidomide, vaccine, and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will undergo leukapheresis and then will receive maintenance lenalidomide with myeloma vaccine and GM-CSF.
3120397|NCT02728102|Active Comparator|Lenalidomide and GM-CSF|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide with GM-CSF.
3120398|NCT02728102|Active Comparator|Maintenance Lenalidomide|Patients will undergo tumor cell collection and autologous stem cell transplant with melphalan. Patients will receive maintenance lenalidomide.
3120399|NCT02728206|Experimental|SOF/VEL|SOF/VEL FDC for 4 weeks starting on the day of or day after the participant's liver transplant
3120400|NCT02728258|Experimental|Treatment (copanlisib)|Patients receive copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3469352|NCT03887481|Experimental|Sham + Language/Cognitive Intervention(s) first|Participants will receive Sham + Language/Cognitive Intervention(s) first and then receive active HD-tDCS + Language/Cognitive Intervention(s) after a three-month washout period.
3469353|NCT03887416|Active Comparator|Dapagliflozin|"The investigational medicinal product (IMP) is Dapagliflozin 10 MG Oral Tablet [Farxiga] given once daily (film coated tablets, oral use).~Dapagliflozin 10 MG Oral Tablet [Farxiga] will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
3120403|NCT02728830|Experimental|Pembrolizumab|"Subjects will receive one dose of 200mg pembrolizumab by IV 14-21 days prior to surgery. Subjects will undergo standard surgical cytoreductive surgery as deemed appropriate by their gynecologic oncologist, followed by standard adjuvant chemotherapy for their cancer as deemed appropriate by their treating physician.~If subject's disease does not get worse following standard of care chemotherapy, they will receive pembrolizumab in the maintenance setting every three weeks for up to a year.~If subject's disease returns after completing a year of pembrolizumab and they have not had adverse reactions to pembrolizumab they may be eligible to continue receiving pembrolizumab for an additional year in the second course phase."
3120404|NCT02728895|Experimental|Cohort 1: Vedolizumab 75 mg|Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
3120405|NCT02728895|Experimental|Cohort 2: Vedolizumab 300 mg|Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
3120406|NCT02728895|Experimental|Cohort 3: Vedolizumab Dose 1|Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.
3120407|NCT02729025|Placebo Comparator|Placebo|Participants received placebo to evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
3120408|NCT02729025|Experimental|Evolocumab 420 mg QM|Participants received 420 mg evolocumab by subcutaneous injection once a month (QM) for 12 weeks.
3120409|NCT02729038|Experimental|Part 1: Subjects with normal renal function (Group A)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
3120410|NCT02729038|Experimental|Part 1: subjects with moderate renal impairment (Group B)|Subjects with moderate renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
3120411|NCT02729038|Experimental|Part 1: subjects with severe renal impairment (Group C)|Subjects with severe renal impairment and subjects with ESRD not on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
3120412|NCT02729038|Experimental|Part 2: subjects with normal renal function (Group D)|Subjects with normal renal function will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
3120413|NCT02729038|Experimental|Part 2: subjects with mild renal impairment (Group E)|Subjects with mild renal impairment will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion.
3120414|NCT02729038|Experimental|Part 2: subjects with ESRD on hemodialysis (Group F)|Subjects with ESRD on hemodialysis will receive a single dose of gepotidacin 750 mg administered as a 2 hour IV infusion starting approximately 2 hours before the initiation of the last hemodialysis session of the week (Period 1) and gepotidacin 750 mg administered as a 2 hour IV infusion starting within 2 hours after completion of the last hemodialysis session of the week (Period 2).
3120415|NCT02729051|Experimental|FF/UMEC/VI closed triple therapy plus Placebo|Subjects will receive FF/UMEC/VI, 100 mcg/62.5 mcg/25 mcg and placebo inhalation powder via the dry powder inhaler (DPI), once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3120416|NCT02729051|Active Comparator|FF/VI plus UMEC open triple therapy|Subjects will receive FF/VI, 100 mcg/25 mcg and UMEC, 62.5 mcg inhalation powder via the DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3120417|NCT02729194|Experimental|Pazopanib|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal) approximately, some sample meals are described in appendix 1) every day in 14 day cycles, with a starting dose of 400 mg and adjusted for the next cycle (dose level +1:600 mg; dose level +2: 800 mg; dose level -1: 200 mg) based on toxicity assessment during or at the end of each cycle.
3469354|NCT03887416|Placebo Comparator|Placebo matching dapagliflozin|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
3469355|NCT03887403|Experimental|Multimodal Intervention|Multimodal Intervention Based on Person-centered Communication
3469356|NCT03887403|Active Comparator|Usual Care|Patients receive usual advices in primary health care centers
3469357|NCT03887377|Experimental|Breast receiving botulinum toxin|"Following reconstruction one horizontal incisional wound will be selected to receive a series of botulinum toxin injections along the wound.~Injection abobotulinum toxin at time of surgery, single injection time with 30 gauge needle superficially, dosage determined by length of scar 5-15U per cm"
3469358|NCT03887377|Placebo Comparator|Breast receiving placebo|The other breast will be injected with bacteriostatic normal saline in a similar fashion to the other breast. The injector will be blinded to the contents of the syringe.
3469359|NCT03887390|No Intervention|Usual Care|Participants in this arm will receive care as usual.
3120418|NCT02729545|Experimental|Tung's acupuncture|The Tung's acupuncture group received acupuncture treatments twice per week for 12 weeks. The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
3120419|NCT02729545|Active Comparator|CPA/EE|Cyproterone acetate/ethinylestradiol (CPA/EE) was taken orally one tablet per day from the 8th day of menstrual cycle or any day for patients with amenorrhea. The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
3120420|NCT02729740|Other|Penumbra Smart System|
3120421|NCT02729753|Other|CryoBalloon™ Full Ablation System|To evaluate CryoBalloon™ Full Ablation System for the ablation of 360 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
3120422|NCT02729753|Other|CryoBalloon™ Swipe Ablation System|To evaluate CryoBalloon™ Swipe Ablation System for the ablation of 90 degrees of human esophageal epithelium in patients scheduled to undergo esophagectomy.
3120423|NCT02729831|Experimental|Interactive Decision Aid and Usual Care|Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
3120424|NCT02729831|Experimental|Video decision aid and usual care|Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
3120425|NCT02729831|Experimental|Interactive Decision Aid and Provider Report|Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
3120426|NCT02729831|Experimental|Video decision aid and Provider report|Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.
3120427|NCT02729896|Experimental|Dose-Escalation Phase|During the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1, Atezo on Day 1, and Pola on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months, during maintenance treatment for FL participants.
3120428|NCT02729896|Experimental|Expansion Phase|For FL during the induction treatment Cycle 1 (21-day cycles): participants will receive obinutuzumab on Days 1, 8, and 15 and Pola at identified RP2D (decided from dose-escalation phase) on Day 1; Cycles 2-6: participants will receive obinutuzumab on Day 1 and Pola at RP2D on Day 1. This is followed by obinutuzumab on Day 1 of every other month starting with Month 1 for 24 months (during maintenance treatment for FL participants).
3120429|NCT02729896|Experimental|Safety Run-In Phase|For DLBCL, during the induction treatment Cycles 1-6 (21-day cycles): participants will receive rituximab on Day 1 and Pola on Day 1.
3120430|NCT02729909|Experimental|Lubiprostone 24 μg|Lubiprostone 24 μg, capsules, orally, twice daily, under fed conditions, for 4 weeks.
3120431|NCT02729909|Placebo Comparator|Placebo|Lubiprostone placebo-matching capsules, orally, twice daily, under fed conditions, for 4 weeks.
3120432|NCT02730130|Experimental|Pembrolizumab Plus Radiotherapy|Subjects will receive pembrolizumab 200 mg as an IV infusion. RT begins D1 prior to dose 1 of Pembrolizumab. Pembrolizumab will be administered as a 30 minute IV infusion. Radiotherapy will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. The dose of radiation will be a standard regimen/fractionation used in palliation: 3000 cGy, delivered in five 600 cGy fractions within 5-7 days.
3120433|NCT02730169|Experimental|BGS649 0.1 mg|BGS649 0.1 mg weekly (1 BGS649 0.1 mg capsule and 2 indistinguishable placebo capsules)
3120434|NCT02730169|Experimental|BGS649 0.3 mg|BGS649 0.3 mg weekly (3 BGS649 0.1 mg capsules)
3120435|NCT02730169|Experimental|BGS649 1.0 mg|BGS649 1.0 mg weekly (1 BGS649 1.0 mg capsule and 2 indistinguishable placebo capsules)
3120436|NCT02730169|Placebo Comparator|Placebo|Placebo weekly (3 indistinguishable placebo capsules)
3120437|NCT02730195|Experimental|Pioglitazone & TKI therapy|Patients receive pioglitazone PO QD on days 1-28. Patients also start or continue the same tyrosine kinase inhibitor (TKI) therapy at the pre-discontinuation doses. Courses repeat every 28 days for 6 months in the absence of disease progression or unacceptable toxicity.
3120438|NCT02730208|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 72 weeks.
3120439|NCT02730208|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed dose combination tablet orally once daily in the morning and placebo matched to IVA tablet orally once daily in the evening for 72 weeks.
3120440|NCT02730234|Experimental|JetStream XC with balloon angioplasty|The intervention consists of JetStream atherectomy of femoropopliteal in-stent restenosis using the JetStream XC device followed by adjunctive balloon angioplasty in all patients.
3120441|NCT02730247|Experimental|ramucirumab + nab-paclitaxel|"Ramucirumab will be administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.~The nab-paclitaxel will be administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle."
3120442|NCT02730260|Active Comparator|Directive|Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
3120443|NCT02730260|Experimental|Nondirective|Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.
3120444|NCT02730351|Experimental|FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®|Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.
3120445|NCT02730351|Experimental|FP 250 mcg + Placebo ELLIPTA®|Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.
3120446|NCT02730377|Experimental|Liraglutide 1.8 mg|Add-on to metformin
3120447|NCT02730377|Active Comparator|OAD|Add-on to metformin. Treatment with one OAD selected at the discretion of the investigator. Subjects randomised to the OAD arm must remain on the same OAD throughout the trial.
3120448|NCT02730403||Opioid Use Disorder Patients|
3120449|NCT02730455|Experimental|natalizumab high dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
3120450|NCT02730455|Experimental|natalizumab low dose|Single IV (intravenous) dose natalizumab at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
3120451|NCT02730455|Experimental|Placebo|Single dose of Placebo IV at baseline at one of two treatment windows, either within 9 hours of last known normal (LKN) or between 9-24 hours after LKN.
3120452|NCT02730598|Experimental|Hybrid Training System (HTS)|HTS stimulation while walking at a comfortable pace for 30 minutes.
3120453|NCT02730598|Active Comparator|Transcutaneous Electrical Nerve Stimulation (TENS)|Sensory TENS while walking at a comfortable pace for 30 minutes.
3120454|NCT02730663|Experimental|Niti-S SPAXUS Stent|Niti-S SPAXUS Stent (TaeWoong Medical Co., Ltd. Korea)
3120455|NCT02730728|Active Comparator|Single shot adductor canal block|adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
3120456|NCT02730728|Active Comparator|24 hour continuous adductor canal block|adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
3120457|NCT02730728|Active Comparator|48 hour continuous adductor canal block|adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
3120458|NCT02730819|Experimental|Illuminate Cream|Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.
3120459|NCT02730871|Experimental|Simbrinza + Duotrav|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
3120460|NCT02730871|Placebo Comparator|Vehicle + Duotrav|Brinzolamide/brimonidine vehicle, 1 drop instilled 2 times per day in affected eye(s) (09:00 and 21:00 hrs) plus travoprost 0.004%/timolol 0.5% solution, 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for 42 days (Treatment Phase)
3120461|NCT02730884|Experimental|Rigosertib|Participants receive oral Rigosertib under fasting conditions twice a day on a continuous basis. Quality of life questionnaire completed on Day 1 of Cycle 1.
3120462|NCT02730962|Experimental|Antibiotics prior to FMT|One week prior to FMT, a course of three oral antibiotics are taken: Vancomycin 500mg, Neomycin 1000mg, and Clindamycin 300mg.
3120463|NCT02730962|Placebo Comparator|Placebo prior to FMT|One week prior to FMT, a course of three sugar pills identical to each antibiotic.
3120464|NCT02730988|Experimental|Weight Loss Lifestyle Counseling|The high protein weight loss group follows the Medifast 4 & 2 & 1 Plan™, a 1200 calorie, high protein diet targeting ~10% weight loss over 24-weeks through a combination of meal replacement products (MRPs), meal plans, and individual nutrition/behavioral counseling. Participants are guided by the study RD on food purchasing and preparation and encouraged to consume only what is approved from the menu. Participants meet bi-weekly for RD-lead behavioral counseling group classes to provide support and introduce new topics in behavioral weight control. Weight is also measured at each session with progress feedback provided to increase motivation. Participants complete daily food logs to verify compliance to the diet.
3120465|NCT02730988|Active Comparator|Weight Stable Lifestyle Counseling|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
3120466|NCT02731131|Experimental|Group A: Monotherapy with Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a alone, administered over 48 weeks.
3120467|NCT02731131|Experimental|Group B: Combination with Peginterferon alfa-2a + Ribavirin|Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.
3120468|NCT02731157|Experimental|Transfusion with rejuvenated red blood cells (RBCs)|Subjects with sickle cell disease will receive RBCs treated with Rejuvesol®. Scheduled red cell exchanges performed with the last 4 units of the exchange having been incubated with Rejuvesol® solution. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
3120469|NCT02731157|Active Comparator|Transfusion with standard red blood cells|Subjects with sickle cell disease will receive standard RBCs. Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
3120470|NCT02731300|Active Comparator|Active tDCS|2 mA of cathodal tDCS placed over M1 for 20 mins
3120471|NCT02731300|Sham Comparator|Sham tDCS|0 mA of sham tDCS placed over M1 for 20 mins
3120472|NCT02731313||Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Tumor samples with histologically confirmed gastric or GEJ adenocarcinoma, any stage, were collected and analyzed. No study visits or interventions were planned.
3120473|NCT02731469|Experimental|BCD-131, 0.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously
3120474|NCT02731469|Experimental|BCD-131, 0.15 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously
3120475|NCT02731469|Experimental|BCD-131, 0.40 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously
3120476|NCT02731469|Experimental|BCD-131, 1.05 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously
3120477|NCT02731469|Experimental|BCD-131, 1.70 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously
3120478|NCT02731469|Experimental|BCD-131, 2.25 mcg/kg SC|Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously
3120479|NCT02731469|Experimental|BCD-131, 4.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously
3120480|NCT02731469|Active Comparator|Mircera®, 1.20 mcg/kg subcutaneously|Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously
3120481|NCT02731469|Active Comparator|Aranesp®, 0.45 mcg/kg subcutaneously|Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously
3120482|NCT02731469|Experimental|BCD-131, optimal dose, intravenously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously
3120483|NCT02731469|Experimental|BCD-131, optimal dose, subcutaneously|Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously
3120484|NCT02731638|Experimental|Intrastromal voriconazole plus natamycin|Intrastromal voriconazole plus standard of care topical treatment for fungal keratitis
3120485|NCT02731638|Active Comparator|Natamycin alone|Standard of care topical treatment for fungal keratitis
3120486|NCT02731690|Experimental|Open Label UX001, 6g/day|
3120487|NCT02731729|Experimental|ipilimumab and nivolumab|For patients in the combination arm, nivolumab will first be administered intravenously at a dose of 1 mg/kg of body weight over a period of 60 minutes, once every 3 weeks for four doses. Thirty minutes after the completion of each nivolumab infusion, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes.
3120488|NCT02731729|Experimental|ipilimumab|In the ipilimumab monotherapy group, patients will receive 3 mg/kg of ipilimumab over a period of 30 minutes once every 3 weeks for four doses.
3120489|NCT02731742|Experimental|Dose A MK-1966 + Dose A SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
3120490|NCT02731742|Experimental|Dose A MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
3120491|NCT02731742|Experimental|Dose B MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
3120492|NCT02731742|Experimental|Dose C MK-1966 + Dose B SD-101|Participants received a combination of MK-1966 (Days 1 and 21) and SD-101 (Days 1, 8, 15 and Day 22) in Part A of the study (approximately 21 days). Participants were to continue in one of two expansion cohorts (Part B or C) and receive up to 8 cycles of treatment (approximately 24 weeks). Each cycle was 21 days.
3120493|NCT02731742|Experimental|Part B Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and up to 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
3120494|NCT02731742|Experimental|Part C Expansion Cohort|Participants were to receive the MTD/MAD of MK-1966 and SD-101 established in Part A for up to 7 additional treatment cycles with MK-1966 and 6 additional treatment cycles with SD-101. Each cycle was to be 21 days.
3120495|NCT02731755|Active Comparator|Oat intervention|67.7g oatflake and 22.5g oatbran concentrate - single intake (mixed with water)
3120496|NCT02731755|Placebo Comparator|Control|39.4g cream of rice, 6.1g sunflower oil, 29.5g skimmed milk, 5.6g pectin powder, 6.5g cellulose and mixed with water
3120497|NCT02731820|Experimental|Treatment group|Potassium citrate Calcium carbonate Vitamin D3
3120498|NCT02731820|Placebo Comparator|Control group, Placebo|Placebo (Excipients) Calcium carbonate Vitamin D3
3120499|NCT02731833|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute
3120500|NCT02731833|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip (1 inch) of toothpaste. Participants will then brush whole mouth thoroughly for at least 1 minute
3120501|NCT02732015|Experimental|Arm I (rolapitant hydrochloride)|"Patients receive treatment as in part I. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
3120502|NCT02732015|Active Comparator|Arm II (fosaprepitant dimeglumine)|"Patients receive dexamethasone IV and ondansetron IV on days 1-5, and fosaprepitant dimeglumine IV over 30 minutes on days 1 of cycle 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY: All patients receive doxorubicin IV over 72 hours, mesna IV, and ifosfamide IV over 3 hours on days 1-4 or 1-5. Patients with sarcomas of small cell histology receive vincristine sulfate IV on day 1. Cycles repeat every 3 weeks following blood count and patient recovery from any acute toxicities."
3120503|NCT02732119|Experimental|Cohort A|Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B
3120504|NCT02732119|Experimental|Cohort B|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
3120505|NCT02732119|Experimental|Cohort C|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
3120506|NCT02732119|Experimental|Group 1|Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally
3120507|NCT02732119|Experimental|Group 2|Ribociclib (200 mg daily), everolimus (5 mg daily) and exemestane (25 mg daily) taken orally
3120508|NCT02732145|Placebo Comparator|Normal vulva|"The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
3120509|NCT02732145|Placebo Comparator|Impaired vulvar skin|"The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
3120510|NCT02732145|Placebo Comparator|Vulvodynia|"The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
3120511|NCT02732145|Active Comparator|Vulvar dermatosis|"The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology."
3120512|NCT02732366|Experimental|Group-based exercise and peer coaching|This treatment arm will include physical therapist-led group-based exercise, goal-setting, peer coaching training, individualized home program, and activity monitoring.
3120513|NCT02732366|Active Comparator|Usual PT and attention control grp class|This arm consists of the continuation of one-on-one PT along with participation in an attention control - healthy living class.
3120514|NCT02732561|Sham Comparator|Sham Device|Sham device
3120515|NCT02732561|Active Comparator|Intervention|CES device. cranial electrotherapy stimulation device. Alpha Stim device
3120516|NCT02732587|Experimental|125 mg Saracatinib|125 mg Saracatinib once daily for 8-11 days
3120517|NCT02732600|No Intervention|Standard Implementation|Standard Implementation sites will receive written guidance and limited consultation by the investigators' team.
3120518|NCT02732600|Experimental|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation.
3120519|NCT02732639|Experimental|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a monotherapy for 48 weeks, followed by 24 weeks of treatment-free follow-up.
3120520|NCT02732847|Other|Post-Dated Prescription|a delayed prescription dated 2 days after clinical office visit
3120521|NCT02732847|Other|Usual|usual date
3120522|NCT02732899|Experimental|Group 1|Sirolimus 440ug for intravitreal injection will be provided in sterile single-use glass vials. One single-dose vial will be packaged in a box for each patient injection. Sirolimus injections will be given at baseline, week 4, 12, 20 and 28. EYLEA® (aflibercept) intravitreal injections will be given at week 1, 8, 16, 24 and 32.
3120523|NCT02732899|Active Comparator|Group 2|Intravitreal injection of EYLEA® (aflibercept) will be given at baseline, week 8, 16, 24 and 32. Sham injections will be given at week 1, 4, 12, 20, and 28 in order to maintain masking of patient to treatment assignment
3120524|NCT02732912|Active Comparator|Control|Patients in this arm will continue current standard management for sleep, which is largely reactive; if a patient requests night sedation or complains that they cannot sleep and that they want help, then zopiclone is prescribed, starting at 3.75 mg.
3120525|NCT02732912|Experimental|Eye mask and ear plugs|General management will be as for the control group. In addition, patients in this group will be given ear plugs and eye shades (masks) to use when trying to sleep. The patient will generally be responsible for using or not using the equipment, though ward nurses may remind patients if they notice that the patient has the equipment.
3120526|NCT02732938|Experimental|PF-04136309 + Nab-p + Gem|"PF-04136309 oral dosing~Nab-paclitaxel IV dosing Gemcitabine IV dosing"
3120527|NCT02732951|Experimental|BI 1026706|
3120528|NCT02732951|Active Comparator|Placebo|
3120529|NCT02733042|Experimental|Arm A: Durvalumab + Lenalidomide ± Rituximab|"Participants assigned to Arm A will receive:~Durvalumab 1500 mg intravenous (IV) infusion on Day 1 of Cycles 1 through 13 (ie, 12 months) and~Lenalidomide orally at assigned dose levels (10 mg, 15 mg or 20 mg) once daily on Days 1 to 21 of:~Cycles 1 through 13 in indolent non-Hodgkin's lymphoma (NHL) or~All cycles of treatment period until disease progression, unacceptable toxicity, or discontinuation for any other reason in aggressive NHL~Rituximab 375 mg/m² IV infusion every week in Cycle 1 (Days 2, 8, 15, 22) and on Day 1 of Cycles 2 through 5.~All treatment cycles were 28 days."
3120530|NCT02733042|Experimental|Arm B: Durvalumab + Ibrutinib|"Participants assigned to Arm B will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Ibrutinib orally at assigned dose levels (280 mg, 420 mg, or 560 mg) once daily until disease progression, unacceptable toxicity or discontinuation for any other reason.~All treatment cycles were 28 days."
3120531|NCT02733042|Experimental|Arm C: Durvalumab + Rituximab ± Bendamustine|"Participants assigned to Arm C will receive:~Durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13~Rituximab 375 mg/m² IV infusion on Day 2 of Cycles 1 through 6 (for CLL the rituximab dose will be 375 mg/m² Cycle 1 first dose and 500 mg/m² for each subsequent dose)~Bendamustine IV infusion at assigned dose levels (70 mg/m² or 90 mg/m²) on Days 1 and 2 of Cycles 1 through 6.~All treatment cycles were 28 days."
3120532|NCT02733042|Experimental|Arm D: Durvalumab Monotherapy|Participants assigned to Arm D will receive durvalumab 1500 mg IV infusion on Day 1 of Cycles 1 through 13. All treatment cycles were 28 days.
3120533|NCT02733367|Experimental|Infacort|Infacort® granules
3120534|NCT02733588|Experimental|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
3120535|NCT02733627|Experimental|BI 1467335 10 mg (low dose)|
3120536|NCT02733627|Experimental|BI 1467335 15 mg (medium dose)|
3120537|NCT02733627|Experimental|BI 1467335 20 mg (high dose)|
3120538|NCT02733627|Placebo Comparator|Placebo|
3120539|NCT02733653|Experimental|Jetstream Atherectomy System|Adjunctive therapy with Jetstream Atherectomy System for percutaneous intervention
3120540|NCT02733757|No Intervention|Sub-Tenon's group control|2% Lidocaine without epinephrine
3120541|NCT02733757|Experimental|Sub-Tenon's group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
3120542|NCT02733757|No Intervention|Peribulbar group control|2% Lidocaine without epinephrine
3120543|NCT02733757|Experimental|Peribulbar group clonidine|2% Lidocaine without epinephrine plus clonidine 1 µg/kg
3120544|NCT02733991|Experimental|Treatment|MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.
3120545|NCT02733991|Active Comparator|Control|MiniMed™640G alone
3120546|NCT02734056|Experimental|Music|The intervention to be administered is music
3120547|NCT02734056|Experimental|Control|There is no intervention listed here because this is the control group, in which there will be no intervention.
3120548|NCT02734147|Active Comparator|High dose IV ascorbic acid|Patients will receive 67 mg/kg IV ascorbic acid in 100 ml normal saline over 30 minutes every 8 hours (200 mg/kg/day) for 72 hours.
3120549|NCT02734147|Placebo Comparator|Placebo|The placebo group will receive 100 ml 0.9% NaCl over 30 minutes every 8 hours for 72 hours.
3120550|NCT02734212|Experimental|Ending Self-Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
3120551|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
3120552|NCT02734238|Placebo Comparator|Energy Deficit|Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.
3120553|NCT02734238|Experimental|Energy Deficit + Testosterone|Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.
3120554|NCT02734355|Active Comparator|Therapy|Telmisartan 80 mg and amlodipine 5 mg tablet by mouth every 24 hours for 7 days
3120555|NCT02734355|Placebo Comparator|Placebo|Placebo (for telmisartan 80 mg and amlodipine 5 mg) tablet by mouth every 24 hours for 7 days
3120556|NCT02734433|Experimental|Pexidartinib|Pexidartinib capsules administered twice daily in the morning and evening. Each cycle of treatment is 28 days in duration. The cycle of treatment is continued until disease progression, unacceptable toxicity, or consent withdrawal.
3120557|NCT02734498|Active Comparator|Right unilateral (RUL) ECT|Right Unilateral placement of treatment electrodes in electroconvulsive treatment.
3120558|NCT02734498|Active Comparator|Bilateral (BL) ECT|Bilateral placement of treatment electrodes in electroconvulsive treatment.
3120559|NCT02734498|No Intervention|Control group|No ECT treatment for control group.
3120560|NCT02734576|Experimental|Venous Sinus Stenting|Venous sinus stenting is the experimental procedure being tested in this protocol and consists of placing a stent into the narrowed veins of the brain. Under general anesthesia, a catheter will be inserted through a vein the upper part of the leg (groin area) and guided through the veins all the way to neck and the head. Then, a balloon will be advanced through the catheter and positioned across the stenosis. The balloon will be carefully inflated for a few seconds. This process is called angioplasty and will partially re-open the narrowing, making placement of the stent easier. The balloon will be removed and then the stent will be advanced through the catheter in neck across the stenosis and carefully deployed. After the procedure, the participants will stay in the intensive care unit for 24 hours for observation
3120561|NCT02734667|Experimental|CGM at diagnosis of T1D|Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
3120562|NCT02734667|No Intervention|Usual Care|Participants receive usual care for T1D for 6 months post diagnosis.
3120563|NCT02734693|Experimental|Dasotraline 4mg|Dasotraline capsule 4mg/day
3120564|NCT02734693|Placebo Comparator|Placebo|Placebo capsule
3120565|NCT02734810|Experimental|Part A|Liprotamase Powder for Oral Solution in Subjects aged ≥7 years of age
3120566|NCT02734810|Experimental|Part B|Liprotamase Powder for Oral Solution in Subjects aged 28 days to <7 years
3120567|NCT02734849|Experimental|25 mg AK001|25 mg AK001 will be administered as multiple doses
3120568|NCT02734849|Experimental|250 mg AK001|250 mg AK001 will be administered as multiple doses
3120569|NCT02734849|Placebo Comparator|Placebo|A placebo comparator consisting of inactive excipients will be administered as multiple doses
3120570|NCT02734862|Experimental|Group 1|"Subjects in the CD101 IV treatment group 1 (Part A Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 400 mg on Day 15 (for all subjects) and an optional dose of 400 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
3120571|NCT02734862|Active Comparator|Group 3|"Subjects in the caspofungin group will receive IV caspofungin (a single 70 mg loading dose on Day 1 followed by 50 mg once daily) for ≥3 days up to a maximum of 21 days for subjects with candidemia only and up to a maximum of 28 days for subjects with IC (with or without candidemia).~After ≥3 days of IV therapy, subjects in the caspofungin group can be switched to oral step-down therapy of fluconazole (a loading dose of 800 mg [4 capsules] on the first day followed by 400 mg [2 capsules]/day thereafter). After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
3120572|NCT02734862|Experimental|Group 2|"Subjects in the CD101 IV treatment group 2 (Part B Only - up to 30 mITT subjects) will receive CD101 IV 400 mg on Day 1 and Day 8, with an optional dose of 200 mg on Day 15 (for all subjects) and an optional dose of 200 mg on Day 22 (only for subjects with IC), if needed.~Daily intravenous placebo infusion when not administered CD101. Daily oral placebo as step down."
3120573|NCT02734953|Experimental|Intervention|Determination of non-invasive pulmonary pressures by CardioMems device interrogation pre- and post-administration of inhaled nitric oxide at 0.075 mg/kg IBW/hr
3120574|NCT02734979|Experimental|Biobridge and lymph node transfer|The investigators will investigate whether addition of the Biobridge scaffold to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm. The investigators will perform lymph scans (lymphoscintigrams) before surgery and one year following surgery to determine the success of the surgery. In addition, the volume of the operated arm will be monitored by repeated measurement with a tape measure. The investigators will also track bioimpedance, a painless technique to detect fluid in the tissues. The investigators will obtain small skin biopsies and blood samples to detect the biological changes that may occur as a result of successful surgery.
3120575|NCT02735044|Experimental|HOE901-U300|HOE901-U300 (Insulin glargine 300 Units/milliliter [U/mL]) Subcutaneous(SC) injection once daily for 12 months.
3120576|NCT02735044|Active Comparator|Lantus|Lantus (Insulin glargine 100 U/mL) SC injection once daily for 12 months.
3120577|NCT02735096|Experimental|Vestibular Patients for EquiCue Testing|Subjects with vestibular deficiency will try the intraoral electronic balance aid to see whether there is improvement in balance.
3120578|NCT02735174|Experimental|Single arm asthma self-management|"Interventions include:~Sensor cap system for inhalers App for SmartPhone Motivational interviews Telehealth clinic visits"
3120579|NCT02735187|Active Comparator|group30|Treatment of the target area with 30 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
3120580|NCT02735187|Active Comparator|group15|Treatment of the target area with 15 minutes of blue light at 453nm compared to Vitamin D creme Daivonex on contralateral Plaque of same patient.
3120581|NCT02735200|Experimental|Topical Vitamin D3 application|Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
3120582|NCT02735200|Active Comparator|Aloe vera gel Application|Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days
3120583|NCT02735382|Experimental|EHR-based referral to quit line|"Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline EHR referral"
3120584|NCT02735382|Active Comparator|Fax-based referral to quit line|"Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication.~Intervention: Behavioral: Tobacco quitline Fax referral"
3120585|NCT02735382|Experimental|EHR-based Clinic Staff|Clinics will use an EHR-based fully-electronic HIPAA-compliant tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
3120586|NCT02735382|Active Comparator|Fax-based referral to quit line Clinic Staff|Clinics will use a paper fax tool to refer their adult patients who use tobacco to the telephone tobacco quitline for tobacco cessation counseling and medication. Staff in these clinics will complete surveys to address Aim 4 of the study.
3120587|NCT02735421|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening on half of the face (determined by randomization)
3120588|NCT02735421|Placebo Comparator|Vehicle gel|Vehicle gel, once daily in the evening on half of the face (determined by randomization)
3120589|NCT02735551|Active Comparator|Non-LARC Group: Short Acting Method|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services"
3120590|NCT02735551|Active Comparator|Control Group: Referral for LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic."
3120591|NCT02735551|Active Comparator|LARC Group: Same Day LARC Placement|"All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention)."
3120592|NCT02735577|Experimental|Disulfiram|Patients in this arm will receive disulfiram 250 mg daily for a total of 40 days.
3120593|NCT02735642|Experimental|SMART Randomization 1 - Referral|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
3120594|NCT02735642|Experimental|SMART Randomization 1 - Referral and SMS|Participants who are HIV positive will be enrolled in the SMART trial adaptive linkage to care intervention pilot. (HIV Positive Cohort approximately N=108).
3120595|NCT02735642|Experimental|SMART Randomization 2 - SMS|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
3120596|NCT02735642|Experimental|SMART Randomization 2 - Incentive|HIV positives that have not successfully linked to care after the first randomization will be re-randomized to receive either an SMS message or economic incentive to link to care. (HIV Positive Cohort approximately N=108).
3120597|NCT02735642|Other|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185).
3120598|NCT02735642|Other|All participants. Approximately (N=1200)|HIV testing options that female youth can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
3132680|NCT03444584|Placebo Comparator|Placebo|Participants will receive subcutaneous dose of placebo matched to MEDI0382 daily for 28 days. Participants were on metformin and dapagliflozin background dual therapy during the treatment period
3120599|NCT02735915|Experimental|GSK1437173A vaccine Group|Subjects who completed vaccination course of 2 doses of HZ/su vaccine (group 50 μg gE/AS01B) in the study Zoster-003 (NCT00434577) were included in this study. 62 of these subjects further received 1 or 2 additional doses of HZ/su vaccine in the revaccination phase of this study
3120600|NCT02735980|Experimental|Prexasertib (Platinum Sensitive Disease)|105 mg/m^2 Intravenous (IV) prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had platinum-sensitive disease (has prior platinum based therapy with subsequent progression greater or less than 90 days after last dose of platinum based therapy).
3120601|NCT02735980|Experimental|Prexasertib (Platinum Resistant Disease)|105 mg/m^2 IV prexasertib administered of every 14 days with extensive stage disease small cell lung cancer (ED-SCLC) who had resistant/refractory disease (did not have an objective response to platinum-based therapy or had progression greater than 90 days after the last dose of platinum).
3120602|NCT02735980|Experimental|Prexasertib Exploratory Addendum (Platinum Sensitive Disease)|40 mg/m^2 IV prexasertib Day 1, 2, and Day 3 of a 14 day cycle in participants with ED-SCLC platinum sensitive disease.
3120603|NCT02736175|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3120604|NCT02736175|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3120605|NCT02736188|Experimental|Drug: Aceneuramic Acid Extended-Release Tablets|Participants will take 4 tablets (500 mg Ace-ER each for 2 g per dose) orally 3 times per day (TID).
3120606|NCT02736409|Experimental|Arms A OBS Completers/ Responders|Arm A Oral Budesonide Suspension Completers/ Responders
3120607|NCT02736409|Placebo Comparator|Arm B OBS Completers/ Responders|Arm B Oral Budesonide Suspension Completers/ Responders. 1:1 randomization for Arms A and B
3120608|NCT02736409|Experimental|Arm C OBS Completers/ Non-Responders|Arm C Oral Budesonide Suspension Completers/ Non-Responders
3120609|NCT02736409|Experimental|Arm D Placebo Completers|Arm D Placebo Completers
3120610|NCT02736474|Experimental|Naltrexone and Bupropion|Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.
3120611|NCT02736474|Placebo Comparator|Placebo Naltrexone and Bupropion|Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.
3120612|NCT02736578|Experimental|Cetuximab IRDye800, 50 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 50 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
3120613|NCT02736578|Experimental|Cetuximab IRDye800, 100 mg|On day 0, participants receive a 100 mg cetuximab loading dose by intravenous infusion (IV), followed 1 hour later by cetuximab-IRDye 800CW IV at 100 mg, followed by surgery with intraoperative imaging within 2 to 5 days.
3120614|NCT02736721|Experimental|Peginterferon alfa-2a|Participants will receive peginterferon alfa-2a subcutaneously in doses between 90 and 450 microgram (mcg) once weekly until medically indicated as judged by the treating investigator.
3120615|NCT02736825|Active Comparator|Group A, Ulthera System with standard transducers|"Subjects randomized to Group A will receive an Ultherapy® treatment to the lower face and neck with a total minimum pulse count of 672 pulses (+5%) at the 4.5mm and 3.0mm depths using standard transducers. Energy levels for each transducer will be set to EL2:~Deep-See (DS) 4-4.5 at 0.9 Joules (J) with pitch of 1.5mm and 17 Thermal Coagulation Points (TCP)s per line~DS 7-3.0 at 0.30J with pitch of 1.1mm and 23 TCPs per line"
3120616|NCT02736825|Experimental|Group B, Ulthera System with prototype 2 simulines transducers|"Subjects randomized to Group B will receive a Ultherapy® treatment with a total minimum pulse count of 336 pulses (+5%) using the prototype 2 simulines transducers at the 4.5mm and 3.0mm depths. Energy levels for each transducer will be set to EL2:~Deep-See 4-4.5 Simulines (DS 4-4.5S) at 1.23J with pitch of 1.5mm and 17 TCPs per line~DS 4-3.0S at 0.88J with pitch of 1.3mm and 20 TCPs per line"
3120617|NCT02736890|Active Comparator|Botulinum Toxin A|Each vial of botulin toxin (100U, BOTOX, Allergan) will be reconstituted with 4ml non-preserved saline solution (0.9%) as recommended by the manufacturer (concentration of 5 units Botulinum Toxin A/0.2ml). Each injection will be 0.2mL (BOTOX, 5 units), administered through a 25 gauge needle. The marked area will have subcutaneous injections, each separated by a radius of 1 cm, from the other injections into the marked area,(maximum of 80 injections, 400 Units).
3120618|NCT02736890|Placebo Comparator|Placebo|Placebo consists of 0.9% normal saline. Each injection will be 0.2mL, administered with a 25 gauge needle subcutaneously into the affected area. The marked area will have subcutaneous injections (maximum of 80) each separated from the surrounding ones by a radius of 1 cm.
3120619|NCT02736955|Experimental|Valbenazine|Fixed dose of valbenazine administered once daily for up to 72 weeks
3120620|NCT02737072|Experimental|20 mg LY2510924 + 1500 mg Durvalumab|20 milligrams (mg) LY2510924 given subcutaneously (SQ) once daily in combination with 1500 mg durvalumab given intravenously (IV) on Day 1 of each cycle (28 days).
3120621|NCT02737072|Experimental|30 mg LY2510924 + 1500 mg Durvalumab|30 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
3120622|NCT02737072|Experimental|40 mg LY2510924 + 1500 mg Durvalumab|40 mg LY2510924 given SQ once daily in combination with 1500 mg durvalumab given IV on Day 1 of each cycle (28 days).
3120623|NCT02737332|Active Comparator|Zytiga® (Abiraterone Acetate)|1,000 MG (4 x 250 mg qd)
3120624|NCT02737332|Experimental|SoluMatrix™ (Abiraterone Acetate)|500 mg (4 x 125 mg qd)
3120625|NCT02737358|Placebo Comparator|Placebo|Matched placebo will be given to half of the study participants.
3120626|NCT02737358|Active Comparator|N-Acetylcysteine (NAC)|NAC will be given to half of the study participants. The dose of NAC will be 2400 mg per day (1200 mg taken twice per day as two 600 mg capsules)
3120627|NCT02737397|Experimental|pain medicine and antihistamine|JMI-001 (SJP-304 and SJP-223)
3120628|NCT02737397|Active Comparator|pain medicine|SJP-304 and placebo
3120629|NCT02737397|Active Comparator|antihistamine|SJP-223 and placebo
3120630|NCT02737397|Placebo Comparator|placebo|placebo and placebo
3132681|NCT03444766|Experimental|Monotherapy|administering nivolumab only
3132682|NCT03444961|Experimental|CAREN system training|CAREN training
3120631|NCT02737501|Experimental|Randomized Phase: Brigatinib 90 mg QD/180 QD|Brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, orally, QD, in each 28-day cycle until PD, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 34.86 months).
3120632|NCT02737501|Active Comparator|Randomized Phase: Crizotinib 250 mg BID|Crizotinib 250 mg, tablets, BID in each 28-day cycle until disease progression, intolerable toxicity, consent withdrawal, or death (The median duration of exposure was 9.26 months).
3120633|NCT02737501|Experimental|Crossover Phase: Brigatinib 90 mg QD/180 mg QD|Participants who experienced PD as assessed by the BIRC or received radiotherapy to the brain while on 'Crizotinib 250 mg BID' therapy in Randomized Phase were crossed over. Following 10-day washout period, crossover participants received brigatinib 90 mg, tablets, orally, QD for first 7 days followed by 180 mg, tablets, orally, QD in each 28-day cycle up to end of the study (The median duration of exposure was 17.25 months).
3120634|NCT02737553|Active Comparator|enclosed morcellation|"In this group, after extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9.~doi: 10.1097/AOG.0000000000000823.)."
3120635|NCT02737553|Active Comparator|vaginal morcellation|In this group, after extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
3120636|NCT02737592|Experimental|Healthy subject|"Healthy subject exposed to Trojan Simply Pleasures Personal Lubricant at least four times weekly for two weeks"
3120637|NCT02737618|Experimental|Healthy subject|"Healthy subjects exposed to Trojan Chameleon Personal Lubricant applied by occlusive patch"
3120638|NCT02737631|Experimental|Healthy subject|"Healthy subjects exposed to Chameleon personal lubricant via occlusive patch"
3120639|NCT02737722|Experimental|Bisphosphocin Nu-3|Dosage Form: Topical Antimicrobial, Dosage: 1mg/mL, 10 mg/mL, 20 mg/mL, 50 mg/mL, 100 mg/mL Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
3120640|NCT02737722|Placebo Comparator|Placebo|Dosage Form: Diluent, Frequency: QD for day 1, 2x daily for 7 days, Duration: 8 days
3120641|NCT02737826|Experimental|Phase - Buprenorphine Initiation|"In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol up to 16mg sublingually over an up to 8 hour induction window. Buprenorphine tolerability will be defined as pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper."
3120642|NCT02737826|Active Comparator|Phase II - Gabapentin + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to gabapentin will receive up to 1600mg oral gabapentin (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
3120643|NCT02737826|Placebo Comparator|Phase II - Placebo + Buprenorphine|Subjects who tolerate sublingual buprenorphine initiation in Phase I will proceed to Phase II, which will involve randomization to gabapentin or placebo, 2 week stabilization period, and up to 8 week buprenorphine tapering period. Those randomized to placebo will receive up to 1600mg oral placebo (double blinded) divided three times daily, titrated over the 2 week stabilization period and continued during the buprenorphine tapering period. During the 2 week stabilization period, buprenorphine will also be titrated up to 24mg as needed/tolerated.
3120644|NCT02737826|Experimental|Phase II - Buprenorphine taper|After a 2 week stabilization period where sublingual buprenorphine is titrated up to 24 mg/day and oral gabapentin/placebo is titrated up to 1600mg/day, subjects will enter a buprenorphine tapering period lasting up to 8 weeks. The suggested buprenorphine taper will be determined by stabilizing dose, but able to be altered by prescriber or participant based on symptoms.
3120645|NCT02737852|Experimental|Healthy subject|"Healthy subject exposed to Trojan Chameleon Personal Lubricant at least four times weekly for two weeks"
3120646|NCT02737891|Experimental|Tesofensine/Metoprolol|Oral tablets Tesofensine/Metoprolol
3120647|NCT02737891|Placebo Comparator|Placebo|Placebo tablets matching oral Tesofensine/Metoprolol
3120648|NCT02737917|Experimental|Diffuse apneic oxygenation|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation) plus the application of oxygen.
3120649|NCT02737917|Other|Usual care|This group of patients will receive the standard of care treatment of rapid sequence intubation (pre-oxygenation, induction and intubation)
3120650|NCT02737930|Experimental|Fluoxetine|20 mg fluoxetine capsule by mouth once daily for 90 days
3120651|NCT02737930|Placebo Comparator|Placebo|Matching placebo
3120652|NCT02738008|Experimental|ARC-520 Injection|Multiple administrations of ARC-520 starting at a dose level of 2 mg/kg, plus entecavir (0.5 or 1.0 mg/day) or tenofovir (300 mg/day)
3120653|NCT02738086|Experimental|Early PABC Intervention|GROUP 1 will participate in the Physical Activity Behavior Change (PABC) intervention phase during the first 3 months. GROUP 1 will then participate in a non-exercise control phase during the second 3 months.
3120654|NCT02738086|Experimental|Wait-List Control Intervention|GROUP 2 will participate in a non-exercise control phase during the first 3 months. GROUP 2 will then participate in the Physical Activity Behavior Change (PABC) intervention phase in the second 3 months.
3120655|NCT02738138|Experimental|ABT-493/ABT-530 for 8 weeks|HCV Genotype (GT)1-6/HIV-1 co-infected non-cirrhotic subjects treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 8 weeks
3120656|NCT02738138|Experimental|ABT-493/ABT-530 for 12 weeks|HCV GT1-6/HIV-1 co-infected subjects with compensated cirrhosis treated with ABT-493/ABT-530 300 mg/120 mg once a day (QD) for 12 weeks
3120657|NCT02738151|Experimental|Toujeo|Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.
3120658|NCT02738151|Active Comparator|Tresiba|Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .
3120659|NCT02738203|Experimental|Experimental, IUD Insertion group|"If the subject is assigned to the experimental group (vaginal lidocaine jelly):~She will be given a pre-filled vaginal inserter with 10 ml of 2% lidocaine jelly) and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
3120660|NCT02738203|Placebo Comparator|Control, IUD Insertion group|"If the subject is assigned to the control group (sterile, surgical lubricant jelly):~•She will be given a pre-filled vaginal inserter with 10 ml of surgical lubricant jelly and will be asked to insert it vaginally 20-30 minutes prior to the start of her procedure. The subject will not know if she received the active drug or a placebo."
3120661|NCT02738255|Active Comparator|Polysomnogram with Varnum Mouthpiece|Varnum mouthpiece, similar to a mouth tape with central opening
3120662|NCT02738255|No Intervention|Regular Polysomnogram|Overnight sleep study with no mouthpiece
3120663|NCT02738333|Experimental|LDV/SOF (Cohort 1)|LDV/SOF FDC for 12 weeks
3120664|NCT02738333|Experimental|SOF+RBV (Cohort 1)|SOF+RBV for 12 weeks
3120665|NCT02738333|Experimental|LDV/SOF (Cohort 2)|Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.
3120666|NCT02738450|Active Comparator|ACI-24 low dose|Vaccine formulation will be administrated s.c. 7 times.
3120667|NCT02738450|Active Comparator|ACI-24 high dose|Vaccine formulation will be administrated s.c. 7 times.
3120668|NCT02738450|Placebo Comparator|Placebo|The placebo is ready-to-use solution for injection, administrated s.c. 7 times.
3120669|NCT02738580|Active Comparator|rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
3120670|NCT02738580|Active Comparator|HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG with normal ovarian function.
3120671|NCT02738775|Experimental|Cohort 1|Participant received intravenous (IV) infusion of ublituximab 150 milligrams (mg)/4 hour (hr) on Day 1, 450 mg/3 hr on Day 15 and 450 mg/1.5 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /3 hr on Day 15 before receiving ublituximab.
3120672|NCT02738775|Experimental|Cohort 2|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1.5 hr on Day 15 and 450 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1.5 hr on Day 15 before receiving ublituximab.
3120673|NCT02738775|Experimental|Cohort 3|Participant received IV infusion of ublituximab 150 mg/4 hr on Day 1, 450 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /4 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
3120674|NCT02738775|Experimental|Cohort 4|Participant received IV infusion of ublituximab 150 mg/3 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /3 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
3120675|NCT02738775|Experimental|Cohort 5|Participant received IV infusion of ublituximab 150 mg/2 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /2 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
3120676|NCT02738775|Experimental|Cohort 6|Participant received IV infusion of ublituximab 150 mg/1 hr on Day 1, 600 mg/1 hr on Day 15 and 600 mg/1 hr on Week 24. Some participants initially received placebo IV infusion /1 hr on Day 1 and /1 hr on Day 15 before receiving ublituximab.
3120677|NCT02738801|Experimental|GLPG1690 600 mg once daily (QD)|
3120678|NCT02738801|Placebo Comparator|Placebo QD|
3120679|NCT02738840|Experimental|Prodigy MRI or Proclaim Elite MR|"The Prodigy MRI system is only MR conditional for scans of the head and extremities (upper except shoulder, lower except hip).~The Proclaim Elite system is MR conditional for scans of the head, extremities or any other body part."
3120680|NCT02738853|Experimental|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of Aortic Stenosis by replacing native valve with the Medtronic Transcatheter Aortic Valve 2.0 System
3120681|NCT02738879|Experimental|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
3120682|NCT02738879|Placebo Comparator|Placebo|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
3120683|NCT02739100|Experimental|Triferic via Hemodialysate|"Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic via the hemodialysate over the course of the dialysis treatment.~Intervention Drug: Triferic"
3120684|NCT02739100|Experimental|Triferic via IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via the unused heparin infusion line (pre-dialyzer).~Intervention: Drug: Triferic"
3120685|NCT02739100|Experimental|Triferic IV infusion|"Patients will receive a single 6.6-mg dose of Triferic iron administered IV over 4 hrs during hemodialysis via an infusion port (post-dialyzer).~Intervention: Drug: Triferic"
3120686|NCT02739269|Active Comparator|AMH group|Serum AMH measurement
3120687|NCT02739269|Sham Comparator|AFC group|AFC measurement
3120688|NCT02739321|Experimental|Mattress Technology On then Off|"Intervention: Sound to Sleep System will be turned on for the first two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration.~No intervention: The mattress technology will be turned off for the second two weeks of the study. During this time, there will be no intervention."
3120689|NCT02739321|Experimental|Mattress Technology Turned Off then On|"No intervention: For the first two weeks of the study, the mattress technology will not be turned off. There will be no intervention during this time.~Intervention: Sound to Sleep System will be turned on for the second two weeks of the study allowing the participant sleeping atop the mattress to feel the vibrations synced to the audio input. Sound to sleep system will be turned on during this phase of the study. The sound to sleep system will sync an audio input with the vibrations of the mattress technology and allow the user to control the intensity of the vibration."
3120690|NCT02739360|Experimental|Idelalisib|Participants will receive idelalisib until unacceptable toxicity, disease progression, study discontinuation, or death occurs.
3120691|NCT02739594|Experimental|Ibandronate|Participants with multiple myeloma will be randomized to receive ibandronate every 4 weeks for a planned duration of 92 weeks.
3120692|NCT02739594|Active Comparator|Zoledronate|Participants with multiple myeloma will be randomized to receive zoledronate every 4 weeks for a planned duration of 92 weeks.
3120693|NCT02739698|Experimental|normothermic (36-37ºC)|Group 1, n=16(normothermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in room temperature (36-37ºC).
3120694|NCT02739698|Experimental|hyperthermic (41-42ºC)|Group 2, n=16 (hyperthermic): Intraperitoneal administration of 60 mg/m2 paclitaxel per 2 liters of 1.5% dextrose in continuous hyperthermic perfusion (41-42ºC).
3120695|NCT02739789|Sham Comparator|Sham tDCS|"tDCS stimulation will be administered over the brain area of interest, but will be shorter in duration than the active treatment"
3120696|NCT02739789|Active Comparator|Active tDCS|tDCS stimulation will be administered over the brain area of interest
3120697|NCT02739828||Patients with Hidradenitis Suppurativa|Patients with moderate or severe HS treated prescribed adalimumab according to the Swedish Summary of Product Characteristics and treated as per routine clinical practice.
3120698|NCT02739984|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once every month (QM) for 12 weeks.
3120699|NCT02739984|Experimental|Evolocumab|Participants received 420 mg evolocumab subcutaneous injection once every month (QM) for 12 weeks.
3120700|NCT02739997|Experimental|MK-7625A + metronidazole|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days. The dose may be reduced to 750 mg (ceftolozane 500 mg/tazobactam 250 mg) for participants with a creatinine clearance (CrCl) of 30-50 mL/min.
3120701|NCT02740049|Experimental|Astma patients|Participant undergoes a bronchoscopy to isolate epithelial cells
3120702|NCT02740114|Active Comparator|Bupivacaine Group|"Local wound infiltration with Bupivacaine immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
3120703|NCT02740114|Experimental|Liposomal Bupivacaine + Bupivacaine Group|"Local wound infiltration with Liposomal Bupivacaine and 0.25% Bupivacaine admixed immediately prior to wound closure during gynecological surgery.~Participants discharged with analgesic opioid regimen of Oxycodone 1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.~Participants complete a pill diary every day for 30 days after hospital discharge.~Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks."
3120704|NCT02740127|Experimental|Caudal Nerve Block + General Anesthesia Group|"Participants receive a caudal nerve block (CNB) prior to surgery and receive general anesthesia during surgery.~Study staff calls participant about 3 days after surgery."
3120705|NCT02740127|Active Comparator|General Anesthesia Alone Group|"Participants receive general anesthesia (GA) during surgery without a caudal nerve block.~Study staff calls participant about 3 days after surgery."
3120706|NCT02740153||Urea Cycle Disorder with Liver Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~History of liver transplant"
3120707|NCT02740153||Urea Cycle Disorder without Transplant|"Age 18 and under~Diagnosed with the following Neonatal-type urea cycle disorders: CPSD, OTCD, ASD or ALD~No history of liver transplant, managed medically"
3120708|NCT02740413||Patients with Haemophilia A|Patients in The MHR diagnosed with Haemophilia A
3120709|NCT02740413||Patients with Haemophilia B|Patients in The MHR diagnosed with Haemophilia B
3120710|NCT02740478||Volunteers|20 volunteer subjects, no selection criteria
3120711|NCT02740504||Subjects|All 20 subjects. Selected to have a range of ages (18 to less than 75) and BMI from 18.5 to 45
3120712|NCT02740517||HUT1|First phase of the home user trial. 19 users, 12 who were part of a couple and 7 who were single.
3120713|NCT02740517||HUT2|"Second phase of home user trial, testing improvements to the device user interface as a result of the experience from HUT1. Total 11 users.~Main change to device was a simpler set of displays and button-sequence on a 24 hour period."
3120714|NCT02740517||HUT3|"Third phase of home user trial, testing the final improvements to the device. A total of 18 users, 16 of which who were part of a couple and 2 who were single.~Main change was the introduction of a scheduled recording option, making the device totally automatic in routine use."
3120715|NCT02740543|Active Comparator|Allergic Asthma (AA)|
3120716|NCT02740543|No Intervention|Control|
3120717|NCT02740582|Experimental|Tolcapone First, then Placebo|Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
3120718|NCT02740582|Placebo Comparator|Placebo First, then Tolcapone|Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
3120719|NCT02740660|Experimental|Caffeine 100mg / Albuterol 4mg|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
3120720|NCT02740660|Placebo Comparator|Placebo|One capsule 3 times per day orally for a total of 8 weeks and family weight management counseling for a total of 8 weeks.
3120721|NCT02740920|Experimental|Pembrolizumab|200mg IV Day 1 every 3 weeks.
3469360|NCT03887390|Experimental|Depression Medication Choice|Participants in this arm will have the Depression Medication Choice decision aid be made available to their clinician to be used during their clinical encounter.
3469361|NCT03887494|Experimental|Y-Strut Implant|Single interventional arm
3469362|NCT03887273|Experimental|Q-Cells dose level 1|One time surgical transplantation of Q-Cells dose level 1 unilaterally into spinal cord demyelinated lesion
3120725|NCT02741076|Experimental|Structured discontinuation opioid therapy Suboptimal Responder|
3120726|NCT02741076|Experimental|Structured discontinuation opioid therapy Optimal responders|
3120727|NCT02741076|Experimental|Continuation of opioid therapy Suboptimal responders|
3469363|NCT03887273|Experimental|Q-Cells dose level 2|One time surgical transplantation of Q-Cells dose level 2 unilaterally into spinal cord demyelinated lesion
3120728|NCT02741076|Experimental|Structured Continuation of opioid therapy Optimal responders|
3120729|NCT02741245|Active Comparator|Ezetimibe 10 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin placebo capsules once daily for 12 weeks
3120730|NCT02741245|Active Comparator|Rosuvastatin 2.5 mg|1 Rosuvastatin 2.5 mg capsule, 1 Rosuvastatin placebo capsule and 1 Ezetimibe placebo tablet once daily for 12 weeks.
3120731|NCT02741245|Active Comparator|Rosuvastatin 5.0 mg|2 Rosuvastatin 2.5 mg capsules and Ezetimibe placebo tablet once daily for 12 weeks.
3120732|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 2.5 mg|1 Ezetimbie 10 mg tablet, 1 Rosuvastatin 2.5 mg capsule and 1 Rosuvastatin placebo capsule once daily for 12 weeks.
3120733|NCT02741245|Experimental|Ezetimibe 10 mg+ Rosuvastatin 5.0 mg|1 Ezetimbie 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules once daily for 12 weeks.
3120734|NCT02741271|Experimental|MF/F MDI 100/10 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF/F MDI 100/10 mcg BID for 24 weeks.
3120735|NCT02741271|Active Comparator|MF MDI 100 mcg BID|Eligible participants will be assigned randomly to receive double-blinded MF MDI 100 mcg BID for 24 weeks.
3120736|NCT02741284|Experimental|No Oxygen|Room air
3120737|NCT02741284|Active Comparator|Oxygen|10L oxygen by nonrebreather mask
3120738|NCT02741297|Experimental|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
3120739|NCT02741310|Placebo Comparator|Placebo|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received another placebo IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
3120740|NCT02741310|Experimental|Erenumab|Participants received a placebo intravenous (IV) infusion on day 1 then 12 mg subcutaneous sumatriptan on day 2 (Part 1). After a 2-day washout participants received 140 mg erenumab IV infusion on day 4 followed by 12 mg subcutaneous sumatriptan on day 5 (Part 2).
3120741|NCT02741518|Active Comparator|Treatment Arm|The treatment arm will receive an induction dose of FMT via capsules (30) followed by monthly maintenance oral capsules(12) at week 4 and week 8. Donor Stool from healthy lean donors and placebo material will be obtained from OpenBiome. OpenBiome, is a nonprofit 501(c)(3) organization that provides hospitals with screened, filtered, and frozen material ready for clinical use
3120742|NCT02741518|Placebo Comparator|Placebo Arm|The placebo group will receive a placebo FMT capsules at the time of their screening colonoscopy followed by monthly intake of oral placebo capsules at week 4 and week 8
3120743|NCT02741596|Experimental|Rollover Participants|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
3120744|NCT02741596|Experimental|Non-rollover Participants|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
3120745|NCT02741635|Experimental|New Nasal Pillows Mask|Participants to use nasal pillows mask one night in lab overnight polysomnography.
3120746|NCT02741687|Experimental|Sitagliptin Arm|"Participants will receive sitagliptin beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
3120747|NCT02741687|Placebo Comparator|Placebo Arm|"Participants will receive a placebo tablet beginning the day prior to surgery and continuing daily during hospitalization (up to 10 days post-surgery).~Point of care (POC) testing will be done four times daily, before meals and at bedtime, or every 6 hours for patients who are not eating (NPO). Patients developing hyperglycemia during or after surgery will be treated with insulin per standard of care.~Patients with fasting and/or premeal blood glucose levels >180 mg/dl will receive supplemental insulin provided on a sliding scale. Patients with two consecutive fasting and/or premeal blood glucose levels >180 mg/dl, or with average daily blood glucose levels >180 mg/dl will be started on rescue therapy with subcutaneous insulin once daily plus correction doses by a sliding scale."
3120748|NCT02741713|Sham Comparator|Interscalene Block plus Sham Block|"Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS Pectoralis block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block."
3120749|NCT02741713|Active Comparator|Interscalene plus PECS Blocks|"Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS Pectoralis 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al."
3120750|NCT02742077|Other|Robotic-assisted PVI|Robotic-assisted peripheral vascular intervention
3120751|NCT02742103|Experimental|CSL_112|CSL112 will be administered intravenously, once weekly for 4 consecutive weeks (4 infusions in total).
3120752|NCT02742103|Placebo Comparator|Placebo|Placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
3120753|NCT02742129|Experimental|AIR001 Crossover to Placebo|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug Nebulized Sodium Nitrite (AIR001) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Placebo instead of AIR001.
3120754|NCT02742129|Placebo Comparator|Placebo crossover to AIR001|Phase 1: Participants will wear an accelerometer device daily but take no study drug for 14 days (washout period). On day 15, participants begin phase I study drug (Placebo) at 46 mg, at minimum of 4 hours apart, for 3 doses per day during the active portion of the participant's day. On day 22 participants increase study drug dose to 80 mg at the same frequency. Regardless of participant's ability to tolerate study drug or if the participant requires down-titration, participants will begin Phase 2. Phase 2: Is identical to Phase 1 except subject will be taking Nebulized Sodium Nitrite (AIR001) instead of Placebo.
3120755|NCT02742441|Experimental|122-0551 Foam|"122-0511 Foam, topically applied twice daily~Intervention: Drug: 122-0551 Foam"
3120756|NCT02742441|Placebo Comparator|Vehicle Foam|"Vehicle Foam, topically applied twice daily~Intervention: Drug: Vehicle Foam"
3120757|NCT02742519|Experimental|Part 1-Sequence 1|ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
3120758|NCT02742519|Experimental|Part 1 - Sequence 2|placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
3120759|NCT02742519|Experimental|Part 2: ivacaftor|open label period
3120760|NCT02742532|Experimental|Oxytocin|Intra-nasal oxytocin (40 IUs; 5 puffs in each nostril)
3120761|NCT02742532|Placebo Comparator|Placebo|Intra-nasal saline placebo (5 puffs in each nostril)
3120762|NCT02742649|Experimental|Fixed Combination (FC) Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one segment of timolol maleate combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
3120763|NCT02742649|Experimental|Bimatoprost Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of bimatoprost and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
3120764|NCT02742649|Experimental|Timolol Ocular Insert|Washout plus Placebo Ocular Insert in each eye for 24 to 48 days, followed by one segment of timolol and one placebo segment (no drug product) combined onto a single ocular insert in each eye for 70 days. Following a second washout period, 0.5% timolol drops twice daily in each eye from Day 99 to 112.
3120765|NCT02742766|Experimental|Part 1 - GSK3008356 single dose and multiple doses|Healthy subjects will receive GSK3008356 in morning as single dose or multiple doses of 5 milligrams (mg), 10 mg, 30 mg,45 mg, 75 mg, 90 mg, 125, 180 mg, 200 mg, 250 mg total daily dose or matching placebo in eleven sequential cohorts while receiving a standard fat meal. The initial dosing for the first cohort will be staggered so that 2 subjects will be dosed as sentinel subjects. Provided there are no safety concerns, the remainder of the subjects scheduled for the cohort may be dosed. Eight subjects will be enrolled in each cohort.
3120766|NCT02742766|Experimental|Part 2 - GSK3008356 14 day repeat dose|Healthy subjects will receive GSK3008356 or matching placebo, as 14 daily doses in the three sequential cohorts. Subjects in cohort 1 will receive their daily dose in morning, while subjects in cohort 2 and cohort 3 will receive their daily dose in evening. In all the three cohorts, Day 1 and day 14 dosing will occur while receiving a standard fat meal in morning. Eight subjects will be enrolled in each cohort.
3120767|NCT02742766|Experimental|Part 3 - GSK3008356 28 day repeat dose|Obese subjects will receive GSK3008356 or matching placebo, as 28 daily doses in the three parallel cohorts. Cohort 1 will evaluate 1 dose strength of GSK3008356 (or matching placebo) administered as morning doses. Cohorts 2 and 3 will evaluate 2 dose strengths (1 per cohort) of GSK3008356 (or matching placebo) administered in the evening. Ten subjects will be enrolled in each cohort.
3120768|NCT02742818|Other|Upper body blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
3120769|NCT02742818|Other|Underbody blanket, Bair Hugger|Patients undergoing EVAR and LEA will use this type of warming blanket.
3120770|NCT02742987|Experimental|Ticagrelor group|Ticagrelor 90 mg twice daily + standard medical therapy
3120771|NCT02742987|Experimental|Clopidogrel group|Clopidogrel 150 mg once daily + standard medical therapy
3120772|NCT02743078|Experimental|Bevacizumab and TTFields Therapy|Bevacizumab starts on the first day (+/- 1 day) of Tumor Treating Fields (TTFields) therapy. Treatment is given until disease progression or the development of adverse events that require complete discontinuation.
3120773|NCT02743117|Experimental|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) fluorescent focus units (FFU) strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
3120774|NCT02743117|Placebo Comparator|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
3120775|NCT02743221|Experimental|Trifluridine/tipiracil + bevacizumab|"Trifluridine/tipiracil (S95005): film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride.~Bevacizumab: concentrate for solution for IV infusion containing 25mg/ml of bevacizumab.~Trifluridine/tipiracil was administered at 35 mg/m2/dose orally within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period, with bevacizumab administered intravenously at the dose of 5 mg/kg every 2 weeks at Day 1 and Day 15.This treatment cycle was repeated every 4 weeks."
3120776|NCT02743221|Active Comparator|Capecitabine + bevacizumab|Capecitabine was administered at 1250 mg/m² orally BID (bis in die)on Days 1-14 of each cycle, with bevacizumab (7.5 mg/kg, IV) administered on Day 1 of each cycle. This treatment cycle was repeated every 3 weeks
3120777|NCT02743312|Experimental|Torso Weights then Sham Weights|"No weights worn for 4 weeks. Garment with torso weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with sham weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
3120778|NCT02743312|Experimental|Sham Weights then Torso Weights|"No weights worn for 4 weeks. Garment with sham weights worn 2-4 hours daily for 2 weeks. Then participants cross-over to wear garment with torso weights for 2-4 hours daily for 2 weeks.~Participants wear the Fitbit Flex throughout."
3120779|NCT02743377|Experimental|Subjects with McCune-Albright syndrome (MAS)|Subjects with McCune-Albright syndrome (MAS) who received 11C-(R)-rolipram whole-body and/or brain PET scans
3120780|NCT02743377|Experimental|Healthy control|Healthy control received 11C-(R)-rolipram whole-body and/or brain PET scans
3120781|NCT02743442|Experimental|Transoral surgery|
3120782|NCT02743494|Experimental|Nivolumab|
3120783|NCT02743494|Placebo Comparator|Placebo|
3120784|NCT02743520|Experimental|Cardiac event monitor|Participants will under go evaluation with a two week cardiac event monitor.
3120785|NCT02743702|Experimental|GROUP RECEIVING RESPIRATORY PHYSIOTHERAPY|Respiratory Physiotherapy sessions were held once a week by the physiotherapist, and four times more for the family at home, for one year. The sessions have a duration between 30 and 45 minutes, varying according to the level of patient cooperation. The exercise program should be repeated in three cycles, although younger children took longer than older in performing them.
3120786|NCT02743702|Experimental|GROUP RECEIVING THEIR USUAL THERAPIES|This group received no approach of their respiratory difficulties by Physiotherapy. Only continued their usual therapies.
3120787|NCT02743780|Experimental|MGV354|Part 3: MGV354 ophthalmic suspension, 1 drop in both eyes once per day for 7 days
3120788|NCT02743780|Placebo Comparator|Placebo|Part 3: MGV354 placebo, 1 drop in both eyes once per day for 7 days
3120789|NCT02743793||Operationally Tolerant Kidney or Liver Allograft Recipients|"Operational tolerance at baseline is defined as:~An absence of any immunosuppressive therapy for ≥ 52 weeks prior to the screening visit;~No evidence of allograft rejection in the 52 weeks prior to the screening visit (Day 0), based on the participant's medical history; and~Normal and stable allograft function at screening visit defined as-~For liver transplant recipients: Liver function tests (ALT, GGT) both less than or equal to the upper limit of normal (ULN)~For kidney transplant recipients: Serum creatinine value corresponds to an estimated glomerular filtration rate (GFR) > 45 ml/min/1.73 m^2."
3120790|NCT02743936|Experimental|NIPPV with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula in place
3120791|NCT02743936|Active Comparator|NIPPV without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula
3120792|NCT02743949|Active Comparator|Esomeprazole 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by esomeprazole 40 mg, over encapsulated tablets, orally, once daily for 4 weeks during the active treatment period.
3120793|NCT02743949|Experimental|Vonoprazan 20 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 20 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the treatment period.
3120794|NCT02743949|Experimental|Vonoprazan 40 mg|Esomeprazole 40 mg over-encapsulated tablets, orally, once daily for 4 weeks then esomeprazole placebo-matching capsules, orally, once daily for 2 weeks during the run-in period, followed by vonoprazan 40 mg, over-encapsulated capsules, orally, once daily for 4 weeks during the active treatment period.
3120795|NCT02743962|Active Comparator|Usual physiotherapy treatment group|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome: dietary advice regarding fluid and fibre intake, advice regarding bladder retraining and 15 minutes manual intra-vaginal pelvic floor muscle myofascial release and gentle stretching each week for 6 weeks. They will be instructed to briefly contract and then fully relax their pelvic floor muscles independently (clothed, in a seated or lying position) for 5 minutes daily.
3120796|NCT02743962|Experimental|Therapeutic Wand group|This group will receive the standard specialist physiotherapy intervention for bladder pain syndrome for 6 weeks, but will also be provided with an intra-vaginal therapeutic wand and taught how to use it. They will then be asked to use the therapeutic wand at home twice a week to release and relax their pelvic floor muscles for 5 minutes.
3120797|NCT02744066|Other|Neonates|Neonates admitted to the NICU will be fitted for NEATCAP, non-invasive novel hearing protection device.
3120798|NCT02744391|Experimental|L-DOPA|Patients will receive titration of L-DOPA from 150 mg to 450 mg.
3120799|NCT02744534|Experimental|Abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants with abnormal FACBC PET-CT scan results will have a PET/ultrasound fusion targeted prostate biopsy followed a standard of care prostate biopsy.
3120800|NCT02744534|Active Comparator|No abnormalities found with FACBC PET-CT|All participants with suspected recurrence of prostate cancer will have the FACBC PET-CT scan performed. Participants without abnormal FACBC PET-CT scan results will have a standard of care prostate biopsy.
3120801|NCT02744755|Experimental|GP2017|Group 1 will receive treatment with 40mg GP2017 (Adalimumab - GP2017) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response continue treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
3120802|NCT02744755|Active Comparator|US Licensed Humira|Group 2 will receive treatment with 40mg Humira® (Adalimumab - US licensed Humira®) by subcutaneous injection every other week up to 24 weeks (Study Period 1) at which patients achieving at least a moderate clinical response will be switched to treatment with 40mg GP2017 subcutaneous injection every other week up to 48 weeks (Study Period 2).
3120803|NCT02744846||Children from birth to 5 years|"Children from birth to 5 years where:~1 or more encounters with length and weight measured in the following age interval: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in either or both of the following age intervals: 4.0 to 5.9 y (age 5 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data"
3120804|NCT02744846||Children from birth to 10 years|"Children from birth to 10 years where:~1 or more encounters with length and weight measured in each of the following age intervals: 0-12 m, 12-30 m, and~> 1 encounter with height and weight measured in the following age interval: 9.0 to 10.9 y (age 10 years), or eligible to be followed to these ages for use in multiple imputation to account for missing data."
3120805|NCT02744898|Experimental|Carboplatin AUC and Abraxane 100mg/m2|
3120806|NCT02745080|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 48.
3120807|NCT02745080|Active Comparator|Adalimumab 40 mg s.c.|Adalimumab 40 mg administered at Baseline followed by dosing every 2 weeks until Week 50.
3120808|NCT02745119|Experimental|Lampalizumab Every 4 Weeks|Participants who received either lampalizumab or sham comparator every 4 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 milligrams (mg) via ITV injection, administered every 4 weeks.
3469364|NCT03887273|Experimental|Q-Cells dose level 3|One time surgical transplantation of Q-Cells dose level 3 unilaterally into spinal cord demyelinated lesion
3120809|NCT02745119|Experimental|Lampalizumab Every 6 Weeks|Participants who received either lampalizumab or sham comparator every 6 weeks in one of the parent studies and completed the Week 96 visit will receive open-label lampalizumab as 10 mg via ITV injection, administered every 6 weeks.
3120810|NCT02745145|Experimental|Abituzumab 1500 milligram (mg)|
3120811|NCT02745145|Experimental|Abituzumab 500 mg|
3120812|NCT02745145|Placebo Comparator|Placebo|
3120813|NCT02745353|Active Comparator|A|Patients in Arm A will receive a single daily dose of 25mg naloxegol for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover treatment period in which the patient will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication.
3120814|NCT02745353|Active Comparator|B|Patients in Arm B will receive the treating physician's usual care for OIC using a stimulant laxative + rescue medication for the 2-week initial treatment period, followed by a 3-day washout period and 2-week crossover period in which the patient will receive a single daily dose of 25mg naloxegol.
3120815|NCT02745392|Experimental|ZP-Zolmitriptan 1 mg|ZP-Zolmitriptan 1 mg patch single administration
3120816|NCT02745392|Experimental|ZP-Zolmitriptan 1.9 mg|ZP-Zolmitriptan 1.9 mg patch single administration
3120817|NCT02745392|Experimental|ZP-Zolmitriptan 3.8 mg|ZP-Zolmitriptan 3.8 mg (1.9 mg x 2 patches) single administration
3120818|NCT02745392|Placebo Comparator|Placebo|Placebo (either single or double patch) single administration
3120819|NCT02745535|Experimental|SOF/VEL/VOX|Fixed dose combination of SOF/VEL/VOX (Sofosbuvir 400mg/Velpatasvir 100mg/ Voxilaprevir 100mg) dosed once daily for 12 weeks.
3120820|NCT02745626|Experimental|Clear Aligner Appliance|Clear Aligners, Align Technology Inc., Santa Clara, California
3120821|NCT02745626|Experimental|Self-ligating Appliance|Carriere Self-Ligating Bracket, Carlsbad, CA
3120822|NCT02745626|Experimental|Conventional bracket appliance|Preadjusted edge wise brackets using elastomeric ties.
3120823|NCT02746107|Experimental|risk presented on 1 diagram|decision aid with risk of stroke presented on 1 diagram (risk under OAC treatment)
3120824|NCT02746107|Active Comparator|risk presented on 2 diagrams|decision aid with risk of stroke presented on 2 diagrams (one presenting risk without and one presenting risk with treatment)
3120825|NCT02746107|Active Comparator|1year risk estimate|risk of stroke presented over a timeframe of 1 year
3120826|NCT02746107|Experimental|5year risk estimate|risk of stroke presented over a timeframe of 5 years
3120827|NCT02746107|Other|CHA2DS2-VASC risk score 1|CHA2DS2-VASC risk score =1
3120828|NCT02746107|Other|CHA2DS2-VASC risk score 2|CHA2DS2-VASC risk score =2
3120829|NCT02746107|Other|CHA2DS2-VASC risk score 3|CHA2DS2-VASC risk score =3
3120830|NCT02746107|Other|CHA2DS2-VASC risk score 4|CHA2DS2-VASC risk score =4
3120831|NCT02746107|Other|CHA2DS2-VASC risk score 5|CHA2DS2-VASC risk score =5
3120832|NCT02746107|Active Comparator|prescription to virtual patient|prescription is done for a virtual patient
3120833|NCT02746107|Experimental|prescription to physician himself|prescription is done to physician himself
3120834|NCT02746406|Experimental|Peritron+|SMIP assessment using Peritron+, Air-Trap Tubing, and a conventional CIC catheter
3120835|NCT02746575|Experimental|treatment|Postsurgical: 5mg metoprolol, IV, prior to extubation, every 5 minutes to achieve target heart rate of 65/min, up to 15mg; then 25mg metoprolol, oral, every 8 hours for 72 hours.
3120836|NCT02746627|Active Comparator|Education|Participants receive educational materials in the mail every 2 weeks for 8 weeks.
3120837|NCT02746627|Experimental|Positive Affect - Text|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations, and gift cards) by SMS. Participants also receive educational materials in the mail every 2 weeks for 8 weeks.
3120838|NCT02746627|Experimental|Positive Affect - Phone|Participants receive positive affect intervention (weekly reminders to use gratitude, self-affirmations, parental affirmations) by phone. Participants receive small gifts in the mail every 2 weeks for 8 weeks. educational materials in the mail every 2 weeks for 8 weeks.
3120839|NCT02746679|Experimental|MBSR Group|The Mindfulness Based Stress Reduction program consisted of eight weekly sessions, each 2.5 hours long, and delivered on consecutive weeks.The Mindfulness Based Stress Reduction therapist participated in the mindfulness exercises with group members during the weekly sessions, and group members were instructed to practice these mindfulness exercises outside group meetings for at least 45 minutes per day, 6 days per week.Group members were taught three main varieties of mindfulness skills: the body scan exercise, sitting meditation, and yoga exercises.The daily homework exercises consisted of repeating body scan work, sitting meditation and yoga exercises at home to provide practice and generalization of the skills.
3120840|NCT02746679|No Intervention|wait-list control group|The patients assigned to the wait-list control group did not receive MBSR intervention for 8 weeks when participants in MBSR were engaged in the MBSR intervention.They only received conventional therapy.
3120841|NCT02746705|Active Comparator|Transcranial Direct Current Stimulation (tDCS)|
3120842|NCT02746705|Sham Comparator|Sham Transcranial Direct Current Stimulation (tDCS)|
3120843|NCT02746809|Experimental|CoreValve Evolut 34R TAVR system|Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.
3120844|NCT02746874|Active Comparator|Active Group|Radiofrequency ablation procedure of the three articular branches of the knee joint. The targets will be thermally lesioned for 2 minutes 30 seconds thereby causing neurolysis.
3120845|NCT02746874|Sham Comparator|Placebo Group|Simulated Radiofrequency Ablation procedure of the three articular branches of the knee joint.The targets will be not be thermally lesioned for 2 minutes 30 seconds therefore not causing neurolysis.
3120846|NCT02746991|Sham Comparator|Sham Injection|Sham Injection
3120847|NCT02746991|Experimental|FAI Insert|FAI Insert (0.18 mg fluocinolone acetonide)
3120848|NCT02747004|Experimental|Abemaciclib + Tamoxifen|Abemaciclib given orally every 12 hours (Q12H) in combination with tamoxifen given orally every day. Participants may continue to receive treatment until discontinuation criteria are met.
3120849|NCT02747004|Experimental|Abemaciclib|Abemaciclib given orally Q12H. Participants may continue to receive treatment until discontinuation criteria are met.
3120850|NCT02747004|Experimental|Abemaciclib + Prophylactic Loperamide|Abemaciclib given orally Q12H in combination with prophylactic loperamide given orally. Participants may continue to receive treatment until discontinuation criteria are met.
3120851|NCT02747043|Experimental|ABP 798|ABP 798 was administered at a dose of 375 mg/m^2 as an intravenous (IV) infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
3120852|NCT02747043|Active Comparator|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 as an IV infusion once weekly for 4 weeks followed by dosing at weeks 12 and 20.
3120853|NCT02747108|Experimental|Blood Test Group|Patients will complete an HbA1c test and then receive brief counseling and written information about their test result based on the American Diabetes Association and National Diabetes Prevention Program guidelines.
3120854|NCT02747108|Active Comparator|Brochure Group (usual care)|Patients will not complete an HbA1c test and will instead receive brief counseling and written information about recommended screenings and immunizations.
3120855|NCT02747186|Active Comparator|Buffered 1% lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves.Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
3120856|NCT02747186|Active Comparator|Non-Buffered lidocaine|"In week One each subject would receive the anesthetic, 5cc, to block the Posterior alveolar, Anterior alveolar, Palatal nerves. Maxillary molar and canine tested for pulpal anesthesia.~At least a week later, injections for the maxillary field block would involve the alternate local anesthetic combination. Maxillary molar and canine tested for pulpal anesthesia."
3120857|NCT02747238|Active Comparator|Ultrasound|Woman requests epidural for pain relief Ultrasound guided CSE placed Continuous epidural infusion started
3120858|NCT02747238|Active Comparator|No ultrasound|Palpation of anatomical landmarks Woman requests epidural for pain relief CSE placed using palpation of anatomical landmarks Continuous epidural infusion started
3120859|NCT02747420|Experimental|Post Tibial Nerve Stimulation Group (PTNS)|
3120860|NCT02747420|Sham Comparator|Sham Group|
3120861|NCT02747433|Active Comparator|ALPS + Robot-Assisted Therapy (RT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 1 hr sessions 3x week for 6 weeks plus ALPS training
3120862|NCT02747433|Active Comparator|ALPS + Robot + Task-Oriented Training (RT-TOT)|Armeo and Amadeo robot-assisted intensive upper extremity therapy 30 mins, 3x week for 6 weeks plus ALPS training. Task oriented training will be provided for remaining 30 min of each treatment session
3120863|NCT02747615|Other|Control group (n=30)|The control group, which consisted of 30 patients who were transfused only allogeneic blood.
3120864|NCT02747615|Active Comparator|Preoperative blood donation (n=30)|the study group including 30patients who were transfused pre-operatively donated autologous blood, either during surgery or after it.
3120865|NCT02747628|Placebo Comparator|C group, (n=20)|C group (n=20) (placebo group) each patient received transdermal placebo patch, identical placebo patches custom-made by 1-800-Patches (Salt Lake City, UT) placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
3120866|NCT02747628|Active Comparator|TDN group, (n=20)|TDN group (n=20) each patient received transdermal therapeutic system- nicotine (15 mg/16 h),Nicorette® invisi 15mg patch releasing 15mg of nicotine over 16h, produced by Lohmann Therapie-System, Germany placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
3120867|NCT02747628|Active Comparator|TDM group, (n=20)|TDM group (n=20) each patient received transdermal therapeutic system- melatonin (7 mg/8h),melatonin sleep patch from Respro Labs ™ containing 7 mg of melatonin placed 2 hours preoperatively for acute postoperative pain after laparoscopic cholecystectomy.
3120868|NCT02747875|Active Comparator|Control - Fentanyl|Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
3120869|NCT02747875|Active Comparator|Treatment - Methadone|Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. The medication will be prepared as described and all research and staff personnel as well as the study participant will be blinded to treatment group assignment.
3120870|NCT02747927|Placebo Comparator|Placebo|Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
3120871|NCT02747927|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received TDV, SC injection, based on the randomization on Day 1 (Month 0).
3120872|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 2.5 mg|1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve low-density lipoprotein- cholesterol (LDL-C) goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg
3120873|NCT02748057|Experimental|Ezetimibe 10 mg + Rosuvastatin 5.0 mg|1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.
3120874|NCT02748070|Experimental|Prednisone|Provided oral steroid and topical steroid
3120875|NCT02748070|Placebo Comparator|Placebo|Provided oral placebo and topical steroid
3120876|NCT02748096|Experimental|Patient Specific Instrumentation|Patients undergoing unicompartmental knee replacement with the additional aid of patient specific instrumentation.
3120877|NCT02748096|Active Comparator|Conventional Instrumentation|Patients undergoing unicompartmental knee replacement using standard instrumentation.
3120878|NCT02748213|Experimental|Herceptin + Taxotere|Participants will receive dual therapy with Herceptin and Taxotere until disease progression, unmanageable toxicity, or withdrawal.
3120879|NCT02748213|Experimental|Herceptin + Taxotere + Xeloda|Participants will receive triple therapy with Herceptin, Taxotere, and Xeloda until disease progression, unmanageable toxicity, or withdrawal.
3120880|NCT02748317|Experimental|Adults with Spinal Cord Injury|Lactobacillus rhamnosus GG
3120881|NCT02748356|Experimental|Individuals with Spina Bifida|Lactobacillus rhamnosus GG
3120882|NCT02748512|Experimental|FAI Insert administered using the Mk II inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
3120883|NCT02748512|Active Comparator|FAI Insert administered using the Mk I inserter|The test article is the Fluocinolone Acetonide Intravitreal (FAI) insert, which contains 0.18 mg FA and delivers FA into the vitreous humor for 36 months, at a nominal rate of approximately 0.2 μg FA/day. The FAI insert will be administered to the study eye as an intravitreal injection through the pars plana.
3120884|NCT02748525|Experimental|CCK then Milk|CCK administered and HIDA scan performed. Results analyzed, if ejection fraction is low, patient is given milk to drink, and HIDA scan performed again. Results are analyzed to determine if ejection fraction is still low.
3120885|NCT02748616|Experimental|Ursodiol|Subjects will begin to take 300 mg Ursodiol following Visit #1 and continue for a total of 8 (eight) weeks.
3120886|NCT02748694|Placebo Comparator|Part 1 (SRD): Placebo Cohorts 1-5|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
3120887|NCT02748694|Experimental|Part 1 (SRD): Cohort 1: TAK-041 5/20 mg|TAK-041 5 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 20 mg, suspension, orally, once on Day 8 in the SRD period.
3120888|NCT02748694|Experimental|Part 1 (SRD): Cohort 2: TAK-041 10/40 mg|TAK-041 10 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period. Participants also received 40 mg, suspension, orally, once on Day 8 in the SRD period.
3120889|NCT02748694|Experimental|Part 1 (SRD): Cohort 3: TAK-041 80 mg|TAK-041 80 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
3120890|NCT02748694|Experimental|Part 1 (SRD): Cohort 4: TAK-041 120 mg|TAK-041 120 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
3120891|NCT02748694|Experimental|Part 1 (SRD): Cohort 5: TAK-041 160 mg|TAK-041 160 mg, suspension, orally, once on Day 1 in fasted healthy participants in the SRD period.
3120892|NCT02748694|Placebo Comparator|Part 2 (MRD): Placebo Cohorts 1-4|TAK-041 placebo-matching suspension, orally, once on Day 1 in fasted healthy participants in the multiple-rising dose (MRD) period.
3120893|NCT02748694|Experimental|Part 2 (MRD): Cohort 1: TAK-041 40/20 mg|TAK-041 40 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 20 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
3120894|NCT02748694|Experimental|Part 2 (MRD): Cohort 2: TAK-041 80/40 mg|TAK-041 80 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 40 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
3120895|NCT02748694|Experimental|Part 2 (MRD): Cohort 3: TAK-041 120/60 mg|TAK-041 120 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 60 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
3120896|NCT02748694|Experimental|Part 2 (MRD): Cohort 4: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 in fasted healthy participants followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in the MRD period.
3120897|NCT02748694|Experimental|Part 3: Relative Bioavailability (RBA)/Food Effect: Regimen A|TAK-041 40 mg, tablet, orally, once on Day 1 in fasted state (Regimen A) in Cohort 1.
3120898|NCT02748694|Experimental|Part 3: RBA/Food Effect: Regimen B|TAK-041 40 mg, tablet, orally, once on Day 1 in fed state (Regimen B) in Cohort 2.
3120899|NCT02748694|Placebo Comparator|Part 4: MRD: Placebo|TAK-041 placebo-matching, suspension, orally, on Days 1, 8, 15 and 22 in participants with schizophrenia
3120900|NCT02748694|Experimental|Part 4: MRD: TAK-041 160/80 mg|TAK-041 160 mg as loading dose, suspension, orally, once on Day 1 followed by 80 mg (half the initial dose) as a maintenance dose on Days 8, 15 and 22 in participants with schizophrenia.
3120901|NCT02748785|Experimental|Group 1 (No MTX Hold before Vaccination)|Group 1 will continue MTX
3120902|NCT02748785|Experimental|Group 2 (MTX hold 4 Weeks before vaccination)|Group 2 will hold MTX 4 weeks before vaccination and resume MTX on the day of vaccination
3120903|NCT02748785|Experimental|Group 3 (MTX hold 2 Weeks before Vaccination)|Group 3 will hold MTX 2 weeks before vaccination and resume MTX 2 weeks after vaccination
3120904|NCT02748785|Experimental|Group 4 (MTX hold on Day of Vaccination)|Group 4 will hold MTX on day of vaccination and resume MTX 4 weeks after vaccination.
3120905|NCT02748863|Placebo Comparator|Placebo|Placebo, provided in a 2 mL pre-filled syringe Placebo, provided in a 1 mL pre-filled syringe
3120906|NCT02748863|Experimental|Secukinumab 2 mL form|Secukinumab 300 mg, provided in a 2 mL pre-filled syringe
3120907|NCT02748863|Active Comparator|Secukinumab 1 mL form|Secukinumab 300 mg provided in 2 pre-filled syringes of 1 mL/150 mg (current approved form)
3120908|NCT02748889|Active Comparator|Carboplatin plus etoposide|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles
3120909|NCT02748889|Experimental|Carboplatin, etoposide and MPDL3280A|Carboplatin AUC 5 iv on day 1 every 21 days for 4 cycles Etoposide 100mg/m2 iv on days 1-3 every 21 days for 4 cycles MPDL3280A (Atezolizumab) 1200mg iv on day 1 every 21 days until progression
3120910|NCT02748928|Experimental|UltraShape Power treatment to abdomen|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape Power device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
3120911|NCT02749201|Experimental|Analysis|Light Intensity and gastric wall thickness analysis
3120912|NCT02749370|Experimental|Etanercept|Participants received etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for an additional 12 weeks.
3120913|NCT02749721|Other|Other - vortioxetine|Open-label vortioxetine
3120914|NCT02749799|Experimental|DFD-01 (betamethasone dipropionate) Spray, 0.05%|DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.
3120915|NCT02749903|Other|Enzalutamide|Patients receive 160 mg enzalutamide orally once daily (1 cycle=28 days). Patients will remain on therapy until progression of disease or development of unacceptable toxicities or patient or physician withdrawal. Patients will undergo radiographic imaging every 2 months while on study treatment in order to determine response.
3120916|NCT02750267|Experimental|Group A|In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission.
3120917|NCT02750267|Experimental|Group B|Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission.
3120918|NCT02750306|Experimental|Suvorexant|Participants will receive 1 suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' suvorexant dose may be increased to 20 mg if their Clinical Global Impression of Insomnia Severity (CGI-S) is ≥3 and investigators feel they can tolerate the increased dose.
3120919|NCT02750306|Placebo Comparator|Placebo|Participants receive 1 placebo-matching suvorexant tablet every night for up to 4 weeks. After 2 weeks of double-blind treatment at 10 mg, participants' placebo-matching dose can be increased to 20 mg if their CGI-S is ≥3 and investigators feel they can tolerate the increased dose.
3120920|NCT02750332|Experimental|Treatment Sequence A (Fed) - B (Fasted)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fed conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120921|NCT02750332|Experimental|Treatment Sequence B (Fasted) - A (Fed)|Subjects will receive a single 10 mg tablet of Nitisinone in treatment period 1 under fasting conditions, and 10 mg tablet of Nitisinone in treatment period 2 under fed conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120922|NCT02750345|Experimental|Sequence TP 1 - TP 2 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1 (TP 1)) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2 (TP 2)) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120923|NCT02750345|Experimental|Sequence TP 1 - Reference - TP 2|Subjects will receive a single 10 mg tablet of Nitisinone (Test Product 1) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120924|NCT02750345|Experimental|Sequence TP 2 - TP 1 - Reference|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120925|NCT02750345|Experimental|Sequence TP 2 - Reference - TP 1|Subjects will receive a single 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120926|NCT02750345|Experimental|Sequence Reference - TP 1 - TP 2|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120927|NCT02750345|Experimental|Sequence Reference - TP 2 - TP 1|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone Baked Tablet (Test Product 2) in treatment period 2, and 10 mg tablet of Nitisinone (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120928|NCT02750410|Experimental|Dulaglutide|Dulaglutide 0.75 milligram (mg) administered once weekly for 16 weeks. After 16-weeks, dulaglutide administered once weekly for 36 weeks.
3120929|NCT02750410|Placebo Comparator|Placebo|Placebo administered once weekly for 16 weeks. After 16-weeks, dulaglutide 0.75 mg administered once weekly for 36 weeks.
3120930|NCT02750501|Other|Single Arm: Open label RELiZORB Cartridge & Impact Peptide 1.5|RELiZORB (immobilized lipase) cartridge and Impact Peptide 1.5 with enteral feedings ranging from 500 mL to 1,000 mL per feeding for a period of 90 days.
3120931|NCT02750514|Active Comparator|Nivolumab|Nivolumab Monotherapy - Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator
3120932|NCT02750514|Experimental|Nivolumab & Dasatinib|Nivolumab in combination with Dasatinib
3120933|NCT02750514|Experimental|Nivolumab & Relatlimab|Nivolumab in combination with Relatlimab
3120934|NCT02750514|Experimental|Nivolumab & Ipilimumab|Nivolumab in combination with Ipilimumab
3120935|NCT02750514|Experimental|Nivolumab & BMS-986205|Nivolumab in combination with BMS- 986205
3120936|NCT02750592|Experimental|secukinumab 150mg|A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.
3120937|NCT02750618|Experimental|Burosumab Q2W|Burosumab subcutaneous (SC) injections every 2 weeks (Q2W) for a total of 160 weeks.
3120938|NCT02750709|Experimental|Treatment Sequence A (TP 1) - B (TP 2) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120939|NCT02750709|Experimental|Treatment Sequence A (TP 1) - C (Reference) - B (TP 2)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120940|NCT02750709|Experimental|Treatment Sequence B (TP 2) - A (TP 1) - C (Reference)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg hard capsule of Orfadin (Reference) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120941|NCT02750709|Experimental|Treatment Sequence B (TP 2) - C (Reference) - A (TP 1)|Subjects will receive a single 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 1, 10 mg hard capsule of Orfadin (Reference) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3, and under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120942|NCT02750709|Experimental|Treatment Sequence C (Reference) - A (TP 1) - B (TP 2)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 2, and 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120943|NCT02750709|Experimental|Treatment Sequence C (Reference) - B (TP 2) - A (TP 1)|Subjects will receive a single 10 mg hard capsule of Orfadin (Reference) in treatment period 1, 10 mg tablet of Nitisinone 10 mg Tablet High Compritol (Test Product 2) in treatment period 2, 10 mg tablet of Nitisinone 10 mg Tablet (Test Product 1) in treatment period 3 under fasting conditions. Each treatment period will be separated by at least 23 calendar days of washout period.
3120944|NCT02750761|Experimental|Group 1 Cohort 1: Tedizolid IV 5 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 5 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120945|NCT02750761|Experimental|Group 1 Cohort 2: Tedizolid IV 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single intravenous infusion of tedizolid phosphate dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120946|NCT02750761|Experimental|Group 2 Cohort 1: Tedizolid IV 6 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 6 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120947|NCT02750761|Experimental|Group 2 Cohort 2: Tedizolid IV 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single intravenous infusion of tedizolid phosphate dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120948|NCT02750761|Experimental|Group 3: Tedizolid oral 4 mg/kg (6 to <12 years)|Participants 6 to <12 years of age received a single dose of tedizolid phosphate oral suspension dosed at 4 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120949|NCT02750761|Experimental|Group 4: Tedizolid oral 3 mg/kg (2 to <6 years)|Participants 2 to <6 years of age received a single dose of tedizolid phosphate oral suspension dosed at 3 mg/kg of total body weight. Maximum dose is 200 mg of tedizolid phosphate.
3120950|NCT02750800||Adalimumab and AbbVie Care 2.0|Adalimumab administered via subcutaneous (SC) injection for 12 months according to the approved EMA label and Hungarian financial protocols and supportive services via the AbbVie Care 2.0 patient support program
3120951|NCT02750813|Other|DT1, then AO1D|Delefilcon A contact lenses worn first, followed by senofilcon A contact lenses. Each product worn bilaterally (in both eyes) for 14 days in a daily wear, daily disposable modality.
3120952|NCT02750813|Other|AO1D, then DT1|Senofilcon A contact lenses worn first, followed by delefilcon A contact lenses. Each product worn bilaterally for 14 days in a daily wear, daily disposable modality.
3120953|NCT02750930|Experimental|Albiglutide arm|Subjects will receive 50 milligrams (mg) albiglutide liquid drug product once weekly via auto-injector for 26 weeks.
3120954|NCT02750943|Experimental|Stannous Fluoride|Participants will apply a full ribbon of dentifrice containing 0.454% w/w stannous fluoride to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
3120955|NCT02750943|Active Comparator|Sodium Monofluorophosphate|Participants will apply a full ribbon of dentifrice containing Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate to the study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening)
3120956|NCT02751320|Experimental|Experimental Dentifrice1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3120957|NCT02751320|Experimental|Experimental Dentifrice 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3120958|NCT02751320|Experimental|Experimental Dentifrice 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3469365|NCT03887468|Active Comparator|"EvoCit"|"Standardized hemodialysis treatments 3x4hours/week. Intervention: EvoCit procedure using a heparin-grafted AN69ST dialyzer in combination with a citric acid enriched dialysate without any systemic anticoagulation."
3120959|NCT02751320|Placebo Comparator|Reference Product 1|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3120960|NCT02751320|Active Comparator|Reference Product 2|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3120961|NCT02751320|Active Comparator|Reference Product 3|Participants will brush their natural teeth with a pre-wetted toothbrush and their assigned dentifrice for one timed minute, ensuring the enamel specimens retained within their mouths are not directly brushed. Participants should then rinse their mouths with 15ml of tap water for approximately 10s.
3120962|NCT02751359|Active Comparator|Active CBD|Each subject will receive each active dose of cannabidiol, one active dose per 3 of the 4 study days. The active cannabidiol doses include 200, 400 and 800 mg of cannabidiol.
3120963|NCT02751359|Placebo Comparator|Placebo|On 1 of the 4 study days, participants will receive placebo cannabidiol (0 mg)
3120964|NCT02751385|Experimental|All Patients|Microgynon alone in Period 1 then with Nintedanib in Period 2
3120965|NCT02751424|Experimental|GSK3342830 single dose in Part 1|Enrolled subject will receive single escalation dose of GSK3342830. The escalating doses will be evaluated in six cohorts as A- 250 mg, B-500 mg, C-1000 mg, D-2000 mg, E-4000 mg, and F-=<6000 mg. In each cohort 6 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 36 subjects will receive GSK3342830. Dose escalation will be based on evaluation of the preceding dose levels in the study.
3120966|NCT02751424|Placebo Comparator|Placebo single dose in Part 1|Enrolled subject will receive single escalation dose of placebo. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 12 subjects will receive placebo.
3120967|NCT02751424|Experimental|GSK3342830 repeat Dose in Part 2|Enrolled subject will receive repeat escalating dose of GSK3342830. GSK3342830 as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. The escalating doses will be evaluated in three cohorts as G-1000 mg, H-2000 and I-4000 mg. In each cohort 8 subjects will receive GSK3342830 in form of infusion for 1 h, therefore approximately 24 subjects will receive GSK3342830. The starting dose and maximum dose may change based on clinical safety and PK findings in Part 1 or earlier doses in Part 2 respectively.
3120968|NCT02751424|Placebo Comparator|Placebo repeat Dose in Part 2|Enrolled subject will receive repeat escalation dose of placebo. Placebo as a single IV infusion will be administered on Day 1, TID (8 hours apart) IV infusions on Days 2 through 14, and a single IV infusion on Day 15. In each cohort, 2 subjects will receive placebo in form of infusion for 1 h, therefore approximately 6 subjects will receive placebo.
3120969|NCT02751450|Experimental|Stannous Fluoride dentifice|Participants will apply (under supervision) a pea-sized dose of experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm) to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted
3120970|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Participants will apply (under supervision) a pea-sized dose of dentifrice containing Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)to each of the two qualifying teeth using their finger by direct application and gently rubbing into the tooth's cervical margin for the allocated time. No rinsing will be permitted.
3120971|NCT02751580|Experimental|Health services research (telehealth)|Patients undergo their first post-treatment visit as a virtual telehealth visit using the JeffConnect application downloaded onto their electronic device.
3120972|NCT02751827||Prospective cohort|"Prospective cohort involving patients treated in four distinct centers. Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
3120973|NCT02751827||Retrospective cohort A|"Retrospective cohort of patients treated at the Institut Bergonié (Bordeaux, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
3120974|NCT02751827||Retrospective cohort B|"Retrospective cohort of patients treated at the Centre Antoine Lacassagne(Nice, France). Patients were treated with a tyrosine kinase inhibitor (TKI) prescribed as part of a marketing authorization (MA).~All patients without major violations of the eligibility criteria are included in the eligible population. In case of violation of the eligibility criteria, the steering committee will assess for each patient, whether the violation is minor or major.~All eligible patients who have received at least one TKI administration were included in analysis."
3120975|NCT02751879||Non small cell lung cancer (NSCLC)|patients with Epidermal growth factor receptor (EGFR) mutation (common mutations), TKI-naïve advanced non small cell lung cancer (NSCLC), treated with Gi(l)otrif® as the first-line treatment for NSCLC within the approved label
3120976|NCT02751931|Experimental|Children (3 to < 12 Years)|Participants aged 3 to < 12 years received initial dose of 25 milligram (mg) of mirabegron orally once daily based on weight (pediatric equivalent dose of 25 mg (milligram) [PED25]) on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50], orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 end-of-study (EOS) or end-of-treatment (EOT).
3120977|NCT02751931|Experimental|Adolescents (12 to < 18 Years)|Participants aged 12 to < 18 years received initial dose of 25 mg of mirabegron orally once daily based on weight [PED25] on day 1. At weeks 2, 4 or 8, participant's were up-titrated to the pediatric equivalent dose of 50 mg in adults [PED50] orally once daily based on the given dose titration criteria. Following week 24, participants stayed on their individual dose level until week 52 EOS or EOT.
3120978|NCT02751983|Experimental|Treatment as usual plus ACT|Participants in this condition will be enrolled in the ACT for Life intervention and still able to engage in treatment as usual.
3120979|NCT02751983|Active Comparator|Treatment as usual|Participants in this condition will not be enrolled in ACT for Life, but will continue to participate in treatment as usual (e.g., inpatient and outpatient mental health care).
3120980|NCT02752048|Experimental|TAS-205（Low dose group）|Low dose group：Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (6.67-13.33 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
3120981|NCT02752048|Experimental|TAS-205（High dose group）|High dose group: Oral administration of tablets for 24 weeks, bis in die (BID) after meal The number of tablets of the study drug corresponding to the dosage (13.33-26.67 mg/kg/dose) by body weight within 14 days before enrollment was to be administered within 30 minutes after breakfast and dinner.
3120982|NCT02752048|Placebo Comparator|Placebo|Placebo group: Oral administration of tablets for 24 weeks, BID after meal
3120983|NCT02752074|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab + Epacadostat
3120984|NCT02752074|Active Comparator|Pembrolizumab + Placebo|Pembrolizumab + Placebo
3120985|NCT02752087|Experimental|U-193 LY900014 Test|LY900014 test dose administered via subcutaneous (SC) injection
3120986|NCT02752087|Active Comparator|U-95 LY900014 Reference|LY900014 reference dose administered via SC injection
3120987|NCT02752256||Intervention/Transfer|Patients who are transferred via air ambulance to a comprehensive stroke center
3120988|NCT02752256||Control|Patients presenting directly to the comprehensive stroke center
3120989|NCT02752490|Active Comparator|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by the American Congress of Obstetrics and Gynecology (ACOG) at the discretion of the primary nurse or physician
3120990|NCT02752490|Experimental|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% fraction of inspired oxygen (FiO2) at 10 liters/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
3120991|NCT02752633|Experimental|Study subjects|Following a 7 day washout period all patients receive allopurinol (400 mg/day) as a single daily dose for 2 weeks. Following another 7 day washout period all participants receive febuxostat, 80 mg/day as a single daily dose, for 2 weeks.
3120992|NCT02752776|Experimental|Secukinumab|All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.
3120993|NCT02752802|Active Comparator|Treatment|The treatment group will include standard of care for diagnostic angiogram along with the utilizization of the DyeVert system.
3120994|NCT02752802|Active Comparator|Control|The control group will include standard of care for diagnostic coronary angiograms.
3120995|NCT02752880|Experimental|YH1 group|YH1 with one batch number was manufactured by Sun Ten Pharmaceutical Co., Ltd., a renowned manufacturer of concentrated herbal extract granules conforming to the standards of good manufacturing practices (GMP) in New Taipei City, Taiwan. YH1 contains Rhizoma Coptidis (50 %) and Shen-Ling-Bai-Zhu-San (SLBZS) (50 %). SLBZS consists of Radix Ginseng, Poria, Rhizoma Atractylodis macrocephalae, Semen Lablab album, Rhizoma Dioscoreae, Embryo Nelumbinis, Radix Platycodonis, Semen Coicis, Fructus Amomi, Fructus Jujubae, and Radix Glycyrrhizae at a 3:3:3:2.3:3:1.5:1.5:1.5:1.5:1.5:3 ratio. Subjects in the YH1 group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
3120996|NCT02752880|Placebo Comparator|placebo group|The placebo was also prepared as granules by Sun Ten Pharmaceutical Co., Ltd., and the packaging of the placebo was identical to that of YH1. Subjects in the placebo group orally ingested two packages of granules (3 g/package) three times daily with warm water after a meal for 12 consecutive weeks.
3120997|NCT02752906|Experimental|MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine-primed adolescents (greater than or equal to [>=] 15 to less than [< ]18 years) or adults (>= 18 years) received a single dose of a MenACYW Conjugate vaccine on Day 0.
3120998|NCT02752906|Active Comparator|Menactra®|Healthy, meningococcal- vaccine-primed adolescents (>= 15 to < 18 years) or adults (>= 18 years) received a single dose of Menactra ® vaccine on Day 0.
3120999|NCT02752958|Experimental|stannous fluoride|This was a non-comparative design study, all the participants applied dentifrice containing stannous fluoride for 1 timed minute, twice daily (morning and evening) for 24 weeks.
3121000|NCT02753075|Experimental|Experimental Oral Rinse 1|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 1 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3121001|NCT02753075|Experimental|Experimental Oral Rinse 2|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Experimental Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3121002|NCT02753075|Placebo Comparator|Placebo Oral Rinse|Brushing with fluoride toothpaste for 1 minute followed by rinsing with 10 ml of Placebo Oral Rinse 2 for 1 minute. This regimen will be performed twice daily for 8 weeks.
3121003|NCT02753400|Experimental|Emixustat hydrochloride|"Week 1- Four tablets (2 placebo, 2 emixustat HCl Strength A)~Week 2- Four tablets (2 placebo, 2 emixustat HCl Strength B)~Week 3- Four tablets (2 placebo, 2 emixustat HCl Strength C)~Week 4- Four emixustat HCl tablets (Strength C)~All tablets are administered orally once daily. After week 4, all subjects will be held at a stable dose for the remainder of the 12-week dosing regimen."
3121004|NCT02753400|Placebo Comparator|Placebo|Four placebo tablets are administered orally once daily for 12 weeks; Subjects in the placebo group will be mock-titrated on the same schedule as those in the active arm.
3121005|NCT02753413|Experimental|RSV group|Subjects in this group will receive a single dose of the RSV vaccine.
3121006|NCT02753413|Active Comparator|Boostrix group|Subjects in this group will receive a single dose of Boostrix.
3121007|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 1b)|"Recommended Phase 2 dose (RP2D) will be determined from the below dose levels:~Dose level 1: PEGPH20 (3.0 microgram per kilogram (mcg/kg)) followed by eribulin mesylate (1.4 milligrams per square meter (mg/m^2)) or~Dose level 0: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.4 mg/m^2) or~Dose level -1: PEGPH20 (1.6 mcg/kg) followed by eribulin mesylate (1.1 mg/m^2)~Dose level 1 can be selected as the RP2D if no more than 1 out of 6 participants has a DLT; DLT was only observed from the first treatment cycle; otherwise, Dose level 0 will be assessed in a second cohort of 6 subjects and will be selected as the RP2D if no more than 1 subject has a DLT. Otherwise, Dose level - 1 will be assessed in a third cohort of 6 subjects. Upon determination of the RP2D, study Phase 1b Expansion Part will proceed to confirm the RP2D, and thereafter Phase 2 part will proceed."
3121008|NCT02753595|Experimental|Eribulin mesylate plus PEGPH20 (Phase 2)|Participants will receive eribulin mesylate and PEGPH20 at the established RP2D level achieved in the Phase 1b.
3121009|NCT02753595|Experimental|Eribulin mesylate (Phase 2)|Participants will receive eribulin mesylate at 1.4 mg/m^2.
3121010|NCT02753699|Experimental|From Study 2210|All participants enrolled from CDEB025A2210 (n=164) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
3121011|NCT02753699|Experimental|From Study 2301|All participants enrolled from CDEB025A2301 (n=397) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
3121012|NCT02753699|Experimental|From Study 2211|All participants enrolled from CDEB025A2211 (n=162) who had been treated with alisporivir during the feeder study. There was no investigational treatment given to participants while enrolled in this follow-up study.
3121013|NCT02753816|Experimental|Tranexamic Acid|1 gram of Tranexamic Acid given over 10 minutes into the vein once prior to surgery
3121014|NCT02753816|Placebo Comparator|Placebo|Placebo given over 10 minutes into the vein once prior to surgery
3121015|NCT02753842|Experimental|Fitted, Then Thin, Then Standard Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
3121016|NCT02753842|Experimental|Fitted, Then Standard, Then Thin Condoms|Participants first received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
3121017|NCT02753842|Experimental|Thin, Then Fitted, Then Standard Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them.
3121018|NCT02753842|Experimental|Thin, Then Standard, Then Fitted Condoms|Participants first received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
3121019|NCT02753842|Experimental|Standard, Then Fitted, Then Thin Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them.
3121020|NCT02753842|Experimental|Standard, Then Thin, Then Fitted Condoms|Participants first received 5 standard condoms, and had a period of 2-4 weeks to use them. They then received 5 thin condoms, and had a period of 2-4 weeks to use them. They then received 5 fitted condoms, and had a period of 2-4 weeks to use them.
3121021|NCT02753881|Active Comparator|whole liver lobe cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a lobar (whole liver) manner.
3121022|NCT02753881|Active Comparator|superselective cTACE doxorubicin|Participants in this arm are administered 10 cc of chemotherapy, with 50mg doxorubicin and 10 mg of mitomycin-C via cTACE delivered in a super-selective (close to the tumor) manner.
3121023|NCT02753920|Active Comparator|Retrograde fill voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via visual analog scale (VAS) scale (however this information will only be used for research purposes).~If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids <200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial."
3121024|NCT02753920|Active Comparator|Force of Stream (FAST) voiding trial method|"Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water.~Catheter is removed~Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction).~The patient will subjectively quantify their force of stream via VAS scale.~If VAS scale >/=50 (>/=50%) the catheter will remain out, patient is discharged home without measuring a PVR~If VAS scale is from 0-49 (=0-49%) a PVR will be checked via bladder scan. If PVR is <500cc, the patient will be discharged without a catheter; if PVR is >/=500cc, the patient will be discharged with a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days."
3121025|NCT02753946|Experimental|ZTI-01|6 g ZTI-01 (IV fosfomycin) intravenously administered every 8 hours (18g total daily dose for 7-14 calendar days)
3121026|NCT02753946|Active Comparator|piperacillin tazobactam|4.5 g piperacillin/tazobactam (4 g piperacillin/0.5 g tazobactam) intravenously administered every 8 hours (13.5g total daily dose for 7-14 calendar days)
3121027|NCT02754310|Active Comparator|Repeated scenarios|Participants in the repeated scenario group will learn the management of a pediatric asthma exacerbation on the same scenario repeated three times. The scenario is a pediatric moderate asthma exacerbation not responding to treatment, .
3121028|NCT02754310|Experimental|Varied scenarios|"Participants in the varied scenarios group will learn the management of a pediatric asthma exacerbation on three different scenarios: a moderate asthma exacerbation, a mild one, and a severe one, for the same length of time than the repeated scenarios group. In this group, there is a variation of scenarios."
3121029|NCT02754427|Experimental|Prospective Surveillance Group|Women assigned to surveillance group were assessed for arm morbidity at pre-surgery and at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any time-point post-surgery, then a physiotherapy intervention was prescribed.
3121030|NCT02754427|Active Comparator|Education Group|Participants in the education group received the usual post-operative follow-up.
3121031|NCT02754440|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
3121032|NCT02754440|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
3121033|NCT02754440|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
3121034|NCT02754492|Experimental|Single Platelet Product|Healthy adult volunteer blood donors that qualify for a single unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
3121035|NCT02754492|Experimental|Double Platelet Product|Healthy adult volunteer blood donors that qualify for a double unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections.
3121036|NCT02754492|Experimental|Triple Platelet Product|Healthy adult volunteer blood donors that qualify for a triple unit platelet collection will undergo plateletpheresis on the Trima Accel® Automated Blood Collection System (Trima Accel System with Version 7.0 Software). Concurrent plasma will be collected in 25% of the collections
3121037|NCT02754518|Other|Open label Entresto|All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.
3121038|NCT02754570|Experimental|Pilocarpine group|Subjects with open-angle glaucoma and ocular hypertension that are currently taking latanoprost
3121039|NCT02754661|Experimental|COLON Capsule endoscopy|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the CCE procedure day. With the exception of Gastrografin, all colon preparation products will be standard colon cleansing products approved by the FDA.~Between 45 and 75 minutes after the final Polyethylene Glycol (PEG) ingestion, the subject will swallow the PillCam COLON Capsule with a cup of water.~If necessary, capsule position will be monitored to ensure adequate booster administration. Subjects will keep a timed diary of key preparation steps and bowel activity, including capsule excretion. Subjects will be allowed to leave the unit 10 hours after capsule ingestion if the capsule is not yet excreted. Subjects leaving before excretion will be instructed to disconnect the recorder at excretion or 12 hours after capsule ingestion (whichever comes first)."
3121040|NCT02754661|Active Comparator|Computed Tomographic Colonography|"Subjects will be instructed to follow a detailed dietary and colon preparation regimen prior to and during the Computed Tomographic Colonography (CTC) procedure day.~The CTC procedure and study interpretation will be conducted in accordance with the ACR-SAR-SCBT-MR Practice Parameter for the Performance of CT Colonography in Adults. Colon insufflation will be performed with the subject in the lateral decubitus or supine position.With the subject in the supine position, a CT scout image will be taken to confirm adequate colon distention. If adequate bowel distention is not achieved, additional air will be insufflated into the colon. After scanning the subject in the supine position, the subject will be placed in the prone position, and additional CO2 will be administered. Subsequently, CT will be performed with the subject in the prone position. If a prone position is not possible for the subject, a left lateral decubitus position is preferred for optimal gas and fluid redistribution."
3121041|NCT02754674|Experimental|Transportal|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with transportal technique
3121042|NCT02754674|Experimental|Outside in|this is a type of anterior cruciate ligament reconstruction. this arm for patients who underwent operation with patients who underwent operation with outside in technique
3121043|NCT02755090|Experimental|Nitrous oxide and IV saline|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
3121044|NCT02755090|No Intervention|Standard Care (IV Sedation and Oxygen)|Within the IV sedation group, women will receive 100mcg fentanyl and 2mg midazolam at least two minutes prior to initiation of the procedure. This group will also receive 100% oxygen by a scented face mask. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
3121045|NCT02755116|Experimental|Olanzapine|10mg pill
3121046|NCT02755116|Placebo Comparator|Placebo|
3121047|NCT02755129|Other|single arm|"Single arm, all the patients enrolled will perform the same walking exercises.~On arrival to the rehabilitation center subjects will have the Reveal LINQ, the 3D-accelerometers (one on the chest by medical-grade adhesives and a second at the level of the waist over the top of a medical grade adhesive) and the Holter attached externally. Then, they will be asked to perform the following exercises:~Walking Exercises-4 Meter Gait Speed (4MGS) Test Walking exercises - Six Minute Walk (6MW) Test~Walking exercises - 4 Meter Gait Speed (4MGS) Test~Walking Exercises - Five Times Sit to Stand (FTSTS) Test~Walking Exercises - Expanded Timed Get-Up-and-Go (ETGUG) Test"
3121048|NCT02755285|Experimental|Single Endoscopy Procedure|All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
3121049|NCT02755649|Experimental|Placebo QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
3121050|NCT02755649|Experimental|Dupilumab 300 mg Q2W + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
3121051|NCT02755649|Experimental|Dupilumab 300 mg QW + TCS|Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety ([Week 28, end of study (EOS) period]).
3121052|NCT02755805|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a strategy training approach that trains individuals to identify problems in the performance of their daily activities, develop strategies to address these problems, and monitor their own performance in the course of their daily routines. Participants use a workbook to support their application of the strategy training.
3121053|NCT02755805|Placebo Comparator|Attention Control|The attention control intervention controls for the non-specific effects of strategy training. The therapists administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. Participants complete a daily journal, merely reviewing their rehabilitation activities.
3121054|NCT02755818||control|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of greater than 60
3121055|NCT02755818||chronic renal disease (CKD3b)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 30-45
3121056|NCT02755818||chronic renal disease (CKD4)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of 15-30
3121057|NCT02755818||chronic renal disease (CKD5)|heparin at 50unit/kg of body weight having glomerular filtration rate (GFR) of less than 15, or on hemodialysis
3121058|NCT02755831|Experimental|Sleep Study + CPAP group|Pregnant women in early pregnancy may be randomized to this arm and be assigned Sleep study + CPAP treatment
3121059|NCT02755831|Other|Standard Prenatal Care group|Pregnant women in early pregnancy may be randomized to this arm and will receive standard prenatal care without CPAP treatment.
3121060|NCT02755935|Experimental|Implanted|Subjects who meet the specified inclusion criteria and are implanted with the CI532 cochlear implant
3121061|NCT02756013|Experimental|Paclitaxel + Carboplatin|Paclitaxel dosed by actual body surface area and not maxed at BSA 2.0. The Carboplatin dose will be calculated according to the Calvert formula using as estimated glomerular filtration rate from the Cockcroft-Gault formula and will be subject to maximum allowed doses.
3121062|NCT02756078|Active Comparator|Group 1 (TEST / CONTROL wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
3121063|NCT02756078|Active Comparator|Group 2 (CONTROL / TEST wear sequence)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST wearing sequence will wear each of the study lenses for 4 weeks according to the manufacturer's guidelines. Subjects will be dispensed the other (second) lens type at the second dispense visit.
3121064|NCT02756182|Experimental|Urodynamics with AC and WP|Patients underwent a conventional urodynamics study utilizing a single catheter technique
3469366|NCT03887468|Active Comparator|"EvoHep"|"Control: EvoHep procedure using a heparin-grafted AN69ST dialyzer in combination with a conventional bicarbonate-based dialysate and standardized systemic anticoagulation using unfractionated heparin."
3469367|NCT03887520|Other|Cardiovascular disease|Patients with established Cardiovascular disease
3469368|NCT03887325|Active Comparator|Maxipost|
3469369|NCT03887325|Placebo Comparator|Saline|
3121069|NCT02756351|Experimental|CytaCoat Nasal Prong|The CytaCoat Nasal Prong is composed of the reference device coated with CytaCoat technology.
3121070|NCT02756351|Active Comparator|Reference Nasal Prong|Inspiration Healthcare Inspire nCPAP Nasal Prong consists of silicone. Is a Conformité Européenne marked (CE-marked) commercially available medical device.
3121071|NCT02756364|Active Comparator|Fulvestrant 500 mg|Fulvestrant 500 mg, intramuscularly (IM), once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 16.0 weeks).
3121072|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 4 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with the sapanisertib 4 mg, capsules, orally, once daily in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 20.1 and 20.3 weeks for fulvestrant and sapanisertib respectively).
3469370|NCT03887364|Active Comparator|Group A-Diaphragmatic breathing exercise|Diaphragmatic breathing exercise
3469371|NCT03887364|Experimental|Group B-Icing and Airflow Stimulation|Icing and Airflow Stimulation
3121073|NCT02756364|Experimental|Fulvestrant 500 mg + Sapanisertib 30 mg|Fulvestrant 500 mg, IM, once on Days 1 and 15 in Cycle 1, and then on Day 1 of each subsequent 28-day cycle along with sapanisertib 30 mg, capsule, orally, once weekly in each 28-day treatment cycle until progressive disease, unacceptable toxicity, or withdrawal of consent (Median duration of treatment was 17.0 weeks for fulvestrant and sapanisertib, each).
3121074|NCT02756572|Experimental|Treatment (chemotherapy, HCT)|See Detailed Description
3121075|NCT02756611|Experimental|Venetoclax|"Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation.~In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, determined on a case by case basis."
3121076|NCT02756624|Experimental|AC-170 0.24%|1 drop in each eye 3 times daily for up to 6 weeks
3121077|NCT02756624|Placebo Comparator|AC-170 Vehicle|1 drop in each eye 3 times daily for up to 6 weeks
3121078|NCT02756637||Prognostic|Patients with NLR who completed curative therapy (surgery with or without chemo)
3121079|NCT02756637||Predictive|Patients with NLR who were assigned to a trial arm (chemo or no chemo)
3121080|NCT02756650|Experimental|Canakinumab|Canakinumab was administered monthly
3121081|NCT02756689|Active Comparator|Inpatient cervical Ripening|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
3121082|NCT02756689|Active Comparator|Outpatient cervical Ripening|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (treatment arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next morning to be admitted to labor and delivery for oxytocin administration.
3121083|NCT02756819||Azilsartan Medoxomil|Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.
3121084|NCT02756832||Alogliptin Benzoate|Participants with diabetes mellitus type 2 (T2DM) who received alogliptin benzoate tablets, orally, as prescribed by physician according to Russian summary of product characteristics (SmPC) were observed for approximately 6 months.
3121085|NCT02756910||Surgery Patients >1.5 Hrs|Use esophageal catheter for core temperature monitoring, Foley catheter for bladder temperature monitoring, and iThermonitor (WT701) for axillary temperature monitoring
3121086|NCT02756949|Experimental|Smartphone-enabled app for linkage to care|Participants in this arm are randomised to receive the smartphone application which provides direct access to HIV-related laboratory test results.
3121087|NCT02756949|No Intervention|Standard of care|Participants in this arm are randomised to receive standard of care services.
3121088|NCT02757092|Experimental|Home-based rehabilitation program|0-2 weeks,1. aerobic exercise intensity was targeted to reach 10-11 points of perceived exercise (RPE) scale 2. raised their upper limbs while simultaneously performing lower-limb stepping at place for 20 min 3.walked at a comfortable speed for 15 min twice per day.4. Triflo-II was performed 8-10 times per hour. inspiratory muscle training with the initial pressure set at 25%-30% of the maximum inspiratory pressure.3-6 weeks, aerobic exercise reach 12-15 points on the RPE scale. upper-limb resistance exercise (raising of a 250-cc water bottle) and lower-limb stepping for 20 min per day , walking exercise for a total of 30 min. Triflo-II was performed 8-10 times per hour, and train the inspiratory muscle with the pressure intensity adjusted to more than 5% of that in the first stage.
3121089|NCT02757092|Active Comparator|standard care|control group accept the pulmonary rehabilitation (breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, chest physical therapy and pain control) only in operation stage on before op-day 3 day and after op-day and without home based pulmonary rehabilitation.
3121090|NCT02757105|Experimental|Group A|BEKINDA 12 mg (Ondansetron Bimodal Release Tablets), once daily for 8 weeks
3121091|NCT02757105|Placebo Comparator|Group B|Placebo, once daily for 8 weeks
3121092|NCT02757326|Experimental|Phase Ib/II|"For Phase Ib, the planned ABC294640 (Opaganib) doses for the escalation phase are: 250, 500, and 750 mg BID given continuously. The dose will be given under fasting conditions (at least 1 hour before or 2 hours after eating). One cycle is 28 days of treatment.~For phase II study, the patients will be treated with single agent ABC294640 at the MTD determined from the phase IB study (or at the highest dose used, if MTD is not reached) until disease progression or intolerable toxicity occurs in an individual patient."
3121093|NCT02757352|Experimental|Q2W Ixekizumab|"Participants received a starting dose of 80 or 160 milligram (mg) of ixekizumab given subcutaneously (SC) at week 0 followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 52 during the double-blind period.~Inadequate responders (IR) as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
3121094|NCT02757352|Experimental|Q4W Ixekizumab|"Participants received a starting dose of 80 or 160 mg of ixekizumab given SC at week 0 followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 52 during the double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label week 16 and 44."
3121095|NCT02757352|Placebo Comparator|Placebo|"Participants received placebo as 2 SC injections Q2W to week 52 during double-blind period.~Inadequate responders as determined by investigators could switch to ixekizumab 80 mg Q2W open label between week 16 and 44."
3121096|NCT02757625|Experimental|DA-9501|A single vial contains an injection solution with 2 mL of dexmedetomidine hydrochloride solution (100 µg/mL as dexmedetomidine) dissolved in physiological saline
3121097|NCT02757768|Experimental|Mirabegron|Participants received initial dose of 25 mg of mirabegron which was increased to 50 mg after 4 weeks. In addition to mirabegron participants received 0.4 mg of oral tamsulosin hydrochloride daily throughout the study.
3121098|NCT02757768|Placebo Comparator|Placebo|Participants received matching placebo in addition to oral tamsulosin hydrochloride daily throughout the study.
3121099|NCT02757950||Exposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
3121100|NCT02757950||Unexposed cohort|Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
3121101|NCT02757963|Other|BPE/BPO screening and IPSS screening tool|Subjects presenting to a GP with a primary complaint other than LUTS will be screened for probable BPH using BPE/BPO screening tool and the IPSS screening tool. Subjects testing positive on the BPE/BPO screening tool or on the IPSS will be enrolled and offered a prostate specific antigen (PSA) test and urinalysis to establish a diagnosis of probable benign prostatic hyperplasia (BPH) (Part I - Visit 1). If the GP determines that the subject has probable BPH (IPSS >=8 and/or BPE/BPO questionnaire >=3 with a PSA >=2 ng per ml), the subject will proceed to Part II and will be scheduled for an urologist assessment and diagnostic tests to confirm or refute a BPH diagnosis and to assess risk of progression of BPH.
3121102|NCT02758119|Experimental|Serious Game|"Participants in the serious game group will be pre-trained before the hands-on sessions with the serious game Staying Alive, available at http://www.stayingalive.fr/index_us.html This game aims at teaching the management of an out-of-hospital cardiac arrest to the general public and health professionals. In this game, the player faces a man who has experienced sudden cardiac arrest and learns the appropriate behavior, movements and techniques that can contribute to saving his life. The first level of the game lasts 4-5 minutes, depending on the skills of the player. It is a point and click game, displayed on a PC computer."
3121103|NCT02758119|Active Comparator|Online course|Participants in the lecture group will watch individually a 4-min video of a PowerPoint presentation with voiceover narration, given in the medical school of Paris Descartes University. The video is edited to contain the same informations on out-of-hospital cardiac management than the serious game, with the same duration.
3121104|NCT02758171|Experimental|Empagliflozin+Linagliptin FDC|One tablet fix dose combination (FDC)
3121105|NCT02758171|Active Comparator|Empagliflozin+Linagliptin single tablets|
3121106|NCT02758210|Experimental|Participants with MICRA Device|Participants that received the MICRA device prior to study enrollment will have monitored use of Smart Phone and Tablet at one study visit. Electrogram printing will take place during use of each device to see if there is any pacing inhibition or asynchronous pacing.
3121107|NCT02758301||Diagnostic|The Reveal LINQ™ Insertable Cardiac Monitor (ICM) device will be inserted in all subjects for continuous monitoring. After the Reveal LINQ™ device is inserted, the LINQ™ HF investigational RAMware will be downloaded to the LINQ™ ICM.
3121108|NCT02758613|Experimental|2 milligram (mg) Baricitinib|2mg Baricitinib administered orally, once on Day 1 and once a day (QD) on Days 4 through 10 (7 days).
3121109|NCT02758613|Experimental|4mg Baricitinib|4mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
3121110|NCT02758613|Experimental|10mg Baricitinib|10mg Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
3121111|NCT02758613|Placebo Comparator|Placebo|Placebo matching Baricitinib administered orally, once on Day 1 and QD on Days 4 through 10 (7 days).
3121112|NCT02758717|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for 7 cycles and 6-8 weeks in cycle 8 in the absence of disease progression or unacceptable toxicity.
3121113|NCT02758899||Diabetic Patients|Patients with diagnosis of type I or type II diabetes, in addition to clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
3121114|NCT02758899||Control Patients|Patients with no diagnosis of diabetes, with a clinical diagnosis of cervical myelopathy or cervical spondylosis requiring anterior cervical discectomy and fusion.
3121115|NCT02759016|Experimental|BI 836826|BI 836826 administered in combination with Standard of Care Ibrutinib
3121116|NCT02759055|Experimental|Clinical Decision Support (CV Wizard)|In the Intervention arm, primary care providers will be provided with an EHR-linked, Web-based clinical decision support system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke, optimizing management and follow up of pre-diabetes patients with uncontrolled CV risk factors.
3121117|NCT02759055|No Intervention|Usual Care|In the No Intervention arm, patients receive usual care from their primary care clinic and care providers.
3121118|NCT02759120|Experimental|Antimicrobial therapy|Co-trimoxazole OR doxycycline
3121119|NCT02759120|Other|Standard of care|Standard of care for patients with IPF for comparison
3121120|NCT02759146|Experimental|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
3121121|NCT02759146|Experimental|Meditative Practice|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
3121122|NCT02759146|No Intervention|Control|Control - no intervention
3121123|NCT02759185|Experimental|High THC cannabis|Provided up to 1.8 g of cannabis per day with more tetrahydrocannabinol than cannabidiol
3121124|NCT02759185|Experimental|High CBD cannabis|Provided up to 1.8 g of cannabis per day of marijuana with more cannabidiol than tetrahydrocannabinol
3121125|NCT02759185|Experimental|THC/CBD cannabis|Provided up to 1.8 g of cannabis per day with an approximately equal amount of tetrahydrocannabinol and cannabidiol
3121126|NCT02759185|Placebo Comparator|Placebo cannabis|Provided 1.8 g of cannabis per day with very low levels of tetrahydrocannabinol and cannabidiol
3469372|NCT03887312|Experimental|t-CETA|Telephone-delivered Common Elements Treatment Approach (t-CETA). t-CETA sessions of up to 30 minutes will be delivered 1-2 times per week for approximately 8-12 weeks. The number and content of sessions will be tailored to each child, thus there will be some variation.
3121127|NCT02759315|Experimental|GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.
3121128|NCT02759315|Experimental|GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
3121129|NCT02759315|Experimental|GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
3121130|NCT02759315|Experimental|GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.
3121131|NCT02759315|Experimental|GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
3121132|NCT02759315|Experimental|GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg|Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.
3121133|NCT02759354|Experimental|Group Vaxelis (3+1)|Participants previously vaccinated with a 3-dose primary series of Vaxelis® at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
3121134|NCT02759354|Active Comparator|Group Infanrix hexa (3+1)|Participants previously vaccinated with a 3-dose primary series of INFANRIX® hexa at 2, 3 and 4 months of age, and a toddler dose at 12 months of age (study V419-007).
3121135|NCT02759354|Experimental|Group Vaxelis (2+1)|Participants previously vaccinated with a 2-dose primary series of Vaxelis® at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
3121136|NCT02759354|Active Comparator|Group Infanrix hexa (2+1)|Participants previously vaccinated with a 2-dose primary series of INFANRIX® hexa at 2 and 4 months of age, and a toddler dose at 11-12 months of age (study V419-008).
3121137|NCT02759471|Experimental|comfilcon A asphere (test)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
3121138|NCT02759471|Active Comparator|comfilcon A sphere (control)|Habitual wearers of comfilcon A sphere lens (control) are refitted with comfilcon A asphere lens (test).
3121139|NCT02759562|Experimental|Andecaliximab 600 mg (Part 1)|Andecaliximab 600 mg weekly for 8 weeks
3121140|NCT02759562|Placebo Comparator|Placebo (Part 1)|Placebo weekly for 8 weeks
3121141|NCT02759562|Experimental|Andecaliximab 300 mg (Part 2)|Andecaliximab 300 mg weekly for 8 weeks
3121142|NCT02759562|Experimental|Andecaliximab 150 mg (Part 2)|Andecaliximab 150 mg + placebo weekly for 8 weeks
3121143|NCT02759562|Placebo Comparator|Placebo (Part 2)|Placebo weekly for 8 weeks
3121144|NCT02759562|Experimental|Open-Label Extension|(Part 1) Andecaliximab 600 mg weekly for 16 weeks; (Part 2) Andecaliximab 300 mg weekly for 16 weeks
3121145|NCT02759575|Experimental|Pembrolizumab|Pembrolizumab every 3 weeks in combination with 7 weeks of radiation therapy and every 3 week cisplatin
3121146|NCT02759692|Active Comparator|Group 1 (Test/Control/Test)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the TEST / CONTROL / TEST wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
3121147|NCT02759692|Active Comparator|Group 2 (Control/Test/Control)|Subjects randomly assigned to the TEST Contact Lens or the CONTROL Contact Lens in the CONTROL / TEST / CONTROL wearing sequence will wear lenses as daily disposable on both eyes for approximately one week each with no washout period between lenses for at least five days, and 8 hours per day.
3121148|NCT02759939|Experimental|Arm 1|
3121149|NCT02759939|Experimental|Arm 2|
3121150|NCT02759939|Experimental|Arm 3|
3121151|NCT02759939|No Intervention|Arm 4|
3121152|NCT02760056|Active Comparator|Liothyronine (cytomel)|Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week
3121153|NCT02760056|Placebo Comparator|Placebo|Subject will take matching placebo twice a day for one week
3121154|NCT02760069|Active Comparator|Inhaled ISO + oral ondansetron|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral elixir comprising ondansetron (4 mg).
3121155|NCT02760069|Experimental|Inhaled ISO + oral placebo|Inhaled isopropyl alcohol pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
3121156|NCT02760069|Active Comparator|Inhaled placebo + oral ondansetron|Inhaled normal saline pads as needed for nausea (up to q30 minutes) and drink oral placebo elixir.
3121157|NCT02760264|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
3121158|NCT02760264|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
3121159|NCT02760264|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
3121160|NCT02760264|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
3121161|NCT02760277|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
3121162|NCT02760277|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
3121163|NCT02760277|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
3121164|NCT02760277|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
3121165|NCT02760368|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg Subcutaneous q4w +placebo+ Methotrexate (oral) in order to maintain the blind, subjects randomized to receive OKZ q4w will receive placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
3121166|NCT02760368|Experimental|Arm 2: Olokizumab q2w|Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
3121167|NCT02760368|Placebo Comparator|Arm 3: Placebo|Placebo Subcutaneous q2w + Methotrexate (oral)
3121168|NCT02760407|Experimental|Arm 1: Olokizumab q4w|Olokizumab 64 mg subcutaneous q4w +placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)
3121169|NCT02760407|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
3121170|NCT02760407|Active Comparator|Arm 3: Adalimumab q2w|"Adalimumab 40mg q2w subcutaneous + Methotrexate~Subjects were administered adalimumab 40 mg q2w via SC injection as an active comparator+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
3121171|NCT02760407|Placebo Comparator|Arm 4: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
3121172|NCT02760433|Experimental|Arm 1: Olokizumab q4w|"Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate~Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)"
3121173|NCT02760433|Experimental|Arm 2: Olokizumab q2w|"Olokizumab 64mg subcutaneous q2w + Methotrexate~64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)"
3121174|NCT02760433|Placebo Comparator|Arm 3: Placebo q2w|"Placebo q2w subcutaneous + Methotrexate~Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)~Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group."
3121175|NCT02760654|Experimental|Online Self Management|Participants will interact with an online self management program based on cognitive behavioral principles for 8 weeks as much as they want.
3121176|NCT02760654|No Intervention|Control|Treatment as usual
3121177|NCT02760810|Experimental|narafilcon A|Subjects who are new contact lens wearers (neophytes) between the ages of 18-45 will be dispensed the Test Lens and evaluated over a period of 2 weeks.
3121178|NCT02760862|Active Comparator|Group (I) (N=25)|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours (Hydrocortisone as sodium succinate, vial, equivalent to hydrocortisone 100mg, Egyptian INT, Pharmaceutical Industries CO. ARE,EIPICO.EGYPT).
3121179|NCT02760862|Active Comparator|Group (II) (N=25)|group (II), received mannitol 20% intravenous fluid (100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis for 48 hours) (Manufactured by Allmed Middle East, Egypt).
3121180|NCT02760927|Experimental|Endotracheal Tube Fastener|The intervention administered is a revised commercially available endotracheal tube holder with a tract to accommodate a subglottic suction lumen of an oral endotracheal tube.
3121181|NCT02761252|Experimental|Bilastine+montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each for treatment
3121182|NCT02761252|Active Comparator|Bilastine+placebo montelukast|Bilastine 20 mg, 10 blister containing 10 tablets + Placebo Montelukast, 10 blister containing 10 film coated tablets each.
3121183|NCT02761252|Active Comparator|Montelukast+placebo bilastine|Placebo Bilastine, 10 blister containing 10 tablets + Montelukast 10 mg, 10 blister containing 10 film coated tablets each.
3121184|NCT02761330|Active Comparator|Etomidate + ECT|General anesthesia for ECT will be induced with etomidate, approximately 0.2 mg/kg (0.1-0.6 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
3121185|NCT02761330|Experimental|Ketamine + ECT|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, an ECT charge will be administered at the previously determined therapeutic dose.
3121186|NCT02761330|Sham Comparator|Ketamine alone|General anesthesia for ECT will be induced with ketamine, approximately 2 mg/kg (1-2.5 mg/kg). Following application of stimulation electrodes to the patients scalp, no ECT charge will be administered.
3121187|NCT02761629|Experimental|Peg-IFN-Alpha-2A+Ribavirin - 48 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 48 weeks.
3121188|NCT02761629|Active Comparator|Peg-IFN-Alpha-2A+Ribavirin - 72 Weeks|Participants will receive Peg-IFN-Alpha-2A and ribavirin for 72 weeks.
3121189|NCT02761642|Experimental|Epoetin Beta|Anemic breast cancer participants will receive epoetin beta treatment for 12 weeks.
3121190|NCT02761733|Experimental|mPOWR System|Moving Patient Outcomes toward Wellness and Recovery (mPOWR) consists of an assessment questionnaire and decision support tools which map onto 6 life domains which are measured by the questionnaire.
3121191|NCT02761733|No Intervention|Control|Treatment as usual
3121192|NCT02761915|Other|Dose Level 1|Patients in Dose Level 1 will receive 1x10^7 1RG-CART/m^2 intravenously (IV) on Day 0.
3121193|NCT02761915|Other|Dose Level 2|Patients in Dose Level 2 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
3121194|NCT02761915|Other|Dose Level 3|Patients in Dose Level 3 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 IV on Day 0.
3121195|NCT02761915|Other|Dose Level 4|Patients in Dose Level 4 will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 IV on Day 0.
3121196|NCT02761915|Other|Dose Level 5|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300 mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 IV which could be be split over two days (Day 0 and Day 1).
3121197|NCT02761915|Other|Patients who underwent leukapheresis but did not proceed to receive any IMP|Patients who were enrolled and underwent leukapheresis but who did not receive any IMP.
3121198|NCT02761967|Experimental|Physical activity|"The women in the EG (Exercise Group) performed moderate physical exercise in water, following the SWEP method (Study of Water-based Exercise during Pregnancy). It consists of performing moderate physical exercise in an aquatic environment from weeks 20 to 37 of gestation. The sessions take place three times weekly, with a duration of 60 minutes each (45 minutes of activity followed by 15 minutes of relaxation). The sessions are composed of three phases: a) warm-up; b) the main phase, divided into aerobic exercise and strength-endurance exercises, designed specifically for pregnant women; c) stretching and relaxation.~After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes."
3121199|NCT02761967|No Intervention|No exercise|"The CG (Control Group) received the standard recommendations during pregnancy, including guidelines from the midwife on the positive effects of physical exercise. These participants received the usual visits from healthcare providers (midwives, obstetricians and family doctor) during pregnancy, as did those in the EG.~After the postpartum period, the women in the control group did not perform regulated physical activity."
3121200|NCT02761980|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|Single dose of 2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg by mouth
3121201|NCT02761980|Active Comparator|Ibuprofen 250 mg|Single dose of 2 caplets of IBU 125 mg by mouth
3121202|NCT02761980|Active Comparator|Acetaminophen 500 mg|Single dose of 1 APAP 500 mg caplet + 1 placebo caplet by mouth
3121203|NCT02761980|Placebo Comparator|Placebo|Single dose of 2 caplets of Placebo by mouth
3121204|NCT02761993|Active Comparator|Group 1|Group 1 received ST266 treatment daily on Days 1 through 5, 8 through 12, 22, and 30, and then monthly for 7 months (Days 60, 90, 120, 150, 180, 210, and 240).
3121205|NCT02761993|Active Comparator|Group 2|Group 2 received ST266 treatment 2x/week (with at least 1 day between treatments) for the first 3 months, and then monthly for 5 months (Days 120, 150, 180, 210, and 240).
3121206|NCT02761993|Placebo Comparator|Group 3|Group 3 received commercially available sterile saline (0.9% sodium chloride) according to the same schedule as Group 1.
3121207|NCT02762071|Active Comparator|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
3121208|NCT02762071|Experimental|Liposomal Bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
3121209|NCT02762084|Experimental|Patidegib gel 2%|Patidegib gel 2%, applied topically, twice daily for 26 weeks
3121210|NCT02762084|Experimental|Patidegib gel 4%|Patidegib gel 4%, applied topically, twice daily for 26 weeks
3121211|NCT02762084|Placebo Comparator|Vehicle gel|Vehicle gel, applied topically, twice daily for 26 weeks
3121212|NCT02762331|Experimental|Vitamin C|Intravenous ascorbic acid 50 mg/kg in 50 mL normal saline every six hours for 48 hours.
3121213|NCT02762331|Placebo Comparator|Normal saline|Intravenous normal saline 50 mL every six hours for 48 hours
3121214|NCT02762370|Experimental|FX006 32 mg|Single 5 mL intra-articular (IA) injection Extended-release Formulation
3121215|NCT02762370|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release Formulation
3121216|NCT02762500|Experimental|LYC-30937-EC 25 mg PO QD|LYC-30937-EC 25 mg by mouth once daily for 8 weeks
3121217|NCT02762500|Placebo Comparator|Placebo PO QD|Matching placebo by mouth once daily for 8 weeks
3121218|NCT02762513|Experimental|Axitinib|Participants will receive 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities
3121219|NCT02762565|Experimental|breast scanner|
3121220|NCT02762578|Experimental|IDegAsp BID|
3121221|NCT02762578|Active Comparator|BIAsp 30 BID|
3121222|NCT02762799|Experimental|Leucostim® --> Neupogen®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
3121223|NCT02762799|Experimental|Neupogen® --> Leucostim®, subcutaneous injections|Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
3121224|NCT02762799|Experimental|Leucostim® --> Neupogen®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
3121225|NCT02762799|Experimental|Neupogen® --> Leucostim®, intravenous injections|Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
3121226|NCT02762877||A|Patients with non-squamous NSCLC either newly diagnosed or progressing on any therapy (except erlotinib, gefitinib, or afatinib)
3121227|NCT02762877||B|Patients with non-squamous NSCLC who are progressing on erlotinib, gefitinib, or afatinib
3121228|NCT02762994|Experimental|BCD-085, 40 mg|Patient will receive 40 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
3121229|NCT02762994|Experimental|BCD-085, 80 mg|Patient will receive 80 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
3121230|NCT02762994|Experimental|BCD-085, 120 mg|Patient will receive 120 mg of BCD-085 subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
3121231|NCT02762994|Placebo Comparator|Placebo|Patient will receive placebo subcutaneously at weeks 0, 1, 2, 4, 6, 8, 10.
3121232|NCT02763046|Experimental|Secukinumab - delayed NSAID tapering|"Induction with secukinumab 150 mg s.c. once per week (Week 0, 1, 2, 3 and 4) followed by maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 8, 12, 16 and 20), with intermittent placebo injections at Week 5, 6, 7, 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (delayed tapering)."
3121233|NCT02763046|Experimental|Secukinumab - early NSAID tapering|"Placebo at weeks 0, 1, 2, 3 to maintain the blind; followed by induction with secukinumab 150 mg s.c. once per week (Week 4, 5, 6, 7, 8) and maintenance with secukinumab 150 mg s.c. every 4 weeks (Week 12, 16 and 20), with intermittent placebo injections at Week 17, 18 and 19 to maintain the blind.~NSAID tapering allowed from Week 4 (early tapering)."
3121234|NCT02763046|Placebo Comparator|Placebo|"Placebo s.c. at Week 0, 1, 2, 3, 4, 5, 6, 7, 8 and 12. After the Week 16 assessments of the secondary endpoint had been performed, these patients received weekly doses of secukinumab 150 mg s.c. (Week 16, 17, 18, 19 and 20).~NSAID tapering allowed from Week 4."
3121235|NCT02763124|Experimental|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to perform one or two corneal arcuate incisions.
3121236|NCT02763189|Active Comparator|Control|Control group will study the learning material independently. 'Self-study'.
3121237|NCT02763189|Experimental|Mentored|Mentored group will study the learning materials and then receive expert mentoring
3121238|NCT02763215||Total|
3121239|NCT02763254|Experimental|baltaleucel-T|Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.
3121240|NCT02763566|Experimental|Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)|Abemaciclib given orally every 12 hours (Q12H) plus anastrozole or letrozole given orally every 24 hours (Q24H) on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
3121241|NCT02763566|Experimental|Placebo + NSAI|Placebo given orally Q12H plus anastrozole or letrozole given orally Q24H on days 1 to 28 of a 28 day cycle. Participants receiving benefit may continue until disease progression.
3121242|NCT02763566|Experimental|Abemaciclib + Fulvestrant|Abemaciclib given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant intramuscularly (IM) on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
3121243|NCT02763566|Experimental|Placebo + Fulvestrant|Placebo given orally Q12H on days 1 to 28 of a 28 day cycle plus fulvestrant IM on days 1 and 15 of cycle 1, then on day 1 of cycle 2 and beyond. Participants receiving benefit may continue until disease progression.
3121244|NCT02763579|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
3121245|NCT02763579|Active Comparator|Placebo + Carboplatin + Etoposide|Participants received intravenous infusions of placebo in combination with carboplatin to achieve an initial target AUC of 5 mg/mL/min followed by etoposide 100 mg/m^2 on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) placebo on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.
3121246|NCT02763644|Experimental|LFG316 plus SoC|LFG316 plus SoC (excluding plasmapheresis and prohibited treatment)
3121247|NCT02763644|Experimental|All SoC first|Standard of Care then LFG316 plus SoC
3121248|NCT02763826|Experimental|Determine the Optimal tDCS current|We will invesitigate the optimal curent in range of 1 mA to 4 mA. We hypothesize that 4 mA is tolerable, safe and can induce the highest level of cortical excitability in the lesional motor cortex.
3121249|NCT02763826|Experimental|Determine the optimal tDCS electrode montage|We hypothesize that the bi-hemispheric stimulation with anodal stimulation on the lesional hemisphere and simultaneous cathodal stimulation on the non-lesional hemisphere induces more cortical excitability in the lesional hemisphere than either anodal stimulation on the affected hemisphere or cathodal stimulation on non-lesional hemisphere alone.
3121250|NCT02763865|Experimental|Active pre-SMA rTMS|The intervention to be administered is the MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil l to administer active rTMS at 1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total. Two Thymapad Stimulus Electrodes will be placed in the appropriate position during active rTMS administration.This intervention method will be used for all 15 treatment sessions (20 minutes/session).
3121251|NCT02763865|Sham Comparator|Sham pre-SMA rTMS|The intervention to be administered is the eSHAM system used in conjunction with the MagVenture MagProx100 Stimulator with the Cool-B65 A/P Coil. For eSHAM administration two Thymapad Stimulus Electrodes will be placed on the scalp location that corresponded to left DLPFC. This intervention method will be used for all 15 treatment sessions (20 minutes/session). Previous studies have shown the eSHAM system effectively blinds participants to rTMS treatment (active versus sham).
3121252|NCT02764151|Experimental|PF-06840003|Daily Oral PF-06840003
3121253|NCT02764164|Experimental|Intervention Active tDCS|Affected subjects receiving up to 2 milliamps (mA) active tDCS, open label
3132482|NCT03430986|Experimental|JUVÉDERM® VOLUMA® with Lidocaine|Participants were treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel during the 24-week Control Period. Participants were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable. Follow-up continued in the 24-week Post-Control period.
3121254|NCT02764190|Experimental|I-ACT with Check Yourself|Adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Check Yourself includes the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive I-ACT and the Check Yourself summary report of health risk behaviors before an adolescent patient's appointment. I-ACT will provide training in adolescent-preferred communication methods and use of Check Yourself as a framework for the provider to use motivational interviewing to consider the patients' change readiness and their personal health goals. I-ACT includes online interactive, case-based learning, with booster sessions and feedback reports to reinforce new skills.
3121255|NCT02764190|No Intervention|Usual care|In the usual care group, adolescents are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive I-ACT or the Check Yourself summary report of the adolescent's health risk behaviors.
3121256|NCT02764229|Experimental|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
3121257|NCT02764320|Active Comparator|Discontinuation|Migraine prophylactic therapy will be initiated or optimized with the immediate discontinuation of the overused medication(s)
3121258|NCT02764320|Active Comparator|Preventive Therapy Only|Migraine prophylactic therapy will be initiated or optimized without the early discontinuation of the overused medication(s)
3121259|NCT02764333|Experimental|vaccine|Patients will receive an intradermal (ID) injection of TPIV200 (500 μg per peptide) and GM-CSF (125 μg per peptide) on Day 1 of cycles 1-6. They will also receive intravenous (IV) injections of durvalumab (750mg) on Days 1 and 15 of cycles 1-12. Radiologic tumor assessment will be repeated every 12 weeks (or 3 cycles) during and after treatment, until time of progression. Treatment will continue until progression, intolerance, withdrawal, study completion, or study termination.
3121260|NCT02764385|Other|AAC only|This is a system-based intervention that involves changes in the EHR regarding documenting tobacco assessment and the capability to order an eReferral to the Quitline. This system-based intervention also changes the role of the medical technical assistant.
3121261|NCT02764385|Other|AAC + TMCP|The Teachable Moment Communication Process is a clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
3121262|NCT02764697|Other|H.P. Acthar Subcutaneous Gel Injection|For the current protocol we are proposing, 40 U/ml, given twice weekly x 8 weeks, followed by once weekly x 4 weeks: a total 20 doses, using the approved route, with the option to do 4 additional doses if resolution is incomplete.
3121263|NCT02764762|Experimental|Vedolizumab 300 mg (IV) + Adalimumab 160-80-40 mg (SC) + Methotrexate 15 mg (Oral)|In Triple Combination Therapy Phase: Vedolizumab 300 mg, intravenous infusion, once at Weeks 0, 2, 6, 14 and 22, with adalimumab 160 mg subcutaneously, once at Week 0, then 80 mg once at Week 2, then 40 mg once at Week 4 and every 2 weeks thereafter until Week 26 along with oral methotrexate 15 mg tablets orally once weekly from Weeks 0 up to Week 34.
3121264|NCT02764775|Experimental|Headed utilization|Use of Headpod for 6 months duration; 3 x per day for a minimum of 15 minutes each time;
3121265|NCT02764970||ivabradine 7.5mg orally|patients are pretreated with ivabradine and bisoprolol orally before Cardiac CT angiogram
3121266|NCT02764970||bisoprolol|patients are only pretreated with bisoprolol orally before Cardiac CT angiogram
3121267|NCT02765035|Experimental|C-Leg 3, then C-Leg 4|Participants are first fitted with a C-Leg 3, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 4, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
3121268|NCT02765035|Experimental|C-Leg 4, then C-Leg 3|Participants are first fitted with a C-Leg 4, receive physical therapy, acclimate for 90 days and are then assessed in the clinic. They then receive a C-Leg 3, receive additional physical therapy and acclimate for 30 days after which they are again assessed in the clinic.
3121269|NCT02765100|Experimental|Low CRP|Subjects have CRP > 3
3121270|NCT02765100|Experimental|High CRP|Subjects have CRP =/> 3
3121271|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1a|USL311, intravenous, once per week, starting at 60 mg/m˄2
3121272|NCT02765165|Experimental|Dose-Escalation USL311, Solid Tumor, Part 1b|USL311, oral, daily, starting at 40 mg
3121273|NCT02765165|Experimental|Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2|USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks
3121274|NCT02765165|Experimental|Dose-Expansion, USL311, GBM, Part 3|USL311, oral, daily, starting at dose determined in Part 1b
3121275|NCT02765165|Experimental|Dose-Expansion, USL311 with Lomustine, GBM, Part 4|USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2
3121276|NCT02765256|Experimental|Fluconazole|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus fluconazole 400 mg orally once daily (Day 1-14). PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
3121277|NCT02765256|Placebo Comparator|Placebo|Vancomycin 500 mg oral suspension four times daily (Day 1-14), plus neomycin 1000 mg orally three times daily (Days 1-3), plus ciprofloxacin 750 mg orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) 238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2, plus placebo for fluconazole. PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
3121278|NCT02765269|Experimental|IPMS group|Cancer patients with pain are asked to use the Intelligent Pain Management System as much as possible to record the degree and location of pain at least once every day. Through assessments of these pain record, physicians could give the patients appropriate advice.
3121279|NCT02765269|No Intervention|Control group|The control group are communicated through conventional method such as telephone calls or door-to-door visit to collect the pain assessment to guide doctors' therapy.
3121280|NCT02765490|Experimental|Group A|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 6 weeks.
3121281|NCT02765490|Experimental|Group B|AL-335 (800 mg), odalasvir (25 mg) and simeprevir (75 mg) once daily during 8 weeks.
3121282|NCT02766023|Experimental|LACTIN-V|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive LACTIN-V 2x10^9 cfu/dose applied vaginally for 5 days then twice weekly for 10 weeks. N=152
3121283|NCT02766023|Placebo Comparator|Placebo|Subjects receive 5-day course of metronidazole gel 7.5 mg/gm daily applied vaginally. Subjects then receive placebo applied vaginally for 5 days then twice weekly for 10 weeks. N=76
3121284|NCT02766088|Experimental|Total Group|Subjects aged between 6 months and 50 years at the time of enrolment living in geographically-defined communities in Latin America and Southeast Asia. The study population comprised household members and should include between 30% and 50% of adults (aged 18 years or above) per site.The appropriate recruitment strategy was selected by each participating site. Two approaches might be considered: a school-based approach and a community-based approach without school involvement The expected period for recruiting the target sample size was approximately three months.
3121285|NCT02766244|Experimental|ICG/SPY|Daily wound care with antibiotic ointments after cleansing plus evaluation using ICG/SPY fluorescence.
3121286|NCT02766283||Iodinated contrast agents|children age 0-3 years (inclusive), who underwent a iodine contrast enhanced radiological examination.
3121287|NCT02766374|Experimental|Heart Rate Variability Biofeedback|"During the first training session, we will measure heart rate variability (HRV) amplitude while the patient breathes for two minutes at a frequency ranging between 4.5-6.5 breaths/min, providing a pacing stimulus for this purpose. In subsequent sessions, the individual will be given personal heart rate variability biofeedback (HRV-BF), and instructed to increase the amplitude of heart rate oscillations, using a cardiotachometer tracing and frequency peaks as biofeedback stimuli, while avoiding hyperventilation symptoms, by breathing more shallowly, although slowly, at whatever frequency produces maximum-amplitude HRV."
3121288|NCT02766374|Placebo Comparator|Placebo Biofeedback|"A credible Placebo Biofeedback (PBO-BF) consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
3121289|NCT02766400|Experimental|Guided Training|"Guided training is a rehabilitation training approach that maximizes the expertise of the patient, by teaching patients to identify and prioritize activities, identify barriers to performing activities, generate their own strategies for addressing these barriers, and apply this process through iterative practice. Guided training equips patients with practical skills that have the potential to generalize beyond activities addressed during the intervention program to novel problematic activities that arise after the intervention program, thereby promoting long-term independence."
3121290|NCT02766400|Active Comparator|Directed Training|Directed training is a rehabilitation approach that maximizes the expertise of the rehabilitation practitioner. Rehabilitation practitioners identify and prioritize problematic activities, identify barriers to performing these activities, generate strategies to address these barriers and instruct patients in these strategies, and repeat the process with a variety of problematic activities identified during the rehabilitation program. Directed training promotes independence with training activities, however the benefits of direct training are likely to be activity-specific (i.e., only promote improvement on the trained activity) and not generalizable to other daily activities. This therapist-directed approach is currently the method used most frequently in acute rehabilitation.
3121291|NCT02766517|Experimental|Capsaicin|Single topical dose of capsaicin
3121292|NCT02766608|Experimental|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3121293|NCT02766608|Experimental|BFF MDI 160/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3121294|NCT02766608|Experimental|FF MDI 9.6 μg|Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
3121295|NCT02766608|Experimental|BD MDI 320 μg|Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
3121296|NCT02766608|Other|Symbicort® TBH 400/12 μg|Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID
3121297|NCT02766673|Active Comparator|Full Dose Albuterol Sulfate|2.5mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
3121298|NCT02766673|Active Comparator|Half Dose Albuterol Sulfate|1.25mg of Albuterol Sulfate will be administered via nebulizer and mechanical ventilator
3121299|NCT02766673|Placebo Comparator|Sterile Saline|3ml of 0.9% sterile saline will be administered via nebulizer and mechanical ventilator
3121300|NCT02766777|Experimental|Lubiprostone|Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
3121301|NCT02766907|Active Comparator|Study|prospective arm receiving cryopreserved amniotic membrane
3121302|NCT02766907|No Intervention|Control|Retrospective review of debridement without cryopreserved amniotic membrane
3121303|NCT02767011|Experimental|THEM|Patients receive telehealth electronic health care monitoring.
3121304|NCT02767011|No Intervention|Standard of Care (SOC)|Patients receive normal standard of follow-up care
3121305|NCT02767128|Experimental|Fer-In-Sol Orally|Patients will receive A single oral dose of Fer-In-Sol at 3 mg Fe/kg body weight (bw).
3121306|NCT02767128|Experimental|Shohl's solution followed by Fer-In-Sol Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7ml/kg bw) followed after 10 minutes by Fer-In-Sol at 3 mg Fe/kg bw.
3121307|NCT02767128|Experimental|Triferic Orally|Patients will receive a single oral dose of Triferic at 3 mg Fe/kg bw.
3121308|NCT02767128|Experimental|Shohl's solution followed by Triferic Orally|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) administered 10 minutes prior to a single oral dose of Triferic at 3 mg Fe/kg bw.
3121309|NCT02767128|Experimental|Shohl's solution followed immediately by Triferic|Patients will receive a single oral dose of Oracit Shohl's solution 0.67 mEq/L (0.7 ml/kg bw) followed immediately by a single oral dose of Triferic at 3 mg Fe/kg bw.
3121310|NCT02767128|Experimental|Triferic via IV|Patients will receive IV Triferic iron 6.6 mg diluted in an appropriate amount of D5W administered as a 120 mL infusion intravenously for 4 hours.
3121311|NCT02767128|No Intervention|Baseline|baseline serum iron profile will be determined for each patient. no study drug will be administered.
3121312|NCT02767271|Experimental|Tinea Pedis|Participants with tinea pedis received luliconazole cream 1% topically once daily in the morning for 15 days (Day 1 through 15). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the ankles.
3121313|NCT02767271|Experimental|Tinea Cruris|Participants with tinea cruris received luliconazole cream 1% topically once daily in the morning for 8 days (Day 1 through 8). The dose was approximately 3.0 grams per application and covered all affected and adjacent areas, including up to the groin, thighs, and abdomen.
3121314|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC (Aim1a)|excitatory rTMS applied over the DLPFC (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
3121315|NCT02767323|Experimental|Active or Sham rTMS over the Parietal cortex (Aim1b)|excitatory rTMS applied over the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
3121316|NCT02767323|Experimental|Active or Sham rTMS over the DLPFC and the Parietal cortex (Aim1c)|excitatory rTMS applied over the DLPFC and the parietal cortex (fMRI-guided). Active and Sham rTMS will be tested in a within subject design
3121317|NCT02767388||HM - Chemotherapy|Study patients diagnosed with HM that are scheduled to receive chemotherapy treatment.
3121318|NCT02767388||HM - No Chemotherapy|Study patients diagnosed with HM that are scheduled to receive non-chemotherapy treatment options.
3121319|NCT02767388||Healthy Controls|Study participants that are demographically matched to HM study patients and meet all inclusion criteria
3121320|NCT02767427|Active Comparator|At-Home Chlorhexidine|Those randomized into the chlorhexidine group will be asked to shower the night before surgery, and to use a standardized pre-packaged Chlorhexidine Wipes (chlorhexidine gluconate wipes) on their surgical site after thoroughly drying those areas. They will be asked to use a second wipe in each area the morning of surgery. Those who forget to use the wipe in the morning were allowed to use the wipe in the pre-operative area and included if this occurs more than one hour before skin prep.
3121321|NCT02767427|Experimental|No At-Home Chlorhexidine|Participants in this group will not use chlorhexidine wipes (no intervention), as is standard of care, prior to their surgical site being cleansed by the surgical team pre-operatively.
3121322|NCT02767492|Experimental|BioDRestore™|BioDRestore™ Elemental Tissue Matrix is a morselized, flowable tissue allograft derived from amniotic tissues. 2cc will be injected in the knee joint.
3121323|NCT02767492|Active Comparator|Corticosteroid|Kenalog (40 mg of 40 mg/ml) will be the steroid utilized as the active comparator to be injected in the knee joint.
3121324|NCT02767531|Experimental|Orlistat|120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
3121325|NCT02767531|No Intervention|Off drug|Standard therapy will be given for three months
3121326|NCT02767609|Experimental|Magentic Resonance Imaging|magnetic Resonance Imaging.
3121327|NCT02767765|Experimental|r-HuEPO|Anemic cancer participants will receive r-HuEPO for 4 weeks.
3121328|NCT02767843|Experimental|treatment|continuous negative external pressure (cNEP) at various negative pressures
3121329|NCT02767869|Experimental|Banaba|Banaba capsules, 500mg, two times per day before meals during 90 days
3121330|NCT02767869|Placebo Comparator|Placebo|Calcined magnesia capsules, 500mg, two times per day before meals during 90 days
3121331|NCT02767934|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients achieving complete MRD response may receive up to 1 additional year of treatment at the discretion of the investigator.
3121332|NCT02767947|Experimental|Luliconazole Cream 1%|Luliconazole cream 1% will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
3121333|NCT02767947|Placebo Comparator|Vehicle Cream|Vehicle cream (containing no active ingredient) will be applied once daily in the morning for 7 days to the area affected with tinea corporis and approximately 1 inch of the immediate surrounding area.
3121334|NCT02768103|Experimental|SCI transfer + training|Individuals with tetraplegia and brachioradialis to flexor pollicis longus transfer will participate in 10 week home training program to improve surgical outcome (pinch strength)
3121335|NCT02768129|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
3121336|NCT02768129|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
3121337|NCT02768194|Experimental|Test Product (0.454% stannous fluoride)|Participants will use dentifrice containing 0.454% stannous fluoride. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
3121338|NCT02768194|Active Comparator|Reference Product (0.76% sodium monofluorophosphate)|Participants will use dentifrice containing 0.76% sodium monofluorophosphate. Appliances brushed ex situ in 1:3 slurry of freshly prepared dentifrice twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in a 1:3 slurry of assigned dentifrice. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
3121339|NCT02768194|Other|Negative Control (Mineral water)|Participants will use commercially available mineral water. Appliances brushed ex situ in mineral water twice daily will be then returned to the participant's mouth. Each appliance will be brushed for 1 minute (2 minutes total for both of the participant's appliances) using an electric toothbrush in mineral water. Appliances will be returned to the participant's mouth and the participant will rinse with 10 mls of mineral water for 5 seconds.
3121340|NCT02768298|Experimental|LCZ696|LCZ696 100 mg oral twice daily (bid) for 2 weeks followed by LCZ696 200 mg oral bid for 10 weeks.
3121341|NCT02768298|Active Comparator|Enalapril|"Enalapril 5 mg oral twice daily (bid) for 2 weeks followed by enalapril 10 mg oral bid for 10 weeks.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid."
3121342|NCT02768558|Experimental|Nivolumab|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by nivolumab
3121343|NCT02768558|Placebo Comparator|Placebo|60 Gy of radiation therapy given concurrently with cisplatin-etoposide chemotherapy followed by placebo
3121344|NCT02768753|Experimental|The Axillary Bilateral-breast Approach (ABBA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3121345|NCT02768753|Experimental|The bilateral Axillo-breast Approach (BABA) group|All patients were told about the operative techniques involved in robotic thyroidectomy via the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA), and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3121346|NCT02768792|Other|open-label, multicenter, single-arm|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2-years of maintenance therapy (i.e., beginning on day 1 of maintenance). Patients who are ineligible for pembrolizumab administration by day 21 will be removed from the study.
3121347|NCT02768870|Experimental|Harpoon Medical Device|This is a prospective, single arm, nonrandomised, multi-center EU study to demonstrate the performance and safety of the Harpoon Medical device in patients with degenerative MR.
3121348|NCT02769065|Placebo Comparator|SRD: Placebo Cohorts 1-6, 18 and 19|TAK-071 placebo-matching capsules, orally, once on Day 1 to non-Japanese healthy participants in the single-rising dose (SRD) period.
3121349|NCT02769065|Experimental|SRD: Cohort 1: TAK-071 1 mg|TAK-071 1 mg, capsule, orally, once on Day 1 to non-Japanese healthy participants.
3121350|NCT02769065|Experimental|SRD: Cohort 2: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety, tolerability and pharmacokinetic (PK) data from cohort 1.
3121351|NCT02769065|Experimental|SRD: Cohort 3: TAK-071 9 mg|TAK-071 9 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK and 12-hour CSF PK data.
3121352|NCT02769065|Experimental|SRD: Cohort 4: TAK-071 20 mg|TAK-071 20 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on the 24-hour post-dose safety and tolerability data from previous cohort.
3121353|NCT02769065|Experimental|SRD: Cohort 5: TAK-071 40 mg|TAK-071 40 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 will be based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 4.
3121354|NCT02769065|Experimental|SRD: Cohort 6: TAK-071 80 mg|TAK-071 80 mg capsules, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 5
3121355|NCT02769065|Placebo Comparator|MRD: Placebo Cohorts 7-9|TAK-071 placebo-matching capsule, orally, once on Day 1 to non-Japanese healthy participants in the multiple-rising dose (MRD) period.
3121356|NCT02769065|Experimental|MRD: Cohort 7: TAK-071 3 mg|TAK-071 3 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability from Cohort 4 and the 24-hour preliminary plasma PK and 12-hour CSF PK data from Cohort 3.
3121357|NCT02769065|Experimental|MRD: Cohort 8: TAK-071 9 mg|TAK-071 9 mg capsules, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants. Dose of TAK-071 was based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
3121358|NCT02769065|Experimental|MRD: Cohort 9: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to non-Japanese healthy participants. Dose of TAK-071 will be based on safety, tolerability and available PK data arising from the ongoing SRD part and previous MRD cohort.
3121359|NCT02769065|Placebo Comparator|MRD: TAK-071 Placebo Cohorts 10-12+Donepezil|TAK-071 placebo-matching capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071.
3121360|NCT02769065|Experimental|MRD: Cohort 10: TAK-071 3 mg+Donepezil 5 mg|TAK-071 3 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
3121361|NCT02769065|Experimental|MRD: Cohort 11: TAK-071 9 mg + Donepezil 5 mg|TAK-071 9 mg capsules, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
3121362|NCT02769065|Experimental|MRD: Cohort 12: TAK-071 15 mg+Donepezil 5 mg|TAK-071 15 mg capsule, orally, once daily along with donepezil 5 mg, tablets, orally, once daily from Day 1 up to Day 21 to non-Japanese healthy participants who were pre-treated with donepezil 5 mg, tablet, once daily for 3 weeks prior to administration of TAK-071. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
3121363|NCT02769065|Experimental|MRD: Placebo Cohorts 13-15|TAK-071 placebo-matching capsule, orally, once on Day 1 to Japanese healthy participants.
3121364|NCT02769065|Experimental|MRD: Cohort 13: TAK-071 3 mg|TAK-071 3 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 7.
3121365|NCT02769065|Experimental|MRD: Cohort 14: TAK-071 9 mg|TAK-071 9 mg capsule or matching placebo, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 8.
3121366|NCT02769065|Experimental|MRD: Cohort 15: TAK-071 15 mg|TAK-071 15 mg capsule, orally, once on Day 1, followed by a washout period of 7 days, then TAK-071 once daily for 21 days to Japanese healthy participants. Dose of TAK-071 was same as the dose used in MRD Cohort 9.
3121367|NCT02769065|Experimental|Cohort 16|
3121368|NCT02769065|Experimental|Bioavailability (BA)/Food Effect: Cohort 17 Sequence ABC|A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 1, followed by B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 2, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
3121369|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence BCA|B: TAK-071 10 mg tablet, orally, once on Day 1 in the fasted state in Period 1, followed by C: TAK-071 10 mg tablet, orally, once on Day 1 in the Fed state in Period 2, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
3121370|NCT02769065|Experimental|BA/Food Effect: Cohort 17 Sequence CAB|C: TAK-071 10 mg tablet, orally, once on Day 1 in the fed state in Period 1, followed by A: TAK-071 10 mg capsule, orally once on Day 1 in the fasted state in Period 2, followed by B: TAK-20 10 mg tablet, orally, once on Day 1 in the fasted state in Period 3 in non-Japanese healthy participants. There was a 21-day washout after each period.
3121371|NCT02769065|Experimental|SRD: Cohort 18: TAK-071 120 mg|TAK-071 120 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 6.
3121372|NCT02769065|Experimental|SRD: Cohort 19: TAK-071 160 mg|TAK-071 160 mg capsule, orally, once on Day 1 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 18.
3121373|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil Placebo|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil placebo-matching tablet, orally on Day 2 to non-Japanese healthy participants.
3121374|NCT02769065|Placebo Comparator|SRD: TAK-071 Placebo+Donepezil|TAK-071 placebo-matching capsule, orally, once on Day 1 followed by donepezil 10 mg tablet, orally, on Day 2 to non-Japanese healthy participants.
3121375|NCT02769065|Experimental|SRD: Cohort 20: TAK-071 40 mg+Donepezil|TAK-071 40 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety, tolerability, and preliminary plasma PK data from Cohort 19.
3121376|NCT02769065|Experimental|SRD: Cohort 21: TAK-071 60 mg+Donepezil|TAK-071 60 mg capsule, orally, once on Day 1 followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 20.
3121377|NCT02769065|Experimental|SRD: Cohort 22: TAK-071 80 mg+Donepizil|TAK-071 80 mg capsule, orally, once on Day 1, followed by donepezil 10 mg, tablets, orally, once on Day 2 to non-Japanese healthy participants. Dose of TAK-071 was based on 24-hour safety and tolerability data from Cohort 21.
3121378|NCT02769247|Experimental|Placebo|Patient will receive placebo oral medication and intrauterine normal saline prior to IUD insertion
3121379|NCT02769247|Experimental|Naproxen/Normal saline|Patient will receive naproxen and intrauterine normal saline prior to IUD insertion
3121380|NCT02769247|Experimental|Placebo oral medication/Lidocaine|Patient will receive placebo oral medication and intrauterine lidocaine prior to IUD insertion
3121381|NCT02769247|Experimental|Naproxen/Lidocaine|Patient will receive naproxen and intrauterine lidocaine prior to IUD insertion
3121382|NCT02769312|Sham Comparator|Sham Stimulation|A sham coil is being used to compare against active coil.
3121383|NCT02769312|Active Comparator|Active Stimulation|An active coil is being used to compare against sham coil.
3121384|NCT02769351||periph. minimal invasive ultrafiltration|Patients with volume overload receiving ultrafiltration
3121385|NCT02769442|Experimental|Terumo SurFlash Plus catheter|Patients randomized to the Terumo catheter
3121386|NCT02769442|Active Comparator|BD Insyte Autoguard catheter|Patients randomized to the BD catheter
3121387|NCT02769481|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for glimepiride daily for the duration of the study.
3121388|NCT02769481|Active Comparator|Glimepiride|Subjects will receive a glimepiride capsule, 2, 4 or 6 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
3121389|NCT02769624|Experimental|Treprostinil|A dose of 18mcg (3 breaths) will be administered using the Tyvaso® (treprostinil) inhalation system. Tyvaso® (treprostinil) inhalation solution is supplied in 2.9 mL clear ampules packaged as four ampules in a foil pouch. Frequency and duration- 3 times over 1 study visit.
3121390|NCT02769624|Placebo Comparator|Placebo|A dose of 3 breaths of placebo will be administered using the Tyvaso® (treprostinil) inhalation system. Placebo will be supplies in matching ampules to treprostinil. Volume will match that of treprostinil. Frequency and duration- 3 times over 1 study visit.
3121391|NCT02769702|Experimental|Intervention|Acthar 80 IU SC twice w eek
3121392|NCT02769858|Experimental|Light Therapy|Participants will use commercially-available light therapy glasses (Re-Timer) daily for 60 minutes for five weeks.
3121393|NCT02770014|Experimental|EGFR mutation Positive, Treatment With Erlotinib|Eligible EGFR mutations include exon 19 deletion or exon 21 L858R mutation. Erlotinib will be initially dosed at a pre-determine dosage daily, and it will be given on a 6-week cycle with treatment administered on an outpatient basis
3121394|NCT02770170|Experimental|BI 655064 dose 1|
3121395|NCT02770170|Experimental|BI 655064 dose 2|
3121396|NCT02770170|Experimental|BI 655064 dose 3|
3121397|NCT02770170|Placebo Comparator|Placebo|
3121398|NCT02770248|Experimental|SIMBRINZA|Brinzolamide 1% / Brimonidine 0.2% tartrate ophthalmic suspension, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
3121399|NCT02770248|Active Comparator|Vehicle|Vehicle, 1 drop 3 times per day in each eye at 8 AM, 3 PM, and 10 PM for 28 days
3121400|NCT02770287|Experimental|Venus Freeze Diamond Polar treatment|Subjects will receive three treatments with the study device, at four week intervals, followed by a one month follow-up visit after the last treatment.
3121401|NCT02770365|Experimental|Test Product|estradiol cream
3121402|NCT02770365|Active Comparator|Reference Product|estradiol cream
3121403|NCT02770365|Placebo Comparator|Placebo product|Placebo cream
3121404|NCT02770521|Experimental|Treprostinil (Part A)|Treprostinil administered as a single subcutaneous (SC) bolus injection.
3121405|NCT02770521|Placebo Comparator|Placebo (Part A)|Placebo administered as a single SC bolus injection.
3121406|NCT02770521|Experimental|LY900014 (Part B)|LY900014 (test) administered as a single SC bolus injection.
3121407|NCT02770521|Active Comparator|Insulin Lispro (Part B)|Insulin lispro (reference) administered as a single SC bolus injection.
3121408|NCT02770547|Active Comparator|Low Heat Thermotherapy|Low heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies low heat to the subject's leg.
3121409|NCT02770547|Experimental|High Heat Thermotherapy|High heat thermotherapy will be applied to subject's leg. Subject will wear a garment through which heated water is circulated which in turn supplies high heat to the subject's leg.
3121410|NCT02770612|Other|Post-cesarean delivery mothers|"Identify eligible women on post-operative day 3. A physician member of the study team will approach participants with study information and consent forms.~After informed consent is obtained, the participant will be taken through a 10 minute shared decision making session (intervention). The participant will then have the opportunity to ask questions, following which they will indicate the number of prescription opioid tablets to be discharged with (primary outcome)~The next contact will be at two weeks after discharge, at which time a member of the study team will contact the participant and administer a brief telephone survey with questions pertaining to perceived pain over time, pain management methods, opioid/pain medication consumption/disposal, and satisfaction with postoperative pain control.~A chart review will be performed by physicians in the research group on participants to gather information on demographics, indications for surgery, etc."
3121411|NCT02770625|Experimental|ISU302|60 U/kg (once every 2 weeks for 6 months)
3121412|NCT02770820|Experimental|Treatment (autologous CD8 T cells)|Beginning 4 weeks after completion of last course of consolidation chemotherapy, patients receive autologous WT1-TCRc4 gene-transduced CD8+ TCM/TN lymphocytes IV over 1-4 hours on day 0 and again after a minimum of 3 weeks. Beginning 6 hours after the second infusion of T cells, patients also receive aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity. Patients who have clinically benefitted from T cell therapy may receive additional infusions of T cells and aldesleukin at the discretion of the PI and the attending physician.
3121413|NCT02770846|Experimental|Immediate loading|Immediate loading of single dental implant in the anterior maxilla with temporary crown in central occlusion
3121414|NCT02770846|Active Comparator|Delayed loading|Delayed loading. 2-stage procedure with a 4 months healing period before fabrication of temporary crown.
3121415|NCT02771093|Experimental|Trelagliptin 100 mg group|Trelagliptin 100 mg once weekly taken orally before breakfast
3121416|NCT02771093|Experimental|Alogliptin 25 mg group|Alogliptin 25 mg once daily taken orally before breakfast
3121417|NCT02771145|Experimental|FID 120947A|FID 120947A contact lens disinfecting solution used with soft contact lenses (study lenses) on a daily basis for 180 days. SCL preservative solution used standard-of-care.
3121418|NCT02771210|Experimental|AIN457/Secukinumab|Secukinumab 150 mg s.c. or Secukinumab 300 mg s.c., respective dose was assigned according to underlying condition, in case of PsA according to severity of concomitant Psoriasis or pre-exposure to anti-TNFα
3121419|NCT02771210|Placebo Comparator|AIN457/Secukinumab Placebo|Secukinumab Placebo s.c.
3121420|NCT02771275|Experimental|Harpoon Medical Device TSD-5|This is a prospective, nonrandomized, single-centered European study designed single arm study to demonstrate the performance and safety of the Harpoon Medical TSD-5 in Subjects with degenerative mitral regurgitation.
3121421|NCT02771340|Experimental|ICON-1 0.3 mg Singe Dose|Patients will receive a single intravitreal dose of ICON-1 0.3 mg
3121422|NCT02771340|Experimental|ICON-1 0.3 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.3 mg, one week apart
3121423|NCT02771340|Experimental|ICON-1 0.6 mg Repeat Dosing|Patients will receive two intravitreal doses of ICON-1 0.6 mg, one week apart
3121424|NCT02771366|Experimental|Fermented Papaya Preparation, then granulated sugar|Participants will start taking the Fermented Papaya Preparation (FPP) three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the granulated sugar in the same way as the FPP was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
3121425|NCT02771366|Placebo Comparator|Granulated Sugar, then Fermented Papaya Preparation|Participants will start taking the granulated sugar three times per day, for 8 week. Then there will be a 6 week washout period. After the washout period the participants will start taking the Fermented Papaya Preparation (FPP) in the same way as the granulated sugar was taken. In addition, the following test will be performed: Magnetic Resonance Spectroscopy (MRS) of the brain, functional magnetic resonance imaging (fMRI), RAND 36-item Health Survey (SF-36) questionnaire, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) blood samples,
3121426|NCT02771522|Other|Active post-othodontic lesions|Imaging with the Calcivis System
3121427|NCT02771574|Experimental|Part A: Lyo avexitide 0.05 mg/kg|Participants will receive lyophilized avexitide (Lyo avexitide) twice daily for 3 days
3121428|NCT02771574|Experimental|Part A: Lyo avexitide 0.15 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
3121429|NCT02771574|Experimental|Part A: Lyo avexitide 0.35 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
3121430|NCT02771574|Experimental|Part A: Lyo avexitide 0.46 mg/kg|Participants will receive Lyo avexitide twice daily for 3 days
3121431|NCT02771574|Experimental|Part B: Liq avexitide 0.38 (±0.03) mg/kg|Participants will receive liquid avexitide (Liq avexitide) twice daily for 3 days
3121432|NCT02771990|Sham Comparator|sham tDCS|10 sessions sham transcranial direct current stimulation (tDCS)
3121433|NCT02771990|Experimental|active tDCS|10 sessions active transcranial direct current stimulation (tDCS)
3121434|NCT02772302|Experimental|Patients|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
3121435|NCT02772302|Experimental|Healthy Controls|Application of bedside, EEG-based mindBEAGLE Brain-Computer Interface
3121436|NCT02772432|Experimental|3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
3121437|NCT02772432|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with specific learning disabilities.
3121438|NCT02772666|Experimental|O-Glass|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations, were enrolled in this study. They were all examined with new device named O-Glass.
3121439|NCT02772666|Active Comparator|Swinging Flash light Test|All study participants who were diagnosed Relative Afferent Pupillary defect(RAPD) positive according to expert specialist investigations were also examined with manual diagnostic method, Swinging Flash light Test(SFT). The standard and most common method for Marcus-Gunn test is Swinging Flashlight Test (SFT), which needs a dark room, and the patient will be asked to look toward a distant object, so the pupils are not focused. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
3121440|NCT02772757|Active Comparator|Standard of Care group|Standard of Care group will receive the standard, face-to-face hearing aid fitting and verification approach
3121441|NCT02772757|Experimental|Average RECD group|This group will have their hearing aid fitting via the coupler using average RECD values during the fitting
3121442|NCT02772757|Experimental|Measured RECD group|This group will have their hearing aid fitting via the coupler using measured RECD values during the fitting
3121443|NCT02772783|Experimental|high GI meal, euglycemic insulin clamp|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia.This condition results in euglycemia with high insulin levels.
3121444|NCT02772783|Experimental|high GI meal, fixed insulin infusion|A nutritional shake with high GI will be consumed. Regular insulin will be administered intravenously at a rate previously established to maintain euglycemia after a low glycemic index meal. This condition results in moderate hyperglycemia with low insulin levels.
3121445|NCT02772783|Active Comparator|low GI meal, euglycemic insulin clamp|A nutritional shake with low GI will be consumed. Regular insulin will be administered intravenously according to a negative feedback algorithm to maintain euglycemia. This condition results in euglycemia with low insulin levels.
3121446|NCT02772809|Other|Stroke survivors with low and moderate motor deficits|Subjects with low and moderate motor deficits will 1) complete exercises with 2 commercial (joystick and wheel) and the Theradrive haptic robot after pre assessment 2) then experience 12 therapy sessions on the Theradrive haptic robot with Adaptive Feedback. 3) Assessments pre and post therapy.
3121447|NCT02772978|Active Comparator|tolcapone arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
3121448|NCT02772978|Placebo Comparator|placebo arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
3121449|NCT02773368|Experimental|IDegLira|
3121450|NCT02773368|Active Comparator|IGlar|
3121451|NCT02773446|Experimental|Cohort 1 group A|Volunteers will receive 8 logs of E. coli strain B7A after overnight fast
3121452|NCT02773446|Experimental|Cohort 1 group B|Volunteers will receive 9 logs of E. coli strain B7A after 90 minute fast
3121453|NCT02773446|Experimental|Cohort 1 group C|Volunteers will receive 9 logs of E. coli strain B7A after overnight fast
3121454|NCT02773446|Experimental|Cohort 1 group D|Volunteers will receive 10 logs of E. coli strain B7A after 90 minute fast
3121455|NCT02773446|Experimental|Cohort 2 group A|subjects from Cohort 1 who met primary endpoint will receive optimal regimen as determined by analysis after Cohort 1.
3121456|NCT02773446|Experimental|Cohort 2 group B|Naive subjects who will receive optimal regimen as determined by analysis after Cohort 1
3121457|NCT02773537|Active Comparator|Randomization Group 1|Femoral nerve catheter and sciatic nerve block
3121458|NCT02773537|Active Comparator|Randomization Group 2|Adductor canal catheter and selective tibial block
3121459|NCT02773537|Active Comparator|Randomization Group 3|Adductor canal catheter only
3121460|NCT02773758|Experimental|Stannous Fluoride Dentifrice|Participants will be instructed to topically dose a dry toothbrush with a full strip of toothpaste, then brush each of the two selected sensitive test teeth first, followed by the whole mouth thoroughly for at least 1 minute twice daily (morning and evening). Participants will be permitted to rinse with tap water.
3121461|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Participants will be instructed to topically apply a full brush head of toothpaste to a dry toothbrush, then brush the whole mouth thoroughly for at least 1 minute. Participants will be permitted to rinse with tap water.
3121462|NCT02773836||Greek cohort|Participants recruited from Greece will receive a questionnaire at pre- and post- intervention
3121463|NCT02773836||German cohort|Participants recruited from Germany will receive a questionnaire at pre- and post- intervention
3121464|NCT02773836||Romanian Cohort|Participants recruited from Romania will receive a questionnaire at pre- and post- intervention
3121465|NCT02773836||Spanish Cohort|Participants recruited from Spain will receive a questionnaire at pre- and post- intervention
3121466|NCT02773836||Hungarian Cohort|Participants recruited from Hungary will receive a questionnaire at pre- and post- intervention
3121467|NCT02773836||Polish cohort|Participants recruited from Poland will receive a questionnaire at pre- and post- intervention
3121468|NCT02774226|Experimental|Tetrahydrobiopterin (BH4)|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following 5mg/kg of Kuvan® or sapropterin dihydrochloride which is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), taken once a day.
3469373|NCT03887312|Active Comparator|Médecins du Monde treatment as usual|Treatment as usual provided by Médecins du Monde. The number and content of sessions will vary depending on the needs of the child.
3121469|NCT02774226|Experimental|Antioxidant Cocktail|Blood samples, flow-mediated dilation, arterial stiffness, lung function, and microvascular function will be performed at baseline and 12 weeks following an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day.
3121470|NCT02774265|Active Comparator|VTE prophylaxis with Enoxaparin 30mg BID|The group receiving VTE prophylaxis with enoxaparin 30mg subcutaneous BID.
3121471|NCT02774265|Active Comparator|VTE prophylaxis with Aspirin 81mg BID|The group receiving VTE prophylaxis with ASA 81mg PO BID
3121472|NCT02774278|Experimental|Erlotinib|Participants will receive erlotinib orally daily until disease progression, unacceptable toxicity or death.
3121473|NCT02774343|Experimental|Pioglitazone + Therapy + Contingency Management|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
3121474|NCT02774343|Placebo Comparator|Placebo + Therapy + Contingency Management|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
3121475|NCT02774616|Other|Ilivia ICD Family|Implant of the new Ilivia ICD Family. Device measurements, pre-defined programming and Adverse Event Reporting
3121476|NCT02774616|Other|Plexa ICD lead|Implant of the new Plexa ICD lead. Device measurements and Adverse Event Reporting
3121477|NCT02774616|Other|Ilivia ICD and Plexa lead|Implant of the new Ilivia ICD Family and the new Plexa lead. Device measurements, pre-defined programming and Adverse Event Reporting
3121478|NCT02774681|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with HER2 positive breast cancer may also receive trastuzumab IV over 30-90 minutes every 3 weeks.
3121479|NCT02774798||Rectal Intussusception and Prolapse|"AAR measurements will be taken from patients with suspected intra-rectal intussusception or rectal prolapse. Subgroup analysis will be performed after grading of rectal prolapse according to the Oxford Grading system. The subgroups will be:~Oxford Grades 1 & 2 - intra-rectal intussusception~Oxford Grades 3 & 4 - intra-anal intussusception~Oxford grade 5 - Overt Rectal Prolapse"
3121480|NCT02774850||Early Discharge Management|Discharge to outpatient management during neutropenia within 3 days after chemotherapy completion in a given course
3121481|NCT02774850||Inpatient Management|Remain hospitalized during chemotherapy-induced neutropenia
3121482|NCT02774941|Active Comparator|Control|Standard single patient-use small volume JN (AirLife™ Sidestream® High-Efficiency Nebulizer, CareFusion, Yorba Linda, CA)
3121483|NCT02774941|Experimental|Study|Vibrating Mesh Nebulizer (Aerogen® Solo with Ultra adapter, Aerogen Ltd, Galway, Ireland)
3121484|NCT02775240|Active Comparator|Digoxin|On Day 1, subjects will receive a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin.
3121485|NCT02775240|Experimental|Maribavir|On Day 8 through Day 15, subjects will receive a 400 mg (2 x 200 mg) BID oral dose of maribavir. Subjects will be given the second dose of maribavir approximately 12 hours after the first dose. On Day 13, subjects will receive a coadministration of a single 0.5 mg (2 x 0.25 mg) oral dose of digoxin and a single 30 mg oral dose of dextromethorphan given with the morning dose of maribavir.
3121486|NCT02775240|Active Comparator|Dextromethorphan|On Day 1, subjects will receive a single 30 mg oral dose of dextromethorphan.
3121487|NCT02775344|Experimental|three dimension laparoscopy|This group of patients will have laparoscopic ovarian cystectomy performed using three-dimension laparoscopy. The procedure will be performed in usual manner.
3121488|NCT02775344|No Intervention|Two dimension laparoscopy|Two-dimension laparosocpy would be used in this group of patient. The procedure will be performed in usual manner.
3121489|NCT02775435|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
3121490|NCT02775435|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
3121491|NCT02775617|Other|Parallel Treatment|Site 1- Parallel Treatment Arm Single dose azithromycin (for yaws) and Ivermectin/Permethrin (for scabies) will be offered on D1. A second dose of Ivermectin/Permethrin will be offered 7-14 days later.
3121492|NCT02775617|Other|Sequential Treatment|"Site 2- Serial Treatment Arm Ivermectin/Permethrin (for scabies) will be offered on D1 with a second dose of Ivermectin/Permethrin offered 7-14 days later..~Single dose azithromycin (for yaws) will be offered at the twelve month follow-up visit."
3121493|NCT02775864||Antipsychotic|Individuals initiating treatment with an antipsychotic medication
3121494|NCT02775864||Antidepressant|Individuals initiating treatment with an antidepressant medication
3121495|NCT02775864||Benzodiazepine|Individuals initiating treatment with a benzodiazepine
3121496|NCT02775864||Mood stabilizer|Individuals initiating treatment with a mood stabilizer
3121497|NCT02775903|Experimental|Azacitidine + Durvalumab|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
3121498|NCT02775903|Active Comparator|Azacitidine Alone|Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
3121499|NCT02775916|Experimental|CDZ173|Capsule
3121500|NCT02775916|Placebo Comparator|Placebo|Capsule matching Placebo
3121501|NCT02776033|Experimental|GSK2982772 receivers in Cohort 1|Randomized subjects will receive GSK2982772 BID (approximately 12 hours apart) via oral route for 84 days.
3121502|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 1|Randomized subjects will receive placebo BID via oral route for 84 days.
3121503|NCT02776033|Experimental|GSK2982772 receivers in Cohort 2|Randomized subjects will receive GSK2982772 TID (approximately 8 hours apart) via oral route for 84 days
3121504|NCT02776033|Placebo Comparator|Placebo receivers in Cohort 2|Randomized subjects will receive placebo TID via oral route for 84 days.
3121505|NCT02776553|Experimental|Active (physical training program)|physical activity + behavioral therapy + nutritional intervention
3121506|NCT02776553|Active Comparator|Control|nutritional intervention
3121507|NCT02776670|Experimental|SYSTANE BALANCE|Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
3121508|NCT02776670|Active Comparator|REFRESH OPTIVE|Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days
3121509|NCT02776683|Experimental|All patients|
3121510|NCT02776904|Other|Healthy athlete|Healthy athletes (14-18 years old) enrolled in sports program in local schools.
3121511|NCT02776904|Other|Concussed athletes|Concussed athletes from a sports related injury who are 14-18 years old and referred to a regional sports concussion clinic.
3121512|NCT02777021||Early Discharge Patients|Patients receiving or having received chemotherapy for AML who are discharged to outpatient management within 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
3121513|NCT02777021||Inpatient Management Patients|Patients receiving or having received chemotherapy for AML who remain in the hospital more than 3 days after chemotherapy completion. Subjects will complete a health related quality of life (HRQOL) survey at baseline and again at the start of the next treatment course. Survey questions will collect information such as patient race and educational level.
3121514|NCT02777086|Experimental|StaySafe|Participants are asked to complete 12 brief, self-administered tablet computer sessions designed to improve decision-making around health risk behaviors. Sessions typically take about 10 minutes each to complete and are scheduled prior to or after probationer group or individual appointments at their probation facility. Sessions are scheduled about once per week.
3121515|NCT02777086|No Intervention|Comparison|Participants are asked to complete baseline, 3-month and 6-month surveys but are not asked to complete StaySafe sessions or other alternate activities.
3121516|NCT02777125|Active Comparator|Albuterol by Metered Dose Inhaler|Albuterol administered via MDI and spacer device with weight and severity based dosing. For weight less than 20 kg: mild and moderate disease 540mcg of albuterol per dose. For weight greater than or equal to 20 kg: mild disease 540 mcg of albuterol per dose and moderate disease 1080 mcg of albuterol per dose.
3121517|NCT02777125|Active Comparator|Albuterol Breath Actuated Nebulizer|Subjects randomized to BAN were evaluated for proper breath actuation technique. For subjects unable to coordinate breath actuation, the RT attached an appropriately sized mask to the device, changed the setting to continuous nebulization and returned upon completion of the treatment. Albuterol dosing was based upon the subject's weight and presenting symptom severity. Children presenting in the mild and moderate severity category weighing less than 20kg, received 2500mcg of albuterol. Children weighing more than 20kg, received 2500mcg of albuterol if their presentation met mild severity criteria, or 5000mcg if they met moderate criteria.
3121518|NCT02777242|Experimental|Testosterone enanthate auto-injector|Testosterone enanthate administered subcutaneously once each week. Auto-injection of QST 50 mg or 75 mg or 100 mg [Device: QuickShot® Testosterone (QST)]
3121519|NCT02777268|Experimental|Infacort 0.5 mg|Multi-particulate granules from 1 (0.5 mg) capsule
3121520|NCT02777268|Experimental|Infacort 2 mg|Multi-particulate granules from 1 (2 mg) capsule
3121521|NCT02777268|Experimental|Infacort 5 mg|Multi-particulate granules from 1 (5 mg) capsule
3121522|NCT02777268|Experimental|Infacort 10 mg|Multi-particulate granules from 1 (10 mg) capsule
3121523|NCT02777268|Active Comparator|Hydrocortisone|1 (10 mg) tablet
3121524|NCT02777333|Experimental|Simulation training|Addition of simulation training during usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
3121525|NCT02777333|No Intervention|Non-simulation/Routine training|Usual clinical training as part of a GMC (General Medical Council) recognised Deanery training programme
3121526|NCT02777554|Experimental|Part 1: Apremilast 30 mg IR BID / Apremilast 75 mg XL QD|Participants received apremilast 30 mg immediate release (IR) tablet twice a day (BID) for 7 days in treatment period 1 then apremilast 75 mg extended release (XL) formulation once a day (QD) for 7 days in treatment period 2.
3121527|NCT02777554|Experimental|Part 1: Apremilast 75 mg XL QD / Apremilast 30 mg IR BID|Participants received apremilast 75 mg XL formulation once a day for 7 days in treatment period 1 then apremilast 30 mg IR tablet twice a day for 7 days in treatment period 2.
3121528|NCT02777554|Experimental|Part 2: Sequence 1|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 2: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 3: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation after a standard meal."
3121529|NCT02777554|Experimental|Part 2: Sequence 2|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 2: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a standard meal; Treatment period 4: Apremilast 75 mg XL formulation after a high-fat meal."
3121530|NCT02777554|Experimental|Part 2: Sequence 3|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a standard meal; Treatment period 2: Apremilast 75 mg XL formulation under fasted conditions; Treatment period 3: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 4: Apremilast 30 mg IR tablet under fasted conditions."
3121531|NCT02777554|Experimental|Part 2: Sequence 4|"Participants received a single dose of apremilast in each of 4 treatment periods according to the following:~Treatment period 1: Apremilast 75 mg XL formulation after a high-fat meal; Treatment period 2: Apremilast 75 mg XL formulation after a standard meal; Treatment period 3: Apremilast 30 mg IR tablet under fasted conditions; Treatment period 4: Apremilast 75 mg XL formulation under fasted conditions."
3121532|NCT02777749|Active Comparator|Adductor Canal Block|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~Adductor Canal Block (ACB)"
3121533|NCT02777749|Active Comparator|Periarticular SB|50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon.
3121534|NCT02777749|Active Comparator|ACB + SB|"15 cc's of 0.5% bupivacaine preoperatively administered by the regional pain anesthesia team in the pre-operative block area, just prior to surgery.~50 cc's of 0.25% bupivacaine will be injected intraoperatively, just prior to wound closure, by the performing surgeon."
3121535|NCT02777827|Experimental|Abediterol dry powder inhaler 0.156 μg|Dry powder for inhalation administered via dry powder inhaler 0.156 μg/inhalation; (1 inhalation)
3121536|NCT02777827|Experimental|Abediterol dry powder inhaler 2.5 μg|Dry powder for inhalation, administered via dry powder, inhaler 2.5 μg/inhalation; (1 inhalation).
3121537|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.05μg|Pressurised metered-dose, inhaler 0.025 μg/puff; (2 puffs).
3121538|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 0.156 μg|Pressurised metered-dose, inhaler 0.078 μg/puff; (2 puffs).
3121539|NCT02777827|Experimental|Abediterol pressurised metered-dose inhaler 2.5μg|Pressurised metered-dose inhaler 1.25 μg/puff; (2 puffs).
3121540|NCT02777827|Placebo Comparator|Placebo|Pressurised metered-dose inhaler (2 puffs) and Dry powder for inhalation administered via dry powder inhaler (1 inhalation).
3121541|NCT02777918|Experimental|Intervention|6 recipes will be sent by post every 2 weeks for a 12 week period. Dietary recommendations will also be provided at the start of the intervention period to increase the relevance of the recipes.
3121542|NCT02777918|No Intervention|Control|Dietary recommendations will be provided at the start of the study period, such that the intervention regards the recipes, not the recommendations
3121543|NCT02777931|Experimental|NFC-1|Doses of NFC-1 will be administered as 100, 200, or 400 mg twice daily as capsules for oral administration.
3121544|NCT02777931|Placebo Comparator|Placebo|Matching placebo capsules.
3121545|NCT02777944|Experimental|Intervention|Access to Motivate: a web-based intervention, in addition to Usual Care
3121546|NCT02777944|No Intervention|Control|Usual Care
3121547|NCT02777970|Experimental|Tramadol/Dexketoprofen|"Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose;~Placebo matching Tramadol Hydrochloride/Paracetamol 75 mg/650mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose."
3121548|NCT02777970|Active Comparator|Tramadol/Paracetamol|"Tramadol Hydrochloride/Paracetamol 75 mg/650 mg, as 2 x [37.5mg/325mg] film-coated tablets, oral single dose;~Placebo matching Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg film-coated tablet oral single dose.~."
3121549|NCT02777970|Placebo Comparator|Placebo|"Placebo matching one film-coated tablet of Tramadol Hydrochloride/Dexketoprofen Trometamol 75mg/25mg oral single dose;~Placebo matching two film-coated tablets of Tramadol Hydrochloride/Paracetamol 37.5mg/325mg oral single dose."
3121550|NCT02778074|Experimental|Internet Cognitive Behavioural Therapy|Participants will perform a nine-week tailored I-CBT program developed to fit CVD patients. The program consists of psychoeducation, relaxation, problem-solving and behavioral activation.
3121551|NCT02778074|Placebo Comparator|Moderated discussion forum|In this arm the participants are allocated to a non mandatory discussion forum for nine weeks. Evert week will participants discuss issues regarding their CVD. Themes discussed are suggested by the study team, and a new theme is added every week. A moderator from the study group act as a supervisor and checks that issues discussed are ok. After the nine week discussion forum the participants are offered the nine week CBT program.
3121552|NCT02778100|Experimental|Nasal Glucagon (NG) - Common Cold|Cohort 1 - Nasal Glucagon (NG) administered once in participants with a common cold.
3121553|NCT02778100|Experimental|Nasal Glucagon (NG) - Symptom-Free|Cohort 1 - NG administered once in participants who have recovered from a common cold.
3121554|NCT02778100|Experimental|NG - Common Cold+Oxymetazoline|Cohort 2 - NG administered once in participants with a common cold who are taking oxymetazoline.
3121555|NCT02778113|Experimental|Nasal Glucagon (NG) - 0.5 mg|Ng dose at 0.5 milligram (mg) administered once in one of four study periods.
3121556|NCT02778113|Experimental|NG - 1.0 mg|Ng dose at 1.0 milligram (mg) administered once in one of four study periods.
3121557|NCT02778113|Experimental|NG - 2.0 mg|Ng dose at 2.0 milligram (mg) administered once in one of four study periods.
3121558|NCT02778113|Active Comparator|SC Glucagon 1 mg|Subcutaneous (SC) glucagon dose of 1 mg, in one of four study periods.
3121559|NCT02778152|Experimental|Laser depilation|Laser depilation to the natal cleft (pilonidal region) monthly for 5 treatments with either an 810nm of Nd:YAG laser dependent on Fitzpatrick skin type and tolerability.
3121564|NCT02778555||Sample 1|In Sample 1 (N=186), our 14-item Daily PCS was administered daily for 14 days to replicate the 3-factor structure at the daily level, and to select the ideal 5 items for a brief Daily PCS.
3121565|NCT02778555||Sample 2|In Sample 2 (N=209), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14.
3121566|NCT02778555||Sample 3|In Sample 3 (N=318), the 5-item Daily PCS was administered daily for 14 days with short forms for PROMIS Pain Intensity, Depression, Anger, and Anxiety included on days 1, 7, and 14. In addition, assessments of pain, mood, activity, sleep, energy level, and positive affect were administered daily for the 14-day period.
3121567|NCT02778867|Active Comparator|1-Food Elimination Diet (1FED)|Participants eliminate milk from the diet in Phase 1
3121568|NCT02778867|Active Comparator|6-Food Elimination Diet (6FED)|Participants eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 1
3121569|NCT02778867|Other|1FED Non-Responders (6FED)|Participants that fail to respond to 1FED in Phase 1 eliminate milk, egg, wheat, soy, nuts, fish from the diet in Phase 2
3121570|NCT02778867|Other|6FED Non-responders (SGC)|Participants that fail to respond to 6FED in Phase 1 administer swallowed glucocorticoids (SGC) (Flovent HFA) 880 mcg twice daily in Phase 2
3121571|NCT02778880|Experimental|Ketamine|Ketamine 1.5 mg/kg intranasally for one dose
3121572|NCT02778880|Active Comparator|Fentanyl|Fentanyl 2 mcg/kg intranasally for one dose
3121573|NCT02778932||Intubation|General anesthesia including intubation and muscle relaxation
3121574|NCT02778932||Laryngeal Mask|General anesthesia including laryngeal mask without muscle relaxation
3121575|NCT02779075|Placebo Comparator|Saline|0.9% NaCL (saline) intravenously for 6 hours.
3121576|NCT02779075|Active Comparator|Exendin-9,39|Exendin-9,39 intravenously for 6 hours.
3121577|NCT02779166|Experimental|Intervention|Received 400mg celecoxib prior to surgery
3121578|NCT02779166|Placebo Comparator|Placebo|Received placebo pill prior to surgery
3121579|NCT02779491|Experimental|Intervention for two weeks|Receipt of the mobile phone application for two weeks
3121580|NCT02779491|No Intervention|Control for two weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
3121581|NCT02779491|Experimental|Intervention for four weeks|Receipt of the mobile phone application for four weeks
3121582|NCT02779491|No Intervention|Control for four weeks|Usual habitual activity - no receipt of mobile phone application for two weeks
3121583|NCT02779543|Active Comparator|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
3121584|NCT02779543|Active Comparator|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
3121585|NCT02779543|Active Comparator|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non dominant hand when prepared for the sleep study by a technician. Subjects willing to wear more than one sleep monitoring device may be fitted with two different sleep monitoring devices, e.g., a Fitbit and a Jawbone UP or a Fitbit and a Microsoft Band. Sleep monitoring device(s) will be removed from the subject's wrist in the morning at the conclusion of the sleep study.
3121586|NCT02779855|Experimental|Talimogene laherparepvec + Chemotherapy|Talimogene laherparepvec with Neoadjuvant Paclitaxel Chemotherapy treatment administration on an outpatient basis. Phase I: Dose Escalation to Determine Maximum Tolerated Dose (MTD). Phase II: Treatment at MTD.
3121587|NCT02780115|Experimental|Cohort 1: Vehicle Control|Vehicle dosed in both eyes administered once daily during office visits 1 through 5.
3121588|NCT02780115|Experimental|Cohort 2: AGN-199201 Dose A and AGN-190584 Dose A|Fixed combinations of AGN-199201 Dose A and AGN-190584 Dose A dosed in both eyes administered once daily during office visits 1 through 5.
3121589|NCT02780115|Experimental|Cohort 3: AGN-199201 Dose B and AGN-190584 Dose B|Fixed combinations of AGN-199201 Dose B and AGN-190584 Dose B dosed in both eyes administered once daily during office visits 1 through 5.
3121590|NCT02780115|Experimental|Cohort 4: AGN-199201 Dose C and AGN-190584 Dose C|Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in both eyes administered once daily during office visits 1 through 5.
3121591|NCT02780115|Experimental|Cohort 5: Vehicle, AGN-199201 Dose C and AGN-190584 Dose C|Dominant eye dosed with Vehicle. Fixed combinations of AGN-199201 Dose C and AGN-190584 Dose C dosed in nondominant eye. Treatment administered once daily during office visits 1 through 5.
3121592|NCT02780167|Experimental|Cohort 1|10 mg of PF-04965842 QD
3121593|NCT02780167|Experimental|Cohort 2|30 mg of PF-04965842 QD
3121594|NCT02780167|Experimental|Cohort 3|100 mg of PF-04965842 QD
3121595|NCT02780167|Experimental|Cohort 4|200 mg of PF-04965842 QD
3121596|NCT02780167|Placebo Comparator|Cohort 5|placebo QD
3121597|NCT02780349|Experimental|WIRION EPS|Single arm study. All patients undergo procedure with the WIRION EPS
3121598|NCT02780388|Placebo Comparator|Placebo|Participants will receive a single intravascular (IV) dose of placebo matched to VIB4920 (formerly MEDI4920) once every 2 weeks (Q2W) from Day 1 up to 12 weeks.
3121599|NCT02780388|Experimental|VIB4920 75 mg|Participants will receive a single IV dose of VIB4920 75 mg Q2W from Day 1 up to 12 weeks.
3121600|NCT02780388|Experimental|VIB4920 500 mg|Participants will receive a single IV dose of VIB4920 500 mg Q2W from Day 1 up to 12 weeks.
3121601|NCT02780388|Experimental|VIB4920 1000 mg|Participants will receive a single IV dose of VIB4920 1000 mg Q2W from Day 1 up to 12 weeks.
3121602|NCT02780388|Experimental|VIB4920 1500 mg|Participants will receive a single IV dose of VIB4920 1500 mg Q2W from Day 1 up to 12 weeks.
3121603|NCT02780622|Experimental|First Warfarin Then Warfarin and Oseltamivir|Participants will receive warfarin (on Days 1-5) in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive oseltamivir 75 milligram (mg) (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
3121604|NCT02780622|Experimental|First Warfarin and Oseltamivir Then Warfarin|Participants will receive oseltamivir 75 mg (orally twice daily on Days 1-4 and once on Day 5) and warfarin in Treatment Period 1, followed by a washout period of at least 4 days (maximum 8 days). Participants will then receive warfarin (on Days 1-5) in Treatment Period 2, and attend a follow-up visit 4-12 days after the last dose in Treatment Period 2. Participants will continue receiving warfarin once daily at a prescribed usual dose throughout the study.
3121605|NCT02780661|Experimental|Denture Cleanser Daily Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 millilitre [ml]) with 1 denture cleansing tablet from Day 0 to Day 7 for 15 minutes (mins). Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
3121606|NCT02780661|Experimental|Denture Cleanser Weekly Use Period|Participants will be instructed to soak upper arch dentures in the evening in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds. Cleaning of upper arch dentures in the morning is not permitted. Lower arch dentures will be cleaned using the participant's normal oral hygiene procedures in the morning and evening. If the participants will have lower removable partial or complete dentures, the soaking of these dentures will be done in a separate cup from the cup provided for soaking the upper denture.
3121607|NCT02780687|Experimental|Afatinib|
3121608|NCT02780700|Experimental|Nintedanib|
3121609|NCT02780700|Experimental|Nintedanib plus capecitabine|
3121610|NCT02780713|Experimental|AZD9496|"This is a fixed sequence study with 5-sequential treatment periods in healthy volunteers. Each volunteer will receive 5 single doses of AZD9496 in different forms, formulations and doses.~Treatment period 1 will assess AZD9496 Variant A: 100mg.~Treatment period 2 will assess AZD9496 Reference: 100mg.~Treatment period 3 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 4 will assess one of AZD9496 Variants, B, C or D: 100mg.~Treatment period 5 will assess one of AZD9496 Variants A, B, C or D: *300mg. *Based on a review of PK and safety results from Treatment Periods 1, 3 and 4, a lower dose of 200 mg may be administered in Treatment Period 5"
3121611|NCT02780765|Experimental|Heated humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using Heated Humidifier (HH). Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
3121612|NCT02780765|Active Comparator|Mist humidifier group|30 postoperative patients with overnight endotracheal intubation will be supplied humidified oxygen using mist nebuliser. Temperature of inspired gas at the Y piece will be measured as surrogate marker for quality of humidification. The suctioning of ETT will be done once every 2 hourly by nurse/ doctor/trained personnel.
3121613|NCT02780856|Other|Sound and unsound teeth|Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System
3121614|NCT02780869|Experimental|Investigational|HEMOBLAST Bellows
3121615|NCT02780869|Active Comparator|Control|Absorbable gelatin sponge, USP with thrombin
3121616|NCT02781051|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks with a 6 month follow up.
3121617|NCT02781311|Experimental|Setipiprant|Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
3121618|NCT02781311|Placebo Comparator|Placebo|Two placebo tablets BID at 12-hour intervals for 24 weeks.
3121619|NCT02781311|Active Comparator|Finasteride|Finasteride 1 mg tablet, orally, once daily for 24 weeks.
3121620|NCT02781324|Experimental|Ultrasonic Bone Scalpel Group|Surgeons will use the ultrasonic bone scalpel, to their discretion, along with standard of care manual devices when performing the posterior spinal fusion.
3121621|NCT02781324|Active Comparator|Standard of Care Group|Surgeons will use, to their discretion, only standard of care manual devices when performing the posterior spinal fusion.
3121622|NCT02781454|Active Comparator|Mexiletine, 300 milligrams|Mexiletine, 300 milligrams by mouth per day for 4 weeks.
3121623|NCT02781454|Active Comparator|Mexiletine, 600 milligrams|Mexiletine, 600 milligrams by mouth per day for 4 weeks.
3121624|NCT02781454|Placebo Comparator|Placebo|Placebo, by mouth per day for 4 weeks.
3121625|NCT02781480|Experimental|Low dose AAV-RPE65|Subretinal administration of a single low dose of range AAV-RPE65
3121626|NCT02781480|Experimental|Intermediate dose AAV-RPE65|Subretinal administration of a single intermediate dose of range AAV-RPE65
3121627|NCT02781480|Experimental|High dose AAV-RPE65|Subretinal administration of a single high dose of range AAV-RPE65
3121628|NCT02781558|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
3121629|NCT02781558|Experimental|SOF/VEL + RBV|SOF/VEL FDC + RBV for 12 weeks
3121630|NCT02781571|Experimental|SOF/VEL|SOF/VEL FDC for 12 weeks
3121631|NCT02781610|Other|ERR-10|ERR treatment duration - 10 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
3121632|NCT02781610|Other|ERR-14|ERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
3121633|NCT02781610|Other|NERR-14|NERR treatment duration - 14 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
3121634|NCT02781610|Other|NERR-21|NERR treatment duration - 21 Day Standard of care IV antibiotic(s) will be selected by the treating physician. Duration of treatment is the assigned intervention.
3121635|NCT02781649|Experimental|Donor genotype 1a no resistance or 1b|Participants who receive donors found to have hepatitis C genotype 1a without resistance Zepatier one tablet daily for 12 weeks
3121636|NCT02781649|Experimental|Donor genotype 1a with resistance|Participants who receive donors found to have hepatitis C genotype 1a with nonstructural protein 5A associated resistance mutations Zepatier one tablet daily for 16 weeks Ribavirin weight based dosing for 16 weeks
3121637|NCT02781649|Experimental|Donor genotype 2 or 3|Participants who receive donors found to have hepatitis C genotype 2 or 3 Zepatier one tablet daily for 12 weeks Sofosbuvir 400 mg daily for 12 weeks
3121638|NCT02781818|Experimental|Triamcinolone Acetonide 10mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 10mg/mL solution.
3121639|NCT02781818|Experimental|Triamcinolone Acetonide 40mg/mL|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of triamcinolone 40mg/mL solution.
3121640|NCT02781818|Placebo Comparator|Normal Saline Placebo|Each lesion randomized to this group will receive a single intralesional treatment with 0.1 mL of sterile normal saline solution.
3121641|NCT02781844|Experimental|A/B or B/A|Participants will be randomized to either receive 25 microgram (mcg) rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 25mcg rhPTH(1-84) BID with no calcium for treatment period 2
3121642|NCT02781844|Experimental|C/B or B/C|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with no calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with no calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with no calcium for treatment period 2
3121643|NCT02781844|Experimental|D/E or E/D|Participants will be randomized to either receive 25mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 25mcg rhPTH(1-84) twice daily with calcium for treatment period 2
3121644|NCT02781844|Experimental|F/E or E/F|Participants will be randomized to either receive 50mcg rhPTH(1-84) twice daily with calcium for treatment period 1 and 100mcg rhPTH(1-84) once daily with calcium for treatment period 2; or 100mcg rhPTH(1-84) once daily with calcium for treatment period 1 and 50mcg rhPTH(1-84) twice daily with calcium for treatment period 2
3121645|NCT02782065||Pediatric patients with Asthma|165 patients aged 7 to 18 years, and 30 patients aged 2 to 6 years
3121646|NCT02782169|Active Comparator|Pregabalin|
3121647|NCT02782169|Placebo Comparator|Placebo|
3121648|NCT02782325|Active Comparator|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
3121649|NCT02782325|Placebo Comparator|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
3121650|NCT02782364||Faecal Incontinence: fast-fill measurement first|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will undergo fast-fill measurement first.
3121651|NCT02782364||Faecal Incontinence: step-wise measurement first.|Observational study where patients with faecal incontinence undergo two AAR measurements; one with the original step-wise technique and the second with the newer fast-fill technique. A further standard manometry measurement will be taken. 18 patients will have step-wise measurement first.
3121652|NCT02782377||Pelvic Floor Dysfunction|"Observational study where patients with pelvic floor dysfunction undergo three AAR measurements. One at baseline, one with the catheter alongside and a third with the rectal balloon inflated. No intervention is performed~Note, that initial inclusion of Squeeze parameters was detailed in error, these were not compared in this study and were compared in previous study"
3121653|NCT02782676|Experimental|Investigational Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
3121654|NCT02782676|Active Comparator|Approved Healon5 OVD|Subjects to receive investigational Healon5 OVD in one eye and control Healon5 in the fellow eye.
3121655|NCT02782741|Experimental|avalglucosidase alfa (GZ402666)|Administered intravenously every 2 weeks
3121656|NCT02782741|Active Comparator|alglucosidase alfa (GZ419829)|Administered intravenously every 2 weeks
3121657|NCT02782780|Experimental|CBTi|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep as well as to work with the patient toward altering sleep habits to increase sleep propensity and regularity. Specifically, participants will receive 8 weekly individual sessions of CBTi according to the VA CBTi protocol. The investigators will follow the semi-structured approach to treatment described in the VA CBTi protocol, which allows the case conceptualization to drive the order in which treatment components are introduced.
3121658|NCT02782780|No Intervention|Monitor Only|Study participants who are randomized to the Monitor Only (MO) control group will be followed for 8 weeks of usual care (i.e., they will be advised to continue doing whatever they were doing to manage their GWI and insomnia symptoms without change dosage or frequency of treatment). Participants randomized to the Monitor Only condition will have the option of receiving CBTi delivered by telephone, at no cost to them, upon completion of post-study procedures.
3121659|NCT02782923|Experimental|s-ACDFwith STISIM|Single-level anterior cervical discectomy fusion
3121660|NCT02782923|Experimental|m-ACDF with STISIM|Multi-level anterior cervical discectomy and fusion
3121661|NCT02782923|Experimental|CDR with STISIM|Cervical disc replacement
3121662|NCT02782923|Experimental|PCLF with STISIM|Posterior laminectomy and fusion
3121663|NCT02782923|Experimental|PCD with STISIM|Posterior cervical decompression procedure
3121664|NCT02782923|Sham Comparator|Control Group with STISIM|
3121665|NCT02783027|Experimental|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants in the experimental group that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
3121666|NCT02783027|No Intervention|Text-Message Assessments Only|Participants in the non-intervention group/arm will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). The inter-shift assessments will query the participant about his/her sleep hours, fatigue, sleepiness, and difficulty with concentration. No intervention messages sent to this group/arm.
3121667|NCT02783066|Experimental|"PulseFlow group"|Eligible subjects will try a new offloading boot for 4 weeks
3121668|NCT02783170|Other|Simultaneous vaccination arm|In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
3121669|NCT02783170|Other|Sequential vaccination arm|In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
3121670|NCT02783443||General anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under general anaesthesia.
3121671|NCT02783443||Regional anesthesia|Adult patients ASA 2-3 undergoing elective total knee replacement surgery under regional anaesthesia.
3121672|NCT02783469||Diabetic neuropathic pain|Those with type 2 diabetes and painful neuropathy
3121673|NCT02783469||Controls|Type 2 diabetics with non-painful neuropathy, or pain without neuropathy
3121674|NCT02783573|Experimental|Lanabecestat 20 milligrams (mg)|Participants received Lanabecestat 20 mg film-coated tablets orally once daily until week 156.
3121675|NCT02783573|Experimental|Lanabecestat 50 mg|Participants received Lanabecestat 50 mg film-coated tablets orally once daily until week 156.
3121676|NCT02783573|Experimental|Placebo/ Lanabecestat 20 mg|Placebo given orally once daily for 78 weeks and then 20 mg of lanabecestat given orally once daily until week 156.
3121677|NCT02783573|Experimental|Placebo/ Lanabecestat 50 mg|Placebo given orally once daily for 78 weeks and then 50 mg of lanabecestat given orally once daily until week 156.
3121678|NCT02783599|Experimental|Olaratumab + Doxorubicin|"Cycle 1: Olaratumab 20 milligram per kilogram (mg/kg) given intravenously (IV) on Day 1 and Day 8 (21 day cycle).~Cycle 2: Olaratumab 20 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycle).~Cycle 3 through Cycle 7: Olaratumab 15 mg/kg given IV on Day 1 and Day 8 plus doxorubicin 75 mg/m2 given IV on Day 1 (21 day cycles)."
3121679|NCT02783599|Experimental|Olaratumab + Radiotherapy Addendum|"Olaratumab given IV on Day 1 and Day 8 (21 day cycle) concurrently with radiotherapy.~Radiotherapy addendum was not implemented."
3121680|NCT02783729|Experimental|Lemborexant 5 milligrams (mg)|Participants will receive one lemborexant 5 mg tablet and one zolpidem-matched placebo tablet each night
3121681|NCT02783729|Experimental|Lemborexant 10 mg|Participants will receive one lemborexant 10 mg tablet and one zolpidem-matched placebo tablet each night
3121682|NCT02783729|Active Comparator|Zolpidem tartrate|Participants will receive one zolpidem 6.25 mg tablet and one lemborexant-matched placebo tablet each night
3121683|NCT02783729|Placebo Comparator|Placebo|Participants will receive one zolpidem-matched placebo tablet and one lemborexant-matched placebo tablet each night
3121684|NCT02783768|Experimental|E-cigarette first|Participants will undergo the e-cigarette exposure prior to the first two MRI measures, and then they will undergo the sham exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
3121685|NCT02783768|Experimental|Sham first|Participants will undergo the sham exposure prior to the first two MRI measures, and then they will undergo the e-cigarette exposure prior to the last two MRI measures. The two MRIs performed under both experimental exposures (e-cigarette and sham) will be enhanced by (1) gadolinium and then (2) hyperpolarized 3-helium.
3121686|NCT02783820|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
3121687|NCT02783820|Placebo Comparator|Placebo to match MMV390048 40 mg|Placebo to match MMV390048 40 mg, tablets, single dose
3121688|NCT02783820|Experimental|MMV390048 80 mg|MMV390048 80 mg, tablets, single dose
3121689|NCT02783820|Placebo Comparator|Placebo to match MMV390048 80 mg|Placebo to match MMV390048 80 mg, tablets, single dose
3121690|NCT02783820|Experimental|MMV390048 120 mg|MMV390048 120 mg, tablets, single dose
3121691|NCT02783820|Placebo Comparator|Placebo to match MMV390048 120 mg|Placebo to match MMV390048 120 mg, tablets, single dose
3121692|NCT02783898|Experimental|Study|All STUDY arm participants will be given an AliveCor Heart Monitor and trained in the use of the device. They will be followed up at 90 days. If a participants allocated to the Study arm, gets an episode of palpitations or pre-syncope and is able to record an AliveCor Heart Monitor ECG during the episode, the participant will email the ECG recorded by the AliveCor app directly to the study team. The study team will review the ECG. If specialist follow-up is not required the study team will inform the participant of this and ask them to arrange general practitioner follow up. If the participant records a serious significant arrhythmia during the study period, the study team will alert the participant immediately and refer them to the cardiac electrophysiology service.
3121693|NCT02783898|No Intervention|Control|All CONTROL arm participants will receive no other intervention. Participants in both groups will be admitted, referred or discharged by the treating clinician according to current hospital protocols. Participants in both groups will be followed up at 90 days through hospital electronic patient record (EPR) systems and through a standardised written questionnaire and follow-up telephone call including symptoms and contact with medical services, satisfaction and compliance.
3121694|NCT02783911|Experimental|Mineral Trioxide Aggregate|Subject with pulpotomy treated with MTA MTA paste (< 1gm) will be placed on pulp orifice once for the life of the primary teeth
3121695|NCT02783911|Experimental|Ferric Sulfate|Subject with pulpotomy treated with FS FS paste (<1gm) will placed on pulp orifice once for 15 secs and removed on primary teeth
3121696|NCT02783950|Other|GC (Decipher) Arm|If enrolled during the Genomic Classifier (GC) period, both subjects and their treating physician will be provided GC (Decipher Prostate Cancer Classifier from GenomeDx) and CAPRA-S scores following prostatectomy.
3121697|NCT02783950|No Intervention|Usual-Care-Based (UC) Arm|If enrolled during the UC period, only the CAPRA-S results will be provided.
3121698|NCT02784106|Placebo Comparator|Placebo: Double-Blind Treatment Period|
3121699|NCT02784106|Experimental|M2951: Double-Blind Treatment Period|
3121700|NCT02784106|Experimental|Placebo/M2951: Open Label Extension Period|
3121701|NCT02784106|Experimental|M2951/M2951: Open Label Extension Period|
3121702|NCT02784275|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 3 mg CHP
3121703|NCT02784275|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 9 mg CHP
3121704|NCT02784275|Experimental|Dose C|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
3121705|NCT02784275|Placebo Comparator|Dose D|Placebo
3121706|NCT02784431|Experimental|Contour Neurovascular System placement|Treatment of intracranial aneurysm with the Contour Neurovascular System device.
3121707|NCT02784444|Active Comparator|MSDC-0602K Dose 1 capsules|MSDC-0602K Dose 1 capsule taken once daily for 360 days
3121708|NCT02784444|Active Comparator|MSDC-0602K Dose 2 capsules|MSDC-0602K Dose 2 capsules taken once daily for 360 days
3121709|NCT02784444|Active Comparator|MSDC-0602K Dose 3 capsules|MSDC-0602K Dose 3 capsules taken once daily for 360 days
3121710|NCT02784444|Placebo Comparator|Placebo capsules|Matching Placebo capsule taken once daily for 360 days
3121711|NCT02784548|Experimental|Virtual reality|Using a Virtual reality (VR) headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
3121712|NCT02784587|Experimental|Stellate Ganglion Block|All patients in the study will receive a stellate ganglion block in order to asses the feasibility and efficacy of this procedure performed by cardiac anesthesiologists in the operating room.
3121713|NCT02784613|Experimental|Ospemifene open label|60 mg ospemifene daily for 20 weeks
3121714|NCT02784704|Experimental|Eravacycline|
3121715|NCT02784704|Active Comparator|Meropenem|
3121716|NCT02784834|Experimental|Dimethyl fumarate (DMF)|"Cohort 1: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 2 x 28 day cycles.~Cohort 2: dimethyl fumarate 120 mg PO BID (approximately 12 hours apart) for 1 week, then escalating to the assigned dose of (240mg PO BID for the remainder of 2 x 28 day cycles.~Cohort 3: dimethyl fumarate 120 mg PO BID for 1 week, then escalate to the dose of 360mg PO BID for the remainder of 2 x 28 day cycles."
3121717|NCT02784925|Other|fatty liver subjects|Ultrasound (US) B mode image is an alternative method to measure tissue structure and has proven to be an accurate technique to measure subcutaneous fat thickness.
3121718|NCT02785159|Experimental|IDP-118 Lotion|Lotion
3121719|NCT02785159|Active Comparator|Tazorac Cream|Cream
3121720|NCT02785159|Active Comparator|IDP 118 Vehicle Lotion|Lotion
3121721|NCT02785159|Active Comparator|IDP-118 Vehicle Cream|Cream
3121722|NCT02785172|Experimental|IDP-118 Lotion|Lotion
3121723|NCT02785172|Active Comparator|Ultravate Cream|Cream
3121724|NCT02785172|Active Comparator|IDP-118 Vehicle Lotion|Lotion
3121725|NCT02785172|Active Comparator|IDP-118 Vehicle Cream|Cream
3121726|NCT02785185|Experimental|IDP-122 Lotion|Lotion
3121727|NCT02785185|Active Comparator|Ultravate Cream|Cream
3121728|NCT02785185|Active Comparator|IDP-122 Vehicle Lotion|Lotion
3121729|NCT02785185|Active Comparator|IDP-122 Vehicle Cream|Cream
3121730|NCT02785354||NOAC|New oral anticoagulant groups
3121731|NCT02785354||VKA|VKA group
3121732|NCT02785406|Experimental|suvorexant|Subjects will receive suvorexant (10 mg week 1, 20 mg week 2), once daily at 10 PM.
3121733|NCT02785406|Placebo Comparator|Placebo|Subjects will receive placebo once daily at 10 PM.
3121734|NCT02785432|Sham Comparator|Sham low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 0 watts for a total of 0 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint. The contact head applicator will be used if soft tissue contact is tolerable. Otherwise, the non-contact head will be utilized.
3121735|NCT02785432|Active Comparator|Active low level laser|Treatment will be administered 2x/w x 4 weeks as a standalone, then 2 times/week x 4 weeks in conjunction with standard physical therapy and counseling. The clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. This equates to standard acceptable dosing of 6-10 j/cm2 over the larger area of treatment. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Areas for administration and contact will otherwise be consistent with the sham group.
3121736|NCT02785458|No Intervention|Usual Care|Subjects will receive the current standard of care.
3121737|NCT02785458|Experimental|EMC2 Strategy|Subjects will receive the EMC2 Strategy. See description of strategy below.
3121738|NCT02785588|Other|3.0 T Neonatal MRI scanner|All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.
3121739|NCT02785770|Experimental|PF-04447943 low dose|25 mg of PF-04447943
3121740|NCT02785770|Experimental|PF-04447943 high dose|100 mg of PF-04447943
3121741|NCT02785770|Placebo Comparator|Placebo|Matching placebo for PF-04447943
3121742|NCT02785770|Active Comparator|Moxifloxacin|400 mg of moxifloxacin
3121743|NCT02785900|Experimental|33A + HMA|33A plus azacitidine or decitabine
3121744|NCT02785900|Active Comparator|placebo + HMA|placebo plus azacitidine or decitabine
3121745|NCT02785913|Experimental|Arm I (GDC-0032)|Patients receive taselisib PO daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3121746|NCT02785939|Experimental|Arm I - Palbociclib|"Participants receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
3121747|NCT02785939|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~Closed to accrual 12/18/2015"
3121748|NCT02785939|Experimental|Arm III - Palbociclib re-reg|"Participants in Arm II eligible for re-registration receive palbociclib PO on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Closed to accrual 09/01/2016"
3121749|NCT02786004|Experimental|Full Field Digital Mammography|2-dimensional breast imaging
3121750|NCT02786004|Experimental|Digital Breast Tomosynthesis|3-dimensional breast imaging
3121751|NCT02786134|Experimental|low-dose methotrexate (LDM)|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dipyridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
3121752|NCT02786134|Experimental|placebo|Patients willing to participate in CIRT will be asked to enroll into the sub-study and may sign the CIRT-CFR informed consent at any point between signing the parent CIRT informed consent and completing the parent CIRT randomization visit (Visit 4). After giving informed consent for the ancillary CIRT-CFR, patients will undergo the baseline rest/dypridamole stress PET scan along with echocardiography. The final PET scan and echocardiogram will occur at approximately 12 months after randomization.
3121753|NCT02786355|Other|Maximum bimanual compression|Squeeze through Frova bougie with maximum bimanual compression
3121754|NCT02786355|Other|Normal bimanual compression|Squeeze through Frova bougie with normal bimanual compression
3121755|NCT02786498|Experimental|High Loading Dose|150,000 IU loading dose vitamin D3 at enrolment and 6 weeks, plus daily dose placebo for 3 months.
3121756|NCT02786498|Experimental|High Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 4,000 IU vitamin D3 per day for 3 months.
3121757|NCT02786498|Experimental|Low Daily Dose|Loading dose placebo at enrolment and 6 weeks, plus 600 IU vitamin D3 per day for 3 months.
3121758|NCT02786498|Placebo Comparator|Control Group|Loading dose placebo at enrolment and 6 weeks, plus daily dose placebo for 3 months.
3469374|NCT03887507|Experimental|Experimental|There will be 3 Vojta therapy sessions conducted on 2 consecutive weeks with an interval of 7 dayssessions, on 1st, 7th and 14th days. Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling Réflex, and 1st phase and 2nd phase Rolling reflex. The relative or close person will be instructed to carry out an exercise protocol to do at home every day for 20 minutes during the 2-week study. All interventions will be made by the principal investigator.
3469375|NCT03887507|Active Comparator|Standard Therapy|The standard group shall perform 4 sessions of physiotherapy in the same period for two consecutive weeks, with one hour per session in its specialized MS association, on 1st, 3rd, 8th, 10th and 15th days. This will be applied by experienced physiotherapists during the treatment of people with MS. The program will consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept. Patients in this group will walk at least for 20 minutes per day during the study period.
3469376|NCT03887338|Other|NIV settings titration|Transnasal Fiberoptic Laryngoscopy will be used during ongoing NIV setting titration. Aim is to titrate NIV setting to be more optimal for laryngeal responses.
3469377|NCT03887208|Experimental|Autologous adipose derived stem cells|Autologous ADSC injection combined with laser therapy of the skin.
3469378|NCT03887208|Placebo Comparator|Placebo - Normal saline injection|Normal sline injection combined with laser therapy of the skin.
3469379|NCT03887247|Active Comparator|E-Mail Alert|Send email to the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager.
3121765|NCT02786719|Experimental|Neuroblastoma treatment without G-CSF|Induction chemotherapy only, including 6 cycles of chemotherapy, tumor resection, and stem cell collection
3121766|NCT02786771|Experimental|Spire device without & with feedback|Participants will receive a Spire device with user-feedback switched off within 4 days of enrollment in the study (shipped within 2 business days after they finish enrollment survey). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After two weeks of baseline with user-feedback off (and a 3 day transition period), participants will turn on the user-feedback for the Spire device which would provide a relaxation aid for the participant for the 6 remaining weeks.
3121767|NCT02786771|Experimental|Muse device & spire device no feedback|Participants in this group will also receive Spire device to assess two weeks of baseline stress levels (with user-feedback off). Participants will be given 4 days, after enrollment, to set up their device before the 2 weeks of baseline. The 2 week baseline will start 4 days after enrollment. After these two weeks, participants will continue to use the Spire device with user feedback off for the remaining 6 weeks while they use the Muse device to manage stress through meditation. They will receive the Muse device 3 days before the end of baseline period with set up instructions and will utilize the three last days of baseline to set up their Muse device, Meditation will begin at the end of baseline (week three) and will continue for the remaining 6 weeks.
3121768|NCT02786810|Other|Contrast|All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.
3469380|NCT03887247|No Intervention|As-Usual|As-usual (no email) approach.
3469381|NCT03887234|Active Comparator|Through the coracoid|The semitendinosus tendon graft goes through the 4.5 mm coracoid drill hole.
3469382|NCT03887234|Experimental|Around the coracoid|The semitendinosus tendon graft goes around the coracoid.
3121769|NCT02786836|Experimental|13C-Methacetin Testing|All patients enrolled into the ALFSG Registry with the duration of illness <26 weeks with (1) severe acute liver injury; International Normalized Ratio (INR) ≥2.0) and not related to acetaminophen overdose, with no evidence of hepatic encephalopathy (HE); and (2) acute liver failure; INR ≥1.5 with presence of any degree of HE will perform the Breath Test.
3121770|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
3121771|NCT02786901|Experimental|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
3121772|NCT02786901|Placebo Comparator|Vehicle Gel|Vehicle
3121773|NCT02786927|Experimental|ELLIPTA - HANDIHALER; HANDIHALER Questionnaire Version 1|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
3121774|NCT02786927|Experimental|ELLIPTA - HANDIHALER; Questionnaire Version 2|Subjects will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the HANDIHALER inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
3121775|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 1|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 1 of the inhaler preference questionnaire.
3121776|NCT02786927|Experimental|HANDIHALER - ELLIPTA; Questionnaire Version 2|Subjects will be dispensed the HANDIHALER inhaler at Visit 1 to use during the first period (once daily for 5-9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5-9 days). At Visit 3, subjects will complete Version 2 of the inhaler preference questionnaire.
3121777|NCT02786953|Experimental|Sleep Promotion|Behavioral sleep-promoting intervention, including components such as limiting caffeine, establishing a media curfew, and positive bedtime routines, as well as needs unique to adolescents with T1D, such as fear of hypoglycemia.
3121778|NCT02786953|No Intervention|Usual Care|Usual Care
3121779|NCT02787044|Experimental|High Dose Influenza Vaccine|High Dose Influenza Vaccine
3121780|NCT02787044|Active Comparator|Standard Dose Influenza Vaccine|Standard Dose Influenza Vaccine
3121781|NCT02787057|Experimental|Control group|IP vancomycin 1g every 5 days combined with IP ceftazidime 1g QD. The duration of treatment was based on internatinal society of peritoneal dialysis (ISPD) guideline recommendations.
3121782|NCT02787057|Active Comparator|study group|IP vancomycin 1g every 5 days combined with oral moxifloxacin 400mg QD. The duration of treatment was based on ISPD guideline recommendations.
3121783|NCT02787083|Experimental|Mirabegron|These patients will receive mirabegron 50mg tablets daily for 12 weeks.
3121784|NCT02787083|Placebo Comparator|Placebo|These patients will receive placebo tablets daily for 12 weeks.
3121785|NCT02787291|Other|Ellipse VR ICD and Durata/Optisure lead|Pts with Ellipse VR ICD and Durata or Optisure RV lead implanted for at least 60 days will receive a non-diagnostic MRI scan of head and chest region
3121786|NCT02787304|Experimental|SHP626 5 Milligram (mg)|Subject will be administered 5 mg SHP626 capsule by orally once daily in a double-blinded fashion
3121787|NCT02787304|Experimental|SHP626 10 Milligram (mg)|Subject will be administered 10 mg SHP626 capsule by orally once daily in a double-blinded fashion
3121788|NCT02787304|Experimental|SHP626 20 Milligram (mg)|Subject will be administered 20 mg SHP626 capsule by orally once daily in a double-blinded fashion
3121789|NCT02787304|Placebo Comparator|Placebo (PBO)|Subject will be administered SHP626 matching PBO capsule by orally once daily in a double-blinded fashion
3121790|NCT02787551|Experimental|Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC)|"Core period: FRC injected subcutaneously once daily (QD) for 26 weeks on top of oral anti-diabetic drug (OAD) therapy. Dose individually adjusted.~Single arm extension period: Participants who completed core treatment period and met eligibility criteria entered in extension treatment period and received same treatment (FRC injected subcutaneously QD on top of OAD therapy) for 26 weeks (up to Week 52). Dose individually adjusted."
3121791|NCT02787551|Active Comparator|GLP-1 Receptor Agonist|Core period: GLP-1 RA receptor agonist (liraglutide QD, exenatide twice daily [BID], exenatide extended-release QW, albiglutide QW, or dulaglutide QW) injected subcutaneously for 26 weeks on top of OAD therapy. GLP-1 RAs were administered as per local labeling at the same dose schedule as prior to randomization.
3121792|NCT02787564|Experimental|Free Fruit and Vegetables|After baseline assessment of food intake patterns, the intervention will consist of providing free fruits and vegetables of their choice for a period of four weeks which will be provided fresh each week. At baseline and at the end of the 4-week period, a FFQ, two 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered.
3121793|NCT02787564|No Intervention|Control Goup|At baseline and at the end of the 4-week period, a FFQ, four 24h-recalls and a questionnaire on consumed fruit and vegetable variety will be administered. At the end of the intervention period they receive once a basket of free fruits and vegetables.
3121794|NCT02787655|Experimental|Aerobic Exercise + Cognitive Training Group|Exercise 3 times a week on a stationary ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes per session; plus 20 minutes of cognitive training using Mindfit program
3121795|NCT02787655|Active Comparator|Cognitive Training Only Group|Cognitive Training Only Group. For this arm of the intervention, randomized participants followed the same guidelines as the cognitive component of the AE+CT group but did not partake in aerobic exercise. To equalize contact/monitoring of the groups this group met for the same total duration time as the AE+CT group; however, instead of aerobic exercise, progressive whole body stretching and toning exercises
3121796|NCT02787681|Experimental|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
3121797|NCT02787694|Experimental|Factor Targeted Walking Training|Individuals undergo 5x 2 week periods of targeted training based upon evaluation of walking factor results
3469383|NCT03887195||students|The clinical sample is made up of 501 students (male and female) in the 4th year of medicine at Paris Descartes University, participating at the obligatory training module during the 2018-2019 academic year : this constitutes the entire population concerned by the intervention.
3469384|NCT03887221|Experimental|Safinamide 50mg|The subjects will receive 50mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
3469385|NCT03887221|Experimental|Safinamide 100mg|The subjects will receive 100mg safinamide on Day 1 of Period 1 and on Days 8 to 14 in period 2.
3121800|NCT02787863|Experimental|COPD with Prevenar-13 (1)|33 patients with COPD. Standard therapy with Prevenar-13.
3121801|NCT02787863|Experimental|Asthma with Prevenar 13 (2)|34 patients with asthma. Standard therapy with Prevenar 13.
3121802|NCT02787863|Experimental|COPD with Pneumo-23 (3)|25 patients with COPD. Standard therapy with Pneumo-23.
3121803|NCT02787863|Experimental|Asthma with Pneumo-23 (4)|25 patients with asthma. Standard therapy with Pneumo-23.
3121804|NCT02787863|Experimental|COPD with Pneumo-23/Prevenar-13 (5)|32 patients with COPD. Standard therapy, vaccinated with pneumococcal polysaccharide vaccine/pneumococcal conjugate vaccine (PPV23/PCV13).
3121805|NCT02787863|Experimental|Asthma with Pneumo-23/Prevenar-13 (6)|18 patients with Asthma. Standard therapy, vaccinated with PPV23/PCV13.
3121806|NCT02787863|Experimental|COPD with Prevenar-13/Pneumo-23 (7)|25 patients with COPD. Standard therapy, vaccinated with PCV13/PPV23.
3121807|NCT02787863|Experimental|Asthma with Prevenar-13/Pneumo-23 (8)|27 patients with Asthma. Standard therapy, vaccinated with PCV13/PPV23.
3121808|NCT02788019|Experimental|Mid-Thigh Adductor Block|Subject will receive a mid-thigh adductor block method using ropivacaine (0.5%, 15 mL).
3121809|NCT02788019|Active Comparator|Distal-Thigh Adductor Block|Subject will receive a distal-thigh adductor block method using ropivacaine (0.5%, 15 mL).
3121810|NCT02788097|Experimental|Progesterone + 4|the transfer of day 5 blastocyst on the 5th day of progesterone supplementation
3121811|NCT02788097|Active Comparator|Progesterone + 5|the transfer of day 5 blastocysts on the 6th day of progesterone supplementation
3121812|NCT02788175|Experimental|HIV-infected Adults on cART|HIV-infected Adults (age 18 - 65) on CART with suppressed viremia
3121813|NCT02788188|Experimental|Cohort 1|Cohort 1: 1mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
3121814|NCT02788188|Placebo Comparator|Placebo|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
3121815|NCT02788188|Experimental|Cohort 2|Cohort 2: 2.5 mg/kg SAB-301 in normal (9%) saline; concentration 1mg/mL (0.1%)
3121816|NCT02788188|Experimental|Cohort 3|Cohort 3: 5mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
3121817|NCT02788188|Experimental|Cohort 4|Cohort 4: 10mg/kg SAB-301 in normal (9%) saline; concentration 4mg/mL (0.4%)
3121818|NCT02788188|Experimental|Cohort 5|Cohort 5: 20mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
3121819|NCT02788188|Experimental|Cohort 6|Cohort 6: 50mg/kg SAB-301 in normal (9%) saline; concentration 20mg/mL (2%)
3121820|NCT02788201|Experimental|Treatment Regimen|Treatment regimen selected by CO eXpression ExtrapolatioN (COXEN) model
3121821|NCT02788279|Experimental|Atezolizumab|Participants will receive atezolizumab monotherapy 1200 milligrams (mg) intravenous (IV) on Day 1 in a 21-day cycle until disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
3121822|NCT02788279|Experimental|Cobimetinib + Atezolizumab|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 plus atezolizumab 840 mg IV on Day 1 and Day 15 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
3121823|NCT02788279|Active Comparator|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
3121824|NCT02788357|Experimental|Atomoxetine with motor training|40 mg atomoxetine paired with task-oriented therapy for 10 consecutive weekdays
3121825|NCT02788357|Placebo Comparator|Placebo with motor training|Placebo capsules paired with task-oriented therapy for 10 consecutive weekdays
3121826|NCT02788474|Placebo Comparator|placebo|
3121827|NCT02788474|Experimental|nintedanib|
3121828|NCT02788513|Experimental|BI 425809 dose 1|
3121829|NCT02788513|Experimental|BI 425809 dose 2|
3121830|NCT02788513|Experimental|BI 425809 dose 3|
3121831|NCT02788513|Experimental|BI 425809 dose 4|
3121832|NCT02788513|Placebo Comparator|Placebo|
3121833|NCT02788656|Experimental|Group A|Group A will receive sacubitril/valsartan + placebo for weeks 1-12. and then sacubitril/valsartan only for weeks 13-32. All subjects in Group A will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device).
3121834|NCT02788656|Active Comparator|Group B|"Group B will receive an Angiotensin-Converting Enzyme Inhibitor (ACEi) or Angiotensin II Type 1 Receptor Blocker (ARB) + placebo for weeks 1-6 (depending on previous background therapy) and then switch to sacubitril/valsartan + placebo for weeks 7-12.~Group B will then receive sacubitril/valsartan only for weeks 13-32. All subjects in Group B will also receive longitudinal pulmonary artery pressure monitoring using a previously placed implantable hemodynamic monitor (CardioMEMS device)."
3121835|NCT02788747|Experimental|4 mg elamipretide|4 mg elamipretide once daily for 28 consecutive days
3121836|NCT02788747|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
3121837|NCT02788747|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
3121838|NCT02788903||Diabetes|During year 1 of the proposed project, the investigative team will identify a valid cohort of patients with type 2 diabetes using EHR data. The cohort of patients under study will be defined as all patients age 18 and older with an indication of type 2 diabetes during the proposed study time frame (2009-2019).
3469386|NCT03887260|Active Comparator|GA group|Patients will receive general anaesthesia for nephrectomy/NSS procedures via lumbotomy. Analgesia will be provided by titration of fentanyl during surgery. An intravenous patient controlled morphine pump will be used postoperatively.
3469387|NCT03887260|Experimental|ESP group|Patients will receive general anaesthesia with ESP block for nephrectomy/NSS procedures via lumbotomy. Catheter will be inserted in the erector spinae plane on the side of surgery. Postoperatively patients will get continuous infusion of 0,125% Bupivacaine+Adrenaline to the catheter for 24h and PCA morphine pump intravenously.
3121839|NCT02788903||Pre-Diabetes|The cohort of patients under study will be defined as patients age 18 and older who are at risk for the development of diabetes, based on being overweight. Patients seen at one of the six PaTH institutions will be included in the at-risk cohort if they have a BMI ≥ 25 kg/m2, based on most recent recorded weight and at least one recorded height.
3121840|NCT02789033|Active Comparator|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
3121841|NCT02789033|Active Comparator|Isosorbide dinitrate spray|Isosorbide dinitrate spray (2.5 mg) is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate.
3121842|NCT02789033|Placebo Comparator|Placebo|Placebo in the same pharmacological presentation
3121843|NCT02789111|Active Comparator|Alvimopan|12 mg alvimopan twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
3121844|NCT02789111|Placebo Comparator|Placebo|Placebo twice a day (either by mouth or by (NG) nasogastric tube) for up to seven days post-operatively, or until the time of discharge, whichever occurs first, to a maximum of 15 doses.
3121845|NCT02789176||Outpatient Enrollees|This is a cohort of 150 subjects who were previously enrolled in the Neonatal Seizure Registry, a multi-center association of institutions across the United States, They were contacted to participate in the study after discharge from the Neonatal Intensive Care Unit (NICU) but prior to the prospective follow up. They were asked to take part in all prospective follow up surveys at 12, 18, & 24 months of age.
3121846|NCT02789176||NICU Enrollees|This is a cohort of 150 subjects who were enrolled in the study prior to discharge from the NICU. They were asked to complete surveys prior to discharge from the NICU, returned to the hospital for a 1 hour EEG to monitor brain activity between 2-4 months of age, & completed the follow surveys at 12, 18, & 24 months of age.
3121847|NCT02789410|Active Comparator|Intrathecal hydromorphone|Patients will be randomized to receive a one time dose of 75 mcg intrathecal hydromorphone as part of their spinal anesthesia.
3121848|NCT02789410|Active Comparator|Intrathecal morphine|Patients will be randomized to receive a one time dose of 150 mcg intrathecal morphine as part of their spinal anesthesia.
3121849|NCT02790073|Other|SNF472|SNF472 for calciphylaxis
3121850|NCT02790138|Placebo Comparator|Placebo IV|Vedolizumab placebo-matching intravenous (IV) infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
3121851|NCT02790138|Experimental|Vedolizumab IV 300 mg|Vedolizumab 300 mg, IV infusion, once at Day 1, Weeks 2, 6, 14, 22, and 30 along with ciprofloxacin 500 mg, tablet, orally twice daily up to Week 4.
3121852|NCT02790437|Experimental|Treatment IdeS|IdeS intravenous infusion
3121853|NCT02790463|No Intervention|Usual Care|Participants recruited in this arm will receive their usual care for gout as they normally would
3121854|NCT02790463|Active Comparator|Intervention|Participants recruited to this arm will receive their usual gout care + pharmacist-led intervention
3121855|NCT02790606|Experimental|Covera(TM) Vascular Covered Stent|Placement of the Covera Vascular Covered Stent following percutaneous transluminal angioplasty (PTA)
3121856|NCT02790736|Experimental|Propranolol|Propranolol 40 mg capsule, given once after fear activation procedure
3121857|NCT02790736|Placebo Comparator|placebo capsule|Placebo capsule, given once after fear activation procedure
3121858|NCT02790788|Experimental|Steroids Group|Intervention: Stress-dose Steroids. Patients will receive methylprednisolone 40 mg (on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation). After resuscitation, patients will be treated with stress-dose hydrocortisone 240 mg daily for 7 days maximum, followed by gradual taper over the next 2 days.
3121859|NCT02790788|Placebo Comparator|Control Group|Intervention: Saline placebo. Patients will receive saline placebo on the first, postenrollment cardiopulmonary resuscitation cycle. Otherwise, advanced life support will be conducted according to the 2015 guidelines for resuscitation. After resuscitation, patients will be treated with saline placebo for a maximum of 9 days (i.e. 7 days corresponding to the stress-dose hydrocortisone treatment of the experimental arm plus 2 days corresponding to the gradual taper of the stress-dose hydrocortisone treatment of the experimental arm).
3121860|NCT02791191|Experimental|Dose 1 LY3202626|3 mg LY3202626 given orally once daily for 52 weeks.
3121861|NCT02791191|Experimental|Dose 2 LY3202626|12 mg LY3202626 given orally once daily for 52 weeks.
3121862|NCT02791191|Experimental|Placebo|Placebo given orally once daily for 52 weeks.
3121863|NCT02791269|Experimental|HBeAg Negative Participants|HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
3121864|NCT02791269|Experimental|HBeAg Positive Participants|HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
3121865|NCT02791308|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1% (Actavis)
3121866|NCT02791308|Active Comparator|Elidel Cream, 1%|Reference listed drug: Elidel 1% cream (Valeant Pharmaceuticals North America LLC)
3121867|NCT02791308|Placebo Comparator|Vehicle Cream|Cream vehicle of the test product (Actavis)
3121868|NCT02791399|No Intervention|Control|Treatment as usual
3121869|NCT02791399|Experimental|ISOP Intervention|Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.
3121870|NCT02791438|Experimental|Azilsartan 2.5 - 20 mg (Weight < 50 kg)|Following a 2-week placebo run-in period, azilsartan 2.5 mg (titrated as needed to the highest dose of 20 mg) was administered orally once daily before or after breakfast, for the participants weighing < 50 kg.
3121871|NCT02791438|Experimental|Azilsartan 5 - 40 mg (Weight ≥ 50 kg)|Following a 2-week placebo run-in period, azilsartan 5 mg (titrated as needed to the highest dose of 40 mg) was administered orally once daily before or after breakfast, for the participants weighing ≥ 50 kg.
3121872|NCT02791490|Experimental|Sitagliptin|Participants will receive sitagliptin 100 mg once daily for 20 weeks. They will also receive immediate-release metformin (Met-IR), which will be titrated from a baseline dose of 1000 mg/day (500 mg/twice a day [b.i.d.]) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
3121873|NCT02791490|Placebo Comparator|Placebo|Participants will receive placebo matching sitagliptin once daily for 20 weeks. They will also receive Met-IR, which will be titrated from baseline dose of 1000 mg/day (500 mg/b.i.d.) up to 2000 mg/day (1000 mg/b.i.d.) by Day 15. Participants will also receive glycemic rescue therapy as needed.
3121874|NCT02791516|Placebo Comparator|Placebo|Participants received placebo subcutaneous injection once a month for 6 months.
3121875|NCT02791516|Experimental|Romosozumab|Participants received 210 mg romosozumab by subcutaneous injection once a month for 6 months.
3121876|NCT02791659|Active Comparator|Left lateral decubitus|In this group, the position will be assigned to Left lateral decubitus during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
3121877|NCT02791659|Experimental|Prone|In this group, the position will be assigned to Prone during ERCP. The radiation from fluoroscopy will be adjusted by automatic beam adjustment function to obtain the image quality.
3121878|NCT02791763|Experimental|Daprodustat in ND participants|Eligible ND participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 milligrams [mg] as recommended) dose once daily for 52 weeks.
3121879|NCT02791763|Active Comparator|Epoetin beta pegol in ND participants|Eligible ND participants will receive subcutaneous (SC) epoetin beta pegol (25, 50, 75, 100, 150, 200 or 250 microgram [µg] as recommended) dose once every 2 or 4 weeks for 52 weeks.
3121880|NCT02791763|Experimental|Daprodustat in PD participants|Eligible PD participants will receive oral daprodustat (1, 2, 4, 6, 8, 12, 18 or 24 mg as recommended) dose once daily for 52 weeks.
3121881|NCT02791893|Experimental|VNS device|Vagus Nerve Stimulation (VNS) hand held device - subjects to utilize the VNS hand held device for 20 weeks total, putting it on the skin overlying the vagus nerve in their neck and then turning it on for 120 second periods three times a day. The device is programmed to deliver only 6 bouts of stimulation per day - one to each side of the neck three times a day
3121882|NCT02791893|Placebo Comparator|Inactive device|Inactive hand held device - subjects to utilize the inactive device for 10 weeks and then will receive the VNS device for the next 10 weeks.
3121883|NCT02791906|Experimental|ISMN Only|Patients receive only ISMN
3121884|NCT02791906|Experimental|ISMN AND Vitamin C|Patients receive both ISMN and Vitamin C
3121885|NCT02791945|Experimental|N-acetylcysteine|N-acetylcysteine capsules daily - up to 3200 mg
3121886|NCT02791945|Placebo Comparator|Placebo|Placebo capsules daily - up to 3200 mg
3121887|NCT02792049|Experimental|Modified Ambu Spur II bag valve mask|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
3121888|NCT02792049|Active Comparator|Conventional Ambu Spur II bag valve mask|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model).
3121889|NCT02792062|Experimental|TAK-385 40 mg (Group A)|A single oral dose of TAK-385 40 milligram (mg) (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
3121890|NCT02792062|Experimental|TAK-385 40 mg (Group B)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
3121891|NCT02792062|Experimental|TAK-385 40 mg (Group C)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
3121892|NCT02792062|Experimental|TAK-385 40 mg (Group D)|A single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 3.
3121893|NCT02792062|Experimental|TAK-385 40 mg (Group E)|A single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 3.
3121894|NCT02792062|Experimental|TAK-385 40 mg (Group F)|A single oral dose of TAK-385 40 mg (one tablet) after breakfast in Period 1, followed by a minimum 14-day washout period between study drugs, further followed by a single oral dose of TAK-385 40 mg (one tablet) before breakfast in Period 2, followed by a minimum 14-day washout period between study drugs and, further followed by a single oral dose of TAK-385 40 mg (one tablet) in fasted condition without breakfast in Period 3.
3121895|NCT02792192|Experimental|Cohort 1A: Atezolizumab (BCG-unresponsive NMIBC)|Participants will receive atezolizumab 1200 mg IV infusion q3w, for a maximum of 32 doses or 96 weeks of therapy, whichever comes first.
3469388|NCT03887182|Experimental|confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
3121896|NCT02792192|Experimental|Cohort 1B: Atezolizumab + BCG (BCG-unresponsive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. Optional BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
3121897|NCT02792192|Experimental|Cohort 2: Atezolizumab + BCG (BCG-relapsing NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
3121898|NCT02792192|Experimental|Cohort 3: Atezolizumab + BCG (BCG-naive NMIBC)|During BCG induction course (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of six doses. During BCG maintenance course 1 (12 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of four doses plus BCG at the assigned dose weekly for a total of three doses. During BCG maintenance courses 2-5 (each 24 weeks), participants will receive atezolizumab 1200 mg IV infusion q3w for a total of eight doses per course plus BCG at the assigned dose weekly for a total of three doses per course.
3121899|NCT02792218|Experimental|OMB 20 mg|Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
3121900|NCT02792218|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
3121901|NCT02792231|Experimental|OMG 20 mg|"Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1~,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide-matching placebo, taken orally once daily"
3121902|NCT02792231|Active Comparator|TER 14 mg|Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter
3121903|NCT02792517|Experimental|Erenumab + Estrogen/Progestin Contraceptive|"Participants received a combination oral contraceptive for 3 28-day cycles during the study.~A single 140 mg dose of erenumab was administered subcutaneously to the abdomen on day 10 of cycle 3 by a healthcare provider."
3121904|NCT02792699|Experimental|ABP 798 / ABP 798|Participants received ABP 798 on days 1 and 15 (dose 1) and a second dose of ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
3121905|NCT02792699|Active Comparator|Rituximab (US) / ABP 798|Participants received rituximab (United States [US] formulation) on days 1 and 15 (dose 1) and transitioned to receive ABP 798 at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
3121906|NCT02792699|Active Comparator|Rituximab (EU) / Rituximab (EU)|Participants received rituximab (European Union [EU] formulation) on days 1 and 15 (dose 1) and a second dose of rituximab (EU formulation) at weeks 24 and 26 (dose 2). Each dose consisted of two 1000 mg intravenous infusions 2 weeks apart.
3121907|NCT02792777||Interviews|Interview participants will be recruited from 3 different care settings: an acute care visit (in the emergency department), a post-acute care visit (within 1 week of a hospital discharge), and a routine primary care visit. Target sample size within each healthcare setting is 30 patients, which is the anticipated number needed for thematic saturation. The total recruitment goal for this cohort is 90-120 participants.
3121908|NCT02792777||Concept Mapping|Concept mapping participants will be recruited from existing clinical and research databases for 3 separate concept mapping groups, each with a target of 20 patients. The total recruitment goal for this cohort is 60 people.
3121909|NCT02792829|Experimental|Lenvatinib 11 mg (suspension formulation)|"Arm 1 will have 2 sequences:~Sequence 1 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg)~Sequence 2 - Treatment Period 1: 11 mg capsules (2 capsules, 1 x 10 mg and 1 x 1 mg); Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg)"
3121910|NCT02792829|Experimental|Lenvatinib 11 mg (2 vs 5 capsules)|"Arm 2 will have 4 sequences:~Sequence 3 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg) WATER; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg) APPLE JUICE~Sequence 4 - Treatment Period 1: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER~Sequence 5 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) WATER; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) APPLE JUICE~Sequence 6 - Treatment Period 1: 11 mg suspension (2 capsules, 1 x 10 mg and 1 x 1 mg capsules) APPLE JUICE; Treatment Period 2: 11 mg suspension (5 capsules, 2 x 4 mg and 3 x 1 mg capsules) WATER"
3121911|NCT02792829|Experimental|Lenvatinib 23 mg|"Arm 3 will have 2 sequences:~Sequence 7 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation~Sequence 8 - Treatment Period 1: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 2 hours after preparation; Treatment Period 2: 23 mg suspension (5 capsules, 2 x 10 mg and 3 x 1 mg capsules) taken 23 hours after preparation"
3121912|NCT02792959|Experimental|Functional imaging|A pilot study to evaluate the response to neoadjuvant chemotherapy for advanced ovarian cancer by multimodal functional imaging (Fusion MRI and FDG-PET-CT)
3121913|NCT02793128|Experimental|UGN-101 instillations|The Mitomycin C (MMC) concentration of UGN-101 to be used in this trial will be 4 mg MMC per 1 mL of TC-3 gel, maximum dose is 15ml. 6 once weekly intravesical instillations for the ablation treatment.
3121914|NCT02793154|Experimental|Part A: Exenatide|Part A is a single arm design and all subjects will receive 10 mcg subcutaneous injection (SC) of exenatide twice daily for 5 days
3121915|NCT02793154|Experimental|Part B: Albiglutide|In Part B, half of the subjects will be randomized to receive albiglutide: On Day 1: Once weekly SC injection at 30 mg for 4 weeks From Week 5, Day 1: Dose will be increased to 50 mg once weekly SC injection for 4 weeks
3121916|NCT02793154|Active Comparator|Part B: Exenatide|"In Part B, half of the subjects will be randomized to receive exenatide: On Day 1: Twice daily SC injection at 5 mcg for 4 weeks.~From Week 5, Day 1: Dose will be uptitrated to 10 mcg twice daily SC injection for 4 weeks"
3121917|NCT02793232|Experimental|Single Ascending Dose Crossover|Single Ascending Dose in 4-way cross-over design (PF-06751979/Placebo).
3121918|NCT02793232|Experimental|Multiple Ascending Dose|Multiple dose administration to Healthy Subjects in parallel cohorts (PF-06751979).
3121919|NCT02793232|Experimental|Multiple Dose Elderly|Multiple dose administration to Healthy Elderly Subjects (PF-06751979). This cohort is optional.
3121920|NCT02793622|Active Comparator|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Women will be given SP (3 full strength tabs, 500 mg/25 mg) every four weeks times during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
3121921|NCT02793622|Active Comparator|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two drugs on day 1 (SP and placebo or DP and placebo) followed by one drug on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
3121922|NCT02793674|Other|Fisher & Paykel high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. All were measured on the Fisher & Paykel HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
3121923|NCT02793674|Other|Vapotherm high flow nasal cannula|All participants in the study were on one or two high flow nasal cannula (HFNC) delivery systems. A subgroup was measured on the Vapotherm HFNC delivery system. The flow rate of the HFNC was adjusted to determine if there exists a change in their effort of breathing.
3121924|NCT02793817|Active Comparator|KPI-121 1.0% Ophthalmic Suspension|dosed BID
3121925|NCT02793817|Placebo Comparator|Vehicle of KPI-121 Ophthalmic Suspension|dosed BID
3121926|NCT02793856|Experimental|A - Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 1 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
3121927|NCT02793856|Experimental|B- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
3121928|NCT02793856|Experimental|C- Two cycles|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 4 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Patients will receive a total of two cycles of treatment."
3121929|NCT02793947|Experimental|Peri-incisional injection|A 100 cc multimodal analgesic cocktail will be injected into the superficial and deep peri-incisional tissues after the completion of femur fracture fixation/instrumentation while the patient remains under general anesthesia and prior to wound closure. This cocktail includes 400 mg of 0.75% ropivacaine (53.33 mL), 0.6 mg of 1 mg/mL epinephrine (0.6 mL), 5 mg of 0.5 mg/mL morphine sulfate (10 mL), and 36.07 mL 0.9% sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.
3121930|NCT02793947|No Intervention|Control (no injection)|Femur fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
3121931|NCT02794103|Experimental|Virtual Reality Distraction|The child will visualize and interact with the virtual environment throughout the hydrotherapy session.
3121932|NCT02794207||Participants|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of the participant's illness and treatment. Several close-ended questions regarding participant's thoughts on potential outcomes will also be included.
3121933|NCT02794207||Caregivers|One qualitative, semi-structured interview will be conducted. Each interview will last approximately 30-45 minutes and may be audio recorded (if consent is provided). Interviews will consist of several open-ended questions focusing on having the participant reflect upon past experiences with neutropenia management and the impact of their child's illness and treatment. Several close-ended questions regarding participant's thoughts on their child's potential outcomes will also be included.
3121934|NCT02794246|Experimental|Single Arm|
3121935|NCT02794441|Experimental|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
3121936|NCT02794441|Placebo Comparator|Placebo|Matched oral solution in same volume per kg as dexamethasone
3469389|NCT03887182|Experimental|suspected not confirmed auditory processing disorders|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic
3121937|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo AZ MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily (QD) for 28 days and Placebo AZ MDI taken as two inhalations twice daily (BD) for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
3121938|NCT02794480|Experimental|Placebo AZ MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive AZ MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
3121939|NCT02794480|Experimental|Placebo ELLIPTA DPI (QD) in P1 and Placebo GSK MDI (BD) in P2|Eligible subject will receive ELLIPTA DPI taken as one inhalation once daily for 28 days and Placebo GSK MDI taken as two inhalations twice daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period.
3121940|NCT02794480|Experimental|Placebo GSK MDI (BD) in P1 and Placebo ELLIPTA DPI (QD) in P2|Eligible subject will receive GSK MDI taken as two inhalations twice daily for 28 days and Placebo ELLIPTA DPI taken as one inhalation once daily for next 28 days. Subject will continue to take asthma maintenance treatment and limited rescue albuterol MDI during the entire 56-day study period
3121941|NCT02794597|No Intervention|Opioid Medication-Assisted Treatment only|Usual care - Opioid Medication Assisted Treatment
3121942|NCT02794597|Experimental|Intervention|Peer led, behavioral sexual health intervention: Sexual Health Initiative for Navigation and Empowerment (SHINE).
3121943|NCT02794727|Sham Comparator|Blinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks but will be blinded to the monitor display.
3121944|NCT02794727|Active Comparator|Unblinded Fitbit|Subjects will wear the physical activity monitor (fitbit) for 12 weeks. They will have access to the monitor display and will have consults with study physician to set goals for the duration of the study.
3121945|NCT02794727|No Intervention|No Fitbit|Subjects will not wear any activity monitor for 12 weeks.
3121946|NCT02794766|Experimental|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion colony forming units (CFU) per oral each 12 hours for 10 days
3121947|NCT02794766|Active Comparator|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
3121948|NCT02794766|Placebo Comparator|Placebo|Placebo 1 gum per oral each 12 hours, for 10 days
3121949|NCT02794844|Experimental|Genotype Guided PPI Dosing|"Genotype Guided PPI Dosing: PI type and dosing will be recommended in real time based on patients' CYP2C19 genotype / metabolizer phenotype.~No other ARM will be studied."
3121950|NCT02794870|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants received a single dose of the RSV LID ΔM2-2 1030s vaccine at study entry (Day 0).
3121951|NCT02794870|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
3121952|NCT02794974|Experimental|with perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%) 3. perivascular block (5ml prilocaine 1%)
3121953|NCT02794974|Experimental|without perivascular block|1. ultrasound-guided intermediate cervical plexus block (20ml ropivacaine 0.75%) 2. facial nerve block (cervical branch) (5ml prilocaine 1%)
3121954|NCT02795117|Experimental|Test product|
3121955|NCT02795117|Active Comparator|Reference product|
3121956|NCT02795117|Placebo Comparator|Placebo product|
3121957|NCT02795767|Experimental|Cohort A: 1.5 mg/kg Emicizumab QW|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) QW SC for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg QW SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
3121958|NCT02795767|Experimental|Cohort B: 3 mg/kg Emicizumab Q2W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 3 mg/kg every 2 weeks (Q2W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
3121959|NCT02795767|Experimental|Cohort C: 6 mg/kg Emicizumab Q4W|Participants will receive emicizumab at a loading dose of 3 mg/kg QW SC for the first 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks (Q4W) SC for a minimum of 52 weeks, or until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria set forth in the protocol, whichever occurs first.
3121960|NCT02795780|Experimental|Follow-up Flortaucipir PET Scan|
3121961|NCT02795819|Experimental|Cohort minus 1 (-1)|Participants take 10 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
3121962|NCT02795819|Experimental|Cohort 1|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
3121963|NCT02795819|Experimental|Cohort 2|Participants take 20 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
3121964|NCT02795819|Experimental|Cohort 3A|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
3121965|NCT02795819|Experimental|Cohort 3B|Participants take 30 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
3121966|NCT02795819|Experimental|Cohort 4A|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 800mg orally daily continuously
3121967|NCT02795819|Experimental|Cohort 4B|Participants take 40 mg AR-42 orally per day on 3 non-consecutive days during the 1st 3 weeks of each 4-week cycle and pazopanib 600mg orally daily continuously
3121968|NCT02795832|Experimental|Cohort 1a|ZPL-5212372 1% w/w Ointment BID
3121969|NCT02795832|Placebo Comparator|Cohort 1b|Placebo Ointment BID
3121970|NCT02795832|Experimental|Cohort 2a|ZPL-5212372 1% w/w Ointment BID
3121971|NCT02795832|Placebo Comparator|Cohort 2b|Placebo Ointment BID
3121972|NCT02795832|Experimental|Cohort 3a|ZPL-5212372 1% w/w OIntment BID
3121973|NCT02795832|Placebo Comparator|Cohort 3b|Placebo Ointment BID
3121974|NCT02796092|Active Comparator|Fibered platinum coils|Embolization of the pelvic veins with platinum fibered coils (Nester. Cook Europe, Bjaeverskov, Denmark)
3121975|NCT02796092|Experimental|Vascular plugs|Embolization of the pelvic veins with vascular plugs (Amplatzer Vascular Plugs II. St. Jude Medical. St. Paul, MN, USA)
3121976|NCT02796144|Active Comparator|Lorcaserin and Metformin|"Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.~Metformin will be administered in dosages of 500 mg with a maximum dose of 2,000 mg."
3121977|NCT02796144|Active Comparator|Lorcaserin|Lorcaserin will be administered in dosages of 10 mg with a maximum dose of 20 mg.
3121978|NCT02796144|Placebo Comparator|Placebo|Matching placebos will be administered for each active drug.
3121979|NCT02796300|Active Comparator|Bioflo Goup|This group will have dialysis using the Bioflo catheter.
3121980|NCT02796300|Active Comparator|Palindrome Group|This group will have dialysis using the Palindrome catheter.
3121981|NCT02796352|Experimental|High dose bolus interleukin-2 (HD IL2)|
3121982|NCT02796560|Experimental|Brand name travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
3121983|NCT02796560|Experimental|Generic travoprost|Patients will be randomized to either start in this arm for the first 3 weeks before the crossover to the other arm for the second 3 weeks or they will start in the other arm for the first 3 weeks before the crossover to this arm for the second 3 weeks.
3121984|NCT02796625|Experimental|Painful Stimuli|Participants will be exposed to painful heat
3121985|NCT02796651|Experimental|Formoterol 6 μg|Participants received formoterol fumarate 6 μg administered via Pressair twice daily (BID).
3121986|NCT02796651|Experimental|Formoterol 12 μg|Participants received formoterol fumarate 12 μg administered via Pressair BID.
3121987|NCT02796651|Experimental|Formoterol 24 μg|Participants received formoterol fumarate 24 μg administered via Pressair BID.
3121988|NCT02796651|Placebo Comparator|Placebo|Participants received placebo to formoterol fumarate administered via Pressair BID.
3121989|NCT02796651|Experimental|Formoterol 20 μg|Participants received Perforomist inhalation solution and were instructed to take one puff from each of the two Pressair inhalers or to inhale one vial from the Perforomist 20 μg inhalation solution BID for 7 ± 1 consecutive days.
3121990|NCT02796651|Experimental|Formoterol 40 μg|Participants received Perforomist 40 μg (2 vials of Performist 20 μg) as a single dose of administration.
3121991|NCT02796664|Experimental|Ginseng|
3121992|NCT02796664|Placebo Comparator|Placebo|
3121993|NCT02796677|Experimental|AB/FF 400/12 μg BID|Participants were administered AB/FF 400/12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
3121994|NCT02796677|Experimental|AB 400 μg BID|Participants were administered AB 400 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
3121995|NCT02796677|Experimental|FF 12 μg BID|Participants were administered FF 12 μg via Pressair®/Genuair® inhaler twice daily for 24 weeks of treatment.
3121996|NCT02796677|Experimental|TIO 18 μg QD|Participants were administered TIO 18 μg via Handihaler® inhale once daily for 24 weeks of treatment.
3121997|NCT02796755|Experimental|Riluzole Arm|Participants will take a daily oral dose of 100 mg of riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
3121998|NCT02796755|Placebo Comparator|Placebo Arm|Participants will take a daily oral dose of 100 mg of a placebo that appears identical to riluzole (50 mg two times per day). Participants will be instructed to take the study medication on an empty stomach (1 hour before or 2 hours after meals).
3121999|NCT02796924|Experimental|Patients|30 sessions of high-frequency (20Hz) repetitive stimulation applied over the right temporal-parietal junction in patients with psychogenic non-epileptic seizures using a MagStim Rapid2 Transcranial Magnetic Simulation machine.
3122000|NCT02796963|Experimental|Immediate Intervention|Men will be exposed immediately to a comprehensive intervention promoting HIV testing.
3122001|NCT02796963|Experimental|Delayed Intervention|Men will be exposed to a comprehensive intervention promoting HIV testing after a delay period.
3122002|NCT02797054|Experimental|Tailored Intervention|Intervention: tailored educational materials. In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
3122003|NCT02797054|Other|Untailored Intervention|Intervention: untailored educational materials. In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
3122004|NCT02797054|Other|Usual Care|Intervention: usual care as experienced during appointment with primary care provider. Participants in the usual care arm will not view any educational materials or complete the baseline survey.
3122005|NCT02797080|Experimental|interferon γ-1b|ACTIMMUNE® will be administered 3 times per week (TIW) by subcutaneous (SC) injection.
3122006|NCT02797132|Experimental|Lumacaftor/Ivacaftor (LUM/IVA)|"Part A (<14 kg): Participants weighing less than (<) 14 kilograms (kg) at screening received LUM 100 milligram (mg)/IVA 125 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part A (>=14 kg): Participants weighing greater than or equal to (>=) 14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 15 days in Part A.~Part B (<14 kg): Participants weighing <14 kg at screening received LUM 100 mg/IVA 125 mg fixed-dose combination every 12 hours for 24 weeks in Part B.~Part B (>=14 kg): Participants weighing >=14 kg at screening received LUM 150 mg/IVA 188 mg fixed-dose combination every 12 hours for 24 weeks in Part B."
3122007|NCT02797171|Experimental|Group 1|Participants will receive 10 mg/kg of VRC01 at Months 0, 2, 4, and 6.
3122008|NCT02797171|Experimental|Group 2|Participants will receive 30 mg/kg of VRC01 at Months 0, 2, 4, and 6.
3122009|NCT02797171|Experimental|Group 3|Participants will receive 30 mg/kg of VRC01LS at Months 0, 3, and 6.
3122010|NCT02797171|Experimental|Group 4|Participants will receive 30 mg/kg of VRC01 at Month 0.
3122011|NCT02797171|Experimental|Group 5|Participants will receive 30 mg/kg of VRC01LS at Month 0.
3122012|NCT02797522|Experimental|NHV Participants: Cohort 1|NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.
3122013|NCT02797522|Experimental|NHV Participants: Cohort 2|NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.
3122014|NCT02797522|Experimental|NHV Participants: Cohort 3|NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.
3122015|NCT02797522|Experimental|NHV Participants: Cohort 4|NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.
3122016|NCT02797522|Experimental|NHV Participants: Cohort 5|NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.
3122017|NCT02797522|Experimental|NHV Participants: Cohort 6|NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.
3122018|NCT02797522|Placebo Comparator|NHV Participants: Placebo|NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.
3122019|NCT02797522|Experimental|CHB Participants: Cohort 3b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
3122020|NCT02797522|Experimental|CHB Participants: Cohort 4b|Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).
3122021|NCT02797522|Experimental|CHB Participants: Cohort 3c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.
3122022|NCT02797522|Experimental|CHB Participants: Cohort 4c|Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.
3122023|NCT02797613|Experimental|Restricted Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
3122024|NCT02797613|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
3122025|NCT02797678|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week. Participants will then be crossed over and will wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week
3122026|NCT02797678|Sham Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers for one week. Participants will then wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night for one week.
3122027|NCT02797808|Experimental|Children with OCD|Children with obsessive compulsive disorder, not currently on medication for OCD
3122028|NCT02797808|Active Comparator|Healthy Control Children|Children without obsessive compulsive disorder
3122029|NCT02797821|Experimental|Asfotase Alfa 0.5 mg/kg Dose|Participants received 0.5 milligrams (mg) per kilogram (kg) of asfotase alfa administered subcutaneously (SC) 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
3122030|NCT02797821|Experimental|Asfotase Alfa 2.0 mg/kg Dose|Participants received 2.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
3122031|NCT02797821|Experimental|Asfotase Alfa 3.0 mg/kg Dose|Participants received 3.0 mg/kg of asfotase alfa administered SC 3 times a week from Weeks 3 through 9 following the initial single dose on Day 1 in Week 1.
3122032|NCT02798211|Active Comparator|Group 1|secukinumab 300mg s.c. injection
3122033|NCT02798211|Active Comparator|Group 2|secukinumab 150 mg s.c. injection
3122034|NCT02798211|Placebo Comparator|Group 3|Placebo s.c. injection
3122035|NCT02798289|Experimental|Active - Device|The Oculeve Intranasal Neurostimulator will be administered once to induce aqueous tear production once following study enrollment.
3122036|NCT02798315||Participants With Hepatitis C Virus (HCV) Genotype 1 or 4|"Participants with HCV genotype 1 or 4 receiving paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± RBV.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
3122037|NCT02798354|Experimental|Reduce Elevated Blood Pressure Errors First|"Will provide baseline data on elevated blood pressure diagnosis and first intervene to reduce missed opportunities for elevated blood pressure diagnosis. Will then intervene to reduce missed opportunities for depression diagnosis and finally, intervene to reduce delayed diagnosis attributable to abnormal laboratory values.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
3122038|NCT02798354|Experimental|Reduce Depression Errors First|"Will provide baseline data on depression diagnosis and first intervene to reduce missed opportunities for depression diagnosis. Will then intervene to reduce delayed diagnosis attributable to abnormal laboratory values and finally, intervene to reduce missed opportunities for elevated blood pressure diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
3122039|NCT02798354|Experimental|Reduce Lab Related Errors First|"Will provide baseline data on delayed diagnosis attributable to abnormal laboratory values and first intervene to reduce delayed diagnosis attributable to abnormal laboratory values. Will then intervene to reduce missed opportunities for elevated blood pressure diagnosis results and finally, to reduce missed opportunities for depression diagnosis.~Quality Improvement Collaborative Intervention will consist of behavioral components, i.e., training, interactions with experts, root cause analyses of errors, idea sharing, best practices dissemination, etc."
3122040|NCT02798380|Experimental|HTS-519 Insert|Active treatment
3469390|NCT03887182|Active Comparator|healthy volunteers|functional MRI, Cortical Brainstem Auditory Evoked Potential, Genetic, multidisciplinary consultation
3469391|NCT03887156|Other|Arm 1|One arm
3122041|NCT02798627|Experimental|NS2359|The initial dose of the NS2359 will be two mg once daily. Patients with difficult adverse events at the 2 mg dose will be allowed to reduce to 1 mg once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
3122042|NCT02798627|Placebo Comparator|placebo|Placebo pills matched to NS2359 pills will be given once daily. Patients with difficult adverse events at the 2 mg placebo will be allowed to reduce to 1 mg placebo once daily. Subjects will participate in weekly cognitive behavioral relapse prevention psychotherapy from week 2 through week 9.
3122043|NCT02798835|Active Comparator|Adductor Canal block|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
3122044|NCT02798835|Active Comparator|Adductor canal block with dexamethasone|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
3122045|NCT02798835|Active Comparator|Adductor canal catheter|Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.
3122046|NCT02798861||CAP assessment|Controlled Attenuation Parameter with Fibroscan 402/530 before liver procurement and after liver transplantation to assess steatosis, and its association with clinical outcomes
3122047|NCT02798952|Experimental|HBV Group|Subjects received a single challenge dose of Engerix-B Kinder.
3122048|NCT02798978|Experimental|Part 1: GSK1795091 or Placebo|In Part 1, subjects in sequential cohorts will receive single ascending doses of intravenous (IV) injection of GSK1795091 or matching placebo, with a starting dose of 7 nanogram (ng), on Day 1 until the highest dose is evaluated.
3122049|NCT02798978|Experimental|Part 2 Cohort 1: GSK1795091|In Part 2 Cohort 1, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and second dose on Day 8 (one week apart)
3122050|NCT02798978|Experimental|Part 2 Cohort 2: GSK1795091|In Part 2 Cohort 2, subjects will receive IV injection of GSK1795091 on Day 1, at dose determined in part 1, and a second dose on Day 15 (two weeks apart)
3122051|NCT02799069|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
3122052|NCT02799069|Active Comparator|MAL Cream|Topical application of MAL cream (Metvix) containing 160 mg/g methyl-aminolevulinate (MAL). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
3122053|NCT02799069|Placebo Comparator|Vehicle|Topical application of matched Placebo to BF-200 ALA gel (without containing active ingredient) ). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1 cm surrounding margin.
3122054|NCT02799082|Placebo Comparator|Vehicle|Topical application of matched placebo gel (without containing active ingredient). Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
3122055|NCT02799082|Active Comparator|BF-200 ALA|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and a 0.5 cm to 1.0 cm surrounding margin.
3122056|NCT02799290|No Intervention|CONTROL|No intervention
3122057|NCT02799290|Experimental|ADIPOSE TISSUE EXTRACT|Adipose Tissue extract application
3122058|NCT02799290|Experimental|PLATELET-RICH PLASMA GEL|PLATELET RICH PLASMA GEL APPLICATION
3122059|NCT02799381|Active Comparator|Optimized Medical Treatment (OMT)|Participants randomized to OMT continued their current anti Parkinson's disease (anti-PD) medication regimen for the duration of the study. All anti-PD medications and medications to treat dyskinesia must have remained stable for the duration of the study unless adjustments were medically indicated. The Investigator provided the prescription for continued OMT.
3122060|NCT02799381|Experimental|Levodopa-Carbidopa Intestinal Gel (LCIG)|The total daily dose of infusion LCIG was composed of three components: (i) the morning dose, (ii) continuous maintenance infusion dose and (iii) extra doses. A temporary nasojejunal (NJ) tube may have been used initially with the infusion pump to determine a participant's response to this method of treatment and to optimize the dose of LCIG before treatment with a permanent percutaneous endoscopic gastrostomy - with jejunal extension (PEG-J) tube was started. Following optional NJ and/or PEG-J placement and, at the investigator's discretion, the participant may have begun initiation and titration of LCIG infusion on Day 1 once tube placement was confirmed. The dose of LCIG was adjusted to obtain the optimal clinical response. The rate of LCIG infusion is typically within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances and runs over a period of 16 consecutive hours each day.
3122061|NCT02799472|Experimental|GSK3196165 + MTX arm|Subjects will receive GSK3196165 (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
3122062|NCT02799472|Placebo Comparator|Placebo + MTX arm|Subjects will receive placebo (initially weekly, then every other week) in combination with MTX (15-25 mg/week) and folic (or folinic) acid (>=5 mg/week).
3122063|NCT02799667|Active Comparator|Standard Dressing|Women will be randomized to receive the standard dressing (sterile gauze, non absorbent sterile gauze, and a waterproof bandage) at the time of fascial closure in a cesarean delivery.
3122064|NCT02799667|Experimental|Negative Pressure Wound Therapy Dressing|Women will be randomized to receive the Negative Pressure Wound Therapy (NPWT) dressing at the time of fascial closure in a cesarean delivery.
3122065|NCT02799745|Active Comparator|Enzalutamide|Participants received 160-milligrams (mg) enzalutamide administered as four 40-mg capsules, orally once daily for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow-up period, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
3122066|NCT02799745|Other|Active Surveillance (AS)|Participants did not receive any study treatment in this arm but were on continued active surveillance (AS) for 1 year of treatment period. Following the 1-year treatment period, all participants were followed for 1 additional year. Post the 1-year follow up, participants then started the continued follow-up period, in which, participants were followed up every 3 months for these 2 years, after which follow-up was either every 6 months up to 36 months or until the end of study (total duration of follow up in the study was approximately up to 35.9 months).
3122067|NCT02799784|Experimental|Sequence 1: UMEC/VI 62.5/ 25 mcg|Subjects will receive UMEC/VI 62.5/25 mcg (as one inhalation) administered QD via the ELLIPTA Inhaler for 8 weeks followed by a washout period of 3 weeks
3122068|NCT02799784|Experimental|Sequence 2: TIO/OLO 5/5 mcg|Subjects will receive TIO/OLO 5/5 mcg (as 2 inhalations of 2.5/2.5 mcg per inhalation) administered QD via the RESPIMAT inhaler for 8 weeks followed by a washout period of 3 weeks
3122069|NCT02800148|Experimental|Azelaic acid foam|
3122070|NCT02800148|Active Comparator|Finacea Foam|
3122071|NCT02800148|Placebo Comparator|Placebo Foam|
3122072|NCT02800213|Experimental|Modified Ambu Spur II bag mask first|A health volunteer uses a modified Ambu Spur II bag valve mask with integrated internal handle (experimental device, not yet FDA approved) to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a conventional Ambu Spur II bag valve mask.
3122073|NCT02800213|Active Comparator|Conventional Ambu Spur II bag mask first|A health volunteer uses a conventional Ambu Spur II bag valve mask to deliver 10 breaths per minute for 3 minutes to a manikin (IngMar RespiTrainer manikin model). Volunteer then repeats the procedures using a modified Ambu Spur II bag valve mask.
3122074|NCT02800356|Experimental|Pseudodrusen|Subthreshold 577 nm yellow wavelength laser photo-coagulator
3122075|NCT02800356|Experimental|Geographic atrophy|Subthreshold 577 nm yellow wavelength laser photo-coagulator
3122076|NCT02800642|Experimental|Intravitreal (IVT) aflibercept|Participants with macular edema secondary to CRVO were treated with the study drug intravitreal aflibercept
3122077|NCT02800928|Experimental|CERC-501|Administered orally once daily, 10mg daily, 8 days
3122078|NCT02800928|Placebo Comparator|Placebo|Administered orally daily, 8 days
3122079|NCT02801006|Experimental|stenfilcon A|Participants will be randomized to wear stenfilcon A lens pair for two weeks during the cross over study.
3122080|NCT02801006|Active Comparator|etafilcon A|Participants will be randomized to wear etafilcon A lens pair for two weeks during the cross over study.
3122081|NCT02801370|Experimental|OTO-201|
3122082|NCT02801370|Sham Comparator|Control|
3122083|NCT02801396|Active Comparator|Group Sequence A, B, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122084|NCT02801396|Active Comparator|Group Sequence B, C, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122085|NCT02801396|Active Comparator|Group Sequence C, A, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122086|NCT02801396|Active Comparator|Group Sequence C, B, A|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122087|NCT02801396|Active Comparator|Group Sequence A, C, B|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122088|NCT02801396|Active Comparator|Group Sequence B, A, C|Subjects will wear Test 1, Test 2, and Control contact lenses in order according to the randomization sequence assigned for approximately 30-60 minutes each, with a 5-minute wash-out period between lenses.
3122089|NCT02801578|Experimental|Ibrutinib|"Participants take Ibrutinib capsules by mouth every day for 3, 28 day cycles.~During Cycle 1, participants receive the highest dose of Ibrutinib by taking 3 capsules each day. During Cycle 2, participants receive the second-highest dose and will take 2 capsules each day. During Cycle 3, participant takes the lowest dose of Ibrutinib and takes 1 capsule each day."
3122090|NCT02801617|Experimental|Sequence 1 (PRO-067)|"study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
3122091|NCT02801617|Active Comparator|Sequence 2 (GAAP Ofteno®)|"study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours"
3122092|NCT02801669|Experimental|DU-176b 15 mg group|DU-176b orally administered at a dose of 15 mg once daily.
3122093|NCT02801669|Placebo Comparator|Placebo group|Placebo orally administered once daily.
3122094|NCT02801877|Experimental|IntelliCare Hub recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and receive coaching for the 8 week IntelliCare program.
3122095|NCT02801877|Experimental|IntelliCare Hub recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App with the recommender system, and independently use the IntelliCare program for 8 weeks.
3122096|NCT02801877|Experimental|IntelliCare Hub no recommender, coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and receive coaching for the 8 week IntelliCare program.
3469392|NCT03887169|Experimental|Methionine|
3122097|NCT02801877|Experimental|IntelliCare Hub no recommender, no coach|Participant is randomly assigned to receive the IntelliCare Hub App without the recommender system, and independently use the IntelliCare program for 8 weeks.
3122098|NCT02801942|Experimental|Healthy subjects|Up to 30 mL of blood sample will be collected from healthy subjects. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, Human Leukocyte antigen D related (HLA-DR) and forkhead box P3 protein also called scurfin (FOXP3).
3469393|NCT03887130|Experimental|Vinorelbine-Capecitabine (arm A)|oral vinorelbine (OV) with capecitabine (CAP)
3469394|NCT03887130|Active Comparator|Gemcitabine-Paclitaxel (arm B)|gemcitabine (GEM) in combination with paclitaxel (PAC)
3122099|NCT02801942|Experimental|Subjects with NOT1D|Up to 30 mL of blood sample will be collected from subjects with NOT1D. Inguinal lymph node fine needle aspirate biopsy and core biopsy will be performed. Leukocyte subset phenotyping will be carried out on iLN-derived cells by assessing expression of (but not restricted to) the following antigens: CD3, CD4, CD8, CD11c, CD14, CD16, CD19, CD24, CD25, CD38, CD45RA, CD56, HLA-DR and FOXP3.
3122100|NCT02802111|Experimental|Albuterol 5 mg first, then levalbuterol 2.5 mg|Patient receives albuterol 5 mg aerosolized first and then 4 hours or greater after receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
3122101|NCT02802111|Experimental|Levalbuterol 2.5 mg first, then albuterol 5 mg|Patient receives levalbuterol 2.5 mg aerosolized first and then 4 hours or greater after receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
3122102|NCT02802241|Experimental|open-label placebo|
3122103|NCT02802241|Experimental|double-blind placebo|
3122104|NCT02802241|Experimental|double-blind peppermint oil|
3122105|NCT02802241|No Intervention|no additional treatment|
3122106|NCT02802319|Experimental|Test: Porcine Xenograft (Zcore)|Ridge preservation bone grafting surgery with porcine xenograft (Zcore)
3122107|NCT02802319|Active Comparator|Active Control: Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting surgery with bovine xenograft (Bio-Oss)
3122108|NCT02802345|Experimental|Nintedanib + placebo matching sildenafil|
3122109|NCT02802345|Active Comparator|Nintedanib + Sildenafil|
3122110|NCT02802449|Placebo Comparator|Placebo|The participant will be randomized to receive two tablets of Placebo (microcrystalline cellulose) to take under direct observation at the baseline and week 2 visit.
3122111|NCT02802449|Active Comparator|25 hydroxy-Vitamin D3 or [25 (OH) D3]|The participant will be randomized to receive two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] to take under direct observation at the baseline and week 2 visit.
3122112|NCT02802501|Experimental|DHA-PQP plus tafenoquine 300 mg single dose|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to the body weight) from Day 1 to Day 3. They will receive double-blind 300 mg single dose of tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
3122113|NCT02802501|Active Comparator|DHA-PQP plus primaquine 15 mg for 14 days|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind 15 mg primaquine (PQ) from Day 1 to Day 14 and matched-placebo for tafenoquine (TQ) on Day 1.
3122114|NCT02802501|Placebo Comparator|DHA-PQP alone (placebo arm)|Subjects will receive open label DHA-PQP, 3 or 4 tablets per day (according to body weight) from Day 1 to Day 3. They will receive double-blind matched-placebo for tafenoquine (TQ) on Day 1 and matched-placebo for primaquine (PQ) from Day 1 to Day 14.
3122115|NCT02802514|Experimental|With Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will undergo off-therapy MRI scan Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI. In session 2, subject will receive single dose each of albiglutide placebo on Day 1 (Week 9) and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
3122116|NCT02802514|Experimental|Without Off therapy MRI in S1:Albiglutide-S1 & Exenatide-S2|In session 1, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 and exenatide placebo on Day 4 followed by a post-dose MRI scan. In session 2, Day 1 (Week 9) subject will undergo off-therapy MRI scan. Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
3122117|NCT02802514|Experimental|With Off therapy MRI in S1:Exenatide-S1 & Albiglutide-S2|In session 1, Day 1 subject will undergo off-therapy MRI scan Subject will receive single dose each of albiglutide placebo on Day 5 and 10 microgram of exenatide on Day 8 followed by a post-dose MRI scan In session 2, eligible subject will receive single dose each of 50 mg albiglutide on Day 1 (Week 9) and exenatide placebo Day 4 followed by a post-dose MRI scan. There will be 6-9 week washout period between Session 1 and Session 2
3122118|NCT02802514|Experimental|Without Off therapy MRI in S1: Exenatide-S1 & Albiglutide-S2|In session 1, subject will receive single dose each of albiglutide placebo on Day 1 and 10 microgram exenatide on Day 4 followed by a post-dose MRI scan. In session 2, subject will undergo off-therapy MRI scan on Day 1 (Week 9). Subject will receive single dose each of 50 mg albiglutide on Day 5 and exenatide placebo on Day 8 followed by a post-dose MRI scan.. There will be 6-9 week washout period between Session 1 and Session 2
3122119|NCT02802735|Experimental|Part 1: Apremilast 20 mg|A single oral dose of 20 mg apremilast.
3122120|NCT02802735|Experimental|Part 1: Apremilast 30 mg|A single oral dose of 30 mg apremilast.
3122121|NCT02802735|Experimental|Part 1: Apremilast 40 mg|A single oral dose of 40 mg apremilast.
3122122|NCT02802735|Experimental|Part 2: Apremilast 30 mg BID|30 mg apremilast orally twice a day (BID) for 14 days.
3122123|NCT02802735|Placebo Comparator|Part 2: Placebo|Matching placebo orally twice a day for 14 days.
3122124|NCT02802865|Active Comparator|Letrozole|Letrozole 2.5 mg orally for 5 days on cycle days 3-7
3122125|NCT02802865|Experimental|Letrozole + Clomiphene|Letrozole 2.5 mg orally for 5 days on cycle days 3-7 AND Clomid 50 mg orally for 5 days on cycle days 3-7
3122126|NCT02802878|Experimental|Hybrid Training|"The hybrid training system combines the applications of neuromuscular electrical stimulation (NMES) with voluntary contractions (NMES-VC). Training will be performed in a seated position with feet not touching the ground, and will involve each knee flexing and extending alternately. The joint range of motion will be restricted to a 90º arc from approximately 10º to 100º of flexion. Each session will consist of 5 sets of 10 repetitions, 3-second knee flexion and extension contractions on each leg. Sets will be separated by 30-sec rest intervals.~Electrodes will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and over the medial and lateral hamstrings on the posterior thigh. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM). A joint motion sensor will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
3122127|NCT02802878|Active Comparator|Low Intensity Exercise|40% 1-repetition maximum isokinetic training with HUMAC NORM in same repetitions/sets as experimental group.
3122128|NCT02803138||Participants with HCV genotype 1 or 4|Ombitasvir/paritaprevir/ritonavir (two 12.5 mg/75 mg/50 mg co-formulated tablets once daily); ± dasabuvir (tablet; 250 mg twice daily); ± weight-based ribavirin (tablets; 1000 or 1200 mg divided twice a day) up to 24 weeks
3122129|NCT02803164|Other|Vacuum-assisted dressing|Eligible subjects will receive negative pressure wound therapy during surgery.
3122130|NCT02803164|Other|Historical control group for comparison|Retrospective review of subjects medical records with open chest wounds who were treated with the traditional treatment techniques.
3122131|NCT02803229|Placebo Comparator|Placebo|matched Placebo arm
3122132|NCT02803229|Experimental|Adderall-XR|Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose
3122133|NCT02803749|Experimental|Buspirone|Flexible dosage buspirone (maximum dosage 30 mg twice daily) for 12 weeks.
3122134|NCT02803749|Placebo Comparator|Placebo|Flexible dosage placebo for 12 weeks.
3122135|NCT02804178|Experimental|ATR-101|Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.
3122136|NCT02804399|Experimental|all subjects|subjects will receive a 100 mg single oral dose of PF-06463922 followed by a 100 mg single dose of PF-06463922 combined with 600 mg QD dose of rifampin with at least 10 days of washout period between two PF-06463922 doses.
3122137|NCT02804594|Active Comparator|N-acetyl cysteine|1250 mg of N-acetyl cysteine three times daily
3122138|NCT02804594|Placebo Comparator|Placebo|placebo three times daily
3122139|NCT02804750|Experimental|Group 1: Low-dose Group|100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
3122140|NCT02804750|Experimental|Group 2: High-dose Group|250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.
3122141|NCT02804763|Placebo Comparator|Placebo|Placebo in a specified sequence for a total of 24 weeks
3122142|NCT02804763|Experimental|DZP dose 1|Dapirolizumab pegol (DZP) dose 1 in a specified sequence for a total of 24 weeks
3122143|NCT02804763|Experimental|DZP dose 2|Dapirolizumab pegol (DZP) dose 2 in a specified sequence for a total of 24 weeks
3122144|NCT02804763|Experimental|DZP dose 3|Dapirolizumab pegol (DZP) dose 3 in a specified sequence for a total of 24 weeks
3122145|NCT02805179|Experimental|High Dose Chemoradiation|Patients will receive high dose radiation based in part on advanced imaging, and concurrent temozolomide. Four weeks after the completion of chemoradiation, patients will receive adjuvant temozolomide.
3122146|NCT02805309|Experimental|Exercise & Cognitive Behavioral Int.|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program and cognitive behavioral interventions.
3122147|NCT02805309|Experimental|Exercise Alone|A physical therapist will make home visits, beginning within 1 week of discharge, to deliver an individualized exercise program, without cognitive behavioral interventions.
3122148|NCT02805309|Active Comparator|Attention Control Education Program|Participants will receive telephone-based education sessions from a study health professional.
3122149|NCT02805647||Fracture/study group|The study group consisted of 100 children aged 3 to 18 years (78% boys) hospitalized in the Department of Pediatric Orthopedics in 2011-2013 due to low-energy fractures
3122150|NCT02805647||Control group|The control group (122 children, 68% boys) consisted of children aged 3 to 17 years, hospitalized for other reasons (injuries, diagnosis of knee ligament injuries and others) without fractures
3122151|NCT02805660|Experimental|Phase 1: Dose Escalation - 50 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
3122152|NCT02805660|Experimental|Phase 1: Dose Escalation - 70 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
3122153|NCT02805660|Experimental|Phase 1: Dose Escalation - 90 mg|The Phase 1 dose escalation established the recommended phase 2 dose (RP2D) of mocetinostat. Participants with advanced solid tumors were included in this Phase.
3122154|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 1|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with no/low programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
3122155|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 2|Participants with non-small cell lung cancer (NSCLC) who were naïve to treatment with immunotherapy, and had a tumor with high programmed cell death ligand 1 (PD-L1) expression were included in this cohort.
3122156|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 3|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent with clinical benefit response followed by progression of disease were included in this cohort.
3122157|NCT02805660|Experimental|Phase 2: Combination Regimen - Cohort 4|Participants with non-small cell lung cancer (NSCLC) who have been previously treated with an anti-programmed cell death ligand 1 (PD-L1) or anti-programmed cell death 1 (PD-1) agent who had progression of disease ≤ 16 weeks after initiation of treatment were included in this cohort.
3122158|NCT02805790|Experimental|Elamipretide, Then Placebo|Participants first received 40 mg of elamipretide once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received placebo administered once daily subcutaneously for 4 weeks.
3122159|NCT02805790|Placebo Comparator|Placebo, Then Elamipretide|Participants first received placebo once daily subcutaneously for 4 weeks. After a washout period of 4 weeks, they then received 40 mg of elamipretide once daily subcutaneously for 4 weeks.
3122160|NCT02805907|Experimental|Intervention Group (IG)|Calcifediol (Hidroferol®) in 16,000-IU ampoules taken weekly by the oral route
3122161|NCT02805907|Placebo Comparator|Control Group (CG)|Placebo in a presentation with an identical appearance taken weekly by the oral route
3122162|NCT02805972|Experimental|Naloxone, then Placebo|4 mg / 0.1 ml Naloxone at visit 1, followed by 0.1 ml saline (Placebo) at visit 2 (with a washout period in between the two visits)
3122163|NCT02805972|Experimental|Placebo, then Naloxone|0.1 ml saline (Placebo) at visit 1, followed by 4 mg / 0.1 ml Naloxone at visit 2 (with a washout period in between the two visits)
3122164|NCT02806024|Experimental|Treatment Arm (Tranexamic Acid, or TXA)|Patients will be randomized to treatment or placebo arms preoperatively. In our treatment arm of pregnant patients with suspected placenta accreta or at high risk for placenta accreta, patients will receive 1 gram intravenous TXA administered over 10 minutes immediately after delivery of the infant. The drug will be prepared and ready to hang at the beginning of the case. The study drug will be administered only once.
3122165|NCT02806024|Placebo Comparator|Placebo Arm|Patients will be randomized to treatment or placebo arms preoperatively. In our placebo arm of pregnant patients with suspected placenta accreta, patients will receive plain normal saline in a 50 cc bag identical to the preparation of study drug immediately after delivery of the infant.
3122166|NCT02806232|Experimental|Part 1, Cohort 1: Biltricide (racemate praziquantel) 20 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 20 milligram per kilogram (mg/kg), three times a day on treatment Day 1.
3122167|NCT02806232|Experimental|Part 1, Cohort 2: Biltricide (racemate praziquantel) 40 mg/kg|Participants received Biltricide (600 mg tablet) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
3122168|NCT02806232|Experimental|Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg|Participants received Racemate Praziquantel oral dispersible tablet (ODT) (150 mg) administered orally at a dose of 40 mg/kg as a single dose on treatment Day 1.
3122169|NCT02806232|Experimental|Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg|Participants received Racemate Praziquantel ODT (150 mg) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
3122170|NCT02806232|Experimental|Part 1, Cohort 5: Levo Praziquantel 30 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 30 mg/kg as a single dose on treatment Day 1.
3122171|NCT02806232|Experimental|Part 1, Cohort 6: Levo Praziquantel 45 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 45 mg/kg as a single dose on treatment Day 1.
3122172|NCT02806232|Experimental|Part 1, Cohort 7: Levo Praziquantel 60 mg/kg|Participants received Levo Praziquantel ODT (150 mg tablet) administered orally at a dose of 60 mg/kg as a single dose on treatment Day 1.
3122173|NCT02806232|Experimental|Part 2, Cohort 8: Levo Praziquantel 50 mg/kg|Participants aged 13-24 months months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
3122174|NCT02806232|Experimental|Part 2, Cohort 9: Levo Praziquantel 50 mg/kg|Participants aged 3 to 12 months received Levo Praziquantel ODT (150 mg) administered orally at a dose of 50 mg/kg as a single dose on treatment day 1.
3122175|NCT02806414|Experimental|Ivermectin|All subjects will be treated with topical ivermectin daily for up to 12 weeks.
3122176|NCT02806505|Experimental|Peginterferon alfa-2a 135 microgram (mcg)|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 135 mcg subcutaneously (SC) once weekly up to Week 48.
3122177|NCT02806505|Experimental|Peginterferon alfa-2a 90 mcg|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a 90 mcg SC once weekly up to Week 48.
3122178|NCT02806544|Experimental|Tamoxifen|Tamoxifen 20mg by mouth daily
3122179|NCT02806713|Placebo Comparator|no phenazopyridine|Patients not receiving phenazopyridine (standard of care)
3122180|NCT02806713|Experimental|phenazopyridine|Patients receiving phenazopyridine
3122181|NCT02806726|Experimental|iDesign 1.3-PRESBY|iDesign 1.3-PRESBY in one eye of subject (experimental) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
3122182|NCT02806726|Active Comparator|iDesign 1.3|iDesign 1.3 in one eye of subject (control) is used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
3122183|NCT02806869|Experimental|Arm #1 - Fasting State, 2 study visits|"Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
3122184|NCT02806869|Experimental|Arm #2 - Fed State, 2 study visits|"Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red~Washout period of at least 7 days~Pulmocare, two 8.0 oz (236.6 mL) cans, followed by single dose of ibuprofen (800 mg tablet) administered with 250 mL of water containing phenol red"
3122185|NCT02806895|Placebo Comparator|Placebo|Once daily dosing
3122186|NCT02806895|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
3122187|NCT02806908|Placebo Comparator|Placebo|Once daily dosing
3122188|NCT02806908|Active Comparator|JZP-110|150 mg/day for first 3 days and 300 mg/day for next 4 days
3122189|NCT02806947|Experimental|Sirolimus|Sirolimus, a steroid-free therapy, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
3122190|NCT02806947|Active Comparator|Prednisone|Prednisone, standard of care therapy for GVHD, will be administered after a diagnosis of standard-risk aGVHD is clinically established.
3122191|NCT02806973|Experimental|Nasal Glucagon (NG) - Treatment 1|One dose of 3 milligram (mg) NG administered in one of four study periods.
3122192|NCT02806973|Experimental|NG - Treatment 2|Two NG doses, 3 mg each dose, administered 15 minutes apart, in the same nostril, in one of four study periods.
3122193|NCT02806973|Experimental|NG - Treatment 3|Two NG doses, 3 mg each dose, administered 15 minutes apart, in opposite nostrils, in one of four study periods.
3122194|NCT02806973|Experimental|NG - Treatment 4|Two NG doses, 3 mg each dose, administered one immediately after the other, in opposite nostrils, in one of four study periods.
3122195|NCT02806986|Experimental|IGSC 20%|13 doses of IGSC 20% in Treatment Stage 1 and 39 doses of IGSC 20% in Treatment Stage 2 for a total of 52 doses if IGSC 20%
3122196|NCT02807259|Experimental|Multi-level intervention|This is a cluster-randomised controlled trial design. The unit of randomisation is village.
3122197|NCT02807259|Other|Control|The intervention will rolled out to all participating villages after 24 months.
3122198|NCT02807376|Active Comparator|Surgeon's 'standard of care' stapler|Surgeon's standard of care stapler
3122199|NCT02807376|Experimental|Ethicon Powered Vascular Stapler|Ethicon Powered Vascular Stapler
3122200|NCT02807402||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, and was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
3122201|NCT02807623|Experimental|Ibuprofen|Randomized and double blinded study participants assigned to Group A intervention will receive an oral NSAID of ibuprofen 800 mgs three times a day for 48 hours.
3122202|NCT02807623|Placebo Comparator|Placebo|Randomized and double blinded study participants assigned to Group B intervention will receive an oral placebo three times a day for 48 hours starting immediately after influenza vaccine receipt.
3122203|NCT02807623|Experimental|Compound Exercise of Push-ups|Randomized study participants assigned to Group C will perform an exercise intervention of push-ups immediately after influenza vaccine receipt.
3122204|NCT02807844|Experimental|Ph Ib: MCS110 1 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 1 mg/kg every 3 weeks (Q3W) + PDR001 100 mg Q3W
3122205|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 100 mg Q3W
3122206|NCT02807844|Experimental|Ph Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 3 mg/kg Q3W + PDR001 300 mg Q3W
3122207|NCT02807844|Experimental|Ph Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 5 mg/kg Q3W + PDR001 300 mg Q3W
3122208|NCT02807844|Experimental|Ph Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W
3122209|NCT02807844|Experimental|Ph Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W|Phase Ib: MCS110 10 mg/kg Q3W + PDR001 300 mg Q3W
3122210|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - TNBC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Triple negative breast cancer (TNBC)
3122211|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - PC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Pancreatic cancer (PC)
3122212|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - EC|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Endometrial cancer (EC)
3122213|NCT02807844|Experimental|Ph II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - ME|Phase II: MCS110 7.5 mg/kg Q3W + PDR001 300 mg Q3W - Melanoma (ME)
3122214|NCT02807857|Other|Patients' heart failure and non-heart failure|No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians
3122215|NCT02807948|Other|Pacemaker, ICD, or CRT device patients|Subjects who need a non-thoracic clinically indicated scan
3122216|NCT02808052|Experimental|Minocin (minocycline) for Injection|Minocin (minocycline) for Injection will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives a single 200-mg dose of Minocin (minocycline) for Injection except for the hemodialysis therapy/end stage renal disease cohort, which receives two 200-mg doses.
3122217|NCT02808130||group H|"Group H: normolipidemic+ periodontally healthy individuals The healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
3122218|NCT02808130||Group G|"Group G: normolipidemic + gingivitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
3122219|NCT02808130||Group CP|"Group CP: normolipidemic + generalized chronic periodontitis individuals the healthy controls were randomly selected from among individuals referred to the Periodontology Department for either dental treatment or check-up.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
3122220|NCT02808130||Group HH|"Group HH: hyperlipidemic + periodontally healthy individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
3122221|NCT02808130||Group HG|"Group HG: hyperlipidemic + gingivitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions."
3132483|NCT03430986|Experimental|No-treatment Control|Participants received no treatment during the 24-week Control Period. After 24 weeks, participants had the option of treatment with JUVÉDERM® VOLUMA® with Lidocaine Injectable Gel in the nose area during the 24-week Post-Control period and were eligible for touch-up treatment 8 weeks after the initial treatment, if applicable.
3469395|NCT03887130|Active Comparator|Gemcitabine-Docetaxel (arm C)|gemcitabine (GEM) in combination with docetaxel (DOC)
3469396|NCT03887039||ADHD group|clinical examination
3469397|NCT03887039||normal group|clinical examination
3469398|NCT03886870|Experimental|Lifestyle and work intervention|Lifestyle intervention with work focus.
3122222|NCT02808130||group HCP|"Group HCP: hyperlipidemic + generalized chronic periodontitis individuals Hyperlipidemia was defined as the presence of one or more altered values of the lipid profile and the following cut-off values were used according to the laboratory's recommendation: TC>200mg/dl; TG>200mg/dl; LDL cholesterol >130 mg/dl; HDL <35mg/dl) (29). The diagnosis of the hyperlipidemia had been made at least 3 months before the study, and no distinction was drawn among the hyperlipidemia types. The samples were obtained after a 12-h fasting period from an antecubital vein.~Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions"
3122223|NCT02808312|Experimental|Cohort 1: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
3122224|NCT02808312|Experimental|Cohort 1: Normal Hepatic Function|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
3122225|NCT02808312|Experimental|Cohort 2: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
3122226|NCT02808312|Experimental|Cohort 2: Normal Hepatic Function|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).
3122227|NCT02808312|Experimental|Cohort 3: Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
3122228|NCT02808312|Experimental|Cohort 3: Normal Hepatic Function|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).
3122229|NCT02808338|Active Comparator|Philips BiPAP AutoSV Advanced System One|"The Bi-Level Positive Airway Pressure system will be used and will be configured with these settings.~P max: 30 EPAP min: 4 EPAPmax: 15 Pressure Support (PS) min: 0 Pressure Support (PS) max: 15 BiFlex: 2 Rate: Auto"
3122230|NCT02808338|Experimental|Modified Philips BiPAP ASV|The modified Philips BiPAP ASV will be configured with these settings P max: 30 EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 15 BiFlex: 2 Rate: Auto
3122231|NCT02808338|Active Comparator|ResMed S7 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~End-expiratory Pressure (EEP): 4 PSmin: 3 PSMax: 16"
3122232|NCT02808338|Active Comparator|ResMed S9 VPAP Adapt|"This is an FDA approved device and the following settings will be administered:~EPAP min: 4 EPAPmax: 15 PS min: 0 PS max: 20 Max Ramp: Off"
3122233|NCT02808429|Experimental|Placebo|
3122234|NCT02808429|Experimental|Atacicept 25 mg|
3122235|NCT02808429|Experimental|Atacicept 75 mg|
3122236|NCT02808819|Other|Benralizumab Arm A|Benralizumab administered subcutaneously every 4 weeks
3122237|NCT02808819|Other|Benralizumab Arm B|Benralizumab administered subcutaneously every 8 weeks
3122238|NCT02808975|Placebo Comparator|Placebo|"Period A: Day 1- 4 subcutaneous (SC) injections; Week 2- 2 SC injections; Weeks 4-12- 1 SC injection each week~Period B: Weeks 13-14- 1 SC injection each week~Period C: Weeks 15-23- 1 SC injection each week"
3122239|NCT02808975|Active Comparator|Adalimumab|"Period A: Day 1- 4 subcutaneous (SC) 40 mg injections; Week 2- 2 SC 40 mg injections; Weeks 4-12- 1 SC 40 mg injection each week~Period B: Weeks 13-14- 1 SC 40 mg injection each week~Period C: Weeks 15-23- 1 SC 40 mg injection each week"
3122240|NCT02809053|Experimental|SAIT101|
3122241|NCT02809053|Active Comparator|MabThera®|
3122242|NCT02809183|Placebo Comparator|Placebo-BID|Administered twice daily (BID) for 14 days
3122243|NCT02809183|Experimental|TRC101 (1.5g BID)|Administered twice daily (BID) for 14 days
3122244|NCT02809183|Experimental|TRC101 (3g BID)|Administered twice daily (BID) for 14 days
3122245|NCT02809183|Experimental|TRC101 (4.5g BID)|Administered twice daily (BID) for 14 days
3122246|NCT02809183|Experimental|TRC101 (6g QD)|Administered once daily (QD) for 14 days
3122247|NCT02809183|Placebo Comparator|Placebo-QD|Administered once daily (QD) for 14 days
3122248|NCT02809430|Experimental|CPAP intervention|Participants will receive 3 nights of auto-CPAP in order to identify those with OSA using flow resistance detected by the device. After 3 nights, those without apparent OSA or with central apnea, and those who simply do not tolerate CPAP will be excluded from the study. An intensive CPAP adherence protocol (iCAP) will be initiated, including collaborative care with rehabilitation nurses, the study's sleep technologist and overnight respiratory therapists. After the run-in period, the sleep technologist will meet at least twice weekly with CPAP-tolerant participants during their rehabilitation stay for further OSA education and encouragement with a target adherence of 4 hours per night. Participants diagnosed with OSA by the device and tolerant will continue CPAP therapy during rehabilitation and at home for a treatment period of 3 months. Adherence will be downloaded remotely from participant's machines to encourage adherence to treatment and troubleshoot any problems with the device.
3122249|NCT02809833||Tocilizumab for RA in Routine Practice|Participants from routine clinical practice in Germany who are receiving tocilizumab for RA according to SmPC are eligible.
3122250|NCT02809846|Active Comparator|Quell Device|Quell is a class II medical device with FDA 510(k) clearance for the symptomatic relief and management of chronic intractable pain, without a prescription. It operates by using an electrical stimulator to activate peripheral sensory nerves and trigger analgesia.
3122251|NCT02809846|Sham Comparator|Sham Quell Device|Identical to Active Comparator, but provides sub-therapeutic electronic stimulation.
3122252|NCT02809859|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
3122253|NCT02809911|Other|Sham of Provant|Sham of Provant Therapy System
3122254|NCT02809911|Other|Active Provant|Active Provant Treatment
3122255|NCT02809976|Experimental|Ruxolitinib 1.5% phosphate cream|Ruxolitinib 1.5% phosphate cream twice daily to vitiligo patches.
3122256|NCT02810327||MZ heterozygote with symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort have symptoms or clinical diagnosis of COPD.
3122257|NCT02810327||MZ heterozygote without symptoms of COPD|Individuals who have previously had testing for Alpha-1 antitrypsin deficiency with genotype MZ (PiMZ) results. Individuals in this cohort do not have symptoms or clinical diagnosis of COPD.
3122258|NCT02810340|Experimental|MCV-5 with adjuvant|Received a single intramuscular injection of Adjuvanted MCV-5.
3122259|NCT02810340|Experimental|MCV-5 without adjuvant|Received a single intramuscular injection of Non-Adjuvanted MCV-5.
3122260|NCT02810340|Active Comparator|Menactra®|Received a single intramuscular injection of Menactra.
3122261|NCT02810392|Active Comparator|Intranasal Insulin|Intranasal Insulin (20 IU BID): Humulin insulin packaged is in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
3122262|NCT02810392|Placebo Comparator|Intranasal Saline|Intranasal saline: Saline is packaged in single-dose ampules and inserted into the VianaseTM chamber. Ampoules are dispensed in 3 week supplies per study visit. Patients/caregivers, investigators, and outcome assessors are masked to group assignment. Subjects will receive their first dose in clinic, and wait 2 hrs to determine any adverse effects of inhaled dose. Glucose levels will be measured to monitor for hypoglycemia and documented. All subjects will check peak dose blood sugar levels with glucometer, 3 times per week during insulin treatment.
3122263|NCT02810418|Experimental|Arm A1, Dose Level 1 (Phase 1, short infusion) 100µg/kg LMB-100|"Arm A1, Dose Level 1, Phase I Short Infusion 100µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Dose level 1 (DL1) Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving short infusion LMB-100+nabpaclitaxel"
3122264|NCT02810418|Experimental|Arm A1, Dose Level-1 (Phase 1, short infusion) 65µg/kg LMB-100|Arm A1, DL-1, Ph I Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel
3122265|NCT02810418|Experimental|Arm A2 (Phase 2, short infusion) 65µg/kg LMB-100|"Arm A2, Phase 2 Short Infusion 65µg/kg LMB-100 +125mg/m^2 nab-paclitaxel~Efficacy determination in patients with pancreatic cancer receiving short infusion LMB-100 + nabpaclitaxel"
3122266|NCT02810418|Experimental|Arm B1, Dose Level 2 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL2, 48-hr Continuous Infusion Single Agent Lead-in 100µg/kg/day LMB-100 Maximum tolerated dose (MTD) determination in patients with pancreatic cancer receiving continuous infusion LMB-100 as single agent
3122267|NCT02810418|Experimental|Arm B1, Dose Level 1 Phase I (Continuous infusion single agent lead-in)|Arm B1, DL1, 48-hr Continuous Infusion Single Agent Lead-in 65µg/kg/day LMB-100
3122268|NCT02810418|Experimental|Arm B1, Dose Level 3R Phase I (Continuous infusion single agent lead-in)|Arm B1, DL3R, 24-hr Continuous Infusion Single Agent Lead-in 100µg/kg LMB-100
3122269|NCT02810418|Experimental|Arm B2 Phase I (continuous infusion combination therapy)|Subjects with pancreatic cancer receiving continuous infusion LMB-100 combination therapy
3122270|NCT02810457|Experimental|FKB238 / paclitaxel / carboplatin|"Drug: FKB238:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~Area Under Curve (AUC) = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
3122271|NCT02810457|Active Comparator|Avastin / paclitaxel / carboplatin|"Drug: Avastin:~15 mg/kg IV infusion on Day 1 of each 21-day cycle.~Drug: Paclitaxel:~200 mg/m2 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles.~Drug: Carboplatin:~AUC = 6.0 IV infusion on Day 1 of each 21-day cycle for at least 4 and no more than 6 cycles."
3122272|NCT02810509||Short-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days < 90 days"
3122273|NCT02810509||Long-term Warfarin-treated cohort|"admission due to AF-related ischemic stroke (known AF or newly detected AF)~long-term warfarin therapy at least for more than 90 days after the 7 days of warfarin adjustment period~for TTR calculation, the number of consecutive INR measurements ≥3 after the 7 days of warfarin adjustment~TTR evaluable days ≥ 90 days"
3122274|NCT02810873|Experimental|F-18-FDG Whole body Scan|STAGE I: Patients with a positive biopsy and abnormal (positive) fludeoxyglucose F18-labeled PET whole-body scan undergo a whole-body copper Cu 64 TP3805-labeled PET scan.
3122275|NCT02810873|Experimental|No F-18-FDG Scan|STAGE II: Patients with a positive biopsy, but no fludeoxyglucose F18 scan undergo a breast fludeoxyglucose F18-labeled PEM Positron Emission Mammography scan followed by a breast copper Cu 64 TP3805-labeled PEM scan.
3122276|NCT02810951|Experimental|FCX-007|"In Phase I, a target of three adult subjects will be enrolled into Group A and a target of three adult subjects will be enrolled into Group B.~In Phase II the study will target enrolling subjects (aged seven (7 years or older) to each arm, but will allow a disproportionate distribution of subjects between Group A and Group B to equal approximately 6 total subjects.~All subjects will receive FCX-007 into one or more paired target wounds as well as to intact skin at least one time during the study with a possible second administration pending laboratory results.~One wound in each target wound pair will be used as control for efficacy and safety evaluations."
3122277|NCT02810964|Experimental|Sulforaphane Nutraceutical|The sulforaphane nutraceutical contains inactive glucoraphanin, a glucosinolate from broccoli seeds, and myrosinase from broccoli sprouts. The ingestion of this compound leads to the hydrolysis of glucoraphanin, the generation of sulforaphane within the gastrointestinal (GI) tract, and the subsequent systemic absorption of the sulforaphane. The dose per tablet is 16 mg of glucoraphanin or 37 µmol; 6 tablets per day should yield about 100 µmol of sulforaphane. The tablets, which will be swallowed, are provided as .375 punch size, round concave tablets. In this arm, the participant will take 6 tablets of the sulforaphane nutraceutical daily for 16 weeks after a 2-week placebo run-in.
3122278|NCT02810964|Placebo Comparator|Identical-appearing Placebo|The inert compound placebo looks identical to the sulforaphane nutraceutical. In this arm, the participant will take 6 tablets of the placebo daily for 16 weeks after a 2-week placebo run-in.
3122279|NCT02811159|Experimental|Telapristone Acetate 12 mg|Telapristone acetate 12 milligrams (mg), orally, once daily for two 18-weeks courses (Treatment Courses 1 and 2) separated by an off-drug interval (ODI).
3122280|NCT02811302|Other|Patients monitored by capnography|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
3122281|NCT02811419|Active Comparator|i-scan|Inspection with i-scan surface enhancement
3122282|NCT02811419|Active Comparator|Standard high-definition white light|Inspection with standard high-definition white light (usual care)
3122283|NCT02811445||High Functioning|Defined by a short physical performance battery score (SPPB) greater than or equal to 11.
3122284|NCT02811445||Low Functioning|Defined by a short physical performance battery score (SPPB) less than or equal to 7.
3122285|NCT02811640||Study Participants|Adults with chronic kidney disease who will have a PD catheter inserted at the Ottawa Hospital
3122286|NCT02811861|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Lenvatinib 18 milligrams (mg) administered orally, once daily, plus everolimus 5 mg administered orally, once daily
3122287|NCT02811861|Experimental|Lenvatinib 20 mg plus pembrolizumab 200 mg|Lenvatinib 20 mg administered orally, once daily, plus pembrolizumab 200 mg administered intravenously (IV), every 3 weeks
3122288|NCT02811861|Active Comparator|Sunitinib 50 mg|Sunitinib 50 mg administered orally, once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off treatment
3122289|NCT02811913|Other|High frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 5 Hz rTMS
3122290|NCT02811913|Other|Low frequency rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was 1 Hz rTMS
3122291|NCT02811913|Other|Sham rTMS|Each subject is provided with three different brain stimulation interventions in a single arm, single session crossover design study. One of the sessions was sham rTMS
3122292|NCT02811965|No Intervention|Control|Pressure mapping is performed without a heel offloading intervention applied.
3122293|NCT02811965|Experimental|Pillow Condition 1|Pressure mapping is performed with the Pillow condition 1 intervention applied to the heel.
3122294|NCT02811965|Experimental|Pillow Condition 2|Pressure mapping is performed with the Pillow condition 2 applied to the heel.
3122295|NCT02811965|Experimental|Heel Foam Pillow|Pressure mapping is performed with the heel foam pillow device applied to the heel.
3122296|NCT02811965|Experimental|Offloading Device A|Pressure mapping is performed with Offloading Device A applied to the heel.
3122297|NCT02811965|Experimental|Offloading Device B|Pressure mapping is performed with Offloading Device B applied to the heel.
3122298|NCT02811965|Experimental|Offloading Device C|Pressure mapping is performed with Offloading Device C applied to the heel.
3122299|NCT02812160|Active Comparator|Spatz3 Adjustable Balloon|Spatz3 Adjustable Balloon with Dietary and exercise counselling
3122300|NCT02812160|No Intervention|Control|Dietary and Exercise counselling
3122301|NCT02812186|Other|Deep to Moderate NMB|This group will undergo deep neuromuscular blockade, defined as post tetanic count (PTC) of 1 to 2, in the beginning portion of the surgery followed by a period of moderate blockade.
3122302|NCT02812186|Other|Moderate to Deep NMB|This group will undergo moderate neuromuscular blockade, defined as 1-2 twitches, in the beginning portion of the surgery followed by a period of deep blockade.
3122303|NCT02812238|Experimental|Arm 1|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
3122304|NCT02812238|Experimental|Arm 2|Either NR at 1000mg/day or placebo for one week, followed by a washout period of 2-3 weeks, then a crossover to placebo or NR at 1000mg/day for one additional week. The end point was analyzed at end of each treatment.
3122305|NCT02812342|Experimental|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
3122306|NCT02812771|Experimental|Efinaconazole|Efinaconazole
3122307|NCT02813070|Experimental|Healthy volunteers|185 MBq [18F] Flutemetamol
3122308|NCT02813070|Experimental|Mild cognitive impairment|185 MBq [18F] Flutemetamol
3122309|NCT02813070|Experimental|Alzheimer's Disease|185 MBq [18F] Flutemetamol
3122310|NCT02813265|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
3122311|NCT02813265|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
3122312|NCT02813421|Experimental|CGM Informed|CGM data was available for use when determining starting insulin pump doses.
3122313|NCT02813421|No Intervention|Control|CGM data will remain secure and not used. Starting insulin pump doses will be made by standard of care.
3122314|NCT02813551|Experimental|Torsemide|Torsemide 20 mg daily for 5 days
3122315|NCT02813551|Placebo Comparator|Placebo|Placebo 20 mg daily for 5 days
3122316|NCT02813577|Other|Lutonix® 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
3122317|NCT02813681|Active Comparator|US-epidural SVD|US-epidural SVD group - participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity
3122318|NCT02813681|Sham Comparator|(US sham- epidural SVD)|US sham- epidural SVD group- participants who received US examination process but with the monitor turned off.
3122319|NCT02813681|Placebo Comparator|SVD without an Epidural|Spontaneous vaginal delivery without an Epidural group The purpose of the control group is to serve as a baseline.
3122320|NCT02813694|Experimental|lefamulin|oral lefamulin, 600mg
3122321|NCT02813694|Active Comparator|Moxifloxacin|oral moxifloxacin, 400mg
3122322|NCT02814175|Active Comparator|Part 1: MTX Escalated Dose|Methotrexate (MTX) escalated to 20 - 25 mg or highest tolerable dose every week (ew)
3122323|NCT02814175|Experimental|Part 1: ADA + MTX|Adalimumab (ADA) 40 mg every other week (eow) in combination with MTX 15 mg ew
3122324|NCT02814175|Active Comparator|Part 2: MTX Escalated Dose|Participants achieving minimal disease activity (MDA) at Week 16 on MTX escalated to 20 -25 mg or highest tolerable dose ew, continued with the same MTX dose
3122325|NCT02814175|Active Comparator|Part 2: ADA + MTX Escalated Dose|Participants not achieving MDA at Week 16 on MTX escalated to 20 - 25 mg or highest tolerable dose ew, received ADA 40 mg eow in combination with MTX 20 - 25 mg or highest tolerable dose ew
3122326|NCT02814175|Experimental|Part 2: ADA|Participants achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had MTX completely withdrawn at Week 16 and continued receiving ADA as monotherapy
3122327|NCT02814175|Experimental|Part 2: ADA ew + MTX|Participants not achieving MDA at Week 16 on ADA 40 mg eow plus MTX 15 mg ew, had ADA escalated to 40 mg ew in combination with MTX 15 mg ew
3122328|NCT02814227|Experimental|Zansors® sleep screening device|Zansors device compared to overnight polysomnography
3122329|NCT02814279|Active Comparator|CAF plus connective tissue graft|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. The connective tissue graft was removed from the palate according to Bruno technique (1994) and sutured in position. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions.
3122330|NCT02814279|Experimental|Tunnel plus connective tissue graft|The tunnel flap was performed according to Zuhr et al., 2007. Following initial sulcular incisions, spit thickness flap was prepared using specific tunneling knives beyond the mucogingival junction and until flap gain mobility. The flap was laterally extended to adjacent papillae that were carefully detached by means of a full-thickness preparation. The connective tissue graft was insert into the tunnel. Sling sutures were performed involving the flap and graft to coronally cover 2 mm above the CEJ.
3122331|NCT02814448|Active Comparator|CO2 standard cryotherapy- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
3122332|NCT02814448|Active Comparator|CO2 standard cryotherapy- single freeze|Single freeze treatment consists of one five-minute freeze
3122333|NCT02814448|Active Comparator|CryoPen- double freeze|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
3122334|NCT02814448|Active Comparator|CryoPen- single freeze|Single freeze treatment consists of one five-minute freeze
3122335|NCT02814448|Experimental|Thermocoagulator|Single heat application at 100 ºC for 40 seconds
3122336|NCT02814565|Experimental|Cyclobenzaprine HCl 15 mg|Cyclobenzaprine Hydrochloride (HCl) extended-release, 15 mg capsules, orally, once daily for 14 days.
3122337|NCT02814565|Placebo Comparator|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules, orally, once daily for 14 days.
3122338|NCT02814643|Experimental|Benralizumab|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
3122339|NCT02814643|Placebo Comparator|Placebo|1 mL fill volume administered every 4 weeks for 3 doses (Weeks 0, 4, and 8). Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
3122340|NCT02814656|Experimental|Cohort 1, AZD8871 300 μg or placebo|In Cohort 1, participants will receive a single dose of AZD8871 300 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
3122341|NCT02814656|Experimental|Cohort 2, AZD8871 600 μg or placebo|In Cohort 2, participants will receive a single dose of AZD8871 600 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
3122342|NCT02814656|Experimental|Cohort 3, AZD8871 900 μg or placebo|In Cohort 3, participants will receive a single dose of AZD8871 900 μg or placebo on Day 1, followed by once daily dosing on Days 5 to 16.
3122343|NCT02814838|Experimental|Ladarixin|Ladarixin oral capsule
3122344|NCT02814838|Placebo Comparator|Placebo|Placebo oral capsule
3122345|NCT02814890|Experimental|Ropivacaine and dexmedetomidine|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine + 1μg/kg dexmedetomidine at the end of video-assisted pneumonectomy.
3122346|NCT02814890|Active Comparator|Ropivacaine only|Thoracic paravertebral block is performed using 75mg/20ml ropivacaine at the end of video-assisted pneumonectomy.
3122347|NCT02815267|Experimental|FMX-101, 4% minocycline foam|Subjects will apply the assigned FMX-101, 4% minocycline foam topically once daily for 12 weeks as directed
3122348|NCT02815267|Placebo Comparator|Vehicle foam|Subjects will apply the assigned vehicle foam topically once daily for 12 weeks as directed
3122349|NCT02815280|Experimental|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
3122350|NCT02815280|Placebo Comparator|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
3122351|NCT02815293|Experimental|AGN-195263|
3122352|NCT02815293|Placebo Comparator|Vehicle|
3122353|NCT02815644|Experimental|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
3122354|NCT02815670|Experimental|Idarucizumab|
3122355|NCT02815709|Experimental|Treatment 1 Oliceridine|
3122356|NCT02815709|Experimental|Treatment 2 Oliceridine|
3122357|NCT02815709|Experimental|Treatment 3 Oliceridine|
3122358|NCT02815709|Placebo Comparator|Placebo|
3122359|NCT02815709|Active Comparator|Morphine|
3122360|NCT02815735|Experimental|comfilcon A|Participants wear comfilcon A lens for 4 weeks during the cross over study.
3122361|NCT02815735|Active Comparator|lotrafilcon B|Participants wear lotrafilcon B lens for 4 weeks during the cross over study.
3122362|NCT02815982|Experimental|NOURISH-T|"The intervention aims to increase caregivers' self-efficacy for behavioral change, and facilitate an authoritarian approach to parenting. Behavioral strategies such as self-monitoring, contingency management, and stimulus control are integrated in these sessions. Further, because participatory experiences enhance overall intervention efficacy, these activities are incorporated throughout, including self-assessments, discussions and experiential activities. Homework is assigned between sessions so skills can be practiced. We also focus on the caregivers' relationship with everyone in the family, not just the identified patient or overweight child."
3122363|NCT02815982|Active Comparator|Enhanced Usual Care|Caregivers randomized to the EUC will attend assessment sessions and an initial session moderated by an independent interventionist. The session addresses the role of diet and exercise in pediatric overweight. In addition, EUC caregivers receive nationally available print or web-based brochures on pediatric overweight on 2 occasions during the study so that similar (but not as intensive) information is provided in the intervention and EUC arms of the study. Participants also receive a booster phone call 2 months after the end of the intervention period.
3122364|NCT02816138|Experimental|Transdermal nicotine patch|Transdermal nicotine patch, administered on awakening and removed at bedtime (16h/d). Dosing 3.5mg patch/daily, titrated over study to maximum dose of 21mg patch/daily.
3122365|NCT02816346|Experimental|Cohort 1: target dose of 500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 510, 717, 588, and 567 CFU)."
3122366|NCT02816346|Experimental|Cohort 2: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 817 CFU), since the attack rate of shigellosis for Cohort 1 was below the protocol target of 60%."
3122367|NCT02816346|Experimental|Cohort 3: target dose of 1000 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1000 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 913 CFU. Although the target dose was the same as Cohort 2, the safety monitoring committee felt that the per-protocol a priori definition of shigellosis was too restrictive and that increasing the dose above 1000 CFU may lead to unnecessarily high toxicity."
3122368|NCT02816346|Experimental|Cohort 4: target dose of 1500 CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1500 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) since the attack rate of shigellosis for Cohort 2 and 3 was below the protocol target of 60%."
3122369|NCT02816346|Experimental|Cohort 5: target dose of CFU|"Shigella sonnei 53G: Investigational Product: One dose of Shigella sonnei rehydrated challenge strain 53G (Lot 1794) suspension in 2 mL of cold sterile water combined and diluted in cold, sterile normal saline 0.9% (i.e. challenge suspension).~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 5 minutes.~Received target dose of 1150 colony-forming units (CFU) of Shigella sonnei 53G (actual dose: 1760 CFU) as the final confirmatory cohort since it was felt that the disease rate and profile of Cohort 4 was appropriate."
3122370|NCT02816398|Experimental|Treatment|Interventional use of experimental Ellipsys catheter system for percutaneous creation of an arteriovenous fistula
3122371|NCT02816710|Experimental|IVC Preoperative group|Conbercept injection before vitrectomy
3122372|NCT02816710|Experimental|IVC Postoperative group|Conbercept injection at the end of vitrectomy
3122373|NCT02816710|Experimental|IVC Pre- and Post-operative group|First conbercept injection before vitrectomy and second at the end of operation.
3122374|NCT02816723|Experimental|Mindfulness|mindfulness/meditation/movement training
3122375|NCT02816723|Active Comparator|Brain Health|Brain Health education class
3122376|NCT02817087|Active Comparator|repetitive Transcranial Magnetic Stimulation -On|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap delivering magnetic stimulation to part of the brain.
3122377|NCT02817087|Sham Comparator|repetitive Transcranial Magnetic Stimulation -Off|Participants wear the repetitive transcranial magnetic stimulation (rTMS) cap that does NOT delivery any magnetic stimulation to the brain.
3122378|NCT02817516|Experimental|Part 1: TAK-828 15 milligram (mg)|TAK-828 15 mg, solution (0.2 milligram per milliliter [mg/mL] or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
3122379|NCT02817516|Experimental|Part 1: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
3122380|NCT02817516|Experimental|Part 1: TAK-828 75 mg|TAK-828 75 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
3122381|NCT02817516|Experimental|Part 1: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
3122382|NCT02817516|Experimental|Part 2: TAK-828 45 mg|TAK-828 45 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
3122383|NCT02817516|Experimental|Part 2: TAK-828 100 mg|TAK-828 100 mg, solution (0.2 mg/mL or 5 mg/mL), orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy Japanese participants.
3122384|NCT02817516|Placebo Comparator|Part 1: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-13, and once on the morning of Day 14 in healthy non-Japanese participants.
3122385|NCT02817516|Placebo Comparator|Part 2: Placebo|TAK-828 placebo-matching solution, orally, twice daily on Days 1-14 in healthy Japanese participants.
3122386|NCT02817555|Active Comparator|Epoetin alfa|Patients who are enrolled and randomized to the Epoetin arm will remain on their current dose and frequency. After the first hemoglobin (Hb) measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on epoetin for the required run-in phase followed by the 12 month active phase.
3132484|NCT03431012|Experimental|Virus Agency/Negative Attribute Framing|Participants in this condition, after reading a hypothetical scenario, received health messages describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing).
3122387|NCT02817555|Active Comparator|Darbepoetin alfa|"Patients who are enrolled and randomized to the Darbepoetin arm will have their epoetin discontinued at the end of the week preceding entry into the study and will switch to darbepoetin on the date that they would normally be receiving their next dose of epoetin.~Switching patients to darbepoetin will be done using the conversion ratio of 200 units of epoetin to 1 μg of darbepoetin as used per week, rounded up or down to the nearest available pre-filled syringe dose available from the manufacturer.~After the first Hb measurement the study algorithm will be used to guide anemia management. The subjects in this arm will remain on darbepoetin for the required run-in phase followed by the 12 month active phase."
3122388|NCT02817594||Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin|"Participants in this observational study received treatment with paritaprevir/ritonavir (r) and ombitasvir with or without dasabuvir ± ribavirin (RBV) for 12 or 24 weeks for the treatment of chronic hepatitis C (CHC), according to hepatitis C virus (HCV) genotype/subtype and stage of liver disease.~The prescription of treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer the patient the opportunity to participate in this study."
3122389|NCT02817763|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of Coronally advanced flap (CAF). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
3122390|NCT02817763|Experimental|CTG plus resin composite restoration|After local anesthesia, a sterile rubber dam was placed to isolate the operative field and the coronal zone of the non-carious cervical lesion restoration was performed with a nanocomposite resin, following the manufacturer's instructions. The apical margin of the restoration was place 1 millimeter beyond to the cemento-enamel junction estimation. In the next session, the surgical procedure performed was the trapezoidal-type of CAF. After the trapezoidal-type of CAF flap was raised, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
3122391|NCT02817776|Experimental|Treatment group|Pulmonary vein isolation (PVI) by RF ablation treatment with the THERMOCOOL SMARTTOUCH® SF catheter in persistent AF population.
3122392|NCT02817828|Experimental|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP tablet
3122393|NCT02817841|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol (E4)/3 mg drospirenone (DRSP) combined oral contraceptive
3122394|NCT02817906|Experimental|ITI-007|9 mg ITI-007 administered as a solid oral dose formulation once daily for 4 weeks.
3122395|NCT02817906|Placebo Comparator|Placebo|Placebo administered as a visually-matched solid oral dose formulation once daily for 4 weeks
3122396|NCT02818036|Experimental|naltrexone|single 50mg dose of naltrexone
3122397|NCT02818036|Placebo Comparator|sugar pill|single sugar pill
3122398|NCT02818114|Experimental|PEET|Peer support interventions as an adjunct to prolonged exposure
3122399|NCT02818244|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
3122400|NCT02818244|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
3122401|NCT02818244|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
3122402|NCT02818244|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
3122403|NCT02818244|Active Comparator|Scosche Rhythm +|Scosche Rhythm + Heart Rate Monitoring Device
3122404|NCT02818569|Experimental|Oral Dexmedetomidine, Then Placebo|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with oral dexmedetomidine and then a night's sleep with a placebo comparator.
3122405|NCT02818569|Experimental|Placebo, Then Oral Dexmedetomidine|This arm will enroll healthy control subjects, who will have an acclimation night followed by a night's sleep with a placebo comparator and then a night's sleep with oral dexmedetomidine .
3122406|NCT02818777|Experimental|cannabidiol|"GWP42003-P oral solution, is purified cannabidiol (purity of ≥98%, 100 mg/ml cannabidiol in sesame oil with anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring).~Started at 5 mg/kg/day and is increased by 2.5-5 mg/kg at 3-5 day intervals to a target dose of 20 mg/kg/day."
3122407|NCT02818920|Experimental|Pembrolizumab prior to and after surgery|
3122408|NCT02818998|Experimental|Aflibercept 2 mg fixed|Participants received fixed dosing of 2 mg aflibercept at injection intervals of 8 weeks
3122409|NCT02818998|Experimental|Aflibercept 2 mg flexible|Participants received flexible dosing of 2 mg aflibercept at injection intervals of ≥8 week
3122410|NCT02818998|Experimental|Aflibercept 2 mg PRN|Participants received monthly monitoring with 2 mg aflibercept injection pro re nata (PRN, as needed)
3122411|NCT02819011|Experimental|MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO for the duration of the study.
3122412|NCT02819011|Active Comparator|No MBB AFO Group|This group will be provided with a pair of New Balance 813 shoes for the duration of the study.
3122413|NCT02819284|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
3122414|NCT02819284|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
3122415|NCT02819297|Experimental|BLI400 Laxative|BLI400 Laxative
3122416|NCT02819297|Placebo Comparator|Placebo|BLI400 placebo
3122417|NCT02819310|Experimental|BLI400 Laxative|BLI400 Laxative
3122418|NCT02819323|Experimental|BLI800 high dose|BLI800 bowel preparation (high dose)
3122419|NCT02819323|Experimental|BLI800 low dose|BLI800 bowel preparation (low dose)
3122420|NCT02819323|Active Comparator|PEG-ELS|PEG based bowel preparation
3122421|NCT02819479|Experimental|Low-dose Intra-arterial Bevacizumab|A single intra-arterial targeted dose of 2.5 mg/kg bevacizumab will be administered after osmotic blood-brain-barrier disruption with intra-arterial 25% mannitol at rate of 4-12 ml/sec for 30 seconds.
3122422|NCT02819557|Experimental|Ataluren|Participants will be administered ataluren orally at a dose of 10 milligrams/kilograms (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening (for a total of 40 mg/kg/day) for up to 52 weeks. Dose will be provided based upon the weight of each participant, which will be assessed every 12 weeks.
3469399|NCT03886870|Experimental|Lifestyle intervention|Lifestyle intervention without work focus.
3122423|NCT02819726|Experimental|SAIT101|In Part A, each patient will receive one course of two 1000 mg SAIT101 infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of SAIT101 on Week 24 and Week 26.
3122424|NCT02819726|Active Comparator|Rituxan|In Part A, each patient will receive one course of two 1000 mg Rituxan infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be randomised in a 1:1 ratio to receive Rituxan or SAIT101 10000 mg infusions on Week 24 and Week 26.
3122425|NCT02819726|Active Comparator|MabThera|In Part A, each patient will receive one course of two 1000 mg MabThera infusions: one on Day 1 and the second on Day 15. In Part B, patients with an inadequate response (<50% improvement from Baseline in swollen and tender joint count at Week 24) will be eligible for a further course of two 1000 mg infusions of MabThera on Week 24 and Week 26.
3122426|NCT02819973|Experimental|Educational Video 1|African American/ Black Video
3122427|NCT02819973|Experimental|Educational Video 2|Caucasian Video
3122428|NCT02819973|Experimental|Usual Care (no video) 3|Standard Care/ No video
3122429|NCT02820038|Active Comparator|Other CMI Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications.
3122430|NCT02820038|Experimental|Other CMI & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive medication guides, or other comparable Consumer Medication Information (CMI), for rheumatoid arthritis medications AND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
3122431|NCT02820038|Experimental|Drug Facts Boxes Only|Approximately 75 participants will be assigned to this study group. Participants will ONLY receive Drug Facts Boxes for rheumatoid arthritis medications.
3122432|NCT02820038|Experimental|Drug Facts Boxes & SMART Program|Approximately 75 participants will be assigned to this study group. Participants will receive Drug Facts Boxes for rheumatoid arthritis medicationsAND will be enrolled into the Strategic Memory Advanced Reasoning Training (SMART) Program.
3122433|NCT02820181|Experimental|novel tracheostomy bi-ties|those with the novel tracheostomy bi-ties
3122434|NCT02820181|Active Comparator|traditional tracheostomy tie|those with traditional tracheostomy tie
3122435|NCT02820298|Experimental|Group 1 - Bexagliflozin dosed in fed state, then in fasted state|Group 1 subjects will take one dose of 20 mg of bexagliflozin with food on day 1 after an overnight fast and will take a second dose of bexagliflozin without food on day 8 after an overnight fast.
3122436|NCT02820298|Experimental|Group 2 - Bexagliflozin in fasted state, then in fed state|Group 2 subjects will take one dose of 20 mg bexagliflozin without food on day 1 after an overnight fast and will take a second dose of bexagliflozin with food on day 8 after an overnight fast.
3122437|NCT02820324|Experimental|Treatment 1 Oliceridine|
3122438|NCT02820324|Experimental|Treatment 2 Oliceridine|
3122439|NCT02820324|Experimental|Treatment 3 Oliceridine|
3122440|NCT02820324|Placebo Comparator|Treatment 4 Placebo|
3122441|NCT02820324|Active Comparator|Treatment 5 Morphine|
3122442|NCT02820597|Experimental|Intervention|Cryoablation with the ClariFix device
3122443|NCT02820844|Experimental|GSK1358820 Injection 100 U|"Initially, subjects will receive a single (double-blind) treatment with GSK1358820 (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment with GSK1358820 (open-label). A third treatment with GSK1358820 (open-label) may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
3122444|NCT02820844|Placebo Comparator|Placebo Injection|"Initially, subjects will receive a single (double-blind) treatment with Placebo (20 injections of 0.5 mL each) into the detrusor muscle of the bladder, using cystoscopy, and under local anesthesia. If the criteria for re-treatment are met between 12 and 36 weeks after the first treatment, subjects will receive a second treatment, this time with open-label GSK1358820. A third treatment with open-label GSK1358820 may be given until 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.~Subjects will receive prophylactic antibiotic therapy beginning up to 3 days prior to treatment and continuing up to 3 days following treatment."
3122445|NCT02820870|Experimental|Primary Care Intervention Group|"Primary care providers will receive a generated print-out of statin recommendations for patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant). Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the teamlets for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guidelines."
3122446|NCT02820870|No Intervention|Usual Care Group|PACT teams that were not randomized to the intervention will serve as a usual care group and will be expected to follow the VA guidelines and HEDIS measures as part of the VA national roll-out.
3122447|NCT02821000|Experimental|Pembrolizumab|Participants receive pembrolizumab 2 mg/kg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3122448|NCT02821104||Healthy Adolescents|Healthy non Hispanic white adolescents
3122449|NCT02821338|Active Comparator|Sequence 1|The treatments will be administered according to a randomly assigned pre-generated sequence involving the randomized, four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
3122450|NCT02821338|Active Comparator|Sequence 2|The treatments will be administered according to a randomly assigned pre-generated sequence involving the four-period, two sequence, fully replicate crossover design. Two study drugs involved are: Lamotrigine Extended Release (generic) and Lamictal XR (brand).
3122451|NCT02821403|Experimental|Young adults|adults without presbyopia who aged 18-35 years
3122452|NCT02821403|Experimental|Middle-aged adults|adults with presbyopia who aged over 40 years
3122453|NCT02821416|Experimental|Benralizumab|Benralizumab administered subcutaneously
3122454|NCT02821416|Placebo Comparator|Placebo|Placebo administered subcutaneously
3122455|NCT02821455||Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
3122456|NCT02821715|Active Comparator|Modafinil + placebo|3 tablets modafinil 100 mg per day and 3 capsules flecainide placebo per day for 2 weeks
3122457|NCT02821715|Experimental|THN102 300/3|3 tablets modafinil 100 mg per day and 3 capsules flecainide 1 mg per day (THN102 as 300 + 3 mg) for 2 weeks
3122458|NCT02821715|Experimental|THN102 300/27|3 tablets modafinil 100 mg per day and 3 capsules flecainide 9 mg per day(THN102 as 300 + 27 mg) for 2 weeks
3122459|NCT02821819|Experimental|Random start ovarian stimulation|"Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.~Interventions:~Random start ovarian stimulation~Gonadotrophins: Urinary FSH 150-225 IU/d~GnRH antagonists: Cetrorelix 0,25 mg/d~GnRH agonist for triggering: Triptorelin 0,2 mg single dose"
3122460|NCT02821910|Experimental|High dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
3122461|NCT02821910|Experimental|High dose, fasted|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fasted conditions
3122462|NCT02821910|Experimental|Low dose, fed|1 fixed dose combination (FDC) tablet vs. 4 single tablets under fed conditions
3122463|NCT02821962|Experimental|Sedentary prompts (VTAP)|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks. Participants will also be provided with a VTAP (activPAL3 VT) monitor to wear during waking hours for weeks 1 through 7 of cardiac rehabilitation. The VTAP will alert participants when they have been sedentary for 30 consecutive minutes.
3122464|NCT02821962|No Intervention|Usual care|Participants will complete supervised exercise sessions as part of cardiac rehabilitation programming on-site twice weekly for a total of 8 weeks.
3122465|NCT02822222|Experimental|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
3122466|NCT02822222|Placebo Comparator|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
3122467|NCT02822235||Crohn's Disease|Participants with diagnosis of moderate to severe Crohn's disease (CD) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and CD at Day 1 were followed up for 12 months in prospective phase.
3122468|NCT02822235||Ulcerative Colitis|Participants diagnosed with diagnosis of moderate to severe ulcerative colitis (UC) for at least 6 months prior to Day 1 were observed to collect the retrospective data including previous inflammatory bowel disease (IBD) treatments (drug dose, treatment duration, drug changes), and use of other health resources related with the management of IBD for previous three years at Day 1. Participants with active IBD and UC at Day 1 were followed up for 12 months in prospective phase.
3122469|NCT02822287|Experimental|2% Acetylcystine Solution|Participants will be orally administered with the clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle over 1 minute or less using an oral syringe.
3122470|NCT02822599|Active Comparator|RiaSTAP|Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.
3122471|NCT02822599|Placebo Comparator|Saline|Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.
3122472|NCT02822612||Retinal Disease|Fifteen subjects with retinal disease. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
3122473|NCT02822612||Glaucoma|Fifteen subjects with glaucoma. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
3122474|NCT02822612||Strabismus|Fifteen subjects with strabismus. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
3122475|NCT02822612||Healthy volunteers|Fifteen healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration.
3122476|NCT02822794|Experimental|SOF/VEL FDC + RBV 12 weeks|SOF/VEL FDC + RBV for 12 weeks in participants with genotype 1 or 2 HCV infection
3122477|NCT02822794|Experimental|SOF/VEL FDC + RBV 24 weeks|SOF/VEL FDC + RBV for 24 weeks in participants with genotype 1 or 2 HCV infection
3122478|NCT02822885|Experimental|ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
3122479|NCT02822950|Other|Ceftazadime/avibactam|Ceftazadime/avibactam 2500 mg (1250 mg for CrCl 31-50 mL/min) IV over 120 minutes, every 8 hours [other antibiotics can also be administered as needed]. Patients will receive at least 3 doses (steady-state) of Avycaz prior to obtaining serum samples.
3122480|NCT02823080|Active Comparator|cetrotide|study group (24 patients = intervention) received intervention for 3-daysCetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
3122481|NCT02823080|No Intervention|no cetrotide|control group (24 patients) did not receive 3-daysCetrorelix Acetate (no intervention). Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8.
3122482|NCT02823431|Active Comparator|Analgesia Arm|Participants randomized to this arm will undergo uroflow studies then be given a 2-hour rest. Urodynamics with the use of Urojet (lidocaine hydrochloride 2%) will then be performed. The lidocaine gel will be placed in and around the urethra. It will be allowed to set for 3 minutes, then the remainder of the standard urodynamic evaluation will be performed. We are using Urojet (lidocaine gel) in an FDA approved manner (for analgesia).
3469400|NCT03887026|Experimental|NKT Low Dose|NKT single dose - Low
3122483|NCT02823431|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given a 2-hour rest. Urodynamic testing without analgesia (standard of care) will then be performed.
3122484|NCT02823457|Other|VBMI intervention group|All patients will receive a 12 week VBMI intervention to promote treatment completion
3122485|NCT02823470|Experimental|Arm A: activated smart device alerts and feedback|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
3122486|NCT02823470|Experimental|Arm B: de-activated smart device alerts/feedback features|LUM/IVA: LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
3122487|NCT02823600|Other|RetinaVue 100 camera|Participants will have a retinal screening completed by study staff using the FDA-approved RetinaVue 100 hand-held camera
3122488|NCT02823964|Experimental|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
3122489|NCT02824198|Experimental|CYD Dengue Vaccine booster Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received a booster injection of CYD dengue vaccine at Day 0 in this study (CYD63).
3122490|NCT02824198|Placebo Comparator|Placebo Group|Participants who received 3 doses of the tetravalent dengue vaccine in a previous CYD dengue vaccine study (CYD28), received an injection of a placebo at Day 0 in this study (CYD63).
3122491|NCT02824224|Experimental|Tamoxifen|Tamoxifen 10mg tablet by mouth twice daily for 7 days
3122492|NCT02824224|Placebo Comparator|Placebo|Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
3122493|NCT02824432|Experimental|TAK-085 2g|A dose of 2 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered once a day immediately after meal.
3122494|NCT02824432|Experimental|TAK-085 4g|A dose of 4 grams of omega-3-acid ethyl esters (TAK-085) will be orally administered twice a day immediately after meal.
3122495|NCT02824562|Other|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain. The participants will complete an outcome assessment within 30 days of the last group session.
3122496|NCT02824562|Other|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group. The participants will complete an outcome assessment within 30 days of the last group session."
3122497|NCT02824913|Experimental|P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution will be administered to approximately 8 patients in Phase I and either 0.05% P-321 Ophthalmic Solution or 0.01% P-321 Ophthalmic Solution or additional 0.017% P-321 Ophthalmic Solution will be administered to approximately 16 patients in Phase II
3122498|NCT02824913|Placebo Comparator|Drug: P-321 Ophthalmic Solution placebo|Placebo treatment administered to approximately 8 patients in Phase I and approximately 16 patients in Phase II
3122499|NCT02825212|Experimental|Participant with Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|"Participants treated with either Harvoni or Epclusa~Harvoni 90mg/400 mg FDC once daily. Subjects will take 1 tablet daily with or without food.~Epclusa 400mg/100mg 400mg/100mg FDC once daily"
3122500|NCT02825251|Experimental|Faster-acting insulin aspart CSII|
3122501|NCT02825251|Active Comparator|NovoRapid® CSII|
3122502|NCT02825550|Experimental|Hepatoma treated using Taiwan ACE Beads|The use of Taiwan ACE Beads (T-ACE) microspheres embolization as a treatment for patients with hepatoma.
3122503|NCT02825680|Active Comparator|Enhanced NCP Support|Teams at facilities who expressed interest in being in the trial but who are not randomly assigned to the experimental arm will be in the active comparator arm. These facilities will receive enhanced support from NCP.
3122504|NCT02825680|Experimental|LEAP Intervention|Cohorts of 6 facilities, who expressed interest in being in the trial, will be randomly selected each quarter, as guided by the stepped-wedge trial design protocol, to participate in LEAP. These facilities will also receive the same enhanced NCP support as received by the active comparator arm.
3122505|NCT02825849|Experimental|PRP intrauterine infusion|Intrauterine infusion of platelet rich plasma in combination with standard treatment, in patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles
3122506|NCT02825849|No Intervention|Control group with standard treatment only|Patients with Asherman's Syndrome or thin uterine lining in frozen embryo transfer cycles undergoing standard treatment protocols
3122507|NCT02825966|Other|AUDICOR then LifeVest then AUDICOR|First, assigned to wear AUDICOR device for 15 minutes. Then assigned to wear the WCD, including 6 hours of overnight wear. Total anticipated wear time with WCD is 12-16 hours. Finally, assigned to wear the AUDICOR device for another 15 minutes after finishing the WCD wear.
3122508|NCT02825992|Other|AcQMap System|All patients who underwent catheter ablation using the AcQMap System
3122509|NCT02826421|Experimental|UltraSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
3122510|NCT02826421|Active Comparator|iTec Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
3122511|NCT02826421|Active Comparator|iSert Preloaded Delivery System|Preloaded IOL delivered via a 2.2 mm clear corneal incision during cataract surgery
3122512|NCT02826421|Active Comparator|Monarch III D Manual IOL Delivery System|Manually loaded IOL delivered via a 2.4 mm clear corneal incision during cataract surgery
3122513|NCT02826603|Experimental|Secukinumab|Secukinumab
3122514|NCT02826603|Active Comparator|Ustekinumab|Ustekinumab
3469401|NCT03887026|Experimental|NKT High Dose|NKT single dose - High
3469402|NCT03887026|Placebo Comparator|Placebo|Placebo single dose
3122515|NCT02826694|Other|Well infant, whole exome sequencing|Healthy infants and their parents enrolled in the study prenatally will participate. After the infant is born saliva sample will be collected for DNA extraction and whole exome sequencing will be done.
3122516|NCT02826694|Other|Diagnosed, whole exome sequencing|Infants and children with diagnosed conditions whose parents enroll in the study and consent to having their child sequenced will have saliva samples obtained and whole exome sequencing will be done on extracted DNA.
3122517|NCT02826798|Experimental|VBI-1501A: 0.5µg with adjuvant|0.5µg CMV vaccine with adjuvant
3122518|NCT02826798|Experimental|VBI-1501A: 1.0µg with adjuvant|1.0µg CMV vaccine with adjuvant
3122519|NCT02826798|Experimental|VBI-1501A: 2.0 µg with adjuvant|2.0 µg CMV vaccine with adjuvant
3122520|NCT02826798|Experimental|VBI-1501: 1.0µg without adjuvant|1.0µg CMV vaccine without adjuvant
3122521|NCT02826798|Placebo Comparator|Placebo|Buffer/sucrose used for VBI-1501 suspension
3122522|NCT02827500|Active Comparator|ivabradine|Active Comparator: ivabradine
3122523|NCT02827500|Placebo Comparator|usual care|Placebo Comparator: usual care
3122524|NCT02827708|Experimental|Semaglutide|
3122525|NCT02827708|Placebo Comparator|Placebo|
3122526|NCT02828020|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
3122527|NCT02828020|Experimental|Ubrogepant 100 mg|2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
3122528|NCT02828020|Placebo Comparator|Placebo|2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.
3122529|NCT02828111|Experimental|Patidegib gel 2% - Cohort 1|Patidegib gel 2%, applied topically, once daily for 12 weeks (Cohort 1)
3122530|NCT02828111|Experimental|Patidegib gel 4% - Cohort 2|Patidegib gel 4%, applied topically, once daily for 12 weeks (Cohort 2)
3122531|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 1|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 1)
3122532|NCT02828111|Experimental|Patidegib gel 2% - Cohort 3|Patidegib gel 2%, applied topically, twice daily for 12 weeks (Cohort 3)
3122533|NCT02828111|Experimental|Patidegib gel 4% - Cohort 4|Patidegib gel 4%, applied topically, twice daily for 12 weeks (Cohort 4)
3122534|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 2|Vehicle gel, applied topically, once daily for 12 weeks (Cohort 2)
3122535|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 3|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 3)
3122536|NCT02828111|Placebo Comparator|Vehicle gel - Cohort 4|Vehicle gel, applied topically, twice daily for 12 weeks (Cohort 4)
3122537|NCT02828137||Low NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio < 1.78
3122538|NCT02828137||Intermediate NLR group|1.78 < Neutrophil-to-Lymphocyte (NLR) Ratio < 3.90
3122539|NCT02828137||High NLR group|Neutrophil-to-Lymphocyte (NLR) Ratio > 3.90
3122540|NCT02828241|Experimental|DFD-04 Ointment|DFD-04 (Itraconazole) Ointment
3122541|NCT02828241|Placebo Comparator|Placebo Ointment|Placebo Ointment
3122542|NCT02828267|No Intervention|Usual Care|In the Usual Care arm, patients will have standard discharge information and instructions without any further health or wellness instruction
3122543|NCT02828267|Experimental|BNI|In the BNI arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions.
3122544|NCT02828267|Active Comparator|BNI plus standard booster|In the BNI plus standard booster arm, patients will receive the 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a test focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. The messages will be standard messages for all those in this arm.
3122545|NCT02828267|Active Comparator|BNI plus personalized booster|In the BNI plus personalized booster arm, patients will receive a 5-30 minute brief negotiational intervention about their alcohol use as well as the standard discharge information and instructions. Then after discharge patients will receive a text focused on reducing alcohol use to a SMS capable cell phone weekly for a total of 6 months of follow up. In the personalized arm, the text sent will be personalized based on information obtained about the patient's reasons for reducing their drinking found in the BNI.
3122546|NCT02828358|Experimental|Treatment (azacitidine, combination chemotherapy)|See Detailed Description
3122547|NCT02828436|Experimental|Spinal Cord Stimulation|Boston Scientific Precision Spectra System
3122548|NCT02828436|Other|Exercise Intervention|If subject cannot tolerate Spinal Cord stimulation they will be assigned this arm
3122549|NCT02828644|Active Comparator|EVO Multitasking|EVO Multitasking is a digital intervention that requires subjects to navigate a character through a game-like space, while collecting objects, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
3122550|NCT02828644|Active Comparator|EVO Words|EVO Words is a digital intervention that requires subjects to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time. The intervention was administered to the subjects during the parent study (Akili-001R)
3122551|NCT02828917|Experimental|MedJ-01 drug eluting stent|MedJ-01 Ridaforolimus eluting coronary stent system
3122552|NCT02828982|Experimental|Powered Ankle Prosthesis|In this condition, the participant is fitted with a powered prosthetic ankle by a certified prosthetist. The ankle is the BiOM which is manufactured by Bionx (which used to be named iWalk). This device was given 510(K) Exempt status by the FDA under (regulation number: 890.3500). Participants will wear the device for 2 weeks.
3122553|NCT02828982|Sham Comparator|Dynamic Response Foot|In this arm, participants will wear their clinically prescribed dynamic response foot. This period is 2 weeks long.
3122554|NCT02829034|Active Comparator|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increase to 1000mg by mouth twice per day
3122555|NCT02829034|Placebo Comparator|Placebo|Placebo by mouth twice per day
3122556|NCT02829138|Placebo Comparator|Non-genetic Group|General Nutrition related to Omega-3 fats: Individuals in this group will be provided with only general nutrition information related to omega-3 fats and health.
3122557|NCT02829138|Experimental|Genetic Group|Genetic information and Omega-3 fat intake: Individuals in this group will be provided with general nutrition information related to omega-3 fats and health, as well as their personal genetic information for a common gene variant related to omega-3 fatty acid metabolism.
3122558|NCT02829294|Experimental|Treatment|E002 - cerumen removal aid will be placed into the ear canal of enrolled subjects for 15 to 30 minutes
3122559|NCT02829307|Experimental|89Zr-GSK3128349|Subjects will receive a single dose of 89Zr-GSK3128349 as an intravenous (IV) infusion over 20 minutes to deliver a dose of 1 mg
3122560|NCT02829320|Experimental|GSK1278863|Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
3122561|NCT02829463||osteoarthritis patients|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients with osteoarthritis. It's not the intervention the study applied, but the subjects' disease demands.
3122562|NCT02829463||healthy controls|3.0 Tesla Magnetic resonance imaging was analyzed. It's the documentation from the outpatients and inpatients without osteoarthritis. It's not the intervention the study applied, but the subjects' non-osteoarthritis knee symptom demands.
3122563|NCT02829775|Experimental|Interferon Alfa-2A in Cancer Participants|Participants who responded to interferon alfa-2A (either pegylated interferon alfa-2A or recombinant interferon alfa 2A) treatment during the parent study will continue to receive the same treatment in this study. Pegylated interferon alfa-2A will be administered subcutaneously once weekly and recombinant interferon alfa 2A will be administered subcutaneously once daily, until disease progression, withdrawal, or death whichever occurs first (up to approximately 3 years).
3122564|NCT02829918|Experimental|Nivolumab Treatment|This is a single arm study with two stage design using nivolumab in advanced biliary tract cancer (BTC), for participants who have failed or are intolerant to at least one line of therapy and no more than 2 lines of therapy. In the first stage, 18 participants will be accrued. If there is at least one response (or several participants with stable disease based on the study team's discretion), an additional 34 patients will be accrued for a total of 52 patients.
3122565|NCT02829944|Experimental|Ropivacaine|Subjects will receive 440 mg ropivacaine and 30 mg ketorolac. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
3122566|NCT02829944|Placebo Comparator|Placebo|Subjects will receive saline placebo. Infusion of study medication will start after the skin is sutured and will continue for 48 hours after cesarean delivery.
3122567|NCT02829983|Active Comparator|clarithromycin group|20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
3122568|NCT02829983|Placebo Comparator|placebo group|20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
3122569|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.005% QD|trabodenoson 6.0% / latanoprost 0.005% QD FDC
3122570|NCT02829996|Experimental|trabodenoson 3.0% /latanoprost 0.005% QD|trabodenoson 3.0% / latanoprost 0.005% QD FDC
3122571|NCT02829996|Experimental|trabodenoson 6.0% /latanoprost 0.0025%QD|trabodenoson 6.0% /latanoprost 0.0025% QD FDC
3122572|NCT02829996|Active Comparator|latanoprost 0.005% QD|latanoprost 0.005% ophthalmic solution QD
3122573|NCT02829996|Active Comparator|latanoprost 0.0025% QD|latanoprost 0.0025% ophthalmic solution QD
3122574|NCT02830074|Experimental|The BEST Program|a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + patient Education + ongoing Support and Training)
3122575|NCT02830074|Active Comparator|Sleep Education and standard SDB treatment|This program includes non-directive sleep education plus standard treatment of SDB.
3122576|NCT02830087|Active Comparator|220 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 220 mmHg.
3122577|NCT02830087|Active Comparator|250 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 250 mmHg
3122578|NCT02830087|Active Comparator|275 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 275 mmHg
3122579|NCT02830087|Active Comparator|300 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 300 mmHg
3122580|NCT02830087|Active Comparator|325 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 325 mmHg
3122581|NCT02830087|Active Comparator|350 mmHg tourniquet cuff pressure|Thigh tourniquet cuff inflated to 350 mmHg
3122582|NCT02830438|Experimental|Shear wave elastography group|Patients referred for kidney biopsy will then undergo shear wave elastography measurements.
3122583|NCT02830776|Experimental|Treatment group|This is a single-arm open label proof of concept pilot study evaluating use of Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping).
3122584|NCT02830880|Experimental|FACBC|Participants with biopsy-proven primary or recurrent castration-resistant prostate carcinoma with skeletal and/or nodal involvement will undergo an FACBC PET-CT scan.
3122585|NCT02830893|Experimental|The LARA Therapy|The LARA arm of this study will use the LARA system while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. LARA is a system that facilitates patients to perform high amounts of arm movement with the affected upper extremity. Study participants are able to actively propel themselves in the unit.
3122586|NCT02830893|Active Comparator|The Standard Therapy|The control arm of this study will use a standard wheelchair while study participants are staying at the acute rehabilitation unit of UC Irvine Douglas Hospital. Study participants will have no exposure to LARA and they will use a standard wheelchair. They will use their unaffected upper and lower extremities to propel themselves in the unit.
3122587|NCT02831257|Experimental|AZD2014|"18 patients will be enrolled in this study in a single stage.~AZD2014 orally, 2 times a day on 2 consecutive day out of every 7 days.~One cycle will consist of 28 days (1 cycle = 28 days)."
3122588|NCT02831387|Experimental|0.017% P-321 Ophthalmic Solution|0.017% P-321 Ophthalmic Solution TID for 28 days.
3122589|NCT02831387|Placebo Comparator|Placebo|P-321 Ophthalmic Solution Placebo TID for 28 days.
3122590|NCT02831569|Experimental|Loxoprofen sodium/methocarbamol FDC|fixed dose combination (FDC) tablets
3122591|NCT02831660|Experimental|idarucizumab|
3469403|NCT03886896|Experimental|Group A - lidocaine group|Group A: children receiving standard general anesthesia with intravenous lidocaine infusion 1,5 mg/kg for 5 minutes before induction of anesthesia. After 5 minutes, lidocaine infusion continued at rate of 1.5 mg/kg/h during operation, and discontinued before move the patients to PACU.
3469404|NCT03886896|No Intervention|Group B - control group|Group B: children receiving standard general anesthesia (involving fentanyl and sevoflurane) without lidocaine infusion
3469405|NCT03886844||Prolacta group|Infants, who received a human milk fortifier based on human milk (12/2015-11/2018), started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity
3469406|NCT03886844||"Frauenmilch Supplement=FMS group"|Infants, who received a human milk fortifier based on bovine milk (05/2012-06/2015), started with an enteral intake of 100 ml/kg
3122596|NCT02831816|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
3122597|NCT02831816|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3122598|NCT02831816|Placebo Comparator|ZP Vehicle|ZP without IPA
3122599|NCT02831855|Experimental|CP-690,550 and methotrexate|Open-label tofacitinib tablet and blinded methotrexate capsule
3122600|NCT02831855|Placebo Comparator|CP-690,550 and placebo|open-label tofacitinib tablet and blinded matching placebo for methotrexate capsule
3122601|NCT02831998|Experimental|ZP (70% IPA)|Isopropyl alcohol (IPA) 70%
3122602|NCT02831998|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3122603|NCT02831998|Placebo Comparator|ZP Vehicle|ZP without IPA
3122604|NCT02832037|Experimental|BI 425809 dose 1|
3122605|NCT02832037|Experimental|BI 425809 dose 2|
3122606|NCT02832037|Experimental|BI 425809 dose 3|
3122607|NCT02832037|Experimental|BI 425809 dose 4|
3122608|NCT02832037|Placebo Comparator|Placebo|
3122609|NCT02832115|Experimental|Study|40 mg of topical lidocaine and 30 mg of topical nitroglycerine is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
3122610|NCT02832115|Placebo Comparator|Control|40 mg of topical lidocaine and placebo is applied to the wrist overlying radial pulse (centered approximately 1 inch proximal to the radial styloid process) at least 60 minutes before arterial puncture. Immediately prior to sterile preparation of access site, transdermal preparation will be removed in the cath lab.
3122611|NCT02832154|Experimental|Supportive Care|Patients complete an initial online questionnaire lasting about 25-30 minutes. Patients complete an internet-delivered PA program during weeks 3-8. Each week consists of didactic material and 20-30 minutes of daily online exercises.
3122612|NCT02832167|Experimental|Nivolumab|
3122613|NCT02832284|Experimental|iNod System|Multi-center, Prospective, Single-arm Feasibility Study with Salvage.
3122614|NCT02832375|Experimental|Experimental: stannous fluoride|Participants will be instructed to dose a dry toothbrush containing 0.454% w/w of stannous fluoride (1000 parts per million [ppm] fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
3122615|NCT02832375|Active Comparator|Standard: sodium monofluorophosphate|Participants will be instructed to dose a dry toothbrush containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride) with a full strip (1 inch) of toothpaste. Participants will then brush each of the two selected sensitive test teeth first followed by the whole mouth thoroughly for at least 1 minute.
3122616|NCT02832622||MPP Programming|This post-market study was designed to characterize the real-world use of MPP technology in patients indicated for CRT device implant. Therefore in order to adequately characterize MPP, data from subjects with MPP programmed continuously or for at least 3 months prior to the final follow-up are reported as the MPP programming group.
3122617|NCT02832674|Experimental|Single Treatment|All enrolled subjects will receive a Percutaneous Radiofrequency Single Treatment'
3122618|NCT02833077|Experimental|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC was injected into the chin at a volume determined by the investigator on Day 0. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 milliliters (mL) for both treatments combined.
3122619|NCT02833077|Other|No Treatment then JUVÉDERM VOLUMA® XC|No treatment for 6 months followed by optional treatment with JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator on Month 6. Participants were eligible to receive touch-up treatment 30 days later, if applicable. The maximum total volume administered was up to 4 mL for both treatments combined.
3469407|NCT03886779|Active Comparator|Prolensa (Bromfenac Ophthalmic Solution) 0.07%|Bausch and Lomb, Rochester, NJ Dose: Subjects will instill one drop into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one days prior to surgery (Day 1), continue on the day of surgery plus 1 hour before surgery and for 14 days after surgery.
3469408|NCT03886779|Active Comparator|Ilevro® (nepafenac ophthalmic suspension ) 0.3%|Alcon Laboratories, Inc., Fort Worth, TX Dose: Subjects will instill one drop of test article into the study (operative) eye once daily for a maximum of 16 days. Dosing will begin one day prior to surgery (Day 1), continue on the day of surgery plus1 hour before surgery and for 14 days after surgery.
3469409|NCT03886948|Experimental|Prefilled Syringe (PFS) with LY3074828|PFSs containing LY3074828
3469410|NCT03886948|Experimental|AutoInjector (AI) with LY3074828|AI containing LY3074828
3469411|NCT03886818|Experimental|PICO strategy|"Use of PICO™ device from the ankle surgery to the post-surgery day 7.~Use of usual care by simple dressings after post-surgery day 7 up to wound healing"
3469412|NCT03886818|Active Comparator|Standard of care|-Usual care by simple dressings after the ankle surgery until the wound healing.
3122620|NCT02833350|Experimental|Cohort 1: GDC-0853 High Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 high dose, orally once daily along with placebo matched to adalimumab, subcutaneously every 2 weeks (Q2W) starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 milligrams per week (mg/week) (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122621|NCT02833350|Experimental|Cohort 1: GDC-0853 Low Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 low dose, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122622|NCT02833350|Experimental|Cohort 1: GDC-0853 Mid Dose + Adalimumab Placebo|Participants of Cohort 1 will receive GDC-0853 mid dose, orally twice daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122623|NCT02833350|Active Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122624|NCT02833350|Placebo Comparator|Cohort 1: GDC-0853 Placebo + Adalimumab Placebo|Participants of Cohort 1 will receive placebo matched to GDC-0853, orally once daily along with placebo matched to adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122625|NCT02833350|Experimental|Cohort 2: GDC-0853 High Dose|Participants of Cohort 2 will receive GDC-0853 high dose, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122626|NCT02833350|Placebo Comparator|Cohort 2: GDC-0853 Placebo|Participants of Cohort 2 will receive placebo matched to GDC-0853, orally twice daily for 12 weeks. Participants will remain on a stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines) and folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
3122627|NCT02833415|Experimental|Empagliflozin|Empagliflozin 10 mg by mouth daily for 3 months.
3122628|NCT02833415|Placebo Comparator|Placebo|Placebo one tablet daily for 3 months
3122629|NCT02833844|Experimental|Double-Blind Placebo SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind placebo subcutaneous (SC) injection every 4 weeks (QM) for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
3122630|NCT02833844|Placebo Comparator|Double-Blind Evolocumab 420 mg SC QM/Open-Label Evolocumab 420 mg SC QM|Double-blind evolocumab SC injection QM for 24 weeks, followed by open-label evolocumab 420 mg SC QM for 24 weeks.
3122631|NCT02833857|Experimental|Etelcalcetide|Participants received a single, intravenous (IV) bolus administration of 0.035 mg/kg etelcalcetide at the end of hemodialysis on study day 1.
3122632|NCT02833922||Women using Dot to avoid pregnancy|Women living in the United States, ages 18-39 who have not used hormonal birth control or been pregnant in the last three months, who are in a relationship with a male sexual partner, and who wish to use the Dot app to avoid pregnancy for at least one year.
3122633|NCT02833948|Active Comparator|ASA + Clopidogrel|ASA (Acetylsalicylic acid) 75-100mg + Clopidogrel 75mg for 90 days, followed by ASA 75-100mg monotherapy
3122634|NCT02833948|Experimental|Rivaroxaban + ASA|Rivaroxaban 10mg + ASA 75-100mg for 90 days, followed by rivaroxaban 10mg monotherapy
3122635|NCT02833974|Experimental|GSK2245035 20 ng|Participants will receive 20 ng of GSK2245035 Nasal spray solution (1 spray=10 ng GSK2245035 per actuation per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
3122636|NCT02833974|Placebo Comparator|Placebo|Participants will receive placebo Nasal spray solution (1 spray per nostril) every week for the duration of 8 weeks administered using a metered Valois VP7 pump
3122637|NCT02834247|Experimental|Part 1: Advanced Solid Tumors|TAK-659 60 milligram (mg), tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 milligram per kilogram (mg/kg), infusion over 60 minutes, intravenously (IV), on Days 1 and 15 in each 28 day treatment cycle until PD or unacceptable toxicity. Dose escalation of TAK-659 to 100 mg may be done using a 3 + 3 dose escalation design to determine a maximum tolerated dose (MTD) and/or RP2D.
3122638|NCT02834247|Experimental|Nivolumab Fixed Dose Cohort|After RP2D of TAK-659 has been identified, based on evaluation of combination with weight-based dose of nivolumab (3 mg/kg), RP2D may be evaluated in combination with a fixed dose of 240 mg IV nivolumab after discussion between investigator and sponsor for all types of advanced solid tumors. For single-agent nivolumab, fixed dose is expected to have equal exposure, safety, and efficacy as weight-based (3 mg/kg) dose. If nivolumab fixed dose is evaluated with TAK-659 RP2D, 3 participants will be initially enrolled into cohort. Following evaluation of safety, efficacy, and any available PK data, along with discussions between investigator and sponsor, 3 additional participants may be enrolled into cohort for a total of 3 to 6 participants. If >=1 out of 6 participants experiences dose-limiting toxicity (DLT) in Cycle 1, or significant safety issues are seen in Cycle 2 and beyond, re-evaluation of TAK-659 RP2D when administered with a fixed dose of nivolumab is permitted.
3122639|NCT02834247|Experimental|Part 2: Metastatic Triple-negative Breast Cancer (TNBC)|Participants with metastatic TNBC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
3122640|NCT02834247|Experimental|Part 2: Metastatic Non-small Cell Lung Cancer (NSCLC)|Participants with metastatic NSCLC will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1.disease or unacceptable toxicity. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
3122641|NCT02834247|Experimental|Part 2: Metastatic HNSCC|Participants with Head and Neck Squamous Cell Carcinoma (HNSCC) will receive TAK-659 at the RP2D as determined in Part 1, tablets, orally, once daily in each 28-day treatment cycle in combination with nivolumab 3 mg/kg, infusion over 60 minutes, intravenously, on Day 1 and Day 15 of each 28 day treatment cycle until PD or unacceptable toxicity. A subset of participants will receive two weeks of TAK-659 monotherapy during Cycle 1, and will receive nivolumab beginning on Day 15 of Cycle 1. The dose of nivolumab will be either 3 mg/kg or 240 mg IV, dependent on whether the 240 mg fixed-dose cohort is evaluated and deemed safe and tolerable. If so, the dosing regimen may switch to 240 mg, on the basis of change in clinical practice and discussion between the investigator and sponsor. If the nivolumab fixed-dose evaluation cohort is not run, the dose of nivolumab for all participants in the dose expansion phase will be 3 mg/kg.
3122642|NCT02834390|Experimental|Quizartinib 20 mg/day|"Participants who received 20 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
3122643|NCT02834390|Experimental|Quizartinib 40 mg/day|"Participants who received 40 mg quizartinib once daily in the morning under fasting conditions.~For the Induction phase, cytarabine (100 mg/m^2/day IV) and either idarubicin (12 mg/m^2/day IV infusion) or daunorubicin (60 mg/m^2/day IV) were co-administered with quizartinib.~For the Consolidation phase, cytarabine (3.0 g/m^2/12 hours IV) was co-administered with quizartinib."
3122644|NCT02834624|Active Comparator|Calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
3122645|NCT02834624|Active Comparator|Poractant Alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
3122646|NCT02834663|Experimental|Lucentis|Patients were administered 0.5-mg IVR injections monthly for 6 months.
3122647|NCT02834806|Experimental|BioNIR drug eluting stent system|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
3122648|NCT02834819|Experimental|Hypertonic Saline|Patients randomized to the hypertonic saline group will be administered one nebulized treatment of 3% hypertonic saline. They will also receive what is considered standard of care, which includes suctioning and supportive care as needed.
3122649|NCT02834819|No Intervention|No treatment|"Patients in the No treatment arm will receive no additional treatment other than standard of care, which includes suctioning and supportive care as needed."
3122650|NCT02835092|Active Comparator|Self-directed Control|
3122651|NCT02835092|Experimental|Take Shape For Life Program|
3122652|NCT02835092|Experimental|Medifast Direct Program|
3122653|NCT02835274|Experimental|Ring mode followed by Unrestricted mode|omni-directional stimulation followed by unrestricted Mode stimulation
3122654|NCT02835274|Active Comparator|Unrestricted mode followed by ring mode|Unrestricted Mode stimulation followed by omni-directional stimulation
3122655|NCT02835339|Active Comparator|MgSO4 4g load, 1g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
3122656|NCT02835339|Experimental|MgSO4 6g load, 2g/hr infusion|Once their obstetrician prescribes magnesium sulfate, participant will be assigned by 50/50 chance to one of two treatment regimens. Participant will be assigned to either a dose of 4 g at the start, followed by 1g every hour; or a dose of 6 g at the start, followed by 2g every hour until treatment for preeclampsia is complete.
3122657|NCT02835495|Experimental|Lifestyle Weight Loss|"Behavioral: HELP Vets Intervention~Lifestyle intervention consisting of 24 weekly group meetings led by a Veteran community health worker and 3 individual sessions with a nutritionist/diabetes educator"
3122658|NCT02835495|Active Comparator|Enhanced Usual Care|"Behavioral: Individual Education Program~Standard care consisting of 2 individual sessions with a nutritionist/diabetes educator and a monthly newsletter"
3122659|NCT02835625|Active Comparator|Digital Breast Tomosynthesis|"Synthetic Mammography (SM) + Digital Breast Tomosynthesis (DBT)~The SM+DBT will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.~Women selected for further assessment (positive screening exam) will be recalled."
3122660|NCT02835625|Active Comparator|Digital mammography|The digital mammograms will be independently read by two radiologists. A consensus meeting will decide whether to recall the woman or not.
3122661|NCT02835677|Experimental|Intervention|Behavioral intervention with caregivers to reduce stress and management of patient concerns, particularly ambulation
3122662|NCT02835690|Experimental|Pembrolizumab 2 mg/kg|Participants receive pembrolizumab 2 mg/kg administered intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
3122663|NCT02835690|Experimental|Pembrolizumab 10 mg/kg|Participants receive pembrolizumab 10 mg/kg administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
3122664|NCT02835690|Experimental|Pembrolizumab 200 mg Fixed Dose|Participants receive pembrolizumab 200 mg fixed dose administered IV Q3W for up to 35 administrations. Cycle 1 is 28 days and subsequent cycles are 21 days.
3122665|NCT02835820|Experimental|Ketogenic Diet Group|Ketogenic meals (3 meals/day, 7 days/week x 12 weeks) prepared and delivered to participants.
3122666|NCT02835820|No Intervention|Patient Choice Diet|Control.
3122667|NCT02835846|Experimental|Estrogen Arm|The intervention for this study is an estrogen cream (i.e., Premarin Cream®). Women in this study will receive this estrogen cream and apply it to their vagina twice weekly for 12 weeks
3122671|NCT02836249|Experimental|TAF|TAF + TDF placebo for up to 144 weeks
3122672|NCT02836249|Active Comparator|TDF|TDF + TAF placebo for up to 144 weeks
3122673|NCT02836249|Experimental|Open-label TAF|All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.
3122674|NCT02836496|Experimental|Mepolizumab|Enrolled subjects will receive either mepolizumab 300 mg or placebo subcutaneous (SC) every 4 weeks while continuing their HES therapy.
3122675|NCT02836496|Placebo Comparator|Placebo|Enrolled subjects will receive either mepolizumab 300 mg or placebo SC every 4 weeks while continuing their HES therapy.
3122676|NCT02836613|Active Comparator|Galcanezumab Reference|Single dose of 240 milligrams (mg) galcanezumab (LY2951742) administered subcutaneously (SC) by manual prefilled syringe (PFS).
3122677|NCT02836613|Experimental|Galcanezumab Test|Single dose of 240 mg galcanezumab (LY2951742) administered SC by autoinjector.
3122678|NCT02836652|Experimental|Treatment Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + placebo (1 pill/day) post HeartMate II implant
3122679|NCT02836652|Active Comparator|Control Arm|Warfarin (INR Target 2.0-2.5, median 2.25, per standard of patient care) + acetylsalicylic acid (ASA) therapy (81mg/day) post HeartMate II implant
3122680|NCT02836769|Experimental|Rehabilitation Consult (RC)|Pilot testing: single group pre-post design
3122681|NCT02836873|Active Comparator|Bexagliflozin tablets, 20 mg|Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
3122682|NCT02836873|Placebo Comparator|Placebo tablets|Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
3122683|NCT02836990|Active Comparator|Prevena|Prevena Incision Management System for vascular surgical groin wounds
3122684|NCT02836990|Active Comparator|Dermabond|Dermabond for vascular surgical groin wounds
3122685|NCT02837029|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive yttrium Y 90 glass microspheres IA. Approximately 4 weeks after yttrium Y 90 glass microspheres treatment, patients receive nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3122686|NCT02837237|Experimental|KBP-5074|Single oral dose
3122687|NCT02837328|Experimental|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
3122688|NCT02837328|Placebo Comparator|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
3122689|NCT02837731|Experimental|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness using the Starling SV monitor will be performed at every clinical decision point for the first 72 hours of study enrollment. Examples of a clinical decision point include a mean arterial pressure (MAP) of < 65, the decision to give additional fluid volume, and the decision to either escalate or wean vasopressors. Fluid responsiveness will be assessed using a passive leg raise (PLR) to guide corresponding treatment.
3122690|NCT02837731|No Intervention|Control|No required therapeutic protocol will be used for patient treatment, and is determined per the discretion of the physician and hospital standards.
3122691|NCT02837744||Axiostat®|Size: 3.5 cm X 3.5 cm
3122692|NCT02837913|Experimental|Underbody warmer on|Underbody warmer will be underneath the patient and turned on.
3122693|NCT02837913|Placebo Comparator|Underbody warmer off|Underbody warmer will be underneath the patient but not turned on.
3122694|NCT02837952|Active Comparator|Fixed Dose Combination(FDC) IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
3122695|NCT02837952|Placebo Comparator|Placebo|Placebo
3122696|NCT02838017|Experimental|Tissue Adhesive|Tissue Adhesive will be placed over subcuticular suture closure.
3122697|NCT02838017|Active Comparator|Steri-Strips|Sterile strips will be placed over subcuticular suture closure.
3122698|NCT02838134|Experimental|Group A: Deep Neuromuscular blockade|An extra bolus of rocuronium after intubation followed by infusion
3122699|NCT02838134|Sham Comparator|Group B: Moderate neuromuscular Blockade|Moderate neuromuscular Blockade No additional rocuronium after intubation.
3122700|NCT02838407|Other|Total group|All enrolled subjects, male or female aged between 6 months included and less than 6 years at the time of enrollment, who visited the hospital with suspected chronic lower respiratory tract infections (LRTIs) and who had an indication for bronchoalveolar lavage (BAL).
3122701|NCT02838420|Experimental|Alectinib|Participants will receive alectinib capsules orally at a dose of 600 mg BID with food until disease progression, unacceptable toxicity withdrawal of consent, or death.
3122702|NCT02838420|Active Comparator|Crizotinib|Participants will receive crizotinib capsules orally at a dose of 250 mg BID with or without food until disease progression, unacceptable toxicity withdrawal of consent, or death.
3122703|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 5)|Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm^2) treatment area, once daily for 5 consecutive days.
3122704|NCT02838628|Experimental|KX2-391 50 mg (Days 1 to 3)|Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm^2 treatment area, once daily for 3 consecutive days.
3122705|NCT02838901|Experimental|Beet It Beetroot Juice|70 cc (3.8 millimoles nitrate) Beet It organic beetroot juice once a day for 30 days. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.
3122706|NCT02838901|Placebo Comparator|Beet It Beetroot Juice Placebo|70 cc Beet It organic beetroot juice (placebo) once a day for 30 days. The placebo beet juice is identical in appearance and taste with nitrate removed. Vitamin C 500 mg (tablets) will be given along with each dose of the juice.Beet It Placebo Beetroot juice.
3122707|NCT02839200|Experimental|ACT-541468 5 mg|Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
3122708|NCT02839200|Experimental|ACT-541468 10 mg|Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
3122709|NCT02839200|Experimental|ACT-541468 25 mg|Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
3122710|NCT02839200|Experimental|ACT-541468 50 mg|Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
3122711|NCT02839200|Active Comparator|Zolpidem|Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
3122712|NCT02839200|Placebo Comparator|Placebo|Each subject receives two placebo capsules, once daily in the evening for 4 weeks
3122713|NCT02839330|Experimental|Group A|aH5N1c lot #1; receive 2 doses (on Day 1 and Day 22)
3122714|NCT02839330|Experimental|Group B|aH5N1c lot #2; receive 2 doses (on Day 1 and Day 22)
3122715|NCT02839330|Experimental|Group C|aH5N1c lot #3; receive 2 doses (on Day 1 and Day 22)
3122716|NCT02839330|Placebo Comparator|Group D|Placebo; receive 2 doses (on Day 1 and Day 22)
3122717|NCT02839681|Experimental|1/Safety Run-in Arm|Subjects will be dosed with the higher of the 2 possible anetumab ravtansine doses (dose level 1) evaluated on the study
3122718|NCT02839681|Experimental|2/Phase 2 Arm|Subjects will be dosed with anetumab ravtansine at the recommended phase 2 dose (dose level 1 if no more than 1 dose limiting toxicity (DLT) occurred in the safety run-in arm, or at dose level -1 otherwise)
3122719|NCT02839746||Dabigatran|Patients switched from vitamin K antagonist (VKA) to dabigatran
3122720|NCT02839772|Active Comparator|Current skin care regimen|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 6 litres of water with added sodium hypochlorite (0.0125%), air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
3122721|NCT02839772|Experimental|Current skin regimen plus 2% glycerine|Legs/feet washed daily for 3 months with soapy water, soak for 30 mins in 1 litre of water with added sodium hypochlorite (0.0125%) and 2% glycerine, air dried, thin layer of petrolatum jelly applied and Whitfields ointment if required for any fungal infection.
3122722|NCT02839798|Experimental|sTMS active|Treatment with the NEST Device
3122723|NCT02839876|Experimental|Intravenous acetaminophen|Subjects receive 1000 mg acetaminophen IV immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an oral placebo.
3122724|NCT02839876|Active Comparator|Oral acetaminophen|Subjects receive 1000 mg acetaminophen PO immediately preoperatively, as well as at 6, 12, and 18 hours postoperatively. At the same time points, subjects will receive an intravenous placebo.
3122725|NCT02839889|Placebo Comparator|Placebo|Placebo once daily for two weeks
3122726|NCT02839889|Active Comparator|Naloxegol|Naloxegol 25mg tablets once daily for two weeks
3122727|NCT02839902|Experimental|TAK-085 4g|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) capsule is orally administered immediately after meal twice a daily (totally 4g per a day) for 8 weeks, plus a stable HMG-CoA reductase inhibitor regimen (started ≥4 weeks prior to informed consent) at a consistent dose.
3122728|NCT02839902|Experimental|Control Group|Stable HMG-CoA reductase inhibitor regimen at a consistent dose only.
3122729|NCT02840097|Experimental|Tranexamic acid dose A|Subjects will receive a 15 mg/kg bolus of tranexamic acid over 10 minutes followed by a 2mg/kg/h over 8 hours. This represents 31mg/kg total dose of TXA.
3122730|NCT02840097|Experimental|Tranexamic acid dose B|Subjects will receive a 30 mg/kg bolus of tranexamic acid over 10 minutes followed by a 4 mg/kg/h over 8 hours. This represents 62 mg/kg total dose of TXA.
3122731|NCT02840097|Placebo Comparator|Placebo|Subjects in the placebo group will receive a bolus dose of normal saline over 10 minutes followed by a normal saline infusion over 8 hours.
3122732|NCT02840253|Experimental|NIRS|Non-invasive near infrared spectroscopy to assess changes in tissue and cerebral oxygenation.
3122733|NCT02840461|Experimental|Ivermectin Cream, 1%|test product, manufactured by Actavis Laboratories UT, Inc.
3122734|NCT02840461|Active Comparator|SoolantraTM (ivermectin) Cream, 1%|reference product, manufactured by Galderma Laboratories, L.P.
3122735|NCT02840461|Placebo Comparator|Placebo/Vehicle cream|Placebo, manufactured by Actavis Laboratories UT, Inc.
3122736|NCT02840474|Experimental|Part A: VRC01LS (40 mg/kg)|VRC-HIVMAB080-00-AB (VRC01LS) - (40 mg/kg) - administered intravenously (IV) at Day 0
3122737|NCT02840474|Experimental|Part B: VRC07-523LS (40 mg/kg)|VRC-HIVMAB075-00-AB (VRC07-523LS) - (40 mg/kg) - administered IV at Day 0
3122738|NCT02840721|Experimental|PF-06480605|PF-06480605 500 mg IV Q2W X 7 doses
3122739|NCT02840916|Experimental|verum laser acupuncture|verum laser acupuncture
3122740|NCT02840916|Sham Comparator|sham laser acupuncture|sham laser acupuncture (no laser output)
3122741|NCT02841033|Experimental|Daratumumab|Daratumumab, 16mg/kg body weight in 1000 mL for the first dose, followed by 500mL for subsequent doses, once weekly for two months, then every 2 weeks for four months, then once each month.
3122742|NCT02841046|Other|group cardiac index|the treatment scheme of goal-directed fluid therapy(GDFT) use cardiac index（CI） as the primary judgment in group cardiac index,Patients in group cardiac index received a therapy with the goal of CI was no less than 2.5L•min-1•m-2 .
3122743|NCT02841046|Experimental|group Stroke Volume Variation|the treatment scheme of goal-directed fluid therapy(GDFT) use Stroke Volume Variation（SVV）and cardiac index（CI）as the primary judgment in group Stroke Volume Variation,Patients in group Stroke Volume Variation received a therapy with SVV was less than 12% and CI was no less than 2.5L•min-1•m-2 .
3122744|NCT02841189|Other|Video laryngoscope intubation|The King Vision Video Laryngoscope will be used for intubation
3122745|NCT02841241|Experimental|Esmolol|Esmolol infusion, started without bolus, with slow upward titration to a maximum infusion rate is protocolized, with a target heart rate of 80-90/min
3122746|NCT02841267|Active Comparator|Low Dose, Cohort 1|4 subjects will be enrolled in cohort 1 and will receive an initial dose of 5mg/kg PF 06252616 IV every 4 weeks. Following 32 weeks of treatment and a safety review, if no stopping rules have been met, subjects will be receive an additional 32 weeks of treatment with 40 mg/kg PF 06252616 IV every 4 weeks.
3122747|NCT02841267|Active Comparator|Middle dose, Cohort 2|8 subjects will be enrolled in cohort 2 and receive 20 mg/kg of PF 06252616 IV every 4 weeks for 32 weeks.
3122748|NCT02841267|Active Comparator|High dose, Cohort 3|8 subjects will be enrolled in cohort 3 and receive 40 mg/kg of PF06252616 IV every 4 weeks for 32 weeks.
3122749|NCT02841397|Experimental|Test group|All subjects will be enrolled into the test group and will receive Masimo Pulse CO-Oximeter for measurement of various physiological parameters.
3122750|NCT02841449|Experimental|Hypohydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 3 mL/kg lean body mass to consume over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass would consume 191 mL water [63.75 kg * 3 mL])
3122751|NCT02841449|Experimental|Rehydrated|After being dehydrated in the heat tent, participants in this trial arm will be given 40 mL/kg lean body mass plus 150 % of their water losses (from the heat tent procedure) over the rest of the day (e.g. a 75 kg participant with a body composition of 85 % fat free mass and lost 1 % of their body mass in the heat tent (0.75 kg) would consume 2550 mL [63.75 kg * 40 mL] + 1125 mL [750 g * 1.5], totalling 3675 mL).
3122752|NCT02841644||Traumatic Arthrotomy- Treated Nonoperatively|Patient diagnosed with traumatic arthrotomy treated nonoperatively.
3122753|NCT02841644||Traumatic Arthrotomy- Treated Operatively|Patient diagnosed with traumatic arthrotomy treated operatively.
3122754|NCT02841709|Experimental|Sequence 1|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D4, D2, D3, D1 and P, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
3122755|NCT02841709|Experimental|Sequence 2|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D2, P, D4, D3 and D1, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
3122756|NCT02841709|Experimental|Sequence 3|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D3, D1, D2, P and D4, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
3122757|NCT02841709|Experimental|Sequence 4|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: P, D4, D1, D2, D3, with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
3122758|NCT02841709|Experimental|Sequence 5|Each subject participates in 5 treatment periods. On the evening of the first 2 days of each period they receive one dose (D) of ACT-541468 or placebo orally in the following order: D1, D3, P, D4 and D2 with D4 = the highest dose (50 mg) and D1 the lowest dose (5 mg). Each treatment period is separated from the next one by a 5- to 12-day washout.
3122759|NCT02841787|Experimental|Individual Internet Intervention (III)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered individually by 2 clinical psychologists.~(iCBT for late life depression without social network included.)"
3122760|NCT02841787|Experimental|Internet Intervention+Peer Supp.(II+PS)|"Coached internet intervention based on the principles of cognitive behavioral therapy (CBT) for depressed older adults delivered with peer support; group moderation was provided by 2 clinical psychologists.~(iCBT for late life depression with social network included.)"
3122761|NCT02841787|No Intervention|Waitlist Control (WLC)|Waiting period, no intervention administered. WLC participants received access to the III following the 8-week waiting period.
3122762|NCT02842060|Experimental|myDEx Intervention|The proposed intervention will consist of a 6-session web-based program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, YMSM will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help YMSM consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
3122763|NCT02842060|Active Comparator|Non-tailored HIV Prevention|The investigators will create a 6-session web-based attention-control comparison to match myDEx in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites.
3122764|NCT02842073|Experimental|Naltrexone and Buproprion|Investigators will use standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) and naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
3122765|NCT02842086|Experimental|F/TAF|F/TAF+ F/TDF placebo for at least 96 weeks
3122766|NCT02842086|Experimental|F/TDF|F/TDF+ F/TAF placebo for at least 96 weeks
3122767|NCT02842086|Experimental|Open-label|Once all participants have been on blinded treatment for at least 96 weeks, the study will be unblinded and participants will be offered the option to continue on open-label F/TAF treatment for 96 weeks.
3122768|NCT02842086|Experimental|Open-Label Extension|Participants who remain on study at Open-label Week 96 will have the option to continue on open-label F/TAF treatment in the Open-label extension phase for 144 weeks.
3122769|NCT02842151|Other|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard). Subject implanted with ACRYSOF® IQ Monofocal IOL Model SN60WF. Autorefraction performed by Topcon® KR-1W Wave-Front Analyzer.
3122770|NCT02842242|Experimental|Open Label|MYK-461
3122771|NCT02842736|Experimental|Endometrial Cryoablation|
3122772|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 1|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 1a) and adults aged 18 to 55 years (Group 1b) received a single dose of MenACYW conjugate vaccine from lot 1 on Day 0.
3122773|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 2|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 2a) and adults aged 18 to 55 years (Group 2b) received a single dose of MenACYW conjugate vaccine from lot 2 on Day 0.
3122774|NCT02842853|Experimental|MenACYW Conjugate Vaccine Lot 3|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 3a) and adults aged 18 to 55 years (Group 3b) received a single dose of MenACYW conjugate vaccine from lot 3 on Day 0.
3122775|NCT02842853|Active Comparator|Menactra®|Healthy, meningococcal-vaccine naive adolescents aged 10 to 17 years (Group 4a) and adults aged 18 to 55 years (Group 4b) received a single dose of Menactra® on Day 0.
3122776|NCT02842866|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, adult participants aged greater than or equal to (≥) 56 years received a single dose of MenACYW Conjugate Vaccine on Day 0.
3122777|NCT02842866|Active Comparator|Group 2: Menomune® Vaccine|Healthy, adult participants aged ≥56 years received a single dose of Menomune®- A/C/Y/W-135 Vaccine on Day 0.
3122778|NCT02843178|Experimental|1: distributed, targeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
3122779|NCT02843178|Active Comparator|2: lump sum, targeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher is restricted to pay for fruits and vegetables.
3122780|NCT02843178|Active Comparator|3: distributed, untargeted vouchers|Participants receive four $5 vouchers each valid for a subsequent week of the month (i.e., one voucher valid for week 1 only, a second for week 2 only, a third for week 3 only, and a fourth for week 4 only), starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
3122781|NCT02843178|Active Comparator|4: lump sum, untargeted vouchers|Participants receive four $5 vouchers each valid for an entire month, starting in month 1 and continuing every month through month 6. The voucher can pay for any food but not tobacco, alcohol or prepared foods.
3122782|NCT02843529|Experimental|Prodromal AD (MCI)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~MCI participants will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
3122783|NCT02843529|Experimental|Preclinical AD (cognitively normal)|"Altoida: neuropsychological, MRI, EEG and CSF biomarkers~Cognitively normal participants at risk will undergo at baseline and every 6 months a neurological examination and a neuropsychological assessment. Alzheimer disease biomarkers' measurements will be performed at inclusion and at the end of the study (or the conversion)."
3122784|NCT02843659|Experimental|BMS-931699|Subcutaneous weekly injection + daily oral placebo tablets
3122785|NCT02843659|Experimental|BMS-986142|Daily oral tablets + subcutaneous placebo (weekly) injection
3122786|NCT02843659|Placebo Comparator|Placebo|Weekly subcutaneous placebo injection +daily oral placebo tablets
3122787|NCT02844439|Experimental|Glioblastoma|The single arm design assessing progression-free survival at 6 months (PFS-6) in the overall population with the ability to detect a rate of 25% is appropriate as a preliminary test of activity in patients with glioblastoma. The sample size of this study is also designed to permit the comparison of results with EGFR amplified and non-amplified tumors, as well as EGFRvIII mutated versus wild-type. The sample size is adequate to characterize the safety profile in patients with glioblastoma.
3122788|NCT02844543|Experimental|Athletes|Participants will be evaluated using the EYE-SYNC eye-tracking device, Desktop Eye-Tracker, and Sport Concussion Assessment Tool (SCAT-3) tool.
3122789|NCT02844569|Experimental|Test|Extraction treated with xenograft bone substitute (BioOss Collagen®) + 3D-collagen matrix (Mucograft Seal®).
3122790|NCT02844569|Active Comparator|Control|Extraction treated with xenograft bone substitute (BioOss Collagen®) + collagen dressing (HeliPlug®).
3122791|NCT02844582|Experimental|Treatment (cabazitaxel, prednisone)|Patients receive cabazitaxel IV over 1 hour on day 1 and prednisone PO BID on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3122792|NCT02844920||Fibroid Treatment|Intrauterine ultrasound guided radio-frequency ablation
3122793|NCT02844998|Active Comparator|Dapoxetine 30 mg|Patients who have sedentary life style will treat with Dapoxetine 30 mg (on demand)
3122794|NCT02844998|Experimental|Moderate Running|Patients who have sedentary life style will be advised moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week. (Minimally active category)
3122795|NCT02844998|Sham Comparator|Sham-controlled|Patients who have sedentary life style will be advised those to walk (not running )at most 30 minutes for 5 days in a week. (Inactive category)
3122796|NCT02845336|Experimental|Celecoxib|Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
3122797|NCT02845336|Active Comparator|Control|Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)
3122798|NCT02845375|Placebo Comparator|PLACEBO|Placebo (normal saline) will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
3122799|NCT02845375|Other|NEOSTIGMINE|intravenous neostigmine will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
3122800|NCT02845375|Experimental|SUGAMMADEX|intravenous sugammade will be administered following a period of muscle relaxation after which respiratory measurements will be obtained.
3122801|NCT02845674|Experimental|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
3122802|NCT02845700|Active Comparator|Perceptual Retraining Treatment (PRT)|"The Perceptual Retraining Treatment will involve systematic presentation of diluted malodors. For each individual, vials on either side of their initial ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor). Each training session will consist of 4 training blocks."
3122803|NCT02845700|Placebo Comparator|Sham Neutral Training (SNT)|Approximately half of the participants will be randomized to the SNT condition designed to control for the effects of time and learning. In the SNT condition, participants will complete the same assessments (including the olfactory bias assessment), as well as a sham training consisting of neutral/neutral odor pairing dilutions, rather than the combat/neutral odor pairings as in the PRT. Following the one-month assessment, they will be given the option to complete the PRT.
3122804|NCT02845752|Active Comparator|Stiolto Respimat|Two actuations of Stiolto Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
3122805|NCT02845752|Placebo Comparator|Placebo Respimat|Two actuations of Placebo Respimat inhaler, taken once daily for 7 days. After a washout period of 14 days, participants will then receive matching Placebo for 7 days.
3122806|NCT02846233|Active Comparator|Treatment group|Interventions: All prandial insulin injections, usually 3 times daily before meals, will be discontinued. Basal insulin, usually once daily at bed time, will be continued at 80 % of the home dose. Albiglutide OR Dulaglutide AND Empagliflozin will be added to metformin and a basal insulin.
3122807|NCT02846233|No Intervention|Control group|Interventions: There will not be any change in insulin therapy, and they will continue to have the usual and standard care through the primary care provider. They should not receive SGLT2i and GLP1 RA during the study period.
3122808|NCT02846324|Experimental|GBT440 600 mg Dose|Parts A and B
3122809|NCT02846324|Experimental|GBT440 900 mg Dose|Part A
3122810|NCT02846324|Experimental|GBT440 1500 mg Dose|Part B
3122811|NCT02846324|Placebo Comparator|Placebo|Parts A and B
3122812|NCT02846415|Experimental|PID group|Experimental group receiving the Play Intervention for Dementia
3122813|NCT02846415|No Intervention|Wait-list control group|Participants will receive usual care offered by the day care centre, including health and social services, and meals, etc.
3122814|NCT02846558|Experimental|Calorie Restriction - Frequent Patient Communication|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Patients will receive initial training in using the app, and then receive weekly supportive messages encouraging them to adhere to the calorie restriction diet between 3- and 6-month followup visits. Results will be compared primarily to those collected from the Standard of Care arm.
3122815|NCT02846558|Experimental|Timing Restriction|MS patients receiving monthly natalizumab infusions who are ineligible for the calorie restriction portion of the study (the Frequent Patient Activation and Standard of Care arms) will be offered the option to enroll in the second part of the study, assessing differences in outcomes between daily 16-hour fasting periods and no dietary changes. Patients in the second part of the study randomized to this arm will consume their normal daily food intake, but restrict eating to an 8-hour period during the day. Results will be compared to patients who do not make any changes to their diet, the No Change arm.
3122816|NCT02846558|Placebo Comparator|Calorie Restriction - Communication Standard of Care|MS patients receiving monthly natalizumab infusions will use the LoseIt! smartphone application to log daily food consumption. Data from the app will be collected at follow-up visits. Besides initial training with the application and 3- and 6-month follow up exams, participants will not receive additional support or interaction from the study team.Results will be compared with those collected from the Frequent Patient Interaction arm.
3122817|NCT02846558|No Intervention|No Diet Change|MS patients receiving natalizumab infusions who were ineligible for the calorie restriction portion of the study (e.g. body mass index < 25 kg/m^2) or did not wish to participate in calorie restriction, may elect to be part of the second portion of the study. If so, they may be randomized to this arm, in which no changes are made to amount or timing of daily food intake. Results will be compared with the experimental Timing arm
3122818|NCT02846714|Experimental|FLARE intervention|All FLARE participants enrolled will receive the intervention
3122819|NCT02846740|Experimental|Adjunctive CES|CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
3122820|NCT02846740|Sham Comparator|Sham control CES|For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.
3122821|NCT02846779|Active Comparator|Low intensity|All participants randomized to this arm will receive quarterly educational mailings and limited telephonic outreach delivered by a pharmacist focused on insulin adherence and glycemic control.
3122822|NCT02846779|Experimental|Moderate intensity|Participants will receive all intervention components as in the low-intensity arm but will receive more frequent pharmacist follow-up and the option of enrolling in a text-messaging program. The pharmacist will also provide limited follow-up with the participant's provider. Only 60% of participants randomized will be targeted to receive the intervention based on adherence risk score.
3122823|NCT02846779|Experimental|High intensity|Participants will receive all intervention components as in the moderate-intensity arm but will receive more frequent pharmacist follow-up. The pharmacist will also provide more follow-up with the participant's provider and/or pharmacist. Only 40% of participants randomized will be targeted to receive the intervention based on adherence risk score and baseline disease control.
3122824|NCT02846792|Experimental|Treatment (plinabulin, nivolumab)|Patients receive plinabulin IV over 30 minutes and nivolumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3122825|NCT02847169|Active Comparator|filcon IV1 toric lens|Participants are randomized to wear filcon IV1 toric lens pair for 1 week during the cross over study.
3122826|NCT02847169|Active Comparator|ocufilcon D toric lens|Participants are randomized to wear ocufilcon D toric lens pair for 1 week during the cross over study.
3122827|NCT02847182|Experimental|Cord Blood Infusion (best source)|Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood.
3122828|NCT02847182|Placebo Comparator|Placebo Infusion|Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor.
3122829|NCT02847260|Experimental|Remodulin|Remodulin will be initiated, whilst subjects are hospitalized (minimum of 72 hours) and under medical supervision, at approximately 2 ng/kg/min as a continuous SC infusion with dose increments of 1-2 ng/kg/min applied approximately every 12 hours according to clinical response and tolerability. Following discharge, dose rate increments are permitted at 1-2 ng/kg/min with a minimum of 24 hours between each dose up-titration. Once a dose rate of 20 ng/kg/min is achieved, the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a target dose of 10, 20, and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively.
3122830|NCT02847494|Active Comparator|Control|Metoclopramide 10mg IV+ dexamethasone 10mg IM
3122831|NCT02847494|Active Comparator|Experimental|Metoclopramide 10mg IV + methylprednisolone acetate 160mg IM
3122832|NCT02847637|Experimental|A: Emicizumab 1.5 mg/kg/week|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
3122833|NCT02847637|Experimental|B: Emicizumab 3 mg/kg/2 weeks|Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 6 years).
3122834|NCT02847637|Active Comparator|C: No Prophylaxis|Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.
3122835|NCT02847637|Experimental|D: Emicizumab 1.5 mg/kg/week (Pre-study FVIII Prophylaxis)|Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).
3122836|NCT02847650|Placebo Comparator|Placebo|
3122837|NCT02847650|Experimental|PF-06649751|
3122838|NCT02847858|Experimental|Health-E You App Participants|
3122839|NCT02847858|No Intervention|Control Group|
3122840|NCT02848079|Experimental|combined TAS-102 and oxaliplatin|"Combination treatment with TAS-102 and oxaliplatin. Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion. In Part 1 treatments were started at level 1 doses, which were based on prior clinical experience with the medications studied. Dose escalation followed a traditional 3+3 design. The subjects in Part 2 were treated with dose level 3.~Oxaliplatin infusion was given on day 1 of each cycle. TAS-102 was taken twice daily on days 1-5 of each cycle."
3122841|NCT02848222|Experimental|Twice Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
3122842|NCT02848222|Experimental|Once Daily Application of Bruder compress|Ten minute application of the Bruder Moist Heat Compress in the evening after lens removal
3122843|NCT02848222|Sham Comparator|Twice Daily Application of warm washcloth|Ten minute application of a hot-water warmed washcloth in the morning prior to contact lens insertion and ten minute application in the evening after lens removal
3122844|NCT02848313|Experimental|Intermediate AMD - HRD without GA|"Participants had one 1 eye with intermediate age-related macular degeneration with high-risk drusen without geographic atrophy [GA]), i.e. the presence of either at least 1 large (≥125 μm) druse or multiple medium-size (63-124 μm) drusen.~Participants received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
3122845|NCT02848313|Experimental|Intermediate AMD with NCGA|"Participants had 1 eye with intermediate AMD with noncentral geographic atrophy [NCGA]; i.e. evidence of GA with cumulative area ≥1.27 mm2 (approximately 0.5 disc area[DA]) by fundus autofluorescence (FAF) that spared the fovea (defined as retinal pigment epithelium (RPE) and outer retina intact by spectral-domain optical coherence tomography [SD-OCT]).~Participants in this arm also received 40 mg dose of elamipretide administered once daily as a 1.0mL SC injection."
3122846|NCT02848326|Placebo Comparator|Placebo|Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
3122847|NCT02848326|Experimental|Atogepant 10 mg QD|Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
3122848|NCT02848326|Experimental|Atogepant 30 mg QD|Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
3122849|NCT02848326|Experimental|Atogepant 30 mg BID|Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
3122850|NCT02848326|Experimental|Atogepant 60 mg QD|Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
3122851|NCT02848326|Experimental|Atogepant 60 mg BID|Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
3122852|NCT02848599|Active Comparator|morphine|The patient-controlled intravenous analgesia with morphine (basal flow of 0.5-2 mg / h, bolus dose of 0.5 mg, lockout interval of 20 minutes, hour limit of 3 doses), which will be carried out 72 hours after the surgery
3122853|NCT02848599|Active Comparator|levobupivacaine|Upon completion of the operation for a period of 72 hours will be implemented continuous epidural local anesthetic through the Patient Controlled Analgesia (PCA) pump (Levobupivacaine 0.125%, basal flow of 6 ml / hour, a bolus dose of 2 ml, lockout interval of 20 minutes, hour limit of 3 doses).
3122854|NCT02848651|Experimental|Atezolizumab|Participants received 1200 milligrams (mg) of atezolizumab administered by intravenous infusion every 21 days until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
3122855|NCT02848664||Dysphagia retraining with device|Participants with dysphagia received baseline testing of dysphagia and dysphagia handicap. Then received training on how to use a vibrotactile device for self training at home. They used the device for 3 months and returned for re-evaluation on testing of dysphagia and feedback on the device
3122856|NCT02848729|Experimental|Treatment A: Oral Acetaminophen|Treatment A = 4 repeat doses of 1,000 mg oral acetaminophen (2 x 500 mg tablets) and an IV infusion of saline every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of intravenous (IV) morphine (0.125 mg/kg) at Hours 0 and 6
3122857|NCT02848729|Experimental|Treatment B: IV Acetaminophen|Treatment B = 4 repeat doses of IV acetaminophen (1,000 mg/100 mL) and 2 placebo tablets every 6 hours (Hours -6, 0, 6, and 12), and 2 infusions of IV morphine (0.125 mg/kg) at Hours 0 and 6.
3122858|NCT02848833||JARDIANCE|T2DM with JARDIANCE
3122859|NCT02849080|Experimental|Semaglutide flexible dosing (3, 7 or 14 mg)|
3122860|NCT02849080|Active Comparator|Sitagliptin 100 mg|
3122861|NCT02849184|Experimental|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) in oral administration, once daily before bedtime; Treatment duration: 2 weeks
3122862|NCT02849184|Placebo Comparator|placebo|Placebo in oral administration, once daily before bedtime; Treatment duration: 2 weeks.
3122863|NCT02849418|Experimental|GSK1358820 Injection 200 U|Subjects will receive a single treatment with 200 U GSK1358820 injection (30 mL of study drug will be administered as 30 injections, each of 1.0 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive a second treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment.
3122864|NCT02849418|Placebo Comparator|Placebo Injection|Subjects will receive a single treatment with placebo (30 injections, each of 1 mL) in the detrusor of bladder, using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents. If the criteria for re-treatment between 12 to 36 weeks after first treatment are met, subjects will receive treatment with GSK1358820. Following this, subjects could receive another re-treatment up to 36 weeks after the first treatment, upon meeting the criteria, provided a minimum of 12 weeks elapse since previous treatment
3122865|NCT02849509||Switch Patients / A|Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
3122866|NCT02849509||New Patients / B|Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).
3122867|NCT02849626|Experimental|Perampanel|Perampanel 0.5 milligrams per milliliter (mg/mL) oral suspension
3122868|NCT02849678|Active Comparator|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia.Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
3122869|NCT02849678|Active Comparator|Ropivacaine|"Ropivacaine is a local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.~Ropivacaine has been safely used in the paravertebral nerve blocks at our institution for several years."
3122870|NCT02849704|Experimental|Chronic Pancreatitis (CP) Subjects|"CP subjects will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary.~Subjects will take Creon36™ for 9 days.~Subjects will have two study visits, one before and one after treatment initiation with Creon36™. Both visits will be identical with the exception of completion of questionnaires and fecal elastase assessment (only Visit 1)."
3122871|NCT02849704|No Intervention|Healthy Controls|Healthy controls will fast for 12 hours prior to the malabsorption blood test (MBT) testing, consume the MBT breakfast meal following this fast, have blood drawn (MBT, vitamins A, D, E and K, zinc, selenium, and prealbumin) prior to MBT breakfast consumption and each hour for 8 hours after consumption, consume a low-fat study lunch, eat a moderate fat diet for 4 days during home diet and stool collection, maintain a 3-day food record, collect stool over 72 hours, have body size and composition assessment, complete quality of life questionnaires, home environment and health questionnaires, and adverse events diary. Controls will only have 1 study visit and receive no intervention.
3122872|NCT02849938|No Intervention|Control Group|Usual care
3122873|NCT02849938|Experimental|Telemedicine Group|TytoCare Device
3122874|NCT02849990|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
3122875|NCT02850068|Experimental|Geniculate Artery Embolization|Patients in this study will receive the geniculate artery embolization (GAE) procedure. The primary aims will be to determine if geniculate artery embolization (GAE) will reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA).
3122876|NCT02850159|Experimental|dual-mode group|the dual-mode NIBS with high-frequency rTMS and tDCS simultaneously
3122877|NCT02850159|Active Comparator|rTMS group|high-frequency rTMS and sham tDCS
3122878|NCT02850276|Experimental|Pyridostigmine|30mg PO three times a day
3122879|NCT02850601|Experimental|Dexamethasone solution|Dexamethasone 0.5 mg/mL, 5ml TID for 4 weeks
3122880|NCT02850601|Active Comparator|Dexamethasone solution in Mucolox™|Compounded dexamethasone 0.5 mg/mL in Mucolox™, 5ml TID for 4 weeks
3122881|NCT02850965|Experimental|BI 695501|
3122882|NCT02850965|Active Comparator|Humira|
3122883|NCT02850978||Spiolto|Patient with COPD to received Spiolto
3122884|NCT02851069||Participants with Hepatitis C Virus Genotype 1 (HCV + GT1)|ABBVIE REGIMEN (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily] with or without dasabuvir [250 mg twice daily]), and with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks in HCV + GT1 participants.
3122885|NCT02851108|Experimental|AS-AQ-MB|Once daily a fixed dose artesunate-amodiaquine formulation combined with once daily methylene blue (15 mg/kg) over a three days period.
3122886|NCT02851108|Active Comparator|AS-AQ-PQ|Once daily a fixed dose artesunate-amodiaquine over three days combined with a single dose of primaquine on day 2 (0.25 mg/kg).
3122887|NCT02851615|Other|SCThrive|SCThrive Intervention for Adolescents with SCD - 6 week self-management group
3122888|NCT02851615|No Intervention|Attention Control|6 weekly 15-20 minute individual phone calls on educational topics. No interventions are included in this arm.
3122889|NCT02851823|Active Comparator|Control Group|Mechanical periodontal treatment: Scaling and root planing were performed with periodontal curettes until the operator feels that root surface is clean, hard and smooth.
3122890|NCT02851823|Experimental|Test Group|Combined laser therapy: An Er:YAG laser (160 mj/pulse, 10 Hz) (AT Fidelis Fotona, Ljubljana, Slovenia) with water irrigation was first used to remove subgingival calculus and infected cementum.The Er:YAG laser beam was delivered into the periodontal pockets using a chisel-shaped quartz tip in contact mode under water irrigation, from a coronal to an apical direction with the tip inclined at 10o to 15o to the root surfaces. After Er:YAG laser application, Nd:YAG laser treatment (AT Fidelis Fotona, Ljubljana, Slovenia) was performed at an energy level of 100 mJ/pulse, and 20 Hz for removing pocket epithelium and detoxiﬁcation purpose. Irradiation was accomplished with a 320 μm fiber optic delivery system. The fiber was inserted into the periodontal pocket base in parallel alignment with the root surface, and the fiber was slowly moved from apical to coronal in a sweeping motion during the laser light emission.
3122891|NCT02852005|Experimental|Group 1: MVA/HIV62B + Placebo|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
3122892|NCT02852005|Experimental|Group 2: MVA/HIV62B + AIDSVAX B/E|Participants who received 3 sequential administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
3122893|NCT02852005|Experimental|Group 3: MVA/HIV62B + Placebo|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive placebo in their right deltoid at Months 0 and 4.
3122894|NCT02852005|Experimental|Group 4: MVA/HIV62B + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive the MVA/HIV62B vaccine in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
3122895|NCT02852005|Experimental|Group 5: Placebo + AIDSVAX B/E|Participants who received 2 sequential priming administrations of JS7 DNA plasmid followed by 2 sequential boost administrations of MVA/HIV62B in HVTN 205 will receive placebo in their left deltoid at Months 0 and 4. They will receive the AIDSVAX B/E vaccine in their right deltoid at Months 0 and 4.
3122896|NCT02852265|Experimental|COC users or new starts|Subjects will have a etonogestrel contraceptive implant placed at enrollment. Women using COC as method of contraception for at least 1 month will be considered COC users. Women starting a COC or recently started a COC within the past month will be considered new starts.
3122897|NCT02852330|Experimental|Voltage tomography|Voltage tomography measurements will be made with the SA16 research software and CS19 (1.6.2) software during and/or immediately after electrode insertion during cochlear implantation and at scheduled post-operative clinical visits.
3122898|NCT02852434|Experimental|Self-administered Gel|Patient-administered, vaginal lidocaine gel (2%)--inserted 15 minutes prior to cervical preparation procedure
3122899|NCT02852434|Active Comparator|Paracervical Block|Provider-administered lidocaine (1%) paracervical injection--administered immediately prior to tenaculum placement
3122900|NCT02852967|Experimental|Belumosudil 200 mg QD + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 matching placebo tablet in the evening
3122901|NCT02852967|Experimental|Belumosudil 200 mg BID (Twice Daily) + Placebo|One belumosudil 200 mg tablet and 1 matching placebo tablet in the morning and 1 belumosudil 200 mg tablet in the evening
3122902|NCT02852967|Experimental|Belumosudil 400 mg QD + Placebo|Two belumosudil 200 mg tablets in the morning and 1 matching placebo tablet in the evening
3122903|NCT02852967|Experimental|Belumosudil 600 mg/day|Two belumosudil 200 mg tablets in the morning and 1 belumosudil 200 mg tablet in the evening
3122904|NCT02852967|Placebo Comparator|Placebo|Two matching placebo tablets in the morning and 1 matching placebo tablet in the evening
3122905|NCT02853032|Active Comparator|Active rTMS to the right DLPFC|Active repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, active rTMS will be delivered at 20 Hertz (Hz) in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
3122906|NCT02853032|Placebo Comparator|Sham rTMS to the right DLPFC|Sham repetitive transcranial magnetic stimulation will be delivered to the right DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, sham rTMS will be delivered at 20 Hz in 2 sec trains with 14 sec inter-train intervals, 20 minutes/session (i.e. 1,600 pulses/session), 7 days/week for 20 consecutive days.
3122907|NCT02853123|Experimental|Tiotropium + Olodaterol|Patients will receive tiotropium 5mcg + olodaterol 5mcg in a fixed dose combination once daily.
3122908|NCT02853123|Active Comparator|Tiotropium|
3122909|NCT02853305|Experimental|Pembrolizumab + ST Chemotherapy (Pembro Combo)|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for a maximum of 35 doses PLUS standard therapy (ST) chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle, OR carboplatin at an area under the curve 5 (AUC 5) (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
3122910|NCT02853305|Experimental|Pembrolizumab (Pembro)|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for a maximum of 35 doses.
3122911|NCT02853305|Active Comparator|ST Chemotherapy (Chemo)|Participants receive ST chemotherapy with EITHER cisplatin 70 mg/m^2 IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine IV infusion 1,000 mg/m^2 on Day 1 and Day 8 of each 3-week cycle OR carboplatin at AUC 5 (or AUC 4.5 if required per local guidelines) IV on Day 1 (or Day 2 if required per local guidelines) of each 3-week cycle + gemcitabine 1,000 mg/m^2 IV on Day 1 and Day 8 of each 3-week cycle.
3122912|NCT02853318|Experimental|Treatment (pembrolizumab, bevacizumab, cyclophosphamide)|Patients receive pembrolizumab IV over 30 minutes and bevacizumab IV over 30-90 minutes on day 1 and cyclophosphamide PO QD on days 1-21. Treatment repeats every 3 weeks for up to 17 courses in the absence of disease progression or unacceptable toxicity. Patients without evidence of disease progression may continue treatment in the absence of disease progression or unacceptable toxicity.
3122913|NCT02853331|Experimental|Pembrolizumab+Axitinib Combination Therapy|Participants receive pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.
3122914|NCT02853331|Active Comparator|Sunitinib Monotherapy|Participants receive sunitinib 50 mg orally once daily for 4 weeks and then are off treatment for 2 weeks.
3122915|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence A-capsules, B-RC, C-HSWG|Subjects will be receive treatment sequence (ABC) which is a single dose of gepotidacin 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 1, 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 2 or 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 3, according to randomization. There will be a washout period of at least 3 days between doses.
3122916|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence C-HSWG, A-capsules, B-RC)|Subjects will receive treatment sequence (CAB) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 1, 1500 mg (three tablets of 500 mg) reference capsule (Treatment A) in Period 2 or 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in Period 3 according to randomization. There will be a washout period of at least 3 days between doses.
3122917|NCT02853435|Experimental|Part1a: Gepotidacin 1500 mg-Sequence B-RC, C-HSWG, A-capsules)|Subjects will receive treatment sequence (BCA) to receive a single dose of gepotidacin 1500 mg (two tablets of 750 mg) RC tablet (Treatment B) in period 1, 1500 mg (two tablets of 750 mg) HSWG tablet (Treatment C) in Period 2, or 1500 mg (three tablets of 500 mg) (Treatment A) in Period 3 reference capsule according to randomization.. There will be a washout period of at least 3 days between doses.
3122918|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence DE-fasted followed by fed|Subjects will receive treatment sequence (DE) according to randomization which is a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fasted condition (Treatment D) in Period 1 followed by fed conditions (Treatment E) in period 2. There will be a washout period of at least 3 days between doses.
3122919|NCT02853435|Experimental|Part1b: Gepotidacin 1500 mg-Sequence ED-fed followed by fasted|Subjects will be receive treatment sequence (ED) according to randomization which is single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a under fed condition (Treatment E) in period 1 followed by fasted conditions (Treatment D) in Period 2. There will be a washout period of at least 3 days between doses.
3122920|NCT02853435|Experimental|Part 2a: Gepotidacin 1500 mg (RC or HSWG)- Japanese subjects|Japanese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
3122921|NCT02853435|Experimental|Part 2b: Gepotidacin 1500 mg (RC or HSWG)- Chinese subjects|Chinese subjects will receive a single 1500 mg (two tablets of 750 mg) dose of gepotidacin tablet (RC or HSWG) selected from Part 1a.
3122922|NCT02853760|Experimental|Outdoor mountain hiking (M)|"First part of the intervention: an uphill walking phase on single trails and forest roads in a sparse forest with view on the mountainous region around Innsbruck for 6 km in around 1.5 hours together with the test leader. Regarding the walking intensity, the participants were instructed to choose a brisk without overspending pace (average speed: 4 km/h).~In the second part of the intervention, the participants were walking downhill on the same track for around 70 minutes back to the starting point to respond to the post-test (average speed: 5.2 km/h)."
3132485|NCT03431012|Experimental|Human Agency/Negative Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of experiencing side effects after using them (Negative Framing health messages).
3122923|NCT02853760|Active Comparator|Indoor treadmill walking (T)|"To ensure that all physical parameters were simultaneous to the outdoor mountain hiking condition, the distance, the difference in height, the average inclination of the track, and the time needed for the outdoor mountain hiking situation were measured in a pilot study.~First part: uphill walking, inclination: 10%, time: 1.5 hours, and speed: 4 km/h (resulting in 600 m difference in height). In accordance to possible differences in outdoor speed, the participants were allowed to change the treadmill's speed in a small range (3.8 to 4.2 km/h) to adapt to the wording brisk without overspending. Second part of the intervention contained 70 minutes of level walking on the same treadmills (5.2 km/h, 6km)."
3122924|NCT02853760|No Intervention|Sedentary control condition (C)|The sedentary control situation was located in a quiet room at the university with access to computers. The participants were allowed to use the computers, to read, and to talk, but had to remain in a sedentary position. To control for possible differences in affective response due to the daytime, the sedentary control condition contained the same timing of the measurements than the intervention condition. Sociodemographic data were collected for 5 to 10 minutes in this condition using a web-based questionnaire.
3122925|NCT02853929|Experimental|dTpa Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
3122926|NCT02853929|Active Comparator|Control Group|This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure
3122927|NCT02854059|Experimental|Treatment IdeS (0.25 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of safety and efficacy in 3 patients receiving 0.25 mg/kg there will be a potential to increase the IdeS dose to 0.5 mg/kg for the remaining 3 patients.
3122928|NCT02854059|Experimental|Treatment IdeS (0.50 mg/kg)|A single 30 minutes i.v. infusion of IdeS (0.50 mg/kg).
3122929|NCT02854527|Experimental|R1 (Reference 1) Digoxin|1 tablet (0.25 mg) digoxin as single dose
3122930|NCT02854527|Experimental|R2 Furosemide|0.1 mL (1 mg) furosemide oral solution as single dose
3122931|NCT02854527|Experimental|R3 Metformin hydrochloride|0.1 mL (10 mg) metformin oral solution as single dose
3122932|NCT02854527|Experimental|R4 Rosuvastatin|1 tablet (10 mg) rosuvastatin as single dose
3122933|NCT02854527|Experimental|T (Test)|1 tablet (0.25 mg) digoxin, 0.1 mL (1 mg) furosemide oral solution, 0.1 mL (10 mg) metformin oral solution, and 1 tablet (10 mg) rosuvastatin, all together as a single dose ('cocktail')
3122934|NCT02854540|Experimental|Hand A (iontophoresis) vs. Hand B (no treatment)|During the treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device. Participants will also be asked to leave the other hand untreated.
3122935|NCT02854605|Experimental|GS-9674 30 mg|GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
3122936|NCT02854605|Experimental|GS-9674 100 mg|GS-9674 100 mg + placebo to match GS-9674 30 mg for 24 weeks
3122937|NCT02854605|Placebo Comparator|Placebo|Placebo to match GS-9674 30 mg + placebo to match GS-9674 100 mg for 24 weeks
3122938|NCT02854631|Experimental|Selonsertib + Prednisolone|Selonsertib + prednisolone for 28 days
3122939|NCT02854631|Placebo Comparator|Prednisolone|Selonsertib placebo + prednisolone for 28 days
3122940|NCT02854800|Experimental|Weekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per week. As part of the current study, they received 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
3122941|NCT02854800|Experimental|Biweekly Opioid Tx|Participants in this group attended an outpatient opioid clinic once bi-weekly. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
3122942|NCT02854800|Experimental|Monthly Opioid Tx|Participants in this group attended an outpatient opioid clinic once per month. As part of the current study, 12-week dosing of varenicline per label recommendations: 0.5mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84). Pill form/blister pack
3122943|NCT02855060|Experimental|Pelvic Binder|Commercially available device used to stabilize the pelvis
3122944|NCT02855060|No Intervention|No Binder|Standard of care
3122945|NCT02855086|Experimental|50 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a lower dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
3122946|NCT02855086|Experimental|100 mg cetuximab-IRDye 800|"Patients receive cetuximab IV over 30 minutes and a higher dose of cetuximab IRDye800 IV over 30 minutes to 1 hour on day 0.~All patients undergo standard of care surgical resection of tumor on days 2 to 5."
3122947|NCT02855164|Experimental|LJN452 10 μg|Tropifexor (LJN452) Part A
3122948|NCT02855164|Experimental|LJN452 30 μg|Tropifexor (LJN452) Part A
3122949|NCT02855164|Experimental|LJN452 60 μg|Tropifezor (LJN452) Parts A + B
3122950|NCT02855164|Experimental|LJN452 90 μg|Tropifexor (LJN452) Parts A + B
3122951|NCT02855164|Placebo Comparator|Placebo A+ B|Placebo Parts A + B
3122952|NCT02855164|Experimental|LJN452 140 μg|Tropifexor (LJN452) Part C
3122953|NCT02855164|Experimental|LJN452 200 μg|Tropifexor (LJN452) Part B
3122954|NCT02855164|Placebo Comparator|Placebo C|Placebo Part C
3122955|NCT02855281||NSCLC with pleural effusion|The population for selection of potential study participants is comprised of clinical routine patients presenting with (suspected malignant) pleural effusion. These patients must have an indication for pleural puncture. The cause and nature of the pleural effusion at this time point will be unknown in many cases. To establish this, further diagnostic procedures are required. Only patients with confirmed diagnosis of non-small cell lung cancer will be included in the data analysis.
3122956|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
3122957|NCT02855359|Experimental|denintuzumab mafodotin + RCHP|Part A: denintuzumab mafodotin (SGN-CD19A) + RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
3122958|NCT02855359|Experimental|denintuzumab mafodotin + RCHOP or RCHP|Part B: denintuzumab mafodotin (SGN-CD19A) + RCHOP or RCHP
3122959|NCT02855359|Active Comparator|RCHOP|Part B: RCHOP alone: (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
3122960|NCT02855437|Active Comparator|Interactive Voice Response|The interactive voice response system (IVR) is an automated telephone system that is used to contact study participants. At enrollment the study coordinator will explain how the IVR works, planned survey schedule, and that participant -initiated calls to IVR are allowed.
3122961|NCT02855437|Active Comparator|RheumPro Smartphone Application|RheumPro is a UAB developed smartphone application to capture patient reported outcomes. At enrollment the study coordinator will explain how RheumPro works, planned survey schedule, and that participant -initiated surveys in RheumPro are allowed.
3122962|NCT02855450|Experimental|rhNGF|rhNGF (Recombinant Human Nerve Growth Factor) 180 μg/ml eye drops solution
3122963|NCT02855450|Placebo Comparator|Vehicle|Ophthalmic Placebo solution
3122964|NCT02855541|Experimental|Cycling intervention|Participants will use a small cycling device (DeskCycle) at their workstation for 15 minutes every hour that they are at work.
3122965|NCT02855567|Active Comparator|Acupuncture|Receives acupuncture during gynecological surgery at 5 known points for pain control. Needles will be placed prior to the start of surgery by an anesthesiologist trained in acupuncture after induction of anesthesia and while the patient is prepped for surgery. They will be in place for 15 minutes.
3122966|NCT02855567|Sham Comparator|Sham acupuncture|Receives acupuncture during gynecological surgery at sham points not associated with pain control. Needles will be placed by the gynecologic surgeon who is not trained in acupuncture after induction of anesthesia and prior to the start of the surgery. The needles will be removed immediately after placement.
3122967|NCT02856035|Experimental|Stroke Group|"Intervention: Stroke subjects will receive neural feedback plus FES and motor learning intervention that spans 3 phases and up to a total of 60 sessions.~Phase I: real-time fMRI neural feedback training; Phase II: rtfNIRS-based neural feedback learning (built upon self-regulation strategies learned in Phase I and also assisted by neurally-triggered, peripherally-directed FES motor practice of wrist and finger extension); Phase III: motor learning minus neural feedback for an additional sessions up to 60 total; Phase IV: follow-up testing at 3 months after-treatment ends"
3122968|NCT02856282||Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Two sprays into each nostril once a day, preferably in the morning. Once symptoms are under control ,a maintenance dose of one spray may be used accordingly
3122969|NCT02856490|Active Comparator|vSculpt with Vibration Only|vSculpt genital device used in vibration mode only.
3122970|NCT02856490|Active Comparator|vSculpt with Vibration and Light|vSculpt genital device used in vibration and light mode.
3122971|NCT02856490|Active Comparator|InTone Device|InTone genital device using electric muscle stimulation only.
3122972|NCT02856555|Experimental|Firsocostat 5 mg|Participants will receive firsocostat 1 x 5 mg + 1 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
3122973|NCT02856555|Experimental|Firsocostat 20 mg|Participants will receive firsocostat 2 X 10 mg + 2 x placebo matched to firsocostat 5 mg for 12 weeks.
3122974|NCT02856555|Experimental|Placebo|Participants will receive 2 x placebo matched to firsocostat 5 mg + 2 x placebo matched to firsocostat 10 mg for 12 weeks.
3122975|NCT02856802|Experimental|DFN-02|Participants self-administered a single-dose of DFN-02 (sumatriptan 10-mg/100 μL nasal spray) intranasally within one hour of an acute migraine pain episode.
3122976|NCT02856802|Other|Placebo|Participants self-administered a single-dose of DFN-02 placebo nasal spray matching DFN-02 intranasally within one hour of an acute migraine pain episode.
3122977|NCT02856828|Experimental|Digital Image Enhancement (DIE) Group|A novel digital image enhancement technology will be used intraoperatively
3122978|NCT02856828|No Intervention|Control Group|Standard intraoperative imaging will be used intraoperatively
3122979|NCT02856880|Experimental|Test zinc-IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 milliliter (mL) water for 60 seconds(s) followed by rinse with 10mL water
3122980|NCT02856880|Experimental|Test zinc non- IPMP toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
3122981|NCT02856880|Active Comparator|Positive control Toothpaste|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
3122982|NCT02856880|Active Comparator|SLS Negative Control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
3122983|NCT02856880|Active Comparator|non-SLS negative control|Rinse with preprepared slurry of toothpaste in 10 mL water for 60s followed by rinse with 10mL water
3122984|NCT02857283|Experimental|Filtered Air, then Ozone|Participants in this arm will first receive filtered clean air followed by ozone
3122985|NCT02857283|Experimental|Ozone, then Filtered Air|Participants in this arm will first receive ozone followed by filtered clean air
3122988|NCT02857816|Other|NURO System PTNM Therapy|Subjects will undergo 12 PTNM therapy sessions, administered weekly, utilizing the NURO system.
3122989|NCT02858050||MEMs Cap Real-Time Monitoring|Group 1 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and will transmit data in real-time
3122990|NCT02858050||MEMs Cap Without Real-Time Monitoring|Group 2 will consist of patient taking hepatitis C medicaitons and will have Portal-724 MEMs cap place in their medication bottle and data will be downloaded at each study visit while taking hepatitis C medications
3122991|NCT02858076|Active Comparator|Intravitreous 2 mg aflibercept injections|Initial injection must be given on the day of randomization. Follow-up injections will be performed as often as every 4 weeks unless criteria for deferral are met.
3122992|NCT02858076|Active Comparator|Prompt vitrectomy plus panretinal photocoagulation|For the prompt vitrectomy + panretinal photocoagulation group, the vitrectomy must be scheduled to be performed within 2 weeks of randomization. Vitrectomy will be performed according to the investigator's usual routine, including pre-operative care, surgical procedure, and post-operative care, although anti-VEGF may not be given post-operatively unless there is recurrent hemorrhage.
3122993|NCT02858154|Other|HFNC and low flow oxygen by nasal cannula|All subjects will receive 3-4 hours of experimental treatment (HFNC) during a research portion of a PSG and then for the 6-8 hours of clinically ordered PSG will receive active comparator (low flow oxygen by nasal cannula)
3122994|NCT02858180|Experimental|Heart Failure Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir (SOF) and 90 mg ledipasvir (LDV)"
3122995|NCT02858180|Experimental|Lung Disease Cohort|"Harvoni (sofosbuvir/ledipasvir fixed dose combination)~1 pill once daily Includes 400 mg sofosbuvir and 90 mg ledipasvir"
3122996|NCT02858349|Experimental|Arm 1|4-week control period with no intervention and 4-weeks of high-intensity interval training
3122997|NCT02858362|Experimental|Cohort 1: SMT C1100 Formulation 1|Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
3122998|NCT02858362|Experimental|Cohort 2: SMT C1100 Formulation 2|Participants received 1 g SMT C1100 formulation 2 orally twice-daily for at least 48 weeks.
3122999|NCT02858362|Experimental|Cohort 3: SMT C1100 Formulation 1|Participants in this cohort had previously received SMT C1100, but were not eligible for Cohorts 1 or 2. Participants received 2.5 g SMT C1100 formulation 1 orally twice-daily for at least 48 weeks.
3123000|NCT02858401|Experimental|Vesatolimod 1 mg (Cohort 1)|Vesatolimod 1 mg for 71 days, while continuing their existing ARV regimen
3123001|NCT02858401|Experimental|Vesatolimod 2 mg (Cohort 2)|Vesatolimod 2 mg for 71 days, while continuing their existing ARV regimen
3123002|NCT02858401|Experimental|Vesatolimod 4 mg (Cohort 3)|Vesatolimod 4 mg for 71 days, while continuing their existing ARV regimen
3123003|NCT02858401|Experimental|Vesatolimod 6 mg (Cohort 4)|Vesatolimod 6 mg for 127 days, while continuing their existing ARV regimen
3123004|NCT02858401|Experimental|Vesatolimod 8 mg (Cohort 5)|Vesatolimod 8 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen
3123005|NCT02858401|Experimental|Vesatolimod 10 or 12 mg (Cohort 6)|Vesatolimod 10 or 12 mg for 127 days administered following overnight fasting, while continuing their existing ARV regimen. Participants will receive 3 administrations of 10 mg, followed by 7 administrations of 12 mg (after review of 10 mg safety data)
3123006|NCT02858401|Experimental|Vesatolimod 12 mg (Optional Cohort 7)|Vesatolimod up to 12 mg for up to 127 days for up to 10 total doses administered following overnight fasting, while continuing their existing ARV regimen
3123007|NCT02858401|Experimental|Vesatolimod 6 mg with an acidic solution (Optional Cohort 8)|Vesatolimod 6 mg for 127 days for up to 10 total doses administered with an acidic solution (cranberry juice), while continuing their existing ARV regimen
3123008|NCT02858401|Experimental|Vesatolimod up to 12 mg (Cohort 9)|Vesatolimod up to 12 mg for 127 days for up to 10 total doses administered following a moderate-fat meal, after the review of the data from the highest tolerated fasted dose cohort while continuing their existing ARV regimen
3123009|NCT02858401|Placebo Comparator|Placebo (Cohorts 1-9)|Placebo to match vesatolimod for 71 or 127 days, while continuing their existing ARV regimen
3123010|NCT02858440|Experimental|DTPa-IPV/Hib Group|All subjects receive three doses of primary vaccination of the study vaccine, Infanrix-IPV/Hib (DTPa-IPV/Hib), at 3, 4.5 and 6 months of age and a single dose of booster vaccination at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
3123011|NCT02858492|Experimental|Subjects receiving GSK2982772 60 mg|Enrolled subjects will receive GSK2982772 60 mg thrice daily (approximately 8 hours apart) for 84 days.
3123012|NCT02858492|Experimental|Subjects receiving Placebo|Enrolled subjects will receive placebo thrice daily (approximately 8 hours apart) for 84 days.
3123013|NCT02858713|Experimental|App as intervention + Enstilar©|Patients prescribed Calcipotriene + Betamethasone Dipropionatecutaneous foam receive the intervention EM with app for smartphone and conventional instruction from a nurse in the consultation.
3123014|NCT02858713|No Intervention|Conventional instructions + Enstilar©|Patients receive conventional instructions from a nurse in the consultation in how to use prescribed Enstilar© with EM.
3123015|NCT02858726|Experimental|CR845 0.5mcg/kg|Part A of study: IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
3123016|NCT02858726|Experimental|CR845 1 mcg/kg|Part A of study: IV CR845 1 mcg/kg administered after each dialysis session (3 times/week)
3123017|NCT02858726|Experimental|CR845 1.5mcg/kg|Part A of study: IV CR845 1.5 mcg/kg administered after each dialysis session (3 times/week)
3123018|NCT02858726|Placebo Comparator|Placebo|Part A of study: IV Placebo administered after each dialysis session (3 times/week)
3123019|NCT02859142|Experimental|Augmented Treatment|"Participants receive 12 weeks of Chantix along with standard smoking cessation treatment of nicotine patches and behavioral counseling visits.~Chantix (Varenicline) and NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
3123020|NCT02859142|Active Comparator|Standard Treatment w/ placebo|"Participants receive 12 weeks of standard smoking cessation treatment of nicotine patches and behavioral counseling visits in addition to placebo pills identical in appearance to varenicline~Placebo pills (identical to varenicline)~NicodermCQ (Nicotine Patches): Administered according to package insert directions~Behavioral Counseling Sessions: Participants will attend one-on-one behavioral counseling sessions with a trained therapist at each of 4 study visits (pre-quit, quit date, week 2, and week 12). Behavioral sessions will involve teaching behavioral skills to assist with smoking cessation, preventing relapse, and coping with physical or emotional changes associated with cravings."
3123021|NCT02859246|Other|Mucinex|600 mg of Mucinex 2 times a day.
3123022|NCT02859324|Experimental|CC-122 with Nivolumab|CC-122 orally 5/7 days with nivolumab Intravenously (IV) 3mg/kg every 2 weeks. Cohorts of up to 6 subjects per dose level until Recommended Phase 2 dose (RP2D).
3123023|NCT02859441|Experimental|E10030 and Ranibizumab|Intravitreal injections of E10030 and Ranibizumab
3123024|NCT02859454|Experimental|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
3123025|NCT02859597|Experimental|High Flow Nasal Cannula|High flow nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
3123026|NCT02859597|Active Comparator|Nasal Cannula|Typical nasal cannula will be utilized to deliver oxygen to morbidly obese patients undergoing deep sedation for gastrointestinal procedures.
3123027|NCT02860130|Experimental|Prismocitrate 18|
3123028|NCT02860130|Active Comparator|No Regional Anticoagulation of CRRT Circuit|
3123029|NCT02860286|Experimental|Open-Label Tazemetostat|Oral Tazemetostat 800mg BID
3123030|NCT02860507|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 0.06 mg/kg and Glycopyrrolate 0.04mg/kg iv
3123031|NCT02860507|Experimental|sugammadex|Sugammadex 4mg/kg
3123032|NCT02860546|Experimental|TAS-102 + Nivolumab|Participants received a dose of 35 milligrams per meter square (mg/m^2) of TAS-102 tablets orally twice per day (BID) within 1 hour after completion of morning and evening meals, in 4-week cycle. In each 4-week cycle, TAS-102 was administered for 2 weeks, as 5 days a week with 2 days rest, followed by a 14-day rest. Also participants received 3 milligrams per kilogram per dose (mg/kg/dose) Nivolumab intravenous (I.V) infusion over 60 minutes every 14 days (on Day 1 and Day 15 of each 4-week cycle).
3123033|NCT02860845|Experimental|Boric acid and probiotics|Boric acid with L.gasseri and L.rhamnosus
3123034|NCT02860845|Active Comparator|Antibiotic/Antifungal|Antibiotic: Clindamicine Antifungal: Clotrimazol
3123035|NCT02860988|Experimental|MCCC Treatment|Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
3123036|NCT02860988|No Intervention|MCCC Comparison|Participants in this condition did not receive reentry services related to responsible parenting, economic stability and mobility, or healthy marriage and relationships.
3123037|NCT02861014|Experimental|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
3123038|NCT02861118||Cohort 1: Crohn's Disease|Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
3123039|NCT02861118||Cohort 2: Ulcerative Colitis|Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.
3123040|NCT02861131|Experimental|Sugammadex|Sugammadex 2 mg/kg IV once at the end of surgery
3123041|NCT02861131|Active Comparator|Neostigmine|Neostigmine 0.07 mg/kg to a maximum of 5 mg (+ Glycopyrrolate 0.1-0.2 mg per 1 mg of Neostigmine administered) IV once at the end of surgery
3123042|NCT02861534|Experimental|Vericiguat|Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily with food, on a background of HF standard of care. The vericiguat dose will be uptitrated to 5 mg and to 10 mg.
3123043|NCT02861534|Placebo Comparator|Placebo|Participants receive a starting matching placebo dose of 2.5 mg taken orally once daily with food, on a background of HF standard of care. The matching placebo dose will be uptitrated to 5 mg and to 10 mg.
3123044|NCT02861586|Experimental|Treatment Group A; MV-CHIK low|"60 subjects will receive i.m. vaccinations with MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123045|NCT02861586|Active Comparator|Treatment Group A/C; Priorix®|"20 subjects will receive i.m. vaccinations with Priorix® on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123046|NCT02861586|Experimental|Treatment Group B; MV-CHIK low|"60 subjects will receive i.m. vaccinations with placebo on study day 0. MV-CHIK low dose (5xE4 (± 0.5 log) TCID50 per 0.3 mL) on day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123047|NCT02861586|Active Comparator|Treatment Group B/D; Priorix®|"20 subjects will receive i.m. vaccinations with placebo on study day 0, Priorix® on day 28 and one boosting dose with Priorix® on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123048|NCT02861586|Experimental|Treatment Group C; MV-CHIK high|"60 subjects will receive i.m. vaccinations with MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 0 and 28, placebo on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123049|NCT02861586|Experimental|Treatment Group D; MV-CHIK high|"60 subjects will receive i.m. vaccinations with placebo on study day 0, MV-CHIK high dose (5xE5 (± 0.5 log) TCID50 per 0.3 mL) on study day 28 and MV-CHIK boosting dose on day 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123050|NCT02861586|Experimental|Measles Booster Group 1|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, MV-CHIK on day 0 and 28 and placebo on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123051|NCT02861586|Experimental|Measles Booster Group 2|"20 subjects will receive i.m. vaccinations with Priorix® on study day -28, placebo on day 0 and 28 and MV-CHIK on day 168 and 196.~Physical examinations, vital signs, pregnancy tests for females, inquiry of adverse events and collection of immunogenicity blood samples will be performed during all visits."
3123052|NCT02861664|Experimental|Test Dentifrice: Stannous fluoride (SnF2)|Participants were instructed to apply a strip of dentifrice containing 0.454% stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
3123053|NCT02861664|Active Comparator|Negative Control Dentifrice: Sodium monofluorophosphate (SMFP)|Participants were instructed to apply a strip of dentifrice containing 1400ppm fluoride as sodium monofluorophosphate (SMFP) to cover the head of the toothbrush and brush their teeth for 1 timed minute, twice daily (morning and evening), following their normal routine. Participants were also permitted to rinse with tap water.
3123054|NCT02861807|Experimental|Active stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to 2.0 milliamps (mA) and guided meditation practice.
3123055|NCT02861807|Sham Comparator|Sham brain stimulation with mindfulness|Brain stimulation with mindfulness-based relapse prevention. Treatment sessions will be 2 hours for 8 sessions, with the first 30 minutes consisting of transcranial direct current stimulation (tDCS) with the current set to ramp up to 2.0 milliamps (mA) and then ramp down to 0.0 mA and guided meditation practice.
3123056|NCT02861937|No Intervention|healthy|"Ten patients with clinically healthy gingiva with probing depth less than 3mm and less than or equal to 10% sites with gingival bleeding on probing present.~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)"
3123057|NCT02861937|Active Comparator|chronic gingivitis|"Chronic gingivitis was defined as having probing depth (PD) less than or equal to 4mm and more than to 25% sites with the gingival bleeding present (BOP)~As there was no attachment loss, it was not necessary for us to calculate RAL ( Relative Attachment Level)~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
3123058|NCT02861937|Active Comparator|chronic periodontitis|"Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of bone loss determined radiographically.~Non surgical periodontal therapy (SRP) was concluded in 3 weeks. Within the duration of the study, all subjects received supportive therapy"
3123059|NCT02862080|Experimental|no intervention; then no intervention; then cathode tsDCS + Ekso; then Ekso; then cathode tsDCS+Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
3123060|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then cathode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Cathode tsDCS + Ekso will combine the use of cathode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
3123061|NCT02862080|Experimental|no intervention; then no intervention; then anode tsDCS + Ekso; then Ekso; then anode tsDCS + Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
3123062|NCT02862080|Experimental|no intervention; then no intervention; then Ekso; then anode tsDCS + Ekso; then Ekso|"Non-invasive transcutaneous spinal direct current stimulation (tsDCS) applies electrical current to the spinal cord via surface electrodes placed on the skin.~Ekso is a type of wearable robotic exoskeleton that provides support to an individual with lower extremity paralysis for standing and walking.~Anode tsDCS + Ekso will combine the use of anode tsDCS application followed by a walking session in Ekso. Ekso will consist of a walking session in Ekso with no tsDCS."
3123063|NCT02862106|Experimental|εPA-44 900μg group-placebo|These subjects from the placebo group of protocol 71006.01 InjectεPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
3123064|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
3123065|NCT02862106|Experimental|εPA-44 900μg group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Inject εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
3123066|NCT02862106|No Intervention|Follow-up group-placebo|These subjects from the placebo group of protocol 71006.01 Do not give any intervention, follow-up observation only
3123067|NCT02862106|No Intervention|Follow-up group-εPA-44 600μg|These subjects from the εPA-44 600μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
3123068|NCT02862106|No Intervention|Follow-up group-εPA-44 900μg|These subjects from the εPA-44 900μg group of protocol 71006.01 Do not give any intervention, follow-up observation only
3123069|NCT02862535|Experimental|Cohort 1: ADX|Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3123070|NCT02862535|Experimental|Cohort 2: ADX + S-1 + Cisplatin|Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3123071|NCT02862535|Experimental|Cohort 3: ADX + S-1 + Oxaliplatin|Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
3123072|NCT02862535|Experimental|Cohort 4: ADX + Nivolumab|Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
3123073|NCT02862548|Experimental|TAF|TAF for 48 weeks
3123074|NCT02862548|Active Comparator|TDF-Containing Regimens|TDF alone or in combination with other approved antivirals per local practice for 48 weeks
3123075|NCT02862548|Experimental|Optional Treatment Extension Phase|After Week 48, participants will be eligible to receive TAF for an additional 144 weeks.
3123076|NCT02862574|Experimental|Andecaliximab 300 mg|Andecaliximab 300 mg for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
3123077|NCT02862574|Experimental|Andecaliximab 150 mg|Andecaliximab 150 mg + placebo for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
3123078|NCT02862574|Placebo Comparator|Placebo|Placebo weekly for 12 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
3123079|NCT02862574|Experimental|Open-Label Extension|On the Week 12 visit, eligible participants may choose to participate in the open-label portion of the study to receive open-label andecaliximab 300 mg for 52 weeks, in addition to their current regimen of a TNF inhibitor and methotrexate.
3123080|NCT02862600|Experimental|Perhexiline|Perhexiline will be administered orally. Dosing will be determined based on plasma level monitoring. For the first 8 week period, the target range will be 100-300 ng/mL, for the second 8 week period, the target range will be 300-500 ng/mL.
3123081|NCT02862730|Experimental|Predictive Low Glucose Suspend Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient. The predictive low glucose suspend system will run through the artificial pancreas controller in predictive low glucose suspend mode and utilize the patient's optimized basal rates, correction factor, and carb ratio, but it will have the additional safety net of the pump suspending insulin when it predicts a hypoglycemic event.
3123082|NCT02862730|Experimental|Dual Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in dual hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery and an increase in glucagon delivery upon detection.
3123083|NCT02862730|Experimental|Single Hormone Closed-loop Arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient using the closed-loop artificial pancreas controller in single hormone mode to manage blood sugar that includes an exercise detection component that includes a reduction in insulin delivery upon detection.
3123084|NCT02862730|Active Comparator|Sensor Augmented Pump Therapy arm|Subjects will undergo an 84 hour study with 24 hours inpatient and 60 hour outpatient with subject's insulin pump and glucose sensor, if he/she typically uses one. Subjects will still wear a heart rate monitor uploading to a smart phone.
3123085|NCT02862912|Experimental|Chloroprocaine (CP)|Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)
3123086|NCT02862912|Active Comparator|Bupivacaine (BUP)|Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml
3123087|NCT02863198|Active Comparator|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
3123088|NCT02863198|No Intervention|non endometrial injury|non endometrial injury was done only for patient of the control group
3123089|NCT02863263|Other|Foam Dressing|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
3123090|NCT02863263|Other|Foam Dressing with Povidone Iodine|Over the course of 12 weeks, dressing is performed twice weekly, but additional dressing changes are allowed, depending on the condition of the pressure ulcer such as excessive exudates on the ulcer. The frequency of dressing change is limited to once daily.
3123091|NCT02863289||Children with proximal humerus fractures|Children aged from 10 to 18-year-old in NHS Tayside whom sustained proximal humerus fractures during year 2008 to 2015.
3123092|NCT02863328|Experimental|14 mg oral semaglutide|
3123093|NCT02863328|Active Comparator|25 mg empagliflozin|
3123094|NCT02863354|Experimental|Q4WKS|"Aflibercept 2 mg every 4 weeks (defined as every 28 days (+ 7 days) and at least 21 days between injections) through week 48. Following week 48, aflibercept 2 mg every 12 weeks through week 96.~If NV or PDR are worse per pre-specified criteria at week 60, or at any study visit thereafter, the subject will be treated every 4 weeks through the end of the study."
3123095|NCT02863354|Experimental|Q12WKS|"Aflibercept 2 mg every 12-weeks. Subjects will be followed every 4 weeks through week 12, and can be treated if the pre-specified criteria are met. Starting at week 12 if NV or PDR are stable or improved (as assessed by investigator) the subject will be monitored and treated at a 12-week interval through week 48. If NV or PDR are worse per the pre-specified criteria at week 12, or at any study visit thereafter, the subject will be treated monthly through the end of the study.~At week 52, aflibercept 2 mg every 4 weeks (defined as 28 days (+ 7 days) and at least 21 days between injections) for subjects with visible retinal non-perfusion. If retinal non-perfusion has completely resolved at week 72, aflibercept every 12 weeks through end of study. For subjects without retinal non-perfusion at week 52, aflibercept 2 mg every 12 weeks through the end of study."
3123096|NCT02863419|Experimental|Oral Semaglutide|
3123097|NCT02863419|Active Comparator|Liraglutide|
3123098|NCT02863419|Placebo Comparator|Placebo|
3123099|NCT02863575|Experimental|Ibuprofen/Caffeine|Ibuprofen 400 mg/ Caffeine 100 mg fixed-dose combination
3123100|NCT02863575|Active Comparator|Ibuprofen|Ibuprofen 400 mg
3123101|NCT02863575|Placebo Comparator|Placebo|Placebo comparator
3123102|NCT02864069|Experimental|Walking Intervention|
3123103|NCT02864069|Experimental|Cognitive Training Intervention|
3123104|NCT02864069|Experimental|Combined Intervention|
3123105|NCT02864082|Experimental|PAT-001 0.1%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
3123106|NCT02864082|Experimental|PAT-001 0.2%|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
3123107|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.1% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
3123108|NCT02864082|Placebo Comparator|Vehicle for PAT-001 0.2% arm|Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
3123109|NCT02864316|Experimental|Radiation-Induced Metastatic Sarcoma|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
3123110|NCT02864316|Experimental|Radiation-Induced Non-Sarcoma Metastatic Solid Tumors|a flat dose of Nivolumab 240 mg will be administered intravenously every 2 weeks until disease progression.
3123111|NCT02864342|Active Comparator|BreatheMate device and application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone with application that sends medication and refill reminders and reminders to complete a COPD questionnaire
3123112|NCT02864342|Placebo Comparator|BreatheMate device without application|BreatheMate Bluetooth device that attaches to Symbicort pressurized Metered Dose Inhaler (pMDI) and cell phone without any reminders or alerts.
3123113|NCT02864355|Active Comparator|Goal Directed Therapy|In this arm patient will have the FloTrac monitor and a Goal Directed Therapy algorithm will be used to manage blood pressures.
3123114|NCT02864355|No Intervention|Usual Care|Standard of care will be used to manage blood pressures.
3123115|NCT02864368|Experimental|5-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
3123116|NCT02864368|Experimental|21-day TMZ: Components A and B|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
3123117|NCT02864368|Experimental|5-day TMZ: Safety Cohort|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine. Vaccine components A and B were administered separately, with a delay between them, to determine if it was an individual component or a combination of the components that resulted in adverse reactions.
3123118|NCT02864368|Experimental|5-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of standard TMZ (150-200 mg/m^2/day on days 1-5 of each 28 day cycle) with PEP-CMV vaccination on Day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
3123119|NCT02864368|Experimental|21-day TMZ: Component A Alone|All patients receive Tetanus-Diphtheria booster vaccine at time of enrollment. Cycles of dose-intensified TMZ (75-100 mg/m^2/day on days 1-21 of each 28 day cycle) with PEP-CMV vaccination on day 23 (-1 day, + 2 days) of each TMZ cycle and tetanus pre-conditioning the day before the first vaccine.
3123120|NCT02864381|Experimental|Andecaliximab + Nivolumab|Andecaliximab 800 mg plus nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 34 weeks at the time of the primary efficacy analysis; up to 101 weeks at the time of the safety follow-up analysis).
3123121|NCT02864381|Active Comparator|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent (up to 41 weeks at the time of the primary efficacy analysis; up to 97 weeks at the time of the safety follow-up analysis).
3123122|NCT02864394|Experimental|Pembrolizumab|Participants with NSCLC receive pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 35 doses (approximately 24 months).
3123123|NCT02864394|Experimental|Docetaxel|Participants with NSCLC receive Docetaxel 75 mg/m^2 IV over 1 hour Q3W until disease progression, toxicity, investigator's decision to discontinue, or consent withdrawal.
3123124|NCT02864706|Experimental|EVEROLIMUS|patients received everolimus (Certican), low-exposure CsA (Neoral), mycophenolate mofetil (MMF) and corticosteroids with CsA withdrawal after 7-11 weeks
3123125|NCT02864706|Active Comparator|Control|patients received standard CsA, MMF and corticosteroids
3123126|NCT02864732|Experimental|Stabilization exercises|The stabilization exercises program will consist of exercises for the lower back and abdomen. These exercises include various types of abdominal bracing and bridging and side bridging. The exercises will be performed in supine, sidelying, and quadruped. It involves activation of muscles, dissociation of lumbar spine movement from extremities movement and endurance.
3123127|NCT02864732|Experimental|Stabilization exercises plus electrical stimulation|The neuromuscular electrical stimulation is a hand-size unit that has four plastic adhesive electrical conductors known as electrodes. These electrodes are going to be placed on the skin covering the lower back muscles. They will deliver an electric current that will generate muscle contraction that resembles normal muscle contraction. This treatment will be given in addition to the stabilization exercise program.
3123128|NCT02865187|Experimental|Vitamin D + hormonal contraception|600IU/day Vitamin D + hormonal contraception
3123129|NCT02865187|Active Comparator|Vit D + non-hormonal contraception|600IU/day Vitamin D
3123130|NCT02865343|Active Comparator|Non-invasive Ventilation(NIV)|Subjects randomized to NIV will perform 12-weeks of FES-row training while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
3123131|NCT02865343|Placebo Comparator|Sham Non-invasive ventilation(NIV)|Subjects randomized to Sham-NIV will perform 12-weeks of FES-row training while receiving sham ventilation applied through a full face-mask.
3123132|NCT02865434|Experimental|Group 1 (RA)|Group 1 will receive 50 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m as a single IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123133|NCT02865434|Experimental|Group 2 (RA)|Group 2 will receive 200 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123134|NCT02865434|Experimental|Group 3 (RA)|Group 3 will receive 400 µg Tc99m-tilmanocept radiolabeled with 10 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123135|NCT02865434|Experimental|Group 4 (RA)|Group 4 will receive 50 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123136|NCT02865434|Experimental|Group 5 (RA)|Group 5 will receive 200 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123137|NCT02865434|Experimental|Group 6 (RA)|Group 6 will receive 400 µg Tc99m-tilmanocept radiolabeled with 5 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123138|NCT02865434|Experimental|Group 7 (RA)|Group 7 will receive 50 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123139|NCT02865434|Experimental|Group 8 (RA)|Group 8 will receive 200 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123140|NCT02865434|Experimental|Group 9 (RA)|Group 9 will receive 400 µg Tc99m-tilmanocept radiolabeled with 1 mCi Tc99m via IV injection. Subjects will receive SPECT Imaging (60 Minutes post-injection) and SPECT Imaging (180 Minutes post-injection).
3123141|NCT02865434|Experimental|Group 10 (Healthy Controls)|Group 10 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
3123142|NCT02865434|Experimental|Group 11 (RA)|Group 11 will receive Tc99m-tilmanocept at the MTD via IV injection, Whole body planar SPECT imaging (15 Minutes post-injection) , Whole body planar SPECT imaging (60 minutes post-injection) , Whole body planar SPECT imaging (180 minutes post-injection), and Whole body planar SPECT imaging (18-20 hours post-injection), Planar Image with both Hands in Field of View (60 minutes and 180 minutes post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after Injection) , Blood Collection for PK Testing (15 minutes post injection) , Blood Collection for PK Testing (60 minutes post injection) , Blood Collection for PK Testing (180 minutes post injection) , and Blood Collection for PK Testing (18-20 hours post injection).
3123143|NCT02865499|Experimental|acarbose|all participants will receive acarbose
3123144|NCT02865538|Placebo Comparator|BAY3427080 Placebo|
3123145|NCT02865538|Experimental|50mg BAY3427080|
3123146|NCT02865538|Experimental|100mg BAY3427080|
3123147|NCT02865538|Experimental|150mg BAY3427080|
3123148|NCT02865538|Experimental|300mg BAY3427080|
3123149|NCT02865590|Experimental|Lyophilized Equine Bone Allograft|Sinus Lift with Lyophilized Equine Bone Allograft
3123150|NCT02865590|Active Comparator|deproteinized bovine bone allograft|Sinus lift with deproteinized bovine bone allograft
3123151|NCT02865720|Experimental|Subjects 2 to 5 years of age|500 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks
3123152|NCT02865720|Experimental|Subjects 6 years of age and older|1000 U of CINRYZE will be administered by IV infusion twice weekly for 12 weeks.
3123153|NCT02865811|Experimental|Pembrolizumab in Combination With PLD|"A safety lead in with 6 patients will be studied prior the start of the treatment.~If 2 out of the first 6 patients develop a dose limiting toxicity (DLT), the dose of PLD will be reduced.~If no more than 1 patient of the first 6 patients has evidence of dose limiting toxicities, the dose level will be considered the maximum tolerated dose (MTD)~Pegylated Liposomal Doxorubicin (PLD) pre-determine dosage will be administered every 4 weeks via IV~Pembrolizumab will be administered as a 30 min IV infusion every 3 weeks at a pre-determine dosage"
3123154|NCT02866175|Experimental|Edoxaban Regimen|Participants will be randomized to receive edoxaban 60 mg once-daily or 30 mg once-daily and clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5 mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) used.
3123155|NCT02866175|Active Comparator|Vitamin K Antagonist Regimen|Participants will be randomized to receive VKA in combination with clopidogrel 75 mg once-daily (or in the presence of a documented clinical need prasugrel [5mg or 10 mg once-daily] or ticagrelor [90 mg twice-daily] may be used) and aspirin (100 mg once-daily, for a minimum of 1 month and up to 12 months duration.
3123156|NCT02866643|Experimental|Delivery Room Insertion|Participants who randomize to this arm will receive the contraceptive implant in the Labor and Delivery room (0-2 hours following delivery).
3123157|NCT02866643|Active Comparator|Postpartum Insertion|Participants who randomize to this arm will receive the contraceptive implant in the postpartum ward room before discharge (24-48 hours following delivery).
3123158|NCT02866695|Other|Open label treatment|All patients will be treated with ingenol mebutate gel 0.015%. There is no placebo or comparator for this study. The investigator will identify the patient's treatment area at Baseline, and provide a detailed application instruction sheet. The first dose will be applied in clinic under the supervision of the investigator.
3123159|NCT02866942|Experimental|Asthma|LAIV administration in children with asthma receiving treatment according to British Thoracic Society step 2+
3123160|NCT02867059|Experimental|first dose|The dose used in the first cohort was determined on the basis of the safety and PK data generated in the FIM study (NCT02661373) currently ongoing in United States (US) and will be 150 mg.
3123161|NCT02867059|Experimental|second dose|Depending on the pharmacodynamics data (effect of SJ733 on parasitaemia) obtained from this first cohort, the dose in Cohort 2 may be adjusted but will not exceed 600 mg.
3123162|NCT02867150|Experimental|Active Device|Active Device: Ward Photonics Photonica Professional Red light therapy system Intervention: Device: Ward Photonics Photonica Professional
3123163|NCT02867163||Knee replacement patients receiving TXA|Patients who receive tranexamic acid during total knee replacement surgery
3123164|NCT02867202|Experimental|Intrauterine balloon|The heart-shaped intrauterine balloon is designed to fit into the cavity of the uterus,and removed on the 7th day after surgery. And hysteroscopy was taken out again after two or three months to re-evaluate the uterine adhesions.
3123165|NCT02867202|Experimental|intrauterine device Plus Foley Catheter|Intrauterine Contraceptive Device Plus Foley Catheter are inserted into the uterine after hysteroscopic adhesiolysis. Foley Catheter is removed after three days while intrauterine device is removed at the second hysteroscopy. Uterine adhesions are judged again at the second hysteroscopy.
3123166|NCT02867605|Other|Healthy Controls ages 18-45 with BMI of 19-25 or 30-35|Single Arm study
3123167|NCT02867618|Experimental|Carfilzomib + TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 and carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle.
3123168|NCT02867709|Experimental|Ubrogepant 25 mg|1 ubrogepant 25 milligram (mg) tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
3123169|NCT02867709|Experimental|Ubrogepant 50 mg|1 ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
3123170|NCT02867709|Placebo Comparator|Placebo|1 placebo-matching ubrogepant tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take placebo-matching ubrogepant tablet or rescue medication, orally, 2 to 48 hours after initial dose.
3123171|NCT02867995|No Intervention|Control|No glaucoma drop aid control
3123172|NCT02867995|Active Comparator|Eye Drop Aids|Participants could be placed into one of the drop aid groups (Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, or the Simply Touch Eye Drop Applicator)
3123173|NCT02868216|Experimental|anger management training|treatment group- Two monthly sessions will address the events triggering anger, the physiology of anger and the influence on the cardiovascular system, the dimesions of anger: cognitive, emotional and behavioral.
3123174|NCT02868216|No Intervention|Without management training|No anger management training
3123175|NCT02868229|Experimental|COR-001|
3123176|NCT02868229|Placebo Comparator|Placebo|
3123177|NCT02868242|Experimental|LDV/SOF|Participants will receive LDV/SOF 90/400 mg fixed dose combination (FDC) (1x 90/400 mg tablet or 4 x 22.5/100 mg tablets based on swallowability assessment during screening) for 12 weeks.
3123178|NCT02868281|Experimental|Subjects recruited at ACT centers|For the subjects who will be recruited in the ACT centers, they will be treated based on the ACT score. If ACT score are = 25 for >=3 months then step-down the treatment; if ACT score >=20, <25 or ACT=25 for <3 months then there will be no change and if ACT score less than (<=) 19 then step-up the treatment.
3123179|NCT02868281|Active Comparator|Subjects recruited in the control centers|For subjects who will be recruited in the control centers, they will be treated based on doctor's subjective judgment.
3123180|NCT02868554|No Intervention|Standard Invisalign Therapy|Patients receiving standard Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 14 days of compliant aligner wear.
3123181|NCT02868554|Experimental|Accelerated Invisalign|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
3123182|NCT02868554|Experimental|Accelerated Invisalign and Vibration|In addition to the accelerated Invisalign protocol described in Arm #2, patients will undergo intraoral vibration therapy using an AcceleDent Aura device for a duration of 20 minutes per day.
3123183|NCT02869295|Experimental|NKTR-214 Dose Escalation|This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured.
3123184|NCT02869334|Experimental|Auditory remediation with active tDCS|Auditory remediation program paired with active transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
3123185|NCT02869334|Experimental|Auditory remediation with sham tDCS|Auditory remediation program paired with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
3123186|NCT02869334|Sham Comparator|Control (computer games with sham tDCS)|Non-remediation, control computer activities (e.g. games) with sham transcranial direct current stimulation (tDCS) for 30 minutes, 2-3 sessions per week
3123187|NCT02869438|Experimental|Benralizumab arm|Benralizumab administered subcutaneously
3123188|NCT02869438|Placebo Comparator|Placebo arm|Placebo administered subcutaneously
3123189|NCT02869451|Experimental|Treatment|Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.
3123190|NCT02869893|Other|Healthy Participants|MRCP with Secretin and MR elastography will be performed on all participants.
3123191|NCT02870101|Other|Intervention|Performance of three nucleic acid amplification tests (NAATs) to detect Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) from swabs collected from the pharynx and rectum. Assays include: Nucleic acid amplification test 1 for NG and CT; Nucleic acid amplification test 2 for NG and CT; and, Nucleic acid amplification test 3 for NG and CT.
3123192|NCT02870205|Experimental|GSP 301 NS|
3123193|NCT02870205|Active Comparator|GOM-NS|
3123194|NCT02870205|Active Comparator|GMM-2 NS|
3123195|NCT02870205|Placebo Comparator|GSP 301 placebo NS|
3123196|NCT02870283|Active Comparator|Lithium|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (A) Started Lithium (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (900-1500mg) Non responsive patients: 2nd step.~Second step: Randomization for lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) OR lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 3rd step.~Third step: Crossover lithium (900mg-1500mg) + valproic acid (1000mg-1500mg) X lithium (900mg-1500mg) + carbamazepine (600mg-1200mg).~Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
3123197|NCT02870283|Active Comparator|Acid Valproic|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (B) Started Valproic Acid (1000mg-1500mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Valproic Acid (1000mg-1500mg) Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + carbamazepine (600mg-1200mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
3123198|NCT02870283|Active Comparator|Carbamazepine|"Subjects were randomized into three groups: (lithium, valproic acid, or carbamazepine).~Group (C) Started Carbamazepine (600mg-1200mg).~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Carbamazepine (600mg-1200mg). Non responsive patients: 2nd step.~Second step: Association with lithium (900mg-1500mg). Non responsive patients: 3rd step.~Third step: Crossover: lithium (900mg-1500mg) + valproic acid (1000mg-1500mg). Non responsive patients: 4th step.~Fourth step: Association with risperidone (1-6mg)"
3123199|NCT02870309|Experimental|Alpha-1 MP|Participants received 8 IV infusions of 60 mg/kg Alpha-1 MP administered weekly at an infusion rate not exceeding 0.08 mL/kg/min over approximately 15 minutes, up to Week 8.
3123200|NCT02870920|Active Comparator|Best Supportive Care|Best supportive care available
3123201|NCT02870920|Experimental|Durvalumab plus Tremelimumab and Best Supportive Care|Tremelimumab 75mg IV 60 minutes Day 1, cycles 1-4 Durvalumab 1500mg IV 60 minutes Day 1 every 28 days. Plus best supportive care
3123202|NCT02870933|Experimental|subject|this arm will receive Transepicardial with Transseptal CD 133+ Implantation
3123203|NCT02870933|No Intervention|control|this arm will not receive Transepicardial with Transseptal CD 133+ Implantation
3123204|NCT02870972|Experimental|Part 1: BCX7353 350 mg once daily|BCX7353 capsules, 350 mg dose administered once per day for 28 days
3123205|NCT02870972|Experimental|Parts 2 and 3: BCX7353 250 mg once daily|BCX7353 capsules, 250 mg dose administered once per day for 28 days
3123206|NCT02870972|Experimental|Parts 2 and 3: BCX7353 125 mg once daily|BCX7353 capsules, 125 mg dose administered once per day for 28 days
3123207|NCT02870972|Placebo Comparator|Parts 1, 2 and 3: Placebo|Placebo capsules, administered once per day for 28 days
3123208|NCT02870972|Experimental|Part 3: BCX7353 62.5 mg once daily|BCX7353 capsules, 62.5 mg dose administered once per day for 28 days
3123209|NCT02871011|Placebo Comparator|Control|Water, delivered as a footbath for 30 minutes, daily for 3 consecutive days.
3123210|NCT02871011|Experimental|Nitric oxide|Nitric oxide delivered as a footbath for 30 minutes, daily for 3 consecutive days.
3123211|NCT02871128|Experimental|Natureheme-iron|Subjects receive 2 capsules per day containing either 1000 mg Fe.
3123212|NCT02871128|Placebo Comparator|Placebo|Subjects receive 2 capsules per day containing starch placebo of similar appearance.
3123213|NCT02871128|Active Comparator|supplement|Subjects receive 1 capsule per day containing either 100 mg Fe.
3123214|NCT02871375|Other|DT1 MF, then Habitual|Delefilcon A multifocal contact lenses in Period 1, followed by subject's habitual multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
3123215|NCT02871375|Other|Habitual, then DT1 MF|Subject's habitual multifocal contact lenses in Period 1, followed by delefilcon A multifocal contact lenses in Period 2. Each product worn bilaterally (in both eyes) for 14 ± 3 days.
3123216|NCT02871440|Experimental|Eye drop 1|Omega 3
3123217|NCT02871440|Active Comparator|Eye drop 2|Optive Advanced
3123218|NCT02871440|Active Comparator|Eye drop 3|Optive
3123219|NCT02871479|Experimental|SAN007 5% cream|A cream containing 5% East Indian sandalwood oil (EISO).
3123220|NCT02871479|Placebo Comparator|Placebo cream|The vehicle cream
3123221|NCT02871479|Experimental|SAN007 10% cream|A cream containing 10% East Indian Sandalwood Oil (EISO).
3123222|NCT02871492|Experimental|Pritelivir 5% w/w ointment|Topical treatment (20 applications), 5 times daily for 4 days
3123223|NCT02871492|Placebo Comparator|Pritelivir ointment matching placebo|Topical treatment (20 applications), 5 times daily for 4 days
3123224|NCT02871492|Active Comparator|Zovirax® cream|Topical treatment (20 applications), 5 times daily for 4 days
3123225|NCT02871570|Experimental|Moderate Hepatic Impairment|A single dose of IV Rivipansel over 20 minutes
3123226|NCT02871570|Experimental|Normal Hepatic Function|A single dose of IV Rivipansel over 20 minutes
3123227|NCT02871635|Experimental|BI 695501|
3123228|NCT02871635|Active Comparator|HUMIRA + BI 695501|
3123229|NCT02871739|Experimental|DA viewing with SPI Feedback|Group 1 receives three decision aids and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
3123230|NCT02871739|Experimental|DA viewing with no SPI Feedback|Group 2 receives three decision aids. This group does not receive any feedback from the SPI.
3123231|NCT02871739|Experimental|Webinar with SPI Feedback|Group 3 receives an online, interactive webinar that focuses on SDM skills in clinical encounters and feedback on their standardized patient (SPI) interaction rating their shared decision making skills and highlighting opportunities for improvement.
3123232|NCT02871739|Experimental|Webinar with no SPI Feedback|Group 4 receives an online, interactive webinar that focuses on SDM skills in clinical encounters. This group does not receive any feedback from the SPI.
3123233|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
3123234|NCT02872012|Experimental|Cryoanesthesia Device -5 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
3123235|NCT02872012|Experimental|Cryoanesthesia Device -7 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
3123236|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 10 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
3123237|NCT02872012|Experimental|Cryoanesthesia Device -10 degrees Celsius for 20 seconds|"All patients will have one eye randomized to receiving anesthesia via the cryoanesthesia device which anesthetizes by chilling rather than by use of drug, prior to receiving an intravitreal injection.~Comment: Cryoanesthesia Device is the name of the device."
3123238|NCT02872012|Active Comparator|Lidocaine|"Participants randomized to this arm will have their other eye receive anesthesia via the current standard of care treatment method (lidocaine) prior to receiving an intravitreal injection.~Lidocaine: Lidocaine will be applied to the non-cryoanesthesia eye."
3123239|NCT02872103|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.
3123240|NCT02872103|Placebo Comparator|Placebo|Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.
3123241|NCT02872142|Experimental|Albutein 5%|Plasma exchanges (PEs) with albutein 5% as a replacement solution during an intensive treatment phase of two PEs per week over 3 weeks followed by maintenance treatment phase of weekly PE for 21 weeks. The dose of albutein 5% for replacement following plasma removal was calculated based on gender, weight, and the hematocrit of the participant.
3123242|NCT02872285|Experimental|LYC-30937-EC 25 mg PO once daily (QD)|LYC-30937-EC 25 mg by mouth once daily for 12 weeks
3123243|NCT02872285|Placebo Comparator|Matching Placebo PO QD|Placebo enteric coated (EC) by mouth once daily for 12 weeks
3123244|NCT02872311|Active Comparator|High Dose Influenza Vaccine|This group will be administered High Dose (HD) influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
3123245|NCT02872311|Active Comparator|Adjuvanted Influenza Vaccine|This group will be administered adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the first and second years of the study.
3123246|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+HD|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year of the study and high dose influenza vaccine (0.5 mL intramuscular (IM) injection) in the second year of the study.
3123247|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine +Adj|This group will be administered standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and adjuvanted influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
3123248|NCT02872311|Active Comparator|Standard Dose Influenza Vaccine+Recomb|This group will be administered a standard dose flu vaccination (0.5 mL intramuscular (IM) injection) in the first year and recombinant influenza vaccination (0.5 mL intramuscular (IM) injection) in the second year of the study.
3123249|NCT02872857|Placebo Comparator|Placebo|
3123250|NCT02872857|Experimental|8mg galantamine twice daily|
3123251|NCT02872857|Experimental|12mg galantamine twice daily|
3123252|NCT02872909|Active Comparator|low irradiance LED PDT|Ambulight LED portable PDT treatment
3123253|NCT02872909|Active Comparator|conventional higher irradiance LED|Conventional LED hospital based standard PDT treatment
3123254|NCT02872935|Placebo Comparator|Placebo: Normal Saline|1ml of Normal Saline will be given intravenously with the administering of the spinal dose
3123255|NCT02872935|Experimental|Glycopyrrolate group|1ml of Glycopyrrolate ( .2mg /ml) will be given intravenously with the administering of the spinal dose
3123256|NCT02873104|Active Comparator|Treatment|truSculpt rf device, therapeutic settings
3123257|NCT02873104|Sham Comparator|Sham|truSculpt rf device, non-therapeutic settings
3123258|NCT02873195|Experimental|Arm I (atezolizumab, bevacizumab, capecitabine)|Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3123259|NCT02873195|Active Comparator|Arm II (placebo, bevacizumab, capecitabine)|Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3123260|NCT02873208|Experimental|ALKS 3831|Oral tablet, daily dosing
3123261|NCT02873221|Active Comparator|Usual Care|Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of migraine attacks for up to 1 year.
3123262|NCT02873221|Experimental|Ubrogepant 50 mg|Ubrogepant 50 mg tablet orally plus placebo-matching ubrogepant tablet for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
3123263|NCT02873221|Experimental|Ubrogepant 100 mg|Ubrogepant 100 mg (two 50 mg tablets) orally for the treatment of a qualifying migraine attack for up to 8 treatments every 4 weeks for up to 1 year. Participants may choose to take a second dose orally after the initial dose if migraine continues or returns.
3123264|NCT02873286|Experimental|Group 1 - Single Low Dose / Booster|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
3123265|NCT02873286|Experimental|Group 2 - Two Low Doses|First dose (Week 0): MVA-BN-RSV 1x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 1x10E8 Inf.U; (intramuscular vaccinations)
3123266|NCT02873286|Experimental|Group 3 - Single High Dose / Booster|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): placebo; Booster dose (Week 56): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
3123267|NCT02873286|Experimental|Group 4 - Two High Doses|First dose (Week 0): MVA-BN-RSV 5x10E8 Inf.U; Second dose (Week 4): MVA-BN-RSV 5x10E8 Inf.U; (intramuscular vaccinations)
3123268|NCT02873286|Experimental|Group 5 - Placebo|First dose (Week 0): placebo; Second dose (Week 4): placebo; (intramuscular vaccinations)
3123269|NCT02873338|Active Comparator|Control (idarubicin+cytarabine)|"Induction:~Idarubicin 12 mg/m2/day by slow (10 to 30 minutes) intravenous (IV) injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Idarubicin 12 mg/m2/day slow (10 to 30 minutes) IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hour IV infusion (Days 1-5)~Consolidation:~• Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)"
3123270|NCT02873338|Experimental|Dociparstat 0.125 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion (Days 1-5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.125 mg/kg/h continuous 24-hr IV infusion on (Days 1-5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hrs, every 12 hrs (Days 1, 3, 5)"
3123271|NCT02873338|Experimental|Dociparstat 0.25 mg/kg|"Induction:~Dociparstat 4 mg/kg initial bolus 30 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-7)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2, 3)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-7)~Reinduction:~Dociparstat 4 mg/kg initial bolus 20 minutes post-idarubicin dose (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5)~Idarubicin 12 mg/m2/day slow IV injection/infusion daily (Days 1, 2)~Cytarabine 100 mg/m2/day continuous 24-hr IV infusion (Days 1-5)~Consolidation:~Dociparstat 4 mg/kg initial bolus 30 minutes post-3-hour cytarabine infusion (Day 1), followed by dociparstat 0.25 mg/kg/h continuous 24-hr IV infusion (Days 1-5; total 120 hours)~Cytarabine 1.0 g/m2 over 3 hours, every 12 hours (Days 1, 3, 5)"
3123272|NCT02873377|Experimental|Enhanced Care|"Interventions: Nicorette Gum/Nicoderm CQ, Behavioral Smoking Cessation Counseling & Smoking Quitline Referral. Participants in the Enhanced Care intervention arm will receive a single face-to-face behavioral counseling session delivered at the construction site lunch truck, two brief follow-up phone counseling calls, fax referral to the Florida tobacco quitline (QL), and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants in will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
3123273|NCT02873377|Active Comparator|Standard Care|"Interventions: Nicorette Gum/Nicoderm CQ, Smoking Quitline Referral. The Standard Care group (NRT) will receive fax referral to the Florida QL and provision of up to 8 weeks of free Nicotine Replacement Therapy (up to 6 weeks provided by the study and 2 weeks provided by the QL). Participants will receive two follow-up phone assessments at 3-, and 6-months of enrollment."
3123274|NCT02873429||Integrative Medicine (Complementary /Alternative)Group|Patients receiving chiropractic care, acupuncture, massage therapy, or meditation training for chronic pain
3123275|NCT02873429||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management, injections, etc.) for chronic pain.
3123276|NCT02873481|Experimental|Yoga (CPC+Y)|Women in Centering Pregnancy Care (CPC) will receive the intervention which is a 30 minute yoga sessions during each of the 2-hour CPC meetings (CPC+Y)
3123277|NCT02873481|No Intervention|Comparison (CPC alone)|To strengthen our ability to examine causal relationships between the intervention and outcomes, we will use longitudinal comparison group data contributed from deidentified archival data from an existing IRB-approved study (PI: Masho) which includes pregnant women who participated in the CPC model of care alone (without the yoga component) and were followed throughout their pregnancies using numerous measures identical to those in the proposed study, including weight/BMI, depressive symptoms, anxiety, and stress.
3123278|NCT02873585|Experimental|Stationary intraoral tomosynthesis|Stationary intraoral tomosynthesis after standard conventional bitewing radiography
3123279|NCT02873689|Experimental|Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsule, orally, once daily for up to 4 weeks.
3123280|NCT02873689|Experimental|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to 4 weeks.
3123281|NCT02873702|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 milligram (mg), delayed-release capsules, orally, once daily for up to 8 weeks in the Healing Period.
3123282|NCT02873702|Experimental|Healing Period: Lansoprazole 30 mg|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks in the Healing Period.
3123283|NCT02873702|Experimental|Maintenance Period: Dexlansprazole 30 mg|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for up to 6 months in the Maintenance period.
3123284|NCT02873702|Experimental|Maintenance Period: Placebo|Participants who will be healed at Week 8 will be randomized to receive dexlansoprazole placebo-matching capsules, orally, once daily for up to 6 months in the Maintenance period.
3123285|NCT02873754|Experimental|STEP UP|STEP UP is an intervention that combines evidence-based telephone cognitive behavioral counseling for smoking cessation, access to nicotine replacement therapy (NRT; including transdermal nicotine patch and either nicotine polacrilex or nicotine lozenge) and bupropion, and intensive mobile contingency management behavioral therapy administered via a smart-phone based application.
3123286|NCT02873923||Patients with a metastatic soft tissue sarcoma|All patients included in eligible clinical trials of the meta-analysis
3123287|NCT02873936|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
3123288|NCT02873936|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + stable dose of permitted csDMARD(s)
3123289|NCT02873936|Placebo Comparator|Placebo|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + stable dose of permitted csDMARD(s)
3123290|NCT02874066|Experimental|PTV/r/OBV/DSV|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBV, 75mg/50mg/12.5mg per tablet, Viekirax): 2 tablets per os per day Dasabuvir (DSV, 250 mg per tablet, Exviera): 1 tablet per os twice per day Treatment duration: 12 weeks
3123291|NCT02874092|Active Comparator|Rheumatoid Arthritis|-Receiving Methotrexate at stable doses of 10 to 25 mg weekly for at least 12 weeks
3123292|NCT02874092|Active Comparator|Osteoarthritis|-Diagnosis of osteoarthritis made by physician.
3123293|NCT02874404|Experimental|Group A (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients receive PI3K delta inhibitor TGR-1202 PO QD on days 1-28 and ibrutinib PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3123294|NCT02874404|Experimental|Group B (Ibrutinib, PI3K delta inhibitor TGR-1202)|Patients receive ibrutinib PO QD on days 1-28 and PI3K delta inhibitor TGR-1202 PO QD and days 9-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3123295|NCT02874404|Experimental|Group C (PI3K delta inhibitor TGR-1202, ibrutinib)|Patients then receive PI3K delta inhibitor TGR-1202 PO QD and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3123296|NCT02874534|Experimental|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions. Session 1 provides orientation and psychoeducation on anhedonia, and activity monitoring is introduced. Sessions 2-3 include structured values assessments of 10 life areas to enhance motivation for sustained behavior change and to clarify goals. Following goals clarification, an activity hierarchy is developed, establishing a set of idiographic behavioral targets across life areas prioritized by ease of implementation to scaffold task engagement during the course of treatment.
3123297|NCT02874534|Active Comparator|Mindfulness Treatment|BATA will be compared to mindfulness based cognitive therapy (MBCT), chosen because its mechanisms of action are hypothesized to impact different brain mechanisms than BATA. Mindfulness is nonjudgmentally bringing awareness and acceptance to one's present-moment experience. MBCT will be administered in an individual format. The MBCT protocol will be modeled on the session outlines presented in Wahbeh et al., 2014. Treatment will be compromised of 15 weekly 45-minute sessions.
3123300|NCT02874794|Experimental|LCZ696 (sacubitril/valsartan)|minimum dose: 24/26mg, BID, oral, tablet maximum dose: 97/103mg, BID, oral, tablet All patients will begin on Dose Level 1 (24/26mg) and will be titrated every two weeks to target Dose level 3 (97/103mg). LCZ696 tablets will be provided for the 12-week open label extension.
3123301|NCT02874794|Active Comparator|Enalapril|minimum dose: 2.5mg, BID, oral, tablet maximum dose: 10 mg, BID, oral tablet All patients will begin on Dose Level 1 (2.5mg) and will be titrated every two weeks to target Dose level 3 (10mg).
3123302|NCT02874846|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye (OU) daily
3123303|NCT02874846|Placebo Comparator|Netarsudil Ophthalmic Solution Vehicle|1 drop in each eye (OU) daily
3123304|NCT02874924|Experimental|Rapamycin|Rapamycin 1mg taken once daily for 8 weeks
3123305|NCT02874924|Placebo Comparator|Placebo|Placebo taken once daily for 8 weeks
3123306|NCT02874924|Experimental|Rapamycin Alone - Cardiovascular Effects|No placebo control; Rapamycin 1mg once daily for 8 weeks
3123307|NCT02875028|Experimental|Vorapaxar|subjects will be treated with 4x2,5mg vorapaxar in empty lactose-starch capsules
3123308|NCT02875028|Placebo Comparator|Placebo|subjects will be treated with 4 empty lactose-starch capsules
3123309|NCT02875080|Experimental|OPC-34712 disintegrating tablet with water|OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
3123310|NCT02875080|Experimental|OPC-34712 disintegrating tablet without water|OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
3123311|NCT02875080|Experimental|OPC-34712 conventional tablet with water|OPC-34712 (4 mg) conventional tablet is administered with water.
3123312|NCT02875340|Experimental|VAL401 treatment|Patients received VAL401 oral formulation once daily according to their level of tolerance (2 mg - 10 mg).
3123313|NCT02875366|Placebo Comparator|Placebo|Placebo matched to LUM/IVA fixed-dose combination tablet orally every 12 hours (q12h) for 24 weeks.
3123314|NCT02875366|Experimental|LUM/IVA|LUM 400 milligram (mg)/IVA 250 mg fixed-dose combination tablet orally q12h for 24 weeks.
3123315|NCT02875392|Experimental|Fucoidan use|FucoHiQ(275mg Oligo Fucoidan + 275mg HS Fucoxanthin) 550mg/capsule 6 per day(before breakfast and supper)
3123316|NCT02875392|Placebo Comparator|placebo pills|placebo capsule 6 per day (before breakfast and supper)
3123317|NCT02875613|Experimental|Avelumab|Avelumab 10mg/kg IV infusion on days 1 and 15 of 28-day cycle
3123318|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
3123319|NCT02875834|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
3123320|NCT02875834|Placebo Comparator|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
3123321|NCT02875977|Experimental|Experimental Counseling|Patients randomized to this arm receive experimental counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout and a 4-minute educational video.
3123322|NCT02875977|Active Comparator|Standard Counseling|Patients randomized to this arm receive standard counseling on the importance of attending PFPT appointments. This includes the standard 2-page educational handout.
3123323|NCT02876055|Active Comparator|Single shot interscalene nerve block|An interscalene nerve block will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles. 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine will be administered.
3123324|NCT02876055|Active Comparator|Continuous interscalene nerve block|"An interscalene nerve block and delivery of a catheter will be performed under continuous live ultrasound guidance, obtaining visualization of the roots or trunks of the brachial plexus in between the anterior and middle scalene muscles.~Initial loading bolus includes 15 to 20 mL of Bupivacaine 0.5% with 1:200,000 Epinephrine. After surgery, the continuous interscalene nerve block catheter will be loaded in the post-anesthesia care unit (PACU) with bupivacaine 0.2% 10 milliliters (mL), and then an infusion will be initiated of bupivacaine 0.2% at 8 to 10 mL per hour."
3123325|NCT02876055|Experimental|Local Infiltration Analgesia (LIA)|"The LIA group will utilize weight based dosing of Ropivacaine as part of a cocktail solution containing ropivacaine, epinephrine, ketorolac, and normal saline 0.9%. Patients will receive a total volume of 120 mL injected strategically in the periarticular structures by the surgeon. This is a one-time injection. This will occur after implantation of the final prostheses, but prior to closure of the fascia."
3123326|NCT02876159|Experimental|Vaccination Naïve|Participants who have received an influenza vaccine in 2 or less of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
3123327|NCT02876159|Experimental|Vaccination Experienced|Participants who have received an influenza vaccine at least 3 of the past 5 years will receive the FDA-approved 2016-2017 influenza vaccine.
3123328|NCT02876172|Experimental|MDMA and CBCT|Cognitive-behavioral conjoint therapy and 2 sessions of MDMA-assisted therapy.
3123329|NCT02876575|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
3123330|NCT02876601|Active Comparator|Defibrotide/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
3123331|NCT02876601|Placebo Comparator|Placebo/LPS|"2ng/kg lipopolysaccharide period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
3123332|NCT02876601|Other|Defibrotide/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
3123333|NCT02876601|Other|Placebo/Placebo|"Placebo (0.9% sodium chloride) period I: 6.25mg/kg bodyweight defibrotide or placebo (0.9% sodium chloride) period II: vice versa~16 healthy volunteers will receive 2ng/kg bodyweight LPS plus Defibrotide or Placebo 4 healthy volunteers will receive 0.9% saline (NO LPS) plus Defibrotide or Placebo"
3123334|NCT02876757||5ARI Users|
3123335|NCT02876757||Non 5ARI users|
3123336|NCT02876887|Active Comparator|Cocoa|Three servings per day of epicatechin-rich (75 mg daily) cocoa beverages for six months.
3123337|NCT02876887|Placebo Comparator|Placebo|Three servings per day of placebo beverages for six months.
3123338|NCT02876900|Experimental|Low dose Asenapine maleate patch|Low dose asenapine maleate, transdermal patches will be compared against placebo patches.
3123339|NCT02876900|Experimental|High dose asenapine maleate patch|High dose asenapine maleate, transdermal patches will be compared against placebo patches.
3123340|NCT02876900|Placebo Comparator|Placebo transdermal patch|Low dose or high dose asenapine maleate transdermal patch will be compared against placebo patches
3123341|NCT02876926|Experimental|"Enhanced home-based testing"|"These participants will download a study-specific smartphone app (eTEST), and receive home-based HIV test kits in the mail every 3 months. These kits will have been fit with sensors that enable remote detection of when the kit was opened. Qualified HIV test counselors (QHTC) will then follow up with these participants within 24 hours of receiving notification that the test has been opened to conduct routine counseling, offer referrals for other services, and connect those with reactive results with follow-up care."
3123342|NCT02876926|Active Comparator|Home-based testing alone|These participants will receive a typical home-based test for HIV in the mail every 3 months, but no phone-based follow-up will be provided.
3123343|NCT02876926|Sham Comparator|Reminders for clinic-based testing|Participants in this condition will receive a letter in the mail every 3 months reminding them to be tested at a local clinic for free.
3123344|NCT02877004|Active Comparator|Laser for 4 weeks|3 Low-Level Laser Therapy Treatments Weekly
3123345|NCT02877004|Active Comparator|Laser for 6 weeks|2 Low-Level Laser Therapy Treatments Weekly
3123346|NCT02877004|Active Comparator|Laser for 12 weeks|1 Low-Level Laser Therapy Treatment Weekly
3123347|NCT02877082|Experimental|Tacrolimus, bortezomib, thymoglobulin|Patients receive tacrolimus IV on day -3 through day 180. Patients may receive tacrolimus PO later at the doctor's discretion. Patients receive thymoglobulin IV on days -3, -2, and -1 and bortezomib IV on day 0 and day 3. Patients undergo allogeneic bone marrow transplant on day 0.
3123348|NCT02877095|Experimental|Active|All subjects in the pilot study will receive the subcutaneous pump to administer a special formulation of furosemide to be delivered subcutaneously.
3123349|NCT02877485|Active Comparator|Triamcinolone acetonide then Ayr spray|This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.
3123350|NCT02877485|Active Comparator|Ayr spray then triamcinolone acetonide|This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.
3123351|NCT02877680|Experimental|Intervention|Smartphone app for parents to track adolescents' strength behaviors related to living with and managing type 1 diabetes, including regular feedback to parents and training about how to recognize and reinforce positive behaviors in teens.
3123352|NCT02877680|No Intervention|Usual Care|Usual diabetes care and study-related data collection, without use of app during the study period. They will be offered an opportunity to try the app and share their feedback with the study team after completing follow-up data collection.
3123353|NCT02877927|Experimental|Omadacycline|Omadacycline tablets
3123354|NCT02877927|Active Comparator|Linezolid|Linezolid tablets
3123355|NCT02878057|Experimental|Advanced Breast Cancer|Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis; Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
3123356|NCT02878213|Experimental|D700 System|Patients referred to catheter-based Atrial-Fibrillation (AF) ablation procedure therapy comprising of Pulmonary Veins Isolation (PVI).
3123357|NCT02878330|Placebo Comparator|Placebo|Participants will receive a single intramuscular (IM) dose of placebo matched to MEDI8897 on Day 1 of the study.
3123358|NCT02878330|Experimental|MEDI8897 50 mg|Participants will receive a single IM dose of MEDI8897 50 milligrams (mg) on Day 1 of the study.
3123359|NCT02878382|Other|Conventional MAL-PDT|Conventional topical PDT with Methylaminolevulinate 16% in one half of the scalp with multiple AKs.
3123360|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol ointment 50 mcg/g applied once a day for 15 consecutive days in one half of the scalp, before Conventional topical PDT
3123361|NCT02878486|Experimental|Group 1|Subjects will have clinic visits, home visits, and telephone visits. Subjects will be asked to wear a wrist monitor (Jawbone Up) for duration of the study, will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
3123362|NCT02878486|Active Comparator|Group 2|Subjects will make clinic visits. At home visits, subjects will meet with the study team to review Physical Activity Education and also be asked to wear the ActivPAL device to assess sitting time.
3123363|NCT02878590|Experimental|BONGO DEVICE|All participants that qualify will receive the intervention of the Bongo device
3123364|NCT02878603|Experimental|caplacizumab|Participants who completed study ALX0681-C301 (NCT02553317) with standard of care (plasma exchange [PE], corticosteroid and other immunosuppressive agents) or caplacizumab with PE and immunosuppressive agents were enrolled in study LTS16371. Participants upon each recurrence of aTTP in LTS16371 and not meeting any criteria (namely: pregnancy, history of severe and/or serious hypersensitivity reaction to investigational medicinal product [IMP], withdrawal before receiving IMP, received more than 1 PE) were treated with caplacizumab initial 10 milligrams (mg) intravenous dose followed by a daily 10 mg subcutaneous injections during the period of PE and for 30 days after stop of PE (and eventually 28-day extension period, if needed). Participants with or without recurrence were followed up twice yearly up to maximum of 36 months in LTS16371.
3123365|NCT02879318|Active Comparator|Gemcitabine plus Nab-Paclitaxel|Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Days 1, 8, 15 Q28 days.
3123366|NCT02879318|Experimental|Gemcitabine + Nab-Paclitaxel + Durvalumab + Tremelimumab|"Gemcitabine 1000 mg/m2 IV & Nab-Paclitaxel 125 mg/m2 until unequivocal progression or unacceptable toxicity. Day 1, 8, 15 Q28 days.~plus Durvalumab 1500mg IV day 1 only Q28 days; and Tremelimumab 75 mg IV Days 1 cycles 1, 2, 3 and 4 only until unequivocal progression or unacceptable toxicity."
3123367|NCT02879383|Experimental|DMR Procedure|Subjects randomized to the DMR procedure are unblinded at 24 weeks and followed for an additional 24 weeks.
3123368|NCT02879383|Sham Comparator|Sham Procedure|Subjects are unblinded at 24 Weeks. Sham subjects to cross over to receive DMR treatment at 24 Weeks and followed up for additional 24 weeks.
3123369|NCT02879578|Experimental|Valbenazine (Children)|Children (6 to 11 years of age) received valbenazine 10 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 20 mg or continue with the participant's current dose for the remainder of the treatment period.
3123370|NCT02879578|Experimental|Valbenazine (Adolescents)|Adolescents (12 to 17 years of age) received valbenazine 20 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 40 mg or continue with the participant's current dose for the remainder of the treatment period.
3123371|NCT02879578|Experimental|Valbenazine (Adults)|Adults (18 to 64 years of age) received valbenazine 40 mg once daily for 4 weeks. At the end of Week 4, investigators could escalate the dose to 80 mg or continue with the participant's current dose for the remainder of the treatment period.
3123372|NCT02879747|Active Comparator|Interventional|Unchanged dose Genotropin
3123373|NCT02879747|Active Comparator|Interventional 2|reduced dose 50% Genotropin
3123374|NCT02879812|Experimental|Multi-Component Intervention|End Stage Renal Disease (ESRD) facilities will receive feedback reports containing facility specific data, an educational webinar for dialysis facility medical directors and staff, and an educational video for patients and staff.
3123375|NCT02879812|Active Comparator|Standard Care + Pamphlet|End Stage Renal Disease (ESRD) facilities will conduct usual care and receive United Network for Organ Sharing (UNOS) educational pamphlets for staff.
3123376|NCT02879994|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3123377|NCT02880137|Experimental|RTMPE|RTMPE with Perflutren Lipid Microsphere (DEFINITY) is a safe and feasible non-invasive technique commonly used to diagnose coronary disease, and offers an attractive alternative for CAV detection.
3123378|NCT02880176|Experimental|Financial Incentive|"Financial Incentive to Increase Ambulation: A financial reward is given on a per day basis when subject meets daily step goal, 1/5 chance to win additional monetary prize if patient uploads step count data for at least 75% of study days.~Subjects will use Fitbit Zip to track step counts"
3123379|NCT02880176|No Intervention|Control (Education)|Subjects in this group will receive standard education on the benefits of post-surgery ambulation only Subjects will use Fitbit Zips to track step counts
3123380|NCT02880189|Other|Single|All subjects will be receiving the Orbera Intragastric Balloon and will be undergoing Endoscopic Ultrasound guided core liver biopsy.
3123381|NCT02880228|Experimental|Treatment (lenalidomide, dexamethasone, pembrolizumab)|Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO daily on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of course 1, day 15 of course 2, and day 8 of course 3. Courses 1-3 repeat beyond 3 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo stem cell transplantation after 4 courses of treatment.
3123382|NCT02880254|Active Comparator|Kurbo only|use of app plus standard of care
3123383|NCT02880254|Active Comparator|Kurbo plus PHC|use of app, personal health coach and standard of care
3123384|NCT02880475|Experimental|OXN prolonged release tablet 5/2.5mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 5/2.5mg for one time.
3123385|NCT02880475|Experimental|OXN prolonged release tablet 20/10mg|The subjects were randomized to receive a single dose of OXN prolonged release tablet 20/10 mg for one time.
3123386|NCT02880514|Experimental|PROPEL Mini Sinus Implant|Placement of the Propel Mini Sinus Implant in one frontal sinus ostia (FSO) assigned to the treatment group following in-office balloon dilation
3123387|NCT02880514|Active Comparator|Balloon Sinus Dilation Alone|In-office balloon dilation of the contralateral frontal sinus ostia (FSO) without implant placement
3123388|NCT02880761|Experimental|Intervention|Patients with AVF will be followed up by a preset following-up system. Interventions would be administered according to the assessment for AVF, which including the surgery and puncture of AVF. For AVF surgery, a certain vein would be used in the operation according to the assessment results. For AVF puncture, the methods, such as 'button hole', 'rope ladder', dwelling needle, would be selected prospectively according to the assessment results.
3123389|NCT02880761|No Intervention|Control|Patients in other hemodialysis centers who are treated by routine protocal would be enrolled into control group. Their clinical data would be collected and compared with intervention group.
3123390|NCT02880852|Experimental|Belimumab 10 mg/kg|In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
3123391|NCT02880865|Experimental|Group 1 - MMR and CD-JEV|Participants receiving one dose of CD-JEV vaccine and one dose of MMR vaccine concurrently at Day 0; Group 1 will also receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
3123392|NCT02880865|Experimental|Group 2 - MMR then CD-JEV|Participants receiving one dose of MMR vaccine at Day 0 and one dose of CD-JEV 56 days later. Group 2 will receive a second dose of MMR per the routine immunization schedule at Day 84 (12 months of age).
3123393|NCT02881008|Experimental|Arm A|Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period
3123394|NCT02881008|Experimental|Arm B|Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period
3123395|NCT02881008|Experimental|Arm C|Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period
3123396|NCT02881008|Active Comparator|Arm D|Entecavir 0.5 mg daily for 24 weeks
3123397|NCT02881008|Experimental|Arm E|Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period
3123398|NCT02881008|Experimental|Arm F|Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period
3123399|NCT02881047|Experimental|rAblative Fractional Laser for Sclerotic GVHD-Associated Joint|"Range of motion limitations and joint contractures due to sclerotic GVHD across a specific joint / limb"
3123400|NCT02881112|Experimental|Active Treatment Arm|Treatment with Provant Therapy System
3123401|NCT02881567|Experimental|Daclizumab|
3123402|NCT02881658|Experimental|Plant sterols-enriched soya beverage provided by Vitasoy|Daily consumption of 2g of plant sterols as provided by one pack of 250 ml of plant sterols-enriched soya beverage for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
3123403|NCT02881658|Placebo Comparator|Soya beverage provided by Vitasoy|Daily consumption of one pack of 250 ml of soya beverage (without plant sterols) for consecutive 3 weeks, each pack consumed once with main meal (i.e breakfast, lunch or dinner).
3123404|NCT02881775|Experimental|rTMS and exercise, then Sham rTMS and exercise|At lab visit, subjects receive repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive sham rTMS and exercise using the same parameters.
3123405|NCT02881775|Sham Comparator|Sham rTMS and exercise, then rTMS and exercise|"At lab visit, subjects receive sham repetitive transcranial magnetic stimulation (rTMS) at 10 Hz, 5 sec on, 55 sec off and quadriceps isometric exercise (5% MVIC) for 15 minutes. This is followed by a wash out period of 1 week. At the next lab visit, subjects receive the true rTMS and exercise using the same parameters."
3123406|NCT02881840|Experimental|14C-APD421|
3123407|NCT02881957|Placebo Comparator|Control|Placebo control (simple oral syrup)
3123408|NCT02881957|Experimental|Vitamin D3|Cholecalciferol/Vitamin D3 (540,000 IU orally or by feeding tube once)
3123409|NCT02881996|Experimental|IV tylenol|Post-operatively, all patients will be placed on a standard patient/nurse controlled analgesia (PCA) according to our pain service protocol which included ketorolac. A 3 hours after first dose of ketorolac, patients in the acetaminophen arm will then receive scheduled 10mg/kg of IV acetaminophen every 6hrs for a total of 3 days in between doses of ketorolac. PCA Pumps will be discontinued with the return of bowel function and transition to oral intake in all patients as per the current protocol. If a patient in the acetaminophen arm is transitioned off of PCA prior to 3 days, IV acetaminophen will be stopped at that time as well. Patients in the control group only may receive oral/rectal acetaminophen as needed for treatment of fevers.
3123410|NCT02881996|Active Comparator|No IV tylenol|Same as above without IV tylenol.
3123411|NCT02882152|Experimental|femoral blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve"
3123412|NCT02882152|Active Comparator|Morphine|intrathecal morphine
3123413|NCT02882633|Active Comparator|Lumbar Plexus Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
3123414|NCT02882633|Active Comparator|Fascia Iliac Block|Subjects will receive single shot local anesthetic, 30 ml bolus of bupivacaine, given preoperatively to help with postoperative pain
3123415|NCT02882711|Experimental|ketamine|
3123416|NCT02882854|Experimental|Guanfacine|Guanfacine 1 mg capsule by mouth, one time prior to surgery.
3123417|NCT02882854|Placebo Comparator|Placebo|Placebo with a similar appearance to guanfacine by mouth one time prior to surgery
3123418|NCT02883244|Experimental|Soft-Picks Advanced|Device: Curved Soft-Picks
3123419|NCT02883244|Active Comparator|Floss|Device: Waxed tape floss
3123420|NCT02883400|No Intervention|SOC-Standard of care|standard of care, nontreatment
3123421|NCT02883400|Experimental|spironolactone|spironolactone
3123422|NCT02883452|Active Comparator|Cohort 1: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
3123423|NCT02883452|Experimental|Cohort 2: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
3123424|NCT02883452|Experimental|Cohort 3: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
3123425|NCT02883452|Experimental|Cohort 4: CT-P13 SC 240 mg|CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
3123426|NCT02883452|Experimental|Arm 1: CT-P13 SC 120/240 mg|CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
3123427|NCT02883452|Active Comparator|Arm 2: CT-P13 IV 5 mg/kg|CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)
3123428|NCT02884089|Placebo Comparator|Placebo + Metformin|Single dose of placebo administered orally followed by a single dose of metformin administered orally in one of four study periods.
3123429|NCT02884089|Experimental|Abemaciclib + Metformin|Single dose of abemaciclib administered orally followed by a single dose of metformin administered orally in one of four study periods.
3123430|NCT02884089|Placebo Comparator|Placebo + Iohexol|Single dose of placebo administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
3123431|NCT02884089|Experimental|Abemaciclib + Iohexol|Single dose of abemaciclib administered orally followed by a single dose of iohexol administered intravenously (IV) in one of four study periods.
3123432|NCT02884414|Experimental|Cutaneous Stimulation|Cutaneous stimulation and/or feedback. This stimulation and/or feedback may be visual, auditory, tactile (e.g. vibratory, temperature), or haptic and is completely external.
3123433|NCT02884427|Experimental|Cathode Stimulation|Group that is involved with the (black) negative electrode seeking the polar effect of nervous increased excitability and conductivity with the current application.
3123434|NCT02884427|Experimental|Anode Stimulation|Group that is involved with the (red) positive electrode seeking the polar effect of nervous excitability and conductivity decreased with the current application.
3123435|NCT02884427|Placebo Comparator|Control|Group that will be placed electrotherapy without operation, but only installation. Patients in this group will see the team work but it will not be delivering current.
3123436|NCT02884492|Experimental|Cognitive impairment|Adults with Alzheimer's disease, preclinical Alzheimer's disease or impairment due to suspected non-Alzheimer's disease pathophysiology will receive 18F-THK- 5351 and/or lumbar puncture (optional).
3123437|NCT02884492|Active Comparator|No cognitive impairment|Normal aging adults will receive 18F-THK- 5351 and/or lumbar puncture (optional).
3123438|NCT02885012|Experimental|Switch to Letairis from Bosentan|Subjects will be switching treatments from Bosentan (Tracleer) to Ambrisentan (Letairis)
3123439|NCT02885012|Experimental|Switch to Letairis from Macitentan|Subjects will be switching treatments from Macitentan (Opsumit) to Ambrisentan (Letairis)
3123440|NCT02885025|Active Comparator|BSE + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
3123441|NCT02885025|Active Comparator|Broccoli Sprout Extract + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
3123442|NCT02885025|Active Comparator|Placebo Pill + Nasal Fluticasone|"subjects will be randomized into 1 of 4 arms:~1. Broccoli Sprout Extract + Nasal Fluticasone 2 Broccoli Sprout Extract + normal saline nasal spray 3. Placebo Pill + Nasal Fluticasone 4. Placebo Pill + normal saline nasal spray"
3123443|NCT02885025|Placebo Comparator|Placebo Pill + normal saline nasal spray|"subjects will be randomized into 1 of 4 arms:~Broccoli Sprout Extract + Nasal Fluticasone~Broccoli Sprout Extract + normal saline nasal spray~Placebo Pill + Nasal Fluticasone~Placebo Pill + normal saline nasal spray"
3123444|NCT02885181|Experimental|GS-9876 - 30 mg|GS-9876 30 mg + filgotinib placebo for 12 weeks
3123445|NCT02885181|Experimental|GS-9876 - 10 mg|GS-9876 10 mg + filgotinib placebo for 12 weeks
3123446|NCT02885181|Experimental|Filgotinib|Filgotinib + GS-9876 placebo for 12 weeks
3123447|NCT02885181|Placebo Comparator|Placebo|GS-9876 placebo + filgotinib placebo for 12 weeks
3123448|NCT02885246||Influenza Virus Positive Group|The group included specimen samples with a laboratory confirmed diagnosis of influenza A and/or B, reported in the Instituto Conmemorativo Gorgas de Estudios de la Salud (ICGES) database of Panama, from January 2011 to December 2017.
3123449|NCT02885350|Active Comparator|Spinal fentanyl|20 micrograms of intrathecally administered fentanyl in single dose. Total volume of intrathecal injection 2 ml.
3123450|NCT02885350|Experimental|Epidural fentanyl|100 micrograms of epidurally administered fentanyl in a single dose. Total volume of epidural injection 7 ml.
3123451|NCT02885350|Active Comparator|Spinal sufentanil|5 micrograms of intrathecally administered sufentanil in a single dose. Total volume of intrathecal injection 2 ml.
3123452|NCT02885350|Experimental|Epidural sufentanil|20 micrograms of epidurally administered sufentanil in a single dose. Total volume of epidural injection 7 ml.
3123453|NCT02885506|Experimental|Cohort 1|Oral administration of P218 capsules 10 mg
3123454|NCT02885506|Experimental|Cohort 2|Oral administration of P218 capsules 30 mg
3123455|NCT02885506|Experimental|Cohort 3|Oral administration of P218 capsules 100 mg
3123456|NCT02885506|Experimental|Cohort 4|Oral administration of P218 capsules 250 mg
3123457|NCT02885506|Experimental|Cohort 5|Oral administration of P218 capsules 500 mg
3123458|NCT02885506|Experimental|Cohort 6|Oral administration of P218 capsules 750 mg
3123459|NCT02885506|Experimental|Cohort 7|Oral administration of P218 capsules 1000 mg
3123460|NCT02885506|Placebo Comparator|Cohort 8 - Pooled Placebo|Oral administration of P218 matching placebo
3123461|NCT02885506|Experimental|Fed - Fasted|Oral administration of P218 capsules 250 mg Under fed then fasted conditions.
3123462|NCT02885506|Experimental|Fasted - Fed|Oral administration of P218 capsules 250 mg Under fasted then fed conditions.
3123463|NCT02885636|Experimental|Inhaled albuterol|2.5 mg inhaled albuterol through a high efficiency nebulizer -single dose
3123464|NCT02885636|Placebo Comparator|Inhaled saline placebo|Inhaled saline through a high efficiency nebulizer -single dose
3123465|NCT02886234|Experimental|Mindfulness training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
3123466|NCT02886234|Active Comparator|Health Coaching (HC)|Eight, 30-minute phone delivered HC sessions once a week for 8 weeks
3123467|NCT02886338|Experimental|capsule endoscopy examination|Capsule endoscopic examination for the esophagus, stomach and duodenum.
3123468|NCT02886494|Active Comparator|BAC treatment|BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
3123469|NCT02886494|Placebo Comparator|Matched vehicle|Matched vehicle, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks
3123470|NCT02886624|Experimental|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
3123471|NCT02886702|Experimental|Test|Tazarotene Cream 0.05% (Fougera Pharmaceuticals Inc.)
3123472|NCT02886702|Active Comparator|Reference|TAZORAC® (tazarotene) Cream 0.05% (Allergan, Inc.)
3123473|NCT02886702|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
3123474|NCT02886715|Experimental|Test|Tazarotene Cream 0.1% (Fougera Pharmaceuticals Inc.)
3123475|NCT02886715|Active Comparator|Reference|TAZORAC® (tazarotene) Cream, 0.1% (Allergan, Inc.)
3123476|NCT02886715|Placebo Comparator|Placebo|Placebo (Vehicle of test product) (Fougera Pharmaceuticals Inc.)
3123477|NCT02886728|Experimental|Filgotinib 200 mg + MTX|Filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
3123478|NCT02886728|Experimental|Filgotinib 100 mg + MTX|Filgotinib 100 mg + placebo to match filgotinib 200 mg + MTX up to 20 mg
3123479|NCT02886728|Experimental|Filgotinib 200 mg Monotherapy|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match MTX
3123480|NCT02886728|Active Comparator|MTX Monotherapy|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + MTX up to 20 mg
3123481|NCT02886923|Experimental|Test/Control Sequence|Subjects will wear the Hioxifilcon A Test contact lens and then the Hioxifilcon A with Cosmetic Ring Control contact lens for approximately three to four hours at each of the two measurement visits.
3123482|NCT02886923|Active Comparator|Control/Test Sequence|Subjects will wear the Hioxifilcon A with Cosmetic Ring Control contact lens and then the Hioxifilcon A Test contact lens for approximately three to four hours at each of the two measurement visits.
3123483|NCT02887183|Other|LCZ696(sacubitril/valsartan)|"Subjects received sacubitril/valsartan (LCZ696) on Day 1. The initial dose was determined by the investigator and per the approved indication described in the United States prescribing information/package insert (USPI). The three doses available were: 24/26 mg (Dose Level 1), 49/51mg (Dose Level 2) and 97/103mg (Dose Level 3).~Titration of the dosage were performed per USPI at 2 to 4 week intervals as clinically tolerated until maximal tolerated or target dosage was achieved. Target dosage was sacubitril/valsartan 97/103 mg twice daily."
3123484|NCT02887404|Experimental|Spine surgery analgesic pathway|"Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
3123485|NCT02887404|Active Comparator|Usual care|"Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg).~Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake).~After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed."
3123486|NCT02887521|Experimental|Pulmonary Rehabilitation (PR)|Patients will receive 10 in-clinic sessions of preoperative Pulmonary Rehabilitation (PR) two weeks prior to surgery. Patients will receive a Participant Manual demonstrating and explaining the rehabilitation process. Patients will also receive a log for recording their efforts and notes for every day until the day of surgery. A video recording of the intervention from start to finish will be provided to all patients. The video recording should be played in all 10 sessions at the registering site. The PR sessions will include breathing awareness, upper and lower extremity exercise, instructions for inspiratory muscle training using the PFlex valve, practice at home and goal setting. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
3123487|NCT02887521|Active Comparator|Standard of Care|Patients will receive a pedometer to monitor their daily steps and a pamphlet with exercises plus the standard course of care for patients undergoing lung resection surgery. The patients will not be asked to return the pedometer. The local institutional coordinator will go over the use of the pedometer and the exercise materials with the patient. The patients will be asked to keep a log of their pre-operative steps and mail the log to the registering site. Patients undergo surgery and will be followed until 6 months following surgery. Patients complete follow up questionnaires at 3 and 6 months after discharge.
3123488|NCT02887989|Experimental|Virtual Reality|Patients will be allowed to use commercially-available VR equipment in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
3123489|NCT02887989|Sham Comparator|'Health and Wellness Channel'|Patients will be allowed to watch relaxing television content in their hospital rooms for up to 20 days, as needed to manage pain as an adjunct to opioid and non-opioid pain medication.
3123490|NCT02888080|Experimental|ACZ885|ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
3123491|NCT02888080|Placebo Comparator|Placebo|Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.
3123492|NCT02888093|Experimental|Absorbable|Absorbable suture (polydioxanone) for uterosacral ligament suspension (USLS)
3123493|NCT02888093|Experimental|Permanent|Permanent suture (Gore-Tex CV2) for uterosacral ligament suspension (USLS)
3123494|NCT02888106|Active Comparator|Arm A|PEG IFN alfa-2a 180 µg for 48 weeks
3123495|NCT02888106|Experimental|Arm B|Myrcludex B 2 mg + PEG IFN alfa-2a 180 µg for 48 weeks
3123496|NCT02888106|Experimental|Arm C|Myrcludex B 5 mg + PEG IFN alfa-2a 180 µg for 48 weeks
3123497|NCT02888106|Experimental|Arm D|Myrcludex B 2 mg for 48 weeks
3123498|NCT02888106|Experimental|Arm E|Myrcludex B 10 mg (10 mg once a day) + PEG-IFN alfa-2a 180 μg during 48 weeks
3123499|NCT02888106|Experimental|Arm F|Myrcludex B 10 mg (5 mg twice a day) + Tenofovir during 48 weeks
3123500|NCT02888171|Experimental|ferric citrate|Participants randomized to the ferric citrate arm will receive 2 grams of ferric citrate three times a day with each meal.
3123501|NCT02888171|Active Comparator|ferrous sulfate|Participants randomized to the ferrous sulfate arm will receive 325 mg of ferrous sulfate three times a day
3123502|NCT02888665|Experimental|Treatment (pembrolizumab, doxorubicin hydrochloride)|Patients receive pembrolizumab IV over 30 minutes on day 1 and doxorubicin hydrochloride IV over 1-3 hours on day 1 of courses 2-7 only. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3123503|NCT02888691|Experimental|Low Carbohydrate Diet|< 100 grams of carbohydrate per day
3123504|NCT02888691|Experimental|High Carbohydrate Diet|> 250 grams of carbohydrate per day
3123505|NCT02888756|Experimental|iHIVARNA-01|Biological: 1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA) 3 vaccinations, two weeks interval
3123506|NCT02888756|Active Comparator|TriMix|Biological: TriMix_300 μg TriMix mRNA 3 vaccinations, two weeks interval
3123507|NCT02888756|Placebo Comparator|Placebo|Water for injection 3 vaccinations, two weeks interval
3123508|NCT02889289|Experimental|Xbox One Kinect Gaming|15 sessions of supervised physical therapy using 2 commercially available Xbox One Kinect game.
3123509|NCT02889393|Experimental|Standard of Care followed by Teduglutide|"Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure."
3123510|NCT02889393|Experimental|Teduglutide followed by Standard of Care|"Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure"
3123511|NCT02889510|Other|liraglutide|7-week subcutaneous liraglutide treatment once daily
3123512|NCT02889510|Other|placebo|7-week subcutaneous placebo treatment once daily.
3123513|NCT02889562|Active Comparator|Apixaban|"Apixaban is to be dosed at 5 mg by mouth twice daily, except in the case of the criteria listed below in dose modifications. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
3123514|NCT02889562|Active Comparator|Warfarin|"While patients are hospitalized, warfarin will be dosed daily, with daily INR monitoring per hospital protocol. Daily doses may vary from 0.5mg to 15mg by mouth, as determined by patient specific factors such as patient size, hepatic function, INR, concomitant medications, diet, or other factors. Based on these factors or others not listed, there may also be days in which the patient is prescribed to not get does not receive a dose of warfarin.~After discharge from the hospital, warfarin dosing will be subsequently managed by an anticoagulation clinic, per established protocols. All patients will have a goal INR of 2-3 during the duration of the study. The duration of therapy will be at least 30 days. The patient's physician may determine that anticoagulation therapy should be continued after the study period, based on their examination of the patient at the 30-day post-operative examination."
3123515|NCT02889796|Experimental|Filgotinib 200 mg|Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)
3123516|NCT02889796|Experimental|Filgotinib 100 mg|Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX
3123517|NCT02889796|Active Comparator|Adalimumab|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX
3123518|NCT02889796|Experimental|Placebo to Filgotinib 200 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
3123519|NCT02889796|Experimental|Placebo to Filgotinib 100 mg|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.
3123520|NCT02889796|Placebo Comparator|Placebo Never Received Filgotinib|Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.
3123521|NCT02889861|Experimental|Regimen 1|IMCgp100 (77 kDa bi-specific protein) weekly dosing regimen (QW)
3123522|NCT02889900|Experimental|combination of cediranib and olaparib|Open label
3123523|NCT02890303|Experimental|Zepto Capsulotomy|This study will evaluate outcome in subjects who have elected to have Zepto capsulotomies during cataract surgery. Effectiveness Rate - An effectiveness rate of 95% complete capsulotomies provides reasonable assurance that the Zepto system is effective. Primary Safety Endpoint - Posterior Capsular Rupture & Vitreous Loss (4% or less)
3469413|NCT03886792|Experimental|Triggered Reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
3123526|NCT02890381|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants received a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
3123527|NCT02890381|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
3123528|NCT02890992|Experimental|Cohort 1 - Alirocumab 30 mg Q2W: <50 kg|"Period 1: Participants with body weight less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 30 milligram(mg) administered every 2 weeks (Q2W) up to 8 weeks added to lipid modifying therapy (LMT).~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 30 mg administered Q2W from Week 16 until they started receiving dose matching to Cohort 2 dosage including dose adjustment to body weight as required. Cohort 2 dosage was: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
3123529|NCT02890992|Experimental|Cohort 1 - Alirocumab 50 mg Q2W: >=50 kg|"Period 1: Participants with body weight greater than or equal to (>=) 50 kg received SC injection of alirocumab 50 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 50 mg administered Q2W from Week 16 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
3123530|NCT02890992|Experimental|Cohort 2 - Alirocumab 40 mg Q2W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 40 mg administered Q2W from Week 16 until switch of dosage in Cohorts 1 and 3. If body weight was still < 50 kg, participants continued to receive SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
3123531|NCT02890992|Experimental|Cohort 2 - Alirocumab 75 mg Q2W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W up to 8 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 75 mg administered Q2W from Week 16 until Week 130."
3123532|NCT02890992|Experimental|Cohort 3 - Alirocumab 75 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered every 4 weeks (Q4W) up to 8 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of alirocumab 75 mg administered Q4W from Week 14 until switch to Cohort 2 dosage including dose adjustment to body weight as required, then Cohort 2 dosage: if body weight was still < 50 kg, participants received SC injection of alirocumab 40 mg administered Q2W until Week 130; if body weight was > = 50 kg participants received SC injection of alirocumab 75 mg administered Q2W until Week 130."
3123533|NCT02890992|Experimental|Cohort 3 - Alirocumab 150 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W up to Week 8 added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 150 mg administered Q4W from Week 14 until switch to Cohort 2 dosage then SC injection of alirocumab 75 mg administered Q2W until Week 130."
3123534|NCT02890992|Experimental|Cohort 4 - Alirocumab 150 mg Q4W: <50 kg|"Period 1: Participants with body weight < 50 kg received SC injection of alirocumab 150 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight < 50 kg received SC injection of Alirocumab 150 mg administered Q4W from Week 12 until Week 48."
3123535|NCT02890992|Experimental|Cohort 4 - Alirocumab 300 mg Q4W: >=50 kg|"Period 1: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W up to 12 weeks added to LMT.~Period 2: Participants with body weight >= 50 kg received SC injection of alirocumab 300 mg administered Q4W from Week 12 until Week 48."
3123536|NCT02891070|Experimental|FS VH S/D 500 s-apr|FS VH S/D 500 s-apr (Tisseel), single use treatment, intraoperative
3123537|NCT02891070|Active Comparator|DuraSeal Dural Sealant|DuraSeal Dural Sealant, single use treatment, intraoperative
3123538|NCT02891174|Active Comparator|Ibuprofen followed by acetaminophen|Ibuprofen administered immediately post-partum, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours followed by acetaminophen, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours.
3123539|NCT02891174|Active Comparator|Acetaminophen followed by ibuprofen|Acetaminophen administered immediately post-partum, 650 mg (2 x 325 mg tablets) every 6 hours for 24 hours followed by ibuprofen, 600 mg (3 x 200 mg tablets) every 6 hours for 24 hours.
3123540|NCT02891200|Experimental|Healthcare professional (HCP) Arm|Healthcare professional (HCP) Arm includes a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
3123541|NCT02891200|Experimental|HCP plus Peer arm|HCP plus Peer arm involves delivering of HCP support as in HCP Arm , along with adding Peer Support Program services. This program is offered to participants by especially trained 'peer mentors' with oversight from a social worker.
3123542|NCT02891408|Experimental|Cohort 1 (Mild Hepatic Impairment): Firsocostat 20 mg|Participants with mild hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
3123543|NCT02891408|Experimental|Cohort 1 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to mild hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
3123544|NCT02891408|Experimental|Cohort 2 (Moderate Hepatic Impairment): Firsocostat 20 mg|Participants with moderate hepatic impairment will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
3123545|NCT02891408|Experimental|Cohort 2 (Normal Hepatic Function): Firsocostat 20 mg|Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single dose of firsocostat 20 mg (2 × 10 mg capsules).
3123546|NCT02891408|Experimental|Cohort 3 (Severe Hepatic Impairment): Firsocostat 5 mg|Participants with severe hepatic impairment will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
3123547|NCT02891408|Experimental|Cohort 3 (Normal Hepatic Function) Firsocostat 5 mg|Matched normal hepatic function participants to severe hepatic impairment participants will receive a single dose of firsocostat 5 mg (1 × 5 mg capsule).
3123548|NCT02891408|Experimental|Cohort 4 (Mild Hepatic Impairment): Fenofibrate 48 mg|Participants with mild hepatic impairment will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
3123549|NCT02891408|Experimental|Cohort 4 (Normal Hepatic Function) Fenofibrate 48 mg|Matched normal hepatic function participants to mild hepatic impairment participants, will receive a single dose of fenofibrate 48 mg (1 × 48 mg tablet).
3123550|NCT02891629|Experimental|Device use in Healthy volunteers|10 healthy volunteers will be recruited
3123551|NCT02891629|Experimental|Device use in ALS patients|5 ALS patients in early stages will be recruited
3123552|NCT02891681|Experimental|NIR/US (Neoadjuvant Chemotherapy Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, end of cycle 5 (only if treatment regimen changed), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
3123553|NCT02891681|Experimental|NIR/US (Neoadjuvant Endocrine Cohort)|"Patients will have the NIR/US baseline scan performed before their first treatment. The desirable schedule will be >= 7 days after initial biopsy to avoid confounding effects from the biopsy related acute inflammatory response.~In addition, patients will also have NIR/US performed at end of cycle 1, end of cycle 2, end of cycle 3, at time of treatment regimen change (only intended for those who have had a change in their regimen), and prior to surgery.~The number of NIR/US study visits may vary (5-6) depending on the patient's treatment regimen"
3123554|NCT02891850|Experimental|Riociguat|PDE5i treatment will be stopped and riociguat treatment initiated following a defined washout period with a starting dose of 1 mg riociguat TID followed by an 8 weeks dose adjustment phase according to the approved riociguat dose adjustment scheme.
3123555|NCT02891850|Active Comparator|PDE-5i|Patients will continue to receive PDE5i treatment as well as other standard of care treatments at the discretion of the investigator up to Week 24. Patients in the experimental and active comparator treatment arms follow the same visit schedule.
3123556|NCT02891863|Experimental|Acute Testing|Single-arm study - all subjects who meet the I&E criteria, sign the consent form and have inducible VT within the protocol-specified criteria may be tested for VT conversion with the LEVER Acute Study System.
3123557|NCT02891915|Active Comparator|Short|200 subjects will receive a short course of the initially prescribed antibiotic for 5 days plus 5 days of matching placebo
3123558|NCT02891915|Active Comparator|Standard|200 subjects will receive a standard course of the initially prescribed antibiotic( Amoxicillin, Amoxicillin-Clavulanate, Cefdinir) for 10 days
3123559|NCT02892019|Active Comparator|Indacaterol acetate 75 μg o.d.|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
3123560|NCT02892019|Active Comparator|Indacaterol acetate 150 μg o.d.|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
3123561|NCT02892110|Experimental|Varenicline|2 mg daily
3123562|NCT02892110|Placebo Comparator|Placebo|2 mg daily
3123563|NCT02892344|Experimental|QMF149 150/80 μg|QMF149 150/80 microgram o.d. delivered via Concept1
3123564|NCT02892344|Active Comparator|MF 200 µg|MF 200 microgram o.d. delivered via Twisthaler®
3123565|NCT02892409|Active Comparator|Clarithromycin + Amoxicillin + Bismuth + Lansoprazole|Clarithromycin 500 milligram (mg), tablets, orally, twice daily, along with amoxicillin 1000 mg capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and lansoprazole 30 mg, capsules, orally, twice daily on Days 1 to 14.
3123566|NCT02892409|Experimental|Clarithromycin + Amoxicillin + Bismuth + TAK-438|Clarithromycin 500 mg, tablets, orally, twice daily, along with amoxicillin 1000 mg, capsules, orally, twice daily, tripotassium bismuth dicitrate 600 mg, tablets, orally, twice daily, and TAK-438 20 mg, tablets, orally, twice daily on Days 1 to 14.
3123567|NCT02892422|Experimental|Flexible-dose of Lu AF35700|
3123568|NCT02892448|Active Comparator|Unilateral Hip Resurfacing|Patients who received either right or left total hip resurfacing procedure. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
3123569|NCT02892448|Active Comparator|Bilateral Hip Resurfacing|Patients who received both right and left hip resurfacing procedure on the same day. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
3123570|NCT02892448|Active Comparator|Non-Metal on Metal Total Hip|Patients who received either a unilateral (one hip) or bilateral (both hips) non-metal on metal total hip arthroplasty. This group of patients will undergo a cardiac magnetic resonance imaging (CMR).
3123571|NCT02892513|Experimental|Active Stimulation|Participants will have active percutaneous auricular neurostimulation for 5 days during and after elective surgery.
3123572|NCT02892513|Sham Comparator|Sham Percutaneous Neurostimulation|Participants will have inactive device worn for 5 days during and after elective surgery.
3123573|NCT02892734|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes Q2W and ipilimumab IV over 90 minutes Q6W in the absence of disease progression or unacceptable toxicity.
3123574|NCT02892760|Experimental|with C-brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
3123575|NCT02893878||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in approximately 10 volunteer practices.
3123576|NCT02893878||Vaccinated_Non GSK Group|Volunteered subjects who received Non-GSK influenza vaccination in approximately 10 volunteer practices.
3123577|NCT02893878||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or Non-GSK not known) in approximately 10 volunteer practices.
3123578|NCT02894502|Experimental|Motivational interviewing only for patients|In this arm the interventions will be delivered only to patients
3123579|NCT02894502|Experimental|Motivational interviewing to patients and caregivers|In this arm the interventions will be delivered both to patients and caregivers
3123580|NCT02894502|No Intervention|Control group|This Group will receive the usual care
3123581|NCT02894840|Active Comparator|an inactivated influenza vaccine|20 volunteers in phase I study and 200 volunteers in phase II study will receive a single dose of a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
3123582|NCT02894840|Placebo Comparator|Placebo|20 volunteers in phase I study and 100 volunteers in phase II study will receive a single dose of placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
3123583|NCT02895035|Active Comparator|Epinephrine|Epinephrine is the intracameral additive during cataract surgery.
3123584|NCT02895035|Active Comparator|Omidria|Omidria is the intracameral additive during cataract surgery.
3123585|NCT02895100|Experimental|PTG-100 (150 mg QD)|Low dose
3123586|NCT02895100|Experimental|PTG-100 (300 mg QD)|Medium dose
3123587|NCT02895100|Experimental|PTG-100 (900 mg QD)|High dose
3123588|NCT02895100|Placebo Comparator|Placebo group|Placebo control
3123589|NCT02895295|Active Comparator|Control|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and will be provided with a list of resources available in the community to help them choose a prescription drug plan.
3123590|NCT02895295|Experimental|Expert Recommendation|"Participants randomized to the Expert Recommendation arm will receive access to a decision support tool that provides personalized expert scores for particular plans based on individual's likely annual out-of-pocket spending, including plan premiums and spending on prescription drugs, and the Medicare star ratings (a measure of customer satisfaction)."
3123591|NCT02895295|Active Comparator|Individual Analysis|"Participants randomized to Individual Analysis arm will receive access to a decision support tool that provides individualized cost information for each plan but not the expert scores for particular plans."
3123592|NCT02895347|No Intervention|Control Group|Participants in the Control Group (CG) were asked to attend an orientation reviewing the study. Three weeks later they returned and were filmed timed completing a suturing activity on the porcine model.
3123593|NCT02895347|Experimental|Experimental Group|Participants in the Experimental Group (EG) were asked to attend an orientation reviewing the study. Then they were instructed to complete 4 activities on the dvSS ® that modeled suturing techniques in minimally invasive robotics-assisted surgery. EG participants repeated these 4 activities over a period of 2 weeks until they reached proficiency (91%) in all 4 activities. 4. Participants were asked to return where they were filmed and timed completing a suturing activity on the porcine model.
3123594|NCT02895360|Experimental|Phase 1|Fixed 3+3 dose escalation of BAL101553 in patients with advanced solid tumors
3123595|NCT02895360|Experimental|Phase 2a|BAL101553 at MTD in patients with platinum-resistant/refractory ovarian cancer or recurrent glioblastoma
3123596|NCT02895945|Experimental|BAX 802 in Surgery|Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.
3123597|NCT02896075|Experimental|Randomized cross-over approach|"The main study was conducted using a randomized controlled cross-over approach. Participants made three visits each for the two video watching interventions. The interventions were separated by a minimum of~1week as a washout. Each intervention included one day of inducing muscle soreness in one leg through eccentric muscle contractions; a second day of testing muscle soreness and pain tolerance and watching a 30-min video (either a comedy or documentary); and a third day of testing muscle soreness and pain tolerance again to see if the effects of the video viewing persisted the next day (i.e., 24 h after the video viewing)."
3123598|NCT02896127|Experimental|Secukinumab|"Secukinumab 150 mg s.c.~Arm includes all patients who received at least 1 dose of study drug including placebo switchers at Week 16"
3123599|NCT02896127|Placebo Comparator|Placebo|Placebo s.c.
3123600|NCT02896296|Experimental|RBP-6000 (100/300 mg Flex)|"On Day 1 of the study all eligible subjects received a single subcutaneous (SC) injection of RBP-6000. Participants returned to the site for monthly injection visits every 28 days (-2/+7 days) for a total of up to 6 injections. Participants were not required to complete all 6 injections and could choose to terminate from the study at any time.~For each injection, participants could receive either a dose of 100 mg RBP-6000 or 300 mg RBP-6000, based on the medical judgement of the investigator."
3123601|NCT02896361|Experimental|Stimulation order 1|"Stimulations delivered in following order:~Standard burst~Burst Microdosing 1~Burst Microdosing 2"
3123602|NCT02896361|Experimental|Stimulation order 2|"Stimulations delivered in following order:~Burst Microdosing 1~Burst Microdosing 2~Standard burst"
3123603|NCT02896361|Experimental|Stimulation order 3|"Stimulations delivered in following order:~Burst Microdosing 2~Standard burst~Burst Microdosing 1"
3123604|NCT02896400|Experimental|BNI+NRT+QL+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
3123605|NCT02896400|Experimental|BNI+NRT+QL|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
3123606|NCT02896400|Experimental|BNI+NRT+Text|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
3123607|NCT02896400|Experimental|BNI+NRT|Brief Negotiated Interview (BNI) Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
3123608|NCT02896400|Experimental|BNI+QL+Text|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
3123609|NCT02896400|Experimental|BNI+QL|Brief Negotiated Interview (BNI) Referral to CT Smokers Quitline (QL)
3123610|NCT02896400|Experimental|BNI+Text|Brief Negotiated Interview (BNI) Registration in SmokefreeText (Text)
3123611|NCT02896400|Experimental|BNI only|Brief Negotiated Interview (BNI)
3123612|NCT02896400|Experimental|NRT+QL+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
3123613|NCT02896400|Experimental|NRT+QL|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Referral to CT Smokers Quitline (QL)
3123614|NCT02896400|Experimental|NRT+Text|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply Registration in SmokefreeText (Text)
3123615|NCT02896400|Experimental|NRT only|Nicotine replacement therapy (NRT) patches and gum, 6 weeks supply
3123616|NCT02896400|Experimental|QL+Text|Referral to CT Smokers Quitline (QL) Registration in SmokefreeText (Text)
3123617|NCT02896400|Experimental|QL only|Referral to CT Smokers Quitline (QL)
3123618|NCT02896400|Experimental|Text only|Registration in SmokefreeText (Text)
3123619|NCT02896400|No Intervention|Control|Control arm, no intervention
3123620|NCT02896569|Experimental|Topical combination therapy|Application of human bone marrow stem cell derived growth factor and cytokines serum followed by a botanical lipid-based occlusive immediately post-radio-frequency treatment of the face
3123621|NCT02896569|No Intervention|Standard of care|No topical therapies for 24 hours post-radio-frequency treatment of the face
3123622|NCT02896595|Active Comparator|General Anesthesia with endotracheal tube|Patients assigned to the ETT tube group will have ETT placed in the safest manner deemed appropriate by attending anesthesiologist. Possible ways to have ETT placed will be using direct laryngoscopy, glidescope or fiberoptic intubations. Size of ETT will be decided based on patient characteristics and discretion of attending anesthesiologist. Once placed, auscultation and capnography will be used to ensure correct placement of ETT.
3123623|NCT02896595|Active Comparator|General Anesthesia with laryngeal mask airway|Patients assigned to the LMA group will have LMA placed in a standard fashion by anesthesia provider. LMA size will be decided based on patient characteristics and at the discretion of attending anesthesiologist. LMA used will be LMA Supreme (Teleflex Medicals, Ireland). Once placed auscultation will be used to ensure correct placement of LMA.
3469414|NCT03886792|Sham Comparator|Social Interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
3123626|NCT02896907|Experimental|Treatment (FOLFIRINOX, ascorbic acid)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on day 1. Patients then receive ascorbic acid IV over 2 hours on days 3, 5, 8, 10 and 12. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3123627|NCT02897115|Experimental|Treat-to-Target (T2T)|Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
3123628|NCT02897115|Active Comparator|Standard of Care (SOC)|Participants received treatment as prescribed by their physician according to the local standard of care.
3123629|NCT02897141|Experimental|mVIP group|This group will receive targeted symptom strategies via a Health Management App developed from the UCSF symptom management manual based on the symptoms that they report. This is the intervention app group.
3123630|NCT02897141|Placebo Comparator|Attention Control Group|This group will received an app without symptom strategies, pre-loaded on their smartphones. This is the control app group.
3123631|NCT02897349|Experimental|linagliptin|
3123632|NCT02897349|Placebo Comparator|Placebo|
3123633|NCT02898077|Experimental|8 milligram/kilogram (mg/kg) Ramucirumab + 80 mg/square meter (mg/m²) Paclitaxel|"8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
3123634|NCT02898077|Experimental|Placebo + 80 mg/m² Paclitaxel|"Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle.~Participants may continue on treatment until discontinuation criteria were met."
3123635|NCT02898103|Experimental|Active Current then Sham then Active Current|Electrical current will be introduced to the insulated percutaneous lead(s) for 5 minutes; then sham/placebo for 5 minutes; and then active electrical current for the following 2-4 weeks
3123636|NCT02898103|Active Comparator|Sham then Active Current|Sham/placebo will be introduced to the insulated percutaneous lead(s) for 5 minutes; then active electrical current for the following 2-4 weeks
3123637|NCT02898116|Experimental|Ensartinib ± Durvalumab|Subjects were to receive ensartinib monotherapy during a pre-immunotherapy Run-in Period for one to two 28-day cycles, followed by combination therapy with ensartinib plus durvalumab for subjects with no DLTs during the Run-in Period.
3123638|NCT02898259|Experimental|Lenalidomide + Ixazomib + Rituximab|Ixazomib will be orally administered with a starting dose of 2.0mg. Lenalidomide will be administered orally with a starting dose of 20mg. Rituximab will be administered intravenously at the standard dose of 375mg/m2. The study will use a standard 3 + 3 design for determination of MTD during cycle 1. There will be three dose levels for escalation, followed by two expansion cohorts of 12 patients each at the MTD, one cohort with follicular lymphoma and one cohort with non-follicular low-grade lymphoma (SLL, marginal zone, lymphoplasmacytic). Patients will be treated for 12 cycles of 4 week duration.
3123639|NCT02898454|Experimental|Dupilumab 300 mg q2w|Dupilumab 300 mg subcutaneous (SC) injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
3123640|NCT02898454|Experimental|Dupilumab 300 mg q2w then q4w|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 and then 300 mg q4w until Week 52 added to background therapy of intranasal MFNS at stable dose. After Week 24, Dupilumab administration was alternated with matched placebo injection every other week up to Week 50.
3123641|NCT02898454|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 SC injection q2w from Day 1 of Week 0 up to Week 52 added to background therapy of intranasal MFNS at stable dose.
3123642|NCT02898597|Experimental|Video|Video-call delivered cognitive behavioral therapy
3123643|NCT02898597|Active Comparator|Voice|Voice-call delivered cognitive behavioral therapy
3123644|NCT02898662|Experimental|AZD1419|Dose adaption of AZD1419, 4 mg or 8 mg or 1 mg based on occurence of AE's
3123645|NCT02898662|Placebo Comparator|Placebo|Matching placebo
3123646|NCT02898740|Experimental|Exercise|Structured exercise
3123647|NCT02898740|Active Comparator|Health Education|Health education
3123648|NCT02898974||Regular Medical Marijuana users|People with MS that are regular Medical Marijuana users
3123649|NCT02898974||Non Users of Medical Marijuana|People with MS that are non users of Medical Marijuana
3123650|NCT02899156|Active Comparator|Flumazenil Infusion|The flumazenil continuous infusion is started at an initial dose of 0.1 mg/hr., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
3123651|NCT02899156|Placebo Comparator|Placebo Infusion|The placebo continuous infusion is started at an initial dose of 0.1 mg/hr (2 ml/hr)., and can be titrated up to a maximum of 0.3 mg/hr. Dose titrations may occur every 60 minutes to maintain RASS scores of 0 to +1. The maximum rate is 0.3 mg/hr.
3123652|NCT02899195|Experimental|Durvalumab|Pemetrexed/cisplatin will be given for up to six 3-week cycles with the addition of concurrent durvalumab every 3 weeks. The first 6 patients who are enrolled and commence treatment will be monitored for safety of the combination. Use of carboplatin in place of cisplatin will be permitted for patients who are ineligible for cisplatin due to impaired renal function at screening. For patients that receive cisplatin, carboplatin may also be substituted after Cycle 1 for cisplatin related toxicity (e.g., grade 3 ototoxicity, grade 3 nausea) at the investigator's discretion. After completion of Cycle 6 of concurrent therapy, patients with stable or responding disease per modified RECIST for malignant mesothelioma will continue on single agent durvalumab every 3 weeks until progression. Maximum duration of durvalumab treatment is 12 months starting from Cycle 1 of concurrent treatment (inclusive of any treatment delays or missed treatments).
3123653|NCT02899299|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
3123654|NCT02899299|Active Comparator|Pemetrexed and Cisplatin (or Carboplatin)|Specified dose on specified days
3123655|NCT02899338|Experimental|BI695501 Autoinjector|
3123656|NCT02899338|Active Comparator|BI695501 Prefilled syringe|
3123657|NCT02899377|Experimental|Group A: Health subjects|During Visit 1, these subjects will undergo the following: An MRI of the salivary glands with one-time intravenous (IV) bolus injection of 0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injection of 500 megabecquerels (MBq) of 11C MET followed by a PET/CT (dynamic scan of the salivary glands followed by head to hip static scan)
3123658|NCT02899377|Experimental|Group B: pSS subjects|During Visit 1, subjects with pSS will undergo the following: An MRI of the salivary glands with IV bolus injection of <=0.1 mmol/kg of gadoterate meglumine and receive one-time IV bolus injections: 500 MBq of 11C-MET (PET/CT: as for Group A) and 200 MBq of 18F-FDG followed by a PET/CT (static head to hip scan)
3123659|NCT02899650|Experimental|Young Fit|Young (18-39 yrs) people who have endurance training habit
3123660|NCT02899650|Experimental|Young Unfit|Young (18-39 yrs) people who have sedentary lifestyle.
3123661|NCT02899650|Experimental|Older Fit|Older (50-80 yrs) people who have endurance training habit
3123662|NCT02899650|Experimental|Older Unfit|Older (50-80 yrs) people who have sedentary lifestyle
3123663|NCT02899689|Active Comparator|Foley Bulb Group|Patients will have a Foley catheter inserted into the internal cervical os.
3469415|NCT03886922|Active Comparator|Glibenclamide and Levcromakalim|Participants will recieve levcromakalim/placebo infusion after glibenclamide administration
3123664|NCT02899689|Experimental|Dilapan Group|Patients will have Dilapan sticks inserted into the internal cervical os.
3123665|NCT02899884||Cohort 1|Participants with cancer pain that is adequately controlled with opioids were observed for a period of 1 month in this observational study.
3123666|NCT02899962|Active Comparator|LEO 90100 aerosol foam|Topical application twice weekly for 52 weeks
3123667|NCT02899962|Placebo Comparator|LEO 90100 aerosol foam vehicle|Topical application twice weekly for 52 weeks
3123668|NCT02899988|Experimental|30 mg Mirikizumab|30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).
3123669|NCT02899988|Experimental|100 mg Mirikizumab|100 mg Mirikizumab administered SC Q8W.
3123670|NCT02899988|Experimental|300 mg Mirikizumab|300 mg Mirikizumab administered SC Q8W.
3123671|NCT02899988|Placebo Comparator|Placebo|Placebo administered SC Q8W.
3123672|NCT02900092|Experimental|Ganaxolone|Participants received ganaxolone
3123673|NCT02900378|Experimental|LCZ696 (Sacubitril/Valsartan)|After randomization, patients in this arm received LCZ696 (Sacubitril/Valsartan) twice daily and matching placebo of Enalapril depending on the patient's previous ACEI/ARB dose (enalapril equivalent dose) for 2 weeks. Patients could start study medication at dose level 1 (24 mg/26 mg LCZ), 2 (49 mg/51 mg LCZ) or 2a (49 mg/51 mg LCZ) or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 97 mg/103 mg bid LCZ696(sacubitril/valsartan) and matching placebo, provided no safety and tolerability issues arised during uptitration.
3132486|NCT03431012|Experimental|Human Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to humans (Human Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
3123674|NCT02900378|Active Comparator|Enalapril|After randomization, patients in this arm received Enalapril twice daily and matching placebo of LCZ696 (Sacubitril/Valsartan) depending on the patient's previous ACEI/ARB for 2 weeks. Patients could start study medication at dose level 1 or 2a or matching placebo bid. After 2 weeks (visit 3) the doses were up-titrated: patients, who started on dose level 2 or 2a received the target dose of study medication (level 3) at this point. After another 2 weeks (visit 4) all patients were to achieve the target dose of 10 mg bid enalapril and matching placebo, provided no safety and tolerability issues arised during uptitration
3123675|NCT02901054|Experimental|open label infusion ondansetron|"A single 4-mL CSF sample per subject.~Serial blood sampling at 0 (pre-infusion), 15, 30, 60, 120, and 180 min after ondansetron administration"
3123676|NCT02901080|Experimental|Cranial electrotherapy stimulation|Alpha Stim AID cranial electrotherapy stimulation, Pregnancy test, Anxiety questionnaire, Quality of life questionnaire, Work and social questionnaire, Sleep questionnaire, Depression questionnaire, Quality of life and financial questionnaire
3123677|NCT02901249|Experimental|Sertraline|"Group Started: sertraline (50mg-200mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with sertraline (50-200mg). Non responsive patients: 2nd step.~Second step: Sertraline 200mg + lithium (900mg-1500mg)~Non responsive patients: 3rd step.~Third step: Nortriptyline 100mg~Non responsive patients: 4th step.~Fourth step: Nortriptyline 100mg + lithium (900mg-1500mg)~Non responsive patients : 5th step~Fifth step : Nortriptyline 100mg + sertraline 200mg Non responsive patients~sixth step: Nortriptyline 100mg + sertraline 200mg + Lithium ( 900mg- 1500mg)"
3123678|NCT02901275|Placebo Comparator|Placebo + Placebo|Within-subject double-blind, double-dummy administration of placebo + placebo. Order of dose randomized session days 2-5.
3123679|NCT02901275|Active Comparator|Hydromorphone (oral) 4mg + Placebo|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + placebo. Always administered during session 1.
3123680|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 2.5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 2.5mg. Order of dose randomized session days 2-5.
3123681|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 5mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 5.0mg. Order of dose randomized session days 2-5.
3123682|NCT02901275|Experimental|Hydromorphone (oral) 4mg / Dronabinol (oral) 10mg|Within-subject double-blind, double-dummy administration of hydromorphone (oral) 4mg + dronabinol (oral) 10mg. Order of dose randomized session days 2-5 but was never the first hydromorphone 4mg + dronabinol combination dose.
3123683|NCT02901431|Placebo Comparator|Placebo|Participants received a matching placebo orally. Approximate treatment duration was up to 24 weeks.
3123684|NCT02901431|Experimental|Balovaptan (RO5285119) 10 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 10 milligrams per day (mg/d) of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
3123685|NCT02901431|Experimental|Balovaptan (RO5285119) 4 mg/d equivalent|Participants received age-adjusted total daily oral dose approximately equivalent to the adult dose of 4 mg/d of balovaptan (RO5285119). Approximate treatment duration was up to 24 weeks. This arm is open only to those participants enrolled prior to Version 6 of the study protocol.
3123686|NCT02901548|Experimental|Durvalumab Plus Cystoscopy|Durvalumab: Fixed dose level IV infusion every 4 weeks for 13 study treatment cycles/infusions over 12 months/1 year. Cystoscopy with biopsy will be performed every 3 months to monitor the treatment response during this one year of treatment phase. It will be performed every 6 months during year 2 of the surveillance phase.
3123687|NCT02901899|Experimental|Treatment (guadecitabine, pembrolizumab)|Patients receive guadecitabine SC on days 1-4 and pembrolizumab IV over 30 minutes on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3123688|NCT02901951|Experimental|HBV Group|Subjects aged 40 to 60 years old who received 3 or 4 doses of Engerix-B (HBV vaccine) 20 to 30 years ago and were administered with a single challenge dose of HBV vaccine in this study at Day 0 (Visit 1).
3123689|NCT02902081|Placebo Comparator|Placebo|Oral placebo administered once prior to subjective drug effects questionnaires and behavioral tasks.
3123690|NCT02902081|Experimental|Cannabidiol|(300 mg, 600 mg, 900 mg) cannabidiol administered once prior to subjective drug effects questionnaires and behavioral tasks.
3123691|NCT02902146|Active Comparator|Bougie|On the first intubation attempt, this arm will attempt to place a bougie into the trachea, followed by an endotracheal tube.
3123692|NCT02902146|Active Comparator|No bougie (endotracheal tube first)|On the first intubation attempt, this arm will attempt to place an endotracheal tube into the trachea directly.
3123693|NCT02902172|Other|Acetaminophen|Patients will be monitored for change in blood pressure
3123694|NCT02902172|Other|NSAID|Patients will be monitored during their postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
3123695|NCT02902237|Experimental|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
3123696|NCT02902770|Active Comparator|Lidocaine and normal saline push|1.5mg/kg IV Lidocaine Drip (given over 10 minutes) and normal saline push
3123697|NCT02902770|Active Comparator|Ketorolac and normal saline drip|IV Ketorolac Tromethamine 30mg push and 10 minute normal saline drip
3123698|NCT02902770|Active Comparator|Lidocaine and Ketorolac|IV Lidocaine Drip and IV Ketorolac Push
3123699|NCT02902809|Experimental|Open-label study to evaluate safety|A fixed 300 mg dose every 2 weeks (Q2W) of tralokinumab administered subcutaneously in subjects with inadequately controlled asthma on medium to high-dose of inhaled corticosteroid plus long-acting β2-agonist.
3123700|NCT02902913|Experimental|Oleocanthal-rich, D2i2|Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)
3123701|NCT02902913|Experimental|Oleacein-rich, D2i0.5|Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)
3123702|NCT02902913|Placebo Comparator|Oleocanthal and Oleacein-low, D2i0|Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)
3123703|NCT02902913|Active Comparator|Ibuprofen|Ibuprofen, 400 mg
3123704|NCT02902965|Experimental|Ibrutinib+ Bortezomib+ Dexamethasone|
3123705|NCT02903030|Experimental|Visbiome, Then Placebo|The probiotic mix (VISBIOME) will be mainly Bifidobacteria and Lactobacilli, in view of the previously reported encouraging clinical studies and safety data.
3123706|NCT02903030|Placebo Comparator|Placebo, Then Visbiome|Placebo matched to probiotic.
3123707|NCT02903121|Experimental|Tamoxifen|Tamoxifen 10 mg (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
3123708|NCT02903121|Placebo Comparator|Placebo|Placebo (oral) twice daily for 7 days to be started following 3 consecutive days of bleeding
3123709|NCT02903238|Experimental|Placebo|placebo capsule
3123710|NCT02903368|Experimental|Arm 1A: AAPL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 6 months~Pts x weeks to RP"
3123711|NCT02903368|Experimental|Arm 1B: APL Neoadjuvant Therapy [Part 1]|"Eligible Participants will be randomized to receive:~APL: Abiraterone acetate (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/day orally) for 6 months"
3123712|NCT02903368|Experimental|Arm 2A: AAPL Adjuvant Therapy [Part 2]|"Eligible Participants will be randomized to receive:~AAPL: Abiraterone acetate (240 mg/day orally), Apalutamide (1000 mg/day orally), Leuprolide (22.5 mg every 12 weeks intramuscularly), Prednisone (5 mg/twice daily orally) for 12 months"
3123713|NCT02903368|No Intervention|Arm 2B: Observation [Part 2]|
3123714|NCT02903394|Experimental|mLCI imaging|mLCI device images cervical epithelium
3123715|NCT02903407|Active Comparator|Midazolam|IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
3123716|NCT02903407|Active Comparator|Propofol or Dexmedetomidine|Propofol or Dexmedetomidine per physician discretion will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
3123717|NCT02903420|Experimental|SAPIEN 3|Transcatheter Aortic Valve Implantation (TAVI) with the Edwards SAPIEN 3 Transcatheter Heart Valve and Delivery System
3123718|NCT02903446|Active Comparator|Intervention|Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
3123719|NCT02903446|No Intervention|Control|Standard urate lowering therapy
3123720|NCT02903511|Experimental|Metformin|Participants will receive metformin 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
3123721|NCT02903511|Placebo Comparator|Placebo|Participants will receive placebo 500 mg tablets, starting with 1 tab twice a day. The dose will be increased by 500 mg every 2 weeks up to 1000 mg by mouth twice a day, as tolerated, for 12 months.
3123722|NCT02903823|Experimental|Baclofen injection at designated spinal level|Days 2,3,4,5 a baclofen injection bolus will be given in the catheter, located at C4, T4, T10 and L2 respectively. Effect of baclofen injection (50 microgram bolus) upon rigidity will be assessed manually using the Modified Ashworth rating score for selected upper and lower extremities.
3123723|NCT02903836|Experimental|Nafithromycin 800 mg 3 days|PO q24h for 3 days; subjects will receive matching placebo , to maintain the blind
3123724|NCT02903836|Experimental|Nafithromycin 800 mg 5 days|PO q24h for 5 days; subjects will receive matching placebo, to maintain the blind
3123725|NCT02903836|Active Comparator|Moxifloxacin 400 mg|PO q24h for 7 days;subjects will also receive two nafithromycin placebo tablets PO q24h on Days 1 through Day 7 to maintain the blind
3123726|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 50mg twice daily|Monotherapy Part 1a: INCB001158 administered orally in patients with advanced/metastatic solid tumors. Escalating doses will be explored to determine the recommended phase 2 dose (RP2D).
3123727|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 75mg twice daily|Monotherapy Part 2a: INCB001158 administered orally at the RP2D in patients with advanced/metastatic NSCLC (EGFR and Anaplastic Lymphoma Kinase (ALK) negative) previously treated with Standard of Care (SOC).
3123728|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 100mg twice daily|Monotherapy Part 2b: INCB001158 administered orally at the RP2D in patients with advanced/metastatic CRC previously treated with SOC.
3123729|NCT02903914|Experimental|INCB00158 was administered as monotherapy at 150mg twice daily|Monotherapy Part 2c: INCB001158 administered orally at the RP2D in patients with Bladder Cancer, Gastric or Gastroesophageal Junction (GEJ) Cancer, Renal Cell Cancer (RCC), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Urothelial Cell Cancer (UCC), or Melanoma, previously treated with SOC.
3123730|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 50mg twice daily|Monotherapy Part 2d: INCB001158 administered orally at the RP2D in patients with any tumor types in Parts 2a, 2b, or 2c.
3123731|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 75mg twice daily|Combination Part 1b: INCB001158 and Pembrolizumab administered in patients with advanced/metastatic NSCLC, Melanoma, Urothelial Cell Cancer, MSI CRC, MSS CRC, Gastric or Gastroesophageal Junction (GEJ) Cancer, SCCHN and Mesothelioma. Multiple dose levels will be explored to determine the recommended phase 2 dose (RP2D).
3469416|NCT03886922|Active Comparator|Glibenclamide and Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
3123732|NCT02903914|Experimental|INCB00158 was administered in combination with pembroluzimab at 100mg twice daily|Part 3a: INCB001158 and Pembrolizumab the combination RP2D in patients with advanced/metastatic NSCLC (EGFR and ALK negative) with disease progression on anti-PD-1 therapy or prolonged stable disease on Pembrolizumab in the immediate prior line of therapy.
3123733|NCT02903914|Experimental|INCB001158 50 mg BID in combination with pembrolizumab|Part C: evaluated a reduced dose of INCB001158 50 mg BID in combination with pembrolizumab with patients with moderately impaired renal function.
3123734|NCT02903966|Experimental|GSK2982772 in Part A double-blind phase|Subjects will receive GSK2982772 60 mg orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
3123735|NCT02903966|Placebo Comparator|Placebo in Part A double-blind phase|Subjects will receive placebo orally three times daily (approximately 8 hours apart) for 42 days (6 weeks).
3123736|NCT02903966|Experimental|GSK2982772 in Part B open label extension phase|Subjects from GSK2982772 and placebo arm who complete Part A study will move to Part B open-label extension phase. All subjects will receive GSK2982772 60 mg three times daily (approximately 8 hours apart) for 42 days (6 weeks).
3123737|NCT02904057|Experimental|Treatment Group|The treatment group will receive Radiesse (+) injectable implant up to 3.0 cc per jawline.
3123738|NCT02904057|No Intervention|Control Group|The control group is not treated. They will undergo assessments such as photographs, jaw grading and jaw function tests.
3123739|NCT02904096|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
3123740|NCT02904096|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
3123741|NCT02904200|Experimental|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
3123742|NCT02904200|Active Comparator|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
3123743|NCT02904226|Experimental|Part A (JTX-2011)|Phase 1 dose escalation and expansion of JTX-2011 by intravenous (IV) infusion
3123744|NCT02904226|Experimental|Part B (JTX-2011 + nivolumab)|Phase 1 dose escalation and expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
3123745|NCT02904226|Experimental|Part C (JTX-2011)|Phase 2 expansion of JTX-2011 by IV infusion
3123746|NCT02904226|Experimental|Part D (JTX-2011 + nivolumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with nivolumab by IV infusion
3123747|NCT02904226|Experimental|Part E (JTX-2011 + ipilimumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
3123748|NCT02904226|Experimental|Part F (JTX-2011 + ipilimumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with ipilimumab by IV infusion
3123749|NCT02904226|Experimental|Part G (JTX-2011 + pembrolizumab)|Phase 1 dose escalation of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
3123750|NCT02904226|Experimental|Part H (JTX-2011 + pembrolizumab)|Phase 2 expansion of JTX-2011 by IV infusion in combination with pembrolizumab by IV infusion
3123751|NCT02904265|Active Comparator|Diazepam|Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
3123752|NCT02904265|Experimental|Acetazolamide|Acetazolamide 8-10 mg/kg (up to a maximum dose of 375 mg) by mouth (PO)divided twice daily X 1 week, then increased to 11-16 mg/kg (up to a maximum dose of 750 mg) by mouth divided twice daily thereafter. Duration of therapy is 4-8 weeks.
3123753|NCT02904512|Active Comparator|Continuous glucose Monitoring and Point of Care blood glucose|Hospitalized patients with Diabetes Mellitus type 2 (DM2) managed with Continuous glucose monitoring (CGM) and Point of Care (POC) Finger sticks blood glucose
3123754|NCT02904512|Placebo Comparator|Point of Care (POC) blood glucose|Hospitalized Diabetes Mellitus type 2 (DM2) patients managed with Point of Care (POC) blood glucose only
3123755|NCT02904902|Experimental|Adalimumab|Open-label adalimumab 160 mg subcutaneous injection at Week 0 (Baseline), 80 mg at Week 2, and 40 mg every week starting at Week 4. After Week 52, Participants who consent to receive the 80 mg eow dose, will switch from 40 mg ew to 80 mg eow at Week 0x (80 mg eow period until the end of the study).
3123756|NCT02904915|Active Comparator|Paracervical block|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
3123757|NCT02904915|Active Comparator|No analgesia|IUD placement with no analgesia.
3123758|NCT02904954|Experimental|Arm 1 (Durvalumab monotherapy)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
3123759|NCT02904954|Experimental|Arm 2 (Durvalumab plus SBRT)|Durvalumab (MEDI4736) 1.12 g administered pre-operatively every 3 weeks for 2 cycles plus radiotherapy delivered in 3 daily fractions starting concurrently with the first cycle of durvalumab (MEDI4736) followed by surgical resection. Durvalumab monotherapy 1.5 g will be given for 12 months post-operatively.
3123760|NCT02905006|Placebo Comparator|Placebo|
3123761|NCT02905006|Experimental|Bimekizumab dosing regimen 1|
3123762|NCT02905006|Experimental|Bimekizumab dosing regimen 2|
3123763|NCT02905006|Experimental|Bimekizumab dosing regimen 3|
3123764|NCT02905006|Experimental|Bimekizumab dosing regimen 4|
3123765|NCT02905006|Experimental|Bimekizumab dosing regimen 5|
3123766|NCT02905149|Experimental|Serrato|Standard anesthesia+serratus plane block.
3123767|NCT02905149|Placebo Comparator|Control|Standard anesthesia
3123768|NCT02905266|Experimental|Nivolumab and Ipilimumab Concomitant Administration|Followed by Nivolumab monotherapy
3123769|NCT02905266|Experimental|Nivolumab and Ipilimumab Sequential Administration|Followed by Nivolumab monotherapy
3469417|NCT03886922|Sham Comparator|Saline|Participants will receive levcromakalim/placebo infusion after glibenclamide administration
3123770|NCT02905331|Experimental|Group 1 (Guselkumab: Placebo)|Participants will receive 100 milligram (mg) guselkumab administered as a 100 milligram per milliliter (mg/mL) solution in a single-use prefilled syringe (PFS) assembled in a SelfDose device at Weeks 0, 4, 12, 20, and 28; liquid placebo for guselkumab 100 mg at Week 16 to maintain the study blind.
3123771|NCT02905331|Experimental|Group 2 (Placebo: Guselkumab)|Partcipants will receive placebo at Weeks 0, 4, and 12 followed by guselkumab 100 mg at Weeks 16, 20, and 28.
3123772|NCT02905435|Experimental|Biodegradable Temporizing Matrix|Biodegradable Temporizing Matrix (BTM)
3123773|NCT02905825|Experimental|Indication for Helicobacter pylori testing|Walk in basis: any pediatric subjects with indication for Helicobacter pylori testing will be enrolled if they meet study eligibility criteria and will perform stool test and urea breath test within a week of each other.
3123774|NCT02905981|Experimental|Period 1: Iron Absorption Tests|During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively). All oral doses will be administered by study personnel at the research center. Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
3123775|NCT02905981|Experimental|Period 2: Dose Titration|Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results. The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results. Period 2 will involve 5 study visits, scheduled every 4 weeks. At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
3123776|NCT02905981|Experimental|Period 3: Hemoglobin Maintenance|Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time. The period will be comprised of 3 study visits, scheduled every 8 weeks.
3123777|NCT02906358|Active Comparator|Community-based pain self-management|Community-based pain self-management: two, one-hour meetings monthly for the first three months (6 meetings) and one meeting per month for the last three months (total 9 meetings)
3123778|NCT02906358|Active Comparator|Clinic-based pain self-management|Clinic-based pain self-management: 30-45 minute individualized meetings once monthly for 6 months (total 6 meetings)
3123779|NCT02906566|Other|Older Group Ages 55-75|Active and Placebo. Participants received retinol lotion on one arm and placebo to match on the other arm.
3123780|NCT02906566|No Intervention|Young Group Ages 18-25|Participants in the group will give tissue sample only for comparison.
3123781|NCT02906579|Experimental|IW-1973|Placebo taken once daily Day 1-Day 3; 10 mg IW-1973 take once daily Day 4-Day 6; 20 mg IW-1973 taken once daily Day 7-Day 9; 30 mg IW-1973 taken once daily Day 10-Day 12; 40 mg IW-1973 taken once daily Day 13-Day 15; 50 mg IW-1973 taken once daily Day 16-Day 18
3123782|NCT02906644|Experimental|Lorcaserin + Patch|Participants will receive lorcaserin (10mg twice a day) and nicotine patches (21mg/24hr) for 14 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
3123783|NCT02906644|Experimental|Patch|Participants will receive nicotine patches (21mg/24hr) and placebo lorcaserin for 2 weeks; after 2 weeks participants will begin to receive active lorcaserin (10mg twice a day) along with the nicotine patches for 12 weeks, at which point the nicotine patch dosage will be reduced to 14mg/24hr for 1 week, followed by 7mg/24hr for 1 week.
3123784|NCT02906670|Experimental|1 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 1 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
3123785|NCT02906670|Experimental|2 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 2 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
3123786|NCT02906670|Experimental|4 mg/kg Q1W|Phase 1a: Patients are administered a weekly dose of 4 mg/kg of Sym013 until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
3123787|NCT02906670|Experimental|6 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 6 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
3123788|NCT02906670|Experimental|9 mg/kg Q1W + Prophylaxis|"Phase 1a: Patients are administered a weekly dose of 9 mg/kg of Sym013 + premedication until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
3123789|NCT02906670|Experimental|6 mg/kg Q2W|Phase 1a: Patients are administered a dose of 6 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
3123790|NCT02906670|Experimental|9 mg/kg Q2W|Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.
3123791|NCT02906670|Experimental|9 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 9 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
3123792|NCT02906670|Experimental|12 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 12 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
3123793|NCT02906670|Experimental|15 mg/kg Q2W + Prophylaxis|"Phase 1a: Patients are administered a dose of 15 mg/kg of Sym013 + premedication every second week until unacceptable toxicity, progressive disease, termination of the trial or patient decision to withdraw.~Premedications for infusion-related reactions included glucocorticoids and an antihistamine (H1 antagonist) prior to each dose of Pan-HER from the beginning of the study. As of Protocol Amendment 5, additional premedications were added which included montelukast, dexamethasone, antihistamine (H2 antagonist), and acetaminophen."
3123794|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort A|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
3123795|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort B|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
3123796|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort C|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
3123797|NCT02906670|Experimental|Phase 2a Dose-Expansion Cohort D|Part 2 is a Phase 2a dose-expansion with Sym013 at the RP2D and regimen. One (1) of 4 tumor types to be evaluated in this arm of the trial will be selected based upon findings from Part 1, additional preclinical data, and additional clinical data available at that time from other agents inhibiting these targets.
3123798|NCT02906696|Experimental|Treatment (bosutinib)|Patients receive bosutinib PO daily on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3123799|NCT02906709|Experimental|Omarigliptin 25 mg|Omarigliptin 25 mg once weekly for 52 weeks (Phase A and B)
3123800|NCT02906709|Experimental|Placebo→Omarigliptin 25 mg|Placebo to Omarigliptin once weekly for 16 weeks (Phase A) switching to Omarigliptin 25 mg once weekly for 36 weeks (Phase B)
3123801|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fed+Tablets Fasted+Solution Fasted)|TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 3.
3123802|NCT02906813|Experimental|TAK-935 300 mg (Tablets Fasted+Solution Fasted+Tablets Fed|TAK-935 300 mg, tablets, orally under fasted state on Day 1 of Intervention Period 1, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 2, followed by a washout period of at least 3 days, further followed by TAK-935 300 mg tablets, orally, 30 minutes after high-fat meal on Day 1 of Intervention Period 3.
3123803|NCT02906813|Experimental|TAK-935 300 mg (Solution Fasted+Tablets Fed+Tablets Fasted)|TAK-935 300 mg, solution, orally, in fasted state on Day 1 of Intervention Period 1, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, 30 minutes after a high-fat meal on Day 1 of Intervention Period 2, followed by washout period of at least 3 days, further followed by TAK-935 300 mg, tablets, orally, under fasted state on Day 1 of Intervention Period 3.
3123804|NCT02906917|Experimental|IDegAsp|
3123805|NCT02906917|Active Comparator|IGlar + IAsp|
3123806|NCT02906930|Experimental|3 mg oral semaglutide|
3123807|NCT02906930|Experimental|7 mg oral semaglutide|
3123808|NCT02906930|Experimental|14 mg oral semaglutide|
3123809|NCT02906930|Placebo Comparator|Placebo|
3123810|NCT02907073|Experimental|Healthy Volunteers|At the study visit, healthy subjects will have an initial physical exam, urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration and blood sampling. Vital signs, and blood samples will be obtained. Subjects will receive an infusion [18F]BF4 over 1 minute and PET imaging will begin. Three (3) PET/CT scanning procedures will be performed over a period of approximately 4 hours with two rest breaks in between. Venous blood samples for clinical laboratory tests will be taken before radiotracer administration and at 1.5 hours post-administration of radiotracer. In addition, venous blood samples will be taken during the PET/CT scans to determine blood pharmacokinetics and metabolite evaluation. Physical exam will be repeated at the end of the study.
3123811|NCT02907073|Experimental|Myeloma patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.
3132487|NCT03431012|Experimental|Virus Agency /Positive Attribute Framing|Participants in this arm, after reading a hypothetical scenario, received a health message describing the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to the pandemic flu virus itself (Virus Agency Assignment framing), whilst describing the side effects of the antivirals in terms of chances of not experiencing side effects after using them (Positive Framing).
3132488|NCT03431337|Experimental|High dose|Amoxicillin/clavulanate 875mg/125mg & amoxicillin 875 mg twice a day x 7 days
3123812|NCT02907073|Experimental|Endometrial cancer patients|For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three endometrial cancer patients when the site is accessible for biopsy.
3123813|NCT02907177|Experimental|Ponesimod|Ponesimod
3123814|NCT02907177|Placebo Comparator|Placebo|Placebo
3123815|NCT02907216|Experimental|Co-administration Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
3123816|NCT02907216|Active Comparator|Staggered Group|Subjects aged 6 to 12 weeks who receive the Squarekids vaccine (diphtheria, tetanus, pertussis and inactivated poliovirus [DPT-IPV] vaccine) according to a 3, 4.5, 6 month schedule and the liquid Rotarix vaccine (oral live attenuated human rotavirus [HRV] vaccine) according to a 2, 3.5 month schedule. The HRV vaccine is administered orally while the DTP-IPV vaccine is administered subcutaneously in the upper arm or upper thigh.
3123817|NCT02907268|Active Comparator|Treatment Arm A|The first treatment group received onabotulinumtoxinA (Botox) on the right side of their face and abobotulinumtoxinA (Dysport) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
3123818|NCT02907268|Active Comparator|Treatment Arm B|The second treatment group received abobotulinumtoxinA (Dysport) on the right side of their face and onabotulinumtoxinA (Botox) on the left side of their face. Baseline treatment at Week 0 included the intradermal injection of onabotulinumtoxinA on one side of the face and abobotulinumtoxinA on the other. Patients were treated at Week 2 with traditional intramuscular injections consisting of onabotulinumtoxinA on the same side of their face as at Week 0 and abobotulinumtoxinA on the other side. Patients were treated based on individual need, and thus the treatment volumes were not controlled or standardized.
3123819|NCT02907489|No Intervention|Control: Calcium Hydroxide|Non-setting Calcium Hydroxide
3123820|NCT02907489|Other|Test: Triple Antibiotic Paste and Anti-Inflammatory Drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
3123821|NCT02907619|Experimental|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
3123822|NCT02907814|Experimental|Uveitis and Cataract Imaging Group|Subjects will undergo up to three optical coherence tomography scans.
3123823|NCT02907814|Experimental|Control|Control subjects will undergo a brief, non-contact eye exam and then undergo up to three optical coherence tomography scans.
3123824|NCT02907892|No Intervention|Control|Standard cesarean section surgical technique per surgeon preference
3123825|NCT02907892|Experimental|Glove Change|Cesarean section including changing of sterile surgical gloves immediately prior to abdominal closure
3123826|NCT02907918|Experimental|Palbociclib + letrozole + trastuzumab +/- goserelin|"Neoadjuvant palbociclib + letrozole (plus goserelin if premenopausal) + trastuzumab for a total of 16 weeks, consisting of (4) 28-day cycles~Definitive surgery will be performed preferably within 6 weeks after the end of Cycle 4. Letrozole and trastuzumab will continue until the day of surgery. Letrozole will continue to be taken daily and trastuzumab will be given every 3 weeks per standard of care guidelines. Adjuvant therapy following definitive surgery will be at the discretion of the treating physician"
3123827|NCT02908100|Placebo Comparator|Placebo|Participants received matching placebo to GDC-0853 orally starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
3123828|NCT02908100|Experimental|GDC-0853 (150mg) QD|Participants received GDC-0853 (150mg) orally once daily (QD) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
3123829|NCT02908100|Experimental|GDC-0853 (200mg) BID|Participants received GDC-0853 (200mg) orally twice daily (BID) starting on Day 1 and ending at Week 48, in combination with background standard of care therapy.
3123830|NCT02908178||Aim 1 Cohort|"The Aim 1 Cohort is constructed to perform analysis to address study objective Aim 1. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 1998 and December 2011, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
3123831|NCT02908178||Aim 2 Cohort|"The Aim 2 Cohort is constructed to perform analysis to address study objective Aim 2. This cohort includes patients diagnosed at ages 67-94 years with DCIS between January 2001 and December 2013, and received BCS as their first surgery. Patients in this cohort include those who received sentinel lymph node biopsy (SLNB) and who didn't receive SLNB.~The Aim 1 Cohort and the Aim 2 Cohort can overlap."
3123832|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 1: 3 to < 9 Years|Participants aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP) guidance, a second dose of Fluzone Quadrivalent vaccine was administered at Day 28.
3123833|NCT02908269|Experimental|Fluzone Quadrivalent Vaccine Group 2: 18 to < 65 Years|Participants aged 18 to < 65 years received one 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
3123834|NCT02908269|Experimental|Fluzone High-Dose Vaccine Group 3: ≥ 65 Years|Participants aged ≥ 65 years received one 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
3123835|NCT02908347|Experimental|MP1032|"Test Product:~100 mg MP1032 (= 2 capsules a 50 mg) are provided orally twice daily for 42 days"
3123836|NCT02908347|Experimental|Placebo|"Placebo to MP1032:~2 capsules of Placebo are provided orally twice daily for 42 days"
3123837|NCT02908464|Experimental|Lumosity (CT Group)|"Patients in the Lumosity arm will be prescribed a perioperative neurocognitive training program created in collaboration with Lumos Labs, Inc. The program will contain brain games that focus on enhancing cognitive abilities in working memory, attention, and processing speed. Participants will be expected to complete at least 2, but no more than 3, 15 minute sessions of training per day. The protocol will be prescribed for 10 days preoperatively, and then for four weeks postoperatively."
3123838|NCT02908464|No Intervention|Usual Care (Control Group)|Patients in the usual care arm will undergo current standard of care for cardiac surgery and postoperative recovery. They will be asked to refrain from acquiring a Lumosity account.
3123839|NCT02908490|Experimental|Initial Sildenafil|Sildenafil 50 mg orally once daily for first 3 months, then after 2-week washout, Placebo orally once daily for 3 months
3123840|NCT02908490|Placebo Comparator|Initial Placebo|Placebo orally once daily for first 3 months, then after 2-week washout, Sildenafil 50 mg orally once daily for 3 months
3123841|NCT02908529|Placebo Comparator|Placebo|Placebo 2 hours before bedtime
3123842|NCT02908529|Active Comparator|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
3123843|NCT02908620|Experimental|One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session.
3123844|NCT02908620|Experimental|2 sprays CTY-5339-A, then 1 spray CTY-5339-CB +1 spray placebo|Two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session.
3123845|NCT02908620|Experimental|One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
3123846|NCT02908620|Experimental|1 spray CTY-5339-CB +1 spray placebo, then 2 sprays CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) and a single spray of vehicle control (CTY-5339-P) (sprayed outside the circumscribed area to avoid dilution of active drug) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a two sprays of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session.
3123847|NCT02908672|Experimental|Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo|Run-In Period (Cycle 1=28 days): Participants will receive vemurafenib 960 mg (four, 240 mg tablets) PO BID along with cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21 followed by vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 22 to 28 and vemurafenib placebo (1 tablet) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive atezolizumab 840 mg IV infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
3123848|NCT02908672|Experimental|Atezolizumab Placebo + Cobimetinib + Vemurafenib|Run-In Period (Cycle1=28 days): Participants will receive vemurafenib 960 milligrams (mg) (four, 240 mg tablets) orally (PO) twice a day (BID) along with cobimetinib 60 mg (three, 20 mg tablets) PO once a day (QD) on Days 1 to 21 followed by vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 22 to 28. Triple Combination Period (Cycle 1 onwards): Participants will receive ATZ placebo by intravenous (IV) infusion on Day 1 and 15, cobimetinib 60 mg (three, 20 mg tablets) PO QD on Days 1 to 21, and vemurafenib 960 mg (four, 240 mg tablets) PO BID on Days 1 to 28 of each 28-day cycle. Study treatment will continue until investigator-determined disease progression, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurs first.
3469418|NCT03887065|Experimental|Starting dose|Three to five patients will receive a daily dose of 1 mg/kg JM-4 (in normal saline) delivered via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
3469419|NCT03887065|Experimental|Intermediate dose of JM-4|Three to five patients will receive a daily dose of 4 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
3469420|NCT03887065|Experimental|High dose of JM-4|Three to five patients will receive a daily dose of 9 mg/kg of JM-4 (in normal saline) via intravenous infusion for no more than 30 minutes for up to 7 consecutive days.
3469421|NCT03886831|Experimental|PRT543|PRT543 will be administered orally
3469422|NCT03887000|Experimental|MAGNESIUM|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
3469423|NCT03887000|Experimental|PLACEBO|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
3469424|NCT03887013|No Intervention|CHD routine therapy|Patients with CHD will be treated with evidence-based therapy including antiplatelet drugs,beta-blockers,statins,angiotensin-converting enzyme inhibitor (ACEI),nitrates,etc. Percutaneous coronary intervention (PCI) could be performed if needed.
3469425|NCT03887013|Experimental|CHD routine therapy+Trimetazidine|Apart from the drug and PCI therapy mentioned above,patients will be given treatment of trimetazidine.
3469426|NCT03887078|Experimental|A. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
3469427|NCT03887078|Experimental|B. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
3123855|NCT02908841|Other|Control|30 patients randomized to the control group and will receive standard of care. Control patients will be managed with direct compression with gauze pads or laparotomy pads for four minutes. If hemostasis is not achieved by compression after four minutes, the source and rate of bleeding will be reevaluated and management will be determined by the surgeon. If the surgeon uses SurgicelSnow to achieve hemostasis at some point after 4 minutes, the patient will be included in the control group, but the data will be and flagged for the analysis. If failure of hemostasis at 4 minutes with an estimated loss of ≥25 cc/min, patient will be managed as per judgment of surgeon. Persistent bleeding at the 10 minute observation point will be treated as per the surgeon's judgment.
3123856|NCT02908841|Other|Treatment|"30 patients randomized to the treatment group will receive Surgicel Snow. For patients with qualifying bleeding (rated on initial evaluation as at least mild) who have been randomized to receive Surgicel Snow, a single thin layer of dry Surgicel Snow will be applied over the area of bleeding and positioned firmly in direct contact to the areas of bleeding with blunt surgical instruments. Surgicel Snow will be left in the cavity to be absorbed. Dry gauze will not be placed over the material. No adjuncts will be added to the enhance hemostasis, but patients with small arteriolar bleeding will have pressure maintained on the bleeding site for 60 seconds. Hemostatic failure at 4 minutes will be reassessed for rate of blood loss and if the rate of loss is estimated at less than 25 cc per minute, additional observations will be made at 7 and 10 minutes."
3123857|NCT02908880|Experimental|MANTA vascular closure device|Open label, single arm study using the MANTA device, developed by Essential Medical, Inc. MANTA is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10-18F) interventional devices.
3123858|NCT02909101|Experimental|Active Cognitive Training (ACT)|Participants will complete computerized games designed to enhance working memory. Participants will complete 48 training sessions over 8 weeks.
3123859|NCT02909101|Sham Comparator|Control Training (CON)|Participants will complete 48 training sessions over 8 weeks. The control games are not designed to enhance memory.
3123860|NCT02909140|Experimental|Topical Mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
3123861|NCT02909140|Experimental|Intracameral Mydriasis|Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
3123862|NCT02909140|Experimental|Topical + Intracameral mydriasis|Topical mydriasis will be with 1 drop of phenylephrine 2.5% and 1 drop of cyclopentolate 1% x 4 doses each, with each drop spaced 5 minutes apart given in the pre-op area. These are the standard dilating drops used for cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia. Intracameral mydriasis will be with 0.2ml to 0.3ml of epinephrine 1:10,000 injected into the anterior chamber at the beginning of the cataract surgery procedure. This is the standard concentration use for intracameral mydriasis in cataract surgery. These patients will also receive intracameral lidocaine 1% for anesthesia.
3123863|NCT02909153|Experimental|single dose of Triferic in the peritoneal dialysis solution|The patient will receive a single dose of Triferic in the peritoneal dialysis solution (IP) during a long (12 hour) peritoneal dialysis dwell. Each Cohort will receive a different ascending IP dose ( 5 mg/L, 12.5 mg/L, 20 mg/L). Blood samples will be drawn periodically over a 12 hour period for analysis.
3123864|NCT02909153|Experimental|single IV dose of Triferic 6.6 mg over a 4 hour period|The patient will receive a single 6.6 mg intravenous (IV) dose of Triferic in the over a 4 hour period. All Cohorts will receive the same IV dose. Blood samples will be drawn periodically over a 12 hour period for analysis.
3123865|NCT02909439|Active Comparator|Neostigmine|Patients in this arm will receive neostigmine for reversal of neuromuscular blockade. Neostigmine is historically the medication that has been used for this purpose.
3123866|NCT02909439|Active Comparator|Sugammadex|Patients in this arm will receive sugammadex for reversal of neuromuscular blockade. Sugammadex is a newer, FDA approved, medication for this purpose.
3123867|NCT02909504|Other|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
3123868|NCT02909764|No Intervention|Control Group|Children will receive regularly salted cereal to consume 4 times per week over a 2-month period.
3123869|NCT02909764|Experimental|Low Sodium Group|Intervention: Children will receive low sodium cereal to consume 4 times per week over a 2-month period.
3123870|NCT02909907|Experimental|150 units of abobotulinumtoxinA|150 units of abobotulinumtoxinA in flexor compartment of dominant arm (75 units in flexor carpi radialis [FCR] and 75 units in flexor carpi ulnaris [FCU]) along with placebo in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU)
3123871|NCT02909907|Experimental|75 units of abobotulinumtoxinA|75 units of abobotulinumtoxinA in FCR and FCU and 25 units in ECR and ECU
3123872|NCT02909959|Active Comparator|Sulforaphane|"Participants will take a sulforaphane supplement 3-8 tablets daily, with dose depending upon body weight. Each tablet contains 125 mg broccoli seed powder and 50 mg broccoli sprout extract, providing approximately 15 µmol sulforaphane.~The weight-based dosing schedule is as follows:~3 tablets (approx. 46.5 µmol SF) if <100 lb; 5 tablets (approx. 77.5 µmol SF) if 100-125 lb; 6 tablets (approx. 93 µmol SF) if 126-175 lb; 7 tablets (approx. 108.5 µmol SF) if 176-199 lb; 8 tablets (approx. 124 µmol SF) if ≥ 200 lb"
3123873|NCT02909959|Placebo Comparator|Placebo|Participants in this arm will take placebo tablets that are identical in shape, size, and color to the sulforaphane tablets. The number of tablets taken per day corresponds to the weight-based schedule described for the sulforaphane arm.
3123874|NCT02910011|Experimental|Topical Administration of Study Drug|2.5 grams of Nanodox 1% (doxycycline monohydrate hydrogel) will be applied topically to an indicated lesion daily for 28 days
3123875|NCT02910037|Experimental|patients enrolled for mNGS testing|Patients with meningitis and/or encephalitis will be enrolled in this study in order to analyze the clinical utility of mNGS for pathogen detection. There is no control group for this study (Investigators will identify historical controls by retrospective chart review and clinical reimbursement documents).
3123876|NCT02910063|Experimental|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.
3123877|NCT02910089|Other|Shared Decision Making/Brief Negotiated Interviewing|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
3123878|NCT02910089|No Intervention|Control Arm|Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.
3123879|NCT02910102|Other|Sequence AB|RVT-101 35 mg in Period II and Placebo in Period IV
3123880|NCT02910102|Other|Sequence BA|Placebo in Period II and RVT-101 35 mg in Period IV
3123881|NCT02910167||Men with spasmodic syndromes|Men with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
3123882|NCT02910167||Women with spasmodic syndromes|Women with any type of gastrointestinal, hepato-biliary, urinary or genital spasmodic syndromes
3123883|NCT02910362|Experimental|Alcon phacoemulsification equipment|cataract surgery performed with the Alcon phacoemulsification equipment
3123884|NCT02910362|Active Comparator|AMO phacoemulsification equipment|cataract surgery with the AMO phacoemulsification equipment
3123885|NCT02910466|Experimental|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on albumin-corrected serum calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
3123886|NCT02910674|Other|One Arm|This is a comparative diagnostic study, no interventional actions are being taken.
3123887|NCT02910713|Experimental|Intranasal Application|Intranasal Tear Neurostimulator applied intranasally device (active), intranasal application for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
3123888|NCT02910713|Sham Comparator|Extranasal Application|Intranasal Tear Neurostimulator device applied extranasally (control) for approximately 3 minutes on Day 0 when the participant experienced an ODS ≥ 3 at 2 or more consecutive time points in at least one eye during the CAE exposure.
3123889|NCT02910739|Experimental|Part I: MK-8931 40 mg in Moderate HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with moderate HI in fasted state (Part I)
3123890|NCT02910739|Active Comparator|Part I: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part I)
3123891|NCT02910739|Experimental|Part II: MK-8931 40 mg in Mild HI Participants|Single oral dose of MK-8931 40 mg tablet in participants with mild HI in fasted state (Part II)
3123892|NCT02910739|Active Comparator|Part II: MK-8931 40 mg in Healthy Participants|Single oral dose of MK-8931 40 mg tablet in healthy matched participants in fasted state (Part II)
3123893|NCT02911025||Patients Treated With Clobazam|Single group, patients treated with clobazam by their treating physician (no interventions from PI), followed longitudinally for 1 week after reaching effective clobazam dose.
3123894|NCT02911116|Experimental|Cohort 1 (Subcutaneous Only)|Subcutaneous injections of Ustekinumab at baseline.
3123895|NCT02911116|Experimental|Cohort 2 (IV and Subcutaneous)|Initial IV infusion of ustekinumab at baseline followed by one subcutaneous injection at Week 8. In participants who demonstrate an allergic reaction to the baseline IV infusion, the second dose at Week 8 can also be administered as an IV infusion instead of a subcutaneous injection.
3123896|NCT02911285|Experimental|NAC/CBT|Participants will receive N-acetylcysteine (NAC) and Cognitive Behavioral Therapy (CBT) for 8 weeks.
3123897|NCT02911285|Placebo Comparator|Placebo/CBT|Participants will receive placebo pills and CBT for 8 weeks.
3123898|NCT02911324|Experimental|Nabilone|Will receive nabilone at 1 mg daily (BID) over 4 weeks.
3123899|NCT02911324|Experimental|Nabilone and EX/RP|Will receive nabilone at 1 mg daily (BID) plus therapist-guided Exposure and Response Prevention Therapy during 4 weeks.
3123900|NCT02911519|Experimental|Brief Group Psychoeducation|It was designed after a review of the literature on the subject; content and procedures will be written in a manual. They will be five sessions of two hours once a week. Each session will be conducted by a clinical psychologist and a general practitioner trained in group management.
3123901|NCT02911519|Active Comparator|Treatment as Usual Only|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
3123902|NCT02911688|Placebo Comparator|placebo|Safflower oil, taken in 2 capsules every 12 hours for a total of 4 doses
3123903|NCT02911688|Active Comparator|gamma tocopherol|gamma tocopherol 1400 mg, taken as 2 700 mg capsules every 12 hours for a total of 4 doses
3123904|NCT02911753|Experimental|Mediterranean Lemonade Consumption|All participants will be asked to consume 32 ounces daily of Mediterranean Lemonade. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
3123905|NCT02911753|Experimental|Green Tea Consumption|All participants will be asked to consume 32 ounces daily of Green Tea. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
3123906|NCT02911753|Placebo Comparator|Flavored Water Consumption|All participants will be asked to consume 32 ounces daily of Flavored Water. The beverage will be previously prepared and packaged by study personnel. Participants will receive their beverage supply on a weekly basis for a total of six weeks.
3123907|NCT02911818|Active Comparator|CMS-Alone|Lifestyle counseling, as currently recommended by the CMS.
3123908|NCT02911818|Active Comparator|CMS-Liraglutide|CMS lifestyle counselling plus liraglutide.
3123909|NCT02911818|Active Comparator|Multi-Component Intervention|CMS-Liraglutide plus a 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
3132489|NCT03431337|Active Comparator|Standard dose|Amoxicillin/clavulanate 875 mg/125mg & placebo (lactase) twice a day x 7 days.
3132490|NCT03431441|Experimental|JJVC Marketed Contact Lens|ACUVUE 2 Vivid Style
3123910|NCT02911818|Active Comparator|12-Week Extension Study: Phentermine Group|After the 1-year trial, half the participants who join the extension study will be randomized to phentermine 15.0 mg/d in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
3123911|NCT02911818|Active Comparator|12-Week Extension Study: Placebo Group|After the 1-year trial, half the participants who join the extension study will be randomized to placebo in a double-blind fashion, while continuing to take liraglutide. They will also continue to receive monthly lifestyle counseling. To be eligible for the extension study, participants must have been assigned to one of two medication groups in the original study.
3123912|NCT02911844|Other|Fulvestrant|500 mg administered intramuscularly (as two 5 mL injections) on days 0, 14, 28 and 56
3123913|NCT02911857|Experimental|Canakinumab (ACZ885)|Participants continued the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All participants received 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
3123914|NCT02911909|Active Comparator|Standard rehabilitation|Patients will receive standard post-operative ACL rehabilitation
3123915|NCT02911909|Experimental|Delfi moderated blood flow restriction|Patients will receive Delfi moderated blood flow post-operative ACL rehabilitation
3123916|NCT02911922|Experimental|Endorectal balloon - Radiation therapy|"Group 1 : Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
3123917|NCT02911922|Experimental|Rectal spacer - Radiation therapy|"Group 2 : Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
3123918|NCT02911948|Experimental|Insulin degludec/liraglutide|
3123919|NCT02911948|Active Comparator|Insulin degludec|
3123920|NCT02912195|Experimental|Intravenous lidocaine|"Participants will receive IV lidocaine (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) over 10 minutes in a 100 mL normal saline minibag followed by a 50 minute IV lidocaine drip (75 mg if <50kg, 100 mg if 50 - 100 kg, and 150 mg if >100 kg) in a 100 mL normal saline minibag.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
3123921|NCT02912195|Active Comparator|Morphine|"ED provider will choose an appropriate dose of intravenous morphine for the patient.~At 20 and 40 minutes, participants can elect to receive morphine 4mg IV as a rescue analgesic."
3123922|NCT02912364|Experimental|Eslicarbazepine|Randomized to eslicarbazepine 800mg po bid in crossover design.
3123923|NCT02912364|Experimental|Carbamazepine|Randomized to carbamazepine 400mg po bid in crossover design.
3123924|NCT02912455|Active Comparator|Study Drug (canagliflozin)|Subjects randomized to study drug will be assigned a six month course starting on canagliflozin 100 mg for two weeks titrated up to 300 mg daily (n= 24).
3123925|NCT02912455|Placebo Comparator|Placebo|Subjects randomized to placebo will be assigned a six month course of one placebo pill daily (n =12).
3123926|NCT02912468|Placebo Comparator|Placebo|Placebo (for dupilumab), 1 subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal mometasone furoate nasal spray (MFNS) at stable dose.
3123927|NCT02912468|Experimental|Dupilumab 300 mg|Dupilumab 300 mg SC injection q2w from Day 1 of Week 0 up to Week 24 added to background therapy of intranasal MFNS at stable dose.
3123928|NCT02912650|Experimental|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 125 mg / Acetaminophen 250 mg
3123929|NCT02912650|Active Comparator|Ibuprofen 250 mg|2 caplets of IBU 125 mg
3123930|NCT02912650|Active Comparator|Acetaminophen 650 mg|2 tablets of APAP 325 mg
3123931|NCT02912650|Active Comparator|Placebo|2 caplets of Placebo
3123932|NCT02913105|Experimental|LMB763|Oral dose once daily for 12 weeks (84 days)
3123933|NCT02913105|Placebo Comparator|Placebo|Oral dose once daily for 12 weeks (84 days)
3123934|NCT02913222|Experimental|Movement Pattern Training (MPT)|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. Movement Pattern Training (MPT) will focus on task-specific training to improve lower extremity movement patterns during basic tasks, such as sit to stand and stairs, and reported patient-specific tasks. Patient education will include instruction in abnormal movement patterns and methods to optimize movement patterns during each task. Exercises will include repeated practice of tasks using optimized movement patterns. Verbal cues and visual aids will be used to assist the participant. Difficulty of the task-specific activities will be progressed by varying repetitions performed, increasing load or changing the support surface.
3123935|NCT02913222|Active Comparator|Standard Rehabilitation|Treatment: 10 sessions over 12 weeks and a home program provided by a physical therapist. Treatment includes assessment of patient goals and patient education. For the Standard Rehabilitation, focus will be on progressive lower extremity and trunk strengthening and lower extremity flexibility. Patient education will include instruction to modify intensity, frequency or duration of patient-specific tasks. Using current clinical practice guidelines and previous reports, strengthening and flexibility exercises will be prescribed and progressed by varying the repetitions performed or increasing the load.
3123936|NCT02913326|Experimental|Dabigatran etexilate|
3123937|NCT02913326|Active Comparator|Warfarin|
3123938|NCT02913482|Experimental|Part 1 (Dose Finding): Risdiplam (RO7034067)|Participants will receive multiple ascending doses of risdiplam (RO7034067), administered orally once daily for a minimum of 4 weeks to select the dose for Part 2. During the first year of treatment, most participants will switch to the Part 2 dose. During the second year of treatment, all Part 1 participants will be receiving the Part 2 dose. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
3123939|NCT02913482|Experimental|Part 2 (Confirmatory): Risdiplam (RO7034067)|Participants will receive risdiplam (RO7034067), administered orally once daily at the dose defined in Part 1 of the study, for a duration of 24 months. They will thereafter enter a 3-year open-label extension phase and continue to receive risdiplam at the same dose.
3123940|NCT02913521|Experimental|Diclofenac Sodium Gel 1%|Apply 4 g of gel to the knee four times a day
3123941|NCT02913521|Active Comparator|Voltaren Gel|Apply 4 g of gel to the knee four times a day
3123942|NCT02913521|Placebo Comparator|Placebo|Apply 4 g of gel to the knee four times a day
3123943|NCT02913924|Experimental|Clonazepam|"Clonazepam will be taken twice per day in the morning and in the evening. Clonazepam is given in a fixed flexible dose schedule with the dose titrated to 2mg per day or the maximum tolerated dose. Clonazepam will be taken for the first 8 weeks of the trial."
3123944|NCT02913924|Placebo Comparator|Placebo|Placebo will be taken twice per day in the morning and in the evening. Placebo will be taken for the first 8 weeks of the trial.
3123945|NCT02914119||Eligible patients|"Patients ≥15 years of age who received general anaesthesia with neuromuscular blockade in the last 18 months up until the time of data collection.~Patients, who are eligible more than once, i.e. undergoing general anaesthesia on more than one occasion, will be included in the analyses as a case for every general anaesthetic received."
3123946|NCT02914132|Other|Seraph 100 Filter|Renal replacement patient with bacteremia.
3123947|NCT02914184|Experimental|Liq_A Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot A, at 6 and 12 weeks of age
3123948|NCT02914184|Experimental|Liq_B Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot B, at 6 and 12 weeks of age
3123949|NCT02914184|Experimental|Liq_C Group|All subjects will receive two doses of PCV-free HRV liquid formulation lot C, at 6 and 12 weeks of age
3123950|NCT02914184|Active Comparator|Lyo Group|All subjects will receive two doses of currently licensed lyophilised HRV vaccine, at 6 and 12 weeks of age
3123951|NCT02914210|Other|Virtual physical therapy|Virtual physical therapy rehabilitation program (VERA) used in the home with care planning and remote support and monitoring by physical therapists
3123952|NCT02914210|Other|Traditional physical therapy|No intervention. Standard home health physical therapy and/or outpatient clinic physical therapy as prescribed.
3123953|NCT02914236|Experimental|Vivaer Stylus|Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area
3123954|NCT02914275|Experimental|Seqirus QIV Cohort A|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
3123955|NCT02914275|Experimental|Seqirus QIV Cohort B|Seqirus Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
3123956|NCT02914275|Active Comparator|Comparator QIV Cohort A|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 6 months through 35 months of age
3123957|NCT02914275|Active Comparator|Comparator QIV Cohort B|Comparator Quadrivalent Inactivated Influenza Vaccine - Subjects 36 months through 59 months of age
3123958|NCT02914457|Experimental|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots during electrophysiological study procedure.
3123959|NCT02914509|Experimental|OTX-TP (sustained release travoprost) Intracanalicular Depot|OTX-TP (sustained release travoprost) Intracanalicular Depot
3123960|NCT02914509|Placebo Comparator|PV (Placebo Vehicle) Intracanalicular Depot|PV (Placebo Vehicle) Intracanalicular Depot
3123961|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 200 mg|Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.
3123962|NCT02914522|Experimental|Induction Study (Cohort A): Filgotinib 100 mg|Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
3123963|NCT02914522|Placebo Comparator|Induction Study (Cohort A): Placebo|Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
3123964|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 200 mg|Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
3123965|NCT02914522|Experimental|Induction Study (Cohort B): Filgotinib 100 mg|Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.
3123966|NCT02914522|Placebo Comparator|Induction Study (Cohort B): Placebo|Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.
3123967|NCT02914522|Experimental|Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).
3123968|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 200 mg|Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
3123969|NCT02914522|Experimental|Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).
3123970|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Filgotinib 100 mg|Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).
3123971|NCT02914522|Placebo Comparator|Maintenance Study: Placebo From Induction Placebo|Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).
3123972|NCT02914548|Experimental|0.3% OPA-15406|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
3123973|NCT02914548|Experimental|1% OPA-15406|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
3123974|NCT02914548|Placebo Comparator|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
3123975|NCT02914795||non-resuscitated myocardial infarction|diagnostic analysis of platelet function of a matched historical cohort of the ATLANTIS-ACS trial
3123976|NCT02914795||resuscitated myocardial infarction|diagnostic analysis of platelet function of the patient cohort included according to the inclusion criteria
3123977|NCT02914834|Experimental|Device Acupuncture|Standardized acupuncture protocol twice per week for 5 weeks for a total of 10 sessions
3123978|NCT02914834|Active Comparator|Non-pain related video health education|The attention control group will receive non-pain related video health education over 5 weeks equal to the approximate 10 hours of treatment for the acupuncture group.
3123979|NCT02915016|Experimental|Group 1: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/MF59 vaccine in their right deltoid at Months 3 and 6.
3123980|NCT02915016|Experimental|Group 2: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
3123981|NCT02915016|Experimental|Group 3: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo in their right deltoid at Months 0 and 1, and placebo and the Protein/AS01B vaccine in their right deltoid at Months 3 and 6.
3123982|NCT02915016|Experimental|Group 4: DNA-HIV-PT123 + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/MF59 vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
3123983|NCT02915016|Experimental|Group 5: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
3123984|NCT02915016|Experimental|Group 6: DNA-HIV-PT123 + Placebo + Protein/AS01B|Participants will receive the DNA-HIV-PT123 vaccine in their left deltoid at Months 0, 1, and 6 and placebo in their left deltoid at Month 3. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
3123985|NCT02915016|Experimental|Group 7: Placebo + Protein/AS01B|Participants will receive placebo in their left deltoid at Months 0, 1, 3, and 6. They will receive placebo and the Protein/AS01B vaccine in their right deltoid at Months 0, 1, and 6 and placebo in their right deltoid at Month 3.
3123986|NCT02915016|Placebo Comparator|Group 8: Placebo|Participants will receive placebo in both their right and left deltoids at Months 0, 1, 3, and 6.
3123987|NCT02915029|Experimental|Education and Lifestyle Coaching|"Education and life style coaching includes:~education about diabetes and kidney disease Coaching /counseling about lifestyle, nutrition and medication adherence"
3123988|NCT02915029|No Intervention|Usual care (UC) control arm|once randomize to the Usual Care control group, the participants are left alone and are suggested to contact their providers for health care. The group gets labs and other survey done at 6 and 12 months of the intervention.
3123989|NCT02915159|Experimental|Abatacept|Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
3123990|NCT02915159|Placebo Comparator|Placebo|Placebo for Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months followed by Open-Label Abatacept for subcutaneous injection 125mg/mL in 1 mL pre-filled syringe for 6 months
3123991|NCT02915302|Active Comparator|Fluzone Quadrivalent Vaccine, 0.25-mL|Participants received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.25-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
3123992|NCT02915302|Experimental|Fluzone Quadrivalent Vaccine, 0.5-mL|Participants received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended per ACIP guidance, a second 0.5-mL dose of Fluzone Quadrivalent vaccine was administered at Day 28.
3123993|NCT02915705|Experimental|Burosumab|Burosumab 0.8 mg/kg starting dose, administered Q2W by SC injection during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants continued to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
3123994|NCT02915705|Active Comparator|Active Control|Multiple daily doses of oral phosphate and one or more daily doses of active vitamin D therapy, titrated and individualized by the investigator based on published recommendations during the Treatment Period (up to Week 64). During the Treatment Extension Period (Week 64 to Week 140), participants crossed over to receive a starting dose of SC burosumab 0.8 mg/kg Q2W. Participants in Japan and Korea did not enter the Treatment Extension Period.
3123995|NCT02915744|Experimental|NKTR-102|In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
3123996|NCT02915744|Active Comparator|Treatment of Physician's Choice (TPC)|In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
3123997|NCT02915783|Experimental|lenvatinib 18 mg/day and everolimus 5 mg/day|Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).
3123998|NCT02915835|Active Comparator|riociguat|Riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
3123999|NCT02915835|Placebo Comparator|Placebo|Matching placebo tablets: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg matching placebo tablet.
3124000|NCT02915874|Active Comparator|Acceptance and Commitment Therapy Behavioral Intervention|"Subjects randomized to the ACT Intervention group will attend a 1-day group workshop in which two broad areas will be covered:~Behavioral Change training will involve a) teaching subjects how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and those related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise;~Mindfulness and Acceptance Training will emphasize new ways of managing troubling thoughts, feelings, and physical sensations (i.e. learning how to recognize, and develop cognitive distances from unhelpful thoughts such as I can't take this anymore and learning how to willingly face experiences that cannot be changed). In-session exercises and practice will be heavily emphasized during the group intervention and handouts will be distributed for home use."
3124001|NCT02915874|No Intervention|Control|Subjects randomized to not receive treatment.
3124002|NCT02915978|Experimental|Lower Dose Fentanyl|Lower dose Fentanyl delivered via sublingual spray every 4 hours.
3124003|NCT02915978|Experimental|Higher Dose Fentanyl Sublingual Spray|Higher dose Fentanyl delivered via sublingual spray every 4 hours.
3124004|NCT02915978|Placebo Comparator|Placebo|Placebo (matching Fentanyl) delivered via sublingual spray every 4 hours.
3124005|NCT02916056|Experimental|Azeliragon 5 mg|Azeliragon (TTP488) 5mg orally once daily for 2 years
3124006|NCT02916407|Active Comparator|Sevoflurane Group|The patients will maintained general anesthesia with sevoflurane.
3124007|NCT02916407|Experimental|Desflurane Group|The patients will maintained general anesthesia with desflurane.
3124008|NCT02916433|No Intervention|Usual care|This group will continue to receive treatments that have already been initiated to manage bronchial secretions.
3124009|NCT02916433|Experimental|Octreotide|This group will continue to receive treatments that have already been initiated to manage bronchial secretions. Additionally, this group will receive parenteral octreotide.
3124010|NCT02916498|Active Comparator|Bipolar then alternative field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with bipolar stimulation for 21 days, then alternative field shape stimulation for 21 days
3124011|NCT02916498|Experimental|Alternative then bipolar field shape stimulation|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System: Spinal cord stimulation for the management of chronic neuropathic pain programmed with alternative field shape stimulation for 21 days, then bipolar stimulation for 21 days
3124012|NCT02916563|Experimental|Altitude|Single arm study Blood Glucose Monitoring System Altitude Performance
3124013|NCT02916693|Experimental|Mirabegron|Participants take 25- 50mg oral Mirabegron tablets daily for 12 weeks,
3124014|NCT02916745|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of 2 mg/kg-porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, a laser light will be applied to the tumor.
3124015|NCT02916927|Experimental|Ketamine IV infusion|Ketamine 0.3 mg/kg in 100 mL normal saline minibag infused over 15 minutes. Placebo: 10 mL normal saline in syringe pushed over 1 minute. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
3124016|NCT02916927|Active Comparator|Ketamine IV push|Ketamine 0.3 mg/kg in a syringe pushed over 1 minutes. Placebo: 100 mL normal saline minibag infused over 15 minutes. Masking: placebo normal saline minibags and placebo syringes will appear identical to the normal saline minibus and syringes with ketamine.
3124017|NCT02917031|Active Comparator|Saxagliptin|one tablet of saxagliptin 5 mg or 2.5 mg + one placebo capsule matching sitagliptin
3124018|NCT02917031|Active Comparator|Sitagliptin|one capsule of sitagliptin 100 mg or 50 mg + one placebo tablet matching saxagliptin
3124019|NCT02917031|Placebo Comparator|Placebo|one placebo tablet matching saxagliptin + one placebo capsule matching sitagliptin
3124020|NCT02917122|Placebo Comparator|sertraline + sham tDCS|Patients will take sham tDCS.
3124021|NCT02917122|Active Comparator|sertraline + active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
3124022|NCT02917265|Experimental|TENS for vagus stimulation|A transcutaneous electrical nerve stimulation (TENS) unit is applied to an area of the external ear that is innervated by the auricular branch of the vagus nerve.
3124023|NCT02917265|Sham Comparator|TENS for sham stimulation|A TENS unit is applied to an area of the external ear that is devoid of vagus innervation.
3124024|NCT02917278|Experimental|Meals|High-protein renal-specific meals
3124025|NCT02917278|No Intervention|Control|No Meals
3124026|NCT02917447|Experimental|DESTRESS-WV|Tailored online intervention for PTSD for women Veterans with coach support.
3124027|NCT02917447|Placebo Comparator|Phone Monitoring|Weekly check-in calls from a study coach.
3124028|NCT02917603|Experimental|Intervention|These family members and residents will use web conferencing technology to attend their quarterly care conferences
3124029|NCT02917603|No Intervention|Control|These family and residents will receive usual care
3124030|NCT02917642|Experimental|Passive Ultrasonic Irrigation Protocol|ultrasonic activation of antimicrobial solutions
3124031|NCT02917642|Active Comparator|Non-Ultrasonic Irrigation Protocol|no-activation of antimicrobial solutions
3124032|NCT02917941|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.
3124033|NCT02918071|Experimental|Arm Benralizumab|Benralizumab administered subcutaneously every 4 weeks
3124034|NCT02918097|Experimental|Lithium Carbonate|"Group Started: Lithium Carbonate (900mg-1500mg)~Subjects evaluated for responsiveness every 2 weeks. Responsive to treatment patients remain in the same step. Max. step duration of 8 weeks.~First step: Monotherapy with Lithium (LSL 0.6-0.8). Non responsive patients: 2nd step.~Second step: Monotherapy with lithium (LSL 1.0-1.2). Non responsive patients: 3rd step.~Third step: Lithium + Sertraline (50mg-200mg). Non responsive patients: 4th step.~Fourth step: Lithium + Nortriptyline 100mg. Non responsive patients: 5th step.~Fifth step: Lithium + Nortriptyline 100mg + Sertraline (100mg-200mg). Non responsive patients: 6th step~Sixth step: Lithium + Nortriptyline 100mg + Sertraline 200mg + Risperidone (1mg-6mg)."
3124035|NCT02918266|Experimental|Part 1: TAK-071 80 mg + Scopolamine 0.5 mg|TAK-071 80 milligram (mg), drug in capsule (DIC), orally, Day 1, followed by scopolamine 0.5 mg, injection, subcutaneously, Day 2. TAK-071 will be taken 24 hours before scopolamine injection.
3124036|NCT02918266|Experimental|Part 2: Treatment Sequence ABDEC|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124037|NCT02918266|Experimental|Part 2: Treatment Sequence BCEAD|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124038|NCT02918266|Experimental|Part 2: Treatment Sequence CDABE|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124039|NCT02918266|Experimental|Part 2: Treatment Sequence DEBCA|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124040|NCT02918266|Experimental|Part 2: Treatment Sequence EACDB|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124041|NCT02918266|Experimental|Part 2: Treatment Sequence ACBED|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period1(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(D). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3132491|NCT03431857||TESS V2 Prosthesis|Single study patient cohort, including 106 patients who meet the inclusion/exclusion criteria and who received the TESS V2 shoulder prosthesis.
3132492|NCT03432390|Experimental|CPAP|
3132493|NCT03432390|Active Comparator|Control|
3124042|NCT02918266|Experimental|Part 2: Treatment Sequence BDCAE|TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(B);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period4(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(E). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124043|NCT02918266|Experimental|Part 2: Treatment Sequence CEDBA|TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(C);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period5(A). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124044|NCT02918266|Experimental|Part 2: Treatment Sequence DAECB|TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(D);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period2(A);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period3(E);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(C); followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(B). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124045|NCT02918266|Experimental|Part 2: Treatment Sequence EBADC|TAK-071 placebo-matching DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period1(E);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period2(B);followed by TAK-071 placebo-matching DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine placebo-matching injection,SC,Day2 of Period3(A);followed by TAK-071 80mg, DIC, orally,Day1, donepezil 10mg, over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period4(D);followed by TAK-071 80mg, DIC, orally,Day1, donepezil placebo-matching over-encapsulated tablet, orally along with scopolamine 0.5mg, injection,SC,Day2 of Period5(C). TAK-071 and donepezil will be taken 24 and 3 hours before scopolamine injection. A washout period of 3-weeks will be maintained between each treatment period.
3124046|NCT02918279|Experimental|Liraglutide|
3124047|NCT02918279|Placebo Comparator|Placebo|
3124048|NCT02918318|Experimental|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
3124049|NCT02918318|Experimental|Esketamine 28 milligram (mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
3124050|NCT02918318|Experimental|Esketamine 56 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
3124051|NCT02918318|Experimental|Esketamine 84 mg|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
3124052|NCT02918357|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
3124053|NCT02918396|Active Comparator|Conventional PVI|Conventional PVI by Radio-frequency Ablation: Wide area circumferential pulmonary vein isolation (PVI) only (current standard of care) using radio-frequency ablation catheters.
3124054|NCT02918396|Experimental|PVI + Scar-based ablation|Scar-Based Radio-frequency Ablation: Pulmonary vein isolation followed by targeting, using radio-frequency ablation, of dense LGE sites on MRI, which are confirmed on bipolar mapping to have voltage <0.3 mV.
3124055|NCT02918396|Experimental|PVI + Modeling-predicted rotors ablation|Rotor Anchors Radio-frequency Ablation: Pulmonary vein isolation followed by radio-frequency ablation of rotor anchors predicted by modeling.
3124056|NCT02918552|Experimental|Treatment|20 or 40 mg sodium nitrite tid
3124057|NCT02918552|Placebo Comparator|Control|20 or 40 mg placebo tid
3124058|NCT02918617|Active Comparator|Control toothpaste containing Novamin® technology|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124059|NCT02918617|Placebo Comparator|Control toothpaste containing 1500 ppm fluoride as MFP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124060|NCT02918617|Experimental|Test toothpaste with nano-HAP (high concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3132494|NCT03432533|Active Comparator|Romosozumab 210 mg QM: PFS|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by HCP administration with PFS.
3124061|NCT02918617|Experimental|Test toothpaste with nano-HAP (low concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124062|NCT02918617|Experimental|Test toothpaste with nano-HAP and potassium nitrate (KNO3)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124063|NCT02918617|Placebo Comparator|Control toothpaste without nano-HAP|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124064|NCT02918617|Experimental|Test toothpaste with nano-HAP (medium concentration)|Participants will be instructed to apply a full ribbon of toothpaste to a damp toothbrush. Participants will then brush for 2 minutes followed by rinsing with 15 mL of water. Participants will be instructed not to eat or drink for 30 minutes following brushing. Brushing will be performed twice a day (morning and evening).
3124065|NCT02918617|Experimental|Test cream with nano-HAP (higher concentration)|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
3124066|NCT02918617|Placebo Comparator|Control cream without nano-HAP|Participants will be instructed to brush for 2 minutes morning and evening with a full ribbon of standard fluoride toothpaste. After the evening brushing, participants will then insert custom-made trays loaded with a full ribbon of cream. Participants will be instructed to remove the trays after 5 minutes and expectorate the cream. Participants will be instructed not to eat or drink until the next morning following cream use.
3124067|NCT02918630|Active Comparator|Nicotine Replacement Therapy - Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
3124068|NCT02918630|Experimental|Nicotine Replacement Therapy + E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
3124069|NCT02918656|Experimental|Infographics|Infographic presentation of health information
3124070|NCT02918656|Active Comparator|Plain Language Summary|PLS presentation of health information
3124071|NCT02918656|Active Comparator|Scientific abstract|Scientific abstract presentation of health information
3124072|NCT02918669|Experimental|coflex|Patients who received the coflex Device in the IDE Study and presented with a spinous process fracture at 24 months (identified by independent radiographic review lab). Patients will undergo a CT Scan.
3124073|NCT02918721|Experimental|Restylane Lidocaine|Restylane Lidocaine will be injected into one side nasolabial fold on Day 1
3124074|NCT02918721|Active Comparator|Restylane|Restylane will be injected into the opposite side nasolabial fold on Day 1
3124075|NCT02918773|Experimental|Smartphone otoscope|Participating clinicians randomized to the smartphone otoscope study arm will use a smartphone otoscope for all otic (ear) examinations for a 6-month period.
3124076|NCT02918773|Active Comparator|Conventional otoscope|Participating clinicians randomized to the conventional otoscope study arm will use a conventional otoscope for all otic (ear) examinations for a 6-month period.
3124077|NCT02918851|Experimental|7-day old RBCs|Transfusion of 7-day stored red blood cells: Subjects will be transfused with their own 7-day old red blood cells
3124078|NCT02918851|Experimental|28-day old RBCs|Transfusion of 28-day stored red blood cells: Subjects will be transfused with their own 28-day old red blood cells
3124079|NCT02918851|Experimental|42-day old RBCs|Transfusion of 42-day stored red blood cells: Subjects will be transfused with their own 42-day old red blood cells
3124080|NCT02918877|Experimental|Inhaled Anesthesia|Patients in the inhaled anesthesia arm will be given sevoflurane anesthesia maintenance for the duration of the procedure including cardiopulmonary bypass.
3124081|NCT02918877|Active Comparator|Intravenous Anesthesia|Patients in the intravenous anesthesia arm will be given total intravenous anesthesia with propofol for the duration of the procedure including cardiopulmonary bypass.
3124082|NCT02918968|Experimental|Enzalutamide 160 mg 1st line AAT/Flutamide 375 mg 2nd line AAT|Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
3124083|NCT02918968|Experimental|Flutamide 375 mg 1st line AAT/Enzaltumide 160 mg 2nd line AAT|Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
3124084|NCT02919007|Experimental|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual. Measure includes the ability to operate the device correctly according to the user manual.
3124085|NCT02919111|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
3124086|NCT02919267|Other|Intra-pulmonary pressure determination|A pressure tubing catheter will be connected to the luerlock adaptor of the bronchial blocker (BB) or to the adaptor located on the side of the occluding system mounted at the extremity of the double lumen tube (DLT). The catheter will then be connected to a differential pressure transducer (AD Instruments, Colorado Springs, CO, USA), allowing direct visualisation of the bronchial pressures. Along with intra-bronchial pressure, esophageal pressure will also be measured to eliminate the pressure generated by the positive pressure of the ventilated lung (Adult esophageal balloon catheter, Cooper Surgical, Trumbull, CT, USA). Intra-bronchial pressures will be measured at end-inspiration and end-expiration.
3124087|NCT02919267|Other|Volume determination|A one-liter bag (Roxon, Etobicoke, ON, Canada) will be filled precisely with 300 mL of air with the use of a calibrated syringe of 3 liters (Hans Rudolph inc, Shawnee, Kansas, United States), through a three-way valve (Hans Rudolph inc, Shawnee, Kansas, United States). Following the filling of the bag, it will be connected to the non-ventilated lumen of the double lumen tube (DLT) or to the bronchial blocker (BB) through the three-way connector. At the end of the observation period, the collector bag will be connected to the calibrated syringe and will emptied from its residual volume.
3124088|NCT02919423|Active Comparator|10 Hz TMS|active TMS will be administered
3124089|NCT02919423|Active Comparator|1 Hz TMS|active TMS will be administered
3124090|NCT02919475|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
3124091|NCT02919475|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
3124092|NCT02919475|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
3124093|NCT02919475|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
3124094|NCT02919475|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
3124095|NCT02919657|Active Comparator|Genepro Gen2 Protein|"1 tablespoon Serving of Genepro Gen2 Protein daily will be used in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
3124096|NCT02919657|Active Comparator|Whey Protein Isolate|"30g Serving of Whey Isolate Protein will be used daily in each subject.~Intervention: Weekly blood draws will determine the effect on blood protein levels."
3124097|NCT02919683|Experimental|Nivolumab With Ipilimumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Ipilimumab to be delivered at a pre-determine dose for one week~Blood Sample Collected~Standard of Care Surgery"
3124098|NCT02919683|Experimental|Nivolumab|"Nivolumab to be delivered at a pre-determine dose for two weeks~Blood Sample Collected~Standard of Care Surgery"
3124099|NCT02919696|Experimental|Abemaciclib Dose Level 1|Abemaciclib 150 milligram (mg) administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable pharmacokinetic (PK) sampling following a single dose and repeated doses.
3124100|NCT02919696|Experimental|Abemaciclib Dose Level 2|Abemaciclib 200 mg administered every 12 hours, orally, cycle 1 and then in cycle 2. Participants may continue to receive treatment until discontinuation criteria are met. One cycle is defined as 28 days. (Cycle 1: 32 days), with modifications during Cycle 1 to enable PK sampling following a single dose and repeated doses.
3124101|NCT02919761|Experimental|Part 1: All Enrolled Participants|All participants receive Acthar Gel 1 mL twice weekly for 12 weeks
3124102|NCT02919761|Experimental|Part 2: Acthar Gel|Participants receive Acthar Gel 1 mL twice weekly for an additional 12 weeks
3124103|NCT02919761|Placebo Comparator|Part 2: Placebo|Participants receive Placebo 1 mL twice weekly for an additional 12 weeks
3124104|NCT02919813|Active Comparator|M-gCBT Group|Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
3124105|NCT02919813|Active Comparator|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
3124106|NCT02919826|Experimental|DBT Group|Adapted Dialectical Behaviour Therapy
3124107|NCT02919826|No Intervention|Control Arm|People in this group will receive treatment as usual
3124108|NCT02919995|Experimental|Higher Dose RPL554|Single dose of inhaled 6 mg RPL554
3124109|NCT02919995|Experimental|Lower dose RPL554|Single dose of inhaled 1.5 mg RPL554
3124110|NCT02919995|Placebo Comparator|Placebo|Inhaled placebo dose
3124111|NCT02920476|Experimental|Treatment arm|TAS-102
3124112|NCT02920528|Placebo Comparator|Placebo|placebo controlled arm
3124113|NCT02920528|Experimental|very low dose ketamine|0.25 mg/kg of sub-dissociative ketamine as an experimental arm
3124114|NCT02920528|Experimental|low dose ketamine|0.50 mg/kg of sub-dissociative ketamine as an experimental arm
3124115|NCT02920749|Other|Sevoflurane group A|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture.
3124116|NCT02920749|Other|Sevoflurane group B|Anaesthesia was maintained with sevoflurane (1-2% end-tidal concentration, MAC 1.0-1.5) in 50% air and 50% oxygen mixture. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
3124117|NCT02920749|Other|Propofol group C|During anaesthesia TIVA was applied with a protocol (6 to 8 mg/kg/h propofol).
3124118|NCT02920749|Other|Propofol group D|Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
3124119|NCT02920918|Active Comparator|Canagliflozin|Canagliflozin will be administered orally in pill form at 100 mg, daily for 12 weeks.
3124120|NCT02920918|Active Comparator|Sitagliptin|Sitagliptin will be administered orally in pill form at 100 mg, daily for 12 weeks.
3124121|NCT02920957|Active Comparator|comfilcon A|Participants are randomized to wear the comfilcon A lens for one month during the cross over study.
3124122|NCT02920957|Active Comparator|senofilcon C|Participants are randomized to wear the senofilcon C lens for one month during the cross over study.
3124123|NCT02920970|Active Comparator|narafilcon A|Participants are randomized to wear narafilcon A lens pair for one week during the cross over study.
3124124|NCT02920970|Active Comparator|stenfilcon A|Participants are randomized to wear stenfilcon A lens pair for one week during the cross over study.
3124125|NCT02920983|Active Comparator|somofilcon A|Subjects are randomized to wear somofilcon A for one week during the cross over study.
3124126|NCT02920983|Active Comparator|nelfilcon A II 2|Subjects are randomized to wear nelfilcon A II 2 for one week during the cross over study.
3124127|NCT02920983|Active Comparator|omafilcon A ll 2|Subjects are randomized to wear omafilcon A ll 2 for one week during the cross over study.
3124128|NCT02921061|Experimental|Treatment (decitabine, G-CLAM)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10. Patients also receive filgrastim SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2-4 hours on days 1-5, and mitoxantrone hydrochloride IV over 60 minutes on days 1-3.~RE-INDUCTION: Patients who do not achieve MRDneg CR after first induction are eligible for re-induction. Patients receive the same treatment as during induction except that decitabine is omitted.~CONSOLIDATION THERAPY: Beginning 6 weeks after achieving MRDneg CR or CR/CR with CRi after induction and/or re-induction, patients are eligible to receive filgrastim, cladribine, and cytarabine as in Induction. Treatment may be repeated for up to 4 courses in the absence of disease progression or unacceptable toxicity. Subsequent consolidation cycles would be given after recovery from the previous cycle (roughly 4-6 weeks)."
3124129|NCT02921087|Other|Test followed by control|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the test daily disposable soft contact lenses at the first visit. Subjects will crossover to the control daily disposable soft contact lenses at the second visit.
3124130|NCT02921087|Other|Control followed by test|Subjects will be randomized in a 1:1 ratio based on a randomization schedule according to sequentially assigned subject numbers to the control daily disposable soft contact lenses at the first visit. Subjects will crossover to the test daily disposable soft contact lenses at the second visit.
3124131|NCT02921295|Active Comparator|Sidekick Stubbies|"Conventional Stubby prostheses were used for baseline measures. In the sequential crossover design, articulated stubby prostheses (Sidekick manufactured by College Park Ind.) were used as intervention"
3124132|NCT02921386|Other|Breakfast A - Fasting|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to Fasting at breakfast and immediately prior to dinner.
3124133|NCT02921386|Other|Breakfast B - 15 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 15 g fat breakfast and immediately prior to dinner.
3124134|NCT02921386|Other|Breakfast C - 30 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 30 g fat breakfast and immediately prior to dinner.
3124135|NCT02921386|Other|Breakfast D - 45 g fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to 45 g fat breakfast and immediately prior to dinner.
3124136|NCT02921386|Other|Breakfast E - High Fat|Oral Testosterone Undecanoate 237 mg administered twice daily immediately prior to high fat breakfast and immediately prior to dinner.
3124137|NCT02921412|No Intervention|enfilcon A (habitual)|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
3124138|NCT02921412|Active Comparator|fanfilcon A|All participants wear enfilcon A toric lens (habitual) and then refitted with fanfilcon A toric lenses.
3124139|NCT02921425|Experimental|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of the Track Health function of the VA's patient health record known as My HealthyVet.
3124140|NCT02921490|Experimental|PET/MR recipients|All recruited patients will undergo FDG PET/MR of the lumbar spine as the single arm of the study.
3124141|NCT02921737|Experimental|Treatment Arm|TAS-102
3124142|NCT02921750|Experimental|Dressing Exufiber®Gelling Fibre Dressing|will receive dressing Exufiber®
3124143|NCT02921750|Active Comparator|Dressing Aquacel®ExtraHydrofiber®Dressing with Strengthenin|Will receive Aquacel®Extra™
3124144|NCT02921841|Experimental|DSTAR|Digital HIV Prevention intervention developed to specifically address the needs of youth in mental health treatment. Sessions introduce affect regulation and cognitive monitoring in sexual situations, and provide basic sexual health skills and education.
3124145|NCT02921841|Active Comparator|DHEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
3124146|NCT02922153|Experimental|Cryoanalgesia + Standard of Care (SOC)|Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
3124147|NCT02922153|Active Comparator|Standard of Care|Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.
3124148|NCT02922582|Experimental|DepoTXA 400mg|400mg Intracapsular at the end of surgery one time
3124149|NCT02922582|Experimental|DepoTXA 800mg|800mg Intracapsular at the end of surgery one time
3124150|NCT02922582|Experimental|DepoTXA 1200mg|1200mg Intracapsular at the end of surgery one time
3124151|NCT02922582|Active Comparator|IV Tranexamic acid (TXA)|1 g of IV TXA at the end of surgery
3124152|NCT02922634||older surgical patients|Older surgical patients presenting for elective spine surgery
3124153|NCT02922738|Experimental|Intervention - VisualDx Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to the intervention arm, refer to VisualDx when they saw a patient who presented with a skin problem. Their patients were assigned to the intervention group and interviewed about the outcomes of their treatment.
3124154|NCT02922738|No Intervention|Control - Usual Care Arm|Arm had 2 levels: provider (cluster) level and patient level. Providers, randomly assigned to control, did not refer to VisualDx but could refer to other information sources or none per usual care. Their patients were assigned to the control group and interviewed about the outcomes of their treatment
3124155|NCT02922868|Experimental|EndoSheath CST-5000 Scope|Cogentix Medical CST-5000 Flexible Video Cystoscope with Slide-On® EndoSheath® Technology. EndoSheath CST-5000 Scope.
3124156|NCT02922868|Active Comparator|Olympus Visera Elite OTV-S190 Scope|Olympus HD Flexible Cysto-Nephro Videoscope (CYF-VH) with Olympus Visera Elite Platform, including OTV-S190 Video Processor CLV-S190 Xenon Light Source. Olympus Visera Elite OTV-S190 Scope.
3132495|NCT03432533|Active Comparator|Romosozumab 210 mg QM: AI/Pen|During the open-label treatment period, participants receive 210 mg romosozumab SC QM by self-administration with AI/pen.
3124157|NCT02922959|Active Comparator|PTOEND|"PTOEND: Personally-tailored opioid overdose prevention education and naloxone distribution.~Participants in this arm will be given a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment."
3124158|NCT02922959|Experimental|PTOEND+PI|"PTOEND+PI: Personally-tailored opioid overdose prevention education and naloxone distribution, plus Peer Intervention.~In addition to a NARCAN (naloxone) nasal spray kit and personally-tailored information packet about opioid overdose and treatment, participants randomized to this arm will also receive the experimental Peer Intervention."
3469428|NCT03887078|Experimental|C. Presurgery Noom Bariatric + Augmentation Noom Bariatric|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation.
3469429|NCT03887078|Experimental|D. Presurgery Noom Bariatric + Augmentation Standard Care|"Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app. Intervention non-responsive individuals will be randomized post-surgery to usual care in which participants are free to seek any assistance for their bariatric post-surgery care during the study period."
3124161|NCT02923115|Experimental|DS-1040b|Participants who are randomized to receive DS-1040b as a single, continuous intravenous infusion (initial loading dose 3-6 mg). All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
3124162|NCT02923115|Placebo Comparator|Placebo|Participants who are randomized to receive placebo as a single, continuous intravenous infusion. All participants will also receive standard of care anticoagulation enoxaparin therapy during the study drug infusion.
3124163|NCT02923167|Experimental|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
3124164|NCT02923180|Experimental|Enoblituzumab|Men with localized intermediate and high-risk prostate cancer will be given neoadjuvant Enoblituzumab 15mg/kg IV weekly for 6 weeks followed by radical prostatectomy on day 50, with follow-up visits 30 days and 90 days post-prostatectomy. PSA values will be tracked for 3 years post-prostatectomy.
3124165|NCT02923245|Experimental|POCUS|Patients will be given consecutive IV fluid boluses until a full bladder is visualized by the ED physician on POCUS or the patient endorses maximal bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician.
3124166|NCT02923245|No Intervention|Usual Care|Patients will be given consecutive IV fluid boluses until the patient endorses sensation of maximum bladder fullness on a 0-4 Likert Scale. The patient will then have a transabdominal pelvic ultrasound performed by a radiologist or ultrasound technician
3124167|NCT02923271|Experimental|Teen-Parent Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen-parent monitoring group involves will send email notifications to the teen when their parent unlocks their phone while driving and vice versa.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
3124168|NCT02923271|Experimental|Teen Only Monitoring Group|"Cellcontrol DriveID device will automatically turn on when the teen or parent begins driving and will be pre-set to block all calls and text messages when the car is in motion but participants will have the ability to override the blocking. The teen only group involves parental monitoring of the teen's cellphone use while driving only. The parent will receive an email notification when their teen unlocks their phone while driving. Both parents and teens will drive under the same restrictions, but only the parent is notified of teen cellphone use.~Participants (parents and teens) will self-report information on their individual driving behaviors for the three weeks prior to study enrollment, including how often they report texting while driving and self-report cellphone use. At the end of the study participants will be asked to report feedback about the use the cellphone blocking technology and their perceptions for whether their safety improved using the technology."
3124169|NCT02923349|Experimental|INCAGN01949|
3124170|NCT02923427|Active Comparator|Laryngeal mask Supreme|"Insertion of the Laryngeal mask Supreme and evaluation of its clinical performance"
3124171|NCT02923427|Experimental|i-gel|"Insertion of the i-gel and evaluation of its clinical performance"
3124172|NCT02923895|Experimental|Test dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will then first brush each of the qualifying test teeth for 30 seconds each followed by the whole mouth thoroughly for at least 1 timed minute twice daily.
3124173|NCT02923895|Active Comparator|Control dentifrice|Participants will be instructed to dose a dry toothbrush with a full strip of toothpaste. Participants will brush the whole mouth thoroughly for at least 1 minute twice daily.
3124174|NCT02923921|Experimental|Pegilodecakin + FOLFOX|Pegilodecakin 5 microgram per kilogram (μg/kg) dosed as one of the following 2 fixed doses: 0.4 milligram (mg) for participants weighing ≤80 kg or 0.8 mg for participants weighing>80 kg on Days 1-5 and Days 8-12 subcutaneously (SC) plus FOLFOX [dl-Leucovorin (dl-LV) 400 milligram per meter square (mg/m2) and oxaliplatin 85 mg/m2 followed by bolus 5-fluorouracil (5-FU) 400 mg/m2 and a 46 to 48 hour infusion of 5- FU 2400 mg/m2] initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression. After discontinuation of FOLFOX in the absence of tumor progression [that is (i.e., completion of the planned 12 cycles or unacceptable FOLFOX related toxicity], Pegilodecakin 10µg/kg maintenance treatment administered as one of the 2 fixed doses, either 0.8 mg for participants weighing ≤80 kg or 1.6 mg for participants weighing>80 kg.
3124175|NCT02923921|Active Comparator|FOLFOX|FOLFOX (dl-LV 400 mg/m2 and oxaliplatin 85 mg/m2 followed by bolus 5-FU 400 mg/m2 and a 46-hour infusion of 5-FU 2400 mg/m2) initiated on Day 1 of a 14-day cycles for up to 12 cycles or until disease progression.
3124176|NCT02924051|Experimental|Motivational Interview (MI)|Intervention group participants receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families, along with monthly motivational interviewing conducted by a trained registered nurse
3124177|NCT02924051|Active Comparator|Cooking Skills/Nutritional Education|Participants in this arm receive cooking skills and nutritional education via cookbooks, cooking classes, food preparation tools and prepared food dishes to take home to their families.
3124178|NCT02924129|Experimental|Evoke SCS with Feedback|closed-loop/automatic stimulation
3124179|NCT02924129|Active Comparator|Evoke SCS with Conventional|open-loop/manual stimulation
3124180|NCT02924350|Experimental|Test dentifrice containing stannous fluoride|All the participants in the test arm applied test dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using test dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
3124181|NCT02924350|Active Comparator|Control dentifrice containing sodium monofluorophosphate|All the participants in the control arm applied control dentifrice on their two test teeth using their finger, followed by brushing these test teeth, followed by brushing the whole mouth using control dentifrice. Participants brushed their teeth for 3 days twice daily (morning /evening).
3124182|NCT02924428|Experimental|Diamondpolar applicator, AC Dual applicator|"Radio frequency (RF) and pulsed magnetic field (PEMF) treatment followed by intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The RF and PEMF applicator has 4 electrodes which emit RF and PEMF simultaneously.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
3124183|NCT02924428|Active Comparator|AC Dual applicator treatment|"Intense pulsed light (IPL) treatment delivered to the skin using the Venus Versa system.~The IPL applicator operates a blue light (415 nm) and also red light (630 nm) simultaneously. The IPL applicator also includes a sapphire cooled light guide of 10x30mm."
3124184|NCT02924688|Experimental|FF/UMEC/VI (100/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124185|NCT02924688|Experimental|FF/UMEC/VI (100/62.5/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (100/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects will also receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124186|NCT02924688|Experimental|FF/UMEC/VI (200/31.25/25) mcg closed triple therapy|Subjects will receive FF/UMEC/VI (200/31.25/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124187|NCT02924688|Experimental|FF/UMEC/VI (200/62.5/25) mcg closed triple therapy|Subjects may receive FF/UMEC/VI (200/62.5/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124188|NCT02924688|Active Comparator|FF/VI (100/25) mcg dual combination therapy|Subjects will receive FF/VI (100/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124189|NCT02924688|Active Comparator|FF/VI (200/25) mcg dual combination therapy|Subjects will receive FF/VI (200/25) mcg inhalation powder via DPI, once daily in the morning. Subjects may receive albuterol/salbutamol as a rescue medication when needed during the treatment period.
3124190|NCT02924883|Experimental|Trastuzumab Emtansine + Atezolizumab|Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion or matching Placebo followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (approximately 29 months)
3124191|NCT02924883|Active Comparator|Trastuzumab Emtansine + Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (approximately 29 months)
3124192|NCT02925078|Other|<2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have <2 mm mucosa thickness.
3124193|NCT02925078|Other|≥2 mm mucosa thickness|A Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT) will be placed in subjects that have ≥2 mm mucosa thickness.
3124194|NCT02925117|Placebo Comparator|Placebo|Participants randomized to receive placebo once daily (QD) for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo once a day for 72 weeks in Period 2.
3124195|NCT02925117|Experimental|Upadacitinib 7.5 mg|Participants randomized to receive upadacitinib 7.5 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 7.5 mg upadacitinib or placebo QD for 72 weeks in Period 2.
3124196|NCT02925117|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 15 mg upadacitinib or placebo QD for 72 weeks in Period 2.
3124197|NCT02925117|Experimental|Upadacitinib 30 mg|Participants randomized to receive upadacitinib 30 mg QD for 16 weeks in Period 1. At Week 16 participants were re-randomized to receive 30 mg upadacitinib or placebo QD for 72 weeks in Period 2.
3124198|NCT02925143|Experimental|E-learning course|
3124199|NCT02925312|Experimental|Intervention|Patients receive the full diabetes pathway intervention consisting of: individualized diabetes self-management education and support; T2DM meds management by clinician-supervised diabetes educators using an evidence-based algorithm and FDA approved anti-hyperglycemic agents; near, real-time blood glucose monitoring, delivered via a combination of two in-person and weekly remote (telephone/text) visits.
3124200|NCT02925312|No Intervention|Matched controls|Patients receive standard of care from their primary care provider. Usual care visits are typically conducted quarterly per national guidelines for management of T2DM in adults, or more frequently as needed.
3124201|NCT02925403|Active Comparator|Group 1|10μg R21/Matrix-M1 on days 0, 28, and 56.
3124202|NCT02925403|Active Comparator|Group 2|50μg R21/Matrix-M1 on days 0, 28, and 56.
3124203|NCT02925403|Placebo Comparator|Group 3|Saline injection on days 0, 28, and 56.
3124204|NCT02925455|Experimental|Stimulation + Video Games|Contralaterally-controlled functional electrical stimulation (CCFES) enables patients with upper extremity hemiplegia to open their paretic hand by stimulating finger and thumb extensors with surface electrodes. CCFES is used during functional task practice and hand therapy video games to link motor intent with execution. Four intuitive and engaging games were developed to provide goal-oriented motor skill training, impairment-appropriate difficulty, and performance feedback that motivates iterative play and skill improvement.
3124205|NCT02925455|Active Comparator|Video Games (no stimulation)|Participants receive duration-matched, identical hand therapy video games and task practice therapy as the experiment arm, but do not receive CCFES to assist hand opening.
3124206|NCT02925494|Experimental|Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA)|Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
3124207|NCT02925494|Experimental|Elagolix|Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD
3124208|NCT02925611|Active Comparator|Isoflurane|Isoflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
3124209|NCT02925611|Active Comparator|Desflurane|Desflurane as an inhalational anaesthetic ,titrated with BIS ( bispectral index) /entropy monitoring,from start to end of surgery.
3124210|NCT02925741|Experimental|Silk-Like Linens|Patients in the experimental arm will be cared for on silk-like bed linens.
3124211|NCT02925741|No Intervention|Standard Cotton Linens|Patients in the standard of care arm will be cared for on standard cotton bed linens.
3124212|NCT02925858|Experimental|Intervention|Intraoperative infusion of ketamine
3124213|NCT02925858|Placebo Comparator|Control|Control group receiving a saline infusion
3124214|NCT02925923|Active Comparator|Ticagrelor|crushed ticagrelor (180 mg); (n=50 patients)
3124215|NCT02925923|Active Comparator|Eptifibatide bolus+clopidogrel|Eptifibatide bolus (180 mcg/kg x 2 boluses) + clopidogrel 600 mg and heparin low-dose (n=50 patients)
3124216|NCT02926027|Active Comparator|Active subjects|Vascepa (4 gm/day), oral dose
3124217|NCT02926027|Placebo Comparator|Placebo subject|oral dose of placebo
3124218|NCT02926209|Active Comparator|Aer-O-Scope First|Patients in this arm will undergo colonoscopy using the Aer-O-Scope followed by colonoscopy using a conventional colonoscope
3124219|NCT02926209|Active Comparator|Conventional Colonoscope First|Patients in this arm will undergo colonoscopy using a conventional colonoscope followed by colonoscopy using the Aer-O-Scope
3124220|NCT02926573|Active Comparator|Gabapentin|Gabapentin liquid by mouth or Per Tube 300mg twice a day
3124221|NCT02926573|Placebo Comparator|Placebo|Placebo liquid by mouth or Per Tube twice a day
3124222|NCT02926677|Experimental|Cue-Centered Therapy (CCT)|Cue-Centered Therapy provides 15 sessions of treatment. Focuses on developing skills in recognizing stress cues and coping skills. Taught to self-soothe without the active involvement of a guardian. Teaches emotional, cognitive, and physiological conditioning to deal with ongoing traumatic stress. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
3124223|NCT02926677|Experimental|Trauma-Focused CBT (TF-CBT)|Trauma-Focused CBT provides 15 sessions of treatment. Focuses on reframing subconscious thought and emotions with emotional and cognitive conditioning. Uses the active involvement and support of guardians. Addresses discrete traumatic incidents in the past. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
3124224|NCT02926677|Experimental|Treatment as Usual (TAU)|TAU is the current Standard treatment at Stanford Youth Solutions will serve as the control. The treatment is known as flexible integrated services. Will have a fNIR (NIRScout) scan at 4 time points throughout study (baseline, midpoint, end of treatment, and 3 month post-treatment)
3124225|NCT02926937|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 400 milligrams (mg) administered as two 200 mg tablets, once daily (QD), before the first meal of the day in the double-blind treatment period for up to 26 weeks.
3124226|NCT02926937|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 Sotagliflozin tablet and 1 matching placebo tablet, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
3124227|NCT02926937|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, QD, before the first meal of the day in the double-blind treatment period for up to 26 weeks.
3124228|NCT02926950|Experimental|Sotagliflozin 400 mg + Metformin|Following a 2-week run-in period, sotagliflozin 400 mg was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
3124229|NCT02926950|Placebo Comparator|Placebo + Metformin|Following a 2-week run-in period, matching placebo was administered as 2 tablets, once daily, before the first meal of the day plus metformin as prescribed by the Principal Investigator for up to 26 weeks in the double-blind Core Treatment Period, and participants continued the same treatment in the double-blind Extension Period for up to 53 weeks.
3124230|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1a) Tibialis Anterior (TA) 150mg|ACE-083 150 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124231|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124232|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3a) Tibialis Anterior (TA) 200mg|ACE-083 200 mg TA bilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124233|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 1b) Biceps Brachii (BB) 150 mg|ACE-083 150 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124234|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 2b) Biceps Brachii (BB) 200 mg|ACE-083 200 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124235|NCT02927080|Experimental|ACE-083 (Part 1, Cohort 3b) Biceps Brachii (BB) 240 mg|ACE-083 240 mg BB unilaterally, once every 3 weeks for up to 5 doses. Drug: ACE-083 Recombinant fusion protein
3124236|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Tibialis Anterior (TA)|"Part 2, double-blind (DB) placebo-controlled (PC). Placebo TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
3124237|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Tibialis Anterior (TA) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg TA bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
3124238|NCT02927080|Placebo Comparator|Placebo (Part 2, DB-PC) Biceps Brachii (BB)|"Part 2, double-blind placebo-controlled. Placebo BB bilaterally, once every 3 weeks for up to 9 doses.~Drug: Placebo Normal saline~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
3124239|NCT02927080|Experimental|ACE-083 (Part 2, DB-PC) Biceps Brachii (BB) 240 mg|"Part 2, double-blind placebo-controlled. ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 9 doses.~Drug: ACE-083 Recombinant fusion protein~Afterwards, participants were rolled over into the open-label portion and received ACE-083 240 mg Biceps Brachii (BB) bilaterally, once every 3 weeks for up to 8 doses.~Drug: ACE-083 Recombinant fusion protein"
3124240|NCT02927171|No Intervention|Usual Care|Skilled nursing facility rehabilitation therapists provide all patients with usual standard of care.
3124241|NCT02927171|Experimental|I-STRONGER|IntenSive Therapeutic Rehabilitation for Older Skilled NursinG HomE Residents (I-STRONGER) Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities. Skilled nursing facility rehabilitation therapists will be trained in I-STRONGER intervention and will implement to all eligible patients as new standard of care.
3124242|NCT02927223|Experimental|Treadmill then Treadmill with Atropine|Patients will undergo treadmill exercise at baseline, then Patients will undergo treadmill exercise after IV atropine
3124243|NCT02927301|Experimental|Atezolizumab|Participants received two cycles of atezolizumab as neoadjuvant therapy prior to surgery. Participants who demonstrated clinical benefit were eligible to receive up to 12 months of atezolizumab.
3124244|NCT02927327|Experimental|PET/MR ZTE MRAC|"PET/MR zero echo time (ZTE) scan for head attenuation and Q.Static . PET/MR ZTE MRAC images to be acquired for post-processing and reader assessment.~Zero Echo Time (ZTE) scan for head attenuation"
3124245|NCT02927327|Experimental|PET/MR Q Static (Q. MRAC)|"Q.Static (Q. MRAC) for respiratory motion correction. PET/MR Q Static (Q. MRAC) images to be acquired for post-processing and reader assessment.~PET/MR Q Static (Q. MRAC)"
3124246|NCT02927366|Experimental|QCC374|Adult patients with pulmonary arterial hypertension (PAH) on QCC374. All patients were initiated at 0.03 mg BID (Day 1-3), and were up-titrated to next higher dose 0.06 mg BID (Day 4) and increased to 0.12 mg BID (Day 7-14).
3124247|NCT02927366|Placebo Comparator|Placebo|Adult patients with pulmonary arterial hypertension (PAH) on placebo matching to QCC374 doses (0.03 mg BID (Day 1-3), 0.06 mg BID (Day 4) and 0.12 mg BID (Day 7-14)).
3124248|NCT02927431|Experimental|Danirixin 15 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 15 mg FBE IV danirixin twice daily with open label 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
3124249|NCT02927431|Experimental|Danirixin 50 mg FBE IV plus 75 mg oseltamivir|Subjects will receive double blind 50 mg FBE IV danirixin twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
3124250|NCT02927431|Placebo Comparator|Placebo of danirixin IV plus 75 mg oseltamivir|Subjects will receive double blind IV placebo of DNX twice daily with 75 mg oral oseltamivir twice daily for 5 days. If a subject is discharged from the hospital in less than 5 days, treatment with IV DNX will be discontinued.
3124251|NCT02927457|Experimental|Group A1- Skin Sites A/C/D (A/P/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% (A) for Area A- PV lesion, Placebo (P) for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124252|NCT02927457|Experimental|Group A2- Skin Sites A/C/D (A/P/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving GSK2646264 1% for Area A- PV lesion, Placebo for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124253|NCT02927457|Experimental|Group A3- Skin Sites A/C/D (P/A/A)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and GSK2646264 1% for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124254|NCT02927457|Experimental|Group A4- Skin Sites A/C/D (P/A/P)|Skin areas A to E in group A are identified skin areas across the back of the subject. Subjects will be receiving Placebo for Area A- PV lesion, GSK2646264 1% for Area C- PV lesion and Placebo for Area D- uninvolved skin once daily for 28 days according to randomisation. Skin areas B- PV lesion and E- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124255|NCT02927457|Experimental|Group B1- Skin Sites F/ G (A/P)|In group B, two chosen lesions will be labeled F and G based on size (F >G). Subjects will be receiving GSK2646264 1% for lesion F and Placebo for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124256|NCT02927457|Experimental|Group B2- Skin Sites F/ G (P/A)|In group B, two chosen skin lesions will be labeled F and G based on size (F >G). Subjects will be receiving Placebo for lesion F and GSK2646264 1% for lesion G once daily for 28 days according to randomisation. Skin area H- uninvolved skin will not be assigned any treatment and will be used for the baseline biopsy.
3124257|NCT02927639|Experimental|Intervention|This group will receive the intervention for 6 months. The intervention will consist of daily text messages sent to the subject's personal mobile device in addition to the usual standard care. Subjects will be incentivized to respond to text messages via a financial reward lottery system. Previously developed text messages based on the ADA behavior goals will be used for this intervention.
3124258|NCT02927639|No Intervention|Control|This group will receive the usual standard of care for 6 months.
3124259|NCT02927795||Spiolto Respimat|QOL measurement of COPD patients taking Spiolto Respimat
3124260|NCT02927834|Active Comparator|Antibiotic only|1. Augmentin (amoxicillin/clavulanate 875/125mg) orally (PO) twice a day for 3 weeks.
3124261|NCT02927834|Active Comparator|Augmentin with 6 day steroid|Augmentin with 6 day prednisone taper (40mg PO daily (QD) for 2 days, 20mg PO QD for 2 days, 10mg PO QD for 2 days, then stop)
3124262|NCT02927834|Active Comparator|Augmentin with 21 day steroid|Augmentin with 21 days prednisone taper (40mg PO QD for 5 days, 30mg PO QD for 5 days, 20mg PO QD for 5 days, 10mg PO QD for 5 days, then stop. )
3124263|NCT02927873|Experimental|RSV LD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV low dose (LD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
3124264|NCT02927873|Experimental|RSV MD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of the RSV middle dose (MD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
3124265|NCT02927873|Experimental|RSV HD Group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of the RSV high dose (HD) vaccine, administered intramuscularly, one each at Day 1 and Day 31.
3124266|NCT02927873|Placebo Comparator|Placebo LD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
3124267|NCT02927873|Placebo Comparator|Placebo MD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.15 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
3124268|NCT02927873|Placebo Comparator|Placebo HD group|RSV-seropositive infants, aged 12 to 23 months at the time of first vaccination, received 2 doses (0.5 mL each) of placebo, administered intramuscularly, one each at Day 1 and Day 31.
3124269|NCT02927925|Experimental|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
3124270|NCT02927938|Other|Evaluable Cohort - Transplant Arm|"Other - Standard of Care Consolidation (HCT)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT); HMA-based induction subjects: Are candidates for (as determined by the investigator) and receive HCT"
3124271|NCT02927938|Other|Evaluable Cohort - Consolidation Chemo Arm|"Other - Standard of Care Consolidation (cytarabine-based chemo)~Enrolled subjects that will contribute to the population of subjects who are evaluable for the primary and secondary objectives. This will not include any subjects who end up in either observational cohort. To be included in the evaluable cohort, the subject must meet the following requirements:~Complete remission (CR1) from standard cytarabine or HMA-based induction therapy per standard clinical criteria (Cheson Criteria)~Have confirmed presence of CD34+CD38-ALDHint population by flow cytometry at the diagnostic LSC assay (LSC0)~Cytarabine-based induction subjects: Are candidates for (as determined by the investigator) and receive consolidation therapy (cytarabine-based chemotherapy or HCT)"
3124272|NCT02927938|No Intervention|Observational Cohort 1|Enrolled subjects who do not achieve a CR to induction therapy, regardless of diagnostic phenotype. Following completion of induction therapy and remission bone marrow aspirate, if a subject is determined to not have achieved a complete remission to induction therapy, he or she would be included in observational cohort 1.
3124273|NCT02927938|No Intervention|Observational Cohort 2|"Enrolled subjects who achieve a CR to induction therapy but meet one or more of the following criteria:~Lack the immunophenotype of interest,~Cytarabine based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit or refusal)] and do not receive consolidation therapy (cytarabine-based chemotherapy or HCT)~HMA-based induction subjects: Are not candidates for [as determined by the investigator (e.g. unfit, lack of donor, refusal)] and do not receive HCT~Final investigator determination of fit-ness can occur at any time until the start of consolidation therapy.~HMA-based induction subjects will not receive consolidation cytarabine-based chemotherapy as part of the evaluable cohort if they do not receive HCT."
3124274|NCT02928029|Experimental|Phase1, arm1: 33 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/ dexamethasone.
3124275|NCT02928029|Experimental|Phase1, arm2: 55 kBq/kg Radium-223 dichloride+SOC|Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/ dexamethasone.
3124276|NCT02928029|Placebo Comparator|Phase2, arm1: Placebo+SOC|Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.
3124277|NCT02928029|Experimental|Phase2, arm2: Radium-223 dichloride+SOC|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone
3124278|NCT02928055|Experimental|PNS (3 hr/day)|The PNS (3 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (3 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
3124279|NCT02928055|Experimental|PNS (6 hr/day)|The PNS (6 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (6 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
3124280|NCT02928055|Experimental|PNS (9 hr/day)|The PNS (9 hr/day) Group will receive peripheral nerve stimulation treatment for three weeks (9 hours daily) with an Intramuscular Electrical Stimulator following a one week electrode stabilization period.
3469430|NCT03887078|Experimental|E. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
3469431|NCT03887078|No Intervention|F. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care responsive individuals will be randomized post-surgery to usual care."
3469432|NCT03887078|Experimental|G. Pre-surgery Standard Care + Augmentation Noom Bariatric|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to Noom Bariatric augmentation."
3124284|NCT02928380|Active Comparator|Reference Denture Adhesive|Participants applied reference denture adhesive as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture which were placed in the mouth.
3124285|NCT02928380|Experimental|Test Denture Adhesive|Participants applied test denture adhesive as 3 continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture, which were placed in the mouth.
3124286|NCT02928380|No Intervention|No Adhesive (Negative Control)|Participants did not apply any denture adhesive in this treatment arm.
3124287|NCT02928770|Experimental|Nastent|A baseline sleep study is obtained from the subject, without wearing the device. The individual wears the device at home for at least 7 nights, and then returns to the sleep lab for an in-laboratory sleep study while wearing the device.
3124288|NCT02928848|Experimental|Real tDCS|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
3124289|NCT02928848|Sham Comparator|Sham tDCS|Sham tDCS uses identical stimulation parameters as the active condition, however terminates after 30 seconds in order to mimic the sensation of real tDCS.
3124290|NCT02928952|Experimental|Diabetes Self Management Education (DSME) + Mind-STRIDE|Will receive routine diabetes self-management education + the Mind-STRIDE intervention
3124291|NCT02928952|No Intervention|DSME alone|Usual care control
3124292|NCT02929329|Experimental|Omecamtiv Mecarbil|Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations < 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and < 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and < 1000 ng/mL maintained a 25 mg BID dosing regimen.
3124293|NCT02929329|Placebo Comparator|Placebo|Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.
3124294|NCT02929407|Experimental|FE 204205|
3124295|NCT02929407|Placebo Comparator|Placebo|
3124296|NCT02929498|Experimental|Arm A: GSK2879552 monotherapy|Subjects will receive GSK2879552 2 milligrams (mg) once daily in each 28 day cycle.
3124297|NCT02929498|Experimental|Arm B: GSK2879552+Azacitidine combination therapy|Subjects will receive GSK2879552 starting at 1 mg once daily in each 28 day cycle and Azacitidine 75 mg/square meter (m2) from Day 1 to Day 7 of each 28 day cycle.
3124298|NCT02929667|Active Comparator|Treatment|Subjects randomized to treatment arm will receive fluoxetine with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
3124299|NCT02929667|Placebo Comparator|Control|Subjects randomized to control arm will receive placebo with titration schedule consisting of 10 mg per day for 1 week, 20 mg per day for 1 week, 40 mg per day for 2 weeks, 20 mg per day for 1 week and 10 mg per day for 1 week. Then stop.
3124300|NCT02929823|Experimental|Low Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.0002% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
3124301|NCT02929823|Experimental|High Dose SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0.001% SJP-0035 ophthalmic solution in the affected eye(s) 4 times daily for 4 weeks.
3124302|NCT02929823|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic solution|Patients will administer 1 drop of 0% SJP-0035 ophthalmic solution (consisting of the vehicle for the solution) in the affected eye(s) 4 times daily for 4 weeks
3124303|NCT02929979|Experimental|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ. BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
3124304|NCT02929979|Placebo Comparator|Placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
3124305|NCT02930005|Experimental|Meclofenamic acid|150mg meclofenamic acid daily for 8 weeks
3124306|NCT02930005|Experimental|Pentosan polysulfate sodium|300mg of pentosan polysulfate sodium daily for 8 weeks
3124307|NCT02930018|Placebo Comparator|Placebo|Drug vehicle only
3124308|NCT02930018|Experimental|Nerinetide (NA-1), 2.6 mg/kg|
3124309|NCT02930174|Active Comparator|Respironics V-60, then Draeger V500|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm one applies the Respironics V-60, then the Drager V-500.
3124310|NCT02930174|Active Comparator|Draeger V500, then Respironics V-60|Testing by applying noninvasive positive pressure ventilation (NPPV) via two different bilevel positive airway pressure (BiPAP) devices . Arm two applies the Drager V-500, then the Respironics V-60.
3124311|NCT02930226|Experimental|1 unit FDP-CPD|Subjects are to have sufficient plasma withdrawn during a single WB collection visit to allow re-infusion with 1 unit of autologous FDP-CPD
3124312|NCT02930226|Experimental|Reinfusion 1 unit FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection visit to allow re-infusion with 1 unit of autologous FDP-ACD
3124313|NCT02930226|Experimental|Reinfusion 2 units FDP-CPD|Subjects are to have sufficient plasma withdrawn during 2 separate WB collection visits to allow re-infusion with 2 units of autologous FDP-CPD
3124314|NCT02930226|Experimental|Reinfusion 2 units FDP-ACD|Subjects are to have sufficient plasma withdrawn during 1 plasmapheresis collection to allow re-infusion with 2 units of autologous FDP-ACD
3124315|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (1st)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
3124316|NCT02930226|Active Comparator|Reinfusion 3 units FDP, 3 units FFP (2nd)|Subjects plasma withdrawn during 2 or 3 plasmapheresis collections to allow re-infusion with 3 units of autologous FDP-ACD and 3 units of autologous control FFP. Subjects will receive in total 6 units over the course of 2 infusion visits. Subjects are to be randomized to treatment schedule arms that dictate the sequence for infusing FDP-ACD and FFP across the 2 infusion visits
3124317|NCT02930343|Active Comparator|group 1- MTX+LEF+HCQ|Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
3124318|NCT02930343|Active Comparator|group 2- MTX+SSZ+HCQ|Combination of Methotrexate (up to 25 mg per week), Sulfasalazine (2g per day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.
3124319|NCT02930590|Experimental|Low Pressure mattress|Alternating Low Pressure mattress with low air loss function (IsoAir, stryker, USA)
3124320|NCT02930590|Experimental|Reactive support surface|Gel mattress (IsoGel, stryker, USA)
3124321|NCT02930590|Active Comparator|Standard mattress|basic foam
3124322|NCT02930824|Experimental|Adult Genotype guided treatment|For adults randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
3124323|NCT02930824|No Intervention|Adult Conventional treatment|For adults randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
3124324|NCT02930824|Experimental|Pediatric Genotype guided treatment|For children randomized to the genotype-supported arm a CYP2C19 genotype will be provided to physicians to assist in dosing.
3124325|NCT02930824|No Intervention|Pediatric Conventional treatment|For children randomized to the conventional arm no genotype will be provided to physicians to assist in dosing.
3124326|NCT02930837|Experimental|alteplase|
3124327|NCT02930941|Experimental|Tranexamic Acid (100 mg/mL)|TXA (100 mg/1mL) sprayed in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
3124328|NCT02930941|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
3124329|NCT02930980|Experimental|Investigational Software|Investigational Software loaded on Micra device
3124330|NCT02931045|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once (loading dose) followed by 90 mg twice daily (maintenance dose)
3124331|NCT02931045|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 mg or 600 mg once (loading dose) followed by 75 mg once daily (maintenance dose)
3124332|NCT02931253|Experimental|Metformin Group|"Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.~Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks."
3124333|NCT02931253|No Intervention|Control Group|Standard of care - ablation only
3124334|NCT02931396|Experimental|FES intervention|Study participants who are randomized into the intervention group will be fitted with a portable commercially available surface FES device and instructed in its use by a study investigator. Participants will be directed to use the FES 30 minutes a day for the first week, one hour a day during the next week, 90 minutes a day during the third week, and then a minimum of 2 hours per day or 10 hours per week for the next three months at home.
3124335|NCT02931396|No Intervention|Control|Participants will be asked to continue their activities of daily living as usual.
3124336|NCT02931539|Experimental|Maribavir Treatment|Participants will receive 400 milligrams (mg) (2x200 mg tablets) maribavir twice daily orally (doses separated by a minimum of 8 hours) for 8 weeks.
3124337|NCT02931539|Active Comparator|Investigator-Assigned Treatment|Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
3124338|NCT02931565|Experimental|IW-1701|Single 5-mg dose of IW-1701 administered orally
3124339|NCT02931565|Placebo Comparator|Placebo|Matching placebo administered orally
3124340|NCT02931838|Experimental|BMS-986165 Dose 1|Specified dose of BMS-986165 on specified days.
3124341|NCT02931838|Experimental|BMS-986165 Dose 2|Specified dose of BMS-986165 on specified days.
3124342|NCT02931838|Experimental|BMS-986165 Dose 3|Specified dose of BMS-986165 on specified days.
3124343|NCT02931838|Experimental|BMS-986165 Dose 4|Specified dose of BMS-986165 on specified days.
3124344|NCT02931838|Experimental|BMS-986165 Dose 5|Specified dose of BMS-986165 on specified days.
3124345|NCT02931838|Placebo Comparator|Placebo|Specified dose of Placebo for BMS-986165 on specified days.
3124346|NCT02932228|Experimental|ImPACT|Patients in ImPACT receive intensive outpatient care from the ImPACT team. The ImPACT team augments existing PACT primary care with intensive services delivered by a multidisciplinary team (including a physician, nurse practitioner, social worker, recreational therapist, and program coordinator). ImPACT program elements include a comprehensive patient assessment, identification and tracking of patients' goals and priorities, care management for medical and social service needs, co-attendance at specialty care appointments, and coordination of care with VA and non-VA providers, including during and after hospitalization.
3124347|NCT02932228|No Intervention|PACT|Patients in PACT receive usual VA primary care through the VA's Patient Centered Medical Home. VA primary care is delivered by PACT teamlets that comprise a primary care provider, nurse, clinical associate, and administrative associate who are supported by social work, pharmacy, and behavioral health services.
3124348|NCT02932267|Experimental|Adapalene / BPO gel|Adapalene 0.3% / BPO 2.5% gel, once daily in the evening
3124349|NCT02932306|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
3124350|NCT02932306|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
3124351|NCT02932332|Active Comparator|High-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (HFOx) is followed by 3 different breathing therapies of Low-flow oxygen (LFOx), High-flow air (HFAir), and Low-flow air (LFAir) with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
3124352|NCT02932332|Active Comparator|Low-flow oxygen: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, HFAir, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
3124353|NCT02932332|Sham Comparator|High-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with High-flow oxygen (LFOx) is followed by 3 different breathing therapies of HFOx, LFOx, and LFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
3124354|NCT02932332|Sham Comparator|Low-flow air: Initial Therapy|4-Period crossover therapy where initial 10 minute breathing treatment with Low-flow air (LFAir) is followed by 3 different breathing therapies of HFOx, LFOx, and HFAir with 10 minute washout period before subsequent treatments for a total 80 minute study period accompanied by shortness of breath questionnaires.
3124355|NCT02932462|Experimental|DSXS 1535|DSXS 1535 topical product
3124356|NCT02932462|Placebo Comparator|Placebo|Vehicle
3124357|NCT02932787|Experimental|Height-adjustable workstation|Participants received a height-adjustable workstation for four weeks
3124358|NCT02932787|No Intervention|Control|
3124359|NCT02932878|Experimental|DSXS topical|administered twice daily for 28 days
3124360|NCT02932891|Experimental|DSXS topical|active treatment
3124361|NCT02932904|Experimental|Vortioxetine 10 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
3124362|NCT02932904|Experimental|Vortioxetine 20 mg|Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
3124363|NCT02932904|Active Comparator|Paroxetine 20 mg|Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
3124364|NCT02932904|Placebo Comparator|Placebo|Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
3124365|NCT02932943|Experimental|Rapastinel 450 mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124366|NCT02932943|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124367|NCT02933034|Experimental|Coronary Disease|Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.
3469433|NCT03887078|No Intervention|H. Pre-surgery Standard Care + Augmentation Standard Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period. Usual care non-responsive individuals will be randomized post-surgery to usual care."
3124368|NCT02933060|Experimental|IV fluid bolus|Patients will receive a 1000 ml bolus of normal saline, administered over 60 minutes.
3124369|NCT02933060|Sham Comparator|Control|Patients will have an IV catheter and will be connected to an IV bag, but will receive only 10 ml of normal saline over 60 minutes.
3124370|NCT02933320|Experimental|Part A: Arm 1: BI-1206 single agent dose escalation phase|BI-1206 given by IV infusion to all patients once weekly for a period of four weeks, patients will then have a follow-up period of four weeks (8 week period classified as induction therapy).
3124371|NCT02933320|Experimental|Part A: Arm 2: Combination of BI-1206 with rituximab escalation phase|Arm 2, an investigation of combination treatment of BI-1206 with rituximab, involving an initial assessment of the appropriate dose of BI-1206 that can be given in combination with rituximab (combination dose escalation cohorts).
3124372|NCT02933320|Experimental|Part B: Arm1: BI-1206 single agent expansion phase|Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
3124373|NCT02933320|Experimental|Part B: Arm 2: Combination of BI-1206 with rituximab expansion phase|Part B Arm 2, an expansion cohort of up to 25 patients treated with a combination of BI-1206 and rituximab at the RP2D as determined in Part A Arm 2. Expansion to include a minimum of 12 CLL patients and six MCL patients.
3124374|NCT02933372|Experimental|Parkinson's Disease Patients|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.
3124375|NCT02933372|Experimental|Healthy Controls|Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.
3124376|NCT02933450|Active Comparator|Patiromer group|Patiromer 25.2 g dose
3124377|NCT02933450|No Intervention|Standard of Care group|Standard of Care
3124378|NCT02933476|Experimental|Vibrotactile Stimulation Treatment|All patients will receive the vibrotactile stimulation treatment. No deception will be used.
3124379|NCT02933489|Experimental|Arm A (DBT, AB-MR)|Participants undergo DBT followed by AB-MR for under 10 minutes on the same day or within 24 hours at baseline and then after 1 year.
3124380|NCT02933489|Experimental|Arm B (AB-MR, DBT)|Participants undergo AB-MR for under 10 minutes followed by DBT on the same day or within 24 hours at baseline and then after 1year.
3124381|NCT02933502|Experimental|DSXS topical product|treatment with DSXS once daily for 28 days
3124382|NCT02933528|Experimental|Dsxs topical product|treatment with DSXS once daily for 28 days
3124383|NCT02933866|Experimental|DSXS topical|applied once daily for 28 days
3124384|NCT02933866|Placebo Comparator|Vehicle topical|applied once daily for 28 days
3124385|NCT02933879|Experimental|NVXT topical|daily dosing for one 8-week treatment period (Treatment Group A) and two 8-week treatment periods separated by a 32-week rest period (Treatment Group B),
3124386|NCT02933879|Placebo Comparator|Placebo (Vehicle) Topical|two 8-week treatment periods separated by a 32-week rest period (Treatment Group C),
3124387|NCT02934178|Experimental|Cohort 1: WRSS1 3 x 10³ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10³ colony-forming units (CFU) of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
3124388|NCT02934178|Experimental|Cohort 2: WRSS1 3 x 10⁴ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁴ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
3124389|NCT02934178|Experimental|Cohort 3: WRSS1 3 x 10⁵ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁵ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
3124390|NCT02934178|Experimental|Cohort 4: WRSS1 3 x 10⁶ CFU|Healthy toddlers receiving 3 oral doses of 3 x 10⁶ CFU of Shigella sonnei Strain WRSS1 approximately 4 weeks apart.
3124391|NCT02934178|Placebo Comparator|Cohort 1: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10³ WRSS1 approximately 4 weeks apart.
3124392|NCT02934178|Placebo Comparator|Cohort 2: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁴ WRSS1 approximately 4 weeks apart.
3124393|NCT02934178|Placebo Comparator|Cohort 3: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁵ WRSS1 approximately 4 weeks apart.
3124394|NCT02934178|Placebo Comparator|Cohort 4: Placebo|Healthy toddlers receiving 3 oral doses of placebo to match 3 x 10⁶ WRSS1 approximately 4 weeks apart.
3124395|NCT02934191|Experimental|Acetaminophen/Oxycodone + Celecoxib|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take celecoxib orally (dose is 6mg/kg twice a day with a maximum dose of 300mg twice a day). The first dose of celecoxib will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
3124396|NCT02934191|Active Comparator|Acetaminophen/Oxycodone + Placebo|Subjects will take acetaminophen orally (dose 15mg/kg/dose) in scheduled doses every 4 hours for the first 5 days. Subjects will also take the placebo orally twice a day. The first dose of placebo will be given preoperatively, within 1 hour prior to entering the operating room. The second dose will be given at bedtime on the night of surgery and subsequent doses will be given 12 hours apart. Supplemental standard of care oxycodone may be used to control breakthrough pain.
3124397|NCT02934347||Supine|A baseline group of adult patients who required intubation as part of their routine anaesthesia who were intubated in the standard horizontal sniffing position.
3124398|NCT02934347||Back-up|A subsequent group of similar the patients who had their anaesthesia induced and tracheas intubated in a 25 degree back-up position achieved by flexion of the operating table at the hips
3124399|NCT02934555|Placebo Comparator|Control|Patients in the control group will receive a liquid placebo, which is 50 mL of Ensure (a dietary supplement). This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
3124400|NCT02934555|Experimental|Ubiquinol|Patients in the experimental group will receive 300 mg of Ubiquinol in a liquid mixture. The liquid Ubiquinol will be mixed with 50 mL of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days, until neurologic recovery, or until hospital discharge.
3124401|NCT02934698|Experimental|Ivacaftor|There is only one arm to this study. The two sisters with Cystic Fibrosis will both receive Ivacaftor for 6 months for their treatment.
3124402|NCT02935036|Experimental|ADPS topical product|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
3124403|NCT02935036|Placebo Comparator|Placebo Control|A thin layer of study medication will be applied to cover affected areas once daily for 12 weeks
3124404|NCT02935062|Active Comparator|Traditional Phonological Therapy|This intervention will be intermediated by the traditional model cycles. This approach has the principle of treating the suppression of operant phonological processes in child's speech, from the awareness of sound-target characteristics operating in that phonological process.
3124405|NCT02935062|Experimental|Software Phonological Therapy- SIFALA|This intervention will be intermediated by the software SIFALA. The software SIFALA, allows to select target segments using the Modelo de Estratos (second model Strata), based on the level segment of production and complexity of distinctive features, from the child's sound system analysis and planned generalizations. It also seeks the treatment of phonological disorders, by selection stimulus words in more favorable environments and playful activities with computer resource for the correct production of the target segment in the words stimulus, promoting the spread segments.
3124406|NCT02935062|Placebo Comparator|Placebo Therapy|No interventional group. This group will be the sham group. The proposed activities will be fun games on the computer, there is no relationship with speech and it will be not emphasized the correct sound production, will only play activities.
3124407|NCT02935179|Placebo Comparator|Control Group|Normal diet with 1500~2000 kcal
3124408|NCT02935179|Experimental|Treatment Group|White sweet potato diet with 1500~2000 kcal
3124409|NCT02935192|Experimental|Vaccine Arm|Seasonal trivalent split, inactivated influenza vaccine
3124410|NCT02935192|Placebo Comparator|Placebo Arm|Phosphate buffered saline
3124411|NCT02935452|Active Comparator|Genie|This group will have the Genie social tool delivered on a one to one basis at discharge points in the study.
3124412|NCT02935452|No Intervention|Normal Care|This group will have the same questionaires at discharge, but will be offered normal care
3124413|NCT02935543|Experimental|CART19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion.
3124414|NCT02935595|Experimental|Ketamine|Slow infusions of ketamine will take place over a time period of 40 minutes.
3124415|NCT02935673|Experimental|Regimen A (Placebo)|Participants of part 1 and part 2 will receive a single loading dose (LD) (Dose 1) followed by 9 maintenance doses (MDs) (Doses 2 to 10) of matching placebo, administered twice daily.
3124416|NCT02935673|Experimental|Regimen B (low-dose lumicitabine)|Participants of part 1 and part 2 will receive a single 750 mg LD (Dose 1) followed by nine 250 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
3124417|NCT02935673|Experimental|Regimen C (High-dose lumicitabine)|Participants of part 2 will receive a single 1000 mg LD (Dose 1) followed by nine 500 mg MDs (Doses 2 to 10) of lumicitabine, administered twice daily.
3124418|NCT02935699|Experimental|Test Drug|JDP-205 Injection, 10 mg/mL, 1 mL
3124419|NCT02935699|Active Comparator|Control|Diphenhydramine Injection, 50 mg/mL, 1 mL
3124420|NCT02935738|Experimental|Prednisolone treated men / positive SPA / IVF|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (greater than five) were admitted to conventional in vitro fertilization (IVF) cycles.
3124421|NCT02935738|Experimental|Prednisolone treated men / negative SPA / ICSI|Infertile men, with anti-sperm antibodies, were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles. Prednisolone treated men, who recovered from anti-sperm antibodies, underwent then sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were admitted to intracytoplasmic sperm injection (ICSI) cycles.
3124422|NCT02935738|No Intervention|Control men / positive SPA / IVF|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having positive SPA results (more than five) were then admitted to in vitro fertilization (IVF) cycle.
3124423|NCT02935738|No Intervention|Control men / negative SPA / ICSI|Infertile men with anti-sperm antibodies who were not treated with prednisolone, which is an intermediate acting corticosteroid, underwent sperm penetration assay (SPA) using zona-free hamster ova. Couples with male partners having negative SPA results (equal or less than five) were then admitted to intracytoplasmic sperm injection (ICSI) cycles.
3124424|NCT02935842|Experimental|Specific SL-therapy for PD (with and without DBS)|Rhythmic specific, intensive and high-frequency SL-therapy. Approx. 45 Min. per session, 3 times per week for 4 weeks
3124425|NCT02935842|Active Comparator|rBMT for PD (with and without DBS)|Rhythmic Balance-Movement Training (rBMT); approx. 30-45 Minutes per session, 3 times per week for 4 weeks
3124426|NCT02935842|No Intervention|PD (with and without DBS); no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
3124427|NCT02935842|No Intervention|Healthy Controls; no therapy|No further recruiting necessary, as data is already at hand via previous research projects.
3124428|NCT02935894|Experimental|Single group|"All subjects will participate in 4 study day visits in the same order.~compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).~compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).~collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).~collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen."
3124429|NCT02936037|Placebo Comparator|GROUP 1|Placebo capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
3124430|NCT02936037|Experimental|GROUP 2|MD1003 capsule, 1 capsule tid (morning,noon and evening) for 15 months and up to 27 months.
3124431|NCT02936076|Active Comparator|Exercise condition|Participants randomized to the exercise condition will participate in a 12-week exercise training program. The exercise intervention will consist of both supervised and unsupervised exercise sessions and progress to 200 minutes/week of moderate-intensity exercise. Exercise bouts will be spread across 4-6 days and be at least 20 minutes in duration. During supervised visits, heart rate will be monitored by a member of the research staff to ensure that exercise is within the prescribed intensity range and ratings of perceived exertion and feeling state will be assessed periodically. Unsupervised exercise will be verified using objective physical activity monitors.
3124432|NCT02936076|Placebo Comparator|Delayed exercise condition|Participants randomized to the delayed exercise condition will be asked not to change their exercise or eating habits over the 12-week period and will complete the same assessment measures as the exercise condition. However, following the completion of the 12-week period, participants will be given two options: 1) receive a one-on-one session with an exercise physiologist at our center and receive a written exercise program, and at this time point all study obligations will be completed, or 2) complete the identical exercise protocol as the 'exercise' condition.
3124433|NCT02936479|Experimental|Berinert treatment|
3124434|NCT02936635|Experimental|Delayed Start Treatment|The Delayed Start Treatment group consisted of patients who received placebo in CY 4031 and tirasemtiv in CY 4033.
3124435|NCT02936635|Experimental|Early Start Treatment|The Early Start Treatment group consisted of patients who received tirasemtiv in both CY 4031 and CY 4033.
3124436|NCT02936648|Experimental|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
3124437|NCT02936869|No Intervention|Control arm|Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.
3124438|NCT02936869|Experimental|Referral incentive arm|"Traditional birth attendants will receive an offer of two-weekly payouts per reported delivery they take that is verified by client.~Traditional birth attendants randomized to this arm will also receive an offer of two-weekly payouts per successful referral of delivery clients to postnatal care within 48 hours of delivery in a facility if verified."
3124439|NCT02937116|Experimental|Phase 1a|"Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.~Drug: IBI308"
3124440|NCT02937116|Experimental|Phase 1b Cohort A|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
3124441|NCT02937116|Experimental|Phase 1b Cohort B|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
3124442|NCT02937116|Experimental|Phase 1b Cohort C|"Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308"
3124443|NCT02937116|Experimental|Phase 1b Cohort D|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308/Cisplatinum/Pemetrexed"
3124444|NCT02937116|Experimental|Phase 1b Cohort E|"Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\gemcitabine\cisplatin"
3124445|NCT02937116|Experimental|Phase 1b Cohort F|"Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\oxaliplatin\capecitabine"
3124446|NCT02937116|Experimental|Phase 1b Cohort G|"Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\etoposide\cisplatin"
3124447|NCT02937116|Experimental|Phase 1b Cohort H|"Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.~Drug: IBI308\irinotecan\5-FU"
3124448|NCT02937168|Experimental|Part 1: PET/CT Scan|Healthy participants will have 2 PET/CT scan in Part 1: within 7 days of eligibility being confirmed, and 7 days after the first PET/CT scan. Participants will receive Fluorodeoxyglucose F-18 (FDG) as part of the PET/CT procedures and will provide sputum/blood samples.
3124449|NCT02937168|Experimental|Part 2: Reslizumab|Reslizumab 3.0 milligrams/kilogram (mg/kg) will be administered by intravenous (IV) infusion, over 20 to 50 minutes, at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
3124450|NCT02937168|Placebo Comparator|Part 2: Placebo|Matching placebo will be administered by IV infusion at Baseline (Day 1) of Part 2. PET/CT scan will be done on Weeks 2, 4 and 6. Participants will receive FDG as part of the PET/CT procedures and will provide sputum/blood samples.
3124451|NCT02937194|Experimental|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) for the expectant mothers and their husbands together with oral health education materials on infant's tooth development and eruption, establishment of proper feeding, dietary and toothbrushing habits will be given before baby delivery. Reinforcement of OHI and demonstrations on how to clean the infant's oral cavities and perform toothbrushing will be delivered after the babies are born.
3124452|NCT02937194|Active Comparator|Pamphlets distribution|Pamphlets for adults' and pregnant women's oral health care will be distributed when recruited and information on the babies' oral health care will be distributed before baby delivery.
3124453|NCT02937350|Experimental|Study Population|D6-25-hydroxyvitamin D3
3124454|NCT02937454|Active Comparator|ferric carboxymaltose|The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
3124455|NCT02937454|Placebo Comparator|normal saline 0.9%|The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
3124456|NCT02937506|Experimental|Propofol|Patients in the treatment arm will be given propofol only when having a colonoscopy.
3124457|NCT02937506|Experimental|Fentanyl Plus Midazolam Only|Patients in the control arm will receive only the standard of care medications, fentanyl and midazolam when having a colonoscopy.
3124458|NCT02937545|Experimental|PGx Only|Patients will receive pharmacogenetic testing. Pharmacists will make recommendations for drug/dose changes based on PGx results.
3124459|NCT02937545|Experimental|PGx + MTM|Patients will receive pharmacogenetic testing along with medication therapy management. Two MTM sessions will be conducted: one at the time testing is ordered and the testing sample is collected, and one when results are returned to the patient. Pharmacists will make recommendations for drug/dose changes based on medication action plan developed during MTM and the PGx results.
3124460|NCT02937558|Experimental|CSI-Glucagon (Double-Blind Phase - 2 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
3124461|NCT02937558|Placebo Comparator|Placebo (Double-Blind Phase - 2 days)|Vehicle solution delivered as a 24-hour continuous subcutaneous infusion via a patch pump.
3124462|NCT02937558|Experimental|CSI-Glucagon (Open-label Phase - Up to 28 days)|Glucagon solution delivered as a continuous subcutaneous infusion via a patch pump at a starting dosage of 5 mcg/kg/hr.
3124463|NCT02937584|Experimental|GP MDI (PT001) 14.4 μg|Glycopyrronium
3124464|NCT02937584|Experimental|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
3124465|NCT02937623|Experimental|Test Product: Dissolvable polymer strip containing Novamin|In this arm, participants received an experimental dissolvable polymer strip containing 15 % weight/weight (w/w) calcium sodium phosphosilicate (Novamin). One strip was applied per test tooth topically by a suitably qualified member of the site staff. Each participant received 2 strips in total (as two test tooth were assessed per participant).
3124466|NCT02937623|No Intervention|Reference Product: No treatment/product|In this arm, participants did not receive any treatment/product.
3124467|NCT02937636|Experimental|Test Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
3124468|NCT02937636|Active Comparator|Reference Product|Participants will apply a full strip of dentifrice to cover the head of the toothbrush provided and brush their teeth with the assigned dentifrice twice daily (morning and evening) for one timed minute following their normal routine.
3124469|NCT02937701|Experimental|ABP 710|"Participants randomized to receive a 3 mg/kg intravenous (IV) infusion of ABP 710 on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants continued receiving 3 mg/kg ABP 710 every 8 weeks through week 46."
3124470|NCT02937701|Active Comparator|Infliximab|"Participants randomized to receive a 3 mg/kg IV infusion of infliximab on day 1, at weeks 2 and 6, and every 8 weeks thereafter until week 22.~At week 22 participants were re-randomized in a 1:1 ratio to either continue receiving 3 mg/kg infliximab every 8 weeks or transition to receive 3 mg/kg ABP 710 every 8 weeks through week 46."
3124471|NCT02937740|Other|Naive patients - ARM 1|"NATESTO Testosterone Nasal Gel administered intranasally to patients with no prior TRT experience. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
3124472|NCT02937740|Other|Non-naive patients - ARM 2|"NATESTO Testosterone Nasal Gel administered intranasally to patients who had prior TRT. Multiple-dose dispenser will be used for gel deposition into the nasal cavity. The dispenser is a finger-actuated, non-pressurized dispensing system designed to deliver 122.5mg of NATESTO (5.5mg testosterone) per actuation.~For BID administration, NATESTO 22 mg/day of testosterone. For the subset of patients that continue on TID, NATESTO 33 mg/day of testosterone."
3124473|NCT02937766|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector weekly over 4 weeks (4 injections)
3124474|NCT02937766|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle weekly over 4 weeks (4 injections)
3124475|NCT02937870|Experimental|Test Product 1|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
3124476|NCT02937870|Experimental|Test Product 2|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
3124477|NCT02937870|Active Comparator|Reference Product|Applied topically to upper denture, to clean dry denture fit surface in a pattern consistent with application instructions.
3124478|NCT02937870|Other|Negative Control|
3124479|NCT02938013|Experimental|Group A|Monoinfected: Sofosbuvir/Velpatasvir/Voxilaprevir SOF/VEL/VOX days 0-7 Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL days 8 (week 2) through 84 (week 12). Post-treatment follow up through week 12.
3124480|NCT02938013|Active Comparator|Group B|Monoinfected: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
3124481|NCT02938013|Active Comparator|Group C|HIV/HCV Co-infection: Sofosbuvir/Velpatasvir (SOF/VEL) days 0 through 7 and Paired liver biopsy at days 0 and 7 (cohort 1) or days 0 and 4 (cohort 2). SOF/VEL on day 8 (week 2) through 84 (week 12) . Post-Treatment follow up through week 12.
3124482|NCT02938052|Experimental|Intervention Arm|"Participants will all undergo a 10-week PP-based health behavior intervention and adherence measurements (baseline and Week 10).~The participants will receive an ActiGraph accelerometer. They will be asked to begin wearing the accelerometer after their initial visit. Participants will wear the ActiGraph for 7 days at baseline and again at 10 weeks."
3124483|NCT02938169|Experimental|walking exercise group|"**walking exercise with bracing exercise~walking exercise: treadmill gait with tolerable gait speed~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
3124484|NCT02938169|Experimental|stabilization exercise group|"** stabilization exercise with bracing exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this."
3124485|NCT02938169|Experimental|walking and stabilization exercise group|"**walking exercise, bracing exercise with stabilization exercise~stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise:treadmill gait with tolerable gait speed"
3124486|NCT02938169|Sham Comparator|flexibility exercise group|"**Stretching exercise(control)~Only educate the flexibility exercise(stretching exercise)~Don't educate the walking exercise method and stabilization exercise method"
3124487|NCT02938494|Experimental|IDP-123 Lotion|Lotion
3124488|NCT02938494|Active Comparator|Tazorac Cream|Cream
3124489|NCT02938494|Active Comparator|Vehicle Lotion|Lotion
3124490|NCT02938494|Active Comparator|Vehicle Cream|Cream
3124491|NCT02938520|Experimental|CAB LA + RPV LA every 4 weeks|After Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will receive oral CAB 30 mg + RPV 25 mg once daily for approximately four weeks. At visit Week 4b subjects will receive an initial loading dose of CAB LA (600 mg) and RPV LA (900 mg) at Week 4b. From Week 8 onwards, subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks.
3124492|NCT02938520|Active Comparator|ABC / DTG / 3TC (600 mg/50mg/300mg) once daily|After the Induction Phase with ABC/DTG/3TC (or DTG + two NRTIs), eligible participants will continue to receive oral ABC/DTG/3TC (or DTG + two NRTIs) initiated during the Induction Phase for 100 weeks. At the end of the Maintenance Phase, eligible participants receiving ABC/DTG/3TC (or DTG + two NRTIs) have the option to continue in the study by switching to CAB LA + RPV LA in the Extension Phase. These participants will transition to LA dosing at either Week 100 (direct to inject) or Week 104b (if using optional oral lead-in with CAB 30 mg + RPV 25 mg once daily).
3124493|NCT02938585|Experimental|Prophylactic treatment|
3124494|NCT02938585|Experimental|On-demand treatment|
3124495|NCT02938949|Active Comparator|Alirocumab|Alirocumab (150 mg) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
3124496|NCT02938949|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once, within the first day of the patient's diagnosis of NSTEMI. Patients will also receive an 80 mg dose of atorvastatin.
3124497|NCT02939014|Experimental|Brentuximab Vedotin 1.8 mg/kg|Brentuximab vedotin 1.8 mg/kg, intravenous (IV) infusion on Day 1 of each 3-week cycle until the sooner of disease progression, unacceptable toxicity, or completion of 16 cycles.
3124498|NCT02939079|Experimental|Fingolimod and Fish Oil|Fingolimod 0.5 mg capsule daily by mouth and Fish Oil 1 g capsule daily by mouth for one year.
3124499|NCT02939079|Active Comparator|Fingolimod and Placebo|Fingolimod 0.5 mg capsule daily by mouth and Placebo capsule daily by mouth for one year.
3124500|NCT02939105|Experimental|CoolSculpting Treatment in the Upper Arm|"Subjects in the study were treated with the CoolSculpting System with one of two vacuum applicator types for bilateral fat reduction in the upper arms. Applicators were used concurrently, with an applicator on each arm. Each subject received 1 or 2 cooling cycles on each arm for 35 minutes at protocol-defined temperatures.~The Investigator selected the applicator for each subject based on the intended fat volume of the treatment area."
3124501|NCT02939131|Experimental|COMB-R|Health and Wellness Cognitive Behavioral Therapy and Medication Management (COMB-R) intervention
3124502|NCT02939131|Active Comparator|Enhanced Standard of Care|Enhanced Standard of Care (ESC)
3124503|NCT02939170|Experimental|DT1 MF MM|Delefilcon A multifocal contact lenses with molded marks on back surface worn bilaterally (in both eyes) for 9 hours
3124504|NCT02939170|Active Comparator|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 9 hours
3124505|NCT02939326|Placebo Comparator|Placebo|"Intervention: Drug: Placebo~Single Injection of placebo into five (5) 0.1 mL IM injections into glabellar area."
3124506|NCT02939326|Active Comparator|EB-001 Dose 1 (1X)|"Intervention: Drug: EB-001~Single Injection of Low Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124507|NCT02939326|Active Comparator|EB-001 Dose 2 (3X)|"Intervention: Drug: EB-001, 3X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124508|NCT02939326|Active Comparator|EB-001 Dose 3 (9X)|"Intervention: Drug: EB-001, 9X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124509|NCT02939326|Active Comparator|EB-001 Dose 4 (12X)|"Intervention: Drug: EB-001, 12X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124510|NCT02939326|Active Comparator|EB-001 Dose 5 (16X)|"Intervention: Drug: EB-001, 16X Dose 1~Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124511|NCT02939326|Active Comparator|EB-001 Dose 6 (21X)|Intervention: Drug: EB-001, 21X Dose 1 Single Injection of EB-001 into five (5) 0.1 mL IM Injections into glabellar area
3124512|NCT02939326|Active Comparator|EB-001 Dose 7 (28X)|"Intervention: Drug: EB-001, 28X Dose 1~Single Injection of Highest Dose of EB-001 into five (5) 0.1 mL IM Injections into glabellar area"
3124513|NCT02939560|Experimental|rTMS|Participants will receive rTMS sessions according to the study protocol.
3124514|NCT02939599|Experimental|QCC374|"placebo patients from QCC374X2201 rolled into extension study will start at 0.03mg b.i.d. or 0.06mg b.i.d. and have the opportunity to up-titrate 0.12mg~-active patients will continue at the dose they finished on the QCC374X2201 study"
3124515|NCT02939651|Experimental|Pembrolizumab|Monotherapy with PD-1 antibody pembrolizumab
3124516|NCT02939716|Active Comparator|Rhubarb|300g frozen rhubarb, microwaved; served with 65g lactose free cream and saccharine sweetener
3124517|NCT02939716|Active Comparator|Bread|2 slices of white bread, 40g each; served with 10g butter
3124518|NCT02939716|Experimental|Lettuce|300g lettuce; served with 30g mayonnaise
3124519|NCT02939781||Febrile critically ill children|Children above 10kg admitted to the paediatric intensive care unit at Great Ormond Street Hospital who are mechanically ventilated and have a high likelihood of developing a fever. Energy expenditure will be measured using indirect calorimetry at baseline, and continuously during fever, until fever subsides.
3124520|NCT02939937|Experimental|phenytoin|patients received phenytoin 100mg three time daily up to 3 months
3124521|NCT02939937|Experimental|placebo|patients received placebo 100 mg three time daily for 3 months
3124522|NCT02939950|Experimental|Bausch + Lomb Samfilcon A Soft Contact Lens|Participants will wear Bausch + Lomb samfilcon A soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
3124523|NCT02939950|Active Comparator|Bausch + Lomb Pure Vision Soft Contact Lens|Participants will wear Bausch + Lomb pure vision soft contact lens in each eye on a 7-day extended daily wear basis for a period of 12 months. The lenses will be worn overnight for up to 6 consecutive nights per week. The lenses will be removed, cleaned, and disinfected with Biotrue multi-purpose solution on the seventh night and re-inserted the following morning. The lenses will be replaced with new lenses on the first monday of each month.
3124524|NCT02940249|Experimental|1.2 g apple polyphenols|1200 mg apple polyphenols delivered in a low sugar drink.
3124525|NCT02940249|Experimental|0.9 g apple polyphenols|900 mg apple polyphenols delivered in a low sugar drink.
3124526|NCT02940249|Experimental|0.6 g apple polyphenols|600 mg apple polyphenols delivered in a low sugar drink.
3124527|NCT02940249|Placebo Comparator|Placebo|No polyphenols delivered in a low sugar drink.
3124528|NCT02940392|Experimental|Rezum Treatment|Patients will receive the Rezūm transurethral needle ablation procedure to treat benign prostatic hyperplasia.
3124529|NCT02940522|Experimental|Treatment A|Subcutaneous (SQ) injection using an autoinjector
3124530|NCT02940522|Active Comparator|Treatment B|Intramuscular injection (IM) using syringe and needle
3124531|NCT02940574|Experimental|Syntocinon (Oxytocin, product code RVG 03716)|Administration via nasal spray
3124532|NCT02940574|Placebo Comparator|Placebo (Physiological water(sodium chloride (NaCl) solution))|Administration via nasal spray
3124533|NCT02940626|Placebo Comparator|Placebo|Placebo administered as 2 separate intravenous (IV) infusions
3124534|NCT02940626|Experimental|ASN100|ASN100 administered as 2 separate intravenous (IV) infusions
3124535|NCT02940691|Experimental|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) daily taken orally for 12 weeks.
3124536|NCT02940730|Active Comparator|Dalbavancin via IV|Dalbavancin will be administered via intravenous administration. Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
3124537|NCT02940730|Active Comparator|Dalbavancin via IP|Dalbavancin will be administered as an intraperitoneal administration. Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
3469434|NCT03886987|Experimental|Device and Control|"Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.~Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml~Negative control: Blank patch Dose: Not applicable"
3469435|NCT03887052|Experimental|Study Arm|Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)
3124538|NCT02940860|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
3469436|NCT03886935||Fontan patients|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
3469437|NCT03886935||Healthy biventricular controls|The serum of Fontan patients is compared to the serum of healthy biventricular controls (Metabolomics)
3124539|NCT02940860|Active Comparator|Iron sucrose|Administered IV
3124540|NCT02940886|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
3124541|NCT02940886|Active Comparator|Iron sucrose|Administered IV
3124543|NCT02941523|Experimental|1a NOX66|"NOX66 administered daily for 14 day in a 21-day treatment cycle. NOX66 treatment given to two cohorts of patients as 1 of 2 dose regimens:~Regimen 1: 400 mg; Regimen 2: 800 mg (idronoxil)"
3124544|NCT02941523|Experimental|1b NOX66 and Carboplatin (combined)|"NOX66 administered on Days 1-7 and carboplatin IV infusion on Day 2 of each 28-day treatment cycle up to 6 cycles.~NOX66 at the same dosage received in the Run-In Arm combined with 2 carboplatin doses starting with low dose carboplatin AUC = 4 for treatment cycles 1-3 followed by higher dose carboplatin AUC = 6 for treatment cycles 4-6."
3124545|NCT02941523|Experimental|2a NOX66 and Carboplatin|"This arm triggered by observed meaningful clinical responses from the 1b Combination Arm in particular disease indications.~Treatment NOX66 + carboplatin administered over 6 cycles each of 28-days at observed clinical response dosage. A maximum of 2 cohorts, each comprising patients with specific tumour type."
3124546|NCT02941614||Intervention|Newly diagnosed breast cancer patients will be offered a brief distress screening questionnaire, the Patient Health Questionnaire (PHQ), around the time of their breast cancer diagnosis and again at subsequent transitions in care as appropriate (e.g., the initiation of chemotherapy).
3124547|NCT02941614||Control|Newly diagnosed breast cancer patients will experience usual care.
3124548|NCT02941627|Experimental|Neuro Cochlear Implant System study group|All patients will receive a Neuro Zti implant and fitted with Neuro One sound processor
3124549|NCT02941640|Experimental|Laparoscopic appendectomy. E group.|The securing the base of appendix by Endo-loop.
3124550|NCT02941640|Experimental|Laparoscopic appendectomy. S group.|The securing the base of appendix by stapler.
3124551|NCT02941640|Experimental|Laparoscopic appendectomy. H group.|The securing the base of appendix by Hem-o-lok clip.
3124552|NCT02941640|Experimental|Laparoscopic appendectomy. DS group.|The securing the base of appendix by DS clip.
3124553|NCT02941692|Experimental|Oxytocin|Participants randomized to this condition will receive 40 IU dose of intranasal oxytocin.
3124554|NCT02941692|Placebo Comparator|Placebo|Participants randomized to this condition will receive a matching dose of intranasal saline spray as placebo.
3124555|NCT02942004|Placebo Comparator|Placebo|Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (μg/kg/h) or 90 μg/kg/h group.
3124556|NCT02942004|Experimental|SAGE-547 60 μg/kg/h|Participants received a 4-hour titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 56 hours), followed by a taper to 30 μg/kg/h (56 to 60 hours).
3124557|NCT02942004|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
3124558|NCT02942017|Placebo Comparator|Placebo|Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
3124559|NCT02942017|Experimental|SAGE-547 90 μg/kg/h|Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).
3124560|NCT02942160|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
3124561|NCT02942264|Experimental|Phase I Arm 1 Dose Dense Temozolomide plus Zotiraciclib (TG02)|dose dense (dd) Temozolomide (TMZ) 125 mg/m^2 x 7 days on / 7 days off plus Zotiraciclib (TG02) dose escalation
3124562|NCT02942264|Experimental|Phase I Arm 2 Metronomic Temozolomide Plus Zotiraciclib (TG02)|metronomic Temozolomide (TMZ) 50 mg/ m^2 daily plus Zotiraciclib (TG02) dose escalation
3124563|NCT02942264|Experimental|Phase II Arm 1 Maximum Tolerated Dose (MTD) of Zotiraciclib (TG02) Plus Temozolomide (TMZ)|"Maximum tolerated dose (MTD) of Zotiraciclib (TG02) from phase I plus and winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I"
3124564|NCT02942264|Active Comparator|Phase II Arm 2 Metronomic Temozolomide (TMZ)|"winner of dose dense (dd) vs metronomic Temozolomide (TMZ) from phase I alone"
3124565|NCT02942407|Experimental|apixaban|apixaban 5 mg twice daily (apixaban 2.5 mg twice daily for selected patients)
3124566|NCT02942407|Experimental|warfarin|warfarin daily dose adjusted to target International Normalized Ration(INR) of 2-3
3124567|NCT02942485|Experimental|Metronidazole|Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
3124568|NCT02942485|Active Comparator|Tinidazole|Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose
3124569|NCT02942576|Experimental|Edoxaban-based regimen|Edoxaban-based regimen for 21 days pre- and 90 days post-ablation period.
3124570|NCT02942576|Active Comparator|VKA-based regimen|VKA-based regimen for 21 days pre- and 90 days post-ablation period (control regimen)
3124571|NCT02942654|Experimental|LY900014|Test formulation. 15-U dose of LY900014 administered subcutaneously (SC) in one of two periods.
3124572|NCT02942654|Active Comparator|Insulin Lispro|Reference formulation. 15-U dose of Insulin Lispro administered SC in one of two periods.
3124573|NCT02942771|Experimental|Cohort 1 - TT301/MW189|TT301/MW189 0.075 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
3124574|NCT02942771|Experimental|Cohort 2 -TT301/MW189|TT301/MW189 0.15 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
3124575|NCT02942771|Experimental|Cohort 3- TT301/MW189|TT301/MW189 0.25 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
3124576|NCT02942771|Experimental|Cohort 4- TT301/MW189|TT301/MW189 0.30 mg/kg IV (or matched placebo). Each subject will receive 1 dose level of study drug twice daily (bid) on Days 1 through 5, inclusive
3124577|NCT02942771|Placebo Comparator|Placebo|No drug intervention.
3124578|NCT02942966|Experimental|Tack Implant|Implantation of a Tack using the Intact Vascular Tack Endovascular System for the repair of post angioplasty dissections below the knee.
3124579|NCT02942979||MISSION Implementation as Usual|Passive implementation or, IU for MISSION-Vet is comprised of a two-hour webinar training, along with key information on how to access and use the MISSION-Vet Treatment Manual and Consumer Workbook. The manual is posted on the web and available inside the VA on the National Center for Homelessness Among Veterans website or at missionmode.org. This passive implementation strategy has been used in previous studies
3124580|NCT02942979||Facilitation Implementation of MISSION|Facilitation is a comprehensive approach in which implementation experts partner with local staff to support implementation planning and to tailor adoption strategies to the local context. Facilitation gives attention to addressing individual- and organizational-level factors that can influence successful implementation of an evidence based practice with good fidelity.
3124581|NCT02943070|Experimental|Rezum Treatment|Patients received the Rezum transurethral needle ablation procedure to treat benign prostatic hyperplasia.
3124582|NCT02943096|Active Comparator|Flavanol|Blinded treatment with either CocoaVia 500mg or placebo.
3124583|NCT02943096|Placebo Comparator|Placebo|Blinded treatment with either CocoaVia 500mg or placebo.
3124584|NCT02943213|Experimental|Treatment Period 1|First dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
3124585|NCT02943213|Experimental|Treatment Period 2|Second dosing period in which all enrolled subjects are administered a single dose of 25 mg Chlorpromazine Hydrochloride Tablet.
3124586|NCT02943226|Experimental|Becton Dickinson Nexiva Diffusics System|Intervention with the new Becton Dickinson Nexiva Diffusics System will be evaluated to see if it will improve image quality compared to the standard catheter.
3124587|NCT02943226|Active Comparator|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to novel 3 hole Becton Dickinson Nexiva Diffusics System to see which catheter provides the best image quality.
3124588|NCT02943447|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
3124589|NCT02943447|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for 12 weeks.
3124590|NCT02943447|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for 12 weeks.
3124591|NCT02943447|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants may have the option to receive open-label cilofexor 100 mg for an additional 96 weeks.
3124592|NCT02943460|Experimental|Cilofexor 100 mg (Blinded Study Phase)|Cilofexor 100 mg + placebo to match cilofexor 30 mg for up to 12.6 weeks
3124593|NCT02943460|Experimental|Cilofexor 30 mg (Blinded Study Phase)|Cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.7 weeks
3124594|NCT02943460|Placebo Comparator|Placebo (Blinded Study Phase)|Placebo to match cilofexor 30 mg + placebo to match cilofexor 100 mg for up to 12.3 weeks
3124595|NCT02943460|Experimental|Cilofexor (Open Label Extension Phase)|Following the Blinded Study Phase, eligible participants received cilofexor for an additional up to 97.4 weeks.
3124596|NCT02943473|Experimental|Ibrutinib|Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose administered on a continuous basis
3124597|NCT02943499|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
3124598|NCT02943499|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
3124599|NCT02943564|Experimental|Rapastinel 225 mg|Rapastinel 225 milligram (mg) weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124600|NCT02943564|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124601|NCT02943564|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124602|NCT02943577|Experimental|Rapastinel 450 mg|Rapastinel 450 mg weekly intravenous (IV) injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124603|NCT02943577|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections. Each participant will continue to take the same dose of antidepressant therapy the participant was receiving prior to entering this study throughout treatment.
3124604|NCT02943668|Experimental|Treatment (deferasirox)|Patients receive deferasirox PO QD. Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
3124605|NCT02943941|Other|All participants|All participants enrolled in a single arm to evaluate effect of variables (posture, respiration, exertion) on pulmonary artery pressure (PAP)
3124606|NCT02944383|Experimental|Gemcabene 300 mg|Participants received 300 mg Gemcabene orally, once daily for 12 weeks.
3124607|NCT02944383|Experimental|Gemcabene 600 mg|Participants received 600 mg Gemcabene orally, once daily for 12 weeks.
3124608|NCT02944383|Placebo Comparator|Placebo|Participants received matching placebo orally, once daily for 12 weeks.
3124609|NCT02944448|Active Comparator|CR845 tablet 1 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
3124610|NCT02944448|Active Comparator|CR845 tablet 2.5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
3124611|NCT02944448|Active Comparator|CR845 tablet 5 mg|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
3469438|NCT03887091|Experimental|Postwire© Virtual Education Cohort|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility.~In randomized into the Virtual Education Cohort:A video based, personalized web page will be created that has information related to the participants therapeutic clinical trial.~This web page will have videos of a research nurse explaining how to take study medication(s), how to fill out the study drug diary, and a description of the main side effects associated with the study drugs.~Clinic Visit Video Recording Cycle 1-4/Day 1~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7"
3124612|NCT02944448|Placebo Comparator|Placebo tablet|Dosing twice a day (BID) for a total of 8 weeks, with each dose administered at least 2 hours prior to or after a meal.
3124613|NCT02944461|Experimental|Dapsone gel 7.5%|Dapsone gel 7.5% to be applied to truncal acne once daily for 16 weeks.
3124614|NCT02944513|Experimental|Experimental|Subjects will receive the Quell device
3124615|NCT02944513|No Intervention|Control|Subjects will not receive the Quell device
3124616|NCT02944565|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
3124617|NCT02944656|Experimental|Gabapentin group|This group will receive local anesthesia per clinic protocol plus Gabapentin 600mg 1-2 hours preoperatively.
3124618|NCT02944656|Placebo Comparator|Placebo group|This group will receive local anesthesia per clinic protocol plus placebo 1-2 hours preoperatively.
3124619|NCT02944968|Experimental|Treatment group|Radiofrequency ablation treatment with the THERMOCOOL SMARTTOUCH® SF-5D catheter in Paroxysmal AF population.
3124620|NCT02945046|Placebo Comparator|Placebo|Participants will receive placebo administered via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injection at Weeks 4 and 8, respectively.
3124621|NCT02945046|Experimental|Fremanezumab 675 mg/Placebo/Placebo|Participants will receive placebo as an approximately 1-hour intravenous infusion followed by fremanezumab at 675 milligrams (mg) administered as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 and placebo administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
3124622|NCT02945046|Experimental|Fremanezumab 900/225/225 mg|Participants will receive fremanezumab at 900 mg administered via an approximately 1-hour intravenous infusion followed by 3 placebo subcutaneous injections at Week 0 and fremanezumab at 225 mg administered as single subcutaneous injection (225 mg/1.5 mL) at Weeks 4 and 8, respectively.
3124623|NCT02945150|Experimental|Elbasvir/grazoprevir for HCV+ kidney transplant recipients|"Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those <75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV)."
3124624|NCT02945254|Active Comparator|Background noise|Overnight sleep study with filtered white noise
3124625|NCT02945254|No Intervention|Silence|Overnight sleep study with normal environmental noise
3124626|NCT02945410|Experimental|Caloric Restriction and High Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 1.7 g protein/kg BW/day.
3124627|NCT02945410|Active Comparator|Caloric Restriction and Normal Protein|Participants will be calorie restricted to 30 kcal/kg FFM/day and consume 0.8 g protein/kg BW/day.
3124628|NCT02945410|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.7 g protein/kg BW/day.
3124629|NCT02945553|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
3124630|NCT02945553|Active Comparator|Microstimulation|Microstimulation
3124631|NCT02945657|Experimental|MM36 1% ointment|MM36 topical ointment, 1%, applied twice daily for 28 days
3469439|NCT03887091|No Intervention|No Video Intervention|"Participants will be administered a brief questionnaire that asks questions about participant internet access, use, and understanding (Appendix B). This questionnaire will be used to determine eligibility~Participants randomized to the control cohort will follow standard of care procedures involving clinic visits that do not include the use of video or access to a personalized web page.~Participants from both groups will be asked to complete two surveys before each Day 1 clinic visit for Cycles 1-7."
3469440|NCT03886883|Experimental|Exercise-induced hypoalgesia (EIH)|Exercise-induced hypoalgesia - isometric muscle contractions of the hand flexors
3124634|NCT02946021|Experimental|Pneumatic Compression-1 session per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (1 session per day) with imaging using NIRFLI with ICG (Indocyanine green).
3124635|NCT02946021|Experimental|Pneumatic Compression-2 sessions per day|Head and neck garments for pneumatic compression device for treatment of lymphedema (2 sessions per day) with imaging using NIRFLI with ICG (Indocyanine green).
3124636|NCT02946034|Experimental|Viekira Pak ± ribavirin or Mavyret|"12 week therapy with Viekira Pak ± ribavirin~8 or 12 week therapy with Mavyret"
3124637|NCT02946073|Placebo Comparator|Placebo|CAM2038 placebo injections
3124638|NCT02946073|Experimental|CAM2038|CAM2038 50 mg/mL q1w at doses of 8 mg, 12 mg, 16 mg, 24 mg, or 32 mg. CAM2038 356 mg/mL q4w at doses of 64 mg, 96 mg, or 128 mg.
3469441|NCT03886883|Active Comparator|Static stretch (SS)|A static stretch of the knee flexors
3469442|NCT03886883|Sham Comparator|Rest|No intervention
3469443|NCT03886883|Experimental|Conditioning painful stimulus (CPM)|Conditioned pain modulation - cold pressure test
3469444|NCT03886961|Experimental|Lung Transplant Patients|For the first four weeks, lung transplant patients will not wear the Reflux Band. Use of the Reflux Band will subsequently commence in the next four weeks.
3469445|NCT03886909|Active Comparator|Home-Based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and periodical phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of transplant.
3469446|NCT03886909|Active Comparator|Prehabilitation Education|Will be offered a prehabilitation and stem cell education class at the Penn State Hershey Cancer Institute.
3469447|NCT03886766|Experimental|Sequence 1,2,3|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period C/ Visit 10: Efavirenz solution, 3 mg, oral administration (product 3)
3469448|NCT03886766|Experimental|Sequence 2,3,1|Period A/ Visit 2: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2) Period B/ Visit 6: Efavirenz solution, 3 mg, oral administration (product 3) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
3124639|NCT02946229|Other|MHD Population Ultrasound|Eligible subjects in a convenience population at the site (Maintenance Hemodialysis, MHD) incidentally undergoingnon-invasive cardiac, pulmonary, and abdominal ultrasound scanning on the commercially available GE Vivid S70 system for use in testing feasibility of new algorithms for processing this data.
3124640|NCT02946385|Experimental|ABCWY_ 0_2 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
3124641|NCT02946385|Experimental|ABCWY_0_2_6 Group|Subjects who received 3 doses of MenABCWY vaccine at Month 0, Month 2 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
3124642|NCT02946385|Experimental|B_0_2 Group|Subjects who received 2 doses of rMenB+OMV vaccine at Month 0 and Month 2 in study V102_15 (NCT02212457), and will receive 1 dose of rMenB+OMV in this extension study
3124643|NCT02946385|Experimental|ABCWY_ 0_6 Group|Subjects who received 2 doses of MenABCWY vaccine at Month 0 and Month 6 in study V102_15 (NCT02212457), and will receive 1 dose of MenABCWY in this extension study
3124644|NCT02946385|Active Comparator|ABCWY Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of MenABCWY in this extension study
3124645|NCT02946385|Active Comparator|rMenB+OMV Naive Group|Subjects who are meningococcal vaccine-naive and of similar age to subjects enrolled from the parent study (NCT02212457), and will receive 2 doses of rMenB+OMV in this extension study
3124646|NCT02946463|Experimental|Ravulizumab|"Participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligram (mg) on Day 1. Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Day 15 and every 8 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
3124647|NCT02946463|Active Comparator|Eculizumab|"Participants received 600 mg of eculizumab on Days 1, 8, 15, and 22, followed by 900 mg of eculizumab on Day 29 and every 2 weeks thereafter for 26 weeks.~After completion of the Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 5 years."
3124648|NCT02946489|Experimental|CI-581a+MET+MBRP|Administration of CI-581a during wk 2 and possibly at wk 3 or 4 at 0.71 mg/kg in the context of a 2 wk course of MET followed by a 4 wk course of MBRP
3124649|NCT02946515|Experimental|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
3124650|NCT02946515|Experimental|Waitlist Control Group|The control group will participate in pre- and post-test assessments of their conversational skills with a trained actor. At the end of the study, the waitlist control group will be allowed to access to the simulation and the study team will provide training to participants upon request.
3124651|NCT02946580|Experimental|MOVANTIK™ (naloxegol)|Subjects in the treatment group will be administered MOVANTIK™ (naloxegol) 25 mg tablet or placebo once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing). Subjects with renal impairments (creatine clearance rate of less than 60 mL/min) will receive a 12.5 mg dose tablet of naloxegol in place of the 25 mg dose as advised by FDA guidelines. For patients who are unable to swallow the tablet whole, the tablet can be crushed and given orally or administered via nasogastric tube.
3124652|NCT02946580|Placebo Comparator|Sugar pill|Matching placebo consists of an inert mixture supplied by AstraZeneca in identical-appearing tablets. Subjects in the placebo group will be administered a placebo tablet once daily beginning 2 hours after the completion of their surgery until their discharge from the hospital (variable timing).
3124653|NCT02946892|Experimental|Carvedilol|Study participants will receive carvedilol for 12 weeks
3124654|NCT02946892|Experimental|Placebo|Study participants will receive placebo (sugar pill) for 12 weeks
3124655|NCT02946918|Experimental|Tablets|Patients in this arm will receive levothyroxine tablets (encapsulated for blinding purposes)
3124656|NCT02946918|Experimental|Gelcaps|Patients in this arm will receive levothyroxine gelcaps (encapsulated for blinding purposes)
3124657|NCT02947984|Experimental|Standard Treatment|Standard radiation therapy: 55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week.
3124658|NCT02947984|Experimental|Higher Dose Treatment|63 CGE in 35 treatments of 1.8 CGE given once a day, for five days of each week.
3124659|NCT02947997||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
3124660|NCT02948426|Experimental|Dose Level 1 - Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml)|Sylatron 25µg (0.1 µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
3124661|NCT02948426|Experimental|Dose Level 2 - Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (75x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
3469449|NCT03886766|Experimental|Sequence 3,1,2|Period A/ Visit 2: Efavirenz solution, 3 mg, oral administration (product 3) Period B/ Visit 6: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1) Period C/ Visit 10: Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
3124662|NCT02948426|Experimental|Dose Level 3 - Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml)|Monocytes (750x10^6); Sylatron 25µg (0.1µg/ml); Actimmune 5mg (0.02µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
3124663|NCT02948426|Experimental|Dose Level 4 - Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml)|Monocytes (750x10^6); Sylatron 250µg (1µg/ml); Actimmune 50mg (0.2µg/ml). The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal.
3124664|NCT02948426|Experimental|EX1 Dose Expansion Arm|10 additional patients will be treated at the maximum tolerated dose (MTD)
3124665|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via e-flow nebulizer, once daily
3124666|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50mg via e-flow nebulizer, once daily
3124667|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via e-flow nebulizer, once daily
3124668|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via e-flow nebulizer, once daily
3124669|NCT02948582|Experimental|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via e-flow nebulizer, once daily
3124670|NCT02948582|Placebo Comparator|Placebo 0.5mL|Placebo 0.5mL via e-flow nebulizer, once daily
3124671|NCT02948634|Sham Comparator|Sham Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy.
3124672|NCT02948634|Active Comparator|Active Phoenix Laser Treatment|Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
3124673|NCT02948777|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
3124674|NCT02948829|Experimental|Tetravalent Dengue Vaccine (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).
3124675|NCT02948959|Placebo Comparator|Placebo|Placebo (for Dupilumab), subcutaneous (SC) injection every 2 weeks (q2w) for 52 weeks in combination with stable-dose background therapy of medium-dose inhaled corticosteroids (ICS) with a second controller medication (i.e., long-acting β2 agonist [LABA], long acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
3124676|NCT02948959|Experimental|Dupilumab|Dupilumab 200 milligrams (mg) (in 1.14 milliliters [mL] for >30 kilograms [kg] bodyweight [BW]) or 100 mg (in 0.67 mL for less than or equal to (<=) 30 kg BW), SC injection q2w for 52 weeks in combination with stable-dose background therapy of medium-dose ICS with a second controller medication (i.e., LABA, LAMA, LTRA] or methylxanthines) or high-dose ICS alone or high-dose ICS with second controller medication. Albuterol/salbutamol or levalbuterol/levosalbutamol was given as reliever medication. Participants were followed up for 12 weeks after last dose (i.e. up to Week 64).
3124677|NCT02949011|Experimental|Baloxavir Marboxil|Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
3124678|NCT02949011|Active Comparator|Oseltamivir|Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
3124679|NCT02949011|Placebo Comparator|Placebo|Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
3124680|NCT02949024|Experimental|TX Naïve Arm|Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.
3124681|NCT02949024|Experimental|Previous TX Arm|Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.
3469450|NCT03886805|Experimental|Dual task with variable- and fixed-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks. From the 1st to 12th week the participants were trained under variable-priority instructions (half the session was focused on balance motor task and half the session focused on cognitive task performance). From the 13th to 24th week) the participants performed dual tasks under fixed-priority instructions (simultaneous focus attention on balance and cognitive tasks). The motor tasks were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks will include activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, working memory, among other cognitive tasks.
3124682|NCT02949128|Experimental|Ravulizumab|"Participants were administered weight-based doses of ravulizumab every 8 weeks for 26 weeks in the Initial Evaluation Period.~After the Initial Evaluation Period, participants could enter an Extension Period and receive ravulizumab until the product registration or approval (in accordance with country-specific regulations) or for up to 4.5 years, whichever occurs first."
3124683|NCT02949141|Experimental|Ultrasound|All patients will initially get an ultrasound (interpreted by emergency department physician) followed by chest x-ray (read by independent radiologist) and computed tomography (read by radiologist)
3124684|NCT02949219|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3124685|NCT02949271|Active Comparator|Programmed Intermittent Epidural Bolus|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive either 6 mL every 45 minutes in the PIEB arm (first bolus 30 minutes after epidural initiation). All study participants will be provided with PCEA set to 8mL boluses with a 10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
3124686|NCT02949271|Active Comparator|Continuous Epidural Infusion|Epidural catheters will be placed at the L3/4 or L4/5 interspace with 4 cm of catheter being left in the epidural space. Epidural analgesia will be initiated and maintained with a solution of ropivacaine 0.1% with fentanyl 2 mcg/ml. After the initial epidural loading dose of 20 mL is administered in incremental fashion, patients will receive 8mL/hr of continuous infusion beginning immediately after the loading dose for the maintenance of analgesia in the CEI arm. All study participants will be provided with PCEA set to 8mL boluses with a10-minute lockout period. The maximum amount of PCEA analgesia will be set to a 1-hour maximum of 45mL.
3124687|NCT02949362|Experimental|Standard of Care (SOC) Treatment +/- Teduglutide|TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment
3124688|NCT02949518|Experimental|Enhanced Recovery Pathway for Spine|
3124689|NCT02949518|No Intervention|Usual Care|
3124690|NCT02949674|Experimental|Bupivacaine|It will be used bupivacaine in surgical site prior surgery (25 mg). At least 10 minutes before skin incision.
3124691|NCT02949674|Experimental|Ropivacaine|It will be used ropivacaine in surgical site prior surgery (37.5 mg). At least 10 minutes before skin incision.
3124692|NCT02949674|No Intervention|Control|No application of anesthetic
3124693|NCT02949908||Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)|
3124694|NCT02949921|Experimental|"Grade 4 Hands group"|"Grade 4 Hands group will be subjects with hand grading of grade 4 (very severe loss of fatty tissue, marked visibility of veins and tendons in the dorsal hand). Grade 4 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 4 Hands group can have up to three retreatments over an 18 month period."
3124695|NCT02949921|Experimental|"Grade 2 or 3 Hands group"|"Grade 2 or 3 Hands group will be subjects with hand grading of grade 2 or grade 3 (moderate to severe loss of fatty tissue, mild to moderate visibility of veins and tendons in the dorsal hand). Grade 2 or 3 Hands group subjects will receive Radiesse injectable implant and 2% lidocaine HCL up to 3 cc (2 syringes) per hand per treatment. Subjects in Grade 2 or 3 Hands group can have up to three retreatments over an 18 month period."
3124696|NCT02949973|Experimental|Voclosporin|Voclosporin, oral, 23.7 mg twice daily (BID)
3124697|NCT02950025|Active Comparator|Online non-adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
3124698|NCT02950025|Experimental|Arm B: Online-Adaptive MRI-guided SBRT|"All patients will be initially planned for stereotactic body radiation therapy to a minimum dose of 50Gy in five fractions to the planning target volume (PTV)~Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site~When patients present for their first SBRT treatment session, the treating physician will evaluate their individual anatomy to determine if adaptive planning is indicated. Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day~Quality of life questionnaire baseline, 6 weeks after treatment conclusion, and 6 months after treatment conclusion"
3124699|NCT02950467|Experimental|Group therapy plus psilocybin|Modified brief Supportive-Expressive Group Therapy will be administered as ten twice-weekly sessions. Oral psilocybin will be administered once in a clinical setting.
3124700|NCT02950545|Experimental|Placebo, Spherical, then Toric Lenses|Crossover order 1
3124701|NCT02950545|Experimental|Placebo, Toric, then Spherical Lenses|Crossover order 2
3124702|NCT02950545|Experimental|Spherical, Placebo, then Toric Lenses|Crossover order 3
3124703|NCT02950545|Experimental|Spherical, Toric, then Placebo Lenses|Crossover order 4
3124704|NCT02950545|Experimental|Toric, Placebo, then Spherical Lenses|Crossover order 5
3124705|NCT02950545|Experimental|Toric, Spherical, then Placebo Lenses|Crossover order 6
3124706|NCT02950558|Active Comparator|Ropivacaine|Single injection of ropivacaine immediately prior to surgery
3124707|NCT02950558|Experimental|Ropivacaine plus Nerve Block|Single injection of ropivacaine immediately prior to surgery plus 5 day ambulatory popliteal nerve block.
3124708|NCT02950753|Experimental|Lactated Ringer|Intravenous bolus of Lactated Ringer solution (30ml/kg) via 18ga IV catheter at wide open.
3124709|NCT02950753|Placebo Comparator|Normal Saline|Intravenous bolus of Normal Saline (30ml/kg) via 18ga IV catheter at wide open.
3124710|NCT02950831|Experimental|Activity and sleep quality recording|Patients will receive a wrist worn accelerometer and accelerometry will be used to monitor physical activity and sleep quality during standard BurstDR Spinal Cord Stimulation clinical treatment
3124711|NCT02951052|Experimental|CAB LA + RPV LA every 4 weeks|Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.
3124712|NCT02951052|Active Comparator|Current antiretroviral regimen|Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.
3124713|NCT02951143|Experimental|Single arm|All participants will complete the same experimental events across 6 laboratory sessions.
3124714|NCT02951143|Experimental|0.4 mg/g Concentration|Participants in this arm will experience the 0.4 mg/g Concentration
3124715|NCT02951143|Experimental|1.3 mg/g Concentration|Participants in this arm will experience the 1.3 mg/g Concentration
3124716|NCT02951143|Experimental|2.4 mg/g Concentration|Participants in this arm will experience the 2.4 mg/g Concentration
3124717|NCT02951143|Experimental|5.2 mg/g Concentration|Participants in this arm will experience the 5.2 mg/g Concentration
3124718|NCT02951143|Experimental|15.8 mg/g Concentration|Participants in this arm will experience the 15.8 mg/g Concentration
3124719|NCT02951156|Experimental|Phase 1b Arm A|avelumab/utomilumab/rituximab
3124720|NCT02951156|Experimental|Phase 1b Arm B|avelumab/utomilumab/azacitidine
3124721|NCT02951156|Experimental|Phase 1b Arm C|avelumab/rituximab/bendamustine
3124722|NCT02951156|Experimental|Phase 3 Arm D (selected from Phase 1b)|Selected regimen from Phase 1b component which may be i) avelumab/utomilumab/rituximab OR ii) avelumab/rituximab/azacitidine OR iii) avelumab/rituximab/bendamustine
3124723|NCT02951156|Active Comparator|Phase 3 Arm E|Investigator's Choice of either rituximab/bendamustine or rituximab/gemcitabine/oxaliplatin
3124724|NCT02951182|Placebo Comparator|Part 1: Placebo - Cohort 1A and 1B Combined|Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.
3124725|NCT02951182|Experimental|Part 1 Cohort 1A: Triple Combination (TC)|Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.
3124726|NCT02951182|Experimental|Part 1 Cohort 1B: TC Low Dose|Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.
3124727|NCT02951182|Experimental|Part 1 Cohort 1B: TC High Dose|Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.
3124728|NCT02951182|Active Comparator|Part 2: TEZ/IVA|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
3124729|NCT02951182|Experimental|Part 2: TC-2|Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.
3124730|NCT02951195|Placebo Comparator|Part 1: Placebo|
3124731|NCT02951195|Experimental|Part 1 Cohort 1A: TC|
3124732|NCT02951195|Experimental|Part 1 Cohort 1B: TC|
3124733|NCT02951195|Experimental|Part 1 Cohort 1C: TC|
3124734|NCT02951195|Active Comparator|Part 2 Cohort 2A: TEZ/IVA|
3124735|NCT02951195|Experimental|Part 2 Cohort 2A: TC|
3124736|NCT02951195|Active Comparator|Part 2 Cohort 2B: TEZ/IVA|
3124737|NCT02951195|Experimental|Part 2 Cohort 2B: TC|
3124738|NCT02951273||Study of cerebral blood flow|Patients undergoing oesophageal- or ventricular resection (n=30)
3124739|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 25mg|Glycopyrrolate Inhalation Solution 25 μg via eFlow nebulizer, once daily
3124740|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 75mg|Glycopyrrolate Inhalation Solution 75 μg via eFlow nebulizer, once daily
3124741|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200 μg via eFlow nebulizer, once daily
3124742|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 200mg Jet|Glycopyrrolate Inhalation Solution 200 μg via jet nebulizer, once daily
3124743|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution 500mg|Glycopyrrolate Inhalation Solution 500 μg via eFlow nebulizer, once daily
3124744|NCT02951312|Experimental|Glycopyrrolate Inhalation Solution1000mg|Glycopyrrolate Inhalation Solution 1000 μg via eFlow nebulizer, once daily
3124745|NCT02951312|Placebo Comparator|Placebo 0.5 mL|Placebo 0.5 mL via jet nebulizer, once daily
3124746|NCT02951351|Active Comparator|Standard procedure + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will be randomized to receive 5% povidone-iodine drop to the conjunctival surface followed by conjunctival culture then re-application of 5% povidone-iodine drop to the conjunctival surface. Injection will then proceed.
3124747|NCT02951351|Experimental|Proparacaine + Culture|Patients will undergo the standard injection protocol. A conjunctival culture will then be obtained followed by the application of povidone-iodine to the eyelashes and eyelid margins. Patients will undergo application of another drop of topical anesthetic followed by conjunctival culture. After the culture, this group of patients will have 5% povidone iodine applied to the conjunctival surface. Intravitreal injection will then proceed.
3124748|NCT02951429|Placebo Comparator|Pirfenidone + Placebo|Participants will receive pirfenidone along with placebo matched to sildenafil, orally, three times a day (TID) for 52 weeks.
3124749|NCT02951429|Experimental|Pirfenidone + Sildenafil|Participants will receive pirfenidone along with sildenafil, orally, TID for 52 weeks.
3124750|NCT02951481||Systematic evaluation by an ID expert.|Patients diagnosed with CDI during 2017 in the University Hospital 12 de Octubre will be systematically evaluated by an Infectious Disease expert to ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes. This group of patients will also receive a close follow up during the period of greatest risk of relapse (8 weeks after completion of antibiotic treatment for CDI) in order to reduce as far as possible, the number of relapses.
3124751|NCT02951481||Retrospective historic cohort.|Patients diagnosed with CDI during 2015 in the University Hospital 12 de Octubre in which a systematic intervention was not done.
3124752|NCT02951533|Experimental|Group I: Guselkumab|Participants will receive Guselkumab 100 milligram (mg) administered as 100 milligram per milliliter (mg/mL) solution subcutaneously (SC) by single-use prefilled syringe (PFS) at weeks 0, 4, 12 and 20.
3124753|NCT02951533|Active Comparator|Group II: Fumaric Acid Esters (FAE)|Participants will receive Fumaderm initial/Fumaderm tablets by self administration at week 0. The individual FAE dose representing the optimal efficacy/tolerability ratio needs to be determined for each participant according to local prescription information. To this aim, FAE doses will be slowly increased beginning with increasing doses of Fumderm initial (containing 30 mg dimethylfumarate) over the first 3 weeks. Thereafter, participants will be switched to Fumaderm tablets (containing 120 mg dimethylfumarate) starting with 1 tablet per day. Fumaderm dose may be increased to a maximum of 3*2 tablets per day. The decision to maintain, increase or decrease the FAE dose depends on efficacy, safety and tolerability.
3124754|NCT02951702|No Intervention|Control|"This will be the historical arm that has not received oral vancomycin but match criteria for high risk"
3124755|NCT02951702|Experimental|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician Intervention type: drug, vancomycin 125 mg daily"
3124757|NCT02951780|Experimental|LY3185643|LY3185643 administered subcutaneous (SC)
3124758|NCT02951780|Experimental|rGlucagon|rGlucagon administered subcutaneous (SC)
3124759|NCT02951819|Experimental|Dara-CyBorD|Subjects will receive Daratumumab along with Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) as induction on a 28-day cycle length and Daratumab and Dexamethasone on Day 1 of each cycle for 12 cycles as maintenance therapy.
3124760|NCT02951884|Experimental|Aspiration|Participants assigned to this arm receive aspiration of the joint alone in which a needle will be introduced into the knee joint to withdraw the blood that collects within the knee.
3124761|NCT02951884|Experimental|Aspiration with injection|Participants assigned to this arm receive aspiration of the knee joint and an injection of 20cc bupivacaine 0.5% with 1:200,000 epinephrine
3124762|NCT02951884|No Intervention|Control|Participants assigned to this arm receive no injection or aspiration therapy.
3124763|NCT02951988|Experimental|Rapastinel 450 mg Weekly|Rapastinel 450 milligrams (mg) intravenous (IV) once a week during OLTP followed by rapastinel 450 mg IV once a week during DBTP.
3124764|NCT02951988|Experimental|Rapastinel 450 mg Every 2 Weeks|Rapastinel 450 mg IV once a week during OLTP followed by rapastinel 450 mg IV once every 2 weeks during DBTP.
3124765|NCT02951988|Placebo Comparator|Placebo|Rapastinel 450 mg IV once a week during OLTP followed by placebo-matching rapastinel 450 mg IV once a week during DBTP.
3124766|NCT02952001||4 mg CLS-TA Suprachoriodal Injection|Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
3124767|NCT02952001||Sham procedure|Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
3124768|NCT02952261|Other|CT-guided localization|This group of participants received conventional CT-guided lung nodule localization.
3124769|NCT02952261|Experimental|template-guided localization|Three-dimensional printed template was customized based on participant's computed tomography information. Participants received template-guided lung nodule localization.
3124770|NCT02952313|Other|Latera Implant|All participants have unilateral or bilateral placement of LATERA Nasal Implants.
3124771|NCT02952586|Experimental|Avelumab + SOC Chemoradiation Therapy|"Avelumab 10 mg/kg IV: Day 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; and Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~Intensity Modulated Radiation Therapy (IMRT) 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
3124772|NCT02952586|Placebo Comparator|Placebo + SOC CRT|"Placebo IV matching avelumab: Days 1 of the Lead-in Phase; Days 8, 25, and 39 of the CRT Phase; Q2W for 12 months during the Maintenance Phase~Cisplatin 100 mg/m2 IV: Days 1, 22, and 43 of the CRT Phase~IMRT 70 Gy/35 fractions/7 weeks; 1 fraction per day, 5 fractions/week for 7 weeks during the CRT Phase"
3124773|NCT02952820|Experimental|lemborexant 5 milligrams (mg)|Lemborexant 5 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
3124774|NCT02952820|Experimental|lemborexant 10 mg|Lemborexant 10 mg will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
3124775|NCT02952820|Placebo Comparator|Placebo matched to lemborexant|Lemborexant-matched placebo will be taken orally in tablet form at home each night immediately before the time the participant intends to try to sleep.
3124776|NCT02952872|Experimental|Arm 1|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and no motivational content.
3124777|NCT02952872|Experimental|Arm 2|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, no animated narrator, and motivational content.
3124778|NCT02952872|Experimental|Arm 3|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and no motivational content.
3124779|NCT02952872|Experimental|Arm 4|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, no human voice, the presence of an animated narrator, and motivational content.
3124780|NCT02952872|Experimental|Arm 5|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and no motivational content.
3124781|NCT02952872|Experimental|Arm 6|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, no animated narrator, and the presence of motivational content.
3124782|NCT02952872|Experimental|Arm 7|7. Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice guiding the intervention, an animated narrator guiding the intervention, and no motivational content.
3124783|NCT02952872|Experimental|Arm 8|Participants will complete a brief tablet-based intervention created to include the following features: no common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
3124784|NCT02952872|Experimental|Arm 9|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and no motivational content.
3124785|NCT02952872|Experimental|Arm 10|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, no animated narrator, and the presence of motivational content.
3124786|NCT02952872|Experimental|Arm 11|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and no motivational content.
3124787|NCT02952872|Experimental|Arm 12|Participants will complete a brief tablet-based intervention created to include the following features: common factors, no human voice, an animated narrator to guide the intervention, and the presence of motivational content.
3124788|NCT02952872|Experimental|Arm 13|13. Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and no motivational content.
3124789|NCT02952872|Experimental|Arm 14|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, no animated narrator, and the presence of motivational content.
3124790|NCT02952872|Experimental|Arm 15|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and no motivational content.
3124791|NCT02952872|Experimental|Arm 16|Participants will complete a brief tablet-based intervention created to include the following features: common factors, a human voice to guide the intervention, an animated narrator to guide the intervention, and the presence of motivational content.
3124792|NCT02952898|Experimental|Test Drug|GDC 695 gel applied topically as directed.
3124793|NCT02952898|Active Comparator|Reference Drug|Diclofenac sodium gel, 3% applied topically as directed.
3124794|NCT02952898|Placebo Comparator|Placebo|Vehicle gel applied topically as directed.
3124795|NCT02953262|Experimental|Encouragement Arm 1|Participants in this encouragement condition will receive a mailed brochure with basic My HealtheVet content and a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
3124796|NCT02953262|Experimental|Encouragement Arm 2|Participants in this encouragement condition will receive the same brochure and training guide as Arm 1 but will also be offered optional attendance at one of several group training sessions.
3124797|NCT02953262|Experimental|Encouragement Arm 3|Participants in this encouragement condition will receive the same as in Arm 2 (brochure, training guide, and group training offer) but will also be offered a one-on-one My HealtheVet training session.
3469451|NCT03886805|Active Comparator|Dual-task with variable-priority instructions|Sixty-minute training sessions, 2 times a week for 24 weeks (48 sessions). From the 1st to 24th week, the participants were trained under variable-priority instructions, in which they were asked to spend half the session focused on balance (motor task) and half the session focused on cognitive task performance. The motor tasks (gait and postural balance) of this protocol were performed in a circuit composed of hula hoops, ropes (in a straight line and zigzag), agility ladder, traffic cones, steps, cardboard box, and other obstacles arranged on the floor (stable surface) or on mattresses (unstable surface), depending on the aiming of each training stage. The cognitive tasks included activities such as saying fruits, animals, cities, and/or person names started with a specific letter, solving mathematical accounts, singing songs, reciting verses, rescue working memory, among other cognitive tasks.
3469452|NCT03886753||Ease|Subjects using Ease as standard treatment. Registry and PK sampling
3469453|NCT03886753||Dream|Subjects using Dream as standard treatment. Registry and PK sampling
3469454|NCT03886753||Soothe|Subjects using Soothe as standard treatment. Registry and PK sampling
3469455|NCT03886753||Shine|Those subjects using Shine as standard treatment. Registry and PK sampling
3469456|NCT03886597|Experimental|60 Arbequina Table Olives|Pharmacokinetics Study
3124798|NCT02953262|Other|Brochure Only Comparison Arm|The Comparison condition will only receive a mailed brochure with basic My HealtheVet content during the trial. (The training guide will be mailed to them after completion of the interview at the end.)
3469457|NCT03886597|Experimental|120 Arbequina Table Olives|Pharmacokinetics Study
3469458|NCT03886597|Experimental|60 Table Olives|Table Olives Nutritional Intervention
3469459|NCT03886597|No Intervention|Control|Control of Table Olives Nutritional Intervention
3469460|NCT03886480|Experimental|SaeboVR|Use of the SaeboVR for task specific upper extremity training
3469461|NCT03886623|Experimental|4-day systematic oral hygiene|The intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery-operated Oral-B Pro-Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro-Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
3469462|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol-Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
3469463|NCT03886532||Medical Marijuana|Those subject taking only medical marijuana as standard of care. Will collect registry data and collect blood samples.
3124799|NCT02953314|Experimental|Part A|"Participants weighing <25 kg received TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days.~Participants weighing ≥25 kg received TEZ 50 mg once daily/IVA 150 mg q12h orally for 14 days."
3124800|NCT02953314|Experimental|Part B|"Participants weighing <40 kg received TEZ 50 mg/IVA 75 mg as fixed dose combination orally once daily in the morning and IVA 75 mg orally once daily in the evening for 24 weeks.~Participants weighing ≥40 kg received TEZ 100 mg/IVA 150 mg as fixed dose combination orally once daily in the morning and IVA 150 mg orally once daily in the evening for 24 weeks."
3124801|NCT02953418|Experimental|Radiofrequency ablation|Step-wise endoscopic RFA with the Barrx™ Flex Radiofrequency Ablation System using will be performed in 3 month intervals up to 12 months.
3124802|NCT02953548|Experimental|GWP42003-P|Administered orally, titrating to a target dose of 40 mg/kg/day. Participants continue at the target dose, or the highest tolerated dose up to the target dose, for the remainder of the 2-week treatment period.
3124803|NCT02953561|Experimental|Treatment (azacitidine, avelumab)|Patients receive azacitidine SC or IV over 10-40 minutes on days 1-7 or on days 1-5 and 8-9. Patients also receive avelumab IV over 60 minutes on days 1 and 14 for 4 courses (or until complete response) and on day 1 for subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3124804|NCT02953639|Placebo Comparator|Placebo|Participants received matching Placebo to Basmisanil orally twice daily for 24 weeks.
3124805|NCT02953639|Experimental|Basmisanil 80mg BID|Participants received Basmisanil 80 mg orally twice daily (BID) for 24 weeks.
3124806|NCT02953639|Experimental|Basmisanil 240mg BID|Participants received Basmisanil 240 mg orally twice daily (BID) for 24 weeks.
3124807|NCT02953678|Experimental|Ruxolitinib in combination with corticosteroids|Participants began oral administration of ruxolitinib at 5 mg twice daily (BID); if stable after the first 3 days of treatment, the dose could be increased to 10 mg BID.
3124808|NCT02953782|Experimental|Phase 1b Cohort 1: Magrolimab 10 mg/kg + Cetuximab 200 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by intravenous (IV) infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 300 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 200 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented progressive disease (PD).
3124809|NCT02953782|Experimental|Phase 1b Cohort 2: Magrolimab 10 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 10 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124810|NCT02953782|Experimental|Phase 1b Cohort 3: Magrolimab 20 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 20 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124811|NCT02953782|Experimental|Phase 1b Cohort 4: Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1 and thereafter, weekly maintenance dose for both magrolimab and cetuximab, will start on Day 1. Each cycle will consist of 4 weeks (28 days). Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both were given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124812|NCT02953782|Experimental|Phase 1b Cohort 5: Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with solid tumor will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1 with weekly dose in Cycle 2 and bi-weekly dose in Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3469464|NCT03886532||CBD only products|Those subjects taking only CBD products as standard of care. Will collect registry data and collect blood samples.
3469465|NCT03886389|Experimental|Carbohydrate/intervention group|Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
3124813|NCT02953782|Experimental|Phase 2 Cohort 1 (KRASwt): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced colorectal cancer (CRC) who are KRAS wild type (KRASwt) and are refractory to anti-EGFRmAb therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Cetuximab will be administered 1 hour prior to magrolimab infusion on days when both are given. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124814|NCT02953782|Experimental|Phase 2 Cohort 2 (KRASm): Magrolimab 30 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRAS mutation (KRASm) who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approximately 3 hours infusion) on Day 1 followed by a maintenance dose of magrolimab 30 mg/kg of body weight by IV infusion (approximately 2 hours infusion) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 2 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124815|NCT02953782|Experimental|Phase 2 Cohort 3 (KRASm): Magrolimab 45 mg/kg + Cetuximab 250 mg/m^2|Participants with advanced CRC with KRASm who have progressed or are not candidates for oxaliplatin or irinotecan-based therapy will receive a priming dose of magrolimab 1 mg/kg of body weight by IV infusion (approx. 3 hours) on Day 1 followed by a maintenance dose of magrolimab 45 mg/kg of body weight by IV infusion (approx. 2 hours) weekly starting on Day 8 followed by Days 15 and 22 in combination with cetuximab at a loading dose of 400 mg/m^2 infused over 120-minutes on Day 8 followed by a weekly maintenance dose of 250 mg/m^2 infusions given over 60 minutes on Days 15 and 22, in Cycle 1. Participants will also receive a loading dose of magrolimab 45 mg/kg of body weight on Day 11 of Cycle 1. After Cycle 1, maintenance dose for both magrolimab and cetuximab will start on Day 1; Days 8 and 22 are removed from Cycle 3 onwards for magrolimab. Each cycle will consist of 4 weeks. Treatment will be administered until unacceptable toxicity, voluntary withdrawal, or documented PD.
3124816|NCT02953821|Experimental|Acthar Gel|Participants receive Acthar Gel every other day for 4 weeks, and then twice per week for 20 weeks
3124817|NCT02953821|Placebo Comparator|Placebo Gel|Participants receive Placebo Gel every other day for 4 weeks, and then twice per week for 20 weeks
3124818|NCT02953860|Experimental|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given, in conjunction with Fulvestrant, PO daily.
3124819|NCT02953873|Other|Conversion Arm|Tacrolimus Extended Release Capsule (goal 5 - 12ng/mL) + Mycophenolate Mofetil ≥500mg twice a day OR Mycophenolate Sodium ≥360mg twice a day+ prednisone ≥ 5mg Daily
3124820|NCT02953886|Experimental|Silver Diamine Fluoride (SDF)|Application of Silver Diamine Fluoride (SDF) to root or cervical carious lesions (cavities). Collection of plaque pre- and one month post-SDF application.
3124821|NCT02953938|Active Comparator|mono therapy|ranibizumab alone
3124822|NCT02953938|Experimental|combination therapy|ranibizumab with Grid&Direct short pulse laser photocoagulation
3124823|NCT02954172|Experimental|Bevacizumab in Combination With Paclitaxel/Carboplatin|Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
3124824|NCT02954172|Active Comparator|IBI305 in Combination with Paclitaxel/Carboplatin|Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
3469466|NCT03886389|No Intervention|Control group|Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.
3469467|NCT03886636|Experimental|Neuroscience pain education group|in Group 1, participants received Neuroscience pain education, manual therapy and a home exercise program.
3469468|NCT03886636|Experimental|Manual therapy group|in Group 2, participants received manual therapy and a home exercise program.
3469469|NCT03886636|Active Comparator|Control group|in Group 3, participants received home exercise program only.
3124825|NCT02954198|Active Comparator|Tacrolimus + MMF|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Tacrolimus Daily (5 -12ng/mL) + mycophenolate mofetil 1g BID + prednisone x 6 months
3124826|NCT02954198|Active Comparator|Envarsus + Everolimus|Tacrolimus IR BID (5-12ng/mL) + mycophenolate mofetil 1g BID + prednisone x at least 3 months, then converted to Envarsus Daily (2-5ng/mL) + Everolimus Daily (3-8ng/mL) + prednisone x 6 months
3124827|NCT02954354|Experimental|Adults: Baloxavir Marboxil|Participants aged 20 to 64 years will receive two or four 20 mg baloxavir marboxil tablets orally on Day 1 and one oseltamivir placebo capsule orally twice a day (BID) on Days 1 to 5.
3124828|NCT02954354|Active Comparator|Adults: Oseltamivir|Participants aged 20 to 64 years will receive 75 mg oseltamivir twice a day on Days 1 to 5 and two or four baloxavir marboxil placebo tablets on Day 1.
3124829|NCT02954354|Placebo Comparator|Adults: Placebo|Participants aged 20 to 64 years will receive two or four baloxavir marboxil placebo tablets on Day 1 and one oseltamivir placebo capsule orally twice a day on Days 1 to 5.
3124830|NCT02954354|Experimental|Adolescents: Baloxavir Marboxil|Participants aged 12 to 19 years will receive two or four baloxavir marboxil 20 mg tablets on Day 1.
3124831|NCT02954354|Placebo Comparator|Adolescents: Placebo|Participants aged 12 to 19 years will receive two or four baloxavir marboxil placebo tablets on Day 1.
3124832|NCT02954458|Experimental|Standard of care (SOC) treatment +/- teduglutide (TED)|Participants will receive 0.05 milligram per kilogram (mg/kg) of teduglutide subcutaneous (SC) injections once daily into 1 of the 4 quadrants of the abdomen or into either the thigh or arm as needed in addition to SOC treatment.
3124833|NCT02954575|Experimental|All patients|All patients will receive Wilate for prophylactic treatment
3124834|NCT02954601|Active Comparator|Placebo|Placebo (fish oil)
3124835|NCT02954601|Active Comparator|Dose1|Dose 1 ORMD-0801 (qd)
3124836|NCT02954601|Active Comparator|Dose2|Dose 2 ORMD-0801 (bid)
3124837|NCT02954601|Active Comparator|Dose 3|Dose 3 ORMD-0801 (tid)
3124838|NCT02954653|Experimental|Dose Escalation|Single agent PF-06747143 dose escalation
3124839|NCT02954653|Active Comparator|Cohort 1|PF-06747143 with standard dose cytarabine and daunorubicin.
3124840|NCT02954653|Active Comparator|Cohort 2|PF-06747143 in combination with Azacitidine or Decitabine.
3124841|NCT02954653|Experimental|Cohort 3|PF-06747143 dose expansion as a single agent.
3124842|NCT02954848|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 placebo-matching tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
3124843|NCT02954848|Experimental|TAK-438 10 mg|TAK-438 placebo-matching tablets, orally, once daily after breakfast for 1 week in run-in period followed by TAK-438 10 mg tablets, orally, once daily after breakfast for up to 4 weeks in treatment period.
3124844|NCT02954887|Experimental|GWP42003-P|"Administered orally, up to the target dose recommended by the data safety monitoring committee.~Participants continue at the target dose, or the highest tolerated dose up to the target dose, for a total of 12 months' treatment."
3124845|NCT02955069|Experimental|PDR001|Subjects with advanced or metastatic, well-differentiated, NET of pancreatic, GI, or thoracic origin or poorly-differentiated GEP-NEC, that have progressed on prior treatment were treated with 400mg PDR001 administered via intravenous infusion once every 4 weeks.
3124846|NCT02955147|Experimental|Ustekinumab plus prednisone|"Ustekinumab: 90 mg of ustekinumab will be administered subcutaneously at baseline, week 4, week 12, week 20, week 28, week 36 and week 44.~Prednisone: All patients will receive a prednisone course tapered according to predefined schedules starting at either 60 mg, 40 mg or 20 mg. The initial dose of prednisone will be chosen by the investigators according to disease severity and comorbid medical conditions. The duration of the prednisone taper will be 6 months in all cases."
3469470|NCT03886519|Active Comparator|BRAP (Bevel/rotate/advance procedure)|The BRAP procedure is a full-thickness beveled full-thickness incision
3469471|NCT03886519|Active Comparator|Trabut 3 mm|The Trabut procedure is a partial-thickness incision through the tarsal conjunctiva and tarsus parallel to the eyelid margin and 3 mm above the lash line.
3469472|NCT03886428|Experimental|100% Portion Size|Test meal with portion size 100% of baseline
3124847|NCT02955186|Experimental|125 mg saracatinib|Participants will take 125 mg of saracatinib daily for 8 days.
3124848|NCT02955186|Placebo Comparator|Placebo|Participants will take placebo daily for 8 days.
3124849|NCT02955212|Placebo Comparator|Placebo / Upadacitinib 15 mg|Participants randomized to receive placebo once daily for 12 weeks in Period 1 followed by upadacitinib 15 mg once daily for up to 52 weeks in Period 2.
3124850|NCT02955212|Experimental|Upadacitinib 15 mg|Participants randomized to receive upadacitinib 15 mg once daily for 12 weeks in Period 1 and up to an additional 52 weeks in Period 2.
3124851|NCT02955329|Experimental|Tobacco Arm|Participants will vape tobacco leaves with nicotine out of the PAX device.
3124852|NCT02955329|Experimental|Cannabis Arm|Participants will vape marijuana leaves with THC (Tetrahydrocannabinol) out of the PAX device.
3469473|NCT03886428|Experimental|125% Portion Size|Test meal with portion size 125% of baseline
3469474|NCT03886428|Experimental|150% Portion Size|Test meal with portion size 150% of baseline
3469475|NCT03886428|Experimental|175% Portion Size|Test meal with portion size 175% of baseline
3469476|NCT03886584|Experimental|Patients with with neuropsychiatric conditions|"In this arm, five groups :~Patients with DFT, diagnosed according Racovsky criteria~Patients with Lewi Body dementia, diagnosed according McKeith criteria~Patients with pre-demential Alzheimer, diagnosed according Dubois criteria~Patients with Alzheimer, diagnosed according MMSE~Patients with bipolar disorder, diagnosed according DSM 5"
3124853|NCT02955329|Experimental|Combined Cannabis and Tobacco Arm|Participants will vape flavorless 6% nicotine e-liquid, followed by THC (Tetrahydrocannabinol) out of the PAX device.
3124854|NCT02955797|Experimental|Group 1(Meningococcal Vaccine-Naive):MenACYW Conjugate Vaccine|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
3124855|NCT02955797|Experimental|Group 2 (Meningococcal Vaccine-Naive): Nimenrix®|Healthy, meningococcal vaccine naive toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
3469477|NCT03886584|Active Comparator|Healthy subjects|Healthy controls appaired in age, sex and educational level
3124856|NCT02955797|Experimental|Group 3 (MenC-Primed): MenACYW Conjugate Vaccine|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
3124857|NCT02955797|Experimental|Group 4 (MenC-Primed): Nimenrix®|Healthy, meningococcal C vaccine primed toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
3124858|NCT02956044|Active Comparator|Group 1: Bexagliflozin alone|
3124859|NCT02956044|Active Comparator|Group 1: Metformin alone|
3124860|NCT02956044|Active Comparator|Group 1: Bexagliflozin + Metformin|
3124861|NCT02956044|Active Comparator|Group 2: Bexagliflozin alone|
3124862|NCT02956044|Active Comparator|Group 2: Glimepiride alone|
3124863|NCT02956044|Active Comparator|Group 2: Bexagliflozin + Glimepiride|
3124864|NCT02956044|Active Comparator|Group 3: Bexagliflozin alone|
3124865|NCT02956044|Active Comparator|Group 3: Sitagliptin alone|
3124866|NCT02956044|Active Comparator|Group 3: Bexagliflozin + Sitagliptin|
3124867|NCT02956057|Active Comparator|PEG1D|Polyethylene glycols single dose a day before colonoscopy
3124868|NCT02956057|Active Comparator|PEG2D|Polyethylene glycols split dose
3124869|NCT02956057|Active Comparator|SPMC1D|Natrium picosulfate/ Magnesium citrate single dose day before colonoscopy
3124870|NCT02956057|Active Comparator|SPMC2D|Natrium picosulfate/ Magnesium citrate split dose
3124871|NCT02956057|Active Comparator|PEGA1D|Polyethylene glycol / Ascorbic acid single dose day before colonoscopy
3124872|NCT02956057|Active Comparator|PEGA2D|Polyethylene glycol / Ascorbic acid split dose
3124873|NCT02956070|Experimental|Experimental|35 patients in this group will undergo the whitening procedure using the Dexamethasone acetate intervention.
3124874|NCT02956070|Placebo Comparator|Placebo|35 patients in this group will undergo the whitening procedure using the Potassium Nitrate intervention
3124875|NCT02956122|Experimental|Study Part 1 - All Participants - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
3469478|NCT03886376|Experimental|Deep Massage|The deep massage was performed three times during a training week, after a physical training and before the swimming training
3469479|NCT03886376|Active Comparator|Superficial Massage|The superficial massage was performed three times during a training week, after a physical training and before the swimming training
3469480|NCT03886376|No Intervention|Control|The control group kept their normal routine of training. Immediately after the physical training the athletes were instructed to wait for 12 minutes (passive recovery) until the beginning of the swim training.
3469481|NCT03886402|Experimental|Treatment|Each subject will receive a single injection of autologous adipose-derived stromal vascular fraction (SVF) and will be monitored for 6 months
3469482|NCT03886441|Experimental|Prevention group|Participants inhaled beclomethasone propionate aerosol daily during chest radical radiotherapy (total dose 60GY).
3469483|NCT03886441|No Intervention|Traditional therapy group|Participants were not given daily inhalation of beclomethasone propionate when undergoing radical chest radiotherapy (total dose 60GY).
3469484|NCT03886467|Active Comparator|Nutrition Education|Households will participate in community-based nutrition education program specifically targeting child nutrition and milk consumption, in addition to general community development activities
3469485|NCT03886467|No Intervention|Control|community development activities only.
3469486|NCT03886610||Healthy controls|Individuals without spinal cord injury
3469487|NCT03886610||Subacute SCI patients|Subacute patients with spinal cord injury (duration >2 weeks)
3124876|NCT02956122|Experimental|Study Part 2 - GLASSIA|Participants to receive GLASSIA (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
3469488|NCT03886610||Chronic SCI patients|Patients with chronic spinal cord injury (duration ≥24 months)
3469489|NCT03886688|Experimental|single ascending|Drug or placebo, oral, fast, single dose ascending
3469490|NCT03886688|Experimental|multiple ascending|Drug or placebo, oral, fast, multiple dose ascending
3469491|NCT03886688|Experimental|Food Effect|Drug or placebo, oral, fed or fast, single dose
3124877|NCT02956122|Placebo Comparator|Study Part 2 - Albumin (Control)|Participants to receive control (intravenously) and methylprednisolone or equivalent steroid (either IV or oral per investigator discretion)
3124878|NCT02956278|Placebo Comparator|BCRP Q141K CC|Participants that are homozygous reference for BCRP Q141K receive at least one 300 mg dose of allopurinol followed by blood/urine collection for up to 72 hours post-dose.
3124879|NCT02956278|Experimental|BCRP Q141K CA|Participants that are heterozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol, with blood/urine collections up to 72 hours post-dose.
3124880|NCT02956278|Experimental|BCRP Q141K AA|Participants homozygous for the BCRP Q141K allele receive at least one 300 mg dose of allopurinol with blood/urine collection for up to 72 hours post-dose.
3469492|NCT03886558|Experimental|Institution Group (n=14)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
3124883|NCT02956460|Active Comparator|fanfilcon A|Participants are randomized to wear fanfilcon A for two weeks during the cross over study.
3124884|NCT02956460|Active Comparator|senofilcon A|Participants are randomized to wear senofilcon A for two weeks during the cross over study.
3124885|NCT02956486|Experimental|Core Study: Elenbecestat 50 mg|Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.
3124886|NCT02956486|Placebo Comparator|Core Study: Placebo|Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.
3124887|NCT02956486|Experimental|Open-label Extension Phase: Elenbecestat 50 mg|Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.
3124888|NCT02956616|Experimental|Enhanced Recovery|Postoperative recovery will follow the usual service protocols as if the patient were not in the study with the exception of components of the enhanced recovery protocol (detailed previously), which will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing. Additionally, participants in this group will receive intravenous ketorolac for pain control and Xylitol chewing gum for improvement of postoperative gastrointestinal function.
3124889|NCT02956616|Active Comparator|Routine Perioperative Care|Postoperative recovery will follow the usual service protocols at our institution. Participants in this group may receive intravenous ketorolac (toradol) for pain control
3124890|NCT02956629|Experimental|HCV GT1|Male and female participants with HCV GT1a or GT1b infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124891|NCT02956629|Experimental|HCV GT2|Male and female participants with HCV GT2 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124892|NCT02956629|Experimental|HCV GT3|Male and female participants with HCV GT3 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124893|NCT02956629|Experimental|HCV GT4|Male and female participants with HCV GT4 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124894|NCT02956629|Experimental|HCV GT5|Male and female participants with HCV GT5 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124895|NCT02956629|Experimental|HCV GT6|Male and female participants with HCV GT6 infection take uprifosbuvir 450 mg + RZR 180 mg for 12 weeks.
3124896|NCT02956746|Experimental|Imovax, SYN023|Subjects will receive SYN023 and 5 doses of Imovax rabies vaccine
3124897|NCT02956746|Active Comparator|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
3124898|NCT02956746|Experimental|RabAvert, SYN023|Subjects will receive SYN023 and 5 doses of RabAvert rabies vaccine
3124899|NCT02956746|Active Comparator|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
3124900|NCT02956837|Experimental|GSK3003891A vaccine formulation 1 Group|Subjects in this group received a single 30 micrograms (µg) dose injection of the investigational GSK3003891A vaccine at Day 0.
3124901|NCT02956837|Experimental|GSK3003891A vaccine formulation 2 Group|Subjects in this group received a single 60µg dose injection of the investigational GSK3003891A vaccine at Day 0.
3124902|NCT02956837|Experimental|GSK3003891A vaccine formulation 3 Group|Subjects in this group received a single 120µg dose injection of the investigational GSK3003891A vaccine at Day 0.
3124903|NCT02956837|Placebo Comparator|Control Group|Subjects in this group received a single placebo injection at Day 0.
3124904|NCT02956967||Patients receiving Nivestim|
3124905|NCT02957123|Experimental|Intranasal auto-M2-BFs|"Intranasally-Administered Bioactive Factors, Produced by Autologous M2 Macrophage (auto-M2-BFs). M2 macrophages were generated in vitro from peripheral blood of patients during 7 days.Cell-free culture medium, containing auto-M2-BFs, was collected and aliquots of 2 mL/vial were cryopreserved.~30 patients with organic brain syndrome will receive auto-M2-BFs with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days."
3124906|NCT02957136|Experimental|Rapid respiratory pathogen test arm|ED patients in this arm will receive a rapid respiratory pathogen nucleic acid amplification test plus usual care.
3124907|NCT02957136|No Intervention|Usual care control arm|ED patients in this arm will receive clinician-directed standard of care, which may include but is not limited to no testing, point-of-care influenza testing, or delayed testing for respiratory pathogens at off-site laboratory.
3469493|NCT03886558|Experimental|Community Group (n=16)|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months. The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
3469494|NCT03886545||caregivers with shoulder pain|
3124908|NCT02957305|Active Comparator|Misoprostol 400 µg|Participants received misoprostol 400 µg: 2 tablets of misoprostol (200µg each) introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration (MVA) procedure.
3124909|NCT02957305|Experimental|Misoprostol 200 µg|Participants received misoprostol 200 µg: 1 tablet of misoprostol introduced into the vagina, at least 6 hours before the Manual Vacuum Aspiration procedure.
3469495|NCT03886545||Healthy subjects|
3469496|NCT03886675|Experimental|carbon-dioxide|Flushing of stent-grafts in TEVAR with carbon-dioxide
3469497|NCT03886675|Active Comparator|Saline|Flushing of stent-grafts with saline
3469498|NCT03886740|Experimental|Tympanostomy with tubes|Tympanostomy with pressure equalization tube placement with Ventilation (Tympanostomy) Tubes
3124910|NCT02957331|Experimental|Propranolol arm|One half of qualifying and consenting subjects will be randomized to receive propranolol. This group will receive study drug 3 times daily (every 8 hours) starting at 20 mg. The dosage may be increased by up to 60 mg/day divided over three daily doses (or an additional 20 mg/dose) as necessary until the heart rate is less than 100. Study drug will be held for hypotension (systolic <100) or bradycardia (heart rate <60 beats per minute). The maximum daily dose for the treatment of hypertension of 640 mg will not be exceeded in this study.
3124911|NCT02957331|No Intervention|Non propranolol arm|Non beta blockade arm will receive standard of care treatment and will not receive beta blockade. If a subject randomized to no Inderal develops hypertension and increased heart rate, he/she will be treated according to standard of care by the trauma team caring for the patient.
3124912|NCT02957357||National Cancer Data Base|Patients within the National Cancer Database with newly diagnosed prostate cancer between 2004 and 2010. Participating institutions each provided a random of sample of 10 patients to be included in the final cohort.
3124913|NCT02957357||NC ProCESS|The North Carolina Prostate cancer Comparative Effectiveness & Survivorship Study (NC ProCESS) is a prospective population-based cohort of >1,000 patients with newly diagnosed prostate cancer, enrolled from January 2011 through June 2013.
3124914|NCT02957682|Experimental|Group 1|Praluent Regimen - Administration through subcutaneous injection
3124915|NCT02957682|Experimental|Group 2|Placebo matching Praluent - Administration through subcutaneous injection
3124916|NCT02957747|Experimental|Safety and Health Experiences Program|Participants in the SHE arm of the study will receive a web-based intervention utilizing motivational interviewing and education.
3124917|NCT02957747|No Intervention|Control|Participants randomized to this arm will receive referrals to VA and community resources
3124918|NCT02957942|Experimental|Spasmodic Dysphonia|1Hz repetitive transcranial magnetic stimulation (rTMS)
3124919|NCT02957942|Active Comparator|Healthy control|Healthy adults 1Hz repetitive transcranial magnetic stimulation (rTMS)
3124920|NCT02958267|Experimental|BMAC injection and PRP injection|Injection of bone marrow aspirate concentrate (BMAC) withdrawn from a bone near the hip into the knee joint (intra-articular) immediately followed by an injection of platelet-rich plasma (PRP) into the knee joint.
3124921|NCT02958267|Active Comparator|Gel-One® hyaluronate injection|Gel-One® is an hyaluronate gel used in the treatment of knee osteoarthritis by injection into the knee joint (intra-articular).
3124922|NCT02958345|Active Comparator|Zostavax|Subjects will receive 0.65 mL of Zostavax subcutaneously in the deltoid region of the upper arm.
3124923|NCT02958345|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an injection of 0.65 mL of sterile normal saline subcutaneously in the deltoid region of the upper arm.
3124924|NCT02958527||venlafaxine|Patients with no experience of using time Effexor(venlafaxine) who will be administered time Effexor(venlafaxine)for the first
3124925|NCT02958553|Other|emPOWER Ankle (powered prosthesis)|The subject's own passive prosthesis will be used as a baseline and crossed over after the emPOWER has been worn 3-4 months. Then the passive foot will be crossed back to the emPOWER for a final series of tests.
3124926|NCT02958787|Experimental|Intervention|Vessel Sparing Radiation Therapy using MRI based treatment planning to limit dose to critical erectile structures
3124927|NCT02958826||No Smoke Evacuation|No Smoke Evacuation Group, anonymous questionnaire administered
3124928|NCT02958826||Smoke Evacuation|Smoke Evacuation Group, anonymous questionnaire administered
3124929|NCT02958956||Ever User of Pioglitazone|Ever user of pioglitazone was defined as having filled 2 prescriptions for the drug within a 6-month period.
3124930|NCT02958956||Never User of Pioglitazone|Never user of pioglitazone, which included participants receiving no diabetes medications, with fewer than 2 pioglitazone prescription fills in a 6-month period, and with use of diabetes medications other than pioglitazone.
3469499|NCT03886740|Experimental|Eustachian tube (ET) dilation|Eustachian tube (ET) dilation with ACCLARENT AERA® Eustachian Tube Balloon Dilation System
3469500|NCT03886727|Active Comparator|Rubber Dam|Isolation of single tooth using rubber dam
3124931|NCT02958969|Experimental|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
3124932|NCT02958982|Experimental|RP3128|RP3128, A CRAC channel modulator
3469501|NCT03886727|Active Comparator|Cotton Roll|Isolation of quadrant using cotton rolls
3469502|NCT03886662|Experimental|LB-100 for Intravenous administration|Phase Ib: Escalating doses of LB-100 administered. Phase 2: Safe dose of LB-100 from phase Ib administered.
3469503|NCT03886363|Experimental|MBSR|MBSR according to international standards (2.5 hours group session once a week in 8 weeks; a silence retreat day; and 45-60 minutes homework six days a week). Content in accordance with MBSR curriculum.
3469504|NCT03886363|No Intervention|Wait-list control|Usual practice
3469505|NCT03886350||Patients with cystic fibrosis|Patients with CF whom follow-up is undertaken at University Hospital of Tours, France
3469506|NCT03886337|No Intervention|Control|The control arm will be surgical care according to usual practice with usual ambient lighting
3469507|NCT03886337|Experimental|Treatment Arm|The treatment arm will include surgical care according to usual practice with germicidal ambient lighting
3469508|NCT03886324|Experimental|DCB Treatment|Stricture patients treated by DCB
3469509|NCT03886311|Experimental|Talimogene laherparepvec, Nivolumab and Trabectedin|"This is an open label phase 2 study using known doses of TALIMOGENE LAHERPAREPVEC injected intratumorally, and NIVOLUMAB AND TRABECTEDIN given intravenously.~A total of 40 previously untreated and treated patients will receive TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks, NIVOLUMAB 240 mg IV over 30 min q 2 weeks and TALIMOGENE LAHERPAREPVEC intratumorally q 2 weeks according to tumor size (see Schematic of Study Design and Imlygic product information; www.accessdata.fda.gov). Patients in this study may continue treatment until significant disease progression (see below for criteria for discontinuation of therapy) or unacceptable toxicity occurs up to one year of therapy."
3469510|NCT03886012|Experimental|Otoband efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to the effective power level. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
3124933|NCT02958982|Placebo Comparator|Placebo|Placebo
3124934|NCT02958995||Full KPNC Cohort|Participants who were members of the KPNC registry (with or without diabetes) were followed up to 15 years (1997-2011) in this epidemiological study.
3124935|NCT02958995||Survey Responders|A subset of KPNC members who completed the Kaiser Diabetes Registry Survey in 1994-1996 and among a random sample of KPNC members who completed the Member Health Survey (MHS), in 1996, 1999, 2002, or 2005 were followed up to 15 years (1997-2011) in this epidemiological study.
3124936|NCT02959138|Experimental|Moderate Renal Impairment (Cohort 1)|Participants with moderate renal impairment and matched healthy controls will receive a single dose of lanraplenib
3124937|NCT02959138|Experimental|Severe Renal Impairment (Adaptive Cohort 2)|Participants with severe renal impairment and matched healthy controls will receive a single dose of lanraplenib
3124938|NCT02959138|Experimental|Mild Renal Impairment (Adaptive Cohort 3)|Participants with mild renal impairment and matched healthy controls will receive a single dose of lanraplenib
3124939|NCT02959177|Experimental|120 milligrams (mg) Galcanezumab|120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.
3124940|NCT02959177|Experimental|240 mg Galcanezumab|120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.
3124941|NCT02959177|Placebo Comparator|Placebo|Placebo administered SC once a month for 6 months.
3124942|NCT02959190|Experimental|120mg/120mg Galcanezumab - Episodic Migraine (EM)|240 milligram (loading dose) of Galcanezumab at first dosing visit followed by 120 milligram (mg) once a month for a year by subcutaneous (SC) injection. EM participants (pts) rolled over from CGAN (NCT02959177) 120 mg Galcanezumab.
3124943|NCT02959190|Experimental|240mg/240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) 240 mg Galcanezumab.
3124944|NCT02959190|Experimental|Placebo/ 120mg Galcanezumab - EM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. EM participants rolled over from CGAN (NCT02959177) placebo.
3124945|NCT02959190|Experimental|Placebo/ 240mg Galcanezumab - EM|240 mg Galcanezumab given SC once a month for a year. EM participants rolled over from CGAN (NCT02959177) Placebo.
3124946|NCT02959190|Experimental|120mg Galcanezumab - CM|240 mg (loading dose) of Galcanezumab at first dosing visit followed by 120 mg once a month for a year by SC injection. Participants with CM were enrolled.
3124947|NCT02959190|Experimental|240mg Galcanezumab - CM|240 mg Galcanezumab given SC once a month for a year. Participants with CM were enrolled.
3124948|NCT02959307|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and, the light energy may activate under-stimulated brain regions.
3124949|NCT02959307|Sham Comparator|Sham Transcranial Light Therapy|For the sham group, The transcranial light therapy device uses nonpenetrating light emitting diode light energy. The sham controls for which participants improve from the actual transcranial light therapy treatment and which participants improve during the study for reasons other than the therapy
3124950|NCT02959437|Experimental|Treatment Group A: Azacitidine + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
3124951|NCT02959437|Experimental|Treatment Group B: INCB057643 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
3469511|NCT03886012|Sham Comparator|Otoband sham efficacy on vertigo|"Participants will be given the transcranial vibrating system (Otoband) to be used during migrane associated vertigo (MAV) attacks. Participants will be able to use the Otoband up to 4 times, 30 minutes each time, per day. The Otoband will be set to an ineffective power level, serving as a placebo. Participants will fill out questionnaires about 4 symptoms associated to MAV: before, during (2 and 20 minutes after turning on the Otoband) and after the session (20 minutes after the Otoband was or has stopped). The conditions evaluated will be: dizziness, nausea, headache and brain confusion.~Participants will complete questionnaires either online using secure HIPPA-compliant webforms, or using pre-printed questionnaires, as they prefer."
3469512|NCT03886116|Active Comparator|Exercise|"Patient randomized are required to squeeze a soft ball 10 times for a set. They are required to perform 3 sets of 10 squeezes each at a 1 Minute interval.~3 sets of exercises to be performed twice in the Morning and Evening, for a total of 6 weeks."
3469513|NCT03886116|No Intervention|No Exercise|Patient is not required to do any exercise.
3469514|NCT03886064|No Intervention|Control group|Only measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling.
3469515|NCT03886064|Other|Interventional group|Measurement of clinical endpoints at time zero, then at 6, 12, 18 and 24 months and minimal counseling followed by multi-behavioral intervention adapted to local resources.
3469516|NCT03886103|Experimental|Healthy volunteer|Single of 14C-PXL770
3469517|NCT03885947|Experimental|VPA expanded cord blood stem cells|"CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood for patients with hematological malignancies undergoing allogeneic stem cell transplantation.~VPA expanded cord blood stem cells in patients with hematological malignancies undergoing allogeneic stem cell transplantation"
3469518|NCT03886077||Hepatitis C Negative Donor Hearts|Hearts for transplantation that are not infected with Hepatitis C. (Negative NAT)
3469519|NCT03886077||Hepatitis C Infected Donor Hearts|Hearts for transplantation that are infected with Hepatitis C. (Positive NAT).
3469520|NCT03886090|Experimental|motor skill practice + aerobic exercise|acute bout of aerobic exercise following motor skill practice
3469521|NCT03886090|Active Comparator|motor skill practice + rest|seated rest following motor skill practice
3124952|NCT02959437|Experimental|Treatment Group C: INCB059872 + Pembrolizumab + Epacadostat|Part 1 is an open-label 3 + 3 + 3 dose-escalation design based on observing each dose level for a period of 42 days. Part 1 will also contain dose-expansion cohorts in previously treated NSCLC and MSS CRC. Part 2 will evaluate the recommended dose determined in Part 1.
3124953|NCT02959671|Experimental|Lower Anterior EXD-952 Self-ligating Brackets|
3124954|NCT02959827||Iodinated contrast agents|Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent
3124955|NCT02959840|No Intervention|Control|No anti-emetic medications and no acupuncture point P6 stimulation prior to administration of the standardized regional anesthesia
3124956|NCT02959840|Active Comparator|Metoclopramide, Ondansetron|10 mg Metoclopramide IV and 8 mg of Ondansetron IV immediately prior to administration of the standardized regional anesthesia
3124957|NCT02959840|Experimental|Acupressure Point P6 stimulator|Acupuncture point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete.
3124958|NCT02959853|Placebo Comparator|weight loss|Patients given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
3124959|NCT02959853|Experimental|aromatase inhibitor (anastrazole) plus weight loss|Patient placed on an aromatase inhibitor anastrazole 1 mg daily plus given counseling on diet and exercise in order to achieve a goal weight loss of 10 percent
3124960|NCT02959866|Experimental|Online income tool|Patients who complete the online income tool with their health provider during the study period.
3124961|NCT02959892|Experimental|TAK-041 20 mg|[11C] PHNO 180 megabecquerel (MBq), injection, intravenously, prior to positron emission tomography (PET) scan on Day 1, followed by amphetamine (AMPH) 0.5 milligram per kilogram (mg/kg), tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 20 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
3124962|NCT02959892|Experimental|TAK-041 40 mg|[11C] PHNO 180 MBq, injection, intravenously, prior to PET scan on Day 1, followed by AMPH 0.5 mg/kg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 2 of Confinement Period 1, followed by a 5 to 45 days of interval period, further followed by TAK-041 40 mg, suspension, orally, once, followed by AMPH 0.5 mg, tablet, orally, once and [11C] PHNO 180 MBq, injection, intravenously, prior to PET scan post-AMPH dose on Day 1 of Confinement Period 2.
3124963|NCT02959944|Experimental|Ibrutinib + Prednisone|"Ibrutinib (420 mg) given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity. The 420 mg dose was adjusted for cytochrome P450 [CYP] inhibitors or hepatic dysfunction as applicable.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
3124964|NCT02959944|Placebo Comparator|Placebo + Prednisone|"Placebo given orally once daily continuously starting on Week 1 Day 1 until cGVHD progression, progression of underlying malignancy, participant begins another systemic treatment for cGVHD or unacceptable toxicity.~Prednisone 1 mg/kg/d given orally once daily continuously starting on Week 1 Day 1 until unacceptable toxicity or until participant is successfully tapered from the prednisone. Starting prednisone dose may be as low as 0.5 mg/kg/d if a participant cannot tolerate higher doses."
3124965|NCT02959970|Experimental|PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5 % gel topically, once-daily to the entire face, neck, upper chest, upper back and shoulders starting from Day 1 under maximal use conditions (2 grams per day) for Day 8 consecutive days, followed by a thin layer to their face and acne-affected areas on the upper chest, upper back, and shoulders for next 11 weeks.
3124966|NCT02959970|Experimental|Non-PK Cohort: ACZONE 7.5%|Participants applied ACZONE 7.5% gel topically, once-daily in a thin layer to their face and acne-affected areas on upper chest, upper back, and shoulders for 12 weeks.
3124967|NCT02959983|Active Comparator|Eluxadoline|Eluxadoline 100 mg oral tablets twice daily (BID) with food for 12 weeks.
3124968|NCT02959983|Placebo Comparator|Placebo|Placebo matching eluxadoline oral tablets BID with food for 12 weeks.
3124969|NCT02959996|Placebo Comparator|Placebo|Normal saline will be infiltrated
3124970|NCT02959996|Active Comparator|Intervention|Liposomal bupivacaine will be infiltrated
3124971|NCT02960217|Experimental|Double-Blind UX007 Followed by Placebo|"Participants will first receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks. After a washout period of 2 weeks, they will then receive placebo for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
3124972|NCT02960217|Experimental|Double Blind Placebo Followed by UX007|"Participants will first receive Placebo for 10 weeks. After a washout period of 2 weeks, they will then receive UX007 (dosed according to an age- and weight-based strategy, up to a maximum daily administration of 130 g) for 10 weeks.~Participants will have the option of rolling into the open label Extension Period, to continue UX007 treatment for up to 3 years."
3469522|NCT03886129||Participants with Transient Ischaemic Attack|"Inclusion Criteria:~Willing to participate~Capacity to consent~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~A diagnosis of acute (≤7 days) TIA, made by a specialist that fulfils the 2009 American Heart Association definition of TIA~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
3124973|NCT02960295|Experimental|Virtual visit|"Self-monitoring of blood glucose (four times daily).~Self-weighing (weekly).~Self-checking of blood pressure (weekly).~Checking fetal heart rate (weekly).~Visits with caregivers."
3124974|NCT02960438|Experimental|E6011 100 milligrams (mg)|In the Treatment Phase, E6011 100 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
3124975|NCT02960438|Experimental|E6011 200 mg|In the Treatment Phase, E6011 200 mg will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
3124976|NCT02960438|Experimental|E6011 400 mg|In the Treatment Phase, E6011 400 mg will be subcutaneously administered at Weeks 0, 1, 2, 4, 6, 8, and 10, and then E6011 200 mg will be subcutaneously administered every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
3124977|NCT02960438|Placebo Comparator|Placebo|In the Treatment Phase, placebo will be subcutaneously administered at Weeks 0, 1, and 2, and then every 2 weeks up to Week 22. In the Extension Phase, E6011 200 mg will be subcutaneously administered every 2 weeks until Week 102.
3124978|NCT02960490|Experimental|E6011 400 mg/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 milligrams (mg) at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
3124979|NCT02960490|Experimental|E6011 400 mg/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive E6011 400 mg at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
3124980|NCT02960490|Experimental|Placebo/E6011 200 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 200 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
3469523|NCT03886129||Healthy Control Participants|"Inclusion Criteria:~Willing to participate~Capacity to consent to the study~Aged >18 years~Able (in the Investigator's opinion) and willing to comply with all study requirements~Good understanding of written and verbal English~Exclusion Criteria:~Unwilling to take part~Unable to consent~Aged <18 years~Unable (in the Investigator's opinion) or unwilling to comply with any study requirements~Female participants who are pregnant, lactating or planning pregnancy during the course of the study~Atrial fibrillation~Severe heart failure (Ejection Fraction <30%)~Severe respiratory disease~Inadequate bilateral transcranial Doppler windows~Carotid stenosis ≥70% (unilateral or bilateral)~Participant enrolled in an interventional research study.~Poor understanding of written and verbal English"
3469524|NCT03886220|Experimental|Participants receiving elagolix|Participants will be administered with elagolix
3469525|NCT03886220|Experimental|Participants receiving placebo|Participants will be administered with placebo
3469526|NCT03886142|Active Comparator|radiofrequency|genicular nerves pulsed radiofrequency
3469527|NCT03886142|Active Comparator|intra-articular platelet rich plasma|injection of platelet rich plasma in the affected joint
3469528|NCT03886298|Experimental|radiofrequency splanchnic denervation|
3469529|NCT03886298|Active Comparator|retrocrural celiac denervation|
3469530|NCT03886025|Experimental|Combined anodal tDCS and cognitive training|Combined anodal tDCS and cognitive training. Anodal tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). Anodal tDCS will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration of each tDCS session will be 20 minutes.
3469531|NCT03886025|Sham Comparator|Combined sham tDCS and cognitive training|Combined sham tDCS and cognitive training. Sham tDCS will be delivered while the participant is completing the cognitive training task (Iowa Gambling Task). For sham tDCS, the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each tDCS session will be 20 minutes.
3469532|NCT03885882|Experimental|Cohort 1: E0302 Sustained Release (SR1) 1500 mcg|Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.
3469533|NCT03885882|Experimental|Cohort 2: E0302 Sustained Release (SR3) 1500 mcg|Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.
3469534|NCT03885882|Experimental|Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg|Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
3469535|NCT03885882|Experimental|Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg|Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.
3469536|NCT03886259|Experimental|Exercise and pain neuroscience education|Subjects with chronic pain after total knee replacement will receive 24 sessions of neuromuscular exercise therapy, supervised by a physiotherapist, and two sessions of pain neuroscience education, conducted by a physiotherapist
3469537|NCT03886259|Active Comparator|Pain neuroscience education|Subjects with chronic pain after total knee replacement will receive two sessions of pain neuroscience education, conducted by a physiotherapist
3469538|NCT03886207|Experimental|Warm water with ginger powder footbath|Participants who receive a warm water with added ginger powder footbath four times a week over a six-week period.
3124981|NCT02960490|Experimental|Placebo/E6011 400 mg|In the Treatment Phase (24 weeks), participants will receive placebo at Weeks 0, 1, and 2, and then every 2 weeks subsequently until Week 10, and will then receive E6011 400 mg every 2 weeks between Weeks 12 and 22 in a double-blind manner. Participants who complete evaluations at Week 24 of the Treatment Phase will enter the Extension Phase (conducted up to Week 104 from the start of the study treatment), in which they will receive open-label E6011 200 mg every 2 weeks until Week 102.
3124982|NCT02960854|Experimental|Nivolumab 1|Dose 1
3124983|NCT02960854|Experimental|Nivolumab 2|Dose 2
3124984|NCT02960893|Experimental|Troriluzole|"Troriluzole - Randomization Phase: Participants received Troriluzole 140 mg capsules orally once daily (QD) for 8 weeks.~Troriluzole/Troriluzole - Extension Phase: Participants received Troriluzole 140 mg capsules orally QD for 48 weeks."
3124985|NCT02960893|Placebo Comparator|Placebo|"Placebo - Randomization Phase: Participants received matching placebo capsules orally QD for 8 weeks.~Placebo/Troriluzole - Extension Phase: Participants who received placebo during randomization phase, received Troriluzole 140 mg capsules orally QD for 48 weeks."
3124986|NCT02960997|Experimental|Sirolimus, then Placebo|Participants will receive Sirolimus, 2% topical ointment for 12 weeks followed by placebo to match sirolimus for 12 weeks.
3124987|NCT02960997|Placebo Comparator|Placebo, then Sirolimus|Participants will receive placebo to match sirolimus for 12 weeks followed by Sirolimus, 2% topical ointment for 12 weeks.
3124988|NCT02961062|Experimental|Treatment Sequence 1|
3124989|NCT02961062|Placebo Comparator|Treatment Sequence 2|
3124990|NCT02961218|Placebo Comparator|Placebo|Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects
3124991|NCT02961218|Experimental|ACZ885|Monthly doses of 300 mg (4 mg/kg for patients ≤ 40 kg) canakinumab s.c.
3124992|NCT02961244|No Intervention|Control Group|Perioperative management and warming was not performed according to a standard normothermia protocol, with our clinic's traditional methods except prewarming.
3124993|NCT02961244|Active Comparator|Intervention Group|Perioperative management and warming was performed according to a standard normothermia protocol with active prewarming.
3124994|NCT02961374|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
3124995|NCT02961751|Other|Ciprofloxacin|One dose of directly-observed ciprofloxacin 500 mg administered orally. N=381
3124996|NCT02961764|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
3124997|NCT02961764|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
3124998|NCT02961790|Experimental|Group I (low-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-49 in the absence of unacceptable toxicity.
3124999|NCT02961790|Placebo Comparator|Group II (low-dose placebo)|Patients receive lower dose placebo PO BID on days 8-49 in the absence of unacceptable toxicity.
3125000|NCT02961790|Experimental|Group III (high-dose oxybutynin chloride)|Patients receive lower dose oxybutynin chloride PO BID on days 8-14 and higher dose oxybutynin chloride on days 15-49 in the absence of unacceptable toxicity.
3469539|NCT03886207|Active Comparator|Warm water only footbath|Participants who receive a warm water only footbath four times a week over a six-week period.
3469540|NCT03885895|Active Comparator|Participants with freckles (one side of the face)|one randomized side of the face will be treated by Intradermal Tranexamic acid
3125001|NCT02961790|Placebo Comparator|Group IV (high-dose placebo)|Patients receive lower dose placebo PO BID on days 8-14 and higher dose placebo on days 15-49 in the absence of unacceptable toxicity.
3125002|NCT02961894|Experimental|Revolution Treatment Arm|This is a single-arm study. All eligible and participating patients will be treated wit the Revolution™ Peripheral Atherectomy System.
3469541|NCT03885895|Active Comparator|Participants with freckles (other side of the face)|other side will be treated by Q switched KTP laser
3469542|NCT03886038|Active Comparator|RA patients on JAK inhibitors|RA patients treated with JAK inhibitors as a monotherapy or in combination with methotrexate/other DMARDS/prednisone for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
3469543|NCT03886038|Active Comparator|RA on synthetic or biological DMARDs|RA patients tretad with syntetic or bioloogial DMARDs for at least 3 months will receive two doses of Shingrix vaccine administrated with at least 2 months apart
3469544|NCT03886038|Active Comparator|healthy controls|healthy individuals without any rheumatic disease or not treated with any immunosupressive drug for any other condition will receive two doses of Shingrix vaccine administrated with at least 2 months apart
3125003|NCT02961920|Experimental|IE ratio 1:1|Set an I(inspiration):E(expiration) ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
3125004|NCT02961920|Active Comparator|IE ratio 1:2|Set an I(inspiration):E(expiration) ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
3125005|NCT02961946|Active Comparator|Sublingual Nitroglycerin spray|Sublingual Nitroglycerin spray of 0.8 mg
3125006|NCT02961946|Active Comparator|Sublingual Nitroglycerin tablet|Sublingual Nitroglycerin tablet of 0.8 mg
3125007|NCT02961946|Active Comparator|Nitroglycerin skin patch|Nitroglycerin skin patch of 0.8 mg/h
3125008|NCT02962284|Experimental|YONSA with Methylprednisolone|Aberaterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
3469545|NCT03886051|Experimental|test group|Connective Tissue Graft before Orthodontic treatment
3469546|NCT03886051|Active Comparator|control group|Orthodontic treatment only
3469547|NCT03885869||Type 2 Diabetics|Type 2 diabetic individuals aged 30-65 years
3469548|NCT03885973|Experimental|Lactobacillus plantarum|1 bottle of fermented milk (100 g) containing probiotic Lactobacillus plantarum IS-10506 1.0x10^8 CFU will be given daily for three weeks.
3469549|NCT03885973|Placebo Comparator|Placebo|1 bottle of fermented milk (100 g) containing placebo will be given daily for three weeks.
3125009|NCT02962427|Experimental|Sphenopalatine Ganglion Block|Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
3125010|NCT02962427|Active Comparator|Epidural blood patch|Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.
3125011|NCT02962609|Experimental|Semielevated Side-Lying Position-ESL|Preterm infants feed in the ESL position. In the ESL position, infant's head and trunk were elevated to an angle of 45-60° with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infants were held in side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and both the head and the neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
3125012|NCT02962609|Experimental|Semielevated Supine Position-ESU|Before feeding: In the ESU position, the head and the trunk of the infant were elevated to an angle of 45-60° with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and the infant was laid in supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas the chin was held in the flexion posture mildly facing the floor.
3125013|NCT02962648|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
3125014|NCT02962674|Other|Treatment|
3125015|NCT02962687|Experimental|Videoconference care management|12-week nurse care management for medically complex Veterans with CI delivered via videoconferencing
3125016|NCT02962687|Active Comparator|Telephone care management|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
3125017|NCT02962739|Active Comparator|33%/67% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
3125018|NCT02962739|Active Comparator|33%/100% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
3469550|NCT03886194|Active Comparator|Thrombolytic group|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip
3469551|NCT03886194|Experimental|Interventional treatment group|Interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
3469552|NCT03885999|Experimental|Fecobionics studies|
3469553|NCT03885921|Experimental|Ezetimibe+Atorvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with atorvastatin 40 mg (starting dose) via oral tablet once daily in the morning (may be titrated up to a maximum daily dose of 80 mg for atorvastatin, if needed) for up to 24 months.
3469554|NCT03885921|Experimental|Ezetimibe+Simvastatin|Participants receive ezetimibe 10 mg via oral tablet once daily co-administered with simvastatin 40 mg (starting dose) via oral tablet once daily in the evening (may be titrated up to a maximum daily dose of 80 mg for simvastatin, if needed) for up to 24 months.
3469555|NCT03886233||Traditional Treatment for Autoimmune uveitis|Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
3469556|NCT03886233||Biological Treatment for Autoimmune uveitis|Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
3469557|NCT03886181|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
3469558|NCT03885856||single row repair technique|patients surgically treated for rotator cuff lesion by single row repair technique
3469559|NCT03885856||double row repair technique|patients surgically treated for rotator cuff lesion by double row repair technique
3469560|NCT03885843|Experimental|RDN Group|renal nerve stimulation, mapping and denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator after renal angiography.
3469561|NCT03885843|Sham Comparator|Sham Group|renal artery angiography group, without any renal nerve stimulation, mapping or denervation
3469562|NCT03886168|Experimental|Immediate IGCIP|Immediate signal processing intervention of a biomedical device
3469563|NCT03886168|Active Comparator|Deferred IGCIP|Delayed signal processing intervention of a biomedical device
3469564|NCT03885778|Experimental|A-fasted dosing followed by fed dosing|Fasted dosing of Besifovir dipivoxil followed by fed dosing; Dosing in the fasted state followed by fed dosing
3469565|NCT03885778|Experimental|B-fed dosing followed by fasted dosing|Fed dosing of Besifovir dipivoxil followed by fasted dosing; Dosing in the fed state followed by fasted dosing
3469566|NCT03885817|Experimental|Exercise training and nutritional guide|Standard recommendations regarding physical activity and nutrition. An individually tailored exercise program and nutritional guide during adjuvant chemotherapy.
3125019|NCT02962739|Active Comparator|67%/33% dosing|The 33% and 67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks; 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks).
3125020|NCT02962739|Active Comparator|67%/100% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
3125021|NCT02962739|Active Comparator|100%/33% dosing|The 33% dosing regimens will use skipped doses spaced by days (i.e. 33% dosing is a daily dose followed by two skipped days, repeated for 12 weeks). 100% will dose daily for 12 weeks, no skipped doses.
3125022|NCT02962739|Active Comparator|100%/67% dosing|67% dosing regimens will use skipped doses spaced by days (i.e. 67% is two daily doses followed by skipping a day, repeated for 12 weeks. 100% will dose daily for 12 weeks, no skipped doses.
3125023|NCT02962882|Experimental|A. Mepilex Border Sacrum (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the sacrum area at pressure points in patients in the ICU, prone to get pressure injuries (PI).
3125024|NCT02962882|Experimental|B. Mepilex Border Heel (Safetac)|A dressing that is a flexible, self-adherent, profylactic, absorbent pad in three layers to be used on the heels (on both left and right heels), in patients in the ICU, prone to get pressure injuries (PI).
3125025|NCT02962908|Experimental|Group 1|(n=74): FLU-v on Day 0 and Day 21
3469567|NCT03885817|Active Comparator|Standard follow-up care|Standard recommendations regarding physical activity and nutrition.
3469568|NCT03885830||Bosutinib|Subjects who have been prescribed or administered bosutinib (Bosulif) for treatment of chronic-phase CML for less than 12 months.
3469569|NCT03885830||Dasatinib|Subjects who have been prescribed or administered dasatinib (Sprycel) for treatment of chronic-phase CML for less than 12 months.
3469570|NCT03885830||Imatinib|Subjects who have been prescribed or administered imatinib (Gleevec) for treatment of chronic-phase CML for less than 12 months.
3469571|NCT03885830||Nilotinib|Subjects who have been prescribed or administered nilotinib (Tasigna) for treatment of chronic-phase CML for less than 12 months.
3469572|NCT03885687|Experimental|Exercise with Music Intervention|The Exercise with Music intervention is a recorded exercise playlist, which is tailored to a patient's individual physical abilities and music choices.
3469573|NCT03885687|Active Comparator|Active Control Group|The active control group will receive exercise brochure and will be advised to exercise at least twice daily.
3469574|NCT03885518|Active Comparator|Intervention|Participants attending the childcare centers randomized to this arm will receive the stencil activities after baseline assessments have been completed. We will follow-up with assessments after 6-8 weeks
3469575|NCT03885518|Placebo Comparator|Wait-List|Participants attending the childcare centers randomized to this arm will receive the stencil activities approximately 8 weeks after enrolling, after baseline and follow-up assessments have been completed.
3125026|NCT02962908|Experimental|Group 2|(n=74): adjuvanted FLU-v on Day 0, saline (0.5mL) on Day 21
3125027|NCT02962908|Placebo Comparator|Group 3|(n=37): saline solution (0.5ml) on Day 0 and Day 21
3125028|NCT02962908|Placebo Comparator|Group 4|(n=37): Adjuvanted placebo on Day 0, saline (0.5mL) on Day 21
3125029|NCT02962934||Non CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam not receiving continuous renal replacement therapy
3125030|NCT02962934||CRRT group|Critically ill patients receiving Ceftolozane-Tazobactam who require continuous renal replacement therapy
3469578|NCT03885791|Experimental|Vaginal cryotherapy - intervention|"The intervention group will be provided with one vaginal cryotherapy tube, filled with a mixture of isopropyl alcohol (2ml) and water (8ml) that has been kept in the freezer. This mixture results in a slushy consistency and prevents the solution from freezing solid thus decreases the risk of discomfort or injury due to the temperature of the tube. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home freezer."
3125031|NCT02962960|Experimental|Anifrolumab - Lower dose|1ml, once every second week, one subcutaneous injection as added to stand of care, from week 0 to week 50
3125032|NCT02962960|Placebo Comparator|Placebo matching for lower dose of Anifrolumab|1ml, once every second week, one subcutaneous injection added to stand of care, from week 0 to week 50
3125033|NCT02962960|Experimental|Anifrolumab - Higher dose|2×1ml, once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
3125034|NCT02962960|Placebo Comparator|Placebo matching for higher dose of Anifrolumab|2×1ml , once every second week, two subcutaneous injections as added to stand of care, from week 0 to week 50
3469579|NCT03885791|Placebo Comparator|Vaginal cryotherapy - control|The control group will be provided with an identical tube that is empty. An empty tube was chosen as the control because a tube with room-temperature liquid may still be perceived as cold. Patients will insert this tube into the vagina to a comfortable depth. A lubricant will be provided for comfort with tube insertion, if necessary. At the conclusion of the treatment, this tube will be washed thoroughly and given to the patient in a clean plastic baggie for use at home. They will be instructed to store these tubes in their home at room temperature.
3469580|NCT03885570||Groups/Cohorts|"1) Patients undergoing mitral valve replacement surgery;2) Age 18-75 years old;3) 48h preoperative biochemical indicators, blood general indicators, coagulation indicators are complete."
3469581|NCT03885440||Young adult, without OSAS|20<=Age<40 years old, apnea-hypopnea index(AHI)<5
3469582|NCT03885440||Young adult, with OSAS|20<=Age<40 years old, AHI>=5
3469583|NCT03885440||older adult, without OSAS|Age>=40 years old, AHI<5
3469584|NCT03885440||older adult, with OSAS|Age>=40 years old, AHI>=5
3469585|NCT03885739|Other|Patients with hip fracture|15 consecutive HF patients who were admitted to a single level 3 center and who report severe pain despite a standardized analgesia protocol. Patients were assessed by the Pain Service as part of a multidisciplinary care pathway and a Continuous Pericapsular Nerve Group blocks was offered as a component of a multimodal analgesic regimen.
3125035|NCT02963311|Experimental|ALN-PCSSC|300 milligrams (mg) administered subcutaneous (SC) on Day 1. Participants with a mean serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels not suppressed by >70% at Day 60 or Day 90, as compared to baseline, will receive a second dose at Day 90 or Day 104, respectively, based on PCSK9 levels from the previous visit. Participants also received standard of care as background therapy.
3125036|NCT02963376|Active Comparator|0.05 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3125037|NCT02963376|Placebo Comparator|0.05 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3469586|NCT03885804|Sham Comparator|Quadratus lamborum dexmedetomidine intravenous group|Patients will receive quadratus lamborum block on the same surgical side.a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
3469587|NCT03885804|Active Comparator|Quadratus lamborum dexmedetomidine perineural group|Patients will receive quadratus lamborum block on the same surgical side. Patients will receive perineural dexmedetomidine of 1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
3469588|NCT03885713|Active Comparator|Patients with treatment|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice, or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice, or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice, or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)-subcutaneus) per clinical practice
3469589|NCT03885713|No Intervention|healthy control|
3469590|NCT03885752|Active Comparator|the control group|
3469591|NCT03885752|Placebo Comparator|the gum group|
3469592|NCT03885583|Active Comparator|thoracic epidural group|patients in this group will receive ultrasound guided thoracic epidural block preoperatively for pain management, continuous infusion of 0.5% bupivacaine through epidural catheter during operation and early post-operative period
3469593|NCT03885583|Active Comparator|paravertebral group|patients in this group will receive ultrasound guided pararvertebral block preoperatively for pain management, continuous infusion of paravertebral bupivacaine 0.5% through paravetebral catheter during operation and early post-operative period
3469594|NCT03885674|Experimental|Reminder Interventions|Receive daily reminders from Kessler Foundation study personnel on when to take their medication.
3469595|NCT03885674|No Intervention|Standard Condition|This group will not receive reminders on when to take their medication from Kessler Foundation staff and will receive the usual and standard care.
3469596|NCT03885700|Experimental|intervention group|
3469597|NCT03885700|No Intervention|control group|
3469598|NCT03885609|Experimental|Treatment - toothwave brush|Subjects using the Silk'n ToothWave RF utilizing toothbrush
3469599|NCT03885609|Sham Comparator|Control - powered toothbrush|Subject using a regular powered toothbrush with no RF.
3469600|NCT03885635|Active Comparator|Hemiarch repair|Standard hemiarch repair with open distal anastomosis in the proximal arch without replacement of the head vessels.
3469601|NCT03885635|Active Comparator|Extended arch repair|Ascending aortic and arch replacement with or without head vessel re-implantation and single TEVAR device placement within 1 week.
3469602|NCT03885258|Experimental|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
3469603|NCT03885479||IBD patients|"Full history taking and examination~Colonoscopy, biopsy and histopathology to determine the extent of the lesion~An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)~Patients will be categorized into 3 groups (UC patients, Crohn disease patients and controls)~All of the following factors will be taken into consideration; type and duration of the treatment, age of diagnosis, BMI, smoking status and activity of the disease at the time of the study"
3469604|NCT03885479||Controls|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
3469605|NCT03885557|Experimental|Group I Experimental Dynamic oscillatory stretch(DOS)|Dynamic oscillatory stretch technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group.
3469606|NCT03885557|Active Comparator|Group II Static Stretching(SS) Group|Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group.
3469607|NCT03885466|Experimental|Nordic walking|Nordic walking exercise intervention, 3 times per week over 12 weeks
3469608|NCT03885466|No Intervention|Control|Waiting list controls will be offered same Nordic walking intervention after 3 month follow-up measurements
3469609|NCT03885336||Both-Quit Group|Couples in which both individuals smoke and both individuals would like to quit smoking.
3469610|NCT03885544|Active Comparator|Controlled lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet without red meat for 3 weeks.
3469611|NCT03885544|Experimental|Controlled unprocessed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with unprocessed red meat for 3 weeks.
3469612|NCT03885544|Experimental|Controlled processed red meat diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian diet with processed red meat for 3 weeks.
3469613|NCT03885453||Panic Disorder / Agoraphobia|Patients with Panic Disorder / Agoraphobia as major diagnosis
3469614|NCT03885453||Depression|Patients with Depression as major diagnosis
3125038|NCT02963376|Active Comparator|0.10 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3125039|NCT02963376|Placebo Comparator|0.10 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3125040|NCT02963376|Active Comparator|0.17 mL/kg DDFPe|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3125041|NCT02963376|Placebo Comparator|0.17 mL/kg Placebo|This study is a randomized, placebo controlled, blinded escalating dose study designed to determine the maximum tolerated dose to intravenous administration of DDFPe. At each of the three dose levels 0.10, 0.17 mL/kg) six subjects will receive DDFPe and two will receive placebo.
3125042|NCT02963506|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
3125043|NCT02963506|Experimental|Bimekizumab Dose 1|Subjects will receive for 12 Weeks Bimekizumab Dose 1 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
3125044|NCT02963506|Experimental|Bimekizumab Dose 2|Subjects will receive for 12 Weeks Bimekizumab Dose 2 and will then be re-randomized to Bimekizumab Dose 3 or Bimekizumab Dose 4 for 36 Weeks.
3125045|NCT02963506|Experimental|Bimekizumab Dose 3|Subjects will receive for 48 Weeks Bimekizumab Dose 3.
3125046|NCT02963506|Experimental|Bimekizumab Dose 4|Subjects will receive for 48 Weeks Bimekizumab Dose 4.
3125047|NCT02963597|Active Comparator|Group A|Standard medical therapy plus AirSense™ 10 AutoSet for 48hrs.
3469615|NCT03885362|Experimental|Dexcom G6 and Abbott Freestyle Libre|"Participants will have a Dexcom G6 sensor and Abbott FreeStyle Libre sensor inserted in the abdomen and upper arm respectively. Participants will be asked to swipe the FreeStyle Libre reader across the sensor a minimum of every 8 hours. Participants will be asked to continue their usual regimen of self-monitoring capillary blood glucose (SMBG).~During haemodialysis, a dialysis circuit blood sample will be drawn at 0 (pre-dialysis) 30, 60, 90, 120, 150, 180, 210 and 240 minutes and immediately after dialysis. Samples from the circuit will be analysed on the YSI glucose analyser. Participants will be asked to change the FreeStyle Libre sensors at day 14. The blinded CGM data will be uploaded at the time of each sensor change by the research team."
3469616|NCT03885427|Experimental|oral ketamine|evaluate sedative,and analgesic effects
3469617|NCT03885427|Active Comparator|nebulized ketamine|evaluate sedative, and analgesic effects
3469618|NCT03885206|Experimental|Hospital|Level of healthcare service: Patients who can be admitted to a municipal acute ward (MAW) will be admitted to the hospital instead, so that the intervention is that patients are admitted to a higher level facility than needed. Recieve medical treatment as usual.
3469619|NCT03885206|No Intervention|Municipal acute ward|Patients admitted to decentralized, municipal acute care wards after being assessed by a referring physician.
3469620|NCT03885232|Experimental|PIVOT with MI|Clinics with providers trained in the Presumptively Initiating Vaccines and Optimizing Talk with Motivational Interviewing intervention (PIVOT with MI)
3469621|NCT03885232|Active Comparator|Control|Control-Care as usual
3469622|NCT03885219|Experimental|nab-paclitaxel and S-1|chemotherapy of Nab-Paclitaxel and S-1, repeat 21 days for up to 8 cycles. The following treatment including pancreatectomy, continuing same chemotherapy, S-1 maintenance therapy, or radiotherapy will be decided after discussion between physicians and patients.
3469623|NCT03885310|Experimental|DCB Treatment|Stricture patients treated by DCB
3469624|NCT03885128|Experimental|Vest arm|high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients
3469625|NCT03885128|Experimental|Quake arm|Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients
3469626|NCT03885349|Experimental|SBIP+ ADAPs-IMP|Experimental condition: Standard batterer intervention program (SBIP) plus individualized motivational plan (IMP) focused in alcohol and/or drugs abuse problems (ADAPs).
3125048|NCT02963597|Placebo Comparator|Group B|Standard medical therapy only.
3125049|NCT02963701|Experimental|Ibuprofen+Pseudoephedrine-HCl|Fixed dose combination
3125050|NCT02963701|Active Comparator|Ibuprofen+Pseudoephedrine-HCl (RhinAdvil®)|Fixed Dose Combination
3125051|NCT02963922|Experimental|liraglutide 3.0 mg|
3125052|NCT02963922|Placebo Comparator|Placebo|
3125053|NCT02963935|Experimental|Liraglutide|
3125054|NCT02963935|Placebo Comparator|Placebo|
3125055|NCT02963974|Experimental|Cochlear Implant|Pediatric patients with single sided deafness will receive a cochlear implant in the ear of loss
3125056|NCT02963987|Experimental|100% Portion Size|100% Food and Beverage Portion Size
3125057|NCT02963987|Experimental|150% Portion Size|150% Food and Beverage Portion Size
3125058|NCT02964078|Experimental|Pembrolizumab and Interleukin-2|Outpatient Intravenous (IV) infusion of Pembrolizumab and Inpatient IV infusion of Interleukin-2.
3125059|NCT02964234|Experimental|Empowerment|Behavior: Empowerment
3125060|NCT02964234|Experimental|Education|Behavior: Education
3125061|NCT02964247|Experimental|liraglutide + SGLT2i ± metformin|
3125062|NCT02964247|Placebo Comparator|liraglutide placebo + SGLT2i ± metformin|
3125063|NCT02964312|Other|Latera Implant|Unilateral or bilateral placement of the Latera nasal implant for support of the lateral nasal wall cartilage.
3125064|NCT02964325|Experimental|Mirasol platelets (MIR PLTs)|Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
3125065|NCT02964325|Active Comparator|Reference platelets (REF PLTs)|Leukoreduced, apheresis platelets stored in 100% plasma
3125066|NCT02964338|Placebo Comparator|Placebo|Participants received placebo via an approximately 1-hour intravenous infusion and as 3 subcutaneous injections at Week 0 followed by placebo administered as single subcutaneous injections at Weeks 4 and 8.
3125067|NCT02964338|Experimental|Fremanezumab 675/225/225 mg|Participants received placebo via an approximately 1-hour intravenous infusion and fremanezumab at 675 milligrams (mg) as 3 subcutaneous injections (225 mg/1.5 milliliters [mL]) at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
3125068|NCT02964338|Experimental|Fremanezumab 900/225/225 mg|Participants received fremanezumab at 900 mg via an approximately 1-hour intravenous infusion and placebo administered as 3 subcutaneous injections at Week 0 followed by fremanezumab at 225 mg administered as single subcutaneous injections (225 mg/1.5 mL) at Weeks 4 and 8.
3125069|NCT02964416|Experimental|Tramadol|Injection Tramadol 100mg diluted in 10 cc syringe (10mg/ml) to be given as 1mg/kg or (1ml/10kg) via intravenous route, once, at the time of dura closure
3125070|NCT02964416|Placebo Comparator|Placebo|0.9% Normal saline in 10 cc syringe,1ml/10kg via intravenous route, once at the time of dura closure
3469627|NCT03885349|Active Comparator|SBIP+IMP|Control condition: Standard batterer intervention program plus individualized motivational plan (SBIP+IMP)
3125071|NCT02964767||HIV mono infection|HIV Patients do not have active Mycobacterium Tuberculosis infection
3125072|NCT02964767||HIV-Tb. co infection|Patients with HIV and MycobacteriumTuberculosis co infections
3469628|NCT03885102|Experimental|Intervention|12 months intradialytic exercise intervention
3469629|NCT03885102|Active Comparator|Usual care|Usual care according to current guidelines
3469630|NCT03885284|Experimental|Dose Level 1|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 8-12 of cycle 6"
3179143|NCT00669734|Experimental|Treatment (vaccine therapy, sargramostim)|Patients receive falimarev vaccine intratumorally using endoscopic ultrasound guidance on day 1. Patients also receive inalimarev vaccine SC on day 1 and sargramostim SC on days 1-4. Patients then receive falimarev vaccine SC on days 15 and 29 and sargramostim SC on days 15-18 and 29-32 in the absence of unacceptable toxicity. Beginning on day 43, patients with stable or improving pancreatic cancer receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity. Beginning on day 71, patients with no irreversible or dose limiting toxicity, receive falimarev vaccine SC and sargramostim SC (given on the day of and for 3 days after each falimarev vaccination) monthly in the absence of disease progression or unacceptable toxicity.
3469631|NCT03885284|Experimental|Dose Level 2|"mFOLFIRINOX + Proton beam radiation~Radiation given on days 15-19 of cycle 6"
3469632|NCT03885180|Experimental|Extend anticoagulation group|Extended the duration anticoauglation to 12 months
3469633|NCT03885180|No Intervention|Stop anticoagulation group|Just stop oral anticoagulation like routine
3469634|NCT03885414|Experimental|OST-VRET + in-vivo transition program|One-session treatment (OST) VRET on-location with clinical psychologist (3 hours), followed by a therapist-guided, four-week online program encouraging transition to real-world, in-vivo exposure exercises.
3469635|NCT03885063|Experimental|Benjamin Rose Institute Care Consultation (BRI-CC)|
3125073|NCT02964897|Experimental|Intervention Arm with Peer Support|Veterans in this arm will receive the peer-support intervention, in addition to the usual care from the Health Care for Reentry Veterans Program.
3125074|NCT02964897|Other|Comparison Arm with Usual Care|Veterans in this arm will be receiving usual care from the Health Care for Reentry Veterans program (but they will not receive the peer-support intervention). They will be selected to be frequency-matched to veterans in the intervention arm by date of release from incarceration.
3125075|NCT02964910|Experimental|the chronic Hepatitis B patients|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
3469636|NCT03885063|No Intervention|No intervention|
3469637|NCT03884959|Experimental|HepaStem Infusion|A calculated dose based on patient's body weight will be administered via Permanent mesenteric Portal Access and Catheter for four times or a Transient Percutaneous Transhepatic Catheter for three times.
3469638|NCT03885011|Experimental|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
3469639|NCT03885011|Active Comparator|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
3469640|NCT03885011|Active Comparator|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
3125076|NCT02964910|Active Comparator|the healthy volunteer|Participants in this arm are aged over 30 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
3125077|NCT02965144||HGG patients|single-group study- long term survivors
3125078|NCT02965378|Experimental|Arm I - AZD4547|Participants receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3125079|NCT02965378|Experimental|Arm II - Docetaxel|"Participants receive docetaxel IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Upon progression, participants may be eligible to re-register to Arm III.~-closed to accrual 12/18/2015"
3469641|NCT03885388|Active Comparator|control arm|single methotrexate multicourse treatment MTX:MTX 0.4mg/kg•d, intramuscular, every two weeks
3469642|NCT03885388|Experimental|experimental arm|combination of methotrexate and actinomycin multicourse treatment, every two weeks MTX+ACTD:Act-d 0.6mg/m2 Day1,2 intravenous (IV) MTX 100mg/m2 IV Day1(after Act-d) MTX 200mg/m2 Ivgtt Day1(after MTX,500mlNS)
3125080|NCT02965378|Experimental|Arm III - AZD4547 re-registration|Participants in Arm II eligible for re-registration receive FGFR inhibitor AZD4547 PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3125081|NCT02965456|Experimental|IDP-121 Lotion|IDP-121 lotion (tretinoin 0.05 percent [%]) will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
3125082|NCT02965456|Placebo Comparator|IDP-121 Vehicle Lotion|IDP-121 lotion vehicle will be applied topically to the face of participants with moderate to severe acne, once daily for 12 weeks.
3125083|NCT02965534|Experimental|Night Spectacle Correction|Refraction for this glasses was obtained at low luminance.
3125084|NCT02965534|Active Comparator|Spectacle Correction for photopic light conditions|Refraction for this glasses was obtained at high luminance level.
3125085|NCT02965573|Active Comparator|ARGX-113|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive ARGX-113
3469643|NCT03885245|Experimental|L-citrulline|L-citrulline with a dose of 15 g/day will be administered in powder form that is mixed with water and taken orally, continuously and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
3469644|NCT03885245|Placebo Comparator|Matching Placebo|Administered in powder form that is mixed with water and taken orally, continuously, and daily for at least 7 weeks. Dispensed at Visits 1 and 1a (if needed). Washout period of at least 5 weeks and then enter crossover phase of an additional 7 weeks. Drug will be dispensed at Visit 4.
3469646|NCT03884933|Experimental|Mobile team community mental health services|
3469647|NCT03884933|No Intervention|Current clinical services|
3125086|NCT02965573|Placebo Comparator|Placebo|During the Treatment period, eligible patients will be randomized at a 1:1 ratio to receive placebo
3125087|NCT02965599|Experimental|GSK3117391|Subjects will receive GSK3117391 (Dose A) for 28 days.
3125088|NCT02965599|Placebo Comparator|Placebo|Subjects will receive placebo for 28 days.
3125089|NCT02965729|Active Comparator|No Pedometer|Participants only participated in the family-based weight management intervention. Participants were not given a pedometer or step goals.
3125090|NCT02965729|Active Comparator|Pedometer Only|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. No step goals were provided.
3125091|NCT02965729|Active Comparator|Pedometer Plus Step Goals|In addition to participating in the family-based weight management intervention, participants were given a pedometer and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10. Participants were given individualized step goals to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
3125092|NCT02965781|Active Comparator|One SADBE application|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. Three weeks after topical sensitization dose patient will receive topical placebo applied to the patient's upper arm.
3125093|NCT02965781|Active Comparator|Two SADBE applications|Patient will receive a topical 2% SADBE sensitization dose applied to the patient's upper arm. A 0.5% SADBE intensification dose will be applied to the patient's upper arm 3 weeks after sensitization dose.
3125094|NCT02965781|Placebo Comparator|Placebo application (DMSO only-No SADBE)|Patient will receive a topical placebo (vehicle-DMSO) dose applied to the patient's upper arm. A topical placebo (vehicle-DMSO) follow up dose will be applied to the patient's upper arm 3 weeks after the first placebo dose dose.
3125095|NCT02965820|Other|OFPM, then HMPS|OPTI-FREE® PureMoist® multi-purpose contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
3125096|NCT02965820|Other|HMPS, then OFPM|Subject's habitual multi-purpose contact lens solution in Period1, followed by OPTI-FREE® PureMoist® contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
3125097|NCT02965833|Other|CCP, then HMPS|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 1, followed by subject's habitual multi-purpose contact lens solution (HMPS) in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
3125098|NCT02965833|Other|HMPS, then CCP|Subject's habitual multi-purpose contact lens solution in Period 1, followed by 3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix contact lens solution in Period 2. Each product used daily per packaging instructions with subject's habitual contact lenses for approximately 30 cleaning and disinfection cycles.
3125099|NCT02965924|Experimental|Phenylephrine|Subjects will receive topical phenylephrine 2.5% eye drop instilled in one eye after all baseline measurements.
3125100|NCT02965989|Experimental|Online training of a nursing technique|Participants receives an individual online training of extraction of blood culture for 3 months (This platform aims to improve knowledge and skills), they are sent 3 homework (one per month) and are evaluated at the end of each.
3125101|NCT02965989|No Intervention|not receive online training|Participants don´t receives an individual online training of extraction of blood culture.Do their work as usual.
3469648|NCT03885323|Experimental|Treatment group|The treatment is conducted with the ToothWave toothbrush Intervention: brushing with RF-utilizing powered toothbrush
3469649|NCT03885323|Placebo Comparator|Control group|Regular powered toothbrush Intervention: brushing with a regular powered toothbrush with no RF
3469650|NCT03885167||Affected Individuals with Known SCA3|In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
3469651|NCT03885167||Healthy Individual Control Subjects|In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
3469652|NCT03885297||Overweight/obese participants|Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan. Patients will additionally receive standard NHS Tier 3 lifestyle advice and support for the duration of the study. Lifestyle modification aimed at weight loss will be delivered by a dietician or other trained health care professional within individual sessions for a period of 6 months. Finally, all patients will be able to withdraw from treatment and/or the study at any point without giving any explanation. This will have no impact in their clinical management.
3469653|NCT03884686|Experimental|Web-based intervention|Patients allocated to intervention arm will have unlimited free access to a web-based education resource.
3469654|NCT03884686|No Intervention|Usual care|Patients allocated to usual care will receive all usual care and education opportunities.
3125102|NCT02966002|Experimental|Intervention: aspirin|650 mg. Twice a day for 8 weeks
3125103|NCT02966015|Experimental|Testing the new Coloplast Test catheter|The subjects used the new Coloplast Test catheter for 1 week
3469655|NCT03885271|Experimental|Group A (Experimental group) Hall Technique|Clinical examination to assess the clinical inclusion criteria. Radiographic examination.The child will be positioned upright in the dental chair . The correct size of PMC for the tooth will be selected. The tooth will be rinsed and dried, and the PMC dried. The PMC will be filled with glass ionomer luting cement. The PMC will be placed evenly over the tooth and the child instructed to bite down firmly until the crown was pushed down over the tooth;If the child was unable or unwilling to bite down on the PMC, finger pressure will be used to seat the crown Extruded cement will be removed, and the child will be asked to keep biting on the Hall PMC until the cement sets and once cement sets, excess cement is removed, floss will be used to clear the aproximal contacts, and post-fitting instructions will be given (Innes et al. 2007).
3469656|NCT03885271|Active Comparator|Group B (control group) Formecresol Pulpotomy|Clinical examination to assess the clinical inclusion criteria. Radiographic examination. The teeth anesthetized, rubber dam isolation, Complete caries removal achieved with a sterile round steel bur in a slow- speed handpiece. Access to the pulp chamber performed using a sterile slow-speed round steel bur. The pulp amputation with a sterile diamond bur in a high-speed handpiece and pulpal debris removed with a sterile saline solution on a sterile cotton pledget. After pulp amputation haemostasis achieved using a sterile cotton pledget. Formocresol (FC) applied using a sterile cotton pledget for 5 minutes. After removal of the formocresol soaked cotton pledget, the pulp chamber rinsed with water using an air-water syringe. The pulp chamber dried with a sterile cotton pledget, followed by application of Zinc Oxide & Eugenol and zinc phosphate. Tooth preparation done to receive stainless steel crown.
3469657|NCT03884946|Active Comparator|Immediate Delivery|Participants randomized into the Immediate Delivery arm (n = 150) receive access to the app immediately upon enrollment, and are given a pre- (baseline) and post- (one month post-baseline) test.
3469658|NCT03884946|Placebo Comparator|Delayed Delivery|Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
3469659|NCT03884881|Other|metagenomic next generation sequencing|Adjust medication for patients with severe pneumonia based on mNGS results
3125104|NCT02966028|Experimental|SNF472 300 mg|Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
3125105|NCT02966028|Experimental|SNF 472 600 mg|Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
3125106|NCT02966028|Placebo Comparator|Matching Placebo|Placebo arm: 2 vials of physiological saline
3179144|NCT00669747|Experimental|A|Carboplatin infused into DCIS-involved duct on Days 1 & 15
3125107|NCT02966275|Experimental|Glucagon-only bionic pancreas - glucagon|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses glucagon from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
3125108|NCT02966275|Placebo Comparator|Glucagon-only bionic pancreas - placebo|"Subjects will wear the bionic pancreas that consists of a continuous glucose monitor linked to a smartphone running a hypoglycemia prevention algorithm that doses placebo from an insulin pump through a subcutaneous infusion set.~Subjects will continue to manage any hypoglycemia that occurs according to the current recommendations of their care provider."
3125109|NCT02966314|Placebo Comparator|Placebo|Placebo contains sodium chloride 0.9% and will be provided by Novartis. Placebo will be administered as a subcutaneous injection.
3125110|NCT02966314|Active Comparator|Omalizumab|Omalizumab is a sterile, white, preservative-free, lyophilized powder, contained in a single-use vial that will be reconstituted with sterile water for injection (SWFI), USP, and administered as a subcutaneous injection. Each omalizumab vial contains 202.5 mg of omalizumab, 145.5 mg sucrose, 2.8 mg L-histidine hydrochloride monohydrate, 1.8 mg L-histidine, and 0.5 mg polysorbate 20. Each vial is designed to deliver 150 mg of omalizumab in 1.2 mL after reconstitution with 1.4 mL SWFI, USP.
3179145|NCT00669747|Experimental|B|Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15
3179146|NCT00669747|Placebo Comparator|C|Normal Saline infused into DCIS-involved duct Days 1 & 15
3469660|NCT03884881|Other|Conventional pathogen detection|Blood, bronchoalveolar lavage fluid (BALF), bronchial secretions samples will be collected and microbiologically tested prior to initial empirical antibiotic use.
3469661|NCT03884868|No Intervention|Control group|Regular nursing visit: 1. Explanation of the meaning of a positive result in the FIT. 2. Explanation of the need to perform a colonoscopy with sedation. 3. Anamnesis. 4. Agreement of the day and hour to perform the colonoscopy. 5. Explanation of the diet and delivery of preparation for the preparation of the colon.
3469662|NCT03884868|Experimental|Intervention group|In addition of the regular nursing visit: the nurse will use iconographies specially designed to communicate the risk of the different possible diagnoses and the complications of the colonoscopy. Because the risks are different according to sex and age, specific iconographies will be developed from the data available in the first screening round.
3469663|NCT03885076||Acute myeloid leukaemia|Patients with Acute Myeloid Leukaemia (excluding M3) at presentation, remission or with refractory or relapsed disease. There is no intervention. This is an observational tissue collection study.
3469664|NCT03884738|Active Comparator|Concentric|Leg Curl Training
3469665|NCT03884738|Active Comparator|Eccentric|Nordic Hamstring Training
3469666|NCT03884738|Active Comparator|Neuromuscular Electrical Stimulation|Stimulation Training
3469667|NCT03884894||sepsis diagnosis by blood colture/molecular biology|fullterm/ preterm neonates hospitalized in NICU with suspect of sepsis
3469668|NCT03884790|Experimental|Surgical repair of long bone defects|The Patients in the study group will be surgically treated and the GreenBone Bone Substitute will be implanted
3469669|NCT03884803|Other|HealthyMoms web-based program|An on-line self-help psychoeducational website for new moms that includes educational learning modules and tools to prevent/reduce depression. .
3469670|NCT03884803|Other|Control group|No access to the intervention but to continue with standard care. Will complete the same questionnaires as the HealthyMoms group.
3469671|NCT03884764|Experimental|PRF on S3 + ganglion impar denervation|patients will receive pulsed radiofrequency on sacral root number 3 in conjunction with ganglion impar denervation by alcohol
3469672|NCT03884764|Active Comparator|ganglion impar denervation|patients will receive ganglion impar denervation by alcohol
3469673|NCT03884751|Experimental|CAR-GPC3 T Cells|The subjects are enrolled into 2 dose levels cohorts in sequence
3469674|NCT03884829|Experimental|CYC140 single agent|CYC140 will be administered as a single agent on Day 1 and Day 8 of each 3 week cycle
3469675|NCT03884712|Experimental|CalmiGo Recipients|This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
3469676|NCT03885141|Placebo Comparator|Men - Placebo|Men - Placebo, 1 tablet if a wake up occurs
3469677|NCT03885141|Experimental|Men - Zolpidem 1.75 mg|Men - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
3469678|NCT03885141|Experimental|Men - Zolpidem 3.5 mg|Men - Zolpidem 3.5 mg, 1 tablet if a wake up occurs
3469679|NCT03885141|Placebo Comparator|Women - Placebo|Women - Placebo, 1 tablet if a wake up occurs
3469680|NCT03885141|Experimental|Women - Zolpidem 1.0 mg|Women - Zolpidem 1.0 mg, 1 tablet if a wake up occurs
3469681|NCT03885141|Experimental|Women - Zolpidem 1.75 mg|Women - Zolpidem 1.75 mg, 1 tablet if a wake up occurs
3469682|NCT03885115|Experimental|Intervention|Participants randomly assigned to the experiential group (EG) will receive a 12-week structured exercise that will consist of two group fitness sessions (i.e. kickboxing, Zumba, fitness yoga, and other aerobic exercises) every week. Certified fitness instructors will lead each session and participants will learn strategies how to be more active during the daily routines at home. Parents or other relatives in the EG will participate in one 2-hour session every four weeks (total of 3 sessions) designed to help them support their children and entire family in being active and eat healthy at home. Parents will meet with a fitness instructor who will provide specific tips on how to increase physical activity at home as well as providing community resources to be active. A basic nutrition education and cooking demonstrations, and healthy recipes will be also provided to parents at these workshops. Data/assessments are collected, pre and post the 12 weeks intervention.
3125111|NCT02966340|Experimental|Prazosin 1st visit, Placebo 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
3125112|NCT02966340|Experimental|Placebo 1st visit, Prazosin 2nd visit|All participants receive 2mg prazosin and placebo in a cross-over design (e.g., one pill per visit). The order of prazosin vs placebo is counterbalanced between subjects (e.g., half participants receive prazosin at study visit 1 and half participants receive placebo at study visit 1).
3125113|NCT02966353|Experimental|All Subjects|10 mg BID (2 tablets of 5mg) was self-administered as starting dose for all patients. This dose was maintained for the first 12 weeks and titrated up thereafter unless they had met criteria for dose hold or dose reduction. Dose was to have been increased or decreased per standardized dosing paradigm and not to have exceeded 25 mg bid.
3125114|NCT02966509|Experimental|A: Intervention Arm|All participants randomized to Arm A will receive the EPAC intervention as well as usual oncologic care.
3469683|NCT03885115|No Intervention|Control|Participants randomly assigned to the control group (CG) will receive once a week recreational structured group play/game sessions led by trained BOUNCE interns/staff. The control group will receive 60 minute of structured free play sessions (i.e. recreational games) once a week for 12 weeks. Every 4 weeks, parents will be given (either sent home with their child or via email or mail) basic nutrition information, healthy recipes, and tips to promote physical activity at home as well as community resources to be active. Data/assessments are collected, pre and post the 12 weeks intervention.
3469684|NCT03884842|Active Comparator|dupilumab|"Dupilumab 300 mg subcutaneously (SC) every 2 weeks as an investigational drug. For those randomized to dupilumab, a loading dose of 600 mg will be given only at randomization/Visit 2.~Sterile dupilumab of will be provided in 150 mg/mL in glass prefilled syringes (2.25 mL total volume) to deliver 300 mg in 2 mL."
3469685|NCT03884842|Placebo Comparator|matched placebo|Sterile placebo for dupilumab will be provided in identically matched glass prefilled syringes to deliver 2 mL.
3469686|NCT03884725|Active Comparator|fibrinogen concentrate|patients randomized to fibrinogen group receive intravenous infusion of drug prepared based on ROTEM measurement of maximum clot firmness (MCF)
3469687|NCT03884725|Placebo Comparator|control|patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF)
3469688|NCT03884972|Experimental|Cohort I (BTK-refractory)|Patients receive venetoclax PO QD beginning on day 1 for 5 weeks (cycle 1). Beginning in cycle 2, patients receive venetoclax PO QD and trabectedin IV over 3 hours on day 1. Cycles 2+ repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3469689|NCT03884972|Experimental|Cohort II (BTK-intolerant)|Patients receive trabectedin IV over 3 hours on day 1 of a 3-week cycle (cycle 1), then receive venetoclax PO QD beginning on day 1 of a 5-week cycle (cycle 2). Beginning in cycle 3, patients receive trabectedin IV over 3 hours on day 1 and venetoclax PO QD every 3 weeks in the absence of disease progression or unacceptable toxicity.
3469690|NCT03884699|Other|Segmental maxillary lefort I re-positioning|Accuracy of the planned virtually re-positioned segmental Lefort I maxilla using a specifically designed patient implant, comparing the virtual plan to the actual postoperative position.
3469691|NCT03884673||DTG+3TC|These cases were given simplified therapy regimen including DTG (50 mg, oral,qd) combined with 3TC (300 mg,oral,qd).
3469692|NCT03884998|Experimental|Treatment (copanlisib and nivolumab)|Participants receive copanlisib IV over 60 minutes on days 1, 8, and 15 and nivolumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3125115|NCT02966509|No Intervention|B: Control Group Arm|All participants randomized to Arm B will receive usual oncologic care.
3125116|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 8 Weeks|Non-cirrhotic participants with hepatitis C virus genotype 5 or 6 received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 8 weeks, according to label.
3179147|NCT00669760||Observation|CF-patients with persistent culture of Staphylococcus aureus in their respiratory specimens
3469693|NCT03884543|Experimental|Individualized high PEEP strategy|Recruitment maneuver (performed after induction of anesthesia, after any disconnection from the mechanical ventilator, and before extubation) followed by the decremental PEEP trial to determine the highest level of PEEP resulting in the lowest driving pressure. This is again followed by a recruitment maneuver, after which PEEP is set at the level indicated by the decremental PEEP trial.
3469694|NCT03884543|No Intervention|Standard low PEEP strategy|PEEP at maximum 5cm H2O. No recruitment maneuvers. Patients are randomized and intraoperatively ventilated with conventional strategy. (PEEP at maximum 5cm H2O without recruitment maneuvers)
3469695|NCT03884621|Experimental|EHP Group|The Enhanced post-discharge home-based care program (EHP) offers one coaching session upon hospital discharge and 12-week home follow-up (including 6 home visits, 6 telephone calls and 24-hour hotline) post hospital discharge to participants by an especially trained nurse case manager with the support of a clinical team. The five intervention protocols integrate with an individualized home-based rehabilitation training and self-care plan.
3469696|NCT03884621|No Intervention|Control Group|Usual discharge care and post-discharge care provided to all stroke patients discharged home.
3469697|NCT03884556|Experimental|Arm 1, Single Agent|TTX-030
3469698|NCT03884556|Experimental|Arm 2, Anti-PD-1 Combination|TTX-030 plus pembrolizumab
3469699|NCT03884556|Experimental|Arm 3, Chemotherapy Combination|TTX-030 plus docetaxel
3469700|NCT03884556|Experimental|Arm 4, Chemotherapy Combination|TTX-030 plus gemcitabine plus nab-paclitaxel
3469701|NCT03884920||Group A Pre-diabetic placebo|Group of pre-diabetics receiving placebo BD for six weeks
3469702|NCT03884920||Group B Pre-diabetic test|Group of Pre-diabetic receiving polyherbal / test candidate 900mg in two divided doses for six weeks
3469703|NCT03884920||Group C Diabetic test|Early onset of Diabetes mellitus receiving polyherbal formulation 1800mg in two divided doses for six weeks
3469704|NCT03884595||No SIRS|Children without clinical signs of SIRS, according to Goldstein criteria.
3469705|NCT03884595||SIRS|Children with clinical signs of SIRS, according to Goldstein criteria.
3469706|NCT03884595||Sepsis|Children with clinical signs of sepsis, according to Goldstein criteria.
3125117|NCT02966795|Experimental|Glecaprevir/Pibrentasvir for 12 Weeks|Participants with hepatitis C virus genotype 5 or 6 and compensated cirrhosis received oral glecaprevir/pibrentasir (300 mg/120 mg) once daily with food for 12 weeks, according to label.
3469707|NCT03884595||Severe sepsis|Children with clinical signs of severe sepsis, according to Goldstein criteria.
3469708|NCT03884595||Septic Shock|Children with clinical signs of septic shock, according to Goldstein criteria.
3469709|NCT03884582||HealthyVolunteers|
3469710|NCT03884491|Experimental|Vortioxetine|
3469711|NCT03884374|Experimental|African American Group|African Americans with knee osteoarthritis (OA).
3125118|NCT02966834|Placebo Comparator|Placebo|Participants will receive matching placebo
3469712|NCT03884374|Experimental|Non-Hispanic White Group|Non-Hispanic whites with knee osteoarthritis (OA).
3469713|NCT03884257|Experimental|Passeo-18 Lux treatment group|These patients will be treated with the Passeo-18 Lux (Biotronik).
3469714|NCT03884257|Active Comparator|IN.PACT Admiral treatment group|These patients will be treated with the IN.PACT Admiral (Medtronic).
3469715|NCT03884231||Leads-only configuration|The leads-only configuration consists of at least one implanted lead protected with a lead protection boot, as well as an optional cranial burr hole cover. Any leads must be completely implanted with the surgical incision closed.
3469716|NCT03884231||Full system configuration|The full system configuration consists of at least one IPG, one lead, one extension, and an optional cranial burr hole cover. All devices must be completely implanted with the surgical incision closed.
3469717|NCT03884348||PAM-treated clarithromycin-resistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and metronidazole (500 mg) three times a day for 7 days in patients with clinically significant point mutations
3469718|NCT03884348||PAC-treated nonresistance group|Treatment with PPI twice a day, amoxicillin (1000 mg) twice a day, and clarithromycin (500 mg) twice a day for 7 day in patients with clinically insignificant point mutations
3469719|NCT03884361|Experimental|Vaginal Microbiome as result of aminocentesis|aginal Microbiome as result of aminocentesis by a blood and a vaginal samples that will taken before and after the aminocentesis
3469720|NCT03884517|Experimental|BAT8003 0.2mg/kg|BAT8003，0.2mg/kg，intravenous infusion, sample size 1-3
3469721|NCT03884517|Experimental|BAT8003 0.5mg/kg|BAT8003，0.5mg/kg，intravenous infusion, sample size 1-3
3469722|NCT03884517|Experimental|BAT8003 1mg/kg|BAT8003，1mg/kg，intravenous infusion, sample size 3
3469723|NCT03884517|Experimental|BAT8003 2mg/kg|BAT8003，2mg/kg，intravenous infusion, sample size 3
3469724|NCT03884517|Experimental|BAT8003 4mg/kg|BAT8003，4mg/kg，intravenous infusion, sample size 3
3469725|NCT03884517|Experimental|BAT8003 6mg/kg|BAT8003，6mg/kg，intravenous infusion, sample size 3
3469726|NCT03884517|Experimental|BAT8003 8mg/kg|BAT8003，8mg/kg，intravenous infusion, sample size 3
3469727|NCT03884517|Experimental|BAT8003 10mg/kg|BAT8003，10mg/kg，intravenous infusion, sample size 3
3469728|NCT03884517|Experimental|Amplification group|BAT8003，intravenous infusion，choose one proper dose from 0.2、0.5、1、2、4、6、8、10mg/kg
3469729|NCT03884322|Experimental|Prepod Group|Premature Infants (31 to 32 weeks gestation on entry to program), healthy who wear a prepod or elastic knit fabric pod with snaps essentially 24 hrs a day with brief breaks for bathing, exams, or parent skin to skin time. The intervention lasts 4 weeks
3469730|NCT03884322|Active Comparator|Control Group|Premature infants (31 to 32 weeks of age on entry to program), healthy who receive a joint compression exercise program approximately 10 minutes a day 5 days a week. The intervention lasts 4 weeks
3469731|NCT03884569||Patients treated with CLET|"Previously treated with CLET patients are included retrospectively, as the follow-up procedure is already stablished in our centre, and patients treated following standard care or through drugs-in-special-situation request in Spain prospectively. Patients are not treated to be included in the study, only the follow-up variables are taken into account."
3469732|NCT03884413||Breast cancer survivors|Study of spontaneous fertility outcomes following breast cancer history
3469733|NCT03884413||Control group|Study of spontaneous fertility outcomes in healthy volonteers population
3469734|NCT03884452|Experimental|Atorvastatin 80 mg|80 mg atorvastatin taken orally, once daily for 12 weeks
3469735|NCT03884452|Experimental|Ezetimibe + Atorvastatin 40 mg|10 mg ezetimibe and 40 mg atorvastatin taken orally, once daily for 12 weeks
3469736|NCT03884452|Experimental|Ezetimibe + Atorvastatin 80 mg|10 mg ezetimibe and 80 mg atorvastatin taken orally, once daily for 12 weeks
3469737|NCT03884452|Experimental|Simvastatin 80 mg|80 mg simvastatin taken orally, once daily for 12 weeks
3469738|NCT03884452|Experimental|Ezetimibe + Simvastatin 40 mg|10 mg ezetimibe and 40 mg simvastatin taken orally, once daily for 12 weeks
3469739|NCT03884452|Experimental|Ezetimibe + Simvastatin 80 mg|10 mg ezetimibe and 80 mg simvastatin taken orally, once daily for 12 weeks
3469740|NCT03884296|Other|Study Phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
3469741|NCT03884465|Experimental|Inhaled dry powder treprostinil (LIQ861)|Full study population receives inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg or 100μg capsule strengths.
3469742|NCT03884400||Subjects who have provided consent for specimen collection|Re-consent will not be required. This protocol allows distribution of the specimens following the terms agreed to by the subject in the original consent.
3469743|NCT03884192|Experimental|Sintilimab Arm|Sintilimab consolidation therapy
3469744|NCT03884192|No Intervention|Observation Arm|Observation
3469745|NCT03884218|Other|Thermal Comfort|Infra red thermal image
3469746|NCT03884244|Active Comparator|taking chewing gum patients|
3469747|NCT03884244|No Intervention|no chewing gum|
3469748|NCT03884309|Experimental|Experimental Hydrolyzed Protein Infant Formula|hydrolyzed protein infant formula powder in cans
3125119|NCT02966834|Experimental|GSK2330672 20 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
3125120|NCT02966834|Experimental|GSK2330672 90 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
3125121|NCT02966834|Experimental|GSK2330672 180 mg once daily|Participants will receive GSK2330672 and matching placebo to maintain blind
3125122|NCT02966834|Experimental|GSK2330672 40 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
3125123|NCT02966834|Experimental|GSK2330672 90 mg twice daily|Participants will receive GSK2330672 and matching placebo to maintain blind
3469749|NCT03884478|Experimental|Alcohol + Stigma Coping PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and two control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on their stigma coping behaviors after answering questions about their stigma coping behaviors and two control topics.
3469750|NCT03884478|Experimental|Alcohol + Control PNF|Participants randomized to this condition will receive gamified personalized normative feedback on their alcohol use after answering questions about alcohol use and control topics in Round 3. Then, in the very next Round of the competition (Round 4), these participants will receive gamified personalized normative feedback on one control topic (Relationships) after answering questions about their stigma coping behaviors and two control topics.
3469751|NCT03884478|Other|Control PNF|Participants randomized to the control arm will answer questions about the same topics as participants in the other conditions in Round 3 (Alcohol Use & Control) and Round 4 (Stigma-Coping & Control). However, in both Rounds 3 and 4 they will receive gamified PNF on control topics.
3469752|NCT03884530|Active Comparator|Ticagrelor ( Brilique) group|the group will receive 180 mg ticagrelor (2 tablets of 90 mg) as a single loading oral dose, and continue on 180 mg ticagrelor (1 tablet of 90 mg every 12 hours) for 3 months
3469753|NCT03884530|Active Comparator|Aspirin Group|The group will receive 300 mg Aspirin (4 tablets of 75 mg) as a single loading oral dose, and will then be commenced on 300 mg Aspirin daily for 2 weeks then 75 mg daily after that for 3 months
3469754|NCT03884335|Active Comparator|epidural group|An epidural catheter was placed at L1-L2 level, and tested, prior to induction. Induction was performed intravenously with fentanyl (1.5mcg•Kg-1), propofol (1.5-2 mg•Kg-1), and rocuronium (0.6 mg•Kg-1). Orotracheal intubation was performed. Prior to skin incision 8 mL of 0.25% levo-bupivacaine were administered epidurally, and a continuous perfusion of 0.125% levo-bupivacaine at 5 mL was started.
3469755|NCT03884335|Experimental|TAP group|Bilateral Transversus abdominis plane blockade (TAP) was performed following induction of anaesthesia ( the same of epidural group) and prior to skin incision, the high-frequency lineal probe (Sonosite MicroMAXXTM) was placed midway between the costal margin and iliac crest, and transversus abdominis muscle located behind the rectus abdominis and below the IOM. 20 mL of LA (bupivacaine 0.375%) was administered via a 22 gauge Quincke spinal needle inserted in-plane on each side of the abdomen. A successful block was recorded if the plane was seen to expand with fluid under ultrasound vision.
3469756|NCT03884127||hyperlipidaemia|On the basis of the intervention of therapeutic sexual life style, a case control study was conducted on the intervention of oral ezetimibe tablet and orlistat capsule for 12 weeks and hyperlipidemia patients who persisted in the use of basic treatment.
3469757|NCT03884270|Experimental|Hypnotherapy|7 sessions of on-line hypnotherapy treatment over the course of 12 weeks (1 new session every 2 weeks)
3469758|NCT03884153|Experimental|CRP apheresis|"CRP apheresis by means of selective apheresis using the PentraSorb-CRP adsorber"
3469759|NCT03883906|Experimental|Viral Specific T-cells (VSTs)|
3469760|NCT03883841||Study group|patients with iron deficiency anemia
3469761|NCT03883841||control group|normal pregnant patients
3469762|NCT03883880|Experimental|Epigallocatechin gallate|Epigallocatechin gallate solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
3469763|NCT03883880|Experimental|Linoleic acid|Linoleic acid emulsion will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
3179148|NCT00669773|Experimental|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
3179149|NCT00669773|Experimental|Docetaxel|
3469764|NCT03883880|Experimental|Capsaicin|Capsaicin solutions will be provided to participants to rinse with daily for two weeks. A control solution will be provided for two weeks as well. Order will be counterbalanced across participants and groups.
3469765|NCT03883815||Assesment treatment intensity|Assesment treatment intensity during neurodevelopmental therapy session and active video games therapy session
3469766|NCT03884062||DAAs-SVR.|annual incidence of HCC in chronic hepatitis C patients with advanced liver fibrosis (F3 and F4) after achieving DAAs-SVR.
3469767|NCT03884426||Patients with MVP|The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.
3469768|NCT03884426||Normal relatives|Related healthy patients, for an average of 6 individuals per family
3469769|NCT03884088|Experimental|Experimental Group: Balance analysis|Balance will be assessed by Computerized Balance system and subjective balance tests.
3469770|NCT03883945|Placebo Comparator|Cohort 1 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
3469771|NCT03883945|Active Comparator|Cohort 1 - 0.033%|Subjects randomized to vehicle will receive AIV001 0.033% administration to the target area.
3469772|NCT03883945|Placebo Comparator|Cohort 2 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
3469773|NCT03883945|Active Comparator|Cohort 2 - 0.1%|Subjects randomized to vehicle will receive AIV001 0.01% administration to the target area.
3469774|NCT03883945|Placebo Comparator|Cohort 3 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
3469775|NCT03883945|Active Comparator|Cohort 3 - 0.3%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
3179150|NCT00669786|Active Comparator|HMG|Human Menopausal Gonadotropin (HMG)
3125124|NCT02967016|Experimental|normal spontaneous vaginal delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
3125125|NCT02967016|Experimental|Cesarean Delivery|Both groups will be asked to wear a fitness tracker (Actigraph GT3X+).
3469776|NCT03883945|Placebo Comparator|Cohort 4 - vehicle|Subjects randomized to vehicle will receive vehicle administration to the target area.
3469777|NCT03883945|Active Comparator|Cohort 4 - 1%|Subjects randomized to vehicle will receive AIV001 0.03% administration to the target area.
3125126|NCT02967354|Experimental|Healthy control|Healthy control
3125127|NCT02967354|Experimental|Obese with oral antidiabetic drugs|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs
3125128|NCT02967354|Experimental|Obese, treated with oral antidiabetic drugs + insulin|BMI>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin
3125129|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs
3469778|NCT03883971|Experimental|3D model|patient is given 3D printed model of her fetus's face
3469779|NCT03883971|Placebo Comparator|picture|patient is given a fetal picture only.
3469780|NCT03883919|Experimental|Group 1: Paricalcitol 75 mcg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 75 mcg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
3469781|NCT03883919|Experimental|Group 2: Paricalcitol 7 mcg/kg Days 1 and 8|"5-FU, LV, and nal-IRI will be administered at standard fixed doses. Briefly, 5-FU will be given at a dose of 2400 mg/m^2 continuous IV infusion over 46 hours, LV will be given at 400 mg/m^2 IV over 30 minutes, and liposomal irinotecan will be given at a dose of 70 mg/m^2 IV over 90 minutes (unless homozygous for the UGT1A1*28 7/7 allele, in which case the dose will start at 50 mg/m^2 and escalate to 70 mg/m^2 in subsequent cycles if no excessive toxicity is experienced) on Day 1 of each 14-day cycle.~Paricalcitol 7 mcg/kg on Days 1 and 8~Treatment with liposomal irinotecan plus 5FU/ LV may continue indefinitely, and treatment with paricalcitol may continue for up to 10 cycles (20 weeks)"
3469782|NCT03884010||Participants|Professional male soccer players from the second professional Mexican division
3125130|NCT02967354|Experimental|Normal weight, treated with oral antidiabetic drugs + insulin|BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin
3125131|NCT02967367|Experimental|Jawbone/Withings sleep trackers, Bodymedia Sensewear|2 types of Consumer sleep trackers, including Jawbone and Withings, and one research actigraph (Bodymedia Sensewear) are added to classical polysomnography in order to assess their accuracy to measure sleep parameters in obstructive sleep apnea patients
3125132|NCT02967393|Active Comparator|IIV4|0.5 mL intramuscular injection
3125133|NCT02967393|Active Comparator|cc IIV4|0.5 mL intramuscular injection
3469783|NCT03884101|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
3125134|NCT02967458|Experimental|Prostate Biopsy Patients|Fifty patients who are scheduled for a clinically indicated prostate biopsy, and who are able to undergo contrast enhanced transrectal ultrasound will be included in this single arm study. Each of the study subjects will receive in intravenous infusion of a microbubble contrast agent known as Definity™, (Perflutren Lipid Microsphere, Lantheus Medical Imaging, Inc; N. Billerica, MA). Based upon our previous experience, two vials of Perflutren Lipid Microsphere will be mixed and diluted in 50 ml of normal saline, yielding a concentration of 49.4 μl/ml. For the purpose of contrast-enhanced imaging, Perflutren Lipid Microsphere will be infused over approximately 10-12 minutes, during which time ultrasound imaging and biopsy will be performed.
3125135|NCT02967510|Experimental|0.005% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3469784|NCT03884101|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
3469785|NCT03884387|Experimental|Use of a Patient Decision Aid|A Patient Decision Aid is used in this arm in the clinical encounter. A tool designed to facilitate shared decision making when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
3469786|NCT03884387|No Intervention|Usual counceling|Usual counseling in the clinical encounter, when patients choose between surgical and non-surgical treatment for lumbar disc herniation .
3469787|NCT03883997||Participants|Professional male soccer players from the second professional Mexican division.
3469788|NCT03884114|Other|All participants|All participants are evaluated on a scenario of pediatric asthma exacerbation using three different evaluation tools: (i) the simulation game EfficAsthme developed to train individuals on the management of pediatric asthma exacerbations; (ii) a MCQ on the same subject developed for the purpose of the study and (iii) HF-simulation, considered as the gold-standard for its enhanced realism.
3469789|NCT03884049|Experimental|Embolization group|Group undergoes transcatheter arterial embolization of neovessels around the knee.
3469790|NCT03884049|Sham Comparator|Sham Embolization Group|Group undergoes sham embolization
3469791|NCT03884036|Active Comparator|Vitamin D group|Vitamin D 200,000 IU (1 cc) IM
3469792|NCT03884036|Placebo Comparator|Control group|Normal saline 1 cc IM
3469793|NCT03883802|Experimental|Foxy-5|Arm will receive Foxy-5 as neo-adjuvant therapy prior to surgical removal of tumour and afterwards until initiation of FOLFOX 6 months regimen
3469794|NCT03883802|Active Comparator|Standard therapy|Surgical removal of tumour followed by 6 months FOLFOX regimen
3125136|NCT02967510|Experimental|0.002% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3469795|NCT03883828|Experimental|Treatment Arm|The purpose of this study is to determine whether bacterial decolonization of the nares and skin prior to treatment with radiotherapy (RT) for patients with cancers of the head and neck or breast, can prevent high-grade radiation dermatitis (RD) and improve quality of life. This study is being conducted because prior studies from this research group have found bacterial colonization in the nose prior to initiation of RT to be associated with an increased risk of high-grade RD. Patients in the treatment arm will receive pretreatment with mupirocin ointment to the nares and chlorhexidine wash to the body while patients in the control arm will receive standard of care treatment. Bacterial cultures will be taken from the nares and skin, and participants will also complete a quality of life questionnaire before and after RT.
3469796|NCT03883828|No Intervention|Control|Patients in the control arm will be treated according to standard of care without any radiation dermatitis prophylaxis.
3469797|NCT03884205||test group|patients with PTCL who receive GDPE/CEOPE as the first-line therapy strategy
3469798|NCT03884205||control group|patients with PTCL who receive CEOPE as the first-line therapy strategy
3469799|NCT03883984|Experimental|Cysteamine|Cysteamine Bitartrate plus standard asthma care
3469800|NCT03883984|Placebo Comparator|Placebo Oral Tablet|Placebo plus standard asthma care
3469801|NCT03883789||Normal pregnancies|Participants who have normal uncomplicated pregnancies
3125137|NCT02967510|Experimental|0.0008% estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3179151|NCT00669786|Active Comparator|r-FSH|Recombinant Follicle Stimulating Hormone
3179152|NCT00669799|Experimental|1|clyndamyacin
3469802|NCT03883789||Pregnancies with complications|Participants who undergo pregnancy with liver disease or develop liver disease or other conditions
3469803|NCT03884166||stroke|
3469804|NCT03884166||control|
3469805|NCT03883958|Active Comparator|TPVB|
3469806|NCT03883958|Experimental|ESPB|
3469807|NCT03883932|Experimental|F3 Program|The F3 group will focus on the fatherhood role each session. The topic of children and parenting will be applied to each of the standard FVEP topics.
3469808|NCT03883932|Active Comparator|FVEP Program|A retrospective control group who received the standard FVEP will be included in this arm.
3469809|NCT03883776|Experimental|healthy volunteers and NET patients|"In the first part of the study, 6 healthy volunteers will receive a single intravenous single injection of Al18F-NOTA-octreotide, followed by whole-body PET/CT scans at various time points for an initial safety assessment and dosimetry study.~In the second part of the study, a single dose of Al18F-NOTA-octreotide will be intravenously injected in 6 patients with neuroendocrine tumors. Patients will first undergo a dynamic PET scan, followed by whole-body PET/CT scans at various time points for a pharmacokinetics study and initial efficacy assessment."
3469810|NCT03883763|Experimental|Hyperbaric Novabupi® 0.5% (bupivacaine S75:R25 + 8% glucose)|
3469811|NCT03883763|Active Comparator|Hyperbaric Neocaine® 0.5% (bupivacaine S50:R50 + 8% glucose)|
3469812|NCT03883672|Experimental|hematopoietic stem cell transplantation|Personality and transactional factors involved in the process and outcomes of hematopoietic stem cell transplantation
3469813|NCT03883737|Experimental|Group 1: PNM in pain knee|participants in whom PNM will be applied to the femoral nerve of the pain knee
3469814|NCT03883737|Experimental|Group 2: PNM in non-pain knee|participants in whom PNM will be applied to the femoral nerve of the non-pain knee
3469815|NCT03883555||Optiflow tm|High flow nasal therapy (HFNT)
3469816|NCT03883555||Non invasive ventilation (NIV)|Non invasive ventilation (NIV)
3469817|NCT03883594|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
3469818|NCT03883893|Active Comparator|IV Tylenol|Participants will receive IV acetaminophen 15mg/kg in the OR.
3469819|NCT03883893|Placebo Comparator|Normal Saline|Participants will receive 0.9% normal saline in the OR. The amount received will be equivalent of what would be given if they were receiving IV acetaminophen.
3469820|NCT03883425||Case 1: formal home service recipients|Adults aged 65 or older living at home who receive formal home service (household, meal delivery, transportation, shopping) at least one a week
3469821|NCT03883425||Case 2: formal home care recipients|Adults aged 65 or older living at home who receive formal home care (shower/bath nursing assistance, nursing care) at least once a week
3469822|NCT03883425||Control: free of formal home care or home service|Adults aged 65 or older living at home who do not receive formal home care or home service.
3469823|NCT03883321||CBSM|Patients included in this group participate in the CBSM program. They attend 10 sessions of stress management according to the CBSM program, 9 take place over 3 months and the tenth session takes place 3 months after the 9th session. The session is composed of relaxation and cognitive and behavioral therapy, which is carried out in groups of 8 to 10 patients
3469824|NCT03883321||Waiting list|"The CBSM group is compared to the waiting list group that does not benefit from the CBSM program. After completing their assessment in the waiting list group, patients in this group will be integrated into the CBSM group but will not be evaluated as such."
3469825|NCT03883308|Experimental|Treatment|Treatment group will receive 6 months of online, computerized, multi-domain cognitive training at home.
3469826|NCT03883308|Active Comparator|Active Control|The Active Control group will receive 6 months of online, computerized cross-word puzzles at home using the same platform as for the Treatment group.
3469827|NCT03883490||Bicuspid Aortic valve|Patients with a bicuspid aortic valve
3469828|NCT03883490||Tri-leaflet Aortic valve|Patients with a tri-leaflet aortic valve
3469829|NCT03883451|Experimental|Helmet type|football player helmet model
3469830|NCT03883529|Experimental|Women reviewing birth experience|Women who had their antenatal care provided at a high-risk antenatal clinic, will be offered to write about and review their birth experience about 6 weeks post-partum with a known midwife from antenatal care.
3469831|NCT03883503|Experimental|Beer alone|Consumption of beer (correlated for weight to reach a blood alcohol concentration of 0.8) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
3469832|NCT03883503|Active Comparator|Beer and water|Consumption of beer and additional water (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of water, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
3469833|NCT03883503|Active Comparator|Beer and stock|Consumption of beer and additional stock(correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
3469834|NCT03883503|Placebo Comparator|Water alone|Consumption of water alone (correlated for weight to reach a blood alcohol concentration of 0.8, 1/3 of stock, 2/3 of beer) during 1 hour. Continues measurement of sodium, osmolality, copeptin, urinary sodium, urinary osmolality over 12 hours.
3469835|NCT03883438|Active Comparator|Coronally advanced flap and acellular dermal graft|In CAF group, after local anesthesia oblique beveled vertical incisions were made at the most mesial and distal line angles of the recessions. These two incisions were connected with an intra-sulcular and interdental sub-marginal incisions in order to create the external surgical papillae. Then the flap was elevated as a split-full-split approach. The apical portion of the flap was reflected as close to the periosteum as possible by mesio-distal and apical sharp dissection parallel to the mucosa to release residual muscle tension and extended beyond the muco-gingival junction to facilitate the passive coronal replacement of the flap over the defects. In both groups ADMG was used as a sub-epithelial graft considering the manufacturer's instructions. The graft was positioned at the level of cemento-enamel junction and extended to the surrounding bone in the apical direction with full closure of the exposed root surfaces.
3125138|NCT02967510|Placebo Comparator|estriol vaginal gel|Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration
3469836|NCT03883438|Experimental|Modified coronally advanced flap and acellular dermal graft|Test group received CAF avoiding vertical releasing incisions (mCAF).
3469837|NCT03883464|Experimental|Low fat intake|Patients who underwent cholecystectomy and were instructed to have a low fat diet.
3469838|NCT03883464|No Intervention|Regular diet|Patients who underwent cholecystectomy and were instructed to have a regular diet.
3469839|NCT03883399||Colorectal surgeons|Survey among Spanish colorectal surgeons
3469840|NCT03883659|Active Comparator|traditional paper hangouts group|patients use the traditional paper hangouts to conduct the home exercise program at home
3469841|NCT03883659|Experimental|smartphone group|patients use the smartphone to conduct the home exercise program at home
3469842|NCT03883711||Patients with acute coronary syndrome or myocardial injury|Incident consecutive patients presenting with acute coronary syndrome or myocardial injury
3125139|NCT02967562|Active Comparator|Inflation Breaths|Five 'inflation breaths' lasting two - three seconds
3469843|NCT03883373||Cortical group|Group of patient who had an alveolar bone graft with cancellous bone and a cortical block
3469844|NCT03883373||Cancellous group|Group of patient who had an alveolar bone graft with cancellous bone only
3469845|NCT03883620|Experimental|Cohort 1 (Initial Safety Cohort) 1 mg/kg|4 participants will be administered Dengushield at 1 mg/kg body weight as Intravenous injection.
3469846|NCT03883620|Experimental|Cohort 2 Experimental 3mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
3469847|NCT03883620|Placebo Comparator|Cohort 2 Placebo 3 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo and enrolled.
3469848|NCT03883620|Experimental|Cohort 3 Experimental 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
3469849|NCT03883620|Placebo Comparator|Cohort 3 Placebo 7 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
3469850|NCT03883620|Experimental|Cohort 4 Experimental 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
3125140|NCT02967562|Experimental|Sustained inflation|One fifteen second 'sustained inflation'
3125141|NCT02967679|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 48 weeks
3469851|NCT03883620|Placebo Comparator|Cohort 4 Placebo 12 mg/kg|Initially two participants will be randomized in 1:1 ratio to Dengushield or placebo as a sentinel cohort. If there are no causally related serious safety findings, remaining 10 participants for that cohort will be randomized in 9:1 ratio to Dengushield or placebo.
3469852|NCT03883412|Experimental|Exercise Alone|16 weeks of treatment
3469853|NCT03883412|Experimental|Liraglutide alone|16 weeks of treatment
3469854|NCT03883412|Experimental|Exercise + Liraglutide|16 weeks of treatment
3125142|NCT02967991|Active Comparator|19 Left|EUS-guided liver biopsy using a19-gauge liver biopsy in the left lobe
3469855|NCT03883477|Experimental|Endoscopic Release|12 patients recommended for surgical treatment of trigger finger will undergo endoscopic release.
3469856|NCT03883477|Active Comparator|Standard Open Release|12 patients recommended for surgical treatment of trigger finger will undergo standard open surgical release.
3469857|NCT03883347|Active Comparator|Group DEX|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.6 mcg / kg / h.
3469858|NCT03883347|Active Comparator|Group REMI|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia. The infusion of the solution will be discontinued and then will be performed in all patients subarachnoid anesthesia. Starting with Tmax, infusion of the solution will be initiated again at a dose of 0.025 mcg / kg / min.
3469859|NCT03883633||Enrolled Participants|All participants enrolled will be tracked from initial assessment to study completion.
3469860|NCT03883685|Experimental|experimental group|40 subjects will be randomly allocated to receive probiotics pills for consecutive 8 weeks.
3469861|NCT03883685|Placebo Comparator|Control group|40 subjects will be randomly allocated to receive placebo pills for consecutive 8 weeks.
3469862|NCT03883295|Experimental|Control|root canal treatment will be initiated
3469863|NCT03883295|Experimental|NeoMTA Plus|vital pulp treatment using neomta plus will be used.
3469864|NCT03883646|Experimental|Mindfulness|Mindfulness
3469865|NCT03883646|Experimental|Relapse Prevention|
3469866|NCT03883646|No Intervention|Waitlist Control|
3469867|NCT03883646|No Intervention|Treatment as Usual|
3469868|NCT03883360|Experimental|Cannabidiol (CBD)|Participants receive CBD daily for 12 weeks.
3469869|NCT03883360|Placebo Comparator|Placebo|Participants receive vehicle not containing any drug daily for 12 weeks.
3469870|NCT03883698|Experimental|ESRD, alternate day dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 400 mg on alternate days. Total duration of treatment will be 12 weeks
3469871|NCT03883698|Experimental|ESRD, daily dose|Participants with end stage renal disease (eGFR <30 ml/min) and hepatitis C virus active infection and treated with sofosbuvir 200 mg daily doses. The total duration of treatment will be 12 weeks
3125143|NCT02967991|Experimental|22 Left|EUS-guided liver biopsy using a 22-gauge liver biopsy in the left lobe
3125144|NCT02967991|Active Comparator|19 Right|EUS-guided liver biopsy using a 19-gauge liver biopsy in the right lobe
3125145|NCT02967991|Experimental|22 Right|EUS-guided liver biopsy using a 22-gauge liver biopsy in the right lobe
3125146|NCT02968004|Experimental|MOD-4023|Once weekly subcutaneous injection of long acting r-hGH (MOD-4023)
3125147|NCT02968004|Active Comparator|Genotropin|Once daily subcutaneous injection of Somatropin (r-hGH; Genotropin)
3125148|NCT02968134|Other|Posaconazole|The study will enrol eight patients with presumed or confirmed systemic fungal infections, who are admitted to ICU
3125149|NCT02968173|Experimental|Children at High Risk of severe RSV Infection|A single IM injection every 30 days beginning at Day 0 for a total of 3-5 injections determined by when in the RSV season a participant was enrolled.
3469872|NCT03883698|Active Comparator|Control|Participants with normal eGFR and hepatitis C virus infection and treated with sofosbuvir 400 mg daily dose. The total duration of treatment will be 12 weeks
3469873|NCT03883269|Experimental|Erythromycin 4%|Erythromycin 4% topical gel formulation, BID, 4 weeks
3469874|NCT03883269|Experimental|Clindamycin 1%|Clindamycin 1% topical lotion formulation, BID, 4 weeks
3469875|NCT03883269|Placebo Comparator|ethanol solution|70% topical ethanol solution, BID, 4 weeks
3469876|NCT03883334|Experimental|Immunomodulator group|Metisoprinol 1 gr every 8 h per ten days during three months plus the combine antiretroviral therapy.
3469877|NCT03883334|No Intervention|Control group|combine antiretroviral therapy only
3469878|NCT03883256|Active Comparator|high flow nasal cannula|Subjects perform a constant-load exercise test with high flow nasal cannula oxygen device.
3469879|NCT03883256|Active Comparator|nasal cannula|Subjects perform a constant-load exercise test with nasal cannula oxygen device.
3469880|NCT03883243|No Intervention|Control|Patients will only receive a brochure explaining the importance of physical activity with recommendations to improve it.
3469881|NCT03883243|Experimental|Telecoaching|Patients will receive a brochure explaining the importance of physical activity with recommendations to improve it. Next to this patients will receive the telecoaching intervention in which a coaching application linked to a step counter is installed on the patients smartphone, which will weekly give a new physical activity goal to improve the amount of steps per day for 8 weeks.
3469882|NCT03883100|Experimental|HQP1351|
3469883|NCT03882996|Experimental|Ezetimibe 10 mg + Atorvastatin|Ezetimibe 10 mg plus atorvastatin 10 to 80 mg daily for up to 12 months
3469884|NCT03882918|Experimental|OV101|once daily at bedtime (gaboxadol)
3125150|NCT02968277|Experimental|Started with Forearm Support Walker (LW Upright)|Data collection began with participants using the LifeWalker Upright Walker then using the two remaining walkers in a randomized order
3125151|NCT02968277|Experimental|Standard Rollator Walker (Control)|Data collection began with participants using a conventional standard rollator (SR) walker then using the two remaining walkers in a randomized order
3125152|NCT02968277|Experimental|Predicate Device (PD)|Data collection began with participants using their own rollator walkers then using the two remaining walkers in a randomized order
3125153|NCT02968368|Experimental|Oral ferric maltol|30mg capsules BID
3469885|NCT03882905|Experimental|Ezetimibe: Base Study|10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
3469886|NCT03882905|Placebo Comparator|Placebo: Base Study|Placebo for ezetimibe 10-mg tablet, oral taken once daily concomitantly with the participant' s current statin therapy for 8 weeks.
3469887|NCT03882905|Experimental|Ezetimibe: Extension|10-mg tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
3469888|NCT03882905|Placebo Comparator|Placebo: Extension|Placebo for ezetimibe tablet, oral taken once daily concomitantly with simvastatin for 48 weeks.
3125154|NCT02968368|Placebo Comparator|Oral placebo|Matching placebo capsules BID
3125155|NCT02968381|Experimental|Imagery Intervention|Participants will receive imagery intervention which includes 6 telephone sessions, an introduction to guided imagery, setting a quit date, setting guided imagery schedule, and a description of and instructions for using the study website.
3469889|NCT03882970|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3469890|NCT03882970|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3469891|NCT03882970|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3125156|NCT02968381|Active Comparator|Control Condition|Participants will receive an attention control condition which includes 6 telephone sessions, an introduction to cognitive behavioral telephone coaching, setting a quit date, creating a quit plan, and a description of and instructions for using the Arizona Smokers' Help Line website.
3469892|NCT03882970|Active Comparator|Insulin Degludec|Insulin degludec administered SC once a day.
3469893|NCT03882931|Experimental|TMS to left DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the left DLPFC and complete a visuomotor rotation task.
3469894|NCT03882931|Experimental|TMS to right DLPFC|Theta Burst Transcranial Magnetic Stimulation will be delivered at 80% of the participants motor threshold to the right DLPFC and complete a visuomotor rotation task.
3469895|NCT03882931|Sham Comparator|TMS Control|A Sham Theta Burst Transcranial Magnetic Stimulation will be delivered to the right/left DLPFC and complete a visuomotor rotation task.
3469896|NCT03882931|Experimental|FUS to right/left DLPFC|Low intensity Focused Ultrasound stimulation will be delivered to either the left or right DLPFC depending on the subject's DLPFC response during their functional MRI flanker task.
3469897|NCT03882957|Active Comparator|Video|videos of media tasks being completed
3179153|NCT00669799|Experimental|2|gentamicin
3179154|NCT00669825|Placebo Comparator|A|Placebo
3179155|NCT00669825|Active Comparator|B|ALV003 (Active Study Drug)
3469898|NCT03882957|Experimental|media multi-task|media tasks
3469899|NCT03882957|Experimental|sustained attention task|a cognitive task that trains sustained attention
3469900|NCT03883139|Active Comparator|JASPER|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing JASPER. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified JASPER for 3 hours a week (3 days, 1 hour per day)."
3469901|NCT03883139|Active Comparator|DTT|"Child will spend 2 hours per week (2 days, 1 hour per day) for the first 10 weeks doing DTT. If the child is an early responder, he/she will remain in the same course for the following 10 weeks.~If child is a slow responder, he/she will be randomized for either combined & enhanced treatment (CET) for 2 hours a week (2 days, 1 hour per day) or Intensified DTT for 3 hours a week (3 days, 1 hour per day)."
3469902|NCT03882853|Active Comparator|Conservative exercise group (CEG)|Conservative exercise group
3469903|NCT03882853|Experimental|Tree pose added exercise group (TPAEG)|Tree pose added exercise group
3469904|NCT03883165|Experimental|high-intensity neck strengthening group|
3469905|NCT03883165|Experimental|low-intensity neck strengthening group|
3125157|NCT02968420|Active Comparator|Group 1|Group 1: girls who received 2 doses of Q-HPV vaccine at 0, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
3469906|NCT03883165|Other|Control group|
3125158|NCT02968420|Active Comparator|Group 2|Group 2: girls who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 9-13 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
3125159|NCT02968420|Active Comparator|Group 3|Group 3: young women who received 3 doses of Q-HPV vaccine at 0, 2, 6 month schedule 8-10 years ago when they were between 16-26 years of age at the time of the first dose. The intervention of a single dose of licensed Gardasil 9 vaccine (Human Papillomavirus 9-valent Vaccine, Recombinant) will be administered at Day 0 of the study.
3125160|NCT02968433|Experimental|Infusions of Young Plasma|"All participants will undergo neuropsychological, neuropsychiatric, and kinematic assessments prior to receiving infusions of young plasma as the treatment.~Participants will receive 1 unit of young plasma, twice a week over a four week duration.~After the four weeks of plasma infusions, participants will undergo neuropsychological, neuropsychiatric and kinematic reassessments. No deception will be used."
3469907|NCT03883022|Experimental|Vancomycin (V Group)|
3469908|NCT03883022|Active Comparator|Without Vancomycin (NV Group)|
3469909|NCT03882866|Experimental|3D-printed non-coplanar template|3D-printed non-coplanar template is used in this group.
3469910|NCT03882866|Active Comparator|3D-printed coplanar template|3D-printed coplanar template is used in this group.
3469911|NCT03882892|Placebo Comparator|Placebo + Atorvastatin|Participants who received placebo in the parent study (P00692) receive placebo (blinded) + atorvastatin (10 mg/day; open-label) in this study.
3469912|NCT03882892|Experimental|Ezetimibe + Atorvastatin|Participants who received ezetimibe + atorvastatin, or atorvastatin alone, in the parent study (P00692) receive ezetimibe (blinded) + atorvastatin (10 mg/day; open-label) in this study.
3469913|NCT03883191|Experimental|Mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
3469914|NCT03883191|Placebo Comparator|Placebo powder|Taking 1 pack of placebo powder three times a day before meals for three months.
3469915|NCT03883230||Patients with chronic wound|All patients will have a Glycologic infection detection test (GLYWD) taken. For this, a standard CE-marked sterile swab is used to take a wound exudate sample. This is then inserted in the GLYWD detection tube device. The device will contain two separate reagents, one in the clear plastic vial end and the other in the foil-sealed compartment. The sterile swab with the wound exudate sample will be pushed into the device, breaking the foil-sealed compartment and allowing the reagents to mix with the sample. the result of the test - to see if there is a bacterial infection present in the wound - is observed up to ten minutes later.
3469916|NCT03883178|Experimental|Neurolysis|
3469917|NCT03882983|Experimental|Antria Cell Preparation Process|Safety will be evaluated by collection of vital signs, EKG, patient surveys, and assessments
3469918|NCT03883087|Experimental|HQP1351|
3469919|NCT03883061||mortality of sepsis|the study sample would be extracted from electronic health records in emergence departments. risk factor analysis and mathematical modeling would be performed to evaluate the significant and independent risk factors and predictive models.
3469920|NCT03883074|Experimental|GERDOff® Plus|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate Melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
3469921|NCT03883074|Placebo Comparator|Placebo|Placebo melt in mouth tablets (1100 mg). 1 tablet q.i.d. (three after meals, one before resting) for three consecutive weeks. After three weeks of wash-out period,patients will take either placebo or GERDOff® Plus q.i.d. (three after meals, one before resting) for another three weeks.
3469922|NCT03883035|Experimental|EAS-aided group|esophagogastroduodenoscopy examination with the assistance of automatic quality-control system
3469923|NCT03883035|No Intervention|control group|conventional standard esophagogastroduodenoscopy examination without the assistance of automatic quality-control system
3469924|NCT03882879|Experimental|Arm 1|Participants in Arm 1 will begin participation in 6 months of karate classes immediately after the pre-intervention study visits.
3469925|NCT03882879|Experimental|Arm 2|Participants in Arm 2 will continue their usual exercise routine for six months followed by karate classes for six months
3469926|NCT03883204|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
3469927|NCT03883204|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
3469928|NCT03883126|Active Comparator|Group A|Group A will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting negative samples.
3469929|NCT03883126|Active Comparator|Group B|Group B will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner for the first 3 weeks of the intervention.For the remaining 9 weeks they will not be required to submit breathalyzer samples.
3469930|NCT03883126|Sham Comparator|Group C|Group C will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will continue to receive incentives for submitting on time samples regardless of alcohol content.
3469931|NCT03883126|Sham Comparator|Group D|Group D will receive nearly immediate monetary payments over the internet each day they remotely provide breathalyzer samples regardless of the alcohol content, but will not receive the payments if they fail to provide samples in a timely manner for the first 3 weeks of the intervention. For the remaining 9 weeks they will not be required to submit breathalyzer samples.
3469932|NCT03883126|No Intervention|Group E|Group E will have no intervention, they will only complete assessment sessions.
3469933|NCT03882840|Experimental|itNK cell therapy group|Patient-originated and induced T-to-natural killer (ITNK) cells, will be administrated to kill tumor cells.
3469934|NCT03882723|Active Comparator|BiTrac MaxShield™ with standard elbow (FFM)|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
3469935|NCT03882723|Active Comparator|BiTrac™ Full Face with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
3469936|NCT03882723|Active Comparator|Respironics PerforMax with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
3469937|NCT03882723|Active Comparator|Philips Respironics AF531 with standard elbow|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
3469938|NCT03882593||Analysis of arterial filters during CPB|This is a clinical and observational study to investigate of blood cells addesion to surfaces of arterial filters during CPB and the impact in coagulations laboratory exams
3469939|NCT03882463|Experimental|insulin pump function|continuous glucose monitoring and then continuous glucose monitoring with the stop insulin pump function
3469940|NCT03882606|Other|SML implantation|prospective study of a cohort of patients with age-related macular degeneration or myopic maculopathy treated with SML implantation
3125161|NCT02968563|Experimental|Tirabrutinib + Idelalisib|Participants will receive tirabrutinib and idelalisib for up to 104 weeks.
3125162|NCT02968563|Experimental|Tirabrutinib + Idelalisib + Obinutuzumab|Participants will receive obinutuzumab over 21 weeks and the combination of tirabrutinib and idelalisib for up to 104 weeks.
3125163|NCT02968576|Active Comparator|Truvada|Naked form Truvada (drug)
3125164|NCT02968576|Experimental|PSS-Truvada|Proteus Sensor System (PSS) (device) encapsulated Truvada (drug)
3469941|NCT03882710|Experimental|metoprolol XR capsule|
3469942|NCT03882710|Placebo Comparator|placebo capsule|
3469943|NCT03882645|Experimental|CHH-diet arm|"During the 4-week intervention period, free meals conformed to CHH-diet will be provided 3 times per daily (breakfast, lunch, dinner). Different center offers different meals of different cuisines but all conformed to CHH-diet. The main nutrientional healthy goal of different cuisines will be achieved through specific nutrient targets, including fat, carbohydrate, protein, dietary fiber, sodium, potassium, magnesium and calcium."
3125165|NCT02968602|Experimental|Minocycline|Participants will take 50 mg minocycline capsules twice daily for 1 week, then take 100 mg capsules twice daily for 1 week.
3179156|NCT00669838||PL|Patients who receive local anesthesia with 2% lidocaine without epinephrine
3469944|NCT03882645|Other|local usual diet arm|During the 4-week intervention period, three meals per day (breakfast, lunch, dinner) will be provided free of charge in line with local dietary characteristics. The energy,protein, carbohydrate, as week as dietary fiber, sodium, calcium, magnesium and potassium will be kept the same as that in the run-in phase.
3469945|NCT03882814||Pethidine group / study group|Study group; patients given pethidine; The partogram was recorded during delivery. Cervical examination was performed at 2 hour intervals. Recorded in the file. 4 cm and greater cervical dilatation; 50 mg intramuscular (IM) injection was given to pethidine. 200 Montevideo units uterine contractions were reached. Maternal vital signs, maternal complications and neonatal APGAR scores were recorded by the clinician 0-5-15-30-45-60 minutes after pethidine injection.
3469946|NCT03882814||control group|The patients who received placebo injection were included in the control group. Saline was given in placebo.
3469947|NCT03882619|Experimental|Calligraphy group|
3469948|NCT03882619|No Intervention|Treatment-as-usual group|
3469949|NCT03882567|Experimental|Electro Neuro adaptative Regulator|8 SCENAR sessions (twice a week) (30 min of duration) following the protocols for treatment several points in the body
3469950|NCT03882567|Sham Comparator|Sham Electro Neuro adaptative Regulator|8 Sham SCENAR sessions (twice a week) (30 min of duration), following the same protocol tan experimental group but the machine will be turn off 30 seconds after starting on the treatment.
3469951|NCT03882775|Experimental|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
3469952|NCT03882775|Active Comparator|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
3125166|NCT02968602|Placebo Comparator|Placebo|Participants will take capsules that match active drug, but contain no active ingredients, twice daily for week 1, and then will take capsules that match active drug, but contain no active ingredients, twice daily for week 2.
3469953|NCT03882632|Experimental|Patients with Fecal Incontinence|Patients will have the opportunity to undergo adipose tissue harvesting and targeted local Injection under ultrasound guidance in muscle defects in the intersphincteric space, all around the remaining portions of the external anal sphincter, and along the course of the pudendal nerves bilaterally
3469954|NCT03882762|Experimental|Group I - Cebranopadol 200 μg tablet|"Mild Renal Impairment:~PK evaluable non-dialyzed patients with mildly impaired renal function (eGFR = 60-89 mL/min/1.73 m2)"
3469955|NCT03882762|Experimental|Group II - Cebranopadol 200 μg tablet|"Moderate Renal Impairment:~PK evaluable non-dialyzed patients with moderately impaired renal function (eGFR = 30-59 mL/min/1.73 m2)"
3469956|NCT03882762|Experimental|Group III - Cebranopadol 200 μg tablet|"Severe Renal Impairment:~PK evaluable non-dialyzed patients with severely impaired renal function (eGFR = 15-29 mL/min/1.73 m2)"
3469957|NCT03882762|Experimental|Group IV - Cebranopadol 200 μg tablet|"Normal Renal Function:~PK evaluable participants with normal renal function (eGFR greater than or equal to 90 mL/min/1.73 m2)"
3469958|NCT03882515|Experimental|Experimental group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after myofascial release
3469959|NCT03882515|Sham Comparator|Sham group|Evaluation of peripheral muscle oxygenation in individuals with muscular idiopathic pain before and after continuous surface slip technique
3469960|NCT03882515|Active Comparator|Control group|Evaluation and reassessment of asymptomatic individuals
3469961|NCT03882476|Experimental|Experimental|The experimental arm will involve patients monitored by InSight.
3469962|NCT03882476|No Intervention|Control|The control arm will have no intervention and will involve patients with the usual standard of care.
3469963|NCT03882788|Active Comparator|Volatile Anesthesia|"In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane.~Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
3179157|NCT00669838||LE|Patients who receive local anesthesia with 2% lidocaine with 1:100.000 epinephrine
3125167|NCT02968758|Experimental|Accuracy Testing|Comparison between GenePOC PCR and Reference Method
3179158|NCT00669890|Experimental|study 515|
3469964|NCT03882788|Active Comparator|Narcotic based anesthesia|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose)."
3469965|NCT03882554|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
3469966|NCT03882450|No Intervention|Neonates with congenital cardiac disease (retrospective)|Medical records of all children 18 and under who underwent CCS (as defined by ICD-9-CM congenital heart disease procedure codes) from January 1, 2011 to December 31, 2016 will be reviewed. Those who developed VFMI following CCS as diagnosed on flexible fiberoptic laryngoscopy will be identified. Inpatient, outpatient and emergency department (ED) records will be studied for details on postoperative length of stay, time to diagnosis of VFMI, time to initiation of oral feeding, ED visits and readmissions for feeding/weight gain or respiratory issues, and otolaryngology intervention.
3469967|NCT03882450|Active Comparator|Neonates with congenital cardiac disease (prospective)|Eligible children with known congenital cardiac disease necessitating cardiothoracic surgery will undergo universal screening, i.e., laryngeal ultrasonography and flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if they are not intubated and are stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope and portable ultrasound system while awake.
3469968|NCT03882502|Experimental|stimulation group|
3469969|NCT03882502|Sham Comparator|sham stimulation|
3469970|NCT03882437|Experimental|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single intravenous (IV) infusion. Subjects will receive one of three dose levels depending on the cohort.
3469971|NCT03882489||Cohort 1 : Height 150-165 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 1 includes patients whose the height is between 150 and 165 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 40 mg in the cohort 1 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 25 to 50 mg for cohort 1.
3179159|NCT00669929||1|patients visited to Severance hospital
3179160|NCT00669929||2|patients visited to Youngdong Severance hospital
3179161|NCT00669929||3|patients visited to Wonju Christian hospital
3469972|NCT03882489||Cohort 2 : Height 166-180 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 2 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 45 mg in the cohort 2 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 30 to 55 mg for cohort 2.
3469973|NCT03882489||Cohort 3 : Height 181-195 cm|Dose-finding study with 4 subjects per dose and a maximum of 40 patients by cohort. The cohort 3 includes patients whose the height is between 166 and 180 cm. To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), isobaric 2-chloroprocaine will be administrated at the dose initial of 50 mg in the cohort 3 for the first 4 subjects. For the next subjects, the doses to administrate will vary 5 mg (0.5 ml) and will be determined by the Continual Reassessment Method (CRM) according to the observed responses in the previous subjects. Doses will be staggered from 35 to 60 mg for cohort 3.
3469974|NCT03882541|No Intervention|Control group|headphones without music, without sedation
3469975|NCT03882541|Active Comparator|sedative group|headphones without music, with sedation
3469976|NCT03882541|Experimental|experimental group|headphones with music, without sedation
3125168|NCT02968914|Active Comparator|Benralizumab by Accessorized Pre-Filled Syringe|Drug administration by Accessorized Pre-Filled Syringe. A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
3125169|NCT02968914|Other|Benralizumab by Autoinjector|Drug administration by Autoinjector A total of 180 subjects will be randomized and will be stratified by weight group (55 to 69.9 kg, 70 to 84.9 kg and 85 to 100 kg). Within each of the 3 weight groups, subjects will be randomized 1:1:1:1:1:1 to 1 of the 6 combinations of treatment (APFS) with injection site (upper arm, abdomen or thigh)
3469977|NCT03882684||Cancer patients|The patients receive the surgery according to the indication of surgery. The diagnosis is confirmed by pathology of removed tissue. The result of imprinting detection are used as cancer group.
3469978|NCT03882684||Benign tumor and other disease patients|Patients ruled out the possibility of malignancy according to biopsy pathology are used as negative control.
3469979|NCT03882671|Experimental|Monitoring Device|Subjects will be asked to wear up to 3 different noninvasive seizure detection devices including EpiTel EpiLog, Empatica E4, GeneActiv
3469980|NCT03882411|Experimental|Electronic shared decision making (eSDM) Tool|When a clinic's randomly allotted intervention period arrives, coronary heart disease patients in a given cluster of clinics will complete a web application, which delivers screening, behavioral activation and shared decision making (eSDM), and providers will receive a patient preference report generated from the application.
3469981|NCT03882411|No Intervention|Usual Care|In the year prior to the allocated intervention period, coronary heart disease patients will receive usual care from their providers.
3469982|NCT03882099||Pregnant women with pre-eclampsia|
3469983|NCT03882099||Pregnant women with eclampsia|
3469984|NCT03882099||Normotensive pregnant women|
3469985|NCT03882112|Experimental|Sequence 1|Period 1: Fasted state + HIP1601 Period 2: Fed state + HIP1601
3469986|NCT03882112|Experimental|Sequence 2|Period 1: Fed state + HIP1601 Period 2: Fasted state + HIP1601
3469987|NCT03882372|Experimental|Nasal high flow|"Following baseline assessment, patients randomized to the nasal high flow arm will be equipped with a nasal high flow device (myAIRVO2) administrated through the Optiflow nasal canula. Flow will be set at the highest flow tolerated (20-30 L/min): initially 30 L/min, progressively decrease if not tolerated. Temperature will be set between 34-37°C according to the tolerance : initially 37°C and decreased if not tolerated. Patients will be asked to use the device 8h per day.~Patients under long-term oxygen will preserve their usual flow. The usual prescribed oxygen flow will then be titrated during nasal high flow to maintain the same baseline transcutaneous oxygen saturation as their conventional oxygen therapy (≥ 90%) to prevent any oxygen dilution effect of nasal high flow."
3469988|NCT03882372|No Intervention|Usual care|"Patient randomized to the control group will have no other specific intervention than their usual care.~Patients under long-term oxygen will preserve their usual flow."
3469989|NCT03882164||Rejection|Patient undergone liver transplant with diagnosis of rejection within 10 days
3469990|NCT03882164||No-Rejection|Patient undergone liver transplant wothout diagnosis of rejection within 10 days
3469991|NCT03882398|Experimental|Experimental group|The experimental group (EG) participated in a once a week physical exercise program for 8 weeks. The session consisted of balance training, followed by aerobic endurance training with exercise peddlers. At the beginning of the program, each session lasted 25 minutes and progressed to 35 minutes, in the last two weeks
3469992|NCT03882398|Active Comparator|Control Group|The control group (CG) only performed routine balance exercises once a week (10 min)
3469993|NCT03882138|Active Comparator|thin biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
3469994|NCT03882138|Active Comparator|thick biotype|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
3469995|NCT03882268|Experimental|MIYCN interventions|10 facilities run by 2 NGOs that will be randomly selected to receive intensified MIYCN interventions.
3469996|NCT03882268|No Intervention|Comparison facilities|10 facilities run by same 2 NGOs that run the intervention facilities, which will not receive any standardized MIYCN interventions.
3469997|NCT03882190|No Intervention|group 1|
3469998|NCT03882190|Experimental|group 2|
3469999|NCT03882151|Experimental|Epilog Preop|patients receive Epilog preop analysis
3470000|NCT03882359|Active Comparator|Definity|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of DEFINITY® 100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
3125170|NCT02968992|Experimental|rhLactoferrin|rH lactoferrin will be provided by Ventria Biosciences. Each capsule will contain 250 mg of rH lactoferrin as active ingredient. Subjects will receive 1500 mg of lactoferrin in capsule form twice a day. Dosing will be six 250 mg capsules twice a day for six months.
3125171|NCT02968992|Placebo Comparator|Placebo|Matching placebo capsule will be provided by Ventria Biosciences and six capsules twice a day will be provided to the subjects in this arm.
3470001|NCT03882359|Experimental|MVT-100|Each subject receives 100 uL x 2, 200 uL x 3, 300 uL x 2 or 1 vial of MVT-100 diluted in 50 mL of NS as follows: Two milliliter bolus over 10 seconds prior to each infusion rate;, then infusions will run for 5 minutes at 60 mL per hour, 5 minutes at 90 mL per hour, 5 minutes at 100 mL per hour and 5 minutes at 120 mL per hour.
3125172|NCT02969018|Experimental|PF-06700841 60 mg followed by 30 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 30 mg PF-06700841 once daily
3125173|NCT02969018|Experimental|PF-06700841 60 mg followed by 10 mg once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
3125174|NCT02969018|Experimental|PF-06700841 60mg once daily followed by 100mg once weekly|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
3125175|NCT02969018|Experimental|PF-06700841 60mg once daily followed by placebo once daily|4 week induction with 60 mg PF-06700841 once daily, followed by 8 week chronic administration of placebo once daily
3125176|NCT02969018|Experimental|PF-06700841 30mg once daily|4 week induction with 30 mg PF-06700841 once daily followed by 8 week chronic administration of 30 mg PF-06700841 once daily
3125177|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 10mg once daily|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 10 mg PF-06700841 once daily
3470002|NCT03882086|Experimental|foot reflexology group|The intervention group was comprised of 30 women in the early postpartum period. Pretest data were collected on the 14th day postpartum. Then a total of four reflexology sessions were applied for 15 minutes in each foot, in the afternoons, every other day between postpartum 14th-20th day, as the women were available. And posttest data were collected on the 20th day postpartum at the end of the four-reflexology sessions.
3470003|NCT03882086|No Intervention|standard care group no reflexology|The control group of this study was comprised of 30 women in the early postpartum period who had sleep problem and gave vaginal birth. Pretest data were collected on the 14th day postpartum. On the 20th day postpartum, the posttest data were assessed during home visits. These women only received routine postpartum care from public health nurses but did not access the reflexology
3470004|NCT03882346|No Intervention|Control Group|Patients in Control Group will receive best supportive care for the disease.
3470005|NCT03882346|Experimental|Experimental Group|Patients in Experimental Group will receive LifeLiver treatment in addition to best supportive care for the disease.
3125178|NCT02969018|Experimental|PF-06700841 30mg once daily followed by 100mg once weekly|4 week induction with 30 mg PF-06700841 once daily, followed by 8 week chronic administration of 100 mg PF-06700841 once weekly
3125179|NCT02969018|Placebo Comparator|Placebo|12 weeks once daily placebo
3470006|NCT03882320|Experimental|Sublingual Patient Controlled Analgesia (PCA)|Sufentanil Sublingual Patient Controlled Analgesia (PCA)
3470007|NCT03882320|Active Comparator|Intravenous Patient Controlled Analgesia (PCA)|Oxycodone Intravenous Patient Controlled Analgesia (PCA)
3470008|NCT03882281|Experimental|A group|Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.
3470009|NCT03882281|Experimental|B group|Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.
3125180|NCT02969031|Experimental|Enhanced SCOPE training|Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients, audio record (using a smartphone application) eight clinic visits with eight different patients. Receive survey feedback as well as the enhanced SCOPE program that provides feedback on their audio-recorded encounters via a web-based interactive program.
3125181|NCT02969031|Active Comparator|Standard Communication training|"Complete a baseline questionnaire, administer satisfaction surveys anonymously to a sample of their patients. Receive the results of the patient surveys and be asked to conduct a quality improvement activity of their own design that responds to the feedback (the current standard communication PIM)."
3470010|NCT03882294|Experimental|Probiotics|Subjects in probiotic group will receive fermented milk containing live cultures Lactobacillus casei Shirota (LcS), 3 x 10^10 CFU/bottle (80 ml)
3470011|NCT03882294|Placebo Comparator|Placebo|Subjects in placebo group will receive milk drink without LcS (80 ml).
3470012|NCT03882307|No Intervention|group1 (naive)|Assess serum level of interleukin-6 and transforming growth factor beta before the course of treatment
3470013|NCT03882307|Active Comparator|group2 (sustained responder)|Assess serum level of interleukin-6 and transforming growth factor beta after three months from the end of treatment Sofosbuvir (SOF) (400 mg once per day) and daclatasvir (DCV)(60mg once per day) or simeprevir (SIM) (150 mg once per day) for 3 months treatment regimens
3470014|NCT03882255|Experimental|Treatment Period 1: Ponesimod (2 mg)|Participants will receive a single dose ponesimod 2 milligram (mg) oral tablet under fed conditions on Day 1. Participants not fulfilling discontinuation criteria can continue to Treatment Period 2 after a washout period of at least 7 days and a maximum of 14 days.
3125182|NCT02969044|Experimental|PF-06651600|Study Drug
3125183|NCT02969044|Placebo Comparator|Placebo|Placebo
3125184|NCT02969187|Experimental|Experimental|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 20 ml of 1.3% Exparel + 30 ml of 0.5% Bupivacaine + 150 ml of Saline
3179162|NCT00669981|Experimental|1|Participants will receive immediate cognitive behavioral couples therapy for PTSD.
3179163|NCT00669981|Active Comparator|2|Participants will receive delayed cognitive behavioral couples therapy for PTSD after a 3-month waitlist period.
3470015|NCT03882255|Experimental|Treatment Period 2:Ponesimod, Propranolol, Placebo Propranolol|Participants who do not fulfill any of discontinuation criteria will be randomized to 1 of 2 Treatments (Treatment A or B) on Day 1. Treatment A: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus placebo propranolol once daily from Day 1 to Day 19; Treatment B: up-titration regimen of ponesimod (2mg-20mg) once daily from Day 5 to Day 19 plus 80 mg propranolol once daily from Day 1 to Day 19.
3125185|NCT02969187|Active Comparator|Control|Patients at our Bariatric Surgery Center of Excellence fulfilling NIH criteria for bariatric surgery and planned operation of laparoscopic Roux-en Y gastric bypass (LRYGB) or laparoscopic sleeve gastrectomy (LSG) as primary bariatric procedure randomized to receive 60ml of 0.5% Bupivacaine + 140 ml of Saline.
3125186|NCT02969317|Experimental|Tiotropium + olodaterol fixed-dose combination|Fixed dose combination
3125187|NCT02969356|Experimental|Dysport|Each subject will undergo two intramuscular injection (treatment) cycles, receiving AbobotulinumtoxinA (Dysport®) 1500 U on Day 1 of each cycle; the two dosing occasions will be separated by at least 12 weeks (maximum 20 weeks). Subjects will also receive daily GSC therapy. The main focus of GSC will be on the primary treatment target (TT) limb (as determined at the Baseline Visit) and then the other limb. All muscle groups requiring active training and/or stretching should be trained. Subjects will be be given a diary to record each day whether they have performed the GSC therapy.
3470016|NCT03882242|Experimental|Intervention Program Facilitators|"Participants will learn about and deliver (facilitate) a prevention program In favor of Myself to school-children"
3470017|NCT03882333|Experimental|Acute exercise|Acute exercise (bicycle at stationary cycle).
3470018|NCT03882333|No Intervention|Rest|Rest (lying down or sitting in a chair) for 30 minutes, i.e. same time duration as in experimental arm.
3125188|NCT02969382|Experimental|SEP-363856|SEP-363856 capsule (50 mg or 75 mg) once daily
3125189|NCT02969382|Placebo Comparator|Placebo|Placebo capsule once daily
3470019|NCT03882008|Experimental|Abatacept|Abatacept 125mg subcutaneous injection weekly for 24 weeks
3470020|NCT03882073|Experimental|Intervention group|Modified amputation procedure
3470021|NCT03882073|Active Comparator|Control group|Standard amputation procedure
3470022|NCT03882125|Experimental|Mindfulness|Assigned to a 6-week mindfulness-based relapse prevention course
3470023|NCT03881982|Experimental|PIMPERNEL Novel Electronic Log - intervention|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
3125190|NCT02969408|Experimental|ABS eMDPI|Participants will receive 90 mcg of ABS via an eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks.
3125191|NCT02969421|Active Comparator|Slow Tenaculum Placement|This group will have their tenaculum placed using the slow method
3125192|NCT02969421|Active Comparator|Cough Method|This group will have their tenaculum placed using the cough method
3125193|NCT02969525|Placebo Comparator|Placebo|Subjects will receive for 12 Weeks Placebo and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
3470024|NCT03881982|Other|PIMPERNEL Novel Electronic Log - control|"The display is an electronic version of the 11 point NRS. An audible 'beep' every 15 minutes prompts the patient to record their pain level.~The display measures 122mm x 30mm x 15mm. Through a wireless connection, the data from the display are transmitted to a display unit (a Nexus tablet)."
3470025|NCT03882216|Experimental|test group pouch technique|free connective tissue graft augmentation using pouch technique
3125194|NCT02969525|Experimental|Bimekizumab dosage regimen 1|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 1 and will then be re-randomized to Bimekizumab dosage regimen 2 or Bimekizumab dosage regimen 3 for 36 Weeks.
3125195|NCT02969525|Experimental|Bimekizumab dosage regimen 2|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 2.
3125196|NCT02969525|Experimental|Bimekizumab dosage regimen 3|Subjects will receive for 48 Weeks Bimekizumab dosage regimen 3.
3125197|NCT02969525|Experimental|Bimekizumab dosage regimen 4|Subjects will receive for 12 Weeks Bimekizumab dosage regimen 4 and will then be re-randomized to Bimekizumab dosage regimen 2 for 36 Weeks.
3125198|NCT02969590|No Intervention|No Intervention: Spontaneous Cycle (1 month)|In order to qualify for the intervention phase, subjects needed to demonstrate favorable mucus at ovulation (Insler score of greater than or equal to 10 within 24h of an LH surge) and progesterone level in the luteal phase consistent with ovulation (a single P4 of greater than or equal to 3ng/ ml between days 18-35 of menstrual cycle).
3125199|NCT02969590|Active Comparator|NET Arm - Norethindrone (4 months)|"This arm will receive Norethindrone (NET) first then experience estradiol withdrawal (E2WD).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
3132496|NCT03432819|Experimental|Siempre Seguiré|We will conduct a small randomized controlled trial (RCT), testing study protocols and materials, the acceptability of randomization, and overall program feasibility. The pilot will help to identify logistical considerations; assess whether the program is acceptable and understandable LMSM; and collect initial data on how successfully the program motivates change in coping and adherence. It will allow us to estimate expected attrition and response rates, and to perform preliminary power analyses in preparation for a fully powered RCT.
3179164|NCT00669994|Experimental|Arm 1|
3179165|NCT00670020|Experimental|1|supplemental perioperative oxygen
3470026|NCT03882216|Experimental|test group modified pouch technique|free connective tissue graft augmentation using modified pouch technique
3470027|NCT03882021|Other|Mapping protocol with GRID catheter|All patient will undergo a protocol required mapping protocol using the GRID catheter.
3125200|NCT02969590|Active Comparator|E2WD Arm - Estradiol (4 months)|"This arm will experience estradiol withdrawal (E2WD) first and then receive Norethindrone (NET).~On the day prior to each admission, we instructed subjects to apply three fresh estradiol (E2) patches (0.3mg/day) to achieve mid-cycle level E2 effects.~On the day of the first and third admission, subjects were randomized to the experimental condition, either: (1) oral progestin administration (e.g., a single dose of 0.35mg norethindrone) with continuation of the E2 patches ; or (2) estradiol withdrawal (e.g., removal of the patches). Subject then received the converse intervention for admissions two and four.~Subjects resumed treatment with the 0.1mg E2 patch until their next scheduled inpatient assessment. We required a minimum of five days at this level before repeating the dose escalation and the next evaluation."
3125201|NCT02969655|Experimental|Daprodustat|Subjects will receive oral daprodustat once daily and intravenous (IV) darbepoetin alfa placebo once weekly for 52 weeks
3125202|NCT02969655|Active Comparator|Darbepoetin alfa|Subjects will receive IV darbepoetin alfa once weekly and oral daprodustat placebo once daily for 52 weeks
3125203|NCT02969707|Experimental|Active rTMS|The active group will receive repetitive Transcranial Magnetic Stimulation
3125204|NCT02969707|Sham Comparator|Sham rTMS|The sham repetitive Transcranial Magnetic Stimulation group will have the stimulation blocked.
3125205|NCT02969863|Active Comparator|Usual Care Arm - Monitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
3125206|NCT02969863|Active Comparator|Usual Care Arm - Unmonitored|"Subjects will manage their own diabetes and will wear a blinded Dexcom G4 CGM to record their glucose data during the week. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
3470028|NCT03881995|Active Comparator|iGlarLixi|Subjects will receive premixed Insulin glargine + lixisenatide once daily for 12 weeks
3470029|NCT03881995|Active Comparator|Insulin glargine|Subjects will receive Insulin glargine once daily for 12 weeks
3470030|NCT03882060|Experimental|rHuEPO|recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
3470031|NCT03882060|Placebo Comparator|Control|Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
3470032|NCT03881956|Other|Women with gestational diabetes|88 women with gestational diabetes (46 for the intervention group and 42 for the control group) were in the arm.
3470033|NCT03881943|Active Comparator|Ticagrelor|Ticagrelor 60mg BD for 3 months
3470034|NCT03881943|Active Comparator|Aspirin|Aspirin 100mg daily for 3 months
3470035|NCT03881930|Experimental|Experimental group|"Balance rehabilitation with modified visual input:~In experimental group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with modified visual input."
3125207|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Monitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
3470036|NCT03881930|Active Comparator|control group|"Balance rehabilitation with no modified visual input:~In control group, patients with chronic acquired demyelinating neuropathy will benefit from 20 rehabilitation sessions with a Physical Therapist and 3 assessments.~They will perform balance training with no modified visual input."
3470037|NCT03881722|Active Comparator|thickened formula|
3470038|NCT03881722|Experimental|Mg alginate|
3470039|NCT03881735|Experimental|Cohort A (enasidenib, hematopoietic cell transplantation)|Patients receive enasidenib PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo a HCT 7-14 days after treatment. Within 30-100 days following the transplant, patients receive enasidenib QD. Treatment repeats every 28 days for 24 cycles in the absence of disease progression or unacceptable toxicity.
3470040|NCT03881735|Active Comparator|Cohort B (enasidenib)|Patients receive enasidenib PO QD. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3470041|NCT03881826|Experimental|Haematological patients|
3470042|NCT03881826|Active Comparator|Healthy volunteers|
3470043|NCT03881774|Experimental|experimental arm|cord blood derived CAR T cells group
3470044|NCT03881904|Active Comparator|OCP Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will receive 0.075mg gestodene/0.03mg ethinylestradiol (Gynera®, Bayer Schering Pharma AG, Germany) from day 2 of the preceding cycle for 21 days followed by GnRH antagonist COH.
3470045|NCT03881904|No Intervention|Control Group|This group will include 373 women with PCOS undergoing a trial of IVF/ICSI. This group will start GnRH antagonist COH directly without OCP pretreatment.
3470046|NCT03881891|Experimental|Follow-app intervention arm|This arm will comprise of patients who are prompted to complete the PROMIS pain intensity scale through text/Short Message Service(SMS) or email mobile device notifications at pre-defined time intervals on Days 1, 3, 5 and 7 post-operatively.
3470047|NCT03881891|No Intervention|Standard care arm|This arm will comprise of patients who receive the usual care.
3470048|NCT03881839||patient in emergency department|
3470049|NCT03881761|Experimental|experimental arm|CAR-T cell group
3470050|NCT03881644|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigran infusion (0.4 mg/min) for 10 mins"
3470051|NCT03881644|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
3470052|NCT03881696|Experimental|Stage 1:Omalizumab as Monotherapy|"Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study."
3470053|NCT03881696|Experimental|Stage 1: Omalizumab OLE|"OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study.~Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic."
3470054|NCT03881696|Placebo Comparator|Stage 1: Placebo for Omalizumab as Monotherapy|"Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food.~Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic.~The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study."
3470055|NCT03881696|Experimental|Stage 2: Omalizumab|"Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table.~After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either:~Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR~Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
3470056|NCT03881696|Experimental|Stage 2: Omalizumab-Facilitated OIT|"OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy~Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
3470057|NCT03881696|Experimental|Stage 2: Omalizumab + Placebo OIT|"OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks.~Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic."
3125208|NCT02969863|Experimental|Bihormonal Bionic Pancreas - Unmonitored|"Subjects will wear the bihormonal bionic pancreas, consisting of a Dexcom G4 CGM, an insulin and glucagon pump and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
3470058|NCT03881696|Other|Stage 3: DBPCFC Based Treatment|"DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods.~Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food;~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food.~The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will remain in Stage 3 until December 2023.~Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3."
3470059|NCT03881579|Other|Usual care|one random half of patients will receive usual care
3470060|NCT03881579|Experimental|intervention arm|one random half of patients will receive enhanced usual care (usual care plus nurse-led supportive care intervention)
3470061|NCT03881592||R-Clb patients|Patients treated with the combination of Rituximab + chlorambucil
3470062|NCT03881592||R-B patients|Patients treated with the combination of Rituximab + bendamustine
3470063|NCT03881592||Obi-Clb patients|Patients treated with the combination of Obinutuzumab + chlorambucil
3470064|NCT03881605|Experimental|MRI screening|Contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain at baseline, 4 months, 8 months and 12 months.
3470065|NCT03881605|No Intervention|Symptom-directed surveillance|Imaging of the brain will take place only if patients develop symptoms that are suggestive of brain metastases (e.g. headaches, vision changes, gait instability).
3470066|NCT03881657|Experimental|Intervention Group|The intervention group received a reverse colocated integrated behavioral health intervention or usual care
3470067|NCT03881657|Active Comparator|Control Group|The control group received behavioral health services only (usual care)
3470068|NCT03881878|Experimental|pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
3470069|NCT03881878|Experimental|non-pathologic Complete response|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) :~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
3470070|NCT03881787|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
3470071|NCT03881787|Active Comparator|Cetuximab|Cetuximab,Erbitux 250mg/m2 single administration
3470072|NCT03881709|Experimental|The intervention group|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
3470073|NCT03881709|No Intervention|The control group|The control group will receive a health education about prostate biopsy.
3470074|NCT03881618|Experimental|electroacupuncture+auricular pressure|a group :electroacupuncture+auricular pressure for 20 minutes twice a week for 4 weeks
3470075|NCT03881618|Active Comparator|auricular pressure|b group :auricular pressure for 20 minutes twice a week for 4 weeks.
3470076|NCT03881553|Experimental|Premature Infants (NICU)|Premature infants receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
3470077|NCT03881553|Experimental|Opioid-Exposed Newborns (NICU)|Opioid-exposed newborns receiving care in the Neonatal Intensive Care Unit (NICU) will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
3470078|NCT03881553|Experimental|Hospitalized Infants (PICU)|Infants receiving treatment in the Pediatric Intensive Care or Inpatient Unit will participate in up to 2 sessions with NEATCAP intervention and up to 2 sessions with SVS mattress intervention.
3470079|NCT03881852|Experimental|AXS-12 (reboxetine)|
3470080|NCT03881852|Placebo Comparator|Placebo|
3470081|NCT03881540|Active Comparator|tDNA-MI group|Follow tDNA intervention and motivational interviewing counselling
3470082|NCT03881540|Active Comparator|tDNA-CC group|Follow tDNA intervention and conventional counselling
3470083|NCT03881540|Other|UC group|Follow a conventional diet with standard diabetes support and lifestyle education
3470084|NCT03881527|Experimental|Resection of the aortic valve leaflets with device|Patients in which the aortic valve has been resected using the nitinol blade
3470085|NCT03881527|Other|Resection of the aortic valve leaflets in standard fashion|Patients in which the aortic valve has been resected using a conventional blade or scissor
3470086|NCT03881813|Experimental|Fiber reinforced composite retainers|Fiber reinforced composite retainers were inserted in group 1 and were evaluated after every 3 months for a follow up period of 3 months.
3470087|NCT03881813|Experimental|Multistranded stainless steel retainers|Multistranded stainless steel retainers were inserted in group 2 and were evaluated after every 3 months for a follow up period of 3 months.
3470088|NCT03881683|Experimental|HRD and BRCA mutations|
3470089|NCT03881969|Experimental|Financial incentive offered|Patient offered £100 incentive payment in initial trial invitation letter.
3470090|NCT03881969|Experimental|No incentive. Payment not offered|Patient sent standard trial invitation letter with no offer of incentive payment.
3470091|NCT03881267|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a venous leg wound in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing and compression
3470092|NCT03881267|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on venous leg wounds in conjunction with standard wound care and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing and compression
3470093|NCT03881280|No Intervention|Control group|Treatment as usual for 4 weeks
3125209|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Monitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored for CGM connectivity and hypoglycemia.~Monitored for hypoglycemia"
3125210|NCT02969863|Experimental|Insulin Only Bionic Pancreas - Unmonitored|"Subjects will wear the insulin only bionic pancreas, consisting of a Dexcom G4 CGM, an insulin pump, and an iPhone running the study algorithm. They will be monitored only for CGM connectivity, not hypoglycemia.~Not monitored for hypoglycemia"
3470094|NCT03881280|Experimental|Intervention group|Education through the app for 4 weeks
3470095|NCT03881306|Experimental|D-TACE|D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
3470096|NCT03881254|Experimental|Human Autologous Homologous Skin Construct (SkinTE™)|SkinTE™, is an autologous, homologous, FDA-registered, cutaneous human cellular and tissue-based product (HCT/P) that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
3470097|NCT03881254|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
3125211|NCT02969876|Other|Study Phase|During this phase participants receive open label vortioxetine for 6 weeks. Participants come to the Depression Clinical & Research Program at the Massachusetts General Hospital for visits once a week. During these visits the participants meet with clinicians and complete cognitive tasks.
3470098|NCT03881423|Active Comparator|Deep block|In the deep NMB-group, a PTC of 1 to 2 twitches was maintained, and NMB was reversed with sugammadex at the end of surgery.
3470099|NCT03881423|Active Comparator|Moderate block|In the moderate NMB group, a TOF count of 1 to 2 was maintained and NMB was reversed with a combination of neostigmine and glycopyrolate at the end of surgery.
3470100|NCT03881189|Experimental|SUNEKOS ® 200|"The 1st intradermal treatment (T1i) with Sunekos ® 200 was carried out during the basal visit (T0), after basal evaluations planned by the study procedure, and then repeated 2 more times with an interval of 15 days (T2i and T3i)"
3470101|NCT03881293|Placebo Comparator|Placebo Lubricant Gel|5 ml water-soluble gel instilled transurethrally ten minutes prior to catheter insertion
3470102|NCT03881293|Active Comparator|Lidocaine 2% Gel|5 ml lidocaine 2% gel instilled transurethrally ten minutes prior to catheter insertion
3470103|NCT03881488|Experimental|Part 1 Dose Escalation|Escalating doses of CTX-471 depending on cohort at enrollment.
3470104|NCT03881488|Experimental|Part 2 Dose Expansion|Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)
3470105|NCT03881475||healthcare workers|Participants will participate in several sessions where they will complete the questionnaires. The questionnaires will be spaced: 0, 1 week, 6 months, 1 year and then at each occupational visit within 5 years.
3470106|NCT03881371|Experimental|Safinamide|Patient will receive film-coated Safinamide tablets orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
3470107|NCT03881371|Placebo Comparator|Placebo|Patient will receive matching placebo orally at an initial dose of 50 mg once daily (OD) and then will be increased the day after the Visit 3/week 2 (ideally at day 15) to the final dose of 100 mg OD. Treatment will continue daily for a total of 16 weeks.
3470108|NCT03881384||ctDNA level|ctDNA level during neoadjuant chemotherapy
3470109|NCT03881176|Experimental|Active|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
3470110|NCT03881397|No Intervention|Control (Track B assessed at Time 2)|A survey regarding tech use, health behaviors and well-being including physical activity, anxiety, and sleep
3179166|NCT00670020|No Intervention|2|Normal
3470111|NCT03881397|Experimental|Online Family Media Use Plan (Track A)|The Online Family Media Use Plan group will receive a link to American Academy of Pediatrics Family Media Use plan at the end of the survey, which describes internet safety ideas for teens and parents to review and create together.
3470112|NCT03881397|Experimental|Media Use Resources Awareness (Track B assessed at Time 3)|Resources offered to parents and teens that include tools and data for safe technology use among teens
3470113|NCT03881111|Experimental|Pembrolizumab + Cisplatin + 5-FU|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W), cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
3470114|NCT03881111|Placebo Comparator|Placebo + Cisplatin + 5-FU|Participants receive placebo to pembrolizumab (saline) IV Q3W, cisplatin 80 mg/m^2 IV Q3W, and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours). All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
3470115|NCT03881410|Experimental|Shear-wave elastography-guided|
3470116|NCT03881410|Active Comparator|Convention ultrasound-guided|
3470117|NCT03881137|Experimental|Intervention|Geriatric assessment with management
3470118|NCT03881137|No Intervention|Control|Patients receiving supportive care and follow up according to routine practice
3470119|NCT03881228|Experimental|Intervention|"at enrollment, caretakers will receive an educational booklet for caretakers explaining why IPT needs to be given~at enrollment and weekly for 24 weeks, caretakers will receive a children's storybook, with weekly installments, over the 6-month course of IPT as a non-monetary incentive~weekly, caretakers will receive short messages services (SMS) reminders delivered to the caretaker for the weekly pick-up."
3470120|NCT03881228|No Intervention|Standard of care|Routine care at the health facility
3125214|NCT02970006|Experimental|neurovisual stimulation|Participants in this study will be adults who have already undergone implantation of SCS for the treatment of their pain conditions. The study involves no further treatment or intervention. Subjects will be approached for participation in this study during their routine postoperative clinical visit to the Center for Neuromodulation at the Ohio State University (OSU).All eligible patients will undergo a one-day visit for the virtual reality and full body illusion intervention. This research will also investigate leg embodiment and leg analgesic effects during SCS integrated with different patterns of virtual leg illumination.
3125215|NCT02970032|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
3470121|NCT03881436|Experimental|Pelvic MRI|"This arm involves patients undergoing a pelvic MRI.~At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
3470122|NCT03881436|Experimental|Pelvic surgery|"This arm involves patients undergoing a pelvic surgery and coming for a postoperative MRI. An additional MRI is performed before the surgery and additional sequences are added to the planned postoperative MRI, at the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography Diffusion Tensor Imaging (DTI) sequence All acquisitions will be done in an acceptable duration (less than 45 minutes)"
3470123|NCT03881449|Experimental|ABILIFY MYCITE Group|"If patients are assigned to the ABILIFY MYCITE treatment group, the patients and physician will initiate the system at the baseline visit, and continue to use the system for 3 months. At any time after the first 3 months, a patient and his or her doctor will have the opportunity to either discontinue or continue using ABILIFY MYCITE for the remainder of the trial (9 additional months; 12 months total) as long as clinically appropriate with the goal of measuring adherence to improve clinical decision-making and care.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
3470124|NCT03881449|No Intervention|Treatment as Usual (TAU) Group|"TAU patients will continue receiving care as recommended by their physician which will include the use of Aripiprazole according to the approved labels.~Both ABILIFY MYCITE and TAU participants will complete a battery of questions related to quality of life, patient usability/satisfaction, etc. at baseline, 3, 6 and 12 months."
3470125|NCT03881150|Experimental|Hybrid Cardiac Rehabilitation|"This intervention is adapted from the Cardiac Rehabilitation Delivery Model for Low-Resource Settings proposed by the International Council of Cardiovascular Prevention and Rehabilitation Consensus Statement. This program will be delivered by an exercise specialist (physiotherapist) and the principal purposes of the exercise sessions is to develop patient self-management related to the physical activity habit, and educate them how to monitor exercise intensity at home and in daily life. The program include 10 face-to-face exercise sessions and a transition to unsupervised phase using mobile technology.~Counseling is considered about physical activity, diet, smoking, and medication compliance."
3470126|NCT03881150|Active Comparator|Standard Cardiac Rehabilitation|The participants in the control group will receive the standard cardiac rehabilitation that is delivered in participating centers. These programs accounts with physicians, nurses, nutritionists and physiotherapists. The programs will be standardized in participating centers in accordance with currents guidelines (only 18-22 face-to-face exercise sessions). Differentially, this programs provide, group education sessions about physical activity, diet, smoking, and medication compliance (without counseling).
3470127|NCT03881202|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
3470128|NCT03881358|Active Comparator|ortho-k lenses and thinner spectacles|participants using conventionally designed ortho-k lenses (target for 4.00D) and thinner spectacles during day time
3470129|NCT03881358|Experimental|newly designed ortho-k lenses|participants using newly designed ortho-k lenses for high myopia (target for full correction)
3470130|NCT03881319|Active Comparator|Conventional Gynecologic Treatment group|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
3470131|NCT03881319|Experimental|Low dose acupuncture group|Acupuncture has fewer acupuncture points.
3470132|NCT03881319|Experimental|High dose acupuncture group|Acupuncture has more acupuncture points.
3125216|NCT02970032|Experimental|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged.
3125217|NCT02970162|Experimental|amifampridine phosphate|amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
3125218|NCT02970162|Placebo Comparator|placebo (for amifampridine phosphate)|placebo by mouth 3 to 4 times per day for 4 days
3125219|NCT02970292|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
3125220|NCT02970292|Placebo Comparator|Placebo|Placebo + background antipsychotic, taken as two tablets, once daily by mouth
3125221|NCT02970305|Experimental|Pimavanserin|Drug- pimavanserin 34 mg, 20 mg, or 10 mg taken as two tablets + background antipsychotic, once daily by mouth
3125222|NCT02970305|Placebo Comparator|Placebo|Placebo, taken as two tablets + background antipsychotic, once daily by mouth
3125223|NCT02970422||Quartile 1 [Mild]|
3125224|NCT02970422||Quartile 2 [Moderate]|
3125225|NCT02970422||Quartile 3 [Severe]|
3125226|NCT02970422||Quartile 4 [Very Severe]|
3470133|NCT03881215|Experimental|Platelet Rich Plasma|PRP
3470134|NCT03881215|Active Comparator|intra-uterine balloon|
3470135|NCT03880955||ReUnion RSA System|"Subject's joint has gross rotator cuff deficiency, a functional deltoid muscle and is anatomically and structurally suited to receive the implant and subject has one or more of the following:~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis or rheumatoid arthritis~Failed previous shoulder joint replacement"
3470136|NCT03880942|Active Comparator|Informative Story Book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
3470137|NCT03880942|Placebo Comparator|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
3470138|NCT03880981|Active Comparator|Acetaminophen|Patients will receive 650mg PO Acetaminophen every 6 hours as needed for pain
3470139|NCT03880981|Active Comparator|Ibuprofen|Patients will receive 600mg PO Ibuprofen every 6 hours as needed for pain
3470140|NCT03881033|Placebo Comparator|P12|
3470141|NCT03881033|Active Comparator|P7+5|
3470142|NCT03881462|Experimental|Axillary nerve block|Axillary nerve block is performed in standardized manner and muscle force is measured before and after the block.
3125227|NCT02970552|Active Comparator|Vaginal Progesterone|Daily self-administered vaginal progesterone
3125228|NCT02970552|Placebo Comparator|Placebo|Daily self-administered indistinguishable placebo
3470143|NCT03880903|Experimental|normal saline with bronchdilator|will recieve treatment with nebulized brochodilator(salbutamol) and normal saline every 4 to 6 hours
3470144|NCT03880903|Experimental|hypertonic saline with bronchodilator|will recieve treatment with nebulized bronchodilator(salbutamol) and hypertonic saline every 4 to 6 hours
3470145|NCT03880903|Experimental|hypertonic saline only|will recieve treatment with nebulized hypertonic saline 3% in adose of 4 ml every 4 to 6 hours
3470146|NCT03880890|Active Comparator|sphenoidotomy (group A)|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus
3470147|NCT03880890|Active Comparator|sphenoid nasalization (group B)|sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
3470148|NCT03881072|Other|Ultrasounicelastography|Ultrasounicelastography:non-invasive, convenient and comprehensive evaluation method.
3470149|NCT03880812|Experimental|Cost group|These patients reviewed total societal costs associated with carpal tunnel release.
3132497|NCT03432819|No Intervention|Control|Control participants will not be randomized to receive the intervention and will receive standard of care during the intervention period. We will offer the program to any interested control participants shortly after the 6-month follow-up surveys are completed.
3470150|NCT03880812|No Intervention|No cost group|These patients did not review total societal costs associated with carpal tunnel release.
3470151|NCT03880968||inactive - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and assigned to sequential tapering group (A1).
3470152|NCT03880968||inactive - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who achieved inactive disease (ASDAS<1.3, group A) at week 12 and then assigned to discontinuation group (A2).
3470153|NCT03880968||low disease activity - half dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to sequential tapering group (B1).
3470154|NCT03880968||low disease activity - full dosage tapering|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to delayed tapering group (B2) with extra 12 weeks of full dose ETN.
3470155|NCT03880968||low disease activity - discontinuation|Active AS patients with AS disease activity score (ASDAS)≥2.1 were recruited from ten hospitals, initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients in this arm were those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) and designated to discontinuation group (B3).
3470156|NCT03880773|Experimental|Stapler|
3470157|NCT03880773|Active Comparator|ultrasonic shears|
3470158|NCT03880916|Experimental|Duloxetine group|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
3470159|NCT03880916|Placebo Comparator|Placebo group|"Phase I (preemptive): 2weeks before operation (Placebo for 2weeks)~Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
3470160|NCT03880734|Experimental|study|Vitamin D.Generic name-Cholecalciferol (40,000 IU).Dose- 80,000. Dosage-2 capsule/week for consecutive 26 weeks
3470161|NCT03880734|Experimental|control|Placebo oral capsule.Dose 80,000.Dosage-2 capsules for consecutive 26 weeks
3470162|NCT03880851|Other|Hypofractionated image-guided radiotherapy|"Hypofractionated image-guided radiotherapy IGRT to a total dose of 60 Gy (20 fractions) is performed.~Weekly MRI are used to estimate volume/deformation changes of OAR and target volume.~Intervention: In case of a significant change of target volume or OARs (threshold based) the radiation treatment plan is adapted on individual MR-anatomy."
3132498|NCT03432858|Active Comparator|Vancomycin|
3132499|NCT03432858|Active Comparator|Cefazolin|
3470163|NCT03880877|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle."
3470164|NCT03880877|Active Comparator|Regorafenib|Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.
3132500|NCT03432858|Placebo Comparator|Saline|
3132501|NCT03433482|Experimental|GSK3536820A ACWY_Liq24 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 24 months, at Day 1 in the Study Phase1.
3132502|NCT03433482|Active Comparator|ACWY_1 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase1.
3470165|NCT03880695|Experimental|Anlotinib+ Liposomal Doxorubicin|Anlotinib Hydrochloride Combined With Liposomal Doxorubicin Liposomal Doxorubicin 50mg/m2 Day 1 every-3-weeks (Q3W) and Anlotinib 12mg QD po at Day 8-21 Q3W and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
3470166|NCT03880760|Experimental|Probiotics capsule|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
3470167|NCT03880760|Placebo Comparator|Placebo capsule|Taking 1 placebo capsule twice a day before meals for six months.
3470168|NCT03880630|Experimental|Chronic respiratory disease|Patients with chronic respiratory disease with inspiratory muscle weakness will be recruited for the study
3470169|NCT03880461|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve GWG within the range recommended by the Institute of Medicine. The lifestyle intervention will be delivered through 1 telephone counseling session with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and weekly e-mails of core lifestyle intervention sessions. Personalized text messages and 1:1 telephone coaching sessions will be given to those who are not meeting the GWG guidelines.
3470170|NCT03880461|No Intervention|Usual Care - Control|Usual Medical Care
3470171|NCT03880578||surgery (withdrawn, not continuing recruiting)|thyroid patients receiving replacement treatment with levothyroxine (LT4) after thyroidectomy
3470172|NCT03880578||radioiodine|thyroid patients receiving replacement treatment with levothyroxine (LT4) following radioiodine treatment
3470173|NCT03880578||control|thyroid patients followed without surgery or radioiodine treatment
3470174|NCT03880448|Experimental|Metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (metronidazole 500mg/8h/7days)
3470175|NCT03880448|Placebo Comparator|Placebo + periodontal surgery|Periodontal surgery + Placebo (cornstarch 500mg/8h/7days)
3470176|NCT03880656|Experimental|Autologous BM-MNCs High Dose|Administration of autologous bone marrow mononuclear cells at High dose (700,000 cells/cc of tissue)
3470177|NCT03880656|No Intervention|Observational Control|Standard of care provided for subjects that have undergone a fasciotomy following a diagnosis of compartment syndrome. No autologous bone marrow mononuclear cells will be administered.
3470178|NCT03880656|Experimental|Autologous BM-MNCs Low Dose|Administration of autologous bone marrow mononuclear cells at a Low dose (350,000 cells/cc of tissue)
3470179|NCT03880799|Experimental|Mindfulness Intervention|Newly diagnosed breast cancer patients who undergo a mindfulness session before their surgical appointment.
3470180|NCT03880838|No Intervention|No contact control|Participants are not contacted.
3470181|NCT03880838|Experimental|Letter|Participants are only contacted through a letter with a personal testimonial.
3470182|NCT03880838|Experimental|Link and no nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and no nudges.
3470183|NCT03880838|Experimental|Link and commitment nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a commitment nudge.
3470184|NCT03880838|Experimental|Link and prevention nudge|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and a prevention nudge.
3470185|NCT03880838|Experimental|Link and both nudges|Participants are sent the Forks Over Knives documentary online link and a letter with a personal testimonial and both commitment and prevention nudges.
3470186|NCT03880838|Experimental|DVD and no nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and no behavioral nudges.
3470187|NCT03880838|Experimental|DVD and commitment nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a commitment nudge.
3470188|NCT03880838|Experimental|DVD and prevention nudge|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and a prevention nudge.
3470189|NCT03880838|Experimental|DVD and both nudges|Participants are sent the Forks Over Knives documentary DVD and a letter with a personal testimonial and both commitment and prevention nudges.
3470190|NCT03880838|Experimental|Link and DVD and no nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and no behavioral nudges.
3470191|NCT03880838|Experimental|Link and DVD and commitment nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a commitment nudge.
3470192|NCT03880838|Experimental|Link and DVD and prevention nudge|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and a prevention nudge.
3470193|NCT03880838|Experimental|Link and DVD and both nudges|Participants are sent the Forks Over Knives documentary online link and DVD and a letter with a personal testimonial and both commitment and prevention nudges.
3470194|NCT03880435|Experimental|Hyalobarrier® gel endo|Application of Hyalobarrier® gel endo immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second-look hysteroscopy)
3470195|NCT03880435|No Intervention|No Hyalobarrier® gel endo|No application of Hyalobarrier® gel endo after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception + application of sterile ultrasound gel into the vagina (to blind all trial participants, fertility physicians and gynaecologists doing second- or third-look hysteroscopy)
3470196|NCT03880539|Other|BEZLO + SOC taper|Single arm of patients treated with BEZLO + SOC oral VAN pulse/taper.
3470197|NCT03880747||Vagus nerve preserving group|Patients who underwent vagus nerve-preserving distal gastrectomy for early gastric cancer
3470198|NCT03880786|Experimental|PNE test lead|
3470199|NCT03880500|Sham Comparator|Patient|25 Patients will receive a spinal manipulative therapy Intervention, the other 25 Patients receive a sham Intervention.
3470200|NCT03880500|No Intervention|Control|No intervention
3470201|NCT03880721||Good prognosis|
3470202|NCT03880721||Poor prognosis|
3470203|NCT03880721||Recurrence|
3470204|NCT03880721||Not Recurrence|
3470205|NCT03880721||Survival|
3470206|NCT03880721||Death|
3470207|NCT03880604|Active Comparator|Triple tourniquets plus TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus1-gram tranexamic acid (10 ml) in 100 ml saline infusion
3470208|NCT03880604|Active Comparator|Triple tourniquets plus placebo to TA|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels.plus placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
3470209|NCT03880487|Experimental|KP-1199|
3470210|NCT03880487|Placebo Comparator|Placebo oral capsules|
3470211|NCT03880487|Active Comparator|Oxycodone oral capsules|
3470212|NCT03880825|Other|Metformin Only|
3470213|NCT03880825|Other|Levoketoconazole Only|
3470214|NCT03880825|Other|Levoketoconazole + Metformin|
3470215|NCT03880344|Experimental|Vibration Therapy + Normal Out-Patient Physiotherapy|Patients' randomized to this group will receive vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months. Regular out-patient department physiotherapy will also be given. They will be assessed 6 weeks and 6 months post operatively.
3470216|NCT03880344|Active Comparator|Normal Out-Patient Department Physiotherapy|Patients randomized to this group will receive regular out-patient department physiotherapy postoperatively for 6 months. They will be assessed 6 weeks and 6 months post operatively.
3470217|NCT03880383|Experimental|Group 1 - Coaching|"Upon enrollment to the study, parents in this group will have immediate access to the full intervention:~Coaching: Telephone contact with coaches, who will provide information, education and support about the child's development. Coaching will be adapted to family needs, situation, preferences and child's condition.~Online parent education: Parents will be provided access to empowering online tools, such as educational resources, chosen or developed by other parents and researchers.~Peer support tools: Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge."
3470218|NCT03880383|Other|Group 2- Partial and delayed coaching|"Parents in this group will have delayed and partial access to coaching, at the end of the 18-month period. Parents in this group will have a one-time session with a developmental coach who can give them guidance about their child's development. Parents in this group will also then get access to online parent education and peer support tools, indefinitely, until the online platform is de-activated.~* Both arms/groups* will obtain usual care for their child, in addition and independent of full or partial coaching."
3470219|NCT03880357|Experimental|Test Product|Betamethasone Scalp Suspension 0.064%;0.0005% (Taro Pharmaceuticals Inc.)
3470220|NCT03880357|Active Comparator|Reference Product|Taclonex® (Calcipotriene Hydrate and Betamethasone Dipropionate) Topical suspension 0.005%/0.064% (LEO PHARMA)
3470221|NCT03880357|Placebo Comparator|Placebo|Vehicle of the test product (Taro Pharmaceuticals Inc.)
3470222|NCT03880396|Other|hypofractionated Rth with weekly cisplatin 40mg/m2|hypofractionated radioyherapy with weekly cisplatin 40mg/m2
3470223|NCT03880422|Experimental|Supportive care (diet, exercise, education)|Patients receive an individualized diet plan for 6 months. Patients complete an individualized home-based exercise program aerobic and resistance exercise over 10-30 minutes per day, at minimum 3 days per week for 6 months, and a progressive resistance exercise program including an individually tailored prescription targeting the chest, shoulders, arms, and leg musculature for 1-4 sets of 10-15 repetitions, 5 days per week over 6 months. Patients also attend monthly educational meetings for 6 months.
3470224|NCT03880370||group 1(group without low back pain)|Participants inclusion criteria an age 18 to 55 years of age who practice sports equal to greater than three hours per week who have not had low back pain or ciatalgia in the last 12 months.
3470225|NCT03880370||group 2 (low back pain group)|Participants inclusion criteria an age 18 and 55 years of age who practice sports equal to greater than three hours a week, with a history of at least one episode of low back pain and / or ciatalgia in the last 12 months lasting no longer than three months and diagnosis of hernia lumbar disc using MRI.
3470226|NCT03880409|Active Comparator|2% lidocaine with 1:000,000 epinephrine|supplemental intraseptal injections using 0.8 mL 2% lidocaine with 1:000,000 epinephrine
3470227|NCT03880409|Active Comparator|4% articaine with 1:000,000 epinephrine|buccal infiltration of 1.8 ml 4% articaine with 1:000,000 epinephrine
3470228|NCT03880149|Experimental|Omega-3 supplementation|Omega-3 fatty supplementation and vitamin E. Each 1 g omega-3 capsule contain 600 mg omega-3 including 400 mg EPA + 200 mg DHA. Individual omega-3 dose will be determined according to the athlete's body mass, 1 g omega-3 / 15 kg body mass per day and vitamin E: 1 capsule of vitamin E (400 IU) for every five omega-3 capsules
3470229|NCT03880149|Placebo Comparator|Placebo|Medium-chain triglyceride (MCT) and vitamin E. Each MCT capsule contain 1 g, the dose will be 115 mg per kg body mass per day, and vitamin E: 1 capsule of vitamin E (400 IU) for every five MCT capsules
3470230|NCT03880331|Active Comparator|Aggressive Debridement|Aggressive and frequent debridement of fibrin and crust from the wound base down to pinpoint bleeding, both by the patient as part of daily wound care at home, and also by the clinician (either physician or experienced dermatologic surgery nurse) during follow-up visits. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return weekly until healed. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
3470231|NCT03880331|Active Comparator|Minimal Debridement|No debridement of fibrin by the patient or the clinician. Exceptions include debridement of dried crust or eschar. Silver nitrate will be used to treat excessive granulation tissue only if the granulation tissue is higher than the level of surrounding skin. Patients will return every two weeks until healed. In between visits at weekly intervals, the patient will be contacted by phone to determine if healing has occurred in between clinic visits11. Patients will be provided with detailed instructions and guidelines to help determine whether healing has taken place.
3470232|NCT03880318|Other|spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies in spasmodic flat foot
3470233|NCT03880045|Active Comparator|Topical TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
3470234|NCT03880045|Active Comparator|placebo to TA plus vasopressin|Intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy plus placebo to tranexamic acid
3470235|NCT03880201||patient undergoing upper limb orthopaedic surgery|The study will be performed on patient undergoing upper limb orthopaedic surgery which will be performed under ultrasound guided supraclavicular block.
3470236|NCT03880162|Experimental|Study intervention|Participants will follow an energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates) for minimum two weeks.
3470237|NCT03880162|Active Comparator|Control intervention|Participants will follow an energy deficient (30% deficit) standard diet (50% of carbohydrates) for minimum two weeks.
3470238|NCT03880253|Experimental|CTP-692 Low Dose or Matching Placebo|Once daily dosing
3470239|NCT03880253|Experimental|CTP-692 Mid Dose or Matching Placebo|Once daily dosing
3470240|NCT03880253|Experimental|CTP-692 High Dose or Matching Placebo|Once daily dosing
3470241|NCT03879889|Experimental|Intervention|Intervention arm will include face-to-face counseling on smoking reduction and adherence to nicotine replacement therapy (NRT) with motivational interviews, provision of free NRT, referral to quit smoking hotline, monthly phone follow-up and two follow-up visits.
3470242|NCT03879889|No Intervention|Control|Smoking parents will be given standard advice on smoking cessation. They will be given an information leaflet showing standard information on the currently available smoking cessation service as well as a smoking cessation hotline.
3470243|NCT03879928|Placebo Comparator|Placebo for SAD|Placebo comparator for SAD
3470244|NCT03879928|Experimental|FM101 75 mg for SAD|Single ascending doses of FM101
3470245|NCT03879928|Experimental|FM101 150 mg for SAD|Single ascending doses of FM101
3470246|NCT03879928|Experimental|FM101 300 mg for SAD|Single ascending doses of FM101
3470247|NCT03879928|Experimental|FM101 600 mg for SAD|Single ascending doses of FM101
3470248|NCT03879928|Experimental|FM101 1200 mg for SAD|Single ascending doses of FM101
3470249|NCT03879928|Experimental|FM101 2400 mg for SAD|Single ascending doses of FM101
3470250|NCT03879928|Placebo Comparator|Placebo for MAD|Placebo comparator for MAD
3470251|NCT03879928|Experimental|FM101 150 mg (QD) for MAD|Multiple ascending doses of FM101
3470252|NCT03879928|Experimental|FM101 450 mg (QD) for MAD|Multiple ascending doses of FM101
3470253|NCT03879928|Experimental|FM101 600 mg (BID) for MAD|Multiple ascending doses of FM101
3470254|NCT03879928|Experimental|FM101 300 mg under fasted condition for FE|Food Effect of FM101
3470255|NCT03879928|Experimental|FM101 300 mg under fed condition for FE|Food Effect of FM101
3470256|NCT03879876|Experimental|Human T Lymphoid Progenitor (HTLP) injection|Human T Lymphoid Progenitor cells (HTLPs) obtained after a brief period of ex vivo culture in the presence of the fusion protein DL-4, Retronectin® and a combination of cytokines
3470257|NCT03880097||Research Biopsy|"The research biopsy is the same procedure as a standard of care percutaneous biopsy. A core (hollow) needle is inserted into the tumour tissue in order to collect tissue samples. The procedure is called a research biopsy as it is an additional procedure to the standard of care, used purely to collect tissue samples for research purposes."
3470258|NCT03879850||Propofol group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - i.v. Propofol - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
3470259|NCT03879850||Volatile group|This is a prospective, observational study in surgical patients undergoing elective surgery under general anesthesia stratified for the anesthetic agent used intraoperatively - volatile anesthetic agent as Sevoflurane or Desflurane - focusing on pre-, intra- and postoperative EEG spectral parameters in elderly patients.
3470260|NCT03879954|Other|OOP-IJV|Out of plane inetrnal jugular vein catetherization
3470261|NCT03879954|Other|IP-SSV|in plane supraclavicular subclavian vein catetherization
3470262|NCT03880071|Experimental|DBT + ACT group|- The experimental group (DBT+ ACT) led in Montpellier during 6 months.
3470263|NCT03880071|Other|DBT group|The control group (DBT) led in Geneva during 12 months.
3470264|NCT03880058|Active Comparator|SLI-F06|
3470265|NCT03880058|Placebo Comparator|Formulation Buffer|
3470266|NCT03879915||Prospective Dental Implant placement|Patients prospectively included and treated following current recommendations
3470267|NCT03879915||Retrospective Dental Implant placement|Patients retrospectively included, that did not benefit from current recommendations
3470268|NCT03880136|Experimental|Sequence 1|Period 1: CTP-543 with meal Period 2: CTP-543 without meal
3470269|NCT03880136|Experimental|Sequence 2|Period 1: CTP-543 without meal Period 2: CTP-543 with meal
3470270|NCT03879980|Placebo Comparator|Non-QL block|The control (non-QL block) group only received fentanyl IV during surgery.
3470271|NCT03879980|Experimental|Bilateral QL block|The patients were in the semi-lateral supine position to show up the side to be blocked. Using USG and 1-6 MHz convex transducer placed in the transverse plane above the iliac crest at the level of the umbilicus. A Stimuplex® 20G 100-mm needle was advanced in anteroposterior direction toward the junction of tapered abdominal muscle layer and QL muscle, and 20 ml of 0.25% bupivacaine was deposited in the anterolateral border of QL muscle at the junction with the transversalis fascia reach outside the anterior layer of transversalis fascia. The lateral approach QL (type I) blocks were performed at both sides of patients. The total amount of bupivacaine was 100 mg for each patient
3470272|NCT03879993|Experimental|Exercise group|Exercise group was resistance training three times per week, during 45 to 60 minutes per day. Training program was composed by bench press, leg press 45°, lat pulldown, knee extension, dumbbell lateral raise, horizontal leg curl, triceps pulldown, seated calf raise, biceps curls and abdominal. Participants should complete 3 series with 8-12 repetitions of each exercise, which was supervised by trained research personnel. There were 60 seconds of interval between series and exercises were separated by a 120 seconds recovery period.
3470273|NCT03879993|No Intervention|Control group|Control group was not do any exercise during intervention period. Participants was asked to keep their habitual routine until finish the final evaluations.
3470274|NCT03880240|Experimental|2 weeks of daily tACS sessions|10 daily (Monday-Friday) 1-hour sessions of tACS stimulation
3470275|NCT03880240|Experimental|4 weeks of daily tACS sessions|20 daily (Monday-Friday) 1-hour sessions of tACS stimulation
3470276|NCT03880240|Experimental|4 weeks of twice daily tACS sessions|20 days (Monday-Friday) of 1-hour sessions of tACS twice per day
3470277|NCT03880240|Sham Comparator|2/4 weeks of Sham tACS sessions|10/20 days (Monday-Friday) of 1-hour sessions of tACS once/twice per day
3470278|NCT03880123|Experimental|Selinexor/Ixazomib|Patients will receive combination treatment with selinexor and ixazomib. The dose of ixazomib is fixed at 4 mg, whereas several different dose levels of selinexor may be evaluated. No patients will receive a placebo.
3470279|NCT03880032|Experimental|Cognitive Behavioral Therapy Intervention for Anxiety|Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
3470280|NCT03880032|No Intervention|Enhanced Usual Care|Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Transportation will be facilitated to assist participants in attending appointments and medically indicated ultrasounds will be paid for (as in the intervention group).
3132503|NCT03433482|Experimental|GSK3536820A ACWY_Liq30 Group|Healthy subjects receiving a single dose of the investigational MenACWY liquid vaccine formulation aged for approximately 30 months, at Day 1 in the Study Phase 2.
3470281|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID|
3470282|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID|
3132504|NCT03433482|Active Comparator|ACWY_2 Group|Healthy subjects receiving a single dose of the licensed GSK's MenACWY vaccine formulation (Menveo), at Day 1 in the Study Phase 2.
3132505|NCT03433677|Experimental|LY900014|100 units per milliliter (U/mL) LY900014 administered by individualized, continuous, subcutaneous insulin infusion (CSII)
3470283|NCT03879863|Experimental|Reproxalap Ophthalmic Solution (0.25%) QID to BID|
3470284|NCT03879863|Placebo Comparator|Vehicle Ophthalmic Solution QID to BID|
3470285|NCT03880279|Experimental|TAC01-CD19|TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.
3470286|NCT03879967|Experimental|Allograft block graft|For lateral alveolar ridge augmentation, all patients will be treated with allograft block with guided bone regeneration. After a minimal healing phase of six months, implants would be placed in the augmented site. After a healing phase of about 4months, the implants would be loaded and then followed until the control appointment approximately 3 years later.
3470287|NCT03879824|Experimental|Radial Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the radial artery (right radial artery only) during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary radial artery access during TAVI"
3470288|NCT03879824|Active Comparator|Femoral Artery Secondary Access During TAVI|"Patients randomized to this arm will undergo primary access for valve placement through the femoral artery and will have secondary vascular access for placement of the pigtail catheter through the contralateral femoral artery artery during their transcatheter aortic valve implantation (TAVI)~The active intervention in this arm of the study is secondary femoral artery access during TAVI"
3470289|NCT03880175|Experimental|FCC DEB and Anti-stigma|
3470290|NCT03880175|Experimental|FCC DEB and HIV info|
3470291|NCT03880175|Experimental|FCC DEB and ART info|
3470292|NCT03880175|Experimental|FCC DEB and HIV-ART info|
3470293|NCT03880175|Experimental|FCC DEB and high coupon value|
3470294|NCT03880175|Experimental|FCC DEB and no info|
3132506|NCT03433677|Experimental|Insulin Lispro|100 U/mL insulin lispro (Humalog®) administered by individualized CSII
3470295|NCT03880175|Experimental|FCC non-DEB and Anti-stigma|
3470296|NCT03880175|Experimental|FCC non-DEB and HIV info|
3470297|NCT03880175|Experimental|FCC non-DEB and ART info|
3470298|NCT03880175|Experimental|FCC non-DEB and HIV-ART info|
3470299|NCT03880175|Experimental|FCC non-DEB and high coupon value|
3470300|NCT03880175|Experimental|FCC non-DEB and no info|
3470301|NCT03880175|Experimental|FCC control and Anti-stigma|
3470302|NCT03880175|Experimental|FCC control and HIV info|
3470303|NCT03880175|Experimental|FCC control and ART info|
3470304|NCT03880175|Experimental|FCC control and HIV-ART info|
3470305|NCT03880175|Experimental|FCC control and High coupon value|
3470306|NCT03880175|No Intervention|FCC control and no info|
3470307|NCT03879837|Experimental|Investigational Test Product|Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation
3470308|NCT03879837|Active Comparator|Reference Listed Drug|Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation
3470309|NCT03879837|Placebo Comparator|Placebo|Placebo pressurized metered dose inhaler, no active content
3470310|NCT03880006|No Intervention|Standard of care|Participants assigned to the Senegalese standard of care treatment for people living with HIV.
3470311|NCT03880006|Experimental|Case management|Individuals in the intervention arm will receive Senegalese standard of care treatment for people living with HIV, and the case management intervention.
3470312|NCT03879811|Experimental|MMR-Proficient Colorectal Cancer|"The first 3 subjects will receive oral TMZ at 150mg/m2 day 1 to 5 during cycle~1, followed by nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1 (i.e. Cycle 2 day 1). Nivolumab will continue for up for 2 years maximum. If confirmed that TMB increased in at least 2 of 3 subjects following 1 cycle of TMZ, then subsequent patients will continue to receive TMZ during cycle 1 only, and the original three participants will not be replaced. If it is determined that TMB did not increase following 1 cycle of TMZ, then subsequent patients will receive TMZ up to cycle 3, those first 3 patients will discontinue further Nivolumab and be replaced and an additional 6 patients will initially be enrolled. If confirmed that TMB increased in at least 1 of 6 subjects following 3 cycles of TMZ, then 12 more patients will be allowed to enroll for a total of 18 in stage I."
3470313|NCT03879798|Experimental|DS-3201b and Irinotecan|The first part of this study is a phase I trial to assess the safety and tolerability of DS-3201b in combination with fixed-dose irinotecan. The second part of this study will be an open label, single-arm phase II study of DS-3201b at the established recommended phase II dose (RP2D) in combination with fixed-dose irinotecan. Dose-Escalation, which enrolled a total of 12 patients at MSK, is completed. Phase 1 of this study determined that the highest and safest dose of DS-3201b in patients was 100 mg daily.
3470314|NCT03879785|Active Comparator|Self-Administration followed by Interviewer-Administered|
3470315|NCT03879785|Active Comparator|Interviewer-Administered followed by Self-Administration|
3470316|NCT03879642|Experimental|REDCHiP|10 week video-based telemedicine intervention to reduce parents hypoglycemia fear
3470317|NCT03879642|No Intervention|Waitlist|10 week no intervention to provide waitlist control condition
3470318|NCT03879616|Experimental|An Enhanced Reminder|"Members randomized to this arm of the study will receive an enhanced reminder protocol, which will include multiple reminders, multiple modalities, and motivational messages. The timing of reminders will depend on the wait time between the date the appointment is made and the date of the appointment.~An email reminder will be sent to all members who have provided their personal email information.~Members will receive up to two text messages that roll over to an IVR automated phone call if the text cannot be delivered.~Members scheduled for colonoscopy will also receive a single IVR-T reminder to begin their bowel prep the morning of the calendar day prior to the procedure."
3470319|NCT03879616|Other|Control|"Members randomized to this arm of the study will receive a single text message that rolls over to an IVR automated phone call if the text cannot be delivered. This message will be delivered 7 business days prior to the appointment. This replicates the current protocol for GI procedures. Of note, members who schedule appointments within 7 days of the procedure currently receive no reminders."
3470320|NCT03879720|Active Comparator|Standard Endotracheal Intubation (SEI)|the patient will be positioned supine on the gurney for intubation, with eventual position in the standard semi-prone ERCP position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed, Propofol and Succinylcholine will be administered per standard of care and intubation will be accomplished by direct laryngoscopy or glidescope, with confirmation of endotracheal tube placement by auscultation.
3470321|NCT03879720|Experimental|Endoscope assisted endotracheal intubation [EAEI]|the patients will position themselves in the semi-prone position on the fluoroscopy table. Anesthesiologist-determined doses of Fentanyl, Versed and Propofol will be administered per standard of care. Succinylcholine will not be administered and therefore the patient will not be paralyzed. The endotracheal tube will be positioned on the mid-distal aspect of the ultra-slim endoscope and the ultra-slim endoscope will then be advanced into the trachea under direct endoscopic visualization to the level of the carina. The anesthesiologist will then advance the endotracheal tube over the endoscope into the trachea, and its position above the carina will be simultaneously confirmed endoscopically with the ultra-slim endoscope.
3470322|NCT03879759|Experimental|Arm 1|NAC - Relapse Prevention (4 wks)
3470323|NCT03879759|Placebo Comparator|Arm 2|NAC - Relapse Prevention (4 wks)
3470324|NCT03879629|Experimental|Pre-Emptive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated one week before start of therapy and continued until end of therapy
3470325|NCT03879629|Experimental|Reactive Strategy|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of subclinical cardiotoxicity, defined by an abnormal global longitudinal strain (GLS) or high-sensitive cardiac troponin (hsTnI) elevation and continued until end of therapy
3470326|NCT03879629|Active Comparator|Standard of Care|Carvedilol titrated to maximally tolerated doses (3.125 mg to 25 mg twice a day) initiated after documentation of a drop in LVEF by >10% to a value less than 53% and continued until end of therapy
3132507|NCT03433703|Experimental|Lenvatinib|Participants will receive lenvatinib 12 or 8 milligrams (mg) once daily in continuous 28-day cycles until disease progression, development of unacceptable toxicity, participant request, withdrawal of consent, or study termination by the sponsor. Upon completion of lenvatinib treatment, eligible participants will receive commercially available systemic TPC for hepatocellular carcinoma in the subsequent treatment period.
3470327|NCT03879707|Experimental|Experimental|Melatonin and magnesium for 14 days
3470328|NCT03879707|Placebo Comparator|Control|Placebo for 14 days
3132508|NCT03433755|Placebo Comparator|Placebo Q2W|Placebo subcutaneous (SC) Q2W for 12 weeks
3132509|NCT03433755|Placebo Comparator|Placebo QM|Placebo SC QM for 12 weeks
3470329|NCT03879577|Experimental|Docetaxel|Investigators will give patients docetaxel through drip every 3 weeks for four doses for 12 weeks before a repeat breast ultrasound. After breast ultrasound, if the investigator feels the injection is good, surgery will be done.
3470330|NCT03879577|Other|Herceptin|Herceptin will be given to patients under the skin of the thigh every 3 weeks for 18 times if they are HER2-positive
3470331|NCT03879577|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with a poor response to docetaxal will receive FEC injection by drip every 3 weeks.
3470332|NCT03879577|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years every 3 months for contraception and fertility preservation.
3470333|NCT03879577|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
3470334|NCT03879694|Experimental|Treatment (SVN53-67/M57-KLH peptide vaccine, octreotide)|Patients receive a SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC on day 0. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Patients also receive octreotide acetate IM on day 0. Cycles of octreotide acetate repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain free of tumor progression at 6 months and do not develop any regimen-related toxicity or serious adverse events will be eligible to receive additional doses of the vaccine and sargramostim every 3 months, for up to 1 year from the start of treatment.
3470335|NCT03879655|Experimental|VTS-270|Eligible participants who transition into this study will receive treatment with VTS-270 at the last dose level administered in Study VTS301, administered IT via LP infusion every 2 weeks, for up to a total duration of 3 years or until the investigator considers VTS-270 to be no longer beneficial to the subject, VTS-270 receives marketing authorization, or the VTS-270 development program is discontinued.
3470336|NCT03879746|Active Comparator|tamsulosin group|the first group will include 40 patients treated with daily administration of tamsulosin 0.4 mg
3470337|NCT03879746|Active Comparator|paroxetine group|the second group will include 40 patients treated with daily administration of paroxetine 20 mg
3470338|NCT03879746|Active Comparator|combined group|the third group will include 40 patients treated with daily administration of tamsulosin 0.4 mg and paroxetine 20 mg
3470339|NCT03879746|Placebo Comparator|placrbo group|the fourth group will include 40 patients will be given placebo
3470340|NCT03879525|Experimental|EMR Group|Participants assigned to this arm will complete the questionnaires in the EMR using the EMR-based-interventional method.
3470341|NCT03879525|Active Comparator|Phone Group|Participants assigned to this arm will complete the questionnaires via the Phone using the Telephone-based-standard method.
3132510|NCT03433755|Experimental|Evolocumab 140 mg Q2W|Evolocumab 140 mg SC Q2W for 12 weeks
3132511|NCT03433755|Experimental|Evolocumab 420 mg QM|Evolocumab 420 mg SC QM for 12 weeks
3470342|NCT03879668||eIPOS|The cohort will include all participants who are cared for by the participating specialist palliative home care teams when implementing eIPOS.
3470343|NCT03879668||Historic control|The cohort will include all participants that were cared for by the participating specialist palliative home care teams in the last 6 months before the implementation of eIPOS.
3470344|NCT03879512|Experimental|Active vaccination arm|All patients receive depletion of regulatory T cells, reoperation, followed by a personalized cancer vaccine and double checkpoint blockade.
3470345|NCT03879590|Experimental|Budesonide and Doxophylline|Budesonide at the same dose in which the subject is currently treated (GINA step 3 or 4) plus doxophylline at a dose of 18 mg / kg per day
3470346|NCT03879590|Active Comparator|Low budesonide and Doxophylline|Reduced dose of inhaled budesonide (GINA step down) plus doxophylline to a dose of 18 mg / kg per day, maximum of 800 mg / day (Group B)
3470347|NCT03879538|Active Comparator|The nitrous oxide group|Nitrous oxide group will receive 50% nitrous oxide mixed with 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
3470348|NCT03879538|Placebo Comparator|The Control Group|Control group will receive 50% oxygen, inhalation therapy for a duration of 2 hours via an FDA-approved mask breathing circuit.
3470349|NCT03879447||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
3470350|NCT03879447||Lumbar spondylolisthesis group|Lumbar spondylolisthesis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manual medicine, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
3470351|NCT03879681|No Intervention|No Intervention|
3470352|NCT03879681|Experimental|Jelly Snakes|
3470353|NCT03879460|Experimental|Open Label|Open label
3470354|NCT03879564|Placebo Comparator|control|0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
3470355|NCT03879564|Experimental|ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
3470356|NCT03879733|Experimental|Intervention group|The group of childcare centers that will receive the intervention during 10 months from sept 2018 - June 2019
3470357|NCT03879733|Other|Wait-list control|"Will receive no intervention and continue with business as usual during the primary intervention period Sept. 2018 - June 2019.~Will receive the intervention from Sept. 2019 - June 2020."
3470358|NCT03879408|Experimental|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
3470359|NCT03879408|Experimental|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
3470360|NCT03879408|Active Comparator|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone + 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
3470361|NCT03879408|Active Comparator|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
3470362|NCT03879408|Placebo Comparator|Placebo tablet|Single dose of four placebo tablets
3470363|NCT03879486|Experimental|PVPI intervention|rectal cleansing and disinfection of the needle tip at transrectal ultrasound guided prostate biopsy
3179167|NCT00670033|Experimental|Travoprost new formulation|Travoprost ophthalmic solution (new formulation), 1 of 3 dose levels, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3470364|NCT03879486|No Intervention|Control arm|controls at transrectal ultrasound guided prostate biopsy
3470365|NCT03879356|Other|Aluminum phosphide patients|effect of N-acetyl cysteine and supportive measures in outcome of aluminum phosphide poisoning cases
3470366|NCT03879382|Experimental|anti-CD19/BCMA CAR-T cells|Administration with anti-CD19/BCMA CAR-T cells in the relapsed and refractory POMES Syndrome patients
3470367|NCT03879421|Active Comparator|Group 1 (Epithelium-off accelerated CXL)|patients with corneal thickness > 400 µm (thinnest location) were assigned into Epi-off accelerated CXL procedure
3125229|NCT02970669|Active Comparator|Enalapril|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of enalapril and 1 tablet of matching placebo sacubitril/valsartan twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 2.5 mg enalapril BID). Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 (i.e. 10 mg enalapril BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on enalapril Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1 of sacubitril/valsartan. Patients may have been sequentially up-titrated to achieve desired dose of Dose Level 3 of sacubitril/valsartan. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
3125230|NCT02970669|Experimental|Sacubitril/Valsartan|"Double blind treatment epoch: Patients randomized to this arm received 1 tablet of sacubitril/valsartan and 1 tablet of matching placebo enalapril twice daily for 8 weeks. All Patients began the study on Dose Level 1 (i.e. 24/26 mg sacubitril/valsartan BID). Patients may have sequentially been up-titrated to achieve desired dose of Dose Level 3 (i.e. 97/103 mg sacubitril/valsartan BID). Patients not tolerating dose escalation could have been titrated down to next lower dose level.~Open-label treatment epoch: All patients entering this epoch (8 weeks) were given sacubitril/valsartan 49/51 mg BID (Dose Level 2) unless they completed the double-blind treatment epoch on Dose Level 1. Instead, these patients entered open-label epoch on Dose Level 1. Patients may sequentially have been up-titrated to achieve desired dose of Dose Level 3. Patients not tolerating dose escalation could have been titrated down to next lower dose level."
3470368|NCT03879421|Active Comparator|Group 2 (Epithelium-on accelerated CXL)|patients with corneal thickness > 380 µm and < 400 µm thinnest location) were assigned into Epi-on Trans-epithelial accelerated CXL procedure
3470369|NCT03879343||Clinical group|Children aged six to eleven with clinical diagnosis of attention deficit / hyperactivity disorder were recruited for interview and completion of questionnaires
3470370|NCT03879343||Control group|Normally developing children aged six to eleven studying in local mainstream primary schools were recruited for completion of questionnaires
3470371|NCT03879174|Experimental|Pembrolizumab + Tamoxifen|Pembrolizumab (200mg IV every three weeks) + Tamoxifen (20 mg OD)
3470372|NCT03879148|Active Comparator|Erector spinae plane block (Group I)|The ultrasound (US) guided ESPB was performed under aseptic conditions at the level of T5 vertebrae using the GE Vivid Q® US device. A high frequency 12 MHz linear US probe was covered with a sterile sheath and placed longitudinally 2-3 cm lateral to the T5 transvers process. After visualizing trapezius, rhomboid major, erector spinae muscles superficial to the hyperechoic transverse process shadow respectively, a 22-gauge 50 mm block needle (Braun Stimuplex Ultra 360, Germany) was inserted in a cephalad to caudad direction. Once the needle tip had been placed within the interfacial plane below the erector spinae muscle, 2 mL of saline were injected to confirm the proper injection site, and then a 20 mL dose of 0.25% bupivacaine was injected. Patients received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit
3470373|NCT03879148|No Intervention|Control group (Group II)|Patients in control group only received fentanyl via a patient controlled analgesia (PCA) device with a protocol of 2 mL (10 µg/mL) bolus without an infusion dose, 20 min lockout time and 4 hour limit.
3470374|NCT03879213|Experimental|Active|freeze-dried red raspberry powder (25 g) in active breakfast meal
3470375|NCT03879213|Placebo Comparator|Placebo|Placebo breakfast
3470376|NCT03879031||Outpatients with low back pain|"All outpatients with non-specific subacute or chronic low back pain will be submitted to a physical therapy program including:~information on pain mechanisms and the favorable nature of non-specific low back pain;~advice on positions, movements and activities recommended or advised against in people with low back pain, both at work and during leisure time;~active postural correction exercises, overactive muscles lengthening and weak musculature strengthening;~passive manual techniques, aimed at muscle relaxation and recovery of lumbar joint mobility.~A cluster of Clinical tests to measure lumbar stability will be administrated before the starting of the first session and at the ending of the last session of the physical therapy program."
3470377|NCT03879239|Active Comparator|Vibrant Capsule mode A|Vibrant Capsule mode A administered 5 times per week
3470378|NCT03879239|Active Comparator|Vibrant Capsule mode B|Vibrant Capsule mode B administered 5 times per week
3470379|NCT03879239|Placebo Comparator|Placebo Capsule|Placebo Capsule administered 5 times per week
3470380|NCT03879252|Experimental|Tooth brushing|
3470381|NCT03879252|Active Comparator|Mouthwash|
3470382|NCT03879122|Active Comparator|ADT + Docetaxel|ADT (androgen deprivation therapy) plus 6 cycles of DOCETAXEL
3470383|NCT03879122|Experimental|ADT + Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus DOCETAXEL plus NIVOLUMAB
3470384|NCT03879122|Experimental|ADT + Ipilimumab / Docetaxel + Nivolumab|ADT (androgen deprivation therapy) plus IPILIMUMAB alternating with DOCETAXEL and followed by NIVOLUMAB
3470385|NCT03879135|Experimental|On-Demand|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
3470386|NCT03879135|Experimental|Prophylaxis|Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE).
3470387|NCT03879395||Cohort|Patients with stage IV malignant melanoma with abdominal metastasis (M1c) that underwent abdominal surgery with metastasectomy during the study period.
3470388|NCT03879070|Experimental|Intervention group|
3470389|NCT03879070|No Intervention|Control group|
3470390|NCT03879278|Other|Treatment 2 mg/kg|Five IV doses of 2 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
3470391|NCT03879278|Other|Treatment 5 mg/kg|Five IV doses of 5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
3470392|NCT03879278|Other|Treatment 12.5 mg/kg|Five IV doses of 12.5 mg/kg NPT189 (n = 6) or matching placebo (n = 2) administered once per week
3470393|NCT03879057|Experimental|Surufatinib 200mg/JS001 240mg|Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
3125231|NCT02970812|Experimental|Electrical Muscle Stimulation|Electrical Muscle Stimulation (EMS) program was consisted of warm-up, warm-down, contraction and relaxation. It was programed to be resemble to actual muscle action of voluntary exercise. To increase energy consumption as high intensity exercise, tripled the contraction duration. EMS group used Program 3 and regulated intensity though channel from 1 to 4.
3470394|NCT03879057|Experimental|Surufatinib 300mg/JS001 240mg|Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
3470395|NCT03879200|No Intervention|Standard Individual care|Historical controls Individual care follows standard individual Swedish antenatal care, i.e.8-9 30 minutes appointments with a midwife during a normal pregnancy including information and regular pregnancy check-ups. Women are offered classes (3 x 2 hours) that provide preparation for birth and parenthood according to the same guidelines. Obstetricians and general practitioners have a consultant role.
3470396|NCT03879200|Experimental|Group antenatal care|Group antenatal care will follow the same guidelines as for individual care but with tailored content provided in language supported group sessions.
3470397|NCT03878901|Sham Comparator|control group|Cotton Blanket Warming (CBW) starts 30 min preoperatively and then continues throughout the entire operation.
3470398|NCT03878901|Experimental|warm group|"Warm according to different hypothermia risk for low risk ---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) continues throughout the entire operation.~moderate risk---Forced-air warming(FAW) starts at least 30 min preoperatively and then Cotton Blanket Warming (CBW) and fluid warming continues throughout the entire operation.~high risk ----Forced-air warming(FAW) starts at least 30 min preoperatively, FAW and fluid warming continues throughout the entire operation."
3470399|NCT03879096|Experimental|Experimental|The sample will receive of a Therapeutic Exercise and Education programme
3470400|NCT03879226|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
3470401|NCT03879226|Experimental|PBMT + training/ placebo + detraining|PBMT applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
3470402|NCT03879226|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and PBMT applied during the detraining period (4 weeks, 3 times a week).
3470403|NCT03879226|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before and after the aerobic training sessions (12 weeks, 3 times a week) and placebo applied during the detraining period (4 weeks, 3 times a week).
3470404|NCT03879018|Experimental|Reinforcement Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For reinforcement training, participants will not see their hand or a cursor, but instead participants will receive target-specific binary feedback after each reach (i.e. based on running average of last 10 reaches to that target). Binary feedback indicates only whether the reach was successful or unsuccessful and provides no specific information about the location of the hand.
3470405|NCT03879018|Experimental|Standard Practice Training|Reach training with visual feedback. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed. During training the participant will reach a total of 400 times. For standard practice, participants will be able to see a cursor that represents the position of the hand at all times and try to make straight reaches to the targets. This type of feedback provided specific information about the location of the hand.
3470406|NCT03878849|Experimental|2X-121|Oral administration of 2X-121 once daily as 600 mg hard gelatin capsules in a 28 days cycle.
3470407|NCT03878888|Experimental|Exparel use in TAP block|Exparel used in bilateral TAP block for open abdomen surgery
3470408|NCT03878888|No Intervention|no TAP block|these patients, N=20, did not received a bilateral TAP block for postoperative pain control. Instead, pain control involves PO/IV pain medications
3470409|NCT03878979|Experimental|Newly diagnosed SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of a newly diagnosed SCCHN.
3470410|NCT03878979|Experimental|Reccurence of SCCHN|One dose of nivolumab given about 4 weeks before surgical resection (removal) of SCCHN which has recurred.
3470411|NCT03879187|Experimental|High-fat diet|Participants underwent a 7 day high-fat, high-energy diet intervention with metabolic measurements before and after
3470412|NCT03878966|Experimental|Invasive Strategy group|Our study will be conducted on at least thirty patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)-which include ST depression myocardial infarction and unstable angina- who will be subjected to the early invasive strategy . Polymer-free drug eluting stents will be used for these patients instead of the usually used polymer-permanent drug eluting stents .
3470413|NCT03878680||13-14 years age group|Children with age 13-14 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
3470414|NCT03878680||6-7 years age goup|Children with age 6-7 years at the time of questionnaires completion, and residing in Dubai and the Northern Emirates of UAE.
3470415|NCT03878940|Other|Primary care patients|All GPs in the municipality of Silkeborg will be invited to participate. Any patient can be referred to the abdominal ´yes-no´ pathway, independently of their willingness to give one´s consent.
3470416|NCT03878953|Experimental|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
3470417|NCT03878914|Experimental|Quick responders (Group A)|"Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.~CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group A (Total duration of therapy 8 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 2 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 2 weeks.~Wean off in 4 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
3470418|NCT03878914|Active Comparator|Slow responders (Group B)|"CORTICOSTEROID THERAPY FOR INITIAL EPISODE Group B: (Total duration of therapy ≥ 12 weeks)~60mg/m2/day or 2mg/kg/day (maximum 60mg) day for 4 weeks~40mg/m2 or 1.5mg (maximum 40mg) every other day for 4 weeks.~Wean off in 4-6 weeks~CORTICOSTEROID THERAPY FOR A RELAPSE~60mg/m2/day or 2mg/kg/day (maximum 60mg) until remission~40mg/m2 or 1.5mg (maximum 40mg) every other day for one week followed by continued weaning until discontinued in 6-8 weeks."
3470419|NCT03879083|Experimental|With reproduction of palatal rugae|Participants will receive maxillary complete dentures with a reproduction of the patients's own palatal rugae to the palatal surface.
3470420|NCT03879083|Active Comparator|Without reproduction of palatal rugae (smooth surface)|Participants will receive maxillary complete dentures with smooth palatal surfaces without a reproduction of the patients's own palatal rugae to the palatal surface.
3470421|NCT03879265||Study group|No intervention. Couples who come to the study center to carry out a PGT-A cycle will be selected. Only couples that will use their own gametes will be selected and the indication of PGT-A will be advanced maternal age, failure of implantation, repeat abortion, male factor or structural chromosomal alterations. The results of chromosomal status of the embryo will be compared using the NICS and the conventional invasive method (PGT-A).
3470422|NCT03878706||GLP1 and SGLT2i group|40 patients treated with a combination of liraglutide and empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
3125232|NCT02970812|Placebo Comparator|Transcutaneous Electrical Nerve Stimulation|Transcutaneous group used Transcutaneous Electrical Nerve Stimulation (TENS) which is the use of electric current produced to stimulate the sensory nerves to block pain signal. It is programed to applied currents regularly, once a second with a frequency of 1 Hz.
3125233|NCT02970942|Experimental|Semaglutide 0,1 mg|
3125234|NCT02970942|Experimental|Semaglutide 0,2 mg|
3470423|NCT03878706||GLP1 group|40 patients treated with liraglutide.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
3470424|NCT03878706||SGLT2i group|40 patients treated with empagliflozin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
3125235|NCT02970942|Experimental|Semaglutide 0,4 mg|
3125236|NCT02970942|Placebo Comparator|Placebo 1|
3125237|NCT02970942|Placebo Comparator|Placebo 2|
3125238|NCT02970942|Placebo Comparator|Placebo 3|
3125239|NCT02970981|Experimental|Nivolumab and Ipilimumab|"Dosing during cycle 1 will consist of: 3 mg/kg of Nivolumab+ Ipilimumab at 1 mg/kg. Each induction treatment cycle is comprised of 4 doses of Nivolumab and 4 doses of Ipilimumab given every three weeks for a total of 12 weeks (cycle 1)~Dosing during cycles 2-5 will consist of flat dose Nivolumab at 480 mg every 4 weeks (Q4W) for 48 weeks."
3125240|NCT02971007|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
3125241|NCT02971007|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
3125242|NCT02971007|Active Comparator|Fluconazole 150 mg|Fluconazole Diflucan
3125243|NCT02971163|Experimental|SynDA|The research coordinator will print the appropriate version of the SynDA based on the patient's individualized risk score and the corresponding estimated probability of a serious medical event within 30 days.
3125244|NCT02971163|No Intervention|Control|Patients in the control arm will receive usual emergency care pertaining to syncope.
3132512|NCT03433794|Placebo Comparator|Control|The control group spent 60 minutes on an online education session (Lilly for Better Health) directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
3179168|NCT00670033|Active Comparator|TRAVATAN|Travoprost ophthalmic solution 0.004%, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3470425|NCT03878706||Control group|40 patients treated with insulin and metformin.All subjects will be submitted to an echocardiographic study in order to estimate the GLS as well as the twisting-untwisting of the left ventricle using speckle tracking imaging. PWV, AIx,SBPao and PPao with Arteriograph, Mobilograph and Complior, and perfused boundary region (PBR) of subglottic vessels using a high-resolution special lens with Sideview Darkfield Imaging technique (Microscan, Glucockeck). PBR consists the cell-free space which is formed from the separation of red blood cells from plasma at the surface of the endothelial glycocalyx.Oxidation load markers, blood glucose, glycosylated hemoglobin HbA1c and a full lipidemic profile will be measured before and after 3 months of treatment.
3470426|NCT03878875||High Noise Exposure|One group (20, 10f:10m) with previous exposure i.e. nightclubs ++
3470427|NCT03878875||Low Noise Exposure|Group (20, 10f:10m) with less exposure measured through NESI
3470428|NCT03879005|Other|Renal scintigraphy|5 mci of 99mTc-DTPA or 99mTc-DMSA is injected once IV. Dose is adjusted according to age and weight.
3470429|NCT03878771|Experimental|autologous Platelet rich fibrin in Orabase (PRF)|applied to oral ulcer and/or mucositis 3 times per day
3470430|NCT03878771|Active Comparator|Clobetasol propionate 0.05%(Dermovate cream) in orabase|applied to oral ulcer and/or mucositis 3 times per day
3470431|NCT03878550||Cases|Male and female adult patients with early-stage hepatocellular carcinoma against a background of liver cirrhosis.
3470432|NCT03878550||Controls|Male and female adult patients with liver cirrhosis at risk for hepatocellular carcinoma.
3470433|NCT03878641|Experimental|Children in Grade 1 to 5 with literacy and language needs|The investigators intend to identify children in Grade 1 to 5 who demonstrate language-based learning difficulties. Using the two-stage screening, the investigators will identify children who produce substantial number of reading miscues and/or self-correct more less 25% of their miscues, and/or who present weaknesses in expressive language skills with a total CUBED score lower than grade-specific cut scores.
3470434|NCT03878810|Experimental|Exergaming, restless legs syndrome (+)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
3470435|NCT03878810|Experimental|Exergaming, restless legs syndrome (-)|A video game-based physical activity training will be applied under a physiotherapist supervision for 2 days/week for 8 weeks.
3470436|NCT03878810|No Intervention|Control, restless legs syndrome (+)|No specific intervention.
3470437|NCT03878810|No Intervention|Control, restless legs syndrome (-)|No specific intervention.
3470438|NCT03878784|Active Comparator|PACAP38 + Imigran|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Imigrane infusion (0.4 mg/min) for 10 mins"
3470439|NCT03878784|Placebo Comparator|PACAP38 + Isotonic Saline|"Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins~AND~Isotonic saline for 10 mins (placebo)"
3470440|NCT03878654|Experimental|Tauroursodeoxycholic Acid|TUDCA 1750 mg daily for 12 weeks
3470441|NCT03878628|Experimental|Adipose tissue-derived mesenchymal stem cells|Approximately 11 million ASCs in a 0.5 ml suspension
3470442|NCT03878992|Other|GHD|GHD patients will be studied two times - one time before initiation of GH replacement therapy and one time following three months of GH replacement therapy. The two trial days are identical
3470443|NCT03878732||Caucasian female|
3470444|NCT03878732||Hispanic female|
3179169|NCT00670033|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) once daily, at 8 PM, for 4 weeks
3179170|NCT00670059|Active Comparator|A|group: single embryo transfer without aneuploidy screening
3470445|NCT03878693|Experimental|A|Oral APAP and IV Fomepizole.
3470446|NCT03878693|Active Comparator|B|Oral APAP.
3470447|NCT03878719|Experimental|Safety Run-in Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules are specified in the protocol."
3470448|NCT03878719|Experimental|Expansion Phase|"binimetinib taken twice daily (BID) and~encorafenib taken once daily (QD)~Dose levels by patient body surface area (BSA) for binimetinib and encorafenib tablets/capsules and pediatric formulations are specified in the protocol."
3470449|NCT03878667|Placebo Comparator|No Diet|No diet or exercise or calcium intervention
3470450|NCT03878667|Experimental|High Calorie Diet|High calorie (2,600 calorie) diet and exercise and calcium
3470451|NCT03878667|Experimental|Low Carbohydrate/High Protein Diet|Low carbohydrate (63% protein, 7% carbohydrate, 30% fat) diet and exercise and calcium
3470452|NCT03878667|Experimental|High Carbohydrate/Low Protein|High carbohydrate (15% protein, 55% carbohydrate, 30% fat) diet and exercise and calcium
3470453|NCT03878394|Experimental|Group 1|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.
3470454|NCT03878394|Experimental|Group 2|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
3470455|NCT03878576|Active Comparator|REFERENCE: white bread - BGL0 [RP]|Participants consume a meal of bread BGL0 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
3470456|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL2 [IP1]|Participants consume a meal of bread BGL2 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
3470457|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL3 [IP2]|Participants consume a meal of bread BGL3 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
3470458|NCT03878576|Experimental|TEST: b-glucan enriched bread - BGL4 [IP3]|Participants consume a meal of bread BGL4 standardised to contain 25 g of available carbohydrates. Sample consumed together with 300 mL of water in up to 15 minutes.
3470459|NCT03878329|No Intervention|standard of care|standard of care treatment
3125245|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp: T1DM|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 milliunit (mU)/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
3125246|NCT02971202|Other|Hyperinsulinemic, euglycemic clamp:MODY2|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
3125247|NCT02971202|Other|Hyperinsulinemic euglycemic clamp:Control|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.~A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study."
3125248|NCT02971228|Experimental|Part 1, Lilly glucagon then ZP4207|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
3470460|NCT03878329|Experimental|remote home monitoring|use of telemedicine based remote home monitoring
3470461|NCT03878368|Experimental|Intervention|32 participants with moderate osteoarthritis will eat soup with the active ingredient once-a-day for 4 days-a-week for 3 months.
3470462|NCT03878368|Active Comparator|Control|32 participants with moderate osteoarthritis will eat soup without the active ingredient once-a-day for 4 days-a-week for 3 months.
3470463|NCT03878524|Experimental|Treatment (biospecimen collection, 2 drug combination)|"TUMOR BIOPSY: Patients undergo collection of tissue samples. Clinical analytics are performed on the samples and analyzed by a clinical tumor board to recommend a treatment option based on those analytics.~SMMART-PRIME TREATMENT: Patients receive a combination of 2 drugs (Drug A and Drug B, selected from interventions below). Doses will be escalated within individual patients over time. As described in detail below, escalation will occur monthly and is anticipated to occur as follows: first month - 100% FDA approved dose Drug A + 25% FDA approved dose Drug B; second month -- 100% dose Drug A + 50% dose Drug B; third month -- 100% dose Drug A + 100% dose Drug B. All dose-escalations will be reviewed and approved by an independent consultant outside of Oregon Health & Science University (OHSU).~Treatment will continue for up to the end of 6 treatment cycles (cycle length is between 21-28 days) in the absence of disease progression or unacceptable toxicity."
3470464|NCT03878615||Elective Hepatic Surgery|Patientes undergoing elective hepatic resection, managed according to departement routine.
3470465|NCT03878264|Experimental|Part 1|On Day 1, participants will receive a single oral dose of CORT118335 900 mg (Treatment A) after an overnight fast, and a 15-minute intravenous infusion of a microdose of 14C-CORT118335 (Treatment B) beginning 2 hours 45 minutes after the oral dose is administered.
3470466|NCT03878264|Experimental|Part 2|On Day 1, participants will receive a single oral dose of 14C-CORT118335 150 mg (Treatment C) after an overnight fast.
3470467|NCT03878186|Experimental|Cognitive behavioral therapy (CBT)|Cognitive behavioral therapy (CBT). Participants will receive the usual care and 6 sessions of cognitive behavioral therapy
3470468|NCT03878186|Other|Usual Care (UC)|Participants will receive Usual Care only
3125249|NCT02971228|Experimental|Part 1, ZP4207 then Lilly Glucagon|In Part 1, 12 patients participated in 1-day treatment arms in random order (iPhone-based Bionic Pancreas using Lilly glucagon and iPhone-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme.
3125250|NCT02971228|Experimental|Part 2, Lilly glucagon then ZP4207|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
3125251|NCT02971228|Experimental|Part 2, ZP4207 then Lilly Glucagon|In Part 2, it was planned to enrol up to 10 new patients to participate in 1-day treatment arms in random order (iLet-based Bionic Pancreas using Lilly glucagon and iLet-based Bionic Pancreas using ZP4207 (dasiglucagon) {experimental drug} with insulin lispro) according to pre-generated randomization scheme. However, due to unavailability of the iLet, the sponsor decided to stop the trial upon completion of Part 1. Part 2 of the trial using the iLet was consequently not conducted.
3125252|NCT02971293|Experimental|AZD8871 100 µg|The subjects will receive AZD8871 100 µg once daily, by dry powder inhaler (DPI) device. The treatment will be administered via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
3125253|NCT02971293|Placebo Comparator|Placebo|The placebo will be administered via single dose DPI that is an adaptation of the commercially available Genuair® with a smaller internal volume to enable delivery of single doses. To maintain blinding, each patient will receive one inhaled dose from placebo DPI provided to him/her on each day of the treatment period.
3125254|NCT02971293|Experimental|AZD8871 600 µg|The subjects will receive AZD8871 600 µg once daily by DPI device via single dose DPI that is an adaptation of the multi-dose Genuair™ used in approved inhalation products.
3125255|NCT02971488||Persons who inject drugs (PWID)|The study population comprises persons who visit the Cañada Real Galiana shantytown on the outskirts of Madrid, where 90% of illegal drugs in the region are sold and consumed.
3125256|NCT02971605|Experimental|Psilocybin|Participants will be administered a 25 mg/70 kg dose of psilocybin
3125257|NCT02971631|Placebo Comparator|Placebo|Infusion of 1% human albumin in normal saline.
3125258|NCT02971631|Experimental|Exendin|Infusion of Exendin 9-39 in 1% human albumin in normal saline
3125259|NCT02971670|Experimental|Dose Group 1|Treatment: rTSST-1 Variant Candidate Vaccine 3 µg
3470469|NCT03878511|Experimental|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
3470470|NCT03878511|Placebo Comparator|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
3470471|NCT03878433|Active Comparator|Drug|Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast
3470472|NCT03878433|Placebo Comparator|No Drug|2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo
3470473|NCT03878355|Experimental|radical endoscopic sinus surgery plus Draf 3 surgery|
3470474|NCT03878355|Experimental|radical endoscopic sinus surgery|
3470475|NCT03878355|Experimental|functional endoscopic sinus surgery|
3470476|NCT03878342|Active Comparator|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
3470477|NCT03878342|Experimental|No Radiotherapy|No Irradiation- Active surveillance
3470478|NCT03878225|Active Comparator|Ketone Mono Ester|"The ketone mono ester is commercially available dietary supplement beverage named H.V.M.N. Ketone Ester, marketed by HVMN Inc®. The KME beverage consists of water, D-β-hydroxybutyrate ester, stevia leaf extract, natural flavors, malic acid, potassium sorbate and potassium benzoate. The active ingredient is the D-β-hydroxybutyrate ester, with each dose containing 25g. Participants will be asked to ingest this 5 times daily for 3 days (72 hours), to a total of 15 doses during the study."
3470479|NCT03878225|Placebo Comparator|Placebo|The placebo beverage will consist of water added with a colorless, bitter flavor enhancer and a sweetening agent (Stevia) to approximate the taste of the KME beverage as closely as possible. The bitter flavor enhancer used is denatonium benzoate (Bitrex®). The placebo beverage will be delivered to patients in bottles identical to those used in the active arm. Patients, investigators and other caregivers will be blinded to treatment allocation until time of database unlock.
3470480|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1|
3470481|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib|
3470482|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1|
3470483|NCT03878472|Experimental|Neoadjuvant immunotherapy with PD-1+apatinib+S1+Oxaliplatin|
3470484|NCT03878238|Placebo Comparator|Placebo|
3470485|NCT03878238|Experimental|Probiotic|
3470486|NCT03878420|Experimental|PBM Treatment|The Valeda™ Light Delivery System will deliver 590, 660 and 850 nm wavelengths together.
3470487|NCT03878420|Sham Comparator|Sham Treatment|The Valeda™ Light Delivery System will deliver non-effective treatment of the 590 and 660 nm wavelengths together.
3470488|NCT03878563||ascites with/without SBP|Cirrhosis with ascites and existing SBP or prior SBP
3470489|NCT03878563||ascites and decreased protein concentrati|Cirrhosis with ascites and decreased protein concentration <1,5 g/d
3470490|NCT03878563||ascites and normal protein concentration|Liver cirrhosis witha scites and protein concentration >1,5 g/d
3470491|NCT03878563||Liver cirrhosis without ascites|Patients with liver corrhosis without ascites
3470492|NCT03878563||Healthy controls without liver cirrhosis or other pathology|Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy
3470493|NCT03878303|Experimental|AC0058TA|AC0058TA will be administered in 25 mg capsules orally at the following doses: 50 mg QD, 100 mg QD, 200 mg QD and 100 mg BID
3470494|NCT03878303|Placebo Comparator|Placebo AC0058TA|Placebo AC0058TA will be administered orally at the equivalent dose of investigational product
3125260|NCT02971670|Experimental|Dose Group 2|Treatment: rTSST-1 Variant Candidate Vaccine 10 µg
3125261|NCT02971670|Experimental|Dose Group 3|Treatment: rTSST-1 Variant Candidate Vaccine 30 µg
3470495|NCT03878212|Experimental|mHealth+I|This group of participants will receive a proactive mHealth with interactivity program which includes two main elements: 1) mHealth application designed by the research team with the information technological support by Smartone and 2) nurse case management supported by a social service team
3470496|NCT03878212|Active Comparator|mHealth|The mHealth group will have access to the health content on the mHealth platform. This group 2018 HMRF Open Call Proposal Section 13: Proposed Research Project 5 will enjoy the same content and client-initiated help if needed. Same as the above group, the client is invited to use the mHealth application. A reminder message will pop up on the screen of smartphone when participants have not used it for more than one week. The participants are encouraged to read the self-care information that is featured in the app. There is a button for the client-imitated call if they would like to consult a nurse.
3125262|NCT02971670|Placebo Comparator|Dose Group 0|Control: Al(OH)3 Adjuvant
3125263|NCT02971683|Active Comparator|Abatacept subcutaneous + Standard Treatment|Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
3470497|NCT03878212|No Intervention|Control|All groups will receive usual community services. The study district provides community-based health talks and basic health checks such as measuring blood pressure and blood glucose that are accessible to all residents, and their participation is voluntary. Both health and social services are available in the community for those who need help, including referral for further help if appropriate. These services are however episodic with design for continuity of care. No mHealth application will be provided to the participants in this group but the individuals are free to do their own surfing for e-health information.
3470498|NCT03878199|Experimental|Treatment (CPX-351, ruxolitinib, allogeneic SCT)|See Detailed Description.
3470499|NCT03878290|Experimental|8-week RiSE|Participate in 8-week Resilience, Stress, and Ethnicity (RiSE) group based stress reduction program in which participants meet every week for approximately 2 hours for 8 consecutive weeks.
3470500|NCT03878290|No Intervention|Control|Treatment as usual
3470501|NCT03878147|Other|HIV infected|HIV infected children
3470502|NCT03878147|Other|HIV exposed uninfected|HIV exposed, uninfected children
3470503|NCT03878147|Active Comparator|HIV unexposed uninfected|HIV unexposed uninfected children (community controls)
3470504|NCT03878069||ERT with ADA|Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
3470505|NCT03878056||Transvaginal mesh|Vaginal surgery (UpholdTM Lite Vaginal Support, Boston Scientific)
3470506|NCT03878056||Robotic sacral colpopexy|Robotic surgery (Artisyn® Y-Shaped Mesh - Ethicon)
3470507|NCT03878121|Experimental|A1|Ad4-Env150KN at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
3470508|NCT03878121|Experimental|A2|Ad4-Env145NFL at Day 0 and 2 months followedVRC-HIVRGP096-00-VP at 6 months.
3470509|NCT03878121|Experimental|B1 (exploratory)|Previously vaccinated; Ad4-Env150KN at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
3470510|NCT03878121|Experimental|B2 (exploratory)|Previously vaccinated; Ad4-Env145NFL at Day 0 and 2 months followed VRC-HIVRGP096-00-VP at 6 months.
3470511|NCT03878082|Active Comparator|propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
3470512|NCT03878082|Active Comparator|propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
3470513|NCT03878082|Placebo Comparator|IVPCA|pain control with IVPCA
3470514|NCT03877978||Severe traumatized patients|Severe traumatized patients with an Index Severity Score (ISS) ≥ 15 admitted to the trauma center of Edouard Herriot Hospital.
3470515|NCT03877991|Experimental|CBD-sesame oil capsule|12 volunteers will receive a single oral dose of CBD in a sesame oil vehicle filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
3470516|NCT03877991|Experimental|CBD-LNL capsule|12 volunteers will receive a single oral dose of CBD-LNL formulation filled in a capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
3470517|NCT03877991|Experimental|CBD powder form capsule|12 volunteers will receive a single oral dose of CBD in powder form filled in a hard gelatin capsule, with 200 mL of water. The dose of CBD to be administrated is 90 mg.
3470518|NCT03877796||Ovarian cancer patients|with formalin-fixed paraffin-embedded (FFPE) tumor tissue available
3470519|NCT03877705|Experimental|Dissolving xylitol chewable tablets|Listerine ready tabs 3 times/day
3470520|NCT03877705|Active Comparator|Xylitol chewing gum|Trident original 3 times/day
3470521|NCT03878017|Experimental|skin marking of clipped axillary LN|all eligible patients underwent skin marking of their clipped axillary LN post neoadjuvant chemotherapy to determine the retrieval rate of the clipped nodes
3470522|NCT03877718|Experimental|Arm 1: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine hydrochloride 18.75mg)
3470523|NCT03877718|Experimental|Arm 2: CL-H1T|Maximum dosage within a 24-hour period: One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5mg)
3470524|NCT03877718|Experimental|Arm 3: Sumatriptan succinate 100 mg|Maximum dose within a 24 hour period: One capsule of sumatriptan succinate 100mg
3470525|NCT03877718|Experimental|Arm 4: Promethazine HCl 18.75 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 18.75mg
3470526|NCT03877718|Experimental|Arm 5: Promethazine HCl 37.5 mg|Maximum dose within a 24 hour period: One capsule of promethazine HCl 37.5mg
3470527|NCT03877718|Experimental|Arm 6: Placebo|Maximum dose within a 24 hour period: One capsule of placebo
3470528|NCT03878043||Patients without Readmissions|Patients with TSDH who were not readmitted within a 6-month time period following their initial visit.
3470529|NCT03878043||Patients with Readmissions|Patients with TSDH who were readmitted within a 6-month time period following their initial visit.
3470530|NCT03877952|Experimental|Study Participants|On Day 1, participants will receive a single oral dose of 14C-CORT125281 360 mg (6 X 60 mg capsules) after an overnight fast.
3470531|NCT03877965||Children with single ventricle congenital heart disease|Receiving digoxin per standard of care during the interstage period
3470532|NCT03877588|Other|Primary retroperitoneal sarcoma|All eligible patients are screened in preoperative phase, at least 30 days before surgery, for presence of protein energetic malnutrition (PEM). PEM is defined according to biochemical and physiological parameters (Table). 3 class of PEM are identified: no PEM, mild PEM and serious PEM. Different nutritional oral supplements are provided according to the degree of malnutrition.
3470533|NCT03877744|Experimental|Interactive virtual presence|Participants will engage remotely with a certified child restraint technician via interactive virtual presence. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed, with the exception that the interaction will occur remotely via interactive virtual presence.
3470534|NCT03877744|Active Comparator|Live technician|Participants will engage live with a certified child restraint technician. They will work together to help the participant install his or her child restraint properly into his or her vehicle. Standard Safe Kids Worldwide protocols will be followed.
3470535|NCT03877835|Other|Ropivacaine|SSNB will be performed with 4 ml ropivacaine 5 mg/ml LSIB will be performed With 15 ml ropivacaine 7.5 mg/ml
3470536|NCT03877848||ACS and Non-ACS|"DAPT will be stopped at 30 days in non-ACS subjects while at ACS Patients it may be maintained for up to 3 months. In patients with ACS or with an ischemic event during the first 30 days, DAPT may be continued at the discretion of the investigator. In ACS patients DAPT should be continued for a maximum of 3 months. For patients with recurrent ischemic events duration of DAPT therapy will be at the discretion of the investigator.~Patients receiving long-term oral anticoagulation with either a Vitamin K inhibitor or a NOAC/DOAC will receive either single antiplatelet therapy with clopidogrel, or DAPT for 30 days (triple therapy) followed by single antiplatelet therapy with clopidogrel. Clopidogrel (75 mg QD) will be given to these patients post procedure for 6 months in stable patients and 12 months in ACS patients."
3470537|NCT03877939||Non-pregnant patients|Patients with β-hCG test < 10 UI/L.
3470538|NCT03877939||Patients with viable pregnancy|Patients with β-hCG test > 10 UI/L whose pregnancy is confirmed between gestational weeks 6 and 8.
3470539|NCT03877939||Patients with biochemical pregnancy|Patients with β-hCG test > 10 UI/L and without sac observed.
3470540|NCT03877939||Patients with ectopic pregnancy|Patients with β-hCG test > 10 UI/L whose sac is implantated outside the uterine cavity.
3470541|NCT03877939||Patients with clinical miscarriage|Patients with β-hCG test > 10 UI/L whose sac is implanted inside the uterine cavity, but non-viable pregnancy is confirmed before gestational week 8.
3470542|NCT03877861||Readiband Sleep Tracking - Patient|This group is comprised of 25 participants with a diagnosis of primary Grade IV glioma. A Readiband™ Sleep Tracker device will be provided to each participant, along with necessary instructions. Participantswill return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits.
3470543|NCT03877861||Readiband Sleep Tracking - Control|Aggregate fatigue data and sleep patterns for a group of 30 healthy controls procured from FatigueScience in a de-identified manner for data analysis purposes.
3470544|NCT03877757||Family Planning Elevated Contraceptive Access Clinics Program|This group consists of community clinics who apply and are accepted for FPE CAP membership during the Family Planning Elevated initiative. These clinics will receive the intervention and will provide monthly service delivery data to the FPE evaluation team.
3470545|NCT03877757||Control Clinics|This group consists of non-participating community clinics matched on clinic size, geography, and client populations who are not interested in participating in the initiative but are willing to provide monthly service delivery data to the FPE evaluation team.
3470546|NCT03877536|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
3470547|NCT03877549|Placebo Comparator|Placebo|10cc 0.0625% bupivacaine
3470548|NCT03877549|Experimental|Low Dose|4mg Dexamethasone + 10cc 0.0625% bupivacaine
3125264|NCT02971683|Placebo Comparator|Placebo of Abatacept subcutaneous + Standard Treatment|Placebo of Abatacept subcutaneous weekly in addition to the subject's current standard treatment for 24 weeks followed by a 28 week open-label period of abatacept treatment plus the subject's current standard treatment.
3179171|NCT00670059|Experimental|B|group: single embryo transfer with aneuploidy screening
3470549|NCT03877549|Experimental|Higher Dose|8mg Dexamethasone + 10cc 0.0625% bupivacaine
3470550|NCT03877809|Experimental|Open label trial|Sirolimus 0.5 mg tablets
3470551|NCT03877874||Asthmatic children|"Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily~Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)."
3470552|NCT03877874||Non-Asthmatic children|no intervention
3470553|NCT03877731|Active Comparator|hypertrophic cariomyopathy, isolated septal myectomy|Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy
3179172|NCT00670098|Experimental|1|
3470554|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + edge-to-edge|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)
3470555|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + sliding plasty|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)
3470556|NCT03877731|Experimental|hypertrophic cariomyopathy, septal myectomy + chordae|Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection
3470557|NCT03877731|No Intervention|Arterial hypertension + left ventricular hypertrophy|Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
3470558|NCT03877731|No Intervention|Control|Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy
3470559|NCT03877627|No Intervention|Negative 1|Patients in this arm will not undergo Pelvic and Peritoneal Lymphadenectomy.
3470560|NCT03877627|Experimental|Negative 2|Patients in this arm will undergo Pelvic and Peritoneal Lymphadenectomy.
3470561|NCT03877692|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg, 80mg after each severe BP
3470562|NCT03877692|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg, 60mg after each severe BP
3470563|NCT03877783|Experimental|group of intervention|"participants receive~personalized advice of a dietician about mediterranean diet~individualized training program,~recommendation about optimized pharmacological treatment as in high risk groups for cardiovascular diseases"
3179173|NCT00670098|Experimental|2|
3179174|NCT00670124|No Intervention|1|Standard medical treatment
3470564|NCT03877783|No Intervention|group of control|"participants receive~written information about the advantages of a healthy diet~written information about the advantages of physical activity,~medical treatment according to the latest version of the national guidelines issued by the Swedish Medical Product Agency"
3470565|NCT03877523|Experimental|Cocarnit|disodium adenosine triphosphate trihydrate 10mg, cocarboxylase 50mg, cyanocobalamin 500mg and nicotinamide 20mg
3470566|NCT03877679|Experimental|turmeric paste|Topical curcumin gel (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University traumeric extracted from Curcuma plant, it has anti-inflammatory, antioxidative and antineoplastic properties ((Nosratzehi et al., 2018), The curcumin is safe even in high doses, Since oxidative stress may play a role in pathophysiology of OLP, and by noting that OLP is a chronic inflammatory disease, the herbs which have both anti-inflammatory and antioxidant properties may efficiently control OLP (Kia et al., 2015).
3470567|NCT03877679|Active Comparator|Triamcenolone in orabase|Triamcenolone + na ploycarboxylate
3470568|NCT03877614||Cardiovascular high-risk (disease) group|A. Coronary artery disease B. Congestive heart failure with reduced ejection fraction C. Hypertrophic cardiomyopathy D. Atrial fibrillation E. Pulmonary hypertension F. Fabry's disease
3470569|NCT03877614||Cardiovascular Low-risk (control) group|Patient with only risk factors with ASCVD score<10% will be recognized as the comparison group
3470570|NCT03877640|Active Comparator|Active EMSELLA treatment|6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology
3470571|NCT03877640|Sham Comparator|Sham EMSELLA treatment|6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology
3470572|NCT03878004|Experimental|Primary Group|135 people who will receive the vaccine in the therapeutic scheme
3470573|NCT03878004|Placebo Comparator|Placebo Group|45 people who will receive placebo in the therapeutic scheme
3470574|NCT03877562|Experimental|Olanzapine plus CORT118335|Participants will receive olanzapine 10 mg oral tablets and double-blind CORT118335 600 mg after breakfast once daily for 14 days.
3470575|NCT03877562|Placebo Comparator|Olanzapine plus Placebo|Participants will receive olanzapine 10 mg oral tablets and double-blind placebo matching CORT118335 oral tablets after breakfast once daily for 14 days.
3470576|NCT03877497|Experimental|SBIRT-A|The screening, brief intervention and referral to treatment (SBIRT) will be adapted and used as the intervention in the experimental arm
3179175|NCT00670124|Active Comparator|2|Standard medical treatment plus hypothermia (33°C) maintained for 72 hours
3179176|NCT00670163|Experimental|1|Participating community will provide Comunidades Positivas plus enhanced partner therapy.
3470577|NCT03877497|Active Comparator|INFO-C|The INFO-C group is a time-matched comparison control where information will be provided on substance use and PrEP services in a non-SBIRT format via printed and audio-visual study material
3470578|NCT03877601|Experimental|Topical administration of bevacizumab-800CW|The tracer will be topically administered 5 minutes prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform).
3470579|NCT03877510|Experimental|Open Label IPX203|Subjects will receive IPX203 140 mg, IPX203 210 mg, IPX203 280 mg, or IPX203 350 mg for approximately 9 months. The dose and dosing frequency will be determined by the investigator.
3470580|NCT03877328|Experimental|Virtual Coach|BiotechCoachForAll
3470581|NCT03877302|Experimental|reflexology group|In addition to providing routine nursing/midwifery care, foot reflexology was applied by the researcher to the pregnant women in the experimental group in the active phase of labor (dilatation 4 cm). By giving appropriate position to the pregnant women, the massage was done to both feet for totally 10 minutes including 5 minutes for each foot starting from right foot under the supervision of a doctor. Whereupon, the reflexology technique was applied by stimulating the nerve points by applying pressure to reflex regions of each foot for 20 minutes as totally 40 minutes for both feet. As reflex points of the feet for manual pressure in labor pain; 1: Solar Plexus, 2: Hypothalamus, 3: Pituitary, 4: Spleen, 5: Thyroid Gland, 6: Adrenal, 7: Intestine, 8: Spinal Cord 9: Uterus, Vagina, Ovaries and Fallopian Tubes were studied.
3470582|NCT03877302|No Intervention|Control Group|The control group received only routine treatment, care, and practices of the hospital. Visual Analog Scale (VAS) and State-Trait Anxiety Inventory (STAI FORM TX-I) were evaluated 2 times as in active (4-7 cm) and transition (8-10 cm) phases in the pregnant women in the control group. After the delivery, the Birth Satisfaction Scale was applied to the women by the researcher.
3470583|NCT03877471|Experimental|Low dosage|The low dosage will inject 2 million MSC-like cells (in 100ul suspension) for each ovary.
3470584|NCT03877471|Experimental|Medium dosage|The medium dosage will inject 5 million MSC-like cells (in 100ul suspension) for each ovary.
3470585|NCT03877471|Experimental|High dosage|The high dosage will inject 10 million MSC-like cells (in 100ul suspension) for each ovary.
3470586|NCT03877263|Other|OB/GYN physician-collected vaginal swab|"Patients assigned to the physician-collected vaginal swab group will have their Vaginal swab for detection of STI collected by their obstetrics and gynecology (OB/GYN) physician.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
3470587|NCT03877263|Other|Patient-collected vaginal swab|"Patients assigned to the patient-collected vaginal swab group will self-collect the Vaginal swab for detection of sexually transmitted infection (STI). Patients who self-collect will receive instructions from their OB/GYN physician and in paper form.~The vaginal swabs will be collected first for all patients, to avoid any swab contact with lubricant. As standard of care, the physician will collect Endocervical swab for detection of STI for this group."
3470590|NCT03877198|Experimental|CLiO2|Automated oxygen control by the CLiO2 algorithm
3470591|NCT03877198|Experimental|Oxygenie|Automated oxygen control by the Oxygenie algorithm
3470592|NCT03877315|Active Comparator|Stemmed|Subjects operated with stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.
3470593|NCT03877315|Active Comparator|Non-Stemmed|Subjects operated with stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.
3470594|NCT03877289|Experimental|Oxybutynin|Children aged 4 - 6 years: Oxybutynin 2.5 mg (2.5ml) po TID Children aged 7 - 16 years: Oxybutynin 5 mg (5ml) po TID
3470595|NCT03877289|Placebo Comparator|Placebo|Orasweet liquid placebo
3470596|NCT03877458|Experimental|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
3470597|NCT03877458|Experimental|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
3470598|NCT03877458|Placebo Comparator|Placebo group|Taking 1 Placebo capsule at bed time everyday for three months.
3470599|NCT03877367|Experimental|Upper Extremity Group, Day 1|"Day 1: This group will receive a pre-test, upper extremity intervention, and post-test.~Day 2: This group will receive a pre-test, lower extremity intervention, and post-test."
3470600|NCT03877367|Experimental|Lower Extremity Group, Day 2|"Day 1: This group will receive a pre-test, lower extremity intervention, and post-test.~Day 2: This group will receive a pre-test, upper extremity intervention, and post-test."
3470601|NCT03877445|Other|Melasma Group exposed left half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
3470602|NCT03877445|Other|Melasma Group exposed right half-face by ORIEL solar simulator|Twelve patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control.
3470603|NCT03877250||Non Small Cell Lung Cancer (NSCLC)|Participants with pathologically confirmed newly diagnosed or recurrent advanced NSCLC that is PD-L1 high by immunohistochemistry
3470604|NCT03877406|Active Comparator|Control group|up-titration of standard medication including monotherapy or combination of Metformin, Sulfonylurea, DPP4 inhibitor
3470605|NCT03877406|Experimental|Study group|addition of empagliflozin 10mg qd on standard oral antihyperglycemic agents
3470606|NCT03877393|Experimental|PRO-GFD|Probiotic supplementation + gluten-free diet
3470607|NCT03877393|Placebo Comparator|PLA-GFD|Placebo supplementation + gluten-free diet
3470608|NCT03877393|Experimental|PRO-GD|Probiotic supplementation + gluten-containing diet
3470609|NCT03877393|Placebo Comparator|PLA-GD|Placebo supplementation + gluten-containing diet
3470612|NCT03877172|No Intervention|Face-mask oxygen therapy|Oxygen delivered through a conventional face mask to keep saturation above 92%.
3470613|NCT03877172|Active Comparator|High-flow nasal cannula|High-flow nasal cannula delivered at 50 L/min and FiO2 adjusted to keep saturation above 92%.
3470614|NCT03877185||3-Injection-Protocol Group|Women in group A (3-Injection-Protocol Group) receive a bolus late luteal dose of Degarelix, a new long acting GnRH antagonist, a sole Elonva injection in the early follicular phase followed by the administration of a single dose of triggering agent (GnRH agonist or hCG a, according to the individual response).
3470615|NCT03877185||Multiple-Injection- Protocol Group|Women assigned to group B (Multiple- Injection- Protocol Group) are administered a single dose of Elonva (corifollitropin alfa) in the early follicular phase followed by daily GnRH antagonist doses, either fixed on day 6 of the stimulation cycle, or when 2 or 3 follicles over 12-14 mm are present. Ovulation triggering is the same as in group A, with either GnRH agonist or hCG a, accordingly.
3470616|NCT03877146|No Intervention|Usual Care Control Condition|As part of usual care, participants will be provided with headphones to listen to music during the biopsy procedure. Music options will include instrumental jazz, classical piano, harp and flute, and world music.
3470617|NCT03877146|Experimental|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. Over the course of the 25-60-minute procedure, approximately 50% of the intervention will be spent completing controlled breathing. The other 50% of the intervention will be spent listening to music, which is part of usual care. Music options will include instrumental jazz, classical piano, harp and flute, nature sounds, and world music.
3470618|NCT03877120|Sham Comparator|Dexmedetomidine|"Dexmedetomidine. Dexmedetomidine use 400 mcg in 100 cc 0.9% physiological solution in continuous infusion starting at a dose of 0.2 mcg / kg / hr titrating until reaching a decrease in the adrenergic response, with a maximum dose of 0.7 mcg / kg / hr7.~Dosage form: DEX 0.2-0.7 mcg/Kg/min."
3470619|NCT03877120|Active Comparator|Diazepam|Dosage form: Diazepam 5-10 mg IV, steps until a maximum dose of 120 mg diazepam
3470620|NCT03877003|Experimental|Egg Intake|Consumption of 3 eggs per day for breakfast during 4 weeks
3470621|NCT03877003|Experimental|Choline Supplement Intake|Consumption of choline supplement 1.5 tablets (approx. 400 mg) with breakfast for 4 weeks
3470622|NCT03877081|Experimental|Probiotics. Intervention patients|This patients will receive 2 doses of oral probiotics a day, for seven days
3470623|NCT03877081|Placebo Comparator|Placebo group|This patients will receive 2 doses of oral placebo a day, for seven days
3470624|NCT03877107|Other|single cohort|Participants presenting at least 2/3 of symptom triad : gait disturbance, urinary symptoms and cognitive disturbance Ventricular enlargement non explained by cortical atrophy Cognitive capacity to understand the study and give informed consent (mini mental state > 13), speaking and reading french.
3470625|NCT03877068|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|Patients will wear a real-time Dexcom G6 CGM, which provide BG readings every 5 minutes for up to 10 days. In addition, patients will undergo POC testing before meals and bedtime per hospital protocol. Insulin therapy will be titrated based on daily CGM printouts, which will include BG readings, glycemic excursions, hypoglycemia and severe hyperglycemia values throughout the day. Patients will wear a CGM in the current approved insertion site, the abdomen, and in the upper arm.
3470626|NCT03877068|Active Comparator|POC BG - Point-of-Care Blood Glucose monitoring|Glucose monitoring by POC testing will be performed before meals and at bedtime. Results will be uploaded in the electronic medical record (EMR) system. The research team together with the PCP team will adjust daily insulin orders based on POC readings (standard of care). In addition, patients will wear a 'blinded' CGM (no results will be visualized by patients, nursing staff, PCP or research teams).
3470627|NCT03877055|Experimental|Copanlisib and Ibrutinib|Copanlisib is given intravenously on days 1, 8, and 15 of 28 day cycles. Ibrutinib is given orally every day on 28 days cycles. The maximum duration of treatment is 36 cycles not exceeding 36 months. In the phase II study, the cohort will expand and accrue patients at the recommended phase II dose of copanlisib and ibrutinib determined during phase I dose escalation. In a simon two stage mini-max design, an initial 18 patients will be enrolled, inclusive of 6 patients treated at MTD or RP2D from phase I study, in first stage.
3470628|NCT03877016|Active Comparator|TENS Eco2|TENS Eco2 is the classical device in patients with chronic neuropathic pain
3470629|NCT03877016|Experimental|actiTENS|ActiTENS is a new TENS device, that seems less cotraining.
3470630|NCT03876899|Active Comparator|Evening Primrose Oil|
3470631|NCT03876899|Placebo Comparator|Placebo|
3470632|NCT03876873|Experimental|Group A|Head Rotation During Face Mask Ventilation. Step 1: Neutral Position (1 minute), Step 2: Head Rotation (1 minute), Step 3: Neutral Position (1 minute)
3470633|NCT03876873|Experimental|Group B|Head Rotation During Face Mask Ventilation. Step 1: Head Rotation (1 Minute), Step 2: Neutral Position (1 minute), Step 3, Head Rotation (1 Minute)
3470634|NCT03876925|Experimental|CT053PTSA|60-100mg
3470635|NCT03877042|Experimental|Experimental|Patients with end-stage knee disease need Total Knee Arthroplasty in both knees.
3470636|NCT03876912|Experimental|GnRH antagonist|Administration of GnRH antagonist (subcutaneous injection, 240 mg) after baseline 18F-PSMA 1007 PET/CT.Then 18F-PSMA 1007 PET/CT is repeated 3 weeks after ADT and at development of CRPC
3470637|NCT03876951|Experimental|vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery
3470638|NCT03876860|Active Comparator|Standard Dilator|Participants in control arm (active comparator) will receive standard vaginal dilator with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
3470639|NCT03876860|Experimental|Silicone Dilator|Participants in experimental arm will receive standard vaginal dilator with addition of silicone ring with standard set of instructions for dilator use, including both verbal and written instructions. Recommended dilator use is three-times weekly for ten minutes
3470640|NCT03877211|Experimental|Cochlear implant users|Adult cochlear implanted patients wearing an Oticon Medical/Neurelec device will have speech audiometry test in noise, psychophysical tuning curves in forward masking and Electrically-evoked Auditory Brainstem Response (EABR) measurement
3470641|NCT03877211|Active Comparator|Normal-hearing subjects|Normal-hearing subjects will have speech audiometry test in noise, psychophysical tuning curves in forward masking, auditory canal examination and tonal audiometry
3179177|NCT00670163|Experimental|2|Participating community will provide enhanced partner therapy alone.
3179178|NCT00670163|Experimental|3|Participating community will provide Comunidades Positivas alone.
3470642|NCT03876678|Experimental|Light therapy and oral L. salivarius AP-32|Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
3179179|NCT00670163|Active Comparator|4|Participating community will provide standard of care.
3179180|NCT00670176|Experimental|I|
3179181|NCT00670189|Experimental|BMS-833923|
3470643|NCT03876678|Experimental|Light therapy and oral B. Animalis subsp. Lactis CP-9|Light therapy and taking 1 B. Animalis subsp. Lactis CP-9 probiotic capsule two times everyday for 7 days.
3470644|NCT03876678|Placebo Comparator|Light therapy and oral placebo|Light therapy and taking 1 placebo capsule two times everyday for 7 days.
3470645|NCT03876704|Experimental|High dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A，200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
3470646|NCT03876704|Active Comparator|Conventional dose of fat-soluble vitamins|Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A，40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
3470647|NCT03876691||Do not resuscitate|Patients who are suggested to family about a do-not-resuscitate order treatment by physicians.
3470648|NCT03876756||PAUR (postpartum acute urinary retention)|patients presenting postpartum acute urinary retention.
3470649|NCT03876756||Control|patients without postpartum acute urinary retention. This group was selected randomly, respecting a 1:1 matching criteria, including the year of delivery and the age of the patient at delivery.
3470650|NCT03876938|Active Comparator|aprepitant|aprepitant / dexamethasone/ ondansetron
3470651|NCT03876938|Experimental|olanzapine 10 mg|olanzapine 10 mg/dexamethasone/ ondansetron
3470652|NCT03876938|Experimental|olanzapine 5 mg|olanzapine 5 mg/dexamethasone/ ondansetron
3470653|NCT03876782||IOLMaster group|IOL power for all cataract participants will be measured with IOLMaster and Verion
3470654|NCT03876626|Other|Provider Participants|Employees who work with medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as providers. Provider participants will receive access to a web based system that allows them to view information for their enrolled clients, securely message clients, and track medication refills. Providers will be asked to participate in a 30-day usability interview and a end-of-study assessment.
3470655|NCT03876626|Other|Patient Participants|Clients who receive medication refills through the AIDS Drug Assistance Program at the Henrico Health Department will be invited to participate in the study as patients. Patient participants will be provided access to a mobile app that allows them to track their mood, stress, and medication adherence, access an anonymous online community, securely message providers, and receive medication refill alerts
3470656|NCT03876717|Experimental|Colesevelam, active arm|"Colesevelam hydrochloride, 625mg tablets. Overencapsulated with DB caps AAA for blinding.~Oral use. Dose: 1, 2, or 3 capsules twice daily. Starting dose 2 capsules twice daily. Dose titration by specific criteria by a central study nurse Treatment duration 12 days"
3470657|NCT03876717|Placebo Comparator|Placebo|Inactive placebo tablets. Overencapsulated with DB caps AAA for blinding. Oral use. Dosage and treatment duration as specified for colesevelam
3470658|NCT03876886|Active Comparator|AC-T(dose-dense)|A: epirubicin, pharmorubicin (EPI) C: cyclophosphamide (CTX） T: paclitaxel (PTX）
3470659|NCT03876886|Experimental|TP(dose-dense)|T: paclitaxel (PTX） P: carboplatin (CBP)
3470660|NCT03876795|Active Comparator|Single intra-articular Bone Marrow Concentrate injection|Single intra-articular Bone Marrow Concentrate injection in the knee
3470661|NCT03876795|Experimental|combined Bone Marrow Concentrate injection|combined Bone Marrow Concentrate injection (intra-articular and intra-osseus)
3470662|NCT03876600|Experimental|conventional hospitalization management.|"The patients who are randomized to have a conventional hospitalization for the pacemaker replacement have conventional management.~In this management patient come to hospital one day before this surgical operation and he is operated next day"
3470663|NCT03876600|Active Comparator|ambulatory management|"The patients who are randomized to have a ambulatory surgery for the pacemaker replacement have ambulatory management.~In the ambulatory hospitalization patients come to hospital and have a surgical operation the same day"
3470664|NCT03876444|Experimental|Intervention arm|Pulse intravenous methylprednisolone (30 mg / kg for 3 days) followed by 1-week taper of oral prednisolone Day 1-3 Intravenous Methylprednisolone in dose of 30 mg/kg/day Day 4-6 Oral Prednisolone in dose of 2mg/kg/day Day 7-10 Oral Prednisolone in dose of 1mg/kg/day
3470665|NCT03876444|Active Comparator|Control|Oral prednisolone (4 mg/kg/day) for 2 weeks followed by tapering over 2 weeks Day 1-14 (2 weeks): dose 4mg/kg/day Day 15-21 (1 weeks): 2mg/kg/day Day 22-28 (1 weeks): 1mg/kg/day
3470666|NCT03876405|Experimental|sensory feedback|"A non-invasive air-mediated sensory feedback system embedded in the prosthesis socket.~Group description: Individuals with acquired forearm amputation."
3470667|NCT03876353|Other|Left Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
3470668|NCT03876353|Other|Right Side|Each participant who participate will have half of their mouth flossed. Either the right or the left side. The investigator will not know which side has been flossed prior to documenting any tooth surfaces with residual plaque
3470669|NCT03876665||Focus Group|"Active Duty Air Force, Army and Navy women diagnosed with PCOS.~Up to three focus groups per service branch will be conducted. Considering attrition for those who may volunteer and not show up for the FG session, the investigators will recruit up to 20 participants per site, with the goal of including a maximum of six participants per FG to maximize individual participation."
3470670|NCT03876314|Experimental|Physical Activity Condition (PAC)|Subjects will be asked to attend virtual exercise sessions 3 times a week for 1 year.
3470671|NCT03876314|No Intervention|Usual Care Control (UCC)|Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.
3470672|NCT03876730||Study group|3-18 aged children with cerebral palsy
3470673|NCT03876470||All Participants|All participants will receive HCV treatment as determined by their provider. HCV treatment is not assigned by the study.
3470674|NCT03876548|Experimental|Cadexomer Iodine Gel|Patients willy apply product to treatment site every other day for the next 28 days and cover with dressing or bandage.
3470675|NCT03876587|Experimental|Pyrotinib Maleate combine with Docetaxel|"Pyrotinib Maleate combine with Docetaxel should be administrate to all subjects.~Initial dose: Pyrotinib Maleate 400mg oral administration everyday plus Docetaxel 75mg per square of BSA every three weeks intravenous injection."
3125265|NCT02971735|Experimental|interactive multimedia module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the interactive multimedia (IM) module consist of integrated text, images, and small game tests (intervention) for 100 minutes. The module is a non-linearity of learning with interaction (student-based choice and pop-up feedback). This context has been adjusted to the same level to that of the PPS module.
3125266|NCT02971735|Active Comparator|Power Point show module|Subjects allocated to this experimental group will receive an intervention of mobile technology of e-learning (M-TEL) using the Power Point show (PPS) module consist of integrated text, images, and audio (intervention) for 100 minutes. The module is a linear learning without interaction. This context has been adjusted to the same level to that of the IM module.
3470676|NCT03876418|No Intervention|Usual Care|Patients undergo twice daily measurement of intra-abdominal pressure. Clinicians manage patients according to usual care.
3470677|NCT03876418|Active Comparator|Aggressive|Patients undergo aggressive surveillance (q6h) if intra-abdominal pressure is elevated as well as prevention and treatment according to protocol driven guidelines adapted from the World Society of the Abdominal Compartment. This may include nasogastric decompression, limiting fluid administration, drainage of ascites, paralysis and/or abdominal decompression.
3470678|NCT03876431|Active Comparator|Traditional Exercise Group|Only traditional exercises will be performed in the early post-op period.
3470679|NCT03876431|Experimental|Easy-Flex Group|Easy-Flex group will be treated with the Easy-Flex device in addition to the traditional exercise program.
3470680|NCT03876509||Impedance Cardiography|Impedance Cardiography
3470681|NCT03876613|Active Comparator|Turkish music group|Rast makam
3470682|NCT03876613|Active Comparator|classical western music|Vivaldi
3470683|NCT03876613|Active Comparator|soft rock music|Elvis presley
3470684|NCT03876613|Placebo Comparator|control group|No music
3470685|NCT03876561|Experimental|Prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 sessions per week before stoma closure and 1 sessions per week during 6 weeks following stoma closure. Complementary sessions are allowed if necessary.
3470686|NCT03876561|No Intervention|No intervention|No pelvic floor prehabilitation will be proposed before stoma closure. The pelvic floor prehabilitation will be proposed to patients suffering from LARS
3470687|NCT03876392|Experimental|magnetic resonance imaging|Detection of bone marrow metastases with magnetic resonance imaging
3470688|NCT03876834|Experimental|study group (group A)|Group (A) included 30 leukemic patients receiving chemotherapy in addition to training by inspiratory muscle trainer(IMT) for 4 weeks, 5 sessions /week
3470689|NCT03876834|No Intervention|control group (B)|Group (B) included 10 leukemic patients receiving chemotherapy only
3470690|NCT03876496|Experimental|SensableCareCare System|The Sensable®Care System uses pressure sensors and computer software to sense how patients are positioned on the bed in order to reduce bed falls. The Sensable®Care System Mattress has sensors embedded in them, which will be monitored by the nurses in the unit.
3470691|NCT03876340|Active Comparator|Current treatment|Patients will receive burn care treatment as dictated by the surgical team (current standard of care).
3470692|NCT03876340|Experimental|Algorithm-dictated treatment|Patients will receive burn care treatment as dictated by the treatment algorithm (PLOS ONE 13(11): e0206477.).
3470693|NCT03876639|Active Comparator|IPM_2/18|Application of formulation IPM_2/18
3470694|NCT03876639|Active Comparator|PAR_2/18|Application of formulation PAR_2/18
3470695|NCT03876327|Experimental|PD patients that will receive FMT|fecal microbial transplantation once at the beginning of the study-15 patients.
3470696|NCT03876327|No Intervention|PD patients that will not receive FMT|do not receive treatment-35 patients.
3470697|NCT03876327|No Intervention|healthy people live with PD patients|do not receive treatment-50 participants.
3470698|NCT03876652|Experimental|DDD-CLS|Patients with a pacemaker programmed in DDD-CLS mode
3470699|NCT03876652|Active Comparator|DDD-R|Patients with a pacemaker programmed in DDD-R mode
3470700|NCT03876574|Experimental|Treatment|"Patients undergo DSA-guided implantation of hepatic artery infusion pump. All patients receive the intervention Hepatic artery infusion of gemcitabine and floxuridine the next day after pump implantation. The HAI therapy is initiated on day 1, 8: Gemcitabine 1g/m2 for 30 minutes, followed by a blended solution which comprised floxuridine (FUDR) at 0.15 mg/kg/day, dexa-methasone (DXM) at 1 mg/m2/day, low molecular heparin 3200U and saline, lasted for 7 days continuously.Standard treatments of NPC, including radiotherapy and chemotherapy (induction chemotherapy, concurrent chemotherapy and adjuvant chemotherapy) are performed as desired."
3470701|NCT03876288||People presenting with the Sx of Gp|People presenting with the symptoms of gastroparesis. The three main interventions are GI neuromodulation, immunotherapy, and pyloric therapies.
3470702|NCT03876145|Experimental|Minimal ovarian stimulation with rec-FSH|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 International Unit (IU) Gonal-f (Follitropin alfa, Merck Serono, Germany) after the seventh day.
3470703|NCT03876145|Experimental|Minimal ovarian stimulation with HMG|The group of minimal ovarian stimulation that will receive 100 mg clomiphene citrate every day from Day 3 to Day 7 of the menstrual cycle and then will be treated with 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) after the seventh day.
3470704|NCT03876145|No Intervention|Mild ovarian stimulation with rec-FSH|The group of mild ovarian stimulation that will receive 150 IU Gonal-f (Follitropin alfa, Merck Serono, Germany) daily from Day 3 of the menstrual cycle.
3470705|NCT03876145|No Intervention|Mild ovarian stimulation with HMG|The group of mild ovarian stimulation that will receive 150 IU Merional (Highly Purified Menotropin، IBSA، Switzerland) daily from Day 3 of the menstrual cycle.
3470706|NCT03876106|Experimental|LUT014 dose level 1|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
3470707|NCT03876106|Experimental|LUT014 dose level 2|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
3470708|NCT03876106|Experimental|LUT014 dose level 3|LUT014 will be topically applied to the face, neck, and upper portion of the anterior and posterior chest once a day for 4 weeks.
3470709|NCT03876197|Experimental|Autologous Adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells transplanted intraglandular in patients with radiation-induced hyposalivation and xerostomia
3470710|NCT03876197|Placebo Comparator|Placebo|2 ml placebo: Isotonic NaCl (0.9mg(ml) and human albumin (HA) 1%
3470711|NCT03875950|Experimental|Training intervention|In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
3470712|NCT03875950|No Intervention|Standard of care control|In this randomized cluster randomized control trial design, the no intervention arm refers to the 12 study sites that are randomly assigned not to receive the clinician training intervention. Instead, these study sites will receive the standard of care, which is no standardized patient actor training, for health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
3470713|NCT03875937|Experimental|Tranexamic acid 1 gram intramuscularly|Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.
3470714|NCT03876119|Experimental|Intraarterial alteplase|"All the patients will be given a 15 minutes IA infusion of alteplase (Actylise®) at a drug concentration of 1.0 mg/ml. At 15 minutes of IA treatment onset, the infusion will be stopped and the angiographic score assessed. If the angiographic score is improved compared with the baseline score the procedure is terminated, otherwise a new angiographic series will be repeated in 10 minutes before the end of the procedure in front and profile projections.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (alteplase) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
3470715|NCT03876119|Placebo Comparator|Placebo|"The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.~Study drug will be prepared according to the following steps:~Dilute 3 vials of 10 mgs (placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml~Calculate the volume of cc of infusion and therefore the total dose as per the formula: (Patient's weight in Kgs multiplied by 0.225)"
3470716|NCT03876080|Experimental|Dry needling|Dry needling intervention to the gastrocnemius muscle trigger point
3470717|NCT03876080|Sham Comparator|Sham needling|Sham dry needling intervention to the gastrocnemius muscle trigger point
3470718|NCT03876171|Experimental|CIFFTA|Family Therapy, Individual Therapy, and Psycho-educational Modules
3470719|NCT03876171|Active Comparator|Standard of Care|The Diversion Programs used by the Juvenile Services Department in Miami-Dade.
3125267|NCT02971800|Experimental|sodium fluorescein|"Once hysterectomy completed, a 10 % solution of sodium fluorescein at a 0,25 ml dose (25 mg) is injected before performing diagnostic cystoscopy for all patient.~Name: Fluorescite Injection 10%, contains sodium fluorescein (equivalent to fluorescein 10% w/v) Dosage : 25 mg Frequency: only once"
3125268|NCT02972242|Active Comparator|Modified Field of View|In patients randomized to undergo the modified non-contrast CT scan to assess coronary calcification burden, this study will be performed by a radiologist and cardiologist as follows: axial acquisition obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage 80kV and tube current 250mA. The scan length will be from 1 cm below the carina to the level beneath the proximal coronary vessels defined as the greatest diameter of the apex of the right atrium.
3125269|NCT02972242|Placebo Comparator|Standard Field of View|In patients randomized to standard coronary artery calcium scoring, this scan will be performed in usual axial fashion obtained at 70% of the R-R interval using the following parameters: rotation time 0.35 sec; collimation of 64 x 0.625mm; detector coverage of 20.0 mm; axial thickness 2.5; tube voltage, 120 kV and tube current 250mA. The scan length, in accordance with current protocol, will be from 1 cm below the carina through the diaphragms.
3470720|NCT03876262|Experimental|Annual Moxidectin|Moxidectin 8mg per oral, administered annually for 24 months
3470721|NCT03876262|Experimental|Biannual Moxidectin|Moxidectin 8mg per oral, administered biannually for 24 months
3125270|NCT02972359|Experimental|Neridronic acid|Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.
3470722|NCT03876262|Active Comparator|Annual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months
3470723|NCT03876262|Experimental|Biannual Ivermectin|Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months
3470724|NCT03875989|Active Comparator|Arm A|
3470725|NCT03875989|Experimental|Arm B|
3470726|NCT03876158|Active Comparator|Prometra® Programmable Pump|Pain scores and drug doses will be prospectively collected for valve-gated Prometra® Programmable Pump system(Flowonix Medical)' at (refill #1, refill #2, refill #3) and will be compared to retrospectively collected pain (VAS) scores and drug doses from the last refill prior to peristaltic pump explant.
3470727|NCT03876158|Other|Prior records for peristaltic pump|Prior pain scores and drug doses from the patients who need a new valve gated pump will be recorded and used for comparison after it is changed.
3470728|NCT03876041|Active Comparator|dexamethasone group|this group will receive Dexamethasone: 0.1 to 0.3 mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
3470729|NCT03876041|Active Comparator|methylprednisolone group|this group will receive Methylprednisolone: 5-10mg/kg as single intra-operative dose and blood samples will be obtained from central venous blood at following time points: immediately after insertion during anesthetic induction (T1), 48hrs post-operative (T2), 72hrs post-operative (T3).
3470730|NCT03875963|Experimental|Antibiotic loaded bone filler|Patients will undergo irrigation and debridement, surgical stabilization as required, and defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin]. The concurrent use of antibiotics is at the discretion of the treating physician.
3470731|NCT03875963|No Intervention|Standard of care|Current standard of care treatment for infected tibial defects or infected tibial nonunions includes treatment with irrigation and debridement, surgical stabilization as required, and defect management as required including placement of a polymethyl methacrylate spacer with or without antibiotics. A second procedure may or may not occur 6-8 weeks later with removal of the cement spacer and bone grafting into the preserved defect. Concurrent use of antibiotics is at the discretion of the treating physician.
3470732|NCT03876067|Experimental|Ozone Group|in which Ozone will be added to cold blood cardioplegia
3470733|NCT03876067|Placebo Comparator|Control Group|: in which in which only cold blood cardioplegia
3125271|NCT02972502|Active Comparator|Metoclopramide (Reglan)|Patients will receive 10 mg of intravenous (IV) metoclopramide following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
3125272|NCT02972502|Experimental|Haloperidol (Haldol)|Patients will receive 2.5 mg of intravenous (IV) haloperidol following a 1-liter bolus of normal saline (NS) and 25 mg of IV diphenhydramine.
3470734|NCT03876249||RSV positive group|Children who had RSV infection within the first 60 days of life
3470735|NCT03876249||RSV negative group|Children without known RSV infection within the first 60 days of life
3470736|NCT03875976|Active Comparator|Fast Track Protocol|Patients treated using Fast Track Care Protocol
3470737|NCT03875976|Active Comparator|Standard Protocol|Patients treated using Standard Care Protocol
3470738|NCT03876015||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks.
3470739|NCT03876184|Experimental|RMO FLi® Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 RMO FLi® Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
3470740|NCT03876184|Experimental|G&H G4 Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 G&H G4 Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
3470741|NCT03876184|Experimental|Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium|"This group has been allocated with upper and lower round 0.014 Orthocare Euroform® Cosmetic Tooth-coloured superelastic Nickel Titanium aesthetic archwires for a duration of 8 weeks."
3470742|NCT03876184|Active Comparator|Conventional superelastic Nickel Titanium|"This group has been allocated with conventional upper and lower round 0.014 superelastic Nickel Titanium archwires for a duration of 8 weeks."
3470743|NCT03876210|Other|Sequence A|"Period 1: PK101-001, PK101-002 / Period 2: PK101~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
3470744|NCT03876210|Other|Sequence B|"Period 1: PK101 / Period 2: PK101-001, P101-002~Number of subject: 23~Wash out Period: over 7 days (between each period)~Dosage: Once daily, at 2D each period"
3470745|NCT03876002|Experimental|[18F]PBR06|To perform kinetic modeling using plasma-based (metabolite corrected plasma concentration) or reference region based methods or simplified quantification methods to assess the ability of [18F]PBR06 PET to measure microglial activation in brain.
3470746|NCT03875898|Experimental|150 g bread fortified (15 g mix fibre)|Volunteers will have to consume daily 150 g of a bread instead of usual bread during eight weeks
3470747|NCT03875898|Placebo Comparator|150 g unfortified bread|Volunteers will have to consume daily 150 g of an unfortified usual bread during eight weeks
3470748|NCT03875911|Active Comparator|Preoperative Subconjunctival injection of MMC|Subconjunctival injection of 0.1 ml of Mitomycin-C 0.002% at the site of future trabeculectomy surgery (2 - 4 weeks preoperatively).
3470749|NCT03875911|Active Comparator|Intraoperative subconjunctival injection of MMC|Intraoperative subjconjunctival injection of 0.1 mL of Mitomycin-C 0.01% (0.1mg/mL) to the site of trabeculectomy
3470750|NCT03875911|Active Comparator|Intraoperative topical application of MMC|Topical application of Mitomycin-C intraoperatively by applying a sponge soaked in 1mL of Mitomycin-C 0.02 mg/mL for 1 minute to the site of trabeculectomy
3470751|NCT03875924||VWD BERHLINGO|Patients with constitutional von Willebrand Disease, of any severity, with or without inhibitor followed in one of the investigator centers
3470752|NCT03875872||Group propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
3470753|NCT03875872||Group inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
3470754|NCT03875833|Experimental|Collagen Nerve Wrap Conduit|
3470755|NCT03875833|No Intervention|Control|
3470756|NCT03875820|Experimental|Dose Escalation Phase|"Escalating doses of RO5126766 and VS-6063 will be evaluated in patients with advanced solid tumours to establish the recommended phase II dose. Dose escalation will follow a 3+3 design with a maximum of four patient cohorts.~This arm is now complete."
3470757|NCT03875820|Experimental|Dose Expansion KRAS mutant NSCLC Cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with KRAS mutant NSCLC (20 patients).
3470758|NCT03875820|Experimental|Dose Expansion biopsy cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients advanced RAS mutant solid tumours with biopsiable disease (6 patients).~This arm is now complete."
3125273|NCT02972515|Experimental|See Me Smoke-Free|"Participants received access to the See Me Smoke-Free mobile application (app) delivered via smart phone, and were asked to use the app most days for 30 days post-enrollment. The app contained five guided imagery audio files (Introduction to Guided Imagery, Be Smoke Free, Eat Well, Get Active, and Feel Fantastic), a tracking calendar, awards, resources, reminders, and tips and techniques."
3470759|NCT03875820|Experimental|Dose Expansion LGSOC cohort|The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with LGSOC (20 patients).
3470760|NCT03875820|Experimental|Dose Expansion CRC cohort|"The dose expansion phase will evaluate the recommended phase II dose of the combination of RO5126766 and VS-6063, as decided in the dose escalation phase in patients with CRC (10 patients).~This arm is now complete."
3470761|NCT03875846||Intraoperative Hemodynamic Improvement|The primary outcome will examine the magnitude of change in the Toe-Brachial Index (TBI) between the beginning and the end of the procedure. The two measurements will be taken before- and after- vascular sheaths had been placed.
3125274|NCT02972554|Experimental|Propanolol Hydrochloride|This is the experimental group given the beta-blocker
3125275|NCT02972554|Placebo Comparator|Placebo|This is the control group given a placebo.
3470762|NCT03875690|Experimental|Experimental group|
3470763|NCT03875690|Placebo Comparator|Control group|
3125276|NCT02972632|Experimental|Vortioxetine 10-20 mg|Vortioxetine 10 mg, tablets, orally, once daily followed by a dose adjustment to a maximum of 20 mg, tablets, orally, once daily up to 12 weeks. The dose may be decreased by 5 mg based on participant's response and tolerability as judged by the investigator.
3125277|NCT02972658|Experimental|AZES Lanabecestat 20 milligrams (mg)/AZFD Lanabecestat 20 mg|Participants who received Lanabecestat 20 mg in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
3470764|NCT03875768|Experimental|Intervention|Participants will track their daily dietary intake for six months using an app and will receive automated feedback daily via text message based on DASH nutrients. Participants in-need of coaching based on their adherence to the key nutrients in the DASH dietary pattern or engagement in the intervention will receive responsive digital coaching from Nourish registered dietitians.
3470765|NCT03875768|No Intervention|Control|Participants will receive information about the DASH dietary pattern and will track their daily dietary intake using an app for six months.
3470766|NCT03875521||12 hours|
3470767|NCT03875521||< 12hours|
3470768|NCT03875560|Experimental|Part A/Single Dose|IC14 0.5, 1.0 or 2.0 mg/kg IV as a single dose (subjects are assigned and not randomized to this arm. When Part A is complete, Enrollment to Part B will commence).
3470769|NCT03875560|Experimental|Part B/Cohort 1|IC14 4 mg/kg/day IV or placebo IV x 1 day.
3470770|NCT03875560|Experimental|Part B/Cohort 2|IC14 8 mg/kg/day IV or placebo IV x 1 day.
3470771|NCT03875560|Experimental|Part B/Cohort 3|IC14 2 mg/kg/day IV x 1 day followed by IC14 1 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
3470772|NCT03875560|Experimental|Part B/Cohort 4|IC14 4 mg/kg/day IV x 1 day followed by IC14 2 mg/kg/day IV x 3 days or placebo IV daily for 4 days.
3125278|NCT02972658|Experimental|AZES Lanabecestat 50 mg/AZFD Lanabecestat 50 mg|Participants who received Lanabecestat 50 mg in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
3125279|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 20 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 20 mg.
3125280|NCT02972658|Experimental|AZES Placebo/AZFD Lanabecestat 50 mg|Participants who received placebo in the feeder study (AZES) were randomized to receive Lanabecestat 50 mg.
3470773|NCT03875807|Active Comparator|0 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 0 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
3470774|NCT03875807|Active Comparator|30 degree Knee Flexion Angle ACLR|At the time of surgery, tunnel position and surgical technique will be standardized for transtibial and anteromedial portal ACLR. Individuals randomized to this arm intra-operatively to undergo fixation of the ACL graft on the tibial side at a KFA of 30 degrees as measured by a sterile goniometer. Grafts will be tensioned according to the maximum surgeon-applied tension at the designated KFA. After surgery, patients will be treated with a standardized accelerated physical therapy protocol
3470775|NCT03875677|Experimental|HD-tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the defined target area
3470776|NCT03875677|Experimental|Conventional tDCS group|Constant current (1mA) will be applied for 20min and the anode will be placed over the standard C3/C4 position
3470777|NCT03875677|Sham Comparator|Sham HD-tDCS group|The stimulator will be shut down after 30s of stimulation. The patients will feel the initial itching sensation at the beginning in order to evaluate the placebo effect.
3470778|NCT03875625|Experimental|Morbid obesity- Bariatric surgery group|Morbid obese subjects who will consent to bariatric surgery
3125281|NCT02973048|Placebo Comparator|Hyperbaric bupivacaine|Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
3179182|NCT00670215|Experimental|Arm 1|
3179183|NCT00670215|Experimental|Arm 2|
3470779|NCT03875625|Experimental|Morbid obesity-Dietitian led life style intervention group|Morbid obese subjects who will not consent to bariatric surgery but instead opt for dietitian led life style intervention
3470780|NCT03875625|Experimental|Mild obesity-Dietitian led life style intervention group|Mild- Moderate subjects assigned through a randomized controlled trial to the dietitian led life style intervention
3470781|NCT03875625|Experimental|Mild obesity-Conventional care group (control)|Mild- Moderate subjects assigned through a randomized controlled trial to conventional care
3470782|NCT03875781|Experimental|A: Modified Folfirinox|"Experimental : preoperative chemotherapy:~Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
3179184|NCT00670254|Experimental|Hydrocortisone|
3470783|NCT03875781|Active Comparator|B: Modified Folfirinox followed by Radiochemotherapy|Active comparator: preoperative chemotherapy : Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively FOLLOWED BY Preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 25 fractions in pelvic volume and 50 Gy in 25 fractions to the tumor
3470784|NCT03875430||Perimenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
3470785|NCT03875430||Postmenopausal|Patients in this group will take one capsule of a dietary supplement containing Humulus lupulus L.
3470786|NCT03875573|Experimental|Chemotherapy and radiotherapy|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy).
3470787|NCT03875573|Experimental|Chemotherapy and pre-operative radiotherapy plus durvalumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w.
3470788|NCT03875573|Experimental|Chemotherapy & pre-op radiotherapy + durvalumab + oleclumab|The combination of weekly paclitaxel 80 mg/m² IV followed by q2w dose-dense doxorubicin-cyclophosphamide (ddAC) (60 mg/m² doxorubicin IV and 600 mg/m² cyclophosphamide IV) and pre-operative radiation therapy on the primary tumour (3x8 Gy) with the addition of the anti-PD-L1 antibody durvalumab IV 1500 mg q4w and the addition of the anti-CD73 antibody oleclumab IV 3000 mg q2w for 4 administrations, followed by q4w for 3 administrations.
3470789|NCT03875755|Experimental|Myo Inositol|The women will receive 2 caps of Myo Inositol with acid folic a day, until delivery
3470790|NCT03875755|Placebo Comparator|Placebo|The women will receive 2 caps of placebo (acid folic) a day, until delivery
3470791|NCT03875742|Other|"Ultraplex 360"|"This group will execute the first TAP block using Ultraplex 360 (Braun) and the second TAP block using  STIMUPLEX D SH, 30° (Braun)"
3470792|NCT03875742|Other|" STIMUPLEX D SH, 30°"|"This group will execute the first TAP block using  STIMUPLEX D SH, 30° (Braun) and the second TAP block using Ultraplex 360 (Braun)"
3470793|NCT03875794|Experimental|Osteopathic Manipulation|"This research will be carried out as a prospective, non-randomized pilot study in women aged 18-40 who are 2 weeks to 28 weeks postpartum.~The intervention investigated in this study is osteopathic manipulation."
3470794|NCT03875495|Experimental|Temferon|"Autologous CD34+-enriched hematopoietic progenitor cells exposed ex vivo to a specific lentiviral vector encoding for the human IFN-ɑ2 gene.~Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of IFN-ɑ2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny."
3470795|NCT03875716|Experimental|Low Risk|"Observation without adjuvant therapy~Pathologic T1-2, N0-1~Minimum of 15 lymph nodes retrieved on neck dissection per dissected side of the neck~-≤2 positive lymph nodes confined to level II and/or level III~No extranodal extension~Clear margins"
3470796|NCT03875716|Experimental|Intermediate Risk|"Reduced-dose radiation (46Gy)~Pathologic T1-2N0-2 and any one of the following features:~->2 positive lymph nodes~<15 lymph nodes retrieved on neck dissection for each side of the neck~Positive lymph nodes in level IB, IV, or V~-≤1mm extranodal extension~Positive lymph node(s) contralateral to the primary tumor~Close margins"
3470797|NCT03875716|Experimental|High Risk|"Postoperative radiation (60Gy) without chemotherapy~Pathologic T1-4N0-2 and any one of the following features:~->1mm extranodal extension~Microscopic positive margins"
3470798|NCT03875404|Experimental|Deep Brain Stimulation subjects|
3470799|NCT03875469|Experimental|CT patients_Centargo_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
3470800|NCT03875469|Experimental|CT-patients_Stellant_1|Adult patients referred for contrast-enhanced computed tomography in study part 1
3470801|NCT03875469|Experimental|CT-patients_Centargo_2|Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)
3470802|NCT03875417||Group A|Patients who developed HCC recurrences after surgery and treated with re-resection, or microinvasive non-surgical means.
3470803|NCT03875417||Group B|Patients who did not develop recurrences after surgery.
3179185|NCT00670254|Placebo Comparator|Placebo|
3470804|NCT03875391|Experimental|Oxytocin and trauma film paradigm|Intervention: Drug: Oxytocin nasal spray
3470805|NCT03875391|Placebo Comparator|Placebo and trauma film paradigm|Intervention: Drug: Placebos
3470806|NCT03875352|Experimental|Neutropenia patients|Patients with neutropenia were treated using the CHG and HMG technique.
3470807|NCT03875352|Experimental|No neutropenia patients|Patients with no neutropenia were treated using the CHG and HMG technique.
3470808|NCT03875365||POPE Patients|Patients who underwent POPE for end-stage achalasia, a sigmoid esophagus, or a redundant conduit that has been used to replace the esophagus.
3470809|NCT03875274|Placebo Comparator|Ropivacaine group|Ropivacaine 0.375% 20 ml + Normal saline 2 ml via FICB
3470810|NCT03875274|Experimental|Ropivacaine and morphine group|Ropivacaine 0.375% 20 ml + Morphine 2 ml via FICB
3470811|NCT03875196|Experimental|Biyofeedback|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes
3470812|NCT03875196|Experimental|Extracorporeal Magnetic Innervation|the patients underwent 16 sessions of biofeedback-assisted pelvic floor muscle training over 8 weeks for 20 minutes and the Extracorporeal Magnetic Innervation application was made for 20 minutes
3470813|NCT03875209|Experimental|Arm 1: 10E8.4/iMab IV or SC HIV-|Arm 1; Groups A-C; 3 dosing groups: HIV-uninfected individuals
3470814|NCT03875209|Experimental|Arm 2: 10E8.4/iMab IV HIV-|Arm 2; Groups D-F; 3 dosing groups: HIV-uninfected individuals
3470815|NCT03875209|Experimental|Arm 3: 10E8.4/iMab IV HIV+|Arm 3; Groups H-I; 2 dosing groups: HIV-infected individuals with HIV-1 RNA levels between 1,000 and 100,000 copies/mL and cluster of differentiation 4 (CD4)>350 cells/mm3
3470816|NCT03875209|Experimental|Arm 4: 10E8.4/iMab SC HIV-|Arm 4; Groups J and K: HIV-uninfected individuals
3470817|NCT03875261|Experimental|Study arm|Participants are treated with the investigational medical product
3470818|NCT03875248|Other|Arm 1. Blood pressure measurement compared to arterial line|Comparative blood pressure measurement with the investigational device and the invasive reference method (arterial line).
3470819|NCT03875248|Other|Arm 2. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in hypertensive patients with the investigational device and the non-invasive reference method (manual cuff).
3470820|NCT03875248|Other|Arm 3. Blood pressure measurement compared to manual cuff|Comparative blood pressure measurement in pregnant women with the investigational device and the non-invasive reference method (manual cuff).
3470821|NCT03875014||group 1|Bipolar hemiarthroplasty grop
3470822|NCT03875014||group 2|Total hip replacement dual mobility group
3470823|NCT03875170|Experimental|Proprioceptive neuromuscular facilitation|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility
3470824|NCT03875170|Active Comparator|Muscle stretching|Each session will last 5 minutes for each subject, taking place two sessions a week, in a period of 6 weeks. The intervention will be made at the beginning of the training session. It will be done for the hip, quadriceps and hamstring muscles with a voluntary antagonist activation to relax the agonist muscle.
3470825|NCT03875300|Experimental|Participants in the Intervention Group|Intervention Group - will undertake a programme of 7 x 2 hour group sessions, following the scripted 'Foodwise in Pregnancy' manual of nutrition information; practical cooking sessions; and information on low impact exercise.
3470826|NCT03875300|No Intervention|Participants in the Control Group|Control Group - will continue with routine antenatal care, unchanged.
3470827|NCT03875313|Experimental|Cohort 1: CB-839 and Talazoparib|600 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
3470828|NCT03875313|Experimental|Cohort 2: CB-839 and Talazoparib|800 mg CB-839 taken twice daily and 1 mg talazoparib taken daily
3470829|NCT03875183|Experimental|INL1 50mg BID|INL1 50mg dose to be given twice daily using one 50mg capsule and two matching placebo capsules at each dose
3470830|NCT03875183|Experimental|INL1 150 mg BID|INL1 150mg dose to be given twice daily using three 50mg capsules at each dose
3470831|NCT03875183|Experimental|INL1 300 mg BID|INL1 300mg dose to be given twice daily using three 100mg capsules at each dose
3470832|NCT03875183|Placebo Comparator|Placebo|Placebo dose to be given twice daily using 3 placebo capsules at each dose
3470833|NCT03875066|Other|A to B|Subjects were involved in an control training program (A). After 2 weeks washout period, Subjects were trained using the other program (B).
3470834|NCT03875066|Other|B to A|Subjects were involved in an control training program (B). After 2 weeks washout period, Subjects were trained using the other program (A).
3470835|NCT03874949|Active Comparator|SEALITE Regular|zinc oxide eugenol sealer
3470836|NCT03874949|Experimental|SEALITE Ultra|zinc oxide eugenol sealer containing 1% Enoxolone (NSAID)
3470837|NCT03874962|Experimental|Routine oral cleaning and professional oral care group|"The subjects in Routine oral cleaning and professional oral care group were received about routine oral cleaning and professional oral care."
3470838|NCT03874962|No Intervention|Routine oral cleaning group|"The subjects in Routine oral cleaning group were received only routine oral cleaning, just maintain daily condition."
3470839|NCT03875157|Experimental|IBI318 DL1|
3470840|NCT03875157|Experimental|IBI318 DL2|
3470841|NCT03875157|Experimental|IBI318 DL3|
3470842|NCT03875157|Experimental|IBI318 DL4|
3470843|NCT03875157|Experimental|IBI318 DL5|
3470844|NCT03875157|Experimental|IBI318 DL6|
3470845|NCT03875157|Experimental|IBI318 DL7|
3470846|NCT03875157|Experimental|IBI318 DL8|
3470847|NCT03875157|Experimental|IBI318 DL7b|
3470848|NCT03875157|Experimental|IBI318 DL8b|
3470849|NCT03875157|Experimental|IBI318 RP2D|
3125282|NCT02973048|Active Comparator|Hyperbaric prilocaine|Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.
3125283|NCT02973087|Experimental|All Study Participants|Participants will receive prophylaxis with rVWF in two cohorts: on-demand (OD) cohort (previously treated with OD) and pdVWF switch cohort (participants switching from prophylactic treatment with pdVWF).
3125284|NCT02973100|Experimental|Dulaglutide 4.5mg|4.5mg of Dulaglutide administered subcutaneously (SC)
3470850|NCT03874832|Experimental|STS101 1.5 mg|STS101 (dihydroergotamine nasal powder), 1.5 mg
3470851|NCT03874832|Experimental|STS101 3.0 mg|STS101 (dihydroergotamine nasal powder), 3.0 mg
3470852|NCT03874832|Experimental|STS101 6.0 mg|STS101 (dihydroergotamine nasal powder), 6.0 mg
3470853|NCT03874832|Active Comparator|DHE intramuscular injection|Dihydroergotamine mesylate
3470854|NCT03874832|Active Comparator|DHE nasal spray|Dihydroergotamine mesylate
3470855|NCT03875053|Experimental|Monitoring device, Quality of Life Assessment, Questionnaire|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
3470856|NCT03874988|Experimental|Portion-Controlled Meals|Participants will receive prepackaged food, delivered biweekly to their home over the course of 13 weeks, with costs covered by the grant. Depending on their calorie goals, participants will drink and eat a mix of shakes and entrees each day, plus up to five fruits and vegetables. HMR entrees and shakes are formulated to provide recommended levels of macronutrients, vitamins, sodium, fat, cholesterol and fiber and fortified to meet at least 100% of the recommended daily allowance for essential vitamins and minerals.
3125285|NCT02973100|Experimental|Dulaglutide 3.0mg|3.0mg of Dulaglutide administered SC
3125286|NCT02973100|Active Comparator|Dulaglutide 1.5mg|1.5mg of Dulaglutide administered SC
3125287|NCT02973100|Placebo Comparator|Placebo|Placebo administered SC
3125288|NCT02973321|Placebo Comparator|Placebo|Placebo (for SAR425899) subcutaneous (SC) injection once daily (QD) from Week 1 to Week 26, matching 3 SAR425899 dose levels of 0.12 mg, 0.16 mg and 0.20 mg.
3125289|NCT02973321|Experimental|SAR425899 0.12 mg|SAR425899 SC injection QD at maintenance dose of 0.12 mg for 25 weeks (Week 2 to Week 26) following 1 week dose increase step (0.06 mg at Week 1).
3470857|NCT03874988|Experimental|Enhanced Self-Monitoring|Participants will be encouraged to self-monitor 4 specific behaviors daily: 1) measuring their food; 2) measuring their physical activity; 3) recording their food, drink, and physical activity; and 4) monitoring their weight. To achieve this aim, participants will attend a single group-based educational session at baseline during which they will be provided the self-monitoring equipment (scale and Garmin vivofit) and receive training about how to use the Lilypad scale and smartphone food tracking app.
3470858|NCT03874988|Experimental|GLB-SCI|The content and delivery format of the developed GLB SCI lifestyle intervention program is subject to change based on guidance of the SCI Consumer Group. Therefore, this section provides a general description of the GLB AIM (lifestyle intervention program adapted for impaired mobility). The content of the GLB AIM core meetings include a mix of in-person (4) and telephone (9) sessions. The initial meeting is conducted in person, with one in-person sessions delivered each month, and the intervening weeks delivered by telephone. To achieve weight loss, participants will be encouraged to follow daily calorie and fat gram goals to achieve a .5 to 1 pound weight loss over the 13 weeks. Participants will also be encouraged to gradually increase their physical activity to ultimately achieve 150 weekly minutes.
3470859|NCT03874988|Experimental|GLB-SCI+|The final multicomponent GLB SCI+ will include combining specific intervention strategies identified from the previous 3 interventions as effective and usable. If all 3 strategies yield evidence in support of being included, the combined intervention would encompass (1) providing prepackaged foods for a specified period of time to facilitate greater initial weight loss, (2) encouraging enhanced self-monitoring of food, physical activity, and weight using devices and apps along with social support, and (3) delivering the further adapted GLB SCI in a group-based format to teach skills helpful in making lifestyle changes.
3470860|NCT03874936|Experimental|A; Dexamethasone twice|24mg intravenous Dexamethasone (Dexavital®, Vital Pharma) 4mg/ml just before the operation and repeated after 24 hours.
3470861|NCT03874936|Experimental|B; Dexamethasone once|24mg intravenous Dexamethasone just before the operation and placebo which is 6ml of isotonic sodium chloride (9mg/ml, 'normal' saline) after 24 hours
3470862|NCT03874936|Placebo Comparator|C; Placebo twice|placebo intravenous just before the operation and repeated after 24 hours
3470863|NCT03874858|Experimental|Nilotinib|Oral 300 mg hard capsules taken once a day
3470864|NCT03874884|Experimental|177Lu-PSMA + olaparib|Patients will receive a fixed 7.4 GBq of 177Lu-PSMA every 6 weeks together with olaparib on days 2-15 of each cycle. A cycle is 42 days long. Patients will receive 4 cycles of treatment. An additional 2 cycles of treatment can be given based on clinical benefit achieved and toxicity experienced.
3470865|NCT03874871||Function preserving gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients indicated for function preserving gastrectomy (including pylorus preserving gastrectomy, proximal gastrectomy, partial gastrectomy), they will receive the function preserving gastrectomy. After the surgery, a close follow up is performed.
3470866|NCT03874871||Standard gastrectomy|After baseline evaluation, a multidisciplinary discussion will be performed for the patients to choose the proper gastrectomy. For patients not indicated for function preserving gastrectomy, they will receive standard gastrectomy. After the surgery, a close follow up is performed.
3470867|NCT03874923|Active Comparator|250 mL of fluid challenge|
3470868|NCT03874923|Experimental|500 mL of fluid challenge|
3470871|NCT03874819|Active Comparator|Control group|Conventional Hemodialysis using a high-flux dialyzer
3470872|NCT03874819|Experimental|Experimental group|Conventional Hemodialysis using a medium cut-of dialyzer
3470873|NCT03874806|Experimental|single|local anesthetic is delivered as a single bolus
3470874|NCT03874806|Active Comparator|continuous|local anesthetic is delivered as a continuous infusion
3470875|NCT03874780|Experimental|Treatment|Subjects treated with Botox (TM) with the Vibe investigational delivery system
3470876|NCT03874741|Experimental|Arm - Experimental|Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3470877|NCT03874390|Experimental|ozone therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
3470878|NCT03874390|Active Comparator|initially periodontal therapy|control group only treated with Initial Periodontal Therapy (IPT), test group treated with IPT an adjunct to gasesos ozone therapy.
3470879|NCT03874585|Active Comparator|Standard Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange) and free nicotine replacement.
3470880|NCT03874585|Experimental|Enhanced Condition|Participants in the standard condition will receive a 30-minute group-based smoking cessation counseling session based on the 5 A's approach (Ask; Advise; Assess; Assist; Arrange), free nicotine replacement, and the 6-week text messaging intervention.
3470881|NCT03874403|Experimental|NIVATS|Patients receiving Non-intubated VATS with DSA changes
3125290|NCT02973321|Experimental|SAR425899 0.16 mg|SAR425899 SC injection QD at maintenance dose of 0.16 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase step (0.06 mg at Week 1 and 0.12 mg at Week 2).
3125291|NCT02973321|Experimental|SAR425899 0.20 mg|SAR425899 SC injection QD at maintenance dose of 0.20 mg for 23 weeks (Week 4 to Week 26) following 3 weeks dose increase step (0.06 mg at Week 1, 0.12 mg at Week 2 and 0.16 mg at Week 3).
3470882|NCT03874403|Other|Intubated VATS|Patients receiving intubated VATS with DSA changes
3470883|NCT03874715|Experimental|Switching arm: Alternative use of SAR341402 and NovoLog|Alternating use of SAR341402 and NovoLog, self-administered by subcutaneous injection at mealtime, starting with NovoLog for the first 4 weeks, then SAR341402 for 4 weeks, followed by NovoLog for 4 weeks and then SAR341402 for the last 4 weeks on top of Lantus as basal insulin.
3470884|NCT03874715|Active Comparator|Non-Switching arm: NovoLog|Continuous use of NovoLog, self-administrated by subcutaneous injection at mealtime, during the 16-week Treatment Period on top of Lantus as basal insulin.
3470885|NCT03874533|Experimental|self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
3470886|NCT03874442|No Intervention|Controls|
3470887|NCT03874442|Experimental|CliniPup|
3470888|NCT03874598|Experimental|Ear acupuncture|
3470889|NCT03874598|Active Comparator|Psychoeducation|
3470890|NCT03874728||Older people at risk of falls|Older people at risk of falls
3470891|NCT03874507|Experimental|Technology-based therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive either virtual reality (VR) or augmented reality (AR) to improve clinical outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step.
3470892|NCT03874507|No Intervention|Standard of Care therapy|Patients who require acute rehabilitation due to deconditioning and surgery will receive physical therapy based on his/her providers recommendations to improve outcomes such as range of motion, gait progression, strength progression, time to first out of bed, time to first step
3470893|NCT03874559||Arm A|All patients enrolled will be placed in Arm A. Serum blood draw samples will be collected as well as additional data from medical records will be collected. This data includes demographic data, clinical information from notes, radiology images and reports, diagnostic test results, and procedure and pathology reports.
3470894|NCT03874429|Experimental|T2259|1 drop in each eye 2 to 4 times daily
3470895|NCT03874429|Active Comparator|Vismed Multi|1 drop in each eye 2 to 4 times daily
3470896|NCT03874416|Experimental|Specific rehabilitation of working memory|Specific rehabilitation of working memory according to hierarchized rehabilitation.
3470897|NCT03874416|Active Comparator|Control group|Non-specific rehabilitation of working memory, usual therapy.
3470898|NCT03874676||PEACE Rounds Clinicians|Nurses, physicians, care managers, chaplains, and other clinicians who attend PEACE rounds as part of their routine work in the hospital.
3470899|NCT03874767|Active Comparator|10th floor south|"The unit in this arm will be assigned physical therapists plus mobility technicians in the first month and only physical therapists in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
3470900|NCT03874767|Active Comparator|6th floor Round Wing|"The unit in this arm will be assigned only physical therapists in the first month and physical therapists plus mobility technicians in the following month.~During months where a unit has been assigned the mobility technicians, the mobility technician, along with nursing staff, will deliver additional prescribed mobility as well as standard-of-care prescribed therapy provided by physical therapy staff:~On evaluation, a PT will assign a JH-HLM scale rating to the patient~If the score is 4 or higher, the PT will add the patient to the mobility technician patient list~The mobility technician will then see that patient daily, unless the score is <4~Each PT session will involve a re-assessment by the PT of the JH-HLM scale rating as well as the Function Independence Measurement (FIM) score, and subsequently will update the recommended therapy if appropriate~The mobility technician will work with PT and nursing to determine the best time to deliver mobility"
3470901|NCT03874637|Experimental|Treatment|Active therapy
3470902|NCT03874637|Sham Comparator|Sham Control|Sham Control
3470903|NCT03874520|Experimental|Video triage|The sick child will be assessed on video by the operator at the call-center.
3125292|NCT02973321|Active Comparator|Liraglutide|Liraglutide SC injection QD at maintenance dose of 1.8 mg for 24 weeks (Week 3 to Week 26) following 2 weeks dose increase steps (0.6 mg daily at Week 1 and by 1.2 mg daily at Week 2).
3470904|NCT03874520|No Intervention|Telephone triage|The sick child will be assessed solely over the telephone by the operator at the call-center.
3470905|NCT03874611|Experimental|electrophysiological data from DBS|
3470906|NCT03874663||Oral HIV Self-testing|Evaluate the acceptability and performance of a directly assisted oral HIV self-testing (HIVST) in a youth population aged 14-24 in Nigeria
3470907|NCT03874650|Experimental|Activity Planning Group|"Those in the Activity Planning group receive training and practice in identifying realistic and safe activities in everyday life that may be enjoyable or rewarding to complete. They gain practice in scheduling activities and identifying and overcoming barriers to completion, such as memory problems, avoidance, sticking to habitual patterns and physical and transport issues.~The intervention will consist of weekly 1 hour group sessions over 8 weeks, as below:~Introduction to Group Therapy Identifying Enjoyable Activities The Automatic Pilot and Planning Pleasurable Activities Goal Review and Balancing Enjoyable and Routine Activities Identifying Solutions to Goal Attainment Increasing Mastery and Managing Fatigue Active Approaches to Engagement Relapse Prevention"
3470908|NCT03874650|Experimental|Activity Engagement Group|"Individuals randomised to this arm will meet weekly for 8 weeks for 1 hour and engage in various potentially rewarding and meaningful social activities such as board games, crafting, and puzzles. Participants in this group will not receive specific training on activity scheduling or overcoming barriers to activity participation. Rather the aim is that participants gain experience of positive reinforcement from the activities and that this explicitly or implicitly challenges potentially negative predictions about such situations and encourages generalised increases in positive activity beyond the group setting. The group will cover activities such as board games, t-shirt making, puzzles, painting, pub quizzes, figurine painting, origami/paper-craft, and clay sculptures."
3125293|NCT02973438|Experimental|Spinal Cord Injury (SCI) Intermittent Hypoxia then SHAM|This arm of individuals with SCI will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
3125294|NCT02973438|Experimental|Control (CON) Intermittent Hypoxia then SHAM|This arm of non injured control subjects will receive Intermittent Hypoxia (IH) and following a 3 week washout, SHAM treatment interventions.
3125295|NCT02973438|Experimental|Spinal Cord Injury (SCI) SHAM then Intermittent Hypoxia|This arm of individuals with SCI will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
3125296|NCT02973438|Experimental|Control (CON) SHAM then Intermittent Hypoxia|This arm of non injured control subjects will receive SHAM and following a 3 week washout, Intermittent Hypoxia (IH) treatment interventions.
3470909|NCT03874650|Placebo Comparator|Waitlist Group|In consenting to the study, individuals understand that access to groups cannot always be immediate. In the design we take advantage of this by completing the outcome measures before and after an 8-week period in participants randomized to this condition. We do not ask participants in any condition to discontinue any clinical services that they currently receive, hence the waitlist forms a treatment as usual control arm against which to judge and effects of the two groups. At the end of the waitlist the participants will be invited to take part in the Activity Planning or Activity Engagement Group depending upon their initial randomisation..
3470910|NCT03874572|Experimental|Allogeneic mesenchymal stem/stromal cell therapy|Treatment with intra-glandular Injections of allogeneic adipose derived stem cells
3125297|NCT02973477|Experimental|Group A: Dapagliflozin/Glimepiride|Participants will take open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride.
3125298|NCT02973477|Experimental|Group B: Glimepiride/Dapagliflozin|Participants will take open-label glimepiride 2 mg daily for 4 weeks and escalate the dose gradually up to glimepiride 4 mg daily (no more than 4 mg daily) as needed based on their glucose monitoring for a total of 12 weeks on glimepiride. Patients will then begin a 2 week washout period where they are not taking any study drugs. After the washout period, participants will receive open-label dapagliflozin 5 mg daily for 4 weeks and escalate the dose gradually up to dapagliflozin 10 mg daily as needed based on their glucose monitoring for a total of 12 weeks on dapagliflozin.
3125299|NCT02973503|Experimental|Elbasvir/Grazoprevir|evaluate the efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
3470911|NCT03874364|Active Comparator|Lidocaine gel, counselling, monitor|
3470912|NCT03874364|Active Comparator|Lidocaine gel, counselling, no monitor|
3470913|NCT03874364|Active Comparator|Lidocaine gel, no counselling, monitor|
3470914|NCT03874364|Active Comparator|Lidocaine gel, no counselling, no monitor|
3470915|NCT03874364|Placebo Comparator|Lubricating gel, counselling, monitor|
3470916|NCT03874364|Placebo Comparator|Lubricating gel, counselling, no monitor|
3470917|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, monitor|
3470918|NCT03874364|Placebo Comparator|Lubricating gel, no counselling, no monitor|
3125300|NCT02973516|Experimental|P03277 triphasic imaging|P03277 will be administered in order to acquire triphasic liver imaging
3125301|NCT02973802|Experimental|ATX-GD-59 treatment|An upward titration over five dose levels (25, 50, 100, 400 and 800 micrograms) followed by 5 doses of 800 micrograms of ATX-GD-59 will be administered two weeks apart by intradermal injection.
3125302|NCT02974010|Experimental|NRX-101|NRX-101 is a fixed dose combination of d-cycloserine and lurasidone
3125303|NCT02974010|Active Comparator|Lurasidone|Lurasidone will be administered in the same dosages as the lurasidone component of NRX-101
3125304|NCT02974088|Experimental|Neem-based lotion plus louse comb|Neem-based conditioning lotion plus head louse detection and removal comb
3125305|NCT02974088|Experimental|Neem-based lotion plus grooming comb|Neem-based conditioning lotion plus regular grooming comb
3470919|NCT03874481||PCI|Patients who had stent
3470920|NCT03874338||Colchicine|
3470921|NCT03874338||Placebo|
3470922|NCT03874273|Experimental|crizotinib +|Patients with unresectable, relapsed or refractory inflammatory myofibroblastic tumor, receiving crizotinib
3470923|NCT03874312||Calibration group|Patients with systolic chronic heart failure who undergo right heart catheterization (RHC) for heart transplant/left ventricular assist device workup.
3470924|NCT03874312||Validation group|Patients with systolic chronic heart failure who undergo RHC for heart transplant/left ventricular assist device workup.
3125306|NCT02974114|Experimental|Paracetamol and caffeine|Participants will be administered test product (containing 500 mg paracetamol and 65 mg caffeine). Two tablets will be taken orally once with 200 mL (milliliters) of water.
3125307|NCT02974114|Experimental|Paracetamol|Participants will be administered test product (containing 500 mg paracetamol). Two tablets will be taken orally once with 200 mL of water.
3125308|NCT02974114|Placebo Comparator|Placebo|Participants will be administered reference product (placebo to match Paracetamol 665mg sustained release tablets). Two tablets will be taken orally once with 200 mL of water.
3470925|NCT03874325|Experimental|Safety Run In: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited. Six participants will be enrolled in the safety run in stage. If 1 or fewer of six participants have a DLT, expansion stage will open to enrollment.
3470926|NCT03874325|Experimental|Expansion: Durvalumab + Aromatase Inhibitor|Participants will be administered 1500 mg Durvalumab intravenously every 4 weeks for 6 cycles. Participants will also take standard of care 1 mg anastrozole daily by mouth for 6 months. Letrozole 2.5 mg or exemastane 25 mg may be substituted for anastrozole if an intolerance to anastrozole is exhibited.
3179186|NCT00670280|Experimental|Intervention Group|Those randomized to the Intervention group will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit.
3470927|NCT03874286||Liver Transplant|Participants will obtain a liver biopsy at 4 months post transplant and 12 months post transplant.
3470928|NCT03874130|Active Comparator|Scopolamine|0.2 mg scopolamine HBr per dose
3470929|NCT03874130|Active Comparator|IV Scopolamine|4.0 μg/kg; 15 minute IV infusion
3470930|NCT03873922|Experimental|Ketogenic diet intervention|Ketogenic meals will be offered for the participants during the trial.
3470931|NCT03873922|No Intervention|Control group|Conventional hospital meals as usual will be offered during the trial.
3470932|NCT03874104|Experimental|Study product|Extensively Hydrolysed Formula containing Pre- and Probiotics
3470933|NCT03874117|Other|Twice weekly hemodialysis|Participants will undergo hemodialysis twice per week.
3179187|NCT00670280|Active Comparator|UC Group|Those randomized to the Usual Care group will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
3179188|NCT00670280|Active Comparator|UC-RM Group|Those randomized to the Usual Care - Reduced Measurement group will receive the same information as the Usual Care group but will be measured less often (only at 6 months post-intervention).
3470934|NCT03874117|Other|Thrice weekly hemodialysis|Participants will undergo hemodialysis three times per week.
3470935|NCT03874195|Active Comparator|Control|"Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care - www.palliativedoctors.org; getpalliativecare.org; and Wikipedia Palliative Care https://en.wikipedia.org/wiki/Palliative care)."
3470936|NCT03874195|Experimental|Intervention|Intervention Arm subjects will receive access to PCforMe.
3470937|NCT03874247|Experimental|Pelubiprofen|
3470938|NCT03874247|Placebo Comparator|Pelubiprofen placebo|
3470939|NCT03874260|Experimental|statin / fenofibrate|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg)+ choline fenofibrate 178.8mg / once a day, P.O
3470940|NCT03874260|Placebo Comparator|statin / fenofibrate placebo|stable statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
3470941|NCT03873909|Active Comparator|Fruit Smoothie|Post-prandial study feeding 155-200 g mamey sapote mesocarp, 6 g of soybean oil , crushed ice and 150-200 g of water to reach a total volume of 450 mL. (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin).
3470942|NCT03873909|Active Comparator|Matrix-Free Shake|Post-prandial study feeding 2 g of carotenoid powder formula (845 µg sapotexanthin, 1.21-1.51 mg cryptocapsin), 37.5 g of sugar, 75 µg of citric acid, 6 g of soybean oil emulsified into 300 g of water using 3 g of soy lecithin as well as ca. 100 g of crushed ice, yielding a shake volume of 450 mL.
3470943|NCT03874143|Experimental|RCom equipped with a smartphone|
3470944|NCT03874143|No Intervention|RCom with paper-based system|
3470945|NCT03873935||Control|Healthy subjects
3470946|NCT03873935||Periodontitis|Patients with periodontal disease
3470947|NCT03873935||Cardiovascular|Patients with cardiovascular disease
3470948|NCT03873935||Periodontitis+Cardiovascular|People with both cardiovascular and periodontitis
3470949|NCT03874039||Healthy Adults|Healthy adults with no prior diagnosis of atopic dermatitis
3470950|NCT03874039||Atopic Dermatitis|Adults with prior diagnosis of Atopic Dermatitis from board certified dermatologist
3470951|NCT03874000|Experimental|Sintilimab plus Metformin Hydrochloride|Patients receive metformin hydrochloride 500mg orally (PO) twice daily (BID). Patients also receive Sintilimab 200mg intravenously (IV) in 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
3470952|NCT03874169||High-Risk of GI Bleed|Patients that have a high risk of having a gastrointestinal bleed upon admission into the ICU based on their medical history and symptoms. These patients will have a biosensor watch, the E4 wristband, placed on them to monitor their vital signs.
3470953|NCT03874026|Experimental|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
3470954|NCT03874208|Other|Patient group|To assess the predictive accuracy of comaScore evaluated in the day 7 - day 45 period post brain injury to predict unfavorable outcome at 1-year after the first insult in patients admitted in ICU after CA, TBI and aSAH, that remain comatose at least 7 days after brain injury.
3470955|NCT03874208|Other|Test group|MRI calibration in each center : test protocol compliance, data transfer procedures and quality of the MRI sequences
3470956|NCT03874052|Experimental|Treatment (ruxolitinib, venetoclax)|Patients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator.
3470957|NCT03874156|Active Comparator|Intervention group|Atorvastatin 40 mg once daily
3470958|NCT03874156|Placebo Comparator|Placebo group|Matched placebo tablet once daily
3470959|NCT03873961|Experimental|High-intensity laser therapy|The participants received stretching and exercise guidance and underwent the BTL-6000 High Intensity Laser 12 W with 10 mm pen applicator high intensity laser procedures (mode = continuous, power = 7 W, dose = 120 J/cm2, total time= 7 min. 8 sec.) 3 times per week (total of 8 procedures).
3470960|NCT03873961|Active Comparator|Low-level laser therapy|The participants received stretching and exercise guidance underwent the LAS-Expert with laser shower applicator Low-level Laser therapy procedures (785 nm wavelength, 4,0 J/cm2, 35cm2, 6:40 min) 3 times per week (total of 8 procedures).
3470961|NCT03873753|Experimental|Oral cleaning|The oral cavity will be clean with gauze and mineral water three times a day.
3470962|NCT03873753|Active Comparator|No oral cleaning|The oral cavity will not be cleaned.
3470963|NCT03873974||Negative trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
3470964|NCT03873974||Positive trial arm|"Venous blood samples will be taken for central laboratory analysis with:~DualDur dark-field microscopic test~DualDur dark-field automatic microscopic test~Western blot IgM and IgG~Bózsik Western blot IgM and IgG~Enzyme-Linked Immunosorbent Assay (ELISA) IgM and IgG~DualDur Polymerase chain reaction"
3470965|NCT03873766|Active Comparator|Intrapleural fibrinolytic therapy (IPFT)|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage~Protocol Image #1: After chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Intrapleural Medications (IPFT): The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day.~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion, a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
3125309|NCT02974140|Experimental|CRS|First surgical eye randomized to Cataract Refractive Suite with second surgical eye (fellow eye) assigned to standard manual technique. Second eye surgery conducted within 7-14 days of the first eye surgery.
3470966|NCT03873766|Active Comparator|Surgery|"Procedure/Surgery: Pleural Sampling~Procedure/Surgery: Pleural fluid drainage: Chest tube placement~Protocol Image #1: Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage.~Other: Surgical Consultation~Surgery: The surgical arm will have either open surgery or a VATS approach at the discretion of the surgeon~Protocol Image #2: Chest X-ray PA/Lateral: The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained~Quality of Life: Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires"
3470967|NCT03873714|Experimental|Pipeline™ Vantage Embolization Device with Shield Technology™|Pipeline™ Vantage Embolization Device with Shield Technology™
3470968|NCT03873883|Experimental|Dose Escalation- Monotherapy|Specified dose on specified days
3470969|NCT03873883|Experimental|EOS100850 and Pembrolizumab Combination Therapy|Specified dose on specified days
3470970|NCT03873883|Experimental|EOS100850 and SOC Combination Chemotherapy|Specified EOS100850 dose on specified days
3470971|NCT03873727|Experimental|Prevenar13/ Pneumovax|Prime-boost strategy combining a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar 13, PCV13) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12).
3470972|NCT03873727|Placebo Comparator|Placebo / Pneumovax|Standard strategy combining a single dose of placebo vaccine (Prevenar 13 placebo) at month 0 (M0) followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPS23) at month 12 (M12)
3470973|NCT03873805|Experimental|Treatment (PSCA CAR T cells)|Patients may receive lymphodepleting regimen including fludarabine IV on days -5 to -3 and cyclophosphamide IV on days -5 to -3 or on days -4 and/or -3. Patients then receive autologous anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T lymphocytes IV over 10-15 minutes at day 0.
3470974|NCT03873844|Experimental|CI Cognitive Therapy|The treatment will have 2 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily life.
3470975|NCT03873831|Active Comparator|Social Skills Control (A-A)|"The children in the A-A condition, a true control, will remain without a dog for the full 10 weeks."
3470976|NCT03873831|Experimental|Social Skills Dog (A-B)|"The A-B condition will involve standard instruction for 5 weeks (A), followed by 5 weeks of group instruction while a therapy dog is present in the room (B)."
3470977|NCT03873831|Experimental|Social Skills Dog (B-A)|"The B-A condition will be identical, except the first 5 weeks of instruction will include the dog, followed by 5 weeks of standard instruction with no dog."
3125310|NCT02974140|Active Comparator|Manual|First surgical eye randomized to standard manual technique with second surgical eye (fellow eye) assigned to Cataract Refractive Suite. Second eye surgery conducted within 7-14 days of the first eye surgery.
3125311|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
3125312|NCT02974153|Experimental|ALD403 (Eptinezumab) Dose Level 2|ALD403 (Eptinezumab) Dose Level 2 (IV)
3125313|NCT02974153|Placebo Comparator|Placebo|Placebo (IV)
3125314|NCT02974296|Experimental|new target TMS|new target transcranial magnetic stimulation guided by MRI
3470978|NCT03873948||Control|Healthy patients
3470979|NCT03873948||Periodontitis|Patients with periodontal disease
3470980|NCT03873948||Cardiovascular|Patients with cardiovascular disease
3470981|NCT03873948||Periodontitis+Cardiovascular|Patients with both periodontal and cardiovascular disease
3470982|NCT03873662||Pediatric patients after out-of hospital cardiac arrest|Pediatric patients after out-of hospital cardiac arrest admitted to Department of pediatric anesthesia and intensive care University hospital in Brno in selected study period with blood sample analysis for neurologic outcome prognostication
3470983|NCT03873857||Venetoclax|"Participants in this observational study will receive treatment with venetoclax for up to 24 months for treatment of relapsed or refractory CLL.~The prescription of a treatment regimen is at the discretion of the physician in accordance with local clinical practice and label, is made independently from this observational study and precedes the decision to offer the patient the opportunity to participate in this study."
3470984|NCT03873818|Experimental|Treatment (ipilimumab, pembrolizumab)|Patients receive ipilimumab IV over 90 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 4 cycles for ipilimumab and up to 35 cycles for pembrolizumab in the absence of disease progression or unacceptable toxicity.
3470985|NCT03873779|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the submental/submandibular area.
3125315|NCT02974296|Active Comparator|standard TMS|standard transcranial magnetic stimulation
3125316|NCT02974543|Other|Sham 1st (Auditory only) then Active (Bimodal)|"To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab.~During active treatment, the device will deliver electric somatosensory and auditory stimulation."
3470986|NCT03873610|Experimental|Stress and Symptom Management Program 1|
3470987|NCT03873610|Experimental|Stress and Symptom Management 2|
3125317|NCT02974543|Other|Active (Bimodal) then Sham (Auditory only)|"During active treatment, the device will deliver electric somatosensory and auditory stimulation.~To mitigate potential placebo effects, subjects receive both a sham treatment and an active treatment. The subjects will be blinded to which treatment they are receiving. Both treatments are delivered using a take-home device programmed in the lab."
3125318|NCT02974634|Active Comparator|Ostomy Self management Training|Ostomy self-management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
3125319|NCT02974634|Placebo Comparator|Usual care|Usual care in peri-operative and long-term settings is not standardized for ostomy patients. Usual care does not provide any formal, reproducible training for patients or their caregivers. It typically consists of an Ostomy Care Nurse who works with patients and caregivers concerning technical issues (fitting, emptying, supplies, surrounding skin care, etc.) while the new ostomate is still an inpatient
3125320|NCT02974842||Pre-Salpingo-Oophorectomy|Women with pelvic mass suspicious for malignancy or have BRCA1 or BRCA2 mutations that will undergo pre-salpingo-oophorectomy.
3125321|NCT02974855|Experimental|PF-06741086 (Cohort 1)|
3125322|NCT02974855|Experimental|PF-06741086 (Cohort 2)|
3125323|NCT02974855|Experimental|PF-06741086 (Cohort 3)|
3125324|NCT02974855|Experimental|PF-06741086 (Cohort 4)|
3125325|NCT02974868|Experimental|Cohort 1|PF-06651600
3125326|NCT02974868|Experimental|Cohort 2|PF-06700841
3125327|NCT02974868|Placebo Comparator|Cohort placebo|placebo
3125328|NCT02975206|Experimental|Serlopitant High Dose|serlopitant tablets - high dose
3125329|NCT02975206|Experimental|Serlopitant Low Dose|serlopitant tablets - low dose
3125330|NCT02975206|Placebo Comparator|Placebo Oral Tablet|matching placebo tablets
3125331|NCT02975297|Experimental|Exenatide plus NRT plus counseling|Once weekly exenatide Injectable Product, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
3125332|NCT02975297|Placebo Comparator|Placebo plus NRT plus counseling|Once weekly placebo, Nicotine Replacement Therapy (NRT) Patch, smoking cessation counseling
3125333|NCT02975336|Placebo Comparator|Double-Blind Placebo-Controlled (DBPC) Period: Placebo|
3125334|NCT02975336|Experimental|DBPC Period: M2951 25 mg QD|
3125335|NCT02975336|Experimental|DBPC Period: M2951 75 mg QD|
3470990|NCT03873792|Other|Allergy pregnant women|
3470991|NCT03873792|Other|Health pregnant women|
3470992|NCT03873896|Experimental|Blocked finger|The experimental arm will be the ring finger of the volunteer that is blocked (randomized either right or left hand) with a digital nerve block (described elsewhere in the submission). The skin wrinkle test (diagnostic test) will be applied to this arm
3470993|NCT03873896|Active Comparator|Unblocked finger|The control arm will be the finger of the same volunteer that is not under the influence of digital nerve block. This will be the corresponding digit (the ring finger) on the opposite hand of the side that was blocked (determined by coin toss). The skin wrinkle test (diagnostic test) will be applied to this arm
3470994|NCT03873688|Experimental|Experimental Group|Patients in experimental group will perform expiratory muscle training as home programme for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device. The intensity of training will been setted 30% of the maximal expiratory pressure level.
3470995|NCT03873688|Sham Comparator|Sham Group|In sham group, patients will perform expiratory muscle training at home for at least five days a week, twice a day for 15 minutes at each session during six weeks by Threshold Positive Expiratory Pressure device that the intensity of training will been setted 5 cm H₂O.
3470996|NCT03873649||Patients with subacute or chronic hypersensitivity pneumonitis|"Procedures that each subject will undergo include:~Chest CT scan to determine extent of disease.~Pulmonary function testing to determine severity of disease.~Bronchoscopy with lavage.~Venipuncture."
3470997|NCT03873649||Healthy Controls|"Inclusion:~Adult between the ages of 18 and 80 years old.~Non-smoker or previous smoker quit >6months ago.~Able to understand the consent process and procedures involved in the study.~Exclusion:~Unable to understand the consent process or procedures involved in the study.~Pregnancy.~Suspicion of current infection or within the past 3 months.~Bleeding disorder or on anti-coagulants other than aspirin.~Any co-morbid condition that increases risk of bronchoscopy including but not limited to cardiac disease, uncontrolled hypertension, uncontrolled diabetes and/or morbid obesity."
3470998|NCT03873675||Study group|Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure.
3125336|NCT02975336|Experimental|DBPC Period: M2951 50 mg BID|
3470999|NCT03873454|Active Comparator|Experimental Group|The experimental group listened to music and wore Sennheiser non-occlusive headphones
3471000|NCT03873454|Other|Control 1 with no music|This cohort wore non-occlusive earphones but did not listen to music
3471001|NCT03873454|Other|Control 2 with no music|The control 2 patients did not listen to music nor wore earphones.
3471002|NCT03873389||Ocrelizumab|All participants enrolled in the study. All participants will be receiving the treatment of interest (Ocrelizumab)
3471003|NCT03873376|Experimental|Opt-in|Receive offer to order self-sampling kit
3471004|NCT03873376|Experimental|Opt-out|Receive self-sampling kit unsolicited
3471005|NCT03873376|Experimental|Control|Receive open reminder to be screened by physician
3471006|NCT03873363|Experimental|PS|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
3471007|NCT03873363|Active Comparator|CR|Implantation of a cruciate retaining Total Knee Arthroplasty.
3471008|NCT03873428|Other|FES PET|1 ) inclusion; 2 ) FGD PET / FES PET; 3) Hormone therapy
3125337|NCT02975336|Experimental|Long-Term Extension (LTE) Period: Placebo/ M2951 50 mg BID|
3125338|NCT02975336|Experimental|LTE Period: M2951 25 mg QD/ M2951 50 mg BID|
3125339|NCT02975336|Experimental|LTE Period: M2951 75 mg QD/ M2951 50 mg BID|
3471009|NCT03873298|Experimental|COPD|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
3471010|NCT03873298|Experimental|IPF|Each participant will undergo two six minute walk tests and the results will be compared within each subject.
3471011|NCT03873337|Experimental|NRT + Persistence Targeted Smoking Cessation in Schizophrenia|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling with a focus on task persistence.
3471012|NCT03873337|Active Comparator|NRT + Modified Clearing the Air|Participants randomized to this intervention will receive 10 weeks of nicotine patch (NRT) plus 8 weeks of cessation counseling that does not focus on task persistence.
3471013|NCT03873350|Experimental|Living kombucha|
3471014|NCT03873350|Placebo Comparator|Heat-sterilized kombucha|
3471015|NCT03873350|No Intervention|Water|
3125340|NCT02975336|Experimental|LTE Period: M2951 50 mg BID/ M2951 50 mg BID|
3471016|NCT03873597|Experimental|Tele-coaching + Usual Care|This group will undergo a 12 week physical activity tele-coaching intervention consisting of a step-counter and smartphone application, in addition to usual care. Usual care will also include sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
3471017|NCT03873597|No Intervention|Usual Care|This group will receive sessions where behavioural strategies will be implemented to promote a physically active lifestyle.
3471018|NCT03873272|Active Comparator|Cryotherapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
3125341|NCT02975349|Experimental|Placebo then Evobrutinib 25 mg QD|Participants who received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1 received Evobrutinib 25 milligram (mg) orally, once daily (QD) in blinded extension (BE) period from week 25 to week 48.
3125342|NCT02975349|Experimental|Evobrutinib 25 mg QD|Participants received Evobrutinib 25 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
3471019|NCT03873272|Active Comparator|Compression Therapy|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
3471020|NCT03873272|Placebo Comparator|Control arm (Loose glove/sock)|Men or women over the age of 18 with a history of stage I-III breast cancer and is scheduled to receive adjuvant or neoadjuvant paclitaxel or docetaxel for at least 12 weeks.
3125343|NCT02975349|Experimental|Evobrutinib 75 mg QD|Participants received Evobrutinib 75 mg orally, QD up to Week 48 in active treatment period 1 and BE period.
3471021|NCT03873311|Experimental|Azacytidine + HAG Regimen|Azacytidine（75mg/m2 ）+ HAG Regimen（Homoharringtonine(HHT) 1mg/(m2.d) , Cytarabine 10mg/(m2.d), G-CSF 200ug/(m2.d) )
3471022|NCT03873311|Active Comparator|Azacytidine|75mg/m2
3471023|NCT03873467|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with stroke, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
3471024|NCT03873467|Other|Wait-List Control|The wait-list control group will receive no intervention for 6 months after enrollment. After the 6 month control period, the wait-list control group will receive the GLB Intervention.
3471025|NCT03873259|Experimental|Treatment Group|Subjects in this arm receive the 10-minute burst wave lithotripsy intervention dose during their standard-of-care lithotripsy procedure.
3471026|NCT03873324|Experimental|CPL500036|"PART A: 7 cohorts are to receive single dose of IMP. Each participant is to take single dose of IMP. There is to be dose escalation between cohorts.~PART B: 4 cohorts are to receive multiple dose of IMP. Each participant is to take IMP once daily for 14 days. There is to be dose escalation between cohorts."
3471027|NCT03873324|Placebo Comparator|Placebo|PART B: 2 Participants from 4 cohorts (total of 8 people) are to receive masking placebo capsules once daily for 14 days. There is to be dose escalation between cohorts. Participants are to be randomized within cohorts.
3471028|NCT03873740|Experimental|Single vaccine group A|This group receive two doses injection of EV71 inactived vaccines(Vero cells) on Day 0 and 30, and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.
3471029|NCT03873740|Experimental|Single vaccine group B|This group receive two doses injection of EV71 inactived vaccines(human diploid cells)on Day 0 and 30, two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.The vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
3471030|NCT03873740|Experimental|Sequential vaccination group A|One dose injection of EV71 inactived vaccines(Vero cells) on Day 0，following one dose of EV71 vaccine(EV71 inactived vaccines(human diploid cells), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
3471031|NCT03873740|Experimental|Sequential vaccination group B|One dose injection of EV71 inactived vaccines(human diploid cells)on Day 0，following one does of EV71 vaccine(Sinovac Vaccine Technology Co., Ltd), and two times of blood sampling on day of 0 and 60 respectively for EV71 neutralizing antibody detection.
3471032|NCT03873155|Experimental|Mindfulness-based cognitive therapy|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in an MBCT intervention whilst the same variables are measured. Following the intervention,there will be a 4-week follow-up period, and MBCT groups will not run during this time.
3125344|NCT02975349|Experimental|Evobrutinib 75 mg BID|Participants received Evobrutinib 75 mg orally, twice daily (BID) up to Week 48 in active treatment period 1 and BE period.
3125345|NCT02975349|Active Comparator|Tecfidera|Participants received Tecfidera 120 mg twice daily (BID) for first 7 days followed by 240 mg orally, BID up to Week 48 in active treatment period 1 and BE period.
3471033|NCT03873142|Experimental|Mindful parenting intervention|There is only one arm in this study. A range of variables will first be measured (daily and weekly) over a baseline period in a group of participants. Following this baseline period, participants will be take part in a mindful parenting intervention whilst the same variables are measured. Following the intervention, there will be an 8-week follow-up period, and mindful parenting groups will not run during this time.
3471034|NCT03873285|Experimental|Genodermatosis patients|Children between 0 to 18 years old with the presence of dermatological symptoms suggesting genodermatosis or presence of systemic symptoms in an undiagnosed patient associated with dermatological manifestations suggestive of a more rare genetic disorder with cutaneous expression
3471035|NCT03873506|Experimental|Mesenchymal Stem Cell|A single intravenous transplantation of Mesenchymal Stem Cell (Dose A - 1 million cells per kg, Dose B - 5 million cells per kg)
3125346|NCT02975349|Placebo Comparator|Placebo|Participants received placebo matched to Evobrutinib tablet orally for 24 weeks in active treatment period 1.
3125347|NCT02975557|Active Comparator|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
3471036|NCT03873220||Monitoring scratch in children|Sensor technology and digital measures will be used to evaluate scratch and sleep in children with atopic dermatitis who will wear watch-like wrist actigraphy devices, sleep monitor, polysomnography, and videography.
3471037|NCT03873519|Experimental|Cold North|Group A: Cold color scheme, room facing North
3471038|NCT03873519|Experimental|Cold South|Group B:Cold color scheme, room facing South
3471039|NCT03873519|Experimental|Warm North|Group C: Warm color scheme, room facing North
3471040|NCT03873519|Experimental|Warm South|Group D: Warm color scheme, room facing South
3471041|NCT03873233|Active Comparator|Volume Controlled Ventilation|Volume Controlled Ventilation with Aisys Carestation ventilator and normal endotracheal tube'
3471042|NCT03873233|Active Comparator|Flow Controlled Ventilation|Flow Controlled Ventilation with Evone ventilator and Tritube
3471043|NCT03873441|Experimental|Computer Games-Aided Balance Training Group|The participants in CGR group will be asked to sit or stand (as per the screening result) on fixed & compliant surfaces; to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects using bi-manual grip gradually progressing to head rotations (mouse mounted on a cap worn by participant); finally using trunk movements as a part of experimental therapy protocol. While performing CGR; children will be standing on a thin pressure mat (placed over fixed or compliant surface). This will allow us to record the information of COP displacement [body sway] while CGR intervention implementation. This information will be used to quantify therapy dosage. The CGR Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
3471044|NCT03873441|Active Comparator|Conventional Balance Training Group|The control group will be receiving the conventional balance training for static and dynamic balance function improvement. The therapy will be provided in sitting or standing (as per the screening result) in a graded manner progressing from fixed surfaces to movable compliant surfaces. The Conventional Balance Training Group will receive a 45-60 minutes of session thrice a week for 12 weeks.
3471047|NCT03873051|Experimental|Challenge-Focused Program|This group will receive the challenge-focused group program
3471048|NCT03873051|Experimental|Rewards-Focused Program|This group will receive the rewards-focused group program
3471049|NCT03873090|Experimental|SBRT in 4 fraction|Selected intermediate risk prostate cancer patients treated with 4 fraction SBRT
3471050|NCT03873246|Placebo Comparator|Placebo|
3471051|NCT03873246|Active Comparator|OC-01 0.1%|
3471052|NCT03873246|Active Comparator|OC-01 0.2%|
3471053|NCT03873077|No Intervention|intravenous analgesia|Patient receives intravenous analgesia: paracetamol 30 mg/kg, diclofenac 75 mg, clonidine 1 µg/kg and morfine 0,05 mg/kg
3471054|NCT03873077|Other|intravenous analgesia + LIA|Patient receives intravenous analgesia and a local infiltration analgesia in the knee
3471055|NCT03873064||patients with solid tumor|All consecutive patients with a histologically confirmed diagnosis of solid tumor referred to any of the Medical Oncology Units of the S.I.C.O.G. cooperative group (http://www.sicog.it/).
3471056|NCT03873129|Experimental|A-CHESS|participant will be using the A-CHESS mobile app for 12 months
3471057|NCT03873025|Experimental|Pembrolizumab and CXD101|"Initial dose ('dose level 0'):-~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 20mg twice daily PO (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity.~Reduced dose level ('Dose level -1'; if >1 DLT observed at dose level 0):~Single 200mg pembrolizumab IV infusion (day 1) in combination with oral CXD101 given twice daily, 20mg in the morning and 10mg in the evening (days 1 to 5) given in 21-day cycles for 2 years or until termination of treatment due to disease progression or unacceptable toxicity."
3125348|NCT02975557|Active Comparator|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
3471058|NCT03872960|Experimental|Intervention Arm: Expedited transfer to a CAC|The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-arrest STE patients. This involves pre-alert of the CAC and strategic delivery of the patient to the catheter laboratory (24 hours a day, 7 days a week). Patients will receive definitive post-resuscitation care: intubation and ventilation, where necessary, targeted temperature management, and goal directed therapies including evaluation and identification of underlying cause of arrest with access to immediate reperfusion if necessary. Prognostication will occur no earlier than 72 hours post-cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest to the designated centre.
3471059|NCT03872960|No Intervention|Control Arm: Current standard of care|The control arm comprises the current standard of pre-hospital advanced life support (ALS) care management for patients with ROSC following cardiac arrest of suspected cardiac aetiology. The patient is conveyed to the geographically closest emergency department. Management thereafter will be as per standard hospital protocols however as in the intervention arm, prognostication is to be delayed in trial patients until at least 72 hours post arrest.
3125349|NCT02975557|Placebo Comparator|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
3125350|NCT02975700|Experimental|PLX3397|"Part 1: Open label, multicenter study includes a dose evaluation portion in which the safety profile of PLX3397 as a single oral agent will be evaluated~Part 2: An expansion cohort in which the efficacy and safety of PLX3397 administered at the recommended Phase 2 dose will be evaluated in patients with unresectable stage III or stage IV KIT-mutated melanoma."
3125351|NCT02975804|Experimental|Interactive computer play (ICP)|The children in the treatment group will receive training on their trunk control using the Tymo in sitting 4 times per week for 20 minutes per session. The treatment will last for 6 weeks. All study children will continue their usual therapies at school.
3125352|NCT02975804|No Intervention|Standard Therapy|Children in the control group will continue their usual therapy.
3125353|NCT02975973|Experimental|2.5mA|Active stimulation group will receive 20 minutes of 2.5 mA transcranial direct current stimulation.
3125354|NCT02975973|Experimental|2.0mA|Active stimulation group will receive 20 minutes of 2.0 mA transcranial direct current stimulation.
3125355|NCT02975973|Experimental|1.5mA|Active stimulation group will receive 20 minutes of 1.5 mA transcranial direct current stimulation.
3125356|NCT02975973|Sham Comparator|0mA|This will be an active sham involving transcranial direct current stimulation, though stimulation will be brief (15 msec) and have low current (0.11 mA) pulses every 550 ms.
3125357|NCT02976103|Other|Standard Care|-Standard Care pain medicine/management will be given
3125358|NCT02976103|Experimental|JACKI® RECOVERY JACKET + Standard Care|"Patient will be encouraged to use the Jacki Recovery Jacket at home~Patient will be taught how to tuck the drainage tubes in the jacket pocket~Patient will be taught how to un-tuck the drainage tubes from jacket pocket~Standard care pain medicine/management will be given"
3125359|NCT02976519|Experimental|BI 443651|
3125360|NCT02976519|Placebo Comparator|Placebo|
3471060|NCT03872934||Turkish music group|Turkish music group (Saba or rast makam)
3471061|NCT03872934||classical western music|classical western music (vivaldi)
3471062|NCT03872934||soft rock music|soft rock music (elvis)
3471063|NCT03872934||control group (group not listening music)|control
3471064|NCT03872765|Other|Patients with chronic anal fissure|Use of laser in surgery of chronic anal fissure instead of the conventional surgical techniques.
3471065|NCT03872921|Experimental|norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg capsules, 6 capsules/day for 2 years
3471066|NCT03872921|Placebo Comparator|Placebo to norUrsodeoxycholic acid|norUrsodeoxycholic acid 250mg Placebo-capsules, 6 capsules/day for 2 years
3471067|NCT03872648||TW-VP (centralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC in a specialized clinic with a centralized structure
3471068|NCT03872648||TW-VP (decentralized delivery structure)|Trans women seeking penile inversion vaginoplasty (TW-VP) assessing THC from different medical locations (decentralized structure)
3471069|NCT03872817|Experimental|Intervention ProLiSMentAl|"Experimental Group receive mental health literacy psychoeducational intervention called ProLiSMentAl that consist of 4 sessions of 90 minutes."
3471070|NCT03872817|No Intervention|Control Group|Control Group receive usual approach.
3471071|NCT03872687|Experimental|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size for 6 months.
3471072|NCT03872687|Active Comparator|interdental brushes|Subjects in this group will only receive interdental brushes 6 months.
3471073|NCT03872999|Experimental|Attentional Control|Visuo-spatial attentional tasks with simple stimuli during functional magnetic resonance imaging (fMRI) scanning.
3471074|NCT03872869|Active Comparator|Hip School|The participants in the Hip School were required to attend three 1.5 hour classes which were conducted by specially trained physiotherapists in premise at Lund University.
3471075|NCT03872869|Active Comparator|Tai Chi for arthritis (TCA)|The treatment intervention with TCA was scheduled in a group setting. Class size for Tai Chi groups was 8- 10 individuals. The group was led by a physiotherapist, specially trained in the concept, in premise at Lund University. The participants in the Tai Chi group were required to attend classes for 12-16 one- hour sessions, twice a week for the first four weeks and then once a week.
3179189|NCT00670293||Subjects with anorexia nervosa|Underweight participants with anorexia nervosa who will restore normal weight levels after inpatient treatment will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
3179190|NCT00670293||Healthy weight controls|Participants who are healthy controls will undergo Positron Emission Tomography (PET) using [11C]raclopride as well as MRI
3179191|NCT00670319|Experimental|1|Raloxifene HCL 60 mg orally once a day
3125361|NCT02977507|Experimental|Lytera 2.0|Lytera 2.0 applied to the affected areas (dark patches) on one side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
3179192|NCT00670319|Experimental|2|Raloxifene HCL 120 mg orally once a day
3179193|NCT00670319|Placebo Comparator|3|
3471076|NCT03872869|No Intervention|Control group|
3471077|NCT03872661|Experimental|Drug and surgery|Neoadjuvant therapy followed by surgery. Neoadjuvant therapy included four drugs. IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles; bevacizumab was administered at a dose of 15 mg/kg; pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles; carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles. Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
3471078|NCT03872674|No Intervention|standard oxygenation(nasal cannula)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula
3471079|NCT03872674|Experimental|high-flow humidified oxygen-delivery system(OptiFlow THRIVE)|Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE
3471080|NCT03872622|Other|CD patients|New onset Crohn's disease patients
3125362|NCT02977507|Active Comparator|4% Hydroquinone Topical Cream|4% hydroquinone topical prescription cream applied to the affected areas (dark patches) on the other side of the face twice a day, in the morning and evening, every day for 12 weeks. SkinMedica Facial Cleanser, SkinMedica Rejuvenative Moisturizer, and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen were also applied to the face as directed.
3471081|NCT03872622|Other|Healthy controls|Patients' family members and healthy subjects undergoing colonoscopy for non-research purposes
3125363|NCT02977572|Experimental|Non-Invasive ventilation (NIV group)|For the NIV group, a BiPAP Vision was used, by setting the Inspiratory Positive Airway Pressure (IPAP) at a level that was required to achieve a tidal volume of approximately 8-10 ml/kg. Also an Expiratory Positive Airway Pressure (EPAP) was set at a minimum of 5 cmH20 during the first hour, gradually increasing until there was a clinical improvement. Fraction inspiratory of oxygen (FiO2) was applied to maintain a transcutaneous arterial oxygen saturation (SaO2) of 92%-94%. NIV was continuously applied until there was a clinical and/or a gasometrical improvement, at which time they were replaced by a Venturi mask with FiO2 of 0.4.
3471082|NCT03872752|Experimental|Lay leader training in FL intervention|Community lay leaders from pre-existing community frameworks will undergo training in a manualized program that enables lay leaders to effectively disseminate food literacy skills through engaging visual and game-based tools in a food literacy workshop. Post training, lay leaders will implement the food literacy workshop in their communities.
3471083|NCT03872635|Experimental|CHO Drinking Grope|receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
3471084|NCT03872635|No Intervention|Traditional fast Grope|fast on standard hospital protocol (8 hour fasting for solid and 4 hour fasting for clear liquid
3471085|NCT03872986|Experimental|SDF+Giomer|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Beautifil II restorative material
3471086|NCT03872986|Experimental|Giomer only|Beautifil II dental restorative material
3125364|NCT02977572|Placebo Comparator|Continuous Positive AirwayPressure CPAP|The CPAP was applied by using a flow generator with adjustable fractional inspired oxygen (FiO2). This was connected to the Positive End-Expiratory Pressure (PEEP) valve that was placed in the face mask. In the second instance, the CPAP system that was used was a Boussignac CPAP System Flow Jet. The Boussignac valve takes gas from a single source and splits it in order to create four high flow jets. These jets converge in the chamber creating a virtual valve. A initial level of 5cmH20 of PEEP was recommended for the first hour of ventilation, with subsequent increments (up to 15cmH20) until a clinical improvement was obtained. CPAP was continuously applied until there was a clinical and/or a gasometrical improvement, at which time it was replaced by a Venturi mask.
3125365|NCT02978157|Active Comparator|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., and levofloxacin 500 mg o.d.
3125366|NCT02978157|Experimental|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
3471087|NCT03872986|Experimental|SDF+GIC|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI) + Equia forte
3471088|NCT03872986|Experimental|GIC only|Equia forte dental restorative material
3471089|NCT03872804|Experimental|Vitiligo patient|Patient has at least 4 patches , one of them will be treated by autologous punch graft , second one by transverse needling , third one with minigraft followed by needling , fourth one as control under treatment with oral pulse steroid with narrow band .
3471090|NCT03872739|Experimental|distilled water|Oral distilled water at the rate of 3 mL/kg/h rate during undergoing enhanced computed tomography examination before 1-2 and after 4-6 hours
3471091|NCT03872739|Placebo Comparator|Saline|intravenous saline hydration at the rate of 1 mL/kg/h rate during undergoing enhanced computed tomography examination before and after 12 hours
3471092|NCT03872856|Active Comparator|BP-ICAN|Participants in the BP-ICAN arm will receive a home blood pressure monitor to be used twice daily for 12 months. Participants' home blood pressure measurements will be shared with their provider and participants will receive a series of text messages including topics on the importance of managing hypertension, reminders to measure blood pressure with their device, and motivational messages on diet and exercise.
3471093|NCT03872856|No Intervention|Control|Participants in the control arm will receive care as usual for the treatment of hypertension
3471094|NCT03872700|Experimental|Intranasal fentanyl|2 mcg/kg INF, administered via intranasal route by atomizer syringe
3471095|NCT03872700|Experimental|Placebo|0.04ml/kg of sterile water, administered via intranasal route by atomizer syringe
3471096|NCT03872830|Experimental|Experimental: group1|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
3471097|NCT03872830|Experimental|Experimental: group2|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
3471098|NCT03872830|Experimental|Experimental: group3|Generic name:Felbinac Trometamol Injection; Placebo:normal saline Dosage form:Injection Dosage:188.5mg Volume:8ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the test drug .
3471099|NCT03872830|Placebo Comparator|Experimental: group4|Generic name:Placebo; Placebo:normal saline Dosage form:Injection Dosage:4ml/injection Volume:10ml Frequency:Multi-dose Duration:1 day. A total of 40 subjects,40 received the placebo.
3471100|NCT03872973|Experimental|Training Group|Neuromuscular training will be performed in this group for 6 weeks.
3471101|NCT03872973|Experimental|Strobe Group|This group will perform neuromuscular training for 6 weeks with a strobe glasses.
3471102|NCT03872973|No Intervention|Control Group|This group will not perform any neuromuscular training program.
3471103|NCT03872596|Experimental|Part A: Sequence 1|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg twice a day (BID) prior to randomization.~Treatment Period:~Participants will receive Seroquel IR (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 11-15."
3125367|NCT02978183|Active Comparator|Group 1|1X ST266 dosed 4 times a day for 8 days
3125368|NCT02978183|Placebo Comparator|Group 2|Placebo dosed 4 times a day for 8 days
3471104|NCT03872596|Experimental|Part A: Sequence 2|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 1-5, Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 6-10 and Seroquel IR (tablet, orally, 300mg, BID) on Days 11-15."
3471105|NCT03872596|Experimental|Part A: Sequence 3|"Titration Period:~All participants will complete the titration period to establish tolerability. Depending on exposure prior to the trial, participants will titrate up to and including a dose of 300mg BID prior to randomization.~Treatment Period:~Participants will receive Quetiapine Formulation B (tablet, orally, 300mg, BID) on Days 1-5, Seroquel IR (tablet, orally, 300mg, BID) on Days 6-10 and Quetiapine Formulation A (tablet, orally, 300mg, BID) on Days 11-15."
3471106|NCT03872596|Experimental|Part B: Sequence 1|Participants will receive Seroquel IR (tablet, orally, 25mg) on Day 1 and Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 4.
3471107|NCT03872596|Experimental|Part B: Sequence 2|Participants will receive Quetiapine formulation established in Part A (tablet, orally, 25mg) on Day 1 and Seroquel IR (tablet, orally, 25mg) on Day 4.
3471108|NCT03872557|Active Comparator|Tyrosine (TYR) depletion, then oral TYR|"TYR supplementation: Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before oral glucose tolerance test (OGTT). On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Visit 2. Placement of intravenous catheter for the collection of serial blood samples and an OGTT with supplementation with oral tyrosine supplement. To supplement the OGTT with Tyrosine, the contents of four (4) L-Tyrosine 500 mg capsule are given 45 minutes before the oral glucose solution is administered. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity."
3471109|NCT03872557|No Intervention|TYR depletion, then no oral TYR|"Subjects will be directed to avoid consumption of L-DOPA and TYR enriched foods for 48 hours before OGTT. On the evening prior to OGTT, subjects will substitute normal meal and snack for three prepackaged tyrosine-phenylalanine-free liquid meals.~Subsequent Visit 3. This visit will consist of placement of intravenous catheter for the collection of serial blood samples and an OGTT without supplementation with oral tyrosine supplement."
3471110|NCT03872583|Experimental|Understanding MRI in MS (website)|Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
3471111|NCT03872583|Active Comparator|Control website|Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
3471112|NCT03872570|Active Comparator|phenylephrine|starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
3471113|NCT03872570|Active Comparator|norepinephrine|starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg
3471114|NCT03872284||1|Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
3125369|NCT02978339|Experimental|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
3471115|NCT03872297|Placebo Comparator|Placebo supplement|Consumption of a non active food complement during 3 months.
3471116|NCT03872297|Active Comparator|Naticol supplement|Consumption of the active food complement during 3 months containing Naticol.
3471117|NCT03872310|Active Comparator|Active comparator|Within group
3471118|NCT03872310|Sham Comparator|Sham comparator|Within group
3471119|NCT03872505|Active Comparator|Chemotherapy + Durvalumab|Arm A: Carboplatin, Paclitaxel and Durvalumab
3471120|NCT03872505|Experimental|Chemo + Durvalumab + Radiation Therapy|Arm B: Carboplatin, Paclitaxel and Durvalumab + Radiation Therapy
3471121|NCT03872245|Experimental|PENS T6 + Probiotics|The patients will receive Probiotics (Adomelle 1caps/12h) associated to PENS T6 during 10 weeks.
3471122|NCT03872245|Active Comparator|PENS T6|The patients will undergo PENS T6 during 10 weeks.
3471123|NCT03872362||Training dataset|No interventions
3471124|NCT03872362||External validation1|No interventions
3471125|NCT03872362||External validation2|No interventions
3471126|NCT03872193|Experimental|Physio Therapy|We intervention this group some routine exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees.
3132683|NCT03445065|Experimental|Cohort 1, Enabled - Eversense XL CGM System|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
3471127|NCT03872193|Experimental|Virtual Reality|This group had physical therapy program plus virtual reality exercises. They had balance exercises, gait training,incline surface gait,bloked surface gait training and recreational activities. Extremity strengthenin exercises,balance exercises and increasing endurance are applied for this amputees. And virtual reality exercises were done for this group. Skiing,kayak, football,rafting and jumping activities were done in this exerciese.
3471128|NCT03872375|Experimental|Intermittent Calorie Restriction + Dietary Counseling|"Participants will be asked to consume a single 530 kilocalorie shake (i.e., High Calorie Boost shake) on a given day for two consecutive days each week. Participants will eat ad libitum during the remaining 5 days. Participants will also receive Registered Dietitian of Nutrition (RDN) consultations about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations in addition to shake consumption.~Subjects are also asked to follow RDN dietary recommendations."
3471129|NCT03872375|Active Comparator|Dietary Counseling|A Registered Dietitian of Nutrition (RDN) will consult with subjects about dietary modifications to induce moderate weight loss. Participants will utilize these recommendations.
3471130|NCT03872336|Experimental|Experimental labetalol dose|Subjects receive 40mg, 60mg 80mg in succession after each severe BP
3125370|NCT02978417|Active Comparator|Vivitrol|All drug court clients in the pilot RCT will receive standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Participants randomized to Vivitrol® will receive standard treatment along with monthly Vivitrol® injections administered by study staff at outpatient visits. Vivitrol® is naltrexone for extended-release injectable suspension. It is an injectable suspension containing 380 mg of naltrexone in a microsphere formulation and 4 mL diluent. The recommended dose of Vivitrol® is 380 mg delivered intramuscularly every 4 weeks or once a month. The injection should be administered by a healthcare provider as an intramuscular (IM) gluteal injection, alternating buttocks for each subsequent injection (see Links section of PRS for more information about Vivitrol).
3179194|NCT00670345|Experimental|1|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
3471131|NCT03872336|Active Comparator|Current standard of care|Subjects receive 20mg, 40mg 80mg in succession after each severe BP
3471132|NCT03872453|Active Comparator|Arm 1 - BHV-3500 (zavegepant) 5 mg|One dose of 5 mg
3471133|NCT03872453|Active Comparator|Arm 2 - BHV-3500 (zavegepant) 10mg|One dose of 10 mg
3179195|NCT00670345|Placebo Comparator|2|Patients belonging to the control group will receive the same volume of saline infusions.
3179196|NCT00670371||1|Patients having the following diagnoses are eligible for inclusion into the study: schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, affective psychosis with mood incongruent delusions, psychotic disorder not otherwise specified or patients being actively psychotic.
3471134|NCT03872453|Active Comparator|Arm 3 - BHV-3500 (zavegepant) 20mg|One dose of 20mg
3471135|NCT03872453|Placebo Comparator|Arm 4 - Matching BHV-3500 (zavegepant) Placebo|One dose of placebo
3471136|NCT03872271|Experimental|Experimental|ileal pouch-anal anastomosis without diverting loop ileostomy
3179197|NCT00670371||2|Closest relative(s) /informal caregiver(s)
3179198|NCT00670384|Active Comparator|Dose Group A|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
3471137|NCT03872271|Active Comparator|Control|ileal pouch-anal anastomosis with diverting loop ileostomy
3471138|NCT03872349|Experimental|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 7.1% from saturated fat; 20.7% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
3471139|NCT03872349|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 14.4% from monounsaturated fat; 7.2% from n-6 polyunsaturated fat).
3471140|NCT03873415|Experimental|Formulation A|Dosage formulation and area of release varies between arms
3471141|NCT03873415|Experimental|Formulation B|Dosage formulation and area of release varies between arms
3471142|NCT03873415|Experimental|Formulation C|Dosage formulation and area of release varies between arms
3471143|NCT03873415|Experimental|Formulation D|Dosage formulation and area of release varies between arms
3471144|NCT03873415|Experimental|Formulation E|Dosage formulation and area of release varies between arms
3471145|NCT03873415|Experimental|Formulation F|Dosage formulation and area of release varies between arms
3471146|NCT03873415|Experimental|Formulation G|Dosage formulation and area of release varies between arms
3471147|NCT03873415|Experimental|Formulation H|Dosage formulation and area of release varies between arms
3471148|NCT03873532|Experimental|Active group|300 mg of surufatinib is given by oral administration once a day (QD) every 3 weeks;
3471149|NCT03873532|Active Comparator|Control group|In each 3-week cycle, Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID) for 2 weeks, followed by 1 week rest period (equivalent to 2500 mg/m2 total daily dose).
3471150|NCT03872219|Placebo Comparator|Placebo|The children will receive and they are exposed daily to harmless materials that look and feel like the biodiversity intervention materials.
3179199|NCT00670384|Active Comparator|Dose Group B|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)
3179200|NCT00670384|Placebo Comparator|Placebo|
3179201|NCT00670397|Experimental|Treatment (PDT)|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3179202|NCT00670410|Experimental|Arm A - Related Donor|Related donor transplant: Patients with a related donor (5/6 or 6/6 HLA matched) will receive immunotherapy with a non-myeloablative preparative regimen of Busulfan and Fludarabine followed by allogeneic stem cell transplant (AlloSCT).
3471151|NCT03872219|Experimental|intervention arm|The children will receive and they are exposed daily to materials of high microbiological biodiversity.
3471152|NCT03872323|Active Comparator|Endovascular treatment|
3471153|NCT03872323|Active Comparator|Open surgery|
3125371|NCT02978417|Active Comparator|Oral naltrexone|Subjects randomized to oral naltrexone in addition to standard psychosocial treatment for opioid dependence from FHR as part of their drug court program participation. Oral naltrexone is the daily tablet formulation naltrexone that carries the same risks and benefits as the long-acting injectable formulation (Vivitrol®), except it does not have any of the risks related to injection (discomfort, potential for infection). Oral naltrexone is administered and provided by FHR to interested and eligible clients as part of the range of their usual care services.
3125372|NCT02978508|Experimental|Permethrin Cream, 5%|Permethrin Cream 5%, topical cream, 60g, maximum of two doses over 28 day treatment duration.
3125373|NCT02978508|Active Comparator|Elimite|"Elimite™ 60g, topical, marketed by Prestium Pharma, Inc. (Prestium), the branded subsidiary of Renaissance Pharma, maximum of two doses over 28 day treatment duration."
3125374|NCT02978781|Experimental|Part A: SAGE-217 Oral Solution|Participants received SAGE-217 10 mg oral solution on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7 with food in the morning.
3125375|NCT02978781|Experimental|Part A: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2 and 30 mg on Days 3 to 7, orally, with food in the morning.
3125376|NCT02978781|Placebo Comparator|Part B: Placebo|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 matching placebo for 7 days beginning on Day 8 with food in the morning.
3125377|NCT02978781|Experimental|Part B: SAGE-217 Capsules|Participants who received maximum tolerated dose of SAGE-217 in Part A and achieved response on Day 8 were randomized to receive to SAGE-217 for 7 days beginning on Day 8 with food in the morning.
3125378|NCT02978781|Experimental|Part C: SAGE-217 Capsules|Participants received SAGE-217 10 mg capsules on Day 1, 20 mg on Day 2, 30 mg on Day 3, orally, with food in the evening. Beginning on Day 4 through Day 14, participants received a 40-mg total daily dose (administered as 10 mg with food in the morning and 30 mg with food in the evening).
3125379|NCT02979054|Experimental|T4020|1 drop every other day during 5 days
3125380|NCT02979054|Placebo Comparator|Saline solution|1 drop every other day during 5 days
3125381|NCT02979197|Experimental|Amlodipine+Celecoxib|OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
3471154|NCT03872232|Experimental|Ezetimibe/Rosuvastatin and Telmisartan|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin and Telmisartan for 8 weeks."
3471155|NCT03872232|Active Comparator|Ezetimibe/Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Ezetimibe/Rosuvastatin for 8 weeks."
3125382|NCT02979197|Active Comparator|Amlodipine+Placebo|OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
3125383|NCT02979197|Sham Comparator|Placebo+Placebo|Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
3471156|NCT03872232|Active Comparator|Telmisartan|"60 subjects will be assigned and the subjects will be administered Telmisartan for 8 weeks."
3471157|NCT03872258|Active Comparator|Control|Counseling on physical activity
3471158|NCT03872258|Experimental|Intervention|Add an intensive program of combined exercise for 6 months and use during this period a Smartband, in order to encourage and increase physical activity and decrease sedentary lifestyle
3471159|NCT03872206|Experimental|HPN536-2001 - Part 1 (Dose Escalation)|Part 1 (Dose Escalation): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic adenocarcinoma, or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion with a fix dose. Dose escalation per cohort until an estimated therapeutic dose level has been reached.
3471160|NCT03872206|Experimental|HPN536-2001 - Part 2 (Dose Expansion)|"Part 2 (Dose Expansion): will include eligible patients with epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, malignant mesothelioma, pancreatic adenocarcinoma or malignant mesothelioma. HPN536 will be administered once weekly via IV infusion.~Group 1: Eligible patients with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.~Group 2: Eligible patients with pancreatic adenocarcinoma.~Group 3: Eligible patients with mesothelioma."
3471161|NCT03872167|Active Comparator|MANUAL|Manual titration of non-invasive mechanical ventilation using polysomnography and randomized
3471162|NCT03872167|Active Comparator|AUTOMATIC|Automatic titration of the non-invasive mechanical ventilation using the same device in an automatic mode with assured volume and pressure support.
3125384|NCT02979249|Experimental|Oral Iron|standard dose of iron pills
3125385|NCT02979262|Experimental|Fathers for Change|Fathers for Change treatment begins with individual-focused sessions followed by co-parenting focused sessions and ending with restorative parenting sessions. The areas of focus for each of the three phases of Fathers for Change are: 1) abstinence from SA and violence; 2) co-parenting; 3) parenting/father-child relationship. Treatment begins with motivational enhancement by focusing the role of men as fathers to their young children, child development and the impact of violence and SA on parenting, and the father's own childhood experiences of SA and violence to highlight the multigenerational nature of these problems. The program then focuses on skills training in the following areas: reducing automatic hostile cognitions and increasing emotion regulation skills, 2) communication and problem solving around co-parenting, and 3) restorative parenting.
3471163|NCT03872154|Experimental|Intervention|"In this group (intervention), physicians will conduct checklist-guided shared decision making to determine the patient's code status. Additionally, physicians will be given a decision aid, which they are told to use to illustrate impact and outcome of in-hospital cardiac arrests.~Ancillary project (patients considered as futile): In this group (intervention), physicians will conduct checklist-guided communication."
3471164|NCT03872154|No Intervention|Usual Care|In this group (control), physicians will conduct code status discussions as usually.
3471165|NCT03872388|Experimental|Group I (atorvastatin)|Patients receive standard of care atorvastatin PO QD for up to 24 months.
3471166|NCT03872388|Active Comparator|Group II (capecitabine)|Patients not eligible to receive atorvastatin, will be enrolled into non-statin observation group with/without capecitabine treatment.
3471167|NCT03872180|Experimental|Venetoclax, bendamustine, obinutuzumab|Patients receive venetoclax PO on days 1-28 of course 1 and days 1-10 of subsequent courses, bendamustine IV on days 1 and 2, and obinutuzumab IV on days 1, 8, and 15 of course 1 and day 1 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unaccepted toxicity.
3471168|NCT03872141||patients with stage I-III breast cancer|Patients with Stage I-III breast cancer who will receive paclitaxel or docetaxel treatments as part of their standard of care adjuvant or neoadjuvant therapy are eligible for this study.
3471169|NCT03872128|Active Comparator|patients receiving 300mg PREG|30 patients randomly assigned to receive 300mg of pregnenolone (PREG) daily.
3471170|NCT03872128|Active Comparator|patients receiving 500mg PREG|30 patients randomly assigned to receive 500mg of pregnenolone (PREG) daily.
3471171|NCT03872128|Placebo Comparator|placebo|30 patients randomly assigned to receive a placebo daily.
3471172|NCT03872024|Experimental|Morbidly obese adult patients|Only one group of patients in the study: morbidly obese adult patients who will have an examination with the XXL probe prototype of the FibroScan 630 Research Model
3471173|NCT03871933||AECOPD|acute exacerbation of COPD
3471174|NCT03871933||stable COPD|
3471175|NCT03872076|Experimental|Plyometric exercises|The subjects included in the experimental group will carry out an intervention using plyometric exercises and isometric exercises with elastic band for the quadriceps muscle. Each session will last 15 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
3471176|NCT03872076|Active Comparator|Isometric exercises|The subjects included in the experimental group will carry out an intervention of isometric exercises with elastic bands for the quadriceps muscle. Each session will last 8 minutes, taking place for 3 days a week, in a period of 8 weeks. The intervention will be made at the beginning of the training session.
3471177|NCT03872050||Rosacea|Patients who have been diagnosed with rosacea
3471178|NCT03872050||Migraine|Patients who have been diagnosed with migraine
3471179|NCT03871881||Atrial septal defect|Patients with an open atrial septal defect, diagnosed in childhood
3471180|NCT03871881||Ventricular septal defect|Patients who had surgical closure of a ventricular septal defect in childhood
3471181|NCT03871881||Healthy control|Healthy, young adults matched on age, gender and education
3471182|NCT03871972|Experimental|UCB injection group|This pilot study includes only 2 subjects who are enrolled by invitation. Both subjects are included in this single arm.
3471183|NCT03871959|Experimental|Pembrolizumab + Debio 1143|"Pembrolizumab : 200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.~Debio 1143 : 3 escalating dose level (100 mg, 150 mg, 200 mg) administered daily for 14 days over a 21-day cycle period."
3471184|NCT03871894|Active Comparator|Control arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy as per the standard enteral nutritional practice in a critical care setting in cirrhotics till the period admitted in ICU(Intensive care unit) 35-40 Kcal/Kg IBW/day; 1.5-2g protein per kg per day.
3471185|NCT03871894|Experimental|Intervention arm|This is the group of critically ill cirrhotic patients on mechanical ventilator support who would receive the nutritional therapy based on indirect calorimetry measurements till the period admitted in ICU(Intensive care unit)
3471186|NCT03871842|Active Comparator|active tDCS|20-minute of daily anodal stimulation (2mA) above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
3471187|NCT03871842|Sham Comparator|sham tDCS|20-minute of daily sham stimulation above the left dorsolateral prefrontal cortex during 5 days per week for 4 weeks.
3471188|NCT03871998|Experimental|Interventional arm|Skin barrier protection in the first 2 months of life.
3471189|NCT03871998|No Intervention|Control arm|Standard skincare advice. No moisturiser in the first 2 months.
3471190|NCT03871907|Active Comparator|Digital technology|standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week
3471191|NCT03871907|No Intervention|Control|standard cardiac rehabilitation program
3471192|NCT03872037|Active Comparator|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
3471193|NCT03872037|Experimental|Selective removal of caries and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
3471194|NCT03872011|Experimental|Vitamin C,thiamine,hydrocortisone|"The combination of vitamin C, thiamine, hydrocortisone :~Vitamin C 2g every 6 hours x 5-days Thiamine 200mg every 12 hours x 5-days Hydrocortisone 200mg as a continuous infusion x 5-days"
3471195|NCT03872011|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
3471196|NCT03871855|Experimental|A:SHR-1702 Dose Escalation|SHR-1702 given intravenously (IV).
3471197|NCT03871855|Experimental|B:SHR-1702 Dose Expansion|SHR-1702 given intravenously (IV).
3471198|NCT03871855|Experimental|C:SHR-1702 and Camrelizumab Dose Escalation|SHR-1702 and Camrelizumab given intravenously (IV).
3471199|NCT03871855|Experimental|D:SHR-1702 and Camrelizumab Dose Expansion|SHR-1702 and Camrelizumab given intravenously (IV).
3471200|NCT03872115|Experimental|Setting 1|PDVibe2 set to high frequency and low amplitude
3471201|NCT03872115|Experimental|Setting 2|PDVibe2 set to high frequency and medium amplitude
3471202|NCT03872115|Experimental|Setting 3|PDVibe2 set to high frequency and high amplitude
3471203|NCT03872115|Experimental|Setting 4|PDVibe2 set to medium frequency and low amplitude
3471204|NCT03872115|Experimental|Setting 5|PDVibe2 set to medium frequency and medium amplitude
3471205|NCT03872115|Experimental|Setting 6|PDVibe2 set to medium frequency and high amplitude
3471206|NCT03872115|Experimental|Setting 7|PDVibe2 set to low frequency and low amplitude
3471207|NCT03872115|Experimental|Setting 8|PDVibe2 set to low frequency and medium amplitude
3471208|NCT03872115|Experimental|Setting 9|PDVibe2 set to low frequency and high amplitude
3471209|NCT03871725|Experimental|Sonodynamic therapy(SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure.
3471210|NCT03871985|Experimental|Lavage combined with aspiration|Intermittent subglottic secretions lavage combined with aspiration
3471211|NCT03871985|Active Comparator|Pure aspiration|Intermittent subglottic secretions aspiration
3471212|NCT03871738|Experimental|Proprioception training|The subjects included in the experimental group will carry out a protocol of proprioception exercises. Each session will last 25 minutes, taking place during 2 sessions a week, in a period of 4 weeks. All interventions will be made before the training session.
3471213|NCT03871738|No Intervention|Control|The subjects included in the control group will not receive intervention and will continue to carry out their daily life in the same way as they have done up to now.
3471214|NCT03871777|Active Comparator|Vegetarians|Healthy vegetarians (vegans and lacto-ovo vegetarians) 18 and 50 years formed this arm.
3125386|NCT02979262|Active Comparator|Parent Education (PE)|PE is an individual intervention.PE was developed to represent parent education and support that is typically available to parents with substance use problems who are at high risk for neglecting their children. Fathers enrolled in PE will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed for work with substance abusing parents. Sample pamphlet topics include routines and rituals, ages and milestones, alternatives to spanking, and nutrition and fitness.
3125387|NCT02979301|Experimental|Tamoxifen 5 mg/day|Women with high background uptake on MBI take 5 mg tam per day for 30 days.
3471215|NCT03871777|Sham Comparator|Omnivores|Healthy omnivores with similar characteristics of vegetarians (age, body mass index, gender and physical activity levels) formed this arm
3471216|NCT03871621|Experimental|Previous diabetic medical treatment & Dapagliflozin|Previous diabetic medication add on SGLT2 inhibitor (Dapagliflozin 10 mg) daily for 6 months
3471217|NCT03871621|Active Comparator|Previous diabetic medical treatment & standard care|Previous diabetic medication with drug adjustment by standard diabetes care except SGLT2 inhibitors for 6 months
3471218|NCT03871790||Participants with colorectal cancer|Participants with colorectal cancer ongoing surgery older than 18 years old.
3471219|NCT03871790||Participants with pancreatic cancer|Participants with pancreatic cancer ongoing surgery older than 18 years old.
3471220|NCT03871660|Other|Patients with diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
3471221|NCT03871660|Other|Patients without diabetes on TPN|Glucose levels will be monitored using the FreeStyle Libre devices over a 14 day period. In this time the patient will receive TPN.
3471222|NCT03871582||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
3471223|NCT03871699|Experimental|Iron Reposition|The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.
3471224|NCT03871803|Active Comparator|Arm A|"Controlled Withdrawal of Beta-blockers and Cardiopulmonary Exercise Testing (CPET) Patient will be assessed for chronotr0pic incompetence by CPET. If the patient exhibits chronotropic incompetence, we will reduce half dose of previous beta-blocker.~A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day.~After second CPET, the patient will introduce the half-dose of beta-blocker and will be evaluated in 3 days. If clinical stability, the patient will introduce the previous dose of beta-blocker A third CPET will be performed at 15-day"
3471225|NCT03871803|Active Comparator|Arm B|"Cardiopulmonary Exercise Testing (CPET) and Controlled Withdrawal of Beta-blockers Patient will be assessed for chronotropic incompetence by CPET.If the patient exhibits chronotropic incompetence, a cardiologist will evaluate clinically the patient and the heart rate in 3 days and will be assessed by CPET at 15-day.~After second CPET, the patient will reduce half dose of previous beta-blocker. A cardiologist will evaluate clinically the the patient and the heart rate in 3 days. If clinical and heart rate stability (below 90 bpm), the patients will withdraw the beta-blocker and will be assessed by CPET at 15-day."
3471226|NCT03871920||intervention|any kind of condition treated by physiotherapists, physical therapy treatment is chosen by treating physiotherapist
3471227|NCT03871946||Experimental group|"Experimental group subjects with impaired fasting glucose (IFG) (Group 1) underwent an oral glucose tolerance test (OGTT), and patients with levels > 140 mg/dL at the 2nd hour were excluded because they were diagnosed with impaired glucose tolerance"
3471228|NCT03871946||control group|The control group (Group 2) comprised 73 patients whose fasting blood glucose level was <100 mg/dL and who agreed to participate in the study.
3471229|NCT03871504|Experimental|submaximal isometric exercise.|submaximal isometric exercise will be performed.
3471230|NCT03871504|No Intervention|Quiet rest.|Subject will rest in seating position for a period that mimics the exercise time.
3125388|NCT02979301|Experimental|Tamoxifen 10 mg/day|Women with high background uptake on MBI take 10 mg tam per day for 30 days.
3125389|NCT02979431|Experimental|ALX-0171 3.0 mg/kg|Inhalation of ALX-0171 3.0 mg/kg once daily for 3 consecutive days
3471231|NCT03871712|Experimental|Motivational Interview (MI)|In the MI arm, a NAV case worker will meet the participants after the baseline assessment (electronic questionnaires) and randomisation and conduct the MI. The NAV case-worker will either meet (or call) again after a few weeks (anticipated 2-4 weeks) and conduct another MI.
3125390|NCT02979431|Experimental|ALX-0171 6.0 mg/kg|Inhalation of ALX-0171 6.0 mg/kg once daily for 3 consecutive days
3125391|NCT02979431|Experimental|ALX-0171 Dose 9.0mg/kg|Inhalation of ALX-0171 9.0 mg/kg once daily for 3 consecutive days
3125392|NCT02979431|Placebo Comparator|Placebo|Inhalation of Placebo once daily for 3 consecutive days
3471232|NCT03871712|Active Comparator|Stratified vocational advice intervention (SVAI)|A trained physiotherapist will call the participants after the baseline assessment and randomisation. The SVAI intervention will be stratified due to the participants risk of long term sick leave estimated by the Orebro Screening Questionnaire and The Keele STarT MSK Tool. The low/moderate risk group will receive 1-2 phone calls, and the high risk group will be followed up 2-4 times. The follow-up can include face to face Meetings bewteen the Physical therapist and the participant, and also the employer and general practitioner when needed. The intervention will include an assessment of the participants obstacles for returning to work and help to develop and implement an action plan to overcome obstacles. The physical therapists' will cooperate with other health care providers and employer when needed.
3471233|NCT03871712|No Intervention|Usual follow-up|This arm will be the control group receiving usual NAV follow-up. The other two groups will also receive usual NAV follow-up additionally to the interventions.
3471234|NCT03872063|Experimental|Myofascial|Each session will last 17 minutes, taking place for 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the technique of myofascial induction and eccentric exercises will be performed.
3471235|NCT03872063|Active Comparator|Eccentric|Each session will have a duration of 9 minutes, taking place during 1 day a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session. After the training, the eccentric exercises will be performed.
3125393|NCT02979444|Experimental|Mothers and Babies Groups Home-Visitor|Women who participate in the home-visitor led arm will receive the intervention from a paraprofessional home-visitor and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
3125394|NCT02979444|Experimental|Mothers and Babies Groups Clinician|Women who participate in the mental health consultant led arm will receive the intervention from a mental health consultant and complete assessments at baseline, post-intervention, and 12 and 24 weeks postpartum.
3125395|NCT02979444|No Intervention|Control|Women who participate in the control arm will not receive the intervention but will complete assessments at baseline, 8 weeks post-baseline, and 12 and 24 weeks postpartum.
3471236|NCT03871517|Experimental|Indobufen|Drug: Indobufen and aspirin mimetic Day 1: The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : Indobufen 100mg + aspirin mimetic The second time: indobufen 100mg
3471237|NCT03871517|Active Comparator|Aspirin|Drug: Aspirin and Indobufen mimetic Day 1:The open labeled aspirin 100mg-300mg. Day 2 to 90±7: The first time : aspirin 100mg+ Indobufen mimetic, The second time: indobufen mimetic.
3471238|NCT03871686|Experimental|Experimental Group|Participants will be asked to complete a brief online program over a 4 to 8-week period. Each week participants will be asked to complete one session of the program online. There are four sessions.
3471239|NCT03871686|No Intervention|Control Group|Participants will receive no intervention from the investigators. Participants may continue services as usual as provided by Children's Brain Tumor Foundation.
3471240|NCT03871530|Experimental|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
3471241|NCT03871530|Experimental|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
3471242|NCT03871530|Experimental|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
3471243|NCT03871530|Experimental|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
3471244|NCT03871530|Experimental|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
3471245|NCT03871530|Experimental|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
3471246|NCT03871530|Experimental|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
3471247|NCT03871530|Experimental|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
3471248|NCT03871530|Experimental|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
3471249|NCT03871530|Experimental|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
3471250|NCT03871530|Experimental|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
3471251|NCT03871530|Experimental|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
3471252|NCT03871530|Experimental|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
3471253|NCT03871530|Experimental|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
3471254|NCT03871673|Active Comparator|Cornstarch|Ingestion of cornstarch, the standard treatment for hepatic GSD.
3471255|NCT03871673|Experimental|Sweet Polvilho|Ingestion of sweet polvilho, the starch in study.
3471256|NCT03871751|Experimental|Safe and Sound Protocol|All child participants will participate in 1 pre-intervention assessment and 1 post-intervention assessment. The auditory intervention (i.e., Safe and Sound Protocol, SSP) will last for 1 hour per day, for 5 consecutive days.
3471257|NCT03871569|Active Comparator|telemedecine nursing home|One buccodental teleexpertise at the completion day and a second buccodental teleexpertise at the end of study
3471258|NCT03871569|No Intervention|control nursing home|Only one buccodental teleexpertise at the end of study
3471259|NCT03871491|Experimental|Intervention|The study intervention is a single 2 g dose of directly observed oral azithromycin.
3471260|NCT03871491|Placebo Comparator|Placebo|By random allocation, participants will receive four oral placebo pills containing a non-antimicrobial agent directly after randomization.
3471261|NCT03871361|Experimental|Abatacept 125 MG/ML Prefilled Syringe|"Participants will inject the drug at home on a weekly basis. Participants will receive the syringes on the visit dates, supplying them for the period until the next visit. At baseline, participants will be explained and shown how to inject the drug themselves.~Subject will have to stop all concomitant immunosuppressive drugs at baseline, e.g. Corticosteroids, Methotrexate, Mofetil Mycophenolate, Azathioprine, Tacrolimus, Sirolimus or Cyclosporin. Other drugs can be continued. In case of recurrence in the abatacept group, the study will end for that subject.~Patients treated with abatacept (ORENCIA) may receive concurrent vaccinations, except for live vaccines. Live vaccines should not be given concurrently with abatacept or within 3 months of its discontinuation."
3471262|NCT03871413|Active Comparator|Manual repositioning maneuver|Diagnostics and treatment of BPPV with manual repositioning maneuvers. In case of posterior canal involvement, Epley's maneuver will be used. In case of horizontal canal involvement, the log roll maneuver will be used.
3471263|NCT03871413|Experimental|Treatment in mechanical rotational chair (TRV-chair)|"Diagnostics and treatment of BPPV with the use of a TRV chair. In case of posterior canal involvement, Epley's maneuver will be used with the addition of 10 kinetic impulses in each position.~In case of horizontal canal involvement, the log roll maneuver will be used with the addition of 10 kinetic impulses in each position."
3471264|NCT03871465|Experimental|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
3471265|NCT03871465|Experimental|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
3471266|NCT03871465|Experimental|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
3471267|NCT03871400|Other|NanoMetalene/PEEK|
3471268|NCT03871400|Other|NanoMetalene/Allograft|
3471269|NCT03871218|Active Comparator|Test Group|Hyaluronic acid application group. After FGG was taken from the donor region in the TG, sterile gauze was applied with moderate pressure for 2 minutes, and HA was applied topically after the bleeding stopped. The cross-linked HA package containing 20 mg/ml Na-hyaluronate, stored at room temperature, was opened, and the protective cap of the syringe was removed.
3471270|NCT03871218|No Intervention|Control Group|In the control group (CG), HA was not applied to the recipient or the donor site.
3471271|NCT03871322|Active Comparator|Vitamin D group|vitamin D supplementation - time to fracture healing
3471272|NCT03871322|Active Comparator|Vitamin D and K2 group|Vitamin D and K 2 supplementation - time of fracture healing
3471273|NCT03871322|Placebo Comparator|Placebo group|Placebo - time to fracture healing
3471274|NCT03871478|Active Comparator|Lidocaine|Buffered lidocaine 1% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
3471275|NCT03871478|Active Comparator|Bupivacaine|Bupivacaine 0.5% with epinephrine 1:200,000 Injected at the start of every Mohs excision stage
3471276|NCT03871478|Active Comparator|Lidocaine and Bupivacaine|"Buffered lidocaine 1% with epinephrine 1:200,000 and bupivacaine 0.5% with epinephrine 1:200,000 injected sequentially.~Injected at the start of every Mohs excision stage"
3471277|NCT03871439|Experimental|PF-05221304 Formulation A|
3471278|NCT03871439|Experimental|PF-05221304 Formulation B|
3471279|NCT03871387|Experimental|Deep Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF = 0 & PTC= 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
3471280|NCT03871387|Active Comparator|Moderate Block Group|"Continuous Rocuronium infusion during surgery~Maintain TOF 1~2~At the end of surgery, IV Sugammadex injection to reverse muscle relaxation. (Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2)"
3471281|NCT03871127||Left main coronary disease|
3471282|NCT03871192|Experimental|FACET JOINT UNDER CT GUIDANCE|Injection of the facet joint under computed tomography guidance
3471283|NCT03871192|Active Comparator|NERVE BLOCK UNDER CT GUIDANCE|Injection of the nerve under computed tomography guidance
3471284|NCT03871192|Experimental|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|Injection of the facet joint under fluoroscopy guidance
3471285|NCT03871192|Active Comparator|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|Injection of the nerve under ultrasound guidance
3471286|NCT03871192|Experimental|FACET JOINT UNDER ULTRASOUND GUIDANCE|Injection of the facet joint under ultrasound guidance
3471287|NCT03871192|Active Comparator|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|Injection of the nerve under computed ultrasound guidance
3471288|NCT03871309||Tigertriever|Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.
3471289|NCT03871452|Active Comparator|ABS in external bleeding|Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
3471290|NCT03871452|Active Comparator|Repetition of ABS stopped bleeding|Repetition of ABS stopped bleeding
3471291|NCT03871205|Experimental|Vaccinated group|Neoantigen loaded-DC vaccination will be performed with 6 doses in total, once per week, adjacent lymph-node injection.
3471292|NCT03871101|Active Comparator|Scalpel|Soft tissue incision with scalpel in second- stage implant surgery.
3471293|NCT03871101|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz H mode, 10% water and 10% air) in second-stage implant surgery.
3471294|NCT03871231|Experimental|Unpinning Termination Therapy Arm|Subjects will have VT/VF induced and the Cardialen External Stimulation System (CESS) device will deliver electrical stimulation to terminate the arrhythmia
3471295|NCT03871036|Experimental|Tremelimumab 75 (R1)|"Run-in phase-1 (R1): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
3471296|NCT03871036|Experimental|Tremelimumab 225 (R2)|"Run-in phase-2 (R2): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 225 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
3471297|NCT03871036|Experimental|Tremelimumab vs Tremelimumab+Durvalumab (R3)|"Run-in phase-3 (R3): n=2 x 3 patients will be randomized over 2 arms:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45~OR~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 75 mg on day 1 of cycles 2-5~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
3471298|NCT03871036|Experimental|Tremelimumab 300 (R4)|"Run-in phase-4 (R4): n=3 patients will be treated with:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
3471299|NCT03871036|Experimental|Tremelimumab 750 (A)|"Arm A:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 750 mg on day 1 of cycles 2-6 and then every 12 weeks until week 45"
3471300|NCT03871036|Experimental|Tremelimumab+Durvalumab (B)|"Arm B:~paclitaxel 70 mg/m2 on day 1, 8, 15 of cycles 1-6~tremelimumab 300 mg once on day 1 of cycle 2~durvalumab 1500 mg on day 1 of cycles 2-12, every four weeks (until week 49)"
3471301|NCT03871036|Experimental|Tremelimumab without paclitaxel (C)|"Arm C (control arm):~• tremelimumab 750 mg on day 1 of cycles 1-5 and then every 12 weeks until week 41"
3471302|NCT03871062|Active Comparator|topical anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
3471303|NCT03871062|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
3132513|NCT03433794|Active Comparator|Intervention Only|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Their email 2 weeks later contained only a reminder to participate in follow-up surveys.
3471304|NCT03871049|Placebo Comparator|group 1|intathecal bupivacaine
3471305|NCT03871049|Active Comparator|group 2|intrathecal bupivacaine with dexamethasone
3471306|NCT03871114||OLP patients|fifteen patients with atrophic /erosive OLP will receive treatment with topical triamcinolone acetonide in orabase 1mg/g 3 times /day and assessed every week for 4 weeks
3471307|NCT03871114||Control group|
3471308|NCT03870880|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during the open label extension.
3471309|NCT03870880|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during the open label extension.
3471310|NCT03870932|Experimental|Motor imagery rehabilitative group (MIG)|"All patients performed 10 treatment sessions, lasting 60 to 90 minutes, twice a week, in groups of three to four patients. The gold standard was to choose simple and safe exercises in order to encourage the patient to repeat the schedule at home. The exercises proposed in the MIG have been chosen respecting the following principles: slowness, painlessness, promoting attention, easy to imagine. The main purpose of motor imagery-based exercises was to bring the patient back to feeling and self-perceiving the execution of the movement. More than the quantity of repetition, the quality of the movement, free from pain, was important."
3471311|NCT03870932|Active Comparator|Control rehabilitative Group (CG)|The CG received a conventional rehabilitation protocol, based on ten 1-hour sessions, held twice a week (over a 5-week period), previously investigated as efficient in FM by the authors and published. The exercises included low-to-moderate impact aerobic training, walking in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes), for a total of 20 consecutive minutes, posture exercises for the back and proprioceptive exercises for the trunk, to improve axial stability. Each exercise was repeated 10 times (3 sets of 10), with a resting period of at least 3 minutes between sets. All sessions ended with stretching and diaphragmatic breathing exercises.
3471312|NCT03870958|Experimental|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
3471313|NCT03870958|Active Comparator|Control|Children allocated to this group will receive the same dietary advices and brushing instructions described in the control arm.
3471314|NCT03871153|Other|Treatment|Neoadjuvant chemotherapy(Durvalumab, Paclitaxel, Carboplatin), radiation and immunotherapy (durvalumab) followed by surgical resection followed by adjuvant immunotherapy (durvalumab)
3471315|NCT03871010||Neutropenia patients, Dept. of Haematooncology|Patients with neutropenia from the Department of Haematooncology were included in this group.
3471316|NCT03871010||No neutropenia patients, Dept. of Haematooncology|Patients without neutropenia from the Department of Haematooncology were included in this group.
3471317|NCT03871010||No neutropenia patients, other clinical depts.|Patients with neutropenia from the other clinical departments of the University Hospital Ostrava were included in this group.
3471318|NCT03870906|Experimental|WhatsApp interaction|Individual and group chat interactions.
3471319|NCT03870906|Placebo Comparator|Text message|Regular text messages with similar frequency to those in the Intervention group.
3471320|NCT03870984|Experimental|wNUTS, low-caloric diet plus nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
3471321|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low-caloric diet personalized on single children's requirements plus nuts (15g hazelnuts+15g nuts without shell) for 3 months.
3471322|NCT03870854|Experimental|PEFA targeted substrate ablation|Use of PEFA strategy to identify and target VT isthmuses.
3471323|NCT03870919|Other|Palbociclib + locoregional treatment|All patients will receive the standard of care treatment ie Palbociclib + letrozole for 24-26 weeks. After this period, patient will have the most adapted locoregional treatment ie surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy. The palbociclib will be continued until progression
3471324|NCT03871088|Active Comparator|Eicosapentaenoic acid (EPA)|Eicosapentaenoic acid (EPA) is an omega-3 fatty acid. In physiological literature, it is given the name 20:5(n-3).
3471325|NCT03871088|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) is an omega-3 fatty acid. In physiological literature, it is given the name 22:6(n-3).
3471326|NCT03871088|Active Comparator|EPA/DHA combination|EPA/DHA means the combination of omega-3 fatty acids Eicosapentaenoic and Docosahexaenoic acids.
3471327|NCT03870867||Seniors who have fallen|Emergency department patients over the age of 65 who present to the emergency department after a fall.
3471328|NCT03871244|Experimental|Restrictive arm (intervention)|Less red blood cell transfusions. The protocol will require that no red blood cell transfusion be given unless the hemoglobin level is below or equal at 70 g per L.
3471329|NCT03871244|Active Comparator|Standard care arm (comparator)|Clinical teams will follow their usual transfusion practices.
3471330|NCT03870945|Experimental|Dose level 1 with 1x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 1x10^6 MBCART2019.1 per kg BW in a single infusion. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
3471331|NCT03870945|Experimental|Dose level 2 with 2.5x10^6 MBCART2019.1 per kg BW|The IMP will be administered as an intravenous infusion. This is a 6+3 trial arm with 2.5x10^6 MBCART2019.1 per kg BW in a single infusion and maximum 2 dose levels. If none or one of the six patients at dose level 1 experiences a dose limiting toxicity, another six patients will be treated at dose level 2. If two DLTs are observed at dose level 1 another three patients will be treated with the same dose. If more than two DLTs are observed at dose level 1, trial will continue at dose level 0. Dose escalation continues until at least >2 patients among a cohort of six to nine patients experience dose-limiting toxicities or dose level 2 is completed. The MTD is defined as the dose level below the dose inducing a DLT in more than 2 patients within one dose level.
3471332|NCT03870828||Study group IPAF|"Patients with IPAF which is defined according to the Work Group of the European Respiratory Society/American Thoracic Society.~The interventions to be administered include:bronchoalveolar lavage and taking bronchial mucosa samples lung function tests,6 minute walk test, use of cough and dyspnea scales, transthoracic echocardiography, blood testing, arterial blood gas and pulse oximetry"
3471333|NCT03870828||Control group CTD-ILD|Patients with connective tissue disease associated intestitial lung disease: rheumatoid arthritis - RA, systemic sclerosis - SSc, polymyositis - PM, dermatomyositis - DM, (anti-synthetase syndrome - AS, Sjögren's syndrome - SjS, mixed connective tissue disease - MCTD ,systemic lupus erythematosus - SLE, diagnosed according to diagnostic criteria issued by European League Against Rheumatism (EULAR) and/or American College of Rheumatology (ACR)
3471334|NCT03870828||Control group ILD|Idiopathic interstitial pneumonia group: idiopathic pulmonary fibrosis - IPF, nonspecific interstitial pneumonia - NSIP, cryptogenic organizing pneumonia - COP, acute interstitial pneumonia - AIP; respiratory bronchiolitis associated interstitial lung disease - RB-ILD, desquamative interstitial pneumonia - DIP, lymphocytic interstitial pneumonia - LIP).
3471335|NCT03871075|Experimental|IPC + exercise|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be helped to engage in home-based walking exercise therapy.
3471336|NCT03871075|Experimental|"IPC + no exercise control"|Participants will be asked to wear the intermittent pneumatic compression device for up to three hours daily. They will be asked to participate in an educational/informational intervention consisting of an attention control intervention
3471337|NCT03871075|Active Comparator|sham control + exercise|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants in this group will be helped to engage in home-based walking exercise therapy.
3471338|NCT03871075|Active Comparator|"sham control + no exercise control"|Participants will be asked to wear a sham intermittent pneumatic compression device for up to three hours daily. The sham device inflates at the same frequency, but to a much lower systolic pressure, compared to the therapeutic pneumatic compression device. Participants will be asked to participate in an educational/informational intervention, designed as an attention control group.
3471339|NCT03870841|Experimental|PC945|PC945 5mg once daily
3471340|NCT03870815||CABG|Patients with CAD who undergoing CABG
3471341|NCT03870815||PCI|Patients with CAD who undergoing PCI with second-generation DES
3125396|NCT02979522|Experimental|Brentuximab vedotin 48 mg/m^2|Brentuximab vedotin 48 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 15 of each 28-day cycle approximately 1 hour after administration of doxorubicin 25 mg/m^2, vinblastine 6 mg/m^2, and Dacarbazine 375 mg/m^2, intravenous infusion, once on Day 1 and 15 of each 28-day cycle for up to 6 cycles. If the first 6 participants complete the dose limiting toxicity (DLT) observation period with 0 or 1 participant experiencing a DLT, 48 mg/m^2 will be established as the recommended dose for phase 2 study. If at any time more than 1 participant out of a maximum 6 DLT-evaluable participants experiences a DLT, brentuximab vedotin dose will be reduced to 36 mg/m^2. If 0 or 1 participant experiences a DLT among the 6 participants treated at 36 mg/m^2, 36 mg/m^2 will be established as recommended dose for phase 2 study. If more than 1 participant experiences a DLT in the first 6 participants treated at 36 mg/m^2, the study will be discontinued.
3125397|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Concomitant Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12 and 2 doses of Cervarix vaccine 0.5 mL Intramuscularly (IM) concomitantly with the 2 first doses of CYD dengue vaccine.
3125398|NCT02979535|Experimental|CYD Dengue Vaccine + Cervarix (Sequential Administration)|Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13 along with the 2 doses of Cervarix vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the 2 first doses of CYD dengue vaccine.
3125399|NCT02979613|Experimental|TAF 25 mg|Double-blind (DB) phase: TAF 25 mg + TDF placebo for up to 53 weeks. Open-label extension (OLE) phase: TAF 25 mg for up to 52 weeks.
3125400|NCT02979613|Active Comparator|TDF 300 mg|DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
3125401|NCT02979626||Moderate-to-severe Influenza|"Children 6 weeks to 8 years of age with influenza-like illness and one of the following:~Fever >39~Lower respiratory tract infection~Acute otitis media~Serious extra-pulmonary manifestations (myositis, encephalitis)"
3471342|NCT03870763|Experimental|Dimethyl Fumarate 240 mg|Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
3471343|NCT03870763|Experimental|Peginterferon Beta-1a 125 µg|Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
3471344|NCT03870763|Placebo Comparator|Placebo|Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)
3471345|NCT03871023|Active Comparator|Simple dressing|Standard, waterproof dressing applied to wound
3471346|NCT03871023|Active Comparator|PICO Dressing|Negative Wound pressure applied second cohort
3471347|NCT03871023|Active Comparator|PREVENA Dressing|Negative wound presure applied to third cohort
3125402|NCT02979626||Mild Influenza|Children 6 weeks to 8 years of age with influenza-like illness (ILI) without the criteria for moderate-to-severe disease (above)
3125403|NCT02979639|Experimental|GSK1437173A Group|Subjects ≥ 50 years of age who will receive two doses of the GSK1437173A vaccine (first dose given at Month 0 and second dose given 2 months later) in this study.
3125404|NCT02979899|Experimental|TRC105 plus votrient|weekly TRC105 i.v. in combination with standard dose votrient by mouth, once daily
3125405|NCT02979899|Active Comparator|votrient|standard dose votrient by mouth, once daily
3471348|NCT03870776|Placebo Comparator|Placebo|Patients will receive the placebo during 42 days.
3471349|NCT03870776|Experimental|MAP4343 group B|Patients will receive daily dose 1 during 42 days.
3471350|NCT03870776|Experimental|MAP4343 group C|Patients will receive daily dose 2 during 42 days.
3471351|NCT03870698|Experimental|Laparoscopic group|The patients who underwent laparoscopic procedures for periampullary tumors
3471352|NCT03870698|No Intervention|Open group|The patients who underwent open procedures for periampullary tumors
3471353|NCT03870594||diabetic|patients suffer from diabetes mellitus
3471354|NCT03870594||non diabetic|patients free from diabetes with normal blood glucose level
3471355|NCT03870633||Observational (medical chart, interview)|Participants undergo medical chart abstraction within 1 week and complete telephone interview over 30-45 minutes within 8 weeks after registration.
3471356|NCT03870607|Experimental|Prebiotics and probiotics group|This group will receive standard nutritional guidance from the institutional routine and prebiotics in combination with probiotics, starting one week before the start of Ch-RT and daily throughout the treatment up to 6 to 8 weeks post Ch-RT at the time of evaluation response (primary outcome).
3471357|NCT03870607|No Intervention|Control group|This group will lead nutritionally based just before starting Ch-RT.
3471358|NCT03870542||Deceased donor kidney transplantation|Patients receiving kidney transplants from deceased donor in the participating centers during the study period
3471359|NCT03870581|Experimental|AI-SMART group|Participants' warfarin therapy were guided by an AI-based miniprogram embedded in the Wechat social software.
3471360|NCT03870581|Active Comparator|Human-SMART group|Participants' warfarin therapy were guided by an human-based miniprogram embedded in the Wechat social software.
3125406|NCT02979925|Experimental|Active transcutaneous magnetic stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
3125407|NCT02979925|Sham Comparator|Sham transcutaneous magnetic stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
3471361|NCT03870789||Retrospective|The Investigators will examine data from 1-year prior to paramedic implementation of the Hamilton Early Warning Score tool.
3471362|NCT03870789||Prospective|The Investigators will examine data from 1-year after paramedic implementation of the Hamilton Early Warning Score tool.
3125408|NCT02980042|Experimental|Switching Group|600 mg of ocrelizumab will be administered as one 600-mg IV infusions at a scheduled interval of every 24 weeks. The first dose of ocrelizumab will be a split dose of 300 mg on day 1 and day 15 followed by 600 mg, six months later. Each ocrelizumab infusion should be given as a slow IV infusion over approximately 150 minutes (2.5 hours) for the 300-mg dose. Ocrelizumab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and ocrelizumab should be infused through a dedicated line.
3471363|NCT03870711|Experimental|group A|10% lidocaine spray
3471364|NCT03870711|Placebo Comparator|group B|sterile water
3471365|NCT03870646|Experimental|Hypertonic saline|Nebulized hypertonic saline of NaCl (7%) in combination with hyaluronic acid
3471366|NCT03870646|Placebo Comparator|Isotonic saline|Nebulized isotonic saline of NaCl (0,9%)
3471367|NCT03870516|Placebo Comparator|Valve replacement according to guideline parameters|One group will be referred for surgery according according to indications for mitral valve replacement in European guidelines for valvular heart diseases published in 2017 and will have speckle tracking echocardiography before surgery and 6 months later for comparison.
3471368|NCT03870516|Active Comparator|Early valve replacement|The other group will include patients with severe asymptomatic mitral regurgitation who have left atrial or left ventricular dysfunction according to speckle tracking echocardiography and will be referred to surgery, then speckle tracking echo will be performed 6 months later.
3471369|NCT03870503|Active Comparator|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
3471370|NCT03870503|Active Comparator|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mc sublingual misoprostol
3471371|NCT03870503|Active Comparator|Carbetocin|The patient will be received Carbetocin 100 mic gm IV
3471372|NCT03870490|Experimental|Healthy Subjects|VNRX-5133 + cefepime
3471373|NCT03870464||Prospective arm|Quality of Life questionnaires EORTC-QoL30 and Euro EQ-5D-5L questionnaires are distributed. Blood samples are collected consecutively during ICI and at a follow-up period of one year. CT-scans extended of thorax, abdomen and the lower extremities are performed at baseline and at 6 months. MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.Prospective registration of irAEs are registered during ICI and for one year of follow-up.Enrolment period 1th of April 2018- 31th of January 2020.
3471374|NCT03870347||Biliary Dilation Cohort|Patients referred for endoscopic evaluation of biliary dilation
3471375|NCT03870477|Other|THP Hip Fracture Plating System|THP Hip Fracture Plating System in Intracapsular and Intertrochanteric Femur Fractures
3471376|NCT03870685|Active Comparator|TAP block with Exparel|Patients will receive immediate postoperative bilateral 2-quadrant TAP block with Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by the anesthesia team.
3471377|NCT03870685|Active Comparator|Surgical Site Infiltration of Exparel|Patients will receive surgical site infiltration of Exparel (liposomal bupivacaine) admixed with bupivacaine HCl and saline by surgeon.
3471378|NCT03870230|Experimental|POAG MD<10dB|patients with primary open angle glaucoma with MD in visual field less than or equal 10dB
3471379|NCT03870230|Experimental|POAG MD>10dB|patients with primary open angle glaucoma with MD in visual field more than 10dB
3471380|NCT03870230|Experimental|NTG MD<10dB|patients with normal tension glaucoma with MD in visual field less than or equal 10dB
3471381|NCT03870230|Experimental|NTG MD>10dB|patients with normal tension glaucoma with MD in visual field more than 10dB
3471382|NCT03870230|Experimental|OHT|patients with ocular hypertension
3471383|NCT03870230|Experimental|controls|healthy, age and sex matched, control subjects
3471384|NCT03870269|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in addition to the source CT/MR image in connection with the case.
3471385|NCT03870269|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case.
3471386|NCT03870256|Active Comparator|TA plus misoprostol|Patient receive 600mic gm sublingual misoprostol plus oral tranexamic acid 1 gm
3471387|NCT03870256|Active Comparator|Carbetocin|Patient receives 100 mic gm carbetocin IV
3471388|NCT03870308|Experimental|Deep Brain Stimulation subjects|
3471389|NCT03870321|Experimental|Core training|The subjects who are in the experimental group will carry out the Core training routine
3471390|NCT03870321|No Intervention|Control|The subjects who are in the control group will not receive intervention and will continue with their daily routine and training
3471391|NCT03870412|Experimental|PEG-rhG-CSF|Jin Youli(PEG-rhG-CSF):From the first cycle of chemotherapy, Jin Youli(PEG-rhG-CSF) was injected subcutaneously 24-72 hours after the end of chemotherapy, 6 mg was given to patients with body weight ≥45 kg, and 3 mg was given for body weight <45 kg. Inject once every chemotherapy cycle.
3471392|NCT03870165|Active Comparator|Salmon|After resistance exercise, participants will ingest 3.5 oz of salmon fillet (21g protein, 24g fat) cooked sous-vide.
3471393|NCT03870165|Experimental|Isolated mixture|After resistance exercise, participants will ingest an isolated amino acid and fatty acid mixture matched to the amino acid and fatty acid content of 3.5 oz salmon fillet.
3471394|NCT03870425|Placebo Comparator|MINCED-SKEWED|Minced meat administered with a skewed protein distribution pattern
3471395|NCT03870425|Experimental|MINCED-EVEN|Minced meat administered with an even protein distribution pattern
3471396|NCT03870399|Experimental|Tamoxifen|The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).
3125409|NCT02980042|Active Comparator|Comparator Group|Standard of care rituximab doses are 1000 mg infusion given as first dose followed by 500mg (or 1000 mg if evidence of early B cell recovery) infusion every 6 months thereafter. Rituximab must not be administered as an IV push or bolus. Well-adjusted infusion pumps should be used to control the infusion rate, and rituximab should be infused through a dedicated line
3471397|NCT03870373||Test Subject|neonatal patients undergoing complex cardiac surgical procedures
3471398|NCT03870386|Experimental|EUS-BD with LAMS|A curvilinear endoscope is inserted orally and advanced to the duodenal bulb. Biliary accessibility is confirmed via EUS and with Doppler to rule out any intervening vessels. For common bile ducts < 15 mm in diameter, the biliary access is established via needle puncture with a 19-gauge needle followed by advancement of a 0.035 or 0.025 inch guidewire. A LAMS (AxiosTM) will then be inserted with cautery assistance without tract dilation and deployed. For common bile ducts > 15 mm, the need for initial needle puncture and wire insertion is at the discretion of the endoscopist. A cholangiogram is then performed through the LAMS with contrast injection. The choice of stent size will be at the discretion of the endoscopist (8 x 8 mm or 6 x 8 mm).
3471399|NCT03870386|Active Comparator|Traditional transpapillary metal stent via ERCP|A duodenoscope is advanced orally to the papilla. The bile duct is then cannulated with a sphincterotome using the guidewire-assisted technique. A cholangiogram is then performed followed by insertion of a self-expanding metal biliary stent. The performance of a biliary sphincterotomy prior to stent insertion and the choice of stent size (10x 40 mm, 10 x 60 mm, 10x 80 mm) will be at the discretion of the endoscopist.
3471400|NCT03870295|Experimental|Patients suffering from polyneuropathies|Type C fibre conduction velocity determination in patients suffering from polyneuropathy
3471401|NCT03870295|Active Comparator|Control patients|Type C fibre conduction velocity determination in control patients
3471402|NCT03870282|Experimental|9h 15m Goal|
3471403|NCT03870282|Experimental|"9h 15m Goal | Texts B"|
3471404|NCT03870282|Experimental|"9h 15m Goal | Texts A"|
3471405|NCT03870282|Experimental|"9h 15m Goal | Texts A&B"|
3125410|NCT02980107|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
3125411|NCT02980107|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
3125412|NCT02980133|Placebo Comparator|Placebo MDPI|Participants received matching placebo via multidose dry powder inhaler (MDPI) for 12 weeks.
3471406|NCT03870282|Experimental|"9h 15m Goal | Incentive B"|
3471407|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts B"|
3471408|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A"|
3471409|NCT03870282|Experimental|"9h 15m Goal | Incentive B | Texts A&B"|
3471410|NCT03870282|Experimental|"9h 15m Goal | Incentive A"|
3471411|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts B"|
3125413|NCT02980133|Experimental|Fp MDPI 25 mcg BID|Participants received 1 inhalation of 25 mcg fluticasone propionate (Fp) via MDPI twice daily (BID) (total daily dose: 50 mcg) for 12 weeks.
3125414|NCT02980133|Experimental|Fp MDPI 50 mcg BID|Participants received 1 inhalation of 50 mcg fluticasone propionate via MDPI BID (total daily dose: 100 mcg) for 12 weeks.
3471412|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A"|
3471413|NCT03870282|Experimental|"9h 15m Goal | Incentive A | Texts A&B"|
3471414|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B"|
3471415|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts B"|
3471416|NCT03870282|Experimental|"9h 15m Goal | Incentive A&B | Texts A"|
3471417|NCT03870282|Experimental|"9h 15m Goal | Incentives A&B | Texts A&B"|
3471418|NCT03870282|Experimental|Personal Goal|
3471419|NCT03870282|Experimental|"Personal Goal | Texts B"|
3471420|NCT03870282|Experimental|"Personal Goal | Texts A"|
3471421|NCT03870282|Experimental|"Personal Goal | Texts A&B"|
3471422|NCT03870282|Experimental|"Personal Goal | Incentive B"|
3471423|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts B"|
3471424|NCT03870282|Experimental|"Personal Goal | Incentive B | Text A"|
3471425|NCT03870282|Experimental|"Personal Goal | Incentive B | Texts A&B"|
3471426|NCT03870282|Experimental|"Personal Goal | Incentive A"|
3471427|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts B"|
3471428|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A"|
3471429|NCT03870282|Experimental|"Personal Goal | Incentive A | Texts A&B"|
3471430|NCT03870282|Experimental|"Personal Goal | Incentive A&B"|
3471431|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts B"|
3471432|NCT03870282|Experimental|"Personal Goal | Incentive A&B | Texts A"|
3471433|NCT03870282|Experimental|"Personal Goal | Incentives A&B | Texts A&B"|
3471434|NCT03870191|Active Comparator|Twin Block Group|This group will receive twin block injections.
3471435|NCT03870191|Active Comparator|Trigger Point Injection Group|This group will receive trigger point injections.
3471436|NCT03870087||Robotic PCI|All subjects treated with CorPath GRX during the PCI procedure.
3471437|NCT03870113|Experimental|Vaccinated group|Patients will be vaccinated with autologous mature dendritic cells-loaded with HPV 16/18 E6/E7, DC vaccine will be injected into the adjacent lymph-node 6 times, once a week.
3471438|NCT03870126|Placebo Comparator|Flavored Beverage Mix 1|Flavored still beverage
3471439|NCT03870126|Experimental|Flavored Beverage Mix 2|Flavored still beverage with polyphenols, concentration 1
3471440|NCT03870126|Experimental|Flavored Beverage Mix 3|Flavored still beverage with polyphenols, concentration 2
3471441|NCT03870126|Experimental|Flavored Beverage Mix 4|Flavored still beverage with caffeine
3471442|NCT03870217||Cochlear implant users with Nucleus and AB devices|Speech recognition will be evaluated after poor electrodes are turned off.
3471443|NCT03869944|Experimental|Intervention|Lamivudine Oral Solution
3471444|NCT03870100|Experimental|Cohort 1|A single subcutaneous injection of SHR-1222 dose 1 versus placebo
3471445|NCT03870100|Experimental|Cohort 2|A single subcutaneous injection of SHR-1222 dose 2 versus placebo
3471446|NCT03870100|Experimental|Cohort 3|A single subcutaneous injection of SHR-1222 dose 3 versus placebo
3471447|NCT03870100|Experimental|Cohort 4|A single subcutaneous injection of SHR-1222 dose 4 versus placebo
3471448|NCT03870100|Experimental|Cohort 5|A single subcutaneous injection of SHR-1222 dose 5 versus placebo
3471449|NCT03870139|Active Comparator|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the dominant lower limb) and supraorbital cathode (ipsilateral to the dominant lower limb)."
3471450|NCT03870139|Experimental|Combined stimulation 1|"Active peripheral electrical stimulation (PES_sensorial) combined with active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
3471451|NCT03870139|Active Comparator|Peripheral stimulation|"Active peripheral electrical stimulation (PES_motor).~PES: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
3471452|NCT03870139|Experimental|Combined stimulation 2|"Active sensorial peripheral electrical stimulation (PES_sensorial) combined with active motor peripheral electrical stimulation (PES_motor)~PES_sensorial: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level~PES_motor: 15 minutes, 30Hz (frequency), 100µs (pulse duration), intensity at motor level."
3471453|NCT03869866|Experimental|MenACYW conjugate vaccine|MenACYW conjugate single injection at Day 0
3471454|NCT03870152|Experimental|EC treatment (Intervention Arm)|Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline. Follow-up is the same as for Control Arm patients: an AFB surveillance visit at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
3471455|NCT03870152|No Intervention|AFB Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB surveillance at 6, 12, 24, and at 36 months post-randomisation; with further AFB surveillance visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
3125415|NCT02980133|Experimental|FS MDPI 50/12.5 mcg BID|Participants received 1 inhalation of 50/12.5 mcg fluticasone propionate/salmeterol (FS) via MDPI BID (total daily dose: 100/25 mcg) for 12 weeks.
3125416|NCT02980211|Experimental|Tooth Extraction and Graft Dehisced Socket|Treatment of dehiscence defects at the time of tooth extraction using a minimally-invasive GBR technique that involves the application of a particulate bone allograft and a non-resorbable PTFE membrane.
3125417|NCT02980224|Experimental|OmegaD|OmegaD Softgels
3125418|NCT02980224|Placebo Comparator|Placebo|Placebo Softgels
3125419|NCT02980523|Experimental|PRO-157 BID (2 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 12 hours per day (BID), for 7 days~instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%)every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
3471456|NCT03869957|Experimental|Intervention group|We will use ~0.8-0.9 g/kg/day of Clinoleic® (80% olive oil/20 soybean oil) + 0.2-0.1 g/kg/day [Omegaven® ](100% fish oil), to cover the proposed amount of n-3 PUFAs for 7 days. The infusion rate should not exceed 0.5 ml Omegaven® / kg body weight / hour = 0.05 g fish oil / kg body weight / hour. The intervention group will return to PN without n-3 PUFA after 7 days.
3471457|NCT03869957|No Intervention|Control group|Will be administering ~1.0 g/kg/d the lipid emulsion Clinoleic® (80% olive oil/20 soybean oil) without n-3 PUFAs.
3471458|NCT03869879|Active Comparator|Feedback-assisted physical therapy|During a visual feedback session, therapists will spend 30min per session using the Mobility Rehab system for gait training with patients. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
3125420|NCT02980523|Experimental|PRO-157 TID (3 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 8 hours per day (TID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
3471459|NCT03869879|Placebo Comparator|Traditional physical therapy|During a regular session, patients with gait impairment will work on gait with the following tasks for 30min: weights on ankles, dual tasks, UE support, partial body weight support, speed challenges, obstacles, and head turning. Therapists may select modality, overground walking and/or treadmill, tasks (dual task, head turns, etc. as above) as appropriate for each patient. They will additionally spend 15min on endurance, strength, and static and dynamic balance in functional tasks.
3125421|NCT02980523|Experimental|PRO-157 QID (4 times per day)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of PRO-157 (pazufloxacin), every 6 hours per day (QID), for 7 days~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day, for 7 days. (Can be applied 15 minutes after PRO 157)"
3471460|NCT03870009|Experimental|ARDS patients|All the patients will be evaluated with the same procedure, as the study relates to evaluation of the diagnostic performance of a semi-automated method to detect cyclic hyperinflation on CT scan
3471461|NCT03870178|Active Comparator|Active tDCS|Anodal tDCS over trunk motor cortex representation. Intensity: 2mA Time: 20 minutes
3471462|NCT03870178|Sham Comparator|Sham tDCS|Anodal tDCS over trunk motor cortex representation. Itensity: 2mA Time: 20 minutes (30s ON)
3471463|NCT03870022|Other|18-80 years of age|Single day study collecting 1 paired breath sample from each subject using two non-invasive breath sampling devices, as well as collecting participant responses to user documentation questions and rating scales.
3471464|NCT03869775||control group|no additional disease
3471465|NCT03869775||working group-1|additional disease only DM and no cardıovascular autonomous neuropathıa
3471466|NCT03869775||working group-2|additional disease only DM and pozitif cardıovascular autonomous neuropathıa
3471467|NCT03869814||Non-cancer|900 asymptomatic individuals without prior history of cancer
3471468|NCT03869814||Cancer|900 individuals with confirmed malignancy
3125422|NCT02980523|Active Comparator|Moxifloxacin (Vigamox®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Moxifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days. (Can be applied 15 minutes after moxifloxacin)"
3125423|NCT02980523|Active Comparator|Gatifloxacin (Zymar®)|"60 eyes of 30 research subjects will be evaluated with the following therapeutic regimen:~instill one drop in each eye of Gatifloxacin, every 8 hours per day, for 7 days.~15 minutes after, instill one drop in each eye of Lagricel Ofteno® (Sodium hyaluronate 0.4%) every 6 hours per day for 7 days.one drop 4 times a day for 7 days in each eye.(Can be applied 15 minutes after gatifloxacin)"
3471469|NCT03869996|Active Comparator|fast track total knee arthroplasties|patients treated using fast track care protocol
3471470|NCT03869996|Active Comparator|standard care total knee arthroplasties|patients treated using standard care protocol
3471471|NCT03870061|No Intervention|Control|
3125424|NCT02980601|Experimental|Integra and a Split Thickness Skin Graft (STSG)|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG.
3125425|NCT02980601|Active Comparator|Split Thickness Skin Graft (STSG)|reconstruction as dictated by the protocol. They will either receive 1) a 0
3471472|NCT03870061|Experimental|Treatment|This arm receives the full New Incentives' conditional cash transfer program (All Babies Are Equal Initiative).
3471473|NCT03869853|Experimental|intervention|Entrepreneurial stimulation and integrated education
3471474|NCT03869853|Experimental|control|no intervention
3471475|NCT03870048|Active Comparator|tDCS effects on pain and fatigue|tDCS Block: The participant will receive tDCS for 20 min at an intensity of 2 mA while seated comfortably and quietly in a room. The intensity will start at 0 mA and will be incrementally increased to 2mA over the initial 30 seconds. At the 19:30 minute time point, the current will gradually be reduced from 2 mA to 0 mA.
3471476|NCT03870048|Placebo Comparator|Sham effects on pain and fatigue|Sham block: Identical to the tDCS block, except the participants will only receive the initial 30 seconds of ramp-up, after which the current will be set to 0 for the remainder of the 20 minutes.
3125426|NCT02980666|Experimental|Teduglutide|Participants will receive teduglutide 0.05 milligram per kilogram per day (mg/kg/day) subcutaneous (SC) injection once daily for 24 weeks.
3125427|NCT02980692|Experimental|SUNPG1623 dose I|low range dose
3125428|NCT02980692|Experimental|SUNPG1623 dose II|mid range dose
3125429|NCT02980692|Experimental|SUNPG1623 dose III|mid range dose
3125430|NCT02980692|Experimental|SUNPG1623 dose IV|mid range dose to high dose
3125431|NCT02980692|Placebo Comparator|Placebo|mid range dose to high dose
3125432|NCT02980705|Experimental|SUNPG1622 I|SUNPG1622 I dose
3471477|NCT03869918|No Intervention|Usual Care|Participant is assigned to undergo standard of care.
3471478|NCT03869918|Experimental|Exercise Group|If the participant is assigned to the exercise group, she will either exercise at home or take a class at the participating facility under the supervision of an instructor.
3471479|NCT03869918|No Intervention|Observational Group|If a subject is eligible, but does not want to exercise, she will be in a third group that is an observation group.
3471480|NCT03869931|Experimental|Fenofibrate|(Refer to intervention)
3471481|NCT03869710|Experimental|Dry-Needling|Ultrasound-Guided Dry-Needling Therapy focused on the active and latent myofascial trigger points.
3471482|NCT03869905|Experimental|Aquamin®|To be taken for 180 days
3471483|NCT03869905|Placebo Comparator|Placebo first then Aquamin®|Placebo: To be taken for the first 90 days. Aquamin®: To be taken for the last 90 days (after crossover)
3471484|NCT03869671|Experimental|PrEP uptake/adherence intervention|A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
3471485|NCT03869671|Active Comparator|Harm reduction standard of care|Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
3471486|NCT03869762|Experimental|Denosumab & Enzalutamide|"120mg subcutaneous injection on Day 1 of every four week cycle, for a maximum of 24 cycles, or until clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason.~160mg PO daily; (4 x 40 mg capsules) until confirmed clinical disease progression, unacceptable toxicity, consent withdrawal or withdrawal for any other reason)"
3471487|NCT03869827||IUGR|All birth between 24 + 0 weeks of amenorrhea and 36 + 6 weeks of amenorrhea with isolated intrauterine growth restriction at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2016.
3471488|NCT03869827||Control|To each of these children with intrauterine growth restriction is matched a control child: the child without intrauterine growth restriction of the same gestational age whose date of birth is consecutive to that of the case.
3471489|NCT03869801|Active Comparator|ESP Block|
3471490|NCT03869801|Active Comparator|QLB block|
3471491|NCT03869736|Experimental|Nitrous Oxide 50% or 25%|Nitrous oxide at an inhaled concentration of 50% or 25%
3471492|NCT03869736|Sham Comparator|Placebo|Oxygen-air mixture
3471493|NCT03869749|Experimental|Learning to BREATHE Plus|It is a 6-week manualized program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University. Adolescents will be sent ecological momentary intervention text messages several times a day (with reminders, encouragement, and guides to practice mindfulness), and also have access to an on demand online library of mindfulness resources.
3471494|NCT03869749|Active Comparator|Health and wellness|It is a 6-week program; each meeting is 1.5 hours, for a total of 9 contact hours. It will be administered in a classroom at Colorado State University.
3471495|NCT03869723||Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
3471496|NCT03869723||Virtual planning|Fibula free flap in mandibular reconstruction using preoperative virtual planning, cutting guides and osteosynthesis plates. Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
3471497|NCT03869983|Active Comparator|Active Comparator|Omnipaque™ (iohexol) Injection, 755 mg/mL iohexol (350 mgI/mL)
3471498|NCT03869983|Experimental|Experimental|CE-Iohexol Injection, 755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL
3471499|NCT03869554|Experimental|Renal disease|detection of Fabry disease
3471500|NCT03869359|Experimental|Group A|Gluten-free diet with placebo powder vs Gluten-free diet with gluten powder
3471501|NCT03869359|Experimental|Group B|Gluten-free diet with gluten powder vs Gluten-free diet with placebo powder
3471502|NCT03869346||GG|wild-type homozygote (CYP3A4*1/*1, GG)
3471503|NCT03869346||GA|mutant heterozygote (CYP3A4*1/*1G, GA),
3471504|NCT03869346||AA|mutant homozygote (CYP3A4*1G/*1G, AA)
3471505|NCT03869411|Experimental|aerobic exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness. The aerobic exercise group will arranged to the supervised aerobic dance program, it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
3471506|NCT03869411|Experimental|home exercise group|This study will recruit qualified diabetic subjects according to their results of maximal aerobic exercise capacity (VO2max) and assign them into aerobic exercise or home exercise groups, based on their willingness.The home exercise group will give the exercise recommendation based on ACSM's guideline, and it's consisted of 50 mins per session, 3 sessions per week and last for 3 months.
3471507|NCT03869411|Active Comparator|health control group|This study will recruit subjects without type 2 diabetes and the age matched to the diabetes groups.
3471508|NCT03869463|Experimental|EF/PS CCT|This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function & processing speed.
3471509|NCT03869463|Active Comparator|Verbal CCT|This group will complete verbal-focused computerized cognitive training.
3471510|NCT03869463|Placebo Comparator|Waitlist Control|This group will not receive cognitive training during study participation.
3471511|NCT03869476|Experimental|BioscoreSMP cohort|
3471512|NCT03869593||Patients presenting E. coli and S. aureus bacteremia|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
3471513|NCT03869489|Experimental|Anodal left dorsolateral prefrontal cortex tDCS stimulation|
3471514|NCT03869489|Experimental|Anodal right dorsolateral prefrontal cortex tDCS stimulation|
3471515|NCT03869489|Sham Comparator|Sham tDCS stimulation|
3471516|NCT03869242|Experimental|Experimental treatment arm|RT with concomitant TMZ and NovoTTF-200A for 6 weeks followed by up to 24 months of maintenance TMZ in combination with NovoTTF-200A.
3471517|NCT03869242|Active Comparator|control arm|RT with concomitant TMZ alone followed by maintenance TMZ chemotherapy in combination with NovoTTF-200A.
3125433|NCT02980705|Placebo Comparator|Placebo|Placebo dose
3471518|NCT03869619||All enrolled patients|All patient who signed the consent form for participation to the study
3471519|NCT03869528|Active Comparator|5 sprays|5 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
3471520|NCT03869528|Experimental|10 sprays|10 sprays of 10% lignocaine administered for topical anaesthesia during flexible bronchoscopy
3471521|NCT03869424|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from rumination. They take the nasal spray once in the laboratory.
3471522|NCT03869424|No Intervention|No-treatment control group|Participants do not receive the nasal spray.
3471523|NCT03869294||LAPC or MPC patients with GS first-line chemotherapy|
3471524|NCT03869567|Experimental|Cone beam CT|A cone beam CT wll be performed just after thrombectomy on patients with acute ischemic stroke
3471525|NCT03869255||Hospitalized patients|Within 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
3471526|NCT03869255||Community patients|"People coming to donate blood in Etablissement Français du Sang will be included and a nasal swab will be performed"
3471527|NCT03869385|Experimental|Albumin group|Patients assigned to the Albumin group will receive a 60 g loading dose of human albumin 20% over 2-3 hours. Serum albumin levels will be maintained at least at 30 g/l in the ICU for a maximum of 28 days following randomization using 40-80 g human albumin 20% infusion.
3471528|NCT03869385|No Intervention|Control group without albumin:|The control group will be treated according to the usual practice with crystalloids as the first choice for the resuscitation and maintenance phase of septic shock.
3471529|NCT03869281||PTA|patients who underwent their first deceased donor PTA, or second deceased donor PTA if their first graft was explanted within a week, at the IRCCS San Raffaele Hospital between 2 January 2005 and 31 December 2017
3471530|NCT03869281||Controls|outpatients with T1D attending the Endocrinology Unit at IRCCS San Raffaele Hospital and patients listed for a first deceased donor PTA
3471531|NCT03869307|Experimental|Shoulder strengthening exercises|Progressive heavy shoulder strengthening exercises three times weekly and advice on load and pain management. Exercise sessions are supervised twice a week corresponding to 32 supervised exercise sessions during the 16 weeks.
3471532|NCT03869307|Active Comparator|Shoulder stability exercises|Recommendations of shoulder stability exercises which are to be performed unsupervised (e.g. at home) three times weekly and advice on load and pain management. Three supervised sessions are offered during the 16 weeks, and exercises are primarily performed unsupervised at home.
3471533|NCT03869320|Experimental|ACT-1004-1239|ACT-1004-1239 will be given as a single oral dose under fasting conditions. Eight doses are planned with a starting dose of 1 mg. The ADME characteristics and absolute bioavailability using a 14C-radiolabeled microtracer will be evaluated as part of the SAD, after the first 3 cohorts have been performed.
3471534|NCT03869320|Placebo Comparator|Placebo|Matching placebo will be given as a single oral dose under fasted conditions. Matching placebo for the oral and intravenous administration of the 14C-radiolabeled ACT-1004-1239 will also be available.
3471535|NCT03869320|Experimental|Food-effect subpart: ACT-1004-1239|ACT-1004-1239 will be given under both fasted (first period) and fed (second period) conditions. The food effect will be evaluated after the first 3 cohorts have been performed.
3471536|NCT03869320|Placebo Comparator|Food-effect subpart: Placebo|Matching placebo will be given under both fasted (first period) and fed (second period) conditions.
3471537|NCT03869398|No Intervention|Control arm: No pre-op medications|patients undergoing total thyroidectomy are started on calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID immediately postoperatively. No pre-operative medications are given
3471538|NCT03869398|Experimental|Intervention arm: Tums and Calcitriol pre-op|patients start calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
3471539|NCT03869268|Active Comparator|No Drug|"Patients will be randomised to receive no drug for the first medication period (10 days).~Patient will then be allocated to receive ticagrelor 90mg twice daily for the second medication period (10 days)"
3471540|NCT03869268|Active Comparator|Ticagrelor 180 mg|"Participants will be randomised to receive loading dose of ticagrelor 180 mg on the last day of the first medication period (10-14 days).~Participants will then be allocated to receive no aspirin but a loading dose of ticagrelor 180 mg on the last day of treatment for the second medication period (10-14 days)."
3125434|NCT02980783|Experimental|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine was injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection was determined by the investigator. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine was injected on Day 14.
3125435|NCT02980874|Experimental|Active|IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections
3125436|NCT02980874|Active Comparator|Control|IVT aflibercept (2 mg/0.05 mL) + sham SC procedure
3471541|NCT03869268|Active Comparator|Aspirin 20mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
3471542|NCT03869268|Active Comparator|Aspirin 20 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 20 mg twice daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 20 mg twice daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
3471543|NCT03869268|Active Comparator|Aspirin 75 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days).~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
3471544|NCT03869268|Active Comparator|Aspirin 75 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 75 mg once daily for the first medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 75 mg once daily for the second medication period (10-14 days)."
3125437|NCT02980978|Experimental|Intervention|Individuals assigned to the intervention group will have supplemental care provided by a registered dietitian/certified diabetes educator which includes counseling on lifestyle to improve diabetes and overall health. Additionally, individuals in this group may be started on medications (or adjustments to current medications) for blood pressure, cholesterol or blood glucose to meet diabetes care goals
3125438|NCT02980978|No Intervention|Standard of Care|Individuals will be followed by their Primary Care Provider as standard of care and per usual clinical need
3471545|NCT03869268|Active Comparator|Aspirin 300 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10 days).~Participants will then be allocated to receive aspirin 300 mg once daily for the second medication period (10-14 days), plus a loading dose of ticagrelor 180 mg on the last day of the period."
3471546|NCT03869268|Active Comparator|Aspirin 300 mg & Ticagrelor 180 mg|"Participants will be randomised to receive aspirin 300 mg once daily for the first medication period (10-14 days) plus a loading dose of ticagrelor 180 mg on the last day of the period.~Participants will then be allocated to receive aspirin 300 mg once daily for the second medicaion period (10-14 days)."
3471547|NCT03869372|Experimental|Healthy subjects|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
3471548|NCT03869372|Experimental|Subjects with IBS|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
3471549|NCT03869372|Experimental|Subjects with FD|"At the baseline session, measures of autonomic activity (electrogastrogram - EGG, electrocardiogram - ECG, cardiac impedance - CI, colonic motility) will be monitored from about 15 minutes before up to 1 hour after consumption of a test meal, water or a nutrient drink. In addition, motor-evoked potentials (MEPs) elicited with paired pulse transcranial magnetic stimulation (ppTMS) will be assessed before and after the meal or drink.~In subsequent sessions, repetitive transcranial magnetic stimulation (rTMS) is applied before the meal or drink."
3471550|NCT03869203|Experimental|Enhanced recovery after surgery (ERAS) patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the ERAS perioperative care.
3471551|NCT03869203|No Intervention|Control patients|Patients planned to undergoing total knee arthroplasty or total hip arthroplasty, following the traditional perioperative care.
3471552|NCT03869229|Active Comparator|osteoarthritis of the knee|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
3471553|NCT03869229|Active Comparator|osteoarthritis of the hip|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
3125439|NCT02981342|Experimental|Abemaciclib|Abemaciclib given orally.
3125440|NCT02981342|Experimental|Abemaciclib + LY3023414|Abemaciclib given orally and LY3023414 given orally.
3125441|NCT02981342|Experimental|Standard of Care (Gemcitabine or Capecitabine)|Gemcitabine given intravenously (IV) OR capecitabine given orally.
3125442|NCT02981368|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
3125443|NCT02981524|Experimental|CY/GVAX with Pembrolizumab|During each 21 day cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 followed by Pembrolizumab at 200mg, the colon cancer vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells for the first 4 cycles of treatment. After cycle 4, cyclophosphamide and GVAX will be administered with every 4th cycle.
3125444|NCT02981602|Experimental|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
3125445|NCT02981602|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
3125446|NCT02981953|Other|Cardioband Tricuspid procedure|Tricuspid valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
3125447|NCT02982018|Experimental|Investigational Contact Lens with UV Blocker|Subjects will be dispensed the investigational contact lens with UV blocker to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
3125448|NCT02982018|Active Comparator|Marketed Contact Lens|Subjects will be dispensed the marketed contact lens to wear daily for a period of 12 weeks with follow-up visits occurring after 1, 2, 4, 8, and 12 weeks. Afterwards, the subjects will wear their habitual contact lenses for a period of two weeks with weekly visits.
3125449|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ1|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 1 of the PQ (PQ1)
3125450|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ2|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 2 of the PQ (PQ2)
3125451|NCT02982187|Experimental|Sub-study 1 : ELLIPTA followed by DISKUS+ HANDIHALER +PQ2|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then DISKUS + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ2
3125452|NCT02982187|Experimental|Sub-study 1 : DISKUS + HANDIHALER followed by ELLIPTA+PQ1|In this sequence, subjects will be randomized to use DISKUS + HANDIHALER in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ1
3471554|NCT03869229|Active Comparator|osteoarthritis of the glenohumeral joint|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)
3471555|NCT03869047|Active Comparator|quadratus lumborum block(dexmedetomidine+bupivacaine)|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine ,total volume 20 ml.
3471556|NCT03869047|Active Comparator|quadratus lumborum block(bupivacaine)|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20%.
3471557|NCT03869164|Experimental|ValmpClamp Arm|
3471558|NCT03869034|Experimental|Combined group (TAI+PD-1)|Patients receive PD-1 inhibitor of Sintilimab on the first day of TAI+PD1 treatment. On the day 2-3 during the same hospitalization, the FOLFOX chemotherapy regimen of TAI is perform for 48 hours. The TAI+PD1 treatment will repeat every 3 weeks until patients receive surgical resection or detect disease progression.
3471559|NCT03869034|Active Comparator|Control group (TAI only)|Patients only receive TAI treatment without PD-1. The FOLFOX chemotherapy regimen of TAI is same as the experimental group and repeat every 3 weeks until patients receive surgical resection or detect disease progression.
3471560|NCT03869086|Experimental|SLOW anthocyanin metabolisers|Participants will be prospectively recruited to the SLOW anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
3471561|NCT03869086|Experimental|FAST anthocyanin metabolisers|Participants will be prospectively recruited to the FAST anthocyanin metaboliser group, following a pre-intervention screen (blueberry challenge). Participants in this arm will consume (in random order) blueberry and placebo interventions (both consumed with an energy dense meal) in a cross-over manner. At least 7 days washout will be observed between the two treatments.
3471562|NCT03869099||Sindh|
3471563|NCT03869099||KPK|
3125453|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ3|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete version 3 of the PQ (PQ3)
3125454|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ4|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete version 4 of the PQ (PQ4)
3471564|NCT03869099||Punjab|
3471565|NCT03869099||Balochistan|
3471566|NCT03869008|Sham Comparator|Sham Device Group|"15 patients will be randomized to the Sham device for the first half of the treatment window then switch to the gammaCore Sapphire device (study device) for the rest of the study.~The Sham device will look exactly like the gammaCore Sapphire device but will not deliver non invasive vagus nerve stimulation."
3471567|NCT03869008|Experimental|gammaCore Sapphire (Study Device) Group|15 patients will be randomized to the gammaCore Sapphire device for the full length of the treatment window.
3471568|NCT03868865|Experimental|Integrative mind-body-medicine group program|The 66 hour program encompasses mindfulness training, yoga, moderate exercise, nutrition, naturopathic self-help strategies, cognitive restructuring and acupuncture for the management of side effects caused by chemotherapy.
3125455|NCT02982187|Experimental|Substudy 2: ELLIPTA followed by TURBUHALER + HANDIHALER +PQ4|In this sequence, subjects will be randomized to use ELLIPTA inhaler in period 1 and then TURBUHALER + HANDIHALER in period 2. At the end of Visit 1, subjects will complete PQ4
3125456|NCT02982187|Experimental|Substudy 2: TURBUHALER + HANDIHALER followed by ELLIPTA+PQ3|In this sequence, subjects will be randomized to use TURBUHALER + HANDIHALER inhaler in period 1 and then ELLIPTA in period 2. At the end of Visit 1, subjects will complete PQ3
3471569|NCT03868852|Experimental|Radiotherapy plus apatinib mesylate|All eligible patients signed informed consent. Three-dimensional conformal intensity modulation (IMRT) technique was used to treat the patients with radiation doses 45 Gy - 54 Gy. All patients took apatinib mesylate tablets 250 mg QD orally from 1 week before radiotherapy to the whole radiotherapy period. They were required to take apatinib mesylate tablets with warm boiling water half an hour after meal. The daily medication time should be as consistent as possible.
3471570|NCT03869021|Active Comparator|Computer guided surgery|A surgical guide is 3d printed to guide through the surgery, the patients of this group will have the distraction surgery by a guide designed by Mimics 19.0, Materialise NV,Belgium
3471571|NCT03869021|Other|No surgical guide (free hand surgery)|control group added to investigate the effect of surgical guide
3471572|NCT03868878|Experimental|Capoeira training group|The experimental protocol for Capoeira program lasted 12 weeks and was performed twice a week with duration of 60 minutes each with warm-up, basic movements in the modality, and 20 minutes with theoretical instructions related to Capoeira and musicality.
3471573|NCT03868878|Sham Comparator|Control group|While the Capoeira group performed the entire class, the Control group performed only the final part (20 minutes) with musicality - singing and touch of typical instruments - and theoretical instructions related to Capoeira.
3471574|NCT03868891|Experimental|EMST150|Subjects with or without cleft palate will use the EMST150 2 times a day for 8 weeks.
3125457|NCT02982213|No Intervention|No companion present|No companion is present during the placement of the epidural catheter.
3125458|NCT02982213|Active Comparator|Companion present|A companion will be present during the placement of the epidural catheter.
3125459|NCT02982239|Other|Sleep Intervention|N=20 Participants received fitness tracker, information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks
3471575|NCT03869138|Experimental|Virtual-reality based dance group|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
3471576|NCT03868917|No Intervention|ultrasound group|The participants have continuous thoracic paravertebral block performed using only the ultrasound approach.
3125460|NCT02982239|Other|Sleep Intervention plus Tech|N=20 Participants received fitness tracker, LED light, Blue-blocking glasses along with information session, a link to complete a daily sleep diary, intermittent text messages that included adherence reminders, encouraging statements, and tips for improving sleep. Daily monitoring with sleep diaries, daily monitoring of sleep tracker sync activity and regret lottery for 10 weeks.
3125461|NCT02982590|Active Comparator|warfarin sodium|warfarin daily, dosage according to INR monitor. Aim INR 2-3
3125462|NCT02982590|Experimental|apixaban|Apixaban 5 MG Oral Tablet [ELIQUIS] will be given for randomly selected patients for 3 months.
3471577|NCT03868917|Experimental|pressure measurement group|The participants have continuous thoracic paravertebral block performed using the ultrasound-guided approach combined with pressure measurement techniqueduring needle advancement.
3471578|NCT03869060|Experimental|Inoculated Group|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) given as a single dose [0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL)] inoculated subcutaneously.
3125463|NCT02982772|Experimental|Tailored Combination Therapy|"Combination of Brief behavioral intervention Plus Nicotine replacement. The test product is a transdermal nicotine patch and Nicotine replacement gums for 12 weeks. The dosage of the test product depends on the amount of cigarettes used.~Doses will be tailored and adjust as need it"
3125464|NCT02982772|Active Comparator|Standard Care Intervention|"Brief behavioral intervention The test product is a transdermal nicotine patch plus regular flavored gums for 10 weeks. The dosage of the test product depends on the amount of cigarettes used.~Standard Flavored gums will be used as needed for 10 weeks."
3471579|NCT03869125||Obstructive sleep apnoea group|Blood pressure measurement
3471580|NCT03869073|Experimental|Low Dose|This treatment arm will receive the highest dose of evolocumab currently marketed and approved: 420mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
3125465|NCT02982863||All Patients|
3125466|NCT02982954|Experimental|ccRCC KPS ≥ 70%|Clear-Cell Renal Cell Carcinoma (ccRCC) with Karnofsky Performance Status (KPS) ≥ 70%
3125467|NCT02982954|Experimental|Non-ccRCC, KPS ≥ 70%|Non Clear-Cell Renal Cell Carcinoma (nccRCC) with KPS ≥ 70%
3125468|NCT02982954|Experimental|RCC with non-active Brain Mets, KPS ≥70%|Renal Cell Carcinoma (RCC) with non-active Brain Metastases, with KPS ≥70%
3125469|NCT02982954|Experimental|any RCC with KPS 50%-60%|Renal Cell Carcinoma (RCC), regardless of any histology or existing non-active brain metastasis, with KPS 50%-60%
3125470|NCT02983058|Other|PET/SPECT and MRI scans|PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation. 30 minutes structural MRI will be obtained to permit co-registration of PET images.
3125471|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 1|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo.
3125472|NCT02983227|Experimental|GDC-0853 (200mg BID) Cohort 2|Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo.
3125473|NCT02983305|Experimental|Retinal Dystrophy|Subjects with retinal dystrophy will have their visual field, gait and self-reported mobility tested at baseline. Subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
3471581|NCT03869073|Experimental|High Dose|This treatment arm will receive double the highest dose of evolocumab currently marketed and approved: 840mg. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
3471582|NCT03869073|Placebo Comparator|Placebo|This treatment arm will receive saline solution. The dose will be given at a single time point within 4 hours of randomization. The dose will be administered through three subcutaneous injections, each in a different quadrant of the abdomen.
3471583|NCT03868943|Experimental|Solriamfetol|Given orally daily
3471584|NCT03868969|Experimental|Fosfomycin|Fosomycin tromethamine, one sachet for 21 days
3471585|NCT03868930|Experimental|STEP-Home|The STEP-Home Arm involves a skills-based intervention focused on Emotional Regulation, Problem Solving, and Attention Training strategies.
3125474|NCT02983305|Experimental|Healthy Age-Matched Controls|Age-matched control subjects without eye disease will have their visual field, gait and self-reported mobility tested at baseline. Control subjects will then be fit with a head-mounted display and undergo a brief training with the investigators to learn about use of the device. After a 2 week period of in-home adaptation to the device, their visual field, gait and self-reported mobility will be retested.
3125475|NCT02983448|Placebo Comparator|Sham stimulation first|"Sham stimulation delivered at the earlobe (devoid of vagal innervation) is given on first session.~Transcutaneous vagus nerve stimulation delivered at the tragus (vagal innervation) is given on second session."
3471586|NCT03868930|Active Comparator|PCGT|The Present Center Group Therapy (PCGT) Arm involves a nonspecific, supportive intervention, focused on identifying and discussing current life stressors.
3471587|NCT03869112|Experimental|Physical activity intervention|Physical activity group will be given a FitBit device to monitor their PA, especially steps count Step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home based intervention.
3471588|NCT03869112|Experimental|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
3471589|NCT03869112|No Intervention|Usual care|Usual care group will have the standard follow up care by rehabilitation clinic without being in any physical intervention.
3471590|NCT03868956|Experimental|Diagnostic strategy|Colour doppler ultrasound (CDUS) with or without D-dimer test to rule-in or rule-out deep vein thrombosis recurrence
3471591|NCT03868995|Sham Comparator|Sham injection|Dextrose water injection to subcutaneous layer at tender point
3471592|NCT03868995|Experimental|Tendon injection|Dextrose water injection to injured tendon
3471593|NCT03868982|Experimental|NAVA group|Participent in this group will received NAVA for two days
3471594|NCT03868982|No Intervention|Control group|Participent in this group will received standard care
3471595|NCT03868813||Interview with People with Diabetes|One-on-One interview with people with diabetes
3471596|NCT03868813||Interview with Health Coaches|One-on-One interview with health coaches
3471597|NCT03868800|Other|SDM-DC|All adult patients with kidney failure referred to a department of renal medicine at one of the four hospitals from the 1st of October 2016 to the 31st of May 2018 were offered the intervention and invited to participate in the study. The inclusion criterion was an estimated glomerular filtration rate below 20 ml/min and based on a clinical judgement made by the contact doctor and/or the contact nurse about the decline in the Estimated glomerular filtration rate to continue. Exclusion criteria were patients who had decided on conservative management, patients with a living donor and a set date for transplantation and patients not able to participate in the intervention due to cognitive impairment. The use of an interpreter was not an exclusion criterion.
3471598|NCT03868839|Experimental|Telmisartan Pill|Subjects will start telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
3471599|NCT03868553||Under-10|
3471600|NCT03868553||Under-12|
3471601|NCT03868553||Under-16 female|
3471602|NCT03868553||Under-16 male|
3471603|NCT03868566|Experimental|SNP-612 dose1|dose1 once a day orally for 12 weeks
3471604|NCT03868566|Experimental|SNP-612 dose2|dose2 once a day orally for 12 weeks
3471605|NCT03868566|Experimental|SNP-612 dose3|dose3 once a day orally for 12 weeks
3471606|NCT03868566|Placebo Comparator|SNP-612 placebo|placebo once a day orally for 12 weeks
3471607|NCT03868644|Experimental|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
3471608|NCT03868644|Experimental|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
3471609|NCT03868644|Experimental|VCT and Condoms|Youth are offered both VCT and condoms.
3471610|NCT03868644|No Intervention|Control|No intervention is provided (beyond the standard available HIV prevention services within the area)
3471611|NCT03868696|Sham Comparator|MUA with sham ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with sham ultrasound (screen concealed from participants)
3471612|NCT03868696|Experimental|MUA with active ultrasound|Participants will undergo standard manipulation (MUA) of wrist fracture with active ultrasound (screen concealed from participants)
3471613|NCT03868527||Hematological diseases|Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital
3471614|NCT03868735|Experimental|CleanSweep Closed Suction System|Device that includes balloon sweeping technology
3471615|NCT03868735|No Intervention|Standard in-line suction device|In-line suction device already in on intubated patients with an endotracheal tube
3471616|NCT03868462|Other|Optical Coherence Tomography (OCT)|
3471617|NCT03868501|Experimental|High Working memory load: n-back task|During the intervention, each participant of this group will finish the 3-back task.
3471618|NCT03868501|Experimental|Low Working memory load: n-back task|During the intervention, each participant of this group will finish the 1-back task.
3471619|NCT03868683|Other|Glucose Reference 1|Glucose solution containing 30 g of glucose
3471620|NCT03868683|Other|Glucose Reference 2|Glucose solution 2 containing 30 g of glucose
3471621|NCT03868683|Other|Glucose Reference 3|Glucose solution 3 containing 30 g of glucose
3471622|NCT03868683|Experimental|Sucrose|Sucrose solution containing 30 g of sucrose
3471623|NCT03868683|Experimental|Regular Bake beans in tomato sauce|Bake bean in tomato sauce with high levels of sucrose (37%)
3471624|NCT03868683|Experimental|Bake beans in tomato sauce, reduced sugar|Bake bean in tomato sauce with medium levels of sucrose (29.9%)
3471625|NCT03868683|Experimental|Bake beans in tomato sauce, low GI|Bake bean in tomato sauce with low levels of sucrose (18.5%)
3471626|NCT03868436|Other|Methoxyflurane (MEOF)-active treatment|single arm study all subjects will be treated with Methoxyflurane 3 mL
3471627|NCT03868488|Experimental|Visual imagery tasks group|During the intervention, each participant of this group will be asked to create visual mental images.
3471628|NCT03868488|Experimental|Auditory imagery tasks group|During the intervention, each participant of this group will be asked to create auditory mental images.
3471629|NCT03868618|Experimental|Genio Therapy|The Genio™ system is an implantable neurostimulation system comprised of one implanted device
3471630|NCT03868722|Experimental|Treatment arm|Treatment with Acalabrutinib and Venetoclax is initiated within 14 days after randomization.
3471631|NCT03868722|No Intervention|Observation arm|Observation period is initiated within 14 days after randomization.
3471632|NCT03868670|Experimental|Responsive Neurostimulation|Surgical arm. Patients expected to receive treatment.
3471633|NCT03868787|Experimental|Active TENS|The active TENS unit consists of the active unit and electrode pads connected to the unit via direct wires. The program that will be used is a high frequency (80Hz) program that runs for an hour in duration. It will be initiated 5 minutes prior to speculum placement. Participants will be instructed to increase the amplitude of the current as needed to provide analgesia but avoiding discomfort from the TENS stimulation
3471634|NCT03868787|Sham Comparator|Sham TENS|The sham TENS will be the same unit without the true TENS electrical connections. The sham group will be given the active unit and have electrode pads placed but without wire connections. These participants will be told the device is a wireless device. They will also be told they may or may not feel sensation from the TENS. This will allow the device to be powered on and run in the same manner as the active group, but will not allow for electrical transmission between the unit and electrodes
3471635|NCT03868514||TiLOOP Bra Pocket|Medical Device
3471636|NCT03868709|Experimental|Penehyclidine group|Penehyclidine inhalation is administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
3471637|NCT03868709|Placebo Comparator|Placebo group|Placebo inhalation is administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
3471638|NCT03868774|Active Comparator|rTMS standard|Low frequency (1 Hz), rTMS 20 sessions given on 20 consecutive days ( except weekends)
3471639|NCT03868774|Active Comparator|rTMS accelerated model|Low frequency ( 1 Hz), right prefrontal transcranial magnetic stimulation. 20 sessions given on 5 consecutive days ( 4 sessions each day)
3471640|NCT03868475|Experimental|Vacuum-assisted percutaneous excision|"Patients will undergo vacuum-assisted percutaneous excision (VAPE). The intervention group will have post-procedure imaging the same day to confirm complete excision.~The intervention group will then have imaging at 6, 12, and 24 months as per the radiology algorithms for following suspicious lesions (BIRADS 3 category). If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The intervention group will also be seen in clinic at 1 month with no imaging and then at 6, 12, and 24 months to correspond to the imaging visits."
3471641|NCT03868475|Active Comparator|Open surgical excision|"Patients will undergo standard open surgical excision.~The control group will then have follow up imaging at 12 and 24 months as per the usual radiology algorithms following excision of a lesion. If at any point during the imaging follow up, a suspicious lesion or calcifications are detected, it would be sampled with core needle biopsy and then surgically excised as appropriate.~The control group will also be seen in clinic at 1 month with no imaging and then at 12 and 24 months to correspond to the imaging visits."
3471642|NCT03868449|Experimental|Question Prompt List|Participants will be given a Question Prompt list that has been developed by the research team
3471643|NCT03868449|Active Comparator|3 questions list|Participants will be given 3 questions from the AskShareKnow method
3471644|NCT03868761|Other|Single Arm|21 male and female teenage participants will be randomized to one of three varying baseline assessment periods of two, four, or six weeks. Multiple baseline is a type of single-case experimental design (SCED) that is a time- and cost-effective method for evaluating efficacy of a new treatment, Sonoma Rises. The randomization of participants to baseline periods of varying lengths enables assessment of whether symptom changes occur when, and only when, the intervention is applied.
3125476|NCT02983448|Active Comparator|Active stimulation first|"Transcutaneous vagus nerve stimulation delivered at the earlobe (vagal innervation) is given on first session.~Sham stimulation delivered at the tragus (devoid of vagal innervation) is given on second session."
3125477|NCT02983552|Experimental|Binocular Computer Game Treatment|Binocular computer game treatment is defined as playing a Dig Rush application on an iPad® 1 hour per day, 5 days per week for 8 weeks in addition to continued spectacle correction (if required)
3471645|NCT03868579|Experimental|Observational (pleuroscopy, medical chart review)|Patients undergo biopsy of the lining of the lung using pleuroscopy. Medical chart of patients is also reviewed.
3471646|NCT03868605|Experimental|EMR/ESD|Standard EMR or ESD technique
3471647|NCT03868605|Experimental|Over- the- scope full- thickness resection device|Endoscopic full thickness resection
3125478|NCT02983552|Active Comparator|Continued Spectacle Correction|Continued spectacle correction is defined as wearing appropriate spectacle correction (if required) for all waking hours, 7 days per week for 8 weeks.
3125479|NCT02983604|Experimental|GS-5829 + exemestane (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with exemestane and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
3125480|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 1b)|Participants will be sequentially enrolled at progressively higher dose levels of GS-5829 (up to 9 mg) in combination with fulvestrant and may continue with treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
3125481|NCT02983604|Experimental|GS-5829 + fulvestrant (Phase 2)|Participants will receive GS-5829 (dose determined from Phase 1b) + fulvestrant until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
3125482|NCT02983604|Active Comparator|Fulvestrant (Phase 2)|Participants will receive fulvestrant alone until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever comes first.
3125485|NCT02983825|Experimental|Continuous positive airway pressure (CPAP) level changes|Protocol guided changes in CPAP level from clinical baseline, with responsiveness in V/Q mismatch guiding subsequent changes; limited to a range of -2 to +3 cm H2O from baseline
3471648|NCT03868748|Placebo Comparator|Placebo|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the placebo treatment arm will consume one placebo capsule per day for 12 weeks
3471649|NCT03868748|Experimental|Low Dose, 12 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the low dose treatment arm will consume one 150 mg beta-arbutin capsule per day for 12 weeks.
3471650|NCT03868748|Experimental|High Dose, 4 weeks|The double-blind phase of the study starts with randomized allocation of eligible participants to one of three treatment arms. Participants randomized to the high dose treatment arm will consume one placebo capsule per day for 8 weeks followed by one 400 mg beta-arbutin capsule per day for 4 weeks.
3471651|NCT03868657|Active Comparator|Moxifloxacin|Per os, 800 mg, once daily for 4 days
3471652|NCT03868657|Placebo Comparator|Placebo|Per os, 800 mg, once daily for 4 days
3471653|NCT03868423|Experimental|Treatment (brigatinib)|Patients receive brigatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3471654|NCT03868397|Experimental|Liver MRI|In this study, MRI refers to phase-contrast 4D flow sequence.
3471655|NCT03868293|Experimental|Drug-Resistant Epilepsy (temporal lobe)|Pulsed low intensity focused ultrasound
3471656|NCT03868306||Iron deficiency anaemia|Microcytic hypochromic anaemic patients with serum ferritin less than 12 Ng /ml
3471657|NCT03868306||Beta thalassemia Trait|Microcytic hypochromic anaemic patients with HBA2 more than 3.2 %
3471658|NCT03868020|Experimental|Diagnostic (fluciclovine F18 PET/CT)|Patients receive fluciclovine F18 IV and undergo PET/CT scan over 20-30 minutes.
3471659|NCT03868280|Active Comparator|Supine Positioning, Fracture Table|During the supine fracture table phase, patients will be positioned supine on a fracture table. The operative leg will be placed in a boot, attached to the traction limb. The non-operative leg will either be scissored away from the operating area in a traction boot (without traction placed) or placed in a stirrup at 90 degrees of hip flexion in hemi-lithotomy. A central post will be used to prevent patient movement during application of traction, and all bony prominences will be padded. Fluoroscopy will be obtained through standard practices intraoperative to document assessment of rotation.
3471660|NCT03868280|Active Comparator|Lateral Positioning, Free drape|During the lateral positioning phase, patients will be placed in lateral position after anaesthetic has been provided. A beanbag will be placed below the patient, and the patient will be safely turned to a lateral position. The beanbag will be inflated, the leg will be prepped, and a free drape will be applied. No traction will be used. Alternatively, some participating sites may use stulberg positioners rather than an inflatable beanbag, based on hospital preference. This positioning mirrors the positioning utilized for the direct lateral, posterior or posterolateral approach to a total hip arthroplasty or hemiarthroplasty
3471661|NCT03868072|Experimental|Reference/Test|"Period 1: XELJANZ 5Mg Tablet 1T~Period 2: Chong Kun Dang Tofacitinib Tablet 1T"
3471662|NCT03868072|Experimental|Test/Reference|"Period 1: Chong Kun Dang Tofacitinib Tablet 1T~Period 2: XELJANZ 5Mg Tablet 1T"
3471663|NCT03868124|Experimental|Implant Group 1|G2TR intraocular implant containing Travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
3471664|NCT03868124|Experimental|Implant Group 2|G2TR intraocular implant containing Travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
3471665|NCT03868124|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
3471666|NCT03868371|Active Comparator|1. high - 2. low|These are the patients receiving a high phosphorous containing meal in the first trial day, and a low phosphorous containing meal in the second trial day.
3471667|NCT03868371|Active Comparator|1. low - 2. high|These are the patients receiving a low phosphorous containing meal in the first trial day, and a high phosphorous containing meal in the second trial day.
3471668|NCT03868176||Experimental: reminder SMS before appointment|SMS before appointment detailing the date of consultation and exams to be performed before
3471669|NCT03868176||Active comparator: standard of care|
3471670|NCT03868137|Placebo Comparator|Placebo|3 doses of placebo identical to study drug will be given to patients starting 1 day before IUD insertion
3471671|NCT03868137|Experimental|Ibuprofen|3 doses of Ibuprofen 800 mg will be given to patients starting 1 day before IUD insertion. Patient will take 800 mg Ibuprofen at noon and 8 PM day before IUD insertion and at 8 AM on the day of IUD insertion.
3471672|NCT03868098|Active Comparator|Crisaborole 2% (application rate A, B, C)|Crisaborole (Marketed drug)
3471673|NCT03868098|Placebo Comparator|Placebo ointment (vehicle)|Placebo
3471674|NCT03868111|Experimental|Sufentanil|Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
3471675|NCT03868111|Experimental|Remifentanil|Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.
3471676|NCT03868189|Experimental|electroneuromyography|
3471677|NCT03868189|Placebo Comparator|control|
3471678|NCT03868241|Experimental|Bactiguard-coated Devices|Patients will receive endotracheal tube, central venous catheter and urinary cather coated with gold, silver and palladium (Bactiguard coating)
3471679|NCT03868241|Placebo Comparator|Control|Shelf endotracheal tube, central venous catheter and urinary cather available at each intensive care unit without any type of coating designed to prevent infection
3471680|NCT03868228|Experimental|Treatment with PIPAC|Patients with colorectal cancer and peritoneal metastases being treated with pressurised intraperitoneal aerosol chemotherapy (PIPAC)
3471681|NCT03868007|Experimental|RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent RIC twice daily for 14 days.And the RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
3471682|NCT03868007|Sham Comparator|sham-RIC group|Patients with AIS complicating ACS who were eligible for this study received standardized medical treatment and secondary prevention, including antiplatelets, low molecular weight heparin for anticoagulation，statins for lipid-lowering and stabilizing plaque, nitrates for vascular expansion and cardiocerebrovascular risk factors management. Administration of antihypertensive, antidiabetic or other agents were elective at the discretion of the treating physician according to the conditions of the patients. In addition, patients underwent sham-RIC twice daily for 14 days.And the sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
3179203|NCT00670410|Experimental|Arm B - Cord Blood Donor|Unrelated cord blood transplant: Patients without a related donor will receive immunotherapy with a non-myeloablative preparative regimen of busulfan and fludarabine followed by allogeneic stem cell transplant (AlloSCT) with either an unrelated umbilical cord blood donor (4/6, 5/6, or 6/6 HLA matched), or a related umbilical cord blood donor (3/6, 4/6, 5/6, or 6/6 HLA matched). Patients will receive Thymoglobulin ((rabbit) Anti-Thymocyte Globulin (ATG)) during the preparative regimen. GVHD prophylaxis will be Tacrolimus and mycophenolate mofetil (MMF).
3471683|NCT03868202|No Intervention|Premenopausal women|Participants will bring into clinic their first voided urine of the day on cycle days 9, 12 and 15 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH.
3471684|NCT03868202|Active Comparator|Postmenopausal women|Participants will bring into clinic their first voided urine of the day on assigned days 1, 4 and 7 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. The participants will then be started on EstroGel© for 14 days from day 7-21. During that time that they are on EstroGel©, the participants will bring into clinic their first voided urine of the day on assigned days 15, 18, and 21 in a urinary collection kit that will be given. A urine dip stick will be performed on the samples. Each time they bring in a sample, they will have a serum blood draw for estradiol and FSH. After the last urinary collection and blood draw, they will discontinue the EstroGel and be started on micronized progesterone if they have a uterus for 12 days.
3471685|NCT03867968|Experimental|TIPS Intervention|The Traumatic Brain Injury Positive Strategies (TIPS) program, is a comprehensive educational and training resource to help families. The web-based product will include: (a) the Training Center, which will provide training in a range of evidence-based strategies within a problem-solving framework; and (b) the TBI Resource Center, an extensive library of educational materials, information, and resources about childhood TBI.
3471686|NCT03867968|Active Comparator|Control|An existing website related to traumatic brain injury.
3471687|NCT03868358|Active Comparator|Real Stimulation|Real Stimulation: active transcranial magnetic stimulation(Intermittent Theta Burst Stimulation).Participants will receive active TMS once daily for two weeks
3471688|NCT03868358|Placebo Comparator|Sham Stimulation|Sham Stimulation:no stimulation.Participants will receive sham TMS once daily for two weeks
3471689|NCT03867955||Patients who have a neurosurgical intervention|Patients who have a neurosurgical intervention will be included. They will have a collection of datas.
3471690|NCT03868215||Patients with endoscopically removed malignant polyps|Patients with endoscopically removed malignant polyps
3471691|NCT03868033|Experimental|Continuous Denosumab|Continuous anti-resorptive therapy by Denosumab for 2 years
3471692|NCT03868033|Experimental|Zoledronic acid to Denosumab|treat with Zoledronic acid for one year and then shift to Denosumab for another one year
3471693|NCT03868033|Experimental|Continuous Zoledronic acid|Continuous anti-resorptive therapy by Zoledronic acid for 2 years
3471694|NCT03868033|Experimental|Zoledronic acid to observation|"treat with Zoledronic acid for one year and then close follow up by bone turn over marker.~resume another dose of Zoledronic acid if elevated CTX level above normal range"
3471695|NCT03868046||Patients treated with ICIs.|All enrolled patients must have been diagnosed with a cancer potentially treatable with ipilimumab, nivolumab, pembrolizumab, atezolizumab or avelumab, alone or in combination, per standard protocol.
3471696|NCT03868319|Experimental|control group|nonprotective ventilation with a tidal volume of 9 ml kg-1 PBW with ZEEP
3471697|NCT03868319|Experimental|LPV group|a tidal volume of 6 ml kg-1 PBW with a 7 cmH2O level PEEP
3471698|NCT03867929||STUDY|Patient with serum 25-Hydroxy vitamin D level <27.32
3125486|NCT02983877|Experimental|iTAB-CV|"In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 1, participants will receive alternating daily texts with educational and motivational content on treatment for high blood pressure and bipolar disorder, and a daily mood rating request to both monitor their mood and to determine adherence to iTAB-CV intervention. Stage 1 will last one month.~In the Individualized Texting for Adherence Building-CV (iTAB-CV) Stage 2, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from Stage 1. Stage 2 will last one month."
3125487|NCT02983981|Experimental|open label|Topicort topical spray
3471699|NCT03867929||CONTROL|Patient with serum 25-Hydroxy vitamin D level >27.32
3471700|NCT03867942|Active Comparator|monolayer group|monolayer of Gemigliptin/Rosuvastatin
3471701|NCT03867942|Experimental|bilayer group|bilayer of Gemigliptin/Rosuvastatin
3471702|NCT03867981|Experimental|Internet weight loss + possibility of brief phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive a brief period (i.e., once/week for 3 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
3125488|NCT02984267|Experimental|Ultrasound Group|The interventional group that will have their spine evaluated by ultrasound prior to epidural placement
3125489|NCT02984267|Other|Palpation Group|The control group that will have their epidural placed in the usual fashion based on palpation
3125490|NCT02984644|Active Comparator|Dapagliflozin|32 subjects will receive dapagliflozin 10mg
3471703|NCT03867981|Experimental|Internet weight loss + possibility of extended phone coaching|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. Some participants in this group will also be selected to receive an extended period (i.e., once/week for 12 weeks) of phone coaching starting at week 5. The first coaching call will be approximately 45 minutes in duration and remaining calls with be 10-15 minutes. Coaches will problem solve with participants and help them develop an individualized meal plan.
3471704|NCT03867981|Active Comparator|Internet weight loss only|Participants randomized to this group will receive a 4-month, Internet-delivered weight loss program followed by an 8-month, Internet-delivered weight loss maintenance program. All individuals will be taught behavioral strategies for changing diet and physical activity behaviors via video lessons. No participants in this group will receive any phone coaching.
3471705|NCT03867994|Experimental|Group (A)|included 49 patients who received high dose statin (80 mg atorvastatin) 12 hours before CC and 40 mg just before CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
3125491|NCT02984644|Placebo Comparator|Placebo|16 subjects will receive placebo
3125492|NCT02984683|Experimental|SAR566658 90 mg/m^2|Participants received SAR566658 90 milligram per square meter (mg/m^2) as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
3471706|NCT03867994|Experimental|Group (B)|included 48 patients who received 12.5 mg carvedilol twice daily for 7 days before CC and continued for 24 hours after the CC +hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization.
3471707|NCT03867994|Experimental|Group (C)|included 47 patients who did not receive any medications but only hydration with saline (0.9% NaCl) at 0.5-1 mg/kg/hour for 4-6 hours before and 4-6 hours after cardiac catheterization
3471708|NCT03867877|Experimental|Periodized Training with Motor Practice|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
3125493|NCT02984683|Experimental|SAR566658 120 mg/m^2|Participants received SAR566658 120 mg/m^2 as intravenous infusion on Day 1 and Day 8 of each 21-day treatment cycle (maximum number of cycles received was 3).
3125494|NCT02984709|Experimental|Positive Psychology Intervention|The text message group will receive the intervention components via text message. They will be instructed to think about things that make them feel good when they are struggling with diabetes management (i.e. gratitude). Also they will be instructed to think about a positive value when they are in a situation that makes it hard to check their blood sugar (i.e. Self-Affirmation). Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths. All adolescents will be given developmentally-appropriate diabetes education material at the time of enrollment.
3125495|NCT02984709|Active Comparator|Education Group|The education group will be given developmentally-appropriate diabetes education material at the time of enrollment.
3125496|NCT02984878|Experimental|Revanesse Ultra|Revanesse Ultra open label retreatment
3125497|NCT02984943|Experimental|Hyperbaric Oxygen|Hyperbaric Oxygen
3125498|NCT02984982|Active Comparator|Standard of Care|Statin therapy (atorvastatin or rosuvastatin) will be administered with or without non-statin lipid modifying therapies (LMTs). Non-statin LMTs will be adjusted by physicians to achieve the LDL-C target level <100 milligrams per deciliter (mg/dL).
3471709|NCT03867877|Experimental|Simple Periodized Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and 60-75% of subjects' maximum strength for the hypertrophy day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down
3471710|NCT03867617|Experimental|Study group|Treatment with regulatory T cells, donor bone marrow and tocilizumab in addition to immunosuppressive drug therapy in kidney transplant recipients
3471711|NCT03867617|Active Comparator|Control group|Immunosuppressive drug therapy without treatment with regulatory T cells, donor bone marrow and tocilizumab in kidney transplant recipients
3471712|NCT03867552|Experimental|Altered gas (86% CO2, 10% N2O, 4% O2)|Surgery with the use of the altered insufflation gas (86% CO2, 10% N2O, 4% O2)
3471713|NCT03867552|Active Comparator|Standard gas (100% CO2)|Surgery with the use of the standardized gas (100% CO2)
3471714|NCT03867760|Experimental|Intervention Group|Participants will use the recorded hypnosis intervention (RHI) at home for 28 days.
3471715|NCT03867760|Active Comparator|Attention Control Group|Participants will use a recorded relaxation intervention at home for 28 days.
3471716|NCT03867539|Active Comparator|Control Group; Bupivacaine + opioids|"This is the standard of care arm. This group will receive pre-operative opioid education and standard of care, which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies."
3471717|NCT03867539|Experimental|Experimental Group: Exparel, no opioids|This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
3471718|NCT03867500|Experimental|Niacin|Intravenous niacin infusion
3471719|NCT03867500|Placebo Comparator|Saline|Intravenous saline infusion
3471720|NCT03867786|Experimental|Exercise Condition|Participants will undergo a 40 minute exercise protocol
3471721|NCT03867786|Active Comparator|Video Control Condition|Participants will view a 40 minute nature video
3125499|NCT02984982|Experimental|Alirocumab|Alirocumab will be given subcutaneously every 2 weeks on top of stable dose statin therapy (atorvastatin or rosuvastatin) with or without stable dose non-statin LMTs.
3471722|NCT03867773|Experimental|4-hour Time restricted feeding|4-h TRF subjects will consume food ad libitum between 3pm and 7pm (4-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 3pm (20-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
3471723|NCT03867773|No Intervention|Control|Controls will be instructed to maintain their weight throughout the trial, and not to change eating or physical activity habits. Controls will visit the research center at the same frequency as the TRF groups (for outcome measurements).
3125500|NCT02984995|Experimental|Initial dose 30 mg/day quizartinib|Participants who received an initial dose of 30 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 60 mg/day at Day 15.
3125501|NCT02984995|Experimental|Initial dose 20 mg/day quizartinib|Participants who received a CYP3A4 strong inhibitor received an initial dose of 20 mg/day of quizartinib and, if no QT prolongation, the dose escalated to 30 mg/day at Day 15.
3471724|NCT03867773|Experimental|6-hour Time restricted feeding|6-h TRF subjects will consume food ad libitum between 1pm and 7pm (6-h feeding window), and refrain from eating and drinking caloric beverages from 7pm to 1pm (18-h fasting window) each day. These subjects will not be instructed to limit/monitor energy intake during the feeding window. Subjects will be encouraged to drink plenty of water during the fasting period.
3471725|NCT03867695|Experimental|Serratus Block|"At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.~Under ultrasonography assistance, block will be performed at the fifth rib in the midaxillary line. Local anesthetic will be injected either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of ropivacaine will be prepared identically by the central pharmacy, without any possible identification of the product."
3471726|NCT03867695|Placebo Comparator|Placebo Block - Control Group|"Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution. Under ultrasonography assistance, placebo will be injected at the fifth rib in the midaxillary line, either superficial to the serratus anterior muscle or deep underneath the muscle.~Anesthesiologists, and all the nurses and caring staff involved in this study will be blinded. Solutions of sterile saline will be prepared identically by the central pharmacy, without any possible identification of the product."
3471727|NCT03867604|Sham Comparator|Sham injection|Subcutaneous injection at upper trapezium muscle level
3471728|NCT03867604|Experimental|Fascia injection|Fascia injection, below upper trapezium muscle
3471729|NCT03867799|Experimental|Nivolumab and Relatlimab|Nivolumab 480mg and Relatlimab 160mg will be administered intravenously every 4 weeks
3471730|NCT03867669|Experimental|Single Patient Room|Patients randomized to this arm will be admitted to a NICU single patient room.
3471731|NCT03867669|Placebo Comparator|Open Bay|Patients randomized to this arm will be admitted to the open bay NICU Unit.
3471732|NCT03867656|Experimental|GLP-2|Glucagon-like peptide 2
3471733|NCT03867656|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
3471734|NCT03867656|Placebo Comparator|Placebo|Saline
3471735|NCT03867578|Other|Exploratory Phase - Standard CT Imaging and HR-MRI|The goal is to test several different novel Magnetic Resonance sequences to determine which gives the best visualization of peritoneal disease.
3471736|NCT03867578|Other|Testing Phase- Conventional and HR-MRI and Ultrasound|Patients will undergo conventional and HR-MRI imaging as well as abdominal ultrasound to define the performance of these methods.
3471737|NCT03867565|No Intervention|No nutritional diagnosis|Patients without nutritional diagnosis get SOC
3471738|NCT03867565|Experimental|Nutritional diagnosis|Patients with nutritional diagnosis get nutritional intervention by dietitian.
3471739|NCT03867591|Experimental|Gastro-AD® Group|The participants randomized to this group 1 g of Gastro-AD® powder per sachet + flavoring agents.
3471740|NCT03867591|Placebo Comparator|Placebo Group|Participants in this arm will take a sachet containing maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
3471741|NCT03867513||mTBI cases|Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
3471742|NCT03867513||Acute trauma controls|Non-head trauma controls matched for age and sex with the mTBI group
3471743|NCT03867734|Experimental|2g Aztreonam|Subjects to receive 2g Aztreonam IM for the treatment of gonorrhea
3471744|NCT03867864|Experimental|Group A|Group A participants will wear the necklace with essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace without essential oil for last 4 weeks (the sixth to ninth weeks).
3471745|NCT03867864|Other|Group B|The group B will wear the necklace without essential oil for the first 4 weeks except take a shower or get to sleep. The participants will stop wearing the necklace for one week (the fifth week) for washout period, and then wear the necklace with essential oil for last 4 weeks (the sixth to ninth weeks).
3471746|NCT03867851|Experimental|IBsolvMIR|Study drug IBsolvMIR administered intravenously at 18 mg/kg on day of transplantation and 3 mg/kg on post-operative days 1, 3, 6.
3471747|NCT03867851|Active Comparator|Heparin|Heparin treatment according to clinical praxis.
3471748|NCT03867708||patients with residual shunt|patient with residual left to right shunt detected by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
3471749|NCT03867708||patients without residual shunt|patient without residual left to right shunt by 2D-TTE at 6 month follow up after ASD device closure guided by 3D-TEE
3125502|NCT02985021|Experimental|Treatment (docetaxel, carboplatin)|"Docetaxel 60 mg/m2 will be administered on Day 1 of each 21-day cycle. Carboplatin Area Under the Curve (AUC) 5 will be administered on Day 1 of each 21-day cycle.~Docetaxel and carboplatin should be administered per institutional guidelines. Treatment will be repeated until disease progression or unacceptable toxicity."
3125503|NCT02985398|Experimental|ALD403 (Eptinezumab) Dose Level 1|ALD403 (Eptinezumab) Dose Level 1 (IV)
3125504|NCT02985684|Experimental|Device|ASD closure with the GORE® CARDIOFORM ASD Occluder
3125505|NCT02985710|Other|Sudoscan only|Patients in this arm will only undergoing testing with Sudoscan.
3125506|NCT02985710|Other|Sudoscan Plus|Patients in this arm will get Sudoscan testing as well as a skin biopsy and QSART testing.
3125507|NCT02985827|Active Comparator|Rohto (r) Hydra|Menthol containing over the counter eyedrop
3125508|NCT02985827|Placebo Comparator|Systane (r) Ultra|Non-Menthol containing over the counter eyedrop
3125509|NCT02985879|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection/Solution for Infusion; intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks
3125510|NCT02985879|Experimental|ABBV-8E12 2000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
3125511|NCT02985879|Experimental|ABBV-8E12 4000 mg|Intravenous infusions at Day 1, Day 15, and Day 29, then every 28 days for 52 weeks; 300 mg/15 mL (participants in countries other than Japan or Spain); 1000 mg/10 mL (for participants in Japan or Spain)
3125512|NCT02985996|No Intervention|Phase I/Pre-Drug|Ten participants will be asked to complete study phase 1. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
3125513|NCT02985996|Experimental|Phase II/Genvoya|Participants will receive one dose Genvoya. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
3125514|NCT02985996|Experimental|Phase II/Truvada|Participants will receive one dose of Truvada. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
3125515|NCT02985996|Experimental|Phase III/Genvoya|Participants will receive Genvoya once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
3125516|NCT02985996|Experimental|Phase III/Truvada|Participants will receive Truvada once daily for ten days. Participants will be asked to provide blood and urine samples and undergo penile, urethral, and rectal swabs. Up to 12 rectal biopsies will be taken.
3471750|NCT03867682|Experimental|Phase I and Phase II|"Lintuzumab-Ac225 administered on Day 1 of each cycle for four cycles (unless in the 0.5 μCi/kg or 0.25 μCi/kg cohorts, where there is a potential for an additional four cycles, pending PI and Medical Monitor review).~Venetoclax taken on Days 1-21 of each cycle for up to 12 cycles.~Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery."
3471751|NCT03867721|Experimental|Ventilator PB560 (Covidien)|The non-dedicated (NON-DED) set comprised a ventilator for MPV (PB560) using a single active tubing with an exhalation valve. A custom-made arm support and plastic mouthpiece were used.
3471752|NCT03867721|Experimental|Ventilator Trilogy (Philips Respironics)|The dedicated (DED) set comprised a ventilator for MPV (Trilogy 100, Philips Respironics; with dedicated software, with a single passive tubing without exhalation valve. A back-up rate set at zero cycle per minute was associated with a kiss trigger, with a smart flexible tube support system and with a silicone made mouthpiece designed as a straw.
3471753|NCT03867812|No Intervention|Fasting + alcoholic drink|No food (0 calories) but 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
3471754|NCT03867812|Experimental|SOBAR bar + alcoholic drink|One 70g bar (210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
3471755|NCT03867812|Active Comparator|Control food + alcoholic drink|48.5g of General Mills Chexmix (Honey Nut Flavor, 210 calories) plus 250ml of water followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
3471756|NCT03867812|Active Comparator|Full meal + alcoholic drink|Stouffer's Bistro Crostini 5 Cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie (635 calories total) followed by an alcoholic drink (a 20% alcohol by volume cocktail dosed so that men receive 0.35g alcohol per kg of body weight and women a 0.30g/kg dose).
3471757|NCT03867630||Runoff Group|Runoff group are the patients whose images were shown root shadow by contrast media.
3471758|NCT03867630||Nonrunoff-Transforaminal group|Nonrunoff-Transforaminal group are the patients whose images are not shown root shadows by contrast media, so additional transforaminal blocks are done.
3125517|NCT02986074|Experimental|Anatomical midline lead first|subjects in this group will receive stimulation first using an anatomical midline placed lead and subsequently using a paresthesia mapping placed lead
3125518|NCT02986074|Experimental|Paresthesia mapping lead first|subjects in this group will receive stimulation first using a paresthesia mapping placed lead and subsequently using an anatomical midline placed lead
3471759|NCT03867630||Nonrunoff-NonTransforaminla group|Nonrunoff-NonTransforaminal group are the patients whose images are not shown root shadows by contrast media, but no additional transforaminal blocks are done.
3471760|NCT03867487|Experimental|Study intervention|Empagliflozin 10 mg will be taken daily
3125519|NCT02986139|Experimental|Sequence AB|Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
3471761|NCT03867487|Placebo Comparator|Control arm|Placebo oral tablet will be taken daily
3471762|NCT03867747|Experimental|Cardiac Radiosurgery|25 Gy in a single fraction
3471763|NCT03867474|Experimental|Intervention (MBSR)|Mindfulness-Based Stress Reduction (MBSR) - Intervention Arm
3125520|NCT02986139|Experimental|Sequence BA|Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).
3125521|NCT02986282|Other|Single arm|Interventions - repeated ankle - brachial index measurement before and after electrical cardioversion in patients with atrial fibrillation
3125522|NCT02986373|Experimental|Risankizumab|Participants received open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 12, 24, and 36.
3125523|NCT02986711|Experimental|Motivational Text Messages|Motivational text messages to help participants stay quit when they leave the hospital.
3125524|NCT02986711|Sham Comparator|Control|Text messages to ask about current smoking status.
3125525|NCT02986802||Genital herpes treated before third trimester|Women with genital herpes receiving treatment before the 3rd trimester
3125526|NCT02986802||Genital herpes treated only during third trimester|Women with genital herpes receiving treatment during the 3rd trimester
3125527|NCT02986802||Genital herpes untreated|Women with untreated genital herpes
3125528|NCT02986802||Control group|Women (controls) with neither genital herpes nor treatment
3125529|NCT02986854|Experimental|Menveo-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menveo 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
3125530|NCT02986854|Experimental|Menactra-Menveo Group|Approximately 300 subjects, who were vaccinated with a single dose of Menactra 4 to 6 years before, will receive one dose of MenACWY-CRM at Day 1.
3125531|NCT02986854|Active Comparator|Naive Group|Aproximately 100 subjects, of similar age to subjects enrolled in other primed groups, who have not received any meningococcal vaccination, will receive one dose of MenACWY-CRM at Day 1.
3125532|NCT02986958|Experimental|Checklist|One-page paper-pencil agenda setting checklist involving two activities for older primary care patients and their family companion. The purpose of the checklist is to 1. clarify the role of the family companion during the visit, and 2. to discuss patient health issues to discuss with the primary care provider
3125533|NCT02986958|Placebo Comparator|Usual Care|Care as usual with their primary care provider
3125534|NCT02987205|Experimental|Revanesse Ultra|Revanesse Ultra in the NLF on one side of the face
3125535|NCT02987205|Active Comparator|Restylane|Restylane injection in the NLF on the other side of the face to optimal correction
3125536|NCT02987231|Sham Comparator|CAF + SHAM|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. Patients randomized to the SHAM Group will receive the simulation of the electrical stimulation process.
3125537|NCT02987231|Experimental|CAF + ES|CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
3125538|NCT02987374|Other|2011-2012 Fluzone IIV3 (IM)|Seasonal trivalent flu vaccine: NDC No 49281-011-50
3179204|NCT00670436|Active Comparator|A 1|paclitaxel eluting PTCA balloon (SeQuent please) after bare-metal stenting of a chronic total occlusion in a native coronary artery
3125539|NCT02987543|Experimental|Olaparib|Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose of 300 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions
3125540|NCT02987543|Active Comparator|Enzalutamide OR abiraterone acetate|"Enzalutamide:~Enzalutamide is available as capsules or tablets containing 40 mg of enzalutamide. Subjects will be administered study treatment orally at a dose of 160 mg once daily.~Abiraterone acetate with prednisone: Abiraterone acetate is available as tablets containing 250 mg or 500 mg of abiraterone acetate. Subjects will be administered study treatment orally at a dose of 1,000 mg once daily in combination with prednisone 5 mg administered twice daily orally. Prednisolone is permitted for use instead of prednisone if necessary."
3471764|NCT03867474|No Intervention|Control - Usual Care|Control
3471765|NCT03867461|Active Comparator|Group A|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group A: Initial Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-80 mmHg, End tidal CO2 38-40 mmHg."
3471766|NCT03867461|Active Comparator|Group B|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group B: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 60-80 mmHg, End tidal CO2 38-40 mmHg,"
3471767|NCT03867461|Active Comparator|Group C|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group C: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 24-26 mmHg, Subsequent Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg,"
3471768|NCT03867461|Active Comparator|Group D|"Adult patients determined to be candidates for venous sinus stenting.~End tidal CO and Mean Arterial Pressure will be adjusted to the following parameters during the intervention:~For Group D: Initial Recording: Mean Arterial Pressure 100-110 mmHg, End tidal CO2 38-40 mmHg, Subsequent Recording: Mean Arterial Pressure 100-100 mmHg, End tidal CO2 24-24 mmHg,"
3471769|NCT03867188|Experimental|Liiposomal Bupivacaine Group|Qualified participants with a soft tissue sarcoma of the thigh will be given the alternative protocol utilizing liposomal bupivacaine (Exparel®). The alternative protocol will utilize general or spinal anesthesia, but will also include the use of intraoperative liposomal bupivacaine instead of a regional nerve block.
3471770|NCT03867188|No Intervention|Control Group|A retrospective control group will be assembled from electronic medical records of 3 patients who underwent resection of a soft tissue sarcoma of the thigh and will be accessed and analyzed for the variable of interest.
3471771|NCT03867097|Placebo Comparator|Placebo|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
3125541|NCT02987621|Experimental|Sham first, wash out 7 days, then tDCS|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
3125542|NCT02987621|Experimental|tDCS first, wash out 7 days, then Sham|"Separated by a minimum of 7 days from the sham treatment in a counterbalance order, all participants will perform leg muscle strength and fatigue testing once with tDCS stimulation.~Leg muscle strength testing will be measured by performing a series of maximal effort knee extension, knee flexion, plantar/dorsi-flexion trials.~Sham: Less than 0V of Transcranial Direct Current Stimulation tDCS: Less than 10V of Transcranial Direct Current Stimulation"
3125543|NCT02987660|Experimental|LASIK with EX500|Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
3125544|NCT02987660|Active Comparator|SMILE with VisuMax|Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
3125545|NCT02987829|Experimental|Dose Level 1: TRC253 40 mg daily|40 mg of single-agent TRC253 to be administered as oral capsules once daily
3125546|NCT02987829|Experimental|Dose Level 2: TRC253 80 mg|80 mg of single-agent TRC253 to be administered as oral capsules once daily
3125547|NCT02987829|Experimental|Dose Level 3: TRC253 160 mg|160 mg of single-agent TRC253 to be administered as oral capsules once daily
3125548|NCT02987829|Experimental|Dose Level 4: TRC253 240 mg|240 mg of single-agent TRC253 to be administered as oral capsules once daily
3125549|NCT02987829|Experimental|Dose Level 5: TRC253 280 mg|280 mg of single-agent TRC253 to be administered as oral capsules once daily
3125550|NCT02987829|Experimental|Dose Level 6: TRC253 320 mg|320 mg of single-agent TRC253 to be administered as oral capsules once daily
3125551|NCT02987868|Active Comparator|Supplement 1st day, placebo 2nd day|Administration of oral supplement (proprietary amino acid derivative blend). Half of the participants took the Amino acid supplement first day and half of the participants took the Amino acid supplement second day.
3125552|NCT02987868|Placebo Comparator|Placebo 1st day, supplement 2nd day|Half of the participants took the placebo first day and half of the participants took placebo second day.
3125553|NCT02987959|Experimental|TAK-228 treatment|Patients with complex genomic sarcomas exhibiting PI3K pathway dysregulation will be treated with TAK-228
3125554|NCT02987972|Experimental|V114 Lot 1|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 1 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
3125555|NCT02987972|Experimental|V114 Lot 2|Infants will receive a 0.5 mL intramuscular injection of V114 Lot 2 at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
3125556|NCT02987972|Active Comparator|Prevnar 13™|Infants will receive a 0.5 mL intramuscular injection of Prevnar 13™ at 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13)
3125557|NCT02988050|Other|Propofol-dexmedetomidine|Propofol-dexmedetomidine Bupivacaine; Lidocaine (local anaesthetics) Epinephrine (with local anaesthetics for skin infiltration)
3125558|NCT02988050|Other|Propofol-remifentanil|Propofol-remifentanil Bupivacaine; Lidocaine Epinephrine (with local anaesthetics for skin infiltration)
3471772|NCT03867097|Active Comparator|Iloprost Injection, for intravenous use|Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line. Study drug will be initiated at a starting dose 0.5 ng/kg/min up to 2.0 ng/kg/min.
3471773|NCT03867383|Experimental|Calcium Chloride|"Non-participating anesthesiologist prepares the drug solution, which is 1 gram of calcium chloride diluted into a total volume of 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour (for a calcium infusion rate of 100 milligrams /minute until the full 1 gram dose is administered).~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
3471774|NCT03867383|Placebo Comparator|Placebo|"Non-participating anesthesiologist prepares the placebo solution, which is 60 milliliters normal saline, labeled only with the study ID number. The solution is administered intravenously utilizing an Alaris syringe pump and microbore tubing, with infusion starting immediately at the time of fetal delivery at a rate of 360 milliliters per hour.~This is a one-time administration. Patients continue to receive all standard care during the Cesarean including 1 unit oxytocin bolus at the time of fetal delivery + continuous oxytocin infusion at 7.5 units per hour per our institution's protocol."
3125559|NCT02988115|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
3125560|NCT02988115|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
3125561|NCT02988193|Experimental|optima4BP Medication Management|"optima4BP will provide a monthly medication optimization to the treating physician for review and subsequent implementation. The Treatment Recommendation will consist of:~curated blood pressure (BP) and heart rate (HR) values reported by the patient through the use of home monitoring BP arm cuff;~medication treatment recommendation;~active link to access additional treatment analysis tools."
3125562|NCT02988193|No Intervention|Usual Care Medication Management|Usual care management will follow medication treatment management according to the physician preference. The treating physician will not be provided with a medication optimization recommendation, nor with monthly curated BP and HR values.
3125563|NCT02988219|Active Comparator|General anesthesia (G)|Holter ECG monitor General anesthesia Open kidney cancer surgery
3125564|NCT02988219|Experimental|Combined general/epidural (G/E)|Holter ECG monitor Epidural anesthesia General anesthesia Open kidney cancer surgery
3125565|NCT02988349|Active Comparator|Caries-free subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
3125566|NCT02988349|Experimental|Caries-active subjects|Subjects will use Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks,.
3125567|NCT02988622|Other|Scar treated with Fraxel and CO2 laser|One half of scar is treated with Fraxel laser and the other half of scar is treated with CO2 laser.
3125568|NCT02988843|Experimental|Brentuximab Vedotin & Bevacizumab|"Bevacizumab will be administered at a dose of 15 mg/kg IV every 21 days; over 90 minutes during 1st infusion, over 60 minutes as 2nd infusion and over 30 minutes for subsequent infusions if prior infusions well tolerated.~Brentuximab vedotin will be administered first at 1.8 mg/kg (maximum dose of 180 mg) IV over 30 minutes every 21 days."
3125569|NCT02988856|Experimental|Magnetic lid system|All participants will trial a commercially available device and an experimental magnetic device.
3125570|NCT02988882|Experimental|OTX-DP|OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use
3125571|NCT02988882|Placebo Comparator|PV|PV (placebo drug delivery vehicle)
3125572|NCT02988986|Experimental|TAK-228 Plus Tamoxifen|"TAK-228 will be orally administered at 30 mg weekly for 16 weeks.~Tamoxifen will be orally administered at 20 mg daily for 16 weeks."
3125573|NCT02989168|Experimental|GBT440 900 mg Dose|"Part A, 900 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
3125574|NCT02989168|Experimental|GBT440 1500 mg Dose|"Part B , 1500 mg~GBT440: Capsules which contain GBT440 drug substance in Swedish orange"
3125575|NCT02989246|Experimental|Intervention Arm|Ventilator management using the proposed protocol in both acute and weaning phases. Patients will be managed according the the Ventilator protocol using the esophageal catheter for the weaning phase
3125576|NCT02989389|Experimental|LY3323795 (Part A)|Participants received escalating doses of 0.3 mg (milligrams), 1 mg, 3 mg, 10 mg, 30 mg and 100 mg of LY3323795 orally.
3125577|NCT02989389|Placebo Comparator|Placebo (Part A)|Participants received placebo identical to LY3323795 orally.
3125578|NCT02989389|Experimental|LY3323795 (Part B)|Participants received 6 mg, 20 mg and 80 mg of LY3323795 orally.
3125579|NCT02989389|Placebo Comparator|Placebo (Part B)|Participants received placebo identical to LY3323795 orally.
3125580|NCT02989389|Experimental|LY3323795 (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
3125581|NCT02989389|Experimental|LY3323795 + Itraconazole (Part C)|Part C was not initiated due to a Lilly internal strategy decision.
3125582|NCT02989493|Experimental|Doxazosin|Participants receive 8 weeks of doxazosin (8mg target dose).
3125583|NCT02989493|Placebo Comparator|Placebo|Participants will receive 8 weeks of matched placebo.
3125584|NCT02989545|No Intervention|Off treatment|2 week period without intervention
3125585|NCT02989545|Experimental|Treatment period|2 week period with intervention
3125586|NCT02989610|Experimental|Omnidirectional followed by directional DBS|Omnidirectional DBS is used for the first 3 months in all subjects, unless not tolerated. Directional DBS is used for months 3-6 in all subjects with a directional DBS lead. Primary endpoint is based on double-blind testing of omnidirectional vs. directional DBS in randomized order at 3-month follow-up visit.
3125587|NCT02989649||Alogliptin or Alogliptin Fixed Dose Combinations (FDCs)|Participants with type 2 diabetes mellitus (T2DM) who received alogliptin or alogliptin FDCs, orally, prescribed by the physician as part of participants' T2DM treatment program (independent of participation in this study) were observed for approximately 6 months, or up to loss to follow-up or death, whichever occurred first.
3125588|NCT02989714|Experimental|HD IL2 and Nivolumab|
3125589|NCT02989727|Experimental|Lamotrigine - melancholic depression|Participants with melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
3125590|NCT02989727|Placebo Comparator|Placebo - melancholic depression|Participants with melancholic depression who were randomly assigned to receive a placebo comparator.
3471775|NCT03867136|Experimental|PZA sensitivity guided ultra-short all Oral Regimen|The PZA sensitivity guided ultra-short regimen consists of two periods of 24-36 weeks. During the first 4-8 weeks(waiting for pyrazinamide drug sensitivity test), the regimen consists of levofloxacin, linezolid, cycloserine, pyrazinamide, and clofazimine. Then based on molecular PZA drug sensitivity results, patients will be in divided into two sub-groups: pyrazinamide-susceptible (PZA-S) patients and pyrazinamide-resistant (PZA-R) patients. The Regimen for PZA-S patients, consisting of levofloxacin, linezolid, cycloserine, and pyrazinamide, are given until the 24th week (prolonged to 28 or 32 weeks if no smear conversion by end of 16th and 20th week). PZA-R sub-group regimen, consisting of levofloxacin, linezolid, cycloserine, and clofazimine given until 36th week (prolonged to 40 or 44 weeks if no smear conversion by end of 16th and 20th week)
3471776|NCT03867136|Active Comparator|Standardized Shorter Regimen|WHO standardized shorter regimen group consists of 36-44 weeks with two phases of treatment. The first is an intensive phase of 16 weeks (extended up a maximum of 20 or 24 weeks in case of lack of smear conversion at the end of 16 or 20 weeks), and included moxifloxacin, amikacin, prothionamide, pyrazinamide, high-dose isoniazid, ethambutol and clofazimine. This is followed by a continuation phase of 20 weeks with the following agents: moxifloxacin, pyrazinamide, ethambutol and clofazimine.
3471777|NCT03867071|Experimental|erythropoietin (EPO) group|
3471778|NCT03867071|Placebo Comparator|Placebo (PLA) group|
3471779|NCT03867110|Placebo Comparator|Placebo|Placebo is to be taken orally once a day (QD) in the morning for 12 consecutive weeks.
3471780|NCT03867110|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) is to be taken orally QD in the morning for 12 consecutive weeks.
3471781|NCT03867110|Active Comparator|Atorvastatin 10 mg|Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471782|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 10 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 10 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471783|NCT03867110|Active Comparator|Atorvastatin 20 mg|Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471784|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 20 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 20 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471785|NCT03867110|Active Comparator|Atorvastatin 40 mg|Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471786|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 40 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 40 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471787|NCT03867110|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471788|NCT03867110|Experimental|Ezetimibe 10 mg + Atorvastatin 80 mg|Ezetimibe 10 mg (MK-0653, SCH 58235) + Atorvastatin 80 mg is to be taken orally QD in the morning for 12 consecutive weeks.
3471789|NCT03867279|Experimental|Flossing|The subjects included in this group will perform a protocol of reeducation exercises plus the application of the Flossing technique. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
3125591|NCT02989727|Experimental|Lamotrigine - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive lamotrigine tablets escalated to a target dose of 200mg/day.
3125592|NCT02989727|Placebo Comparator|Placebo - nonmelancholic depression|Participants not meeting DSM-IV-TR diagnostic criteria for melancholic depression who were randomly assigned to receive a placebo comparator.
3471790|NCT03867279|Active Comparator|Reeducation exercises|The subjects included in this group will carry out a protocol of reeducation exercises. The intervention will last 4 weeks, with two weekly sessions of 15 minutes each
3471791|NCT03867370|Experimental|Group A|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
3471792|NCT03867370|Experimental|Group B (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W and lenvatinib for up to 48 weeks.
3125593|NCT02989805|Active Comparator|Professional Care Manager|Each participating site will have a nurse or social worker to provide care management. Training activities will include modules for each of the key domains covered in the intervention: shared decision making, action planning; motivational interviewing; and mental health as a cornerstone of recovery, working effectively within the mental health system; and self-care and stress management.
3125594|NCT02989805|Experimental|Peer Specialist Care Manager|Each participating site will have a peer specialist to provide care management. Peer specialists will have a minimum of a high school education, a history of a mental illness, be self-described as 'in recovery,' and have reliable transportation to the study site. All certified peer specialists will receive training in a curriculum that supports identifying and pursuing goals for recovery; developing and documenting recovery-focused treatment plans; and supporting linkages with community-based services. Peers learn to help other individuals with mental health conditions to facilitate mental health dialogues; explore mental health choices and options; identify and work with a clinician; and obtain access to community health supports.
3125595|NCT02990000|No Intervention|Pragmatic Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a pragmatically matched provider (control group)
3125596|NCT02990000|Experimental|Scientific Match|Randomly assigned, by a case-assigning administrator, to naturalistic treatment with a scientifically matched provider (experimental group)
3179205|NCT00670436|Active Comparator|A2|historical population of patients with a chronic total occlusion in a native coronary artery treated with the paclitaxel eluting Taxus stent (Boston Scientific)
3471793|NCT03867370|Active Comparator|Group C (Toripalimab, Lenvatinib)|During the neoadjuvant period, the patients will receive a single dose JS001 intravenous infusion of 480 mg in combination with oral lenvatinib at a starting dose of 8 or 12 mg once a day. After the operation, the patients will receive JS001 240 mg Q3W for up to 48 weeks.
3471794|NCT03867175|Experimental|Arm 1 Stereotactic Body Radiation Therapy/Pembrolizumab|3-10 treatments of SBRT/ pembrolizumab IV for 30 minutes every 3-4 weeks for 1 year at doctor's discretion.
3471795|NCT03867175|Experimental|Arm 2 Pembrolizumab|Patients receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
3471796|NCT03867253|Active Comparator|ORY-2001 Low dose|0.6mg ORY-2001 capsule
3471797|NCT03867253|Active Comparator|ORY-2001 High dose|1.2mg ORY-2001 capsule
3471798|NCT03867253|Placebo Comparator|Placebo|Placebo capsule
3471799|NCT03867214|Experimental|Experimental|"Receiving TXA, Study group~Tranexamic acid, Study group tranexamic acid 1g,~intravenous injection, pre-operationally"
3471800|NCT03867214|Placebo Comparator|Placebo Comparator|"Normal saline, Control group~Not receiving tranexamic acid, Control group Normal~saline 100mL, intravenous injection, pre-operationally"
3471801|NCT03867292|Experimental|Myofascial|The subjects that include the experimental group will receive an intervention through myofascial therapy of crossed hands and electrotherapy
3471802|NCT03867292|Active Comparator|Electrotherapy|The subjects that are included in the experimental group will receive an intervention through electrotherapy
3471803|NCT03867396|Active Comparator|Cochlear Implant and Hearing Aid|Subject wears a hearing aid on the contralateral side of the cochlear implant. Subject will use a clinic-loaned Naida hearing aid for listening tests.
3471804|NCT03867396|Active Comparator|Cochlear Implant alone|Subject only uses the cochlear implant; hearing on the contralateral side is unaided.
3125597|NCT02990338|Active Comparator|Pd (pomalidomide + dexamethasone)|Participants received pomalidomide 4 milligrams (mg) Per os (PO) on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants greater than or equal to (>=) 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).
3125598|NCT02990338|Experimental|IPd (isatuximab + pomalidomide + dexamethasone)|Participants received isatuximab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants >= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).
3125599|NCT02990910|Other|Individualized opioid analgesia|One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine.Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
3125600|NCT02990910|Other|conventional opioid analgesia|Another group: all received 25μg/kg morphine .Scored every 10 minutes until CHEOPS<=6 and Aldrete score>9.
3125601|NCT02991040|Experimental|Revanesse Ultra+|Revanesse Ultra+ (with lidocaine) vs Revanesse Ultra without lidocaine
3125602|NCT02991118|Experimental|bempedoic acid|bempedoic acid 180 mg/day
3125603|NCT02991118|Placebo Comparator|Placebo|Placebo control
3471805|NCT03867396|Experimental|Cochlear Implant and CROS|Subject wears the CROS device on the contralateral side of the cochlear implant. Subject will use a clinic-loaned CROS device.
3471806|NCT03867344|Active Comparator|Hypoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute hypoglycemic hyperinsulinemic clamp procedure (50mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
3125606|NCT02991729|Active Comparator|Routine care|These patients will receive routine care at our institution for counseling on aneuploidy screening; they will be counseled by a genetic counselor on options, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey immediately following genetic counseling.
3125607|NCT02991729|Experimental|Experimental|These patients will use an iPad-based decision aid explaining options for aneuploidy screening and testing. They will then immediately be counseled by a genetic counselor on their options as is routine at our institution, and following counseling, will select their test of choice. All patients will complete a knowledge and demographics questionnaire prior to genetic counseling. Patients in this arm will then complete a knowledge and decisional conflict survey following use of the decision aid, and again immediately following genetic counseling.
3125608|NCT02991820|Experimental|Inexperienced users|Inexperienced users will include trainees (SRNAs, residents, fellows, and medical students) and nurses at NCH.
3471807|NCT03867344|Placebo Comparator|Normoglycemia|Participants undergo Autonomic Nervous System (ANS) Testing (measurement of Baroreflex Sensitivity using the Modified Oxford test) followed by a functional MRI (fMRI) scan. The next day, participants undergo one 120-minute normoglycemic hyperinsulinemic clamp procedure (90mg/dL) in the morning followed by ANS Testing and an fMRI scan. Four days later, participants undergo repeat ANS Testing and an fMRI scan.
3471808|NCT03867318|Experimental|Atorvastatin Monotherapy|Participants receive double-blind atorvastatin 10 mg once daily (QD) via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 80 mg (10 mg open label plus 70 mg double blind).
3471809|NCT03867318|Experimental|Ezetimibe + Atorvastatin|Participants receive double-blind ezetimibe 10 mg QD via oral tablet PLUS open-label atorvastatin 10 mg QD via oral tablet for the entire duration of the study. Double-blind atorvastatin is to be added to the regimen for participants not achieving LDL-C target (≤100 mg/dL; 2.59 mmol/L). The maximum possible total daily dose of atorvastatin received in this group is 40 mg (10 mg open label plus 30 mg double blind).
3471810|NCT03867331|Experimental|5 microgram VLPM01|5 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
3471811|NCT03867331|Experimental|15 microgram VLPM01|15 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
3471812|NCT03867331|Experimental|30 microgram VLPM01|30 microgram doses of VLPM01 vaccine, intramuscular administration, n=10
3471813|NCT03867331|Experimental|Controlled Human Malaria Infection (CHMI) Phase|Infectivity Control Participants, n=6
3471814|NCT03867058||Cochlear implant users with Nucleus and AB devices|"Temporal processing acuity will be compared using electrodes or electrode configurations that create broad versus sharp spatial excitation.~Speech recognition will be compared in the same group of subjects using electrode-dependent focused versus monopolar stimulation."
3471815|NCT03867123|Experimental|Arm 1 (chemoradiation phase)|"Radiotherapy (RT) + temozolomide (TMZ) + 2-OHOA (during Concurrent phase - duration 6 weeks)*:~2-OHOA will be initiated at the start of the concurrent phase and will be administered on a continuous daily basis together with TMZ and RT for 6 weeks at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~RT will be administered only during the concurrent phase, consisting of fractionated focal irradiation administered using 1.8- 2 Gy/fraction, daily for 5 days/week for 6 weeks, for a total dose of up to 60 Gy.~TMZ will be administered during the concurrent phase at a starting dose of 75 mg/m2/day given daily for 6 weeks.~* One extra week may be allowed."
3471816|NCT03867123|Experimental|Arm 2 (maintenance phase)|"TMZ + 2-OHOA (during Maintenance phase with TMZ 200 mg/m2/day at Cycle 2 - duration 8 weeks):~2-OHOA will be initiated on day 2 of Cycle 2 of the maintenance phase, when TMZ 200 mg/m2/day is given and administered on a continuous basis for two 28-day cycles. 2-OHOA will be administered at the selected dose, either 12 g/day (4 g tid), 8 g/day (4 g bid) or 4 g/day (4 g od).~TMZ will be administered at 200 mg/m2/day given daily the first 5 days for two 28-day cycles (if no toxicity is seen). In case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery.~Both arms will be followed by a 4-week safety follow-up"
3471817|NCT03867162|Experimental|Live Attenuated Tularemia Vaccine|0.06 mL of Tularemia Vaccine, Live, Attenuated, NDBR 101, Lot 4
3471818|NCT03867149|Other|patient with first thalamic infarct|Patient with first thalamic infarct, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
3471819|NCT03867149|Other|healthy subject matched with control|Healthy subject matched with control, they will undergo detailed neuropsychological assessment of memory, language, executive functions and mood along detailed neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI.
3125609|NCT02991820|Experimental|Experienced users|Experienced users will include faculty pediatric anesthesiologists CRNAs.
3125610|NCT02991859|Experimental|Arm AB - FF followed by FP|Each treatment period (TP) comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or FP. In TP 1, subjects will receive evening (PM) dose of 1 puff of FF 25 microgram (mcg) (Total daily dose [TDD] = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puff of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puff of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by morning (AM) and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
3125611|NCT02991859|Experimental|Arm AC - FF followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or BUD. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD = 100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD = 1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
3125612|NCT02991859|Experimental|Arm AD - FF followed by ELLIPTA Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FF or ELLIPTA Placebo. In TP 1, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phases followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. Washout period will be of 25-42 days.
3125613|NCT02991859|Experimental|Arm BA - FP followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or FF. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
3132684|NCT03445065|Active Comparator|Cohort 1, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 1 included patients with clinically confirmed diagnosis of Type 1 or Type 2 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and had an HbA1c >8%. All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
3471820|NCT03867032|Experimental|Cochlear implant users|The group will receive auditory training (psychophysical), and will be evaluated for speech recognition to determine the effect of training.
3471821|NCT03867409|Experimental|Concordant virtual human|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
3471822|NCT03867409|Experimental|Dis-concordant virtual human|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.
3471823|NCT03867409|Experimental|Concordant text|Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
3125614|NCT02991859|Experimental|Arm BC - FP followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or BUD. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD = 400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
3125615|NCT02991859|Experimental|Arm BE - FP followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either FP or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Each TP will be followed by a washout period of 25-42 days.
3125616|NCT02991859|Experimental|Arm CA - BUD followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FF. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
3125617|NCT02991859|Experimental|Arm CB - BUD followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or FP. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD =500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
3179206|NCT00670475|Active Comparator|P (Pircoxicam Group)|in this arm 100 patients with osteoarthritis of knee will receive piroxicam gel in blinded 60 grams tubes,they will be instructed to use 1 gram of piroxicam gel (with inserted dispensing device) three times in a day on the affected knee.
3471824|NCT03867409|Experimental|Dis-concordant text|Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.
3471825|NCT03867240|Experimental|Gabapentin|Gabapentin is a common neuropathic medication used in the treatment of chronic pain. Gabapentin will be given preoperative and continued for 5 days postoperatively.
3471826|NCT03867240|Placebo Comparator|Placebo|Control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group.
3471827|NCT03867019||Subjects with BPPV|"Patients diagnosed with BPPV, who meet the following criteria:~Main complain of spinning sensation (Vertigo) when changes are made in head position relative to gravity.~Positive Dix-Hallpike / Supine Roll Test, confirmed by presence of nystagmus."
3471828|NCT03867019||Subjects without BPPV (Control group)|Patients who do not suffer from dizziness / spinning sensation (Vertigo), and do not meet the exclusion criteria in the study.
3471829|NCT03867045|Experimental|mRCC treated with cabozantinib|Nine patients with mRCC initiating cabozantinib therapy who meet subject eligibility criteria.
3471830|NCT03866980|Experimental|AK105 plus Carboplatin and Pemetrexed|Subjects receive AK105 200 mg intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
3471831|NCT03866980|Placebo Comparator|Placebo plus Carboplatin and Pemetrexed|Subjects receive placebo intravenously (IV) plus pemetrexed 500 mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV plus pemetrexed 500 mg/m^2 IV Q3W until progression.
3471832|NCT03867006|No Intervention|control group|Patients will be randomized in the control group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis and Dual Energy X-ray Absorptiometry (DEXA).
3471833|NCT03867006|Experimental|protein group|Patients will be randomized in the protein group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein.
3471834|NCT03867006|Experimental|protein and carbohydrates group|Patients will be randomized in the protein and carbohydrates group. They will have test MNA (Mini Nutritional Assessment), frailty screening tool (questionnaire FiND), clinical examination, blood sample, blood sample with heparin, white blood cells, urine sample, stool sample, maximal voluntary contraction of quadriceps, walking test, get up-and-go test, Hand Grip test, physical activity questionnaire, bioelectrical impedance analysis, Dual Energy X-ray Absorptiometry (DEXA) and protein and carbohydrates.
3125618|NCT02991859|Experimental|Arm CE - BUD followed by DISKUS Placebo|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either BUD or DISKUS Placebo. In TP 1, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each DISKUS Placebo in second, third and fourth phase; and AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. Washout period will be of 25-42 days.
3125619|NCT02991859|Experimental|Arm DA - ELLIPTA Placebo followed by FF|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or FF. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FF 25 mcg (TDD = 25 mcg) in first phase followed by PM dose of 1 puff of FF 100 mcg (TDD = 100 mcg) in second phase; PM dose of 1 puff of FF 200 mcg (TDD = 200 mcg) in third phase; PM dose of 2 puffs of FF 200 mcg (TDD = 400 mcg) in fourth phase and PM dose of 4 puffs of FF 200 mcg (TDD = 800 mcg) in fifth phase. Washout period will be of 25-42 days.
3125620|NCT02991859|Experimental|Arm EB - DISKUS Placebo followed by FP|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either DISKUS Placebo or FP. TP 1, subjects will receive PM dose of 1 puff of DISKUS Placebo in first phase followed by AM and PM doses of 1 puff each of DISKUS Placebo in second, third and fourth phase; AM and PM doses of 2 puffs each of DISKUS Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of FP 50 mcg (TDD = 50 mcg) in first phase followed by AM and PM doses of 1 puff each of FP 100 mcg (TDD = 200 mcg) in second phase; AM and PM doses of 1 puff each of FP 250 mcg (TDD = 500 mcg) in third phase; AM and PM doses of 1 puff each of FP 500 mcg (TDD = 1000 mcg) in fourth phase and AM and PM doses of 2 puffs each of FP 500 mcg (TDD = 2000 mcg) in fifth phase. Washout period will be of 25-42 days.
3125621|NCT02991859|Experimental|Arm DC - ELLIPTA Placebo followed by BUD|Each TP comprises of 5 consecutive 7-day dosing phases with escalating doses of either ELLIPTA Placebo or BUD. In TP 1, subjects will receive PM dose of 1 puff of ELLIPTA Placebo in first, second and third phase followed by PM dose of 2 puffs of ELLIPTA Placebo in fourth phase and PM dose of 4 puffs of ELLIPTA Placebo in fifth phase. In TP 2, subjects will receive PM dose of 1 puff of BUD 100 mcg (TDD =100 mcg) in first phase followed by AM and PM doses of 1 puff each of BUD 200 mcg (TDD =400 mcg) in second phase; AM and PM doses of 1 puff each of BUD 400 mcg (TDD = 800 mcg) in third phase; AM and PM doses of 2 puffs each of BUD 400 mcg (TDD =1600 mcg) in fourth phase and AM and PM doses of 4 puffs each of BUD 400 mcg (TDD = 3200 mcg) in fifth phase. Washout period will be of 25-42 days.
3125622|NCT02991898|Experimental|Treg Infusion|The Treg cell infusion is given no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion
3125623|NCT02992067||Operable breast cancer|clinical stage: cTis, cI, cII, cT3N1M0
3125624|NCT02992119|Experimental|Group 1|RTS,S/AS01B Fractional dose
3125625|NCT02992119|Experimental|Group 2|Double RTS,S/AS01E Fractional dose
3125626|NCT02992119|Experimental|Group 3|RTS,S/AS01E Standard dose
3125627|NCT02992119|Experimental|Group 4|RTS,S/AS01E + DHA-PIP+PQ Standard dose
3125628|NCT02992119|Experimental|Group 5|RTS,S/AS01E Fractional dose
3125629|NCT02992119|Experimental|Group 6|RTS,S/AS01E + DHA-PIP+PQ Fractional dose
3125630|NCT02992119|Experimental|Group 7|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose
3125631|NCT02992132|Experimental|Pimavanserin 34 mg|Drug- pimavanserin tartrate, 34 mg, taken as two 17 mg tablets, once daily by mouth
3125632|NCT02992132|Experimental|Pimavanserin 20 mg|Drug- pimavanserin tartrate, 20 mg, taken as two 10 mg tablets, once daily by mouth
3125633|NCT02992132|Placebo Comparator|Placebo|Placebo, taken as two tablets, once daily by mouth
3125634|NCT02992197|Active Comparator|Rotarix, single dose|Rotarix 1.5 mL (standard single dose) and 1.5 mL of placebo by mouth (sterile, pharmacy-grade water) at both 6 and 10 weeks of life
3125635|NCT02992197|Experimental|Rotarix, double dose|Rotarix 3 mL by mouth (two standard doses administered simultaneously) at both 6 and 10 weeks of life
3125636|NCT02992236|Placebo Comparator|Placebo|Infusion (6 hours) of Saline
3125637|NCT02992236|Active Comparator|VAS203|Infusion (6 hours) of VAS203 (10 mg/kg)
3125638|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with reduced ejection fraction
3125639|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with reduced ejection fraction
3125640|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with reduced ejection fraction
3125641|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with reduced ejection fraction
3125642|NCT02992288|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with reduced ejection fraction
3125643|NCT02992288|Placebo Comparator|Placebo|Chronic heart failure with reduced ejection fraction
3125644|NCT02992418|Experimental|Concomitant Administration Group|Participants will be administered the first dose of CYD dengue vaccine concomitantly with a dose of Tdap vaccine.
3471835|NCT03866993|Experimental|AK105 plus Carboplatin and Paclitaxel|Subjects receive AK105 200 mg intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
3471836|NCT03866993|Placebo Comparator|placebo plus Carboplatin and Paclitaxel|Subjects receive placebo intravenously (IV) plus Paclitaxel 175mg/m^2 IV and carboplatin area under the curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by AK105 200 mg IV Q3W until progression.
3471837|NCT03866954|Experimental|Intravenous administration of EE-TP|Intravenous administration of EE-TP. The starting dose will be Dose Level 1, with potential subsequent dose levels of Dose Level 2 and Dose Level 3 dependent on whether metabolic correction is achieved or not.
3471838|NCT03866967|Experimental|AK105|Subjects receive AK105 200 mg intravenously (IV) once every 2 weeks (Q2W) until progression.
3471839|NCT03866928|Experimental|Stiripentol|
3471840|NCT03866850||Cochlear implant users with late-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration).~Examine neural spatial excitation patterns with long and short phase duration. Measure speech recognition using long and short phase duration stimulation patterns."
3471841|NCT03866850||Cochlear implant users with early-onset deafness|"Examine charge integration (Detection threshold as a function of phase duration) and compare that with the late-onset group.~Examine neural spatial excitation patterns with long and short phase duration within the non-leaky phase duration range.~Measure speech recognition using long and short phase duration stimulation patterns."
3471842|NCT03866746|Active Comparator|Group A|received aflibercept injections alone
3125645|NCT02992418|Experimental|Sequential Administration Group|Participants will be administered the first dose of CYD dengue vaccine 28 days after a dose of Tdap vaccine.
3125646|NCT02992691|Experimental|Test Product 1|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
3125647|NCT02992691|Experimental|Test Product 2|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
3125648|NCT02992691|Experimental|Test Product 3|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
3125649|NCT02992691|Active Comparator|Positive Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
3125650|NCT02992691|Other|Negative Control|Participants will be instructed to dose a toothbrush with full ribbon of dentifrice. Participants will brush their teeth once for one timed minute.
3125651|NCT02992899|Experimental|Vagal Nerve Stimulation|Participants randomized to this arm will receive stimulation of the vagus nerve in conjunction with stress exposure.
3125652|NCT02992899|Sham Comparator|Sham Stimulation|Participants randomized to this arm will receive sham stimulation of the vagus nerve in conjunction with stress exposure.
3125653|NCT02993224|Experimental|Deferasirox DT followed by deferasirox FCT|Participants were treated with deferasirox DT followed by deferasirox FCT (core phase). Those who entered the extension phase were treated with deferasirox FCT
3125654|NCT02993250|Experimental|Cohort 1 (Chronic Hepatitis C Without Cirrhosis)|Participants will receive 800 milligram (mg) AL-335 +odalasvir (ODV) 25 mg+simeprevir (SMV) 75 mg once daily for 8 weeks in Cohort 1.
3125655|NCT02993250|Experimental|Cohort 2 (Chronic Hepatitis C With Compensated Cirrhosis)|Participants will receive AL-335 800 milligram (mg)+ODV 25 mg+SMV 75 mg once daily for 12 weeks in Cohort 2. Dosing in cohort 2 will be started according to decision of Data Review Committee (DRC).
3125656|NCT02993302|Active Comparator|PTU-Oral 1α-D3|patients were given oral 1α-D3 at dose of 1.5 mcg once daily for 8 weeks in addition to propylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
3125657|NCT02993302|Placebo Comparator|PTU-Placebos|patients were given placebo tablets for 8 weeks in addition topropylthiouracil (PTU) 300 mg daily for 8 weeks as the treatment for Graves' disease with thyrotoxicosis
3125658|NCT02993445|Experimental|Alternate Nostril Breathing|The procedure for ANB begins by bringing the right hand up to the nose; with the ring finger over the left nostril and the thumb over the right nostril, so that the nostrils may be closed by the fingers. The first step in the cycle is to hold the right nostril closed with the thumb, and exhale completely through the left nostril in a slow and controlled fashion, free from exertion and jerkiness. At the end of the exhalation, the patient will inhale slowly and completely back through the left nostril. At this point the patient will close the left nostril with the ring finger, open the right nostril by releasing the thumb, and repeat the exhale-inhale process through the right nostril, completing one cycle. Then the patient will switch back to the left nostril and begin the cycle again. This cycle will be performed for one session lasting approximately 5 minutes.
3125659|NCT02993445|Experimental|Foot Reflexology|The procedure for FR focuses on activating specific reflex areas on the foot linked with the eye and eye disease, via massage. Although in the interest of repeatable precision, we have decided to use a FR board (fig.1) to conduct the procedure. This board has two foot shaped pieces of wood mounted on a flat board with springs. On top of these wooden feet are small wooden nodes, which are organized at precise locations to activate the reflexology of the foot by stimulation certain pressure points. The patient will be instructed to rest their feet on these boards with a comfortable pressure for a period of 5 minutes.
3125660|NCT02993471|Experimental|Drug Cocktail|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally once in Period 1 (day 1).
3471843|NCT03866746|Experimental|Group B|received 3 aflibercept injections followed by micropulsed laser
3471844|NCT03866863||HFME births.|All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant from 1st of january 2011 to 31 december 2017.
3471845|NCT03866694|Experimental|BRIGHT|Building Resilience through Intervention: Growing Healthier Together (BRIGHT) weekly home-based intervention from the third trimester of pregnancy through 6 months postpartum. A licensed clinician meets with mother and infant to promote attunement and optimal parent-child interactions. Additionally, the mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic
3471846|NCT03866694|Active Comparator|STAR/TAU+|The mother receives monthly handouts focused on information about child development and recovery from substance misuse while parenting, along with the standard of care at a high risk maternal-fetal medical clinic.
3471847|NCT03866655|Experimental|Intervention|
3471848|NCT03866655|No Intervention|Control|
3125661|NCT02993471|Experimental|Drug Cocktail + Ixekizumab|Drug cocktail (caffeine, warfarin [plus vitamin K], omeprazole, dextromethorphan, and midazolam) administered orally twice in Period 2 (day 8 and day 85). Ixekizumab administered subcutaneously (SC) on multiple occasions in Period 2.
3125662|NCT02993731|Experimental|Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
3471849|NCT03866837|Active Comparator|Study group A: GOS|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) and galacto-oligosaccharides (GOS), 7.5 mg.
3471850|NCT03866837|Active Comparator|Study group B: bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), bovine lactoferrin (bLF), 1.0 g.
3471851|NCT03866837|Active Comparator|Study group C: GOS + bLF|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]), galacto-oligosaccharides (GOS), 7.5 mg, and bovine lactoferrin (bLF), 1.0 g.
3471852|NCT03866837|Placebo Comparator|Study group D|This study group will receive daily in-home fortification for 6 months with multiple micronutrient powders with 5 mg iron (as sodium iron EDTA [2.5 mg] and ferrous fumarate [2.5 mg]) alone, with no galacto-oligosaccharides (GOS), and no bovine lactoferrin (bLF).
3471853|NCT03866681|Experimental|Patients cohort|A total of 40 patients with refractory classic PNH will be included and will be intervened by a combined therapy including sirolimus and low-dose warfarin
3471854|NCT03866915||Patients undergoing elective surgery|All patients older than 18 years undergoing elective surgery that receive a preoperative visit by anesthesiologists in which Aortic pulse wave velocity measurement and the 6 minutes walking test (6MWT) is carried out
3471855|NCT03866629||Lifitegrast 5%|Patients will receive lifitegrast 0.5% eye drops twice daily 4 weeks prior to cataract surgery.
3125663|NCT02993731|Active Comparator|Arm 2: Nab-paclitaxel with Gemcitabine|Patients randomized to this arm will receive weekly nab-paclitaxel and gemcitabine administered intravenously, once weekly, on 3 of every 4 weeks.
3125664|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Concomitant Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 milliliter (mL) subcutaneously (SC) at Day 0, Month 6, and Month 12; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Day 0 and Month 6. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL Intramuscular (IM), concomitantly with the first 2 doses of CYD dengue vaccine.
3125665|NCT02993757|Experimental|CYD Dengue Vaccine + Gardasil (Sequential Administration)|Dengue immune participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Month 1, Month 7, and Month 13; whereas dengue non-immune participants received only 2 doses of CYD vaccine at Month 1 and Month 7. Both immune and non-immune participants received 2 doses of Gardasil vaccine 0.5 mL IM at Day 0 and Month 6 sequentially (i.e., one month before) to each of the first 2 doses of CYD dengue vaccine.
3125666|NCT02993783|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once on Days 1, 15, 43, 71 and 99.
3125667|NCT02993783|Experimental|Vedolizumab 600 mg|Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99.
3125668|NCT02993926||Treatment Phase: Enantone|Participants with CPP who were treated with Enantone (≥ 30 μg/kg up to 180 μg/kg) for at least 9 continuous months and who initiated and received the last dose of treatment during the index period from 01 September 1998 to 30 September 2018 (the mean duration of Enantone exposure was 22.3 months, ranging from 10.1 to 52.4 months).
3125669|NCT02993926||Follow Up: Participants No longer Treated for CPP|Participants who had completed their CPP during the treatment phase with Enantone and were no longer on treatment in the follow-up phase (the mean duration of follow up was 8.75 months with a range of 1.9 to 29.5 months).
3125670|NCT02993926||Follow Up: Treated with Non-Enantone GnRHa after Enantone|Participants who were continuing their CPP treatment with a non-Enantone gonadotropin releasing hormone agonist (GnRHa) after treatment with Enantone in the follow-up phase (the mean duration of follow up while on another GnRHa was 10.80 months with a range of 2.8 to 20.5 months, and the mean duration of follow up after stopping treatment was 4.26 months with a range of 0.0 [i.e. 1 day] to 12 months).
3125671|NCT02994056|Experimental|SOF/VEL+ RBV|SOF/VEL FDC plus RBV for 12 weeks
3125672|NCT02994108|Experimental|txt2protect|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules. Module 1 addressed information about HPV infection and HPV vaccination. Module 2 addressed motivation to receive HPV vaccine. Module 3 addressed behavioral skills and self-efficacy for initiating and completing the 3-dose series (e.g., talking with their doctor about the vaccine). Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~txt2protect: Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination."
3125673|NCT02994108|Active Comparator|Sexual Health Control|"Content was delivered in 2 phases over 36 weeks. During Phase 1 (weeks 1-3), participants received 10-12 messages daily. During Phase 2 (weeks 4-36), message frequency decreased to monthly messages. Phase 1 content was presented in 3 modules; however, unlike the treatment group, content was topic-based rather than theory-based and focused on general sexual health. Module 1 addressed basic facts about HIV and sexually transmitted infections (STI), including HPV. Module 2 addressed HIV/STI prevention (e.g., condom use, PrEP) and will included basic facts about HPV vaccination currently available online. Module 3 addressed tips for healthy relationships. Phase 2 booster messages largely reinforced Phase 1 content to foster continued engagement with the program.~Sexual Health Control: Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination."
3471856|NCT03866720|Active Comparator|Carbohydrate rich breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
3125674|NCT02994238|Experimental|Intervention|The intervention group will have the full Remote Health Management Sensor Platform. Research staff will review uploaded sensor data on a daily basis. If participants are enrolled into the control group, they will only receive Standard Asthma Education. The Standard Asthma Education follows the National Asthma Education and Prevention Program (NAEPP) guidelines for asthma management. This will include the following topics: 1. Explanation of symptoms; 2. Asthma triggers (description and how to avoid them); 3. Using medications (how to use prescribed asthma medications, the difference between controller medications and rescue inhalers, how to use a spacer, how to use a mask); and 4. Managing asthma control (purpose of asthma control test, asthma action plan, how to use a peak flow meter).
3125675|NCT02994238|No Intervention|Control|The control group will receive only standardized education.
3471857|NCT03866720|Experimental|Whey protein enriched breakfast|Participants will consume a porridge breakfast that is considered in line with typical carbohydrate consumption for this meal.
3471858|NCT03866720|No Intervention|Extended morning fast|Participants will extend their overnight fast until the ad libitum lunch is provided.
3125676|NCT02994394|Experimental|OPC41061(15 mg) disintegrating tablet with water|OPC41061 (15 mg) orally disintegrating tablet is administered with water.
3125677|NCT02994394|Experimental|OPC-41061(15 mg) disintegrating tablet without water|OPC41061 (15 mg) orally disintegrating tablet is administered without water.
3125678|NCT02994394|Experimental|OPC-41061(15 mg) conventional tablet with water|OPC-41061 (15 mg) conventional tablet is administered with water.
3125679|NCT02994394|Experimental|OPC41061(30 mg) disintegrating tablet with water|OPC41061 (30 mg) orally disintegrating tablet is administered with water.
3125680|NCT02994394|Experimental|OPC-41061(30 mg) disintegrating tablet without water|OPC41061 (30 mg) orally disintegrating tablet is administered without water.
3125681|NCT02994394|Experimental|OPC-41061(30 mg) conventional tablet with water|OPC-41061 (30 mg) conventional tablet is administered with water.
3125682|NCT02994654|Experimental|ReCell|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Investigational treatment will be randomly allocated to either Area A or Area B
3125683|NCT02994654|Experimental|Control|All subjects will receive both ReCell and skin graft. Each patient serves as their own control. Their study treatment area (burn injury) will be divided into Area A and Area B. Control, which is the Investigator's pre-determined graft plan will be randomly allocated to either Area A or Area B
3125684|NCT02994732|Experimental|[14C]-BVD-523 600mg single dose|Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
3125685|NCT02994940|Experimental|Oral Acetaminophen|Group 1 will receive oral acetaminophen 30mg/kg 30-60 minutes prior to scheduled surgery time . Group 1 patients will receive placebo IV infusion just prior to surgery incision.
3125686|NCT02994940|Experimental|Intravenous Acetaminophen|Group 2 will receive placebo oral medication at approximately 30-60 minutes prior to scheduled surgery. Group 2 patients will receive IV acetaminophen 15 mg/kg just prior to surgery incision.
3125687|NCT02994979|Experimental|Delirium-prevention group|Multicomponent delirium prevention intervention led by a Certified Nursing Assistant (CNA) adapted for the long-term care setting from the Hospital Elder Life Program.
3125688|NCT02994979|Sham Comparator|Usual care group|Usual care plus a sham visit from the intervention CNA
3125689|NCT02995915|Experimental|Tele-health Mobile Contingency Management Intervention|This arm includes a proactive tele-health intervention that combines evidence-based telephone cognitive behavioral treatment for alcohol and smoking cessation, a tele-medicine clinic for access to smoking cessation pharmacotherapy (including nicotine replacement therapy and bupropion), and mobile contingency management treatment administered via a smart-phone based application (mobile CM).
3125690|NCT02995915|Active Comparator|Tele-health for Alcohol and Smoking Cessation|This arm includes a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same evidence-based telephone CBT for alcohol and smoking cessation, and tele-medicine clinic for access to smoking cessation pharmacotherapy as in the mCM intervention, but does not include mCM. Instead, participants will receive monetary compensation for each assessment, regardless of abstinence.
3125691|NCT02995980|Experimental|Contrast enhanced mammography vs standard digital mammogram|Contrast-enhanced spectral mammography for the detection breast cancer .
3125692|NCT02996097|Experimental|CO2 ablative laser plus intralesional triamcinolone acetonide|A topical eutectic mixture of local anesthetics (EMLA) cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
3125693|NCT02996097|Active Comparator|Intralesional triamcinolone acetonide alone|A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. The other chosen lesion would be treated with intralesional triamcinolone acetonide alone at 4 week intervals.
3125694|NCT02996448|Experimental|NDV 3A vaccine|Participants will receive a single dose of 0.5 mL (300 micrograms of rAls3) administered via IM injection.
3125695|NCT02996474|Experimental|Pembrolizumab and Decitabine for treatment of AML|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Up to eight cycles of pembrolizumab will be given during the initial induction phase. Each cycle is 21 days. Decitabine will be administered at a dose of 20 mg/m2 by intravenous infusion over approximately 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7) for treatment relapsed/refractory AML.
3125696|NCT02996500|Experimental|Arm 1: 20 mg QD|PF-06650833 , 20 mg QD
3471859|NCT03866902|Experimental|Nutrition and Physical Activity Intervention|"Classes for the intervention mothers will be run by a bilingual interventionist and will last 105 minutes weekly for 12 weeks and then monthly for 6 months.~Classes for intervention group children will be 105 minutes weekly for 12 weeks and then monthly for 6 months."
3471860|NCT03866902|Active Comparator|English for Second Language Intervention|"Mothers in the control group will receive English as a Second Language (ESL) classes taught by professional ESL teachers; they will receive the same number of contacts and time as the intervention group mothers for 105 minutes weekly for 12 weeks and 105 minutes monthly for 6 months.~Children in the control group will be read to and color with crayons 105 minutes weekly for 12 weeks and then 105 minutes monthly for 6 months."
3471861|NCT03866876||Hôpital Femme Mère Enfants births|
3471862|NCT03866733|Active Comparator|Narcotics group (group N)|intervention: injection of boluses of intra venous Narcotics (fentanyl) in the dose of (3-5 mcg/kg) during the surgery after induction of anesthesia. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till 48 hours after surgery. NSAID every 12 hrs if there is no contraindication and iv acetaminophine igm/6hrs.
3471863|NCT03866733|Experimental|Erector spinea block group (group B)|intervention: after induction our intervention will be the performance of ultrasound guided bilateral continous Erector spinea block with insertion of catheters then 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 8 ml/h. morphine 0.5mg/kg as rescue analgesia will be started upon arrival till extubation and iv acetaminophine igm/6hrs.
3471864|NCT03866941||synthetic cannibinoids users|
3471865|NCT03866824|Experimental|PRP group|
3125697|NCT02996500|Experimental|Arm 2: 60 mg QD|PF-06650833, 60 mg QD
3125698|NCT02996500|Experimental|Arm 3: 200 mg QD|Pf-06650833, 200 mg QD
3125699|NCT02996500|Experimental|Arm 4: 400 mg QD|PF-06650833, 400 mg QD
3125700|NCT02996500|Placebo Comparator|Placebo|Placebo, 0 mg BID
3125701|NCT02996500|Active Comparator|Arm 5: Tofacitinib|Tofacitinib 5 mg BID
3125702|NCT02996591|Active Comparator|Spinal anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. Spinal protocol: 45-60 mg 1.5% mepivacaine, depending on the expected case duration (45 mg for cases with projected duration 1-2 hours, 60 mg for cases with projected duration 2-3 hours). Intraoperative sedation maintained with propofol infusion and ketamine, 10 mg/hr.
3125703|NCT02996591|Active Comparator|General anesthesia with popliteal and adductor canal blocks.|Ultrasound (US) guided sciatic nerve blocks in the popliteal fossa and adductor canal block with 25 mL and 10 mL, respectively, of 0.25% bupivacaine (plus 2 mg preservative-free (PF) dexamethasone / 30 ml), performed under procedural IV sedation protocol. IV sedation protocol: midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg, + propofol as needed. General anesthesia protocol: After induction with propofol and insertion of the LMA, anesthesia maintained with titrated propofol infusion, sevoflurane, ketamine 10 mg/hr.
3125704|NCT02996682|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3125705|NCT02996682|Experimental|SOF/VEL + RBV|SOF/VEL + RBV for 12 weeks
3125706|NCT02996864|Experimental|Healthy Detours App|Participants will be encouraged to use the Healthy Detours app daily to track food, physical activity, and sleep.
3125707|NCT02996864|Placebo Comparator|Fat Secret App|Participants will be encouraged to use the FatSecret application daily to track food and physical activity.
3125708|NCT02996968|Experimental|Self-removal group|The patients randomized to the self-removal group will be provided with a diagrammatic handout and will be instructed to remove their indwelling urinary catheter at home on the morning of Postoperative day 7.
3125709|NCT02996968|No Intervention|Office-removal group|The patients randomized to the office-removal group will visit the office for a repeat voiding trial on postoperative day 6-8 (postoperative day 7 will be encouraged). At this visit, the patients will undergo a backfill voiding trial.
3125710|NCT02997085|Experimental|Live-Action 360° Video Virtual Reality|
3125711|NCT02997085|Active Comparator|CGI 360° Video Virtual Reality|
3125712|NCT02997085|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the VR exposure. After completion of the study visit, participants in the waitlist condition will be given the option of viewing either the Live-Action 360° 3D HD VVR or the CGI 360° 3D VVR.
3125713|NCT02997163|Experimental|Group A (control, normal renal function)|
3125714|NCT02997163|Experimental|Group B (mild renal impairment)|
3125715|NCT02997163|Experimental|Group C (moderate renal impairment)|
3125716|NCT02997163|Experimental|Group D (severe renal impairment)|
3125717|NCT02997176|Experimental|Group A (control, normal hepatic function)|
3125718|NCT02997176|Experimental|Group B (mild hepatic dysfunction)|
3125719|NCT02997176|Experimental|Group C (moderate hepatic dysfunction)|
3125720|NCT02997176|Experimental|Group D (severe hepatic dysfunction)|
3125721|NCT02997722|Experimental|Ketamine infusion|Assignment to this arm involves receiving a single IV infusion of ketamine 0.5 mg/kg given over 45 minutes.
3125722|NCT02997722|Placebo Comparator|Normal Saline infusion|Assignment to this arm involves receiving an IV infusion of normal saline over the course of 45 minutes.
3471866|NCT03866824|Active Comparator|reference treatment|
3471867|NCT03866811|Experimental|Intervention arm|The intervention consists of a brief contraception educational video and then the 10-week texting intervention which consists of 30 automated, personalized and interactive texting algorithms (3 texts per week).
3471868|NCT03866811|No Intervention|Control arm|Patients randomized to the control arm will receive the current standard discharge instructions provided in the investigator's ED.
3471869|NCT03866577|Experimental|Part A|Healthy volunteers will receive a single ascending dose of M254 or placebo
3471870|NCT03866577|Experimental|Part B|Immune thrombocytopenic purpura (ITP) patients will receive a single ascending dose of M254 followed by IVIg
3471871|NCT03866577|Experimental|Part C|ITP patients will receive a single dose of M254 or IVIg, followed by a single dose of the other drug approximately 28 days later
3471872|NCT03866577|Experimental|Part D|ITP patients will receive repeated doses of M254
3125723|NCT02997735|Experimental|Electronic Quitline Referral|The electronic quitline referral will be embedded within the Tobacco Treatment CDS tool, a CDS system previously developed to help pediatricians provide smoking cessation counseling and treatment to parents who smoke, modeled off the CEASE intervention, an evidence-based approach for implementing smoking cessation treatment of parents in the pediatric setting. The parental tobacco treatment CDS tool prompts the pediatric clinician to ask the parent about smoking status and assess interest in quitting (at all well-child and acute visits), links to an electronic nicotine replacement therapy prescription for parents interested in quitting, and guides appropriate documentation. Electronic referral to the quitline will be made by clicking an automated link embedded in the tool that will send the parent smokers' names and telephone numbers (entered by the clinician) directly to the Pennsylvania (PA) Free Quitline.
3125724|NCT02997735|Other|Standard of Practice|All procedures implemented in the standard referral approach will be identical to those in the electronic referral approach with the exception of providing the telephone number for the Quitline to the parent (rather than electronic referral). The clinician workflow will be nearly the same, in that the clinician will use the link embedded in the tobacco treatment CDS tool to add the quitline to the patient's discharge paperwork (rather than automatically refer to the quitline).
3125725|NCT02997904|Experimental|Resultz Lice and Egg Elimination Kit|Resultz combing solution, head lice comb and instructions for use in a kit: apply liquid then comb out for 1 hour
3125726|NCT02997904|Placebo Comparator|Placebo Lice and Egg Elimination Kit|20% glycerin combing solution, comb and instructions for use in a kit: apply liquid then comb out for 1 hour
3125727|NCT02998021|Experimental|Resistance Training - Vibrating Dumbbell|Study participants who are randomized into the vibration exercise group will complete an in-home exercise program using a vibrating dumbbell.
3125728|NCT02998021|Active Comparator|Resistance Training - Standard Dumbbell|Study participants who are randomized into the control exercise group will complete an in-home exercise program using standard dumbbells.
3125729|NCT02998151|Experimental|All Study Participants|Participants received, in random order, a single dose of placebo, acamprosate, lovastatin, minocycline, or baclofen, with a two-week washout period between doses. Midway through the study (n=16) it was determined that acamprosate was undetectable in serum and this intervention was replaced by baclofen. Remaining participants (n=13) received baclofen and 5 participants were re-enrolled to receive baclofen or a second round of placebo, so investigators and participants would remain blinded to drug status during the baclofen visit. The second round of placebo was not analyzed.
3125730|NCT02998476|Experimental|Group A Parsaclisib (no prior BTK inhibitor)|Parsaclisib in subjects who were not previously treated with a BTK inhibitor.
3125731|NCT02998476|Experimental|Group B Parsaclisib (prior BTK inhibitor)|Parsaclisib in subjects who were previously treated with a BTK inhibitor.
3125732|NCT02998541|Experimental|SHP640|Participants will receive one drop of SHP640 (0.1 percent [%] dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
3125733|NCT02998541|Active Comparator|PVP-I 0.6%|Participants will receive one drop of 0.6% PVP-I ophthalmic solution in each eye QID for 7 days.
3125734|NCT02998541|Placebo Comparator|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID for 7 days.
3125735|NCT02998554|Experimental|SHP640|Participants instructed to instill 1 drop of SHP640 (Povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
3125736|NCT02998554|Placebo Comparator|Placebo|Participants instructed to instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
3125737|NCT02998671|Experimental|Group 1: CJM112 high dose|CJM112 high dose in treatment period 1; CJM112 high dose in extension period 2
3125738|NCT02998671|Experimental|Group 2: CJM112 low dose|CJM112 low dose in treatment period 1; CJM112 low dose in extension period 2
3125739|NCT02998671|Placebo Comparator|Group 3: Placebo, CJM112 low dose or high dose|Placebo in treatment period 1; CJM112 low dose or CJM112 high dose in extension period 2
3125740|NCT02998684|Active Comparator|Active Transcranial Direct Current Stimulation|Participants will receive active Transcranial Direct Current Stimulation
3125741|NCT02998684|Sham Comparator|Sham Transcranial Direct Current Stimulation|Participants will receive sham Transcranial Direct Current Stimulation
3125742|NCT02998996|Experimental|Immunose™ FLU 1%,|15 µg haemagglutinin(HA)/strain and 1% Endocine™
3125743|NCT02998996|Experimental|Immunose™ FLU 2%,|15 µg HA/strain and 2% Endocine™
3125744|NCT02998996|Experimental|Influenza antigen,|15 µg HA/strain
3125745|NCT02998996|Placebo Comparator|Saline (NaCl),|Placebo
3125746|NCT02998996|Active Comparator|i.m. comparator,|15 µg HA/strain
3125747|NCT02998996|Active Comparator|i.n. comparator|
3125748|NCT02999100|Experimental|Group 1 -IH oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 400 micrograms (mcg) IH oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
3471873|NCT03866889|Experimental|Strength|Maximum strength protocol based on a Maximum Repetition (1RM). The aim of the application of the training is to produce an increase in strength based on training with high loads (80% 1RM), individually and covering the muscles of the lower extremity (quadriceps, hamstrings, gluteus maximus).
3471874|NCT03866889|Active Comparator|Normal activity|The subjects included in the control group will perform the same physical activity to improve the strenght until the beginning of the study. The exercises will be done in the same conditions and with the same period (4 days / week)
3125749|NCT02999100|Experimental|Group 1 -IM oxytocin|Women with an uncomplicated pregnancy in third stage of labour will be enrolled in the arm. Subjects will receive 10 I.U. IM oxytocin. Subjects will be followed up in-person or via telephone within approximately 24 hr post dose and once between 7 days to 14 days
3125750|NCT02999100|Experimental|Group 2 (IH and IV oxytocin)|Group 2 will enrol healthy, non-pregnant, non-lactating female subjects of childbearing potential, and each subject will participate in 2 dosing sessions. Group 2 will be divided into two cohorts: Cohort A will enrol women on a combined oral contraceptive, and Cohort B will enrol women who are not using a hormonal form of contraceptive. Group 2 subjects will randomized to receive IH oxytocin, and IV oxytocin in a cross fashion. Subjects will be followed up in-person once between 7 days to 21 days
3471875|NCT03866772|Active Comparator|MISOPROSTOL|"oral misoprostol, 50 microgram, every 4 hours~Repeat treatment every 4 hours until active labour begins: regular painful contractions (≥ 3 in 10 min), cervical dilatation ≥ 3 cm~maximal number of doses: 6~Oxytocin infusion can be initiated 4 hours after the last dose of Misoprostol.~Failure of induction will be considered if no cervical change nor uterine contractions have begun during 24 hours of treatment.~Electronic fetal monitoring should be performed for 30 min after administration of misoprostol and 60 min after any tachysystole."
3125751|NCT02999178|Experimental|Nintedanib|
3125752|NCT02999178|Placebo Comparator|Placebo|
3125753|NCT02999191|Experimental|BI 1467335 (Treatment A)|Tablet under fasted conditions
3125754|NCT02999191|Experimental|BI 1467335 (Treatment B)|Oral solution under fasted conditions
3125755|NCT02999191|Experimental|BI 1467335 (Treatment C)|Tablet under fed conditions
3125756|NCT02999633|Experimental|Isatuximab|Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
3125757|NCT02999672|Experimental|Cohort 1 (UBC)|First six participants with locally advanced (unresectable and not treatable with curative intent) or metastatic UBC will initially receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
3125758|NCT02999672|Experimental|Cohort 2 (Pancreatic cancer/cholangiocarcinoma)|First six participants with metastatic pancreatic cancer/cholangiocarcinoma will receive Regimen A (trastuzumab emtansine at a dose of 2.4 mg/kg qw). An iDMC will assess the safety among the first six participants and decide whether dose will be switched to Regimen B (trastuzumab emtansine at a dose of 3.6 mg/kg q3w).
3125759|NCT02999763|Experimental|Abdominal fat reduction treatment|SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
3125760|NCT03000010|Active Comparator|Incisional Wound Vac|We will attach sponges and a suction tube to the incision after surgery. We will leave it on for 72 hours. From then on, patients will get the care that patients normally get after spinal fusion surgery.
3125761|NCT03000010|Active Comparator|Normal Gauze Bandage Group|We will cover patients incision with regular gauze bandages. These are the bandages that patients normally get after spinal fusion surgery. They will be left on for 72 hours.
3125762|NCT03000075|Placebo Comparator|Placebo (Part A)|Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3125763|NCT03000075|Experimental|Risankizumab 75 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3125764|NCT03000075|Experimental|Risankizumab 150 mg (Part A)|Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
3125765|NCT03000088||60° angle group|intubate using McGrath Videolaryngoscope with 60° angled stylet
3125766|NCT03000088||90°angle group|intubate using McGrath Videolaryngoscope with 90° angled stylet
3125767|NCT03000166|Experimental|Step-Up Intervention Group|Participants assigned to the Step-up intervention group will receive a 12-week physical activity intervention which includes components of education, negotiated collaboration to set individual physical activity goals during chemotherapy cycles, and tools for self-monitoring of physical activity.
3125768|NCT03000166|No Intervention|Attention Control Group|Participants assigned to the attention control group will receive usual guidance about maintaining physical activity during chemotherapy from their oncology providers.
3125769|NCT03000283|Experimental|Conivaptan Treatment Group|All seven patients in this arm will receive conivaptan as described in Interventions.
3125770|NCT03000309|Other|Apremilast|Apremilast, 30 mg. tablets, two times a day for 16 weeks
3125771|NCT03000348|Active Comparator|High Dose, Once per day|Patient takes one oral dose of Cysteamine (high dose) per day, in the morning. The patient takes two oral placebo doses, one at mid-day and one in the evening.
3125772|NCT03000348|Active Comparator|High Dose, Twice per day|Patient takes two oral doses of Cysteamine (high dose) per day, one in the morning and one in the evening. The patient takes one oral placebo dose, at mid-day.
3125773|NCT03000348|Active Comparator|High Dose, Three times per day|Patient takes three oral doses of Cysteamine (high dose) per day, one in the morning, one at mid-day and one in the evening.
3125774|NCT03000348|Placebo Comparator|Placebo|Patient takes three oral doses of placebo, one in the morning, one at mid-day and one in the evening.
3125775|NCT03000348|Active Comparator|Low Dose, Three times per day|Patient takes three oral doses of Cysteamine (low dose) per day, one in the morning, one at mid-day and one in the evening.
3125776|NCT03000348|Active Comparator|Mid-Range Dose, Three times per day|Patient takes three oral doses of Cysteamine (mid-range dose) per day, one in the morning, one at mid-day and one in the evening.
3471876|NCT03866772|Active Comparator|DOUBLE BALLOON|"Insertion of the DBD as instructed by the manufacturer, removal after 6 hours.~Artificial rupture of membranes (AROM) if suitable + IV oxytocin administration~If AROM cannot be performed- oxytocin infusion will be initiated at first.~If Bishop <3 after DBD removal, clinical evaluation and lag time before considering other methods for ripening is suitable and is up to the physician on call."
3471877|NCT03866772|Active Comparator|MISOPROSTOL+DOUBLE BALLOON|
3471878|NCT03866551|Experimental|Interventional Arm|The initial phase of the study will utilize the Reprieve Cardiovascular System to support a treatment algorithm that maximizes diuretic administration while carefully monitoring patient physiologic and hemodynamic status to ensure safe decongestion.
3471879|NCT03866395|No Intervention|Control Group|drug therapy according to the guidelines
3125777|NCT03000452|Experimental|Administration of Daratumumab (DARA) plus Durvalumab (DURVA)|"Subjects will also receive IV DURVA at 1500 mg on Day 2 (Cycle 1) and on Day 1 (Cycles ≥ 2) of each 28-day treatment cycle.~Subjects will receive intravenous (IV) DARA at 16 mg/kg on the same dosing schedule (weekly [QW], every 2 weeks [Q2W], or every 4 weeks [Q4W] of each 28-day treatment cycle) received during their last prior therapy containing DARA at the time of DARA progression"
3125778|NCT03000530|Experimental|Part A: SAGE-217|Participants received SAGE-217, 30 milligrams (mg), oral solution, once daily for 14 days, as tolerated.
3125779|NCT03000530|Placebo Comparator|Part B: Placebo|Eligible participants received matching placebo capsules once daily for 14 days.
3125780|NCT03000530|Experimental|Part B: SAGE-217|Eligible participants received SAGE-217, 30 mg, oral capsules, once daily for 14 days.
3125781|NCT03000569|Experimental|Part A: Antiparkinsonian Agent(s) Followed by SAGE-217|Participants on a stable morning dose of levodopa (including carbidopa-levodopa) as antiparkinsonian agent(s) from Days 1 to 3, stopped levodopa and received SAGE-217 at a dose of 30 mg per day, oral solution, for Days 4 to 7 in the morning with food. Stable doses of other antiparkinsonian agents and dose reductions in SAGE-217 were allowed between Days 1 to 7. Participants resumed stable morning dose of levodopa from Days 8 to 14.
3125782|NCT03000569|Experimental|Part B: Antiparkinsonian Agent(s) + SAGE-217|Participants on a stable dose of antiparkinsonian agent(s) received SAGE-217, up to 30 mg per day, capsules, for Days 1 to 7 in the evening with food.
3125783|NCT03000608|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
3125784|NCT03000608|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
3125785|NCT03000673|Active Comparator|Dose Sequence 1|UFH, BMS-986177 - dose 1, BMS-986177 - dose 2, Enoxaparin
3125786|NCT03000673|Active Comparator|Dose Sequence 2|BMS-986177 - dose 1, Enoxaparin, UFH, BMS-986177 - dose 2
3125787|NCT03000673|Active Comparator|Dose Sequence 3|BMS-986177 - dose 2, UFH, Enoxaparin, BMS-986177 - dose 1
3125788|NCT03000673|Active Comparator|Dose Sequence 4|Enoxaparin, BMS-986177 - dose 2, BMS-986177 - dose 1, UFH
3125789|NCT03000686|Experimental|Treatment sequence AB|Subjects will receive GSK2586881 in period 1 and saline placebo in period 2. There will be a washout period of 3-14 days between two treatments
3125790|NCT03000686|Experimental|Treatment sequence BA|Subjects will receive saline placebo in period 1 and GSK2586881 in period 2. There will be a washout period of 3-14 days between two treatments
3125791|NCT03001011|Placebo Comparator|Placebo|Participants received placebo (for Renvela) orally 3 times per day (TID) for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus less than or equal to (<=) 4.6 mg/dL (<=1.49 mmol/L).
3125792|NCT03001011|Experimental|Renvela|Participants received Renvela orally TID for up to 8 weeks. One to five tablets were taken with meals, as directed by physician and were titrated (up to a maximum of 15 tablets per day) to reach a target goal of serum phosphorus <=4.6 mg/dL (<=1.49 mmol/L).
3125793|NCT03001076|Experimental|bempedoic acid|bempedoic acid 180 mg tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
3125794|NCT03001076|Placebo Comparator|placebo|Matching placebo tablet taken orally, daily. Patients remain on ongoing ezetimibe therapy (study provided)
3125795|NCT03001219|Placebo Comparator|Part 1: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
3125796|NCT03001219|Experimental|Part 1: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
3125797|NCT03001219|Placebo Comparator|Part 2: Placebo|Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
3125798|NCT03001219|Experimental|Part 2: RO7123520|Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.
3125799|NCT03001219|Placebo Comparator|Part 3: Placebo|"Participants will receive placebo (matched to RO7123520) on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
3125800|NCT03001219|Experimental|Part 3: RO7123520|"Participants will receive RO7123520 on Days 1, 14, 28, and 56 with pre-trial anti-TNF-alpha and methotrexate.~NOTE: Part 3 was not conducted."
3125801|NCT03001258||PO (program organizers)|"PO (program organizers): Employed by Brac as field level organizers. A two day presbyopia screening training were provided.~A total of eight POs organized eye camps in two sub districts. POs were responsible for identifying the presbyopia patients through screening and SS assisted in organizing and mobilizing the community people for the eye camps, and glass sale (on the spot). Four camps were organized per day for five days by four POs in each sub-district. Thus a total of 40 eye camps were held in two sub districts by eight POs."
3125802|NCT03001258||USS (Upgraded Shashthya Shebika)|"USS (Upgraded Shashthya Shebika): A new caddre of community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, 20 USSs were assigned in two upazillas to run the two camp-day i.e. screening patients and selling glasses during the total 40 eye camps."
3471880|NCT03866395|Experimental|Ivabradine Group|drug therapy according to the guidelines + Ivabradine 5 mg twice a day
3471881|NCT03866369|Experimental|Experimental|IMP Under investigation
3471882|NCT03866369|Placebo Comparator|Placebo to Match|
3471883|NCT03866564||Multi-Afflicted|Participants with multiple self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
3471884|NCT03866564||Un-Afflicted|Participants who report no afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
3471885|NCT03866564||Single Afflicted|Participants with one self reported afflictions will undergo comprehensive research health screenings including Echocardiography (to define cardiac dysfunction), Neuropsychological Testing (to define neurocognitive disease), Pain Catastrophizing Scale (to define chronic pain), and Nocturnal Polysomnography (to define sleep apnea).
3471886|NCT03866499|Experimental|BPI-7711|180 mg BPI-7711 capsule + 250mg gefitinib placebo tablet, QD
3471887|NCT03866499|Active Comparator|Gefitinib|180 mg BPI-7711 placebo capsule + 250mg gefitinib tablet, QD
3125803|NCT03001258||SS (Shashthya Shebika)|"SS: Community health workers of Brac. A two day presbyopia screening training were provided.~In this arm, the SS, undertook the screening of potential presbyopia cases. A total of 27 SS organized 25 eye camps in eight days in two upazilas."
3125804|NCT03001453|Active Comparator|Liposomal bupivacaine|Periarticular infiltration cocktail of 20cc of liposomal bupivacaine with 20cc of normal saline and 40cc of 0.25% bupivacaine with epinephrine
3125805|NCT03001453|Active Comparator|Bupivacaine with epinephrine|Periarticular infiltration cocktail of 60cc of 0.25% bupivacaine with epinephrine
3125806|NCT03001557|Experimental|Lemborexant 2.5 milligrams (mg)|Participants will take one lemborexant 2.5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
3125807|NCT03001557|Experimental|Lemborexant 5 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
3125808|NCT03001557|Experimental|Lemborexant 10 mg|Participants will take one lemborexant 10 mg tablet and one lemborexant-matched placebo tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
3125809|NCT03001557|Experimental|Lemborexant 15 mg|Participants will take one lemborexant 5 mg tablet and one lemborexant 10 mg tablet orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
3125810|NCT03001557|Placebo Comparator|Lemborexant-matched placebo|Participants will take two lemborexant-matched placebo tablets orally each night for 28 consecutive nights immediately (i.e., within 5 minutes) before the time the participant intends to try to sleep.
3125811|NCT03001674|Experimental|IABP recipient|Referred for clinically indicated right heart catheterization with intervention of IABP placement prior to LVAD surgery.
3125812|NCT03001674|Experimental|Control|Control subjects undergoing left heart catheterization with an LV ejection fraction > 50%, and without a history of heart failure symptoms who did not receive IABP therapy were enrolled.
3125813|NCT03001778|Experimental|Usability Testing|Prototype testing
3125814|NCT03001843|Active Comparator|Non-Ketamine|This group will receive intraoperative narcotics as is usually done for this surgery. This arm will not receive Ketamine.
3125815|NCT03001843|Active Comparator|Ketamine|This group will receive an intraoperative infusion of ketamine rather than narcotics to control pain.
3125816|NCT03002012|Experimental|Sertraline|Fluconazole Standard of Care + Sertraline
3125817|NCT03002012|Placebo Comparator|Control|Fluconazole Standard of Care + Placebo Oral Tablet
3125818|NCT03002038|Experimental|Azathioprine|Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.
3125819|NCT03002038|Experimental|Rituximab|Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.
3125820|NCT03002077|Experimental|Rapastinel|Rapastinel 450 milligrams (mg) intravenous (IV) open label weekly or every two weeks, based on investigator's discretion for 52 Weeks.
3125821|NCT03002194|Experimental|RF and PEMF therapy|Each subject is to receive 8 weekly study treatments. The study treatment consists of Glide (medical grade glycerin) being applied thoroughly to the study treatment area (face). The energy will be delivered by the Diamondpolar applicator attached to the Venus Versa, a medical device approved by health regulatory authorities, to deliver combined radiofrequency (RF) and pulsed electromagnetic field (PEMF) energies. Change in skin elasticity will be measured by Cutometer. Change in appearance will be assessed by independent reviewer using photographs.
3125822|NCT03002311|No Intervention|Control|Receiving current standard of care as designated by emergency department (ED) standard operating practice.
3125823|NCT03002311|Experimental|Epharmix/CareSignal eHealth Intervention|After randomization, participants receive text reminders to have a follow-up visit. The participant can respond to these messages via numerical or binary answers (Y/N).
3125824|NCT03002454|Experimental|99mTc MDP Injection:neutron-bombardment|Oncologic indication for which a bone scan would normally be indicated. Participant having recently had a bone scan using Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from fission-sourced 99Mo. The images of the 99mTc MDP Injection-neutron-bombardment will be compared to the previous (on file) images from the 99mTc MDP Injection-fission
3471888|NCT03866330|Active Comparator|osteoarthritis of the knee|Intraarticular injection of WJMSC
3471889|NCT03866330|Active Comparator|osteoarthritis of the hip|Intraarticular injection of WJMSC
3471890|NCT03866330|Active Comparator|osteoarthritis of the glenohumeral joint|Intraarticular injection of WJMSC
3471891|NCT03866304|Experimental|Picosecond Laser|Treatment with investigational wavelengths of the S2 laser for tattoo removal.
3471892|NCT03866616|Active Comparator|Control (usual care)|"Behavioral: This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
3471893|NCT03866616|Experimental|Intervention (group sessions)|Behavioral: Brain Builders Parenting Class-intervention (BBPC). Participants who are selected via the lottery to participate in the BBPC program will be asked to attend six, 1-hour classes, every other week over a 12 week period of time.
3471894|NCT03866356|Experimental|Intervention group|The intervention group received care according to the SICP (Table 2). One of the researchers gave each participant one-on-one education in line with SICP. They were also provided with the booklet that had been prepared in accordance with SICP. The participants were phoned every week for eight weeks and offered counseling within the scope of SICP and then were reevaluated at the end of eight weeks (Post-intervention). The participants were followed from the eighth to the twelfth week without any intervention (4-week post-intervention).
3471895|NCT03866356|No Intervention|Control group|The control group received no intervention during the eight-week intervention period. The control group received standard care. The women were given no educational materials.
3125825|NCT03002506|Experimental|ceftolozane/tazobactam|One dose of 3 grams ceftolozane/tazobactam will be administered to each study participant.
3125826|NCT03002610|Active Comparator|PLS|The control group will receive PLS: text format with simple explanation of the survey topic main findings and is intended for lay audience.
3125827|NCT03002610|Experimental|Infographics|Infographics format of a Cochrane systematic review summary represents the experimental intervention in the trial, where the results are presented with text and pictures.
3125828|NCT03002610|Active Comparator|Scientific abstract|Scientific abstract is the text written for the academic population and practitioners. It is also intended for control group.
3125829|NCT03002623|Experimental|Group|CUDC-907 for thyroid cancer
3125830|NCT03002753|Experimental|DM|Group of patients receiving detached mindfulness (for details, see detailed description of the study)
3125831|NCT03002753|Active Comparator|CR|Group of patients receiving cognitive restructuring (for details, see detailed description of the study)
3125832|NCT03002753|No Intervention|WL|Waitlist control group, which, however, is again randomized after the waiting time in order to receive one of the two interventions (DM or CR).
3125833|NCT03002818||HCV Genotype 1 Participants|Participants receiving paritaprevir/ritonavir/ombitasvir with dasabuvir (Viekirax®/Exviera®, 3D regimen)
3125834|NCT03002974|Experimental|Anakinra 100 mg|1 subcutaneous injection of Anakinra 100 mg once daily for 5 days, 1 subcutaneous injection of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
3125835|NCT03002974|Experimental|Anakinra 200 mg|2 subcutaneous injections of Anakinra 100 mg (2 syringes) once daily for 5 days and 1 single intramuscular injection of Placebo to Triamcinolone Acetonide 40 mg
3125836|NCT03002974|Active Comparator|Triamcinolone 40 mg|2 subcutaneous injections of Placebo to Anakinra 100 mg once daily for 5 days and 1 single intramuscular injection of Triamcinolone Acetonide 40 mg
3125837|NCT03003000|Experimental|ibuprofen + caffeine|Fixed Dose Combination
3125838|NCT03003000|Active Comparator|ibuprofen|
3125839|NCT03003000|Placebo Comparator|placebo|
3125840|NCT03003130|Experimental|Restylane Defyne|Single injection and optional touch up injection with Restylane Defyne in NLF
3125841|NCT03003130|Active Comparator|Restylane|Single injection and optional touch up injection with Restylane in NLF
3125842|NCT03003390|Experimental|Prophylaxis with enoxaparin|A clinical nurse will administer enoxaparin subcutaneously <24 hours after insertion of the central venous catheter and then give enoxaparin subcutaneously every 12 hours until the removal of the catheter.
3125843|NCT03003390|No Intervention|Control arm|Participants randomized to the control arm will receive no 'placebo' intervention.
3125844|NCT03003494||Spiolto® Respimat®|consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC
3125845|NCT03003520|Experimental|DUR + R-CHOP|"On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP (IV rituximab 375 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 (maximum dose of 2.0 mg total), and cyclophosphamide 750 mg/m^2); Participants also were administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months."
3125846|NCT03003520|Experimental|DUR + R2-CHOP|"Participants start the study on durvalumab in combination with R-CHOP (as described in Arm DUR + R-CHOP). Based on their DLBCL Cell-of-Origin subtype (test typically done between cycles 1 and 2), participants with ABC subtype continue the study taking durvalumab in combination with R2-CHOP. On Day 1 of each 21-day cycle, participants received durvalumab 1125 mg intravenously (IV) followed by R-CHOP. Participants were also administered daily oral or IV prednisone/prednisolone 100 mg from Day 1 to 5. In addition, a daily oral lenalidomide 15 mg was administered from Day 1 to 14 of each 21-day cycle. Induction treatment continued for a total of 6-8 cycles.~Participants who achieve a complete response or partial response continue with consolidation therapy treatment consisting of durvalumab monotherapy 1500 mg by IV on Day 1 of each 28-day cycle for up to a total of 12 months.~Enrollment into Arm B was discontinued."
3125847|NCT03003676|Experimental|Experimental: ONCOS-102+cyclophosphamide+pembrolizumab|"Part I: Patients will receive 3 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, and 8) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. They will then receive pembrolizumab i.v., 2mg/kg or 200mg flat dose, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24).~Part II: Patients will receive 4 doses of intratumoral (i.t.) injection of ONCOS-102 (days 1, 4, 8 and 15) at 3x10^11 viral particles (VP), preceded by intravenous (i.v.) cyclophosphamide priming 1-3 days prior to day 1. ONCOS-102 will be given in combination with Pembrolizumab starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity or clinically relevant disease progression, whichever occurs first. Pembrolizumab will be given according to institutional practice (2mg/kg or 200mg flat dose)."
3125848|NCT03003793||Control group|Healthy control subjects
3125849|NCT03003793||Atopic dermatitis/eczema group|Patients with atopic dermatitis
3125850|NCT03003949|Placebo Comparator|Placebo Patch and Placebo Capsule|Placebo patches worn for 16 weeks. On the 9th week of patch, oral placebo capsule taken daily for 12 days. Following the 16 weeks of patch use oral placebo capsule taken daily for 12 days.
3471896|NCT03866525|Experimental|Dose escalation and dose expansion|"A 3+3 dose-escalation strategy is used in the phase 1 part and 3 dose levels (10e6, 10e7 and 10e8 CCID50/mL) of OH2 are assessed as single agent and in combination with HX008. The recommended dose levels are then determined and adopted in the phase 2 part for dose-expansion.~In the phase 2 dose-expansion part, OH2 will be delivered as single agent in cohort 1, in combination with irinotecan in cohort 2, in combination with HX008 in cohort 3 and 4. There are no comparator arms for these cohorts."
3471897|NCT03866668|Experimental|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
3471898|NCT03866291||ESBL carrier|"This cohort is followed for a year with additional selective ESBL cultures after 1, 3, 6 and 12 months. In the end of the year a questionnaire is handed in to the study group.~Sera is donated after 4-6 weeks and in year."
3471899|NCT03866291||Non ESBL-carrier|No further rectal cultures. In the end of the year a questionnaire is handed in to the study group. Sera is donated after 4-6 weeks and in year.
3471900|NCT03866343|Active Comparator|Low AGE diet|Subjects will be asked to consume a diet containing a low AGE content for 4 weeks.
3471901|NCT03866343|Other|High AGE diet|Subjects will be asked to consume a diet containing a high AGE content for 4 weeks.
3125851|NCT03003949|Active Comparator|Estradiol patch and progesterone capsule|Estradiol patches worn for 16 weeks. On the 9th week of patch, oral progesterone capsule taken daily for 12 days. Following the 16 weeks of estradiol patch use oral progesterone capsule taken daily for 12 days.
3125852|NCT03004469|Experimental|P-3074 + Finasteride Placebo|Participants received topical application of P-3074 contained finasteride 0.25% in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 milligram (mg) tablet orally once daily for 24 weeks.
3125853|NCT03004469|Placebo Comparator|P-3074 Vehicle + Finasteride Placebo|Participants received topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) and followed by placebo of finasteride 1 mg tablet orally once daily for 24 weeks.
3125854|NCT03004469|Active Comparator|Oral Finasteride + P-3074 Vehicle|Participants received finasteride 1 mg tablet orally once daily followed by topical application of P-3074 vehicle in morning onto dry scalp only (up to 4 puffs) for the 24 weeks.
3125855|NCT03004534|Experimental|Presurgical Molecular Assessment|Oral 300 mg darolutamide tablet; dose of 600 mg (2 x 300 mg tablets) b.i.d.
3125856|NCT03004638|Experimental|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
3125857|NCT03004638|Placebo Comparator|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
3125858|NCT03004638|Experimental|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
3125859|NCT03004638|Experimental|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
3125860|NCT03004638|Experimental|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
3125861|NCT03004638|Placebo Comparator|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
3125862|NCT03004846|Experimental|Part A: GSK2981278 4%|Subjects will receive topical application of GSK2981278 4% ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
3125863|NCT03004846|Experimental|Part B: GSK2981278 4% and vehicle|In Part B, subjects will receive topical application of GSK2981278 4 % ointment or vehicle ointment twice daily for 8 weeks. Based on new safety information, the concentration of GSK2981278 may be lowered to 2% or 0.8%.
3125864|NCT03004911|Experimental|Mobile application|
3125865|NCT03004911|Active Comparator|Paper booklet|
3125866|NCT03004924|Experimental|SHP640|Participants will instill 1 drop of SHP640 (povidone-iodine [PVP-I] 0.6 percent [%] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) for 7 days.
3125867|NCT03004924|Active Comparator|PVP-I 0.6%|Participants will instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID for 7 days
3125868|NCT03004924|Placebo Comparator|Placebo|Participants will instill 1 drop of placebo ophthalmic solution in each eye 4 times QID for 7 days.
3125869|NCT03005041|Experimental|Test Product 1|Participants will rinse their mouth with 15 mL of the product swishing for 30 seconds.
3125870|NCT03005041|Other|Test Product 2|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds. Participants then spit out the water.
3125871|NCT03005054|Experimental|StrataGraft skin tissue|
3125872|NCT03005067|Experimental|Carbomer 980 (1146A)|Participants will be administered test product (nasal spray) containing carbomer 980 gel. Three actuations per nostril per dose will be applied, each actuation will be 140µL (microliters) i.e. equivalent to 140mg.
3125873|NCT03005067|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980. Three actuations of placebo nasal spray per nostril per dose; each actuation will be 140µL.
3125874|NCT03005106|Experimental|StrataGraft Skin Tissue|
3125875|NCT03005288|Experimental|BYM338 10 mg/kg|Bimagrumab (BYM338) 10 mg/kg up to maximum 1200 mg, every 4 weeks until week 44 (12 doses)
3125876|NCT03005288|Placebo Comparator|Placebo|Placebo, every 4 weeks until week 44 (12 doses)
3125877|NCT03006341||Dabigatran etexilate|NVAF patients initiating dabigatran etexilate
3125878|NCT03006341||Warfarin|NVAF patients initiating warfarin
3125879|NCT03006393|Experimental|Infliximab|Participants randomized to the infliximab group will receive one infusion of infliximab at 5mg/kg body weight.
3125880|NCT03006393|Placebo Comparator|Placebo|Participants randomized to the placebo group will receive one placebo infusion.
3179207|NCT00670475|Experimental|O (olive oil group)|in this arm 100 patients with osteoarthritis of knee will receive virgin olive oil in blinded 60 grams tubes,they will be instructed to use 1 gram of olive oil (with inserted dispensing device) three times in a day on the affected knee.
3471902|NCT03866421||Kidney transplanted patients|"Number of patients: 16~Patients on the waiting list for kidney transplantation with a living donor. The patients are screened with an OGTT before participation in the study, thereby excluding patients with diabetes mellitus.~Patients in this group are examined three times (baseline (before transplantation) and after three and twelve months after transplantation).~Same interventions as in the control Group.~Including/ Exclusion criteria are listed under the section Eligibility"
3471903|NCT03866421||Control group|"Number of patients: 16~Participants in this group are matched on age and BMI according to the kidney transplanted patients.~Participants are screened with an OGTT before participation since only persons with normal glucose tolerance may be included in the study.~Furthermore, participants have to have normal kidney function.~Participants in this group are only examined once. Same interventions as in the kidney transplanted patient group"
3471904|NCT03866408|Active Comparator|Immediate weight loss - placebo|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to placebo during this period.
3471905|NCT03866408|Placebo Comparator|Deferred control group - placebo|After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are also randomized to placebo. At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without placebo.
3125881|NCT03006458|Experimental|comfilcon A|"Participants were randomized to wear comfilcon A toric lenses for two weeks during the cross over study.~The final optical design of comfilcon A contact lens was optimized to improve the quality and two further studies (CV-18-10 and CV-18-11) were conducted after completion of this study to evaluate the modified optical design."
3471906|NCT03866408|Active Comparator|Immediate weight loss - pioglitazone|Upper body obese participants randomized to this group; all will begin their immediate participation in a comprehensive lifestyle obesity treatment program after completion of baseline studies. Half of the volunteers will be randomized to pioglitazone during this period.
3471907|NCT03866408|Active Comparator|Deferred group - pioglitazone|"After baseline studies, UBO participants randomized to this group will wait without any intervention for 4 months, with continued monitoring to assure weight stability - this group will be the half of volunteers randomized to deferred weight loss intervention that are randomized to pioglitazone. They will be monitored to prevent the usual but modest weight gain associated with pioglitazone. They will be on pioglitazone during the 'wait' period.~At the end of this 'wait' period they will be enrolled in the same comprehensive lifestyle obesity treatment program for 4 months, but without pioglitazone."
3471908|NCT03866473|Experimental|Retilux Photobiomodulation|670nm wavelength device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device).
3471909|NCT03866473|Sham Comparator|Sham Light Device|Broad spectrum light device twice a day for 90 seconds through 4 months. At the 4-month visit, participants who have not already received alternative treatments for DME will return the original device and receive the alternative treatment group device (i.e. the sham group will receive an active treatment device and the active treatment group will receive a sham device)
3471910|NCT03866486||IVUS-guidance group|The patients who underwent drug-eluting stents implantation with IVUS guidance.
3471911|NCT03866486||Angiography-guidance group|The patients who underwent drug-eluting stents implantation with angiography guidance without IVUS.
3125882|NCT03006458|Active Comparator|omafilcon B|Participants were randomized to wear omafilcon B toric lenses for two weeks during the cross over study.
3471912|NCT03866447|Active Comparator|vitamin D versus placebo|This group will be treated by topical Vitamin D analogue (Calcipotriol) versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
3125883|NCT03006471|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
3471913|NCT03866447|Active Comparator|Adapalene versus placebo|this group will be treated by topical Adapalene (0.1%) versus versus placebo (panthenol).split face.half of the face will be treated by vitamin d and the other by placebo(panthenol)
3471914|NCT03866252|Experimental|Treatment Arm|Subjects in the treatment arm will receive 100 μg LSD (first session) and 100 or 200 μg LSD (second session) per os.
3125884|NCT03006471|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
3471915|NCT03866252|Active Comparator|Control Arm|Subjects in the control arm will receive 25 μg LSD (first session) and 25 μg LSD (second session) per os.
3471916|NCT03866317|Experimental|Secukinumab|Secukinumab 300 mg injection at week 0, 1, 2, 3, 4, then every 4 weeks until week 12
3471917|NCT03866161||CPAP group|Obstructive sleep apnea patients treated with continuous positive airway pressure
3125885|NCT03006562|Experimental|Subcutaneous Heparin|Patients randomized to the pharmacologic VTE prophylaxis arm will receive a dose of subcutaneous heparin 5,000 units prior to incision, and subcutaneous heparin 5,000 units every 8 hours after surgery until discharge.
3125886|NCT03006562|No Intervention|Control|Patients randomized to the control arm will receive routine care with intermittent pneumatic compression devices.
3125887|NCT03006848|Experimental|Avelumab|"All participants with recurrent/refractory osteosarcoma who consent to the study.~Interventions: Avelumab and quality of life questionnaires."
3125888|NCT03006887|Experimental|lenvatinib 20 mg plus pembrolizumab 200 mg|Participants with selected tumors will receive oral lenvatinib at a starting dose of 20 milligrams (mg) once daily in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination of the study.
3179208|NCT00670501|Experimental|1|LY333334 40 micrograms/day plus calcium and vitamin D
3179209|NCT00670501|Experimental|2|LY333334 20 micrograms/day plus calcium and vitamin D
3179210|NCT00670501|Placebo Comparator|3|Placebo plus calcium and vitamin D
3471918|NCT03866265|Active Comparator|Supplement Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a food supplement capsule (containing 0.125 g of FGE-Salmon-PLs) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the food supplement will now be administered the placebo capsules for 28 days (a placebo capsule per day)"
3471919|NCT03866265|Placebo Comparator|Placebo Group|"10 Subjects will provide baseline blood samples at day 0. Just after they will be initially administered a placebo capsule (containing 0.125 g of glycerin) per day for a period of 28 days.~After the period of 28 days, each participant will provide blood samples at the 29th day.~Then a washout period of 14 days will follow, in which each participant will not be administered any kind of capsules.~After this washout period of 14 days, each participant will provide again new baseline blood samples and then in a crossover design the participants of this group that were initially administered the placebo capsules will now be administered the food supplement capsules for 28 days (a food supplement capsule per day)"
3471920|NCT03865979|Active Comparator|Intervention Arm|"Subject CT images assessed by Viz RECRUIT software in real time analysis All subjects in which the Viz RECRUIT software is utilized will be identified per cohort described below per PI confirmation of ENRICH Trial status/Study ID.~Cohort A: Subjects with imaging data Cohort B: Subjects with imaging data and ultimately enrolled as part of the ENRICH Trial"
3471921|NCT03865979|No Intervention|Control Arm|Subjects enrolled as part of the ENRICH Trial prior to Viz RECRUIT software activation
3471922|NCT03866005|Placebo Comparator|Placebo Arm - Standard Treatment|50 subjects with center-involved diabetic macular edema (CI-DME) and scheduled for treatment with intravitreal injection of anti-VEGF agents will receive softgel placebo containing canola oil, 2 capsules per day during the study duration
3471923|NCT03866005|Experimental|Experimental Arm - 2 DiVFuSS formula softgel capsules|50 subjects receiving two DiVFuSS softgels per day
3471924|NCT03866005|Experimental|Experimental Arm - 4 DiVFuSS formula softgel capsules|50 subjects receiving 4 DiVFuss softgels per day
3471925|NCT03866018|Experimental|Adapted physical activity|Patients will participate in an adapted physical activity workshop.
3471926|NCT03865940|Experimental|Lidocaine then Lidocaine + Guanfacine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine."
3471927|NCT03865940|Experimental|Lidocaine + Guanfacine then Lidocaine|"Trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine + 250 mcg guanfacine (Day 1).~Patient will return between Day 15-28 and trigeminal nerve block will be performed with injection of 6 mL of 1% lidocaine."
3471928|NCT03866213||Quantitative Measurement of Bilirubin|Bilirubin content of the neonate will be measured by the following: BiliSpec, laboratory spectophotometric bilirubinometer (Reichert UNISTAT), and transcutaneous bilirubinometer. The infant may or may not be receiving phototherapy treatment at the time of sample measurement.
3471929|NCT03865914||Type 2 diabetic nephropathy|The cohort will be followed for at least two years. The cohort will be divided into 2 groups according the pathological results of patients,and at least 3 groups according to clinical features such as renal function and proteinuria.
3471930|NCT03866031|Experimental|M:2.75|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 2.75 mm
3471931|NCT03866031|Experimental|M3.25|12 Patients will be provided with 4 mini implant-supported mandibular overdentures d: 3.25 mm
3471932|NCT03866031|Experimental|S3.75|12 Patients will be provided with 2 standard sized implant-supported mandibular overdentures d: 3.75 mm
3471933|NCT03865992|Experimental|Arm I (nanoemulsion curcumin)|Patients receives nanoemulsion curcumin orally (PO) twice daily (BID) for up to 3 months in the absence of disease progression or unacceptable toxicity.
3471934|NCT03865992|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for up to 3 months in the absence of disease progression or unacceptable toxicity.
3471935|NCT03866057||1 study group|All patients hospitalized in 4 intensive rehabilitation Structures of Don Gnocchi Foundation during the enrollment period, suffering from acute (within 30 days) ischemic or emorragic stroke
3471936|NCT03865888|Active Comparator|Cyclosporins 0.05 % treated eyes|Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
3471937|NCT03865888|Active Comparator|Tacrolimus 0.03% treated eyes|Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months
3471938|NCT03865901||Non-diabetic pregnant women|Non-diabetic women with singleton pregnancy undergoing screening for gestational diabetes who provide plasma samples for testing with the Mellitus GCD59 Test
3471939|NCT03865849|Active Comparator|Conventional radiofrequent treatment|The patient is placed in a supine position on a fluoroscopy table with the index knee flexed 10-15°. The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 10 mm active tip
3471940|NCT03865849|Active Comparator|Cooled radiofrequent treatment|The procedure is performed with a 100 mm long, 18 G straight RF cannula/introducer (Halyard) with a probe/electrode with a 100 mm long, 17 G RF cannula/introducer with an 18 G cooled probe/electrode with a 4 mm active tip (Halyard/Coolief).
3125889|NCT03006926|Experimental|lenvatinib 8 or 12 mg plus pembrolizumab 200 mg|Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.
3125890|NCT03007225|Active Comparator|group 1 Drug eluting beads intervention|Twenty-five patients underwent Chemoembolization with Drug eluting beads. using Drug eluting Doxorubicin hydrochloride (100-150 mg)
3471941|NCT03866044||Parkinson's Disease (PD)|"Patients with Parkinson's Disease meeting the following criteria:~Inclusion criteria:~Aged 18 or more.~Clinically established or probable PD according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of other neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
3471942|NCT03866044||Healthy participants|"Healthy participants age- and sex-matched to the PD group.~Inclusion criteria:~Age- and sex-matched to PD group (aged 18 or more)~Signed informed consent~Exclusion criteria:~Pregnancy or breastfeeding~History of neurologic or psychiatric disease~Pacemaker or other implanted electronic devices~Claustrophobia"
3471943|NCT03866096|Experimental|Experimental|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training and a CORE strengthening program
3471944|NCT03866096|Active Comparator|Control|Each session will last 20 minutes, taking place during 2 days a week, in a period of 6 weeks. The intervention will be made prior to the training session. The subjects of the experimental group will receive an intervention through neuromuscular training.
3471945|NCT03866083|Experimental|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
3471946|NCT03866083|Active Comparator|Stadard Medical treatment|Stadard Medical treatment
3125891|NCT03007225|Active Comparator|group 2 Conventional TACE intervention|Twenty-five patients underwent conventional Chemoembolization (cTACE) using the standard TACE technique
3471947|NCT03866122|Experimental|Neonatal Temperature Monitor|One or more test devices (NTM, Bempu, Thermospot) will be attached to the infant in the neonatal intensive care unit (NICU) or KMC ward along with the Philips Intellivue patient monitor. Temperature will be monitored continuously using each device for up to 72 hours.
3471948|NCT03865823||anal Fistula|patient with anal fistula with indication to surgical treatment
3125892|NCT03007394|Active Comparator|Lorcaserin|10 mg capsule by mouth, twice a day, for 13 weeks
3471949|NCT03865875|Experimental|Multimodal Prehabilitation Program|"Pretreatment exercise program and nutrition program~-The prehabilitation intervention will include the following components: (1) a standardized fitness program and (2) nutritional counseling and optimization. Patients are enrolled in the program within 8 weeks of being diagnosed and continued until operation"
3471950|NCT03865862|Experimental|Experimental|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
3471951|NCT03865862|Active Comparator|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series.
3125893|NCT03007394|Placebo Comparator|Placebo Oral Capsule|10 mg placebo capsule, twice a day, for 13 weeks
3125894|NCT03007472|Experimental|CI532/N7 study group|All subjects will receive a CI532 cochlear implant (intervention) and be fit with the CP1000 sound processor
3179211|NCT00670514|Active Comparator|1 Nix Individual|High Treatment Intensity
3471952|NCT03866109|Experimental|Temferon|Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
3471953|NCT03866070|Experimental|Experimental|The subjects that are part of the experimental group will carry out the intervention thought the performance of strengthening exercises of the shoulder and scapula, and capsular stretches.
3471954|NCT03866070|Active Comparator|Control|Subjects that are part of the control group will perform shoulder strengthening exercises exclusively.
3471955|NCT03865797|Experimental|Experimental|Before carrying out each session of the intervention, each subject included in the experimental group will have a sports bandage on both ankles. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
3471956|NCT03865797|Active Comparator|Control|The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up. The duration of each session will be 15 minutes, with two sessions per week, during a period of 4 weeks.
3471957|NCT03865784|Experimental|Experimental|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises with tension and stretching will be performed
3471958|NCT03865784|Active Comparator|Control|Each session will be held in a group and will last 35 minutes, taking place 2 sessions a week, in a period of 4 weeks. The intervention will be carried out at the end of the training session and after drying the sweat of the area to be treated. After the training, the Core and Kinesiotape exercises technique will be performed without tension or stretching
3125895|NCT03007953|Experimental|Intervention|This is a nurse-led telephone-based program integrating palliative care into usual oncologic care for patients diagnosed within 2 months of any type and stage of lung cancer, who will receive therapy other than solely surgical resection. The intervention lasts for the duration of patients' primary lung cancer treatment (usually 3-4 months).
3125896|NCT03007953|No Intervention|Usual Care|Subjects randomized to the usual care arm will receive medical oncology, radiation oncology, pulmonary, CT surgery, as indicated by the type and stage of cancer. At the completion of their primary lung cancer treatment, they will be disenrolled from the study.
3125897|NCT03007966|Active Comparator|Ilioinguinal / Iliohypogastric Block|Patient's randomized to receive an Ilioinguinal / Iliohypogastric nerve block (IINB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a supine position in a manner consistent with the technique described by Willschke, but modified to utilize an in-plane technique rather than an out-of-plane technique for needle to ultrasound probe orientation. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
3125898|NCT03007966|Experimental|Quadratus Lumborum Block|Patient's randomized to receive a Quadratus Lumborum block (QLB) for post operative analgesia following inguinal herniorrhaphy will have said block performed in a lateral position in a manner consistent with the technique described by Børglum. Either a Sonosite linear HFL38x/13-6 MHz or Sonosite curvilinear C60x/5-2 MHz probe will be utilized to visualize the pertinent ultrasound anatomy. A Pajunk 21g x 100mm Sono Plex Stim Cannula will be utilized to appropriately deposit a single local anesthetic aliquot consisting of 25cc's of bupivacaine 0.25% with epinephrine 5mcg/cc and clonidine 1.66mcg/cc.
3179212|NCT00670514|Placebo Comparator|2 Fimpa dig fri|Low Treatment Intensity
3471959|NCT03865706|Experimental|Inulin 32 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.
3471960|NCT03865706|Experimental|Inulin 16 g/day|Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.
3471961|NCT03865706|Placebo Comparator|Placebo|Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.
3471962|NCT03865602|Experimental|Sepsis Transition And Recovery (STAR)|Virtual sepsis navigation delivered across the peri-hospital discharge interval
3471963|NCT03865602|Active Comparator|Usual Care|Patients and their providers will have no access to the STAR program. Aspects of usual care will be determined by treating clinicians independent of trial assignment.
3471964|NCT03865771|Experimental|EPILEPSY GROUP|"Patients with typical BECTS (benign group) or atypical BECTS or ECSWS (severe group)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography (standard of care procedure): 2h wake and whole night~Sleep diary"
3471965|NCT03865771|Other|CONTROL GROUP|"Patients hospitalized for non neurologic illness (diabetes, nephropathy, chronic intestinal disease)~Medical visit~Neuropsychological testing~Neuropsychological procedure~Video EEG and polysomnography : 2h wake and whole night~Sleep diary"
3471966|NCT03865758|Experimental|IN2L enhanced therapy|The intervention to be delivered is the use of the IN2L computer system to deliver video, music, and exercises to patients receiving physical and occupational therapy. Therapists will select the specific IN2L that will be most appropriate given each person's rehabilitation goals and personal preferences.
3471967|NCT03865758|No Intervention|Usual OT and PT services without IN2L|The intervention to be delivered is physical therapy and occupational therapy to improve functioning.
3471968|NCT03865472|Experimental|Arm I (rTMS)|Patients undergo rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
3471969|NCT03865472|Sham Comparator|Arm II (sham rTMS)|Patients undergo sham rTMS QD or BID over 16 minutes for 8, 12, or 16 days.
3471970|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
3471971|NCT03865485|Experimental|Length: long; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
3471972|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
3471973|NCT03865485|Experimental|Length: long; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - long: 10 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters;~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
3471974|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster:high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
3471975|NCT03865485|Experimental|Length: short; Engagement booster: high; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - high: Engagement Boosters (i.e., a communication booster including weekly text messages reminders and 5-minute phone consultations twice a month from facilitators and an enhanced incentives package (including lunch (approx. 1-3€), a food parcel (approx. 2 - 5 €), reimbursement for local transport (FYR of Macedonia and Republic of Moldova only) at each group session and an award for attendance (if parents did not miss more than 1 session, approx. 5-20€) and raffle prizes at the end of the program),~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
3471976|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: high|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - high supervision: Fidelity Boosters (i.e., 5 structured intensive video feedback supervision sessions for facilitators)."
3471977|NCT03865485|Experimental|Length: short; Engagement booster: low; Fidelity booster: low|"Behavioral: Parenting for Lifelong Health (PLH)~Program length - short: 5 group sessions of the PLH 2-9 intervention delivered every other week (i.e., relationship building, positive reinforcement, setting limits, and effective discipline);~Engagement booster - low: No Engagement Boosters~Fidelity booster - low supervision: No Fidelity Boosters (i.e., supervision on demand only)."
3179213|NCT00670553|Experimental|LBH589|
3179214|NCT00670566|Experimental|1|
3471978|NCT03865615|Experimental|Oxytocin First|Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.
3471979|NCT03865615|Experimental|Placebo First|Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.
3471980|NCT03865550|Placebo Comparator|Placebo|
3471981|NCT03865550|Active Comparator|Ketamine|
3471982|NCT03865745|Experimental|Korean Red Ginseng|Product: Red ginseng Everytime 1 pack(3g/day)
3471983|NCT03865563|Experimental|Pancreatic adenocarcinoma|Participants with resectable, borderline-resectable or locally-advanced pancreatic adenocarcinoma will receive pancreatic retrograde venous infusion of gemcitabine/lipiodol
3471984|NCT03865693|Experimental|scarmbler treatment group|Each Scrambler therapy with the MC5-A Calmare® therapy device (Competitive Technologies, Inc. Fairfield, USA ) was performed for 40 min daily (Monday through Friday) for 10 consecutive days. The experimental participants were received scarmbler therapy 10 times for 2 weeks. The stimulus was increased to the maximum intensity bearable by the individual patient without causing any additional pain or discomfort.
3471985|NCT03865693|Sham Comparator|sham treatment group|conservative management without scarmbler therapy
3471986|NCT03865680|Experimental|MI varnish|MI Fluoride varnish: 5% sodium fluoride varnish water based, sugar free containing RecaldentTM (CPP-ACP) (GC AMERICA INC.3737 West 127th Street, Alsip, IL 60803 U.S.A). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
3471987|NCT03865680|Active Comparator|Duraphat Fluoride varnish|Duraphat Fluoride: varnish 5% sodium fluoride varnish (Colgate, New York, N.Y.). The varnish will be applied at baseline 2 and 4 weeks on the whole set of teeth of the participants with partial cotton roll isolation , saliva ejector and according to the manufacturer's instructions. Participants will receive oral hygiene instructions, prophylaxis without paste.
3471988|NCT03865576||Thomas Jefferson University|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
3179215|NCT00670592|Other|HCD122|
3179216|NCT00670618|Experimental|1|CPP-ACP (GC Tooth Mousse)
3179217|NCT00670618|Experimental|2|GCC-ACP (GC MI Paste Plus)
3179218|NCT00670618|Experimental|3|Fluoride (Elmex Medical Gel)
3179219|NCT00670618|No Intervention|4|Control group
3179220|NCT00670657|Experimental|1|AmBisome® 2 mg/kg/day in a unique daily IV administration
3179221|NCT00670670|Experimental|1|CPP-ACP (GC Tooth Mousse)
3179222|NCT00670670|Experimental|2|CPP-ACP (GC MI Paste Plus)
3179223|NCT00670670|No Intervention|3|Control group
3179224|NCT00670683||A|
3179225|NCT00670696|Experimental|A|Rapydan medicated plaster administered 30 minutes prior to cannulation on Visit 1 and tetracaine gel administered 45 minutes prior to cannulation on Visit 2.
3179226|NCT00670696|Active Comparator|B|Tetracaine gel administered 45 prior to cannulation on Visit 1 and then Rapydan administered 30 minutes prior to cannulation on Visit 1
3179227|NCT00670722||A|
3471989|NCT03865576||Honor Health in Phoenix|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors."
3471990|NCT03865576||Emory University Hospital in Atlanta|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device.~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors"
3471991|NCT03865576||University of Washington|"Patients in intensive care with altered intracranial pressure.~Intervention: Non-invasive ICP measurement using transorbital Doppler ultrasound device. .~Comparison of measurements obtained with values derived from surgically implanted ICP monitoring sensors and lumbar puncture"
3471992|NCT03865524|Experimental|Experimental|Total knee arthroplasty implanted with GPS navigation system.
3471993|NCT03865524|Active Comparator|Control|Total knee arthroplasty implanted with standard guides.
3471994|NCT03865732|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
3471995|NCT03865732|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
3471996|NCT03865459|Experimental|Video group|The video group watched relaxing video with a ceiling mounted television during the whole cystoscopy.
3471997|NCT03865459|No Intervention|Control group|The control group received the standard treatment from a surgical technician who works in the cystoscopy during the whole procedure.The control group didn't watch relaxing video during the procedure.
3471998|NCT03865537|Experimental|Cold snare & Eleview injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview
3471999|NCT03865537|Experimental|Cold Snare & Placebo injection|Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo
3472000|NCT03865537|Active Comparator|Hot snare & Eleview injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview
3125899|NCT03007979|Experimental|Palbociclib + letrozole or + fulvestrant|"Palbociclib should be taken by mouth with food on a 5 days on/2 days off schedule (meaning: on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle).~Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle.~Patients who are receiving fulvestrant will receive it as two intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.~Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- or peri-menopausal women only.~Optional research biopsy at baseline and progression~Blood for research at baseline, cycle 1 day 15, cycle 2 day 1, every 2-3 months (to coincide with imaging studies), and time of progression"
3125900|NCT03008070|Experimental|IVA337 1200mg|IVA337 400mg, once a day (Quaque Die, QD) with food
3179228|NCT00670722||B|
3472001|NCT03865537|Active Comparator|Hot snare & Placebo injection|Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo
3472002|NCT03865641|Experimental|Virtual reality intervention|Experimental group : virtual reality intervention
3472003|NCT03865641|No Intervention|Control group|conventional rehabilitation without virtual reality intervention
3472004|NCT03865667||Primary Total Hip Arthroplasty|Single-arm, single-center, prospective follow-up study with consecutively enrolled newly or previously implanted subjects with the PROFEMUR® Preserve Femoral Stem(s) and CoCr (cobalt-chromium) Modular Neck combined with other Wright Medical Technologies (WMT) or MPO (MicroPort) THA (Total Hip Arthroplasty) components including acetabular shells, acetabular liners and femoral heads.
3472005|NCT03865654|Experimental|Surveillance Mammography Communication Tool|"Conduct 30 telephone-based patient interviews~4-6 focus groups with oncologists and primary care providers (PCs) to learn their perceptions and thoughts about when to stop surveillance mammography~Perform cognitive testing of the communication tool"
3472006|NCT03865433|Experimental|Exercise Group|Intervention: aerobic exercise Subjects in the exercise group will be prescribed exercise at a target heart rate (THR) of approximately 80% of the achieved heart rate during the Buffalo Concussion Treadmill Test (BCTT). They will be given this prescription in writing to provide to their athletic trainer. Subjects will complete 30 minutes of daily exercise (including 5 minutes of warm up and 5 minutes of cool down) on an exercise bike or walking and supervised by an athletic trainer. This program may be modified by increasing heart rate threshold 5-10 beats per minute per week by the athletic trainer as the heart rate for symptom exacerbation increases.
3472007|NCT03865433|Placebo Comparator|Placebo/Stretching|Intrvention: stretching program Subjects assigned to the Stretching/Placebo group will be given a stretching protocol and instructions to report to their athletic trainer on a daily basis as soon as possible. . Subjects will then complete a 15-25 minute stretching program under supervision by the athletic trainer or other designated research personnel. The stretching protocol will be progressive and will change weekly as subjects continue their recovery.
3472008|NCT03865368|Experimental|Active Whole Body Vibration Training|Exercises were taught during the first session, active training was done in the second session, and acute evaluations were made during the third session. Both groups performed the dynamic exercises, under supervision, on the whole body vibration device with 10-second rest intervals. Throughout the WBVT session, the vibration amplitude was set to 2 mm and exercise frequency 30 Hz.
3472009|NCT03865368|Active Comparator|Control Group|The same exercises as the aWBVT group were performed on the vibration platform, with the vibration application turned off
3472010|NCT03865498|Experimental|Hispanic dementia caregivers|De-identified followers of our Hispanic dementia caregiver Twitter network will receive messages from the network (Twitter for Hispanic caregivers' intervention).
3472011|NCT03865498|Experimental|African American dementia caregivers|De-identified followers of our African American dementia caregiver Twitter network will receive messages from the network (Twitter for African American caregivers' intervention).
3472012|NCT03865511|Experimental|TAGRISSO® 80mg (Osimertinib)|"Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.~Tumor biopsies performed at baseline and clinical progression. ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial."
3472013|NCT03865355||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high-grade glioma (grade III and grade IV (glioblastoma (GBM)))~Planned treatment (surgery followed by radiation therapy (RT) alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
3125901|NCT03008070|Experimental|IVA337 800mg|IVA337 400mg, once a day (Quaque Die, QD) with food
3125902|NCT03008070|Placebo Comparator|Placebo|Placebo to match, once a day (Quaque Die, QD) with food
3125903|NCT03008174|Experimental|Intervention|"Early one-way speaking valve (OWSV) assessment by speech language pathologist (SLP) following 12-24 hours after percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Third OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between second and third sessions per standard of care."
3125904|NCT03008174|No Intervention|Control|"Standard OWSV evaluation with SLP following 48-60 hours from initial percutaneous tracheostomy procedure.~Second OWSV evaluation with SLP following first tracheostomy tube change. Participants may receive additional SLP sessions between first and second sessions per standard of care."
3472014|NCT03865355||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low-grade (grade I/II) glioma~Planned treatment either expectant monitoring or surgery followed by RT alone or Chemotherapy alone or a combination of RT/Chemotherapy"
3125905|NCT03008213|Experimental|Netupitant and Palonosetron|Subjects will be allowed to participate only once in the study. Study Day 1 will be the day of Akynzeo® dosing. Subjects will receive a single capsule of Akynzeo® (300 mg of netupitant and 0.5 mg of palonosetron) on Study 1.
3125906|NCT03008369|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO once daily on days 1-28. Courses repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3125907|NCT03008460|Experimental|Eziclen®/Izinova®|
3125908|NCT03008460|Active Comparator|Klean-Prep®|
3125909|NCT03008590|Other|Naltrexone first then placebo|Naltrexone for 8 weeks, then placebo for 8 weeks, blinded cross-over design
3472015|NCT03865355||Cohort 3 / Conditionally healthy volunteers|"Cohort 3:~No oncological disease was diagnosed~Planned treatment (reconstructive surgery after craniofacial trauma)"
3472016|NCT03865199|Experimental|Intervention Group|The intervention arm will view a digital story on a tablet created by the research team, then respond to a writing prompt. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
3472017|NCT03865199|No Intervention|Control Group|The control group will receive care as usual at the abortion clinic. A baseline abortion stigma and psychological distress survey will be taken at enrollment and then again at follow-up after 2-4 weeks.
3472018|NCT03865186|Experimental|intervention group|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
3472019|NCT03865186|Experimental|control group|no intervention was applied to the control group
3472020|NCT03865238|Experimental|EV71vac|
3472021|NCT03865238|Placebo Comparator|Placebo|
3472022|NCT03865264|Active Comparator|Living Liver donor|"Recovery enhancement program:~At least 6 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
3472023|NCT03865264|Active Comparator|Living Kidney donor|"Recovery Enhancement Program~At least 4 weeks of physical and relaxation skills training pre-transplant.~Taking nutritional drink for 5 days before and after the surgery.~Opioid sparing pain management."
3472024|NCT03865264|No Intervention|Living Kidney donor (Control)|"Subjects maintain the same lifestyle without practicing physical training, relaxation skills or nutritional drink before and after the surgery.~To control post-op pain, subject will use medication per standard of care, including PCA pump."
3472025|NCT03865251|Experimental|experimental group|Kinesiology tape application to dominant leg during lying and standing positions
3472026|NCT03865134||Laser Group|Children with premature retinopathy treated with Laser therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
3472027|NCT03865134||Anti-VEGF Group|Children with premature retinopathy treated with anti-VEGF therapy. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
3472028|NCT03865134||Regrese Group|Children with premature retinopathy haven't applied any invasive treatment method. All cases are evaluated with Snellen Test, Autorefractometer, Titmus Stereo Fly Test, Optical Kohlerans Tomography, Peabody Developmental Motor Scales - II. Investigation of Visual Motor Integration will evaluate with Beery- Buktenica Developmental Test of Visual Motor Integration and Peabody. Parents are evaluated World Health Organization Quality of Life - BREF and State - Trait Anxiety Inventory.
3472029|NCT03865290|Experimental|Healthy Control Ondansetron 8 mg|Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
3125910|NCT03008590|Other|Placebo first then naltrexone|Placebo for 8 weeks, then naltrexone for 8 weeks, blinded cross-over design
3125911|NCT03008707||Group 1|Patients who undergo Laparoscopic Peritoneal Lavage
3125912|NCT03008707||Group 2|Patients who have a laparoscopically approached sigmoidectomy
3179229|NCT00670722||C|
3179230|NCT00670722||D|
3472030|NCT03865290|Experimental|Diabetic (DM) gastroenteropathy Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
3472031|NCT03865290|Experimental|Non-ulcer dyspepsia (NUD) Ondansetron 8 mg|"Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.~Oral Ondansetron 8 mg administered three times a day for weeks 3-6"
3472032|NCT03865290|Placebo Comparator|Healthy Control Placebo|Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
3472033|NCT03865290|Placebo Comparator|Diabetic (DM) gastroenteropathy Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
3125913|NCT03008837|Experimental|PENFS|Veterans with fibromyalgia who meet study criteria and are randomized to the experimental group will receive standard therapy in addition to percutaneous electrical neural field stimulation (PENFS), which involves placement of small electrodes through a similar process to ear acupuncture to the ear. These electrodes are attached to a battery pack that is taped behind the ear and worn for 5-day intervals. The intention of this FDA-approved device is to relieve pain, though data on its effectiveness is still limited. Device placement (series of 4, weekly) will be performed by an Anesthesiology Pain Clinic provider. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
3179231|NCT00670761|Active Comparator|1|treatment with 600mcg oral misoprostol
3472034|NCT03865290|Placebo Comparator|Non-ulcer dyspepsia (NUD) Placebo|"Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.~Oral matched placebo administered three times a day for weeks 3-6"
3472035|NCT03865342|Experimental|Noom Coach DPP|Individuals will receive special instructions on how to use the app and will self-monitor their weight, exercise and receive daily DPP core content through the app over 16 weeks plus guidance from a coach, and will thereafter receive post-core DPP content up to 52 weeks.
3472036|NCT03865342|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their medical care during the study period plus a paper version of the DPP curriculum."
3472037|NCT03865225|Sham Comparator|Control group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes sham-biofeedback over a period of three days
3472038|NCT03865225|Active Comparator|Treatment group acute ischaemic stroke|Acute ischaemic stroke patients receiving 9 x 10 minutes biofeedback sessions over period of three days
3472039|NCT03865160|Active Comparator|Atropine eye drops, 0.01%|Atropine eye drops, 0.01%, both eyes at bedtime
3472040|NCT03865160|Placebo Comparator|Placebo (NaCl 0.9%) eye drops|Placebo (NaCl 0.9%) eye drops, both eyes at bedtime
3472041|NCT03864939|Experimental|dHAM|dHAM wrap is placed during RRP.
3472042|NCT03864939|Placebo Comparator|Standard|A standard RRP is performed.
3472043|NCT03864991|No Intervention|Routine Care|This group will be followed up for routine care, maintaining a standard log book for documenting blood sugar and insulin dosages per advice and explanation by doctors, nurses and nutritionists.
3472044|NCT03864991|Active Comparator|e-device for step count (fit-bit)|This group will receive e-device for step count (fit-bit) in addition to routine care.
3472045|NCT03864991|Active Comparator|e-messages for log book|This group will receive daily e-messages for maintaining log book in addition to routine care.
3472046|NCT03864991|Active Comparator|e-messages for log book & fit-bit|This group will receive e-device for step count (fit-bit), daily e-messages for maintaining log book for blood sugar, insulin dosages and step count in addition to routine care.
3472047|NCT03865056|Experimental|High-Flow Nasal Cannula|
3472048|NCT03865056|Experimental|Noninvasive ventilation|
3472049|NCT03865277|Other|standard radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to standard radiation dose, 70 Gy standard radiochemotherapy
3472050|NCT03865277|Experimental|dose-escalated radiochemotherapy, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, randomized to escalated radiation dose, 77 Gy radiochemotherapy
3472051|NCT03865277|Experimental|escalated radiochemoth., carbon boost, hypoxic|HPV (-), hypoxic in 18F-MISO PET after 2 weeks of radiochemotherapy, non-randomised arm (only possible in the trial center Heidelberg), 77 Gy radiochemotherapy (boost with carbon)
3472052|NCT03865277|Other|standard radiochemotherapy, oxic|HPV (-), oxic in 18F-MISO PET after 2 weeks of radiochemotherapy, 70 Gy standard radiochemotherapy
3179232|NCT00670761|Active Comparator|2|treatment with 400mcg sublingual misoprostol
3179233|NCT00670761|Active Comparator|3|treatment with Manual Vacuum Aspiration (MVA)
3472053|NCT03865277|Other|standard radiochemotherapy (70 Gy)|HPV (+), HPV positive patients will get the same imaging and clinical examinations as HPV negative patients. This measure is necessary to further elucidate the prognostic role of hypoxia and HPV status and their correlation, the information will be important for consecutive clinical trials. 70 Gy standard radiochemotherapy.
3472054|NCT03865004|Placebo Comparator|Placebo|
3472055|NCT03865004|Active Comparator|Paracetamol|
3472056|NCT03865004|Active Comparator|Dexketoprofene|
3472057|NCT03865316|Experimental|SedLine Vs Comparator Test Group|
3472058|NCT03864913|Experimental|Randomized SQ vs IM|Subjects randomized to either SQ or IM testosterone injections follow study protocol.
3472059|NCT03864913|Experimental|Non-randomized SQ|Subjects choose to participate in study, but decline to randomize and select SQ injections. Follow same study protocol.
3472060|NCT03864913|Experimental|Non-randomized IM|Subjects choose to participate in study, but decline to randomize and select IM injections. Follow same study protocol.
3472061|NCT03865030|Active Comparator|psoriatic patients|psoriatic patients that are recruited from the dermatology clinic. This arm will undergo audiovestibular evaluation.
3472062|NCT03865030|Active Comparator|healthy volunteers|Healthy volunteers that are members of the hospital staff and will be recruited from the hospital. This arm will undergo audiovestibular evaluation.
3472063|NCT03865147|Experimental|Phase 1 open, pilot phase|A pilot group of 10 patients who will receive Tri-Solfen only (non-randomised) once, prior to debridement
3472064|NCT03865147|Experimental|Phase 2 - Tri-Solfen|A group of 20 patients who will receive EMLA cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by a single application of Tri-Solfen.
3472065|NCT03865147|Active Comparator|Phase 2 - Standard Care|A group of 20 patients who will receive EMLA Cream (60 minute application) to anaesthetise the leg ulcer prior to surgical wound debridement, followed on completion of surgery by standard of care post-operative analgesia.
3472066|NCT03865147|Experimental|Phase 3 - Tri-Solfen|A group of 20 patients who will receive two applications of Tri-Solfen (2mL/10cm2), once prior to debridement and once on completion of the procedure.
3472067|NCT03865147|Active Comparator|Phase 3 - EMLA|A group of 20 patients who will receive EMLA Cream (60-minute application) prior to surgical debridement
3472068|NCT03865082|Experimental|IO Naive Subjects MSS CRC|8mg Tilsotolimod by intratumoral injection plus 3mg/kg Nivolumab (every three weeks for four doses followed by 480mg dose every four weeks) and 1mg/kg Ipilimumab every three weeks for four doses intravenous
3472069|NCT03865121|Experimental|Nicotine Nasal Spray 10 MG/ML|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
3472070|NCT03865108|Experimental|Pessary and Progesterone|Women already receiving a pessary in addition to the standard progesterone through the TOPS trial will undergo ultrasound imaging and cervical speculum examination for information collection.
3472071|NCT03865108|Placebo Comparator|Progesterone only|Women already receiving the standard progesterone only will undergo ultrasound imaging and cervical speculum examination for information collection.
3472072|NCT03865069|Active Comparator|automated oxygen control with VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) with automated pressure control (Volume Guarantee®).
3472073|NCT03865069|Active Comparator|automated oxygen control without VG®|Automated oxygen control using closed loop inspired oxygen (CLiO2™) without automated pressure control (Volume Guarantee®).
3472074|NCT03864822|Experimental|Active tDCS|30s ramp to 2mA with 20 minute session of active High-Definition Transcranial Direct Current Stimulation at 2mA
3472075|NCT03864822|Placebo Comparator|Sham tDCS|30s ramp to 2mA with High-Definition Transcranial Direct Current Stimulation, then device stops stimulating for 20 minutes
3472076|NCT03864887||Brain death patients for HLH Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
3472077|NCT03864887||Brain death patients for LHL Oxygen|Brain-dead patients were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
3472078|NCT03864887||Healthy people for HLH Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of high-low-high procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
3472079|NCT03864887||Healthy people for LHL Oxygen|Healthy people were supplied with oxygen at varied FIO2 at medical premised range.The protocol is Oxygen supply of low-high-low procedure. During the procedures, the Δ[Hb] and Δ[HbO2] time courses were collected by Optical monitor for hemodynamic parameter.
3472080|NCT03864926|Active Comparator|Standard of Care|Standard of Care Tacrolimus
3472081|NCT03864926|Experimental|Experimental|Envarsus XR
3472082|NCT03864978|Experimental|Rifaximin-EIR 800 mg BID for 10 days|2 x rifaximin delayed release 400 mg tablet twice a day (total daily dose of rifaximin: 1600 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
3179234|NCT00670787|Active Comparator|Combination pill|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
3179235|NCT00670787|No Intervention|Control group|combination therapy of angiotensin receptor antagonists (losartan potassium 50mg, candesartan 8mg, valsartan 80mg, telmisartan 40mg or olmesartan 20mg) and thiazide or thiazide-like diuretics (hydrochlorothiazide 6.25-12.5mg, trichlormethiazide 0.5-1.0mg, indapamide 0.5-1.0mg or chlorthalidone 6.25-12.5mg)
3179236|NCT00670813|Experimental|Modafinil (Vigil)|"Modafinil Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives 200 mg of Modafinil each at 12:00, 24:00 and again at 12:00 o' clock"
3179237|NCT00670813|Placebo Comparator|Placebo|"Placebo Arm: during the 40 h sleep deprivation period (morning until evening next day) the depressed patient receives Placebo at 12:00, 24:00 and again at 12:00 o' clock"
3179238|NCT00670826|Experimental|1|Use of the Dynatherm Medical vitalHEAT vH2 Temperature Management System to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
3179239|NCT00670826|Active Comparator|2|Use of the Arizant Healthcare Bair Hugger Temperature Management System & Bair Hugger Upper Body Blanket to warm patients undergoing orthopedic surgical procedures with an expected duration 2-3 hours and requiring general anesthesia.
3179240|NCT00670839|Active Comparator|A|GenHevac-B 20 microgram intramuscular use at M0, M1 and M6
3179241|NCT00670839|Experimental|B|GenHevac-B 40 microgram intramuscular use at M0, M1 and M6
3179242|NCT00670852||I|Patients who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting from the investigator of this study will be recruited for this study.
3179243|NCT00670865|Experimental|eDischarge|The eDischarge arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use the electronic discharge summary program.
3179244|NCT00670865|No Intervention|Traditional|"The traditional arm will consist of two teams on the General Internal Medicine ward at St. Michael's Hospital who have been randomly assigned to use traditional, dictated discharge summaries."
3179245|NCT00670878|Experimental|A|
3179246|NCT00670878|Active Comparator|B|
3179247|NCT00670891|Experimental|HBOT|HBOT
3179248|NCT00670904|Active Comparator|1|Pharmacist-delivered group program for smoking cession.
3179249|NCT00670904|Placebo Comparator|2|Brief standard care session for tobacco smoking cessation delivered over the telephone.
3179250|NCT00670917|Active Comparator|L14 acupoint|
3179251|NCT00670917|Sham Comparator|Sham Point|
3179252|NCT00670943||A|Patients with stable CAD with scheduled discontinuation of clopidogrel
3179253|NCT00670943||B|Patients with stable CAD not taking clopidogrel
3179254|NCT00670969||A|People who will have the portable measurement taken first and handheld measurement taken second
3179255|NCT00670969||B|People who will have the handheld measurement taken first and portable measurement taken second
3179256|NCT00671008||A|
3179257|NCT00671008||B|
3179258|NCT00671021||1|Patients suffering from stable CAD, on chronic ASA therapy
3179259|NCT00671047||1|SLE subjects with flares in the last 12 months in specific organ systems.
3179260|NCT00671073|Active Comparator|1|Oglemilast low dose, oral administration once daily for 12 weeks
3179261|NCT00671073|Active Comparator|2|Oglemilast middle dose, oral administration, once daily for 12 weeks
3179262|NCT00671073|Active Comparator|3|Oglemilast high dose, oral administration, once daily for 12 weeks.
3179263|NCT00671073|Placebo Comparator|4|Placebo
3179264|NCT00671086|Experimental|Ramelteon 8 mg QD|
3179265|NCT00671086|Experimental|Ramelteon 16 mg QD|
3179266|NCT00671099|Experimental|1|Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid
3179267|NCT00671099|Placebo Comparator|2|Placebo
3179268|NCT00671112|Experimental|Everolimus and Bortezomib|Patients will receive a combination of Everolimus by mouth and Bortezomib intravenously for a 21 day cycle.
3179269|NCT00671125|Experimental|Ramelteon 8 mg QD|
3179270|NCT00671125|Experimental|Ramelteon 16 mg QD|
3179271|NCT00671125|Placebo Comparator|Placebo|
3179272|NCT00671138|Active Comparator|I|Arm I will be inoculated with the human hookworm necator americanus at weeks 0 and 12.
3179273|NCT00671138|Placebo Comparator|II|Arm II participants will receive and identical sham-inoculums comprising a diluted amount of 0.2ml McIlhenny & Co Tabasco Pepper Sauce®
3179274|NCT00671151|Active Comparator|1|Low-dose theophylline on top of standard therapy for COPD exacerbation
3179275|NCT00671151|No Intervention|2|Standard therapy for COPD exacerbation
3179276|NCT00671190|Experimental|Ramelteon 1 mg QD|
3179277|NCT00671190|Experimental|Ramelteon 2 mg QD|
3179278|NCT00671190|Experimental|Ramelteon 4 mg QD|
3472083|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 30 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 30 days
3472084|NCT03864978|Experimental|Rifaximin-EIR 400 mg BID for 10 days|1 x rifaximin delayed release 400 mg tablet + 1 x placebo tablet twice a day (total daily dose of rifaximin: 800 mg) for 10 days and 2 x placebo tablets twice a day for the following 20 days
3472085|NCT03864978|Placebo Comparator|Two placebo tablets BID for 30 days|2 x placebo tablets twice a day for 30 days
3472086|NCT03864835|Experimental|Moderate intensity aerobic exercise|All subjects will undergo DXA and CRF measurement (relative VO2max) under the supervision of an American College of Sports Medicine (ACSM)-certified fitness professional and study physician at the Penn State PM&R Research Laboratories. Subjects selected for the interventional pilot trial will receive a FitBit Charge2 HR and be instructed on how to use a FitBit Hear Rate monitor, Fitbit application, Fitbit website, and Fitabase (secure data management platform utilized by >400 clinical trials). Participants will record their daily food and beverage intake through the Fitbit app. Individualized feedback will be provided by a registered dietician (RD). Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist.
3472087|NCT03864809||psoriasis patients|sleep disturbance
3472088|NCT03864809||atopic dermatites patients|sleep disturbance
3472089|NCT03864809||control|sleep disturbance
3472090|NCT03864783|Experimental|Curcumin (Meriva®)|Meriva® 500 mg tablet (contains 100 mg curcumin) Dosage: 2 tablets twice daily for 42 days (+/- 3 days)
3472091|NCT03864783|Placebo Comparator|Placebo|Placebo. Dosage: 2 tablets twice daily to mimic Meriva® tablets.
3472092|NCT03865017|Experimental|Regulatory T cells|Biologicals: Autologous Regulatory T cells (1.7*10^5 cells/kg, i.v) other name: GB301
3472093|NCT03865017|Placebo Comparator|Placebo|Saline+cell suspension solution infusion
3472094|NCT03864666|Other|Sequence 1|Treatment RTRT
3472095|NCT03864666|Other|Sequence 2|Treatment TRTR
3125914|NCT03008837|Active Comparator|Standard Therapy|Veterans with fibromyalgia who meet study criteria and are randomized to standard therapy will receive physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist. fMRI evaluation of neural changes, assessment of function and quality of life improvements will be performed at the beginning and end of the study.
3125915|NCT03008889|Experimental|Participants taking NAC|Participants randomized to the active treatment study arm will receive gradually increasing doses of N-acetylcysteine (NAC) given as a dissolving tablet in juice or water. NAC is an over-the-counter oral dietary supplement that will be used a higher than usual doses in this study.
3472096|NCT03864718||complex anal fistula|
3472097|NCT03864679|Experimental|Exercise|Subjects will perform a cycling tests
3472098|NCT03864497||Orthotopic liver transplantation candidates|No intervention, imaging test and risk stratification as part of routine clinical care.
3472099|NCT03864757|Experimental|UVFP correction surgery|Short-term implantation of VOIS and evaluation of voice quality and glottal closure.
3472100|NCT03864770|Experimental|Extracorporeal shock wave therapy and general physical therapy|In this arm, the subjects will receive the intervention of extracorporeal shock wave therapy and general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
3472101|NCT03864770|Active Comparator|Only general physical therapy|In this arm, the subjects will only receive the intervention of general physical therapy 3 times a week for 2 weeks, in total 6 times treatments and will be arrange to take efficacy two assessment on 1 week and 2 weeks after 6 times treatments separately.
3472102|NCT03864380||Person running a marathon|"Exams performed before (1 month maximum) and after the marathon (1 hour maximum) :~Color retinography Optical Coherence Tomography - Angiography (OCT-A) Blood pressure measurement"
3472103|NCT03864549|Experimental|probiotic femina II|research group will receive the probiotic formula Femina II (2 capsules/day) until delivery.
3472104|NCT03864549|Placebo Comparator|Placebo|control group will receive a placebo (2 capsules/day) until delivery.
3125916|NCT03008889|Placebo Comparator|Participants taking Placebo|Participants randomized to placebo will receive dissolving tablets identical in size and appearance to the active treatment. Placebo capsules contain inactive ingredients.
3125917|NCT03008915|Active Comparator|Aspirin first then placebo|Aspirin 81mg for 2 weeks followed by a washout period and then placebo for 2 weeks
3472105|NCT03864731|Other|Bone conduction device - ADHEAR|Patients will receive a hearing aid (ADHEAR). Hearing assessment will be carried out. Quality of life measurement will be carried out.
3472106|NCT03864471|Experimental|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
3472107|NCT03864471|Active Comparator|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
3472108|NCT03864484|Experimental|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, participants watch a video using the iPad Application displaying positive word stimuli.
3472109|NCT03864484|Active Comparator|Usual rehabilitation|The control group receives usual rehabilitation.
3472110|NCT03864562||Black African or Caribbean|Healthy individuals of black African or Caribbean descent
3472111|NCT03864562||White European|Healthy individuals of white European descent
3472112|NCT03864341|Experimental|Homelessness Prevention Services|
3472113|NCT03864263||Children with HBsAg-positive patients|Children from a father or mother who are infected with HBV
3125918|NCT03008915|Placebo Comparator|Placebo first then aspirin|Placebo for 2 weeks followed by a washout period and then aspirin 81mg for 2 weeks
3125919|NCT03009162|Experimental|Renal impaired participants|Participants received single 200 milligrams (mg) oral tablet of lasmiditan.
3125920|NCT03009162|Experimental|Healthy participants|Participants received single 200 mg oral tablet of lasmiditan.
3472114|NCT03864263||Children without a family history of HBV|Children without a family history of HBV infection
3472115|NCT03864250|Experimental|Tacrolimus monotherapy|
3125921|NCT03009396|Experimental|RHB-104 - patients on ACTIVE therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
3125922|NCT03009396|Experimental|RHB-104 - patients on PLACEBO therapy in RHB-104-01 study|Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
3472116|NCT03864250|Active Comparator|Tacrolimus combined with hormone therapy|
3472117|NCT03864393|Experimental|Multimodal overground locomotor training|Individuals with Parkinson's Disease that meet the inclusion/exclusion criteria and enrolled in the study will participate in a 12-week multimodal exercise training intervention performed twice per week.
3472118|NCT03864328|Experimental|RVT-1601 Low Dose|
3472119|NCT03864328|Experimental|RVT-1601 Mid Dose|
3472120|NCT03864328|Experimental|RVT-1601 High Dose|
3125923|NCT03010137|Placebo Comparator|Standard Closure|After surgical closure is complete, the patient receives standard of care operative incision treatment (dermabond/topical skin adhesive).
3125924|NCT03010137|Active Comparator|Incisional Negative Pressure Wound Therapy|After surgical closure is complete, an incisional negative pressure wound therapy device is applied to the incision in its entirety. This device is placed on the wound, sterilely, in the operating room, at the conclusion of the procedure. The incisional negative pressure wound therapy device is to remain in place for 7 days, and is removed in clinic after completion.
3125925|NCT03010254|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
3125926|NCT03010254|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
3125927|NCT03010462|Active Comparator|Active|Intervention: Device: NBS-guided rTMS + task-oriented rehabilitation
3125928|NCT03010462|Sham Comparator|Control|Intervention: Device: NBS-guided Sham rTMS + task-oriented rehabilitation
3472121|NCT03864328|Placebo Comparator|Placebo|
3472122|NCT03864536|No Intervention|No-contact control|No-contact control
3472123|NCT03864536|Active Comparator|Psychoeducation control|Receives general psychoeducation on dementia prevalence, prognosis, and risk factors,
3472124|NCT03864536|Experimental|Psychoeducation + CogRx|Receives same general psychoeducation on dementia and will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
3472125|NCT03864601|Experimental|14C-JNJ-56136379|Participants will receive a single oral 25 milligram (mg) dose of 14C-JNJ-56136379 on Day 1 under fed conditions.
3472126|NCT03864523|Experimental|XAMNPIO|Pioglitazone 15 mg tablets 2/day during 2 years
3472127|NCT03864354||Participants|Participants were adults with a diagnosis of asthma, treated using a standardized Osteopathic Manipulative Treatment protocol.
3472128|NCT03864419|Experimental|Cohort I (pediatric BL)|Patients receive cyclophosphamide IV and vincristine IV on day 1, and prednisone IV or PO on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients then receive rituximab IV or rituximab hyaluronidase SC, cyclophosphamide IV, vincristine IV, and methotrexate IV on day 1. Cycles repeat every 14 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
3472129|NCT03864419|Experimental|Cohort II (DLBCL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC, cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1, and prednisone PO on days 1-5 of cycle 1. Cycles repeat every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
3472130|NCT03864419|Experimental|Cohort III (Adult BL)|Patients receive rituximab IV or rituximab and hyaluronidase human SC in day 1, etoposide IV, doxorubicin IV, and vincristine IV on days 1-4. Patients also receive cyclophosphamide IV on day 5 and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
3472131|NCT03864419|Experimental|Cohort IV (MCD)|Patients receive rituximab IV or rituximab and hyaluronidase human SC on days 1, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
3472132|NCT03864588|Placebo Comparator|Control|Anesthesiologist preforms ultrasound guided adductor canal block post-operatively
3472133|NCT03864588|Experimental|Intervention|Surgeon preforms inter-operative adductor canal block
3472134|NCT03864575|Experimental|Combination Group|Celecoxib 400 mg/d Nivolumab 240 mg q2w
3472135|NCT03864458|Experimental|KHK7791 A|Patients take KHK7791 low dose BID.
3472136|NCT03864458|Experimental|KHK7791 B|Patients take KHK7791 middle dose BID.
3472137|NCT03864458|Experimental|KHK7791 C|Patients take KHK7791 high dose BID.
3472138|NCT03864458|Experimental|KHK7791 D|Patients start at KHK7791 high dose and can down titrate weekly ,based on a GI tolerability question.
3472139|NCT03864458|Placebo Comparator|Placebo|Patients take Placebo BID.
3472140|NCT03864367||Device|This group will use the MWeST lift device along with regular physical therapy. The lift device is the Prism Medical FGA-700 Bariatric Floor Lift including a sling to assist in walking.
3472141|NCT03864367||Control|This group will only receive regular physical therapy.
3472142|NCT03864432|Experimental|25mg SAD|
3472143|NCT03864432|Experimental|50mg SAD|
3472144|NCT03864432|Experimental|100mg SAD|
3472145|NCT03864432|Experimental|50mg Multiple dosing|
3472146|NCT03864315|Experimental|Vitiligo|30 Patients with Vitiligo
3472147|NCT03864211|Active Comparator|Toripalimab monotherapy|Toripalimab is administrated intravenously (240mg, Q3W) continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
3472148|NCT03864211|Experimental|Thermal ablation plus toripalimab|One to five target lesions will be ablated completely. Toripalimab therapy will be initiated on day 3 or day 14 after ablation ((240mg, Q3W) ). Toripalimab is administrated continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends.
3472149|NCT03864302|Experimental|Motor Imagery|"The intervention group is informed about the concept of motor imagery (MI) for performance enhancement and are instructed in using the modified PETTLEP framework for TURB (table 1).(18) The intervention group performs a MI training session (MITS) prior to each VR simulation procedure.~Table 1: PEELP framework:~Physical: Sitting in front of the simulator, aloud to touch and move the scope Environment: Simulated sounds from the OR, including electrical device feedback from devices and vital measures Task: Four standardized TURB cases Timing: Each MI session is temporal to a simulated TURB case, max. 10 minutes Learning: Think aloud the major steps of the procedure using Emotions: Imagine the emotions when the surgery progresses and when an adverse event occurs Perspectives: Internal perspective thinking then I…"
3472150|NCT03864302|No Intervention|Control|The control group proceeds directly to standard VR-simulator training.
3472151|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody positive)|
3472152|NCT03864185|Placebo Comparator|Placebo group (IgG4 autoantibody positive)|
3472153|NCT03864185|Active Comparator|Rituximab group (IgG4 autoantibody negative)|
3472154|NCT03864198|Other|Genante (Tm)|Genante tablets One tablet in the morning and one tablet in the evening for 3 months
3472155|NCT03864237|Experimental|Alcohol texts|Participants assigned to this arm will receive a text message each day for 10 weeks, containing factual information about campus drinking norms.
3472156|NCT03864237|Placebo Comparator|Attention control|"Participants assigned to this arm will receive a text message each day for 10 weeks, containing this day in history facts."
3472157|NCT03864172|Placebo Comparator|Usual intake + placebo fruit juice|Placebo fruit flavoured juice powder
3472158|NCT03864172|Active Comparator|Usual intake +SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF)
3472159|NCT03864172|Active Comparator|Adequate calcium +fruit juice placebo|Placebo fruit flavoured juice powder added with 600 mg calcium to meet RNI intake
3472160|NCT03864172|Active Comparator|Adequate calcium + SCF fruit juice|Fruit flavoured juice powder added with 12 g soluble corn fiber (SCF) and 600 mg calcium to meet RNI intake
3472161|NCT03864159|Experimental|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time.The intervention through the suction cups will consist of its application and produce increased flexibility of the hamstring musculature. The technique will be performed with the subject in prone position, on the stretcher, while the physiotherapist will be placed next to the member to be treated. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
3472162|NCT03864159|Active Comparator|Foam roller|The intervention will be carried out before starting the training session. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
3472163|NCT03864146|Experimental|Pioglitazone|Pioglitazone titrated to 45mg by mouth each day
3472164|NCT03864146|Placebo Comparator|Placebo|placebo, identical 45mg pill
3472165|NCT03864068|Placebo Comparator|Placebo Treatment bid|Women with PCOS (N = 30) will receive the daily placebo (maltodextrin and inulin) in an identical fashion as the active study group and will be monitored the same.
3472166|NCT03864068|Experimental|Active Treatment with Inositol 1gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 1000 mg of myo-inositol and 25 mg of d-chiro-inositol) over the initial 3 mos RCT period.
3472167|NCT03864068|Experimental|Active Treatment with Inositol 2 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 2000 mg of myo-inositol and 50 mg of d-chiro-inositol) over the initial 3 mos RCT period.
3472168|NCT03864068|Experimental|Active Treatment with Inositol 3 gm/bid|Women with PCOS (N = 30) will receive daily inositol powder BID as active drug (each dose with 3000 mg of myo-inositol and 75 mg of d-chiro-inositol) over the initial 3 mos RCT period.
3472169|NCT03863912|Active Comparator|Disney|watch Disney movies and fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
3472170|NCT03863912|Other|Control|fill out EORTC QLQ-C30 (Version 3) and EORTC QLQ-FA12 surveys
3472171|NCT03864133|Other|Omidria|Phenylephrine/Ketorolac (1%/0.3%) will be administered to all participants enrolled into the study.
3472172|NCT03863951||Patients with poststroke depression|No intervention
3472173|NCT03863951||Patients without poststroke depression|No intervention
3472174|NCT03863990||Patients with PAH|Adult male and female patients from Argentina diagnosed with pulmonary arterial hypertension (PAH) of WHO functional class I between 01-Jan-2012 and 31-Dec-2017 and with at least one year of follow-up.
3472175|NCT03863925|Experimental|Propofol Target Controlled Infusion Group (Group T)|Patients in group T underwent anesthesia with Propofol (dosage form: 10mg/mL) target controlled infusion by Schnider model, starting at concentration of effect site (Ce) of 1.5 mcg/mL and titrating to achieve Observer's Assessment of Alertness/Sedation (OAA/S) Scale level 3 (responds only after name called loudly or repeatedly). Patients were paralyzed with suxamethonium (dosage form: 20mg/mL; dosage: 1mg/kg) once adequate sedation level achieved. TCI was stopped once the psychiatrist applied electroconvulsive stimulation to patients' bilateral frontal regions. Assisted ventilation with bag-valve-mask device by experienced anesthesiologists was began since patients were sedated until adequate spontaneous respiration was regained after each single electroconvulsive therapy (ECT) session. Every patient receive total six to twelve ECT sessions, and each ECT session was conducted one day apart.
3125929|NCT03010488|Experimental|Rapid Sleep Shift|Assigned Sleep Times designed to shift sleep times over several days from Baseline to desired through morning light therapy while wearing goggles.
3125930|NCT03010488|Active Comparator|Gradual Sleep Shift|Assigned Sleep Times designed gradually shift sleep from current to desired sleep times while using morning light therapy while wearing goggles.
3125931|NCT03010501|Experimental|100% Food Energy Density|Baseline Food Energy Density
3125932|NCT03010501|Experimental|80% Food Energy Density|Lower Food Energy Density
3125933|NCT03010501|Experimental|120% Food Energy Density|Higher Food Energy Density
3472176|NCT03863925|Active Comparator|Propofol Bolus Group (Group B)|Patients in group B underwent anesthesia with bolus of propofol for sedation, and the dosage raged between 0.75 to 1.5 mg/kg to achieve at least OAA/S scale level 3. Dosage of suxamethonium, application of electroconvulsive stimulation, ventilation maneuver, frequency of ECT session, and number of total ECT sessions were same as patients in group T.
3472177|NCT03863821|Experimental|HHHFNC group|Practice 6 MWT with HHHFNC
3472178|NCT03863821|No Intervention|non-HHHFNC group|Practice 6 MWT without HHHFNC
3472179|NCT03863808|Experimental|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
3472180|NCT03863808|Active Comparator|Strengthening and Core Stability|"Following assessment 12 sessions over 6 weeks will start, focusing on strengthening exercises of the transversus abdominis and lumbar multifidus muscles (Angela Searle, 2015).~Exercises will be graduated according to the patient pain tolerance."
3472181|NCT03864445|Experimental|KHK7791|Patients take KHK7791 BID and can down titrate, based on a GI tolerability question.
3472182|NCT03864445|Placebo Comparator|Placebo|Patients take Placebo BID.
3472183|NCT03863977|Active Comparator|Dex4 group|After the surgery, the patients in this group will receive 4 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
3472184|NCT03863977|Active Comparator|Dex8 group|After the surgery, the patients in this group will receive 8 mg dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
3472185|NCT03863977|Active Comparator|control group|After the surgery, the patients in this group will 1mg/kg of 0.5% bupivacaine in the TAP block.
3472186|NCT03863886|Experimental|Crohn's Disease|20 patients with Crohn's disease with at least colonic involvement will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
3472187|NCT03863886|Experimental|Ulcerative Colitis|20 patients with ulcerative colitis will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
3472188|NCT03863886|Experimental|Non-IBD Controls|20 patients without inflammatory bowel disease (controls) will undergo endoscopic ultrasound assessment of the thickness of wall layers (mucosa, submucosa, muscularis propria, total wall) at the rectum and cecum region during their standard-of-care colonoscopy.
3472189|NCT03863938|Experimental|Tegoprazan 50mg under fasting condition|Treatment A: single oral administration of Tegoprazan 50mg tablet under fasting condition once a day
3472190|NCT03863938|Experimental|Tegoprazan 50mg before the meal|Treatment B: single oral administration of Tegoprazan 50mg tablet before the meal once a day
3472191|NCT03863938|Experimental|Tegoprazan 50mg after the meal|Treatment C: single oral administration of Tegoprazan 50mg tablet after the meal once a day
3472192|NCT03863847|Active Comparator|Online Neurofeedback|This intervention entails online feedback of pain-related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
3472193|NCT03863847|Sham Comparator|Online Sham Neurofeedback|This intervention entails online sham feedback of non-pain related neuronal oscillation power, and will be visualized to the individual for patient training purposes and for the eventual self-control of this brain activity.
3472194|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 minutes|Blood test
3472195|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 7 minutes|Blood test
3472196|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 15 minutes|Blood test
3472197|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 30 minutes|Blood test
3472198|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1 hour|Blood test
3472199|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 1.5 hours|Blood test
3472200|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2 hours|Blood test
3472201|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 2.5 hours|Blood test
3472202|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3 hours|Blood test
3472203|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 3.5 hours|Blood test
3472204|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4 hours|Blood test
3472205|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 4.5 hours|Blood test
3125934|NCT03010527|Placebo Comparator|Placebo|Subjects with a PASI90 response at Week 12 and receiving Placebo in PS0010 entering PS0011 will receive Placebo.
3179279|NCT00671190|Experimental|Ramelteon 8 mg QD|
3179280|NCT00671190|Placebo Comparator|Placebo QD|
3472206|NCT03863964|Active Comparator|plasma TXA and ROTEM test at 5 hours|Blood test
3472207|NCT03864003|Experimental|Experimental group|Participants randomized to the experimental group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a Community Health Worker.
3472208|NCT03864003|Active Comparator|Control Group|Participants randomized to the control group will receive hearing aid fitting and verification services via teleaudiology with local, hands-on support from a non-Community Health Worker (undergraduate student in Speech, Language, and Hearing Sciences).
3472209|NCT03863860|Experimental|Fluzoparib capsules, 50mg per capsule|Fluzoparib capsules, PO
3472210|NCT03863860|Placebo Comparator|Placebo capsules, 50mg per capsule|Placebo capsules, PO
3472211|NCT03863782||Sarcoid uveitis|The cohort is composed by patients diagnosed or treated for sarcoid uveitis in the departement for Internal Medicine, Croix Rousse Hospital, Lyon, France.
3472212|NCT03864016|Other|Standard group|
3125935|NCT03010527|Experimental|Bimekizumab dosing regimen 1|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 1 in PS0010 will be assigned to a higher dosing regimen."
3125936|NCT03010527|Experimental|Bimekizumab dosing regimen 2|"Subjects with a PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 entering PS0011 will receive the same dosing regimen.~Subjects who do not achieve PASI90 response at Week 12 receiving dosing regimen 2 in PS0010 will be assigned to a higher dosing regimen."
3472213|NCT03864016|Experimental|Pupillometry group|
3472214|NCT03864094|Active Comparator|Ephedrine Propofol Remifentanil|Prophylactic Ephedrine
3472215|NCT03864094|Active Comparator|Phenylephrine Propofol Remifentanil|Prophylactic Phenylephrine
3472216|NCT03864094|Active Comparator|Norepinephrine Propofol Remifentanil|Prophylactic Norepinephrine
3125937|NCT03010527|Experimental|Bimekizumab dosing regimen 3|Subjects that were initially randomized to bimekizumab dosage regimen 3, 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3.
3125938|NCT03010631|Active Comparator|Cohort 1 (Treatment Sequence AB)|Cohort 1: Treatment A. Capsule Fasted (7-day Washout) then Treatment B. Sprinkle Formulation, Fasted
3472217|NCT03864094|Sham Comparator|Sodium chloride Propofol Remifentanil|NaCl Placebo
3472218|NCT03863769||Lumbar Spinal Stenosis|Questionnaire, chiropractic treatment, and posture and performance testing.
3472219|NCT03863899|Experimental|Nerve block|ultrasound-guided ilioinguinal iliohypogastric nerve block performed by the anaesthesiologist for Transaortic valve implantation (TAVI) insertion with eventual additional intraoperative analgesia (AIA) and/or additional postoperative analgesia (APA)
3472220|NCT03863899|Active Comparator|Local infiltration|local anaesthesia infiltration performed by the operator for TAVI insertion with eventual intraoperative additional analgesia (AIA) and/or postoperative analgesia (APA)
3472221|NCT03863834|Experimental|Treatment arm|Subjects receive the RFAL treatment
3472222|NCT03863704|Sham Comparator|nerve stimulation ear then leg|Subjects in this arm will be randomized to receive nerve stimulation with TENS of the ear followed by leg stimulation
3472223|NCT03863704|Sham Comparator|nerve stimulation leg then ear|Subjects in this arm will be randomized to receive leg nerve stimulation with TENS followed by ear nerve stimulation
3472224|NCT03863704|Other|Subjects receiving Infliximab|Subjects on Infliximab as part of their clinical care will not be randomized as the study treatment for these subjects will be the same. The sham arm is not included for patients on infliximab.
3125939|NCT03010631|Experimental|Cohort 1 (Treatment Sequence BA)|Cohort 1: Treatment B. Sprinkle Formulation, Fasted (7-day Washout) then Treatment A. Capsule Fasted
3125940|NCT03010631|Experimental|Cohort 2 (Treatment Sequence CD)|Cohort 2: Treatment C: Sprinkle Formulation, Fed (7-day Washout) then Treatment D: Sprinkle Formulation, Fasted
3472225|NCT03863691|Active Comparator|amisulpride group|300 mg of the atypical antipsychotic drug amisulpride
3472226|NCT03863691|Placebo Comparator|placebo group|Similar looking capsules for placebo control
3472227|NCT03863873|Active Comparator|PRP Injection Group|PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
3472228|NCT03863873|Active Comparator|Steroid injection Group|A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection
3472229|NCT03863743|Other|Control|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. Patient will undergo treating physician's standard of care for total hip or knee replacement. Patient will receive bladder scans in PACU, upon admission to the nursing unit, and prior to discharge (post-void).
3472230|NCT03863743|Experimental|Experimental|Patient will complete IPSS score, medical history, and risk factors for POUR will be evaluated. If considered high risk (determined by IPSS), then patient Patient will undergo integrated care pathway that avoids narcotics. Bladder volume will be measured in PACU, after admission to the nursing unit, and prior to discharge from the hospital (post-void).
3472231|NCT03863730|Experimental|Profermin Plus®|Intervention group will be drinking the liver-specialized product Profermin Plus®, based on fermented oats, Lactobacillus Plantarum 299v, barley malt and lecithin. The product also contains Thiamin, which is beneficial in patients with liver diseases.
3472232|NCT03863730|Active Comparator|Fresubin®|Fresubin® is a standard FSMP and will be used as control product. Since Profermin Plus® is a disease-specific FSMP, the documentation must prove an effect that cannot be achieved by modification of the normal diet alone or by standard FSMP's. Therefor the comparator must be a standard FSMP, i.e. a nutritionally complete FSMP with standard nutrient formulation, which may constitute the sole source of nourishment of a person, hence the reason for using Fresubin® as comparator.
3125941|NCT03010631|Experimental|Cohort 2 (Treatment Sequence DC)|Cohort 2: Treatment D: Sprinkle Formulation, Fasted (7-day Washout) then Treatment C. Sprinkle Formulation, Fed
3179281|NCT00671216|Experimental|Period 1|Subjects will receive first placebo, then GSK233705, GW642444 and combination of GSK233705 and GW642444
3125942|NCT03010683|Active Comparator|liraglutide|
3125943|NCT03010683|Active Comparator|Metformin|
3125944|NCT03010800|Experimental|With Yoni.Fit|Subjects will perform the Abbreviated Pad Test with the Yoni.Fit first, then without the Yoni.Fit.
3125945|NCT03010800|Experimental|Without Yoni.Fit|Subjects will perform the Abbreviated Pad Test without the Yoni.Fit first, then with the Yoni.Fit.
3125946|NCT03011034|Experimental|Talacotuzumab|Participants will receive talacotuzumab 9 milligram per kilogram (mg/kg) intravenously (IV) on Days 1 and 15 for all cycles. Each treatment cycle is of 28 days. The talacotuzumab arm of the study is closed for enrollment.
3179282|NCT00671216|Experimental|Period 2|Subjects will receive first combination of GSK233705 and GW642444, then placebo, GSK233705 and GW642444
3472233|NCT03863652||Snuffboxer|Patients undergoing percutaneous coronary intervention via snuffbox approach
3472234|NCT03863561||Waiting room sample|Patients with type 1 or type 2 diabetes attending an LMC Diabetes & Endocrinology specialist clinic in Ontario completed the SCPI in the waiting room while attending their usual appointment with their healthcare provider.
3472235|NCT03863561||DSME Intervention|Patients with poor glycemic control (A1C >8.0%) were enrolled into a diabetes self-management education (DSME) program. The SCPI was completed at their first and last visit and and their individual results were incorporated into the care paths that were then customized for that participant. The patient met with a diabetes educator five to seven times over the course of three to four months.
3472236|NCT03863405|Experimental|Metformin Group|850 mg metformin twice daily for six months in addition to standard therapy
3472237|NCT03863405|Active Comparator|Control Group|placebo in addition to standard therapy for rheumatoid arthritis
3472238|NCT03863587|Experimental|HLX12 group|HLX12 are given intravenous infusion 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
3472239|NCT03863587|Active Comparator|Cyramza (Ramucirumab) group|Ramucirumab are given intravenous infusion of Cyramza 8 mg/kg, prepared with normal saline to an administration volume of 250 mL, and the administration time is 90 min (± 10 min).
3472240|NCT03863574|Experimental|Saroglitazar Magnesium 2 mg|Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.
3472241|NCT03863574|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.
3472242|NCT03863574|Placebo Comparator|Placebo|Placebo tablet orally once daily in the morning before breakfast for 24 weeks.
3472243|NCT03863379||Neurodisabled persons|Persons with various neurodisabilities
3472244|NCT03863379||Control group|Able bodied persons
3472245|NCT03863392|Experimental|oral|patients undergoing induction of labour using misoprostol oral solution
3472246|NCT03863392|Experimental|vaginal|patients undergoing induction of labour using vaginal misoprostol
3472247|NCT03863678|Experimental|Neurodevelopmental therapy|Group 1 will only receive Neurodevelopmental therapy (NDT), for 12 sessions.
3472248|NCT03863678|Experimental|Neurodevelopemental therapy and dry needling therapy|Group 2 will receive Neurodevelopmental therapy (NDT) and dry needling therapy, for 12 sessions.
3472249|NCT03863418|Experimental|Lactobacillus rhamnosus GG|Lactobacillus rhamnosus GG (10 billion Colony Forming Units/CAPSULE)
3472250|NCT03863418|Placebo Comparator|placebo|maltodextrin
3472251|NCT03863639||Pre-Eclampsia|15 English-speaking women with severe pre-eclampsia
3472252|NCT03863639||Control|15 English-speaking pregnant controls with uncomplicated pregnancy matched by age and gestational age
3472253|NCT03863535|Experimental|Intravitreal conbercept+Panretinal coagulation|
3472254|NCT03863535|Active Comparator|Panretinal coagulation|
3472255|NCT03863665|Experimental|Telemetric Bluetooth home BP monitors|Telemetric Bluetooth home BP monitors will be provided to participants during their inpatient stay or clinic visit, and will commence 3- times-daily readings immediately. The BP monitoring team will assess BP readings daily and advise medication adjustments to achieve a target BP of <120/80 mm Hg
3472256|NCT03863665|No Intervention|Standard clinical care|Standard clinical care including usual BP treatment, without home monitoring, undertaken in the clinical care setting
3472257|NCT03863509||Exclusive Smokers|Smokes Daily; >/= 5 cigarettes/day for last 6 months
3125947|NCT03011034|Experimental|Daratumumab|Participants will receive daratumumab 16 mg/kg IV on Days 1, 8, 15, and 22 for Cycles 1 and 2; on Days 1 and 15 for Cycles 3 to 6; and on Day 1 for all subsequent cycles. Each treatment cycle is of 28 days.
3179283|NCT00671216|Experimental|Period 3|Subjects will receive first GSK233705, then GW642444, combination of GSK233705 and GW642444 and later placebo
3472258|NCT03863509||Exclusive E-Cig users|E-cig usage >/= 5 days/week for last 3 months
3472259|NCT03863509||Never users|< 100 cigarettes in lifetime, none for > 5 years; < 3 E-cig usage in lifetime
3472260|NCT03863626|Active Comparator|Frusemide IV shots = group A|Frusemide as IV shots
3472261|NCT03863626|Active Comparator|Frusemide IV infusion = group B|Frusemide as continuous IV infusion
3472262|NCT03863717|Experimental|Arm Endurance Exercise Training Group|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
3472263|NCT03863717|Active Comparator|Control Group|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
3472264|NCT03863275|Other|No intervation|Children between the ages of 7 and 12 diagnosed with class II dental classification, who attend the Leonardo Da Vinci School after carrying out an intraoral and extraoral photography study and diagnostic impressions with study models accepting participation in the study, Children over the age of 12 who have an agreement according to the results of medical care. Patients with Pierre Robin syndrome or any form of cleft.
3472265|NCT03863275|Experimental|Myofunctional apparatus|Boys and girls between 7 and 12 years skeletal class II, for the study group the individuals will be selected from the UNICIEO postgraduate clinic of orthopedic clinic orthodontics after conducting a full clinical case study exposed to a board of specialist teachers in orthodontics, where by means of several diagnostic methods a skeletal class II is confirmed that involves a treatment with myofunctional apparatus SN1; patients presenting syndromes that generate craniofacial alterations, patients with previous orthopedic treatment, patients with signs of condyle lesions, patients with Pierre Robin syndrome or any form of slit will be excluded.
3472266|NCT03863236|Active Comparator|regular diet|The control group (group 1) will continue their regular diet.
3472267|NCT03863236|Active Comparator|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support two weeks before the operation and the nutritional support will continue 10 days after the operation.
3472268|NCT03863613|Active Comparator|Pessary group|A soft, flexible, silicone pessary, purchased from the manufacturer (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix by 4 senior clinicians, who had experienced with pessary used, within one week of randomisation. Size of the pessary will be determined at the time of speculum inspection.
3472269|NCT03863613|Active Comparator|Cerclage group|Women will be receiving the cervical cerclage according to local protocol, within a week after randomisation. 3 senior clinicians who had experienced with cerclage, will perform cerclage, using Mc Donald technique, under spinal anaesthesia.
3472270|NCT03863613|Active Comparator|Pessary plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the pessary that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
3472271|NCT03863613|Active Comparator|Cerclage plus progesterone group|400 mg vaginal progesterone, purchased from the manufacturer (Cyclogest® 400mg, Actavis, United Kingdom), will be applied once daily at bedtime, starting from the day of randomisation, in addition to the cerclage that has been placed. Participants will be asked to record their drug application in a patient diary sheet for up to 140 days.
3472272|NCT03863470|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 12 weeks of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the ICU. The length of the control phase will differ for each ICU cluster, depending on the sequence in which ICU-clusters are assigned to switch to the intervention phase.
3472273|NCT03863470|Active Comparator|Early mobilization intervention|The clinical team will set a standardized mobility goal for each patient during morning rounds and display the goal on the patient's door. A facilitator will be established in the ICU to communicate mobility goals and activities across clinical personnel shifts. Patient mobility scores will be displayed to clinical and administrative staff in the ICU via the ICU board.
3125948|NCT03011099|Experimental|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
3472274|NCT03863600||Midwife-led continuity of care|Women receiving midwife-led model of care though the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
3472275|NCT03863600||Regular care|Women receiving regular maternal care through the continuum of pregnancy, birth and postnatal period, and who registered at the governmental clinic in a rural village.
3472276|NCT03863366|Experimental|Prucalopride|1mg prucalopride capsule
3472277|NCT03863366|Placebo Comparator|Placebo|Lactose placebo capsule
3472278|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-1)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-1 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
3472279|NCT03863327||Acute Coronary Occlusion or near-occlusion (TIMI 0-2)|a. Acute occlusion proven on angiogram (an acute culprit lesion with TIMI 0-2 flow, or description of acute total thrombotic occlusion) b. Acute culprit lesion (any TIMI score) with Peak cTNI > 10 ng/mL or cTnT > 1.0 ng/mL c. If no catheterization performed (contraindicated, not compatible with goals of care, etc), then highly elevated troponin as above plus a new/presumed new focal wall motion abnormality on echocardiography d. Positive ECG findings (by any criteria) with death occurring before attempted emergent coronary angiography and autopsy confirming ACO. For cases with positive ECG findings and death before cath but NO autopsy, these will be marked and saved in a separate group, not to be used in the primary analysis.
3472280|NCT03863327||Acute severe 3-vessel disease or critical left main stenosis|"Severe 3-vessel disease: >/=75% stenosis in all three major coronary vessels (or equivalents in the case of anatomic variants or preexisting bypass) with an acute culprit lesion (TIMI<3) or~Left main stenosis > 50% (see Smith review paper for reference): acute left main culprit of any TIMI score, or any lesion of the left main with TIMI<3 or~Any other cardiac catheterization findings prompting initiation of emergent coronary artery bypass grafting within the next 120 hours"
3472281|NCT03863327||No evidence of acute coronary occlusion|"At least three sequential negative cardiac biomarkers within 24 hours of presentation~cardiac catheterization showing no culprit lesion.~Angiogram showing an acute culprit lesion but both no occlusion (TIMI 2 or greater) and troponins not exceeding the cutoff above~If positive troponin values present but no angiography, then the patient must have echocardiography showing no wall motion abnormality and troponin values less than the above cutoff~If the patient has insufficient data to classify into one of these categories, the patient must be excluded from the study as they cannot be classified as ACO or non-ACO. For example, patients with extremely high troponin but no culprit seen on cath may have acute occlusion with complete autolysis of thrombus, myocarditis, spasm, etc. Thus the investigators cannot classify them as NO ACO when the possibility of ACO remains and cannot be disproven."
3472282|NCT03863353|Experimental|Education Intervention|This group will receive the scenario-tailored STOMP educational feedback
3125949|NCT03011099|Active Comparator|Conventional Physical Therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
3125950|NCT03011333|Experimental|Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 60 mg/1.8 mg via nerve block.
3472283|NCT03863353|No Intervention|Control|This group will receive only standard of care information.
3472284|NCT03863132|Active Comparator|TAVR Group|Patients will be treated by transcatheter aortic valve repair (TAVR).
3472285|NCT03863132|No Intervention|Medical Treatment Group|Patients will receive optimal medical treatment alone.
3472286|NCT03863249|Active Comparator|The exCELLigence system|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics selected by 'the exCELLingence' system will be started at the second SRP visit."
3472287|NCT03863249|Active Comparator|Origen|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Origen' laboratories analysis will be started at the second SRP visit."
3472288|NCT03863249|Active Comparator|Echevarne|"Following the baseline examination each of the 20 randomly selected patients will be informed about the cause of periodontal disease.~The 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The study participants will undergo SCALE AND ROOT PLANING (SRP). SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~The adjunctive antibiotics agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit."
3472289|NCT03863171||Ocular ischemia syndrome|Patients with ocular ischemia syndrome
3472290|NCT03863171||Control|Patients with age-related macular degeneration
3472291|NCT03863288|Placebo Comparator|Intranasal Spray Placebo|Nasal spray of placebo liquid solution as a single dose. fMRI scan pre and post administration.
3472292|NCT03863288|Active Comparator|Oxytrocin Intranasal Spray 8IU|Nasal spray of Oxytocin8IU liquid solution as a single dose. fMRI scan pre and post administration.
3472293|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 24IU|Nasal spray of Oxytocin 24IU liquid solution as a single dose. fMRI scan pre and post administration.
3472294|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 48IU|Nasal spray of Oxytocin 48IU liquid solution as a single dose. fMRI scan pre and post administration.
3472295|NCT03863288|Active Comparator|Oxytocin Intranasal Spray 80IU|Nasal spray of Oxytocin 80U liquid solution as a single dose. fMRI scan pre and post administration.
3472296|NCT03863431|Active Comparator|High-fat diet|"Participants will consume a diet rich in fat (approximately 65% of total energy) and low in carbohydrate for 14 days.~Measurements will be made at 0, 7 and 14 days."
3472297|NCT03863431|Active Comparator|High-carbohydrate diet|"Participants will consume a diet rich in carbohydrate (approximately 70% of total energy) and low in fat for 14 days.~Measurements will be made at 0, 7 and 14 days."
3472298|NCT03863444|Active Comparator|Control Group|Routine Care
3472299|NCT03863444|Experimental|Intervention Group|Routine Care + Prenatal Preparation Education
3472300|NCT03863301|Experimental|MR-guided single dose preoperative PBI|
3472301|NCT03863223|Experimental|A|Pyrotinib Plus trastuzumab and docetaxel
3472302|NCT03863223|Placebo Comparator|B|Placebo plus trastuzumab and docetaxel
3125951|NCT03011333|Experimental|Group 2: HTX-011|HTX-011(bupivacaine/meloxicam), 120 mg/3.6 mg via nerve block.
3125952|NCT03011333|Experimental|Group 3: HTX-011|HTX-011(bupivacaine/meloxicam), 240 mg/7.2 mg via nerve block.
3125953|NCT03011333|Experimental|Group 4: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via nerve block.
3125954|NCT03011333|Experimental|Group 5: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/ 12 mg via instillation.
3125955|NCT03011333|Active Comparator|Group 6: Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg via nerve block.
3125956|NCT03011333|Placebo Comparator|Group 7: Saline Placebo|Saline placebo via nerve block.
3472303|NCT03863314|Active Comparator|In-Person Simulation|Participants will experience in-person simulations of different workplace scenarios such as medical error and workplace harassment
3472304|NCT03863314|Experimental|Virtual Simulation|Participants will experience virtual simulations of different workplace scenarios such as medical error and workplace harassment via Virtual Reality headset.
3472305|NCT03863145|Experimental|1|Part 1 (Dose Escalation): 100 mg daily.
3472306|NCT03863340|Experimental|short interruptions of work tasks|randomly start with or without short interruptions on the first experimental day and without or with them on the second experimental day
3472307|NCT03863197|Experimental|Intervention group|During a 12-week period children receive 3-4 sessions of progressive strength training per week on top of the usual care. All children will be provided with an individualized training program and supporting equipment. One or 2 session per week will be performed under supervision of the physical therapist, whilst the remaining sessions will be performed at home. Progression is closely monitored by the principal investigator and training programs are adjusted if necessary.
3472308|NCT03863197|No Intervention|Waitlist-control group|The waitlist-control group will continue their usual care without additional treatment for 12-weeks, followed by a 12-week period of progressive supervised home-based strength training.
3472309|NCT03863093|Experimental|An erythritol powder|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
3472310|NCT03863093|Active Comparator|ultrasonic instrumentation|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
3472311|NCT03862846|Experimental|Group|REN001 Low Dose
3472312|NCT03862833|Experimental|experimental group|"Zoledronic acid and IL-2 Zoledronic acid: 4 mg~Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion"
3472313|NCT03862833|No Intervention|control group|no experimental treatment
3472314|NCT03863002|No Intervention|Standard Medical Treatment|Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS]).
3472315|NCT03863002|Experimental|Mesenchymal Stem Cell|Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.
3125957|NCT03011840|No Intervention|Pre intervention|"In the first part planned over 2months (Jan - Feb), feedback forms will be collected from patients at the end of minor OT procedure. The number of postponement or rescheduling of cases will be noted.~Postponement or rescheduling of case is defined as an event when the patient who is called for his turn in minor OT is deferred for any amount of time in account of starvation not adequate, investigations not brought, medications not taken as prescribed."
3125958|NCT03011840|Experimental|Post Intervention|In the intervention phase, the patient information leaflet (PIL) will be handed over to all patients planned for procedure in the minor OT complex. This leaflet will be handed over by the attending doctor in the Head neck OPD. The checklist pertaining to counselling at the Head neck OPD will be ticked after they are carried out. The patient will be instructed to read leaflet carefully and carry the leaflet on the day of Minor OT procedure. In the minor OT the discharge checklist in the PIL would be carried out by all concerned including the surgical, anesthesia and nursing team. The impact of use of PIL will be assessed by noting the number of postponement or rescheduling of cases.
3472316|NCT03862872|Experimental|Anti-Aging Formula|4 capsules daily of high-EPA fish oil, borage oil, zeaxanthin, lutein and vitamin D providing 1050 mg of Eicosapentaenoic acid (EPA) and 350 mg of Docosahexaenoic acid (DHA), 120 mg of Gamma-linolenic acid (GLA), 2.5 mg of zeaxanthin, 5 mg of lutein and 25 μg (1000 IU) of vitamin D3 for 90 days.
3472317|NCT03862872|Active Comparator|Control Fish Oil|4 capsules daily of 1,106 mg each of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil providing 816 mg EPA and 572 mg DHA total for 90 days.
3472318|NCT03862872|Placebo Comparator|Inert Placebo|4 capsules daily of 1040 mg each of corn oil for 90 days.
3472319|NCT03862976|Experimental|computerized cardiotocography|computerized cardiotocography
3472320|NCT03862976|Active Comparator|standard cardiotocography|standard cardiotocography non stresstest
3472321|NCT03862950|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
3472322|NCT03862950|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
3472323|NCT03862924|Experimental|Active condition|Participants in the active condition will be provided with the Standardized Research Electronic Cigarette (SREC) and will be encouraged to use the SREC whenever they would normally smoke a cigarette.
3472324|NCT03862924|No Intervention|Standard Condition|Participants in this condition will be asked to continue to smoke their usual brand of cigarettes.
3472325|NCT03862794|Experimental|high total and high broad spectrum prescribing letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
3125959|NCT03011892|Placebo Comparator|Double Blind (DB): Vehicle BID|Participants applied vehicle cream twice daily (BID) for 8 weeks DB period.
3125960|NCT03011892|Active Comparator|DB: Triamcinolone (TAC) 0.1% BID/Vehicle Cream BID|Participants applied triamcinolone 0.1% cream BID for 4 weeks followed by vehicle cream for 4 weeks in DB period.
3125961|NCT03011892|Experimental|DB: Ruxolitinib 0.15% Once Daily (QD)|Participants applied ruxolitinib 0.15% cream QD for 8 weeks in DB period.
3125962|NCT03011892|Experimental|DB: Ruxolitinib 0.5% QD|Participants applied ruxolitinib 0.5% cream QD for 8 weeks in DB period.
3472326|NCT03862794|Active Comparator|high total and high broad spectrum prescribing control|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive the standard practice overall prescribing letter as a control
3472327|NCT03862794|Experimental|high total prescribing only intervention letter|social norm feedback letter with bar chart GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive a letter that has specific information about the percentile they are on for overall prescribing and a bar chart representing their overall prescribing compared to the average
3472328|NCT03862794|Active Comparator|high total prescribing control letter|standard social norm feedback letter GPs who prescribe more than 1.161 Antibacterial Items/ STAR-PU and less than 10% broad spectrum receive the standard practice overall prescribing letter as a control
3472329|NCT03862794|Experimental|moderate total prescribing and high broad spectrum letter|social norm feedback letter with bar chart GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum will receive a letter that has specific information about the percentile they are on for broad spectrum prescribing and a bar chart representing their broad spectrum prescribing compared to the average
3472330|NCT03862794|No Intervention|moderate total prescribing and high broad spectrum control|GPs who prescribe more than 0.965 but less than 1.161 Antibacterial Items/ STAR-PU and more than 10% broad spectrum receive no letter, which is standard practice, as a control.
3472331|NCT03863080|Experimental|Regimen A|RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
3472332|NCT03863080|Experimental|Regimen B|RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
3472333|NCT03863080|Placebo Comparator|Placebo|Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
3472334|NCT03862963|Active Comparator|Standard of Diabetes Care|Standard of diabetes care in the Marshall Islands
3472335|NCT03862963|Experimental|Lifestyle Intervention|Plant-based, whole foods diet with moderate exercise
3472336|NCT03863015|Active Comparator|Tocilizumab|A one hour infusion of a single 8mg/kg dose (max. 800mg) of tocilizumab to attenuate systemic inflammation after out-of-hospital cardiac arrest, given as early as possible after hospital admission.
3472337|NCT03863015|Placebo Comparator|Isotonic saline|A one hour infusion of isotonic saline
3472338|NCT03862937|Experimental|Experimental|The experimental group will perform 12 weeks of strength training twice a week associated with whey protein supplementation.
3472339|NCT03862937|Placebo Comparator|Placebo|The placebo group will perform 12 weeks of strength training twice a week associated with maltodextrin supplementation.
3472340|NCT03863054||>40% wound area reduction after 1 month|Subjects to continue with standard practice for the next 12 weeks, or until the wound has completely healed.
3472341|NCT03863054||<40% wound area reduction after 1 month|Subjects to be fitted with NATROX™ after 1 month, over a period of 12 weeks or until the wound has completely healed.
3472342|NCT03862716|Experimental|Intervention|Drug: IDegLira - sc injection; Drug: metformin - oral administration; Drug: insulin degludec - sc injection; Behavioral: lifestyle therapy, diet and exercise
3472343|NCT03862716|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
3472344|NCT03862703|Experimental|Experimental group|PTSD Help intervention combined with care as usual.
3472345|NCT03862703|No Intervention|Control group|Care as usual.
3472346|NCT03863028||Novice|Residents with no individual experience in TUR-B defined as no prior hands-on surgical experience in TURB
3472347|NCT03863028||Intermediates|Residents who have performed 10 to 30 TURBs.
3472348|NCT03863028||Experienced|Consultants with experience in the procedure defined as more than 100 TURBs.
3472349|NCT03862690||Participants with Type 2 Diabetes Mellitus|A broad adult population of patients with type 2 diabetes (T2D) requiring insulin therapy in different basal-bolus treatment regimens.
3472350|NCT03863548||Continuation of antithrombotic drugs|operation carried out without stopping anticoagulants
3472351|NCT03863548||Stop anti thrombotic drugs|operation performed with stopping the anticoagulants
3472352|NCT03862768|Experimental|Surgery following imatinib|Surgery requires at least removal of all drug-resistant lesions. Imatinib 400 MG/d should be taken once the patients resume oral diet.
3472353|NCT03862768|Active Comparator|Imatinib escalation or sunitinib|Escalation of imatinib or replacement of sunitinib are both conventional salvage treatments for imatinib-resistant GISTs. There is no high-level evidence to suggest which method is better. So patients are free to choose imatinib 600 MG/d or sunitinib 37.5 MG/d
3472354|NCT03862443|Experimental|Fixed Incentive|Eligible to earn a weekly payment during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will win $5; high adherence threshold (brushing twice per day for 14 days in a week) will win $10.
3472355|NCT03862443|Experimental|Drawing Incentive|Eligible to earn a weekly drawing entry with different winning probabilities during the 2-month incentive intervention period. Possible weekly winnings depend on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
3125963|NCT03011892|Experimental|DB: Ruxolitinib 1.5% QD|Participants applied ruxolitinib 1.5% cream QD for 8 weeks in DB period.
3125964|NCT03011892|Experimental|DB: Ruxolitinib 1.5% BID|Participants applied ruxolitinib 1.5% cream BID for 8 weeks in DB period.
3125965|NCT03011892|Placebo Comparator|Open-Label (OL): Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3125966|NCT03011892|Active Comparator|OL: TAC BID/Vehicle BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3472356|NCT03862443|No Intervention|Control - Delayed Incentive|No rewards during the first 2-months, but information on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app. After the Month 2 follow-up visit, may opt to participate in a delayed 2-month open label extension to earn the same monetary rewards the fixed incentive intervention group could earn Baseline through Month 2. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
3472357|NCT03862781|Other|Intra-corporeal|Right Hemicolectomy
3125967|NCT03011892|Experimental|OL: Ruxolitinib 0.15% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3472358|NCT03862781|Other|Extra-corporeal|Right Hemicolectomy
3472359|NCT03862677||Patients with (suspicion of) primary EOC|
3472360|NCT03862677||Patients with recurrent EOC|
3472361|NCT03862573|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during the dental procedure
3472362|NCT03862573|No Intervention|Control (Standard of Care)|Participants are distracted with Standard-of-Care by dentists and/or parents.
3472363|NCT03862456|Experimental|azythromycin + periodontal surgery.|Periodontal surgery + Azithromycin (500 mg every 24 h for 3 days).
3472364|NCT03862456|Active Comparator|metronidazole + periodontal surgery|Periodontal surgery + Metronidazole (500 mg every 8 h for 7 days).
3472365|NCT03862898|Experimental|lumbar stabilization group- thoracic|Lumbar stabilization and thoracic mobilization in a closed kinetic chain (LSTMC) group performed this exercises from the least to the largest painless motion amplitude and accordingly divided into three phases. The first phase lasted for two weeks, the second three and the last third phase, also for three weeks, and a total of 8 weeks.
3472366|NCT03862898|Active Comparator|lumbar stabilization group|Lumbar stabilization in a closed and opened kinetic chain (LSCO) group also performed exercises from the least to the largest painless motion amplitude in three phases.
3472367|NCT03862586|Experimental|N-acetyl cysteine|Twenty two infertile women with the onset of endometrial preparation for evaluating genes expression, received 1200 mg of oral N-acetyl cysteine for at-least six weeks before starting ovarian stimulation
3179284|NCT00671216|Experimental|Period 4|Subjects will receive first GW642444, then combination of GSK233705 and GW642444, placebo, and later GSK233705
3179285|NCT00671229||1|African American
3179286|NCT00671229||2|Caucasian
3472368|NCT03862586|Placebo Comparator|Placebos|Eighteen infertile women with the onset of endometrial preparation for evaluating genes expression, received placebo effervescent tablet for at-least six weeks before starting ovarian stimulation
3472369|NCT03862495|Experimental|Chlamydia Screening and Treatment|At the time of recruitment and prior to delivery, this group will have immediate testing for C. trachomatis and N. gonorrhoeae. Physicians will notify C. trachomatis positive results to pregnant women and suggest them and their spouses to get treated according to the national standard treatment plan for Chlamydia (Azithromycin 1g, single oral administration). Patients will be followed up to confirm cure of C. trachomatis in one month. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
3472370|NCT03862495|Experimental|Control|This group will have testing after delivery (immediately following childbirth) or in the event of an adverse pregnancy outcome for C. trachomatis and N. gonorrhoeae. In the event of a positive test, patients will be informed of the positive test results the same way as the intervention group. Specific treatment options will be the same as the intervention group. Physicians will ask patients to return to Nanhai Hospital one month after treatment for test of cure. Partner notification and treatment will be suggested for pregnant women who test positive for Chlamydia.
3472371|NCT03862651|Experimental|Cangrelor|Cangrelor, 0.75 μg/Kg/min, a cangrelor infusion will be started in addition to SOC when the P2Y12 inhibitor has been discontinued after the need for surgery has been determined. The infusions (cangrelor or matching placebo) will continue throughout the pre-operative period
3472372|NCT03862651|No Intervention|placebo|patients will receive only standard of care, in which the P2Y12 inhibitor is discontinued after the need for surgery has been determined and a placebo infusion is administered
3472373|NCT03862430|Experimental|NVX 108|NVX-108 infusion in conjunction with Radiation Treatment and temozolimide
3472374|NCT03862430|Placebo Comparator|Placebo|Placebo Saline infusion in conjunction with Radiation Treatment and temozolimide
3472375|NCT03862521|Experimental|Low carbohydrate diet group|Low carb diet, carbohydrates make up 30-40% of total daily calories.
3472376|NCT03862521|Experimental|Very low carbohydrate diet|Very low carb diet, carbohydrates make up 20-29% of total daily calories.
3472377|NCT03862638|Experimental|Yoga Therapy|Yoga therapy session lasted for 60 minutes consisting physical posture, Breath work, Relaxation, guided meditation, chants and combination techniques for groups sessions.
3472378|NCT03862508|Experimental|Experimental|Five Plyometric exercises
3472379|NCT03862508|No Intervention|Control|Subjects included in the control group will not receive any intervention
3472380|NCT03862612|Active Comparator|Erector Spinae Plane Block|This group will receive an Erector Spinae Plane Block under ultrasound guidance while under General Anaesthesia
3472381|NCT03862612|Experimental|Serratus Anterior Plane Block|This group will receive a Serratus Anterior Plane Block under ultrasound guidance while under General Anesthesia
3179287|NCT00671242||I|L-[3-18F]-α-methyltyrosine (18F-FMT) is an amino-acid tracer for PET. We have conducted a clinicopathologic study to elucidate the correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in the patients with non-small cell lung cancer
3179288|NCT00671242||Nuclear|
3179289|NCT00671255|Experimental|Ramelteon 4 mg QD|
3179290|NCT00671255|Experimental|Ramelteon 8 mg QD|
3179291|NCT00671255|Placebo Comparator|Placebo|
3472382|NCT03862534|Experimental|CAF|After the restoration of the enamel patients were treated with a CAF
3472383|NCT03862534|Experimental|CAF + CTG|After the restoration of the enamel patients were treated with a CAF + CTG
3472384|NCT03862547|Experimental|Men with ED and diabetes|"A peripheral blood sample from the cubital vein~A collection of peripheral blood from the routinary cubital vein for hormone dosage and metabolic evaluation~An introverted cavernous infiltration of Prostaglandin E1 to achieve erection (Aprostadil);~A blood sample from both the corpus cavernosum and the cubital vein, once the erection is achieved Baseline interaction of prostaglandin E1 on the concentration of NGF released in the medium and on the expression of its receptors Evaluation of NGF and Cytokine levels Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs"
3472385|NCT03862599|Sham Comparator|Standard care + sham ESWT|Cialis and Vacuum pump + sham Extra-corporeal shockwave therapy (ESWT)
3472386|NCT03862599|Active Comparator|Standard care + active ESWT|Cialis and Vacuum pump + active Extra-corporeal shockwave therapy (ESWT)
3472387|NCT03862417|Experimental|Schroth exercise group|Will attend 5 1-hr long individual sessions to learn Schroth exercises and the home program. A 30-min. daily home program of 3 to 4 exercises will be progressed by the certified Schroth therapist using an algorithm. Patients will attend weekly 1-hr long group therapist-led exercise classes for 3 months. At each group class, adequate exercise performance will be assessed using the checklist. An algorithm guides the prescription of exercises intensity and progression from static to dynamic depending on the participant's ability. Prescription begins with Sitting on a Ball. If performed adequately, a more challenging exercise is attempted. The 3 most challenging exercises performed adequately as per the checklist will be prescribed with a detailed handout.
3472388|NCT03862417|No Intervention|Control group|Observation without treatment or with previously prescribed pain medication is the current standard for adults with degenerative scoliosis not planning surgery.
3472389|NCT03862560|Experimental|Experimental group|Female soccers that perform a strength training
3472390|NCT03862560|No Intervention|Control group|Female soccers that do not perform a strength training
3472391|NCT03862404|Placebo Comparator|Control group|Patients in this group receive Normal Saline injection in the inter pleural space
3472392|NCT03862404|Experimental|Experimental group|Patients in this group receive Bupivacaine 0.25% + Epinephrine 5 mcg/ml injection in the inter pleural space
3125968|NCT03011892|Experimental|OL: Ruxolitinib 0.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3125969|NCT03011892|Experimental|OL: Ruxolitinib 1.5% QD to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3125970|NCT03011892|Experimental|OL: Ruxolitinib 1.5% BID to Ruxolitinib 1.5% BID|Following DB Period, at Week 8, participants who met criteria (compliant with the protocol and no safety concerns) received open-label treatment with ruxolitinib 1.5% cream BID for 4 weeks.
3125971|NCT03012061|Placebo Comparator|Placebo|Subjects will be administered placebo once daily via the ELLIPTA® dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks. ELLIPTA is a registered trademark of the GSK group of companies.
3179292|NCT00671268|Experimental|1|strict subcutaneous
3472393|NCT03862391|Active Comparator|Postsurgical Pain|pain is defined as unpleasant sensation that can range from mild, localized discomfort to agony.
3472394|NCT03862391|Active Comparator|Postanesthesia nausea and vomiting|nausea defined as feeling of sickness or discomfort in the stomach that may come with an urge to vomit.
3472395|NCT03862313|Experimental|active-rtACS arm|Active rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
3472396|NCT03862313|Sham Comparator|sham-rtACS arm|Sham rtACS on 10 consecutive working days, in addition to standard-of-care corticosteroid treatment.
3472397|NCT03862248|Experimental|High-Dose Isoniazid|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
3472398|NCT03862248|Experimental|High-Dose Rifampicin|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
3472399|NCT03862248|Active Comparator|World Health Organisation (WHO) regimen|WHO levofloxacin-strengthened regimen (6EHRZLfx)
3472400|NCT03861988|Experimental|Open label ketamine|Patients will receive an intravenous ketamine infusion during surgery.
3472401|NCT03861988|Experimental|Double blind ketamine|Patients will receive an intravenous ketamine infusion during surgery.
3472402|NCT03861988|Placebo Comparator|Double blind placebo|Participants will receive placebo (normal saline infusion) during surgery.
3179293|NCT00671268|Placebo Comparator|2|strict subcutaneous
3472403|NCT03862105|Experimental|Health App with Provider Monitoring/Care|30 patients enrolled by the study team will receive notifications through a mobile health app (Twistle) before and after surgery. Patient Reported Outcome data will be collected through patient responses in this app and timely clinician feedback will be provided to patients to prevent complications and readmission.
3472404|NCT03862235||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
3472405|NCT03862235||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
3472406|NCT03862235||Sedentary control|"This group were sedentary men without cardiovascular disease.~Cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and transthoracic echocardiography (speckle tracking)."
3472407|NCT03861975|Experimental|Breast Cancer-Related Lymphedema Measurements|Absolute volume of the upper extremities will be assessed using the LymphaTech Scanner and the Perometer.
3472408|NCT03862222||Cognitively normal - low risk|Adults aged 55-80 without subjective memory complaints, family history of Alzheimer's disease, or genetic risk for Alzheimer's disease.
3472409|NCT03862222||Cognitively normal - high risk|Adults aged 55-80 with subjective memory complaints, first degree family history of Alzheimer's disease, and at least one copy of the APOE E4 gene, a risk gene for Alzheimer's disease
3472410|NCT03862222||mild cognitive impairment|Adults aged 55-80 who have a confirmed diagnosis of mild cognitive impairment.
3472411|NCT03862222||mild dementia|Adults aged 55-80 with mild dementia due to probable Alzheimer's disease.
3472412|NCT03862274||CLN2 Natural History Control Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are untreated or not receiving cerliponase alfa.
3125972|NCT03012061|Experimental|UMEC 62.5 mcg|Subjects will be administered UMEC 62.5 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
3125973|NCT03012061|Experimental|UMEC 31.25 mcg|Subjects will be administered UMEC 31.25 mcg once daily via the ELLIPTA dry powder inhaler (DPI) for 24 weeks. Subjects will also receive FF 100 mcg once daily, in the morning for 24 weeks.
3125974|NCT03012191|Experimental|Gentamicin|Topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
3472413|NCT03862274||CLN2 Treatment Group|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
3472414|NCT03862326|Other|Group Training|Group Training of the women with incontinence - with 5-8 women in each group. This is also Usual Care
3472415|NCT03862326|Experimental|Individual training|Individual pelvic floor exercises one-to-one with the physiotherapist
3472416|NCT03862326|Experimental|Individual training with biofeedback|Individual pelvic floor exercises one-to-one with the physiotherapist but with ultrasound used as biofeedback, and to check if the women are contracting the right muscles.
3472417|NCT03862287|Active Comparator|Intrathecal Lidocaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median or paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 60 mg of isobaric preservative-free Lidocaine 2% will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
3472418|NCT03862287|Active Comparator|Intrathecal Bupivacaine|Patients will receive spinal anesthesia in the sitting position under strict sterile conditions in the operating room. Using a median/paramedian approach, the spinal needle will be inserted into the L2-3 or L3-4 interspace to reach the subarachnoid space. After confirming the space by free flow of CSF, 6 mg of 0.5% isobaric bupivacaine will be injected. Sedation using propofol infusion (50-100 mcg/kg/min) and fentanyl (0.5-1 mcg/kg) will be given throughout the procedure as required.
3472419|NCT03862053|Active Comparator|Manuka honey eyedrops|optimel manuka eyedrops 10 ml used as directed in a CAC (Conjunctival allergen challenge) study
3472420|NCT03862053|Placebo Comparator|Normal saline 0.9% eyedrops|sterile normal saline eyedrops used as directed in a CAC (conjunctival allergen challenge) study
3472421|NCT03862261|No Intervention|Standard-of-Care|Pediatric TB services based on current routine approach (national standard of care)
3472422|NCT03862261|Experimental|Intervention|Integrated pediatric TB services
3472423|NCT03862196|Experimental|Intervention|Participants will receive 2 tailored text messages weekly from a trained counselor during 3 months.
3472424|NCT03862196|No Intervention|Control|Participants will receive standard of care: pre and post counseling after being diagnosed with HIV
3472425|NCT03862378||Group One|All patients underwent gastric or colorectal cancer surgery in the participating centers will be included. Clinical data, drainage cytokine levels will be recorded.
3125975|NCT03012334|Experimental|Lasmiditan 50mg (milligrams)|Participants received 50mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
3472426|NCT03862365||Polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy with pain.
3472427|NCT03862365||Polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of polyneuropathy without pain.
3472428|NCT03862365||Diabetic polyneuropathy with pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy with pain.
3472429|NCT03862365||Diabetic polyneuropathy without pain|Clinical and diagnostic test evaluation for the establishment of diabetic polyneuropathy without pain.
3472430|NCT03862365||Carpal tunnel syndrome with pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome with pain.
3472431|NCT03862365||Carpal tunnel syndrome without pain|Clinical and diagnostic test evaluation for the establishment of carpal tunnel syndrome without pain.
3472432|NCT03862001|Experimental|LungCARE Group|The intervention group will receive the LungCARE intervention
3472433|NCT03862001|No Intervention|Comparison Group|The comparison group will receive usual care.
3472434|NCT03862352||Coronary artery perforation (iatrogenic)|Any coronary artery perforation defined according to the Ellis criteria.
3472435|NCT03862079|Experimental|Arm I (TGD + FMT)|Patients receive piperacillin-tazobactam PO TID and nystatin QID. Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
3472436|NCT03862079|Experimental|Arm II (FMT)|Patients undergo stem cell transplantation on day 0, then undergo FMT via enema over 5-10 minutes within 3 weeks after transplantation.
3472437|NCT03862079|Active Comparator|Arm III (standard therapy)|Patients receive standard of care.
3472438|NCT03862014|Experimental|SDF only|SDF will be applied on molars with MIH
3472439|NCT03862014|Active Comparator|SDF+ARR|SDT+ARR will be applied on molars with MIH
3472440|NCT03862183||dyslipidemia in hypertension|
3472441|NCT03862183||hypertension|
3472442|NCT03861949|No Intervention|Conventional|preoxygenation done with 100% oxygen in supine position
3125976|NCT03012334|Experimental|Lasmiditan 100mg|Participants received 100mg of Lasmiditan tablets given as single oral doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
3472443|NCT03861949|Experimental|Positive-pressure|preoxygenation done with 5 cmH2O CPAP (continuous positive airway pressure) in supine position with 100% oxygen
3472444|NCT03861949|Experimental|Head-up|preoxygenation done in 25 degree head-up position with 5 cmH2O CPAP with 100% oxygen
3125977|NCT03012334|Experimental|Lasmiditan 200mg|Participants received 200mg of Lasmiditan tablets given as single doses on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
3125978|NCT03012334|Active Comparator|Alprazolam 1mg|Participants received 1mg of Alprazolam tablets as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
3125979|NCT03012334|Placebo Comparator|Placebo|Participants received placebo tablets identical to Lasmiditan, administered as single oral dose on Day 1, 7, 14, 21, or 28 (dependent upon the assigned treatment sequence) in the morning.
3125980|NCT03012477|Experimental|cisplatin + AZD1775|"Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.~AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.~At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3)."
3125981|NCT03012594|Experimental|Lanreotide|Open label
3179294|NCT00671281|Experimental|B|This group will be the experimental group which will receive tranexamic acid in oral form three days before and six days after surgery.
3472445|NCT03862157|Experimental|Treatment (venetoclax, azacitidine, pevonedistat)|Patients receive venetoclax PO QD on days 1-28, azacitidine IV or SC on days 1-7, and pevonedistat IV over 60 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3472446|NCT03862209|Experimental|Community mental health team (CMHT)|CMHTs will be multidisciplinary; that is, staff will be appointed to the CMHTs that include nurses, social workers, psychiatrists, psychologists, and in this project, a peer expert (a person with lived experience of mental health services). All staff within the CMHT will have defined roles and responsibilities that align with the staff functions, roles and linkages detailed in evidence-based service delivery models for community mental health teams. Participant will randomly be assigned to CMHT that will provide outreach mental health care during the project.
3472447|NCT03862209|No Intervention|Standard care|Health care settings and their providers randomised to the control condition receive usual care: participant will gain standard care; ambulatory care, day hospitals or hospital admission.
3472448|NCT03862092|Experimental|Patients with acute abdominal pain|Salivary VZV-DNA PCR was performed in patients who visited the emergency room due to acute abdominal pain.
3472449|NCT03861884||Cognitive assessments|Neurocognitive assessments, Birmingham Cognitive Screen
3472450|NCT03861884||MRI at 3T|Brain Imaging: MRI at 3T
3472451|NCT03861884||MRI at 7T|Brain imaging: Ultrahigh Field MRI at 7T
3472452|NCT03861923|Experimental|Dry needling and exercise|
3472453|NCT03861923|Sham Comparator|Sham dry needling and exercise|
3472454|NCT03861910||extensively hydrolyzed casein formula+LGG|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG as exclusion diet
3472455|NCT03861910||extensively hydrolyzed whey formula;|subjects with IgE mediated cow milk allergy treated with extensively hydrolyzed whey formula as exclusion diet
3472456|NCT03861910||hydrolyzed rice formula|subjects with IgE mediated cow milk allergy treated with hydrolyzed rice formula as exclusion diet
3472457|NCT03861910||soy based formula|subjects with IgE mediated cow milk allergy treated with soy based formula as exclusion diet
3472458|NCT03861910||amino-acid based formula|subjects with IgE mediated cow milk allergy treated with amino-acid based formula as exclusion diet
3472459|NCT03862170|Active Comparator|Ciprofloxacin|Patients in this arm will receive Ciprofloxacin 400mg IV 120mn (prophylactic antibiotic) before their HDR brachytherapy
3472460|NCT03862170|Experimental|Cefazolin|Patients in this arm will receive Cefazolin 2000mg IV 60mn (prophylactic antibiotic) before their HDR brachytherapy
3472461|NCT03862170|No Intervention|No prophylactic antibiotics|Patients in this arm will not receive any prophylactic antibiotics before their HDR brachytherapy
3472462|NCT03862144|Experimental|Netupitant/Palonosetron & Dexamethasone|"Netupitant/Palonosetron (NEPA) will be administered orally at the dose of 300 MG (milligrams) netupitant/0.5 palonosetron 1 hour before the start of any chemotherapy cycle.~Dexamethasone 12 mg will be added on day 1 only of each cycle."
3472463|NCT03861871|Experimental|Fenfluramine Hydrochloride|
3472464|NCT03861858|Experimental|DBT-A|The standard treatment to be delivered to all participants is DBT-A, which is a treatment model adapted from DBT. DBT-A is an adaptation for adolescents with emotion dysregulation and BPD features (Miller, Rathus, & Linehan, 2007; Rathus & Miller, 2015). DBT-A involves weekly individual therapy with the adolescent, weekly multifamily skills group in which adolescents and family members participate, as needed phone coaching, and weekly consultation team for the therapists.
3472465|NCT03861767|Experimental|SPRY: Metformin LD-SC|"LD-SC (low-dose, short course)~Participants take Metformin ER 500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472466|NCT03861767|Experimental|SPRY: Metformin LD-IC|"LD-IC (low-dose, intermediate course)~Participants take Metformin ER 500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472467|NCT03861767|Experimental|SPRY: Metformin LD-LC|"LD-LC (low-dose, long course)~Participants take Metformin ER 500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472468|NCT03861767|Experimental|SPRY: Metformin ID-SC|"ID-SC (intermediate-dose, short course)~Participants take Metformin ER 1000 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472469|NCT03861767|Experimental|SPRY: Metformin ID-IC|"ID-IC (intermediate-dose, intermediate course)~Participants take Metformin ER 1000 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472470|NCT03861767|Experimental|SPRY: Metformin ID-LC|"ID-LC (intermediate-dose, long course)~Participants take Metformin ER 1000 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472471|NCT03861767|Experimental|SPRY: Metformin HD-SC|"HD-SC (high-dose, short course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 7-28 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472472|NCT03861767|Experimental|SPRY: Metformin HD-IC|"HD-IC (high-dose, intermediate course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 29-90 days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472473|NCT03861767|Experimental|SPRY: Metformin HD-LC|"HD-LC (high-dose, long course)~After a 7 day run-in of Metformin ER 1000 mg, participants take Metformin ER 1500 mg daily for 90+ days prior to their elective surgical procedure as determined by the patient's scheduling of their surgery. Participants take this same dose of Metformin ER for 90 days after their surgical procedure."
3472474|NCT03861767|Placebo Comparator|SPRY: Placebo|Participants are randomized to receive dose matched placebo to take daily for either short-, intermediate-, or long-course.
3472475|NCT03861598|Experimental|Cohort 1|Carvedilol orally with standard chemotherapy starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
3472476|NCT03861611|Experimental|Ketorolac + Educational Intervention|Participants may be randomized to receive Ketorolac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
3472477|NCT03861611|Experimental|Ibuprofen + Educational Intervention|Participants may be randomized to receive Ibuprofen for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
3472478|NCT03861611|Experimental|Diclofenac + Educational Intervention|Participants may be randomized to receive diclofenac for their LBP. Research personnel will provide each participant with a 15-minute educational intervention.
3472479|NCT03861572|Experimental|Isokinetic eccentric group|The isokinetic eccentric training will be carried out with the volunteers positioned seated on the dynamometer with the apparent axis of the ankle joint rotation aligned with the dynamometer's axis of rotation. Movement will be executed in the angular velocity of 30°·s-1. Ankle range of motion (ROM) will be standardized for all participants in 50º, which shall respect each individual's maximal dorsiflexion amplitude. The 50° eccentric training ROM will start from each subject's 80% of the maximal dorsiflexion. This procedure will be used to ensure that all subjects perform training on the same plantar flexor muscular length, which should promote the same level of muscular requirement among the participants. This methodology was recently used by GEREMIA and VAZ (2016) study.
3472480|NCT03861572|Active Comparator|Traditional eccentric training|Participants will be engaged in an intervention program consisting of 12 weeks of traditional eccentric training. The training will be carried out with the volunteers at gym in stand position. Concentric phase will be realized with both legs and the eccentric one only with one of them. Training progression will be the same from de isokinetic eccentric group. The same periodization from eccentric group will be used to permit us a posteriori comparison between groups. Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions. Each training session will comprise the same specific warming protocol for the ankle joint from the eccentric training.
3472481|NCT03861793|Experimental|ALKS 4230|Administered via SC injection once every 7 days or once every 21 days at escalating doses
3472482|NCT03861793|Experimental|ALKS 4230 + pembrolizumab|ALKS 4230 will be administered via SC injection once every 7 or 21 days at escalating doses or at the recommended phase 2 dose and schedule; pembrolizumab will be administered as an intravenous infusion given over 30 minutes; the dose level for pembrolizumab will be 200 mg per the approved label. In December 2020, an RP2D of 3 mg with an administration schedule of q7d was determined for SC ALKS 4230.
3472483|NCT03861741|Experimental|Participants|All participants will be screened through complete clinical evaluations, genetic tests and imaging modalities (TTE and MRI) for the presence of newly Non Syndromic-Thoracic Aortic Diseases. Demographic and clinical data from all participants will be collected using case report forms, and by accessing their medical records. Data on imaging investigations will be obtained from TTE and MRI. Blood samples will be used for the purpose of isolation of genetic material and subsequent whole exome sequencing along with the analysis of selected loci. Additional citrated blood samples and plasma will be collected and stored for the potential analysis of circulating microvesicles and miRNA.
3472484|NCT03861715||Single Dose antagonist Degarelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with a single dose Degarelix.
3472485|NCT03861715||Multidose antagonist Ganirelix|The blastocyst formation rate and live birth rates of patients who followed GnRH antagonist protocol with multidose dose Ganirelix.
3472486|NCT03861832|Experimental|Nutraceutical, KB220Z|A nutraceutical pill containing pro-dopamine precursors
3472487|NCT03861832|Placebo Comparator|Placebo|A placebo that looks the same and is in a similar bottle
3472488|NCT03861520||16-24 weeks Pregnant womes|Pregnant Women at (16-24) weeks of gestation for mid trimester anomaly scan with one sonographic fetal soft marker or more.
3472489|NCT03861650|Experimental|Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate is prepared from bone marrow by aspiration by wide bore needle and then prepared by centrifugation to get rich mix of MSCs to improve healing
3472490|NCT03861650|Sham Comparator|Saline|Sham or placebo drug in the control group
3472491|NCT03861481|Experimental|Rozanolixizumab|Subjects will be randomized to receive predefined subcutaneous doses of rozanolixizumab at a specified frequency
3472492|NCT03861481|Placebo Comparator|Placebo|Subjects will be randomized to receive predefined subcutaneous doses of placebo at a specified frequency
3472493|NCT03861637|Active Comparator|drug : ESA for p correction of PTA|ESA (Aranesp or mir-CERA) injection 1 mg per kg sc every week for 1 year to correct PTA to level between 12-13g/dl.
3472494|NCT03861637|Active Comparator|ara or cera|ESA (Aranesp) 1mg/ kg (or equivalent doses) of MIR-CERA injection for 1 year to correct PTA to level between 13-15g/dl.
3472495|NCT03861819|Experimental|VIIT Intervention|This is a single-arm trial. The intervention itself proceeds as follows: After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total.
3472496|NCT03861507|Other|Patient|Patient undergoing standard care prostate high dose rate brachytherapy.
3472497|NCT03861468|No Intervention|Usual care|Patients in the usual care group will be referred to their general practitioner (GP) / primary care practitioner as usual.
3472498|NCT03861468|Active Comparator|Early care|A different care pathway will be followed by the patients randomized to this group. They will be referred to a specialist (pneumologist) for OSA diagnosis and treatment if necessary
3472499|NCT03861676|Experimental|Focal brachytherapy|"Drug: 18F-DCFPyl Other names: PET, PSMA~Procedure: Focal brachytherapy with PSMA PET imaging Other names: Radiotherapy, Radiation, Prostate seed implant, Focal therapy"
3472500|NCT03861585|Experimental|semantic group|"Half of the participants (named the semantic group) perform a semantic categorisation task."
3472501|NCT03861585|Experimental|emotional group|"Half of the participants (named the emotional group) perform an emotional evaluation task."
3472502|NCT03861494|Other|Enhanced Stroke Education|This group of participants will receive enhanced education provided by the Stroke Coordinator at the time of discharge. The enhanced education session will last 30 minutes with the participant.
3472503|NCT03861494|Other|Usual Stroke Education|This group of participants will receive the usual stroke education provided by the usual Neuroscience Registered Nurse throughout the hospitalization and at the time of discharge.
3472504|NCT03861624|Experimental|Intramedullary nailing|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures via Intramedullary nailing with standard SIGN nail.
3472505|NCT03861624|Active Comparator|External Fixation|Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures External Fixation with uniplanar Dispofix external fixator.
3472506|NCT03861546|Experimental|Healthy lifestyle Shared Medical Appointment (SMA) program|South Asian (SA) adults with prediabetes and Type 2 Diabetes (T2D) that are 'information rich' and have variation in background characteristics will be identified. Dyads (spouses, parent/adolescent or young adult child, peers) will participate in a 16-week culturally-tailored, community-informed pre-post SMA intervention to improve health behaviors.
3472507|NCT03861806|Experimental|PAS true|Participants will receive paired associative stimulation therapy with a modulatory inter-stimulus interval.
3472508|NCT03861806|Sham Comparator|PAS sham|Participants will receive paired associative stimulation therapy with a non modulatory inter-stimulus interval.
3472509|NCT03861390|Active Comparator|Prednisone, then Placebo|
3472510|NCT03861390|Placebo Comparator|Placebo, then Prednisone|
3472511|NCT03861689|Active Comparator|Tight control arm|Patients in the tight control arm will have additional FiLAC treatment within 24 months if the anatomy of the fistula is favourable. MRI pelvis will be performed at baseline and every 6 months. Biologic dosage will be adjusted according to MRI pelvis findings.
3472512|NCT03861689|No Intervention|Control arm|Patients in the control arm will have management according to physician own decision.
3472513|NCT03861663|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
3472514|NCT03861429|Experimental|Me & My Wishes Intervention/Group 1|In Group 1 (early intervention group) NHs, video recording, editing, and viewing will occur within three months of baseline.
3472515|NCT03861429|Other|Me & My Wishes Wait-list control/Group 2|In Group 2 (delayed sharing) NHs, residents will be on a wait-list; after the delayed start, their video will be produced and viewed within three months.
3472516|NCT03861455|Experimental|dupilumab group|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
3472517|NCT03861455|Placebo Comparator|placebo group|patient receive placebo
3472518|NCT03861754|Experimental|Lifestyle modification|intensified Behavioural Modification (iBM) group receiving lifestyle counselling
3472519|NCT03861754|Experimental|Lifestyle modification and exercise 1|"Intensified Behavioural Modification and exercise from 0 to 3 months (CWT1) group:~Lifestyle counselling 3 months Exercise intervention from 0 to 3 months"
3472520|NCT03861754|Experimental|Lifestyle modification and exercise 2|"Intensified Behavioural Modification and exercise from 6 to 9 months (CWT2) group:~Lifestyle counselling 3 months Exercise intervention from 6 to 9 months"
3472521|NCT03861754|No Intervention|Control Group|Control group, no intervention, only measurements and questionnaires
3472522|NCT03861299|Experimental|Awake craniotomy|Cortical stimulation is performed with a bipolar electrical stimulator. The Boston naming test and repetition of words is done in cooperation with a neuropsychologist/linguist, who will inform the neurosurgeon of any kind of speech arrest or dysarthria. When localizing the motor and sensory cortex, the patient is asked to report any unintended movement or sensation in extremities or face. Functional cortical areas are marked with a number. When the tumour margins or white matter is encountered or when on regular neuronavigation the eloquent white matter tracts are thought to be in close proximity, subcortical stimulation (biphasic currents of 8-16 mA, pulse frequency 60 Hz, single pulse phase duration of 100 microsec., 2-second train) is performed to localize functional tracts.
3472523|NCT03861299|Active Comparator|Craniotomy under general anesthesia|Trephination and tumour resection are performed without any additional neuro-psychological monitoring or brain mapping, guided by STEALTH-neuronavigation.
3472524|NCT03861312|Experimental|Neck Laterality|It was done with 20 images of necks and 4 seconds for each image in the Vanilla program of the tablet application.
3472525|NCT03861312|Experimental|Foot Laterality|It was done with 20 images of feet and 4 seconds for each image in the Vanilla program of the tablet application.
3472526|NCT03861403|Experimental|All Solid Tumors|"Phase 1b, Part 1 Dose Escalation: TRX518 + CTX Combination (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Assigned dose of cyclophosphamide administered intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle~Phase 1b, Part 2 Dose Escalation: TRX518 + CTX + avelumab in (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide administered at the MTD from Part 1 intravenously on C1D1 and may be re-administered on D1 of a subsequent cycle"
3472527|NCT03861403|Experimental|Advanced Triple Negative Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
3472528|NCT03861403|Experimental|Advanced Hormone Receptor+/Endocrine Refractory Breast Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
3472529|NCT03861403|Experimental|Advanced Metastatic Castration-Resistant Prostate Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
3472530|NCT03861403|Experimental|Advanced Platinum-Resistant Ovarian Cancer|"Phase 2a Dose Expansion: TRX518 + CTX Combination + avelumab (28-Day Cycle):~Subjects receive the following treatment:~Fixed dose of TRX518 administered intravenously on D2 and D16 per cycle~Fixed dose of avelumab administered intravenously on D2 and D16 per cycle~Fixed dose of cyclophosphamide identified in Phase 1b administered on C1D1 and may be re-administered on D1 of a subsequent cycle"
3472531|NCT03861416|Experimental|Unifuzol® 1.4% 500 ml|Patients receive the infusion of investigational drug L-arginine 1.4% 500 ml IV daily for 10 days
3472532|NCT03861416|Experimental|Unifuzol® 1.4% 250 ml|Patients receive the infusion of L-arginine 1.4% 250 ml + placebo 250 ml IV daily for 10 days
3472533|NCT03861416|Placebo Comparator|Placebo 500 ml|Patients receive the infusion of placebo solution for intravenous infusions 500 ml IV daily for 10 days.
3472534|NCT03861377|Active Comparator|Remifentanil R2|Low dose Remifentanil induction dose (R2)
3472535|NCT03861377|Active Comparator|Remifentanil R4|Medium dose Remifentanil induction dose (R4)
3472536|NCT03861377|Active Comparator|Remifentanil R8|Medium dose Remifentanil induction dose (R8)
3472537|NCT03861351|Experimental|Mini WELL Toric Ready intraocular lens|
3125982|NCT03012672|Experimental|Arm I (higher-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, higher dose cladribine IV over 2 hours on days 1-5, higher dose cytarabine IV over 2 hours on days 1-5, and higher dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 2 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3125983|NCT03012672|Experimental|Arm II (lower-dose)|"INDUCTION: Patients receive G-CSF SC on days 0-5, lower dose cladribine IV over 2 hours on days 1-5, lower dose cytarabine IV over 1 hour on days 1-5, and lower dose mitoxantrone IV over 60 minutes on days 1-3. Treatment repeats every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients who achieve CR/CRi with up to 6 courses of Induction receive G-CSF, cladribine, and cytarabine as in Induction. Courses repeat every 6 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3472538|NCT03861364|Active Comparator|High Propofol|High Propofol induction dose
3472539|NCT03861364|Active Comparator|Low Propofol|Low Propofol induction dose
3472540|NCT03861143|Experimental|BT-11 low-dose (500 mg)|Oral
3472541|NCT03861143|Experimental|BT-11 high-dose (1,000 mg)|Oral
3472542|NCT03861143|Placebo Comparator|Placebo|Oral
3472543|NCT03861026|Experimental|Intervention group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the interventional group, an alarm threshold at 90% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 90% of the baseline measurements. The intervention will be commenced within 15 seconds of the reduction in rSO2 value."
3472544|NCT03861026|No Intervention|Control group|"Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively.~In the control group, the cerebral oximetry monitor screen will be concealed, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in cerebral oximetry application and unaware of the study design."
3472545|NCT03861104|Active Comparator|group watched video|"patients will watch the medical video before filling out the spielberger state anxiety inventory at the time of nasal packing removal.~intervention is watching informative video."
3472546|NCT03861104|No Intervention|group without video|patients will fill out the spielberger state anxiety inventory without watching the video at the time of nasal packing removal
3472547|NCT03861195||Da Vinci Robotic Surgical System|
3472548|NCT03861195||conventional laparoscopic surgery|
3472549|NCT03861247|Active Comparator|Control group|
3472550|NCT03861247|Experimental|Intervention group|
3472551|NCT03861052|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3472552|NCT03861052|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3472553|NCT03861052|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3472554|NCT03861052|Active Comparator|0.75 mg Dulaglutide|0.75 mg dulaglutide administered SC once a week.
3472555|NCT03861169|Experimental|Viscoeleastic delivery & trabeculotomy|Patients with open angle glaucoma and cataract
3472556|NCT03861156|Experimental|D-0316|Firstly, D-0316 was orally given 75mg for a cycle(21 days), if tolerated, the dose will be increased to 100mg. Otherwise, the dose will be maintained at 75mg.
3472557|NCT03861130||Kawasaki disease|Kawasaki disease affected childrens
3472558|NCT03860974|Experimental|Serratus Plane (single injection)|A single injection serratus plane block will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL on each side for bilateral surgery)
3472559|NCT03860974|Active Comparator|Paravertebral (single injection)|Single injection paravertebral blocks will be administered using ropivacaine 0.5% with epinephrine 1:200,000-400,000 (20 mL for unilateral surgery; 16 mL each side for bilateral surgery)
3472560|NCT03861039|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3472561|NCT03861039|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3125984|NCT03012828|Experimental|Moxidectin 4mg|10 subjects will receive a single oral dose of moxidectin 4mg
3125985|NCT03012828|Experimental|Moxidectin 8mg|10 subjects will receive a single oral dose of moxidectin 8mg
3472562|NCT03861039|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3472563|NCT03861182|Other|Adult Healthy Volunteers|
3472564|NCT03861182|Other|Neonates|
3472565|NCT03861208|Experimental|diet|high fiber high protein foods served in childcare centers are offered for meals and snacks
3472566|NCT03861208|Other|usual diet|foods representing the usual diet in childcare centers are offered for meals and snacks
3472567|NCT03860948|Experimental|Savolitinib Test Preparation|The subjects in this arm will receive Test preparation (T). T is dry granulation savolitinib tablets.
3472568|NCT03860948|Experimental|Savolitinib Reference Preparation|The subjects in this arm will receive Reference preparation(R). R is wet granulation savolitinib tablets.
3472569|NCT03861065|Experimental|Tertiary Wound Closure|In the alternative tertiary wound closure, the wound will be partially closed rather than being left open. Sutures in the skin will be placed but not closed. A vacuum assisted closure device will be placed over the wound to help healing. After 4-7 days, the vacuum device will be removed, and the participant's doctor will close the wound.
3472570|NCT03861065|Active Comparator|Historical Wound Closure|"The standard approach to your wound would be to leave it partially open and let it heal over a period of 3-6 months (secondary closure)."
3472571|NCT03861260|Other|Rigid Cystoscopy and Urethral dilatation|Rigid cystoscopy, performed under General Anaesthetic, followed by intervention of urethral dilatation with Hagar dilators.
3472572|NCT03861260|Other|Flexible cystoscopy and Glycosaminoglycan Layer replacement|Flexible cystoscopy, under Local Anaesthetic, followed by the intervention, which is 6 installations of Ialuril (a Glycosaminoglycan Layer replacement)
3472573|NCT03860896|Experimental|GB004|GB004 for oral administration daily
3472574|NCT03860896|Placebo Comparator|Placebo|Placebo for oral administration daily
3472575|NCT03861013|Experimental|Intervention group|Participation in a multidimensional stress prevention program (GeDStress).
3472576|NCT03861013|No Intervention|Wait-list control group|Participants on the wait-list control group will not receive any treatment between the baseline and last follow-up. After the study has ended, they have the option to participate in the program.
3472577|NCT03860870|Experimental|Clenbuterol|Subjects ingest 80 micrograms of clenbuterol tablets
3472578|NCT03860870|Placebo Comparator|Placebo|Subjects ingest placebo tablets
3472579|NCT03860857|Experimental|Age 60-65 ApoE e4+|Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3125986|NCT03012828|Experimental|Moxidectin 16mg|10 subjects will receive a single oral dose of moxidectin 16mg
3125987|NCT03012828|Experimental|Moxidectin 24mg|10 subjects will receive a single oral dose of moxidectin 24mg
3472580|NCT03860857|Experimental|Age 66-70 ApoE e4-|Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472581|NCT03860857|Experimental|Age 66-70 ApoE e4+|Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472582|NCT03860857|Experimental|Age 71-75 ApoE e4-|Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472583|NCT03860857|Experimental|Age 71-75 ApoE e4+|Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472584|NCT03860857|Experimental|Age 76-80 ApoE e4-|Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472585|NCT03860857|Experimental|Age 76-80 ApoE e4+|Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472586|NCT03860857|Experimental|Age 81-85 ApoE e4-|Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3125988|NCT03012828|Experimental|Moxidectin 36mg|10 subjects will receive a single oral dose of moxidectin 36mg
3125989|NCT03012828|Placebo Comparator|Placebo|10 subjects will receive a single oral dose of placebo
3125990|NCT03012841|Experimental|Treatment Arm|Subjects enrolled and treated with Arctic Front Advance Cardiac CryoAblation Catheter
3472587|NCT03860857|Experimental|Age 81-85 ApoE e4+|Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.
3472588|NCT03860597|Active Comparator|Memantine|
3472589|NCT03860597|Placebo Comparator|Placebo|
3472590|NCT03860766|Sham Comparator|Sham Group (G-S)|The LED will be positioned across the quadriceps and hamstring bilaterally, however, there will be no light emission. However, the volunteer will perform the strength training protocol.
3472591|NCT03860766|Experimental|50J Infrared LED Group (G-50J)|The LED with a wavelength of 940nm, 50J power, will be applied throughout the quadriceps and hamstrings bilaterally, just before the strength training protocol.
3472592|NCT03860766|Experimental|240J Infrared LED Group (G-240J)|The LED with a wavelength of 940nm, 240J power, will be applied across the quadriceps and hamstrings bilaterally, just before the strength training protocol.
3472593|NCT03860766|Experimental|Progressive dose infrared LED group (G-50-240J)|The LED with a wavelength of 940nm, initial energy of 50J with an increment of 38J each week to the final energy of 240J, will be applied throughout extension of the quadriceps and hamstrings bilaterally, immediately prior to the performance of the strength training protocol
3472594|NCT03860831|Experimental|intranasal (IN)|"Group IN will receive nasal ketamine+midazolam mixture by mucosal atomisation device: midazolam (0.2 mg/kg) +ketamine (5mg/kg).~the calculated dose will be equally divided into the two nostrils by the parents"
3472595|NCT03860831|Active Comparator|intramuscular (IM)|"Group IM will receive intramuscular administration of liquid ketamine +midazolam mixture:midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.~Mild to moderate restraint was done with the help of the parents during drug administration."
3125991|NCT03013985|Experimental|Basal bolus insulin with glargine U300 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U300 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose described above will be given. Half of TDD will be given as glargine U300 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
3125992|NCT03013985|Active Comparator|Basal bolus insulin with glargine U100 and glulisine insulin|Subjects treated with insulin prior to admission will receive 80% of the total daily dose (TDD) given as basal bolus insulin regimen with glargine U100 once daily plus rapid-acting glulisine insulin before meals. In insulin-naïve subjects treated with oral agents, the oral antidiabetic drugs will be discontinued and the bolus insulin dose as described above will be given. Half of TDD will be given as glargine U100 and half as glulisine. To prevent hypoglycemia, if a subject is not able to eat, the dose of glulisine will be held.
3125993|NCT03014011|Other|Hypoglycaemic clamp first, then euglyceamic clamp|First intervention with a hypoglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with an euglycaemic clamp (approximately 5 hours).
3125994|NCT03014011|Other|Euglycaemic clamp first, then hypoglycaemic clamp|First intervention with an euglycaemic clamp (one examination day of approximately 5 hours), there after a wash out period of 21-42 days, then second and final intervention day with a hypoglycaemic clamp (approximately 5 hours).
3472596|NCT03860545||non-AKI|patient without acute kidney injury (AKI) during perioperative observation period
3472597|NCT03860545||AKI|patient with diagnosis acute kidney injury (AKI) established during perioperative observation period
3472598|NCT03860610||Patient group 1 after THA|Patients who have already received a THA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
3472599|NCT03860610||Patient group 2 after TKA|Patients who have already received a TKA (N=30) for OA will be assessed 1 year postoperatively (Visit A); Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
3472600|NCT03860610||Patient group 3 before THA|Patients with severe hip OA (N=30) scheduled to receive a THA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
3125995|NCT03014180|Experimental|"In-Clinic LVAT"|All subject prior to study enrollment has been implanted with a CRT-D device. During follow-ups, under the supervision of the physician, the algorithm embeded in the device is activated with a password. The feature is deactivated at the end of each follow-up.
3125996|NCT03014479|Experimental|Trelagliptin|Trelagliptin 100 mg, orally, once weekly for up to 12 weeks. Trelagliptin 50 mg, orally, once weekly for up to 12 weeks in patients with moderate renal impairment.
3125997|NCT03014479|Active Comparator|Daily DPP-4 inhibitors|An inhibitor orally administered at the dosage and administration in the package inserts for each drug, for up to 12 weeks.
3472601|NCT03860610||Patient group 4 before TKA|Patients with severe knee OA (N=30) scheduled to receive a TKA will be assessed preoperatively (Visit 1), 12 weeks postoperative (Visit 2) and 1 year postoperative (Visit 3). Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
3472602|NCT03860610||Healthy control group|Age-matched healthy control subjects (N=30);Interventions in this Group: 'Muscle strength test', 'Dynamic stability test during level and uphill walking', 'Postural stability test', 'EuroQol Group Health questionnaire (EQ-5D-5L)', 'HOOS/ KOOS', ' Muscle activity test', 'Passive range of motion'
3125998|NCT03014492|Experimental|Collar Group|Soccer girls that wore the collar device
3125999|NCT03014492|No Intervention|No Collar Group|soccer girls that did not wear the collar
3472603|NCT03860506|Experimental|PSI-697|
3126000|NCT03014674|Experimental|Liquid mepolizumab in safety syringe|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled syringe within a safety syringe according to randomization.
3472604|NCT03860506|Placebo Comparator|Placebo|
3472605|NCT03860740||High intensity physical exercise|Supervised Exercise Group: Customized and supervised exercise high intensity training program during 2-3 weeks previous surgery.
3126001|NCT03014674|Experimental|Liquid mepolizumab in an autoinjector|Subjects will receive a single dose of 100 mg liquid mepolizumab administered subcutaneously using a prefilled autoinjector, according to randomization.
3126002|NCT03014674|Active Comparator|Lyophilised mepolizumab from vial|Subjects will receive a single dose of 100 mg reconstituted lyophilized mepolizumab manually administered subcutaneously according to randomization
3472606|NCT03860740||Control|Supervised Stretching Group: a stretching and body balance classes will be developed to control the possible confounders and to control the exercise level of participants.
3472607|NCT03860818|No Intervention|Control Arm|Usual Care
3472608|NCT03860818|Experimental|Intervention Arm|Technology-enabled pharmacist intervention
3126003|NCT03014700|Active Comparator|Cryoprecipitate Arm|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
3472609|NCT03860519|Experimental|Intervention Group|"The components of the intervention unique to the treatment group include: 1) access to the Propeller Health Asthma App on his/her phone, which includes tracking of ICS and SABA usage; 2) receipt of NorthShore Connect physician alerts (these will be sent by the asthma nurse on behalf of the NS physician) if he/she has poor adherence ie missed 4 consecutive days of all of his/her controller medication dosages and their sensor has sent heartbeat to application OR at risk alerts if a patient transitions to a not well controlled or poorly controlled status (defined by the NHLBI guidelines); and 3) monthly phone calls with a nurse from his/her asthma doctor's office to review ICS and SABA usage reports (provided by Propeller Health on their Propeller Health dashboard)."
3472610|NCT03860519|Experimental|Control Group|The control group will not receive access to view the contents of the Propeller Health Asthma App on his/her phone, NorthShore Connect alerts for missing ICS or overuse of SABA, or for his/her asthma doctor (the asthma nurse will be viewing this information on behalf of the asthma doctor) to view his/her ICS and SABA use on the Propeller Health dashboard until after the 3-month study has been completed.
3472611|NCT03860532|Active Comparator|HMPL-011 tablets|A sigle total oral dose of 1200 mg tablets (600 mg tablet X 2)
3472612|NCT03860532|Active Comparator|HMPL-011 capsules|A sigle total oral dose of 1200 mg capsules (200 mg tablet X 6)
3472613|NCT03860792|Experimental|Ketogenic Diet|Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein as energy). The diet will encourage ≥4 servings of non-starchy vegetables and 1/2 cup of berries daily. Participants will be provided an emulsified medium chain triglyceride supplement with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
3472614|NCT03860792|Active Comparator|Therapeutic Lifestyles Changes Diet|Study partners will be instructed to assist participants in adherence to the Therapeutic Lifestyles Changes diet. The diet consists of 20-35% fat, 50-60% carbohydrate, and ~15% protein as energy. Fat intake will comprise <7% saturated fat, ≤20% monounsaturated fat, and ≤10% polyunsaturated fat as total energy. Cholesterol consumption will be ≤200mg per day. Participants are encouraged to eat ≥2 servings of fruit and ≥5 servings of vegetables per day.
3472615|NCT03860662|Active Comparator|Spastic hemiplegia , Botox|Botulinum toxin (BTX), being one of the most potent biological toxins, acts by blocking neuromuscular transmission via inhibiting acetylcholine release. Currently, focal spasticity is being treated successfully with BTX via injecting in the spastic muscles( Dose: 300-400 iu). Two antigenically distinct serotypes of BTX are available on the market as type A and B.
3472616|NCT03860662|Other|Spastic hemiplegia, Baclofen|Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The recommended dosing regimen is initiated with 5 mg 3 times a day. It can be increased by 15-mg/d increments at 3-day intervals as needed. Dosing should not exceed 80 mg/d.
3126004|NCT03014700|Active Comparator|Fibrinogen Concentrate Arm|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
3126005|NCT03015116|Active Comparator|Usual Care|Participants will complete 6 weeks of stretching and cryotherapy
3126006|NCT03015116|Experimental|PBM 10 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 10 Watts power) over 3 weeks
3126007|NCT03015116|Experimental|PBM 25 Watts|Participants will complete 6 weeks of stretching and cryotherapy, plus 9 treatments of PBM (810/980 nm continuous wave, 25 Watts power) over 3 weeks
3179295|NCT00671281|Placebo Comparator|A|This will be the control group which will take the placebo medication for 3 days before and six days after their functional endoscopic sinus surgery (FESS).
3179296|NCT00671294|Experimental|Ramelteon and Placebo QD (9 possible combinations total)|
3472617|NCT03860714||study group|400 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China].We do the neuropsychological tests,MMSE,CCI，CDR,QoR-40,GDS,CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，NRS once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
3472618|NCT03860571|Placebo Comparator|Placebo|
3472619|NCT03860571|Experimental|BT-11|
3472620|NCT03860441|Experimental|Intervention group|Participants in the intervention group received 24 sessions of computerized cognitive training, with a total time of 960 min.
3472621|NCT03860441|Active Comparator|Active control group|Participants in the control group attended activities separate activities, such as learning about healthy lifestyle, had cooking and other social lessons for the same amount as the intervention group performed cognitive training.
3179297|NCT00671307|Placebo Comparator|Placebo|Placebo
3179298|NCT00671307|Experimental|Low dose|3 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
3179299|NCT00671307|Experimental|Mid-dose|6 mg/kg of rhu-pGelsolin given as an IV infusion over 1 hour
3179300|NCT00671307|Experimental|High dose|6 mg/kg of rhu-pGelsolin given a an IV infusion over 1 hour once a day for 3 days
3472622|NCT03860558|Experimental|Lifestyle Intervention|20 overweight men with T1D or T2D will undergo an intensive 3 month lifestyle intervention program aimed at improving metabolic health, glycemic control, and body weight.
3472623|NCT03860558|Active Comparator|No-Intervention Controls|10 overweight men with T1D or T2D will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
3472624|NCT03860558|Active Comparator|Healthy Controls|10 healthy men will be assessed at baseline and at 3 months. They will not participate in a lifestyle intervention.
3126008|NCT03015142||New image-guidance software|Patients in this group had spine surgery with new image-guidance software application.
3126009|NCT03015181|Experimental|Group 1: 1 mg/kg IV Single Dose|Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
3472625|NCT03860675|Active Comparator|persons with Multiple Sclerosis (MS)|
3472626|NCT03860675|Placebo Comparator|Healthy controls|
3472627|NCT03860389|Experimental|Exercise effects on anxiety|An exercise programme will be administered 3 times a week for up to an 16 week period of time in a school setting. Each exercise class will last 60 minutes. The exercise classes will involve aspects of fundamental movement skills and will be fun for the students to participate in.
3472628|NCT03860688|Experimental|Teduglutide + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
3472629|NCT03860584|Experimental|MFGM-enriched full-fat dairy milk|Participants in this arm will receive MFGM-enriched full-fat dairy milk (3 servings/d) that contains MFGM at 10% phospholipid (relative to total lipid content) delivering MFGM at ~10-times that in full-fat dairy milk.
3472630|NCT03860584|Placebo Comparator|Soy phospholipid/lecithin milk|Participants in this arm will receive a matched dairy milk that instead contains soy phospholipid/lecithin.
3472631|NCT03860493||Study group|Only patients who might benefit from intraoperative fluorescent tissue perfusion assessment according to the primary surgeon will be enrolled in the study. The patients will be screened and consent during their office visit with their surgeon at the Cleveland Clinic Foundation. Each surgeon will follow the standard Open surgical protocol of his/her subspecialty, and will comply with the following additional steps according to the type of surgery:
3472632|NCT03860636||Fresh Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at three different points during their treatments.~The day they receive their HCG trigger,~The day of transvaginal oocyte retrieval (TVOR) and~The day of embryo transfer (ET)."
3472633|NCT03860636||Frozen Embryo Transfer|"Women will be invited to attend and have transvaginal ultrasound scans (TVUS) and blood tests at two different points during their treatments.~The day we coordinate with embryologist (day of progesterone +/-1)~The day of embryo transfer (ET)."
3472634|NCT03860480|Active Comparator|ESP with Bupivacaine 0.5%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of bupivacaine at a concentration of 0.5% with epinephrine 1:200 000 will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
3472635|NCT03860480|Sham Comparator|ESP with Saline 0.9%|"The Erector Spinae Block (ESP) will be performed using the method described by Forero et al and Hamilton et al. in 2017 by an expert regional anesthesiologist.~Thirty milliliters of a placebo solution (normal saline) will be injected depending on the patient's allocation.~Patient controlled analgesia (PCA) settings for both groups will remain the same: hydromorphone with a bolus of 0,2 mg, lockout time of 5 minutes and no background infusion. The PCA will be started when the patient is transferred to the postanesthesia care unit (PACU)."
3472636|NCT03860649|Experimental|Nordic Walking|The patient walk program consists of 3 moments: warm up, walk and stretch. They will do a brief free walking warm-up for 3 minutes in the Self-selected walking speed - SSWS (3 'SSWS), then walk according to the training cycle, the intensity will be between 60 to 80% of the Heart of Ratio reserve. In addition, the intensity of the classes will be measured in each phase by the Borg Scale of Perceived Exertion.
3472637|NCT03860649|Experimental|Jogging|This group will undergo 24 Dance sessions. Aquatic therapy patients will receive deep water running intervention with the use of flotation vests. The exercises will consist of: immersion, balance, strength, agility, and movement within the water. The intensity of the classes will be measured in each moment and by the Borg Scale of Perceived Exertion.
3472638|NCT03860649|Experimental|Dance|This group will undergo 24 Dance sessions inspired by Forró dance rhythm and Samba dance rhythm. Classes will be divided into four stages: Joint warm up and stretching on the chairs; strengthening, balance and rhythm exercises with the support of the barre; exercises inspired by the Samba and Forró dance (Brazilian ballroom dance) basic steps; and Final cool down. The intensity of the classes will be measured according to the beats per minute (BPMs) of the songs used in each moment and by the Borg Scale of Perceived Exertion.
3472639|NCT03860649|Experimental|Pilates Training|"Classes composed of three phases: Warming up, main part and back to calm. Warming up will begin with pre-Pilates training exercises for 5 minutes (eg. breathing exercises, hip joint mobilization, shoulder girdle, etc.), the main part of the lesson will be the Pilates training drill sequence for the beginner level that will be conducted for 50 minutes in which all exercises will be performed on the floor.~The sequence of the eighteen exercises of the main part of the lesson is described in the table below. Back to Calm: will be carried out for 5 final minutes with standing exercises with the subject reclining on the wall to reconnect the subject with orthostatic posture.~In the each of the phases of the lesson will be shown to the subject the table of BORG with the objective of measuring the intensity of perceived exertion, using the Borg Scale of Perceived Exertion."
3472640|NCT03860350|Active Comparator|Aged Garlic Extract|The participants will ingest 600 mg of Aged Garlic Extract in two capsules two times a day i.e. 1200 mg/day during a period of one year.
3472641|NCT03860350|Placebo Comparator|Placebo|The participants will ingest 600 mg of placebo in two capsules two times a day i.e. 1200 mg/day during a period of one year.
3472642|NCT03860415|Experimental|Probiotic|Vivomixx
3472643|NCT03860415|Placebo Comparator|Placebo|
3472644|NCT03860454||Lamin DCM (LMNA+)|Adults with known pathogenic lamin (LMNA+) gene mutation.
3472645|NCT03860454||Wild types DCM (DCMwt)|Adults with heart muscle failure but normal (wild-type) LMNA gene (DCMwt).
3472646|NCT03860454||Healthy Volunteers (HV)|Matched healthy volunteers (HV).
3472647|NCT03860428|Active Comparator|Rectal ibuprofen|Early treatment of PDA that starts within the first 3 days of life using rectal ibuprofen q24h for 3 days, dosages: 20 mg/kg + 10 mg/kg + 10 mg/kg
3472648|NCT03860428|Active Comparator|Intravenous paracetamol|Early treatment of PDA that starts within the first 3 days of life using intravenous paraceta-mol 15 mg/kg q6h for 3 days
3472649|NCT03860428|Sham Comparator|Expectant Treatment|Expectant PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA unless defi-nitely needed based of the predefined infant's condition.
3472650|NCT03860805|Active Comparator|Laparoscopic tubal ligation|Patients who seek for surgical permanent contraception and randomized to laparoscopic tubal ligation
3126010|NCT03015181|Experimental|Group 2: 5 mg/kg IV Single Dose|Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
3179301|NCT00671320|Active Comparator|Arm 1|
3472651|NCT03860805|Active Comparator|Laparoscopic bilateral salpingectomy|Patients who seek for surgical permanent contraception and randomized to laparoscopic bilateral salpingectomy
3472652|NCT03860402||Pre-warmed drug|Pre-warmed (38°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
3472653|NCT03860402||Room temperature drug|Room temperature (20°C) ropivacaine (7.5mg/ml) 19ml and fentanyl 50ug are injected via the epidural route at the L3-4 interspace.
3472654|NCT03860363||Treatment Group|Patients selected to participate.
3472655|NCT03860337|Experimental|Alginate then Control|This group will be given the alginate then the control sausages
3472656|NCT03860337|Experimental|Control then Alginate|This group will be given the control then alginate sausages
3472657|NCT03860376||Chemorefractory or relapsed patients|We intend to enroll chemorefractory or relapsed pediatric patients with all types of cancers where tumor tissue would be available for ex vivo drug screening and genomic profiling. The results of the drug sensitivity assay and genetic screening will be used to inform treating physician about patient-specific drug sensitivity or resistance guiding best therapy choices.
3472658|NCT03860324|No Intervention|Control-group|No peripheral nerve block
3472659|NCT03860324|Experimental|Single-shot erector spinae plane block|The patient is positioned in lateral decubitus. The anesthesiologist uses a linear high-frequency probe in a longitudinal direction laterally to the mid-sagittal plane at the level of L4 until the transverse process is identified and, more superficial, the erector spinae muscle. A 22G needle of 80mm is introduced in-plane craniocaudally towards the transverse process of L4 until its tip is in the plane deep to the erector spinae muscle. Single-shot block with 30ml of ropivacaine 0,5% + adrenaline 100mcg
3472660|NCT03860324|Active Comparator|Single-shot fascia iliaca block|The patient is positioned in dorsal decubitus. The anesthesiologist uses a linear high-frequency probe in a transversal direction, below the crural arch so as to identify the femoral artery. Afterwards the probe is moved laterally to find the iliac muscle and its fascia. A 22G needle of 80mm is introduced in-plane latero-medially until its tip is below the fascia iliaca (between the muscle and its fascia). Single-shot block with 40ml of ropivacaine 0,2%.
3472661|NCT03860298|Experimental|NaviFUS System|FUS treatment for 10 minutes
3472662|NCT03860233|Experimental|Visit 1 Randomization|At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
3472663|NCT03860233|Experimental|Visit 2 Crossover Randomization|At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.
3472664|NCT03860142||full-term child born|use of a new scale to rate the severity of food disorders on full-term child born
3472665|NCT03860142||premature child born|use of a new scale to rate the severity of food disorders on premature child born
3472666|NCT03860012|Experimental|Folic Acid 800 mcg once weekly|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
3472667|NCT03860129|Other|ISO|Drug name: Isoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (0.5 Vol%)
3472668|NCT03860129|Other|SEVO|Drug name: Sevoflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (1.0 Vol%)
3472669|NCT03860129|Other|DES|Drug name: Desflurane Dosage form: inhalational Dosage: ml/h Concentration: 0.5 MAC (3.0 Vol%)
3472670|NCT03859947||Patients with acute bronchiolitis|
3472671|NCT03860311|Experimental|Bladder Ultrasound|The bladder ultrasound group will undergo point-of-care ultrasound upon enrollment, and bladder ultrasound will be repeated every 30 minutes, unless the patient's bladder is full at time of initial scan.
3472672|NCT03860311|Active Comparator|Standard of Care|Bladder (Urethral) Catheter group. The standard of care group will undergo placement of a urethral bladder catheter to allow retrograde filling of the bladder.
3472673|NCT03860168|Other|PICU Up! pre- and post-implementation|Each unit will begin in the baseline, usual care phase and then be randomized to implement the PICU Up! program during a set time period, followed by the post-implementation phase.
3472674|NCT03860116|Experimental|Intervention group|participants in this arm receive the APP-based case management service and standard-of-care followup service.
3472675|NCT03860116|Active Comparator|control group|participants in the control arm receive standard-of-care followup service
3472676|NCT03860220|Active Comparator|NEWSTATIN TS|Triple therapy (Telmisartan + Amlodipine + Rosuvastatin 40/5/10mg)
3472677|NCT03860220|Placebo Comparator|CADUET|Dual therapy (Amlodipine + Atorvastatin 5/10mg)
3472678|NCT03860207|Experimental|Hu3F8-BsAb|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle. In cycle 1, blood is drawn for PK studies.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
3472679|NCT03860259|Placebo Comparator|Control|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with an empty cryopuncture with no nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
3472680|NCT03860259|Active Comparator|Intervention|Auriculotherapy will be performed by PI using a cryopuncture device in the pre-operative setting with nitrogen gas. The patient will receive an interscalene nerve block, standard of care treatment for surgery, post-operative pain management, and physical therapy.
3472681|NCT03860194|Experimental|Supp group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Supp group were provided with Protison with High Protein 51(Original Flavor) containing supplements in addition to their regular daily meals to achieve 1.5 g protein/kg (BW)/day on the basis of this guideline."
3472682|NCT03860194|No Intervention|Diet group|"Each participant received nutritional counseling and recommended each of them to consume 1.5 g protein/kg body weight (BW)/day. Participants were encouraged to consume a balanced diet with six food groups follow Daily dietary guideline of 2013  as recommended by the Ministry of Health and Welfare of Taiwan. However, 1.2 g protein/kg body weight (BW)/day was suggested from this guideline.~Subjects in the Diet group were instructed to consume ordinary high protein foods to achieve 1.5 g protein/kg body weight (BW)/day on the basis of this guideline, and suggested to equally distribute their meal time."
3126011|NCT03015181|Experimental|Group 3: 5 mg/kg SC Single Dose|Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
3126012|NCT03015181|Experimental|Group 4: 20 mg/kg IV Single Dose|Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
3472683|NCT03860025||Single dislocation.|Patients with a single postoperative hip dislocation without subsequent revision surgery.
3472684|NCT03860025||Recurrent dislocation.|Patients with two or more postoperative hip dislocations without subsequent revision surgery.
3472685|NCT03860025||Revision due to dislocation.|Patients with one or more postoperative hip dislocations with subsequent revision surgery due to recurrent instability.
3472686|NCT03860025||Controls.|Matched patients without postoperative hip dislocation or revision of any reason.
3472687|NCT03859986|Experimental|ALX-101 Gel 5%|ALX-101 Gel 5% applied topically twice daily for 56 days
3472688|NCT03859986|Placebo Comparator|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle applied topically twice daily for 56 days
3472689|NCT03860090|Active Comparator|AXILLARY VEIN ACCESS|This group of subjects will receive the implant of device via fluoroscopy-guided axillary puncture technique.
3472690|NCT03860090|Active Comparator|CEPHALIC VEIN ACCESS|This group of subjects will receive the implant of device via optimized cephalic vein cutdown technique.
3472691|NCT03859934|Active Comparator|Melatonin|10 mg melatonin each day 1 hour before bedtime for 3 months
3472692|NCT03859934|Placebo Comparator|Placebo|Placebo each day 1 hour before bedtime for 3 months
3472693|NCT03859908|Experimental|Iodine-Povacrylex Alcohol|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of Iodine-povacrylex 7mg/ml plus isopropyl alcohol 0.74 ml/ml (DuraPrep) , fabricated by 3M, as the experimental intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Centers of Disease Control
3472694|NCT03859908|Active Comparator|Chlorhexidine Alcohol|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML: preoperative asepsis with subject already lying down in the operating room, already with anesthesia, before dressing and incision, with single dose applicator of chlorhexidine 20 mg/ml plus isopropyl alcohol 0.7 ml/ml (SoluPrep), fabricated by 3M, as the control intervention. Will be applied from the center of the abdomen centrifuge as recommended by the Center of Disease Control
3472695|NCT03860077|Experimental|Very Low Nicotine Content Cigarettes|
3472696|NCT03860077|Active Comparator|Normal Nicotine Content Cigarettes|
3472697|NCT03859921|Experimental|Dydrogesterone group|Oral dydrogesterone 10mg tds will be given for two weeks from the next day of the LH surge or hCG induced ovulation.
3472698|NCT03859921|Placebo Comparator|Placebo group|Placebo will be given given for two weeks from the next day of the LH surge or hCG induced ovulation.
3472699|NCT03859895||Observational (without bone scan)|Former Observational Arm participants of the ZiPP trial.
3472700|NCT03859895||Observational (with bone scan)|Former Interventional Arm participants of the ZiPP trial.
3472701|NCT03859518||patients with Vitiligo|
3472702|NCT03859518||control|
3472703|NCT03859856||women with Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus
3472704|NCT03859856||women without Type 1 diabetes mellitus|Reproductive age women diagnosed with type 1 diabetes mellitus to serve as control
3126013|NCT03015181|Experimental|Group 5: 40 mg/kg IV Single Dose|Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
3126014|NCT03015181|Experimental|Group 6: 5 mg/kg SC Multiple Doses|Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
3126015|NCT03015181|Experimental|Group 7: 20 mg/kg IV Multiple Doses|Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.
3126016|NCT03015194|Experimental|Laceration of Anterior Mitral Leaflet in Mitral Valve Failure Participants With no Surgical Option|The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TMVR. These are all guided by fluoroscopy combined with transesophageal echocardiogram (TEE) or intracardiac echocardiography.
3126017|NCT03015220|Experimental|Oral semaglutide 3 mg|
3126018|NCT03015220|Experimental|Oral semaglutide 7 mg|
3472705|NCT03859583|Experimental|Capsaicin|4 tsp of cayenne pepper in a 60g omelette
3472706|NCT03859583|Placebo Comparator|Control|60 g omelette
3472707|NCT03859830|Experimental|Artis Dialysis System|One midweek HDF session for a duration of 4 hours.
3472708|NCT03859830|Active Comparator|AK200 Ultra S|One midweek HDF session for a duration of 4 hours.
3472709|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose A|Resected participants are administered with Pancrelipase dose A. At week 1,5, or 9, participants who meet dose modification criteria will be administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
3472710|NCT03859869|Experimental|Resected Participants Receiving Pancrelipase Dose B|Resected participants are administered with Pancrelipase dose B. Participants will also receive a matching placebo for blinding purposes.
3472711|NCT03859869|Experimental|Non-Resected Participants Receiving Pancrelipase Dose B|Non-resected participants are administered with Pancrelipase dose B.
3472712|NCT03859570|Experimental|Pentoxifylline|Pentoxifylline and standard of care therapy
3472713|NCT03859570|Placebo Comparator|Placebo|Placebo and standard of care therapy
3472714|NCT03859531||CF patients planned to receive Orkambi|CF patients carrying the F508del mutation on both alleles planned to receive Orkambi therapy
3472715|NCT03859700|Experimental|DBV712 250mcg|
3472716|NCT03859687|Experimental|Intervention group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) plus a liquid oral vitamin A supplementation
3472717|NCT03859687|Experimental|Control group|PCV (Prevnar-13 Vaccine) and the hepatitis A vaccine (Havrix Vaccine) only, 'No vitamin A supplementation'
3472718|NCT03859882|Experimental|Caffeine|Caffeine 5 mg/kg/day in 2 administration (08:00 and 14:00) per day
3472719|NCT03859882|Placebo Comparator|placebo|in 2 administration (08:00 and 14:00) per day
3126019|NCT03015220|Experimental|Oral semaglutide 14 mg|
3126020|NCT03015220|Active Comparator|Dulaglutide 0.75 mg|
3126021|NCT03015532|Experimental|Cohort 1, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
3472720|NCT03859843|Active Comparator|PRP|
3472721|NCT03859843|Active Comparator|Chemical peeling (Salycilic acid)|
3472722|NCT03859843|Active Comparator|Chemical peeling (Jessenr's solution)|
3472723|NCT03859596||MGB/OAGB|Consequent group of patients who underwent MGB/OAGB
3472724|NCT03859765|Experimental|HCT Symptoms and Steps|HCT Symptoms and Steps participants will complete in-person (3) and video-conferencing (4) coping skills training and activity coaching sessions teaching cognitive behavioral coping skills to manage pain, fatigue, and distress and increase activity. Participants will be given a wireless activity tracker and a smartphone for accessing the study mobile app.
3472725|NCT03859765|No Intervention|HCT Education|HCT Education participants will receive 1 brief in clinic session prior to discharge home providing education related to symptom management and physical activity, and a wireless activity tracker. HCT Education participants will also receive 6 brief phone calls upon return home.
3472726|NCT03859778||pharmacy students|
3472727|NCT03859635|Active Comparator|Ultrasound guided Liposomal Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
3472728|NCT03859635|Active Comparator|Ultrasound guided Standard Bupivacaine Erector Spinae Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Buvicaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
3472729|NCT03859635|Active Comparator|Surgeon Infiltration|At the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
3472730|NCT03859648|Experimental|Bone Conduction Implant|All subjects will be implanted with the bone conduction implant.
3472731|NCT03859479|Experimental|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
3472732|NCT03859479|Active Comparator|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
3472733|NCT03859713|Experimental|PT followed by Switching to CBT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will switch to 8 weekly sessions of cognitive behavioral therapy (CBT) as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
3472734|NCT03859713|Experimental|PT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of evidence-based physical therapy (PT). At the 10-week follow-up participants who are non-responders to Phase I PT will receive 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I PT, he or she will receive up to 2 more PT sessions in Phase II of treatment.
3472735|NCT03859713|Experimental|CBT followed by Switching to PT in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of evidence-based physical therapy (PT) as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
3472736|NCT03859713|Experimental|CBT followed by Mindfulness in Phase II for nonresponders|Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
3472737|NCT03859726||Compliance group|6hLC≥10% NIRS Sublingual microcirculation
3472738|NCT03859726||Non compliance group|6hLC<10%
3472739|NCT03859440|Experimental|DSiHy (test lens)|
3472740|NCT03859440|Active Comparator|Silicone hydrogel soft contact lens CE-marked for daily use|
3472741|NCT03859492||Intermediate or high-risk breast cancer subjects|Subjects with a negative mammogram who are intermediate or high-risk for breast cancer will get supplemental screening with contrast enhanced digital mammography (CEDM)
3472742|NCT03859804|Experimental|Group 1|In Group 1, Patients detected with a PI-RADS (Prostate Imaging Reporting and Data System) ≥3 lesion on MpMRI underwent MpMRI-guided MRI- US fusion prostate biopsy. In this fusion biopsy, 12 core standard biopsy and 2-4 cores of biopsies from lesions defined on multiparametric prostate MRI
3472743|NCT03859804|Active Comparator|Group 2|In Group 2, patients who had no suspected lesions or had a PI-RADS <3 lesion on MpMRI underwent Transrectal ultrasound guided 12 core prostate biopsy (SPB).
3472744|NCT03859505|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
3126022|NCT03015532|Experimental|Cohort 1, Group 2: HTX-011|HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
3126023|NCT03015532|Placebo Comparator|Cohort 1, Group 3: Saline Placebo|Saline placebo via injection
3472745|NCT03859505|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) active.
3472746|NCT03859284|Active Comparator|flowable resin-composite|"3M flowable composite is a conventional restoration to treat anterior carious cervical lesions. considered to be the gold standard of the flowable composites.~other names: ''flowable composite ''"
3472747|NCT03859284|Experimental|self-adhering flowable|intervention one is moist bonding self adhering flowable composite that binds to tooth without an adhesive system
3472748|NCT03859284|Experimental|self-adhering flowable with adhesive|intervention two moist bonding self adhering flowable composite that binds to tooth with the aid of adhesive system to improve the clinical performance
3126024|NCT03015532|Active Comparator|Cohort 1, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
3126025|NCT03015532|Experimental|Cohort 2, Group 1: HTX-011|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
3126026|NCT03015532|Experimental|Cohort 2, Group 2: HTX-011 + Ropivacaine|HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
3126027|NCT03015532|Placebo Comparator|Cohort 2, Group 3: Saline Placebo|Saline placebo via injection
3126028|NCT03015532|Active Comparator|Cohort 2, Group 4: Bupivacaine HCI|Bupivacaine HCl without epinephrine, 125 mg via injection
3179302|NCT00671320|Active Comparator|Arm 2|
3472749|NCT03859297|Experimental|Rumination-Focused CBT|RF-CBT is a manual-based treatment for prevention of depression, includes focus on ruminations, mental habits, concreteness training, and mindfulness.
3472750|NCT03859297|No Intervention|Treatment as Usual|Participants are allowed to continue any therapy outside of the treatment study.
3472751|NCT03859297|Active Comparator|Relaxation-based therapy|RelaxT includes an active comparison treatment that can be used to monitor and modify physiological responses to stress
3472752|NCT03859271|Experimental|brief motivational interviewing|Participants will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
3472753|NCT03859271|Placebo Comparator|Placebo Control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
3472754|NCT03859245|Experimental|Experimental group|Subjects in the experimental group will receive clinically prescribed meal plans designed to facilitate prolonged benign dietary ketosis (BDK) purposed at glucose regulation, improved insulin sensitivity and restored metabolic flexibility. Photobiomodulation therapy, via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
3472755|NCT03859245|Active Comparator|Control group|Subjects in the control group will follow current dietary protocol (Standard American Diet- SAD). Photobiomodulation therapy,via Joovv red light/infrared LED device, will be administered three times per week, 20 minutes per session.
3472756|NCT03859232|Experimental|Delta Dry® Pantaloon Group|
3472757|NCT03859232|Active Comparator|Cotton Padding Group|
3179303|NCT00671333|Active Comparator|1|(LRTI) Ligament reconstruction and tendon interposition
3472758|NCT03859362|Experimental|Ertapenem in urosepsis|Ertapenem PK studies were carried out on the 3rd dose of ertapenem administration. Blood samples (3 mL) were obtained by direct venipuncture at the following times: shortly before (time zero) and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after the start of ertapenem administration. All blood samples were added to a heparinized tube and centrifuged at 1,000 g for 10 min at 4°C within 5 min.
3472759|NCT03859375||2 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint two of a predefined area of the skin.
3472760|NCT03859375||3 paints of skin disinfectants|Standard microbial swabs (eSWAB) to do microbial skin counts in the disinfection area after paints of skin disinfectants will be taken by the operating room-nurses prior to skin disinfection and after paint three of a predefined area of the skin.
3472761|NCT03859180|Experimental|Focused breathing intervention group|Participants randomized to this group will be taught how to perform focused breathing for the self-management of anxiety and asked to practice for 4 minutes each day during a six week period. They may practice focused breathing in addition to the twice daily practices if they experience anxiety. They will be asked to document in a diary each time they practice focused breathing.
3472762|NCT03859180|No Intervention|Control group|The participants randomized to this group with not be required to perform any additional behaviors for the six week period of the study. After completing post-tests they will be taught how to perform focused breathing for the self-management of anxiety.
3472763|NCT03859466|Experimental|Intervention Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information: This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
3472764|NCT03859466|No Intervention|Control Arm|For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio
3472765|NCT03859817||Patients with albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
3472766|NCT03859817||patients with normo albuminuria|Comparison of eGFR values and ketonemia in diabetic patients
3179304|NCT00671333|Active Comparator|2|Ascension PyroDisk
3179305|NCT00671346||1|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg and vitamin B12 0.4 mg
3472767|NCT03859349|Active Comparator|Systematic Sampling|Patients will undergo systematic sampling of lymph node stations in the mediastinum with a minimum sampling of 3 stations: 4R, 4L and 7, as is the standard of care. Other stations may be included at the endoscopist's discretion. CLNS is not used for this arm.
3472768|NCT03859349|Experimental|Selective Targeted Sampling|"Patients will first undergo endosonographic assessment of 3 mediastinal lymph node stations (i.e. 4R, 4L, and 7) using the four criteria of the CLNS. Lymph node stations that exhibit a CLNS >1/4 will be biopsied as is standard of care. Lymph node stations with CLNS ≤ 1/4 will be marked as not requiring biopsy but will be biopsied nevertheless, so that there is no deviation from the standard of care. Other stations may be included at the endoscopist's discretion."
3472769|NCT03859141|Experimental|Experimental group-phase Ⅰ|Quadrivalent influenza vaccine
3472770|NCT03859141|Experimental|Experimental group-phase Ⅲ|Quadrivalent influenza vaccine
3472771|NCT03859141|Active Comparator|Control group 1-phase Ⅲ|Trivalent influenza vaccine (contains B/Victoria strain)
3472772|NCT03859141|Active Comparator|Control group 2-phase Ⅲ|Trivalent influenza vaccine (contains B/Yamagata strain)
3472773|NCT03859024|Active Comparator|Standard Protocol|Patients will receive the historical standard for pain management, which may include narcotics during and after surgery. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
3472774|NCT03859024|Experimental|Enhanced Recovery Protocol|A combination regimen of acetaminophen, Celebrex and gabapentin pre-op, with 30 mL of 0.5% bupivacaine and 4 mg of dexamethasone given as a perineal nerve block at the time of urethroplasty surgery. Narcotics will be administered judiciously and ass seen fit by the anesthesia and/or surgical teams. Postoperative prescriptions ibuprofen 800 mg, and acetaminophen 1000 mg to be taken on a scheduled basis then as needed. Another prescription for oxycodone will be given to be used only if needed.
3472775|NCT03859310||Normal|no glaucoma or retinal pathology or corneal conditions
3472776|NCT03859310||Glaucoma|diagnosis of glaucoma
3472777|NCT03859310||Retina|diagnosis of AMD, DR or other retinal pathology
3472778|NCT03859310||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
3472779|NCT03858998|Experimental|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
3472780|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
3472781|NCT03859401|Experimental|Control - Experimental Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Control-Experimental Arm will undergo the Control Admission first, utilizing an artificial pancreas (AP) controller that does not anticipate exercise (rMPC - naïve model predictive control), followed by the Experimental Admission, which will utilize an AP controller that has the ability to anticipate exercise (EnMPC - ensemble model predictive control). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
3472782|NCT03859401|Experimental|Experimental - Control Admissions|Subjects will be randomized following the Data Collection Phase in a 1:1 ratio. Subjects in the Experimental-Control Arm will undergo the Experimental Admission first, utilizing an artificial pancreas (AP) controller that has the ability to anticipate exercise (EnMPC), followed by the Control Admission, which will utilize an AP controller that does not have the ability to anticipate exercise (rMPC). During the 36-hour admissions, subjects will begin using the study AP system (control or experimental) on Day 1 around midday with a scheduled exercise activity in the evening. Day 2 will consist of minimal activity and subjects will be discharged in the evening on Day 2.
3472783|NCT03859011|Experimental|Acupuncture|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks), then no acupuncture between 10 weeks and 6 months. After treatment is completed, final measurement instruments are applied at 6 months. Questionnaires will be readministered at 2.5 and 6 months.
3472784|NCT03859011|Placebo Comparator|"Usual care"|After obtaining baseline data and questionnaires, patients will receive usual care (for example physical therapy, oral pain medication or ointments) for 6 months. Questionnaires will be readministered at 2.5 and 6 months. After the control phase the participants will continue usual care (for example physical therapy, oral pain medication or ointments), plus acupuncture 2X/week over 2 weeks, then once per week over 8 weeks (12 total treatments over 10 weeks, 8.5 months), then no acupuncture between 8.5 months and 12 months.
3472785|NCT03859193|No Intervention|Standard care|
3472786|NCT03859193|Experimental|Video|Participants will watch an Nutritional video at their second high risk visit
3472787|NCT03859050|Experimental|LPS arm|
3472788|NCT03859154||Viper bite victims|Snakebite victims in whom the snake has been brought and positively identified as Viperidae AND simultaneous aPTT has been sent AND consenting to be part of the study
3472789|NCT03859154||Nonvenomous snakebite|"age and gender matched victims of snake bite in whom the culprit snake brought along has been identified as a non venomous one.~AND consenting to be part of the study"
3472790|NCT03859102|No Intervention|ERAS Control/non-ERAS group|Standard usual care after cardiac surgery.
3472791|NCT03859102|Experimental|ERAS group|"Enhanced Recovery After Cardiac Surgery. Pre-op carbohydrate drink, Lansoprazole and Gabapentin.~Intra-operative: IV Paracetamol, Dexamethasone, Ondansetron, Local Anaesthetic to wounds.~Post-op: Gabapentin PO, Paracetamol IV then PO, Ondansetron IV for 24hrs. Opiate sparing. Early extubation, early mobilisation, early removal of invasive devices. Early discharge."
3472792|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3126029|NCT03015649|Experimental|SCOUT device|"The study population consists of 25 - 35 adult surgical patient volunteers who plan to have definitive breast cancer surgery at Memorial Healthcare System (MHS) Hospitals after neoadjuvant treatment.~The investigator will identify subjects who meet inclusion/exclusion criteria, obtain patient's consent and schedule the subject for the SAVI SCOUT Surgical Guidance System procedure. All study participants will receive the same treatment assignment, i.e. lesion localization with the SCOUT device 31 - 365 days prior to surgery. Neoadjuvant treatment decisions will be determined by patient's medical oncologist."
3472793|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472794|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472795|NCT03859219|Experimental|Dose 1 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472796|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472797|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472798|NCT03859219|Experimental|Dose 2 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3126030|NCT03015961|Active Comparator|EXPAREL admixed with bupivacaine HCl|EXPAREL 266 mg + bupivacaine HCl
3126031|NCT03015961|Placebo Comparator|Bupivacaine HCl|Bupivacaine HCl
3472799|NCT03859219|Experimental|Dose 3 of rozanolixizumab in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of rozanolixizumab in order to maintain the blinding.
3472800|NCT03859219|Placebo Comparator|Placebo in Japanese subjects|Japanese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
3472801|NCT03859219|Placebo Comparator|Placebo in Chinese subjects|Chinese subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
3472802|NCT03859219|Placebo Comparator|Placebo in Caucasian subjects|Caucasian subjects will be randomized to receive a predefined dosage of placebo in order to maintain the blinding.
3472803|NCT03858985|Active Comparator|Transcutaneous Vagus Nerve Stimulation|Cervical Transcutaneous vagus nerve stimulation. Participants will undergo once daily cervical transcutaneous vagus nerve stimulation.
3472804|NCT03858985|Sham Comparator|Sham Vagus Nerve Stimulation|Sham Cervical Transcutaneous Vagus Nerve Stimulation. Participants will undergo once daily sham cervical transcutaneous vagus nerve stimulation.
3472805|NCT03859037|Experimental|Umbilical cord milking|One group will have umbilical cord milking and will ba assessed for blood pressure,oxygen saturation and heart rate by monitor
3472806|NCT03859037|Placebo Comparator|Immediate cord clamping|One group will have immediate cord clamping and will be assessed for bloob pressure,heart rate,oxygen saturation by monitor
3472807|NCT03859115|Active Comparator|preanesthesia-TENS|Patients in preanesthesia-TENS group receive TENS for 30 minutes at one arm before anesthesia.
3472808|NCT03859115|Sham Comparator|preanesthesia-sham|Patients in preanesthesia-sham group receive sham stimulation for 30 minutes at one arm before anesthesia.
3472809|NCT03859115|Experimental|sevoflurane-TENS|Patients in sevoflurane-TENS group receive TENS for 30 minutes at one arm under sevoflurane anesthesia.
3472810|NCT03859115|Active Comparator|sevoflurane-sham|Patients in sevoflurane-sham group receive sham stimulation for 30 minutes at one arm under sevoflurane anesthesia.
3126032|NCT03016078|Other|Mepilex Border Post-Op Ag Dressing|A soft silicone foam dressing that absorbs wound exudate maintains a moist wound healing environment and has antimicrobial properties
3126033|NCT03016312|Experimental|Atezolizumab + Enzalutamide|Participants will receive atezolizumab along with enzalutamide until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
3179306|NCT00671346||2|Participants in NORVIT and WENBIT allocated to daily oral treatment with folic acid 0.8 mg, vitamin B12 0.4 mg and B6 40 mg.
3179307|NCT00671346||3|Participants in NORVIT and WENBIT allocated to daily oral treatment with vitamin B6 40 mg.
3472811|NCT03859115|Experimental|propofol-TENS|Patients in propofol-TENS group receive TENS for 30 minutes at one arm under propofol anesthesia.
3472812|NCT03859115|Active Comparator|propofol-sham|Patients in propofol-sham group receive sham stimulation for 30 minutes at one arm under propofol anesthesia.
3472813|NCT03859076|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
3179308|NCT00671346||4|Participants in NORVIT and WENBIT allocated to daily oral treatment with placebo
3472814|NCT03859076|Active Comparator|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
3472815|NCT03859206|Experimental|empyema patients having medical thoracoscopy|"patients having empyema will undergo medical thoracoscopy as follow :~With the closed biopsy forceps, step by step, fibrinous septae will be perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.~the intervention : is breaking the septation within the loculated empyema"
3472816|NCT03859206|No Intervention|tube thoracostomy in patients with empyema|after confirmation of diagnosis of empyema Following , a chest tube (gauge 26-28) will be introduced and connected to underwater seal. The wound was then closed around the tube by stitches to fix it in position.
3472817|NCT03858972|Experimental|Tesetaxel (oral) and capecitabine (oral)|"Cohort 1: Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle.~Cohort 2: On Cycle 1, Day -1, either a single morning dose of capecitabine at 825 mg/m2 (Cohort 2A) or 1,250 mg/m2 (Cohort 2B). On Cycle 1, Day 1, a single dose of tesetaxel (27 mg/m2), followed 2 hours later by capecitabine (825 mg/m2), followed by an evening dose of capecitabine (825 mg/m2). Capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the morning dose on Day 2 through evening dose on Day 14 of Cycle 1. Starting with Cycle 2, tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle."
3472818|NCT03858959|Experimental|HYBENX® Oral Tissue decontaminantTM (HBX)|HYBENX® Oral Tissue decontaminantTM is a concentrated aqueous solution of sulfonated aromatics and free sulphates. Once placed onto susceptible organic material, the product instantly absorbs free and electrostatically bonded water, denaturing the molecular structure of the organic matter. Biofilm is expected to be especially sensitive to the disruptive action of HBX solution by virtue of its porous structure and high water content.
3126034|NCT03016312|Active Comparator|Enzalutamide|Participants will receive enzalutamide alone until investigator-assessed confirmed radiographic disease progression per PCWG3 criteria or unacceptable toxicity (up to approximately 42 months).
3126035|NCT03016325|Experimental|Part 1 Cohort 1 HNO Donor|
3126036|NCT03016325|Placebo Comparator|Placebo Part 1 Cohort 1|
3126037|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- low dose|
3472819|NCT03858959|Active Comparator|Chlorhexidine Digluconate CorsodylTM (CHX)|Chlorhexidine Digluconate CorsodylTM Dental Gel 1% is an antiseptic gel with cationic nature, effective against a wide range of Gram positive and negative bacteria, favourable to the plaque control and oral inflammation prevention.
3472820|NCT03858946|Sham Comparator|Simple trapeziectomy|Simple trapeziectomy with two sham incisions for primary thumb carpometacarpal osteoarthritis
3472821|NCT03858946|Experimental|Weilby|Ligament reconstruction interpositions arthroplasty modo Weilby for primary thumb carpometacarpal osteoarthritis
3472822|NCT03858933|Experimental|Limbic Modulation Index Neurofeedback|"This arm of the study will undergo a novel neurofeedback treatment, targeting downregulation of deep limbic structures, specifically the amygdalae.~Participants in this arm will complete 15 neurofeedback sessions."
3126038|NCT03016325|Experimental|Part 2 Cohort 2 HNO Donor- high dose|
3472823|NCT03858933|Active Comparator|Alpha/Theta Neurofeedback|"This arm of the study will undergo a proven PTSD neurofeedback treatment, alpha/theta regulation, during which participants will try various mental strategies to increase the presence of theta waves.~Participants in this arm will complete 15 neurofeedback sessions."
3472824|NCT03858777|Active Comparator|Sarcoidosis patients without evidence of active myocarditis|A single blood draw.
3472825|NCT03858777|Experimental|Sarcoidosis patients with evidence of active myocarditis|Two blood draws 2 months apart.
3472826|NCT03858777|Active Comparator|Acute ST elevation myocardial infarction (STEMI)|Three blood draws, baseline, 6 hours and 24 hours.
3126039|NCT03016325|Placebo Comparator|Placebo Part 2 Cohort 2|
3472827|NCT03858777|Placebo Comparator|Healthy controls|A single blood draw
3472828|NCT03858725|Experimental|D569/CKD-374 5mg|"Period 1: D569 Tab. 1T~Period 2: CKD-374 5mg Tab. 1T"
3472829|NCT03858725|Experimental|CKD-374 5mg/D569|"Period 1: CKD-374 5mg Tab. 1T~Period 2: D569 Tab. 1T"
3472830|NCT03858660||Elderly|Healthy elderly No intervention.
3472831|NCT03858738||group A: women aged 25-49 years|"Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5.~Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device."
3472832|NCT03858738||Group B: Women aged 25-49 years or 50 ≥|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 1 or 2.Thermography examination was performed with the use of Braster device.
3126040|NCT03016403|Experimental|Stepped-Care Intervention|Intervention strategies are grounded in evidence-based Cognitive Behavioral Therapy (CBT), that includes stress management and relaxation treatment strategies and coping skills training. Treatment strategies have been adapted from the Transactional Model of Stress and Coping (TMSC), a theoretical model that predicts that individuals who are able to cope and adapt to the stress related to cancer treatment or caregiving will report less psychological distress than those unable to cope.
3126041|NCT03016403|Active Comparator|Enhanced Usual Care|Denver Health, St. Mary's and St. Joseph's hospitals provide supportive mental health care for patients such as printed materials, support groups, crisis counseling, and specialized care (e.g., psychiatric medication). Because the amount of usual mental health care that each patient receives varies at each site, the investigators will standardize and monitor the usual care arm across the three sites with an enhanced usual care condition.
3472833|NCT03858738||Group C: Woman aged 50 years or over|Patient who had breast ultrasound done and classified according to the BI-RADS US classification, and the result was in category 4 or 5. Patient with indications for biopsy unless breast biopsy was performed in the last 3 months (except for FNA). Thermography examination was performed with the use of Braster device.
3472834|NCT03858673||Ligations group|VTH via the Tsuzi method with residual uterine ligament ligation (ligations group)
3472835|NCT03858673||Without ligations group|Traditional VTH without residual uterine ligament ligation (without ligations group)
3472836|NCT03858621|Experimental|fentanyl NOL guided|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following a predeterminate NOL index + heart rate + mean arterial blood pressure variations.
3472837|NCT03858621|No Intervention|fentanyl standard analgesia|A bolus of 2 mcg/kg IV Fentanyl will be given at the induction of the anesthesia. A bolus of 0,5 - 1 mcg/kg IV Fentanyl will be given at the time of incision and during surgery following the heart rate and mean arterial blood pressure variations.
3472838|NCT03858829|Experimental|fear of movement scale|
3472839|NCT03858556||Patients with lumbar disc herniation|"3times(baseline, 1weeks, 2weeks) of Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion in inpatients with lumbar intervertebral disc herniation hospitalized at Korean medicine hospital.~-Integrative Korean medicine treatment Procedure/Surgery: Chuna manipulation Drug: Herbal medicine Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s) Other: Other intervention(s)"
3472840|NCT03858556||Normal|"baseline Observation of gait, Oswestry disability index, EQ5D-5L, Lumbar Range of motion.~-No treatment"
3472841|NCT03858751|Placebo Comparator|Placebo|Placebo capsule before bedtime
3472842|NCT03858751|Experimental|LTM1201AZ|LTM1201AZ capsule before bedtime
3472843|NCT03858751|Experimental|LTM1201AT|LTM1201AT capsule before bedtime
3472844|NCT03858751|Experimental|LTM1201AG|LTM1201AG capsule before bedtime
3472845|NCT03858751|Experimental|LTM1201AD|LTM1201AD capsule before bedtime
3472846|NCT03858816|Experimental|Mixture probiotics|The probiotic contain 1 ×10^9 CFU/1 capsule of mixture probiotics, taking 1 probiotic capsule for up to 4 months after birth.
3472847|NCT03858816|Placebo Comparator|Placebo|Taking 1 placebo capsule for up to 4 months after birth.
3472848|NCT03858569|Active Comparator|Oxytocin|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus
3472849|NCT03858569|Active Comparator|Oxytocin plus uterine massage|10 units of oxytocin will be given intramuscularly immediately after delivery of the fetus and transabdominal uterine massage will be performed.
3472850|NCT03858920||General Responder Cohort (GRC) WTC Responders|General Responder Cohort (GRC) and who have chosen to undergo annual medical monitoring and treatment of their WTC-related conditions at Mount Sinai's Irving J. Selikoff Center for Occupational and Environmental Medicine (SCOEM), which is directed by Dr. M. Crane
3472851|NCT03858920||General Responder Cohort (GRC) Non WTC Responders|Members of the World Trade Center General Non Responder Cohort.
3472852|NCT03858608|Experimental|Counterweight Plus|"Total Diet Replacement phase (0-12 weeks) 825-853kcal/day low energy liquid diet (LELD) for 12 weeks Food Reintroduction phase (13-18 weeks) Wk 13: 400kcal/d LELD + 1 low-fat meal/day (c. 360-400 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1000kcal/day Wk 15: 200kcal/d LELD + 2 low-fat meals/day (c. 720-800 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1200kcal/day.~Wk 17: 3 low-fat meals per day (c.1080-1200 kcal) + 2 servings of fruit, 200mls skimmed milk and free vegetables. Total intake: 1400kcal/day.~Weight maintenance phase (wks 19-52) Low-fat healthy eating weight loss maintenance intervention [target below 30% energy from fat, with flexibility to optimise individual compliance, to a maximum of 35%]"
3472853|NCT03858608|Active Comparator|Usual asthma care|Usual asthma management
3472854|NCT03858855|Experimental|Group I (bergamot essential oil)|Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
3472855|NCT03858855|Experimental|Group II (chamomile essential oil)|Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
3472856|NCT03858855|Experimental|Group III (ginger essential oil)|Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
3126042|NCT03016598|Experimental|Oxytocin|Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
3126043|NCT03016598|Placebo Comparator|Placebo|Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
3472857|NCT03858855|Active Comparator|Group IV (almond essential oil)|Patients inhale 7 drops of almond essential oil and complete journal as in group I.
3472858|NCT03858842||PF-ILD and SSc-ILD patients|PF-ILD and SSc-ILD patients
3472859|NCT03858790|Experimental|Experimental|Subjects' PINS spinal cord stimulator randomized to this arm is on always
3472860|NCT03858790|Sham Comparator|Control|Subjects' PINS spinal cord stimulator randomized to this arm is off for a week
3126044|NCT03017079|Experimental|semi-solidification with nutrient|"semi-solidification with nutrient:after infusion of semi-solid agent, enteral nutrition is applied less than 60 mins.~Intervention: Other: bolus Intermittent enteral feeding"
3126045|NCT03017079|Placebo Comparator|Standard enteral nutrition|"After infusion of Sterile Water for Injection,bolus Intermittent enteral feeding via the nasogastric tube is applied less than 60 mins.~Intervention: Other: Standard enteral feeding"
3126046|NCT03017235|Experimental|NaP/MC Oral Solution|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
3126047|NCT03017235|Active Comparator|PREPOPIK®|
3472861|NCT03858803|Active Comparator|FM2 first, LAST delayed|Parent intervention, Families Matter 2 (FM2), immediate, adolescent intervention, Living as a Safer Teen (LAST), delayed six months
3472862|NCT03858803|Active Comparator|FM2 and LAST simultaneous|Parents participate in Families Matter 2 (FM2) and adolescents in Living as a Safer Teen (LAST) intervention immediately following the baseline assessment.
3472863|NCT03858803|Active Comparator|Comparison arm|Comparison arm in which both parents and adolescents will be offered their respective interventions following the final assessment. Following the final assessment parents will be offered the Families Matter (FM2) intervention and youth the Living as a Safer Teen (LAST) intervention as an ethically justified service.
3472864|NCT03858881|Active Comparator|PROJECT PERSONALITY|
3472865|NCT03858881|Experimental|VR PERSONALITY PROJECT|
3472866|NCT03858881|Placebo Comparator|SHARING FEELINGS PROGRAM|
3472867|NCT03858868|Experimental|Church and park-based intervention|Participants at intervention churches will be offered: texting intervention (messages about physical activity); peer leader training; walking groups; park-based fitness classes; sermons; participation in park advisory board; community advocacy.
3126048|NCT03017261|Experimental|TSolution One®|This group will undergo total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
3472868|NCT03858868|Other|Publicly available physical activity materials|Participants at control churches will be offered standard health educational materials (brochures, tip sheets, posters) about physical activity.
3472869|NCT03858543|Experimental|Fractional laser treatment & Poly-L Lactic Acid (Sculptra)|One Fractional laser treatment on half of the body with Sciton Laser and Scluptra
3472870|NCT03858543|Active Comparator|Fractional laser treatment|One Fractional laser treatment on half of the body with Sciton Laser
3472871|NCT03858517||ReUnion TSA System|"Subject with one or more of the following diagnoses will be treated with the ReUnion TSA System:~Aseptic necrosis of the humeral head~Painful, disabling joint disease of the shoulder resulting from degenerative arthritis, rheumatoid arthritis or post-traumatic arthritis~Failed previous total shoulder replacement, resurfacing or other procedure"
3472872|NCT03858686|Active Comparator|400 mg FP-025 capsules|Based on a double-blind randomized schedule, 16 subjects will receive FP-025 capsules in Period 1 and matching placebo FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
3472873|NCT03858686|Placebo Comparator|FP-025 Placebo Capsules|Based on a double-blind randomized schedule, 16 subjects will receive matching placebo FP-025 capsules in Period 1 and FP-025 capsules in Period 2. Both study periods will follow the same schedule of procedures, with a washout period of at least 3 weeks and up to 7 weeks between study periods.
3472874|NCT03858530|Experimental|All Patients Enrolled|All patients will undergo limited abdominal US with Doppler and SWE once a week upon admission for conditioning until the patient day +30 BMT or discharge, whichever comes first. Additional ultrasounds will also be performed if SOS is suspected.
3472875|NCT03858582|Experimental|Arm A|Patients with R0 resection will receive pembrolizumab 200mg for 32 cycles.
3472876|NCT03858582|Experimental|Arm B|Patient who had R1 resection will receive radiation 52.8Gy/24Fx with pembrolizumab 200mg for 32 cycles. Patients who had R2 resection will receive radiation 59.4Gy/27Fx with pembrolizumab 200mg for 32 cycles.
3472877|NCT03858582|Experimental|Arm C|Patients who showed non-progressive disease (PD) to initial neoadjuvant therapy but remained unresectable will receive radiation 59.4Gy/27Fx with 200mg for 32 cycles.
3126049|NCT03017508|Experimental|BHV-0223 (Sublingual Riluzole)|Participants will be given one dose of BHV-0223 (sublingual riluzole) 35mg before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
3472878|NCT03858465|Active Comparator|25 mg of ephedrine|participants who will receive intravenous 1,25mg/min ephedrine during 20 minutes (total dosage is 25 mg of ephedrine).
3472879|NCT03858465|Active Comparator|0,3 mg of phenylephrine|participants who will receive intravenous 0,015mg/min phenylephrine during 20 minutes (total dosage is 0,3mg of phenylephrine).
3472880|NCT03858504|Experimental|Yoga Group|The yoga program will include breathing exercises, different postures, and meditation. The yoga will be performed in groups. The program will be supervised a physical therapist for two times in a week for eight weeks . A session will be fifty minutes (5-10 minutes: warming-up, 20-25 minutes: postures, 10-15 minutes: cooling down).
3472881|NCT03858504|Active Comparator|Home Exercise Group|Home exercise program will consist of trunk strengthening exercises. The patients will be asked to check the exercise days. Patients will be contacted with telephone once a week.
3472882|NCT03858426||Children with eosinophilic esophagitis|"Inclusion criteria:~Children from 1 month to 18 years with a new diagnosis of eosinophilic esophagitis according to recent European guidelines (symptoms of esophageal dysfunction + eosinophilic infiltrate of the esophagus > 15 eos / CGA)~And they need to start treatment with one of the following options: PPI, diet excluding cow's milk and gluten, or swallowed corticosteroids~Exclusion criteria:~Presence of pathological eosinophilia at the gastric or duodenal level (eosinophilic gastroenteritis)~Simultaneous treatment with more than one treatment modality (PPI, empirical elimination diet, swallowed corticosteroids)."
3472883|NCT03858452|Active Comparator|Pelvic floor muscles training group|Pelvic floor muscles exercises twice a day for 30 min
3472884|NCT03858452|Active Comparator|Diaphragm muscles training group|Breathing exercises twice a day for 30 min
3472885|NCT03858452|Active Comparator|Abdominal muscles training group|Abdominal muscles exercises twice a day for 30 min
3472886|NCT03858478|Experimental|Biktarvy arm|one tablet of BIKTARVY including [TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg) ] one tablet once a day for 48 weeks
3472887|NCT03858309|Experimental|Breathing Group 1|Arm 1 will receive an 8-week intervention that consists of a set of breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
3472888|NCT03858309|Active Comparator|Breathing Group 2|Arm 2 will receive an 8-week intervention that consists of slow breathing practices through 60-minute weekly group on-site sessions (1day/week) with a 20-minute daily home sessions (in between on-site sessions; 6 days/week).
3472889|NCT03858491|Experimental|Cobicistat|Cobicistat will serve as experimental drugs, and will be added to the regular treatment with osimertinib. Combination-treatment will be started at 150 milligram cobicistat, and can be increased to a maximum daily dose of 600 milligram cobicistat (four times 150 milligram).
3472890|NCT03858699||Individuals with stroke|Participants in sub-acute and chronic phases post-stroke (>1 month post-stroke) will be recruited for participation in this study.
3472891|NCT03858699||Adult control participants|Even age distributions will be recruited in the adult control group, stratified under 40 years old and over 40 years old.
3126050|NCT03017508|Placebo Comparator|Placebo|Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
3126051|NCT03017612|Experimental|Single Arm Study|Evaluating the safety and effectiveness of the raindrop near vision inlay implanted in bilateral pseudophakic subjects
3126052|NCT03017846|Experimental|Cantharidin Treatment|Subjects with lesions treated with topical cantharidin every 3 weeks up to 12 weeks.
3126053|NCT03017924|Experimental|Q collar|Subjects that will wear the Q collar during the breacher training
3126054|NCT03017924|No Intervention|No collar|Subjects that will not wear the Q collar during the breacher training
3126055|NCT03017937|Experimental|Q- collar|All subjects will wear 3 sizes of the q-collar and ultrasound images of the jugular vein will be measured with each collar. Also, each subject will wear a pressure collar and ultrasound images of the jugular vein will be captured at each pressure point (0.1-0.5)
3126056|NCT03018028|Experimental|Oral semaglutide 3 mg|
3126057|NCT03018028|Experimental|Oral semaglutide 7 mg|
3126058|NCT03018028|Experimental|Oral semaglutide 14 mg|
3472892|NCT03858322|Experimental|Carboplatin + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Carboplatin will be administered intravenously 3 times per cycle"
3472893|NCT03858322|Experimental|Cyclophosphamide + Paclitaxel|"Paclitaxel will be administered intravenously 3 times per cycle~Cyclophosphamide will be administered once per cycle"
3472894|NCT03858387||Meropenem|Critically ill patients who require meropenem therapy
3472895|NCT03858387||Imipenem|Critically ill patients who require imipenem therapy
3472896|NCT03858595|Experimental|Intervention|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. Investigators will train our study participants (high-risk pregnant women) on how to use Salu Health Gauge to measure BP as well as how to charge them. Trained FFWs will visit the households weekly and synchronize the device with a tablet computer to collect the stored data. The FFWs will measure the weight of the participants using a digital weighing scale at enrollment and on a monthly bases thereafter. Investigators will keep monitoring up to termination of pregnancy. in any health issue arises, our health worker will ensure that an appropriate referral is made to a tertiary care facility. This intervention will be in addition to the conventional antenatal and postnatal care."
3472897|NCT03858595|No Intervention|Control group|All those women randomized to the control arm will receive conventional antenatal and postnatal care only. Investigators will collect the outcome data from the households and/or the health centers by follow-up visits or over phone. Investigators will consell participants, women both in the control group, to make at least four antenatal visits. In addition, Investigators will provide counselling about eating healty and keeping physically active during pregnancy. Investigators will provide general nutrition education on taking balanced energy and protein diet.
3472898|NCT03858218||Pediatric cancer survivors group|Childhood cancer survivors refers to those who have completed cancer treatment for at least six months, the pediatric cancer survivors must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese.This group will be required to fill in the questionnaires set.
3126059|NCT03018028|Placebo Comparator|Oral placebo|
3126060|NCT03018028|Active Comparator|Liraglutide 0.9 mg|
3472899|NCT03858218||Healthy children group|Healthy children must be aged 9 - 17 years, and able to communicate in Cantonese and read Chinese. This group will be required to fill in the questionnaires set.
3472900|NCT03858413||Chronic kidney disease stage V|No intervention
3472901|NCT03858413||Chronic kidney disease stage III|No intervention
3472902|NCT03858101||PKU subjects|
3472903|NCT03858101||Age and sex-matched non-PKU comparison subjects|
3126061|NCT03018106|Experimental|Ospemifene|Women randomized to this arm will receive 60mg oral ospemifene, taken daily, for 12 weeks
3126062|NCT03018106|Active Comparator|Estrogen|Women randomized to this arm will receive 0.5mg vaginal conjugated estrogens, placed vaginally twice per week, for 12 weeks
3126063|NCT03018223|Experimental|Conditioning/HCT/GVHD Prophylaxis|"Pre-HCT Conditioning, HCT, GVHD Prophylaxis.~Conditioning regimen: To reduce heterogeneity, two commonly used myeloablative (MAC) and reduced intensity (RIC) regimens are permitted on this trial. Myeloablative conditioning: fludarabine, busulfan. Reduced intensity conditioning: fludarabine, cyclophosphamide, total body irradiation.~Peripheral blood hematopoietic cell transplantation~Graft vs. Host Disease (GVHD) prevention treatment: cyclophosphamide, mycophenolate mofetil, sirolimus.~Growth factor support: G-CSF"
3126064|NCT03018249|Active Comparator|Arm I (medroxyprogesterone acetate, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24.
3179309|NCT00671359|Experimental|after fast|Administration of a single oral dose of 600mg TR-701 to subjects in the fasted state.
3126065|NCT03018249|Experimental|Arm II (medroxyprogesterone acetate, entinostat, hysterectomy)|Patients receive medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Patients undergo hysterectomy between days 21-24.
3126066|NCT03018340|Experimental|Pimavanserin 34 mg + SSRI/SNRI|Drug- pimavanserin, 34 mg, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
3126067|NCT03018340|Placebo Comparator|Placebo + SSRI/SNRI|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
3472904|NCT03858231|Active Comparator|Opioid|
3472905|NCT03858231|Active Comparator|Non-opioid|
3472906|NCT03858192|Experimental|Elective colorectal surgery|Patients who are expected to undergo a major colorectal surgery procedure will be recruited to this study preoperatively and followed-up until three months postoperatively.
3472907|NCT03858192|Experimental|Emergency abdominal surgery|Patients who are admitted as an emergency and undergo abdominal surgery will be recruited from general surgery wards either preoperatively or within 48 hours of surgery. They will be followed-up until three month postoperatively.
3472908|NCT03858192|Experimental|Medical patients|Patients admitted under general medicine with an infection will be recruited from general medicine wards within 48 hours of admission. They will be followed-up until three month post-admission
3472909|NCT03858283|Experimental|Mindfulness Based Health Care Program|
3472910|NCT03858283|No Intervention|Control|
3472911|NCT03858270|Experimental|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
3472912|NCT03858270|Placebo Comparator|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week placebo will be administered at 10 mg tablet twice/day for 51 weeks.
3472913|NCT03858257|Experimental|High flow nasal oxygen|The gas temperature will commence at the 'High' setting (ranges 30-32º Celsius) and titrated downwards if the patient complains of irritation. The gas flow rate will commence at 30 liters per minute prior to sedation administration and be titrated up to 70 liters per minute as tolerated by the patient after sedation has been administered. The fraction of oxygen in the gas will be commenced at 50% (same as that delivered from 6 liters per minute via facemask) and can be titrated upward according to patient requirements (i.e. increased if there is evidence of hypoventilation, airway obstruction or inadequate oxygenation, decreased during use of diathermy). Anesthesia Assistants at the site will be provided with training in the use of this mode of oxygen delivery prior to study commencement.
3472914|NCT03858257|Other|Standard oxygenation|Supplemental oxygen through a facemask with the flow rate chosen by the clinician responsible for sedation as per their standard practice. The oxygen flow rate is typically commenced at 6 liters per minute and can be titrated up to 15 liters per minute.
3472915|NCT03858374|Experimental|Experimental group|Patients in experimental group were transferred by air-suspending mattress.
3472916|NCT03858374|Active Comparator|control group 1|Patients in control group 1 were transferred by slide board.
3472917|NCT03858374|Active Comparator|control group 2|Patients in control group 2 were transferred by bedsheet.
3472918|NCT03858244||IS with SDB|Idiopathic scoliosis with untreated and treated sleep-disordered breathing
3472919|NCT03858244||IS without SDB, controls|Idiopathic scoliosis without sleep-disordered breathing, control group
3472920|NCT03858127||Male infants born <32 weeks gestation|
3472921|NCT03858179|Experimental|PBMT + training/ PBMT + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
3472922|NCT03858179|Experimental|PBMT + training/ placebo + detraining|PBMT applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
3472923|NCT03858179|Experimental|Placebo + training/ PBMT + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and PBMT applied during the detraining period (4 weeks, 2 times a week).
3472924|NCT03858179|Placebo Comparator|Placebo + training/ placebo + detraining|Placebo applied before the strength training sessions (12 weeks, 2 times a week) and placebo applied during the detraining period (4 weeks, 2 times a week).
3472925|NCT03858153|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®) involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
3126068|NCT03018691|Experimental|0.3% OPA-15406 Ointments|Subjects were treated with assigned 0.3% OPA-15406 ointment twice daily.
3126069|NCT03018691|Experimental|1% OPA-15406 Ointments|Subjects were treated with assigned 1% OPA-15406 ointment twice daily.
3126070|NCT03018691|Placebo Comparator|Placebo Ointments|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
3126071|NCT03018925||Ulcerative Colitis|"The proposed study will include 15 UC anti-TNF naïve patients . We will consider remission when patients have an endoscopic Mayo score ≤1, and activity index score, Mayo= 0 points.~Stool samples will be collected before starting Anti-TNF treatment (M0), and then every 3 months (M1, M2, M3 and M4) to complete the study.~GOLIMUMAB induction with 200mg at week 0, and 100mg at week 2. Under 70kg, the follow up treatment will be 50mg/month, and 100mg/month in patients over 70kg, as clinical practice."
3126072|NCT03018938|Experimental|Insulin Analog Mid Mixture|Insulin analog mid mixture given subcutaneously (SC).
3472926|NCT03858153|Active Comparator|Nutrition Education|Nutrition education involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
3472927|NCT03858166|Active Comparator|Standard group|6mg PEG-rhG-CSF was administrated subcutaneously in 24h after chemotherapy.
3472928|NCT03858166|Experimental|Adjusted group|6mg PEG-rhG-CSF was administrated subcutaneously when ANC < 1000/mm3 after chemotherapy.
3472929|NCT03858062|Active Comparator|Open loop|14 days patient-managed Insulin pump therapy (with or without glucose sensor) with blinded continuous glucose monitoring
3472930|NCT03858062|Experimental|Closed loop|4-6 training + 14 days automated blood glucose control with the Artificial pancreas (Inreda Diabetic)
3472931|NCT03858114|Experimental|Mild-to-moderate physical activity|Three sessions/week, for 12 weeks, of mild-to-moderate physical activity, of mixed type (aerobic-anaerobic), supervised by expert and qualified personnel (physical education instructors) and performed in a gym.
3472932|NCT03858114|Active Comparator|Cultural group program|Cultural group program with thematic meetings and one visit/week to places of historical and artistic interest in the city of Cagliari, Sardinia, accompanied by expert guides (accredited tour guides).
3472933|NCT03858439|Experimental|Intervention|Single arm study. All participants will receive dietary intervention.
3472934|NCT03857958|Experimental|FCSEMS|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In FCSEMS group, patients are inserted with Fully covered self-expandable metal stent (FCSEMS) bilaterally for malignant hilar biliary stricture via endoscopic retrograde cholangio-pancreatography.
3472935|NCT03857958|Active Comparator|Plastic stent|In patients with malignant hilar biliary obstruction, endoscopic drainage is performed for biliary drainage. Since intrahepatic bile ducts are separated, it is preferable to insert a stent into bilateral intrahepatic bile ducts for bile drainage if possible. In plastic stent group, patients are inserted with plastic stents bilaterally for malignant hilar biliary stricture.
3472936|NCT03858088||Training set|Cohort of consecutive liver transplants performed in 2016-2017 from 14 liver transplant centers in Italy
3472937|NCT03858088||Validation set|Cohort of consecutive liver transplants performed in 2016-2017 from 2 liver transplant centers in the United Kingdom
3472938|NCT03858075|Experimental|Single ascending doses with BLU-782|
3472939|NCT03858075|Placebo Comparator|Single ascending doses with placebo|
3472940|NCT03858075|Experimental|Multiple ascending doses with BLU-782|
3472941|NCT03858075|Placebo Comparator|Multiple ascending doses with placebo|
3126073|NCT03018938|Experimental|Basal Insulin Analog|Basal insulin analog given SC.
3126074|NCT03019055|Experimental|CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
3179310|NCT00671359|Experimental|After high fat food|Administration of a single oral dose of 600mg TR-701 to subjects in the fed state.
3179311|NCT00671372|Experimental|Cohorts 1-5|
3179312|NCT00671372|Experimental|Cohorts 6, 6A, 7, 7A|
3472942|NCT03858075|Experimental|Food effect of BLU-782 taken with food|
3472943|NCT03858075|Experimental|Food effect of BLU-782 taken without food|
3472944|NCT03857984|Experimental|Erythrocyte Fatty-Acid Status|Erythrocyte Fatty-Acid Status Profiling of HD patients are studied before and after a single HD using LC-MS / MS
3472945|NCT03857971|Other|Coronary OCT imaging of non flow-limiting lesion|Coronary OCT imaging will be performed of fractional flow reserve (FFR) negative lesions to assess plaque morphology.
3472946|NCT03858296|Experimental|Emotional awareness|4 modules of emotional awareness training
3472947|NCT03858296|Experimental|Cognitive reappraisal|4 modules cognitive reappraisal training
3472948|NCT03858296|Experimental|Awareness + reappraisal|4 modules emotional awareness and cognitive reappraisal training
3472949|NCT03857997||Patients|
3472950|NCT03857997||Parents|
3472951|NCT03857789|Other|Regular care|Participant will be received by Healthcare professional (HCP). The HCP will administer a questionnaire. The HCP will discuss the results.
3472952|NCT03857789|Experimental|New care|Participant will be received by Healthcare professional (HCP). The social robot will administer a questionnaire. The HCP will discuss the results.
3472953|NCT03858023|Experimental|Hippotherapy|Children in hippotherapy arm will participate in hippotherapy (30 min/sessions, twice a week, 15 weeks)
3472954|NCT03858023|No Intervention|Control|Children in control group will not receive hippotherapy
3472955|NCT03857854|Experimental|treatment group|pirfenidone group
3472956|NCT03857854|Placebo Comparator|placebo group|control group
3472957|NCT03857737|Experimental|ESD group|This group include patients who are going to undergo endoscopic submucosal dissection for early gastric cancer.
3472958|NCT03857737|Active Comparator|Surgery group|This group include patients who are going to undergo surgery for early gastric cancer.
3472959|NCT03857724|Experimental|prolapse surgery|
3472960|NCT03857802|Experimental|Sleep hygiene intervention|In the experimental group will proceed to the explanation of sleep hygiene measures to improve the quality of sleep. After 3 months, at the next health check, the quality of sleep questionnaire will be carried out together with the blood extraction.
3472961|NCT03857802|No Intervention|No sleep hygiene intervention|In the no intervention group, the same follow-up visits and the same blood extractions will be carried out, but no educational activity on sleep will be carried out.
3472962|NCT03857672|Experimental|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT arm will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience). The participants will undergo 6 weekly sessions each lasting 30-40 minutes.
3472963|NCT03857672|No Intervention|Usual Care|The study therapist will notify participants assigned to Usual Care via the participant's preferred mode of communication (phone, U.S. mail, or email). People assigned to usual care will be encouraged to continue using the health care services available to them to address their pain. The study therapist will emphasize the importance of completing the outcome assessments. The treatments usual care participants actually received will be assessed at 6 and 12 weeks.
3472964|NCT03857932|Experimental|SLNB and non-slns resection|"Participants only receive SLNB~preoperative CT lymphography~SLNB with stained non-SLN resection~SLNB with ARM dissection"
3472965|NCT03857932|Experimental|SLNB group|Participants only receive SLNB
3472966|NCT03857685||Proliferation in an in-vitro model|An in-vitro model is used to study lens epithelial cell proliferation
3472967|NCT03858036|Active Comparator|Epi-OFF CXL|The Epi-ON treatment will be performed without removal of the corneal epithelium. Ricrolin+will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-ON treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-ON treatment.
3472968|NCT03858036|Active Comparator|Epi-ON CXL|The Epi-OFF treatment will be performed with removal of the corneal epithelium before the first dose of riboflavin is administered. Ricrolin+ will be used as the riboflavin formulation for the pre-treatment and irradiation steps of the Epi-OFF treatments. The VEGA UV-A light will be used during the irradiation steps of the Epi-OFF treatment.
3472969|NCT03857893|Active Comparator|Control Group : pH-Cream|Control Group will be only treated with a fixed amount (1g) of pH-cream (Cetomacrogol cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days and if deem necessary, additional doses can be applied and notified in the calendar provided).
3472970|NCT03857893|Experimental|Dynamic Quadripolar Radio-Frequency treatment|"Experimental Group will be treated with Dynamic Quadripolar Radio-Frequency (DQRF) (with Eva™ Device) for 8 weeks (+ 4 weeks). The Dynamic Quadripolar Radio-frequency sessions will involve -5 sessions (one every 14-21 days), if necessary External treatment (vulvar - will be applied before internal treatment for more comfort) : 10 minutes (5 minutes left side, 5 minutes right side), and Internal treatment (VVA, Vaginal Laxity, Mild-Stress Urinary Incontinence (SUI)): 20 minutes.~In parallel, patients can also apply pH-cream (Cetomacrogol cream) (one dose of 1g) if they judge necessary but they are not allowed to use it during the seven days before radiofrequency session. If they use pH-cream, they must notify it in the calendar provided."
3472971|NCT03857906||IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease Intra-Aortic Ballon Pump insertion 1-6 hours prior to surgery
3472972|NCT03857906||No-IABP group|Over 18 years With ischemic heart disease Multivessel disease with/without LMCA involvement High-risk coronary disease No IABP
3472973|NCT03857919|Experimental|TearCare|Subjects will have heat applied to the eyelids for 15 minutes followed by manual expression of the meibomian glands.
3472974|NCT03857919|Active Comparator|LipiFlow|Subjects will have heat and pressure applied to the eyelids for 12 minutes.
3472975|NCT03857698|Experimental|Evaluation of pain|The patient's pain will be evaluated by VAS (visual analog scale) at the end of the treatment, at the end of the treatment and at the end of the 3 months follow-up. For this, a 10 cm long line will be drawn. 0: painless and 10: the most severe pain is described and the patient will be asked to mark the value corresponding to the pain (rest, activity and night pain) on the scale.
3472976|NCT03857698|Experimental|Evaluation of joint range of motion|The flexion and extension range of motion of the knee joints of the patient will be measured in the prone position using a universal goniometer before and after the training.
3472977|NCT03857698|Experimental|Assessment of balance|Postural stability will be evaluated by a Prokin brand balance device (ProKin, Tecnobody, Bergamo, Italy), a force platform. After the tests are explained to the patients, the physical characteristics of the patients (age, height, body weight) will be recorded on the device and the device will be calibrated. The patients' feet will be placed naked on the platform with reference to the lines on the x and y axis. During the test, the arms will be in free position near the body. The tests will be performed on both feet with both eyes open and eyes closed. Each test will last 30 seconds. After each test has been completed, the device will be recalibrated. As a result of the tests, the ellipse area (mm2) and perimeter (mm) parameters will be recorded for statistical analysis. In addition, the patient's stability limits will be calculated as a percentage.
3472978|NCT03857698|Experimental|Evaluation of functional performance|A timed up and go test is a test that assesses the mobility and lower extremity mobility. For this test, the patient will be asked to lift from a chair with armrest (sitting height: 46 cm), walk 3 meters as fast as possible, turn around the colored band marked on the floor and sit in the same chair. The elapsed time for the motion will be recorded in seconds.
3472979|NCT03857698|Experimental|Lumbar lordosis angle assessment|During the test, patients will be asked to stand upright in a comfortable position. In the evaluation of the lumbar lordosis, the inclinometer will first be fixed to the T12-L1 backbone and then to the L5-Sl backbone and the angular values in both measurements will be collected and recorded as lordosis angle.
3179313|NCT00671385||Women 21-50 years old|Women without a diagnosis of cancer or a history of cancer.
3179314|NCT00671398|Experimental|Ramelteon 8 mg QD|
3126075|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
3179315|NCT00671398|Experimental|Ramelteon 16 mg QD|
3179316|NCT00671398|Placebo Comparator|Placebo|
3179317|NCT00671411|Experimental|1|Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
3472980|NCT03857698|Experimental|Evaluation of knee functionality|It will be measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). There are three subgroups, namely pain, stiffness and function. A total of 24 questions (pain 5 questions, 2 questions of malfunction and 17 questions of function) and the scale answered by patients are completed in approximately 5 minutes. The scale is a 5-point Likert-type scale (0 = none 1 = mild 2 = moderate 3 = severe 4 = very severe). The score range for the subgroup of pain is 0-20, for the subgroup group 0-8 and for the subgroup of function is 0 - 68. The total WOMAC score is obtained by the sum of these 3 points and the maximum total WOMAC score is 96. There is a linear ratio between the scores obtained from the WOMAC index and the presence of symptoms. The high scores were associated with severe symptoms, more disability and poor health status, whereas low scores indicated that symptoms, pain, and functionality were good.
3472981|NCT03857698|Experimental|Assessment of lower extremity muscle endurance|The patient will be asked to sit on the chair as fast as possible, so that the chair, which has a 46 cm height, will be crossed in the chest. The stopwatch is started with the command given to the patient and stopped in 30 seconds. The number of repetitions will be recorded.
3472982|NCT03857776|Other|Open dialogue about CAM|"Participation in an open dialogue about CAM with a nurse specialist. The dialogue will be based on the fundamentals of person-centered care and include patient preferences and wishes, reliable information and counselling, and advice about the potential risks and benefits of using CAM.~The dialogue is estimated to last approximately 60 minutes and all dialogues will be conducted by the same nurse. Depending on patient needs and wishes there may be a follow-up consultation one month after the first dialogue."
3472983|NCT03857776|Other|Standard care|Standard care including referral to a homepage about complementary alternative medicine
3472984|NCT03857373||Renal Cancer|Patients identified with RCC
3472985|NCT03857568|Experimental|SHR0410 group|SHR0410 will be dosed
3472986|NCT03857568|Experimental|Placebo|Placebo will be dosed
3126076|NCT03019055|Experimental|CAR-20/19-T cells (7.5 x10^5 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
3472987|NCT03857399|Experimental|Arm-1|Patients will be assigned to receive intravenous local caspofungin (70 mg on day 1 and 50 mg once daily),If the study therapy was well tolerated but fever persisted for four or more days and the patient's clinical condition deteriorated, the dosage could be increased to 70 mg once daily.For patients who have no evidence of baseline or breakthrough fungal infection, study therapy was administered until the absolute neutrophil count was at least 500 per cubic millimeter and for up to 72 hours thereafter. The onsite investigator determined the duration of therapy for patients with baseline or breakthrough fungal infections; however,it was recommended that treatment be given for at least 14 days and for at least 7 days after neutropenia and symptoms resolved.
3472988|NCT03857399|Active Comparator|Arm-2|Patients will be assigned to receive intravenous original caspofungin (70 mg on day 1 and 50 mg once daily),the therapeutical duration is 4 Days.
3472989|NCT03857633||Pre Dialysis (CKD Stage 4/5)|Patients recruited from low clearance clinic with advanced CKD (stage 4/5). Patients will undergo Cardiac MRI 1 - With Gadolinium Contrast at the time of recruitment and Cardiac MRI 2 - With Gadolinium Contrast at time of commencement on renal replacement therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
3472990|NCT03857633||Haemodialysis Dialysis (CDK Stage 5d)|Patients started on Haemodialysis will have Cardiac MRI 3 - With Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
3472991|NCT03857633||Peritoneal Dialysis (CDK Stage 5d)|Patients started on Peritoneal Dialysis will have Cardiac MRI 3 - Without Gadolinium Contrast after 6 months of therapy. Patients will have Peripheral Whole Blood Samples taken at defined intervals.
3472992|NCT03857711|Active Comparator|Conventional CABG|Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)
3472993|NCT03857711|Active Comparator|CABG+ PVI|CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)
3472994|NCT03857711|Active Comparator|CABG+ PVI+amiodarone|CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)
3472995|NCT03857711|Active Comparator|CABG+amiodarone|CABG+class III antiarrhythmic drug- amiodarone, group, n=70
3472996|NCT03857490|Experimental|Intervention|Lower leg heat therapy via water immersion up to the knee in a circulated bath (water temperature 42°C, 4 times per week, 45 minutes per session) for 8 weeks.
3472997|NCT03857490|Placebo Comparator|Control|Lower leg immerse in a thermoneutral water bath (33°C), 4 times per week, 45 minutes per session for 8 weeks.
3472998|NCT03857646|Other|Intralipid|
3472999|NCT03857646|Other|SMOF lipid|
3473000|NCT03857659|Experimental|Point of care ultrasound (POC-US)|Point of care ultrasound (POC-US) to measure abdominal circumference and amniotic fluid every 4 weeks from 28-36 weeks
3473001|NCT03857659|Active Comparator|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
3473002|NCT03857529|Experimental|conventional tDCS concurrent with CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
3473003|NCT03857529|Experimental|unconventional tDCS concurrent with CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
3473004|NCT03857529|Experimental|conventional tDCS preceding CCFES|tDCS anode placed over the lesioned hemisphere and cathode placed over the non-lesioned hemisphere
3473005|NCT03857529|Experimental|unconventional tDCS preceding CCFES|tDCS cathode placed over the lesioned hemisphere and anode placed over the non-lesioned hemisphere
3473006|NCT03857529|Sham Comparator|sham tDCS with CCFES|sham tDCS preceding and concurrent with CCFES
3473007|NCT03857516||Recipients of cardiac resynchronization therapy|Consecutive patients with de novo implantation of a cardiac resynchronization defibrillator or pacemaker.
3473008|NCT03857425|Experimental|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks
3473009|NCT03857425|Experimental|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
3473010|NCT03857425|Experimental|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
3473011|NCT03857347|Experimental|Brief Psychoeducation Intervention|2 group session psychoeducation intervention feasibility study
3473012|NCT03857763|Experimental|Apatinib+Paclitaxel+Cisplatin+RT|Apatinib：250mg,po,qd, d1-35; Paclitaxel：50mg/m2 iv, d1，8，15，22，29; Cisplatin: 30mg/m2 iv, d1，8，15，22，29; Radiotherapy：41.4Gy/23f , 1.8Gy/f，5 f/w
3473013|NCT03857386||PECS group|Preoperative bilateral PECS I + PECS II Pecs block performed by anaesthetist using ultrasound guidance in plane approach
3473014|NCT03857386||Control group|Bilateral local anesthesia infiltration Local infiltration anesthesia performed by surgeon during the operation
3473015|NCT03857438||Bipolar Mania|Diagnosis of BD type I, manic episode according to DSM-5 given by the following doctor
3473016|NCT03857438||Healthy Control|showing normal mental capacity during interview, have more than five years of public education, no diagnosis of substance or alcohol abuse in the last three months (except nicotine and caffeine, no presence of family history of mood or psychotic disorder, and no presence of psychiatric disorder during interview or in the past, no presence of severe organic disease.
3473017|NCT03857464|Other|Crossover Arm One|Hospital wards in this arm will use C. DIFF QUIK CHEK COMPLETE® for near-patient testing for the first phase of the crossover. For the second phase of the crossover, Arm One will utilize standard operating procedure testing for C. difficile infections using the centralized testing facilities.
3473018|NCT03857464|Other|Crossover Arm Two|Hospital wards in this arm will utilize testing for C. difficile infections using the centralized testing facilities in phase 1 and will switch to using C. DIFF QUIK CHEK COMPLETE® for near-patient testing in phase 2 of the crossover design.
3473019|NCT03857321|Experimental|Insulin first, then placebo|Participants will be randomly assigned to receive regular insulin (U100, 20 IU) administered with an intranasal nebulizer-like device. Participants in this arm will then receive placebo at visit 3 during second intervention period.
3473020|NCT03857321|Experimental|Placebo first, then insulin|Participants will be randomly assigned to receive placebo administered with an intranasal nebulizer-like device. At visit 3 during second intervention period, participants in this arm will receive insulin.
3473021|NCT03857815|Experimental|SBRT in combined with anti-PD-1 antibody|HCC Patients will be received stereotactic body radiation therapy (SBRT) to primary lesions or metastatic lesions, such as liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
3473022|NCT03857581|Experimental|Clozapine Arm|
3473023|NCT03857581|Active Comparator|Olanzapine Arm|
3473024|NCT03857412|Sham Comparator|Non capsular polishing|No capsular polishing taking place during cataract surgery
3473025|NCT03857412|Active Comparator|Capsular polishing|Capsular polishing taking place during cataract surgery
3473026|NCT03857360|Active Comparator|Pentabiocel|Oral administration of one sachet of Pentabiocel for 12 consecutive weeks.
3473027|NCT03857360|Placebo Comparator|Placebo|Oral administration of one sachet of Placebo per day for 12 consecutive weeks.
3473028|NCT03857308|Experimental|Mindfulness Training|
3473029|NCT03857308|Active Comparator|Reappraisal Training|
3473030|NCT03857334|Experimental|Arm A|
3473031|NCT03857334|Active Comparator|Arm B|
3473032|NCT03857477||Stage 1|Caucasian men aged 55-69 to undergo genetic SNP profiling.
3473033|NCT03857477||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer will be offered an MRI scan, prostate biopsy and prostate cancer screening.
3473034|NCT03857503||Coronary Lesion Assessment with iFR|Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.
3473035|NCT03857269|Experimental|Acupoint Massage group|Choose Chinese medicine acupuncture points： Shenting, Baihui, Sishencong, Diwei, Chengling, Fengchi, Fengfu，Zusanli and Sanyinjiao，32 points per acupressure.32 times per acupoint.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
3473036|NCT03857269|Experimental|Aromatherapy group|Make a 5x5cm bag and put a cotton ball in the bag and the bag is clipped to the patient's collar.Dispense 10% lavender essential oil, 2-3 drops a day in cotton balls.Cotton ball replacement daily. Intervention frequency will be monday to saturday per week for 6 months.（n=30）
3473037|NCT03857269|Experimental|Acupoint Massage and Aromatherapy group|At the same time as the acupressure, the essential oil is applied to the collar and begins to sniff.Intervention frequency will be monday to saturday per week for 6 months.（n=30）
3473038|NCT03857269|No Intervention|Blank control group|The group selects elderly people with MCI who do not receive intervention after informed.Participate in routine activities of Nursing homes.
3473039|NCT03857282|Active Comparator|Aerobic Exercises|Bicycling Exercise (lower Limb)
3473040|NCT03857282|Experimental|Tai Chi Exercises|Tai Chi Exercises (yang 24 Postures)
3473041|NCT03857204|Experimental|performing US scans for fetal weight assessment.|
3473042|NCT03856957|Experimental|Endocuff colonoscopy|Colonoscopy performed with Endocuff
3473043|NCT03856957|Placebo Comparator|Conventional colonoscopy|Colonoscopy performed without any device
3473044|NCT03857009||Symptomatic|No intervention.
3473045|NCT03857009||Asymptomatic|No intervention.
3473046|NCT03857113||PSMA-radioguided surgery|Tc-99m-PSMA combined with a gamma probe, guidance of the surgical resection of recurrent PC lymph node metastases
3473047|NCT03856892|Experimental|Active intervention|Intensive breath-based Hatha yoga program (more breath, more hours of practice)
3473048|NCT03856892|Active Comparator|Active Control|Less intensive practice on body (not breath) based yoga practices
3473049|NCT03856892|No Intervention|Passive control|No intervention is followed other than daily duties while in the same environment as both of the active groups.
3473050|NCT03857048|Active Comparator|Control|Persons with obesity who do not undergo weight loss will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
3473051|NCT03857048|Experimental|Reduced obese + diet + exercise|Persons with obesity randomized to a weight loss program consisting of caloric restriction, behavioral support, and supervised endurance exercise training. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
3473052|NCT03857048|Active Comparator|Reduced obese + diet group|Persons with obesity randomized to a weight loss program consisting of caloric restriction and behavioral support. Following weight loss persons in this group will participate in an inpatient assessment to measure metabolic responses to a 3 day eucaloric diet or a 3 day overfeeding challenge. Participants will be followed for 1 year after the metabolic studies to track longitudinal changes in body weight and other relevant health outcomes.
3473053|NCT03857139|Experimental|NRT smoking Cessation Intervention|All participants will be provided with the Nicotine Patch as an intervention
3473054|NCT03857035|Experimental|Piezosurgery group|"One side of the patients will be randomly selected and labeled as experimental group. In experimental group, impacted third molar will be extracted using piezosurgery."
3473055|NCT03857035|Placebo Comparator|Rotary Instruments Group|"The other side will be accepted as control group. In the control group, impacted third molar will be extracted using conventional rotary instruments."
3473056|NCT03857152|Other|Patient receiving CESM|Patients will receive CESM in addition to normal standard treatment.
3473057|NCT03856853|Experimental|treatment group|pirfenidone group
3473058|NCT03856853|Placebo Comparator|placebo group|placebo group
3473059|NCT03857126||Pregnancy volunteer subjects|"Subjects who will agree to participate in the investigator's study will be pregnant healthy subjects with no particular antecedent, followed at the University Hospital of Grenoble for a physiological pregnancy; their child will be not affected by any prenatal pathology.~Subjects will be enrolled in a 30 min monitoring phase to collect signals from ECG-PCG-CTG abdominal and thoracic non invasive sensors."
3473060|NCT03857191||Patients already treated for OSA|The first group involves patients already diagnosed and treated for sleep apnea that will follow the nutritional psychocomportemental rehabilitation
3473061|NCT03857191||Patients with a high OSA risk|This group concerns patients with a high OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
3473062|NCT03857191||Patients with a low OSA risk|This group concerns patients with a low OSA risk according to their Berlin questionnaire score that will follow the nutritional psychocomportemental rehabilitation
3473063|NCT03857022|Experimental|Enhanced External Counterpulsation|"Subjects of Heart failure with 'Enhanced External Counterpulsation therapy"
3473064|NCT03857022|No Intervention|"No 'Enhanced External Counterpulsation"|"Subjects of Heart failure without 'Enhanced External Counterpulsation therapy"
3473065|NCT03857100|Active Comparator|Intervention|Receives letter and report
3473066|NCT03857100|No Intervention|Control|Does not receive letter and report
3473067|NCT03857074|Experimental|Open Label, Green Light Exposure|This is a single-center, open label, pilot feasibility study. Patients with epilepsy will be exposed to a narrow band of green light at low intensities (1-10 cd/m2). The investigators will record 30 minutes of scalp EEG prior to the light exposure and 30 minutes of scalp EEG recording post-light exposure. The number of epileptic spikes per minute at baseline will be compared to epileptic spike count per minute post-treatment, to determine whether green light exposure effectively decreases the number of epileptic spikes, in patients with ≥1 epileptic spike per minute at baseline.
3473068|NCT03856983|No Intervention|Control group|Control group who will do usual rehabilitation.
3473069|NCT03856983|Experimental|Experimental group|Experimental group who will do usual rehabilitation and visualization of point-light human actions
3473070|NCT03857061||COPD Patients|This is a prospective cohort study enrolling patients with COPD to 1) wear a smartwatch that passively senses heart rate, motion, audio, 2) use a smartphone that can obtain oxygen saturation upon demand, 3) use a self-management app on the smartwatch, smartphone and a webapp.
3473071|NCT03856905|Active Comparator|Physical therapy group|The children in this group will receive the conventional physical therapy program (CPTP). It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neuro-developmental techniques, and gait training. The total program will be conducted for 1 h, three sessions/week for 12 weeks.
3473072|NCT03856905|Experimental|Extra-corporeal shock wave therapy group|The children in this group only will receive the extra-corporeal shock wave therapy (ESWT). An electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG) will be used. The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode, one session/week for 12 weeks. The treatment is painless and does not require any kind of anesthesia or the use of analgesic drugs
3473073|NCT03856905|Experimental|Functional electrical stimulation group|"The children in this group will receive the functional electrical stimulation (FES). The FES will be applied by using the WalkAide system (Innovative Neurotronics, Austin, TX, USA).~The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait."
3473074|NCT03856866|Experimental|Hydroxychloroquine|Hydroxychloroquine: liquid suspension, 4mg/kg/day by mouth, divided bid for 84 days.
3473075|NCT03856866|Placebo Comparator|Placebo|Liquid suspension compounded to mimic the taste, appearance and texture of the investigational agent.
3473076|NCT03856970|Experimental|Part 1: Healthy Volunteers|Microgestin® (EE 30 μg and NET 1500 μg) single dose (Day 1). After a 10-14 day washout, Microgestin® single dose (Day 14) PLUS IW-3718 1500 mg twice daily (Days 13 to 19).
3473077|NCT03856970|Experimental|Part 2: Healthy Volunteers|Levothyroxine 600 μg single dose (Day 1). After a 35-39 day washout, levothyroxine 600 μg single dose (Day 39) PLUS IW-3718 1500 mg twice daily (Days 38 to 41).
3473078|NCT03856970|Experimental|Part 3: Healthy Volunteers|"Phase 1: Glyburide 5 mg single dose (Day 1). After a 7-10 day washout, glyburide 5 mg single dose (Day 11) PLUS IW-3718 1500 mg twice daily (ie, Days 10 to 14).~Phase 2: Digoxin 0.25 mg single dose (Day 23). After a 10-14 day washout, digoxin 0.25 mg mg single dose (Day 35) PLUS IW-3718 1500 mg twice daily (Days 34 to 42)."
3473079|NCT03856918|Experimental|PEEP 3 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 3 cm of water during thoracic surgery.
3473080|NCT03856918|Experimental|PEEP 6 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 6 cm of water during thoracic surgery.
3473081|NCT03856918|Experimental|PEEP 9 cm of water|Patients allocated in this group will be applied protective one-lung ventilation using tidal volume of 5 ml/kg predicted body weight with PEEP of 9 cm of water during thoracic surgery.
3473082|NCT03857217||Post-cardiotomy patients|Patients submitted to cardiac surgery
3473083|NCT03856814||Patients with varicose veins|Patients with varicose veins, indicative for treatment with EndoVenous Laser Ablation (EVLA) using the ELVeS® Radial® 2ring slim fiber or Surgery (ligation/stripping) according to the standard of care of the participating investigators.
3473084|NCT03856827|Experimental|IW-6463|IW-6463 tablets administered orally as single ascending doses, multiple ascending daily doses, and single doses with or without food
3473085|NCT03856827|Placebo Comparator|Placebo|Matching placebo tablets administered orally
3473086|NCT03856801|Experimental|Whole-body vibration in normoxia condition|Training session in normoxia condition
3473087|NCT03856801|Experimental|Whole-body vibration in hypoxia condition|Training session in hypoxia condition
3473088|NCT03856736|Experimental|MIAT|Composite of the execution of moderated-intensity aerobic training (MIAT) twice week.
3473089|NCT03856736|Experimental|Control|Consisting of two session per week of different activities, such as body relaxation, low-intesity/volume of aerobic exercise to mimic sham group.
3473090|NCT03856658|Experimental|Floxuridine (FUDR) via HAI pump|Once enrolled, patients will undergo surgical placement of the HAI pump. This can be accomplished using minimally invasive or open techniques with an anticipated hospital stay of approximately 3-5 days. Prior to discharge from the hospital or at the first postoperative visit the pump is filled with FUDR according to the following equation: 0.12 mg/kg/d (using ideal body weight). This fill initiates day 1 of a 4-week cycle. The chemotherapy is infused by the pump continuously over 14 days. On day 15 (+/-4 days), the remaining chemotherapy is removed from the pump which is refilled with heparinized saline (30,000 units). This remains for an additional 2 weeks until the pump is refilled with FUDR at the start of the next cycle. Treatment is continued for a maximum of 6 cycles or as limited by toxicity. This regimen has been utilized with an acceptable safety profile in the setting of colorectal liver metastases.
3473091|NCT03856593|Experimental|Letter A Intervention|The intervention arm will involve letter A sent to prescribers in Los Angeles County.
3473092|NCT03856593|Experimental|Letter B Intervention|The intervention arm will involve letter B sent to prescribers in Los Angeles County.
3473093|NCT03856437|Experimental|Gain-framed messages|Participants in this arm receive gain-framed HPV vaccination messages.
3473094|NCT03856437|Experimental|Loss-framed messages|Participants in this arm receive loss-framed HPV vaccination messages.
3473095|NCT03856762|Experimental|Traditional Jiangnan diet|Subjects will be supplied with traditional Jiangnan diet and APP-based behavioral modification
3473096|NCT03856762|Experimental|Mediterranean diet|Subjects will be supplied with Mediterranean diet and APP-based behavioral modification
3473097|NCT03856762|Experimental|Current Shanghai diet|Subjects will be supplied with current Shanghai diet and APP-based behavioral modification
3473098|NCT03856606|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will not be asked to perform interval exercise.
3473099|NCT03856606|Experimental|Prolonged sitting with interval exercise|Subjects will be asked to undergo prolonged sitting (~14 hours) of 1 day and will be asked to perform interval exercise every hour on the hour.
3473100|NCT03856515|Experimental|E-cigarettes with Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
3473101|NCT03856515|Placebo Comparator|E-cigarettes without Nicotine|Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.
3473102|NCT03856580|Experimental|Self-injection|Participants will be trained on how to self-inject (intramuscular, gluteal muscle) an inert version of injectable cabotegravir. The inert substance is intended to mimic injectable cabotegravir as closely as possible (e.g., injection equipment, location of injection, volume of injection is identical to injectable cabotegravir). Specifically, participants will self-inject their choice of 300mg vitamin B12 or saline (3ml fluid) every 2 months for a total of 6 months (for a total of 4 injections). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as instructions on how to self-inject, FAQs about self-injection, study contact information, etc..
3473103|NCT03856580|Experimental|"Injection by HCP at drop-in clinics"|"Participants will report to a drop-in clinic, where a healthcare provider will inject them with an inert version of injectable cabotegravir. Visits will take <10 minutes, and participants will be able to come whenever they want (when their injection is due) during clinic drop-in hours, which will be staggered in 2-hour windows during each week day. The inert substance that will be injected is intended to mimic injectable cabotegravir as closely as possible (described above). Participants will complete interviews and brief surveys on their experience. Additionally, they will be given access to an mHealth app to improve adherence, which will contain informational content such as drop-in clinic hours, directions to the drop-in clinic site, study contact information, etc..."
3473104|NCT03856580|No Intervention|Control group|Participants will make an appointment when their injection is due to report to our clinic to complete injections. Visits and the injection protocol will follow similar procedures to HPTN-083/084. Participants will not have access to the mHealth adherence app.
3473105|NCT03856645|Experimental|OKG-0301 0.012% w/v|
3473106|NCT03856645|Experimental|OKG-0301 0.03% w/v|
3473107|NCT03856645|Placebo Comparator|Vehicle Control|
3126077|NCT03019055|Experimental|CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg)|Dose Escalation Phase: CAR-20/19-T transduced with a lentiviral vector to express an anti CD19 and anti CD20 tandem receptor coupled to CD3ζ and 4-1BB signaling domains will be administered by IV injection. Patients will receive one of four dose levels based the study protocol. Cells will be given over 2 days, 30% of cells infused on Day 0 and 70% of cells infused on Day 1 in the Phase 1 portion and as a single infusion in the Phase 1b portion.
3126078|NCT03019107|Experimental|VentFree Stimulation|Breath synchronized abdominal NMES
3473108|NCT03856671|Experimental|oral antibiotics+mechanical bowel preparation|Liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. A combination of neomycin 1g and metronidazole 0.2g every 6 hours was also administrated. Enteroclysis was conduted for patients on surgical morning.
3473109|NCT03856671|No Intervention|simple mechanical bowel preparation|Only liquid diet and polyethylene glycol with 2L water was administrated orally 1 day before surgery. Enteroclysis was conduted for patients on surgical morning.
3473110|NCT03856710|Active Comparator|Group 1 (Self-gripping Mesh),|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive self-gripping mesh
3473111|NCT03856710|Active Comparator|Group 2 (Stapled Mesh)|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh , which would be decided by randomization by sealed envelope. This group will receive stapled mesh
3473112|NCT03856632|Active Comparator|Risk Factor Modification (RFM)|A structured risk factor modification (RFM) program currently offered to all patients who are overweight or obese undergoing an ablation procedure for atrial fibrillation.The RFM program is already offered through our Center for Atrial Fibrillation and is managed by a nurse practitioner. The RFM program will provide patient teaching and education on weight, fitness,blood pressure control, glucose control, cholesterol, sleep apnea, smoking, and alcohol.
3473113|NCT03856632|Experimental|RFM plus Liraglutide|In addition to RFM, Liraglutide will be administered. Liraglutide is an FDA approved medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management of obese adults with weight-related comorbid conditions.
3473114|NCT03856489||Patients|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 10 am.
3473115|NCT03856489||Nurses|This study group will consist of patients hospitalized at ICU, who will be given the Richards-Campbell Sleeping Questionnaire (RCSQ) to fill in every morning between 7 am and 7:30 am.
3473116|NCT03856385|Experimental|Mindful Walking|Four weekly 60 minute sessions of mindful walking.
3473117|NCT03856385|No Intervention|Control|Weekly email messages encouraging physical activity.
3473118|NCT03856372|Experimental|Hypofractionated|42.5 Gy / 16 fractions, 2.66 Gy per fraction, 5 fractions weekly
3473119|NCT03856372|Active Comparator|Conventional|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
3473120|NCT03856697|Experimental|Abivertinib Maleate Capsules+ Placebo Gefitinib Tablets|Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Placebo Gefitinib Tablets (250 mg orally, once daily), in accordance with the randomization schedule.
3473121|NCT03856697|Active Comparator|Gefitinib Tablets+ Placebo Abivertinib Maleate Capsules|Placebo Abivertinib Maleate Capsules (300 mg , orally, twice daily) plus Gefitinib Tablets(250 mg orally, once daily), in accordance with the randomization schedule.
3473122|NCT03856411|Experimental|Group TORIPALIMAB combined with standard chemotherapy|
3473123|NCT03856411|Placebo Comparator|Group Placebo combined with standard chemotherapy|
3473124|NCT03856554|Experimental|Patients indicated for TLIF|Patients with lumbar degenerative spondylolisthesis, indicated for TLIF surgery
3473125|NCT03856541|Experimental|SHR-A1403 Dose Escalation|SHR-A1403 given intravenously (IV).
3473126|NCT03856502|Experimental|group that received dexamethasone (DLSA)|The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
3473127|NCT03856502|Active Comparator|group without dexamethasone (LSA)|The control group of 30 patients ASA status 2 or 3 received 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
3473128|NCT03856463|Experimental|Intervention Group Arm|Patients randomized into the intervention will be assigned a lay patient navigator who will provide information regarding early advance care planning, documentation of goals of care, and coordinating home-based care. The intervention arm will also receive usual care as provided by their local oncologists.
3473129|NCT03856463|Active Comparator|Control Group Arm|The control group will receive usual care as provided by their local oncologists.
3473130|NCT03856749|Experimental|Treatment|The wheelchair user and caregiver will be trained together on wheelchair skills using remote technology (Zoom for healthcare and/or Facetime).
3473131|NCT03856749|No Intervention|Control|The wheelchair user and caregiver will receive the same self-study materials provided to the Treatment arm. Usual care, which may include wheelchair skills training for both wheelchair users and caregivers( but which often does not do so to an adequate extent) by wheelchair user's clinical therapist.
3473132|NCT03856424|Other|Modality 1 - Washout - Modality 2 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473133|NCT03856424|Other|Modality 1 - Washout - Modality 3 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473134|NCT03856424|Other|Modality 2 - Washout - Modality 1 - Washout - Modality 3|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473135|NCT03856424|Other|Modality 2 - Washout - Modality 3 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473136|NCT03856424|Other|Modality 3 - Washout - Modality 2 - Washout - Modality 1|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473137|NCT03856424|Other|Modality 3 - Washout - Modality 1 - Washout - Modality 2|Three different 30-minute modalities of deventilation will be performed in a randomized order in each patient. Washout periods of 30 minutes will occur between tested modalities.
3473138|NCT03856333|Other|traditional treatment|30 minutes of conventional TENS, 20 minutes of hotpack, 8 minutes of therapeutic ultrasound and isotonic, isometric, stretching and relaxation exercises 2 weeks, 5 days in a week.
3126079|NCT03019107|Sham Comparator|Sham Stimulation|Sham breath synchronized abdominal NMES
3126080|NCT03019289|Experimental|pridopidine|Pridopidine (TV-7820) capsules
3126081|NCT03019406|Experimental|Cohort 1: Avalglucosidase Alfa 20 mg/kg|Avalglucosidase alfa, 20 mg/kg intravenous (IV) infusion every other week (qow) for 25 weeks in the Primary Analysis Period (PAP), followed by same treatment from Week 26 up to Week 371 in extension treatment period (ETP).
3126082|NCT03019406|Experimental|Cohort 2: Avalglucosidase Alfa 40 mg/kg|Avalglucosidase alfa 40 mg/kg IV infusion qow for 25 weeks in the PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
3473139|NCT03856450|Active Comparator|Control-arm group|The control-arm group will consist of healthy volunteers with no known prior trauma in the wrists. The diagnostic truth for subjects in the control-arm will be no fracture and the treatment truth will be no treatment.
3473140|NCT03856450|Experimental|Test-arm group|The test-arm group will consist of subjects who present with a wrist injury and initial SOC X-ray imaging results show a confirmed or suspected distal radius or scaphoid fracture, for which additional diagnostic imaging shall be ordered. Diagnostic truth for subjects in the test-arm will be the per-subject clinical diagnosis and the treatment truth will be the per-subject treatment received.
3126083|NCT03019406|Experimental|Cohort 3a: Avalglucosidase Alfa 40 mg//kg|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received avalglucosidase alfa 40 mg/kg (the highest tolerated dose) IV infusion qow for 25 weeks in PAP, followed by same treatment from Week 26 up to Week 371 in ETP.
3126084|NCT03019406|Experimental|Cohort 3b: Alglucosidase Alfa in PAP|After determination of the highest tolerated avalglucosidase alfa dose in Cohort 1 and Cohort 2 (after at least 5 participants in each Cohort 1 and Cohort 2 had received the 7th dose of avalglucosidase alfa or completed Week 13 with a minimum of 6 infusions), participants received alglucosidase alfa at their current stable dose (defined as dose [between 20 mg/kg qow and 40 mg/kg weekly as per physician] administered regularly for a minimum of 6 months immediately prior to entry in this study) IV infusion for 25 weeks in PAP. After PAP, participants received avalglucosidase alfa 40mg/kg IV infusion qow from Week 26 up to Week 371 in ETP.
3473141|NCT03856346||Phaco-vitrectomy|
3473142|NCT03856099|Experimental|TTAC-0001|TTAC-0001 with dose assigned to each dose group will be administered
3473143|NCT03856034|Experimental|Fetoscopic repair|
3473144|NCT03855982||myocarditis induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by a drug, with a chronology compatible with the drug toxicity
3473145|NCT03855956|Experimental|KB174 Arm|KB174 is a novel mixture of oligosaccharides.
3473146|NCT03855956|Other|Maltodextrin Arm|Maltodextrin is a commercially available easily digestible polysaccharide.
3473147|NCT03855943|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
3473148|NCT03856190|Active Comparator|"Fasting and best practice nutrition"|Initial fasting followed by 11 weeks plant-based diet
3473149|NCT03856190|Active Comparator|Standard Nutrition Counselling|12 weeks standard antiinflammatory diet
3473150|NCT03856060|Experimental|Group I (questionnaires, videos)|Patients complete questionnaires and watch a video portraying a physician using a standard EHR and then another portraying a physician using an integrated model of EHR during communication over 35 minutes.
3126085|NCT03019458|Experimental|MINGO|MINGO is a supplement consisting of local ingredients such as moringa, rice and mung beans, which can be added to any type of edible paste, food, and liquid. The experimental group is required to take 6 sachets per day for 12 weeks in addition to their regular diet. They are required to keep a daily food diary
3126086|NCT03019458|No Intervention|Control|The control group is required to eat their normal diet. They are also required to keep a daily food diary.
3473151|NCT03856060|Experimental|Group II (video, questionnaire)|Patients complete questionnaires and watch a video portraying a physician using an integrated model of EHR and then another portraying a physician using a standard EHR during communication over 35 minutes.
3473152|NCT03855917|Experimental|Sof plus G/P|Four weeks of sofosbuvir (400mg) plus glecaprevir-pibrentasvir (300mg/120mg) will be administered, followed by immediate retreatment of virological relapse with glecepravir/pibrentasvir (300mg/120mg) for 12 weeks, in treatment-naïve participants with chronic HCV infection and early liver disease (F0-F2).
3473153|NCT03856216|Experimental|Group I (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
3473154|NCT03856216|Experimental|Group II (inotuzumab ozogamicin, chemotherapy, transplant)|See Detailed Description.
3473155|NCT03856151|Active Comparator|Group 1|"For Group 1, each subject will receive Treatment 1# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 2#.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks. Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks."
3473156|NCT03856151|Active Comparator|Group 2|"For Group 2, each subject will receive Treatment 2# first. Then, it takes 2-week washout period with regular dialysis 3 times per week and then receive Treatment 1#.~Treatment 2# will be regular dialysis 3 times per week plus HEALTHY BOX Powered heating pad on acupoint CV4 at the abdomen for 1 hour during dialysis, also for 4 weeks.~Treatment 1# will be regular dialysis 3 times per week for 4 weeks."
3473157|NCT03856229|Active Comparator|Group A conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
3473158|NCT03856229|Experimental|Group B shortened steroid regimen|"Subjects will receive the shortened steroid regimen for the severity of pneumonia with prednisone or equivalent with methylprednisolone, depending the severity of pneumonia:~Moderate PCP. 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~Severe PCP. 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
3473159|NCT03856021|Active Comparator|Microfracture|
3473160|NCT03856021|Active Comparator|Microfracture with Bone Marrow Aspirate Concentrate|
3126087|NCT03019549|Experimental|Rosuvastatin|Period 1: 20 mg rosuvastatin administered once orally (PO)
3473161|NCT03856294|Experimental|Rikkunshito|Rikkunshito: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
3473162|NCT03856294|Placebo Comparator|Placebo|Placebo: 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
3473163|NCT03856008|Experimental|Exercises focused on flexor muscles.|Flexor cervical stabilization exercises will be applied.
3473164|NCT03856008|Experimental|Exercises focused on extensor muscles.|Extensor cervical stabilization exercises will be applied.
3126088|NCT03019549|Experimental|Lanabecestat + Rosuvastatin|Period 2: 50 mg Lanabecestat (LY3314814) administered orally (PO) Day 1 to Day 12 Rosuvastatin: 20 mg co-administered PO on Day 8
3473165|NCT03856008|No Intervention|Control.|No intervention will be applied.
3473166|NCT03856281|Experimental|Intervention Group A|LymphAssist IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
3473167|NCT03856281|Experimental|Intervention Group B|Sequential IPC device - participants act as their own control for 5 weeks, receiving standard care only. After 5 weeks the group use the device twice a day, every day for a 5 week period.
3473168|NCT03856268||ARM 1: 'Surgical Menopause' Group|Premenopausal women having an oophorectomy.
3473169|NCT03856268||"ARM 2: Drug-Induced Menopause'"|Premenopausal women with gonadal suppression
3473170|NCT03856268||'Comparative (Control)' Group|Premenopausal women with regular cycles.
3473171|NCT03855930||micturition induced PLP|"10 Patients with chronic post amputation micturition induced PLP.All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.~All patients will go through functional MRI study"
3473172|NCT03855930||non micturition induced PLP|10 Patients with chronic post amputation with PLP and without post amputation micturition induced PLP All subjects must fulfill all of the inclusion criteria and meet none of the exclusion criteria.All patients will go through functional MRI study
3473173|NCT03855930||healthy volunteers|10 healthy volunteers. All patients will go through functional MRI study
3473174|NCT03856177|Experimental|Neutral|A neutral mood induction will include reading a dull text while listening to non-evocative music for 5-15 minutes.
3473175|NCT03856177|Experimental|Evocative|A mood induction procedure will be utilized. The procedure consists of a combination of re-experiencing an autobiographical sad personal event while listening to their choice of one of four sad music selections commonly used in mood induction. Visual analogue scale ratings will assess momentary sadness prior to, following, and at subsequent time points around the mood induction procedure.
3473176|NCT03856242|No Intervention|No intervention|It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
3473177|NCT03856242|Active Comparator|Tamsulosin|This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
3473178|NCT03856242|Active Comparator|TURP|This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).
3473179|NCT03856112|Experimental|Arm I (ixazomib, venetoclax, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, venetoclax PO QD on days 1-28 and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3473180|NCT03856112|Active Comparator|Arm II (ixazomib, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3473181|NCT03856112|Experimental|Arm III (ixazomib, venetoclax, dexamethasone)|PI-refractory patients receive ixazomib citrate, venetoclax and dexamethasone as Arm I.
3473182|NCT03856125|Experimental|PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
3473183|NCT03856125|Sham Comparator|Sham PENS plus exercise group|4-week intervention program with 2 weekly treatment sessions, one of sham percutaneous electrical stimulation and supervised exercise and the other one, domiciliary exercise.
3473184|NCT03856073|Experimental|Novice|Anesthesiologists without experiment of manufacturing bronchoscopy.
3473185|NCT03855904|Experimental|TC-325|The intervention (experimental) arm patients are treated initially with TC-325 alone. Treatment failure for TC-325 is defined as endoscopists cannot achieve hemostasis with 1 syringe (20gm) of TC-325.
3473186|NCT03855904|Active Comparator|Traditional treatment (Control group)|Control group patients initially receive usual standard of (traditional) endoscopic treatment (SET) as defined by injection therapy with another modality or sole/combination use of thermal or mechanical modalities. Crossovers to either treatment arm are permitted if immediate haemostasis does not achieved with standard endoscopic or TC-325 application.Treatment failure of SET is defined as endoscopists cannot achieve hemostasis by selected SET.
3473187|NCT03855891|Experimental|Study group|A group of patients with blood tests
3473188|NCT03855865|Experimental|Rapastinel|Rapastinel (450 mg prefilled syringe, weekly intravenous IV administration).
3473189|NCT03855865|Active Comparator|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
3473190|NCT03855865|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
3473191|NCT03855852|Active Comparator|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
3473192|NCT03855852|Experimental|Xenograft and A-PRF|Placing the implant with xenograft and A-PRF at esthetic zone of maxillary ridge when 2-4 mm of implant threads exposure .
3473193|NCT03855839||Healthy participants|Participants will be ask to perform a repetitive upper limb task while posture is being monitored.This will be done while wearing a posture shirt, compression shirt or no shirt.
3473194|NCT03855761|Experimental|Intervention group|Experimental Occupational Therapy services
3473195|NCT03855761|Active Comparator|Comparison group|Treatment as usual
3473196|NCT03855800|Experimental|Clinical Follow-up|"Participants not undergoing surgery will be assigned to the Clinical Follow-up study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. All participants in the Clinical Follow-up group will be contacted yearly for a telephone interview until they undergo surgery, die, receive a diagnosis that excludes them from the study, or for 3 years, and interval medical records will be obtained and reviewed. During follow-up results of clinically indicated follow-up imaging studies will be abstracted"
3473197|NCT03855800|Other|Surgical|"Participants scheduled for surgical resection after their initial clinical evaluation will be assigned to the Immediate Surgery study group. Blood, stool, pancreatic juice and cyst fluid collection will be done as per protocol. Participants in the Immediate Surgery group will be followed until the surgical pathology of their pancreatic cyst is known."
3473198|NCT03855488|Experimental|Standard cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively
3473199|NCT03855488|Experimental|Imagery enhanced cognitive bias modification|Listen to descriptions of ambiguous scenarios that resolve positively while engaging in imagery
3473200|NCT03855488|Placebo Comparator|Neutral Control Condition|Listen to descriptions of neutral scenarios
3473201|NCT03855826|Experimental|Nifekalant Hydrochloride|Nifekalant hydrochloride (50mg) should be dissolved into a 50ml dilution solution (0.9% sodium chloride injection or 5% glucose injection), and configured as 1mg/ml solution of nificaine hydrochloride. The dosage should be taken as needed. The diluted solution should be used within 24 hours. The amount of fluid per hour should not exceed 50ml when intravenously infused. It is recommended to use intravenous pump.
3473202|NCT03855826|Active Comparator|Amiodarone|The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
3473203|NCT03855475|Experimental|Aerobic exercise|Exercise training
3473204|NCT03855475|Active Comparator|Stretching|Control
3473205|NCT03855787|Active Comparator|Ureteral stent group|A ureteral stent will be placed after ureteroscopy.
3473206|NCT03855787|Active Comparator|No ureteral stent group|A ureteral stent will not be placed after ureteroscopy.
3126089|NCT03019575|Experimental|Corifollitropin alfa (CFA)+human Chorionic Gonadotropin (hCG)|Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was >60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
3473207|NCT03855553|Experimental|FBT|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
3126090|NCT03019627|Experimental|rhNGF 20μg/mL|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
3126091|NCT03019627|Placebo Comparator|Vehicle|vehicle eye drops six times daily
3473208|NCT03855553|Experimental|CBT-E|10 families will be randomized to receive 10 - 16 weeks of eating disorder treatment for their adolescent.
3473209|NCT03855644||Pelvic fracture patients|(1) 1<Age<80, and Chinese residents living in China more than 3 years; (2) Hemoglobin value less than 100g/L during hospitalization; Not suffered from pelvic fracture within 3 months; Not suffer from pathological fractures of the pelvis caused by malignant tumors; without chronic anemia and coagulopathy; accept blood transfusion
3473210|NCT03855540||Study group|Adult patients with documented paroxysmal, nonvalvular atrial fibrillation with CHA2DS2-VASc score > 2 (for females > 3) and sinus rhythm at the time of inclusion. In total 100 patients will be included.
3473211|NCT03855540||Control group|"Patients without a history of palpitations or irregular heart rhythm. AFib will be excluded with the help of 7 days ECG Holter and ECG event recorder monitoring. In total 100 patients will be included.~Propensity matching according to the:~CHA2DS2-VASc parameters~LVEF: preserved (<40%), mid-range (40-49%) and reduced (>50%)~Presence of diastolic dysfunction~Glomerular filtration rate: (≥1,5 ml/s), (1,4-1 ml/s) and (0,9-0,5 ml/s)~Drugs: ACE-I/ARB, betablockers, digoxin, amiodarone~BMI: (<30kg/m2), (30-39kg/m2) and (≥40kg/m2)~Smoking (>5 cigarettes per day)"
3473212|NCT03855631||Kabuki syndrome/ unaffected parents|Intervention on primary cultured cells from 4 patients with KS and sex match parents
3473213|NCT03855683|Experimental|Group therapy (Unified Protocol)|Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.
3473214|NCT03855462|Experimental|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with silicon oil medium-chain triglycerides (MCT) as tamponade agent :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)"
3473215|NCT03855813|Other|Test-retest reliability|Patients with knee osteoarthritis will perform the 30 seconds chair stand test as a self test twice at home to evaluate intra rater reliability. Same patients will be tested with the same performance test by a physical therapist to evaluate the inter rater reliability.
3473216|NCT03855657||Inflammatory Bowel Disease Patient|Patient with confirmed diagnosis of Inflammatory Bowel Disease
3473217|NCT03855657||Healthy control|Controls (non-IBD) will comprise individuals undergoing colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms, and friends and spouses or partners of patients at Prince of Wales Hospital or Alice Ho Miu Ling Nethersole Hospital, or any individuals who are interested to participate in this study.
3473218|NCT03855657||Healthy relatives of Inflammatory Bowel Disease patient|Relatives or household members of both patients with IBD or other diseases and controls will be recruited.
3473219|NCT03855501|Active Comparator|Mineral trioxide aggregate|The root canals were gently instrumented with K-files and copious irrigation was done with 2.5% sodium hypochlorite(NaOCI) by means of a 30 gauge endodontic irrigating needle . After drying with large sterile paper points, calcium hydroxide(CH) paste was mixed with saline and applied to the root canal with a lentulo spiral filler at low speed. A cotton pellet was used to gently compress CH into the root canal and its placement was examined radiographically before placing ZOE as temporary restoration into the access cavity. After one week, CH was removed from the canal by using both the files and the irrigation with 2.5% NaOCI and 17% ethylenediaminetetraacetic acid (EDTA). A final irrigation was made with 2% chlorhexidine (CHX) before obturation. Following drying the root canal with sterile paper points, MTA was placed with a MTA Endo Gun into the apical portion of canals with a minimum 4-mm thickness and adapted to the canal walls with an endodontic hand plugger.
3473220|NCT03855501|Active Comparator|Calcium hydroxide|After using the same biomechanical root canal preparation protocol, the root canal was filled to working length with CH paste. Both clinical and radiographical examinations were performed to evaluate the barrier formation and periapical healing. When a continuous hard tissue barrier was observed apically on radiographs that was verified by clinical probing and complete or significant periapical healing was noticed, the root canal was obturated and coronary restorations were completed as done in MTA group
3473221|NCT03855735|Experimental|Intervention Group (IG)|Those who give birth and relatives who have been arbitrarily assigned to the control group receive online training on different communication models competencies and will gain access to the digital app.
3473222|NCT03855735|No Intervention|No Intervention|Those who give birth and relatives who have been arbitrarily assigned to the control group do not receive any training on different communication models competencies and will not gain access to the digital app. The control group will receive a paper-pencil version.
3473223|NCT03855566|Other|Intervention|Enrolled participants will receive the intervention.
3473224|NCT03855722|Experimental|RIPC|RIPC will consist of setting a tourniquet to donor thigh and inflating it to 300mmHg four times 5 minutes with 5 minutes deflating in between each. RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
3126092|NCT03019744|Experimental|MeCFES|25 daily sessions (45 minutes each) of MeCFES-assisted task-oriented upper limb rehabilitation
3126093|NCT03019744|Active Comparator|Control|25 daily sessions (45 minutes each) of usual care task-oriented upper limb rehabilitation
3126094|NCT03019783|Placebo Comparator|Remains on baseline HIV regimen|Subjects are enrolled and either kept on their baseline regimen. This is being designated the placebo comparator.
3126095|NCT03019783|Active Comparator|Atazanavir switch|These subjects are switched to an atazanavir-based regimen.
3473225|NCT03855722|Sham Comparator|Sham-RIPC|Sham-RIPC will consist of setting a tourniquet to donor thigh without inflating it and keeping it in place for 35 min. Sham-RIPC-intervention will be performed twice: First after brain death and second time before procurement procedure.
3473226|NCT03855774|Other|Polymorphisms|Classification of sleep disorders prevalence through polymorphisms
3473227|NCT03855514|Active Comparator|NuShield|NuShield® is a sterile, dehydrated placental allograft
3473228|NCT03855514|No Intervention|Standard of Care|Standard of Care (SOC) includes, but is not limited to, surgical debridement, aggressive infection management, offloading, and maintenance of appropriate cleansing at the time of each dressing change.
3473229|NCT03855579|Experimental|Levosimendan|Intraoperative infusion of Levosimendan
3473230|NCT03855579|Active Comparator|Milrinone|Intraoperative infusion of Milrinone
3473231|NCT03855423|Experimental|Tocotrienol-rich Fraction (TRF)|Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.
3473232|NCT03855410|Experimental|S4E App intervention|Participants in the S4E group will receive the tobacco modules via iPads in a private room. The intervention will last approximately 20 minutes. Content includes the theoretically driven components of S4E: (a)Storytelling scenarios, (b) an introduction video, tobacco use knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent tobacco use, (e) clinician-youth communication, and (f) highlighting prevention principles. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
3473233|NCT03855410|Experimental|Attention-Matched Control|Participants in the Attention-Matched Control group will receive a portable document format (PDF) version of the tobacco module content, an enhancement to the care they would receive should they not join the study. Participants in this group also receive usual care. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services. Adolescents will be compensated $20 at baseline and $40 at 30-day follow-up. To minimize bias, randomization will occur prior to baseline assessment.
3473234|NCT03855527|Experimental|Silver Diamine Fluoride (SDF) group|Atraumatic restorative technique will be performed. Then the cavities will be dried with a gentle flow of compressed air. One drop of silver diamine fluoride (Advantage Arrest Silver Diamine Fluoride 38% - Bottle) will be dispensed into a dappen dish. A micro brush will be bent, dipped into SDF and dabbed on the side of the dappen dish to remove excess liquid before application. SDF will be applied directly to affected tooth surface and dried with gentle flow of compressed air for 1 minute. Excess SDF will be removed with cotton roll. Teeth will be restored with glass ionomer cement (GC Fuji IX).
3473235|NCT03855527|Active Comparator|Chlorhexidine group|Atraumatic restorative treatment will be performed. Then, the cavities will be disinfected by placing a cotton pellet soaked in chlorhexidine solution (Consepsis®2% Chlorhexidine Antibacterial Solution) for 1 minute, air dried and restored using glass ionomer cement.
3473236|NCT03855527|Sham Comparator|Atraumatic Restorative Treatment without Disinfection|Cavities will be cleaned according to the ART approach.The cavity will be enlarged if needed using sterile hatchet.The carious dentin will be removed with excavators starting at the enamel-dentine junction. The unsupported thin enamel will be fractured off with the hatchet. The caries will be removed carefully until firm dentin is reached (physically resistant to hand excavation). The cavity will be cleaned with wet cotton pellets. Cavities will be restored immediately using conventional glass ionomer cement. All the cavities in the 3 groups will be temporary restored with glass ionomer cement handled according to manufacturer's instructions, however acid etching will not be carried out in order to make sample collection easier following the experimental period.
3473237|NCT03855397|Experimental|Microneedles|Application of microneedle patch, 30G hypodermic needle (positive control) and flat patch (negative control) in the lip, buccal, tongue, palatal and gingival mucosa for pain and safety assessment
3473238|NCT03855293|Other|Study group|rhexis protection shield
3473239|NCT03855293|No Intervention|Control group|regular surgery
3473240|NCT03855215|Experimental|Intervention|"The ACTIM CRP Rapid Test (Medix, Biochemica) will be made available to the healthcare workers at the CHCs for use in patients in the target population.~Printed guidance will be issued for the performance and interpretation of the CRP test results in terms of antibiotic guided treatment. The treating healthcare worker will decide based on their clinical evaluation whether or not to comply with this guideline. This guidance will also be discussed during the training sessions.~The healthcare workers are recommended to use the CRP tests in all patients meeting the target population. The CRP cut-offs will be recommended below in the absence of warning signs of severity:~CRP level < 10 mg/L: no antibiotics are recommended CRP level from 10 mg/L to 40 mg/L: antibiotics are unlikely to be needed but should be considered in cases of high clinical concern CRP level > 40 mg/L: antibiotics are recommended."
3473241|NCT03855215|No Intervention|Control|Working as routine
3473242|NCT03855124||healthy participants|Participants will be ask to perform a repetitive upper limb task while posture and muscle activity is being monitored.This will be done while wearing a posture shirt or without a shirt
3473243|NCT03855345|Experimental|Control group|In this group, the participants will be submitted to the conventional treatment. The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
3126096|NCT03019796|Experimental|PLACEBO FIRST THEN MEDICATED|Subjects first receive the PLACEBO tablet during 72 hours (full withdrawal). After a week of taking again their medication (MEDICATION TRIAL), they will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
3473244|NCT03855345|Experimental|aPDT group|In this group, besides the conventional treatments, patients will also receive aPDT. aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
3473245|NCT03855306|Experimental|A Test|Test drug (Glibesyn) 1 tablet contains 5 mg Glibenclamide
3473246|NCT03855306|Active Comparator|B Reference|Reference drug (Daonil) 1 tablet contains 5 mg Glibenclamide
3126097|NCT03019796|Experimental|MEDICATED FIRST THEN PLACEBO|Subjects first receive their antihypertensive MEDICATION tablet (habitual dose prescribed by their primary care doctors). After a week they will take a PLACEBO tablet for 72 hours and will be tested again. This procedure will be repeated before and after 4 months of aerobic training.
3473247|NCT03855384|Experimental|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
3126098|NCT03019887|Experimental|reduction group|dose reduction of antipsychotics at a rate not exceeding 50mg chlorpromazine equivalent/week
3126099|NCT03019939|Experimental|Prevention (isavuconazole)|Patients receive isavuconazole PO every 8 hours for 6 doses and then Once a day (QD) or IV over 1 hour every 8 hours for 6 doses and then QD for up to 4 days for 12 weeks in the absence of disease progression or unacceptable toxicity.
3126100|NCT03019965|Active Comparator|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam 300mg/kg/day, divided into 4 doses/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 30 minutes infusion every 6 hours.
3126101|NCT03019965|Experimental|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam initial doses 75mg/kg in 30 minutes infusion, immediately thereafter continue 300mg/kg/day, diluted in 5% glucose solution, at a concentration of 50mg/ml, to be administered in 24 hours infusion every 24 hours, as determined by antibiotic stability at room temperature.
3473248|NCT03855384|Placebo Comparator|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|
3473249|NCT03855332|Placebo Comparator|Placebo|"All participants will undergo three phases in random order:~The placebo phase will include overencapsulated placebo, matched to overencapsulated active agents, 2 tablets 3 times daily"
3473250|NCT03855332|Experimental|Sildenafil|25mg three times daily, overencapsulated tablet, increased after 1 week to 50mg three times daily
3473251|NCT03855332|Active Comparator|Cilostazol|50mg bd, overencapsulated tablet (with midday placebo), increased after 1 week to 100mg bd (with midday placebo)
3473252|NCT03855020||observational cohort|Patients enrolled in this observational cohort would have regular blood taking for EBV DNA examination at baseline, after every cycle of chemotherapy, every week during radiotherapy, and 1-3 months after chemo-radiotherapy until EBV DNA becomes undetectable for at least two times.
3126102|NCT03019965|Active Comparator|Intermittent Imipenem|Imipenem 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes infusion every 6 hours.
3126103|NCT03019965|Experimental|Extended Imipenem|Imipenem initial doses 20mg/kg in 60 minutes infusion, immediately thereafter continue 80mg/kg/day, divided into 4 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 6 hours infusion every 6 hours, as determined by antibiotic stability at room temperature.
3126104|NCT03019965|Active Comparator|Intermittent Meropenem|Meropenem 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution, at a concentration of 7mg/ml, to be administered in 60 minutes every 8 hours.
3473253|NCT03855358|Experimental|TQB2450 Injection and Anlotinib Hydrochioride Capsules|
3473254|NCT03855254|Experimental|Positive communication|
3126105|NCT03019965|Experimental|Extended Meropenem|Meropenem initial doses 35mg/kg in 60 minutes infusion, immediately thereafter continue 100mg/kg/day, divided into 3 doses/day, diluted in 0.9% saline solution at a concentration of 7mg/ml, to be administered in 8 hours infusion every 8 hours, as determined by antibiotic stability at room temperature.
3126106|NCT03020004|Experimental|Danoprevir,Ritonavir, Peg-IFN,RBV|Participants will receive a combination of Ritonavir-boosted Danoprevir 100mg/100mg BID, subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and oral Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg) for 12 weeks.
3473255|NCT03855254|No Intervention|Control (neutral communication)|
3473256|NCT03855254|Experimental|Negative communication|
3473257|NCT03855241|Active Comparator|Informational Sheet|Persons picking up an opioid prescription will receive an informational sheet that describes how to properly dispose of leftover opioid medications
3473258|NCT03855241|Active Comparator|Drug Disposal Kit|Persons picking up an opioid prescription will receive a drug disposal kit (DisposeRx Drug Disposal kit) and instructions on how to use it
3473259|NCT03855241|No Intervention|No intervention|Persons picking up an opioid prescription will receive no additional information or materials on disposal.
3473260|NCT03855280|Experimental|APVO101|
3473261|NCT03855267|Placebo Comparator|Group A|Propofol 20 mg/ml, recommended anesthesia induction dose of 0.1~0.125 ml/kg, anesthesia maintenance pump speed of 0.2~0.5ml/kg/h. keep bispectral index within 40 # 60
3473262|NCT03855267|Active Comparator|GroupB|EP1:3, that is, 10ml etomidate was mixed with 30ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
3473263|NCT03855267|Active Comparator|Group C|EP1:1, that is, 20ml etomidate was mixed with 20ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
3473264|NCT03855267|Active Comparator|Group D|EP3:1, that is, 30ml etomidate was mixed with 10ml propofol, the recommended anesthesia induction dose was 0.1-0.125ml /kg, and the anesthesia maintenance pump speed was 0.2-0.5ml /kg/h.keep bispectral index within 40 # 60.Propofol 20 mg/ml,etomidate 2mg/ml.
3473265|NCT03855202|Experimental|infusion froup 1|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
3473266|NCT03855202|Experimental|infusion group 2|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
3473267|NCT03855202|Experimental|infusion group 3|PS,dose is 70mg/kg
3473268|NCT03855202|Placebo Comparator|Placebol|0.9% sodium chloride installation after 24 hours
3473269|NCT03854916|Experimental|Caminemos Juntas App|Participants use the Caminemos app.
3473270|NCT03854916|Active Comparator|World Walking App|Participants use the World of Walking App.
3473271|NCT03855371|Experimental|Decitabine plus arsenic trioxide|decitabine: 20mg/m2/d, intravenously, d1-d5, q4w arsenic trioxide: 0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
3473272|NCT03854955|Experimental|iScribes|Device-based scribing service used for dictation and documentation.
3473273|NCT03854955|No Intervention|Traditional Dictation|Standard dictation and documentation methods used.
3473274|NCT03855176|Active Comparator|1-dose group|Provide 1 booster dose of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
3473275|NCT03855176|Experimental|2-dose group|Provide 2 booster doses of HAV vaccine (Vaqta Injectable Product) to those who failed to response after primary HAV vaccination.
3473276|NCT03855046|Experimental|Xeomin|Complex treatment of chronic anal fissure with drug-induced relaxation of the internal sphincter with Botulinum Toxin Type A. (IncobotulinumtoxinA 50 U Intramuscular Powder for Solution).
3473277|NCT03855046|Active Comparator|Xeomin control|Complex treatment of chronic anal fissure with lateral subcutaneous sphincterotomy.
3179318|NCT00671450||Group 1|Participants will be patients diagnosed with PTSD but with no history of TBI. Participants must be between the ages of 19 and 39. Participants must be compentent to sign a consent form and be willing ot participate in a vision screening.
3179319|NCT00671463|Experimental|1|Pre-operative pancreatic duct stenting
3473278|NCT03855319|Experimental|SMR neurofeedback training to MCI|"A sensorimotor/theta neurofeedback training consisted of 20 individuals sessions, twice a week during 11 weeks maximum. For each subject, NF was planned and conducted by a neuropsychologist experienced in neurophysiology an neurofeedback. Each session lasted 1h10 minutes and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustement of the calibration.~NF training (tasks and video described below)(45minutes)~Feedback and debriefing about the session (15 minutes)"
3473279|NCT03855007|Experimental|Iguratimod|The participants plan to be treated with iguratimod alone, or along with methotrexate (MTX), hydroxychloroquine (HCQ) , prednisone (Pred) step by step
3473280|NCT03854968|Experimental|Quality control|The participants home mechanical ventilator will be tested in order to performe a quality control
3473281|NCT03855072|Experimental|Customized plate fixation|"Customized Plate fixation of Vertical Ramus Osteotomy after Mandibular Setback~- intervention:~All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together"
3473282|NCT03855072|Active Comparator|maxillomandibular fixation|"Mandibular Setback by Vertical Ramus Ostotmy fixed with Maxillomandibular fixation~- intervention:~All cases will undergo one surgery under general anesthesia~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint"
3473283|NCT03855163|Experimental|Inspection visits|Regulatory tool to ensure enterprise compliance with legal requirements
3473284|NCT03855163|Experimental|Guidance workshops|Regulatory tool applied to inform and advise enterprises on legal requirements and how to realize compliance with such requirements
3473285|NCT03855163|Experimental|Online risk assessment tool|Regulatory tool applied to aid enterprises in conducting written objectives concerning health, environment and safety activities
3473286|NCT03855163|No Intervention|Control group|The Labour Inspection Authority will not preform any intervention activities in enterprises assign to the control group
3473287|NCT03854864||Oncologists|French oncologists
3473288|NCT03855033|Experimental|Media Aware Sexual Health - High School|Students received the web-based Media Aware Sexual Health - High School program.
3473289|NCT03855033|No Intervention|Typical Health Education Programming|Students received their regular health education programming not related to sexual health education.
3473290|NCT03854981|Placebo Comparator|Standard Care|If subjects are assigned to this group they will not be provided materials to increase exercise participation. Subjects will however be asked to participate in the standard education sessions that are provided to all bariatric surgery patients. This standard care includes meetings with a nutritionist, psychologist, and bariatric surgeon.
3473291|NCT03854981|Active Comparator|Exercise + Standard Care|Subjects will be asked to exercise 5 days/week for 30 min/day at an intensity of 65-85% of their measured HRmax. Walking will be the main type of exercise. In addition to this training program, subject's will participate in the standard education sessions that are provided to all bariatric surgery patients.
3473292|NCT03854851|Experimental|NALDEBAIN|In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.
3473293|NCT03854851|Active Comparator|MORPHINE|In group MORPHINE, subjects will receive morphine as needed after surgery.
3473294|NCT03855098|Other|Fruit and Vegetable biomarkers|Each participant will consume the test foods over different weeks
3473295|NCT03854994|Experimental|Anti-CD19 CAR-T Cells Injection|Dosage form：injection Dosage:1-5x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes Frequency: total one time
3126107|NCT03020069|Experimental|Glucose Meter|Continuing Glucose Monitoring Device
3126108|NCT03020069|Active Comparator|No Glucose Meter|Average Blood glucose measure
3473296|NCT03854890|No Intervention|Lymphadenectomy without indocyanine green injection|Laparoscopic lymphadenectomy will be performed in a standard way.
3473297|NCT03854890|Experimental|Lymphadenectomy with indocyanine green injection|Injection of indocyanine green to the submucosal layer around rectal cancer 1 day before surgery. Laparoscopic proctectomy with lymph nodes dissection will be performed under near-infrared imaging.
3473298|NCT03855137|Active Comparator|Atogepant 30 mg BID|Taken twice daily
3473299|NCT03855137|Active Comparator|Atogepant 60 mg|Taken once daily
3473300|NCT03855137|Placebo Comparator|Placebo|Taken twice daily
3473301|NCT03854838|Experimental|Toripalimab +Radiotherapy|Radiotherapy, intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks ) will be administered as an intravenous infusion over 60 minutes.
3473302|NCT03854903|Experimental|Dose Level A1|"Palbociclib: 75mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
3473303|NCT03854903|Experimental|Dose Level A2|"Palbociclib: 75mg daily for the first 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle"
3473304|NCT03854903|Experimental|Dose Level B1|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 300mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
3473305|NCT03854903|Experimental|Dose Level B2|"Palbociclib: 100mg daily for 21 days of each 28 day cycle~Bosutinib: 500mg on days 1-5 of each week of the 28 day cycle~Fulvestrant: 500mg on days day 1, 5, and 28 of each 28 day cycle"
3473306|NCT03854799|Experimental|CHEMORADIOTHERAPY PLUS AVELUMAB|"CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70"
3473307|NCT03854929|Active Comparator|Ciprofloxacin|Each sachet CIPROFLOXACIN of 3g powder contains: 250mg Ciprofloxacin HCl, dissolved in water, dosed to 15mg/kg body weight /twice daily (apart 12 hours)/ 3 days.
3473308|NCT03854929|Experimental|Azithromycin|Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days
3473309|NCT03854812|Active Comparator|Group M|magnesium sulphate as adjuvant to propofol
3473310|NCT03854812|Active Comparator|Group F|fentanyl as adjuvant to propofol
3473311|NCT03854825||AKI|patients with postoperative AKI defined by KDIGO
3473312|NCT03854825||no AKI|patients without postoperative AKI defined by KDIGO
3473313|NCT03854877|Experimental|Health behaviour intervention|Personalised health behaviour e-health intervention. The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to promote health habits. Based on personal needs participants can choose tasks for physical activity, relaxation, healthy eating, sleep etc. They get regular feedback, tasks and support from their personal trainer via phone and computer.
3473314|NCT03854877|No Intervention|Control group|Only before and after measurements
3473315|NCT03854942|Other|First Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET followed by 7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
3473316|NCT03854942|Other|Second Arm|7 days placebo intake - i.v. injection of physiological saline solution (0,9%) - PET - 7 days naltrexone intake (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) - injection of physiological saline solution (0,9%) - PET
3473317|NCT03854942|Other|Third Arm|7 days placebo intake - i.v. injection of ethanol solution (6 Vol.-%) - PET - 7 days naltrexone (Nemexin, 50 mg once daily during the first 2 days, 100 mg daily for the following 5 days) intake - i.v. injection of ethanol solution (6 Vol.-%) - PET
3473318|NCT03854786|Active Comparator|Oxyjun|Oxyjun- 400 mg OD after breakfast
3473319|NCT03854786|Placebo Comparator|Methyl Crystalline Cellulose|Methyl Crystalline Cellulose- 400 mg OD after breakfast
3473320|NCT03854643|Experimental|Pilates group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
3473321|NCT03854643|Experimental|Control group|17 (seventeen) volunteers of both genders, aged between 18 and 35 years, were recruited for at least 3 (three) months with non-specific back pain. These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
3126109|NCT03020082|Experimental|Danoprevir, Ritonavir, Peg-IFN,RBV|Participants will receive Ritonavir- boosted Danoprevir 100mg/100mg BID in combination with subcutaneous injection of weekly peginterferon alfa-2a at 180 mcg and RBV administered orally 500mg (5 tablets)( body weight <75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg for 12 weeks.
3179320|NCT00671463|No Intervention|2|Control group, no endoscopy and no stent pre-operatively
3473322|NCT03854565||Mild ARDS|patients have mild ARDS according to Berlin definition
3473323|NCT03854565||Moderate ARDS|patients have moderate ARDS according to Berlin definition
3473324|NCT03854565||Severe ARDS|patients have severe ARDS according to Berlin definition
3473325|NCT03854708|Experimental|3 pmol/kg*min pancreatic polypeptide|3 pmol/kg*min of pancreatic polypeptide was intravenously infused.
3473326|NCT03854708|Experimental|10 pmol/kg*min pancreatic polypeptide|10 pmol/kg*min of pancreatic polypeptide was intravenously infused.
3473327|NCT03854708|Placebo Comparator|Placebo|0.9 % saline solution was intravenously infused.
3473328|NCT03854760|Experimental|anesthesiologist with limited experiment|Anesthesiologists with limited experiment of bronchoscopy.
3473329|NCT03854682|Experimental|Surgical|Radiofrequency microtenotomy (RF): A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
3473330|NCT03854682|Active Comparator|Non-surgical|Strength training: Consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
3473331|NCT03854773|Active Comparator|Erector spinae block (Group ESPB)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
3473332|NCT03854773|Active Comparator|Thoracal paravertebral block group (Group TPVB)|In group B, TPVB will be performed. US probe will be placed 2-3 cm laterally following the visualization T5 spinous process in sagittal orientation. The ribs and transverse processes will be visualized as hyperechoic structures. The costotransverse ligament will be visualized in the superior, and the pleura in the anterior region. Using in plane technique, the block needle will be inserted in the cranio-caudal direction until the costotransverse ligament will be passed. For confirmation of correct position of the needle, 5 ml saline will be injected. After the negative aspiration of cerebrospinal fluid, blood and air; 20 ml of 0.25% bupivacaine will be performed and it will be seen of moving downwards of the pleura during the injection
3473333|NCT03854773|Other|Control group (Group C)|Patients in control group will be only received fentanyl via a patient controlled analgesia (PCA) device.
3473334|NCT03854669|Experimental|Assessing pain reporting accuracy|Subjects will undergo pre-operative evaluation of their pain reporting accuracy ability in order to assess its relation to post-operative acute pain and analgesic consumption
3473335|NCT03854721|Experimental|VAX014|Intravesical VAX014 (dose: 3.33x10^10 - 9.0x10^11 recombinant bacterial minicells (rBMCs)), given once per week for Weeks 1-6
3473336|NCT03854539|Experimental|Active Stimulation 0.5|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
3473337|NCT03854539|Sham Comparator|Sham Stimulation|0.5mA intermittent transdermal stimulation of the aurical vagus stimulation5 Hz 30 seconds on/30 seconds off for five cycles
3473338|NCT03854539|No Intervention|No Stimulation|0.0 mA (sham) intermittent transdermal stimulation of the aurical vagus stimulation, 0 Hz 30 seconds on/30 seconds off for five cycles
3473339|NCT03854539|Experimental|Active Stimulation 1.0|0.5 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles.
3473340|NCT03854539|Experimental|Active Stimulation 0.25|0.25 mA intermittent transdermal stimulation of the aurical vagus stimulation 30 seconds on/30 seconds off for five cycles
3473341|NCT03854331|Experimental|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
3473342|NCT03854331|No Intervention|Standard care|Danish antenatal standard care is 3 visits at the general practitioner, 5 midwife controls and 2 ultrasound scans
3473343|NCT03854435|Experimental|Heart rate assessed by using a stethoscope (auscultation)|Heart rate will be assessed by using a stethoscope (auscultation) in newborn infants immediately after birth
3473344|NCT03854435|Active Comparator|Heart rate assessed by palpation of the umbilical cord|Heart rate will be assessed by palpation of the umbilical in newborn infants immediately after birth
3473345|NCT03854383|Sham Comparator|Misoprostol alone|Enrolled women will receive 25 πg of misoprostol which will be placed intravaginally 4 hourly, maximum up to 5 doses
3473346|NCT03854383|Active Comparator|Isosorbide mononitrate with misoprostol|Enrolled women will receive 25 πg of misoprostol together with 40 mg isosorbide mononitrate which will be placed intravaginally 4 hourly, maximum up to 5 doses
3473347|NCT03854513||-Group 1 (anuric)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output less than 100ml / day
3473348|NCT03854513||Group 2 (good UOP)|patients on maintenance hemodialysis after 6 months to 1 year or more and urinary output 400ml / day or more
3473349|NCT03854292||Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopic electrocoagulating roller ball
3473350|NCT03854292||Laparoscopic tubal disconnection|Coagulation of the mid isthmus region of the affected Fallopian tube, with the bipolar forceps. using direct current that was no greater than 25 Watts.
3473351|NCT03854656|No Intervention|Control|Control group for 13 weeks (n=50). Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
3473352|NCT03854656|Experimental|Time-restricted eating|Time-restricted eating for 13 weeks (n=50). In addition to the intervention, participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
3473353|NCT03854630|Active Comparator|Standard dose (20µg)|Three doses of 20µg HBV vaccine given intramuscularly at week 0, 4, 24.
3473354|NCT03854630|Experimental|Double dose (40µg)|Three doses of 40µg HBV vaccine given intramuscularly at week 0, 4, 24.
3473355|NCT03854617|Experimental|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
3473356|NCT03854617|Active Comparator|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period.
3473357|NCT03854591||Gunshot related injury|Patients admitted to orthopaedic trauma service with gunshot related injury
3473358|NCT03854526||Patients without Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months and with at least one tooth with coronal dental restoration
3473359|NCT03854526||Patients with Gougerot Sjogren disease|New patient, or patient, with no history of a dental examination in the last six months, with at least one tooth with coronal dental restoration and presenting a Gougerot Sjogren disease
3473360|NCT03854409|Experimental|Part A - Deltoid Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
3473361|NCT03854409|Experimental|Part A - Gluteal Site: Single Dose Group|Participants will receive a single dose of aripiprazole LAI.
3473362|NCT03854409|Experimental|Part A - Deltoid Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
3473363|NCT03854409|Experimental|Part A - Gluteal Site: Multiple Dose Group|Participants will receive five injections of aripiprazole LAI, administered at monthly intervals.
3473364|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (X)|Participants will receive a single dose of aripiprazole LAI.
3473365|NCT03854409|Experimental|Part B - Gluteal Site: Group 1 (Y)|Participants will receive a single dose of aripiprazole LAI.
3473366|NCT03854409|Experimental|Part B - Gluteal Site: Group 2|Participants will receive a single dose of aripiprazole LAI.
3473367|NCT03854357|Experimental|Additional Isolated Subscapularis Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
3126110|NCT03020095|Experimental|Ravidasvir,Danoprevir/r,RBV|Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks.
3473368|NCT03854357|Active Comparator|Standard Post-Operative TSA Rehabilitation|Patients will be randomized to receive additional isolated subscapularis specific rehabilitation exercises during their standard post-operative physical therapy sessions after anatomic total shoulder arthroplasty.
3473369|NCT03854487|Experimental|Mirror therapy|
3473370|NCT03854487|Sham Comparator|Sham mirror|
3473371|NCT03854487|Active Comparator|Covered mirror|
3473372|NCT03854344|Experimental|Group 1|Liposomal Bupivicaine (266mg/20ml) will be diluted into Lactated Ringer solution (280 ml) and injected once intra-operatively subcutaneously before donor site harvesting
3473373|NCT03854344|Active Comparator|Group 2|Lidocaine (50 mg/50 ml) will be diluted into Lactated Ringer (1000ml) and injected once subcutaneously before donor site harvesting
3473374|NCT03854279|Experimental|Bizact|Tonsillectomy will be done With the Bizact device
3473375|NCT03854279|Active Comparator|Electro-scissor|Tonsillectomy will be done With electro-scissors
3473376|NCT03854305|Experimental|PRV-6527|Oral administration, 2X daily for 12 weeks
3473377|NCT03854305|Placebo Comparator|Placebo|Oral administration, 2X daily for 12 weeks
3473378|NCT03854396|Active Comparator|Intravaginal prasterone insert|Nightly intravaginal prasterone insert for 24 weeks
3473379|NCT03854396|Placebo Comparator|Intravaginal placebo insert (Witepsol H-15)|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks
3473380|NCT03854266|Experimental|Catheter directed thrombolysis|Low dose alteplase (4/8 milligram) will be infused over 2 hours locally in the pulmonary arteries at the site of the thrombus through an infusion catheter with sideholes (Unifuse, AngioDynamics, US)
3473381|NCT03854266|Active Comparator|Unfractionated heparin|Initial dose of unfractionated heparin is 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time is 1.5-2.3 times control value.
3473382|NCT03854240|Active Comparator|Classic block (Group C)|In group C, classic technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and multifidus muscles. Between these muscles, block needle will be inserted within in plane technique in a lateral-to-medial direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
3473383|NCT03854240|Active Comparator|Modified block (Group M)|In group M, modified technique will be performed. US probe will be placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe will be moved forward to the lateral to visualize the longissimus and iliocostal muscles. Between these muscles, block needle will be inserted within in plane technique in a medial-to-lateral direction in the interfascial plane. Once the needle tip will be placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 20 mL will be injected in each side (total 40 mL)
3473384|NCT03854422|Active Comparator|Left Position during colonoscopy|Left position, the patient will be in the left-side position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.Moreover, process recall, sedation amounts and pain scale will be measured after the procedure..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent (midazolam) used during the process is paid attention to be equal. All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
3473385|NCT03854422|Active Comparator|Left Supine Position during colonoscopy|Left Supine position, the patient will be in the left and supine ( after splenic flexura) position during the entire colonoscopy period. If necessary, change of position and pressure will be allowed. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured.
3473386|NCT03854422|Active Comparator|Dynamic position during colonoscopy|Dynamic position, the patient will be stared as left position during colonoscopy period. If necessary, change of position and pressure will be allowed at any time. During this procedure, the time to reach the cecum and terminal ileum, patient comfort, and the process memory lost will be measured..During the process, it will be examined whether there is any need for loop formation, repositioning requirement and pressure requirements. The type and amount of anesthetic agent used during the process is paid attention to be equal. The use of midazolam as an anesthetic agent was planned.All procedures will be done with the same brand device. After the procedure, a mini questionnaire will be applied to the patients for the pain scale.
3473387|NCT03854110|Experimental|GP-2250 Monotherapy|GP-2250 in doses of 250 mg up to 30 grams intravenously on Days -7, 1, 8, 15 of a 28 day cycle with gemcitabine 1000 mg/m2 on Days 1, 8, 15 days of the cycle.
3473388|NCT03854149||Adults with CHD & non-valvular atrial arrhythmias|Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)
3473389|NCT03854058||OHS or elevated OHS-risk (stages 0-IV)|"stage 0: OHS-risk (OSA / no hypercapnia)~stage I: obesity associated hypoventilation (intermittent hypercapnia during sleep, arterial carbon dioxide partial pressure (PaCO2) or transcutaneous carbon dioxide partial pressure (PtcCO2) morning ~ evening), bicarbonate < 27 mmol/L awake)~stage II: obesity associated hypoventilation (intermittent hypercapnia during sleep, PaCO2 or PtcCO2 morning > evening, bicarbonate ≥ 27 mmol/L awake)~stage III: OHS (hypercapnia, carbon dioxide partial pressure (PCO2) > 45 mmHg awake)~stage IV: OHS with end organ damage (hypercapnia , PCO2 > 45 mmHg awake, cardiometabolic comorbidities)~diagnostic tests: magnetic phrenic nerve stimulation, diaphragmatic ultrasound"
3473390|NCT03854123||Old MS patients|"75 to 77 years old MS patients whose disease began at 65 years old or earlier will be retrieved from the Observatoire français de la sclérose en plaques (OFSEP)."
3473391|NCT03854162|Active Comparator|FREEHAND|For these cases, the regular protocol of the study site is observed. The operator has the plan at their disposal projected on a screen in the operating theater. The preparation of the bony bed and the insertion of the implant are performed freehand, without any guidance. The positions and directions are determined with the naked eye, observing the plan projected on the screen. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
3126111|NCT03020160|Experimental|Emicizumab: Expansion Part|Participants will received SC emicizumab at a loading dose of 3 mg/kg every week for initial 4 weeks followed by a maintenance dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
3126112|NCT03020160|Experimental|Emicizumab: PK Run-in Part|Participants will received SC emicizumab at a dose of 6 mg/kg every 4 weeks for a minimum of 24 weeks.
3126113|NCT03020407|Experimental|IVC Ultrasound-guided|The treating physician will promptly assess the IVC diameter to obtain the collapsibility index (IVCCI) (or distensibility index, IVCDI) of an eligible patient. A previous study showed that IVCCI > 40% were strongly associated with fluid responsiveness. Accordingly, the patient will be given 10 ml/kg of bolus of 0.9% normal saline solution (NSS) each time when the IVCCI > 40% is discovered and serial measurements will be done after each intravenous bolus is achieved until the IVCCI < 40 % during our protocol. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
3179321|NCT00671541|Active Comparator|Merogel stent vs. Nasopore Stent|This study has two arms consiting of 50 subjects each (100 total) Arm 1 will recieve the standard stent (merogel)in their right sinus and a nasopore stent in their left sinus.
3473392|NCT03854162|Active Comparator|PILOT|The SMART Guide surgical template is applied only in the initial phase of the operation. After having prepared soft tissue access, the template is placed, and only one drilling is performed through its sleeve, with the so-called pilot drill. The resulting borehole serves as directional guidance for the drills applied later in the process. Further drilling and implant insertion are both performed freehand. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
3473393|NCT03854162|Active Comparator|PARTIAL GUIDE|The only non-guided step is implant insertion, that is, all drilling happens through the SMART Guide surgical template. After having prepared soft tissue access, the guide is placed, and all drillings are performed through it, according to the surgical protocol. Here the depth of the bony bed is also determined, as the sleeve does not allow the drill to move any deeper than planned. At the end of the operation, the operation site is checked, hemostasis is provided, and the operator records the operation in the source documentation. 2±1 days later, a postoperative CT scan is taken. A follow-up visit is due 14±2 weeks later, after the osseointegration period.
3473394|NCT03854162|Active Comparator|FULL GUIDE|"The SMART Guide surgical template is used for all steps of the operation, including the insertion of the implant. Apart from this, the procedure is exactly the same as described under partial guide."
3473395|NCT03854175|Active Comparator|Sildenafil group|40 women are give sildenafil citrate 25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle, in addition to oral 2mg of estradiol valerat 6-8 hourly from the day 2-14 of the menstrual cycle
3473396|NCT03854175|Active Comparator|estradiol group|40 women are given oral estradiol valerate tablets 2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium in addition to placebo in the same way as sildenafil
3473397|NCT03853915|Experimental|FDG PET Scan|[F-18] - FDG PET Scan and blood sample to measure HPV DNA
3473398|NCT03854201|Experimental|Personalized Exercise Counseling (PEC)|The Personalized Exercise Counselling intervention includes 3 face-face counseling sessions and 4-6 phone calls during six months. In addition, the participants are provided with the ExSed® interactive accelerometer to record their physical activity 24/7 from which they will receive personal daily feedback on their smart phone, which is provided to each person not having a suitable one of their own to be used during the 6-month intervention period.
3473399|NCT03854201|No Intervention|Control-arm|The participants only take part in the study measurements at baseline and the three follow-up time points. They will be provided personal written information by the UKK Institute on their blood sugar and lipid profiles, objectively measured physical activity (light, moderate, vigorous), standing, sedentary behaviour and sleep, and the three fitness tests measuring flexibility, muscular strength and cardiorespiratory fitness.
3473400|NCT03853941|No Intervention|Control|Patients in the control group will receive treatment as usual.
3473401|NCT03853941|Experimental|Experimental|The experimental group will receive clinical treatment as usual, however, the healthcare professionals treating them will have received training on how to enhance patient adherence via the use of a motivationally supportive communication style. Thus, the style/language healthcare professionals use to convey usual treatment recommendations may differ.
3473402|NCT03853954|Experimental|Methoxyflurane|Dosage form: inhalation Dosage: 3 mL methoxyflurane per inhaler, to be self-administered Frequency: maximum one inhaler (3 mL) per patient Duration: <15 minutes
3473403|NCT03853980|Experimental|Rotational fractional resection (RFR)|Single treatment of skin resection (removal of loose skin)
3473404|NCT03854214|Active Comparator|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc) with stimulation on.
3473405|NCT03854214|Sham Comparator|Passive Cycling|The passive cycling group will use the same RT300 ergometer with stimulation off.
3473406|NCT03853850|Experimental|Intervention|Participating mothers will receive mobile phone text messages during their babies' first 6 months of life. Messages will educate mothers on breastfeeding and proper infant feeding.
3473407|NCT03854097|Experimental|Active PAD group|-40mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
3473408|NCT03854097|Experimental|Placebo PAD group|-10mmHg of Intermittent Negative Pressure (INP) for 4-8 weeks.
3473409|NCT03854097|Experimental|Healthy Volunteers|-40 mmHg of Intermittent Negative Pressure (INP) for 5 days
3473410|NCT03854071|Other|Group 1|Heart failure patients with preserved ejection fraction
3473411|NCT03854071|Other|Group 2|Heart failure patients with reserved ejection fraction
3473412|NCT03854071|Other|Group 3|Patients with pulmonary hypertension
3473413|NCT03854071|Other|Group 4|Patients with acute myocardial infarction
3473414|NCT03854071|Other|Group 5|Patients with suspected but not treated coronary artery disease
3473415|NCT03854071|Other|Group 6|Healthy Volunteers
3473416|NCT03853993|Experimental|Experimental group-phase I|Quadrivalent influenza vaccine
3473417|NCT03853993|Experimental|Experimental group-phase III|Quadrivalent influenza vaccine
3473418|NCT03853993|Active Comparator|Control group-1-phase III|Trivalent influenza vaccine (contains B/Victoria strain)
3473419|NCT03853993|Active Comparator|Control group-2-phase III|Trivalent influenza vaccine (contains B/Yamagata strain)
3473420|NCT03853863|Experimental|minimalist shoes walking group (MSW)|Subjects in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., in-school walking training with minimalist shoes).
3473421|NCT03853863|Active Comparator|traditional shoes walking group (TSW)|Subjects in the TSW group will be given a pair of protective shoes with arch support while following the same wearing pattern as the MSW group (i.e., in-school walking training with protective shoes).
3473422|NCT03854084|Experimental|Intervention group|The cranial osteopathic techniques
3473423|NCT03854084|Sham Comparator|control group|Control group
3473424|NCT03854188|Experimental|Acupuncture treatment|Patients diagnosed with chronic pelvic pain will be offered acupuncture treatment as an adjuvant therapy to standard of care treatment.
3473425|NCT03854045|Experimental|Home-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the home with 2 clinicians present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR but are not eligible for Medicaid reimbursement.
3473426|NCT03854045|Active Comparator|Clinic-based|Clinicians at the FQHC will identify and offer the opportunity to receive telepsychiatry in the clinic with 1 clinican present. The patients are not required to agree to the evaluation to receive the services. The services are entered into their EHR and eligible for Medicaid reimbursement.
3473427|NCT03854019|Experimental|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|Dextromethorphan/quinidine (DM/Q) 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
3473428|NCT03854019|Placebo Comparator|Placebo|Placebo one capsule once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
3473429|NCT03853967|Experimental|screening|participants performed lung cancer screening by Low Dose CT scan
3473430|NCT03854006|Active Comparator|Freeze cycle: 240 s - TTI <75 s or 2x240 s - >75 s|"In the first group freeze duration is 240s if TTI (time-to-isolation) is < 75 s. In case of TTI>75s a 240s bonus freeze is applied.~If no TTI could be documented, a single 240 s freeze cycle is applied in this group in case of balloon temperature -40°C (degrees Celsius) after 60 s."
3473431|NCT03854006|Active Comparator|Freeze cycle: TTI+120 s|In the second group freeze duration is TTI (time-to-isolation) +120 s. If no TTI could be documented, a single 180 s freeze cycle is applied in this group in case of balloon temperature -40 °C after 60 s.
3473432|NCT03853785|Active Comparator|Intralesional MMR vaccine|Intralesional Mumps, measles and rubella (MMR) vaccine in genital warts
3473433|NCT03853785|Active Comparator|intralesional candida antigen|intralesional candida antigen in genital warts
3473434|NCT03853785|Active Comparator|Topical Podophyllin|Topical Podophyllin in genital warts
3473435|NCT03853655|No Intervention|Control arm|Patients in this arm will be observed and kept under active follow-up after surgery for the primary.
3473436|NCT03853655|Experimental|Study arm|Intervention in the study arm will be in the form of post-operative adjuvant radiotherapy starting within 6-weeks after primary surgery.
3473437|NCT03853720|Experimental|Intervention arm|combined and simultaneous balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices
3473438|NCT03853889|Active Comparator|preepidural ONSD|The diameter of the optic nerve sheath to be measured(ONSD) with the help of ultrasonography before epidural anesthesia(pre epidural ONSD). The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
3473439|NCT03853889|Experimental|post epidural ONSD|The diameter of the optic nerve sheath to be measured with the help of ultrasonography Immediately after epidural anesthesia(post epidural ONSD) (T1), 15 minutes (T2), 30 min (T3), 60. min (T4) epidural anesthesia. The measurement will be measured 3 mm behind the optical disc. The measurements shall be applied in both transverse and sagittal planes for both eyes and the arithmetic mean of the four measured values.
3473440|NCT03853928|Experimental|Probiotics|50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .
3473441|NCT03853928|Placebo Comparator|Placebo|5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly). Duration of treatment Continuous, 1 cycle per month. Continuous treatment will be carried out from randomization to the development of the primary event or until the end of the study.
3473442|NCT03853681|Other|additional blood sampling|
3473443|NCT03853603|Placebo Comparator|Placebo|Maltodextrin
3473444|NCT03853603|Active Comparator|Santa herba extract|Santa herba extract
3473445|NCT03853707|Experimental|Arm A (ipatasertib, carboplatin, paclitaxel)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3473446|NCT03853707|Active Comparator|Arm B (ipatasertib and carboplatin)|Patients receive ipatasertib PO QD on days 1-28. Patients also receive carboplatin IV over 30 minutes on days 1, 8, and 15 or days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3473447|NCT03853707|Experimental|Arm C (ipatasertib, capecitabine, atezolizumab)|Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3473448|NCT03853837||Prospective Fontan patients|Fontan patients to be enrolled and complete study tests/procedures
3473449|NCT03853837||Retrospective Fontan patients|Fontan patients to be retrospectively reviewed and used as control subjects
3473450|NCT03853525|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with BAY207543 is investigated.
3473451|NCT03853525|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 randomized to one side of the inguinal region and semisolid vaseline to the other side of the inguinal region after laser depilation. The side with vaseline is investigated.
3473452|NCT03853811|Experimental|Mitchell Shoe + AFO|Group will receive standard Mitchell shoes along with the custom orthotic insert.
3473453|NCT03853811|No Intervention|Standard Mitchell Shoe (Control - Standard Treatment)|Group will receive standard treatment which includes bracing with standard Mitchell shoes (no custom orthotic). Patients would receive this treatment regardless of study participation.
3473454|NCT03853668|Active Comparator|aerobic exercise group|"aerobic exercises (intervention) on treadmill for 10 weeks, 3 times/week for duration of 30-45 min/session.~Exercise intensity is 50-65%of maximal heart rate (MHR)"
3473455|NCT03853668|Experimental|aerobic and resisted exercise|combined resisted and aerobic exercises (intervention) for 10 weeks (circuit weight training and treadmill training respectively) 2 times/week for a duration of 30-45 min/session Exercise intensity is 50-65%of maximal heart rate (MHR) for aerobic part and 50% of 1 repetition maximum (1RM) for resistance part.
3473456|NCT03853746|Experimental|Ocrelizumab|All participants will receive Ocrelizumab
3473457|NCT03853408||First Admission|Cholecystectomy during first admission
3473458|NCT03853408||Second Admission|Cholecystectomy during second admission
3473459|NCT03853564|Experimental|Video-Feedback Group (VFG)|Dyads of mothers and their infant with developmental disability who are exposed to the video-feedback intervention focused on different domains of mother-infant quality of interaction (number of sessions: 6).
3473460|NCT03853564|Sham Comparator|Phone-Call Group (PCG)|Dyads of mothers and their infant with developmental disability who are not exposed to the video-feedback intervention, instead they receive phone calls focused on obtaining descriptions of different domains of infant behavioral development (number of sessions: 6)
3473461|NCT03853824|Other|Intervention arm|Patients randomised to increased postoperative surveillance.
3473462|NCT03853824|Other|Control arm|Patients randomised to usual postoperative care.
3473463|NCT03853642||Single-arm trial|Patient receiving blood sampling, spirometry and Feno
3473464|NCT03853590|Active Comparator|Laparoscopic Adjustable Gastric Band|Subjects who elected to undergo Laparoscopic Adjustable Gastric Band intervention were examined prior to surgery and at 2, 3, 6 months after operation.
3473465|NCT03853590|Experimental|Roux-en-Y gastric bypass surgery|Subjects who elected to undergo Roux-en-Y gastric bypass surgery were examined prior to surgery and at 2, 3, 6 months after operation.
3473466|NCT03853538|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
3473467|NCT03853538|Active Comparator|Women_Hemiface Vaseline|Adult women receive the test product randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
3473468|NCT03853577|Active Comparator|Psilocybin|
3473469|NCT03853577|Placebo Comparator|Placebo|
3473470|NCT03853694|Active Comparator|Group 1 (Standard of Care Group)|150 mcg Duramorph® + postoperative multi-modal pain regimen. No EXPAREL TAP infiltration
3473471|NCT03853694|Experimental|Group 2 (Duramorph + EXPAREL TAP)|50 mcg Duramorph + EXPAREL TAP infiltration + postoperative multi-modal pain regimen.
3473472|NCT03853694|Experimental|Group 3 (EXPAREL TAP)|EXPAREL TAP infiltration + postoperative multi-modal pain regimen. No Duramorph.
3473473|NCT03853902|Experimental|Mindfulness Program Online|Online 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
3473474|NCT03853902|Active Comparator|Mindfulness Program Face-to-Face|In-person 4-week mindfulness program that is intended to reduce stress and improve the quality of life of patients with metastatic prostate cancer
3473475|NCT03853239|Active Comparator|face mask crossover nasal ventilation|
3473476|NCT03853239|Active Comparator|nasal ventilation crossover face mask|
3473477|NCT03853265|No Intervention|Control|
3473478|NCT03853265|Experimental|Virtual Reality|Simulated dental office visit
3473479|NCT03853382|Experimental|Cognitive Analytic Informed Brief Therapy|
3473480|NCT03853382|No Intervention|Treatment As Usual|
3473481|NCT03853304|Experimental|Quadruple-Fortified Salt (QFS)|Salt fortified with iron, iodine, folic acid, and vitamin B12
3473482|NCT03853304|Experimental|DFS + Folic acid|Salt fortified with iron, iodine, and folic acid
3473483|NCT03853304|Experimental|DFS + Vitamin B12|Salt fortified with iron, iodine, and vitamin B12
3473484|NCT03853304|Active Comparator|Double-fortified salt (DFS)|Salt fortified with iron and iodine
3473485|NCT03853512|Experimental|Women_Inguinal side BAY207543|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with BAY207543 will be investigated.
3473486|NCT03853512|Active Comparator|Women_Inguinal side Vaseline|Adult women apply BAY207543 to one side of the inguinal region, and semisolid vaseline to the the opposite side after skin peeling. The area with the vaseline will be investigated.
3473487|NCT03853447||Diagnostic imaging|"The progression of fibrosis will be assessed based on diagnostic imaging of thre subgroups including~Patients with chronic pancreatitis (CP; N=50) of any aetiology, except gallstones, based on MANNHEIM.~Patients with their first attack of acute pancreatitis (AP; N=50) of any aetiology except gallstones using the revised Atlanta criteria for AP.~Patients with recurrent AP (RAP; N=50) except gallstones, defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria."
3473488|NCT03853343|Placebo Comparator|Placebo|3 capsules per day (1 before each meal) of cellulose
3473489|NCT03853343|Active Comparator|Seaweed extract|3 capsules per day (1 before each meal) of seaweed extract
3473490|NCT03853278|Experimental|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill trainings and 12 follow-up telephone calls.These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
3473491|NCT03853278|No Intervention|No intervention control group|The control group will receive health education leaflets.
3473492|NCT03853460|Active Comparator|epidural group|ULTRASOUND GUIDED thoracic epidural at T 12 WILL BE INSERTED before anaesthesia induction
3473493|NCT03853460|Active Comparator|quadus lumborum group|bilateral ultrasound guided quadratus lumborum catheter will be inserted before anaesthesia induction
3473494|NCT03853421|Experimental|Dose cohort 3 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
3473495|NCT03853421|Experimental|Dose cohort 6 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
3473496|NCT03853421|Experimental|Dose cohort 9 mg/kg sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
3473497|NCT03853434|Experimental|Embolization|After angiography all metastases with poor/moderate vascularization will be embolized with acrylic glue in the treatment group.
3473498|NCT03853434|No Intervention|No embolization|After angiography all metastasis with poor/moderate vascularization will not be embolized with acrylic glue in the control group
3473499|NCT03853291|Experimental|PICT Workbook|PICT Workbook components will include: a) training using an observational assessment tool to detect pain in PWD, b) coaching and feedback by a research nurse in effective strategies for communicating with providers about PWD's pain, c) future planning for what steps to take when a pain symptom is detected, and d) updating the caregiver's skill set.
3473500|NCT03853291|Active Comparator|Information Pamphlet|Informational pamphlet about pain in dementia and a link to the Alzheimer's Association website.
3473501|NCT03853356||Lumbar spondylodesis involving 1-2 levels (L4-L5 and/or L5-S1)|
3473502|NCT03853395|Active Comparator|Control Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will not receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant.
3473503|NCT03853395|Experimental|Experimental Arm|Participants on this arm of the study will provide trough blood samples and complete participant questionnaires. Their research teams will return clinical information about them to the University of Manchester. Clinicians for this group of participants will receive blood results (about drug levels or anti-drug antibodies) or treatment advice from the University of Manchester about their participant. They will be able to act accordingly.
3473504|NCT03853330|Active Comparator|Thoracic Epidural Analgesia group|25 patients will receive ultrasound-guided thoracic epidural analgesia for multiple fracture ribs at the level of T8 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
3473505|NCT03853330|Active Comparator|Erector spinae plane block group|25 patients will receive ultrasound-guided ESP block for multiple fracture ribs at the level from T1 to T5 with 7.5-12 ml of Bupivacaine HCl Inj 0.25% as a loading dose followed by catheter insertion and infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h. For breakthrough pain bolus of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution 5-10 ml can be used.
3473506|NCT03853317|Experimental|Treatment with avelumab, haNK™ and N-803|The primary objective is to determine the efficacy of the combination treatment of avelumab, haNK, and N-803 in subjects with MCC that has progressed on or after checkpoint inhibitor therapy by objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on Blinded Independent Central Review (BICR).
3473507|NCT03853629||CF|"Age 1-17~Diagnosis of Cystic Fibrosis~Living in or around London"
3473508|NCT03853629||Controls|"Age 1-17~Healthy~Living in or around London"
3473509|NCT03853252|Other|Skin biopsy|
3473510|NCT03853499||Successful vacuum extraction|Patients for whom vacuum extraction was successful
3473511|NCT03853499||Failed vacuum extraction|Patients who had an emergency caesarean section after failed vacuum extraction
3473512|NCT03853200|Experimental|Group I|QMix the solution under investigation which includes CHX EDTA and detergent QMix Root Canal Irrigant
3473513|NCT03853200|Active Comparator|Group II|it involves use of two irrigant solutions, 17%EDTA+2%Chlorhexidine
3473514|NCT03853200|Active Comparator|Group III|17% EDTA with no antibacterial activity . the control group
3473515|NCT03853174|Active Comparator|ET|Active Comparator: ET Endurance training were prformed. Intensity was gradually increased.
3473516|NCT03853174|Other|RT|Resistance training were prformed. Intensity was gradually increased.
3473517|NCT03852836|Other|1.5T magnetic field|For each patient who undergo a 1.5T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
3473518|NCT03852836|Other|3T magnetic field|For each patient who undergo a 3T MRI, 3 sequences will be done: (i) a conventional SPACE sequence, (ii) an ultra-rapid sequence (sequence CS-SPACE) acquired in apnoea and (iii) an accelerated sequence (sequence CS-SPACE) but remaining synchronized with the breath.
3126114|NCT03020407|No Intervention|Usual care|Patients will be promptly and empirically treated by 30 ml/kg loading of NSS in this treatment arm. After the NSS bolus, treatment with either the additional intravenous fluid or a vasopressor is given depended on physicians' discretion during the 6-hour study period. Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
3126115|NCT03020472|Experimental|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist LAIV (Intranasal) Seasonal live, attenuated influenza vaccine
3126116|NCT03020498|Other|Group A: 8-17 yo identical twins|Group A: 8-17 year-old identical twin pairs randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV)) within the pair
3473519|NCT03852823|Experimental|SG001|Recombinant Human Anti-PD-1 Monoclonal Antibody
3473520|NCT03853148|Active Comparator|Otago|The Otago exercise program consists of the following: 1) A series of warm-up exercises, 2) Select exercises from the 17 Otago exercises which challenge the participant's strength and balance for up to 30 minutes, three times a week, 3) A walking program for up to 30 minutes, three times a week. Each Otago will be tailored for each participant's ability level.
3126117|NCT03020498|Other|Group B: 8-30 yo non-twin|Group B: 8-30 years old non-twin individuals randomly assigned to Fluzone (trivalent, inactivated influenza vaccine (TIV)) or FluMist (live, attenuated influenza vaccine (LAIV))
3473521|NCT03853148|Active Comparator|Otago + Gentle yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the Otago+GYYB group each exercise and their perceived benefits.
3473522|NCT03853148|Active Comparator|Otago + GYYB + Behavioral activation|This condition will incorporate OEP and GYYB as above and will also include behavioral activation to address motivation and affect. Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities. Each participant outlines general values and specific behaviors that 'demonstrate' each value, compiling a list of the latter. This list is then used to generate 10 to 20 highly defined values-based, reinforcing activities. Next, this list is combined with the activities outlines in Otago and GYYB and this master list is used to schedule these values-based activities for the next two days.
3473523|NCT03853148|Experimental|Caregiver Gentle yoga & yogic breathing|The GYYB is a one-hour program containing gentle physical Yoga postures that participants could practice sitting on a chair for 30 minutes. These exercises are designed based on improving the overall flexibility, bodily control and mindfulness in movements. Following the gentle yoga postures, the participants will perform Yogic breathing exercises for 30 minutes. These exercises are known to promote relaxation, mood, pain and anxiety scores that are highly relevant to the target population and are reported to stimulate measurable biomarker changes in the saliva. During the in-person session the Yoga instructor will explain the GYYB program to participants in the GYYB group each exercise and their perceived benefits.
3473524|NCT03853096|Experimental|Subcutaneous cefazolin arm|"A patient receiving a standard deltopectoral approach will have the planned incision site divided into thirds. This will produce 6 segments. Each segment will be biopsied using a commercially available dermatology punch and sent for colony count prior to local antibiotic infiltration. Cefazolin will be administered to one half of the incision only, into three segments. Following 60 minutes of operative time, the biopsies will be repeated and sent for colony count for comparison.~Cefazolin administered will be 100mg/mL in 3 aliquots for 3 site administrations leading to a total subcutaneous injection of approximately 900mg. There will be a one time administration of the antibiotics in a subcutaneous route."
3473525|NCT03852784||Bone and joint infection with Streptococcus peumoniae|Patients having had an osteoarticular infection with Streptococcus peumoniae
3473526|NCT03853161|Experimental|Vapotherm arm|Preterm infants in this arm will be given respiratory support of heated humidified high flow via Precision Flow Vapotherm, Exeter, USA
3473527|NCT03853161|Experimental|NIPPV arm|Preterm infants in this arm will be given respiratory support of Nasal Intermittent Positive Pressure Ventilation via the Leoni Plus neonatal ventilator
3473528|NCT03853057|Experimental|non-invasive ventilation|Non-invasive positive pressure at different body positions: sitting - supine - prone - right lateral and left lateral.
3473529|NCT03853135||Behçet group|Forty two patients diagnosed to have Behçet disease fulfilling the International Study Group Criteria for Behçet disease in whom measurement of serum endocan levels will be performed.
3473530|NCT03853135||control group|including 42 age and sex matching healthy volunteers as control group in whom measurement of serum endocan levels will be performed.
3473531|NCT03852732|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
3126118|NCT03020498|Other|Group C: 70-100 yo non-twin|Group C: 70-100 years old non-twin elderly adults given Fluzone (trivalent, inactivated influenza vaccine (TIV))
3473532|NCT03852979|Experimental|neo-adjuvant chemotherapy|The patients are given weekly paclitaxel 80 mg/m2 + carboplatin AUC=2 (or AUC=6 per three weeks) during 12 weeks/4 courses followed by conization if tumor size is reduced to <2 cm
3473533|NCT03852745|Other|Cognitive Behavioral Therapy|Online cognitive behavioral therapy intervention for 2 hours a week for 12 weeks.
3473534|NCT03853031|Active Comparator|LVEDA guided intraoperative fluid therapy|Patients in TEE group will be given crystalloid fluids during surgery guided by LVEDA cm2 to be maintained between 10 -18 cm2 , if LVEDA < 10 cm2 then 200ml colloid bolus will be given and increase in LVEDA noted.
3473535|NCT03853031|Active Comparator|CVP guided intraoperative fluid therapy|Patients in CVP group will be given crystalloid fluids during surgery guided by CVP values to be maintained between 10 -16 cms of water H2O ,if CVP value < 10 cms H2O then 200 ml colloid bolus will be given and increase in CVP value noted.
3473536|NCT03852953||Study 1: Under- and overdiagnosed group|Non-proportional stratified sample of women diagnosed with interval or screen-detected breast cancers after participation in BreastScreen Norway. This sample will include under- or overdiagnosed cancers, as well as cancers that were not under- or overdiagnosed.
3473537|NCT03852953||Study 2: Rate of overdiagnosis group|Women residing in Norway, born between 1927 and 1934 (inclusive). This cohort will include women who have attended screening and who have not attended screening.
3473538|NCT03852953||Study 3: Awareness and knowledge group|Women aged 50-69, and practising family doctors aged 25-75, currently living in Norway.
3179322|NCT00671541|Experimental|bacitracin vs. gentamicin treated stent|The second arm will consist of 50 new subjects. These 50 subjects will have a nasopore stent placed in the left sinus. The first 25 subjects will have nasopore stent placed postoperatively with a bacitracin soaked nasopore in right sinus the second 25 will have a gentamycin soaked nasopore stent in right sinus.
3473539|NCT03852992|Experimental|Safety Group|"will participate in one visit, receiving laser assisted delivery of minoxidil and PK data. The safety group treatments will follow dose escalation as follows:~Safety Participant 1: Post-laser 5mg minoxidil (0.25ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 2: Post-laser 10mg minoxidil (0.5ml of 20mg/ml sterile solution, applied post-laser procedure)~Safety Participant 3: Post-laser 20mg minoxidil (1mL of 20mg/mL sterile solution, applied post-laser procedure)"
3473540|NCT03852992|Placebo Comparator|Placebo|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Saline 0.9%: 2ml of sterile saline solution applied post-laser procedure"
3473541|NCT03852992|Experimental|Treatment A|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure"
3473542|NCT03852992|Experimental|Treatment B|"Laser: Fractional ablative, deep mode, 5% fractional coverage~Post-Laser Minoxidil 2%: 2ml of 20mg/ml sterile solution, applied post-laser procedure~At-Home Minoxidil 5%: 2ml of 50mg/ml foam q24 h for duration of study"
3473543|NCT03852966|Experimental|CBT-i/ADHD|Behavioral treatment for sleep problems in ADHD
3473544|NCT03852849|No Intervention|routine care group|Medical institutions will provide patients routine care according to the national program standard.
3473545|NCT03852849|Experimental|medicine intervention group|The dosage of 400 mg EFV will be used in the antiviral therapy.
3473546|NCT03852849|Experimental|consolidated intervention group|Medical institutions will provide personal involved intervention strategies as well as the providing of dosage form of 400 mgEFV in their antiviral therapy.
3473547|NCT03853005|Placebo Comparator|Group A (controlled group)|They will not receive HVHDF treatment
3126119|NCT03020524|Experimental|Dose level 1:|Autologous CD4 T-Cells0.8-1x10^9 transduced CD4+T-cells administered IV as a single dose
3473548|NCT03853005|Active Comparator|Group B (HVHDF group)|They will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours. The survival status of all of the subjects were followed up at 28 days after being diagnosed as severe sepsis.
3473549|NCT03852940|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
3473550|NCT03852940|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
3473551|NCT03853122|Active Comparator|Best current practice exercise programme|"Therapeutic physical exercise, best current practice:~Achilles tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: two exercises performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Patellar tendinopathy: ALFREDSON ECCENTRIC PROTOCOL: one exercise performed eccentrically, twice daily, 7 days/week, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group).~Gluteal Tendinopathy: EXERCISE LEAP PROTOCOL, from daily to twice weekly, 14 weeks (6 weeks are added to the program to match the volume of weeks of the experimental group)."
3473552|NCT03853122|Experimental|Experimental exercise programme|"Therapeutic physical exercise common for the three locations (Achilles, patellar and gluteal tendinopathy), based on an individual dosage and neuromuscular adaptations (five stages):~Strength training four exercises, once daily, three times/week, 14 weeks Aerobic training: Once daily, twice weekly"
3473553|NCT03853018|No Intervention|Control group|The control group is instructed to continue their habitual daily physical activity patterns and sedentary behaviour
3473554|NCT03853018|Experimental|CWAT intervention group|The CWAT group will receive the activity tracker. Subjects will receive inactivity alerts after 1 hour of inactivity to break up sitting time and avoid prolonged sitting. During the interruptions they will be asked to walk for several minutes.
3473555|NCT03853018|Experimental|CWAT + motivation intervention group|Subjects randomised into the CWATLDP intervention will receive the activity tracker and will be stimulated with the aid of coaching sessions and goal setting.
3473556|NCT03853083|Experimental|Hypoxi Equipment|
3473557|NCT03853083|Active Comparator|Recumbent Bicycle|
3473558|NCT03852914|Experimental|Experimental: Sodium Hyaluronate 2%|Each patient will receive a single injection of SH2%
3126120|NCT03020524|Active Comparator|Dose level 2|Autologous CD4 T-Cells 2.4-3x10^9 transduced CD4+ T-cells administered IV as a single dose
3126121|NCT03020524|Active Comparator|Dose level 3|Autologous CD4 T-Cells 0.8-1x10^10 transduced CD4+ T-cells administered IV as a single dose
3179323|NCT00671567|Experimental|Ramelteon 8 mg QD|
3179324|NCT00671567|Experimental|Ramelteon 16 mg QD|
3179325|NCT00671567|Placebo Comparator|Placebo|
3179326|NCT00671580|Experimental|A|PZ-601
3179327|NCT00671580|Experimental|B|PZ-601
3179328|NCT00671580|Active Comparator|C|Standard of Care
3179329|NCT00671593|Experimental|Experimental inhaled dust mite|All subjects receive the same experimental inhaled challenge interventions
3473559|NCT03853044|Experimental|Chidamide plus CHOP|Participants received six 21-day cycles of chidamide, combined with six cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (21-day cycles).
3473560|NCT03852771|Experimental|Treatment|All participants will receive the intervention
3473561|NCT03852875|Experimental|Education|Patients in the experimental arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will also receive feedback on their intake exercise stress test.
3473562|NCT03852875|Sham Comparator|Control|Patients in the Control arm will receive a 1-on-1 education session to review the their CR participation. As part of the discussion about their CR participation, these patients will NOT receive feedback on their intake exercise stress test.
3473563|NCT03852758|Experimental|Outdoor Exercise|2 sessions of outdoor exercise per week
3473564|NCT03852758|Experimental|Indoor Exercise|2 sessions of indoor exercise per week
3473565|NCT03852706|Experimental|LORETA|In the first session, Low Resolution Brain Electromagnetic Tomography (LORETA) will be used in combination with Z-scores to identify participants' resting state EEG differences relative to a database of norms of their demographic. EEG abnormalities which are consistent with the research literature on neural changes associated with AVH will then be targeted for normalization using neurofeedback training using LORETA in combination with Z-scores.
3473566|NCT03852706|Other|Treatment as usual|Maintenance use of an atypical antipsychotic (e.g., clozapine) with support, when needed, of a community nurse.
3473567|NCT03852797|Active Comparator|Ketamine|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
3473568|NCT03852797|Active Comparator|Ketamine + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of ketamine (from 10 -7M to 10 -4M)
3473569|NCT03852797|Active Comparator|Propofol|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
3473570|NCT03852797|Active Comparator|Propofol + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of propofol (from 10 -7M to 10 -4M)
3473571|NCT03852797|Active Comparator|Etomidate|The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
3473572|NCT03852797|Active Comparator|Etomidate + oytocin|The myometrial samples are bathed in an oxytocin solution (20nM) with increasing concentrations of etomidate (from 10 -7M to 10 -4M)
3473573|NCT03852472|Placebo Comparator|Group A|Placebo b.i.d
3473574|NCT03852472|Active Comparator|Group B|Avacopan 10 mg b.i.d
3473575|NCT03852472|Active Comparator|Group C|Avacopan 30 mg b.i.d
3473576|NCT03852420|Experimental|Treatment with the LUMINIZE RF Balloon Catheter|Subjects undergoing cardiac ablation procedure LUMINIZE™ RF Balloon Catheter System.
3473577|NCT03852628|Active Comparator|2mg Buprenex and 380mg Vivitrol|"2mg Buprenex and 380mg Vivitrol~Buprenex (buprenorphine) 2mg sublingual (SL) (taken every day for 12 weeks) , with Vivitrol (naltrexone) 380mg intramuscular injection (IM) (given every 4 weeks)"
3473578|NCT03852628|Placebo Comparator|Placebo|"Placebo (SL pill qd, IM injection q4weeks)~Placebo pill (taken sublingual every day for 12 weeks) and IM placebo (given intramuscular injection, every 4 weeks at baseline, week4 and week8)"
3473579|NCT03852641|Experimental|Bolus gavage feeds|Bolus gavage feeds over 15-30 minutes
3473580|NCT03852641|Experimental|Continuous feeds|Continuous feeds over 2.0 hrs
3473581|NCT03852459|Experimental|Active Arm|S-Ibuprofen Topical Gel 5%
3473582|NCT03852459|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
3473583|NCT03852615|Experimental|Ovarian torsion|Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion, that went through laparoscopic ovarian de-torsion surgery
3473584|NCT03852615|Other|No ovarian torsion|Control group - Women admitted to the gynecological emergency room with high clinical suspicious of ovarian torsion and went through laparoscopic surgery, however no ovarian torsion has been demonstrated
3473585|NCT03852329|Experimental|Navigated|Lateral skull base navigation intervention is applied
3473586|NCT03852303|Active Comparator|ivermectin once a year|Ivermectin one dose per year and anti-epileptic treatment
3473587|NCT03852303|Experimental|ivermectin 2 times a year|Ivermectin one dose 2 times a year and anti-epileptic treatment
3473588|NCT03852303|Experimental|ivermectin 3 times a year|vermectin one dose 3 times a year and anti-epileptic treatment
3473589|NCT03852316|Experimental|Click Device|Each subject (females 14 years of age and older) will perform a self-collection vaginal swab for the Click device and be randomized to a particular order for three vaginal swab collections (performed by Health Care Providers (HCP) as defined by state/local regulatory authorities) for comparator methods. N=1750
3473590|NCT03852602||Group Control|Analgesic application15 minutes before the end of the treatment will constitute the control group.
3473591|NCT03852602||Group preemptive|Patients who underwent analgesic 15 minutes after the induction of general anesthesia .
3473592|NCT03852368|Experimental|The Effects of Light Exercise in Executive Functions|The effects of light exercise in executive functions of adolescents
3473593|NCT03852368|Experimental|The Effects of Moderate Exercise in Executive Functions|The effects of moderate exercise in executive functions of adolescents
3473594|NCT03852368|Experimental|The Effects of Heavy Exercise in Executive Functions|The effects of heavy exercise in executive functions of adolescents
3473595|NCT03852511|Experimental|Intravenous|Patients will receive three single doses of NG-350A by IV infusion, followed by multiple cycles of check point inhibitor treatment.
3473596|NCT03852654|Experimental|treatment|
3473597|NCT03852485||Normal|no glaucoma or retinal pathology or corneal conditions
3473598|NCT03852485||Glaucoma|diagnosis of glaucoma
3473599|NCT03852485||Retina|diagnosis of AMD, DR or other retinal pathology
3473600|NCT03852485||Cornea|wear contact lens or prior refractive surgery or having dry eye or KCN
3473601|NCT03852576|Experimental|Esophagus sprayed with KSP/QRH dimer|Area of interest in subject's esophagus sprayed with KSP/QRH dimer and imaged with the SFE probe
3473602|NCT03852446|Experimental|Part 1: Single Ascending Dose|
3473603|NCT03852446|Experimental|Part 2: Bioavailability and Food Effect|"Single dose of Indoximod HCL (F2) formulation under fasting conditions~Single dose of Indoximod HCL (F2) formulation under fed conditions~Single dose of Indoximod base formulation under fasting conditions"
3473604|NCT03852407|Experimental|Fludarabine-Melphalan-Cyclophosphamide|FM-PTCy conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and cyclophosphamide 50 mg/kg on days +3 and +4.
3126122|NCT03020537|Other|Group A: 1-2 years old|Group A: 1-2 years old, seasonal influenza vaccine-naive. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone (pediatric formulation).
3473605|NCT03852407|Experimental|Fludarabine-Melphalan-thymoglobulin|FM-ATG conditioning will consist in IV fludarabine 30 mg/m2 on days -6, -5, -4, -3, and -2 (total dose 150 mg/m2), melphalan given at the dose of 100 mg/m2 on day -2, and ATG (Thymoglobulin®, Genzyme), at a dose of 2.5 mg/kg/d on days -2 and -1.
3473606|NCT03852563|Experimental|Women_Hemiface BAY207543|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with BAY207543 is investigated.
3473607|NCT03852563|Active Comparator|Women_Hemiface Vaseline|Adult women receive BAY207543 randomized to one hemiface and semisolid vaseline to the other hemiface after ablative skin lasering. The hemiface with vaseline is investigated.
3473608|NCT03852589|Active Comparator|C-MAC Videolaryngoscope|C-MAC Videolaryngoscope: An intubating device that is used for endotracheal intubation. Proseal laryngeal mask airway will be inserted with C-MAC Videolaryngoscope
3473609|NCT03852589|Active Comparator|Blind|Proseal laryngeal mask airway will be inserted with digital finger
3473610|NCT03852498|Experimental|Lenti-D Drug Product|
3473611|NCT03852251|Experimental|AK104|AK104 IV every 2 weeks (q2w)
3473612|NCT03852251|Experimental|AK104 and chemotherapy|"AK104 IV every 2 weeks (q2w)~oxaliplatin IV 85 mg/m2 q2w~capecitabine 1000 mg/m2，twice a day (bid) for day 1 to day 10 per cycle"
3473613|NCT03852550|Experimental|Usual Care + MyREADYTransition[TM] BBD App|Participants in the experimental Intervention group continue to get the same care they have been getting (their usual care) and they receive the MyREADY Transition[TM] BBD App e-health application. There are 19 parts in the App with videos and games to help youth learn and practice ways to manage their health. There are approximately 5-7 hours of content in total. Participants will be asked to wait at least one day between the parts. There is a timer in the App to help to moderate pace and align with how young people learn and digest information. Participants can choose how much time they want to take to do the App. It is recommended that participants make their own routine for using it. The recommended shortest and longest intervention exposure times are: 1 part each day (this will take 19 days to do all of the App), 1 part each week (this will take 19 weeks to do all of the App).
3473614|NCT03852550|No Intervention|Control Group: Usual Care|Participants in the no intervention Control group continue to get the same care they have been getting (their usual care). The researchers aim to supply the App to participants in both the intervention and control group for a limited time after participation in the study.
3473615|NCT03852199||Case Group|Our study was performed with 30 healthy individuals at Hacettepe University, Faculty of Physical Therapy and Rehabilitation. The FS of the knee joint was measured with a Pressure Biofeedback Device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN), a device similar to a sphygmomanometer. To correlate the outcomes of biofeedback device, simultaneously, a surface electromyography (EMG) data of M. Quadriceps femoris muscle activation levels from the individuals were recorded.
3473616|NCT03852355|Active Comparator|Radiofrequency|bilateral 3rd occipital nerve RF under fluoroscopic guidance
3473617|NCT03852355|Active Comparator|Systemic steroid|received systemic steroids oral prednisolone tablet, 10 mg/day.
3473618|NCT03852238||Cases: patients with hepatocellular carcinoma on non-cirrhotic|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
3473619|NCT03852238||Control: patients without hepatocellular carcinoma|Blood test and self-administrated questionnaires (medical history of the participant and his / her family, tobacco consumption, alcoholic and non-alcoholic beverages consumption, eating habits, type of employment and exposure, stays abroad longer than 1 month
3473620|NCT03852212|No Intervention|Control Group|The control group did not received any treatment
3473621|NCT03852212|Experimental|Manipulation|Experimental group received the osteopathic maneuver and the blood value were measured at baseline, after 2,5 and 10 minutes.
3473622|NCT03852225||OHCA patients|Patients resuscitated for out-of-hospital cardiac arrest of non-traumatic origin and investigated by intra-arrest echocardiography.
3473623|NCT03852186|Active Comparator|Cognitive behavioral therapy|Manualized group-based cognitive behavioual therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
3473624|NCT03852186|Experimental|Acceptance and commitment therapy|Manualized group-based Acceptance and Commitment therapy delivered by clinical psychologists and psychiatrists. The treatment consists of 14 sessions of each 2 hours.
3473625|NCT03852381|Experimental|Spinal Cord Stimulation|"At baseline, the following data will be recorded: standard-of-care questionnaire scores, neuroimaging (fMRI, MEG), psychophysical testing (QST), accelerometer sleep and activity data.~The trial will proceed as follows:~Day 1-4: Paresthesia-based SCS (PB-SCS)~Day 5-8: No SCS (placebo)~Day 9-12: PF-SCS~Neuroimaging and psychophysical testing will be conducted at the end of the trial, and will be assessed 6-months post-implantation of the SCS device along with adverse effects. A decision to implant the SCS system will be made based on reduction of patient pain intensity by 50% in PB-SCS and/or PF-SCS modes, but not with placebo SCS.~Based on the response in the trial, the patient will either not be a candidate for an SCS implant, or they will receive one of the four modes upon implantation (PB-SCS, or one of the three PF-SCS: Burst, High Frequency, High Density)."
3473626|NCT03852108|Experimental|Group comfort care|Socio-aesthetic care
3473627|NCT03852108|No Intervention|Group control|Conventional care
3126123|NCT03020537|Other|Group B: 18-30 years old|Group B: 18-30 years old, who did not receive the 20l2-2013 seasonal influenza vaccine. Given intramuscular,inactivated influenza vaccine-trivalent (IM IIV3) - Fluzone.
3126124|NCT03020550||GERD Patients|Subjects with active GERD symptoms.
3473628|NCT03852121|Experimental|Intervention group|Participants will receive bibliotherapy without withdrawing from the usual care. They will be asked to read the designated manual (consists of eight chapters) within a recommended period of time (over 8 weeks). Weekly telephone coaching will also be provided to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves. An orientation will be organized before the first session. Two booster sessions will be organized during the study.
3473629|NCT03852121|No Intervention|Control group|The participants in the control group will only receive usual care provided by the community health professionals.
3473630|NCT03852095||minor trauma|Child from 1 to 18 years old suffering an isolated minor trauma presenting at the hospital emergency services.
3473631|NCT03852173|Experimental|"Intervention group Wasserschulen"|Schools receive refillable drinking bottles for all school children and drying racks for each classroom. Schools receive special project educational material and informational material and one training session for teachers. The intervention will be implemented during one school year (2018/2019), but schools can use the material and bottles also after ending of the intervention period.
3473632|NCT03852173|No Intervention|Control group|No intervention (usual education). Schools do not receive any project material. Schools got the information that they are part of a study on drinking and eating habits of third grade elementary school children.
3473633|NCT03852147|Active Comparator|Control group|hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.
3473634|NCT03852147|Experimental|Experimental group|perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine.
3473635|NCT03852160|Experimental|Esketamine + Oral Antidepressants|Participants will receive esketamine as nasal spray (28 milligram [mg] [initial dose for elderly participants 65-74 years of age] on Day 1 and then uptitrated to 56 mg on Day 4, 56 mg [initial dose for adult participants aged 18-64 years and may be used for all age groups throughout the study] or 84 mg [maximum uptitrated esketamine dose]) twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral anti depressants (AD) (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
3473636|NCT03852160|Active Comparator|Placebo + Oral Antidepressants|Participants will receive matching placebo as nasal spray twice-weekly with a flexible dose regimen from Day 1 until Day 28 (Week 4), once weekly from Week 5 to Week 8 and once-weekly or once every other week from Week 9 to Week 32. The dose may be increased/decreased at any visit or may remain the same as determined by the investigator based on efficacy and tolerability. In addition, participants will initiate a new standard-of-care oral AD (escitalopram, sertraline, duloxetine, agomelatine, mirtazapine, bupropion or trazodone prolonged release) on Day 1, taken daily for the duration of the study.
3473637|NCT03851913|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
3473638|NCT03851913|No Intervention|control group|no neo-adjuvant treatment before operation
3473639|NCT03851874|Active Comparator|Gastric bypass bariatric surgery|Patients in this arm underwent Roux-en-Y gastric bypass bariatric surgery for the treatment of morbid obesity
3473640|NCT03851874|Active Comparator|Sleeve gastrectomy bariatric surgery|Patients in this arm underwent sleeve gastrectomy bariatric surgery for the treatment of morbid obesity
3126125|NCT03020576|Active Comparator|Conventional Therapy|Participants randomized to this arm will receive conventional based therapy to their affected upper limb dose matched with the Robotic Therapy group. These interventions are aimed at increasing range of motion, strength and function at the shoulder, elbow, wrist and hand.
3126126|NCT03020576|Experimental|Robotic Therapy|Participants randomized to this arm will receive robotic based therapy using the Amadeo Hand Robot device to improve range of motion, strength, and coordination to the wrist and hand.
3473641|NCT03851978|Experimental|Pharmacist Vaccine Education|
3473642|NCT03851900|Experimental|Teethmate Desensitizer (TM)|Calcium phosphate biomimetic material that forms hydroxyapatite from tetracalcium phosphate and dicalcium phosphate anhydrous and plug the dentin tubules causing remineralization and dentin hypersensitivity relief.
3473643|NCT03851900|Active Comparator|Clearfil SE Bond 2 (SE)|Two-step self etch adhesive resin treating dentin hypersensitivity b covering a film layer after light-curing.
3473644|NCT03851900|Placebo Comparator|Distilled water|Distilled water with no desensitizing components.
3473645|NCT03851809|Experimental|neurologic intensive care in acute brain injury|With the guidance of Taiwan Neurosurgical Society and Taiwan Neurological Society, patients in the control group were given the consistent treatment. (http://www.neurosurgery.org.tw/nsr/tbi/main.htm and http://www.stroke.org.tw/guideline/guideline_1.asp). The intensive treatments were established according to the traumatic brain injury treatment guidelines and spontaneously intracerebral hemorrhage general treatment principles from these two society in Taiwan.
3473646|NCT03851991|Active Comparator|arbidol|200mg, three times per day, for 2-5 Days.
3473647|NCT03851991|Placebo Comparator|Placebos|two capsules, three times per day, for 2-5 Days.
3473648|NCT03851887|Experimental|treatment group|TAI combine SBRT
3473649|NCT03851770|Other|refractory epilepsy patients|All patients belong to the refractory epilepsy group. Intervention: Characterization of Vagus nerve stimulation: Evoked potentials (EP) are recorded using an EEG/EP digital acquisition system
3473650|NCT03852056|Placebo Comparator|MFP Fluoride toothpaste|Commercially available, monofluorophosphate (MFP) toothpaste. Fluoride level is 0.76%
3473651|NCT03852056|Experimental|Stannous Fluoride Toothpaste|New toothpaste containing 0.454% stannous fluoride.
3473652|NCT03851835|Experimental|Ondansetron Oral Solution|Ondansetron Oral Solution (4mg/5mL solution) - Dose = 0.15mg/kg. One dose every 8 hours (q8h). Six doses over 48 hours.
3473653|NCT03851835|Placebo Comparator|Placebo Oral Solution|Compounded Placebo Oral Solution to match experimental arm
3473654|NCT03852134|Experimental|MOCC Group|The OB provider will hold the baby at/below the placenta, provide warmth, stimulate the baby and suction the mouth/nose for 30 secs.S/He will then clamp and cut the cord about 5 cm from the the introitus (vaginal deliveries) or from the abdominal incision (C-Sections) before handing the baby with the long-cut cord to the neonatal team to resuscitate/ stabilize the baby. A member of the neonatal team will milk the long-cut cord slowly 1 time from the cut end toward the infant over 10 secs before clamping and cutting the cord 1-2 cm from the umbilical stump. The neonatal team will provide PPV to the baby (during the milking process) if the baby is not breathing. If the baby is breathing during the milking process the team will continue the stabilization as per standard NRP practice.
3473655|NCT03852134|Active Comparator|DCC group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
3473656|NCT03851718|Experimental|Acupuncture Procedure|Acupuncture is a type of Traditional Chinese Medicine (TCM) therapeutic approaches involving the insertion and manipulation of fine needles in specific points. Mothers in acupuncture group will be given three standardized sessions of acupuncture within 5 weekdays, preferably on 3 consecutive days.
3473657|NCT03851718|Active Comparator|Power pumping|Power pumping is a pumping strategy that mimics normal infant cluster feedings by repeatedly emptying mother's breast very frequently in an effort to increase breast milk supply. As there is no standardized protocol of power pumping, one of the most popular recommendations will be adapted as the study power pumping instruction. It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days.
3473658|NCT03852069|Placebo Comparator|Placebo|16 g maltodextrin/day + recipes based on vegetables poor in inulin-type fructans
3473659|NCT03852069|Experimental|Inulin|16 g inulin/day + recipes based on vegetables rich in inulin-type fructans
3126127|NCT03020615|Active Comparator|Stable Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 1 (Stable Dosing) continues standard treatment.
3473660|NCT03852043|Experimental|High-intensity interval training|
3473661|NCT03852043|Active Comparator|Moderate-intensity continuous training|
3473662|NCT03851939|Experimental|treatment group|Transarterial Chemoinfusion (TAI) Combine Toripalimab
3473663|NCT03851848|Experimental|Joint mobilization (JM) group|The Maitland mobilization technique will target three main joints of the affected foot in order to facilitate major ankle and foot movements: (1) Talocrural joint Anterior-posterior (AP) mobilization will be performed to enhance ankle dorsiflexion ROM; (2) first metatarsal phalangeal joint (FMTP) AP glide will be performed to facilitate big toe extension ROM; (3) subtalar joint traction will be performed to increase both foot eversion and inversion ROM, and lateral glide will be performed to reinforce inversion ROM.
3473664|NCT03851848|Experimental|Myofascial release (MFR) group|The MFR technique will be performed as a direct trigger point release followed by deep soft tissue release for the calf muscles (gastrocnemius and soleus) and the plantar fascia .
3473665|NCT03852017|Experimental|Mindfulness Audio Program|Mindfulness Audio Program is a daily audio-session, which teaches emotional self-regulation skills through the adoption of mindful awareness practices into one's life
3473666|NCT03852017|Active Comparator|Music Audio Program|Music Audio Program is a daily audio session of peaceful and relaxing music
3473667|NCT03852030|Experimental|Mindfulness text/email message|"Weekly MBSR specific text or email messages related to course teachings were sent.~TYPES OF MESSAGES INCLUDED: Non-reaction; Non-Judgment; Awareness; Loving Kindness; Acceptance."
3126128|NCT03020615|Experimental|Intensive Dosing|In the first 8 weeks (± 2 weeks) of this study, participants will receive standard treatment [a fixed dose of 20 (± 2.5) mg/kg/day of hydroxyurea]. After 8 weeks (± 2 weeks) of standard treatment, participants will be randomized (like flipping a coin) to one of two treatment groups. Group 2 (Intensive Dosing) will have their HU dose increased by 5 mg/kg/day every 8 weeks up to a maximum of 35 mg/kg/day.
3126129|NCT03020641|Experimental|Low pneumoperitoneum pressure.|Pneumoperitoneum pressure at 8 mmHg or lower.
3126130|NCT03020641|Active Comparator|standard pneumoperitoneum pressure|Pneumoperitoneum pressure at 12 mmHG or higher
3126131|NCT03020719|Experimental|Oral Glutathione|Oral Glutathione oral powder at 65mg/kg/day
3473668|NCT03852030|Placebo Comparator|Health promotion text/email message|Weekly general/informational texts or emails about healthy living and lifestyle were sent. TYPES OF MESSAGES INCLUDED: Diet; Exercise; Sleep; Illness; Stress.
3473669|NCT03852030|No Intervention|No text/email message|No texts or emails were sent. There are no examples or descriptions for these messages, because no messages were sent to this group.
3473670|NCT03851861|Experimental|Mediterranean Diet|Participants will be given individualized diet education on the Mediterranean diet and instructed to follow the diet for the 5-week intervention period. Individualized diet education will be administered by a licensed, registered dietitian nutritionist (RDN) followed by weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
3473671|NCT03851952|Other|Optilume DCB|Optilume Drug Coated Balloon (DCB) treatment for the treatment of urethral stricture as approved for use in Canada
3473672|NCT03851783|Experimental|Solar-powered oxygen|Solar panels used to drive an oxygen concentrator will deliver medical grade oxygen at a rate of 1-5L/min, for the treatment of children with hypoxemia.
3473673|NCT03851783|No Intervention|Standard of care|Patients presenting with hypoxemia and pneumonia will be treated by standard of care prior to the implementation of solar-powered oxygen at a chosen site. This may include some allocation of oxygen via cylinders, but will likely be minimal or not available.
3473674|NCT03852004|Experimental|Osteopatic treatment|An osteopatic treatment will be realised by osteopath
3473675|NCT03852004|Placebo Comparator|simulated osteopathic treatment|A simulated ostepathic treatment will be realised by osteopath
3473676|NCT03851731|Experimental|Naltrexone|Subject received a single intranasal dose of 2 mg naltrexone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
3473677|NCT03851731|Experimental|Naloxone|Subject received a single intranasal dose of 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
3473678|NCT03851731|Experimental|Naltrexol|Subject received a single intranasal dose of a combination of 2 mg naltrexone and 4 mg naloxone for a total of 3 times in a 13 day period with a 4-day washout period between each does until all treatments were administered
3473679|NCT03851757|Active Comparator|waist-shaped interdental brush|waist-shaped interdental brush, use four times per interdental space
3126132|NCT03020719|Placebo Comparator|Placebo|Placebo oral powder at 65mg/kg/day
3126133|NCT03020745|Experimental|Part 1, Cohort A : GSK3389404 30 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 30 mg or matching placebo
3126134|NCT03020745|Experimental|Part 1, Cohort B: GSK3389404 60 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 60 mg or matching placebo
3126135|NCT03020745|Experimental|Part 1, Cohort C: GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
3473680|NCT03851757|Active Comparator|cylindric interdental brush|cylindric interdental brush, use four times per interdental space
3473681|NCT03851679||pregnancy woman|woman who are submitted to elective Cesarean Section in spinal anesthesia
3473682|NCT03851705|Experimental|Part 1 - Inclisiran|Participants will receive a dose of 300 milligram (mg) Inclisiran sodium administered by SC injection on Day 1 and Day 90.
3473683|NCT03851705|Placebo Comparator|Part 1 - Placebo|Participants will receive a dose of placebo administered by SC injection on Day 1 and Day 90.
3473684|NCT03851705|Experimental|Part 2 - Inclisiran|All participants will receive a dose of 300 mg inclisiran sodium administered by SC injection on Days 270, 450 and 630. (Participants who were on placebo in Part 1, will receive the first dose of inclisiran on Day 180.)
3473685|NCT03851432|Experimental|Janagliflozin 25 mg plus metformin|Each patient will receive 25 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
3473686|NCT03851432|Experimental|Janagliflozin 50 mg plus metformin|Each patient will receive 50 mg of Janagliflozin plus metformin for 52 weeks (a 24-week core period followed by a 28-week extension period)
3473687|NCT03851432|Placebo Comparator|Placebo/Janagliflozin plus metformin|In the core period, each patient will receive placebo plus metformin for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin plus metformin until Week 52.
3473688|NCT03851692|Active Comparator|60s (group E)|Intravenous cannulation was released either 60 s following loss of lid reflex in group E
3473689|NCT03851692|Active Comparator|90 or 120 s (groupe L)|Intravenous cannulation was released either 90 or 120 s following loss of lid reflex in group L
3473690|NCT03851575|Active Comparator|Control arm|Usual guideline therapy
3473691|NCT03851575|Experimental|Accelerated arm|Accelerated treatment of endocarditis
3473692|NCT03851354|Other|Ultrasound meal accomodation test|ultrasound guided gastric dynamics test for tolerance of enteral feeding, 500 ml of water with protein (glutamine or casseinate) wil be administrated
3473693|NCT03851562|Experimental|Alprostadil 20 micrograms|1 μg / kg patient weight up to a maximum of 60 μg
3473694|NCT03851562|Placebo Comparator|Placebo (physiological saline solution)|Placebo (physiological saline solution)
3473695|NCT03851406|Active Comparator|5% Hypertonic Saline|Subjects will inhale 5% hypertonic saline
3126136|NCT03020745|Experimental|Part 1, Cohort C1 (optional): GSK3389404 120 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 120 mg or matching placebo
3126137|NCT03020745|Experimental|Part 1, Cohort D: GSK3389404 </= 240 mg SC or Placebo|Enrolled subjects (HBeAg-positive and/or HBeAg negative) will receive single SC injection of GSK3389404 <= 240 mg or matching placebo
3179330|NCT00671632|Experimental|Ramelteon, triazolam, and placebo (56 poss. combinations)|Ramelteon, triazolam, and placebo (56 possible combinations total)
3473696|NCT03851406|No Intervention|No Treatment|No inhaled treatment
3473697|NCT03851289|Experimental|test (PRF-CS)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and calcium sulfate was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
3473698|NCT03851289|Active Comparator|control (PRF-X)|After atraumatic tooth extraction, the socket was gently curettage and irrigated with saline. Combination of platelet-rich fibrin and xenograft (MinerOss® X) was placed into the socket followed by a PRF plug . Black silk suture (3-0) was placed on mesial, mid and distal using simple interrupted technique.
3473699|NCT03851640|Experimental|HC-1119|80mg;
3473700|NCT03851640|Placebo Comparator|placebo|80mg;
3473701|NCT03851341|Experimental|GLH1SM tablet 100/1000 mg in FDC|GLH1SM tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
3473702|NCT03851341|Active Comparator|Janumet XR tablet 100/1000 mg in FDC|Janumet XR tablet (Sitagliptin 100 mg and Metformin 1000 mg in Fixed Dose Combination), single dose administration
3473703|NCT03851653|Experimental|Lifestyle Intervention Group (LIG)|Participants from this group will receive a cognitive-behavioral intervention addressing weight loss and lifestyle habits such as hypocaloric diet, moderate exercise, smoking and alcohol avoidance, and sleep hygiene. This behavioral intervention will be combined with the usual treatment for OSA, i.e. CPAP.
3473704|NCT03851653|No Intervention|Control group|Participants from the control group will not receive any type of intervention apart from the usual care (CPAP).
3473705|NCT03851614|Experimental|Cohort A|Olaparib (given orally at a dose of 300 mg twice a day) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
3473706|NCT03851614|Experimental|Cohort B|Cediranib (given orally at a dose of 20 mg daily, 5 days on 2 days off) in combination with Durvalumab (given intravenously at a dose of 1500 mg every 4 weeks)
3473707|NCT03851250|Experimental|MRx-4DP0004|"MRx-4DP0004 is a Live Biotherapeutic Product containing 10^9 to 10^10 Colony Forming Units.~Participants randomised to this arm will take 2 capsules twice daily at approximately 12 hour intervals for 12 weeks."
3473708|NCT03851250|Placebo Comparator|Placebo|"Participants randomised to this arm will take 2 capsules of placebo twice daily at approximately 12 hour intervals for 12 weeks.~All participants will receive placebo in a single blind manner for two weeks in addition to the 12 weeks of double blind treatment."
3473709|NCT03851367|Experimental|Sling suspension therapy|3-week duration of exercises using red cord and consisting of 15 sessions for 30 minutes each.
3473710|NCT03851367|Active Comparator|Swiss ball therapy|3-week duration exercise for trunk muscles strengthening and posture improvement consisting of 15 sessions for 30 minutes each.
3473711|NCT03851627|Active Comparator|Testosterone undecanoate|intramuscular Testosterone undecanoate 1000mg/4ml
3473712|NCT03851627|Placebo Comparator|Testosterone like Placebo|intramuscular Testosterone undecanoate like Placebo
3473713|NCT03851588|Active Comparator|Supplementary dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
3473714|NCT03851588|Placebo Comparator|Placebo dose|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
3473715|NCT03851419||People living with HIV|People living with HIV (ART naive or on ART)
3473716|NCT03851419||People not infected with HIV|HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
3473717|NCT03851315||LBBAP group|patients received left bundle branch area pacing
3473718|NCT03851315||traditional RVP group|Age and sex-matched patients received traditional right ventricular pacing
3473719|NCT03851172|Experimental|Nepafenac and cyclopentolate|Nepafenac 1 mg eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
3473720|NCT03851172|Experimental|Ketorolac and cyclopentolate|Ketorolac 0.5% eye drops two times before surgery and cyclopentolate eye drops two times before cataract surgery
3473721|NCT03851172|Placebo Comparator|Cyclopentolate and saline 0.9%|Cyclopentolate eye drops two times before surgery and saline 0.9% eye drops two times before cataract surgery
3473722|NCT03851536|Experimental|Transvaginal Ultrasound Guided ET|Transvaginal ultrasound is used to guide ET
3473723|NCT03851536|Experimental|Transabdominal Ultrasound Guided ET|Transabdominal ultrasound is used to guide ET
3473724|NCT03851549|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring Systems (BGMS): Results obtained from the new BGMS for UP are compared to a reference instrument (YSI 2300)
3473725|NCT03851224|Active Comparator|control group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with no graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
3473726|NCT03851224|Active Comparator|study group|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced with autogenous bone graft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
3473727|NCT03851224|Active Comparator|study group 2|under local anaesthesia patients hopeless teeth are be extracted. then immediate implant is palced withxenograft and immediate temporary prothesis is loaded upon the immediate implants.implant stability is evaluated immediately and 3 months post operatively
3473728|NCT03851393|Experimental|Peptest™ analysis of saliva pepsin|Induction of cough with inhaled citric acid and measurement of saliva pepsin following citric acid cough challenge using the peptest lateral device
3473729|NCT03851276|Other|Patients with 3-vessels diseased referred to CABG surgery|Patients with 3-vessel disease (with or without left main involvement) for which the regular and conventional Heart Team has made already the decision to refer the patient for CABG treatment.
3473730|NCT03850951|Experimental|"Lingual appliances AO®"|Patients with moderate crowding will be treated without extraction using lingual fixed appliances from American Orthodontics company.
3473731|NCT03850951|Experimental|"Labial appliances AO®"|Patients with moderate crowding will be treated without extraction using labial fixed appliances from American Orthodontics company.
3473732|NCT03851042|Experimental|Virtual Reality Head set in PACU|Use of VR Headset in PACU post hysterectomy for up to 4 hours.
3473733|NCT03851042|Active Comparator|No intervention|Routine PACU care post hysterectomy for up to 4 hours
3473734|NCT03851055|Active Comparator|intervention group|will receive zinc supplementation
3473735|NCT03851055|No Intervention|Control group|Patients will receive placebo only
3473736|NCT03851198|Experimental|Mild Cognitive Impairment patients|Subjects diagnosed with mild cognitive impairment, who will receive the best treatment of clinical practice, will be recruited. They must be more than 60 years old.
3126138|NCT03020745|Experimental|Part 2: GSK3389404 or placebo SC|Enrolled subjects will receive different parallel dose level and regimens of GSK3389404 or placebo SC at dose determined in part 1. The treatments for Part 2 are 60 mg GSK3389404 weekly, 120 mg bi-weekly GSK3389404, 120 mg GSK3389404 weekly or placebo.
3179331|NCT00671645|Experimental|1|
3473737|NCT03851198|Active Comparator|Healthy Subjects/ Match control|Healthy subjects of the same age as people with mild cognitive impairment.
3473738|NCT03851666|Placebo Comparator|12 weeks daily administration Placebo|Intervention: 12 weeks daily administration. The placebo is a powder: microcrystalline cellulose. The daily dose administrated is 15 grams.
3473739|NCT03851666|Experimental|12 weeks daily administration Cereal 1|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 1).~The daily dose administrated is 15 grams."
3473740|NCT03851666|Active Comparator|12 weeks daily administration Cereal 2|"Intervention: 12 weeks daily administration. The plant-based hydrolysate is a powder. The product results from an extraction of the protein of a cereal (Cereal 2).~The daily dose administrated is 15 grams."
3473741|NCT03851068|Experimental|Tria Aortic Valve|Patients receiving the Foldax Tria Aortic Valve
3473742|NCT03851159|Placebo Comparator|No Intervention: HIV-negative|HIV-negative patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
3473743|NCT03851159|Experimental|Intervention: HIV-|HIV-negative patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
3473744|NCT03851159|Placebo Comparator|No Intervention: HIV+|HIV-positive patients are selected to receive the placebo for the first two weeks of first-line TB treatment.
3473745|NCT03851159|Experimental|Intervention: HIV+:|HIV-positive patients are selected to receive the food supplement for the first two weeks of first-line TB treatment.
3473746|NCT03851471|Experimental|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
3473747|NCT03851263|Experimental|Evolocumab|All subjects are treated with evolocumab 140mg every 2 weeks (q2w) starting on day 1 and ending on day 1071 (week 153).
3473748|NCT03851120|Experimental|Intervention|150 pregnant women will be given Probiotics and 480 mg DHA, psychosocial stimulation, and healthy eating education
3473749|NCT03851120|Placebo Comparator|Control|150 pregnant women will be given placebo probiotics and 240 mg DHA, psychosocial stimulation, and healthy eating education
3473750|NCT03851146|Experimental|LeY CAR T cells|"One arm study consisting of 3 + 3 dose escalation study design (see below) followed by dose expansion phase at determined MTD.~Dose level : Target Number LeY CART cells infused *~-1 (if needed): 1 x 10e8~2 x 10e8~5 x 10e8~1 x 10e9~5 x 10e9~Targeted number of LeY CAR T cells (minus 40% acceptance range) for manufacture according toTGA-approved standard protocols~Treatment follows a lymphodepleting, chemotherapy regimen that consists of Fludarabine (25 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 consecutive days prior to cell infusion, with chemotherapy completed at least 48 hours before the re-infusion of the LeY CAR T cells."
3473751|NCT03850990|Experimental|Placebo group|In the first visit, this group will learn about placebo pills from a video and will be placebo pills to take twice a day for 8 weeks. They will be asked to take the pills in conjunction with following the weight-loss protocol.
3473752|NCT03850990|Experimental|No placebo group|In the first visit, this group will learn about placebo pills from a video but will not be given placebo pills. They will follow the weight-loss protocol without placebo pills.
3473753|NCT03851445|Other|Lung-MAP Screening|This is a screening study and does not have an intervention. LUNGMAP is an overarching umbrella study to which patients are screened and then assigned to a treatment sub-study. The treatment sub-studies are standalone trials and have their own NCT numbers. The Lung-MAP Study is considered a single study under one IND, consisting of the Screening Protocol and multiple sub-studies. Each sub-study protocol operates independently and has its own version date.
3473754|NCT03850938|Experimental|Conventional Kyphoplasty|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon.
3473755|NCT03850938|Active Comparator|Kyphoplasty with Rotary Cutter|The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration, which may induce a cavity with barriers pushed by balloon dilatation. Then, the structure of the cavity is destroyed by a rotary cutter. Finally, the cement is injected, which may effectively interdigitates with the healthy cancellous bone.
3473756|NCT03851029|Experimental|Tai chi|(Yang 24 postures) Moderate intensity HRR (40%-60%)
3473757|NCT03851029|Active Comparator|Aerobic Training|Elliptical Moderate intensity HRR (40%-60%)
3473758|NCT03850977||Patients and controls|Patients diagnosed with chronic pancreatitis or cirrhosis and healthy controls
3126139|NCT03020888|Experimental|Magseed and Sentimag|"Magseed marker deployed to mark a breast lesion under imaging guidance up to 30 days prior to surgery.~Marker located during surgery using the Sentimag system, and removed with the lesion."
3126140|NCT03020966|Experimental|Oral Tylenol|Patient group receiving 1000mg of oral acetaminophen and an intravenous placebo
3473759|NCT03850925|Experimental|Picosecond laser|Intervention: four consecutive sessions of 1,064-nm picosecond laser at 3-week intervals
3473760|NCT03850925|Active Comparator|Fractional laser|Intervention: four consecutive sessions of nonablative fractional laser at 3-week intervals
3473761|NCT03850964|Active Comparator|Pazopanib|Pazopanib 50mg oral daily dosing [two 25mg capsules]. If after 3mths primary endpoint not achieved, and safety is maintained, consideration for advance in dose to up to 100mg daily
3473762|NCT03850964|Placebo Comparator|Placebo oral capsule|Placebo
3473763|NCT03850860||empirical antibotherapy currently used|patients having had a vancomycin and piperacillin-tazobactam combination as empirical antibiotherapy
3473764|NCT03850860||another empirical antibotherapy|patients having had a vancomycin and cefepime combination as empirical antibiotherapy
3473765|NCT03850821|Experimental|Connect Social Mechanisms Intervention|"The primary components of the intervention included: Get-to-know-you sessions aimed specifically at providing youth guided social opportunities to foster friendships, group belonging, and social skills, and novel socially-oriented 'PA sessions' infused within the daily time slot that ASPs' allocated towards recreation. Drawing from theoretical models of motivation, and the investigators' previous ASP studies, key essential elements were identified for facilitating improvements in targeted PA social mechanisms (i.e., friendships, group belonging, and staff connection) and included: 1) social-emotional goal-oriented support, 2) collaborative/cooperative play centered on friendship and informal fun; 3) equal treatment/access, and; 4) inclusive and engaging."
3473766|NCT03850821|No Intervention|Typical ASP curriculum wait-list control|No intervention was implemented within the active wait-list control condition, which served as the typical ASP curriculum control/comparison. After completion of the 8-week intervention (12 weeks including baseline and post-intervention data collection), the control condition received the social mechanisms curriculum as a token of appreciation for participating in measurement.
3126141|NCT03020966|Experimental|Intravenous Tylenol|Patient group receiving 1000mg of intravenous acetaminophen and an oral placebo
3126142|NCT03020992|Experimental|Certolizumab Pegol|Subjects will receive a loading dose of Certolizumab Pegol (CZP) 400 mg subcutaneously (sc) administered at Baseline, Week 2, and Week 4 followed by CZP 200 mg sc every two Weeks
3126143|NCT03021005|Experimental|Self Testing Kit|"This group will be provided a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will also be provided 5 referral cards to give to their partners and peers in the drug, sex, and social networks for them to request a free HIV self-testing kit from the I Want The Kit website."
3126144|NCT03021005|No Intervention|No Self Testing Kit|"This group will not receive a free Food and Drug Administration-approved HIV self-testing home kit (OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test). Participants in this group will not receive referral cards for their partners or peers for them to request a free HIV self-testing kit from the I Want The Kit website."
3126145|NCT03021018|Experimental|Brivaracetam (BRV) 100 mg|Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period
3473767|NCT03850834|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|
3473768|NCT03850834|Placebo Comparator|Placebo Enteric-coated Tablets|
3473769|NCT03850886|Experimental|Niacinamide group|Niacinamide oral tablets as Nature's Life 1000 mg tablets once daily for 3 months diabetes management including metformin or Sulphonylurea
3473770|NCT03850886|Active Comparator|Control group|diabetes management including metformin or Sulphonylurea
3473771|NCT03850899||Cases|Heavy drinkers with alcoholic hepatitis
3126146|NCT03021018|Experimental|Brivaracetam (BRV) 200 mg|Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period
3126147|NCT03021018|Active Comparator|Lorazepam (LZP)|Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.
3126148|NCT03021187|Experimental|Semaglutide 3 mg|
3126149|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg|
3126150|NCT03021187|Experimental|Semaglutide 3 mg + 7 mg + 14 mg|
3126151|NCT03021187|Placebo Comparator|Placebo|
3126152|NCT03021265||T80/A5/H12.5 FDC|Patients with hypertension
3126153|NCT03021304|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in Safety syringe|Subjects will receive 3 doses of 100 mg mepolizumab, liquid drug product in safety syringe, subcutaneously as a single injection that is self-administered in the thigh, abdomen or administered in the upper arm (by caregiver only) at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
3473772|NCT03850899||Controls|Heavy drinkers without significant liver disease
3473773|NCT03850899||Donor|Healthy non-drinkers
3126154|NCT03021343|Active Comparator|Colchicine|Colchicine 2 mg 12-24 hours prior to surgery and 1 mg 4 hours before or immediately after surgery and then continued at a dose of 0.5 mg twice daily until hospital discharge. Half the dose was given to patients weighing <70 kg or intolerant to the full dose.
3126155|NCT03021343|No Intervention|No colchicine|In this arm no active medication was administered
3126156|NCT03021499|Experimental|Voclosporin|oral, 23.7 mg twice daily (BID)
3473774|NCT03850873|Experimental|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m to 120mg once daily
3473775|NCT03850769|Experimental|nab-paclitaxel and S-1|neoadjuvant chemotherapy with Nab-paclitaxel and S-1, repeat every 21 days for 4 cycles.
3473776|NCT03850756||1: No smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers"
3473777|NCT03850756||2: No smokers with risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers"
3473778|NCT03850756||3: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers Predisposition to kidney injury biomarkers~Also tobacco consumption will be measured"
3473779|NCT03850756||4: Smokers without risk factors|"A smoker is defined as: any person who habitually consumes tobacco at the time of taking the sample or who has left it in the last 12 months (WHO, 2008).~The following circumstances involved in the development of kidney damage will be considered a risk factor: Diabetes Mellitus, Hypertension and / or frequent use of NSAIDs (more than three days a week during the three months prior to sampling)~In these patients kidney function will be evaluated by:~Early kidney damage biomarkers~Also Tobacco consumption will be measured"
3473780|NCT03850600|Experimental|Diet-CD|dietary intervention: 8-10 weeks of diet intervention
3473781|NCT03850600|No Intervention|No-Diet-CD|Usual diet with no intervention
3473782|NCT03850600|No Intervention|No-Diet-Control|Unaffected controls at the same gestational stage will follow usual diet and no intervention
3473783|NCT03850470||Patients with Musculoskeletal Pain|Subjects reporting for care with complaints of musculoskeletal pain will be examined and a diagnosis and plan of care will be established. The accuracy of the clinical examination will be compared to pathology detected by MRI
3473784|NCT03850561|Active Comparator|Coenzyme Q10 200|Coenzyme Q10 200mg/day for 3 months
3126157|NCT03021499|Placebo Comparator|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules twice daily (BID)
3126158|NCT03021538||Cardiopulmonary Bypass|There will be 40 patients placed on cardiopulmonary bypass during lung transplantation.
3126159|NCT03021538||Extracorporeal Membrane Oxygenation|There will be 40 patients placed on ECMO during lung transplantation.
3126160|NCT03021642|Experimental|First Tepotinib Test, Then Tepotinib Reference|
3473785|NCT03850561|Active Comparator|Coenzyme Q10 400|Coenzyme Q10 400mg/day for 3 months
3473786|NCT03850639|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
3473787|NCT03850639|No Intervention|Wait list control|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment after 4 weeks.
3126161|NCT03021642|Experimental|First Tepotinib Reference, Then Tepotinib Test|
3473788|NCT03850548||Prosthetic joint infection with Cutibacterium acnes|Chronic infections on articular prostheses with Cutibacterium acnes diagnosed by specific PCR
3473789|NCT03850626||Immunotherapy Trees|Patients allergic to tree pollen
3473790|NCT03850626||Immunotherapy Grass|Patients allergic to grass pollen
3473791|NCT03850626||Immunotherapy Mites|Patients allergic to HDM
3126162|NCT03021668|Experimental|Prevena Peel & Place Dressing for wound closure|In the participants randomized to this arm the surgical site will be closed using Prevena Peel & Place Dressing.
3126163|NCT03021668|Placebo Comparator|Standard closure of the wound|In the participants randomized to this arm the surgical site will be closed using the standard closure technique.
3126164|NCT03021759|No Intervention|Control|No intervention
3126165|NCT03021759|Experimental|Active choice|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin.
3126166|NCT03021759|Experimental|Active choice with social comparison feedback|Physicians will be asked to review a list of their patients eligible for statin therapy who are not yet prescribed a statin and make an active choice whether or not to prescribe a statin. Physicians will receive social comparison feedback informing them of how their performance compares to their peers
3126167|NCT03022045|Experimental|Risankizumab 75 mg|Participants randomized to receive risankizumab 75 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
3126168|NCT03022045|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg at Week 0, Week 4, and every 12 weeks up to Week 172.
3126169|NCT03022084|Experimental|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
3126170|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
3473792|NCT03850652|Active Comparator|Prebiotic (Synergy-1)|Prebiotic (Synergy-1) + Iron supplement
3473793|NCT03850652|Placebo Comparator|Maltodextrin|Placebo (Maltodextrin) + Iron Supplement
3473794|NCT03850691|Experimental|Cohort 1: Nivolumab|
3473795|NCT03850691|Experimental|Cohort 2: Nivolumab & Ipilimumab|
3473796|NCT03850483|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
3473797|NCT03850483|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
3473798|NCT03850483|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
3473799|NCT03850483|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
3473800|NCT03850483|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
3473801|NCT03850483|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
3473802|NCT03850483|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
3473803|NCT03850483|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
3473804|NCT03850483|Experimental|PF-06700841 3% cream BID|PF-06700841 3% cream applied twice daily (BID)
3473805|NCT03850574|Experimental|HM43239|This phase 1/2 study consists of dose escalation and expansion. Dose escalation cohort is planned up to 10 dose levels. If subject in the dose escalation cohort at any dose level achieves clinical response then the dose level will continue to enroll.
3473806|NCT03850522|Experimental|Vaccination|Vaccination with PD-L1 peptide
3473807|NCT03850613|Experimental|Intervention arm|Participants in the intervention arm download the E-painting mobile app and use this app to make their own painting.
3126171|NCT03022370|Experimental|Stepping Stones and Creating Futures|Participants receive the Stepping Stones and Creating Futures intervention, comprising of 21 participatory/inter-active sessions, delivered by a trained facilitators. Each session last approximately 3 hours. Sessions are delivered twice a week. Sessions are primarily single sex, with 20 participants per group.
3126172|NCT03022370|No Intervention|Wait-list control|Participants receive no intervention until after final data collection occurs, at which point they will be offered Stepping Stones and Creating Futures.
3126173|NCT03022396|Other|Group A: age 8-17 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
3473808|NCT03850730|Experimental|Pazopanib|Pazopanib, initiated after a baseline period at 25mg oral dosing daily, for this one treatment arm, to be compared to the patient's baseline. If endpoint not achieved and safety demonstrated in 2-3mths, an advance of dose to 50mg daily for the ensuing 3mths of study will be considered.
3473809|NCT03850717||Traditional Chinese Acupuncture|"Use traditional acupuncture, stronger, deeper, harder-acupuncture"
3473810|NCT03850717||Japanese Acupuncture|"Use traditional shallow, lighter acupuncture, softer-acupuncture"
3473811|NCT03850392|Active Comparator|ice|"16 knee arthritis patients treated by local ice (Thermogel®, Artsana, Grandate, Italy - 30 minutes application - twice within one single day).~Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle."
3473812|NCT03850392|Active Comparator|CO2|16 knee arthritis patients treated by local hyperbaric cold CO2 at -78°C (Cryo+®, Cryonic, Salins-les-Bains, France - 2 minutes-applied twice within one single day). Just before the first cold application, at 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®, Ethypharm, Saint-Cloud, France) was performed before removing the needle.
3473813|NCT03850392|No Intervention|contralateral non-treated knees|16 contralateral arthritic knees : the synovial fluid was collected and analysed according to the same procedure but no cold treatment was applied (while the corresponding contralateral arthritic knees were treated by ice) : At 9 a.m., and 24 hours later (day=1 at 9 a.m), an arthrocentesis was performed. Standard analyses were performed on the synovial fluid (bacteriology, cytology and microcrystal microscopic assessment). Furthermore, a part of the synovial fluid was centrifuged then frozen at -80°C. For the second arthrocentesis, after the synovial fluid was gathered for the same analyses, an intra-joint corticosteroid injection (Triamcinolone, HEXATRIONE®,Ethypharm, Saint-Cloud, France) was performed before removing the needle.
3126174|NCT03022396|Other|Group B: age 18-30 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
3126175|NCT03022396|Other|Group C: age 18-30 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
3126176|NCT03022396|Other|Group D: age 40 - 59 yo identical twins|Individual twins to receive Fluzone® (intramuscular)
3126177|NCT03022396|Other|Group E: age 40 - 59 yo fraternal twins|Individual twins to receive Fluzone® (intramuscular)
3473814|NCT03850587|Experimental|YYC301-1 & Celocoxib placebo|"YYC301-1 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-1 is a capsule. It is composed of Celocoxib 200mg and Tramadol 37.5mg complex)."
3473815|NCT03850587|Experimental|YYC301-2 & Celocoxib placebo|"YYC301-2 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-2 is a capsule. It is composed of Celocoxib 200mg and Tramadol 75mg complex)"
3473816|NCT03850587|Experimental|YYC301-3 & Celocoxib placebo|"YYC301-3 one capsule and Concomitant Drug Celocoxib placebo.~*YYC301-3 is a capsule. It is composed of Celocoxib 200mg and Tramadol 150mg complex)"
3473817|NCT03850587|Active Comparator|YYC301 placebo & Celecoxib|Concomitant Drugs with Celecoxib 200mg and YYC301 one capsule.
3473818|NCT03850405|Experimental|Chocolate|20 patients (matched per gender) undergoing a diet which includes 25g of dark chocolate (70%), i.e. ca. 145 kcal per day
3473819|NCT03850405|No Intervention|Control|20 patients (matched per gender) undergoing a low-fat dietary regimen
3473820|NCT03850665|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
3473821|NCT03850665|Active Comparator|Anterolateral approach|Anterolateral Approach surgery to replace the hip.
3473822|NCT03850665|Active Comparator|Posterolateral approach|Posterolateral Approach surgery to replace the hip.
3473823|NCT03850535|Experimental|Dose-Escalation Phase|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to European LeukemiaNet [ELN] 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
3473824|NCT03850535|Experimental|Post-Consolidation Phase|Participants who are idasanutlin treatment-naive, had received induction and chemotherapy consolidation for AML outside of the study, and were in minimal residual disease (MRD)-positive remission after induction will be enrolled in this cohort to receive maintenance treatment with single-agent idasanutlin.
3473825|NCT03850535|Experimental|Expansion Phase: Favorable/Intermediate-Risk AML|Participants with newly diagnosed, previously untreated, favorable or intermediate risk AML (according to ELN 2017 criteria) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
3473826|NCT03850535|Experimental|Expansion Phase: High-Risk AML|Participants with newly diagnosed, previously untreated, high-risk AML (defined as adverse risk according to ELN 2017 criteria, and secondary AML) will undergo the treatment sequence of induction, consolidation, and maintenance. For induction, participants will be treated with idasanutlin (at the recommended Phase 2 dose) plus cytarabine and daunorubicin. At the investigator's discretion for consolidation, either participants will be treated with idasanutlin and cytarabine or they will undergo Allo-HSCT. For maintenance, participants will be treated with single-agent idasanutlin.
3473827|NCT03850132|Experimental|FAM-SOTC-PL|Grief responses, levels of vulnerability, measured using the Adult Attitude to Grief scale (AAG), a self-administered questionnaire
3473828|NCT03850158|Experimental|Interventional Arm, ICG and NIR imaging|NIR fluorescence imaging is performed after white light laparoscopy. 0.3mg/kg bodyweight of ICG is administered i.v. All suspected lesions are removed and labeled whether they are seen in WL or NIR imaging or both. Evaluation is performed after the histological analysis of the lesions.
3473829|NCT03850288||Anorexia Nervosa|"Patients with a diagnosis of anorexia nervosa (According to the DSM-V criteria). These patients are characterized by a restriction of food intake leading to weight loss or a failure to gain weight resulting in a significantly low body weight of what would be expected for someone's age, sex and height. Moreover, there is a fear of becoming fat or of gaining weight.Then, these patients have a distorted view of themselves and of their condition."
3473830|NCT03850288||Bulimia Nervosa|"Patients with a diagnosis of bulimia nervosa. According to the DSM-V criteria, these patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time, an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode, recurrent inappropriate compensatory behaviour in order to prevent weight gain, such as self-induced vomiting, misuse of laxatives, diuretics, or other medications, fasting, or excessive exercise.~The binge eating and inappropriate compensatory behaviours both occur, on average, at least once a week for three months. Moreover, there is a self-evaluation influenced by body shape and weight."
3473831|NCT03850288||Binge Eating Disorder|Patients with a diagnosis of Binge Eating Disorder. These patients are characterized by recurrent episodes of binge eating (eating, in a discrete period of time (e.g. within any 2-hour period), an amount of food that is definitely larger than most people would eat during a similar period of time and under similar circumstances), a sense of lack of control over eating during the episode. The binge eating episodes are associated with three or more of the following: eating much more rapidly than normal, eating until feeling uncomfortably full, eating large amounts of food when not feeling physically hungry, eating alone because of feeling embarrassed by how much one is eating, feeling disgusted with oneself, depressed or very guilty afterward,marked distress regarding binge eating is present. Moreover, binge eating occurs, on average, at least once a week for three months
3473832|NCT03850314|Experimental|Glycine|Glycine total daily dose of 150mg/kg divided three times daily with meals (powder dissolved in 1 cup of water) for 12 weeks.
3473833|NCT03850119|Experimental|Intradermal Nanofat|This side of the scar received intradermal injection of nanofat during the closure of the donor site.
3473834|NCT03850119|No Intervention|Control|This side of the scar received no injection.
3473835|NCT03850301|Experimental|Etifoxine then XBD173|
3473836|NCT03850301|Experimental|XBD173 then Etifoxine|
3473837|NCT03850184||Mental Health Professionals|Psychiatrists, Psychologists, Nurses working with patients with mental disorders
3473838|NCT03850080|Experimental|Autologous Conditioned Serum|Patients that were deemed admissible to the trial received 1 intra-articular injection of autologous conditioned serum (Orthokine®) for 4 consecutive weeks at the site of OA. These patients were then followed at 1 month and 6 months for clinical and functional evaluation using VAS for pain, WOMAC, and KSS.
3473839|NCT03850106|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose)
3473840|NCT03850106|Active Comparator|Indus810|Indus810 ( 500mg/d)
3473841|NCT03850262||patients with posterolateral corner trauma of the knee|
3473842|NCT03850171|Experimental|ExEarly|Patients completing the exercise training concurrent to anthracycline chemotherapy treatment during months 1 to 3
3473843|NCT03850171|No Intervention|ExStandard|Patients will be encouraged to continue with their regular physical activity routine and will be medically managed as per standard of care by their Cardiologist and Oncologists.
3473844|NCT03850197||TMM followed by EarPopper + Tympanometry|"Participants will be asked to complete the tubomanometry (TMM) then EarPopper plus tympanometry tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize Eustachian tube (ET) pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
3473845|NCT03850197||EarPopper + Tympanometry followed by TMM|"Participants will be asked to complete the EarPopper plus tympanometry then TMM tests for each ear, followed by video otoscopy. Nasal endoscopy will also be performed on adult subjects to visualize ET pharyngeal opening and the functional anatomy of surrounding structures during maneuvers. These maneuvers include swallowing, Fish maneuver, and blowing out into the EMST-150, and are used to elevate the soft palate to trigger an ET opening."
3473846|NCT03850210|Experimental|Short Splint|
3473847|NCT03850210|Active Comparator|Traditional, Long Splint|
3473848|NCT03850327|Experimental|BIOMONITOR III|
3126178|NCT03022396|Other|Group F: age 70 - 100 yo identical twins|Individual twins to receive Fluzone® (intramuscular) or High Dose Fluzone® (intramuscular)
3126179|NCT03022422|Other|Group B: 18-30 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
3473849|NCT03849989|Experimental|Hailey Hailey|"Patients with Hailey Hailey, diagnosis confirmed by histopathology or genetics, with therapy resistant skin lesions suitable for ablative lasertherapy.~Skin biopsy specimens will be taken before and after lasertherapy at three time points.~Before treatment:~Affected skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy Healthy skin within same anatomical region 4 mm punch for immunofluorescence and RNA extraction~Immediately after treatment of the treated area:~2 mm punch for histopathology~Six weeks after treatment:~Treated skin 4 mm punch for immunofluorescence and RNA extraction 2 mm for electron microscopy"
3473850|NCT03849963|Experimental|Hyperpolarized [13C]pyruvate|Hyperpolarized stable isotope injection ([13C]pyruvate) during magnetic resonance spectroscopic imaging
3473851|NCT03849950|Experimental|SMARTCare|"Training in self-management support (SMS) strategies for ambulatory nursing staff~A web-based self-management education (I-Can-Manage Cancer) for patients~Telephone-based, nurse-led health coaching~Optional end of study patient interview (sub-study)"
3473852|NCT03849950|Active Comparator|Control|1. Training in self-management support (SMS) strategies for ambulatory nursing staff
3473853|NCT03849976||Experimental group|Patients accompanied to the operating room by a stretcher bearer trained in therapeutic communication
3473854|NCT03849976||Control group|Patients accompanied to the operating room by a stretcher bearer not trained in therapeutic communication
3473855|NCT03849872|Experimental|Part 1 Absolute Bioavailability|Single oral dose of 10 mg ONO-5788 capsule followed by iv infusion 100 μg/ 41 kBq (1.1 μCi) [14C]-ONO-5788 in 6 healthy male subjects.
3473856|NCT03849872|Experimental|Part 2 Mass Balance|Single oral dose of 10 mg [14C]-ONO-5788 capsule containing 4.1 MBq (111 μCi) [14C]-radioactivity in 6 healthy male subjects.
3473857|NCT03849885|No Intervention|Standard Skin Prep|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
3473858|NCT03849885|Experimental|Experimental Skin Prep with BPO|"Patients will undergo a skin cleansing protocols using 4% Chlorhexidine gluconate (CHG) cloths.~Following the CHG wipes, patients will be prepped with 5% BPO gel applied directly to the biopsy site.~After the skin prep, three 3-mm punch (Acu-Punch, Acuderm, Fort Lauderdale, FL) skin biopsies will performed for both an anterior-based hypothetical incision, and for a more lateral/posterior incision, for a total of 6 biopsies taken per subject."
3473859|NCT03849898||Mandibular Fracture|"Elderly patients of > 60 years who present a mandibular fracture~Surgery or Non-surgical fracture treatment will be applied according to routine clinical practice"
3473860|NCT03849859|Active Comparator|Single plastic stent|Deployment of single plastic stent
3473861|NCT03849859|Active Comparator|Multiple plastic stents|Deployment of multiple plastic stent
3473862|NCT03850028|Other|Imaging cohort|All study participants will be allocated to this arm (single-arm study). Study participants will undergo a maximum of 3 89Zr-atezolizumab PET scans.
3473863|NCT03849924|Experimental|Self-affirmation|Participants assigned to the self-affirmation intervention condition will undergo a self-affirmation intervention in the form of a questionnaire at time point one (one week after the intervention). This is a brief intervention that involves forming self-affirming implementation intentions. Implementation intentions are formulated plans that encourage one to link critical situations with appropriate behavioural responses. In this study participants are encouraged to write out the stem and their response to the stem from the four options.
3473864|NCT03849924|Experimental|Self-affirmation 'booster'|Participants assigned to this condition will undergo the self-affirmation intervention described above twice, in comparison to just once, in the form of a questionnaire at time points one (one week after the intervention) and two (two weeks after the intervention).
3473865|NCT03849924|No Intervention|Control|Participants assigned to the control condition will not undergo a self-affirmation intervention. Instead they will still complete the same questionnaire as participants in the intervention conditions but without the self-affirmation intervention included (normally included on the last page of the questionnaire).
3473866|NCT03849846||Adults with low socio-economic status|Four focus groups will be conducted with adults with low socioeconomic status recruited through community centres in the Québec City area.
3473867|NCT03849833|Other|Vitamin D3 supplementation|All participants will be selected for treatment with cholecalciferol, vitamin D3 supplementation and included in this single arm
3473868|NCT03849794|Experimental|Experimental group|Chiropractic Care Plus Physiotherapy
3473869|NCT03849794|Active Comparator|Control group|Physiotherapy
3473870|NCT03849807|Experimental|Experimental group|Chiropractic care
3473871|NCT03849807|Active Comparator|Control group|Usual health care
3473872|NCT03849781|Active Comparator|Intervention|NeoBeat will be placed on all newborns immediately after birth to assess the heartrate for at least 5 minutes, or longer if the newborn needs resuscitation. Intervention subjects will have a visible display of the heart rate on the NeoBeat, to guide healthcare providers in further management of the newborn.
3473873|NCT03849781|No Intervention|Standard Care|NeoBeat will be placed on the newborn to collect information on heart rate, but heart rate is not displayed to the healthcare providers. If the newborn is in need of resuscitation to initiate spontaneous respiration, the baby will be transferred to the resuscitation bay. According to recommendations the heart rate should be assessed and positive pressure ventilation initiated within one minute of life. Standard care is to assess heart rate by conventional ECG and/or pulse oximetry, alternatively auscultation of the heart.
3473874|NCT03849625||NSAID sensitivity|Patients diagnosed with an immediate reaction to aspirin/NSAIDs/or paracetamol
3473875|NCT03849508|Active Comparator|phenylephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of phenylephrine started at an initial rate of 0,5mcg/kg/ min. The rate will be adjusted according to maternal systolic blood pressure.
3473876|NCT03849508|Experimental|Norepinephrine|Spinal anesthesia with bupivacaine, sufentanil and morphine will be performed and prophylactic infusion of norepinephrine tartrate started at an initial rate of 0,1mcg/kg/min. The rate will be adjusted according to maternal systolic blood pressure.
3473877|NCT03849612|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
3126180|NCT03022422|Other|Group C: 18-30 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
3126181|NCT03022422|Other|Group D: 40-64 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
3126182|NCT03022422|Other|Group E: 40-64 yo fraternal twins (TIV)|Individual twins to receive Fluzone® standard TIV
3126183|NCT03022422|Other|Group F: 65-100 yo identical twins (TIV)|Individual twins to receive Fluzone® standard TIV
3126184|NCT03022422|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Individual twins to receive High-Dose Fluzone® TIV
3473878|NCT03849521||Asymptomatic group|Group with asymptomatic patients with carotid atherosclerosis.
3473879|NCT03849521||Symptomatic group|Group with symptomatic patients with carotid atherosclerosis.
3473880|NCT03849664|Experimental|Cytoflavin®|Patients of group I will receive the experimental drug Cytoflavin®, manufactured by POLYSAN (Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Cytoflavin® solution(Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered IV for 7 days, and Cytoflavin® enteric-coated tablets (Inosine + Nicotinamide + Riboflavin + Succinic Acid) will be administered for 25 days (in total 32 days of treatment).
3473881|NCT03849664|Placebo Comparator|Placebo|Patients of group II will receive placebo (manufactured by POLYSAN, Russia), on the day before surgery, during the surgical intervention, and in the postoperative period. Placebo solution will be administered IV for 7 days, and placebo enteric-coated tablets will be administered for 25 days (in total 32 days of treatment).
3473882|NCT03849742|Experimental|Heath services research (Uber rides)|Patients receive Uber rides to and from scheduled radiotherapy appointments for up to 6 months.
3473883|NCT03849729|Active Comparator|Phentermine|Low-calorie diet + Phentermine Capsules 15 mg po by 6 weeks, one time a day before bariatric surgery.
3473884|NCT03849729|Placebo Comparator|Placebo|Low-calorie diet + Placebo Capsules po by 6 weeks, one time a day before bariatric surgery.
3473885|NCT03849560|Experimental|Grippol® Quadri|"Grippol® Quadri, a quadrivalent inactivated subunit influenza vaccine. Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
3473886|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Yamagata lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Yamagata lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Yamagata lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
3473887|NCT03849560|Active Comparator|Grippol® Plus, trivalent (Victoria lineage)|"Grippol® Plus, trivalent inactivated polymer-subunit influenza vaccine containing Victoria lineage type B influenza virus antigen.~Dosage form: suspension for intramuscular and subcutaneous injection. Dosage: 0.5 ml (1 dose)~Active ingredients:~type A (H1N1) influenza virus antigen 5 µg;~type A (H3N2) influenza virus antigen 5 µg;~type B (Victoria lineage) influenza virus antigen 5 µg;~immunoadjuvant Polyoxidonium® (azoximer bromide) 500 µg."
3473888|NCT03849534|Active Comparator|Soft occlusal appliance|Individually casted appliances
3473889|NCT03849534|Active Comparator|Jaw exercises|Resistance exercises to do twice a day
3473890|NCT03849534|Active Comparator|Counseling|Just information at the first visit
3473891|NCT03849482||Parotid Gland Neoplasms|"Preoperative Assessment of Parotid Gland Neoplasms with:~Clinical Evaluation;~Fine Needle Aspiration Cytology;~Multiparametric Magnetic Resonance Imaging.~Postoperative Collection of Final Histopathological Diagnosis"
3473892|NCT03849703|Experimental|Full Intervention #1|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the coparenting curriculum before the romantic relationships curriculum.
3473893|NCT03849703|Experimental|Full Intervention #2|Participants will receive both of our target curricula but in alternate order. This treatment group will receive the romantic relationships curriculum before the coparenting curriculum.
3473894|NCT03849703|Other|Partial Intervention #1|Participants will receive the romantic relationships curriculum along with the control curriculum.
3473895|NCT03849703|Other|Partial Intervention #2|Participants will receive the coparenting curriculum along with the control curriculum.
3473896|NCT03849677||Omnivore|
3473897|NCT03849677||Vegan|
3473898|NCT03849378|Experimental|Sargassum Horneri Extract group|This group takes Sargassum Horneri Extract for 12 weeks.
3473899|NCT03849378|Placebo Comparator|Placebo group|This group takes Placebo Extract for 12 weeks.
3473900|NCT03849599|Experimental|PRV-300|Subjects in this arm will receive the study drug, PRV-300, via IV infusion, followed by an 8-week follow-up period.
3473901|NCT03849599|Placebo Comparator|Placebo|Subjects in this arm will receive placebo via IV infusion, followed by an 8-week follow-up period.
3473902|NCT03849547|Experimental|App training group|Subjects in App training group will receive App Balance training via smartphone application.
3473903|NCT03849547|Active Comparator|Home training group|Subjects in Home training group will receive Home Balance training advised by physical therapist.
3473904|NCT03849547|No Intervention|Control group|Control group will receive only education of ankle injury prevention related information.
3473905|NCT03849573|Experimental|Mindfulness-based stress reduction + Hormone Therapy Education|
3473906|NCT03849573|Active Comparator|Hormone Therapy Education + Overall Health Education|
3473907|NCT03849365|Experimental|TOOKAD VTP|TOOKAD is administered as part of focal VTP under general anaesthetic. TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
3473908|NCT03849495|Experimental|Group A|"Period 1: D745~Period 2: CKD-370"
3473909|NCT03849495|Experimental|Group B|"Period 1: CKD-370~Period 2: D745"
3473910|NCT03849456|Experimental|GWP42006|Oral solution taken twice daily with food for 52 weeks.
3473911|NCT03849404|Experimental|AVT02 100mg/mL (Adalimumab Biosimilar)|Patients will be randomized to AVT02 on 1: 1 basis from the dosing day of Day 1 until week 48
3473912|NCT03849404|Experimental|EU-Humira 100mg/mL (Adalimumab Originator)|Patients will be randomized to EU-Humira on 1: 1 basis from the dosing day of Day 1 until week 48
3473913|NCT03849755|Other|PEPPER/Control|Group with intervention applied (PEPPER system) during the first three months and then, after wash -out period, swap to control group (using standard bolus calculator) for the next 3 months.
3179332|NCT00671697|Experimental|Dose Level 1 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.1 mg/kg/day IV x 5 days followed by weekly doses of 0.1 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3126185|NCT03022435|Other|Group B: 18-30 yo identical twins (LAIV)|Participants to receive FluMist® LAIV by nasal spray.
3473914|NCT03849755|Other|Control/PEPPER|Group without intervention applied (using standard bolus calculator) during the first three months and then, after wash -out period, swap to intervention group (using PEPPER system) for the next 3 months.
3473915|NCT03849391|Experimental|Skate group|This group takes Skate Skin extract for 12 weeks
3473916|NCT03849391|Placebo Comparator|Placebo group|This group takes Placebo for 12 weeks
3473917|NCT03849417||Late-life Depression|Patients aged over 60 years old with severe depression
3473918|NCT03849417||Late-life Depression (ECT)|Patients aged over 60 years old with severe depression who are referred for treatment with electroconvulsive therapy
3473919|NCT03849417||Healthy Controls|Healthy volunteers over 60 years old who will form a comparison group
3473920|NCT03849352|Other|Lifestyle Arm|Can people living with and beyond colorectal cancer make lifestyle changes with the support of health technology
3473921|NCT03849209|Experimental|Stylet Slow-Pull Technique group|In patients randomized to the stylet slow-pull techniques an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
3473922|NCT03849209|Active Comparator|Standard Suction Technique group|In patients randomized to the standard suction technique an endoscopic ultrasound-guided fine needle biopsy of the pancreatic mass were made with a 20 Gauge needle (EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA): 15 to-and-fro movements within the lesion were performed with the use of a 10-mL suction syringe.
3473923|NCT03849339|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
3473924|NCT03849339|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
3473925|NCT03849248|Experimental|Intervention|This group of babies will have a maternal scented cloth placed under their heads
3126186|NCT03022435|Other|Group B: 18-30 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
3126187|NCT03022435|Other|Group D: 40-64 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
3126188|NCT03022435|Other|Group F: 65-100 yo identical twins (TIV)|Participants to receive Fluzone® standard TIV
3126189|NCT03022435|Other|Group F: 65-100 yo identical twins (High-Dose TIV)|Participants to receive High-Dose Fluzone® standard TIV
3126190|NCT03022526|Experimental|CSE|intrathecal bupivacaine 2.5mg + fentanyl 15mcg followed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
3473926|NCT03849248|No Intervention|Control|This group of babies will have a clean non- maternal scented cloth placed under their head
3126191|NCT03022526|Active Comparator|Epidural|epidural bupivacaine 0.083% + fentanyl 2mcg/mL (8mL) followed by fentanyl 100mcg (2mL); follwed by infusion (PCEA): bupivacaine 0.083% with fentanyl 2mcg/mL: basal 8mL/hr, demand 8mL, 2 boluses per hour allowed, total maximum hourly allowance 24mL
3126192|NCT03022617|Experimental|Study Group|Open-label drug administration group. No comparator.
3473927|NCT03849222|Active Comparator|Ca(OH)2 Apexification|Apexification was performed with calcium hydroxide. calcium hydroxide dressing was applied directly against the open apex .The canals were back filled with Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
3473928|NCT03849222|Experimental|Ca(OH)2 Apexification with apical matrix|Treated by condensation of calcium hydroxide dressing against an internal matrix , a piece (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy) was gently compacted toward the apex before insertion of Ca(OH)2 dressing, followed by proper coronal seal. Patients were recalled every 3, 6 and 12 months for evaluation clinically and radiographically. Once the calcific apical barrier was detected the root canals were then obturated and final restoration was done.
3473929|NCT03849222|Active Comparator|MTA Apexification|Apexification was performed with MTA as apical plug. A 3-5 mm thickness of MTA using a hand plugger was applied as apical plug and verified radiographically. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
3126193|NCT03022630|Other|Comprehensive Palliative Care services|Comprehensive Palliative Care services in addition to usual hepatic care
3126194|NCT03022630|Other|Usual hepatic care|Usual hepatic care
3473930|NCT03849222|Experimental|MTA Apexification with apical matrix|An internal (apical) matrix was used as a base for condensation of MTA apical plug, a pieces of (4X4mm) of resorbable collagen membrane (Biocollagen; Bioteck:Turin, Italy)were compacted toward the apex with premeasured suitable size schilder plugger. Moist cotton pellet was placed over the MTA followed by application of coronal seal. After 48 h, the set of the MTA was checked and final obturation of the root canal was done
3473931|NCT03849183|Experimental|Nitroglycerin|Nitroglycerin 5mcg/kg (0.5cc) is subcutaneously injected before radial artery cannulation.
3473932|NCT03849183|Active Comparator|Control|Normal saline (0.5cc) is subcutaneously injected before radial artery cannulation.
3473933|NCT03849287|Experimental|Group 1|"Period 1: CKD-333, formula I~Period 2: CKD-333, formula II~Period 3: CKD-330, D090"
3473934|NCT03849287|Experimental|Group 2|"Period 1: CKD-333, formula I~Period 2: CKD-330, D090~Period 3: CKD-333, formula II"
3473935|NCT03849287|Experimental|Group 3|"Period 1: CKD-333, formula II~Period 2: CKD-330, D090~Period 3: CKD-333, formula I"
3473936|NCT03849287|Experimental|Group 4|"Period 1: CKD-333, formula II~Period 2: CKD-333, formula I~Period 3: CKD-330, D090"
3473937|NCT03849287|Experimental|Group 5|"Period 1: CKD-330, D090~Period 2: CKD-333, formula I~Period 3: CKD-333, formula II"
3473938|NCT03849287|Experimental|Group 6|"Period 1: CKD-330, D090~Period 2: CKD-333, formula II~Period 3: CKD-333, formula I"
3473939|NCT03849144|Experimental|Therapy dog activity|Interact with visiting therapy dogs for 15 minutes on two Fridays
3473940|NCT03849144|Active Comparator|Low impact physical activity|Participate in 15-minute low impact physical activity on two Fridays
3473941|NCT03849274|Experimental|Smart Scar Care Pad+Pressure Garment|For experiment group, subject will be intervened by SSCP plus PG
3473942|NCT03849274|Active Comparator|Pressure Garment|For control group, subject will be intervened by conventional PG only
3473943|NCT03849274|No Intervention|Non-eligible patients (with VSS less than 4)|Non-eligible subjects with VSS less than 4 will be followed up for 6 months and assessment results will be recorded.
3473944|NCT03849313|Experimental|AVT02 100mg/mL|Biosimilar Adalimumab AVT02
3473945|NCT03849313|Active Comparator|EU-Humira 100mg/mL|EU Approved Adalimumab originator Humira
3473946|NCT03849313|Active Comparator|US-Humira 100mg/mL|US licensed Adalimumab originator Humira
3473947|NCT03849196|Experimental|2L PEG-Asc|2L PEG-Asc for bowel preparation
3473948|NCT03849196|Active Comparator|1L PEG-Asc & 'Bisacodyl 10Mg Suppository|1L PEG-Asc with 'Bisacodyl 10Mg Suppository for bowel preparation
3473949|NCT03849157|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
3473950|NCT03849157|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
3126195|NCT03022799|Experimental|KM-819|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
3126196|NCT03022799|Placebo Comparator|Placebo|Each cohort consists of 8 subjects; 6 subjects will receive planned dose of KM-819 and 2 subjects will receive placebo.
3473951|NCT03849118|Experimental|89Zr-girentuximab|A single administration of 37 Megabecquerel (MBq) (±10%) 89Zr-girentuximab, containing a mass dose of 10 mg of girentuximab, followed by a diagnostic scan on Day 5 ± 2 days after administration.
3473952|NCT03849170|Experimental|Psychological Intervention|Six session intervention, each session 20-25 minutes in length. Stress inoculation technique-based intervention. Participants will be taught stress coping skills and relaxation skills such as self-efficacy statements, imagery, relaxation breathing, relaxation scripts, thought stoppage, cognitive reframing, positive self-talk, goal setting, event planning, and preparing for competition
3473953|NCT03849170|Placebo Comparator|Health Intervention|Six session intervention, each session 20-25 minutes in length. Participants will be taught relevant health and nutrition guidelines and practice using a food diary app (MyFitnessPal). Nutrition and health content will include such topics as reading Canadian food labels, vitamins and supplements, effects of alcohol on performance and recovery, vegetarian vs. omnivore diets, and hydration & performance.
3473954|NCT03848975|Experimental|Simulation training for ECV|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the Control group for VE : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
3473955|NCT03848975|Experimental|Simulation training for VE|For the intervention (trained) group, the training sessions will be conducted over six months. During this period participants will continue their daily clinical practice in the delivery room: when one of these maneuvers is needed, a case report form (CRF) will be completed by the participant. This group is the the control group for for ECV : The control group will learn obstetric maneuver during daily clinical practice in the delivery room under supervision (usual resident training without simulation sessions). When one of these maneuvers is needed, a case report form (CRF) will be completed by the participant.
3473956|NCT03849014|Active Comparator|Dynamic Hip Screw|Dynamic Hip Screw is used for internal fixation of fractures of the certain types of hip fractures. The implant assembly consisting of a lag screw, a side plate, and cortical screws that fix the side plate to the proximal femoral shaft.
3473957|NCT03849014|Active Comparator|Proximal Femoral Nail|The Proximal Femoral Nail offers osteosynthesis for the several types of hip fractures. It consists of an anatomically curved nail, double neck screw, and two locking screws for distal end.
3473958|NCT03849027|Experimental|Methoxyflurane|"Inhaled methoxyflurane once-off dose of 3 ml will be administered via the inhaler at each dosing visit .~Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®)."
3473959|NCT03849027|Sham Comparator|Sham Methoxyflurane|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test
3473960|NCT03848897|Experimental|Non falling elderly|
3473961|NCT03848897|Experimental|Falling elderly|
3473962|NCT03848897|Experimental|Non falling patients with Parkinson's disease|
3473963|NCT03849261|Experimental|Group 1|"Period 1: D635~Period 2: CKD-387"
3473964|NCT03849261|Experimental|Group 2|"Period 1: CKD-387~Period 2: D635"
3473965|NCT03849079|Experimental|Hyponut|
3473966|NCT03848819|Other|Control pursed lip breathing|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe adopting the pursed lip breathing technique. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
3473967|NCT03848819|Experimental|pNIV|Patients will undergo one intermittent exercise protocols on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min recovery periods in between work bouts. During the 1st min of each recovery period patients will breathe via the VitaBreath device. During the 2nd min of each recovery period patients will breathe normally. Patients will also score the intensity of their perceived dyspnoea using the Borg 1-10 scale. Cardiac output and stroke volume will be measured non-invasively using a cardio-impedance method (physio-flow) throughout the exercise and recovery periods. Respiratory muscle activation (EMG) and local respiratory muscle oxygen tissue oxygenation (NIRS) will be continuously recorded non-invasively using optodes placed on the skin throughout the exercise and recovery periods. In addition, arterial oxygen saturation will be recorded throughout the exercise and recovery periods using a pulse oximeter.
3473968|NCT03849066||Part 1: Cross-Sectional PRSA|This will be a cross-sectional analysis of 300 children with neurological impairment and polypharmacy.
3473969|NCT03849066||Part 2: Longitudinal PRSA|This will be a 12-month prospective cohort study of 50 children with neurological impairment and polypharmacy.
3473970|NCT03848962||Subjects for observational study|Various conditions & healthy subjects
3473971|NCT03849092|Experimental|Financial incentive|3 municipalities will receive 120.000 DKK for financial incentives.
3473972|NCT03849092|Experimental|Campaigns|3 municipalities will receive 120.000 DKK for campaigns.
3473973|NCT03849092|No Intervention|Control|"6 clean control municipalities perform their smoking cessation activities as usual. They wont receive any financial resources. These muncipalities have not been randomly selected but have been matched (by number of smokers attending the smoking cessation groups in the municipality in 2017, the year before the intervention). 3 of them are Campaing Control group and 3 are Finacial Incentives Control group."
3473974|NCT03848858|Experimental|EMDR plus TAU|20 individual weekly sessions of 60 minutes each of Eye Movement Desensitization and Reprocessing Therapy (EMDR), plus Treatment as Usual (TAU), applying first the standard EMDR protocol (Shapiro, 2005), and then a specific protocol for the sequelae of somatic illness and medical trauma (Hase, 2018).
3473975|NCT03848858|No Intervention|TAU only|The patients in this condition are newly diagnosed and will be introduced to the study in their first appointment with the Infectious Diseases Unit, in which analyses of HIV-related biological markers are taken. In a follow up appointment between 1 and 2 weeks later, antiretroviral treatment is initiated. There is a further check-up 1-2 months after initiating antiretroviral treatment, and then 6-monthly check-ups. In these checkups, measures of CD4 and the CD4/CD8 ratio are taken and treatment adherence is reviewed. The patients receiving EMDR therapy will also participate in these activities.
3126197|NCT03022916|Active Comparator|Nail Polish + Efinaconazole Solution|One big toe will receive application of Efinaconazole Solution on top of nail polish (without the presence of a top coat or base coat)
3473976|NCT03849053|Experimental|Mézières method|
3473977|NCT03849053|Active Comparator|Control Group|
3473978|NCT03848637|Experimental|Group 1|"Period 1: D387 (reference drug)~Period 2: CKD-387 (test drug)"
3473979|NCT03848637|Experimental|Group 2|"Period 1: CKD-387 (test drug)~Period 2: D387 (reference drug)"
3473980|NCT03848611|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
3473981|NCT03848767|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
3473982|NCT03848806|Experimental|HAT1 topical|HAT1 topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
3473983|NCT03848806|Active Comparator|Calcipotriol|Calcipotriol topical cream will come in a blinded bottle. Patients, investigators, and the trial sponsor will be unaware of the trial group assignments. Packaging and labeling of the test and comparator products will be identical to maintain the blind.
3473984|NCT03848884|Experimental|Adherence monitoring and education|
3473985|NCT03848936||adult cerebral palsy patients|>18 age cerebral palsy diagnosed patients evaluated with a survey.
3473986|NCT03848793|Other|HS-20004 or placebo treatment (Low dose)|HS-20004 or placebo SC once daily (Low dose)
3473987|NCT03848793|Other|HS-20004 or placebo treatment (median dose 1)|HS-20004 or placebo SC once daily (median dose 1)
3126198|NCT03022916|Placebo Comparator|Nail Polish Only|Both big toes will use nail polish only
3473988|NCT03848793|Other|HS-20004 or placebo treatment (median dose 2)|HS-20004 or placebo SC once daily (median dose 2)
3473989|NCT03848793|Other|HS-20004 or placebo treatment (high dose)|HS-20004 or placebo SC once daily (high dose)
3473990|NCT03848624|Experimental|Cycling Group|Intention driven motor-assisted voluntary cycling with electrical stimulation
3473991|NCT03848598||Responders|Patients suffering from patellar tendinopathy who have complete pain resolution after performing isometric exercises.
3473992|NCT03848598||Non-responders|Patients suffering from patellar tendinopathy who do not have complete pain resolution after performing isometric exercises.
3473993|NCT03848702|Experimental|Healthy volunteers|All volunteers wore the DRFB
3473994|NCT03848702|Experimental|Patients with DRF|All patients wore the DRFB
3473995|NCT03848741|Placebo Comparator|Non-exercise control with placebo|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the β-hydroxy β-methylbutyrate (HMB) Plus Vitamin D (VitD) capsules.
3473996|NCT03848741|Experimental|Non-exercise control with HMB+VitD|Participants will be asked to maintain their normal physical activity and dietary habits during the 12-week intervention. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
3126199|NCT03022916|Active Comparator|Base Coat + Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with base coat and top coat.
3473997|NCT03848741|Active Comparator|Resistance exercise training with placebo|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 placebo capsules (calcium lactate), twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Placebo capsules match the size, color, weight, and number of capsules per dose compared to the HMB + VitD capsules.
3473998|NCT03848741|Experimental|Resistance exercise training with HMB+VitD|Participants will complete 12-weeks (3 days per week) of a whole-body progressive resistance exercise training program. Physical activity, diet, urine and blood samples will be collected every 4 weeks. Each participant will consume 3 HMB+VitD capsules, twice a day with a meal or snack for a total of 6 capsules per day. Participants will be asked to take capsules ~30-60 minutes before resistance exercise. Each capsule contains 500 mg calcium HMB and 333.33 IU Vitamin D for a total of 3.0 g HMB and 2000 IU Vitamin D per day.
3473999|NCT03848585|Experimental|Pilloxa Pillbox|
3474000|NCT03848585|Sham Comparator|Non active Pilloxa Pillbox|
3474001|NCT03848663|Experimental|Patients with scotoma|No remapping (control condition), traditional remapping, personalized remapping
3474002|NCT03848663|Active Comparator|Normally sighted with artificial scotoma|No remapping (control condition), traditional remapping, personalized remapping
3126200|NCT03022916|Active Comparator|Nail Polish + Top Coat + Efinaconazole Solution|One big toe will receive application of Efinaconazole solution on top of nail polish with top coat.
3126201|NCT03022981|Experimental|12 to < 18 Years Old|"PK Lead-in Phase: Sofosbuvir/Velpatasvir (SOF/VEL) 400/100 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 400/100 mg once daily for 12 weeks."
3474003|NCT03849001|Experimental|Exercise Conditions|"Participants will undergo four Exercise Conditions (i.e., light intensity leg cycling, moderate intensity leg cycling, vigorous intensity leg cycling, and a seated, quiet rest) in a randomized, counterbalanced order."
3474004|NCT03848559|Experimental|Airway device placement|airway device is placed during the dive
3474005|NCT03848494||Gastroesophageal reflux disease|Patients submitted to primary minimally invasive surgery for gastroesophageal reflux disease or hiatus hernia
3474006|NCT03848728|Experimental|Intervention Clinics|SEARCH Youth combination intervention, which includes life-stage assessment and counseling, rapid VL feedback, structured choice clinic access, and e-collaboratives chat-based discussion among providers
3126202|NCT03022981|Experimental|6 to < 12 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks."
3179333|NCT00671697|Experimental|Dose Level 2 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.2 mg/kg/day IV x 5 days followed by weekly doses of 0.2 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3474007|NCT03848728|No Intervention|Control Clinics|Optimized country standard of care
3474008|NCT03848507|Experimental|20% Albumin|Administration of 3ml per kg bodyweight of 20% albumin within 30 min during cystectomy.
3474009|NCT03848689||FQ PPA Group|Fluoroquinolone Preprescription Authorization from Infection Control consult, once, prior to prescribing fluoroquinolone
3474010|NCT03848689||Control Group|No preprescription authorization needed from Infection control prior to prescribing fluoroquinolone
3474011|NCT03848546|Experimental|PDA|Intervention group: receives the personalized dietary advice
3474012|NCT03848546|Active Comparator|Control|Receives the general advice (two flyers containing information about fiber intake)
3474013|NCT03848533|Experimental|melatonin plus metformin|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before bedtime) per 90 days."
3474014|NCT03848533|Active Comparator|metformin plus placebo|"It will be indicate metformin 850 mg tablets, once a day in the morning (before breakfast) per 90 days.~Will administrate homologated placebo once a day in the night (before bedtime) per 90 days."
3474015|NCT03848533|Experimental|melatonin plus placebo|"It will be indicate homologated placebo once a day in the morning (before breakfast) per 90 days.~Will administrate melatonin 5 mg lengthed release capsules, once a day in the night (before sleep) per 90 days."
3474016|NCT03848390|Experimental|Modified Time-restricted Feeding|
3474017|NCT03848390|Active Comparator|Conventional diet|
3474018|NCT03848520||Total Knee Arthroplasty|Internal Registry of Patients having a TKA and with a high (>=9) activity-scale score at anytime between preoperatively and now.
3474019|NCT03848351|No Intervention|Control Group|70 patients not receiving oral hygiene instructions or devices and continuing with their routine oral hygiene habits
3474020|NCT03848351|Active Comparator|Test Group|"70 patients receiving intense oral hygiene instructions assisted by specific software or devices as well as oral hygiene (OH) tools (electric toothbrush, interdental floss, toothpaste) Thus, interventions will consist of.~Oral Hygiene Instruction (OHI)~Professional supragingival scaling and polishing"
3179334|NCT00671697|Experimental|Dose Level 3 Arsenic Trioxide & Decitabine|"Arsenic trioxide loading dose of 0.3 mg/kg/day IV x 5 days followed by weekly doses of 0.3 mg/kg IV for 15 additional weeks.~Decitabine 20 mg/m2 IV every day on days 1-5 of a 4 weeks cycle for 4 cycles."
3474021|NCT03848338|Other|Pilot Group|Intra and Post-operative Electrocochleography
3474022|NCT03848442|Experimental|UPART intervention group|A 1-group pretest-posttest design was conducted. Outcomes were evaluated on four occasions; twice during baseline separated by six weeks and immediately following a 12-week 'uptime' participation intervention and after a further 12 weeks (follow-up).
3179335|NCT00671736|Experimental|1|daily inhalation
3474023|NCT03848572|No Intervention|Usual care|Patients will enter standard 12-month clinical follow-up
3474024|NCT03848572|Experimental|Re-Score strategy|Patients will enter a novel strategy of 12-month follow with repetitive assessment of PRECISE-DAPT score at 3-month intervals
3474025|NCT03848650|Experimental|Opsens Medical OptoWire|Subjects who will have or recently had FFR using the Opsens Medical OptoWire Deux FFR system.
3474026|NCT03848182|Experimental|Gemcitabine with TT vaccine booster|Gemcitabine will be delivered as is standard of care. Patients diagnosed with pancreatic ductal carcinoma (PCD) will be treated with Gemcitabine and boosted once with the human childhood vaccine to TT
3474027|NCT03848468|Active Comparator|CH(conventional Hemorrhoidectomy)|conventional hemorrhoidectomy
3474028|NCT03848468|Experimental|LH (Ligasure Hemorrhoidectomy)|Ligasure hemorrhoidectomy
3474029|NCT03848780|Experimental|Desflurane Group|Thirty minutes before initiation of ischemia the surgeon was instructed to notify the anesthesiologist. At this single time point, propofol infusion was stopped and substituted with the volatile anesthetic desflurane to achieve a Minimum Alveolar Concentration of 1. The procedure included a 5-minute induction of desflurane, a 20-minute preconditioning and a 5-minute washout period when propofol was reintroduced and desflurane stopped.
3474030|NCT03848780|No Intervention|Control Group|No pharmacological preconditioning was implemented
3179336|NCT00671736|Experimental|2|inhalation every other day
3179337|NCT00671736|Experimental|3|inhalation twice a week
3474031|NCT03848234|Experimental|A Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
3474032|NCT03848234|Placebo Comparator|B Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks
3474033|NCT03848104||bone and joint infection treated with cefoxitin|patients having had a bone or joint infection treated by cefoxitin in combination. Cefoxitin has been administered by continuous way, at home. A serum dosage of cefoxitin has been systematically achieved at equilibrium.
3474034|NCT03848117|Active Comparator|(DTF massage & Mill's manipulation)(Group 1)|For any given subject in group 1, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in 1st group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
3474035|NCT03848117|Active Comparator|( Taping & MWM) (Group 2).|For any given subject in group 2, PRTEE pain and functional disability evaluations and Hand grip strength were completed on the same day. Then each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain, increase functional activity level, and improve hand grip strength. Each subject was evaluated for changes in symptoms on 1st week, 2nd week, 3rd week and 4th week.
3474036|NCT03848273||Ischemic|questionnaire, physical-neurological examination, labor investigations, EEG
3474037|NCT03848273||Hemorrhagic|questionnaire, physical-neurological examination, labor investigations, EEG
3474038|NCT03848273||Control|questionnaire, physical-neurological examination, labor investigations, EEG
3474039|NCT03848364|Experimental|Hip Hop Stroke 2.0 intervention group|"Students in 4th and 5th grade will receive the intervention, Hip Hop Stroke 2.0, disseminated and implemented by local Stroke Centers - uses a framework of Child-Mediated Health Communication to make children stroke literate and then empower these stroke literate students with the tools required to successfully communicate actionable stroke knowledge (recognition of stroke symptoms and the urgency of calling 911) to their parents and grandparents at home."
3474040|NCT03848169|Experimental|Experimental group|Ultrasound guidance will be used with a high- frequency linear transducer.After the joint has been identified, the researcher will ask the patient to hold mouth in a neutral position. Masseter, temporalis, medial and lateral pterygoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection. Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, 0.5 ml of normal saline will be injected (to decrease the impedance of the tissues), the electrode will be inserted, and extra-articular PRF will be performed during 4 minutes at 42 degrees Celsius for each muscle. At the end of each muscle treatment, 1 ml of local anesthetic (lidocaine 1%) will be injected through the RF needle, and the needle will be removed.
3474041|NCT03848169|Sham Comparator|Control Group|Ultrasound guidance will be used with a high- frequency linear transducer. After the joint has been identified, the researcher will ask the patient to hold his or her mouth in a neutral position. Masseter, temporalis and lateral pterigoid muscles will be then identified, and with a sterile marker the operator will determine the best point of entry for each muscle injection (mainly over the most common sites of trigger points for the masticatory muscles). Lidocaine 1% will be injected for the skin, always under ultrasound vision. RF needle (18 G, 50 mm of length and active tip of 3 mm) will be inserted into each one of the muscles mentioned previously. Then, through the RF needle, an electrode will not be inserted, but a simulation for PRF will be done during 4 minutes for each muscle (sham). At the end of each muscle puncture, 1 ml of local anesthetic (lidocaine 1%) will be injected through the needle, and the needle will be removed.
3474042|NCT03848078|Other|Optical Coherence Tomography arm|In the intervention arm, OCT imaging is performed which will take about 3 minutes. The decision on the most adequate treatment strategy will be based directly on the OCT diagnosis, but only when there is certainty about the presence of BCC and BCC subtype according to the OCT diagnosis. A 'safety' biopsy will be performed after the OCT scan. In patients where the OCT diagnosis leaves doubt or it is certain that there is no BCC, a biopsy will be taken anyway and the treatment decision will be based on the result of this punch biopsy.
3474043|NCT03848078|No Intervention|Regular care arm|In patients assigned to regular care, the result of punch biopsy will always be used to decide which treatment is most adequate. Therefore, a next consultation will be planned to discuss the outcome of the biopsy and the intended treatment strategy.
3126203|NCT03022981|Experimental|3 to < 6 Years Old|"PK Lead-in Phase: SOF/VEL 200/50 mg once daily for 7 days for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 7 days for participants who weigh < 17 kg. Participants who complete the PK lead-in phase, continue into the treatment phase with no interruption of study drug administration and additional participants will be enrolled into the treatment phase once the appropriateness of the dose is confirmed by PK results from the PK lead-in phase.~Treatment Phase: SOF/VEL 200/50 mg once daily for 12 weeks for participants who weigh ≥ 17 kg. SOF/VEL 150/37.5 mg once daily for 12 weeks for participants who weigh < 17 kg."
3126204|NCT03023137|Active Comparator|Walking & dietary modification (W&D)|W&D should begin when participants wish to conceive. The intervention was standardized by training of research staff. Careful instructions about walking speed and diet would be given to participants assigned to W&D at enrolment and at each consultation.
3474044|NCT03848065|Experimental|V114-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of V114 on Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
3474045|NCT03848065|Experimental|V114-IM|Infant participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at Visit 1, 2, 3 and 5 (approximately 3, 4, 5, and 12 to 15 months of age).
3474046|NCT03848065|Active Comparator|PCV13-SC|Infant participants will receive a single 0.5 mL subcutaneous (SC) injection of pneumococcal 13-valent conjugate vaccine (PCV13) at Visit 1, 2, 3 and 5(approximately 3, 4, 5, and 12 to 15 months of age).
3474047|NCT03848260|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time (duration: 30-120 mins/each time) and 3 times within 3 months.~Intervention: using the magnetic device prototype"
3179338|NCT00671736|Placebo Comparator|4|daily inhalation
3179339|NCT00671775||Bariatric surgery patients|
3474048|NCT03848299|Experimental|Experimental: Single Arm|All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.
3474049|NCT03848130|Active Comparator|Knee Taping with Home Exercises (Group 1)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into knee taping group.Each subject in first group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
3126205|NCT03023137|No Intervention|Controls|No recommendations regarding diet or physical activity were given to controls. Antiemetics such as ondansetron would be given to controls complaining of vomiting.
3126206|NCT03023176|Other|Healthy 1-8 year-old twins|Healthy 1-8 yr old identical and fraternal twin pairs given trivalent, inactivated influenza (Fluzone® standard IIV3 0.5ml or Fluzone® standard IIV3 Pediatric Dose) per participant age and standard of care.
3474050|NCT03848130|Active Comparator|Lateral wedge insoles with Home Exercises (Group 2)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into lateral wedge insole group.Each subject in second group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
3474051|NCT03848130|Active Comparator|Traditional Physiotherapy with Home Exercises (Group 3)|Knee osteoarthritis patients were assessed by general demographic questionnaire, rapid assessment of physical activity (RAPA) to determine physical activity level and Knee injury and Osteoarthritis Outcome Score (KOOS) to determine the level of pain severity,stiffness, functional activities, recreational activities and Quality of life for enhancing functional independence and were assigned into traditional physiotherapy group.Each subject in third group completed 4 weeks of physical therapy sessions which were aimed to decrease pain and stiffness, increase functional activity level, and improve quality of life. Each subject was evaluated for changes in symptoms on, 1st week, 2nd week, 3rd week and 4th week.
3474052|NCT03848247|Experimental|Control group|Participants will be injected with 0.5ml Isotonic saline into a neck muscle
3474053|NCT03848247|Experimental|Neck pain|Participants will be injected with 0.5ml NGF into the a neck muscle
3126207|NCT03023397|Other|Der f treated Non-smoker|
3474054|NCT03848091||Antibiotic pretreatment|patients having had an antibiotic pretreatment before a one-step exchange arthroplasty
3474055|NCT03848156||CRSwNP AERD allergic|Patients suffering from chronic rhinosinusitis with nasal polyps, allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
3474056|NCT03848156||CRSwNP AERD non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy and aspirin exacerbated respiratory disease - biopsy for RNA sequencing
3474057|NCT03848156||CRSwNP non-allergic|Patients suffering from chronic rhinosinusitis with nasal polyps without allergy - biopsy for RNA sequencing
3474058|NCT03848156||CRSwNP allergic|Patients suffering from chronic rhinosinusitis with nasal polyps with allergy - biopsy for RNA sequencing
3474059|NCT03848286|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
3474060|NCT03848039|Experimental|Gardasil-9|Intramuscular Gardasil-9 vaccination at 0, 2 and 6 months.
3126208|NCT03023397|Other|Der f treated Cigarette smoker|
3126209|NCT03023397|Other|Der f treated E-cig user|
3474061|NCT03848039|Placebo Comparator|Placebo|Placebo injection at 0, 2 and 6 months
3474062|NCT03847753||Danish population|The cohort includes all those born in Denmark between 1900-2015, and who resided there in the period of 2000-2016.Whether they received a diagnosis of one of the following mental disorders will be ascertained: Organic Disorders, Substance Use Disorders, Schizophrenia Disorders, Mood Disorders, Eating Disorders, Neurotic Disorders, Personality Disorders, Intellectual Disorders, Developmental Disorders, Behavioral Disorders The risk of receiving a later diagnosis of one of the following types of general medical conditions will then be estimated: Circulatory, Endocrine, Pulmonary and Allergy, Gastrointestinal, Urogenital, Musculoskeletal, Hematological, Cancer, Neurological
3474063|NCT03848000|Experimental|Exercise Programme and NHS Standard Care|Exercise and NHS standard care.
3474064|NCT03848000|Active Comparator|NHS Standard Care only|Alcohol addiction counselling.
3474065|NCT03847740|Experimental|Right Isometric Thumb Force (ITF) handle|
3474066|NCT03847740|Experimental|Left Isometric Thumb Force (ITF) handle|
3126210|NCT03023423|Experimental|Treatment Arm A: Atezolizumab|Participants in Treatment Arm A will receive Atezolizumab 1,200 milligram (mg) intravenously (IV) on Day 1 of every 21-day cycle. Participants with confirmed disease progression based on RECIST 1.1 may cross over to Arm B and receive daratumumab and atezolizumab, provided crossover eligibility criteria are met.
3179340|NCT00671775||Weight loss programs|
3179341|NCT00671801|Experimental|Irinotecan + Lenalidomide|Irinotecan 200 mg/m^2 intravenous once every 2 weeks on days 1 and 15; Lenalidomide orally 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
3179342|NCT00671814|Experimental|1|Single oral dose of TR-701 given once at 200mg, 400mg, 600mg, 800mg, and 1200mg. Multiple oral doses of TR-701 given once daily for 21 days at 200mg, 300mg and 400mg.
3474067|NCT03847779|Experimental|Non-neuropathy|"Type 2 diabetic without neuropathy:~Negative findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) <3~Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
3474068|NCT03847779|Experimental|Neuropathy|"Type 2 diabetic with neuropathy~Positive findings on Semmes-Weinstein monofilament~Neuropathy symptom score (NSS) >3~Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~pedometer during 4 days~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
3474069|NCT03847779|Experimental|Controls|"matched for age, sexe and BMI with diabetic patients.~Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:~rest cutaneous microcirculation (perfusion and vasomotion)~Exercise cutaneous microcirculation (perfusion and vasomotion)~Foot lowering cutaneous microcirculation (perfusion and vasomotion)~Hyperthermia cutaneous microcirculation (perfusion and vasomotion)~blood sampling~heart rate variability at rest~international Physical Activity Questionary~Qualify of Life questionary (EQVOD)"
3474070|NCT03847974|Experimental|LIB003|LIB003
3474071|NCT03847766|Experimental|PRO-based follow-up|Patients will receive a questionnaire every 3 months. The PRO questionnaire is used as decision aid together with other available clinical data to decide whether the patient needs a visit or not. Hence, patients only visit the outpatient clinic if there is a clinical need or a patient's wish. The actual response for each questionnaire automatically results in a colour code (green, yellow or red). A red or yellow response indicates that the patient needs to be contacted. A green colour indicates no need for a visit. Based on an overview of the questionnaire and the patient's blood samples a physician decides whether this patient should have a telephone consultation or the patient needs to be seen in the clinic.
3474072|NCT03847766|Experimental|PRO-based telephone consultations|Patients receive an electronic questionnaire every 3 months prior to a scheduled telephone consultation.The PRO questionnaire is used as dialogue support during the telephone consultation. The actual response for each item automatically results in a colour code (green, yellow or red). A red response indicates that the patient has a problem; a yellow colour indicates a potential problem, while a green colour indicates no problems.
3474073|NCT03847766|No Intervention|Usual outpatient follow-up visits|Patients in the control group will continue to have usual scheduled outpatient follow-up visits at the hospital initiated by the physician every 3 months. These patients do not use the clinical PRO questionnaire, but complete the research questionnaires.
3126211|NCT03023423|Experimental|Treatment Arm B: Atezolizumab and Daratumumab|Participants will receive daratumumab 16 milligram per kilogram [mg/kg] (Safety Run-in and Treatment Arm B) Intravenously (IV) weekly for 3 cycles (Day 1, 8 and 15), and Day 1 of every 21-day cycle thereafter. Atezolizumab will be administered at 1200 mg IV on Day 2 of Cycle 1 and on Day 1 of every 21-day cycle thereafter. Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met.
3126212|NCT03023488|Experimental|Flexible ureteroscopy arm|the findings of patients undergoing flexible ureteroscopy + laser lithotripsy for renal stones according to EAU Guidelines Doppler Ultrasound examination has been performed in the pre-operative and post-operative periods
3474074|NCT03847883|Active Comparator|0.6 mg/kg Ateplase|Low dose 0.6 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke (n = 26 in cohort A)
3474075|NCT03847883|Active Comparator|0.75 mg/kg Ateplase|Low dose 0.75 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A)
3474076|NCT03847883|Active Comparator|0.9 mg/kg Ateplase|Low dose 0.9 mg/kg Ateplase injection with in 4.5 Hr after onset of stroke(n = 26 in cohort A and n= 330 in Cohort B)
3474077|NCT03848013|Active Comparator|Treatment|Treatment of cases of melasma using Q switched Nd YAG laser and Fractional CO2 laser separately and in combination
3474078|NCT03848013|No Intervention|Follow -up period|follow up of the treated cases for 2 months
3474079|NCT03848026||Group 1|middle ear fluid viscosity <439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
3474080|NCT03848026||Group 2|middle ear fluid viscosity >439 centipoise (cP), Tympanostomy tube extrusion time of the all patients recorded prospectively
3474081|NCT03847688||Treatment resistant Major Depressive Disorder|
3474082|NCT03847805|Experimental|Experimental|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
3474083|NCT03847805|Active Comparator|Control|The control group followed a program of glenohumeral stabilization exercises,
3126213|NCT03023553|Other|TIV Group|Healthy adult males and females, 18-30 years of age. Immunization with standard trivalent, inactivated influenza vaccine (TIV), Fluzone®.
3126214|NCT03023553|Other|LAIV Group|Healthy adult males and females, 18-30 years of age. Immunize with intranasal live, attenuated influenza vaccine (LAIV), FluMist®.
3474084|NCT03847818|Experimental|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|
3126215|NCT03023683|Other|Group A: 2-8 yo healthy non-twins|Participants will be given seasonal live, attenuated influenza vaccine (LAIV), FluMist® . Children with no prior influenza vaccine history will receive a second dose of LAIV at least 28 days after the first study dose.
3126216|NCT03023683|Other|Group B: 18-49 yo healthy non-twins|Participants will be given seasonal LAIV, FluMist® .
3126217|NCT03023709|Other|Pilot phase|Participants will receive the current seasonal quadrivalent, inactivated influenza vaccine (IIV4)/Fluzone® given intramuscularly to confirm the safety of administering the seasonal influenza vaccine 3-14 days prior to tonsillectomy.
3474085|NCT03847727||Experimental: 6 cycles BR -> 4 x BR|Induction plus BR as maintenance (N=56)
3474086|NCT03847727||Proper historical control: 6 cycles BR|Induction only (N=56)
3474087|NCT03847792|Active Comparator|Group DB/Dexamethasone-Bupivacaine|Patients were received an intra-articular injection of 8mg dexamethasone added to18mL of 0.25% bupivacaine
3474088|NCT03847792|Active Comparator|Group FB /Fentanyl-Bupivacaine|Patients were received an intra-articular injection of 1 ug/kg fentanyl added to 18 mL of 0.25% bupivacaine
3474089|NCT03847792|Placebo Comparator|Group PB/Placebo-Bupivacaine|Patients were received an intra-articular injection of 2 mL isotonic saline added to 18 mL of 0.25% bupivacaine
3474090|NCT03847714|Active Comparator|Probiotic|Bifidobacterium bifidum W23, B. lactis W51, B. lactis W52, Lactobacillus acidophilus W22, L. casei W56, L. paracasei W20, L. plantarum W62, L. salivarius W24, Lactococcus lactis W19, 7.5 × 109 Colony Forming Units/g twice daily dissolved in water
3474091|NCT03847714|Placebo Comparator|Placebo|3g of a similar looking and tasting powder, twice daily
3474092|NCT03847636|Active Comparator|Familial Adenomatous Polyposis (FAP)|Individuals with duodenal adenomas (DAs) and FAP with Spigelman class 2,3 or 4, treated with cryoballoon ablation (intervention)
3474093|NCT03847636|Active Comparator|Sporadic duodenal adenomas|Individuals with at least 1 sporadic duodenal adenoma (DA) between 1-5 cm in maximum diameter, treated with cryoballoon ablation (intervention)
3474094|NCT03847909|Experimental|DCR-PHXC|Intervention, drug, DCR-PHXC
3474095|NCT03847909|Placebo Comparator|Placebo - Sterile Normal Saline (0.9% NaCl)|Placebo, sterile normal saline (0.9% NaCl) for subcutaneous (SC) injection
3474096|NCT03847831|Experimental|PPASF Group|"Schools enrolled in the postprimary active school flag program. All 17 elements are included. Feasibility is measured of the 17 elements.~Student representatives are selected to have accelerometer, physical health measures and perceived health collected for feasibility purposes."
3474097|NCT03847649|Active Comparator|Cohort 1: High Risk|
3474098|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm A|
3474099|NCT03847649|Active Comparator|Cohort 2: Standard Risk - Arm B|
3126218|NCT03023709|Other|Study phase|Participants will be given the current year's quadrivalent, live, attenuated seasonal influenza vaccine (LAIV4)/FluMist® intranasally 3-14 days prior to tonsillectomy.
3474100|NCT03847584||Adults-low socioeconomic status|Survey completed by adults with low socioeconomic status
3474101|NCT03847584||Adults-middle/high socioeconomic status|Survey completed by adults with middle/high socioeconomic status
3474102|NCT03847675|Experimental|Intervention|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age. A 4:50 minutes video clip would be shown during the initial visit. This video discusses the benefits of reading displaying practical tips for parents; it includes tips on how to read, pointing at the words.~A schematic pamphlet highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents.~After each visit participants will receive an age appropriate book for their child.~Focus groups will be conducted by a qualitative researcher"
3474103|NCT03847675|No Intervention|Control|The research assistant gives routine advice on child development including importance of reading and advice on nutrition and safety and gives parents a leaflet about early child development and complementary feeding
3474104|NCT03847857|Experimental|Surgery+PFS|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal anastomosis during McKeown esophagectomy.
3474105|NCT03847857|Placebo Comparator|Surgery|Arm B underwent conventional anastomosis during McKeown esophagectomy.
3474106|NCT03847935||Surgery|Patients who underwent surgical release of A1 pulley
3474107|NCT03847935||corticosteroid injections only|Patients who underwent local corticosteroid injections only, and no other treatment
3474108|NCT03847935||hand therapy only occupational/physical|1 visit: orthosis fabrication, range of motion, nodule and ice massage.
3474109|NCT03847935||Injection and Hand therapy|This group of participants received a combination of corticosteroid injection in the affected finger and one visit of hand therapy.
3474110|NCT03847935||Modality Hand Therapy|Ongoing hand therapy treatment, which included the above plus modalities such as ultrasound or iontophoresis.
3474111|NCT03847935||Injection and Modality Hand Therapy|Ccombination of local cortiscosteroid injection to the affected digit and ongoing hand therapy with modalities.
3474112|NCT03847571||Acetazolamide|Oral administration of acetazolamide 5 mg/kg/day for 4 weeks
3474113|NCT03847922|Placebo Comparator|Control group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection plus self-administered room air
3474114|NCT03847922|Experimental|Study group|lidocaine gel injected in the urethra 10 minutes prior to calcium hydroxylapatite injection + self-administered Pro-Nox 50% nitrous oxide/50% oxygen.
3474115|NCT03847844|Experimental|Group A|Cyto-MSC (5 million UCMSCs per kg bodyweight) and standard treatment
3474116|NCT03847844|Placebo Comparator|Group B|Placebo (normal saline) and standard treatment
3474117|NCT03847961|No Intervention|Control Group|The control group receive routine treatment of sepsis only. All sites agree, when feasible, to follow the tenets of the Surviving Sepsis Campaign clinical practice guidelines for management of sepsis.
3474118|NCT03847961|Experimental|Experimental Group|The experimental group receive routine treatment of sepsis combined with hemoperfusion with cytokine adsorption column (CA330).
3474119|NCT03847896|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
3474120|NCT03847896|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
3474121|NCT03847896|Active Comparator|BD MDI (PT008) 160 µg|
3474122|NCT03847896|Active Comparator|AS MDI (PT007) 180 µg|
3474123|NCT03847896|Placebo Comparator|Placebo MDI|
3474124|NCT03847506|Experimental|EZE/ROS+CAN/AML|Ezetimibe/Rosuvastatin 10 mg/10 mg and Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
3474125|NCT03847506|Active Comparator|CAN/AML|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg, once a day for 6 weeks
3474126|NCT03847506|Active Comparator|EZE/ROS+CAN|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg, once a day for 6 weeks
3474127|NCT03847493||Patients with suspected sepsis|Patients admitted in the ICU with the clinical suspicion of infection/sepsis.
3474128|NCT03847493||Non-sepsis Patients (control group)|Patients admitted in the ICU with other conditions apart from infection/sepsis.
3474129|NCT03847532|Other|Patients with mutations in the MutYH-gene|Patients with established diagnosis of MutYH-associated polyposis with monoallelic and biallelic mutations in the MutYH-gene
3474130|NCT03847532|Other|Patients with multiple colon polyps|Number of polyps from 4+
3474131|NCT03847532|Other|Control sample|Patients who did not have colon polyps
3474132|NCT03847519|Experimental|Safety Phase Part A|"Enroll subjects with metastatic squamous or non-squamous NSCLC who have become refractory or intolerant to standard therapy. ADXS-503 monotherapy will be evaluated at 2 planned escalating dose levels:~Dose level 1: 1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
3474133|NCT03847519|Experimental|Safety Phase Part B|"Enroll subjects with metastatic squamous or non-squamous NSCLC. ADXS-503 will be evaluated at 2 planned escalating dose levels in combination with a fixed dose of pembrolizumab:~Dose level 1: 1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.~Dose level 2: 5e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
3474134|NCT03847519|Experimental|Efficacy Phase Part C|"Enroll subjects with metastatic squamous or non-squamous NSCLC.~1e8 CFU of ADXS-503 + 200 mg of pembrolizumab, IV, every 3 weeks for up to 2 years or until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met."
3126219|NCT03023722|Experimental|All Subjects|Patients with advanced metastatic pancreatic cancer who have measurable disease
3126220|NCT03023813|Experimental|Intervention|Individualized preventive care recommendations will be distributed to subjects.
3474135|NCT03847545|Experimental|Intervention|The participants who have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as cases and will receive Fampridine throughout the trial.
3474136|NCT03847545|No Intervention|Non-treated controls|Participants who do not have an effect of 20% or more after 14 days of Fampridine treatment, measured using 6 Spot Step Test (SSST) or Timed 25 Footwalk (F25-FW), will continue as untreated controls. They will not receive Fampridine in the remainder of the trial.
3474137|NCT03847623|Experimental|Curcumin|Capsules, taken orally, 8g per day (Bi-daily dosing)
3474138|NCT03847623|Placebo Comparator|Placebo|Capsules, taken orally, bi-daily dosing
3474139|NCT03847558||sexual maturation in patient receiving iron chelation|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
3474140|NCT03847363||general anesthesia|patients underwent general anesthesia
3474141|NCT03847363||general and epidural anesthesia|patients underwent general and epidural anesthesia
3474142|NCT03847363||general anesthesia combined with nerve block|patients underwent general anesthesia combined with nerve block
3474143|NCT03847454|Experimental|Intervention REACH group|The intervention REACH consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity. The participants will receive 30 min training every day during 3 weeks. 3 times a week the standard training will be replaced with the intervention. The training is conducted/ supervised by a physiotherapist.
3474144|NCT03847454|Active Comparator|Control group (Standard of care)|The participants will receive the standard of care as intervention which consists of 30 min training every day during 3 weeks. The training is conducted by a physiotherapist.
3474145|NCT03847298||Pacemaker|
3474146|NCT03847298||Control|
3126221|NCT03023813|No Intervention|Control|Usual care
3126222|NCT03023813|Experimental|Development Phase|Non-randomized receipt of individualized preventive care recommendations
3126223|NCT03023826|Experimental|LY3202626 (R-Fasting)|Single oral dose of LY3202626 (R) capsule under fasting conditions.
3474147|NCT03847207|Experimental|Part 1 Single Ascending Dose|Eight subjects in up to 8 cohorts will be dosed. A single subcutaneous injection of HTL0030310 or placebo will be administered. In each cohort, 6 subjects will receive HTL0030310 and 2 subjects will receive placebo.
3474148|NCT03847207|Experimental|Part 2 Pasireotide PD Assessment|Sixteen subjects in 2 cohorts (8 subjects per cohort) will be dosed on 4 occasions. Within each cohort, 4 subjects will be randomised to active dosing with CRH with desmopressin, GHRH and OGTT challenge and 4 subjects will be randomised to placebo dosing with CRH with desmopressin, GHRH and OGTT challenge.
3474149|NCT03847207|Experimental|Part 3 Proof of Pharmacological Effect|Up to 80 subjects in 4 cohorts (up to 20 subjects per cohort) will be dosed in up to 3 study periods. In each period, subjects will receive active drug or placebo with GHRH, OGTT and CRH with desmopressin (optional).
3126224|NCT03023826|Experimental|LY3202626 (T1-Fasting)|Single oral dose of LY3202626 (T1) tablet under fasting conditions.
3126225|NCT03023826|Experimental|LY3202626 (T1-Fed)|Single oral dose of LY3202626 (T1) following a high fat breakfast.
3474150|NCT03847246|Active Comparator|Baraclude® tablets，1.0 mg|
3474151|NCT03847246|Experimental|Entecavir tablets，1.0 mg|
3474152|NCT03847259||A(public school)|"it will be consists of 200 adolescent female from public schools, their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire.~pain will be evaluated by VISUAL ANALOG SCALE(VAS) .stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21)."
3474153|NCT03847259||B(international school)|it will be consists of 200 adolescent female from international schools their age will be ranged from 13 to 17 years, initiated menstrual cycle and BMI more than 20.mechanical posture changes will be evaluated by Posture screen mobile. back pain and life style will be evaluated by (BackPEI) questionnaire .pain will be evaluated by VISUAL ANALOG SCALE (VAS).stress will be evaluated by Depression Anxiety Stress Scales-21(DASS-21).
3474154|NCT03847467|Experimental|2'-Fucosyllactose|"Phase I: 36 young adult participants aged 18-25 years. Group 1: 1 gm per day n=12 (6UC/6CD) Group 2: 5 gm per day n=12 (6UC/6CD) Group 3: 10 gm per day n=12 (6UC/6CD)~Phase II (post Phase I interim safety analysis): 120 participants aged 11-25 years Group 1: 1 gm per day n=40 (20UC/20CD) Group 2: 5 gm per day n=40 (20UC/20CD) Group 3: 10 gm per day n=40 (20UC/20CD)"
3474155|NCT03847467|Placebo Comparator|Placebo|"Phase I: 20 young adult participants age 18-25 years dosed at 2 gm placebo per day. (10UC/10CD)~Phase II (post Phase I interim safety analysis): 40 participants age 11-25 years dosed at 2 gm placebo per day. (20UC/20CD)"
3474156|NCT03847155|Experimental|Nicotine|The patients randomized into this study arm will receive a medical intervention - nicotine patch for the period of a maximum of 7 days.
3474157|NCT03847155|Placebo Comparator|Placebo|The patients randomized into this study arm will receive a placebo patch for the period of a maximum of 7 days.
3474158|NCT03847272|Experimental|Patients|
3474159|NCT03847480|Experimental|Dose painting|Dose painting
3474160|NCT03847311|Placebo Comparator|Placebos|Subjects will receive sugar pill.
3474161|NCT03847311|Active Comparator|Sulfasalazine|Subjects will receive the active drug.
3474162|NCT03847441|Active Comparator|Group I|
3474163|NCT03847441|Active Comparator|Group II|
3474164|NCT03847441|Active Comparator|Group III|
3474165|NCT03847441|Placebo Comparator|Group IV|
3474166|NCT03847142|Experimental|ASTHMAXcel arm|The ASTHMAXcel arm represents the study intervention, which is a patient-facing mobile application for adult patients with asthma.
3474167|NCT03847142|Active Comparator|Usual care arm|This arm represents usual care delivered in the outpatient primary care setting at the study sites.
3474168|NCT03847129|Experimental|Biofeedback training group|The participants in the biofeedback training group attend a 30 minute biofeedback protocol per session, two times a week for six to eight weeks that is also combined with the regular diabetic care treatment in the Occupational Therapy Room.
3474169|NCT03847129|Active Comparator|Home-based training group|The participants in this group receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment.
3474170|NCT03847129|No Intervention|Control group|The participants in the control group receive only diabetes disease prevention consultation once and outcome assessments twice.
3474171|NCT03847402|Experimental|GDD intervention|The early integrated intervention for GDD
3474172|NCT03847402|Active Comparator|GDD non-intervention|Community intervention for GDD
3474173|NCT03847402|Experimental|ASD intervention|The early integrated intervention for ASD
3474174|NCT03847402|Active Comparator|ASD non-intervention|Community intervention for ASD
3474175|NCT03847402|Experimental|ADHD intervention|The early integrated intervention for ADHD
3474176|NCT03847402|Active Comparator|ADHD non-intervention|Community intervention for ADHD
3474177|NCT03847324|Active Comparator|Usual Care|Group-based preoperative biomedical education, postoperative hospital and home rehabilitation.
3474178|NCT03847324|Experimental|PNE|Usual care + Preoperative Pain Neuroscience Education
3474179|NCT03847324|Experimental|Multimodal Physiotherapy|Usual care + Preoperative Multimodal physiotherapy
3474180|NCT03847077|Experimental|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application
3474181|NCT03847077|Active Comparator|Standard counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
3474182|NCT03847337|Experimental|New to diagnosis|We will test two telemedicine tools with children who have not been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
3474183|NCT03847337|Experimental|Previously diagnosed|We will test two telemedicine tools with children who have been previously diagnosed with autism or developmental delay. The two telemedicine tools are the Screening Tool for Autism in Toddlers (TELE-STAT) and the Autism Spectrum Disorder (ASD-PEDS).
3474184|NCT03847103|Experimental|Robotic-aided rehabilitation with bilateral practice|In addition to a 10-minutes sensorimotor stimulation programs, the experimental group received 40-minutes Robotic-assisted Therapy with Bilateral Practice programs.
3474185|NCT03847103|Active Comparator|Unilateral task-specific training|In addition to a 10-minutes sensorimotor stimulation programs, the control subjects received 40-minute unilateral task-specific training.
3474186|NCT03846986|Active Comparator|Apple Juice1|100% Apple Juice
3474187|NCT03846986|Experimental|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
3474188|NCT03846986|Placebo Comparator|Raw Apple|Raw Apple
3474189|NCT03846817|Experimental|FAIS with intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
3474190|NCT03846817|Experimental|FAIS without intra-articular hip pain|"12-week of semi-standardized, progressive physiotherapist-led treatment supervised by a physiotherapist blinded to clinical and objective findings.~The treatment program will consist of one weekly exercise training session at Hvidovre Hospital supervised by a physiotherapist and twice-weekly unsupervised exercise training sessions performed at home for a consecutive period of 12-weeks (12 supervised sessions; 24 unsupervised sessions).~In conjunction with the physiotherapist-led treatment, participants will be advised to modify potential aggravating physical activitie, and gradually increase their level of activity during the treatment period."
3474191|NCT03847038|Experimental|Intervention|Multimodal lifestyle-interventional. Participants are disclosed their 5-year dementia risk estimate
3474192|NCT03846739|Active Comparator|Oxytocin & Placebo, 6 IU|Intranasal administration, 6 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
3474193|NCT03846739|Active Comparator|Oxytocin & Placebo, 12 IU|Intranasal administration,12 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
3474194|NCT03846739|Active Comparator|Oxytocin & Placebo, 24 IU|Intranasal administration, 24 IU oxytocin nasal spray or placebo. Imaging starting 45 min after nasal spray administration.
3474195|NCT03847012|Experimental|patients with coronary artery diseases|The investigators will recruit 30 subjects with CAD who are referred to phase II cardiopulmonary rehabilitation exercise training. After at least 3 times of familiar with the cardiopulmonary rehabilitation training machine, the subjects performed the treadmill or stationary bicycle and exercise to personalized target heart rate for 10 minutes, take a rest until the heart rate recover to the resting heart rate, and then repeated the exercise in another exercise mode.
3474196|NCT03846661|Active Comparator|Physiomesh|Patients undergoing laparoscopic incisional hernia repair reinforced with a Physiomesh.
3474197|NCT03846661|No Intervention|other mesh|Patients undergoing laparoscopic incisional hernia repair reinforced with other meshes than Physiomesh.
3474198|NCT03846726||observation group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and refused surgery but went on with the watch and wait approach.
3474199|NCT03846726||surgery group|Pathologically confirmed stage II/III rectal adenocarcinoma patients who received neoadjuvant chemoradiotherapy followed by a clinical complete response, and received radical resection.
3474200|NCT03846973|Experimental|Tranexamic acid|group-I will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes followed by an intravenous infusion of 1 g TXA to be given and completed over 8 h in the hospital
3474201|NCT03846973|Placebo Comparator|Placebo|group-II will include 110 patients with initial pre-hospital TXA administered slowly over 10 minutes but will receive placebo (normal saline) infusion to be given and completed over 8 h in the hospital
3474202|NCT03846843|Experimental|OCR-002 - Treatment A|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions
3474203|NCT03846843|Experimental|OCR-002 - Treatment B|A single 5 g oral dose of OCR-002 oral solution administered under fed conditions
3474204|NCT03846843|Experimental|OCR-002 - Treatment C|A single 5 g intravenous dose of OCR-002 solution infused over 1 hour under fasting conditions
3474205|NCT03846843|Experimental|OCR-002 - Treatment D|A single 5 g oral dose of OCR-002 oral solution administered under fasting conditions following discontinuation of lactulose
3474206|NCT03846843|Experimental|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
3474207|NCT03846843|Experimental|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
3126226|NCT03023878|Experimental|Blinatumomab|"Blinatumomab was administered as a continuous intravenous (IV) infusion. Cycle 1 was 12 weeks (84 days) in duration with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, 112 µg/day for 6 weeks, followed by a 4-week treatment free time.~An optional 4-week Cycle 2 of blinatumomab was available for participants whose disease did not progress, with step dosing of 9 µg/day for 7 days, 28 µg/day for 7 days, and 112 µg/day for 14 days.~There was a safety follow-up for 30 days. And a long-term follow-up of up to 8 months for a maximum of 1 year from first dose of blinatumomab or until participant death."
3126227|NCT03023891|Experimental|Prednisone|"Each participant will received a single dose of oral 60 mg of prednisone~Visit 1: Baseline Oral Glucose Tolerance Test (OGTT) and White Blood Count (WBC) count Visit 2: Prednisone 60mg oral at 7am, OGGT and WBC count at 4 to 8 hours post drug"
3126228|NCT03024112|Experimental|Heated humidified high-flow nasal cannula (HHFNC) oxygen|The intervention group received HHFNC O2 at a set flow of 40L/min. FiO2 was titrated by respiratory therapists to maintain SpO2 ≥ 90%. The HHFNC O2 apparatus included: 1) Air-Oxygen blender - capable of delivering 21-100% FiO2 at flow rates up to 60L/min, 2) Heated Humidifier - providing active heating and humidification to the delivered air-O2 blend, 3) Nasal cannula - larger diameter, slightly elongated nasal cannula with single limb connection to humidifier
3126229|NCT03024112|Active Comparator|Standard oxygen Therapy|The standard O2 treatment group received usual nasal cannula or face mask oxygen titrated by nurses as necessary to maintain SpO2 ≥ 90%.
3474208|NCT03846843|Experimental|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
3474209|NCT03846869|Experimental|major cations|bood sample
3474210|NCT03846908|Experimental|MCT|subjects start with MCT fat load
3474211|NCT03846908|Experimental|SFA|subjects start with SFA fat load
3126230|NCT03024606|Active Comparator|texting group|text messages focused on smoking cessation and pregnancy
3126231|NCT03024606|No Intervention|control group|No text messages
3126232|NCT03024970|Experimental|stenfilcon A lens with solution additive (test)|Participants were randomized to wear the stenfilcon A lens with solution additive (test) for 1 month during the cross over study.
3474212|NCT03846908|Experimental|MUFA|subjects start with MUFA fat load
3474213|NCT03846921||Viral infection|Patients with proven viral infections will have laboratory blood test taken
3474214|NCT03846921||Bacterial Infection|Patients with proven bacterial infections will have laboratory blood test taken
3474215|NCT03846700|Experimental|aquablation|patients with prostatic volume included between 30 and 120 ml will be treated with water jet (aquablation). patients with prostatic volume > 65 ml will be compared with holep arm and patients with prostatic volume included between 30 and 65 ml will be compared with pvp arm.
3474216|NCT03846700|Active Comparator|holep|patients with prostatic volume > 65 ml will be treated with holmium laser technique (Holep)
3474217|NCT03846700|Active Comparator|pvp|patients with prostatic volume included between 30 and 65 ml will be treated with photoselective vaporization of prostate (pvp).
3474218|NCT03846960|Experimental|preterm infants|A prospective study to assess the safety and efficacy of surfactant administration via thin catheter using a specially adapted VNscope, originally used for endotracheal intubation and adapted for the administration of surfactant without the placement of an endotracheal tube. A feasibility study of 10 preterm infants 30-36 gestational age at birth, that requires surfactant administration for the indication of respiratory distress syndrome, and do not require immediate intubation
3474219|NCT03846947|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
3126233|NCT03024970|Active Comparator|stenfilcon A lens (control)|Participants were randomized to wear stenfilcon A (control) lens pair for 1 month during the cross over study.
3126234|NCT03025217|Experimental|TLC Program|The TLC Program consists of one in-person visit with a licensed dietician and biweekly phone coaching sessions. During the program, the dietician will 1) identify specific nutrition goals, 2) review and tailor the education materials to the patient's needs, and 3) set up regular telephone coaching sessions of up to two sessions per month for six months for each patient. Motivational interviewing and nutrition/health coaching will be provided.
3474220|NCT03846713|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
3474221|NCT03846713|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
3474222|NCT03846856||Ovarian cancer patients|Biopsy will be taken from ovarian cancer patients and sent to laboratory for analysis
3474223|NCT03846934||Ultrasonography thoracic|Ultrasonography thoracic
3474224|NCT03846895|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following:~Power: 40 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 3~D-pulse mode."
3474225|NCT03846895|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following:~Power: 0.5 watts,~Dwell time:1000μs,~Spacing 1000 μm,~Depth: SmartStak parameter 1,~Smart-pulse mode."
3474226|NCT03846752|Active Comparator|7 Fr. radial access|radial artery access for complex PCI
3474227|NCT03846752|Active Comparator|7 Fr. femoral access|femoral artery access for complex PCI
3474228|NCT03846765|Experimental|Phenylephrine continuous infusion|
3474229|NCT03846765|Experimental|Dobutamine continuous infusion|
3126237|NCT03025945|Experimental|nepafenac 0.3%|nepafenac 0.3% ophthalmic solution dosed once daily
3126238|NCT03025945|Placebo Comparator|Saline Solution|sterile saline drops with a pH approximately of 7.0 and osmolality of 290 mOsm/kg, dosed at once daily
3474230|NCT03846648|Active Comparator|Cypep-1|"CyPep-1 cream 1% (w/w) will be applied once daily on a 5x5 cm healthy skin area on the upper back and on 1 to max 3 common warts on the (dorsal/palmar) side of the hand.~In Part 1 the dosing will be performed once daily for 7 days. The dose of 200 μL CyPep-1 cream will be applied on a 5x5 cm on the back by clinical staff. In addition, up to 3 common warts will be treated with 20 μL of the CyPep1 cream per day.~In Part 2 subjects will administer 20-30 mg CyPep-1 cream once daily at home after instruction by clinical staff. The total treatment period will be 28 days, possibility of a maximum extension of three days is allowed."
3126239|NCT03026075|Experimental|Colonoscopy with MCS|Standard colonoscopy procedure with Motus Cleansing System
3126240|NCT03026088|Experimental|Bisoprolol|
3474231|NCT03846648|Placebo Comparator|Placebo|Placebo cream (the same as that of the drug product CyPep-1 1% (w/w) but without the active substance) will be applied once daily on the same areas as described above.
3126241|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine by intravenous (IV) infusion 6 weeks apart (Day 1 of Cycles 1 and 3), and 2 doses of 360 mg nivolumab IV 3 weeks apart beginning on Cycle 2 (Day 1 of Cycles 2 and 3).~Participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 4 until disease progression."
3179343|NCT00671814|Placebo Comparator|2|Single oral dose of placebo given in cohorts 1-5. Multiple oral doses of placebo given once daily for 21 days in cohorts 6-8 and twice daily for 21 days in cohort 10.
3179344|NCT00671814|Active Comparator|3|Oral doses of 600mg linezolid given twice daily for 21 days.
3474232|NCT03847025||Lead extraction|Patients undergoing clinically indicated lead extraction procedures.
3474233|NCT03846609|Experimental|double balloon platform|Device: double balloon interventional platform (DiLumen)
3474234|NCT03846609|Active Comparator|no double balloon platform|Device: no double balloon interventional platform (DiLumen)
3474235|NCT03846518|Active Comparator|Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
3474236|NCT03846518|Experimental|mini Hyrax group|Seventeen patients will be submitted to rapid maxillary expansion (RME) using the mini Hyrax expander. The activation protocol will be 2 turns a day up to obtain transverse overcorrection.
3474237|NCT03846479|Experimental|Itacitinib|Itacitinib 200 mg administered orally daily
3474238|NCT03846453|Experimental|0.25% HL036 Ophthalmic Solution|HL036 ophthalmic solution
3474239|NCT03846453|Placebo Comparator|Placebo|Placebo vehicle solution
3474240|NCT03846466|Experimental|Part1 Dose 1A|Single administration
3474241|NCT03846466|Placebo Comparator|Part1 Dose 1P|Single administration
3474242|NCT03846466|Experimental|Part1 Dose 2A|Single administration
3474243|NCT03846466|Placebo Comparator|Part1 Dose 2P|Single administration
3474244|NCT03846466|Experimental|Part1 Dose 3A|Single administration
3474245|NCT03846466|Placebo Comparator|Part1 Dose 3P|Single administration
3474246|NCT03846466|Experimental|Part1 Dose 4A|Single administration
3474247|NCT03846466|Placebo Comparator|Part1 Dose 4P|Single administration
3474248|NCT03846466|Experimental|Part1 Dose 5A|Single administration
3474249|NCT03846466|Placebo Comparator|Part1 Dose 5P|Single administration
3474250|NCT03846466|Experimental|Part1 Dose 6A|Single administration
3474251|NCT03846466|Placebo Comparator|Part1 Dose 6P|Single administration
3474252|NCT03846466|Experimental|Part1 Dose 7A|Single administration
3126242|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 1 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 1 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After a 6-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
3474253|NCT03846466|Placebo Comparator|Part1 Dose 7P|Single administration
3474254|NCT03846466|Experimental|Part2 Dose 1A|Multiple administration
3474255|NCT03846466|Placebo Comparator|Part2 Dose 1P|Multiple administration
3474256|NCT03846466|Experimental|Part2 Dose 2A|Multiple administration
3126243|NCT03026166|Experimental|Rovalpituzumab Tesirine and Nivolumab + Ipilimumab 3 mg/kg|"Participants will receive 2 doses of 0.3 mg/kg rovalpituzumab tesirine IV 6 weeks apart (Day 1 of Cycles 1 and 3), nivolumab 1 mg/kg every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5), and ipilimumab 3 mg/kg IV every 3 weeks for 4 cycles beginning on Cycle 2 (Day 1 of Cycles 2-5).~After an 8-week washout, participants will then receive maintenance therapy with 480 mg nivolumab IV once every 4 weeks from Cycle 6 until disease progression."
3126244|NCT03026257|Experimental|AOHG|Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized
3126245|NCT03026257|Active Comparator|Habitual|Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)
3126246|NCT03026283||1: HeartFlow CT-FFR Arm|All patients who consent will receive HeartFlow CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
3474257|NCT03846466|Placebo Comparator|Part2 Dose 2P|Multiple administration
3474258|NCT03846531|Active Comparator|Nano-Pulse Stimulation (NPS) Lesion|Three of four selected SK lesions receive Nano-Pulse Stimulation treatment.
3474259|NCT03846531|No Intervention|Non-Treated Lesion|One of four SK lesions is randomized to not receiving Nano-Pulse Stimulation treatment.
3474260|NCT03846440||Participants|Middle to older aged (>50 years) Mexican adults attending to the Geriatrics Department from the Western General Hospital (Zapopan, Jalisco,Mexico).
3474261|NCT03846362|Experimental|intermediate risk MRD2>0,1%|MRD2>0,1% - FLA - MRD3 - HSCT
3474262|NCT03846271|Experimental|Oxytocin then placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo.
3474263|NCT03846271|Experimental|Placebo then oxytocin|Participants first receive placebo. After a washout period of 2 weeks, they receive oxytocin (24 IU).
3474264|NCT03846596||Evaluated|An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
3474265|NCT03846570|Active Comparator|Formoterol-beclomethasone|Formoterol (fumarate dehydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler.
3474266|NCT03846570|Placebo Comparator|Placebo|Matching placebo (identically package) administered BID
3474267|NCT03846375|Experimental|Participants in DBT|Psychotherapy: The participants will be given standard DBT treatment.
3474268|NCT03846375|Other|Control Group|Control Group at preintervention.
3474269|NCT03846232||Cognitive impairment. Alzheimer's disease|Diagnosed with AD as defined per the International Working Group IWG 2 criteria (fulfilling core clinical criteria plus positive core AD CSF biomarkers)
3474270|NCT03846232||Cognitively unimpaired, preclinical Alzheimer's disease|Normal cognition as defined by the ALFA study cognitive workup Positive amyloid PET in the last 30 months
3474271|NCT03846232||Cognitively unimpaired, control|Normal cognition as defined by the ALFA study cognitive workup Negative amyloid PET in the last 30 months
3474272|NCT03846388|Other|Patients with unexplained infertility|
3474273|NCT03846388|Other|patients with tubal, male factor or polycystic ovary syndrome|
3474274|NCT03846258|Active Comparator|Low bicarbonate arm (22 mmol/L)|PHOXILLUM solutions are used as a replacement solution in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 22 mmol/L.
3474275|NCT03846258|Active Comparator|High Bicarbonate (32 mmol/L)|PrismaSATE is another replacement solution used in Continuous Renal Replacement Therapy. The one to be used in this study has bicarbonate concentration of 32 mmol/L.
3474276|NCT03846557||Treatment|Transcatheter Aortic Valve Implantation (TAVI)
3474277|NCT03846583|Experimental|Dose Escalation|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
3474278|NCT03846583|Experimental|Arm A: Active Brain Metastases|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
3474279|NCT03846583|Experimental|Arm B: Surgical Resection Needed|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
3474280|NCT03846583|Experimental|Arm C: Progressive Extracranial Disease|"Tucatinib is administered orally twice daily~Abemaciclib is administered orally twice daily~Trastuzumab is adminidtered intravenously once every three weeks~Aromatase Inhibitor is administered orally once daily"
3474281|NCT03846245||Young adults group|Cognitively unimpaired 18-25 years old
3474282|NCT03846245||Old adults group|Cognitively unimpaired >= 70 years old
3474283|NCT03846323|Experimental|Visiting policies: open 24h/24|Visiting policies: 24 hours a day, 7 days a week
3474284|NCT03846323|Other|Restriction of visiting policies|Restriction of visiting policies < 6 hours
3474285|NCT03846336|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS and physician-administered EDSS range of 1-3.5.
3474286|NCT03846336|Other|Healthy individuals|20 healthy volunteers with matching ages and genders.
3474287|NCT03846349|Experimental|Study Group|Participants from the study group will follow an upper airway reinforcement regimen using the IOPI device over 6 weeks. The reinforcement protocol will be adapted each week to improve Percentage of initial strength Exercises will be adapted each week
3474288|NCT03846349|Sham Comparator|Control group|"Participants from the control group will perform a sham reeducation protocol using an EMT threshold at minimal resistance. The expiratory pressure will remain unchanged over the weeks."
3474289|NCT03846310|Experimental|Dose Escalation Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer.
3474290|NCT03846310|Experimental|Dose Escalation Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with standard doses of carboplatin/pemetrexed chemotherapy regimen and pembrolizumab in participants with Non-Small Cell Lung Cancer.
3474291|NCT03846310|Experimental|Dose Expansion Arm 1|Zimberelimab will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
3474292|NCT03846310|Experimental|Dose Expansion Arm 2|The etrumadenant at RDE determined from the dose escalation phase will be administered in combination with standard carboplatin and pemetrexed chemotherapy regimen and zimberelimab in participants with Non-Small Cell Lung Cancer harboring a sensitizing EGFR mutation.
3474293|NCT03846180||Terlipressin group|Cirrhotic patients with acute gastrointestinal bleeding received terlipressin with or without somatostatin/octreotide.
3474294|NCT03846180||Somatostatin/Octreotide group|Cirrhotic patients with acute gastrointestinal bleeding received somatostatin and/or octreotide without terlipressin.
3474295|NCT03846414||PEG-rhG-CSF group|This group comprised 1000 patients who received a single subcutaneous injection of PEG-rhG-CSF 24 hours after the end of chemotherapy for each chemotherapy cycle. The dose of PEG-rhG-CSF is determined by the patients' body weight, patients with body weight ≥45 kg is given to PEG-rhG-CSF 6 mg each time, patients<45 kg is given to PEG-rhG-CSF 3 mg each time.
3474296|NCT03846414||rhG-CSF group|This group comprised 500 patients who received rhG-CSF 5 μg/kg/day by subcutaneous injection 24 hours after the end of chemotherapy or the appearance of CIN until the ANC was ≥2.0x109/L for each chemotherapy cycle.
3474297|NCT03846544|No Intervention|control group|
3474298|NCT03846544|Experimental|double pick up group|
3474299|NCT03846284|Placebo Comparator|Bupivacaine (B group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion 50 cm saline with rate 10-20 ml/h according to child weight."
3474300|NCT03846284|Experimental|Magnesium sulfate caudal (MC group)|"caudal block with bupivacaine 0.25% 1mg/kg + Magnesium sulfate 50 mg diluted in 10 cm saline.~+ I.V injection of 10 cm saline over 10 mins then, I.V infusion of 50 cm saline with rate 10-20 ml/h according to child weight."
3474301|NCT03846284|Experimental|Magnesium sulfate I.V (M V group)|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
3474302|NCT03846167||FTT PET/CT|"The imaging procedure may include one or both of the following imaging sessions; 1) a 45- 60 minute dynamic scan, starting at approximately the same time as the injection and/or 2) a skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.~Participants will be asked to complete the following research procedures: [18F]FTT PET/CT scan before surgery or treatment [18F]FTT PET/CT scan after you start treatment (optional)"
3474303|NCT03846206|Experimental|mediterranean diet|Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
3474304|NCT03846206|No Intervention|Usual diet|Patients do usual diet for three months
3474305|NCT03846427|Experimental|Zanubrutinib|
3474306|NCT03846141|Placebo Comparator|Placebo|Room air for inhalation
3474307|NCT03846141|Experimental|Hydrogen|Hydrogen (4%) for inhalation
3474308|NCT03846037|Placebo Comparator|Ground|Participants in this group perform protocol exercises on a stable surface.
3474309|NCT03846037|Experimental|vibrating platform|Participants in this group perform protocol exercises on a vibrating platform.
3474310|NCT03846115|Experimental|Peer-Led Seeking Safety app|This app is designed for Peer-Led Seeking Safety and includes enhanced app features.
3474311|NCT03846115|Active Comparator|Control app|This is a basic app that controls for time and attention. The basic app serves as the intervention in this trial.
3474312|NCT03846011||Experiment group|All eligible patients administered for active stone removal.
3474313|NCT03846102|Experimental|Levobupivacaïne|"Fascia Iliaca Compartment Block with Levobupivacaine Hydrochloride (weight based dosage and volume)~Ideal Body Weight : Levobupivacaïne dose (mg) : Dose/kilogram (mg/kg) : Total volume (ml)~[<64 kg : 100 mg : 2.0 mg/kg : 40 ml]~[65-74 kg : 125 mg : 1.9 mg/kg : 45 ml]~[≥ 75 kg : 150 mg : 2.0 mg/kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
3126247|NCT03026530|Experimental|Pulmonary recruitment maneuver|Ventilator-piloted pulmonary recruitment maneuver at the end of laparoscopic bariatric surgery.
3126248|NCT03026530|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic bariatric surgery.
3474314|NCT03846102|Placebo Comparator|Placebo|"Fascia Iliaca Compartment Block with placebo (Sodium Chloride 0.9%), similar volume to experimental arm.~Ideal Body Weight : Total volume (ml)~[<64 kg : 40 ml]~[65-74 kg : 45 ml]~[≥ 75 kg : 50 ml]~Acetaminophen 1 gram (tablets) 4 times daily.~Patient Controlled Analgesia Pump with morphine 1 milligram per dose."
3474315|NCT03845907|Active Comparator|Imagio Gen 1B|Gen 1B duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System and the Gen1B duplex probe
3474316|NCT03845907|Active Comparator|Imagio Gen 1|Gen 1 duplex probe ultrasound / optoacoustic imaging of the breast and axillary lymph node, with the IMAGIO System
3474317|NCT03846089||Retrograde reperfusion|After completion of the inferior vena cava anastomosis, the clamps were removed to allow retrograde reperfusion of the graft.
3474318|NCT03846089||Antegrade reperfusion|After completion of the inferior vena cava anastomosis, the portal vein anastomosis is completed and then the clamps were removed to allow antegrade reperfusion of the graft.
3474319|NCT03845972|No Intervention|before SSFTB|
3474320|NCT03845972|Experimental|after SSFTB|
3474321|NCT03846024|Experimental|RibFx belt arm|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
3474322|NCT03846024|No Intervention|Control|"Patients in the control arm receive normal standard of care for rib fractures at the participating institution.~The current standard of care for rib fractures at the University of Vermont (participating institution) is as follows: includes oral and IV analgesia and other multimodal pain control as appropriate, including muscle relaxants such as methocarbamol (robaxin) unless there is a contraindication, pulmonary hygiene/toilet and respiratory care (including frequent evaluations by physicians, respiratory therapists, and nursing staff, early mobilization, and monitoring for pulmonary complication (via vital signs, pulse oximetry, oxygen requirement, chest imaging if appropriate)."
3474323|NCT03846154|Experimental|Intervention group|"Children and adolescents in the intervention group received:~A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance is provided~If needed legal assistance is provided"
3474324|NCT03846154|No Intervention|Control group|The control group was invited to participate in three interviews getting small amounts of money (~2,5 €) as decompensation of their time.
3474325|NCT03845959|Experimental|TD0019.6cap|estimated dose, 2 oral capsules/time x 3 times/day
3474326|NCT03845959|Experimental|TD0019.9cap|1.5 times of estimated dose 2 oral capsules/time x 3 times/day
3474327|NCT03845959|Placebo Comparator|Placebo|Placebo 2 placebo oral capsules /time x 3 times/day
3474328|NCT03845868||Egang hospital physical examination center|
3474329|NCT03845868||Ezhou CDC physical examination center|
3474330|NCT03845855|Experimental|Virtual reality with robotic gait|virtual reality treatment with robotic gait therapy 2 times for week by 6 weeks.
3474331|NCT03845855|Active Comparator|Robotic gait therapy only|only robotic gait therapy 2 times for week by 6 weeks
3474332|NCT03845894|Active Comparator|Liposomal Bupivacaine ISB|
3474333|NCT03845894|Active Comparator|Bupivacaine with adjuvants ISB|
3474334|NCT03845998|Experimental|three-finger method|"The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers. That is what we call the three-finger method.~The intervention is to use the three-finger method."
3474335|NCT03845998|Active Comparator|weight-related method|"The size of the laryngeal mask airway for each patient was determined by the manufacturer's weight-related guidelines. That is what we call the weight-related method.~The intervention is to use the weight-related method."
3126249|NCT03026556||Dabigatran vs. Rivaroxaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
3126250|NCT03026556||Dabigatran vs. Apixaban|OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
3179345|NCT00671827||Robotic Gynecologic Surgery|Patients who have undergone or will undergo a robotic-assisted gynecologic procedure.
3179346|NCT00671866||1|Agricultural Workers
3179347|NCT00671866||2|Non - Agricultural Workers
3474336|NCT03845751|Experimental|ADT protocol|ADT protocol is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). Additionally, oral antiandrogen bicalutamide 50 mg once per day is given for 3 months, starting the same day of LHRH agonist injection. ADT protocol starts one month prior to the scheduled HIFU session. The intervention of the study is HIFU hemi-ablation combined with ADT.
3474337|NCT03846050|Experimental|BAC Feedback, immediate onset|"Participants will receive aBAC Feedback/Warning intervention based on their assessed BAC. Participants in this arm will have a warning presented on their smartphone when they provide a breath sample that indicated their BAC has reached a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will start their 6 week AA portion of their participation immediately after their laboratory session, and will be followed for 6 weeks afterwards.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
3126251|NCT03026777|Experimental|Fluid Loading|(1) 500 milliliters of an intravenous crystalloid solution of the operator's choosing will be (2) infused at any time after randomization and prior to the administration of procedural medications from (3) above the level of the central or peripheral intravenous or intraosseus access used and allowed to infuse by gravity and (4) stopped after 500 mL have infused. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
3126252|NCT03026777|No Intervention|Usual Care|No intravenous fluids are started after the decision is made to perform endotracheal intubation. All intravenous infusions preceding the decision to perform endotracheal intubation will not be altered.
3179348|NCT00671866||3|Kibbitz Residents working else where
3474338|NCT03846050|Experimental|BAC Feedback, delayed onset|"Participants will receive the BAC Feedback/Warning intervention based on their assessed BAC during drinking events.The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.~In this condition, participants will be followed for 6 weeks after their laboratory session prior to starting their 6 week AA portion of their participation.~Comparisons between the two experimental conditions will allow for inferences about the onset and offset of any effects of the BAC Feedback/Warning intervention."
3474339|NCT03846050|Placebo Comparator|Minimal Assessment Control|"Participants will receive the No BAC Feedback/Warning intervention. Participants in this condition will complete the laboratory and interview portions of the project. However the AA portion of the project will not contain warning about their BAC (No BAC Feedback/Warning) and will ask fewer questions regarding their AID decisions.~The role of this condition is to provide a baseline comparison of AID behavior for the two active assessment conditions."
3474340|NCT03846063|Experimental|Intervention: Home-based rehabilitation program|"A twelve-week home-based exercise strategy will be offered to patients after their discharge from the hospital. This home-based exercise strategy will be delivered by means of videos on a tablet-pc and consist of specified exercise instructions for improving muscle strength, balance and functional movements.~The intervention group will be compared with existing patientdata who received usual care in the Netherlands"
3474341|NCT03845777||Surgical Staff|The surgical staff group is the only group of the study. Blood samples of the surgical staff before and after the using antiseptics solution that include iodine were analyzed.
3474342|NCT03845881|Active Comparator|Opioid|Multi-Modal Pain Protocol with Opioids Following Total Joint Arthroplasty
3474343|NCT03845881|Placebo Comparator|Non Opioid|Multi-Modal Pain Protocol without Opioids Following Total Joint Arthroplasty
3474344|NCT03845608|Experimental|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity
3474345|NCT03845608|Other|Intraperitoneal Hydrocortisone|Drug Injection: 100mg of Hydrocortisone will be injected In the peritoneum
3474346|NCT03845608|No Intervention|control group|In the controls, carbon dioxide will be removed by the traditional passive deflation of abdominal cavity.
3474347|NCT03845543|Experimental|Luminor-14 paclitaxel eluting balloon|Pre-dilatation of 180 seconds with a standard non-drug-coated semi-compliant balloon followed by a dilatation with a Luminor-14 paclitaxel eluting balloon (3µg/mm² balloon surface).
3474348|NCT03845985|Experimental|Seeking Safety + Signs of Safety toolkit|Participants randomized to receive the intervention will be provided 12 one-hour weekly individual treatment sessions with one of four ASL-fluent study clinicians in Massachusetts. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
3474349|NCT03845985|No Intervention|Assessment-only Waitlist Control|Participants randomized to the waitlist control condition will be offered the opportunity to receive the 12-session Seeking Safety + Signs of Safety toolkit intervention after an approximate 16 week waiting period. This 16 week waiting period is equivalent to the current waitlist to receive psychotherapy services through the PI's outpatient clinic. Assessments will occur at baseline, week 4, week 8, immediate post-treatment/week 12, and one-month follow-up/week 16.
3474350|NCT03845764||Rapid on-site evaluation (ROSE)|Evaluation, made by a pulmonologist, a pathologist and a molecular pathologist, of the tumor burden in ROSE slides produced from endoscopic procedures aimed at sampling intrathoracic lymphadenopathy and pulmonary nodules
3474351|NCT03845621|Active Comparator|CM-OA-OA-CM Sequence|Use of a conventional custom-made mouthguard (CM) while playing water polo for first and fourth weeks and the occlusal-adjusted custom-made mouthguard (OA) for the second and third weeks.
3474352|NCT03845621|Active Comparator|OA-CM-CM-OA Sequence|Use of an occlusal-adjusted custom-made mouthguard (OA) for the first and fourth weeks and a conventional custom-made mouthguard (CM) while playing water polo for the second and third weeks.
3474353|NCT03845673|Experimental|Psyllium|This group of patients was given psyllium for 6 weeks
3474354|NCT03845673|Experimental|Bowel recipe|This group was administered a specialized bowel recipe for 6 weeks
3474355|NCT03845530|Active Comparator|Hemodialysis group|Blood sample taken and sent to laboratory for analysis
3474356|NCT03845530|Active Comparator|Peritoneal dialysis|Blood sample taken and sent to laboratory for analysis
3126253|NCT03026803|Experimental|Oxaliplatin and Capecitabine|21 day cycle with Oxaliplatin 50mg/m2 day 1 and day 8 administered IV, Capecitabine 750 mg/m2 bid p.o. daily from day 1 to day 14
3474357|NCT03845712|Experimental|MT1621, dC/dT|This is an open label study with all participants in a single arm. Patients will take MT1621 up to a maximum of 400 mg/kg/day. MT1621 is deoxycytidine (dC) and deoxythymidine (dT) powders for solution for reconstitution in water. Study drug will be supplied as powder in packets containing 0.5 or 2.0 g or 4.0 g of dC or dT, and is typically dosed three times/day. MT1621 should be administered with food.
3474358|NCT03845595|Experimental|(LF-rTMS) group|Patients in the study group were treated with the contralesional (LF-rTMS) once per day for 20 minutes, Daily, 5 sessions per week (Sunday to Thursday), for 2 consecutive weeks in addition to the conventional upper limb physical therapy interventions.
3126254|NCT03027466|Experimental|Baseline Affirmation and Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study and will receive affirmation text messages throughout the study"
3474359|NCT03845595|Active Comparator|Control group|Patients in the control group were treated with the conventional upper limb physical therapy interventions (40 minutes to 1 hour, daily, 5 times per week for two consecutive weeks )
3474360|NCT03845465|Active Comparator|Education|Participants in the Education group will complete a behavioral health contract and will receive an educational packet.
3474361|NCT03845465|Experimental|PA + Education|Participants in the Positive Affect + Education group will complete a behavioral health contract and receive an educational packet. In addition, they will receive intervention components aimed at inducing positive affect.
3474362|NCT03845920|Other|tDCS sham + placebo|tDCS= transcranial direct current stimulation drugs= placebo (cellulose [2 grams])
3474363|NCT03845920|Experimental|tDCS sham + tyrosine|tDCS= transcranial direct current stimulation drugs= tyrosine (2 grams)
3474364|NCT03845920|Experimental|tDCS anodal + placebo|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= placebo (cellulose [2 grams])
3474365|NCT03845920|Experimental|tDCS anodal +tyrosine|tDCS= anodal transcranial direct current stimulation of the dorsolateral prefrontal cortex drugs= tyrosine (2 grams)
3474366|NCT03845829|Experimental|Patients with TBAD treated with TEVAR|In situ laser assisted fenestration for the left subclavian artery during the TEVAR procedure for TBAD.
3474367|NCT03845569|Other|Habitual Protein phase|A trial investigating protein oxidation/metabolism that was used to model resistance trained individual's habitual dietary protein intake (2.2g/kg/d).
3474368|NCT03845569|Experimental|Moderate Protein Phase|A series of three trials over a one week period investigating protein oxidation/metabolism that was used to investigate the metabolic response of decreased protein intake (1.2g/kg/d) over a period of five days (trials on days 1, 3, 5 following reduction in protein intake from 2.2g/kg/d to 1.2g/kg/d) relative to the Habitual protein phase trial.
3474369|NCT03845647|Experimental|Tumor diameter<=2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0 differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
3474370|NCT03845647|Experimental|Tumor diameter>2cm study group|In order to provides a new theoretical basis for the operation of central lymph node in cN0(Clinically N0) differentiated thyroid cancer,researchers are going to complete this study to evaluate the significance of contralateral central lymph node dissection in unilateral cN0 differentiated thyroid carcinoma.At the same time,it may play a certain impact on the revision of surgical guidelines for differentiated thyroid cancer.
3474371|NCT03845582|Experimental|ALK-001|Capsule
3474372|NCT03845582|Placebo Comparator|Placebo|Capsule
3474373|NCT03845387|Experimental|KDT-3594|
3474374|NCT03845387|Other|Pramipexole|Reference drug
3474375|NCT03845478|Active Comparator|Control Group (CG)|Education, modifying diet and physical activity
3474376|NCT03845478|Experimental|Intervention Group (IG)|Education and modifying diet and physical activity with prescription and goal setting
3474377|NCT03845413|Active Comparator|Intervention|The intervention arm consisted of 12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
3474378|NCT03845413|Active Comparator|Control|The control arm consisted of a home visit by the Community Health Worker scheduling an appointment for the participant to attend the tobacco cessation program at the local Basic Health Unit.
3474379|NCT03845361|Experimental|C. hand|Radial artery cannulation
3474380|NCT03845361|No Intervention|N.C. hand|No cannulation of the radial artery
3474381|NCT03845660|No Intervention|Usual Care|Providers taking care of patients randomized to this arm will have no alert related to the patients prognosis.
3474382|NCT03845660|Experimental|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
3474383|NCT03845686||Subacute Stroke Sample|Participants with first-ever left-brain stroke, < 4 weeks post stroke, age >18 years, right-handed, fluent and literate in English prior to stroke, no prior neurological disorders or clinical stroke event, <4 weeks post-stroke; able to undergo an MRI and complete study tasks, and presence of reading deficits.
3474384|NCT03845686||Chronic Stroke Sample|The same group of participants examined in the chronic post-stroke period (>3 months post-stroke)
3474385|NCT03845335|Experimental|HA-coated hybrid implant|Patient allocated to this group will receive an iMAX® Hyaluronic Acid-coated hybrid dental implant for their dental implant-supported restoration.
3474386|NCT03845335|Active Comparator|Moderately rough implant|Patient allocated in this group will receive an iMAX® non-coated moderately rough dental implant with a machined neck their dental implant-supported restoration.
3474387|NCT03845283|Experimental|Physical Activity|Participants will receive the core 6-month weight loss program and the tailored intervention to promote structured physical activity.
3126255|NCT03027466|Active Comparator|Baseline Affirmation and No Affirmation Texts|"Participants will be given a Baseline Affirmation Quiz at the beginning of the study but will not receive affirmation text messages throughout the study"
3126256|NCT03027466|Active Comparator|No Baseline Affirmation and Affirmation Texts|"Participants will not be given a Baseline Affirmation Quiz but will receive affirmation text messages throughout the study"
3126257|NCT03027466|Placebo Comparator|No Baseline Affirmation and No Affirmation Texts|Participants will experience the Smoke Free United Kingdom (UK) app without any affirmation content Smoke Free UK app (no baseline affirmation quiz and no affirmation text messages)
3126258|NCT03027557|Experimental|Combined treatment.|20 subjects will be treated with combined 60mg denosumab bi-annually , 30 mg cinacalcet daily and 50 micrograms vitamin-D daily.
3474388|NCT03845283|Experimental|Core Program|Participants will receive the core 6-month weight loss program alone. This program includes weekly lessons for the first 12 weeks and monthly lessons for the remaining 12 weeks. Participants will track their intake, physical activity, and weight, input these data into the system, and received tailored feedback.
3474389|NCT03845283|Experimental|Physical Activity & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the virtual meetings to support weight loss.
3474390|NCT03845283|Experimental|Virtual Meetings|Participants will receive the core 6-month weight loss program and the virtual meetings to support weight loss.
3474391|NCT03845283|Experimental|Physical Activity & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and access to the virtual reality platform for behavioral weight loss skills training.
3474392|NCT03845283|Experimental|Virtual Reality|Participants will receive the core 6-month weight loss program and access to the virtual reality platform for behavioral weight loss skills training.
3126259|NCT03027557|Active Comparator|Monotherapy|20 subjects will receive 60mg denosumab bi-annually, placebo and 50 micrograms vitamin-D daily.
3126260|NCT03027557|Placebo Comparator|Placebo|20 subjects will receive a saline injection bi-annually (blinded), placebo-tablets and 50 micrograms vitamin-D daily.
3126261|NCT03027661|Placebo Comparator|Control Group|Injection of 10 mL of 0.9% sodium chloride into the cervical stroma divided between 3 and 9 o'clock
3126262|NCT03027661|Active Comparator|Study Group|Injection of 10 mL of 0.5% bupivacaine into the cervical stroma divided between 3 and 9 o'clock.
3126263|NCT03028012|Experimental|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI.
3126264|NCT03028012|Experimental|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI.
3474393|NCT03845283|Experimental|Physical Activity, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the virtual meetings to support weight loss, and access to the virtual reality platform for behavioral weight loss skills training.
3474394|NCT03845283|Experimental|Virtual Reality & Virtual Meetings|Participants will receive the core 6-month weight loss program, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
3474395|NCT03845283|Experimental|Physical Activity & Bite Counter|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, and the Bite Counter device to reduce dietary intake.
3474396|NCT03845283|Experimental|Bite Counter|Participants will receive the core 6-month weight loss program and the Bite Counter device to reduce dietary intake.
3474397|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
3474398|NCT03845283|Experimental|Bite Counter & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and the virtual meetings to support weight loss.
3474399|NCT03845283|Experimental|Physical Activity, Bite Counter, & Virtual Reality|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
3474400|NCT03845283|Experimental|Bite Counter & Virtual Reality|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, and access to the virtual reality platform for behavioral weight loss skills training.
3474401|NCT03845283|Experimental|Physical Activity, Bite Counter, Virtual Reality & Meetings|Participants will receive the core 6-month weight loss program, the tailored intervention to promote structured physical activity, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
3474402|NCT03845283|Experimental|Bite Counter, Virtual Reality, & Virtual Meetings|Participants will receive the core 6-month weight loss program, the Bite Counter device to reduce dietary intake, access to the virtual reality platform for behavioral weight loss skills training, and the virtual meetings to support weight loss.
3474403|NCT03845348|Experimental|TD3|TD3, bi-daily x 4 weeks
3474404|NCT03845348|Experimental|TD7|TD7, bi-daily x 4 weeks
3474405|NCT03845348|Active Comparator|Ketoconazole 2%|Ketoconazole 2% shampoo bi-daily x 4 weeks
3474406|NCT03845322|Experimental|Curcumin pills group|24 Patient will receive Curcumin (CC) pills, within 24 hours post-operatively (as long as they are able to take oral medication). It will then be continued TID
3126265|NCT03028012|Experimental|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI.
3132685|NCT03445065|Experimental|Cohort 2, Enabled - Eversense XL CGM System|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Enabled group were trained and allowed to use the Eversense XL system for continuous glucose monitoring (CGM). They were not allowed to use another CGM or FGM system.
3474407|NCT03845322|Placebo Comparator|Placebo group|24 Patient will receive Placebo pills, within 24 hours post-operatively (as long as they are able to take oral medication. It will then be continued TID.
3474408|NCT03845309|Experimental|Nutritional intervention for CHF|
3474409|NCT03845192|Other|ORI measurement by Radical-97|"In this arm ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®"
3474410|NCT03845205|Experimental|Integrated AUD Treatment (IAT)|IAT will include computer-delivered CBI in the hospital, nurse-delivered clinical monitoring and treatment adherence counseling, and at-home participation in web-based, 7-session computerized cognitive-behavioral therapy (CBT4CBT), supplemented by tailored text messages. Alcohol pharmacotherapy will be added to behavioral treatments as needed.
3474411|NCT03845205|No Intervention|Treatment As Usual|All LT patients receive physician instructions to not drink alcohol. Consistent with current discharge procedures, AH patients are encouraged to engage in alcohol treatment services. Patients receive regular blood draws for monitoring of liver function, and regular phone calls for post-operative monitoring.
3474412|NCT03845231|Other|unvaccinated|will receive no Flucelvax vaccination and will receive human challenge virus
3474413|NCT03845231|Experimental|Vaccinated|will receive Flucelvax vaccination and human challenge virus
3474414|NCT03845270|Experimental|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
3474415|NCT03845244|Active Comparator|Flow reduction first group|Flow reduction first -> FiO2 reduction -> conventional oxygen therapy
3474416|NCT03845244|Active Comparator|FiO2 reduction first group|FiO2 reduction first -> flow reduction -> conventional oxygen therapy
3474417|NCT03845244|Active Comparator|Simultaneous reduction group|Simultaneous (Flow and FiO2) reduction -> conventional oxygen therapy
3474418|NCT03845296|Experimental|Treatment (rucaparib)|Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3474419|NCT03845257||Patients with COPD|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
3474420|NCT03845257||Patients with asthma|"The following parameters are to be evaluated:~Blood eosinophils~FeNO~Eosinophils in bronchoalveolar lavage~Tissue eosinophilia (protected specimen brush sampling, endobronchial biopsy)"
3474421|NCT03845179|Placebo Comparator|Placebo|Placebo tablet for placebo treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
3474422|NCT03845179|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor treatment for active treatment period. Following treatment: 2 separate interventions/study days (placebo infusion and GIP receptor antagonist)
3474423|NCT03845036|Experimental|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
3474424|NCT03845036|Active Comparator|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
3474425|NCT03845153|Active Comparator|Metformin|20 post-menopausal women with a bone fracture treated with metformin Retard 850 mg once daily for two weeks then 850 mg twice daily for three months.
3474426|NCT03845153|Placebo Comparator|Placebo|20 post-menopausal women with a bone fracture treated with placebo once daily for two weeks then twice daily for three months.
3474427|NCT03845010|Active Comparator|Sotalol|
3474428|NCT03845010|Active Comparator|Flecainide and verapamil|
3474429|NCT03845010|Active Comparator|Catheter ablation|
3474430|NCT03844958|Experimental|Red Furu|Volunteer was randomized into group red furu
3474431|NCT03844958|Experimental|Fresh Tofu|Volunteer was randomized into group tofu
3474432|NCT03845049|Experimental|group aflibercept|
3474433|NCT03845049|Placebo Comparator|control group|
3474434|NCT03845166|Experimental|XL092 Single-Agent Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 3-6 subjects in a standard 3 plus 3 design."
3474435|NCT03845166|Experimental|XL092 Single-Agent Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).
3474436|NCT03845166|Experimental|XL092 + Atezolizumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
3474437|NCT03845166|Experimental|XL092 + Atezolizumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).
3474438|NCT03845166|Experimental|XL092 + Avelumab Dose-Escalation Cohorts|"Subjects will accrue in cohorts of 2-6 subjects in a rolling 6 design."
3126266|NCT03028025|Active Comparator|TR Band Only|TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
3179349|NCT00671892|Experimental|Challenge|"Experimental Challenge Challenge 1 saline 5000EU 10,000EU 20,000EU~Challenge 2 Saline 40,000EU 80,000EU"
3474439|NCT03845166|Experimental|XL092 + Avelumab Expansion Cohorts|The MTD or recommended dose from the dose-escalation stage may be further explored in advanced urothelial carcinoma (UC).
3474440|NCT03845075|Experimental|active arm|The active medication arm will be given co-administration of 0.5 mg tesofensine/50 mg metoprolol daily for 24 weeks.
3474441|NCT03845075|Placebo Comparator|placebo arm|The placebo arm will receive matching placebo tablets.
3474442|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 40%|
3474443|NCT03845114|Active Comparator|Continuous exercise - Basal insulin reduced by 80%|
3474444|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 40%|
3126267|NCT03028025|Experimental|Statseal with TR Band|StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
3126268|NCT03028103|Experimental|Part A and B|"Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.~Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19."
3126269|NCT03028129|Experimental|Treatment|Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
3474445|NCT03845114|Active Comparator|Interval exercise - Basal insulin reduced by 80%|
3474446|NCT03844997|Experimental|Palbociclib + CPX-351|"Palbociclib will be administered orally on day -1 and -2 at 125 mg PO during the phase IIaportion (dose level 0).Day 0 will be rest and then CPX-351 at 100 u/m2 will be started on days 1, 3, and 5 along with Palbociclib day 2, 4, and 6 followed by rest/monitoring period (day 7-28).~If Grade 3-4 non-hematologic toxicity is observed in 1 or less of 6 patients treated, the study will move to Phase IIb. If Grade 3-4 non-hematologic toxicity is observed in 2 or more of 6 patients treated, 6 additional patients will be treated on the Phase IIa portion at a lower dose level (100 mg po) until a Phase IIb safe dose schedule is defined at which 1 or less out of 6 patients on the Phase IIa experience Grade 3-4 non-hematologic toxicity. After the Phase IIa portion ensures safety, the study will proceed with phase IIb. The phase IIb component is a Simon 2-stage design trial whose objective is to assess the clinical efficacy of the combination of Palbociclib and CPX-351."
3474447|NCT03844841|Active Comparator|Propofol|Active agent: Propofolum (2,6-Diisopropylphenol). Route of administration: intravenous
3474448|NCT03844841|Active Comparator|Dexmedetomidine|Active agent: Dexmedetomidinum ut Dexmedetomidini hydrochloridum. Route of administration: intravenous
3474449|NCT03844984|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
3474450|NCT03844984|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
3474451|NCT03844932|Experimental|ST-0529 18.75 mg*|"ST-0529: 18.75 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
3474452|NCT03844932|Experimental|ST-0529 37.5 mg*|"ST-0529: 37.5 mg orally twice daily (BID)~*Jan 2021 update: following the IDMC recommendation, this arm has been dropped"
3474453|NCT03844932|Experimental|ST-0529 75 mg|ST-0529: 75 mg orally twice daily (BID)
3474454|NCT03844932|Placebo Comparator|Matching Placebo|Placebo: matching placebo orally twice daily (BID)
3179350|NCT00671905|Active Comparator|1|Circumferential PV isolation
3474455|NCT03845088||Children TMJA or condyle absence with Jaw Deformity|inclusion criteria: <12 years old; Unilateral temporomandibular joint ankylosis or condyle absence； Temporomandibular joint reconstructed with costochondral graft；
3474456|NCT03845023|Placebo Comparator|Placebo|Placebo
3474457|NCT03845023|Active Comparator|Dose 1|AD036 Dose 1
3474458|NCT03845023|Active Comparator|Dose 2|AD036 Dose 2
3474459|NCT03845023|Active Comparator|Dose 3|AD036 Dose 3
3474460|NCT03845127|Experimental|Revivent TC Ventricular Enhancement System plus GDMT|Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
3474461|NCT03845127|Active Comparator|GDMT Only|Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.
3474462|NCT03844867|Experimental|Filippo Cea and Carmel|Subjects <65 years.
3474463|NCT03844854|No Intervention|Control Group|Without intervention.
3474464|NCT03844854|Experimental|Research Group|With providing stabilization occlusal splint and manual therapy.
3474465|NCT03844906|Experimental|SAGE-718|
3474466|NCT03844906|Placebo Comparator|Placebo|
3474467|NCT03844880|Experimental|Emotional Awareness and Expression Therapy|Seeks to reduce physical (e.g., pain) and emotional (e.g., depression, anxiety) symptoms by helping individuals become aware of their emotions, express them, and resolve emotional conflicts. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
3474468|NCT03844880|Active Comparator|Cognitive Behavior Therapy|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
3474469|NCT03844971|Experimental|Computer assisted surgery|Intervention will be fabrication of patient specific surgical guide for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction using patient computed tomography with the aid of computer aided surgical simulation software
3474470|NCT03844828|Experimental|POD FT IOL Implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT and POD F.
3474471|NCT03844815|Experimental|Treatment|"Cycle 1 of Treatment will be Decitabine days 1-10 plus Venetoclax ramp up on days 1-3 followed by Venetoclax target dose on days 4-21~Cycle 2 of Treatment will be Decitabine days 1-10 plus Venetcolax target dose days 1-21~During maintenance Decitabine on days 1-5 plus Venetoclax days 1-21"
3474472|NCT03844646|Experimental|CGM plus dietitian|Intermittent use of a continuous glucose monitor (CGM) plus dietitian support
3474473|NCT03844646|Other|Dietitian only|Dietitian support only
3474474|NCT03844555|Experimental|End Stage Renal Disease|Single oral dose of elafibranor 120mg
3474475|NCT03844555|Experimental|Healthy|Single oral dose of elafibranor 120mg
3474476|NCT03844581|Active Comparator|interferential current|interferential current with a constant frequency of 100Hz for pain relief, then using rhythmic frequency of 1-100 Hz that help to disperse infiltration and adhesions for 8 successive weeks
3474477|NCT03844581|Active Comparator|anticholinergics|anticholinergics (propiverine hydrochloride 20 mg/once per day in the morning) for 8 successive weeks
3474478|NCT03844503|Placebo Comparator|Cereal Bar no fiber|Cereal bar without fiber
3474479|NCT03844503|Active Comparator|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
3474480|NCT03844503|Active Comparator|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
3474481|NCT03844438|Experimental|LPM3480226|LPM3480226 tablet will be orally administered，bid，28 days are considered as 1 cycle. The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg,200 mg,400 mg,600mg.
3474482|NCT03844607|Experimental|Active tDCS|Participants will receive 5 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
3474483|NCT03844607|Sham Comparator|Sham tDCS|Participants will receive 5 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
3474484|NCT03844568|Experimental|nasal CPAP group|Applying nocturnal nasal continuous positive airway pressure in additional to usual pneumonia treatment
3474485|NCT03844568|No Intervention|Control group|Usual pneumonia treatment
3474486|NCT03844633|Experimental|Intervention arm|Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth
3474487|NCT03844633|Placebo Comparator|Placebo arm|0.9% sodium chloride injection provided within 48 hours of childbirth
3474488|NCT03844633|No Intervention|Open arm|No intervention provided
3474489|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivery)
3474490|NCT03844490|Experimental|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontaneous pulsation stops.~At this time, cord clamping will be made."
3474491|NCT03844451|Experimental|Liposomal bupivicaine with nerve block|The treatment group will receive an intraoperative V2 trigeminal nerve block using liposomal bupivacaine in addition to a standard bupivacaine nerve block.
3474492|NCT03844451|Placebo Comparator|Nerve block only|The control group will undergo conventional perioperative management without an ERAS protocol and standard bupivacaine intraoperative nerve block.
3474493|NCT03844542|Experimental|Therapeutic plasma exchange|Perform therapeutic plasma exchange in addition to standard care for patients with sepsis induced multi-organ failure
3474494|NCT03844542|No Intervention|Standard care alone for sepsis|Standard care for patients with sepsis induced multi-organ failure
3474495|NCT03844789|Experimental|Closed Loop Control (CLC)|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology & Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
3474496|NCT03844789|Active Comparator|Control Group|Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.
3474497|NCT03844776|Active Comparator|Co-Amoxiclav postoperatively alone|• Treatment 1: 0.9% normal saline irrigation immediately after the surgery with course of Co-Amoxiclav 625 mg 0.2% chlorhexidine mouthwash following the surgery for 5 days (control group)
3474498|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with Metronidazole postoperatively|• Treatment 2: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of Metronidazole 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
3474499|NCT03844776|Active Comparator|Co-Amoxiclav preoperatively with amoxicillin postoperatively|• Treatment 3: 625 mg Co-Amoxiclav and 1g Paracetamol preoperatively and 0.2% chlorhexidine mouthwash immediately before the surgery with course of amoxicillin 500 mg and 0.2% chlorhexidine mouthwash following the surgery for 5 days
3474500|NCT03844477|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB with local anesthetic is given preoperatively
3474501|NCT03844477|Placebo Comparator|Placebo control|Single-injection of QLB with NS is given preoperatively
3474502|NCT03844620|Experimental|Arm I (ctDNA testing, regorafenib, TAS-102)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle. Patients in this arm will get ctDNA testing and will continue treatment beyond 1st cycle depending on ctDNA results. Beyond that patients will continue treatment in the absence of disease progression or unacceptable toxicity.
3474503|NCT03844620|Active Comparator|Arm II (SOC)|Patients will receive either regorafenib by mouth on days 1-21 every 28 day cycle or TAS-102 by mouth twice daily on days 1-5 and 8-12 every 28 day cycle as per standard of care. Patients in this arm will continue treatment in the absence of disease progression or unacceptable toxicity.
3474504|NCT03844529|Experimental|Sunmax FULLSGEN with Lidocaine|A subject would only receive single injection treatment(day 1) using Sunmax FULLSGEN , and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
3474505|NCT03844529|Active Comparator|Sumax FACIALGAIN collagen Implant with Lidocaine|A subject would only receive single injection treatment(day 1) using Sumax FACIALGAIN collagen Implant with Lidocaine, and there would be 6 follow-up visits at 4th, 12th, 24th, 36th and 52nd week after injection treatment.
3474506|NCT03844724|Experimental|Group A|subjects using the drug-eluting PTA balloon dilatation catheter
3474507|NCT03844724|Active Comparator|Group B|subjects using the peripheral balloon dilatation catheter
3474508|NCT03844737|Experimental|VisuXL® Treatment|
3474509|NCT03844698||Patients with Sarcoidosis and Cancer|These group of patients have a diagnosis of Sarcoidosis and Cancer on the Pathological Report.
3474510|NCT03844594|Experimental|Eptifibatide Drug: Eptifibatide Injection|
3474511|NCT03844685|Experimental|Treatment group|1 tablet /day of MCE-11 (Promensil) taken orally for 24 months
3474512|NCT03844685|Placebo Comparator|Placebo group|Placebo tablet (without active principle) given once a day for 24 months
3474513|NCT03844711|Experimental|Transcutaneous electrical diaphragmatic stimulation (TEDS)|For transcutaneous electrical diaphragmatic stimulation, surface electrodes will be used that will be positioned at the transcutaneous motor points of the diaphragm.
3474514|NCT03844711|Experimental|Inspiratory Muscle training (IMT)|The training will start with a minimum load of 50% and will be progressed until reaching 60% of the PImax.
3474515|NCT03844711|Active Comparator|Conventional physiotherapy|The protocol of physiotherapy by the physiotherapists of HCPA will be twice a day and consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
3474516|NCT03844763|Experimental|Phase I - II trial of CTX, RT, Avelumab|CTX: 50 mg Daily untill PD or major toxicity; Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity; RT: 8 Gy single shot day 8.
3474517|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with pacing
3474518|NCT03844516|Sham Comparator|Peak oxygen uptake test without pacing|Peak VO2 test without pacing
3474519|NCT03844425|Active Comparator|Conventional Vacuum-Formed Retainers|Vacuum-formed retainers constructed on conventional stone models.
3474520|NCT03844425|Experimental|Vacuum-Formed Retainers From SLA|Vacuum-formed retainers constructed on 3D reconstructed models using stereolitography (SLA) technique.
3474521|NCT03844425|Experimental|Vacuum-Formed Retainers From FDM|Vacuum-formed retainers constructed on 3D reconstructed models using fused deposition modeling technique (FDM).
3126270|NCT03028129|Placebo Comparator|Control|Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).
3126271|NCT03028142|Experimental|Lower Dose Nebulised Treatment|1.5 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
3126272|NCT03028142|Experimental|Higher Dose Nebulised Treatment|6 mg nebulised RPL554 twice daily plus 10 mcg tiotropium DPI once daily for 3 days
3126273|NCT03028142|Placebo Comparator|Placebo|Nebulised RPL554 matched placebo twice daily plus 10 mcg tiotropium DPI once daily for 3 days
3474522|NCT03844126|Experimental|Patients attending the classes|The patients attending the transition classes will receive a survey to assess transition preparedness before and after attending the class.
3474523|NCT03844100|Experimental|Patients with Refractory Functional Dyspepsia|"Patients with FD diagnosed by the Rome IV criteria, patients with Refractory Functional Dyspepsia~Person who have had early satiation and bothersome postprandial fullness for minimum 3 days a week and epigastric pain and epigastric soreness for minimum 1 day a week~Person with above symptoms that started at least 6 months before and continused for minimum 3 months~Person having no possible causes of above symptoms including organic disease, structural modification, systemic disease, and endocrinology-metabolic disease~Person who do not respond to at least 2 general treatments for FD~Dyspepsia symptoms that can disrupt daily life (global overall symptom scale score =>5)"
3474524|NCT03844295|Experimental|Activated Inspire® Upper Airway Stimulation System|INSPIRE® device will be active a month
3474525|NCT03844295|Placebo Comparator|Inactivated Inspire® Upper Airway Stimulation System|"After a period 15 days of wash-out the INSPIRE® device will be inactivated for a second period of one month."
3474526|NCT03844230|Other|Inhibition Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Inhibition, Experimental I- Inhibition, Experimental II- Inhibition). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
3474527|NCT03844230|Other|Stimulation Group|Randomly selected habitual and non habitual LCS consumers will be assessed on three different oral glucose tolerance test conditions (i.e. Control - Stimulation, Experimental I- Stimulation, Experimental II -Stimulation). A separate visit will evaluate their sweet taste perception and preferences (Sensory evaluation).
3474528|NCT03844204|Experimental|Servo-controlled system|The temperature probe of the servo-controlled system will be positioned on the patient's abdomen with an adhesive tape. The body temperature will be set at 37°C.
3474529|NCT03844204|Active Comparator|No servo-controlled system|The temperature of the infant warmer will be manually set at maximum of power output.
3474530|NCT03844191|Experimental|Part 1 Cohort 1|Cohort 1: 0.05 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
3474531|NCT03844191|Experimental|Part 1 Cohort 2|Cohort 2: 0.075 mg/kg RUC-4/placebo 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
3474532|NCT03844191|Experimental|Part 2 Cohort 1|Cohort 1: initial dose to be selected by the Safety Review Committee (SRC) after completion of Part 1 (the same initial dose used in Part 1 or one of the previously studied higher doses that is lower than the overall RUC-4 BED) 7 subjects will be enrolled: 6 subjects will receive a single subcutaneous dose of RUC-4 and 1 subject will receive matched placebo.
3474533|NCT03844191|Experimental|Part 2 Cohorts 2-3|7 subjects (6 receiving RUC-4, 1 receiving placebo) will be enrolled in each dose cohort, with a safety evaluation performed after 2 subjects in a dose cohort receive RUC 4 and at the completion of dosing for all subjects in the dose cohort. Dose escalation to be determined by the SRC charter and will continue until identification of the overall RUC-4 BED or MTD
3474534|NCT03844191|Experimental|Part 2 Dose Expansion Cohort 1|"14 subjects will receive a selected dose of RUC-4 based on SRC review of dose escalation data.~In the expansion cohort, 7 subjects weighing 55 to 65 kg and 7 subjects weighing 100 to 120 kg will be enrolled; 12 subjects will receive a single subcutaneous dose of RUC-4 and 2 will receive matched placebo"
3474535|NCT03844152|Experimental|Fermented whey concentrate|Volunteers will receive the premixed water and fermented whey in weekly deliveries in 1.5L bottles and a drinking glass with a clear indication of the required 200ml volume. Participants will be asked to drink 200 ml of the supplemented water twice daily for the active intervention period.
3474536|NCT03844139||Feeding pump group(continous)|Using the feeding pump to give patients prescribed enteral nutrient solution through nasogastric tube in 24 hours
3474537|NCT03844139||Glycerin syringe group(intermittent)|Using the glycerin syringe to give patients prescribed enteral nutrient solution through nasogastric tube in 4-5 times
3474538|NCT03844113|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
3126274|NCT03028220|Active Comparator|Real time continuous glucose monitoring|Use of Dexcom G5 continuous glucose monitoring
3126275|NCT03028220|Active Comparator|Flash glucose monitoring|Use of Abbott FreeStyle Libre flash glucose monitoring
3474539|NCT03844113|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo for 6 months
3474540|NCT03844282||CArBON (baseline)|The RESCUE-RACER programme is formed of two studies; baseline (CArBON) and one post-injury (CARS). At baseline the larger CArBON study involves completion of a thorough single baseline neuroscientific assessment of healthy motorsport competitors including clinical, neuropsychological, neurocognitive, biomarker and vestibulo-ocular assessments, in addition to MRI of the brain.
3126276|NCT03028324|Experimental|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
3126277|NCT03028363|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
3126278|NCT03028363|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
3126279|NCT03028415|Experimental|AMPLEX|
3126280|NCT03028415|Active Comparator|Autogenous Bone Graft (ABG)|
3126281|NCT03028467|Experimental|GSK3196165 Dose 1|Participants will receive GSK3196165 Dose 1 weekly as a single subcutaneous (SC) injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then every other week (EOW) injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
3179351|NCT00671905|Active Comparator|2|HF stimulation-guided and anatomic ablation of the main right and left atrial GP.
3474541|NCT03844282||CARS (exposure to a potentially concussive event)|The RESCUE-RACER programme has a single post-injury study; after involvement in a potentially concussive event sustained during motorsport, CARS serially repeats the CArBON assessment battery in the immediate post-concussion recovery period. CARS participants will under-go post-exposure neuroscientific assessments immediately after injury and then at one, two and three weeks post-injury. If symptoms persist beyond this time, a further two assessments at monthly intervals will be offered.
3474542|NCT03844269|Experimental|AKL-T01|
3474543|NCT03844308|Experimental|Group 1|Participants will be asked to complete Isha Kriya meditation twice daily for a total of six weeks in phase 1.
3474544|NCT03844308|Active Comparator|Group 2|Participants will be asked to refrain from meditating for the first 6 weeks (phase 1) and then asked to complete Isha Kriya meditation for another 6 weeks (phase 2)
3474545|NCT03844256|Experimental|Regimen A|"Nivolumab monotherapy at 480mg fixed dose administered intravenously (IV) over 60 minutes every 4 weeks for 3 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
3474546|NCT03844256|Experimental|Regimen B|"Nivolumab at 3 mg/kg administered IV over 60 minutes combined with ipilimumab at 1 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
3474547|NCT03844256|Experimental|Regimen C|"Nivolumab at 1 mg/kg administered IV over 60 minutes combined with ipilimumab at 3 mg/kg administered IV over 90 minutes every 3 weeks for 4 doses.~All study participants can opt for an additional 10 administrations of nivolumab 480mg fixed dose at intervals of 4 weeks, from week 13 to week 52."
3474548|NCT03844061|Experimental|MMF + Rituximab + Belimumab|Two infusions of 1000 mg of Rituximab, two weeks apart, weekly subcutaneous injections of 200 mg of Belimumab, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
3474549|NCT03844061|Placebo Comparator|MMF + Placebo + Placebo|Two placebo infusions of normal saline, two weeks apart, weekly saline placebo subcutaneous injections, and background MMF, 1000 -1500 mg twice daily for 48 weeks.
3474550|NCT03844217|Experimental|Macimorelin 0.5mg/kg body weight|"Visit 1: oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin.~Visit 2: After a washout-phase of 1 week, participants will undergo the oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight. Study procedures are equal compared to visit 1.~Macimorelin 0.75mg/kg body weight"
3474551|NCT03844360|Experimental|Antineoplastic Drugs and Anti-infective Drugs|Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
3474552|NCT03844373|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.
3126282|NCT03028467|Experimental|GSK3196165 Dose 2|Participants will receive GSK3196165 Dose 2 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
3126283|NCT03028467|Experimental|GSK3196165 Dose 3|Participants will receive GSK3196165 Dose 3 weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
3126284|NCT03028467|Placebo Comparator|Placebo|Participants will receive placebo weekly as a single SC injection by an un-blinded administrator. There will be 5 weekly injections (Days 1, 8, 15, 22 and 29), then EOW injections at Days 43, 57 and 71 (Weeks 6, 8 and 10 respectively). Participants will also receive a stable dose of methotrexate during the Treatment Period.
3126285|NCT03028870|Experimental|V120083 30 mg|V120083 30-mg capsules taken orally twice daily
3126286|NCT03028870|Experimental|V120083 60 mg|V120083 60-mg (2 x 30 mg) capsules taken orally twice daily
3126287|NCT03028870|Active Comparator|Naproxen|Naproxen 500-mg capsules taken orally twice daily
3126288|NCT03028870|Placebo Comparator|Placebo|Capsules to match V120083 and/or naproxen taken orally twice daily
3474553|NCT03844399||Patients|Cancer patients who are scheduled to undergo an ablation or biopsy of a liver or kidney tumour
3474554|NCT03844035|Experimental|Oral irrigator group|Fifteen patients using toothbrush and oral irrigator(oxytet oral irrigatör).All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual).PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites.Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
3474555|NCT03844035|Experimental|Interdental brush group|Fifteen patients using toothbrush and interdental brush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
3474556|NCT03844035|Active Comparator|Control group|Fifteen patients using only toothbrush.All patients were told to use Modified Bass method of tooth brushing technique. PI, GI, PPD and CAL values were measured with William's probe (Hu-Fried, Chicago, IL, A.B.D) around the teeth and with plastic probe around the implants. All clinical parameters were evaluated on each of the six regions of the implant (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual). PICF was collected one day after the clinical examination from buccal aspects of the mesial and distal surfaces at the interproximal sites. Following the initial clinical records, all patients were performed full mouth instrumentation and described oral hygiene procedure according to their groups.
3474557|NCT03844074|Experimental|bevacizumab|ONS-5010
3474558|NCT03844074|Active Comparator|ranibizumab|
3474559|NCT03844009|Experimental|Debriefing|Participant's of the debriefing group had a computer integrated debriefing at the end of each scenario of the computer-based simulator
3126289|NCT03028896|No Intervention|standard|In the neck flexed and the head extended position, hold mask like a pen with the index finger placed anteriorly at the junction of the cuff and tube, push the mask backwards maintaining pressure against the palate until resistance is felt.
3474560|NCT03844009|No Intervention|No debriefing|Participant's of the debriefing group had no computer integrated debriefing at the end of each scenario of the computer-based simulator
3474561|NCT03843983|Other|Lipiflow treatment|Lipiflow® application: Treated with Lipiflow. All patients in this study are treated with Lipiflow once.
3474562|NCT03844022||McArdle disease|Glycogen storage disease
3474563|NCT03844022||Healty controls|Age and gender matched
3474564|NCT03844243|Experimental|NGF condition + Control condition|"All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
3474565|NCT03844243|Experimental|Control condition + NGF condition|"All participants will receive 3 single injection of isotonic-saline (9%/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle.~After 4 weeks:~All participants will receive 3 single injection of NGF (1ug/0.5ml) repeated over 3 separate days in their dominant tibialis anterior muscle."
3474566|NCT03843827|Active Comparator|Group A (LMA Group)|Active Comparator: Group A (LMA Group) LMA-Classic™ laryngeal mask airway (Classic™LMA) by Dr. Archie Brain into clinical practice in 1988 brought about a revolution in anesthesia. In the literature, there are over 2,500 studies supporting Classic™ LMA usage. Following the success and popularity of Classic™ LMA, many different variants of this device have been designed and marketed,trying to offer a simple and effective alternative to the endotracheal intubation.
3474567|NCT03843827|Active Comparator|Group B (I gel Group)|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature,thus minimising air leakage
3474568|NCT03843866|Active Comparator|Suture & steri-strips|
3474569|NCT03843866|Active Comparator|Adhesive Glue|
3474570|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv3 (M3) given IM at Day 0
3474571|NCT03844386|Experimental|MVA.tHIVconsv4 (M4)|Participants in this arm receive one vaccine dose of MVA.tHIVconsv4 (M4) given IM at Day 0
3474572|NCT03844386|Experimental|MVA.tHIVconsv3 (M3)+MVA.tHIVconsv4 (M4)|Participants in this arm receive a single combined dose containing each vaccine type MVA.tHIVconsv4 (M3) + MVA.tHIVconsv4 (M4) given IM at Day 0
3474573|NCT03844386|Placebo Comparator|Placebo|Participants in this arm receive one saline (placebo) dose given IM at Day 0
3474574|NCT03844165|Experimental|Diet change (red rice) with yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
3474575|NCT03844165|Active Comparator|Yoga|Following randomisation, participants are given a schedule of group and personal meetings and details of each session. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
3474576|NCT03843801|Active Comparator|Volume reduction|Intragastric sutures are done to reduce the volume of the stomach
3126290|NCT03028896|Experimental|rotational|After insertion of the entire cuff inside the mouth, the LMA FlexibleTM was rotated counter-clockwise through 90° and was advanced through the right side of the tongue until the resistance was felt, and then was returned back in the hypopharynx.
3126291|NCT03028974|Other|Group A: 2-4 yo LAIV4 (Return)|Participants are given quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® . For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1. All participants in this group will be asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
3126292|NCT03028974|Other|Group B: 2-4 yo LAIV4 (Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. For children requiring 2 doses of vaccine, a second immunization will be given at Day 28-32 after Dose 1.
3474577|NCT03843801|Active Comparator|Gastric emptying reduction|Intragastric sutures are done to slower the gastric emptying
3474578|NCT03843801|Active Comparator|Increasing distension|Intragastric sutures are done to maximalize the gastric distension
3474579|NCT03843775|Experimental|Binimetinib and Encorafenib|Patients will be initially enrolled to the approved dose of encorafenib 450 mg oral QD and binimetinib 45 mg PO BID, dose level 1. If confirmed this dose level is safely tolerated in the study population, we will then escalate treatment to dose level 2 with the novel dosing regimen of encorafenib 450 mg oral QD continuous and binimetinib 60 mg oral BID 21 days on/7 days off.
3474580|NCT03843970|Experimental|Levobupivacaine Hydrochloride 0,5%|The doses used of Levobupivacaine Hydrochloride 0.5% will be 6 mg and the dose of fentanyl 10 μg.
3474581|NCT03843970|Active Comparator|isobaric bupivacaine 0,5%|The doses used of isobaric bupivacaine will be 6 mg and the dose of fentanyl 10 μg.
3474582|NCT03843957|Experimental|"Clinic Patients on high touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
3474583|NCT03843957|Experimental|"Clinic Patients on low touch Strategy"|"English-speaking patients aged 50-74 who are seen in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
3474584|NCT03843957|Experimental|"Clinic personnel on high touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the high touch Implementation strategy."
3474585|NCT03843957|Experimental|"Clinic personnel on low touch Strategy"|"Clinic personnel (e.g., administrators, nurses, providers) who are involved with the implementation of mPATH-CRC, in the study clinics randomized to mPATH-CRC utilizing the low touch Implementation Strategy"
3474586|NCT03843840||Diseased Retina|
3474587|NCT03843749|Experimental|HER2-positive Metastatic Colorectal Cancar|
3474588|NCT03843996|Experimental|Treatment left|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
3474589|NCT03843996|Experimental|Treatment right|A randomized side of the scalp will be treated with Stratamed®, the other side with standard clinical practice.
3474590|NCT03844178|Active Comparator|The right eyes with compensation for Pupil centroid shift|
3474591|NCT03844178|Active Comparator|The left eyes without compensation for Pupil centroid shift|
3474592|NCT03843853|Experimental|Pemetrexed + S-1 + Bevacizumab|Pemetrexed 500 mg/m2 d1+ S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14 + Bevacizumab 7.5 mg/kg d1; Repeated every 3 weeks
3474593|NCT03843931|Active Comparator|GLA:D|8 weeks of education (1 session/week for 2 weeks) and exercise therapy (2 sessions/week for 6 week)
3474594|NCT03843931|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injection (5 ml of 0.9% sodium chloride) every 2 weeks over an 8-week period
3474595|NCT03843879|Active Comparator|TAP Block|Single-injection transversus abdominis plane block
3474596|NCT03843879|Active Comparator|IV Lidocaine|Continuous intravenous lidocaine infusion
3474597|NCT03843918|Experimental|Group A (Phase II only)|LAE001+ADT
3474598|NCT03843918|Placebo Comparator|Group B (Phase II only)|Placebo+ADT
3474599|NCT03843788|Experimental|Post-CS TENS|The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site. Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
3474600|NCT03843788|Experimental|Opioid Addicted Post-CS TENS|Subjects will be targeted on the basis of opioid addiction and usage of methadone maintenance. The patients in the intervention group will be educated on the proper way to utilize the transcutaneous electrical nerve stimulation (TENS) unit. They will apply the the patches of the TENS unit around the C-section site). Starting 8 hours after C-Section, the TENS unit will be turned on and will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy. Routine pharmacologic care will also be available.
3474601|NCT03843788|No Intervention|Post-CS Routine Care|Routine pharmacologic care will be provided.
3474602|NCT03843788|No Intervention|Opioid Addicted Post-CS Routine Care|Routine pharmacologic care will be provided.
3474603|NCT03843658||Rheumatoid Arthritis|Clinician diagnosed rheumatoid arthritis
3474604|NCT03843658||Spondyloarthropathy|Ankylosing spondylitis and psoriatic arthritis
3474605|NCT03843658||Crystalline arthritis|Gout and Pseudo gout
3474606|NCT03843658||Connective Tissue Disease|Lupus, myositis, scleroderma, and sjogren's
3474607|NCT03843658||Non-Inflammatory arthritis|E.g. Osteoarthritis and Fibromyalgia
3474608|NCT03843814|Experimental|APT MRI|"Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment."
3474609|NCT03843944|Experimental|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
3474610|NCT03843710|Experimental|7.5mg CNM-Au8|7.5mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
3474611|NCT03843710|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
3474612|NCT03843710|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
3474613|NCT03843710|Experimental|60mg CNM-Au8|60mg suspension of clean-surfaced, faceted, gold nanocrystals in 120ml of sodium bicarbonate buffered water
3474614|NCT03843697|Experimental|Patients with IBD who develop resistance to anti TNF|Patients with inflammatory bowel disease who developed partial or complete resistance to anti TNF based drugs
3474615|NCT03843736|No Intervention|Health control group|Participants are healthy women and there are no interventions.
3474616|NCT03843736|Experimental|Lifestyle interventions group|Participants are PCOS patients and only will be given lifestyle interventions.
3474617|NCT03843736|Experimental|Probiotic Agent group|Participants are PCOS patients and will be given lifestyle interventions + Probiotic Agent interventions.
3474618|NCT03843736|Experimental|Oral contraceptive group|Participants are PCOS patients and will be given lifestyle intervention + Oral contraceptive interventions.
3474619|NCT03843671|Experimental|Group 1|Hyperbaric oxygen Hyperbaric chamber
3474620|NCT03843671|Sham Comparator|Group 2|Sham for hyperbaric oxygen Hyperbaric chamber
3474621|NCT03843684|Experimental|Knee osteoarthritis patients|
3474622|NCT03843580|No Intervention|Standard Allocation|apnea without oxygenation like usual traitement
3474623|NCT03843580|Experimental|oxygenation optiflow|optiflow oxygenation during apnea
3474624|NCT03843645|Active Comparator|general anesthesia group|patients allocated to the general anesthesia group will be subjected to general anesthesia with sevoflurane (inhalational agent) used for maintenance
3126293|NCT03028974|Other|Group C: 2-4 yo LAIV4 (Swab/Single Yr)|Participants are given LAIV4/ FluMist® and participate for single year. NP swabs are collected; no blood samples will be collected for this group. For children requiring 2 doses of vaccine, a second immunization will be given at least 28 days after Dose 1.
3474625|NCT03843645|Active Comparator|regional anesthesia group|patients allocated to the regional anesthesia group will be subjected to combined spinal-epidural anesthesia with ropivacaine and fentanyl
3474626|NCT03843606|Experimental|diet 1|60% fat, 15% protein, 25% carbohydrates
3474627|NCT03843606|Experimental|diet 2|70% fat, 15% protein, 15% carbohydrates
3474628|NCT03843606|Experimental|diet 3|80% fat, 15% protein, 5% carbohydrates
3474629|NCT03843437|Experimental|Tencel Therapeutic Garments|Children in this group will wear Tencel Therapeutic Garments
3474630|NCT03843437|Placebo Comparator|Cotton Therapeutic Garments|Children in this group will wear Cotton Therapeutic Garments
3474631|NCT03843398|Experimental|Minilaparotomy Group|Participants in this arm undergo colorectal cancer resection via minilaparotomy.
3474632|NCT03843398|Active Comparator|Laparoscopy Group|Participants in this arm undergo laparoscopic colorectal cancer resection.
3474633|NCT03843320||SAVR|"Patients with aortic stenosis undergoing surgical aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~INSPIRIS RESILIA;~EDWARDS INTUITY;~Carpentier-Edwards PERIMOUNT Magna-Ease."
3474634|NCT03843320||TAVR|"Patients with aortic stenosis undergoing transcatheter aortic valve replacement using an approved medical device for this intended use.~Patients will be enrolled in this group only if the device is one of the following:~SAPIEN 3;~SAPIEN XT."
3474635|NCT03843333|Experimental|CHW Intervention|CHWs will deliver three intervention components (Tai Ji Quan: Moving for Better Balance, Behavioral Activation, and Resource Navigation) to all participants at intervention sites over a 6-month period.
3474636|NCT03843333|Active Comparator|Enhanced Usual Care|Comparison participants will receive a guide on community resources for older adults, and assistance from the research team in making initial connections to resources if desired.
3474637|NCT03843476||Surgical with Rod|The patient is being treated with the patient specific rod with a surgery date planned
3474638|NCT03843593||Melanoma patients|This is a pilot prospective study to identify the factors patients consider in deciding whether or not to undergo adjuvant therapy. Patients are eligible regardless of whether they decide to accept adjuvant therapy. If the researcher plans to treat the participant with pembrolizumab instead of nivolumab, it should be known that although the video discusses nivolumab, the risks and benefits are the same.
3126294|NCT03028974|Other|Group D: 6 - 23 mos old IIV4 (Return)|Participants are given a quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® . For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1. Participants are asked to return annually for repeat immunization per ACIP guidelines and blood sample collection.
3474639|NCT03843541|Experimental|Active test treatment-NAC|NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
3474640|NCT03843541|Active Comparator|Active control treatment-Ambroxol hydrochloride|Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
3474641|NCT03843541|Placebo Comparator|Placebo|Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
3474642|NCT03843385|Experimental|faecal microbiota filtrate|Encapsulated faecal microbiota filtrate . 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
3474643|NCT03843385|Active Comparator|faecal microbiota|Encapsulated faecal microbiota. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
3474644|NCT03843385|Sham Comparator|Placebo|Placebo: Encapsulated sterile saline. 2×5 frozen capsules by mouth on 5 consecutive days per week (5 days on and 2 days off; week 1 - week 12) with water or apple juice.
3474645|NCT03843424|Active Comparator|Enhanced Standard of Care (eSOC)|This group will receive the eSOC program. A minimum of 6 visits to the primary care provider (PCP) and includes assessment of weight status, patient/family motivation and readiness to change, promotion of healthy eating and activity habits, and use of health behavior change strategies.
3474646|NCT03843424|Active Comparator|Family-Based Behavioral Treatment (FBT + eSOC)|This group will receive eSOC plus the FBT program. Family-based behavioral treatment (FBT), an effective treatment that targets both child and parents meeting regularly with a health coach for healthy eating, activity, positive parenting strategies, and managing environmental cues.
3474647|NCT03843528|Experimental|Combined therapy|"Patients will be enrolled in blocks of 3, with vorinostat dose-escalation according to 3+3 study design.~Low-dose azacitidine will be administered in a fixed dose to all patients, for days 1-5 of each 28 day cycle."
3474648|NCT03843502|Experimental|Kava Pharmacokinetics Group|Each subject will take three 75 mg kava dietary supplement capsules in a single dose/timepoint and nine blood draws will be collected over an eight hour period following adminstration of kava.
3474649|NCT03843268|Active Comparator|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS)
3474650|NCT03843268|Placebo Comparator|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger.
3474651|NCT03843463|Experimental|Naming Treatment + Escitalopram|10 mg escitalopram daily for three months (escalating from 5 mg per day for the first week and tapering to 5 mg per day for the last two weeks)
3474652|NCT03843463|Placebo Comparator|Naming Treatment + Placebo|10 mg placebo daily for three months
3474653|NCT03843281|Experimental|Paracetamol|Paracetamol 1 g (100 mL) IV + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
3126295|NCT03028974|Other|Group E: 6 - 23 mos old IIV4 (Single Yr)|Participants are given IIV4/ Fluzone® and participate for a single year. For children requiring 2 doses of vaccine (vaccine-naïve), a second immunization will be given at Day 28-32 after Dose 1.
3474654|NCT03843281|Placebo Comparator|Placebo|Placebo (NaCl 0.9% 100 mL IV) + Morphine 0.1 mg/kg IV (repeatable in Doses of 0.05 mg/kg), 100 patients over 4 hours
3474655|NCT03843294|Experimental|Nivolumab with TAA-T cell|Patients will receive doses of Nivolumab at a minimum of 8 weeks prior to first TAA-T cell infusion and additional dose(s) of Nivolumab will be given after 4 weeks following second TAA-T cell infusion starting at week 7 from first infusion of TAA-T.If patient meets eligibility criteria for TAA-T cell infusion, the patient will receive two TAA-T cell infusions given 2 weeks apart
3474656|NCT03843242|Experimental|Pacemaker with Fixed long AV delay|"Patients who meet the inclusion criteria and is implanted with a Biotronik Enitra 8 DR-T pacemaker are eligible.~The pacemaker was programmed with a long and fixed atrioventricular interval for the first 3 months.~Definition of fixed AV delay (than intrinsic AV conduction) • If P-wave exists: intrinsic AV conduction time = As ~ Vs interval in the marker channel sensed AV delay = intrinsic AV conduction time + 20 msec paced AV delay = sensed AV delay + 30 msec • If no P-wave exits: intrinsic AV conduction time = Ap ~ Vs interval in the marker channel paced AV delay = intrinsic AV conduction time + 20 msec sensed AV delay = paced AV delay - 30 msec • If the intrinsic AV conduction time is ≥ 300ms, make paced/sensed AV delay 350/320 msec"
3474657|NCT03843242|Experimental|Pacemaker with VpS® algorithm on|Vp Suppression ON algorithm: This feature promotes the intrinsic AV conduction by only pacing the ventricle when intrinsic conduction becomes unstable or disappears. Depending on the presence or absence of AV conduction, the feature is implemented either in the ventricular pacing suppression state ADI(R), which promotes the intrinsic conduction, or in the DDD(R) ventricular pacing state Vp DDD(R), which provides ventricular pacing. Automatic switching capabilities between those two states promotethe intrinsic conduction as much as possible without harming the patient. Scheduled Vs searching tests look for intrinsic conduction using an extended AV delay of 450ms.
3474658|NCT03843242|Experimental|Pacemaker with IRSplus algorithm on|IRS plus algorithm: This algorithm incorporates two different functions: the first is scan hysteresis, which better enables the heart to pace on its own by periodically extending the search time for its natural pacing stimulus (the intrinsic AV conduction) over six consecutive atrial cycles. The second is the repetitive hysteresis, which recognizes when the heart is not pacing on its own (a consistent loss of intrinsic AV conduction lasting for six consecutive atrial cycles) and switches the mode of the device from extended to basic atrioventricular (AV) delay.
3474659|NCT03843229|Experimental|treatment group|The treatment group receives Cinobufacini injection 20ml via hepatic artery during Transarterial Chemoembolization(TACE) operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
3474660|NCT03843229|Other|control group|The control group only receives Transarterial Chemoembolization (TACE).
3474661|NCT03843515|Experimental|Neoadjuvant nivolumab|All subject will receive 400mg flat dose nivolumab in the neoadjuvant setting
3474662|NCT03843307|Experimental|Electrical stimulation|
3474663|NCT03843567|Placebo Comparator|Didactic Training|Training will be conducted in a classroom for those participants randomised to receive didactic training, with training provided via a PowerPoint (Microsoft Inc., Redmond, Washington, USA) presentation by an expert endoscopist. An endoscopist with extensive experience in optical characterisation using virtual chromoendoscopy reviewed all teaching material.
3474664|NCT03843567|Active Comparator|Computer-based self-training|Participants randomised to the computer-based self-learning group will be given the same PowerPoint presentation as the didactic group and completed the training in a separate room. Participants completed training without feedback interaction.
3474665|NCT03843359|Experimental|Part 1A: Participants receiving GSK3745417, Dose-escalation Cohort|
3474666|NCT03843359|Experimental|Part 2A: Participants receiving GSK3745417 + dostarlimab, Dose escalation Cohort|
3126296|NCT03028974|Other|Group F: 9-13/18-49 yo LAIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given LAIV4/ FluMist® . Participants will participate for a single year.
3126297|NCT03028974|Other|Group G: 9-13/18-49 yo IIV4 (Single Yr)|Participants 9-13 year old and 18-49 year old are given IIV4/ Fluzone® and participate for single year.
3126298|NCT03028987|Other|LAIV randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone® .
3126299|NCT03028987|Other|IIV4 randomized|Volunteers are past participants who have been identified as HLA DR1501+ or DR0701+ by lab assay results. All participants will be randomized within the twin pair to receive either the seasonal quadrivalent live, attenuated influenza vaccine (LAIV4)/ FluMist® or the seasonal quadrivalent inactivated influenza vaccine (IIV4)/ Fluzone®
3179352|NCT00671905|Active Comparator|3|HF stimulation-guided and anatomic ablation of the main right and left atrial GP followed by circumferential PV isolation
3179353|NCT00671944|Experimental|1|Low protein diet
3474667|NCT03843255||Part 1: Dilated Cardiomyopathy patients|Approximately 1200 patients recruited prospectively from participating sites with a diagnosis of Dilated Cardiomyopathy (DCM). Will also include approximately 800 retrospective patients diagnosed with DCM currently biobanked by the lead site.
3126301|NCT03029091|Experimental|EoE +/- CTD|Participants with EoE with and without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
3126302|NCT03029091|Experimental|EoE + CTD|Participants with EoE with CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
3126303|NCT03029091|Experimental|EoE - CTD|Participants with EoE without CTD receive Losartan Potassium, 0.7 - 0.9 mg/kg (titration)/1.0 - 1.4 mg/kg (maintenance) daily for 16 weeks
3126304|NCT03029143|Experimental|Lead-in Period: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion once at Day 1 and at Week 2 . Participants were then assessed to estimate the vedolizumab clearance at Week 5 and response at Week 6.
3126305|NCT03029143|Experimental|Randomized Treatment Period (RTP): Standard Treatment Arm|Following Lead-in Period, participants received vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W) at Weeks 6, 14 and 22 as standard treatment plus 18 weeks follow-up.
3126306|NCT03029143|Experimental|RTP: Dose Optimized Arm|Following Lead-in Period, participants received vedolizumab 600 mg, IV infusion at Week 6, followed by Regimen A: vedolizumab 300 mg once in every 4 weeks (Q4W) thereafter (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up, or Regimen B: vedolizumab 600 mg, IV infusion Q4W (Weeks 10, 14, 18, 22 and 26) plus 18 weeks follow-up based on drug clearance.
3126307|NCT03029208|Experimental|Daprodustat treated anemic subjects|Subjects will receive oral daprodustat once daily.
3126308|NCT03029208|Active Comparator|Darbepoetin alfa treated anemic subjects|Subjects will receive darbepoetin alfa subcutaneously or intravenously.
3126309|NCT03029247|Active Comparator|Participants receiving Epoetin alfa|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
3126310|NCT03029247|Experimental|Participants receiving Daprodustat|On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.
3126311|NCT03029585|Experimental|NanoPac® 100 mg/m2|Intraperitoneal NanoPac® 100 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
3474668|NCT03843255||Part 2: Heritable Cardiovascular Disease|Patients may be recruited with other diagnosed heritable cardiovascular disorders. Family members of patients may be invited to take part in the study. Children may also be approached to take part in the study.
3474669|NCT03843060|Experimental|Single AZD9977|During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.
3474670|NCT03843060|Experimental|Itraconazole + AZD9977|During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
3474671|NCT03843034||Study group|Infertile women with autoimmune disease
3474672|NCT03843034||Control group|Women from couples with severe male infertility
3474673|NCT03843086|Active Comparator|720 Low Intensity shockwave therapy|Five daily sessions within a week, Monday thru Friday, in which 720 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)
3474674|NCT03843086|Active Comparator|600 Low Intensity shockwaves therapy|"Three weekly sessions for 2 consecutive weeks, Monday-Wednesday-Friday, in which 600 shocks of treatment energy applied every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor in terms of type and dose of drug, for the remainder of study duration."
3474675|NCT03843203|Sham Comparator|s-tDCS|- Intervention: 'Transcranial Direct Current Stimulation - tDCS The patients will receive tDCS sham treatment. The patients will receive sham tDCS treatment over primary motor cortex. According to 10-20 EEG system, anode will be placed at left C3 and cathode at o contralateral F3. In sham stimulation the device only release flow current, in the first 30 s of session and in the remaining 30s in the end of the session, during 20 minutes.
3474676|NCT03843203|Active Comparator|M1 a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over primary motor cortex.~According to 10-20 EEG system, anode will be placed at left C3 and cathode at contralateral supraorbital Fp2.~Active stimulation uses a 2 milliamperes current during 20 minutes."
3474677|NCT03843203|Active Comparator|DLPFC a-tDCS|"Intervention: 'Transcranial Direct Current Stimulation - tDCS~The patients will receive tDCS active treatment over dorsolateral prefrontal cortex.~According to 10-20 EEG system, anode will be placed at left F3 and cathode at contralateral F4.~Active stimulation uses a 2 milliamperes current during 20 minutes."
3474678|NCT03843190|Experimental|Take Off Pounds Sensibly (TOPS)|This group will receive TOPS intervention at the start of the study.
3474679|NCT03843190|Other|Waitlist control|This group will be the control group for the initial year of the study. Then at the completion of the study they will receive the TOPS intervention.
3474680|NCT03842956|Active Comparator|Primary wound healing|Primary woundclosure in Allgöwer suture technique
3474681|NCT03842956|No Intervention|Secondary wound healing|no closure, open wound healing
3474682|NCT03843099|Active Comparator|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
3474683|NCT03843099|Experimental|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
3474684|NCT03843177||Ingrown toenails|
3474685|NCT03843177||Control|
3474686|NCT03842943|Experimental|Combination T-VEC/Pembrolizumab|"Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab~T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.~Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection."
3474687|NCT03843112|Active Comparator|Vivag Plus|Vivag Plus vaginal supplements one capsule every night for ten days start cycle day 6-7.
3474688|NCT03843112|Placebo Comparator|Placebo|Placebo vaginal supplements one capsule every night for ten days start cycle day 6-7.
3474689|NCT03843047|Other|Dual cigarette smokers/e-cigarette users|Dual cigarette smokers/e-cigarette users will be recruited.
3474690|NCT03843047|Other|Exclusive cigarette smokers|Exclusive cigarette smokers with minimal prior e-cigarette experience will be recruited.
3474691|NCT03842904|Experimental|Trimbow pMDI|Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation solution.
3474692|NCT03842904|Active Comparator|Fostair pMDI|Fostair 100/6 micrograms per actuation pressurised inhalation solution.
3474693|NCT03842852||LTEPR|Patients who underwent inguinal hernia repair laparoscopic extra-peritoneal repair under general anesthesia.
3474694|NCT03842852||OPHSR|Patients that underwent inguinal hernia repair open using prolene hernia system mesh under general or regional anesthesia.
3474695|NCT03842995|Placebo Comparator|Genetic Counselor|Standard of Care. Parents/caregivers of neonates enrolled in SouthSeq will receive counseling on their child's Whole Genome Sequencing (WGS) results from Genetic Counselors
3126312|NCT03029585|Experimental|NanoPac® 200 mg/m2|Intraperitoneal NanoPac® 200 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
3126313|NCT03029585|Experimental|NanoPac® 300 mg/m2|Intraperitoneal NanoPac® 300 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
3126314|NCT03029585|Experimental|NanoPac® 400 mg/m2|Intraperitoneal NanoPac® 400 mg/m2 applied immediately post-cytoreductive surgery, followed by standard of care intravenous chemotherapy.
3474696|NCT03842995|Experimental|Trained Healthcare Provider|Healthcare providers (e.g., neonatologists and neonatology nurse practitioners) will receive training to competently deliver Whole Genome Sequencing results to parents/caregivers of neonates enrolled in SouthSeq
3474697|NCT03843021||VAD Healthcare Providers|Adult healthcare providers of VAD therapy recipients.
3474698|NCT03842761|Experimental|Dose group 1|Low Dose
3474699|NCT03842761|Experimental|Dose group 2|Medium Dose
3474700|NCT03842761|Experimental|Dose group 3|High Dose
3474701|NCT03842761|Experimental|Dose Group 4|Dose for healthy volunteers dependent on results from prior dose groups with patients
3474702|NCT03842553||Police officers|Police officers from the cantonal police forces in Bern, Switzerland
3474703|NCT03842553||Firefighters|Firefighters from the professional fire service of the Canton Bern, Switzerland
3474704|NCT03842553||Ambulance personnel|Ambulance personnel of the Canton Bern, Switzerland
3474705|NCT03842553||Emergency nurses|Emergency nurses of the Emergency Unit of the University Hospital of Bern, Switzerland
3126315|NCT03029585|Active Comparator|Standard of Care Intravenous Chemotherapy|Standard of care intravenous chemotherapy (with platinum and taxane agents) administered per institutional standards.
3474706|NCT03842553||Psychiatric nurses|Psychiatric nurses of the University Hospital of Psychiatry, University of Bern, Switzerland
3126316|NCT03029624|Experimental|Treatment Arm|Treatment Arm receives implanted eCoin device and therapy is turned ON.
3126317|NCT03029650|Active Comparator|Transderm Scop®|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
3474707|NCT03842748||Retrospective study group|200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
3126318|NCT03029650|Experimental|Intravenous scopolamine hydrobromide|Each of the subjects will receive a single intravenous dose of 0.4 mg scopolamine hydrobromide and will wear the Transderm Scop® patch (1.5 mg) for 3 days in a crossover design with adequate washout in between. Subjects will be randomized to Group 1 (Transderm Scop® first followed by intravenous scopolamine hydrobromide) and remaining subjects will be randomized to Group 2 (intravenous scopolamine hydrobromide first followed by Transderm Scop®).
3474708|NCT03842748||Prospective observational study group|100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
3474709|NCT03842657|Other|calcium-free citrate-containing dialysate|Dialysis session will be performed with a non-heparin grafted membrane, a dialysate without calcium (0 mmol/L) and citrate 0.8 mmol/L, a reinjection of a calcium solution (300 mM) according to the ionic dialysance, and no heparin addition
3474710|NCT03842657|Other|heparin-grafted membrane|dialysis session will be performed with a heparin-grafted membrane, a dialysate with calcium (1.65 mmol/L) and citrate 0.8 mmol/L, and no heparin addition
3474711|NCT03842722||Critically ill septic patients|Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.
3474712|NCT03842917||Patient starting bevacizumab treatment for cancer|Taken biological samples (urine and blood) and blood pressure measurement on patients starting bevacizumab treatment for cancer
3474713|NCT03842826||Athlete|Male athletes performing sports ≥ 1x/week Age: 18-40 years
3474714|NCT03842800|Other|ASD Patients|This arm consists of patients diagnosed with Autism Spectrum Disorder (ASD) that will receive an MRI.
3474715|NCT03842800|Other|Schizophrenic Patients|This arm consists of patients diagnosed with Schizophrenia that will receive an MRI.
3474716|NCT03842800|Other|Healthy Controls|This arm consists of healthy control volunteer participants that will receive an MRI.
3474717|NCT03842800|Experimental|Healthy Controls with Ketamine|This arm consists of healthy control volunteer participants that elect to receive ketamine prior to receiving an MRI.
3474718|NCT03842735|Experimental|exercise and rehabilitation counselling|Subjects enrolled in exercise group make physical exercises and receive rehabilitative counselling indications
3474719|NCT03842735|Other|rehabilitation counselling|Subjects enrolled in exercise group only receive rehabilitative counseling indications.
3474720|NCT03842839|Experimental|COPD in Grade A|Patient with Grade A COPD (according to GOLD 2019), will start to use Tiotropium once daily.
3474721|NCT03842839|Active Comparator|COPD in Grade C|Patient with Grade C COPD (according to GOLD 2019), will start to use Olodaterol + Tiotropium once daily.
3474722|NCT03842774|Experimental|Test group|taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks
3474723|NCT03842774|Placebo Comparator|Control group|taken 3 tablets of placebo once a day for 12 weeks
3474724|NCT03842579|Experimental|Exercise and Protein (EXEPROT)|Participants in EXEPROT receive: a high-protein diet combined with Resistance training. The high-protein diet is based on milk-based protein-rich products to supplement the habitual diet (corresponding to a protein intake of 1.5 g/kg/day). 4-day food records are used to estimate the needed protein. Of the shelf-products (e.g. milk, cheese) are used considering the individually preferences. Products are delivered once a week. The training intervention includes progressive explosive type heavy-resistance training two times per week. The intervention runs for 16 weeks. Adherence to the training protocol is monitored at each session. Adherence with the nutrition protocol is monitored daily plus at phone follow-ups where participants are asked about e.g. appetite, weight, habitual intake.
3474725|NCT03842579|Active Comparator|Protein-only (PROT)|"Participants in PROT-group receive the nutritional intervention: The high-protein diet.~The diet is based on daily milk-based protein-rich products to supplement the habitual diet (corresponding to a total protein intake of 1.5 g/kg/day). The needed amount of protein supplementation is estimated from 4-day food records. Of the shelf-products (e.g. milk, skyr, cheeses) are used considering the individually preferences. Products will be delivered once a week at the home of the participant. The intervention runs for 16 weeks.~Adherence with the nutrition protocol is monitored daily (registration of compliance with the dietary plan) as well as at phone follow-ups where participants are asked about e.g. changes in appetite, weight, and habitual intake."
3474726|NCT03842579|Active Comparator|Recommendations (REC)|"Participants in the REC-Group receive the comparative intervention: Recommendations.~The official national dietary recommendations for adults >65 years, developed by the Ministry of Environment and Food of Denmark, and related materials is given to the participants and they are encouraged to follow the guidelines (recommending a protein intake of 1.0-1.3 g/kg/day). The intervention runs for 16 weeks.~During the intervention all groups will receive two seminars on specific topics related to healthy ageing (e.g. talks on physical activity, sedentary behaviour, and nutrition)."
3474727|NCT03842670|Active Comparator|Cognitive-Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking.
3474728|NCT03842670|Active Comparator|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual.
3474729|NCT03842605|Experimental|Strength training|
3474730|NCT03842709|Placebo Comparator|Standard Treatment + Placebo|Patients reporting sub-optimal results of pain therapy, assigned to placebo in addition to routine care.
3474731|NCT03842709|Experimental|Standard Treatment + Pramipexole|Patients reporting sub-optimal results of pain therapy, assigned to receive pramipexole in addition to routine care.
3474732|NCT03842644|Experimental|Tension Reduction|Tension reduction device for 3 months post surgery
3474733|NCT03842644|No Intervention|Control|No tension reduction
3474734|NCT03842631||Superficial Group|Hemangioma depth evaluated by B-ultrasonoscope is lower than or equal to 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
3474735|NCT03842631||Deep Group|Hemangioma depth evaluated by B-ultrasonoscope is more than 6mm. After enrollment, patients would be subject to external use of Timolol Maleate 0.5% Oph Soln for the treatment of hemangioma.
3474736|NCT03842527|Active Comparator|Standard Fasting Group|Ultrasound scan of gastric antrum 1 hour prior to procedure. Patients assigned to this group will follow standard fasting procedures of no eating or drinking 8 hours prior to C-section.
3474737|NCT03842527|Experimental|Carbohydrate Loading Group|"Ultrasound scan of gastric antrum 1 hour prior to procedure.~Patients assigned to this group must stop eating 8 hours prior to their scheduled C-section time.~The night before their C-section they must drink 800mL of 100% apple juice (not from concentrate) OR 800mL of cranberry juice cocktail, not both~The day of their C-section, starting 3 hours before surgery and to be finished 2 hours before surgery time, patients must drink 400mL of 100% apple juice OR 400mL of cranberry juice cocktail, not both~Please note:~The apple juice must be 100% juice, not from concentrate~The cranberry juice cocktail must not be plain cranberry juice"
3126319|NCT03029715|Other|Intravenous anaesthesia|Propofol Dexmedetomidine Remifentanil
3126320|NCT03029715|Other|Inhalation anaesthesia|Desflurane Remifentanil
3474738|NCT03842787||SLE patients with lupus Nephritis|"14 SLE patients with lupus Nephritis~Biological analysis and biopsy were (routinely) performed~Ethics The protocol will be submitted to a randomly chosen Institutional Review Board (Comité de Protection des Personnes), in compliance to French regulation.~Investigators will include patients followed for routine care. Patients will be informed that samples (serum and kidney biopsy) that are performed for routine patient care will subsequently be used for research purposes, with no additional blood draw/biopsy. They will sign informed consent."
3474739|NCT03842540|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
3474740|NCT03842540|Active Comparator|PartyWise Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
3474741|NCT03842514|Experimental|High-emulsifier to Low-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days high-emulsifier (soya lecithin) low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate"
3474742|NCT03842514|Experimental|Low-emulsifier to High-emulsifier|"Phase 1: No intervention - 7 days food diary (recording at home, usual diet)~Phase 2: 14 days low-emulsifier low-calorie diet at 100% resting metabolic rate~Phase 3: No intervention - 7 days washout with usual diet~Phase 4: 14 days high-emulsifier( soya lecithin) low-calorie diet at 100% resting metabolic rate"
3474743|NCT03842384|Experimental|distress tolerance training|computer- and text- message delivered intervention that enhances motivation through personalized feedback and increases tolerance of distress through skills training.
3474744|NCT03842384|Other|treatment as usual|standard outpatient buprenorphine treatment
3474745|NCT03842501|Placebo Comparator|Placebo|
3126321|NCT03029780|Experimental|Co-Administration|Nivolumab and Ipilimumab Co-Administration
3126322|NCT03029780|Experimental|Sequential Administration|Nivolumab and Ipilimumab Sequential Administration
3126323|NCT03029819|Active Comparator|Mindfulness-based Addiction Treatment (MBAT)|Nicotine patch; self-help guide; MBAT
3126324|NCT03029819|Experimental|iQuit Mindfully|Nicotine patch; self-help guide; MBAT; text messaging
3474746|NCT03842501|Experimental|Release supplement|
3474747|NCT03842449|Experimental|Smoking pregnant woman withCO measurement|
3474748|NCT03842449|Other|Smoking pregnant woman without CO measurement|
3474749|NCT03842449|Other|Non Smoking pregnant woman|
3474750|NCT03842397|Experimental|Implanted Patients|Implantation of Kephalios Device 1
3474751|NCT03842462|Active Comparator|nCPAP|neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-8 cmH2O) by pure CPAP system , with FiO2 (0.21～0.40)adjusted to target SpO2 from 89% to 94%
3474752|NCT03842462|Active Comparator|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec (according to clinicians'evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
3126325|NCT03029988|Experimental|Cohort 1|Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
3474753|NCT03842462|Experimental|NHFOV|"- neonates assigned to NHFOV will be started with the following boundaries, according to available physiological and mechanical data, as suggested elsewhere:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 89%-94%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-15Hz). c)Inspiratory time 50% (1:1).[ d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2O); amplitude will be titrated according to PaCO2."
3474754|NCT03842488|Experimental|RAL 1200 QD|Start treatment with Raltegravir (RAL) 1200mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
3126326|NCT03029988|Experimental|Cohort 2|"Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data."
3126327|NCT03030183|Experimental|Zilucoplan (RA101495)|Subjects will receive RA101495 at the dose of 0.3 mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
3474755|NCT03842488|Active Comparator|DRV/cb|Start treatment with Darunavir/Cobicistat (DRV/cb) 800-150mg QD plus tenofovir alafenamide/emtricitabine (FTC/TAF)
3474756|NCT03842475||Surgical cohort|Patients with type 2 diabetes undergoing Roux-en-Y gastric bypass surgery
3126328|NCT03030599|Placebo Comparator|Placebo|Placebo
3126329|NCT03030599|Experimental|JZP-258|JZP-258
3474757|NCT03842475||Control|Healthy volunteers with normal body mass index
3474758|NCT03842319|Experimental|Control|In patients allocated to the control group, the currently used Spanish Mediterranean diet will be recommended as part of a standard high-quality secondary prevention program, where the patient is invited to participate in a single 45 minute nutritional educational group session. Interventions: Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation
3474759|NCT03842319|Experimental|High-intensity MedDiet|Patients allocated to the interventional group will be individually evaluated by a dietitian and will participate in dedicated individual and group sessions at baseline, and at 3, 6, 9 and 12 months. In the interventional group, a personalized MedDiet will assess chemical and nutritional composition and total energy intake will be adapted to participant's weight, age, and requirements, and the dietitian's tailored advice to his/her individual needs. A 14-item dietary screen for adherence to the Mediterranean diet will be used to personalize the intervention and negotiate dietary changes. Furthermore, free virgin olive oil, recipes, shopping list and designed weekly menus will be provided to maximize the differences between groups. Interventions: MedDiet, Microbiota analysis, Immunological analysis, Proteome analysis, Metabolome analysis, Clinical evaluation, Diet evaluation
3474760|NCT03842241||WIth foot orthoses|Device: Non-custom made foot orthoses
3474761|NCT03842241||Without foot orthoses|Other: without foot orthoses
3474762|NCT03842423||Study Group|All patients under the age of 18 who were treated for upper extremity injuries between 2002 and 2018 and receiving brachial plexus anaesthesia.
3474763|NCT03842254|Experimental|Single arm|Single dose of erythropoietin 10,000 units to be administered subcutaneously at time of enrollment.
3474764|NCT03842150||derivation cohort|
3474765|NCT03842150||validation cohort|
3474766|NCT03842410|Other|Single-Incision Sling|Intervention with in office solyx suburethral sling DISST
3474767|NCT03842280||Prolonged mechanical ventilation|Prolonged mechanical ventilation with tracheostomy
3126330|NCT03030638||Olodaterol|Patients initiating Olodaterol for the first time
3474768|NCT03842202|Experimental|Semaglutide|Participants will receive increasing doses of semaglutide. The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks.
3126331|NCT03030638||Indacaterol|Patients initiating Indacaterol for the first time
3474769|NCT03842202|Placebo Comparator|Placebo (Semaglutide)|Participants will receive placebo (semaglutide). The treatment period from first treatment (Day 1) to end of the treatment (Day 141) will be 20 weeks
3474770|NCT03842215||silver hair people|Exam subject's physical function by a smart physical exam
3474771|NCT03842033|Other|PEAKmAAP|"The Pulmonary Education and Asthma Knowledge mobile asthma action plan (PEAKmAAP) group will use a mobile app that will help manage asthma. Participants will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. mAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification."
3474772|NCT03842033|Other|PEAKmAAP-Data Sharing (DS)|PEAKmAAP with Data Sharing (PEAKmAAP-DS) group will be asked to enter asthma symptoms or peak flow every day. The PEAKmAAP guides participants when to take asthma medicines and sends reminders to take their medicines every day. PEAKmAAP also provides reminders when to get asthma medicines refilled. Asthma education messages and video links are also pushed via notification. The primary care provided (PCP) will receive monthly reports to help them know how the participant's asthma symptoms are over time.
3474773|NCT03842033|Other|Nutrition Map (NutriMap) Usual Care|Participants in this arm will use a smartphone application that sends daily non-asthma-related reminder for attention control. Participants will be asked to log their daily fruits and vegetables eaten. Participants will answer survey questions about their asthma and symptoms management.
3126332|NCT03030989|Active Comparator|Chlorhexidine Gluconate 2% Wipe|
3126333|NCT03030989|Placebo Comparator|Placebo wipe|
3474774|NCT03842085|Experimental|MBS301|Drug: Recombinant Humanized Bispecific Monoclonal Antibody MBS301
3474775|NCT03842332|Experimental|Resilience Training|This group will participate in the 12 week Life Skills and Resilience Program that includes vocational skills and adult skills important for an adult in society. Participants will also receive standard case management plus resiliency-focused support to encourage family and young adult interaction with professionals and peers. Case managers will then utilize a resiliency framework for their interaction with the participant.
3474776|NCT03842332|No Intervention|Standard Care|This group will receive case management referral to community training programs when requested by family, or need (as identified by case worker). Standard case management includes intake includes housing counseling, case management with mental health and behavioral services, and referral to day programs as needed and identified by case management
3474777|NCT03842371||Sepsis with type 2 diabetes|Sepsis patients with type 2 diabetes
3474778|NCT03842371||Sepsis without type 2 diabetes|Sepsis patients without type 2 diabetes
3474779|NCT03842371||Volunteers|Healthy volunteers
3474780|NCT03842124|Active Comparator|Intervention|Use of bidirectional rail (superior and inferior approaches) and force sensing using a force gauge to optimize Force application to less than 8 lbs during the extraction procedure.
3474781|NCT03842124|No Intervention|Control|Conventional lead extraction procedures using a superior approach is performed by experienced operators. Although force information is available the operators are blinded to the information. Inferior rail is left to the discretion of the operator.
3474782|NCT03842267|Active Comparator|Gemigliptin 50mg|
3474783|NCT03842267|Placebo Comparator|Gemigliptin Placebo|
3474784|NCT03842176||Neoadjuvant chemotherapy|CTC of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
3474785|NCT03842176||Surgery|CTC of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
3474786|NCT03842072|No Intervention|No post-operative bracing|patients in this arm will not be prescribed a cervical collar following anterior cervical discectomy and fusion surgery
3474787|NCT03842072|Active Comparator|Post-operative bracing|Patients in this arm will be prescribed a cervical collar following anterior cervical discectomy and fusion surgery.
3474788|NCT03842059|Experimental|Computer-aided detection|
3474789|NCT03842059|Placebo Comparator|Standard colonoscopy|
3474790|NCT03841955|Experimental|Experimental group|Peripheral implantation of central venous catheters and accessories with high pressure tolerance
3474791|NCT03841955|Experimental|Control group|Peripheral intubation of central venous catheter
3474792|NCT03842046|Active Comparator|phenylephrine infusion|phenylephrine infusion (30 mL/h corresponding to 50 μg/min)
3474793|NCT03842046|Active Comparator|norepinephrine infusion|norepinephrine infusion (30 mL/h corresponding to 4 μg/min)
3474794|NCT03841903||relapsing-remitting MS undergoing spinal cord MRI|
3474795|NCT03841903||secondary progressive MS undergoing spinal cord MRI|
3474796|NCT03841903||primary progressive MS undergoing spinal cord MRI|
3474797|NCT03841903||healthy control (HC) undergoing spinal cord MRI|
3474798|NCT03842007|Active Comparator|Healthy Individuals|Sixty healthy individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
3474799|NCT03842007|Active Comparator|Constipated Individuals|60 constipated individuals (20 men and 40 women) will undergo an anorectal study which comprises of a rectal barostat study followed by fecoflowmetry
3474800|NCT03842020|Experimental|Amiodarone dosage|Blood pharmacokinetics samples
3474801|NCT03841864|Other|Grade 1 Vein Visualization|Visual vein classification grade described as excellent Visualization. Objective vein criteria to be included in this group are vein raised above skin and wider than 1mm. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
3474802|NCT03841864|Other|Grade 2A Vein Visualization|Veins that don't fit grade 1 or 2b classification (see respective group descriptions). This groups visual vein classification is described as fair visualization. Initial IV placement will be traditional attempt but subsequent attempts will be provider discretion for traditional vs ultrasound guided placement
3474803|NCT03841864|Other|Grade 2b Vein Visualization|Only faint vein shadow appearance described as poor visualization. Initial IV placement attempt will be ultrasound guided
3474804|NCT03841864|Other|Grade 3 Vein Visualization|No vein visualization. Initial IV placement attempt will be ultrasound guided
3474805|NCT03841734|Experimental|Treatment bosentan|
3474806|NCT03841630|Experimental|LY3437943|Escalating doses of LY3437943 administered as an injection under the skin in healthy participants
3474807|NCT03841630|Placebo Comparator|Placebo|Matching placebo administered as an injection under the skin in healthy participants
3126334|NCT03031431|Experimental|Non-Electric Infant Warmer|In line with current recommended practice, mothers will be encouraged to provide Kangaroo Mother Care (KMC) whenever possible. If an infant's temp is not rising by ½ degree C per hour with KMC alone, the infant warmer will be offered as an addition by the study team. If the mother is not available for KMC at any time, the infant will be warmed exclusively with the warmer. Bundling in clothes will only be used in addition to the warmer per carer preference. Temp measurement of the infant, warmer, and ambient air will be measured every 15 mins for the first hr, then hrly and as needed for the remainder of use or until warmer endpoint is reached (warmer temp below 36 degrees or phase-change material hardens [soft, semisoft, or hardened]).
3126335|NCT03031496|Experimental|Test A followed by Ref B of HCTZ 50mg+ Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
3126336|NCT03031496|Experimental|Ref B followed by test A of HCTZ 50mg + Amiloride HCl 5mg|Eligible participants following an overnight fast of at least 10 hours, will be administered the study drug orally with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
3126337|NCT03031678|Other|Study procedures|
3126338|NCT03031795|Experimental|experimental|ketorolac, oral, 20 mg, 1 dose, 45 minutes prior to IUD placement
3474808|NCT03841981||I- Hypothalamic amenorrhea|10 women with exercise-associated hypothalamic amenorrhea
3474809|NCT03841981||II- Hyperandrogenic polycystic ovary syndrome|5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.
3474810|NCT03841981||III- Non-hyperandrogenic polycystic ovary syndrome|5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome
3474811|NCT03841981||IV- Trained women without ovulatory dysfunction|10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.
3474812|NCT03841981||V- Non-hyperandrogenic healthy women|10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis
3474813|NCT03841968|Active Comparator|Dynamic needle tip positioning|Dynamic needle tip positioning
3474814|NCT03841968|Active Comparator|Conventional long-axis|Conventional long-axis
3474815|NCT03841942|Other|clinically-based spacing|All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
3474816|NCT03841942|Other|Trough level-based spacing|Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.
3474817|NCT03841604|Experimental|Experimental|Safinamide methanesulfonate film coated tablets once daily
3474818|NCT03841604|Placebo Comparator|Placebo|Safinamide methanesulfonate matching placebo film coated tablets once daily
3474819|NCT03841617|Active Comparator|124I PET/CT scan after rhTSH|124I PET/CT scan after preparation with human recombinant TSH
3474820|NCT03841617|Active Comparator|124I PET/CT scan after thyroid hormone withdrawal|124I PET/CT scan after preparation with thyroid hormone withdrawal
3474821|NCT03841994||Preterm infant cohort|Preterm infants who were born <28 weeks of gestational age
3474822|NCT03841695|Experimental|Treatment Group|Experimental group received Robot Assisted Training (RMTC finger-hand robot (Mirror Hand)) and traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
3474823|NCT03841695|Active Comparator|Control Group|Control group received traditional occupation therapy (Conventional OT) for 1 hour and forty minutes.
3474824|NCT03841838|Experimental|Energy drink|Two 12 oz bottles of energy drink
3474825|NCT03841838|Placebo Comparator|Placebo|Two 12 oz bottles of placebo drink
3474826|NCT03841773|Experimental|TNX-102 SL Tablet 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
3474827|NCT03841773|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
3474828|NCT03841851|No Intervention|temporization without soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization ."
3474829|NCT03841851|Active Comparator|temporization with soft tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area~traditional drilling for immediate implant placement .~immediate temporization .~subepithelial connective tissue graft from the palate ."
3126339|NCT03031795|Placebo Comparator|placebo|look alike placebo
3126340|NCT03031899||Rose Bengal positive lesion and biopsy|Lesions that were stained positive with rose bengal were biopsied and assessed for dysplasia
3474830|NCT03841890|Experimental|Intubation with the Clarus Video System as a video stylet|
3474831|NCT03841890|Experimental|Intubation with the Clarus Video System as a lightwand|
3474832|NCT03841890|Active Comparator|Intubation with direct laryngoscope|
3474833|NCT03841721|Experimental|linezolid 300 mg|
3474834|NCT03841643|Active Comparator|C group|In the C group, the cranial bone defect will be reconstructed with HydrosetTM (Stryker, New Jersey, USA), calcium phosphate cement, according to the current standard practice at the department.
3474835|NCT03841643|Experimental|P group|In the P group, the cranial bone defect will be reconstructed with a patient-specific implant (KLS Martin, Tuttlingen, Germany).
3474836|NCT03841825|No Intervention|Control|No messages or oral hygiene instructions
3474837|NCT03841825|Experimental|Text message reminders|Standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays
3126341|NCT03031899||Toluidine blue positive lesion and biopsy|Lesions that were stained positive with toluidine blue were biopsied and assessed for dysplasia
3126342|NCT03031938|Other|Cohort 1|Long term observational study of subjects from tanezumab parent study
3474838|NCT03841825|Active Comparator|In-person oral hygiene instructions|Oral hygiene instructions and motivation during visit
3474839|NCT03841825|Experimental|Text messages and in-person instructions|standardized text reminding patients to brush their teeth will be sent at 5:15 PM on Thursdays and oral hygiene instructions and motivation during visit
3474840|NCT03841786|Placebo Comparator|Control diet|Participants will be asked to consume a normal diet supplemented with sodium chloride (sodium chloride tablets, USP, 1 gram; 3 tablets per day) and potassium chloride (Klor-Con, 8 mEq; 0.5 tablets per day) for 1 week.
3474841|NCT03841786|Experimental|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet with supplemental phosphorus (K-Phos Neutral tablets, 250 mg; 4 tablets a day) for 1 week.
3474842|NCT03841929|Experimental|Study Arm|ELGANs recruited to the study group in addition to standard of care will have continuous cerebral NIRS monitoring for the initial 72 hours and TNE studies at definitive time frames and a hemodynamic report will be provided to the clinical team using the results of the multimodal monitoring and clinical data. The report will be a description of the hemodynamic status without any suggestions for management.
3474843|NCT03841929|No Intervention|Standard Arm|ELGANs recruited into Standard arm will have the standard monitoring including cardiorespiratory monitoring. The invasive blood pressure monitoring, NIRS and TNE monitoring as per the clinical team's discretion - consistent with the current standard of care. No hemodynamic report will be provided routinely.
3474844|NCT03841552|Experimental|Augmented Feedback|The exercises were conducted with the aim of improving postural- and movement control and awareness of the lumbar spine in both treatment groups. Both groups received nine 30-minute therapy sessions, during which they performed a series of exercises from an exercise catalogue. The exercises were selected based on their compatibility with the AF-system. Each patient performed impairment-specific exercises. The AF group received additional AF feedback during both the therapy sessions and the home exercise program, by combining the exercises with games designed to target movement control, body awareness, and stabilisation exercises.
3474845|NCT03841552|Active Comparator|Control Group|The control group performed the impairment-specific exercises without AF. The control group was able to receive conventional visual feedback, such as use of mirrors, as deemed appropriate by the therapists but no AF.
3474846|NCT03841747|Experimental|Pembrolizumab + Paclitaxel|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W) plus 80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
3474847|NCT03841747|Active Comparator|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
3474848|NCT03841526|Experimental|Glucagon RTU, 50% insulin pump reduction|
3474849|NCT03841526|Placebo Comparator|Placebo, 50% insulin pump reduction|
3474850|NCT03841526|Experimental|Glucagon RTU, no basal rate reduction|
3474851|NCT03841539|Experimental|Mediterranean Diet|Follow a Mediterranean eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
3474852|NCT03841539|Active Comparator|Low-fat Diet|Follow a low-fat eating pattern and take a study supplement for one year. Dietary education will be provided by a Registered Dietitian.
3474853|NCT03841578|Experimental|Healthy|10 participants (matched per gender), aged 25-35 years old who accepts the consumption of dark chocolate plus a 'NutriDrink' previous to signing an informed consent and providing authorization to the handling of their personal data
3474854|NCT03841812|Experimental|Propofol|5mg/kg/h Propofol continue infusion during the maintain of anesthesia during the maintain of anesthesia.
3474855|NCT03841812|Experimental|Propofol & Sevoflurane|2mg/kg/h Propofol & 1% Sevoflurane group continue infusion(Balance anesthesia) during the maintain of anesthesia
3474856|NCT03841591|Active Comparator|Insulin Group|This includes women with GDM allocated to receive insulin treatment. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
3474857|NCT03841591|Active Comparator|Metformin Group|This includes women with GDM allocated to receive metformin treatment. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
3474858|NCT03841877|Experimental|AH Plus-Cervical|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
3474859|NCT03841877|Experimental|MTA Fillapex-Cervical|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned at the cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
3474860|NCT03841877|Experimental|AH Plus-2mm|"The objective is evaluate the color change (ΔE00) originated from epoxy resin (AH Plus) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
3474861|NCT03841877|Experimental|MTA Fillapex-2mm|"The objective is evaluate the color change (ΔE00) originated from mineral trioxide aggregate (MTA Fillapex) endodontic sealer, sectioned 2 mm below cervical level.~The ΔE00 will be evaluated using the measurements data obtained in a period between the immediate endodontic treatment versus after 3, 6 and 12 months.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
3474862|NCT03841513|No Intervention|Control|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, without the addition of a laparoscopic/robotic Burch colposuspension
3474863|NCT03841513|Active Comparator|Laparoscopic Burch Colposuspension|Patients in this arm will undergo standard laparoscopic or robotic sacrocolpopexy, with the addition of a laparoscopic/robotic Burch colposuspension
3474864|NCT03841370||endodontic|"The color of anterior (incisors and canines) and posterior (premolar) teeth treated at a private clinic in the city of Pelotas will be evaluated. Data will be collected regardless of technique, treatment time and sealer used.~The ΔE00 will be evaluated using the measurements obtained in the homologous tooth (without endodontic treatment) versus the measurement obtained from the tooth treated endodontically.~The values of ΔE00 obtained for each sealer, cut and time will be analyzed by multifactorial analysis to verify associations of the outcomes with the ΔE00."
3126345|NCT03032263|Active Comparator|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
3126346|NCT03032263|Experimental|Video Laryngoscopy|These patients will undergo Video Laryngoscopy for nasal intubation. We will observe and record incidence of Magill forcep use, presence or absence of nasal bleeding, and the grade of laryngeal view. We will also record any general narrative comments from the provider about the ease or difficulty of intubation.
3474865|NCT03841409||Bupivacaine dosage in ESP block|The pharmacokinetics of bupivacaine 0.5% with epinephrine 5 mcg/mL for a total dose of 2mg/kg of ideal body weight following an ESP block will be determined by the collection of blood samples at predetermined time points.
3126347|NCT03032380|Experimental|Cefiderocol|Participants will receive 2 g cefiderocol administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
3126348|NCT03032380|Active Comparator|Meropenem|Participants will receive 2 g meropenem administered intravenously every 8 hours for 7 to 14 days and 600 mg linezolid administered intravenously every 12 hours for at least 5 days.
3474866|NCT03841435|Experimental|Hypofractionated Radiotherapy|15 Gy given in 3 fractions over 2 weeks
3474867|NCT03841292|Active Comparator|Active tDCS+Varenicline|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
3474868|NCT03841292|Sham Comparator|Sham tDCS+Varenicline|Sham tDCS (Nuraleve, Canada)(30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session. Daily stimulation between Monday to Friday for the first two weeks and then booster sessions every other week for the next 10 weeks.
3474869|NCT03841383||Healthy controls|
3474870|NCT03841383||Hypertensive patients|
3474871|NCT03841305|Active Comparator|portal vein embolization|Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.
3474872|NCT03841305|Experimental|liver venous deprivation|Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.
3474873|NCT03841396|Active Comparator|Fraxiparine|Nadroparine, Pre-filled syringe, 3800IU, single dose
3474874|NCT03841396|Active Comparator|Clexane|Enoxaparin, Pre-filled syringe, 40 mg, single dose
3474875|NCT03841487||Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI).
3474876|NCT03841487||PCI alone|In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
3474877|NCT03841344|Active Comparator|Healthy volunteers|MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP
3474878|NCT03841344|Active Comparator|Treatment naive patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH initiating PAH therapy for the first time"
3474879|NCT03841344|Active Comparator|Treatment change patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients diagnosed with PAH, currently on PAH therapy who are undergoing an escalation of PAH therapy"
3474880|NCT03841344|Active Comparator|Stable patients|"MRI 6 minute walk test, incremental shuttle walk test, NT-Pro BNP and BNP~Patients with PAH who are NOT undergoing changes in their treatment regime"
3474881|NCT03841500|Active Comparator|Aperture (biocomposite screw) fixation|"16 patients in this arm underwent ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw (BioComposite Screw, Arthrex, North Naples, FL; or MILAGRO screw, DePuy Mitek, Raynham, MA, USA).~Intervention: ACL reconstruction with the allograft fixed in the femoral tunnel with a biocomposite interference screw."
3474882|NCT03841500|Active Comparator|Suspensory (endobutton) fixation|"17 patients in this arm underwent ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button (TightRope, Arthrex, North Naples, FL, USA).~Intervention: ACL reconstruction with the allograft secured in the femoral tunnel with a cortical button."
3474883|NCT03841357|Experimental|Abatacept and Usual Care|Weekly abatacept injection at standard dosing for weight plus usual care with steroid joint injection and non-steroidal anti-inflammatory drugs per the discretion of the treating provider
3474884|NCT03841357|Active Comparator|Usual Care|Usual care includes steroid joint injections and treatment with non-steroidal anti-inflammatory drugs at the discretion of the treating provider
3474885|NCT03841474|Experimental|Intervention I|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
3474886|NCT03841474|No Intervention|Control|Cardiovascular patients after PCI without depressive symptoms and without the need for psychiatric intervention
3474887|NCT03841474|Experimental|Intervention II|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of cardiovascular patients after PCI with mild, moderate or severe depression
3474888|NCT03841253|Experimental|Observation Phase|A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser. The refractive outcome will be compared to the refractive change predicted by the EpiMaster application software.
3474889|NCT03841253|Experimental|Treatment Phase|If the transition criteria are met during the observational phase, the treatment phase will be initiated. A trans-epithelial PTK procedure will be performed using the MEL 90 excimer laser, including a refractive component according to the values determined using the EpiMaster application software.
3474890|NCT03841318|Experimental|Sjogren's Syndrome|
3474891|NCT03841136|Experimental|anlotinib combined with EP|anlotinib combined with etoposide and platinum
3474892|NCT03841227|Active Comparator|Active-tDCS|10 patients will receive Active-tDCS intervention (2mA, 20 min) at home.
3474893|NCT03841227|Sham Comparator|Sham-tDCS|10 patients will receive Sham-tDCS intervention (2mA, 20 min) at home.
3474894|NCT03841201|Experimental|Treatment|"Lenvatinib peroral qd (8 mg for patients with body weight <60kg and 12 mg for patients with body weight ≥ 60kg)~Nivolumab i.v. q2w (240mg fixed dose IV) max. 36 cycles"
3474895|NCT03841123|Experimental|Intervention|At the maternity wards mothers will receive dietary counseling and leaflets as a reminder to prevent the early introduction of added sugar and ultra-processed foods.
3474896|NCT03841123|No Intervention|Control|At the maternity wards mothers assigned to control groups will have all the health assistance related to the maternity routine without any interference from the study protocol.
3474897|NCT03841097|Active Comparator|Extended Release Tacrolimus Tablets|Dosed once daily in the morning and started at a dose of 0.14 mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
3474898|NCT03841097|Active Comparator|Immediate Release Tacrolimus Capsules|Dosed twice daily 12 hours apart and started at a dose of 0.1mg/kg/day by the first day after kidney transplant (post-operative day 1). This medication will be given with rabbit antithymocyte globulin (rATG) induction, oral mycophenolate mofetil (MMF) and oral steroids to help prevent rejection. These medications will be ordered per standard of care both inpatient and outpatient.
3474899|NCT03841071||ROM/CFS intervention|The ROM/CFS group (N>100), consists of patients who have undergone urostomy, colostomy, or ileostomy operations, and who are included in the routine follow-up program of the outpatient ostomy clinic at the Department of Surgery, Førde Central Hospital from April 2018 to June 2021.
3474900|NCT03841084|Active Comparator|Conservative Oxygen Management Strategy|Patients allocated to the conservative strategy will have the ECMO blender oxygen fraction (FbO2) will be titrated to achieve a post-oxygenator saturations of 92-96% (the FbO2 cannot be reduced to lower than 0.5). Post-oxygenator arterial blood gases (ABG's) will be taken to ensure safety and to allow for adjustments to be made. The ventilator FiO2 will be titrated to patient oxygen saturations (SpO2) of 92-96%.
3474901|NCT03841084|Active Comparator|Liberal Oxygen Management Strategy|Patients allocated to the liberal strategy will have the FbO2 set at 1.0 at all times. The ventilator FiO2 will be titrated to achieve a patient oxygen saturations (SpO2) of 97-100% (but not lower than 0.5).
3474902|NCT03841058|Active Comparator|Abaloparatide|Abaloparatide 80 mcg dose administered subcutaneously with a pen once daily for 6 months
3474903|NCT03841058|Placebo Comparator|Placebo|Placebo administered subcutaneously with a pen once daily for 6 months
3474904|NCT03841045||ulcerative colitis patient|people that have UC diagnosis can participate in the study. the disease can be at any level and the patients can handle any medications.
3474905|NCT03841045||CD patient|people that have CD diagnosis can participate in the study. the disease can be at any label and the patients can handle any medications.
3474906|NCT03841045||Health people|control group. no IBD patients can be included. patients with other diseases can be included.
3474907|NCT03841006||patient group|symptomatic patient and suspicious to have ODS by history and clinical examination those patient will have MRI defecography
3474908|NCT03841006||asymptomatic group|Asymptomatic group not suspicious to have ODS by history or clinical examination they will undergone MRI defecography
3474909|NCT03840954|Experimental|Neuromuscular Electrical Stimulation|The experimental group will receive the application of NMES associated with conventional physiotherapy. After the NMES application, conventional physiotherapy will be performed. The exercises performed will be according to the patient's physical condition, and the conducts will always be performed seeking the maximum possible functional performance for the patient. The conducts adopted according to the standard routine of the HCPA stroke unit are: passive, active, assisted and / or active exercises; muscle stretching; selective hip extension; trunk stabilization training in sedestation; orthostasis training and walking training.
3474910|NCT03840954|No Intervention|Group Control|The control group will only receive conventional physiotherapy, composed of the same exercises performed in the experimental group.
3126349|NCT03032393|Experimental|Dominant|Subjects in the experimental group were instructed to stand with hands on their hips, elbows pointing out and feet approximately one foot apart for 20 seconds.
3126350|NCT03032393|Active Comparator|Submissive|Subjects in the control group were instructed to stand with hands and arms wrapping around the torso and feet together for 20 seconds.
3126351|NCT03032510|Experimental|Eravacycline (Intravenous)/Levofloxacin (Oral)|
3474911|NCT03840694|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
3474912|NCT03840694|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
3474913|NCT03841188|Other|Nutritional Orientation|The patients received a nutritional orientation with emphasis in food rich in calcium
3126352|NCT03032510|Active Comparator|Ertapenem (Intravenous)/Levofloxacin (Oral)|
3126353|NCT03032523|Experimental|Remote Monitoring CGM Group|Participants wear a CGM that is blinded at bedside (to participant and clinical staff) but remotely monitored by study staff. If a blood sugar less than 46 mg/dl occurs, the study staff receive a notification and ask the clinical staff to perform a confirmation standard of care glucose test.
3126354|NCT03032523|No Intervention|Blinded CGM Group|Participants wear a blinded CGM during the study period. Values are blinded to study staff, participant, and clinical staff.
3474914|NCT03841461||Academicians|The academicians working in any program of any higher education institution
3474915|NCT03840668|Experimental|Dry eye|Participants who will be using the USB-powered eye mask.
3474916|NCT03840655||palmar hyperhidrosis|VATS R4 Sympathicotomy performed on all patients. Fluorescent thoracoscopy was used to identify the shifting mode of sympathetic ganglions.
3474917|NCT03841019|Experimental|magnetic seizure therapy|12 treatment sessions of MST, three times per week.
3474918|NCT03841019|Active Comparator|electroconvulsive therapy|12 treatment sessions of ECT, three times per week.
3474919|NCT03841032|Experimental|Sunscreen Lotion|Subjects with rosacea will apply the test sunscreen lotion to the face for 4 weeks
3474920|NCT03840746|No Intervention|Habitual diet|participants remain on their habitual diet
3474921|NCT03840746|Experimental|Tomato, onion and lovage soup (TOL)|One tin of soup containing Tomato onion and lovage daily for 6 weeks
3474922|NCT03840746|Experimental|TOL soup with inulin|One tin of Tomato, onion and lovage soup with added inulin for 6 weeks
3474923|NCT03840889||Women with a severe late PPH|Women with a severe late PPH will be recruited prospectively after verification of the inclusion criteria by a gynecologist-obstetrician or the investigating midwives, who will provide the patients information about the study and include them unless they object
3474924|NCT03840915|Experimental|Cohort A: Cisplatin or Carboplatin + Pemetrexed + M7824|
3474925|NCT03840915|Experimental|Cohort B: Carboplatin + Paclitaxel or Nab-paclitaxel + M7824|
3474926|NCT03840915|Experimental|Cohort C: Cisplatin or Carboplatin + Gemcitabine + M7824|
3474927|NCT03840915|Experimental|Cohort D: Docetaxel + M7824|
3474928|NCT03840681|Experimental|Ridge augmentation by collagen membrane|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at defected area then covered at the defected area by a collagen membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
3474929|NCT03840681|Active Comparator|augmentation by titanium reinforced PTFE|"Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
3474930|NCT03840759|Experimental|usual care|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant and inpatient geriatric consultation team after a complete geriatric assessment (CGA). The CGA includes the assessment of depression, dementia, physical performance of Activity of Daily Living (ADL) and nutrition using Geriatric Depression Scale (GDC-15), Mini-Mental State Examination (MMSE), Barthel Index (BI), and Mini Nutritional Assessment-Short Form (MNA®-SF) respectively. Besides the geriatric physician, our multidisciplinary team included a social worker, nutritionist and physical therapist. In the control group, the participants only received routine hospital care and no geriatric physician was consulted.
3474931|NCT03840798||Pretest/Baseline period|
3474932|NCT03840798||Posttest/go-live period|
3474933|NCT03840941||Frail patients with COPD|No intervention
3474934|NCT03840941||Non-frail patients with COPD|No intervention
3474935|NCT03840876|Experimental|Group J|Jet ventilation was achieved via supraglottic jet oxygenation and ventilation with WEI NASAL JET (WNJ).
3474936|NCT03840876|No Intervention|Group I|Patients were ventilated with a small size endotracheal tube.
3126357|NCT03032965|Experimental|Adenosine and Isoproterenol|Patients in this group will receive 12-24mg of adenosine for each PV in order to assess dormant PV conduction.
3126358|NCT03032965|Other|Isoproterenol|This group will not receive adenosine during the procedure.
3126359|NCT03033108|Experimental|Emixustat Dose 1|lowest dose of once-daily oral emixustat
3474937|NCT03840616|Experimental|VT-1161 150 mg capsule|
3474938|NCT03840616|Active Comparator|Fluconazole 150 mg|
3474939|NCT03840785|Experimental|interventional group A|2 tango session per week during 6 month (M0 to M6)
3474940|NCT03840785|Placebo Comparator|Control group B|2 tango session per week during 3 month (M3 to M6)
3126360|NCT03033108|Experimental|Emixustat Dose 2|middle dose of once-daily oral emixustat
3126361|NCT03033108|Experimental|Emixustat Dose 3|highest dose of once-daily oral emixustat
3474941|NCT03840629||Hypotonic fluid maintenance|exclusive administration of 0.33% saline mixed with potassium and dextrose 5%
3474942|NCT03840629||Isotonic fluid maintenance|exclusive administration of 0.9% saline
3126362|NCT03033134|Experimental|BSJ003W|BSJ003W implant group
3126363|NCT03033394||Beta-lactam antibiotic|Observational pharmacokinetic study of non-critical care patients receiving beta-lactam antibiotics for management of infections.
3126364|NCT03033511|Experimental|Rovalpituzumab tesirine/dexamethasone|Rovalpituzumab tesirine/dexamethasone every 6 weeks (q6 wk); omitting every third cycle
3126365|NCT03033511|Experimental|Placebo|Placebo q6 wk; omitting every third cycle
3474943|NCT03840863|Experimental|Commercially-Available Energy drink|Healthy volunteers willing to consume two cans of energy drinks (16 oz./can) daily for 4 weeks
3474944|NCT03840850|Experimental|Intervention and usual care|Risk communication intervention and usual care including personalized lifestyle advice
3474945|NCT03840850|No Intervention|Usual care only|Usual care including personalized lifestyle advice
3474946|NCT03840460||Pancreatic Cancer|Patients who are investigated for and subsequently diagnosed with early/advanced pancreatic adenocarcinoma or a precursor lesion or a pancreatic neuroendocrine tumour.
3474947|NCT03840369|Experimental|rTMS to the Right Dorsolateral Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsolateral Prefrontal Cortex (DLPFC). The right DLPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
3474948|NCT03840369|Experimental|rTMS to the Right Dorsomedial Prefrontal Cortex|Patients will engage in a one-week placebo control lead-in (5 treatments) and then a four-week treatment protocol (20 treatments) to the right Dorsomedial Prefrontal Cortex (DMPFC). The right DMPFC will be located with MR brain scans and the BrainSight TMS neuronavigation software. The intensity of the rTMS will be 100-120% of resting motor threshold amplitude, 1500 pulses applied consistently with a frequency of 1 Hz.
3474949|NCT03840382|Experimental|Tele-PrEP Intervention|The telemedicine intervention will allow participants to discuss HIV prevention and PrEP with PrEP specialists at an academic medical center via videoconference from their local community based organization (CBO). During the intervention, participants will gain information related to HIV and PrEP, view a video to improve motivation for engagement in PrEP related care, and receive resources to address barriers to care.
3474950|NCT03840473|Experimental|MET+ICT+Conventional intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by ICT (90-second hold-time) and MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
3474951|NCT03840473|Experimental|MET+Conventional Intervention|Hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) followed by MET (5-second hold-time, 3-second relaxation by exhalation while reaching the new barrier).
3474952|NCT03840473|Active Comparator|Conventional Intervention|Received hot packs (75°C) for 20 minutes and supervised active stretching exercises for upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions) only.
3126366|NCT03033745|Experimental|IgPro20 (Pump-Assisted Volume Cohort)|Weekly volumes per injection site of 25 mL up to 50 mL administered subcutaneously.
3126367|NCT03033745|Experimental|IgPro20 (Pump Assisted Flow Rate Cohort)|Weekly flow rates per injection site of 25 mL/hour up to 100 mL/hour administered subcutaneously.
3126368|NCT03033745|Experimental|IgPro20 (Manual Push Flow Rate Cohort)|Frequent (ie, 2 to 7 times per week) flow rates per injection site of 25 to 30 mL/hour up to 120 mL/hour (equivalent of approximately 0.5 mL/minute up to 2 mL/minute) administered subcutaneously.
3474953|NCT03840486|Active Comparator|Non-rebreather mask (NRBM)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-rebreather mask (NRBM) overlying the sensor. The participants will be randomized to the order of their treatment sequence as follows: oxygen at 15 LPM for 3 minutes, at 35 LPM for 3 minutes, or at flush rate (55 LPM) for 3 minutes. The maximal reading at the end of this will be recorded, then the study subjects will be allowed to rest until their EtO2 returns to their baseline. They will then be placed back on NRBM at flush rate, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
3474954|NCT03840486|Active Comparator|Non-invasive ventilator mask (NIV)|Prior to the start of the study procedure, a nasal cannula end-tidal oxygen (EtO2) sensor will be placed on the participant's face with the non-invasive ventilator mask (NIV) overlying the sensor. Participants will be randomized to the order of their treatment sequence as follows: NIV at 50% FiO2 for 3 minutes, NIV at 75% FiO2 for 3 minutes, NIV at 100% FiO2 for 3 minutes, the maximal reading at the end of this trial will be recorded. The study subjects will be allowed to rest until their EtO2 returns to their baseline, then they will be placed back on NIV at 100% FiO2, allowed to rise to the maximal reading of the previous step, then do a single breath exhaled EtO2 measurement.
3126369|NCT03033784|Experimental|Autism Spectrum Disorder (ASD)|Male participants diagnosed with ASD will receive 12 puffs (6 in each nostril) of intranasal oxytocin (syntocinon) and placebo (assigned randomly) during 4 study visits.
3126370|NCT03033784|Placebo Comparator|Healthy Control|Age matched healthy controls will receive placebo intranasal spray (12 puffs, 6 per nostril) during one study visit.
3474955|NCT03840304|Experimental|Yoga Group|Participants in the intervention group engaged in a 8-week yoga program delivered at their place of work (IT companies). Sessions were group-based, prescribed three sessions per week during break time (30-mins).
3474956|NCT03840304|No Intervention|Wait-list Group|Participants in Wait-List control were not given any intervention. 8-weeks, group followed usual break time.
3474957|NCT03840577|Placebo Comparator|Clinical monitoring group|In the clinical monitoring group, the doses of sedative drugs will be regulated according to the patient's RASS. The RASS of the patient will be evaluated twice per nursing shift (every 4 hours). The BIS monitor will be placed on the patient, but blind to the nursing team, with the objective to measure the BIS values.
3474958|NCT03840577|Experimental|BIS group|"In the group Sedation guided by BIS, the sedation will be guided by the value of BIS. The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.~According to the BIS value of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation."
3474959|NCT03840538|Experimental|Probiotic group|Probiotic complex capsule taken twice daily for 5weeks
3474960|NCT03840538|Placebo Comparator|Placebo group|Placebo capsule taken twice daily for 5 weeks
3474961|NCT03840330|Experimental|High-intensity interval training group|Frequency: 2 days/weeks; Intensity: 16-18 Börg/85-100%VO2max; Recovery: Active; Duration: 1 hour.
3474962|NCT03840330|Experimental|Moderate-intensity interval training group|Frequency: 2 days/weeks; Intensity: 12-14 Börg/60-70% VO2max; Recovery: Active; Duration: 1 hour.
3474963|NCT03840330|No Intervention|Control group|Maintain their normal daily activities throughout the sixteen-week experimental period.
3474964|NCT03840603|No Intervention|Control|Usual care of patients with suspected Low RespiratoryTract Infection at the discretion of the attending physician. Care may entail a CRP and/or a PCT measurement, but no nasopharyngeal swab sampling.
3474965|NCT03840603|Experimental|Film Array RP2 Assay guided|In the emergency room a nasopharyngeal swab sample will be collected from subjects with a suspected Low RespiratoryTract Infection for the Film Array RP2 Assay guided plus a blood sample for the PCT assay if the PCT measurement has not been already prescribed.
3126371|NCT03034018|Experimental|suvorexant|suvorexant 10-20 mg taken at bedtime for four weeks
3126372|NCT03034018|Placebo Comparator|placebo|placebo taken at bedtime for four weeks
3126373|NCT03034057|Other|sayana press|single arm
3126374|NCT03034135|Experimental|DSF-Cu|Disulfiram/copper (oral capsules) dosed 80 mg/1.5 mg three times a day for approximately 6 months.
3126375|NCT03034460|Experimental|CD5024 1% cream|Active drug;
3474966|NCT03840525|Experimental|Qigong Intervention|The qigong intervention consists of 1 hour/week qigong classes for 12 weeks at our community partner site. The first 2 weeks will include 2 hours/week classes. In addition, each participant will be instructed to practice qigong at home for 90 minutes.
3126376|NCT03034460|Placebo Comparator|CD5024 cream placebo|Placebo of active drug;
3126377|NCT03034460|Other|CD0271/CD1579 gel|Positive control;
3474967|NCT03840525|Sham Comparator|Sham Qigong|This group will also have 1 hour/weekly classes that include movements that are similar to qigong but will not include the meditation or breathwork that will be included in the actual qigong intervention arm.
3474968|NCT03840525|No Intervention|Treatment-as-usual|This group will receive no classes.
3474969|NCT03840512|Experimental|Oral CBD 75 BID|
3474970|NCT03840512|Experimental|Oral CBD 150 BID|
3474971|NCT03840512|Experimental|Oral CBD 300 BID|
3474972|NCT03840421|Experimental|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
3474973|NCT03840421|Active Comparator|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m² d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
3474974|NCT03840291|Experimental|Edoxaban treatment|"Men or women aged ≥ 20 years with NVAF patients who has LAA thrombi documented by transesophageal echocardiography (TEE) up to 72 hours prior to start of study medication are eligible.~Patients in this group are taking Lixiana® (Edoxaban) 60mg for resolution of left atrial appendage thrombi~Reduced (30mg) dose is administered in patients with one or more of the following clinical factors:~Moderate or severe renal impairment (creatinine clearance (CrCL) 15 - 50 mL/min)~Low body weight ≤ 60 kg~Concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporin,dronedarone, erythromycin, or ketoconazole."
3126378|NCT03034460|Other|CD0271/CD1579 gel placebo|Placebo of positive control;
3126379|NCT03034577|Active Comparator|ModNMB|"Moderate Neuromuscular block: participants will receive moderate neuromuscular blockade with rocuronium aiming for TOF 0-2 twitches, with neostigmine reversal when the TOF at least 3 twitches. The depth of neuromuscular block may be reduced after completion of the majority of surgical excision to TOF 3 or more~Neostigmine"
3474975|NCT03840590|Experimental|AI-assisted Colonoscopy|Participants in this arm undergo AI-assisted colonoscopy using CSK AI system.
3474976|NCT03840590|Active Comparator|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy.
3126380|NCT03034577|Active Comparator|DeepNB|Deep Neuromuscular block: participants will receive DNB aiming for a post tetanic count of 1-2, which will be maintained until removal of the laparoscopic ports, with reversal using sugammadex
3126381|NCT03034772|Active Comparator|Dorzolamide-timolol|Topical dorzolamide-timolol twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
3126382|NCT03034772|Placebo Comparator|Artificial tears|Topical artificial tears twice daily for the study duration. All patients will continue to receive intravitreal anti-VEGF injections at regularly scheduled intervals.
3474977|NCT03840395|Active Comparator|Active PES|Patients randomized to receive active Pharyngeal Electrical Stimulation (PES) via a Phagenyx Catheter.
3474978|NCT03840395|Sham Comparator|Sham PES|Patients randomized to sham will not receive any Pharyngeal Electrical Stimulation (PES) but will still have the Phagenyx Catheter inserted.
3474979|NCT03840564||Group point of care (POC)|All the analyzes will be done in delocalized
3474980|NCT03840564||control group|the analyzes will be done at the central laboratory
3474981|NCT03840356||Postoperative|The study will evaluate orthopedic postoperative patients during the hospitalization.
3474982|NCT03840434|Other|CCS group|Measurements by intramuscular punction and non invasive tool
3474983|NCT03840317|Experimental|Senl_1904A CD19 CAR-T|Autologous CD19-targeting CAR T cells, dosage 3*10^5/kg, intravenous injection once
3474984|NCT03840317|Experimental|Senl_1904B CD19 CAR-T|Autologous CD19-targeting CAR T cells,dosage 3*10^5/kg, intravenous injection once
3474985|NCT03840551|Other|Subjects|Subjects involved are required to do some specific motor tasks, commonly found in all main sports. Evaluated with inertial sensors (XSENS) and marker-based motion capture (BTS)
3474986|NCT03840447|Experimental|Chronic Disease Self-Management programme|
3474987|NCT03840499||Willing to participate in clinical study|
3474988|NCT03840499||Not-willing to participate in clinical study|
3474989|NCT03840408|Experimental|Mitochondrial therapy with radiofrequency ablation|
3474990|NCT03840408|Active Comparator|Surgery|
3474991|NCT03840265|Other|Carotid endarterectomy|All patients in this study will undergo carotid endarterectomy procedure
3474992|NCT03840343|Experimental|Lower Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Lower Dose.
3474993|NCT03840343|Experimental|Higher Dose MSC|This arm will receive autologous adipose-derived Mesenchymal stem/stromal cells (MSC) Higher Dose
3474994|NCT03840109||All Participants|All participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. The participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
3474995|NCT03839927||Evaluation Group|Survey Application
3474996|NCT03840031|Experimental|Orange Fleshed Sweet Potato High Iron|Meal sequence B, OFSP High Fe
3474997|NCT03840031|Active Comparator|Orange Fleshed Sweet Potato Control|Meal sequence A, OFSP control
3474998|NCT03839875|Experimental|Active Treatment|
3474999|NCT03840018|No Intervention|Control|Sending doctors the lists of patients that meet the inclusion criteria to have their treatment reviewed
3475000|NCT03840018|Other|Letter by post to patients|Patients were sent a letter explaining the risks of using PPIs at long-term high doses and encouraging them to visit their doctor
3475001|NCT03840239|Experimental|TNT arm|"Drug: Neoadjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles; adjuvant chemotherapy, Capecitabine, 2 cycles or physicians' decision.~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
3475002|NCT03840239|Active Comparator|CRT arm|"Drug: Neoadjuvant chemotherapy, Capecitabine, 5 weeks; adjuvant chemotherapy Capeox (Capecitabine + Oxaliplatin), 6 cycles.~External beam radiotherapy: Neoadjuvant, 50 Gy, 2 Gy/session; 25 fractions. Procedure: 'Watch and wait strategy' or surgery including local excision, intersphincter resection or total mesorectal excision or other kinds of surgeries."
3475003|NCT03840122|Experimental|A - ACB + IPACK with injection|50 arms: ACB + IPACK block with injection of local anesthetic of Ropivacaine, Epinephrine, Ketorolac, Clonidine and saline
3475004|NCT03840122|Active Comparator|B - ACB + IPACK without injection|50 arms: ACB + IPACK block without injection of local anesthetic
3126383|NCT03034915|Experimental|UMEC/VI 62.5/25 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC/VI 62.5/25 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
3475005|NCT03839888|Experimental|0.125% atropine group|patients used the 0.125 % atropine eyedrop every night before sleep for 7 days
3475006|NCT03840226|Active Comparator|Magnesium|oral magnesium oxide tablets [Magnox 520 TM (magnesium oxide monohydrate, 520 mg/day of elemental magnesium), Naveh Pharma, Israel]
3126384|NCT03034915|Experimental|UMEC 62.5 mcg via ELLIPTA + placebo via DISKUS|Subjects will be instructed to self-administer one dose of UMEC 62.5 mcg inhalation powder each morning via ELLIPTA DPI and placebo twice daily (morning and evening) via DISKUS DPI.
3126385|NCT03034915|Experimental|Salmeterol 50 mcg via DISKUS + placebo via ELLIPTA|Subjects will be instructed to self-administer one dose of salmeterol 50 mcg twice daily (morning and evening) via DISKUS DPI and placebo once daily morning via ELLIPTA DPI.
3475007|NCT03840226|Placebo Comparator|Placebo|Placebo tablets
3475008|NCT03839953|Active Comparator|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
3475009|NCT03839953|Experimental|Supervised Exercise Program|Patients will receive best medical therapy plus participation in a 12-week supervised exercise program.
3475010|NCT03840057|Experimental|Azithromycin|Participants randomized to the azithromycin arm would receive 250mL of reconstituted solution containing 500mg of generic azithromycin to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic or renal impairment. No dose adjustment is made for geriatric population.
3475011|NCT03840057|Experimental|Metoclopramide|Participants randomized to the metoclopramide arm would receive 2mL of solution containing 10mg of generic metoclopramide to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy. No dosage adjustment is made for those with hepatic impairment. A 50% dose reduction is made for those with creatinine clearance of less than 40mL/minute. No dose adjustment is made for geriatric population.
3475012|NCT03840057|Placebo Comparator|Placebo|Participants randomized to the placebo arm during Part 1 (azithromycin) of the study would receive 250mL of 0.9% sodium chloride solution to be administered as a slow intravenous infusion over 1 hour by the primary team 30-120 minutes prior to endoscopy. Participants randomized to the placebo arm during Part 2 (metoclopramide) of the current study would receive 2mL of 0.9% sodium chloride solution to be administered as a direct intravenous push by the primary team 5-60 minutes prior to endoscopy.
3126386|NCT03034928|Other|Test 1/Control 1, then Control 2/Test 2|Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
3126387|NCT03034928|Other|Test 2/Control 2, then Control 1/Test 1|Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
3475013|NCT03840044|Other|Healthy volunteers|Healthy volunteers will perform the same protocol as foreseen for asthmatic patients. Both will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
3475014|NCT03840044|Other|Asthmatic subjects|Asthmatic patients will perform the same protocol as foreseen for healthy volunteers. They will perform the cold air exercise test with pre -and post-exposure evaluation of on FEV1, respiratory symptoms, functional airway integrity, local and systemic inflammation and on the airway microbiome.
3475015|NCT03839901|Experimental|isometric training programme|'Home exercise programme' consisting of isometric exercises with participants followed up at week 1, 4, 6 and 8.
3475016|NCT03839901|Experimental|isotonic training programme|'Home exercise programme' consisting of isotonic exercises with participants followed up at week 1, 4, 6 and 8.
3126388|NCT03034928|Other|Control 1/Test 1, then Test 2/Control 2|Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
3126389|NCT03034928|Other|Control 2/Test 2, then Test 1/Control 1|Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
3126390|NCT03034954|Active Comparator|Active HD-tDCS|"Participants will receive real HD-tDCS (3 milliamps for 20 minutes) for a single session."
3126391|NCT03034954|Sham Comparator|Sham HD-tDCS|Participants will undergo the exact same procedures as the active group but will receive sham stimulation for a single session.
3126392|NCT03034967|Experimental|Danirixin 5 mg|Eligible participants will receive danirixin 5 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
3126393|NCT03034967|Experimental|Danirixin 10 mg|Eligible participants will receive danirixin 10 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
3475017|NCT03840083|Experimental|Sleep|Individuals will either nap (Exps 1, 4) or have overnight sleep (Exps 2, 3, 5, 6)
3475018|NCT03840083|No Intervention|Wake|Individuals will stay awake for the same amount of time as they slept in the sleep condition
3475019|NCT03839914|Active Comparator|Intervention - Vancomycin|Intervention: 1g vancomycin powder locally applied to the deep wound and subcutaneous layer prior to closure.
3475020|NCT03839914|No Intervention|Control - No vancomycin application|No intervention, control group All other wound closure procedure and wound care and monitoring are the same
3475021|NCT03839862||Responder|Patient responding to TNF-inhibition
3475022|NCT03839862||non-Responder|Patient not responding to TNF-inhibition
3475023|NCT03840096|Experimental|Quadriceps NMES using Breg Flex|
3475024|NCT03840096|No Intervention|Control|
3475025|NCT03840252|Active Comparator|PD patients: Parkinson's disease group|"Diagnosis of idiopathic PD by United Kingdom Brain Bank criteria, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Movement Disorder Society (MDS)-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
3475026|NCT03840252|Active Comparator|PSP patients|"Application of the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of probable PSP, evaluation of PSP rating scale, exclusion of other significant neurological or orthopedic problems; ages of 21-90; able to walk 25 feet unassisted and without any assistive device.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis;MDS-UPDRS Behavioral: PD-MCI-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
3475027|NCT03840252|Active Comparator|HC: healthy control group|"Healthy adults ages 21-90 without movement disorders, psychiatric disorders, or dementia.~Imaging: rsfMRI, diffusion tensor imaging; Motor evaluation: 3D gait analysis; Behavioral: PD-Mild Cognitive Impairment (MCI)-specific Level II battery (Mov Dis. 2015 Mar; 30(3): 402-406)"
3475028|NCT03839966|Experimental|Active Treatment|Interpretation Bias Modification for Loneliness
3475029|NCT03839966|Active Comparator|Control Treatment|Healthy Habits Psychoeducation and Relaxation.
3475030|NCT03839797|Experimental|Cadet Healthy Personal Skills|Cadet Healthy Personal Skills
3475031|NCT03839797|Active Comparator|Standard Health Education|Standard Health Education
3126394|NCT03034967|Experimental|Danirixin 25 mg|Eligible participants will receive danirixin 25 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
3126395|NCT03034967|Experimental|Danirixin 35 mg|Eligible participants will receive danirixin 35 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
3126396|NCT03034967|Experimental|Danirixin 50 mg|Eligible participants will receive danirixin 50 mg tablet with food twice daily along with standard care of treatment for 24 weeks.
3126397|NCT03034967|Placebo Comparator|Placebo|Eligible participants will receive placebo tablet with food twice daily along with standard care of treatment for 24 weeks.
3126398|NCT03035032|Experimental|Leuprolide Acetate 22.5 milligrams (mg)|Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
3126399|NCT03035318|Active Comparator|DePuy Global® Anchor Peg Glenoid|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Glenoid Instrumentation to position the glenoid component.
3126400|NCT03035318|Experimental|DePuy Instrumentation with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses DePuy Global® Anchor Peg Instrumentation with SmartBone™, to position the glenoid component.
3126401|NCT03035318|Experimental|IRI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBone™, to position the glenoid component.
3126402|NCT03035318|Experimental|RTI with SmartBone™|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses Real Time Instrumentation (RTI), with a SmartBone™, to position the glenoid component.
3126403|NCT03035318|Experimental|IRI with SmartBase|In the setting of Anatomic Total Shoulder Arthroplasty, this arm uses an Intelligent Reusable Instrumentation (IRI), with a SmartBase™, to position the glenoid component.
3126404|NCT03035487|Experimental|Micro-ultrasound|"Transrectal micro-ultrasound guided prostate biopsy, where images will be compared with images from standard of care modalities:~Low resolution transrectal ultrasound examination (LR-TRUS)~Multi-parametric MRI (mpMRI) examination performed according to the PI-RADS v2 protocol"
3126405|NCT03035708|Experimental|varenicline|1 mg BID (2 capsules BID)
3126406|NCT03035708|Placebo Comparator|Placebo|1 mg BID (2 capsules BID)
3126407|NCT03035760|Experimental|1|3 mg/kg orally once daily for 5 days (n = 8)
3126408|NCT03035760|Experimental|2|7.5 mg/kg orally once daily for 5 days (n = 8)
3126409|NCT03035760|Experimental|3|15 mg/kg orally once daily for 5 days (n = 8)
3475032|NCT03839836|No Intervention|Baseline|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack without the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
3475033|NCT03839836|Experimental|5% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 5%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
3475034|NCT03839836|Experimental|10% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 10%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
3475035|NCT03839836|Experimental|15% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 15%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
3475036|NCT03839836|Experimental|20% child's body weight|Children between six and 12 years, no pain in the lower limb and back at the time of examination using a backpack load was added to the BPs 20%, of the child's body weight, the spatio-temporal parameters are measured with the OptoGait® system
3475037|NCT03839849|Experimental|i-PRF (Test)|injected subgingivally i-PRF after scaling and root planing
3475038|NCT03839849|Active Comparator|saline (Control)|injected subgingivally saline after scaling and root planing
3475039|NCT03839706|Experimental|PET MRI Arm|Patient enrolled in the study will have a PET MRI exam scheduled before transplant
3475040|NCT03840200|Experimental|Ipatasertib + Rucaparib|A Dose-Escalation Phase (Part 1) in participants with previously treated advanced breast cancer, ovarian cancer, or prostate cancer. There will be a 7-day run-in period with ipatasertib alone prior to Cycle 1, Day 1. After the completion of the ipatasertib run-in period, participants will begin Cycle 1, Day 1 of the ipatasertib and rucaparib combination treatment. Each cycle has 28 days. Participants will be split into 4 cohorts: Dose Level 1 group - 300 mg ipatasertib once daily (QD) + 400 mg rucaparib twice daily (BID), Dose Level 2a: 300 mg ipatasertib QD + 600 mg rucaparib BID, Dose Level 2b: 400 mg ipatasertib QD + 400 mg rucaparib BID, Dose Level 3: 400 mg ipatasertib QD + 600 mg rucaparib BID
3475041|NCT03840200|Experimental|Part 2: Ipatasertib + Rucaparib|A Dose-Expansion Phase (Part 2) - The recommended dose identified in Part 1 (highest dose level of ipatasertib and rucaparib with an acceptable safety profile and less than one-third of participants experience a dose limiting toxicity) will be evaluated in participants with advanced prostate cancer who have had at least one line of prior therapy with second-generation androgen-receptor (AR)-targeted agents (e.g., abiraterone, enzalutamide, apalutamide).
3475042|NCT03840070|Experimental|Potenfill|
3475043|NCT03839654|Experimental|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
3475044|NCT03839654|No Intervention|non-continuous positive airway pressure|The non-CPAP treatment group received baseline medicine treatment without CPAP treatment.
3475045|NCT03839693|Placebo Comparator|Vehicle|Vehicle
3475046|NCT03839693|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
3475047|NCT03839693|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
3475048|NCT03839719|Experimental|Group OC|"Ocimum sanctum (OC) is a natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is also listed by the U.S. FDA as an herb Generally Recognized As Safe (GRAS) for its intended use as a therapeutic herb. Pharmacological constitutes present in the extract are eugenol, Urosolic acid, Carvacrol, linalool , limatrol, caryophyllene, and methyl carvicol. The literature showed that Ocimum sanctum extract has significant anti-gingivitis and anti-inflammatory effect as mouthrinse.~Other Names:~Tulsi Holy Basil"
3475049|NCT03839719|Active Comparator|Group CHX|"Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in a variety of oral disorders in various formulations.~As an antimicrobial agent, chlorhexidine is effective in vitro against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes and yeasts and fungi. The digluconate of chlorhexidine (1:6Di 4' chlorophenyl-diguani-dohexane) is a synthetic antimicrobial drug which has been widely used as a broad spectrum antiseptic.~Other Names:~Chlorhexidine"
3475050|NCT03839719|Placebo Comparator|Group PI|"Group PI: Placebo (Distilled water) as the mouthrinse.~Placebo (Distilled water) 10 ml is used as mouthrinse. Distilled water is commonly used as an excipient in a variety of drugs and it is also widely used as a placebo.~Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.~Treatment was carried out by placing 03 sterile agar plates uncovered at pre-designated sites to collect samples of aerosolized bacteria."
3475051|NCT03839615|Active Comparator|guided bone regeneration using ptfe|"Augmented anterior maxillary bone ridge using ptfe with 1:1 autogenous bone and xenograft mixture~Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a ptfe membrane which will be stabilized by tacks."
3475052|NCT03839615|Experimental|collagen membrane|"Local anesthesia will be given to the patient. intervention:~Flap will be done.~In the group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks."
3475053|NCT03839628|Experimental|Reduced Physical Activity|Participants will reduce their physical activity levels for 2-weeks by approximately 75% of their baseline level of physical activity
3475054|NCT03839576|Experimental|Computerized cognitive training|The computerized cognitive training will take place at each participant's residence. Participants will be asked to practice at least 1 session a day for 6 months, and a session lasts for 60 minutes.
3475055|NCT03839576|Experimental|Lower extremity strengthening|"This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months.~Each session will last 60 min."
3475056|NCT03839576|Experimental|Tai chi chuan|The 8-form Yang-style tai chi intervention will take place at a subject's residence or the neighborhood once a week for 6 months, and each session will last for 60 minutes.
3126410|NCT03035760|Experimental|4|3 mg/kg orally, one dose received following a fast (n=6) or high fat meal (n=6) on Day 1 and crossed over to opposite arm to receive drug following high fat meal or fast on Day 8
3126411|NCT03035864|Experimental|rhNGF 20 µg/ml|Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily
3475057|NCT03839576|No Intervention|Social interaction|Immediately after the baseline assessment, the care manager will visit the subject in this group once for comparability with the other two intervention groups.
3475058|NCT03839979||HCV positive patients|Patients tested positive for the hepatitis c virus antibodies by BIOLINE HCV kits.
3475059|NCT03839979||HCV negative patients|Patients tested negative for the hepatitis c virus antibodies by BIOLINE HCV kits.
3475060|NCT03839667|Experimental|intensive diet intervention group|The participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
3475061|NCT03839667|Experimental|Enhanced physical activity group|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
3475062|NCT03839667|Experimental|Standard education group|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
3475063|NCT03839758|Active Comparator|TSA Standard|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
3126412|NCT03035864|Placebo Comparator|Vehicle|Vehicle eye drops six times daily
3126413|NCT03035916|Experimental|Transversus abdominis plane block|The TAP group receives ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia.
3126414|NCT03035916|Active Comparator|Epidural anesthesia|The Epidural group receives epidural block (T8-9) 2 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
3126415|NCT03035916|Placebo Comparator|Control|The Control group receives standard IV-inhaled general anesthesia.
3475064|NCT03839758|Active Comparator|RTSA standard|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done following surgeon evaluation of the 2D CT scan with the institution software. Generic guides included in the regular instrumentation set will be used
3475065|NCT03839758|Experimental|TSA blueprint|This group will include patients schedule for a total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
3475066|NCT03839758|Experimental|RTSA blueprint|This group will include patients schedule for a reverse total shoulder arthroplasty. Glenoid preparation will be done using the personalized guide provided by Wright-Tornier. This guide will be ordered after CT-scan measurement, using Blueprint software prior to surgery.
3475067|NCT03839771|Placebo Comparator|Arm A: Placebo|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for Placebo for AG-120 (IDH1): 500 mg dose/day~The dosage for Placebo for AG-221 (IDH2): 100mg dose/day"
3475068|NCT03839771|Experimental|Arm B: Ivosidenib (IDH1) or Enasidenib (IDH2)|"Cycle 1: day 1-start cycle 2 | Cycle 2: day 1 - start consolidation treatment | Consolidation treatment: day 1 - start maintenance | Maintenance treatment: day 1- day 730 (2 years) |~The dosage for AG-120 (IDH1): 500 mg dose/day~The dosage for AG-221 (IDH2): 100mg dose/day"
3475069|NCT03839589|Experimental|MBSR-A|Intervention Mindfulness Condition: MBSR is a structured intervention delivered through an 8-week course. Mindful breathing, awareness, walking, and attention are core activities taught and practiced during and outside of the course.
3475070|NCT03839589|Placebo Comparator|Wait-listed MBSR-A|The MBSR-A Wait-listed group: This wait-listed group will be followed with the same outcome assessments as the MBSR- A immediate group but will receive no intervention until after outcomes from group 1 are collected at 3 months, when they will also receive the MBSR-A
3475071|NCT03839732||Vascular Calcification Group|Patients with prevalent vascular calcifications will be analysed to verify the intra- and inter-observer reliability of the score of abdominal aorta calcifications
3475072|NCT03840213||Patients undergoing chemotherapy treatment|Patients over 18 years of age, followed at the ICLN day hospital or hospitalized and undergoing chemotherapy treatment
3475073|NCT03839784||Neurocognitive Assessment Arm|
3475074|NCT03839940|Experimental|Group I (dexamethasone)|Patients receive 10mg oral everolimus daily as standard of care and 10ml dexamethasone oral mouthwash, swished for 2-minutes daily, for 8 weeks.
3475075|NCT03839940|Placebo Comparator|Group II (placebo)|Patients receive 10mg oral everolimus daily as standard of care and 10ml placebo oral mouthwash, swished for 2-minutes daily, for 8 weeks.
3475076|NCT03839602|Experimental|reducing CTV|The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTV was divided into CTV1 (high risk) and CTV2 (low risk) according to the biological behavior and characteristics of early-stage NPC. The prescribe doses of GTVnx, GTVnd, CTV1 and CTV2 were 68Gy, 60-66Gy, 60Gy and 50-54Gy in 30 fractions, respectively.
3126416|NCT03035929|Experimental|Healthy|"10 Healthy subjects will undergo study procedures at four study visits.~All subjects will undergo the same procedures and interventions."
3475077|NCT03839810|Experimental|stochastic resonance|stochastic resonance electrical stimulation is applied to the upper extremity during the subjects perform upper extremity motor function.
3475078|NCT03839810|Sham Comparator|sham stimulation|sham electrical stimulation (same electrode location, but no electrical current is applied) is applied to the upper extremity during the subjects perform upper extremity motor function.
3475079|NCT03839563|Experimental|Conventional exercise|This exercise will comprise stretching, muscle strengthening, and balance training at increasing difficulty levels, tailored and supervised by a physical therapist, and will take place at a subject's residence or in the neighborhood once a week for 6 months. Each session will last 60 min.
3475080|NCT03839563|Experimental|Tai chi chuan|The 8-form Yang-style tai chi chuan intervention will take place at a subject's residence or in the neighborhood once a week for 6 months, and each session will last 60 min.
3126417|NCT03035942|Experimental|D Group|Dexamethasone 8 mg
3126418|NCT03035942|Experimental|O group|Ondansetron 4 mg
3475081|NCT03839563|No Intervention|Health education/usual physical activity|After the baseline, the case manager will visit subjects in this group once for comparability with the other two intervention groups and instruct them to maintain their usual physical activity.
3475082|NCT03839550|Experimental|Apatinib Mesylate +SHR-1210|Experimental arm: Apatinib mesylate +PD-1 antibody SHR-1210 for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
3475083|NCT03839550|Active Comparator|Hepatic Arterial Infusion(HAI)|Active Comparator arm: HAI for adjuvant therapy of HCC with high incidence of tumor recurrence after hepatic resection
3475084|NCT03839498|Experimental|Axitinib (AG-013736)|Subjects with Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma will receive 16 weeks of therapy (Axitinib), and be seen in clinic every 4 weeks to monitor therapy.
3475085|NCT03839524|Experimental|TG4050 arm|Patients in this arm will receive injections of TG4050 Investigational Medicinal Product.
3475086|NCT03839485|Active Comparator|Pasta Guedes-Pinto|Endodontic treatment using Guedes-Pinto Paste
3126419|NCT03035942|Placebo Comparator|S group|Normal saline (5 mL total volume)
3475087|NCT03839485|Experimental|Pasta Guedes-Pinto without antibiotic|Endodontic using Guedes-Pinto paste without antibiotic
3475088|NCT03839420|Experimental|CZM IOL|
3475089|NCT03839420|Active Comparator|Competitor IOL|
3475090|NCT03839251|Other|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
3475091|NCT03839342|Experimental|Binimetinib + Encorafenib|Binimetinib and encorafenib are administered orally on a twice daily or once daily schedule, respectively in 28-day cycles. Treatment will continue until it is discontinued due to unacceptable toxicity, clinical or radiological disease progression as per RECIST 1.1, investigator decision, and/or withdrawal of consent.
3475092|NCT03839459|Experimental|Denosumab|
3475093|NCT03839329|Experimental|ACT Group Condition|The ACT group condition will receive two 90-minute group Acceptance and Commitment Training (ACT) workshops (scheduled approximately one week apart) and will complete assessments.
3475094|NCT03839329|No Intervention|Assessment-Only Condition|The Assessment-only condition will not receive any intervention and will only complete assessments.
3475095|NCT03839394|Experimental|Educational pamphlets + telephone|
3475096|NCT03839394|Active Comparator|Educational pamphlets|
3475097|NCT03839407|Experimental|MUSE device Class 21|Participants will utilize the MUSE device for 12 weeks during the intervention period.
3126420|NCT03035955|Active Comparator|Azelaic acid|azelaic acid (Finacea® Gel, 15%) twice daily on either the left side or the right side of the face and no treatment on the other side of the face
3126421|NCT03035955|No Intervention|no treatment|no treatment on the other side of the face
3126422|NCT03036072|Active Comparator|Strict Normothermia|Patients will be rewarmed to 36.5 degrees centigrade in the operating room and maintained here by conventional means in the PICU.
3475098|NCT03839407|No Intervention|No MUSE device Class 21|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
3475099|NCT03839407|Experimental|MUSE device Class 22|Participants will utilize the MUSE device for 12 weeks during the intervention period.
3475100|NCT03839407|No Intervention|No MUSE device Class 22|Participants will not utilize the MUSE device for 12 weeks during the non-intervention period.
3475101|NCT03839264||Graft stenosis and thrombosis|Diagnostic performance for stenosis at angiography of non invasive screening tools (duplex ultrasound, access blood flow (Qa), dynamic and static dialysis machine venous pressures, dynamic dialysis machine arterial pressure, and monitoring) and incipient thrombosis (within 4-month period) of the presence and degree of stenosis at angiography, non invasive screening techniques and acute hypotensive episode/s during the follow-up
3475102|NCT03839108|Active Comparator|Paraffin wax group|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
3475103|NCT03839108|Experimental|Prolotherapy group|"Drug = prolotherapy (%15 dextrose solution) into hand joints~%15 dextrose solution will be injected into medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period."
3475104|NCT03839147|Experimental|Education and Counseling|After obtaining written informed consent, the data collection form, Spielberger State Anxiety Scale and visual analogue scale scoring scale were applied to both groups by face to face interview during the day giving appointment for hysterosalpingography. Immediately after the questionnaires were applied, the nurse gave individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. This education consisted of the definition and the purpose of hysterosalpingography, when and how it was applied, in what cases it was applied, whether it was a painful procedure, possible side effects and additional benefits of infertility treatment
3475105|NCT03839147|No Intervention|Control group|Participants in the control group received standard care (verbal information about procedure and a short written information about the procedure) and no intervention (education and counseling) was performed. Both groups were re-evaluated using the same scales after the hysterosalpingography. Within 5 minutes of completing the hysterosalpingography procedure, participants were asked to evaluate their pain in order to characterize pain intensity using the visual analogue scale .
3475106|NCT03839225|Other|Children, Adolescents and Adults|children, adolescents and adults who have been victims of the armed conflict in the municipalities of Soacha-Cundimanarca (Colombia)
3475107|NCT03839173|No Intervention|Retrospective Chart Review|Retrospective Chart Review for historical controls. Historic controls fed cow's milk fortifier
3475108|NCT03839173|Experimental|Prospective|"All neonates with birth weights ranging from 750-1500 grams and gestational ages 23-33 weeks admitted to the NICU at Augusta University within 24 hours of life will be eligible for screening within 72 hours of admission and upon parent's or legal guardian's consent.~Infants will be fed a human milk fortifier made with donor human milk. Data will be compared with historic control data."
3475109|NCT03839160|Active Comparator|SAPB group. Group S|In this group, serratus anterior plane block (SAPB) was performed before extubation with injection of 30 ml of 0.25% bupivacaine hydrochloride followed by 0.1ml/kg/hr of 0.12% bupivacaine hydrochloride. In addition to SAPB, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
3475110|NCT03839160|Placebo Comparator|Control group. Group C|In this group, intravenous patient-controlled-analgesia morphine was used. Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
3475111|NCT03839121||single arm: CRT-DX|
3475112|NCT03839134|Experimental|Pain of buccal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) buccal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
3475113|NCT03839134|Active Comparator|Pain of buccal injection without DentalVibe®|Local anesthesia (LA) for buccal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
3475114|NCT03839134|Experimental|Pain of palatal injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) palatal injection. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
3475115|NCT03839134|Active Comparator|Pain of palatal injection without DentalVibe®|Local anesthesia (LA) for palatal infiltration using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
3475116|NCT03839134|Experimental|Pain of block injection with DentalVibe®|DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
3475117|NCT03839134|Active Comparator|Pain of block injection without DentalVibe®|Local anesthesia (LA) injection for inferior alveolar nerve (IAN) block using Lidocaine Epinephrine dental injection. No tissue vibrations will be performed before or during the injection.
3126423|NCT03036072|Experimental|Delayed Rewarming|Patient will be rewarmed to 35.0 degrees centigrade in the operating room, then slowly rewarmed to normal physiologic temperature over 12 hours by using a servo-controlled cooling blanket. Normothermia will be maintained by the cooling blanket for an additional 12 hours.
3126424|NCT03036124|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
3475118|NCT03839316|Active Comparator|tDCS group|"Sixteen stroke patient receiving bihemispheric tDCS in addition to a conventional physiotherapy (PT) and occupational therapy (OT) program for five consecutive days per week for a three week period (a total of fifteen sessions).~The one hour long conventional PT sessions will include an upper extremity range of motion, strengthening and neurofacilitation exercise program. The one hour long OT sessions will include task specific exercises chosen according to the patient's functional status, including activities aimed at improving gross and fine motor function of the upper extremities.~The tDCS application will be applied at the beginning of each OT session and will be continued for a total of thirty minutes at 2 mA."
3475119|NCT03839316|Sham Comparator|Sham group|Sixteen stroke patient receiving a conventional PT and OT program and sham tDCS for 5 consecutive days per week for a 3 week period ( a total of 15 sessions). The one hour long conventional PT and OT sessions will be the same as in the tDCS group. For sham tDCS, electrode application and positioning will be the same as the intervention group and will be applied at the beginning of each OT session as previously described. The current will initially be increased up to 2 mA, so to provide the typical initial tingling sensation, and slowly decreased over 30 seconds and consequently switched off. The electrodes will be removed after a total of thirty minutes.
3475120|NCT03839290||Bilateral cleft lip and palate patients|Newborns with complete bilateral cleft lip and palate (cBCLP) and bilateral cleft lip and palate with tissue bridges (BCLP + B) analyzed one year after neonatal cheiloplasty
3475121|NCT03839290||Unilateral cleft lip and palate patients|Newborns with complete unilateral cleft lip and palate (cUCLP) and unilateral cleft lip and palate with tissue bridges (UCLP + B) analyzed one year after neonatal cheiloplasty
3475122|NCT03839446|Experimental|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6
3475123|NCT03839368|Experimental|K plate|fixation of angle fracture using K plate versus two miniplates
3475124|NCT03839368|Active Comparator|Conventional two miniplates|fixation of angle fracture using K plate versus two miniplates
3475125|NCT03839303|Experimental|Mini Implant Supported Appliance|this group will receive an Infra-zygomatic Mini Implant Supported Appliance after leveling and alignment of the four upper incisors for 8 months or till class I canine or incisors realation is reached with follow up every month
3475126|NCT03839303|Active Comparator|Headgear|this group will receive a high pull headgear appliance attached to a removable acrylic maxillary splint for 8 months or till class I canine or incisors realation is reached with follow up every month
3475127|NCT03839433|Active Comparator|ciclesonide positive|"Half of the Mannitol positive patients were given ciclesonide. Half of the Mannitol negative patients were given ciclesonide. All patients in the ciclesonide positive arm received ciclesonide."
3475128|NCT03839433|Placebo Comparator|Placebo|"Half of the Mannitol positive patients were given a placebo. Half of the Mannitol negative patients were given a placebo. All patients in the placebo arm received placebo."
3475129|NCT03839277|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
3475130|NCT03839277|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
3475131|NCT03839082|Active Comparator|Usual Care then FitBit|This is the waitlist control arm.
3475132|NCT03839082|Experimental|FitBit then Usual Care|Intervention includes education, physical activity, and a nutrition assessment.
3475133|NCT03838965|Experimental|biobeat sensor|
3475134|NCT03838900||Cohort A|Individuals who have not started Loop or who have been on Loop fewer than 7 days at the time of enrollment.
3475135|NCT03838900||Cohort B|Participants who have been using Loop 7 or more days at the time of enrollment.
3475136|NCT03839017|Experimental|Digital cognitive aid|The leader uses a digital cognitive aid designed as a smartphone app during advanced combat casualty care. Intervention: Device: SIMMAXMARCHERYAN2 Digital cognitive aid during the management of simulated war wounded.
3475137|NCT03839017|Experimental|Without digital cognitive aid|The leader practices advanced combat casualty care without the digital cognitive aid designed as a smartphone app. Intervention: Device: SIMMAXMARCHERYAN2 Without digital cognitive aid during the management of simulated war wounded.
3475138|NCT03838848|Experimental|Safety cohort KN046 3mg|Subjects with Non-small Cell Lung Cancer (NSCLC) (failed or did not tolerant to platinum-containing regime and did not treat with programmed cell death protein 1/the programmed death-ligand 1 (PD1/PDL-1) checkpoint inhibitor previously) will receive KN046 3 milligram per kilogram (mg/kg), every other weeks (Q2W)
3475139|NCT03838848|Experimental|Safety cohort KN046 5mg|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and did not treat with PD1/PDL-1 checkpoint inhibitor previously) will receive KN046 5 mg/kg, Q2W
3475140|NCT03838848|Experimental|Efficacy cohort KN046|Subjects with NSCLC (failed or did not tolerant to platinum-containing regime and failed to PD1/PDL-1 checkpoint inhibitor) will receive KN046
3475141|NCT03839238|Experimental|Meniscus Injured patients|hESC Derived MSC Like Cell
3475142|NCT03838822|Experimental|Intervention|Oral administration of cofactors, 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
3475143|NCT03838913||IPNB|intraductal papillary neoplasm of the bile duct
3475144|NCT03838926|Experimental|Trichostatin A|
3475145|NCT03838991|Experimental|Monostotic fibrous dysplasia|Patients with monostotic Fibrous dysplasia.
3475146|NCT03838991|Experimental|Polyostotic fibrous dysplasia|Patients with polyostotic Fibrous dysplasia.
3475147|NCT03838991|Active Comparator|Controls|Control patients having a scheduled surgery for osteoarthritis.
3475148|NCT03838783|No Intervention|Usual CSII|Continue to use the established CSII insulin therapy
3475149|NCT03838783|Experimental|Untethered CSII|Basal dosing - total CSII basal dose will be delivered by 50% through continuing CSII therapy used prior to study enrollment and 50% through the addition of once daily insulin degludec injected in the morning; Bolus dosing - continue the established bolus insulin dose
3475150|NCT03838809|Experimental|INTERVENTION|A group that underwent a neurological physiotherapy program with electromyography-biofeedback on the hand and the foot
3475151|NCT03838809|Active Comparator|CONTROL|A group that underwent a conventional physiotheraphy intervention
3475152|NCT03838796|Active Comparator|lenvatinib|use lenvatinib after liver resection in HCC patients
3475153|NCT03838796|Active Comparator|lenvatinib and TACE|use lenvatinib and TACE after liver resection in HCC patients
3475154|NCT03838952|Experimental|Chinese herbal medicine group|drug for the subjects
3475155|NCT03838835|Experimental|Equine-facilitated group therapy|
3475156|NCT03838835|Experimental|Augmented equine-facilitated CBT group program|
3475157|NCT03838835|Other|Wait List Control (WLC)|
3475158|NCT03839004|Experimental|Intervention group|200 woman with single spontaneous pregnancies who recieve, as well as traditional obstetrical care, yoga classes, myndfulness classes, coaching, nutrition counselling and osteopathic treatment
3475159|NCT03839004|No Intervention|Controls|200 woman with single spontaneous pregnancies recieving traditional obstetrical care
3475160|NCT03839069|Experimental|Minor Salivary Gland Transplantation|Cicatrizing conjunctivitis patients that received minor salivary gland transplantation for dry eye treatment.
3475161|NCT03839043|Experimental|"Quit for a bit"|"Brief behavioral intervention (~5 min) that focus on quitting smoking from the morning of surgery until one week after surgery + Quit for a bit SMS program."
3475162|NCT03839043|Active Comparator|"Quit for good"|"Brief behavioral intervention (~5 min) that focus on quitting smoking permanently for as long as possible + Quit for good SMS program."
3475163|NCT03839030|Experimental|MBHP-Educa|Experimental: Intervention Group A novel Mindfulness-based Health Promotion program for Educators for active teachers will be employed. The intervention will be held once a week for 8-weeks, two-hour meetings (16.0-h total). Participants will be encouraged to meditate for 10-30 min/day via audio recording.
3475164|NCT03839030|No Intervention|Control Group|Control Group Teacher education as usual. These participants will participate in teacher training (Neuroscience for Education - Neuro Educa). The Neuro-Educa will be held once a week for 8-weeks, two-hour meetings (16.0-h total).
3475165|NCT03838887||control group|"Pregnant women:~Age between 18-35 years~Parity: primigravidas and multiparas.~Have no history of preeclampsia or eclampsia.~Have no history of chronic hypertension.~Not diabetic.~Not have antiphospholipid syndrome.~Not have autoimmune disease such as SLE"
3475166|NCT03838887||High risk group|"Pregnant women with:~History of preeclampsia -Eclapmsia~Chronic hypertension~Diabetic~Antiphospholipid syndrome.~Autoimmune syndrome such as SLE."
3475167|NCT03839056||IC+PIEB+PCEA high flow|Continuous Epidural Infusion to 3ml/h more Programed Intermittent Epidural Boluses of 7ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
3475168|NCT03839056||PIEB+PCEA high flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of high flow as clinical practice routine
3475169|NCT03839056||PIEB+PCEA standar flow|Programed Intermittent Epidural Boluses of 10ml every hour with PCEA of 5 ml (interval of closing of 20min and maximum dose for hour of 15ml) administered with system of infusion of standar flow as clinical practice routine
3126425|NCT03036124|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
3126426|NCT03036150|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
3126427|NCT03036150|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
3475170|NCT03838861|Active Comparator|Control|Standard follow-up in doctors setting
3475171|NCT03838861|Experimental|Intervention|Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
3475172|NCT03838601|Experimental|MET-4|Subjects diagnosed with Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma (LA-OPSCC) will receive treatment with MET-4 in addition to standard of care CRT. MET-4 is administered orally as an initial daily loading dose over 2 days followed by a daily maintenance dose of MET-4 and will be administered until week 4 of CRT or unacceptable toxicity whichever occurs earlier and in the absence of criteria to discontinue MET-4.
3475173|NCT03838705|Other|bariatric surgery patients|patients aged 18-65 years with ASA status II-III, BMI>40 who were undergoing bariatric surgery operation
3475174|NCT03838679||Cohort 1|80 participants with neovascular AMD and a minimum history of 12 months of anti- VEGF therapy will be included in cohort 1 and examined only once (1 study visit).
3475175|NCT03838679||Cohort 2|40 participants with treatment-naive neovascular AMD receiving standardized anti- VEGF therapy will be included in cohort 2 and followed for 12 months (6 study visits).
3475176|NCT03838666|Experimental|Suspension of human autologous MSC 3P|Patients will receive perioperative hAMSC (1.5 ml) treatment in order to accelerate the healing of the surgically repaired rotator cuff and increase the mechanical properties of the tendon.
3475177|NCT03838367|Experimental|Phase I-Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort A: 350 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
3475178|NCT03838367|Experimental|Phase I-Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort B: 525 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
3475179|NCT03838367|Experimental|Phase I-Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin|Cohort C: 700 mg PRO 140 SC weekly + AUC 5 Carboplatin every 3 weeks
3475180|NCT03838367|Experimental|Phase II- MTD to be established for the combination treatment|MTD PRO 140 SC + AUC 5 Carboplatin in 30 subjects
3475181|NCT03838484|Experimental|Healthy: placebo first, nicotine last|Healthy controls will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
3475182|NCT03838484|Experimental|Healthy: nicotine first, placebo last|Healthy controls will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
3475183|NCT03838484|Experimental|SCZ: placebo first, nicotine last|Subjects with schizophrenia (SCZ) will apply placebo skin patch for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a nicotine patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the second visit in week 2.
3475184|NCT03838484|Experimental|SCZ: nicotine first, placebo last|Subjects with schizophrenia (SCZ) will apply nicotine skin patch (7 mg/24 hour dose) for up to two hours prior to behavioral and EEG task during the first visit in week 1. After a washout period, they will return and apply a placebo patch for up to two hours prior to behavioral and EEG task during the second visit in week 2.
3475185|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts <350 cells/µL|Intervention to be administered: Prevenar13
3475186|NCT03838497|Active Comparator|HIV-infected subjects with CD4 T-cell counts ≥350 cells/µL|Intervention to be administered: Prevenar13
3475187|NCT03838315|Experimental|Neural Mobilization with Soft Tissue Mobilization|"Neural Mobilization with Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization and Post Isometric Relaxation Techniques.~Frequency for Neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 40mints each session)"
3475188|NCT03838315|Active Comparator|Neural mobilization without Soft Tissue Mobilization|Neural Mobilization without Soft Tissue Mobilization group will be assessed by spurling's test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Neural Mobilization Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 30mints each session)
3475189|NCT03838588||T-MENC Study Group|"In the study, 200 of stage IB,II and IIIA non-small cell lung cancer patients obtained radical resection will be recruited. All the patients will receive biopsy genotype assay and ctDNA liquid biopsy. The abundance of mutations of ctDNA was tracked at 4 time points, including:~st: 10 Days after patients received radical resection.~nd: When patients finished the chemotherapy or target drug delivery two cycles.~rd: 10 Days after patients finished the chemotherapy or target drug delivery four cycles.~th: When tumor recrudescence / 2 years after radical resection. Tumor genomic clonal evolution was assessed by analyzing the relative abundance of mutations in plasma circulating tumor DNA (ctDNA)."
3475190|NCT03838640|Experimental|Study group|Consecutive eligible patients requiring endoscopic surgery for sinonasal pathology Transnasal localization of internal carotid artery with TEE ECHO device will be performed
3475191|NCT03838328|Experimental|Dose group 1|The dose regimen of tranexamic acid in group 1 includes a loading dose of 30mg/kg before skin incision and a maintenance dose of 20mg/kg/hr until the end of the operation.
3475192|NCT03838328|Experimental|Dose group 2|The dose regimen of tranexamic acid in group 2 includes a loading dose of 20mg/kg before skin incision and a maintenance dose of 15mg/kg/hr until the end of the operation.
3126428|NCT03036163|Experimental|Cohort 1|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 40 mg (1 capsule)
3126429|NCT03036163|Experimental|Cohort 2|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 80 mg (2 capsules)
3475193|NCT03838328|Active Comparator|Dose group 3|The dose regimen of tranexamic acid in group 3 includes a loading dose of 10mg/kg before skin incision and a maintenance dose of 10mg/kg/hr until the end of the operation.
3475194|NCT03838523|Experimental|OLP group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women allocated to this group receive an 4-week Open Label Placebo treatment. After 4 weeks, they are randomized again to either continue or discontinue the OLP treatment for another 4 weeks."
3475195|NCT03838523|No Intervention|No-treatment group|"At baseline, patients are given an explanation about why placebos without deception might be effective.~Women assigned to the no-treatment group do not receive any treatment as part of the study."
3475196|NCT03838432|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
3475197|NCT03838406|Experimental|BRCA1 positive|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
3475198|NCT03838406|Active Comparator|BRCA1 negative|"FOLFOX or CAPOX Chemotherapy~FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + 5-FU 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
3475199|NCT03838341||Included|The consecutive patients with atrial fibrillation assigned to totally thoracoscopic stand-alone left atrial appendage occlusion using AtriClip® for stroke prevention.
3475200|NCT03838445|Experimental|Therapy: V-Wave Shunt|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation.
3475201|NCT03838263|Experimental|Experimental arm|Experimental arm with nivolumab 2 infusions (2 weeks apart) before Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
3126430|NCT03036163|Experimental|Cohort 3|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 160 mg (4 capsules)
3126431|NCT03036163|Experimental|Cohort 4|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 320 mg (8 capsules)
3475202|NCT03838263|Active Comparator|Control arm|Control arm: Standard of care chemoradiation for 7 weeks with high-dose cisplatin (100 mg/m²) at week 1, 4 and 7
3475203|NCT03838575|Active Comparator|A - NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
3475204|NCT03838575|Active Comparator|B - SKIN PREP|"Mechanism: A broad-spectrum antiseptic to clean and prepare the skin prior to surgery.~Supplier: BD"
3475205|NCT03838575|Active Comparator|C - DRAPE|"Mechanism: A thin impregnated plastic sheet applied to the prepared skin prior to incision to maintain sterility.~Supplier: 3M Infection Prevention"
3475206|NCT03838575|Active Comparator|D - SPONGE|"Mechanism: Small absorbable sponges placed into the wound at the time of closure which deliver high concentrations of antibiotic locally to kill pathogens present that may go on to cause SSI.~Supplier: SERB"
3475207|NCT03838575|Active Comparator|E - SKIN PREP and DRAPE|See descriptions in single arms (B & C)
3475208|NCT03838575|Active Comparator|F - SKIN PREP and SPONGE|See descriptions in single arms (B & D)
3475209|NCT03838575|Active Comparator|G - DRAPE and SPONGE|See descriptions in single arms (C & D)
3475210|NCT03838575|Active Comparator|H - SKIN PREP and DRAPE and SPONGE|See descriptions in single arms (B, C & D)
3475211|NCT03838354|Experimental|A|Chidamide 2.5 mg po tiw
3475212|NCT03838354|Experimental|B|Chidamide 5 mg po tiw
3126432|NCT03036163|Experimental|Cohort 5|6 male healthy volunteers each of whom received once single oral dose of PBTZ169 - 640 mg (16 capsules)
3126433|NCT03036163|Experimental|Cohort 6|5 male healthy volunteers each of whom received once daily for 14 days 320 mg of PBTZ169 (8 capsules 40 mg)
3126434|NCT03036163|Experimental|Cohort 7|5 male healthy volunteers each of whom received once daily for 14 days 640 mg of PBTZ169 (16 capsules 40 mg)
3126435|NCT03036215|No Intervention|Traditional Self-Care Control Arm|Traditional self-care includes focusing on rest and healing through changes in chewing, diet, heat/cold, over the counter analgesics, and reducing strain from oral and sleeping habits. Participants will also participate in usual care from the dentist such as a splint or anti-inflammatory medications. Participants will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end). .
3126436|NCT03036215|Experimental|PACT Experimental Arm|If selected for the PACT care arm, participant will be prompted to complete a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. Participant will also participate in usual care from the dentist such as a splint or anti- inflammatory medications.Participant will complete follow-up measures at 8-weeks (post-intervention) and at 16-weeks (2 months after program end).
3475213|NCT03838380|No Intervention|conventional management group|The conventional management group received standard GDM management and could freely use the smartphone healthcare application.
3126437|NCT03036293|Experimental|Tenoten, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
3475214|NCT03838380|Experimental|mobile management group|The mobile management group received mobile healthcare services through smartphone application specifically developed for this trial including tailored mobile coaching.
3126438|NCT03036293|Placebo Comparator|Placebo, 2 tablets twice daily (4 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in the mouth until dissolution, without meal.
3126439|NCT03036293|Experimental|Tenoten, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
3475215|NCT03838614|Experimental|RAS-MPT group|Rhythmical auditory stimulation gait training and muscle power training group
3126440|NCT03036293|Placebo Comparator|Placebo, 2 tablets 4 times daily (8 tablets/day)|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets 4 times daily (8 tablets/days). The tablets should be held in the mouth until dissolution, without meal.
3126441|NCT03036384|Experimental|Cohort 1 : HB prilocaine 2%, 45mg|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3126442|NCT03036384|Experimental|Cohort 2 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3475216|NCT03838614|Experimental|RAS group|Rhythmical auditory stimulation gait training group
3475217|NCT03838614|Experimental|MPT group|Muscle power training group
3475218|NCT03838614|Other|Control group|Usual care group
3475219|NCT03838419|Active Comparator|BCS + WBI|breast conserving surgery followed by whole breast irradiation
3475220|NCT03838419|Experimental|BCS + IORT|Breast conserving surgery incl intraoperative radiotherapy
3475221|NCT03838250|Experimental|Cellgram™ (Bone marrow-derived MSCs)|Infusion Cellgram™(Bone marrow-derived MSCs). Single dose administration of approximately 5 x 10^7 cells/10 mL (range: 4.5 x 10^7 to 5.5 x 10^7 cells/10 mL) via the hepatic artery.
3475222|NCT03838276|Active Comparator|AL150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
3475223|NCT03838276|Experimental|AL100 BPL150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
3475224|NCT03838237||Fabry Disease patients|Patients with genetic diagnosis of Fabry Disease, clinical indication to Migalastat and signs of cardiac involvement (early or advanced) will undergo cardiological evaluation before and 18 months after therapy with Migalastat (123 mg every other day)
3475225|NCT03838211|Experimental|stimulation group|Anodal tDCS + intensive cognitive Training
3475226|NCT03838211|Sham Comparator|sham group|Sham tDCS + intensive cognitive Training
3475227|NCT03838224|Experimental|Dry needling|Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves.
3475228|NCT03838224|Sham Comparator|sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
3475229|NCT03838289||Individuals with absent filling of CVs|Individuals with absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
3475230|NCT03838289||individuals without any absent filling of CVs|Individuals without any absent filling of following CVs: superficial middle cerebral vein, vein of Labbe, vein of Trolard, Sphenoid sinus, thalamostriate vein, Internal cerebral vein, Rosenthal's vein
3475231|NCT03838510|Experimental|Brief Counseling Intervention|
3475232|NCT03838510|No Intervention|Control Group|
3475233|NCT03838302||Transvaginal retrieval|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
3126443|NCT03036384|Experimental|Cohort 3 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3475234|NCT03838302||Transabdominal retrieval|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
3126444|NCT03036384|Experimental|Cohort 4 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3126445|NCT03036384|Experimental|Cohort 5 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3126446|NCT03036384|Experimental|Cohort 6 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3475235|NCT03838107||Inpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the inpatient FIRST clinic at CCHMC and one of their parents or legal guardian.
3475236|NCT03838107||Outpatients|Observation and measure of trajectory of recovery in CRPS. This group will include children diagnosed with CRPS and undergoing regular therapy at the outpatient Pain Management Center at CCHMC and one of their parents or legal guardian.
3475237|NCT03838107||Healthy Controls|For comparison purposes, healthy controls and one of their parents or legal guardian will be enrolled in this study as well.
3475238|NCT03838146|No Intervention|Non-Exercise Control|This group will come in regularly for measurements, but will not have an exercise intervention. If necessary for retention of participants, then we will meet with controls 3 times a week to stress reduction techniques.
3475239|NCT03838146|Experimental|Resistance Type of Exercise|This group will participate in resistance exercise intervention 3 times per week from enrollment to delivery.The resistance training (RT) group will perform three sets of 12-15 repetitions of 10-12 resistance exercises in a circuit, with rest of 30-60 seconds between sets as needed. Participants will use a combination of Cybex machines (Cybex International, Medway, MA), resistance bands, and free weights. Routines will change every 3 weeks to add variety and improve compliance.
3475240|NCT03838146|Experimental|Combination Type of Exercise|This group will participate in combination (aerobic+resistance) exercise intervention 3 times per week from enrollment to delivery. The combination (CT) group will alternate between resistance and aerobic exercises. Participants will perform 4.5 minute bouts of aerobic exercise and perform four resistance exercises of 12-15 repetition that vary between aerobic bouts[17-19]. The aerobic exercise bouts will be performed on the aerobic machine of the participant's choosing as described above. The resistance routine will follow similar guidelines as the resistance group.
3475241|NCT03838146|Experimental|Aerobic Type of Exercise|This group will participate in aerobic exercise intervention 3 times per week from enrollment to delivery. The aerobic training (AT) group will perform a continuous aerobic exercise of their choosing (e.g., treadmill, ellipticals, stairs, Zumba, or outside walking/jogging). Participants' ability to choose an aerobic activity that they are comfortable with and enjoy is intended to improve compliance.
3475242|NCT03838081|Experimental|Group 1|Group 1: Patients who were given only basic information verbally
3475243|NCT03838081|Experimental|Group 2|Group 2: Patients with detailed written information about preoperative, intraoperative, and postoperative periods
3475244|NCT03838081|Experimental|Group 3|Group 3: Patients with previous experience and knowledge about third molar extraction
3475245|NCT03838055|Experimental|SLN only|Pelvic SLN's defined by ICG injected cervically
3475246|NCT03838185|Experimental|Study Drug|Healthy young male subjects will receive a single ascending oral dose of J147 following an overnight fast of at least 8 hours. Healthy elderly subjects will receive doses that have been found to be safe in healthy young subjects.
3475247|NCT03838185|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo with 240 mL non-carbonated water in the morning following an overnight fast of at least 8 hours.
3475248|NCT03838172||Parents|Parents who have a burned child
3475249|NCT03838068|Active Comparator|Mineral trioxide aggegate|white mineral trioxide aggregate (MTA) calcium silicate-based cement
3475250|NCT03838068|Experimental|Biodentine|calcium silicate-based cement that consists of tricalcium silicate, dicalcium silicate, calcium carbonate, calcium oxide, zirconium oxide, and CH.
3475251|NCT03837886|Experimental|Alkalosis group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of sodium bicarbonate
3475252|NCT03837886|Placebo Comparator|Placebo group|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
3475253|NCT03837847|Experimental|Intervention|Participants in this group will receive 12 weekly health coaching calls followed by 12 weeks of living a normal life.
3475254|NCT03837847|Active Comparator|Attention Control|Participants in this group will receive 6 educational guides and 6 calls to remind them to read the educational guides (over a 12 week period). The participants will then move to 12 weeks of weekly health coaching calls.
3475255|NCT03838094|Active Comparator|MTA Group|pulpotomy technique using fast-setting mineral trioxide aggregate (MTA) to be considered the control group for vital pulp therapy and was placed over the amputated pulps for 18 months. This group will be compared with the Biodentine group as the intervention group
3475256|NCT03838094|Experimental|Biodentine group|3 mm- thick Biodentine covered radicular pulp to allow pulp regeneration
3475257|NCT03838133|Experimental|TLC590 dose 1 (152 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3475258|NCT03838133|Experimental|TLC590 dose 2 (190 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3475259|NCT03838133|Experimental|TLC590 dose 3 (228 mg)|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3475260|NCT03838133|Active Comparator|Naropin®|Naronpin injection contains ropivacaine HCl 50 mg (0.5%, 10 mL)
3475261|NCT03838133|Placebo Comparator|Placebo|Normal Saline (0.9% sodium chloride, 10 mL)
3475262|NCT03838133|Active Comparator|Bupivacaine|Bupivacaine HCl 50 mg (0.5%, 10 mL)
3475263|NCT03837821|Experimental|All Subjects|Abemaciclib 200 mg oral, every 12 hours
3475264|NCT03837769|Experimental|Aktiia SA PulseWatch|Aktiia OBPM PulseWatch wrist device
3475265|NCT03837951||Uninjured hands|healthy participants without injuries to hands or wrists
3475266|NCT03837951||Injured hands|participants undergoing medical treatment for recent hand or wrist injury
3475267|NCT03837795|Experimental|Neurofeedback therapy group|
3475268|NCT03837743|Experimental|DUR-928 Topical Solution|DUR-928 Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
3475269|NCT03837743|Placebo Comparator|Vehicle Topical Solution|Vehicle Topical Solution applied topically once daily to one target lesion on an arm for approximately four weeks.
3475270|NCT03837691|Experimental|g-Cath EZ|Placement of Snowshoe suture anchors from g-Cath EZ Delivery Catheters, in a defined pattern in the mid and distal portions of the stomach, along with a moderate intensity diet & exercise program, to treat primary obesity.
3475271|NCT03837691|No Intervention|Diet and Exercise|A moderate intensity diet & exercise program to treat primary obesity
3475272|NCT03837912|Experimental|Patient reported safety experiences fed back to PC providers|The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
3475273|NCT03837912|No Intervention|Patient reported safety experiences not fed back to providers|Waiting list: the practices allocated to the control group will receive the intervention (feedback report) after the trial finished (i.e., after post-intervention data collection has been completed).
3475274|NCT03837977|Active Comparator|nal-IRI, 5-FU and racemic folinic acid|liposomal Irinotecan (naI-IRI) (80mg/m*2 intravenously over 90 minutes (± 10 minutes) prior to Fluorouracil (5-FU) 5-FU 2400 mg /m*2 BSA infusor over 46 hours racemic folinic acid (as per local standard practice) every 14 days
3475275|NCT03837977|Active Comparator|docetaxel|75mg/m*2 intravenously over 60 minutes) every 21 days]
3475276|NCT03838003|Experimental|Experimental: Training group|Patients admitted due to decompensated heart failure who will perform the training protocol - ERIC protocol
3475277|NCT03838003|No Intervention|No Intervention: Control group|Patients admitted due to decompensated heart failure who will perform the standard rehabilitation nursing care for this type of patients
3475278|NCT03838029|Active Comparator|Propranolol and etodolac|Both study medications will be given orally for an intervention phase of 35 days as follows. Etodolac:400mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery and the following morning, 40 mg PO bid for following 6.5 days, and 20 mg PO bid for next 22 days.
3475279|NCT03838029|Placebo Comparator|Placebo|Same schedule as in the active comparator arm
3475280|NCT03837834|Experimental|4 MIN X 4 MIN HIIT of FES-LCE|4 min of high-intensity phase intersperses with 4 min of low-intensity phase for a total of 5 bouts.
3475281|NCT03837834|Experimental|2 MIN X 2 MIN HIIT of FES-LCE|2 min of high-intensity phase intersperses with 2 min of low-intensity phase for a total of 10 bouts.
3475282|NCT03837782|Experimental|minimally invasive surgery|"Patients were randomized to undergo minimally invasive radical resection (endoscopic surgery or robotic assisted surgery). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability)."
3475283|NCT03837782|No Intervention|open surgery|"Patients were randomized to undergo open radical resection (laparotomy). Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery.~Patients were eligible if they had colorectal adenocarcinoma; had a disease stage of I (T1,T2), IIABC (T3-T4ab) or IIIABC (TanyN1-2) according to the staging system of NCCN; and had an Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale, with higher values indicating greater disability).~Exclusion criteria included a history of abdominal or pelvic radiotherapy, or evidence of metastatic disease on positron-emission tomography-computed tomography, magnetic resonance imaging, or computed tomography."
3475284|NCT03837938|Experimental|Levopront® syrup 30 mg/5 ml|Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml t.i.d. for 7 days The study drugs will be taken t.i.d. (with the interval of not less than 6 hours, between meals) during 7 days.
3475285|NCT03837938|Active Comparator|Libexin® 100 mg tablets|"Libexin® (prenoxdiazine) 100 mg tablets~1 tablet t.i.d. for 7 days."
3475286|NCT03838016|Experimental|Treatment cohort with classic galactosemia|These children and their parents receive the Babble Boot Camp intervention and also participate in the close monitoring activities (progress reports that the speech-language pathologist generates during the online meeting with the family; monthly daylong audio recording; questionnaires that are sent out every three to six months; formal speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years).
3475287|NCT03838016|Experimental|Treatment cohort with classic galactosemia, delayed start|The children in the control cohort enter the study when they are younger than 5 months old and participate in the close monitoring until they are 24 months old. They start getting the same treatment type and intensity as the treatment cohort but at a delayed age, when they turn 15 months.
3475288|NCT03838016|No Intervention|Older control cohort with classic galactosemia|The children in the older control cohort are 6 months to 4 1/2 years old and provide standardized test results in the area of speech and language development at child ages 2 1/2, 3 1/2, and 4 1/2 years. They receive no treatment and no close monitoring. These families provide questionnaire information every three months until child age 24 months.
3475289|NCT03838016|No Intervention|Typical controls|These children are free of any medical or developmental diagnosis. They enter the study at ages 2 to 5 months and provide close monitoring data until they are 24 months old, then they receive standardized speech and language testing at ages 2 1/2, 3 1/2, and 4 1/2 years, just like the treatment cohort, but the typical controls receive no treatment under this study.
3475290|NCT03837808|Experimental|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT
3475291|NCT03837808|Active Comparator|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT
3475292|NCT03837925|Experimental|ATORVASTATIN|Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine
3475293|NCT03837925|Placebo Comparator|PLACEBO|Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm
3475294|NCT03837665|Experimental|PRP Treatment|Participants receive platelet rich plasma treatment. Participants will be asked to make up to 5 trips to the clinic (one for eligibility, one for the PRP, three follow-up visits). Participation is expected to last up to about 6 weeks. After the second visit and application of PRP, patients will be monitored closely for any complications or concerns. This will include a follow up phone call 3-5 days after the initial application of PRP. Patients will also be followed closely in 2 week intervals or sooner should any problems or concerns arise.
3475295|NCT03837873|Experimental|DLCL002 protocol|Patients will receive R-DA-EDOCH(rituximab, etoposide, dexamethasone, vincristine, cyclophosphamide, doxorubicin) as induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by two courses of R(2)-DHAP(rituximab, lenalidomide(only for patients with non-GCB DLBCL), dexamethasone, cisplatin, cytarabine). Patients who achieved CR+good PR(Deauville score 4) after the rescue therapy will be consolidated with ASCT,and those remain in PR(Deauville score 5) will receive other rescue treatments.
3475296|NCT03837522|Active Comparator|Procurement Biopsy: Frozen section|In the routine care condition, biopsies will be processed immediately as a frozen section.
3475297|NCT03837522|Active Comparator|Procurement Biopsy: Permanent section|In the intervention group, the biopsy processing will be delayed to permanent section, and therefore not available until allocation is complete.
3475298|NCT03837535||Patients undergoing surgery|Swedish patients, >18 years undergoing surgery 2007-2014
3475299|NCT03837704|Active Comparator|IQOS Arm|Patients diagnosed with AAA, switching from cigarette smoking to IQOS use
3475300|NCT03837704|Active Comparator|CC Arm|Patients diagnosed with AAA, continuing to smoke cigarettes
3475301|NCT03837704|Active Comparator|Smoking Cessation Arm|Patients diagnosed with AAA, who have completely stopped smoking and are not using any other tobacco or nicotine-containing product(s)
3475302|NCT03837509|Experimental|INCB001158 + daratumumab SC|INCB001158 + daratumumab
3475303|NCT03837509|Active Comparator|Daratumumab monotherapy and crossover to INC001158+ daratumumab SC|Daratumumab will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
3475304|NCT03837509|Experimental|INCB001158 monotherapy and crossover to INC001158+ daratumumab SC|INCB001158 will be administered as monotherapy, once confirmed disease progression participants will be crossed over to INCB001158+daratumumad combination therapy.
3475305|NCT03837561|Experimental|Cunox|Cunox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
3475306|NCT03837561|Active Comparator|Botox|Botox (botulinum toxin type A), 0.1 mL injected into each of 5 sites once.
3475307|NCT03837548|Experimental|Training with Neurofeedback|
3475308|NCT03837548|Experimental|The other Training with Neurofeedback|
3475309|NCT03837210|Experimental|Test Drug|This group is treated with Herbal formulation.
3475310|NCT03837210|Active Comparator|Control Drug|This group is treated with Quintuple therapy
3475311|NCT03837301|Experimental|NESS-EFTR|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation (basin dissection)
3475312|NCT03837288|No Intervention|Vaginal progesterone only|continue on vaginal progesterone only
3475313|NCT03837288|Experimental|Cervical cerclage plus vaginal progesterone|cerclage with vaginal progesterone.
3475314|NCT03837249|Placebo Comparator|Passive Personal Sleep Monitoring|Wears personal sleep monitor but does not actively self-monitor (will have access to the sleep data and self-monitoring after 4 weeks).
3475315|NCT03837249|Active Comparator|Individual Personal Sleep Monitoring|Wears personal sleep monitor and actively self-monitoring sleep and using data to self-manage sleep.
3475316|NCT03837249|Active Comparator|Socially Supported Sleep Monitoring|Wears a personal sleep monitor, actively self-monitoring using sleep data to self-manage sleep and shares data for supportive self-management.
3475317|NCT03837431||CL suspicion|Individuals presenting with clinical suspicion of CL
3475318|NCT03837275|Experimental|humsfe|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique)
3475319|NCT03837275|Active Comparator|closed sinus lift|transcrestal maxilllary sinus floor elevation
3475320|NCT03837353|Experimental|Cohort 1A|"Cohort 1A Dose Level 1: DKN-01 300 mg intravenously (IV) on Days 1 and 15, docetaxel 75 mg/m2 on Day 1 every 3 weeks (21- day cycles).~Dose Level 2: DKN-01 600 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles).~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15, docetaxel 75 mg/m 2 on Day 1 every 3 weeks (21-day cycles)."
3475321|NCT03837353|Experimental|Cohort 1B|Cohort 1B: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
3475322|NCT03837353|Experimental|Cohort 1C|Cohort 1C: DKN-01 at MTD or highest dose tested: Days 1 and 15, docetaxel 75 mg/m2 Day 1 of every 3 weeks (21-day cycles)
3475323|NCT03837353|Experimental|Cohort 2A|"Dose Level 1: DKN-01 300 mg IV on Days 1 and 15 of a 28-day cycle. Dose Level 2: DKN-01 600 mg IV on Days 1 and 15 of a 28-day cycle.~Dose Level -1: DKN-01 150 mg IV on Days 1 and 15 of a 28-day cycle."
3475324|NCT03837353|Experimental|Cohort 2B|Cohort 2B: DKN-01 at MTD or highest dose tested: Days 1 and 15 (28-day cycles)
3475325|NCT03837197|Experimental|Kidney-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 2000 ml for kidneys.
3475326|NCT03837197|No Intervention|Kidney-Static Cold Storage|Kidneys undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
3475327|NCT03837197|Experimental|Liver-Hypothermic oxygenated|Belzer machine perfusion solution at 4°C-10°C in sterile conditions and continuous oxygenation (partial pressure of oxygen=500-600 mmHg) will be used for perfusion 3000 ml for livers.
3475328|NCT03837197|No Intervention|Liver-Static Cold Storage|Livers undergoing SCS will be stored in sterile organ bags with Celsior or University of Wisconsin solution and cooled in ice.
3126447|NCT03036384|Experimental|Cohort 7 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3126448|NCT03036384|Experimental|Cohort 8 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3475329|NCT03837626|Placebo Comparator|Placebo|6 months of daily placebo
3475330|NCT03837626|Experimental|Amiloride|6 months of amiloride (max dose 5 mg) treatment
3475331|NCT03837470|Experimental|Saline Loading and Diuretic Challenge|Subjects receive intravenous infusion of 0.9% Sodium Chloride, followed by diuretic challenge with bolus injection of Furosemide 40 mg
3475332|NCT03837405|Active Comparator|Diet Education|All participants will receive instruction in the Carbohydrate-Restricted (CR) diet and basic behavioral strategies in weekly, in-person, group sessions for 3 months. The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat.
3475333|NCT03837405|Experimental|Diet Education + Mindfulness|In addition to the diet components described above, participants randomized to the Education + Mindfulness (Ed+MBI) group will receive MBI components using the Eat Right Now (ERN) platform. This will consist of two integrated components: 1) use of the ERN app at home, during the week, to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based discussions of how the mindful eating practices are going, trouble-shooting obstacles/pain points, and doing group exercises and reflecting on them.
3475334|NCT03837327||Adnexal Mass|Women with an adnexal mass (pelvic mass) as confirmed by imaging
3475335|NCT03837457|Experimental|Cobomarsen|
3475336|NCT03837379|Other|Treatment As Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
3475337|NCT03837379|Experimental|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
3475338|NCT03837366|Experimental|Activity Tracker with Health Coaching|Participants assigned to this condition will receive a Fitbit activity tracker to use for 3 months. Also, they will be asked to come in for a visit approximately one week following baseline assessments. Using the principles of Motivational Interviewing and Habit Formation, participants will discuss their perceived benefits and barriers of becoming more physically active with a member of the research team. They will also be encouraged to set a goal related to using their Fitbit to increase their physical activity. Lastly, they will be given information regarding habit formation and encouraged to identify one or more cues that regularly occur in their daily life to check their Fitbit data as a prompt to engage in physical activity.
3475339|NCT03837366|Active Comparator|Activity Tracker alone|Participants assigned to this condition will use their Fitbit on their own for the duration of 3- month intervention, similar to the experience of participants buying the device off-the-shelf.
3475340|NCT03837613||Group 1 (TT<4mm)|Patients with a preoperative tumor thickness less than 4 mm. Intervention: tumor resection and neck dissection
3475341|NCT03837613||Group 2 (TT >= 4mm)|Patients with a preoperative tumor thickness equal to or more than 4 mm Intervention: tumor resection and neck dissection
3475342|NCT03837145||Liver transplant recipients|Adult patients requiring elective post-operative ventilation after a living donor liver transplant receiving intravenous propofol infusion for sedation titrated to Bi-Spectral Index (BIS) score of 60-80,as per our institutional protocol.
3475343|NCT03837340|Experimental|FACT|Patients with SMI, receiving evidence-based interventions by the community mental health teams (CMHTs), inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
3475344|NCT03837340|Active Comparator|CAU (Care as usual)|Patients with SMI receiving usual care, meaning mostly medical treatment
3475345|NCT03837223||"patients underwent rescue protocols and fresh embryotransfer"|they were patients with good prognosis with a mean age of 34.13 ± 4.42 years, with a good ovarian reserve
3475346|NCT03837106|Experimental|Rehabilitation program|Home and supervised exercise program specific to musicians. Injury prevention and management education program specific to musicians.
3475347|NCT03837106|No Intervention|No intervention|Control group, no intervention
3475348|NCT03837236|Experimental|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
3126449|NCT03036384|Experimental|Cohort 9 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3126450|NCT03036384|Experimental|Cohort 10 : HB prilocaine 2%, (30-55mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2%, associated with sufentanyl, will be administrated at the dose initial of 45 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). Possible dose levels are 30, 35, 40, 45, 50, 55mg.
3475349|NCT03836911|Active Comparator|serious game|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a serious game
3475350|NCT03836911|Other|Classic program|the effect on physical performance of a personalized, 12-weeks rehabilitation program using a classical exercise program in older subjects living in a nursing home
3475351|NCT03837184|Experimental|Onasemnogene Abeparvovec-xioi|Participants will receive a single dose of onasemnogene abeparvovec-xioi, administered intravenously.
3475352|NCT03836872|Experimental|True Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints. Bilateral acupoints will be stimulated including Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
3475353|NCT03836872|Sham Comparator|Sham Acupuncture|In addition to the routine methods of care, patients allocated to the sham control group will receive sham acupuncture treatment at sham acupoints with superficial needling
3475354|NCT03836872|No Intervention|Standard Control Group|The third arm will be a standard care control arm.
3475355|NCT03837054|Other|Breast cancer patients with external polychemotherapy|
3126451|NCT03036813|Active Comparator|Dose 1|voxelotor
3126452|NCT03036813|Active Comparator|Dose 2|voxelotor
3126453|NCT03036813|Placebo Comparator|Placebo|Placebo
3126454|NCT03036839|Experimental|LDV/SOF for 8 weeks|Treatment-naive participants with genotype 1 without cirrhosis will receive LDV/SOF for 8 weeks
3126455|NCT03036839|Experimental|LDV/SOF for 12 weeks|Treatment-experienced participants with genotype 1 and treatment-naive or treatment-experienced participants with genotype 2 (Taiwan only), 4, 5 and 6 without cirrhosis will receive LDV/SOF for 12 weeks
3475356|NCT03837171|Active Comparator|Liberal strategy|Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
3475357|NCT03837171|Experimental|Restrictive strategy|Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
3475358|NCT03837041|Active Comparator|Reconditioning Proprioception group|Training Proprioception 1 hour for 2 day a week
3475359|NCT03837041|No Intervention|Control group|
3475360|NCT03836807|Experimental|Ketoprofen|Single oral administration of Ketoprofen lysine salt 40 mg granules
3475361|NCT03836807|Placebo Comparator|Placebo|Single oral administration of placebo granules
3475362|NCT03836937|Experimental|Obeticholic acid|Patients diagnosed as NAFLD with raised ALT will be treated with both life style modification and Obeticholic acid. Obeticholic acid will be given as 10 mg twice daily. Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
3475363|NCT03836937|No Intervention|Lifestyle modification|Patients diagnosed as NAFLD with raised ALT will be given only life style modification.Life style modification includes moderate exercise that is 30 minutes brisk walking a day with dietary advice to avoid fatty foods and excessive sugar containing diet and intake of at least 3 vegetables per day.
3475364|NCT03837132||Advanced pancreatic cancers|Newly diagnosed patients with advanced pancreatic cancer
3126456|NCT03036839|Experimental|LDV/SOF for 24 weeks|Participants with compensated cirrhosis will receive LDV/SOF for 24 weeks
3126457|NCT03036852|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3126458|NCT03037203|Experimental|Arm A|JZP-110 and Placebo
3126459|NCT03037203|Experimental|Arm B|JZP-110 and Placebo
3126460|NCT03037203|Placebo Comparator|Arm C|Placebo
3475365|NCT03836742||HF RCA|Cardiovascular surgery patients treated with hemofiltration with regional citrate anticoagulation
3475366|NCT03836703|Active Comparator|Single Dose Daily Iron|single dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
3475367|NCT03836703|Experimental|Double dose Daily iron|Double dose daily Iron'IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE supplementation From 14 weeks gestation to prevent iron deficiency anemia
3475368|NCT03836690|Experimental|Donor T cells depleted of CD62L+ cells (CD62L- Tem)|Donors will undergo a steady state apheresis for the collection of T cells. Selection of CD62L- Tem at the required dose will be performed at UCL Centre for Cell, Gene and Tissue Therapeutics (CCGTT). Donor Tem will be infused into patients on day 24-32 following allo-Stem Cell Transplant.
3475369|NCT03837158|Experimental|Control-group|Two Tissue Level TiZr Sand blasted long grit acid-etched (SLA) implants placed in positions 33 and 43 (diameter 3.3mm, length ≥10mm), early loading
3475370|NCT03837158|Experimental|Experimental-group|Four narrow-diameter implants (NDI) TiZr SLA implants in positions 34, 32, 42, and 44 (diameter 2.4mm, length ≥10mm), immediate loading
3475371|NCT03836924||Perampanel|Participants receiving perampanel tablets, orally according to prescribing information and the treating physician's clinical judgment will be observed prospectively for up to 6 months or participant withdrawal, whichever occurs first.
3475372|NCT03836716|Experimental|Arimoclomol|Arimoclomol, capsule
3475373|NCT03836898|Experimental|Implantation phakic intraocular lens|Presbyopic posterior chamber phakic intraocular lens IPCL implanted to the participants eye
3475374|NCT03836885|Experimental|Apremilast|Oral tablet
3475375|NCT03836885|Placebo Comparator|Placebo|Oral tablet
3475376|NCT03836820|Experimental|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
3475377|NCT03836820|Experimental|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
3475378|NCT03836820|Experimental|Clinical pilates and Aerobic exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
3475379|NCT03837002|Experimental|foot care protocol|foot examination at the first interview, foot care and training once a month and weekly follow-up for 3 months, foot examination at the last interview (six month)
3475380|NCT03837002|No Intervention|Control|foot examination at the first interview, foot examination at the last interview (six month)
3475381|NCT03836755|Other|METACOS|Required to do some motor tasks during static and dynamic RSA
3475382|NCT03836976|Experimental|All participants|All participants receive auditory gamma sensory stimulation.
3475383|NCT03836833|Experimental|4in1 granules|Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks, Followed by Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.
3475384|NCT03836833|Experimental|LPV/r Pellets Plus ABC/3TC|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets) administered twice daily for at least 3 weeks.~Followed by Abacavir/Lamivudine/ Lopinavir/Ritonavir (30/15/ 40/10mg ;4-in-1) Fixed-Dose Combination in granules formulation administered twice daily for at least 3 weeks"
3475385|NCT03836846|Placebo Comparator|Treatment As Usual|Standard of care as usual with follow-up at 1-, 3-, and 6-months
3475386|NCT03836846|Active Comparator|Intervention with CBT Mobile App|Treatment as usual with additional treatment using cognitive behavioral therapy (CBT) mobile apps (ie What's Up?)
3475387|NCT03837080|Experimental|Nutrition Education|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care will go through a series of individual and group nutrition educations. Educations are specifically tailored for chronic pain patients, based on our preliminary findings on this group of patients.
3475388|NCT03837080|No Intervention|Control|Participants suffering from chronic pain enrolled in the 4-week Pain Management Clinic organized at the Department of Anesthesiology, Resuscitation and Intensive Care. Patients will receive all treatments (e.g. physical therapy) except the nutrition education.
3475389|NCT03836768|Experimental|Experimental Treatment|DTRMWXHS-12, oral capsule, daily, 28 days as a cycle
3475390|NCT03836781|Active Comparator|ketorolac 3%|ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
3475391|NCT03836781|Other|chlorhexidine 2%|chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
3475392|NCT03837119||Heterozygous Hemoglobinopathy|pregnancy outcome in women with heterozygous hemoglobinopathy
3475393|NCT03837119||No Heterozygous Hemoglobinopathy|pregnancy outcome in women without heterozygous hemoglobinopathy
3475394|NCT03836651|Active Comparator|Control Group|Following completion of baseline data collection, participants will be randomized to one of two groups. The research assistant will open a pre-assigned envelope in which group assignment was determined by a random number/block generator. The intervention is designed to complement guideline directed medical management. Therefore, both the intervention and control group will continue to be medically managed by their health care provider as usual. In order to avoid introducing the confound of extra attention paid to the intervention group, the control group will have the same visit and call schedule as the intervention group.
3475395|NCT03836651|Experimental|Intervention Group|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants assigned to the intervention group will receive dietary antioxidants as V8® Low Sodium 100% vegetable juice.
3475396|NCT03836638|Experimental|Low dose young subjects|Group 1 patients will be 25-35 years old and will be injected with 30 units of botulinum toxin into the upper face
3475397|NCT03836638|Experimental|Low dose older subjects|Group 2 patients will be older than 45 and will be injected with 30 units of botulinum toxin into the upper face
3475398|NCT03836638|Active Comparator|high dose older subjects|Group 3 patients will be older than 45 and will be treated with the usual 50 units dose into the upper face (control group)
3475399|NCT03836443|Active Comparator|NAFL patients (group 1)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
3475400|NCT03836443|Active Comparator|NASH patients (group 2)|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal)."
3475401|NCT03836547|Experimental|Multicomponent Intervention for weight loss|12-week intervention that consists of Weight Watcher on-line program, Garmin Fitness Tracker, blue-tooth scale, and telephonic health coaching.
3475402|NCT03836547|Active Comparator|Wait-list Control|The participant will receive usual care for 12 weeks and then will compassionately be offered the active intervention.
3475403|NCT03836495|Experimental|White bread unfortified (WB)|bread with no lysine no phosphorus
3475404|NCT03836495|Experimental|White bread fortified with lysine (WB-L)|Bread with lysine
3475405|NCT03836495|Experimental|White bread fortified with phosphorus (WB-P)|bread with phosphorus
3475406|NCT03836495|Experimental|White bread fortified with lysine and phosphorus (WB-LP)|Bread with phosphorus and lysine
3475407|NCT03836625|No Intervention|Control|The control arm will receive standard CareConekta, which will track their mobility with no additional features.
3475408|NCT03836625|Experimental|Intervention|The intervention arm will receive standard CareConekta, plus text notifications of nearby ART facilities when they have traveled >50 km from the study site for >7 days. At enrollment, participants in the intervention arm also will be able to opt-in to phone call(s) and/or WhatsApp message(s) from study staff to when they have met this travel threshold. The study staff calls and messages will ask about medication supply and will provide assistance with nearby facilities, if requested.
3126461|NCT03037281||Septic|Patients admitted to the intensive care unit with a diagnosis of sepsis. For the purposes of this study, patients must have a diagnosis of sepsis; SIRS (2 of pulse >90, WCC, BP, Oxygen(Dellinger et al., 2013)) with microbiological evidence of infection (positive blood culture, urine dipstick, compatible history or examination, radiographic evidence)
3475409|NCT03836391|Experimental|Nudge Intervention|"Each of 7 intervention message options has specific decision rules (including weighed/not weighed and progress toward daily dietary and activity goals) that make a participant eligible to receive a specific intervention type at a specific time (decision points).~At each decision point (early morning, morning, midday, and evening), the system evaluates which intervention options a participant is eligible to receive, and randomly chooses one intervention option from that list. Then the participant is randomly assigned to either receive or not receive that intervention message (with a 50-50 probability)."
3475410|NCT03836482|Experimental|Selective Cytopheretic Device|
3475411|NCT03836365|Active Comparator|Preoperative counseling office visit|Participants will present for an in-person preoperative counseling office visit (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
3475412|NCT03836365|Active Comparator|Preoperative counseling phone call|Participants will receive a preoperative counseling phone call (preoperative counseling session). This will occur within a few weeks of surgery. Preoperative counseling topics are standardized and will be identical with each arm.
3475413|NCT03836612||People with inflammatory bowel disease|Adults (18+) with inflammatory bowel disease registered with a contributing GP practice during the study period
3475414|NCT03836612||Controls|Adults (18+) without inflammatory bowel disease registered with a contributing GP practice during the study period
3475415|NCT03836378|Experimental|Deep Cleaning and Intervention|One side of the participant's mouth will receive a deep cleaning in addition to the placement of a BioXclude™ membrane in the deep pocket sites. The participant will then be followed for 9 months with routine care.
3475416|NCT03836378|No Intervention|Deep Cleaning Only|One side of the participant's mouth will receive deep cleaning (scaling and root planning) only. The participant will then be followed for 9 months with routine care.
3475417|NCT03836508|Active Comparator|Medium cut-off|Medium cut-off dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using high-flux dialyzers.
3126462|NCT03037281||Healthy volunteers|Healthy volunteers will be approached within the Department of Cardiovascular Sciences, and provided with the PIS, with consent taken by one of the investigating team.
3126463|NCT03037307|Experimental|Test product|Participants will topically apply the test product to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
3126464|NCT03037307|Active Comparator|Positive Control|Participants will topically apply the positive control to clean wet denture (upper denture) fit surface in a pattern consistent with product label and application instructions.
3126465|NCT03037307|Other|Negative Control|Participants of this group will not be assigned to any treatment.
3126466|NCT03037489|Experimental|MIV-711|MIV-711 for a total of 26 weeks
3126467|NCT03037541|Experimental|Group 1 Carac (fluorouracil) 0.5% cream|Carac cream (fluorouracil) 0.5% applied daily on the face for one week
3126468|NCT03037541|Placebo Comparator|Group 2 Placebo|Placebo Cetaphil cream applied daily on the face for one week
3126469|NCT03037580|Experimental|Oral treprostinil|Sustained-release oral tablets for TID administration
3126470|NCT03037580|Placebo Comparator|Placebo|Placebo (sugar pill) for TID oral administration
3126471|NCT03037619|Experimental|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months.
3126472|NCT03037619|Experimental|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
3126473|NCT03037905|Experimental|SignatureSuite OR|The intervention is exposure to the operating room environment created by the device SignatureSuite OR Integration System by STERIS Corporation.
3126474|NCT03037905|No Intervention|Standard OR|Standard operating room without SignatureSuite OR Integration System by STERIS Corporation.
3126475|NCT03037983|Active Comparator|Active rTMS|Subjects will receive actual rTMS treatment.
3126476|NCT03037983|Sham Comparator|Sham rTMS|Subjects will attend and sit through the session, but no rTMS treatment will be actually delivered to them.
3475418|NCT03836508|Active Comparator|High-flux|High-flux dialyzers will be used in this group containing 26 randomized patients for three months. At the end of the third month with crossover, this groups of patients will start using medium cut-off dialyzers.
3475419|NCT03836586|Experimental|Pain Catastrophizing Reduction Group|This group will be assigned to a 30-minute, single-session cognitive-behavioral intervention designed to reduce pain catastrophizing.
3475420|NCT03836586|Active Comparator|Pain Education Group|This group will receive general information about the neurobiology of pain and knee OA.
3475421|NCT03836573|Experimental|E-cigarette only decision aid|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of information on e-cigarettes only. Patients will only be enrolled in this group in phase II if they self-identify as 'uninterested in quitting cigarettes'. During the physician encounter will be given harm-reduction guidance.
3475422|NCT03836573|Experimental|E-cigarette and Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. Patients will only be enrolled in this group in phase II if they self identify as 'interested in quitting and using e-cigarettes'. During the physician encounter will be given e-cigarette cessation guidance.
3475423|NCT03836573|Experimental|Standard Smoking Cessation Group|Patients will be provided with the Smoking Cessation iPad Decision Aid Tool consisting of standard smoking cessation and e-cigarette options. All patients in phase I will be enrolled in this group. In addition, patients in phase II who self-identify as 'interested in quitting but do not use e-cigarettes' will also be enrolled in this group. During the physician encounter will be given standard smoking cessation guidance.
3475424|NCT03837262|Experimental|Flash glucose monitoring|Flash glucose monitoring continuously for 6 weeks then once a month up to 24 weeks, with structured education
3475425|NCT03836287|Experimental|Active|Sofpironium bromide, 15% gel, once per day
3475426|NCT03836287|Placebo Comparator|Vehicle|Vehicle gel, once per day
3475427|NCT03836430|Experimental|Newborn Behavioral Observation|The Newborn Behavioral Observation-Family Wellness (NBO-FW) intervention is the experimental arm of this RCT. It consists of 3 NBOs - 2 during the birth hospitalization and the third at 6 weeks post-discharge as well as a journal with prompts for mothers to reflect on their infant's behavior and their own transition to motherhood. NBOs are clinical relationship-building tools used by trained clinicians/therapists to help parents understand their babies' unique language.
3475428|NCT03836430|No Intervention|Usual care|This arm is the usual care arm. Of note, both arms receive 2 parenting books, one at hospital discharge and one at 6 weeks post-discharge.
3475429|NCT03836170|Experimental|Laparoscopic cholecystectomy|A laparoscopic cholecystectomy was performed to remove the gallbladder
3475430|NCT03836599|Experimental|24 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol from Day -7 to Day -1. During the Treatment Period, participants will be administered 24 mg verinurad with 300 mg allopurinol once daily on Days 1 to 7.
3475431|NCT03836599|Experimental|12 mg Verinurad+300 mg allopurinol|During Run-in Period, participants will be dosed with 300 mg of allopurinol once daily from Day -7 to Day -1. During Treatment Period, participants will receive a single dose of 12 mg verinurad and 300 mg allopurinol on Day 1. No dosing will be done on Day 2. Participants will continue dosing on Day 3 and will be dosed once daily until Day 9.
3475432|NCT03836599|Placebo Comparator|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
3475433|NCT03836196|Experimental|Combined radiation treatment|Combined low-dose-rate brachytherapy and external beam radiation therapy
3475434|NCT03836248|Other|1-Current practice Medication treatment|Medication treatment according to current practice.
3475435|NCT03836248|Sham Comparator|2- Sham osteopathic treatment|Medication treatment according to current practice + sham osteopathic treatment.
3475436|NCT03836248|Experimental|3- Osteopathic treatment|Medication treatment according to current practice + osteopathic treatment.
3475437|NCT03836209|Experimental|Arm A|"Induction: Daunorubicin, cytarabine and gilteritinib. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and gilteritinib."
3475438|NCT03836209|Active Comparator|Arm B|"Induction: Daunorubicin, cytarabine and midostaurin. Depending on response, second cycle of Induction may be given.~Consolidation: High-dose cytarabine and midostaurin."
3475439|NCT03836560|Active Comparator|Usual group|"Usual group with nicotine patch only:~Usual care involved counseling and 8 weeks of single NRT of nicotine patch. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches."
3475440|NCT03836560|Active Comparator|Intervention group|"Nicotine patch and nicotine gum:~Intervention consisted of counseling and 8 weeks of combined NRT of nicotine patch and gum. For those smoking 20 or more cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 21mg patches, then 2 weeks of 14mg patches, followed by 2 weeks of 7mg patches. For those smoking 10 to 19 cigarettes per day before quitting, the NRT patch regimen was 4 weeks of 14mg patches, followed by 4 weeks of 7mg patches. 2mg nicotine gum was used once every 1 to 2 hours when required."
3475441|NCT03836118||IUI|all the IUI with controlled ovarian stimulation cycles in an academic tertiary ART center between January 1997 and December 2017
3475442|NCT03836456|Experimental|Experimental Intervention|Mindfulness Based Stress Resilience Training: This approach will be conducted with study participants for 4 weeks. One evening per week.
3475443|NCT03836456|Active Comparator|Active Control Intervention|Health Enhancement Program: This is a validated active comparator used in Mindfulness-based training studies. It will be conducted with the participants one evening per week for 4 weeks.
3475444|NCT03836326|Experimental|Sensorimotor intervention|Is a 15-minute intervention consisting of tactile (i.e., stroking the whole body) and oral input (i.e., stroking the oral structures) for 15 minutes duration. The program will start 24 hours after nasal continuous positive airway pressure (NCPAP) is discontinued and 24 hours after 80 ml/kg/day of enteral feeds are tolerated. The program will be administered once a day for 10 days, within a 14-day period. The parents will perform all the interventions in the NICU. The infants will remain in the isolette for the duration of the program. This intervention does not involve any drugs or medical procedures. It is an intervention commonly used by occupational and physical therapists in the neonatal intensive care unit.
3475445|NCT03836326|Other|Control|Infants in the control group will receive standard care only.
3475446|NCT03836144||Cystinuria|10 patients with cystinuria. Experimental. Urine collected before treatment initiation and 3 months after. Treatment: Usual alkalizing treatment using oral potassium citrate. The initial dosage will be 4 g/day divided into 3 to 4 oral daily doses. If the objective of urinary pH is not reached after the first two weeks of treatment, the dose will be increased by 2 grams (6 grams total). If the urinary pH remains below 7.5 after 2 weeks with 6 grams of potassium citrate per day, the alkalizing treatment will then be supplemented with oral sodium bicarbonate in the form of Vichy water or officinal preparation. This treatment is the usual treatment recommended for cystinuria .
3475447|NCT03836144||Non cystinuria nephrolithiasis|20 patients with a nephrolithiasis not due to cystinuria. Control group. Urine collected once to study biomarkers of inflammation No intervention.
3475448|NCT03836144||Inflammatory nephropathy|"10 patients with an inflammatory nephropathy of glomerular or tubulo interstitial origin (confirmed by renal biopsy).~Control group. Urine collected once to study biomarkers of inflammation. No intervention."
3475449|NCT03836274|Experimental|Experimental|Patients established on an oral nutritional supplement (ONS), requiring nutritional supplementation of at least 300kcal/day will be changed onto an equivalent prescription of AYMES 'MONACO' for a period of 9 days.
3475450|NCT03836352|Experimental|Arm 1 (All cohorts)|DPX-Survivac, Cyclophosphamide, Pembrolizumab
3475451|NCT03836352|Experimental|Arm 2 (Ovarian cohort only)|DPX-Survivac, Pembrolizumab
3475452|NCT03836313|Experimental|cryoneurolysis treatment|TKA patients randomized to receive preoperative rehabilitation and cryoneurolysis treatment with the iovera° device (n=70)
3475453|NCT03836313|No Intervention|no cryoneurolysis treatment (standard of care)|TKA patients randomized to receive preoperative rehabilitation only (no cryoneurolysis treatment) (n=70)
3475454|NCT03836040|Experimental|Dose level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
3179354|NCT00671957||Patients undergoing gastric bypass|"Patients undergoing gastric bypass surgery and who are participants in Longitudinal Assessment of Bariatric Surgery (LABS-2).~Inclusion Criteria:~No acute illnesses~Weight less than 227 kg (limit of Bod Pod and Treadmill)~Able to walk at 2.4 mph for 15 minutes (needed for the energy expenditure testing)~No tobacco use~Ability to stop alcohol consumption during test phases~For female subjects; no plans for pregnancy in 24 months and menstrual cycles of 21-35 days~No history of eating disorder~No history of current substance abuse~No history of chest pain or shortness of breath at rest or on exertion.~Negative pregnancy in women."
3475455|NCT03836040|Experimental|Dose level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
3475456|NCT03836040|Placebo Comparator|Placebo|Subjects will be randomized to a placebo comparator.
3475457|NCT03836534||patient coming to the emergency department|the group studied only concern adult adults consulting in the emergency departments and leaving after their consultations, during the permanence of care
3475458|NCT03836222|Experimental|PCS499 MR Tablet Prototype 2|600 mg single dose
3475459|NCT03836222|Active Comparator|Trental MR tablet 400mg|single dose
3475460|NCT03836222|Experimental|PCS499 MR Tablet Prototype 4|600mg single dose
3475461|NCT03836222|Experimental|PCS499 MR Tablet Prototype 1|600mg single dose
3475462|NCT03836222|Active Comparator|Trental MR Tablet|400 mg multiple dose
3475463|NCT03836222|Experimental|PCS499 MR Tablet 900mg|multiple dose
3475464|NCT03836222|Experimental|PCS499 MR Tablet 600mg|multiple dose
3475465|NCT03836157|Experimental|Mirvetuximab and Bevacizumab|"Mirvetuximab Soravtansine 6mg/kg IV (adjusted ideal body weight), on day 1 of each 21 day cycle.~Bevacizumab 15 mg/kg, IV, on day 1 of each 21-day cycle."
3475466|NCT03836300|Experimental|Infants with FXS and their parent/primary caregiver|Implement intervention in two phases
3475467|NCT03835988|Experimental|Geniculate Artery Embolization|Patients undergoing geniculate artery embolization. Patients will be assessed and followed post-procedurally to detect changes in knee pain and function. Medication use, adverse events and performance based tests of physical function will also be recorded. A pre-procedural MRI will be compared to a 6 month post-procedure MRI to assess for changes in synovitis and assess for complications.
3475468|NCT03836404|Experimental|Iliac Crest reconstruction surgery|The patients in the study group will be surgically treated and the GreenBone bone substitute will be implanted
3475469|NCT03836183|Other|ultrasound|"ultrasound is the only study group for all the patients~pleuropulmonary ultrasound~clinical examination~fibroscopy."
3475470|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
3475471|NCT03835884|Experimental|AR-13503 Implant 10.6 Dose|Single dose of AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
3475472|NCT03835884|Experimental|AR-13503 Implant 21.2 Dose|Single dose of AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
3475473|NCT03835884|Experimental|AR-13503 Implant 42.4 Dose|Single dose of AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye of up to 6 subjects (3 nAMD and 3 DME) who will be followed for 24 weeks
3475474|NCT03835884|Experimental|AR-13503 Implant 63.6 Dose|Dose of AR-13503 Implant 63.6 Dose (63.6 µg) administered into a single eye of up to 5 subjects (DME) who will be followed for 24 weeks. Subjects may qualify to receive an additional dose at Week 12.
3475475|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid AB|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
3475476|NCT03835910|Active Comparator|No Incentive, Corticosteroid AB|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in A-B order (corticosteroids, then lidocaine only)"
3475477|NCT03835910|Experimental|Social Incentives and Gamification, Corticosteroid BA|"Participants will receive a support person and be able to interact with a web-based platform to progress through levels based on their achievement of step goals.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
3475478|NCT03835910|Active Comparator|No Incentive, Corticosteroid BA|"Participants will only receive reminders to sync their activity monitor.~The participants will receive injections in B-A order (lidocaine only, then corticosteroids)"
3475479|NCT03835780||People with inflammatory bowel disease|All individuals with an existing or incident diagnosis of IBD during the study period
3475480|NCT03835780||People with rheumatoid arthritis|All individuals with an existing or incident diagnosis of RA during the study period
3475481|NCT03835780||People with psoriatic arthritis|All individuals with an existing or incident diagnosis of IBD during the study period
3475482|NCT03835780||Controls|Age, gender and primary care practice matched individuals without an existing or incident diagnosis of IBD, RA, or PsA during the study period
3475483|NCT03835962|Experimental|Intervention Arm|All participants will be asked to attend one experimental session. During the session, participants will listen one auditory stimulus sequence including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
3475484|NCT03836001|Placebo Comparator|Placebo Oral Tablet|We aim to recruit at least 20 patients who will undergo two months of dosing with placebo (inactive drug or sugar pill), followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant at 5 mg (taken by mouth) daily for continued safety monitoring.
3475485|NCT03836001|Active Comparator|Serlopitant Tablet|We aim to recruit at least 20 patients who will undergo two months of Serlopitant dosing, followed by one month of wash-out. All patients will be offered the option of participating in a 12-month open label extension with serlopitant 5 mg (taken by mouth) daily for continued safety monitoring.
3475486|NCT03835806|Active Comparator|Elastikon - traditional|The participant will be randomized to a treatment arm according to their racing bib number. Even bib numbers will be in the Elastikon treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape, sprayed with adhesive spray and then covered with Elastikon.
3475487|NCT03835806|Experimental|Rocktape - novel|The participant will be randomized to a treatment arm according to their racing bib number. Odd bib numbers will be in the Rocktape treatment arm. The researcher will evaluate the blister and treat according to treatment arm with the following blister treatment device intervention: the blister will be prepped per routine, drained, covered with paper tape and then covered with Rocktape
3475488|NCT03835832||HIV-infected participants who receive TST test|0.1 ml of tuberculin purified protein derivative will be intra-dermally inoculated on the forearm of the HIV-infected participants. They will learn how to interpret the results of the TST test. When they return to the clinic, the nurse will also interpret the results of the TST test. The results from the participants will be compared to the nurses' interpretation. We will assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the innovative method.
3475489|NCT03835845|Experimental|PICO7Y|PICO 7Y is a single-use NPWT System consisting of a small portable pump & pump clip, 2 AA batteries, 2 large multisite dressings, 2 extension tubes and secondary fixation strips.
3475490|NCT03835689|Experimental|Strongest Families Program Self-Managed (no coaching)|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
3475491|NCT03835689|Experimental|Strongest Families Program with Group Telephone Coaching|They will receive Strongest Families intervention immediately as well as the usual care services available for the 10 month study period.
3475492|NCT03835689|No Intervention|Information Resource Website|They will not receive Strongest Families Intervention during the 10 month study phase, but will receive the usual care services and access to an Information Resource Website.
3475493|NCT03835741|Experimental|Automated Oxygen titration|In this arm, an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
3475494|NCT03835741|Other|Manual Oxygen titration|In this arm, a manual adjustment of oxygen during patient hospitalisation by hospital staff
3475495|NCT03835767|Experimental|Milk DBPCFC|There are two double blind placebo controlled food challenges. The first challenge is to baked milk. The following participants will undergo this DBPCFC: -All participants who eat baked milk less than once per month. -Participants who never eat baked milk or straight milk. .On the first day of this challenge, participants will be randomized to either milk Baked milk or rice milk. Dry milk powder or corn starch. or placebo, and then will be challenged with the other food on the next day.
3475496|NCT03835767|Experimental|One-Step Open Feeding|Participants who are consuming baked milk, straight milk, and/or peanut products at least once per week will do a one-step oral food challenge.
3475497|NCT03835767|Experimental|Peanut DBPCFC|The DBPCFC for peanut allergy will be done with either peanut flour or a placebo (oat flour). The following participants will undergo this DBPCFC: -All participants who eat peanut less than once per month -Participants who never eat peanut. never eat peanut On the first day of this challenge, participants will be randomized to either peanut or placebo, and then will be challenged with the other food on the next day.
3475498|NCT03835767|Experimental|Two-Step Open Feeding|Participants who consume baked milk, straight milk, and/or peanut products less than once per week but at least once per month will do a two step open oral food challenge.
3475499|NCT03835793||Early-RRSO|"RRSO before the age of 45 years~RRSO was done 10 or more years ago"
3475500|NCT03835793||Late-/non-RRSO group|"Natural menopause ≥ 50 years of age~No RRSO ≤ age of 55~No treatment-induced menopause ≤ 50 years of age"
3475501|NCT03836014|Experimental|Fixed duration therapy for 24 months.|Daratumumab, Lenalidomide, Dexamethasone
3475502|NCT03836014|Active Comparator|Continuous therapy|Daratumumab, Lenalidomide, Dexamethasone
3475503|NCT03835702|No Intervention|Usual care with non-sleep provider|Participant will continue the follow up for sleep apnea with the non-sleep provider
3475504|NCT03835702|Experimental|SAM Clinic Intervention|Participants will attend a sleep apnea management group based intervention to improve PAP adherence.
3475505|NCT03835663||Patients with non erosive reflux|Patients with symptoms of reflux but no evidence of oesophagitis or Barretts oesophagus on endoscopy.
3475506|NCT03835663||Patients with erosive reflux|Patients with symptoms of reflux with evidence of oesophagitis or Barretts oesophagus on endoscopy.
3475507|NCT03835663||Patients with no reflux|Patients with healthy oesophago-gastric mucosa and no symptoms of reflux.
3475508|NCT03835611|Experimental|Intervention group|"Intervention Group: Participants in the intervention group will receive DT TT with GTP. GTP consists of standard treadmill nested with a pressure mapping system and an interactive computer game based sub-station in front of the treadmill. A miniature motion mouse with inbuilt sensors that enables real-time movements to be translated in computer sub-station by standard USB will be used. This miniature mouse will be secured to a helmet that participants will wear while walking on the treadmill to interact with computer sub-station. Participants will be expected to play commercial computer games while standing on compliant surface or walking on the treadmill. The motion mouse will help participants to control computer games hand free."
3475509|NCT03835611|Active Comparator|Control Group|Control group: Participants in the control group will undergo a mixture of current gait training programs available for people with Parkinson Disease. The protocol will be:
3475510|NCT03835676|Experimental|Pulmonary hypertension treated with Treprostinil|Thirty patients who will be treated with Treprostinil.
3475511|NCT03835715|Experimental|Vortioxetine|
3475512|NCT03835520|Experimental|MOLECULAR TARGETED THERAPIES|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
3475513|NCT03835520|Experimental|IMMUNOTHERAPY|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
3475514|NCT03835637|Experimental|Regimen A|
3475515|NCT03835637|Experimental|Regimen B|
3475516|NCT03835637|Experimental|Regimen C|
3475517|NCT03835637|Experimental|Regimen D|
3475518|NCT03835637|Experimental|Regimen F|
3179355|NCT00671996|Active Comparator|A|Mangafodipir treatment
3179356|NCT00671996|Placebo Comparator|B|
3179357|NCT00672009|Experimental|One|
3475519|NCT03835637|Experimental|Regimen H|
3475520|NCT03835637|Experimental|Regimen I|
3475521|NCT03835468|Experimental|Galacto-oligosaccharides (GOS) Group|Participants in this group will receive the daily dosage of galacto-oligosaccharides (GOS) prebiotic for 4 weeks
3475522|NCT03835468|Placebo Comparator|Maltodextrin Group|Participants in this group will receive the daily dosage of Maltodextrin placebo for 4 weeks
3475523|NCT03835429|Experimental|MyTAP oral appliance plus mouth shield|MyTAP plus mouth shield
3475524|NCT03835442|Active Comparator|baclofen arm|baclofen 10mg tid for 4 weeks
3179358|NCT00672035|Experimental|1|7.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3179359|NCT00672035|Experimental|2|7.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3475525|NCT03835442|Placebo Comparator|placebos arm|placebo tid for 4 weeks
3475526|NCT03835936|Active Comparator|Manual maneuvers physiotherapy|The protocol of physiotherapy treatment techniques consists of 20 minutes of FR based on prolonged slow expiration and cough provoked.
3475527|NCT03835936|Experimental|High frequency compression chest wall|The protocol consists in the application of the Smart Vest® device for high frequency compression of the chest wall, with a fixed frequency of 13 Hz and a time of 15 minutes. Then during 20 minutes will apply the same protocol as in the manual maneuvers group.
3475528|NCT03835624||juvenile idiopathic arthritis|about 60 cases of children with juvenile idiopathic arthritis diagnosed according to ILAR classification criteria of juvenile idiopathic arthritis will be recruited from pediatric rheumatology clinic of Benha university hospital serum interleukin 33 and its relative expression in peripheral blood mononuclear cells (PBMNCs) will be measured in their blood samples also IL-33 will be measured in synovial fluid samples
3475529|NCT03835624||control group|"about 60 apparently healthy children with comparable age and sex to the patients.~serum interleukin 33 and its relative expression in PBMNCs will be measured in their bloodsamples."
3475530|NCT03835572|Experimental|CircaHealth|The CircaHealth group will receive access to an online educational module on circadian rhythms and health as their intervention. Every week for six weeks, these participants will receive a new module that contains videos, quizzes, behavioral modification checklists, and journal prompts.
3475531|NCT03835572|Active Comparator|Sleep hygiene materials|The control group will receive publicly available materials about sleep hygiene from the National Sleep Foundation and/or the American Academy of Sleep Medicine every week for six weeks as their intervention.
3475532|NCT03835871|Experimental|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 12 weeks
3475533|NCT03835871|Experimental|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg per day Daily dose of Beclomethasone 200 µg 1 inhalation 100 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
3475534|NCT03835871|Experimental|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg per day Daily dose of Beclomethasone 100 µg 1 inhalation 50 μg ex-valve 2 times a day for 12 weeks Intervention: Drug: Placebo 1 inhalation 2 times a day for 12 weeks
3475535|NCT03835871|Placebo Comparator|placebo|Intervention: Drug: placebo 2 inhalations 2 times a day for 12 weeks
3475536|NCT03835559|Active Comparator|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure for treatment of incompetent Saphenous Veins is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
3475537|NCT03835559|Active Comparator|Surgical stripping|For treatment of incompetent Saphenous Veins, surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries under all types of anesthesia (general, spinal, regional block, or local anesthesia). The saphenous vein is then removed using a stripper. Compression stocking is apply.
3475538|NCT03835507|Placebo Comparator|Control group|Inject Normal saline 100ml * 12 times (1month apart)
3475539|NCT03835507|Experimental|Low dose group|Inject 500IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
3475540|NCT03835507|Experimental|High dose group|Inject 750IU/kg of EPO mixed with normal saline 100ml * 12 times (1month apart)
3132514|NCT03433794|Experimental|Intervention-plus-Booster|Participants navigated through Alcohol 101 Plus (TM) for 60 minutes. This is an online intervention, free to institutions and individuals. It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide basic information such as sex, weight, and state of residence so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. Importantly, their email 2 weeks later contained a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and reported harm reduction strategies.
3475541|NCT03835585|Experimental|Gun lock|Participants will be provided a gun lock and video instructions for its proper use, in addition to standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling).
3475542|NCT03835585|Active Comparator|Standard intervention|Participants will be provided standard suicide risk interventions (i.e., standardized full suicide risk assessment, safety planning, lethal means counseling) without a gun lock. A gun lock and video instructions will be provided upon completion of the study.
3475543|NCT03835494|Experimental|Fallot patients|Fallot patients
3475544|NCT03835494|Experimental|healthy controls|healthy volunteers
3475545|NCT03835390|Experimental|Intervention|Participants who agree to participate in the SIMDiscovery program will be asked if they would like to participate in the research. If they consent, they will fill out pre- and post-questionnaires concerning quality of life, anxiety levels concerning the surgery, and a knowledge assessment.
3475546|NCT03835533|Experimental|Cohort A: NKTR-214 + Nivolumab|
3475547|NCT03835533|Experimental|Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab|
3475548|NCT03835533|Experimental|Cohort C: CDX-301 + INO-5151 + Nivolumab|
3475549|NCT03835416|Experimental|WL-Control|0.8 g protein per kg body weight. Seven servings of whey protein powder (15 g/serving) per week will be provided to participants to support diet affordability.
3475550|NCT03835416|Experimental|WL-Protein|>30 g of high quality protein per meal, 1.2 g protein/kg body weight/day. Fourteen servings of high quality (30 g/serving) protein (lean meats, low fat dairy products) provided to participants each week to increase compliance.
3475551|NCT03835273||Control group|Fifty control participants who have not received upper gastrointestinal surgery.
3475552|NCT03835273||Minimally invasive surgery|Fifty patients who have undergone minimally invasive removal of oesophagus more than one year ago.
3475553|NCT03835273||Open surgery|Fifty patients who have undergone open removal of oesophagus more than one year ago.
3475554|NCT03835260|Other|Pivot Breath Sensor (user group)|Self-reported daily smokers of 2 or more cigarettes per day
3475555|NCT03835481|Placebo Comparator|Placebo|Blinded period of Placebo until Week 12
3475556|NCT03835481|Experimental|BI 730357 Fasted Condition|Blinded period of BI 730357 until Week 12 (4 dose levels or placebo as continued from trial 1407-0030). Open label period of BI30357 from Week 12 to end of trial (2 dose levels).
3475557|NCT03835481|Experimental|BI 730357 Fed Condition|Patients entering extension trial from Part 2 of trial 1407-0030
3475558|NCT03835286|Experimental|Vitamin C|Vitamin C experimental group
3475559|NCT03835286|Placebo Comparator|Control|Placebos Controlled group
3475560|NCT03835403|No Intervention|Usual Care (control arm)|These cardiac arrests will receive standard EMS response.
3475561|NCT03835403|Experimental|HeartRunner Activation|For these cardiac arrests, HeartRunners will be activated in addition to standard EMS response.
3475562|NCT03835338|Experimental|Test Group|The test group will receive Pulmonary Vein Isolation, LAA Isolation and LAA Occlusion with the WATCHMAN LAAC Device
3475563|NCT03835338|Active Comparator|Control Group|The control group will receive Pulmonary Vein Isolation
3475564|NCT03835351|Other|Intraoperative urinary catheter|After induction of general anesthesia, a standard catheterization kit available at the institution where the surgery is being performed will be used to place the urinary catheter using standard sterile technique.
3475565|NCT03835351|No Intervention|No intraoperative urinary catheter|No intraoperative urinary catheter will be used during the case
3475566|NCT03835325|Experimental|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
3475567|NCT03835312|Experimental|Interventional|Sequential transplantation of umbilical cord blood stem cells and islet cells
3475568|NCT03835299|No Intervention|Fear Control|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions then proceed through the normal blood donation process.
3475569|NCT03835299|Experimental|Fear Intervention|Participants who report blood donation-related fear who are assigned to this study arm will answer several questions and view a brief presentation of coping strategies presented via a computer tablet. They will then proceed through the normal blood donation process.
3475570|NCT03835299|No Intervention|No Fear Control|Participants who report no blood donation-related fear will proceed through the normal blood donation process.
3475571|NCT03835195|Experimental|Diabetes Disease Management Program|Diabetes Disease Management Program
3475572|NCT03835195|Active Comparator|Usual Care Process|Usual care process
3475573|NCT03835377|Experimental|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
3475574|NCT03835377|Active Comparator|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety)
3126478|NCT03038113|Experimental|Part 1: Single-Ascending Dose (SAD)|Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.
3475575|NCT03835182|Active Comparator|Ultrasound group|Thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The ultrasound group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and ultrasound 1MHz frequency (ten minutes) applied to the lower back, abdominal and lower back muscle strengthening exercises.
3475576|NCT03835182|Active Comparator|Short wave diathermy group|The short wave diathermy group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The short wave diathermy group will be treated with a hotpack (20minutes), transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) and short wave diathermy at a frequency of 27.12MHz (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
3475577|NCT03835182|Other|Control group|The control group will consist of thirty one patients receiving a total of ten sessions of physical therapy over a two week period. Each week the patients will receive five session of physical therapy on consecutive days. The control group will be treated with a hotpack (20minutes) transcutaneous electrical nerve stimulation (TENS) at a frequency of 100Hz intensity adjusted to the patient's tolerability (twenty minutes) applied to the lower back , abdominal and lower back muscle strengthening exercises.
3475578|NCT03834896|Experimental|Experimental|Patients with dysphagia requiring Stage 1, 2 or 3 thickened fluids as determined by Speech and Language Therapist and who are expected to require provision of Stage 1, 2 or 3 thickened fluids for at least 2 further weeks.
3475579|NCT03834818|Experimental|COMPAS Participants|Patents between the ages of 18 and 90 who are undergoing orthopedic surgery at Duke Health will be eligible for enrollment.
3475580|NCT03834766|Active Comparator|AMPH ER Tab|Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg
3475581|NCT03834766|Placebo Comparator|Matching Placebo|Matching Placebo Tablets 5, 10, 15 and 20 mg
3475582|NCT03834857|Other|single|Implantation of Stentrode TM device
3475583|NCT03834870|Experimental|Elder adults in emergency department setting|Elder mistreatment in an Emergency Department setting.
3475584|NCT03834831|Active Comparator|Coenzyme Q10|Coenzyme Q10 200mg/day for 3 months
3475585|NCT03834831|Active Comparator|Selenium|Selenium mcg/day for 3 months
3132515|NCT03434119|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine/lixisenatide) once daily in the morning within 1 hour before breakfast, on top of oral anti-diabetic drug (OAD) therapy for 26 weeks.
3132516|NCT03434119|Active Comparator|Lantus|Lantus (Insulin glargine) once daily at any time of the day but at about the same time every day on top of OAD therapy for 26 weeks.
3475586|NCT03834974|Experimental|Sun Safety Social Media Challenge|During this 4-week intervention, participants will be incentivized to create sun safety social media messages that will be distributed on our sun safety Twitter and Facebook feeds.
3475587|NCT03834974|Active Comparator|Digital Health Social Media Challenge|During this 4-week intervention, participants will be incentivized to create posts that promote the use of technology to engage in healthy lifestyle behaviors (diet, exercise) on our digital health Twitter and Facebook feeds.
3475588|NCT03834948|Experimental|AO-176 Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
3475589|NCT03834948|Experimental|AO-176 Dose Expansion|Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.
3475590|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
3475591|NCT03834948|Experimental|AO-176 + Paclitaxel Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + paclitaxel.
3475592|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Escalation|Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT.
3475593|NCT03834948|Experimental|AO-176 + Pembrolizumab Dose Expansion|Once the MTD/RP2D has been established, tumor-speciﬁc dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efﬁcacy of AO-176 + pembrolizumab.
3475594|NCT03835208|Experimental|Low-morning-carbohydrate|"Low morning intake and high evening intake of carbohydrates. This means a distribution of carbohydrate as follows:~10% morning, 40% lunch, 50% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
3475595|NCT03835208|Experimental|High-morning-carbohydrate|"High morning intake and low evening intake of carbohydrates.~This means a distribution of carbohydrate as follows:~50% morning, 40% lunch, 10% dinner. The overall recommendations for macro- and micronutrient intake for GDM patients will be met."
3475596|NCT03834844|No Intervention|Usual Care|patient receives same care as patients not enrolled in study intervention
3475597|NCT03834844|Experimental|AF education|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week.
3475598|NCT03834844|Experimental|Mindfulness Meditation Practice|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
3475599|NCT03834844|Experimental|Weekly Phone Calls|Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
3475600|NCT03834844|Experimental|AF Education and Mindfulness Meditation|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6.
3475601|NCT03834844|Experimental|AF Education and Weekly Phone Calls|Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
3475602|NCT03834844|Experimental|Mindfulness Meditation and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
3475603|NCT03834844|Experimental|Meditation and Education and Phone Calls|Each participant watches an mindfulness meditation introductory video in the initial session and then is asked to practice for 10 minutes each day using a guided audio, which includes a different topic each week. Participant receives 6 modules of AF education topics that are intended to be completed consecutively, one each week. The time duration of the guided meditations increases to 15 minutes each day during Weeks 3-6. Each week for the six-week intervention, the researcher will contact the participant by phone at an agreed upon time and will discuss any questions, issues or concerns that are voiced by the participant within 5-15 minutes.
3475604|NCT03835039||HIE|Infants with a diagnosis of HIE
3475605|NCT03834740|Experimental|Cohort 1: last dose 1 to 3 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 1: last ribociclib+everolimus dose 1 to 3 hours prior to craniotomy for tumor resection"
3475606|NCT03834740|Experimental|Cohort 2: last dose 7 to 9 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 2: last ribociclib+everolimus dose 7 to 9 hours prior to craniotomy for tumor resection"
3475607|NCT03834740|Experimental|Cohort 3: last dose 23 to 25 hours prior to resection|"Three to fourteen patients will receive ribociclib and everolimus orally-administered in 5 daily doses with the last dose being administered at one of 3 intervals before brain tumor resection:~• Cohort 3: last ribociclib+everolimus dose 23 to 25 hours prior to craniotomy for tumor resection"
3475608|NCT03835117|Experimental|Wide-spectrum nutritional supplement|The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion.
3475609|NCT03835117|Placebo Comparator|Placebo control|Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing.
3475610|NCT03834805|Experimental|Pregnant women with a normal pregnancy|Assesment of fetal lung and liver stiffness with 2D Ultrasounds Shear Wave Elastography
3475611|NCT03835000||Pre operative patient|Patients who will require orthopedic surgery for corrective, replacement or repair
3475612|NCT03835091||Patient with mechanical ventilation and sedation|All patient hospitalized in intensive care under sedation and mechanical ventilation without neurologic disorder
3475613|NCT03834935|Experimental|Pim|20 patients receiving topical Elidel (pimecrolimus 1%) bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
3475614|NCT03834935|Placebo Comparator|Pl|20 patients receiving placebo (control group), cold cream bid on the affected area for 9 weeks.Sunscreens will not be indicated, and hygienic habits will not be changed.
3132517|NCT03434249|Experimental|Group I|patients who take Bifidobacterium BB-12® (Bifidolactis Infant), 6 drops a day (guaranteeing a billion of living cells) for 28 consecutive days;
3475615|NCT03835104|Active Comparator|CRP in all|"All children will undergo a CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
3475616|NCT03835104|Experimental|CRP in high risk children only|"Children who are positive on a clinical prediction rule for serious infections in children will undergo CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes using the Afinion 2 (Abbott).~There will be only 1 test at study entry"
3475617|NCT03834714|Active Comparator|Noise Stimulus and Infrared Light|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive infrared light therapy for 2 out of the 4 visits and sham infrared light therapy for the other 2 visits.
3475618|NCT03834714|Sham Comparator|Noise Stimulus and Sham|All participants will receive noise stimulus at each of the 4 visits. In addition, they will receive sham infrared light therapy for 2 out of the 4 visits and infrared light therapy for the other 2 visits.
3475619|NCT03834883|Experimental|Postmenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
3475620|NCT03834883|Placebo Comparator|Postmenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
3475621|NCT03834883|Experimental|Premenopausal women: Progesterone|Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
3126479|NCT03038113|Experimental|Part 2: Multiple Ascending Dose|Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.
3126480|NCT03038126|Active Comparator|CCHT|Veterans Administration (VA) CCHT with an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
3475622|NCT03834883|Placebo Comparator|Premenopausal women: Placebo|Subjects will receive oral placebo, two capsules once daily every evening for 7 days
3475623|NCT03834909|Active Comparator|Standard Dose Truvada®|Standard Dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), one tablet each day
3475624|NCT03834909|Experimental|Pregnancy-Adjusted Truvada®|Pregnancy-Adjusted dose Truvada® - Tenofovir disoproxil fumarate (TDF) 300 mg/Emtricitabine (FTC) 200 mg fixed dose combination (Truvada®), two tablets each day
3475625|NCT03835065|Active Comparator|Long Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
3475626|NCT03835065|Experimental|Short Arm Fiberglass Cast|Conscious sedation will be provided to patient while the reduction is performed by a cast trained orthopedic resident using standard techniques under fluoroscopic guidance. The arm will be held by an assistant or finger traps in the absence thereof. The arm will not be suspended until after the manipulation is performed. A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
3475627|NCT03834922||Total knee arthroplasty|Patients undergoing total knee arthroplasty
3126481|NCT03038126|Placebo Comparator|Usual care|
3475628|NCT03834922||Sternotomy|Patients undergoing sternotomy
3475629|NCT03834922||Breast|Patients undergoing breast surgery
3475630|NCT03834922||Endometriosis|Patients undergoing endometriosis-related surgery
3475631|NCT03834701|Experimental|EUS guided radiofrequency ablation|Radiofrequency ablation will be performed using a system that consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure.
3475632|NCT03834610|Active Comparator|Group A|receive L-arginine 5 g oral caps daily for 8 weeks serum testosterone level measurement penile doppler
3475633|NCT03834610|Active Comparator|Group B|receive tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
3475634|NCT03834610|Active Comparator|Group C|receive L-arginine 5 g oral caps plus tadalafil 10 mg oral tablets daily for 8 weeks serum testosterone level measurement penile doppler
3475635|NCT03834610|Placebo Comparator|Group D|receive oral methyl cellulose daily for 8 weeks serum testosterone level measurement penile doppler
3475636|NCT03834623|Experimental|CC-122 Plus Nivolumab|Participants will take CC-122 orally at 2mg daily for 5 consecutive days every 7 days, with intravenous nivolumab (240mg) in days 1 and 15 within a 28-day cycle.
3475637|NCT03834662|Experimental|Dose Level 1: 180 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks. Starting dose for dose escalation.
3475638|NCT03834662|Experimental|Dose Level 2: 550 mg/m2 of AVID200|Intravenous infusion of AVID200 over 1 hour administered every three weeks.
3475639|NCT03834662|Experimental|Dose Level 3: 1100 mg/m2|Intravenous infusion of AVID200 over 1.5 hours administered every three weeks.
3475640|NCT03834636|Active Comparator|Nanoparticulated composite - self-etch|
3475641|NCT03834636|Active Comparator|Nanoparticulated composite - total-etch|
3475642|NCT03834636|Active Comparator|Nanohybrid composite - self-etch|
3475643|NCT03834636|Active Comparator|Nanohybrid composite - total-etch|
3475644|NCT03834441|Other|Oral screening|
3126482|NCT03038308|Experimental|ROP Intervention|Patients with hyperprolactinemia were treated with long-term ROP therapy for 6 months in an open-label dose escalation study
3126483|NCT03038399|Experimental|Dose Level Group 1|Participants enrolled in Dose Level Group 1 will receive vamorolone 0.25 mg/kg/day.
3126484|NCT03038399|Experimental|Dose Level Group 2|Participants enrolled in Dose Level Group 2 will receive vamorolone 0.75 mg/kg/day.
3126485|NCT03038399|Experimental|Dose Level Group 3|Participants enrolled in Dose Level Group 3 will receive vamorolone 2.0 mg/kg/day.
3126486|NCT03038399|Experimental|Dose Level Group 4|Participants enrolled in Dose Level Group 4 will receive vamorolone 6.0 mg/kg/day.
3126487|NCT03038438|Experimental|Abre|Abre Venous Self-expanding Stent System
3475645|NCT03834441|Other|Written screening|
3475646|NCT03834454|Active Comparator|Bupivacaine 5 mg|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
3475647|NCT03834454|Active Comparator|Bupivacaine 7.5 mg|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
3475648|NCT03834415|Experimental|Lactobacillus reuteri DSM17038|Lactobacillus reuteri DSM17038, 1x108 CFU once a day for 30 days
3475649|NCT03834415|Placebo Comparator|Placebo probiotics|Placebo for probiotics, pols drops similar in consistency and flavor as experimental product
3126488|NCT03038620|Experimental|Liraglutide 3.0 mg|"Drug: Liraglutide Active Drug~Other Names:~Saxenda~Escalate the liraglutide (active) dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
3126489|NCT03038620|Placebo Comparator|Placebo|"Drug: Placebo (for Liraglutide at a concentration of 6.0 mg/mL) Placebo tablet manufactured to mimic Liraglutide at a concentration of 6.0 mg/mL~Other Names:~Placebo~Saline injection~Escalate the Placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day through subcutaneous injection."
3179360|NCT00672035|Experimental|3|22.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3475650|NCT03834480|Experimental|• Steroid Group (S)|
3475651|NCT03834480|Experimental|• Platelet rich plasma Group (PRP)|
3475652|NCT03834389|Experimental|Experimental Group|Experimental group: case-based teaching method applied
3475653|NCT03834389|No Intervention|Control Group|Control group: classical teaching method applied
3475654|NCT03834649|Active Comparator|Mucograft|Soft tissue augmentation of the defective alveolar ridge using Mucograft inside the prepared vestibular pouch leaving part of the mucograft exposed at the crestal area and will be sutured using 5/0 suture material around the defect margin and secured in the vestibular pouch.
3475655|NCT03834649|Experimental|Partially de-epithelialized connective tissue graft|Soft tissue augmentation of the defective alveolar ridge using Partially de-epithelialized connective tissue graft by preparing vestibular pouch at the defect site and place the de-epithelialized part inside the pouch leaving the epithelialized part sutured and exposed at the crestal area
3475656|NCT03834519|Experimental|Pembrolizumab + Olaparib|Participants receive olaparib 600 mg as two 150 mg oral tablets twice daily (BID) continuously until progression PLUS on Day 1 of each 21-day cycle, pembrolizumab 200 mg by intravenous (IV) infusion for up to 35 cycles (approximately 2 years).
3475657|NCT03834519|Active Comparator|Abiraterone + Prednisone or Enzalutamide|Participants receive abiraterone acetate (participants previously treated with enzalutamide) 1000 mg as two 500 mg or four 250 mg oral tablets once daily (QD) PLUS prednisone 10 mg as one 5 mg tablet BID until progression OR Participants receive enzalutamide (participants previously treated with abiraterone acetate) 160 mg as four 40 mg oral tablets or capsules OR two 80 mg tablets QD until progression.
3475658|NCT03834428|Active Comparator|No Text Message Control|Participants randomized to this arm will receive education about the ICOUGH protocol which includes the importance of ambulation.
3475659|NCT03834428|Experimental|Text Message Intervention|Participants randomized to this arm will receive daily text message reminders to ambulate in the hospital in addition to education about the ICOUGH protocol which includes the importance of ambulation.
3475660|NCT03834558|No Intervention|Control Group|They will follow their daily routine without added exercise
3475661|NCT03834558|Experimental|Intervention Group|They will perform the mixed exercise program
3475662|NCT03834506|Experimental|Pembrolizumab+Docetaxel|On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by intravenous (IV) infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months). Participants also receive pembrolizumab 200 mg by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years).
3475663|NCT03834506|Placebo Comparator|Placebo+Docetaxel|"On Day 1 of each 21-day cycle, participants receive dexamethasone 8 mg by oral tablets at 12 hours, 3 hours and 1 hour prior to docetaxel administration PLUS docetaxel 75 mg/m^2 by IV infusion for up to a maximum of 10 cycles (approximately 7 months). Participants receive prednisone 5 mg by oral tablets twice daily during each docetaxel cycle up to a maximum of 10 cycles (approximately 7 months).~Participants also receive placebo by IV infusion on day 1 of each 21-day cycle for up to a maximum of 35 cycles (approximately 2 years)."
3475664|NCT03834688|Experimental|Induction|Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.
3475665|NCT03834584|Experimental|AG-636|AG-636 dosed orally.
3475666|NCT03834571|Experimental|Arm I (standard care, carboplatin, paclitaxel)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3475667|NCT03834571|Active Comparator|Arm II (standard care, active monitoring)|"STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.~4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months."
3475668|NCT03834467|Experimental|Arm 1 - Elevation Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 1 then presents the Moral Elevation stimulus video after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
3475669|NCT03834467|Sham Comparator|Arm 2 - Control Stimulus Video|All subjects complete the Levenson Psychopathy Scale first. Arm 2 then presents the control stimulus (nature video) after playing the first AlAn's Short Game v.2 (session 1). Participants will then play the AlAn's Short Game v.2 (session 2) for a second time and then fill out an Adverse Childhood Experiences Questionnaire (ACES), Social Connectedness survey, and Demographics form.
3475670|NCT03834259|Active Comparator|Group 1|12.5 mg 0.5% hyperbaric bupivacaine
3475671|NCT03834259|Active Comparator|Group 2|10 mg 0.5% hyperbaric bupivacaine
3475672|NCT03834259|Active Comparator|Group 3|12.5 mg 0.5% hyperbaric bupivacaine
3475673|NCT03834207|Experimental|Intervention Group|Use of the C3-Cloud IT system
3475674|NCT03834233|Experimental|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
3475675|NCT03834272|Experimental|1st Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3475676|NCT03834272|Experimental|2nd Tier Dose Level- LUM Imaging System|3 patients will be administered a single dose of LUM015 at 1.5 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3475677|NCT03834272|Experimental|3rd Tier Dose Level- LUM Imaging System|12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
3475678|NCT03834298|Experimental|Four Food Elimination Diet (FFED)|There is one arm to the study. All participants meeting eligibility will be assigned to intervention / treatment with a previously defined four food elimination diet (FFED) (Aim 1). This is a longitudinal study in which outcome measures including symptoms, QOL and inflammation at baseline and at 2, 4 and 6 weeks after starting stand of care (SOC) FFED will be measured. Participants meeting eligibility for Aim 2 will have foods added back to the diet using a specified protocol.
3475679|NCT03834324|Experimental|intervention|FES
3475680|NCT03834181|Experimental|Monitoring evaluation|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"
3475681|NCT03834311|Experimental|isokinetic|
3475682|NCT03834311|Active Comparator|exercise band|
3475683|NCT03834285||Cirrhosis in pregnancy|Cirrhotic patients with a confirmed pregnancy will be placed into Cohort 1.
3475684|NCT03834285||Pregnancy-associated liver diseases|Patients who develop Acute Fatty Liver of Pregnancy, HELLP Syndrome / Intrahepatic Cholestasis of pregnancy will be placed into Cohort 2.
3475685|NCT03834038|Experimental|Open Label Lyophilized Fecal Microbiota Transplantation|Eligible participants with history of recurrent or refractory CDI
3475686|NCT03833973||Runners|Long-distance runners, marathon runners, 5 km and 10 km runners, both female and male aged 20 - 40 years, participating in regular training and competitions.
3126490|NCT03038815|Experimental|Controll-VACOped-Ortho Tri|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the VACOped as the first intervention.
3475687|NCT03833973||Soccer Players|High Level soccer players, both female and male aged 15-30, participating in all games
3475688|NCT03834051|Experimental|Open Label|Fecal Microbiota Transplantation
3475689|NCT03833934||Plasma Next Generation Sequencing (NGS)|Subjects will be sent blood collection kits with the necessary materials for local draws and those specimens will be sent directly by the subjects to the central laboratory (Resolution Bioscience) for plasma NGS. Plasma NGS results will be returned to the subject, their treating physician and study team, aiming to return results within 2 weeks by Resolution Bioscience.
3475690|NCT03833999|Experimental|Ondansetron and lactulose|Ondansetron 8mg three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
3475691|NCT03833999|Placebo Comparator|Placebo and lactulose|placebo oral capsule, one three times daily for 48 hours lactulose 20ml twice daily for 48 hours Serial abdominal MRI imaging
3475692|NCT03834142|Experimental|Intervention|NSS-2-Bridge auricular therapy will be given in addition to standard of care.
3475693|NCT03834142|No Intervention|Control|No intervention, subject receives standard of care
3475694|NCT03834103|Other|Arm 1: Self-rehabilitation arm|Self-rehabilitation arm
3475695|NCT03834012|Experimental|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 ug per day Daily dose of Beclomethasone 800 ug 4 inhalations 100 μg ex-valve 2 times a day for 6 weeks
3126491|NCT03038815|Experimental|Controll-Ortho Tri-VACOped|All participants are in the control and the two intervention group. The instant change of the ankle joint motion is analyzed. For control, the participants are wearing Sport shoes.This group had the Ortho Tri first intervention
3126492|NCT03038867|Experimental|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
3475696|NCT03834012|Active Comparator|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day 4 inhalations 80 μg ex-actuator 2 times a day for 6 weeks
3126493|NCT03038867|Placebo Comparator|Placebo|Placebo
3475697|NCT03834012|Placebo Comparator|Placebo|Intervention: Drug: placebo 4 inhalations 2 times a day for 6 weeks
3475698|NCT03834012|Experimental|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg per day Daily dose of Beclomethasone 400 µg 2 inhalations 100 μg ex-valve 2 times a day for 6 weeks Intervention: Drug: Placebo 2 inhalations 2 times a day for 6 weeks
3475699|NCT03833921|Other|Abiraterone acetate + prednisone|All subjects will receive abiraterone acetate and prednisone, as per standard of care. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone twice per day. Subjects will continue to take abiraterone acetate and prednisone until confirmed disease progression.
3475700|NCT03833882|Experimental|MAF1217/Cationorm|
3475701|NCT03833882|Experimental|Cationorm/MAF1217|
3475702|NCT03834129|Experimental|(Dex group) intravenous infusion of dexmedetomidine|Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%
3475703|NCT03834129|Placebo Comparator|(Control group) intravenous infusion of physiological serum|Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%
3475704|NCT03833895|Experimental|Group 1 Elements|Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
3126494|NCT03038880|Experimental|6 mg Faricimab Q12W|6 mg faricimab was given by intravitreal (IVT) injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by 6 mg faricimab IVT injection once every 12 weeks (Q12W) from Week 24 up to Week 48 (injections at Weeks 24, 36, and 48; 3 injections).
3475705|NCT03833895|Experimental|Group 2 Elements|Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
3475706|NCT03833895|Placebo Comparator|Group 3 Elements|In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.
3475707|NCT03834116|Experimental|Inspiratory muscle training group|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
3475708|NCT03834116|No Intervention|Control group|The control group will receive standard treatment in a fast-track design.
3475709|NCT03833908|Experimental|patients receiving MAF-1217|patients receiving MAF-1217 from week -2 to week 2 (preand post-surgery, total 4 weeks), standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin for 7 days) from day 0 (post-surgery.
3475710|NCT03833908|No Intervention|patients receiving just standard antibiotic therapy|patients receiving just standard antibiotic therapy (ofloxacin) from day -3 before surgery, and standard postoperative treatment (topical steroid, dexamethasone for 10 days + antibiotic, ofloxacin 7 days) from day 0 (postsurgery).
3475711|NCT03833986|Experimental|Stress management program|The stress program will be delivered to experimental group in a six-sessions for two weeks, each session will take 2 hours (2 hours/six sessions /two weeks).
3475712|NCT03833986|No Intervention|Control|There is no intervention for controlled group during workshop but they are put on a waiting-list to receive the intervention after the active treatment group does.
3475713|NCT03834090|Experimental|rESWT|the group receiving rESWT
3475714|NCT03834090|Active Comparator|supervised exercises|the group receiving supervised exercises
3475715|NCT03833947|Experimental|lignocaine with bicarbonate|Endotracheal tube cuff was filled with mixture of 7.5% sodium bicarbonate with 2% lignocaine in a ratio of 0.5:9.5 ml
3475716|NCT03833947|Active Comparator|lignocaine with dexamethasone|Endotracheal tube cuff was filled with mixture of dexamethasone with 2% lignocaine in a ratio of 0.5:9.5 ml
3475717|NCT03834194|Experimental|Lottery + Monthly Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
3126495|NCT03038880|Experimental|6 mg Faricimab Q16W|6 mg faricimab was administered by IVT injection once every 4 weeks (Q4W) up to Week 12 (4 injections), followed by no doses up to Week 24 when a protocol-defined assessment of disease activity was performed. Participants with disease activity at Week 24 initiated 6 mg faricimab IVT Q12W dosing, and participants without disease activity at Week 24 initiated 6 mg faricimab IVT once every 16 weeks (Q16W) dosing for the remainder of the study.
3126496|NCT03038880|Active Comparator|0.5 mg Ranibizumab Q4W|0.5 mg of ranibizumab was administered by IVT injection once every 4 weeks (Q4W) for 48 weeks (13 injections).
3126497|NCT03039023|Experimental|Whole Hardboiled Eggs|Subjects will consume four (4) pre-cooked, pre-peeled whole hardboiled eggs per day for 28 days.
3475718|NCT03834194|Experimental|Lottery + Overall Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
3126498|NCT03039023|Experimental|Choline Bitartrate Tablets|Subjects will consume two (2) 500mg choline bitartrate tablets per day for 28 days.
3126499|NCT03039023|Experimental|Hardboiled Eggs + Choline Bitartrate Tablets|Subjects will consume both four (4) whole, pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
3126500|NCT03039023|Experimental|Egg Whites + Choline Bitartrate Tablets|Subjects will consume both the egg whites (no yolks) of four (4) pre-cooked, pre-peeled hardboiled eggs and two (2) 500mg choline bitartrate tablets per day for 28 days.
3126501|NCT03039023|Experimental|Phosphatidylcholine Capsules|Subjects will consume six (6) 420 mg phosphatidylcholine capsules by mouth per day for 28 days.
3126502|NCT03039088||Fibromyalgia patients|
3126503|NCT03039088||Not fibromyalgia patients|
3126504|NCT03039179|Experimental|Polyurethane foam|
3126505|NCT03039179|No Intervention|standard care|Only application of the Walker in the immediate postoperative period.
3132518|NCT03434249|Placebo Comparator|Group II|patients who take Bifidolactis Infant Placebo 6 drops a day for 28 consecutive days.
3475719|NCT03834194|Experimental|Lottery + Overall Weight|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings ($0, $2, $15 or not eligible for lottery due to lack of weighing). Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
3126506|NCT03039192|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care (SOC) antidepressant treatment.
3126507|NCT03039192|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25) along with standard of care antidepressant treatment.
3475720|NCT03834194|Experimental|Lottery + Monthly Weight + Exercise|Participants will be eligible for a daily lottery if they have weighed themselves in the previous day on the e-scale. For each day of the study, participants will be informed of the study's randomly-generated winning lottery number and their winnings if any. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
3475721|NCT03834194|Experimental|Loss + Monthly Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, participants will be specifically notified that they would have received $14 had they had gained within the recommended range for the month, drawing on research showing that loss aversion can be motivating.
3475722|NCT03834194|Experimental|Loss + Overall Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
3475723|NCT03834194|Experimental|Loss + Overall Weight|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the Institute of Medicine gestational weight gain recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit.
3475724|NCT03834194|Experimental|Loss + Monthly Weight + Exercise|Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will receive $14 per month if they have gained within the recommended monthly range for their BMI category. Otherwise, they will be notified that they would have received $14 had they had gained within the recommendation for the month. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
3475725|NCT03833869|Experimental|Assisted hatching|Five-day frozen embryos will undergo assisted hatching prior to embryo transfer
3475726|NCT03833869|No Intervention|Control|Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer
3126508|NCT03039283||Nucleus CI532 cochlear implant|
3126509|NCT03039543|Active Comparator|moderate neuromuscular blockade|During operation, intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2). Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2.
3126510|NCT03039543|Experimental|deep neuromuscular blockade|During operation, intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade. Patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
3126511|NCT03039569|Experimental|Text messaging|Participants will receive 3 messages weekly consisting of nutrition education and diabetes self-management information and skills for 3 months (12 weeks).
3475727|NCT03834077|Experimental|Tissue flossing|Conventional physiotherapy consisted in electrotherapy and stretching in addition to tissue flossing.
3475728|NCT03834077|Placebo Comparator|Placebo comparator|Conventional physiotherapy consisted in electrotherapy and stretching in addition with tissue flossing without tension.
3475729|NCT03833843||TGA|
3126512|NCT03039569|No Intervention|Control|Participants will not receive text message intervention. This is the measurement-only group
3126513|NCT03039621|Experimental|Ergoferon|Tablet for oral use, 1 tablet per intake (outside a meal/feeding). On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day (total 8 tablets). From day 2, one tablet is taken every 8 hours. The drug is administered outside a meal (in the interval between meals or 15 minutes before meal or fluid intake). Keep the tablet in the mouth, without swallowing, until completely dissolved. For young children (aged 6 months to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature. The therapy lasts for 5 days.
3126514|NCT03039621|Placebo Comparator|Placebo|Placebo using Ergoferon scheme.
3179361|NCT00672035|Experimental|4|22.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3475730|NCT03834155|Experimental|Hospital-based CR + Mobile Application|Traditional hospital-based cardiac rehabilitation with mobile application.
3475731|NCT03834155|Experimental|Choice CR + Mobile Application|Choice of hospital or home-based cardiac rehabilitation with mobile application.
3475732|NCT03834155|Experimental|Hospital-based CR + Mobile Application + Nudge|Hospital-based cardiac rehabilitation with mobile application and nudges.
3126515|NCT03039686|Experimental|RO7239361 Low Dose|Participants received low dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received low dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
3475733|NCT03834155|Experimental|Choice CR + Mobile Application + Nudges|Choice of Hospital or home-based cardiac rehabilitation with mobile application and nudges.
3475734|NCT03833830||longterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) >20 injections
3475735|NCT03833830||shortterm treatment group|previous treatment (before Optical Coherence Tomography angiography (OCTA)) < 5 injections
3475736|NCT03833804|Experimental|NLP (natural language processing) pre-screen|Automated processing of clinical notes collected during routine care in first 24 hours of hospital admission to identify individuals at-risk for substance misuse to receive standard-of-care full screening and assessment, brief intervention, or referral to treatment (SBIRT) intervention.
3475737|NCT03833518|Experimental|Hand impairment due to stroke or spinal cord injury|Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.
3475738|NCT03833505||Group 1,|E. vermicularis-positive
3475739|NCT03833505||Group 2|E. vermicularis-negative
3475740|NCT03833778|Other|Intervention group|Answering disease related questions during playing a tablet game
3475741|NCT03833778|No Intervention|control group|
3475742|NCT03833817|Experimental|Intervention arm|This study is a single arm study in which patients and caregivers will be given the experimental intervention (TAC intervention) with assessments pre and post intervention. The intervention will consist of six 45-minute telephone-delivered sessions. Session topics will include: (a) Distress management/tolerance (Sessions 1 and 2); (b) communication skills (Sessions 3 and 4); (c) guided review of prognostic information (Session 5); and (d) Intervention review and future plan (Session 6). Sessions will be completed by the individual (Sessions 1 and 3) and dyad (Sessions 2, and 4-6).
3179362|NCT00672035|Experimental|5|37.5µg LT Dose placed at the Deltoid on Day 0 and Day 21
3475743|NCT03833648|No Intervention|Arm 1 - Usual Care|No intervention, patients will receive treatment as usual. Patients will download the UControl Pain app on their personal cell phones and will complete the four study surveys via the app or via REDCap.
3475744|NCT03833648|Experimental|Arm 2 - UControl Pain App with Education|Patients will install the UControl Pain app on their personal cell phones. The app will include educational information about pain management, e.g., using acetaminophen and NSAIDs for pain, as well as information on addiction and safe storage of medications. Subjects will also complete the four study surveys via the app or via REDCap.
3475745|NCT03833752|Experimental|Flexible Cystoscopy|Diagnostic flexible cystoscopy for the patients in this arm
3475746|NCT03833752|Active Comparator|Rigid Cystoscopy|Diagnostic rigid cystoscopy is done for the patients in this arm
3475747|NCT03833739|Experimental|Upper Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the upper and lower arches.~starting treatment in the upper arch The upper ach was bonded for 28 patients and teeth alignment was started using round 0.014NiTi arch wire. The 0.014NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. Orthodontic treatment was continued in the upper arch with arch wire sequence of 0.014NiTi, 0.018NiTi, 0.016X0.022NiTi, 0.019X0.025NiTi, and 0.019X0.025stainless steel arch wires. The patients were followed up on a monthly basis until sufficient proclination of the upper incisors achieved to establish an overjet of at least 4 mm. After reaching the full working arch wire in lower arch (0.019 X 0.025stainless steel wire), lateral cephalogram and study models were taken."
3475748|NCT03833739|Experimental|Lower Arch Treatment First|"Intervention : using fixed orthodontic pre-adjusted edgewise appliance in the lower arch and anterior bite plate in the upper arch.~The lower arch was bonded after taking the pretreatment records. At the same appointment an anterior bite plate in the upper arch was delivered to prevent shearing off the mandibular incisor brackets and help in correction of anterior deep bite .After lower arch alignment and leveling in the same arch wire sequence as the other group and 0.019 X 0.025stainless steel arch wire was reached, the anterior bite plate was removed and the upper arch was bonded. The same arch wire sequence was used in the upper arch as was used in the lower arch. When the full working arch wire (0.019 X 0.025stainless steel arch wire) was reached in the upper arch, study models and lateral cephalogram were taken."
3475749|NCT03833791|Active Comparator|Control Group (CON)|education and modifying diet
3475750|NCT03833791|Experimental|Moderate physical activity Group (PAM)|education, modifying diet and physical activity prescription
3475751|NCT03833791|Experimental|Intensity physical activity Group (PAI)|education, modifying diet and physical activity prescription
3475752|NCT03833401|Sham Comparator|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation. This will serve as control group.
3475753|NCT03833401|Experimental|Autologous tissue transplantation|Root canal disinfection will be performed and revascularization will be induced with autologous tissue transplantation.
3475754|NCT03833635|Experimental|OMT|
3475755|NCT03833635|Placebo Comparator|Control|
3475756|NCT03833687|Experimental|Profhilo®|"The 1st treatment was performed during the basal visit and repeated after 1 month.~3 mL of Profhilo® for each brachial zone, 1.5 mL for hemiabdomen was injected into the middle-deep dermis by needle (29 G) using a bolus technique called BAP (Bio Aesthetic Point technique); this technique involves a series of 10 micro-wheals on 3 horizontal-levels for each tested areas (3-4-3 injection points respectively for the 1st, the 2nd and the 3rd horizontal-level). The amount of product to be injected was of 0.3 ml for each point."
3475757|NCT03833544|Experimental|Treatment Arm|Exercise training: Progressive resistance training of hip, knee, and ankle flexors.
3475758|NCT03833726|Experimental|LED group|Participants who will submitted to active procedure with LED. Both groups will be submitted to kinesiotherapy.
3475759|NCT03833726|Sham Comparator|Control group|Participants who will submitted to sham procedure with heated gel. Both groups will be submitted to kinesiotherapy.
3475760|NCT03833375|No Intervention|Usual Care (n=20)|Control: general information about TBI from Center for Disease Control (CDC)/about stroke/Intracerebral Hemorrhage (ICH) from American Heart/Stroke Association
3475761|NCT03833375|Experimental|Decision Aid (n=20)|Paper Decision aid (share decision making tool) with worksheet for surrogates
3475762|NCT03833531|Active Comparator|PTSD-ImRS|PTSD treatment
3475763|NCT03833531|Experimental|Integrated SFT-ImRS|Integrated PTSD-PD treatment
3475764|NCT03833661|Experimental|M7824|
3475765|NCT03833492|Experimental|Underwater EMR|"The patients who are randomized to the  Underwater EMR arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
3475766|NCT03833492|No Intervention|Traditional EMR|"The patients who are randomized to the  Traditional EMR arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
3475767|NCT03833349|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
3475768|NCT03833349|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
3475769|NCT03833349|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
3475770|NCT03833609|Experimental|Online yoga training (Group A)|Participants will receive an e-pamphlet on physical exercise developed by The Arthritis Society, and will be invited to complete a yoga training program. The yoga training program is a structured low-intensity Vishwas-Raj. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
3475771|NCT03833609|Experimental|Online aerobic dance training (Group B)|Participants will receive the e-pamphlet on physical exercise and will be invited to complete an aerobic dance program. The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
3475772|NCT03833609|No Intervention|Wait list control (Group C)|Participants will receive the e-pamphlet on physical exercise and will be instructed to continue with their current medical care while they are on the wait list (12 weeks). After the completion of the study, the yoga and aerobic dance training videos will be available to all participants including those in the control group. In recruitment documents, this group will be termed the e-pamphlet group.
3475773|NCT03833596|Active Comparator|Standard course CS with Regular Food|40 mg a day of oral Prednisone for 2 weeks with subsequent taper of daily dose by 5 mg per week.
3475774|NCT03833596|Experimental|Standard course CS with EEN|40 mg a day of oral Prednisone for 2 weeks and taper of daily dose by 5 mg per week and Exclusive Enteral Nutrition for 6 weeks.
3475775|NCT03833596|Experimental|Short course CS with EEN|40 mg a day of oral Prednisone for 3 days and taper of daily dose by 5 mg every 3 days and Exclusive Enteral Nutrition for 6 weeks.
3475776|NCT03833622|Experimental|Shared decision aid assessment|Patients will be selected to have a goals of care discussion with an emergency physician utilizing a pilot decision aid and will be asked for feedback to assist with refinement of the decision aid.
3475777|NCT03833557|Active Comparator|Nanohydroxyapatite Pulpotomy|"Biphasic calcium phosphate. Straumann BoneCeramic Regenerative Pulpotomy of 24 mandibular second primary molars using Nanohydroxyapatite~In Group 1: 24 mandibular second primary molars Caries removal and deroofing of pulp chamber Following the manufacturer's instructions, Nanohydroxyapatite was mixed with distilled water to homogeneous consistency then introduced into the pulp chamber and condensed properly against the pulp orifices.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy"
3475778|NCT03833557|Active Comparator|MTA Pulpotomy|"Angelus Grey MTA , Regenerative Pulpotomy Pulpotomy of 24 mandibular second primary molars using MTA Caries removal and deroofing of pulp chamber The MTA powder was mixed with sterile water in a 3:1 powder/water ratio according to the manufacturer's instructions to obtain a thick creamy paste, then placed on the floor of the pulp chamber using a messing gun and compacted against the pulp orifices with a condenser over a moist cotton pellet.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation at one, three ,six & 12 months after pulpotomy."
3126516|NCT03039686|Experimental|RO7239361 High Dose|Participants received high dose RO7239361 SC on specified days of the 48-week DB period. Following the DB period participants received high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
3179363|NCT00672035|Experimental|6|37.5µg LT Dose placed at the Lower Back on Day 0 and Day 21
3126517|NCT03039686|Placebo Comparator|Placebo|Participants received matching placebo solution subcutaneously (SC) on specified days of the 48-week double-blind (DB) period. Following the DB period participants received low dose or high dose RO7239361 on specified days for up to 192 weeks during the open-label period followed by 24 weeks of follow-up.
3126518|NCT03039699|Experimental|Ergoferon|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
3126519|NCT03039699|Placebo Comparator|Placebo|Tablet for oral use. Dose per administration - 1 tablet per intake (outside a meal/feeding). Within the first 2 hours - 1 tablet every 30 minutes, followed by 3 more tablets at time intervals equally separated throughout the rest of the day; from day 2 to day 5 - 1 tablet 3 times daily.
3126520|NCT03039738|Active Comparator|Telemetry Monitoring Arm|The telemetry group will serve as the control group and will be monitored via the site's standard of care telemetry protocols.
3475779|NCT03833557|Active Comparator|Formocresl Pulpotomy|"Buckley' s Formocresol , Fixation pulpotomy Pulpotomy of 24 mandibular second primary molars using Formocresol Caries removal and deroofing of pulp chamber~A cotton pellet with formocresol was placed on the pulp stumps then removed and ZO/E dressing was condensed against the pulp stumps.~All Molars were finally restored with stainless steel crowns cemented with GI cement . An immediate postoperative radiograph using periapical film size two was taken.~Clinical and radiographic evaluation: All treated patients were followed up at one, three , six & 12 months after the pulpotomy for clinical and radiographic evaluation. Independently, two examiners evaluated the teeth clinically and radiographically."
3126521|NCT03039738|Experimental|Surveillance Monitoring Arm|Subjects in the surveillance monitoring group will alternatively be admitted to medical surgical unit and be monitored via the surveillance monitoring platform.
3126522|NCT03040011|Experimental|Bupivacaine/Dexamethasone Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of a mixture of 20 milliliters of 0.25% bupivacaine (2.5mg/milliliter ) and 2 milliliters of dexamethasone (4mg/milliliter). The total amount of the bupivacaine/dexamethasone solution will be divided equally between the four injection sites.
3475780|NCT03833336|Placebo Comparator|Placebo|normal saline solution plus oral lactose capsules
3475781|NCT03833336|Active Comparator|Intravenous ferric carboxymaltose|Ferric carboxymaltose 500-1000 mg at 0,6,12,24 weeks ( adjusted by protocol)
3475782|NCT03833336|Active Comparator|Oral iron A: ferroglycine sulfate|oral capsules of ferroglycine sulfate iron until week 24
3475783|NCT03833336|Active Comparator|Oral iron B: sucrosomial iron|oral capsules of sucrosomial iron until week 24
3475784|NCT03833466|Experimental|metformin and chemotherapy|
3475785|NCT03833570|Experimental|Melatonin therapy|"Rapid Release Capsules Melatonin, 10 mg in combination with the symptomatic treatment~Symptomatic treatment which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Melatonin capsules dose: Two tablets,30 minutes before sleeping once daily for six weeks~Symptomatic treatment dose: Three times a day for six weeks"
3475786|NCT03833570|Active Comparator|Conventional therapy|"Conventional therapy (symptomatic treatment) which included:~Miconaz oral gel~BBC oral spray~Oracure gel~Alkamisr sachets~Dose: Three times a day for six weeks"
3475787|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Naive)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
3475788|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Naive)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
3475789|NCT03833362|Experimental|NVR/RTV + PEG-INF/RBV (Treatment Failure)|"Narlaprevir - 2 tablets once a day orally~Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG-INF alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG-INF alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
3179364|NCT00672035|Experimental|7|50µg LT Dose placed at the Deltoid on Day 0 and Day 21
3475790|NCT03833362|Active Comparator|PEG-INF/RBV (Treatment Failure)|"Placebo Narlaprevir - 2 tablets once a day orally~Placebo Ritonavir - 1 capsule once a day orally~Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b - subcutaneous injection once weekly. Patients will be instructed by the investigator on how to self-administer the drug and will be given at each dispensing visit the quantity of PEG-INF alfa-2a and PEG-INF alfa-2b needed between visits.~Ribavirin - twice daily orally. In the case of co-administration with PEG alfa-2a: 5 RBV capsules (2 in the morning + 3 in the evening) or 6 RBV capsules (3 in the morning + 3 in the evening) - weight based. In the case of co-administration with PEG alfa-2b: 4 RBV capsules (2 in the morning + 2 in the evening) - minimal dose or 7 (3 in the morning + 4 in the evening) - maximal dose"
3475791|NCT03833583|Experimental|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
3475792|NCT03833583|Sham Comparator|Sham tDCS|Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator
3475793|NCT03833765|Experimental|CAF+XCM|An envelope split-full-split thickness flap without vertical incisions will be carried out in the gingival recession area. Afterwards, a xenogenic collagen matrix (XCM) will be applied to all teeth with recession defect. The XCM will be cut into the right dimensions, measured with the probe, and its measurements recorded; then it will be placed from the CEJ to the bone crest on the recipient bed using single sutures, 7/0 PGA sutures. The matrix will be rehydrated with blood, in order to reconstitute and maintain the maximal thickness possible. The flap will be closed slightly coronal to the CEJ with a sling suture using resorbable PGA 6/0 sutures and avoiding any compression of the matrix.
3475794|NCT03833765|Active Comparator|CAF alone|An envelope split-full-split thickness flap without vertical incisions will be carried out. The root surfaces will be mechanically treated with the use of curettes. A sharp dissection into the vestibular lining mucosa will be then carried out to eliminate muscle tension. Sling sutures will be performed to accomplish a precise adaptation of the buccal flap on the exposed root surfaces and to stabilize every single surgical papilla over the de-epithelialized anatomic papillae.
3475795|NCT03833414||(Group1)|Triceps lifting approach .
3475796|NCT03833414||(Group 2)|olecranon osteotomy approach
3475797|NCT03833453|Active Comparator|PTSD-EMDR|PTSD treatment
3475798|NCT03833453|Experimental|Integrated DBT-EMDR|Integrated PTSD-PD-treatment
3475799|NCT03833440|Experimental|Durvalumab + Monalizumab|
3475800|NCT03833440|Experimental|Durvalumab + MEDI9447|
3475801|NCT03833440|Experimental|Durvalumab + AZD6738|
3475802|NCT03833440|Active Comparator|Docetaxel|
3475803|NCT03833388|Experimental|TOP1630 Ophthalmic Solution|
3475804|NCT03833388|Placebo Comparator|Placebo to TOP1630 Ophthalmic Solution|
3475805|NCT03833102||Colonized patients' group (CPG)|all adult patients hospitalized in or consulting the Rennes University Hospital, known as S. aureus colonized could be included. In our institution, S. aureus colonization in the nostrils is screened in all patients supposed to undergo neurosurgical or orthopedic surgery.
3475806|NCT03833102||SAB patients' group (SAB)|"all adult patients with SAB could be included. S. aureus colonization in the nostrils will be systematically screened immediately after the first result of positive S. aureus blood culture. Two subgroups will be individualized depending on the SOFA Score:~Severe patients~Non-severe patients"
3475807|NCT03833297||Hepatological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hepatological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
3475808|NCT03833128|Experimental|Group 1 - Part A|REN001 Low Dose oral once daily x 12 weeks
3475809|NCT03833128|Experimental|Group 2 - Part A|REN001 High Dose oral once daily x 12 weeks
3475810|NCT03833128|Experimental|Group 3 - Part B|REN001 High Dose oral once daily x 12 weeks
3475811|NCT03833024|Active Comparator|Venixxa|Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months
3126523|NCT03040011|Active Comparator|Bupivacaine Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.25% bupivacaine (2.5mg/milliliter). The total amount will be divided equally between the four injection sites.
3475812|NCT03833024|Placebo Comparator|Placebo|"Placebo for 6 months~1 Tablet, BID (morning and evening) for 6 months"
3475813|NCT03833115|Experimental|vaginal gel containing sodium lauryl sulfate|
3475814|NCT03833011|No Intervention|no intervention|
3475815|NCT03833011|Experimental|Osteopathic manipulation|
3475816|NCT03833193|Experimental|Hypofractionated radiotherapy|The patients received daily accelerated radiotherapy with a total dose of 60Gy, delivered at 3Gy per fraction, five fractions per week, completed within 4 weeks.
3475817|NCT03832972||Women using birth control|
3475818|NCT03832972||Women not using birthcontrol|
3475819|NCT03833245|No Intervention|Control|The standard care condition includes brief case management and referral. The brief case management involves the participant speaking to a hospital social worker who conducts a patient needs assessment in the areas of behavioral health and social services. All patients will be referred to MAT and any identified behavioral health or social service needs.
3475820|NCT03833245|Experimental|Patient Navigation|The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention.
3475821|NCT03833154|Experimental|SoC SBRT + Durvalumab Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Durvalumab (PD-L1 monoclonal antibody) 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met."
3475822|NCT03833154|Placebo Comparator|SoC SBRT + Placebo Therapy|"SBRT - delivered in 3, 4, 5 or 8 fractions.~Placebo (matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met."
3475823|NCT03833232|Experimental|omentopexy and cyanoacrilate glue|Apposition of omentum with cyanoacrilate glue after gastric section
3475824|NCT03833232|No Intervention|gastrectomy without omentopexy|Gastric section without omentopexy
3475825|NCT03833206|Experimental|1 PDC-1421 Capsule|1 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
3475826|NCT03833206|Experimental|2 PDC-1421 Capsules|2 PDC-1421 Capsule, trice daily, p.o. after meal for 28 days
3475827|NCT03833076|Experimental|GROUP A: Medical Device Procto|"Medical device Procto presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
3475828|NCT03833076|Placebo Comparator|GROUP B: Matching placebo|"Investigational Product (IP) placebo presents itself as a translucent green gel with a typical smell; it is intended for topical use.~Posology: external or internal use by means of the provided rectal applicator and following the instructions on the package insert. It can be applied when needed, after intimate cleansing, at any time."
3475829|NCT03833219|No Intervention|Control (monitor only)|Continue in monitoring only mode
3475830|NCT03833219|Experimental|Social comparison feedback|Report user's handheld phone use/ hour of driving for week. Compare this week's performance to distribution for driver cohort.
3475831|NCT03833219|Experimental|End of rating period incentive|Monitor throughout intervention period and compare overall use to distribution for cohort. Notify participant at end of intervention period regarding the amount they have earned.
3475832|NCT03833219|Experimental|End of rating period incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant at end of intervention period regarding the amount they have earned.
3475833|NCT03833219|Experimental|Weekly loss-framed incentive + social comparison feedback|Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned.
3475834|NCT03833219|Experimental|Larger weekly loss-framed incentive+social comparison feedback|"Monitor throughout intervention period and compare weekly phone use to driver cohort distribution. Send weekly push notification to provide feedback. Notify participant weekly regarding the amount they have earned. Incentive amount is higher than Weekly loss-framed incentive + social comparison feedback Arm."
3179365|NCT00672035|Experimental|8|50µg LT Dose placed at the Lower Back on Day 0 and Day 21
3475835|NCT03833258|No Intervention|Rehabilitation with precautions|Patients in this arm will continue with rehabilitation following routine care recommendations after total hip replacement; therefore following precautions.
3475836|NCT03833258|Experimental|Rehabilitation with no precautions|Patients in this arm will continue with rehabilitation after total hip replacement without precautions, being permitted to move within limits of their own pain only.
3475837|NCT03833271|Active Comparator|TNF-alpha inhibitor|
3475838|NCT03833271|Active Comparator|Methotrexate|
3475839|NCT03833271|Active Comparator|Healthy|
3475840|NCT03833063|Placebo Comparator|placebo|injections with sodium chloride
3475841|NCT03833063|Active Comparator|botulinum toxin A|injections with botulinum toxin A
3126524|NCT03040011|Placebo Comparator|Placebo Arm|After sterile preparation in lithotomy position, investigators will perform bilateral levator ani muscle injection via the obturator foramen (transobturator). After transobturator injections are performed on each side, bilateral pudendal nerve blocks will be performed transvaginally as described in the literature. The solution injected at all 4 of the above injections sites will consist of 20 milliliters 0.9% saline (normal saline). The total amount will be divided equally between the four injection sites.
3475842|NCT03832933|Experimental|High Protein Diet|
3475843|NCT03832933|Active Comparator|Standard Protein Diet|
3475844|NCT03832959|No Intervention|Non esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation to study esophageal lesions. The esophageal protection probe will not be used.
3475845|NCT03832959|Experimental|Esophageal protection|Patients in this group will undergo a first atrial fibrillation catheter ablation procedure with pulmonary vein isolation, using the esophageal protection probe EnsoETM
3126525|NCT03040024|Experimental|Ketamine 0.5 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 0.5 mg/kg.
3475846|NCT03832985|Experimental|Receive an adult-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with adult onset of disease.
3475847|NCT03832985|Experimental|Receive a pediatric-onset result|Compare change in psychosocial outcomes and health behaviors of those with a pathogenic variant in a gene associated with pediatric onset of disease or with risk reduction interventions that begin in childhood.
3475848|NCT03832985|Active Comparator|Control - No result|Compare change in psychosocial outcomes and health behaviors of those without a genomic result.
3475849|NCT03833284|Experimental|Participant Barriers to TVU Screening|Patients with a history of pre-term birth will be identified through a review of their medical history. Patients will then be asked to complete a survey assessing their knowledge of transvaginal ultrasound screening. Patients will then be asked to attend in-person or online workshops designed to increase patient knowledge of TVU screening guidelines and benefits. Finally, patients will complete exit surveys to determine whether their attitudes and beliefs towards screening have changed over time.
3475850|NCT03833284|Experimental|Provider Barriers to TVU Screening|Obstetric and Gynecologic Providers will be identified based on prior working relationships with the University of Kentucky outreach programs. Chosen providers will be asked to complete a survey assessing their attitudes towards TVU screening. Following completion, providers will be asked to attend either in-person or online workshops designed to increase provider knowledge of TVU screening guidelines and benefits. Finally, providers will complete exit surveys to determine whether their attitudes and beliefs toward screening have changed over time.
3475851|NCT03832894|Active Comparator|Group receiving oestradiol tablets in addition to progesterone|"Group A :Will receive 400mg progesterone in the form of vaginal or rectal suppositories in addition to estradiol valerate oral tablets in a dose of 4mg/day(2x2), for luteal phase support. Starting from the day of ovum pickup and for 14 days after embryo transfer.~Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer."
3475852|NCT03832894|Placebo Comparator|Group not receiving oestradiol tablets.|Group B : Will receive a dose of 400mg progesterone in the form of vaginal or rectal suppositories in addition to 2 placebo oral tablets(similar to estrogen tablets) for luteal phase support, from the day of Ovum pickup and for 14 days after embryo transfer
3475853|NCT03832777|Active Comparator|5 Hz Stimulation|This group will receive 5Hz (Hertz) Dorsomedial Prefrontal Cortex repetitive Transcranial Magnetic Stimulation with 1500 pulses per session, once per weekday, with a final result of 15 sessions in this modality.
3475854|NCT03832777|Placebo Comparator|Placebo Stimulation|This group will receive the Sham modality simulating 1500 pulses of 5Hz Transcranial Magnetic Stimulation for 15 sessions, one per weekday.
3475855|NCT03832803|Experimental|Empty Bladder|Empty bladder prior to treatment.
3475856|NCT03832803|Other|Full Bladder|Conventional drinking protocol - 200ml water prior to treatment.
3475857|NCT03832829|Experimental|Indirect restorations with SR Nexco|Large posterior defects with at least one or more cuspal coverage in molars will be restored using the materials listed (SR Nexco). Procedures will be done using local anesthesia. The procedure, starts with removal of caries or defective restorations and coronal relocation of the the margins using flowable composite with maximum thickness 1 to 1.5 mm and followed by resin composite build-up. Defined principles of morphology driven preparation technique will be followed Impression making, fabrication of indirect restoration with SR Nexco and adhesive cementation will be completed according to manufacturer's instructions.
3475858|NCT03832582|Experimental|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
3475859|NCT03832569|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
3475860|NCT03832660|Active Comparator|Lifestyle|Lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
3475861|NCT03832660|Active Comparator|Sacubitril/Valsartan|Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
3126526|NCT03040024|Experimental|Ketamine 1.0 mg/kg|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV ketamine at 1.0 mg/kg.
3126527|NCT03040024|Placebo Comparator|Placebo|Participants undergoing surgery for otolaryngeal cancer will be randomized to receive one dose of IV saline/placebo.
3475862|NCT03832660|No Intervention|Usual Care|The participants in control group do not undertake lifestyle or sacubitril / valsartan intervention.
3475863|NCT03832504|Experimental|38°C and 60% RH + No intervention|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
3475864|NCT03832504|Experimental|38°C and 60% RH + Fan|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
3475865|NCT03832504|Experimental|38°C and 60% RH + Skin wetting|The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
3475866|NCT03832504|Experimental|38°C and 60% RH + Fan + Skin wetting|Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
3475867|NCT03832504|Experimental|46°C and 10% RH + No intervention|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.
3475868|NCT03832504|Experimental|46°C and 10% RH + Skin wetting|The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.
3179366|NCT00672035|Placebo Comparator|9|Placebo (0µg LT) placed at the Deltoid on Day 0 and Day 21
3179367|NCT00672035|Placebo Comparator|10|Placebo (0µg LT) placed at the Lower Back on Day 0 and Day 21
3179368|NCT00672048|Other|1|
3179369|NCT00672048|Other|2|Control group to receive annual continuing education
3475869|NCT03832816|Placebo Comparator|Placebo|Distilled Water
3475870|NCT03832816|Experimental|Vaporized THC alone|5mg pure THC
3475871|NCT03832816|Experimental|Vaporized low CBD alone|50mg pure CBD
3475872|NCT03832816|Experimental|Vaporized medium CBD alone|100mg pure CBD
3475873|NCT03832816|Experimental|Vaporized high CBD alone|200mg pure CBD
3475874|NCT03832816|Experimental|Vaporized low CBD with THC|50mg pure CBD paired with 5mg THC
3475875|NCT03832816|Experimental|Vaporized medium CBD with THC|100mg pure CBD paired with 5mg THC
3475876|NCT03832816|Experimental|Vaporized high CBD with THC|200mg pure CBD paired with 5mg THC
3126528|NCT03040154|Experimental|Intervention Arm|Culturally-tailored video that includes parent testimonials, health and mental health clinicians, community-based providers, and church leaders
3475877|NCT03832608||Older adults and Sarcopenia|Older adults with and without Sarcopenia living in Valencia Province.
3475878|NCT03832556|Experimental|Preoperative evaluation: CT + MRI|"Preoperative evaluation by 2 examinations: CT scan and MRI.~CT scan with biphasic injection of contrast product;~MRI with injection of contrast."
3475879|NCT03832621|Experimental|temozolomide + nivolumab + ipilimumab|Temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks, for two cycles followed by TC scan assessment: if SD/PR/CR second treatment phase with nivolumab 480 mg i.v. every 4 weeks, low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks and temozolomide at the previously adopted schedule
3475880|NCT03832634|Other|Fetal Genome Profiling|Trophoblast cells will be collected from the cervix approximately 5-6 weeks once pregnancy is achieved.
3475881|NCT03832595|Active Comparator|Usual care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
3475882|NCT03832595|Experimental|Intervention Arm|Patients will receive a care bundle
3126529|NCT03040154|Other|Control Arm|Usual care video publicly available describing the evidence-based parenting intervention
3126530|NCT03040336|Experimental|Prehabilitation|Standard of care + Prehabilitation
3475883|NCT03832673|Experimental|Pembrolizumab + Epacadostat|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles) Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
3475884|NCT03832530|Experimental|HIV-uninfected women|"A sample of 150 women, aged 18-35, likely to be fertile based on reproductive health history, with reported personal or partner desire to have a child in the next year and who self-reports having a relationship with a partner she reports as HIV-infected or likely to be HIV-infected (e.g. taking medicine daily, goes to clinic routinely, has HIV-infected partners, he has implied that he is sick but has not disclosed). All women are offered comprehensive safe conception counseling -- this is the intervention -- inclusive of daily oral TDF/FTC as PrEP."
3475885|NCT03832712|Active Comparator|Surgical|Participants randomized to surgery
3475886|NCT03832712|Active Comparator|Medical|Participants randomized to best medical treatment
3475887|NCT03832868|Experimental|Pre-visit decision aid|Patients receiving the decision aid pre-visit will be given a paper copy of the decision aid in the waiting room and will have a minimum of 15 minutes to review it - either in the waiting room or in the exam room while waiting for the electrophysiologist.
3475888|NCT03832868|Experimental|Post-visit decision aid|Patients receiving the decision aid after the encounter will meet with the electrophysiologist first and receive the aid afterward.
3126531|NCT03040336|No Intervention|Standard of Care|Standard of Care
3126532|NCT03040362|Experimental|[14C]-lasmiditan|[14C]-lasmiditan administered as a 200 mg (approximately 100 µCi) oral solution
3179370|NCT00672061|Experimental|Ramelteon 16 mg QD or Placebo QD|
3179371|NCT00672074|Active Comparator|1 Ipamorelin|
3179372|NCT00672074|Placebo Comparator|2 Placebo|
3179373|NCT00672087||A|Chronic prostatitis/chronic pelvic pain syndrome patients
3475889|NCT03832686|Experimental|Virtual Coach App|Participants in the experimental arm (Group A) will receive a comprehensive swallowing rehabilitation app. This study seeks to determine if a mobile application may enhance adherence to swallowing therapy in patients undergoing radiation therapy for head and neck cancer. No devices - outside of the Smartphone already owned by the participant - will be used in this study. Similarly, no drugs, biological materials, or other substances will be used.
3475890|NCT03832686|No Intervention|Standard of Care|The paper group (Group B) will be given paper exercise logs to fill out Participants will be educated regarding potential radiation-related side effects and trained in the same series of swallowing exercises by the SLP. The paper log treatment group will serve as a standard treatment group. As adherence is a primary goal of the target intervention, paper logging will be necessary to determine relative adherence while minimizing reporting bias.
3475891|NCT03832764||ANSPEC-PRO|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via prototype ANSPEC-PRO - correlated to a NRS number given by the awake patient in PACU/ICU.
3475892|NCT03832764||MEDSTORM|These patients are selected (after randomized selection) to be monitored non-invasively for pain level via MEDSTORM - correlated to a NRS number given by the awake patient in PACU/ICU.
3475893|NCT03832751|Experimental|vitiligo patients|Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
3475894|NCT03832751|Active Comparator|Healthy controls|Tissue levels of human beta-defensin 1 in healthy controls
3475895|NCT03832699|Experimental|Oral progesterone|
3475896|NCT03832699|Active Comparator|Vaginal progesterone|
3475897|NCT03832725|Active Comparator|High protein (HP) weight loss diet|A weight loss high protein (HP) (30% Kcal protein, 40% Kcal carbohydrate (CHO) and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.
3475898|NCT03832725|Active Comparator|High carbohydrate (HC) weight loss diet|"A weight loss high carbohydrate (HC) (15% Kcal protein, 55% Kcal CHO and 30% Kcal fat) diet will be given to the subjects on that arm of study to pick up weekly for 6 months.~Intervention with the HC diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
3475899|NCT03832491|Other|Control Group|"Home Based Therapy: 16 patients with PCD~Airway clearence techniques, everday of the week, during eight weeks"
3475900|NCT03832491|Experimental|Game and home based therapy group|"Game based approach programme: 16 patients with PCD~Game based approach programme will be done using the exergame with the game console, fourty minutes three times per week for eight weeks.~Exergame includes five games selected from two kinects games CD. Each game will be played for five games set.~Airway clearence techniques, everday of the week, during eight weeks"
3475901|NCT03832478|Experimental|Virtual Reality Headset Given|Virtual Reality headset (Samsung Gear VR) with mindfulness meditation app is given for patient use prior to surgery date and for duration of postoperative stay.
3475902|NCT03832465|Experimental|Intraluminal Levofloxacin powder therapy|Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
3475903|NCT03832465|Active Comparator|Intraluminal Levofloxacin solution therapy|Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
3475904|NCT03832517|Active Comparator|Single intravenous doses of RC-01|Single escalating doses of RC-01 from 200 mg to 1600 mg
3475905|NCT03832517|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match RC-01
3475906|NCT03832517|Active Comparator|Multiple intravenous doses of RC-01|Two or three times daily escalating intravenous doses of RC-01 for 10 days. Doses to be determined
3475907|NCT03832517|Placebo Comparator|Multiple intravenous doses of placebo|Two or three times daily intravenous doses of placebo to match RC-01
3179374|NCT00672087||B|Painful bladder syndrome/interstitial cystitis patients
3179375|NCT00672087||C|Asymptomatic controls
3475908|NCT03832855|Experimental|Treatment|4 mg pING-hHER3FL ID or IM
3475909|NCT03832348|Experimental|PET scan imaging|PET scan will be performed each of three first cycles of pembrolizumab to describe the early tumour metabolic changes during the first line of treatment.
3475910|NCT03832335||Phakic group|21 eyehealthy individuals examined for baseline stereopsis and impact of aniseikonia on stereopsis. An non-invasive measurement.
3475911|NCT03832335||Cataract group|11 patients awaiting cataract surgery on both eyes. Measurement of baseline stereopsis and impact of artificial induced aniseikonia on stereopsis. A non invasive measurement that are repeated after dilatation of the eyes and again six weeks after surgery.
3126533|NCT03040414|Active Comparator|PID Algorithm|Participants will receive insulin delivered by the Medtronic Minimed 670G 3.0 HCL system using a PID algorithm..
3126534|NCT03040414|Experimental|PID + Fuzzy Logic Algorithm|Participants will receive insulin delivered by the Medtronic advanced hybrid closed loop system (Minimed 670G 4.0 AHCL) with Guardian Sensor (3) continuous glucose monitoring sensor.
3126535|NCT03040427|Experimental|AL or TTR type amyloidosis|The participants will undergo F-18 florbetapir PET scan.
3179376|NCT00672113|Experimental|Arm 1|
3179377|NCT00672113|Active Comparator|Arm 2|
3475912|NCT03832153||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
3475913|NCT03832153||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
3475914|NCT03832088|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated for sarcopenia and balance disorders
3475915|NCT03832231|Experimental|Ventilator liberating trial|The diaphragmatic function of patients undergoing a ventilator liberating trial will be determined with transient shear wave elastography.
3475916|NCT03832244||Simple snoring|Patients undergoing to Sub-mental ultrasonography with Normal sleep: Fewer than 5 events per hour measured in over-night polysomnography
3475917|NCT03832244||Mild OSA|Patients undergoing to Sub-mental ultrasonography with Mild sleep apnea: 5 to 14 events per hour measured in over-night polysomnography
3475918|NCT03832244||Moderate OSA|Patients undergoing to Sub-mental ultrasonography with Moderate sleep apnea: 15 to 29 events per hour measured in over-night polysomnography
3475919|NCT03832244||Severe OSA|Patients undergoing to Sub-mental ultrasonography with Severe sleep apnea: 30 or more events per hour measured in over-night polysomnography
3475920|NCT03832309|Active Comparator|Group 1|Packet 1: The Physician will be asked to instruct the patient as empathetically and confidently as possible, that the drug the patient will be given will make them feel no pain, cause them to forget the procedure, and allow them to dream the dream of their choice.
3475921|NCT03832309|Other|Control Arm|Half of the participants will receive the sedation medication with the usual conversation while the physician is giving the medication to the patient. The other half of the participants will have a more positive conversation, (which is the study intervention), with the physician while being given the medication. Both group's emergence reactions, if any, will be compared to see if the positive conversation reduced the side effect.
3475922|NCT03832413||Stroke|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475923|NCT03832413||TBI|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475924|NCT03832413||ABD|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475925|NCT03832413||Fibromyalgia|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475926|NCT03832413||PDD|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475927|NCT03832413||ADHD|Diagnostic Test: DELPhI (TMS-EEG analysis)
3126536|NCT03040466|Active Comparator|reusable fiberoptic ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using reusable fiberoptic flexible ureteroscope (URF-P6, Olympus). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
3475928|NCT03832413||MCI|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475929|NCT03832413||Dementia|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475930|NCT03832413||Healthy|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475931|NCT03832413||Cognitive impairment|Diagnostic Test: DELPhI (TMS-EEG analysis)
3475932|NCT03832361|Experimental|IMGN853|IMGN853 administered 6 mg/kg adjusted ideal body weight (AIBW) once every three weeks (Q3W)
3475933|NCT03832114|Experimental|Cohort A - no kidney transplant|C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
3475934|NCT03832114|Experimental|Cohort B - kidney transplant|C3G patients who have received a kidney transplant and have C3G recurrence.
3475935|NCT03832049|Active Comparator|15 to 26 years - 3 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses
3475936|NCT03832049|Experimental|9 to 14 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
3475937|NCT03832049|Experimental|4 to 8 years - 2 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses
3475938|NCT03832049|Experimental|9 to 14 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
3475939|NCT03832049|Experimental|4 to 8 years - 1 dose|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose
3475940|NCT03832452|Experimental|Part A: Treatment 1|A single oral dose of 2000 mg lucerastat on Day 1 and of 4000 mg lucerastat on Day 3
3475941|NCT03832452|Placebo Comparator|Part A: Treatment 2|A single oral dose of placebo on Day 1 and 3
3475942|NCT03832452|Active Comparator|Part B: Treatment A|A single oral dose of 400 mg moxifloxacin
3475943|NCT03832452|Experimental|Part B: Treatment B|A single oral dose of 1000 mg lucerastat
3126537|NCT03040466|Experimental|disposable digital ureteroscope|For this arm, participants will receive the ureteroscopy for their kidney and ureter stones using disposable digital flexible ureteroscope (LithoVue, Boston Scientific). The surgical method of the ureteroscopy will be a standard fashion same as other arms.
3475944|NCT03832452|Experimental|Part B: Treatment C|A single oral dose of 4000 mg lucerastat
3475945|NCT03832452|Placebo Comparator|Part B: Treatment D|A single oral dose of placebo
3475946|NCT03832400|Experimental|MET-2 20 g|Subjects will be given a once-daily loading dose of 5 grams (g) of MET-2 in the form of 10 MET-2 capsules orally for the first 4 days. For the following 10 days, patients will take 1.5 g MET-2 in the form of three MET-2 capsules taken once-daily
3475947|NCT03832400|Experimental|MET-2 40 g|Subjects will be given a once-daily loading dose of 10 g of MET-2 in the form of 20 MET-2 capsules orally for the first 4 days. For the following 10 days, subjects will take 1.5 g MET-2 in the form of three MET-2 capsules taken once daily
3475948|NCT03832400|Placebo Comparator|Placebo oral capsule|Subjects receive 10 placebo capsules that are identical in appearance to the MET-2 capsules
3475949|NCT03832075|Experimental|postmenopausal osteoporosis|Postmenopausal osteoporotic patients evaluated with Berg Balance Scale, Timed Up and Go test and Korebalance balance system for balance disorder.
3475950|NCT03832179|Active Comparator|Anti-vascular endothelial growth factor|Intravitreal Bevacizumab, Ranibizumab, or Aflibercept
3475951|NCT03832179|Experimental|Ozurdex|Intravitreal Ozurdex
3475952|NCT03832218|Other|Mitochondrial disease|Psychiatric assessment
3475953|NCT03832192|Experimental|care.coach Avatar|
3126538|NCT03040479|Experimental|Mild hepatic impairment|lasmiditan 200 mg single dose
3475954|NCT03832192|No Intervention|Control|
3475955|NCT03832283|Other|Usual Care Depression Screening|Patients randomized to this intervention arm will receive usual care annual depression screening when they come in for a clinic visit and are due for screening. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression screening. The CAD-MDD/CAT-DI screening during clinic visit will occur in a patient room, prior to their appointment with a primary care provider.
3475956|NCT03832283|Experimental|Population MyChart Depression Screening|Patients randomized to this intervention arm will continue to receive usual care annual depression screening when they come in for a clinic visit and are due for screening. In addition, they will receive email invitations to complete the CAD-MDD/CAT-DI screening via MyChart. Email invitations will be sent at preset intervals until depression screening is completed, or the end of the 1-year follow-up period, whichever comes first.
3475957|NCT03832283|Other|Usual Care Depression Monitoring|Patients who have depression and are randomized to this intervention arm will receive usual care PHQ-9 monitoring during clinic visits. When the patient comes in for a visit, a best practice alert in the EHR will indicate that the patient requires depression assessment.
3475958|NCT03832283|Experimental|Population MyChart Depression Monitoring|Patients who have depression and are randomized to this intervention arm will continue to receive usual care depression monitoring when they come for clinic visits. In addition, they will receive email invitations at preset intervals to complete the CAT-DI monitoring via MyChart. Invitations will be sent until major depressive disorder (MDD) remission is achieved, or the 1-year follow-up period ends, whichever comes first.
3126539|NCT03040479|Experimental|Moderate hepatic impairment|lasmiditan 200 mg single dose
3475959|NCT03832270|Experimental|Parents InC|Group parenting support intervention based around four pillars: 1) empowerment/ownership; 2) education on ADHD and its effect on family identity/ values; 3) positive parenting in the context of ADHD; 4) making sense of ADHD in a developmental context. It is delivered over 5 weekly 2-hour sessions, a 6 week break, and a follow-up session.
3475960|NCT03832270|Active Comparator|Incredible Years|A group parenting support intervention aimed at strengthening parent-child interactions and attachment, reducing harsh discipline and fostering parents' ability to promote children's social, emotional, and academic development. The IY programme is delivered over 14 weekly 2-hour sessions. IY facilitators are videotaped during sessions to maintain intervention fidelity. IY also includes 1-4 pre-intervention preparation sessions which may involve home visits and telephone support and reminders.
3126540|NCT03040479|Experimental|Healthy participants|lasmiditan 200 mg single dose
3475961|NCT03832023|No Intervention|Facility-based model|Standard of care of each country
3475962|NCT03832023|Experimental|Community-based model|Screening and initiating preventive therapy in communities
3475963|NCT03832166|Experimental|Fruits and Vegetables Only|This group will receive a prescribed amount of free fruits and vegetables (F & V) for 6 weeks through pick-up at a farm stand, or direct delivery. After 6 weekly pick-up/deliveries, participants will be provided vouchers and reminders to obtain F&V at farm stands for an additional 18 weeks with minimal contact
3475964|NCT03832166|Experimental|Fruits and Vegetables and Cook|"In addition to the prescribed amount of free F&V, participants will receive 6 weekly, group nutrition and cooking education classes based on The Happy Kitchen curriculum. Participants will also receive free ingredients to complete the recipe from each weekly session at home."
3475965|NCT03832101|Experimental|Difficult face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Thereafter, participants in the Difficult group will undergo training involving discriminations between highly similar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
3475966|NCT03832101|Experimental|Easy face discrimination|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Easy group will discriminate between dissimilar faces. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
3475967|NCT03832101|Active Comparator|Control|All participants will complete 5 training and testing sessions in total, once a day, over the course of a week (weekdays). On the first day, participants will go through an initial test (Cambridge Face Memory Test; approximately 15 minutes) to determine their baseline facial recognition ability. Those in the Control group will perform a simple face-matching exercise. This training will last for approximately 30 minutes. Each participant's involvement in the study will last only 5 consecutive days. The total participation time is 7.5 hours per participant.
3475968|NCT03832257|Experimental|ECHO CT Intervention|Weekly video conference between hospitalist at Beth Israel and skilled nursing facilities.
3126541|NCT03040674||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
3126542|NCT03040687|Experimental|Anti-CS6 group|Anti-CS6 BSIgG and challenge strain CS6-expressing ETEC (B7A)
3126543|NCT03040687|Experimental|Anti-whole cell B7A|Anti- whole cell B7A (killed) BSIgG and challenge strain CS6-expressing ETEC (B7A)
3126544|NCT03040687|Experimental|control Immunoglobulin group|Negative Control (Nonhyperimmune BSIgG placebo) and challenge strain CS6-expressing ETEC (B7A)
3475969|NCT03832257|Other|Matched Non- Participating Facilities|Matched non-participating facilities
3475970|NCT03832205||Capaciflector monitoring group|Patients undergoing their pre-planned, routine cardiopulmonary exercise test (CPET). Additional, non-invasive capaciflector monitoring only - no therapeutic intervention.
3475971|NCT03832439|Active Comparator|Probiotic|This arm will be receiving probiotic supplements.
3475972|NCT03832439|Placebo Comparator|Placebo|This arm will be receiving placebo containing microcrystalline cellulose.
3126545|NCT03040713|Experimental|FTD Subjects|Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan
3126546|NCT03040804|Experimental|Low Dose Radiotherapy|Patients will receive skin-directed radiotherapy, using a total prescription dose of 7.5 gy in five fractions of 1.5 gy over one week
3475973|NCT03832296|Experimental|Weight-Loss Maintenance|Weight Loss Maintenance Intervention
3475974|NCT03832296|Active Comparator|Health Education (Attention Control)|Health Education Intervention
3475975|NCT03832426|Experimental|Narlaprevir single - Healthy|2 tablets of 100 mg Narlaprevir once a day
3475976|NCT03832426|Experimental|Narlaprevir single - Hepatic Impairment|2 tablets of 100 mg Narlaprevir once a day
3475977|NCT03832426|Experimental|Narlaprevir+Ritonavir - Healthy|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
3475978|NCT03832426|Experimental|Narlaprevir+Ritonavir - Hepatic Impairment|Narlaprevir 100 mg (1 tablet of 100 mg) and Ritonavir 100 mg (1 tablet of 100 mg) once a day
3475979|NCT03832036|Experimental|Patients with lumbar disc herniation|
3475980|NCT03831997||Historical Controls|The retrospective arm will consist of our control group, it will be derived from a retrospective medical chart review of all patients with CSDH at the facility.
3475981|NCT03831997||Prospective Arm|The prospective arm of the study will be looking at the effects of Dextrose 5% W/ Sodium Chloride 0.225% on the recurrence rate defined by the need for secondary surgical intervention for residual/recurrent CSDH) of CSDH in a 3-month post-operative window.
3475982|NCT03831984|Active Comparator|0,09% Bromfenac|Topical 0,09% Bromfenac twice daily 3 days before surgery
3126547|NCT03040986|Experimental|Treatment (selumetinib sulfate)|Patients receive selumetinib sulfate by mouth (PO) twice daily (BID). Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity
3475983|NCT03831984|Placebo Comparator|0,1% sodium hyaluronate|Topical 0,1% sodium hyaluronate twice daily 3 days before surgery
3475984|NCT03831867|Experimental|Pilates|This group is the experimental group. The intervention program consisted on performance Pilates method exercise program during the sessions of Physical Education.
3475985|NCT03831867|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
3475986|NCT03831763|Active Comparator|ColdZyme|
3475987|NCT03831763|No Intervention|Optional care only|
3475988|NCT03831633|Experimental|AKYNZEO|
3475989|NCT03831633|Active Comparator|Standard of Care|
3475990|NCT03831737|Experimental|Group 1: In-Person|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will participate in in-person physical therapist-led instructional sessions three times per week. Each stretch will be performed twice, one on the left and one on the right. The therapist will describe what to do and briefly demonstrate each stretch. Stretches will be held for 45-60 seconds with therapist instructions and modification as needed based on subject technique."
3475991|NCT03831737|Experimental|Group 2: Video|"During the initial 3 month control period, subjects are asked not to begin any new exercise or stretching program during this time.~During the 3 month intervention period that follows, subjects will complete sessions three times per week, led by a physical therapist and viewed remotely via pre-recorded video using a smartphone application."
3475992|NCT03831542||direct aspiration group|Transvaginal ultrasound-guided oocyte retrieval was performed 36 hours after ovulation trigger. A 17-gauge double lumen needle will be used to aspirate a single follicle without flushing. If an oocyte is obtained, the subject will be assigned to group 1. If not, operator will proceed with follicular flushing.
3475993|NCT03831542||flushing group|If an oocyte is not obtained with direct aspiration, operator will proceed to follicular flushing and the subject will be assigned to group 2 if an oocyte is obtained following follicular flushing.
3475994|NCT03831828||Lymph node metastasis Positive|good prognosis; without Lymph node metastasis.
3475995|NCT03831828||Lymph node metastasis Negative|poor prognosis; with Lymph node metastasis.
3475996|NCT03831724|Experimental|EndoFLIP™ System|Device interventions included in this arm: HRM, EGD including biopsies, EndoFLIP and Bravo
3475997|NCT03831698|Experimental|Omega-3, 2 grams|Omega-3 fatty acid ethyl esters (2 grams) orally (by mouth) once per day for 12 months
3475998|NCT03831802|Experimental|experimental group|The experimental group will make use of the Alert app that sends alarms to patients mobile devices, and if desired to the mobile devices of their caregivers. This group will also use the Mate app which is used as a seizure diary
3475999|NCT03831802|Active Comparator|Control group|The control group will only use the Mate app and not the Alert app. This group will thus not receive any notification, from the device, and will be unaware, of the devices performance
3476000|NCT03831815||Grupo C: cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
3476001|NCT03831815||Grupo R: rocuronium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist who participated in the surgery. In group C, patients received cisatracurium and in group R, rocuronium was administered to patients.
3476002|NCT03831919|Experimental|SYNC III accommodative support lenses|Wear spectacles with SYNC III accommodative support lenses (add +0.75)
3126548|NCT03041025|Experimental|Cohort 1: GSK2330811 100 mg|During Cohort 1, participants will receive a single dose of GSK2330811 100 mg by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
3126549|NCT03041025|Experimental|Cohort 2: GSK2330811 300 mg|During Cohort 2, participants will receive a single dose of GSK2330811 300 mg by SC injection (3 vials of 1 mL each of GSK2330811 100 mg) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
3126550|NCT03041025|Placebo Comparator|Cohort 1: Placebo|During Cohort 1, participants will receive a single dose of placebo by SC injection via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
3126551|NCT03041025|Placebo Comparator|Cohort 2: Placebo|During Cohort 2, participants will receive a single dose of placebo by SC injection (3 vials of 1 mL each) via needle and syringe in to the abdomen, thigh or upper arm by the investigator or designee at every other week from D1 to D71 (total 6 doses) for 10 weeks. Participants will be followed-up up to W28 D197.
3476003|NCT03831919|Placebo Comparator|control|Wear single vision spectacles (no add)
3476004|NCT03831607|Experimental|KHK7791|Patients start at KHK7791 30 mg BID and can down titrate weekly to 20, 15, 10, and 5 mg BID, sequentially based on a GI tolerability question.
3476005|NCT03831594|Experimental|Standard Physiotherapy and Galvanic Vestibular Stimulation|Standard physiotherapy concurrently with Galvanic Vestibular Stimulation for 45 minutes a day for two weeks (five days per week)
3476006|NCT03831594|Active Comparator|Standard Physiotherapy|Standard Physiotherapy for 45 minutes a day for two weeks (five days per week)
3476007|NCT03831776|Experimental|Bosutinib-Ropeginterferon combination|
3476008|NCT03831776|Active Comparator|Bosutinib monotherapy|
3476009|NCT03831893|Sham Comparator|Control|A food product similar to the test products but without nopal
3476010|NCT03831893|Experimental|Nopal food product 1|Food product with Nopal
3476011|NCT03831893|Experimental|Nopal food product 2|Food product with Nopal
3476012|NCT03831789|Active Comparator|Unilateral cerebellar rTMS|
3476013|NCT03831789|Experimental|Bilateral cerebellar rTMS|
3476014|NCT03831841|Experimental|Intervention|Multicomponent exercise programe involving all physical fitness paramenters and consisting on sesions of 1 hour, 3 days a week.
3476015|NCT03831841|No Intervention|Control|Control group with no intervention programe
3476016|NCT03831555|Active Comparator|PREP-C|The research assistant will complete the abbreviated PREP-C survey with the study participants either before or after their medical appointment. The PREP-C tool is accessed online at https://prepc.org/.
3476017|NCT03831555|No Intervention|Standard of care|Participants will receive the standard of care (usual care) for chronic HCV infection.
3476018|NCT03831516||Non Invasive Electroanatomical Mapping|Patients will undergo non invasive electroanatomical mapping (CardioInsight by Medtronic) prior and during an invasive electrophysiology study and ablation of ventricular Arrhythmias.
3476019|NCT03831750|Experimental|Stress Reduction Intervention|Participants will receive the standard of care for IBD and training and access to an online stress reduction intervention.
3476020|NCT03831750|No Intervention|Control|Participants will receive the standard of care for IBD.
3476021|NCT03831581|Experimental|Erector Spinae Plane Block|Patients with chest pain or upper abdomen underwent Erector Spinae Plane Block guided by ultrasound, bupivacaine 0.5% 20 ml was administered in the interfascial plane between the transverse process of T5 and the erector muscles of the spine, 60 minutes after dermatomes distribution was evaluated with pinprick and cold.
3476022|NCT03831399|Placebo Comparator|Control Group|"Subjects in control group will receive placebo (lactose) 6g/day in two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
3476023|NCT03831399|Active Comparator|Intervention Group|"Subjects in intervention group will receive leucine 6g/day, in tin two doses, in two spoon at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks.~The product will be delivered in powder, in white jars, without label, and will only carry the patient number on the outside, 4 jars per participant."
3476024|NCT03831334|Experimental|Minoxidil Treatment|Low dose oral minoxidil
3476025|NCT03831386|Active Comparator|Vacuum|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care. Participants in this arm will undergo Vacuum-Based IPC.
3476026|NCT03831386|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned at bedside. Participants in this arm will undergo Gravity-Based IPC.
3476027|NCT03831321|Active Comparator|Diclofenac group|The group who are 50 mg Diclofenac Sodium and lubricant gel administered one hour before cystoscopy and local
3126552|NCT03041038|Experimental|Secukinumab|Secukinumab 300mg (liquid formation) administered subcutaneously weekly for 5 weeks then monthly until end of trial
3126553|NCT03041038|Placebo Comparator|Placebo|Placebo (sterile saline) 2ml administered subcutaneously weekly for 5 weeks then monthly until end of trial
3126554|NCT03041090|Experimental|Static Imaging participants|"This arm of the study assessed participants' static PET/CT images. These were the standard of care images acquired after their standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (Lucerno Device Identity Document (LD ID), Lucerno Device 1 (LD1), Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
3476028|NCT03831321|Placebo Comparator|Placebo|The group who are not administered 50 mg Diclofenac Sodium before cystoscopy and administered lubricant gel just before local cystoscopy
3476029|NCT03831347|Experimental|Hatha Yoga|12 weeks of modified Hatha Yoga specifically designed to be administered to teens with depression.
3476030|NCT03831477|Experimental|80 pin applicator|
3476031|NCT03831477|Active Comparator|160 pin applicator|
3476032|NCT03831464|Experimental|Metformin treatment group|
3476033|NCT03831464|Placebo Comparator|Placebo control group|
3476034|NCT03831438|Other|Dose escalation|"Sequential escalating doses of AVID200 when administered once every 2 weeks (Q2W) by 1-hour intravenous (IV) infusion to patient cohorts with diffuse cutaneous systemic sclerosis (dcSSc).~Each 2-week dosing period equals 1 cycle; patients may receive up to 3 cycles of AVID200 (i.e., dosing on D1, 15, and 29 of overall 6 week treatment period)."
3476035|NCT03831412|Active Comparator|CBT-I|5 sessions of treating insomnia
3476036|NCT03831412|Active Comparator|ERRT|5 sessions of treating post-trauma nightmares
3476037|NCT03831269|Active Comparator|Azithromycin|The dose of azithromycin will be 10mg/kg/day oral suspension for 3 consecutive days for pediatric patients (<12 years old) and 500mg/day in three consecutive days for adults. The cycle will be repeated every seven days (3 cycles/month) and will be repeated if required according to patient's response up to 6 cycles. Side effects of therapy will be recorded. This protocol is based on previous case reports.
3476038|NCT03831269|Active Comparator|Nb UVB|Patients recruited for nbUVB phototherapy will have an initial dose of 0.3J-0.5J according to Fitzpatrick's skin type. The dosage will be increased by 0.3J in every other treatment session. The sessions will be given 3 times weekly until improvement is noted or reaching 8 weeks at the EOS. We arrived at this initial dose based on our previous experience with Egyptian patients in Kasr Alainy phototherapy unit in Dermatology Department, Cairo University.
3476039|NCT03831243|Active Comparator|Single fraction of 8 Gy|The current standard treatment will be prescribed, i.e. a 3D-conformal radiotherapy of a single fraction dose of 8.0 Gy to the metastasis with a planning target volume (PTV) margin for set-up and positioning uncertainties of 1 cm. This can be performed at any linear accelerator.
3476040|NCT03831243|Experimental|Single fraction of 20 Gy|Within the framework of stereotactic body radiotherapy, a single fraction dose of 20.0 Gy will be delivered to the metastasis using a PTV margin of 3-5 mm based on high-precision image-guided radiotherapy (IGRT). Therefore, only linear accelerators with the European Organization for Radiotherapy & Oncology advisory committee on radiation oncology practice (ESTRO-ACROP) specifications for SBRT can be accepted. A risk-adapted approach will be applied, aiming for the highest possible dose no less than 16 Gy, while respecting the tolerances of critical organs at risk (e.g. spinal cord, cauda equina, brainstem etc.).
3476041|NCT03831035||15 patients and both parents.|The patients are aged 12 months or under hospitalized in the ICU suffering from multiple congenital malformations and/or neurologic symptoms.
3476042|NCT03831178|Experimental|DHA|Participants will take 11 capsules per day containing DHA-enriched triglyceride oil (1 g capsules containing at least 400 mg DHA) for a total of 5 g DHA/day divided into three times daily with meals or as tolerated.
3476043|NCT03831178|Placebo Comparator|Placebo|Participants will take 11 capsules per day containing corn/soy oil blend capsules divided into three times daily with meals or as tolerated.
3476044|NCT03831139|Experimental|Prevention|TIM&SARA has a duration of 16 fifty-minute sessions and is organized in five modules. The first module (2 sessions) outlines the rationale for the program and establishes connections between group leaders and adolescents. The next module (2 sessions) focuses on helping adolescents to consider already existing goals, set new ones, and learn how to achieve goals to build up the motivation of the youth to learn and apply the material of the following modules. The third module (6 sessions) focuses on understanding the relations among cognitions, emotions, and behaviors, and teaching the participating youths how to identify and challenge negative cognitions. The forth module (5 sessions) trains the youth in assertive and social competent social behavior. Finally, the last session is a review session and includes a celebration. All parts of the program use illustrative, culturally relevant situations introduced by the participating adolescents.
3126555|NCT03041090|Experimental|Dynamic image participants|"This arm of the study assessed participants' dynamic PET/CT images. These were the study related images of and around the injection site acquired during the participants' standard of care uptake time. These images were assessed visually by a board certified physician and using the Time Activity Curves from the sensor data.~Intervention was Lucerno sensors (LD ID, LD1, Lucerno, Lara) placed on participant to monitor radiotracer activity at and around injection site."
3126556|NCT03041116|Experimental|Fosmetpantotenate|Administered as powder for reconstitution.
3126557|NCT03041116|Placebo Comparator|Placebo|Administered as powder for reconstitution.
3126558|NCT03041181|Experimental|Arm A - Single Agent Chemotherapy + Nivolumab|"Single Agent Chemotherapy of choice plus nivolumab:~Taxotere Pemetrexed Gemcitabine"
3126559|NCT03041181|Active Comparator|Arm B - Single Agent Chemotherapy|Single Agent Chemotherapy of choice Taxotere Pemetrexed Gemcitabine
3126560|NCT03041298||All included patients|All included patients underwent MR mammography with Dotarem
3126561|NCT03041441|Experimental|MRICP method|MRI sequences have been developed that may be able to estimate ICP in a non-invasive fashion.6-10 The MRI-based method for measurement of ICP (MRICP method) is based on basic principles of the cranio-spinal CSF physiology: The mono-exponential relationship between intracranial volume and pressure leads to a linear relationship between elastance (i.e., the derivative of pressure with respect to volume) and pressure.
3476045|NCT03831139|No Intervention|Control|The youth participate in school as usual.
3476046|NCT03831152|Experimental|Experimental ADV7103|All patients receive ADV7103 at their individualized dose
3476047|NCT03831113|Experimental|Buprenorphine Magnitude Group|Subjects will receive alternating reductions of 1 mg and then 2 mg weekly. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
3476048|NCT03831113|Experimental|Buprenorphine Frequency Group|Subjects will receive dose reductions of 2 mg on alternating intervals of 1 and 2 weeks. Subjects on TID or QID dosing, as prescribed by their MAT provider, will be assigned to either the Magnitude or Frequency group (n=10).
3476049|NCT03831113|Experimental|Buprenorphine Dosing Group|Subjects will receive dose reductions identical to either the Magnitude (alternating 1 and 2 mg reductions) or Frequency (2 mg reductions on alternating 1 and 2 week intervals) groups. Subjects on BID dosing, as prescribed by their MAT provider, will be assigned to the Dosing group (n=10).
3476050|NCT03831100|Experimental|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
3476051|NCT03831100|Placebo Comparator|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. AC consists of 5 weekly sessions of videos about HNC survivorship that are delivered using a telemedicine platform. Each AC session is a compilation of shorter videos featuring HNC survivors, caregivers, and oncologists discussing non-body image aspects of HNC survivorship.
3476052|NCT03831256|Active Comparator|Standard of care (2nd tier NIPS)|For the standard-of-care arm (2nd tier NIPS) women will undergo Traditional integrated prenatal screening i.e. traditional biochemical (+/- NT) and those with a positive screen for T21 or T18 will be offered Second-tier Non-invasive prenatal screening (NIPS) (for T21, T18, T13) or Invasive prenatal testing for fetal aneuploidy. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
3476053|NCT03831256|Experimental|First-tier NIPS|For the intervention arm (1st tier NIPS) women will receive First-tier Non-invasive prenatal screening (NIPS) i.e. provide a blood sample between 10-13+5 weeks gestation with NIPS results within 7 - 10 days of sample collection. Ultrasound examination in first and second trimester will be done based on clinical care practice ordered by health care provider. In case of a failed NIPS test (expected to be between 2% and 4% of samples), a new blood sample will be drawn for NIPS retest as well as for a traditional SIPS(serum integrated prenatal screening) or QUAD(quadruple marker prenatal screening) screen (depending on gestational age). Pregnant women with a positive NIPS test will be offered Invasive prenatal testing for fetal aneuploidy (fetal chromosome analysis).
3476054|NCT03831373|Experimental|Upper-limb-focused resistance training|
3476055|NCT03831373|Experimental|Lower-limb-focused resistance training|Lower-limb-focused resistance training with elastic bands.
3476056|NCT03831373|Active Comparator|Stretching exercise|Stretching exercise program in a sitting position.
3476057|NCT03831126||betamethasone treatment|
3476058|NCT03831204||AHF/HFpEF|AHF with preserved ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
3476059|NCT03831204||AHF/HFrEF|AHF with reduced ejection fraction Acoustic cardiography was performed for all participants using the BIOPAC Prognostic scores were calculated for every patient
3476060|NCT03831087|Other|TAVR-CMR|"All MR examinations will be performed with a 1.5-T clinical MR imaging unit (AVANTO_fit; Siemens, Erlangen, Germany). The MR protocol consists of a Navigator-gated free breathing 3D whole-heart coronary magnetic resonance angiography (MRA), axial 2D true fast imaging with steady-state free precession (true-FISP) during free breathing covering whole body trunk and a coronal 3D fast low-angle shot (FLASH) Gd-MRA."
3476061|NCT03831087|Other|TAVR-CT|All CT examinations will be performed on a 128-slice dual-source CT and high-pitch factor. Prospective electrocardiographic synchronization will be applied, triggered into the diastolic phase for the heart. An injected bolus of 70 to 110 mL of nonionic iodine contrast agent will be applied with 370 mg/mL iodine concentration, using an automatic injector at a flow rate of 5 mL/s, followed by 40 mL saline solution. Contrast agent volume for each patient will be calculated by scan time and body weight. Patients will be placed supine with arms overhead. The scan length range from supraaortic branches to the groins.
3476062|NCT03831061|Experimental|Cognitive stimulation|"10 sessions of 45 minutes/week during 10 weeks. Each session included : (a) temporo-spatial orientation , (b) activities related to memory, orientation, language, praxis, gnosis, calculation, perception, reasoning, visual attention, and executive functions, (c) individual practical exercises and (d) correction of the practical exercises.~There are 54 participants subdivided into two groups of 27 participants that perform the same intervention in different days of the week."
3476063|NCT03831061|No Intervention|Control group (No intervention)|There are 68 participants in total. These participants did not receive intervention.
3476064|NCT03831165|Experimental|melatonin 3mg + Acyclovir 400mg|GI - melatonin 3mg + Acyclovir 400mg
3476065|NCT03831165|Active Comparator|Acyclovir 400mg|GII - Acyclovir 400mg twice a day
3476066|NCT03831165|Placebo Comparator|placebo + melatonin 3mg|GIII - placebo + melatonin 3mg
3476067|NCT03831009|Active Comparator|Weight-bearing stable/Gravity stable|Ankles that are considered stable using weight-bearing radiographs AND gravity stress test will be assigned to conservative treatment
3476068|NCT03831009|Active Comparator|Weight-bearing stable/Gravity unstable|Ankles that are considered stable using weight-bearing radiographs but unstable using gravity stress test will be assigned to conservative treatment
3476069|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity unstable|Ankles that are considered unstable using weight-bearing radiographs AND gravity stress test will be assigned to open reduction internal fixation (ORIF)
3476070|NCT03831009|Active Comparator|Weight-bearing unstable/Gravity stable|Ankles that are considered unstable using weight-bearing radiographs but stable using gravity stress test will be assigned to open reduction internal fixation (ORIF)
3476071|NCT03831425|Experimental|Coenzyme Q|Each patient will be asked to take part in a 6 wk trial of pharmaceutical grade CoQ10 and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk CoQ10 trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
3476072|NCT03831425|Placebo Comparator|Placebo|Each patient will be asked to take part in a 6 wk trial of placebo and will be randomly assigned to a start time. There will be a 6 wk washout period between treatment and placebo arms. At baseline, if this is the first arm, testing will include determination of muscle function based on our 3 min step test, muscle power (maximal jump, handgrip), strength (Queens' Square), endurance (6MWT), fatigue (PedsQL fatigue scale), physical activity level (3DPAR), attention (ADHDT scale), cognition (MoCA), physical function (CHAQ).and quality of life (PedQL). Following the 6 wk placebo trial, testing will include repeat determination of all of the above as well as determination of total aerobic capacity (maximum cycle ergometry) and muscle metabolism (31P-MRS ergometry).
3476073|NCT03831295|Experimental|Treatment (SD-101, BMS-986178)|"SAFETY COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 8 and 15, and IV over 30 minutes on days 8, 29 and 58.~EXPANSION COHORT: Patients receive TLR9 agonist SD-101 IT on days 1, 8 and 15. Patients also receive anti-OX40 antibody BMS 986178 IT on days 1, 8 and 15, and IV over 30 minutes on days 1, 29 and 58."
3476074|NCT03830983||Stroke of likely cardioembolic cause or undetected mechanism|Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.
3476075|NCT03830983||Atherosclerotic stroke|Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% and presence of severe small vessel disease possibly including micro bleeds.
3126562|NCT03041467|Experimental|IN.PACT AV DCB|"PTA will be performed using the IN.PACT AV Access Drug Coated Balloon. IN.PACT AV Access DCB was the device name used during the clinical study. Medtronic has changed the name of the device to IN.PACT™ AV Paclitaxel-Coated Balloon Catheter (also referred as IN.PACT AV DCB). Hence, throughout posting, the study device will be referred to as the IN.PACT AV DCB."
3126563|NCT03041467|Active Comparator|Standard Balloon Angioplasty|PTA will be performed using a commercially available uncoated PTA balloon.
3126564|NCT03041636|Experimental|Treatment (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Treatment continues for up to 3 years in the absence of disease progression or unacceptable toxicity. Treatment beyond 3 years may be permitted after discussion with the principal investigator.
3126565|NCT03041792|Experimental|Active|Liraglutide
3476076|NCT03830983||Controls|Age and sex matched healthy controls with no history of stroke or AF.
3476077|NCT03831308||Breast cancer new diagnosis|group will include volunteer women, diagnosed with breast cancer, in any stage, aged 18y or more; at least 100 patients will be recruited in medical oncology appointments; all subjects should be periodically submitted to non-invasive evaluation tests - that is, clinical test/clinical and physical assessment to collect information on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
3476078|NCT03830814||Cases|Patients with heart failure with reduced ejection fraction (HRrEF) who have indications for the use of sacubitril/valsartan as recommended by recent guidelines
3476079|NCT03830827|Experimental|MBRP+vortioxetine intervention|"Participants who allocate to the experimental group will receive 8-week 10-20mg/day vortioxetine combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~10-20mg/day vortioxetine will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
3476080|NCT03830827|Experimental|MBRP intervention|"Participants who allocate to the control group will receive 8-week 1-2#/day placebo combined with MBRP intervention.The MBRP intervention is composed of 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists to prevent MA relapse.~1-2#/day placebo will sent every day and 2-hour MBRP intervention per week until the end of 8-week intervention . They will also receive 10 visits: visit 1 (week 0): medical and psychiatric screening; visit 2-9 (week 1, 2, 3, 4, 5, 6, 7 and 8): depressive symptoms and cognitive function, MA use, and MA craving; visit 10 (week 24): MA use (assessment of relapse rates), assessment of depressive symptoms, improvement in cognition and MA craving."
3126566|NCT03041792|Placebo Comparator|Placebo|Placebo comparator
3126567|NCT03041896||Decompression|Standard of care decompression for spinal stenosis, 1 or 2 levels.
3126568|NCT03041896||Fusion|Standard pedical and rod fixation with standard decompression, 1 or 2 levels.
3126569|NCT03041896||coflex®|Decompression surgery with the coflex® Interlaminar Technology, 1 or 2 levels.
3476081|NCT03830905|Experimental|XC221|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
3476082|NCT03830905|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo once daily during 3 days of treatment period
3126570|NCT03041896||Hybrid|coflex and fusion at adjacent levels
3126571|NCT03041909|Experimental|Single Arm|Single Arm / open label
3476083|NCT03830918|Experimental|Arm A (temozolomide, niraparib, atezolizumab)|Patients receive temozolomide PO QD on days 1-5 and niraparib PO QD on days 1-28. Cycles repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
3476084|NCT03830918|Active Comparator|Arm B (atezolizumab)|Patients receive standard of care atezolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
3476085|NCT03830762|Experimental|Cohort 1 / Cohort 2 (Active)|20mg or 30mg capsules of Xanamem respectively, to be administered PO once daily.
3476086|NCT03830762|Placebo Comparator|Cohort 1 / Cohort 2 (Placebo)|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
3476087|NCT03830957|Active Comparator|Ivabradine|
3126572|NCT03042299|Experimental|TAK-536 Granules + TAK-536 Tablet|TAK-536 10 milligram (mg), granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
3126573|NCT03042299|Experimental|TAK-536 Tablet + TAK-536 Granules|TAK-536 10 mg, tablet (commercial formulation), under fasted condition, orally, once on Day 1 of Intervention Period 1, followed by a Washout Period of at least 6 days, further followed by TAK-536 10 mg, granules (pediatric formulation), under fasted condition, orally, once on Day 1 of Intervention Period 2.
3476088|NCT03830957|Active Comparator|metoprolol|
3476089|NCT03830736|Placebo Comparator|Control product|A glucose solution (glucose and water) based on 42 gram carbohydrates.
3126574|NCT03042312|Experimental|177Lu-PSMA-617 (6.0 GBq)|Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
3476090|NCT03830736|Experimental|Oat Beverage 1|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
3476091|NCT03830736|Experimental|Oat Beverage 2|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
3476092|NCT03830736|Experimental|Oat Beverage 3|The test product is an oat based beverage with added vegetable oil. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
3476093|NCT03830736|Experimental|Oat Beverage 4|The test product is an oat based beverage. The test portion is based on 42 gram available carbohydrates and consumed as a breakfast meal prior to determinations of test variables in the morning.
3476094|NCT03830801|Experimental|IVLCM tethered capsule for biopsies|IVLCM tethered capsule for obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk.
3476095|NCT03830788|Active Comparator|Brachytherapy|radiation by brachytherapy: brachytherapy by Iodine 125 delivering 144 Gy to the prostate
3476096|NCT03830788|Experimental|stereotactic body radiotherapy (SBRT)|radiation by SBRT: SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate. The prostate can be tracked/localized/treated thanks to the Cyberknife or a conventional linac equipped with an ExacTrac or a Calypso4D system.
3132521|NCT03434457||Prenatal and 3 to 72 months|
3476097|NCT03830970|Experimental|1 cup of canned beans of multiple varieties|Consumption of 1 cup of canned beans of multiple varieties each day for 4 weeks
3476098|NCT03830970|Experimental|1/2 cup of canned beans of multiple varieties|Consumption of 1/2 cup of canned beans of multiple varieties each day for 4 weeks
3476099|NCT03830970|Other|1 cup of White rice|Consumption of 1 cup of white rice each day for 4 weeks
3476100|NCT03830775|Experimental|Experimental - PRP injection|2cc of PRP is injected into the ulnocarpal joint
3476101|NCT03830775|Placebo Comparator|control - Saline injection|2cc of 0.9% sterile saline is injected into the ulnocarpal joint
3476102|NCT03830944||G1|"Study subjects with STEMI and increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
3476103|NCT03830944||G2|"Study subjects with STEMI and no increased inflammatory response at 7 days after STEMI~Interventions:~Blood sampling~transthoracic echocardiography~Late Gadolinium-Enhancement Cardiac Magnetic Resonance~Coronary Angio Computed Tomography"
3476104|NCT03830476|Experimental|Acceptance- and Commitment therapy group|Experiment group that receives the treatment direct after the baseline measurement.
3476105|NCT03830476|Active Comparator|Treatment as usual|Comparison group that receives treatment as usual and the Navigator ACT intervention appr 6 months later.
3476106|NCT03830502||Salpingectomy|Women who gave consent for opportunistic prophylactic bilateral salpingectomy during cesarean section as a Surgical sterilization procedure
3476107|NCT03830502||Tubal ligation|Women who refused salpingectomy and gave consent for tubal ligation during cesarean section as a Surgical sterilization procedure
3476108|NCT03830489|Experimental|Large volume based preparation|This strategy will consist of split dose 4 L polyethylene glycol plus 10 mg bisacodyl plus 3 days of fiber-free diet.
3476109|NCT03830489|Active Comparator|Low volume based preparation|This strategy will consist of split dose 2 L polyethylene glycol plus Ascorbic acid plus 1 day of fiber-free diet
3476110|NCT03830632|Experimental|Plyometric Training Program|The plyometric training group participated in a 6-week training program performing a variety of plyometric exercises designed for the lower extremity , while the control group did not participate in any plyometric exercises. All subjects were instructed not to start any lower extremity strengthening programs during the 6-week period and to only perform activities of normal daily living.
3476111|NCT03830632|Active Comparator|Traditional Training|"AEROBIC TRAINING - A minimum of two low-intensity sessions a week consisting of 1 hour running. .~SHUTTLE SPRINTS - Placed two cones roughly 25 yards apart. Ask cricketer to sprint as fast as back and forth between the cones 12 times, for a total of six round-trips. ask them to finish in one minute. give rest for up to five minutes, then repeat once or twice."
3476112|NCT03830671|Experimental|investigational arm|the arm was given investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）and the total duration of the regimen is 18 months.
3126575|NCT03042312|Experimental|177Lu-PSMA-617 (7.4 GBq)|Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
3126576|NCT03042559|Active Comparator|Protonics knee brace|All subjects were fitted with a regular-sized Protonics knee brace with resistive settings to resist knee flexion.
3126577|NCT03042559|Experimental|Sport cords|Resistive sports cord to resist knee flexion.
3126578|NCT03042702|Experimental|Kevetrin 250 mg/m2 IV Cohort 1|Kevetrin 250 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (750 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
3126579|NCT03042702|Experimental|Kevetrin 350 mg/m2 IV Cohort 2|Kevetrin 350 mg/m2 IV per dose every other day (q.o.d.)/ 3 doses per week (1050 mg/m2 per week), for 3 weeks (single cycle; total 9 doses) Follow-up For 3 weeks after Kevetrin treatment ends
3126580|NCT03042715||Psychological Intervention refinement|"Eight weekly sessions in-person or via telephone~Qualitative interviews~Feedback from 5-10 caregivers to refine the intervention."
3476113|NCT03830515|Experimental|Closure of lacerations with microMend|Laceration closure with microMend
3476114|NCT03830463|Experimental|CTP-692|
3126581|NCT03042767|Experimental|IMM-124E Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive 600mg of IMM-124E powder three times daily for twelve weeks.
3126582|NCT03042767|Placebo Comparator|Placebo Group|Participants with nonalcoholic fatty liver disease (NAFLD) will receive placebo powder three times daily for twelve weeks.
3126583|NCT03042910|Experimental|Patients with advanced solid tumors|Talazoparib 1 mg daily
3476115|NCT03830463|Placebo Comparator|Placebo|
3476116|NCT03830528|Experimental|Part A-1|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
3476117|NCT03830528|Experimental|Part A-2|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
3476118|NCT03830528|Experimental|Part A-3|There will be 3 cohorts of Japanese healthy men dosed with single doses of KW-6356 (3 planned dose levels) or with placebo.
3476119|NCT03830528|Experimental|Part B|There will be one cohort of Japanese healthy men dosed with multiple doses of KW-6356 or placebo and one potential additional cohort (KW-6356 dose as determined in Part A or placebo)
3476120|NCT03830528|Experimental|Part C-1|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
3476121|NCT03830528|Experimental|Part C-2|There will be 2 cohort of Japanese and Caucasian healthy men dosed with multiple doses of KW-6356 (KW-6356 dose as determined in the previous studies)
3476122|NCT03830528|Placebo Comparator|Placebo|
3476123|NCT03830684|Experimental|low-dose group|Baicalein Tablets group
3476124|NCT03830684|Experimental|high-dose group|Baicalein Tablets group
3476125|NCT03830684|Placebo Comparator|placebo group|control group
3476126|NCT03830593||Group 1|laparoscopic adrenalectomy group 1: tumor size as < 6 (group1)
3126584|NCT03043079|Experimental|Ventral Hernia|Twenty-five patients diagnosed with ventral hernia
3476127|NCT03830593||Group 2|Laparoscopic adrenalectomy group2: tumor size ≥ 6 cm (group2)
3476128|NCT03830593||Learning Curve|The patients, underwent laparoscopic adrenalectomy, were also classified into group A (1-25), B (26-50), C (51-75), and D (76-102) according to the chronological order of their surgery in order to evaluate the learning curve.
3476129|NCT03830567||Pharmacist prescription|
3476130|NCT03830567||Clinician prescription|
3126585|NCT03043079|Other|Healthy Volunteers|Twenty-five volunteers without ventral hernia
3126586|NCT03043079|Other|Active Health Volunteers|Ten healthy volunteers with an International Physical Activity Questionnaire (IPAQ) with the scoring result of High or Vigorous Intensity
3126587|NCT03043105|Experimental|TCP regimen|Thalidomide, cyclophosphamide and prednisone （TCP regimen）would be used for newly-diagnosed symptomatic MCD patients
3126588|NCT03043274|Experimental|Cangrelor|Approximately 30 patients in this arm will receive standard STEMI care but will also receive standard dosing of cangrelor at the time of their PCI.
3126589|NCT03043274|No Intervention|No cangrelor|Approximately 30 patients in this arm will receive standard STEMI but will not receive cangrelor at the time of their PCI.
3126590|NCT03043365|Experimental|Arm 1: Control Fish Oil first, then Saury Oil|Subjects randomized to the control fish oil arm will take the equivalent to 3g of control /day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the LCMUFA-rich saury oil capsule arm
3476131|NCT03830723|Other|Rekovelle (Follitropin delta)|All participants will receive a prescription for study medication Rekovelle (follitropin delta)
3476132|NCT03830606|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
3476133|NCT03830645|Experimental|Platelet rich plasma group|
3476134|NCT03830879||No treatment|This cohort study have any no treatment.
3476135|NCT03830749|Experimental|Single Arm|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
3476136|NCT03830658|Experimental|Structured Intervention on Self-care with AVF|The structured intervention designed for this study was a multimethod approach with the purpose of capturing the learning styles of most patients through the use of written, listening and visual learning (10). Structured Intervention on Self-care with AVF (SISC-AVF) has been designed taking into account the structure of care to the person with AVF developed by Sousa (11). The SISC-AVF had the purpose of identifying the signs/symptoms or situations jeopardizing AVF working and includes both a theoretical and a practical part.
3476137|NCT03830658|Active Comparator|Usual-Care Control|Educational training was given during HD sessions. The dialysis nurse provided information about arteriovenous fistula care and trained the patient when he/she felt it was required. The dialysis units had no documentation concerning the educational training given to patients and the moment to provide such information was not defined, either.
3476138|NCT03830697|Experimental|Menstruation situation TCM symptom score standard|
3476139|NCT03830697|Placebo Comparator|Sham intervention|
3476140|NCT03830554|Experimental|intervention group|product name: organic Atlas cedar wood essential oil (Cedrus Atlantica): the intervention group smell 2 drops of organic Atlas cedar wood essential oil (applied on cotton ball) for a period of five consecutive nights (at least 8 hours each night).
3476141|NCT03830554|No Intervention|control group|participants of this group received no intervention.
3476142|NCT03830580|Experimental|Sung voice|
3476143|NCT03830580|No Intervention|Control|
3476144|NCT03830424||Control group|Healthy term newborns without pain relief during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
3476145|NCT03830424||Sucrose group|Healthy term newborns with oral application of sucrose during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
3476146|NCT03830424||Mother milk group|Healthy term newborns with oral application of mother milk during pain stimulus (intramuscular K vitamin administration and heel lancing for blood spot examination).
3476147|NCT03830320|Active Comparator|Healthy Volunteers|In the first stage, twenty (20) healthy adult subjects will be injected with [64Cu]FBP8 to establish the safety, whole body distribution, metabolism, pharmacokinetics, and radiation burden of the probe. All subjects will be imaged using PET/MR. Healthy subjects will undergo blood collection before, during, and after the scan. Healthy subjects will also undergo electrocardiogram before and after the scan. An interim review of the data will be conducted after the first six subjects receive the study agent and complete all safety assessments.
3476148|NCT03830320|Experimental|Atrial Fibrillation Patients|In the second stage, forty (40) patients with LAA thrombus documented by TEE will be injected with [64Cu]FBP8 and imaged for LAA thrombus with MR-PET. The TEE studies in these patients will be part of their routine clinical care.
3476149|NCT03830437||Case group|The group will be subjected to double weighing, before and after the next 6 breastfeeding. Breastfeeding will be carried out each 4 hr.
3476150|NCT03830437||Control group|The group will be subjected to monitoring of body weight only at 24, 36 hr and 48 hr of life.
3476151|NCT03830398|Active Comparator|Paracetamol|Parol group: intravenous infusion in 30 min Generic name: Parol Dosage form: intravenous Dosage: 1 gr Frequency: preop one dose only Duration: For one week
3476152|NCT03830398|Active Comparator|Deksketoprofen trometamol|Sertofen group: intravenous infusion in 30 min Generic name: Sertofen Dosage form: intravenous Dosage: 50 mg Frequency: preop one dose only Duration: For one week
3476153|NCT03830398|Placebo Comparator|Placebo|Placebo group: intravenous infusion in 30 min Generic name: Serum physiologic Dosage form: intravenous Dosage: 100 ml Frequency: preop one dose only Duration: For one week
3476154|NCT03830242|Experimental|<Sup>18<Sup>F-FDG PET/CT study group|<Sup>18<Sup>F-FDG PET/CT dynamic scan,Pathological examination and gene detection Diagnostic Test: <Sup>18<Sup>F-FDG PET/CT dynamic scan The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
3476155|NCT03830242|Other|B-ultrasonography group|B-ultrasonography,Pathological examination and gene detection Diagnostic Test:B-ultrasonography The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
3476156|NCT03830268|Experimental|MCT intake in young participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in young participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
3476157|NCT03830268|Experimental|MCT intake in older participants|"Different conditions paired with a dietary MCT beverage over an 8-hour metabolic day protocol in older participants.~Interventions:~No MCT intake with breakfast, no lunch (i.e. CTL)~No MCT intake with lunch, no breakfast (i.e CTL inverted)~10g of Betaquik with breakfast, no lunch (i.e BQ10)~20g of Betaquik with breakfast, no lunch (i.e BQ20)~10g of Betaquik with low-carbs breakfast, no lunch (i.e BQ10LC)~10g of Betaquik with lunch, no breakfast (i.e BQ10 inverted)"
3476158|NCT03830138||Acute coronary syndrome patients:|One hundred patients with acute coronary syndrome.
3476159|NCT03830138||Controls:|Fifty healthy control
3476160|NCT03830151|Experimental|Diagnostic (carbon C 13 pyruvate, MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and then undergo an MRSI scan.
3476161|NCT03830346|Experimental|Experimental|In the experimental group, instrument-assisted soft tissue mobilization techniques and post-isometric horizontal adduction stretches were performed. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment.
3476162|NCT03830346|Experimental|Control|Control group only underwent soft tissue mobilization. With the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times.
3476163|NCT03830164|Experimental|Treatment (atorvastatin, vitamin E, pentoxifylline)|Patients receive atorvastatin PO QD for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Beginning week 7, patients receive atorvastatin PO QD, vitamin E PO QD, and pentoxifylline PO TID for up to 12 months in the absence of disease progression or unacceptable toxicity.
3476164|NCT03830359|Other|T2769|T2769 Ophthalmic solution One drop in each eye 3 to 6 times daily
3476165|NCT03830073||Group I:|Seventy patients with pancreatitis
3476166|NCT03830073||Group II:|Thirty healthy controls
3126591|NCT03043365|Experimental|Arm 2: Saury Oil first, then Control Fish Oil|Subjects randomized to the LCMUFA-rich saury oil arm will take the equivalent to 3g of control/day (12 gel capsules/day) for 8 plus or less 2 weeks and crossover to the control fish oil capsule arm
3126592|NCT03043365|No Intervention|Washout Period|8 week washout period to occur between week 8 and week 16. No study supplement taken by subject at this time.
3476167|NCT03830112|Experimental|Pilates exercise with Theraband|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based exercises with Theraband® (blue color) from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based exercises with Theraband® (blue color) from week five to eight.~(saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
3476168|NCT03830112|Active Comparator|Pilates exercise|"24 exercise sessions, 3x weekly (on alternate days).~11 Pilates-based mat exercises from week one to four. (hundred,roll up, one leg circle,rolling like a ball,single leg stretch, double leg stretch,single straight leg stretch, double straight leg lower lift, criss-cross, spine stretch, corkscrew).~12 Pilates-based mat exercises from week five to eight. (saw, rest position, shoulder bridge, side, kick, front ad back, up and down, teaser, swimming, leg pull front, mermaid, seal, push up).~Every participant will perform three isometric repetitions of 30 seconds per exercise, with 10 seconds recovery between repetitions and 30 seconds rest between each exercise."
3476169|NCT03830385|Experimental|Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or|
3476170|NCT03830372|Experimental|VR Tier One|"Patients will receive:~10 sessions of 20 minutes of VR Tire One therapeutic game,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
3476171|NCT03830372|Active Comparator|Control|"Patients will receive:~10 sessions of 20 minutes of Schultz Autogenic Training,~60 minutes of individual physiotherapy based on the Bobath and PNF concept with elements of manual therapy,~30 minutes individual aerobic training,~30 minutes balance exercises."
3126593|NCT03043534|Experimental|Gel and Brush|The Experimental group of subjects will be given the study product Pre-Shave Gel and Brush. The gel and brush will be used prior to their normal shave routine. Subjects will shave at least 3 times weekly.
3126594|NCT03043534|No Intervention|Control|Subjects will use their normal razors and shave products during the six week study. Subjects must shave at least 3 times weekly. No change in normal shaving is done in this group
3126595|NCT03043560|Experimental|Ezogabine|Participants will receive treatment with ezogabine up to 900mg/day.
3126596|NCT03043560|Placebo Comparator|Placebo|Participants will receive treatment with a matching placebo pill.
3126597|NCT03043599|Experimental|Combination Therapy|Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy. Radiotherapy, followed by a 14 to 21 day break between radiotherapy and the beginning of study drug treatment.
3126598|NCT03043651|Experimental|Oral treprostinil|Sustained-release tablets for TID administration
3126599|NCT03043872|Experimental|Arm 1|durvalumab+tremelimumab+EP (carboplatin or cisplatin + etoposide)
3476172|NCT03830086|Other|Group A: general anesthesia|Patients undergoing gynecological laparoscopic surgery under general anesthesia, using the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium, Sevoflurane
3476173|NCT03830086|Other|Group B: regional anesthesia|Patients undergoing gynecological laparoscopic surgery under regional anesthesia, using the following drugs: Sufentanil, Bupivacaine
3476174|NCT03830216|Experimental|Treatment Arm|Study subjects will administer prandial insulin to manage their diabetes using a connected insulin pen and smartphone app with integrated dose calculator.
3476175|NCT03830216|Sham Comparator|Control Arm|Study subjects will administer prandial insulin to manage their diabetes using an inactive connected insulin pen without smartphone app.
3476176|NCT03830177|Experimental|Adults|All adults in the study will receive the treatment for dry scalp.
3476177|NCT03830177|Experimental|Children|All children in the study will receive the treatment for dry scalp.
3476178|NCT03830294|Experimental|Self-adhesive Group|The participants used the adhesive breast prosthesis that adheres to the skin.
3476179|NCT03830294|Active Comparator|Conventional Group|The participants used the conventional breast prosthesis that was placed inside a bra and did not directly adhere to the skin.
3476180|NCT03830190|Experimental|Intervention group|Parkinson's disease nurse specialist care
3476181|NCT03830190|No Intervention|Control group|No intervention
3476182|NCT03830125|Experimental|Single Ascending Doses|
3476183|NCT03830125|Experimental|Multiple Ascending Doses|
3476184|NCT03829878|Experimental|CP101|CP101 (Full Spectrum Microbiota) Capsule
3476185|NCT03829878|Placebo Comparator|Placebo|Placebo for CP101
3476186|NCT03830047|Active Comparator|nd yag laser|Applying nd yag laser to vulva
3476187|NCT03830047|Sham Comparator|Co2 laser|Applying CO2 laser to vulva
3476188|NCT03829995|No Intervention|Control group|Participants in the control group received the normal care following the Danish standard procedure.
3476189|NCT03829995|Active Comparator|Intervention group|Participants in the intervention group received the normal care following the Danish stadard procedure. Additionally the participants was also offered the possibility to contact a hospital pharmacy department by phone or mail for drug counseling.
3476190|NCT03829865||Water-perfused HREM|Healthy volunteers examined with water-perfused high resolution esophageal manometry
3476191|NCT03829865||Solid-state HREM|Healthy volunteers examined with high resolution esophageal manometry with solid-state catheter
3476192|NCT03830034|Experimental|Amino Acid chelated iron tab 15 mg group|Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) prepared by egyptian pharmaceutical company (nerhadou) once daily (a dose recommended by the company of the product).
3476193|NCT03830034|Active Comparator|Ferrous Fumarate tab 350 mg( 115 mg elemental iron) group|Contain 75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.
3476194|NCT03829956|Other|Snoring and mild OSA|This cohort of participants has been diagnosed with primary snoring or mild obstruction sleep apnoea. A medical device (intra-oral tongue stimulation device) will be introduced for 6 weeks and the effects will be assessed by comparing the outcome measures before and after the intervention.
3126600|NCT03043872|Experimental|Arm 2|durvalumab+EP (carboplatin or cisplatin + etoposide)
3126601|NCT03043872|Active Comparator|Arm 3|EP (carboplatin or cisplatin + etoposide)
3126602|NCT03043885|Experimental|PRF|
3126603|NCT03043885|Experimental|PRF+FDBA|
3126604|NCT03043885|Active Comparator|FDBA|
3126605|NCT03043885|Active Comparator|Blood Clot|
3126606|NCT03044028|Experimental|NMES preoperative and postoperative|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study
3126607|NCT03044028|Experimental|NMES postoperative only|Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study
3132522|NCT03434834|Experimental|OCT of esophagus|optical coherence tomography of esophagus
3476195|NCT03829696|Experimental|Non-pregnant women|"Participants will be provided Mifeprex® (oral mifepristone 200 mg) and misoprostol 800 mcg to be administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone) if unintended pregnancy occurs during the study period and the participant would like to end of the pregnancy. Participants who test positive for pregnancy will consult with a study clinician over the phone prior to administering mifepristone and misoprostol, and will then attend an in-person follow-up visit.~All participants will be provided with a single dose of ella® (ulipristal acetate emergency contraception 30 mg) by a clinician at the beginning of the study, as well as 6 AccuHome® midstream urine pregnancy tests."
3476196|NCT03829839|Active Comparator|Oxytocin or PLC|Single dose of intranasal oxytocin (24 international units) or PLC.
3476197|NCT03829839|Active Comparator|Lorazepam or PLC|Single dose of lorazepam (1mg) or PLC
3476198|NCT03830021|Experimental|Salt reduction program|Salt reduction program.
3476199|NCT03830021|Active Comparator|Healthy lifestyle program|Healthy lifestyle program.
3476200|NCT03829891|Experimental|Beinaglutide|"Beinaglutide for 8 weeks,~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
3476201|NCT03829891|Active Comparator|glargine|"Glargine for 8 weeks,~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
3476202|NCT03829748|Experimental|Intermittent aspiration|Empty syringe of 10cc and intermittent aspiration during puncture
3476203|NCT03829748|No Intervention|Continous/standard aspiration|Empty syringe of 10cc and continous aspiration during puncture
3476204|NCT03829761|Experimental|Cerebellar rTMS|Cerebellar rTMS. 1Hz repetitive transcranial magnetic stimulation (rTMS) to cerebellar vermis.
3476205|NCT03829761|Sham Comparator|Sham TMS|Sham TMS. Sham transcranial magnetic stimulation to cerebellar vermis.
3476206|NCT03829735|Experimental|Children and their mothers|Human biological samples from children aged 9 to 12 months and their mothers. Capillary and venous blood samples.
3476207|NCT03829943||Vitamin D deficiency|The study group will be males discovered to have Vitamin D deficiency.
3476208|NCT03829943||Control group|The control group will be males with normal Vitamin D status
3476209|NCT03829969|Experimental|Toripalimab|Toripalimab combine with paclitaxel and cisplatin
3476210|NCT03829969|Placebo Comparator|placebo|Placebo combine with paclitaxel and cisplatin
3476211|NCT03829774|Experimental|Primary Relief v 2.0 Device|The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
3476212|NCT03829774|Placebo Comparator|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
3476213|NCT03830008|No Intervention|Enhanced Treatment As Usual (ETAU)|The control group will receive enhanced treatment as usual (ETAU). ETAU means that the research team will advise the participants to contact their doctor in case of physical or mental health problems. Moreover, the research team will hand over the list with the general practitioners (GP) in the neighborhood of the participant and the written information (official booklet) about the operating of the Swiss health care system. Adequate treatment will be provided by this physician, usually, a general practitioner who acts as a gate-keeper (an asylum seeker or refugee has to go first to his/her assigned GP in order to get access to the health care system).
3476214|NCT03830008|Experimental|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on Cognitive Behaviour Therapy (CBT) techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
3476215|NCT03830060||Group I:|Fifty AP patients on admission
3476216|NCT03830060||Group II:|The previous AP patients after 72 hours
3476217|NCT03829670||Delirium Group|"UBACC: University of California, San Diego Brief Assessment of Capacity to Consent.~The participant may decline participation after this UBACC (University of California, San Diego Brief Assessment of Capacity to Consent) assessment and will be removed from the study.~The Short IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) is administered to the legally authorized representative or caregiver by Dr. Schmidt. If the potential participant scores 3.3 or lower, the participant will continue in the delirium group. If higher, patient likely with pre-existing dementia. These patients are not eligible for study participation.~Delirium Rating Scale 98 will be performed on the ALGH (Advocate Lutheran General Hospital) rehabilitation unit~Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
3476218|NCT03829670||Patients without delirium|"Cytochrome P450 testing~Delirium Status: Admission, Hospital Discharge, Outpatient Visit~FIM (The Functional Independence Measure) scores on admission and discharge. FIM efficiency score."
3476219|NCT03829709|Experimental|Intervention Group|The inspiratory muscle training (IMT) will be performed in the morning shift for 30 minutes, 3 times a week for 5 weeks. The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
3476220|NCT03829826||Patients receiving IVIg|Patients are currently receiving IVIg regularly for at least every 6 weeks and exhibit a favorable response will be recruited into the study (11 patients). They will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their impairment using the previously validated Stiffness and Sensitivity scales and quality of life questionnaire (QoL) at weeks 0, 4, 8, 12. At week 12, prior to the first SCIg infusion, blood will be drawn for humoral (immunological) studies. One week following the last dose of IVIg (at week 13), the participants will be started on SCIg at a total dose equivalent to the monthly dose of IVIg they have been receiving.
3476221|NCT03829826||de novo SCIg patients/IVIg-Naive Group|This other arm of the trial will include 11 patients naïve to IVIg who do not receive other immunotherapies while being symptomatic. These patients after a 12-week observation period will start directly on SCIg drug (HYQVIA), following the same schedule as described above for the previous group.
3476222|NCT03829800|Experimental|Ensure® Abbott Nutrition|A standard nutritional formula not specific for diabetics
3476223|NCT03829800|Experimental|Glucerna® Abbott Nutrition|A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
3476224|NCT03829800|Experimental|Diasip® Nutricia Advanced|A formula whose composition has isomaltulose and resistant starch
3126608|NCT03044028|No Intervention|No intervention|Subject will not be given device and will undergo the standard rehab protocol alone
3126609|NCT03044106|Active Comparator|CLRT, Then Sham|Subjects performed the KEA, HHD, PPT functional tests on their right hamstring before and after the CLRT intervention.
3126610|NCT03044106|Sham Comparator|Sham, Then CLRT|The Sham procedure was identical to CLRT except the laser device was placed in placebo mode: all device indicator lights and sounds will be functional but no laser light will be emitted from probe aperture.
3132523|NCT03434977|Experimental|TAK-536 10 mg (fasted) + TAK-536 10 mg (fed)|TAK-536 10 milligram (mg) granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) in the morning under fasted condition, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) after starting breakfast.
3476225|NCT03829800|Active Comparator|Glicolab®|Glucose solution
3476226|NCT03829787||Bipolar without Anxiety or Substance Use Disorder|Subjects who are diagnosed with bipolar disorder but do not have any current anxiety or substance use disorders
3476227|NCT03829787||Bipolar disorder with a current anxiety disorder only|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) but not a current substance use disorders
3476228|NCT03829787||Bipolar disorder with a current anxiety disorder and a current|Subjects who are diagnosed with bipolar disorder and a current anxiety disorder (generalized anxiety disorder, panic disorder, and/or social phobia) AND a current substance use disorders
3476229|NCT03829787||Bipolar disorder with a current substance use disorder only|Subjects who are diagnosed with bipolar disorder & a substance use disorders but not a current anxiety disorder
3476230|NCT03829787||Healthy Volunteers|
3476231|NCT03829813|Experimental|Patients|Music therapy sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour. Music therapy includes a variety of techniques used to target mood, pain, socialisation, expressive speech, attention/cognitive or sensorimotor functional goals.
3476232|NCT03829813|Experimental|Family|Family participation in music therapy treatment sessions. Planned 1:1 within acute neurology/rehabilitation patient rooms, or private rooms by a qualified music therapist once weekly and/or group music therapy sessions maximum 6-8 patients for less than or equal to one hour.
3476233|NCT03829813|Experimental|Administration and Staff|Staff/Administration are not participants in music therapy, but rather have observed sessions, or worked as co-treating clinicians with music therapists for patient participants.
3476234|NCT03829904|Experimental|VGH-BPH1 group|VGH-BPH1 includes Ji Sheng Shen Qi Wan 2.5g, Sangpiaoxiao powder 1.0g, Wuyao 0.3g, Yizhiren 0.3g, Danshen 0.3g, Yinyanghuo 0.3g, Fupenzi 0.1g, Huangbo 0.25g and Zhimu 0.25g, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
3476235|NCT03829904|Placebo Comparator|Control group|Placebo includes corn starch plus caramel coloring, and added 1/100 VGH-BHP1 compound, three times per day, each serving a small packet of 5.3 grams of concentrated granules.
3476236|NCT03829917|Experimental|Paromomycin and Miltefosine|Paromomycin-Aquaphilic cream applied topically once daily for 28 days plus oral miltefosine pills 2.5 mg/day [50 mg tid] for 28 days.
3476237|NCT03829917|Active Comparator|Miltefosine|Miltefosine pills alone [2.5 mg/day [50 mg tid] for 28 days. This group will also receive Aquaphilic-vehicle cream for 28 days
3476238|NCT03829917|Active Comparator|Paromomycin|Paromomycin-Aquaphilic cream applied topically once daily for 28 days.
3476239|NCT03829982|Experimental|bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
3476240|NCT03829982|Experimental|dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
3476241|NCT03829930|Experimental|Entinostat and Enzalutamide|Entinostat and Enzalutamide
3476242|NCT03829410|Experimental|Onvansertib + FOLFIRI + Bevacizumab|"Phase 1b: Onvansertib escalating starting dose of 12 mg/m2 orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab.~Phase 2: Onvansertib Recommended Phase 2 Dose (RP2D) orally Day 1 through 5 every 14-days over two treatment courses (1 cycle) in combination with FOLFIRI (180 mg/m2 irinotecan, 400 g/m2 leucovorin, 400 mg/m2 bolus 5-fluorouracil (5-FU), and 2400 mg/m2 continuous intravenous infusion 5-FU) + 5 mg/kg bevacizumab, with treatment modifications or delays based on unresolved toxicity experienced during a previous cycle."
3476243|NCT03829384|Experimental|mRNA-1944|Escalating dose levels
3476244|NCT03829384|Placebo Comparator|Placebo|Saline
3476245|NCT03829449|Experimental|rVA576 Coversin|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin) for up to 4 years.
3476246|NCT03829553|Experimental|Hypofractionated radiotherapy|Patients with an indication for regional nodal irradiation will received 2.67 Gy for 16 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67 Gy for 4 fractions following breast conserving surgery
3476247|NCT03829553|Active Comparator|Conventional radiotherapy|Patients with an indication for regional nodal irradiation will received 2 Gy for 25 fractions to chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2 Gy for 5 fractions following breast conserving surgery.
3476248|NCT03829371|Experimental|ARM A|"ARM A~Velcade (V):~1.3 mg/m2 subcutaneously on days 1, 4, 8, 11, 22, 25, 29 and 32 in cycles 1-4;~1.3 mg/m2 subcutaneously on days 1, 8, 22 and 29 from cycle 5.~Melphalan (M):~- 9 mg/m2 orally on days 1, 2 3 and 4 of each cycle.~Prednisone (P):~- 60 mg/m2 orally on days 1, 2, 3 and 4 of each cycle. Each cycle is a 42-day cycle. Duration: Maximum 9 cycles can be performed."
3476249|NCT03829371|Experimental|ARM B|"ARM B:~Lenalidomide (R):~-25 mg orally on days 1-21 of each cycle.~Dexamethasone (d):~-40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is a 28-day cycle. Duration: until PD or intolerance."
3476250|NCT03829566|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
3476251|NCT03829631|Experimental|Intervention|Participants will be instructed to follow their current low back pain management program, in addition, they will be instructed to wear a lumbar brace (Horizon 627 Lumbar Brace) during the day for four weeks only when they are in pain in addition to their current management program.
3476252|NCT03829631|No Intervention|Control|Participants will be instructed to follow their current low back pain management program.
3476253|NCT03829592|Placebo Comparator|misoprostol in neutral media|Intervention : misoprostol in a neutral media will be given to women to induce labour
3476254|NCT03829592|Active Comparator|Misoprostol in acidic media|Intervention : misoprostol in acidic media will be given to induce labour
3476255|NCT03829592|Sham Comparator|Misoprostol in alkaline media|Intervention : misoprostol in alkaline media will be given to induce labour
3476256|NCT03829527|Experimental|Psychotherapy|
3476257|NCT03829267|Experimental|eFIT Behavioral Intervention|Intervention: Participants randomized to the eFIT condition will join a 1-hour peer group meeting online each week, called eFIT intervention. They will learn about accountability partners, and use the group as an accountability partner to state and attain physical fitness goals.
3476258|NCT03829267|Active Comparator|eJournal Behavioral Intervention|Intervention: Participants in the eJournal condition will spend 1-hour online each week engaged in an active journaling activity, called eJournal Intervention. They will also receive the same psychoeducational materials online as the eFIT participants are presented in group.
3476259|NCT03829241|Experimental|Arm 1: BHV-4157- Experimental|
3476260|NCT03829241|Placebo Comparator|Arm 2: Placebo Comparator Drug|
3476261|NCT03829475|Experimental|FMT + Bezlo|Patients in this arm will received an FMT via colonoscopy ( 250ml) as well as a single IV infusion of bezlotoxumab (10mg/kg) that will take place over 60 mins.
3476262|NCT03829475|Placebo Comparator|FMT + Placebo|Patients in this arm will receive a single FMT via colonoscopy (250ml) and a placebo (saline) infusion (250cc) over
3476263|NCT03829358|Experimental|Probiotic|Lactobacillus plantarum IS-10506
3476264|NCT03829358|Placebo Comparator|Placebo|Placebo
3476265|NCT03829280|Experimental|Cognitive Adaptation Training|Psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery.
3476266|NCT03829280|Active Comparator|Community Treatment|Medication follow-up and case management as provided by the community mental health center according to usual care.
3476267|NCT03829345|Experimental|Olaparaib|Olaparib will be given 300mg bd for a 28 day cycle.
3476268|NCT03829488|Experimental|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
3476269|NCT03829488|Active Comparator|0.9% SODIUM CHLORIDE 9g/L injection BP|0.9% saline intravenous fluid therapy will be used for all maintenance, replacement and resuscitation purposes from randomization onwards until 48 hours post-transplant, or until fluid therapy is no longer required, if earlier.
3476270|NCT03829605||Group I:|Fifty AMI patients on admission
3476271|NCT03829605||Group II:|The previous AMI patients after 12 hours
3476272|NCT03829514|Experimental|Fenofibrate|Single arm. Participants will take study medication
3476273|NCT03829176|No Intervention|Standard-of-Care|Participants who are randomized to not have whole genome sequencing performed on their sample. These participants will have standard-of-care genetic testing only (ordered by their clinical provider) and will not receive genetic results as part of this study.
3476274|NCT03829176|Experimental|Whole Genome Sequencing|Participants who are randomized to have their genome sequenced and receive a whole genome sequencing report. Results disclosure sessions will include a discussion of the whole genome sequencing report, how the results compare to their standard-of-care genetic testing report, and any potential relevant recommendations. Participants in this arm will receive a copy of their whole genome sequencing report accompanied by a summary letter written by a study genetic counselor.
3476275|NCT03829319|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
3476276|NCT03829319|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
3476277|NCT03829644|Experimental|Intervention|Participants in the intervention arm will be fitted with a semi-rigid prefabricated lumbar brace (Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618) in addition to their current back pain management program.
3132524|NCT03434977|Experimental|TAK-536 10 mg (fed) + TAK-536 10 mg (fasted)|TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 1 (6 days) after starting breakfast, followed by wash-out (6 days), followed by TAK-536 10 mg granule formulation (pediatric formulation), once daily on Day 1 of Period 2 (6 days) in the morning under fasted condition.
3476278|NCT03829644|No Intervention|Control|Participants in this arm will be instructed to follow their current back pain management program.
3476279|NCT03829189|Active Comparator|inulin|
3476280|NCT03829189|Placebo Comparator|maltodextrin|
3476281|NCT03829137|Experimental|Verum laser acupuncture|Verum laser acupuncture：Low level laser therapy stimulates 7 acupuncture points on both sides of the body .
3476282|NCT03829137|Sham Comparator|Sham laser acupuncture|sham laser acupuncture (no laser output)
3476283|NCT03829215|Experimental|CAERVest cooling device|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, the CAERvest device will be filled and placed on the supine patient's chest. A recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an additional endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device. The CAERvest device will be removed, when a temperature below 34°C is reached.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
3476284|NCT03829215|No Intervention|Control|"After checking inclusion and exclusion criteria and immediately after return of spontaneous circulation, a recording esophageal temperature probe will be inserted and connected to the defibrillator. Then the patient will be transported to the Emergency Department.~After admission to the emergency department, an endovascular cooling device will be placed and the patient will be cooled to 33°C for 24 hours with the endovascular cooling device.~Then the patient will be rewarmed at 0.25 °C/h. After rewarming, the temperature will be controlled to be below 37.5°C for until 48 hours after cardiac arrest."
3476285|NCT03829293|Experimental|High-flow nasal cannula oxygenation group|Participants in the experimental group will receive high-flow nasal oxygen therapy (HFNO) during gastrointestinal endoscopy under sedation (with a flow at 70L/min and oxygen inspired fraction (FiO2) 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
3476286|NCT03829293|No Intervention|Standard Oxygenation|Participants in the current standard of care will receive standard oxygenation by nasal prongs (with a flow at 6L/min) or naropharyngeal catheter (with a flow at 5L/min) or standard face mask (with a flow at 6L/min)
3476287|NCT03829436|Experimental|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
3476288|NCT03829436|Experimental|Part 2 TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression.
3476289|NCT03829436|Experimental|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
3476290|NCT03829436|Experimental|Part 4 TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
3476291|NCT03829163|Active Comparator|Conventional Walker Group|
3476292|NCT03829163|Experimental|HAW Group|
3476293|NCT03829254|Experimental|NUC-7738|NUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
3476294|NCT03829085|Active Comparator|Early oral refeeding|"The patients will be started the oral refeeding from the first day of admission in the hospital.~Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day"
3476295|NCT03829085|No Intervention|FASTING|The oral diet will be reintroduced in a traditional stepwise manner until the symptoms, signs, inflammatory parameters of AP have resolved
3476296|NCT03829124|Experimental|ketamine + propofol group|use ketamine + propofol for ECT induction
3476297|NCT03829124|Active Comparator|propofol group|use propofol only for ECT induction
3476298|NCT03828877|No Intervention|Group C|Arm: Group C control group. Non-acupuncture group. Gruop C will be Control group.
3476299|NCT03828877|Active Comparator|Group A|Arm: Group A, group of acupuncture Akupunktur will be done with Pres Needle (0.22x1.5 mm) Blood will be taken for the measurement of IL 17 and IL 23 from Group A (Acupuncture) patients 24 hours prior to endovenous ablation procedure. Then, with press needle (0.22x1.5) LU 9 (Taiyuan), LU7 (Lieque), SP 6 (Sanyinjiao) , ST 36 (Zusanli), LI 4 (Hegu) and LIV 3 (Taichong) points will be applied acupuncture.On the 3rd day, patients will be called for control. Blood will also be taken from the blood to measure IL 17, IL 23 values.
3476300|NCT03829072|Experimental|cooking Education and adapted physical activity|
3476301|NCT03828890|Other|Single Arm Trial|Intervention includes screening eye exam using Optos technology
3476302|NCT03829150|Experimental|Dexlansoprazole MR group|Dexlansoprazole MR 60 mg qd.,clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
3476303|NCT03829150|Experimental|lansoprazole group|Lansoprazole 30 mg bid., clarithromycin 500 mg bid., amoxicillin 1 g bid. and metronidazole 500 mg bid. for 7 days
3476304|NCT03828916|Other|NuShield|
3476305|NCT03829033|Active Comparator|Radiotherapy delivered with photons|
3476306|NCT03829033|Experimental|Radiotherapy delivered with protons|
3476307|NCT03829020|Experimental|Treatment (metformin, nelfinavir)|Patients receive metformin hydrochloride PO on days 1-14, nelfinavir mesylate PO BID on days 1-14, and bortezomib SC on days 1, 8, and 15. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3476308|NCT03828968|Other|Bladder scan|Bladder scan performed on resident in homes for aged
3476309|NCT03829202|Experimental|A-B-A Group|Daily use of own mechanical knee for 4 weeks (A), followed by RheoKnee microprocessor prosthetic knee for 4 weeks (B), and concluding with own mechanical knee for 4 weeks (A).
3476310|NCT03829202|Experimental|B-A-B Group|Daily use of RheoKnee microprocessor prosthetic knee for 4 weeks (B), followed by own mechanical knee for 4 weeks (A), and concluding with RheoKnee microprocessor prosthetic knee for 4 weeks (B).
3132525|NCT03435055|Experimental|Nitrous Oxide - inhaled|Each volunteer will participate in one scanning visit in which simultaneous functional magnetic resonance imaging (fMRI) and electroencephalogram (EEG) data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanalgesic levels (35% inhaled concentration) over 40 minutes.
3132526|NCT03435081|Experimental|2 milligram (mg) Baricitinib|2 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
3132527|NCT03435081|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally every day. Placebo administered orally to maintain the blind.
3476311|NCT03829111|Active Comparator|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3476312|NCT03829111|Experimental|Arm II (CBM588, nivolumab, ipilimumab)|Patients receive clostridium butyricum CBM 588 probiotic strain PO BID, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Beginning in cycle 5, treatment with clostridium butyricum CBM 588 probiotic strain and nivolumab repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3476313|NCT03828942||Hematological toxicity induced by drugs and chemotherapies|Case reported in the World Health Organization (WHO) of hematological toxicities of patient treated by a drug, with a chronology compatible with the drug toxicity
3476314|NCT03828981|Active Comparator|fast-track recovery program|"Pre-operative Verbal and video information Tobacco cessation Daily physical activity Light meal 6 hours and clear liquids up to 2 hours before surgery No bowel preparation A warm blanket Premedication paracetamol 1g and tematsepam 20mg~Intraoperatively For nausea and voimiting dexamethasone 10mg, dehydrobensperidol 1mg and ondancetron 4mg before emergence Analgesia: ropivacain at port sites before incision and at vaginal vault Opioids intravenously at discretion of anesthesiologist supplemented with Dexketoprofen 50mg Urinary catheter early removal Postoperative Pain: tramadol 50mg and ketoprofen100mg i.v., oral opioid if needed; patients with normal pain control receive oral pregabalin 25mg every 8 hours, paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours until discharge Out of bed after 2 hours from the end of surgery A liquid diet, if tolerated regular normal diet. For emesis ondansetron 4mg"
3476315|NCT03828981|No Intervention|conventional recovery program|"Preoperative preparation Verbal and written information Cessation of oral intake after previous midnight. Premedication paracetamol 1g+ diatsepam 5mg.~Intraoperative A warm blanket at the start of procedure. Prophylaxis for nausea and vomiting: Dexamethasone 5mg at induction, and Dehydrobenzperidol 1mg, ondancetron 4mg before emergence. Analgesia: injection of ropivacain 5% 20ml at port sites at the end of surgery, Opioids i.v. (oxycodone)~Postoperative Pain medication:Opioids i.v. (oxycodone), paracetamol 1000mg every 8 hours, ibuprofen 600mg every 8 hours Urinary catheter removal on next morning. Prolonged bowel and bed rest and gradual reintroduction of feeding."
3476316|NCT03828955|Experimental|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage.
3476317|NCT03828955|Placebo Comparator|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage.
3476318|NCT03828721|Active Comparator|Control - screen time reduction|Families assigned to the control arm in each age category will receive customary ROR, including the provision of an age-appropriate children's book, and reading-related developmental surveillance and anticipatory guidance. In addition, control families will receive a new children's book reinforcing AAP screen-based media recommendations.
3476319|NCT03828721|Experimental|Rx for Success Smartphone Application|"Families in the intervention arm in both age categories will receive enhanced ROR involving the provision of the Rx for Success (RS) application at the baseline visit (6 months old and 18 months old, respectively). No additional intervention will take place, other than push notifications and other content such as demonstration videos built into the RS application."
3476320|NCT03828929|Experimental|Vitamin C and Thiamine|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
3476321|NCT03828929|Placebo Comparator|Placebo|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
3476322|NCT03829046|Placebo Comparator|Placebo|Placebo SC QM
3476323|NCT03829046|Active Comparator|Evolocumab|Evolocumab SC 420mg/dL QM
3476324|NCT03828994|Experimental|TECH-PN|Participants receive community health nurse visits, text-messaging support, additional testing and field based visits with a nurse practitioner.
3476325|NCT03828994|No Intervention|TECH-N|Participants receive enhanced standard of care with community health nurse visits and text-messaging support.
3476326|NCT03828864|Active Comparator|Active Pulsed Shortwave therapy|Application of the medical device emitting pulsed shortwave therapy. The medical device is used over the site of pain.
3476327|NCT03828864|Placebo Comparator|Placebo Pulsed Shortwave therapy|Application of the medical device that does not emit pulsed shortwave therapy. The medical device is used over the site of pain.
3476328|NCT03828565|Active Comparator|ScvO2 group|ScvO2 and Pulse Pressure Variation (PPV) : every 30 min (%) ScvO2 Evolution in case of corrective maneuver (%) PPV evolution in case of filling test (%)
3476329|NCT03828565|No Intervention|Control group|End-systolic Volume (ESV) : every 30 min (mL) ESV evolution in case of filling test (%)
3476330|NCT03828786|Active Comparator|Endometrial scratching group|Endometrial scratching will be done with a Pipelle in uterus.
3476331|NCT03828786|No Intervention|Control group|This group will proceed with intrauterine insemination without endometrial scratching according to clinic's standard procedure
3476332|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
3476333|NCT03828578|Experimental|High flow oxygen therapy|"Patients allocated to the intervention group will receive high flow oxygen therapy via the tracheostomy tube from cessation of mechanical ventilation. The HFOT will provide oxygen therapy at a flow rate of 50-60 litres per minute at a FiO2 titrated by the bedside clinician to maintain a peripheral oxygen saturation of 95% of more (unless otherwise clinically indicated and documented by an appropriate consultant).~Once transferred to the ward patients will continue to receive HFOT 24 hours per day at a rate of 50-60 litres per minute at a maximum oxygen concentration of 40% to achieve oxygen saturations 95% and above (unless otherwise documented).~Patients may be disconnected from the HFOT for short periods for toileting, mobilising etc. Tracheostomy weaning will continue as per standard practice with an aim of cuff deflation followed by decannulation once clinically appropriate. systems. Following decannulation patients will resort to standard oxygen therapy as needed."
3476334|NCT03828578|No Intervention|Standard Care|Patients randomised to the standard care study arm will receive routine post-operative care as currently performed within the host organisation. Following cessation of mechanical ventilation, oxygen therapy will be delivered using equipment and rates appropriate to the clinical picture. On transfer to the ward patients will continue with existing methods of oxygen therapy and will be weaned from these accordingly. Patients will continue to use heat moisture exchanges (e.g. Swedish nose or Buchannan protectors) as clinically indicated, as well as having saline nebulisers prescribed and administered as per standard. Tracheostomy weaning will continue in accordance with current practice. Data on all of the applied procedures will be recorded.
3476335|NCT03828838|Experimental|Lu-177 PSMA-617|Two cycles with 3 and 3-6 GBq Lu-177 PSMA-617 (including 3D-dosimetry)
3476336|NCT03828643||Cases|Cases received secukinumab at the dose 300 mg every 4 weeks from the beginning.
3476337|NCT03828643||Controls|Controls received secukinumab at the dose 300 mg with loading dose at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing.
3476338|NCT03828708|Experimental|Standard iron arm|Participants randomized to this arm will consume infant formula containing 12 mg/L of iron, equivalent to the standard iron content in U.S. infant formula
3476339|NCT03828708|Experimental|Low iron arm|Participants randomized to this arm will consume infant formula containing 5 mg/L of iron, equivalent to the standard iron content in European infant formula
3476340|NCT03828409|Active Comparator|Short stitch|short stitch used as one arm
3476341|NCT03828409|Active Comparator|Long stitch|Long stitch as conventional mass-closure technique
3476342|NCT03828656|Experimental|Open Label Treatment Arm|Open-label Intervention with the NightWare Therapeutic System every night.
3476343|NCT03828435|Experimental|healthy control|This group does not undergo any treatment . Intervention : rTMS
3476344|NCT03828435|Experimental|stroke patient|"this group undergoes rehabilitative therapy. It is a 24-week program and stroke patients practice the physical exercise for 1 hour each time. The intensity is three times a week.~Intervention : rTMS"
3476345|NCT03828604|Experimental|Stress; Trier Social Stress Task|5 min challenging speech task, 5 min challenging math task; performed in front of evaluators
3476346|NCT03828604|Active Comparator|Placebo Trier Social Stress Task|5 min speech task, 5 min math task; performed alone
3476347|NCT03828682|Experimental|Prospective Arm|"De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Once-daily tacrolimus XR 0.8mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 24-hr trough levels of 8-12ng/mL up to day 30 followed by 24-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
3476348|NCT03828682|Active Comparator|Comparator arm|"Historical control arm consisting of the following~De novo kidney transplant recipients receiving:~rabbit antithymocyte globulin induction (1.5mg/kg, dosage range 4-6mg/kg total dose over 5-10 days) 5-day steroid withdrawal (methylprednisolone 500mg IV on day 1 (day of transplant), 250mg IV on day 2, 125mg IV on day 3, prednisone 80mg PO on day 4, 60mg PO on day 5 and then no more steroids Twice-daily tacrolimus 0.1mg/kg/day started when or when serum creatinine is <4mg/dL or by 48 hours of transplant to target 12-hr trough levels of 8-12ng/mL up to day 30 followed by 12-hour trough targets of 5-10ng/mL Mycophenolate mofetil (1000 mg PO BID) or mycophenolic acid (720mg PO BID) twice daily started prior to surgery"
3476349|NCT03828591|Other|Group A (intensive support)|Patients that receive standard and intensive psychological support during hospitalization
3476350|NCT03828591|Other|Group B (standard support)|Patients that receive only standard psychological support during hospitalization
3476351|NCT03828513|Active Comparator|High flow nasal cannula oxygen applied|High flow nasal cannula oxygen is start at a flow rate of 80 L/min with 100% oxygen in the preoperative period.
3476352|NCT03828513|Active Comparator|High flow nasal cannula oxygen is not applied|Preoxygenation will be applied with an oxygen supplement of 5 l/min to an endtidal O2> 90%.
3476353|NCT03828669||Usual Care|Prior to the roll-out of the Recovery Toolkit program, all post-surgical patients receiving current standard of care are given pain care surveys at hospital discharge. Survey questions ask about pain, and satisfaction with pain care. The investigators will conduct chart review for pain and opioid use.
3476354|NCT03828669||Recovery Toolkit|After launch of the Recovery Toolkit program on Jan 25, all post-surgical patients will be offered a Recovery Toolkit by a unit nurse. A pain survey will be administered at hospital discharge to assess about pain in the hospital, satisfaction with pain care, whether they received a Toolkit, use of the Toolkit, and likelihood to recommend the Toolkit. The investigators will conduct chart review for pain and opioid use.
3476355|NCT03828461|Experimental|BITS + VR|Facilitated group therapy with behavioral practice; 16 weeks
3476356|NCT03828773|Other|high-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): homozygous for rs230561 and/or rs381652
3476357|NCT03828773|Other|low-risk PTX3 SNPs|risk predicted by genotyping two PTX3 single nucleotide polymorphisms (SNPs): other than homozygous for rs230561 and/or rs381652
3476358|NCT03828812|Active Comparator|Breakfast promotion|Receiving the recommendation of daily breakfast
3476359|NCT03828812|Active Comparator|Nighttime snack reduction|Receiving the recommendation of reducing nighttime snack frequency
3476360|NCT03828812|Experimental|Breakfast promotion + nighttime snack reduction|Receiving the recommendation of daily breakfast + reducing nighttime snack frequency
3476361|NCT03828851|Experimental|Experimental group|ADL training program.
3476362|NCT03828851|No Intervention|Control group|Receive rehabilitation program in the hospital.
3476363|NCT03828760|Experimental|Music Listening|Patients will receive music of choice to listen to using a music-playing device in the waiting room prior to IUD insertion, as well as during the procedure.
3476364|NCT03828760|No Intervention|Standard Care|Patients will receive standard care (excluding the use of music) from providers at the clinic to minimize pain and anxiety during the procedure.
3476365|NCT03828383|Experimental|In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
3476366|NCT03828383|Sham Comparator|Limited In-Home Technology System|The full system (sensors for entry, activity, temperature, water leak; voice control; digital display; local router) will be installed in the homes of caregivers by a member of the research team (blind as to arm of the study). Monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a nine month period with questionnaires (e.g., health and well-being) administered 4 times (at the time of installation and every 3 months thereafter).
3476367|NCT03828526|Experimental|High Fidelity Simulation|"Students will be exposed to the intensive care setting where they will have to solve issues related to general nursing care, including the stages of the medication process that involve the nurses' performance and their complexity.~During the experience of the scenario will be provoked external factors, such as telephone ringing, visit of the professional of the infection commission, to evaluate the reactions of the student and the strategies adopted to minimize the occurrence of adverse events against such external factors.~Subsequently, they will participate in the debriefing, where they will be reflected on the positives and those that should be adjusted to promote safer nursing care related to drug administration."
3476368|NCT03828526|Active Comparator|Traditional teaching strategy|Participants will be submitted to an expository-dialogue class, which will be given based on the recent literature and subdivided into the following axes: 1) patient safety; 2) medication process; 3) adverse drug events; 4) the critical patient in intensive care and its specificities. Afterwards, students will be directed to an environment with an anatomical piece for drug preparation and administration training.
3476369|NCT03828331||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-55 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
3476370|NCT03828292|Experimental|Part 1: Belantamab mafodotin Monotherapy|
3476371|NCT03828292|Experimental|Part 2: Arm A: Belantamab mafodotin+Bortezomib/Dexamethasone|
3476372|NCT03828292|Experimental|Part 2: Arm B: Belantamab mafodotin+Pomalidomide/Dexamethasone|
3476373|NCT03828357||Ellipse VR with Durata|Ellipse VR single-chamber ICD with a Durata defibrillation lead
3476374|NCT03828357||Ellipse DR with Durata & Tendril STS|Ellipse DR dual-chamber ICD with a Durata lead in the right ventricle (RV) and a Tendril STS lead in the right atrium (RA).
3476375|NCT03828357||Ellipse DR with Optisure and Isoflex|Ellipse DR dual-chamber ICD with an Optisure defibrillation lead in the right ventricle (RV) and an Isoflex lead in the right atrium (RA).
3476376|NCT03828357||Quadra Assura MP CRT-D|Quadra Assura MP CRT-D with an Optisure or Durata defibrillation lead in the RV, an Isoflex or Tendril STS lead in the RA, and a Quartet lead in the LV
3476377|NCT03828474|Experimental|Acetazolamide 125mg twice daily|Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
3476378|NCT03828474|Experimental|Acetazolamide 62.5mg twice daily|Acetazolamide pill 62.5mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses
3476379|NCT03828318|Experimental|Patient Activation Arm|
3476380|NCT03828318|No Intervention|Standard Care Arm|
3476381|NCT03828370|Active Comparator|Usual & Customary Information Group|"Study Cohort Assessment:~Baseline 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
3476382|NCT03828370|Experimental|B-SMART Intervention Group|"Study Cohort Assessment:~Baseline Web App Intervention 3 month follow-up/ post-test 9 month follow-up/post test & Interlock Ignition Device"
3132528|NCT03435081|Placebo Comparator|Placebo|Placebo administered orally every day.
3476383|NCT03828279||hereditary angioedema type I|Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
3476384|NCT03828279||hereditary angioedema type II|Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
3132529|NCT03435185|Active Comparator|Blockade Group|Lidocaine injections. Procedure. Grater occipital nerve and supraorbital nerve were blocked with %2 lidocaine. These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
3476385|NCT03828344|Experimental|hUC-MSC treatment|BX-U001 (hUC-MSC suspension) will be tested at dose of 0.75 or 1.5×10^6 cells/kg of body weight via a single IV infusion using a blood transfusion kit.
3476386|NCT03828344|Placebo Comparator|Placebo control|The control arm will be given placebo which contains the same cell suspension solution but without cells. Placebo will be given the same way as BX-U001 via a single IV infusion using a blood transfusion kit.
3476387|NCT03828500|Experimental|Experimental Arm|encouraged by Research Assistant to drink clear fluids up to 2 hour limit. Arm 2 - standard of care
3476388|NCT03828500|No Intervention|Control Arm|
3476389|NCT03828305|Experimental|Training and creation of the Network-CPR|Training in CPR
3476390|NCT03828305|Active Comparator|Control Group|Primary Care Center Emergency Personnel
3476391|NCT03828175|Other|cop variables|non invasive cop vsriables correlation to basic monitoring variables during prone position spinal anesthesia intervention pcnl operation at basic ,1hour and 2hours .
3476392|NCT03828123|Experimental|Autologous Multipotent MSC|Patients with intrathecal administration of Suspension of human autologous MSC 3P in 1.5 ml
3476393|NCT03828136|Experimental|ACDF with Novum Vitrium® Cervical Interbody Device|A resorbable cervical interbody cage.
3476394|NCT03828136|Active Comparator|ACDF with Allograft|Structural allograft made from structural corticocancellous allograft bone.
3476395|NCT03828227|Active Comparator|"Candidate group OPTIMOX plus bevacizumab (Arm A)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles and then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)"
3476396|NCT03828227|Active Comparator|"Candidate group - Capecitabine-bevacizumab (Arm B)"|"Patients with :~Serum albumin level ≥ 30g/L,~ECOG PS 0-1 (whatever mini GDS score) or ECOG PS 2 with mini GDS 0 (ie, no depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
3476397|NCT03828227|Active Comparator|"Non candidate group - Capecitabine-bevacizumab"|"Patients with:~Serum albumin level < 30g/L.~And/ or ECOG PS 2 and mini GDS ≥ 1 (ie, depression).~This treatment regimen will be given until disease progression (PD) or unacceptable limiting toxicity, as follows:"
3476398|NCT03828006|Experimental|Active Group|One tablet per day through oral administration of a dietary supplement containing red rice yeast as the main active ingredient
3476399|NCT03828006|Placebo Comparator|Placebo Group|One tablet per day of placebo.
3476400|NCT03828032|Experimental|Mannitol injection|The participant receive mannitol injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
3476401|NCT03828032|Experimental|Hypertonic saline injection|The participant receive hypertonic saline of specific concentration injection to decrease intracranial pressure in the ward with optical probes on his/her forehead.
3476402|NCT03828019|Active Comparator|Adalimumab (ADA)|"Adalimumab administered by subcutaneous injection at dosage and frequency specified below; total duration of treatment is 12 months.~Adults (≥ 18 years of age) and adolescents ≥30 kg: 80 mg as initial dose; one week later by 40 mg then 40 mg every two weeks. Adolescents <30 kg: 40 mg as initial dose; one week later 20 mg then 20 mg every 2 weeks."
3476403|NCT03828019|Active Comparator|Conventional immunosuppression (CON)|"Conventional immunosuppressive agent selected by study ophthalmologist at dose and frequency specified below;12 month treatment duration.~Azathioprine: initially 2 mg/kg/day; max dose 200 mg/day. Methotrexate initially 15mg/wk; max dose 25 mg/wk. Mycophenolate initially 1 gm BID; max dose1.5 gm BID. Cyclosporine (Sandimmune - dose 2.5 mg/kg BID and Neoral dose 2 mg/kg BID. Tacrolimus initially 1 mg BID; max dose 3 mg BID."
3476404|NCT03827941|Active Comparator|1 Hz group|1 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
3476405|NCT03827941|Active Comparator|20 Hz group|20 Hz Auricular transcutaneous electrical nerve stimulation High-functioning individuals with autism randomized to this group will receive 20 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
3476406|NCT03827876|Experimental|Open Label Enstilar|once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
3476407|NCT03828240|Other|Enhanced rehabilitation|
3476408|NCT03827928|Experimental|Yoga/meditation|A 6-week yoga/meditation intervention.
3476409|NCT03827928|No Intervention|Wait list|A wait list control period.
3476410|NCT03827863||ARDS WITH ACP|"Diagnostic criteria for ARDS ARDS defined as within 1 week of a known clinical insult or new or worsening respiratory symptoms. ARDS was classified as mild (200 mmHg < PaO2/FIO2≤300 mmHg), moderate (100 mmHg < PaO2/FIO2≤200 mmHg) and severe (PaO2/FIO2≤100 mmHg) according to the value of PaO2/FiO2 ratio. Importantly, the PaO2/FiO2 ratio value is considered only with a CPAP or PEEP value of at least 5 cmH2O.~Ultrasound diagnostic criteria for ACP The specific diagnostic parameters are as follows: TR>2.8m/s; RVEDA/LVEDA>0.6 or Right ventricle/left ventricle basal diameter ratio>1.0 or systolic D sign; IVC >2cm with decreased inspiratory collapse; Pulmonary Regurgitation Velocity >2.2m/s."
3476411|NCT03827863||ARDS WITHOUT ACP|Diagnosis as ARDS but no ultrasound evidence of ACP.
3476412|NCT03828110||Children with neurological impairment|
3476413|NCT03827954|Experimental|Experimental Treatment|HeartMapp+CT
3476414|NCT03828084|Experimental|Formulation A|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation A) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
3476415|NCT03828084|Experimental|Formulation B|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation B) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
3476416|NCT03828084|Experimental|Formulation C|3 test capsules of combination decitabine/THU (5 mg/250 mg per capsule; Formulation C) given as a single oral dose with approximately 240 mL (8 fluid ounces) of ambient temperature water.
3476417|NCT03828084|Active Comparator|Reference Formulation|3 capsules of THU (250 mg per capsule) given as a single oral dose with approximately 240 mL of ambient temperature water, followed by a single oral dose of 3 capsules of decitabine (5 mg per capsule) given 1 hour later with approximately 240 mL of ambient temperature water.
3476418|NCT03828097|Experimental|Experimental supplement|Participants in this arm will receive two capsules per day containing a total of 1 mg boron, 600 mcg folate, 8 mg iron, 50 mg magnesium, 320 mg omega-3 (DHA+EPA), 8 mcg vitamin B12, 50 mcg vitamin D3, and 7 mg vitamin E
3476419|NCT03828097|Placebo Comparator|Placebo|Participants in this arm will receive two capsules per day containing safflower oil
3476420|NCT03827902||Intervention Group|A Telcare 2.0 BGM, which is FDA cleared, will be used to upload blood glucose measurements to a cloud server accessible by providers. Intervention group will participate in an integrated care model where they will attend Diabetic Clinic and Foot Wound appointments on the same day.
3476421|NCT03827902||Control Group|Control Group will receive usual care (a non-integrated care model where Diabetes Clinic and Foot Wound appointments are on separate days.) These patients will not receive a blood monitoring glucose device.
3476422|NCT03827915|No Intervention|Third trial of DC cardioversion|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive a third trial of DC cardioversion (Standard of care)
3476423|NCT03827915|Experimental|Double sequential external defibrillation|Patients with atrial fibrillation who fail to revert to sinus rhythm after two failed DC cardioversion attempts will receive DSED
3476424|NCT03828058|Experimental|Envarsus XR|Envarsus XR orally administered Daily
3476425|NCT03828058|Active Comparator|Prograf|"Prograf PO administered twice daily Generic Name: tacrolimus~Dosage of prograf will be determined by trough levels and adjusted accordingly"
3476426|NCT03827889|Experimental|WMP of fluoride varnish|Whole mouth protocol group
3476427|NCT03827889|Experimental|TWLP of fluoride varnish|Tooth with lesion Protocol
3476428|NCT03827889|Active Comparator|DHP (educational intervention)|Diet and Hygiene guidance Protocol
3476429|NCT03828188|Experimental|group A|"Red Ginseng Concentrated Powder in 12 weeks → rest in 4 weeks → Placebo 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
3476430|NCT03828188|Experimental|group B|"Placebo 12 weeks→ rest in 4 weeks → Red Ginseng Concentrated Powder in 12 weeks.~Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)~Placebo: Red Ginseng Concentrated Powder: 2 times daily(4.9 g/day)"
3476431|NCT03828071|Other|stem cell transplantation|patients enrolled in this study will received autologous hematopoietic stem cell transplantation as the initial treatment.
3476432|NCT03827785|Experimental|rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 30 days.
3476433|NCT03827785|Sham Comparator|sham rTMS treatment group|Stimulate the dorsal lateral prefrontal cortex with the sham iTBS pattern and coil. The therapy will be conductedfor 30 days.
3476434|NCT03827772|Experimental|Intervention Arm: Fecal microbiota transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
3476435|NCT03827772|Other|Control Arm|Nutritional supplementation, supportive management
3476436|NCT03827707|Experimental|Noise|
3476437|NCT03827707|Sham Comparator|Silence|
3476438|NCT03827655|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
3476439|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily postsurgery until return of upper and lower GI function or for up to 10 days.
3476440|NCT03827655|Experimental|TAK-954 0.5 mg/100 mL + Placebo|TAK-954 0.5 mg/100 mL, 60-minute infusion, intravenously, once presurgery on Day 1 and once daily placebo infusions postsurgery up to Day 10 or until resolution of upper and lower GI function.
3476441|NCT03827837|Experimental|SHR-1210 combined with Famitinb|SHR-1210 + Famitinib
3476442|NCT03827824|Experimental|Hysteroscopy & Virtual reality glasses|Hysteroscopy with use of virtual reality glasses
3476443|NCT03827824|Active Comparator|Hysteroscopy|Hysteroscopy without use of virtual reality glasses
3476444|NCT03827850|Active Comparator|Cohort 1 FGFR trans|Cohort 1: Activating (high confidence) FGFR translocations (max. 15 patients) under daily Erdaifitinib treatment
3476445|NCT03827850|Active Comparator|Cohort 2 FGFR mut|Cohort 2: Activating (high confidence) hotspot FGFR mutations (max. 15 patients) under daily Erdafitinib treatment
3476446|NCT03827850|Active Comparator|Cohort 3 FGFR other|Cohort 3: Activating (low confidence) FGFR alteration (max. 20 patients)
3476447|NCT03827811||PandrTB cohort|endTB participants on experimental regimen
3476448|NCT03827603|Experimental|patients with AIHA and CLL|patients with CLL and in Steroid Refractory AIHA receive ibrutinib 420 mg per day till progression or intolerance
3476449|NCT03827460|Experimental|Free access alcohol self-administration|During the 2.5-hour free-access self-administration sessions, the participant may choose to complete a task for an alcohol or water reward. Interventions include Abstinence from Alcohol and Usual Drinking
3476450|NCT03827460|Experimental|Clamped alcohol exposure|A battery of behavioral tasks will be administered to participants before, and at the beginning and end of a 3 hour clamped exposure to alcohol (fixed at 80 mg/dL). EEG will be recorded throughout to assess event related potentials associated with task performance. Interventions include Abstinence from Alcohol and Usual Drinking.
3476451|NCT03827460|Experimental|2 year followup|Participants from both Arm 1 and Arm 2 will be surveyed every 2 months for alcohol consumption for 2 years following the Experimental phase. Interventions include Abstinence from Alcohol and Usual Drinking.
3476452|NCT03827590|Experimental|HLIM|HLIM+SA160021 Placebo+SA160022 Placebo
3476453|NCT03827590|Active Comparator|SA160021|HLIM Placebo+SA160021+SA160022 Placebo
3476454|NCT03827590|Active Comparator|SA160022|HLIM Placebo+SA160021 Placebo+SA160022
3476455|NCT03827590|Placebo Comparator|Placebo|HLIM Placebo+SA160021 Placebo+SA160022 Placebo
3476456|NCT03827577|Experimental|LAT arm|"Lung resection (if primary in place) + local ablative therapy of all metastatic sites + standard medical treatment.~patients may be enrolled either before any systemic therapy or after 3 months of treatment without progression according to local coordinator decision"
3476457|NCT03827577|Active Comparator|Control Arm|"Standard medical treatment~Local ablative therapy on the brain will be administered in any case to patients harboring cerebral oligometastases"
3476458|NCT03827525||Cognitive and Behavioral Therapy|There is no group, the study will be based on single case method. The sudy concerns 5 patients with a Williams Syndrome
3476459|NCT03827499|Experimental|Ex-HMB|HMB dietary supplementation and Multicomponent physical exercise program
3476460|NCT03827499|Experimental|NoEx-HMB|HMB Dietary supplementation
3476461|NCT03827499|Placebo Comparator|Ex-Plac|Multicomponent physical exercise program
3476462|NCT03827499|No Intervention|Controls|No intervention
3476463|NCT03827642|Experimental|Cohort 1: Treatment Sequence A-D-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
3476464|NCT03827642|Experimental|Cohort 2: Treatment Sequence B-C-D-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
3476465|NCT03827642|Experimental|Cohort 3: Treatment Sequence C-A-B-D|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
3476466|NCT03827642|Experimental|Cohort 4: Treatment Sequence D-B-A-C|Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
3476467|NCT03827551|Experimental|Parkinson's Patients|
3476468|NCT03827616|Active Comparator|2,5 Gy|hypofractionated dosing 28 fractions x 2,5 Gy over 38 days (prostate 28 x 2,5Gy - 70Gy, seminal vesicles 28 x 2Gy - 56 Gy, node lympaticus ( if Rouch formula> 15% or N1) 28 x 1,8 Gy - 50,4 Gy).
3476469|NCT03827616|Active Comparator|3 Gy|hypofractionated dosing 20 fractions x 3 Gy over 26day (prostate 20 x 3Gy - 60Gy, seminal vesicles 20 x 2,5Gy - 50 Gy, node lympaticus ( if if Rouch formula> 15% or N1 ) 20 x 2,2 Gy - 44 Gy).
3476470|NCT03827668|Experimental|Single arm|The study will have only one study group in a fixed-sequence type of design with two periods
3476471|NCT03827720|Experimental|Control|Healthy volunteers monitored with Sense Device
3476472|NCT03827720|Experimental|Intracranial Hemorrhage|Intracranial hemorrhage patients monitored with Sense Device
3476473|NCT03827720|Experimental|Acute Ischemic Stroke with LOV|Acute Ischemic Stroke patients that have large vessel occlusion monitored with SENSE Device
3476474|NCT03827720|Experimental|AIS without LOV|Ischemic Stroke patients that do not have large vessel occlusion monitored with SENSE device
3476475|NCT03827629|Experimental|Cohort 1: Treatment Sequence A-B-C|Participants received Treatment A on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
3476476|NCT03827629|Experimental|Cohort 2: Treatment Sequence B-C-A|Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
3476477|NCT03827629|Experimental|Cohort 3: Treatment Sequence C-A-B|Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
3476478|NCT03827629|Experimental|Cohort 4: Treatment Sequence A-C-B|Participants received Treatment A on Day 1 of Period 1, Treatment C on Day 1 of Period 2, and Treatment B on Day 1 of Period 3.
3476479|NCT03827629|Experimental|Cohort 5: Treatment Sequence C-B-A|Participants received Treatment C on Day 1 of Period 1, Treatment B on Day 1 of Period 2, and Treatment A on Day 1 of Period 3.
3476480|NCT03827629|Experimental|Cohort 6: Treatment Sequence B-A-C|Participants received Treatment B on Day 1 of Period 1, Treatment A on Day 1 of Period 2, and Treatment C on Day 1 of Period 3.
3476481|NCT03827408|Active Comparator|Midazolam group (MDZ)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.5 mg/kg Midazolam.
3476482|NCT03827408|Experimental|Dexmedetomidine group (DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 5µg/kg Dexmedetomidine.
3476483|NCT03827408|Experimental|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Twenty four pediatric dental patients will receive a procedural sedation session, using Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.
3476484|NCT03827694||Patients with possible PIMI|
3476485|NCT03827681|Experimental|TIPS + Vasoactive Drug|
3476486|NCT03827681|Active Comparator|SEMS + Vasoactive Drug|
3476487|NCT03827382|Active Comparator|Intervention|Patients with intensive Lifestyle intervention
3476488|NCT03827382|No Intervention|Control|Patients with Standard Diabetes care
3476489|NCT03827486|Active Comparator|Standard of care|
3476490|NCT03827486|Experimental|Domicilary exercise program|
3476491|NCT03827733||AD patients|Participants who are diagnosed with AD.
3476492|NCT03827733||Partners of the AD patients|Partners of AD patients who live together with the AD patients.
3476493|NCT03827733||Elderly participants with normal cognition|Community dwelling elderly with normal cognition and with AD.
3476494|NCT03827434|Active Comparator|Continuous glucose Monitoring and Clarity|Patients with DM2 and abnormal glycemic control followed by Continuous glucose Monitoring, using Clarity software
3476495|NCT03827434|Placebo Comparator|Point of Care Fingerstick Glucose values|Patients with DM2 and abnormal glycemic control followed by Point of Care Fingerstick Glucose values
3132530|NCT03435185|Placebo Comparator|Placebo Group|Saline injections. Procedure. Grater occipital nerve and supraorbital nerve were injected with saline.These injections were repeated weekly for three weeks. After treatment was completed, patients were followed up for 2 months at the polyclinic to assess the clinical response.
3476496|NCT03827174|Active Comparator|Comparison intervention|Return To Work Coordination: external and internal coordination regarding sick leave. Establishment of a common return to work plan between employer and employee.
3476497|NCT03827174|Experimental|Experimental intervention|"Return To Work Coordination + Behaviour Change Ability Programme~Behaviour Change Ability Programme:~Return to work coordination~Education for employers and employees in pain neuroscience, validation, and problem-solving~Patient specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
3476498|NCT03827369||ICU patient|Pulse pressure of the radical artery was obtained by arterial line. The output of the transducer was connected to an IBM PC for analysis via an A/D converter with sampling rate = 250 datapoints/sec. The pulse spectrum was analyzed with the Fourier transformation using T (period) = 1 pulse time.
3476499|NCT03827109|Experimental|Mentoring program|The Mentoring Program consists of year-long, 1:1 mentee-mentor relationships with group educational activities, online educational information, and a parent support component. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month. Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. They also provide opportunities to socialize with other mentors and mentees: lunch and games are provided before or after the educational event. Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing. Parents join the mentees and mentors for the educational topics. Due to the COVID-19 pandemic, these activities can be conducted virtually.
3476500|NCT03827109|Active Comparator|Educational activity program|The Educational Activity comparison group consists of separate educational group events on the same topics (with no social time), educational information posted online, and monthly encouragement to engage in activities in the community. Due to the COVID-19 pandemic, participants are encouraged to interact socially in safe ways, e.g., outdoors or virtually.
3476501|NCT03827239|No Intervention|Control|No intervention. Study participants will be seated during the entire sedentary 3-hour time period and wheeled to phlebotomy (and exercise) stations when required. During the sedentary period, participants will eat the food according to the study protocol and be seated at desks and allowed to read and use computers.
3476502|NCT03827239|Experimental|Intervention|Will disrupt their sedentary time with 3 minute exercise sessions every 30 minutes
3476503|NCT03827187|Experimental|Motor imagery based Brain computer interfacing|Brief assessment of motor imagery in response to command, auditory feedback training and responding to binary yes-no closed questions through Electroencephalography based Brain-computer interfacing.
3476504|NCT03827070|Experimental|Talcum powder & Afatinib|Talcum powder 4 g + Afatinib 0,4 g. Is entered once
3476505|NCT03827148|Experimental|Intervention: Pharmacist-delivered pharmaceutical care|The intervention consist of a pharmacist providing pharmaceutical care with aim to improve the treatment outcomes. It will be in the form of a single face-to-face session by pharmacist. Moreover, a specially designed rheumatoid arthritis disease education literature will be provided in both Urdu and English languages to patients for home use. The patients will be provided a contact number at which the pharmacist will be available at all times for the next three months (week 12). A specially designated counselling area in the pharmacy department of the hospitals served as venues for intervention.
3476506|NCT03827148|No Intervention|Control: Usual Care|The patient in control group will have usual care without pharmacist intervention.
3476507|NCT03827122|Experimental|Group one|Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks
3476508|NCT03827096|Experimental|Human AMSC (passage 3) 3P in 1.5 mL|Patient receiving the investigational medicinal product - suspension of human autologous MSC 3P in 1.5 mL
3126611|NCT03044197|Experimental|MRI/ultrasound transperineal prostate biopsy|In arm A, all patients with positive mpMRI evidence of lesions suspicious for PCa, i.e. PI RADS ≥ 3 will be submitted to transperineal mpMRI-targeted prostate biopsy (arm A MRI+). The gland and the regions of interest will be contoured, and the prostate contour will be fused in real time with the TRUS image. Biopsies will be performed via a transperineal approach in the operating room. The patient will be placed in dorsal lithotomy position. mpMRI-targeted biopsies will be performed on regions of interest, and three to six cores will be obtained for biopsy from each lesion and is standard of care according to START criteria for targeted biopsy. In cases of negative mpMRI results i.e. PI RADS<3, arm A patients will undergo TRUS-guided transrectal 12-core prostate biopsy (arm A MRI-) as described in arm B.
3132531|NCT03435211|Experimental|INVSENSOR00006|All subjects consented are enrolled into the test group and received the INVSENSOR00006.
3476509|NCT03827057|Experimental|Reconsolidation of Traumatic Memories (RTM)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. RTM will follow a manual developed by the Research and Recognition Project, who will also train and supervise the therapists. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
3476510|NCT03827057|Active Comparator|Prolonged Exposure (PE)|"Participants in each arm of the study will receive up to 10 90-minute manualized treatment sessions. PE will follow a manual written by the Foa and colleagues, and the therapists will be trained by expert trainers from the Center for Deployment Psychology. It is anticipated that these treatments will most often be administered once per week for 10 weeks. To best meet participant needs, we will allow therapy in either arm to be massed in the pattern recently reported by Foa et al. for PE, with sessions separated by at least 24 hours over two weeks. This schedule has been used with both RTM and PE without hurting response rates, and may reduce drop-out rates. Participants who achieve remission of their PTSD before 10 sessions, measured by a PCL5 <34, can decide with their therapist whether early cessation of therapy is appropriate."
3476511|NCT03827005|Placebo Comparator|placebo|3 grams cornstarch once per day for one day.
3476512|NCT03827005|Experimental|L-arginine|3 g L-arginine once per day for one day.
3476513|NCT03827018|Active Comparator|mavrilimumab|Subjects randomized to mavrilimumab will receive 150 mg every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
3476514|NCT03827018|Placebo Comparator|placebo|Subjects randomized to placebo will receive placebo every other week by subcutaneous injection co-administered with a 26-week corticosteroid taper.
3476515|NCT03827083||Spinal anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
3476516|NCT03827083||General anesthesia|Evaluation of cognitive functions of patients under 65 years of age with lower extremity surgery by cerebral pulse oximetry
3476517|NCT03827044|Experimental|Avelumab|6 months of 2 weekly Avelumab
3476518|NCT03827044|No Intervention|No intervention|After standard adjuvant 5FU based chemotherapy, patients will have no active intervention but will start standard follow up.
3476519|NCT03827356|Experimental|"High intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). High intensity group: 15 cycles, 1 minute each one, 40% MIP with IMT. 1 minute to rest between cycles.
3476520|NCT03827356|Active Comparator|"Low intensity group"|Intervention is administrated with an inspiratory muscle trainer (IMT). Low intensity group: 15 cycles, 1 minute each one, 20% MIP with IMT. 1 minute to rest between cycles.
3476521|NCT03827200|Experimental|Ambrisentan|Ambrisentan
3476522|NCT03827304|Experimental|Burns dressings patients|Virtual Reality pain distraction games scenarios
3476523|NCT03827278|Experimental|HIV Negative Host talaromyces using Voriconazole|Voriconazole On the first day, 6 mg/kg bid was given, and then 4 mg/kg bid was given intravenously for 6 days, and then oral voriconazole 200 mg bid was administered to maintain treatment for at least 6 months.
3476524|NCT03827278|Experimental|HIV Negative talaromyces AMB Sequential Itraconazole|Amphotericin B (AMB) sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until cluster of differentiation 4 (CD4+ T) cells are greater than 100 cells/L for at least 6 months
3476525|NCT03827031|No Intervention|Control group|
3476526|NCT03827031|Experimental|B1 interventional group|
3476527|NCT03827031|Experimental|B2 interventional group|
3476528|NCT03827317|Other|HER2 positive metastatic breast cancer|8 HER2 positive patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
3476529|NCT03827317|Other|HER2 negative metastatic breast cancer|8 HER2 negative patients (determined using the most recent biopsy) will be recruited. Dynamic [18F]GE-226 PET imaging over 90 minutes, radial artery sampling will be performed to establish the pharmacokinetic profile of [18F]GE-226 and hence determine the optimal imaging time point for [18F]GE-226 PET scans. Tumour uptake in individual metastases (and the target lesion) will be reported. Uptake will be compared between HER2 positive and negative tumours.
3476530|NCT03827135|Active Comparator|Traditional physical therapy|Cervical isometrics and Muscle Stretching
3476531|NCT03827135|Experimental|Cyriax manipulation|Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle stretching.
3476532|NCT03827161|Experimental|Arm I (glucosamine sulfate/chondroitin sulfate tablet)|Patients receive glucosamine sulfate/chondroitin sulfate tablet PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm II.
3476533|NCT03827161|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO on days 1-14 in the absence of disease progression or unacceptable toxicity. Fourteen days later, patients crossover to Arm I.
3476534|NCT03826979|Experimental|Pilates treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
3476535|NCT03827291|Experimental|Quadratus lumborum block|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
3476536|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia.
3476537|NCT03826693|Experimental|Experimental: Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
3476538|NCT03826693|Placebo Comparator|Control: Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
3476539|NCT03826719|Experimental|NBP607QIV|1 dose of 0.5mL by Intramuscular injection
3476540|NCT03826719|Active Comparator|Agrippal|1 dose of 0.5mL by Intramuscular injection
3476541|NCT03826732|Experimental|Guided self-help based on ACT|Participants follow a self-help program and receive weekly support by trained facilitators
3476542|NCT03826732|No Intervention|Wait-list control|Participants are informed that they will receive the intervention after the 6-month follow-up assessment
3476543|NCT03826940|Experimental|NF1 - experimental|
3476544|NCT03826940|Placebo Comparator|NF1 - control|
3476545|NCT03826940|Experimental|ASD - experimental|
3476546|NCT03826940|Placebo Comparator|ASD - control|
3476547|NCT03826953|Other|Nurse led allergy clinic|nurse led allergy clinic
3476548|NCT03826758|Other|E-DYNAMIC CDS|E-DYNAMIC clinical decision support (CDS) retrieves near-real time patient data from the electronic health record to help primary care providers identify patients with stage 3-5 CKD, present ASCVD risk, statin use and clinical recommendations for ASCVD risk reduction at point of care. E-DYNAMIC directs referrals to nurses for CKD education and to dietitians for MNT. Providers are also nudged to prescribe statin medications and address hypertension management.
3476549|NCT03826758|No Intervention|Standard care|No change in their clinical practice.
3476550|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin. Subjects to receive single dose of test material such that each subject receives 1.8 mcg/kg body weight of tutin.
3476551|NCT03826862|Experimental|intervention group|All patients receive CT three-dimensional reconstruction before surgery.
3476552|NCT03826862|No Intervention|control group|All patients did not receive CT three-dimensional before surgery
3476553|NCT03826576|Experimental|Intervention Group|Intervention group will receive a Multicomponent Intervention.
3476554|NCT03826576|No Intervention|Control Group|Control group will not receive any kind of intervention, only it will receive information about AMED criteria and allergens of food.
3476555|NCT03826511|Active Comparator|Tiszasüly mud-pack|Patients in the Tiszasüly mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
3476556|NCT03826511|Active Comparator|Kolop mud-pack|Patients in the Kolop mud-pack group got hot mud-packs for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
3476557|NCT03826875|Experimental|Treatment|Patients randomized to the fluoxetine treatment group will be initially prescribed fluoxetine 20mg/day for a period of one year.
3476558|NCT03826875|Placebo Comparator|Placebo|Patients randomized to the placebo group will be initially prescribed placebo 20mg/day for a period of one year.
3476559|NCT03826680|Active Comparator|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by an ENT physician by flexible fiberoptic laryngoscopy before the surgery
3476560|NCT03826680|Active Comparator|Direct laryngoscopy|The same patients evaluated by flexible fiberoptic laryngoscopy will be evaluated by an anesthesiologist by direct laryngoscopy during surgery under general anesthesia
3476561|NCT03826784|Experimental|BHA|Subjects treated with BHA + standard of care
3476562|NCT03826784|No Intervention|Control|Subjects treated as per standard of care
3476563|NCT03826823|Experimental|infertile women|infertile women undergoing hysterosalpingography for evaluating fallopian tubes
3126612|NCT03044197|Active Comparator|transrectal ultrasound-guided prostate biopsy|TRUS-guided transrectal prostate biopsy will be performed using a disposable 18-gauge biopsy gun with a specimen size of 18-22 mm (Bard Medical, Covington, GA, USA). The 12 cores will be obtained from 12 separate anatomical regions of the prostate which is standard practice in performing TRUS-guided transrectal prostate biopsy: left medial apex, left lateral apex, left medial midgland, left lateral midgland, left medial base, left lateral base, right medial apex, right lateral apex, right medial midgland, right lateral midgland, right medial base and right lateral base.
3126613|NCT03044249|Experimental|MP-101|"Week 0:~Participants received 20 milligrams (mg) MP-101 orally QD (1 x 20-mg caps) and 2 placebo caps.~Week 1:~Participants received 40 mg MP-101 orally QD (2 x 20-mg caps) and 1 placebo caps.~Week 2 through Week 9:~Participants received 60 mg MP-101 orally QD (3 x 20-mg caps )."
3476564|NCT03826589|Experimental|Avelumab and Axitinib|"Avelumab: IV treatment; administered at 10 mg/kg IV every two weeks in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)~Axitinib: Oral treatment; administered at 5 mg PO BID in a 4-weekly cycle up to 12 cycles or until disease progression or intolerable side effects (whichever occurs first)"
3476565|NCT03826810|Experimental|aPDT + ART group|In this group, both aPDT and ART were performed.
3476566|NCT03826810|Experimental|ART group|In this group, only ART was performed.
3476567|NCT03826706|Active Comparator|C-MAC Videolaryngoscope D blade|Patients was intubated with C-MAC videolaryngoscope D blade.
3476568|NCT03826706|Active Comparator|McGrath MAC Videolaryngoscope X3 blade|Patients was intubated with McGrath MAC Videolaryngoscope X3 blade
3126614|NCT03044249|Placebo Comparator|Placebo|Participants received 3 capsules (caps) of placebo orally once daily (QD) during Week 0, Week 1, and Week 2 through Week 9.
3132532|NCT03435224|Experimental|INVSENSOR00012|All subjects consented are enrolled into the test group and will receive the INVSENSOR00012.
3132533|NCT03435497|Experimental|Game Changers Intervention|Game Changers is an intervention that aims to empower and mobilize people living with HIV to be agents for HIV prevention and behavioral change in their social networks.
3132534|NCT03435497|No Intervention|Control|The control group will receive standard of care during the intervention assessment period. All control participants will be offered the Game Changers program once all assessments for the primary study outcomes have been completed.
3476569|NCT03826836|No Intervention|Control Group|Treatment as usual (i.e. best medical treatment).
3476570|NCT03826836|Experimental|Mindfulness-based stress reduction|Treatment as usual (i.e. best medical treatment) in combination with an eight-week mindfulness-based stress reduction programme.
3476571|NCT03826771|Experimental|POWER training|high velocity strength training
3476572|NCT03826771|Active Comparator|Stretching|Upper and lower body range of motion exercises
3476573|NCT03826628|Experimental|0.5% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
3476574|NCT03826628|Experimental|1.0% Rapamycin cream, topical|Rapamycin cream topical, 0.5% w/w, applied once daily before bed on affected area for 26 weeks
3476575|NCT03826628|Placebo Comparator|Placebo|Placebo cream topical, applied once daily before bed on affected area for 26 weeks
3476576|NCT03826498|Experimental|CP CB-MNC injection|CP CB-MNC injection from different donors and standard therapy.
3476577|NCT03826498|Other|Standard therapy|Patients with standard therapy as control group
3476578|NCT03826615|Experimental|Gabapentin|Gabapentin premedication group
3476579|NCT03826615|No Intervention|No medication|Control group
3476580|NCT03826641|Experimental|Sequence 1|Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801
3476581|NCT03826641|Experimental|Sequence 2|Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805
3476582|NCT03826641|Experimental|Sequence 3|Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801
3476583|NCT03826641|Experimental|Sequence 4|Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805
3476584|NCT03826602|Experimental|Tucatinib plus metformin|Tucatinib administered twice daily on Days 2-8. Metformin administered as a single dose on Days 1 and 8. Iohexol administered via IV push on Days 1 and 8
3126615|NCT03044353|Experimental|Group 1: Cardiac TTR amyloidosis (ATTR-CM) participants|Cardiac transthyretin (TTR) amyloidosis (transthyretin amyloid cardiomyopathy [ATTR-CM]) participants with mutant genotypes primarily associated with familial amyloidotic cardiomyopathy (FAC) and wild-type TTR will be included. Participants will receive 6 anti-SAP treatments, consisting of carboxy pyrrolidine hexanoyl pyrrolidine carboxylate (CPHPC) followed by anti-SAP monoclonal antibody (mAb) at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC intravenous (IV) infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered intravenous infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 milligrams (mg) (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as subcutaneous (SC) injection for 11 days from the day of first dose of anti-SAP mAb.
3126616|NCT03044353|Experimental|Group 2: Post-chemotherapy AL Amyloidosis participants|Immunoglobin light chain amyloidosis (AL) participants who attain either a very good partial response (VGPR), or complete response (CR), to systemic chemotherapy (including autologous stem cell transplantation) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered by as SC injection for 11 days from the day of first dose of anti-SAP mAb.
3476585|NCT03826563|Placebo Comparator|Placebo|Subjects will receive pill placebo nightly
3476586|NCT03826563|Experimental|Melatonin|Subjects will receive oral melatonin tablets 2.5-10mg nightly for 2 weeks. All will receive melatonin 5mg for one week, then at the 1 week visit, the dose can be continued at 5mg or adjusted to 2.5mg or 10mg nightly based on clinical assessment of patient response and side effects.
3476587|NCT03826550|Experimental|Diclofenac Sodium Gel3%|Diclofenac Sodium Gel 3%, dosed twice daily for 60 days.
3476588|NCT03826550|Active Comparator|Solaraze|Solaraze Gel dosed twice daily for 60 days.
3476589|NCT03826550|Placebo Comparator|Placebo|Placebo Gel dosed twice daily for 60 days.
3476590|NCT03826654|Experimental|fortified oil|daily intake of fortified sunflower oil (700IU vitamin D/ 35g)
3476591|NCT03826654|Placebo Comparator|control|daily intake of plain oil
3476592|NCT03826485|Experimental|A group|Period 1: PRIC Period 2: Pranlukast hydrate
3476593|NCT03826485|Experimental|B group|Period 1: Pranlukast hydrate Period 2: PRIC
3476594|NCT03826524|Active Comparator|Low Dose Epinephrine|Epinephrine up to 2mg total
3476595|NCT03826524|Active Comparator|Standard Dose Epinephrine|Epinephrine up to 6mg total
3476596|NCT03826927||AF and cerebrovascular event|patients with AF and recent (< 3 month) stroke or transient ischaemic attack (TIA) or intracranial haemorrhage (ICH) with or without pre-existing oral anticoagulation, in whom treatment with NOACs or VKAs is initiated or continued for prevention of ischemic events
3476597|NCT03826446|Other|Open Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did open complete mesocolic excision procedures
3476598|NCT03826446|Other|Laparoscopic Surgery|Patients diagnosed as operable right sided colon cancer were enrolled in this study and did laparoscopic complete mesocolic excision procedures
3476599|NCT03826368||TBI Controls|Adult men and women between 18 and 55. No prior history of traumatic brain injury. Experienced taking hemp-derived botanicals.
3476600|NCT03826368||TBI HDS|Adult men and women between 18 and 55. History of traumatic brain injury. Experienced taking hemp-derived botanicals.
3476601|NCT03826459|Active Comparator|Locked Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & locking technique. The second layer will be performed based on surgeon preference.
3476602|NCT03826459|Experimental|Non-Locking Uterine Closure|Participants will undergo two-layer closure of the hysterotomy site at the time of cesarean section. The first layer will use a running & non-locking technique. The second layer will be performed based on surgeon preference, but cannot be of a locking technique.
3476603|NCT03826472|Experimental|Almond Butter|Participants will consume one ounce per day (~32 g) of almond butter as an evening snack (i.e., after dinner and before sleep).
3476604|NCT03826472|No Intervention|No-snack Control|Participants will consume nothing besides water after dinner/bed sleep.
3476605|NCT03826433|Experimental|Treatment Group|Mesenchymal Stem Cells : through peripheral intravenous slowly, every time 6*10^7 (30ml) Other medication of Treatment Group: before the30min of first time to inject stem cells, Intravenous methylprednisone 20mg. All patients require oral nucleoside drugs resistant hepatitis B virus treatment.Use stem cell therapy, by Peripheral iv, 6 * 10 ^ 7 (30 ml)
3476606|NCT03826433|No Intervention|Control Group|Control Group: Using basic contrast .
3179378|NCT00672152|Experimental|A-WT1 derived peptides|"Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
3179379|NCT00672165|Experimental|1|This is a phase I, dose-escalation trial. The starting dose level will be 0.5 μCi/kg of 225Ac-HuM195. Three to six patients will be treated at each dose level, and dose escalation will proceed if less than 33% of patients in a cohort experience dose limiting toxicity. Six patients will be treated at the maximum tolerated dose
3476607|NCT03826329||Study Cohort|The observational study included all patients who had been admitted for their first ACDF surgery during the 16-year span, began on January 1st, 1998 till the end of 2013, recorded in the NHIRD. The admission for cervical disc herniation and spondylosis were identified using the ICD9-CM diagnostic codes of 722.0, 722.4 and 722.71, while the surgery of ACDF was confirmed with the procedure codes of 80.51, 81.00 and 81.02 during the same hospitalization.
3476608|NCT03826407||DOC patients|Patients in coma (GCS score of 3-8) or with other disorder of consciousness, primarily Minimally Conscious State (MCS) or Unresponsive Wakefulness Syndrome (UWS; also known as vegetative state)
3476609|NCT03826407||Healthy Control|Matched healthy controls without current neurological diagnoses
3476610|NCT03826316|Experimental|Mutonpain Injection 10 mg/ml|
3476611|NCT03826303|Experimental|E-cigarette with ethanol, 1 puff|
3476612|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 1 puff|
3476613|NCT03826303|Experimental|E-cigarette with ethanol, 10 puffs|
3476614|NCT03826303|Placebo Comparator|E-cigarette without ethanol, 10 puffs|
3476615|NCT03826394|Experimental|Exercise Intervention|Exercise intervention with the aim of incrementally increasing physical activity to meet the national recommendation of 150 minutes a week of moderate-vigorous physical activity, reducing BMI and improving overall health.
3476616|NCT03826394|Experimental|Dietary Intervention|Staged dietary intervention with the aim of improving eating behaviours, reducing BMI and improving overall health.
3476617|NCT03826381||Study 1: DM2 + normal kidney function|"Number of patients: 54~Patients in this group are diagnosed with Diabetes type 2. Kidney function: eGFR is > 60, absence of clinical proteinuria.~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions and the same as in the other group.~The patients are examined once."
3476618|NCT03826381||Study 1: DM2 + CKD stage 3-5|"Number of patients: 54~Patients in this group are all diagnosed with diabetes type 2. Furthermore, the patients have chronic kidney disease stage 3-5 (eGFR <60).~Inclusion- and exclusion criteria are listed under section Eligibility. Examinations performed in this group are listed under the section Groups and Interventions are the same as in the other group.~The patients are examined once."
3126617|NCT03044353|Experimental|Group 3: Newly diagnosed Mayo stage II/IIIa AL participants|Newly diagnosed Mayo stage II/IIIa AL participants who attain a free light chain CR during the first 3 cycles of first-line chemotherapy where the first cycle was cyclophosphamide, bortezomib, dexamethasone (CyBorD) will be included. Participants will receive 6 anti-SAP treatments, consisting of CPHPC followed by anti-SAP mAb at monthly intervals. During each anti-SAP treatment, participants will receive CPHPC IV infusion once daily for up to 72 hours. After 72 hours of CPHPC administration, participants will be administered IV infusion of anti-SAP mAb over 6-8 hours each on Days 1 and 3. The starting dose level of anti-SAP mAb will be 600 mg (divided into 2 infusions of 300 mg). In each treatment session, CPHPC will be administered as SC injection for 11 days from the day of first dose of anti-SAP mAb.
3476619|NCT03826355|Active Comparator|Stripping technique|The endometrioma is removed according to standard surgery.
3476620|NCT03826355|Experimental|Laser technique|The endometrioma is drained, everted and then the inner wall of the endometrioma is vaporised with CO2 laser
3476621|NCT03826017|Experimental|Catechin high contain greentea extract|Catechin high contain greentea extract for 260 mg/day 12 weeks.
3476622|NCT03826017|Placebo Comparator|Placebo|Placebo for 12 weeks.
3476623|NCT03826290|Experimental|Intervention arm|When patients are seen in clinics in this arm, the clinical providers will have access to the intervention (EHR-integrated diabetes dashboard).
3476624|NCT03826290|No Intervention|Control arm|When patients are seen in clinics in this arm, the clinical providers will not have access to the intervention (EHR-integrated diabetes dashboard). The providers will have access to the usual decision support tools and information sources.
3179380|NCT00672191|Experimental|1|
3179381|NCT00672217|Placebo Comparator|Behavioral Placebo Therapy|Behavioral Placebo Treatment
3476625|NCT03825952|Experimental|Participants using MERM device|Participants will use an electronic medication monitor to measure their adherence to ART in routine clinical care.
3179382|NCT00672217|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (CBTI)
3179383|NCT00672230|Experimental|Lut Supp|
3179384|NCT00672269||1|Families with carcinoid in multiple family members
3179385|NCT00672282|Placebo Comparator|A|
3179386|NCT00672282|Active Comparator|B|
3179387|NCT00672295|Experimental|Dasatinib, paclitaxel,and carboplatin|Combination of dasatinib, paclitaxel,and carboplatin
3476626|NCT03825965|Experimental|Cannabidiol (CBD)|Oral medicinal cannabis (125 mg cannabidiol daily suspended in oil)
3476627|NCT03825965|Placebo Comparator|Placebo|Visually identical placebo (medium chain triglyceride oil)
3476628|NCT03825926||Gestational Diabetes Mellitus|The diagnosis of GDM is based on a 75-g oral glucose tolerance test (OGTT) performed between 24 and 28 gestational weeks, according to the American diabetes association (ADA) criteria (fasting ≥ 5.1 mmol/L, 1 h ≥ 10.0 mmol/L, 2 h ≥ 8.5 mmol/L). Recruited patients were accepted the standard of treatment of GDM according to the American college of obstetricians and gynecologists (ACOG) practice bulletin on gestational diabetes mellitus.
3476629|NCT03825926||Non-Gestational Diabetes Mellitus|normal group
3476630|NCT03826030|Sham Comparator|Sham tDCS + mCIMT|Sham tDCS (Transcranial direct current stimulation) administers no dose or zero milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
3476631|NCT03826030|Active Comparator|2 mA tDCS + mCIMT|2 mA tDCS (Transcranial direct current stimulation) administers low dose or 2 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
3476632|NCT03826030|Active Comparator|4 mA + mCIMT|4 mA tDCS (Transcranial direct current stimulation) administers high dose or 4 milliampere stimulation through the tDCS device, during Constraint Induced Movement Therapy (mCIMT)
3476633|NCT03825887|Active Comparator|Group A-PCA Morphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
3476634|NCT03825887|Experimental|Group B-PCA Nalbuphine|Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10 mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40 mcg /kg/ hour.
3476635|NCT03826251||systematic nasogastric tube|NGT was left systematically after surgery and removed after the first flattus
3476636|NCT03826251||Non systematic nasogastric tube|Nasogastric tube was removed immediately after surgery and was replaced in case of vomiting
3476637|NCT03826121|Experimental|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks
3476638|NCT03826121|Placebo Comparator|Placebo|placebo for 12 weeks
3476639|NCT03826147|Active Comparator|Nitrate-rich beetroot juice|Daily dose of nitrate-rich beetroot juice (70 mL) for 3 months.
3476640|NCT03826147|Placebo Comparator|Nitrate-depleted beetroot juice|Daily dose of nitrate-depleted beetroot juice (70 mL) for 3 months. The nitrate-depleted beetroot juice is identical in appearance, taste and caloric content to nitrate-rich beetroot juice, but with nitrate removed.
3179388|NCT00672308|Experimental|1|Benefiber (25 g/L)
3179389|NCT00672308|Experimental|2|Benefiber (50 g/L)
3476641|NCT03826186|Active Comparator|Traditional epidural group|The traditional approach to placing thoracic epidurals by loss-of-resistance technique using a ground glass syringe will be used in this group.
3476642|NCT03826186|Experimental|CompuFlo epidural group|This device (CompuFlo) will aid in correct placement of the epidural by electronically sensing pressure in real time and by providing a numerical value on a read out screen to determine a loss of resistance. There is also an audio signal that signals a loss of resistance.
3476643|NCT03826043|Experimental|Experimental arm|Hospitalized patient
3476644|NCT03826238||ARBD and depression|10 patients with ARBD and at least moderate depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale ≥ 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
3476645|NCT03826238||ARBD and no depression|10 patients with ARBD and no clinically relevant depressive symptoms (MoCA < 26, Hamilton Depression Rating Scale < 17). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
3476646|NCT03826238||Healthy|10 healthy controls (no ARDB, no depression, no cognitive deficit). Intervention: The Validation Gate task, a visual attention task where the subject must detect discontinuities in the moving trajectory of circles on the screen while EEG is recorded.
3476647|NCT03826069|Active Comparator|Conventional Simulation Curriculum|Four, one-hour small-group sessions on the theory of colonoscopy including pathology, anatomy, and therapeutic technique. Following each session, a multiple choice test on topics covered will be administered. In addition, this group will be given a total of six hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (5 hours). During the high-fidelity simulation, endoscopic procedures will be performed with instructor support. The difficulty of the therapeutic intervention (polypectomy) will rise after each successfully completed module. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
3476648|NCT03826069|Experimental|Augmented Reality Group|This group will receive the same 4 hours of small group teaching and 6-hours of hands-on simulator training. The intervention is the augmented reality-based curriculum: (1) a brief explanation of the principles of AR and how it will be used during the VR simulations and (2) performance of the therapeutic procedure (polypectomy) as demonstrated by the real-time AR platform. Specific videos corresponding to the therapeutic intervention and pathology (e.g pedunculated vs non-pedunculated polyp) will be available every time a polypectomy is required. Each new module will come with increased technical challenges and will require adjustment to previously used technique by the learner. The last two hours of training on the high-fidelity simulator will consist of two integrated scenarios.
3179390|NCT00672308|Experimental|3|the reduced-osmolarity WHO-ORS without Benefiber.
3179391|NCT00672334|Placebo Comparator|2|sodium chloride at 0.5 mmol/kg loading pre-induction and then at 0.2 mmol/kg/hr over 24 hours after induction until the next day
3476649|NCT03825913|Active Comparator|Exercise Intervention|"Subjects in the exercise group will participate in a 3-month exercise program at the University of Miami UHealth Fitness and Wellness Center. Participants will complete two exercise sessions a week, each 45-60 minutes long and on a one-on-one basis.~In addition to two site visits, the participants will receive a tailored daily home-based walking plan. The participants will use physical activity trackers (Fitbit®), with an ultimate goal of achieving 10,000 steps by the end of the intervention.~Participants in the exercise intervention will complete 24 sessions."
3126618|NCT03044418||anesthesia with laser tube|The special endotracheal (ET) laser tube is tested during endolaryngeal laser surgery. Anesthesia type is the total intravenous anesthesia with propofol. We tested the application of ET laser tube in propofol anesthesia.
3126619|NCT03044431||Cell therapy treated|All patients/participants enrolled will undergo cell therapy
3126620|NCT03044574|Experimental|Experimental group (SCD + GCS + LMWH)|"SCD: Intermittent pneumatic compression (IPC) with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.~GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
3126621|NCT03044574|Active Comparator|Control group (GCS + LMWH)|"GCS: Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge~LMWH: LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge."
3126622|NCT03044691|No Intervention|Control Clinic|The control group will have to complete the Adaptive Reserve and Change Process Capability Questionnaire and Clinician Survey at baseline and 9 months. Clinicians will provide their usual care related to tobacco and nicotine product use screening and cessation recommendations. Medical record of patients will be reviewed at baseline and at 6 months.
3126623|NCT03044691|Experimental|Intervention Clinic|Participants will be asked to complete the Youth Tobacco and Nicotine Product Questionnaire and Parent Brief Questionnaire (PBQ) using the ResearchACTS software at the point of care. A follow-up survey Youth Tobacco and Nicotine Product Primary Care survey will be administered to participants at least 30 days after their clinic visit.
3126624|NCT03044730|Experimental|Treatment (pembrolizumab, capecitabine)|Patients receive pembrolizumab IV on day 1 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3126625|NCT03044886|Experimental|2000IU/day|Subjects took 2000IU vitamin D per day
3126626|NCT03044886|Experimental|1000IU/day|Subjects took 1000IU vitamin D per day
3476650|NCT03825913|Sham Comparator|Wellness Intervention|For 3 months, the wellness education group will not be offered any form of supervised exercise program or receive any specific instructions on physical activity as part of the study. The participants in this group will attend educational sessions about different wellness topics, such as nutrition, sleep, weight management, mindfulness, and the overall benefits of increased physical activity. The wellness visits will be held two times per month, and similar to the exercise sessions of the intervention arm, they will be 45-60 minutes long and on a one-on-one basis. Participants in the wellness education group will complete 6 sessions.
3476651|NCT03825900|Active Comparator|Active tDCS|Active transcranial direct current stimulation
3476652|NCT03825900|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
3476653|NCT03826134|Experimental|[11C]-PXT012253|
3476654|NCT03826160||Tesamorelin|Individuals who plan to initiate tesamorelin clinically
3476655|NCT03826160||No Treatment|Individuals who decline to initiate tesamorelin despite a clinical indication
3476656|NCT03826056|Active Comparator|Current standard education group|A study team member will use the current hospital standard educational material to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
3476657|NCT03826056|Experimental|New personalized education group|A study team member will use the new personalized educational materials to explain the discharge diagnosis to the patient, the treatment, and the follow up needed. The study team member will also give a survey with a preaddressed envelope to each participant to complete at his or her convenience.
3476658|NCT03826277|Experimental|Melanostop peel treatment group|"Adult women aged between 20-50 years old.~Melasma on the face~Fitzpatrick phototypes I-IV~Presenting facial melasma~In good health condition"
3476659|NCT03826004|Placebo Comparator|Placebo|Saline solution 2ml before anesthetic induction
3476660|NCT03826004|Experimental|Clemastine|Clemastine fumarate 2mg/2ml before anesthetic induction
3476661|NCT03825978|Active Comparator|Intervention|An individual and comprehensive prenatal genetic counseling was given to all pregnant women in the intervention group, including all screening tests and diagnostic tests for prenatal diagnosis and screening tests at the first antenatal visit.
3476662|NCT03825978|No Intervention|Control|There was no intervention from the first antenatal visit in the control group. Routine clinical information was given about prenatal screening and diagnostic tests.
3476663|NCT03825848|Experimental|Left Portal Vein Branch|Shunt left portal vein branch during the trans jugular intrahepatic portal systemic shunt
3476664|NCT03825848|Experimental|Right Portal Vein Branch|Shunt right portal vein branch during the trans jugular intrahepatic portal systemic shunt
3476665|NCT03825861|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
3476666|NCT03826420|Experimental|Secure Confinement Group|Parolees assigned to this group will be assigned sanctions that include secure confinement.
3476667|NCT03826420|Experimental|Work Release Group|Parolees assigned to this group will be assigned sanctions that include work-release.
3476668|NCT03826420|Experimental|GPS Supervision Group|Parolees assigned to this group will be assigned sanctions that include GPS supervision.
3476669|NCT03826420|No Intervention|Control Group|
3476670|NCT03825744|Experimental|Hetrombopag Olamine+Standard Therapy|
3476671|NCT03825744|Placebo Comparator|Placebo+Standard Therapy|
3476672|NCT03826173|Experimental|Positive Psychology|On a weekly basis, participants will engage in group-based intervention sessions that focus on personal strengths and the value of positive emotions and cognitions. Participants will receive daily text-messages addressing the content introduced during group sessions.
3476673|NCT03826173|Active Comparator|Physical Activity Promotion|On a weekly basis, participants will engage in group-based intervention sessions that focus on the standard physical activity promotion components of the PPPA condition. Participants will receive daily text-messages addressing the content introduced during group sessions.
3476674|NCT03826212|Experimental|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
3476675|NCT03826212|Placebo Comparator|Placebo|Placebo 1,600 mg/day for 12 weeks.
3476676|NCT03825809|Experimental|Post-Operative Non Opioid Pain Protocol|"Patients will be administered a post-operative non-opioid pain protocol consisting of:~Celecoxib Ketorolac Gabapentin Acetaminophen Diazepam"
3476677|NCT03825809|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen 5-325
3476678|NCT03825627|Active Comparator|Antisaccade Task (active tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
3126627|NCT03044886|Placebo Comparator|Placebo|Subjects took placebo
3126628|NCT03045081|No Intervention|Usual care|Patients receive outcome tracking tool, PainTracker, but no additional web-based support for self-management
3476679|NCT03825627|Sham Comparator|Antisaccade Task (sham tDCS)|During the antisaccade task, the investigators will show participants computer-generated images depicting clothed and sexually relevant (nude) children, young adults and adults of both genders. Images will be drawn from the Virtual People Set and the Not-Real-People Set (Pacific Psychological Assessment Corporation, 2004). Pedophilic participants are expected to show a sexual preference towards a prepubescent body scheme whereas stimuli displaying adolescence and adulthood (sexual maturity) are expected to be sexually preferred by the teleiophilic control participants. In this arm sham Transcranial Direct Current Stimulation will be used during the task.
3476680|NCT03825627|Active Comparator|Approach Avoidance Task (active tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm active Transcranial Direct Current Stimulation will be used to influence performance.
3476681|NCT03825627|Sham Comparator|Approach Avoidance Task (sham tDCS)|During the Approach-Avoidance Task (AAT), participants will look at a series of images depicting children and adults wearing swimsuits. The images were sampled from internet advertisements and do not constitute legally objectionable material. When sourcing the images, rigorous attention was paid to meet the criteria for fair use indicated by the American Psychological Association. There are 160 images in total. Half of the images will be used in the active and the other half in the sham condition (i.e., 20 female adults, 20 female children, 20 male adults, and 20 male children per condition). In this arm sham Transcranial Direct Current Stimulation will be used during the task.
3476682|NCT03826342|Experimental|Health Check-up for Expectant Moms|Theory-driven and derived from empirical support
3476683|NCT03826342|Active Comparator|Time, attention, and information-matched control|Well-validated
3126629|NCT03045081|Experimental|PainTracker Self-Manager|Patients are invited to complete the web-based PainTracker Self-Manager and interact with a nurse care manager who supports chronic pain self-management
3126630|NCT03045302|Experimental|BIM23B065|
3476684|NCT03826108||Cases|Patient who underwent a primary hip (total or partial) or knee arthroplasty and developed a PJI that was culture-confirmed for SA during the first year after the procedure.
3476685|NCT03826108||Controls|Patient who underwent a primary hip or knee arthroplasty and did not develop any type of PJI during the first year after the procedure.
3476686|NCT03825835|Active Comparator|30% group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
3476687|NCT03825835|Experimental|60% group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
3476688|NCT03825601|Other|Patients with multiple sclerosis|The multiple sclerosis group (n=30) will be subdivided in two subgroups: 15 patients with a relapsing remmitting MS (RRMS), and 15 patients with a primary progressive MS (PPMS).
3126631|NCT03045328|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD beginning on week 1 day 1. Treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity. Patients also receive venetoclax PO QD beginning on week 9 day 1. Treatment with venetoclax continues up to week 61 day 7 in the absence of disease progression or unacceptable toxicity.
3126632|NCT03045653|Experimental|treatment arm|receiving a treatment of tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
3476689|NCT03825601|Other|healthy subjects|15 healthy subjects will be included. Among them 7 to 8 subjects will be matched for age and gender with the RRMS subgroup, and 7 to 8 will be matched for age and gender with the PPMS subgroup.
3476690|NCT03825731|Experimental|GC022|The patients will receive GC022 CAR-T treatment. GC022 dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
3476691|NCT03825718|Experimental|CAR-T treatment group|The patients will receive one dose of GC007F. GC007F dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
3476692|NCT03825562|Experimental|research group|Research group is attending the ACT intervention first and from before and afte measurement are compared to the control group
3476693|NCT03825562|Active Comparator|control group|Control group is offered to attend the intervention afterwards
3476694|NCT03825588|Experimental|ASAP + BRITE + TAU (treatment as usual)|Participants in this arm receive the ASAP (As Safe As Possible) intervention, during their transition from inpatient to outpatient care, as well as the BRITE smart phone app for distress tolerance/emotion regulation and safety planning. Participants will also receive usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3476695|NCT03825588|Experimental|BRITE + TAU (treatment as usual)|Participants in this arm will receive the BRITE smart phone app for distress tolerance/emotion regulation and safety planning as they proceed from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3476696|NCT03825588|Experimental|ASAP + TAU (treatment as usual)|Participants in this arm will receive the ASAP (As Safe As Possible) intervention during their transition from inpatient to outpatient care, in addition to usual treatment protocols that all adolescents admitted to their respective Inpatient Psychiatry program receive. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3476697|NCT03825588|Active Comparator|TAU (treatment as usual) alone|Participants in this grouping are studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants complete paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3476698|NCT03825471|Experimental|electrotherapy|Patients undergoing CES and general anesthesia in colon cancer surgery
3476699|NCT03825471|Placebo Comparator|Opioid Anesthetics|Patients undergoing general anesthesia in colon cancer surgery
3476700|NCT03825705|Experimental|Anlotinib + TQB2450|TQB2450 1200 mg IV on Day 1 of each 21-day cycle plus Anlotinib capsules given orally in fasting conditions , once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)
3476701|NCT03825575|Experimental|Incontinence and low level laser therapy|Intervention: Low level laser therapy (sacral neuromodulation or photobiomodulation) will be administered to patients with fecal incontinence
3476702|NCT03825510|Experimental|Treatment Arm|
3476703|NCT03825614|Experimental|training gruop|The plates exercise program is concerned with the following main principles: efficient breathing, mental concentration, relaxation, correct spine elongation and posture, correct abdominal muscle control over spine stability and mobility, correct function of each upper and lower limb, precision, lowing integrated movement, and achieving muscle strength and stamina.
3476704|NCT03825614|Active Comparator|training group|Therapeutic exercise program was designed according to the American Collage of Sports Medicine's recommendations for healthy people. The exercise program was conducted using low- to moderate-intensity therapeutic exercises. These therapeutic exercises included a short educational talk that provided information on proper body mechanics, the benefits of exercise, realistic goal-setting, and overcoming common barriers (such as fear) when developing an exercise routine.
3476705|NCT03825614|No Intervention|Control group|Participants in the control group have no exercise in this study.
3476706|NCT03825770|Experimental|"The PEP Program"|"The PEP (Personal Energy Planning) Program"
3476707|NCT03825770|Active Comparator|General Education|General Education about Kidney Disease
3476708|NCT03825549|No Intervention|Control|No intervention
3476709|NCT03825549|Experimental|Individual Audit|Clinicians will receive individual audit feedback informing them of their performance.
3476710|NCT03825549|Experimental|Peer Comparison|Clinicians will receive peer comparison feedback informing them of how their performance compares to their peers.
3476711|NCT03825549|Experimental|Individual Audit and Peer Comparison|Clinicians will receive individual audit feedback informing them of their performance and peer comparison feedback informing them of how their performance compares to their peers.
3126633|NCT03045809||Women at risk of urogenital infections|Adult women living in the city of Kigali who are at high risk of HIV/urogenital infections (defined as having had more than one sexual partner in the last 12 months OR having been treated for a sexually transmitted infection (STI) in the last 12 months) regardless of the presence of current urogenital symptoms. Women who are known to be HIV-positive and/or pregnant are not excluded. All eligible women will be offered urogenital infection point-of-care tests.
3476712|NCT03825757|Experimental|Primaspan tablet 250 mg|Primaspan tablet 250 mg (Acetyl salicylic acid): 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
3476713|NCT03825757|Placebo Comparator|Placebo tablet|Placebo Oral Tablet: 1/2 tablet once daily during 1 month. 1 tablet once daily during 10 months. If not tolerated the dose 1 tablet x1/day, the patient is allowed to continue with the dose of 1/2 tablet x1/day.
3476714|NCT03825354|Experimental|Brief Intervention and contact (BIC)|Brief education about suicidal behaviour and follow up contacts for 6 months in addition to treatment as usual. follow up will occur at the following time points post discharge: weeks 1, 2, 4, 6, 8, 12, 16 and 20. this will occur in addition to treatment as usual.
3476715|NCT03825354|No Intervention|control|control will continue treatment as usual which is whatever the clinical team decides upon post discharge. data will be collected on repeated suicidal behaviour through medical records with consent.
3126634|NCT03045861|Experimental|Cohort 1-GSK2838232 100 mg + Cobicistat 150 mg in Part A|During Part A (Cohort 1), subjects will receive a single dose of GSK2838232 100 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
3126635|NCT03045861|Experimental|Cohort 2-GSK2838232 200 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 2), subjects will receive a single dose of GSK2838232 200 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
3126636|NCT03045861|Experimental|Cohort 3-GSK2838232 50 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 3), subjects will receive a single dose of GSK2838232 50 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
3126637|NCT03045861|Experimental|Cohort 4-GSK2838232 20 mg + Cobicistat 150 mg in Part B|During Part B (Cohort 4), subjects will receive a single dose of GSK2838232 20 mg and Cobicistat 150 mg once daily each morning with a light breakfast meal and 240 mL of water from Day 1 to Day 10. Subjects will be followed up to Day 22.
3476716|NCT03825497|Experimental|Intervention|1) On admission, patients will receive a welcome folder focusing on physical activity; 2) daily during hospitalization, patients will be encouraged to walk along a walk path in the hallway; 3) during hospitalization, patients will be encouraged to consult and use posters with exercises (sit to stand, heel raise, balance); 4) on admission, patients will receive a prescribed walk plan with 3 daily walking sessions to perform during hospitalization (3 times 1 minute, 5 minutes or 10 minutes); 5) during hospitalization patients will be motivated to pick up of clothes and beverages themselves; 6) patients will be discharged with a walk plan to use at home; 7) after discharge the municipality will follow up on patients receiving home care and patients with a rehabilitation plan
3476717|NCT03825497|No Intervention|Usual care|All patients admitted to the control wards will receive usual care during and after hospitalization.
3476718|NCT03825666|Experimental|Active|Intervention with drink pre surgery and chewing gum post surgery. No subgroups, combined intervention will be assessed. ProvideXtra® Fresenius Kabi plus standard consumer xylitol chewing gum.
3476719|NCT03825666|No Intervention|Control|control group following standard guidelines
3476720|NCT03825380|Experimental|T4032|
3476721|NCT03825380|Active Comparator|Lumigan®|
3476722|NCT03825341|Active Comparator|Arm 1 Liquid Hydroxyurea|In Arm 1 of this study, n=18 infants ages 9 months to 2 years will be administered an extemporaneous oral liquid formulation of HU on a single occasion followed by PK sampling. The dose administered will be ~20 mg/kg/day or the infant's usual daily dose.
3476723|NCT03825341|Active Comparator|Arm 2 Hydroxyurea Oral Capsule|In Arm 2, n=30 children who range in age from 2 to 18 years will be administered oral capsule HU, both a sprinkle formulation and capsules (Droxia® 200 mg), on two separate occasions separated by at least 1 but no more than 30 days in a randomized, crossover fashion. The doses of HU on each occasion will be rounded to the nearest 200 mg and will not exceed 35 mg/kg or 2000 mg
3476724|NCT03825185|Experimental|Transcervical Thymectomy|50 patients were randomized to transcervical thymectomy for treatment of myasthenia gravis.
3476725|NCT03825185|Experimental|TranssternalThymectomy|50 patients were randomized to transternal thymectomy for treatment of myasthenia gravis.
3476726|NCT03825302||Males with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
3476727|NCT03825302||Females with asthma|Induced sputum, methacholine challenge, and mannitol challenge will be performed.
3476728|NCT03825263|No Intervention|Control|Participants receive normal treatment
3476729|NCT03825263|Experimental|Intervention|Participants administer Intermittent Pressure Compression using the Lymphassist in addition to normal treatment
3476730|NCT03825523|Experimental|Group A Immediate treatment (iART)|Other: time to start the ART within 48 hours of admission to hospitalization
3476731|NCT03825523|Active Comparator|Group B Conventional treatment (cART)|Other: time to start the ART, after the opportunistic disease has been controlled, at the discretion of infectious disease specialist.
3476732|NCT03825250|No Intervention|Group A: Control|Standard of care
3476733|NCT03825250|Experimental|Group B: Sodium Valproate Treatment|15 mg/kg for 1-2 weeks
3476734|NCT03825250|Experimental|Group C: Sodium Valproate Treatment|15 mg/kg for 4-6 weeks
3126638|NCT03045887|Experimental|Part A Cohort 1: Placebo- GSK2292767 (GSK) 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3126639|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-Placebo-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, placebo in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3476735|NCT03825250|Experimental|Group D: Sodium Valproate Treatment|25 mg/kg for 4-6 weeks
3476736|NCT03825172||Group I|Caudal Epidural Ultrasonography will be performed in patients aged between 1-24 months
3476737|NCT03825172||Group II|Caudal Epidural Ultrasonography will be performed in patients aged between 25-48 months
3476738|NCT03825172||Group III|Caudal Epidural Ultrasonography will be performed in patients aged between 49-84 months
3476739|NCT03825211|Experimental|Continuous suture|All parts of the perineal lesion (vaginal mucosa , perineal muscle and skin) be sutured with the same suture thread. A single suture for perineal lesion
3476740|NCT03825211|Active Comparator|Discontinuous suture|Interrupted suture technique: vaginal mucosa, perineal muscle and skin are sutured with separate and different threads, that is, the vaginal mucosa is sutured with a thread, then independently the perineal muscle is sutured with another type of thread and finally the skin is also sutured independently with another different thread. Three independent sutures for each of the parts that form a single perineal lesion
3476741|NCT03825159|Experimental|ES group|Using spinal orthosis with an integrated system of electric surface stimulation and heat sensing.
3476742|NCT03825159|Active Comparator|brace group|Using spinal orthosis BRACE
3476743|NCT03825445|Experimental|GnRHa trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial; Ferring Pharm Co, Switzerland) for ovulation trigger.
3476744|NCT03825445|Experimental|hCG trigger|Infertile patients underwent ovarian stimulation, started on cycle day eight with 75 IU Menogon (Ferring Pharm Co, Switzerland) daily. Ultrasound monitoring was required after every 2-3 days of stimulation and adjustments to dose and duration were tailed according the patient's response. Ovulation was triggered when at least one and no more than 3 follicles reached ≥18mm in diameter. Patients were then randomly assigned to receive hCG (Pregnyl 5000IU; Organon Pharm Co, Nertheland) for ovulation trigger.
3476745|NCT03825237||With sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
3476746|NCT03825237||Without sleep bruxism by polysomnography|Adults (20 to 60 years) and elderly (> 60 years), (WHO-World Health Organization, 2015) who had undergone polysomnography (PSG) from January 2015 to December 2017 were assessed. All self-reports and PSG exams were included and reviewed. The participants were excluded if they presented with a history of neurological or degenerative disorders, and any objection to take the polysomnography test.
3476747|NCT03825198|Active Comparator|ESB group|"Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.~Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea."
3476748|NCT03825198|Sham Comparator|SHAM group|Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
3476749|NCT03825367|Other|Open label design|Nivolumab and 5-azacytidine,
3476750|NCT03825640|Experimental|Community treatment Adherence at Re-Entry (CARE)|"CARE will begin within the 2 months before prison release, and will continue for 6 months after re-entry. CARE will be comprised of: a) 3 individual sessions with the CARE counselor; b) 1 optional family/significant other (SO) session; and c) 11 brief (15-20 min) follow-up telephone contacts with prisoners and their SO over the first 6 months post-release.~The CARE intervention will incorporate motivational strategies from existing interventions (e.g., Acceptance and Commitment Therapy) in order to clarify values and goals to enhance motivation for community treatment engagement and behavior change. CARE will also integrate bipolar disorder psychoeducation and strategies from existing family models of intervention for BD (e.g., McMaster Model of Family Functioning) that are designed to improve family communication, social support, and problem-solving around BD illness management over this vulnerable transition period."
3476751|NCT03825146|Experimental|Treatment Arm (AMPC)|AMPC will be intravenously infused.
3476752|NCT03825276|Experimental|Mango consumption|
3476753|NCT03825536|Experimental|Oral methamphetamine|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the experimental treatment arm, an initial 10 mg of oral methamphetamine study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose two hours later.
3476754|NCT03825536|Placebo Comparator|Placebo oral capsule|Participants will be randomized to either oral methamphetamine versus placebo treatment first using a random number generator. Whichever treatment the participant receives first, they will receive the other treatment (placebo or oral methamphetamine) for their second treatment phase starting at approximately Day 77. For the placebo treatment arm, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
3476755|NCT03825315|Experimental|DAXI for Injection: LOW Dose|LOW Dose Group
3476756|NCT03825315|Experimental|DAXI for Injection: HIGH Dose|HIGH Dose Group
3476757|NCT03825315|Placebo Comparator|Placebo|Placebo Group.
3476758|NCT03825328|Experimental|Chemotherapy|Albumin-binding paclitaxel+S1 / gecitabine+oxaliplatin Interchanged every 2 cycles
3476759|NCT03824821||IBS|
3476760|NCT03824951|Experimental|Anti-CD19 iCAR NK Cells|
3126640|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg- GSK 200 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
3476761|NCT03825133|Experimental|Bone Marrow Aspirate Concentrate|Patients treated with single injection of BMAC in the knee
3476762|NCT03825133|Experimental|Leukocyte Rich Platelet Rich Plasma|Patients treated with single injection of LR-PRP in the knee
3476763|NCT03825133|Experimental|Hyaluronic Acid|Patients treated with 3 single injection of high molecular HA in the knee ( one injection weekly)
3476764|NCT03824860|Experimental|Yoga Program|Eight-weeks, therapist and self-guided yoga
3476765|NCT03824860|No Intervention|Treatment as usual|Control group participants will continue to receive usual care and symptom management strategies from clinicians during the study.
3476766|NCT03824769|Active Comparator|Behavioral Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
3476767|NCT03824769|Experimental|Behavioral Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
3476768|NCT03824847|Active Comparator|Intervention group|Intervention group: clarithromycin 1 tablet (250mg) twice daily for three days
3476769|NCT03824847|Placebo Comparator|Placebo group|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days.
3476770|NCT03824899|Experimental|CRT group|Patients With Advanced Rectal Cancer receiving CPT-11-based CRT and blood concentration check
3476771|NCT03824743||Lactate Ringer|Patients managed with Ringer Lactate
3476772|NCT03824743||Plasma-Lyte|Patients managed with Plasma-Lyte
3476773|NCT03824925|Placebo Comparator|Placebo oral zinc capsules|Group A: It was the control group. Participants were advised to start taking placebo capsule of Zinc in a look alike preparation on their first day of chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended
3476774|NCT03824925|Experimental|Zinc Sulfate 220 MG|Group B: Cap zinc 220 mg (equivalent to 50 mg of elemental zinc) on 1st day of their chemo-radiotherapy and continued taking it a month after their chemo-radiotherapy ended.
3476775|NCT03824730||Endovascular occlusions group|Group of patients with aorto-iliac occlusive disease (TASC B, C, D) in whom stenting of the Common and/or External Iliac Arteries were performed
3476776|NCT03824886|Experimental|Implementation of skin care algorithm|In the interventional nursing homes, a structured skin care prevention package based on a newly developed evidence-based skin care algorithm will be implemented at the nursing homes and delivered by nurses.
3476777|NCT03824886|No Intervention|Standard Care|In the control group, no additional intervention will be implemented. PU and IAD prevention and basic hygiene and skin care activities are routinely conducted in German nursing homes. This is considered as 'usual practice'.
3476778|NCT03824782|No Intervention|Standard of Care|Infants in the control arm received standard examinations to screen for retinopathy of prematurity.
3476779|NCT03824782|Experimental|Standard of Care + Phototherapy Mask|Infants in the treatment arm will have a standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided. Infants will then receive standard examinations to screen for retinopathy of prematurity. The mask will be removed for the examination but reapplied promptly afterward.
3476780|NCT03825081|Experimental|Intervention|"Interventions will be the drugs:~pilocarpine - 0.5%~brimonidine - 0.2%~One drop of each of the study drugs will be placed in the non-dominant eye and patient will be evaluated for adverse events. At hour 1 and 3 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured and patient will be evaluated for adverse events. At hour 6 vision will be measured for distance at 20 ft and reading at 14 inches; pupil size will be measured; patient will be evaluated for adverse events; and quality of life/satisfaction survey (NEI RQL-42) will be given to patient."
3476781|NCT03825068|Active Comparator|ESP block group|patients receive ESP Bock with local anaesthetics
3476782|NCT03825068|Placebo Comparator|control group|general anaestesia
3476783|NCT03825029|Experimental|Pillow Group|There will be a pillow placed between the patients legs during their operation.
3476784|NCT03825029|No Intervention|Control Group|They will receive a normal total hip arthroplasty.
3476785|NCT03824873|Active Comparator|internal iliac artery ligation + cesarean hysterectomy|
3476786|NCT03824873|Active Comparator|cesarean hysterectomy|
3476787|NCT03824665|Active Comparator|Nalbuphine Group|Nalbuphine Group (Nalbuphine) 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 4mg nalbuphine
3476788|NCT03824665|Active Comparator|Fentanyl Group|Fentanyl Group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml saline containing 20 μg fentanyl
3476789|NCT03824665|Active Comparator|Control group|Control group 8 ml of LAM which consisted of: 6 ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, plus 1 ml normal saline
3476790|NCT03824678|Experimental|Administration of CC-220|All subjects will receive one 1-mg CC-220 capsule administered orally with approximately 240 mL of non-carbonated, room temperature water, and administered by trained clinical staff.
3476791|NCT03824938|Experimental|Aspirin|Aspirin 650 mg capsule by mouth, single dose
3476792|NCT03824938|Active Comparator|Acetaminophen|Acetaminophen 650 mg capsule by mouth, single dose
3476793|NCT03824938|Placebo Comparator|Placebo|Placebo 650 mg capsule by mouth, single dose
3476794|NCT03825016|Experimental|Lidocaine|Lidocaine Hydrochloride
3476795|NCT03825016|Experimental|Diclofenac|Oral Diclofenac
3476796|NCT03825055||Young patients with MS|young adults (i.e., 18-45 years) newly diagnosed with MS (Case-Only)
3476797|NCT03824639|Experimental|Exercise group|Structured exercise
3476798|NCT03824639|Active Comparator|Control group|Health education
3476799|NCT03824652|Experimental|Usual Diet + Walnuts|Usual diet with the addition of two ounces of walnuts daily, phone counseling with dietitian, for 4-10 weeks
3476800|NCT03824652|Active Comparator|Usual Diet|Usual diet for 4-10 weeks
3476801|NCT03824717|Other|Ropivacaine dosage|Dose finding study - The volume of 0.5% ropivacaine used to achieve surgical anesthesia in infraclavicular brachial plexus block
3476802|NCT03824756|Experimental|NGO supported GMP program|Intervention: NGO supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
3476803|NCT03824756|Active Comparator|Non-supported GMP program|Comparison: Non-supported GMP program Site: Community clinic Duration: 12 months Study participants: 6-12 months aged children living within community clinic catchment area
3476804|NCT03824834|Experimental|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) with supervised exercise training.
3476805|NCT03824834|Placebo Comparator|Exercise training with placebo|Placebo treatment with supervised exercise training.
3476806|NCT03824795|Active Comparator|Group 1: 125mg b.i.d. for 10 days|Patients will be administered an oral dose of 125mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
3476807|NCT03824795|Active Comparator|Group 2: 250mg b.i.d. for 10 days|Patients will be administered an oral dose of 250mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
3476808|NCT03824795|Active Comparator|Group 3: 500mg b.i.d. for 10 days|Patients will be administered an oral dose of 500mg b.i.d. MGB-BP-3 for 10 days (Day 1 to Day 10).
3476809|NCT03824691|Experimental|Cabozantinib + Durvalumab|Subjects will receive 1500 mg durvalumab (MEDI4736) IV infusion every 28 days + Cabozantinib 40 mg orally once daily
3126641|NCT03045887|Experimental|Part A Cohort 1: GSK 50 µg-GSK 200 µg-GSK 1000 µg|Subjects will receive an inhaled single dose of GSK2292767 50 µg in Period 1, GSK2292767 200 µg in Period 2, and GSK2292767 1000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3126642|NCT03045887|Experimental|Part A Cohort 2: Placebo-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of placebo in Period 1, GSK2292767 500 µg in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3476810|NCT03824613||Endometrial cancer patients|
3476811|NCT03824613||Control group|Patients without cancer
3476812|NCT03824626||TEVAR patients|patients scheduled for thoracic endovascular aortic repair
3476813|NCT03824418||Chromoendoscopy follow-up|
3476814|NCT03824418||Autofluorescence follow-up|
3476815|NCT03824288|Active Comparator|The landmark technique|PTA a needle aspiration attempted according to the landmark technique is conducted. If the initial aspiration is unsuccessful, two additional attempts are made in the middle and lower pole of the tonsil.
3476816|NCT03824288|Experimental|Ultrasound-guided aspiration|An intraoral ultrasound is conducted with a Burr-Hole N11C5s transducer (BK Ultrasound) and if an abscess cavity is suspected, an ultrasound-guided aspiration is performed with an in-plane needle guide attached to guide the needle.
3476817|NCT03824431||patients with endoscopic microerosions|"==Patients with typical symptoms of Gastroesophageal Reflux Disease(GERD):~1- High resolution definition with NBI endoscopic findings of mucosal microerosions in distal esophagus .~."
3126643|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-Placebo- GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, placebo in Period 2, and GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3476818|NCT03824431||patients without microerosions|2- High resolution definition with NBI endoscopic without findings of mucosal microerosions in distal esophagus .
3179392|NCT00672334|Experimental|1|The active intervention is loading (05. mmol/kg) pre-surgery and continuous infusion of bicarbonate at 0.2 mmol/kg/hr for 24 hours after induction
3476819|NCT03824444|Experimental|Treatment|Implant and followup
3476820|NCT03824275|Experimental|18F- DCFPyL PET/CT|Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
3476821|NCT03824262|Experimental|Group I|HICO-VARIOTHERM 550 and Mistral-Air Plus forced-air warming device
3476822|NCT03824262|Active Comparator|Group II|Mistral-Air Plus forced-air warming device
3476823|NCT03824483|Experimental|BOVEN regimen|"Patients will be given zanubrutinib (160mg by mouth BID) and obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter). Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter."
3476824|NCT03824379|Experimental|Magnesium arm|30 patients will receive the standard therapy (anti-diabetic ) + magnesium supplement
3476825|NCT03824379|Active Comparator|Control|30 patients will receive the standard therapy (anti-diabetic)
3476826|NCT03824535|Experimental|Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)|Patients receive 18F-FSPG IV and, undergo a PET/CT scan over 30-60 minutes. Within 24 hours-14 days, patients receive 18F-FDG IV and undergo a second PET/CT scan over 30-60 minutes.
3476827|NCT03824561||Vedolizumab 300 mg|Vedolizumab IV infusion 300 mg, at Weeks 0, 2 and 6, and every 8 weeks thereafter, for up to 54 weeks. Participants will receive IV infusion as part of routine medical care.
3476828|NCT03824327|Experimental|Treatment (BOLD fMRI, papaverine hydrochloride, SBRT)|Patients undergo BOLD fMRI and receive papaverine hydrochloride IV on day 1. Within 30-90 minutes, patients undergo a second BOLD fMRI. Patients then receive papaverine hydrochloride IV and within 30-90 minutes after dose undergo SBRT for a up to 4-5 sessions over 2 weeks.
3476829|NCT03824171|Experimental|Raloxifene 60mg/Cholecalciferol 800IU to AD-102|Period 1: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
3476830|NCT03824171|Experimental|AD-102 to Raloxifene 60mg/Cholecalciferol 800IU|Period 1: Raloxifene 45mg/Cholecalciferol 800IU, 2 tab, QD, Per oral Period 2: Raloxifene 60mg/Cholecalciferol 800IU, 2 tab, QD, Per oral
3476831|NCT03824457|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours). The period of the treatment with the study drug lasts 3 days.
3476832|NCT03824457|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
3476833|NCT03824587|Experimental|Tenapanor 30 mg BID|"During the Double-Blind Treatment Period, subjects will receive tenapanor starting at a dose of 30 mg bid (three 10 mg tablets each time).~Investigators may decrease or increase the dose of study medication based on s-P levels and/or gastrointestinal (GI) tolerability in 10 mg increments to a minimum of 10 mg bid or a maximum of 30 mg bid at any time during the Double-Blind Treatment Period."
3476834|NCT03824587|Placebo Comparator|Placebo|same size, weight and appearance of experimental drug
3476835|NCT03824106|Experimental|Arm1.Socialization|Participants will attend twice-weekly classes (one-hour each) at the YMCA led by an experienced instructor and volunteers who will help facilitate social interactions. Sessions will include structured social activities (such as icebreakers and cards) and guest speakers with topics relevant to seniors. Light refreshments will be served at each session.
3476836|NCT03824106|Experimental|Arm2.Group Exercise|"Participants will attend the exercise program, twice-weekly, classes at one of three YMCA sites in Hamilton/Brantford/Burlington for 6-months. In the first 15-minutes, participants will check-in and report any injuries/concerns. The exercise component will be an hour followed by time allotted for participants to socialize.~Supplemental Home Exercise: In accordance with recent guidelines to achieve 3 hours/week for fall prevention practice in older adults."
3476837|NCT03824106|Experimental|Arm3.Multi-modal Intervention|"Group Exercise/Supplemental Home Exercise: This will be delivered identically to Arm 2. However, participants in each arm of the trial will attend separate exercise classes at the YMCA to avoid possible contamination.~Protein Supplementation: the protein supplement (each serving) contains 350 kcal, 20-gram protein, 1.5 g β-Hydroxy β-Methylbutyrate (HMB), and participants are advised to take this with a meal or within 3 hours of exercise on activity days."
3476838|NCT03824184|Active Comparator|manipulation of endometrium|Manipulation of endometrium with saline
3476839|NCT03824184|No Intervention|control group|Control group : No intervention
3126644|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-Placebo|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2 and placebo in Period 3. There will be a washout of approximately 4 weeks between doses.
3476840|NCT03824314|Experimental|Group M|. Group M (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg) ) intrathecally
3476841|NCT03824314|Experimental|group F|"group F (n = 40) receive 2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg) intrathecally.~Under all aseptic precautions, spinal anaesthesia will be given in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position"
3476842|NCT03824119|Active Comparator|Standard Postpartum Care|Subjects will receive NSAIDs (e.g. ibuprofen, ketorolac) for routine postpartum pain management.
3476843|NCT03824119|Active Comparator|Standard Postpartum Care without NSAIDs|Subjects will receive standard postpartum care without NSAID administration for pain management. Acetaminophen or narcotics will be substituted for ibuprofen as indicated by provider.
3476844|NCT03824301|Active Comparator|Volume-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with volume-controlled ventilation
3476845|NCT03824301|Active Comparator|Pressure-controlled ventilation|During cardiopulmonary bypass period the patients were ventilated with pressure-controlled ventilation
3476846|NCT03824301|No Intervention|No ventilation|During cardiopulmonary bypass period the patients were disconnected from ventilator
3126645|NCT03045887|Experimental|Part A Cohort 2: GSK 100 µg-GSK 500 µg-GSK 2000 µg|Subjects will receive an inhaled single dose of GSK2292767 100 µg in Period 1, GSK2292767 500 µg in Period 2, GSK2292767 2000 µg in Period 3. There will be a washout of approximately 4 weeks between doses.
3126646|NCT03045887|Experimental|Part B: GSK|Subjects will receive inhaled repeat dose of GSK2292767 2000 µg once daily for 14 days.
3126647|NCT03045887|Experimental|Part B: Placebo|Subjects will receive inhaled repeat dose of placebo once daily for 14 days.
3126648|NCT03045926|Experimental|Diosmectite (Smecta®)|5 weeks of diosmectite 3g, 3 times daily.
3126649|NCT03046056|Experimental|Filgotinib 200 mg|Filgotinib 200 mg tablet + placebo to match (PTM) filgotinib 100 mg tablet for up to 27 weeks.
3126650|NCT03046056|Experimental|Filgotinib 100 mg|Filgotinib 100 mg tablet + PTM filgotinib 200 mg tablet for up to 26.3 weeks.
3126651|NCT03046056|Placebo Comparator|Placebo|PTM filgotinib 200 mg tablet + PTM filgotinib 100 mg tablet for up to 28.7 weeks.
3126652|NCT03046212|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (exercises).
3126653|NCT03046212|Active Comparator|Physical therapy|This group received only conventional physical therapy (exercises).
3179393|NCT00672347|Active Comparator|B|compare caudal anesthesia with bupivacaine alone or in addition to morphine, clonidine or both
3476847|NCT03824145|Experimental|Immediate Intervention|"The experimental arm will receive a 12-week lifestyle intervention that promotes nutritional and physical activity changes concordant with those contained in the ACS nutrition and physical activity guidelines for cancer survivors. The 12-week intervention includes:~1) a curriculum binder covering 12-weekly topics and including self-monitoring tools to support adherence; 2) lifestyle coaching for 12-weeks, with four in-person supervised exercise sessions and eight telephone-based sessions; 3) exercise supplies (Fitbit, resistance bands), 4) twice weekly text messaging targeting self-efficacy and social support; and 5) attendance to three cooking classes emphasizing plant-based eating."
3476848|NCT03824145|No Intervention|Wait List Control|The Wait List Control group receives no intervention for 12-weeks. Following the 12-week waitlist period, the wait list control group participants receive the experimental intervention.
3476849|NCT03824392|Experimental|Cohort 1|ATYR1923 1.0 mg/kg or placebo
3476850|NCT03824392|Experimental|Cohort 2|ATYR1923 3.0 mg/kg or placebo
3476851|NCT03824392|Experimental|Cohort 3|ATYR1923 5.0 mg/kg or placebo
3476852|NCT03824509||Patients with an echocardiagram who suffered a stroke or TIA|"Medical record number~Sex~Age~BMI~Body surface area~Smoking status~Congestive heart failure~Hypertension~Diabetes,~Previous history of heart attack or vascular disease~Previous history of stroke~Date of stroke~Type of stroke~CHA2DS2-VASc scores~On an anticoagulant yes/no at time of stroke~Date of atrial fibrillation diagnosis~Date of echocardiogram~Echocardiographic features:~a. Left atrial volume, indexed to body surface area (BSA) b. Left ventricular hypertrophy 4. Stroke outcome:~Mortality~NIH Stroke Scale~Modified Rankin Scale~Discharge placement:~i. Home ii. Long term care iii. Skilled nursing facility e. 6-month survival"
3476853|NCT03824509||Control Group - matched CHA2DS2-VASc score, age, and gender|"Controls from both PBMC and MMC will be obtained. Controls are patients from 2014-2017 with matched age (+/- 5 years), gender, and CHA2DS2-VASc score who had atrial fibrillation and had not had a documented stroke or TIA in EPIC or the Get with the Guidelines registry maintained at PBMC. Controls must have an echocardiogram on record and have a diagnosis of atrial fibrillation at the time of the echocardiogram."
3476854|NCT03824132|Experimental|Intervention Group|
3476855|NCT03824132|Active Comparator|Waitlist Control Group|
3476856|NCT03824574|Experimental|Treatment arm|Subjects receiving the clear mandibular advancement appliance
3126654|NCT03046225|Experimental|Electrical stimulation|This group received application of transcutaneous electrical nerve stimulation (TENS) associated with conventional physical therapy (continuous passive movement device and exercises).
3126655|NCT03046225|Active Comparator|Physical therapy|This group received only conventional physical therapy (continuous passive movement device and exercises).
3126656|NCT03046446|Experimental|FX006 32 mg|Single intra-articular injection
3476857|NCT03824366|Experimental|Volumetric MR imaging planning|"All patients will undergo volumetric MR imaging on treatment days in positioning appropriate for the specific treatment site.~Patients will receive standard of care palliative radiation therapy"
3476858|NCT03824353|Experimental|Social Intelligence Training|The social intelligence training is delivered online to individuals in midlife (ages 40 and older). This is the sole active treatment condition within this RCT.
3476859|NCT03824353|Placebo Comparator|Attention Control|The attention control condition, known as The Healthy Living program provides information about different aspects of health.
3179394|NCT00672347|Active Comparator|C|compare caudal anesthesia with bupivacaine plus clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or morphine plus clonidine
3179395|NCT00672347|Active Comparator|M|compare caudal anesthesia with bupivacaine plus morphine with caudal anesthesia with bupivacaine alone or in addition to clonidine or morphine plus clonidine
3476860|NCT03824067|Active Comparator|Standard of Care Early Infant Diagnosis|Conventional laboratory based (standard of care - SOC) early infant diagnosis (EID) testing: SOC EID
3476861|NCT03824067|Experimental|Point of Care Early Infant Diagnosis|The intervention is Point of Care (POC) early infant diagnosis (EID) testing, where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
3476862|NCT03824496||Suspected acute stroke|"Any patient with suspected acute stroke triggering a stroke code and had a brain imaging angiogram"
3476863|NCT03824093|Active Comparator|AFIX Only|Practices enrolled in the AFIX only arm will receive an in-person AFIX consultation that includes assessment of current HPV vaccination rates and feedback on strategies to increase vaccination rates.
3476864|NCT03824093|Active Comparator|AFIX+ Provider Communication Training|Practices enrolled in the AFIX+ Provider Training arm will receive an in-person AFIX consultation along with a brief communication training for providers and poster and brochure displays in clinic waiting and exam rooms.
3476865|NCT03824249|Experimental|Spontaneous breathing|Performance of indirect calorimetry in spontaneously breathing children through the use of indirect calorimetry.
3476866|NCT03824249|Experimental|NIV-CPAP|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 centimeters of water (cmH2O). CPAP will be applied via single-limb circuit with intentional leak.
3476867|NCT03824249|Experimental|NIV-PS|Performance of indirect calorimetry in children undergoing Non-invasive continuous positive airway pressure (CPAP) of 4 cmH2O and Pressure support (PS) of 8 cmH2O. Non-invasive ventilation will be applied via single-limb circuit with intentional leak.
3476868|NCT03824054||colorectal resection arm|Patients affected by symptomatic deep infiltrating endometriosis involving the bowel and submitted to colo-rectal resection
3476869|NCT03824197|Other|EVOO-phenol high|Extra-virgin olive oil rich with oleocanthal and other phenolic compounds that will be added to daily diet
3476870|NCT03824197|Other|OO-phenol low|Olive oil with low phenolic content that will be added to daily diet
3476871|NCT03824405|Active Comparator|BTX 1204|BTX 1204 twice daily
3476872|NCT03824405|Placebo Comparator|Vehicle|Vehicle twice daily
3476873|NCT03824340|Active Comparator|Doxycycline before ICSI|extra medications (Doxycycline ) group before ICSI : in which Women who will receive the Doxyxycline before ICSI Intervention : Women will receive Doxycycline before ICSI
3476874|NCT03824340|No Intervention|control group|control group : No intervention : in which Women willnot receive the extra medications (Doxycycline ) before ICSI
3476875|NCT03824158|Active Comparator|Facilitated advance care planning (in-person or telephonic)|Patients randomized to this arm will participate in in-person or telephonic facilitated advance care planning (ACP) discussions using the Respecting Choices model.
3476876|NCT03824158|Active Comparator|Web-based advance care planning|Patients randomized to this arm will participate in web-based ACP via the PREPARE website.
3476877|NCT03824002|Experimental|patients treated with dulaglutide|Diabetes therapy with dulaglutide and various combinations of aspart insulin, glargine, metformin, repaglinide
3476878|NCT03824002|Active Comparator|patients not treated with dulaglutide|Diabetes therapy with various combinations of aspart insulin, glargine, metformin, repaglinide but without dulaglutide
3476879|NCT03824210||Stage 1|School children age 11-18 (from two nominated schools) and young carers 11-18
3476880|NCT03824210||Stage 2|Young carers from Young Carers in Herts 11-18
3476881|NCT03824028||Clareon IOL AutonoMe|Prior implantation with Clareon intraocular lenses (IOLs) using the Clareon® IOL AutonoMe™ automated preloaded delivery system
3476882|NCT03824015|Experimental|KAPA intervention arm|KAPA participants who completed the 24-week commissioned Falls Management Exercise program received six sessions of motivational interviewing over a six-month period. KAPA intervention sessions were held in accessible, community venues located within the local authorities of Derby City, Leicestershire and Rutland Counties. The KAPA intervention was delivered face-to-face by Postural Stability Instructors, in a group setting, using motivational interviewing. Sessions lasted between 60 to 90 minutes. Postural Stability Instructors delivered KAPA intervention sessions by telephone if a participant did not, or was unable to, attend a face-to-face session.
3476883|NCT03824015|Other|Usual care|The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package.
3476884|NCT03824041|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
3476885|NCT03824041|Experimental|Aronia full spectrum - half dose|Formulation containing 50% Aronia full spectrum and 50% placebo, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
3476886|NCT03824041|Experimental|Aronia full spectrum - full dose|Formulation of 100% Aronia full spectrum, two capsules once a day, in a 500 mg capsule regimen (total intake 1000 mg)
3476887|NCT03823911|Active Comparator|HIV Mono-Infected|Patients infected with HIV only, and not currently or previously infected with hepatitis C.
3476888|NCT03823911|Experimental|Hepatitis C Mono-Infected|Patients infected with Hepatitis C and have no evidence of active HIV or hepatitis B infection
3476889|NCT03823911|Experimental|HIV and Hepatitis C Co-Infected|Patients co-infected with HIV and hepatitis C, and have no evidence of active hepatitis B infection.
3476890|NCT03823846|Experimental|Experimental Group|Patients in the experimental group were received doctor-nurse-patient cooperative analgesic linkage program.
3476891|NCT03823846|Active Comparator|control group|Patients in the control group were received routine analgesic and functional rehabilitation.
3476892|NCT03823677|No Intervention|control group 15|"Protein expression and emotional test~15 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
3476893|NCT03823677|No Intervention|control group 30|"30 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
3476894|NCT03823677|No Intervention|control group 60|"60 minutes normoxia~Interventions:~Blood drawing 1 Minute before and 1 Minute after the pressure chamber Phase for Proteomic profiling with 2D-gels~Emotional tests (tears, stroop, mood) during the pressure chamber phase"
3476895|NCT03823677|Experimental|hypoxia 5000ft group 15|Intervention: 15 minutes hypoxia
3476896|NCT03823677|Experimental|hypoxia 5000ft group 30|Intervention: 30 minutes hypoxia
3476897|NCT03823677|Experimental|hypoxia 5000ft group 60|Intervention: 60 minutes hypoxia
3476898|NCT03823677|Experimental|hypoxia 8000ft group 15|Intervention: 15 minutes hypoxia
3476899|NCT03823677|Experimental|hypoxia 8000ft group 30|Intervention: 30 minutes hypoxia
3476900|NCT03823677|Experimental|hypoxia 8000ft group 60|Intervention: 60 minutes hypoxia
3476901|NCT03823677|Experimental|hypoxia 10000ft group 15|Intervention: 15 minutes hypoxia
3476902|NCT03823677|Experimental|hypoxia 10000ft group 30|Intervention: 30 minutes hypoxia
3476903|NCT03823677|Experimental|hypoxia 10000ft group 60|Intervention: 60 minutes hypoxia
3126657|NCT03046472|Experimental|Once a month and once a week.|"Personally meeting once a month of Physical Therapy treatment for Postural Behavior.~In addition exercise group meeting once a week. The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. The Participants in this group will get also a group exercise meeting once a week That meeting will long 45 minutes and will include the exercise that were given as home work and more.~Total duration 12 weeks/3 months"
3476904|NCT03823677|Experimental|hypoxia 15000ft group 15|Intervention: 15 minutes hypoxia
3476905|NCT03823677|Experimental|hypoxia 15000ft group 30|Intervention: 30 minutes hypoxia
3476906|NCT03823677|Experimental|hypoxia 15000ft group 60|Intervention: 60 minutes hypoxia
3476907|NCT03823703|Experimental|Miricorilant- 900 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 900 mg miricorilant once daily for 12 weeks.
3476908|NCT03823703|Experimental|Miricorilant- 600 mg|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive 600 mg miricorilant plus placebo once daily for 12 weeks.
3476909|NCT03823703|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-860 will be randomized to receive placebo once daily for 12 weeks.
3476910|NCT03823872|Experimental|Overweight|Participants with BMI 25-29.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
3476911|NCT03823872|Experimental|Obese|Participants with BMI 29.9-34.9 kg/m2 undergo structured exercise for weight loss. They are randomized to the following interventions: 1) time restricted feeding = only eat between 12pm-8pm or 2) normal feeding= eat on normal schedule.
3126658|NCT03046472|Active Comparator|Once a month only.|"Personally meeting once a month only for Physical Therapy treatment for Postural Behavior.~The intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day. Total duration 12 weeks/3 months"
3476912|NCT03823807|Experimental|SH-1028|QD,Oral
3476913|NCT03823651|Experimental|Patient|These are patients undergoing hematopoetic stem cell transplant. Patients will complete Interval training, undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
3476914|NCT03823651|Experimental|Caregiver|These are the assigned caregivers for transplant patients. Caregivers will undergo psychiatric consult, nutrition/diet evaluation and referral to social worker.
3476915|NCT03823768|Active Comparator|Arm 1: Control|Tacrolimus immediate release twice daily for 6 months
3476916|NCT03823768|Experimental|Arm 2: Intervention|Envarsus daily for 6 months.
3476917|NCT03823820||Cesarean section|Women attending for elective CS.
3476918|NCT03823820||Induction of labour|Women admitted for induction of labour and expected to stayed in hospital for more than 24 hours.
3476919|NCT03823820||pregnancy complication group|"Maternal condition that could affect body fluid including:~Pre-eclampsia requiring hospital admission.~Hyperemesis gravidarum.~Major postpartum haemorrhage."
3476920|NCT03823820||control|Gestational age matched controls.
3476921|NCT03823963|Other|Standard care|pressure ulcer prevention standard care
3476922|NCT03823963|Experimental|standard care + Mepilex® Border|pressure ulcer prevention standard care + Mepilex® Border applied on sacrum
3476923|NCT03823898|Experimental|Supervised exercise|"Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants were involved in two supervised exercise sessions per week plus healthy lifestyle interactive sessions.~The experimental intervention consisted of: a) monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study; b) The supervised exercise sessions were prescribed using an aerobic mode performed at a moderate-to-vigorous intensity during 45 minutes, twice a week, preferably during the weekends."
3476924|NCT03823898|Active Comparator|Control Group|Participants in this group received a lifestyle intervention from baseline to 4 months. From 4 to 16 months participants received no intervention
3476925|NCT03823898|Experimental|Monthly behavioral sessions|"Participants in this group received a lifestyle intervention from baseline to 4 months and then from 4 to 16 months participants were involved in non-supervised exercise group sessions with monthly behavioral sessions.~The experimental intervention consisted of monthly behavioral sessions consisted of lifestyle interactive sessions took place monthly and covered and followed contents that were addressed during the first 4 months of the study"
3476926|NCT03823794||Prevalent case of atopic dermatitis|People with atopic dermatitis meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
3476927|NCT03823794||Controls|Age, gender and primary care practice-matched controls without a diagnosis of atopic dermatitis or another exclusion condition (psoriasis, photodermatitis, or ichthyosis) and registered with one of the study practices for one or more years during the study period.
3476928|NCT03823989|Experimental|Promitil 1.25 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.25 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
3476929|NCT03823989|Experimental|Promitil 1.5 mg/kg|Two treatment cycles, intravenous infusion of Promitil at a dosage of 1.5 mg/kg delivered at 21 days interval and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
3476930|NCT03823989|Experimental|Promitil 1.8 mg/kg|two treatment cycles, intravenous infusion of Promitil at a dosage of 1.8 mg/kg delivered at 21 days interval (confirmatory cohort) and a 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
3476931|NCT03823690|Active Comparator|EUS-guided gastrojejunostomy|"The procedures would be performed under conscious sedation or monitored anesthesia by a therapeutic gastroscope. The endoscope would be used to reach the site of obstruction. The stricture would be cannulated with a 0.025 or 0.035 guide-wire. The double balloon occluder would then be inserted on guidewire beyond the duodenal-jejunal flexure and the two balloons of the occluder would be inflated.~A segment of duodenum/jejunum would then be occluded and saline would be injected. A linear echoendoscope would then be inserted into the stomach to guide insertion of the gastrojejunostomy stent."
3476932|NCT03823690|Active Comparator|Pyloro-duodenal stent|The uncovered DS used in this study is Wallflex (Boston, Natick, MA, USA), made of nitinol wire, with a diameter of 22mm and length of 6, 9, 12cm. This stent is a braided stent with high axial force, good flexibility and conformability.
3476933|NCT03823729|Experimental|Elosan Cabin|Treatment with Elosan cabin
3476934|NCT03823729|No Intervention|No Treatment|Continuation of taking pain medication as prescribed before study start.
3476935|NCT03823495|Experimental|Experimental group|12-week PAP (one 1-hour session per week). Each session includes 20-minute exercise, 30-minute interactive pain management education, practices on non-drug management techniques, and portfolio entry for activities of the day.
3476936|NCT03823495|No Intervention|Control group|The control group will receive the usual care and a pain management pamphlet distributed by nursing home staff
3126659|NCT03046966|Other|Intervention Control: No Training|Does not receive hands-on intubation training in the Simulation Lab.
3126660|NCT03046966|Other|Intervention: Receives Training|Receives hands-on intubation training in the Simulation Lab.
3179396|NCT00672347|Active Comparator|CM|compares caudal anesthesia with bupivacaine, morphine and clonidine with caudal anesthesia with bupivacaine alone or in addition to morphine or clonidine
3179397|NCT00672360|Experimental|1|
3476937|NCT03823664||Type 2 Diabetic|"Fasting Plasma Glucose ≥126 mg/dL (7.0 mmol/L). OR * A1C ≥6.5% (48 mmol/mol). OR * Patients with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).OR* 2-h Plasma Glucose ≥200 mg/dL (11.1 mmol/L) during oral glucose tolerance test*~* American Diabetes As. (ADA) type 2 diabetes diagnosis criteria"
3126661|NCT03047174|Experimental|Arm A: Treatment with Mepitel® Film|"Arm A:~Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing."
3126662|NCT03047174|Active Comparator|Arm B: Treatment with Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily.~Mometasone furoate cream is used in the treatment of inflammatory skin disorders. In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone. It reduces inflammation by causing several effects such as reversing the activation of inflammatory proteins, activating the secretion of anti-inflammatory proteins, stabilizing cell membranes, and decreasing the influx of inflammatory cells. The exact anti-inflammatory mechanism of action is unknown."
3476938|NCT03823664||Prediabetic|"Fasting Plasma Glucose 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (Impaired Fasting Glucose)* OR A1C 5.7-6.4% (39-47 mmol/mol)* OR 2-h Plasma Glucose during 75-g Oral Glucose Tolerance Test 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (Impaired Glucose Tolerance)*~* ADA prediabetes criteria"
3476939|NCT03823664||Healthy|Healthy glucose metabolism and according to endocrinology visit no health problems related or affect cardiorespiratory fitness and other parameters examined in this study.
3476940|NCT03823508|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (left dorsolateral prefrontal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
3476941|NCT03823508|Placebo Comparator|sham tDCS|Patients will receive sham tDCS (15 secondes of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (256 channels EEG).
3476942|NCT03823950|Experimental|Receive G-CSF 72 hours following chemotherapy|"Children will be enrolled during the first four rounds of chemotherapy. Upon enrollment, children will receive G-CSF at 24 hours following chemotherapy. G-CSF will be discontinued when absolute neutrophil count (ANC) has increased post nadir in accord with G-CSF administration guidelines. Parents and children will then complete questionnaires to determine rates of side effects and needle distress at the end of G-CSF during their next regular outpatient oncology clinic visit.~Following children's next course of chemotherapy, G-CSF will be started 72 hours after completion of chemotherapy."
3476943|NCT03823950|No Intervention|Historical Controls|Four matched historical controls who received G-CSF at 24 hours following chemotherapy for each patient enrolled will be selected as each enrolled patient completes G-CSF therapy.
3476944|NCT03823599|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
3476945|NCT03823599|Active Comparator|control group|Alcohol brief intervention
3476946|NCT03823612|Experimental|GC tooth mousse|Drug: GC tooth mousse it contains complex of Casein Phosphopeptide,Amorphous Calcium Phosphate ( CPP-ACP ) other name: Tooth Mousse (Bio-available calcium and phosphate, without fluoride)
3476947|NCT03823612|Active Comparator|clinpro tooth creme|"it contains 0.21% Sodium Fluoride, Anti-Cavity Paste is an advanced formula containing an innovative tri-calcium phosphate ingredient~other name:0.21% w/w Sodium Fluoride Anti-Cavity Paste with Tri-Calcium Phosphate"
3476948|NCT03823638|Experimental|D-Mannitol|Oral Supplement of the investigated substance: D-Mannitol powder (manufacturer Roquette)
3476949|NCT03823638|Placebo Comparator|Placebo|Oral Supplement of the placebo: Dextrose monohydrate powder (manufacturer Roquette)
3179398|NCT00672360|Placebo Comparator|2|
3179399|NCT00672373|Experimental|A|Active treatment with EGb-761 capsules (80mg each capsule), 3 capsules each day for 12 weeks
3476950|NCT03823352|Experimental|Antroquinonol|Patients will receive Antroquinonol 200 mg BID on Day 1 for 4 weeks or until transfusion of red blood cell or platelet ≧ 2, unacceptable toxicity, non-compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
3476951|NCT03823586||Children|
3476952|NCT03823586||Adolescents|
3179400|NCT00672373|Placebo Comparator|B|Matching placebo treatment
3476953|NCT03823313|Experimental|Spiritual Care Assessment and Intervention|
3476954|NCT03823560|Experimental|GROUP A: medical device Celegyn®|"Medical device Celegyn® presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
3476955|NCT03823560|Placebo Comparator|GROUP B: matching placebo|"Investigational Product (IP) placebo presents itself as a white ivory cream (cream-like oil-in-water topical emulsion) with a typical smell; it is intended for topical use.~Posology: It is to be applied preferably in the evening, once a day, for the first seven days, and every other day until the end of the study (i.e. during the second and third week) according to the following:~for external (vulvar) use: it should be applied as needed directly to the affected area with a gentle massage;~for internal (vaginal) use: use the vaginal applicators provided and follow the directions of use, according to package insert"
3476956|NCT03823924||Psoriatic arthritis|
3476957|NCT03823924||Healthy volunteers|
3476958|NCT03823625|Experimental|ARM A: Nivolumab plus Ipilimumab|Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months. Platinum-based chemotherapy will be given up to 6 cycles.
3476959|NCT03823625|Experimental|ARM B: Platinum-based chemotherapy plus Nivolumab|Platinum-based chemotherapy will be given up to 6 cycles. Immunotherapy will be given up to disease progression, toxicity or patient refusal and in any case for up to 24 months.
3476960|NCT03823781|Experimental|milrinone|milrinone milrinone will be administered intravenously at a rate of 0.75ug/kg/min for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
3476961|NCT03823781|Placebo Comparator|normal saline|placebo placebo (normal saline) will be administered intravenously for 35 hours, and baseline catecholamines will be administered at the discretion of the physician.
3476962|NCT03823859||Healthy volunteers|"Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
3476963|NCT03823859||Patients with thyroid dysfunction|"Patients with Primary hypothyroidism newly diagnosed, Primary hypothyroidism substituted, hyperthyroidism, secondary hypothyroidism~Blood sampling (fT3, fT4, TSH, Lipids, Glucose, HbA1c)~Indirect calorimetry~Dual energy X-ray Absorptiometry (DXA)"
3476964|NCT03823339||Patients with type 2 diabetes (T2DM)|Patients with T2DM treated with any basal insulin or glucagon-Like peptide-1 receptor agonist (GLP-1 RA) (including once weekly GLP-1 RA) with/without oral antidiabetic drug (OAD) treatment, and with inadequate glycaemic control, for whom the physician had decided to intensify their treatment with Xultophy®
3476965|NCT03823417|Placebo Comparator|Normal saline placebo|the participant will get saline 0.9% intravenous infusion for the duration of the surgery
3476966|NCT03823417|Experimental|Intravenous Tranexamic acid|Intravenous TXA will be given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
3476967|NCT03823573|Experimental|Rapid recovery protocol|They will start walking the day of surgery. Levobupivacain 5mg/ml will be placed in the knee tissues. Tranexamic acid inside the knee. No drains.
3476968|NCT03823573|Active Comparator|Classic protocol|They will start walking 3 days after surgery. Levobupivacain 5 mg/ml will be placed in the femoral nerve. Tranexamic acid inside the knee. A Redon drain will be used.
3476969|NCT03823456|Experimental|True self-acupressure group|"True self-acupressure group [Enhanced standard care + True self-acupressure intervention protocol]:~Participants in this group will practice the four-week acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly phone call follow up from researchers."
3476970|NCT03823456|Placebo Comparator|Sham self-acupressure group|Patients in this group will practice the four weeks sham self-acupressure protocol plus standard care. When participants admit hospital to receive chemotherapy treatment, they will receive a self-acupressure training section. Participants will be requested to practice sham acupressure at home once a day at night time (before going to bed) for four weeks. During the four weeks treatment, participants will receive a weekly follow up phone call from researchers
3476971|NCT03823456|No Intervention|Enhanced standard care group|The standard care for cancer patients undergoing chemotherapy includes health assessment, regular health advice regarding symptoms that patients report and nutrition advice during taking chemotherapy treatment. Apart from the standard care, we provide participants a leaflet with 10 recommendations which help participants manage insomnia, depression, and anxiety. By providing this leaflet, we slightly enhance the standard care but do not contaminate the effective of the intervention since these tips are basic and participants can easily read about them on the internet or newspaper. In addition, to minimize the bias caused by contacting between interventionist and participants, we also provide participants in the enhanced standard care group weekly follow up phone call in four weeks.
3476972|NCT03823079|Experimental|rhTPO arm|"rhTPO: 300 u/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
3476973|NCT03823079|Active Comparator|rhIL-11 arm|"rhIL-11: 50 ug/kg, subcutaneous injection, per day. (stopped as soon as the platelet count rises to normal)~Concurrent Chemoradiotherapy:~Radiation: judged according to the tumor site and radiotherapy purpose.~Irinotecan: 80 mg/m2 (UGT1A1*28 6/6) or 65 mg/m2 (UGT1A1*28 6/7)~Raltitrexed: 3 mg/m2 q3w"
3476974|NCT03823183|Experimental|Multi-domain training|Group that receives cognitive training and physical training
3126663|NCT03047447|Experimental|Ketogenic group|10-week diet with controlled glycemic indices provided for ketogenic group. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
3126664|NCT03047447|Active Comparator|Exercise group|Exercise group maintained normal diet for 10-weeks and exercised 3-5 days per week. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
3126665|NCT03047447|Active Comparator|Non-exercise|Non-exercise group maintained normal diet for 10-weeks with no exercise. Baseline triglyceride, HgA1c, VO2 max, body mass index (BMI), resting metabolic rate (RMR), blood ketone levels and body fat mass measurements were assessed at week 0 and week 3, 6 and 10.
3126666|NCT03047551|Active Comparator|Transabdominal Sonography|"Subjects will receive transabdominal sonography using a standard ultrasound device to determine medical abortion eligibility.~A transabdominal ultrasound is used to look at the pelvic organs. Gel is placed on your abdomen. Then a small, handheld unit called a transducer is gently moved around to view the pelvic organs. The transducer sound waves make a picture on the TV screen."
3126667|NCT03047551|Active Comparator|Transvaginal Sonography|"Subjects will receive transvaginal sonography using a standard ultrasound device to determine medical abortion eligibility.~Transvaginal ultrasound is an examination of the female pelvis and urogenital tract (kidneys and bladder). It differs from an abdominal ultrasound as it looks at the pelvic organs from inside the vagina."
3476975|NCT03823183|Experimental|Cognitive training|Group that receives cognitive training and physical control activity
3476976|NCT03823183|Experimental|Physical activity|Group that receives control cognitive activity and physical training
3476977|NCT03823183|Active Comparator|Active control|Group that receives cognitive control activity and physical control activity
3476978|NCT03823222|Experimental|Duckweed protein|20 gram of isolated protein
3476979|NCT03823222|Experimental|Whey protein|20 gram of isolated protein
3476980|NCT03823066|Experimental|Coach Pepper|Pepper is a humanoid socially assistive robot
3476981|NCT03823170|Experimental|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW (Therapy EC, DMC) will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
3476982|NCT03823170|Active Comparator|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish (Duraphat), with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
3126668|NCT03047720|Other|One: Study Phases (S1 and S2)|The therapeutic phase of this study for the participant in Arm One will be: 6 weeks of behavioral modifications plus the Lully device (S1), followed by 6 weeks of behavioral modifications only without the device (S2)
3126669|NCT03047720|Other|Two: Study Phases (S2 and S1)|The therapeutic phase of this study for the participant in Arm Two will be: 6 weeks of behavioral modifications only without the device (S2), followed by 6 weeks of behavioral modifications plus use of the Lully device(S1)
3476983|NCT03823170|Experimental|Laser therapy and fluorotherapy|The teeth will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
3476984|NCT03823157|Experimental|Tai Chi|Tai Chi exercise
3476985|NCT03823404|Experimental|COR388 80 mg bid|
3476986|NCT03823404|Experimental|COR388 40 mg bid|
3476987|NCT03823404|Placebo Comparator|Placebo bid|
3476988|NCT03823209|Experimental|Social Network Approach|"Participants will receive brief HIV counseling at baseline visit.~Leaders of social networks will be determined using data from participants. These leaders will then be invited to attend a 5-session small-group training that will teach them how to communicate the benefits of PrEP to their social network members.~All social network members will be asked about intervention exposure at 6- and 15-month followups."
3476989|NCT03823209|Active Comparator|Comparison|Participants will receive brief HIV counseling at baseline visit.
3476990|NCT03823261|Experimental|CBT|
3476991|NCT03823235|Experimental|Culture of human embryo in non-humidified incubator|Embryo culture after in vitro fertilization in incubator with no humidity
3476992|NCT03823235|No Intervention|Culture of human embryo in humidified incubator|Embryo culture after in vitro fertilization in incubator with humidity
3476993|NCT03823144|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with solid tumors during surgical resection.
3476994|NCT03823482|Experimental|Lidocaine group|Participants in lidocaine group, following induction to general anesthesia, will have lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation. Maximum dosage of lidocaine won't exceed 400 mg.
3476995|NCT03823482|No Intervention|Control group|Participants in control group will have general anesthesia without lidocaine administration.
3126670|NCT03047980|Experimental|Sirolimus|All subjects will receive the sirolimus oral solution to be taken at home twice daily and will be treated on an outpatient basis. The drug will be taken for six months.
3126671|NCT03048006||All included patients|All included patients underwent MRI with Dotarem
3179401|NCT00672386|Experimental|001|JNJ16269110 5 mg twice daily for 12 weeks
3179402|NCT00672386|Experimental|002|JNJ16269110 10 mg twice daily for 12 weeks
3476996|NCT03823053|Active Comparator|Control Group|The control group will be given home based traditional scoliosis exercise training for 8 weeks, 5 days a week for 30 minutes. The content of the physiotherapy program; posture, interscapular muscle strengthening, stretching and lateral flexion exercises are formed.
3476997|NCT03823053|Experimental|Training Group|"In addition to home based traditional scoliosis exercise, the training group will also receive core stabilization exercise training for 8 weeks, 5 days a week, for 30 minutes. Core stabilization training; exercises for 2 muscle systems that contribute to spinal stability are given. The first one is the local system muscles; multifidus, transversus abdominis, diaphragm and pelvic floor muscles. The second, the global system includes large superficial muscles, such as erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and latissimus dorsi."
3179403|NCT00672386|Experimental|003|JNJ16269110 15 mg twice daily for 12 weeks
3179404|NCT00672386|Placebo Comparator|004|Placebo twice daily for 12 weeks
3476998|NCT03823040|Active Comparator|Tinox® group|Male patients (12 to 43 years old) including 5 cases tinea pedis, 9 tinea versicolor and treated with oxiconazole nitrate cream 1%.
3476999|NCT03823040|Experimental|Oxiconazole nitrate SLNs loaded gel group|13 males and one female (17 to 50 years old) including 3 cases tinea pedis, 8 tinea versicolor, 3 tinea circinate and treated with oxiconazole nitrate SLNs loaded gel
3179405|NCT00672399|Experimental|Sequence 1|Period 1 = placebo exenatide/placebo moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
3179406|NCT00672399|Experimental|Sequence 2|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
3477000|NCT03823105|Experimental|Nocturnal Recording|Recording of photoplethysmographic pulse wave and accelerometry with two devices (OHR Tracker, PulseWatch) in parallel to the standard polysomnography
3179407|NCT00672399|Experimental|Sequence 3|Period 1 = placebo exenatide/moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/placebo moxifloxacin
3179408|NCT00672399|Experimental|Sequence 4|Period I = placebo exenatide/moxifloxacin; Period II = exenatide/placebo moxifloxacin; Period III = placebo exenatide/placebo moxifloxacin
3477001|NCT03823118|Experimental|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
3477002|NCT03823196|Experimental|Verum900|The arm will receive 900 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
3477003|NCT03823196|Experimental|Verum1800|The arm will receive 1800 mg of Sinetrol® Xpur, a blend of citrus and guarana extracts, daily for 16 weeks
3126672|NCT03048058|Experimental|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
3477004|NCT03823092||Normal|phakic participants with no evidence of eye disorders
3477005|NCT03823092||Cataract|participants with cataract
3477006|NCT03823092||AMD|participants with age related macular degeneration
3477007|NCT03823092||Pseudophakic|particpiants who have had cataract surgery with intraocular lens implant
3477008|NCT03823092||other macula|participants with macular ddisorders other than AMD
3477009|NCT03823092||DR|participants with diabetic retinopathy
3477010|NCT03823014|Experimental|External Erectile Prosthesis|Study participants will be recruited as couples (transgender man + sexual partner.) Couples will use an external erectile prosthesis (Elator) over the course of 1 month and keep track of their experiences. 20 men and their partners will be enrolled.
3477011|NCT03823248|Experimental|MoLuoDan and Sanchi powder group|Experiment group: oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day, + oral administration of Folic Acid Tablet simulation half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
3477012|NCT03823248|Active Comparator|Folic Acid Tablet group|Control group: oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day, + oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day, + oral administration of folic acid tablets half a hour after meal for 5 mg each time for 3 times a day. The medication period was 24 weeks.
3477013|NCT03822988||patients accepting to answer to the survey|patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
3179409|NCT00672399|Experimental|Sequence 5|Period I = placebo exenatide/placebo moxifloxacin; Period II = placebo exenatide/moxifloxacin; Period III = exenatide/moxifloxacin
3179410|NCT00672399|Experimental|Sequence 6|Period I = exenatide/placebo moxifloxacin; Period II = placebo exenatide/placebo moxifloxacin; Period III = placebo exenatide/moxifloxacin
3477014|NCT03822975|Experimental|Bivalirudin|Bivalirudin with prolonged full dose infusion during primary PCI
3477015|NCT03822975|Active Comparator|Heparin|Heparin alone during primary PCI
3477016|NCT03822871|Experimental|Cohort A-J|Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled.
3477017|NCT03822871|Experimental|Cohort K - at Recommended Phase 2 Dose|Cohort F: Patients with mCRPC and progressive disease on at least 1 androgen signaling inhibitor will be enrolled at the recommended phase 2 dose.
3477018|NCT03822832|Experimental|Spesolimab|i.v.
3477019|NCT03822832|Placebo Comparator|Placebo|i.v.
3477020|NCT03822910||Healthy Controls|Matched Healthy Controls
3477021|NCT03822910||Firt Episode Psychosis (FEP)|subjects before and after antipsychotic treatment
3477022|NCT03822923|Experimental|Experimental group|Neurodynamics (Dynamic Neural Mobilization) with conventional treatment (stretching, AROM) will be applied.
3477023|NCT03822923|Active Comparator|control group|Conventional treatment (stretching, AROM) will be applied
3477024|NCT03822936|Experimental|Preoperatory chemoradiation therapy with carbon ions|Chemoradiation followed by surgery
3477025|NCT03822780|Experimental|HCQ Therapy|"Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.~Assess the efficacy and safety of HCQ after 6 months treatment compared with any other routine therapy before HCQ therapy (such as inhaling oxygen, corticosteroid, anti-infection therapy, nutritional support)"
3477026|NCT03822819|Experimental|probiotic cocktail capsules uptake|Participants take two capsules of probiotic cocktail everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
3477027|NCT03822819|Placebo Comparator|placebo capsules uptake|Participants take two capsules of placebo everyday for 30 days in a double-blinded masking. Stool samples will be collected before and after capsule uptake and be analyzed for VRE number and microbiota change.
3477028|NCT03822702|No Intervention|1st part:System development of Adult|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
3477029|NCT03822702|No Intervention|1st part:System development of Child|"No intervention. Subjects need to use 6 types of special pen to do the specific writing tasks for one hour.~The same tasks will be ask to do again three days later."
3477030|NCT03822702|No Intervention|2nd part:Handwriting Difficulty|No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour with sensors on the hand. A handwriting screening questionnaire shall be filled.
3179411|NCT00672464|Active Comparator|Olanzapine only|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine
3477031|NCT03822702|Experimental|3rd part: Biofeedback Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Biofeedback Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
3477032|NCT03822702|Experimental|3rd part: Motor Training|"This program includes 1 hour pre-test, 8 times training and 1 hour post-test. For pre-test, subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~For post-test, the same procedure will be ask to do again about one and a half month later .~After pre-test, eight times of Motor Training will be asked. Each time will take 50 minutes, one or two times a week. All training will be completed in about one and a half month."
3477033|NCT03822702|No Intervention|3rd part:Control Group|"No intervention. Subjects need to do the specific writing tasks and fine motor test for one hour. A handwriting screening questionnaire shall be filled.~The same procedure will be ask to do again about one and a half month later."
3477034|NCT03823027|Experimental|Single-arm|The device will be taken before three daily main meals togteher with water. The dose will be escalated from 1g per main meal to the full dose of 3g per main meal. The device is provided in foil stick-packs packed in boxes with weekly supply. The treatment is for 12 weeks.
3477035|NCT03822962|Other|Standard Tylenol Regimen|"Patient will be given a standard regimen:~Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed."
3477036|NCT03822962|Active Comparator|Ibuprofen 600mg|Tylenol 1000 mg by mouth every 6 hours scheduled and ibuprofen 600 mg tablet by mouth every 8 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
3477037|NCT03822728|No Intervention|Without 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), the patients will undergo surgery without 3D-DESS MRI (currently routine practice).
3477038|NCT03822728|Experimental|With 3D-DESS MRI|As for deep seated tumors in preoperative CT or US (or tumors in both superficial and deep parotid glands), preoperative 3D-DESS MRI will be additionally performed to delineate the intra-parotid facial nerve.
3477039|NCT03822624|Experimental|Probiotic group|
3477040|NCT03822624|Placebo Comparator|Placebo group|
3477041|NCT03822598|Experimental|Intervention group|Teaching Recovery Techniques implemented 1- 3 weeks after recruitment
3477042|NCT03822598|Active Comparator|Wait-list control group|Delayed implementation of Teaching Recovery Techniques (after the experimental group has completed the program)
3477043|NCT03822754|Experimental|Experimental Group|sIPV-bOPV-bOPV vaccination schedule
3477044|NCT03822754|Active Comparator|Control Group|wIPV-bOPV-bOPV vaccination schedule
3477045|NCT03822715|Experimental|Dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day) + standard of care aromatase inhibitors
3477046|NCT03822806|Experimental|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise (using the videogame JustDance) for the first 30 minutes of those 2 hours using the video game (continuing to wear the patch for 90 minutes after exercise).
3477047|NCT03822676|Experimental|Stent|Prophylactic pancreatic stent before segmental pancreatic surgery
3477048|NCT03822676|No Intervention|No stent|No prophylactic stent before surgery
3126673|NCT03048058|Active Comparator|brimonidine topical gel 0.33% & SOC|Topical drug and standard of care follow-up, no weekly survey; only survey during 3 month and 6 month visits
3126674|NCT03048383|Active Comparator|OnabotulinumtoxinA Injectable Product|onabotulinumtoxinA (Botox®, Allergan) administered for n=15 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
3477049|NCT03822663|Experimental|Caffeine supplementation|Group taking oral CAF (Caffeine) supplementation in a different-dose crossover regimen.
3477050|NCT03822663|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo.
3477051|NCT03822689|Active Comparator|Gas flow:2L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
3477052|NCT03822689|Active Comparator|Gas flow:5L|use different type ventilator breathing tube as follow Ventilator breathing tube F2220-M: Folding; D: 22mm; L:2.0M Ventilator breathing tube F2216-M: Folding; D: 22mm; L:1.6M Ventilator breathing tube F1520-M: Folding; D: 15mm; L:2.0M Ventilator breathing tube F1516-M: Folding; D: 15mm; L:1.6M Ventilator breathing tube U1016-M: Unfolding; D: 10mm; L:1.6M Ventilator breathing tube U1516-M: Unfolding; D: 15mm; L:1.6M Ventilator breathing tube CA20-.M: Co-axis; L:2.0M Ventilator breathing tube CA16- M: Co-axis; L:1.6M
3477053|NCT03822767|Experimental|Experimental Group|sIPV-sIPV-bOPV vaccination schedule
3477054|NCT03822767|Active Comparator|Control Group|wIPV-wIPV-bOPV vaccination schedule
3477055|NCT03822949|Experimental|Experimental: Exposed to Day light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive an intense (bright light, Square One Wake Up Light NatureBright 10,000 LUX) box. The patient will start using the light box prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of light therapy.
3477056|NCT03822949|Sham Comparator|Sham Comparator: Exposed to Room light|Patients undergoing primary sternotomy cardiac surgery: Patients will be enrolled 10 to 1 days prior to surgery and will receive a placebo/control device (dim/night light box). The patient will start using the light box 7 days prior to surgery every morning from 8.30 to 9.00 AM. Blood /buccal swabs will be collected on the day of enrollment (10 to 1 days prior to surgery) between 7 and 10 AM without any light therapy and on the day of surgery between 7 and 10 AM before anesthesia induction after one week of placebo therapy.
3477057|NCT03822611|Experimental|Targeted Subsidy|In these communities, households identified as vulnerable receive a voucher for a free latrine sub-structure (slab + pit lining), redeemable with local sanitation suppliers.
3477058|NCT03822611|No Intervention|No subsidy|In these communities, no household receives a voucher.
3477059|NCT03822637|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC coadministered with albuterol and delivered via nebulizer three times per day for fourteen days.
3477060|NCT03822637|Placebo Comparator|0.9% saline|Normal saline will be coadministered with albuterol as the placebo agent via a nebulizer three times per day for fourteen days.
3477061|NCT03822507|Experimental|KHK7580 1mg-12mg|
3477062|NCT03822507|Active Comparator|Cinacalcet 25mg-100mg|
3477063|NCT03822559|Experimental|DE-111A eye drops|
3477064|NCT03822559|Active Comparator|0.0015% tafluprost eye drops|
3477065|NCT03822845|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET/CT scan
3477066|NCT03822546|Experimental|Conventional cigarette|The subject's preferred brand of commercially available conventional cigarette
3126675|NCT03048383|Active Comparator|AbobotulinumtoxinA Injectable Product|abobotulinumtoxinA (Dysport®, Medicis) administered for n=13 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
3126676|NCT03048383|Active Comparator|Incobotulinumtoxin A Injectable Product|incobotulinumtoxinA (Xeomin®, Merz) administered for n=10 total treatments. Each patient in this arm was administered the Synkinesis Assessment Questionnaire (SAQ) to assess severity of synkinesis pre-treatment. SAQ was administered again at 1, 2, and 4 weeks post-treatment and improvements were compared to the other arms of the study.
3477067|NCT03822546|Active Comparator|myblu 25 mg freebase|myblu pod-system containing 25 mg nicotine ('freebase') tobacco flavour
3477068|NCT03822546|Active Comparator|myblu 16 mg nicotine salt|myblu pod-system containing 16 mg nicotine salt tobacco flavour
3477069|NCT03822546|Active Comparator|myblu 25 mg nicotine salt|myblu pod-system containing 25 mg nicotine salt tobacco flavour
3477070|NCT03822546|Active Comparator|myblu 40 mg nicotine salt|myblu pod-system containing 40 mg nicotine salt tobacco flavour
3477071|NCT03822546|Active Comparator|blu PRO 48 mg nicotine salt|blu PRO open-system containing 48 mg nicotine salt tobacco flavour
3477072|NCT03822585|Other|Close Relatives Of β-thalassemia|Laboratory diagnostic tests as (CBC, Iron Study, Serum Ferritin, HPLC, Genetic study) will be done to Brothers, Sisters & Cousins of β-thalassemia Children With Microcytic Hypochromic Anemia Attending Assiut University Child Hospital
3126677|NCT03048422|Experimental|Arm 1: Maternal DTG+FTC/TAF|Mothers randomized to receive dolutegravir (DTG) plus emtricitabine/tenofovir alafenamide (FTC/TAF) during pregnancy, through delivery, and for 50 weeks postpartum.
3126678|NCT03048422|Experimental|Arm 2: Maternal DTG+FTC/TDF|Mothers randomized to receive DTG plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
3477073|NCT03822481|Experimental|Experimental|Participants in this arm were given the MCD. The MCD is a mindful eating intervention aimed at facilitating weight loss and cultivating a present centred awareness. The MCD consists of ten questions that an individual must consider while eating. Participants were required to consider the questions while eating (no writing required). Participants were asked to use the MCD at their three main meals (breakfast, lunch, dinner). The
3477074|NCT03822481|No Intervention|Control|Participants in this arm were required to eat as normal and were not given the MCD until the study was complete.
3477075|NCT03822429||women < 35 years old|
3126679|NCT03048422|Active Comparator|Arm 3: Maternal EFV/FTC/TDF|Mothers randomized to receive efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) during pregnancy, through delivery, and for 50 weeks postpartum.
3126680|NCT03048422|No Intervention|Arm 1 Infants|Infants born to women in Arm 1. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
3126681|NCT03048422|No Intervention|Arm 2 Infants|Infants born to women in Arm 2. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
3126682|NCT03048422|No Intervention|Arm 3 Infants|Infants born to women in Arm 3. Infants did not directly receive study intervention, but may have been exposed to the randomized treatment through placental or breastmilk transfer.
3179412|NCT00672464|Experimental|Added Metformin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin
3477076|NCT03822429||women between 36 and 38 years old|
3477077|NCT03822429||women between 39 and 40 years|
3477078|NCT03822429||women > 41 years old|
3477079|NCT03822533|Other|Physiotherapist as primary assessor|"The healthcare process will be started with a physiotherapist assessment and treatment. Treatments could involve individual or group treatment including patient education and physical exercise.~Patients can seek a physician anytime after the first assessment with the physiotherapist."
3477080|NCT03822533|Other|Physician as primary assessor|"The Healthcare process will be started with a physician assessment and treatment. Treatments could involve drug prescription, referral to x-ray, referral to other healthcare providers and sick-leave.~Patients can seek a physiotherapist anytime after the first assessment with the physician."
3477081|NCT03822494|Experimental|Dose Escalated CyberKnife SBRT|
3477082|NCT03822273|Experimental|Traditional acupuncture (TA)|The subject will receive real acupuncture treatment once per day for 3 days after enrollment.
3477083|NCT03822273|Active Comparator|Laser acupuncture (LA)|The subject will receive laser acupuncture treatment once per day for 3 days after enrollment.
3477084|NCT03822273|Placebo Comparator|Sham laser acupuncture (SLA)|The subject will receive sham laser acupuncture treatment once per day for 3 days after enrollment.
3477085|NCT03822403|Active Comparator|EQUIA|EQUIA Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
3477086|NCT03822403|Active Comparator|Gradia Direct Posterior|Gradia Direct Posterior The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
3477087|NCT03822572|Experimental|A - endurance exercise|All patients receive a pulse-controlled endurance exercise program based on the study results by O'Donovan. The individual pulse-controlled endurance exercise should be performed 3 times a week. On the basis of age, weight, sex and body fat the normal weight will be calculated. The kilocalories (kcal), which correspond to the metabolic equivalent task (MET) hour per week, will be calculated after age and gender adjustment of the normal weight. The endurance exercise will be increased gradually until reaching 18 MET-hours/wk during the year of endurance exercise. Patients in arm A can perform different types of endurance exercise (bicycling, cross walking, jogging, walking, nordic walking, cross country skiing)
3477088|NCT03822572|Other|B - control arm|Patients in this arm should maintain their habitual physical activity pattern as before the diagnoses of colorectal cancer.
3477089|NCT03822143|Experimental|Fetus anemia diagnosis|Diagnosis of anemia in the fetus through use of ultrasound data collection
3477090|NCT03822156||Cavitary Pulmonary Tuberculosis|The patients who are diagnosed with the cavitary pulmonary tuberculosis
3477091|NCT03822156||Endobronchial Tuberculosis|The patients who are diagnosed with the endobronchial tuberculosis
3477092|NCT03822286|Experimental|Intervention|E-training course programs, counseling mentoring supports and support group gatherings meeting.
3477093|NCT03822286|Active Comparator|Control|Traditional classroom teaching course programs.
3477094|NCT03822247|Experimental|Multidisciplinary Recovery Program|"Two cohorts of patients will randomly be placed in either experimental od no intervention group.~Patients undergoing Multidisciplinary Recovery After Surgery Program will gain better preparation for early mobilization after surgery, nutritional support, individually modified analgesia and psychological support during inpatient treatment. Program includes preoperative, intraoperative and postoperative multidisciplinary comprehensive interventions."
3477095|NCT03822247|No Intervention|Conventional Perioperative Care|Patients undergoing conventional care
3477096|NCT03822299|No Intervention|Placebo|Patients receive suspension of their own feces.
3477097|NCT03822299|Active Comparator|30 g donor dose|Patients receiving 30 g of a healthy donor feces.
3477098|NCT03822299|Active Comparator|60 g donor dose|Patients receiving 60 g of a healthy donor feces.
3477099|NCT03822234|Experimental|Modified ileal conduit|With our modified ileal conduit technique
3477100|NCT03822234|No Intervention|Conventional ileal conduit|Conventional ileal conduit
3477101|NCT03822208|Active Comparator|AL003 by intravenous (IV) infusion|Single-doses of AL003 in dose-escalating cohorts Multiple doses of AL003 in single cohort
3477102|NCT03822208|Placebo Comparator|Placebo by intravenous (IV) infusion|Matching saline solution will be administered for placebo subjects
3477103|NCT03822455|Active Comparator|OligoG DPI|Active DPI containing the oligosaccharide OligoG and excipients
3477104|NCT03822455|Placebo Comparator|Placebo DPI|Placebo DPI containing lactose and excipients
3477105|NCT03822195||asymptomatic|asymptomatic patients undergoing carotid endoarterectomy for stenosis >70% (velocimetric criteria at echodoppler)
3477106|NCT03822195||symptomatic|symptomatic (TIA, crescendo TIA, minor stroke) patients undergoing carotid endoarterectomy, independently from stenosis evaluated by echodoppler
3477107|NCT03822260||Sur1/ Trpm 4 acitivities at SAH|only after collecting sample,
3477108|NCT03822520|Experimental|Celecoxib, Moxifloxacin, Water in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day"
3477109|NCT03822520|Experimental|Celecoxib, Water, Moxifloxacin in order|"Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day"
3477110|NCT03822520|Experimental|Moxifloxacin, Water, Celecoxib in order|"Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
3477111|NCT03822520|Experimental|Water, Moxifloxacin, Celecoxib in order|"Intervention Pure water: Water 150ml by mouth without any drug, once for one day~Wash-out period (3~6 days)~Intervention Moxifloxacin: Moxifloxacin 400 mg tablet and water 150ml by mouth, once for one day~Wash-out period (3~6 days)~Intervention Celecoxib: Celecoxib 400 mg capsule and water 150ml by mouth, daily for 6days"
3477112|NCT03822364|Experimental|A-1 (009-1 -> active comparator)|Part A, Arm 1 (Inhaled apomorphine, Dose 1 followed by commercially available active comparator)
3477113|NCT03822364|Experimental|A-2 (active comparator -> 009-1)|Part A, Arm 2 (commercially available active comparator followed by Inhaled apomorphine, Dose 1)
3477114|NCT03822364|Experimental|B-1a (009-2)|Part B, Arm 1 (Inhaled apomorphine, Dose 2)
3477115|NCT03822364|Placebo Comparator|B-1p (009-0)|Part B, Arm 1 (Inhaled placebo)
3477116|NCT03822364|Active Comparator|B-2a (009-3)|Part B, Arm 2 (Inhaled apomorphine, Dose 3)
3477117|NCT03822364|Placebo Comparator|B-2p (009-0)|Part B, Arm 2 (Inhaled placebo)
3477118|NCT03822364|Experimental|B-3a (009-4)|Part B, Arm 3 (Inhaled apomorphine, Dose 4)
3477119|NCT03822364|Placebo Comparator|B-3p (009-0)|Part B, Arm 3 (Inhaled placebo)
3477120|NCT03822364|Experimental|C-1a (009-3)|Part C, Arm 1 (Inhaled apomorphine, Dose 3)
3477121|NCT03822364|Placebo Comparator|C-1p (009-0)|Part C, Arm 1 (Inhaled placebo)
3477122|NCT03822364|Experimental|C-2a (009-4)|Part C, Arm 2 (Inhaled apomorphine, Dose 4)
3477123|NCT03822364|Placebo Comparator|C-2p (009-0)|Part C, Arm 2 (Inhaled placebo)
3477124|NCT03822364|Experimental|C-3a (009-5)|Part C, Arm 3 (Inhaled apomorphine, Dose 5)
3477125|NCT03822364|Placebo Comparator|C-3p (009-0)|Part C, Arm 3 (Inhaled placebo)
3477126|NCT03822221|Experimental|SK20º|MVIC and NMES with hip at 85º and knee at 20º
3477127|NCT03822221|Experimental|SK60º|MVIC and NMES with hip at 85º and knee at 60º
3477128|NCT03822221|Experimental|LK20º|MVIC and NMES with hip at 0º and knee at 20º
3179413|NCT00672464|Experimental|Added Simvastatin|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Simvastatin
3477129|NCT03822221|Experimental|LK60º|MVIC and NMES with hip at 0º and knee at 60º
3477130|NCT03822052|Active Comparator|Primiparous Patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
3477131|NCT03822052|Active Comparator|Primiparous Patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
3477132|NCT03822052|Active Comparator|Multiparous patient, Unfavorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
3477133|NCT03822052|Active Comparator|Multiparous patient, Favorable Bishop Score|Patient to receive D5LR or LR at 125 cc/hr
3477134|NCT03822130|Placebo Comparator|Group 1|Systemic Chemotherapy + Oral Chemotherapy Group
3477135|NCT03822130|Experimental|Group 2|Arterial catheter infusion chemotherapy plus oral chemotherapy group
3477136|NCT03822130|Experimental|Group 3|Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group
3477137|NCT03822104|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
3477138|NCT03822104|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
3179414|NCT00672464|Experimental|Added Metf. + Simv.|Newly Admitted Patients with Schizophrenia or Schizoaffective Disorder Who Are Receiving Olanzapine with Added Metformin and Simvastatin
3179415|NCT00672464|No Intervention|Matched Controls|Matched Control Subjects by age, race, and gender
3477139|NCT03822117|Experimental|Pemigatinib|"Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements* (not eligible for Cohort A)).~*Only FGFR fusions or rearrangements with an intact kinase domain are eligible"
3477140|NCT03822091|Active Comparator|TERLIPRESSIN GROUP|
3477141|NCT03822091|Experimental|TERLIPRESSIN WITH NORADRENALINE GROUP|
3477142|NCT03822065|Experimental|Sequence 1: LY03005 Fed Crossover to Fasted|Sequence 1 will receive a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 2.
3477143|NCT03822065|Experimental|Sequence 2: LY03005 Fasted Crossover to Fed|Sequence 2 will receive a single oral dose of LY03005 (80 mg) under fasted conditions in Treatment Period 1 and a single oral dose of LY03005 (80 mg) under fed conditions in Treatment Period 2.
3477144|NCT03822312|Experimental|DBT-TOBI|"Subjects will be imaged using DBT-TOBI at the time points indicated in the Study Calendar (Baseline, before cycle 2, and additional optional time points).~Both breasts will be measured in turn.~Each breast is symmetrically centered on the x-ray detector/optical illuminator and is first compressed according to standard mammography procedures to determine the amount of force needed for each given patient~An optional Magnetic Resonance Imaging TOBI (MRI-TOBI) scan will also be performed."
3477145|NCT03822338|Experimental|Pneumoperitoneum preconditioning group|Participant assigned to the this group will receive a treatment consisting of three cycles of 5 min insufflation (intra-abdominal pressure at 15 mmHg) and 5 min desufflation, after complete anesthesia and successfully implanting the veress.
3477146|NCT03822338|Sham Comparator|Control group|Participants in the control group will receive the same placement of the veress but without insufﬂation and subsequent desufﬂation.
3477147|NCT03822026|Other|patients with severe TBI|Patients with severe TBI enrolled in the study undergo an hyperventilation test, in which the alveolar ventilation is increased by a stepwise increase in tidal volumes and respiratory rate until a reduction of etCO2 of 0.7 kPa is achieved.
3477148|NCT03822169|Experimental|Choline added as a phospholipid|A shake with phospholipid-bound choline (and bound DHA),
3477149|NCT03822169|Active Comparator|Choline added as a salt|control shake with choline added as a salt and added DHA.
3477150|NCT03822013|Experimental|Miglustat|"Miglustat is administered, dose is adjusted according to Body Surface Area as below:~>1.25 : 200 mg TDS 0.88-1.25 : 200mg BID 0.73-0.88 :100mg TDS 0.47-0.73 : 100mg BID <0.47 :100mg daily"
3477151|NCT03822013|No Intervention|No Miglustat|
3179416|NCT00672503||1|Patients who acquired a CA-UTI in the PICU between 2004-2007.
3477152|NCT03822000||Elderly Patients with Femoral Fracture|Elderly patients with fall-induced femoral fracture. Patients were categorized into two groups: death (n = 42) and survival (n = 2,365).
3477153|NCT03821961|Experimental|Metabolic surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
3477154|NCT03821987|Experimental|BFCA regimen|"Detail: Patients enrolled in this study would receive Busulfan(B) (IV)0.8mg/kg Q6hx2d,Fludarabine(F) 30mg/m2x5d ,cyclophosphamide(C) 25mg/kg/dx4d,thymoglobulin (A :rATG ,Sang Stat,France) 2.5mg/kg/dx4d.~BM or Blood samples from patients were obtained to assess engraftment and chimerism after HSCT. The time point that we monitored BM or blood samples included at 1 month,2 months, 3 months,6 months, 9 months and 1year,2years,3years 5 years after HSCT."
3477155|NCT03821844|Experimental|Music and Memory|Music and Memory is a personalized music program in which nursing home staff provide people with dementia with music playlists tailored to their personal history of music preferences.
3477156|NCT03821844|No Intervention|Usual Care|Usual care for managing agitated and/or aggressive behaviors in the nursing home setting.
3477157|NCT03821909||Pancreatic cancer|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology.
3477158|NCT03821909||Benign pancreatic diseases|Endoscopic ultrasound-guided protal venous blood sampling will be performed for each patient. And the diagnosis will be confirmed by tissue pathology, e.g. PCLs.
3477159|NCT03821974|Experimental|dry group|The sequence of the technique of the puncture is dry-wet-dry-wet.
3477160|NCT03821974|Experimental|wet group|The sequence of the technique of the puncture is wet-dry-wet-dry.
3126683|NCT03048500|Experimental|Treatment (metformin hydrochloride, nivolumab)|Patients receive metformin hydrochloride PO once QD on days -7 to -1 and 1-28. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4, then over 60 minutes on day 1 beginning course 5. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or withdrawal of consent.
3126684|NCT03048747|Experimental|Tolvaptan|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
3126685|NCT03049215|Active Comparator|Lumen Apposing Metal Stent (LAMS)|Subjects randomized to LAMS alone will undergo EUS-guided transmural placement of an Axios stent with a 15 mm luminal diameter.
3126686|NCT03049215|Active Comparator|LAMS plus double pigtail stent|Subjects randomized to LAMS plus double pigtail stent will undergo EUS-guided transmural placement of a single Axios stent with a 15 mm luminal diameter. Following this, wire access across the stent lumen will be achieved using a 0.035 inch hydrophilic guidewire, and a double pigtail plastic biliary stent (6 French, 7 French, or 10 French at the discretion of the endoscopist) will be deployed over the wire.
3126687|NCT03049280|Experimental|Transoral robotic surgery|
3126688|NCT03049488|Experimental|Group 1: DS-Cav1 (50 mcg)|"DS-Cav1 (50 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
3126689|NCT03049488|Experimental|Group 2: DS-Cav1 (50 mcg) + alum|"DS-Cav1 (50 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
3126690|NCT03049488|Experimental|Group 3: DS-Cav1 (150 mcg)|"DS-Cav1 (150 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*The Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection, and for 5 additional subjects who were enrolled to evaluate the safety or immunogenicity of a single vaccine dose."
3126691|NCT03049488|Experimental|Group 4: DS-Cav1 (150 mcg) + alum|"DS-Cav1 (150 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
3477161|NCT03821831||Continuous Positive Airway Pressure|This group consists of consenting patients and their parents who choose Continuous Positive Airway Pressure (CPAP). The CPAP is a type of therapy that applies mild air pressure to a person's upper airway to keep their airway open so that they can breathe normally while they sleep.
3477162|NCT03821831||Orthodontic Intervention|This group consists of consenting patients and their parents who choose orthodontic intervention will be seen by participating orthodontists who will determine types of orthodontic intervention; mandibular advancement devices or rapid maxillary expansion devices. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
3477163|NCT03821831||Control|This group consists of consenting patients and their parents who choose to remain untreated. In this group, the patients will also receive a biometric shirt to use once every two weeks, to monitor their sleep during the study.
3477164|NCT03821792|Experimental|Treatment (abiraterone acetate, prednisone, apalutamide)|Patient receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Cycles repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
3477165|NCT03821922||pregnancy-induced pregnancy|Those women (subjects) with pregnancy-induced pregnancy.
3477166|NCT03821922||Control|Those healthy pregnant women
3477167|NCT03821649|Experimental|SOONER Training and Naloxone Kit|Participants in this arm will be shown the SOONER overdose response training video at the time of recruitment and given the SOONER Naloxone kit to take home.
3477168|NCT03821649|Active Comparator|Community or Hospital-Based Training|Control arm - participants in this arm will be referred to the standard of care for Naloxone training. This standard of care includes community-based OEND programs and/or an existing hospital-based OEND program..
3477169|NCT03821662|Experimental|OT Diabetes Self-Management Intervention|The intervention is organized into five modules. Each participant receives an individually tailored combination of modules, and treatment activities within each module, as established through collaborative goal setting between the participant and OT during the initial evaluation. The five modules are: (1) Living with Diabetes-addressing gaps in the knowledge and skills necessary to effectively manage diabetes; (2) Access and Advocacy-strategies to collaborate and communicate with healthcare providers; (3) Activity and Health-analyzing daily habits and routines; (4) Social Support-strategies to address diabetes care in various social environments and to identify sources of support; (5) Emotional Well-Being-strategies to address stress, diabetes burnout, and depression.
3477170|NCT03821688|Experimental|SAS-JB|laparoscopic single anastomosis sleeve jejunal bypass
3477171|NCT03821688|Active Comparator|MGB|laparoscopic mini gastric bypass
3477172|NCT03821688|Active Comparator|LSG|laparoscopic sleeve gastrectomy
3126692|NCT03049488|Experimental|Group 5: DS-Cav1 (500 mcg)|"DS-Cav1 (500 mcg) administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
3126693|NCT03049488|Experimental|Group 6:DS-Cav1 (500 mcg) + alum|"DS-Cav1 (500 mcg) + alum administered IM by Needle/Syringe (Day 0 and Week 12*)~*To evaluate the safety or immunogenicity of a single vaccine dose, the Week 12 dose was optional for the last 5 subjects who enrolled in this group and received the Day 0 injection."
3126694|NCT03049501|Experimental|Caregiving Condition|Participants will receive a computer tablet and have access to web-based skill building sessions, videos from experts, annotated resources and information and tips on caregiving-related topics
3126695|NCT03049501|Placebo Comparator|Nutrition Condition|Participants will receive a computer tablet and have access to web-based training sessions on different topics related to nutrition.
3477173|NCT03821701|Experimental|Newly diagnosed HFrEF ARNI|Newly diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
3477174|NCT03821701|Active Comparator|Newly diagnosed HFrEF ACEI/ARB|Newly diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
3477175|NCT03821701|Experimental|Prior diagnosed HFrEF ARNI|Prior diagnosed HFrEF patients will be administered ARNI Entresto according to the clinical condition among the whole study.
3477176|NCT03821701|Active Comparator|Prior diagnosed HFrEF ACEI/ARB|Prior diagnosed HFrEF patients will be administered ACEI/ARB according to the clinical condition among the whole study.
3477177|NCT03821896|Experimental|Conversation Cards for Adolescents and Goal-Setting|Adolescents in the experimental arm will receive the tool 15 minutes prior to their appointment with their primary care provider. They will be instructed to familiarize themselves with the tool and to select the top 3 factors that resonate most with them in their attemps to change their lifestyle habits. They will then proceed to their clinical appointment to set one S.M.A.R.T. goal based on their selections and in collaboration with their primary care provider.
3477178|NCT03821896|Active Comparator|Goal-Setting|Adolescents in the control arm will not complete the tool activity, but will still set a S.M.A.R.T. goal with their primary care provider.
3477179|NCT03821623|Experimental|Nicotinamide riboside|Subjects will take 500 mg of the vitamin B3-precursor, nicotinamide riboside (NIAGEN) twice per day (1,000 mg per day total) for 3 months.
3477180|NCT03821623|Placebo Comparator|Placebo|Subjects will take placebo pills twice a day for 3 months.
3477181|NCT03821753||Case|Patients with glycemic variability, defined by a coefficient of variation (CV)> 36%, calculated from continuous glucose measurements data by Free Style Libre® (Abbott)
3477182|NCT03821753||Control|Patients without glycemic variability, defined by a coefficient of variation (CV) ≤ 36%, calculated from Free Style Libre® data and matched to patients in the Case group for HbA1c (+/- 0.5%)
3477183|NCT03821870||Standard treatment|Standard first line treatment
3477184|NCT03821714|Experimental|Glucocorticoid combination therapy Group|Hydrocortisone 200mg continuous intravenous infusion(24h) combined with vitamin C1.5g intravenous infusion every 6 hours and vitamin B1 200mg intravenous infusion every 12 hours.
3477185|NCT03821714|Active Comparator|Glucocorticoid Group|Hydrocortisone 200mg continuous intravenous infusion(24h)
3477186|NCT03821779|Experimental|Group 1: Go-no-go phase|"The presence of significant prefrontal oscillations in the EEG recording 2-6Hz band during in vivo social exposure (oral presentation to examiners) will be assessed in 10 subjects with social anxiety disorder. EEG will be recorded immediately before, during and after oral presentations to examiners.~Psychometric evaluation will be performed prior to experimental sessions. Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods (wainting, presentation, recovery).~Results of EEG recordings in the first 10 subjects will lead to continuation (presence of significant slow prefrontal oscillations during anxiety) or interruption (absence of signification oscillation) of the study."
3477187|NCT03821779|Experimental|Group 2.1|"In group 2.1, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~real exposure: oral presentation to a panel of examiners~virtual reality : oral presentation to virtual examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
3477188|NCT03821779|Experimental|Group 2.2|"In group 2.2, 10 subjects will undergo 2 sessions in a cross-over design with EEG recording immediately before, during and after:~virtual reality : oral presentation to virtual examiners~real exposure: oral presentation to a panel of examiners~Rating of anxiety levels will be performed by subjects using a Visual Analogue Scale of anxiety during each of the 3 experimental periods for each session.~Psychometric evaluation will be performed prior to experimental sessions."
3477189|NCT03821467|Experimental|Healthy subjects|Dual beam Doppler Fourier-domain OCT (DOCT) Dynamic Vessel Analyzer (DVA) Optical coherence tomography (OCT)
3477190|NCT03821428|Experimental|Acupuncture|Needling of acupoints P6 and CV24 with indwelling permanent needles, withdrawn after TEE procedure
3477191|NCT03821428|Placebo Comparator|Control|Application of Placebo needles in the areas of P6 and CV24 acupoints
3477192|NCT03821805|Experimental|Foot reflexology massage group|The duration of intervention was 30 min (15 min massage duration for each leg)
3477193|NCT03821805|No Intervention|Control group|Rest for 30 min
3477194|NCT03821480|Experimental|Fluconazole 50 mg, Manufacturer: Amboise|Test drug
3477195|NCT03821480|Active Comparator|Fluconazole 50mg, Manufacturer:West Ryde|Reference drug
3477196|NCT03821441|Experimental|bOPV(Candy)|"bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
3477197|NCT03821441|Experimental|bOPV(Liquid)|"bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.~0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops each person;be be equivalent to 0.1ml each person )"
3477198|NCT03821441|Experimental|bOPV（liquid）|bOPV(Liquid):Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral Produced by Beijing Tiantan Biological Products Co., Ltd. 1.0ml each bottle,2 drops each person(be be equivalent to 0.1ml each person).(total content of polio virus≥6.12lgCCID50，type1 polio virus≥6.0 lgCCID50，type 3 polio virus ≥5.5lgCCID50 in each 0.1 ml)
3477199|NCT03821636|Sham Comparator|Standard Roux-en-Y|
3477200|NCT03821636|Active Comparator|Long alimentary limb Roux-en-Y|
3477201|NCT03821324|Other|Intervention|Device: Venus Viva
3477202|NCT03821532|No Intervention|Control group|Each family will receive a randomized packet containing educational information, rewards charts and an adult literacy test. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms and adherence to the treatment plan.
3477203|NCT03821532|Experimental|Experimental group|Each family will receive a randomized packet containing educational information, rewards charts, an adult literacy test and a constipation action plan tool. The treatment plan will be determined based on recommendations from the clinical guidelines for the Evaluation and Treatment of Functional Constipation Infants and Children as published by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. At the first visit, the parent(s) will complete an adult literacy test and an initial paper questionnaire regarding symptoms, adherence to the treatment plan and demographics. At 1 month, the primary investigator will call each family and administer a phone survey regarding symptoms and adherence to the treatment plan in the past month. At 3 months, the families will return for a follow up visit with their 3 month reward charts and complete a final paper survey regarding the child's symptoms, adherence to the treatment plan, and action plan utility.
3126696|NCT03049748|Active Comparator|Control Group|Participants in the control group (20 LVAD patients) will receive usual care over 6 months. Usual care consists of routine clinic visits/follow-up at 1, 3, and 6 months post hospital discharge. A customary LVAD self-management/discharge education and training will be provided to patients and caregiver before hospital discharge and as need throughout the duration of the study. The control group will NOT receive the VAD Care App.
3179417|NCT00672503||2|Patients who did not acquire a CA-UTI while hospitalized in the PICU but had an indwelling urinary catheter between 2004-2007.
3179418|NCT00672503||A|Nurses currently employed in the PICU at Children's Mercy Hospital.
3477204|NCT03821766||Heart failure|Patients suffering from heart failure regardless to the etiology will undergo cardiac catheterization according to their medical condition. the SCG and BCG signals will be recorded along with the intracavitary pressure profiles detected invasively with the cardiac catheterization.
3477205|NCT03821350|No Intervention|Control Group|The control group was given verbal information
3477206|NCT03821350|Experimental|Leaflet Group|The second group was given verbal information and a detailed information leaflet with written and visual content
3477207|NCT03821597|Experimental|Sequential compression devices|Sequential compression devices (SCDs) are applied during surgery.
3477208|NCT03821597|Active Comparator|No sequential compression devices|No sequential compression devices are applied.
3477209|NCT03821415|Experimental|1 - RP101 0.05%|RP101 0.05% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
3477210|NCT03821415|Experimental|2 - RP101 0.1% / Placebo|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye in the morning (q.d.) followed by one drop of placebo each eye in the evening for 90 consecutive days
3477211|NCT03821415|Experimental|3 - RP101 0.1%|RP101 0.1% (w/w) 17β-oestradiol-3-phosphate ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
3477212|NCT03821415|Placebo Comparator|4 - Placebo|RP101 matching placebo, ophthalmic sterile solution, one drop each eye every 12 h (b.i.d.) for 90 consecutive days
3477213|NCT03821155|Active Comparator|Neuritis vestibularis (group 1)|"Corticosteroid (prednisolone)"
3477214|NCT03821155|Experimental|Neuritis vestibularis (group 2)|"Corticosteroid (prednisolone) + vestibular rehabilitation"
3477215|NCT03821454|Experimental|Capecitabine|The experimental group received oral capecitabine for eight cycles.
3477216|NCT03821454|Placebo Comparator|Placebo|The placebo group received oral placebo for eight cycles.
3477217|NCT03821181|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
3477218|NCT03821181|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
3477219|NCT03821142|Experimental|Calistar S|Single arm cohort trial
3477220|NCT03821493|Experimental|PF-06651600 treatment arm|This arm includes two treatment periods. Period 1-Single oral dose of PF-06651600 30 mg as tablets on Day 1 followed by Period 2 in which itraconazole 200 mg (oral solution) is given for 5 days. On Day 4 of Period 2, a single oral dose of PF-06651600 30 mg is given with itraconazole
3477221|NCT03821168|Active Comparator|intravitreal injection of bevacizumab and erythropoietin|erythropoietin:
3477222|NCT03821168|Active Comparator|intravitreal injection of bevacizumab|bevacizumab:1.25 mg
3477223|NCT03821818||Control|Food Allergen Elimination only
3477224|NCT03821818||Allergen Elimination + Willis Exercise|Subjects will have food allergens eliminated and also perform Aerobic-surge, brief high intensity exercise > 75% max HR), five times/day.
3477225|NCT03820999|Experimental|Teaching arm|The Primary Health Care physicians getting oral and written information on tick-bites and Lyme disease with focus on Lyme neuroborreliosis.
3179419|NCT00672503||a|Root Cause Analysis on all patients who acquired a CA-UTI during 2009.
3179420|NCT00672529|Active Comparator|Intervention Group|
3179421|NCT00672529|Placebo Comparator|Placebo Group|
3477226|NCT03820999|No Intervention|Passive arm|The Primary Health Care physicians that does not get contacted with an offer to receive oral and written information.
3477227|NCT03821025|Active Comparator|Multiple Plastic Stents|Patients will receive two 8.5Fr Platic biliary stents placed side by side across the biliary stricture.
3477228|NCT03821025|Active Comparator|Self-expandable Metal Stents|Patients will receive a fully covered Self-expandable Metal Stents (10mm) across the biliary stricture
3477229|NCT03821116|Experimental|Milk|At least 500 ml of Swedish milk daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
3477230|NCT03821116|Experimental|Soured milk (filmjölk)|At least 500 ml of Swedish soured milk (filmjölk) daily for three weeks (crossover). Intervention and crossover preceded by 3 weeks with max 50 ml of milk or soured milk (filmjölk) daily. Fat content of milk and soured milk should be the same: 0.5%, 1.5% or 3%.
3477231|NCT03820934|Other|Patients undergoing Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these test. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
3477232|NCT03820921||PATIENTS WITH PANCREATIC CANCER|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNB for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNB will be further verified during a clinical follow-up of at least 6 months.~Immunochemistry will be performed on the EUS-FNB specimens to determine PD-L1 expression and MMR status"
3477233|NCT03820843|Experimental|Art therapy|Art therapy and standard orthophonic rehabilitation
3477234|NCT03820843|No Intervention|Control group|Only standard orthophonic rehabilitation
3477235|NCT03820856|Experimental|acupuncture plus fire needle group|
3477236|NCT03820856|Active Comparator|acupuncture group|
3477237|NCT03820830|Experimental|Palbociclib plus standard endocrine therapy|Palbociclib 125 mg/day tablet taken orally for 21 days, followed by 7 days rest for 3 years from randomization, plus standard endocrine therapy for at least 3 years from randomization.
3477238|NCT03820830|Active Comparator|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
3477239|NCT03820869|Active Comparator|Control|Children with ASD
3477240|NCT03820869|Experimental|Intervention|Children with ASD
3477241|NCT03820739||Cohort 1|Subjects who received an Ebola vaccine prime vaccination in EBOVAC-Salone are eligible for enrolment in this study. Adults are defined as participants 18 years of age or older at the time of prime vaccination, and children are defined as participants aged 1 to 17 years at the time of prime vaccination in EBOVAC-Salone.
3477242|NCT03820739||Cohort 2 (offspring)|Infants conceived by a female participant in EBOVAC-Salone during the 3 months following vaccination with Ad26.ZEBOV or during the 28 days following vaccination with MVA-BN®-Filo.
3477243|NCT03820882|Experimental|stent retriever(Catfish)|Mechanical thrombectomy with Catfish flow restoration device
3477244|NCT03820882|Active Comparator|stent retriever(Solitaire FR)|Mechanical thrombectomy with Solitaire FR flow restoration device
3477245|NCT03820713|Experimental|Investigational arm|Treatment group receives a concentrate of coagulation factors. The device concentrates coagulation factors from donor plasma; the concentrate is applied to the surgical site intended to reduce the incidence, extent and severity of postoperative adhesions.
3477246|NCT03820713|Placebo Comparator|Control arm|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
3477247|NCT03820700|No Intervention|Control group|[Randomized] Patients in control group will receive regular nursing care but no behavioral therapy intervention.
3477248|NCT03820700|Experimental|Hypnosis (Hypn)|[Randomized] Patients will receive a hypnosis recorded audiotape.
3477249|NCT03820700|Experimental|Virtual reality (VR)|[Randomized] Patients will see a 3D movie with a beautiful landscape.
3477250|NCT03820700|Experimental|Virtual reality hypnosis (VRH)|[Randomized] Patients will see the same 3D film combined with a hypnotic voice.
3477251|NCT03820674|Experimental|Energy Conservation plus Problem Solving Therapy Intervention|Receiving experimental intervention
3477252|NCT03820674|Active Comparator|Health Education Intervention|Receiving control intervention
3477253|NCT03820661|Other|High Resolution Ultasound|Diagnostic high resolution ultrasound pre-operatively and intraoperatively
3477254|NCT03820648|Experimental|Alexis® device|In this group, we will be used WP dual-ring Alexis® (Figure 1). The Alexis® 's size will be decided on the basis of abdominal incision (Alexis® X-Large or Alexis® XX-Large will be used for 11-17cm or 17-25 cm incision length respectively)
3477255|NCT03820648|Active Comparator|Standard 3M™ Steri-Drape 2|In this group, we will be used Standard 3M™ Steri-Drape 2
3179422|NCT00672542|Experimental|A|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from untreated monocytes
3477256|NCT03821194|Experimental|Gua sha group|do gua sha for the subjects
3477257|NCT03821194|Active Comparator|control group|give hot pack for the subjects
3477258|NCT03820609|Experimental|Digital Intervention|Make a Change is a universal sexual assault (SA) prevention program that aligns with best-practices in prevention, utilizes the theory and strategies of serious games for health, and addresses risk and protective factors for SA across the social ecology of individual, peer and community factors that foster SA. This novel digital application also leverages theories of behavior change within serious games for health, and integrates successful practices in videogame design to promote engagement, learning and skill-building.
3477259|NCT03820596|Experimental|Sintilimab+Chidamide|"Sintilimab：200mg(fixed dosage), ivd, qd, q21d~Chidamide:~Phase I: 20mg-30mg,biw,continued oral，to evaluate RP2D. Phase II：RP2D，continued oral"
3477260|NCT03820570|Experimental|lichtenstein|hernia repair
3477261|NCT03820635||Calcified|those with evidence of vascular calcification
3477262|NCT03820635||Non-calcified|those with no evidence of vascular calcification
3477263|NCT03820622|Experimental|DIOR group|in this group, patients will be treated with Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
3477264|NCT03820622|Active Comparator|Bingo group|in this group, patients will be treated with Paclitaxel-Eluting Balloon (Bingo)
3477265|NCT03820531|Experimental|Suspected mucinous pancreas cyst|In all pancreas cysts > 15mm and/or pancreas duct dilatation > 5mm in patients who are fit for surgery EUS-guided pancreas cyst fluid aspiration is conducted. In cyst fluid CEA and lipase examination, cytology and Next Generation Sequencing is performed. After that, the pancreas cyst will be resected and histopathologically analysed.
3477266|NCT03820518|Experimental|High-dose|Receiving 60 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
3477267|NCT03820518|Experimental|Low-dose|Receiving 20 ng/kg/day of calcitriol and 30 mg/kg/day of elemental phosphorus.
3477268|NCT03820492|Other|Patient with left-main stenosis|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
3477269|NCT03820557|Experimental|Decision Counseling|Patients undergo participation in the DCP prior to an audio-recorded oncology appointment.
3477270|NCT03820479||Apfel score 1|Female
3477271|NCT03820479||Apfel score 2|Female, non smoker
3477272|NCT03820479||Apfel score 3|Female, non smoker, under 40 years old
3477273|NCT03820479||Apfel score 4|Female, non smoker, under 40 years old, previous history of PONV
3477274|NCT03820453|Experimental|Active group|One tablet per day in the morning through oral administration of a dietary supplement containing Tribulus terrestris as the main active ingredient. During three months with the possibility to extend for another three months.
3477275|NCT03820453|Placebo Comparator|Control group|One tablet per day in the morning through oral administration of Placebo. During three months.
3477276|NCT03820440|Experimental|Treatment - hemodynamic tests|"Treatment - hemodynamic tests:~The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.~The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds"
3477277|NCT03820427||bronchial asthma|Patients with known or suspected asthma.
3179423|NCT00672542|Experimental|B|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with control siRNA
3477278|NCT03820427||pulmonary healthy controls|Patients without known or suspected pulmonary disease
3477279|NCT03820414|Experimental|CRV101 Group 1|Subjects receive 2 doses of the candidate CRV-101 formulation 1, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
3477280|NCT03820414|Experimental|CRV 101 Group 2|Subjects receive 2 doses of the candidate CRV-101 formulation 2, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
3477281|NCT03820414|Experimental|CRV 101 Group 3|Subjects receive 2 doses of the candidate CRV-101 formulation 3, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
3477282|NCT03820414|Experimental|CRV 101 Group 4|Subjects receive 2 doses of the candidate CRV-101 formulation 4, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
3477283|NCT03820414|Placebo Comparator|Control Group|Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 2 Month schedule.
3477284|NCT03820401|Experimental|Solacea_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477285|NCT03820401|Experimental|Solacea_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477286|NCT03820401|Experimental|FX800_postHDF_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477287|NCT03820401|Experimental|FX800_postHDF_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~blood & dialysate sampling at 60min after dialysis start~microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477288|NCT03820401|Experimental|Solacea_HD_1/1anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3126697|NCT03049748|Experimental|Intervention Group|Participants in the experimental group (20 LVAD patients) will receive usual care plus VAD Care App. They will implement LVAD self-management as directed by VAD Care App. The app will be used daily by patients and/or caregivers for over 6 months. Their LVAD self-management competencies will be assessed at months 1 and 5 post hospital discharge with a review of LVAD self-management skills provided by the LVAD RN Coordinator.
3477289|NCT03820401|Experimental|Solacea_HD_1/2anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro, Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477290|NCT03820401|Experimental|FX800_HD_1/1anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477291|NCT03820401|Experimental|FX800_HD_1/2anticoagulation|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477292|NCT03820401|Experimental|FX800_HD_1/2anticoagulation_albuprime|"intervention:~choice of dialyzer: FX800 dialyzer (Fresenius Medical Care, Germany)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only half of his/her standard anticoagulation dose~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477293|NCT03820401|Experimental|Evodial_HD_no anticoagulation|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477294|NCT03820401|Experimental|Evodial_HD_no anticoagulation_albuprime|"intervention:~choice of dialyzer: Evodial 1.3 (Baxter, USA)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~preparation of dialyzer: the dialyzer was preprimed with albumin solution~measurement:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477295|NCT03820401|Experimental|Solacea_preHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477296|NCT03820401|Experimental|Solacea_postHDF_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3126698|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Single dose|One drop in the study administered one time only for one day
3126699|NCT03049852|Placebo Comparator|Vehicle|One drop in the study administered three times daily (TID) for 4 weeks
3126700|NCT03049852|Experimental|CBT-001 Ophthalmic Solution Multidose|One drop in the study administered three times daily (TID) for 4 weeks
3126701|NCT03049917|No Intervention|No incentive|No incentive
3126702|NCT03049917|Experimental|KES financial incentive 1|Kenyan Shillings conditional cash transfer upon HIV testing
3477297|NCT03820401|Experimental|Solacea_HD_1/4anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: the patient receives only 1/4th of his/her standard anticoagulation dose~measurements:microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477298|NCT03820401|Experimental|Solacea_preHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: pre dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477299|NCT03820401|Experimental|Solacea_postHDF_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: post dilution hemodiafiltration~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477300|NCT03820401|Experimental|Solacea_HD_no anticoagulation|"intervention:~choice of dialyzer: Solacea dialyzer (Nipro Japan)~choice of dialysis mode: hemodialysis~choice of anticoagulation strategy: no anticoagulation is administered~measurements:~- microCT scanning of rinsed and dried dialyzer, post dialysis in order to count open fibers"
3477301|NCT03820466|Active Comparator|Aspirin|Aspirin 100 mg once daily and Placebo Atorvastatin once daily
3477302|NCT03820466|Active Comparator|Atorvastatin|Atorvastatin 20 mg once daily and Placebo Aspirin once daily
3477303|NCT03820466|Experimental|Aspirin-Atorvastatin|Aspirin 100 mg once daily and Atorvastatin 20 mg once daily
3477304|NCT03820466|Placebo Comparator|Placebo|Placebo Aspirin once daily and Placebo Atorvastatin once daily
3477305|NCT03820336|Experimental|Extra Virgin Olive Oil|
3477306|NCT03820336|Placebo Comparator|Control Oil|
3477307|NCT03820310|Experimental|Experimental group|traditional therapy plus autologous Tcm cellular immunotherapy.
3477308|NCT03820310|No Intervention|control group|traditional therapy alone, such as radiotherapy or chemotherapy.
3477309|NCT03820297|Other|Anti-Stigma Group|Complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.
3477310|NCT03820271|Other|SuperMELD|
3477311|NCT03820245|Experimental|Bixin|Consumption of 0.05 mg bixin/kg b.w. through capsules (once a day) by 7 days in the morning.
3477312|NCT03820245|Experimental|Norbixin|Consumption of 0.05 mg norbixin/kg b.w. through capsules (once a day) by 7 days in the morning.
3179424|NCT00672542|Experimental|C|Vaccination with melanoma tumor associated antigen RNA loaded dendritic cells derived from monocytes transfected with siRNA targeting the three inducible immunoproteasome subunits
3179425|NCT00672568|Experimental|1|4975
3477313|NCT03820245|Active Comparator|Lycopene|Consumption of 0.05 mg lycopene/kg b.w. through capsules (once a day) by 7 days in the morning.
3477314|NCT03820245|Placebo Comparator|Placebo|Consumption of 0.05 mg placebo/kg b.w. through capsules (once a day) by 7 days in the morning.
3477315|NCT03820232||Surgical patients|Patients who were candidates for major or urological surgery under general anaesthesia will be observed. In particular, the core body temperature will be measured with both a single-use oesophageal probe and a SpotOn® heated controlled servo sensor.
3477316|NCT03820219|Placebo Comparator|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
3477317|NCT03820219|Active Comparator|Prevena™ system|The Prevena™ System is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment, until it is removed at Post-Operative Day 7.
3477318|NCT03820206|Active Comparator|Tranexamic acid group|1 g (10 mL) tranexamic acid (Kapron, Amoun, Egypt; stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
3477319|NCT03820206|Placebo Comparator|Control group|30 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
3477320|NCT03820193|Experimental|Post-Operative Non Opioid Pain Protocol|Patients will be administered a post-operative non-opioid pain protocol consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
3477321|NCT03820193|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
3477322|NCT03820141|Experimental|Durvalumab + Trastuzumab + Pertuzumab|Durvalumab, trastuzumab, and pertuzumab will be administered on Day 1 every 3 weeks for 6 cycles. Trastuzumab will be administered as 8 mg/kg intravenous (IV) loading dose, followed by 6 mg/kg IV. Pertuzumab will be administered as 840 mg IV loading dose, followed by 420 mg. Durvalumab will be administered at a fixed dose of 1120 mg IV.
3477323|NCT03820154|Active Comparator|Skin Prick Test TAPE|"The Skin Prick Test Tape is an innovative sterile all-in drug carrying 8 allergens and 2 control solutions including prick needles in one Tape for easy use and standardization. Single use. Reading of wheal reactions after 15 minutes, facilitated by stripes with the allergen names."
3477324|NCT03820154|Active Comparator|Skin Prick Test|The conventional SPT is the world-wide standard in allergy Type 1 diagnosis for inhalant and food allergens. Drops of allergens are applied to the forearm and, with the help of a lancet, brought into the skin. Reading of wheal reactions after 15 minutes.
3477325|NCT03820180|Experimental|Test Product|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
3477326|NCT03820180|Active Comparator|Reference Product|ADVAIR DISKUS® 250/50
3477327|NCT03820128|Active Comparator|Very early refeeding|"Very early diet intervention: refeeding within 24 hours from the hospital admission.~Participants will be encouraged to start eating immediately after the time of admission. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
3126703|NCT03049917|Experimental|KES financial incentive 2|Kenyan Shillings conditional cash transfer upon HIV testing
3179426|NCT00672568|Experimental|2|4975
3477328|NCT03820128|Active Comparator|Early refeeding|"Early diet intervention: refeeding after 24 hours from the hospital admission .~During the first 24 hours after admission participants will be on fluid only (orally and/or intravenously). Later on they will be encouraged to start eating. They will be able to choose the meal from the list with no amount or calories restriction.They will be asked to conduct the daily diet diary - time of feeding, quality and quantity of the foods ingested. Laboratory tests will be performed at the study entry, on the day of 3 and 5 of hospitalization and on the day of discharge."
3477329|NCT03820115|Experimental|Elastic abdominal binder|
3477330|NCT03820115|No Intervention|No binder|
3477331|NCT03820076|Experimental|dose 1|AZT-04
3126704|NCT03049917|Experimental|KES financial incentive 3|Kenyan Shillings conditional cash transfer upon HIV testing
3126705|NCT03049917|Experimental|KES financial incentive 4|Kenyan Shillings conditional cash transfer upon HIV testing
3477332|NCT03820076|Experimental|dose 2|AZT-04
3477333|NCT03820076|Experimental|dose 3|AZT-04
3477334|NCT03820063|Experimental|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22~Patients who do not achieve pCR will complete a total of nine cycles taxane-containing chemotherapy followed by 14 cycles of treatment with adjuvant T-DM1."
3477335|NCT03820037|Active Comparator|OPC, Ongentys|Single oral doses of 50 mg opicapone, administered using the reference (Ongentys ®) active pharmaceutical ingredient (API) source
3477336|NCT03820037|Experimental|BIA 9-1067|Single oral doses of 50 mg opicapone, administered using the test (BIA 9-1067)
3477337|NCT03820011|Experimental|PEM-Plus Group|For Aim 1, 6 parents of young children were recruited to perform tasks related to navigating the PEM+ interface. Data on completion rate and time, as well as user satisfaction, were analyzed to guide PEM+ improvements. For Aim 2, we recruited 26 participants to enroll in a feasibility trial of PEM+. Caregivers who completed the YC-PEM e-PRO to evaluate their child's participation clicked on a weblink to begin PEM+, whereby they built on their YC-PEM responses for the purpose of creating a participation-focused care plan to share with their child's rehabilitation team. Caregivers were instructed to complete the PEM+ over a two-week (14 day) period because it mimics what would be provided in routine care.
3126706|NCT03050203|Experimental|custom pack|
3477338|NCT03819985|Experimental|Treatment (hypofractionated RT)|Patients receive hypofractionated radiation therapy in 15 daily fractions over 3 weeks in the absence of disease progression or unacceptable toxicity.
3477339|NCT03819946|Experimental|Study Group- esophgeal cooling|In this study arm, the participants will have esophageal protection during their catheter ablation procedure, utilizing the esophageal cooling device (Attune Medical, Chicago, IL). During catheter ablation, the cooling device is set to cooling levels.
3477340|NCT03819946|Active Comparator|Control group- esophgeal temperature probe|In this control group, the participants will have esophageal protection utilizing the standard method in current practice, which is an esophageal temperature probe. If recorded temperatures rise above 38 degrees during ablation, ablation treatment is halted in this region.
3477341|NCT03819972|Placebo Comparator|Control|Participants will ingest a drink containing 25 g whey protein hydrolysate (227 mg of total calcium ingested)
3477342|NCT03819972|Active Comparator|Dose 1|Participants will ingest a drink containing 25 g whey protein hydrolysate and 3179 mg Capolac (984 mg of total calcium ingested)
3477343|NCT03819972|Active Comparator|Dose 2|Participants will ingest a drink containing 25 g whey protein hydrolysate and 6363 mg Capolac (1742 mg of total calcium ingested)
3477344|NCT03819972|Active Comparator|Dose 3|Participants will ingest a drink containing 25 g whey protein hydrolysate and 9547 mg Capolac (2500 mg of total calcium ingested)
3477345|NCT03819998||PCOS group|women who have PCOS
3477346|NCT03819998||control group|women who donnot have PCOS
3477347|NCT03819933|Other|Pregnant women and their partners|"For the qualitative arm of this mixed method study, using an exploratory sequential design, investigators will enroll ~ 30 adult pregnant women admitted estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners to participate in a post-counseling semi-structured interview to explore preferred language and approaches, and better inform questionnaire development. Sample size will be up to 30 families, or until thematic saturation is achieved (total up to 60 if all partners agree to participate).~For the quantitative arm of this study, investigators will enroll ~100 adult pregnant women admitted between estimated 22 0/7-25 6/7 weeks' estimated gestation and their partners (up to total ~200 if all partners present and agree to participate)."
3126707|NCT03050203|Active Comparator|standard care|
3126708|NCT03050216|Experimental|Cy, FLU, Haplo NK and ALT-803|"Preparative Regimen of Fludarabine and Cyclophosphamide~ALT-803 Activation of Donor NK Cells~ALT-803 to Facilitate NK Cell Survival and Expansion"
3126709|NCT03050294|Active Comparator|Control- Atopic Dermatitis|Participants with atopic dermatitis will receive desoximetasone and no calls.
3126710|NCT03050294|Experimental|Atopic Dermatitis Intervention|Participants with atopic dermatitis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
3126711|NCT03050294|Active Comparator|Control- Psoriasis|Participants with psoriasis will receive desoximetasone and no calls.
3126712|NCT03050294|Experimental|Psoriasis Intervention|Participants with psoriasis will receive desoximetasone and will be called twice each day, morning and evening, at predetermined times to go over their use of the medication.
3179427|NCT00672568|Experimental|3|4975
3179428|NCT00672568|Placebo Comparator|4|Placebo
3179429|NCT00672581|Experimental|1|Control (healthy volunteers)
3126713|NCT03050307|Experimental|TAK-438 20 mg|Helicobacter Pylori positive (HP+) participants: TAK-438 20 mg tablet, twice daily (BID) along with lansoprazole placebo-matching, capsule BID in addition to bismuth-containing quadruple antibiotic therapy for the first 2 weeks. Following 2 weeks of eradication therapy participants received TAK-438 20 mg QD along with lansoprazole matching placebo 30 mg, capsule QD for up to 6 weeks. HP negative (HP-) participants: TAK-438 20 mg tablet, (QD) along with lansoprazole matching placebo, 30 mg capsule QD for up to 8 weeks.
3126714|NCT03050307|Experimental|Lansoprazole 30 mg|HP+ participants: Lansoprazole 30 mg, capsule, orally, BID and TAK-438 placebo-matching tablet, orally, BID along with bismuth-containing quadruple antibiotic therapy for first 2 weeks. Following 2 weeks participants received Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 6 weeks. HP- participants: Lansoprazole 30 mg, capsule, orally, QD along with TAK-438 placebo-matching tablet, orally, QD for up to 8 weeks.
3477348|NCT03819933|Other|Counseling MFM and Neonatology providers|Investigators will enroll ~100 counseling Maternal-Fetal Medicine (MFM) specialists and 100 counseling Neonatologists (total ~200 providers), who provided counseling to the enrolled pregnant women between 22 0/7-25 6/7 weeks' estimated gestation for anticipated extremely preterm delivery. This assumes 1 counseling provider from MFM and 1 from Neonatology per pregnant woman, although there could be more if a consult is performed by both an attending physician and a training fellow or practitioner, or less, if a counseling provider declines to participate in the study. There will be anticipated repetition of counseling providers, accounted for in the statistical analysis. Providers will be asked to complete educational interventions to improve counseling at extreme prematurity.
3477349|NCT03819920|Placebo Comparator|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
3179430|NCT00672581|Experimental|2|Mild Hepatic Impairment
3179431|NCT00672581|Experimental|3|Moderate Hepatic Impairment
3477350|NCT03819920|Active Comparator|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
3477351|NCT03819907|No Intervention|Control|"15 participants will be randomly assigned to the control group. They will receive no intervention other than the injection (which is not a part of the trial).~Pre-injection they will receive all baseline measures and questionnaires. Post injection they will receive the primary outcome measures: 1) Numeric Pain Rating Scale and 2) Anxiety thermometer"
3477352|NCT03819907|Active Comparator|Audiovisual (AV) Guided Relaxation|Combination Product: Audiovisual Guided Relaxation Five-minute guided relaxation delivered via a computer screen and speakers
3477353|NCT03819907|Experimental|Virtual Reality (VR) Guided Relaxation|"Combination Product: Virtual Reality Guided Relaxation Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.~Other Names:~• Samsung Galaxy 7s/Samsung adaptable VR headset"
3477354|NCT03819894|Experimental|Intervention|The intervention is the introduction of a lower female threshold. In cluster-randomized trials, the cluster (i.e., hospital) is the unit of randomization.
3477355|NCT03819894|No Intervention|Control|The control phase will be standard of care, with the use of an overall population hs-cTn T and I threshold, for both men and women, to identify those with myocardial injury/infarction.
3477356|NCT03819868|Active Comparator|High Cost|Restoration using a high-cost sealant
3477357|NCT03819868|Experimental|Low Cost|Restoration using a low-cost sealant
3477358|NCT03819881|Experimental|STMC-103H|"Oral administration of STMC-103H twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
3477359|NCT03819881|Placebo Comparator|Placebo|"Oral administration of placebo twice daily, randomized 3:1 (STMC-103H:Placebo) in three age-descending groups:~Part 1: 20 subjects 18-40 years of age Part 2: 20 subjects, 12-17 years of age Part 3: 20 subjects, 2-11 years of age"
3477360|NCT03819842|No Intervention|Aphakic Measure only|Eye measured in aphakic state only
3477361|NCT03819842|Active Comparator|Pseudophakic measure|Eye measured in aphakic state then again in pseudophakic state with toric IOL using the ORA System. Pseudophakic measurement obtained will provide data about placement of toric iol and the surgeon will use that data to rotate the iol if necessary.
3477362|NCT03819816|Experimental|DEA-App|The intervention (DEA) group will receive the newly developed app.
3179432|NCT00672581|Experimental|4|Severe Hepatic Impairment
3477363|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
3477364|NCT03819803|Experimental|Steroid refractory GI-aGvHD|"Patients with GI-aGvHD not sufficiently responding to GvHD therapy with corticosteroids.~Intervention: Fecal microbiota transplantation"
3477365|NCT03819790|Experimental|Insulin Glargine + GLP-1 RA|Insulin Soliqua (a titratable combination of insulin Glargine + GLP-1 RA) will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with or without metformin.
3477366|NCT03819790|Active Comparator|Basaglar/Lantus + gliclazide MR|Basal insulin Basaglar/Lantus will be administered at the subject's end-of run-in phase insulin dose (minimum dose of 15 units in both arms) every morning (before first meal of day) and titrate by one unit per day until fasting glucose level of 4-5.5 mmol/L is obtained, with gliclazide MR 60 mg OD, with or without metformin.
3477367|NCT03819777||Idiopathic PAH|
3477368|NCT03819777||CTD-PAH|
3477369|NCT03819777||CTD without PAH|
3477370|NCT03819764|Active Comparator|Aerobic Exercise & Repetitive Task Practice|"Participants will perform the following:~45 minutes of cycling~45 minutes of upper extremity repetitive arm exercises"
3477371|NCT03819764|Active Comparator|Upper Extremity Repetitive Task Practice Only|"Participants will perform the following:~1. 90 minutes of upper extremity repetitive arm exercises"
3477372|NCT03819738|Experimental|fMRI intervention|
3477373|NCT03819725|Other|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla® ) and glucose measurements will be monitored during 2-5 days. Oral food intake will be recorded.
3179433|NCT00672607|Experimental|1|
3179434|NCT00672607|Placebo Comparator|2|
3179435|NCT00672659|Active Comparator|1|Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
3477374|NCT03819751|Other|MRI-targeted prostate biopsy|Participants receive both type of MRI-targeted biopsy. Patients are randomized with one half having visual registration first and the other half having software registration first.
3477375|NCT03819712|Experimental|No recurrent UTI|Healthy female volunteer aged 18 to 28 years reporting a single cystitis since the age of 14 years
3477376|NCT03819712|Experimental|Recurrent UTI|
3477377|NCT03819686|Experimental|Living ACTS website|In addition to the provision of standard transplant education procedures, a patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching the 20-minute video).
3477378|NCT03819686|Other|Standard transplant education procedures|Usual Care, which involves the provision of standard transplant education procedures at each transplant center, which entail reviewing a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two 10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
3477379|NCT03819673|Experimental|Intervention Group (IG)|Care based on the computerised decision-support tool
3477380|NCT03819673|No Intervention|Control Group (CG)|Usual care advice by primary care provider or dietitian of participating hospital
3477381|NCT03819660|Experimental|amifampridine phosphate|Oral tablets, 15 to 80 mg per day in divided doses 3 to 4 times a day for up to 18 months.
3477382|NCT03819699|Experimental|Cohort 1 - dose regimen 1|Cohort 1: encompasses patients enrolled prior to the PA1
3477383|NCT03819699|Experimental|Cohort 2 - dose regimen 2|Cohort 2: 10 patients who will receive one administration of booster vaccine prior to the first IMP administration
3477384|NCT03819699|Experimental|Cohort 2 - dose regimen 3|Cohort 2: 10 patients who will not receive a booster vaccine
3477385|NCT03819647|Experimental|stiripentol (Diacomit)|
3477386|NCT03819621|Experimental|OCULAR PROSTHESIS MOTILITY|All participants ocular prosthesis motility will be measured using the mediGrid app, Image J software in comparison to the ruler as a gold standard.
3477387|NCT03819608|Experimental|real APT+ real iTBS|real APT+ real iTBS included 30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. iTMS will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right dorsolateral prefrontal cortex at 80% active motor threshold .
3477388|NCT03819608|Active Comparator|real APT + placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. APT-III is a computer based cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
3477389|NCT03819608|Active Comparator|placebo APT+ real iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Bursts of TMS pulses will be applied at 5Hz rate; each burst consists of 3 pulses delivered at 50Hz rate. The bursts are applied for 2s with 8s inter-burst-intervals, for a total of 600 pulses. The total stimulation time per session is approximately 192s (~ 3 minutes). Participants randomized to active iTBS will receive stimulation at the right DLPFC at 80% active motor threshold .
3477390|NCT03819608|Active Comparator|placebo APT+ placebo iTBS|30 1-hour treatment sessions will be provided 3/week. Sessions will be conducted for 10 weeks. Placebo APT-III is a computer based active control cognitive training program. Participants randomized to placebo iTBS will not receive any iTBS stimulation.
3126715|NCT03050320|Experimental|Exercise|The participants in this arm will be asked to attend 3 group classes per week for 12 weeks taught by a certified exercise instructor. Five class times will be offered per week. These classes included a warm-up, static poses shown to decrease knee joint loading, and a cool down including flexibility exercises. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
3477391|NCT03819595|Experimental|Supervised arm|Supervised exercise. The intervention will be a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
3477392|NCT03819595|Active Comparator|Control arm|"Supervised exercise.The intervention will be a Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.~After 3 months, it become supervised arm"
3477393|NCT03819582|Experimental|Intraocular lens|Subjects implanted with the EyeCee One Intraocular lens
3477394|NCT03819569|Active Comparator|Biopsy|Subjects receive a renal cell biopsy prior to making a decision about treatment
3477395|NCT03819569|Sham Comparator|No Biopsy|Subjects do not receive a renal cell biopsy prior to making a decision about treatment
3477396|NCT03821311|Experimental|Computed tomography examination|Each patient will undergo a low-dose supine position chest CT scan including end-inspiratory and expiratory acquisitions, corresponding to the routine protocol for COPD patients, except that this end-inspiratory/end-expiratory CT is repeated 3 times for total of 6 CT acquisitions.
3477397|NCT03819543|Experimental|Transcranial Direct Current Stimulation|
3477398|NCT03819556|Active Comparator|Active immunotherapy with milk protein|Daily dose fresh milk protein increased in 11 steps
3477399|NCT03819556|No Intervention|Control|Diet free from milk protein
3477400|NCT03821545|Active Comparator|Lidocaine Group|
3477401|NCT03821545|Active Comparator|Ketamine Group|
3477402|NCT03821545|Active Comparator|Lidocaine and Ketamine Group|
3477403|NCT03821545|Placebo Comparator|Placebo (0.9% NaCl) Group|
3477404|NCT03821675|Active Comparator|Active|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
3477405|NCT03821675|Sham Comparator|Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
3477406|NCT03819530|Experimental|Supplementation Group|Receives baseline deworming medication. Intervention: receive daily micronutrient supplementation packets- 6 month supply, to be taken every day. Blood iron and anthropometric measurements taken at 0 and 6 months.
3477407|NCT03819530|No Intervention|Control Group|Receives baseline deworming medication. Blood iron and anthropometric measurements taken at 0 and 6 months.
3477408|NCT03821571|Experimental|Patient with primary aldosteronism|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
3477409|NCT03821571|Active Comparator|Patient with essential hypertension|Brain MRI with T1WI, T2WI, FLAIR, thin-sliced T1WI, DWI, TOF, and blood sensitive sequence (SWI) will be performed.
3477410|NCT03819517|Active Comparator|Resveratrol|500 mg of time released micronized trans-Resveratrol
3477411|NCT03819517|Placebo Comparator|Placebo|Placebo will be used in the form of an empty white colored soft vegetarian capsule as resveratrol is presented
3477412|NCT03819504|Experimental|4-D navigated stereotactic radiosurgical ablation|Patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias will undergo 4-D navigated stereotactic radiosurgical ablation
3477413|NCT03821389|Experimental|NIOD Frequencer of 40Hz|40 Hz of NIOD will be applied and then 60Hz will be used 3 hours later. 60 Hz of NIOD will be applied and then 40Hz will be used 3 hours later for the rest of the patients. The investigators will analyze the difference in average effects between 40Hz and 60Hz.
3477414|NCT03821389|Active Comparator|NIOD Frequencer of 60Hz|
3477415|NCT03821285|Experimental|pulmonary rehabilitation|Pulmonary rehabilitation program
3477416|NCT03821506|Experimental|Dynamic light|The experimental intervention is the installation of a dynamic LED-light system in 10 separate patient single rooms. The system includes three elements: a window jamb built-in light panel, two ceiling mounted lamps, and a wall mounted lamp. All lamps will have a dynamic, time dependent frequency distribution and intensity of light.
3477417|NCT03821506|Placebo Comparator|Usual care|The usual care is constant standard LED-light with two elements: two ceiling mounted lamps and a wall mounted lamp.
3477418|NCT03821337|Experimental|rTMS|Participants will receive 18 sessions of active rTMS delivered at 120% rMT.
3477419|NCT03821337|Placebo Comparator|Sham TMS|Participants will receive 18 sessions of sham rTMS delivered through an inactive coil.
3477420|NCT03821207|Active Comparator|The exercise group|The group will be instructed to perform stretching exercises including the pelvic and lumbar regions 3 times a day for the first 3 days of the menstrual cycle
3477421|NCT03821207|Active Comparator|The abdominal massage group|The group will be instructed to massage the abdomen for 10 mins a day on the first 3 days of the menstrual cycle.The massage is to be applied as effleurage (light touch) clockwise over the abdomen
3477422|NCT03821207|Placebo Comparator|The control group|The control group will perform no exercise or massage.
3477423|NCT03821376|Experimental|Renal malignancy|Patients with renal mass(es) identified by cross sectional imaging, specifically ultrasound following the intravenous injection of Lumason
3477424|NCT03821402|Experimental|DAXI for injection dose LOW DOSE|LOW dose group
3477425|NCT03821402|Experimental|DAXI for injection dose MEDIUM DOSE|MEDIUM dose group
3477426|NCT03821402|Experimental|DAXI for injection Dose HIGH DOSE|HIGH dose group
3477427|NCT03821402|Placebo Comparator|Placebo|Placebo group
3477428|NCT03821298|Experimental|Standard of Care|short thumb orthoses during ADL, joint reeducation for hand used, radial nerve gliding exercises and thumb proprioception exercises
3477429|NCT03821220|Active Comparator|Group A|Patients will receive an activity tracker and written information for pre-diabetic, on top of their usual care.
3477430|NCT03821220|Active Comparator|Group B|Patients will receive an activity tracker, written information for pre-diabetic, and personalized physical activity prescription, on top of their usual care.
3477431|NCT03821220|Active Comparator|Group C|Patients will receive an activity tracker, written information for pre-diabetic, personalized physical activity prescription, three sessions of motivational interview support from trained physician assistants, and two session of dietitian support, on top of their usual care.
3477432|NCT03821129|Other|GORE® CARDIOFORM Septal Occluder|Single Arm Commercially available GORE® CARDIOFORM Septal Occluder
3477433|NCT03821103|Experimental|Standard training arm|The standard training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period.
3477434|NCT03821103|Experimental|Behavioral economic enhanced arm|The behavioral economic enhanced training arm will consist of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone Emergency Department administration within 3 month study period in addition to an opt-out invitation, loss-framed incentivization, and weekly tailored text message-based reminders
3477435|NCT03819335|Active Comparator|Standard care|Usual follow-up of diabetes type 1 with face-to-face visits
3477436|NCT03819335|Experimental|mySugr app|Telemedical assistance with mySugr app
3477437|NCT03819296|Experimental|Supportive Care (standard of care, sample collection, FMT)|"PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples.~PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples.~PROJECT 3: Patients undergo FMT."
3126716|NCT03050320|Other|No Exercise|The participants in this arm will be asked to refrain from changing their physical activity over the 12 weeks and maintain any strategies typically used to manage knee and/or hip pain. Since it is known that exercise is beneficial for pain management and strengthening in knee OA, participants randomized to the no exercise group will be offered the same exercise program following completion of the study. Measurements will be obtained at baseline (before intervention) and at follow-up (following intervention). Outcomes included clinical mobility; pain; isometric leg strength; cardiovascular fitness; and resilience.
3126717|NCT03050359|Experimental|TAK-438 20 mg|H. pylori negative (HP -) participants: TAK-438 20 mg, tablets, orally, once daily (QD) and lansoprazole placebo-matching capsules, orally, QD for up to 6 weeks. H. pylori positive (HP +) participants: TAK-438 20 mg, tablets, orally, twice daily (BID) and lansoprazole placebo-matching capsules, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed byTAK-438 20 mg, tablets, orally, QD and lansoprazole placebo-matching capsules, orally, QD for up to 4 weeks.
3477438|NCT03819270|Experimental|LY3372689|Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
3477439|NCT03819270|Placebo Comparator|Placebo|Matching placebo administered orally in healthy participants in one of three study periods
3477440|NCT03819309|Experimental|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
3477441|NCT03819309|Active Comparator|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
3126718|NCT03050359|Experimental|Lansoprazole 30 mg|H. pylori negative (HP -) participants: lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, QD for up to 6 weeks. HP + participants: lansoprazole 30 mg, capsules, orally, BID and TAK-438 placebo-matching tablets, orally, BID for first 2 weeks along with Bismuth-Containing Quadruple Therapy followed by lansoprazole 30 mg, capsules, orally, QD and TAK-438 placebo-matching tablets, orally, BID for up to 4 weeks.
3126719|NCT03050372|Experimental|Active Low Field Magnetic Stimulation|LFMS - Active
3477442|NCT03821012||CSCAP-1|STEMI with symptom onset within 12 h regardless of whether receiving reperfusion or symptom onset within 12-24 h of needing PPCI
3477443|NCT03821012||CSCAP-2|STEMI patients with symptom onset within 30 days
3126720|NCT03050372|Sham Comparator|Sham Low Field Magnetic Stimulation|LFMS - Sham
3126721|NCT03050450|Experimental|dose level 1|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
3126722|NCT03050450|Experimental|dose level 2|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
3477444|NCT03821012||CSCAP-3|STEMI patients with symptom onset within 30 days
3477445|NCT03819348||TSM of HIV-negative Host|Eligible patients were HIV-infected adults who had talaromycosis that was confirmed by either microscopy or culture.
3477446|NCT03819283|Other|Hepatic evaluation|
3477447|NCT03819244|Experimental|Diode laser|Soft tissue incision with 940 nm Gallium Aluminum Arsenide diode laser, at implant recovery settings (2.5 W output power, average power: 1.25 W, pulse length : 1.00 ms, pulse interval: 1.00 ms) in second-stage implant surgery.
3477448|NCT03819244|Experimental|Erbium laser|Soft tissue incision with 2780 nm Er,Cr:YSGG laser, at implant recovery settings (2.00 W power, 100 Hz, H mode, 10% water and 10% air) in second-stage implant surgery.
3477449|NCT03819426|Experimental|High Intensity Interval Training|Participants will be shown the appropriate techniques and intensity (high intensity; i.e., 70-90% of maximum heart rate (220-age) with a verified online youtube video. Participants will be provided with this video and other options that can be followed to complete 15 minute HIIT interventions at home. Interventionist will observe participant engaging in HIIT for 15 minutes. HIIT intervention (for 15 minutes) will also be observed during Session 4 and 8.
3477450|NCT03819426|Experimental|Walking|This intervention will be demonstrated during Session 1. Participants will be shown the appropriate walking intensity (low intensity; i.e., approximately 50% of maximum heart rate (220-age) or lower) by interventionist. Interventionist will observe participant engaging in walking at appropriate intensity level for 15 minutes. Walking intervention (for 15 minutes) will also be observed during Session 4 and 8.
3477451|NCT03821363|Experimental|Low dose group|SCT-I10A will be administered at a dose of 60mg, Q3W up to 24 months.
3477452|NCT03821363|Experimental|Middle dose group|SCT-I10A will be administered at a dose of 200mg, Q3W up to 24 months.
3477453|NCT03821363|Experimental|High dose group|SCT-I10A will be administered at a dose of 600mg, Q3W up to 24 months.
3477454|NCT03820986|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule daily for up to at least 2 years.
3477455|NCT03820986|Active Comparator|Pembrolizumab+Placebo|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS placebo for lenvatinib via oral capsule daily for up to at least 2 years.
3477456|NCT03819231|Experimental|Mindfulness and intranasal oxytocin|Given oxytocin through intranasal administration and self-directed mindfulness training.
3477457|NCT03819231|Active Comparator|Mindfulness and placebo|Given sterile saline through intranasal adminstration and self-directed mindfulness training.
3477458|NCT03819231|Sham Comparator|Sham mindfulness and placebo|Given sterile saline through intranasal adminstration and sham self-directed mindfulness training.
3477459|NCT03819361||Suspected OSA|
3477460|NCT03820973|Experimental|Brief CBT for Anxiety|Participants will receive Brief Cognitive Behavioral Therapy for Anxiety (bCBT). Sessions with clinicians will be provided via VA Video Connect to Home (VVC-H). Participants will have the option to select from a list of skills to tailor to his/her preferences. Participants will be able to receive up to 9 total sessions and generally last 30 to 40 minutes. For the purpose of this study, treatment duration will be limited to 3 months to ensure standardization of study outcome measures.
3126723|NCT03050450|Experimental|dose level 3|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
3477461|NCT03819322|Experimental|HCV seropositive non-viremic (HCV Ab+/NAT-) donor|"Liver recipients will be monitored for HCV for one year following transplant. When HCV RNA is detected, the transmission-triggered treatment phase will be initiated.~Recipients will be treated with 12-week oral course of sofosbuvir/velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg)."
3477462|NCT03819322|Experimental|HCV seropositive viremic (HCV Ab+/NAT+) donor|Post-operative day 1, liver recipients will be treated with 12-week oral course of sofosbuvir/ velpatasvir (Epclusa®), a fixed-dose combination of a nucleotide analogue HCV NS5B polymerase inhibitor (sofosbuvir - 400mg) and a NS5A inhibitor (velpatasvir - 100mg).
3477463|NCT03819166|Experimental|experimental group|The participants recruited in the group will receive the input of deep touch pressure during their procedures of dental treatment.
3477464|NCT03819166|Sham Comparator|control group|The participants recruited in the group will not receive the input of deep touch pressure during their procedures of dental treatment.
3477465|NCT03819192||neonates with signs of EONS|
3477466|NCT03819192||neonates without signs of EONS|
3477467|NCT03819192||pregnant women with PPROM|
3477468|NCT03820908|Experimental|Bisantrene|patients will receive bisantrene 250mg/m2/d for 7 days
3477469|NCT03819205|Experimental|kinesiotaping group(before/after)|"Hemiplegic CP:Kinesiotaping on the affected side~Diplegic, tetraplegic CP: side of upper extremity which children have been used to but have obstacles in daily life~intervention Duration: For 1 week at least 2-3 hours a day, renewing if it's necessary.~Note:Patients will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day.~Evaluation: In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion"
3477470|NCT03819257||Patients with perianal Crohn's disease.|
3477471|NCT03819140|Active Comparator|Continuous OCP Therapy|Participants randomly assigned to this arm will receive 8 packs of a 21 day oral contraceptive pills (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which comes in a formulation of 21 days of active hormone and 7 days of sugar pills. In this arm, participants will only be expected to take active hormone pills (colored pills) for the 6 months straight without stopping or taking the sugar pills in each pack.
3477472|NCT03819140|Active Comparator|Cyclical OCP Therapy|Participants randomly assigned to this arm will receive 6 packs of a 21 day oral contraceptive pill (OCP) called Yasmin (3 mg Drospirenone/0.03 mg Ethinyl estradiol) which has 21 days of active hormone and 7 days of sugar pills. Participants will take one pill daily for 6 months and be expected to take the sugar pills at the end of each monthly pack prior to starting a new pack.
3126724|NCT03050450|Experimental|dose level 4|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)
3477473|NCT03819036|Experimental|Patients|Questionnaires for patients requiring dental emergencies care
3477474|NCT03819179|Experimental|Serum|Burt's Bees Serum
3477475|NCT03819179|Experimental|Serum with Biulin|Burt's Bees Serum with Biulin
3477476|NCT03819179|Experimental|Serum with Berenew Complex|Burt's Bees Serum with Berenew Complex
3477477|NCT03819179|Experimental|Serum with Ecoskin|Burt's Bees Serum with Ecoskin
3477478|NCT03819179|Experimental|Serum with Bonicell|Burt's Bees Serum with Bonicell
3477479|NCT03819023|No Intervention|Normal subjects|
3477480|NCT03819023|Active Comparator|respiratory suppressing drugs|
3477481|NCT03819101|No Intervention|Arm A|Standard of Care (SOC) for CRPC
3477482|NCT03819101|Experimental|Arm B|SOC + acetylsalicylic acid 100 mg daily
3126725|NCT03050450|Experimental|dose level 5|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)
3477483|NCT03819101|Experimental|Arm C|SOC + atorvastatin 80 mg daily
3477484|NCT03819101|Experimental|Arm D|SOC + acetylsalicylic acid 100 mg daily + atorvastatin 8
3477485|NCT03820804||Diet-treated|Patients with Phenylketonuria under dietary treatment.
3477486|NCT03820804||Sapropterin-treated|Patients with Phenylketonuria under sapropterin treatment.
3126726|NCT03050541|Experimental|MDMA at Memory Encoding|20 healthy adult volunteers will be randomly assigned to the encoding group (MDMA at Encoding). This group will receive capsules before viewing the study materials, and at retrieval two days later, but they will receive MDMA only in the capsule appropriate to their condition, and the next session capsule will contain placebo.
3126727|NCT03050541|Experimental|MDMA at Memory Retrieval|20 healthy adult volunteers will be randomly assigned to the retrevial group (MDMA at Retrevial). This group will receive placebo before viewing the study materials, and MDMA at retrieval two days later..
3477487|NCT03820791|Experimental|Poster|A poster with pictorial information about dysphagia-specific food procedures placed in patients' rooms for one month
3477488|NCT03820791|No Intervention|No poster|No poster is placed in patients' room.
3477489|NCT03819088|Experimental|Group I (zinc months 1 and 2)|Patients receive zinc PO TID for months 1 and 2 only of the first 4 months on therapy.
3477490|NCT03819088|Experimental|Group II (zinc months 3 and 4)|Patients receive zinc PO TID for months 3 and 4 only of the first 4 months on therapy.
3477491|NCT03819127|Active Comparator|Metformin|metformin 1 g twice a day for 24 weeks
3477492|NCT03819127|Experimental|Metformin plus vildagliptin|metformin 1 g plus vildagliptin 50 mg twice a day for 24 weeks
3477493|NCT03820778|Experimental|Study Arm|Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.
3477494|NCT03819062|Experimental|Refractory Constipation with LLLT|Low level laser therapy (LLLT) will be administered to patients with severe refractory chronic constipation
3477495|NCT03818867|Experimental|Cerclage arm|Pregnancies which had cervical cerclage inserted.
3477496|NCT03818867|No Intervention|No-cerclage arm|Pregnancies which did not have cervical cerclage inserted.
3477497|NCT03819010|Active Comparator|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
3477498|NCT03819010|Active Comparator|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole (2,5 mg/day during 28 days of each Cycle) + Palbociclib (125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer interventions: Letrozol (2,5 mg/day during 28 days of each Cycle)+ Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer
3477499|NCT03818997|Experimental|BTC Cohort|Patient in BTC cohort will receive immune therapy and DKN-01 IV until PD
3179436|NCT00672659|Placebo Comparator|2|Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
3477500|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab + paclitaxel (Arm 1)|Patient randomized in the EGC Arm 1 will receive immune therapy, DKN-01 and chemotherapy intravenously (IV) until PD.
3477501|NCT03818997|Experimental|EGC cohort: DKN-01/atezolizumab without paclitaxel (Arm 2)|Patient randomized in the EGC Arm 2 will receive immune therapy and DKN-01 IV until PD
3477502|NCT03819075|Experimental|Laser|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units.
3477503|NCT03819075|Active Comparator|Control|Standard periimplantitis treatment will be conducted in the control group.
3477504|NCT03818958||active spondyloarthritis|subjects with active spondyloarthritis with a BASDAI greater than 4
3477505|NCT03818958||remission spondyloarthritis|subjects presenting with a remission spondyloarthritis defined by a BASDAI less than 4
3477506|NCT03818958||controls without spondyloarthritis|controls without spondyloarthritis or other chronic inflammatory rheumatism and without fibromyalgia
3477507|NCT03818958||fibromyalgia|subjects with fibromyalgia
3477508|NCT03818841|Experimental|High-flow nasal cannula group|Patients randomised in this group will receive oxygen therapy via a high-flow nasal cannula device with a 60 L/min flow and a 100% fraction of inspired oxygen
3477509|NCT03818841|Other|Non-rebreathing oxygen mask group|In this group patients will be treated with standard oxygen therapy delivered through a non-rebreathing face mask with a 15 L/min flow
3477510|NCT03818828|Experimental|TTAX01|TTAX01 will be applied directly to the wound surface and fixed with sterile adhesive strips, plus a secondary foam dressing held in place by multi-layer compression bandaging. A single layer of the test article should cover the entire open surface of the wound. TTAX01 may overlap onto adjacent healthy tissue and must be fenestrated prior to or after fixture. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case product will be withheld; or, if the test article has been accidentally dislodged within 1-week post application, it may be replaced at the subsequent treatment visit.
3477511|NCT03818906|Active Comparator|Control Group|Patients with first or second molars where the extractions will be performed in a conventional way without any additional local treatment to be done in the alveolus. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
3477512|NCT03818906|Experimental|Test Group 1|Patients with first or second molars where the extractions will be performed in a conventional way and after extraction will be performed aPDT inside the alveolus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
3477513|NCT03818906|Experimental|Test Group 2|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia, the fresh socket will receive local application of infrared in the outer vestibular portion. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
3477514|NCT03818906|Experimental|Test Group 3|Patients with first or second molars where the extractions will be performed in a conventional way and immediately after the exodontia the approaches from the previous groups (Test Group 1 and 2 (aPDT + infrared) will be done. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th. Subjective evaluation of swelling in 48 hours and 7th day.
3477515|NCT03818945|Other|Sodium Fluoride Varnish|
3477516|NCT03818945|Active Comparator|PRG barrier Giomer|
3477517|NCT03818932|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
3477518|NCT03818932|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-acetaminophen
3477519|NCT03818919|Experimental|Post-Operative Non Opioid Pain Protocol|Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam
3477520|NCT03818919|Active Comparator|Post-Operative Traditional Pain Protocol|Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500
3477521|NCT03820687|Active Comparator|Intervention Group|Participants in the intervention group will receive 3 components: 1) a culturally tailored clinical trial educational video, 2) a brochure and 3) support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option for cancer.
3477522|NCT03820687|Active Comparator|Usual Care Control Group|Participants in the usual care control group will receive a general clinical trial fact sheet.
3477523|NCT03818568|Experimental|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
3477524|NCT03818568|Active Comparator|Control|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression).
3126728|NCT03050541|Placebo Comparator|Placebo at both sessions|20 healthy adult volunteers will be randomly assigned to the placebo group (no drug at either session). This group will receive only placebo during study, session before viewing the study materials, and at retrieval two days later.
3126729|NCT03050619||New users of Empagliflozin|New users of empagliflozin
3126730|NCT03050619||New users of Other SGLT2 inhibitors|New users of other SGLT2 inhibitors
3477525|NCT03818724||CoolLoop® cryoablation system|Cryoablation for treatment of atrial fibrillation using the CoolLoop® cryoablation system
3477526|NCT03818893|Experimental|New Combination Immunotherapy|"Patients will receive Pembrolizumab once every 3 weeks and a maximum of 35 doses over 105 weeks .~The patients should be inpatient during treatment with GEN0101 in each treatment cycle and may be outpatient during off-treatment period with GEN0101, observation period, follow-up period with Pembrolizumab.~GEN0101 in a vial will be reconstituted with 1 mL of sterile distilled water and then will be injected intracutaneously (including skin tumor site). Nonetheless, it will not be deemed as deviation if an injection has been given subcutaneously unintentionally, e.g., leakage around the peri-injection sites.~A dose will be 60,000 mNAU in total, and 1 mL per injection site should be administered to 6 injection sites in total. For a patient, the total dose in a treatment cycle will be 360,000 mNAU (360 NAU), and the total dose over 2 treatment cycles will be 720,000 mNAU (720 NAU)."
3477527|NCT03818685|Experimental|Nivolumab + Ipilimumab|Nivolumab (360 mg IV, every 3 weeks) for 8 doses and Ipilimumab (1 mg/kg, IV, every 6 weeks or every 2 doses of Nivolumab in case of dose delays) for 4 doses.
3477528|NCT03818685|Active Comparator|Capecitabine|Capecitabine (1000 mg/m2 twice a day, Bis In Die), 14 days on / 7 days off for 8 cycles.
3477529|NCT03818633|Experimental|Elastic abdominal binder|
3477530|NCT03818633|No Intervention|No binder|
3477531|NCT03818789|Experimental|Mindfulness|A mindfulness training is applied to see if it supports exercise endurance in-lab and during follow-up
3477532|NCT03818789|Placebo Comparator|Control|A study skills video is shown intended to have no effect on exercise but to match for time.
3477533|NCT03818737|Experimental|Autologous BMAC versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either bone marrow derived mesenchymal stem cells (MSCs) or corticosteroid (CS) injection (30:10). All subjects randomized to this arm will undergo bone marrow aspiration, but will only receive one of the injections. At each site, 30 subjects in this arm will receive a standard Orthobiologic injection of Bone Marrow Concentrate (BMAC) and 10 will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
3477534|NCT03818737|Experimental|Adipose-derived SVF versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of Adipose-derived Stromal Vascular Fraction (SVF) or corticosteroid (CS) (30:10). All subjects randomized to this arm will undergo small volume lipoplasty, but will only receive one of the injections. At each site, 30 subjects in this arm will receive the Adipose-derived Stromal Vascular Fraction (SVF) and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
3477535|NCT03818737|Experimental|Umbilical Cord Tissue (UCT) versus corticosteroid|Forty subjects will be randomized to this arm at each site. They will be further randomized within the arm in a 3:1 ratio to receive either an injection of cryopreserved doses of cord tissue MSCs or corticosteroid (30:10) injected into the knee. At each site, 30 subjects in this arm will receive the umbilical cord tissue MSCs and 10 subjects will receive the CS injection. All injections will be made into the knee joint via ultrasound guidance using a standard approach.
3477536|NCT03818581|Active Comparator|Treatment Group|
3477537|NCT03818581|Placebo Comparator|Placebo Responders|
3477538|NCT03818581|Active Comparator|Placebo Non-responders Re-randomized to Treatment|
3477539|NCT03818581|Placebo Comparator|Placebo Non-responders Re-randomized to Placebo|
3477540|NCT03818802|Active Comparator|Nicotinamide Riboside|NR is a single chemical moiety containing nicotinamide and ribose. The investigational product is a synthetic NR that is nature-identical to naturally-occurring NR, does not induce flushing or pruritus and has no effect on lipid levels.
3477541|NCT03818802|Placebo Comparator|Placebo|Correspondent placebo, a pill not containing the active component.
3477542|NCT03818854|Experimental|Human Mesenchymal Stromal Cells|A single dose of 10 million cells/kg predicted body weight (PBW) Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells will administered intravenously over approximately 60-80 minutes.
3126731|NCT03050619||New users of Other non-insulin GLDs|New users of other non-insulin GLDs
3126732|NCT03050697|Experimental|HMTIOL|HARMONI® Modular Toric Intraocular Lens implanted in the capsular bag following removal of the cataractous lens, intended for lifetime use
3179437|NCT00672672|Experimental|II|Patients who do not receive platlet gel.
3477543|NCT03818854|Experimental|Cell Reconstitution Media|A single dose of cell reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40) will administered intravenously over approximately 60-80 minutes.
3477544|NCT03818672|Experimental|Rifaximin|Rifaximin 550 mg BID
3477545|NCT03818984|Experimental|Safer Conception Intervention|Men will participate in 3 counseling sessions with a lay counselor. In the first session, the counselor will share information on the various safer conception strategies and help the participant think about developing a healthy plan. In the following 2 sessions, the counselor and the participant will work together to develop a healthy baby plan using motivational interviewing and problem solving. In the 2 booster sessions, the counselor and the participant will check in to evaluate the success of the plan and make changes as necessary.
3477546|NCT03818711|Experimental|Communication & Coping Intervention|A cognitive behavioral intervention for mothers of adolescents with type 1 diabetes to improve coping and the quality of parental involvement.
3477547|NCT03818711|Active Comparator|Education & Check Ins|The comparison group receives educational materials on diabetes management and phone calls, as well as access to a secret Facebook group with daily posts on diabetes management.
3477548|NCT03818555|Other|Sebacia Microparticles Treatment|
3477549|NCT03818750|Experimental|Experimental arm|"Patients (60) will be selected from the Alcohol Use Disorders Identification Test (AUDIT-C) :~light drinkers (score between 1 to 3)~heavy drinkers (score between 4 to 7) Two clinical visits will be realized in less than 4 weeks"
3126733|NCT03050775|Experimental|Heated Ventilator Circuit|Heated and humidified inspired gases using the ANAPOD™ Heat and Humidification System (Westmed; Tucson, Arizona, USA) circuit prior to induction of general anesthesia in addition to standard ventilation and temperature management.
3126734|NCT03050775|Active Comparator|Standard Ventilator Circuit|Standard ventilation and temperature management.
3126735|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 1 day|Experiment 1
3126736|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 3 days|Experiment 1
3179438|NCT00672685|Experimental|1|Omega-3 group without any intervention
3477550|NCT03818451|No Intervention|Control Group|"All patients are treated by standard treatments according to patterns of severity and in the light of different variables, mainly represented by the conditions of cerebral hemodynamics. These procedures can be summarized as follows:~Surgical evacuation of hemorrhagic masses and brain contusion~Medical management aimed to maintenance of euvolemia and adequate brain perfusion. Prevention of secondary complications of critical illness included: preventive treatment of venous thromboembolism (VTE) and seizures~Patient who undergo surgical treatment, will recieve also postoperative intensive care treatments including: position of the head high, lower values of end-tidal CO2, sedation with reduced metabolic consumption of O2, increase in plasma osmolarity by administration of mannitol in controlled doses or hypernatremia, therapeutic CSF drainage"
3477551|NCT03818451|Experimental|Study Group|Standard treatment plus specific treatment. The investigational agent, the co-ultraPEALut, is administered orally twice daily (every 12 h) for 180 days in association with the specific therapy (e.g., antiplatelet agents, anticoagulants, antiepileptic drugs) commonly administered to these patients and/or with drugs prescribed for comorbidities (i.e. diabetes, arterial hypertension).
3477552|NCT03818438||Case subjects adult patients with chronic ankle instability|"Male or female subjects aged 18-45, presenting :~at least one acute lateral ankle sprain (i.e. initial ankle sprain more than 12 months before inclusion),~at least one residual symptom (giving way OR sensation of instability OR recurrent ankle sprain), confirmed by a score < 24 on the Chronic Ankle Instability Tool (CAIT)~Impact on activities of daily living and sport, score < 90% on Foot and Ankle Ability Measure (FAAM) and < 80% on FAAM-sport Case subjects are free of any other lower extremity pathologies or pain Subjects presenting bilateral chronic ankle instability are excluded"
3126737|NCT03050801|Experimental|Parietal Cortex rTMS stimulation - 4 days|Experiment 1
3126738|NCT03050801|Experimental|Experiment 2 - Parietal Cortex rTMS stimulation - 3 days|Experiment 2
3477553|NCT03818438||Healthy subjects|Male or female subjects aged 18-45 (matched with case Healthy subjects), without any lower extremity pathologies
3477554|NCT03818503||OligoCare|Patients with oligometastatic disease treated with radical radiotherapy
3477555|NCT03818503||ParticleCare|Patients with cancer treated with particle therapy
3477556|NCT03818412|Experimental|Soft Tissue Sarcoma|"A sample of archival tumor tissue will be collected.~Blood samples (about 20-30 mL or 1-2 tablespoons each sample) will be taken:~Prior to planned radiation treatment~2-4 weeks after cancer surgery~Every 12 weeks after surgery for up to 2 years"
3477557|NCT03818490|Experimental|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes at the start of their medical office visit.
3477558|NCT03818490|No Intervention|Control|Patients in this group did not experience an intervention.
3126739|NCT03050801|Experimental|Experiment 2 - Vertex rTMS stimulation - 3 days|Experiment 2
3126740|NCT03050801|Experimental|Experiment 2 - Prefrontal Cortex rTMS stimulation - 3 days|Experiment 2
3126741|NCT03050918|Active Comparator|Phone Call Group (Intervention Arm)|Follow-up phone call intervention: Patients will receive the first call attempt within 72 hours of hospital discharge with a maximum of 3 call attempts by the study nurse made up until post-discharge day 7. The semi-structured script embedded within the program specific electronic health record Discharge Phone Call Starform is used to guide a conversation to obtain information on potential causes of hospital readmission that can be identified and addressed to improve each patient's transition to outpatient care.
3477559|NCT03818542|Experimental|Arm 1: ABBV-181 IV|A single dose of ABBV-181 administered via intravenous (IV) infusion on Day 1.
3477560|NCT03818542|Experimental|Arm 2: ABBV-368 IV|A single dose of ABBV-368 administered via intravenous (IV) infusion on Day 1.
3477561|NCT03818542|Experimental|Arm 3: ABBV-927 IV|A single dose of ABBV-927 administered via intravenous (IV) infusion on Day 1.
3477562|NCT03818542|Experimental|Arm 4: ABBV-927 IT|A single dose of ABBV-927 administered via intratumoral (IT) injection on Day 1.
3477563|NCT03818386|Experimental|AGuIX® + Whole Brain Radiation Therapy|"Intervention: Drug: AGuIX® + WBRT~Other Names:~Gadolinium-chelated polysiloxane based nanoparticles~3 intravenous injections at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~Fr1: AGuIX® injection before the first radiation session~Fr6: AGuIX® injection before the sixth radiation session~30 Gy in 10 fractions of 3 Gy over 2-3 weeks"
3477564|NCT03818386|Active Comparator|Whole Brain Radiation Therapy|Intervention: Radiation: Whole Brain Radiation Therapy ( WBRT) 30 Gy in 10 fractions of 3 Gy over 2-3 weeks
3477565|NCT03818282|Experimental|Paclitaxel for injection (albumin-bound)|
3477566|NCT03818191|Active Comparator|Acamprosate|"All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.~The most common side effect associated with acamprosate use is diarrhea, which occurs in approximately 16% of patients. Other frequently occurring side effects include asthenia, nausea, pruritus, and flatulence, headache, abdominal pain, flu syndrome, edema, weight gain, and myalgia."
3477567|NCT03818191|Placebo Comparator|Placebo|All participants will be randomized to receive acamprosate or placebo in a double-blinded placebo-controlled trial.
3477568|NCT03818152|Other|study group|Reliability study isokinetic strength assessment of the lower limbs.
3477569|NCT03818165|Experimental|CAR2 Anti-CEA CAR-T cell|3 doses of CAR2 Anti-CEA CAR-T cells for each cycle; up to 3 additional cycles received per investigator discretion
3477570|NCT03818126|Experimental|del Nido cardioplegia|
3126742|NCT03050918|No Intervention|Usual Care Group (Control Arm)|Patients assigned to the control group receive standard discharge planning and follow-up per the usual care of their medical providers.
3126743|NCT03051100|Experimental|Triplet Therapy|Bempedoic acid 180 mg, ezetimibe 10 mg, and atorvastatin 20 mg taken orally, daily.
3126744|NCT03051100|Placebo Comparator|placebo|Matching placebos taken orally, daily.
3477571|NCT03818126|Active Comparator|cold blood cardioplegia|
3477572|NCT03818347|Experimental|oxyhydrogen generator (AMS-H-03)|Model: AMS-H-03 Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively In this group, the patients will inhale hydrogen and oxygen with oxyhydrogen generator. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3477573|NCT03818347|Placebo Comparator|Control|In this group, the patients will inhale normal air with analogue machine. The check indexes are questionnaire of sleep, diet and exercise, CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3477574|NCT03818243|Experimental|RLS-|patients with Parkinson disease without RLS
3477575|NCT03818243|Experimental|RLS+|patients with Parkinson disease with RLS
3477576|NCT03818217|Experimental|Coach Pepper group|Pepper is a humanoid socially assistive robot.
3477577|NCT03818217|Other|Tablet group|Tablet training
3477578|NCT03818308|Experimental|Sofosbuvir and Velpatasvir|SOF/VEL FDC film-coated tablet, oral, SOF 400 mg/VEL 100 mg daily, 8 weeks
3477579|NCT03818022|Experimental|Experimental|Patients receiving Cryoneurolysis (Iovera) prior to total knee arthroplasty
3477580|NCT03818022|No Intervention|Control|
3477581|NCT03818009||women undergoing elective CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
3477582|NCT03818009||women undergoing emergency CS under general anesthesia|Early postoperative assessment of the cognitive function of patients through evaluation document which will be filled by the anesthesiologist.
3477583|NCT03817918|Experimental|Determination of local pleural strain|The local pleural strain will be determined over three consecutive respiratory cycles using lung ultrasonography
3477584|NCT03817970|Experimental|Granisetron|Participants randomized to an antiemetic regimen containing granisetron 2 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
3126745|NCT03051165|Other|Hypoglossal Nerve Stimulation Treatment Withdrawal|Recipients of hypoglossal nerve stimulation (HGNS) who agree to participate in the study will have additional tests done to monitor cardiovascular responses to HGNS therapy and the temporary withdrawal of treatment.
3477585|NCT03817970|Experimental|Ondansetron|Participants randomized to an antiemetic regimen containing ondansetron 8 mg oral or IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
3477586|NCT03817970|Experimental|Palonosetron|Participants randomized to an antiemetic regimen containing palonosetron 0.25 mg IV and evaluated for cisplatin toxicity after the first dose of cisplatin.
3477587|NCT03818295|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-praliciguat
3477588|NCT03817996||HFNC + hypoperfusion + Responders|"Patients treated with HFNC presenting with any sign of hypoperfusion, in whom volume expansion was planned by the attending physician.~Clinical signs of inadequate tissue perfusion were suspected at the bedside by observing hypotension (systolic blood pressure <90 mm Hg or the need for norepinephrine), oliguria (urine output <0.5 mL/kg/hr), and cool, mottled extremities.~Their CO increases >15% after passive leg raising."
3477589|NCT03817996||HFNC + hypoperfusion + Non-Responders|Same as previous but their CO do not increase >15% after passive leg raising maneuver.
3477590|NCT03818256|Experimental|CORT118335- 600 mg|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive 600 mg miricorilant for 12 weeks.
3477591|NCT03818256|Placebo Comparator|Placebo|Patients who meet the entry criteria for the Study CORT118335-876 will be randomized to receive placebo for 12 weeks.
3477592|NCT03817905|Experimental|Patient navigator|Participant meets the patient navigator at their colonoscopy appointment and discusses any problems they experienced in getting the colonoscopy done. Participant will tell navigator in their own words their experience and whether they faced any barriers to scheduling and colonoscopy completion.
3477593|NCT03817866||BRAHMS CgA II KRYPTOR|Adult patients with well defined grade 1 and grade 2 GEP-NETs. Serial serum samples from all patients will be analyzed using the BRAHMS CgA II KRYPTOR Assay.
3477594|NCT03818113||HTK-Bretschneider cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with HTK-Bretschneider cardioplegic solution
3477595|NCT03818113||St. Thomas cardioplegic solution|Patients undergoing mitral valve reconstruction via minimal invasive antero- lateral thoracotomy in cardioplegia with St. Thomas cardioplegic solution
3477596|NCT03818269|Other|Septic shock|
3477597|NCT03818269|Other|Control|
3477598|NCT03817931|Placebo Comparator|Placebo|Placebo pill identical will be identical to tablets in the other 2 arms.
3477599|NCT03817931|Active Comparator|Anticholinergic|Solifenacin 5 mg tablet orally once daily for 30 days
3477600|NCT03817931|Active Comparator|Beta-3 agonists, adrenergic|Mirabegron 25 mg tablet orally once daily for 30 days
3477601|NCT03817892|No Intervention|Unguided 2 minutes (U2)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines."
3477602|NCT03817892|Experimental|Unguided 4 minutes (U4)|"The External Chest Compression are performed without guidance of the CPRmeter device (according to the current guidelines).~The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)"
3477603|NCT03817892|Experimental|Guided 2 minutes (G2)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 2 minutes according to the current guidelines.
3477604|NCT03817892|Experimental|Guided 4 minutes (G4)|The External Chest Compression are performed with guidance of the CPRmeter device. (Guidance of the External Chest Compression) The duration or rhythm of a relay during which a rescuer performs External Chest Compression before being relayed by another rescuer is 4 minutes. (Rhythm of a relay 4 minutes)
3477605|NCT03818061|Experimental|HPV +|Patient with Human papillomavirus (HPV +) treated by Atezolizumab combined with Bevacizumab.
3477606|NCT03818061|Experimental|HPV -|Patient without Human papillomavirus (HPV - ) treated by Atezolizumab combined with Bevacizumab.
3477607|NCT03818074|Experimental|Boston Wavewriter (1000Hz) spinal cord stimulation|To investigate the response to high frequency (1000Hz) in patients who are due to have spinal cord stimulation for neuropathic back pain.
3477608|NCT03818087||Elevate|Participants over the age of 70 years old with early-stage breast cancer will be recruited.
3477609|NCT03818178|Experimental|Intralipid|
3477610|NCT03818178|Experimental|Palm Oil|
3477611|NCT03818178|Placebo Comparator|Saline|
3477612|NCT03818204|Experimental|Experimental Group|"The purpose of the experimental group is to test the intervention. Participants will have their acuity measured (refraction as needed), slit lamp with Nafl & NEI scale, visual functioning questionnaire (VFQ), cognitive assessment (MOCA).The eye lid will be prepped and video recorded.The masked clinical staff will then apply the polarized magnets and perform a number of measurements to ascertain effectiveness of intervention.~-Intervention - Magnetic Levator Prosthesis (MLP)"
3477613|NCT03818204|Other|Control/Normal Vision Group|"The purpose of the normal vision group is to test the experimental setup prior to enrolling ptosis patients. If the measurements of the normal vision group are found to be non-different to the experimental group, the data will be pooled.~-Intervention - Magnetic Levator Prosthesis (MLP)"
3477614|NCT03818048|Experimental|Group Propofol|propofol infusion
3477615|NCT03818048|Experimental|Group Sevoflurane|inhalation with sevoflurane
3477616|NCT03818334|Experimental|Post Cyclophosphamide|Cyclophosphamide 50 mg/Kg on days +3 and +4 AND Calcineurin Inhibitor from day +5 AND Mycofenolate Mofetil from day +5 until day +35
3477617|NCT03818334|Active Comparator|Thymoglobulin (ATG)|Thymoglobulin (ATG) total dose 5 mg/Kg from day -4 until day -1 AND Calcineurin Inhibitor from day +5 AND Methotrexate on days +1, +3, +6 and +11
3477618|NCT03817801|Experimental|non-slip element (NSE) predilation|In the NSE predilation group, NSE predilation will be performed for all lesions preparation before drug-coated balloon (DCB) treatment.
3477619|NCT03817801|Active Comparator|non-compliant (NC) balloon predilation|In the NC balloon predilation group, NC balloon predilation will be performed for all lesions preparation before DCB treatment.
3477620|NCT03817983||MRE review for axSpA|Review of MRE scan for evidence of axSpA in Crohn's disease patients
3477621|NCT03817827|Experimental|Acupuncture|this group will receive Acupuncture therapy for 30 minutes three times per week
3477622|NCT03817827|Experimental|diet modification|this group will receive diet using soy products a
3477623|NCT03817827|Experimental|combined group|will receive both acupuncture therapy and soy products
3477624|NCT03817788|Active Comparator|polyethylene glycol group (group P)|For all patients of this group, polyethylene glycol solution should be taken orally for colonic cleansing of colonoscopy
3477625|NCT03817788|Experimental|sodium phosphate group (group S)|For all patients of this group, sodium phosphate solution should be taken orally for colonic cleansing of colonoscopy
3477626|NCT03818321|Experimental|Methenamine Hippurate with Cranberry|Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
3477627|NCT03818321|Placebo Comparator|Placebo with Cranberry|"Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016."
3477628|NCT03817749|Experimental|Experimental|"Participants will consume 20 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period~Participants will wear a continuous glucose monitor for 6 consecutive days during the supplementation period."
3477629|NCT03817749|Placebo Comparator|Placebo|Participants will consume a flavor matched placebo drink and undergo the same procedures described in the Experimental Arm
3477630|NCT03817541|Experimental|Bariatric surgery|Patients due for bariatric surgery, BMI > 30
3477631|NCT03817541|Experimental|Cholecystectomy|Normal weight patients due for cholecystectomies
3477632|NCT03817619|Active Comparator|Treatment R (reference)|Single-dose ELB/GZR as a whole tablet in a fasted state.
3477633|NCT03817619|Experimental|Treatment T (test)|Single-dose crushed ELB/GZR in a fasted state.
3126749|NCT03051256|Experimental|REL-1017 25 mg|REL-1017 75 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 25 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
3477634|NCT03817567|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|6.0mg/kg QW for 6 weeks, then 8.0mg/kg Q2W
3477635|NCT03817502|Experimental|Cariprazine 1.5 mg/d|Cariprazine capsules, oral administration, once daily.
3126750|NCT03051256|Experimental|REL-1017 50 mg|REL-1017 100 mg of powder in 100 mL of Ocean Spray® Diet Cranberry Juice daily on Day 1, 50 mg of powder in 100 mL Ocean Spray® Diet Cranberry Juice daily on Day 2-7.
3477636|NCT03817502|Experimental|Cariprazine 4.5 mg/d|Cariprazine capsules, oral administration, once daily.
3477637|NCT03817502|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
3477638|NCT03817411|Active Comparator|Telatinib+Capecitabine+Oxaliplatin|Patients receive Telatinib orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
3477639|NCT03817411|Placebo Comparator|Placebos+Capecitabine+Oxaliplatin|Patients receive placebo orally (PO) twice daily (bid) on days 1-21 and Capecitabine PO on days 1-14, then stopped for 7 days, and Oxaliplatin by intravenous injection on day 1 of every cycle. Courses repeat every 21 days.
3477640|NCT03817658|Experimental|SHR-1210|SHR-1210
3477641|NCT03817658|Placebo Comparator|placebo|placebo
3477642|NCT03817476|Experimental|T1-T2-R|
3477643|NCT03817476|Experimental|T1-R-T2|
3477644|NCT03817476|Experimental|T2-T1-R|
3477645|NCT03817476|Experimental|T2-R-T1|
3477646|NCT03817476|Experimental|R-T1-T2|
3477647|NCT03817476|Experimental|R-T2-T1|
3477648|NCT03817671|Other|Control arm (5% O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 5% O2, and 89.3% N2 till embryo transfer
3477649|NCT03817671|Experimental|Experimental arm (2%O2)|After thawing, embryos will be cultured in 25 μl drop of pre-equilibrated dishes of media covered with a layer of oil for 1.5 hours at 5.7% CO2, 2% O2, and 92.3% N2 till embryo transfer
3477650|NCT03817645|Experimental|Panaceo MED|Zeolite, Medicinal product, class IIa for oral intake, daily intake of 2 sachets (3 g), for 3 months.
3126751|NCT03051256|Placebo Comparator|Placebo|100 mL Ocean Spray® Diet Cranberry Juice will be administered as a single oral dose daily for 7 days.
3126752|NCT03051607|Experimental|Tozadenant|120 mg twice daily. At Week 2 or thereafter doses of 60 mg BID and 120 mg BID will be permitted.
3477651|NCT03817645|Placebo Comparator|Control|Micro crystalline cellulose daily intake of 2 sachets (3 g), for 3 months.
3477652|NCT03817450|Experimental|Daily Mouth Care|The intervention consists of training in Mouth Care Without a Battle (MCWB) techniques and support in established quality improvement techniques. MCWB is a system-level, evidence based, tested approach to person-centered daily mouth care, which includes tooth-brushing, flossing, care of the gums, and denture care. MCWB provides training to all certified nursing assistants (CNAs) and nursing supervisors, and also supports the designation and specialized training of a CNA to serve as a dedicated, full-time Oral Care Aide (OCA) to provide mouth care to the residents who are at greatest risk for pneumonia and require specialized support to achieve good oral hygiene.
3477653|NCT03817450|No Intervention|Standard Mouth Care|Nursing homes will continue to provide standard mouth care to all residents. Nursing home staff will not receive training or supplies in the control condition.
3477654|NCT03817723||Specialist surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy. C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
3477655|NCT03817723||Resident surgeon|Radiation exposure of intraoperative cholangiography during cholecystectomy.C-arm cholangiography is performed routinely. KAP (Kerma area product) is the product of air Kerma in the center of the imaging area multiplied with size of the imaging area. For simplicity we have unified varying units received from different c-arms and will only use Gray multiplied by square centimeters (Gycm2 ). KAP values were measured using inbuilt ionization chambers in c-arms. For this study we collected the KAP values from exposure and pulsed fluoroscopy. We also recorded the fluoroscopy time (s).
3477656|NCT03817489|Experimental|Intervention: Baduanjin qigong|This arm of participants will be receiving the Baduajin qigong intervention.
3477657|NCT03817489|Experimental|Intervention: Mindfulness meditation|This arm of participants will be receiving the Mindfulness meditation intervention.
3477658|NCT03817489|No Intervention|Control|This arm of participants will not receive any intervention and are allocated as a Wait-list Control group.
3477659|NCT03817736|Experimental|START-FIT|"Single group assignment combining TACE and SBRT with immune checkpoint inhibitor as treatment in HCC patients.~Procedure of TACE will be standardized.~SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.~An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons."
3477660|NCT03817385|Experimental|repetitive TMS (Transcranial Magnetic Stimulation)|rTMS and physical / occupational therapy
3126753|NCT03051633|Experimental|Be Under Your Own Influence Intervention|School-based anti-substance use communications campaign
3126754|NCT03051633|No Intervention|Control|Assessment only
3477661|NCT03817385|Experimental|robotic GT (Gait Training)|robotic gait training for 20 times and physical / occupational therapy
3126755|NCT03051646|Experimental|Acetylsalicylic acid first, placebo second|Participant is administered acetylsalicylic acid one hour prior to exercise.
3477662|NCT03817385|No Intervention|traditional rehabilitation|patient only received traditional rehabilitation program
3477663|NCT03817684|Experimental|BPN14770 10mg bid|10 mg bid dose of the Drug BPN14770
3477664|NCT03817684|Experimental|BPN 14770 25mg bid|25mg bid dose of the Drug BPN14770
3126756|NCT03051646|Placebo Comparator|Placebo oral capsule first, ASA second|Participant is administered placebo one hour prior to exercise.
3126757|NCT03051672|Experimental|Pembrolizumab With Radiation|"pembrolizumab : 200 mg intravenously 2 to 7 days prior to radiotherapy (RT) and on day 1 of repeating 21-day cycles. Treatment up to 35 cycles.~Palliative radiation: a total dose of 20 Gy in 5 fractions"
3477665|NCT03817684|Placebo Comparator|Placebo|
3477666|NCT03817398|Experimental|Basic Science (stop taking TKI, biospecimen collection)|Patients stop taking TKI medication within 10 days after enrollment. Patients undergo peripheral blood collection to monitor loss of MMR every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3. Patients who lose their molecular remission may restart TKI medication and are monitored every 4 weeks in year 1, every 6 weeks in year 2, and every 12 weeks in year 3.
3126758|NCT03052257|Experimental|Intervention|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
3126759|NCT03052257|Active Comparator|Control|"Participants will be randomized to receive either a general eye health educational session (control arm) or an educational intervention developed to improve glaucoma medication adherence (intervention arm). All participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
3126760|NCT03052322|Experimental|MSB11022|
3126761|NCT03052322|Active Comparator|EU-Humira|
3126762|NCT03052426|Active Comparator|30 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 30 minutes throughout their workday.
3477667|NCT03817424|Experimental|Cohort 1: VIB7734 Dose 1|Participants will receive VIB7734 Dose 1 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
3477668|NCT03817424|Experimental|Cohort 2: VIB7734 Dose 2|Participants will receive VIB7734 Dose 2 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
3477669|NCT03817424|Experimental|Cohort 3: VIB7734 Dose 3|Participants will receive VIB7734 Dose 3 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
3477670|NCT03817424|Placebo Comparator|Placebo|Participants will receive placebo matching to VIB7734 via injection q4w for a total of 3 doses on Days 1, 29, and 57.
3477671|NCT03817697||Drug users|The cohort will be constituted of adult patients drug users, substituted/weaned or not, consulting at the Croix-Rousse CSAPA
3477672|NCT03817372|Active Comparator|Anterior-posterior electrode position|The anterior electrode is placed in the left parasternal area (precordium). The posterior electrode is placed in the left lower-scapular region with the electrode edge left to the spinal column.
3477673|NCT03817372|Active Comparator|Anterior-lateral electrode position|The anterior electrode is placed in the right parasternal area below the clavicle. The lateral electrode is placed with the center of the electrode in the left mid-axillary line in level with the V6 electrocardiogram electrode.
3477674|NCT03817307|Experimental|USPIO enhanced-MRI|The contrast agent ferumoxtran-10 will be administered intravenously under constant medical supervision 24-36 hours before performing a T2* weighted MRI scan (prior to surgery).
3477675|NCT03817359|Experimental|Mix infusion using single TCI pump|participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump infusion
3477676|NCT03817359|No Intervention|Separate infusion using two TCI pumps|participants receive total intravenous anesthesia with remifentanil and propofol separately by two TCI pumps infusion
3477677|NCT03817086|Experimental|Hand coordination and mental practice|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to mentally imagine doing the task with an action observation of perfect performance.
3477678|NCT03817086|Active Comparator|Hand coordination and action observation|In a total of 12 training sessions (days), 3 sessions per week over 4 weeks, participants practice physical in-phase and out-of-phase movement of both limbs for 40 minutes. Every 10 minutes, participants get a 2 minutes break during which the participants are asked to observe a visual feedback of performance.
3477679|NCT03817346|Active Comparator|Experimental GT-002 SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Six of out 8 subjects per cohort will be randomized to receive GT-002.
3477680|NCT03817346|Placebo Comparator|Experimental Placebo oral capsule SAD|Healthy volunteers meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 7 dose ascending cohorts) to receive either GT-002 or placebo. The study drug (GT-002 or placebo) will be administered orally as a single dose. Two of out 8 subjects per cohort will be randomized to receive GT-002.
3477681|NCT03817021|Experimental|All Factors On|Nutrition and Physical Activity Self-Assessment of Childcare (Core NAP SACC) will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned on
3477682|NCT03817021|Experimental|NAP SACC on/ECE on/Parent RF on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned on Child regulation in the classroom will be turned off
3477683|NCT03817021|Experimental|NAP SACC on/ECE on/Child Regulation on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned on
3477684|NCT03817021|Experimental|NAP SACC on/ECE on|Core NAP SACC will be turned on Early Childhood Education Training will be turned on Parent Responsive Feeding will be turned off Child regulation in the classroom will be turned off
3477685|NCT03817021|Experimental|NAP SACCon/Parent RF on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned on
3477686|NCT03817021|Experimental|NAP SACC on/Parent RF on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned on Child regulation in the classroom turned off
3126763|NCT03052426|Active Comparator|60 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 60 minutes throughout their workday.
3477687|NCT03817021|Experimental|NAP SACC on/Child regulation on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned on
3477688|NCT03817021|Experimental|NAP SACC on|Core NAP SACC turned on Early Childhood Education Training turned off Parent Responsive Feeding turned off Child regulation in the classroom turned off
3126764|NCT03052426|Active Comparator|90 Minute Group|This group will use the Ergotron WorkFit-TL (a sit to stand work station) and be required to alternate periods of sitting and standing every 90 minutes throughout their workday.
3477689|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) post-EBRT|Prostatic Urethral Lift (PUL) following External Beam Radiotherapy (EBRT)
3477690|NCT03817216|Experimental|Prostatic Urethral Lift (PUL) pre-BT|Prostatic Urethral Lift (PUL) preceding Brachytherapy (BT)
3477691|NCT03817216|Active Comparator|Prostatic Urethral Lift (PUL) post-BT|Prostatic Urethral Lift (PUL) following Brachytherapy (BT)
3477692|NCT03817034|Experimental|Multimodal Analgesia|
3477693|NCT03817229|Active Comparator|Control Group|mHealth education module and automated digital reminders
3477694|NCT03817229|Experimental|Treatment Group|mHealth education module, automated digital reminders, and individualized adherence feedback (stage 1 SMART). After three months of intervention, the treatment group will be evaluated for responsiveness (> 95%) based on the 30-day adherence outcome (stage 2 SMART). If participants in the treatment group demonstrate adherence > 95%, they will continue with the treatment arm of receiving automated digital reminders and individualized adherence feedback. If they are deemed to be non-responsive (adherence < 95%), they will be re-randomized to either: 1) continued automated digital reminders and individualized adherence feedback or 2) a mHealth problem solving module with three therapist-guided problem-solving sessions.
3477695|NCT03817294|Active Comparator|Eccentric cycling|
3477696|NCT03817294|Active Comparator|Concentric cycling|
3477697|NCT03817294|Active Comparator|Single leg cycling|
3477698|NCT03817294|Active Comparator|Lower limb resistance training|
3477699|NCT03817242|Active Comparator|tympanoplasty with tragal cartilage|Tympanoplasty was performed using tragal cartilage graft
3477700|NCT03817242|Active Comparator|tympanoplasty with temporalis fascia|Tympanoplasty was performed using temporalis fascia graft
3477701|NCT03817047|Experimental|Physical active learning (PAL)|"Three components:~Physical education (60 minutes)~Physical active learning (30 minutes)~Physical activity (30 minutes)"
3477702|NCT03817047|Experimental|Don't worry - be happy|"Two components:~Physical education (60 minutes) - don't worry class~Physical activity (60 minutes) - be happy class"
3477703|NCT03817047|No Intervention|Control group|Current practice
3477704|NCT03817099|Experimental|My Dia-RNP|In the My Dia-RNP group, participants will undergo the pre-RNP assessment 2 weeks before Ramadan. They will be given a nutrition education based on the Ramadan Nutrition Plan Guide published by IDF-DAR Practical Guidelines. They will also be asked to incorporate diabetes-specific nutrition formula (Nutren untuk Diabetik®) within the prescribed calories before Ramadan period to help them familiarise with a dietary change.
3126765|NCT03052517|Experimental|QAW039 150mg|QAW039 Dose 1 once daily
3126766|NCT03052517|Experimental|QAW039 450 mg|QAW039 Dose 2 once daily
3126767|NCT03052517|Placebo Comparator|Placebo|Placebo once daily
3126768|NCT03052530|Experimental|Sapphire II PRO|Single arm with investigational Sapphire II PRO 1.0 and 1.25 mm PTCA dilatation catheters
3126769|NCT03052608|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
3126770|NCT03052608|Active Comparator|Crizotinib|Crizotinib single agent, 250 mg (1 x 250) oral capsules, BID, continuously
3126771|NCT03052725|Experimental|reslizumab 110 mg|Reslizumab was administered as 110 mg subcutaneous (sc) injection in the thigh, abdomen, or upper arm(s) once every 4 weeks for a total of 9 doses.
3477705|NCT03817099|Active Comparator|Usual Care|Participant in this group will continue in a usual care (UC) group. They will receive dietary advice based on the Practical Guide to Diabetes Management in Ramadan produced by Ministry of Health (2015).
3477706|NCT03817177|Placebo Comparator|nasal prong|conventional nasal prong application after the surgery in postanesthetic care unit (PACU)
3477707|NCT03817177|Experimental|high flow nasal cannula oxygenation|high flow nasal cannula application after the surgery in postanesthetic care unit (PACU)
3477708|NCT03817281||Accuryn Monitoring System|Observational only (no intervention). Study Cohort is patients using the Accuryn Monitoring System as a standard-of-care digital urimeter, during their standard course of treatment.
3477709|NCT03817190|Experimental|2g Oral DS107|2g DS107 (4 DS107 capsules) administered once-daily for 16 weeks
3477710|NCT03817190|Placebo Comparator|Placebo|Placebo (4 placebo capsules) orally administered once-daily for 16 weeks
3477711|NCT03817060|Active Comparator|Cleavage|Embryos cryopreserved with vitrification at the cleavage stage (day 3) of embryo development
3477712|NCT03817060|Active Comparator|Blastocyst|Embryos cryopreserved with vitrification at the blastocyst stage (day 5 or 6)
3477713|NCT03816995|Active Comparator|Alexis O Wound Protector|Participants will undergo standard surgical procedure using the Alexis O wound protector.
3477714|NCT03816995|Experimental|CleanCision Wound Protector|Participants will undergo standard surgical procedure using the CleanCision Wound Retraction and Protection System
3477715|NCT03816969|Active Comparator|Self-pressurized air-Q with blocker|Self-pressurized air-Q with blocker has a greater seal pressure compared to Air-Q blocker, easier and faster in insertion and has less morbidity and complications while and after insertion
3477716|NCT03816969|Active Comparator|Air-Q ILA blocker|It has a drain tube through which a suction tube is passed
3477717|NCT03816982|Active Comparator|Bupivacaine HCl/Bupivacaine CISB|23 patients will be enrolled to receive a single-injection bupivacaine HCL interscalene block with bupivacaine CISB added.
3477718|NCT03816982|Experimental|Liposomal Bupivacaine Added to Interscalene Block|23 patients will be enrolled to receive a single-injection bupivacaine HCl interscalene block with liposomal bupivacaine added to same injection.
3126772|NCT03052751|Experimental|Dosage Regimen 1|Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
3126773|NCT03052751|Experimental|Dosage Regimen 2|Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).
3126774|NCT03052764|Active Comparator|BOTOX® 100 U/BOTOX® 100 U|BOTOX® (onabotulinumtoxinA) 100 U injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
3126775|NCT03052764|Placebo Comparator|Placebo/BOTOX® 100 U|Placebo (saline) injection into the bladder on Day 1 and a second injection BOTOX® 100 U after Week 12 if applicable.
3126776|NCT03052816|Experimental|ICE T|"ICE PACKS applied to the perineum every hour for 20 minutes ATC until discharge.~6 hours from the time of first dose of surgery patients will receive 30mg of IV toradol ATC until discharge.~Once out of the PACU will receive 1 gram of Tylenol every 6 hours for a total of 4 grams daily ATC until discharge~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with PO Tylenol and PO toradol PRN."
3126777|NCT03052816|Active Comparator|Standard|"Motrin 600mg PO Q4h PRN pain 1-3~Percocet 1 tab PO Q4-6 hours PRN 4-6 pain~Percocet 2 tabs PO Q 7-10 hours PRN 7-10 pain~Patients will receive dilaudid 0.2mg IV Q3 hr PRN for breakthrough pain.~Patients will be discharged home with Motrin and Percocet for pain PRN."
3477719|NCT03817320|Other|Open label design|Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin
3477720|NCT03817203|Experimental|Kinesio tape group|Kinesio tape application and pelvic floor exercise have been applied
3477721|NCT03817203|Sham Comparator|Control group|Sham kinesio tape application and pelvic floor exercise have been applied
3477722|NCT03817164|Active Comparator|Active Treatment|Active stimulation pulsed current delivered over 15 minutes.
3477723|NCT03817164|Sham Comparator|Control Treatment|Active stimulation pulsed current (alternative frequency) delivered over 15 minutes.
3477724|NCT03816943|No Intervention|Control|control group with no intervention
3126778|NCT03052920|Experimental|Cochlear Implantation|Cochlear implantation of the poor hearing ear
3477725|NCT03816943|Experimental|Whatsapp|intervention group receiving a Whatsapp instant text message with encouraging words after bond up of fixed appliances
3477726|NCT03816943|Experimental|Call|intervention group receiving a phone cal with encouraging words after bond up of fixed appliances
3477727|NCT03816930|Active Comparator|Mechanical cord usage|Mechanical retraction
3477728|NCT03816930|Active Comparator|Chemical contained retraction usage|Chemical retraction
3477729|NCT03816930|Active Comparator|MZ-6 laser tip used throughing|Laser retraction
3477730|NCT03816917||topical treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: only topical/UV therapy (no systemic therapy)
3477731|NCT03816917||systemic treatment|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy, but no biologicals. Topical therapy is permitted.
3477732|NCT03816917||biologics|100 consecutive patients with cutaneous psoriasis, stratified on current therapy for cutaneous symptoms: systemic therapy with biologics. Other systemic and topical therapy is permitted.
3477733|NCT03816956|Experimental|Study treatment|Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
3477734|NCT03816956|Placebo Comparator|Placebo treatment|Control group: Placebo administered intravenously the day of enrolment.
3126779|NCT03052959|Experimental|Immediate Intervention|
3126780|NCT03052959|Other|Wait List Intervention|
3126781|NCT03052972|Experimental|Amyloid Positive|Clinically normal amyloid positive subjects from BIOCARD study receiving a flortaucipir PET scan
3126782|NCT03052972|Experimental|Amyloid Negative|Clinically normal amyloid negative subjects from BIOCARD study receiving a flortaucipir PET scan
3126783|NCT03053050|Experimental|SEL 18 mg|"Randomized Phase: Selonsertib (SEL) 18 mg tablet + placebo to match SEL 6 mg tablet for 240 weeks~Open-Label (OL) Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
3126784|NCT03053050|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
3126785|NCT03053050|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg tablet + placebo to match SEL 18 mg tablet for 240 weeks~OL Phase: Participants who experience a hepatic clinical event or have biopsy confirmed progression to cirrhosis during the randomized phase, prior to completing the Week 240 visit, will be offered the option to roll over into an OL phase to receive OL SEL 18 mg for a total treatment duration of 240 weeks inclusive of the randomized phase."
3179439|NCT00672685|Experimental|2|Omega-3 combined group (Omega-3 + multi-domain intervention)
3179440|NCT00672685|Experimental|3|Placebo combined group (Placebo + multi-domain intervention)
3179441|NCT00672685|Placebo Comparator|4|Placebo group without any intervention
3179442|NCT00672698||I|VASCULAR SURGERY
3477735|NCT03816904||Breast or prostate cancer|Taken blood samples on patients hospitalized in medical oncology day hospital at the University Hospital of Tours or CHC oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer
3477736|NCT03817268|Experimental|Capecitabine monotherapy group|
3477737|NCT03817268|No Intervention|Control group|
3477738|NCT03817255|Experimental|Substance use|In this screening intervention, participants complete a substance use questionnaire (=intervention).
3477739|NCT03817255|Active Comparator|Physical activity|In this screening control condition, participants complete a physical activity questionnaire (=control).
3477740|NCT03817112|Active Comparator|Dexmedetomidine|Infusion of dexmedetomidine
3477741|NCT03817112|Active Comparator|Propofol|Propofol infusion
3477742|NCT03816878|Experimental|Cohort 1: pLAIV Recipients|Participants who have received the pandemic live attenuated influenza vaccines (pLAIVs) H2N2, H6N1, or H9N2 during a previous CIR study will receive a single dose of 0.5 mL H5N1 pISV vaccine at Day 0.
3477743|NCT03816878|Experimental|Cohort 2: pLAIV Naive|Participants who have never previously received a pLAIV will receive one dose of 0.5 mL H5N1 pISV vaccine at Day 0.
3477744|NCT03816852|Experimental|High dose group|Intravenous infusion with hucMSCs, 9*10^7 cells, 30ml
3477745|NCT03816852|Experimental|Medium dose group|Intravenous infusion with hucMSCs, 6*10^7 cells, 30ml
3477746|NCT03816852|Experimental|Low dose group|Intravenous infusion with hucMSCs, 3*10^7 cells, 30ml
3477747|NCT03816722|Experimental|intervention|Patients starting the cross over with 6 weeks of high flow treatment with Airvo2 in addition to usual care
3477748|NCT03816722|Experimental|control|Patients starting the cross over in the usual care Group but after 6 weeks receiving High Flow treatment with Airvo2
3477749|NCT03816735|Active Comparator|hyaluronic acid suppository therapy|"Women receive a vaginal suppository called Cikatridina manufactured by the company Angelini to treat women with GSM. Angelini Pharma Österreich GmbH's headquarters are located in Brigittenauer Lände 50-54, 1200 Wien, Austria. The suppositories contain ontain hyaluronic acid, tea tree oil, tigergras extract, and aloe vera."
3477750|NCT03816735|Active Comparator|Juliet feminine laser|The fractional microablative laser with 2940 nm wavelength has a high degree of absorption in water and selectively stimulates the synthesis of sub-mucosal collagen. The erbium-doped yttrium-aluminum-garnet (Er:YAG) laser has been successfully used in the field of plastic skin rejuvenation and reconstruction. The procedure is based on photothermic treatment of connective tissue: It has been established in animal and human studies that it affects collagen remodeling resulting in tightening of the supportive tissue.
3477751|NCT03816774|No Intervention|PEG split-dose|Group A: PEG split dose ending 3 hours before colonoscopy
3477752|NCT03816774|Active Comparator|PEG split-dose and simethicone|Group B: 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
3126786|NCT03053063|Experimental|SEL 6 mg|"Randomized Phase: SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label (OL) Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
3179443|NCT00672698||II|DIGESTIVE SURGERY
3179444|NCT00672698||III|BILIARY TRACT SURGERY
3477753|NCT03816748|Experimental|intervention|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept HFNC treatment
3477754|NCT03816748|No Intervention|control|Patients who underwent minimally invasive esophagectomy surgery in our hospital and transfer to intensive care unit, and accept usual care
3477755|NCT03816644|Experimental|5-Cog|The 5-Cog coupled with a decision tree is a simple, 5-minute procedure that will identify older persons with cognitive impairment in primary care settings, and flag them for further evaluation. The 5-Cog includes the Picture Memory Impairment Screen (PMIS), Motoric Cognitive Risk syndrome (MCR), and the Symbol Match test. The 5-Cog will be given after randomization and before the patients sees the physician. The 5-Cog will sort patients with 'cognitive impairment' from those with 'no cognitive impairment'. After completing the 5-Cog, the non-physician tester will send a message through the Electronic medical record (EMR) system to provide the physician with the 5-Cog results and guide the them through the follow-up based on the results.
3477756|NCT03816644|Active Comparator|Health Literacy & Grip Assessment|The 5 minute assessment includes the Short Assessment of Health Literacy (SAHL) and a grip assessment measured using a handgrip dynamometer. After completing the SAHL and grip assessment, the non-physician tester will send a message through the EMR to provide the physician with the results from the assessments and guide the them through the follow-up based on the results.
3477757|NCT03817073|Experimental|Iowa Oral Performance Instrument (IOPI)|All MS patients will be included in this arm to compare with a historical control arm. Iowa Oral Performance Instrument (IOPI).
3477758|NCT03816579|Experimental|PRO-A|Beef protein
3477759|NCT03816579|Experimental|PRO-B|Complementary proteins at each meal
3477760|NCT03816579|Experimental|PRO-C|Complementary proteins over 24 hours
3477761|NCT03816579|No Intervention|CON|Low protein (<5 g) meal
3477762|NCT03816592||Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
3477763|NCT03816592||Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
3126787|NCT03053063|Experimental|SEL 18 mg|"Randomized Phase: SEL 18 mg plus placebo to match SEL 6 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
3126788|NCT03053063|Placebo Comparator|Placebo|"Randomized Phase: Placebo to match SEL 6 mg plus placebo to match SEL 18 mg for up to 240 weeks.~Open-Label Phase: Participants who experienced a hepatic clinical event during the randomized phase prior to completing the Week 240 visit, will be offered the option to receive OL SEL 18 mg daily for a total treatment duration of 240 weeks inclusive of the Randomized Phase."
3179445|NCT00672711||C|APS
3477764|NCT03816488|Experimental|Metformin|Self-administered metformin (patient's usual dose) taken 2 hours prior to surgery
3477765|NCT03816488|Experimental|Salsalate|Self-administered salsalate taken 2 hours prior to surgery
3179446|NCT00672711||B|HPS
3179447|NCT00672711||A|LPS
3477766|NCT03816488|No Intervention|Placebo|Self-administered placebo taken 2 hours prior to surgery
3477767|NCT03816540|Experimental|FXTAS-affected|FXTAS-affected participants will receive HRV and respiratory coherence biofeedback training for 20 sessions.
3477768|NCT03816540|Active Comparator|FXTAS-unaffected|FXTAS-unaffected participants will be assessed to compare the effects of biofeedback based on FXTAS status. This arm will receive HRV and respiratory coherence biofeedback training for 20 sessions.
3477769|NCT03816631|Experimental|Part A: Group 1: Severe hepatic function|Participants with severe hepatic function will receive single oral dose of pimodivir 600 milligram (mg) (2*300 mg tablet) under fasted condition on Day 1.
3477770|NCT03816631|Experimental|Part A and B: Group 2: Normal hepatic function|Participants with normal hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
3477771|NCT03816631|Experimental|Part B: Group 3: Moderate hepatic function|Participants with moderate hepatic function will receive single oral dose of pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
3477772|NCT03816631|Experimental|Part B: Group 4: Mild hepatic function|Participants with mild hepatic function will receive single oral dose of Pimodivir 600 mg (2*300 mg tablet) under fasted condition on Day 1. The recruitment in Part B will be started based on assessment by Sponsor upon evaluation of partial data obtained in Part A.
3477773|NCT03816553|Experimental|SHR-1210 + Apatinib|Participants receive SHR-1210 200mg (3mg/kg for underweight patients) intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity
3477774|NCT03816566|Experimental|Wearable Device and PSG|The device under investigation (the patch) will be used in patients undergoing overnight polysomnography simultaneously, to compare the accuracy of the investigational device against the gold standard for the diagnosis of sleep apnea.
3477775|NCT03816618|Experimental|CONTROL|CONTROL GROUP
3477776|NCT03816618|Experimental|TREATMENT1|TREATMENT GROUP 1
3477777|NCT03816618|Experimental|TREATMENT2|TREATMENT GROUP 2
3477778|NCT03816618|Experimental|TREATMENT3|TREATMENT GROUP 3
3477779|NCT03816826|Experimental|laser|athletes with acute soft tissue injuries will be recruited in the study , patients will be treated using the the laser therapy
3477780|NCT03816826|Experimental|strain/counter strain|athletes with acute soft tissue injuries will be treated with with strain counter strain technique
3477781|NCT03816826|Experimental|combination therapy|combination of laser therapy along with strain counter strain technique to visualize the effect the
3477782|NCT03816475|Experimental|Hypofractionated radiotherapy|5x5 Gy radiotherapy and delayed surgery (after 6-8 weeks)
3477783|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones.
3477784|NCT03816501|Other|no music|preoperative music will not be listened
3477785|NCT03816527||AUD patients|Individuals with alcohol use disorder
3477786|NCT03816527||Healthy controls|Healthy controls
3477787|NCT03816670|Experimental|poor responders day 2|"poor responders women stimulated with CF from day 2 of menstrual cycle"
3477788|NCT03816670|Experimental|poor responders day 4|"poor responders women stimulated with CF from day 4 of menstrual cycle"
3477789|NCT03816670|Experimental|normal responders day 2|"normal responders women stimulated with CF from day 2"
3477790|NCT03816670|Experimental|normal responders day 4|"normal responders women stimulated with CF from day 4"
3477791|NCT03816670|Experimental|high responders day 2|"high responders women stimulated with CF from day 2"
3477792|NCT03816670|Experimental|high responders day 4|"high responders women stimulated with CF from day 4"
3477793|NCT03816514|Experimental|SpHb monitoring group|In SpHb monitoring group, noninvasive, continuous SpHb monitoring will be done using Radical-7 pulse CO-Oximeter. The patients will be managed according to the prespecified protocol based on the SpHb values.
3477794|NCT03816514|Active Comparator|Control group|In control group, patients will receive conventional management without the SpHb monitoring. In these patients, the information about hemoglobin concentration of the patients will be obtained from hemoglobin measurement analyzed by point-of-care (POC) equipment, as usual standard care.
3477795|NCT03816800|Placebo Comparator|Placebo-Allergic|Over the course of 6 months allergic participants receive twice daily a placebo tablets.
3477796|NCT03816800|Active Comparator|Active-Allergic|Over the course of 6 months allergic participants receive twice daily a dietary supplement containing whey protein-bound, chelated iron.
3477797|NCT03816410|Experimental|LAA amputation group|
3477798|NCT03816410|No Intervention|No LAA amputation group|
3477799|NCT03816449|Active Comparator|experimental group|Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
3477800|NCT03816449|Placebo Comparator|control group|Control group will include about postmenopausal women who will not practice exercise program (aerobic exercise, resistance training and balance exercise) .They will continue to carry out activities of daily living, which are conducted daily before inclusion in the study. These patients will be asked to not include in any other program of physical activity and exercise during the research period (12 weeks). After this period, patients will be offered to participate in the same exercise program that had patients from the experimental group.
3477801|NCT03816436||Follow- up (FU) assessment on clavicular non- union|clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting
3477802|NCT03816787|Experimental|dry cupping for patients of low back pain|Patients will receive four consecutive dry cupping therapy application in one month.
3477803|NCT03816787|Active Comparator|dry cupping for health people|Health people will receive four consecutive dry cupping therapy application in one month.
3477804|NCT03816423|No Intervention|Traditional counseling|Patients will undergo routine prenatal care visit with clinical practicioner only
3477805|NCT03816423|Experimental|video group|"Participants randomized to the intervention group (video education) will view the prenatal screening video How to Decide About Prenatal Genetic Testing, followed by a routine prenatal appointment."
3477806|NCT03816384|Active Comparator|Standard of Care|Patients will receive Standard of Care, commercially available catheter utilized by hospital system.
3477807|NCT03816384|Experimental|Drain Line Clearance (DLC) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and plain silicone catheter.
3477808|NCT03816384|Experimental|Drain Line Clearance and Silver (DLCS) Group|Patients will receive FDA-approved Accuryn Monitoring System with active drain line clearance and silver-doped silicone catheter.
3477809|NCT03816397|Active Comparator|Continue adalimumab|Patients randomized to this arm will continue adalimumab at their current dose (either 20mg/0.2mL or 40mg/0.4mL) administered subcutaneously every other week.
3477810|NCT03816397|Placebo Comparator|Stop adalimumab|Patients randomized to this arm will receive a volume-matched placebo (0.8mL) administered subcutaneously every other week.
3477811|NCT03816371|Active Comparator|supine 0 degree head-of-bed elevation|0 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
3477812|NCT03816371|Experimental|30 degree head-of-bed elevation|30 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
3477813|NCT03816371|Experimental|45 degree head-of-bed elevation|45 degree head-of-bed elevation was arranged as soon as the patient was admitted to the bed following thyroidectomy.
3126789|NCT03053102|Experimental|Danicopan|Starting doses of danicopan ranged from 100 to 150 milligrams (mg) three times daily (TID), with subsequent dose escalation up to 200 mg TID based on response (clinical and biochemical) for 28 days (Part 1). Participants with reductions in lactate dehydrogenase (LDH) meeting specified criteria were offered continued dosing beyond Day 28, for up to 8 additional weeks (Part 2).
3179448|NCT00672724|Experimental|Ramelteon 8 mg QD|
3179449|NCT00672724|Placebo Comparator|Placebo|
3477814|NCT03816280||Group T2DM-alpha|Patients with diabetes mellitus undergoing CPB with alpha-stat acid-base management
3477815|NCT03816280||Group T2DM-pH|Patients with diabetes mellitus undergoing CPB with pH-stat acid-base management
3477816|NCT03816280||Group Ctrl-alpha|Control patients undergoing CPB with alpha-stat acid-base management
3477817|NCT03816280||Group Ctrl-pH|Control patients undergoing CPB with pH-stat acid-base management
3477818|NCT03816267|Active Comparator|Nebulizer|Containing salbutamol
3477819|NCT03816267|Experimental|Metered Dose Inhaler and spacer|Containing Salbutamol
3477820|NCT03816241|No Intervention|Control|Vignette contains no extra information.
3477821|NCT03816241|Experimental|Frame|Vignette is framed in a particular manner
3179450|NCT00672750||I|Patients of Dr C Miller who have undergone laparoscopic myomectomy from 1999- to present
3477822|NCT03816241|Experimental|Norms|Vignette contains extra information about norms
3477823|NCT03816241|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
3477824|NCT03816215|Experimental|Adolescent Participants|Participants will be assigned to participate in community service (from a menu of options) for 30 hours.
3477825|NCT03816059||Hospitalized - ACS|Hospitalized patients with acute coronary syndrome
3477826|NCT03816059||Hospitalized - stroke|Hospitalized patients with stroke
3477827|NCT03816059||Hospitalized - chronic lung disease|Hospitalized patients with exacerbation of chronic lung disease
3179451|NCT00672763|Active Comparator|A|Standard corticosteroid treatment PLUS Vitamin D3 (Colecalciferol).
3477828|NCT03816059||Outpatient|Outpatients
3477829|NCT03816293|Active Comparator|Negative Pressure Wound Therapy|NPWT use on closed incision for 7 days after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
3477830|NCT03816293|No Intervention|Control Dressing|Standard dressing on closed incisions after c-section, abdominal hysterectomy, and colon surgery in patients with diabetes and/or obesity
3477831|NCT03816306||Single group study|
3477832|NCT03816137|Active Comparator|ConM SOSIP and Mosaic SOSIPs|"ConM SOSIP 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
3477833|NCT03816137|Active Comparator|EDC ConM SOSIP and Mosaic SOSIPs|"EDC ConM SOSIP 100G Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
3477834|NCT03816137|Active Comparator|ConS UFO and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
3477835|NCT03816137|Active Comparator|EDC ConS UFO and Mosaic SOSIPs|"EDC ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0, 3 and 6 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
3477836|NCT03816137|Active Comparator|ConS UFO and ConM SOSIPs and Mosaic SOSIPs|"ConS UFO 100g Intramuscular injections into the left or right arm Administered at 0 and 3 months~ConM SOSIP Administered at 12 months~Mosaic SOSIPs 100ug (3x33ug) Intramuscular injections into the left or right arm Administered at 12 months only"
3477837|NCT03816007|Experimental|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
3477838|NCT03816007|Active Comparator|Relaxation/Health Education|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator.
3477839|NCT03816085|Experimental|Shoe with 4 cm heel|Shoes with 4 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
3477840|NCT03816085|Experimental|Shoe with 10 cm heel|Shoes with 10 cm heel will be applied to women. Tests to measure balance, muscular endurance and function will be done while they wear this shoe.
3477841|NCT03816085|No Intervention|Without shoes|Women will be included in the tests to measure balance, muscular endurance and function without shoes.
3477842|NCT03816033|Active Comparator|Cryotherapy|Cryotherapy ablation energy will be utilised in the catheter ablation procedure
3477843|NCT03816033|Active Comparator|Radiofrequency|Radiofrequency ablation energy will be utilised in the catheter ablation procedure
3477844|NCT03816020|Active Comparator|NR Group|Participants receiving Nicotinamide Riboside capsules, 500mg BI'D for 30 days
3126790|NCT03053180||Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir|"Participants with chronic hepatitis C (CHC) genotype 1b (GT1b) and compensated liver cirrhosis received paritaprevir/ritonavir (r), ombitasvir and dasabuvir (3DAA ABBVIE REGIMEN) for 12 weeks.~The prescription of a treatment regimen was at the discretion of the physician in accordance with local clinical practice and label, was made independently from this observational study and preceded the decision to offer a patient the opportunity to participate in this study."
3126791|NCT03053271|Experimental|ATR-101|During the 4-week randomized withdrawal period, eligible subjects will receive ATR-101 at the same dose level being used at the completion of the open-label dose-escalation period.
3477845|NCT03816020|Placebo Comparator|Placebo Group|Participant receiving Placebo BIDfor 30 days
3477846|NCT03816072|Active Comparator|Propofol|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with intravenous anaesthesia (propofol).
3477847|NCT03816072|Active Comparator|Sevoflurane|ASA-I/II patients undergoing elective, non-cardiothoracic surgery with inhalational anaesthesia (sevoflurane).
3477848|NCT03816202||Sundt Carotid Shunt|Subject has undergone a endarterectomy procedure with the use of the Sundt Carotid Shunt.
3477849|NCT03816189||Diffuse SSc|Recruitment of 20 patients with diffuse SSc
3477850|NCT03816189||Limited SSc|Recruitment of 20 patients with limited SSc
3477851|NCT03816189||Healthy subjects|Recruitment of 20 healthy subjects (control)
3477852|NCT03816046|Experimental|Technique 1 The Quadrant technique|Intervention: 25 Botulinum Toxin injections. 5 vertical lines and 5 horizontal lines will be draw on the hair bearing area of the armpit amounting to 25 injection points being more concentrated on the center. Each injection consists of 5Units of abobotulinum
3477853|NCT03816046|Experimental|Technique 2 the six injection technique|Intervention: 6 Botulinum Toxin injections. will consist on 6 injections in the hair bearing area equally spaced with each consisting of 8units
3477854|NCT03816124|Experimental|Genicular RF|Patients who will receive genicular radiofrequency ablation
3477855|NCT03815903|Active Comparator|A - induction chemotherapy|
3477856|NCT03815903|Experimental|B - chemoradiotherapy|
3477857|NCT03815864||D2SA+|Median fluoresce intensity > or = 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
3477858|NCT03815864||D2SA-|Median fluoresce intensity < 1000 on Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation
3477859|NCT03815942|Experimental|Intermediate risk prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injection of MVA.5T4 and nivolumab infusion on week 1. Patients will undergo radical prostatectomy on week 6.
3477860|NCT03815942|Experimental|Advanced metastatic prostate cancer|ChAdOx1.5T4 on week 0 followed by booster injections of MVA.5T4 on week 4, ChAdOx1.5T4 on week 12 and MVA.5T4 on week 16. Nivolumab infusions are to be administered on week 4, 8 and 12.
3477861|NCT03815968|Experimental|low sodium diet|women diagnosed with oligohydramnios designated for conservative management applying a low-salt diet.
3126792|NCT03053271|Placebo Comparator|Placebo|During the 4-week randomized withdrawal period, eligible subjects will receive a placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
3126793|NCT03053401|Active Comparator|Adductor Canal block|Adductor Canal Block performed at mid-thigh level to block the saphenous nerve under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
3126794|NCT03053401|Active Comparator|Femoral Nerve block|Femoral Nerve Block performed under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
3126795|NCT03053427|Placebo Comparator|Placebo|Placebo was administered orally once daily after the evening meal.
3477862|NCT03815968|No Intervention|regular diet|women diagnosed with oligohydramnios designated for conservative management applying a regular diet.
3179452|NCT00672763|Placebo Comparator|B|Standard corticosteroid treatment PLUS placebo (Migliol Oil)
3179453|NCT00672776|Experimental|1|paroxetine
3477863|NCT03815890|Experimental|1A; LumB|Nivolumab
3477864|NCT03815890|Experimental|1B; TNBC|Nivolumab
3477865|NCT03815890|Experimental|2A; LUMB|Nivolumab and ipilimumab
3477866|NCT03815890|Experimental|2B; TNBC|Nivolumab and ipilimumab
3477867|NCT03815890|Experimental|3B; TNBC, High TIL|Nivolumab and ipilimumab
3477868|NCT03815877|Active Comparator|The intervention group (C group receiving caffeinated coffee)|100cc coffee at 3, 6 and 9 hours after the Cesarean section
3477869|NCT03815877|Placebo Comparator|The control group (N group receiving decaffeinated coffee)|100cc decaf coffee at 3, 6, 9 hours after the Cesarean section
3477870|NCT03815708||wheelchair rugby players|well-trained spinal cord injured wheelchair rugby players
3477871|NCT03815708||wheelchair basketball players|well-trained spinal cord injured wheelchair basketball players
3477872|NCT03815760|Experimental|Exercise with Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~The BFR cuff will be applied to the upper arm. Arterial occlusion will be set to 50%.~Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps. The occlusion will be maintained for the 8 min treatment period."
3477873|NCT03815760|Active Comparator|Exercise without Blood Flow Restriction|"Subjects will perform the sidelying external rotation exercise 2x a week for 8 weeks.~This group will not have BFR applied. Subjects will perform 4 sets (30, 15, 15, 15 reps) with a 30 sec rest period between reps."
3477874|NCT03815747|Experimental|Treatment Group|Treatment with the investigational device - High- Intensity Focused Electromagnetic (HIFEM) Field Device
3477875|NCT03815994|Experimental|Experimental: group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
3477876|NCT03815994|Sham Comparator|group 2|Decubitus Position with the limbs raised withou tNeuromuscular Electrical Stimulation and after Neuromuscular Electrical Stimulation.
3477877|NCT03815617|Active Comparator|Probiotic|The study design is a crossover randomized double-blind two-block placebo-controlled single center trial with an allocation ratio of 1:1 conducted between February 2017 and May 2018. Subjects are randomized at baseline visit to receive Block 1 (Zircombi 3 g, containing Bifidobacterium longum BB536 four billion CFU, Lactobacillus rhamnosus HN001 one billion CFU with B6 vitamin 1.4 mg) and Block 2 (placebo: maltodextrins, corn starch, silicon dioxide) depending on the randomization sequence. Subjects received one sachet pack daily containing placebo or probiotic. The active treatment was undistinguishable from placebo by physical and organoleptic characteristics. Participants in the study followed a free diet.
3477878|NCT03815617|Placebo Comparator|Placebo|Same appearance of probiotic.
3477879|NCT03815604|Experimental|RCT-IHS|Behavioral: At the Zurich site, the experimental intervention is called Independent Housing and Support
3477880|NCT03815604|Active Comparator|RCT-RCS/TAU|Behavioral: At the Zurich site, the comparator is usual residential care
3477881|NCT03815604|Experimental|OSD-IHS|Behavioral: At the Berne site, the experimental intervention is called Independent Housing and Support
3126796|NCT03053427|Experimental|Gabapentin enacarbil|Gabapentin enacarbil was administered orally once daily after the evening meal. Participants with an estimated creatinine clearance of ≥ 60 mL/min to < 90 mL/min at the start of the run-in period were administrated gabapentin enacarbil 300 mg for 1 week followed by gabapentin enacarbil 600 mg for 11 weeks.
3477882|NCT03815604|Active Comparator|OSD-RCS/TAU|Behavioral: At the Berne site, the comparator is usual residential care
3477883|NCT03815630|Experimental|PD-1 and dc-cik treatment group|
3477884|NCT03815838|Experimental|PET imaging|18F-FDOPA and 18F-Fallypride PET imaging
3477885|NCT03815669||Arthroscopic subacromial decompression|Patients referred to arthroscopic subacromial decompression
3477886|NCT03815656|Experimental|Implanted RC+S|Implanted Medtronic RC+S IPG with dual DBS electrodes in STN and GPi. DBS stimulation will be administered to: 1) STN alone, 2) GPi alone, 3) cooperative STN + GPi, and 4) adaptive, closed-loop stimulation of STN and/or GPi.
3477887|NCT03815955|Experimental|Non-Sedentary Behaviour Group|Participants in this arm will model the primary care team as they engage in minimal sedentary behaviour and replace sitting with standing and light, incidental movements.
3477888|NCT03815955|No Intervention|Standard Care Control Group|Participants that are limited to standing, due to amputations, diabetic foot pain and ulcers, or sensory diabetic neuropathy, will follow standard care and attend the DIGMA in a seated position.
3477889|NCT03815786|Experimental|CKD patients|CKD patients stage 3b-4 will follow a 2-months supplementation of either symbiotic or placebo
3477890|NCT03815786|Other|Controls|Healthy volunteers will follow a 2-months supplementation of either symbiotic or placebo
3477891|NCT03815851|Experimental|experimental：prophylactic drainage|leave prophylactic drainage after surgery
3477892|NCT03815851|No Intervention|control|not leave prophylactic drainage after surgery
3477893|NCT03815591|Experimental|adolescents between ages of 10-16|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, attitudes, intentions, social norms, and behaviors around tobacco use, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
3477894|NCT03815526|Experimental|Dynamic tape|
3477895|NCT03815526|Experimental|Kinesio tape|
3477896|NCT03815526|Experimental|Sport tape|
3477897|NCT03815721|Experimental|daily stimulation|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 7 times per week.
3477898|NCT03815721|Experimental|stimulation every other day|30-minute sessions of transcutaneous spinal cord stimulation using the Stimulette r2x+ will be repetitively applied 3 times per week.
3477899|NCT03815552|Experimental|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with type 1 Diabetes.The System will be set to provide realtime glucose information, including alarms and alerts in the home settings für 180 days.
3477900|NCT03815812|Experimental|IBI306|Participants received one of 6 dose levels of IBI306 administered as multiple subcutaneous dose
3126797|NCT03053492|Experimental|Duck Duck Punch|Subjects in this arm will engage in Duck Duck Punch Play, a custom designed computer game developed for stroke rehabilitation for 6 weeks.
3126798|NCT03053492|Active Comparator|Commercially Available Game|Subjects in this arm will engage in a Commercially Available Game Play off-the-shelf computer game for 6 weeks.
3477901|NCT03815812|Placebo Comparator|placebo|Participants received matching placebo dose regimen by subcutaneous injection.
3477902|NCT03815513|Experimental|cases|Patient with spontaneous intracerebral hemorrhage
3477903|NCT03815513|Experimental|controls|Healthy control without history of symptomatic cerebrovascular diseases
3477904|NCT03815500|Experimental|Patients with open surgical wounds|Patients with open surgical wounds will undergo enhanced packing education with curriculum designed for learners with low literacy, dyslexia or associated learning disorders.
3477905|NCT03815565|Experimental|levobupivacaine 0.125%|continuous femoral block with levobupivacaine 0.125%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
3477906|NCT03815565|Active Comparator|ropivacaine 0.2%|continuous femoral block with ropivacaine 0.2%. Use of PCA pump with the following parameters: 5 ml/h; bolus 5 ml; lockout 30 minutes
3477907|NCT03815539|Experimental|dry eye group|Part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
3126799|NCT03054051|Experimental|Tumaini Mobile Phone Game|Participants randomized to this arm will be invited to play the Tumaini game.
3179454|NCT00672776|Placebo Comparator|2|placebo
3179455|NCT00672789|Experimental|1|Blood Smear Education
3477908|NCT03815487|Experimental|Therapy with Hybrid Closed Loop (HCL)|"The Intervention is the specific function of the Insulin Pump from Medtronic® with the name MiniMed® 670G (MMT-1780) to deliver Insulin as medication.~This Medtronic MiniMed 670G Insulin Pump in Auto Mode is an Hybrid closed loop (HCL) system including an Auto Mode function. It provides as intervention several additional effects concerning automatically insulin delivery by pump: e.g. in case of high values (or predicted) - more insulin will be administered automatically, in case of low values (or predicted) - the insulin infusion will be decreased a suspended and resumed again. The patients will wear the pump continuously."
3477909|NCT03815487|Active Comparator|Sensor Augmented Pump (SAP) therapy|"The Intervention is the specific therapy of the Sensor Augmented Insulin Pump MiniMed® 670G (MMT-1780) without Auto Mode.~This Medtronic MiniMed 670G Insulin Pump without Auto Mode' is a Sensor Augmented Pump (SAP) therapy and means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. The patients will wear the pump also continuously, but have to respond manually after the alarm. There are no automatically steps from the pump."
3477910|NCT03815734|No Intervention|control group|Non intervention group
3477911|NCT03815734|Experimental|intervention group|motor imagery group
3477912|NCT03815799|Experimental|Erector Spinae Plane Block Group|"Procedure:~In addition to routine standard perioperative and postoperative analgesic protocol participants will recieve erector spinae block under ultrasound guidence after the strict aseptic precautions."
3477913|NCT03815799|Sham Comparator|Control|Routine standard perioperative and postoperative analgesic protocol will be given.
3477914|NCT03815474|Experimental|anlotinib & epirubicin& ifosfamide|interventions:Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
3477915|NCT03815461|Experimental|experiment group|Nab-paclitaxel+S-1
3477916|NCT03815448|Experimental|Methotrexate|Methotrexate 2.5mg/ tablet, oral, once a week, 2-6 tablets each time
3477917|NCT03815448|Placebo Comparator|Placebo|Placebo 2.5mg/ tablet,oral,once a week,2-6 tablets each time
3477918|NCT03815344|Active Comparator|Standard|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy.
3477919|NCT03815344|Experimental|Standard-Vaginal Misoprostol|Use of laparoscopic injection of diluted vasopressin (20units in 100mL 0.9NS) prior to incision throughout the myomectomy. 400mcg of misoprostol placed in the vagina at HUMI/foley placement .
3477920|NCT03815305|Active Comparator|Topical CA and Placebo Oral Drug|Patient given 10gr 1% CA ointment and 56 pcs of placebo drug
3477921|NCT03815305|Placebo Comparator|Petroleum Jelly and placebo oral drug|Patient given 10gr petroleum jelly 100% topical ointment and 56 pcs of placebo drug
3126800|NCT03054051|No Intervention|Standard of Care|Participants randomized to this arm will receive no intervention beyond the current standard of care for sexual education.
3126801|NCT03054064|Experimental|All Enrolled Subjects|All enrolled subjects will receive gait training with the Indego.
3126802|NCT03054077|No Intervention|Control or Group 1|This group receives standard of care for the child receiving a sedated procedure. There is no intervention for this group.
3477922|NCT03815305|Experimental|Centella asiatica extract and Topical CA|Patient given 10gr 1% CA ointment and 56 pcs of drug containing CA
3477923|NCT03815331|Experimental|PD treatment with Xiaflex® plus Aveed|Peyronie's Disease treatment with Xiaflex® and Aveed®. All 20 subjects will be treated with Xiaflex® and Aveed®. The data collected from this pilot project will be analyzed and compared to historical data regarding treatment for PD with Xiaflex® alone.
3477924|NCT03815318|Experimental|Recombinant Human Coagulation FVIII|Participant receivedSCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
3477925|NCT03815201|Placebo Comparator|Group 1|exercise training program: 2 non-consecutive days per week during 12 weeks plus placebo ingestion post-training
3477926|NCT03815201|Active Comparator|Group 2|exercise training program: 2 non-consecutive days per week during 12 weeks plus leucine-enriched protein supplementation post-training
3477927|NCT03815643|Experimental|Avelumab|
3477928|NCT03815435|Experimental|Balanced anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/ kg) + Propofol (2-3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: Desflurane 0.8-1.2 MAC + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60
3477929|NCT03815435|Experimental|Total intravenous anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/kg) + Propofol (2 -3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: continuous administration of Propofol 6-12 mg /kg/h + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60 Hypotensives: Nitro Pohl 1mg/ml 0-10 ml/h
3477930|NCT03815357||Children with IPD|Children with IPD will be referred for immunological evaluation. The protocol for immune work up will be the same but between centres there is variation in the age criteria for referral i.e. >2 years in some, >6 months in others.
3477931|NCT03815266|Experimental|Patient with first ischemic or hemorrhagic stroke|"Patient with first ischemic or hemorrhagic stroke will be included. They will have the following program Computerized Mirror Therapy (CMT) associated at transcranial Direct Current Stimulation (tDCS). This program will consist of 5 sessions per week for 4 weeks (20 minutes).~In more, they will have the following tests: Tolerance Assessment Questionnaire, Ashworth's scale, Frenchay arm test, Abilhand questionnaire, Fugl-Meyer test, and Goal Attainment Scaling (GAS)."
3126803|NCT03054077|Experimental|Intervention group or Group 2|This group receives an iPad with downloaded games to play while waiting for the sedation/procedure and then resume play upon return to the recovery area and awakening.
3126804|NCT03054103|Placebo Comparator|Midazolam alone|Drug: Midazolam titrated 0.5-2.0 mg + normal saline placebo. Midazolam + Normal saline
3126805|NCT03054103|Active Comparator|Midazolam + Ketamine 5 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 0.5 ML. Midazolam + Ketamine 10 MG/ML: 0.5 ML
3126806|NCT03054103|Active Comparator|Midazolam + Ketamine 10 mg|Drug: Midazolam titrated 0.5-2.0 mg + Ketamine 10 MG/ML: 1 ML. Midazolam + Ketamine 10 MG/ML: 1 ML
3126807|NCT03054337|Experimental|Vadadustat, Dose 1|Daily oral dose
3126808|NCT03054337|Experimental|Vadadustat, Dose 2|Daily oral dose
3477932|NCT03815214|Experimental|Diet Intervention|The diet intervention is a partial meal replacement program using the commercially available OPTAVIA® Optimal Weight 4&2&1 Plan™. In the OPTAVIA program, subjects are asked to eat 6 times each day, once every 2 to 3 hours.
3477933|NCT03815214|Placebo Comparator|Enhanced Standard Care|The control group will receive instruction on a healthy diet as defined by the United States Department of Agriculture.
3477934|NCT03815370|Placebo Comparator|Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
3477935|NCT03815370|Experimental|Device: ABRO™Binder Arm|Intervention is the usual care (listed above) plus a novel new abdominal binder device called ABRO™
3477936|NCT03815383|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
3477937|NCT03815253|Experimental|Acupuncture group|"Body electro-acupuncture will be conducted for 2 sessions per week over 8 consecutive weeks.~Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
3477938|NCT03815253|Placebo Comparator|sham-acupuncture group|"As to the participants allocated to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to act as sham control at the same acupoints with same stimulation modality. However, the needles will be only adhered to the skin instead of insertion. The validity and credibility of this model has been well demonstrated."
3126809|NCT03054337|Experimental|Vadadustat, Dose 3|Daily oral dose
3126810|NCT03054337|Placebo Comparator|Placebo|Daily oral dose
3477939|NCT03815084|Experimental|PD-1 and DC-NK treatment group|
3477940|NCT03815045|Active Comparator|Landmark-based lumbar puncture|Landmark-based LP
3477941|NCT03815045|Active Comparator|Ultrasound-guided lumbar puncture|Ultrasound-guided LP
3126811|NCT03054350|Experimental|Vadadustat, Dose 1|Daily oral dose
3126812|NCT03054350|Experimental|Vadadustat, Dose 2|Daily oral dose
3126813|NCT03054350|Experimental|Vadadustat, Dose 3|Daily oral dose
3126814|NCT03054350|Placebo Comparator|Placebo|Daily oral dose
3179456|NCT00672789|Active Comparator|2|Standard education
3179457|NCT00672802|Experimental|Ramelteon 16 mg QD and Placebo QD|
3179458|NCT00672828|Active Comparator|Non-tailored CRC screening brochure|Participants undergo a baseline interview via telephone and receive a non-tailored CRC screening brochure in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
3477942|NCT03815409|Experimental|BWSTT group|The sessions were conducted on a treadmill with partial weight unload.
3477943|NCT03815409|Other|Control group|The traditional PT rehabilitation treatment included passive, active and active-assisted exercises, according to the methods commonly used (Kabat, Bobath).
3477944|NCT03815032|Experimental|Optowire Deux FFR assessment (1)|"A total of 45 consecutive patients will be recruited:~group 1 (n=30): To assess the differences in FFR measurements (drift) made by the OptoWire Deux FFRTM guidewire by comparison of simultaneous data of two different OptoWire DeuxTM guidewires"
3477945|NCT03815032|Experimental|Optowire Deux FFR assessment (2)|group 2 (n=15): To assess the differences in FFR measurements (drift) obtained from an OptoWire DeuxTM FFR guidewire and compare it to the FFR measurement by a VERRATATM guidewire
3477946|NCT03815227|Experimental|Outpatient birth|Maternity out the same date or the next day of the birth
3477947|NCT03814902|Experimental|Electronic Tracking Device|Participants will be given a wearable electronic tracking device (ETD) to use for their child with autism spectrum disorder (ASD) for 6 weeks.
3477948|NCT03814980|Experimental|Pilot Study|Participants will be shown how to use a mindful breathing software application. The software will be used for 1 week. At the end of the week, participants will evaluate the software.
3477949|NCT03815136|Active Comparator|Chewing Gum|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy. Subjects chewed one piece of gum for approximately 15 min every 30 min at the first hour of the examination.
3477950|NCT03815136|Placebo Comparator|Control|The control group will not chew chewing gum while undergoing capsule endoscopy.
3477951|NCT03815279|Experimental|High-risk SMM and MM|"Twelve cycles of Carfilzomib-Lenalidomide-Dexamethason. Each cycle is 28 days. Carfilzomib intravenous, days 1, 8 and 15 (starting dose, 20 mg/m2 on day 1 of cycle 1; target dose, 56 mg/m2 thereafter) during cycles 1 through 12.~Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks then 20 mg weekly for 16 weeks and thereafter 10 mg weekly for 16 weeks.~Maintenance (1 year):~Carfilzomib intravenous days 1 and 15 (56 mg/m2) during cycles 13 through 24. Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks Dexamethasone 10 mg weekly for 52 weeks."
3477952|NCT03815279|Experimental|Intermediate-risk SMM|"Lenalidomide 25 mg orally once a day (3 weeks on/one week off) for 52 weeks. Dexamethasone 40 mg weekly for 16 weeks, then 20 mg weekly for 16 weeks.~Maintenance (1 year):~Lenalidomide 10 mg orally once a day (3 weeks on/one week off) for 52 weeks."
3477953|NCT03815019|Experimental|Megestrol|"Megestrol is a steroid and progestational drug FDA approved for treating anorexia or weight loss in patients with acquired immunodeficiency syndrome. Its use in the current protocol is off label to stimulate appetite in tube-fed infants and toddlers who are weaning from tube feedings and learning to eat. The precise mechanism of action that leads to increased appetite and weight gain is unknown, but is probably related to megestrol's glucocorticoid effect.~The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable."
3477954|NCT03815019|Placebo Comparator|Placebo|Subjects randomized to the placebo protocol will receive a placebo syrup identical in taste and smell to megestrol at the same intervals as those in the megestrol group but the syrup will contain no active ingredients.
3477955|NCT03815071|Experimental|ips-nsc treatment group|
3477956|NCT03814954|Active Comparator|Salbutamol|Patients will receive salbutamol (2 units/kg) with 3 ml normal saline by nebulizer.
3126815|NCT03054428|Experimental|Placebo|Participants received placebo matching dupilumab once every 2 weeks (Q2W) (including doubling the amount of placebo on day 1 to match the loading dose). In order to maintain blinding for the study, participants in the <60 kilogram (kg) weight stratum received, in a 1:1 ratio, either placebo matching 200 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose) or placebo matching 300 milligram (mg) dupilumab (including doubling the amount of placebo on day 1 to match the loading dose). In the ≥60 kg weight stratum, the participants randomized to the placebo group received placebo matching 300 mg dupilumab (including doubling the amount of placebo on day 1 to match the loading dose).
3477957|NCT03814954|Experimental|Epinephrine|Patients will receive epinephrine (0.5 mg/dose) with 3 ml normal saline by nebulizer.
3477958|NCT03814928|Experimental|Caregivers e-Learning Intervention|
3477959|NCT03815149||patients with intracranial aneurysm(s)|Standard of care elective, unscheduled or emergency procedures for the treatment of an unruptured or ruptured intracranial aneurysm(s) using a Pipeline™ Flex Embolization Device(s) with Shield Technology™
3477960|NCT03815097|Experimental|Intervention|Monitored anesthesia care with a mapleson circuit and nasal trumpet
3477961|NCT03815097|No Intervention|Standard of care|Standard monitored anesthesia care
3477962|NCT03814941||paper-based anesthesia record|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by paper-based documented anesthesia record."
3477963|NCT03814941||electronic documents|"The AIMS sampled the vital signs from the monitor every minute and stored in the database.~The incidence of artifacts in the AIMS database was evaluated by electric documented anesthesia record."
3477964|NCT03814967|Experimental|DLPFC Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex.
3477965|NCT03814967|Active Comparator|Occipital Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the occipital cortex.
3477966|NCT03814967|Sham Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
3477967|NCT03814876|Experimental|SCI intervention|Spinal cord injury intervention group
3477968|NCT03814876|Active Comparator|SCI control|Spinal cord injury control
3477969|NCT03814876|Experimental|TBI intervention|Traumatic brain injury intervention group
3477970|NCT03814876|Active Comparator|TBI control|Traumatic brain injury control group
3477971|NCT03814733|Experimental|Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477972|NCT03814733|Experimental|Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477973|NCT03814733|Active Comparator|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477974|NCT03814733|Active Comparator|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477975|NCT03814733|Placebo Comparator|Placebo for Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477976|NCT03814733|Placebo Comparator|Placebo for Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477977|NCT03814733|Placebo Comparator|Placebo for Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
3477978|NCT03814759|Experimental|SP+CCRT|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks
3477979|NCT03814824|Active Comparator|VLE without IRIS, followed by VLE with IRIS|VLE (Volumetric laser endomicroscopy) performed alone, followed by IRIS (Intelligent real-time image segmentation) imaging.
3477980|NCT03814824|Active Comparator|VLE with IRIS, followed by VLE without IRIS|VLE (Volumetric laser endomicroscopy) performed with IRIS (Intelligent real-time image segmentation) imaging, followed by VLE alone.
3477981|NCT03814655|Experimental|Full digital workflow|"Intraoral scan of the partially edentulous site, antagonists and occlusion registration. Radiopaque tray customization over the partially edentulous arch.~CBCT with customized radiopaque tray.~Merging files in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Digital impression for final screw-retained crown/bridge.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
3477982|NCT03814655|Active Comparator|Partially digital workflow|"Impression of the edentulous arch and antagonist, occlusion registration. Radiopaque tray customization over the edentulous arch.~CBCT with customized radiopaque tray.~Stone models alone, maximum intercuspal position and customized radiopaque tray will be scanned using a desktop scanner.~Merging files (CBCT and model stl) in R2 Gate software and implant planning.~Guided implant insertion with immediate loading, if possible. Megagen dental implants will be inserted.~Classic impression in customized tray with Impregum.~Functional models will be scanned using the same desktop scanner.~Final screw-retained crown/bridge manufacturing.~Assessment of accuracy by comparing stl files (planned and postimplant insertion)."
3126816|NCT03054428|Experimental|Dupilumab 300 mg Q4W|Participants received once every 4 weeks (Q4W) subcutaneous (SC) injections of 300 milligrams (mg) dupilumab following a loading dose of 600 mg on day 1. In order to maintain blinding, all participants received an injection once every 2 weeks (Q2W) from day 1 to week 14. Participants received placebo 2 milliliter (mL) injection at the weeks dupilumab was not given.
3477983|NCT03814564||Circulatory failure / NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit (ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the (near-infrared spectroscopy) NIRS-substudy.
3477984|NCT03814564||Circulatory Failure / no NIRS monitoring|Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring intensive care unit(ICU) care, including both surgical and medical ICU patients with circulatory shock will be included in the near-infrared spectroscopy (NIRS) substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data (without NIRS monitoring). Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria.
3126817|NCT03054428|Experimental|Dupilumab 200 mg or 300 mg Q2W|Participants with baseline weight <60 kg received once every 2 weeks (Q2W) subcutaneous (SC) injections of 200 milligrams (mg) dupilumab following a loading dose of 400 mg on day 1. Participants with baseline weight ≥60 kg received Q2W SC injections of 300 mg dupilumab following a loading dose of 600 mg on day 1.
3126818|NCT03054506|Experimental|CSP01|Subjects in the experimental group will receive CSP01, a non-systemic, orally administered hydrogel capsule, twice a day. CSP01 capsules are taken prior to a meal with water, after which the small particles within the capsules hydrate and expand in the stomach and small intestine. By acting as a bulking agent and possibly reducing colonic transit time through increase of colonic water content, CSP01 may contribute to constipation relief.
3126819|NCT03054506|Active Comparator|Carboxymethylcellulose (CMC)|Subjects in the active control group will receive orally administered 3 capsules of carboxymethylcellulose (CMC) capsules twice a day.
3477985|NCT03814564||Gut dysbiosis, delirium and long term cognition|"ASSESS-shock participants that have been treated at Meilahti ICU:s and survived the ICU admission to discharge, who are living in the Helsinki and Uusimaa Hospital District area or reasonable traveling distance to the unit for cognitive testing.~Cognitive function testing is performed after ICU discharge and at 3 and 6 months after ICU discharge. Testing of the microbiome is performed by collecting and analyzing fecal samples at ICU admission and at 7 days after ICU admission."
3477986|NCT03814603||African Americans|
3477987|NCT03814603||Non-Hispanic Whites|
3477988|NCT03814668|Experimental|Probiotic powder|One sachet of Probiotic powderwill be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
3477989|NCT03814668|Active Comparator|Lactase|One sachet of Lactase powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
3477990|NCT03814668|Placebo Comparator|Placebo|One sachet of placebo powder will be consumed with 25 g lactose in 250 ml of water in the beginning of a 6-hour challenge at the study visits.
3477991|NCT03814811||Bone metastasis(+) with low cOC|Patients who have bone metastasis with low number of circulating osteocalcin-positive (cOC) cells
3477992|NCT03814811||Bone metastasis(+) with high cOC|Patients who have bone metastasis with high number of circulating osteocalcin-positive (cOC) cells
3477993|NCT03814811||Bone metastasis(-) with low cOC|Patients who have metastasis only in extraskeletal sites with low number of circulating osteocalcin-positive (cOC) cells
3477994|NCT03814811||Bone metastasis(-) with high cOC|Patients who have metastasis only in extraskeletal sites with high number of circulating osteocalcin-positive (cOC) cells
3477995|NCT03814525|Active Comparator|Photobiomodulation group|PBM will be applied after the surgeries with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
3477996|NCT03814525|Placebo Comparator|Control group|Participants will be attended in the same way as the PBM group. The person who is responsible for the application of the PMB will simulate the irradiations by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off.
3477997|NCT03814577|Active Comparator|Desflurane|Anesthesia will be maintained with Desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture.Total Intravenous Anesthesia will not be used in this group. While target desflurane minimum alveolar concentration (MAC) will be 1-1.5 and Bispectral Index values will be between 40-60, the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
3477998|NCT03814577|Experimental|Total Intravenous Anesthesia|Total Intravenous Anesthesia: Anesthesia will be maintained with inhalation with a flow of 2 L/min in 0.5 O2 oxygen air mixture. Desflurane will not be used in this group. Total Intravenous Anesthesia (propofol and remifentanyl infusion) will be performed to the patients while target Bispectral Index values were between 40-60. Also the flow rate will be adjusted to 2 L/min. Total Antioxidant Status and Total Oxidant Status will be then measured. Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
3477999|NCT03814551||Comparison|Cohort of participants who regularly eat in cafeteria without health signage.
3478000|NCT03814551||Signage|Cohort of participants who regularly eat in cafeteria in which health signage is placed.
3478001|NCT03814486||patient transfused in platelet in the 6 last months of life|patient with hematological malignancies follow or hospitalised at least once in CHU of Besancon died in the period of the study transfused at least once in the 6 months of life
3478002|NCT03814395||Exposure group|Group with environmental, nutritional or lifestyle exposures
3478003|NCT03814395||Non-exposed group|Group without any environmental, nutritional and lifestyle exposures
3478004|NCT03814798|Experimental|Cohort 1|IGSC 20% daily push versus every 2 weeks pump or the reverse sequence
3478005|NCT03814798|Experimental|Cohort 2|IGSC 20% daily push versus once a week pump or the reverse sequence
3478006|NCT03814798|Experimental|Cohort 3|IGSC 20% daily push versus 2 times per week pump or the reverse sequence
3478007|NCT03814798|Experimental|Treatment-Naive IGSC 20% pump dosing|IGSC 20% 150 mg/kg
3478008|NCT03814408|Experimental|RP-L102|RP-L102 is a self-inactivating lentiviral vector carrying the therapeutic FANCA gene
3478009|NCT03814512|Experimental|Extended Sleep Intervention (ES)|Participants will receive a Standard Care Diet and Physical Activity Education Intervention (SC) and an Extended Sleep Intervention (ES). For the SC, participants will have their diet, physical activity, and screen time assessed by study interventionist. Prescribed goals will be determined collaboratively through discussion with participants and parents. For the ES, participants will subsequently be prescribed a sleep schedule that allows them to obtain 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively.
3478010|NCT03814473|Experimental|Dietary intervention|All participants will follow an ad libitum self-administered Paleo diet for 8-weeks
3478011|NCT03814694|Experimental|CRHP Diet|Hypo-energetic carbohydrate-reduced high-protein (CRHP) dietary intervention with a controlled 5-7% loss in body weight.
3478012|NCT03814694|Active Comparator|CD Diet|Hypo-energetic conventional diabetes (CD) dietary intervention with a controlled 5-7% loss in body weight.
3478013|NCT03814629|Other|precancerous lesions of gastric cancer|120 cases of chronic atrophic gastritis with intestinal metaplasia or dysplasia,It was randomly divided into 60 cases of treatment group and 60 cases of control group,treatment group was given Weifuchun tablets,The control group was given vitamin tablets.
3478014|NCT03814434|Experimental|Smokers with Periimplantitis group|Heavy smokers patients with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
3478015|NCT03814434|Experimental|Type 2 Diabetes with Periimplantitis group|Patients diagnosed with Type 2 Diabetes with periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
3478016|NCT03814434|Experimental|Chronic Periodontitis with Periimplantitis group|Patients diagnosed with Chronic Periodontitis and periimplantitis will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
3478017|NCT03814434|Experimental|Control with Periimplantitis group|Systemically healthy patients with periimplantitis will be included in this group. Patients will be evaluated and will have their clinical, biological and radiographic data collected at baseline, after non-surgical and surgical treatment and after 3, 6 and 12 months.
3126820|NCT03054506|Placebo Comparator|Placebo|Matching placebo consists of an inert mixture supplied by Gelesis Inc. in identical-appearing capsules.Subjects in the placebo group will be administered 3 capsules of placebo twice a day.
3126821|NCT03054649|Experimental|Cohort 1|Study eye: Primary implantation of HMIOL system with toric optic and no intraoperative optic exchange
3478018|NCT03814707|Active Comparator|Topical application 0.2%Hyaluronic Acid|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting and covered by periodontal pack
3478019|NCT03814707|Experimental|Platelet Rich Fibrin|Palatal donor site will receive a platelet rich fibrin and then will be sutured by criss cross suture then covered by periodontal pack.
3126822|NCT03054649|Experimental|Cohort 2|Fellow eye: Primary implantation of HMIOL system with monofocal optic, followed by intraoperative optic exchange (toric or non-toric optic)
3126823|NCT03054740|Active Comparator|Gebauer Ethyl Chloride|Device: Vapocoolant (Ethyl Chloride Mist Spray)
3478020|NCT03814447|Experimental|anti- MESO CAR-T cells|The subjects in this arm will receive Cyclophosphamide 300mg/m2/d and Fludarabine 30mg/m2/d d-4~-2. Then anti- MESO CAR-T cells will be injected by a dose of 5×106/kg once at d1(rang from d1-3).
3126824|NCT03054740|Placebo Comparator|Nature's Tears|Device: Sterile Water
3126825|NCT03054805|Experimental|Magnesium oxide and MIYAIRI-BM|"Magnesium oxide 125 mg twice per day for children with weight < 15 kg, 250 mg twice per day for weight <15-30 kg, and 500 mg twice per day for weight > 30 kg for 12 weeks.~MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks."
3478021|NCT03814720|Experimental|Group 1|5 subjects, ages 18-40 will be administred 20 mcg IM of H1ssF 3928 on Day 0.
3478022|NCT03814720|Experimental|Group 2A|12 subjects, ages 18-40 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
3478023|NCT03814720|Experimental|Group 2B|12 subjects, ages 41-49 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
3478024|NCT03814720|Experimental|Group 2C|12 subjects, ages 50-59 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
3478025|NCT03814720|Experimental|Group 2D|12 subjects, ages 60-70 will be administered 60 mcg IM of H1ssF 3928 on Day 0 and Week 16.
3478026|NCT03814772||Liver transplant|"18 years to 65~48h preoperative biochemical indicators, blood general indicators, coagulation test complete"
3478027|NCT03814616|Experimental|Arm Pyramax 3 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for three days (Arm A)
3478028|NCT03814616|Experimental|Arm Pyramax 2 days|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for two days (Arm B)
3478029|NCT03814616|Experimental|Arm Pyramax 1 day|Pyramax (pyronaridine tetraphosphate 180mg:artesunate 60mg) will be administered, once per day according to body weight for one day (Arm C)
3478030|NCT03814642|Active Comparator|Clopidogrel 75 mg|Oral administration of clopidogrel 75 mg tablet once daily for 7 days
3478031|NCT03814642|Experimental|Clopidogrel 75 mg + Tegoprazan 50 mg|Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
3478032|NCT03814642|Experimental|Clopidogrel 75 mg + Esomeprazole 20 mg|Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
3478033|NCT03814356|Experimental|IV MPH|All patients will receive IV Methylphenidate (MPH). Patients will receive escalating daily doses of IV MPH starting at 0.5 mg/kg, increasing stepwise to 1.0mg/kg and 2.0 mg/kg unless an adverse event (AE) necessitates dose de-escalation or a serious adverse event (SAE) necessitates that the patient stop participation in the study.
3478034|NCT03814421|Experimental|Low dose intermittent|Pantoprazole 40mg as a bolus injection daily for 72hours
3478035|NCT03814421|Active Comparator|High dose continous|Pantoprazole 40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours
3478036|NCT03814291|Experimental|cohort 1 IBI302 treated with first dose level of IBI302|
3478037|NCT03814291|Experimental|cohort 2 IBI302 treated with second dose level of IBI302|
3478038|NCT03814291|Experimental|cohort 3 IBI302 treated with third dose level of IBI302|
3478039|NCT03814291|Experimental|cohort 4 IBI302 treated with fourth dose level of IBI302|
3478040|NCT03814291|Experimental|cohort 5 IBI302 treated with fifth dose level of IBI302|
3478041|NCT03814291|Experimental|cohort 6 IBI302 treated with sixth dose level of IBI302|
3478042|NCT03814343|Active Comparator|Active comparator|10 patients with NDMs onychomycosis treated with amphotericin B in 30% DMSO.
3478043|NCT03814343|Placebo Comparator|control comparator|10 patients with NDMs onychomycosis treated with 30% DMSO.
3478044|NCT03814369|Experimental|AmplifEYE colonoscopy|Colonoscopy performed with AmplifEYE equipped
3478045|NCT03814369|No Intervention|Standard colonoscopy|Standard colonoscopy performed
3478046|NCT03814460||Control Group|A control group of healthy subjects with no previous history of neurological disorders or conditions. This group pf participants will be selected in a similar population based-cohort than the other two study groups.
3478047|NCT03814460||Acute Stroke Group|In this group, participants who suffered a previous stroke within 3 months before data collection will be included.
3478048|NCT03814460||Chronic Stroke Group|In this group, only participants who have suffered a previous stroke of more than 3 months duration before data collection will be included.
3478049|NCT03814304|Experimental|Personalized tDCS|Personalized tDCS: This intervention is designed to facilitate the excitability of the left dlPFC. The direct current delivered by any one electrode will not exceed 2.0 mA; the total amount of current from all electrodes will not exceed 4 mA. Each 20-minute session will begin and end with a 60-second ramp up/down of current amplitude to maximize comfort.
3478050|NCT03814304|Sham Comparator|Active-Sham|The investigators will use an active sham in which very low-level currents (0.5 mA total) will be transferred between electrodes in close proximity on the scalp throughout the entire 20-minute session. This intervention will be optimized to each participant to deliver currents designed to not significantly influence their cortical tissue, but still mimic the cutaneous sensations induced by tDCS.
3478051|NCT03814330|Placebo Comparator|Sedation/Analgesia|Patients with applied sedation analgesia will perform State-Trait Anxiety Inventory and Quality of Recovery Score
3478052|NCT03814330|Active Comparator|Laryngeal Mask Airway|Patients with applied Laryngeal Mask Airway will perform State-Trait Anxiety Inventory and Quality of Recovery Score
3478053|NCT03814200|Experimental|Treatment period A|"Treatment A1: saline 0.9%~followed by~Treatment A2: ACT-246475"
3478054|NCT03814200|Experimental|Treatment period B|"Treatment B1: rifampicin~followed by~Treatment B2: ACT-246475"
3478055|NCT03814265|Experimental|Intervention|Laughter yoga group
3126826|NCT03054805|Active Comparator|Magnesium oxide|MIYAIRI-BM 1 package (1g) divided as 0.5 g twice per day for children with weight < 15 kg, 2 packages divided as 1 g twice per day for weight 15-30 kg, and 3 packages divided as 1.5 g twice per day for weight > 30 kg for 12 weeks.
3126827|NCT03054805|No Intervention|Healthy Children|Healthy Children
3478056|NCT03814265|No Intervention|Control|No intervention
3478057|NCT03814382|Experimental|Acupuncture|All subjects will receive up to 10 needles for 20 minutes for 1 treatment using acupuncture needles.
3478058|NCT03814278|Experimental|Complete bed rest|Participants on complete bed rest group kept antepartum confinement to bed with toileting restricted to bedpan use. Participants in this group received prophylactic subcutaneous enoxaparin (40mg/day).
3478059|NCT03814278|Experimental|Activity restriction group|Activity restriction group had motion limited to bathroom privileges and walks to the ward canteen four times per day.
3126828|NCT03054844|Experimental|PREMED|Patients will receive 0.25 mL of IN 4% lidocaine (10 mg) in each naris (total of 0.5 mL/20 mg for both nares) preceding adminstration of IN midazolam.
3126829|NCT03054844|Experimental|PREMIX|Patients will receive midazolam mixed with 0.5 mL of 4% lidocaine (20 mg).
3126830|NCT03054857|Experimental|Dex group|After skin incision, the Dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
3478060|NCT03814252|Experimental|Lesion-targeted ablation with MRI-TULSA|Intervention: Targeted lesion based thermoablation of MRI-visible biopsy proven clinically significant prostate cancer. Ablative effect is aimed to cover lesion with 5 mm MRI based healthy tissue overlap wherever possible but not compromising viability of critical tissues, mainly the wall of rectum.
3478061|NCT03814213||No-CGA|Patients were not initially offered CGA due to no booking for CGA
3126831|NCT03054857|Placebo Comparator|Placebo group|The control group received a loading dose and continuous IV infusion of normal saline at the same rate.
3126832|NCT03054870|Other|Xe-133 Followed by Technegas|Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
3478062|NCT03814213||CGA alone|Patients had CGA, but no tailored follow-up upon identified problems
3478063|NCT03814213||CGA with tailored care|CGA and a tailored follow-up and care for 90 days following the CGA
3478064|NCT03814226|Experimental|PACAP-38 infusion|According to main hypothesis PACAP-38 is expected to induce headache. PACAP-38 causes marked vasodilation visible to investigator. PACAP38 (10 pmol/kg/min) is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
3478065|NCT03814226|Active Comparator|VIP infusion|According to main hypothesis VIP is not expected to induce headache. VIP also causes marked vasodilation visible to investigator, which is why VIP is chosen as an active comparator. VIP (10 pmol/kg/min) is infused over 20 minutes. VIP is infused over 20 minutes, patients are observed before (15 minutes), during and after (70 minutes) infusion. Blood samples are drawn at fixed time-points.
3478066|NCT03814239||no protocol|liberal fluid therapy
3478067|NCT03814239||protocol|fluid therapy according to stroke volume variation (SVV) monitor, tranexamic acid administration, use of cell saver
3478068|NCT03813875||TEE (transesophageal echocardiography)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~TEE group: the routine sedation medication for the procedure include midazolam (approximately 1~5mg per patient), alfentanil (200~1000mcg per patient) and propofol (small boluses of 10~20mg on demand, total dose usually below 100mg per patient depending on the overall examination timespan) all in intravenous boluses. Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
3478069|NCT03813875||LMA (laryngeal mask airway)|"This is a purely observational study of the routine anesthestic practice involving the simultaneous use of three drugs.~LMA group: routine induction medications include propofol (50~200mg per patient), fentanyl (50~150mcg per patient) and sevoflurane (machine setting at 1.5% to 3% according to clinical needs). Patients are monitored with standard monitors (electrocardiography, Non-invasive blood pressure, and pulse oximetry), bispectral index (BIS) and analgesia nociception index (ANI). Patients are observed in the recovery unit with designate nursing staff until full conscious recovery before discharge."
3478070|NCT03813810||Normal|People without any chronic pulmonary diseases.
3126833|NCT03054922|Active Comparator|Normal Saline|0.9% Sodium Chloride
3478071|NCT03813810||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease.
3478072|NCT03813810||Asthma|Patients with asthma
3126834|NCT03054922|Active Comparator|Lactated Ringers|"Each 100 mL of Lactated Ringer's Injection USP contains:~Sodium Chloride USP 0.6 g; Sodium Lactate USP 0.31 g; Potassium Chloride USP 0.03 g; Calcium Chloride Dihydrate USP 0.02 g; Water for Injection USP qs"
3126835|NCT03054922|Active Comparator|Normosol-R|Each 100 mL of Normosol-R contains sodium chloride, 526 mg; sodium acetate, 222 mg; sodium gluconate, 502 mg; potassium chloride, 37 mg; magnesium chloride hexahydrate, 30 mg.
3126836|NCT03055000|Experimental|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
3478073|NCT03813810||Idiopathic pulmonary fibrosis|Patients with idiopathic pulmonary fibrosis
3478074|NCT03813784|Experimental|A|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 250 mg PO qd.
3478075|NCT03813784|Active Comparator|B|Capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus Oxaliplatin 130 mg/m^2, IV q3w
3478076|NCT03813784|Experimental|C|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210
3478077|NCT03813901|Experimental|Samalochana Counselling group|Arsha Vidya advaita vedanta based counselling were given to the women
3478078|NCT03813901|Other|Wait-list control group|Wait list group were not given any supportive care during the period. After that, they were offered the similar program as Counselling group.
3478079|NCT03813979|Experimental|Hepatic impairment group|Dolutegravir in HIV-seronegative subjects with severe hepatic impairment (child-Pugh score 10 or greater)
3179459|NCT00672828|Experimental|Interactive computer intervention|Participants undergo a baseline interview via telephone and complete an interactive computer intervention in the clinic prior to visit with healthcare provider. Participants then undergo telephone interviews at 1 week, 6 months, and 15 months.
3179460|NCT00672867|Experimental|1|Clevudine
3179461|NCT00672867|Active Comparator|2|Adefovir
3478080|NCT03813979|Active Comparator|Matched controls|Dolutegravir in control group matched for gender, age and BMI with subjects in hepatic impairment group
3478081|NCT03814070|Active Comparator|Non-reinforced full arch acrylic restorations|
3478082|NCT03814070|Experimental|full arch acrylic restorations with fiber-reinforced framework|
3478083|NCT03814135|Experimental|HIPNOS 3|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 3 and 1 placebo tablet, oral, once a day."
3478084|NCT03814135|Experimental|HIPNOS 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Hipnos 5 and 1 placebo tablet, oral, once a day."
3478085|NCT03814135|Placebo Comparator|HIPNOS Placebo|The study is double-dummy. Thus, the patient will take 2 tablet of placebo, oral, once a day.
3478086|NCT03814096|Experimental|Syphilis POC-prenatal screening|Syphilis prenatal screening late in gestation at 24-28 weeks (at the time of the routine prenatal care clinic visit for the routine Glucose Tolerance Test [GTT]) using the Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
3478087|NCT03814148|Experimental|LENINGRADO 5|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Leningrado 5 association and 1 tablet Natrilix® SR placebo."
3478088|NCT03814148|Active Comparator|Natrilix® SR|"The study is double-dummy. Thus, the patient will take 2 tablets, as follow:~1 tablet Natrilix® SR 1,5 mg and 1 tablet Leningrado 5 association placebo."
3478089|NCT03814122|Experimental|ABCR Treatment Group|Group that is immediately administered action-based cognitive remediation intervention.
3478090|NCT03814122|Active Comparator|Waitlist Control Group|Group that is waitlisted (i.e., receives treatment-as-usual) and after approximately 8 weeks received action-based cognitive remediation intervention
3478091|NCT03813992|Active Comparator|MED2005 0.2%|MED2005 0.2% w/w gel to deliver 0.6 mg dose of GTN applied topically prior to a sexual intercourse attempt
3478092|NCT03813992|Active Comparator|MED2005 0.4%|MED2005 0.4% w/w gel to deliver 1.2 mg dose of GTN applied topically prior to a sexual intercourse attempt
3478093|NCT03813992|Active Comparator|MED2005 0.6%|MED2005 0.6% w/w gel to deliver 1.8 mg dose of GTN applied topically prior to a sexual intercourse attempt
3478094|NCT03813992|Placebo Comparator|Placebo vehicle|Placebo vehicle applied topically prior to a sexual intercourse attempt
3478095|NCT03814109|Experimental|LENINGRADO|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet Leningrado association,1 tablet indapamide placebo, 1 tablet levamlodipine placebo, oral, once a day."
3478096|NCT03814109|Active Comparator|Indapamide|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet indapamide 1,5 mg, 1 tablet Leningrado association placebo, and 1 tablet levamlodipine placebo, oral, once a day."
3126837|NCT03055000|Experimental|AGS-v with adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL)on Day 0 and on Day 21
3126838|NCT03055000|Placebo Comparator|Placebo|WFI (0.5mL) on Day 0 and Day 21
3478097|NCT03814109|Active Comparator|Levamlodipine|"The study is triple-dummy. Thus, the patient will take 3 tablets, as follow:~1 tablet levamlodipine 2.5/ 5 mg, 1 tablet indapamide placebo, and 1 tablet Leningrado association placebo, oral, once a day."
3478098|NCT03814031||EAD|Early allograft dysfunction (EAD), which was defined by the presence of one or more of the following: total bilirubin (t-bil) ≥ 10 mg/dL (171 μmol/L) or, INR ≥ 1.6 on day 7, and ALT/AST > 2,000 IU/L within the first 7 days.
3478099|NCT03814031||Non EAD|No EAD
3478100|NCT03814083|Experimental|Active-tDCS and Sham-tDCS|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, for sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
3126839|NCT03055156|Experimental|Low rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
3126840|NCT03055156|Experimental|High rebound mattress toppers|sleep with mattress topper during overnight diagnostic sleep study
3126841|NCT03055195|Experimental|Mepolizumab|Eligible subjects will receive mepolizumab 100 mg subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
3126842|NCT03055195|Placebo Comparator|Placebo|Eligible subjects will receive matching placebo subcutaneously every 4 weeks on Day 1, Week 4, Week 8, and Week 12
3126843|NCT03055221|Experimental|Intravenous Treprostinil|Intravenous treprostinil was supplied as 1 mg/mL.
3126844|NCT03055260|Experimental|Blood flow restriction cuff|This group will receive an active cuff that partially restricts blood flow to the experimental limb.
3179462|NCT00672880|Experimental|1|Psychotherapy
3478101|NCT03814083|Active Comparator|Active-tDCS and wait-list|For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends. On the other hand, participants in the wait-list control group will not receive any intervention.
3478102|NCT03814083|Sham Comparator|Sham-tDCS and wait-list|For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participant will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode. On the other hand, participants in the wait-list control group will not receive any intervention.
3478103|NCT03813927|Experimental|Vitamin D|supplementation with tablet 170 μg Vitamin D each day.
3478104|NCT03813927|Placebo Comparator|Placebo|Placebo, tablet with 20 μg Vitamin D each day.
3478105|NCT03813940|Experimental|HPV Vaccine,135μg/0.5ml|Participants in this arm would receive 135μg/0.5ml HPV vaccines
3478106|NCT03813940|Experimental|HPV Vaccine,270μg/1.0ml|Participants in this arm would receive 270μg/1.0ml HPV vaccines.
3478107|NCT03813914|Experimental|Sineos|Glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills/day for 3 months
3478108|NCT03813914|Placebo Comparator|Placebo comparator|placebo 2 pills/day for 3 months
3478109|NCT03814057||Elderly Medical Patients at hospital admission|
3478110|NCT03813953|Experimental|Local Anaesthetic Wound Infiltration|Wound catheter delivering local anaesthetic for 48 hours post-operatively following liver resection
3478111|NCT03813953|Active Comparator|Epidural|Conventional practice following liver resection
3478112|NCT03813888|Experimental|Arsha Vidya Group|After school, children joined regular sessions in Arsha Vidya study centre to practice, vedic chants, vedanta reading, yoga and group activities within the ashram.
3478113|NCT03813888|Other|Usual Activity Group|After school, control group were asked to conitue their usual routine.
3478114|NCT03813823||Phobic|Adults aged 18-40 exhibiting high levels of self-reported phobic symptoms to spiders
3478115|NCT03813823||Nonphobic|Adults aged 18-40 exhibiting low levels of self-reported phobic symptoms to spiders
3478116|NCT03813797|Experimental|Arm A: Low Pressure (5-7 mmHg)|Laparoscopic colectomy surgery with low pressure (5-7mmHg)
3478117|NCT03813797|Active Comparator|Arm B: Standard pressure (12-15 mmHg)|Laparoscopic colectomy surgery with standard pressure (12-15mmHg)
3126845|NCT03055260|Placebo Comparator|Blood Flow restriction Cuff-Placebo|This group will wear a placebo cuff, of which will not restrict blood flow at all.
3126846|NCT03055338|Experimental|MK-8189|Participants receive MK-8189 (4 mg controlled release [CR] oral tablet[s]) in combination with placebo matching risperidone (oral capsule[s]) once daily (QD) for 4 weeks. Over the initial 7 treatment days, MK-8189 is titrated from 4 mg to 12 mg as follows: 4 mg (1 tablet; Day 1); 8 mg (2 tablets; Day 4); and 12 mg (3 tablets; Day 7). Placebo matching risperidone is also titrated as follows: 1 capsule (Day 1), 2 capsules (Day 4), and 3 capsules (Day 7). After Day 7, MK-8189 is maintained at 12 mg (3 tablets) in combination with placebo matching risperidone (3 capsules), QD for 3 weeks.
3478118|NCT03813667|No Intervention|Control|The control patients have standard care given through the WVU hospital and outpatient clinics, prescribed by the patient's pulmonologist and recorded in the medical record
3478119|NCT03813667|Experimental|Intervention|The FamPALcare intervention group receives all standard care plus 2 weeks of home EOLPC coaching by community nurses experienced in end-of-life palliative care.
3478120|NCT03813576|Other|All participants|Only 1 arm in the study. All women will undergo both self-collected swab and clinician-collected swab
3478121|NCT03813563||Mix group|Patients who used two balanced salt solutions during icu stay
3478122|NCT03813563||RL group|Patients who have only used lactated Ringer's during icu stay
3478123|NCT03813563||PLA group|Patients who have only used PlasmaLyte during icu stay
3478124|NCT03813771|Experimental|Abnormal T-cells: Benepali + T2T Care|"Treatment Arm C will receive Benepali and methotrexate combination therapy and followed as per T2T care over a total duration of 24 weeks. Sulfasalazine or Hydroxychloroquine may be added to therapy at follow up visits in-line with T2T care.~Benepali will be administered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).~Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks."
3478125|NCT03813771|Active Comparator|Abnormal T-cells: Methotrexate + T2T Care|"Treatment Arm B will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination synthetic DMARD (Including sulfasalazine and/or hydroxychloroquine).~therapy if not achieving low disease activity (LDA) at, or after, 8 weeks)."
3478126|NCT03813771|Other|Normal T-cells: Methotrexate + T2T Care|Treatment Arm A will receive standard T2T care as per Arm B.
3478127|NCT03813550|Other|PXE cohort 2019-2020|PXE patient cohort monitored at referral centre from 2019 to 2020: fecal and blood samples
3478128|NCT03813472||Atopic Dermatitis|Evaluate sensor performance for hydration sensing.
3179463|NCT00672880|Active Comparator|2|Spine Education
3179464|NCT00672880|Placebo Comparator|3|Standard Care
3179465|NCT00672893||Observation|Patients who present to the clinic with airway obstruction and who are designated to undergo intervention
3179466|NCT00672906|Experimental|1|Group Parent Training/Adolescent Skills Training
3478129|NCT03813472||Healthy aged matched controls|Evaluate sensor performance for hydration sensing.
3478130|NCT03813615|Experimental|"Pilot Proof-of-Concept"|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear (breast, prostate, and endometrial) or non-linear (lung) dosing schedule for a minimum of 2 weeks.
3478131|NCT03813615|Experimental|Phase 1a: Dose-Finding / Escalation|Individualized, progressive aerobic training consisting of treadmill walking ranging from a total of 90 mins/wk to 450 mins/wk delivered over 3 to 7 sessions/wk following a linear or non-linear dosing schedule for a minimum of 2 weeks.
3478132|NCT03813615|Experimental|Phase 1b: Dose-Expansion|Individualized, progressive aerobic training consisting of treadmill walking delivered to achieve the RP2D identified in the phase 1a trial for a minimum of 2 weeks.
3478133|NCT03813680|Active Comparator|PVM group|This group included 30 participants. Passive vertebral mobilization was given along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
3478134|NCT03813680|Active Comparator|PNF group|This group included 30 participants. PNF exercise in the form of diagonal pattern neck movements was along with routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care
3478135|NCT03813680|Active Comparator|RPT(Routine Physiotherapy) group|This group included 30 participants.Routine physiotherapy comprising TENS, Hotpack/IRR, Isometric neck exercise and postural care.
3126847|NCT03055338|Active Comparator|Risperidone|Participants receive risperidone (2 mg oral capsule[s]) in combination with placebo matching MK-8189 (oral tablet[s]), QD for 4 weeks. Over the initial 7 treatment days, risperidone is titrated from 2 mg to 6 mg as follows: 2 mg (1 capsule; Day 1); 4 mg (2 capsules; Day 4); and 6 mg (3 capsules; Day 7). Placebo matching MK-8189 is also titrated as follows: 1 tablet (Day 1), 2 tablets (Day 4), and 3 tablets (Day 7). After Day 7, risperidone is maintained at 6 mg (3 capsules) in combination with placebo matching MK-8189 (3 tablets), QD for 3 weeks.
3126848|NCT03055338|Placebo Comparator|Placebo|Participants receive both placebo matching MK-8189 (oral tablet[s]) as well as placebo matching Risperidone (oral capsule[s]), QD for 4 weeks. Over the initial 7 treatment days, placebo matching both MK-8189 and risperidone are respectively titrated as follows: 1 tablet/1 capsule (Day 1); 2 tablets/2 capsules (Day 4); and 3 tablets/3 capsules (Day 7). After Day 7, placebo matching both MK-8189 and risperidone are respectively maintained at 3 tablets/3 capsules, QD for 3 weeks.
3126849|NCT03055494|Experimental|Secukinumab|Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
3478136|NCT03813641|Experimental|RALOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Raltitrexed 3mg/m2, i.v.gtt 15min ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
3478137|NCT03813641|Active Comparator|CAPOX + bevacizumab|Oxaliplatin 130mg/m2, i.v.gtt 2h, d1 Capecitabine 1000mg/m2, po. ,d1 Bevacizumab 7.5mg/kg, i.v.gtt, d1 The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
3478138|NCT03813706|Active Comparator|LN-prRLN dissection|
3478139|NCT03813706|Experimental|no LN-prRLN dissection|
3478140|NCT03813693|Experimental|towels with chlorhexidine gluconate 2%|Composed of 25 patients, who received 2 towels with chlorhexidine gluconate 2% packages each containing six towels and detailed instructions on the form and sequence of application of the towels; the time of application, that is, the night before surgery, between 20 and 22h, and, on the morning of surgery, between 5 and 6h; besides other general orientations.
3478141|NCT03813693|Active Comparator|chlorhexidine gluconate 2% liquid|Composed of 23 patients, two 100 ml flasks of chlorhexidine gluconate 2% liquid were supplied, and detailed instruction manual for the product, containing form and application sequence; time of application (the night before surgery, between 20 and 22h, and on the morning of surgery, between 5 and 6h); and general guidelines.
3478142|NCT03813628|Experimental|polished celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
3478143|NCT03813628|Experimental|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
3478144|NCT03813628|Active Comparator|contralateral natural teeth|the poilshed and glazed all ceramic crowns will be compared by the contralateral natural teeth
3478145|NCT03813758||finger after digital nerve cut|
3478146|NCT03813758||healthy finger|
3478147|NCT03813394|Experimental|Treatment Arm A|Intravenous pembrolizumab alone,D8 of 21-day cycle.
3478148|NCT03813394|Experimental|Treatment Arm B|Intravenous pembrolizumab preceded by an infusion of bevacizumab (Day 1 of 21-day cycle).
3478149|NCT03813433|Experimental|Enosequence|3-4 mm of Endosequence will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
3478150|NCT03813433|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of Mineral Trioxide Aggregate will be applied over the blood clot in group I. Material will be packed using condenser with light pressure. Periapical radiograph will be taken to ensure coronal seal in the second visit of revascularization
3126850|NCT03055494|Placebo Comparator|Placebo|Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
3126851|NCT03055624|Experimental|Prostate artery embolization|Single arm study of patients undergoing the prostate artery embolization procedure with Embosphere particles.
3126852|NCT03055650|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
3126853|NCT03055806|Experimental|IX-01 1200 mg|1200 mg dose comprising three 400 mg caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
3478151|NCT03813745||early denudation|Cumulus-oocyte complexes will be denudated in 30 min after oocyte retrieval
3478152|NCT03813745||late denudation|Denudation will be done 2 hr after oocyte retrieval
3478153|NCT03813329|Placebo Comparator|Placebo|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of Calcium carbonate
3478154|NCT03813329|Active Comparator|Acute Sodium Bicarbonate|3 doses of calcium carbonate (110 mg·kg-1, 130 mg·kg-1, 160 mg·kg-1), followed by one acute does (300 mg·kg-1) of sodium bicarbonate.
3478155|NCT03813329|Experimental|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
3478156|NCT03813732|Other|orbital fracture|using the trans-conjunctival approach with lateral canthotomy
3478157|NCT03813277|Experimental|Dexmedetomidine|Dexmedetomidine 100microg/ml
3478158|NCT03813537|No Intervention|Standard of Care|The control will be discharged with standard of care follow-up instructions and scheduled for a standard follow-up clinic visit within 2-3 weeks post-op.
3478159|NCT03813537|Experimental|Phone Call|The experimental group will receive a phone call intervention 3 days post-op. During this phone call, the patient will be asked questions using a study questionnaire based on the most frequent indications for readmission post colorectal surgery. Based on the responses, patients will be advised to maintain the scheduled appointment, visit the clinic within 48 hours, or go to the Emergency Department immediately.
3126854|NCT03055806|Placebo Comparator|Placebo|Three placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
3478160|NCT03813485|Active Comparator|Dry needling in upper trapezius|"Patients receive dry needling in latent myofascial trigger point in upper trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
3478161|NCT03813485|Experimental|Dry needling in lower trapezius|"Patients receive dry needling in latent myofascial trigger point in lower trapezius. The needle was penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
3478162|NCT03813316|Experimental|Interventional Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin after receiving extra training on individualized care.
3478163|NCT03813316|Experimental|Control Arm|Adding a DPP-4i (sitagliptin) and/or an SGLT2i (ertugliflozin) to metformin as per standard care/Diabetes Canada guidelines.
3478164|NCT03813498|Experimental|intervention group|
3478165|NCT03813498|Other|control group|
3478166|NCT03813420||Physiotherapy students|"Pittsburgh Sleep Quality Index-PSQI:The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month~International Physical Activity Questionnaire-IPAQ: The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as the intensity of physical activity in the last seven days.~Short Form-36-SF-36: The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts."
3478167|NCT03813524|Experimental|Cardiovalve Transfemoral Mitral Valve|Replacement valve delivered through a transfemoral access and transseptal approach
3478168|NCT03813602|Experimental|Cannabis sativa|a 750 mg cannabis cigarette with 12.5% THC
3478169|NCT03813290|Experimental|Neuro-Technological Intervention|"Participants will attend a total of 8 x 30 minutes intervention sessions (twice a week) for four consecutive weeks, starting within 1 week after baseline assessment.~Participants will also be required to fill up some questionnaires at baseline and post-intervention visits."
3478170|NCT03813264|Experimental|preliminary arm|pairs of patients and their therapists
3478171|NCT03813303|Active Comparator|Midazolam group|Midazolam and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist . Complications and procedure and recovery times were recorded for comparison with the Fentanyl group.
3478172|NCT03813303|Active Comparator|Fentanyl group|Fentanyl and Propofol administered for sedation in colonoscopy elective patients by anesthesiologist .Complications and procedure and recovery times have were recorded for comparison with the Midazolam group.
3478173|NCT03813381|Experimental|Intervention Arm (IA)|Patients randomized in the Intervention Arm (IA) will be given personalized diet based on calorie and protein restriction. Calorie restriction will be up to 600 kcal below patients' energy requirements and the amount of protein will be 0.8g of protein/Kg body weight mostly form plant-origin food.
3478174|NCT03813381|No Intervention|Control Arm (CA)|Participants in the CA will be given information about the importance of a healthy lifestyle in reducing the risk of cancer and will receive a leaflet based on WCRF/AICR recommendations.
3478175|NCT03813355|Experimental|Active stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with active stimulations
3478176|NCT03813355|Sham Comparator|Sham stimulation|Brain stimulation by Transcranial Direct Current Stimulation (tDCS) with inactive stimulations
3478177|NCT03813043|Other|Midazolam|Midazolam 2 mg as started dosage will be used for first patients and for the other patients will receive an predetermined dosage accordingly
3478178|NCT03813004|Experimental|Young healthy adults|
3478179|NCT03813342|Experimental|Multichannel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 4 channels of visual information, each of which represents a joint angle (right and left hips, right and left knees).
3126855|NCT03055806|Experimental|IX-01 800 mg|800 mg dose comprising two 400 mg caplets and one placebo caplet administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
3126856|NCT03055806|Experimental|IX-01 400 mg|400 mg dose comprising one 400 mg caplet and two placebo caplets administered orally at least 1 hour before or after food and 1-6 hours prior to sexual activity
3126857|NCT03055832|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
3126858|NCT03055832|Active Comparator|LipiFlow Thermal Pulsation System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
3126859|NCT03055858|Experimental|PDA closure|
3126860|NCT03055897|Experimental|iLux 2020 System|Meibomian gland treatment (Day 0) according to instructions for use (IFU)/User Manual
3126861|NCT03055936|Experimental|A1|levodopa 50 mg, carbidopa 12.5 mg
3126862|NCT03055936|Experimental|B1|levodopa 50 mg, carbidopa 65 mg
3478180|NCT03813342|Experimental|Single Channel Visual Feedback|Gait training with visual feedback of joint kinematics. The visual feedback will contain information about the lower limb joint angles. We will instruct subjects to use the feedback to reach a target walking pattern. In this arm, subjects will receive 1 channel of visual information that encompasses information from 4 lower limb joint angles (right and left hips, right and left knees).
3478181|NCT03813147|Experimental|Treatment (cytarabine, azacitidine, pevonedistat, fludarabine)|Patients receive cytarabine intrathecally on day 0 at least 24 hours prior to the start of each cycle. Patients then receive azacitidine IV over 15 minutes QD on days 1-5, pevonedistat IV over 60 minutes on days 1, 3, and 5, and fludarabine phosphate IV over 30 minutes QD and cytarabine IV over 1-3 hours QD on days 6-10. Patients with CNS2 or CNS3 receive cytarabine intrathecally or methotrexate intrathecally, hydrocortisone intrathecally, and cytarabine intrathecally on days 8 and 11-34. Cycles continue for 35 days in the absence of disease progression or unacceptable toxicity. Patients with stable or greater with non-hematologic toxicities probably or definitely related to pevonedistat may receive an additional cycle of treatment.
3478182|NCT03813251|Experimental|Assigned Interventions|ForConti Contix Fecal Incontinence Management System (FIMS)
3478183|NCT03813199|Experimental|ABX464 50mg + methotrexate|"Participants will receive one capsule of 50mg ABX464 plus one capsule of matching placebo once daily for 12 weeks~+ methotrexate"
3478184|NCT03813199|Experimental|ABX464 100mg + methotrexate|"Participants will receive two capsules of 50mg ABX464 once daily for 12 weeks~+ methotrexate"
3478185|NCT03813199|Placebo Comparator|Placebo + methotrexate|"Participants will receive two capsules of matching placebo once daily for 12 weeks~+ methotrexate"
3478186|NCT03813069|Other|Laboratory study|
3478187|NCT03813069|Other|Field study: IR3535|
3478188|NCT03813069|Other|Field study: Permethrin lower dose|
3478189|NCT03813069|Other|Field study: Permethrin higher dose|
3478190|NCT03813069|No Intervention|Field study: control arm|
3478191|NCT03813108|Experimental|1: 3: NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
3478192|NCT03813108|Experimental|2: 3: Low dose NF135 CPS-immunization challenged by NF135|10 volunteers will receive three immunizations with 5 NF135.C10 infected Anopheles mosquitoes under mefloquine profylaxis. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
3478193|NCT03813108|Experimental|3: NF135 CPS-immunization (A/L) challenged by NF135|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes.
3478194|NCT03813108|Experimental|4: 3: NF135 CPS-immunization (A/L) challenged by NF54|10 volunteers will receive three immunizations with 15 NF135.C10 infected Anopheles mosquitoes and are presumptively treated with artemeter/lumefantrine starting on day 7 after each immunization. Volunteers will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
3478195|NCT03813108|Other|5: Control group challenged by NF135.C10 Cohort A|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
3126863|NCT03055936|Experimental|C1|levodopa 50 mg, carbidopa 65 mg, ODM-104 50 mg
3478196|NCT03813108|Other|6: Control group challenged by NF54 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF54 infected Anopheles mosquitoes 19 weeks after the last immunization.
3478197|NCT03813108|Other|7: Control group challenged by NF135 Cohort B|Challenge infection control group: 3 volunteers will receive no immunization and will be challenged by the bites of 5 NF135.C10 infected Anopheles mosquitoes 19 weeks after the last immunization.
3126864|NCT03055936|Experimental|D1|levodopa 50 mg, carbidopa 65 mg, ODM-104 100 mg A4 ; B4 l; C4 ; D4 levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
3126865|NCT03055936|Experimental|A2|levodopa 100 mg, carbidopa 25 mg
3126866|NCT03055936|Experimental|B2|levodopa 100 mg, carbidopa 65 mg
3126867|NCT03055936|Experimental|C2|levodopa 100 mg, carbidopa 65 mg, ODM-104 50 mg
3126868|NCT03055936|Experimental|D2|levodopa 100 mg, carbidopa 37,5 mg
3126869|NCT03055936|Experimental|A3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
3126870|NCT03055936|Experimental|B3|levodopa 150 mg, carbidopa 65 mg
3126871|NCT03055936|Experimental|C3|levodopa 150 mg, carbidopa 65 mg, ODM-104 50 mg
3126872|NCT03055936|Experimental|D3|levodopa 150 mg, carbidopa 65 mg, ODM-104 100 mg
3126873|NCT03055936|Experimental|A4|levodopa IR 100 mg (Sinemet), carbidopa 25 mg
3126874|NCT03055936|Experimental|B4|levodopa 100 mg, carbidopa 65 mg
3126875|NCT03055936|Experimental|C4|levodopa 100 mg, carbidopa 25 mg, ODM-104 100 mg
3126876|NCT03055936|Experimental|D4|levodopa 100 mg, carbidopa 65 mg, ODM-104 100 mg
3126877|NCT03055988|Experimental|Tiotropium/Olodaterol Fixed Dose Combination|
3126878|NCT03055988|Active Comparator|Fluticasone Propionate + Salmeterol Fixed Dose Combination|
3126879|NCT03056040|Experimental|Ravulizumab|"On Day 1, participants received weight-based doses of ravulizumab ranging from 2400 to 3000 milligrams (mg). Thereafter, weight-based doses of ravulizumab ranging from 3000 to 3600 mg were administered on Days 15, 71, and 127.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
3179467|NCT00672906|Active Comparator|Active Comparator|Family Therapy according to the Maudsley Model
3179468|NCT00672919|Experimental|Pioglitazone QD|(and stable statin therapy)
3478198|NCT03813225|No Intervention|Conventional Analgesia|"These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation for handling an analgesic in cardiovascular surgery, this start in surgery with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.~and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus."
3478199|NCT03813225|Experimental|Serrato intercostal plane Block|These patients will receive the protocol multimodal analgesia patients receive on the Colombian Cardiovascular Foundation with Lidocaine 0.5mcg/k. Dexamethasone 8mcg, Fentanyl Bolus: 7mcg/k . infusion of Fentanyl 4 mcg/k/h start after induction , go down to 2 Mcg/k/h during extracorporeal circulation , after extracorporeal circulation the infusion will be suspended of Fentanyl.In this Arm the patient will give a bilateral serratus intercostal plane block, will be performed echo-guided puncture in the line anterior axillar with fifth costal arch, whit 21 ml of anesthetic mass, 20 ml of Levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone. and the postoperative analgesia will be 500mg of acetaminophen oral and Analgesia, patient controlled with Fentanyl 20mcg/bolus
3478200|NCT03813056|Experimental|Glanatec|Glanatec eye drops will be administered 6x per day for 2-4 weeks
3126880|NCT03056040|Active Comparator|Eculizumab|"Participants received 900 mg of eculizumab every 2 weeks (q2w) for 26 weeks.~After completion of the 26-week Primary Evaluation Period, participants had the opportunity to enter the Extension Period, wherein participants will receive weight-based doses of ravulizumab for up to 3 years."
3126881|NCT03056144|Experimental|Intervention group|The participants will undergo the whole body vibration therapy 1 session per day, 3 days per week for 4 weeks. The whole total whole body therapy session will last 18 minutes with 9 minutes of vibration.
3478201|NCT03813056|Placebo Comparator|Placebo Control|Optive artificial tears will be administered 6x per day for 2-4 weeks
3126882|NCT03056300|Experimental|Powered vascular stapler|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler
3126883|NCT03056352|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg administered intravenously over 15 minutes
3478202|NCT03813134|Active Comparator|Immediate PCI with medical therapy|"Group 1 will receive immediate revascularisation with Percutaneous Coronary Intervention (PCI) to the culpirit lesion only) + standard care (pharmacological support titrated to attain SBP >90mmHg).~No mechanical support device allowed."
3478203|NCT03813134|Experimental|Immediate PCI with early VA-ECMO|Group 2 will receive immediate PCI plus standard pharmacological support with early peripheral veno-arterial ECMO.
3478204|NCT03813160|Experimental|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily
3126884|NCT03056456|Experimental|LY900014|LY900014 (Treatment B) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
3126885|NCT03056456|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro (Treatment A) delivered via an insulin pump as a continuous infusion under the skin, with various intermittent bolus doses immediately before meals over 3-days per period.
3478205|NCT03813160|Experimental|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily
3126886|NCT03056573|Experimental|Subclavian/axillary|Subclavian/axillary access route
3478206|NCT03813160|Placebo Comparator|Placebo|Subjects will receive placebo twice daily
3478207|NCT03812965|Experimental|Group 1 - Botulinum Toxin type A (4 points of application)|4 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle and Levators labii superioris muscle (n=10 Patients)
3478208|NCT03812965|Experimental|Group 2 - - Botulinum Toxin type A (2 points of application)|2 points of Botulinum Toxin application in the muscles: Levators labii superioris alaeque nasi muscle (n=10 Patients)
3478209|NCT03813186|Experimental|ASTX727 + Day 2 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 2 of Cycle 1.
3478210|NCT03813186|Experimental|ASTX727 + Day 4 Food|Subjects will receive ASTX727 on Days 1-5 of Cycle 1 and a high-calorie, high-fat breakfast meal of 800-1000 calories pre-dose on Day 4 of Cycle 1.
3126887|NCT03056573|Experimental|Transaortic|Transaortic access route
3126888|NCT03056690|Experimental|ASP0819|Participants received ASP019 15 mg capsules, orally, once daily in the morning, with or without food for 8 weeks.
3179469|NCT00672945|Experimental|PRX-03140|
3478211|NCT03813173|Active Comparator|central cervical dissection|
3478212|NCT03813173|Experimental|non central cervical dissection|
3478213|NCT03812978|No Intervention|Control|Standard treatment
3478214|NCT03812978|Experimental|Intervention|Standard treatment and intervention (Smart phone application)
3478215|NCT03813030|Experimental|Pilot Study|Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 6 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.
3478216|NCT03813030|Experimental|Pivotal Study|"Dermal-sampling visit: Measurement of dermal pharmacokinetic (PK) parameter (AUC, Cmax) of lidocaine/ prilocaine using dermal open flow microperfusion (dOFM) and dermal microdialysis (dMD) after topical application of Lidocaine 2.5% and Prilocaine 2.5% cream in 20 participants. Additionally systemic appearance of lidocaine/prilocaine is measured by blood sampling.~Clearance Visit: Clearance of lidocaine will be evaluated after intravenous infusion of lidocaine."
3478217|NCT03813095|Experimental|APH-1501 400mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 400mg BID( twice daily) for 28 days.
3478218|NCT03813095|Experimental|APH-1501 600mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 600mg BID ( twice daily) for 28 days.
3478219|NCT03813095|Experimental|APH-1501 800mg|Nano-encapsulated for oral delivery. The study is planned for patients to receive APH 1501 800mg BID ( twice daily) for 28 days.
3478220|NCT03813095|Placebo Comparator|Placebo Comparator: Placebo|Nano-encapsulated for oral delivery. The study is planned for patients to receive a placebo dose BID ( twice daily) for 28 days.
3126889|NCT03056690|Placebo Comparator|Placebo|Participants received ASP019 matching placebo capsules, orally, once daily in the morning, with or without food for 8 weeks.
3126890|NCT03057132|Experimental|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
3478221|NCT03813082|Experimental|Sleep deprivation young men|Young study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
3478222|NCT03813082|Experimental|Sleep deprivation older men|Older study participants will complete four nights in the sleep laboratory, whereas they will stay awake during one night. PET brain imaging will be conducted at the same circadian time on three consecutive afternoons (prior, during and after prolonged wakefulness). Additionally, validated tests of vigilance and cognitive performance will be administered and the brain waves will be recorded in wakefulness and sleep.
3478223|NCT03812900|Experimental|Formulation A|Echinacea purpurea alcoholic extract lozenges (novel formulation)
3478224|NCT03812900|Experimental|Formulation B|Echinacea purpurea alcoholic extract spray (novel formulation)
3478225|NCT03812900|Active Comparator|Formulation C|Echinacea purpurea alcoholic extract tablet (basic formulation, reference)
3478226|NCT03812900|Active Comparator|Formulation D|Echinacea purpurea alcoholic extract, drops (basic formulation, reference)
3478227|NCT03812913||Turner Syndrome|"35 girls with Turner syndrome (except patients with part of a Y chromosome in their karyotype and r(X) cases).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
3478228|NCT03812913||isolated GHD|"35 girls with isolated Growth Hormone Deficiency (GHD).~age : 7 years -16 years and 11 months.~Psychological evaluation of cognition, social cognition and affective cognition"
3478229|NCT03812783|Experimental|HAIC of FOLFIRINOX plus sorafenib|
3478230|NCT03812783|Active Comparator|HAIC of FOLFOX plus sorafenib|
3478231|NCT03812796|Experimental|Domatinostat plus Avelumab|This is a multicentre open-label, phase II non-randomised clinical trial domatinostat plus avelumab (two separate cohorts in phase IIB part of trial).
3478232|NCT03812861|Experimental|CAMDS bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients with the help of a cognitive aid bundle
3478233|NCT03812861|No Intervention|No bundle|25 surgical teams will manage 10 standardised simulated deteriorating ward patients without the help of a cognitive aid bundle
3478234|NCT03812809|Experimental|BPI-7711|BPI-7711: 180mg, QD, oral
3478235|NCT03812874|Experimental|PTX-9908 Injection group|IV injection.
3478236|NCT03812874|Placebo Comparator|Placebo/Vehicle group|IV injection
3478237|NCT03812848|No Intervention|Pre program implementation|All hospitalized patients on therapeutic anticoagulant medication during the pre-implementation period of the anticoagulation stewardship program.
3478238|NCT03812848|Experimental|Post program implementation|All hospitalized patients on therapeutic anticoagulant medication during the post-implementation period of the anticoagulation stewardship program.
3478239|NCT03812822|Experimental|Insole Group|Gait and foot posture analysis with and without the insole.
3478240|NCT03812822|No Intervention|Control Group|Gait and foot posture analysis.
3478241|NCT03812757||Supraclavicular fossa US scanning|Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
3478242|NCT03812406|Experimental|FAUCS|Patients undergoing a cesarean section using the FAUCS technique
3478243|NCT03812406|Active Comparator|Control|Patients undergoing a cesarean section using the traditional (Misgav-Ladach) technique
3478244|NCT03812731|Active Comparator|Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2 mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive CEB with 0.2 % ropivacaine 1-ml/kg for maintaining analgesia"
3478245|NCT03812731|Active Comparator|Non- Caudal Group|"Children will receive oral midazolam 0.25 mg/kg thirty minutes before induction. Inhalational induction will be carried with incremental concentration of sevoflurane upto 8% in 50% oxygen and nitrous oxide mixture. As soon as the child will be asleep, ASA standard monitors (SPO2, HR, ECG and NIBP) will be attached. Intravenous access with age appropriate IV cannula will be secured. Injection fentanyl citrate 2-mcg/ kg followed by injection atracurium 0.5 mg/kg will be administered. Appropriate size LMA Pro SealTM will be inserted and pressure controlled ventilation will be instituted.~Children in will then receive fentanyl citrate 1-mcg/kg/hr for maintaining analgesia"
3478246|NCT03812640|Experimental|Vicryl|Vicryl suture
3478247|NCT03812640|Active Comparator|Nylon|Nylon suture
3478248|NCT03812497|Experimental|Obese Children Group|To reduce the weight, every obese children will receive individualized education program about a way of dietary control and exercise in their usual life. This individualized education program, developed by investigators, specialized dietitian and exercise teacher, is scheduled once a month.
3478249|NCT03812497|No Intervention|Normal Weight Children Group|Normal weight children
3179470|NCT00672945|Placebo Comparator|Placebo|
3179471|NCT00672971|Experimental|1|4% dimethicone foam
3179472|NCT00672971|Active Comparator|2|1% permethrin
3179473|NCT00672997|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3179474|NCT00672997|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3478250|NCT03812549|Experimental|Sintilimab Combined with SBRT and LDRT|"Part A-Dose escalation cohort. DOSE LEVEL: Stereotactic body radiation therapy (SBRT) dose at 30 Gy/3f + Low Dose Radiotherapy (LDRT) dose from 2 Gy to 10Gy + anti-PD-1 inhibitor 200mg.~Part-B - Expansion cohort. SBRT dose at 30 Gy/3f + LDRT + anti-PD-1 inhibitor 200mg, LDRT dose at MTD determined in Part A ."
3478251|NCT03812380|Experimental|EffCaMgCit|19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate; designed to be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. Each sachet of EffCaMgCit will contain 400 units of vitamin D.
3478252|NCT03812380|Placebo Comparator|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
3478253|NCT03812458|Experimental|Guidance|The intervention group will consist of the relatives who will receive a printed brochure and are encouraged to visit a website with detailed information and with simple language regarding the ICU environment (treatments, care, alarms, multidisciplinary team) and the characteristics of critically ill patients (organ dysfunction, prognosis, palliative care, organ dysfunction).
3478254|NCT03812458|No Intervention|Control|The families who will not receive the brochure and are not encouraged to visit the website.
3478255|NCT03812523|Active Comparator|Control|Duloxetine 60 mg qd
3478256|NCT03812523|Experimental|Intervention|Lorcaserin 10 mg bid
3478257|NCT03812562|Experimental|Treatment (yttrium Y 90 glass microspheres, nivolumab)|Patients receive standard of care yttrium Y 90 glass microspheres IV. Within 1-2 weeks of completing of yttrium-90 treatment, patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. If imaging shows adequate FLR and at least stable disease, patients will undergo resection within 2 weeks after the last dose of nivolumab. Patients who do not complete resection due to feasibility and have progressed or have evidence of high-risk explant may continue to receive nivolumab IV every 2 weeks for up to 1 year.
3478258|NCT03812393|Experimental|Treatment|TNBC patients with HER2 signal positive are treated with neratinib for 3 weeks followed by 12 weeks of neratinib in combination with weekly paclitaxel and carboplatin
3478259|NCT03812419|Active Comparator|group I|Esomeprazole 40 mg capsules once daily for 6 months
3478260|NCT03812419|Active Comparator|group II|Pantoprazole 40 mg tablets once daily for 6 months
3132686|NCT03445065|Active Comparator|Cohort 2, Control - Usual Glucose Monitoring System (SMBG or FGM)|Cohort 2 included patients with Type 1 diabetes mellitus for ≥1 year and using insulin by multiple-daily subcutaneous injections or insulin pump and spending >1.5 hours per day with a sensor mean glucose of <70 mg/dL for at least 28 days (time in hypoglycemia). All participants had the Eversense XL Glucose Sensor subcutaneously implanted into their arm of choice. Those randomized into the Control group were to continue using their usual glucose monitoring system (self-monitoring of blood glucose [SMBG] or flash glucose monitoring [FGM]), and the implanted Eversense XL CGM System remained in blinded mode.
3478261|NCT03812744|Experimental|WCCE|
3478262|NCT03812744|Placebo Comparator|Placebo|
3478263|NCT03812692||MATRx plus test|All participants will complete the MATRx plus test unattended in the home. Not all participants will be predicted responders to oral appliance therapy; both predicted responders and non-responders will undergo an outcome home sleep apnea test with a custom oral appliance in place to validate the prediction made by the test. Twenty participants will also complete an in-lab sleep study prior to the home study.
3478264|NCT03812705|Experimental|fecal microbiome transplantation|"Perform fecal microbiome transplantation to patient under colonoscopy or gastroscopy: injection of 200~300 ml fecal microbiome fluid as fecal microbiome transplantation to left colon by Colonoscopy or duodenum through duodenum tube by gastroscopy;~If patient's condition is stable or improved within 1 week, second fecal microbiome transplantation may be performed 1 week later, up to 4 times will be performed if patient response;~If patient's condition is not improved after the second fecal microbiome transplantation, stop fecal microbiome transplantation."
3478265|NCT03812536|No Intervention|SOC Voiding Protocol|Patients in the control group will follow the standard of care protocol and are required to void post anorectal surgery before being discharged home.
3478266|NCT03812536|Experimental|No Void Intervention|Patients in the experimental group (No Void Intervention) will be discharged home without voiding spontaneously.
3478267|NCT03812718|Active Comparator|ETT Group|"Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.~Intraoperative ventilation will be instituted through a polyvinyl chloride (PVC) ETT (Portex, Smiths Medical ASD, Inc, Minneapolis, USA). The size of the tube will be standardized for the male (7.5 mm ID) and the female (6.5 MM ID)."
3478268|NCT03812718|Active Comparator|PLMA Group|Anesthesia will be induced with fentanyl-citrate (3µg/kg) and propofol (dose determined by automated system based on continuous BIS feedback from the patients). Atracurium besylate 0.5-mg/kg will be given to facilitate placement of airway device. Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA. intraoperative ventilation will be maintained with PLMA (Telefex Medical, Westmeath Ireland) whose size would be selected based on body weight. In patients weighing 30-50 kg PLMA # 3.0, 50-70 kg PLMA # 4.0, and 50-100 kg PLMA # 5.0 will be inserted.
3478269|NCT03812627|Experimental|Re-intervention of hip prosthesis made of ceramic or metal|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis with friction couples of: ceramic-on-ceramic or metal-on-metal~(25 patients by group)"
3478270|NCT03812627|Experimental|Re-intervention of hip prosthesis of stainless steel ball|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 patients for re-intervention of hip prosthesis of stainless steel ball."
3478271|NCT03812627|Experimental|Re-intervention of knee prosthesis|"Re-intervention surgery: blood, urine, hair, synovial fluid and peri-prosthetic tissue collections.~50 inpatient subjects for re-intervention of knee prosthesis polyethylene-on-metal."
3478272|NCT03812627|Experimental|Dead patients IMD holders autopsied|Autopsy: 80 dead patients IMD holders will be autopsied.
3478273|NCT03812627|Active Comparator|Dead patients non-IMD holders autopsied|Autopsy: dead patients non-IMD holders autopsied, 30 subjects in this arm.
3478274|NCT03812627|Active Comparator|patients before first prosthesis surgery|Before the initial prosthesis surgery: 30 patients Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections will be done
3478275|NCT03812185|No Intervention|TEE image before suctioning orogastric tube|for intraoperative TEE used cardiac or transplant cases, TEE images will be stored before and after suctioning orogastric tube which is attached to TEE probe cover. This Arm is TEE image BEFORE suctioning.
3478276|NCT03812185|Experimental|TEE image after suctioning orogastric tube|This Arm is TEE image AFTER suctioning
3179475|NCT00673010|Experimental|1|131 I-iodine (131-I), 124 I-iodine (124-I)
3179476|NCT00673023|Experimental|1|
3478277|NCT03812445|No Intervention|No Intervention|the patients in this arm will not receive probiotics.
3478278|NCT03812445|Experimental|Experimental|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus for 3 months.
3478279|NCT03812432|Experimental|near-infrared cholecystocholangiography|Each subject enrolled in this study will undergo near-infrared cholangiography fluorescence. Once the fundus is grasped and retracted, a needle-tipped cholangiogram catheter is introduced through the skin, adjacent to gallbladder. The catheter, guided by a grasping or dissecting instrument, is used to puncture the infundibulum of the gallbladder. Nine milliliters of bile is aspirated from the gallbladder into a syringe and and a indocianine green solution is injected into the gallbladder. The catheter is removed and the puncture site pinched closed with a grasper. Dissection is then performed under either ambient light or near-infrared mode. The surgical view of the gallbladder dissection is toggled back and forth between the two viewing.
3478280|NCT03812653|Experimental|Intervention Arm: CPAP with Usual Care.|6 months of CPAP plus usual medical therapy.
3478281|NCT03812653|No Intervention|Control Arm: Usual Care.|6 months of usual medical therapy alone.
3478282|NCT03812770|Experimental|Sorafenib plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
3478283|NCT03812770|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
3478284|NCT03812588|Placebo Comparator|Clinical Frequency Management: Placebo|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
3478285|NCT03812588|Placebo Comparator|Research Frequency Management: Placebo|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
3126891|NCT03057366|Experimental|[14C]-Pevonedistat 25 mg/m^2|[14C]-pevonedistat (containing approximately 60-98 mCi [approximately 2.22-3.626 MBq] of radioactive tracer), infusion, intravenously, single dose on Day 1 of Week 1 in Part A. After completion of Part A, participants will have opportunity to continue into Part B. Participant will receive Pevonedistat 25 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles along with docetaxel 75 mg/m^2, infusion, intravenously, over 1 hour on Day 1 of each 21 day cycle; or pevonedistat 20 mg/m^2, infusion, intravenously, single dose on Days 1, 3 and 5 of each 21 day cycle, for up to 12 cycles, followed by paclitaxel 175 mg/m^2, infusion, intravenously, over 3 hours along with carboplatin 20 mg/m^2, infusion, intravenously, over 30 minutes on Day 1 of 21 each cycle up to 12 cycles. Based on investigator and sponsor discretion, participants deriving benefits will continue to receive current combination therapy or pevonedistat alone beyond 12 cycles.
3126892|NCT03057496|Experimental|Intervention|Participants will use the collision warning device as much as possible for about one month during everyday activities, when walking indoors and outdoors.
3126893|NCT03057613|Experimental|Pembrolizumab + post operative radiotherapy|IMRT 60-66Gy for 6 weeks in combination with Pembrolizumab every 3 weeks for 16 weeks
3126894|NCT03057704|Active Comparator|Intravenous lidocaine: flushed|Lidocaine injection flushed
3126895|NCT03057704|Experimental|Intravenous lidocaine: tourniquet|Lidocaine injection tourniquet
3126896|NCT03057977|Experimental|Empagliflozin|
3126897|NCT03057977|Placebo Comparator|Placebo|
3126898|NCT03058679|Experimental|Specific Carbohydrate Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
3126899|NCT03058679|Active Comparator|Mediterranean Style Diet|For the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
3126900|NCT03058692|Experimental|M-001 + IIV4|0.4 ml injection of M-001 (1 mg dose) intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
3179477|NCT00673023|Experimental|2|
3179478|NCT00673023|Experimental|3|
3179479|NCT00673036||1|Adults (female and male) with a acute coronary syndrome
3179480|NCT00673062|Experimental|SCH 900538|
3179481|NCT00673062|Active Comparator|Encapsulated pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
3478286|NCT03812588|Active Comparator|Clinical Frequency Management: Escitalopram|Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
3478287|NCT03812588|Active Comparator|Research Frequency Management: Escitalopram|Weekly study visits, treatment with double-blind, placebo controlled escitalopram 10 mg/day, raised to 20mg/day at week 4 if non-responders. If they respond, will be treated in a 3-month Continuation Phase with monthly site visits.
3478288|NCT03812484|Experimental|SCF Parole|Parolee supervised under the SCF Supervision model
3478289|NCT03812484|Active Comparator|Parole-As-Usual|Parolees are supervised under standard parole supervision practice in New Jersey.
3478290|NCT03812276||Study Group|Neodent Acqua GM Helix dental implants will be placed. Multiple implants may be placed in a single subject.
3478291|NCT03812250|Active Comparator|ERCP assisted trans-papillary drainage|ERCP assisted trans-papillary drainage for malignant biliary obstruction
3478292|NCT03812250|Active Comparator|EUS-guide biliary drainage|EUS-guide biliary drainage for malignant biliary obstruction
3478293|NCT03812354|Active Comparator|THRIVE 2L/kg/min using OptiFlow|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
3478294|NCT03812354|Experimental|THRIVE 4L/kg/min using OptiFlow|"After apnea sets in and mask ventilation is successfully established, randomization envelopes are opened and according to group allocation, the following oxygen delivery system is applied.~High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand."
3478295|NCT03812315|Experimental|Propolis chewing gum|2 % pure raw propolis, 20-35% gum base, 2.5% flavors, 0.3% sorbitol and 0.3% coloring substance. Children will be instructed to chew the specially prepared propolis chewing gum for at least 20 minutes, twice daily, after breakfast and before bedtime.
3478296|NCT03812315|Active Comparator|Propolis mouthwash|The formulation includes 2% pure raw propolis, 40 ml flavors, 150 ml propylene glycol, 60 gm sorbitol, 0.1 g coloring substance and water. Children will be instructed to rinse using the prepared propolis mouthwash for 1 min, twice a day, after breakfast and before bedtime.
3478297|NCT03812068|Experimental|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
3478298|NCT03812068|Active Comparator|Developmental behavioral intervention|only parent-mediated developmental behavioral intervention
3478299|NCT03812120|Placebo Comparator|Classical Treatment|In this arm, dural closure will be performed with the classical fibrine sealants.
3478300|NCT03812120|Active Comparator|L-PRF|In this arm, dural closure will be performed with the autologous L-PRF
3478301|NCT03812237|Experimental|(EWB) Early Weight Bearing (2 Weeks Post-op)|Subjects in the EWB group were allowed to begin bearing 50 pounds (lbs) through their hindfoot in either the boot or the short leg cast at the two-week visit. They were allowed to advance their weightbearing as tolerated by 25 lbs every four days until full weightbearing through the hindfoot was achieved.
3478302|NCT03812237|No Intervention|(SOC) Standard of Care Weight Bearing (6-8 Weeks Post-op)|Subjects in the SOC group were allowed to heel touch weightbear for balance only on the operative foot until the six to eight week visit. At this visit all subjects were placed into a short leg walking boot. Non-weightbearing patients were permitted to begin the progressive weightbearing protocol, without hindfoot restriction.
3478303|NCT03812042||Screen population|The study population will comprise of patients of healthcare institutions in the Washington, D.C. metro area including but not limited to hospitals, clinics, and doctor's offices.
3478304|NCT03812146|Experimental|PC-TIME|PC-TIME consists of meeting with a behavioral health provider for 5, 30-minute sessions that will be delivered over the course of 8 weeks (spaced about 1-2 weeks apart). PC-TIME sessions integrate two effective treatments: motivational enhancement therapy approaches and brief Prolonged Exposure.
3478305|NCT03812146|Active Comparator|PC-TAU|Primary Care - treatment as usual. Participants in PC-TAU will be referred to the PCMHI mental health provider within their primary care team, and will receive whichever care or intervention is typically provided. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team.
3478306|NCT03812055||LSD|Subjects diagnosed or suspected to have any of the following lysosomal storage diseases: Gaucher disease, Fabry disease, Pompe disease, Mucopolysaccharidoses.
3478307|NCT03812055||Control|Subjects with no known lysosomal storage disorder
3478308|NCT03812198|Active Comparator|Group 1-1|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 modified release tablet; LEO 32731 blend, hard capsule; LEO 32731 API hard capsule (reference formulation).
3478309|NCT03812198|Active Comparator|Group 1-2|Part 1: Subjects will receive 3 doses of LEO 32731 in different formulations, as follows (1 dose per formulation/treatment period): LEO 32731 soft capsule; LEO 32731 gastro-resistant capsule; LEO 32731 API hard capsule (reference formulation).
3478310|NCT03812198|Experimental|Group 2-1|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
3478311|NCT03812198|Experimental|Group 2-2|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
3478312|NCT03812198|Experimental|Group 2-3|"Part 2: Subjects will receive 3 doses of the same LEO 32731 formulation under different conditions, as follow (1 dose per condition/treatment period): fasted, after low-fat breakfast, after high-fat breakfast.~The formulation depends on the outcome of Part 1."
3478313|NCT03812198|Placebo Comparator|Group 3-1|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
3478314|NCT03812198|Placebo Comparator|Group 3-2|Subjects will be dosed twice daily from Days 1-17 (morning dose only on Day 17) with LEO 32731 or placebo. The formulation depends on the outcome of Part 2.
3478315|NCT03812289|Experimental|Treatment (SBRT)|Patients undergo SBRT on days 1, 3, 5, 7, and 9 in the absence of disease progression or unacceptable toxicity.
3478316|NCT03812003|Experimental|remifentanil|After emergence and extubation of endotracheal tube, remifentanil 1mcg/kg were diluted with 0.9% saline to 50 ml, added in IV bag, and drip for 30 minutes.
3478317|NCT03812003|No Intervention|no intervention|After emergence and extubation of endotracheal tube, 0.9% saline 50ml were added in IV bag and drip for 30 minutes.
3126901|NCT03058692|Placebo Comparator|Placebo+ IIV4|0.4 ml injection of placebo intramuscularly on Day 1 and Day 22, followed by 0.5 ml injection of IIV4 (60 mcg HA) intramuscularly on Day 172 (n=60)
3126902|NCT03058991|Experimental|Distress Tolerance Intervention|For the Distress Tolerance Intervention, the investigators will use a Mindfulness Based Stress Reduction (MBSR) program that has been adapted for use with adolescents. This version of MBSR follows closely the original conceptualization developed by Kabat-Zinn. The focus is on formal and informal mindfulness practices, which encourage participants to foster intention, attention and attitude. The investigators will make slight modifications to the delivery of the MBSR intervention to take into account the developmental period of their participants (e.g., attention span) to encourage retention and increase relevancy. These changes will also allow the investigators to match the duration with their Working Memory Intervention.
3126903|NCT03058991|Experimental|Working Memory Intervention|"For the working memory training, the investigators will use the Cogmed RM program. Participants will be asked to use the program, while supervised twice a week, each time for an hour, for 8 weeks. Participants will also be asked to use the program on the other days for 25-35 minutes. The program resembles a video game, and comprises several different games that require visuo-spatial working memory (remembering the position of objects) and a combination of verbal and visual working memory (remembering phonemes, letters, and digits). The program adapts to the user's performance, such that trainees are able to perform at the limit of their ability, stimulating WM capacity adaptation."
3478318|NCT03812211|Active Comparator|Active Supplement|Participants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
3478319|NCT03812211|Placebo Comparator|Placebo|Participants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
3126904|NCT03058991|Active Comparator|Control Informational Intervention|This Control Informational Intervention has been used in the investigators' and other's previous studies. In the current application, it will match the session time of the Distress Tolerance and Working Memory interventions and will omit a focus on smoking (which is specific to the SPII intervention provided across all interventions), and will consist of discussions of a variety of healthy lifestyle topics, such as healthy eating, stress/time management, and recommended health screenings.
3126905|NCT03059810|Experimental|Participating Subjects|Participating Subjects who are habitual soft contact lens wearers, aged 40 to 70 years of age, will be dispensed investigational contact lenses to be worn from 12-16 days, to include a total of 3 visits.
3126906|NCT03059901|Experimental|More App Notifications|Participants receive more notifications than the Active Comparator group from the Caminamos app to walk.
3126907|NCT03059901|Active Comparator|Normal App Notifications|Participants receive less notifications than the Experimental group from the Caminamos app to walk.
3126908|NCT03060447|Experimental|Vesatolimod|Participants in Period 1 will receive 10 doses of vesatolimod (4 mg to 8 mg) once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and vesatolimod and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
3132687|NCT03445156|Experimental|Pilot Study|After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game or a nonviolent shooting video game for 20 minutes. Video game play was recorded. A debriefing followed.
3132688|NCT03445156|Experimental|Experiment Proper|"After giving their consent, participants completed a survey. Next, they were randomly assigned to play either a violent First-Person-Shooter video game, a nonviolent shooting video game, or a nonviolent non-shooting video game for 20 minutes. Next, they shot a training pistol at a mannequin 20 feet (6.1 meters) away using 16 Velcro bullets. A debriefing followed."
3478320|NCT03812029|Experimental|EYP001a 100 mg BID|Oral dose twice daily for 12 weeks (84 days)
3478321|NCT03812029|Experimental|EYP001a 200 mg QD|Oral dose once daily for 12 weeks (84 days)
3478322|NCT03812029|Experimental|EYP001a 400 mg QD|Oral dose once daily for 12 weeks (84 days)
3478323|NCT03812029|Placebo Comparator|Placebo|Oral dose twice daily for 12 weeks (84 days)
3478324|NCT03812029|Experimental|EYP001a 100 mg QD|Oral dose once daily for 12 weeks (84 days)
3478325|NCT03811938|Active Comparator|Pulmonary Vein Isolation|Historical control from cases performed in year 2017 at Hammersmith Hospital. Intervention: Pulmonary vein isolation.
3478326|NCT03811938|Experimental|Low voltage ablation|Active arm, Intervention: Standard pulmonary vein isolation and Low Voltage Ablation.
3478327|NCT03812081|Active Comparator|Group A Baska Mask|In which Baska Mask Airway (size 3,4,5) will used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
3478328|NCT03812081|Active Comparator|Group B Proseal Mask|In which Laryngeal Mask Airway- Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
3132689|NCT03445195|Experimental|Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin|
3478329|NCT03811899|Experimental|18F-DCFPyL PET/CT imaging|We will use technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.
3132690|NCT03445195|Placebo Comparator|Placebo + Imipenem/Cilastatin|
3478330|NCT03812107|Experimental|Moderate Treatment Approach|Participants in this arm who relapse will be able to move more freely between follow up steps and are hypothesized to require fewer provider visits than those in the intensive treatment arm.
3478331|NCT03812107|Active Comparator|Intensive Treatment Approach|Participants in this arm who relapse will follow the current guidelines follow up steps of weekly, then every two weeks and finally monthly provider visits.
3179482|NCT00673062|Placebo Comparator|Placebo Capsules|
3179483|NCT00673140|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3478332|NCT03811860|Active Comparator|Once Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium once daily at bedtime. After 4-6 days, a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (twice daily dosing, if they have not already done so). Frequency of selected medication use is noted.
3478333|NCT03811860|Active Comparator|Twice Daily Dosing|In this arm of the study, participants receive the prescribed dose of lithium divided into two daily doses. After 4-6 days a steady state lithium serum level and serum creatinine are taken, and they crossover to the other arm (once daily dosing, if they have not already done so).Frequency of selected medication use is noted.
3478334|NCT03812016|Experimental|Determine device feasibility|"by evaluating efficacy and safety of the device prototype. Test the device one time ( duration: 30-120 mins/each time) and 3 times within 3 months.~Intervention: using the magnetic device prototype"
3478335|NCT03812172||Blacks/Hispanics with Heart Failure|Blacks/Hispanics with heart failure due to transthyretin cardiac amyloidosis will be identified by 99mTc-PYP scintigraphy. Those with transthyretin cardiac amyloidosis will be further subtyped into those with a genetic cause (ATTRm) and those with a non-genetic cause (ATTRwt - wild type transthyretin cardiac amyloidosis).
3478336|NCT03811964|Other|primary sleep-wake disorder|Subjects with primary sleep-wake disorder
3478337|NCT03811964|Other|neurological pathology|subjects presenting a neurological pathology with disorder of the controls of the wake and the sleep
3478338|NCT03811964|Other|psychiatric pathology|subject presenting a psychiatric pathology with disorder of the controls of the wake and the sleep
3478339|NCT03811964|Other|ophthalmological pathology|subject presenting an ophthalmological pathology with possible alteration of the photoreception and / or phototransduction
3478340|NCT03811964|Other|photosensitivity|subjects with photosensitivity with regulation disorder of sleep and wake
3478341|NCT03811964|Other|group control|healthy subject
3478342|NCT03811977|Experimental|Test group|Test group will receive investigational product - lutein syrup (2 mg/mL; daily dose 20 mg). Participants in this group will test continuous administration of investigational product for 12 weeks.
3478343|NCT03811977|Placebo Comparator|Placebo group|Placebo group will receive placebo product - placebo syrup (lutein 0 mg/mL; daily dose 0 mg). Continuous administration of placebo product for 12 weeks.
3478344|NCT03811795|Other|Arm 1-Repeat Cryoballoon Ablation|Subjects will be randomized to repeat cryoballoon ablation.
3478345|NCT03811795|Other|Arm 2-Radiofrequency Ablation|Participants will have radiofrequency ablation guided by high-fidelity mapping (Rhythmia) following an initial cryoballoon ablation.
3478346|NCT03811990|No Intervention|Control|
3478347|NCT03811990|Active Comparator|Intervention|
3478348|NCT03811730|Experimental|TEE group|Eligible patients would be conducted TEE examination by researcher A,The examination results are judged by A and provided to the physician of this patient,
3478349|NCT03811730|Active Comparator|TTE group|Eligible patients would be conducted TTE examination by researcher B,The examination results are judged by B and provided to the physician of this patient,
3132691|NCT03445390|Experimental|Acetaminophen First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive acetaminophen first.
3179484|NCT00673205|Placebo Comparator|A|
3179485|NCT00673205|Active Comparator|B|
3179486|NCT00673218|Placebo Comparator|1|Saline injection to match active
3179487|NCT00673218|Experimental|Treatment|Active treatment with Xolair 150 to 375 mg is administered SC every 2 or 4 weeks
3179488|NCT00673270|Experimental|1|Fludrocortisone and Hydrocortisone
3126909|NCT03060447|Experimental|Placebo|Participants in Period 1 will receive 10 doses of placebo matched to vesatolimod once every 14 days over a 20-week period along with their prescribed ART. Participants in Period 2 (ATI) will discontinue ART and placebo and will be monitored for rebound in HIV-1 plasma viremia for 24 weeks. Participants who restart ART during Period 2 due to virologic rebound will complete the ART Re-Initiation Visits, and then Post-ART Re-suppression Visits monthly for 6 additional months. Participants who complete 24 Weeks of ATI without restarting ART will move onto Period 3 and have 2 options. They can remain off ART for up to an additional 24 weeks. Those who restart ART at the start of Period 3 will complete ART Re-initiation Visits and then Post-ART Re-suppression Visits monthly for 6 additional months.
3478350|NCT03811717|Experimental|FAST+EX - FAST|FAST+EX then FAST alone
3478351|NCT03811717|Experimental|FAST - FAST+EX|FAST alone then FAST+EX
3478352|NCT03811847|Experimental|Methylphenidate|During this study, participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order.
3478353|NCT03811847|Placebo Comparator|Placebo|During this study the participants will get both the study drug Methylphenidate Extended Release Capsule and the placebo in random order. Placebo is being used in this study to compare to see if any improvements in cognition other areas are due to the study drug or due to other reasons.
3478354|NCT03811743|Experimental|Adolescents Participants|Adolescents will participate in the Dyad Plus program along with their caregivers. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
3478355|NCT03811743|Experimental|Caregivers of adolescents participants|Adult caregivers will participate in the Dyad Plus program along with their youth participants. The Dyad plus program consist of the combination of two existing programs (Brenner FIT for adolescents and By Design for the adult caregivers) with a new, novel coordination component
3478356|NCT03811808||MSA patients|patients diagnosed with possible or probable multiple system atrophy
3126910|NCT03060486|Experimental|HYBENX®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
3126911|NCT03060512|Active Comparator|Crossover Group 1|"Crossover Group Movantik to Polyethylene Glycol 3350~2-period, 2-treatment cross-over model: Subjects will be randomized to Movantik during Treatment period 1 (2 weeks), then crossed over to receive Polyethylene Glycol 3350 for Treatment period 2 (2 weeks) after 1 week washout."
3478357|NCT03811782|Experimental|Single-task Training Group|Single-task walking group
3478358|NCT03811782|Experimental|Dual-task Training Group|Dual-task walking group
3478359|NCT03811782|Experimental|Analogy Training Group|Analogy walking group
3478360|NCT03811925|Other|DCB|
3478361|NCT03811925|Other|Stenting|
3478362|NCT03811821|Active Comparator|Biofeedback (BIO)|Participants will receive biofeedback intervention during five (5) required weekly 1-hour sessions. A 6th treatment session will be made available for participants if it is shown through anorectal manometry that they are having trouble understanding directions given during the first five sessions.
3478363|NCT03811821|Active Comparator|Injection (INJ)|Bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
3478364|NCT03811912|Experimental|CTP-543 QD Dose Regimen|Oral tablet for 24 Weeks
3478365|NCT03811912|Experimental|CTP-543 BID Dose Regimen|Oral tablet for 24 Weeks
3478366|NCT03811639|Active Comparator|RF ablation|Patients treated with point-by-point radio-frequency ablation
3478367|NCT03811639|Experimental|Cryoballoon ablation|Patients treated with cryoballoon ablation
3478368|NCT03811613|Experimental|Photobiomodulation group|"17 Parkinson´s disease patients were randomly assigned to the photobiomodulation group (experimental group).~Intervention: Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength in six 1-minute blocks alternating the LEDs between the right and left temples, with a 30-second rest between blocks."
3126912|NCT03060512|Active Comparator|Crossover Group 2|"Crossover group Polyethylene Glycol 3350 to Movantik~2-period, 2-treatment cross-over model: Subjects will be randomized to Polyethylene Glycol 3350 during Treatment period 1 (2 weeks), then crossed over to receive Movantik for Treatment period 2 (2 weeks) after 1 week washout."
3126913|NCT03060551|Experimental|SVF injection|SVF was obtained from lipoaspirates, using an automated processing system, and subsequently injected into the subcutaneous tissue of each finger in contact with neurovascular pedicles
3478369|NCT03811613|Sham Comparator|Sham group|"18 Parkinson´s disease patients were randomly assigned to the sham group.~Intervention: Procedures for the sham group were identical as the photobiomodulation one, except that patients received photobiomodulation during only 5 seconds followed by 55 seconds with no treatment (equalling 1/12th of the energy used for the intervention group)."
3478370|NCT03811704|Experimental|Experimental group|Hepatectomy procedures were performed under Laparoscopic surgical navigation system and Indocyanine Green guidance.
3478371|NCT03811652|Experimental|NSCLC-Sq/HNSCC|Patients with advanced or metastatic NSCLC-Sq or HNSCC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen (platinum-based for HNSCC). PDL-1 positive patients should have received previous PD-1 or PD-L1 inhibitor where available.
3478372|NCT03811652|Experimental|Small Cell Lung Cancer|Patients with advanced SCLC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior standard of care regimen.
3126914|NCT03060759|Active Comparator|Light Therapy-Spectrum 1|Light from 'active' spectrum
3126915|NCT03060759|Placebo Comparator|Light Therapy-Spectrum 2|Light from 'placebo' spectrum
3126916|NCT03061097|Experimental|Treatment (autologous fecal microbiota preparation)|"Participants randomized into the treatment arm will receive a single dose of autologous fecal microbiota preparation (auto-FMP) via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months.~Route of Administration: Enema Dosing Regimen: 125mL x 1 dose"
3132692|NCT03445390|Experimental|Placebo First|Patients in this group are presenting for 2 surgeries and will be administered intravenous acetaminophen in one surgery and placebo in the other. Patients in this group will be randomized to receive placebo first.
3478373|NCT03811652|Experimental|Colorectal Cancer|Patients with metastatic adenocarcinoma of the colon or rectum who have received and have progressed, or have documented intolerance, on prior thymidylate synthase inhibitor (eg, 5-fluorouracil (5-FU), capecitabine, raltitrexed, tegafur-uracil (UFT), irinotecan, and oxaliplatin for metastatic disease. If patients progress within 6 months of their last dose of adjuvant therapy this should be considered as a line of therapy in the metastatic setting. Patients with known RAS wildtype tumors must have received and progressed, or have documented intolerance, on anti-EGFR antibody. Patients with microsatellite instability-high or deficient mismatch repair tumors, must have received and progressed, or have documented intolerance on a PD-1 inhibitor, or PD-1 inhibitor plus cytotoxic T-lymphocyte antigen-4 inhibitor treatment where available.
3478374|NCT03811652|Experimental|Pancreatic Ductal Adenocarcinoma|Patients with unresectable, locally advanced or metastatic PDAC who have recurrence after, or are refractory or intolerant to standard therapy, including at least one prior line of treatment.
3478375|NCT03811652|Experimental|Metastatic Castration-Resistant Prostate Cancer|Patients with mCRPC who have received prior treatment with abiraterone or enzalutamide, with or without a prior taxane-based chemotherapy in the mCRPC setting.
3478376|NCT03811652|Experimental|Other advanced/metastatic target expressing solid tumors|Patients with advanced or metastatic solid tumors not defined by other treatment arms who have positive expression of the protein target and have exhausted all approved therapies
3478377|NCT03811691|Other|1.5 Tesla MRI Scan|Subjects will undergo 1.5T MRI exam
3478378|NCT03811691|Other|3 Tesla MRI Scan|Subjects will undergo 3T MRI exam
3478379|NCT03811678|Experimental|50 mg single dose|It includes two groups, one group is a pilot study, 2 healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet . Another group is a formal study, healthy subjects receive a single dose of 50 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
3478380|NCT03811678|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg Kangdaprevir Sodium Tablet (N=20) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
3478381|NCT03811678|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
3478382|NCT03811678|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
3478383|NCT03811678|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
3478384|NCT03811678|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo (N=2).
3478385|NCT03811678|Experimental|100 mg multiple dose|Healthy subjects, receiving 100 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
3478386|NCT03811678|Experimental|200 mg multiple dose|Healthy subjects, receiving 200 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
3478387|NCT03811678|Experimental|400 mg multiple dose|Healthy subjects, receiving 400 mg Kangdaprevir Sodium Tablet (N=10) or matching placebo(N=2) once daily (q.d.) for 5 days.
3478388|NCT03811457|Experimental|Welgenaleucel (UWC19)|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage: 100mL in total Frequency:the first day, the second day, the third day Duration:total three times
3478389|NCT03811418|Experimental|Kanjinti/Pertuzumab plus Vinorelbine|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus vinorelbine.
3478390|NCT03811418|Active Comparator|Kanjinti/Pertuzumab plus Docetaxel|Patients will receive Kanjinti® (trastuzumab-biosimilar) plus pertuzumab plus docetaxel.
3478391|NCT03811496||GD-PD|Patients and carriers of Gaucher disease with confirmed mutations in GBA gene who have developed Parkinson's disease symptoms
3478392|NCT03811496||GD-nonPD|Patients with Gaucher disease but no known Parkinson's symptoms
3478393|NCT03811496||nonGD-nonPD|Non-Gaucher disease/healthy controls
3126917|NCT03061097|Placebo Comparator|Placebo|Participants randomized to the placebo arm will receive a single dose of placebo FMT via enema following an infectious episode requiring antibiotics, with follow-up at day 3, 7, 28, and 6 months. The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
3126918|NCT03061175|Experimental|Arm I (Web-Based Contralateral Prophylactic Mastectomy CPM-DA)|Patients receive a website address, a secure username and password, and instructions for using the web-based Contralateral Prophylactic Mastectomy (CPM)- Decision Aid (DA).
3478394|NCT03811431|Experimental|CEUS guidance|SonoVue 2, 4 ml
3478395|NCT03811431|Experimental|Conventional US guidance|No drugs
3478396|NCT03811301|Experimental|Interventional|Wireless Implantable Neurodevice Microsystem
3478397|NCT03811600||OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour
3126919|NCT03061175|Experimental|Arm II (Usual Care)|Patients undergo usual care available to patients considering CPM and receive information from a medical oncologist about CPM.
3126920|NCT03061188|Experimental|Treatment (veliparib, nivolumab)|Patients receive veliparib PO BID on day 1 and nivolumab IV over 30 minutes on days 1 and 15 of courses 1-4 and IV over 60 minutes on day 1 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3126921|NCT03061214|Experimental|Semaglutide 0.5 mg OW + sitagliptin placebo OD|
3478398|NCT03811600||Non OSAS patients|45 patients investigated for suspected OSAS with an apnea hypopnea index <15 per hour
3478399|NCT03811444|Experimental|simulation of skin pricking type 420|The evaluator simulated the capillary blood sampling with the safety lancet type 420
3478400|NCT03811444|Experimental|simulation of skin pricking type 430|The evaluator simulated the capillary blood sampling with the safety lancet type 430
3478401|NCT03811444|Experimental|simulation of skin pricking type 520|The evaluator simulated the capillary blood sampling with the safety lancet type 520
3478402|NCT03811535|Experimental|Somapacitan weekly|Participants will receive somapacitan weekly for 52 weeks (main trial period). Participants completing the main trial period in both the treatment arms ('Somapacitan weekly' and 'Norditropin® daily') will receive somapacitan weekly for 3 years (extension trial period).
3478403|NCT03811535|Active Comparator|Norditropin® daily|Participants will receive Norditropin® daily for 52 weeks (main trial period).
3478404|NCT03811314|Experimental|Strength training|Muscle strength training programs
3478405|NCT03811314|Experimental|Aerobic training|Aerobic training programs
3478406|NCT03811353||Children with cerebral palsy|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
3478407|NCT03811353||Healthy children|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale. Tongue control will also be evaluated by Tongue Thrust Rating Scale.
3126922|NCT03061214|Experimental|Semaglutide 1 mg OW + sitagliptin placebo OD|
3478408|NCT03811275|Experimental|Sequence #1|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention A followed by nine 30 minute sessions (over 3 weeks) of intervention B.
3478409|NCT03811275|Experimental|Sequence #2|Participants will receive nine 30 minute sessions (over 3 weeks) of intervention B followed by nine 30 minute sessions (over 3 weeks) of intervention B.
3478410|NCT03811548|Experimental|Janagliflozin 25mg|Each patient will receive 25 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
3478411|NCT03811548|Experimental|Janagliflozin 50mg|Each patient will receive 50 mg of Janagliflozin once daily for 52 weeks (24 weeks core period followed by 28 Weeks Extension period)
3478412|NCT03811548|Experimental|Placebo/Janagliflozin|In the core period, each patient will receive placebo once daily for 24 weeks and will then switch from placebo to 25 mg or 50 mg of Janagliflozin once daily until Week 52.
3478413|NCT03811626|Experimental|Intervention|Patient who underwent cognitive-behavioral rehabilitation
3478414|NCT03811626|No Intervention|Comparator|Patient with no specific management
3478415|NCT03811587|Experimental|Treatment group|Diabetes type 2 patients will take a fasting mimicking diet of 5 consecutive days a month, for a duration of 12 months. Besides this, they will receive usual diabetes care from the general practitioner.
3478416|NCT03811587|No Intervention|Control group|Diabetes type 2 Patients will have no intervention, they will receive usual diabetes care from the general practitioner.
3478417|NCT03811483||Female gender|
3478418|NCT03811483||Male gender|
3478419|NCT03811379|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
3478420|NCT03811522||Carbon Dioxide Insufflation|Received CO2 insufflation during procedure
3478421|NCT03811522||Air Sufflation|Received ambient insufflation during procedure
3478422|NCT03811509|Active Comparator|AI with osteoporosis|Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
3478423|NCT03811509|No Intervention|AI without osteoporosis|All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.
3478424|NCT03811327|Experimental|Treatment group|Zero-time Exercise group
3478425|NCT03811327|No Intervention|Waitlist group|
3478426|NCT03811288||Participants with type 2 diabetes mellitus (T2DM)|T2DM patients being managed in both primary and specialist care in 10 selected countries.
3478427|NCT03811392|Active Comparator|Hernioraphy/Caudal block|patients will receive a caudal block after induction of general anaesthesia.
3478428|NCT03811392|Active Comparator|Hernioraphy/Quadratus Lumborum block|patients will receive ultrasound guided quadrates lumborum block (QL )
3478429|NCT03811262|Active Comparator|ESP BLOCK|Intervention:30 ml of 0.25% Levobupivacaine where: ESP block as described by Forero at T5 level (single injection between transversour process and erector spinae muscles)
3478430|NCT03811262|Active Comparator|PECS block|Intervention:30 ml of 0.25% Levobupivacaine where:PECS II block as described by Blanco.
3478431|NCT03811405|Experimental|Patients with Essential Tremor|Patients with chronically implanted DBS devices for ET who experience progressive worsening of tremor symptoms over time. The DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation. The following random conditions will be applied: (1) Home Settings; (2) VIN Biphasic; (3) Stimulator Off. A 30-minute washout period will be applied between each of the random conditions. Therefore, each patient will serve as their own control.
3478432|NCT03811106|Active Comparator|NMES + PT|NMES will be applied to the back muscles with the chattanooga intelect advanced device. In addition, conventional physiotherapy and rehabilitation applications will be made.
3478433|NCT03811106|Other|PT|Conventional physiotherapy and rehabilitation practices will be carried out.
3478434|NCT03811236|Experimental|Cold exposure|
3478435|NCT03811236|No Intervention|Room temperature|
3478436|NCT03811119|Active Comparator|MANTA vascular closure device|Arteriotomy closure with a collagen-based vascular closure device (MANTA™)
3478437|NCT03811119|Active Comparator|Suture based vascular closure device|Arteriotomy closure with 2 or more suture-based vascular closure devices (ProGlide)
3478438|NCT03810885|Experimental|Salt reduced bread|Bread with reduced salt content
3478439|NCT03810885|Experimental|Dietary advice and Salt reduced bread|bread with reduced salt content, dietary advice
3478440|NCT03810885|Placebo Comparator|Normal bread|Bread with standard salt content
3478441|NCT03810963|Experimental|FES Cycling and Nutrition Counseling|"Device:~HIIT-FES cycling will be performed 30 minutes per session, 3 times per week for 3 weeks combined with~Behavior:~Nutrition counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
3478442|NCT03810963|Other|Nutritional Counseling Only|"Behavior:~Nutritional counseling will be completed via telephone for 30 minutes once per week for 8 weeks."
3478443|NCT03810898|Experimental|Phase 1 (a & b)|"Radioligand [¹¹C]CHDI-00485180-R and/or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 young (< 35) HCs/ Imaging- MRI and PET/~Both radioligands administered- 1x each/ Optional CSF collection for HDGECs"
3126923|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 0.5 mg OW|
3126924|NCT03061214|Active Comparator|Sitagliptin OD + semaglutide placebo 1 mg OW|
3179489|NCT00673270|Experimental|2|Fludrocortisone and placebo of Hydrocortisone
3478444|NCT03810898|Experimental|Phase 2a|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
3478445|NCT03810898|Experimental|Phase 2b|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x -HCs/"
3478446|NCT03810898|Experimental|Phase 2c|"Per Radioligand- Radioligand [¹¹C]CHDI-00485180-R or Radioligand [¹¹C]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/~1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs~1 Radioligand administered 1x- HCs/"
3478447|NCT03810872|Other|Open label|Afatinib 40 mg/day during Period 1 Afatinib 40 mg/day + Paclitaxel 80mg/kg/3w during Period 2
3478448|NCT03811028|Experimental|SOBI003|"SOBI003 solution, 20 mg/mL, is mixed with NaCl 0.9% infusion solution prior to administration. For a bodyweight < 25 kg, the total infusion volume is 100 mL. For a bodyweight ≥ 25 kg, the total infusion volume is 250 mL.~SOBI003 is administered as i.v. infusions given once weekly for a duration of 80 weeks (from Week 25 until Week 104 following the first 24 weeks of SOBI003 administration in the FIH study (SOBI003-001) study. The SOBI003 dose will be adjusted to the highest dose that has been declared safe by the safety review committee on the FIH study.Hence, dose adjustments may occur a couple of times on the extension study until the final decided dose has been determined."
3478449|NCT03811223|Experimental|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
3478450|NCT03811223|Placebo Comparator|Placebo|Placebo injection once every 2 weeks for 12 weeks
3478451|NCT03811054|Experimental|Apatinib combined with EGFR-TKI|Apatinib 250 millgram（mg/day（d））combined with EGFR-TKI
3478452|NCT03810937|Active Comparator|Group sniffing (S)|intervention: Head position changes : we will start by performing first videolaryngoscopy to find best view in flat position then the anesthesiologist will remove the Glidescope and the patient will be positioned in sniffing position using the pillow and another videolaryngoscopy will be attempted in sniffing position to find best view in this position and the patient will be intubated in this position.
3478453|NCT03810937|Active Comparator|Group Flat (F)|intervention: Head position changes same procedure will be done but starting from sniffing position and the patient will be intubated in flat position.
3478454|NCT03810950|Experimental|Social Stress Test|Participants undergo the Trier Social Stress Test before Barlab-Exposure
3478455|NCT03810950|Active Comparator|Control Condition|Participants reads newspaper before Barlab-Exposure
3478456|NCT03811184||MemScreen|Each participants will undergo MemScreen : a screening tool on smartphone for detecting mild cognitive impairment.
3478457|NCT03811158|Experimental|HHHFNC group|On HHHFNC FiO2 will setting as same as SBT before extubation Flow rate: 50L/min
3478458|NCT03811158|Sham Comparator|UHFOM group|On Aerosol mask FiO2 will setting as same as SBT before extubation Flow rate: 15L/min
3478459|NCT03811067|No Intervention|Control group|
3478460|NCT03811067|Active Comparator|TAP group|Transversus abdominis plane block administered group
3478461|NCT03811067|Active Comparator|RS group|Rectus sheath block administered group
3478462|NCT03811041|Experimental|PC articulated with MDA|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM).Finally, the patient will be oriented to the MDA of Brest and will meet again the GP at 6 and 12 month to answers the same tests.
3478463|NCT03811041|Active Comparator|Routine cares|Depressed parent encountered in PC for confirmation of depression with Hopkins Symptom Checklist-25 (HSCL25) scale. If confirmed, the adolescent will also be encountered by the GP for a screening test of depression (Adolescent Depression Rating Scale - ADRS). If negative, the patient will go out of the study. If positive, 2 others tests will be performed to study the intensity of the depression (Child depressionInventory - CDI) and the quality of life (Pediatric Quality of Life InventoryTM). Finally, the patient will be oriented to the routine cares and will meet again the GP at 6 and 12 month to answers the same tests.
3478464|NCT03811041|Experimental|Parental depression|Parental depression will be studied. Depressed adolescent encountered in MDA of Marseille for confirmation of depression with 3 tests : ADRS, CDI and PedsQL. If positive, the parent will come to the MDA for a screening test of depression (HSCL25). Parents and adolescent are seen only once.
3478465|NCT03810989|Experimental|infra-red sauna|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
3478466|NCT03810989|Experimental|argometer and treadmill|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
3478467|NCT03810989|Experimental|combination of sauna and hot bath|During the intervention phase, the patient will be dialysed twice weekly on Saturday and Wednesday. During the in-between three days, the patients will be subjected to an intervention as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
3478468|NCT03810989|Experimental|combination of sauna and hot bath in CKD|During the ﬁrst month (control phase), S Cr, BUN, serum K and serum phosphorus will be measured weekly and the mean will be calculated. During the next two months (intervention phase) the patient will be subjected to three session of sauna of 15 minutes duration separated by ten minutes rest outside the sauna then the patients will be immersed up to neck for one hour in water at 37 -43 C .
3478469|NCT03811197|Experimental|individual MNT|Dietary counseling via face to face meeting
3478470|NCT03811197|Experimental|Individual MNT and T|Dietary counseling via face to face meeting and Telemedicine
3478471|NCT03811197|Experimental|Individual MNT and HS|Dietary counseling via face to face meeting and Hypnotic Suggestions
3478472|NCT03810846|Experimental|Exercise|Walking football exercise program
3478473|NCT03810976|Experimental|eribulin+gemcitabine|The dose is 1.4 mg/m2 for 5 minutes intravenously. If necessary, the dose may be diluted in up to 100 mL of saline solution prior to intravenous administration. Gemcitabine doses 1000 mg/m2 intravenously for 30 minutes. After completion of the eribulin injection, intravenously inject gemcitabine. One cycle is 3 weeks, and the treatment is carried out on the 1st day and the 8th day for each cycle.
3478474|NCT03810924|Active Comparator|Control|Participants reads newspaper before Barlab-Exposure
3478475|NCT03810924|Experimental|Experimental 1 (Distress)|Participants undergo the Trier Social Stress Test before Barlab-Exposure
3478476|NCT03810924|Experimental|Experimental 2 (Eustress)|Participants ride an ergometer before Barlab-Exposure
3478477|NCT03811080|Experimental|DWP14012 A mg|DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks
3478478|NCT03811080|Experimental|DWP14012 B mg|DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks
3478479|NCT03811080|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
3478480|NCT03811249|Experimental|Implantation-Non-randomized|Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively for an additional 36 month period to measure long term safety and effectiveness outcomes.
3478481|NCT03810911|Active Comparator|Early start|Participants given study drug immediately at randomization
3478482|NCT03810911|No Intervention|Delayed start|Participants given study drugs 12 weeks after randomization
3478483|NCT03810833|Experimental|Participants with Brilliance sensor placement|Brilliance device sensors placed on the left and right pectoralis major, remaining for 48 hours
3478484|NCT03811145|Experimental|Tendoncel|Topically applied experimental gel - Tendoncel. 80ul applied once a day for 21 consecutive days.
3478485|NCT03811145|Placebo Comparator|Placebo control gel|Placebo control gel. Similar to Tendoncel but without platelet derived small molecules and growth factors. 80ul applied once a day for 21 consecutive days.
3478486|NCT03810820|Other|Outpatient TAVI|Consecutive patients scheduled for outpatient TAVI.
3478487|NCT03810794|Experimental|Acupuncture Treatment Group|Participants in this group will be given acupuncture treatment in combination with donepezil for 12 weeks.
3478488|NCT03810794|Active Comparator|Donepezil Group|Participants in this group will be given only donepezil for 12 weeks.
3478489|NCT03810560|No Intervention|open flap debridement|surgical treatment of periodontal pocket without any intervention
3478490|NCT03810560|Active Comparator|laser device with open flap debridement|surgical intervention associated with application of Erbium chromium: YSGG laser therapy
3478491|NCT03810664|Experimental|Somatrogon pre-filled PEN|
3478492|NCT03810664|Active Comparator|Somatrogon frozen liquid formulation|
3478493|NCT03810716|Experimental|Interactive Platform|Tha participants in this group will see the interactive platform and answer a survey before and after the intervention. Their clinical health records will be checked one month ago.
3478494|NCT03810716|No Intervention|Control|The participants in this group will answer the survey. Their clinical health records will be checked one month ago.
3126925|NCT03061331|Experimental|Treatment Sequence 1|LUM/IVA in Treatment Period 1; washout; placebo in Treatment Period 2
3126926|NCT03061331|Experimental|Treatment Sequence 2|Placebo in Treatment Period 1; washout; LUM/IVA in Treatment Period 2
3126927|NCT03061513|Active Comparator|Ubiquinol|600mg ubiquinol daily for 24 weeks
3126928|NCT03061513|Placebo Comparator|Placebo|Placebo daily for 24 weeks
3126929|NCT03061812|Experimental|Rovalpituzumab tesirine|"Rovalpituzumab tesirine IV administration (dosing based on actual body weight) on Day 1 of a 42-day cycle for 2 cycles, with up to 2 additional cycles permitted.~Dexamethasone coadministered orally (PO) twice daily at a dose of 8 mg on Day -1, Day 1, and Day 2 of each 42-day cycle in which rovalpituzumab tesirine is administered."
3126930|NCT03061812|Active Comparator|Topotecan|Topotecan given as an intravenous (IV) infusion over 30 minutes at a dose of 1.5 mg/m^2 on Days 1 to 5 of each 21-day cycle.
3126931|NCT03062228||Controls|"Healthy, Ghanaian women who have recently delivered a live birth at the Korle Bu Teaching Hospital.~No interventions will be administered."
3126932|NCT03062267|No Intervention|Treatment as Usual|Treatment as usual for 3 months.
3126933|NCT03062267|Experimental|Mobile Interventionist|Participants will exchange text messages with a mobile interventionist throughout the day for 3 months.
3126934|NCT03062488|Active Comparator|opioid only|2 mcg/Kg of fentanyl
3126935|NCT03062488|Active Comparator|opioid plus PO analgesic|2 mcg/Kg of fentanyl plus PO acetaminophen 15 mg/Kg
3126936|NCT03062488|Active Comparator|opioid plus IV acetaminophen|2 mcg/Kg of fentanyl plus 15mg/Kg of IV acetaminophen
3126937|NCT03062605|Active Comparator|Treatment(TX)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The first treatment group (TX) rinsed with NaOCL (0.3%) for one minute followed by rinsing with iodine (10%) for one minute
3126938|NCT03062605|Active Comparator|Control (CT)|. Participants were assigned randomly to one of two treatment groups and continued in parallel for the three-month duration of the study. The control group (CT) rinsed with iodine (10%) for minute. The CT group was a positive control. Both of these treatments were done only once at the baseline. The reminder of the three-month study was to obtain saliva samples at specific times to determining microbial levels.
3132693|NCT03446053|Experimental|N-Rephasin® SAL200|Forty subjects will be randomly assigned to receive either N-Rephasin® SAL200 injection or a placebo administered by a 60-min intravenous infusion. Within each group, 8 subjects (6 active and 2 placebo) will receive a single dose of 6 mg/kg, followed by multiple ascending dose of 3, 6, 9, and 12 mg/kg/day.
3132694|NCT03446053|Placebo Comparator|INT200-Placebo|Saline
3478495|NCT03810586|Experimental|Comparing blood pressure measurement|In each volunteer, non-invasive measurements of blood pressure will be taken at the same time using a holter manometry device (HUGECARE NIBP Monitor) and the Biobeat BB-613 device, and compared, to show the accuracy and the comparability of the BB-613. As mentioned in the protocol, there would be no medical interventions within the scope of this study. In case hypertension will be observed in a volunteer, the volunteer will be advised by the investigators to see his physician for further evaluation.
3478496|NCT03810651|Other|Renal tumors|Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
3179490|NCT00673270|Experimental|3|Placebo of Fludrocortisone and Hydrocortisone
3179491|NCT00673270|Placebo Comparator|4|Placebo of Fludrocortisone and placebo of Hydrocortisone
3478497|NCT03810534|Experimental|Connect-Home|Connect-Home intervention at the skilled nursing facility and at the subject's home.
3478498|NCT03810534|No Intervention|Control|Standard discharge planning at the skilled nursing facility only.
3478499|NCT03810573|Experimental|NB1-1.5|NB1 low dose
3478500|NCT03810573|Experimental|NB1-2.0|NB1 high dose
3478501|NCT03810573|No Intervention|Autograft|Autograft
3478502|NCT03810599|Other|Early cardiac rehabilitation|Single Group: 5 week cardiac rehabilitation programme. Pre-post comparison.
3478503|NCT03810781||Cervical Spondylotic Myelopathy (CSM)|Degenerative cervical myelopathy, encapsulates a cascade of events leading to significant degenerative changes in discs, formation of osteophytes, facet hypertrophy, calcification of the posterior longitudinal ligament and ligamentous flavum with resultant canal stenosis and segmental instability.
3478504|NCT03810625|Experimental|Sequence AB|D-0502 Dose Patients will get D-0502 single agent once in the fasted state and once in the fed state.
3478505|NCT03810625|Experimental|Sequence BA|D-0502 Dose Patients will get D-0502 single agent once in the fed state and once in the fasted state.
3478506|NCT03810677||Patients with varicose veins, eligible for EVLA|
3478507|NCT03810703|Placebo Comparator|placebo arm|Participant will receive placebo oral capsule during this four hour session.
3478508|NCT03810703|Experimental|amphetamine 10 mg arm|Participant will receive d-amphetamine 10 mg oral capsule during this four hour session.
3478509|NCT03810703|Experimental|amphetamine 20 mg arm|Participant will receive d-amphetamine 20 mg oral capsule during this four hour session.
3478510|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 1|mRNA-3704
3478511|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 2|mRNA-3704
3478512|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 3|mRNA-3704
3478513|NCT03810690|Experimental|Dose Escalation Phase: Dose Level 4 (optional)|mRNA-3704
3478514|NCT03810690|Experimental|Dose Expansion Phase: mRNA-3704|
3478515|NCT03810742|Experimental|Nanoliposomal Irinotecan + TAS-102|different dosage combination by Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
3478516|NCT03810755|Other|Control group|Personalized program (PVS), of proven effectiveness for the promotion of physical activity, diet and smoking cessation.
3478517|NCT03810755|Other|Supervision group|Personalized Supervised physical activity: personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
3478518|NCT03810547|Active Comparator|Spinal anesthesia|Patients undergoing abdominoplasty under spinal anesthesia may need to drug administration like propofol or ketamine or change anesthesia to general anesthesia.
3478519|NCT03810547|No Intervention|General anesthesia|General anesthesia for abdominoplasty
3478520|NCT03810495|Experimental|OLANI (naltrexone implant)|2 OLANI containing 60% naltrexone (1.8 g total) administered one time subcutaneously
3478521|NCT03810521|Experimental|CLT low-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 2x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
3478522|NCT03810521|Experimental|CLT medium-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 20x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
3478523|NCT03810521|Experimental|CLT high-dose|Umbilical cord derived-mesenchymal stromal cells at a dose of 80x10e6 cells / 3mL injected by an intra-articular infiltration of affected knee
3478524|NCT03810456|Active Comparator|iCBT|Patients in this arm will receive transdiagnostic CBT delivered in an intensive format over one weekend.
3478525|NCT03810456|Active Comparator|sCBT|Patients in this arm will receive transdiagnostic CBT delivered in a standard weekly format for 12 weeks.
3478526|NCT03810456|No Intervention|TAU|Patients in this arm will not receive transdiagnostic CBT but will receive treatment as usual.
3478527|NCT03810443|Experimental|pulmonary arterial hypertension|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
3478528|NCT03810300|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
3478529|NCT03810300|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
3478530|NCT03810300|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
3478531|NCT03810300|Experimental|Cash transfer + nutrition BCC|1500 taka ($18.75) per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
3478532|NCT03810300|Experimental|Food transfer + nutrition BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly. Nutrition behavior change communication (weekly, one-hour group-based meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings).
3478533|NCT03810300|Experimental|Control|No transfer, no behavior change communication
3478534|NCT03810430|Active Comparator|intervention group|ten clusters (villages) were received health promotion activities during six months of interventions
3478535|NCT03810430|No Intervention|control group|10 clusters (villages) were not received intervention during the intervention period and by the end of study, it will be compared with the intervention group to measure the change in the primary and secondary outcomes.
3478536|NCT03810170|Active Comparator|control|control group receives 2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
3478537|NCT03810170|Experimental|intervention|intervention group receives safe sex and HIV/STD prevention education via a website, and weekly emails on with positive psychology-based happiness and resilience boosting activities
3478538|NCT03810118|Experimental|Treatment|All the enrolled patients will receive the same mini-fluid challenge test of 100ml and then will complete the 4 ml/kg fluid challenge in either 10 or 20 minutes
3478539|NCT03810287|Experimental|Patients receiving Domperidone|Patients with upper GI symptoms who have failed or suffered adverse effects from standard medical therapy.
3478540|NCT03810131|No Intervention|Waitlist control|This is a group who are waiting for treatment (the control group)
3478541|NCT03810131|Experimental|BOA online intervention|The is the group who are receiving the BOA online intervention.
3478542|NCT03810157|Experimental|Laser-assisted hatching system|Embryos were exposed to a dose of laser energy focused outside the zona pellucida by aser-assisted hatching system.
3478543|NCT03810157|No Intervention|Control group|Nothing is done.
3478544|NCT03810339|Experimental|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
3478545|NCT03810326|Experimental|Intervention|
3478546|NCT03810105|Experimental|Castration Sensitive Biochemically Recurrent Prostate Cancer|Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer
3478547|NCT03810196|Other|TBI regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma will receive total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI).
3478548|NCT03810196|Other|TBI or busulfan regimen|Standard of care myeloablative regimens will be used based on disease type and clinical status at time of transplant. Patients not diagnosed with ALL or lymphoblastic lymphoma may receive either total body irradiation (TBI) regimen (thiotepa, cyclophosphamide, TBI) or busulfan containing regimen (thiotepa, cyclophosphamide, busulfan).
3179492|NCT00673283|Experimental|A|
3478549|NCT03810391|Experimental|preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group A were >11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
3126939|NCT03062891|Experimental|Online CBT for insomnia|"CBT participants will receive six weekly sessions delivered by an animated 'virtual therapist' (The Prof) via the online platform 'Sleepio'. The programme comprises a fully automated media-rich web application, driven dynamically by baseline, adherence, performance and progress data, and provides additional access to elements such as an online library with background information, a community of fellow users, and support, prompts and reminders sent by e-mail.~CBT content was consistent with the literature (4) and covered behavioral (e.g., sleep restriction, stimulus control) and cognitive (e.g., putting the day to rest, thought restructuring, imagery, articulatory suppression, paradoxical intention, mindfulness) strategies, as well as additional relaxation strategies (progressive muscle relaxation and autogenic training) and advice on lifestyle and bedroom factors (sleep hygiene). The intervention was based upon a previously validated manual (4)."
3478550|NCT03810391|Placebo Comparator|preoperative anxiety and saline|preoperative anxiety scores of patients in Group B were >11 and received an infusion of the same volume of physiological saline
3478551|NCT03810391|Experimental|non-preoperative anxiety and butorphanol|preoperative anxiety scores of patients in Group C were ≤ 11 and received an intravenous loading dose of 15ug/kg butorphanol 5 min before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
3126940|NCT03062891|No Intervention|Puzzles|Each week participants will be sent a puzzle to complete online (e.g. logic puzzles, crosswords etc). The puzzles have been designed to be cognitively engaging and take a similar amount of time to one session of Sleepio (20-25 minutes).
3478552|NCT03810391|Placebo Comparator|non-preoperative anxiety and saline|preoperative anxiety scores of patients in Group D were ≤11 and received an infusion of the same volume of physiological saline
3478553|NCT03810352||Patients with ITP|Patients with primary or secondary immune thrombocytopenia
3478554|NCT03810378|Experimental|Mediterranean Diet (Med-Plus)|Participants will follow a Mediterranean-type diet (Med-Plus) for 12 weeks. This diet will maximize the intake of vegetables, legumes, fruits and nuts, whole intact grains/cereals and fish; and minimize the intake of meat, poultry, and dairy. It will exclude added sugars and refined grains.
3478555|NCT03810378|Experimental|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.
3478556|NCT03810209|Active Comparator|magnesium sulphate group|The investigator injected 28.5 mL of bupivacaine 0.5% and 1.5 ml MgSo4 (150 mg), a total volume of 30 ml, it was confirmed visually by the ultrasound.
3478557|NCT03810209|Placebo Comparator|control group|The investigator injected 28.5 mL of Bupivacaine 0.5% and 1.5 mL of normal saline, a total volume of 30 ml, it was confirmed visually by the ultrasound.
3478558|NCT03810404|Experimental|Sodium bicarbonate supplementation|Group taking oral SB supplementation in a different-dose regimen.
3478559|NCT03810404|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (NaCl).
3126941|NCT03062917|Other|Emergency Department|Babies with suspected respiratory tract infection (RTI) in the ED
3478560|NCT03810365|Experimental|Behavioral: Brief behavioral treatment for insomnia|Brief behavioral treatment for insomnia includes 45 minute individual intervention with two follow up phone calls.
3478561|NCT03810365|Active Comparator|Behavioral: Healthy eating control|Healthy eating control involves a 45 minute individual session with two follow up phone calls.
3478562|NCT03810274||3DV+TPS|This experiment included a total of 300 patients with nasopharyngeal carcinoma, using 3DV + TPS software and imported TPS, domestic TPS, these three sets of TPS delineate bilateral crystal, bilateral optic nerve, bilateral eyeball, bilateral parotid gland, oral cavity, spinal cord There are 12 organs in the brainstem and brain, and the accuracy and speed of the 3 sets of TPS sketches are compared.
3478563|NCT03810066|Experimental|Osimertinib|
3478564|NCT03809845|Active Comparator|Motor neuron disease|
3478565|NCT03809845|Active Comparator|Benign fasciculation syndrome|
3478566|NCT03809949|Active Comparator|Fentanyl Opioid Anesthesia|Fentanyl (1mg/kg i.v.) will be administered before general anaesthesia (GA). GA will be maintained with inhalation anaesthetics (isoflurane) at a minimum alveolar concentration of 0.7-1.3.
3478567|NCT03809949|Placebo Comparator|Saline Nonopioid Anesthesia|Opioid free anesthesia (syringe of saline is given instead of fentanyl) and the same general anesthesia is given as group A(muscle relaxant ,propofol, inhalation for maintance).
3478568|NCT03809975|Active Comparator|Control Arm|"Current model of care~Patients will undergo the current standard of care in the Orthopaedic Outpatient Clinic in Tan Tock Seng Hospital. Patients will undergo routine consultation with an orthopaedic surgeon and will be provided with standard treatment as necessitated based on the assessment of the orthopaedic surgeon. Subsequent follow up appointments will be scheduled at the discretion of the orthopaedic surgeon. Patients will be referred to the physiotherapists, dietitian and psychologists as necessary for regular or adhoc sessions at the discretion of the allied health professional."
3478569|NCT03809975|Experimental|Intervention Arm|"Multidisciplinary Community Program~Community based, personalized, structured, 12-week multidisciplinary program that includes Orthopaedics, Physiotherapy, Dietitics, Psychology interventions. This intervention involves the use of formal assessment such as BMI and psychological questionnaires to determine the need for dietetics or psychological intervention. In addition, there are educational sessions to improve patient's understanding of osteoarthritis and improve their activation level. An optional support group session will be arranged at approx. 3-4 months after completion of the 12-week intervention program to improve sustainability of treatment effect."
3478570|NCT03809767|Experimental|CS1003 monoclonal antibody|
3478571|NCT03809780|Experimental|Lenalidomide,dexamethasone|"high dose: lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly~low dose: lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly Schedule"
3478572|NCT03810001|No Intervention|standard ICSI procedure|a single spermatozoon was injected into the ooplasm
3478573|NCT03810001|Experimental|modified ICSI procedure|slight mechanical stimulation before standard ICSI procedure
3478574|NCT03810027||OAB with nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Precence of nocturnal polyuria will be classified in this group.
3478575|NCT03810027||OAB without nocturnal polyuria|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. Nocturnal polyuria was defined when the proportion of nighttime voided volume over 24-hour voided volume was greater than 33% for ≥65 year-old women, and when the proportion of nighttime voided volume over 24-hour voided volume was greater than 20% for <65 year-old women. Absence of nocturnal polyuria will be classified in this group.
3478576|NCT03810040|Active Comparator|Odd-numbered days|Once odd-numbered days the zytoges of IVF cycle were collected. The 140 microns denuding pipette was used.
3478577|NCT03810040|Experimental|Even-numbered days|Once even-numbered days the zytoges of IVF cycle were collected. The 150 microns denuding pipette was used.
3478578|NCT03809793|Active Comparator|Acipimox ingestion|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor), muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest 250 mg of Acipimox 1 hour before each exercise session of the 12 week intervention.
3478579|NCT03809793|Placebo Comparator|No drug|Individuals in this group will undergo pre-assessments for body composition (DXA), Insulin sensitivity (Hyperinsulinaemic Euglycaemic clamp and continuous glucose monitor) with muscle biopsies pre- and post- clamp for analysis of lipid metabolites, liver fat (MRI) and exercise capacity (VO2 max). Participants will then ingest nothing prior to their exercise sessions during the 12-week exercise programme.
3478580|NCT03809754|Experimental|OCT-guided PCI|
3478581|NCT03809754|Sham Comparator|Angiography-guided PCI|
3478582|NCT03809702|Active Comparator|Pregabalin group|Group 1: Pregabalin tablet 75 mg orally twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment Here, the intervention is administration of Pregabalin tablet 75 mg
3478583|NCT03809702|Placebo Comparator|Placebo group|Group 2: Placebo tablet twice daily for 4 weeks will be given to the subjects in this group along with other routine treatment
3478584|NCT03809871|Experimental|Biomarker group|These participants will receive information about cardiometabolic biomarkers pre and post weight management course
3478585|NCT03809871|No Intervention|Control group|They will receive the same weight management programme as the experimental group, but they will not have biomarker information.
3478586|NCT03809858|Experimental|Klue App Use then Usual Care|Subjects will use the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will discontinue Klue App use and will continue the final 6 weeks without the product.
3478587|NCT03809858|Experimental|Usual Care then Klue App Use|Subjects will begin the study without using the Klue App during the first 6 weeks of the trial. At 6 weeks, subjects will begin the use of the Klue App and will continue the final 6 weeks with the product.
3478588|NCT03809936|Active Comparator|real tDCS|real tDCS:anodal transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
3478589|NCT03809936|Sham Comparator|sham tDCS|sham tDCS:sham transcranial direct current stimulation were delivered over the left DLPF cortex for 20 minutes in patients.
3478590|NCT03810261|Experimental|Oil-based vitamin D group|Oil-based vitamin D, 1000 IU/day for 8 weeks
3478591|NCT03810261|Experimental|Water-based vitamin D group|Water-based vitamin D, 1000 IU/day for 8 weeks
3478592|NCT03810261|Experimental|Vitamin D capsules group|Vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks
3478593|NCT03810261|No Intervention|Control group|This group will receive no intervention.
3478594|NCT03809819||Patients with MRKHS|Thirteen patients with MRKHS who underwent laparoscopic Vecchietti vaginoplasty
3478595|NCT03809819||Control group|A control group of 13 age-matched, childless, sexually active women
3478596|NCT03809741|Experimental|Preventing L&D Infections|Low-cost bundled L&D infection prevention interventions will be implemented, including education, visual reminders, feedback, and alcoholic hand rub supply. Infection control practices and child delivery outcomes will be assessed after implementation of these interventions.
3478597|NCT03809897|Experimental|Varenicline|Patients randomized to the experimental arm will receive 3 days of 0.5 mg of varenicline, followed by 4 days of 1 mg of varenicline (until day 7). Finally, until week 12, they will receive 2 mg of varenicline. Varenicline is supplied in capsules and taken orally.
3478598|NCT03809897|Active Comparator|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21 mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
3126942|NCT03062917|Other|Paediatric Wards|Babies with diagnosed RSV infection admitted to paediatric wards
3126943|NCT03062917|Other|Paediatric Intensive Care|Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation
3478599|NCT03809923|Experimental|Dexmedetomidine Combined With Lidocaine Infusion Affect PONV|
3478600|NCT03809923|Experimental|Effect of infusion saline on PONV|
3478601|NCT03809923|Experimental|Effect of infusion lidocaine on PONV|
3478602|NCT03809923|Experimental|Effect of infusion dexmedetomidine on PONV|
3478603|NCT03809988|Experimental|Interventional Arm (Arm A)|Patients will receive palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks in combination with endocrine therapy (letrozole or fulvestrant).
3478604|NCT03809988|Active Comparator|Control Arm (Arm B)|Patients will receive endocrine therapy (letrozole or fulvestrant).
3478605|NCT03809806|Other|patients after hysterectomy|modified anterior transvaginal mesh surgery
3478606|NCT03809637|Experimental|pemetrexed+cisplatin|Patients with metastatic sarcoma who underwent one chemotherapy regimens are treated with the combination of pemetrexed and cisplatin, and the treatment is repeated until the disease progression. pemetrexed 500 mg / m2 (day 1) and cisplatin 75 mg / m2 (day 1) are intravenously injected. 21 days is one cycle, and it is carried out by co-administration up to 6 cycles. After 7 cycles, intravenous injection of pemetrexed alone at intervals of 3 weeks until disease progression.
3478607|NCT03809728|Other|IBD patients|All patients with an established Crohn's disease or ulcerative colitis
3478608|NCT03809689|Other|acute infarction|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
3478609|NCT03809689|Other|acute infarction requiring reperfusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT at 1, 4 and 12 weeks after cardiac event
3478610|NCT03809689|Other|chronic ischemic occlusion|patients will have a 82-Rb and a 68Ga-NODAGA-RGD PET/CT before and 2 months after reperfusion treatment
3478611|NCT03809650|Experimental|Open-label treatment period|oral administration of macitentan 10 mg once daily
3478612|NCT03809676||heaart transplant recipients|
3478613|NCT03809676||healthy controls|
3478614|NCT03809663|Experimental|Tezepelumab high dose|subcutaneous injection every 2 weeks
3478615|NCT03809663|Experimental|Tezepelumab low dose|subcutaneous injection every 4 weeks
3478616|NCT03809663|Experimental|Tezepelumab medium dose|subcutaneous injection every 2 weeks
3478617|NCT03809663|Placebo Comparator|Placebo|subcutaneous injection every 2 weeks or every 4 weeks
3478618|NCT03809832||Patients with COPD|Patients established on home non-invasive ventilation for COPD admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
3478619|NCT03809832||Patients with OHS|Patients established on home non-invasive ventilation for obesity hypoventilation syndrome admitted for respiratory review will have a microbiological sampling of the ventilator humidifier
3478620|NCT03809546|Placebo Comparator|Placebo|
3478621|NCT03809546|Active Comparator|7.5 mg THC|
3478622|NCT03809546|Active Comparator|15 mg THC|
3478623|NCT03809559||Biliary Conditions|Participants who have a history of a biliary tree related condition
3478624|NCT03809559||Liver conditions|Participants who have a history of a non-biliary tree related liver condition
3478625|NCT03809559||Healthy Volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
3478626|NCT03809598|Experimental|Mindfulness Based Cognitive Therapy|MBCT adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support. The intervention is focused on skill development through active engagement in mindfulness practices and exercises to increase awareness of thoughts, feelings and behavior in session, and assignment and review of daily home practices.
3478627|NCT03809598|No Intervention|Treatment as Usual|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
3478628|NCT03809286|Experimental|Active Stimulation|Participants will be receiving active rTMS.
3478629|NCT03809286|Sham Comparator|Sham Stimulation|Participants will be receiving sham stimulation with a smaller coil housed within the rTMS device.
3478630|NCT03809299|Other|Ad libitum meal timing first|This arm will receive the ad libitum meal timing intervention first, followed by the twice a day feeding intervention.
3126944|NCT03062917|Other|Health Controls|Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures
3126945|NCT03062917|Other|Controls in Paediatric Intensive Care|Babies without RSV infection but requiring mechanical ventilation in PICU
3126946|NCT03063086|Active Comparator|Sequence 1|A-B-C
3126947|NCT03063086|Active Comparator|Sequence 2|A-C-B
3126948|NCT03063086|Active Comparator|Sequence 3|B-C-A
3126949|NCT03063086|Active Comparator|Sequence 4|B-A-C
3126950|NCT03063086|Active Comparator|Sequence 5|C-A-B
3126951|NCT03063086|Active Comparator|Sequence 6|C-B-A
3126952|NCT03063125||Bladder Cancer Patients|Patients with bladder cancer scheduled to undergo radical cystectomy (RC).
3126953|NCT03063255|Active Comparator|Obturator block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with obturator block.
3126954|NCT03063255|Active Comparator|Neuromuscular block|Comparing the incidence of adductor spasm in patients undergoing general anesthesia with neuromuscular blocking agents.
3126955|NCT03063294|Active Comparator|Toolkit only|Clinics in this arm are given access to an online care coordination toolkit.
3126956|NCT03063294|Experimental|Toolkit plus coaching|Clinics in this arm are given access to an online care coordination toolkit plus quality improvement support from a distance-based coach.
3126957|NCT03063385|Experimental|Parental communication intervention|The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
3126958|NCT03063385|Active Comparator|Health promotion control condition.|The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.
3126959|NCT03063437|Experimental|Active: Encapsulated Fecal Microbiota Preparation|Single dose of oral, encapsulated fecal microbiota preparation (30 capsules per dose) with follow-up at 3 days, 10 days, 28 days, and 6 months.
3478631|NCT03809299|Other|Twice a day meals first|This arm will receive the twice a day feeding intervention first, followed by the ad libitum meal timing intervention.
3478632|NCT03809403||"No touch group:"|Patients with left sided colic adenocarcinoma who underwent left colectomy with an early ligation of mesenteric vessels
3478633|NCT03809403||"Mobilisation first group"|patients with right colic adenocarcinoma who underwent right colectomy with early mobilisation of the tumor followed by the ligation of the vessels.
3478634|NCT03809377||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
3478635|NCT03809494|Experimental|Treatment Arm|Patients assigned to the treatment arm will be injected with autologous concentrated total nucleated cells (TNCs) three times at six week intervals.
3478636|NCT03809494|Placebo Comparator|Saline (Control Arm)|Patients assigned to the control arm will be injected with saline three times at six week intervals.
3478637|NCT03809364|Experimental|START Together|Couples randomized to START Together will receive the manualized treatment to enhance women's medication adherence. The treatment is 5 sessions in length and conducted weekly. Sessions are 60 - 75 minutes. Couples have the option of completing up to 3 additional booster sessions. Total treatment therefore ranges between 5 to 8 sessions.
3478638|NCT03809364|No Intervention|Standard of Care (SOC)|Couples randomized to SOC will receive referrals to local HIV clinics to support medication adherence (for women) or other HIV-related issues (for men).
3478639|NCT03809312|Active Comparator|Clavulin group with polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
3478640|NCT03809312|Placebo Comparator|Placebo group with polyps|Group who will receive placebo after the endoscopic sinus surgery in prophylactic and who have polyps in the surgery
3478641|NCT03809312|Active Comparator|Clavulin group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
3126960|NCT03063437|Placebo Comparator|Placebo: Encapsulated Placebo|Single dose of oral, placebo capsule (30 capsules per dose) with follow-up at 3 days, 10 days, and 28 days, and 6 months.
3478642|NCT03809312|Placebo Comparator|Placebo group without polyps|Group who will receive clavulin after the endoscopic sinus surgery in prophylactic and who haven't polyps in the surgery
3478643|NCT03809507||NC Clinicians|Qualtrics Survey of NC Clinicians with DEA registration
3478644|NCT03809481|Experimental|Danaparoid Sodium|Subjects will receive danaparoid via IV infusion for at least 7 days then transition to a VKA. IV loading bolus injection of 2250 U, followed by 400 U/h for 4 hours, then 300 U/h for 4 hours, then a maintenance infusion of 150-200 U/h.
3478645|NCT03809481|Active Comparator|Argatroban|Subjects will receive argatroban 2 microgram/kg/min as a continuous infusion, titrated to an aPTT that is 1.5 to 3.0 x initial baseline value, but not exceeding 100 seconds.
3478646|NCT03809468|No Intervention|control|Routine follow up of a clinic visit at 1-2 weeks postop, and 6-8 weeks postop.
3478647|NCT03809468|Experimental|study|phone call follow up instead of clinic visit follow up at 1-2 weeks, followed by 6-8 week clinic follow up
3478648|NCT03809520|Experimental|Experimental: pedCAT|Subjects in this group will undergo weight-bearing CT (pedCAT) imaging at 6 months, 12 months, and 18 months post-ankle injury.
3478649|NCT03809585||Iris Tumors|This group will consist of 50 adults age 18 or older who have been diagnosed with either melanotic or amelanotic iris tumors. Iris tumor diagnosis will be confirmed by biopsy when possible or based upon clinical features (if patient declines biopsy or if not medically indicated) according to standard-of-care guidelines.
3478650|NCT03809585||Healthy Controls|This group will consist of 50 adults age 18 and older who have healthy eyes.
3478651|NCT03809442|Experimental|Ropivacaine with Ketamine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that possesses both central and peripheral analgesic effects. Preincisional infiltration of ketamine prolongs the time to first analgesic requirement and also decreases the total amount of analgesics used postoperatively.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group)."
3478652|NCT03809442|Experimental|Ropivacaine with Tramadol|"Tramadol hydrochloride is a synthetic analog of codeine that acts on both opioid (weak mu receptor agonist) and nonopioid receptors (inhibits reuptake of nor-adrenaline and serotonin as well as release stored serotonin from nerve endings) which play a crucial role in pain inhibition pathway.~It also blocks nerve conduction which imparts its local anesthetics like action on peripheral nerves.~In one study it was found that the addition of tramadol or midazolam to caudal epidural ropivacaine prolongs the duration of analgesia without causing significant side effects.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group)."
3478653|NCT03809442|Experimental|Ropivacaine with Midazolam|"The analgesic effect of extradurally administered midazolam is through γ-amino butyric acid (GABA)/benzodiazepine system of spinal cord.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group)."
3478654|NCT03809442|Experimental|Ropivacaine with Dexamethasone|"The glucocorticoid dexamethasone appears to be effective in a small number of preclinical and clinical studies and found that dexamethasone prolongs analgesia from interscalene blocks using ropivacaine or bupivacaine, with the effect being stronger with ropivacaine.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group)."
3478655|NCT03809442|Experimental|Ropivacaine with Dexmedetomidine|"Dexmedetomidine is a new highly selective alpha2 (a2) agonist with known sedative, antihypertensive, anxiolytic, and analgesic properties.~In one study, it was found that wound infiltration with combined ropivacaine and dexmedetomidine found to be significantly superior for postoperative analgesia compared with either combined ropivacaine and tramadol or ropivacaine alone for lumbar discectomies.~Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kgdexmedetomidine (8mL per incision) (Dexmedetomidine group)."
3478656|NCT03809442|Placebo Comparator|Ropivacaine|"Ropivacaine is a propyl analog of bupivacaine with longer duration of action with much safer cardiotoxicity profile than bupivacaine. Ropivacaine has the same analgesic effects as bupivacaine and levobupivacaine, but it is associated with a low incidence of motor block. Thus, ropivacaine appears to be an important component for local anesthesia and postoperative analgesia.~Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg."
3478657|NCT03809455|Experimental|FAR Arm|
3478658|NCT03809455|Placebo Comparator|Placebo Arm|
3478659|NCT03809325||Participants with Schizophrenia|No intervention will be administered as a part of this study. Participants diagnosed with schizophrenia, who have been treated with 4 to 6 injections of paliperidone palmitate 3-month formulation (PP3M), together with the corresponding physician, and the corresponding nurse and carer where applicable for each participant will be enrolled in this survey. The data source for this study will be the online questionnaire used for each participant, physician, and the corresponding nurse and carer where applicable.
3478660|NCT03809351|Experimental|[F-18]AV-1451-PET/MRI|All participants in this study will undergo a tau-PET imaging using the tracer [F-18]AV-1451 with a simultaneous PET/MRI system. The [F-18]AV-1451 dosage is 740MBq (10 mCi) given intravenously, and the PET/MRI imaging will occur 75-105 min after tracer injection.
3478661|NCT03809260|Experimental|Part 1|Metformin/Vancomycin
3478662|NCT03809260|Experimental|Part 2|Metformin
3478663|NCT03809416|No Intervention|Control|32 biopsy specimens from acne scars will be excised without any treatment.
3478664|NCT03809416|Sham Comparator|Lasers plus Normal Saline Solution|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of normal saline solution.
3478665|NCT03809416|Active Comparator|Lasers plus Platelets Rich Plasma (PRP)|32 biopsy specimens will be excised immediately after being treated with lasers and subsequent injection of platelets Rich Plasma (PRP).
3179493|NCT00673296|Other|A|Patients receive intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
3179494|NCT00673322|Experimental|Gene Modified T Cells|Modified T cells
3478666|NCT03809338||flight attendant women|Assesment antral follicle count on day 3 5ml blood sample to be taken
3478667|NCT03809338||day working women|Assesment antral follicle count on day 3 5ml blood sample to be taken
3478668|NCT03809273|Experimental|Yangxinshi|
3478669|NCT03809273|Active Comparator|Trimetazidine|
3478670|NCT03809026||Study group|Couples where the men have Klinefelter's syndrome, maturation stop in the spermatogenesis or failed retrieval of testicular sperm by conventional techniques with needle or TruCut, and where testicular sperm could be obtained by micro-TESE.
3478671|NCT03809026||Control group|Couples as in the study group, but where testicular sperm could not be obtained by micro-TESE. The oocytes therefore must be fertilized using donor sperm.
3478672|NCT03808987|Experimental|CHW+CPP brief prenatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
3478673|NCT03808987|Experimental|CHW+CPP brief postnatal onset|Participants will receive Child-Parent Psychotherapy (CPP) for 6 months, beginning postnatally, in addition to services from a Community Health Worker (CHW)
3478674|NCT03808987|Experimental|CHW+CPP 12 months|Participants will receive Child-Parent Psychotherapy (CPP) for 12 months, beginning prenatally, in addition to services from a Community Health Worker (CHW)
3478675|NCT03808987|Experimental|CHW only|Participants will receive services from a Community Health Worker (CHW) without Child-Parent Psychotherapy (CPP)
3478676|NCT03808935|Experimental|Medical cannabis|Capsules containing cannabis extract, dissolved in high-oleic sunflower oil, and CBD/THC in a 16:1 ratio.
3478677|NCT03808935|Placebo Comparator|Placebo Control|"Capsules containing a high-oleic sunflower oil, calorie-equated to the active treatment. There will be no active compounds in the placebo treatment.~Following treatment with placebo, all participants in this group will begin treatment with medical cannabis."
3478678|NCT03809013|Experimental|RC48-ADC|Participants will be treated with RC48-ADC 2.0 mg/kg, once every 2 weeks (Q2W) until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
3126961|NCT03063476|Experimental|Healthy|"Two healthy subjects will be enrolled and each will undergo study procedures at one visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of C-13 labeled lysine (5 g) in 50 ml water. This amount of lysine is equivalent to that which is found in a 5oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of approximately 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
3126962|NCT03064113|Experimental|Sequence 1|Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg
3126963|NCT03064113|Experimental|Sequence 2|Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg
3126964|NCT03064113|Experimental|Sequence 3|Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg
3126965|NCT03064113|Experimental|Sequence 4|Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo
3179495|NCT00673335|Experimental|Treatment arm|Letrozole, 1 tablet
3179496|NCT00673335|Placebo Comparator|Placebo|Comparator, 1 tablet
3179497|NCT00673348||1|Patients suspected of invasive fungal infection (proven or probable cases) with immunocompromised state (for example, during neutropenia, receiving HSCT) in Catholic Hematopoietic Stem Cell Transplantation [HSCT] Center in Seoul, Korea.
3478679|NCT03808974|Experimental|Intervention|The intervention group will be shown an educational video
3478680|NCT03808974|Active Comparator|Control|The control group will be given an educational leaflet
3478681|NCT03809065|Experimental|group N|Patients in this group will receive Nitroglycerin infusion for deliberate hypotension at a rate of 0.5-2 μg /kg/min .
3478682|NCT03809065|Active Comparator|group L|Patients in this group will receive Labetalol infusion for deliberate hypotension at a rate of be 0.5-2 mg/kg/h .
3478683|NCT03809091||Bronchiectasis|The patient with bronchiectasis who has no apparent bronchiectasis-causing etiology will be enrolled. The patient's family who has no bronchiectasis will be also enrolled to identify the patient-specific variants.
3478684|NCT03808961|Active Comparator|Group 1 ? Niacin Arm|Oral 100 mg fixed dose twice daily x 18-months (200 mg total / day) with assessments @ baseline, 6 month, 12 month and 18 months
3478685|NCT03808961|Active Comparator|Group 2 ? Niacinamide Arm|Oral 100 mg fixed dose twice daily (200 mg total / day) x 18-months with assessments @ baseline, 6 month, 12 month and 18 months
3478686|NCT03808961|Placebo Comparator|Group 3 ? Placebo Wait-listed Arm|Oral placebo twice daily x 18- months with assessments @ baseline, 6 month, 12 month and 18 months
3478687|NCT03808909|Experimental|Doula|Participants will be assigned a doula.
3478688|NCT03808909|No Intervention|Control|Participants will not be assigned a doula.
3478689|NCT03809143|Experimental|Depot buprenorphine arm|All participants will receive monthly injections of depot buprenorphine (RBP-6000, Sublocade)
3478690|NCT03809195|Experimental|Hypnosis Intervention|The intervention is clinical hypnosis--a single in-person session followed by instructions to listen to audio recordings at home. The sessions consist of the provider's voice guiding the participant into a relaxed and focused state and providing therapeutic suggestions--for example, to replace discomfort with a more pleasant sensation, to ease anxiety, and to increase energy.
3478691|NCT03809195|No Intervention|Waitlist Control|This group will serve as a control comparison and be offered the intervention after control data collection is complete.
3478692|NCT03809117|Experimental|Experimental|Gastrointestinal Polymerase Chain Reaction test performed and results communicated to treatment provider. Followed by usual care per treating physician.
3478693|NCT03809117|Active Comparator|Control|Gastrointestinal Polymerase Chain Reaction test performed at the conclusion of the study. Clinician will not be informed of results. Usual Care performed per treating physician.
3478694|NCT03808896|Active Comparator|bougie-assisted intubation|use bougie as guide, intubation with loading endotracheal tube under direct or video laryngoscopy
3478695|NCT03808896|Active Comparator|intubation with epiglottic lifting|Lifting of epiglottis with stylet-equipped endotracheal tube to assist intubation under direct or video laryngoscopy
3478696|NCT03808896|No Intervention|Traditional intubation|intubation under direct or video laryngoscopy without epiglottis lifting nor bougie-assited
3478697|NCT03809221|Experimental|early follicular phase down-regulation|Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle. If complete pituitary down-regulation is achieved after 28-42 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours after pre-ovulatory hCG injection transvaginally under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
3478698|NCT03809221|Active Comparator|luteal phase down-regulation|Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle. If complete pituitary down-regulation is achieved after 14-21 days, exogenous gonadotropins will be given according to the participants' BMI. The physician will monitor the follicular growth and the serum hormone level and adjust the dose of exogenous gonadotropins accordingly. When the desired follicle size is reached, human chorionic gonadotropin will be administered. Oocyte retrieval will be performed 36-38 hours later under ultrasound monitoring. Oocyte retrieved will be cultured in vitro for 3-6h before being fertilized via IVF or ICSI. Two top-quality Day 3 cleavage embryos will be transferred 72h after retrieval.
3478699|NCT03809156|Experimental|Combo Riociguat and Ambrisentan Therapy|Riociguat Oral Product and Ambrisentan Oral Product to be given in combination to de novo (untreated) patients.
3478700|NCT03808922|Experimental|Cohort 1 and Cohort 2 Treatment|DAS181 4.5mg qd x 7 OR 10 days
3478701|NCT03808922|Placebo Comparator|Cohort 1 and Cohort 2 Placebo|Placebo qd x 7 OR 10 days
3478702|NCT03808922|Experimental|Cohort 3|DAS181 4.5mg qd x 7 OR 10 days (≥ 40 kg) DAS181 2.5mg qd x 7 OR 10 days (< 40kg)
3478703|NCT03808922|Experimental|Cohort 4|DAS181 4.5mg qd x 7 OR 10 days
3478704|NCT03808922|Experimental|DAS181 COVID-19 Treatment|DAS181 4.5mg q12h x 7 OR 10 days
3478705|NCT03808922|Placebo Comparator|DAS181 COVID-19 Placebo|Placebo q12h x 7 OR 10 days
3478706|NCT03809169|Experimental|ROSE with guide sheath|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique and presence of ROSE
3478707|NCT03809169|Experimental|ROSE without guide sheath|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no guide sheath and the presence of ROSE.
3478708|NCT03809169|Experimental|Guide sheath without ROSE|Patients will undergo pEBUS with a regular size bronchoscope using the guide sheath technique but without ROSE.
3478709|NCT03809169|Experimental|No guide sheath without ROSE|Patients will undergo pEBUS with a slim bronchoscope combined with a 1.7mm radial probe but no the guide sheath an without the presence of ROSE.
3478710|NCT03808870|Experimental|NBM-BMX|
3478711|NCT03808857|Experimental|GB226|Geptanolimab Injection,3mg/kg once per 2 weeks
3478712|NCT03808844|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
3478713|NCT03808844|Active Comparator|Propofol|2.0mg/kg/1.0mg/kg
3478714|NCT03809130|Experimental|Arm I (Untire application)|Patients use Untire application intervention after baseline up to 6 months.
3478715|NCT03809130|Active Comparator|Arm II (Untire application)|Patients use Untire application intervention after 3 months up to 6 months.
3478716|NCT03809078|Experimental|68Ga RM2 first followed by 68Ga PSMA11|Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
3478717|NCT03809078|Experimental|68Ga PSMA11 first followed by 68Ga RM2|Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2
3478718|NCT03809234|Experimental|Ondansetron with Tariquidar|The participants will receive an IV ondansetron infusion with tariquidar. Participants will receive either 8mg or 16 mg of iv ondansetron, with 4mg/kg tariguidar.
3478719|NCT03809234|Placebo Comparator|Ondansetron with Placebo|The participants will receive an IV ondansetron infusion with D5W as placebo. Participants will receive either 8mg or 16 mg of iv ondansetron.
3478720|NCT03808701|Experimental|low dose group|Initially, 9.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 12.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3478721|NCT03808701|Experimental|HIGH dose group|Initially,12.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 15.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3179498|NCT00673374||1|All consecutive emergency department patients undergoing abdominal CT for non-traumatic abdominal pain and tenderness will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
3179499|NCT00673426|Experimental|A|
3478722|NCT03808831|Experimental|Experimental groups|Subjects in the experimental group will wear the fall detection and prevention system on the lower back. The system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
3478723|NCT03808831|Sham Comparator|Sham group|In the sham group, subjects wear a sham system with record but no alert function.
3478724|NCT03808818|Active Comparator|Arm A (smoking assessment, quitting advice, Quitline referral)|Patients receive an assessment of smoking status and provision of quitting advice through the screening and referral process, and are referred to the NCI Smoking Quitline.
3478725|NCT03808818|Experimental|Arm B (virtual counseling sessions, NRT)|Patients receive an initial virtual counseling session with a study-designated tobacco treatment coach via MGH TeleHealth over 40 minutes and up to 10 more virtual counseling sessions over 15 minutes for approximately 6 months. Patients also receive up to 12 weeks of NRT (patch and lozenge combined or alone).
3478726|NCT03808805|Experimental|studied group|Aprepitant 80 mg daily - 14 days Plus placebo of Hydroxyzine - 14 days
3478727|NCT03808805|Active Comparator|comparative group|Hydroxyzine 25 mg/d - 14 days Plus placebo of Aprepitant - 14 days
3478728|NCT03808714|Active Comparator|Intervention|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session (delivered by a trained Community Health Worker) plus pharmacological consultation(s) via telemedicine, but this will be determined during pretesting.
3478729|NCT03808714|Active Comparator|Control|"Alabama Tobacco Quitline, which is considered the standard-of-care for smoking cessation in Alabama."
3478730|NCT03808740|Experimental|Roux-en-Y gastric bypass (RYGB)/Atomoxetine|Participants with standard of care RYGB will receive atomoxetine, 0.5 mg/kg/day for 3 days
3478731|NCT03808740|Experimental|Vertical sleeve gastrectomy (VSG) /Atomoxetine|Participants with standard of care VSG will receive atomoxetine 0.5 mg/kg/day for 3 days
3478732|NCT03808740|Placebo Comparator|Roux-en-Y gastric bypass (RYGB)/Placebo|Participants with standard of care RYGB will receive placebo 0.5 mg/kg/day for 3 days
3478733|NCT03808740|Placebo Comparator|Vertical sleeve gastrectomy (VSG)/ Placebo|Participants with standard of care VSG will receive placebo 0.5 mg/kg/day for 3 days
3478734|NCT03808584|No Intervention|Control group|The patients in the control group will receive standard physiotherapy and will be instructed to limit core muscle activity and weight bearing according to their pain symptomatology. Standard physiotherapy for all hospitalised patients includes early mobilization and exercises to prevent thrombosis and pulmonary complications (atelectasis, pneumonia, diaphragmatic deconditioning), balance training and endurance and exercise training
3478735|NCT03808584|Experimental|Intervention group|The patients in the intervention group will be given exercises to perform postoperatively.They will be instructed by a physiotherapist in how to perform the four specific exercises targeting core muscles. The patient will perform these exercises daily during hospitalization under the supervision of the physiotherapist and then at home for two months after the operation. The intensity of the exercises will be adjusted daily to the physical capabilities of the patient. They will also benefit from standard physiotherapy as described above.
3478736|NCT03808753|Experimental|Treatment - hemodynamic tests: EEOT and mFC|Interventions: all the enrolled patients will be tested using the EEOT and the mFC.
3478737|NCT03808779|Experimental|Radiofrequency Ablation|Eligible participants with PTMC will be randomly assigned to this group and undergo radiofrequency ablation(RFA) procedure.
3126968|NCT03064152|No Intervention|Control|Patients who experience postpartum hemorrhage will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, activated partial thromboplastin time (aPTT), fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the control group will be blinded to ROTEM results.
3126969|NCT03064152|Experimental|ROTEM|Patients will receive standard of care for labor and delivery, cesarean delivery, and postpartum care. Transfusion will be based on standard of care utilizing clinical criteria of hemodynamics (noninvasive blood pressure, heart rate, arterial line if deemed clinically useful) and coagulation labs (PT, aPTT, fibrinogen, complete blood count). In addition to standard of care, additional ROTEM blood assays will be performed at any time routine coagulation labs are sent. Providers in the ROTEM group will receive real-time ROTEM results and a previously validated ROTEM-based transfusion algorithm for PPH.
3126970|NCT03064438|Experimental|ACU-D1 Ointment|Twice-daily application of ACU-D1 ointment to the face for 12 weeks.
3126971|NCT03064438|Placebo Comparator|ACU-D1 Ointment Vehicle|Twice-daily application of ACU-D1 ointment vehicle to the face for 12 weeks.
3126972|NCT03064451|Experimental|Intervention|cartofinder guided ablation followed by PVI
3478738|NCT03808779|Active Comparator|Conventional Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/thyroid lobectomy procedure.
3126974|NCT03064841||Outpatient with confirmed T2DM|subjects with confirmed T2DM
3478739|NCT03808766|Other|Tumor <=3cm|Embolization with particulate or liquid embolic agent
3478740|NCT03808766|Other|Tumor >3cm to 7cm|Embolization with particulate or liquid embolic agent
3478741|NCT03808766|Other|Tumor > 7cm|Embolization with particulate or liquid embolic agent
3478742|NCT03808792||Ovarian cancer patients|Patients with abdominal or pelvic mass suspicious of primary ovarian, tubal or peritoneal cancer submitted to the index test (Ultrasound, CT and WB/DWI-MRI) with perspective of primary surgery
3126975|NCT03065023|Experimental|Group A: Cutaenous lesions|Participants with transdermally/transmucosally injectable tumors including cutaneous, subcutaneous or lymph node injectable tumors received escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection twice each week (Q2W) over a period of 4 weeks. Participants may have continued to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years).
3126976|NCT03065023|Experimental|Group B: Liver lesions|Participants with injectable liver tumors or liver metastases were to receive escalating doses of MK-4621 via intratumoral (IT)/intralesional (IL) injection once each week over a period of 4 weeks. Participants were to have been able to continue to receive study treatment beyond Cycle 1 for the remaining duration of the study as long as clinical benefit (no overt clinical progression or toxicity considered to be intolerable as per Investigator's assessment) was present (up to approximately 2 years). (Group B was not started. Development will continue with new protocol.)
3126977|NCT03065075|Experimental|Phenazopyridine|Participant is given Phenazopyridine 200mg on postoperative day 1
3478743|NCT03808649|Active Comparator|Individualized group|Participants are given different volume of a preparation of mannitol based on BMI as oral contrast agent over an hour prior to the examination.
3478744|NCT03808649|Experimental|conventional group|Participants are given 1500ml of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
3478745|NCT03808610|Experimental|Experimental (venetoclax, vincristine, cyclophosphamide)|See Detailed Description.
3478746|NCT03808662|Experimental|Arm 1: Early Stereotactic Body Radiotherapy/SBRT|SBRT to all oligoprogressive sites
3478747|NCT03808662|Active Comparator|Arm 2:Standard of Care|
3478748|NCT03808597|Experimental|Intervention group|The participants in this group will be exposed to digital health promotion. Please note that the participants are not randomly chosen, but stratified after the project villages. The participants in this group belong to the villages: Izazi and Migoli.
3126978|NCT03065075|No Intervention|No Phenazopyridine|Participant is not given Phenazopyridine on postoperative day 1
3126979|NCT03065179|Experimental|Nivolumab/Ipilimumab plus SBRT|Induction Dual Immune Checkpoint Inhibition with nivolumab and ipilimumab plus SBRT to 1-2 metastatic sites, followed by nivolumab monotherapy
3126980|NCT03065205|Experimental|Single Arm|Patients will have adherence monitoring devices placed on their asthma inhalers (both daily and rescue medication). Adherence information will be sent to their PCP, specialist and school nurse monthly. Additionally, the navigator will speak with families every 2 months to discuss adherence data and address barriers.
3126981|NCT03065283|Active Comparator|Diaphragmatic release|The stretching of the peripheral fibers of the diaphragm
3126982|NCT03065283|Placebo Comparator|Diaphragmatic release control|In both placebo techniques, only the light touching of the contacts of the volunteers' skin
3126983|NCT03065400|Experimental|Pembolizumab|
3126984|NCT03065530|Placebo Comparator|control group|"The placebo group will pumped in the same volume of saline 0.9% as calculated by parturients' weight in 30 min and receive 1mg butorphanol after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
3126985|NCT03065530|Experimental|Dexmedetomidine 0.03ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.03ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
3126986|NCT03065530|Experimental|Dexmedetomidine 0.05ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.05ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
3126987|NCT03065530|Experimental|Dexmedetomidine 0.08ug/kg/h group|"This group will receive 0.5ug/kg intravenous dexmedetomidine diluted to 4ug/ml in 30 min and 1mg butorphanol tartrate after delivery.~Postoperative analgesic formula: 3ug/kg/h butorphanol tartrate with 0.08ug/kg/h dexmedetomidine, diluted with normal saline to 100ml. Background dose: 2ml/h, PCA: 0.5ml, locking time: 15 min."
3126988|NCT03065647|No Intervention|Standard Care|Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols at the scene of the cardiac arrest.
3126989|NCT03065647|Experimental|Expedited Transport|"Intervention: Expedited Transport with Mechanical CPR.~After initial Basic Life Support (BLS) and Advanced Cardiovascular Life Support (ACLS) by Emergency Medical Services (EMS) per existing EMS protocols, patients with refractory cardiac arrest are transported to an ECPR capable emergency department with ongoing mechanical CPR and ACLS for possible initiation of extracorporeal cardiopulmonary resuscitation (ECPR)."
3126990|NCT03066193|Experimental|Dronabinol and Palmitoylethanolamide|All participants will be titrated up on Dronabinol dose during the first week of the trial (2.5mg Dronabinol for 3 days and then 5mg Dronabinol for 4 days increasing to 10mg Dronabinol for the remainder of the trial). Dronabinol will only be increased to 10mg at the week 1 assessment if the subject is tolerating the 5mg dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. All participants will receive two 400mg tablets of PEA daily for the same 12 weeks that they receive the Dronabinol.
3126991|NCT03066609|Experimental|Secukinumab 150mg|Secukinumab 150mg s.c.
3478749|NCT03808597|No Intervention|Control group|"The participants in this group will be not be exposed to digital health promotion, but the villages will receive the intervention after one year. Please note that the participants are not randomly chosen, but stratified after the project villages.~The participants in this group belong to the villages: Kimande and Idodi."
3478750|NCT03808532|Experimental|High-Risk with Moisturizer|
3478751|NCT03808532|No Intervention|High-Risk without Moisturizer|
3478752|NCT03808675|Experimental|Aerobic|Participants randomized to aerobic exercise
3478753|NCT03808675|Other|Control|Participants randomized to usual care with PD specific health education
3478754|NCT03808571||Study group|Pregnancies complicated with intrauterine growth restricted fetuses
3478755|NCT03808571||Control group|Healthy pregnancies
3478756|NCT03808636||TB patients|Any patient with possible or diagnosed tuberculosis who is capable to give informed consent will be offered to be included in the trial
3478757|NCT03808545|Active Comparator|BIPAMS|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS group will continue receiving the established BIPAMS intervention for the remainder of the trial.
3478758|NCT03808545|Experimental|BIPAMS + Diet|All participants will receive the standard BIPAMS intervention for the first 8 weeks of the trial.Those in the BIPAMS+Diet arm will begin receiving dietary materials in week 9.
3478759|NCT03808376|Experimental|Continuous Glucose Monitoring Device|The Eversense® 180 CGM System
3478760|NCT03808428|Experimental|Ankle Group|Integrated with force and motion sensors to identify gait phase and classify user walking intention using machine learning control algorithm.
3478761|NCT03808415|Experimental|EMG-driven|The hand training system functions as a biofeedback device which surface electromyography (EMG) sensors are used to capture the user's own muscle signals to activate the system for moving his/her paretic hand.
3478762|NCT03808519|Experimental|n3 PUFA|n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
3478763|NCT03808519|Placebo Comparator|Placebo|Organic Sunflower Oil 5000mg per day
3478764|NCT03808558|Experimental|TVB-2640|Patients will be administered TVB-2640 100mg/m2 orally once a day for 8 weeks.
3478765|NCT03808441|No Intervention|Standard Arm|"Dabrafenib + Trametinib~Switch to N+I at first progression"
3126992|NCT03066609|Experimental|Secukinumab 300mg|Secukinumab 300mg s.c.
3126993|NCT03066609|Placebo Comparator|Placebo|Placebo to secukinumab s.c
3126994|NCT03066622|Active Comparator|Standard of Care|IV Morphine or any medication per attending decision
3126995|NCT03066622|Experimental|Olanzapine|oral rapidly dissolving olanzapine (Zydis) 5 mg for analgesia in acute primary headaches.
3126996|NCT03066778|Experimental|Pembrolizumab+EP|During each 21-day cycle, participants receive pembrolizumab 200 mg intravenously (IV) Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
3126997|NCT03066778|Active Comparator|Placebo+EP|During each 21-day cycle, participants receive placebo (normal saline solution) IV on Day 1 PLUS etoposide 100 mg/m^2 IV on Days 1, 2 and 3 PLUS investigator's choice of platinum (carboplatin titrated to an AUC 5 IV on Day 1 OR cisplatin 75 mg/m^2 IV on Day 1).
3126998|NCT03066804|Experimental|sacubitril/valsartan (LCZ696)|"All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.~Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).~In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally)."
3126999|NCT03066804|Active Comparator|Comparator|"Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).~Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).~Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).~Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo."
3127000|NCT03066830|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received two Sotagliflozin tablets of 200 mg, orally once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
3127001|NCT03066830|Placebo Comparator|Placebo|Following a 2-week run-in period, participants were randomized to matching placebo administered as 2 tablets, once daily, before the first meal of the day plus Metformin and Sulfonylurea as prescribed for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 79 weeks.
3127002|NCT03066947|Experimental|SV-BR-1-GM Monotherapy|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation; SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2); Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation
3127003|NCT03066999|Active Comparator|Cystoscopy|will have catheter placement using the cystoscopy method
3478766|NCT03808441|Active Comparator|ctDNA Guided Switch|"Dabrafenib + Trametinib~Switch to N+I when ctDNA levels in the blood have dropped by ≥80%."
3478767|NCT03808506||Ulcerative colitis patients|Patients with documented ulcerative colitis who are initiating adalimumab therapy will have baseline bowel ultrasound and fecal calprotectin completed.
3478768|NCT03808324|Experimental|Heart transplant recipients|
3478769|NCT03808480|Experimental|CA and Nivolumab|"After 1 cycle of cyclophosphamide and doxorubicin (CA) induction therapy, Nivolumab 360mg flat dose will be given on day 1 with CA chemotherapy in a 21-day cycle.~After the completion of 4 cycles of CA chemotherapy, Nivolumab will be continued as a single agent at a dose of 480mg flat dose every 4 weeks until loss of clinical benefit"
3478770|NCT03808285||mandibular osteomylitis|description of mandibular osteomylitis due to denosumab
3478771|NCT03808467|Experimental|CRT + TAU|Cognitive Remediation Therapy + Treatment As Usual
3478772|NCT03808467|Other|TAU only|Treatment As Usual
3478773|NCT03808233||Spinal Muscular Atrophy Type 1|Non rolling infants or children with SMA
3478774|NCT03808233||Non Rolling Function matched control|Non rolling typically developing infant
3478775|NCT03808207|Experimental|Intervention group|Increase of the average intake of dietary DHA: dietary advices concerning the concentration of docosahexaenoic acid (DHA) in several foods; the recommended daily or weekly intake of different food options (animal, vegetal) in order to reach the average intake of 300-350 mg DHA/day
3478776|NCT03808207|No Intervention|Control group|No specific dietary advice; Only endorsement and promotion of breastfeeding.
3478777|NCT03808363|Experimental|High Intensity Interval Training Group|Approximately eight individuals with spinal cord injuries will participate in high intensity interval training for 6 weeks
3478778|NCT03808168|Active Comparator|Arm 1|Nivolumab, 3 mg/kg Iv, day 1
3478779|NCT03808168|Active Comparator|Arm 2|Nivolumab, 3 mg/kg IV, days 1, 15, 29
3478780|NCT03808350|Placebo Comparator|Families Excluded From Presence at Procedures|Families not invited to remain for ICU procedures
3478781|NCT03808350|Active Comparator|Families Invited to Be Present at Procedures|Families invited to remain for ICU procedures
3478782|NCT03808142||Treatment|During a 3-months period all patients with an active myBETAapp account were invited to participate in the study (3-month invitation period=enrollment period). Patients seek more information about the study were able to access a detailed informed consent form via their app providing step-by-step background information. Those patients were wishing to participate in the study were able to provide (electronic) informed consent (ICF).
3478783|NCT03808116|Experimental|SmartBx biopsy collection|"Biopsy cores will be collected from the breast during US guided biopsy procedure.~The number of cores taken will be decided per the physician discretion according to the clinical demand.~Additional two biopsy core will be taken the SmartBx cassette"
3478784|NCT03808311|Experimental|Intensive BP treatment arm|Participants in the intensive BP treatment arm will be treated to a systolic BP target of <120 mmHg.
3478785|NCT03808311|Other|Standard BP treatment arm|Participants in the standard BP treatment arm will be treated to a systolic BP target of <140 mmHg.
3478786|NCT03808259|Experimental|Part 1: OTF Sublingual and IV|Participants will receive (S)-ketamine oral thin film (OTF) at a dose of 7 milligram (mg) [cohort 1], 14 mg [cohort 2], and 28 mg [cohort 3] via sublingual route or 14 mg (S)-ketamine intravenous (IV) infusion for 40 minutes or matching placebo in 1 of 3 serial cohorts. Dose escalation decisions to further cohorts of Part 1 will be made based on safety and tolerability profile of the preceding lower dose level.
3478787|NCT03808259|Experimental|Part 2: IV Different Infusion Duration|Participants will receive single dose (S)-ketamine less than or equal to (<=)14 mg IV at a different infusion duration or matching placebo at a different infusion duration. The infusion duration and dose will be chosen after completion of Part 1.
3478788|NCT03808194|Active Comparator|Optimized ART linkage package|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART.
3478789|NCT03808194|Experimental|Conditional lottery incentive|Participants in this arm will receive a clinic referral card and text messages to support linkage to ART and will be entered into a lottery each time they meet the following conditions: visited the clinic by month 1, initiated treatment by month 3, and achieved viral suppression by month 6
3478790|NCT03808129|Active Comparator|ESP Group: Bupivacaine and lidocaine|ESP Group: Bupivacaine and lidocaine: Erector Spinae Plane Block : (1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine) was administered.
3478791|NCT03808129|No Intervention|control group|Control Group:
3478792|NCT03808103|Placebo Comparator|Placebo|Dose is 1mL of placebo given orally twice a day for 15 days
3478793|NCT03808103|Experimental|Phage|Dose is 1mL of bacteriophage preparation given orally twice a day for 15 days
3127004|NCT03066999|Active Comparator|DirectVision|will have catheter placement using DirectVision.
3127005|NCT03067129|Experimental|Cohort 1: Adult formulation GLE/PIB, participants 12 to < 18 yrs|Adult formulation of glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg co-formulated film-coated tablets once daily (QD) by mouth for 8, 12, or 16 weeks depending on hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to < 18 years of age
3127006|NCT03067129|Experimental|Cohort 2: Pediatric formulation GLE/PIB, participants 9 to < 12 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to < 12 years of age
3127007|NCT03067129|Experimental|Cohort 3: Pediatric formulation GLE/PIB, participants 6 to < 9 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to < 9 years of age
3127008|NCT03067129|Experimental|Cohort 4: Pediatric formulation GLE/PIB, participants 3 to < 6 yrs|Pediatric formulation of separate glecaprevir (GLE)/pibrentasvir (PIB)15.67% and 8.25% film-coated pellets/granules dosed based on body weight/age once daily (QD) by mouth for 8, 12, or 16 weeks depending on HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to < 6 years of age
3127009|NCT03067311|Experimental|I-CAT|A novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping given by trained clinicians.
3127010|NCT03067311|Active Comparator|Treatment as Usual|Usual treatment provided at the University of North Carolina at Chapel Hill (UNC) Outreach and Support Intervention Services (OASIS) Clinic by trained clinicians.
3127011|NCT03067441|Experimental|Open-Label bempedoic acid|bempedoic acid 180 mg tablet
3127012|NCT03067506||Participants With Major Depressive Disorder (MDD)|Participants with MDD were provided with an Apple watch on which brief cognitive and mood tests were evaluated daily up to 6 weeks.
3478794|NCT03808246|Experimental|naive/realistic environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
3478795|NCT03808246|Experimental|informed/realistic environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the realistic environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
3478796|NCT03808246|Experimental|informed/laboratory-like environment|"This arm includes included participants who are informed in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
3478797|NCT03808246|Experimental|naive/laboratory-like environment|"This arm includes included participants who are naive in terms of self-injector pens and who have been randomly attributed to the laboratory-like environment condition of simulation.~The intervention is using the demo version of a self-injector pen."
3478798|NCT03808181|Other|Active treatment with ChloraSolv|Single arm
3478799|NCT03808454|Experimental|Platelet rich plasma (PRP)|PRP injection only
3127013|NCT03067948|Experimental|Intervention - Positive Screen Shared|In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to the participant's next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to the next HIV primary care visit.
3127014|NCT03067987|Active Comparator|720 shockwave therapy|5 daily sessions of shockwave therapy within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
3127015|NCT03067987|Active Comparator|600 shockwave therapy|"Three sessions of shockwave therapy per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~Following the last treatment session, each patient will resume his baseline consumption of phosphodiesterase 5 inhibitor, in terms of type and dose of drug, for the remainder of study duration."
3127016|NCT03068091|Other|Pulmonary Assessment|All participants will undergo a Chest CT scan and pulmonary function testing
3127017|NCT03068312|Experimental|Sequence 1: First Ivacaftor (IVA) Then Placebo|Participants received IVA 150 milligram (mg) every 12 hours (q12h) for 8 weeks in treatment period 1 followed by placebo matched to IVA for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
3127018|NCT03068312|Experimental|Sequence 2: First Placebo Then IVA|Participants received placebo matched to IVA for 8 weeks in treatment period 1 followed by IVA 150 mg q12h for 8 weeks in treatment period 2. A washout period of 8 weeks was maintained between the 2 treatment periods.
3127019|NCT03068455|Experimental|nivolumab + ipilimumab|Specified Dose on Specified Days
3127020|NCT03068455|Experimental|nivolumab|Specified Dose on Specified Days
3127021|NCT03068468|Experimental|BIIB092|Participants will receive BIIB092 50 mg/ml intravenous (IV) infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
3127022|NCT03068468|Placebo Comparator|Placebo|Participants will receive BIIB092 matching placebo IV infusion once every 4 weeks for 48 weeks in double blind treatment period followed by BIIB092 50 mg/ml IV infusion once every 4 weeks starting at Week 52 up to Week 208.
3127023|NCT03068611|Active Comparator|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
3127024|NCT03068611|Experimental|Alcohol-focused Web-Based Smoking Cessation|A modified version of the website and text messaging program that is publicly available through BecomeAnEX.com. This version includes specific information and feedback on alcohol use, allows participants to consider benefits of changing drinking, plans for changing drinking, and strategies. Participants have access to the website whenever they wish.
3127025|NCT03068715|Experimental|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
3127026|NCT03068715|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
3127027|NCT03068754|Experimental|Arm A: Treatment Period Acthar|"Participants receive one 0.2 mL subcutaneous (SC) injection (shot under the skin) of the study drug (Acthar), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of tapering off the drug, ending their participation by Week 39."
3127028|NCT03068754|Placebo Comparator|Arm B: Treatment Period Placebo|"Participants receive one 0.2 mL SC injection that looks like Acthar, but has no drug in it (Matching Placebo), daily for up to 36 weeks.~Those who do not continue into the extension period will have 3 weeks of simulated tapering, ending their participation by Week 39."
3127029|NCT03068754|Experimental|Arm C: Extension Period Acthar-Acthar|Participants who receive Acthar during the treatment period and continue into the extension period do not go through the treatment-period tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
3127030|NCT03068754|Experimental|Arm D: Extension Period Placebo-Acthar|Participants who receive Placebo during the treatment period and continue into the extension period do not go through the treatment-period simulated tapering, but receive one 0.2 mL SC injection of Acthar, daily for up to 48 weeks, followed by 3 weeks of tapering off the drug, ending their participation within about 21 months.
3127031|NCT03068767|Experimental|Vitamin D group|Patients receiving vitamin D supplement (2000 IU/day) for 2 months
3127032|NCT03068767|No Intervention|Control group|Patients without receiving vitamin D supplement
3127033|NCT03068897|Active Comparator|Metaxalone|"Ibuprofen 600mg mg + metaxalone 400-800mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
3127034|NCT03068897|Active Comparator|Tizanidine|"Ibuprofen 600mg mg + tizanidine 2-4mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
3127035|NCT03068897|Active Comparator|Baclofen|"Ibuprofen 600mg mg + baclofen 10-20 mg every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
3127036|NCT03068897|Placebo Comparator|Placebo|"Ibuprofen 600mg mg + placebo, 1 or 2 capsules, every 8 hours, as needed for low back pain, x 7 days.~All participants receive a brief educational intervention."
3478800|NCT03808454|Experimental|PRP+Rehabilitation|PRP injection combined with rehabilitation
3478801|NCT03808454|Active Comparator|Rehabilitation|Rehabilitation treatment only
3478802|NCT03808155|Active Comparator|Tamsulosin|The study specific product Tamsulosin 0.4mg, a tablet which is taken once a day per os five days prior to the operation and two days after the operation.
3478803|NCT03808155|Placebo Comparator|Placebo Oral Tablet|The placebo is taken once a day per os five days prior to the operation and two days after the operation.
3478804|NCT03808220||post-surgical patients|post-surgical patients > 18 years
3127037|NCT03068949|Active Comparator|FluBlok|FluBlok 0.5 mL given IM X1
3127038|NCT03068949|Active Comparator|Fluzone|Fluzone 0.5 mL given IM X1
3127039|NCT03068949|Active Comparator|FluCelVax|FluCelVax 0.5 mL given IM X 1
3127040|NCT03068949|Active Comparator|Fluzone HD|Fluzone HD 0.5 mL given IM X1
3127041|NCT03069313|Experimental|Arm I|Oral Vitamin B12
3127042|NCT03069352|Experimental|Venetoclax + Low Dose Cytarabine (LDAC)|Venetoclax 600 mg orally every day (QD) plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
3127043|NCT03069352|Placebo Comparator|Placebo + LDAC|Matching placebo to venetoclax orally QD plus LDAC 20 mg/m² subcutaneously on Days 1 to 10 of each 28-day cycle.
3127044|NCT03069365|Experimental|GLE/PIB for 8 weeks|HCV genotype 1,2,4-6 non-cirrhotic, treatment-naive or treatment-experienced; genotype 3 non-cirrhotic, treatment-naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 8 weeks
3127045|NCT03069365|Experimental|GLE/PIB for 12 weeks|HCV genotype 1,2,4-6 compensated cirrhosis, treatment-naive or treatment-experienced; genotype 3 compensated cirrhosis, treatment- naïve participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 12 weeks
3127046|NCT03069365|Experimental|GLE/PIB for 16 weeks|HCV genotype 3 non-cirrhotic or with compensated cirrhosis, treatment-experienced participants treated with glecaprevir/pibrentasvir (GLE/PIB): three 100 mg/40 mg co-formulated tablets once daily with food for 16 weeks
3127047|NCT03069482|Experimental|Learn to Quit|A smartphone app developed by the research team designed for people with serious mental illness, that provides Acceptance and Commitment Therapy skills to address (a) smoking cessation and (b) mental health symptoms.
3127048|NCT03069482|Active Comparator|NCI QuitGuide|A smartphone app developed by the National Cancer Institute which uses smoking cessation recommendations contained in the US DHHS Clinical Practice Guidelines.
3127049|NCT03069677|Active Comparator|Music group|research-selected music
3127050|NCT03069677|Active Comparator|Midazolam group|IV midazolam (1mg to 2mg max)
3127051|NCT03069716|Experimental|Smartphone Text Messaging|"Group receives personalized, health coaching via smart text messages."
3127052|NCT03069716|Other|No Smartphone Text Messaging|"Group does not receive personalized, health coaching via smart text messages."
3127053|NCT03069989|Experimental|Cohort 1 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
3127054|NCT03069989|Placebo Comparator|Cohort 1 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
3127055|NCT03069989|Experimental|Cohort 2 GSK3008348|Participants will receive a single nebulized dose of GSK3008348 during each of 2 planned dosing periods and up to 3 microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
3127056|NCT03069989|Placebo Comparator|Cohort 2 Placebo|Participants will receive a single nebulized dose of placebo during each of 2 planned dosing periods and up to 3 microdose of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
3127057|NCT03070171|Experimental|Dabigatran Etexilate Capsule|
3127058|NCT03070171|Experimental|Dabigatran Etexilate Tablet|
3127059|NCT03070236|Experimental|Patient-reported Outcomes Survey|The survey will administered online, over the phone, or via mail.
3127060|NCT03070392|Experimental|IMCgp100|Biologic:IMCgp100 (Soluble gp 100-specific T cell receptor with anti - CD3 scFV: IMCgp100)
3127061|NCT03070392|Active Comparator|Investigator's Choice|"1 of 3 Investigator's Choice options: Systemic Dacarbazine~1 of 3 Investigator's Choice options: Systemic Ipilimumab~1 of 3 Investigator's Choice options: Systemic Pembrolizumab"
3127062|NCT03070431|Experimental|High-precision RT 5x5 Gy in 1 week|Patients with motor deficits of the lower extremities due to metastatic spinal cord compression (MSCC) will receive 5x5 Gy of high-precision RT in 1 week.
3127063|NCT03070470|Active Comparator|Ranolazine|Ranolazine 1500 mg two times per day for 2.5 days
3127064|NCT03070470|Active Comparator|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3
3127065|NCT03070470|Active Comparator|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg two times per day for 2.5 days
3127066|NCT03070470|Active Comparator|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3
3127067|NCT03070470|Placebo Comparator|Placebo|Placebo capsules
3127068|NCT03070470|Active Comparator|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
3127069|NCT03070483|Experimental|Vitamin D|Participants will all receive supplementation with cholecalciferol 5000 IU and calcium citrate 1000 mg daily for 3 months
3127070|NCT03070548|Experimental|ADME|1 mg talazoparib containing100 μCi of 14C-radiolabeled talazoparib
3179500|NCT00673491|Experimental|1|Patients treated according to clinical pathways
3179501|NCT00673491|No Intervention|2|Patients treated according to usual care
3478805|NCT03808220||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
3478806|NCT03807986|Experimental|Nanofat grafting and PRP injection|Striae diatensae will be treated by nanofat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
3478807|NCT03807986|Experimental|Microfat grafting and PRP injection|Striae diatensae will be treated by microfat grafting once every three months for 2 times combined with PRP injection once a month for 6 times.
3478808|NCT03807934|Experimental|Active High-Definition Stimulation|Active high-definition stimulation of targeted brain regions involved in perception and cognition.
3478809|NCT03807934|Sham Comparator|Sham High-Definition Stimulation|Sham high-definition stimulation of targeted brain regions involved in perception and cognition.
3127071|NCT03070730|Other|Atenolol|"In this arm subjects are randomized to atenolol 50 mg qd, droxidopa 100 mg/300 mg tid and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
3127072|NCT03070730|Other|Placebos|"In this arm subjects are randomized to placebo tid.~Placebo is used to control the administration effect."
3478810|NCT03808038||No Diary Group|Group completed daily questionnaires for four weeks, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
3478811|NCT03808038||Diary Start Group|Group completed bladder diaries in week 1, daily questionnaires in week 1, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
3478812|NCT03808038||Daily Start Group|Group completed daily questionnaires in week 1, bladder diaries in week 2, a weekly questionnaire at the end of each week, and a monthly questionnaire at the end of the study
3478813|NCT03807947|Experimental|Radial access|
3127073|NCT03070730|Other|Droxidopa|"In this arm subjects are randomized to droxidopa 100 mg/300 mg tid, atenolol 50 mg qd, and placebo tid.~Atenolol is used to examine the effect of non-selective beta adrenoreceptor antagonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia patients.~Droxidopa is used to examine the effect of direct alpha-1 adrenoreceptor agonist on primary and secondary endpoints in neuropathic and non-neuropathic postural tachycardia (POTS) patients."
3127074|NCT03070782|Experimental|Cohort A: ISIS 681257: 20 mg Q4W|Cohort A participants received 20 milligrams (mg) ISIS 681257, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
3127075|NCT03070782|Experimental|Cohort B: ISIS 681257: 40 mg Q4W|Cohort B participants received 40 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
3127076|NCT03070782|Experimental|Cohort C: ISIS 681257: 60 mg Q4W|Cohort C participants received 60 mg of ISIS 681257, SC injection, once Q4W, for up to 49 weeks and a maximum of 13 doses.
3127077|NCT03070782|Experimental|Cohort D: ISIS 681257: 20 mg Q2W|Cohort D participants received 20 mg of ISIS 681257, SC injection, once every 2 weeks (Q2W), for up to 51 weeks and a maximum of 26 doses.
3127078|NCT03070782|Experimental|Cohort E: ISIS 681257: 20 mg QW|Cohort E participants received 20 mg of ISIS 681257, SC injection, once weekly (QW), for up to 52 weeks and a maximum of 52 doses.
3127079|NCT03070782|Placebo Comparator|Placebo|Participants in each cohort were randomized to receive placebo at a dose-matched volume of study drug (ISIS 681257).
3127080|NCT03070964|Experimental|Plitidepsin|
3127081|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase I|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
3127082|NCT03071094|Experimental|Pexa-Vec combined with Nivolumab - Phase IIa|Participants were administered Pexa-Vec (pexastimogene devacirepvec) as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4 and nivolumab intravenously every 2 weeks (from week 2).
3127083|NCT03071263|Experimental|Group 1 - Patiromer|spironolactone + blinded patiromer
3127084|NCT03071263|Experimental|Group 2 - Placebo|spironolactone + blinded placebo
3127085|NCT03071276|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
3127086|NCT03071744|Other|Lazanda|"Study drug, Lazanda, will be self-administered intranasally during this study. The dose of Lazanda is not predicted from the daily maintenance dose of opioid used to manage persistent cancer pain and must be determined by dose titration. The minimal effective intranasal dose from the radiation therapy simulation will be the dose used as pre-medication prior to any further radiation therapy fractions (up to 10 fractions).~Lazanda should be administered 15 (T-15) minutes prior to laying on the hard surface for each simulation visit. If the response to the titrated Lazanda dose markedly changes, an adjustment of dose may be necessary to ensure that an appropriate dose is maintained as deemed by the investigator."
3127087|NCT03071887|Experimental|Intervention|Treatment arm - Relaxation Response Resiliency Program (3RP) (this is an open pilot; the treatment arm is the only arm)
3127088|NCT03072043|Experimental|Phase 1b Dose Escalation|Participants will receive intravenous infusions of APR-246 as a lead-in phase on days -14 to -11 starting at Dose Level 1 prior to starting cycle #1 of combination therapy with azacitidine. Combination therapy will consist of APR-246 on days 1-4 and azacitidine on days 4-10 (or days 4-5 and 8-12) of a 28 day cycle.
3179502|NCT00673504|Experimental|A|Gemcitabine + Sunitinib
3179503|NCT00673504|Other|B|Gemcitabine
3478814|NCT03807947|Active Comparator|Transfemoral Access|
3478815|NCT03807960|Experimental|visual|The video about patient controlled analgesia device (PCA) usage will shown to the patients via notebook.
3478816|NCT03807960|Experimental|written|The written form which include the same knowledge will give to the patient for reading.
3478817|NCT03807960|Other|control|The anesthesiologist will describe the PCA usage as in the routine care to the control group patients.
3478818|NCT03808090|Experimental|Normal Individuals|Normal individuals: no prior history of KS, no obesity, no diabetes
3478819|NCT03808090|Experimental|Calcium Oxalate Kidney Stone Formers|Those individuals that have a high propensity to form calcium oxalate kidney stones
3478820|NCT03808090|Experimental|Type 2 Diabetes|Those individuals that have been diagnosed with type 2 diabetes
3478821|NCT03808090|Experimental|Type 2 diabetic kidney stone formers|Those individuals that have been diagnosed with type 2 diabetes and kidney stones.
3478822|NCT03807973|Experimental|Fibromyalgia|
3478823|NCT03807973|Experimental|Chronic Fatigue Syndrome|
3478824|NCT03807973|Experimental|Multiple Sclerosis|
3478825|NCT03807973|Experimental|Healthy Controls|
3478826|NCT03808051|Experimental|Physiological-based cord clamping|Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
3127089|NCT03072043|Experimental|Phase 2 Treatment|Participants will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing schedule as in Phase 1b.
3127090|NCT03072160|Experimental|Cohort 1: Participants that had an immune stimulating cancer vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 1: cancer vaccine"
3127091|NCT03072160|Experimental|Cohort 2: Participants that have had no vaccine|"Pembrolizumab 200 mg will be administered as a 30 minute intravenous (IV) infusion every 3 weeks for two years.~Group 2: had no previous vaccine"
3127092|NCT03072186|Experimental|near-infrared light nasal endoscope used with ICG|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery and tumor dissection: before intradural dissection and during tumor dissection.
3127093|NCT03072550|Experimental|Multi-center open label|Thirty Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
3127094|NCT03072602|Experimental|African-American|Healthy self-identified African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
3127095|NCT03072602|Active Comparator|White|Healthy self-identified white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB). On 4th day, participants will come to the clinic in fasting state and drink 75 gm of oral glucose solution, followed by blood collection every hour for 8 hours.
3127096|NCT03072719|Experimental|Dentifrice containing stannous fluoride|Toothpaste
3127097|NCT03072719|Active Comparator|Dentifrice containing Sodium Monofluorophosphate|Toothpaste
3127098|NCT03072732|Other|study arm 1 - below left axilla|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed below left axilla and the ZOE Fluid Status Monitor
3127099|NCT03072732|Other|study arm 2-upper left pectoral area|20 patients undergoing hemodialysis, with at least 10 of these patients having congestive heart failure, will have the u-Cor system placed on the upper left pectoral area and the ZOE Fluid Status Monitor
3127100|NCT03072875|Experimental|CAMS-RAS|In this single-arm study design, all enrolled patient participants are asked to provide feedback on the CAMS-RAS prototype as it is developed for this study. Feedback will be gathered via survey measure and interview.
3127101|NCT03072953|Other|APD334|APD334 active treatment for 12 weeks.
3127102|NCT03073005|No Intervention|Traditional VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer.
3127103|NCT03073005|Experimental|Simulation-based VAD training|Patients and caregivers will receive traditional training for their VAD via a video produced by the VAD manufacturer and then participate in simulation-based mastery learning for VAD management
3127104|NCT03073148|Experimental|Tangible Boost|Participants will treat their lenses with Tangible Boost after 30 days and again after 60 days.
3127105|NCT03073148|Placebo Comparator|Control|"Participants will treat their lenses with a placebo Tangible Boost kit containing saline after 30 days and again after 60 days."
3127106|NCT03073200|Experimental|Ixekizumab|Ixekizumab given subcutaneously (SC) during the double-blind treatment period and the open-label maintenance period.
3127107|NCT03073200|Placebo Comparator|Placebo|Placebo given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period.
3127108|NCT03073200|Experimental|Open-Label Etanercept|Etanercept given SC during the double-blind treatment period and then ixekizumab given SC during the open-label maintenance period. Participants will only be randomized to etanercept in countries where it is approved for severe pediatric psoriasis treatment.
3127109|NCT03073213|Experimental|Ixekizumab single dose|Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
3127110|NCT03073213|Experimental|Ixekizumab Multiple Regimen 1 (80mg Q2W)|Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
3127111|NCT03073213|Experimental|Ixekizumab Multiple Regimen 2 (80mg Q4W)|Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.
3127112|NCT03073486|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face for 12 weeks
3127113|NCT03073486|Placebo Comparator|Olumacostat Glasaretil Gel, Vehicle|Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
3127114|NCT03073759|Experimental|dTCS|Patient will receive dTCS with direct current (maximum of 2 mA) stimulation delivered through surface electrodes (TransQE from IOMED®, surface area: 25 cm2) using a Phoresor® II Auto (Model No. PM850, IOMED®, Salt Lake City, Utah 84120, USA) or Sham stimulation.
3127115|NCT03073759|Sham Comparator|Sham|Patients will receive a sham.
3179504|NCT00673517||1|Patients randomized to high frequency oscillation
3179505|NCT00673517||2|Patients randomized to conventional lung protective ventilation
3478827|NCT03808051|Active Comparator|Time-based cord clamping|Infants are clamped first and then moved to the standard resuscitation table for further treatment and intervention needed for cardiopulmonary stabilisation. Clamping is time based and performed immediately or delayed at 30-60 seconds, depending on the clinical condition of the infant. Uterotonic drugs are administered immediately after cord clamping.
3478828|NCT03807999|Active Comparator|Nab-paclitaxel + Gemcitabine|Nab-paclitaxel 125 mg/m2 as 30- to 40-minute infusion (maximum infusion time not to exceed 40 minutes) once weekly for 3 weeks followed by a week of rest. plus Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) once weekly for 3 weeks followed by a week of rest.
3478829|NCT03807999|Experimental|Gemcitabine|Gemcitabine 1000 mg/m2 as a 30- to 40-minute infusion (maximum 40 minutes) administered weekly for 7 weeks followed by a week of rest (8-week cycle; cycle 1 only), followed by cycles of weekly administration for 3 weeks (on days 1, 8, and 15) followed by one week of rest (4-week cycle).
3478830|NCT03808025|Experimental|education|The teaching arm would consist of a standardized dialogue the surgeon will complete with the patient in order to familiarize the patient with the risks of over-prescribing opioid medication and set patient expectations regarding the clinic's opioid prescribing pattern protocol, in an effort to minimize the number of opioid pills prescribed or refills required, the amount actually used, and the untoward side effects of opioid use (e.g. respiratory depression, nausea, sedation, restriction from driving, and access to and use by those the medication was not intended).
3478831|NCT03808025|No Intervention|no education|Standard preoperative care without dedicated teaching regarding opioid use and risks
3478832|NCT03807895|Experimental|REBT Career Intervention|High-school students in the experiment group attend to eight modules of career intervention with rational emotive behavioral therapy (REBT) techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive Restructuring, Exposure/behavior activation and problem solving, Planning, Goal Setting.
3478833|NCT03807895|Active Comparator|Regular Career Intervention|High-school students in the treatment as usual group attend to eight modules of career intervention with regular career intervention techniques. The eight modules aim a different component: Psychoeducation, Information about the self and the world of work, Steps of Decision making, Problem solving, Planning, Goal Setting.
3478834|NCT03807908|Experimental|Intervention Tape|"The intervention includes 3 strips of tape; 2 (1 on each side) placed vertically along the lumbar erectors and 1 horizontally at the posterior superior iliac spine.~Subjects will wear the tape for as long as possible up to 5-7 days."
3478835|NCT03807908|Sham Comparator|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction.~Subjects will wear the tape for as long as possible up to 5-7 days."
3478836|NCT03807921|Experimental|Warfarin|"Warfarin will be started 48-72h after aortic valve replacement. Dose will be 5 mg daily in order to obtain an Internation normal ratio (INR) of 2-3. Warfarin treatment will continue for 3 months.~Aspirin will be administered 100 mg daily."
3478837|NCT03807921|Active Comparator|Aspirin only|Aspirin will be started 48-72h after aortic valve replacement. Dose will be 100 mg daily. Patients who undergo coronary artery revascularization will receive 325 mg daily.
3478838|NCT03807596|Active Comparator|SRP group|Chronic periodontitis patients with type 2 diabetes mellitus recieved Periodontal treatment in the form of scaling & root planing (SRP) alone.
3478839|NCT03807596|Experimental|Hyaluronic acid & SRP group|Chronic periodontitis & type 2 diabetes mellitus patients received Periodontal treatment in the form of scaling & root planing (SRP) with the adjunctive use of hyaluronic acid.
3478840|NCT03807713|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
3478841|NCT03808012|Experimental|Braking after inguinal hernia surgery|Cohort testing of driving performance in a brake simulator in patients before and after scheduled inguinal hernia surgery
3478842|NCT03807687||Patient with pancreatic disease|Patients diagnosed with pancreatic disease evaluated at this institution.
3478843|NCT03807726|Experimental|Intervention Group|Both standard usual care and the integrated breastfeeding education program (IBEP) will be provided to the participants in the intervention group. The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy. The details of each education components are presented at the following section.
3478844|NCT03807726|No Intervention|Control Group|The mother and her partner in the control group will receive the standard usual care provided at the study site. The study site hospital where follows the 10 steps of the Baby Friendly Hospital Initiative will provide breastfeeding care during prenatal check-up and postpartum care. The standard care protocols encompass elements such as prenatal breastfeeding consultation using breastfeeding pamphlets, and postpartum care like skin to skin contact, rooming- in, and breastfeeding consultation using pamphlets. The pregnant women need to register for childbirth class which contains only one breastfeeding class by themselves if needed. After delivery, the mothers are taught on breastfeeding knowledge and skills by the nurses at the postpartum ward or nursey.
3478845|NCT03807856|Active Comparator|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
3478846|NCT03807856|Active Comparator|Standard of Care|Standard treatment for acute pancreatitis
3478847|NCT03807804|Experimental|HLCM051 group【ARDS caused by pneumonia cohort】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
3478848|NCT03807804|No Intervention|Standard treatment group【ARDS caused by pneumonia cohort】|•Patients will receive the standard therapy
3478849|NCT03807804|Experimental|HLCM051 group【ARDS caused by COVID-19 cohort 】|"Patients will receive the standard therapy~A single, one-time dose of HLCM051 9.0×108 (±20%) cells are intravenously infused as a naturally dropped single dose over 30 to 60 minutes at the maximum infusion speed of 10 mL/minute"
3127116|NCT03073798|Active Comparator|Medication|Roflumilast. 500 mcg of Roflumilast daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of placebo.
3478850|NCT03807791|Experimental|Patient living in the Unit of Long Term Care|Patient living in the Unit of Long Term Care without any limit time
3478851|NCT03807661|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
3127117|NCT03073798|Placebo Comparator|Placebo|Placebo. 500 mcg of Placebo daily for 4 weeks, then there will be a 4 week wash-out phase (no medication) and a second 4 week period of Roflumilast
3478852|NCT03807843|Experimental|Treatment Arm|Subjects randomized to the treatment arm will receive two vaccinations with MV-CHIK, a recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. The vaccinations will be provided on days 0 and 28 after enrollment.
3478853|NCT03807843|Placebo Comparator|Placebo Arm|Subjects randomized to the placebo arm will receive two injections of sterile physiological saline. The injections will be provided on days 0 and 28 after enrollment.
3478854|NCT03807830|Other|One arm feasbility study|
3478855|NCT03807882|Experimental|Test group|Bilateral Maintenance ECT (B/L M-ECT)
3478856|NCT03807882|Active Comparator|Control group|Clozapine monotherapy. Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
3478857|NCT03807557|Experimental|Robotic mCIMT group|1 hour unilateral robotic therapy, followed by 30 minutes of functional practice of affected UE using shaping technique, 3/week for 8 weeks and restraint of the unaffected limb at home for 2 hrs per day
3478858|NCT03807557|Active Comparator|Control group|conventional upper extremity rehabilitation training 1.5 hours per session, 3/week for 8 weeks and home exercise 2 hrs per day
3478859|NCT03807869|Experimental|coexisting glaucoma and cataract|Patients with coexisting glaucoma and cataract qualified to combined glaucoma surgery
3478860|NCT03807752|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
3127118|NCT03073876|Experimental|Drug|Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
3127119|NCT03073876|Placebo Comparator|Placebo|"Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment."
3127120|NCT03074162|Experimental|Diclofenac Sodium (A)|
3478861|NCT03807752|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
3478862|NCT03807609|Experimental|CON .|The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
3478863|NCT03807609|Experimental|EX -30.|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
3478864|NCT03807609|Experimental|EX-180|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their appetite feelings will be assessed at regular intervals.
3478865|NCT03807583|No Intervention|Control group|
3478866|NCT03807583|Active Comparator|AMINOVEN® 10%|"The AMINOVEN® 10% comparative product is a drug in the form of a 130 mL intravenous infusion solution. This product is composed of amino acids.~The product is administered per os during the first hour of dialysis sessions for the duration of the study."
3478867|NCT03807583|Experimental|RENORAL®|"The product under study RENORAL® is notified to the DGCCRF with the status of food supplement for medical purposes (FSMP) and specific for renal insufficiency.~The product is a beverage packaged in 150 mL aluminum cans. It contains a liquid solution of native milk proteins and partially hydrolyzed whey proteins."
3478868|NCT03807674|Other|Control group - Healthy teeth|Patients with clinically healthy third molar or premolar teeth with indications for extraction; no clinical signs of pulpitis, no caries, no indications for the replacement of an old filling that is 1 mm from the pulp space as determined on the radiograph; a normal response to the cold test, and no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
3478869|NCT03807674|Experimental|Test group - Teeth with pulpitis|Patients with symptomatic pulpitis resulting from caries; tooth pain defined as sharp, dull, localized or diffuse; pain at night; a symptomatic tooth with a positive response to the cold test and lingering pain; intermittent or continuous episodes of spontaneous pain (with no external stimulus) that could last from a few minutes up to a few hours; no apical radiolucency on the radiograph. For teeth of this group coronal pulpotomy was applied.
3478870|NCT03807635|Experimental|simulation of skin pricking type 450|The evaluator simulated the capillary blood sampling with the safety lancet type 450
3478871|NCT03807635|Experimental|simulation of skin pricking type 610|The evaluator simulated the capillary blood sampling with the safety lancet type 610
3478872|NCT03807570|Experimental|Morus Alba L. extract|Morus Alba L. extract 30 ml/day for 12 weeks
3478873|NCT03807570|Placebo Comparator|Placebo|Placebo 30 ml/day for 12 weeks
3478874|NCT03807206||Flashmob 2019|Patients from the following hospitals will receive a questionnaire/structured intereview: Erasmus MC, Franciscus Gasthuis & Vlietland, Ikazia, Haaglanden Medisch Centrum, Albert Schweitzer ziekenhuis, Jeroen Bosch ziekenhuis, Rijnstate ziekenhuis, Amphia ziekenhuis, Tergooi klinieken, Medisch Spectrum Twente, Reinier de Graaf gasthuis. Pending: Maasstad ziekenhuis
3478875|NCT03807297|Other|TIVA - total intravenous anaesthesia|only intravenous type of anaesthesia using Injection propofol, 10 mg and Injection dexmedetomidine drug infusion will be infused for maintenance of anaesthesia
3478876|NCT03807297|Other|Inhalational anaesthesia|In this group, both nitrous oxide and sevoflurane will be given for maintenance of anaesthesia
3478877|NCT03807219|Active Comparator|Magnox Comfort|80 subjects will be on the Magnox Comfort arm.
3478878|NCT03807219|Placebo Comparator|Placebo|80 subjects will be on the Placebo arm.
3478879|NCT03807284|Experimental|A group psycho-social course|The intervention group received a group psycho-social course, a 2 hour, weekly, eleven week intervention delivered by a health professional working in stroke and usual care.
3127121|NCT03074162|Experimental|Diclofenac & Capsaicin (B)|
3127122|NCT03074162|Active Comparator|Diclofenac Sodium Topical Gel|
3478880|NCT03807284|No Intervention|Control Group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
3478881|NCT03807531|Other|Treatment with TSS|This is a single-arm study. Participating subjects will be treated with the Temporary Spur Stent System (TSS)
3478882|NCT03807310|Experimental|Group Long-drink|"83 COPD patients will receive:~Targeted nutrient supplementation (Long-drink) once daily~Counselling once monthly"
3478883|NCT03807310|Placebo Comparator|Group Placebo|"83 COPD patients will receive:~Isocaloric placebo supplement once daily~Counselling once monthly"
3127123|NCT03074331|Experimental|SOF/VEL|SOF/VEL for 12 weeks
3127124|NCT03074409|Experimental|oxytocin|intranasal administration of oxytocin
3478884|NCT03807310|No Intervention|Healthy control group|30 healthy controls will be included for baseline comparison of the microbiome composition. These healthy controls will only perform a subset of baseline measurements and will not be included in the intervention.
3478885|NCT03807505|Active Comparator|Interscalene nerve block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot interscalene brachial plexus nerve block or an interscalene brachial plexus nerve catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
3478886|NCT03807505|Active Comparator|Erector Spinae Plane block|Patients undergoing rotator cuff repair surgery or total shoulder arthroplasty will undergo a single shot erector spinae plane block or receive erector spinae plane catheter. In the preoperative area, all participants will be asked baseline indicators of pain level via a Numeric Rating Scale (NRS, 0-10, where 0 is no pain and 10 is the worst imaginable pain) and diaphragmatic excursion will be measured bilaterally using ultrasonography before nerve block placement. Motor and sensory exams will also be performed. The same parameters will be measured 30 minutes after the block is performed. In the recovery room, those with nerve catheters will receive a dose of local anesthetic. All patients will have the same parameters measured 30 minutes postoperatively.
3478887|NCT03807375|Other|CPAP|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O. The process will continue until the end-tidal O2 concentration ≥ 90% is removed.
3478888|NCT03807375|No Intervention|standard preoxygenation|During the preoxygenation, the ventilator device will be put in spontaneous mode and the procedure will continue until the End-tidal O2 concentration ≥90% is removed without additional pressure.
3478889|NCT03807362|Experimental|CC-11050 treatment|200mg CC-11050 will be administered twice daily as a pill taken with food (at breakfast and evening meal) for participants with moderate to severe ENL for 10 days, then up to 28 days (during Step 1) and then up to 1 year (during Step 2).
3478890|NCT03807401|Active Comparator|Classical prismatic adaptation|Classical prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
3478891|NCT03807401|Experimental|Virtual prismatic adaptation|virtual prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
3478892|NCT03807401|Experimental|Imaged prismatic adaptation|Imaged prismatic adaptation arm will be divided into two subgroups corresponding to the side of the prismatic displacement (right or left)
3478893|NCT03807492||EMPOWeR Study|This is a cohort study, with initial patient assessments and longitudinal follow-up. Participation of subjects will be indefinite, which will be discussed in the informed consent.
3478894|NCT03807388|Experimental|ReMindCare Intervention Group|"Patients from First Episode of Psychosis Unit who will use ReMindCare app.~ReMindCare is an user-friendly app which conducts daily evaluations of the health status of patients with psychosis by some quick questions that patients will have to answer."
3478895|NCT03807388|Other|Treatment as Usual|Patients from First Episode of Psychosis Unit who will follow psychiatric usual care.
3478896|NCT03807258|Experimental|COPD patients group|COPD patients undergoing transcranial magnetic stimulation (TMS) evaluations.
3478897|NCT03807258|Active Comparator|Controls group|Healthy matched controls undergoing transcranial magnetic stimulation (TMS) evaluations.
3478898|NCT03807518|Experimental|Structured Exercise Intervention|The exercise training program was designed to improve physical fitness while the patients are receiving neoadjuvant treatment prior to surgery and for a 6 week period after surgery once patients are deemed fit to return to training.
3478899|NCT03807518|No Intervention|Standard Oncological Care|This group will receive standard oncological care and will receive no formal education of exercise intervention.
3478900|NCT03807427|Experimental|READY-Nepal|Skills groups based on dialectical behavior therapy principles delivered over 10-12 weeks in a classroom format.
3127125|NCT03074409|Placebo Comparator|placebo|intranasal administration of the same ingredient except oxytocin
3127126|NCT03074500|Experimental|Kinesiotaping|Kinesio taping by using space correction and fascia correction techniques every 3 days for 2 weeks in addition to exercises
3127127|NCT03074500|Sham Comparator|Sham taping|Sham taping without using any techniques every 3 days for 2 weeks in addition to exercises
3478901|NCT03807427|No Intervention|Waitlist Control|Adolescent participants assigned to the control condition will be placed on a waitlist for future enrollment in READY-Nepal. After primary data collection has ceased, those assigned to the control arm will receive the identical READY-Nepal intervention delivered in the experimental condition.
3478902|NCT03807466|Active Comparator|Dynamic/Interactive Report|LTC physician receives dynamic/interactive report only
3478903|NCT03807466|No Intervention|Static/Paginated Report|LTC physician receives static/paginated report only
3478904|NCT03807466|Active Comparator|LTC Physicians Enrolled in Reports|"All LTC physicians who receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
3478905|NCT03807466|No Intervention|LTC Physicians Not Enrolled in Reports|"All LTC physicians who do not receive a dynamic or paginated report~[note: this is not part of randomization assignment, but a quasi-experimental study]"
3478906|NCT03807323|Experimental|'Lifestyle counselling and exercise' .|The study is a single-arm study where all participants undergo the same intervention 'Lifestyle counselling and exercise' .
3478907|NCT03807349|Other|N-Force Screws|N-Force Screws augmented with N-Force Blue in Intracapsular Femur Fractures.
3478908|NCT03807271|Experimental|Smart Pilot(R) View|Anesthesia provided by standard procedure, additionally guided by Smart Pilot(R) View, a device with calculated and graphically produced depth of anesthesia.
3478909|NCT03807271|No Intervention|Standard|Anesthesia provided by standard procedure.
3478910|NCT03807453||Psoriasis Vulgaris patients-Lesion|
3478911|NCT03807453||Psoriasis Vulgaris patients-Lesion free|
3478912|NCT03807453||Seborrheic Dermatitis-Lesion|
3478913|NCT03807453||Seborrheic Dermatitis-Lesion free|
3478914|NCT03807453||Control Group|
3127128|NCT03074500|Other|Control|Stretching and strengthening exercises of wrist
3127129|NCT03074630|Experimental|Dapagliflozin 10mg and Rosuvastatin 10mg|Rosuvastatin 10mg once daily for 9 weeks, with 5 weeks of once daily Dapagliflozin 10mg added
3478915|NCT03807336|Experimental|Experiential Condition|This group will receive an experiential version of the program Emotion-Focused Skills Training for Parents, meaning they will engage in tasks that are supposed to activate the parents emotional system, providing them with a deeper sense of understanding towards their child.
3478916|NCT03807336|Active Comparator|Psychoeducational version|This group will receive a non-experiential, psychoeducational version of the program Emotion-Focused Skills Training for Parents, meaning they will not engage in tasks that are meant to activate the parents emotional system.
3478917|NCT03807479|Experimental|Ponatinib|Patients in this treatment arm receive Ponatinib: starting dose 30 mg once-daily. Doses may be increased in case of inappropriate response and reduced to manage drug-related adverse events (AEs) and may be re-escalated once events resolve.
3478918|NCT03807440||Subjects with Diabetes Mellitus, Type 2|
3478919|NCT03807180|Other|Group of Tai Chi|Group of Tai Chi intervention include 18 patients with AS. Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques, will be applied by an experienced physiotherapist who is trained with Tai Chi. The training will take 60 minutes, 2 days a week and 10 weeks in total.
3478920|NCT03807180|No Intervention|Group of control|Conventional exercises are stretching for the cervical, thoracic and lumbar flexibility, shoulder circumference, hamstring and erector spinal muscles, strengthening exercises for abdominal, back and proximal muscles. The exercises that will be taught in detail to each stage of the patient will be performed at home by the patient for 60 minutes, 2 days a week. The patients will be inspected and controlled by monthly controls.
3478921|NCT03807193|Experimental|Fixed treatment, weekly support|Receives a predetermined treatment program and have weekly support.
3478922|NCT03807193|Experimental|Fixed treatment, support on demand|Receives a predetermined treatment program and have access to support on demand.
3478923|NCT03807193|Experimental|Selected treatment, weekly support|Select their own treatment material and have weekly support.
3478924|NCT03807193|Experimental|Selected treatment, support on demand|Select their own treatment material and have access to support on demand.
3478925|NCT03807167|Experimental|Patients|
3478926|NCT03807167|Active Comparator|healthy controls|
3478927|NCT03807154|Experimental|Internet-based cognitive behavioral therapy (ICBT)|A nine-week long ICBT intervention with therapist support.
3179506|NCT00673530|Experimental|1|evidence based clinical nutrition concept
3478928|NCT03807154|Experimental|Internet-based Interpersonal Therapy (IIPT)|A nine-week long intervention based in interpersonal psychotherapy with therapist support.
3478929|NCT03807154|No Intervention|Wait-list|Wait-list control group
3478930|NCT03807141|Experimental|Diet arm|"Modified Atkins diet will be administered with carbohydrate restriction to 10 grams per day. Proteins will be allowed unrestricted and fats will be actively encouraged.~The ongoing antiepileptic medication will be continued unchanged"
3478931|NCT03807141|No Intervention|Control|The control group will continue their anti-epileptic medication unchanged with no additional dietary input
3478932|NCT03807050|Experimental|Astaxanthin|Astaxanthin capsules containing 50 milligram astaxanthin derived from the yeast Phaffia rhodozyma (Xanthophyllomyces dendrorhous)
3478933|NCT03806985|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
3478934|NCT03806985|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
3478935|NCT03806985|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
3478936|NCT03806985|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
3478937|NCT03806985|Experimental|High Dose Psilocybin/Low Dose Psilocybin|Subjects in this arm receive high dose psilocybin in the first session and low dose psilocybin in the second session.
3478938|NCT03806985|Experimental|Low Dose Psilocybin/High Dose Psilocybin|Subjects in this arm receive low dose psilocybin in the first session and high dose psilocybin in the second session.
3478939|NCT03807102|Experimental|Tumor Vaccine|Injection of NeoAntigen Tumor Vaccine
3478940|NCT03806842|Experimental|Easytech group|patients who require a reverse total shoulder, meet the eligibility criteria and receive the Easytech Reversed Shoulder System
3478941|NCT03806920|Active Comparator|Intervention A|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
3478942|NCT03806920|Active Comparator|Intervention B|"Nutritional intervention in healthy subjects and T2DM subjects:~Accompanying a carbohydrate based breakfast, participants ingest either 50 g palatinose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
3478943|NCT03806920|Active Comparator|Intervention C|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g sucrose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
3478944|NCT03806920|Active Comparator|Intervention D|"Nutritional intervention in healthy subjects:~Accompanying a protein-based breakfast, participants ingest either 50 g isomaltulose followed by a standardized lunch on 1 single day. In addition, blood samples are taken over 8 hours."
3127130|NCT03074682|Experimental|Lifeflow|Participants in this arm will use the Lifeflow device to administer fluid in a simulation in a simulation setting.
3127131|NCT03074682|Active Comparator|Push/Pull|Participants in this arm will use the Push/Pull method to administer fluid in a simulation in a simulation setting.
3179507|NCT00673530|Other|2|care as usual
3179508|NCT00673543||1|Pregnant women with insulin requiring diabetes
3127132|NCT03074682|Active Comparator|Pressure Bag|Participants in this arm will use a Pressure Bag to administer fluid in a simulation in a simulation setting.
3127133|NCT03075085|Active Comparator|Basic WISE strategy|These participants will be asked to implement the basic WISE strategy used in previous studies.
3127134|NCT03075085|Experimental|Enhanced WISE strategy|These participants will be asked to implement the enhanced WISE strategy.
3127135|NCT03075163|Experimental|Acupressure|Manual pressure will be applied on the wrists bilaterally.
3127136|NCT03075163|Active Comparator|Ondansetron|Ondansetron (Zofran) is used for the treatment of nausea and vomiting.
3127137|NCT03075267|Experimental|PT010 (BGF MDI) 320/14.4/9.6 µg|PT010 Budesonide, Glycopyrronium and Formoterol Fumurate Metered Dose Inhaler (BGF MDI) 320/14.4/9.6 µg
3127138|NCT03075267|Experimental|PT010 (BGF MDI) 160/14.4/9.6 µg|PT010 (BGF MDI) 160/14.4/9.6 µg
3179509|NCT00673543||2|Pregnant women without insulin requiring diabetes
3179510|NCT00673556|Experimental|Course A1|
3179511|NCT00673556|Placebo Comparator|Course A2|
3478945|NCT03806816|Experimental|HYPOTHERMIA / MELATONIN group|HIE infants who will receive melatonin in addition to the routine cooling treatment
3478946|NCT03806816|Experimental|HYPOTHERMIA / PLACEBO group|HIE infants who will not receive melatonin in addition to the routine cooling treatment
3478947|NCT03806959|Other|Pan Capsule and colonoscopy|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only
3478948|NCT03806881||Treatment group|Patients treated with a Glenius Glenoid Reconstruction System
3478949|NCT03806933|Experimental|NT 201 Dose group 1|Stage 1 and 2. Intramuscular injection into the glabellar area.
3478950|NCT03806933|Experimental|NT 201 Dose group 2|Stage 1. Intramuscular injection into the glabellar area.
3478951|NCT03806933|Experimental|NT 201 Dose group 3|Stage 1. Intramuscular injection into the glabellar area.
3478952|NCT03806933|Experimental|NT 201 Dose group 4|Stage 2. Intramuscular injection into the glabellar area.
3478953|NCT03806933|Experimental|NT 201 Dose group 5|Open Label Extension Period. Intramuscular injection into the glabellar area.
3478954|NCT03807115|Other|Intervention|Arm: Intervention: Implementation of stroke mobility guidelines
3478955|NCT03807115|No Intervention|Control|Arm: Control: Usual care
3478956|NCT03806998|Experimental|Ketoacid supplementation|Will receive a ketoacid supplement containing 630 mg of ketoacids in a dose of 1 tablet every 5 kg of body weight
3478957|NCT03806998|Placebo Comparator|Placebo|Will receive placebo tablets in a dose of 1 tablet every 5 kg of body weight
3478958|NCT03807076|Other|GIP-A|Infusion of GIP-A alone as a study tool.
3478959|NCT03807076|Placebo Comparator|Placebo|Saline
3478960|NCT03806686|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
3478961|NCT03806686|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
3478962|NCT03806686|Placebo Comparator|Control group|Participants will receive 0.5 mL Placebo (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
3478963|NCT03806712||patient|patient with advanced, non curative hematological malignancies multi method questionary, at least 1 hour per patient
3478964|NCT03806712||hematologist|medical practitioner of platelet transfusion multi method questionary, at least 1 hour per hematologist
3478965|NCT03806712||Nurses|nurses working in hematology, practicing platelet transfusion multi method questionary, at least 1 hour per nurse
3127139|NCT03075267|Experimental|PT003 (GFF MDI) 14.4/9.6 µg|PT003 (GFF MDI) 14.4/9.6 µg
3132699|NCT03446690|Experimental|MI Varnish Group|33 subjects were prospectively recruited for the project in the MI Varnish group. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, UAB. MI Varnish were applied on their teeth initially for 4 weeks (twice) and then 3 monthly intervals.
3478966|NCT03806855||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
3478967|NCT03806855||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
3478968|NCT03807011|Active Comparator|fentanyl|A bolus dose of fentanyl 2 μg/kg was administered intravenously at anesthetic induction
3478969|NCT03807011|Active Comparator|remifentanil|Remifentanil was continuously infused at a rate of 0.2 μg/kg/min from anesthetic induction to the end of surgery
3478970|NCT03807024||OAB-wet|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet.
3478971|NCT03807024||OAB-dry|The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The absence of urgency associated incontinence was defined to be OAB-dry.
3179512|NCT00673556|Experimental|Course B|Open label extension
3179513|NCT00673582|Experimental|1|10 mg/day rosuvastatin for 96 weeks
3478972|NCT03806829|Active Comparator|Water + Meal|250 ml Water and a high calorie, high fat meal (>900 kcal, 50g fat)
3478973|NCT03806829|Experimental|Red Wine + Meal|250 ml Red Wine and a high calorie, high fat meal (>900 kcal, 50g fat)
3478974|NCT03806829|Experimental|Green Tea + Meal|250 ml Green Tea and a high calorie, high fat meal (>900 kcal, 50g fat)
3478975|NCT03806829|Experimental|Orange Juice + Meal|250 ml Orange Juice and a high calorie, high fat meal (>900 kcal, 50g fat)
3179514|NCT00673582|Placebo Comparator|2|Placebo
3478976|NCT03806699|Experimental|Low dose ID93+GLA-SE|Participants will receive 0.5 mL (2 μg ID93 + 5 μg GLA-SE) intramuscular injection (IM) into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
3179515|NCT00673608|Experimental|Deferasirox|
3478977|NCT03806699|Experimental|High dose ID93+GLA-SE|Participants will receive 0.5 mL (10 μg ID93 + 5 μg GLA-SE) IM injection into deltoid area, three times in 4-week intervals on Days 0, 28, and 56.
3478978|NCT03806699|Placebo Comparator|Control group|Participants will receive 0.5 mL (physiological saline) IM injection into deltoid area, three times on 4-week intervals on Days 0, 28, and 56.
3478979|NCT03806673|Active Comparator|primipara|primipara subjected to their first epidural block
3478980|NCT03806673|Active Comparator|multipara|multipara subjected to their repeated epidural block.
3478981|NCT03806751|Experimental|[O-15]water PET/MRI|Volunteers will have two brain PET/MRI scans; first scan after injection of [O-15]water; second scan after injection of 1 gram of acetazolamide followed by injection of [O-15]water.
3478982|NCT03807063|Experimental|Treatment (rivogenlecleucel)|Each subject may receive up to 3 IV infusions of rivogenlecleucel at intervals no less than 28 days apart. Subjects who meet protocol-specified severity criteria for acute GVHD, chronic GVHD, cytokine release syndrome (CRS), prolonged aplasia or encephalopathy will be treated with rimiducid infusion(s).
3478983|NCT03806946||group1|ADHD with normal EEG
3478984|NCT03806946||group 2|ADHD with abnormal EEG
3478985|NCT03806946||group 3|Epilepsy
3127140|NCT03075410|Experimental|Cohort 1- GSK3036656 in Part A|During Part A (Cohort 1), Subjects will receive a single dose of GSK3036656 in the morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. The total daily dose for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The starting dose in Part A will be 5 mg and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
3127141|NCT03075410|Placebo Comparator|Cohort 1- Placebo in Part A|During Part A (Cohort 1), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done in Part A once results from the food effect analysis are available. Placebo for the treatment (dosing) period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group which will be determined based on from previous cohorts. For the food effect assessment, placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
3127142|NCT03075410|Experimental|Cohort 2- GSK3036656 in Part A|During Part A (Cohort 2), Subjects will receive a single dose of GSK3036656 in morning on Day 1 in each period after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. The total dose for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. The dose will be selected on basis of safety, tolerability and PK data from the previous treatment period or cohort and will then be escalated up to a dose no higher than 1500 mg. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the selected dose will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
3179516|NCT00673621|Experimental|1|
3179517|NCT00673634|Active Comparator|1|Standard preoxygenation
3179518|NCT00673634|Active Comparator|2|BiPAP assisted preoxygenation
3179519|NCT00673647|Experimental|1|Individual psychotherapy including cognitive behavioral components, motivational interviewing techniques and case management
3179520|NCT00673647|No Intervention|2|Delayed treatment control group
3179521|NCT00673686|Active Comparator|Arm 2|
3478986|NCT03806946||group 4|Healthy control group
3179522|NCT00673686|Experimental|Arm 1|
3478987|NCT03806946||group 5|ADHD and epilepsy
3478988|NCT03806725||Liver transplant (LTx) candidates with eGFR>=60|Liver transplant candidates with renal function defined by eGFR above or equal to 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement.
3478989|NCT03806725||LTx candidates with eGFR<60|"Liver transplant candidates with decreased renal function.~Defined by eGFR less than 60 ml/min/1.73m2, eGFR is determined by Cystatin C measurement."
3478990|NCT03806764|No Intervention|Retrospective study|Medical records of 250 allo-HSCT recipients will be evaluated retrospectively to determine the incidence and clinical outcomes of CMV viremia post HSCT, including both the direct (CMV disease) and indirect (such as invasive fungal infection, other viral infections, bacterial infection) effects on clinical outcomes.
3478991|NCT03806764|Other|Prospective study|"120 recipients of allo-HSCT will be recruited into the prospective part of the study. Participants will be reviewed pre-transplant, 6, 12, 24 and 52 weeks following HSCT during routine clinical visits. clinical assessment will be made such as CMV viremia, transplant related complications and current medications.~Participants who are at high risk of CMV will have study blood sampling taken to assess immune functions"
3478992|NCT03806595|Experimental|Intranasal lidocaine|1mL of lidocaine 2% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
3478993|NCT03806595|Placebo Comparator|Intranasal normal saline|1mL of saline 0.9% will be instilled in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
3478994|NCT03806777|Experimental|Intra-nasal dexmedetomidine|A single dose of dexmedetomidine, determined by a biased coin algorithm (min: 1 mcg/kg; max: 4 mcg/kg or 200mcg), will be delivered intranasally 45min before an MRI scan.
3478995|NCT03807037|Experimental|Treatment|Mixed tocotrienols 200mg, twice daily (400mg/day)
3478996|NCT03807037|Placebo Comparator|Control|Matching Placebo (Placebo oral capsule)
3478997|NCT03806868|Active Comparator|Intervention group|The Intervention group will receive a voucher for ordering foods (ONLY omega-3 rich foods) weekly (4 times).
3478998|NCT03806868|Sham Comparator|Control group|The Control group will receive a voucher for ordering foods in general (any type of foods) weekly (4 times). Participants will NOT be limited to purchasing foods rich in omega-3.
3478999|NCT03806582|Active Comparator|intervention|intervention with norepinephrine to reach a MAP of 85 mmHg for a maximum duration of 1 hour, observation of the effect on right ventricular function
3479000|NCT03806582|No Intervention|control|control group; treatment according to current standards, observation of the effect on right ventricular function
3479001|NCT03806738|Experimental|Shared Decision Making Questionnaire|"Patients randomized to the intervention arm will receive the intervention-specific Carevive questionnaire, which includes standard questions with additional decision-making questions. These surveys will be repeated every 6 months until the patient has received a TP.~One month or at the next visit following the decision, the patient will be asked to complete a research survey using REDCap."
3479002|NCT03806738|Other|Standard of Care Questionnaire|"Patients randomized to standard of care will receive the standard-of-care Carevive questionnaire used to generate TPs at time of enrollment and then every 6 months for patients with MBC who have not made a treatment decision until a treatment decision is made.~One month or at the next visit following the decision, the patient will be asked to complete a post-treatment survey using REDCap."
3479003|NCT03806894||Jewish communities|Ashkenazi, Sephardi, Ethiopian
3479004|NCT03806894||Arab populations|Muslim, Christian, Druze
3479005|NCT03806621||Rotational Atherectomy|
3127143|NCT03075410|Placebo Comparator|Cohort 2- Placebo in Part A|During Part A (Cohort 2), Subjects will receive a single matching placebo in morning on Day 1 in each of the 4 treatment (dosing) periods after an overnight fast of at least 8 hours. Dosing with food may also be done once results from the food effect analysis are available. Placebo for the treatment period may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same period. One of the 4 dosing periods will be food effect group, determined based on from previous cohorts, where the placebo will be given with a high fat meal. There will be a 2 week washout between doses initially but the washout period may be modified depending on emerging data from previous cohorts. Subjects will be followed up to 2 weeks from the last dose.
3127144|NCT03075410|Experimental|Cohort 3- GSK3036656 in Part B|During Part B (Cohort 3), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from Part A. Subjects will be followed up to 2 weeks from the last dose.
3479006|NCT03806569|Active Comparator|MAC-cbt group treatment for adult ADHD|"The patients will be treated with psychological group treatment for 8 sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process. This will be called Mindfulness, Acceptance and Commitment-Therapy for adult Patients with ADHD"
3479007|NCT03806569|Sham Comparator|Relaxation-group for adult ADHD|"The patients will be treated with a relaxation-treatment, long-time established as Jacobson muscle relaxing technique."
3479008|NCT03806413||Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
3127145|NCT03075410|Placebo Comparator|Cohort 3- Placebo in Part B|During Part B (Cohort 3), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
3132700|NCT03446690|Other|Control group|A control group was comprised of 29 orthodontically treated subjects who received routine treatment and oral hygiene regimes. All subjects will be patients seeking orthodontic treatment at the Department of Orthodontics, School of Dentistry, University of Alabama at Birmingham. No intervention for this group.
3132701|NCT03446781|Active Comparator|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
3132702|NCT03446781|Placebo Comparator|Placebo|Placebo
3479009|NCT03806426|Experimental|Treatment Group A|Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg
3479010|NCT03806426|Placebo Comparator|Treatment Group B|Placebo 500mg
3479011|NCT03806439||Patients undergoing radical cystectomy.|After approval of local ethical committee and patient consent, the study will be done on patients undergoing radical cystectomy surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6, 9 and 12 months after surgery.
3479012|NCT03806478|Experimental|0.5 µg|Intranasal (IN) nanoparticles - 0.5 micrograms. The study is planned to include 1 dose of APH 1105 / 0.5 µg, administered twice a week for 12 weeks, for a total of 24 doses.
3479013|NCT03806478|Experimental|1.0 µg|Intranasal (IN) nanoparticles - 1.0 micrograms. The study is planned to include 1 dose of APH 1105 / 1.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
3479014|NCT03806478|Experimental|2.0 µg|Intranasal (IN) nanoparticles - 2.0 micrograms. The study is planned to include 1 dose of APH 1105 / 2.0 µg, administered twice a week for 12 weeks, for a total of 24 doses.
3479015|NCT03806478|Placebo Comparator|Placebo|Intranasal (IN) Placebo nanoparticles. The study is planned to include 1 dose of placebo drug administered twice a week for 12 weeks, for a total of 24 doses.
3479016|NCT03806452|Experimental|Hydroxycarbamide|"Hydroxycarbamide will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Hydroxycarbamide will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
3479017|NCT03806452|Placebo Comparator|Placebo|"Placebo will be supplied as 100 mg or 1000 mg film-coated tablets. The posology will be based on the patient's body weight (bw). Placebo will be prescribed at a dose of 15 mg/kg bw/day and will be adminitered for 6 months.~Hydroxycarbamide will be administered for 12 months for patients qualified as responders willing to continue to participate in the trial."
3479018|NCT03806465||Feasibility survey|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age. For the midline household survey, this would be restricted to children aged 12-23 months of age.
3479019|NCT03806465||Sentinel hospital surveillance|These will be children living in the vaccinating and in non-vaccinating areas aged less than 5 years of age who are hospitalized in the 18 sentinel hospitals.
3479020|NCT03806465||Community mortality surveillance|These will be children whose deaths are reported in the vaccinating and in non-vaccinating areas aged less than 5 years of age .
3479021|NCT03806530|Active Comparator|Gabapentin + Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
3479022|NCT03806530|Placebo Comparator|Gabapentin + Placebo Ropinirole|Gabapentin 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
3479023|NCT03806530|Placebo Comparator|Ropinirole + Placebo Gabapentin|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole 0.50 mg capsule, once daily for 4 weeks.
3132703|NCT03446846|Experimental|5.0 mg MIN-117|MIN-117 5.0 mg (consisting of two 2.5 mg capsules) orally daily for 6 weeks
3479024|NCT03806530|Placebo Comparator|Placebo Gabapentin + Placebo Ropinirole|Gabapentin placebo 100 mg capsule, once daily for 4 weeks. Ropinirole placebo 0.50 mg capsule, once daily for 4 weeks.
3479025|NCT03806179|Experimental|Betalutin with rituximab treatment|Betalutin administered with lilotomab pre-dose on day 0; rituximab administered weekly x 4 doses from day 7, then every 3 months for 2 years
3479026|NCT03806114|Other|Anterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
3132704|NCT03446846|Experimental|2.5 mg MIN-117|MIN-117 2.5 mg (consisting of one 2.5 mg capsule and one placebo capsule) orally daily for 6 weeks
3479027|NCT03806114|Other|Posterior Approach Precautions|This group receives precautions and have a total hip arthroplasty with a posterior approach.
3479028|NCT03806114|Other|Anterior Approach No Precautions|This group receives does not precautions and have a total hip arthroplasty with an anterior approach.
3479029|NCT03806114|Other|Posterior Approach No Precautions|This group receives does not receive precautions and have a total hip arthroplasty with a posterior approach.
3479030|NCT03806322|Experimental|Cold-pack Group|One group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs
3479031|NCT03806322|Experimental|Intermittent Pneumatic Compression|The second group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression
3479032|NCT03806296|Experimental|Manipulation|"For ~2 weeks, participants will be asked to adhere to the following:~Sleep scheduling--advance bedtime by 1.5 hours ( + sleep duration)~Decrease evening blue light exposure via blue blocker goggles (2 h before bed)~Increase morning bright light exposure via bright light goggles (30 m after rise)~Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
3479033|NCT03806296|Active Comparator|Control|"For ~2 weeks, participants will asked to adhere to the following:~- Monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraph"
3479034|NCT03806335|Experimental|Infiltration|Patients will receive pre-incision infiltration of 2.5 ml local anesthesia mixture in each tonsil.
3479035|NCT03806335|Placebo Comparator|Placebo|Patients will receive pre-incision infiltration of 2.5 ml saline in each tonsil.
3479036|NCT03806075|Experimental|Peutz-Jeghers patients|All Peutz-Jeghers patients meet the clinical criteria
3132705|NCT03446846|Placebo Comparator|Placebo|Placebo (consisting of two placebo capsules) orally daily for 6 weeks
3132706|NCT03446885|Experimental|Lab visit 1|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
3479037|NCT03806075|Placebo Comparator|Health persons|Those without Peutz-Jeghers syndrome
3479038|NCT03806244|No Intervention|PREOP|Navigation without intraoperative acquisition of images: Use of conventional preoperative images (CT-MRI) to establish intraoperative navigation.
3479039|NCT03806244|Experimental|PEROP|Navigation with intraoperative acquisition of images: Intraoperative acquisition (robotic c-Arm) of images to establish intraoperative navigation.
3479040|NCT03806218|Active Comparator|TICW-RFA|Bipolar RFA using twin internally cooled-wet electrodes
3479041|NCT03806218|Active Comparator|SC-RFA|Switching monopolar RFA using separable clustered electrodes
3479042|NCT03806062|Active Comparator|control group|10 mg domperidone 3 times a day after meals) and advice about lactation, nutrition and fluid intake all through the treatment period (4 weeks)
3479043|NCT03806062|Active Comparator|Laser group|"The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session on both breasts.~The mother had one session every other day, three sessions weekly for four weeks. (Total 12 sessions)"
3479044|NCT03806062|Active Comparator|Electro acupuncture group|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze) using surface electrodes
3479045|NCT03806088||patients of chronic kidney disease|no interventions
3479046|NCT03806036|Active Comparator|Vitamin D group|50 women will receive 300.000 I.U single dose of VIT D IM injection (Memphis company) , and in the next menstrual cycle induction done by clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
3479047|NCT03806036|Placebo Comparator|Control group|50 women will receive clomiphen citrate 100mg daily for 5 days starting from third day of menstruation and HMG single dose on 8th day
3479048|NCT03806504|Active Comparator|high PEEP|35 cm/H2O PEEP, 2-3 ml/kg tidal volume,45 seconds, after cardiopulmonary bypass
3479049|NCT03806504|Active Comparator|control group|6 cm/H2O PEEP, 6-8 ml/kg tidal volume, continues, after cardiopulmonary bypass
3479050|NCT03806166|Experimental|Shorter Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by one week or less of systemic antibiotic therapy, for bone and joint infection.
3479051|NCT03806166|Active Comparator|Long Systemic Antibiotics|Participants will receive local antibiotic therapy at the time of surgery, followed by four weeks or more of systemic antibiotic therapy (standard treatment recommended by international guidelines), for bone and joint infection.
3479052|NCT03805997|Experimental|Experimental Group|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
3479053|NCT03805997|Placebo Comparator|Control Group|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
3479054|NCT03805984|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
3479055|NCT03805984|Placebo Comparator|Placebo Comparator Group A|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
3479056|NCT03805984|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA® 2000 device
3479057|NCT03805984|Placebo Comparator|Placebo Comparator Group B|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device
3479058|NCT03805906||Primary group|Ultrasound-Guided L5 Dorsal ramus block
3479059|NCT03805828|Experimental|Expermental|In the intervention group, the educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism.
3479060|NCT03805828|Active Comparator|Control|In the control group, the educational about communicable disease among childhood deliver as a one-day event in four sessions: (1) introduction and background communicable disease of childhood,(2) communicable diseases of childhood (Chicken Pox, Diphtheria,and pertussis[a whooping cough]),(3) communicable diseases of childhood (Measles,Mumps,rubella[German Measles]and Poliomyelitis(,and (4) infection control.
3479061|NCT03805958|Experimental|Pre-procedure|Confirmed landmark by ultrasound scan before procedure
3127146|NCT03075410|Experimental|Cohort 4- GSK3036656 in Part B|During Part B (Cohort 4), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
3132707|NCT03446885|Experimental|Lab visit 2|40 mg of Vyvanse administered q.a.m. or Placebo administered in random, counter-balanced fashion.
3179523|NCT00673699||A|Seventy dyspeptic consecutive patients that going upper gastrointestinal endoscopy
3179524|NCT00673725|Experimental|1|
3479062|NCT03805958|Active Comparator|Real time|Confirmed landmark by ultrasound scan during procedure
3479063|NCT03806023|Experimental|All subjects|All subjects undergo same full protocol, including PNS and TMS at rest and active hand movements (signals from thumb muscle) triggered PNS and TMS.
3479064|NCT03805945|Experimental|dexmedetomidine group|After umbilical cord was cut, a loading dose of dexmedetomidine was pumped at 0.5ug/kg within 10min, followed by a further infusion of dexmedetomidine at 0.5ug /kg/h until the end of the surgery.Then connected with patient-controlled intravenous analgesia pump (dexmedetomidine 2ug/kg + sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
3479065|NCT03805945|Placebo Comparator|control group|Continuous infusion of saline after the umbilical cord was cut until the end of the operation.Then connected with patient-controlled intravenous analgesia pump (sufentanil 1.5ug/kg + dolasetron 25mg/100ml saline).
3179525|NCT00673751|Placebo Comparator|2|subcutaneous isotonic saline
3479066|NCT03805854|Experimental|Transcranial alternating current stimulation (tACS)|
3479067|NCT03805802|Experimental|active product|Once daily ad libitum consumption of one package of the fiber product 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
3479068|NCT03805802|Placebo Comparator|reference product|Once daily ad libitum consumption of one package of placebo during 6 weeks (blinded phase). Once daily ad libitum consumption of one package of the fiber product 6 weeks (open phase).
3479069|NCT03806010||Quantitative sensory testing|QST will be performed at baseline two weeks and 2 months
3479070|NCT03806140|Active Comparator|Intervention group|Receive daily text messages
3479071|NCT03806140|No Intervention|Control group|No text messages, only written educational materials
3479072|NCT03806348|Experimental|Resuturing|Early resuturing of perineal wound dehiscence. Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
3479073|NCT03806348|No Intervention|Conservative treatment|Antibiotics: Amoxicillin 500 mg, Clavulanic Acid 125 mg and Metronidazole 400 mg by mouth, every 8 hours, for at least 6 Days.
3479074|NCT03805763|Experimental|Large extent of ILM Peeling|Extent of ILM peeling is 4DD and the ILM flap is inserted
3479075|NCT03805763|Experimental|Small extent of ILM Peeling|Extent of ILM peeling is 2DD and the ILM flap is inserted
3179526|NCT00673751|Active Comparator|1|subcutaneous GLP-2
3179527|NCT00673777|Experimental|A|
3479076|NCT03806374|Active Comparator|Fentanyl|Administered propofol and fentanyl for induction.
3479077|NCT03806374|Active Comparator|Ketamine and lidocaine|Administered propofol, ketamine and lidocaine for induction.
3479078|NCT03805724||Periodontally healthy subjects|They will be selected from healthy subjects who attend the restorative dental clinic and has clinically healthy gingiva with zero plaque index, gingival index and clinical attachment level & probing depth ≤ 3 mm. Plaque samples will be collected.
3479079|NCT03805724||Chronic Periodontitis|Chronic periodontitis patients having probing depth of ≥3 mm and clinical attachment level ≥ 1 mm. Plaque samples will be collected.
3479080|NCT03805724||Chronic Gingivitis|Gingivitis patients having signs of clinical inflammation with no clinical attachment loss. Plaque samples will be collected
3479081|NCT03805776|Experimental|Interventional|Will observe intermittent fasting
3479082|NCT03805776|No Intervention|Control|
3479083|NCT03806192|Experimental|Group A (psychoeducational counseling sessions via telephone)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via telephone.
3479084|NCT03806192|Experimental|Group B (psychoeducational counseling sessions in person)|Participants attend 5 psychoeducational counseling sessions over 30-60 minutes via video teleconference.
3479085|NCT03806101|Experimental|Arm 1|Single dose of rosuvastatin on Day 1 of Period 1 and Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 2.
3479086|NCT03806101|Experimental|Arm 2|Single dose of rosuvastatin on Day 1 + PF-04965842 on Days 1 to 3 of Period 1 and single dose of rosuvastatin on Day 1 of Period 2.
3479087|NCT03806153|Active Comparator|Conventional morphology arm (reference method)|
3479088|NCT03806153|Experimental|Morphokinetic arm|
3479089|NCT03806049|Experimental|A: triplet|chemotherapy-free combination of niraprib + bevacizumab + Dostarlimab
3479090|NCT03806049|Experimental|B: Doublet|chemotherapy-free combination of niraparib + bevacizumab
3479091|NCT03806049|Active Comparator|C: standard of care|Standard of care chemotherapy: Carboplatin + paclitaxel
3479092|NCT03805516|Experimental|Intervention|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly SCOPP-CW educational modules delivered via WeChat.~6 bi-weekly WeChat tailored messages based on based on the participant's tracker information, personal goals, and preferences"
3479093|NCT03805516|Active Comparator|Control|". Daily use of a Fitbit Alta HRTM to identify behavior patterns.~12 weekly non-tailored educational modules on general health topics delivered via WeChat."
3479094|NCT03805698|Experimental|Platelet-rich Plasma (PRP) group|"Twenty-four (24) subjects undergoing arthroscopic debridement for TFCC tears will be treated intraoperatively with PRP (24 subjects).~Intervention: use of Cascade device; Autologous Fibrin & Platelet System; once processed, the PRP is injected into the debrided wrist"
3479095|NCT03805698|Active Comparator|Standard Treatment group|"Twenty-four (24) subjects undergoing arthroscopic debridement for TFCC tears will undergo treatement, as is standard of care, followed by no treatment with PRP (24 subjects).~Intervention: No PRP injection into debrided wrist"
3479096|NCT03805594|Experimental|Schedule 1 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Beginning in cycle 2, patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
3479097|NCT03805594|Experimental|Schedule 2 (lutetium Lu 177-PSMA-617, pembrolizumab)|Patients receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
3479098|NCT03805594|Experimental|Schedule 3 (lutetium Lu 177-PSMA-617, pembrolizumab)|Starting day -21, patients receive pembrolizumab IV over 30 minutes. Patients also receive lutetium Lu 177-PSMA-617 IV over 20-30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients who achieve SD or better may receive 17 additional cycles (approximately 1 year) of pembrolizumab.
3479099|NCT03805737|Experimental|Indoor Daylight PDT Therapy|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will be exposed to natural sunlight through a window for 2 hours. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
3479100|NCT03805737|Active Comparator|FDA Approved Standard Light Therapy Treatment|Ameluz will be applied to skin. This will be followed by a 30-minute incubation period. Subsequently, you will receive Red Light Treatment for 10 minutes. Post-treatment assessments will be performed and you will be given instruction on appropriate sun protection methods.
3479101|NCT03805607|Placebo Comparator|Placebo|1 ml of normal saline
3479102|NCT03805607|Experimental|Ketorolac|30 mg of ketorolac in 1 ml
3479103|NCT03805568|Active Comparator|dexmedetomidine infusion group|dexmedetomidine infusion (loading dose of 1 ㎍/kg over 10 min and continuous infusion of 0.3-0.6 ㎍/kg/h) during the surgery
3479104|NCT03805568|Active Comparator|remifentanil infusion group|remifentanil of 4 ng/ml during induction, followed by remifentanil infusion (1.5~2.5 ng/ml) during the surgery
3479105|NCT03805633||Sarcoidosis Patients|Patients referred to UAB Pulmonology who are diagnosed with sarcoidosis.
3479106|NCT03805633||Diabetes Patients|Patients followed by UAB Endocrinology with diabetes mellitus.
3479107|NCT03805633||Sarcoidosis and Diabetes patients|Patients followed by UAB Pulmonary and/or UAB Endocrinology with both sarcoidosis and diabetes mellitus.
3479108|NCT03805711|Experimental|Aortic Valve Replacement with HLT® Transcatheter System|Replacement of aortic valve using the HLT® Transcatheter System (HLT System) comprised of The Meridian® II Valve with TriVent™ Anticalcification Treatment and The Pathfinder® II Delivery System
3479109|NCT03805399|Experimental|pyrotinib with capecitabine|If patients were LAR subtype with HER2 gene activated mutation
3479110|NCT03805399|Experimental|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype without HER2 gene activated mutation, but had PIK3CA mutation, enter into arm B1; If patients were LAR subtype without HER2 gene activated mutation or PIK3CA mutation, enter into arm B2
3479111|NCT03805399|Experimental|anti PD-1 with nab-paclitaxel|If patients were IM subtype(CD8 positive T cell more than 20%)
3132708|NCT03447015|Experimental|Ambulation during labour|"women will be encouraged to ambulate Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
3132709|NCT03447015|No Intervention|Standard Maternity care|women will receive usual maternity care.
3132710|NCT03447249|Placebo Comparator|Placebo|Participants who received placebo matched to VX-659/TEZ/IVA for 24 weeks in the TC treatment period.
3479112|NCT03805399|Experimental|PARP inhibitor included therapy|If patients were BLIS subtype and had a BRCA gene pathogenic mutation
3479113|NCT03805399|Experimental|BLIS with anti-VEGFR included therapy|If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation
3479114|NCT03805399|Experimental|MES with anti-VEGFR included therapy|If patients were MES subtype and without PI3K/AKT pathway activation
3479115|NCT03805399|Experimental|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation
3479116|NCT03805620|Active Comparator|Phys Group|physical training group
3479117|NCT03805620|Active Comparator|Cog Group|cognitive training group
3479118|NCT03805620|Experimental|Phys-Cog Group|combined physical-cognitive training group
3479119|NCT03805620|No Intervention|Con Group|educational control group
3479120|NCT03805555|Active Comparator|Radiofrequency ablation|Best radiofrequency ablation
3479121|NCT03805555|Experimental|Cryoballoon ablation|Best cryoballoon ablation
3479122|NCT03805295|Experimental|Spring 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Winter-Spring 2018. They will serve as the control group in Fall 2018.
3479123|NCT03805295|Experimental|Fall 2018 Participation|Students in this arm (40 per school, up to 120 total) will participate in the BOKS program in Fall 2018.
3479124|NCT03805646|No Intervention|No Mobile Phone-administered Triage Tool|For each hospital site: Baseline data will be collected for six months.
3479125|NCT03805646|Experimental|Mobile Phone-administered Triage Tool|"For each hospital site: After the first six months of baseline data collection, the mobile phone-administered triage tool (or Mobile Phone-based Triage Tool) will be implemented for a year."
3479126|NCT03805282|Experimental|Female 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
3479127|NCT03805282|Active Comparator|Male 18 to 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
3479128|NCT03805282|Active Comparator|Male > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
3479129|NCT03805282|Active Comparator|Female > 60 years old|This adaptive dose-finding group will receive continuous infusion lidocaine using the biased coin method for finding the 95% effective dose (ED95%) for cough suppression. All patients will also receive remifentanil 0.025mcg/kg.h during emergence.
3479130|NCT03805542|No Intervention|Control group|I-stage nephrostomy（Double J stent placement under cystoscopy） and II-stage operation
3479131|NCT03805542|Experimental|I-stage operation group|Disinfection of pelvis with 0.5% iodophors
3479132|NCT03805477|Experimental|Nintedanib|Nintedanib 150 mg Kps bid (oral)
3479133|NCT03805464|Experimental|Knee Joint Effusion|Participants will receive a one-time injection of 60mL of sterile saline into the suprapatellar space of the dominant lower extremity. This injection will be conducted under ultrasound guidance by a board-certified orthopedic surgeon.
3479134|NCT03805360|Sham Comparator|ESP block with normal saline|An erector spinae plane block will be performed and a single dose of Normal Saline Flush, 0.9% Injectable Solution will be administered into the target muscle plane.
3127147|NCT03075410|Placebo Comparator|Cohort 4- Placebo in Part B|During Part B (Cohort 4), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
3179528|NCT00673803|Other|A|cataract surgery, implantation of a Polylens Y10
3479135|NCT03805360|Experimental|ESP block with local anesthetic|An erector spinae plane block will be performed and a single dose of 0.5% ropivacaine will be injected into the target muscle plane.
3479136|NCT03805503|Experimental|chloroprocaine 1% injectable solution|"Prospective, up-down sequential allocation : first patient receives 50mg intrathecal chloroprocaine 1%.~An effective result will decrease the test dose of chloroprocaine with 2 mg for the next patient in this study.~An ineffective result will increase the test dose of chloroprocaine with 2 mg for the next patient in this study."
3479137|NCT03805308|No Intervention|Medical Management|Patients randomized to the medical therapy arm will receive standard medical therapy based on current AHA guidelines.
3479138|NCT03805308|Experimental|Intra-arterial Therapy|For patients randomized to the intra-arterial therapy arm, sites will use local protocols for femoral access, sedation, heparin infusion, monitoring, etc. Mechanical thrombectomy will be performed with FDA-approved thrombectomy devices in accordance with the IFU.
3479139|NCT03805178|Experimental|Rejection post-transplant|Treatment with Belatacept and Carfilzomib for subjects who show evidence of antibody-mediated rejection (AMR) following lung transplantation.
3479140|NCT03805178|Experimental|Pre-transplant desensitization|Treatment with Belatacept and Carfilzomib for subjects with elevated human leukocyte antigen (HLA) antibodies prior to lung transplantation.
3479141|NCT03805425|Experimental|Photorefractive intrastromal corneal crosslinking (PiXL)|Patients undergo PiXL where the UVA light is delivered in customized patterns and corneal changes are achieved. For hyperopia, a ring shape irradiation is used to steepen the central cornea. An oxygen mask is used to enhance the crosslinking efficacy. A dedicated riboflavin formulation penetrates the corneal stroma. Pulsed UVA light with oxygen triggers the covalent bonds of collagen strands in riboflavin soaked cornea.
3479142|NCT03805269|Experimental|TAP block|USG guided TAP block
3479143|NCT03805269|Active Comparator|wound infiltration|local anesthetics infiltration at surgical incision site
3479144|NCT03805126|Experimental|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
3479145|NCT03805126|Active Comparator|Usual Care|Usual care includes consultation with a social worker and a community health worker.
3479146|NCT03805347|Experimental|Medication|Extract of Helminthostachys zeylanica(L.)Hook in capsule, 1gm/time, 3 times daily
3479147|NCT03805347|Placebo Comparator|Starch|Starch in capsule，1gm/time, 3 times daily
3479148|NCT03805139|Experimental|Ajwa Dates group|55-65gms Ajwa dates 7 days a week for 6 weeks
3479149|NCT03805139|No Intervention|Control|No intervention
3132711|NCT03447249|Experimental|VX-659/TEZ/IVA TC|Participants who received VX-659 240 mg/TEZ 100 mg/IVA 150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
3179529|NCT00673803|Other|B|cataract surgery, implantation of a Polylens Y30
3479150|NCT03805113|Experimental|Intervention group|Treatment with magnetotherapy device 15 20-minute-sesions every consecutive working day.
3479151|NCT03805113|Placebo Comparator|Control group placebo|Treatment with misconnected magnetotherapy device 15 20-minute-sesions every consecutive working day.
3479152|NCT03805412|Active Comparator|DEXCOM G6 RT-CGM|These participants will wear blinded continuous glucose monitoring for 10 days at baseline and 14 weeks. They will also complete real-time continuous glucose monitoring (RT-CGM) for 10 days at 2 weeks and 6 weeks. They will receive Nutrition and exercise counseling at week 2 and 6. They will also receive additional training on continuous glucose monitoring.
3479153|NCT03805412|No Intervention|Blinded CGM|These participants will have blinded continuous glucose monitoring(CGM) at the baseline and last 14 weeks. They will not wear continuous glucose monitoring at the interim appointments. They will receive 2 session of nutrition and exercise counseling at week 2 and 6.
3479154|NCT03805022|Experimental|Arm A|"Control-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 3 cycles in neoadjuvant setting.~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
3479155|NCT03805022|Experimental|Arm B|"Experimental-Arm phase III high-risk CINSARC:~Patients will be treated by doxorubicin (60-75mg/m² day or 20-25 mg/m² per day from day1 to day 3) + ifosfamide (7,5-9 g/m² over 3 days with mesna and G-CSF) of a 21-days cycle for up to 6 cycles in neoadjuvant setting.~Neoadjuvant chemotherapy will be followed by surgery. If indicated, radiotherapy could be prescribed at the discretion of the investigator (in neoadjuvant or adjuvant setting)."
3479156|NCT03805022|Experimental|Prospective cohort|Patients will be treated at the discretion of the investigator
3479157|NCT03805334|Experimental|Touchpoints|Subjects will wear Touchpoints devices on both ankles daily for 10 days. The devices will be worn ~1 hour before bedtime and through the night. They will be removed upon waking in the morning.
3479158|NCT03804957|Active Comparator|CT-guided core needle biopsy (CNB)|18 gauge ct-guided lung biopsy
3479159|NCT03804957|Experimental|CNB followed by ABPI.|17 gauge coaxial needle for a 18g ct-guided lung biopsy followed by autologous blood patch injection
3479160|NCT03804970|Experimental|Intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+ Having the Diabetic Club+Watching brief video and basic explanation for disease
3179530|NCT00673829|Experimental|Phase Ia|
3179531|NCT00673829|Experimental|Phase Ib: Control|
3479161|NCT03804970|Experimental|Adjusted intervention group|Cash rewards for the fellow up+SMS reminders for participants and their family+Showing retinal photos to participants+Having the Diabetic Club+Watching brief video and basic explanation for disease( But the intensity of intervention based on the severity of diabetic disease)
3479162|NCT03804970|Active Comparator|Control group|Watching brief video and basic explanation for disease
3479163|NCT03805087|Experimental|Coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
3479164|NCT03805061|Active Comparator|Aerobic exercise group|Group 1 was 'aerobic exercise group'. Patients in this group were included in an aerobic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed for a period of ; 8 weeks, 3 days a week, 30-45 minutes each patient according to the progressive exercise method. 5-10 minutes warm-up exercise was performed before starting to work, 5-10 minutes stretching exercise at the end of the exercise.
3479165|NCT03805061|Active Comparator|Isokinetic exercise group|Group 2 was 'isokinetic exercise group'. Patients in this group were included in an isokinetic exercise rehabilitation program that they would apply for 3 days per week for 8 weeks. Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low resistance for 5 minutes before starting to exercise, and exercise was applied for 5-10 minutes to cool down at the end of the study.
3479166|NCT03804931|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation
3479167|NCT03804931|Sham Comparator|placebo fecal microbiota transplantation|Infusion of Saline
3479168|NCT03804931|Other|Traditional treatments|Drug:5-Aminosalicylic acid(5-ASA) and/or Prednisone
3479169|NCT03805100|Experimental|Xlucane|Xlucane (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
3479170|NCT03805100|Active Comparator|Lucentis|Lucentis (0.05 mL of 10 mg/mL ranibizumab) in the study eye monthly for 52 weeks.
3479171|NCT03805152|Active Comparator|Neuronox(R) intramuscular injection|Neu-botulinum Toxin Type A (Neuronox(R) - botulinum toxin type A product by medyceles company , Korea) 50 units Intramuscular injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks ( 2 times , 12 week interval)
3479172|NCT03805152|Active Comparator|Dysport (R) intramuscular injection|Abo-botulinum Toxin Type A (Dysport (R) - botulinum toxin type A product by IPEN company, France ) 250 unit Intramuscular Injection in the affected neck muscle that cause cervical dystonia every 12 weeks for 24 weeks (2 times , 12 week interval)
3479173|NCT03805451|Experimental|Life Steps for PrEP for Youth|Life Steps for PrEP for Youth was derived from our prior PrEP work supported by the National Institute of Mental Health and will be tailored for YMSM/TWSM based on the findings from 20 qualitative interviews with YMSM and TWSM and 10 qualitative interviews with key informants. It will likely consist of four weekly sessions at the time of PrEP initiation and two booster sessions, which occur two and three months after PrEP initiation. Overall, the core components of the intervention will focus on medication adherence, sexual behavior, and problem solving barriers to adherence, using motivational interviewing when needed.
3179532|NCT00673842|Experimental|Implantable Cardioverter Defibrillator + Usual Care|Medtronic ICD
3479174|NCT03805451|No Intervention|Standard of Care|After being prescribed PrEP, participants will receive standard-of-care adherence support for PrEP. They will have blood collected for medication adherence measures and will complete computer assisted behavioral surveys during study visits. Participants in this arm will also be followed for 6 months.
3479175|NCT03805009|Experimental|Robotic Group (RG)|Robotic Group (RG) will perform, in addition to conventional therapy, gait training using an end-effector robotic device for Robot-Assisted Gait Training (RAGT), 3 times/week for 20 sessions. During the training, patients will be asked to walk, at a varying speed, for 45 minutes and a partial Body Weight Support (BWS). Participants will start with 30-40% of BWS and an initial speed of 1.5 km/h; increasing to a maximum of between 2.2 and 2.5 km/h and reducing the initial BWS to 15%. The therapist will provide any help during sessions if required. Over 45 minutes, the patient simulates a minimum of 300 steps; patients could rest during the session, though they will be asked to walk continuously for a minimum of 5 minutes during each session.
3479176|NCT03805009|No Intervention|Conventional Group (CG)|Conventional Group (CG) will perform conventional gait rehabilitation program. The treatment will include: muscle strengthening exercises and stretching of the lower limb, and static and dynamic exercises for the recovery of balance in the supine and standing positions using assistive devices; training gait exercises with parallel bars or in open spaces performed both with and without assistive devices; training to climb up and down stairs; exercises to improve proprioception in the supine, sitting and standing positions, using a proprioceptive footboard; exercises to improve trunk control.
3479177|NCT03804853|Experimental|Immediate Active Shoulder Rehabilitation|
3479178|NCT03804853|Active Comparator|Traditional Should Rehabilitation|
3479179|NCT03804944|Active Comparator|ARM 1|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
3479180|NCT03804944|Active Comparator|ARM 2|Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
3479181|NCT03804944|Active Comparator|ARM 3|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days + Focal hypo-fractionated radiation therapy - 8 Gy x 3 fractions starting day 8, (every other day (M/W/F or W/F/M or F/M/W).
3479182|NCT03804944|Active Comparator|ARM 4|Ftl-3 ligand, self administered subcutaneous injections at day 1 for 5 consecutive days+ Focal hypo-fractionated Radiation therapy starting day 8, - 8 Gy x 3 fractions, every other day (M/W/F or W/F/M or F/M/W). + Pembrolizumab, on day 12 (last day of radiotherapy), 200mg IV infused over 30 minutes then repeated every 3 weeks until disease progression or unacceptable toxicity.
3479183|NCT03805035|Sham Comparator|sham EA group|Minimal needling at ST36 and GB34 (n=10)
3479184|NCT03805035|Experimental|true EA group|EA at ST36 and GB34 (n=10)
3479185|NCT03805035|Active Comparator|EA+antihistamine(low dose) group|EA at ST36 and GB34 plus low-dose chlorpheniramine( Dexchlorpheniramine maleate 2mg/tab, 1 tab; n=10)
3479186|NCT03805035|Active Comparator|EA+antihistamine(high dose) group|EA at ST36 and GB34 plus high-dose chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 2 tabs; n=10)
3479187|NCT03805048|Other|Native Vessel PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the native vessel will be performed according to current standard. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using four complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation and retrograde dissection reentry.
3479188|NCT03805048|Other|Graft PCI|All patients with a significant stenosis (>50% on coronary angiography) in a venous bypass graft discussed in the local heart team for revascularization will be screened for potential inclusion in the study. Percutaneous coronary intervention of the bypass graft will be performed following current standards and at the discretion of the operating interventional cardiologist. Only commercially available second generation DES will be used in the treatment of bypass grafts. The second generation DES used in this study will be the XIENCE Sierra stent. The use of a filter-wire during the procedure will be left at the discretion of the operator.
3132712|NCT03447314|Experimental|Part 1a: 50ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 50 nanogram (ng) intravenously (IV) on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3174998 24 milligram (mg) administered at 3-week intervals (Q3W) via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
3479189|NCT03804983|Active Comparator|Hybrid Closed Loop (HCL)|Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ with Hybrid Closed Loop (HCL) or the Control-IQ with MyTDI. Participants randomized to Control-IQ, participants will continue using their home insulin parameters during the ski admission and then 5 additional days at home.
3479190|NCT03804983|Experimental|Control-IQ with MyTDI|"Eligible participants will be screened and enter the data collection period for approximately 5 days at home. Prior to participating in the 72-hour ski admission, participants will be randomized 1:1 to the use of Control-IQ or the Control-IQ with MyTDI. Participants randomized to Control-IQ with MyTDI, participants will be adjusted as noted below during the ski admission and will then continue these parameters for 5 additional days at home:~A single basal rate equal to total daily insulin (TDI)/48 will be implemented across the whole day~A single correction factor (CF) of 1650/TDI will be implemented across the whole day~Carbohydrate ratios (CR) will be set at:~00:00-04:00 CR=450/TDI~04:00-11:00 CR=360/TDI~11:00-00:00 CR=450/TDI TDI will be set at the internal Control-IQ estimation total daily dose; if not available, total daily dose over the last 5 days will be used."
3479191|NCT03804866|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
3479192|NCT03804866|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
3479193|NCT03804788|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for six (6) weeks.
3479194|NCT03804788|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants.
3479195|NCT03804905|Experimental|Drug cards|Eligible patients of physicians allocated to the drug cards arm will receive drug cards from their physician.
3479196|NCT03804905|No Intervention|Usual care|Eligible patients of physicians allocated to the usual care arm will continue to access their medications through self-pay or other mechanisms.
3479197|NCT03804814|Active Comparator|Motivational Interviewing Training|Health care providers will be trained in motivational interviewing for use in Hepatitis C patient encounters.
3479198|NCT03804814|No Intervention|Standard Clinical Encounter|Health care providers will not be trained in motivational interviewing for use in Hepatitis C patient encounters.
3479199|NCT03804801|Experimental|Intervention Arm (or Group)|This arm will receive the intervention (Hibiscus Sabdariffa extract supplement)
3479200|NCT03804801|No Intervention|Control Arm (or Group)|This arm will receive no intervention whatsoever, not even placebo
3479201|NCT03804892|Experimental|Acipimox ingestion|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test. Following this, participants will ingest 250 mg of Acipimox, before undertaking 45 minutes walking on a treadmill. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
3479202|NCT03804892|Other|No drug|Participants will undergo pre assessment testing of a body composition (DEXA), a maximal aerobic fitness test, and an oral glucose tolerance test.Participants will then undergo a 45 minute walk on a treadmill with no Acipimox ingestion. A muscle biopsy will be taken pre, immediately post and 3 hours post the walking trial. Blood samples will be taken at regular intervals throughout.
3479203|NCT03804840|Placebo Comparator|Placebo|
3479204|NCT03804840|Active Comparator|7.5 mg THC|
3479205|NCT03804840|Active Comparator|15 mg THC|
3479206|NCT03804775||case group|patients presenting with gallstone disease
3479207|NCT03804775||control group|inpatients with no history of gallstones
3479208|NCT03804697|Experimental|selective anticoagulation group|"Selective anticoagulation group used anticoagulant when thromboelastogram（TEG） indicated hypercoagulability.~TEG was performed 1 day before the surgery, 1 day after the surgery, 3 days after the surgery, and 5 days after the surgery.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
3479209|NCT03804697|Active Comparator|conventional anticoagulation group|"The Intervention for conventional anticoagulation group was using anticoagulant until one month after surgery routinely.~The dosage regimen of anticoagulant was hypodermic injection 0.4 ml low molecular weight heparin per day for 5 days and oral administration of 10 mg Rivaroxaban until one month after the surgery."
3479210|NCT03804762|Experimental|patients received treatment of TS-RECS|
3479211|NCT03804749|Experimental|Group 1-1|The dose of suramin sodium is 10 mg/kg
3479212|NCT03804749|Placebo Comparator|Group 1-2|The placebo is 0.9% sodium chloride injection
3479213|NCT03804749|Experimental|Group 2-1|The dose of suramin sodium is 15mg/kg
3479214|NCT03804749|Placebo Comparator|Group 2-2|The placebo is 0.9% sodium chloride injection
3127148|NCT03075410|Experimental|Cohort 5- GSK3036656 in Part B|During Part B (Cohort 5), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
3127149|NCT03075410|Placebo Comparator|Cohort 5- Placebo in Part B|During Part B (Cohort 5), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
3479215|NCT03804749|Experimental|Group 3-1|The dose of suramin sodium is 20mg/kg
3479216|NCT03804749|Placebo Comparator|Group 3-2|The placebo is 0.9% sodium chloride injection
3479217|NCT03804736|Active Comparator|FMT-c|Patients in this arm received FMT-c (15 capsules every 12 h for 2 days)
3479218|NCT03804736|Experimental|FMT-c lactobacillus|Patients in this arm received FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
3479219|NCT03804476|Experimental|AER-271|The experimental drug AER-271 will be administered in this Arm. In Part A single ascending doses will be administered by IV bolus infusion of AER-271 formulated in phosphate buffered normal saline over a 30-min period. In Part B multiple ascending doses of AER-271 will be administered by IV 30-min bolus infusion BID for 72 hours. AER-271 will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours.
3479220|NCT03804476|Placebo Comparator|Placebo|A placebo control will be administered in this Arm. In Part A phosphate buffered normal saline will be administered over a 30-min period. In Part B multiple doses of phosphate buffered normal saline will be administered by IV 30-min bolus infusion BID for 72 hours. This placebo will also be administered as an initial bolus dose over 30-min then continuous infusion over 72 hours. In both Parts, the volume of placebo administered will be the same as the Experimental Arm.
3132713|NCT03447314|Experimental|Part 1a: 100ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
3479221|NCT03804580|Experimental|osimertinib|All patients recieve osimertinib
3479222|NCT03804398|Experimental|optimal PEEP group|The study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained
3479223|NCT03804398|Active Comparator|PEEP level of 5 cmH2O group|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
3479224|NCT03804515|Experimental|14C-labeled Poziotinib|
3479225|NCT03804489|Experimental|Decision aids group|Shared decision making using decision aids,
3127150|NCT03075410|Experimental|Cohort 6- GSK3036656 in Part B|During Part B (Cohort 6), Subjects will receive a single dose of GSK3036656 once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive repeat single dose of GSK3036656 once daily over a period of 14 days. Dosing with food may also be done if there are PK or tolerability reasons making it preferable to dose in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours on discretion of the GSK study team and the principal investigator. Appropriate dose and dose regimen will be selected on available safety, tolerability and PK data from preceding repeat dose cohorts from Part B. Subjects will be followed up to 2 weeks from the last dose.
3127151|NCT03075410|Placebo Comparator|Cohort 6- Placebo in Part B|During Part B (Cohort 6), Subjects will receive a single matching placebo once daily in morning on Day 1 after an overnight fast of at least 8 hours. Subjects will receive a placebo once daily over a period of 14 days. Dosing with food may also be done if the active treatment is given in a fed state (dose will be given with a high fat meal.). The total dose may also be divided into 2 or 3 smaller doses administered within 24 hours in a similar manner if divided for subjects receiving active treatment in the same cohort. Subjects will be followed up to 2 weeks from the last dose.
3479226|NCT03804489|No Intervention|Control group|Standard oral explanation with booklet.
3479227|NCT03804463|Experimental|radical surgery group|Endometrial cancer radical surgery to be administered in this arm.
3479228|NCT03804463|Experimental|fertility preservation group|Fertility-sparing surgery to be administered in this arm.
3479229|NCT03804463|Experimental|ovarian preservation group|Ovarian preservation surgery to be administered in this arm.
3479230|NCT03804450|Experimental|Test group|The root canals were instrumented using Pro-taper next rotary files till size X3. REPs via blood clot using calcium hydroxide were then applied
3479231|NCT03804450|Experimental|Control group|The root canals were instrumented using Pro-taper next rotary files till size X5. REPs via blood clot using calcium hydroxide were then applied.
3479232|NCT03804385|Other|intercostal tube|insertion of intercostal tube is surgical operation used in pneumothorax
3479233|NCT03804606|Experimental|High benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
3479234|NCT03804606|No Intervention|High benefit, no MTM|This arm will comprise patients with heart failure who are predicted to receive high benefit (reduction in mortality risk) by addressing open care gaps. Following randomization, they will continue to receive clinical standard-of-care: regular follow-ups with Community Medicine (every 3 months) and Cardiology (every six months). Importantly, these individuals are eligible for referral to MTM at the discretion of their physicians.
3479235|NCT03804606|Active Comparator|Low benefit, MTM|This arm will comprise patients with heart failure who are predicted to receive low benefit (reduction in mortality risk) by addressing open care gaps. They will be selected based on age, sex, and risk-matching to the High benefit, MTM arm. They will be referred to MTM pharmacy for review of treatments in an attempt to close appropriate care gaps.
3479236|NCT03804372|Experimental|Study group|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
3479237|NCT03804541|Experimental|[14C]Ensartinib|To investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose (200mg, 100µCi) of [14C]Ensartinib to healthy Chinese male subjects。
3479238|NCT03804554||Patients taking nivolumab|
3479239|NCT03804502|Experimental|TearCare|Subjects will receive one TearCare treatment at the baseline visit
3479240|NCT03804671|Experimental|All Subjects|Test treatment T followed by Reference treatment R
3479241|NCT03804619|Experimental|Left DLPFC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the left dorsolateral prefrontal cortex (L-DLPFC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
3479242|NCT03804619|Experimental|ACC aiTBS stimulation|Participants will receive aiTBS (intermittent theta burst stimulation) to a brain area called the anterior cingulate cortex (ACC). Stimulation intensity will be individualized according to the individual's resting motor threshold.
3479243|NCT03804528|Experimental|Exercise group|Each participant will engage in 60 minute daily sessions delivered 3 times/week for 8 consecutive weeks (a total of 24 sessions).
3479244|NCT03804684|Experimental|Healthy Controls|Healthy subjects between 21 and 80 years of age with no eye diseases. Eyes will have normal appearing optic nerve and retina, intraocular eye pressure less than 19 millimeters of mercury, normal, reliable standard automatic perimetry and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
3479245|NCT03804684|Experimental|Mild Glaucoma|Subjects between 21 and 80 years of age with Mild Glaucoma. Eyes will have reliable standard automatic perimetry with no more than -6 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
3479246|NCT03804684|Experimental|Moderate Glaucoma|Subjects between 21 and 80 years of age with Moderate Glaucoma. Eyes will have reliable standard automatic perimetry with between -6 mean and -12 mean deviation and spherical refraction less than 3 diopters and cylinder correction equal to 2 diopters or less. All subjects will perform Standard Automatic Perimetry Humphrey Field Analyzer and visuALL Field Analyzer to measure peripheral and central visual field.
3479247|NCT03804567|Experimental|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs (chronic pain) that are troubling them.
3479248|NCT03804567|Active Comparator|Routine low back pain management|Normal accepted physiotherapy treatment for persistent low back pain.
3127152|NCT03075501|Active Comparator|Paired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in only one room.
3127153|NCT03075501|Other|Unpaired|Individuals receive drug (stimulant, or sedative) on two separate occasions and placebo on two separate occasions. Individuals receive drug in both rooms.
3127154|NCT03075527|Experimental|Tremelimumab + Durvalumab|Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression.
3127155|NCT03075553|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3127156|NCT03075644|Experimental|Somapacitan|
3127157|NCT03075644|Active Comparator|Norditropin|
3127158|NCT03075761|Experimental|Intervention|Participants randomized to the intervention arm will receive a Fitbit, formal 30-minute education session on post-thrombotic syndrome (PTS) and benefits of increased physical activity. An individualized activity prescription will be provided and participants will be asked to maintain the target level of activity for 12 weeks after determining their habitual activity in the first 4 weeks.
3127159|NCT03075761|Active Comparator|Control|Participants randomized to the control arm will receive a formal 30-minute education session on post-thrombotic syndrome (PTS) and the benefits of increased physical activity. Their physical activity will be self-reported in an activity log and by the Gordin activity questionnaire over the 16-week intervention period.
3179533|NCT00673842|Active Comparator|Usual Care|Usual post-MI care
3179534|NCT00673868|Experimental|1|
3179535|NCT00673868|No Intervention|2|
3479249|NCT03804645|Experimental|Cohort 1|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
3479250|NCT03804645|Experimental|Cohort 2|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
3479251|NCT03804645|Experimental|Cohort 3|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
3479252|NCT03804645|Experimental|Cohort 4|In Part A, each subject will receive AZD9977 as a single dose on 4 different occasions under fasting conditions, separated by at least 48 hours.
3479253|NCT03804645|Experimental|Cohort 5|In Part B, each subject will receive one formulation from Part A chosen for further development, dose under fed conditions, followed by dose under fasted condition.
3479254|NCT03804723|Experimental|GC withdrawal|
3479255|NCT03804723|Placebo Comparator|non GC withdrawal|
3479256|NCT03804411|Experimental|Treatment chosen by automated decision-making system|Group A: type 2 diabetic patients randomized to receive antidiabetic drugs according to predictors chosen with developed automated decision-making system: subgroup 1A- addition of vildagliptin 100 mg/day, subgroup 2A - addition of sitagliptin 100 mg/day, subgroup 3A- addition of dapagliflozin 10 mg/day, subgroup 4A- addition of empagliflozin 10 mg/day, subgroup 5A- addition of liraglutide 1,2-1,8 mg/day, subgroup 6A- addition of exenatide 20 μg/day, subgroup 7A - addition of glimepiride, subgroup 8A - addition of gliclazide.
3479257|NCT03804411|Experimental|Treatment based on standard recommendations|Group B: type 2 diabetic patients randomized to receive antidiabetic drugs according to standard recommendations : subgroup 1B- addition of vildagliptin 100 mg/day, subgroup 2B - addition of sitagliptin 100 mg/day, subgroup 3B- addition of dapagliflozin 10 mg/day, subgroup 4B- addition of empagliflozin 10 mg/day, subgroup 5B- addition of liraglutide 1,2-1,8 mg/day, subgroup 6B- addition of exenatide 20 μg/day, subgroup 7B - addition of glimepiride, subgroup 8B - addition of gliclazide.
3479258|NCT03804424|Experimental|Cohort 1: Pilot 64Cu-LLP2A Imaging|"16 adult individuals (6-8 patients with known MM; 6-10 healthy volunteers)~All subjects who enter the study in Cohort 1 will be injected with up to 11 mCi of 64Cu-LLP2A and will undergo body imaging at least twice within 0-30 hrs following administration of 64Cu-LLP2A to study tracer biodistribution and calculate human dosimetry~6 subjects will also undergo dynamic study for 60 mins immediately after administration of 64Cu-LLP2A."
3479259|NCT03804424|Experimental|Cohort 2: Quantitative 64Cu-LLP2A Imaging|"20 patients with MM will be recruited~Subjects who enter on study in Cohort 2 will undergo a 60-min dynamic imaging over the known site of disease (OR pelvis and lower lumbar spine, if no site of disease is known). Following a simple DIXON MRI or low dose CT scan for attenuation correction, subjects will be injected with a dose of up to11 mCi of 64Cu-LLP2A and a list mode dynamic imaging acquisition will begin for a total of 60 mins. Following the dynamic study, or at the optimal time point determined from cohort 1 imaging, after a simple DIXON or low dose CT scan for body (top of the head to below the knees) attenuation correction, emission scans (2-5 min per bed position) will be performed"
3479260|NCT03804359|No Intervention|GEMRITUX protocol|6 months of symptomatic antihypertensive and antiproteinuric therapy, and if the nephrotic syndrome persists at month-6 (urinary protein/creatinine ratio (UPCR) remains > 3.5 g/g and albuminemia < 30 g/l), two 375 mg/m2 rituximab infusions at 1-week interval.
3479261|NCT03804359|Experimental|Personalized treatment|"restricted anti-CysR activity at inclusion : 6-month symptomatic antihypertensive and antiproteinuric treatment (KDIGO)~restricted anti-CysR activity after 6 months of symptomatic treatment with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 375 mg/m2 rituximab infusions at 1-week interval;~Anti-CTLD1/7 activity at inclusion or after 6 months with persisting nephrotic syndrome (UPCR remains > 3.5 g/g and albuminemia < 30 g/l): two 1g rituximab infusions at 2-week interval at month 0 and/or month 6."
3479262|NCT03804021||1|Subjects who received a dose of ADVM-043 in a prior clinical study
3179536|NCT00673907|Sham Comparator|1|Clean air
3479263|NCT03804333|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
3479264|NCT03804333|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
3479265|NCT03804086|Experimental|Test Group|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement (OFD).
3479266|NCT03804086|Active Comparator|Control Group|Open flap debridement alone.
3479267|NCT03804242|Experimental|Black Youth M.A.T.T.E.R.|The session topics are as follows: (1) Debunking the Stigma of Mental Health in the Black Community, (2) School to Prison Pipeline, (3) Achievement Gap, (4) Cultural Barrier that Black Students Experience with Teachers, (5) Trauma 101, (6) Trauma 102, (7) Actions of Today, Blueprints for Tomorrow: Youth Organizing to Transform Education film, (8) My Voice Will Be Heard (Part I), and (9) My Voice Will Be Heard (Part II). The intervention will be conducted in 2-hour weekly group sessions.
3479268|NCT03804242|No Intervention|Usual Care|All participants already participate in Youth Justice Coalition's Free LA High School. Those in control condition will participate in educational activities as usual.
3479269|NCT03804281|Experimental|Test group|esthetic crown lengthening with microsurgical approach
3479270|NCT03804281|Active Comparator|Control group|esthetic crown lengthening with conventional approach.
3479271|NCT03804307|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
3479272|NCT03804307|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
3479273|NCT03804034|Experimental|Occlusal trauma group|an occlusal interference was placed on the lower teeth as follows. Articulating paper was used to mark the contact area between the upper and lower premolars indicated for extraction. Once established, the marked area on the lower premolar was acid-etched with 37% phosphoric acid for 15 s, washed, and dried. A bonding agent was placed and light-cured for 15 s, and finally, a 1- to 2-mm block of resin was placed over the contact area and light-cured for 40 s. Articulating paper was used again to verify that only the premolars that were going to be extracted had contact during normal occlusion as well as in lateral movements. Patients were given chewing gum and indications to repeat 20 masticatory cycles for 30 s, followed by a 30-s rest interval, and repeat the sequence again for a period of 30 min. This chewing cycle was repeated three times every 8 h for the first 24 h
3479274|NCT03804034|Experimental|Moderate orthodontic force group|A convertible standard buccal tube was bonded over the buccal face of the first molar with resin and a McLaughlin, Bennett, and Trevisi slot size 0.022 bracket was bonded over the buccal face of the premolars. One 0.0017 × 0.025 in titanium molybdenum alloy wire cantilever was inserted into each first molar tube, and the wire was bent buccally to form a helix. The cantilever was clinched to the distal end of the tube, and a tipping and extrusive force was applied on the premolar. The activation angle was 45° with a force of 56 g, which was applied to the tooth for 24 h before it was extracted.
3479275|NCT03804034|Experimental|Occlusal trauma and moderate orthodontic force group|the combination of occlusal trauma and orthodontic force .
3479276|NCT03804034|No Intervention|Control Group|No experimental device to produce occlusal trauma or orthodontic forces
3479277|NCT03804151|Experimental|FitSpirit Intervention|FitSpirit physical activities and events are organized by participants' schools during the school year. Girl-only activities such as physical activity sessions, speaking engagements, turnkey running program and special events can be offered. The number, type and frequency of activities are decided by each school.
3479278|NCT03804320|Other|Patients with small renal masses|Active surveillance
3479279|NCT03804164|Experimental|Supportive Care (psycho-educational sessions)|Patients participate in a psycho-educational program weekly over 2 hours for 6 weeks.
3479280|NCT03803982|Experimental|Deep Neuromuscular Blockade, Sugammadex|All patients will receive anesthetic induction and maintenance as per routine using a combination of propofol, opioids, dexamethasone, and 0.6 mg/kg of rocuronium for induction. Patients will also receive lidocaine 1 mg/kg/hour IV infusion, followed by 3-5 mg of morphine equivalents prior to extubation. Patient monitoring will be according to local practice and consist of electrocardiography, blood pressure, heart rate and bispectral index monitoring. Neuromuscular function will be monitored every 20 minutes using a standardized nerve monitor. After induction and intubation, patients in the Deep Neuromuscular Blockade group (experimental group) will receive additional rocuronium to achieve a NMB blockade of TOF of 0 twitch and maintained at this level until reversal.
3479281|NCT03803982|No Intervention|Standard Anesthetic|Patients in the standard anesthetic (or control group) will also receive anesthetic induction as per routine using a combination of propofol, opioids, dexamethasone, and rocuronium, with a lidocaine infusion. Patient monitoring will be similar to the experimental group, with electrocardiography, blood pressure, heart rate, and bispectral index monitoring. Patients in the control group will receive rocuronium 30 mg intravenous prior to intubation, followed by repeated 10 mg doses to reach a TOF of 1-2 twitches.
3479282|NCT03803995|Other|Mapping and Pacing the His Bundle|All patients will be in this arm. Mapping and Pacing the His Bundle will be performed.
3479283|NCT03804177|Experimental|implant with hyaluronic melatonin vit c|implant placement with topical application of hyaluronic and melatonin and systemic administration of vitamin C
3479284|NCT03804177|Active Comparator|immediate implant|immediate implant placement alone without melatonin or hyauronic acid nor vitamin c
3479285|NCT03804229|Experimental|active group|Take two pills (100 mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
3479286|NCT03804229|Placebo Comparator|control group|Take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
3479287|NCT03804190||1-5years experience|1-5years of experience working as otorhinolaryngologist
3479288|NCT03804190||5-10 years experience|5-10years of experience working as otorhinolaryngologist
3479289|NCT03804190||10-15years experince|10-15years of experience working as otorhinolaryngologist
3179537|NCT00673907|Experimental|2|Wood smoke particle concentration of 200 ug/m3
3479290|NCT03804190||15_20years experience|15-20years of experience working as otorhinolaryngologist
3479291|NCT03804073|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
3127160|NCT03075839|Experimental|Cigarette Brand Switching|Adult smokers will be switched from using menthol cigarettes to non-menthol cigarettes
3127161|NCT03075878|Experimental|Cohort 1: ALXN1830|SYNT001 Dose 1
3479292|NCT03804073|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
3479293|NCT03804255||Observational (survey)|Participants complete a self-administered web-based Biomarker Survey and may also complete an Outcome Validation Survey.
3479294|NCT03803930|Other|Arm 22G+SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
3479295|NCT03803930|Other|Arm 22G+MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
3479296|NCT03803930|Other|Arm 20G+SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
3479297|NCT03803930|Other|Arm 20G+MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
3479298|NCT03804203|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
3479299|NCT03804203|Experimental|short course treatment|patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
3479300|NCT03804047|Experimental|Kinesio Tape (KTG)|Participants allocated into the KTG will receive a single time application of the kinesio tape flexible tape (Kinesio® Tex, Albuquerque, NM, USA) in the upper-body (i.e., back part of the trunk) and in the lower-body (i.e., legs and ankle) according to standardized procedures (https://kinesiotaping.com/how-to/). The tape is latex-free and wearable for weeks without causing skin irritation (i.e., hypoallergenic); and safe for populations ranging from pediatric to geriatric. The tape will be applied by a Physical Therapist with experience in tape application. Tape application will be conducted in a private room with a complete structure for the procedure.
3479301|NCT03804047|Sham Comparator|Sham Tape (STG)|Participants allocated into the STG will receive a single time application of an inflexible tape (i.e., sham tape) in the same body segments as the intervention condition. Tape application will be conducted in a private room with a complete structure for the procedure.
3479302|NCT03803956|Active Comparator|Active PBMT|Application of PBMT (Photobiomodulation Therapy) with a total dose of 850 Joules.
3479303|NCT03803956|Placebo Comparator|Placebo PBMT|Application of placebo PBMT (Photobiomodulation Therapy) without any dose (0 Joule).
3479304|NCT03804008|Active Comparator|Fundamental advice and a heel cup|
3479305|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise|
3479306|NCT03804008|Active Comparator|Fundamental advice and a heel cup plus exercise and injection|
3479307|NCT03803943|Experimental|Parent-Implemented Communication Intervention (PICT)|Participants assigned to the PICT condition will receive weekly hour long intervention sessions in their home for 6 months. Parents will learn four sets of communication support strategies: (a) visual (e.g., modeling language within the child's line of sight), (b) interactive (e.g., following the child's attentional focus), (c) responsive (e.g., responding to all communicative attempts), and (d) linguistically stimulating (e.g., modeling language targets, expanding child communication).
3479308|NCT03803943|Placebo Comparator|No Intervention - Business-as-usual control|Participants assigned to the BAU control group will not receive the PICT intervention.
3127162|NCT03075878|Experimental|Cohort 2: ALXN1830|SYNT001 Dose 2
3127163|NCT03075891|Experimental|Ivermectin 1% cream + Doxycycline 40 mg MR capsules|
3479309|NCT03803969|Other|ConfirmRx (Insertable Cardiac Monitor)|This is a single arm study where in patients with an approved indication for a cardiac monitor will receive a ConfirmRx Device.
3479310|NCT03803917|Other|Treatment|Injection with freshly collected autologous adipose tissue
3479311|NCT03804294||vitamin D-ART|Infertile couples who undergo their ﬁrst IVF/ICSI and IUI cycle in Reproductive Medicin Center of Peking university Third Hosiptal.
3479312|NCT03803904|Experimental|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
3479313|NCT03803904|Active Comparator|Control|Participants in the control group will be equalized (frequency and duration) to the Spin group for contact and monitoring. As such they will report to the same facility and interact with the same experienced interventionist; however instead of progressive Spin exercise they will participate in sessions focused on balance and stretching. Similar to the aerobic intervention, these exercises will take place in a group setting and heart rate will be consistently monitored during each session to verify heart rate does not reach 50% HRR.
3127164|NCT03075891|Placebo Comparator|Ivermectin 1% cream + Oral placebo capsules|
3127165|NCT03075904|Experimental|Cohort 1: ALXN1830|Participants received 5 doses of ALXN1830 10 mg/kg administered weekly.
3179538|NCT00673907|Experimental|3|Wood smoke particle concentration of 400 ug/m3
3479314|NCT03803891||Endoscopic full-thickness resection|Patients with neoplastic lesions less than 30mm unresectable en bloc by other less invasive endoscopic techniques, including lesions suggestive of T1 colorectal cancer, subepithelial tumors, lesions with diverticular involvement, lesions with no-lifting sign (recurrent, incomplete prior resection or untreated lesions).
3479315|NCT03803878||Group 1|Group 1 is anticipated to consist of 300 women with MUI, and the categorization function of MESA questionnaire will be validated among those patients.
3479316|NCT03803878||Group 2|Group 2 is anticipated to consist of 282 women with urgency-predominant MUI.
3479317|NCT03803878||Group 3|Group 3 is anticipated to consist of 94 women with urgency-predominant MUI.
3479318|NCT03803865|Active Comparator|Headspace|30-day smartphone based mindfulness training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
3479319|NCT03803865|Active Comparator|Recharge|30-day smartphone based reflection and problem solving training intervention consisting of 10-minutes for the first 10 days, 15 minutes for the next 10 days, and 20 minutes for the final 10 days.
3479320|NCT03803553|Experimental|ctDNA-POSITIVE: FOLFIRI Protocol|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- ctDNA-POSITIVE: FOLFIRI Protocol~FOLFIRI chemotherapy via intravenous infusion on days 1-3 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drugs~5-Fluorouracil~Irinotecan~Leucovorin"
3479321|NCT03803553|Active Comparator|ctDNA-POSITIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~-- Active surveillance.~Observation and monitoring with imaging (every 3 months), tumor markers, and ctDNA draws every 1 month for the initial 6 months.~After 6 months, followed with ctDNA, tumor markers, and scans every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician. ."
3479322|NCT03803553|Active Comparator|ctDNA-NEGATIVE: ACTIVE SURVEILLANCE|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests. If these tests show that the participant is eligible to participate in the research study . The participant will be randomized into 1 of 3 groups : ctDNA-Positive: Folfiri or ctDNA-Positive: Active Surveillance or ctDNA Negative: Active Surveillance~- Observation and monitoring with imaging, tumor markers, and ctDNA collections every 3 months for the first 3 years and every 6 months thereafter.~Additional scans and tumor markers will be at the discretion of the clinician"
3479323|NCT03803553|Experimental|ctDNA-POSITIVE MSI-H: NIVOLUMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and MSI-H, the participant will not be randomized and will be placed into the group: ctDNA positive, MSI-H: Nivolumab~-ctDNA-Positive, MSI-H: Nivolumab Protocol~Nivolumab treatment via intravenous infusion on day 1 of each cycle. Cycle is 28 days long. This will occur for up to 12 cycles (48 weeks).~infusions will consist of the drug Nivolumab"
3479324|NCT03803553|Experimental|ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB|"Pre-screening evaluation, including tumor assessment, tumor sequencing and blood tests.~If these tests show that the participant is eligible to participate in the research study and is ctDNA positive and has a BRAF mutation, the participant will not be randomized and will be placed into the group: ctDNA positive, BRAF mutant: Encorafenib/Binimetinib/Cetuximab~-ctDNA-Positive, MSI-H: Encorafenib/Binimetinib/Cetuximab Protocol~Encorafenib/Binimetinib treatment is received orally every day and Cetuximab via intravenous infusion on day 1 of each cycle. Cycle is 14 days long. This will occur for up to 12 cycles (24 weeks).~infusions will consist of the drug Cetuximab"
3479325|NCT03803852|Experimental|0°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 0°
3479326|NCT03803852|Experimental|45°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 45°
3479327|NCT03803852|Experimental|90°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 90°
3479328|NCT03803852|Experimental|135°|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon or Hoya Nanex on axis 135°
3479329|NCT03803618||Confirmed dengue case|Dengue cases who are 9-14 years old during the dengue mass vaccination program in Cebu with <5 days history of fever, admitted in the participating hospitals with dengue virus confirmation by RT-PCR
3479330|NCT03803618||Control|Age and sex matched neighborhood controls
3479331|NCT03803644|Experimental|Administration of CC-92480 - Part 1|dose escalation
3479332|NCT03803644|Experimental|Administration of CC-92480 under fasted conditions - Part 2|Food effect
3479333|NCT03803644|Experimental|Administration of CC-92480 under fed conditions - Part 2|food effect
3479334|NCT03803657||Neonates|Neonates 0-28 days
3479335|NCT03803657||Infant|29 days to 1 year
3479336|NCT03803657||Child|>1 year and <10 kg
3479337|NCT03803488|Experimental|simulation of injection|The evaluator simulated the injection with the DropSafe safety pen needle and a pen injector with a sterile, water-filled cartridge using an orange.
3479338|NCT03803540|Experimental|Fecal Microbiota Transplantation|Lean healthy donor frozen fecal microbiota will be administered via duodenal infusion in an upper gastrointestinal endoscopy
3479339|NCT03803722|Experimental|Arm A Eyestil Protection®|"No inferiority of Eyestil Protection® unidose versus Vismed® unidose The intervention consists of Eyestil Protection® : sterile preservative free, medical device, class IIa and CE marked. It contains 0.2% xanthan gum, presented in 0.3 ml unidose containers. It is not available yet on the French Market.~dosage: 6 drops a day for three months period."
3127166|NCT03075904|Experimental|Cohort 2: ALXN1830|Participants were to receive 3 doses of ALXN1830 30 mg/kg administered weekly (loading) followed by 5 doses of ALXN1830 10 mg/kg administered every other week or 10 weekly doses of ALXN1830 IV (maintenance).
3127167|NCT03076190|No Intervention|Active Control Group (Health Education)|"Prior to surgery:~Demographics survey~Baseline surveys~Participants receive online information regarding nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery.~Follow-up questions about the handouts (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
3127168|NCT03076190|Experimental|My Surgical Success Treatment Group|"Prior to surgery:~Demographics survey~Baseline surveys~Intervention:~90-minute psychoeducational My Surgical Success video that emphasizes catastrophizing treatment.~audio file~personalized plan that incorporates the information learned in the video.~Follow-up questions about the video (detailed above)~Post-surgery:~Daily surveys (detailed above)~Follow-up surveys (2, 4, 8, and 12 weeks after surgery)"
3179539|NCT00673946|Active Comparator|1|In this arm, patients are monitored with oximeters displaying true saturation values
3479340|NCT03803722|No Intervention|Arm B Vismed®|"Vismed®: sterile preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate, presented in 0.3 ml unidose containers. It is already on the French market.~dosage: 6 drops a day for three months period."
3127169|NCT03076333|Experimental|Single Arm: PET/MR|Each patient will undergo three combined PET/MR scans. The pre-treatment PET, mid-treatment PET and MR, and post-treatment PET are for research purposes and not part of the patient's standard of care (pre-treatment MR and post-treatment MR).
3479341|NCT03803670||acute lymphoblastic leukemia patients|We observed within adult patients with ALL three groups of patients: patients without central nervous system (CNS) involvement, patients with manifest CNS involvement and patients with occult CNS involvement.
3479342|NCT03803683|Experimental|mLab App Intervention|Youth randomized to the intervention arm (arm 1) will be provided with the mLab App, 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at their 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
3479343|NCT03803683|Active Comparator|Standard of Care HIV Information Control Arm|Youth randomized to the Standard of Care HIV information control arm (arm 2) will receive standard-of-care HIV/STI testing-related risk reduction counseling, a box of condoms, PrEP assessment, and referral information for clinics that provide PrEP during their first visit. Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including pre-exposure prophylaxis (PrEP) and HIV testing information that is found on the CDC website.They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
3479344|NCT03803683|Active Comparator|HIV Home Tests|Youth randomized to the HIV home testing arm (arm 3) will be provided with the 2 OraQuick tests (including the package insert), and a box of condoms to take home at baseline. They will receive 2 more OraQuick tests at the 6 month visit. At their baseline appointment, youth will also be sent an email or text with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the CDC website. They will also receive a study information card listing the Columbia University School of Nursing / Lurie Children's study teams' contact information.
3127170|NCT03076359|Active Comparator|Standard of Care|Intervention: This group will receive only standard of care HIV treatment, including ART medications (First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
3127171|NCT03076359|Experimental|Traditional Healer Support Program|"This group will receive standard of care as described above. In addition, the investigators will assess an intervention partnership with traditional healer including: community and clinic based support from a trained traditional healer.~The intervention includes: (1) healer visits to the patient at home, healer support for couples counseling, healer provision of nutritional advice, and healer counsel about the importance of adherence. If anything is amiss, the healer will accompany the patient to the health facility for additional clinical services. In addition, the healer will accompany the patient on all regularly scheduled clinical visits."
3127172|NCT03076515|Active Comparator|Nerivio Migra active|This arm will use the active device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
3479345|NCT03803748|Experimental|Eyestil Plus®|"It's a clinical comparative performance study. Eyestil Plus® eyedrops multidose to be not inferior to Vismed multidose eye drops. Eyestil Plus is an ophthalmic aqueous formulation, multidose sterile preservative free, medical device, class IIB and CE marked. It contains 0.4% sodium hyaluronate. It is not available yet in the French Market.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period,"
3479346|NCT03803748|No Intervention|Vismed|"Vismed Multi® is also a sterile multidose preservative free, medical device class IIb and CE marked. It contains 0.18% sodium hyaluronate.~The dosage per medical device will be 6 drops a day per dry eye during the three months study period.~The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes."
3479347|NCT03803709|Placebo Comparator|placebo|"maltodextrin received at 4g/day on day 3 and 4~maltodextrin received at 8g/day from day 5 to 14~maltodextrin received at 16g/day from day 15 to 20"
3479348|NCT03803709|Experimental|inulin|"inulin received at 4g/day on day 3 and 4~inulin received at 8g/day from day 5 to 14~inulin received at 16g/day from day 15 to 20"
3479349|NCT03803592|Experimental|Dyadic MCS program|"Participants from the experimental group will receive a dyadic multisensory and cognitive stimulation (MCS) programme.~The MCS program is a 15- week program. In the first 4 weeks, participants will attend the center-based Face-to-face (FTF) session twice a week (8 sessions), while in the remaining week (5th-15th Week), home-based sessions will be delivered by the caregivers with the PWD at home and was suggested to deliver the intervention 3 times/week at home. The home-based sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions over the intervention period."
3479350|NCT03803592|No Intervention|Control group|Participants from the control group will receive usual care and no intervention will be received.
3479351|NCT03803800|Experimental|Classic training & beta-alanine|Subjects following 12 weeks of classic, progressive endurance training, with the addition of ergogenic supplements (beta-alanine supplementation).
3479352|NCT03803800|Placebo Comparator|Classic training & placebo|Subjects following 12 weeks of classic, progressive endurance training, without the addition of ergogenic supplements (placebo supplements).
3479353|NCT03803800|Experimental|Periodized training & beta-alanine|Subjects following 12 weeks of periodized exercise training, with the addition of ergogenic supplements (beta-alanine supplementation).
3479354|NCT03803800|Placebo Comparator|Periodized training & placebo|Subjects following 12 weeks of periodized exercise training, without the addition of ergogenic supplements (placebo supplements).
3479355|NCT03803527|Experimental|EST|"All subjects enrolled into the study will:~Complete a clinical history~Have vitals obtained~Complete Patient-reported outcomes~Have Esophageal mucosal biopsies collected as part of standard of care at the time of the most recent endoscopy to report the peak eosinophilia per hpf.~Complete the Esophageal String test"
3479356|NCT03803787|Experimental|QT/RT + Budesonide|Patients are receiving chemotherapy (QT) and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
3479357|NCT03803787|No Intervention|QT/RT + No medication|Patients are receiving chemotherapy (QT) and radiotherapy (RT) without intervention therapy and followed during 12 months.
3479358|NCT03803787|Experimental|Target drug/RT + Budesonide|Patients are receiving target therapy and radiotherapy (RT) plus inhaled Budesonide with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
3479359|NCT03803787|No Intervention|Target drug/RT + No medication|Patients are receiving target treatment and radiotherapy (RT) without intervention therapy and followed during 12 months.
3479360|NCT03803514||Treated group (rEPO)|"Patients with ESRD in HD, and medical indication of recombinant EPO for management of anemia (Hb < 10 g/dL). Ambulatory hemodialysis 3 times per week.~Recombinant beta-epoetin (Recormon) will be used, according to current recommendations.~Clinical and laboratory data will be obtained before and during the study. The primary outcome (changes of plasma intact FGF23) will be measured during the follow-up, up to 12 weeks."
3479361|NCT03803514||Control group|"Patients with ESRD and HD, without medical indication of recombinant EPO (Hb > 10 g/dL). Ambulatory hemodialysis 3 times per week.~Follow-up for 3 months, similar than rEPO group. Clinical and laboratory data will be obtained before and during the study, similar periods than rEPO group.~The primary outcome (changes of plasma FGF23) will be measured every 2 week during the evaluation period."
3479362|NCT03803826|Experimental|CRT-D re-programming|"The ineffective previously implanted CRT-D is reprogrammed under supervision of transthoracic echocardiography to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains.~Transthoracic echocardiography is performed prior to optimization and 3 months after optimization (i.e., 3 and 6 months after the CRT implantation) and and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods re-programming of the interventricular interval"
3479363|NCT03803826|No Intervention|Control Group|Only trans-thoracic echocardiography is performed during follow-ups at 3 and 6 months from CRT implantations performed and New York Heart Association Classification (NYHA Classification; total score range 1-4) is being determined in accordance with the standard NYHA methods
3479364|NCT03803449|Active Comparator|Control group|Participants are given standard regimen: 50-200mg propofol and 1 mg midazolam
3479365|NCT03803449|Experimental|Fentanyl group|Participants are given intervention regimen: 50ug fentanyl, plus 50-200mg propofol and 1 mg midazolam.
3479366|NCT03803436|Experimental|Study arm|Liver transplant
3479367|NCT03803436|Active Comparator|Parallel arm|Chemotherapy
3479368|NCT03803696|Active Comparator|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
3479369|NCT03803696|Active Comparator|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
3479370|NCT03803839|Active Comparator|Clodronate|1 mM clodronate (60 mg in 1000 ml saline) was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the clodronate solution. The time for rinsing was about one minute.
3479371|NCT03803839|Placebo Comparator|Saline|1000 ml saline was used intraoperatively during total hip arthroplasty: before installation of the prosthesis, the rinsing was performed with pulsatile lavage using the saline solution. The time for rinsing was about one minute.
3479372|NCT03803358|Experimental|cycle exercise with additional NIV|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
3479373|NCT03803358|Active Comparator|cycle exercise without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
3479374|NCT03803423|Experimental|The Donor App|Select physicians and research staff from about 15 transplant hospitals will be given access to distribute the application to patients who the above people feel could benefit from the application. After obtaining informed consent, an approved member of the study team will enter the participant's name, contact info, and organ needed into the Donor App's secure management portal to send an email or text message with a unique and protected invitation link to the participant. Using this link the participant will be allowed to use the Donor App indefinitely.
3479375|NCT03803371|Experimental|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets by mouth on Day 1 of period 1 or 2
3479376|NCT03803371|Active Comparator|Ultracet tablet|Ultracet tablet (Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg) by mouth on Day 1 of period 1 or 2
3479377|NCT03803254|Experimental|HAIC plus lenvatinib and PD-1 antibody|Hepatic arterial infusion chemotherapy plus lenvatinib and programmed cell death protein-1 antibody
3127173|NCT03076515|Sham Comparator|Nerivio Migra placebo|This arm will use the sham device for acute treatment of migraine at the migraine symptoms onset. the device will be applied on the upper arm and controlled by a dedicated smartphone application.
3479378|NCT03803254|Active Comparator|HAIC plus lenvatinib|Hepatic arterial infusion chemotherapy plus lenvatinib
3479379|NCT03803124|Active Comparator|Tolvaptan|"Drug: Tolvaptan~1 tablet before renography"
3479380|NCT03803124|Placebo Comparator|Placebo|"Placebo~1 tablet before renography"
3479381|NCT03803267|Active Comparator|Erector spinae plane block|Patients will receive bilateral ultrasound-guided erector spinae plane block as an adjuvant analgesic technique
3479382|NCT03803267|Active Comparator|Quadratus lumborum block|Patients will receive bilateral ultrasound-guided quadratus lumborum block as an adjuvant analgesic technique
3479383|NCT03803319|Active Comparator|Fibre 1 (combined fibres)|Ingestion of 150mls water with 7.5g fibre (two times a day)
3479384|NCT03803319|Active Comparator|Fibre 2 (natural fibres)|Ingestion of 150mls water with 15g fibre (two times a day)
3479385|NCT03803319|Placebo Comparator|Dietary Supplement (placebo)|Ingestion of 150mls water with 7.5g (two times a day)
3479386|NCT03803384|Experimental|ESWT Order A and B|First Endurance Shuttle walk test (A) with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92% and second Endurance Shuttle walk (B) test with supplemental Oxygen therapy via constant oxygen flow rates
3479387|NCT03803384|Experimental|ESWT Order B and A|First Endurance Shuttle walk test (B) with supplemental Oxygen therapy via constant oxygen flow rates and second Endurance Shuttle walk (A) test with supplemental Oxygen therapy via auto-regulated oxygen flow rates (FreeO2) to maintain a oxygen saturation of 92%
3479388|NCT03803293|Other|Primary cohort|All eligible Biobank participants that receive the majority of their care at Mayo Clinic based on EHR length and depth had pharmacogenomic testing done.
3479389|NCT03803176||Periodontally healthy subjects|Healthy subjects who attended the restorative dental clinic and have clinically healthy gingiva with zero plaque index (PI), gingival index (GI), and CAL (≤3 mm PD). Oral hygeine instructions will be given to these patients.
3479390|NCT03803176||Chronic Periodontitis|Patients with severe Chronic Periodontitis having a pocket depth (PD) of ≥5 mm and a clinical attachment level (CAL) ≥5 mm. Open flap debridement (surgical periodontal therapy) will be carried out for these patients after scaling & root planing.
3479391|NCT03802955|Experimental|ADG106 Dose escalation|
3479392|NCT03803137|Experimental|VOC analysis|VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection
3479393|NCT03803033|Experimental|Intervention|The objective of the group was to introduce an experimental clinical pharmacy-based home medication review service in the outpatient clinic setting of the Jordan University Hospital in Amman, Jordan. The intervention under evaluation in the study is the pharmacy-based home medication review service.
3479394|NCT03803033|No Intervention|Control|The objective of the control group was to identify changes in treatment and associated costs that take place in patients as part of the usual practice, as compared to the intervention arm, regardless of the clinical pharmacist service intervention.
3479395|NCT03803150|Experimental|PRA approach|PRA extends downward in curvilinear fashion in cervicomastoid skin crease
3479396|NCT03803150|Active Comparator|RT approach|RT begins 5mm below the ear lobe and continues 3 to 3.5cm inferiorly.
3479397|NCT03803280||Traditional care|Patients with major abdominal surgery without before a enhanced recovery program was stablished
3127174|NCT03076970|Experimental|Lasmiditan 200 mg|single oral tablet
3479398|NCT03803280||ERAS care|Patients with major abdominal surgery within a enhanced recovery program was stablished
3479399|NCT03803241|Experimental|PVE + CD133|preop portal vein embolization + stem cells infusion
3127175|NCT03076970|Active Comparator|Sumatriptan 100 mg|single oral tablet
3479400|NCT03803241|Sham Comparator|PVE|only preop portal vein embolization
3479401|NCT03803202|Experimental|Stage 1, Group 1 ASP3772 in Adults|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.
3127176|NCT03076970|Experimental|Combination of lasmiditan and sumatriptan|single oral tablet of each
3127177|NCT03076983||ICU Patients|Patients currently on or scheduled for ventilator care in the intensive-care-unit (ICU)
3479402|NCT03803202|Active Comparator|Stage 1, Group 1 PCV13 in Adults|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
3479403|NCT03803202|Experimental|Stage 2, Group 2 ASP3772 in Elderly|Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels
3179540|NCT00673946|Experimental|2|In this arm, patients are monitored with oximeters with displayed saturations 3 percentage points above true values
3479404|NCT03803202|Active Comparator|Stage 2, Group 2 PCV13 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PCV13 on Day 1.
3479405|NCT03803202|Active Comparator|Stage 2, Group 3 PPSV23 in Elderly|Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.
3479406|NCT03803111|Experimental|Initial FCM|Intravenous iron supplementation with FCM, subsequent (after 2 months) exercise training program
3127178|NCT03076983||OLV Patients|Patients scheduled for elective surgery receiving one-lung-ventilation (OLV)
3127179|NCT03076996|Experimental|Online support group|Participants will be enrolled to receive six sessions from the Positive Connections curriculum through the m/eHealth intervention that will use Facebook to conduct online structured support groups.
3127180|NCT03077165|Experimental|Group A|S42909 dose 100 mg p.o., 50 mg bid
3127181|NCT03077165|Experimental|Group B|S42909 dose 200 mg p.o., 100 mg bid
3127182|NCT03077165|Experimental|Group C|S42909 dose 400 mg p.o., 200 mg bid
3127183|NCT03077165|Experimental|Group D|S42909 dose 800 mg p.o., 400 mg bid
3127184|NCT03077165|Experimental|Group E|S42909 dose 1200 mg p.o., 600 mg bid
3127185|NCT03077165|Placebo Comparator|Group F|Placebo p.o. bid
3127186|NCT03077438|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MenACYW Conjugate vaccine on Day 0.
3179541|NCT00673972|Active Comparator|EPS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
3479407|NCT03803111|Experimental|Initial exercise|Exercise training program, subsequent (after 2 months) intravenous iron supplementation with FCM
3479408|NCT03803189|Experimental|Personalized eToolkit|The intervention arm will receive a personalized eToolkit with community and electronic supports each time they complete a survey, and their PCP will receive supports in the EMR to facilitate postpartum mental healthcare.
3479409|NCT03803189|No Intervention|Usual care|The control arm will not receive intervention materials, unless they express suicidality, in which case they will receive a message with supports for suicidality including local emergency departments and crisis lines and an urgent message via EMR and fax will be sent to their PCP. Control arm participants will be asked to complete a baseline e-survey in their third trimester, and a follow-up e-survey 24-weeks after their baby is born.
3479410|NCT03803007|Experimental|Intravenous glenzocimab (ACT017) 1000 mg|Intravenous glenzocimab (ACT017) 1000 mg to be added to a tissue plasminogen activator +/- mechanical thrombectomy
3479411|NCT03803007|Placebo Comparator|Intravenous Placebo|Intravenous Placebo to be added to a tissue plasminogen activator +/- mechanical thrombectomy
3479412|NCT03803306|Experimental|Vedic Medical Astrology Group (VMA)|
3479413|NCT03803306|Sham Comparator|Placebo vedic medical astrology (PMA)|
3479414|NCT03802942|Experimental|Glucerna|2 bottles of Glucerna per day (237 ml per bottle for a total of 474 ml/d) on top of the meal plan supplied by the hospital.
3479415|NCT03802942|No Intervention|Control|Regular meal plan supplied by the hospital
3479416|NCT03803020||single coronary chronic total occlusion|"symptomatic stable angina of single coronary chronic total occlusion without other coronary artery stenosis scheduled for elective PCI.~fractional flow reserve and SPECT detection before and after intervention."
3479417|NCT03802851|Experimental|Holmium Laser Enucleation of Prostate (HoLEP)|Patients in this arm will undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS). Patients will undergo HoLEP one time and will return for standard of care follow up.
3479418|NCT03802851|No Intervention|Control Arm|Patients in this arm will undergo no additional interventions and will not undergo holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms and instead follow standard of care treatment and follow up.
3479419|NCT03803215||Theophylline group|Patients who have electrocardiographic documentation of asystolic syncope will be treated with oral theophylline at tailored dosage
3127187|NCT03077438|Active Comparator|Group 2: MENVEO® Vaccine|Healthy, meningococcal-vaccine naïve participants aged 2 to 9 years received a single dose of MENVEO® Conjugate vaccine on Day 0.
3127188|NCT03077607|Experimental|Arm A|Subjects will receive a 0.5 mg talazoparib and 100 mg itraconazole.
3479420|NCT03803215||Control untreated group|A propensity-score matched control group is generated from the large database of patients who had received an implantable loop recorder
3479421|NCT03803163|Experimental|TransCon Treprostinil|
3479422|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab Alone|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab.
3479423|NCT03802747|Experimental|Y-90, SBRT, and Durvalumab + Tremelimumab|Six patients will be enrolled in cohorts of three to be administered Y-90, SBRT, and Druvalumab + Tremelimumab.
3479424|NCT03802838|Active Comparator|Acupuncture|Acupuncture+Amisulpride
3479425|NCT03802838|Other|Amisulpride|Amisulpride only.
3127189|NCT03077607|Experimental|Arm B|Subjects will receive 1 mg talazoparib and 600 mg rifampin.
3179542|NCT00673972|Active Comparator|PDS|Patients with functional dyspepsia will be classified into EPS or PDS two subgroups according to Rome III diagnostic criteria.
3479426|NCT03802903|Experimental|Remo-Wax|Test product will be applied into ear canal for 20-60 minutes.
3479427|NCT03802669||caries free children aged between 3-6|
3479428|NCT03802669||caries active children aged between 3-6|
3479429|NCT03802669||caries free children aged between 6-12|
3479430|NCT03802669||caries active children aged between 6-12|
3479431|NCT03802669||caries free adult aged between 18-25|
3479432|NCT03802669||caries active adult aged between 18-25|
3479433|NCT03802682|Experimental|Treatment Sequence AB|Participants will receive a single dose of apalutamide 240 milligram (mg) (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 1 (Treatment A [reference]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 2 (Treatment B [test]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
3479434|NCT03802682|Experimental|Treatment Sequence BA|Participants will receive a single dose of apalutamide 240 mg (4*60 mg tablets) as a dispersed mixture in applesauce under fasted conditions on Day 1 of Treatment Period 1 (Treatment B [test]) followed by a single dose of apalutamide 240 mg (4*60 mg tablets) swallowed whole under fasted conditions on Day 1 of Treatment Period 2 (Treatment A [reference]). Study treatment periods will be separated by a washout interval of at least 42 days and no more than 56 days between doses.
3479435|NCT03802799|Experimental|ZYN002|ZYN002 - CBD Transdermal Gel
3479436|NCT03802708|Other|control|control
3479437|NCT03802877|Active Comparator|Resource bank|The web-based resource bank includes information and perspectives about GDM, nutrition, and physical activity. The information is presented through video capsules, on-line text, printable pdfs, and podcasts. It is presented by health care professionals and patients.
3479438|NCT03802877|Experimental|Resource bank and ePlatform|In addition to resource bank access, participants will receive a digital scale, physical activity monitor (pedometer), and ePlatform log-in information. They will track daily weights and step counts. They will receive prompts to access educational and motivational tools based on the data that they enter and whether or not they enter data. The investigators will use the ePlatform developed by StepsCount, a Canadian pedometer company with a well-developed ePlatform for pedometer data upload, tracking, and automated messaging. The company is permitting us further customization for study purposes. Data will be uploaded onto a secure cloud-based platform controlled by the pedometer and digital scale companies.
3127190|NCT03077646|Experimental|Be SMART alone|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information.
3479439|NCT03802877|Experimental|Resource bank and health coach|"In addition to resource bank access, the coach will contact the participant weekly (telephone, text, email) to discuss progress and challenges in terms of achieving physical activity goals, rate of GWG, and maintaining health eating patterns, as well as any concerns.Participants not randomized to a coaching strategy will be advised to consult with their treating healthcare team directly if they develop symptoms of concern.~The coach will encourage participants to track their weight gain and physical activity (e.g., walks, classes, activity lists, etc.) and to share this information. However, they will not have access to the study ePlatform and will not be provided with pedometers or digital scales."
3479440|NCT03802877|Experimental|Resource bank with ePlatform and coach|Participants will have resource bank access as well as ePlatform and coaching interventions.The health coach will have access to the data on the ePlatform. They will receive telephone calls from the research assistant/health coach if they are off target despite the platform tools and support. They will be encouraged to consult the resource bank and will brainstorm with the health coach to decide how to achieve their GWG and step count targets.
3479441|NCT03802929||Derivation Cohort|"Derivation Cohort of Diagnostic Prediction Model:~Participants will be recruited from the emergency department of five general urban hospitals in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; from March 1, 2019. The investigators will randomly assign 70% participants to a derivation cohort.~Derivation Cohort of Prognostic Prediction Model:~Patients with VTE from 5 thrombosis centers in China, including Shanghai Tenth People's Hospital; Nanfang Hospital of Southern Medical University; First Affiliated Hospital, Sun Yat-Sen University; Zhongshan Hospital Xuhui Branch, Fudan University; Shanghai Baoshan Luo Dian Hospital; between January 2014 and December 2018."
3479442|NCT03802929||Validation Cohort|"Validation Cohort of Diagnostic Prediction Model:~The investigators plan to randomly assign 30% participants for developing the diagnostic prediction model to a Validation cohort.~Validation Cohort of Prognostic Prediction Model:~New individuals selected by the same inclusion and exclusion criteria as the derivation cohort of prognostic prediction model from the same institutions as a validation cohort of prognostic prediction model will be recruited from January 2019."
3479443|NCT03802617|Experimental|MR13A9 low dose|
3479444|NCT03802617|Experimental|MR13A9 medium dose|
3479445|NCT03802617|Experimental|MR13A9 high dose|
3479446|NCT03802617|Placebo Comparator|Placebo|
3479447|NCT03802734|Experimental|Mindful Meditation App|Group A will be given a free subscription to a mindful meditation phone app for six months. They will also be given an actigraph and a general pregnancy and sleep information leaflet.
3479448|NCT03802734|No Intervention|No Meditation App|Group B will be given an actigraph and a general pregnancy and sleep information leaflet only.
3479449|NCT03802812|No Intervention|Conventional arm|"Perform bronchial washing using conventional methods.~CT-guided thick bronchoscope"
3479450|NCT03802812|Active Comparator|Investigational arm|"Perform bronchial washing using investigational methods.~virtual bronchoscopic navigation (VBN)-guided thin bronchoscope (4.0mm of outer diameter)"
3479451|NCT03802604|Experimental|Talimogene laherparepvec + Atezolizumab|"Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 & 5 - 10^8 PFU/mL.~Atezolizumab 840 mg"
3479452|NCT03802578|Experimental|EXERCISE GROUP|Patients in the exercise group performed a program of strengthening, stretching and resistance upper limbs exercises (Hand exercise), of 30 minutes duration daily, for 12 weeks in addition to medical care.
3479453|NCT03802578|No Intervention|CONTROL GROUP|Patients in the control group continued their usual medical care.
3479454|NCT03802721|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
3479455|NCT03802721|Experimental|Brussels sprouts before 50 ng dose|Subjects will consume 50 g (about 1/2 cup) of lightly steamed Brussels sprouts each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
3479456|NCT03802721|Experimental|DIM supplement before 50 ng dose|Subjects will consume 300 mg DIM supplement ( 2 capsules of BioResponse DIM® 150) each evening for 7 days prior to taking capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP). A 300 mg DIM dose will be co-administrated with the 50 ng BaP dose
3479457|NCT03802656|Experimental|Anterior Vertebral Body Tethering|Subjects who will be undergoing the anterior vertebral body tethering surgery.
3479458|NCT03802448|Active Comparator|Control group|"composed of fifteen pregnant women who only wore a natural wrist splint during sleeping for 4 weeks.~A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping"
3479459|NCT03802448|Experimental|Study group|"a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
3479460|NCT03802591|Experimental|CS1001 monoclonal antibody|in combination with Oxaliplatin and Capecitabine
3479461|NCT03802591|Placebo Comparator|CS1001 placebo|in combination with Oxaliplatin and Capecitabine
3127191|NCT03077646|Experimental|Be SMART + MD review|Parents/guardians in this study group will watch a 5.5 minute Be SMART video and receive the handouts reviewing the information and will also have an MD review the information (via a checklist to standardize the MD review).
3127192|NCT03077646|Active Comparator|Control: TSE materials|"Parents/guardians in this study group will watch a video Kids and Smoke Don't Mix and receive handouts reviewing information on tobacco smoke exposure (TSE)."
3479462|NCT03802396|Experimental|CN-105|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
3127193|NCT03077659|Experimental|NanoPac® 6 mg/mL|NanoPac® 6 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
3127194|NCT03077659|Experimental|NanoPac® 10 mg/mL|NanoPac® 10 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
3127195|NCT03077659|Experimental|NanoPac® 15 mg/mL|NanoPac® 15 mg/mL injected into the prostate lobe containing the dominant lesion at a volume of 20% prostate lobe volume
3127196|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 1|Patients are randomized to receive methenamine hippurate in one arm if they are diagnosed with recurrent urinary tract infections.
3479463|NCT03802396|Placebo Comparator|Placebo|"Cohort 1: 67 Patients Dose of CN-105: 0.1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 2: 67 Patients Dose of CN-105: 0.5 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17~Cohort 3: 67 Patients Dose of CN-105: 1 mg/kg Patients receiving drug: 50 Patients receiving placebo: 17"
3479464|NCT03802331|Experimental|Test Treatment|fed
3479465|NCT03802331|Experimental|Reference Treatment|fasted
3479466|NCT03802461|Active Comparator|Fecal Microbiota Transplantation (FMT)|Bowel lavage preparation followed by FMT administered by enema, given on 3 occasions. Fecal filtrate for FMT will be prepared from 50 g of healthy donor stool, homogenized, and diluted in 300 mL sterile normal saline.
3479467|NCT03802461|No Intervention|Standard of Care|Patients in this arm will not receive intervention and will be on standard of care .
3479468|NCT03802487|Experimental|Sotagliflozin|One treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer plus charcoal. The other treatment period includes a single oral dose of sotagliflozin + IV microdose 14C-sotagliflozin tracer without charcoal.
3479469|NCT03802552|Experimental|Cefadroxil then Cephalexin|Receive cefadroxil first, then receive cephalexin after washout.
3479470|NCT03802552|Experimental|Cephalexin then Cefadroxil|Receive cephalexin first, then receive cefadroxil after washout.
3479471|NCT03802357|Experimental|High training intensity|Exercise Training with high intensities consists of a cycling Interval Training at 100% of the individual Peak work rate, resistance Training for 3 sets à 8 repetitions and squats on a Vibration plate.
3479472|NCT03802357|Active Comparator|moderate training intensity|Exercise Training with moderate intensities consists of a cycling endurance Training at 60% of the individual Peak work rate, resistance Training for 3 sets à 20 repetitions and squats on the floor.
3127197|NCT03077711|Active Comparator|Patients with recurrent UTIs arm 2|Patients are randomized to receive trimethoprim in the other arm if they are diagnosed with recurrent urinary tract infections.
3127198|NCT03077724|Experimental|Fish Oil|4.2 grams per day of n-3 long chain polyunsaturated fatty acids (LCPUFA)
3179543|NCT00673985|Active Comparator|1|"PTA Only: Active Comparator~Percutaneous transluminal angioplasty (PTA) alone"
3179544|NCT00673985|Experimental|2|"Test Arm: Experimental~The main objective of this study is to assess the safety and effectiveness of the Edwards Lifesciences LifeStent nitinol self expandable stent device and its delivery system in the treatment of occlusive superficial femoral artery (SFA) disease."
3479473|NCT03802786|Experimental|Moderate hepatic impairment|Single dose of Imeglimin
3479474|NCT03802786|Experimental|Normal hepatic function|Single dose of Imeglimin
3127199|NCT03077724|Placebo Comparator|Placebos|Olive oil supplements
3479475|NCT03802526|Experimental|NVP-1805-R1|"Drug: NVP-1805-R1~1 tablet, oral dosing"
3479476|NCT03802526|Experimental|NVP-1805-R2|"Drug: NVP-1805-R2~1 tablet, oral dosing"
3479477|NCT03802526|Experimental|NVP-1805-R1 and NVP-1805-R2|Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)
3479478|NCT03802318|Experimental|HDDT group|high dose PPI induction (oral rabeprazole 20mg qid) for 3 days, then 14 days combined with amoxicillin (regular dose, daily 2 g, 500mg qid) for high frequency dual therapy.
3479479|NCT03802318|Placebo Comparator|CATT group|conventional triple therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid)
3479480|NCT03802318|Experimental|LHDT group|high dose PPI (oral rabeprazole 20mg qid) induction for 3 days, then Rabeprazole 20 mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd for 14 days.
3479481|NCT03802318|Placebo Comparator|LATT group|levofloxacin base rescue therapy 14 days (rabeprazole 20 mg bid, amoxicillin 1 g bid, levofloxacin 500 mg qd)
3479482|NCT03802422|Experimental|Vitamin B12 hydrodissection|Ultrasound-guided hydrodissection with Vitamin B12 between carpal tunnel and median nerve.
3479483|NCT03802422|Placebo Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
3127200|NCT03077893|Experimental|Active Group|Treatment with active Provant Therapy System
3479484|NCT03802513|Other|Single arm|This study has 1 health-related intervention. Veterans with somatosensory tinnitus will receive individualized physiotherapy.
3127201|NCT03077893|Sham Comparator|Sham Group|Treatment with Inactive (sham) Provant Therapy System
3127202|NCT03077919|Active Comparator|Stellate Ganglion Block (SGB)|7-10 mL 0.5% ropivacaine injected under ultrasound visualization ventral to right longus coli muscle (around and into the ventral fascia) and into the longus coli immediately dorsal to the presumed ventral fascia, at the level of the C6 anterior tubercle (landmarks for stellate ganglion).
3479485|NCT03802370|Other|single am|single arm , superiority trial , tunneling technique in connective tissue graft around dental implants
3479486|NCT03802760||TAVI patients|Patients undergoing transfemoral TAVI
3479487|NCT03802760||MitraClip patients|Patients undergoing MitraClip implantation
3479488|NCT03802760||TricuspidalClip|Patients undergoing TricuspidalClip implantation
3479489|NCT03802292|Active Comparator|Single Ascending Dose YQ23|
3479490|NCT03802292|Placebo Comparator|Single Dose Placebo|
3479491|NCT03802539|Experimental|Glass Liner|Tooth restoration with a glass ionomer liner material under a nanohybrid composite resin
3479492|NCT03802539|No Intervention|No liner|Tooth restoration without a glass ionomer liner material under a nanohybrid composite resin
3479493|NCT03802435|Experimental|Two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 10cc 5% dextrose (3 months interval)
3479494|NCT03802435|Active Comparator|One-session of ultrasound-guided PIT|one-session of ultrasound-guided PIT with 10cc 5% dextrose and 10cc normal saline separately (3 months interval)
3479495|NCT03802435|Placebo Comparator|Two-session of ultrasound-guided nerve hydrodissection|two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
3479496|NCT03802253|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
3479497|NCT03802253|Active Comparator|RCD|Participants in this group will focus on standard care with daily reduced calorie diet (RCD)
3479498|NCT03802123|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5 mg to 1.5 mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 5 to 6 weeks after start of IOT.
3127203|NCT03077919|Sham Comparator|Sham Treatment|1-2 mL preservative-free normal saline, injected under ultrasound visualization anterolateral to right anterior tubercle of C6.
3479499|NCT03802006||fasted patient with previous gastrectomy|The fasted patient with previous subtotal gastrectomy except exclusion criteria are included
3127204|NCT03078075|Experimental|Active Medication Combination (AMC)|injectable extended release naltrexone plus once daily oral extended-release bupropion tablets
3127205|NCT03078075|Placebo Comparator|Matched Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
3479500|NCT03802071|Experimental|Durvalumab+doxorubicin combination|
3479501|NCT03802136||high concentration of biomarkers|the patients with biomarkers level over the normal max value
3479502|NCT03802136||low concentration of biomarkers|the patients with biomarkers level below the normal max value
3479503|NCT03802149|Experimental|Ulipristal Acetate|Participants will be administered a one time dose of 90mg ulipristal acetate 18-24-hours prior to dilation and evacuation (surgical abortion) for cervical preparation.
3479504|NCT03802279||Rhabdomyolysis with myoblasts back up|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited from a diagnostically muscle biopsy and whose myoblasts are available.~Patients benefit from an effort test as part of their care."
3479505|NCT03802279||Rhabdomyolysis|"Patients with a rhabdomyolysis linked to a hereditary disease of metabolism who have benefited or not from a diagnostically muscle biopsy but whose myoblasts are not available.~Patients benefit from an effort test as part of their care."
3479506|NCT03802279||Witness patients : effort test|10 patient-matched healthy controls for age and sex having performed an effort test and cardiac exploration as part of their care.
3479507|NCT03802279||Witness patients : myoblasts|6 healthy controls matched by age and sex having performed a muscle biopsy as part of their care and whose myoblasts are kept.
3479508|NCT03802019|Experimental|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will complete a 30-day experimental period when they will continue to receive their own preferred brand of cigarettes (i.e., control group).
3479509|NCT03802019|Experimental|LNC Cigarettes + Gray Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in standard investigational packaging (gray).
3479510|NCT03802019|Experimental|LNC Cigarettes + Red Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in red packaging.
3479511|NCT03802019|Experimental|LNC Cigarettes + Blue Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in blue packaging.
3479512|NCT03802019|Experimental|LNC Cigarettes + Plain Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in plain packaging.
3479513|NCT03802032|Experimental|Study Group|15g of Topical Xylocaine gel
3479514|NCT03802032|Placebo Comparator|Control group|15g of KY Jelly
3479515|NCT03801954||RC Patients|Patients at the University of Kansas Medical Center who have not yet had their radical cystectomy, after their radical cystectomy, or between the completion of chemotherapy and the radical cystectomy.
3132714|NCT03447314|Experimental|Part 1a: 150ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
3179545|NCT00674037|Experimental|inclusion with financial motivation|75 euros for each patient included
3479516|NCT03801967|Experimental|AZD9977|Each participant will receive AZD9977 at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
3479517|NCT03801967|Placebo Comparator|Placebo|Each participant will receive placebo at the selected dose level on Day 1 and from Day 3 to 9, with single dose on Day 1 and Day 9 and twice a day (BID) dosing on Day 3 to Day 8. No dose will be given on Day 2.
3479518|NCT03802058|Experimental|Nab-paclitaxel|Nab-paclitaxel and carboplatin for Injection; thoracic radiation therapy
3479519|NCT03802201|Experimental|PTG-300 Active|Drug: PTG-300 Subcutaneous
3479520|NCT03802097|Experimental|Treatment group|No antimicrobial prophylaxis
3479521|NCT03802097|No Intervention|Control group|Antimicrobial prophylaxis
3479522|NCT03802214||vedolizumab-UC-naïve to TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients who are naïve to TNF-antagonist therapy
3479523|NCT03802214||vedolizumab-UC- previous TNF-antagonist|standard vedolizumab induction therapy for ulcerative colitis patients with previous TNF-antagonist exposure
3479524|NCT03802266|Experimental|Electromagnetic Navigation group|Electromagnetic Navigation Guided Transthoracic Needle Aspiration
3479525|NCT03802266|Active Comparator|CT group|CT-guided Transthoracic Needle Aspiration
3479526|NCT03802084|Experimental|vactosertib/imatinib combination|
3479527|NCT03802162|Experimental|CKD-355A|
3479528|NCT03802162|Experimental|CKD-355B|
3479529|NCT03802162|Active Comparator|D797, D324|
3479530|NCT03801980|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
3479531|NCT03801980|Placebo Comparator|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
3479532|NCT03801889|Experimental|Cohort 1|SP-420 initially at 28 mg/kg
3479533|NCT03801889|Experimental|Cohort 2|SP -20 initially at 56 mg/kg
3479534|NCT03801889|Experimental|Cohort 3|SP-420 initially at 84 mg/kg
3127206|NCT03078127|Active Comparator|Sequence A|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), Whole body vibration, High Frequency Chest Wall Oscillation (HFCWO, aka Vest or TheVest®), Oscillatory Positive Expiratory Pressure (OPEP) (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
3179546|NCT00674037|No Intervention|no incentive|no incentive
3179547|NCT00674050|Experimental|1|
3179548|NCT00674063|Experimental|1|Dose regimen 1
3179549|NCT00674063|Experimental|2|Dose regimen 2
3479535|NCT03801941|Experimental|Group A|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with the ATLAS Device at the 4th day and without the device at the 5th day of a 4 weeks rehabilitation program.
3479536|NCT03801941|Experimental|Group B|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without the ATLAS Device at the 4th day and with the device at the 5th day of a 4 weeks rehabilitation program.
3479537|NCT03802045|Experimental|Low frequency EA|"25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 2Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm)."
3479538|NCT03802045|Experimental|High frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
3479539|NCT03802045|Experimental|Alternating frequency EA|"25 participants will receive 25 participants will receive bilateral application of electroacupuncture using a previously calibrated EL 608 electrostimulator (NKL® portable), with the following parameters: balanced asymmetrical biphasic polarized pulse with continuous pulse train with 100Hz and 2Hz for 3 seconds each; 100ms pulse duration and 0.5ms pulse width; and the maximum current (amplitude) intensity tolerated by the patient and intensified so that sensory habituation is avoided. Trichotomy will be carried out when necessary and the skin will be disinfected with 70% alcohol. With the participant lying down in a ventral position, the needles will be inserted at a 90º inclination with the skin, to a depth at which that the patient reports the deQi sensation (≅ 1.5cm).~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
3479540|NCT03802045|Active Comparator|Control Group|"25 participants will follow exactly the same protocol as the experimental groups, however they will not undergo electrical stimulation, as the acupuncturist will activate channels that are not connected to the patient.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
3479541|NCT03802045|Placebo Comparator|Placebo Group|"25 participants will will follow exactly the same protocol as the experimental groups, however an adhesive moxa (Dong Yang®) will be placed on each acupoint and the needle will be inserted over it, so that the participant only feels the needle prick, but without perforation of the skin and the deQi sensation. In addition, as in the control group, the electrodes will be connected to the needles, however, no electrical current will be applied.~Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used. The sessions will last 30 minutes, twice a week, for 5 weeks, totaling 10 sessions."
3127207|NCT03078127|Active Comparator|Sequence B|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), HFCWO, OPEP, Whole body vibration (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
3479542|NCT03802240|Experimental|Sintilimab +IBI305+Pemetrexed+Cisplatin|
3479543|NCT03802240|Experimental|Sintilimab +Placebo2+Pemetrexed+Cisplatin|
3479544|NCT03802240|Active Comparator|Placebo1+Placebo2+Pemetrexed+Cisplatin|
3479545|NCT03801876|Experimental|Group I (PBT, Chemotherapy, Esophagectomy)|Patients undergo PBT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing PBT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
3479546|NCT03801876|Active Comparator|Group II (IMRT, Chemotherapy, Esophagectomy)|Patients undergo IMRT over 28 fractions 5 days a week for 5.5 weeks to a total dose of 50.4 Gy. Patients also receive chemotherapy (Choice of 3 regimens: 1. Carboplatin/Paclitaxel, 2. FOLFOX/CAPOX or 3. Docetaxel/5-FU [with capecitabine as an acceptable substitute for 5-FU]) per institutional standards while undergoing IMRT. Within 4-8 weeks after completion of chemotherapy and radiation therapy, patients may undergo an esophagectomy per physician discretion.
3127208|NCT03078127|Active Comparator|Sequence C|"In this arm, the interventions were performed in the following order:~Baseline (prior to randomization), OPEP, Whole body vibration, HFCWO (note this is different than the sequence shown in the example latin square shown in the included protocol, as that was meant to serve as an example -- actual randomization and formulation of the employed latin square / sequence generator was performed following completion of the protocol)"
3127209|NCT03078478|Experimental|IDeg 200 U/mL|
3127210|NCT03078478|Active Comparator|IGlar 300 U/mL|
3127211|NCT03078504|Experimental|Experimental arm|The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics
3127212|NCT03078556|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 1, B: DTG 3TC FDC formulation 1 tablet in Period 2.
3179550|NCT00674076||sleep apnea|a patient has been diagnosed as having obstructive sleep apnea
3479547|NCT03801850|Experimental|observational cohort|
3479548|NCT03801837|Active Comparator|Macadamia Nut Diet|This group will have their habitual diet supplemented with appropriate portion of Macadamia Nuts (15% of daily calories or 30-45 grams based on Kcal requirement of the individual)
3479549|NCT03801837|Placebo Comparator|Control Diet|This group will continue with their Habitual Diet
3479550|NCT03801824|Active Comparator|Standard Nutrition Therapy|Subjects in this group receive a standard nutrition therapy based on local guidelines that is usually high in fibre with moderate to high glycemic index food
3479551|NCT03801824|Experimental|Low Glycemic Index|Subjects in this group receive intervention on low glycemic index foods
3479552|NCT03801603|Experimental|HPV Vaccination Training and Education|Participants will be educated on the importance of HPV vaccination.
3479553|NCT03801577|Experimental|Hepaxa|Subjects will receive Hepaxa according to standard use (4 capsules daily over a 6 month period)
3479554|NCT03801642|Experimental|Dapagliflozin|10 mg dapagliflozin oral tablet taken once daily for 12 weeks
3479555|NCT03801642|Placebo Comparator|Matching placebo|Placebo oral tablet taken once daily for 12 weeks
3479556|NCT03801746|Experimental|Vadadustat, Cyclosporine|Part 1: Arm 1: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral cyclosporine 500 mg in a crossover design
3479557|NCT03801746|Experimental|Vadadustat; Probenecid|Part 1: Arm 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with oral Probenecid 500 mg Q12h in a fixed sequence design
3479558|NCT03801746|Experimental|Vadadustat and Rifampin|Part 2: Subjects will receive vadadustat 300 mg alone and vadadustat 300 mg in combination with IV rifampin 600 mg in a cross-over design
3479559|NCT03801772|Active Comparator|Metronome|This arm will be using the metronome as a pacing device during aquatic exercises.
3479560|NCT03801772|No Intervention|Control|The patients will be educated on proper performance of aquatic exercises following normal physical therapy procedures. Patients will start with 10-20 repetitions of the exercises depending on their physical ability and progressed as the patient's strength and endurance improve. Each session will last approximately 30 to 45 minutes. The BORG scale (a valid, subjective measure of perceived exertion) will be used as a monitoring device to ensure that a desired level of exercise intensity is reached. The desired level is a score between 12 and 16. The patients will be asked to rate their level of exertion at the end of each session. Intensity of the exercises will be adjusted the next session if the patient's reported level of exertion does not fall within the desired range. The pain rating and the BORG number will be recorded for both groups in the chart and flow
3479561|NCT03801616|Experimental|Virtual Reality|Every participant is provided with a VR headset
3479562|NCT03801733|Experimental|Rosuvastatin, Vadadustat|Part 1: Subjects will receive rosuvastatin 20 mg alone, vadadustat 600 mg alone, followed by rosuvastatin 20 mg in combination with vadadustat 600 mg in a fixed-sequence dosing design.
3479563|NCT03801733|Experimental|Sulfasalazine. Pravastatin, Vadadustat|"Part 2, Arm 1: Subjects will receive sulfasalazine 500 mg alone followed by sulfasalazine 500 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 2, Arm 2: Subjects will receive pravastatin 40 mg alone followed by pravastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
3479564|NCT03801733|Experimental|Atorvastatin, Simvastatin, Vadadustat|"Part 3, Arm 1: Subjects will receive atorvastatin 40 mg alone followed by atorvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design.~Part 3, Arm 2: 24 subjects will receive simvastatin 40 mg alone followed by simvastatin 40 mg in combination with vadadustat 600 mg once a day in a fixed-sequence dosing design."
3479565|NCT03801707|Experimental|Intervention group|kidney transplant recipients who receive kidney allograft from hepatitis C viremic donors followed by treatment with direct acting antiviral therapies.
3479566|NCT03801668|Experimental|Nab-P/S-1|Patients in this arm receive chemotherapy with Albumin-bound Paclitaxel plus S-1.
3479567|NCT03801668|Active Comparator|SOX|Patients in this arm receive chemotherapy with Oxaliplatin plus S-1.
3479568|NCT03801629|Experimental|High Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.07 mg/kg).
3479569|NCT03801629|Experimental|Low Morphine Dose|Subjects in this experimental arm will receive a single intramuscular morphine dose (non-dominant deltoid muscle; 0.04 mg/kg).
3479570|NCT03801798|Experimental|NAs antivirals + GC1102 180,000 IU|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17 : IV bolus injection twice a week~V18 to V33 : IV bolus injection once a week"
3479571|NCT03801798|Placebo Comparator|NAs antivirals + GC1102 Placebo|"All patients are currently being treated with long-term NA treatment(more than 24 weeks) and will continue using these during the study.~Each vial contains 1mL of study drug or placebo; Single IV bolus injection of 18mL~V2 to V17: IV bolus injection twice a week~V18 to V33: IV bolus injection once a week"
3479572|NCT03801785|Experimental|Children induced to suck pacifiers.|Children will suck a pacifier of identical shape and type and will be allowed other NNS habits.
3479573|NCT03801785|No Intervention|Children induced to stop sucking.|Children will be induced by DDSs to stop sucking and their parents will be advised how to stop their children's NNS habits.
3479574|NCT03801551|Experimental|Patient|
3479575|NCT03801564|Experimental|Platelet Rich Plasma Group (PRP)|Platelet Rich Plasma Treatment Group (PRP): The blood is drawn from the antecubital vein to the 10cc line of EasyPRP syringe consisted 1.5ml of anticoagulant. The syringe is centrifuged at a rate of 1200 g for 2 minutes. Then the syringe is rotated and the lower chamber filled with erythrocytes is discharged. The connector is inverted and the air gap is discharged. The injector is again centrifuged at 1200G for 10 minutes. Then the injector is rotated in the direction of the arrow, the lower stopper is removed. The application injector of 3cc with connector is placed in the EasyPRP injector. 1 ml of the PRP containing Buffycoat is separated for content analysis, the remaining 2 ml of the string is injected. Injection is repeated one month interval
3479576|NCT03801564|Experimental|Hyaluronic acid Group (HA)|Hyaluronic Acid Treatment Group (HA): 2 ml HA (32mg / ml) containing 1.6% sodium hyaluronate is injected intraarticular. The molecular weight is 800 - 1200 K Dalton. The viscosity is 20 pascal / s. The pH of the product is 7-7.5.Injection is repeated one month interval.
3479577|NCT03801460|No Intervention|SOC|Standard of Care
3479578|NCT03801460|Experimental|RAPR|Remotely administered physiological reconditioning program
3479579|NCT03801486||Experimental (SCF40)|At the experimental data collection visits participants consumed 255g of pasta made with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
3479580|NCT03801486||Control (SEM100)|At the control data collection visits participants consumed 255g of pasta made with 100% semolina flour (SEM100) with butter.
3479581|NCT03801421|Experimental|Continous suture group|The surgical incision will be treated by mass continous suture with PDS.
3179551|NCT00674076||control|a case who has a negative polysomography or noraml score of Pittsburg sleep questionaire
3479582|NCT03801421|Active Comparator|Control group|The surgical incision will be treated by interrupted suture with thread.
3479583|NCT03801343|Experimental|Nutrakos®|12 female subjects aged 35-70, have taken during a meal, for the 1 month ,2 stick packs/die of the food supplement
3479584|NCT03801720|No Intervention|Control Group|Utilize standard practice for obtaining a CCU in pre-continent children; this consists of cleaning the GU area with betadine and waiting 5 minutes for micturition to occur.
3479585|NCT03801720|Experimental|Experimental Group|Consists of cleaning the GU area with betadine followed by using an ultrasound probe to apply cool ultrasound gel and subprapubic pressure to the patient to induce micturition.
3479586|NCT03801655|Experimental|Bio-Kult|4 capsules/day
3479587|NCT03801655|Placebo Comparator|Placebo|4 capsules/day
3479588|NCT03801590|Experimental|CXL on patients with infectious keratitis|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .
3479589|NCT03801382|Other|Digital / Paper|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
3479590|NCT03801382|Other|Paper / Digital|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.
3479591|NCT03801382|Other|Digital / Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.
3479592|NCT03801382|Other|Paper / Paper|Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.
3479593|NCT03801382|Other|Digital|Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A
3479594|NCT03801759|Experimental|Vadadustat, digoxin|Arm 1: Subjects will receive a single oral dose of digoxin 0.5 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of digoxin 0.5 mg.
3479595|NCT03801759|Experimental|Vadadustat, adefovir|Arm 2: Subjects will receive a single dose of oral adefovir 10 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone and in combination with a single dose of adefovir.
3479596|NCT03801759|Experimental|Vadadustat, Furosemide|Arm 3: Subjects will receive a single dose of oral furosemide 40 mg alone, followed by a washout period and repeat doses of vadadustat 600 mg QD alone, and in combination with a single dose of furosemide 40 mg.
3127213|NCT03078556|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A and will receive B: DTG 3TC FDC formulation 1 tablet in Period 1 and A: DTG 50 mg and 3TC 300 mg single entities in Period 2.
3479597|NCT03801512|Experimental|Steroid Injections|Inject steroid at neuritis nerve root.
3179552|NCT00674089|Active Comparator|1|Routine Post-partum Care and Vitamin A supplementation (50,000 IU) to the Newborn
3479598|NCT03801512|Experimental|Acupuncture|Acupuncture at acupoints BL23 to BL26.
3479599|NCT03801512|Experimental|Platelet Rich Plasma Injection|Inject Platelet Rich Plasma at neuritis nerve root.
3479600|NCT03801681||myocarditis|patients with clinically suspected myocarditis
3479601|NCT03801499|Experimental|Lenvatinib|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3479602|NCT03801538|Experimental|PEG-IFN group|"patients were treated with NAs once a day and PEG-IFN once a week for 12 weeks. At week 12, the decrease of HBsAg was evaluated.~①If the decrease of HBsAg is more than 50%. NAs was stopped. PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96.~②If the decrease of HBsAg is less than 50%.NAs and PEG-IFN was extended to week 24. Then, If the decrease of HBsAg is more than 50%. NAs was stopped, PEG-IFN Treatment was continued for a prolonged period (no more than 96 weeks) until the endpoint was achieved, or terminated in week 96. If the decrease of HBsAg is less than 50%. PEG-IFN was stopped, patients were treated with NAs once a day and then followed up for 48 weeks."
3479603|NCT03801538|Other|NAs group|CHB patients do not need to change their NAs treatment.
3479604|NCT03801330|Active Comparator|Usual Care|Participants in the Usual Care Pulmonary Rehabilitation will receive usual care pulmonary rehab program. Usual care programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is usual care exercise and education, which is personalized for each participant. No drugs are being tested in this study.
3479605|NCT03801330|Experimental|Software Tool|Participants in the Pulmonary Rehabilitation Software-Based Home Program will use a digital software tool (APP) to obtain the pulmonary rehab home program. Home programs typically consist of exercises including upper extremity strengthening, lower extremity strengthening, aerobic exercises such as walking and balance training. Each program is personalized as per the participant's ability. The intervention is exercise and education, which is personalized for each participant. No drugs are being tested in this study.
3479606|NCT03801304|Experimental|Atezolizumab associated with vinorelbine|"Atezolizumab will be administered with IV infusions. The first one will be a 60-min IV infusion; the subsequent infusions will last 30 minutes when well-tolerated at the dose of 1200 mg on day 1 of each 21-day cycle.~Vinorelbine capsules are taken orally on days 1, 3 and 5 of each week of the 21-day cycle. Vinorelbine will be administered at the dose of 40 mg per day on days 1, 3 and 5 of each week of the 21-day cycle. In case of toxicity, the dose will be decreased to 30 mg."
3479607|NCT03801252|Experimental|Cefazolin + Azithromycin|Women will be randomized 1:1 to receive cefazolin 2 grams intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and azithromycin 500 mg intravenously once at the start of the labor induction
3479608|NCT03801252|Placebo Comparator|Placebo + Placebo|Women will be randomized 1:1 to receive placebo intravenously at the start of the labor induction and every 8 hours thereafter for a maximum of three doses and placebo intravenously once at the start of the labor induction
3479609|NCT03800966|Experimental|Intervention|The intervention leaflets will contain information on the TI's tactics to get young people to smoke.
3479610|NCT03800966|Placebo Comparator|Control|The control leaflets will contain information on the tobacco control in Hong Kong.
3479611|NCT03801083|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with locally advanced, recurrent, or metastatic biliary tract cancers will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of up to 2x10^11 lymphocytes infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
3479612|NCT03801213|Active Comparator|Urinary catheterization|
3479613|NCT03801213|Experimental|manual bladder stimulation Technique|
3479614|NCT03801187|Sham Comparator|Chlorhexidine|Access flap will be raised to gain access to the implant surface. Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in Chlorhexidine.
3479615|NCT03801187|Experimental|Er:YAG laser|Er: Yag laser treatment will be provided on the implant surface.
3479616|NCT03801187|Active Comparator|Air Powder|An Air-Powder treatment will be provided on the implant surface
3479617|NCT03801122|Experimental|Tranexamic acid 3g/day|Administration of tranexamic acid 3g/day, with 3 injections/8 hours.
3479618|NCT03801122|Experimental|Tranexamic acid 1.5g/day|Administration of tranexamic acid 1.5g/day, with 3 injections/8 hours.
3479619|NCT03801122|No Intervention|No treatment|No treatment (no administration of tranexamic acid)
3479620|NCT03801200|Experimental|Apatinib combined with Radiotherapy|"Drugs: Apatinib Apatinib (500 mg/d) was given orally for one week before the brain radiotherapy, and then, continued to be administered at the same way during the brain radiotherapy period (3 weeks). It was given for another one week after the end of the brain radiotherapy.~Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy/15 to patients with 1-5 metastatic lesions."
3479621|NCT03801200|No Intervention|Radiotherapy alone|"Radiotherapy: Intensity-modulated radiotherapy (IMRT).~According to the patients KPS score, GPA score, the number and size of metastatic lesions can be selected:~37.5Gy/15 fractions of whole brain irradiation for multiple brain metastases were more than 5;~The whole brain was irradiated with 37.5Gy/15 and simultaneous integrated boost dose of 52.5Gy /15 to patients with 1-5 metastatic lesions."
3479622|NCT03801291|Active Comparator|Transvaginal repair|Repair of anterior rectocele via the vagina
3479623|NCT03801291|Active Comparator|Transperineal repair|Repair of anterior rectocele via the perineum
3127214|NCT03078556|Experimental|Subjects receiving high fat meal: Part 1|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 1 tablet with high fat meal in Period 3 to study the effect of food on tablet.
3127215|NCT03078556|Experimental|Treatment sequence A/C: Part 2|Eligible subjects will be randomized in sequence A/B and will receive A: DTG 50 mg and 3TC 300 mg single entities in Period 1 and C: DTG 3TC FDC formulation 2 tablet in Period 2.
3127216|NCT03078556|Experimental|Treatment sequence C/A: Part 2|Eligible subjects will be randomized in sequence C/A and will receive C: DTG 3TC FDC formulation 2 tablet in Period 1 and A: DTG 50 milligram (mg) and 3TC 300 mg single entities in Period 2.
3479624|NCT03801226|Experimental|10% dextrose in sterile water|Patients randomized to this arm will undergo a two-hour dwell with 10% dextrose in sterile water at their first visit and Dianeal Low-Calcium with 4.25% Dextrose at their second visit.
3479625|NCT03801226|Active Comparator|Dianeal Low-Calcium with 4.25% Dextrose|Patients randomized to this arm will undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first visit and 10% dextrose in sterile water at their second visit.
3479626|NCT03801031|Active Comparator|Lidocaine|Patients being treated for gynecologic cancer assigned aqueous lidocaine solution as intervention to use during sexual encounters.
3479627|NCT03801031|Placebo Comparator|Placebo|Patients being treated for gynecologic cancer assigned placebo solution as intervention to use during sexual encounters.
3479628|NCT03801239||patients with Overactive Bladder (OAB)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
3127217|NCT03078556|Experimental|Subjects receiving high fat meal: Part 2|Eligible subjects will be administered single dose of DTG 3TC FDC formulation 2 tablet with high fat meal in Period 3 to study the effect of food on tablet.
3479629|NCT03801239||patients with Mixed Urinary incontinence (MUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
3479630|NCT03801239||patients with Stress Urinary Incontinence (SUI)|Patients completed the Polish version of the OABSS on two separate visits: Week 0 and Week 2 and additionally UDI-6, IIQ-7 during visit- Week 2.
3127218|NCT03078582|Experimental|Zilucoplan (RA101495) treatment naive|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)
3479631|NCT03801135|No Intervention|Electrolyte&Albumin Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin.
3479632|NCT03801135|Experimental|Fibrinogen Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution and albumin. Fibrinogen concentrate will be infused afterwards.
3479633|NCT03801135|Active Comparator|FFP Treatment Group|One calculated plasma volume will be replaced with a mixture of electrolyte replacement solution, albumin and fresh frozen plasma.
3479634|NCT03801174|Experimental|Partner-assisted intervention|Patients and partners will receive intervention
3479635|NCT03801174|Active Comparator|Patient-only intervention|Patients will receive intervention
3479636|NCT03800979|Experimental|Tofacitinib|All participants will take Tofacitinib 5 mg twice daily for 24 weeks to treat extensive and recalcitrant alopecia areata.
3127219|NCT03078582|Experimental|Zilucoplan (RA101495) previously on eculizumab|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)
3127220|NCT03078595||von Willebrand disease type 2 and 3|Examinations (haematologically and periodontally) of von Willebrand disease patients with type 2 and 3 and healthy controls to evaluate whether type 2 and 3 VWD determines an increased susceptibility to gingival bleeding in response to the oral biofilm
3479637|NCT03801161|No Intervention|Healthy infants|
3479638|NCT03801161|Experimental|Infants with an inflammatory condition|Investigators will also use pentavalent (PENTA) vaccine as a means to induce controlled inflammation (closely mimic to natural infection). PENTA is a combination of five different vaccine antigens (Hepatitis B (HBV)/ Haemophilus influenza type b (Hib) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
3479639|NCT03801317|Experimental|BC/ egg|4.3 grams egg powder + 5.7 grams bovine colostrum
3479640|NCT03801317|Placebo Comparator|Control|15 grams corn-soya blend
3479641|NCT03801057|Active Comparator|MPH_active|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH). Random sequence of arms.
3479642|NCT03801057|Placebo Comparator|MPH_placebo|Daily intake at breakfast of supplementary placebo. Random sequence of arms.
3479643|NCT03800953|Experimental|Avelumab (Bavencio)|This is a single arm, and open label study. All the subjects recruited will receive Avelumab.
3479644|NCT03801369|Experimental|Treatment (Olaparib and Durvalumab)|Patients with biopsy proven TNBC will undergo a pre-treatment biopsy, after which they will receive a 28 days induction treatment of olaparib (oral, twice a day). At the 2 week mark, patients will then undergo a repeat on-treatment biopsy. Beginning cycle 2, durvalumab will be administered (IV over 1 hr) every 4 weeks, in addition to olaparib. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients deriving clinical benefit from treatment may, at the investigator's discretion and in the absence of disease progression or unacceptable toxicity, may continue on therapy beyond the planned 13 cycles.
3479645|NCT03800927|Placebo Comparator|Sham Ultrasound Device|No ultrasound treatment
3479646|NCT03800927|Active Comparator|Active Ultrasound Device|Active treatment
3479647|NCT03801018||Parents who have used the donation of gametes|
3479648|NCT03801018||Children born of gametes donation|
3479649|NCT03801070||Less than median number necrosectomies|Group one includes patients who underwent less than median number necrosectomies
3479650|NCT03801070||At least the median number of necrosectomies|Group two includes patients who underwent at least the median number of necrosectomies
3479651|NCT03801096|Experimental|Narrative Based Therapuetic Assessment|
3127221|NCT03078595||controls|For each case (VWD) a respective haematologically healthy control is recruited from the gingivitis and periodontitis patients of the Department of Periodontology, Centre for Dentistry and Oral Medicine (Carolinum), Johann Wolfgang Goethe-University Frankfurt/Main. Each control is matched to one of the respective cases for sex, age (±5 years), self-reported smoking status (current smoker/non-smoker), number of remaining teeth (±2 teeth), and periodontal diagnosis (gingivitis, chronic or aggressive periodontitis).
3479652|NCT03801096|Active Comparator|Health Education (HE)|
3479653|NCT03800914|Experimental|High Intensity Interval Training|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 36 minutes of interval aerobic exercise on a cycle ergometer alternating every 30 seconds between 100% of peak work rate, achieved on the cardiopulmonary exercise test (CPET), plus upper and lower resistance training.
3127222|NCT03078647|Experimental|Profound treatment to small areas|Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms
3127223|NCT03078751|Experimental|Ribociclib + adjuvant endocrine therapy (ET)|"Patients in this arm took Ribociclib in combination with standard adjuvant endocrine therapy.~ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen (Tamoxifen no longer permitted after protocol amendment 2)"
3127224|NCT03078751|Placebo Comparator|Placebo + adjuvant endocrine therapy (ET)|Patients in this arm took Placebo in combination with standard adjuvant endocrine therapy. ET was one of these 4: Letrozole, Anastrozole, Exemestane, Tamoxifen
3479654|NCT03800914|Active Comparator|Traditional pulmonary rehabilitation|Participants will undergo a twice-weekly supervised exercise training program for eight weeks. Each session will involve 30 minutes of continuous aerobic exercise on a cycle ergometer at 60% of the peak work rate achieved on the CPET, plus upper and lower resistance training.
3127225|NCT03078816|Experimental|DBS active|"All participants will be enrolled in DBS placement and active stimulation. The following components will be used:~Activa PC Primary Cell Neurostimulator - (Model 37601)~Activa RC Rechargeable Neurostimulator - (Model 37612)~Activa SC Single Cell Neurostimulator (Models 37602 and 37603)~DBS Lead - (Model 3387)~DBS Extension - (Models 37085/6)~Patient Programmer - (Model 37642)~Test Stimulator - (Model 3625)~N'Vision Clinician Programmer - (Model 8840)~N'Vision Software Application Card - (Model 8870)"
3479655|NCT03800940|Experimental|Fistulography and trans-drain occlusion|Fistulography is performed to assess the condition of the fistula, and trans-drain occlusion is performed by injecting glue (NBCA and Lipiodol) through the drain to occlude the tract.
3479656|NCT03800940|Sham Comparator|Fistulography|Fistulography is performed to assess the condition of the fistula, without trains-drain occlusion.
3479657|NCT03800732|Experimental|Night workers.|Night workers of the military police of Minas Gerais, Uberlândia, who will participate in the three interventions of the study.
3479658|NCT03800706|Experimental|TQB2450|
3479659|NCT03800888|Experimental|Arm A|Participants in Arm A will receive a Wisepill device for Real- time monitoring plus Daily SMS reminders plus Social Supporter notifications (for 3 months) sent according to participant's preferred time and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
3479660|NCT03800888|Experimental|Arm B|Participants in Arm B will receive a wisepill device for Real-time monitoring plus Weekly SMS reminders plus Social support notifications (for 3 months) sent according to participant's preferred time and date and then shall receive Linked SMS for missed dose (Right after missed dose) plus Social Support notifications (3 months).
3127226|NCT03078907|Experimental|Selexipag|Selexipag is up-titrated from Day 1 to Week 12 to the individualized highest tolerated dose (HTD), which can range from 200 mcg b.i.d. to 1600 mcg b.i.d., in 200 mcg steps starting with 200 mcg b.i.d. Then, the dose is increased in increments of 200 mcg b.i.d., usually at weekly intervals, depending on the dose tolerability. Up-titration is followed by a stable maintenance treatment period at the highest tolerated dose, from Week 13 to Week 24.
3127227|NCT03078907|Placebo Comparator|Placebo|Regimen and titration scheme similar to those in the selexipag group
3479661|NCT03800888|No Intervention|Arm C|Participants in Arm C will receive only the Wise pill device (No SMS)
3479662|NCT03800836|Experimental|Arm A1: Ipat + Atezo + Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479663|NCT03800836|Experimental|Arm A2: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479664|NCT03800836|Experimental|Arm A3: Ipat + Atezo + Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479665|NCT03800836|Experimental|Arm B1: Ipat + Atezo + Nab-Pacl|Safety Run-In (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479666|NCT03800836|Experimental|Arm B2: Ipat + Atezo + Nab-Pacl|Expansion (Cohort 1): Participants will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by IV infusion on Days 1 and 15 of each 28 day cycle. Nab-paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479667|NCT03800836|Experimental|Arm C1: (Ipat + Pacl) (2 weeks) + Atezo|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479668|NCT03800836|Experimental|Arm C2 (Ipat + Pacl) (2 weeks) + Atezo|Expansion (Cohort 1): Participants will receive a 2-week lead in of ipatasertib in combination with paclitaxel, followed by atezolizumab in an initial 28-day (1 cycle) period. Ipatasertib will be administered orally daily on Days 1-21, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Atezolizumab will be administered by IV infusion on Day 15. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3127228|NCT03078946|Active Comparator|Dexmedetomidine Group (N=30)|
3127229|NCT03078946|Active Comparator|Morphine with Midazolam (N=30)|
3127230|NCT03079375|No Intervention|usual care|no pharmaceutical intervention.
3127231|NCT03079375|Sham Comparator|basic intervention|Medication review
3127232|NCT03079375|Sham Comparator|extended intervention|medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
3127233|NCT03079531|Experimental|Secukinumab arm|Participants receive secukinumab (7 doses over a 16-week study period).
3127234|NCT03080142|Experimental|Group 1|Single injection of Exparel
3179553|NCT00674089|Placebo Comparator|2|Routine Post-partum Care with Placebo to the Newborn
3179554|NCT00674102|Experimental|ASA404|
3127235|NCT03080142|Active Comparator|Group 2|Injection of Ropivicaine (Naropin) bolus and placement of Ropivicaine catheters
3132715|NCT03447314|Experimental|Part 1a: 200ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
3179555|NCT00674141|Other|1|only one experimental treated group
3479669|NCT03800836|Experimental|Arm D1: (Atezo + Pacl) (2 weeks) + Ipat|Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479670|NCT03800836|Experimental|Arm D2: (Atezo + Pacl) (2 weeks) + Ipat|Expansion (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479671|NCT03800836|Experimental|Arm E: Ipat + Atezo|Participants (Cohort 2) will receive Ipatasertib orally daily on Days 1-28 of Cycle 1 (35-day cycle) and on Days 1-21 of subsequent cycles (28-day cycles). Atezolizumab will be administered by IV infusion on Days 8 and 22 of Cycle 1 and on Days 1 and 15 of subsequent cycles. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479672|NCT03800836|Experimental|Arm F1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
3479673|NCT03800836|Experimental|Arm F2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
3479674|NCT03800836|Experimental|Arm G1: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Safety Run-In (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
3479675|NCT03800836|Experimental|Arm G2: Ipat + Atezol + AC / Ipat + Atezo + Pacl|Expansion (Cohort 3): Participants will receive in Cycles 1 and 2 (28 day cycles), Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15 and AC (Doxorubicin and Cyclophosphamide) via IV infusion on Days 1 and 15. In Cycles 3-5, participants will receive Ipatasertib orally daily on Days 1-21, Atezolizumab via IV infusion on Days 1 and 15, with Paclitaxel administered by IV infusion on Days 1, 8, 15 and 22. All participants in this cohort will continue to be treated for five cycles (28-day cycles; 20 weeks) or until disease progression or unacceptable toxicity, whichever occurs first.
3127236|NCT03080454|Placebo Comparator|Sham Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
3127237|NCT03080454|Active Comparator|Anodal Doublestim|Participants first received 5 daily, consecutive 20 min sessions of sham Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). After a washout period of 1 week, they then received 5 daily, consecutive 20 min sessions of anodal Doublestim (trans-spinal direct current stimulation + peripheral direct current stimulation). For all participants, the sham condition preceded the anodal Doublestim condition.
3127238|NCT03080493|Active Comparator|Gabapentin|"Gabapentin 600 mg PO - first dose in clinic prior to osmotic dilator placement, second dose 8 hours later (at home)~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
3127239|NCT03080493|Placebo Comparator|Placebo oral capsule|"Matched placebo~Will receive standard regimen of acetaminophen/codeine and ibuprofen to take as needed for pain overnight"
3127240|NCT03080961|Experimental|Before and after VIBLOK|The degree to which HSV-2 is blocked by the VIBLOK cream is determined by comparing the amount of HSV in the external genital area before and after application of the cream. So participants are their own control.
3127241|NCT03081117|Experimental|Insulin, intranasal|Regular insulin, 20 IU intranasal twice a day for 24 weeks; 0.2 mL per dose
3127242|NCT03081117|Placebo Comparator|Placebo, intranasal|Saline solution (placebo), intranasal twice a day for 24 weeks; 0.2 mL per dose
3127243|NCT03081884|Experimental|FACBC PET-CT Imaging|Individuals who have been diagnosed with primary prostate carcinoma and do not have definitive findings of systemic metastasis with conventional imaging will have a whole body FACBC PET-CT scan.
3127244|NCT03082196|Experimental|Test varnish|Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
3479676|NCT03800836|Experimental|Arm H: Ipat + Atezo + Pacl|Participants (Cohort 4) will receive ipatasertib orally daily on Days 1-21 of each 28 day cycle, and atezolizumab will be administered by intravenous (IV) infusion on Days 1 and 15 of each 28 day cycle. Paclitaxel will be administered by IV infusion on Days 1, 8, and 15 of each 28 day cycle. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
3479677|NCT03800901|Active Comparator|Control|The Control arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will not be offered Continuing Medical Education (CME) or American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
3479678|NCT03800901|Experimental|CME|The CME arm will be asked to care for online, Quality IQ patient simulations and will receive feedback based on their care decisions made in each case. The feedback will identify correct care, unneeded care, or gaps in care and recommend or reinforce evidence-based care decisions and includes references. This arm will be offered Continuing Medical Education (CME) and American Board of Internal Medicine (ABIM) Part II Maintenance of Certification (MOC) credits for their participation.
3479679|NCT03800680|No Intervention|Usual Care (Arm 1)|Participants will receive usual care by their diabetes clinics.
3479680|NCT03800680|Experimental|DMP (Arm 2)|Participants will receive usual care by their diabetes clinics and the Diabetes Management Package (DMP).
3479681|NCT03800680|Experimental|DMP + M-POWER Rewards (Arm 3)|Participants will receive usual care by their diabetes clinics, the Diabetes Management Package (DMP), and the financial incentive program, M-POWER Rewards.
3479682|NCT03800641|Experimental|oral administration|oral administration of dexmedetomidine 4μg/kg
3479683|NCT03800641|Active Comparator|intravenous administration|intravenous administration of dexmedetomidine 0.8μg/kg
3127245|NCT03082196|Active Comparator|Standard varnish|The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.
3127246|NCT03082261|Other|All enrolled subjects|All subjects enrolled into the study with intent to treat with either a Prodigy, Prodigy MRI, or Proclaim Elite Implantable Pulse Generator (IPG).
3127247|NCT03082586|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
3127248|NCT03082586|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
3127249|NCT03082586|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
3479684|NCT03800641|Experimental|nasal administration|nasal administration of dexmedetomidine 1μg/kg
3127250|NCT03082586|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
3127251|NCT03082586|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
3127252|NCT03082586|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
3127253|NCT03082599|Active Comparator|Emmetropia both eyes (OU) group|Symfony Toric IOL target refraction both eyes emmetropia (±0.25D).
3127254|NCT03082599|Experimental|Nanovision group|Symfony Toric IOL target refraction for the dominant eye will be plano (±0.25D) and for the non-dominant eye -0.50 ±0.16 D.
3127255|NCT03083093||CTEPH patients|the initial CTPA scan will be reviewed in patients diagnosed with CTEPH after an episode of an acute PE
3127256|NCT03083093||non CTEPH patients|the initial CTPA scan will be reviewed in patients after an episode of an acute PE in whom CTEPH was excluded
3127257|NCT03083132|Active Comparator|Early-start|24 weeks of modafinil 50 mg oral daily
3127258|NCT03083132|Placebo Comparator|Delayed-start|12 weeks of oral placebo followed by 12 weeks of modafinil 50 mg oral daily
3127259|NCT03083379|Active Comparator|Volumetric Incentive Spirometry|Incentive Spirometry
3127260|NCT03083379|Experimental|EzPAP® POSITIVE AIRWAY PRESSURE|EzPAP
3127261|NCT03083470|Experimental|SOR007 0.15%|SOR007 Ointment 0.15% applied to the face twice daily for 28 days
3127262|NCT03083470|Experimental|SOR007 0.3%|SOR007 Ointment 0.3% applied to the face twice daily for 28 days
3127263|NCT03083470|Experimental|SOR007 1.0%|SOR007 Ointment 1.0% applied to the face twice daily for 28 days
3127264|NCT03083470|Experimental|SOR007|SOR007 Ointment 2.0% applied to the face twice daily for 28 days
3127265|NCT03083470|Sham Comparator|Ointment Vehicle|SOR007 Ointment vehicle applied to the face twice daily for 28 days
3127266|NCT03083483|Experimental|Bilateral M1, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the bilateral M1 areas of the brain by measurement of 20% length of periauricular distance left and right of the vertex. The anode was placed on the left side and the cathode was placed on the right side.
3127267|NCT03083483|Experimental|SMA, active tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants randomized to this cohort had tdcs applied over the supplementary motor area. The cathode was placed 10% of nasion-inion distance above the nasion and 15% of nasion-inion distance anterior to the vertex.
3479685|NCT03800823|Experimental|Parent group & mHealth component|The intervention in the present study is a 10 week parent training group session (More and Less Program) followed by a 6-month mobile phone based intervention. Both components aim to develop healthy lifestyle behaviours regarding dietary habits and physical activity in 2-6 year olds. The intervention is delivered towards the parents.
3479686|NCT03800823|Active Comparator|Standard care|Standard care for overweight and obesity
3479687|NCT03800810|Experimental|Control|Week 1: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
3479688|NCT03800810|Experimental|Intervention 1|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
3479689|NCT03800810|Experimental|Intervention 2|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis)
3479690|NCT03800810|Experimental|Intervention 3|Week 1: Intraarticular injection of 10x10^6 unit of umbilical cord mesenchymal stem cells in 2 ml conditioned medium, 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis) Week 2: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories) Week 3: Intraarticular injection of 2 ml hyaluronic acid (Synvisc-One® Hylan G-F 20, Sanofi-Aventis), 8 IU recombinant human somatropin (Novell-Eutropin®, Novell Pharmaceutical Laboratories)
3479691|NCT03800563|Experimental|Laser assisted liposuction|Laser Assisted Liposuction with the LipoLife system.
3479692|NCT03800875|Experimental|Insulin-Pramlintide Closed-Loop Strategy|Fast-acting insulin will be delivered using two separate infusion pumps. The pumps' infusion rates will then be changed manually based on the computer-generated recommendation. The computer-generated recommendations are based on a dosing algorithm. With no-meal announcement or carbohydrate counting, the dual-hormone closed-loop system will be fully reactive, and insulin and pramlintide dosages will be based solely on sensor readings
3479693|NCT03800875|Active Comparator|Insulin-alone Closed Loop Strategy|"Fast-acting insulin will be delivered by a subcutaneous insulin infusion pump based on an algorithm that automatically adjusts insulin rates based on a dosing algorithm. The carbohydrate content for every ingested meal will be entered into the algorithm to calculate the insulin prandial bolus based on each participant's insulin-to-carbohydrate ratio. The carbohydrate content will be entered at the onset of the meal.~Drug(s): Insulin (FiAsp)"
3479694|NCT03800719|Experimental|Intervention Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, regular messages through Instant Messaging (IM), psychosocial support and referral to SC services through IM
3479695|NCT03800719|Active Comparator|Control Group|AWARD advice, health warning leaflet, active referral to smoking cessation (SC) services, SMS message on general health
3479696|NCT03800667|Experimental|Women on a vitamin C regimen|Women who are undergoing elective gynecological surgeries and who are randomized to take 1000 mg of vitamin C for one month,
3479697|NCT03800667|No Intervention|Women not taking vitamin C|Women who are undergoing elective gynecological surgeries and who are randomized not to take any vitamin C for one month.
3479698|NCT03800745|No Intervention|No Medication|No intervention is assigned in Arm A.
3479699|NCT03800745|Experimental|Colace|This is Arm B. Docusate sodium(Colace) is prescribed as100mg twice daily orally. Patients will be instructed to begin taking this the evening of surgery through postoperative day five.
3479700|NCT03800745|Experimental|Miralax|This is Arm C. Miralax 17 grams oral powder pack daily is prescribed to be taken with breakfast. Patients will be instructed to begin taking this the morning after surgery through postoperative day five.
3479701|NCT03800771|Experimental|Practice dual-task tests|"The study consists to practice these dual-task tests with a new device which name is Cycléo BRAU that allows to the patients to achieve carefully an attentional task: cycle. Results will be compared tothe results obsvered during the routine GAITRITE analysis ( a validated tool for elderly patients and gait analysis)."
3479702|NCT03800862||CTP and CT-FFR|"This will be a prospective, observational study designed to include a convenience sample of all qualifying patients undergoing myocardial CTP and CT-FFR.~The study will enroll patients who have chest discomfort and will require further evaluation for the presence of coronary artery disease. Patients in the study will include those who have had a clinically indicated CCTA for suspicion of coronary artery disease and are determined to have a coronary stenosis ≥50% and ≤99%. However, patients with Left main disease greater than 50% and occluded vessels Coronary Artery Disease Reporting and Data System (CAD RADS 5) will be excluded from the study. CCTA is a clinically indicated and standard of care procedure at Lancaster General Hospital.~."
3479703|NCT03800498|Experimental|Intervention|For twelve weeks, only intervention group were given DASH education
3479704|NCT03800498|No Intervention|Controlled|Controlled group not received DASH education
3479705|NCT03800602|Experimental|Treatment (nivolumab, metformin)|Patients receive metformin PO BID starting on day 1. After 14 days of metformin only period patients also receive nivolumab IV every 4 weeks starting on day 15. Courses repeat every 28 days for up to 2 years in the absence of disease progression, unacceptable toxicity or consent withdrawal.
3479706|NCT03800693|Active Comparator|2-hour infusion group|Patients receive oxaliplatin IV and leucovorin IV over 2 hours on day 1. Patients also receive a lower dose of fluorouracil IV over 2-4 minutes followed by a higher dose IV continuous over 4-6 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3479707|NCT03800693|Experimental|6-hour infusion group|Patients receive oxaliplatin IV over 6 hours on day 1. Patients also receive leucovorin and fluorouracil as in the 2-hour infusion group. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3479708|NCT03800381||Active TB only|Children with clinical diagnosis or acid-fast bacilli (AFB) smear positive TB disease
3479709|NCT03800381||Active TB with HIV Co-infection|Children with clinical diagnosis or AFB smear positive TB disease who test positive for HIV infection
3479710|NCT03800485|Experimental|IMT-GE|the participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will increase from the 15% of the maximal inspiratory preassure until the 60% of the maximal inspiratory preassure.
3479711|NCT03800485|Placebo Comparator|IMT-GP|The participants will perform a training protocol of the inspiratory muscles during 8 weeks with a load that will be the 10% of the maximal inspiratory preassure during all the 8 weeks
3479712|NCT03800407||EFV-based ART|ART-naïve HIV-infected children aged 3 - 14 years who initiate EFV-based ART
3479713|NCT03800407||Concurrent EFV-based ART plus anti-TB therapy|ART-naïve HIV-infected children aged 3 - 14 years with TB coinfection who initiate EFV-based ART while receiving first-line anti-TB therapy
3479714|NCT03800589|Active Comparator|phaco and Ex-Press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to phacoemulsification with implantation of the Ex-Press
3479715|NCT03800589|Active Comparator|deep sclerectomy, phaco and Ex-press|patients with co-existing cataract and glaucoma, qualified to the combined glaucoma surgery according to the protocol which were randomized to deep sclerectomy, phacoemulsification, ExPress implantation
3479716|NCT03800550|Experimental|Treatment Sequence 1: Bedaquiline and Clarithromycin|Participants will receive bedaquiline on Day 1 in Period 1, followed by clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 2. There will be washout period of at least 28 days starting on Day 1.
3479717|NCT03800550|Experimental|Treatment Sequence 2: Clarithromycin and Bedaquiline|Participants will receive clarithromycin on Days 1-14 and bedaquiline on Day 5 in Period 1, followed by bedaquiline on Day 1 in Period 2. There will be a washout period of at least 28 days starting after bedaquiline administration on Day 5.
3479718|NCT03800186||Trauma femoral fracture|Patients to be aged ≥20 years and hospitalized for the treatment of femoral fracture following injury. Patients were grouping into five subgroups as patients with fracture of proximal type A, proximal type B, proximal type C, femoral shaft, and distal femur.
3479719|NCT03800238|Experimental|Telehealth Delivery Format|This group will participate in the Powerful Tools for Caregivers program using a telehealth delivery method.
3479720|NCT03800238|Active Comparator|Standard Delivery Format|This group will participate in the Powerful Tools for Caregivers program in person.
3479721|NCT03800251|Other|Fasting parturients at term|Fasting parturients at term, admitted for elective cesarean section, who consent to partake in the study
3479722|NCT03800459|Experimental|Experimental: Intervention group|Experimental: Intervention group
3479723|NCT03800459|No Intervention|Control:no intervation group|Control:no intervation group
3479724|NCT03800264|Active Comparator|BISOPROLOL|BISOPROLOL 5mg per oral (P.O.) in the evening of the operation and then one dose (5 mg) every twenty four hours during the next two days.
3479725|NCT03800264|Active Comparator|hydrocortisone|hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the next two days.
3479726|NCT03800472|Experimental|GLPG3312 SAD IR (Part 1)|Single doses of GLPG3312 IR
3479727|NCT03800472|Placebo Comparator|Placebo SAD IR (Part 1)|Single doses of Placebo IR
3479728|NCT03800472|Experimental|GLPG3312 SAD MR (Part 2)|Single doses of GLPG3312 MR
3479729|NCT03800472|Placebo Comparator|Placebo SAD MR (Part 2)|Single doses of Placebo MR
3479730|NCT03800472|Experimental|GLPG3312 FE MR (Part 3)|Single dose of GLPG3312 MR in fed and fasted state
3479731|NCT03800472|Experimental|GLPG3312 MAD MR (Part 4)|Multiple doses of GLPG3312 MR
3479732|NCT03800472|Placebo Comparator|Placebo MAD MR (Part 4)|Multiple doses of Placebo MR
3479733|NCT03800472|Experimental|GLPG3312 MAD MR optimized (Part 4)|Multiple doses of GLPG3312 MR
3127268|NCT03083483|Sham Comparator|sham tDCS|Participants will complete 6 sessions of the FLS peg transfer task over a 7-day time span. Participants in this group were either randomized into either Bilateral or SMA configurations using the same measurements, but did not receive active stimulation. Half of these subjects will be placed in the SMA configuration and the other half in the bilateral M1 electrode configuration.
3127269|NCT03083639|Experimental|Esomeprazole 40 mg Capsule + Esomeprazole 40 mg Tablet|Esomeprazole 40 mg, capsule, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg tablet, orally, once on Day 1 of Intervention Period 2.
3479734|NCT03800472|Placebo Comparator|Placebo MAD MR optimized (Part 4)|Multiple doses of Placebo MR
3479735|NCT03800394||HIV only|Adolescents aged 10-19 years with HIV infection
3479736|NCT03800394||HIV/TB|Adolescents aged 10-19 years with HIV and TB coinfection
3479737|NCT03800420|Experimental|BBT-401-1S|BBT-401-1S, Oral capsule, QD
3479738|NCT03800420|Placebo Comparator|Placebo|Placebo, Oral capsule, QD
3127270|NCT03083639|Experimental|Esomeprazole 40 mg Tablet + Esomeprazole 40 mg Capsule|Esomeprazole 40 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by 6 days of washout period, followed by esomeprazole 40 mg capsule, orally, once on Day 1 of Intervention Period 2.
3127271|NCT03083769||Cohort 1|The retrospective cohort consists of about 839 kidney transplant recipients from Nanfang Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
3127272|NCT03083769||Cohort 2|The retrospective cohort consists of about 663 kidney transplant recipients from Guilin No. 924 Hospital. These patients used tacrolimus as immunosuppressive drug for preventing the rejection.The side effects (acute rejection, nephrotoxicity and neurotoxicity) will be recorded.
3479739|NCT03800797|Experimental|LX-P group|loxoprofen sodium hydrogel patch (LX-P) 100 mg per day for 4 weeks
3479740|NCT03800797|Active Comparator|LX-T group|loxoprofen sodium tablet (LX-T) 60 mg t.i.d. for 4 weeks
3479741|NCT03800654|Other|Mindful Action for Pain (MAP) Development|In the first arm, MAP will be fully developed.
3479742|NCT03800654|Active Comparator|MAP vs. CBT-CP|In the second arm, MAP will be compared to CBT-CP to establish feasibility of a larger, future trial.
3479743|NCT03800342|Experimental|Healthy|Healthy individuals will participate in two separate days of cardiopulmonary exercise testing (CPET) (separated by a minimum of two, maximum of 7 days apart) prior to starting the aerobic exercise training program (AET). Individuals will then complete a 4-5 week (4x/week x 17 sessions) continuous, high-intensity AET. Each training session will consist of cycling for 3-5 minutes to warm-up, 45 minutes at 70% of heart rate reserve (HRR-determined from pre-training CPET), and 5-10 minutes to cool down. Following the AET, individuals will repeat the two separate days of CPET performed pre-training.
3479744|NCT03800316|Experimental|Synchronous Video Consultation|Testing the feasibility of a synchronous video consultation in the field prior to emergency department arrival.
3479745|NCT03800277|Experimental|Cranberry and Agaves|Cranberry extract (2 capsules) + Agaves powder (1 single-dose packet)
3479746|NCT03800277|Experimental|Cranberry and placebo|Cranberry extract (2 capsules) + Placebo powder (1 single-dose packet)
3479747|NCT03800277|Experimental|Placebo and Agaves|Placebo (2 capsules) + Agaves powder (1 single-dose packet)
3479748|NCT03800277|Placebo Comparator|Placebo and placebo|Placebo (2 capsules) + Placebo powder (1 single-dose packet)
3479749|NCT03800446|Other|Intervention|All patients will undergo testing with the study intervention (point of care) and routine testing with serum ferritin (venous blood sample).
3479750|NCT03800290|Experimental|Clenbuterol hydrochloride|"Subjects will ingest clenbuterol hydrochloride capsules (20 microgram/each) twice daily (40 microgram/day) for a maximum of 14 days.~Subjects that received the clenbuterol hydrochloride capsules (at random) in the first study period will receive the placebo capsules during the second study period."
3479751|NCT03800290|Placebo Comparator|Placebos|"Subjects will ingest placebo capsules matching the clenbuterol hydrochloride capsules one time per day for a maximum of 14 days.~Subjects that received the placebo capsules (at random) in the first study period will receive the clenbuterol hydrochloride capsules during the second study period."
3479752|NCT03800147|Active Comparator|High-fat diet|"Participants will follow a high-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
3479753|NCT03800147|Active Comparator|Low-fat diet|"Participants will follow a low-fat diet. During the intervention phase, they will inoculate Mutaflor Suspension (E. coli Nissle 1917) (Single dose, 5 ml = 5x10^8 CFU).~Blood samples, stool samples and clinical information will be collected during the study."
3479754|NCT03800303|Experimental|two-week family-based treatment|Active treatment includes a two-week family-based partial hospitalization treatment utilizing and integrated therapeutic design.
3479755|NCT03800524|Experimental|Tauroursodeoxycholic acid (TUDCA)|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
3479756|NCT03800524|Placebo Comparator|Reference therapy|"Placebo capsules identical to active compound~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
3479757|NCT03800368|Experimental|High-endurance group|This group of subjects will receive 2-3 sessions of high-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will interchange between the aerobic and anaerobic state.
3479758|NCT03800368|Experimental|Low-endurance group|This group of subjects will receive 2-3 sessions of low-intensity cycling exercise training per week, for a total of 12 weeks. The exercise the subjects received will maintain at an aerobic level.
3479759|NCT03800368|Active Comparator|Psycho-education|This group of subjects will receive 2-3 sessions of psycho-education class per week, for a total of 12 weeks. The content of the class includes non-exercise related psycho-education content to participants (e.g., food hygiene, psychological well being, food nutrition, etc).
3479760|NCT03800225|Experimental|Repair|Anterior cruciate ligament repair with internal brace after anterior ligament rupture.
3479761|NCT03800225|Active Comparator|Patella tendon graft|The Patella tendon graft is harvested and used as a knew anterior cruciate ligament after rupture.
3479762|NCT03800537|Experimental|All Participants|All participants will receive the investigational MR Fingerprinting sequence.
3479763|NCT03800433|No Intervention|control|23 patients will receive their usual dose of erythropoietin stimulating agents and their routine treatment.
3479764|NCT03800433|Experimental|test|23 patients will receive the intervention drug Pentoxifylline (Trental 400 milligram(MG) Extended Release Oral Tablet) twice daily in addition their usual dose of erythropoietin stimulating agents and their routine treatment.
3479765|NCT03800511||repeated caesarean section|full term pregnant women with singleton baby with a history of at least previous one caesarean section
3479766|NCT03800108|Other|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
3479767|NCT03799848|Experimental|Vadadustat|Group 1: Subjects with moderately impaired hepatic function (Child-Pugh Class B) Group 2: Normal healthy volunteers Group 3: Subjects with mildly impaired hepatic function (Child-Pugh Class A)
3479768|NCT03799835|Active Comparator|Arm A : control arm|"BCG therapy only~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1)."
3479769|NCT03799835|Experimental|Arm B: experimental arm|"BCG therapy + administration of atezolizumab~BCG therapy will be administered in two phases:~induction phase: weekly administration of full dose of BCG intravesically up to 6 weeks, starting on the day of the first induction instillation (D1)~maintenance phase: full-dose BCG administered once per week for 3 weeks, at week 13 (i.e. 3 months after the first BCG instillation of induction, D1), at week 26 (6 months from D1) and week 52 (12 months from D1).~atezolizumab is administered by IV infusion every 3 weeks (21 [± 2] days) for 1 year (18 cycles as a maximum)."
3479770|NCT03799874|Experimental|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 3 days.
3479771|NCT03799874|Placebo Comparator|Medical air|Inhaled Medical Air for up to 90 minutes daily for 3 days.
3127273|NCT03083847|Experimental|Pilot (1a): 1 injection of 5x10^4 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 5x10^4 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
3479772|NCT03799796|Experimental|Flash Glucose Monitoring with Online Peer Support|Pre-Test-Post-Test
3127274|NCT03083847|Experimental|Pilot (1b):1 injection of 1x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
3127275|NCT03083847|Experimental|Pilot (1d):1 injection of 2x10^5 PfSPZ Challenge+pyrimethamine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 50mg of pyrimethamine dosed on days 2 and 3 after injection
3127276|NCT03083847|Experimental|Pilot (5a): 1 injection of 1x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 1x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
3127277|NCT03083847|Experimental|Pilot (5b): 1 injection of 2x10^5 PfSPZ Challenge+chloroquine|Pilot Phase - 1 injection of 2x10^5 sporozoites of PfSPZ Challenge (NF54) with 1000mg of chloroquine (loading dose) 2 days prior to injections and 500mg (maintenance dose) 5 days post injection
3479773|NCT03799809|Active Comparator|Voriconazole|Will receive 400 mg of Intrabronchial Voriconazole every week for 4 weeks along with standard medical therapy.
3479774|NCT03799809|No Intervention|Control|Will receive standard medical therapy alone (hemostatics, anti-tussive and others as deemed appropriate by treating physician)
3479775|NCT03799978|Experimental|Treatment A: ACT-541468 50 mg under fasted conditions|Single oral dose administered on Day 1 under fasted conditions.
3479776|NCT03799978|Experimental|Treatment B: ACT-541468 50 mg under fed conditions|Single oral dose administered on Day 1 administered after food intake.
3479777|NCT03799744|Experimental|VCN-01 and Durvalumab; concomitant.|Combination VCN-01 (single iv dose) with Durvalumab, Concomitant schedule; Dose Escalation of VCN-01
3479778|NCT03799744|Experimental|VCN-01 and Durvalumab; sequential|Combination VCN-01 (single iv dose) with Durvalumab, Delayed schedule (14 days); Dose Escalation of VCN-01
3479779|NCT03799679|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1* 12 cycles ( weekly), followed by epirubicin 90mg/m2, iv, d1 + cyclophosphamide 600mg/m2, iv, d1 * 4 cycles (14 days per cycle)
3479780|NCT03799731|Experimental|Cohort I: GM102 single agent|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22 of each 28-day cycle
3479781|NCT03799731|Experimental|Cohort II: GM102 + trifluridine/tipiracil|GM102 will be intravenously administered at the dose of 7 mg/kg on Days 1, 8, 15 and 22, and trifluridine/tipiracil will be orally administered at the dose of 35 mg/m² twice daily on Days 1 to 5 and days 8 to 12 of each 28-day cycle
3479782|NCT03799640|Experimental|Standard Yoga|Yoga will be performed using linear forward and backward movements.
3479783|NCT03799640|Experimental|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses. .
3479784|NCT03799640|Experimental|Educational Control|Lectures on Health and Wellness
3479785|NCT03799692|Experimental|Chemotherapy|Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, Carboplatin AUC=2, iv, d1, 8, 15, 4 cycles (21 days per cycle).
3479786|NCT03799627|Experimental|Vadadustat|The initial dose of vadadustat (300, 450, or 600 milligrams [mg]) will be based upon the dose of epoetin alfa dose participants had received prior to vadadustat treatment
3479787|NCT03799627|Experimental|Vadadustat TIW|Participants randomized to vadadustat (Main and erythropoiesis-stimulating agent [ESA] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
3479788|NCT03799627|Active Comparator|Epoetin alfa|Epoetin alfa
3479789|NCT03799588|Experimental|Biphasic Chest Cuirass Arm|This is the only arm in the study and all patients will receive negative pressure ventilation via the biphasic chest cuirass.
3479790|NCT03799575||A|Two samples of ILM per patient are harvested, group A will be immediately fixed and submitted to Optic Microscopy (OM) and Transmission Electron Microscopy (TEM) analysis, and another sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
3479791|NCT03799575||B|Group B sample will be incubated in enriched medium 199 (Gibco) for 20 minutes at room temperature, after which it will also be fixed and submitted to OM and TEM analysis.
3479792|NCT03799536|Experimental|Sequence AB|Subjects assigned to sequence AB will receive a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 1 and a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
3479793|NCT03799536|Active Comparator|Sequence BA|Subjects assigned to sequence BA will receive a single 160 mg dose of the reference product Sotalex (1 x 160 mg tablet) marked as B in the sequence in the period 1 and a single 160 mg dose of the test product Sotalol (1 x 160 mg tablet) marked as A in the sequence in the period 2 . These treatments will be administered orally with approximately 200 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
3479794|NCT03799510|Experimental|Group 1|Healthy school children with no infectious history of Schistosomiasis receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
3479795|NCT03799510|Experimental|Group 2|School children with an infectious history of S. haematobium and-or S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
3479796|NCT03799510|No Intervention|Group 3|School children with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (2-4 weeks prior to the first vaccine injection) not receiving vaccine. Control group.
3479797|NCT03799458|Active Comparator|Active Stimulation|Active HD-tDCS will be delivered while subjects perform sensory training tasks.
3127278|NCT03083847|Experimental|Main (2a):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+NF54|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + homologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (NF54) at 12 weeks after third injection
3127279|NCT03083847|Experimental|Main (2b):3 doses of 2x10^5 PfSPZ Challenge+pyrimethamine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + pyrimethamine on days 2 and 3 post injection + heterologous CHMI with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
3479798|NCT03799458|Sham Comparator|Sham Stimulation|Sham HD-tDCS will be delivered while subjects perform sensory training tasks.
3479799|NCT03799458|No Intervention|Imaging Only|40 subjects will undergo initial testing only as a healthy control group.
3479800|NCT03799432|Experimental|TF-CBT Learning collaborative + COAST-IS|In addition to participating in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls, organizations will receive additional training and tailored implementation support.
3479801|NCT03799432|Active Comparator|TF-CBT Learning collaborative|Organizations will participate in a learning collaborative for implementing trauma-focused cognitive behavioral therapy (TF-CBT) with periodic coaching calls.
3479802|NCT03799406|Active Comparator|Intervention group|cholecalciferol at dose of 100 IU/Kg/day
3479803|NCT03799406|Placebo Comparator|Placebo group|placebo
3479804|NCT03799328|Experimental|multi-OIT|Low dose OIT with multiple allergens
3479805|NCT03799302|No Intervention|Standard Consultation|Sites in this arm will receive the standard consultation from the TFCO or MDFT purveyors
3479806|NCT03799302|Experimental|SIC Coaching Consultation|In addition to the standard consultation from the TFCO or MDFT purveyors, sites in this arm will also receive feedback on how they are doing in terms of completing expected activities in their efforts to implement the designated EBP.
3479807|NCT03800121||localized and metastatic sarcomas|"In total, several blood tests specific to the EXOSARC study will be necessary:~A first blood test of 7 mL during the initial assessment (inclusion)~Then four blood samples of 32mL distributed over 6 months (localized sarcoma group) or three blood samples of 32mL performed during chemotherapy treatments (metastatic sarcoma group)."
3479808|NCT03800095|Experimental|Conventional haematological care|Patients with haematological malignancy Conventional haematological care
3479809|NCT03800095|Experimental|Conventional care associated with a monthly consultation|Patients with haematological malignancy Conventional care associated with a monthly consultation realized by a palliative and supportive care team
3479810|NCT03799237|Experimental|GOS trap and dengue NS1 antigen kit|Gravid Oviposition Sticky (GOS) traps will be placed to trap adult Aedes mosquitoes and changed weekly. NS1 will be used to detect dengue in trapped Aedes mosquitoes. When dengue NS1 positive mosquitoes are found, community will be alerted via flyers, banners and other means. Routine Aedes/dengue control and surveillance will be carried out as usual as per the current Ministry of Health guidelines.
3479811|NCT03799237|No Intervention|Control|The GOS traps will be placed randomly in the control arm once per month for entomological survey. Routine Aedes control and surveillance will be carried out as per the current Ministry of Health guidelines. Dengue control measure will be initiated by the health authorities when human cases are reported from this arm.
3479812|NCT03799224|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for recurrent and refractory acute leukemia at the time of HLA-mismatched HSCT~Details:~The conditioning therapy for human leukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2"
3479813|NCT03799224|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD (minimal residual disease) at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, semustine (Me-CCNU, 250 mg/m2), orally once on day -3."
3479814|NCT03799718|Experimental|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
3479815|NCT03799315|Experimental|Jail-Based Use of Smoking Cessation Treatment (JUST)|Participants will receive guidline-based smoking cessation counseling while in jail and phone-based smoking cessation counseling sessions and nicotine lozenges after release from jail.
3479816|NCT03799315|No Intervention|Enhanced Treatment As Usual (TAU)|Participants will receive the usual, limited smoking cessation treatment while in jail, plus an additional health and wellness education session in jail. Nicotine lozenges will be offered at the end of the study to those who did not quit smoking.
3479817|NCT03799172||Echinocandin group|Echinocandin group is the group of patients who received echinocandins as first-line therapy for candidemia
3479818|NCT03799172||Triazole group|Triazole group is the group of patients who received triazoles as first-line therapy for candidemia
3479819|NCT03799133|Experimental|Patients with Florence device|Patients with the Florence catheter placed and connected to the Florence monitor to measure XL trend.
3127280|NCT03083847|Experimental|Main (3):3 doses of 2x10^5 PfSPZ Challenge+chloroquine+7G8|Main Phase - 3 monthly doses of 2x10^5 sporozoites of PfSPZ Challenge + weekly chloroquine (1000mg given 2 days prior to injections and 500mg given 5 days post injection and weekly thereafter until 5 days post third injection) + heterologous controlled human malaria infection (CHMI) with 3.2x10^3 PfSPZ Challenge (7G8) at 12 weeks after third injection
3179556|NCT00674167|Experimental|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel and cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
3479820|NCT03799120|Placebo Comparator|tamsulosin QD + Placebo|0.4 mg tamsulosin QD + Placebo QD
3479821|NCT03799120|Experimental|tamsulosin BID|0.4 mg tamsulosin BID
3479822|NCT03799094|Experimental|Experimental group|75 patients received a weekly intravenous Vitamin C injection (dose: 30 g / time, once a week, treatment termination when the disease progress is confirmed) in combination with daily taking tyrosine kinase inhibitor.
3479823|NCT03799094|Experimental|Control group|75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)
3479824|NCT03799081|Other|Fetoscopy in missed abortion|Women who have decided to undergo fetoscopy in missed abortion
3479825|NCT03799068|Active Comparator|suprazygomatic maxillary nerve block|the group were given a bilateral suprazygomatic maxillary nerve block with 0.125% bupivacaine, 2 ml on each side, the total dose of bupivacaine not exceeding 2 mg/kg.
3479826|NCT03799068|Active Comparator|surgical site infiltraion|the group were given peri-incisional infiltration with 0.125% bupivacaine, 2 ml on each side. In all cases the block was given by the anaesthetist and the infiltration by the surgeon.
3479827|NCT03799042|Experimental|Vitural Reality|Virtual Reality 3D glass
3479828|NCT03799042|Active Comparator|Inter-generation interaction|Elders-teenager interaction
3479829|NCT03799250|Experimental|Goal Directed Hemodynamic Therapy|"The GDT (Goal Directed Therapy) group will not receive any maintenance fluid. Fluid boluses will be given according to the flowchart attached.~Baseline MAP and HR will be measured in the pre-anesthetic clinic or if not available will be recorded according to community medical record.~Measurements of hemodynamic variables including heart rate and automatic non-invasive blood pressure measurements as well pulse oximetry as routine procedures will be recorded and stored by Metavision system (iMDsoft company) at regular intervals, all according to standard clinical practice.~Blood gases measurement will be performed upon admission and at discharge. Urine output will be measured and recorded every hour.~Other laboratory exams will be taken based on the physician discretion unrelated to the participation in the study."
3479830|NCT03799250|Active Comparator|Control Group|The control group will receive standard care which includes fluid maintenance program as dictated by the operating room anesthesiologist and as needed boluses through the PACU (Post Anesthesia Care Unit) stay.
3479831|NCT03799029|Active Comparator|active control group low-intensity|Low intensity version of the same cognitive training program Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
3479832|NCT03799029|Experimental|experimental training group cognitive training|a multifactorial cognitive program that tackles working memory, attention, inhibition, planification and reasoning Exercice are realized at home using a computer 25 sessions of 30-45 minutes are realized five days per week during 5 weeks
3479833|NCT03799029|No Intervention|control healthy participants|Just a control group including healthy participants No intervention
3479834|NCT03798990||users of French roads|all road users circulating on French roads outside over-seas
3479835|NCT03798964||Elective term cesarean|Low-risk women undergoing elective term cesarean section
3127281|NCT03083847|Experimental|Main Phase (4a) - Infectivity Control: NF54 (homologous) CHMI|Main Phase - Infectivity Control with one dose of 3.2x10^3 sporozoites of PfSPZ Challenge (NF54) (homologous) controlled human malaria infection (CHMI)
3479836|NCT03798964||Term vaginal delivery|Low-risk women undergoing term vaginal delivery
3479837|NCT03798964||Preterm vaginal delivery|Women undergoing preterm vaginal delivery
3479838|NCT03798912|Active Comparator|Intravenous octreotide group|Octreotide 100 mcg will be injected intravenously and serial blood samples will be collected for PK analysis
3479839|NCT03798912|Experimental|RaniPill A group|In 20 subjects, a RaniPill with a small balloon size will be administered and serial blood samples will be collected for PK analysis
3127282|NCT03083847|Experimental|Main Phase (4b) - Infectivity Control: 7G8 (heterologous) CHMI|Main Phase - Infectivity Control with 3.2x10^3 sporozoites of PfSPZ Challenge 7G8 (heterologous) controlled human malaria infection (CHMI)
3479840|NCT03798912|Experimental|RaniPill B group|In 20 subjects, a RaniPill with a larger balloon size will be administered and serial blood samples will be collected for PK analysis
3479841|NCT03798912|Experimental|RaniPill C group|In 20 subjects, a RaniPill with a different size will be administered and blood samples will be collected for the presence of drug
3479842|NCT03798899|Experimental|Penthrox® (Methoxyflurane)|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
3479843|NCT03798899|Placebo Comparator|Normal Saline|"Patients will be asked to inhale Penthrox® intermittently or continuously to obtain adequate analgesia.~Penthrox® or placebo will be administered in combination with standard analgesic treatments usually used according to the emergency department protocol (SoC).~Duration of treatment: 1 administration (with a maximum of 2 inhalers) during passage to emergency."
3479844|NCT03798873|Experimental|FeelWell™ Compression garment use with increase mobility|"Subjects are randomized to wear custom-fitted FeelWell™ Compression garment daily during regular and exercise activities.~Subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity."
3479845|NCT03798873|Other|Increase mobility|For the control group, subjects will work with physical therapist and exercise physiologist to increase strength, mobility and activity. The control group will not be assigned a compression garment during the trial.
3479846|NCT03798886||Natural frozen embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. After spontaneous ovulation, embryo transfer will be planned. Luteal phase support will not be used.
3479847|NCT03798886||modified natural embryo transfer group|In this group all embryos will be frozen when transfer planned sonographic follicle diameter measured. When follicle diameter is 16-17 mm we will apply hCG (recombinant hCG). After ovulation, embryo transfer will be done. Luteal phase support will not be used.
3479848|NCT03798834|Experimental|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
3479849|NCT03798834|Placebo Comparator|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
3479850|NCT03798821|Experimental|Experimental|One capsule a day will be consumed. At breakfast for the six weeks.
3479851|NCT03798821|Placebo Comparator|Comparator|One capsule a day will be consumed. At breakfast for the six weeks.
3479852|NCT03798808|Experimental|Family Nutriathlon group|Web-based nutrition program (encouraging consumption of fruits, vegetables and dairy products through an online platform)
3479853|NCT03798808|No Intervention|Control group|General nutrition guidelines (e.g. following Canada's Food Guide)
3479854|NCT03798769|Experimental|Supportive Oncology Care at Home|"The Supportive Oncology Care at Home intervention entails the following:~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers for phone calls and home visits by Medically Home based on a clinician-derived algorithm~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
3127283|NCT03083990|Experimental|Group A|IBI 305 ,3mg/kg, infusion in 90 minutes
3127284|NCT03083990|Active Comparator|Group B|Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes
3127285|NCT03084302||Pregnant women|Women in their first trimester of pregnancy, aged 18-45, who plan to receive their prenatal care from University of Pittsburgh Medical Center providers.
3127286|NCT03084315|Sham Comparator|E-Cig Zero Nicotine|E-Cigarette with no nicotine added
3479855|NCT03798730|Experimental|Solid Model|"Cake~-Control Vanilla Cake and Protein Fortified Vanilla Cake~Biscuit -Control Lemon Biscuit and Protein Fortified Lemon Biscuit"
3479856|NCT03798730|Experimental|Liquid Model|"Whey Protein Beverages~Native sample (protein unheated)~Denatured whey protein (protein heated to denature)"
3479857|NCT03798691|Active Comparator|Anti-TNF monotherapy|Patients with IBD on Anti-TNF monotherapy will be given the shingrix vaccine. Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.
3479858|NCT03798691|Active Comparator|Vedolizumab|"Patients with IBD on vedolizumab monotherapy will be given the shingrix vaccine.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
3479859|NCT03798678|Experimental|Treatment (CB-839 HCI, dexamethasone, carfilzomib)|Patients receive glutaminase inhibitor CB-839 Patients receive glutaminase inhibitor CB-839 hydrochloride PO every 12 hours on days 1-28, dexamethasone PO on days 1, 2, 8, 9, 15, 16, and 23, and carfilzomib IV over 10 minutes on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
3479860|NCT03798652||Patients referred for CABG|Patients with known coronary artery disease referred for isolated surgical revascularisation, who will be invited to attend our facility for a research CMR scan, a research 3D transthoracic echocardiogram and a 6 minute walk test
3479861|NCT03798782|Experimental|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root.
3479862|NCT03798782|Active Comparator|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
3127287|NCT03084315|Active Comparator|E-Cig 24mg Nicotine|E-cigarette with 24mg of nicotine added
3127288|NCT03084471|Experimental|Combination therapy|"Combination therapy (durvalumab + tremelimumab) : Patients will receive the combination therapy followed by monotherapy via intravenous (IV) infusion once Q4W:~Durvalumab 1,500 mg + tremelimumab 75 mg on Week 0, for up to a maximum of 4 doses (or cycles) and~Durvalumab 1,500 mg starting 4 weeks after the last infusion of the combination or discontinuation of tremelimumab."
3127289|NCT03084471|Experimental|Monotherapy|Monotherapy (Durvalumab 1,500 mg): Patients will receive durvalumab 1,500 mg via IV infusion Q4W on Week 0.
3479863|NCT03798743|Experimental|Sintilimab Combined With Docetaxel|Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
3479864|NCT03798639|Experimental|Arm I (nivolumab, radiation therapy)|Patients receive nivolumab IV over 30 minutes at week 0. Treatments repeat every 4 weeks for 1 year in the absence of disease progression or unacceptable toxicity. Beginning week 2, patients also receive radiation therapy on Monday-Friday or 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity.
3479865|NCT03798639|Active Comparator|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes at week 0. Treatments repeat every 2 weeks for nivolumab and 6 weeks for ipilimumab for up to 1 year in the absence of disease progression or unacceptable toxicity.
3479866|NCT03798613|Active Comparator|Apple Watch 4 Series Device|Apple watch 4 series heart rate monitoring device
3479867|NCT03798613|Active Comparator|Continuous Telemetry|Standard continuous telemetry monitoring device
3479868|NCT03798600||Critically ill patients|"20 patients consecutively admitted in the ICU with severe sepsis or septic shock requiring caspofungin therapy will be considered for this observational study.~Inclusion Criteria:~Adult ICU patients (>18 yrs) with severe sepsis or septic shock undergoing caspofungin therapy based on clinical judgement (empiric therapy) or microbiological result (targeted therapy).~Exclusion criteria:~Concomitant ciclosporin or rifampicin therapy. Pregnancy Continuous renal replacement therapy Severe Liver failure (Child Pugh score > 6)"
3127290|NCT03084796|Experimental|Treatment A|CHF 5259 pMDI 6.25 μg, 1 inhalation twice daily (bid); (total daily dose [TDD] of CHF 5259 12.5 μg)
3127291|NCT03084796|Experimental|Treatment B|CHF 5259 pMDI 12.5 μg, 1 inhalation bid; (TDD of CHF 5259: 25 μg)
3127292|NCT03084796|Experimental|Treatment C|CHF 5259 pMDI 12.5 μg, 2 inhalations bid; (TDD of CHF 5259: 50 μg)
3479869|NCT03798587||OS patients|"Patients with age ≥18 years that were/can be recruited within the IRCCS Istituto Ortopedico Galeazzi BioBanca (ethical committee approval n. 29/INT/2017).~Patients with age <18 years: will be additionally recruited besides the IRCCS Istituto Ortopedico Galeazzi BioBanca.~The target group corresponds to patients hospitalized at Istituto Ortopedico Galeazzi, undergoing surgical eradication of primary osteosarcoma.~Patients will be considered eligible for enrollment in the study if able to sign the consent to the procedure after appropriate information from the reference surgeon or signed by parents or legal guardian after appropriate information from the reference surgeon (if age <18).~Inclusion Criteria:~Indication for primary OS eradication surgery~Patients hospitalized in Istituto Ortopedico Galeazzi~Exclusion criteria:~-Patients not able to sign the Informed Consent."
3479870|NCT03798561|Experimental|82 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 82 µg/cm2 single application in 7 days or Placebo TG (6 subjects ASN008: 2 subjects placebo) (6:2)
3479871|NCT03798561|Experimental|164 µg/cm2 ASN008 TG or Placebo|PART A: ASN008 TG 164 µg/cm2 single application in 7 days or Placebo (6:2)
3479872|NCT03798561|Experimental|328 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 328 µg/cm2 single application in 7 days or Placebo (6:2)
3479873|NCT03798561|Experimental|492 µg/cm2 ASN008 TG or Placebo|Part A: ASN008 TG 492 µg/cm2 single application in 7 days or Placebo (6:2)
3479874|NCT03798561|Experimental|ASN008 TG TBD Cohort 1 or Placebo|Part B: ASN008 TG Cohort 1 daily application for 15 days or Placebo (9 subjects ASN008: 3 subjects Placebo) (9:3)
3479875|NCT03798561|Experimental|ASN008 TG TBD Cohort 2 or Placebo|Part B: ASN008 TG Cohort 2 daily application for 15 days or Placebo (9:3)
3479876|NCT03798561|Experimental|ASN008 TG TBD Cohort 3 or Placebo|Part B: Placebo TG Cohort 3 daily application for 15 days or Placebo (9:3)
3127293|NCT03084796|Experimental|Treatment D|CHF 5259 pMDI 25 μg, 2 inhalations bid; (TDD of CHF 5259: 100 μg)
3127294|NCT03084796|Placebo Comparator|Treatment E|Placebo, 2 inhalations of CHF 5259 pMDI-matched Placebo bid;
3479877|NCT03798548|Experimental|Brief Bedside CBT|
3479878|NCT03798548|No Intervention|Treatment As Usual|
3479879|NCT03798574||IMD Case|No intervention
3479880|NCT03798574||Control|No intervention
3479881|NCT03798522|Experimental|erector spinae plane block group (ESPB) n=14|Bilateral ultrasound guided erector spinae plane block will be performed in the lateral position at T7 vertebrae and before induction of GA. 20 ml of local anesthetic solution (20 ml bupivacaine (Sunnypivacaine, Sunny pharmaceutical, Egypt) 0.25%) will be injected in-plane into the ESP. This procedure will be repeated on the other side taking care not to exceed the maximum recommended doses (2 mg/kg of IBW for bupivacaine) and then GA will be conducted .
3479882|NCT03798522|Active Comparator|general anesthesia group (GA) n= 14|these patients will receive iv nalbuphine in dose of 2mg /kg according to ideal body weight after induction of GA
3479883|NCT03798509|Experimental|Human CD19 targeted T Cells Injection|
3479884|NCT03798470|Experimental|Cohort|Intervention with FAVOR peer recovery coaching. Patients identified in the ED as opioid overdose and enrolled in the current study.
3479885|NCT03798457||Patients with CAP hospitalized in IM|Data of Patients with Community-acquired pneumonia (CAP) hospitalized in Internal Medicine Units will be collected for this study; no intervention is planned for this study
3479886|NCT03798444||Bone mineral denstiy|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry in all subjects.Accroding to The World Health Organization, we defined osteoporosis as a T-score ≤-2.5,and the non osteoporosis as T-score>-2.5.
3479887|NCT03798444||Vertebral fractures|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray. A visual semi-quantitative method was used, with fractures defined as a vertebral height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra.
3479888|NCT03798431|Experimental|M-ROCC|Mindful Recovery OUD Care Continuum (M-ROCC) builds on other mindfulness interventions for addictive disorders, but is specifically designed with the clinical needs of OUD patients on buprenorphine and logistic needs of primary care OBOT clinicians in mind. It focuses on integration of mindfulness practice for living well through stress, anxiety, depression, pain and addiction recovery. M-ROCC curriculum has three primary components, including a low-dose mindfulness phase, an intensive mindfulness training phase and then ongoing mindful recovery support.
3479889|NCT03798418|Active Comparator|exercise group|elastic band strengthening exercise
3479890|NCT03798418|Experimental|exercise combine diet counseling group|elastic band strengthening exercise combined diet counseling.
3479891|NCT03798405|Experimental|Proactive|"Proactive Analgesic Inpatient Narcotic-Sparing:~Pain management in patients in the proactive physician-behavior group will be based on the IBD Pain orderset in our EMR. This orderset is already in use and standard-of-care at Cedars. The orderset uses pain medications, which have evidence for use in IBD. The orderset is simply a guide to clinicians and does not force any doctor or patient to be in a protocol."
3479892|NCT03798405|No Intervention|Reactive (Control Group)|Pain management in patients in the reactive group (control group) will follow traditional prescribing habits. As different providers vary in the way they treat pain, analgesic medication prescribing in the control group will be inherently variable in nature. The control group does not constitute a lack of treatment or placebo; rather, pain management in the control group will not be proactive as in the intervention group.
3479893|NCT03798392|Active Comparator|SP group|
3479894|NCT03798392|Active Comparator|Baska group|
3479895|NCT03798353|Experimental|Experimental group|"The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.~In addition, the matrix-cell (PeriCord) construct will be placed on the ischemic area of the non-candidate revascularization area and will be fixed using surgical glue.~PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix ."
3127295|NCT03084796|Active Comparator|Treatment F|Tiotropium (TIO) 18 μg, SPIRIVA® HandiHaler®, 2 inhalations once daily (od) of the content of 1 capsule; (TDD of TIO: 18 μg)
3127296|NCT03085017|Active Comparator|Ostene|Application of Ostene onto cut sternal site for hemostasis.
3127297|NCT03085017|Experimental|BoneSeal|Application of BoneSeal onto cut sternal site for hemostasis.
3479896|NCT03798353|Active Comparator|Control group|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed.
3479897|NCT03799276|Experimental|Opticare study|"Phase I: Identification and Selection of study population The first step will include an active search by OPTICARE team for vulnerable and lost to follow up patients~Phase II: Implementation of the individualized follow-up program The patients who agree to participate to the program will be defined as the OPTICARE population."
3479898|NCT03798340|Experimental|Vibratory perturbed task-specific movement training|Intervention: 10 minutes of traditional sensorimotor facilitation followed by 20 minutes of vibratory perturbed task-specific movement training
3127298|NCT03085095|Experimental|Relugolix|Relugolix for 48 weeks
3479899|NCT03798340|Active Comparator|Traditional task-oriented facilitation|Intervention:10 minutes of traditional sensorimotor training followed by 20 minutes of reach-to-grasp and hand release training.
3479900|NCT03798379|Active Comparator|Exercise group|Eligible patients who were planned to receive neurotoxic chemotherapy
3479901|NCT03798379|No Intervention|Control group|Patients eligible for the study and received the 3rd cycle of chemotherapy
3479902|NCT03798314|Experimental|Treatment (nivolumab and pomalidomide)|Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
3479903|NCT03800199|Experimental|Perceptive Rehabilitation (PR-group)|Perceptive rehabilitation group will receive a treatment that, as described by on Paolucci et al. (2015). This treatment will include small latex cones with different resistance. In each session there will be over 100 cones will be placed on a rigid wood with using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks. There will be in total 16 sessions.
3479904|NCT03798249|Active Comparator|Gluten|Patients will receive acutely 16 g of gluten and 2 muffins glutenfree with 8 g of gluten, twice a day, during 5 days
3479905|NCT03798249|Placebo Comparator|Placebo|Patients will receive acutely 16 g of whey protein and 2 glutenfree muffins, twice a day, during 5 days
3479906|NCT03798275|Active Comparator|the study group|healthy pregnant women with borderline oligohydramnios who accept to drink a cup of coffee
3479907|NCT03798275|No Intervention|the control group|healthy pregnant women with normal amniotic volume
3479908|NCT03798288|Experimental|Usual care + selfBACK|"The selfBACK system constitutes a data-driven decision support system that uses case-based reasoning to capture and reuse participant cases to suggest the most suitable self-management plan for participants. The system is an intelligent system delivering self-management plans tailored to individual participant characteristics. Information about participant characteristics is collected via a (baseline) questionnaire, weekly self-reports via the app on symptom progression etc., and a wristband that detect daily number of steps. The weekly plans are presented in an app to participants.~The weekly plan includes three categories of content;~information/education~recommended daily number of steps~recommended strength and flexibility exercises"
3479909|NCT03798288|Active Comparator|Usual care|Any diagnostic or treatment-related pathway (e.g. receive information, advice or treatment) as instructed by their health care professional. Patients are allowed to seek care, treatment or help elsewhere as normal.
3479910|NCT03798262|Active Comparator|Gluten|Patients receive 16 g of gluten acutely and afterwards 2 glutenfree muffins with 8 g of gluten for 5 days sub-acutely
3479911|NCT03798262|Placebo Comparator|Placebo|Patients receive 16 g of whey protein acutely and afterwards 2 glutenfree muffins for 5 days sub-acutely
3479912|NCT03798236|Experimental|PBF-1650 40mg|
3479913|NCT03798236|Experimental|PBF-1650 80mg|
3479914|NCT03798236|Experimental|PBF-1650 120mg|
3479915|NCT03798236|Experimental|PBF-1650 240mg|
3479916|NCT03798236|Placebo Comparator|Placebo|
3479917|NCT03798223|Experimental|180/low|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
3479918|NCT03798223|Experimental|180/high|SLT treatment in the lower half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
3479919|NCT03798223|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
3127299|NCT03085095|Active Comparator|Leuprolide Acetate|Leuprolide acetate for 48 weeks
3127300|NCT03085238|Experimental|M-Trap|
3479920|NCT03798223|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
3479921|NCT03798210|Placebo Comparator|Placebo|Look and taste-alike placebo tablets in white plastic vials.
3479922|NCT03798210|Experimental|Lactobacillus reuter's|Lactobacillus reuteri tablets in white plastic vials.
3479923|NCT03798197|Active Comparator|30 mg estetrol (E4) without food (fasted)|Treatment A (reference): One 30 mg E4 tablet administered orally following an overnight fast of at least 10 hours.
3479924|NCT03798197|Experimental|30 mg estetrol (E4) with food (fed)|Treatment B (test): One 30 mg E4 tablet administered orally 30 min after the start of an FDA prescribed high-fat breakfast preceded by at least a 10 hours overnight fast.
3127301|NCT03085758|Experimental|Treatment Arm A|Intravenous infusion over approximately 1 hour of single i.v. dose of 2 mg/kg Adrecizumab (treatment arm A)
3127302|NCT03085758|Experimental|Treatment Arm B|Intravenous infusion over approximately 1 hour of single i.v. dose of 4 mg/kg Adrecizumab (treatment arm B)
3479925|NCT03800069||Arm 1|A finger stick sample is collected and tested on the study device.
3479926|NCT03800082|No Intervention|Control|Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
3479927|NCT03800082|Experimental|Treatment|Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention. The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics). Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check. A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness. Participants will be directed to the PC for technical problems.
3479928|NCT03798145|Experimental|Surgical Retinotomy|Surgical retinotomy will be constructed in the area of the scotoma.
3479929|NCT03798106|Experimental|durvalumab+pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
3127303|NCT03085758|Placebo Comparator|Control group|Intravenous infusion over approximately 1 hour of single i.v. dose of Placebo of Adrecizumab (control group)
3479930|NCT03798119|Experimental|Switch to TAF|Subjects who meet the inclusion and exclusion criteria will switch prior NUCs to TAF 25 mg/day for 96 weeks
3479931|NCT03798080|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
3479932|NCT03798080|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
3479933|NCT03798184|Experimental|Selective-etch with bioglass surface roughening|
3127304|NCT03085797|Experimental|Mepolizumab 100 mg SC + MF|Participants will receive total thirteen doses of 100 mg SC of mepolizumab in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
3479934|NCT03798184|Active Comparator|Selective-etch without bioglass surface roughening|
3479935|NCT03798184|Experimental|Self-etch with bioglass surface roughening|
3479936|NCT03798184|Active Comparator|Self-etch without bioglass surface roughening|
3479937|NCT03798054|Experimental|Soliqua (insulin glargine/lixisenatide)|iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning on top of metformin for 24 weeks.
3179557|NCT00674167|Experimental|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
3479938|NCT03798054|Active Comparator|Lantus (insulin glargine)|Insulin glargine will be self-administered subcutaneously once daily at any time of the day on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
3479939|NCT03798054|Active Comparator|Lyxumia (lixisenatide)|Lixisenatide will be self-administered subcutaneously once daily according to the locally approved label on top of metformin for 24 weeks. Injection time should be determined on the day of randomization, and should remain about the same until the end of the treatment period.
3479940|NCT03799861||Epoch 1: Care prior to HBB training|A period of demographic and birth outcome data collection for a retrospective cohort of all infants born in the three study hospitals during the 18 months prior to the start of Epoch 2, reflecting care prior to HBB training.
3479941|NCT03799861||Epoch 2: HBB with NeoBeat|Implementation of Helping Babies Breathe training in combination with NeoBeat for detection of HR in non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for prospective cohort of all infants born in the three study hospitals for a 9-month period.
3479942|NCT03799861||Epoch 3: HR-guided HBB|Implementation of HR-guided Helping Babies Breathe training with NeoBeat for measurement of HR throughout resuscitation of non-breathing newborns, after which demographic and birth outcome data will be abstracted from the medical record along with observational data on resuscitation for a prospective cohort of all infants born in the three study hospitals for a 9-month period.
3479943|NCT03799965|Active Comparator|ERAS protocol are evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
3479944|NCT03799965|Active Comparator|ERAS protocol are not evaluated|"It is to compare the durations of stay in the intensive care unit and in hospital~It is to compare the incidences of complications of the groups"
3479945|NCT03798028|Experimental|UC-MSCs treatment|the participants will receive the single-dose UC-MSCs (1×10^6 cells/kg ) in combined with the present treatment.
3479946|NCT03798028|No Intervention|no UC-MSCs treatment|the participants will receive the placebo in combined with the present treatment.
3479947|NCT03797989|Experimental|Phase A: Group 1|Each volunteer will receive one vial of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
3479948|NCT03797989|Experimental|Phase A: Group 2|Each volunteer will receive a fifth of a vial (1:5 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
3479949|NCT03797989|Experimental|Phase A: Group 3|Each volunteer will receive one twentieth of a vial (1:20 dilution) of P. vivax infected inoculum (parasitised red blood cells) at the first blood-stage controlled human malaria infection (CHMI). The optimal dose will be determined following the first CHMI and the selected dose will be administered to all volunteers (Groups 1-3) at both the second and third CHMI.
3127305|NCT03085797|Placebo Comparator|Placebo SC + MF|Participants will receive total thirteen doses of SC matching placebo in thigh, abdomen or upper arm every 4 weeks for 52 weeks on top of SoC which includes daily nasal spray of mometasone furoate.
3479950|NCT03797989|Experimental|Phase B: Group 4|The six volunteers from Groups 1, 2 and 3 in will undergo secondary challenge using the optimal inoculum, as determined in Phase A of the study. They will constitute 'Group 4' in Phase B. This will occur approximately eight months (and up to nine months) later after their primary challenge.
3479951|NCT03797989|Experimental|Phase B: Group 6|Three new malaria naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls to Group 4.
3479952|NCT03797989|Experimental|Phase C: Group 5|The six volunteers from Group 4 in Phase B will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 5 in Phase C. This will occur approximately sixteen months (and up to twenty months) later after their secondary challenge.
3479953|NCT03797989|Experimental|Phase C: Group 7|The three volunteers from Group 6 who underwent primary challenge in Phase B undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will now form Group 7 in Phase C. This will occur approximately six months (and up to nine months) later after their primary challenge.
3479954|NCT03797989|Experimental|Phase C: Group 9|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 5 and 7.
3479955|NCT03797989|Experimental|Phase D: Group 8|The three volunteers from Group 7 in Phase C will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 8 in Phase D. This will occur approximately five months (and up to ten months) after their secondary challenge.
3479956|NCT03797989|Experimental|Phase D: Group 10|The four to eight volunteers from Group 9 in Phase C will undergo secondary challenge, using the optimal inoculum as determined in Phase A, and form Group 10 in Phase D. This will occur approximately six months (and up to nine months) later after their primary challenge.
3479957|NCT03797989|Experimental|Phase D: Group 12|Four to eight new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 8 and 10.
3479958|NCT03797989|Experimental|Phase E: Group 11|The four to eight volunteers from Group 10 in Phase D will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 11 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
3479959|NCT03797989|Experimental|Phase E: Group 13|The four to eight volunteers from Group 12 in Phase D will undergo secondary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 13 in Phase E. This will occur approximately five months (and up to ten months) after their secondary challenge.
3479960|NCT03797989|Experimental|Phase E: Group 15|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Groups 11 and 13.
3479961|NCT03797989|Experimental|Phase F: Group 14|The four to eight volunteers from Group 13 in Phase E will undergo tertiary challenge, again using the optimal inoculum as determined in Phase A, and will constitute Group 14 in Phase F. This will occur approximately five months (and up to ten months) after their secondary challenge.
3479962|NCT03797989|Experimental|Phase F: Group 16|Two new malaria-naïve volunteers will be recruited to undergo primary challenge using the optimal inoculum, as determined in Phase A of the study. They will act as controls for Group 14.
3479963|NCT03799822|Active Comparator|Control|Hemodialysis patients with non valvular atrial fibrillation receiving warfarin
3479964|NCT03799822|Experimental|rivaroxaban|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od
3479965|NCT03799822|Experimental|rivaroxaban + K2|Hemodialysis patients with non valvular atrial fibrillation receiving rivaroxaban 10 mg od + vitamin K2 supplements
3479966|NCT03799887|Active Comparator|0% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
3479967|NCT03799887|Experimental|10% unweighed BWSTT|0% unweighed Body Weight Supported Treadmill Training
3479968|NCT03799887|Experimental|20% unweighed BWSTT|20% unweighed Body Weight Supported Treadmill Training
3479969|NCT03799900|Experimental|Part 1, Cohort 1: Ketamine Low Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
3127306|NCT03085836|Experimental|TAK-438 10 milligram (mg) Once Daily|TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
3127307|NCT03085836|Experimental|TAK-438 20 mg Once Daily|TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
3479970|NCT03799900|Placebo Comparator|Part 1, Cohort 1: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
3479971|NCT03799900|Experimental|Part 1, Cohort 2: Ketamine Medium Dose|Some participants will be administered a single IV dose of ketamine on Day 1.
3479972|NCT03799900|Placebo Comparator|Part 1, Cohort 2: Placebo|Some participants will be administered a single IV dose of placebo on Day 1.
3479973|NCT03799900|Experimental|Part 1, Cohort 3 (Optional): Ketamine High Dose|Optional: some participants will be administered a single IV dose of ketamine on Day 1.
3479974|NCT03799900|Placebo Comparator|Part 1, Cohort 3 (Optional): Placebo|Optional: some participants will be administered a single IV dose of placebo on Day 1.
3479975|NCT03799900|Experimental|Part 2, Qualification Phase: Ketamine|Participants will receive IV ketamine on Day 1 and placebo on Day 2 in a randomized crossover manner.
3479976|NCT03799900|Placebo Comparator|Part 2, Qualification Phase: Placebo|Participants will receive IV ketamine on Day 2 and placebo on Day 1 in a randomized crossover manner.
3179558|NCT00674167|Experimental|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycles.
3479977|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Low Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
3479978|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel Medium Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
3479979|NCT03799900|Experimental|Part 2, Treatment Phase: Rapastinel High Dose|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
3479980|NCT03799900|Active Comparator|Part 2, Treatment Phase: Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
3479981|NCT03799900|Placebo Comparator|Part 2, Treatment Phase: Placebo|Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
3479982|NCT03799926|Experimental|Stratum 1: 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
3479983|NCT03799926|Experimental|Stratum 1: 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
3479984|NCT03799926|Experimental|Stratum 1: placebo of 8.4 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
3479985|NCT03799926|Experimental|Stratum 1: placebo of 16.8 g patiromer|Non-dialysis subjects with serum potassium 5.1 to < 6.0 mEq/L range at baseline
3479986|NCT03799926|Experimental|Stratum 2: 8.4 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
3479987|NCT03799926|Experimental|Stratum 2: 16.8 g patiromer|Non-dialysis subjects with serum potassium 6.0 to < 6.5 mEq/L range at baseline
3479988|NCT03799926|Experimental|Stratum 3: 8.4 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
3479989|NCT03799926|Experimental|Stratum 3: 16.8 g patiromer|Dialysis subjects with serum potassium 5.5 to < 6.5 mEq/L range at baseline
3479990|NCT03798015||mitral valve surgery|outcome of mitral valve surgery (stroke yes or no)
3479991|NCT03799939|Active Comparator|Intervention group|Polyvinylidene fluoride mesh used in this trial (Dynamesh IPST) is synthetic mesh with central tube to accommodate bowel tightly and designed to prevent and treat parastomal hernia.
3479992|NCT03799939|No Intervention|Control group|Participants in control group are operated with no preventive mesh.
3479993|NCT03797976|Experimental|Parkinson's Disease Group|MIP and MEP Respiratory Function Test Strength Test
3479994|NCT03798002|Experimental|Neuro-muscular exercise training Group|Neuro-muscular exercise training will be administer to Knee OA patients.
3479995|NCT03798002|Active Comparator|quadriceps training program|quadriceps stretching and strengthening exercises will be administer to Knee OA patients.
3479996|NCT03799757|Active Comparator|Bupivacaine|The wound was installed by 40ml of 0.25% bupivacaine through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes.
3479997|NCT03799757|Placebo Comparator|Placebo|The wound was installed by 40ml of 0.9% normal saline through axillary and chest wall drains (20ml in each drain). Then, the drains were clamped for 20 minutes. (placebo group)
3479998|NCT03799913|Experimental|anti-MESO CAR-T cells|Administration with anti-MESO CAR-T cells in the MESO-positive ovarian cancer patients
3479999|NCT03797963|Active Comparator|PBM+ACB|Porcine bone mineral (Symbios Xenograft) + autogenous cortical bone
3480000|NCT03797963|Experimental|ABB+ACB|Anorganic bovine bone (BioOss Xenograft) + autogenous cortical bone
3480001|NCT03799666|Experimental|Pulmonary Rehabilitation Group|Patients will participate in a 12-week community-based pulmonary rehabilitation programme.
3480002|NCT03799666|Active Comparator|Standard Care Group|Patients will continue to receive the standard care, which means the daily medication prescribed by the pshysician from the primary care centre team.
3480003|NCT03797833|No Intervention|Standard treatment|ECV according to standard practice.
3480004|NCT03797833|Active Comparator|Spinal anaesthesia|ECV after low dose spinal anaesthesia (Bupivacain 2,5 mg plus Sufentanil 5 micrograms (µg)
3480005|NCT03799653||Nurses|All subjects are registered nurses in Xiamen, China
3480006|NCT03797846|Active Comparator|Corneal Suture|intraoperative fixation with the suture in clear cornea qualified to the combined glaucoma surgery
3480007|NCT03797846|Active Comparator|Muscle Suture|intraoperative fixation with the bridle suture for superior rectus muscle qualified to the combined glaucoma surgery
3179559|NCT00674180||1|a workbook alone
3179560|NCT00674180||2|a workbook alone and the addition of computerized tailoring using onsite computer kiosks with touch screen monitors
3480008|NCT03797898|Experimental|Intervention|Parents will meet with a Parent Coach during child's routine well visits, and have access to the parent coach between visits for additional follow up and concerns, and have access to a preventive care text messaging services (Healthy Txt).
3480009|NCT03797898|No Intervention|Control|usual care well child care
3480010|NCT03799601|Experimental|combination of docetaxel, carboplatin and anlotinib|
3480011|NCT03797755||Palliative Cancer Patients|Stage IV cancer patients evaluated for palliative radiotherapy.
3480012|NCT03797885||Patients with type 2 diabetes mellitus (T2DM)|Patients with type 2 diabetes, at the hospital setting.
3480013|NCT03797885||Patients with T2DM and established cardiovascular disease|Subgroup of patients with type 2 diabetes and established cardiovascular disease
3480014|NCT03797768|Experimental|Intervention|
3480015|NCT03797768|No Intervention|Control|
3480016|NCT03797950|No Intervention|Control|No active intervention
3480017|NCT03797950|Experimental|Voice Reminder (Group A)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Enrolled women will receive reminders via mobile phone to highlight the importance of early vaccinations for newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Information on where and when these vaccines will be available in the woman's community will be provided."
3480018|NCT03797950|Experimental|Cash Incentive (Group B)|"Community-appointed volunteers will document births in the community and will receive small monetary rewards via mobile money for all documented births. Volunteers will encourage enrolled women to seek early vaccination for their newborns. Messages will recommend that women take their newborns to get the BCG and Polio0 vaccine as soon as possible after birth (within the first two weeks of life for Polio0 and within the first month for BCG). Volunteers will provide information on where and when these vaccines will be available in the woman's community. Volunteers and enrolled women will receive small monetary rewards via mobile money for receiving OPV0 and BCG vaccinations on time."
3480019|NCT03797716|No Intervention|Standard Care arm|"Participants will receive standard of care from the pre-assessment clinic until discharge.~A typical preparatory National Health Service pathway would include: meeting a specialist nurse in the preoperative assessment clinic; a preoperative anaesthetic and surgical consultation; interaction with health play specialists on the day of surgery; and distraction interventions such as hand-held tablets during induction of anaesthesia. Participants may have inhalation or intravenous induction depending on the primary management plan of the anaesthetist in charge.~Participants in the standard care arm will also receive a virtual reality cardboard headset, which can be taken home, personalised and decorated before use with virtual reality apps available to download from the app stores."
3480020|NCT03797716|Experimental|Intervention arm|Participants allocated to the intervention arm will receive the same peri-operative management as the standard care arm and will also receive an access code enabling them to use the Little Journey app in the weeks leading up to their operation. We suggest the Little Journey app is used in the days to weeks leading up to the child's operation depending on their age. On downloading the app, if parents/carers insert the age of the child and date of surgery into the Little Journey app they will be sent a push notifications reminding them when to use it according to their child's age. However, it can be used as frequently as the child and/or their parents or carers wish before the operation.
3480021|NCT03797742||NC|Patients without heart failure.
3480022|NCT03797742||DCM|Dilated cardiomyopathy patients.
3480023|NCT03797742||ICM|Ischemic cardiomyopathy patients.
3127308|NCT03085836|Experimental|TAK-438 20 mg Twice Daily|TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
3127309|NCT03085914|Experimental|Treatment Group A|Epacadostat + pembrolizumab + mFOLFOX6 (oxaliplatin, leucovorin, 5-fluorouracil)
3480024|NCT03797638|Experimental|Patients with writer's cramp|Patients with writer's cramp
3480025|NCT03797638|Other|Control subjects|Control subjects, without writer's cramp, matched with case subjects with age, gender and hand writing
3480026|NCT03797703|Experimental|Treatment|Patients will be randomly allocated into the treatment group. The treatment group will receive a 15 mL lidocaine gel enema rectally immediately following completion of the procedure.
3480027|NCT03797703|No Intervention|Control|Patients will be randomly allocated into the control group. The control group will not receive a rectal enema.
3480028|NCT03799562|Experimental|Pregnenolone|Placebo lead in 14 DAYS, followed by Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
3480029|NCT03799562|Placebo Comparator|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
3480030|NCT03797807|Experimental|MINST|Minimally invasive non surgical treatment
3480031|NCT03797807|Active Comparator|MIST|Minimally invasive surgical treatment
3480032|NCT03797807|Active Comparator|GTI + MINST|Minimally invasive non surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
3480033|NCT03797807|Active Comparator|GTI + MIST|Minimally invasive surgical treatment + Geometric/Thermal Imaging (GTI subgroup)
3480034|NCT03797937|Experimental|Multiple sclerosis (MS) patients|Patients will undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
3480035|NCT03797937|No Intervention|Healthy controls|Healthy controls will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
3127310|NCT03085914|Experimental|Treatment Group B|Epacadostat + pembrolizumab + gemcitabine and nab-paclitaxel
3127311|NCT03085914|Experimental|Treatment Group C|Epacadostat + pembrolizumab + carboplatin and paclitaxel
3127312|NCT03085914|Experimental|Treatment Group D|Epacadostat + pembrolizumab + pemetrexed and investigators choice of platinum agent
3127313|NCT03085914|Experimental|Treatment Group E|Epacadostat + pembrolizumab + cyclophosphamide
3127314|NCT03085914|Experimental|Treatment Group F|Epacadostat + pembrolizumab + gemcitabine and investigators choice of platinum agent
3480036|NCT03797937|No Intervention|Multiple sclerosis (MS) patients undergoing a relapse|Multiple sclerosis (MS) patients undergoing a relapse will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
3480037|NCT03797937|No Intervention|Multiple sclerosis (MS) patients from multiplex MS families|Multiple sclerosis (MS) patients from multiplex MS families will not undergo magnetic resonance imaging (MRI). Stool and blood samples will be collected.
3127315|NCT03085914|Experimental|Treatment Group G|Epacadostat + pembrolizumab + investigators choice of platinum agent and 5-fluorouracil
3480038|NCT03797612|Experimental|Brivoligide Injection 660 mg/6 mL|Subjects randomized to the active treatment group will receive a single 660 mg/6 mL intrathecal administration of brivoligide injection as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
3480039|NCT03797612|Placebo Comparator|Placebo 6 mL|Subjects randomized to the placebo group will receive a single 6 mL intrathecal injection of placebo as a slow bolus injection just prior to administration of spinal anesthesia, via the same needle.
3127316|NCT03085927|Experimental|Arm 1-Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
3127317|NCT03085927|Experimental|Arm II- Audio-Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
3127318|NCT03086018|Experimental|Successor hearing aid to Juna|The intervention is the new device which is the successor to the Juna device. The participants will use their current device as a control. The will wear the intervention device for approximately two weeks.
3127319|NCT03086057|Experimental|Strength Based Case Management|Stage 1: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
3127320|NCT03086057|Experimental|PrEP adherence training and counseling|Stage 2: Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
3127321|NCT03086057|No Intervention|Standard of Care:Stage 1|Stage 1: Referral to The Miriam Hospital PrEP Clinic.
3480040|NCT03797651|Active Comparator|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
3480041|NCT03797651|Experimental|Very-short DAPT within 1 month|Patient will stop aspirin after discharge (DAPT less than 1 months after PCI) (ticagrelor monotherapy). Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
3480042|NCT03797677|Experimental|Home based airway clearance with Metaneb|"Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting.~The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment."
3480043|NCT03797781|Experimental|High protein|
3480044|NCT03797781|Experimental|Low protein|
3480045|NCT03797781|Experimental|Minimum protein|
3480046|NCT03797729|Placebo Comparator|Normal saline|
3480047|NCT03797729|Experimental|Tirofiban|
3480048|NCT03797924|Active Comparator|ICBN with ropivacaine|Participants will receive ICBN with ropivacaine. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
3480049|NCT03797924|Placebo Comparator|No ICBN block|Participants will have the site prepped, but no ICBN block given. In order to blind anesthesia providers in the room and nurses in PACU, the site of injection for ICBN will be prepped with tinted chlorhexidine in all patients.
3480050|NCT03797794|Experimental|PESF-treatment|The group undergoing the pulsating electrostatic field intervention
3480051|NCT03797794|Sham Comparator|Placebo-treatment|The group undergoing the SHAM Pulsating Electrostatic Field
3480052|NCT03797625|Experimental|Endostar Combined With IP|Endostar15mg/m2 Irinotecan 60mg/m2，D1，8 DDP 60mg/m2，D1
3480053|NCT03797664|Experimental|Experimental: CDX-6114|7.5, 15.0 and 22.5g
3480054|NCT03797664|Placebo Comparator|Placebo Comparator: Placebo|Phosphate Buffer Diluent Solution
3480055|NCT03797586|Experimental|Electroacupuncture group|Bilateral ST25,SP14, ST37 will be used in the EA group. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal , where patients will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40 mm needles will be vertically inserted approximately 15 mm deep, followed by three-time manipulation of even lifting and twisting method to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
3480056|NCT03797586|Sham Comparator|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 points will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes with only the initial 30 seconds on.
3480057|NCT03797599|Experimental|20 minutes of mindfulness practice|Two sessions a week for two weeks of: 5 minutes listening to audio book excerpts followed by 20 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
3480058|NCT03797599|Active Comparator|5 minutes of mindfulness practice|Two sessions a week for two weeks of: 20 minutes listening to audio book excerpts followed by 5 minutes of audio guided mindfulness practice. Participants will be asked not to engage in formal mindfulness practice outside of these sessions during the study.
3480059|NCT03797599|Placebo Comparator|Audio book control|Two sessions a week for two weeks of: 25 minutes listening to audio book excerpts (with non mindfulness practice). Participants will be asked not to engage in formal mindfulness practice during the study.
3480060|NCT03797573|Active Comparator|active tDCS|Patients will receive tDCS (bilateral fronto-central stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
3480061|NCT03797573|Sham Comparator|sham tDCS|Patients will receive sham tDCS (5 seconds of stimulation) during 20 minutes preceded and followed by a clinical assessment (Modified Ashworth Scale and Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
3480062|NCT03799419|Experimental|Cognitive bias modification with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting interpretation bias
3480063|NCT03799419|Sham Comparator|Psychoeducation with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of psychoeducation
3480064|NCT03799419|Experimental|Approach avoidance training with treatment as usual|Participants in this group will receive usual treatment in the program and 8 sessions of a computerized cognitive training targeting automatic approach tendencies
3480065|NCT03799419|Sham Comparator|Inactive sham approach avoidance training|Participants in this group will receive usual treatment in the program and 8 sessions of a sham approach avoidance training
3480066|NCT03799445|Experimental|Treatment (nivolumab, ipilimumab, IMRT)|Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
3480067|NCT03797482||Intra-operative tumour tissue biopsies|Intra-operative tumour tissue biopsies will be collected for all patients
3480068|NCT03797456|Experimental|ICP-022|
3127322|NCT03086057|No Intervention|Standard of Care: Stage 2|Stage 2: Doctor visit every three months to assess for side effects and receive a HIV test.
3127323|NCT03086135|Experimental|Bone-conduction hearing device|The bone-conduction hearing device Osia system allows a direct bone-conduction through an osseointegrated implant. A magnet allows the external Sound Processor to be placed in the correct position over the implanted system including an inner magnet.
3127324|NCT03086213|Experimental|paravertebral nerve block group|non-intubated thoracic paravertebral nerve block of regional anesthesia Thoracic paravertebral nerve block of regional anesthesia at the T4 thoracic interspace
3127325|NCT03086213|Active Comparator|intercostals nerve block group|non-intubated intercostal nerve block of regional anesthesia Thoracic intercostal nerve block of regional anesthesia at the T3/4/5 thoracic interspace
3127326|NCT03086265|Experimental|THRIVE|high flow nasal oxygen
3127327|NCT03086265|Active Comparator|Endotracheal tube|tracheal intubation
3480069|NCT03797287|Experimental|Tensor Tunnler|The Tensor Tunneler (Chattanooga, TN) will be used to create the bone tunnels during the arthroscopic procedure. This is an FDA approved device and is used currently in routine clinical practice.
3480070|NCT03797287|Active Comparator|Smith and Nephew PEEK Helicoil Anchor|The anchors used in this trial are FDA approved and are used currently in routine clinical practice (Anchor Rotator Cuff Repair).
3480071|NCT03797534|No Intervention|Standard anticoagulant group|
3480072|NCT03797534|Experimental|Bayesian model group|
3480073|NCT03797391|Experimental|Dose Escalation-Part 1, Expansion-Part 2|"In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks)."
3480074|NCT03797508|Other|threatened miscarriage|ultrasound ,CA125,progesterone
3480075|NCT03797417||Disease|patients with vitiligo
3480076|NCT03797417||Healthy Control|healthy control
3480077|NCT03797339||Discovery cohort|1000 cases of coronary heart disease follow-up cohort was used for multi-omics target discovery.During the follow-up period, the information about the occurrence and risk factors of adverse cardiovascular events will be collected.
3480078|NCT03797339||Validation corhort|3000 coronary heart disease follow-up cohorts was used for validating the results from the discovery corhort. During the follow-up period, the occurrence and risk factors of adverse cardiovascular events.Predictive mathematical models based on multi-omics combination will be constructed finally.
3480079|NCT03797300|Experimental|Primary|
3127328|NCT03086330|Experimental|Semaglutide|
3127329|NCT03086330|Placebo Comparator|Placebo|
3480080|NCT03797118|Experimental|FFRct|Patients will receive cCTA, ICA, FFRct, and FFRinv per protocol.
3480081|NCT03797352|No Intervention|Control|Receive healthy ageing advice every 3 months for the duration of 12 months
3179561|NCT00674180||3|a workbook, the addition of computerized tailoring using onsite computer kiosks with touch screen monitors, and staff consultations.
3127330|NCT03086343|Active Comparator|Abatacept|500 mg (for body weight <60 kg); 750 mg (for body weight 60-100 kg); and 1000 mg (for body weight >100 kg) intravenous (IV) infusion at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20
3127331|NCT03086343|Experimental|Upadacitinib 15 mg|One 15 mg tablet taken once per day by mouth for 24 weeks
3480082|NCT03797352|Experimental|Intervention|To participate in supervised Multicomponent exercise (combined exercise and cognitive activity) up to three times a week for 6 months and receive healthy ageing advice
3480083|NCT03797365|Active Comparator|Classical rehabilitation|Twenty women will benefit from two-phases perineal rehabilitation: first phase pelvic floor muscles (PFM)'s analytic rehabilitation, then a functional rehabilitation.
3127332|NCT03086356|Experimental|All Subjects|Dabigatran etexilate alone (days 1-4) and (days 8-10) and with Idarucizumab (day 11)
3127333|NCT03086408|Experimental|THRIVE|high flow nasal oxygen
3127334|NCT03086408|Active Comparator|endotracheal tube or supraglottic airway|tracheal intubation or supraglottic airway device
3127335|NCT03086447|Experimental|Experimental: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed the investigational contact lens to be worn from 28-36 days, to include a total of 5 visits.
3127336|NCT03086447|Active Comparator|Control: Participating Subjects|Subjects who are habitual soft toric contact lens wearers, aged 18 to 40 years of age, will be dispensed marketed contact lens to be worn from 28-36 days, to include a total of 5 visits.
3127337|NCT03086460|Experimental|Treatment A|"Treatment A, CHF 1531 pMDI:~CHF 1531 pMDI 6 μg total daily dose (TDD):~1 inhalation of CHF 1531 pMDI 3 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
3127338|NCT03086460|Experimental|Treatment B|"Treatment B, CHF 1531 pMDI:~CHF 1531 pMDI 12 μg TDD:~1 inhalation of CHF 1531 pMDI 6 μg/actuation plus 1 inhalation of CHF 1531 matched Placebo BID."
3480084|NCT03797365|Experimental|Classical and cognitive associated rehabilitation|Twenty women will receive, added to the classic perineal rehabilitation, the cognitive rehabilitation and will have to execute twice a day the rehabilitation protocol.
3480085|NCT03797040|Experimental|4 million PLX-R18 cells/kg-up to a maximal dose of 400 million|
3480086|NCT03797053||Cohort 1 : metastatic cohort|Cohort1: Cohort of patients with stage III inoperable or IV metastatic melanoma This cohort will enable the achievement of objectives 1 (proof of concept) and 2 (establishment of prognostic and predictive value).
3480087|NCT03797053||Cohort 2 : adjuvant cohort|"Cohort 2: Cohort of patients with melanoma who are candidates for sentinel lymph node analysis.~This group includes patients with melanoma in whom sentinel lymph node testing is performed. According to current French recommendations, these are patients whose primary melanoma has a Breslow index (thickness) of more than 1 mm or ulcerated primary melanoma (loss of the epidermis)."
3480088|NCT03797248||Cohort 1|adjuvant chemotherapy combined with Chinese herbal medicine
3127339|NCT03086460|Experimental|Treatment C|"Treatment C, CHF 1531 pMDI:~CHF 1531 pMDI 24 μg TDD: 2 inhalations of CHF 1531 pMDI 6 μg/actuation BID."
3480089|NCT03797248||Cohort 2|adjuvant chemotherapy only
3480090|NCT03797014|Experimental|B/F/TAF|Treatment group (1-arm study)
3480091|NCT03797131|Experimental|KB195 Arm|
3480092|NCT03797196|Active Comparator|group 1|standard tacrolimus with mycophenolate mofetil
3480093|NCT03797196|Experimental|group 2|low dose tacrolimus with everolimus
3480094|NCT03797209|Experimental|AXIOS Patient|
3480095|NCT03797079|Active Comparator|Group A (ESP block)|Ultrasound-guided ESP block will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
3480096|NCT03797079|Active Comparator|Group B (TEA)|TEA will be performed under strict aseptic precautions with patient in the sitting position. Catheter insertion will be performed and bupivacaine will be administered.
3127340|NCT03086460|Experimental|Treatment D|"Treatment D, CHF 1531 pMDI~CHF 1531 pMDI 48 μg TDD: 2 inhalations of CHF 1531 pMDI 12 μg/actuation BID."
3480097|NCT03797105|No Intervention|Control, 0 days|control group, no intervention
3480098|NCT03797105|Experimental|1 day|received the intervention 1 day/week
3480099|NCT03797105|Experimental|3 days|received the intervention 3 days/week
3127341|NCT03086460|Experimental|Treatment E|"Treatment E, Matched placebo~Placebo: 2 inhalations of CHF 1531 pMDI matched Placebo BID."
3127342|NCT03086460|Active Comparator|Treatment F|"Treatment F, Formoterol fumarate inhalation solution (IS)~Perforomist® IS (active comparator, open-label) 40 μg TDD: 1 inhalation, 20 μg/ 2 mL vial, 1 vial BID."
3127343|NCT03086551|Experimental|Experimental|Application of active continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
3127344|NCT03086551|Placebo Comparator|Control|Application of sham continuous theta burst stimulation over dorsolateral prefrontal cortex prior to upper limb motor practice.
3127345|NCT03086707|Active Comparator|Cigarette smokers|"Subjects who have smoked at least 20 cigarettes per day for at least the past 5 years.~Subjects will be allowed to use their own brand of non-menthol cigarettes. There will be no smoking restriction after the discharge at Visit 3 and during the 1 day follow-up period."
3127346|NCT03086707|No Intervention|Never smokers|"Subjects who have smoked less than 100 cigarettes throughout their lifetime and no cigarettes in the past 3 years.~Subjects will not be allowed to smoke until discharge at Visit 3."
3127347|NCT03087019|Experimental|Pembrolizumab + Radiation|"Up to 5 metastatic lesions targeted with radiation~Over 5 fractions starting within 7 calendar days following the first dose of pembrolizumab~Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
3127348|NCT03087019|Experimental|Pembrolizumab|"Pembrolizumab will be administered on day 1 of each 21day cycle~Pembrolizumab is delivered intravenously"
3480100|NCT03797105|Experimental|5 days|received the intervention 5 days/week
3480101|NCT03797092|Active Comparator|Active|Allogeneic adipose-derived stromal cells (CSCC_ASC)
3480102|NCT03797092|No Intervention|Control group|No treatment
3480103|NCT03797027|Other|No cushion|Patients in no cushion group undergo prone percutaneous nephrolithotomy without an abdominal cushion
3480104|NCT03797027|Other|5 cm cushion|Patients in 5 cm cushion group undergo prone percutaneous nephrolithotomy with an 5 cm abdominal cushion
3480105|NCT03797027|Other|10 cm cushion|Patients in 10 cm cushion group undergo prone percutaneous nephrolithotomy with an 10 cm abdominal cushion
3480106|NCT03796936|Experimental|3MDR With Eye Movement Component (EM+)|All participants will complete 10 treatment sessions (3 preparatory, 6 3MDR and 1 concluding), led by a trained therapist, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component. For those in the EM+ intervention group, the EM component starts after the participant has thoroughly discussed a picture with the therapist; a red ball starts at one edge of the screen, moves rapidly back and forth across it, and upon reaching either edge, a 2-digit number appears superimposed in white on the ball. The number changes every time the ball meets either edge. The participant is asked to track the ball and call out the displayed numbers.
3480107|NCT03796936|Active Comparator|3MDR Without Eye Movement Component (EM-)|All participants will complete 10 treatment sessions (three preparatory sessions, six 3MDR sessions and one concluding session; see Table 1), led by a therapist who has been completed training in the conduct of this form of therapy, with the only difference between the intervention groups being the presence (EM+) or absence (EM-) of the eye movement component.There will be no exposure to the distractor stimulus (red ball) for those in the EM- intervention group.
3480108|NCT03797443|Experimental|AA NABPLAGEM|Ascorbic Acid Paclitaxel protein-bound cisplatin gemcitabine
3480109|NCT03796884|Experimental|Arm I (linaclotide)|Patients receive linaclotide PO daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
3480110|NCT03796884|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7.
3480111|NCT03796845|Experimental|No-limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
3480112|NCT03796845|Active Comparator|Limited movement after surgery|Participants should move their arms with restricted movements on the first postoperative day, with maximum amplitude of 90º for flexion and abduction of the shoulder, until withdrawal surgical points. Actual hospital's routine.
3480113|NCT03796754|Active Comparator|YoBEKA Intervention|
3480114|NCT03796754|No Intervention|Control group|
3127349|NCT03087513|Active Comparator|Initial Arm|The study participants will receive either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline).
3127350|NCT03087513|Active Comparator|Crossover Arm|The study participants will receive the study medication that was not given in the initial arm (either Sugammadex (2 mg/kg in 10 ml 0.9% normal saline) or placebo (10 ml of 0.9% normal saline) .
3127351|NCT03087604|Active Comparator|Traditional Technique Group|In the traditional loss of resistance technique group, the epidural catheter will be placed after achieving loss of resistance to air. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.
3480115|NCT03797222|Experimental|Vitamin E Supplementation|Daily oral supplementation with Vitamin E (alpha-tocopherol) for 2 weeks.
3480116|NCT03796702|Experimental|Early closure of preventive ileostomy|A preventive ileostomy is closed 30 days after the primary surgery
3480117|NCT03796702|Experimental|Late closure of preventive ileostomy|A preventive ileostomy is closed 90 days after the primary surgery
3480118|NCT03796780|Active Comparator|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil for 6 weeks
3480119|NCT03796780|Placebo Comparator|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil for 6 weeks
3480120|NCT03797183||Premature Infants|Premature infants >1 month of age currently hospitalized with bronchopulmonary dysplasia (BPD) without acute respiratory infection
3480121|NCT03797183||Chronic Respiratory Disease|Participants ages >1 month-21 years with chronic respiratory disease due to underlying neuromuscular disease
3480122|NCT03797183||Neuromuscular Disease|Participants ages 21-40 years with confirmed neuromuscular disease with an echo completed within the preceding 12 months of study participation of Duchenne muscular dystrophy (DMD) or other diagnoses associated with mild cardiomyopathy
3480123|NCT03797183||Healthy Controls|Age and height matched healthy controls
3480124|NCT03796975|Experimental|Combination of Pioglitazone and Metformin Tablets|dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
3480125|NCT03796975|Active Comparator|Metformin Hydrochloride Tablets|dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
3480126|NCT03796767|Experimental|Arm A (radiation therapy)|Patients with bone metastases undergo SBR) or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion.
3480127|NCT03796767|Experimental|Arm B (salvage oligometastasectomy)|Patients with nodal metastases undergo salvage oligometastasectomy.
3480128|NCT03796767|Experimental|Arm C (salvage oligometastasectomy, radiation therapy)|Patients with nodal metastases undergo salvage oligometastasectomy. Following recovery, patients undergo SBRT or hypofractionated radiation per institutional standard of care guidelines at investigator's discretion. Within 4 months following completion of salvage therapy (defined as the combination of oligometastasectomy and/or bone radiation) and depending on PSA response as well as previous treatment, patients may receive adjuvant nodal IMRT.
3480129|NCT03797001|Experimental|anakinra|Anakinra subcutaneous injection, 100 mg daily for 24 weeks
3480130|NCT03797001|Placebo Comparator|placebo|Placebo subcutaneous injection, daily for 24 weeks
3480131|NCT03796871|Experimental|Dermapol|Use of the experimental medical device
3480132|NCT03797235|Experimental|Dominant Arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the dominant forearm
3127352|NCT03087604|Experimental|Electric Stimulation Group|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall. After placement of the catheter a standard test dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine will be administered.Solution for Thoracic epidural block.Thoracic epidural block with Electrical Nerve stimulation
3480133|NCT03797235|Active Comparator|Non-dominant arm|Two ultrasound guided nerve blocks (block of the ulnar and median nerve) on the non-dominant forearm.
3480134|NCT03796923|Active Comparator|Intervention I|Intervention (I): early follow-up visit from the community nurse within 24 hours after discharge
3480135|NCT03796923|Experimental|Intervention II|Intervention (II): early follow-up by the geriatric team within 24 hours after discharge
3480136|NCT03796923|Other|Control|Usual care: individualized follow-up performed by the GP and municipality services
3480137|NCT03796910|Experimental|SPR720 for SAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
3480138|NCT03796910|Placebo Comparator|Placebo for SAD|2 out of 8 subjects per cohort will be randomized to receive placebo
3480139|NCT03796910|Experimental|SPR720 for MAD|6 out of 8 subjects per cohort will be randomized to receive SPR720
3480140|NCT03796910|Placebo Comparator|Placebo for MAD|2 out of 8 subjects per cohort will be randomized to receive placebo
3480141|NCT03796650|Experimental|Fecal microbiota transplantation|Fecal microbiota from healthy, screened stool donors at the University Hospital of North Norway. Patients will receive one FMT enema immediately after enrolment.
3480142|NCT03796650|Active Comparator|Antibiotic treatment|Patients randomized to the control group will receive a ten-day course of oral vancomycin four times a day. This is according to international guidelines for primary C. difficile treatment.
3480143|NCT03796793|Experimental|Wound Edge Debridement Group|Participants in this group will receive wound edge debridement in addition to standard of care (SOC) treatment for up to 4 weeks.
3480144|NCT03796793|Active Comparator|Standard care group|Participants in this group will receive only the standard care of treatment for up to 4 weeks.
3480145|NCT03796715||Red Cell Distribution Width (RDW)|RDW was assessed as part of complete blood count analysis using SYSMEX XN-550 automated analyzer
3480146|NCT03796715||Presepsin (sCD14-ST)|Presepsin analysis was done by utilising Elisa technique using kits from (MyBioSource, San Diego, CA 92195-3308 USA)
3480147|NCT03796624|Experimental|Investigational Device Micropure 1.2.3.|"Implantation of monofocal intraocular lens (IOL) Micropure 1.2.3. in one of the eyes of the study subject"
3480148|NCT03796624|Active Comparator|Comparator PODEYE|"Implantation of monofocal intraocular lens (IOL) PODEYE in the contralateral eye of the study subject"
3480149|NCT03796572|Experimental|Infraclavicular Regional Block|This group is given ropivacaine 0.5% up to a max of .5 ml/kg until appropriate ultrasound guided spread is achieved.
3480150|NCT03796572|Sham Comparator|Puncture Wound|This group is given the same puncture wound and dressing given to the experimental group.
3480151|NCT03796897|Experimental|Leucine-enriched protein + exercise|whey protein- hydrolyzed whey protein-micellar casein blend (50:43:7 whey:hydrolyzed-whey:casein), vitamin D, and free leucine
3480152|NCT03796897|Sham Comparator|Habitual diet + exercise|habitual diet only
3480153|NCT03796663|Active Comparator|Mindful Parenting Only|"Participants in this arm will receive only the Mindful Parenting Program at the start of the study. Bögels and Restifo's (2014) Mindful Parenting Program is an adaptation for parents of MBCT, and MBSR; the program will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will be asked continue to participate in data collection for the post-intervention assessment time point (i.e. 8 weeks after the completion of the Mindful Parenting group sessions) and for the 2-month follow up assessment time point (i.e. 16 weeks after the completion of the Mindful Parenting group sessions). After they have completed both assessments, they will be offered the opportunity to participate in the MATCH BPT program if they so choose (no data will be collected)."
3127353|NCT03087643|Experimental|Passive mobilization - PM|Participants will receive 2 times a day, for 5 days a week 30 minutes of passive leg movement treatment including knee flexo-extension in addition to their standard therapies.
3480154|NCT03796663|Experimental|Mindful Parenting and BPT Combined|"Participants in this arm will receive the Mindful Parenting Program at the start of the study, which will consist of 7-weekly 2.5-hour parent group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children.~Following the completion of the Mindful Parenting Sessions, participants in this arm will receive receive individually-implemented MATCH BPT sessions, which will consist of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 1 hour sessions. The MATCH manual is comprised of 33 modules (i.e. coping, giving effective instructions, learning to relax, etc.). For the purpose of this study we will be utilizing the section on BPT, which consists of 12 modules with corresponding handouts and worksheets."
3480155|NCT03796585|Experimental|Intervention|Pharmacists assigned to this group will receive an immunization registry training program and informational flyer.
3480156|NCT03796585|Active Comparator|Control|Pharmacists assigned to this group will receive an informational flyer. They will not receive training.
3480157|NCT03796598|Placebo Comparator|Placebo|Oral and rectal placebo at visit 2 Oral placebo at day 30
3480158|NCT03796598|Active Comparator|Group 3: Oral placebo and rectal FMT|Oral placebo and rectal FMT at visit 2 Oral placebo at day 30
3480159|NCT03796598|Active Comparator|Group 2: Oral FMT and rectal placebo|Oral FMT and rectal placebo at visit 2 Oral FMT at day 30
3480160|NCT03796598|Experimental|Group 1: Dual Oral and rectal FMT|Dual Oral and rectal FMT at visit 2 Oral FMT at day 30
3480161|NCT03796637|Experimental|nmDMD Participants|Participants who have been receiving ataluren, dosed daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening, for >=9 months from ongoing PTC-sponsored nmDMD clinical trials.
3480162|NCT03796559|Experimental|Magseed marker|Magseed marker deployed percutaneously, prior to patient undergoing neo-adjuvant chemotherapy (NAC), under ultrasound guidance to mark a lymph node intended for selective surgical removal post NAC.
3480163|NCT03796494|Active Comparator|Control Group|The control group is considered, using the company's classic multi-position straight anti-rotational abutment
3480164|NCT03796494|Experimental|Test group|The test group is considered, where the new multi-position straight esthetic anti-rotational slim abutment is used
3480165|NCT03796533|Other|Posaconazole pharmacokinetics|Patients with AML over the age of 18 years treated with intensive chemotherapy in induction and consolidation whose was under antifungal prophylaxis by PCZ formulation tablets.
3480166|NCT03796520||Patients suspected for epilepsy|The cohort includes patients referred to the participating centers on suspicion of epilepsy, provided their seizure onset was at 10 years of age or older.
3480167|NCT03796455|Experimental|Fish Oil|2.0 g EPA + DHA / day + placebo powder
3480168|NCT03796455|Experimental|Fish Oil and HMB|2.0 g EPA + DHA + 3.0 g HMB / day
3480169|NCT03796455|Placebo Comparator|Placebo|3 g/d soy oil: corn oil (50:50 ratio) + placebo powder
3480170|NCT03796403|Experimental|diclofenac and bupivacaine group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
3480171|NCT03796403|Placebo Comparator|bupivacaine only group|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum, divided in 10 sites before closure and a 3 mL of sterile water was intramuscularly injected immediately after complete the procedure.
3480172|NCT03796507|Experimental|Temozolomide Arm|This study will only include one treatment group who will receive oral temozolomide at 75 mg per square meter of body surface area daily for 21 days before progressing to standard chemoradiation treatment.
3480173|NCT03796416|Active Comparator|misoprostol|"Induction using misoprostol:~Insert misoprostol 25 micrograms in the posterior fornix of the vagina digitally Repeat cervical exam every 4 hours"
3480174|NCT03796416|Experimental|Misoprostol and foley bulb|"Induction using Foley balloon combined with misoprostol:~A 26 French intracervical Foley balloon will be inserted above the internal os at the start of induction, inflated using 80cc of sterile water.~If a Foley balloon is not able to be inserted at the time of starting induction of labor, misoprostol 25microgram can be inserted in the posterior fornix of the vagina and the misoprostol protocol followed."
3480175|NCT03796442|Experimental|AVALUS group|patients who will undergo aortic valve replacement with Avalus bioprosthesis
3480176|NCT03796442|Active Comparator|CEPME group|patients who will undergo aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
3127354|NCT03087643|No Intervention|Control group - ctrl|Participants will receive ther standard therapies.
3127355|NCT03087786|Experimental|Nicotine Bitartrate 4mg Lozenge|Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
3127356|NCT03087786|Active Comparator|Nicotine Polacrilex 4mg Lozenge|Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days
3127357|NCT03087851|Active Comparator|6-month group|Zoledronic acid will be administered at study day 0. If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered.
3127358|NCT03087851|Active Comparator|9-months group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l) or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 3.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
3179562|NCT00674193||Observational (pharmacological study)|Patients undergo blood and urine collection prior to, periodically during, and after treatment with dactinomycin and vincristine for pharmacokinetic, pharmacodynamic, and pharmacogenetic analysis. Samples are analyzed using a liquid chromatography-tandem mass spectrometry assay. Genomic DNA extracted from peripheral blood mononuclear cells is isolated and analyzed by polymerase chain reaction and genotyping assays for genetic variation in genes relevant to the pharmacology of dactinomycin and vincristine.
3179563|NCT00674232|Experimental|Misoprostol|Group 1 randomized to take single dose of 600 mcg oral misoprostol
3179564|NCT00674232|Other|Surgical treatment|Group 2 randomized to receive standard surgical treatment as per local protocol (D&C or MVA)
3179565|NCT00674245|Active Comparator|Pantoprazole|40 mg once daily for four weeks improves sleep quality in patients with GERD
3179566|NCT00674245|Placebo Comparator|placebo|To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
3179567|NCT00674258|Experimental|B|
3179568|NCT00674271||Diabetics|100 patients with newly diagnosed (<5 years since diagnosis) type 2 diabetes referred from general practitioners to Medical Department M, Aarhus University Hospital, Denmark.
3179569|NCT00674271||Controls|100 healthy (no diabetes or prediabetes in oral glucose tolerance test) control subjects matched for age and gender
3127359|NCT03087851|Active Comparator|Observation group|"Zoledronic acid will be administered depending on increase in s-CTX (above 1.26 ug/l), decrease in BMD (more than 5% at any site), or the occurrence of an osteoporotic clinical vertebral or hip fracture, but no later than at month 6.~If s-CTX increases above 1.26 ug/l or BMD decreases more than 5% at any site a second infusion of zoledronic acid will be administered."
3127360|NCT03088137|Experimental|Primapur (Follitropin alfa)|
3127361|NCT03088137|Active Comparator|Gonal-f (Follitropin alfa)|
3127362|NCT03088267|Active Comparator|Active Treatment|Double blind amphetamine extended-release oral suspension, 2.5 mg/mL, 6, 7 or 8 mL po QAM
3127363|NCT03088267|Placebo Comparator|Placebo Treatment|Double blind placebo, 6, 7 or 8 mL po QAM
3127364|NCT03088345|Experimental|Vasopressin, Arginine|Patients randomized to this arm will receive a continuous arginine vasopressin in normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
3127365|NCT03088345|Placebo Comparator|Placebo|Patients randomized to this arm will receive a continuous normal saline carrier infusion immediately following the modified ultrafiltration (MUF) period of their cardiac surgery.
3179570|NCT00674336|Experimental|Shellfish with Norovirus|We dosed shellfish with Norovirus and challenged human volunteers with Shellfish that had norovirus
3480177|NCT03796377|Other|Rivaroxaban|Single oral dose of 20 mg rivaroxaban
3480178|NCT03796377|Other|Rivaroxaban after CYP- and P-gp induction|Single oral dose of 20 mg rivaroxaban after pretreatment with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
3480179|NCT03796351|Experimental|MT10107(botulinum toxin type A)|Subjects will be administered a single equivalent dose of MT10107 by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
3480180|NCT03796351|Active Comparator|BOTOX® 50U(botulinum toxin type A)|Subjects will be administered a single equivalent dose of BOTOX® 50U by intramuscular injection to the EDB muscles of contralateral feet in five treatment group.
3480181|NCT03796299||1|Patients with bladder cancer
3480182|NCT03796299||2|Patients with upper urinary tract cancer
3480183|NCT03796299||3 (control)|Controls
3480184|NCT03796312|Experimental|Tub Bathing|In this group, preterm infants were given tub bathing.
3480185|NCT03796312|Active Comparator|Sponge Bathing|Separate cotton cloths were prepared for each body area in the sponge bath. The room temperature was set to 26-27°C to prevent hypothermia. The temperature of the water used for sponge bathing was set to 37-38°C. Alongside the bath, the infant was placed on a flat, protected surface and washed from a bowl of water, using the same mild cleanser. The eyes, face, and head were wiped and dried while the baby was wrapped in a blanket. The wrap was opened so that body parts could be washed, dried, and then immediately rewrapped, after which infants were diapered.
3480186|NCT03796429|Experimental|GS+Toripalimab|
3480187|NCT03796338||Critically ill patients|age > 18 years
3480188|NCT03796390|Experimental|CD123 CAR-T cells|Patients will be be treated with CD123 CAR-T cells
3480189|NCT03796078|Active Comparator|Bimaxillary surgery (MMA)|Bimaxillary Orthognathic Surgery. MMA
3480190|NCT03796078|Active Comparator|monomaxillary surgery (Isolated MaxS)|Monomaxillary surgery (Isolated MaxS)
3480191|NCT03796078|Active Comparator|monomandibullary surgery (Isolated MandS)|Monomandibular surgery (Isolated MandS)
3480192|NCT03796364|Active Comparator|control group|standard SRILI treatment
3480193|NCT03796364|Experimental|observation group|Endostar® plus standard treatment
3480194|NCT03796221|Active Comparator|Control Group|Will receive standard pediatric obesity treatment
3480195|NCT03796221|Experimental|Intervention Group|Will receive standard pediatric obesity treatment and parenting videos
3480196|NCT03796156|Experimental|Aspirin|75mg of non enteric coated aspirin once daily added to usual medications
3480197|NCT03796156|No Intervention|Usual care|Usual medications only
3480198|NCT03795974|Active Comparator|MNC & MSC with Control|One intrathecal injection of Hematopoietic stem cells and Mesenchymal stem cells derived from allogenic umbilical cord for each group of 36 cases of spastic CP and neurorehabilitation during the 12 months of follow up of clinical evaluation of developmental functions and spasticity
3480199|NCT03795974|Experimental|MNC & MSC|Comparison of effects of intrathecal injection of MNC and MSC on improvement of developmental functions and spasticity of CP patients
3480200|NCT03796000||colonoscopy: obese and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
3179571|NCT00674375|Experimental|1|Primary care clinicians (physicians, nurse practitioners, and physician assistants) randomized to the intervention arm will receive electronic alerts within the electronic medical record system during office visits with patients complaining of chest pain.
3179572|NCT00674375|No Intervention|2|Primary care clinicians randomized to the 'no intervention' arm will evaluate and treat patients complaining of chest pain without the aid of electronic risk alerts.
3179573|NCT00674401|Active Comparator|1|"In patients with paroxysmal atrial fibrillation: Empirical pulmonary vein antrum circumferential isolation.~In patients with persistent atrial fibrillation: Empirical circumferential PV antrum isolation w/out roof line."
3480201|NCT03796000||colonoscopy: obese and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
3127366|NCT03088748||Smith & Nephew Journey II PCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior cruciate retaining total knee arthroplasty
3480202|NCT03796000||colonoscopy: lean and smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
3480203|NCT03796000||colonoscopy: lean and non-smoker|"10 small tissue samples of the Colon transversum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
3480204|NCT03796000||gastroscopy: obese and non-smoker undergoing bariatric surgery|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample~1cm long piece of the jejunum, which is usually disposed during bariatric surgery."
3480205|NCT03796000||gastroscopy: lean and non-smoker|"6 small tissue samples of the gastric corpus and 6 of the Duodenum~3 EDTA blood samples and 1 Serum blood sample~in some cases 1 single stool sample"
3480206|NCT03796091|Active Comparator|Educational Brochure|Participants will read an educational brochure from the National Eating Disorder Association and will receive referral resources.
3480207|NCT03796091|Active Comparator|Body Project Traditional|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project group therapy program (Stice & Shaw, 2001).
3480208|NCT03796091|Active Comparator|Body Project Expanded|Participants will complete group therapy for 1-hour per week for 4 weeks consisting of the Body Project Expanded group therapy program (Green et al., 2017).
3480209|NCT03796052|Experimental|Avena Sativa Skincare Regimen|Avena sativa-containing body wash, body cream, and anti-itch balm
3480210|NCT03796117|Experimental|Experimental Group 1: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
3480211|NCT03796117|Experimental|Experimental Group 2: healthy young|Participants receive two interventions (Pulsed Current - PC, or Russian Current - RC) in a specific order, according to randomization. Evoked torque, discomfort level, current intensity, neuromuscular efficiency, clinical efficiency and fatigability level will be evaluated.
3480212|NCT03796130|Experimental|(A)Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomlyallocated intotwo groups.~In group (A): myomectomy will be performed before ART~In group 1, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
3127367|NCT03088748||Smith & Nephew Journey II BCR TKA|Subjects implanted with a Smith & Nephew Journey II posterior bi-cruciate retaining total knee arthroplasty
3480213|NCT03796130|No Intervention|(B) No myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (B):women will have their trial of ART without myomectomy"
3480214|NCT03795961|Experimental|Active tDCS group|This group will include 42 patients with CTS Intervention (active transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
3480215|NCT03795961|Sham Comparator|Sham tDCS group|This group will include 42 patients with CTS Intervention (sham or inactive transcranial direct current electrical stimulation) Stimulation site (M1) Stimulation mode (anodal) Duration of session (20 minutes) Stimulation intensity (2 mA) Number of sessions (5 sessions) Intervals (every another day)
3480216|NCT03795922|Experimental|MT10109L|MT10109L will be injected into the GL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
3480217|NCT03795922|Placebo Comparator|Placebo|Placebo will be injected into the GL: initial double-blind treatment on Day 1.
3480218|NCT03796169|Experimental|Endoscopist|Intervention for personal notification, open notification and colonoscopy quality education by a GI faculty
3480219|NCT03796286|Placebo Comparator|Control bar (0 g fiber)|Each subject will be randomly assigned to consume a control sports bar-type product (0 grams of fiber) at one treatment visit.
3480220|NCT03796286|Experimental|Medium-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 10 grams of fiber) at one treatment visit.
3480221|NCT03796286|Experimental|High-fiber bar|Each subject will be randomly assigned to consume sports bar-type product (containing 20 grams of fiber) at one treatment visit.
3480222|NCT03796195|Experimental|.5% Bupivacaine|Guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
3480223|NCT03796143|Experimental|ACT self-help book condition|Participants in this condition will be asked to read The Mindfulness and Acceptance Workbook for Depression by Strosahl and Robinson (2008), a self-help book based on acceptance and commitment therapy.
3480224|NCT03796143|Active Comparator|CBT self-help book condition|Participants in this condition will be asked to read Cognitive Behavioral Workbook for Depression by Knaus (2006), a self-help book based on acceptance and commitment therapy.
3480225|NCT03796143|Other|Choice of two self-help books|Participants in this condition will have the option of receiving either the self-help book by Strosahl and Robinson (2008) or the book by Knaus (2006).
3480226|NCT03796026|Experimental|Seltorexant Followed by Placebo|Participants will receive seltorexant (40 milligram [mg] capsules) once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive matching placebo orally once daily for 4 consecutive days.
3480227|NCT03796026|Experimental|Placebo Followed by Seltorexant|Participants will receive placebo once daily for 4 consecutive days, and after a washout period of 7 to 10 days, participants will receive seltorexant (40 mg capsules) orally once daily for 4 consecutive days.
3480228|NCT03796234|Experimental|Dietary and physiotherapy|A multidisciplinary program was developed. 3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
3480229|NCT03796234|Experimental|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
3127368|NCT03088800|Active Comparator|Oral Ibuprofen|Oral Ibuprofen at 10mg/kg dose and placebo of equal volume
3127369|NCT03088800|Active Comparator|Oral APAP|Oral APAP at 15 mg/kg and placebo of equal volume
3480230|NCT03796104||Deficiency of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production Deficiency
3480231|NCT03796104||Presence of delta-hemolysine|Implant infected by Staphylococcus aureus with delta-haemolysin Production
3480232|NCT03795987|Experimental|Open Label Treatment Arm|Intervention with NightWare Therapeutic System
3480233|NCT03795896|Experimental|Optic nerve sheath diameter|The intracranial pressure will be measured by optic nerve sheath diameter while the patient in supine position with 30 -degree bed position .The linear probe in the two -dimensional mode will be placed gently on the upper eyelid without pressure .In linear horizontal orientation for both right and left optic nerve sheath will be measured
3127370|NCT03088800|Active Comparator|Oral Ibuprofen and Oral APAP|Oral Ibuprofen at 10mg/kg dose and APAP at 15mg/kg dose.
3127371|NCT03088917||lost to follow-up patients|This so-called lost population consists of all patients, that in the past have been diagnosed with hepatitis C at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015.
3127372|NCT03089047|Experimental|Rejuvenated RBC Transfusion|Washed and Rejuvenated autologous blood
3480234|NCT03795909|Experimental|Ruxolitinib and Placebo|Ruxolitinib 2.5 mg twice daily by oral
3127373|NCT03089047|Sham Comparator|Standard RBC Transfusion|Washed autologous blood (so as to maintain equivalent unit volume and Hct)
3127374|NCT03089216|Experimental|Combined Bleaching(2x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
3480235|NCT03795909|Placebo Comparator|Placebo and Ruxolitinib|Sugar pill 2.5 mg twice daily by oral
3480236|NCT03795870|Active Comparator|Polymeric Tube Feeds|This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.
3480237|NCT03795870|Active Comparator|Blenderized Tube Feeds|This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.
3480238|NCT03795935|Experimental|Treatment|Patients who were previously implanted with a traditional DBS lead and have subsequently developed stimulation induced side effects will gain significantly more tremor control without side effects when re-implanted with a directional DBS lead. We expect these patients' quality of life will improve. These patients typically will have had significant tremor relief (greater than 75% reduction from preoperative tremor rating scale) without side effects at their one year post operative follow-up. With the expected disease progression they will have had to increase their DBS stimulation to the degree that their DBS now causes side effects in order to block their tremor
3480239|NCT03795883||Participants with atrial fibrillation|Patients with atrial fibrillation admitted for standard pulmonary vein ablation.
3480240|NCT03795883||Participants without atrial fibrillation|Patients without atrial fibrillation admitted for standard left sided supra ventricular tachycardia ablation or patients admitted to mitral clip procedure.
3480241|NCT03795948|Other|PROM Evaluation for stroke patients|Patient will be enrolled and PROMs will be collected.
3480242|NCT03795844|Active Comparator|Nathanson retractor|Liver retraction in group 1, a 5 mm incision was made under xiphoid during the operation, and Nathanson retractor was placed and liver left lobe retraction would be achieved.
3480243|NCT03795844|Active Comparator|snake retractor|Liver retraction in group 2 ; 5 mm incision under the xiphoid will be used. Snake retractor was placed and liver left lobe retraction would be achieved.
3480244|NCT03795844|Active Comparator|fan retractor|Liver retraction in group 3 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus
3480245|NCT03795844|Active Comparator|CONTROL GROUP|Liver retraction in group 4 ; through a 5 mm trocar entrained from the intersection of the right midclavicular line and a 4 cm superior umbilicus will be provided with the aid of laparoscopic grasper without any special tools
3480246|NCT03795818|Other|IPT-A|Interpersonal psychotherapy for adolescents (IPT-A) is a psychosocial treatment for adolescents. It has been shown to be effective for adolescents with depression. It is now being studied as to its benefit for adolescents who meet criteria for PTSD or have subthreshold PTSD symptoms.
3480247|NCT03795792|Experimental|Curcumin|Curcumin 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
3480248|NCT03795792|Placebo Comparator|Hydrollased collagen|Hydrolyzed collagen 1.2 g / black pepper 10 mg a day for 3 months, plus recommendations to decrease calories intake and do exercise.
3480249|NCT03795584||Endoclip papillaplasty|Endoclip papilloplasty was performed to repair the Oddi sphincter using sterile repositionable hemostasis clipping device (Micro-tech (Nanjing), Co., Ltd.; stainless-steel). The participants underwent SOM before, immediately after EST, and 3 weeks after EST with endoclip papilloplasty. The participants were followed for 3 days during hospitalized.
3480250|NCT03795688||Basic, non-imaging group|"Pregnant women who will deliver by planned caesarian. Participants enrolled in the study that are not eligible for the imaging subgroup.~All participants start in the basic program. Includes collection of blood, cerebrospinal fluid, saliva, hair, placenta tissues, umbilical cord blood and psychometrics."
3480251|NCT03795688||Extended, imaging group|A subgroup of 70 pregnant women who will deliver by planned caesarian selected towards either high (N=35) or low (N=35) risk for perinatal depression will undergo brain imaging in addition to the elements of the basic program. The extended imaging program includes functional and structural magnetic resonance imaging, positron emission tomography (PET) and a semistructured interview for depression symptoms (HAM-D17).
3480252|NCT03795571|Experimental|R2-GOD|
3480253|NCT03795636|Experimental|Garlic extracts root canal irrigation group|"Experimental group treated with garlic extract~A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water"
3480254|NCT03795636|Active Comparator|Sodium hypochlorite root canal irrigation group|Control group which treated conventionally using .5 ml of 5.25% NaOCl (COLTENE®ENDO, Switzerland)
3480255|NCT03795649|No Intervention|The control group (Group K)|The control group (Group K) is comprised of surgical patients who will not receive blood transfusion, and who have contraindications for Tranexamic Acid.
3480256|NCT03795649|Active Comparator|Group A, Tranexamic acid|The treatment group (Group A) is comprised of the patients who will receive Tranexamic acid 1g intravenous 15 min. before releasing the pneumatic tourniquet and the repeating dose 3 hours later
3480257|NCT03795649|Other|Group B, autologous transfusion|The treatment group (Group B) will be comprised of the patients who in the second selection have one or more contraindications for Tranexamic Acid administration and transfusion of autologous blood will be performed.
3480258|NCT03795649|Other|Group C, alogenous transfusion|The treatment group (Group C) contraindications for Tranexamic Acid administration and the transfusion of alogenous blood will be performed in the case of acute haemorrhage followed by patient's hemodynamic instability.
3480259|NCT03795597|Experimental|Carfilzomib IV at dose: 20 mg/m2|The participants will receive Carfilzomib IV at dose: 20 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and Granulocyte-Colony stimulating factor (G-CSF) given daily until engraftment occurs.
3480260|NCT03795597|Experimental|Carfilzomib IV at dose: 27 mg/m2|The participants will receive Carfilzomib IV at dose: 27 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
3480261|NCT03795597|Experimental|Carfilzomib IV at dose: 36 mg/m2|The participants will receive Carfilzomib IV at dose: 36 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
3480262|NCT03795597|Experimental|Carfilzomib IV at dose: 45 mg/m2|The participants will receive Carfilzomib IV at dose: 45 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
3480263|NCT03795597|Experimental|Carfilzomib IV at dose: 56 mg/m2|The participants will receive Carfilzomib IV at dose: 56 mg/m2 on days -9 and -8 over 30 minutes. The participant will receive Busulfan IV over 3 hours every 24 hours for a total of 4 doses from Day -6 to Day -3 and Melphalan IV over 15-30 minutes for one dose on day -3.The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs.
3480264|NCT03795675|Experimental|Meniere's Disease/Vestibular Schwannoma|Individuals diagnosed with Meniere's disease and undergoing labyrinthectomy or diagnosed with vestibular schwannoma and undergoing surgical excision via translabyrinthine approach for treatment will receive cochlear implant at the time of surgery.
3480265|NCT03795831||Cohort|Adult patients, undergoing surgery requiring general anesthesia, planned to be monitored with a system that accurately measures and stores the intra-arterial waveform.
3480266|NCT03795779|Experimental|CLL1-CD33 cCAR T cells|CLL1-CD33cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs
3480267|NCT03795532|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes. The rest of the session at 22kv (full power).
3480268|NCT03795532|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
3480269|NCT03795545|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
3480270|NCT03795545|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
3480271|NCT03795662||Community-acquired pneumonia|Adults over 18 years old admitted with confirmed community-acquired pneumonia.
3480272|NCT03795610|Experimental|Arm A: IPI-549 40 mg PO qdaily|Patients enrolled in Arm A will receive IPI-549 40 mg by mouth daily for at least 21 days
3480273|NCT03795805|Other|TKA and Tourniquet|Total knee arthroplasty and use of tourniquet limb cuff at 270 mmHg
3480274|NCT03795805|Experimental|Intraarticular lidocain|Total knee arthroplasty with Intaarticular lidocain
3480275|NCT03795714||Intravascular Imaging and Physiologic Assessment|330 patients with suspected ischemic heart disease and who underwent IVUS or OCT assessment and invasive physiologic assessment.
3480276|NCT03795558|Experimental|Etelcalcetide 2.5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3127375|NCT03089216|Experimental|Combined Bleaching(2x20) with arginine|Combined Bleaching(2x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
3480277|NCT03795558|Experimental|Etelcalcetide 5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3480278|NCT03795558|Experimental|Etelcalcetide 7,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3127376|NCT03089216|Experimental|Combined Bleaching(1x20)|In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide
3480279|NCT03795558|Experimental|Etelcalcetide 10 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3480280|NCT03795558|Experimental|Etelcalcetide 12,5 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3480281|NCT03795558|Experimental|Etelcalcetide 15 mg|Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly
3480282|NCT03795519|Experimental|Healthy Male Volunteers|Single oral dose of [14C]-olinciguat
3480283|NCT03795623|Sham Comparator|Conventional arm|Muted audio recordings of the patients relatives.
3480284|NCT03795623|Experimental|Voice-Weaning arm|Audio recordings of the patients relatives including information on the patient's condition and recurrent request to breath in and out.
3480285|NCT03795727|Experimental|Sectional matrix|precontoured sectional matrix band
3480286|NCT03795727|Active Comparator|Circumferential matrix|Circumferential matrix band applied by tofflemire retainer
3480287|NCT03795740|Experimental|Precise|precise PEA therapy with the guide of 3-D imaging techniques
3480288|NCT03795740|Placebo Comparator|Placebo|traditional PEA therapy solely by surgical probe and traditional CT scanning/pulmonary angiography method
3480289|NCT03795506|Experimental|Active TLA Device|12 week overnight treatment with the active Temperature Controlled Laminar Airflow device.
3480290|NCT03795506|Placebo Comparator|Placebo TLA Device|12 week overnight treatment with the placebo Temperature Controlled Laminar Airflow device.
3480291|NCT03795493|Experimental|Intervention Group|Standard chemotherapy treatment and oncology care plus short-term diet and exercise intervention.
3480292|NCT03795493|No Intervention|Control Group|Standard chemotherapy treatment and oncology care.
3480293|NCT03795441|Experimental|Ad26.RSV.preF|Participants will receive one intramuscular injection of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on Day 1.
3480294|NCT03795480|Experimental|MOOD|"The online program MOOD is based on methods of cognitive behavior therapy (KVT) and contains elements of mindfulness and metacognition. Participants can contact a moderator (trained psychologists) if they have any questions. However, this function is optional. The program consists of nine interactive modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention."
3480295|NCT03795480|No Intervention|Control|The wait-list control group does not receive additional treatment. However, previously started therapies (psychotherapy/ psychopharmacotherapy) may be continued during the study. Individuals of the wait-list control group receive access to MOOD after completion of the post-assessment.
3480296|NCT03795454|Experimental|Singing Kangaroo|The parent is singing during the skin-to -skin sessions Musical therapeutist gives the instructions
3480297|NCT03795454|No Intervention|Silent Kangaroo|The parent is silent during the skin-to -skin sessions Musical therapeutist gives the instructions
3480298|NCT03795090|Active Comparator|Regular Patient privacy curtain|Control arm is a regular patient privacy curtain, washed and dried in hospital laundry using commercially available sodium hypochlorite and hydrogen peroxide.
3127377|NCT03089216|Experimental|Combined Bleaching(1x20) with arginine|Combined Bleaching(1x20) with arginine In-office: 35% hydrogen peroxide of 20 minutes each. At-home: 10% carbamide peroxide Desensitizing agent: dentifrice containing 8% arginine and calcium carbonate.
3179574|NCT00674401|Active Comparator|2|"In patients with paroxysmal atrial fibrillation: High frequency sites ablation in the LA.~In patients with persistent atrial fibrillation: A combined approach involving pulmonary vein antrum isolation w/out roof line and high frequency sites ablation"
3480299|NCT03795090|Experimental|Antimicrobial Coated Curtains|Treatment arm is an antimicrobial coated curtains, which is obtained by dipping the hospital laundered curtains into the antimicrobial coating. The curtains are then dried and provided to the nursing/supporting staff.
3480300|NCT03795064|Experimental|Immediate Intervention|Patients in this group will be treated with foam sclerotherapy immediately in the first visit to outpatient clinic (immediate intervention).
3480301|NCT03795064|Active Comparator|Early Intervention|Patients in this group will be treated with foam sclerotherapy in the following visit to outpatient clinic at four weeks (early intervention).
3480302|NCT03795428|Experimental|Pemziviptadil (PB1046) Injection-OL Active Drug-Up-Titration to Stable Dose|Pemziviptadil (PB1046) Injection: Regardless of dose assignment, all subjects will be up-titrated in 0.2 mg/kg weekly increments, beginning with 0.4 mg/kg at Week 1, to the target dose of 1.2 mg/kg or higher depending on safety and tolerability.
3480303|NCT03795051|Experimental|Navigated TMS|Each participant will receive 30 sessions of 10 Hz or 20 Hz navigated transcranial magnetic stimulation over the left DLPFC.
3480304|NCT03795259|Active Comparator|Sevoflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 2% sevoflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
3480305|NCT03795259|Active Comparator|Desflurane|Anesthesia will be induced with thiopenthal 5-6 mg/kg and fentanyl 2 mcg/kg. Then rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%. Anesthesia will continue with 6% desflurane while the patient is ventilated in volume controlled mode (FiO2: 40%, I/E: 1/1.5, PEEP: 5 cmH2O, tidal volume: 8ml/kg). Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given to measure the time for TOF to reach 90%.
3480306|NCT03795077|No Intervention|Control group|Control group followed traditional lectures about professional ethics during 3 months as usual.
3480307|NCT03795077|Experimental|Experimental group|Experimental group followed the programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used. Techniques used: concept maps, glossaries, brainstorming, four corners activity, aquarium, philip 6-6, kahoot, Realm Individual-Process Situation, reduced groups, guided debates, and discussion groups.
3480308|NCT03795116|Experimental|LED-RL phototherapy|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
3480309|NCT03795116|Sham Comparator|Mock irradiation|Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week after surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks.
3480310|NCT03795285||Septic neonates:|fifty neonates with sepsis.
3480311|NCT03795285||Controls:|twenty healthy neonates.
3480312|NCT03795272|Experimental|Rucaparib|Patients will be treated with active oral drug, Rucaparib twice daily for 24 months
3480313|NCT03795272|Placebo Comparator|Placebo|Patients will be treated with oral placebo twice daily for 24 months
3480314|NCT03795194|Other|8-day|8-day course of ampicillin clavulanate antibiotic
3480315|NCT03795194|Other|4-day|4--day course of ampicillin clavulanate antibiotic
3480316|NCT03795415||Immediate Arm (G1)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G1 will receive the intervention Gundo-So immediately. (From month 3 to month 6).~112 women will be in immediate arm in 14 groups of 8 women."
3480317|NCT03795415||Delayed Arm (G2)|"3 months after enrollment, each big groups of 16 will be split in two groups. Women in G2 will receive the intervention Gundo-So 3 months after. (From month 6 to month 9).~112 women will be in delayed arm in 14 groups of 8 women."
3127378|NCT03089580|Experimental|Intense Pulsed Light Treatment|Participants will have one eye randomized to receive the intense pulsed light (IPL) therapy treatment while their other eye will receive the sham treatment. Participants will receive approximately 15 light spots to areas around the eye, lower eyelid, cheek, side of the nose and temple. The energy level will be based on skin type. IPL will be administered 4 times throughout the study.
3480318|NCT03795311|Experimental|Administration of chemotherapy molecules|"The treatment period is divided into 15-day periods.~Schema of the administration to the treatments which will proceed in the same way with each cycle:~Bevacizumab (5 mg/kg; during 30 min) + Oxaliplatine (85 mg/m2, during 2 hours) + Acide folinique (400 mg/m2) or Levofolinate de calcium (200 mg/m2) AND Irinotecan (during 2 hours) + 5-fluorouracile (2400 mg/m2 ; 46 hours) + Irinotecan (1 hour)"
3480319|NCT03795129|Experimental|SleepLife Application w/FitBit|"Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application."
3480320|NCT03795129|Active Comparator|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
3480321|NCT03795220|Active Comparator|Vaginal progesterone + transfer 6. day|Lutinus + blastocyst warming and transfer 6 days after hCG trigger
3480322|NCT03795220|Active Comparator|Vaginal progesterone + transfer 7. day|Lutinus + blastocyst warming and transfer 7 days after hCG trigger
3480323|NCT03795220|Active Comparator|No progesterone + transfer 6. day|No Lutinus + blastocyst warming and transfer 6 days after hCG trigger
3480324|NCT03795220|Active Comparator|No progesterone + transfer 7. day|No Lutinus + blastocyst warming and transfer 7 days after hCG trigger
3127379|NCT03089580|Placebo Comparator|Sham Treatment|Participants will have the other eye randomized to receive a sham treatment. The sham treatment will be conducted by placing the intense pulsed light (IPL) device to approximately 15 areas around the eye, lower eyelid, cheek, side of nose and temple without delivery of the light. The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
3127380|NCT03089697|Experimental|N-Rephasin® SAL200|To assign the study group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with N-Rephasin® SAL200 (3mg/kg); N-Rephasin® SAL 200 is given by intravenous only once at Day 1.
3127381|NCT03089697|Placebo Comparator|Placebo|To assign the control group, administer the conventional standard treatment (CST) (antibiotics) for MRSA/MSSA with Formulation buffer (placebo); Placebo (INT200) is given by intravenous only once at Day 1 (same way with Experimental group)
3127382|NCT03089853|Experimental|Intervention Arm|Subjects randomized to intervention arm will have a device applied to their thigh on either side, and subject to neuromuscular electrical stimulation for 30 minutes daily for 2 weeks, followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
3127383|NCT03089853|No Intervention|Usual Care Arm|Usual care will consist of a protocolized regimen of 5 days of systemic steroids, unless the treating physician determines a different regimen, in which case the change will be documented.
3179575|NCT00674414|Active Comparator|Arm I|Patients receive trastuzumab (Herceptin®) IV once weekly for 6 weeks. Patients then undergo surgery.
3179576|NCT00674414|Experimental|Arm II|Patients receive trastuzumab as in arm I and oral everolimus once daily for 6 weeks. Within 24 hours after completing everolimus, patients undergo surgery.
3179577|NCT00674427|Experimental|CR|Subjects who are in CR ater 6-12 weeks after aDLI
3480325|NCT03795324|Experimental|Redlove Apple|"Redlove Apple intervention~This product is a biofortified cultivar apple with anthocyanins."
3127384|NCT03089879|Experimental|Shigella Group|Healthy male and female subjects, aged 22 to 50 years, previously primed with 3 doses of the GVGH Shigella sonnei 1790GAHB vaccine in the H03_01TP parent study and who had undetectable antibody titers at baseline, received one intramuscular booster dose of the same vaccine in the current study, at Day 1.
3480326|NCT03795324|Experimental|Green Apple|"Green Apple intervention~This product is a common cultivar apple without anthocyanins."
3480327|NCT03795324|Experimental|Aronia Drink|"Aronia drink intervention~This product is an infusion of aronia fruit extract rich in anthocyanin."
3480328|NCT03795402||Group A|Three microneedle device samples will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1. Two skin biopsies of 4 millimeter (mm) will be performed on Day 1. No investigational drug product will be administered during this study.
3480329|NCT03795402||Group B|One microneedle device sample will be collected from a psoriasis lesion and from nonlesional (healthy) skin on Day 1 and at Weeks 2 and 4. Two skin biopsies of 4 mm will be performed on Day 1. No investigational drug product will be administered during this study.
3480330|NCT03795142|Experimental|single intravenous dose; BGB149|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
3179578|NCT00674427|Experimental|Not in CR|Subjects not in CR after 6-12 weeks after aDLI
3480331|NCT03795142|Placebo Comparator|single intravenous dose; placebo|A single intravenous dose of BGB 149 or matched placebo will be administered on day 1 ascending doses will be administered in cohorts of 6 (randomised 4:2, active: placebo) at a planned four dose levels (maximum of six dose levels to be investigated under initial approved protocol) A sentinel cohort of 2 volunteers will randomly receive (1:1) either experimental or matched placebo infusion
3480332|NCT03795246|Experimental|Study Process|Consultation, Biological Test, Pelvic Ultrasound
3480333|NCT03795207|Experimental|Arm SBRT + DURVALUMAB|"Radiation (SBRT) + Immunotherapy treatment (Durvalumab)~64 patients will be enrolled in this arm~Durvalumab, will be started one month prior to SBRT and then given for a total of 12 months.~Patient will receive one injection per months (1500 mg/cycle)~SBRT will be started one month after Durvalumab and patients will receive 3 fractions of radiation"
3480334|NCT03795207|Active Comparator|Arm SBRT|"Radiation (SBRT)~32 patients will be enrolled in this arm~Patients will receive only 3 fractions of radiation"
3480335|NCT03795389|Experimental|3.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD. separate n=8 of study group with T1D or T2D with CKD stage 4).
3480336|NCT03795389|Experimental|5.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
3480337|NCT03795389|Experimental|8.0 µg/kg SC, single dose|n=8, study group of T1D or T2D with stage 3 CKD.
3480338|NCT03795350|Experimental|TRIMBOW|"Experimental: BDP/FF/GB~4 puffs of 99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI"
3480339|NCT03795168|Experimental|Transcranial vibrating system effect|"Participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. During the first 2 weeks (4 visits), 20 participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) and the other 20 participants without. The following 2 consecutive weeks (4 visits), participants will perform their PT exercises wearing the TCVS if they weren't previously, or won't wear the device during their PT exercises if they were previously.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
3480340|NCT03795168|Sham Comparator|Vs transcranial vibrating system sham|"40 participants will be enrolled for a 4 week period and will have 2 vestibular physical therapy (PT) visits per week. Participants will perform their PT exercises (30 minutes or less if the participant is too dizzy to finish) wearing the transcranial vibration system (TCVS) at optimal vibrating frequency or wearing the TCVS at irrelevant vibrating frequency (sham). The TCVS and TCVS sham will be labeled A or B by the sponsor. The investigators and participants will not know which TCVS is optimal or sham. The sponsor will randomly assign participants TCVS A or B.~Outcomes measured:~at every visit: dizziness at the end of PT exercise (with dizziness symptom scale DSS); duration of PT exercise~at the first and last visit: force plate system assessment (balance)"
3480341|NCT03795337|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
3480342|NCT03794960|Experimental|TOL-3021|
3480343|NCT03794960|Placebo Comparator|TOL-3021 Placebo|
3480344|NCT03794973|Experimental|TOL-3021|TOL-3021 2 mg/mL
3480345|NCT03794973|Placebo Comparator|TOL-3021 Placebo|TOL-3021 Placebo
3480346|NCT03794895|Experimental|Single arm clinical trial|
3480347|NCT03794856||Asthma patients|Asthma patients will undergo behavioral testing and imaging at a single timepoint.
3480348|NCT03794856||Healthy Volunteers|Healthy volunteers will undergo behavioral testing and imaging at a single timepoint.
3480349|NCT03795012|Active Comparator|Eribulin monotherapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle
3480350|NCT03795012|Active Comparator|eribulin plus endocrine therapy|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21- day cycle, in combination with endocrine therapy (aromatase inhibitor). AI must be identical to the last AI administered to the patient, whether in the adjuvant or metastatic setting.
3480351|NCT03795038|Other|Lipoprotein Apheresis MONET and DALI|"Patients routinely treated with MONET:~The first subgroup will be treated first with the MONET adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber System.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the MONET adsorber system"
3480352|NCT03795038|Other|Lipoprotein Apheresis DIAMED and DALI|"Patients routinely treated with DIAMED:~The first subgroup will be treated first with the DIAMED adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DALI adsorber system.~The second subgroup will be treated first with the DALI adsorber system for three consecutive treatments followed by a treatment for three consecutive treatments with the DIAMED adsorber System."
3480353|NCT03795025|Experimental|3x10RM + no training|
3480354|NCT03795025|Experimental|6x10RM + no training|
3127385|NCT03089879|Experimental|Placebo Group|Healthy male and female subjects, aged 22 to 50 years, who previously received placebo in the H03_01TP parent study and who had undetectable antibodies at baseline, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
3127386|NCT03089879|Experimental|Naïve Group|Healthy male and female subjects, aged 22 to 50 years, who were not part of H03_01TP parent study, received one intramuscular GVGH Shigella sonnei 1790GAHB vaccine dose in the current study, at Day 1.
3480355|NCT03795025|Experimental|3x10RM + 6x10RM|
3480356|NCT03795025|No Intervention|Control|This arm includes 3 weeks of testing and 7 weeks of no intervention and post tests, followed by 7 weeks of progressive unilateral strength training 3 times per week for 7 weeks. Both legs exercises individually with 3 sets of 10 maximal repetitions.
3480357|NCT03794947|Experimental|Remote Ischaemic Conditioning|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The blood pressure cuff in the active treatment arm will inflate to 200 mmHg (arm) and 220 mmHg (leg). RIC will be completed 3 times weekly for 4 weeks.
3480358|NCT03794947|Sham Comparator|Sham Intervention|4 cycles of 5 minutes of upper or lower (depending on tolerability) limb ischaemia followed by 5 minutes of reperfusion. This will be delivered using a manual shygnomanometer applied to the upper arm or leg and activated to go through 4 such cycles automatically. The arm and leg blood pressure cuffs in the sham intervention will inflate to 20mmHg. Sham will be completed 3 times weekly for 4 weeks.
3480359|NCT03794804|Active Comparator|ColdZyme|"ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
3480360|NCT03794804|Placebo Comparator|Placebo|"Water based mouth spray manufactured to be similar to ColdZyme® Mouth Spray. The IP should be applied every second hour up to 6 times, with each time 2 sprays (1 dose) per occasion.~The IP use should start when following conditions have been fulfilled:~Answering Yes to either of the questions in the subject daily diary: Do you think/feel you have a cold? or Do you think/feel you are coming down with a cold (might be having the first signs of cold)? AND~A Jackson score of at least 1 in the subject's cold diary (mild = present, but not disturbing or irritating) for any symptom except headache~The IP should be used until 2 days after the subject is symptom free (=answering No to the question Do you think that you are still sick with this respiratory infection? for 2 days in a row), but not longer than 10 days in total."
3480361|NCT03794791||education|Education will be used to see whether or not improve the HCV screening and diagnosis in HBsAg(+) patients. Blood test ,HCV-RNA quantification test and HCV genotyping will be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
3480362|NCT03794791||no education|There is no education at all.Screening and diagnosis of HCV infection in HBsAg(+) patients are based on voluntary. Blood test ,HCV-RNA quantification test and HCV genotyping will still be employed to evaluate the prevalence of HBV-HCV co-infection. Awareness of HCV infection in HBV/HCV cohort and analysis of risk factors will also be assessed.
3480363|NCT03794765|Experimental|Antibiotic|Standard of Care (steroids, prophylactic anticoagulation, oral nutrition) And Antibiotics (Inj Ceftriaxone 1 gram intravenous twice daily And Inj Metronidazole 500 mg intravenous thrice daily) for initial 48 hours
3480364|NCT03794765|Placebo Comparator|Placebo|Standard of care (steroids, prophylactic anticoagulation, oral nutrition) And Placebo infusions similar to the active drugs
3480365|NCT03794934|Placebo Comparator|Control|Without structured education when applying CGM for 3months, and as a sequential extension clinical trial, after 3 months, structured education is provided, followed by CGM apply
3480366|NCT03794934|Active Comparator|Intervention|provide structured education when applying CGM for 3 months
3480367|NCT03794726|Active Comparator|Orthodontic Molar Protraction|Molar protraction using orthodontic tooth movement alone
3480368|NCT03794726|Experimental|Orthodontic Molar Protraction and PAOO|Molar protraction using orthodontic tooth movement and adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO)
3480369|NCT03794700|No Intervention|Control|
3480370|NCT03794700|Other|Intervention|Participants will receive hospice decisional support materials and be asked to review them. Participants will provide feedback on tools and complete feasibility, efficacy and knowledge assessments.
3480371|NCT03794674||MPI test group|50 eligible patients. Frailty level independently assessed by two reviewers based on the medical records and assessed by one research assistant based on bedside testing.
3480372|NCT03794713|Experimental|Patient support tool group|Subjects were managed the HR by using the Patient Support Tool through a smart phone application and a wristband and be guided by physicians
3480373|NCT03794713|No Intervention|Control group|Subjects were received a usual patient care at baseline, which left to the discretion of physicians, without any specific intervention at follow-up period
3480374|NCT03794908|Experimental|Light therapy A via the Re-Timer®|"60 minutes/day~For the first hour after waking"
3480375|NCT03794908|Active Comparator|Light therapy B via the Re-Timer®|"60 minutes/day~For the first hour after waking"
3480376|NCT03794687||Distal Radial Artery|Left heart catheterization via the distal radial artery (dorsal aspect of the hand at the base of the thumb).
3480377|NCT03794843|Experimental|Nimodipine Injection (II)|The specification of this injection is 5 ml: 4 mg , which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:16 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
3480378|NCT03794843|Experimental|Nimodipine Injection|The specification of this injection is 50 ml: 10 mg ,which is administered by constant infusion intravenously with an infusion pump. The injection and 0.9% sodium chloride injection is simultaneously infused at a ratio of 1:4 (injection: combined infusion). The rate of intravenous drip was started at 0.5 mg/h for 2 hours, and the rate of intravenous drip was 1.0 mg/h after 2 hours, and continuous infusion for 12 hours, for a total of 11 mg of nimodipine.
3480379|NCT03794505|Active Comparator|Shoulder infiltration|Shoulder infiltration using 2 ml of Lidocaine 2% Injectable Solution and methylprednisolone acetate 40 mg
3480380|NCT03794505|Experimental|Suprascapular nerve block|Suprascapular nerve block ultrasound guided using 25 mg of Ropivacaine HCl Inj 7.5 MG/ML and methylprednisolone acetate 40 mg
3480381|NCT03794869|Experimental|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of the core: awareness of breathing, front and side plate abdominal, glute bridge/hip elevations, lift extended leg, pelvic tilt, hamstring stretch, strengthening lower abdominals, cat-camel posture, trunk rotations with flexed knees, rolling in sitting and lumbar extension with hip extensión in prone
3480382|NCT03794869|Active Comparator|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
3480383|NCT03794544|Experimental|Arm A: Durvalumab monotherapy|durvalumab IV
3480384|NCT03794544|Experimental|Arm B: Durvalumab + Oleclumab|durvalumab IV and oleclumab IV
3480385|NCT03794544|Experimental|Arm C: Durvalumab + Monalizumab|durvalumab IV and monalizumab IV
3480386|NCT03794544|Experimental|Arm D: Durvalumab + Danvatirsen|danvatirsen IV and durvalumab IV
3480387|NCT03794921|No Intervention|Usual Care|Patients referred to conventional PR or eligible for PR but declined. Using a standardized script at the randomization phone call, study staff will deliver verbal instructions to slowly and steadily increase one's walking and exercise each week. Participants will be asked to perform exercise of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover. Use of the Borg rating scale for dyspnea will be reviewed with each participant. Exercise is defined as planned PA, outside of activities performed as part of one's daily routine. Exercise can be walking in the community or using exercise equipment at a local gym. Adapted written materials reinforce the verbal instructions. Participants will receive this 45-page spiral-bound book with information about aerobic and strength training exercises.
3480388|NCT03794921|Experimental|Every Step Counts Intervention|Patients referred to conventional PR or eligible for PR but declined. After randomization to ESC, participants will be mailed detailed instructions about the website. They will be asked to wear the lightweight, unobtrusive pedometer every day, except while asleep or showering/bathing, during the 12-week intervention period. Subjects will be instructed to upload their date and time-stamped step-count data to the study website as often as they wish, but at least weekly. Each week, the study computer will run the goal calculation algorithm and provide each participant with his/her daily step-count goal for the week. The week's step-count goal will be prominently displayed on each subject's personal study web page. Participants will be instructed to exercise and reach their individualized step-count goals with walking of moderate intensity for at least 30 minutes on most days of the week, defined as a dyspnea level of 4-5 on the Borg scale and taking 1-2 minutes to recover.
3480389|NCT03794778|Experimental|study group|pegylated liposomal doxorubicin 30 mg/m2, i.v.,d1; carboplatin AUC 5,i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
3127387|NCT03089944|Experimental|Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
3127388|NCT03090100|Experimental|Group I: Guselkumab Plus Placebo|Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.
3127389|NCT03090100|Active Comparator|Group II: Secukinumab|Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
3127390|NCT03090256|Experimental|PanOptix IOL|AcrySof® IQ PanOptix™ IOL, bilateral implantation
3127391|NCT03090620|Experimental|Physostigmine|Physostigmine 0.02 mg/kg IV bolus (max of 2 mg), which can be repeated at 10 minutes, followed by a 0.02 mg/kg/hr (max of 2 mg/hr) infusion for 4 hours.
3480390|NCT03794778|Active Comparator|chemotherapy|paclitaxel 175 mg/m2, i.v.,d1; carboplatin AUC 5, i.v.,d1; once every 21days, 3~6 cycles for early stage patients and 6 cycles for late stage.
3480391|NCT03794739||Healthy subjects|"Healthy subjects without diabetes, no recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
3480392|NCT03794739||T1D individuals|"Type 1 diabetic individuals with at least 3-year of duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
3127392|NCT03090620|Experimental|Lorazepam|Lorazepam 0.05 mg/kg IV bolus (max 2 mg), which can be repeated at 10 minutes if inadequate patient response, followed by a Normal Saline infusion for 4 hours.
3132716|NCT03447314|Experimental|Part 1a: 250ng GSK1795091 + 24mg GSK3174998|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3174998 24 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3174998 24 mg at Q3W interval.
3179579|NCT00674440|Experimental|1|Children diagnosed with hyperinsulinism who have failed other non-surgical interventions and will be scheduled for surgery. Eligible children in this arm will PET imaging with F-DOPA prior to surgery.
3480393|NCT03794739||T2D individuals|"Type 2 diabetic individuals with at least 5-year duration of the disease. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
3480394|NCT03794739||AutoAb+ individuals|"Individuals at risk for type 1 diabetes, with one or more autoantibody detected. No recent surgery interventions, no malignancies no pregnancy.~No intervention. No age limit."
3480395|NCT03794986|Experimental|Motivational Interviewing|Sexual and gender minority males who are sexual abuse survivors.
3480396|NCT03794986|Active Comparator|MI with trauma-informed SGM affirmative care|MI w/trauma-informed SGM affirmative care
3480397|NCT03794830|Experimental|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
3480398|NCT03794830|Active Comparator|electrotherapy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions of electrotherapy).
3480399|NCT03794622||Bone marrow concentration group|Consecutive patients receive intramedullary nail fixation with bone marrow concentration.
3480400|NCT03794622||Historical control group|Previous age- and gender-matched patients who receive intramedullary nail fixation only.
3480401|NCT03794648|Experimental|Intervention Group|
3480402|NCT03794648|No Intervention|Control Group|
3480403|NCT03794635|Experimental|Patients|Latino/a advanced cancer patients
3480404|NCT03794635|Experimental|Caregivers|Caregivers of Latino/a advanced cancer patients
3480405|NCT03794570|Sham Comparator|Control|Patients in this group will have BFR tourniquet applied but inflated to only minimal pressure.
3480406|NCT03794570|Experimental|Blood Flow Restriction (BFR) Therapy|Patients in this group will have BFR tourniquet applied and inflated to 80% limb occlusion pressure
3480407|NCT03794518|Experimental|Pioglitazone Plus dapaglifliozin|Pioglitazone 15mg and dapaglifliozin 10mg together in T2DM patients having HF and HFpEF conditions
3480408|NCT03794518|Placebo Comparator|Placebo|Beta blockers, ACEI, ARB, and aldosterone
3480409|NCT03794661|Experimental|Single Arm|Clinician programmer electrode screening mode tool
3480410|NCT03794557|Experimental|PUL-042|PUL-042 Inhalation Solution
3480411|NCT03794557|Placebo Comparator|Placebo|Sterile Water for injection
3480412|NCT03794479||Travellers|Adults planning for travel
3480413|NCT03794492|Experimental|Mycophenolate mofetil|One arm: Mycophenolate mofetil 500mg Tab. or 250mg Cap.
3480414|NCT03794596|Experimental|(Arm A) Avelumab + PPI|21 patients into Arm A: Avelumab + Proton Pump Inhibitor (PPI)
3480415|NCT03794596|Experimental|(Arm B) Avelumab + Aspirin + PPI|21 patients into Arm B: Avelumab + Aspirin + PPI
3480416|NCT03794219|Experimental|Kinesio tape plus NSAID|Kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions in addition to 750 mg/day oral naproxen.
3480417|NCT03794219|Active Comparator|NSAID|750 mg/day oral naproxen is administered for 10 days.
3480418|NCT03794427|Experimental|unilateral lumbosacral nerve block|Sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5 will be performed
3480419|NCT03794427|Active Comparator|Spinal anesthesia|spinal anesthesia will be performed
3480420|NCT03794375|Active Comparator|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
3480421|NCT03794375|Experimental|Telehealth|"The patients will be discharged from the HCPA thyroid disease outpatient clinic, being instructed to seek the primary care level according to their place of residence to schedule a routine consultation in up to six months.~After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed."
3480422|NCT03794245|Experimental|Men-Centered HIV Testing|Mobile HIV testing is conducted at sites in the community where men gather.
3480423|NCT03794245|Active Comparator|Clinic-based HIV Testing|Men are referred to the nearest clinic for HIV counseling and testing
3480424|NCT03794245|Experimental|Linkage to Care for HIV+ Men|The patient coordinator arranges an appointment time at the clinic and accompanies the patient to the initial visit
3480425|NCT03794245|Active Comparator|Clinic Referral for HIV+ Men|Men diagnosed with HIV are referred to the nearest clinic for treatment of HIV
3480426|NCT03794102|Active Comparator|Ureteroscopy with water irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Water will be used as the irrigation fluid during the ureteroscopy.
3480427|NCT03794102|Active Comparator|Ureteroscopy with saline irrigation|Participants meeting medical requirements to undergo ureteroscopy will undergo a routine cystoscopy and ureteroscopy following standard techniques. Saline will be used as the irrigation fluid during the ureteroscopy.
3127393|NCT03090958|Experimental|AllyQuest Pilot|The research assistant (RA) will meet with participants in person to explain the study in detail, facilitate app download and login onto participants' phones, and provide an app site tour to highlight features. Participants will complete a baseline demographic and risk assessment administered via a computer assisted survey instrument (CASI). At the end of the one-month field trial, participants will undergo a debriefing session to evaluate their experience using the app, overall satisfaction and any problems they encountered.
3127394|NCT03091179|Experimental|THRIVE|high flow nasal oxygen
3127395|NCT03091179|Active Comparator|Endotracheal tube|tracheal intubation
3127396|NCT03091192|Experimental|Savolitinib|See: intervention description
3127397|NCT03091192|Active Comparator|Sunitinib|See: intervention description
3127398|NCT03091348|Experimental|SQ - IM|Subcutaneous testosterone injection followed by intramuscular testosterone injection
3127399|NCT03091348|Experimental|IM - SQ|Intramuscular testosterone injection followed by subcutaneous testosterone injection
3480428|NCT03794063||Robson group 1|Nulliparous women, single cephalic, more than or equal to 37 weeks, in spontaneous labour
3480429|NCT03794063||Robson Group 2|Nulliparous women, single cephalic, more than or equal to 37 weeks, induced or Caesarean section before labour
3480430|NCT03794063||Robson Group 3|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more than or equal 37 weeks gestation in spontaneous labour
3480431|NCT03794063||Robson Group 4|Multiparous women with out a previous Caesarean section , with a single cephalic pregnancy, more or equal 37 weeks gestation who had labour induced or were delivered by Caesarean section before labour
3480432|NCT03794063||Robson Group 5|All Multiparous women with at least one CS with a single cephalic pregnancy, more or equal to 37 weeks gestation
3480433|NCT03794063||Robson Group 6|All nulliparous women with a single breech pregnancy
3480434|NCT03794063||Robson Group 7|Multiparous women with a single breech pregnancy including women with previous Caesarean section
3480435|NCT03794063||Robson Group 8|All women with multiple pregnancies including women with previous Caesarean sections
3480436|NCT03794063||Robson Group 9|All women with a single pregnancy with a transverse or oblique lie, including women with previous Caesarean Section (s)
3480437|NCT03794063||Robson Group 10|All women with a single cephalic pregnancy less than 37 weeks gestation, including women with previous Caesarean section (s)
3480438|NCT03794128||1 - patient-specific neoantigen cancer vaccine production|
3480439|NCT03794128||2 - shared neoantigen cancer vaccine screening|
3480440|NCT03794453||Stroke patients|
3480441|NCT03793985|Experimental|A (R+T+R+T)|Period 1 : R Period 2 : T Period 3 : R Period 4 : T
3480442|NCT03793985|Active Comparator|B (T+R+T+R)|Period 1 : T Period 2 : R Period 3 : T Period 4 : R
3480443|NCT03794076|Active Comparator|Cromoglycate|Cromoglycate nasal spray
3480444|NCT03794076|Placebo Comparator|Placebo|Saline nasal spray
3480445|NCT03794440|Experimental|Sintilimab +IBI305|
3480446|NCT03794440|Active Comparator|Sorafenib|
3480447|NCT03794037|Active Comparator|control|dydrgesterone 10 mg( tab)/12hs/14 days
3480448|NCT03794037|Experimental|study|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days
3480449|NCT03794232|Experimental|Test group|NIUCHANG（Soluble dietary fiber + prebiotics）：Oral, 1 bag (15g) once a day, taking 24 weeks
3480450|NCT03794232|Placebo Comparator|Control group|Placebo（inactive drug ingredient）：Oral, 1 bag (15g) once a day, taking 24 weeks
3480451|NCT03794271|Experimental|Pupilometer group|In this group, intraoperative analgesia is performed using pupilometer guided anesthesia.
3480452|NCT03794271|Active Comparator|SPI group|In this group, intraoperative analgesia is performed using SPI guided anesthesia
3480453|NCT03794310|Experimental|NPF-08 （1-day treatment）|
3480454|NCT03794310|Experimental|NPF-08 （2-day split dose）|
3480455|NCT03794310|Active Comparator|Moviprep（1-day treatment）|
3480456|NCT03794154|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
3480457|NCT03794154|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg as Cymbalta by mouth on Day 1 of period 1 or 2
3480458|NCT03794323|Experimental|BI 764122|
3480459|NCT03794323|Placebo Comparator|Placebo|
3480460|NCT03794167|Experimental|busulfan cyclophosphamide etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6, cyclophosphamide 50mg/kg/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
3480461|NCT03794167|Active Comparator|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6 melphalan 50mg/m2/day i.v. on days -3 and -2 etoposide 400mg/m2 day i.v. on days -5 and -4
3480462|NCT03793972|Experimental|Triage with referral to primary care|Triage and referral according to eMTS.
3480463|NCT03793972|Active Comparator|Triage without referral to primary care|Weekends with usual care
3480464|NCT03794206|Experimental|Treatment Arm|Single-arm of subjects who receive treatment with Vesair Balloon
3480465|NCT03794336|Experimental|Alogliptin|Single dose of alogliptin once daily for 16 weeks
3480466|NCT03794336|Active Comparator|Acarbose|Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
3480467|NCT03794180|Experimental|TJ003234|0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg via single IV infusion
3480468|NCT03794180|Placebo Comparator|Placebo|0 mg/kg via single IV infusion
3480469|NCT03794011|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
3480470|NCT03794141|Experimental|Tervas|Follow up group from an earlier study. Information on risk gene status. All test persons were given information on healthy diet and life style.
3480471|NCT03794141|Experimental|Informed|Information on risk gene status was given before intervention. All test persons were given information on healthy diet and life style.
3480472|NCT03794141|Active Comparator|non informed|Information on risk gene status was not given before intervention. All test persons were given information on healthy diet and life style.
3480473|NCT03794297|Experimental|Treatment (dabrafenib mesylate, trametinib dimethyl sulfoxide)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3480474|NCT03794050|Experimental|resistance training exercise|All participants complete one session of resistance training exercise
3480475|NCT03794050|Experimental|aerobic training exercise|All participants complete one session of aerobic training exercise
3480476|NCT03793959|Experimental|Synbiotic Supplement|Daily synbiotic supplement (5g prebiotic fiber + 8 billion CFU probiotic B. lactis, identical to Placebo-- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
3480477|NCT03793959|Placebo Comparator|Placebo Supplement|Daily placebo supplement (5g maltodextrin, identical to Experimental -- white powder), along with a daily Fe supplement (140 mg FeSO4/d) for 8 weeks.
3480478|NCT03794414|Experimental|fluid responder|patients with 10% or more increase in stroke volume after fluid challenge. Both arms receive PEEP challenge.
3480479|NCT03794414|Experimental|fluid non-responder|patients with no increase or less than 10% increase in stroke volume after fluid challenge. Both arms receive PEEP challenge
3127400|NCT03091361||All patients (imaging/no intervention)|There is only one group in this study, the imaging/no intervention group. These patients will meet all enrollment criteria and bacterial (red or cyan) fluorescence will be visualized within or around their wound with the MolecuLight i:X imaging device. A targeted curettage sample will be taken from the site of fluorescence and sent for microbiological analysis. There will be no intervention or followup.
3480480|NCT03793946|Experimental|AB-assistant|Use of the AB-assistant app by physicians in intervention wards.
3480481|NCT03793946|No Intervention|Standard antimicrobial stewardship|Physicians on these wards will use conventional ways to assess local guidelines to prescribe antimicrobials.
3480482|NCT03793894|Active Comparator|Enhanced usual care|"All trial participants will receive smoking cessation counseling (standard of care) and will be given the AHRQ Is Lung Cancer Screening Right for me? patient decision aid to review independently while in the hospital."
3480483|NCT03793894|Experimental|Inpatient SDM + CHW Navigation|In addition to the smoking cessation counseling and decision aid received by all subjects, intervention subjects will receive shared decision making (SDM) + CHW navigation.
3480484|NCT03793920|Experimental|PEA patients without alcohol disorder|A group of 36 PEA patient without alcohol-dependence (AD), performing 6 behavioral tasks.
3480485|NCT03793920|Sham Comparator|PEA patients with alcohol disorder|A group of 36 PEA participants, currently alcohol-dependent, performing 6 behavioral tasks.
3480486|NCT03793920|Sham Comparator|Healthy controls with AD father|A group of 36 non-alcohol-dependent controls whose father was alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
3480487|NCT03793920|Sham Comparator|Healthy controls without AD father|A group of 36 non-alcohol-dependent controls whose father was not alcohol-dependent during their childhood and adolescence, performing 6 behavioral tasks.
3480488|NCT03793699||case group : realized a suicide attempt|adults having realized a suicide attempt and without histories of suicide attempt.
3480489|NCT03793699||control group : only suicidal ideas|adults having suicidal ideas without suicidal acting out and without histories of suicide attempt.
3480490|NCT03793790|Experimental|Group 1|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
3480491|NCT03793790|Experimental|Group 2|Conditioning nocebo effects on pain with a partial reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
3480492|NCT03793790|Experimental|Group 3|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and counterconditioning of the previously induced nocebo effect (attenuation).
3480493|NCT03793790|Experimental|Group 4|Conditioning nocebo effects on pain with a continuous reinforcement schedule (induction) and extinction of the previously induced nocebo effect (attenuation).
3480494|NCT03793790|Sham Comparator|Group 5|Sham conditioning of nocebo effects on pain (induction) and extinction (attenuation).
3480495|NCT03793647|Active Comparator|Low Intensity EMS|Conventional Stimulation
3480496|NCT03793647|Experimental|High Intensity EMS|Russian Stimulation
3127401|NCT03091400|Experimental|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
3480497|NCT03793647|Placebo Comparator|Placebo|no Stimulation, supported by phone contact
3480498|NCT03794258|Experimental|SOF+DCV+CDI-31244|Subjects will receive two weeks of sofosbuvir, daclatasvir, and CDI-31244 if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
3480499|NCT03794258|Experimental|SOF+DCV+CDI-31244+ASV|Subjects will receive two weeks of sofosbuvir, daclatasvir, CDI-31244 and asunaprevir if they achieve HCV RNA < 500 IU/mL on Day 2 and HCV RNA < LLOQ (< 25 IU/mL) on Week 1.
3480500|NCT03793621|Experimental|BI 730357|
3480501|NCT03793621|Placebo Comparator|Placebo|
3480502|NCT03793712|Experimental|Lu AF11167 low dose|
3480503|NCT03793712|Experimental|Lu AF11167 high dose|
3480504|NCT03793712|Placebo Comparator|Placebo|
3480505|NCT03793777|Placebo Comparator|placebo|microcrystalline cellulose supplementation
3480506|NCT03793777|Experimental|Aronia|aronia melanocarpa supplementation
3480507|NCT03793764|Active Comparator|Group T|At the end of the surgery USG guided TAP block will be performed with 20 mL of 0.25% isobaric bupivacaine.
3480508|NCT03793764|Active Comparator|Group Q|At the end of the surgery USG guided QL block will be performed with 20 mL of 0.25% isobaric bupivacaine.
3480509|NCT03793764|No Intervention|Group C|In this group no intervention will be performed after the end of operation.
3480510|NCT03793881|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
3480511|NCT03793881|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Cardiology.
3127402|NCT03091400|Placebo Comparator|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
3127403|NCT03091439|Experimental|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
3480512|NCT03793868|Experimental|Low dose|Perampanel 4mg PO x1
3480513|NCT03793868|Placebo Comparator|Placebo|Receiving placebo
3480514|NCT03793868|Experimental|High dose|Perampanel 8 mg PO x1
3480515|NCT03793816|Active Comparator|BiZact™ device|"BiZact™ device will be used appropriately to its purpose to remove one tonsil by:~Incision of the anterior palatal arch~Locating of the cranial pole of the tonsil~Dissection of the tonsil capsule~Localized coagulation of bleeding vessels~Detaching of the inferior pole from the pharynx tissue"
3480516|NCT03793816|Active Comparator|Cold steel dissection (CD)|Cold steel dissection (CD) with localized cauterization for hemostasis serves as the comparative procedure within each patient (cross-over).
3480517|NCT03793608|Experimental|Dupilumab|Open label weight base subcutaneous (SC) injection every two (Q2) weeks.
3480518|NCT03793725|Experimental|SHR-1210 + Apatinib|Drug: SHR-1210 SHR-1210 was administered 200mg iv every 2 weeks Drug: Apatinib Apatinib was administered 500mg oral daily during the first 2 weeks and then 250 mg qd
3127404|NCT03091439|Active Comparator|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
3480519|NCT03793673|Other|Standard Care: Standard appointments|"Usual in-person medical appointments. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
3480520|NCT03793673|Other|Standard Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
3480521|NCT03793673|Other|CoYoT1 Care: Standard Appointment|"In-person - medical appointments with provider and/or team. See previous detailed description.~COVID-19 Update: Current clinic appointments consist of telehealth appointments only. Any additional community and CHLA based educational and support events will be following COVID-19 guidelines."
3480522|NCT03793673|Other|CoYoT1 Care: Telehealth appointments|Telehealth - with provider and/or team. See previous detailed description.
3127405|NCT03091478|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg every 3 weeks
3127406|NCT03091673|Experimental|G-Pen (glucagon injection) 0.5 mg|A single 0.5 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
3127407|NCT03091673|Experimental|G-Pen (glucagon injection) 1.0 mg|A single 1.0 mg subcutaneous (SC) injection of G-Pen (glucagon injection)
3127408|NCT03091738|Experimental|Ramelteon Pill|Patients given ramelteon and re-evaluated after 15 days of therapy
3480523|NCT03793842|Experimental|Usual care then PEEP titration by EIT|Patients in the usual care first group will continue to receive mechanical ventilation according to the University of Michigan ARDS protocol high-PEEP arm
3480524|NCT03793842|Experimental|PEEP titration by EIT then usual care|Patients in the high PEEP titration by EIT first will have receive ventilation with a PEEP determined by EIT titration procedure.
3480525|NCT03793738|Active Comparator|anterior component separation|The anterior component separation technique requires an extensive subcutaneous flap elevation, incision of the external oblique aponeurosis, and incision of the posterior rectus sheath.
3480526|NCT03793738|Active Comparator|posterior component separation|The posterior component separation technique utilized the retromuscular space, accessed by incising the posterior rectus sheath and dissecting the posterior sheath between the internal oblique and transversus abdominis muscles.
3480527|NCT03793582||Study group|All subjects agreeing to participate and meeting inclusion criteria but not meeting exclusion criteria
3480528|NCT03793517|Experimental|Decitabine plus mBU/CY for HLA-mismatched HSCT|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of HLA-mismatched HSCT.~Details:~The conditioning therapy for human eukocyte antigen (HLA)-mismatched HSCT patients was decitabine plus modified BU/CY and ATG,consisting of decitabine 100mg·m-2·d-1 q12h on days-12 and -11,cytarabine (Ara-C 4 g·m-2·d-1) intravenously on days -10 to -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3, and ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2."
3480529|NCT03793517|Experimental|Decitabine plus mBU/CY for matched sibling transplant|"Decitabine plus mBU/CY as precondition regimen for High Risk Acute Leukemia With MRD at the time of matched sibling transplant.~Details:~In matched sibling transplantations, patients received decitabine 100mg·m-2·d-1 q12h on days-12 and -11,hydroxycarbamide (80 mg/kg) orally on day -10 and a lower dose of Ara-C (2 g·m-2·d-1) on day -9, busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, cyclophosphamide (CY 1.8 g·m-2·d-1), intravenously on days -5 to -4, simustine (Me-CCNU, 250 mg/m2), orally once on day -3."
3480530|NCT03793686|Experimental|Experimental|PBCLN-003, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
3480531|NCT03793686|Placebo Comparator|Placebo|Placebo, daily in 3 divided oral doses for 7 days, 2 ascending dose cohorts
3480532|NCT03793803|Experimental|Home Palliative Care|Randomized to Intervention Arm
3480533|NCT03793803|No Intervention|Control Arm|Usual Care - Patients will be cared for by the physician who treats their primary illness(es).
3480534|NCT03793569|No Intervention|Control group|Participants will be recruited and asked to complete Edinburgh Postnatal Depression Scale (EPDS) at specific timepoints postpartum.
3480535|NCT03793569|Experimental|Intervention group|Participants will be recruited, asked to complete Edinburgh Postnatal Depression Scale at specific timepoints postpartum, and attend a peer discussion group.
3480536|NCT03793491||Patients having Parkinson's disease|Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease. Patients will have TCI scale and PDQ-39 scale.
3480537|NCT03793413|Experimental|Surgical group|
3480538|NCT03793413|No Intervention|Observation group|
3480539|NCT03793855|Experimental|Nutritional Strategy|Nutritional counseling based on the quality of the diet, the Food Guide for the Brazilian Population and concepts of mindfulness and mindful eating; dietary guidance based on feasible goals built together (patient and nutritionist).
3480540|NCT03793855|Active Comparator|Dietary Prescription|Individualized dietary prescription according to the guidelines of the Brazilian Society of Diabetes.
3480541|NCT03793530|Experimental|Bone marrow concentration group|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
3480542|NCT03793530|Active Comparator|Control group|Transforaminal lumbar interbody fusion with local bone graft
3480543|NCT03793634|Experimental|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect.
3480544|NCT03793634|Active Comparator|Topical Triamcinolone Acetonide|topical triamcinolone acetonide is the gold standard treatment of oral lichen planus.
3480545|NCT03793595|Experimental|Seated Battle Ropes Protocol|
3480546|NCT03793595|Active Comparator|Seated Upper Extremity Arm Bike|
3480547|NCT03793426||Fibryga|Fibryga (human plasma-derived fibrinogen concentrate)
3480548|NCT03793387|Experimental|Pre-op|
3480549|NCT03793387|Active Comparator|Intra-op|
3480550|NCT03793439|Experimental|Open-label treatment|All subjects will receive tofacitinib 5mg twice daily from week 0 to week 16, and a corticosteroid taper starting at week 16. Participants also undergo spirometry, RNA sequence testing, and laboratory evaluations.
3480551|NCT03793439|Experimental|Open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
3480552|NCT03793192|Experimental|PACE2 Intervention|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity. In addition, participants randomized to the PACE2 intervention will receive written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
3480553|NCT03793192|No Intervention|Enhanced Usual Care|All participants will receive usual healthcare as per their treating medical team and carry a pedometer for recording of physical activity.
3480554|NCT03793101||BiMICS 1.4|Group 1.4 - Patients operated with 1.4 mm BiMICS technique
3480555|NCT03793101||BiMICS 1.8|Group 1.8 - Patients operated with 1.8 mm BiMICS technique
3480556|NCT03793361|Experimental|Arm A|Regorafenib
3480557|NCT03793361|Placebo Comparator|Arm B|Placebo
3480558|NCT03793231||Fungal Cases|Patients with confirmed invasive fungal infections according to internationally accepted criteria identified by active manual surveillance. Clinical data will be sent to fungalAi platform technology for disease classification.
3480559|NCT03793231||Control patients|Patients without invasive fungal infections.Clinical data will be sent to fungalAi platform technology for disease classification.
3480560|NCT03793127|Other|Young group|20-40 years of age
3179580|NCT00674440|Experimental|3|Children diagnosed with hyperinsulinism who have had partial pancreas removal but still display signs of hyperinsulinism. Eligible children in this arm may have PET imaging with F-DOPA.
3179581|NCT00674440|Experimental|2|Children diagnosed with hyperinsulinism who are successfully managed with diazoxide, octreotide, other medications,and/or tube feedings. Eligible children in this arm will PET imaging with F-DOPA.
3179582|NCT00674453|Experimental|Lasofoxifene 0.25 mg/d|
3179583|NCT00674453|Placebo Comparator|Placebo|
3480561|NCT03793127|Other|Old group|60-80 years of age
3480562|NCT03793270||patients|"1. Group 1: 30 diseased with Early Rheumatoid Arthritis from 6months to 1 year).~drugs described in the clinic."
3480563|NCT03793270||patients 2|2. Group 2: 30 diseased with late/chronic Rheumatoid Arthritis. drugs described in the clinic.
3480564|NCT03793270||healthy donors|3. Group 3: 30 healthy controls. No drugs.
3480565|NCT03793036|No Intervention|FAST group|preoperative fasting
3127409|NCT03091751|Experimental|BeneFIX|BeneFIX is a recombinant FIX provided in a vial containing 100 IU/mL lyophilized nonacog alfa accompanied with solvent for reconstitution and injection.
3127410|NCT03091777|Experimental|Test Drug|GDC-229 gel applied vaginally as directed.
3480566|NCT03793036|Experimental|CHO group|preoperative nutrition The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
3480567|NCT03793348|Experimental|Micro-exisional skin removal|Micro-coring of skin on the facial and neck areas will be conducted in one treatment and followed for 90 days post treatment.
3480568|NCT03793309|Experimental|Low dose|Subjects in this group receive 400 IU vitamin D daily for 4 weeks.
3480569|NCT03793309|Experimental|High dose|Subjects in this group receive 800 IU vitamin D daily for 4 weeks.
3480570|NCT03793322|Experimental|Indocyanine-Green(ICG) injection group|
3127411|NCT03091777|Active Comparator|Reference Drug|Metronidazole Vaginal Gel, 0.75% applied vaginally as directed.
3127412|NCT03091777|Placebo Comparator|Vehicle Placebo Gel|GDC-229 Vehicle
3127413|NCT03091920|Experimental|IW-1973 QD/QD|On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
3179584|NCT00674505|Other|Treatment, Open label, Single Group Assignment|
3480571|NCT03793283||Continous Subcutaneous Insulin Infusion|"All T1DM adult patients attended in Ciudad Real General University Hospital and treated with CSII.~Forty-five patients are actually treated with CSII in our hospital."
3480572|NCT03793283||Multiple dose insulin injections (MDI):|"Forty-five T1DM adult patients attended in Ciudad Real General University Hospital and treated with MDI.~MDI patients will be selected through simple random sampling (1:1) from our T1DM patient database."
3480573|NCT03793296|Experimental|Paravalvular leak|After transcatheter- or surgical valve replacement
3480574|NCT03793244||Experimental: TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
3480575|NCT03793244||Active Comparator: TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL Indirect calorimetry and/or VCO2 measurements will be taken periodically while in the TARGET main study
3480576|NCT03793153|No Intervention|Control|Standard Lower Segment Cesarean Section (LSCS) will be done.
3480577|NCT03793153|Active Comparator|Study|Uterine Cooling Technique: Standard LSCS will be done except immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. The skin of the abdomen will be draped to prevent contact with the cold towels. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
3480578|NCT03792997|Active Comparator|control|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid
3480579|NCT03792997|Experimental|study|regular treatment with embryo transfer in the form of progesterone I.M. & Supp. in addition to low dose aspirin & folic acid but the investigators add in this arm lipid emulsion & prednisolone & LMWH
3480580|NCT03793374||Axillary osmidrosis patients|Patients with axillary malodor and require surgical intervention. The subcutaneous apocrine glands shaving were used.
3480581|NCT03793075|Placebo Comparator|Propofol group (P)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of propofol 17 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
3480582|NCT03793075|Active Comparator|Ketamine group ((K)|The maintenance of anesthesia , patient will receive sevoflurane 1%-2.5% with intravenous infusion of ketamine 5 mcg /kg/min and 0.5 mg/kg fentanyl will be given if the heart rate or mean blood pressure increased by 30 % or more from the basal readings
3480583|NCT03793218|Experimental|Latera Device|The LATERA (Spirox Inc., Menlo Park, CA) device, an absorbable nasal implant comprised of a 70:30 blend of poly(L-lactide) and poly(D-lactide), is designed to provide support to the upper and lower lateral cartilages, thereby correcting nasal wall collapse. The implant was first used in the US and cleared by the FDA in 2016. It is designed as a ribbed cylindrical structure with a forked distal end. The implant is delivered endonasally, with a 16-gauge catheter, lateral to the upper and lower lateral cartilages and over the ascending process of the maxilla. The forked end rests on the ascending process of the maxilla and the flexible implant provides support the nasal sidewall soft tissue and cartilage. This non-toxic, biocompatible co-polymer has an extensive use in a variety of medical devices including suture materials and implants. In vivo studies demonstrate the copolymer to reliably decompose over an 18-24 month period.
3480584|NCT03793218|Active Comparator|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
3480585|NCT03793205|Experimental|Long-acting G-CSF group|Patients in long-acting G-CSF group accept long-acting with or without short-acting G-CSF.
3480586|NCT03793205|Experimental|Short-acting G-CSF group|Patients in long-acting G-CSF group only accept short-acting G-CSF.
3480587|NCT03793114|Experimental|Detectable levels of adrenal hormones|Patients with detectable serum levels of adrenal hormones will go through cosyntropin stimulation testing.
3480588|NCT03793114|Active Comparator|Controls with undetectable hormone levels|Twenty patients without detectable serum levels of adrenal hormones will serve as controls in cosyntropin stimulation testing.
3480589|NCT03793114|No Intervention|Undetectable levels of adrenal hormones|Patients without detectable serum levels of adrenal hormones. Cosyntropin stimulation testing will not be performed.
3480590|NCT03793114|Other|Congenital adrenal hyperplasia (CAH) control group|Mapping adrenal steroid profile in patients with congenital adrenal hyperplasia (CAH) with confirmed total deficiency of 21-hydroxylase.
3480591|NCT03793114|Other|Bilaterally adrenalectomized control group|Mapping adrenal steroid profile in patients who are bilaterally adrenalectomized.
3480592|NCT03793114|Experimental|Diurnal variation in residual adrenocortical hormone levels|Patients with detectable serum levels of adrenal hormones will go through a 30-hour ambulatory sampling of interstitial fluid for mapping of any diurnal variation in endogenous adrenocortical secretion.
3480593|NCT03793114|Experimental|Repeated cosyntropin testing in newly diagnosed patients|Newly diagnosed patients will be invited to go through repeated cosyntropin testing to delineate the natural progression of adrenocortical failure.
3480594|NCT03793114|Active Comparator|Cardiovascular and inflammatory biomarkers|Compare cardiovascular and inflammatory biomarker profiles in patients with and without residual production of adrenocortical steroids
3127414|NCT03091920|Experimental|IW-1973 BID (Twice Daily)/QD|On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
3127415|NCT03091920|Placebo Comparator|Placebo|On Days 1-14: Placebo taken in AM and in PM.
3480595|NCT03792867|Experimental|Radical Resection and HIPEC|
3127416|NCT03092024|Experimental|SPIN-HAND program|
3127417|NCT03092024|No Intervention|Not Offered the SPIN-HAND program|Treatment as usual
3127418|NCT03092089|Experimental|Adult patients with high risk STEMI|Adult patients presenting with high-risk STEMI will receive sonothrombolysis with Definity in addition to standard of care (reperfusion therapy with PPCI)
3480596|NCT03792880|Active Comparator|Control arm|Usual follow-up in Healthcare System for patients with obstructive sleep apnea and CPAP treatment
3480597|NCT03792880|Experimental|Intervention arm|Usual follow-up in the Healthcare System for patients with obstructive sleep apnea and CPAP treatment and a telematic control and self-management program
3480598|NCT03792776|Active Comparator|Air|Endotracheal tube cuff inflation with air
3480599|NCT03792776|Experimental|Lidocaine 1%|Endotracheal tube cuff inflation with Lidocaine 1%
3480600|NCT03792776|Experimental|Lidocaine 2%|Endotracheal tube cuff inflation with Lidocaine 2%
3480601|NCT03792893|Experimental|Higher Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
3480602|NCT03792893|Experimental|Lower Blood Pressure|BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
3480603|NCT03792828|Active Comparator|Control|Duloxetine HCl 30mg is not used.
3480604|NCT03792828|Experimental|Duloxetine|One capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation.
3480605|NCT03792724|Experimental|Cohort A|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg every 4 weeks (Q4W) from Cycle 3 and beyond
3480606|NCT03792724|Experimental|Cohort B|Three doses of intratumoral urelumab will be administered, every 4 weeks. after which Nivolumab will be given at a fixed dose of 240 mg for Cycle 2 and at a fixed dose of 480 mg Q4W from Cycle 3 and beyond
3480607|NCT03792789|Experimental|mCIMT with real rTMS|Modified Constraint Induced Movement Therapy (mCIMT) with real Repetitive Transcranial Magnetic Stimulation (rTMS). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with real rTMS over contralateral primary motor cortex.
3480608|NCT03792789|Sham Comparator|mCIMT with sham rTMS|Modified Constraint Induced Movement Therapy with sham Repetitive Transcranial Magnetic Stimulation (using sham coil). 10 sessions of mCIMT will be administered using physical rehabilitation protocol along with sham rTMS over contralateral primary motor cortex using sham coil which simulated sound and touch of real coil but has no electro-magnetic waves.
3480609|NCT03792971|Experimental|Fixed Sequence|
3480610|NCT03792646|Experimental|Experimental|The experimental group will inject 20 grams of whey protein diluted in water after the exercise training.
3480611|NCT03792646|Placebo Comparator|Placebo|The placebo group will inject 20 grams of maltodextrin diluted in water after the exercise training.
3480612|NCT03792698|Experimental|Aidcube utilization|"Aidcube is a fully customizable, commercially available digital app-based platform to deliver home-based pulmonary rehabilitation for patients. On the patient-facing side, patients can view their daily exercise prescription, descriptions and videos demonstrating correct execution of the exercises, document completion of exercises, and message their health-care provider. On the provider-facing side, from over 150 available exercises, surveys, and activities, providers can design a fully-customized exercise prescription. Based on real-time patient feedback, the exercise prescription can be progressed (i.e., advanced and/or modified) by adding repetitions or time to specific exercises or adding new activities. The provider can also message the patient from within the Aidcube environment."
3480613|NCT03792984|Placebo Comparator|Metformin + Placebo|
3480614|NCT03792984|Experimental|Calcium carbonate + Vitamin D3 + Metformin|
3480615|NCT03792802|Active Comparator|classic port sites|. Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent
3480616|NCT03792802|Active Comparator|same dermatome port sites|One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port.
3480617|NCT03792815|Experimental|busulfan melphalan etoposide|busulfan 3.2 mg/kg/day i.v. on day -7, -6, and -5 etoposide 400 mg/m2 i.v. on day -5 and -4 melphalan 50mg/m2/day i.v. on day -3 and -2
3480618|NCT03792685|Experimental|Normal weight|Normal weight men. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
3127421|NCT03092375|Experimental|Arm A: G/P 300 mg/120 mg QD for 12 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg (3 Glecaprevir/Pibrentasvir (G/P) 100mg/40mg Tablets once-daily by mouth) for 12 weeks.
3480619|NCT03792685|Experimental|Overweight/obesity|Men with overweight or obesity. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
3480620|NCT03792685|Experimental|Diabetes|Men with prediabetes or type 2 diabetes mellitus. Interventions: normo-carbohydrate meal intake, high-carbohydrate meal intake, high-fat meal intake, high-protein meal intake.
3480621|NCT03792932|Active Comparator|Laparoscopic distal pancreatectomy|
3480622|NCT03792932|Active Comparator|Open distal pancreatectomy|
3480623|NCT03792919|Experimental|Cessation of NAs treatment|Chronic hepatitis B patients who meet the criteria to stop the current anti-HBV Neucleos(t)ides treatment will stop their NAs at the baseline of the clinical trial.
3480624|NCT03792919|Active Comparator|Keep on current NAs treatment|Chronic hepatitis B patients who meet the criteria to stop anti-HBV Neucleos(t)ides treatment will choose to keep on their current NAs treatment from the baseline of the clinical trial.
3480625|NCT03792906|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
3127422|NCT03092375|Experimental|Arm B: G/P 300 mg/120 mg QD for 16 Wks|Non-cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once-daily by mouth for 16 weeks (G/P 300 mg/120 mg QD for 16 Wks)
3127423|NCT03092375|Experimental|Arm C: G/P 300 mg/120 mg QD + RBV 12 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily plus Ribavirin 200Mg Tablet (2-3 tablets) twice a day for 12 weeks (G/P 300 mg/120 mg QD + RBV 12 Wks)
3127424|NCT03092375|Experimental|Arm D: G/P 300 mg/120 mg QD for 16 Wks|Cirrhotic subjects will take Glecaprevir/Pibrentasvir (G/P) 300mg/120mg once daily for 16 weeks (G/P 300 mg/120mg QD for 16 Wks)
3480626|NCT03792906|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion.
3480627|NCT03792633|Experimental|Newly Diagnosed VHR B-ALL or High-Risk Relapse of B|
3480628|NCT03792633|Experimental|Poor Response to Prior B Cell Directed Engineered cell therapy|
3480629|NCT03792529||breast cancer with HER2 overexpression|
3480630|NCT03792529||hormone receptor-positive breast cancer|
3480631|NCT03792529||triple negative breast cancer|
3480632|NCT03792945|Active Comparator|extracorporeal shock wave therapy|ESWT will be applied to Group 1 once a week for a total of 3 weeks. Modus ESWT device will be used. The patient's wrist will be applied at a pressure of 4 bar and 2000 Hz at a frequency of 5 Hz. Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
3480633|NCT03792945|Active Comparator|local injection|40 mg of local Depomedrol (methylprednisolone) injection will be applied to group 2 once. Injection will be made from wrist with carpal tunnel syndrome.Patients will be given a splint at night and when they do not use their hands during the day. Participants will use the carpal tunnel wrist brace 3 months.
3480634|NCT03792945|No Intervention|carpal tunnel wrist brace|"Patients will be given a carpal tunnel wrist brace at night and when they do not use their hands during the day.~Participants will use the carpal tunnel wrist brace 3 months."
3480635|NCT03792763|Experimental|Arm A, denosumab|"Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]~Every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
3480636|NCT03792763|Placebo Comparator|Arm B, placebo|"Placebo 1.7 ml Subcutaneous Solution~SC every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM~Calcilac 500 mg/400 I.E. (Calcium/Vitamin D3) Concomitant medication, oral, 1 chewable tablet / day"
3480637|NCT03792711|Experimental|HMB group|2 servings (440 mL)/day Ensure® Plus Advance for use as a supplement with or between meals
3480638|NCT03792711|No Intervention|Control group|Standard of care includes mainly dietary consultation for healthy aging by dietitians to reach sufficient dietary protein intake.
3480639|NCT03792594||Bone marrow concentration group|The patients receive arthroscopic repair with bone marrow concentration.
3480640|NCT03792594||Historical control group|The patients receive arthroscopic repair only
3127425|NCT03092479|Experimental|Behavioral Intervention|4-month bi-weekly comprehensive postoperative behavioral support program addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
3480641|NCT03792620|Experimental|Cyclo Thal Dex Daratumumab|"Eligible patients will be enrolled and treated according to the following elicited schema: Cyclo Thal Dex- Daratumumab (cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week (28 days cycle)- 4 cycles. ) + Daratumumab 16mg/Kg every week on cycles 1 and 2 and every other week at cycles 3 and 4- (total of 12 doses). Then Daratumumab 16mg/Kg after D+30, every other week as pre consolidation until starts full consolidation D+90-120 every other week (total of 4 doses) + thal100mg D1-28 during sixteen weeks as full consolidation. Follow by Daratumumab 16mg/Kg once a month as maintenance until progression or limiting adverse event (total of 28 planning doses).~Total scheme Daratumumab doses= 50 doses = PROTOCOL MAXDARA."
3480642|NCT03792542|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
3480643|NCT03792568|Experimental|ALK mutation|
3480644|NCT03792581|Active Comparator|EV1000 monitor|MAP management will be done as usual ( adjustment by nurses) and fluid management will be managed using the EV1000 monitoring device with the automated decision support system
3127426|NCT03092479|No Intervention|Usual Care|Usual postoperative follow-up per the GHS Center for Nutrition and Weight Management guidelines.
3127427|NCT03092726|Experimental|ASP8062|Participants received 30 mg of ASP8062 orally once daily for 8 weeks.
3480645|NCT03792581|Experimental|EV1000 monitor + closed-loop system|fluid management will be done using the automated decision support system and MAP will be adjusted by the automated closed-loop system for vasopressor administration
3480646|NCT03792555|Experimental|Paltusotine|
3480647|NCT03792555|Placebo Comparator|Placebo|
3127428|NCT03092726|Placebo Comparator|Placebo|Participants received matching placebo orally once daily for 8 weeks.
3127429|NCT03092752||Patients with T2DM|
3127430|NCT03092791|Experimental|Adult Lead-in Cohort: sIPV High Dose|Sabin-based inactivated poliomyelitis vaccine (sIPV) containing 3, 100, and 100 D-Ag units (DU) of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
3127431|NCT03092791|Placebo Comparator|Adult Lead-in Cohort: Placebo|Placebo, intramuscular injection on Day 1.
3480648|NCT03792503|Experimental|Apatinib，Pemetrexe|Pemetrexe 500 mg/m2 d1×q3w; Apatinib 500 mg Po qd
3480649|NCT03792490|Experimental|Fasudil 30 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 30 mg/ day Frequency: 2 x 15 mg Duration of treatment: 20 days
3480650|NCT03792490|Experimental|Fasudil 60 mg|Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes Dosage: 60 mg/ day Frequency: 2 x 30 mg Duration of treatment: 20 days
3480651|NCT03792490|Placebo Comparator|Placebo|Sodium chloride (NaCl) 0.9% Dosage form: intravenous, application over 45 minutes Dosage: 100 ml Frequency: 2 x Duration of treatment: 20 days Do2 x 1 ml, NaCl 0.9%
3480652|NCT03792217|Experimental|1.3% NaOCl|Root canal irrigation done using 1.3% NaOCl.
3480653|NCT03792217|Active Comparator|5.25% NaOCl|Root canal irrigation done using 5.25% NaOCl.
3480654|NCT03792204||PD patients with wearing-off effect|"people who have been clinically diagnosed with Parkinson's disease (PD) and have received anti PD therapy would be recruited into the study. The anti -PD treatment would not be changed in the population of the participants.~We would use the tool of 'Wearing-off 9 questionnaire' to determine the prevalence of Wearing-off phenomenon in Parkinson's patients in Shanghai"
3480655|NCT03792230|Experimental|Video|This group received educatıon via video material
3480656|NCT03792230|Experimental|Brochure|This group received education via written material (brochure)
3480657|NCT03792230|No Intervention|Control|This group received standart clinical education
3480658|NCT03792256|Experimental|Treatment (Palbociclib)|Patients receive Palbociclib 50 mg/m^2 (starting dose with maximum dose of 100 mg) PO (or via NG-tube) once daily on Days 1-21; Intrathecal cytarabine (IT ARAC) age-based dosing on Day 1, Doxorubicin 60 mg/m^2 IV push or infusion over 1-15 min on Day 4; Prednisone or prednisolone 40 mg/m^2 PO divided BID or TID on days 4-31; Vincristine 1.5 mg/m^2 (maximum dose 2 mg) IV push or mini-bag per institutional policy on days 4, 11, 18, and 25; and Pegaspargase 2500 IU/m^2 IV over 1-2 hours on Days 5, and 18. If CNS3 leukemia is present, patients receive Intrathecal Triple Therapy (ITT) age-based dosing on days 4, 11, 18, and 25. Patients known to be CNS3 at study entry may receive ITT on Day 1 rather than IT ARAC. If CNS1 and 2 leukemia present, patient receive Methotrexate (IT MTX) age-based dosing on Days 18 and 32. Treatment will be given for one cycle, 32 days, in the absence of disease progression or unacceptable toxicity.
3480659|NCT03792139|Experimental|LY3200882|LY3200882 administered orally.
3480660|NCT03792139|Experimental|Itraconazole + LY3200882|Itraconazole + LY3200882 administered orally.
3179585|NCT00674518|Experimental|Counseling|One-on-one sessions conducted by a professional motivational counselor to explore ways to help motivate participants to exercise, eat healthier, and lose weight.
3179586|NCT00674518|Experimental|Group|A nutrition and exercise specialist will lead and teach a group of 4 to 5 subjects in healthy nutrition, exercise and weight loss habits
3179587|NCT00674518|Active Comparator|MD Advice|A physician will provide exercise and nutrition advice to participants immediately following testing
3480661|NCT03792269|Experimental|Multi-channel chemotherapy|Patients will receive intraperitoneal irinotecan (50mg, d1, q2w).
3480662|NCT03792269|Active Comparator|Control Group|Patients will receive intravenous oxaliplatin (130mg/m^2, d1, q3w), and oral capecitabine (1.0g, d1-14, q3w).
3480663|NCT03792178|Active Comparator|Nano resin composite|are types of synthetic resins which are used in dentistry as restorative material or adhesives.
3480664|NCT03792178|Experimental|Bulk fill composite|Bulk- ll composites are claimed to be restorative materials used in deep preparations and effectively photoactivated in layers up to 4 mm.
3127432|NCT03092791|Experimental|Toddler Lead-in Cohort: sIPV High Dose|sIPV containing 3, 100, and 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Day 1.
3127433|NCT03092791|Active Comparator|Toddler Lead-in Cohort: Reference IPV|Reference IPV, intramuscular injection on Day 1.
3127434|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Low Dose|sIPV containing 0.75, 25, 25 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29, 57 and 365.
3480665|NCT03792295|Experimental|Multimodal Therapy|Patients will receive scheduled ibuprofen 400mg po q 4 hours and acetominophen 1gram po q 8 hours during the post operative phase and oxycodone 5mg po q 4 to 6 hours as needed for pain control.
3480666|NCT03792295|Active Comparator|Classic/standard opiod Therapy|Patients will receive oxycodone 5mg po q 4 to 6 hours as needed during their post operative phase for pain control.
3480667|NCT03792152|Experimental|rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd(15mg If creatinine clearance is between 30-49 ml/min ).
3127435|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV Medium Dose|sIPV containing 1.5, 50, 50 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
3179588|NCT00674531|Other|1|Enterovirus RNA analysis
3179589|NCT00674544|No Intervention|Control group|No intervention, regular kindergarten program
3179590|NCT00674544|Experimental|Intervention group|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
3179591|NCT00674635|Placebo Comparator|Placebo|matching placebo
3179592|NCT00674635|Active Comparator|GSK315234A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
3480668|NCT03792152|Active Comparator|Warfarin|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
3480669|NCT03792347|Experimental|Arm 1|Arm 1:preoperative pembrolizumab with chemoradiotherapy group Participants will receive carboplatin (AUC=2) IV and paclitaxel (50mg/m²) IV on day 1,8,15,22,29. And radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week. Participants will also receive pembrolizumab (2mg/kg) IV on days 15 and 29. Surgery will be performed within 6 weeks after completion of preoperative therapy described above.
3480670|NCT03792412|Experimental|Intervention: Usability Questionnaire|Patients hand over the usability questionnaire to evaluate the self developed structured follow-up program in form of a so-called pass to their family doctor twice in six months. Family doctors examine the postbariatric patient using the pass and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator.
3480671|NCT03792412|Other|Control: Usability Questionnaire|"Patients hand over the usability questionnaire to evaluate the state of the art guideline for postbariatric follow up appointments in form of a folder Metabolische Chirurgie und die perioperative Betreuung to their family doctor twice in six months. Family doctors examine the postbariatric patient using the guideline and evaluate the usability by filling out the questionnaire and return the usability questionnaire to the investigator."
3480672|NCT03792282|Experimental|TRF|Participants in this group will focus on time restricted feeding (TRF) in addition to daily calorie restriction.
3480673|NCT03792282|Active Comparator|RCD|Participants in this group will focus on daily reduced calorie diet (RCD).
3480674|NCT03792321|Active Comparator|Testosterone|Testosterone arm patients were receiving testosterone undecanoate 1000 mg intramuscular injections two years; according to the protocol every 10 weeks
3127436|NCT03092791|Experimental|Infant Dose Ranging Cohort: sIPV High Dose|sIPV containing 3, 100, 100 DU of poliovirus types 1, 2, and 3, intramuscular injection on Days 1, 29 57 and 365.
3127437|NCT03092791|Active Comparator|Infant Dose Ranging Cohort: Reference IPV|Reference IPV, intramuscular injection on Days 1, 29 57 and 365.
3127438|NCT03092934|Experimental|25 milligrams (mg) LY3295668 (Phase 1)|25 milligrams (mg) LY3295668 twice daily (BID) administered orally in 21-day cycles.
3480675|NCT03792321|Placebo Comparator|Placebo|Placebo arm patients were receiving placebo throughout the first year of this study and testosterone undecanoate 1000 mg intramuscular injections during second year.
3127439|NCT03092934|Experimental|50 mg LY3295668 (Phase 1)|50 mg LY3295668 BID administered orally in 21-day cycles.
3480676|NCT03792386|Active Comparator|Ultrasound guidance with fluoroscopic confirmation|Patients in which the intervention will be performed using ultrasound guidance with fluoroscopic confirmation
3480677|NCT03792386|Active Comparator|Fluoroscopic guidance with ultrasonographic confirmation.|Patients in which intervention will be performed using fluoroscopic guidance with ultrasonographic confirmation.
3480678|NCT03792425|Other|implant with immediate temporization|Immediate nonfunctional loading
3480679|NCT03792425|Other|Delayed implant without temporization|Conventional loading protocol
3127440|NCT03092934|Experimental|75 mg LY3295668 (Phase 1)|75 mg LY3295668 BID administered orally in 21-day cycles.
3127441|NCT03092934|Experimental|25 mg LY3295668 (Phase 2)|25 mg LY3295668 BID administered orally in 21-day cycles.
3480680|NCT03792360|Experimental|Single Arm|
3480681|NCT03792243||Parastomal hernia|Patients undergoing parastomal hernia repair in Denmark between 2007 and 2017
3480682|NCT03792399|Experimental|Immediate feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to immediate feedback after data downloaded into computer.
3127442|NCT03092960|Active Comparator|Minimal intensity intervention|Patients assigned to this group will received the Minimal intensity intervention.
3127443|NCT03092960|Experimental|HOMBRE|Patients assigned to this group will receive the HOMBRE intervention
3127444|NCT03093025|Experimental|TS-121 10mg|
3127445|NCT03093025|Experimental|TS-121 50mg|
3127446|NCT03093025|Placebo Comparator|Placebo|
3127447|NCT03093181|Placebo Comparator|No treatment and Standard cleanser|Participants randomised to the no treatment regimen will use the standard cleanser (only) twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours.
3127448|NCT03093181|Experimental|Test product and Standard cleanser|Participants randomised to test product regimen will be instructed to use the standard cleanser and test product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the test product cream immediately after cleansing.
3480683|NCT03792399|Other|Delayed feedback counseling|Professional CGM calibrate blood glucose via a glucsoe-oxidase-impregnated membrane during a 5 day period. The patient wearing professional CGM is randomized to delayed feedback (standard care, i.e., CGM graphs interpretation at scheduled 3 months outpatient visit).
3480684|NCT03792373||frailty|
3480685|NCT03792373||nonfrailty|
3480686|NCT03792308|Experimental|SPR206|"SAD Cohorts: Subjects will receive single doses of SPR206 via IV infusion over one hour. Planned doses to be studied are: 10, 25, 50, 100, 200, 300, 350 and 400mg. If the 300 mg dose is not deemed safe and well-tolerated, a dose of 250 mg will be used.~MAD Cohorts: Subjects will receive SPR206 via IV infusion over one hour q8h for 7 consecutive days (Cohorts 9 - 12) and over one hour q8h for 14 consecutive days (Cohort 13). Up to five dose groups will be studied. Planned doses will be 25 mg, 50 mg, 100 mg and 150 mg with dosing occurring q8h for 7 consecutive days (Cohorts 9 - 12) and q8h for 14 consecutive days (Cohort 13). Cohort 13 participants will be dosed at a dose deemed safe and tolerable, not to exceed the maximum dose tested in previous MAD dose cohorts.~."
3480687|NCT03792308|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD Cohorts: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over one hour.~MAD Cohorts: Subjects will receive q8h infusions of placebo over 1 hour for 7 consecutive days (Cohorts 9 - 12) and q8h infusions of placebo over 1 hour for 14 consecutive days (Cohort 13)."
3480688|NCT03792009|Experimental|Paracervical block with 5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
3480689|NCT03792009|Placebo Comparator|Paracervical block with normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
3480690|NCT03792165|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
3480691|NCT03792165|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
3480692|NCT03792061|Experimental|Strategy Training|Strategy training is an activity intervention training approach developed based on the theoretical tenets of metacognitive training. The purpose of strategy training is to guide individuals to generate problem-solving skills to address challenges that they identify in daily activities.
3480693|NCT03792061|No Intervention|Reflective listening|Participants in the control group will receive dose-matched non-active intervention carried out by a trained research staff. The staff will use scripted questions to provoke participants to describe their experiences and feelings about their disease and their usual-care rehabilitation activities.
3480694|NCT03792100|Experimental|SmofKabiven emulsion for infusion|SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
3480695|NCT03792100|Active Comparator|"Hospital compounded All in one emulsion for PN"|"Hospital compounded All in one emulsion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drugs will be 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%."
3480696|NCT03791957||Group A - Healthy Periodontium|Absence of clinical signs of inflammation like bleeding on probing, erythema, edema, attachment loss, bone loss, patient symptoms, (bone levels at 1-3mm apical to CEJ) n=20
3480697|NCT03791957||Group B - Gingivitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla, n=20
3480698|NCT03791957||Group C - Periodontitis|Presence of cardinal signs of inflammation along with, bleeding and discomfort on gentle probing, loss of knife-edged margin and blunting of papilla,periodontal pocketing, clinical attachment loss, radiographically assessed bone loss n=20
3480699|NCT03791944|Experimental|3DV+TPS/VARIAN|Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
3480700|NCT03791944|Active Comparator|TPS/VARIAN|Use imported Varian TPS to map targets and develop treatment plans.
3480701|NCT03791944|Experimental|3DV+TPS/ Domestic accelerator|Use 3DV+TPS to map targets and develop treatment plans.
3480702|NCT03791944|Active Comparator|TPS/ Domestic accelerator|Adopt domestic TPS hook target and develop treatment plan.
3480703|NCT03791996|No Intervention|"Late cranioplasty"|Subjects undergoing cranioplasty within 3 months after craniectomy.
3480704|NCT03791996|Experimental|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
3127449|NCT03093181|Active Comparator|Positive control and positive cleanser|Participants randomised to positive control regimen will be instructed to use the positive cleanser and positive control product twice a day (morning and night). Morning and evening applications should be separated by at least 8 hours. Participants will be instructed to apply the positive control cream immediately after cleansing.
3127450|NCT03093207|Placebo Comparator|Control group|In this group (n = 17), patients will take placebo pills and open flap debridement will be performed to treat residual pockets.
3127451|NCT03093207|Experimental|Test Group|In this group (n = 17), patients will take 3 g of omega-3 polyunsaturated fatty acids plus 100 mg of aspirin daily supplementation over a period of 180 days and open flap debridement will be performed to treat residual pockets.
3480705|NCT03792074|Experimental|SCT510 combined paclitaxel and carboplatin|SCT510 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
3480706|NCT03792074|Active Comparator|Bevacizumab combined paclitaxel and carboplatin|Bevacizumab 15mg/kg+ paclitaxel 175mg+ carboplatin (AUC=5), intravenous infusion，on day 1，Once every 3 weeks;Four to six cycles in a row
3480707|NCT03792113|Experimental|Autologous fibrin glue|The periodontal flap will be approximated on the test site using autologous fibrin glue on the under surface of the raised flap up to 2 mm from the coronal margin and repositioned back on to the root surface. Thereafter, the tissues will be kept in position with a gentle pressure using a wet gauze for 30 - 60 seconds.
3480708|NCT03792113|Active Comparator|4-0 silk suture|The periodontal flap will be approximated using 4-0 black silk suture.
3480709|NCT03791905|Experimental|TP Arm|Patients with baseline PET scan assigned to this Arm will receive two cycles of 3-weekly schedule of induction chemotherapy with paclitaxel/cisplatin (TP), consisting of paclitaxel 150 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to FOLFOX regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
3480710|NCT03791905|Experimental|FOLFOX Arm|Patients with baseline PET scan assigned to this Arm will receive three cycles of 2-weekly schedule of induction chemotherapy with FOLFOX (oxaliplatin, leucovorin, 5-FU), consisting of oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2, and 5-FU 2 g/m2 on day 1. Repeat PET was performed on days 36-42 and changes in SUVmax from baseline were assessed. PET responders (≥35% decrease in SUVmax) continued on the same chemotherapy regimen during radiotherapy, whereas PET non-responders (<35% decrease in SUVmax) crossed over to TP regimen concomitantly with radiation. All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is generally 50-60 Gy in 25-28 fractions.
3480711|NCT03792087|Experimental|SmofKabiven Peripheral|Continuous intravenous Infusion for SmofKabiven Peripheral via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
3480712|NCT03792087|Active Comparator|Hospital compounded emulsion|Continuous intravenous Infusion for Hospital compounded emulsion via peripheral or central venous access for 14-24 hours/day. Target dose 34.3 ml per kg body weight/day. Duration of treatment 5 consecutive days.
3480713|NCT03791892|Experimental|Shoulder mobilization Group|Kaltenborn mobilization will be applied to patient in experimental group only.
3480714|NCT03791892|Active Comparator|Conventional treatment Group|Application of conventional treatment that includes stretching and strengthening exercises of shoulder.
3480715|NCT03791931|Other|Patients|Oxidative stress measurement in cleavage state embryos
3480716|NCT03791879|Active Comparator|• Group A will take Caudal Levob 0. 125%+ DEXM 0.5µg/k|
3480717|NCT03791879|Active Comparator|• Group B will take Caudal Levob 0.125%+ DEXM 1µg/kg.|
3480718|NCT03791879|Active Comparator|• Group C will take Caudal Levob 0. 125%+ DEXM 1.5 µg/|
3480719|NCT03791879|Active Comparator|• Group D will take Caudal Levob 0. 125%+ DEXM 2µg/kg.|
3480720|NCT03791918|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3480721|NCT03791918|Active Comparator|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
3480722|NCT03792022||Group 1|Adherence to timely vaccine uptake
3480723|NCT03792048|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
3480724|NCT03792048|No Intervention|Manual Anastomosis|Manual Anastomosis for bilioenteric anastomosis and pancreaticojejunostomy
3127454|NCT03093272|Experimental|ARN-509 Combined With Docetaxel|"Apalutamide (ARN-509) will be taken orally at home daily~Docetaxel will be administered every 3 weeks intravenously~Prednisone will be taken orally twice daily~Leuprolide Acetate will be administered at the specification of the physician"
3480725|NCT03792035|Experimental|Experimental group|First time given 8 capsules of Tongxinluo, then given 4 capsules of Tongxinluo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
3127455|NCT03093324|Experimental|ALKS 8700|Oral capsules, administered orally twice daily.
3127456|NCT03093324|Active Comparator|Dimethyl Fumarate|Oral capsules, administered orally twice daily.
3480726|NCT03792035|Placebo Comparator|Control group|First time given 8 capsules of placebo, then given 4 capsules of placebo, tid, po.Dosage form: capsule;Dose: 0.26g/capsule;Duration:1 year
3480727|NCT03791814|Experimental|Zepatier treatment|Open-label Zepatier (grazoprevir 100 mg and elbasvir 50 mg) will be administered in this study. Daily treatment of Zepatier for a 12-week duration will be administered.
3480728|NCT03792126|No Intervention|Standard Care|
3480729|NCT03792126|Experimental|Implicit Learning Approach|
3127457|NCT03093350|Experimental|TAA-Specific CTLs|Patients receiving TAA-specific CTLs as therapy for breast cancer.
3127458|NCT03093415|Active Comparator|Old Town Clinic, Medication Assisted Therapy group|25 People Who Inject Drugs engaged in a Medication Assisted Therapy treatment program for their substance use disorder, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
3480730|NCT03791801|Active Comparator|Neostigmine|Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1
3480731|NCT03791801|Active Comparator|Sugammadex|Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).
3480732|NCT03791983|Experimental|Therapy Group|
3480733|NCT03791983|Other|Control Group|
3480734|NCT03791788||QFR Group|Patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, NSTEMI (non ST-segment elevation myocardial infarction), or STEMI (ST-segment elevation myocardial infarction) with non-culprit stenosis who underwent FFR measurement and were able to analyze QFR.
3480735|NCT03791866|Experimental|30% target total enteral nutrition|
3480736|NCT03791866|Experimental|60% target total enteral nutrition|
3480737|NCT03791866|Active Comparator|100% target total enteral nutrition|
3480738|NCT03791775|Experimental|Polidocanol 3% Foam|Patients enrolled in the study, according to the inclusion and exclusion criteria, will undergo sclerotherapy performed with polidocanol foam (Atossisclerol® 3%, Chemische Fabrik Kreussler & Co. GmbH, Wiesbaden, Germany).
3480739|NCT03791827||Corticosteroid|Pediatric lupus nephritis treated with hydroxychloroquine and corticosteroid
3480740|NCT03791827||Corticosteroid and cyclophosphamide|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclophosphamide
3480741|NCT03791827||Corticosteroid and mycophenolate mofetil|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and mycophenolate mofetil
3179593|NCT00674648|Experimental|1|This is a non-randomized single institution phase I dose escalation trial, designed to evaluate the toxicity and anti-viral activity of CMV-pp65 peptide-specific T cell lines, generated in vitro from CMV seropositive normal HSCT and 3rd party donors, when adoptively transferred to treat recipients of these transplants who have a CMV infection or persistent CMV antigenemia and are therefore at high risk of a life-threatening CMV infection.
3179594|NCT00674687|Placebo Comparator|Sequence 1|
3480742|NCT03791827||Corticosteroid and azathioprine|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and azathioprine
3480743|NCT03791827||Corticosteroid and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and tacrolimus
3480744|NCT03791827||Corticosteroid and cyclosporine A|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid and cyclosporine A
3179595|NCT00674687|Experimental|Sequence 2|
3480745|NCT03791827||Corticosteroid, mycophenolate mofetil and tacrolimus|Pediatric lupus nephritis treated with hydroxychloroquine, corticosteroid, mycophenolate mofetil and tacrolimus
3480746|NCT03791827||Retuximab|An option for refractory lupus nephritis
3480747|NCT03791697|Active Comparator|Telephone Group|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes."
3480748|NCT03791697|No Intervention|In Person Clinic Visit Group|For the patient randomized into the clinic group, the clinic visit will entail questions about common postoperative complications (including fever, nausea/vomiting, pain, urinary symptoms, constipation, etc.). As per usual, vital signs and a focused physical examination will be completed at the clinic visit. All clinic visits will be performed by an FPRMS fellow and/or attending physician
3480749|NCT03791684|Active Comparator|Accelerated Cross Linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 18mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 5 min, delivering a dose of 5.4 J/cm2.
3480750|NCT03791684|Active Comparator|Standard Cross linking|Ultraviolet A radiation of 365 nm wavelength (CCL-365 vario, Peschke Meditrade GmbH, Switzerland), and an irradiance of 3mW/cm2 (spot size 7mm), at a distance of 45 mm from the cornea, was applied for a period of 30 min, delivering a dose of 5.4 J/cm2.
3480751|NCT03791671|Experimental|individual balance training|"After the initial assessments, the three week intervention time begins, which is completed with the reassessments.~The patients receive 2x weekly individual balance training for 25 minutes each. This runs in addition to the normal, prescribed rehabilitation program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period."
3480752|NCT03791671|Active Comparator|group balance training|"The patients receive 2x weekly group balance training for 25 minutes each. This runs in addition to the normal, prescribed rehab program. The rehabilitation program includes at least 3 therapies daily. These may be group therapies, speech therapy, occupational therapy, neuropsychology and physiotherapy adapted to the needs of the patient. In physiotherapy and occupational therapy no balance training will be performed during the intervention period.~In group therapy are 3 to 6 patients with different neurological diagnoses. As it is usual in rehabilitation everyday life."
3179596|NCT00674713|Experimental|A|Patients receiving acupuncture at P6 point plus physiological saline solution
3480753|NCT03791710|Placebo Comparator|control group|this group of patients are treated with the regular conventional methods like application of topical agents e.g silver sulphadiazine
3480754|NCT03791710|Active Comparator|fat grafting group|this group of patients will have the autologous fat grafting for their burn wounds
3480755|NCT03791970|Experimental|DCB for post-dilation|DCB was used for post-dilation after stent placement. The DCB for post-dilation in this study is Orchid 035 DCB Catheter.
3480756|NCT03791970|Active Comparator|POBA for post-dilation|POBA was used for post-dilation after stent placement. POBA Catheter for post-dilation in this study can be Mustang, Dorado or others balloon catheters.
3480757|NCT03791736|Experimental|Sandostatine|Injection of Sandostatine
3480758|NCT03791762|Experimental|WaveOne Gold|Root canal preparation with WaveOne Gold instrumentation system in a reciprocating manner
3480759|NCT03791762|Experimental|Reciproc Blue|Root canal preparation with Reciproc Blue instrumentation system in a reciprocating manner
3480760|NCT03791762|Experimental|ProTaper Next|Root canal preparation with ProTaper Next instrumentation system in a rotating manner
3480761|NCT03791840||Ultrasound evaluation|Eligible patients undergo lymph node biopsy or lymph node dissection. Before surgery, the status of axillary lymph node status was evaluated using ultrasound. After surgery, all lymph node specimens would be collected and be assessed using ultrasound in a special evaluation system in vitro.
3480762|NCT03791372|Placebo Comparator|Placebo|0.9% sodium chloride infusion any time after entering the Placebo Group, doses is 20-30ml. The infusion speed is 1ml/min.
3480763|NCT03791372|Experimental|Cord Blood Mononuclear Cells(CBMNC)|Autologous Umbilical Cord Blood Mononuclear Cells Therapy any time after the diagnosis of cerebral palsy, doses is 20-30ml (total Mononuclear cells>1*10^7/kg). The infusion speed is 1ml/min.
3480764|NCT03791749|Experimental|Breastfeeding Support|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. Mothers will be asked to perform a simple technique while breastfeeding at least once a day.
3480765|NCT03791749|No Intervention|Standard Care|Home visits will be conducted at 2-3 and 6-8 weeks post-delivery. No intervention will be administered.
3480766|NCT03791502|Experimental|Pilates Method Exercises - lower volume|The prescription will consist of 18 exercises, performed in a single series of seven to 10 repetitions, 60 seconds rest between exercises. Each week the exercises will be changed and the same exercise can only be repeated every three weeks. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises, but without modifying the repetitions. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
3480767|NCT03791502|Experimental|Pilates Method Exercises - higher volume|The participants will conduct a Pilates exercise program based on the recommendations of the American College Medicine of Sports. The prescription will consist of 12 exercises, performed in three sets of seven to ten repetitions and 60s of rest between sets. Every four weeks the exercises will be changed. The progression will occur increasing the resistance of the springs and the level of difficulty of the exercises. Training intensity will be measured using Modified Borg's Perceived Effort Scale and then kept moderate throughout the program.
3480768|NCT03791502|No Intervention|Group control|The subjects allocated in the control group will remain with their usual activities, and after the reevaluation will be offered the intervention that presents the greater size of effect.
3480769|NCT03791723|Experimental|Sacubitril/valsartan|After catheter ablation, during a single blind, run-in period, participants received placebo. Then started with 50 mg sacubitril/valsarta for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
3480770|NCT03791723|Active Comparator|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40mg Valsartan twice daily qd for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
3480771|NCT03791528|Active Comparator|Kinesio-taping Treatment Group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the sacroiliac joint (SIJ), and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
3480772|NCT03791528|No Intervention|Control Group|Without Kinesio-taping treatment evaluated at baseline and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire
3480773|NCT03791476|Placebo Comparator|Control Group|Intervention is saline solution placebo (0.9% Sodium Chloride IV to equal volume of investigational arm: intraoperatively, and then every 12 hours x 2 = total of 3 doses)
3480774|NCT03791476|Experimental|rhC1INH|Intervention is rhC1INH 100 U/kg intraoperative followed by 50 U/kg every 12 hours x 2 = total of 3 doses (200 U/kg)
3480775|NCT03791580|Experimental|Commitment nudge|Primary care clinicians in the practice assigned to this arm will receive only the commitment nudge.
3179597|NCT00674713|Active Comparator|B|Patients receiving ondansetron plus sham acupuncture
3480776|NCT03791580|Experimental|Justification nudge|Primary care clinicians in the practice assigned to this arm will receive only the justification nudge.
3480777|NCT03791580|Experimental|Commitment + Justification nudges|Primary care clinicians in the practice assigned to this arm will receive both the commitment nudge and the justification nudge.
3480778|NCT03791580|No Intervention|Non-participating|Primary care clinicians in Northwestern-affiliated practices other than the 3 pilot-participating practices will not receive any study interventions.
3480779|NCT03791385|Experimental|Study subjects|Children with ASD and their parents/caregivers were trained on tooth-brushing twice, two weeks apart using Picture Exchange Communication System (PECS) PECS as a pictures/cards series showing a structured tooth-brushing method.
3480780|NCT03791515|Active Comparator|Calcitonin Gene-Related Peptide (CGRP)|"30 patients with PPTH will be allocated to receive intravenous infusion of 1.5 µg/min calcitonin-gene related peptide over 20 minutes~Other Name: CGRP"
3480781|NCT03791515|Placebo Comparator|Placebo|"30 patients with PPTH wil be allocated to receive 40 mL Placebo (isotonic saline) over 20 minutes.~Other Name: Isotonic Saline"
3480782|NCT03791632|No Intervention|witness|2 control CE2 classes without oral sensitization actions
3127459|NCT03093415|Active Comparator|Outside In Clinic, Needle Exchange Program|25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
3480783|NCT03791632|Experimental|group intervention 1|2 CE2 classes with a classical lecture style presentation
3480784|NCT03791632|Experimental|group intervention 2|2 CE2 classes with an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
3480785|NCT03791632|Experimental|group intervention 3|2 CE2 classes with digital media intervention
3480786|NCT03791541|No Intervention|No Intervention|Only surveys will be done and re admissions tracked. No additional interventions based on survey results will be done.
3480787|NCT03791541|Experimental|Intervention|"Pharmacist Services~Surveys plus increased outpatient pharmacist/pharmacy student services including but not limited to pre and post clinic visit phone calls, prescription counseling, and helping with adherence and compliance with medications. Increased services will be given based on survey results."
3480788|NCT03791463|Experimental|After meal|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered after consumption of a low calorie, low-fat breakfast (within 30 minutes after starting food intake).
3480789|NCT03791463|Experimental|Fasting|Each subject will receive a single oral dose of 90 mg salvianolic acid A. Each dose will be administered at the end of a 10-hour fast.
3127460|NCT03093415|Other|OHSU Hepatology Clinic, Academic center Retrospective Cohort|50 people with substance use disorder and HCV engaged with an Academic Hepatology Clinic (Oregon Health & Sciences University, OHSU) and treated with elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.
3480790|NCT03791645|Experimental|SKY Intervention|Participants in the intervention group will get to participate in the SKY program, for 5 days with each day session taking 3 hours/day. SKY program involves a) specific breathing exercises and social interaction with other participants in the program. Following completion of the program, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use. After completion of the 5 day SKY program, participants will practice SKY every day at home for 30 days. They will also need to attend 4 weekly group sessions during this period and each session is expected to last 1 hour. At the end of the 30 day period, another set of questionnaires will be administered to collect information regarding stress, mood, and opioid use.
3480791|NCT03791645|No Intervention|Usual treatment|Participants assigned to the control group will not have access to the SKY program but will continue with usual care. They will also complete questions after 5 days and again after 30 days.
3480792|NCT03791658|Other|Asthmatics|"From the patients file the following information will be collected by the investigators:~Age~Sex~FEV1 derived from the last spirometry (including spirometry performed on day of study visit).~GINA step (Global Initiative for Asthma).~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of asthma.~FENO (Fraction Exhaled Nitric Oxide) from the day of the study visit (if available).~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The Asthma Control Test (ACT)"
3480793|NCT03791658|Other|COPD-patients|"From the patients file the following information will be collected by the investigators:~Age~Sex~Pack Years~GOLD stage (Global Initiative for Chronic Obstructive Lung Disease)(post-bronchodilator FEV1)~Number of exacerbations in the year prior to the study.~The prescribed medication: type of inhaler, number of inhalers for maintenance treatment, number of inhalations a day.~Number of different medications taken by the patient on a daily basis, excluding the inhalers for maintenance treatment of COPD.~Patients will fill out:~The 12-question TAI-questionnaire (test for the adherence to inhalers)~The COPD Assessment Test (CAT)"
3480794|NCT03791437|Experimental|Experiment groups|Post chest operative use Digital chest drainage system until Patient's discharge day
3480795|NCT03791437|Active Comparator|Control groups|Post chest operative use traditional drainage system until Patient's discharge day Not use Digital chest drainage system
3480796|NCT03791333||multi trauma patients group|
3480797|NCT03791554|Active Comparator|Group A : Lateral closed Tunnel|"Laterally closed tunnel procedure with subepithelial connective tissue graft (sCTG) After local anesthesia, root planing will be performed. Recession defect - a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~• Recipient site; Using either single or mattress sutures, the graft will be pulled and fixed mesially and distally at the inner aspect of the pouch. The graft will be adapted to the CEJ by means of a sling suture. Margins of the pouch will be pulled together over the graft and sutured with interrupted sutures to accomplish tension-free complete or partial coverage of the graft as well as the denuded root surface."
3480798|NCT03791554|Active Comparator|Group B : Tunneling|"Tunnel procedure with subepithelial connective tissue graft (sCTG) - Control:~At the recipient site (recession defect): a tunneling technique will be prepared using sulcular incision is made through the gingival margin and extends post the mucogingival line leaving the interdental papilla intact.~Then the graft is placed and secured in the recipient site. The flap is displaced to be in a coronal position using a sling suture with no suturing to approximate the margins together."
3480799|NCT03791398|Experimental|ONC201 Level 1 (Starting Dose Level)|625mg ONC201 Cycle 1 Day -7 dose then once week
3480800|NCT03791398|Experimental|ONC201 Level 2|500 mg ONC201 Cycle 1 Day -7 dose then once week
3480801|NCT03791398|Experimental|ONC201 Level 3|375 mg ONC201 Cycle 1 Day -7 dose then once week
3480802|NCT03791398|Experimental|Nivolumab|240mg IV flat dose q 2 weeks
3480803|NCT03791424|Experimental|Midazolam|Midazolam 2 mg was administered 5 min. after placebo and 5 min. before inducton to general anaesthesia IV.
3480804|NCT03791424|Placebo Comparator|Control|Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
3480805|NCT03791177|Experimental|Study Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
3480806|NCT03791177|Sham Comparator|Control Group|A total of 70 patients were included in the study. Using simple randomization method, the patients were acknowledged about the aim of the study and the cards with letters C (control) and S (study) were placed in closed envelopes and the patients were asked to draw a random envelope. After the draw, two groups were formed according to the letter as group I consisted of patients with C letter and group II consisted of patients with S letter.
3480807|NCT03791021||third trimester pregnant women|the group of participants in this research would include approximately 100 subjects in the third trimester of their pregnancy. the participants would be collected in the central area of Israel from various socioeconomic groups. each participant would be asked to make draw a person (DAP) test, and answer a number of questionnaires including Edinburgh Postnatal Depression Scale (EPDS), Beck Depression Inventory II (BDI-II), and Traumatic Events Questionnaire (TEQ).
3480808|NCT03791294|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
3480809|NCT03791294|No Intervention|Control|No treatment
3480810|NCT03791060|Experimental|Secukinumab Subcutaneous Injection|"300 mg q weekly for 5 weeks followed by 300 mg q 4 weeks.~Each subject will receive 300mg of Secukinumab by using 2 syringes of 150mg each as a subcutaneous injection at weeks 0,1,2,3,4 then every 4 weeks for a total of 9 doses over 24 weeks."
3480811|NCT03791099|Experimental|Metronidazole|19,8 mg of metronidazole in one polymer matrix
3480812|NCT03791099|No Intervention|Only SRP|standard non-surgical treatment- scaling/root planing
3480813|NCT03791138|Experimental|intervention group|Care as usual and an online patient decision aid
3480814|NCT03791138|No Intervention|control group|Care as usual with a standard information leaflet
3480815|NCT03791047|Experimental|Experimental Group: Balance analysis|Sixty older subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
3127461|NCT03093454|No Intervention|Control|No intervention patient will receive current standard of care treatment and will answer surveys to collect data.
3480816|NCT03791047|Active Comparator|Control Group:Balance Analysis|Sixty young subjects will be evaluated in this study. Muscle thickness and balance will be assessed by ultrasonography and Computerized Balance system respectively.
3480817|NCT03791255|Experimental|Resin Modified Calcium Silicate|light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
3480818|NCT03791255|Active Comparator|Light Cured Calcium Hydroxide|gold standard for pulp capping, It allows for the formation of a reparative dentine bridge through cellular differentiation, extracellular matrix secretion and subsequent mineralization.
3480819|NCT03791112|Experimental|50mg QD|Participants received 50 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480820|NCT03791112|Experimental|100mg QD|Participants received 100 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480821|NCT03791112|Experimental|200mg QD|Participants received 200 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480822|NCT03791112|Experimental|300mg QD|Participants received 300 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480823|NCT03791112|Experimental|400mg QD|Participants received 400 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480824|NCT03791112|Experimental|500mg QD|Participants received 500 mg BPI-16350 administered orally (PO), once daily (QD), in a fasted state on Days 1 to 28 of a 28-day cycle.
3480825|NCT03791268||Group A|Gastric Cancer Patients who underwent Chemotherapy and will have gastric cancer surgery.
3480826|NCT03791307|Experimental|Traditional Pilates group|This group will perform only exercises based on the traditional Pilates method
3480827|NCT03791307|Experimental|Modified Pilates group|This group will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer
3480828|NCT03791307|No Intervention|Control group|This group will not perform any physical exercise during the trial period.
3480829|NCT03791203|Experimental|Calorie restriction (MACR)|Participants restricted 70% of their energy needs over 24 hours on a calorie restriction day alternate with a feeding day for the next 24 hours, where they were allowed eating (ad libitum). The calorie restriction and feeding days begun at 9 am each day, and on the calorie restriction day, meals were consumed between 2 pm and 8 pm to ensure that they underwent the same duration of calorie restriction. On each calorie restriction day, they were allowed energy-free beverages and sugar-free gum and encouraged to drink plenty of water. Diet plans were self-selected using detailed individualized food portion lists, meal plans, and recipes. Participants received phone calls from the investigator and four 2-weekly appointments with a dietitian. Adverse experiences were assessed every 2 weeks.
3480830|NCT03791203|No Intervention|Control group|Participants in the control group continued their usual habitual diet for 8 weeks. No specific dietary advice or educations were provided throughout the entire trial.
3480831|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 30mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg +Placebo of AD-35 30mg, once daily in the second 26 weeks (oral)
3480832|NCT03790982|Placebo Comparator|Placebo of AD-35 60mg /AD-35 60mg|Placebo of AD-35 60 mg Placebo of AD-35 30mg x two tablets, once daily in the first 26 weeks (oral), then AD-35 30mg x two tablets, once daily in the second 26 weeks (oral)
3480833|NCT03790982|Experimental|AD-35 30 mg+Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, once daily for 52 weeks (oral)
3480834|NCT03790982|Experimental|AD-35 60 mg|AD-35 60 mg AD-35 30 mg× two tablets, once daily for 52 weeks (oral)
3480835|NCT03791281|Experimental|BASIS|Received a 3-hour BASIS implementation strategy.
3480836|NCT03791281|Active Comparator|Attention Control|Received a 3-hour session designed to control for dose, information provided, and presenter effects.
3127462|NCT03093454|Experimental|Lavender Group|Patient will receive lavender essential oil topically and by inhalation during their hospital stay while at the same time receiving regular standard of care.
3480837|NCT03790839|Experimental|Sequential arm ABC|A: Sitagliptin 100 mg QD in the morning on Days 1-5; B: Sitagliptin 100 mg QD in the morning and dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
3480838|NCT03790826|Experimental|Cystoscopic Inspection|"Comparison of bladder damage with traditional Foley catheter and the Kohli Atraumatic catheter.~Interventions: cystoscopy"
3480839|NCT03791216||Psoriasis patients to be treated only topically|
3480840|NCT03791216||Psoriasis patients with moderate-to-severe psoriasis who begin|
3480841|NCT03791216||Age-, sex- and BMI percentile-matched controls|
3132717|NCT03447314|Experimental|Part 1b: 50ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
3179598|NCT00674713|Other|C|Patients receiving ondansetron plus acupuncture at P6 point
3179599|NCT00674713|Placebo Comparator|D|Patients receiving physiological saline solution plus sham acupuncture
3480842|NCT03791216||Patients being treated with isotretinoin for acne|
3480843|NCT03791242|Active Comparator|Group 1|33 morbidly obese patients with severe OSAS and suitable for gastric bypass surgery, who underwent 4 weeks of CPAC treatment (these patients will not be required to change their eating habits) according to the standard
3480844|NCT03791242|Active Comparator|Group 2|33 morbidly obese patients with severe OSAS and BS candidates who underwent CPAC + KMED treatment for 4 weeks
3480845|NCT03790995||High risk prostate cancer|"Patients with initial cT2c-3-4, cN +, Gleason score (GS) more than 7 or PSA > 20ng/mL were labelled as high-risk prostate cancer.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
3480846|NCT03790995||Low - intermediate risk prostate cancer|"Initial PSA levels less or equal than 20 ng/mL with GS of 7 or less and cT1-2a-2b, 2 were labelled as low and intermediate risk prostate cancer and served as a control group.~Both groups received robot assisted laparoscopic prostatectomy. Matching across age (continuous), year of surgery (2009+2010, 2011, 2012, 2013, 2014, 2015+2016), nerve sparing (bilateral, unilateral or no nerve sparing) and centre size (continuous). 1:1 coarsened exact matching. Continuous variables are temporarily coarsened as followed: age (<55, 55-<65, 65-<75, 75+) and centre size (<50, 50-<100, 100+ cases/year)."
3480847|NCT03791164|Experimental|Pain Toolkit plus the Back Book|Participants who are being discharged from the regional back pain pathway who are allocated the 'Pain Toolkit' booklet along with the control intervention 'the Back Book'. They follow the interventions in the 'PainToolkit' for 12 months and are followed up 6 months and 1 year.
3480848|NCT03791164|Active Comparator|Back Book|Participants who are being discharged from the regional back pain pathway who are allocated 'the Back Book'. They are followed up 6 months and 1 year. This is the control group.
3480849|NCT03790930||thin layer CT|Thin-layer CT will be manually labeled and used to train, validate and test deep learning algorithm.
3480850|NCT03791190|Active Comparator|No-anticoagulation|Patients accepted no-anticoagulation CRRT. Blood flow 200 ml/h. The replacement fluid was infused 50% predilution and 50% post-dilution at the speed of 2 L/h.
3480851|NCT03791190|Experimental|Regional citrate anticoagulation|"Patients accepted regional citrate anticoagulation. Blood flow 120-220 ml/h. Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.~Adjusting the infusion rate of sodium citrate and blood flow according to pre- and post-filtration ionCa2+.~Adjusting the infusion rate of calcium gluconate according to the serum ionCa2+ level."
3480852|NCT03791125|Experimental|Experimental|
3480853|NCT03791125|Placebo Comparator|Placebo|
3480854|NCT03790969|Experimental|26 gauge needle|intervention group
3480855|NCT03790969|Active Comparator|23 gauge needle|control group
3480856|NCT03790735||Diagnostic test|Targeted chromosomal aberrations detection by FISH (MDA TEST).
3480857|NCT03790800|Experimental|Intervention group|If systolic blood pressure>180:IV Urapidil 25mg If systolic blood pressure>150 (or 5 mins after first bolus) : IV Urapidil 25mg and to maintain this level after admission to hospital in those with confirmed acute stroke for the next 7 days (or hospital discharge if earlier)
3480858|NCT03790800|No Intervention|control group|To receive blood pressure management according to standard local guidelines which recommend blood pressure lowering in hospital if systolic level is >220mmHg. This level will be considered by ambulance staff as a threshold for treatment if considered clinically important.
3480859|NCT03790891|Experimental|CD19-TriCAR-T/SILK|CD19-TriCAR-T/SILK cells will be administered intravenously
3480860|NCT03790787|Experimental|Sequential arm ABC|A: Empagliflozin 25 mg QD in the morning on Days 1-5; B: Empagliflozin 25 mg in the morning and Dorzagliatin 75 mg BID (morning and evening) on Days 6-10, with only the morning dose on Day 10; C: Dorzagliatin 75 mg BID (morning and evening) on Days 11-15, with only the morning dose on Day 15.
3480861|NCT03790657|Experimental|tDCS Dosage A|"mild electrical stimulation (Dosage level A) delivered to the frontal region of the brain during practice of a complex walking task"
3480862|NCT03790657|Experimental|tDCS Dosage B|"mild electrical stimulation (Dosage level B) delivered to the frontal region of the brain during practice of a complex walking task"
3480863|NCT03790722|Experimental|Higher Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure. Intervention: Ergometry H
3480864|NCT03790722|Experimental|Lower Blood Pressure|Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure. Intervention: Ergometry L
3480865|NCT03790852|Experimental|KSI-301 2.5 mg|KSI-301 2.5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
3179600|NCT00674726||Group I|Patients with acute appendicitis
3480866|NCT03790852|Experimental|KSI-301 5 mg|KSI-301 5 mg, 3 monthly initiating doses, with subsequent doses per protocol-specified retreatment criteria
3480867|NCT03790696|Experimental|Active Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
3480868|NCT03790696|Sham Comparator|Sham Cognitive Training|Participants will complete 30-45 minute cognitive training program twice a week for four weeks.
3127463|NCT03093480|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants were to receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 48 Weeks in ITI Period. Participants who met the criteria for immune tolerance induction (ITI) success entered the tapering period and received rFVIIIFc at a dose adjusted according to Investigator judgment based on the FVIII activity levels and with the aim of tapering the rFVIIIFc dose to reach a prophylactic dosing regimen within 16 weeks (4 months). Follow-Up was for 32 weeks under an adjusted prophylactic regimen according to Investigator judgment.
3127464|NCT03093662|Experimental|Ventilation with nasal cannula|Non-invasive positive pressure ventilation with nasal cannula.
3179601|NCT00674726||Group II|Patients with acute gastroenteritis
3480869|NCT03790904|Active Comparator|Co. mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
3480870|NCT03790904|Placebo Comparator|Kin mouthwash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
3480871|NCT03790904|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
3480872|NCT03790644|Experimental|exoskeleton assist|walking with assist of a powered exoskeleton
3480873|NCT03790761|Experimental|PREP 8.0 Curriculum|All participants enrolled in the program will be given the PREP 8.0 curriculum - there will be no comparison group.
3480874|NCT03790670|Experimental|Leukine Treatment|24 month regimen of Leukine administered as a weight-based dose at 3 µg/kg/day for 5 days (week), followed by a 2-day holiday (weekend)
3179602|NCT00674752|Experimental|A|
3179603|NCT00674752|Experimental|B|
3480875|NCT03790774|Experimental|Neurofeedback|Three times per week, for six weeks, participants will receive biofeedback about the quality of their electroencephalograms (EEG; neurofeedback) during a letter identification task.
3480876|NCT03790748|Experimental|Conventional Epidural Technique|Procedure: Standard Lumbar Epidural Block using Touhy Epidural Needle (18G) at L4-5 inter-space and Epidural Catheter (20G) was inserted then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
3480877|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 25G Whitacre needle|Procedure: 25G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
3480878|NCT03790748|Active Comparator|Dural Puncture Epidural Technique using pencil-point 27G Whitacre needle|Procedure: 27G Dural Puncture Epidural Block at L4-5 inter-space then bupivacaine 0.5% 15-20 ml with 50ug fentanyl was given.
3480879|NCT03790709|Experimental|High dose ANAVEX2-73|High dose active once daily orally
3480880|NCT03790709|Experimental|Mid dose ANAVEX2-73|Mid dose active once daily orally
3480881|NCT03790709|Placebo Comparator|Placebo oral capsule|Placebo dose once daily orally
3480882|NCT03790813|Experimental|Eligible patients|
3480883|NCT03790631||imipenem TDM|Adult patients receiving imipenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480884|NCT03790631||meropenem TDM|Adult patients receiving meropenem for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480885|NCT03790631||piperacillin TDM|Adult patients receiving piperacillin (with or without tazobactam) for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480886|NCT03790631||flucloxacillin TDM|Adult patients receiving flucloxacillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480887|NCT03790631||amoxicillin TDM|Adult patients receiving amoxicillin for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480888|NCT03790631||ceftazidime TDM|Adult patients receiving ceftazidime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480889|NCT03790631||cefepime TDM|Adult patients receiving cefepime for suspected or confirmed bacterial infection. TDM will be performed to assess intermediate and trough levels once the patient is at steady-state.
3480890|NCT03790683|Experimental|EnsoETM + Standard of Care|Participants receive esophageal warming in addition to standard of care surface warming from the time they enter the OR until released to the PACU.
3480891|NCT03790683|Active Comparator|Standard of Care|Participants receive standard of care surface warming from the time they enter the OR until released to the PACU.
3480892|NCT03790592|Experimental|trifocal IOL|patients implanted with a trifocal intraocular lens
3480893|NCT03790540|Experimental|Injection with the aid of DentalVibe|"1 mL of Mepivacaine HCl 2%, 1/20000 Levonordefrin will be injected using a 27 gauge dental needle.~DentalVibe is a small, handheld cordless device that has a charging docking station. A demonstration of DentalVibe (DV) will be performed by putting it into direct contact with the children's nails before applying the device intraorally. Then, the device will be placed on the oral mucosa to enclose the injection site before administering local anesthesia and Potential subject-expectancy effects and pressure from the placement of DV will be controlled. The device will be turned on to stimulate the area of needle penetration. After 5 seconds of vibration, the needle will be inserted. The device will continue vibrating during needle insertion and anesthetic injection."
3480894|NCT03790540|Active Comparator|Injection with topical benzocaine 20%|Topical anesthesia -Benzocaine gel 20%. Tissues will be dried using (2 X 2) gauze to enhance the absorption of the benzocaine gel 20% around the site of the needle penetration and will be left in contact with the soft tissue for one minute. Then the local anesthetic solution (1 ml Mepivacaine HCl 2%, 1/20000 Levonordefrin) will be injected using a 27 gauge dental needle.
3179604|NCT00674752|Placebo Comparator|C|
3179605|NCT00674778|Experimental|1|Radial approach
3480895|NCT03790605|Experimental|1% curcumin chip|Following routine full mouth scaling and root planing within 48 hours, a single chip of 1% curcumin will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)
3480896|NCT03790605|Placebo Comparator|Placebo chip|Following routine full mouth scaling and root planing within 48 hours, a single placebo chip will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)
3480897|NCT03790501||People living with HIV (PLHIV).|We will recruit and enroll 850 people living with HIV (PLHIV) to participate in this longitudinal observational study.
3480898|NCT03790449|Experimental|PreLiFe-programme|A Mobile Preconception Lifestyle programme
3480899|NCT03790449|Other|Attention Control|Attention Control Programme
3480900|NCT03790527|Experimental|CBM training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the CBM training group; Each participant will do these task twice( e.g. Before training and after training)"
3480901|NCT03790527|Sham Comparator|Sham training|"participants have to complete the picture assessment task ; Approach-avoidance Task(AAT) and cue-induced task in the fMRI；data on game-craving level, game hours, the ability of self-control and emotion regulation are also collected.~Half of the participants will be random-assigned into the sham training group; Each participant will do these task twice( e.g. Before training and after training)"
3480902|NCT03790345|Experimental|Experimental group 1|15 subjects will be randomly assigned to adjuvant treatment with 200mg of vitamin B6 (pyridoxine).
3480903|NCT03790345|Experimental|Experimental group 2|15 subjects will be randomly assigned to adjuvant treatment with 2mg of vitamin B12 (cobalamin).
3127465|NCT03093662|Active Comparator|Ventilation without nasal cannula|Non-invasive positive pressure ventilation without nasal cannula.
3480904|NCT03790345|Sham Comparator|Placebo oral tablet|15 subjects will be randomly assigned to adjuvant treatment with placebo.
3480905|NCT03790618|Placebo Comparator|Placebo|Subjects will attend one session during which they will receive a placebo capsule.
3480906|NCT03790618|Experimental|Low dose MDMA|Subjects will attend one session during which they will receive 0.75mg/kg MDMA.
3480907|NCT03790618|Experimental|High dose MDMA|Subjects will attend one session during which they will receive 1.5mg/kg MDMA.
3480908|NCT03790618|Experimental|Methamphetamine|Subjects will attend one session during which they will receive 20mg methamphetamine.
3480909|NCT03790566|Experimental|Erector spinae plane block|With the patient in lateral decubitus position (surgical side up), the transverse processes of T10-T12 vertebrae and erector spinae (ES) fascia are visualized 1-2 cm lateral to the vertebral spine using a linear ultrasound probe. A 22G peripheral block needle is introduced with in-plane technique under the ES muscle and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
3480910|NCT03790566|Active Comparator|Transversus abdominus plane block|With the patient in supine position, three layers of abdominal muscle are visualized using the linear ultrasound probe held with the long axis on the mid-axillary line above the iliac crest. 22G peripheral block needle is introduced in-plane into the fascia between the internal oblique and transversus abdominus muscles and local anesthetic solution (0.5 ml/kg 0.25% bupivacaine) is injected in this plane after a test injection with 0.5 ml of 0.9% NaCl solution to visualize opening of ESP.
3480911|NCT03790475|No Intervention|Current screening practice.|Subjects randomized into this group will receive named invitations for colonoscopy with pre-specified date, contact details of dedicated screening center. Invitations will be sent 6 weeks prior to suggested date of screening test. All subjects not responding to the invitation will receive a reminder letter 3 weeks prior to proposed appointment date. Additionally, a re-invitation for colonoscopy (screening test in 6 weeks) will be sent to participants not responding to the first invitation and the reminding letter.
3480912|NCT03790475|Experimental|Sequential screening strategy.|"Subjects randomized into this group will be initially invited to participate in a screening colonoscopy as per group 1. All subjects who will refuse colonoscopy or do not respond to invitation within 6 weeks since the first letter, will receive another invitation letter with FIT test enclosed.~The screening office will contact persons with a positive test result in order to determine the date of the colonoscopy appointment.~A negative test result will be sent together with a recommendation to have another screening test performed 2 years later and information about the possible delivery of the test in two years."
3480913|NCT03790475|Experimental|Multiple options screening strategy.|"Subjects in this group will receive a letter with an offer to choose between colonoscopy or FIT screening.~The first letter will include an invitation with a scheduled date of colonoscopy (in 6 weeks) and a FIT kit.~Three weeks before a scheduled date of colonoscopy subjects randomized into this group will receive a reminder letter with an information about proposed screening methods. After the scheduled date of the colonoscopy examination, subjects who will not respond to the invitation for colonoscopy and will not send the FIT test back to the laboratory will receive another invitation for colonoscopy (in 6 weeks) and a FIT kit."
3480914|NCT03790215|Experimental|cohort for treatment|Participants enrolled are given dydrogesterone tablet of 10mg twice a day, from day 15 to day 24 of the menstrual cycle over a period of 3 months.
3480915|NCT03790228|Experimental|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
3480916|NCT03790189|Experimental|Bone Marrow Concentrate|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
3480917|NCT03790241|Experimental|Young males of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
3480918|NCT03790241|Experimental|Young females of normal corpulence|Insertion of a catheter to people ageg between 18 and 25; IBM between 18,5 and 25
3480919|NCT03790241|Experimental|Aged males of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
3480920|NCT03790241|Experimental|Aged females of normal corpulence|Insertion of a catheter to people ageg between 60 and 75; IBM between 18,5 and 25
3480921|NCT03790241|Experimental|Obese young males|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
3127466|NCT03093870|Experimental|Varlitinib and Capecitabine|
3127467|NCT03093870|Placebo Comparator|Placebo and Capecitabine|
3127468|NCT03094195|Experimental|EMA401 25mg BID|Ema401 25 mg was administered orally twice a day
3127469|NCT03094195|Experimental|EMA401 100mg BID|Ema401 100 mg was administered orally twice a day
3127470|NCT03094195|Placebo Comparator|Placebo BID|Matching placebo capsules administered orally twice a day
3127471|NCT03094325|Experimental|Septal myectomy|
3480922|NCT03790241|Experimental|Obese young females|Insertion of a catheter to people ageg between 18 and 25; superior or equal to 30
3480923|NCT03790241|Experimental|Obese aged males|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
3480924|NCT03790241|Experimental|Obese aged females|Insertion of a catheter to people ageg between 60 and 75; IBM superior or equal to 30
3480925|NCT03790202||single cohort of up to 30 patients|patients with acute or chronic lower limb wounds to be treated with the VistaCare® device
3480926|NCT03790332|Experimental|Phase 1/2|"Part A: Subjects ≥1 to <12 years of age with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy, will receive oral ibrutinib once daily to determine Recommended Pediatric Equivalent Dose (RPED).~Part A Continuation: Subjects participating in Part A may continue receiving daily ibrutinib until the RPED is determined, at which time their dose may be adjusted to the RPED.~Part B: Subjects ≥1 to <12 years of age( upper age limit is < 22 years) with moderate or severe cGVHD after failure of 1 or more lines of systemic therapy or with newly diagnosed moderate or severe cGVHD will be dosed at the RPED. Subjects ≥12 will be given 420mg orally ibrutinib once daily."
3480927|NCT03790553|Active Comparator|50.4Gy|Total radiotherapy dose of 50.4Gy.
3480928|NCT03790553|Experimental|61.2Gy|Total radiotherapy dose of 61.2Gy.
3480929|NCT03790176|Other|A - patients on automated peritoneal dialysis|each of n=8 patients will receive one single intravenous infusion of ceftazidime/avibactam (CAZ/AVI) 2g/0.5g over two hours. Subsequently, PK of CAZ/AVI will be determined in plasma and peritoneal dialysis fluid (and urine, if applicable) at protocol-defined time points over 24 hours.
3480930|NCT03790176|Other|B - critically ill patients with pneumonia|following one intravenous dose of 2g/0.5g CAZ/AVI (which patients will receive based on clinical indication by their treating physician), PK of CAZ/AVI will be determined at protocol-defined time points over one dosing interval in plasma and in epithelial lining fluid (ELF).
3480931|NCT03790267||Hip arthroplasty|
3480932|NCT03790267||Knee arthroplasty|
3127472|NCT03094611|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.
3127473|NCT03094637|Experimental|Treatment (azacitidine, pembrolizumab)|Patients receive azacitidine Intravenous (IV) over 10-40 minutes or Subcutaneous (SC) on days 1-7, and pembrolizumab IV over 30 minutes every 3 weeks. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3480933|NCT03790267||Shoulder arthroplasty|
3480934|NCT03790462|Experimental|Music intervention group 1|"Raga A will be played for 10 minutes & data collected."
3127474|NCT03094806|Experimental|Acapella Vibratory PEP Therapy Device|Subject will use the device 3 times a day throughout hospital stay
3127475|NCT03094806|Placebo Comparator|Sham Acapella Vibratory PEP Device|Subject will use the sham device 3 times a day throughout hospital stay
3127476|NCT03095027|Other|FID122819, then stenfilcon A|FID122819 contact lenses worn first, followed by stenfilcon A contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
3127477|NCT03095027|Other|Stenfilcon A, then FID122819|Stenfilcon A contact lenses worn first, followed by FID122819 contact lenses, as randomized. Each product worn in both eyes in a daily disposable mode for at least 8 hours per day, 5 days per week, for 1 week
3127478|NCT03095053|Active Comparator|PGT-A group|Next Generation sequencing preimplantation genetic testing for aneuploidy
3127479|NCT03095053|No Intervention|Morphology group|morphological assessment of blastocyst by light microscope
3480935|NCT03790462|Experimental|Music intervention group 2|"Raga B will be played for 10 minutes & data collected."
3480936|NCT03790462|Experimental|Music intervention group 3|"Raga C will be played for 10 minutes & data collected."
3480937|NCT03790462|No Intervention|Control group|Subject relaxes without music for 10 minutes and electrophysiological parameters will be collected
3480938|NCT03790371|Active Comparator|misoprostol group|misoprostol (misotac® sigma pharmaceutical industries) 200 mcg vaginally applied ten and four hours prior to the second attempt of IUD insertion
3480939|NCT03790371|Placebo Comparator|placebo|while the control group received a placebo tablet in the same regimen as the study group.
3127480|NCT03095118|Experimental|Daratumumab|Subjects will receive daratumumab intravenously at a dose of 16 mg/kg once weekly for 8 weeks followed by once every 2 weeks for 8 additional doses
3127481|NCT03095456|Experimental|Revefenacin|Active Revefenacin and placebo (in place of Spiriva Handihaler®)
3127482|NCT03095456|Active Comparator|Spiriva Handihaler®|Active Spiriva Handihaler® and placebo (in place of Revefenacin)
3127483|NCT03095508|Experimental|Angal S (Arm A)|Patients received Angal S, topical spray [Menthol], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
3127484|NCT03095508|Active Comparator|ANTI-ANGIN® FORMULA (Arm B)|"Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution"
3127485|NCT03095521|Experimental|Arm A|Angal, lozenges, per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution, if this will happen earlier than 4th day of treatment.
3127486|NCT03095521|Active Comparator|Arm B|ANTIANGIN ® FORMULA, 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution, if this will happen earlier than 5th day of treatment.
3127487|NCT03095599|Experimental|Vaccine|Received one dose of IVACFLU-S vaccine intramuscularly.
3127488|NCT03095599|Placebo Comparator|Placebo|Received one dose of placebo intramuscularly.
3127489|NCT03095638|Experimental|Treatment sequence A/B: Part 1|Eligible subjects will be randomized in sequence A/B in Part 1 and will receive A: conventional 10 mg DTG tablet (5 tablets) in Period 1 and B: conventional 50 mg DTG tablet in Period 2, administered directly to mouth.
3179606|NCT00674778|Active Comparator|2|Femoral approach
3480940|NCT03790319||Single Workshop 'The Emotional Backpack'|Subjects of this group are participating in one single workshop over three days.
3480941|NCT03790319||Year Program 'The Power of Feelings'|Subjects of this group are participating in three workshops of over 3 days each in a continuing group over nine months. They are animated to deal with the content inbetween the workshops through biweekly e-mails and to exchange in couples.
3480942|NCT03790163|Placebo Comparator|levobupivacaine at ( 23˚C)|Levobupivacine hydrochloride at ( 23˚C) will be received 3.5 ml levobupivacaine at the operating room temperature 23˚C will be administered
3480943|NCT03790163|Active Comparator|Warm levobupivacaine at (30˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (30˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
3127490|NCT03095638|Experimental|Treatment sequence B/A: Part 1|Eligible subjects will be randomized in sequence B/A in Part 1 and will receive B: conventional 50 mg DTG tablet in Period 1 and A: conventional 10 mg DTG tablet (5 tablets) in Period 2, administered directly to mouth.
3179607|NCT00674830|Experimental|1|professionally administered cognitive-behavioral therapy
3480944|NCT03790163|Active Comparator|Warm levobupivacaine at (37˚C)|Drug:Warm levobupivacaine hydrochlorid (3.5 ml) will be warmed at (37˚C) for 24 hours. The empty syringes and needles ,in their packaging, will be held at the same temperature before the spinal anesthesia
3480945|NCT03790410|Active Comparator|Control group-Complex pulmonary rehab.|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings."
3480946|NCT03790410|Active Comparator|Inspiratory muscle training group|"Complex pulmonary rehabilitation:~The complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.~Inspiratory muscle training~The training program contains strengthening exercises on the diaphragm muscle."
3480947|NCT03790436|Experimental|Betaquik|
3480948|NCT03790358|Placebo Comparator|Placebo|Placebo
3480949|NCT03790358|Experimental|low dose MDMA|6.5ug dose of serotonin agonist
3480950|NCT03790358|Experimental|medium dose|13ug dose of serotonin agonist
3480951|NCT03790358|Experimental|high dose|26ug dose of serotonin agonist
3480952|NCT03790488|Experimental|JTX-4014|Phase 1 dose escalation of PD-1 inhibitor mAb JTX-4014 by intravenous infusion
3480953|NCT03790384|No Intervention|Bacillus Calmette-Guérin|Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
3480954|NCT03790384|Experimental|Mytomicin and Bacillus Calmette-Guérin|Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
3480955|NCT03790514|Experimental|Heat Wrap Group|
3480956|NCT03790514|Placebo Comparator|Control Group|
3480957|NCT03790423|Experimental|18F-ASIS PET|One injection of 18F-ASIS (app. 200 MBq) followed by 3 PET/CT scans 1 hour, 2 hours and 4hours post-injection
3480958|NCT03790280|Experimental|Standard of Care PLUS HFO|Surgery is tailored by HFOs and standard ECoG interpretation (spikes on intra-operative ECoG or seizure onset on extra-operative ECoG) (arm 1).
3480959|NCT03790280|No Intervention|Standard of Care|Surgery is tailored by standard ECoG alone (arm 2).
3480960|NCT03790293|Experimental|Rituximab|Rituximab in combination with reduced corticosteroids is administrated
3480961|NCT03790293|Active Comparator|Standard corticosteroid|Standard corticosteroid is administrated
3179608|NCT00674830|Experimental|2|self-administered form of cognitive behavioral therapy
3179609|NCT00674830|Placebo Comparator|3|usual care
3480962|NCT03790150||Mechanically Ventilated Patients|All patients admitted to the critical care unit and require mechanical ventilation
3480963|NCT03790033|Experimental|UCHA group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Shinhwa Pharmaceutical company
3480964|NCT03790033|Placebo Comparator|Placebo group|2.5g, three times a day, each taken before or between meals for 8 weeks. Manufacturing company: Tsumura Co., Tokyo, Japan
3480965|NCT03790020|Active Comparator|transversus abdominis plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
3480966|NCT03790020|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
3480967|NCT03790020|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the appendix excision area-periappendiciall area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periappendicial area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
3480968|NCT03790020|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
3480969|NCT03790059|Experimental|RFA combined with H101 group|The experimental group was RFA combined H101.H101 has oncolysis in HCC after RFA and reduce tumor recurrence.
3480970|NCT03790059|Other|Conventional RFA group|The standard control group was the conventional RFA.Using RFA for the treatment of small HCC.The efficacy was compared with that of the experimental group combined with H101.
3480971|NCT03790072|Experimental|Treatment Arm|"After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0."
3480972|NCT03789929||The Emotional Backpack|Healthy adults participating in the offered online-course on their own initiative.
3480973|NCT03789929||Feelings as Powers|Healthy adults participating in the offered online-course on their own initiative.
3480974|NCT03789890|Experimental|Healthy men|Healthy male adults from Germany receiving BAY1902607 during study period 1 (length = 6 days) and BAY1902607 + Itraconazole during study period 2 (length = 15 days), separated by a washout phase.
3127491|NCT03095638|Experimental|Treatment sequence C/D/E: Part 2|Eligible subjects will be randomized in sequence C/D/E in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
3127492|NCT03095638|Experimental|Treatment sequence D/E/C: Part 2|Eligible subjects will be randomized in sequence D/E/C in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
3127493|NCT03095638|Experimental|Treatment sequence E/C/D: Part 2|Eligible subjects will be randomized in sequence E/C/D in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
3127494|NCT03095638|Experimental|Treatment sequence C/E/D: Part 2|Eligible subjects will be randomized in sequence C/E/D in Part 2 and will receive C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 1, E: conventional 25 mg DTG tablet administered as direct to mouth in Period 2 and D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 3.
3480975|NCT03789838||Before of sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
3480976|NCT03789838||Sepsis rapid response team|Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
3480977|NCT03789942|Active Comparator|1. Local anaesthesia for oral surgery|Administration of local anesthesia, 40mg.epinephrine once. Oral surgery procedures Suturing End of procedure
3480978|NCT03789942|Active Comparator|2. Local anesthesia with Midazolam|"Administration of 40mg. epinephrine once, and Oral Sedation with Midazolam 0,5 mgr per kilo once.~Oral surgery procedures Suturing End of procedure"
3480979|NCT03789942|Active Comparator|3. Local anesthesia and sedation|"Administration of 40mg. epinephrine once, and Inhalation Sedation by Nitrous Oxide / Oxygen.~Nitrous oxide sedation Oral surgery procedures Suturing End of procedure Reduce nitrous oxide concentration"
3480980|NCT03790085|Experimental|Risperidone|It can be used after schizophrenia is diagnosed. Risperidone affects prolactin and may affect menstruation in young women, so we will try not to use it in such patients. Patients were randomized to a single Risperidone control trial for 8 weeks to evaluate the clinical efficacy of the patients. Risperidone routine daily 2-6 mg, up to 8 mg, can be taken orally twice a day.
3480981|NCT03790085|Experimental|Olanzapine|It can be used after schizophrenia is diagnosed. Olanzapine is not generally used in patients with diabetes and hyperlipidemia. Patients were randomized to a single Olanzapine control trial for 8 weeks to evaluate the clinical efficacy of the patients. Olanzapine is available once or twice a day, starting at 5 mg daily and up to 20 mg daily.
3480982|NCT03790085|Experimental|Aripiprazole|It can be used after schizophrenia is diagnosed. Aripiprazole has no specific contraindications. Patients were randomized to a single Aripiprazole control trial for 8 weeks to evaluate the clinical efficacy of the patients. Aripiprazole is taken orally once a day, starting at 10 mg daily and up to 30 mg daily.
3480983|NCT03789916|Experimental|DAPT|"Dual antiplatelet therapy: acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die"
3480984|NCT03789916|Active Comparator|SAPT|"Single antiplatelet therapy: acetylsalicylic acid 100 mg/die"
3480985|NCT03790137|Experimental|Treatment group|The treatment group will include approximately 10 pediatric and young adult patients (ages 4-25 years) seen by Elizabeth A. Thiele, M.D., Ph.D. at MGH's Pediatric Epilepsy Clinic. Subjects will be treated on an outpatient basis and will not require hospital admission. The treatment group will receive the investigational new drug, Fenfluramine Hydrochloride for up to 6 months.
3480986|NCT03789955|Experimental|Fluoroscopic-guided TEB|After assessment of the epidural space using the loss of resistance technique with air under fluoroscopic guidance, six fluoroscopic views will be obtained: true anteroposterior, contralateral oblique (CLO) at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral for comparison CLO view with lateral view.
3480987|NCT03790111|Experimental|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg|Xermelo 250mg plus 1L therapy for a week, then Xermelo 500mg plus 1L therapy for the duration of the study
3480988|NCT03789981||At diagnosis|Immunogenic profile in patients affected by primary or secondary AML at diagnosis
3480989|NCT03789981||At relapse|Immunogenic profile in patients affected by primary or secondary AML at relapse
3480990|NCT03790007|Active Comparator|Transversus Abdominis Plane Block|Transversus abdominis plane block (10 cc / 10 cc, 0.5% bupivacaine to the right and left transversus abdominis muscle regions) will be applied.
3480991|NCT03790007|Active Comparator|TROCHAR SITES LOCAL ANESTHETIC INJECTION|local anesthetic injection (6 cc to subxiphoid and infraumbilical trocar sites, 4 cc instead of 2 cc, 0.5% bupivacaine solution to be applied)
3480992|NCT03790007|Active Comparator|INTRAPERİTONEAL LOCAL ANESTHETIC SPREADING METHOD|Intraperitoneal direct vision of the gallbladder excision area-periportal area under the direct injection of local anesthetic spraying process (percutaneous method injected into the periportal area 1: 1 diluted with 20 cc SF, 20 cc 0.5% bupivacaine solution total 40 cc spraying will be applied.
3480993|NCT03790007|No Intervention|CONTROL GROUP|group will be the control group and any of these methods will not be applied,
3480994|NCT03789994|Experimental|Affective touch group|"Survivors in the intervention group will receive a total of 36 sessions of a 15-minute affective touch intervention performed by their family caregivers in their homes. Sessions will be scheduled for every alternate weekday (three times a week) for 12 weeks. A trained research nurse (RN) will conduct three 30-minute caregiver training sessions to support the caregivers in delivering the affective touch.~To put caregivers in a more relaxed mood for delivering the intervention, the RN will work with them to identify a time that they feel less burdensome, and teach them to perform deep breathing for relaxation before the affective touching begins. Also, the survivor-caregiver dyad will be asked to sit in a comfortable position and switch off television or radio during the intervention."
3480995|NCT03789994|Other|Fine motor group|To address the additional attention given by caregivers during affective touch, the control group will be asked to sit beside the survivors when they go through the fine motor exercises which are commonly used for rehabilitation. Caregivers will be instructed to provide only necessary help in preparing the equipment, and to avoid touching or talking to the survivors during the 15-minute exercise session. Two such sessions will be arranged for survivors to master the skills needed, and for caregivers to practise the required level of interaction during the exercise training. Participants will be instructed to do the exercise three times a week (every alternate weekday) over 12 weeks.
3480996|NCT03789708|Experimental|A|Patients will receive 10 g of Gum Arabic supplementation daily for four weeks. Gum Arabic is provided in the form of easily soluble granules. Participants are asked to dissolve it in water or juice and drink it.
3480997|NCT03789708|Placebo Comparator|B|Patients will receive 5 g of maltodextrin supplementation daily for four weeks. Maltodextrin is an easily digested polysacharide provided in the form of soluble whitish powder that has no taste or odor. Participants are asked to dissolve it in water or juice and drink it.
3480998|NCT03789708|Experimental|C|Patients will receive 20 g of Gum Arabic supplementation daily for four weeks
3480999|NCT03789708|Experimental|D|Patients will receive 40 g of Gum Arabic supplementation daily for four weeks
3481000|NCT03789695|Experimental|Dabigatran etexilate|Dabigatran etexilate (Pradaxa) 110 mg b.i.d. or 150 mg b.i.d. according SmPC during 2 years
3481001|NCT03789695|Active Comparator|Warfarin|Warfarin under the control of INR once a month (target range 2.0 - 3.0) during 2 years
3127495|NCT03095638|Experimental|Treatment sequence D/C/E: Part 2|Eligible subjects will be randomized in sequence D/C/E in Part 2 and will receive D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 1, C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 2 and E: conventional 25 mg DTG tablet administered as direct to mouth in Period 3.
3127496|NCT03095638|Experimental|Treatment sequence E/D/C: Part 2|Eligible subjects will be randomized in sequence E/D/C in Part 2 and will receive E: conventional 25 mg DTG tablet administered as direct to mouth in Period 1, D: 5 mg dispersible DTG tablet (5 tablets) administered as direct to mouth in Period 2 and C: 5 mg dispersible DTG tablet (5 tablets) administered as a dispersion and immediately taken in Period 3.
3481002|NCT03789851|Experimental|core needle biopsy|All patients enrolled in this study received a ultrasound-guided multipoint core needle biopsy after surgery.
3481003|NCT03790098|Experimental|Yoga Class Participants|Group 1 participants will meet twice per week for one hour to practice restorative-flow yoga with a certified yoga instructor. There will be a total of 24 classes. Group 1 participants will also receive an at-home supplemental booklet, a yoga video led by the class instructor, and encouragement to practice two additional days each week at home. They will be asked to fill out a form to record their at-home practice.
3481004|NCT03790098|No Intervention|No Classes|Group 2 participants will not attend yoga classes as part of the study and will be asked not to begin yoga classes outside the study. After the 24 classes, they will be given the 'at-home' supplemental materials.
3127497|NCT03095651|Experimental|T1DM MK-5160 16 nmol/kg|Participants with T1DM received MK-5160, 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3481005|NCT03789799|Experimental|TIAB treatment|From the first postoperative day for ten days, single vaginal capsule per day of TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
3481006|NCT03789799|Placebo Comparator|Placebo|From the first postoperative day for ten days, single vaginal capsule per day of sodium Hyaluronate, and Aloe Barbadensis Extract vaginal capsule.
3481007|NCT03789682||FUSCC cystectomy cohort|patients underwent cystectomy in Fudan University Shanghai Cancer Center
3481008|NCT03789786||Cases (+SDR)|Patients with cerebral palsy that underwent an SDR
3481009|NCT03789786||Controls (-SDR)|Matched patients with cerebral palsy but did not undergo an SDR
3481010|NCT03789734|Experimental|BLS-M22 or Placebo 500mg group|Single Ascending Dose (SAD): BLS-M22 500mg or Placebo 500mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
3481011|NCT03789734|Experimental|BLS-M22 or Placebo 1,000mg group|Single Ascending Dose (SAD): BLS-M22 1,000mg or Placebo 1,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
3481012|NCT03789734|Experimental|BLS-M22 or Placebo 2,000mg group|Single Ascending Dose (SAD): BLS-M22 2,000mg or Placebo 2,000mg (n=9; BLS-M22=7, Placebe=2) Oral Administration
3481013|NCT03789734|Experimental|Multiple Ascending Dose group|Multiple Ascending Dose (MAD): BLS-M22 2,000mg or Placebo 2,000mg(n=10; BLS-M22=8 or Placebo=2) Oral Administration
3481014|NCT03789643|Experimental|JTT-251 Dose 1|One dose of study drug by mouth daily for 24 weeks
3481015|NCT03789643|Experimental|JTT-251 Dose 2|One dose of study drug by mouth daily for 24 weeks
3481016|NCT03789643|Experimental|JTT-251 Dose 3|One dose of study drug by mouth daily for 24 weeks
3481017|NCT03789643|Placebo Comparator|Placebo|One dose of study drug by mouth daily for 24 weeks
3127498|NCT03095651|Experimental|T1DM MK-5160 32 nmol/kg|Participants with T1DM received MK-5160, 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3127499|NCT03095651|Experimental|T1DM MK-5160 64 nmol/kg|Participants with T1DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3127500|NCT03095651|Active Comparator|T1DM Glargine 0.4 U/kg|Participants with T1DM received Glargine 0.4 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3127501|NCT03095651|Experimental|T2DM MK-5160 16 nmol/kg|Participants with T2DM received MK-5160 16 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3179610|NCT00674843|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3481018|NCT03789435||Amputees|Patients underwent trans-tibial and trans-femoral amputation of any etiology at the Rizzoli Orthopedic Institute from 2015 to 2017 with the presence of analgesia data for surgery in a computerized record (SIR, Rizzoli information system). A questionnaire for the detection of residual limb pain will be administrate to all the survivors.
3481019|NCT03789552|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 8 weeks."
3481020|NCT03789552|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi.~Subjects in this group will use four T89 capsules each time by oral administration twice daily for 8 weeks."
3481021|NCT03789552|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 8 weeks.
3481022|NCT03789565||Group 1. Healthy individuals from periodontal perspective:|GI < 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
3481023|NCT03789565||Group 2. Individuals diagnosed with Gingivitis|GI > 1, PD ≤ 3 mm, CAL = 0 mm, with no apparent bone loss on radiography.
3127502|NCT03095651|Experimental|T2DM MK-5160 32 nmol/kg|Participants with T2DM received MK-5160 32 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3179611|NCT00674856|Experimental|naproxcinod|naproxcinod 750mg(375mg caps x2), administered twice a day.
3481024|NCT03789565||Group 3. Individuals diagnosed with CP|GI > 1, PD ≥ 5 mm, CAL ≥ 3 mm, with apparent bone loss on radiography.
3481025|NCT03789812|Active Comparator|Manual Toothbrush with Superfloss|Patients in this group will receive Manual Toothbrush (Oral B) and Superfloss (Oral B) and will be instructed to use them three times a day.
3481026|NCT03789812|Experimental|Electric Toothbrush with Superfloss|Patients in this group will receive Electric Toothbrush (JETPIK) and Superfloss (Oral B) and will be instructed to use them three times a day.
3481027|NCT03789812|Experimental|Manual Toothbrush with Water Flosser|Patient in this group will receive Manual Toothbrush and Dental Water Jet and will be instructed to use them three times a day.
3481028|NCT03789812|Experimental|Electric Toothbrush with Water Flosser|Patient in this group will receive Electric tooth brush (JETPIK) and water flosser and will be instructed to use them three times a day.
3481029|NCT03789578|Experimental|Semaglutide plus insulin 287|Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).
3481030|NCT03789578|Experimental|Semaglutide alone|Participants will get a single dose of semaglutide (treatment B) alone.
3481031|NCT03789578|Experimental|Insulin 287 alone|Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.
3481032|NCT03789448|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
3481033|NCT03789448|Experimental|Early Access to ART for All|HIV-positive individuals who are aged 18 years or older are initiated on ART regardless of client's immunological and clinical staging (excluding pregnant or breastfeeding women)
3481034|NCT03789370|Active Comparator|Propofol|Total intravenous anaesthesia with propofol for maintainance of anaesthesia.Dose adjusted according to the Bispectral Index (BIS) indication (maintained 40-50). Initial dose 10 mg/kg/h for10 min, 8 mg/kg/h for 10 min and then 6 mg/kg/h).
3481035|NCT03789370|Active Comparator|Sevoflurane|Sevoflurane for maintainance of anaesthesia. Dose 1 MAC adjusted according to the Bispectral Index (BIS) indication (maintained 40-50).
3481036|NCT03789526|Experimental|Group 1|Group one: 26 patients DM patients with tenosynovitis were injected by triamcinolone under ultrasound guidance.
3481037|NCT03789526|No Intervention|Group 2|Group two: 26 patients DM patients with tenosynovitis were injected by triamcinolone under clinical guidance.
3481038|NCT03789461|Experimental|Fecal Microbiota Transplantation|FMT infusion
3481039|NCT03789630||Monitoring arm|Monitoring subjects undergoing total knee replacement surgery using the wearable biosensor to continuously monitor physiology biomarkers.
3481040|NCT03789487|Experimental|Non-responders to CRT|Non-responders to CRT who will undergo an electrical optimization of the settings of their device
3481041|NCT03789396||Pre-implementation|The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
3481042|NCT03789396||Post-implementation|The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.
3481043|NCT03789201|Experimental|Healthy Volunteers|thematic permission to use non-invasive techniques regarded as having minimal risk in healthy individuals, such as, MRI, EEG, EMG, lowfrequency stimulation(= 1 Hz), electrical stimulation of the skin to mimic thesomatosensory artifact of TMS, and behavioral tests
3481044|NCT03789539|Active Comparator|LD Universal Influenza Vaccine Uniflu|low dose of Uniflu vaccine 0.5 ml (20 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
3481045|NCT03789539|Active Comparator|HD Universal Influenza Vaccine Uniflu|high dose of Uniflu vaccine 0.5 ml (40 mkg of recombinant protein HBc-4M2eh) administrated intramuscularly 2 times at 21 days intervals
3481046|NCT03789539|Placebo Comparator|Placebo|saline 0.5 ml
3481047|NCT03789253||AS cohort with progression|AS cohort with tumor progression
3481048|NCT03789253||AS cohort without progression|AS cohort without tumor progression
3481049|NCT03789513|Other|Triage with different options|"All women will have an HPV test, partial genotyping (16/18/45 versus other high-risk HPV [hr-HPV]) and VIA. The different options for triage that will be compared are:~Participants hr-HVP+ and VIA+ participants selected for treatment;~Participants HPV 16/18/45+ selected for treatment;~Participant HPV 16/18/45+ and/or VIA+ selected for treatment;"
3481050|NCT03789721||Adrenoleukodystrophy|All patients living in the United States diagnosed with adrenoleukodystrophy, either by newborn screen, based on family history or otherwise, are eligible to participate in this study.
3481051|NCT03789344|Experimental|Acupuncture treatment|
3481052|NCT03789344|Active Comparator|Psychotherapy|
3481053|NCT03789344|Placebo Comparator|blank control|
3481054|NCT03789422|Active Comparator|Association drugs|levocetirizine 10mg/day + tranexamic acid (AT) 2g/day for a month
3481055|NCT03789422|Active Comparator|one drug|Levocetirizine 20 mg/day for a month
3481056|NCT03789266|Experimental|Drain ablation - Non Aspiration mode|Drain ablation will be done in non Aspiration mode
3481057|NCT03789266|Other|Drain ablation - Aspiration mode|Drain ablation will be done in Aspiration mode
3481058|NCT03789331||Transgender Male individuals|"Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery.~Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
3481059|NCT03789331||Normal healthy female individuals|"Group Description: Healthy women with normal sexual orientation.~Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position."
3481060|NCT03789227|Placebo Comparator|Group C|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 4 ml saline in a total volume 12 ml.
3481061|NCT03789227|Active Comparator|Group D|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 8 mg dexamethasone with 4 ml saline in a total volume 12 ml.
3481062|NCT03789227|Active Comparator|Group K|ganglion impar block :patients will receive a premixed solution of 3 ml lidocaine 2%, 5 ml absolute alcohol 95% and 15 mg ketorolac with 4 ml saline in total volume 12 ml.
3481063|NCT03789409|Experimental|Intermittent Fasting|Over rehabilitation treatment during and admission (at least 1 week), intermittent fasting (IF) for more than 12 hours (water can be allowed). For subgroup assignment, participants can choose IF1 (eat early in the evening and late in the morning) or Post-IF2 (eat the remaining two meals without breakfast), depending on own their faver.
3127503|NCT03095651|Experimental|T2DM MK-5160 64 nmol/kg|Participants with T2DM received MK-5160 64 nmol/kg, and placebo to glargine daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3127504|NCT03095651|Active Comparator|T2DM Glargine 0.6 U/kg|Participants with T2DM received Glargine 0.6 U/kg and placebo to MK-5160 daily for 12 days. Dextrose was administered as needed to maintain blood sugar.
3481064|NCT03789409|No Intervention|Ad libitium|Participants will be allowed to have hospital meals and all the desired intake without time limit.
3481065|NCT03789656|Experimental|Paltusotine|
3481066|NCT03789318|Active Comparator|CA-008|
3481067|NCT03789318|Placebo Comparator|Placebo|
3481068|NCT03789357||Single Arm|All patients admitted to the Acute Stroke Unit
3481069|NCT03789110|Experimental|Nivolumab+Ipilimumab|"Ipilimumab is administered intravenously every 6 weeks~Nivolumab is administered intravenously every 2 weeks"
3481070|NCT03789136||Primary colon cancer|
3481071|NCT03789136||Liver metastases|
3481072|NCT03789136||Inguinal hernia (control)|
3481073|NCT03789136||Abdominal hysterectomy (control)|
3481074|NCT03789123|Experimental|Study Group (patients with OMA)|"I) Untreated patients (n=142)~II) Dienogest (n=142)~III) Dienogest/Estradiol valerate+Dienogest (n=142)"
3127505|NCT03095885|Other|Test Meal|controlled oxalate-rich test meal
3127506|NCT03095976|Experimental|Test group|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects.
3481075|NCT03789123|Sham Comparator|Control Group(patients without OMA)|"I) Untreated patients (n=142)~II) Dienogest/Estradiol valerate+Dienogest (n=142)"
3481076|NCT03789149|Experimental|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG)
3481077|NCT03789071||Patient scheduled for general anesthesia with intubation|Patients in this group (only group) will have clinical airway assessment and external ultrasound assessment of the airway
3481078|NCT03789214|Placebo Comparator|Placebo|Placebo sleep medication (Placebo oral capsule)
3481079|NCT03789214|Active Comparator|Low Dose Suvorexant|Low dose sleep medication
3127507|NCT03096314|Active Comparator|High dose vitamin D formulation|A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.
3127508|NCT03096314|Placebo Comparator|Placebo|A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.
3179612|NCT00674869|Experimental|1|pit and fissure sealant on one randomized tooth by pair of permanent molar
3481080|NCT03789214|Active Comparator|High Dose Suvorexant|High dose sleep medication
3481081|NCT03788967|Experimental|TBPM-PI-HBr 300 mg film-coated tablets|TBPM-PI-HBr 600 mg administered orally three times per day for 7 to 10 days.
3481082|NCT03788967|Active Comparator|Ertapenem|Ertapenem for IV injection administered as a 1-gram IV infusion over 30 min once daily for 7 to 10 days.
3481083|NCT03788954|Active Comparator|Kinesiotaping on FCU|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. flexor carpi ulnaris.
3481084|NCT03788954|Active Comparator|Kinesiotaping on ECR|Muscle fasilitation and Fascia Correction techniques of Kinesiotaping on m. extensor carpi radialis.
3481085|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on FCU|Same kinesiotape used on m. flexor carpi ulnaris without any taping techniques.
3481086|NCT03788954|Placebo Comparator|Plasebo Kinesiotaping on ECR|Same kinesiotape used on m. extensor carpi radialis without any taping techniques.
3481087|NCT03788915|Active Comparator|Online dietician lifestyle counseling|Online dietetic lifestyle counseling
3481088|NCT03788915|Placebo Comparator|Usual care|Usual care
3481089|NCT03789058|Active Comparator|Surgical with conventional NSAID 3 times/day|Control group will have surgical intervention to remove wisdom tooth and receive conventional NSAID treatment three times per day
3481090|NCT03789058|Experimental|Surgical with conventional NSAID 2 times/days|The experimental group will have surgival intervention to remove wisdom tooth and receive NSAID treatment only two times per day: once after breakfast and once after lunch, but not at night.
3481091|NCT03788889|Active Comparator|Lorazepam + Ketamine + Placebo A|"Ketamine - infusion (0.15 - 0.4 mg/kg/hr) and placebo injections titrated by increases of 0.075 mg/kg/hr every 30 minutes for Clinical Institute Withdrawal Assessment for Alcohol (revised version) (CIWA-Ar) greater than or equal to 10 in addition to lorazepam symptom-triggered therapy~Ketamine dosing will be based on ideal body weight~Ketamine infusion will be discontinued once CIWA-Ar less than 10 for 4 hours"
3481092|NCT03788889|Active Comparator|Lorazepam + Phenobarbital + Placebo B|"Phenobarbital - IV push (260 mg loading followed by 130 mg q1 hour) with placebo infusion until CIWA-Ar less than 10 with a maximum daily dose of 10mg/kg in addition to lorazepam symptom-triggered dosing for recurrent symptoms (Gold 2007)~Maximum daily dose will be used in order to prevent over sedation as well as provide adequate storage in pharmacy monitored refrigerators for study drugs"
3481093|NCT03788889|Placebo Comparator|Lorazepam + Placebo A + Placebo B|Lorazepam will be administered every 30 minutes as indicated based on CIWA-Ar protocol for Cottage Health in addition to placebo injections and placebo infusion
3481094|NCT03788824||pCLE group|pCLE is used to distinguish the inflammation activity of UC, and compared with histology
3481095|NCT03788902|Experimental|ADHD group|This group was examined twice - once after taking Ritalin and once after taking placebo
3481096|NCT03788902|No Intervention|Healthy control|Children with the same demographics as children with ADHD but without ADHD or a first degree relative with ADHD
3481097|NCT03789084|Experimental|Cognitive-Behavioral Therapy|Brief Cognitive-Behavioral Therapy for Health Anxiety
3481098|NCT03789084|Other|Referral to mental health provider|Provider makes referral to a mental health provider
3481099|NCT03788863||Pregnant women exposed to glucocorticoids|Pregnant women exposed to any glucocorticoid or corticosteroid or steroids in early pregnancy or first trimester of pregnancy
3481100|NCT03788863||Non-exposed pregnant women|Women not using any glucocorticoid or corticosteroid or steroids during pregnancy
3481101|NCT03788837|Experimental|intravenous Ilomedin|a first dose of Ilomedin of 0.5ng/kg/ min with increments every 30 minutes up to a maximum of 1,5 ng/kg/min for 48h
3481102|NCT03788837|Placebo Comparator|Intravenous Placebo|Treatment with intravenous NaCl 0.9% therapy with incremental infusion rate every 30 minutes for 48h
3481103|NCT03788941||LAAC plus Catheter ablation|Patients will receive both left atrial appendage closure and catheter ablation of atrial fibrillation for treatment.
3481104|NCT03788941||Catheter ablation|Patients will only receive catheter ablation of atrial fibrillation for treatment.
3179613|NCT00674869|No Intervention|2|No intervention
3179614|NCT00674882||Participants|Data Collection
3179615|NCT00674895|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3179616|NCT00674908|Experimental|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
3481105|NCT03788876|Active Comparator|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre until discharge and the protocol of physiotherapy by the physiotherapists of HCPA twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
3481106|NCT03788876|Sham Comparator|Conventional care|The protocol of physiotherapy by the physiotherapists of HCPA and Irmandade da Santa Casa de Misericórdia de Porto Alegre twice a day that will consist in exercises for bronchial hygiene, exercises for pulmonary reexpansion and exercises of passive mobilization.
3481107|NCT03788772|Experimental|Adults patients hospitalized in ICU|Adult patients hospitalized in the intensive care unit (ICU) for severe infections (sepsis and septic shock) or or non-septic shock (cardiogenic or hemorrhagic shock)
3481108|NCT03789032|Experimental|Rabeprazole and Vadadustat|Subjects will receive vadadustat 300 mg on day 1, rabeprazole 20 mg every 12 hours on days 2 through 5 and vadadustat 300 mg and rabeprazole on day 6
3481109|NCT03788798|No Intervention|Standard clinical pathway|A standard clinical pathway for TKA has been compulsively implemented for medical cost containment and quality assurance to meet with the Taiwan Diagnosis-Related Groups (TW-DRGs) payment system since 1997. The clinical pathway for TKA undertakes with preadmissions, anesthetic, surgery, and physiotherapy assessment. Medical, nursing, and physiotherapy assessment were put down for each postadmission day. The time from admission to surgery, the use of intravenous antibiotics injection and intravenous fluid were all assessed. Discharge criteria were active knee flexion to 90 degrees, having the ability to walk with aids and clean wound condition with any infection sign. The pathway was initially set for a 6-day postoperative length of stay.
3481110|NCT03788798|Experimental|Patient Infotainment Terminal|Patients who have additional access to an integrated infotainment system and are cared by a standard clinical pathway. The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
3481111|NCT03788733|Experimental|Melatonin|Melatonin ORAL FILM 3mg will be taken by the subject once a day for 8 weeks
3481112|NCT03788733|Placebo Comparator|placebo|ORAL FILM 3mg placebo will be taken by the subject once a day for 8 weeks
3481113|NCT03788785|Experimental|Experimental arm|The specific tobacco cessation intervention of the treatment group will begin during the diagnostic phase of the HNSCC by three ½ hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days top. The most important point is that this intervention will be provided by trained nurses of the health care team within the ENT department, rather than in an external smoking cessation center.
3481114|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
3481115|NCT03788694|Experimental|Intranasal Ketamine|Subjects will receive study medication, intranasal ketamine.
3481116|NCT03789006|Active Comparator|ATG|Induction with antithymocyte immunoglobulin (Rabbit) (Grafalon) and maintenance with tacrolimus, azathioprine and prednisolone
3481117|NCT03789006|Active Comparator|BAS|Induction with interleukin 2 receptor antagonist (basiliximab) and maintenance with tacrolimus, mycophenolate mofetil and prednisolone
3481118|NCT03788720|Experimental|Suture|Women undergoing suturing of the ovarian cortex after laparoscopic enucleation of endometriomas.
3481119|NCT03788720|Sham Comparator|No suture|Women undergoing laparoscopic enucleation of endometriomas without subsequent suture of the ovarian cortex.
3481120|NCT03789019|Experimental|BP-C1|"Dose-response part: patients who have completed the first 32-day treatment period with BP-C1 under Protocol BMC2011-1/Protocol MBC-BPC1/IIB or Protocol BMC2012-4, and having a maximum of moderate toxicity at the end of treatment are offered to continue in the second 32-day treatment period with BP-C1 under the protocol BMC2011-02. Patients completing 64-day treatment period with BP-C1 will be followed up for 28 days.~Follow-up study: the patients will be given BP-C1 as long as they obtain benefit from the treatment (i.e. until disease progression or increase in toxicity not above moderate grade)."
3481121|NCT03788616|Active Comparator|Group I|Group I : will consist of 30 teeth that will be restored by high-viscosity glass ionomer (Fuji IX Extra) with ART approach
3179617|NCT00674908|Active Comparator|Easy 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
3179618|NCT00674921|Placebo Comparator|1|It will comprise patients randomized to receive the placebo (stop cotrimoxazole prophylaxis) at CD4 counts of 200 or more but less than 350 cells/ul as they continue with HAART. Patients will be followed until they achieve a CD4 count of 350 cells/ul.
3132718|NCT03447314|Experimental|Part 1b: 100ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
3481122|NCT03788616|Active Comparator|Group II|Group II : will consist of 30 teeth that will be restored by bioactive restorative material (ACTIVA KIDS bioactive restorative material) with ART approach.
3481123|NCT03788759|Experimental|Experimental group|25 subjects will be randomized to 100mg of alpha-lipoic acid.
3481124|NCT03788759|Placebo Comparator|Placebo group|25 subjects will be randomized to placebo.
3481125|NCT03788668|Active Comparator|Hyoid suspension with barbed reposition pharyngoplasty|
3481126|NCT03788668|No Intervention|barbed reposition pharyngoplasty|
3481127|NCT03788681|Active Comparator|"oral estradiol  estradiol valerate"|"this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI .This group will receive oral estradiol  estradiol valerate  (Cyclo-Progynova® , 2mg , Bayer Schering Pharma Ag , Germany ) from within 24 hours ovum pickup of the cycle."
3481128|NCT03788681|Placebo Comparator|placebo|this group will include ( 85 ) poor responder women undergoing a trial of IVF/ICSI . This group will receive oral placebo (tablets) from within 24 hours ovum pickup of the cycle
3481129|NCT03788707|Experimental|Passive leg raising|Passive leg raising for 3 minutes after 20 seconds of lying flat
3481130|NCT03788603|Experimental|Rogaratinib (BAY1163877)|Eligible patients will be selected based on the confirmation of high fibroblast growth factor receptor (FGFR) 1, 2, 3 or 4 mRNA expression levels in archival or fresh tumor biopsy specimens collected before the start of screening
3481131|NCT03788629|Experimental|Study Group 1|Bobath Concept+ Talocrural joint Mulligan MWM techniques were applied to this group.
3481132|NCT03788629|Active Comparator|Study Group 2|Subtalar joint Mulligan MWM techniques were applied to this group in addition to Bobath Concept+ Talocrural joint Mulligan MWM techniques
3481133|NCT03788486|Experimental|2-3 Joule light device for MGD/Dry eye|patients who qualify for the study will receive interventional in office treatments with the light treatment device in the upper and lower lids for defined periods of time twice weekly for a total of one month. Non-invasive tear break up, subjective questionnaires and corneal fluorescein staining will be measured through the course of the study.
3481134|NCT03788408|Experimental|Intensive Psychotherapy Case Management|Treatment group received Intensive Psychotherapy and Case Management (IPCM) delivered by psychotherapists and social worker with expertise in refugee trauma and mental health.
3481135|NCT03788408|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual group received ongoing care from their primary care providers without the involvement of CVT (except for the collection of outcomes). TAU patients could be referred to a full range of outpatient and community-based behavioral health services by their primary care physician.
3481136|NCT03788538|No Intervention|group 1 with no dexmedetomidine|
3481137|NCT03788538|Experimental|group 2 with dexmedetomidine 0.25μg/kg/h|
3481138|NCT03788538|Experimental|group 2 with dexmedetomidine 0.5μg/kg/h|
3481139|NCT03788330|Experimental|Fresh air system with filtration|A fresh air ventilation system combined with PM2.5 filtration is applied in one primary school classroom.
3132719|NCT03447314|Experimental|Part 1b: 150ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
3481140|NCT03788330|Placebo Comparator|Fresh air system with no filtration|A fresh air ventilation system with no PM2.5 filtration is applied in a parallel classroom.
3481141|NCT03788330|No Intervention|Natural ventilation|Natural ventilation system was applied in the 3rd classroom as normal.
3481142|NCT03788304|Active Comparator|Non invasive ventilation|"Respiratory assistance is provided by a NIV either Puritan Bennet 840 , Engström Carestation or Hamilton-G5 , will be used for conventional non-invasive ventilation via an oronasal mask. Settings will be adjusted based on the clinical assessment of the respiratory therapist . Initial setting includes: -~Positive End Expiratory Pressure (PEEP): 5 cmH2O.~Pressure support (PS): 12-20 cmH2O.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
3481143|NCT03788304|Experimental|High flow nasal cannula|"High flow nasal cannula consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers a modified gas flow up to 60 l/ min .~will be set with: -~Temperature at 37°C or 34°C~Flow rate 30: 50 L/min.~FiO2 will be adjusted to achieve a SpO2 at least 95%"
3481144|NCT03788343|Experimental|Phenylalanine|"Capsules containing 250 mg Phenylalanine (Phe). The daily dose will be chosen according to gender and weight at the time of T1 and will be divided in 3 separate doses. The assigned dose of the IMP will be kept throughout the whole study and weight fluctuations will not be considered.~Female~<60 kg: 1500 mg per day (divided in 3 doses): 250 mg 2-2-2-0~≥60 kg: 2000 mg per day (divided in 3 doses): 250 mg 2-2-4-0~Male~<60 kg: 2500 mg per day (divided in 3 doses): 250 mg 4-2-4-0~≥60 kg: 3000 mg per day (divided in 3 doses): 250 mg 4-4-4-0~Phe capsules can be ingested before, during or after a meal or together with other amino acid supplements. The last capsule of the given intervention period will be timed to be ingested with the last meal before the study visit.~Patients will take Phe for 4 weeks."
3481145|NCT03788343|Placebo Comparator|Placebo|"Capsules containing 250mg Placebo. Placebo capsules will be administered in identical manner to Phe capsules.~Patients will take the Placebo for 4 weeks."
3481146|NCT03788395|Experimental|Symbicort Turbohaler plus Turbo+|10 asthmatic children
3481147|NCT03788395|Active Comparator|Symbicort Turbohaler without Turbo+|10 asthmatic children
3481148|NCT03788278||PTSD patients|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
3481149|NCT03788278||Non PTSD participants|"Participants will attend clinical surveillance once every week or two. During the follow-up period, the participant will be checked as usual and will have to fill in questionnaires.~Participants will be required to wear the smart watch at all times and will need to recharge it at least once every three days.~Participants will be required to answer digital questionnaires twice a day via smartphone."
3481150|NCT03788369||Multivessel coronary artery disease|must include left anterior descending artery
3481151|NCT03788239|Experimental|Arm 1|Right knee wound closure by staples and Left Knee wound closure by sutures
3481152|NCT03788239|Experimental|Arm 2|Right knee wound closure by sutures and Left Knee wound closure by staples
3481153|NCT03788447|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
3481154|NCT03788447|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
3481155|NCT03788577|Experimental|Oligonol intake group|This experimental arm will be applied for Oligonol 200mg/tab 1 tab per day. The program will last for 12 weeks.
3481156|NCT03788577|Placebo Comparator|Placebo group|This Placebo arm will be given capsules made of starch 1 tab per day. The program will last for 12 weeks.
3481157|NCT03788499|No Intervention|Control arm|routine oral care and functional exercise.
3481158|NCT03788499|Experimental|Massage arm|Massage of Maxillofacial and oral cavity plus routine oral care and functional exercise
3481159|NCT03788291|Experimental|Acalabrutinib and Rituximab treatment|"Rituximab: administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, Then 50 mg SQ thereafter.~Acalabrutinib: 100 mg po BID starting on day 8 of cycle 1.~Patients who have attained a complete response who are also MRD negative at cycle 12 will undergo a BM biopsy to confirm CR and MRD negatively. If confirmed, the patient will stop therapy and be followed until disease progression.~Patients not in a MRD negative CR, will continue acalabrutinib.~Repeat response assessments (CTs, MRD testing in blood) will be performed at 24 cycles of therapy for those continuing on acalabrutinib. If both negative the patient will undergo a BM biopsy to confirm CR and MRD negativity. If confirmed, the patient will stop therapy and be followed until disease progression. In the absence of a CR or if MRD +, acalabrutinib may be continued until disease progression, unacceptable toxicity or physician/patient discretion."
3481160|NCT03788460||childrens population with lack of Factor VI|"We will check PT levels, we will concentrate the data in the table, along with personal information such as age and gender.~We will try to conduct a statistical relationship between the PT values and Factor VII levels, to look for statistical significance, we will try to find a model for predicting the level of factor VII based on PT"
3481161|NCT03788525|Experimental|Reduced recreational screen time|Reducing recreational screen-based media use for a period of 2 weeks
3481162|NCT03788525|Experimental|Timed recreational screen time|Reduced and timed recreational screen-based media use for a period of 2 weeks
3481163|NCT03788512||AICVD patients with CoCCA|acute ischemic cerebrovascular disease patients with coexistence of cerebral and coronary atherosclerosis.
3481164|NCT03788590|Experimental|Jenscare TAVI|Patients undergoing a Jenscare TAVI and delivery system
3481165|NCT03788200|Active Comparator|post-injury bracing with rigid cervical collar|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
3481166|NCT03788200|Active Comparator|posterior C1-2 instrumented fusion|Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
3481167|NCT03788265|Experimental|injection|
3481168|NCT03788434|Experimental|VE303 High Dose|Study subjects assigned the the high dose VE303 arm will take 10 capsules containing VE303 per day for 14 days.
3481169|NCT03788434|Experimental|VE303 Low Dose|Study subjects assigned to the low dose VE303 arm will take 2 capsules containing VE303 per day for 14 days.
3481170|NCT03788434|Placebo Comparator|Placebo|Study subjects assigned to the placebo dose arm will take placebo capsules each day for 14 days. The capsules will not contain any VE303.
3481171|NCT03788226|Experimental|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
3481172|NCT03788226|Active Comparator|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
3481173|NCT03788356|Experimental|Diaphragmatic breathing|Diaphragmatic breathing exercise for 15 minutes.
3481174|NCT03788356|Experimental|10% inspiratory muscle training|Inspiratory muscle training at 10% intensity of maximal inspiratory pressure for 15 minutes
3481175|NCT03788356|Experimental|30% inspiratory muscle training|Inspiratory muscle training at 30% intensity of maximal inspiratory pressure for 15 minutes
3481176|NCT03788356|Experimental|60% inspiratory muscle training|Inspiratory muscle training at 60% intensity of maximal inspiratory pressure for 15 minutes
3481177|NCT03788252|Active Comparator|Renamezin|oral treatment duration: three times a day, 7 capsules (2g) once, for 48 weeks
3481178|NCT03788252|No Intervention|Non-Renamezin|no use of Renamezin
3481179|NCT03788057|Other|stable asthma|"In patients with previously stable course of the asthma, every 3 months the symptoms are evaluated and the dose of ICS is customized - in accordance with the GINA guidelines. This decision is based solely on clinical data (control of symptoms) and is the same as in patients not participating in the study.~In patients participating in the study, inflammatory parameters are also measured (sputum eosinophilia, eNO, EBT, bronchial reactivity), but results are not known to clinician taking decision about possible ICS dose reduction."
3481180|NCT03787992|Experimental|Alflutinib Mesylate (AST2818) +placebo|AST2818 (80 mg or 40 mg orally, once daily) plus placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule
3481181|NCT03787992|Active Comparator|Gefitinib + placebo AST2818|Gefitinib (250 mg orally, once daily) + placebo AST2818 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule.
3481182|NCT03788031|Experimental|Perceptual learning group - Amblyopia|Visual training
3481183|NCT03788031|Active Comparator|Perceptual learning group - Control|Visual training
3481184|NCT03788031|Placebo Comparator|Occlusion therapy - Amblyopia|Patching
3481185|NCT03788421|Active Comparator|Study group|Women undergoing elective bilateral salpingectomy during cesarean section with LIGASURE.
3481186|NCT03788421|Active Comparator|Control group|Women undergoing elective bilateral salpingectomy during cesarean section with traditional step by step clamping and suturing.
3481187|NCT03788005|Active Comparator|Intervention group|"Early mobilization as soon as possible, within a maximum of 12 hours post-surgery.~Subdural drains will be closed when the patient is allowed to mobilize and will be open during a nocturnal period of 8 hours. Subdural drains will be removed past 48 hours of surgery."
3481188|NCT03788005|No Intervention|Control Group|Bed rest with head of bed at 0 degrees for 48h. Subdural drains will be removed past 48 hours of surgery.
3481189|NCT03788044|Experimental|Application-driven education (AF-EduApp substudy)|Education will be given via a newly developed application. Medication adherence (oral anticoagulation) will be measured using a special bottle cap that fits on a medication bottle. The patients in this group will receive feedback (notification and/or alarm) during the entire study period via this application when these patients have to take their medication.
3481190|NCT03788044|Experimental|In-person education (AF-EduCare study)|Education will be given on regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
3481191|NCT03788044|Experimental|Online education (AF-EduCare study)|Education will be given on regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special bottle cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
3481192|NCT03788044|No Intervention|Standard care (AF-EduCare study and AF-EduAppsub study)|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
3481193|NCT03788109|Other|device: combined solid state HRiM|combined solid state high resolution esophageal impedance and manometry (HRiM)
3481194|NCT03788096|Experimental|PS-PICS Peer Support Intervention|ICU mentors will be responsible for providing support to survivor participants randomized to the PS-PICS peer support intervention. Mentors will be trained in motivational interviewing techniques to engage mentees in goal setting and emotional management that is not readily accessible as part of discharge planning.
3481195|NCT03788096|Placebo Comparator|Usual Care Group|A control intervention will be used to provide comparison data consistent with usual care (absence of structured peer support telephone intervention) to evaluate the impact of the PS-PICS peer support intervention.
3481196|NCT03787979|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
3481197|NCT03787979|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
3481198|NCT03787901|Experimental|Morula Vitrification Arm|
3481199|NCT03787901|Active Comparator|Blastocyst Vitrification Arm|
3481200|NCT03787940|Active Comparator|Standard INH for Non-rapid acetylators|Participant with slow or intermediate acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid)
3481201|NCT03787940|Active Comparator|Standard INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with standard chemotherapy (3 months HRZE followed by 9 months HRE with standard dose isoniazid )
3481202|NCT03787940|Experimental|High dose INH for rapid acetylators|Participant with rapid acetylators(one of N-Acetyltransferase Type 2 Genotype) administered with high dose isonized treatment (3 months HRZE followed by 9 months HRE with high dose isoniazid)
3481203|NCT03788161|Experimental|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
3481204|NCT03788161|Placebo Comparator|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
3481205|NCT03788083|Placebo Comparator|placebo|
3481206|NCT03788083|Active Comparator|TriMix|
3481207|NCT03787953||Anti-PD-1/PD-L1 antibodies|Patients with advanced solid tumors who visited Department of Medical Oncology, Chinese PLA General Hospital from 2015 to 2019 and received anti-PD-1/PD-L1 antibody therapy
3481208|NCT03788018|Experimental|Effect of IV lidocaine and dexmedetomidine on PONV|
3481209|NCT03788018|Experimental|Effect of IV saline on PONV|
3481210|NCT03788122|Other|Parents eligible for fetal surgery|Parents eligible for fetal surgery will undergo two or three in-depth face-tot-face interviews, to determine their perception of acceptability of fetal surgery.
3481211|NCT03787758|Experimental|SAGE-718|
3481212|NCT03787914|Experimental|Intervention arm|Intervention arm patients were served by outreach mobile teams for oral anti-TB treatment under DOTS at the place of their convenience by health care professionals
3481213|NCT03787914|Active Comparator|Control arm|Control arm patients were given the traditional facility based DOTS treatment. Control arm was not served by the outreach mobile teams.
3481214|NCT03788174|Experimental|Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
3481215|NCT03787836|No Intervention|Controls|The primary purpose of the control participants are to provide a measure of variability. They will be used in our calculations of typical error to classify participants as responders or non-responders, and to quantify inter-individual variability.
3481216|NCT03787836|Experimental|Exercisers (Maintained)|The maintained exercise group will complete the original 16-week exercise intervention at an intensity of 4.5 metabolic equivalents (METs), and repeat the intervention for another 12-weeks following its completion.
3481217|NCT03787836|Experimental|Exercisers (Increased Intensity)|The increased intensity exercise group will complete the original 16-week exercise intervention, followed by an additional 12 week intervention completed at an intensity of 6.0 METs.
3481218|NCT03787927|Other|5 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 5 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day RTP, then 5 day CSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481219|NCT03787927|Other|5 day RTP, then 5 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 5 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~The first 20 participants who complete the study will be randomized to this arm or '5 day CSP, then 5 day RTP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481220|NCT03787927|Other|5 day RTP, then 10 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 10 day autologous CSP (cold-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481221|NCT03787927|Other|5 day RTP, then 15 day CSP|"Participants will first complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). Then they will complete collection and transfusion of 15 day autologous CSP (cold-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481222|NCT03787927|Other|10 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 10 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets).The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 20 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 10 day CSP' and '10 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481223|NCT03787927|Other|15 day CSP, then 5 day RTP|"Participants will first complete collection and transfusion of 15 day autologous CSP (cold-stored platelet). Then they will complete collection and transfusion of 5 day autologous RTP (room-temperature-stored platelets). The day before each transfusion, Aspirin (325mg) and Clopidogrel (600mg) will be administered.~After the first 40 complete data sets are obtained from subjects, the next 20 complete data sets will be obtained (if progression to this arm is indicated) by randomizing subjects between '5 day RTP, then 15 day CSP' and '15 day CSP, then 5 day RSP.'~Interventions include: Aspirin, Clopidogrel, Autologous Platelet Transfusion (cold-stored 15 days), Autologous Platelet Transfusion (room-temperature-stored 5 days)"
3481224|NCT03787875||Control|The control group included 10 periodontally healthy subjects without signs or symptoms of periodontal disease.
3481225|NCT03787875||Study|"The study group included 15 subjects diagnosed with mild or advanced chronic periodontitis. Each periodontal patient had one non-affected single-rooted tooth (healthy site) and another single-rooted tooth with periodontitis (periodontitis site) with the following features:~Healthy site: a single-rooted tooth with probing depths below or equal to 3 mm without recession and without bleeding on probing.~Periodontitis site: another single-rooted tooth from the same patient with clinical attachment loss equal to or greater than 6 mm and bleeding upon probing."
3481226|NCT03787602|Experimental|Experimental: Stage 1, Arm 1b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
3481227|NCT03787602|Experimental|Experimental: Stage 1, Arm 2b|KRT-232 180mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
3481228|NCT03787667||Patients with pathologically diagnosed colorectal cancer|Patients with pathologically diagnosed colorectal cancer
3481229|NCT03787563|Active Comparator|Active Herbal tea|One tea bag infusion three times a day each before breakfast, lunch and dinner.
3481230|NCT03787563|Placebo Comparator|Placebo Tea|Similar looking tea bag infusion three times a day each before breakfast, lunch and dinner.
3481231|NCT03787550||Model building group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to six blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
3481232|NCT03787550||Model validation group|The data from the patients in the model building group will be used to build the population PK/PD model. Two to three blood samples will be collected during at least one dose interval at the steady-state, including one sample from the start of ECMO and one at the end of ECMO.
3481233|NCT03787823|Other|Retzius-sparing RARP|Arm B randomizes men with an indication for radical robotic Prostatectomy (RARP) to retzius-sparing transdouglas RARP
3481234|NCT03787823|Other|anterior transperitoneal RARP|Arm A randomizes men with an indication for radical robotic Prostatectomy (RARP) to anterior transperitoneal RARP
3481235|NCT03787732|Active Comparator|Fluid Bolus|For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
3127509|NCT03096353|Experimental|Naloxone, then Placebo|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again."
3481236|NCT03787732|Active Comparator|No Fluid Bolus|For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
3481237|NCT03787771||FMT recipents|Subject who has received or planning to receive FMT or other gut-related microbiota products in routine clinical practice or research
3481238|NCT03787771||FMT donors|Subject who has donated stool or planning to donate stool for FMT or production of other gut-related microbiota products in routine clinical practice or research.
3481239|NCT03787589|Experimental|Exercise Intervention|Participants in this arm will receive standard of care along with the exercise prescription intervention
3481240|NCT03787589|No Intervention|Standard of Care|This group will receive standard of care treatment including regular verbal encouragement to exercise (monthly) by dialysis unit staff.
3481241|NCT03787654|Experimental|electroacupuncture group|Acupoints of bilateral Zhongliao (BL33), Huiyang (BL35) and Sanyinjiao (SP6) are stimulated by Huatuo Brand disposable needles and SDZ-V electronic apparatus.
3481242|NCT03787654|Sham Comparator|sham electroacupuncture group|Sham acupoints 1 cun(≈15mm) horizontally outwardly lateral to BL33 and BL35, and 0.5 cun(≈10mm) horizontally behind SP6 are stimulated superficially with a small electricity current by needles of 0.30×40mm size and SDZ-V electronic apparatus.
3481243|NCT03787654|Active Comparator|Solifenacin group|subjects will orally take Solifenacin 5-10mg per day.
3481244|NCT03787784|Experimental|AI visible group|
3481245|NCT03787784|No Intervention|AI invisible group|
3481246|NCT03787719|Experimental|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment (Monday and Friday or Tuesday and Saturday).
3481247|NCT03787719|No Intervention|Thrice per week dialysis|Standard thrice-weekly 4 hour dialysis treatment (Monday, Wednesday and Friday or Tuesday, Thursday and Staurday)
3481248|NCT03788135|Experimental|Quadriceps cooling|Participants in this group will receive a cold pack on anterior thigh muscles for 20 minutes.
3481249|NCT03788135|Experimental|Hamstring cooling|Participants in this group will receive a cold pack on posterior thigh muscles for 20 minutes.
3481250|NCT03788135|Experimental|Calf cooling|Participants in this group will receive a cold pack on posterior leg muscles for 20 minutes.
3481251|NCT03788135|Experimental|Back cooling|Participants in this group will receive a cold pack on posterior low back muscles for 20 minutes.
3481252|NCT03788135|No Intervention|Control|The participants in the control group will be rested for 20 minutes without any intervention.
3127510|NCT03096353|Experimental|Placebo, then Naloxone|"Day one - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of normal saline. When infusion levels reached stability, sensory testing was performed again.~Day two - During MRI session participant underwent sensory stimulus testing followed by bolus and infusion doses of naloxone (0.05 mg/kg bodyweight). When infusion levels reached stability, sensory testing was performed again."
3127511|NCT03096444|Experimental|Topical KeAmLi combo|Topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
3127512|NCT03096444|Experimental|Topical ketamine|Topical ketamine 10% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
3481253|NCT03787745|Active Comparator|Ischemic postconditioning|In addition to state of the art primary PCI in patients with TIMI0-1 ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed, however thrombectomy will not be allowed
3481254|NCT03787745|Placebo Comparator|Conventional|State of the art primary PCI in patients with TIMI0-1 will be performed, however thrombectomy will not be allowed
3481255|NCT03787680|Experimental|Cohort 1 (DRPro)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair proficient (DRPro).
3481256|NCT03787680|Experimental|Cohort 2 (DRDef)|Patients with metastatic castration-resistant prostate cancer (mCRPC) who are DNA repair deficient (DRDef).
3481257|NCT03787459|Active Comparator|oseltamivir plus placebo|
3481258|NCT03787459|Experimental|oseltamivir plus arbidol|
3481259|NCT03787394|Experimental|FAAA-enriched|food products enriched with FAAA-conjugates
3481260|NCT03787394|Placebo Comparator|Plain|Food products without FAAA-conjugates
3481261|NCT03787706|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
3481262|NCT03787706|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
3481263|NCT03787381|Other|Intervention|Uterine scar will be evaluated by vaginal ultrasound examination
3481264|NCT03787524||Dysphagia group|Acute stroke patients who will be diagnosed dysphagia according to VFSS results.
3481265|NCT03787524||No dysphagia group|Acute stroke patient who showed no dysphagia according to VFSS results.
3481266|NCT03787355|Experimental|Cone Morse Connection Implants|2 neighboring Morse connection Implants
3481267|NCT03787355|Active Comparator|platform matched implants|2 neighboring platform matched implants.
3481268|NCT03787641|Other|Protamine doze|Protamine Sulfate will be administered through an infusion pump in aliquots at a predefined rate (25 mg/min). Blood samples will be withdrawn after each aliquot and quantified for anti-Xa, IIa and ACT.
3481269|NCT03787173|No Intervention|Manual standard ventilator settings|Inspiratory trigger set at 2 l/min, Expiratory trigger set at 25% of peak inspiratory flow
3481270|NCT03787173|Active Comparator|Manual optimized ventilator settings|Inspiratory trigger and Expiratory trigger settings optimized by investigator
3481271|NCT03787173|Experimental|Automated ventilator settings|Inspiratory trigger and Expiratory trigger settings automatized
3481272|NCT03787498|Experimental|PLX2853|Approximately 30 subjects will be enrolled as part of dose escalation to identify the MTD/RP2D of PLX2853. Up to 6 additional subjects may be enrolled at the MTD/RP2D to further characterize the PK and PDy of PLX2853.
3481273|NCT03787238|Experimental|non-invasive Vagus Nerve Stimulation|nVNS (non-invasive vagus nerve stimulation) treatment with the gammaCore Sapphire device and standard of care
3481274|NCT03787238|No Intervention|Standard of Care|Standard of Care treatment
3481275|NCT03787290|Experimental|Tocilizumab|Participants will receive tocilizumab followed by whole-body hyperthermia
3481276|NCT03787290|Active Comparator|Placebo|Participants will receive a placebo followed by whole-body hyperthermia
3481277|NCT03787342|Experimental|"DFI Double Flap Incision"|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
3481278|NCT03787342|Experimental|"MPRI Modified PRI"|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
3481279|NCT03787342|Experimental|"CALF Coronally Advanced Lingual Flap"|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
3481280|NCT03787342|Active Comparator|"PRI Periosteal Releasing Incision"|A full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured as a whole unit.
3481281|NCT03787511|Other|Diabetic patients with chronic cough|Diabetic patients with chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
3481282|NCT03787511|Other|Diabetic patients without chronic cough|Diabetic patients without chronic cough defined by cough lasting for more than 8 weeks. Cough assessment, neurological tests and cardiovascular tests and skin biopsy.
3481283|NCT03787693|No Intervention|Stroke Symmetric Non-VR|In this control arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
3481284|NCT03787693|Experimental|Stroke Symmetric VR|In this experimental arm, stroke survivors who walk symmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
3481285|NCT03787693|No Intervention|Stroke Asymmetric Non-VR|In this control arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a non-virtual reality environment.
3481286|NCT03787693|Experimental|Stroke Asymmetric VR|In this experimental arm, stroke survivors who walk asymmetrically will walk on a split-belt treadmill in a VR - virtual reality environment.
3481287|NCT03787329||Bone marrow concentration group|The patients receive core decompression surgery with bone marrow concentration.
3481288|NCT03787329||Historical control group|The previous age-, gender-, and stage-matched patients who received core decompression surgery only.
3481289|NCT03787225|Experimental|NNC0174-0833 (0.3 mg)|Participants will receive single dose of NNC0174-0833
3481290|NCT03787225|Experimental|NNC0174-0833 (0.9 mg)|Participants will receive single dose of NNC0174-0833
3481291|NCT03787225|Experimental|NNC0174-0833 (1.8 mg)|Participants will receive single dose of NNC0174-0833
3481292|NCT03787225|Placebo Comparator|Placebo (NNC0174-0833)|Participants will receive placebo (NNC0174-0833)
3481293|NCT03787186|Experimental|GLPG1690 oral and IV|GLPG1690 film-coated tablets followed by [14C]-GLPG1690 solution for infusion
3481294|NCT03787186|Experimental|[14C]-GLPG1690 capsules|[14C]-GLPG1690 capsules
3481295|NCT03787251|Experimental|experimental group|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
3481296|NCT03787251|Active Comparator|Control group|"The chemotherapeutic drug chosen by the investigator (if not used in the previous treatment regimen, it cannot be selected).~The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient decease. If the adverse event grade 3 and above Or non-hematologic toxicity of grade II and above appeared, allowing the dose to be lowered twice."
3481297|NCT03787316|Experimental|Experimental group|4-weeks use of specially produced shock absorbing insoles and the daily home exercise program during this 4 weeks. Daily exercises include M. gastrocnemius, soleus, tibialis anterior, tibialis posterior stretching, strengthening of the anterior, lateral, posterior compartmental and foot intrinsic muscles of the foot, eccentric exercise of gastrocnemius and soleus.
3481298|NCT03787303|Experimental|Triiodothyronine (T3)|Following discontinuation of L-thyroxine (T4), triiodothyronine (T3) will be initiated at a 3:1 ratio. The dose will be titrated by the investigator to maintain levels of free T4 < 50% of normal range while maintaining a euthyroid state. Triiodothyronine (T3) tablets for oral administration will be prescribed once or twice daily depending on the total dose. Treatment duration will be approximately 9 months during which time the subjects will continue to be treated and monitored as usual for their metastatic breast cancer. During the study period and at the conclusion of the study period, there will be continuous evaluations of the disease status and thyroid status with the option of resuming the original thyroid replacement or continuation of the triiodothyronine (T3).
3481299|NCT03787407|Experimental|Mindfulness training with neurofeedback|mindfulness training with neurofeedback using mobile application instruction and review of the application will be provided
3481300|NCT03787407|Active Comparator|Mindfulness training|mindfulness training using mobile application instruction and review of the application will be provided
3127513|NCT03096444|Experimental|Topical amitriptyline|Topical amitriptyline 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
3127514|NCT03096444|Experimental|Topical lidocaine|Topical lidocaine 5% will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
3481301|NCT03787407|No Intervention|Self-care|
3481302|NCT03787420|Active Comparator|traditional communication system|
3481303|NCT03787420|Experimental|intelligent communication system|
3481304|NCT03787446||Multiple Sclerosis (MS) patients|3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
3481305|NCT03787446||Healthy Controls (HC)|3 Healthy volunteers aged between 18-60 years of age
3481306|NCT03787082|Experimental|Chlorhexidine Gluconate Mouthwash|rinse with chlorhexidine gluconate 0.12% (15mL) mouthwash before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
3481307|NCT03787082|Placebo Comparator|Placebo Mouthwash|rinse with placebo mouthwash (15mL) before administration of 14N Sodium Nitrate 1,000 mg/11.18 mmol, oral
3481308|NCT03787108||Children with suspected NAFLD|Children with overweight or obesity. Both children that are and children that are not suspected of having NAFLD (based on ultrasound and laboratory findings) are included.
3127515|NCT03096444|Placebo Comparator|Topical vehicle|Topical vehicle (PCCA Lipoderm) will be applied to one four 4 x 4 cm predefined skin areas on the ventral forearms during one of two study visits. The pre-treatment will occur under topical occlusion for 30 minutes to allow the ointment to be adsorbed. Following this, residual ointment will be removed and sensory testing, strictly within the pretreated area, will commence.
3127516|NCT03096483|Experimental|OEC Elite Imaging Arm|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system
3127517|NCT03096730|Placebo Comparator|Normal Saline|Normal saline is intravenously administrated before anesthesia induction and intraoperative pain management was with remifentanil
3127518|NCT03096730|Sham Comparator|Sufentanil|Normal saline is intravenously admistrated before anesthesia induction and intraoperative pain management was with sufentanil
3127519|NCT03096730|Active Comparator|Dexmedetomidine|Dexmedetomidine is intravenously administrated at a dose of 0.5ug/kg 10min before anesthesia induction and intraoperative pain management was with remifentanil
3127520|NCT03096730|Active Comparator|Nalmefene|Nalmefene is intravenously administrated at a dose of 0.2ug/kg before anesthesia induction and intraoperative pain management was with remifentanil
3127521|NCT03096730|Active Comparator|Dexmedetomidine-Nalmefene|A dose of 0.1ug/kg nalmefene and a dose of 0.25ug/kg dexmedetomidine for 10 minutes before anesthesia induction and intraoperative pain management was with remifentanil
3127522|NCT03096847|Experimental|ribociclib + letrozole cohort A|"ribociclib + letrozole cohort A - postmenopausal women, or men; naïve.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily."
3127523|NCT03096847|Experimental|ribociclib + letrozole cohort B1|"ribociclib + letrozole cohort B1 - premenopausal women or perimenopausal women; naïve~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
3481309|NCT03787134|Experimental|2016-0500-Healthy YoungAdults|working memory and attention
3481310|NCT03787264|Experimental|BAAG|"Debulking: 2 debulking cycles (q 28d) of bendamustine will be administered unless the patient has a contraindication or a debulking is not clinically indicated~Induction: 6 cycles (q 28d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance: max. 8 cycles (q 84d) of Obinutuzumab + Acalabrutinib + Venetoclax~Maintenance treatment will be continued until (whichever occurs first):~12 weeks (approx. 3 months) after confirmation of achievement of a CR/CRi and MRD negativity~maintenance cycle 8~progression of CLL or start of a subsequent therapy~unacceptable toxicity"
3481311|NCT03787160|Active Comparator|CDH Group|10 patients after surgical closure of CDH will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity). Thereafter patients will receive probiotic treatment with OmniBiotic6 (R) (Allergosan, Graz, Austria) 1 sachet daily for 3 months (probiotic treatment). Three months after discontinuing probiotic treatment VOC testing (VOC probiotics), fecal microbiome sampling (fecal microbiome probiotics) and deep induced sputum testing (pulmonary microbiome probiotics) will be repeated and compared to the results of the initial tests.
3481312|NCT03787160|Other|Control Group|10 healthy controls (age and sex matched) will undergo VOC profile analysis (2 breath samples) (initial VOC), fecal sampling for 16S rDNA based pyrosequencing (initial fecal microbiome) and deep induced sputum sampling for 16S rDNA pyrosequencing (initial pulmonary microbiome), bicycle spiroergometry to determine the maximum oxygen uptake (maximum oxygen uptake), body plethysmography, spirometry and N2-multiple breath washout testing to determine the functional residual capacity (functional residual capacity).
3481313|NCT03787485||LINKS Participants|Study participants who took part in the LINKS intervention.
3481314|NCT03787485||Electronic Medical Record Controls|The principal analytical strategy is propensity score matching, which will lead to the generation of a natural control group from the health centers existing electronic medical records. Propensity matching is highly effective in addressing selection bias of known confounders and enables causal inferences when randomization is not possible, feasible or appropriate, by creating matched groups with similar covariate distributions. Matched controls will be extracted from the electronic medical record from the participating clinics.
3481315|NCT03787199|Experimental|Andago|Application of walking over-ground with body-weight support in the Andago
3481316|NCT03787199|Active Comparator|Treadmill|Application of walking on a treadmill with body-weight support
3481317|NCT03786939|Other|On-pump CABG.|On-pump CABG.
3481318|NCT03786939|Other|Off-pump CABG.|Off-pump CABG.
3481319|NCT03786939|Other|Pump-assisted CABG.|Pump-assisted CABG.
3481320|NCT03787433||ARC - Assisted Rehabilitation Care|All study participants will be asked to use ARC during for their post-stroke home based rehabilitation for up to 6 months.
3127524|NCT03096847|Experimental|ribociclib + letrozole cohort B2|"ribociclib + letrozole cohort B2 - premenopausal women or perimenopausal women or postmenopausal women, or men; pre-treated.~All patients received ribociclib 600mg p.o. daily + Letrozole 2.5 mg p.o. daily.~Premenopausal patients additionally received goserelin 3.6 mg i.m. monthly"
3127525|NCT03096873|No Intervention|No Exercise (CON)|Twenty obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake: 1921.7 kcal/day
3481321|NCT03787056|Other|Cancer patients|420 patients affected by different types of cancer and treated in a curative or a palliative intent. In total 17 cohorts will be open, including: breast cancer, head and neck carcinomas, renal cell carcinoma, prostate carcinoma, lung carcinoma, hepatocellular carcinoma, colorectal carcinoma, thyroid cancer, pancreatic adenocarcinoma, ovarian adenocarcinoma, glioblastoma, endometrial adenocarcinoma, bladder carcinoma, oesophago-gastric carcinoma, B-cell lymphoma, gastric carcinomas. Patients enrolled in curative intent treatment cohorts will never have been previously treated for their cancer. Patients enrolled in non-curative intent treatment cohorts will have never been treated for their metastatic cancers previously, or have developed advanced/metastatic diseases as relapses of localized cancers previously treated with curative intent therapeutic strategies. Other cohort will be open (stability cohorts) : nychtemer cohort and post-operative kinetic cohort.
3481322|NCT03787147|Other|Spinal Injection|Adults receiving Spinal Injection(SI) without Virtual Reality(VR).
3481323|NCT03787147|Active Comparator|Google Cardboard|Adults receiving SI while using Google Cardboard Virtual reality head mounted display powered by a iPod touch
3481324|NCT03787147|Active Comparator|Oculus|Adults receiving SI while using VR with Oculus Rift.
3481325|NCT03786861|Active Comparator|42 eyes in aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free in aberration free group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
3127526|NCT03096873|Experimental|Exercise (EX)|Twenty obese adolescent girls. This arm performed combined exercise training 5 times a week for 12 weeks. Caloric intake: 1921.7 kcal/day
3481326|NCT03786861|Active Comparator|24 eyes in corneal WFG group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing corneal WFG patterns in corneal WFG group provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
3127527|NCT03097029|Experimental|Pancreatic Enzymes|All subjects in this study will have exposure to therapy with pancreatic enzymes for a period of about ten days.
3127528|NCT03097133|Experimental|Esketamine + Standard of care|Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
3127529|NCT03097133|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
3481327|NCT03786887|Experimental|Nalbuphine|
3481328|NCT03786978|Experimental|Structured pharmaceutical care|Patients receive a structured pharmaceutical care until one year after hospital discharge
3481329|NCT03786978|Active Comparator|Comparator group|Patient received a single phone call 30 days after basal hospital discharge.
3481330|NCT03786848|Experimental|MiniPDX Group|Patients medication plan based on MiniPDX drug sensitivity test.
3127530|NCT03097289|Experimental|Platelets stored in InterSol|Platelets collected on the Trima Accel system and stored in 65% InterSol/35% plasma
3127531|NCT03097315|Experimental|4 mg CLS-TA Suprachoriodal Injection|Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA
3127532|NCT03097341|Experimental|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
3481331|NCT03786796|Experimental|Olaparib|Participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L that have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF therapy with measureable disease on CT imaging according to RECIST 1.1 criteria. Participants will be initially treated with olaparib 150mg by mouth twice daily for one month. After one month of therapy, the dose will be increased to 300mg by mouth twice daily provided there are no grade 3 or greater adverse events experienced. Reassessment will occur at least monthly for toxicity. Radiological scans will be performed every 3 months to assess disease response. Treatment will be continued until clinical and/or radiographic progression according to RECIST 1.1 criteria or unmanageable toxicity requiring cessation.
3127533|NCT03097341|Experimental|xisomab 3G3- Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
3481332|NCT03787043|Experimental|Sequence Group A|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fed"
3481333|NCT03787043|Experimental|Sequence Group B|"1st period: FDC(MP-513 10mg/Metformin XR 750mg) under fed~2nd period: FDC(MP-513 10mg/Metformin XR 750mg) under fasted"
3481334|NCT03787017|Experimental|Sequence Group A|"1st period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted~2nd period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted"
3481335|NCT03787017|Experimental|Sequence Group B|"1st period : 1 tablet of FDC(MP-513 20mg/Metformin XR 1000mg), single-dose under fasted~2nd period : coadministration of 1 tablet of MP-513 20mg and 1 tablet of Metformin XR 1000mg, single-dose under fasted"
3127534|NCT03097341|Experimental|xisomab 3G3- Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
3481336|NCT03787004|Experimental|Part 1 Cohort 1 (Single Dose)|Single 100 mg oral dose of CNTX-6970 (film-coated tablet or enteric-coated tablet)
3481337|NCT03787004|Experimental|Part 1 Cohort 2 (Single Dose)|Single 100 mg oral dose of CNTX-6970 film-coated tablet
3481338|NCT03787004|Experimental|Part 2 (Multiple Ascending Dose)|100 mg, 300 mg, and 600 mg CNTX-6970 oral tablet
3481339|NCT03787004|Placebo Comparator|Part 2 Placebo|Placebo oral tablet
3481340|NCT03786913||children with muscle disease|fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.
3127535|NCT03097341|Experimental|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
3481341|NCT03786913||control group|20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline
3481342|NCT03786770|Experimental|Cohort 1: Dose A|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
3127536|NCT03097341|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
3127537|NCT03097484|Experimental|Standard therapy plus Aromatherapy|These infants will receive aromatherapy, consisting of Lavender and Chamomile essential oils, in addition to standard care, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
3481343|NCT03786770|Experimental|Cohort 2: Dose B|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
3481344|NCT03786770|Experimental|Cohort 3: Dose C|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
3481345|NCT03786770|Experimental|Cohort 4: Dose D|Subjects will receive DaxibotulinumtoxinA for injection for the treatment of Forehead Lines (FHL) and Glabellar Lines (GL).
3481346|NCT03786809|Experimental|Experimental|Women will use Cimifuga Racemosa for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
3481347|NCT03786809|Placebo Comparator|Placebo|Women will use Placebo for 28 days and will be submitted to measurement of the diameter of the brachial artery before and after treatment
3481348|NCT03786822|Experimental|Non-fluoroscopic Cryoballoon PVI|"Observation of pressure waveform change at the tip of the cryoballoon catheter from left atrial pressure to pulmonary vein pressure waveform.~Intracardiac echocardiography (ICE) imaging with no Doppler color evidence of peri-balloon high velocity leaks.~Intracardiac echo imaging showing no evidence of leak during agitated saline contrast injection into cryoballoon catheter positioned at pulmonary vein ostium."
3481349|NCT03786822|Active Comparator|Fluoroscopic Cryoballoon PVI|Standard cryoballoon PVI using radio opaque contrast pulmonary vein angiography
3481350|NCT03786757|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy.
3481351|NCT03786757|No Intervention|dual antiplatelet therapy (DAPT)|Conventional dual antiplatelet therapy will be adopted.
3481352|NCT03787030|Experimental|Vitamin E acetate|Commercially available plastic tubes containing vitamin E acetate ointment (Filme Olio, Hulka SRL, Italy) were purchased from pharmacies. The dosage for all the patients was 1ml of ointment (containing 1100% vitamin E), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
3127538|NCT03097484|No Intervention|Standard therapy ALONE|These infants receive standard care ONLY, which includes morphine replacement therapy, infant massage, PT, OT, and music therapy.
3127539|NCT03097588|Experimental|Supportive care (NEPA)|"Within 60 minutes before standard of care BEAM treatment, patients receive netupitant and palonosetron hydrochloride PO on days 1, 3, and 6.~Netupitant: 300 mg, QD, Given PO Palonosetron Hydrochloride: 0.5 mg, QD, Given PO Questionnaire Administration: Ancillary studies"
3481353|NCT03787030|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
3481354|NCT03786835|No Intervention|Control (No intervention)|Participants will not undergo any treatment. Continue with usual daily activities and diet for 6 months.
3481355|NCT03786835|Experimental|Nutrition group|Participants will receive protein enriched food to supplement the diet for 6 months.
3481356|NCT03786835|Experimental|Exercise group|Participants will exercise 3 times a week for 60 minutes each time over 6 months.
3127540|NCT03097614|Experimental|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
3127541|NCT03097653|Experimental|Decision-aid|
3127542|NCT03097653|Active Comparator|Standard information|
3127543|NCT03097783|Experimental|Restylane Perlane Lidocaine|Single injection and optional touch up injection with Restylane Perlane Lidocaine in Midface
3127544|NCT03097783|No Intervention|No intervention arm|No treatment
3127545|NCT03097861|Active Comparator|Lubiprostone Capsule|Lubiprostone 24 mcg capsule twice daily (BID) for 7 days.
3127546|NCT03097861|Experimental|Lubiprostone Sprinkle|Lubiprostone 24 mcg sprinkle BID for 7 days.
3127547|NCT03097861|Placebo Comparator|Placebo|Placebo matching to lubiprostone (sprinkle/capsule) BID for 7 days.
3127548|NCT03098030|Experimental|Part 1: Dinutuximab + Irinotecan|Dinutuximab (10 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of every 21 days (q21d). Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
3127549|NCT03098030|Active Comparator|Part 2: Irinotecan|Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle.
3127550|NCT03098030|Experimental|Part 2: Dinutuximab + Irinotecan|Dinutuximab (16 mg/m^2 IV) + Irinotecan (350 mg/m^2 IV) on Day 1 of each q21d cycle. Dinutuximab dose will be escalated in 2 mg/m^2 increments per cycle if maximal pain is <Grade 2 (and without opioids) and otherwise tolerated, up to a maximum dose of 17.5 mg/m^2 IV.
3127551|NCT03098030|Active Comparator|Part 2: Topotecan|Topotecan (1.5 mg/m^2 IV) on Days 1 to 5 of each q21d cycle.
3127552|NCT03098173|Experimental|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
3127553|NCT03098173|Active Comparator|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
3127554|NCT03098420|Placebo Comparator|Control Group|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.
3127555|NCT03098420|Active Comparator|2mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.
3127556|NCT03098420|Active Comparator|4mg Dexamethasone|20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.
3127557|NCT03098433|Experimental|Liothyronine|Each participant will receive a single dose of lithyronine
3127558|NCT03098433|Active Comparator|Levothyroxine|Each participant will receive a single dose of levothyroxine
3481357|NCT03786835|Experimental|Nutrition + Exercise group|Participants will receive protein enriched food to supplement the diet and exercise 3 times a week for 60 minutes each time over 6 months.
3481358|NCT03786601||Group A,|High-risk HPV infection in postmenopausal women
3481359|NCT03786601||Group B|High-risk HPV negative in postmenopausal women
3481360|NCT03786601||Group C|High-risk HPV infection in gestational women
3127559|NCT03098433|Placebo Comparator|Placebo|Each participant will receive a single dose of placebo
3127560|NCT03098550|Experimental|Immunotherapy Combination|TNBC and PAC participants who are deriving clinical benefit will continue to be treated with the nivolumab plus daratumumab combination therapy
3127561|NCT03098550|Experimental|Nivolumab Monotherapy|NSCLC patients who are deriving clinical benefit will be treated with nivolumab monotherapy
3127562|NCT03098615|Other|Jublia (Efinaconazole 10% Topical Solution) + nail polish|Subjects with distal lateral subungual onychomycosis (DLSO) with dermatophytoma.
3127563|NCT03098745|Active Comparator|Omafilcon A|Participants are randomized to wear omafilcon A lens pair bilaterally for 1 hour during the study.
3127564|NCT03098745|Active Comparator|Somofilcon A|Participants are randomized to wear somofilcon A lens pair bilaterally for 1 hour during the study.
3127565|NCT03098745|Active Comparator|Omafilcon A - Proclear (PC)|Participants are randomized to wear omafilcon A - PC lens pair bilaterally for 1 hour during the study.
3127566|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (5 mg)|Chronic heart failure with preserved ejection fraction
3127567|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (10 mg)|Chronic heart failure with preserved ejection fraction
3127568|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (20 mg)|Chronic heart failure with preserved ejection fraction
3127569|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (30 mg)|Chronic heart failure with preserved ejection fraction
3127570|NCT03098979|Experimental|Neladenoson bialanate (BAY1067197) (40 mg)|Chronic heart failure with preserved ejection fraction
3127571|NCT03098979|Placebo Comparator|Placebo|Chronic heart failure with preserved ejection fraction
3127572|NCT03099096|Experimental|Mepolizumab SC 100 mg/milliliter (mL) in autoinjector|Three doses of mepolizumab liquid drug product in autoinjector will be self-administered by the subject/caregiver at 4-weekly intervals; 2 doses will be administered under observation in the clinic (at Week 0 and 8). One dose will be administered outside the clinic and without observation (within 24 hours after attending the clinic at Week 4).
3127573|NCT03099161|Experimental|Preladenant 25 mg Twice a Day (BID)|During an initial dose evaluation phase, participants received 25 mg of preladenant orally twice a day (BID) on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was to be established based on the number of dose limiting toxicities (DLTs) at each dose level administered. Participants continued receiving 25 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
3127574|NCT03099161|Experimental|Preladenant 50 mg BID|During an initial dose evaluation phase, participants received 50 mg of preladenant orally BID on Days 1 through 21 of each 21-day cycle (for a maximum of 35 cycles) until the RP2D could be established. The RP2D was established based on the number of DLTs at each dose level administered. Participants continued receiving 50 mg of preladenant BID on Days 1 through 21 of each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
3127575|NCT03099161|Experimental|Preladenant + Pembrolizumab|During an initial dose evaluation phase, participants received 25 mg of preladenant administered orally BID on Days 1 through 21 in combination with 200 mg pembrolizumab administered as an intravenous (IV) infusion on Day 1 of each 21-day cycle (for a maximum of 35 cycles). Participants continued receiving preladenant 25 mg BID in combination with 200 mg pembrolizumab for each infusion cycle until discontinuation or receiving a maximum of 35 cycles.
3127576|NCT03099187|Experimental|Pirfenidone|Participants will receive pirfenidone 267 mg capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
3481361|NCT03786601||Group D|High-risk HPV negative in gestational women
3481362|NCT03787069|Experimental|Lignocaine group|This group will be given 1.5 mg/kg I/V lignocaine before intubation
3481363|NCT03787069|Placebo Comparator|Placebo|This group will be given 6 ml normal saline before intubation
3481364|NCT03786679|Active Comparator|Orthosis group|An orthosis with the broken arm in neutral position fixed for four weeks. After these four weeks the patient is instructed to start rehabilitation.
3481365|NCT03786679|Active Comparator|Early rehabilitation group|The patient is instructed to start early rehabilitation about one week after the trauma.
3481366|NCT03786731|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
3481367|NCT03786731|No Intervention|CAU group|Care-As-Usual group
3481368|NCT03786705||Trauma patients' SBP ≥ 90 mm Hg with EMS|Only patients who were transferred by emergency medical service from the accident site with a systolic blood pressure ≥ 90 mm Hg at the ER were included in this study. The enrolled trauma patients divided into 2 groups, those who had received blood transfusion ≥ 10 U (massive transfusion) and those who had not (non-massive transfusion).
3481369|NCT03786874|Active Comparator|20 teams the first year (G1)|control group
3481370|NCT03786874|Experimental|20 teams second year (G2)|case group with implementation of the multi-unit team accompaniment intervention.
3481371|NCT03786523|Experimental|TRF|Time Restricted Feeding
3481372|NCT03786523|Active Comparator|CER|Continuous Energy Restriction
3481373|NCT03786588||Group A|Vaginal microbiota in gestation CPP women without HPV infection
3481374|NCT03786588||GroupB|Vaginal microbiota in gestation women without CPP and HPV infection
3481375|NCT03786510|Active Comparator|Active control|The control group received Community Center for Dementia's usual care of regular health check-up.
3481376|NCT03786510|Experimental|Intensive + Maintenance program|The INT+MNT group participated in a 4-week intensive program followed by a 20-week maintenance program
3481377|NCT03786510|Experimental|Intensive program only|The INT only group participated in a 4-week intensive program
3481378|NCT03786562|Placebo Comparator|Placebo group|
3481379|NCT03786562|Active Comparator|Nalbuphine group|
3481380|NCT03786614|Active Comparator|Discontinuation arm|This group will be discontinued from serotonergic antidepressants and shifting them to other categories of antidepressants, i.e., medications that work through dopamine or nor-epinephrine, or by reducing the serotonin signal rather than increasing synaptic serotonin, as might be accomplished with low dose, sub-anti-psychotic doses of some second-generation anti-psychotics.
3481381|NCT03786614|Active Comparator|Continuation arm|This group will continue taking serotonergic antidepressants which is the standard care of treatment.
3481382|NCT03786575|Experimental|NGS detection group|Before treatment, the patients in the study group underwent NGS detection of ctDNA and formulated endocrine treatment plan according to the test results. After 2 months of endocrine therapy, all patients underwent NGS detection of ctDNA, and the efficacy was evaluated according to RECIST v1.1 standard.
3127577|NCT03099187|Experimental|Placebo|Participants will receive matching placebo capsule three times a day from Day 1 to 7 followed by 2 capsules three times a day from Day 8 to 14 then 3 capsules three times a day from Day 15 up to Week 24.
3127578|NCT03099369|Experimental|Daily Step-based Exercise Group|"The experimental group will receive the following 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day (based on evidence that at least 5,000 a day is associated with better health). The Fitbit Fitness Monitor used for tracking.~Week 1: walk at least 3,000 steps every day.~Week 2: walk at least 3,500 steps every day.~Week 3: walk at least 4,000 steps every day.~Week 4: walk at least 4,500 steps every day.~Weeks 5-12: walk at least 5,000 steps every day."
3481383|NCT03786549|No Intervention|Control|Patients included in this arm wil have usual follow-up.
3481384|NCT03786549|Experimental|Care transitional program|"Patients included in this arm will get a care transitional program. Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
3481385|NCT03786536|Experimental|Treatment|All volunteers will receive the same treatment
3481386|NCT03786315||Usual care|Older patients with multimorbidity and the GPs with whom they consult, from across five GP practices in Devon
3481387|NCT03786328|Other|Clinical cases of Mental Disorder|The group of individuals identified with a clinical mental disorder on the basis of the diagnostic interviews This group will be assigned to Standard Psychiatric Treatment
3481388|NCT03786328|Other|Subclinical cases of Mental Disorder|The group of individuals identified with a sub-clinical mental condition on the basis of the diagnostic interviews This group will be assigned to Preventive Psychological Treatment
3481389|NCT03786289|Experimental|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection
3481390|NCT03786289|Active Comparator|Recombinant human erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection
3481391|NCT03786484|Experimental|PBF-999 20 mg|
3481392|NCT03786484|Experimental|PBF-999 40 mg|
3481393|NCT03786484|Experimental|PBF-999 80 mg|
3481394|NCT03786484|Experimental|PBF-999 120 mg|
3481395|NCT03786484|Experimental|recommended phase 2 dose (RP2D)|
3481396|NCT03786276|Experimental|Exercise-Only|Exercise-Only condition, 12 exercise sessions on a stationary recumbent bicycle over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
3481397|NCT03786276|Experimental|VR-WMR-Only|Virtual Reality Working Memory Retraining-Only condition, 12 working memory retraining sessions over 4 weeks. After 4 weeks, the participants will have a 1-week washout followed by Active VR-WMR arm.
3481398|NCT03786276|Experimental|Active VR-WMR|After 4 weeks in one of the first two arms, the participants will have a 1-week washout followed by the Active VR-WMR arm. Participants will complete 12 Active VR-WMR sessions on a stationary recumbent bicycle over 4 weeks.
3481399|NCT03786367||CTEPH|Clinically stable patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) recruited from the Pulmonary Hypertension outpatient clinics at Hotel Dieu Hospital, Kingston, Ontario.
3481400|NCT03786367||Control|Age and sex-matched healthy control data collected as part of previous studies will be used as historic controls for this study.
3481401|NCT03786432|Experimental|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
3481402|NCT03786419|Experimental|Atezolizumab|Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
3481403|NCT03786263||Prospective Treatments for NS|"Observation of children (between the ages of 1 and 17) who are diagnosed with Nephrotic Syndrome at their initial presentation, first or second relapse.~Observation of children who receive Glucocorticoids to treat Nephrotic Syndrome.~Observation of children who receive other drugs (Second Line Agents) for Nephrotic Syndrome."
3481404|NCT03786471|Active Comparator|Health Systems-Based Dementia Care|Dementia care that is based in the health care system, which partners with community-based organizations to provide comprehensive, coordinated, patient-centered care. The health system-based dementia care arm uses a Dementia Care Specialist (Nurse Practitioner or Physician Assistant) supervised by a physician to tailor and facilitate dementia care delivery in collaboration with the primary care physician (co-management). The Health Systems-Based Dementia Care arm is based on UCLA's Alzheimer's and Dementia Care Program.
3481405|NCT03786471|Active Comparator|Community-Based Dementia Care|Dementia care that is based in community organizations, which gives equal attention to patients and their primary family or friend caregivers. The community-based dementia care arm uses Care Consultants (Social Workers or Nurses). Patients with dementia are engaged in the program whenever possible. Caregivers can be the sole program participant, when patients are too impaired. The program establishes a long-term relationship between Care Consultants and families. The exact content of assistance provided is tailored to the preferences of individual patients and caregivers, and is holistic in the range of potential concerns of problems addressed. The Community-Based Dementia Care arm is based on the Benjamin Rose Institute on Aging's Care Consultation Program.
3481406|NCT03786471|Other|Enhanced Usual Care|Dementia care that most closely corresponds to traditional care. This arm will also receive standardized educational materials (hard copies and internet-based resources), referral to the Alzheimer's Association 1-800 national helpline to speak to a master's level consultant for decision-making support, crisis assistance, and caregiver education, as well as referral to local programs and services.
3481407|NCT03786224|Experimental|Abstinent|
3481408|NCT03786341|Experimental|with auxiliary illuminator|the walking training was by conventional strategy with lase quad-cane.
3481409|NCT03786341|Placebo Comparator|control group|Ambulation training WITHOUT laser quad-cane.
3481410|NCT03786354|Experimental|Arm A (IMRT)|Patients undergo Intensity-Modulated Radiation Therapy over 5 weeks.
3481411|NCT03786354|Experimental|Arm B (3DCRT)|Patients undergo 3-Dimensional Conformal Radiation Therapy over 5 weeks.
3481412|NCT03786172|Experimental|Smoking cessation Intervention|Standardised counseling session + motivational gadget + Nicotine replacement therapy (NRT)
3481413|NCT03786172|Active Comparator|Usual care|A 10-second brief advice to quit smoking
3481414|NCT03786458|Experimental|Cancer and Fertility Decision making|Cancer and Fertility Decision aid
3481415|NCT03786302|Experimental|TAMP bioglass|Tailored amorphous multiporous bioglass (TAMP-BG) of 70% SiO2 / 30% CaO was prepared according to Wang et al. (2011, 2013) in the tissue engineering lab, Faculty of Dentistry, Alexandria University as follows: Scaffolds were grounded to 180- to 300-μm particle size and sterilized at 180°C for 2 hours. The resulting powder was mixed with distilled water to obtain a putty like consistency that was carried to the pulp chamber and condensed lightly on the pulp stumps.
3481416|NCT03786302|Active Comparator|Biodentine ™|Biodentine ™ (BD) pre-dosed capsule were gently tapped on a hard surface to diffuse the powder. Five drops of the liquid from the single dose dispenser were poured into the capsule and mixed for 30 seconds at 4,200 rpm in an amalgamator according to manufacturer's instructions to obtain putty- like consistency. (Powder-liquid system). It was then be carried to the pulp chamber and condensed lightly on the pulp stumps. Final restoration was applied after 12 minutes, allowing Biodentine ™ to set.
3481417|NCT03786211|Active Comparator|IANB without panoramic|They will get Ianb without using panoramic
3481418|NCT03786211|Experimental|IANB with panoramic|They will get IANB by the guide of panoramic
3481419|NCT03786393||Fibromyalgia|100 participants diagnosed with fibromyalgia according to ACR 1990 criteria.
3481420|NCT03786393||Control|
3481421|NCT03786133||type 2 diabetics|Analysis of microbiological tests in chronic periodontitis patients with type 2 diabetes mellitus
3481422|NCT03786133||non-diabetics|Analysis of microbiological tests in chronic periodontitis patients without type 2 diabetes mellitus
3481423|NCT03786120||1|First 25 subjects
3481424|NCT03786120||2|Second cohort of 25 subjects
3127579|NCT03099369|Active Comparator|Symptom-based Exercise Group|"The active comparator group (ie. control group) will receive the following 12-week symptom-based exercise prescription (adapted from practice guidelines).~Walk on a flat surface at a constant speed until there is mild to moderate pain~Rest until the pain has completely ceased~Resume walking at the same speed~Increase the speed when you can walk 8 minutes without stopping for leg symptoms~Continue this exercise routine for 45 consecutive minutes, 3 to 5 days a week."
3127580|NCT03099538|Experimental|Ixekizumab|Ixekizumab subcutaneous 160mg week 0, 80mg weeks 2, 4, 6, 8, 10, 12.
3127581|NCT03099655|Experimental|Attain Stability Quad Lead|Attain Stability Quad Lead (Model 4798) - Single arm study.
3127582|NCT03099694|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) - as a primary mode of ventilation in premature infants with RDS
3481425|NCT03786094|Active Comparator|Eribulin|
3481426|NCT03786094|Experimental|Balixafortide + eribulin|
3481427|NCT03786081|Experimental|A: Tisotumab Vedotin + bevacizumab|Dose escalation: Tisotumab vedotin in combination with bevacizumab once every three weeks in previously treated patients
3481428|NCT03786081|Experimental|B: Tisotumab vedotin + pembrolizumab|Dose escalation: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
3481429|NCT03786081|Experimental|C: Tisotumab vedotin + carboplatin|Dose escalation: Tisotumab vedotin in combination with carboplatin once every three weeks in previously treated patients
3481430|NCT03786081|Experimental|D: Tisotumab vedotin + carboplatin|Dose expansion:Tisotumab vedotin in combination with carboplatin once every three weeks in previously untreated patients
3481431|NCT03786081|Experimental|E: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously untreated patients
3481432|NCT03786081|Experimental|F: Tisotumab vedotin + pembrolizumab|Dose expansion: Tisotumab vedotin in combination with pembrolizumab once every three weeks in previously treated patients
3481433|NCT03786081|Experimental|G: Tisotumab vedotin monotherapy|Dose expansion: Tisotumab vedotin monotherapy weekly for three weeks and 1 week off (28 day treatment cycle) in previously treated patients.
3481434|NCT03785951|Experimental|Whey Protein Isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
3481435|NCT03785951|Experimental|Wheat Protein|Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
3481436|NCT03785951|Experimental|Wheat protein with leucine|Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
3481437|NCT03786003|Experimental|VATS|Video-assisted thoracoscopic surgery
3481438|NCT03786003|Active Comparator|Thoracotomy|Open surgery
3481439|NCT03786406||T2DM patients seen in routine practice|All anti-diabetic and cardiovascular (CV) medication will be prescribed at the physician's discretion under routine clinical practice conditions.
3481440|NCT03785873|Experimental|Nal-Irinotecan and Nivolumab|
3481441|NCT03786185|Experimental|Adolescents with dyslexia|MusicPlast training
3481442|NCT03786185|Active Comparator|Adolescents without dyslexia|MusicPlast training
3481443|NCT03786185|Experimental|Young Adults|MusicPlast training
3481444|NCT03786185|Active Comparator|Young Adults Control|MusicPlast Control, in a similar design as MusicPlast
3481445|NCT03786185|Experimental|Seniors|MusicPlast training
3481446|NCT03786198|Experimental|a) Home-based walking intervention|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy
3481447|NCT03786198|Active Comparator|b) Physical activity according to standard recommendations|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
3481448|NCT03786237|Experimental|Treatment Oral Capsules / Intravenous|
3481449|NCT03785938|Experimental|Probiotic|"Participants will start the course of liquid probiotic on the first day of their course of chemotherapy. This can be taken orally, or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day"
3481450|NCT03785938|Placebo Comparator|Placebo|"Participants will start the course placebo on the first day of their course of chemotherapy. This can be taken orally or using an nasogastric or gastrostomy tube and will continue this for 14 days. Doses will be adjusted according to the age of the participant as follows:~1-4 years:20ml once a day 4-11 years: 0.5ml/kg once a day 12-18 years: 1ml/kg once a day~Placebo will be delivered in similar, packaging, appearance and taste."
3481451|NCT03786055|Experimental|Somatic Yoga and Meditation (SYM)|Participants will engage in 16 sessions of somatic yoga and meditation with appropriate props as needed over 8 weeks and continue with a home practice. Application of SYM throughout activities of daily living is reinforced. All sessions are facilitated by trained yoga therapists.
3481452|NCT03785795||Uncertain diagnosis of true labor|Patients who cannot be accurately classified as experiencing true labor or false labor based on standard clinical assessments.
3481453|NCT03785704|Experimental|Xinmailong injection group|given 5 mg/kg of Xinmailong injection every cycle on d0, d1, d2, d3, d4 on the same chemotherapy regimen (EC-T) as those in the control group.
3481454|NCT03785704|No Intervention|control group|receive conventional EC-T regimen chemotherapy (Epirubicin 45mg/m2 d1, 2 + cyclophosphamide 600mg/ m2 d1, repeated every 14 or 21 days for 4 cycles, followed by paclitaxel 175 mg/m2 (or docetaxel 75 mg/m2) on day 1, repeated every 21 days for 4 cycles).
3481455|NCT03785886|Experimental|Walking group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
3481456|NCT03785886|Experimental|Chinese Square Dancing group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
3481457|NCT03785886|Experimental|Control group|"The study is a randomized 3-month community-based exercise intervention with a control group and 2 different exercise groups: walking group and Chinese square dancing group.~Eighteen communities will be selected in Beijing, and they will be age matched and randomly grouped into walking, Chinese square dancing and control groups. Each community will include twenty subjects (ten patients with hypertension and ten patients with hypertension complicated with type 2 diabetes) aged 40-69 years."
3481458|NCT03786029|Experimental|A (Acetaminophen)|22 children will receive 320mg (10ml) 30 minutes before the local anesthesia injection.
3481459|NCT03786029|Placebo Comparator|B (Placebo)|22 children will receive 10ml 30 minutes before the local anesthesia injection.
3481460|NCT03786029|Experimental|C (Ibuprofen)|22 children will receive 200mg (10ml) 30 minutes before the local anesthesia injection.
3481461|NCT03785782||Women scheduled for biopsy|40 participants with diagnosed BIRADS-4a, 4b, 4c, or -5 masses will be recruited. The investigators aim to have approximately 10 in each of the BIRADS categories (4a, 4b, 4c, 5), resulting in 40 total subjects for Aim #1.
3481462|NCT03785782||Women scheduled for neoadjuvant chemo|40 participants with malignant masses undergoing neoadjuvant chemotherapy (NAC) will be recruited.
3481463|NCT03785769|Active Comparator|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by HVGIC restoration.
3481464|NCT03785769|Experimental|HVGIC restoration with non pre-etching|HVGIC restoration without the pre-etching of the surface.
3481465|NCT03785990||preterms with enterostomy|GA 23±0/7 - 31±6/7 with clinically indicated operations because of NEC (necrotising enterocolitis) or FIP (focal intestinal perforation). Operation after birth (within 14 days) and at term (enterostomy closure) Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)
3481466|NCT03785990||preterms without enterostomy|"GA 23±0/7 bis 31±6/7 with a clinically indicated operation (e.g. herniotomy) at term, without any abdominal problems.~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
3481467|NCT03785990||term infants|"GA ≥34±0/7 with a clinically indicated operation directly after birth (within 14 days) (e.g. gastroschisis).~Analysis of the blood, subcutaneous adipose tissue und total adipose tissue (PEAPOD)"
3481468|NCT03786016|Experimental|8-Days in an Isolation, Confinement Unit|Subjects will spend 7-night/8-day in an isolated and confined unit with up to 3 other subjects.
3481469|NCT03785717|Active Comparator|ROG only|cancellous (1-2 mm) & cortical (250-1000 mm) bone allograft and pericardium membrane without extracorporeal shockwave therapy
3481470|NCT03785717|Active Comparator|ROG & ESWT|cancellous 1-2mm & cortical 250-1000mm Bonegrafts and membrane with extracorporeal shockwave therapy
3481471|NCT03785899|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
3481472|NCT03785899|Experimental|SPOCnew and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
3481473|NCT03785899|Experimental|SPOCnew and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with new algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
3481474|NCT03785899|Active Comparator|SPOCold and 2s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 2s."
3481475|NCT03785899|Active Comparator|SPOCold and 8s SpO2 averaging|"routine manual control (RMC) + automatic oxygen control (SPOC) with old algorithm of the fraction of inspired oxygen (FIO2).~The SpO2 signal averaging time is 8s."
3481476|NCT03785821|Experimental|BMSO|Bitter melon seed oil supplementation
3481477|NCT03785821|Placebo Comparator|OO|Olive oil supplementation
3481478|NCT03785808|Experimental|Diet A (low carbohydrate)|Dietary Intervention A will be a low-carbohydrate/high fat, ketogenic-type diet. The diet will include salads, leafy green and non-starchy vegetables, nuts and seeds, eggs, fish and shellfish, and meats in most meals. Grains and added sugars will be excluded, and starchy vegetables, fruits, berries, and legumes will be limited to below 10% of total calorie intake. In addition full fat yogurt, cheeses, and butter will be allowed in moderate amounts. Participants will be encouraged to eat freely from whole-foods rich in fats such as avocados, nuts, seeds, olives, coconut and to use coconut, medium-chain triglyceride (MCT), olive, and avocado oils for cooking and baking on that diet. Participants will aim to fulfill at least 65% of their total calorie requirements from fats.
3481479|NCT03785808|Experimental|Diet B (low fat)|Dietary Intervention B will be low-fat, high carbohydrate whole-foods, plant-based diet. Most animal products and concentrated plant-based protein sources (such as soy isolates) will be excluded. Whole grains, particularly in their cooked form, legumes, vegetables, and fruits will be encouraged while excluding added sugars and refined grains. Added fats and oils will be discouraged on this diet as dietary fat should comprise less than 10% of total energy. Participants can eat freely from all types of fruits, vegetables, and cooked whole grains. Legumes will be emphasized as a replacement for meat and dairy products. Proteins similar to beef, pork, poultry, and dairy products, should be strictly limited, while lean proteins such as eggs, fish, and shellfish may be included occasionally.
3481480|NCT03785808|Active Comparator|Diet C (USDA control)|The control dietary intervention will be based on the 2015 USDA Dietary Guidelines for Americans, with a slightly higher amount of protein than recommended for the general population, and will be comprised of grains (of which ~50% should be consumed as whole grains), 3 servings per day of non-fat or low-fat dairy, legumes, fruit, vegetables, fish, vegetable oils and margarines, and limited quantities of meat, eggs, added sugars, nuts/seeds. Participants will be encouraged to reduce sodium intake to less than 2300 mg (1500 mg for participants over 51 yrs. old) per day, and to consume less than 10% of calories from saturated fat.
3481481|NCT03785860|Placebo Comparator|Placebo|On the Placebo arm of the intervention, participants will consume a placebo powder.
3481482|NCT03785860|Active Comparator|Dietary Fiber|On the Dietary Fiber arm of the intervention, participants will consume a fiber powder.
3481483|NCT03785743|Experimental|TLPD|Total laparoscopic pancreaticoduodenectomy for pancreatic cancer
3481484|NCT03785743|Experimental|OPD|Open pancreaticoduodenectomy for pancreatic cancer
3481485|NCT03786042|Active Comparator|E-cigarette ad exposure|Participants in the e-cigarette ad exposure condition will view e-cigarette ads on the computer screen while having their eye movements tracked
3481486|NCT03786042|Sham Comparator|non e-cigarette ad exposure|Participants in the non e-cigarette ad exposure condition will view non e-cigarette ads on the computer screen while having their eye movements tracked
3481487|NCT03785730|Experimental|Non-restorative cavity control - NRCC|Enlargement with metallic sandpaper associated with toothbrushing/1000 ppm fluoride toothpaste.
3481488|NCT03785730|Active Comparator|Resin composite restoration - RCR|Selective carious lesion removal and restoration with resin composite.
3481489|NCT03785756|Experimental|Prolonged Release Group|Ibuprofen 300 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
3481490|NCT03785756|Active Comparator|Immediate Release Group|Ibuprofen 200 mg Oral Tablet Placebo of IR tablet Placebo of PR tablet
3481491|NCT03785756|Placebo Comparator|Placebo Group|Placebo of IR tablet Placebo of PR tablet
3481492|NCT03785652|Experimental|LY03005 extended-release tablets|LY03005 extended-release tablets at 4 doses 40 mg, 80mg, 120mg or 160mg
3481493|NCT03785652|Placebo Comparator|Placebo|Placebo tablet
3127583|NCT03099694|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in premature infants with RDS
3127584|NCT03100058|Experimental|LIK066 2.5mg qd (Epoch 3)|LIK066 2.5mg qd (once daily) dosing frequency for 24 weeks.
3127585|NCT03100058|Placebo Comparator|Placebo (Epoch 3)|Matching placebo tablets for 24 weeks
3127586|NCT03100058|Experimental|LIK066 10mg qd (Epoch 3)|LIK066 10mg qd (once daily) dosing frequency for 24 weeks
3481494|NCT03785496|Experimental|PDR001|PDR001 will be administered once every 3 weeks via i.v. infusions over 30 minutes, respectively. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. A scheduled dose of ongoing study drugs may be delayed by up to 7 days to recover from previous AEs or a missed visit. If a scheduled dose of ongoing study drugs is delayed longer than 7 days due to an unresolved AE, the administration should be skipped and treatment resumed at the next scheduled dose. The assessment schedule will be shifted accordingly.
3481495|NCT03785392|Active Comparator|Group 1 Inplane|Study with the technique Inplane group
3481496|NCT03785392|Active Comparator|Group 2 out of plane|Study with the technique out of plane
3127587|NCT03100058|Experimental|LIK066 50mg qd (Epoch 3)|LIK066 50mg qd (once daily) dosing frequency for 24 weeks
3127588|NCT03100058|Experimental|LIK066 150mg qd (Epoch 3)|LIK066 150mg qd (once daily) dosing frequency for 24 weeks
3127589|NCT03100058|Experimental|LIK066 2.5mg bid (Epoch 3)|LIK066 2.5mg bid (once daily) dosing frequency for 24 weeks
3481497|NCT03785483|Experimental|Motivation|Using implementation intention techniques such as action planning. Every week, participants state when, where, and what kind of prescribed exercises they will do.
3481498|NCT03785483|Active Comparator|Mindfulness|10 minutes of audio recordings daily. Recordings contain: awareness of the breath, acceptation of thoughts and emotions, awareness of postures, awareness during stretching, awareness of a single movement (moving legs up while standing).
3481499|NCT03785483|No Intervention|Treatment as usual|Physical activity prescribe 120 minutes per week.
3481500|NCT03785665|Experimental|Participants|All study participants will be examined by the MD1 capsules, 2-5 capsules per person, one capsule at a time. Efforts will be made to maintain balanced numbers between men and women and even distribution of ages
3127590|NCT03100058|Experimental|LIK066 5mg bid (Epoch 3)|LIK066 5mg bid (once daily) dosing frequency for 24 weeks
3127591|NCT03100058|Experimental|LIK066 25mg bid (Epoch 3)|LIK066 25mg bid (once daily) dosing frequency for 24 weeks
3127592|NCT03100058|Experimental|LIK066 50mg bid (Epoch 3)|LIK066 50mg bid dosing frequency for 24 weeks
3127593|NCT03100058|Experimental|LIK066 qd/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
3127594|NCT03100058|Experimental|LIK066 bid/LIK066 35mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
3127595|NCT03100058|Experimental|Placebo/LIK066 25mg qd (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
3127596|NCT03100058|Placebo Comparator|Placebo/Placebo (Epoch 4)|Between week 24 to week 48, the patients who received a once daily regimen in the first 24 weeks will receive Dose A of LIK066 once daily and patients who received a twice daily regimen in the first 24 weeks will receive Dose B LIK066 once daily
3127597|NCT03100123|Active Comparator|Standard of Care Arm|Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.
3127598|NCT03100123|Experimental|Experimental Arm|Open-label low-dose Aspirin 81 mg daily from randomization until delivery.
3481501|NCT03785418|Experimental|Experimental Arm|Multicomponent Risk Factor Modification Intervention focused on healthy eating, regular exercise and behavioural therapy
3481502|NCT03785418|No Intervention|Control Arm|Standard Clinical Practice
3481503|NCT03785457|Experimental|Repetitive Trunk Extension|Participants with low back pain will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds, repeated five times with 15-second rest breaks
3481504|NCT03785457|Experimental|Sustained Trunk Extension|Participants with low back pain will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks
3481505|NCT03785431|Experimental|Intervention|Patient diagnosed with ST elevation myocardial infarction will undergo bioresorbable stent deployment in culprit lesion.
3481506|NCT03785535|Experimental|Actual treatment|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (2-90 Hz), low intensity and long daily duration (3h).
3481507|NCT03785535|Sham Comparator|Sham|Sham treatment will be applied using identical instruments and with power and duration programmed identically. However, in this case, the output will not be the signal activating the vibration motors, but rather an electrical signal turning on an incorporated pilot light indicating that the (simulated) treatment was operating
3481508|NCT03785587|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 24 weeks
3481509|NCT03785691|Experimental|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
3481510|NCT03785691|Experimental|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
3481511|NCT03785691|Placebo Comparator|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
3481512|NCT03785353|Experimental|PNE Group|A group of Spanish-speaking individuals will listen to a translated lecture related to PNE (PNE lecture). They will fill out the R-NPQ pre and post the lecture.
3481513|NCT03785613|Experimental|Test Product T1: Buprenorphine patch (9 mg)|"Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T1: simultaneous application for 96 hours on the upper back."
3481514|NCT03785613|Experimental|Test Product T2: Buprenorphine patch (3.8 mg)|"Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters. Single application of patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to T2: simultaneous application for 96 hours on the upper back."
3481515|NCT03785613|Active Comparator|Reference Product R: Transtec patch (20 mg)|"Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters. Single application of transdermal patch during 96 hours, on skin in the midclavicular line directly under the clavicle.~Matching placebo patch to R: simultaneous application for 96 hours on the upper back."
3481516|NCT03785522||Tresiba®|Patients with type 2 diabetes in Saudi Arabia are to receive Tresiba® (Insulin degludec) for 26 weeks.
3481517|NCT03785600|Experimental|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
3481518|NCT03785600|Sham Comparator|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
3481519|NCT03785366|Experimental|VeraCept|VeraCept subjects will be inserted with VeraCept on Day 1. At Day 57 subjects will be informed that they received VeraCept and may continue in the study for up to 5 years
3481520|NCT03785366|Active Comparator|ParaGard|ParaGard subjects will be inserted with ParaGard on Day 1. At Day 57 subjects will be informed that they received ParaGard and may choose to have the ParaGard removed or continue use per standard of clinical care.
3481521|NCT03785561||Exposed (intervention) group|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital.
3481522|NCT03785561||Unexposed (comparator) group|The unexposed group is defined as patients, diagnosed with a musculoskeletal disorder receiving standard clinical care at the outpatient osteoarthritis clinic at Bispebjerg and Frederiksberg Hospital. They are not currently enrolled in a health research study concerning their musculoskeletal disorder at Bispebjerg and Frederiksberg Hospital
3481523|NCT03785379|Active Comparator|Caloric restriction and early SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a caloric restriction and early exercise training (SSET) during the first 12-week, followed by no exercise at health centers for 3 months. Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
3481524|NCT03785379|Active Comparator|Caloric restriction and late SSET|Patients will participate to a short lifestyle intervention (LSI), consisting of four weekly group-led lessons lasting 60-90 minutes to educate them on specific dietary and physical activity recommendations for improving health and metabolic control. At the end of the 1-month LSI, participants will start a one-year caloric restriction with no exercise at health centers for 3 months, and then a 12-week exercise training (SSET). Between the 6- and the 12-month assessments, participants will continue caloric restriction and will be encouraged to freely exercise.
3481525|NCT03785444||Intensive Care Patients|Postoperative patients who have been admitted to intensive care
3481526|NCT03785444||Non-Intensive Care Patients|Postoperative patients who have not been admitted to intensive care but to the normal ward
3481527|NCT03785470|Experimental|Fructose and physical inactivity|Subjects will consume 6 cans of soda per day and restrict their physical activity.
3481528|NCT03785275||Subjects with stable near-normal T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
3481529|NCT03785275||Subjects with unstable T1D|"Mixed-meal tolerance test~Intravenous injection with gallium-68-exendin followed by a PET/CT scan"
3481530|NCT03785327|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
3481531|NCT03785327|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
3481532|NCT03785327|Experimental|Autism Training Program|Training program designed to increase autism understanding followed by behavioral testing Intervention:Training program
3481533|NCT03785327|No Intervention|Social interaction without intervention|Control condition: Behavioral testing without an intervention component
3481534|NCT03785340|Experimental|OCU-310|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks
3481535|NCT03785340|Placebo Comparator|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks
3481536|NCT03785145|Experimental|MT10109L|MT10109L will be injected into the LCL: initial double-blind treatment on Day 1, and up to 2 open-label study interventions during the retreatment period.
3481537|NCT03785145|Placebo Comparator|Placebo|Placebo will be injected into the LCL: initial double-blind treatment on Day 1.
3481538|NCT03785314|Active Comparator|injection under sitting position|saline injection under sitting position during thoracic epidural catheterization
3481539|NCT03785314|Active Comparator|injection under lateral decubitus position|saline injection under lateral decubitus position during thoracic epidural catheterization
3481540|NCT03785158|Active Comparator|Melatonin|3 mg of liquid melatonin by oral route for 8 days. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
3481541|NCT03785158|Placebo Comparator|Placebo Group|Similar looking/tasting 3 mg (5 ml) placebo syrup administered preoperatively by oral route and for the next 7 days or until discharge. The 1st dose will be given 1-2 hours prior to the surgery, followed by bed time doses (between 7-9 pm) given on postoperative day (POD) 1 until discharge or for the first 7 days.
3481542|NCT03785132||cardiac surgery|Patients who underwent cardiac surgery with cardiopulmonary bypass
3481543|NCT03785223|Experimental|Methylphenidate Hydrochloride Controlled-Release Capsules|Flexibly dosed at 25-100 mg per day
3481544|NCT03785223|Placebo Comparator|Placebo Capsules|1-4 capsules daily
3481545|NCT03785106|Experimental|1HP|4-week daily regimen of weight-based RPT and INH, plus pyridoxine (vitamin B6)
3481546|NCT03785106|Active Comparator|3HP|12-weekly INH/RPT regimen, plus pyridoxine (vitamin B6)
3481547|NCT03785002|Experimental|vegetarian|Individuals who do not consume meat (vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
3481548|NCT03785002|Active Comparator|non vegetarian|Individuals who do consume meat (non vegetarian dietary pattern) will undergo strength training sessions and guidance on protein intake (at least 20g for breakfast, lunch, and dinner)
3481549|NCT03785236||Tx-group|T1D patients that received islet of Langerhans transplantation (Tx) at least 3 months earlier
3481550|NCT03785236||Control group|T1D patients that await islet of Langerhans transplantation
3481551|NCT03785015|Experimental|Withold aspirin till after endoscopic haemostasis|Withhold the standard treatment of aspirin within 12 hours after endoscopic haemostasis.
3481552|NCT03785015|Active Comparator|Withold aspirin till 72 hours|Withhold the standard treatment of aspirin till 72 after endoscopic haemostasis.
3481553|NCT03785288|Active Comparator|HDR VBT 3 fxs of 7Gy|Arm 1: HDR vaginal brachytherapy 3 fractions of 7Gy
3481554|NCT03785288|Active Comparator|HDR VBT 6 fxs of 4Gy|Arm 2: HDR vaginal brachytherapy 6 fractions of 4Gy
3481555|NCT03785184|Experimental|Venetoclax + Lenalidomide + Dexamethasone|Venetoclax up to 800 mg orally every day (QD) QD on Days 1 - 28 plus lenalidomide up to 25 mg orally QD on Days 1 - 21 (28 day cycle) plus dexamethasone up to 40 mg orally once weekly (QW).
3481556|NCT03785249|Experimental|Phase 1 Dose Exploration|Dose escalation of MRTX849 to determine maximum tolerated dose
3481557|NCT03785249|Experimental|Phase 1b Expansion|Expansion cohort to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 to recommend Phase 2 regimens
3481558|NCT03785249|Experimental|Phase 2|Separate cohorts of patients stratified by histological diagnosis, prior treatment history or co-mutation status (e.g., STK11) for evaluation of clinical activity of MRTX849
3481559|NCT03785249|Experimental|Pilot Phase 1b Combination with Pembrolizumab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with pembrolizumab in patients with NSCLC
3481560|NCT03785249|Experimental|Pilot Phase 1b Combination with Cetuximab|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with cetuximab in patients with CRC
3481561|NCT03785249|Experimental|Pilot Phase 1b Combination with Afatinib|Phase 1 evaluation of the safety, tolerability, PK and clinical activity of MRTX849 in combination with afatinib in patients with NSCLC
3481562|NCT03785119||Standard strategy|According to embryo quality (morphologic criteria)
3481563|NCT03785119||Experimental strategy|Association of embryo quality and sCD146 rate
3481564|NCT03785028|Experimental|Experimental Arm|Only arm of this basic science study, participants will undergo working memory and attention tasks
3481565|NCT03784950|Experimental|Rating tool only|Rating eConsults from peer specialists in first phase
3481566|NCT03784950|Experimental|Feedback only|Receiving feedback from peer specialists in first phase
3481567|NCT03784950|Experimental|Rating Tool plus Feedback|Both rating and feedback in second phase.
3481568|NCT03785301|Experimental|FGM group|Diabetic patients will use FreeStyle Libre Flash Glucose Monitoring (FGM) system(unmasked) to monitor glucose level once a month for 3 months.
3481569|NCT03785301|No Intervention|SMBG group|Diabetic patients will use Standard Blood Glucose Monitoring (SMBG) to monitor glucose level for 3 months. A 14-day masked wear of FreeStyle Libre H Flash Glucose Monitoring system is included for these subjects once a month, to collect glycaemic variability data for comparison to the intervention group of the study.
3481570|NCT03785054|Experimental|Cohort 1|6 subjects receiving a single dose of 1 mg capsule HTL0014242 and 2 subjects receiving matching placebo oral capsule
3481571|NCT03785054|Experimental|Cohort 2|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481572|NCT03785054|Experimental|Cohort 3|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481573|NCT03785054|Experimental|Cohort 4|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481574|NCT03785054|Experimental|Cohort 5|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481575|NCT03785054|Experimental|Cohort 6|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481576|NCT03785054|Experimental|Cohort 7|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481577|NCT03785054|Experimental|Cohort 8|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481578|NCT03785054|Experimental|Cohort 9|6 subjects receiving single dose of HTL0014242 and 2 subjects receiving matching placebo oral capsule. The dose of HTL0014242 selected in an escalating manner following review of safety and tolerability data from the previous lower dose level.
3481579|NCT03785041|Active Comparator|Levobupivacaine and tramadol Preemptive|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular preemptive.
3481580|NCT03785041|Active Comparator|Tramadol and levobupivacaine postoperative|20 ml 0.5% Levobupivacaine + 100 mg tramadol injected intraarticular postoperative.
3481581|NCT03785041|Active Comparator|Tramadol and levobupivacaine preemptive and postoperative|20 ml 0.25% Levobupivacaine + 50 mg tramadol injected intraarticular preemptive and postoperative.
3481582|NCT03785041|Active Comparator|Levobupivacaine|20 ml 0.5% Levobupivacaine only injected intraarticular preemptive.
3481583|NCT03784911||During Cancer Treatment Group|Participants' body composition will be estimated using a SOZO device at 5 different time points across their cancer treatment. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, cancer distress assessment, ECOG performance status, hand grip strength test, and 24-hour food recall. DEXA scans will be performed before treatment and after completion of treatment.
3481584|NCT03784859||All patients in study|5 consecutive patients with breast cancer or a breast cancer-causing gene that elect to undergo bilateral breast reconstruction will be Insertion of Tissue Expander with Fluid Reservoir as the first stage of reconstruction. Post-surgical care will be similar as patients with conventional expanders, except that during office visits, fluid will be transcutaneously aspirated from the fluid reservoir on each side.
3481585|NCT03784976|Experimental|Intervention|Patients in the intervention group will first undergo 3 months of regular care and then 3 months of biweekly yoga classes. Participants will complete surveys at baseline, 3 months (after of control care), 6 months (after 3 months of biweekly yoga classes), and 12 months (after 6 months of observation and optional yoga practice).
3481586|NCT03784976|No Intervention|Control|The study lasts 12 months for the intervention and 9 months for the control group with an optional 3 month yoga therapy session offered at the end
3481587|NCT03785080|Experimental|restart NOAC very early|restart NOAC within 24 hours
3481588|NCT03785080|Active Comparator|restart NOAC early|restart NOAC at 72 - 84 hours
3481589|NCT03784846|Experimental|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, cognitive behavioral therapy (CBT), and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
3127605|NCT03100344|Experimental|Group 1|Nemolizumab (low dose)
3127606|NCT03100344|Experimental|Group 2|Nemolizumab (medium dose)
3127607|NCT03100344|Experimental|Group 3|Nemolizumab (high dose)
3127608|NCT03100344|Placebo Comparator|Group 4|Nemolizumab placebo
3127609|NCT03100500|Experimental|QMF149|All eligible patients take QMF149 150/320 μg once daily over 52 weeks.
3127610|NCT03100825|Experimental|QVM149|All eligible patients take QVM149 150/50/160 μg once daily over 52 weeks.
3127611|NCT03100838|Experimental|Nifedipine (Generic)|1 x 60 mg Nifedipine extended-release tablet
3127612|NCT03100838|Active Comparator|Nifedipine (Brand)|1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet
3127613|NCT03100838|Active Comparator|Nifedipine (Generic) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg Nifedipine extended-release tablet on day 7
3127614|NCT03100838|Active Comparator|Nifedipine (brand) + PPI|1 x 40 mg/1100 mg omeprazole/sodium bicarbonate capsule daily over a period of 7 days + 1 x 60 mg PROCARDIA XL (nifedipine) extended-release tablet on day 7
3127615|NCT03100864|Experimental|Spesolimab|
3127616|NCT03100942|Experimental|Lanraplenib|Lanraplenib + filgotinib placebo + tirabrutinib placebo for up to 49.4 weeks.
3481590|NCT03784846|Active Comparator|Stress Management Education|SME was designed as an active control condition for other mindfulness-based intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
3481591|NCT03784846|No Intervention|No Intervention Control|No contact control condition (other than baseline, post, and follow-up assessments)
3481592|NCT03784781||Asthmatic children|Severe uncontrolled asthma is defined by the need to maintain a treatment with high doses of inhaled corticosteroids and a long-acting bronchodilator (B2LDA) and/or an anti-leukotriene
3481593|NCT03784781||Controls|Non-asthmatic children, paired in age, requiring bronchial endoscopy with BAL and bronchial mucosa biopsy.
3481594|NCT03784794|Experimental|Thromboelastometry|Decision to treat will be guided with thromboelastometry results, for fribrinogen deficiency the investigators will treat with fibrinogen concentrate (human), for correction of factor deficiency Prothrombin Complex Concentrates, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
3481595|NCT03784794|Active Comparator|STANDARD COAGULATION TEST ALGORITHM|Decision to treat will be guided by standard cogulation lab test (Thrombine time, Active Thromboplastine time, Clauss fibrinogen, platelets count etc) for fribrinogen deficiency the investigators will treat with cryoprecipitates, for correction of factor deficiency fresh frozen plasma, Platelets with the use of platelets and Red Blood Cells for correcting hemoglobin levels
3481596|NCT03784820|Experimental|UNITE|UNITE is a manualized cognitive-behavioral couple therapy (CBCT) intervention that engages the couple to address the core psychopathology of BED.
3481597|NCT03784820|Active Comparator|CBT-E|CBT-E is a trans-diagnostic cognitive behavioral individual therapy treatment for eating disorders. It has been shown to be effective in numerous controlled and open trials.
3481598|NCT03784768|Experimental|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.
3481599|NCT03784768|Active Comparator|Control Group|Patients in the control group will be received 60-minute conventional pysiotherapy session for 5-days in a week, over 4-week. Each physiotherapy session will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
3481600|NCT03785067|Experimental|Triple Pill (Active Treatment)|"Main Study: Fixed low-dose combination BP-lowering pill (Triple Pill) telmisartan 20mg + amlodipine 2.5mg + indapamide 1.25mg~Sub-Study: single-arm"
3481601|NCT03785067|Placebo Comparator|Placebo|"Main Study: Matched placebo, received via blinded study capsules~Sub-Study: single-arm"
3127617|NCT03100942|Experimental|Filgotinib|Filgotinib + lanraplenib placebo + tirabrutinib placebo for up to 50.4 weeks.
3127618|NCT03100942|Experimental|Tirabrutinib|Tirabrutinib + filgotinib placebo + lanraplenib placebo for up to 50.3 weeks.
3481602|NCT03784729|Experimental|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted."
3481603|NCT03784729|Sham Comparator|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm.
3481604|NCT03784664|Active Comparator|Arterial blood gas|
3481605|NCT03784664|Experimental|Veinous blood gas|
3481606|NCT03785171||Moyamoya disease|The cohort includes patients with Moyamoya disease diagnosed by DSA examination who are treated by surgical revascularization.
3127619|NCT03100942|Placebo Comparator|Placebo, then active treatment|"Filgotinib placebo + lanraplenib placebo + tirabrutinib placebo for 24 weeks. Following completion of the Week 24 assessments and procedures, participants will be rerandomized 1:1:1, in a blinded fashion and receive either of the following study drugs through Week 48:~filgotinib + lanraplenib placebo + tirabrutinib placebo~lanraplenib + filgotinib placebo + tirabrutinib placebo~tirabrutinib + filgotinib placebo + lanraplenib placebo"
3127620|NCT03100968|Active Comparator|Palpation Group|The palpation group will have an epidural placed after manual palpation of the spine.
3127621|NCT03100968|Active Comparator|Ultrasound Group|The ultrasound group will have an epidural placed after identifying midline with the ultrasound.
3127622|NCT03101020|Experimental|Experimental Group|The participants will receive standard care physiotherapy plus active visceral manipulation
3127623|NCT03101020|Placebo Comparator|Control Group|The participants will receive standard care physiotherapy plus placebo visceral manipulation
3127624|NCT03101033|Experimental|Epidural neuroplasty group|This group will be given epidural neuroplasty once enrolled.
3127625|NCT03101033|Active Comparator|Transforaminal steroid injection group|This group will be given transforaminal betamethasone injection once enrolled, if no obvious pain relief was reported, another epidural injection will be given one week later.
3481607|NCT03785093||Chinese Family|Chinese parents and their offsprings
3481608|NCT03784885|Experimental|30 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 30 μg of AD07010
3481609|NCT03784885|Experimental|45 μg of AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine in 45 μg of AD07010
3481610|NCT03784885|Active Comparator|AD07010|All subjects in this group received 2 doses of 22.2 μg HA antigens from inactivated trivalent influenza vaccine
3481611|NCT03784716|Experimental|Ketogenic Diet|Ketogenic Diet for 28 Days
3481612|NCT03784716|Active Comparator|Standard Weight Loss Diet|Standard Weight Loss Diet for 28 Days
3481613|NCT03784742|Active Comparator|Nitrate-rich Beetroot juice|Nitrate-rich beetroot juice equivalent to 3.7 mg nitrate per kg body weight daily for 8 weeks.
3481614|NCT03784742|Placebo Comparator|Placebo beetroot juice|Placebo beetroot juice (equivalent volume to the amount of nitrate-rich beetroot juice consumed) daily for 8 weeks.
3481615|NCT03784534|Experimental|Healthy volunteers|"Subjects will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each subject to evaluate their motor skills: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer~anatomical MRI (T1 and tensor imaging) scan)"
3481616|NCT03784534|Experimental|Patients|"Patients will be asked to perform:~high= density (64 sensors) EEG~clinical and behavioral data will be also collected from each patient to assess their motor recovery progress: the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, Fugl Meyer, test of Ashworth~anatomical MRI (T1 and tensor imaging) scan)"
3481617|NCT03784495|Placebo Comparator|Placebo (P)|Placebo.
3481618|NCT03784495|Experimental|Melatonin (M)|1 mg/day of melatonin.
3481619|NCT03784495|Experimental|Essential Aminoacids (eAA)|4 g/day of essential aminoacids
3481620|NCT03784495|Experimental|Essential Aminoacids + Melatonin (eAAM)|4 g/day of essential aminoacids and 1 mg/day of melatonin
3481621|NCT03784469|Experimental|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
3481622|NCT03784469|No Intervention|Control group|No changing body position in bed,remaining supine position in complete bed rest and immobilized for four hours.
3481623|NCT03784599|Experimental|Trastuzumab-emtansine and osimertinib|"Trastuzumab-emtansine 3.6 mg/kg, intravenously, every 3 weeks~Osimertinib 80 mg once daily, orally, continuous~Treatment will be continued until tumor progression (according to RECIST v1.1) confirmed by tumor imaging, unacceptable toxicity, or death occurs."
3481624|NCT03784638|Experimental|lingually-based triangle flap design|In the experimental group, an incision will be made adjacent to the distal surface of the mandibular second molar, and extended along the sulcus to the distobuccal corner of the mandibular second molar. An oblique vestibular incision will made and extended into the vestibular fornix of the mandible, aligned with the mesiobuccal cusp of the second molar. It was continued posterosuperiorly towards the anterior border of mandibular ramus. The lingually-based triangle flap design will be used.
3481625|NCT03784638|Placebo Comparator|buccally based triangle flap design|In the control group, an incision will be made from the anterior border of the mandibular second molar. It will be extended along the sulcus to the distobuccal corner of the second molar crown. The incision will be continuous with vertical incision. The buccally based triangle flap design will be used.
3481626|NCT03784573|Active Comparator|Dog + handler|
3481627|NCT03784573|Placebo Comparator|No dog|
3127626|NCT03101111|Experimental|MV-CHIK and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive a 5E+05 (+/- 0.5 log) TCID50 intramuscularly in the deltoid muscle of one arm.~On day 0 they will receive a dummy injection of placebo (physiological saline) subcutaneously in the contralateral arm."
3481628|NCT03784612|Experimental|App-technology group|"Participants in the App-technology group arm will use a newly developed smartphone application (app), containing a 12-week healthy eating program.~Intervention: App-technology for healthy eating habits."
3481629|NCT03784612|No Intervention|Control group|The control group will receive standard care.
3481630|NCT03784690|Experimental|Individualized BP group|Individualized intraoperative BP management
3481631|NCT03784690|Placebo Comparator|Standard treatment group|Standard intraoperative BP management
3481632|NCT03784703|Experimental|Atrovastatin|atorvastatin (40 mg per day) for 6 months
3481633|NCT03784703|Experimental|Rosuvastatin|Rosuvastatin (10 mg per day) for 6 months
3481634|NCT03784807||Infected|Patients with prosthetic joint or osteoarticular infection
3481635|NCT03784807||Not infected|Patients with implant failure not due to infection
3127627|NCT03101111|Active Comparator|MMR-vaccine and Placebo|"Subjects will receive two injections on study day 0 and one injection on day 28.~On both days they will receive dummy injections of placebo (physiological saline) in the deltoid muscle of one arm.~On day 0 they will receive MMR-vaccine subcutaneously in the contralateral arm."
3481636|NCT03784677|Experimental|Treatment (TRPV6 calcium channel inhibitor SOR-C13)|Patients receive TRPV6 calcium channel inhibitor SOR-C13 IV over 2 hours on days 1, 2, 8, 9, 15, 16, 22, and 23. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3481637|NCT03784560||study group|anesthesia residents with 24 hours working shift
3481638|NCT03784443|Active Comparator|Iluvien Arm|Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
3481639|NCT03784443|Sham Comparator|Control Arm|To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.
3481640|NCT03784417|Experimental|EUS-guided laser ablation|Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
3481641|NCT03784404|Active Comparator|Non surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
3481642|NCT03784404|Active Comparator|Surgicel group|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
3481643|NCT03784625|Experimental|therapeutic dose activity (level 1)|[131]ICF01012 at a therapeutic dose of 800 MBq/m² , single dose at D11 (intravenous administration)
3481644|NCT03784625|Experimental|therapeutic dose activity (level 2)|[131]ICF01012 at a therapeutic dose of 1600 MBq/m² , single dose at D11 (intravenous administration)
3481645|NCT03784625|Experimental|therapeutic dose activity (level 3)|[131]ICF01012 at a therapeutic dose of 2700 MBq/m² , single dose at D11 (intravenous administration)
3481646|NCT03784625|Experimental|therapeutic dose activity (level 4)|[131]ICF01012 at a therapeutic dose of 4000 MBq/m² , single dose at D11 (intravenous administration)
3481647|NCT03784378|Experimental|Participants previously enrolled on Study of RXDX-105|Participants were previously enrolled on Study of RXDX-105
3481648|NCT03784430|Active Comparator|Implant|Immediate dental implant placement
3481649|NCT03784430|Experimental|Implant+CTG|Immediate dental implant placement with CTG.
3481650|NCT03784521|Experimental|In-line filtration|For patients randomized to in-line filtration, in-line filters (Pall, Dreieich, Germany) are used for all intravenous access during operation and postoperative period in intensive care unit (ICU).
3127628|NCT03101150|Active Comparator|400 IU Vitamin D3|400IU vitamin D3 contained in antenatal multivitamin once daily by mouth starting from 14 weeks of pregnancy till delivery.
3127629|NCT03101150|Experimental|4000 IU Vitamin D3|4000 IU Vitamin D3 drops once daily by mouth starting from 14 weeks of pregnancy till delivery.
3127630|NCT03101241|Experimental|CX-8998|
3127631|NCT03101241|Placebo Comparator|Placebo|
3127632|NCT03101267|Experimental|ASP4070 4 mg|Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.
3127633|NCT03101267|Experimental|ASP4070 1 mg|Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.
3127634|NCT03101267|Placebo Comparator|Placebo|Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.
3481651|NCT03784521|Active Comparator|Control|For patients randomized to control group, All intravenous access is managed routinely according to local standard care without filtration during operation and postoperative period in ICU.
3481652|NCT03784547||multiple sclerosis patients|multiple sclerosis patients receiving ocrelizumab 600 mg endovenous every 6 months
3481653|NCT03784508||Bariatric surgery|200 consecutive patients that will undergo bariatric surgery as a routinary procedure at our site
3481654|NCT03784352|Experimental|Virtual Reality (VR)|The intervention will consist of standard of care (SOC) in addition to the use of virtual reality. SOC consists of the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device) Patients assigned to the VR group will interact with VR through mobile-based VR googles.
3481655|NCT03784352|No Intervention|No Virtual Reality (VR)|This arm will receive regular standard of care (SOC), the same that would be received if they were not enrolled in the study. SOC will include the technician/care provider explaining the procedure while using speech to be comforting and supportive in addition to parent/guardians being allowed to console and distract their child during the procedure and interacting with other distractions techniques that may be available (ie. ipad, or mobile device)
3481656|NCT03784456|Experimental|25% protein group|This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
3481657|NCT03784456|Active Comparator|15% protein group|This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product. The meals would be provided 2 times per day, 5 days per week. The program will last for 12 weeks.
3481658|NCT03784365|Active Comparator|First group|This group will receive an intravenous antibiotic for three days. The first dose will be given within half hour before the POEM procedure.
3481659|NCT03784365|Experimental|Second group|This group will receive only one dose of intravenous antibiotic within half hour before the POEM procedure
3481660|NCT03784339|Placebo Comparator|Physiotherapy|Participants will receive standard physiotherapy care, which will involve strength exercises and taping.
3481661|NCT03784339|Experimental|Physiotherapy + education|Physiotherapy + education Standard physiotherapy care plus 30 minute education session addressing fear of movement and catastrophizing thoughts.
3481662|NCT03784391||Treatment|Patients diagnosed with acute and chronic Chagas' disease, respectively, who were treated with nifurtimox
3481663|NCT03784391||Reference|Patients diagnosed with acute and chronic Chagas' disease, respectively, who did not receive antitrypanosomal treatment
3481664|NCT03784131|Experimental|Personalized Tissue Engineered Vein|P-TEV
3481665|NCT03784092|No Intervention|control|
3481666|NCT03784092|Experimental|feedback|
3481667|NCT03784066|Active Comparator|A|Durvalumab
3481668|NCT03784066|Active Comparator|B|Durvalumab + Tremelimumab
3481669|NCT03784144|Experimental|Cognitive Strategy|Performing a mathematical subtracting task (starting at 300, by sevens)
3481670|NCT03784144|Active Comparator|Control|The patients will perform both tests without any cognitive condition
3481671|NCT03784105|Experimental|Codeine|
3481672|NCT03784105|Placebo Comparator|Siripus simplex|
3481673|NCT03784248||asymptomatic carrier|
3481674|NCT03784248||uninfected subjects|
3481675|NCT03784209||lesions observed by pCLE|pCLE is used to distinguish the suspected lesions detected by white light endoscopy.
3481676|NCT03784313|Experimental|Perforators flaps (PF group)|
3481677|NCT03784313|Sham Comparator|Secondary intention wound healing|
3481678|NCT03784014|No Intervention|Arm No NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. Thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment.~Note that for these participants and under specific conditions, subsequent NGS analyses may be allowed within the scope of the trial"
3481679|NCT03784014|Experimental|Arm NGS|"Patients will be treated by standard first-line systemic treatment and tumor assessment will be performed every 2 cycles during treatment. After tumor assessment at the end of first-line systemic treatment and regardless of tumor response as per RECIST v1.1, participants will be discussed within a multidisciplinary tumor board (molecular tumor board-MTB) which aims at discussing the genomic profiles and at providing a therapeutic decision for each participant.~Patients for whom a targetable genomic alteration has been highlighted will be proposed to enter in a subsequent single-arm phase II sub-trials. Otherwise, thereafter, disease will be managed as per standard care depending on tumor response observed at the end of the first-line treatment"
3481680|NCT03784014|Experimental|Arm NGS - Targeted therapy|Targeted therapy from a list of 10 targeted treatment strategies, guided by the genomic analyses: Nilotinib capsule per os 400 mg bd, continuous dosing ; Ceritinib capsule per os 450 mg od, continuous dosing; Capmatinib tablet per os 400 mg bd, continuous dosing; Lapatinib tablet per os 1500 mg od, continuous dosing; Trametinib tablet per os 2 mg od, continuous dosing; association of Trametinib tablet per os 2 mg od and Dabrafenib capsule per os 150 mg bd, continuous dosing; association of Olaparib tablet per os 300 mg bd, continuous dosing and Durvalumab intra-veinous 1500 mg on day 1, Q4W; Palbociclib capsule 125 mg od, 3 weeks on/1 week off; Glasdegib tablet per os 300 mg od, continuous dosing; TAS-120 tablet per os 20 mg od, continuous dosing.
3481681|NCT03784170|Experimental|Treatment|FemPulse System at one device setting
3481682|NCT03784170|Sham Comparator|Control|FemPulse System at a different device setting
3481683|NCT03784183|Experimental|moderate AD-experimental|Experimental Intervention: The CS shall be carried out in groups (5-7 participants), twice a week. Each session lasts 90 minutes. CS sessions begin with a training for temporal and spatial orientation in which participants are asked to recognize and recall the date and the place with the help of some environmental aids (calendars, clocks, pictures and maps). Then the participants complete an array of cognitive tasks for memory, attention, language, visuo-spatial functions and executive functions. These tasks range from individual paper-and-pencil exercises to verbal-learning exercises that have to be solved by the group.
3481684|NCT03784183|Experimental|mild AD-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
3481685|NCT03784183|Experimental|MCI-experimental|"Experimental Intervention: the same of the moderate AD-experimental arm"
3481686|NCT03784183|No Intervention|moderate AD-placebo|
3127635|NCT03101293|Experimental|TAK-831 400 mg Fasted + TAK-831 400 mg Fed|TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 2.
3127636|NCT03101293|Experimental|TAK-831 400 mg Fed + TAK-831 400 mg Fasted|TAK-831 400 mg, film-coated tablets, orally under fed state, once on Day 1 of Intervention Period 1, followed by 7 days washout period, further followed by TAK-831 400 mg, film-coated tablets, orally under fasted state, once on Day 1 of Intervention Period 2.
3481687|NCT03784183|No Intervention|mild AD-placebo|
3127637|NCT03101358|Experimental|SOR007 0.15%|0.15% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
3481688|NCT03784183|No Intervention|MCI-placebo|
3481689|NCT03784326|Experimental|Treatment (oxaliplatin, fluorouracil, atezolizumab, surgery)|Patients receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Within 4-6 weeks of treatment completion, patients undergo surgical resection. Beginning 6 weeks after surgery, patients continue to receive oxaliplatin IV over 2 hours, fluorouracil IV continuously over 48 hours, and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive atezolizumab monotherapy IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3481690|NCT03784196||Acute Whiplash Associated Disorders|People suffering from acute WAD at the time of recruitment.
3481691|NCT03784196||Healthy controls|Participants with no neck pain during the past 6 months, chronic pain or other medical disorders relevant to this study.
3127638|NCT03101358|Experimental|SOR007 1.0%|1.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days
3127639|NCT03101358|Experimental|SOR007 2.0%|2.0% SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment applied topically twice daily for 28 days or up to 56 days
3481692|NCT03784274||Stakeholders|Key stakeholders involved program and policy making
3481693|NCT03784222|Experimental|treatment group|188 first episode schizophrenia patients, receiving blonanserin treatment, 60 of the patients receive MRI and serum BDNF test
3481694|NCT03784222|Other|control group|60 subjects without schizophrenia, only receiving MRI and/or serum BDNF
3481695|NCT03784261|Active Comparator|SAR, usually subucutaneous injection every 2 weeks|
3481696|NCT03784261|Active Comparator|TCZ, usually subucutaneous injection every 2 weeks|
3481697|NCT03784261|Active Comparator|ABT, usually subucutaneous injection every week|
3127640|NCT03101371|Active Comparator|Standard of care catheter insertion|Standard of care catheter insertion in which catheter is inserted right out of package/non-treated catheter.
3127641|NCT03101371|Experimental|Aseptic protocol for catheter insertion|Aseptic protocol for catheter insertion using Povidone Iodine treated catheter and maintaining plastic sleeve on catheter
3481698|NCT03783897|Experimental|EDP-305 and Oral Contraceptive|
3481699|NCT03784287|Experimental|AX 250|All subjects will receive AX 250 at the MTTD established in 250-201, 300mg administered weekly by ICV infusion that will continue for up to 240 weeks.
3481700|NCT03783910|Experimental|GRT9906|"Participants received 80-240 mg of GRT9906 oral for up to 6 weeks (1 week of titration, 5 weeks of maintenance treatment).~Participants started with 40 mg of GRT9906 on the first and 80 mg (40 mg twice daily) on the second day. They could increase the dose every day by 1 tablet (i.e., GRT9906 40 mg), up to a maximum daily dose of 240 mg (120 mg twice daily). Participants experiencing adverse events could reduce the dose to the next lower, better tolerated daily dose (but not lower than 80 mg [40 mg twice daily]). By Day 8, every participant had reached their optimal daily dose and was asked to continue on the identified dosing regimen for the following 5 weeks."
3481701|NCT03783910|Placebo Comparator|Placebo|Participants received Placebo (2-6 tablets daily) oral for up to 6 weeks.
3481702|NCT03784053||Immersive virtual reality|Participants will receive eight 30-minute sessions of immersive virtual reality.
3481703|NCT03784027|Experimental|Automated closed loop insulin delivery (intervention arm)|"Unsupervised home use of day and night automated hybrid closed loop insulin delivery system over 16 weeks.~Intervention: Device: CamAPS FX"
3481704|NCT03784027|Active Comparator|Sensor augmented pump therapy (control arm)|Sensor augmented pump therapy over 16 weeks.
3481705|NCT03783949|Active Comparator|Standard arm (arm A)|Carboplatin (AUC5 d1, q3w i.v.) in combination with Paclitaxel (175 mg/m² d1, q3w i.v.) or Carboplatin (AUC4 d1, q3w i.v.) in combination with Gemcitabine (1000 mg/m² d1, d8, q3w i.v.) followed by maintenance therapy with Niraparib (200/ 300 mg oral daily, q4w)
3481706|NCT03783949|Experimental|First experimental arm (arm B)|Ganetespib (150 mg/m2, d1, q3w) in combination with Carboplatin (AUC5 d1, q3w i.v.) followed by maintenance treatment with Niraparib (200/ 300 mg oral daily, q4w)
3481707|NCT03783949|Experimental|Second experimental arm (arm C)|Ganetespib (150 mg/m² d1, q3w i.v.) plus Carboplatin (AUC5 d1, q3w i.v.) followed by Ganetespib (100 mg/m² d1, d8, d15, d22, q4w i.v.) and Niraparib (200 mg oral daily, q4w)
3481708|NCT03783936|Other|Induction and Maintenance|"Cycles 1-9; Induction; Cycle = 14 days~mFOLFOX6~oxaliplatin 85 mg/m2 IV Day 1 and~leucovorin 400 mg/m2 IV Day 1 and~5 fluorouracil 400 mg/m2 IV bolus and 2400 mg/m2 IV over 46 hours Day 1 and~Trastuzumab 6 mg/kg IV loading dose C1D1 then Trastuzumab 4 mg/kg IV Day 1 and~Avelumab 800 mg IV Day 1~Cycles 10 and subsequent; Maintenance; Cycle = 14 days~Trastuzumab 4 mg/kg Day 1 and Avelumab 800 mg Day 1"
3481709|NCT03784040|Experimental|(Arm A) OTSGC-A24 + nivolumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.
3481710|NCT03784040|Experimental|(Arm B) OTSGC-A24 + nivolumab + ipilimumab|Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.
3481711|NCT03783988|Other|Open uncontrolled pharmacokinetic study|Single armed - All subjects receive one dose of topical combination gel containing TRIAC and DHEA
3481712|NCT03783858|Other|Single|
3481713|NCT03783845|Experimental|test group|"Metronidazole 400mg,three times daily for two weeks~Amoxicillin 500mg,three times daily for two weeks."
3481714|NCT03783845|No Intervention|control group|no intervention during study period
3127642|NCT03101462|Active Comparator|Group 1|One dose of 0.5 mL Licensed Inactivated Influenza Vaccine (IIV) on Day 0
3127643|NCT03101462|Active Comparator|Group 2|One dose of 0.5 mL Licensed Live Attenuated Influenza Vaccine (LAIV) on Day 0
3127644|NCT03101514|Experimental|Kanglaite group|Kanglaite 200ml is injected once a day from Monday to Friday during radiotherapy.
3481715|NCT03783728||Untreated Latent Tuberculosis Infection|Isoniazid 900 mg orally + Rifapentine 600 mg orally + Pyridoxine 50 mg orally once a week for 12 weeks
3481716|NCT03783754|Experimental|Triple Pill (Active Treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
3481717|NCT03783754|Placebo Comparator|Placebo|received via blinded study oral capsules
3481718|NCT03783572|Experimental|Stroke patients|40 stroke patients : Injection of the TBA and the investigator will compare the measure of spastic cocontraction index (ICCS) during different movement before versus 4 weeks after injection of TBA : Clinical evaluation and Instrumental evaluation TBA injections are performed as part of routine care
3481719|NCT03783572|Active Comparator|Control Group|The control group : Clinical evaluation consists in the search for criteria of non-inclusion and manual laterality score The will ha an Instrumental review just like the patient : concomitant evaluation of the 3D kinematics of the dominant upper limb, EMG of the triceps brachii muscles, biceps brachii, brachio-radial, brachial; associated with EEG recording, during active extension and elbow flexion movements, of the dominant upper extremity, at spontaneous and maximal speed Clinical evaluation
3127645|NCT03101566|Experimental|Gemcitabine + Cisplatin + Nivolumab|"Drug: Gemcitabine 1000 mg/m2 IV on days 1,8 every 3 weeks~Drug: Cisplatin 25 mg/m2 IV on days 1,8 every 3 weeks~Drug: Nivolumab 360 mg IV on day 1 every 3 weeks~If there is continued benefit after 6 months, then:~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
3127646|NCT03101566|Experimental|Nivolumab + Ipilimumab|"Drug: Ipilimumab~1 mg/kg IV on day 1 every 6 weeks~Drug: Nivolumab 240 mg IV on day 1 every 2 weeks"
3481720|NCT03783715||Ketoprofen|Participants will take ketoprofen for six months. They will have evaluations at baseline and month 6.
3481721|NCT03783637|Other|Whole Grain Oat|Volunteers will consume a breakfast meal containing whole grain oats after 7 days of a whole grain free diet.
3481722|NCT03783637|Other|Whole Grain Wheat|Volunteers will consume a breakfast meal containing whole grain wheat after 7 days of a whole grain free diet.
3481723|NCT03783793|Experimental|Mindfulness Training App|
3481724|NCT03783793|Active Comparator|Cognitive Training With 2048|
3481725|NCT03783494|Experimental|Target-controlled infusion (TCI)|Target-controlled infusion (TCI) with propofol up to 5.5µg/ml during an anticipated average maximal time of 15 minutes
3481726|NCT03783663|Experimental|Sleep education plus Misfit Shine 2|This arm receives sleep education from the study nurse and also receives a Misfit Shine 2 to wear for 12 weeks to self-monitor sleep.
3127647|NCT03101592|No Intervention|Standard of care ART dispensing|The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
3481727|NCT03783663|No Intervention|sleep education only|This arm receives only sleep education from the study nurse.
3481728|NCT03783767|Experimental|Leadership Intervention Group|Teachers in the intervention group will receive a half day workshop from a member of the research team. These teachers will then provide a four week training program to Grade 6/7 students, who will then deliver a 10-week fundamental movement skill (FMS) training program to Grade 3/4 students.
3481729|NCT03783767|No Intervention|Waitlist Control|This group of students and teachers will act as a waitlist control group. Therefore, during the same time that the other group is receiving the intervention, this group will proceed with their normal practices.
3481730|NCT03783468|Experimental|light sedation pressure support ventilation|
3481731|NCT03783481|Experimental|Mobile community group|join the mobile community via the smartphone application
3481732|NCT03783481|Active Comparator|No community group|
3481733|NCT03783624|Experimental|Hypnosis|"This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: in this deeply relaxed state, you can imagine that your feet are covered in anesthetic… a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again…."
3481734|NCT03783624|Placebo Comparator|Open Label placebo|This consists in information provided with a placebo pill. Patients are asked to take the placebo pills as a self-healing ritual. The information relies on 4 points of explanation, i.e. (1) the placebo effect can be powerful, (2) the body automatically can respond to taking placebo pills like Pavlov dogs who salivated when they heard a bell, (3) a positive attitude can be helpful but is not necessary, and (4) taking the pills faithfully for the full duration of treatment is critical.
3481735|NCT03783624|No Intervention|Usual care|Patients continue with their usual treatments
3481736|NCT03783442|Experimental|Tislelizumab + chemotherapy|Tislelizumab administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
3481737|NCT03783442|Active Comparator|Placebo + chemotherapy|Placebo administered with chemotherapy doublet (any of the two available chemotherapy drug combinations) for up to 24 months
3481738|NCT03783676|Experimental|Remifentanil group|Will receive remifentanil bolus and infusion guided by an algorithm
3481739|NCT03783676|Placebo Comparator|Control group|Will receive normal saline bolus and infusion guided by the remifentanil algorithm
3481740|NCT03783650|Experimental|Cohort 1|0-6 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist, Registry & BP measurement 7-12 months: QIC with Subspecialist to improve communication and standardize, 13-18 months: Hub and Spoke co-management QIC with Primary care and Subspecialist 19-24 months: Sustainability of changes
3481741|NCT03783650|Active Comparator|Cohort 2|0-6 months: Control condition Usual Care and Registry & BP measurement, 7-12 months: Quality Improvement Collaborative (QIC) with PCP and without subspecialist 13-18 months: QIC with Subspecialist to improve communication and standardize 19-24 months: Hub and Spoke co-management QIC with Primary care and Subspecialist
3481742|NCT03783819|Active Comparator|Active treatment|One forearm will be treated with ointment containing Hypericum perforatum oil. Forearm (left or right) will be chosen according to randomization protocol.
3481743|NCT03783819|Placebo Comparator|Placebo treatment|Other forearm will be treated with placebo ointment. Forearm (left or right) will be chosen according to randomization protocol.
3481744|NCT03783806||Osteoarthrosis (OA)|Patients with primary osteoarthrosis, waiting for a total hip replacement. Determination of functional status, posturography measurements, postural tests.
3481745|NCT03783806||Rheumatoid arthritis (RA)|Patients with rheumatoid arthritis affecting hip joint. Determination of functional status, posturography measurements, postural tests.
3481746|NCT03783806||Control (C)|The healthy reference group was matched with the patient groups for age, gender and body mass index (BMI). Determination of functional status, posturography measurements, postural tests.
3481747|NCT03783598|Experimental|intervention group|The intervention group received problem solving therapy as 6 modules. Each module was included at least 1 session per week that is nearly 60 minutes, and the amount of weekly sessions was arranged according to the needs of the person.Individuals has an opportunity was provided for identify problems meaningful for themselves and to start their change from the activities they valued by using the COPM.
3481748|NCT03783598|No Intervention|control group|Control group had not any intervention we have an education to control group about diabetes and healthy life conditions.
3481749|NCT03783455|Active Comparator|Non arthroscopic joint lavage (NAJL)|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper.
3481750|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the NAJL plus corticosteroid group was given an intra-articular injection containing 40 mg of triamcinolone acetonide.
3481751|NCT03783455|Active Comparator|Non arthroscopic joint lavage plus hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution, followed by an injection of local anesthetic (5 mL of 2% mepivacaine hydrochloride) into the outer mediopatellar zone. The anesthetic was allowed to act, and an access way was then opened with a No. 16 abocat. Any effusion in the joint was drained. Then, approximately 100 mL of cold saline was instilled through the outer access way. Once the knee was distended, a further 5 mL of local anesthetic was injected into the inner mediopatellar zone, and a new abocat guide was used to establish the inner drainage way. The lavage proper involved instillation of 4 L of cold (8ºC) saline at a constant flow-rate using a dropper line connected to the entry way; the inner zone was also connected to another, free-fall dropper. Following administration of the joint lavage, the patients were given an intra-articular injection containing 4 ml of a bioengineered hyaluronic acid.
3481752|NCT03783455|Active Comparator|Intraarticular injection of hyaluronic acid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
3481753|NCT03783455|Active Comparator|Intraarticular injection of corticosteroid|Establishment of sterile areas and cleaning of the skin around the knee with a povidone-iodine solution. This was followed by an intraarticular injection containing 40 mg of triamcinolone acetonide.
3481754|NCT03783585|Experimental|cognitive behavioral therapy for insomnia (CBT-I)|Participants randomized to this arm will participate in a 6-week web-based cognitive behavioral therapy for insomnia (CBT-I) program.
3481755|NCT03783585|Experimental|CBT-I + biweekly support|Participants randomized to this arm will participate in a 6-week web-based CBT-I program. In addition, biweekly support consisting of one-on-one, semi-structured, online video-chat sessions (via HIPAA-compliant Zoom) or phone calls will be conducted every other week.
3481756|NCT03783559|Experimental|Arm A|TACE plus chemotherapy ± target therapy
3481757|NCT03783559|Active Comparator|Arm B|chemotherapy ± target therapy
3481758|NCT03783364|Experimental|preoperative|preoperative radiotherapy
3481759|NCT03783364|Active Comparator|postoperative|postoperative radiotherapy
3481760|NCT03783533|Experimental|Adolescents|Adolescents with PHQ-9 scores between 5 and 12 (Mild Range) who do not report current suicidality (Pine et al., 1999) will be recruited from clinician target users' practice settings. The investigators will recruit new adolescents for each Aim to decrease bias in feedback and outcomes.
3481761|NCT03783520|Experimental|Er,Cr:YSGG Laser|In laser group, each root canal was dried with paper points and then Er,Cr:YSGG (Biolase™, Waterlase™, San Clemente, CA, USA) was used for intracanal disinfection with the following parameters: panel output power of 0,75 W, pulse frequency of 20 Hz, and 1% water pressure to 10% air pressure ratio laser with RFT3 tips (415 µm diameter radial firing tip RFT3 Endolase, Biolase Technology, Inc; calibration factor of 0.85). The fiber was placed at 1mm short of the WL. Irradiation was delivered along the entire length of the root canal with helicoradial movements, 1mm per seconds in speed. This procedure was repeated three times and kept for 20 seconds between each irradiation.
3481762|NCT03783520|Active Comparator|Sodium hypochlorite|In control group, each canal were irrigated with 6 ml of 2,5% NaOCl. For the final irrigation, 5 ml of sterile saline were used. During irrigation, needle was inserted 1 mm short of the WL.
3481763|NCT03783247|Experimental|FIB|hip fracture with fascia Iliaca block
3481764|NCT03783247|Experimental|PENG|Hip fracture with Pericapsular nerve group block
3481765|NCT03783507|Experimental|Order 1|Meal 1, Meal 2, Meal 3, Meal 4
3127648|NCT03101592|Experimental|Three-month ART dispensing|Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
3481766|NCT03783507|Experimental|Order 2|Meal 2, Meal 3, Meal 4, Meal 1
3481767|NCT03783507|Experimental|Order 3|Meal 3, Meal 4, Meal 1, Meal 2
3481768|NCT03783507|Experimental|Order 4|Meal 4, Meal 1, Meal 2, Meal 3
3481769|NCT03783338|Active Comparator|Physical therapy group|Group A will consist of 15 children and will receive the conventional physical therapy program only. This group will be used to compare the results of the other two groups.
3481770|NCT03783338|Experimental|Physical therapy and aerobic exercises group|Group B will consist of 15 children and will receive the conventional physical therapy program and aerobic exercises.
3481771|NCT03783338|Experimental|Physical therapy, aerobic exercises and vitamin D group|Group C will consist of 15 children and will receive the conventional physical therapy program, aerobic exercises and an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) .
3481772|NCT03783416|Experimental|Ixazomib (NINLARO®)|Treatment will follow a 28-day cycle. Participants will take one Ixazomib (NINLARO) capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free week, in sequence, for the duration of the trial.
3481773|NCT03783416|Placebo Comparator|Placebo|Treatment will follow a 28-day cycle. Participants will take one placebo capsule orally on days 1, 8, and 15 of each 28-day cycle, followed by one treatment-free, in sequence, for the duration of the trial.
3481774|NCT03783312|Placebo Comparator|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
3127649|NCT03101592|Experimental|Six-month ART dispensing|Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
3127650|NCT03102034|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants received a single dose of the D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
3127651|NCT03102034|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
3127652|NCT03102190|Experimental|Phase Ib|The phase Ib study will consist of an accelerated titration, intrapatient dose escalation cohort, with double-dose step design of Verapamil Hydrochloride. Intranasal BID for 1 week. Dose escalation will occur weekly as a doubling of the dose from 10-120mg Verapamil delivered in 240mL buffered normal saline. If a single, any course, dose-limiting toxicity (DLT) or second, any course, IT occurs, two additional patients will be recruited at that identified dose and Phase Ib will revert to a standard 3+3 design. If any patient un-enrolls while the dose escalation is still occurring, they will be replaced to maintain 3 patient cohorts. The maximal administered dose (MAD) will be considered that at which at least 2 DLTs or 4 ITs occur and the MTD will then be assigned to the immediate preceding dose.
3481775|NCT03783312|Active Comparator|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
3481776|NCT03783312|Active Comparator|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. Electroconvulsive therapy (ECT) is one of the effective and life-saving treatment modality used in psychiatry for a long time because it responds more rapidly than pharmacological treatment.
3481777|NCT03783390|No Intervention|Orientation|Informed consent, height, weight, and blood pressure measurement. A link to an online survey the participant and their parent can fill out at home about the participant's medical history will be given.
3481778|NCT03783390|No Intervention|Measurement session Pre/Post Intervention|Questionnaires completed, blood draws, and fixed and ad lib meals completed to measure appetite and hormones. DXA completed.
3127653|NCT03102437|Experimental|Optimizer Smart System|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
3481779|NCT03783390|No Intervention|Home Assessments Pre/Post intervention|24-hour dietary recalls. Physical activity measured by monitors (Actigraph, ActivPAL).
3481780|NCT03783390|No Intervention|Physical Activity Session Pre/Post intervention|DXA, and Fitness testing to measure VO2submax and VO2max. Cognitive assessments will be administered.
3481781|NCT03783390|No Intervention|fMRI Session Pre/Post intervention|The participant will have an fMRI completed and answer questions related to 60 food and activity images while in and out of the fMRI machine.
3481782|NCT03783390|Experimental|Exercise Intervention/Newsletter|After completion of the initial fMRI session the participant will be randomly assigned to intervention for 3 months and then complete another round of assessments described as above (except for the orientation session).
3481783|NCT03783611|Experimental|Intervention group|The intervention group has access to the MyPlan 2.0. eHealth intervention. MyPlan is a eHealth intervention designed to increase physical activity. The intervention is based on the self-regulation theory and focuses on pre- and post-intentional processes to increase physical activity.
3481784|NCT03783611|No Intervention|control group|The control group receives no intervention
3481785|NCT03783429|Active Comparator|Intervention group|The intervention group will receive low-dose digoxin
3481786|NCT03783429|Placebo Comparator|Placebo group|The placebo group will receive a matching placebo
3481787|NCT03783182|Active Comparator|Betapred|16 'Betamethason Sodium Phosphate' tablets dissolved in one ml of water as part of the premedications given to the patient 30 min before the surgery
3481788|NCT03783182|Placebo Comparator|Placebo|One ml of 10% glucose solution as part of the premedications given to the patient 30 min before the surgery
3481789|NCT03783377|Experimental|ARO-APOC3|
3481790|NCT03783377|Placebo Comparator|Placebo|
3481791|NCT03783195|Experimental|High GRS group|This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
3481792|NCT03783195|Experimental|Low GRS group|This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
3481793|NCT03783260|Experimental|Single|All participating subjects will undergo two, 2-day Mediterranean diet feeding periods separated by a 14-day period of Canadian diet
3481794|NCT03783299|Experimental|Village-based MTAT|"Intervention: For all households in intervention villages, after obtaining informed consent, MTAT will be conducted with all household members aged 18 months and older.~The MTAT team will test each individual using both a standard RDT and HS-RDTs. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
3481795|NCT03783299|Experimental|Peer navigator-led FTAT|"Intervention: Peer navigators will actively seek non-village based HRPs in forested areas, rice fields and plantations, and any other non-permanent settlements within target health center catchment areas, and conduct FTAT among all consenting individuals.~The Peer Navigators will test each individual using both a standard RDT and HS-RDT. Positive cases will be treated with age-appropriate doses of Artemether-lumefantrine (AL) and Primaquine Phosphate (SLD-PQ)"
3481796|NCT03783325|Other|UV Counseling|Evaluate the effectiveness of dosimetry feedback on sun exposure behaviors, attitudes, and awareness in patients diagnosed with melanoma.
3481797|NCT03783325|Experimental|Visual Analysis - UV Photo|Assess the relationships between UV camera score, silicone mold of a skin patch, phenotypic evaluation and sun-exposure behaviors. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
3481798|NCT03783325|Experimental|Biological Sample|Determine the relationship between measures of sun exposure and genomic characteristics of tumors in melanoma patients. Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
3481799|NCT03783104|Experimental|250μg of vitamin B12 supplementation|Group 1 (Intervention) will receive 250μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
3481800|NCT03783104|Active Comparator|50μg of vitamin B12 supplementation|Group 2 (Control) will receive 50μg of vitamin B12 supplementation delivered daily to the mother from 12 weeks gestation up to 6 months post-partum.
3481801|NCT03783273|Experimental|Whey protein complex-bound D3 + juice|200 microgram vitamin D3 in a whey protein-complex added to 500 mL of juice.
3481802|NCT03783273|Active Comparator|D3 + juice|200 microgram vitamin D3 added to 500 mL of juice.
3481803|NCT03783273|Active Comparator|D3 + milk|200 microgram vitamin D3 added to 500 mL of skimmed-milk.
3481804|NCT03783273|Active Comparator|D3 droplets|200 microgram vitamin D3 as droplets + 500 mL of water.
3481805|NCT03783273|Placebo Comparator|No vitamin D|500 mL of Water.
3481806|NCT03783221|Experimental|High-fat diet|
3481807|NCT03783221|Active Comparator|High-residue diet|
3481808|NCT03783208|Experimental|G-CSF|Patients in the G-CSF group will receive G-CSF once a day on hCG day, before hCG injection. The procedure involved the administration of G-CSF through slow infusion into the endometrial cavity using a soft embryo transfer catheter.
3127654|NCT03102645|Experimental|Imipramine first|A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2
3481809|NCT03783208|Placebo Comparator|Control group|Normal saline of 1 mL was infused into the endometrial cavity in the same way in patients in the control group
3481810|NCT03783169||Symptomatic patients|All pregnant women (under the care of the Maternal-Fetal Medicine physicians or Faculty Medical Center physicians with MFM involvement) experiencing a hypertensive emergency (sustained systolic blood pressure > 160 mmHg or sustained diastolic blood pressure > 110 mmHg {or both} on at least two consecutive occasions 15 minutes apart). All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
3481811|NCT03783169||Asymptomatic patients|All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
3481812|NCT03783117|Experimental|Magnetic field treatment|Each subject will place his/her right arm into a bore of the Magnetic Blood Pressure Lowering (MBPL) Device for magnetic treatment of 15 minutes, while the blood pressure is monitored with the left arm. The MBPL device produces a magnetic field around 1T parallel to the blood flow inside the arm. The subject's blood pressure will be lowered. The subject needs to come back to check the blood pressure 24 hours after the treatment.
3481813|NCT03782987|Experimental|Treatment T|BI 730357 plus Itraconazole
3481814|NCT03782987|Experimental|Treatment R|BI 730357 alone
3481815|NCT03783065|Experimental|Experimental group|Procedure: Laparoscopic splenectomy and pericardial devascularization Drug: Propranolol
3481816|NCT03783065|Active Comparator|Control group|Procedure: Endoscopic therapy Drug: Propranolol
3481817|NCT03782961|Experimental|Stand up|After application of the product (sodium lactate and combination of polymers) will remain standing for 30 minutes
3481818|NCT03782961|Experimental|Lying down|After application of the product (sodium lactate and combination of polymers) remained lying down with the legs stretched for 30 minutes;
3481819|NCT03783078|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W) intravenous (IV), for up to 35 administrations (approximately 2 years)
3481820|NCT03783052|Other|Healthy volunteers|11 Healthy volunteers
3481821|NCT03783052|Other|Obese volunteers|11 Obese Volunteers
3481822|NCT03783052|Other|Roux-en-Y Gastric Bypass patients|6 volunteers with a Roux-en-Y Gastric Bypass
3481823|NCT03783052|Other|Sleeve Gastrectomy patients|6 volunteers with a Sleeve Gastrectomy
3481824|NCT03783052|Other|Volunteers with obesity|6 obese volunteers
3481825|NCT03783156|Other|hot snare|polypectomy with hot snare
3481826|NCT03783156|Other|cold snare|polypectomy with cold snare
3481827|NCT03782935|Experimental|prenatal multivitamin mineral supplement|received prenatal multivitamin mineral supplement at time of enrollment TheraVit multivitamin/mineral prenatal supplement with instructions to take 1 per day through the remainder of pregnancy
3481828|NCT03782935|Experimental|prenatal multivitamin mineral supplement plus choline|received prenatal multivitamin mineral supplement plus additional choline supplemental vitamin TheraVit multivitamin mineral supplement plus 750 mg. choline with instructions to take1 multivitamin mineral supplement and 750 mg. per day of choline through the remainder of pregnancy
3481829|NCT03782935|No Intervention|Comparison|Advised to follow obstetrics standard of care which is to take a prenatal vitamin/mineral supplement
3481830|NCT03782974|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day (containing 200mg of beta glucan) for a total duration of 8 weeks.
3127655|NCT03102645|Experimental|Placebo first|A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2
3127656|NCT03102710|Experimental|tDCS Enhancement|In this group, the transcranial direct current stimulation (tDCS) stimulates the areas of the brain being examined in this study to increase their activity.
3481831|NCT03782974|Placebo Comparator|Placebo|Participants were treated with 2 tablets of placebo per day (contain no beta glucan) for a total duration of 8 weeks.
3481832|NCT03783013|Other|No Soy and Low Lycopene Juice|Participants will consume two cans daily of a low lycopene tomato juice in addition to a diet low in lycopene and isoflavones.
3481833|NCT03783013|Other|Soy and Lycopene Juice|Participants will consume two cans daily of a high lycopene tomato juice with added soy germ extract in addition to a diet low in lycopene and isoflavones.
3481834|NCT03782896||mastectomy group|All patients who received the mastectomy (breast conserving surgery and sentinel lymph node dissection)
3481835|NCT03782740|Experimental|Dysmenorrhea Melatonin 10 mg|In the dysmenorrhea group: 2 capsules with 5 mg melatonin will be given in the evening for seven days consecutively during menstruation for two mentrual cycles. Compared with placebo.
3481836|NCT03782740|Experimental|Endometriosis Melatonin 20 mg|In the endometriosis group: 4 capsules with 5 mg melatonin will be given every evening during eight weeks. Compared with placebo.
3481837|NCT03782857|Experimental|Intervention group|Initiation/stepwise escalation of antihypertensive medication in case of blood pressure above individual target Initiation/stepwise escalation of cholesterol lowering medication in case of LDL-cholesterol above individual target Advice on healthy lifestyle and life long adherence to preventive medication
3481838|NCT03782857|No Intervention|Control group|Participants had the usual treatment: all patients were invited to one visit in the outpatient clinic three months after discharge with a diagnosis of stroke/TIA
3481839|NCT03782766|Experimental|piezosurgery|group 1 consisted of 18 molars (13 molars from patients with bilateral first molar extraction space and 5 molars from patients with unilateral first molar extraction space) where piezocesion was performed immediately before molar protraction
3481840|NCT03782766|No Intervention|No piezocision|group 2 consisted of 21 molars (13 from patients with bilateral first molar extraction space and 8 molars from patients with unilateral first molar extraction space) where molar protraction was performed with no piezocesion
3127657|NCT03102710|Experimental|tDCS Inhibition|In this group, the transcranial direct current stimulation (tDCS) inhibits the areas of the brain being examined in this study to decrease their activity.
3127658|NCT03102710|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation (tDCS) does not provide real stimulation though you will not know this until your debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
3127659|NCT03102736|Placebo Comparator|Placebo and Ketamine|Placebo saline given over 240 minutes + 0.5 mg/kg ketamine given over 40 minutes
3127660|NCT03102736|Experimental|Nitroprusside and Ketamine|0.5 mcg/kg/min nitroprusside given over 240 min (4 hours) - 0.5 mg/kg ketamine given over the last 40 min of the nitroprusside infusion (starting at minute 200 the two drugs are given together)
3127661|NCT03102762|Experimental|Botulinum Toxin Type A (BTX-A) Group|Experimental: BTX-A Group The treatment group, 35 patients, will be injected with 100 units BTX-A one day following penile colour Doppler assessment.
3179619|NCT00674921|Active Comparator|2|It will comprise patients randomized to continue with cotrimoxazole prophylaxis and HAART at CD4 counts of 200 or more but less than 350 cells/ul. These patients will be followed until they achieve a CD4 count of 350 cells/ul and above, at which point they will be considered for the second randomization.
3481841|NCT03782766|Other|Late piezocision|group 3 consisted of 21 molars (group 2 subjects where piezocession was carried on after 3 months of molar protraction with no piezocesion.
3481842|NCT03782792|Experimental|Spesolimab|
3481843|NCT03782792|Experimental|Placebo|
3481844|NCT03782688||Single-arm cohort|Patients with significant coronary stenosis by invasive fractional flow reserve (FFR≤0.80)
3481845|NCT03782831|Experimental|TACE plus PD-1 antibody|Patients received hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3481846|NCT03782831|Active Comparator|TACE alone|Patients received hepatic intra-arterial infusion with lipiodol mixed with hemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA) on demand. In addition, patients received placebos intravenously every 2 weeks
3481847|NCT03783000|Experimental|All subjects|Treatment T followed by Treatment R
3481848|NCT03782948|Active Comparator|Controls|"In each session, the group will undergo standard gait training on BART without pelvic perturbations, i.e.,~walk a virtual track on the BART without pelvic perturbations (i.e., the pelvic brace of the BART device will be set to follow the patient's motion) for 10 minutes;~practise gait symmetry and take-off using visual feedback without pelvic perturbations in two 10-minute sessions."
3481849|NCT03782948|Experimental|Experimental|"In each session, the group will undergo robotised gait training with BART with pelvic perturbations, i.e.,~walk a virtual track on the BART with pelvic perturbations during virtual uphill walk and virtual curved walk for 10 minutes;~practise gait symmetry and take-off using visual feedback with pelvic perturbations for 10 minutes;~practise dynamic gait balance using pelvic perturbations during treadmill walking for 10 minutes."
3481850|NCT03782779|Experimental|Breathing program and regular exercise|Diaphragmatic Breathing Program plus regular upper and lower limb exercises
3481851|NCT03782779|Active Comparator|Regular Exercise|Regular upper and lower limb exercises
3481852|NCT03782909|Experimental|Behaviour change intervention|Intensive behaviour change for 6 weeks, followed by a maintenance phase for 6 weeks
3481853|NCT03782675|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device the device is turned on or not.
3481854|NCT03782675|Experimental|Air Barrier System|In the experimental (interventional) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
3481855|NCT03782805|Experimental|treatment group|Group receiving a supplement of 10,000 IU of cholecalciferol (Euro-Pharm International, Canada) to be taken 3 times a week for a period of six months.
3481856|NCT03782805|Placebo Comparator|Placebo group|Group receiving a placebo tablet (containing microcrystalline cellulose: 66.3%, starch: 33.2%, magnesium stearate: 0.5%, per serving) to be taken 3 times a week for a period of six months
3481857|NCT03782753||Group A|25 LRRK2-PD patients
3481858|NCT03782753||Group B|25 idiopathic PD patients
3481859|NCT03782753||Group C|25 HC subjects
3481860|NCT03782922|Experimental|Exercise Training Program|
3481861|NCT03782922|No Intervention|Control|
3481862|NCT03782818|Experimental|Olaparib|After a 4-week pre-treatment phase to ensure that patients are on stable doses of PAH medication, patients will be given progressive doses of olaparib up to 300 mg BID for 24 weeks.
3481863|NCT03782662|Experimental|RV521 plus Itraconazole|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D7 plus Itraconazole 100 mg capsules for oral administration, a 200 mg dose administered once daily on D4 - D10, inclusive
3481864|NCT03782662|Experimental|RV521 plus Verapamil|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D11 plus Verapamil, 80 mg tablets for oral administration, an 80 mg dose administered TDS daily on D4 - D14, inclusive
3481865|NCT03782662|Experimental|RV521 plus Rifampicin|RV521 drug substance in capsule for oral administration, a single 200 mg dose administered on D1 and a single 200 mg dose administered on D10 plus Rifadin, Rifampicin, 300 mg capsules for oral administration, a 600 mg dose administered once daily on D4 - D10, inclusive
3481866|NCT03782662|Experimental|RV521 plus Midazolam|RV521 drug substance in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
3481867|NCT03782662|Placebo Comparator|Placebo plus Midazolam|Placebo for RV521 in capsule for oral administration, 200 mg dose administered BID on D2 - D15, inclusive plus Buccolam 10 mg oromucosal solution of midazolam, oral syringes, a single 10 mg dose administered on D1 and a single 200 mg dose administered on D15
3481868|NCT03782844|Experimental|Conventional fixed CPAP and simple CPAP|Participants in this group were manually titrated . They were treated with conventional fixed pressure CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
3481869|NCT03782844|Experimental|Auto CPAP and simple CPAP|Participants in this group after being manually titrated were treated with Auto RemStar CPAP and Simple CPAP for two separate nights in random order monitored by full polysomnography.
3481870|NCT03782623||Intensive care patients after elective open aortic surgery|
3481871|NCT03782623||Intensive care patients after bilateral lung transplantation|
3481872|NCT03782623||Anesthetic intensive care patients, unplanned admission|
3481873|NCT03782714|Experimental|Low-level laser therapy group|This group of teeth received laser irradiation after amputation of coronal pulp
3481874|NCT03782714|No Intervention|Formocresol group|This group of teeth received the gold standard medication (formocresol) after coronal pulp amputation
3481875|NCT03782610||Primary Study Cohort|450 Infants
3481876|NCT03782610||Validation Cohort|225 Infants. Will allow subsequent validation of models derived from the Primary Study Cohort.
3481877|NCT03782649|Experimental|RSP-08|All subjects undergo the same procedures. Subjects will be subjected to measurements on the IMD (Working Model 3.4NR), FreeStyle Libre, Dexcom, microdialysis, venous and capillary blood collection.
3481878|NCT03782584|Experimental|Modified Pilates Exercise Group|they will be involved in a modified pilates exercise training for a total of 6 weeks a day, 2 days a week.
3481879|NCT03782584|Other|Control Group|they will be given daily life advises to prevent neck pain
3127662|NCT03102762|Placebo Comparator|Placebo Group|"Saline Group:~The control group, 35 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment."
3127663|NCT03102879|Experimental|Regenerative Endodontic Procedure (REP)|umbilical cord-derived mesenchymal stem cells encapsulated in a plasma-derived biomaterial.
3127664|NCT03102879|Active Comparator|Conventional Root Canal Treatment|Conventional endodontic procedure
3481880|NCT03782480|Active Comparator|Intrarosa|Daily intravaginal administration at bedtime of one insert containing 6.5mg (0.50%) prasterone for 26 weeks
3481881|NCT03782480|Placebo Comparator|Placebo|Daily intravaginal administration at bedtime of one insert containing placebo for 26 weeks
3481882|NCT03782428|Active Comparator|Probiotic group|27 participants received probiotics twice daily for six months
3481883|NCT03782428|Placebo Comparator|Placebo group|25 participants received placebo twice daily for six months
3481884|NCT03782402|Experimental|Cannabinoids of varied strength|Strengths of cannabinoids will vary across groups
3481885|NCT03782402|Active Comparator|Cannabinoids of various strengths|Strengths of cannabinoids will vary across groups
3481886|NCT03782363|Experimental|Autologous CIK Dose level 1|autologous CIK at dose level 1
3481887|NCT03782363|Experimental|Autologous CIK Dose level 2|autologous CIK at dose level 2
3481888|NCT03782363|Experimental|Autologous CIK Dose level 3|autologous CIK at dose level 3
3481889|NCT03782363|Experimental|Autologous CIK Dose level 4|autologous CIK at dose level 4
3481890|NCT03782493|Experimental|Enhanced Milieu Teaching-Sentence Focus|The study intervention is a behavioral intervention which will include individually teaching caregivers to use the intervention strategies from the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention using a manualized protocol (Teach-Model-Coach-Review). Caregivers will participate in 66 intervention sessions across 18 months, targeting vocabulary and grammar as well as the transition to decontextualized language.
3481891|NCT03782493|No Intervention|Business-as-usual control|Caregivers in the control group will participate in community-based intervention services and receive the same printed intervention instructions, books, and toys at the same intervals as the treatment group, but will not receive EMT-SF intervention.
3481892|NCT03782454||intensive care patients with sepsis|Adult patients with verified or suspected sepsis admitted to the intensive care department from the emergency department
3481893|NCT03782441|Experimental|RSP-19|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 42 days.
3481894|NCT03782558||Patients with CTS|Surgical transection of transverse ligament
3481895|NCT03782519|Experimental|Incremental hemodialysis|Patients who will begin HD with two treatment sessions per week
3481896|NCT03782519|Active Comparator|Conventional hemodialysis|Patients who will begin HD three times a week
3481897|NCT03782220|Experimental|Kinesio taping group|"Kinesio taping group~Application of kinesio taping to sternocleidomastoid, upper trapezium, levator scapulae muscles.~Once a week , for 4 weeks"
3481898|NCT03782220|Placebo Comparator|Shame taping group|"Shame taping group~Application of kinesio band to same muscles except for the defined method which is considered to be ineffective.~Once a week , for 4 weeks"
3127665|NCT03102918|Active Comparator|Cannabidiol|Epidiolex
3481899|NCT03782506|Experimental|Interactive Music Therapy|Ten 45-minute individual interactive music therapy sessions.
3481900|NCT03782506|Active Comparator|Verbal-based Support|Ten 45-minute individual verbal support sessions.
3481901|NCT03782467|Experimental|ATOR-1015|ATOR-1015 administered by intravenous infusions every 2 weeks until confirmed progressive disease, unacceptable toxicity or withdrawal of consent.
3481902|NCT03782389||Elite football players aged 16-40 years|
3481903|NCT03782415|Experimental|MN-166 and temozolomide|Part 1: Combination treatment of MN-166 60 mg/day (30 mg twice a day) for 28 days and temozolomide 150 mg/m² on Days 1-5 of 28-day cycle. Part 2: Open-label, fixed-dose MN-166 and temozolomide combination treatment for 6 cycles until disease progression, unacceptable tolerability and/or toxicity or loss of life.
3481904|NCT03782012|Experimental|Knowledge Supported|Students will have 30 seconds to view pictures of the knowledge base items and discuss relations among items.
3481905|NCT03782012|Experimental|Knowledge Not Supported|Students will be provided 30 seconds to view pictures of the knowledge base items.
3481906|NCT03782311||2 groups: OHSE-high and OHSE-low|"OHSE-high: Group with ≥ 50 OHSE scores received motivation and oral hygiene instructions .~OHSE-low: Group with < 30 OHSE scores received motivation and oral hygiene instructions ."
3481907|NCT03782038|Experimental|Micro-coring of scars with MCD|Micro coring of acne scars and straie will be conducted in up to 3 treatments and followed 6 months post last treatment with MCD.
3127666|NCT03102918|Placebo Comparator|Placebo|Placebo
3127667|NCT03103061|Experimental|Myocardial Stress CT Perfusion|Low-radiation, dynamic perfusion CT of the heart in patients with suspected ischemic chest pain and a moderate or severe stenosis seen on coronary CTA. Lexiscan(TM) will be used as the pharmacological stress agent (coronary vasodilator).
3481908|NCT03781999|Experimental|Actiful|a supplement containing 500 mg orange extract and 200 mg pomegranate actives
3481909|NCT03781999|Placebo Comparator|Placebo|Maltodextrin
3127668|NCT03103100|Active Comparator|1% Lidocaine|Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine
3481910|NCT03782025||Patients with increased PK-INR|Critically ill patients with spontaneously increased prothrombin complex (PK-INR) who are given phytomenadione intravenously at the discretion of the treating physician
3481911|NCT03782246|No Intervention|Usual Care|No intervention, participant will continue their usual care for pain and MS. We will collect information about what treatments are used by the usual care participants. They will be offered the opportunity to participate in one of the two active study treatments (MBCT or CBT) after completion of the 6-month followup.
3481912|NCT03782246|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Participants will attend eight, 2-hour group treatment MBCT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. MBCT integrates mindfulness meditation practices within a CBT-oriented framework to address not only unhelpful pain cognitions and behaviors but also attentional control, decoupling of attention from emotion, mindful cognitions, and meditative behavior.
3481913|NCT03782246|Experimental|Cognitive Behavioral Therapy (CBT)|Participants will attend eight, 2-hour group treatment CBT sessions delivered using free video-conferencing technology. Groups will consist of 6-8 people who also have MS and chronic pain. Participants will be asked to practice skills learned in session between sessions. CBT focuses on increasing adaptive pain coping strategies and reducing unhelpful thoughts and behaviors related to pain. Strategies include relaxation techniques, goal-setting, activity pacing, and changing unhelpful thinking patterns.
3481914|NCT03781947|Experimental|90 mg s.c.|A single s.c. injection of 90 mg teverelix TFA administered on Day 1
3481915|NCT03781947|Experimental|60 mg s.c.|A single s.c. injection of 60 mg teverelix TFA administered on Day 1
3481916|NCT03781947|Experimental|90 mg i.m.|A single i.m. injection of 90 mg teverelix TFA administered on Day 1
3127669|NCT03103100|Active Comparator|0.25% Bupivacaine|Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine
3481917|NCT03781947|Experimental|120 mg s.c.|A single s.c. injection of 120 mg teverelix TFA administered on Day 1
3481918|NCT03782103|Experimental|Zurex Prep (70% IPA)|Isopropyl alcohol (IPA) 70%
3481919|NCT03782103|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3481920|NCT03782103|Placebo Comparator|Zurex Prep Vehicle|Zurex Prep without IPA
3481921|NCT03782064|Experimental|Nivolumab+DC/myeloma fusions/GM-CSF|"Nivolumab will be given every two weeks~The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle"
3481922|NCT03782129||Diabetic patients with DFU|Diabetic patients with DFU diagnosed in 2010
3481923|NCT03782155|Experimental|HMB and glutamine supplementation|Patients with type 2 diabetes with supplementation HMB 3g, powder once a day and glutamine powder 14g once a day supplementation during 15 days.
3481924|NCT03782155|Placebo Comparator|placebo patients|Patients with type 2 diabetes with placebo( calcium caseinate) supplementation during 15 days 17g of powder once a day
3481925|NCT03782090|Active Comparator|Control|Endobronchial intubation using conventional technique with left-sided double-lumen endotracheal tube (Shiley®, Covidien, Mansfield, MA, USA)
3481926|NCT03782090|Experimental|Experimental|Endobronchial intubation using novel left-sided double-lumen endobronchial tube (Ankor®,Insung Medical, Wonjou, S. Korea)
3127670|NCT03103100|Active Comparator|Bupivacaine plus Lidocaine|Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.
3127671|NCT03103438|Experimental|Cohort 1|his cohort includes one subject who will receive the maximum safe starting dose of BCD-089 (0.06 mg/kg) subcutaneously. If the dose limitating toxicity occurs within the first seven days after injection the study will be stopped. If there is no DLT within mentioned above period then Cohort no.2 is included.
3127672|NCT03103438|Experimental|Cohort 2|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.3 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no.3 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 3.
3481927|NCT03782194|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MRI data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
3481928|NCT03782194|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
3481929|NCT03782051|Active Comparator|Phacovisco group|group had combined phacoemulsification and viscocanalostomy
3481930|NCT03782051|Active Comparator|OloPhacovisco group|group had combined phacoemulsification and viscocanalostomy and Ologen
3481931|NCT03781960|Experimental|Abemaciclib & Nivolumab|Subjects will receive abemaciclib monotherapy 150mg twice daily for seven days then will initiate nivolumab 480mg IV every 28 days while continuing twice daily abemaciclib.
3481932|NCT03781908|Experimental|Silver Nitrate Pleurodesis|Patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%
3481933|NCT03781908|Active Comparator|Indwelling Pleural Catheter|Catheters will be inserted in an outpatient setting under local anaesthesia.The typical drainage schedule is every other day using disposable plastic bottles (550 mL to 1 L)
3481934|NCT03782142||Group A NRTI + NNRTI|Based on current regimens that are commonly used (2017-2018 ART guidelines), our groups will include NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an NNRTI (Non-nucleoside reverse transcriptase inhibitor, Rilpivirine
3481935|NCT03782142||Group B NRTI + boosted PI|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and a boosted Protease Inhibitor: Prezcobix- [darunavir+cobicistat combination]
3481936|NCT03782142||Group C NRTI + II|NRTI such as TAF (tenofovir alafenamide) or TDF (tenofovir disoproxil fumarate) and an Integrase inhibitor (dolutegravir)
3481937|NCT03781921||BN|Females with a current diagnosis of Bulimia Nervosa between 18 and 50 years old
3481938|NCT03781921||Controls|Females with no current or past diagnosis of any eating disorder; between 18 and 50 years old
3481939|NCT03781895|Placebo Comparator|A0|"A0- On day 0,before intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
3481940|NCT03781895|Placebo Comparator|A90|"A90- On day 90,after intervention placebo,~Microcrystalline Cellulose (303.8gm)~Butylated Hydroxy Toluene (0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~weekly,orally,for 90days"
3481941|NCT03781895|Active Comparator|B0|"B0- On day 0,before intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
3481942|NCT03781895|Active Comparator|B90|"B90- On day 90,after intervention cholecalciferol,~Cholecalciferol (40,000IU)~Microcrystalline Cellulose (58.1 gm)~Butylated Hydroxy Toluene ( 0.2mg)~Magnesium Stearate (3mg)~Gelatin Capsule Shell (1mg)~80.000IU/week,orally,for 90 days"
3481943|NCT03781882|Active Comparator|Intervention group|All patients in this group will be manged as usual with infiltration of platelet rich plasma in thee wound edges during closure of the wounds
3481944|NCT03781882|Active Comparator|Control group|All patients in this group will be managed by repair of wounds without infiltration of platelet rich plasma
3481945|NCT03781765|Active Comparator|Methylphenidate|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
3481946|NCT03781765|Active Comparator|Atomoxetine|0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
3481947|NCT03781843|Active Comparator|Genicular nerve block with lidocaine|The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 6 mL of a solution containing 6 mL of 2% lidocaine or 6 mL dextrose or 6 mL saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves Interventions: Drug: 6 mL 2% lidocaine Procedure: Genicular nerve block
3481948|NCT03781843|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a saline was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Saline Procedure: Genicular nerve block"
3481949|NCT03781843|Placebo Comparator|Genicular nerve block with dextrose|"The ultrasound-guided genicular nerve block was performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler was used to identify the arterial structures which serve as landmarks for the corresponding nerves.~10 cm 21 G insulated block needle was inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle time is confirmed, 5 mL of a dextrose was slowly injected. Spread of local anesthetic was documented adjacent to the target nerve. This procedure was performed at the site of the three genicular nerves.~Interventions:Drug: Dextrose Procedure: Genicular nerve block"
3481950|NCT03781869|Experimental|Anlotinib + Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, and Anlotinib 12mg/d on day 1 to day 14 , repeated every 21 days, a total of 4-6 cycles, and then continue to take Anlotinib 12mg/d on day 1 to day 14, repeated every 21 days until progressive Disease(PD).
3481951|NCT03781869|Placebo Comparator|Chemotherapy|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 75mg/m2 on day 1, repeated every 21 days, a total of 4-6 cycles, and then follow up observation until PD.
3481952|NCT03781830|Experimental|mHealth Intervention|Participants will receive the mHealth application either while they are an inpatient post-transplant, or at one of their post-transplant clinic visits. Study personnel will assist participants with downloading the mHealth application and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
3481953|NCT03781856|Experimental|La Vida Buena Program|Administered in a group setting over the course of 8 weeks in a community setting.
3481954|NCT03781856|Active Comparator|Brief educational session|Administered one on one or in a group setting in a one-hour session at the clinic
3481955|NCT03781739|Experimental|MANP|subjects receiving MANP (2.5 micrograms/kg, single subcutaneous injection)
3481956|NCT03781739|Placebo Comparator|Placebo|subjects receiving placebo (saline solution, single subcutaneous injection)
3481957|NCT03781687|Active Comparator|Bilateral|Bilateral ESP block will be performed
3481958|NCT03781687|Active Comparator|Unilateral|Unilateral ESP block will be performed
3481959|NCT03781596|Experimental|Fluticasone and omeprazole|These patients will be prescribed swallowed fluticasone and omeprazole to be taken together for the 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
3127673|NCT03103438|Experimental|Cohort 3|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 0.625 mg/kg.If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 4 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 4.
3127674|NCT03103438|Experimental|Cohort 4|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.0 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 5 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 5.
3481960|NCT03781596|Placebo Comparator|Fluticasone and placebo|These patients will be prescribed swallowed fluticasone and a placebo medication that appears identical to omeprazole to be taken together for an 8 week period. Dosing will be based on weight and age. Primary outcome measure will be the change in esophageal biopsy histology, or number of eosinophils per high powered field, from week 0 to week 8. Secondary outcomes will include changes in the following variables between week 0 and 8: eotaxin staining of the esophageal biopsy tissue, endoscopic scoring from photos of the esophagus obtained during endoscopy, and symptom scoring based on surveys.
3481961|NCT03781622|Experimental|WOLF Thrombectomy Device Arm|Patients enrolled in the study who received the treatment and who met all Inclusion and Exclusion Criteria
3481962|NCT03781804|Active Comparator|OPN-375 186 μg BID|OPN-375 186 μg BID x 24 Weeks
3481963|NCT03781804|Active Comparator|OPN-375 372 μg BID|OPN-375 372 μg BID x 24 Weeks
3481964|NCT03781804|Placebo Comparator|Placebo|Matching Placebo BID x 24 Weeks
3481965|NCT03781674|Active Comparator|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg(4 tablets) daily beginning at 18-22 weeks gestational age
3481966|NCT03781674|Active Comparator|progesterone 200mg plus placebo to progesterone 200 mg|Women received vaginal progesterone suppositories in a dose of 200 mg(2 tablets) daily beginning at 18-22 weeks gestational age plus 2tablets placebo to vaginal progesterone
3481967|NCT03781674|Placebo Comparator|placebo to progesterone 400 mg|Women received 4 tablets placebo to vaginal progesterone suppositories
3481968|NCT03781752|Experimental|Methylphenidate|Youth with ADHD
3481969|NCT03781648|Other|WL withdrawal method|Active Comparator: WL was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
3481970|NCT03781648|Experimental|NBI withdrawal method|Experimental: NBI was used on withdrawal. During the insertion phase, air pump was turned off to avoid inadvertent insufflations. Water exchange with infusion pump was used to open the lumen and simultaneous suction of infused water to allow passage of the scope in clear water. Withdrawal phase done using air insufflation.
3481971|NCT03781635|Active Comparator|bolus of intravenous ketamine|A bolus of 0.25mg.kg-1 of ketamine will be first administered at the time of incision (T0) then every single hour for the rest of the surgery. Study starts at incision (T0) for ketamine administration and ends when the surgical team starts closing the deep layers of the abdominal incision.
3481972|NCT03781635|Experimental|continuous infusion of intravenous ketamine|An infusion of 0.25 mg.kg-1.h-1 is started at T0 (incision) with an infusion pump and is kept at the same rate until the surgical team starts closing the deep layers of the abdominal incision. Consumption of the infusion pump is noted at T0 (incision) and at each hour during the surgery until the infusion is discontinued.
3481973|NCT03781531||Venous thromboembolism|Patients presenting with venous thromboembolism (thrombosis in the deep venous system of upper or lower extremities or iliac veins and/or pulmonary embolism) as detected by ultrasonography, phlebography, computer tomography, or angiography
3481974|NCT03781544|Experimental|Diclofenac|Diclofenac (Diclofenacum natricum) A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
3481975|NCT03781544|Active Comparator|Paracetamol|"Paracetamol (Paracetamol Sintetica):~A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm)."
3481976|NCT03781544|Experimental|Tramadol|"Tramadol (Tramadol-Mepha):~A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm)."
3481977|NCT03781518|Experimental|ridge splitting|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic mandible and splinting with screws
3481978|NCT03781518|Active Comparator|khoury shell technique|bone block is taken from the ramus to augment deficient posterior mandible and splinting with screws
3481979|NCT03781557|Experimental|High-concentrated DHA|High-concentrated DHA fish oil softgels
3481980|NCT03781557|Experimental|High-concentrated EPA|High-concentrated EPA fish oil softgels
3481981|NCT03781557|Placebo Comparator|Olive Oil|Olive Oil softgels
3481982|NCT03781661|Experimental|Intervention Group|The participants in the intervention group will be provided with extended information of the advantages of the CT examination of the heart's arteries. This will be given to the participants both orally and written in form of a leaflet. In addition will they be given the opportunity for a visual go-through of their own calcium score images. After this they will be informed of the normal examination result.
3481983|NCT03781661|No Intervention|Control group|Control Group receives standard care.
3481984|NCT03781713|Active Comparator|STUDY GROUP|patients who triggered triggers and had interventions. Kdigo: interventions to prevent renal replacement therapy Delta SOFA: interventions to improve SOFA score Hypoglycemia: Interventions to prevent new episodes of hypoglycemia in the next 24 hours Drug interaction risk D or X - Intervention in the therapeutic plan in order to avoid adverse drug reactions. Antimicrobial stewardship: optimization of antimicrobial therapy based on Gram stain, MALDI TOF, MIC, antimicrobial susceptibility
3481985|NCT03781713|No Intervention|CONTROL GROUP|patients who did not triggered triggers
3481986|NCT03781505|Experimental|Intravenous paracetamol with Caudal Ropivacaine|"Paracetamol is widely accepted and most commonly used as an adjuvant for postoperative analgesia. It also improves the quality of recovery by attenuating the pain associated with the surgical position. Adverse effects associated with the paracetamol are rare <1/10000, which includes malaise, increased level of hepatic transaminases and hypersensitivity reaction. It has been studied in combination with caudal analgesia with bupivacaine through the rectal route 7,8 with variable results.~Caudal anaesthesia is effective in alleviating pain below the umbilicus. Also if the caudal block is administered at the beginning of surgery, the effect will start wearing off 2 to 3 hours post surgery. Administration of paracetamol towards end of surgery may help with both these issues. In this study we aim to investigate the effect of adding intravenous paracetamol in combination with caudal analgesia with ropivacaine, hoping that it may improve quality of postoperative analgesia and recovery."
3481987|NCT03781505|Placebo Comparator|Placebo|Intravenous Normal Saline with Caudal Ropivacaine
3481988|NCT03781700|Experimental|Prednisolone|Prednisolone
3481989|NCT03781700|Placebo Comparator|Placebo|Placebo oral tablet
3481990|NCT03781609|Active Comparator|Roller system group (RG)|A group performing motor learning manual wheelchair propulsion repetitions on a roller system.
3481991|NCT03781609|Active Comparator|Overground group (OG)|A group performing motor learning manual wheelchair propulsion repetitions overground.
3481992|NCT03781609|Placebo Comparator|Placebo - Wheelchair skills group (WSG)|A group receiving conventional manual wheelchair skills training.
3481993|NCT03781791|Experimental|Active Treatment|ENT-01 tablet will be taken once daily by mouth.
3481994|NCT03781791|Placebo Comparator|Placebo Treatment|Placebo tablet will be taken once daily by mouth.
3481995|NCT03781583|Experimental|HMD|"We have several versions (listed below) of a headworn smartHMD. Each can provide verbal and/or tactile feedback to the user. Feedback is controlled by either the experimenter or by computer vision algorithms.~1. The ODG Smartglasses is commercially available. This system uses computer vision to guide a user to the destination using audio and/ or vibration feedback.~2) Tactile stimulator array. This device uses an Arduino Micro, HC-05 Bluetooth Module, L293D Motor Driver and coin vibration motors attached to a head-worn headband or glasses frame. The motors can be controlled directly by an experimenter or by computer vision algorithms.~3) Computer Vision Navigation prototyping system consists of two components: Intel RealSense camera and Alienware M15 laptop.~All participants will receive the same 3 interventions: no HMD used, HMD worn but not active, and HMD worn and active. Participants may be tested with any or all of the systems described above."
3481996|NCT03781466|Active Comparator|Cervical cerclage|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm
3481997|NCT03781466|Active Comparator|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
3481998|NCT03781466|Active Comparator|Cervical cerclage plus vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤25mm plus Daily vaginal progesterone 400mg from diagnosis of the short cervix to 36 weeks
3481999|NCT03781427|Active Comparator|Standard care|Cardiac resynchronization therapy: Usual output programming
3482000|NCT03781427|Experimental|High output|Cardiac resynchronization therapy: High output programming
3482001|NCT03781388|Experimental|Starting dose of Bupivacaine (9 mg)|The starting dose of hyperbaric bupivacaine for the first patient in this study will be 9mg; the dose for the subsequent subject will be based on the response of the preceding subject as per the Narayana Rule, a modification of the biased-coin design (BCD) up-down sequential method (UDM).
3482002|NCT03781388|Experimental|Subsequent dose|
3482003|NCT03781440|Experimental|Bilateral ESP catheter with Lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
3482004|NCT03781440|Placebo Comparator|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
3482005|NCT03781258|Other|Anit-thrombotic monotherapy|Patients with HeartMate 3 LVAS transitioning from Warfarin and Acetylsalicylic Acid (ASA) therapy to receive anti-thrombotic monotherapy (ASA).
3482006|NCT03781271|Experimental|Fraction 1-Addition of EMN|During the fraction 1 insertion, the custom MRI-compatible vaginal cylinder will be placed in the patient, and will contain the 6 degree-of-freedom (DOF) sensor. The electromagnetic navigation system and computer will have been setup in the operating room (OR) prior to the procedure and will be used to actively insert up to 25 catheters into the target. The catheters will be inserted using a custom metallic stylet that has a custom 5-DOF sensor embedded in the tip for tracking its position in real-time. The physician may use ultrasound for assistance in target visualization as well. Catheter deflections will be detected and corrected for in real-time by the radiation oncologist as the catheter is inserted into the patient during the procedure, this will occur when the EM system is in use.
3482007|NCT03781271|Experimental|Fraction 3-Addition of EMN|For the second group of patients in the trial the same protocol will be followed as in the first group, the only difference will be that the electromagnetic navigation is used during the second implantation procedure immediately preceding fraction 3 as opposed to fraction 1, the time at which it was used for the first group of patients.
3482008|NCT03781323|Experimental|mFOLFOX (5-Fluorouracil Leucovorin Oxaliplatin)|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
3482009|NCT03781102|Experimental|Intervention|Arm 1, or intervention participants (n=60), will participate in a 16-week face-to-face diabetes prevention group program '16-Week Diabetes Prevention Program for Mothers and Children' and then will transition to a 16-week follow-up period.
3127675|NCT03103438|Experimental|Cohort 5|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 1.6 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 6 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 6.
3132720|NCT03447314|Experimental|Part 1b: 200ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
3482010|NCT03781102|Other|Wait-listed Control|Arm 2, or wait-listed controls (n=60), will receive the typical standard of care during the first 16-weeks, followed by the 16-week face-to-face group diabetes prevention program '16-Week Diabetes Prevention Program for Mothers and Children'.
3482011|NCT03781310|Experimental|Dose reduction|Reduce the Tocilizumab dose at the baseline visit (week 0) and maintain that dose until 20 weeks of follow-up. The reduced dose is dependent of the tocilizumab serum concentration, measured at the screening visit, and is calculated according to the pre-defined dose-reduction algorithm.
3482012|NCT03781310|Active Comparator|Maintain dose|Maintain the original dose at baseline visit (week 0) until 20 weeks of follow-up.
3482013|NCT03781076|Experimental|Sleep Intervention|1-hour brief behavioral intervention to improve sleep consolidation and nocturnal sleep duration.
3482014|NCT03781076|No Intervention|Control|"In this care as usual arm, no specific behavioral sleep intervention is provided."
3482015|NCT03781154|Experimental|Group-based exercise|Virtually-delivered supervised exercise sessions will take place twice per week for approximately one hour, and include aerobic, muscular strength and endurance, balance, and flexibility components.
3482016|NCT03781154|No Intervention|Control Group|A physical activity education control group
3482017|NCT03781232|Experimental|RSP-09-01|Enrolled subjects will perform 4 daily measurement session during their regular stay at the clinic. A measurement session consists of a reference capillary blood sample and two measurements on the Prototype 0.3.
3482018|NCT03781232|Experimental|RSP-09-02|Enrolled subjects will measure at home for 26 six days and visit the clinic two times. During home measurements, 6 measurement sessions will be performed by the subject a day. A measurement session consists of two BGMs, two CGMs and two measurements on the Prototype 0.3. On in-clinic visits the subject will be administered a high glucose breakfast and the following 6-7 hours, measurement sessions will be performed every 15 minutes.
3482019|NCT03781349|Active Comparator|MENS|MENS are applied through placement of six electrodes (size of 4x4cm), of which four were placed exactly like the TENS electrodes and the other two, one in the palm and the other at the height of the asteroid ganglion. Duration of the intervention was 24 min for a total of 15 sessions. The frequency was 50 Hz and the intensity was 100 μA.
3482020|NCT03781349|Active Comparator|TENS|TENS are applied through the placement of four electrodes on either side of the deltoid muscle, on the front and back surfaces of the shoulder joint for 20 min and each patient received 15 sessions (five per week). A constant current of high frequency was used (100 HZ) and its intensity was initiated at 10mA and was then gradually increased to 15mA
3482021|NCT03781063|Experimental|Lasofoxifene|5 mg/d of oral lasofoxifene
3482022|NCT03781063|Active Comparator|Fulvestrant|500 mg fulvestrant intramuscular (IM)
3482023|NCT03781206|No Intervention|Standard of Care (SOC)|After stoma reversal, patients of SOC group will be treated as for normal clinical practice, using a simple adhesive wound dressing.
3482024|NCT03781206|Experimental|Negative Pressure Wound Therapy (NPWT)|PICO™ 7 will be applied after stoma reversal
3482025|NCT03781167|Experimental|ABBV-951|Participants will receive ABBV-951 by continuous subcutaneous infusion (CSCI) for 52 weeks.
3482026|NCT03780998||Group-1 (n: 50): Healthy cases|Control group
3482027|NCT03780998||Group-2 (n:50): Grade 1 hemorroid|With perianal examination diagnosed of grade 1 hemorroidal disease
3482028|NCT03780998||Group-3 (n:50): Grade 2 hemorroid|With perianal examination diagnosed of grade 2 hemorroidal disease
3482029|NCT03780998||Group-4 (n:50): Anal fissure cases|With perianal examination diagnosed of anal fissure cases
3127676|NCT03103438|Experimental|Cohort 6|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.2 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 subjects are observed to have DLT, the dose level is escalated one step for the next cohort no. 7 of 3 subjects, and the process continues as above. If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level. If none of these additional 3 patients show DLT, the dose level is escalated for the next Cohort no. 7.
3127677|NCT03103438|Experimental|Cohort 7|This cohort includes 3 subjects who will receive the single subcutaneous injection of BCD-089 at a dose of 2.9 mg/kg. If at least 2 subjects are observed to have DLT, this dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If exactly 1 of the 3 subjects treated show DLT, 3 additional subjects are treated at the current dose level.
3482030|NCT03780998||Group-5 (n:50): Simple perianal fistula|With perianal examination diagnosed of uncomplicated, simple perianal fistula cases
3482031|NCT03781362|Experimental|CPI-100 Monotherapy|"Dose Escalation Groups:~CPI-100 will be administered via intravenous infusion once every 2 weeks (Q2W) for up to 5 dose levels and once every 3 weeks (Q3W Arm A) for up to 4 dose levels in a 3 + 3 dose escalation study~Dose Expansion Group: Maximum tolerated dose or the recommended Phase 2 dose (RP2D) from dose escalation group"
3482032|NCT03781362|Experimental|CPI-100 Combination with Capecitabine|CPI-100 will be administered via intravenous infusion once every 3 weeks in combination with oral capecitabine for up to 4 dose levels in a dose escalation study (Q3W Arm B)
3482033|NCT03781284|Experimental|PET/MRI with bowel purgation|
3482034|NCT03781284|Experimental|PET/MRI without bowel purgation|
3482035|NCT03781128|Other|LSD, Placebo|Lysergic acid diethylamide (3 x 100 µg LSD in three weeks, per os) followed by Placebo
3482036|NCT03781128|Other|Placebo, LSD|Placebo (3 x 1 vial looking like LSD in three weeks, per os) followed by Lysergic acid diethylamide
3482037|NCT03781141|Experimental|Absorbable suture|Wound closure with absorbable suture.
3482038|NCT03781141|Active Comparator|Non-absorbable suture|Wound closure with non-absorbable suture.
3482039|NCT03781115|Experimental|Ziprasidone|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug ziprasidone (Geodon). The investigators will start with a single 20mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 40 and 60mg tablets). If Ziprasidone causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG) taken.
3482040|NCT03781115|Experimental|Olanzapine|The investigators will conduct a pilot dose-response evaluation of a single dose of the anti-psychotic drug olanzapine (Zyprexa). The investigators will start with a single 2.5 mg pill given to (3) subjects and will increase the dosage in sequential subjects until the desired sedation effect is achieved (i.e. 5, 7.5, and 10 mg tablets).If olanzapine causes the desired sedation effect additional healthy subjects will be recruited to take the medication and have an electroencephalogram (EEG).
3482041|NCT03781115|Placebo Comparator|Placebo Comparator|The investigators have prepared a placebo which duplicates the exact color and size of the study drug capsule to use as a non-drug control.
3482042|NCT03780985|Active Comparator|intrauterine device insertion with a suture fixation|Intruterine device through hysterotomy incision during cesarean section with a suture fixation
3482043|NCT03780985|Active Comparator|intrauterine device insertion without a suture fixation|IUD through hysterotomy incision during cesarean section without a suture fixation
3482044|NCT03781050|Experimental|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
3482045|NCT03781011|Experimental|TMAO high producer|Low carnitine/choline diet intervention
3482046|NCT03781011|Active Comparator|TMAO low producer|Low carnitine/choline diet intervention
3482047|NCT03780972|Active Comparator|Cohort 1 Dose A|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 1
3482048|NCT03780972|Active Comparator|Cohort 2 Dose B|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 2
3482049|NCT03780972|Active Comparator|Cohort 3 Dose C|Intravitreal injection of 50 μl of ONL1204 liquid formulation to deliver dose 3
3482050|NCT03780972|Active Comparator|Cohort 4 Dose D|Intravitreal injection of 100 μl of ONL1204 liquid formulation to deliver dose 4
3482051|NCT03780946||Magnetic group|Magnetic anastomosis for pancreaticojejunostomy
3482052|NCT03780946||Control group|Traditional hand-sewn for pancreaticojejunostomy
3482053|NCT03780933|No Intervention|control group|conventional treatment (corticosteroids, mechanical ventilation)
3482054|NCT03780933|Experimental|test group (vitamin C)|high dose vitamin c iv infusion
3482055|NCT03780842|Experimental|Invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in intubated newborns
3482056|NCT03780842|Experimental|Non-invasive NAVA ventilation|A titration protocol will be used for changing NAVA levels in newborns with non-invasive NAVA ventilation (= with a nasal interface).
3482057|NCT03780816||Pilot Site: Norris Cotton Cancer Center|Observation and interview protocols will be piloted at this site. The content of these observations and interviews will not be analyzed for content.
3482058|NCT03780816||Karmanos Cancer Institute|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
3482059|NCT03780816||UNC Lineberger Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
3482060|NCT03780816||UAB O'Neal Comprehensive Cancer Center|Observations and interviews will be analyzed to identify any emergent concepts, categories, and relationships in the data.
3482061|NCT03780881|Experimental|Expectation confirmation|The participants in this group receive manipulated feedback indicating that their performance was very good in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
3482062|NCT03780881|Experimental|Expectation disconfirmation|The participants in this group receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
3482063|NCT03780751|Experimental|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
3482064|NCT03780751|Experimental|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
3482065|NCT03780751|No Intervention|Waitlist|Participants will receive no immediate treatment but will be able to choose either MIND or COPE after a six months waiting period.
3482066|NCT03780894|Experimental|Experimental treatment|The active treatment consists of intravenous injection of 2g of fibrinogen concentrate, 1g of tranexamic acid, 2 red bood cells concentrate O Rh(D) negative (Banc de Sang i Teixits, Barcelona, Spain), and crystalloids at pre-hospital phase of care.
3482067|NCT03780894|Active Comparator|Standard treatment|Patients in the control arm will be treated according the existing protocols based on crystalloids and tranexamic acid administration.
3482068|NCT03780673|Experimental|Simvastatin 20 mg + Rifaximin 400 mg|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 months
3482069|NCT03780673|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin|Placebo of simvastatin and placebo of rifaximin orally for 12 months
3482070|NCT03780686|Active Comparator|Dopamine and norepinephrine infusion|Infusion doppamine (2-5mcg/kg/min) and norepinephrine (3mcg/kg/h) with restricted fluid
3482071|NCT03780686|Active Comparator|Norepinephrine|Infusion norepinephrine (3mcg/kg/h) with restricted fluid.
3482072|NCT03780686|No Intervention|Standard fluid management|Standard fluid managements.
3127678|NCT03103542|Experimental|Recombinant coagulation factor VIII Fc (rFVIIIFc)|Participants will receive rFVIIIFc at a dose of 200 international units (IU)/kilogram (kg) as once daily injections or divided on several injections per day at the discretion of the Investigator, starting at baseline visit up to maximum of 60 Weeks during the ITI Period. Participants who meet the criteria for ITI success will enter a tapering period of 16 weeks where the dose will be tapered down until a prophylactic dose, as judged by the Investigator, is achieved and thereafter a follow-up period of 32 weeks where the patient will continue to receive prophylactic treatment with rFVIIIFc.
3482073|NCT03780855|Experimental|nerve scaffold group|the experimental group of cases with peripheral sensory nerve injuries will be treated with nerve scaffold.
3482074|NCT03780855|No Intervention|non-nerve scaffold group|the control group of cases will be treated without nerve scaffold.
3482075|NCT03780920|Active Comparator|Osteopathic treatment|
3482076|NCT03780920|No Intervention|Control group|
3482077|NCT03780556|Active Comparator|Lornixicam|Patients received lornoxicam 8 mg intravenous to control pain
3482078|NCT03780556|Active Comparator|Pethidine|Patients received pethidine 50mg intravenous to control pain
3482079|NCT03780868|Active Comparator|external DCR|"A curvilinear incision of 10-15 mm length was made along the anterior lacrimal crest .~The smaller end of the blunt dissector was used to fracture Lamina papyracea, the parchment like bone of the posterior half of the lacrimal fossa. the nasal mucosa was stripped from lacrimal bone with the help of Traquair's periosteal elevator, An osteotomy of approximately 12.5 x10mm was created with successive punching of bone by Cittelli's punch. Lacrimal sac and nasal mucosa were opened in a 'H' fashion with the no.11 Bard-Parker blade and Bowman's probe was in place, to form a large anterior and smaller posterior flap."
3482080|NCT03780868|Active Comparator|silicone intubation with MMC|"Bowman's probe was gently inserted into the inferior canalicular system, until a hard stop was felt in the lacrimal sac, after which it was rotated into the NLD to reach below the inferior concha. The probe was then withdrawn via the inferior punctum and the process was repeated for the upper canaliculus.~After irrigation with normal saline to confirm duct patency, irrigation was performed by introducing 1 ml of MMC (0.5 mg/ml) into the duct with a syringe, the ocular surface then irrigatedby normal saline. Intubation was done by a silicone tube connected by each of its end to a malleable steel guide. A grooved director was placed under the inferior turbinate to guide the probe out of the nose, after which the steel guide was cut from the silicone tube"
3482081|NCT03780621|Experimental|Andrographis and Withania|Active ingredient: 550 mg of Andrographis paniculata (standardized to 40 mg andrographolides) and Withania somnifera (standardized to 10 mg withanolides) taken twice daily, once in the morning and once in the evening
3482082|NCT03780621|Placebo Comparator|Placebo|550 mg capsule visually identical to the active dietary supplement, containing brown sugar, microcrystalline cellulose, corn starch, and magnesium stearate
3482083|NCT03780907|Experimental|E2007 1 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
3482084|NCT03780907|Experimental|E2007 2 mg|Tablet, once daily to be taken in the morning by mouth, one hour before breakfast, with a glass of water.
3482085|NCT03780907|Placebo Comparator|Placebo|Tablet, once daily to be taken in the morning, one hour before breakfast, with a glass of water.
3482086|NCT03780634|Experimental|HAIC plus PD-1 antibody|Participants received PD-1 antibody intravenously and hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3482087|NCT03780634|Active Comparator|HAIC plus sorafenib|Participants received sorafenib capsules 400mg bid in continuous 21-day treatment cycles, and received hepatic artery infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3482088|NCT03780478|Experimental|SPG Block|Sphenopalatine ganglion block
3482089|NCT03780478|Placebo Comparator|Placebo Control|Saline injection
3482090|NCT03780491|No Intervention|Control|The first 50 patients will have usual care with providers conducting the visit in their typical manner.
3482091|NCT03780491|Experimental|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
3127679|NCT03103763||Aged 90 and older|Subjects 90 years and older with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
3127680|NCT03103763||Aged 80-89|Subjects aged 80-89 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
3127681|NCT03103763||Aged 70-79|Subjects aged 70-79 with atrial fibrillation, taking warfarin, followed by the Penobscot Bay Medical Center Anticoagulation Services.
3482092|NCT03780582|Experimental|Probabilistic Classification|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan."
3482093|NCT03780582|Experimental|Classification Plus Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. They also see ROIs identified by the AI that represent lung nodules."
3482094|NCT03780582|Experimental|Classification With Delayed Detection|"Radiologists see a score from 1-100 that represents the AI's prediction of whether the CT-scan comes from a patient with cancer or not before beginning their analysis of the scan. After identifying their own ROIs, the radiologist then can see ROIs identified by the AI that represent lung nodules before making final decisions."
3482095|NCT03780764|Active Comparator|Conventional fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch."
3482096|NCT03780764|Experimental|Self ligating fixed appliance|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side."
3482097|NCT03780777|Experimental|Home Hazard Removal Group|A tailored home-modification (home-hazard removal) intervention for residents with a high fall risk, delivered in the home by occupational therapists over one to two visits and with a booster session at three months.
3482098|NCT03780738||Control|Chinese Han people to do physical examination in physical examination center of Guangdong Provincial People's Hospital
3482099|NCT03780738||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Guangdong Provincial People's Hospital
3482100|NCT03780829|Experimental|hypoxia plus training|combined hypoxia treatment with exercise training
3482101|NCT03780829|Sham Comparator|sham hypoxia plus training|combined sham hypoxia treatment with exercise training
3127682|NCT03103906|Experimental|Group 1 (Test Product)|Participants will apply test product (approximately 0.6-1 grams (g)) to full face topically twice daily (morning and evening) after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
3482102|NCT03780829|Experimental|hypoxia plus training plus NMDA agonist|combined hypoxia treatment with exercise training and with NMDA agonist treatment
3482103|NCT03780829|Placebo Comparator|hypoxia plus training plus sham NMDA agonist|combined hypoxia treatment with exercise training and with sham NMDA agonist treatment
3482104|NCT03780712||Sepsis Risk Group|419 infants born from mothers at risk to deliver babies with neonatal infections in Cotonou hospitals (Benin) 166 infants without sepsis born from mothers enrolled in a study to monitor pregnancy-associated malaria and Intrauterine growth restriction in Benin
3482105|NCT03780790|Active Comparator|Quadratus Lumborum Block|US-guided quadratus lumborum block will be performed with 0,5 ml/kg 0.25% Bupivacaine in the anterior layer of the thoracolumbar fascia between psoas major and quadratus lumborum muscles
3482106|NCT03780790|Active Comparator|Transversus Abdominis Plane Block|US- guided transversus abdominis plane block will be performed with 0,5 ml/kg 0.25% Bupivacaine into the fascial plane between internal oblique muscle and transversus abdominis muscle
3482107|NCT03780790|Active Comparator|Caudal Block|US-guided caudal epidural block will be applied to 0.7 ml/kg 0.25 % Bupivacaine up to a maximum of 20 mL
3482108|NCT03780647||Patients with suspicion of thoracic outlet syndrome|
3482109|NCT03780218||Experimental Group:Respiratory function|Patients with burn injury will be included in this study. Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed on the discharge week.
3482110|NCT03780218||Control Group:Respiratory function|Healthy subjects will be included in this study.Their respiratory functions will be evaluated. Pulmonary function test, respiratory muscle strength and peripheral muscle strength will be assessed.
3482111|NCT03780192||Treatment|Bifurcation lesion treatment using provisional stent technique
3482112|NCT03780244|Experimental|Investigational Study Product|Injection with Sculptra Aesthetic reconstituted with 8ml Sterile Water for Injection (SWFI)
3482113|NCT03780244|Active Comparator|Reference Product|Injection with Sculptra Aesthetic reconstituted with 5ml SWFI
3482114|NCT03780257|Experimental|QR-421a|Single dose administration
3482115|NCT03780257|Sham Comparator|Sham-procedure (dose cohort 1&2 only)|Sham-procedure (no experimental drug administered)
3482116|NCT03780569|Experimental|NovoTTF-200A/Radiotherapy/Temozolomide|Patients will receive multiple 1 month courses of continuous NovoTTF-200A treatment together with standard Radiotherapy/Temozolomide followed by maintenance Temozolomide.
3482117|NCT03780205||Bilateral Group|Patients have bilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 each eye.
3482118|NCT03780205||Unilateral Group|Patients have unilateral amblyopia, which is defined that best-corrected visual acuity of <20/30 in the amblyopic eye; and interocular difference of best-corrected visual acuity at least two logMAR lines.
3482119|NCT03780452||Tibiotalocalcaneal arthrodesis with DynaNail|Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
3482120|NCT03780166|Experimental|Parsaclisib|
3482121|NCT03780374|Active Comparator|Sound Processing Principle 1|Sound Processing Principle 1 will be applied in the hearing aid.
3482122|NCT03780374|Experimental|Sound Processing Principle 2|Sound Processing Principle 2 will be applied in the hearing aid.
3482123|NCT03780374|Experimental|Sound Processing Principle 3|Sound Processing Principle 3 will be applied in the hearing aid.
3482124|NCT03780387|Experimental|Inhaled Allergen Challenge|Felis Catus sensitive, mild asthmatics will undergo inhaled allergen challenge.
3482125|NCT03780465|Active Comparator|Oral idronoxil|10 male and female subjects randomised to 400 mg active Oral idronoxil suspension or oral placebo suspension (n=8 active; n= 2 placebo).
3482126|NCT03780465|Experimental|NOX66 400 mg|10 male and female subjects randomised to 400 mg active NOX66 (A) suppository or 400 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
3482127|NCT03780465|Experimental|NOX66 600 mg|10 male and female subjects randomised to 600 mg active NOX66 (A) suppository or 600 mg active NOX66 (B) suppository or suppository placebo (n=8 active; n= 2 placebo).
3482128|NCT03780322|Experimental|Armeo Spring Pediatric|This group will receive training with Armeo Spring Pediatric in 45 minute sessions, 3 times a week, for a total of 15 sessions
3482129|NCT03780322|Active Comparator|Conventional physical and occupational therapy|This group will receive combined physical and occupational therapy in 45 minute sessions, 3 times a week, for a total of 15 sessions.
3482130|NCT03780348|Experimental|New Method|'New' weight-for-height method will be used to assess children assigned to this arm
3482131|NCT03780348|Active Comparator|Existing Method|'Existing' weight-for-height method will be used to assess children assigned to this arm
3482132|NCT03780348|Experimental|Health Extension Workers|Health Extension workers will do weight-for-height assessment using the new method
3482133|NCT03780361|Experimental|Aflibercept injection group|"drug: Eylea (aflibercept) (11.12mg/0.278ml) dose: 2mg (0.05ml) usage: With topical anesthesia and intravitreal injection of aflibercpt in aseptic condition.~frequency and duration: monthly intravitreal aflibercept injections."
3482134|NCT03780530|Active Comparator|subcuticular suturing|
3482135|NCT03780530|Active Comparator|surgical glue|
3482136|NCT03780530|Active Comparator|adhesive steri-strip tape|
3482137|NCT03780595|Experimental|Passiflora|
3482138|NCT03780595|Placebo Comparator|Control|
3482139|NCT03780426|Experimental|tSMS left motor cortex (sham right)|30 min of tSMS applied to the left motor cortex with sham on the right motor cortex
3482140|NCT03780426|Experimental|tSMS right motor cortex (sham left)|30 min of tSMS applied to the right motor cortex with sham on the left motor cortex
3482141|NCT03780413|Active Comparator|PR-ESSENCE treatment|The treatment group receives PR-ESSENCE for 10 weeks. Outcome measures are collected pre- and post-treatment, and after 6 months and one year.
3482142|NCT03780413|Active Comparator|Control (TAU)|"The control group receives 10 weeks of treatment as usual (TAU) (that is the standard psychoeducation, support and treatment given to all youth after neuropsychiatric assessment at our clinic), followed by 10 weeks of PR-ESSENCE. Outcome measures were collected pre- and post-treatment, and after 6 months and one year."
3482143|NCT03780309|Active Comparator|EXERCISE|Participants participated in a the exercise training program and engaged in exercise self-monitoring.
3482144|NCT03780309|Experimental|EXERCISE+PEH|Participants participated in the exercise training program and engaged in exercise self-monitoring and blood pressure self-monitoring (daily and before and after exercise).
3482145|NCT03780270|Active Comparator|Control|"Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application at Day 0 and Day180.~=> Group: Fluoride Varnish"
3482146|NCT03780270|Experimental|Test1|"Single application of Curodont Repair (P11-4) at Day 0 followed by a Fluoride Varnish (Fluor Protector S; Ivoclar, 7'700 ppm F-) application. Another fluoride Varnish application at Day180.~=> Group: Curodont Repair + Fluoride Varnish"
3482147|NCT03780270|Experimental|Test2|"Single application of Curodont Repair (P11-4) at Day 0. Curodont Protect (tooth gel containing P11-4 matrix) is handed out and subjects are asked to apply it 2x weekly at home after regular teeth cleaning in the evening for the whole study period (Day 360).~=> Group: Curodont Repair + Curodont Protect"
3482148|NCT03780543|Active Comparator|HBeAg-negative Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were standard of care nucleos(t)ide (SOC NrtI)-suppressed and HBeAg-negative will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time they will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years.
3482149|NCT03780543|Active Comparator|HBeAg-positive Subjects from Parent Study ABI-H0731-201|Subjects who on Day 1 of parent study ABI-H0731-201 (NCT03576066) were SOC NrtI-suppressed and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated. Subjects who meet the virologic response criteria will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years. Subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.
3482150|NCT03780543|Active Comparator|Subjects from Parent Study ABI-H0731-202|"Subjects who on Day 1 of parent study ABI-H0731-202 (NCT03577171) were treatment-naive and HBeAg-positive will receive ABI-H0731 + SOC NrtI for at least 52 weeks, after which time their viral response will be evaluated.~Subjects who meet the virologic response criteria at Week 52 will continue to receive ABI-H0731 + SOC NrtI for an additional 96 weeks, after which time their viral response will be evaluated at Week 148. Subjects who meet the virologic response criteria at Week 148 will discontinue both ABI-H0731 and SOC NrtI and be monitored for up to 3 years, while those subjects with insufficient virologic response will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks.~Subjects with insufficient virologic response at Week 52 will discontinue from ABI-H0731 and continue on SOC NrtI for 12 weeks."
3482151|NCT03780075|Experimental|1.11GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
3482152|NCT03780075|Experimental|1.85GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
3482153|NCT03780075|Experimental|3.70GBq of 177Lu-EB-PSMA-617|The patients were intravenously injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA617 and underwent 68Ga-PSMA PET/CT scans before and after the treatment.
3482154|NCT03779815|Experimental|[18F]Florbetaben PET/CT imaging|"Maximally 18 subjects with multiple myeloma (up to 6 subjects in whom amyloidosis in suspected and up to 12 subjects in whom amyloidosis is not suspected)~Intravenous injection of [18F]Florbetaben and PET/CT scanning~Intervention: Drug ([18F]Florbetaben)"
3482155|NCT03779893|Active Comparator|conventional group|Conventional resin based Pits & fissures sealant 3M™ Clinpro™ Sealant is administrated
3482156|NCT03779893|Experimental|bioactive group|Bioactive Pits & fissures sealant BioCoat® by Premier®.
3482157|NCT03779906|Experimental|ISOVUE|Isovue will be given to all subjects per the standard of clinical care.The specific iodine concentration and volume of ISOVUE used during the radiologic procedure will depend on the type of procedure and the standards in place at the site where the procedure is performed.
3482158|NCT03780062|Experimental|S100B protein dosing|
3127683|NCT03103906|Other|Group 2 (No Treatment)|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Participants will massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
3482159|NCT03779776|Experimental|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at1500 IU/day and vitamin D at 500 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 ml/kg/d, containing VA 230 IU/kg/d, VD 80 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
3127684|NCT03103919|Active Comparator|Rotigotine + Standard Care|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms. The optimal dose of Neupro for any given subject will be determined by standard clinical practice.
3127685|NCT03103919|Experimental|Rotigotine + Standard Care + Kinesia-360™ wearable device|Subjects will use the Kinesia-ONE™ wearable device in-clinic at Visit 1 and Visit 2 for recording of specific motor symptoms, and additionally subjects will use the Kinesia-360™ wearable device at home while awake for continuous measurement of motor symptoms. The Investigator will use these symptom data to provide feedback to subjects on their motor symptoms and to supplement standard of care to titrate the optimal dose of Neupro for any given subject.
3127686|NCT03104192|Active Comparator|Develop & Refine MOWI w/o Amulet (2A)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults without the use of Amulet technology.
3127687|NCT03104192|Experimental|MOWI Weight Loss Maintenance|Evaluate the feasibility, acceptability, and potential effectiveness of an 8-session, tri-weekly, psychosocial skills group intervention to support weight loss maintenance post-MOWI.
3482160|NCT03779776|Placebo Comparator|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 ml/kg/d,containing VA 230 IU/kg/d,VD 80 IU/kg/d ) within daily on parenteral nutrition until fed 120ml/kg.
3482161|NCT03780049|Experimental|HAIC plus H101|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery
3482162|NCT03780049|Active Comparator|HAIC|Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery
3482163|NCT03780036|Experimental|porous collar|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous, to allow for bone ingrowth and stabilization of the implant.
3482164|NCT03780036|Experimental|porous collar with hydroxyapathite|Patients with neoplasm of femur bone who require segmental bone resection and replasement with a large prosthesis would receive an implant which collar (a circular part that comes into direct contact with the remaining bone) will be porous and covered with hydroxyapathite particles, to allow for bone ingrowth and stabilization of the implant.
3482165|NCT03779945|Active Comparator|posteriolateral lumbar fusion +bone graft+ PRP|the addition of autologous platelet rich plasma to the bone graft
3482166|NCT03779945|Active Comparator|posteriolateral lumbar fusion+bone graft only|posteriolateral lumbar fusion with adding autologus bone graft alone posteriolateral lumbar fusion only
3482167|NCT03779802|Experimental|CRT device|Patients implanted with a CRT device who will undergo a non-invasive hemodynamic evaluation of different pacing modes
3482168|NCT03780608|Experimental|GC|Patients with refractory gastric cancer who have failed secondary chemotherapy treatments for advanced disease will be enrolled. Patients must have imaging confirmed progression on previous chemotherapy for gastric cancer treatment with at least one measurable lesion per modified RECIST 1.1. GC patients must not have received previous therapy with immune checkpoint inhibitors. Prior exposure to AZD6738 is not allowed.
3482169|NCT03780608|Experimental|Melanoma|Patients with metastatic melanoma patients who have failed prior anti-PD(L)1 will be enrolled. Anti-PD(L)1 therapy should be the immediate prior regimen before study entry.
3482170|NCT03780296|Experimental|Real-Time Action Observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
3482171|NCT03780179|Experimental|MMRvaxpro|
3482172|NCT03780179|Placebo Comparator|Placebo|
3482173|NCT03779854|Experimental|Arm I (chemotherapy, naive T-cell depleted PBSC)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive naive T-cell depleted PBSCs on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
3482174|NCT03779854|Active Comparator|Arm II (chemotherapy, unmanipulated T cell replete BM)|"CONDITIONING REGIMEN A: Patients undergo TBI BID on days -10 to -7, then receive thiotepa IV over 3 hours QD on days -6 and -5, and fludarabine IV over 30 minutes once daily on days -6 to -2.~CONDITIONING REGIMEN B: Patients undergo TBI BID on days -8 to -5, then receive fludarabine IV over 30 minutes QD on days -4 to -2, and cyclophosphamide IV over 1 hour QD on days -3 and -2.~CONDITIONING REGIMEN C: Patients receive fludarabine IV over 30 minutes QD on days -6 to -2, busulfan IV over 180 minutes QD on days -5 to -2, and undergo total body irradiation BID on day -1.~TRANSPLANT: Patients receive unmanipulated T cell-replete BM on day 0.~GVHD PROPHYLAXIS: All patients receive tacrolimus IV beginning on day -1 and methotrexate IV on days 1, 3, 6, and 11."
3127688|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit (2B)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology.
3179620|NCT00674921|Placebo Comparator|A|This arm will comprise patients who have achieved a CD4 count of 350 or more cells/ul either at the beginning of the study or once they have reached this threshold at the end of follow up in arms 1 and 2. They (including those previously in Arm 1) will receive the placebo (stop cotrimoxazole prophylaxis) after the second randomization but continue with HAART.
3179621|NCT00674921|Active Comparator|B|It will comprise patients randomized to continue or start with cotrimoxazole prophylaxis and HAART at CD4 of 350 or more cells/ul after second randomization. Some of them will have used cotrimoxazole prophylaxis whilst they were in arm 2 and others in arm 1 will restart cotrimoxazole prophylaxis at this stage.
3179622|NCT00674934|Experimental|1|Radiation
3482175|NCT03779789|Experimental|vortioxetine|
3482176|NCT03779789|Active Comparator|SSRIs|
3482177|NCT03779971|Placebo Comparator|Control|The placebo comparator will be a fully controlled diet made from typical American foods and containing no beans or pulses.
3482178|NCT03779971|Experimental|Lentil|The lentil arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain lentils.
3482179|NCT03779971|Experimental|Chickpeas|The chickpea arm will consist of a fully controlled diet made from the same foods as the placebo arm and will also contain chickpeas.
3482180|NCT03779919|Experimental|High Energy|Extracorporeal shock wave therapy with 0.3 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
3482181|NCT03779919|Experimental|Low Energy|Extracorporeal shock wave therapy with 0.05 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
3482182|NCT03779919|Placebo Comparator|Sham|Extracorporeal shock wave therapy with 0 millijoule/mm2 of 3000 shots will be administered via sonographic guidance of the target calcific tendinitis.
3127689|NCT03104192|Active Comparator|Develop & Refine MOWI w Fitbit/Protein (2P)|Develop and refine a mHealth obesity wellness intervention (MOWI) for rural, older, obese adults with the use of Fitbit technology augmented by whey protein.
3127690|NCT03104322|Other|Observation sequence|Period 1: patientMpower platform+usual care for 8 weeks; Period 2: usual care alone for 8 weeks
3127691|NCT03104647|Experimental|VRP-Clinic|VRP-Clinic software on a virtual reality platform
3482183|NCT03780283|Experimental|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
3482184|NCT03780283|No Intervention|placebo|observation
3482185|NCT03779958||Study Group|All patients will be given information about a mobile app to use during the recovery period to assist with hand therapy activities
3482186|NCT03780335||MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
3482187|NCT03780335||Non-MVO group|CMR was performed in all the cases. According to the results of CMR, we divided the study population into MVO group and Non-MVO group.
3482188|NCT03780088|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
3482189|NCT03779737|Active Comparator|Habitual training|The control group will be monitored passively for the detection of adverse or secondary events.
3482190|NCT03779737|Experimental|Muscular resistance training|This phase includes the execution of the study with three arms, one group will be assigned to strength training and the other to aerobic capacity training, taking into account the plan of sessions per week.
3482191|NCT03779737|Experimental|Cardiorespiratory training|In stage, a combined program of strength and aerobic capacity will be implemented, which will last six months more than will be compared with the previously defined control group.
3127692|NCT03104725|Experimental|Healthy Volunteers|HVs who undergo 2 LPs as inpatients, with 48 hours between LPs and no NAC treatment
3127693|NCT03104725|Experimental|PD Patients|Patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day).
3127694|NCT03104738|No Intervention|50% reduction of basal insulin dose|This is the institutional standard of care. The evening before surgery, 20 subjects will reduce their basal insulin dose to 50%.
3179623|NCT00674960|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3179624|NCT00674999|Experimental|1|Amnion with processing procedures involving the use of trypsin-Edetic Acid(EDTA)
3179625|NCT00674999|Experimental|2|Amnion with processing procedures involving the use of Dispase II
3482192|NCT03779750||End Stage Renal Disease Patients|complete blood picture blood urea s.creatinine urine analysis calcium phosphorus parathyroid hormone. 4- Hepatitis BsAg,HCV-Abs and HIV.
3482193|NCT03779711|Experimental|Treatment|Autologous (self) mononuclear cells derived from umbilical cord blood and that meet all release criteria are injected into the surface of the right heart muscle to achieve the target dose of 1-3 million cells per kilogram body weight . This is a one time treatment at the time of Stage II Glenn surgery .
3482194|NCT03779711|Active Comparator|Control|Clinical data will be collected before, during and after the Stage II surgical standard of care procedure. Requires additional imaging studies at 3 months that are not standard of care in addition to some blood tests that would be beyond standard of care. Information will be collected to document the clinical outcomes and will be compared with the information from the group receiving the investigational treatment used in this study.
3482195|NCT03779698|Experimental|BiodentineTM pulpotomy group|A Bioactive Dentine Substitute (BiodentineTM, Septodont Ltd., Saint Maur des Faussés, France) was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface.
3482196|NCT03779698|Active Comparator|Formocresol pulpotomy group|A sterile cotton pellet moistened with 1:5 concentration formocresol (Buckley's Formocresol, Sultan Healthcare, Englewood, NJ, USA) then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing.
3482197|NCT03779685|Active Comparator|General anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
3482198|NCT03779685|Experimental|Regional anesthesia|Breast cancer surgery (Tumor Stage 1-3, Nodes 0-2 as determined according to the NCI stage definitions http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page3/print)
3482199|NCT03779633|Experimental|Linoladiol Estradiol|Linoladiol Estradiol cream 6 weeks before surgery of pelvic organ prolapse
3482200|NCT03779633|Placebo Comparator|Placebo|Placebo cream 6 weeks before surgery of pelvic organ prolapse
3482201|NCT03779542||open-angle group|ACD > 2.68 measured by the swept source AS-OCT and angle > Shaffer 2 in four quadrants under gonioscope
3482202|NCT03779542||narrow-angle group|ACD≤2.68 measured by the swept source AS-OCT and angle≤Shaffer 2 in four quadrants under gonioscope
3482203|NCT03779516|Active Comparator|Group C|In Control Group, 4 mL of saline solution was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
3482204|NCT03779516|Active Comparator|Group L|In Lidocaine Group 4 mL of 4% lidocaine was administered using a face mask and a compressed gas-powered jet nebulizer for 15 min
3482205|NCT03779607|Active Comparator|IPS e.max Press(lithium di silicate)|Lithium disilicate reinforced glass ceramics are available in the market in two forms according to the technique of manufacturing, either heat pressed ingots or CAD/CAM blocks for milling. The heat pressed lithium disilicate glass ceramic consists of approximately 70% lithium disilicatecrystals(the main crystal phase) having a needle like shape that are embedded in a glassy matrix. The crystals length is about 3 to 6 μm. The heat pressed ingots are fully crystallized and the restoration is fabricated by the lost wax technique where the lithium disilicate ingots are pressed into the investment mold at high temperature. The pressed lithium disilicate has strong flexural strength values(range 400 ± 40 MPa)
3482206|NCT03779607|Experimental|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
3482207|NCT03779451|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery
3482208|NCT03779451|Active Comparator|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily at bedtime starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
3482209|NCT03779451|No Intervention|control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
3482210|NCT03779555||Patients taking lenalidomide for multiple myeloma|-Patients will be seen at baseline, 1 month (+/- 1 week), 2 months (3-5 weeks following 1-month assessment), and 3 months (3-5 weeks after 2-month follow-up)
3482211|NCT03779594|Experimental|treatment group|patients who met the inclusion criteria will be allocated to the treatment group, and will receive acetazolamide from time of diagnosis until shunt surgery (2-6 weeks).
3482212|NCT03779464|Experimental|S/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
3482213|NCT03779464|Active Comparator|Gem/nab|Nab-paclitaxel 125 mg/m² (D1, D8, q3w) and Gemcitabine 1000 mg/m² (D1, D8, q3w)
3482214|NCT03779568|Experimental|Dose adjustment of bupivacaine|Patient will receive isobaric bupivacaine based on previous patient experience.
3482215|NCT03779581|Experimental|Exercise Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting. In addition, 7 of the randomly selected patients received De-rotation Breathing Exercises.
3482216|NCT03779581|Active Comparator|Control Group|postural correction exercise on the wall and in front of the mirror, Exercise on a Swiss ball, Hanging on wall ladder for 1-2 minutes five times and side bending and extension exercises of the spine with theraband in standing and sitting.
3482217|NCT03779659|Experimental|Synapse TENS device|SYnapse TENS device will be used for alleviating pain through electrical stimulation. This is a battery powered device where an electrical current is applied intra-orally on the buccal and lingual sides using an intra-oral pad applicator. This device has been cleared for marketing by the Food and Drug Administration (FDA) and the prescribed electrical field falls almost a 10 factor level lower than routine pulp testing devices used in dentistry. The TENS device was previously tested in a pilot study with promising results. Chair side application and at-home use of the device by the patient was shown to drastically reduce pain and discomfort associated with orthodontic tooth movement.
3482218|NCT03779659|Active Comparator|Topical anesthetic gel|Topical anesthetic Gel is the active comparator in this study. The topical anesthesia (anesthetic gel) Centrix LolliCaine with 20% benzocaine in single package of 0.3 ml will be used. The amount of local anesthetic used will not exceed the maximum allowable dose, which will be calculated for each patient based on his/her age and weight prior to the dental procedure. This will be done based American Association of Pediatric Dentistry guidelines for the use of local anesthesia.
3482219|NCT03779646|Experimental|bisoprolol fumarate|In this arm, the participants will receive different dose of bisoprolol fumarate.
3482220|NCT03779646|No Intervention|Control|In the control (no beta blocker) group, the patients not taking beta blocker will receive outpatient clinic or video visit every 8 weeks and provide their cardiac symptoms, heart rate, blood pressure and ECG. After 12 months , the patients will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG,BNP and echocardiography records.
3482221|NCT03779672|Active Comparator|Memantine Hydrochloride 10 mg Placebo|"Blue colour capsules, for oral administration, containing 5 mg of active memantine or matching placebo for oral administration.~Dose regimen:~Memantine Hydrochloride~Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Washout (Weeks #7-8)~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps"
3179626|NCT00674999|Active Comparator|3|Prepared Antibiotic ointment Polysporin, Bacitracin and Mycostatin
3482222|NCT03779672|Placebo Comparator|Placebo Memantine Hydrochloride 10 mg|"Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Washout (Weeks #7-8) Memantine Hydrochloride~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
3482223|NCT03779399||Patient with benign ovarian tumor|25 patients with benign ovarian tumor (cystadenoma) were admitted to IInd Department of Gynecology, Lublin Medical University, Lublin, Poland.
3482224|NCT03779399||Patient with borderline tumor|11 women with borderline ovarian tumor were admitted to IInd Department of Gynecology
3482225|NCT03779399||Patient with ovarian cancer|24 women with ovarian cancer were admitted to IInd Department of Gynecology
3482226|NCT03779399||Patient without ovarian pathology|20 patient with unexpleined infertility were admitted to IInd Department of Gynecology
3482227|NCT03779282||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving ketodex
3482228|NCT03779282||study|pediatric patients undergoing outpatient strabismus surgery, and receiving ketodex
3482229|NCT03779321|Other|Lean panelists|Lean panelists or normal weight panelists with a BMI between 18.5 and 24.9 Acceptability was assessed
3482230|NCT03779321|Other|Obese panelists|Obese panelists with a BMI between 25 and 29.9 Acceptability was assessed
3482231|NCT03779269|Experimental|color meditation|only color meditation
3482232|NCT03779269|Experimental|Sound meditation|Only sound mediation
3482233|NCT03779269|Experimental|Color and sound combined meditation|Combined group
3482234|NCT03779269|No Intervention|Control group|Only control group
3482235|NCT03779425|Experimental|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
3482236|NCT03779256||Women with bowel endometriosis.|"Women with symptomatic bowel endometriosis scheduled for surgical treatment investigated with 2D transvaginal ultrasound before surgery at Hospital St John of God, Vienna, Austria; Oslo university hospital, Oslo, Norway and Nepean Hospital, Sydney, Australia.~The women recruited at Oslo university hospital, Norway will also have a magnetic resonance imaging (MRI) of the abdomen and pelvis before surger."
3482237|NCT03779386|Experimental|Music during labor and delivery|Music during labor and delivery
3482238|NCT03779386|No Intervention|No music during labor and delivery|No music during labor and delivery
3482239|NCT03779412|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Happiness Trap by Harris (2008), a self-help book based on acceptance and commitment therapy.
3482240|NCT03779412|Active Comparator|MBSR self-help book condition|Participants in this condition will be assigned to read A Mindfulness-Based Stress Reduction Workbook by Stahl and Goldstein (2010), a self-help book based on Mindfulness-Based Stress Reduction.
3482241|NCT03779295|Experimental|Pulse laser therapy applied to right side of face|
3482242|NCT03779295|Experimental|Pulse laser therapy applied to left side of face|
3482243|NCT03779477|Experimental|Coping with Stress Course|The Coping with Stress Program that consists of 8 sessions will be implemented to the experimental group. 8-10 adolescents will be included in this program. The session frequency will be one session per week. After the completion of 8 sessions, two 90-minute sessions will be carried out each month in the following two months.
3482244|NCT03779477|No Intervention|Control|There will be no intervention in the control group. If the program will be effective, this group will also undergo the Coping with Stress Program after the termination of the study.
3127695|NCT03104738|Experimental|25% reduction of basal insulin dose|The evening before surgery, 20 subjects will reduce their basal insulin dose to 25%.
3482245|NCT03779360|Active Comparator|Subjects 1-6|7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
3482246|NCT03779360|Experimental|Subjects 7-24|7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
3482247|NCT03779360|Active Comparator|Subjects 25-30|0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
3482248|NCT03779347|Experimental|Schistosomiasis treated during pregnancy|Praziquantel 40mg/kg once will be given during pregnancy at second to third trimester
3482249|NCT03779347|Active Comparator|Schistosomiasis treated after pregnancy|Praziquantel 40mg/kg once will be given to parturient after delivery during lactation
3482250|NCT03779347|Experimental|All study participants|UCP-LF CAA and composite diagnostic reference test based on extensive egg microscopy, plus serology, plus qPCR on egg DNA, and plus POC-CC will be used to detect schistosomiasis infection in pregnant women
3482251|NCT03779529|Active Comparator|Arm label extra-vergin olive oil (EVOO)|Participants will ingest two tablespoons of extra-vergin olive oil (EVOO) Coratina during the day: one spoon containing 10g of olive oil (>5mg of total biophenols/kg of olive oil) at lunch and one at dinner. The total biophenols ingested per day will be >10mg.
3482252|NCT03779529|Active Comparator|Arm label refined olive oil (ROO)|Participants will ingest two tablespoons of refined olive oil during the day: one spoon containing 10 g of refined olive oil at lunch and one at dinner.
3482253|NCT03779230|Experimental|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
3482254|NCT03779373|Active Comparator|EV1000 monitoring|This group of patients will receive fluid administration during surgery based on a manual GDFT protocol actually in place in the department using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
3482255|NCT03779373|Experimental|EV1000 monioring with the decision (AFM)|This group of patients will receive fluid administration during surgery based on a novel clinical decision support system for GDFT guidance using the EV1000 monitoring device (Edwards Lifesciences, Irvine, USA)
3482256|NCT03779178|Experimental|Landiolol group|Landiolol perfusion in incremental doses (range 0.5 to 10 µg/kg/min) over 2 hours
3127696|NCT03104816|Experimental|Acetaminophen IV Soln 10 MG/ML (A)|Patients in group A will receive 1 g of IV acetaminophen 15 minutes prior to wound incision, and every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
3127697|NCT03104816|Experimental|PO acetaminophen (B)|Patients in group B will receive 1 g of PO acetaminophen prior to surgery, and 1 g of oral acetaminophen every 4 to 6 hours postoperatively for a total of 4 grams in 24 hours.
3482257|NCT03779178|Placebo Comparator|Placebo group|Placebo perfusion in incremental doses (range 0.03 to 0.6 mL/kg/h) over 2 hours
3482258|NCT03779438|Active Comparator|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
3179627|NCT00675012|Experimental|A|
3482259|NCT03779438|Placebo Comparator|placebo to 17-OHPC|patients received weekly placebo to 17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
3482260|NCT03779308|Experimental|Intervention|The participants will receive whole body vibration therapy while standing with hand support on a vibration platform.
3482261|NCT03779217||group A|In this group there are women in that the mammography shows a breast represented by 80% of adipose tissue and less than 20% by fibro-glandular tissue.
3482262|NCT03779217||group B|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range of 50-75% and for the rest by fibro-glandular tissue
3482263|NCT03779217||group C|In this group there are women in that the mammography shows a breast represented by adipose tissue in the range 25-50% and the rest is from fibro-glandular tissue.
3482264|NCT03779217||group D|In this group there are women in that the mammography shows a breast represented by almost entirely fibro-ghiandular tissue.
3482265|NCT03779113|Experimental|Treatment|All patients to received study drug (HMPL-523)
3482266|NCT03779139|Active Comparator|Intrahepatic islets alone|
3482267|NCT03779139|Experimental|Intrahepatic and omental pouch islets|
3482268|NCT03779139|Sham Comparator|Normal Volunteers|
3482269|NCT03779126|Experimental|Active comparator|Low frequency electrical stimulation for 60 minutes, three times a week during 60 days.
3482270|NCT03779126|Experimental|Other|High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
3482271|NCT03779126|Experimental|Experimental group|Low and High frequency electrical stimulation for 60 minutes, three times a week during 60 days.
3482272|NCT03779126|Placebo Comparator|Placebo|Placebo electrical stimulation for 60 minutes, three times a week during 60 days. In the intervention groups will be used highest intensity tolerated by the individual, and in the sham will be maintained the minimum intensity after beginning of the perception of the electric current
3482273|NCT03779204|Experimental|Rent subsidies + Mentorship|Participants in this arm (n = 12) will receive rent subsidies (ranging from $400 - $500/month) for 24 months as part of the intervention and be matched with an adult mentor recruited by one of the community partners.
3127698|NCT03104816|Active Comparator|Hydromorphone (control arm) (C)|Patients in the control arm (Group C) will not receive acetaminophen for 24 hours.
3127699|NCT03104985|Active Comparator|Conventional treatment|"Conventional treatment only.~An elastic compression of lower extremities: elastic bandages or compression hosiery of class 2~Pharmacotherapy: Anavenol, Aescusan, Glyvenol; drugs of the Benzopyrone group, including Troxevasin and Venoruton. Trental, Aspirin and Ticlid (Ticlopidine). Nonsteroidal anti-inflammatory drugs (Nimesil, OKI), various ointments containing Heparin, corticosteroids, as well as nonsteroidal anti-inflammatory drugs. Antibiotic therapy.~Topical treatment: in the presence of purulent discharge (phase I of the wound healing process) - bandaging with antiseptic solutions (1% Iodopiron solution, 0.1% Chlorhexidine solution) and hydrophilic ointments (Levosin, Levomecol). In phases II and III - after ulcer cleansing the preparations based on Hyaluronic acid (Curiozin)."
3482274|NCT03779204|Active Comparator|Rent subsidies only|Participants in this arm (n = 12) will receive rent subsidies only (ranging from $400 - $500/month) for 24 months as part of the comparator group intervention. This group will not receive mentorship.
3482275|NCT03779009|Experimental|Tracer injection|
3482276|NCT03779035|Experimental|Gemcitabine plus Capecitabine|Gemcitabine (1000 mg per square meter) on days 1 and 8 Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
3482277|NCT03779035|Active Comparator|Capecitabine|Capecitabine (1250 mg per square meter) twice a day on days 1-14. Treatment repeats every 3 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
3482278|NCT03778814|Experimental|TCR-T cell therapy group|Appropriate lung cancer or other solid tumor patients who could benefit from immunotherapy will be treated with targeting TCR-T cells.
3482279|NCT03778918||inflammatory bowel disease|inflammatory bowel disease such as Ulcerative colitis and Crohn's disease
3482280|NCT03778918||IBS or Normal Control|irritable bowel syndrome patients normal patients
3482281|NCT03779191|Experimental|Intervention|Patients in this intervention arm will receive the therapeutic combination of Alectinib dosed PO 600 mg bis in die (BID) with meals and Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
3482282|NCT03778892|Experimental|Novel Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
3482283|NCT03778892|No Intervention|Standard Intervention|Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
3482284|NCT03778931|Experimental|Elacestrant|Subjects in Arm 1 will receive elacestrant
3482285|NCT03778931|Active Comparator|Standard of Care (SoC)|Subjects in Arm 2 will receive Investigator's choice of one of the Standard of Care drugs (fulvestrant, anastrozole, letrozole, or exemestane)
3482286|NCT03779087|Experimental|10d TL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
3482287|NCT03779087|Active Comparator|10d AL quadruple therapy|esomeprazole 40 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, amoxicillin 500 mg and metronidazole 250 mg q.i.d. for 10 days
3482288|NCT03779100|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3482289|NCT03778827|Experimental|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of one weekly 60-minute individual parent training session and 12 weekly hours ( 3 hours per day for 4 days per week) with the child in center-based therapy environment for a total of 13 weekly treatment hours.
3482290|NCT03778827|No Intervention|Delayed Treatment Group (DTG)|Delayed Treatment Group will consist of treatment as usual. At the end of controlled phase, participants in the DTG will be offered PRT-C in a preschool setting in an open-label fashion with a design similar to the double-blind phase.
3482291|NCT03778801||fibromyalgia syndrome|Thirty patients with a diagnosis of fibromyalgia syndrome according to the 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria and a disease duration of longer than three months
3482292|NCT03778801||chronic neck pain|30 patients with chronic neck pain lasting for more than three months and didn't meet 2016 revised American College of Rheumatology Fibromyalgia Syndrome diagnostic criteria.
3482293|NCT03778801||healthy controls|30 healthy controls without pain or additional disease
3482294|NCT03778970|Experimental|Pain Neuroscience Education + Exercises|The PNE will follow the principles established by Explain Pain, addressing reconceptualization of pain, emphasizing modern neuroscience concepts. The PNE workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic.
3482295|NCT03778970|Active Comparator|Self-Management Education + Exercises|"The Self-Management Education (SME) strategy will be aligned with the Back Book concepts, focused on behavior change and encouraging participants to be active despite of the pain. The SME workshop will last 40 minutes (2 sessions). The movement control exercises will consist of active exercises that address posture and control of movements which are impaired and trigger pain. The session will last approximately 30 minutes, starting with the execution of the coordination exercises in the control of movement with an intensity of 10 to 30 repetitions and then performing exercises for stretching in 3 series of 30 seconds. Finally, strengthening exercises in 3 sets of 15 repetitions will be implemented. The exercises will be administered 1 session/week (volunteers will be oriented to execute the same exercises at home twice a week). The volunteers will receive 8 sessions at the clinic."
3482296|NCT03778853|Experimental|Anlotinib Hydrochloride|Anlotinib Hydrochloride p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
3482297|NCT03778983||Pediatric Live Transplantation Group|Children who underwent pediatric Ltx at RenJi Hospital before 12 month, and now age between 2 and 7 years;
3482298|NCT03778983||Control group|The reference group included same age- and gender-matched children without a chronic health condition.
3482299|NCT03778749|Experimental|electromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
3482300|NCT03778749|Experimental|acceleromyographic NMT monitoring at the hand|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
3482301|NCT03778749|Experimental|acceleromyographic NMT monitoring at the eyebrow|In 20 mechanically ventilated ICU patients, TOF measurements will be performed every 24 hrs, once a day, at the same time, over the 72 hrs the study will take place in the ICU.
3482302|NCT03778866|Experimental|Bicarbonate-buffered Medium|
3482303|NCT03778866|No Intervention|HEPES-MOPS-buffered Medium|
3482304|NCT03778762|Active Comparator|Blind tracheal intubation through AirQ|Patients were intubated through the air-Q blindly
3482305|NCT03778762|Placebo Comparator|Fiberscopic tracheal intubation through AirQ|Patients were intubated through the air-Q using fibreoptic bronchoscope
3482306|NCT03778905||stroke patient with complete post-acute care hospitalization|This study aims on stroke patients with complete rehabilitative program in post acute care institution and we try to assess their functional improvements after rehabilitative training.
3482307|NCT03778944|Active Comparator|M group|Mannitol infusion
3482308|NCT03778944|Active Comparator|D group|Dopamine infusion
3482309|NCT03778944|Active Comparator|C group|Adequate hydration
3482310|NCT03779022||Sensitive|Sensitive group was defined ad complete response (CR) and/or partial response (PR). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
3482311|NCT03779022||Resistant|Resistant group was defined ad progression disease (PD) and/or stable disease (SD). Blood samples for microRNA were collected before neoadjuvant chemotherapy, evaluation of clinical disease response and surgery.
3482312|NCT03778996|Experimental|Maintenance Treatment: Ewing's Sarcoma|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus
3482313|NCT03778996|Experimental|Salvage Treatment: Sarcoma|Combination metyrosine-derivative, low-dose methoxasalen, phenytoin and sirolimus
3482314|NCT03779048|Active Comparator|Behavioral Treatment + Placebo|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
3482315|NCT03779048|Active Comparator|Behavioral Treatment + Medication|"All participants will complete an initial 4-week behavioral treatment (BT) run-in. Participants with suboptimal early weight loss in the BT run-in will then be randomly assigned to 24 additional weeks of: 1) BT plus placebo (BT+P); or 2) BT plus medication (BT+M; phentermine 15.0 mg) in a double-blinded fashion. Both treatment groups will continue to attend individual BT sessions and will take a once daily study medication (placebo or phentermine 15.0 mg) for the duration of the intervention period.~Early BT responders identified during the run-in will receive the same 24-week BT program, but will not receive study medication or be included in the randomized trial."
3482316|NCT03778879|Experimental|Group 1:With CCX872-B|Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
3482317|NCT03778879|No Intervention|Group 2:Without CCX872-B|SBRT Alone: 25 Gy in 5 fractions over 5-7 days
3482318|NCT03778723|Experimental|Total intravenous anesthesia (TIVA)|Patients will receive total intravenous anesthesia using Propofol and Midazolam
3482319|NCT03778723|Active Comparator|Inhalation Anesthesia|Patients will receive Inhalation anesthesia using Sevoflurane
3482320|NCT03779061|Experimental|Remimazolam Tosilate|
3482321|NCT03779061|Active Comparator|Propofol|
3482322|NCT03778775||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and liver stiffness measurement by FibroTouch.
3482323|NCT03778697|Experimental|Adolescent Endosleeve|Patients who will undergo endoscopic sleeve gastroplasty
3482324|NCT03778788|Active Comparator|App group|Participants will receive the MetS mobile application (MetS app) instalment and briefing by a research assistant (RA2) after the educational talk. They will be able view the booklet content in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting for their exercise plan and exercise record.
3482325|NCT03778788|Active Comparator|Booklet group|The participants will additionally receive a Hong Kong version Lifestyle Intervention Programme (LIP) booklet to take home and use for 20 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
3482326|NCT03778788|Active Comparator|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 20 weeks.
3482327|NCT03778619|Experimental|single arm|"Phase 1~MG4101 (Allogeneic Natural Killer cell): i.v bi-weekly~Group 1: 1 x 10^7 cells/㎏~Group 2: 3 x 10^7 cells/㎏~Group 3: 9 x 10^7 cells/㎏~Interleukin-2 (IL-2): s.c bi-weekly with MG4101 at 1X10^6 IU/m2 per day.~Rituximab: 375mg/m2. i.v. weekly for the first 2 cycles only (8 doses). monthly (3-6 cycle)~Lymphodepletion: Fludarabine 20mg/m2 + Cyclophosphamide 250 mg/m2 i.v. D-3, D-2, D-1 of 1st, 3rd, and 5th cycle~Phase 2a Administration of recommended dosage of MG4101 determined from Phase 1 will be applied in Phase 2a. Dosage regimens for lymphodepletion, IL-2 and Rituximab will be the same as Phase 1."
3482328|NCT03778684|Experimental|Normal Body mass index without central obesity|
3482329|NCT03778684|Experimental|High Body mass index with central obesity|
3482330|NCT03779074|Active Comparator|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days.
3482331|NCT03779074|Experimental|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days.
3482332|NCT03779074|Experimental|14d high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
3482333|NCT03778632|Experimental|Study Group|Intensive stuttering group therapy which was included individualized desensitization exercises was applied with the study group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
3482334|NCT03778632|Active Comparator|Control Group|Standard intensive stuttering group therapy was applied with the control group. Family training was applied with the parents a month before the therapy. Ten days (4.5 hours a day, a total of 45 hours therapy) of intensive stuttering group therapy was applied.
3482335|NCT03778658|Experimental|Outpatient Physical Activity Program|The intervention will investigate a multi modal outpatient physical activity program incorporating both strength training utilizing resistance bands, as well as an aerobic activity based on hip-hop dancing.
3482336|NCT03778736|Experimental|Cumulase denudation|
3482337|NCT03778736|No Intervention|Hyaluronidase denudation|
3482338|NCT03778450||Analgesics, Opioid|Patients are only included if they have been diagnosed in at least three quarters in the study period with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3. At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
3482339|NCT03778450||Non-Opioid Analgesic|Patients are only included if they have been diagnosed in at least three quarters in 2012 with one of the following diagnoses: R51, R52*, M00*-M99*, G43*-G44*, G50.0 or G50.1, F45.4*, G62*, or E10.4*-E14.4 plus G63.3.At least one diagnoses must be between 1 January 2012 and index treatment and main and secondary hospital diagnoses (i.e. Haupt- und Nebendiagnosen) will be used to include the patients.
3482340|NCT03778346|Experimental|CAR-T therapy in multiple myeloma|In order to assess the safety and validity of using the Fourth Genenation of CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD38-CART , Integrin β7-CART or 10 different combinations ,subjects will receive 10^6-10^7/Kg transduced CAR-T cells at one time.
3482341|NCT03778398|Experimental|Neurologic music therapy|Patients will receive 2 days of 40 minutes per week, total 3 months of customized piano training. Each session will be started with finger warming exercises, then with the right hand, left handed and with both hands, a simple pentatonic array will be played. In the following lessons, notes will be marked with colors and simple songs will be taught.
3482342|NCT03778333|Experimental|Open label single arm study|All patients will be treated with 1 single dose of IV infusion of autologous bone-marrow derived mesenchymal stem cells (1-2 million cells/kg body weight) and their therapeutic response will be followed over 48 weeks.
3482343|NCT03778476|Experimental|Isometric Exercise|Participants will perform a submaximal voluntary contraction of the quadriceps muscle to task failure.
3482344|NCT03778476|No Intervention|Quiet Rest|Participants will sit quietly for a period of time that mimics the exercise.
3482345|NCT03778463|Experimental|Synovectomy|
3482346|NCT03778463|No Intervention|No synovectomy|
3482347|NCT03778307||Trauma exposed without PTSD|Individuals with a history of trauma exposure who do not have current PTSD
3482348|NCT03778307||Trauma exposed with PTSD|Individuals with a history of trauma exposure and a current diagnosis of PTSD
3482349|NCT03778411||cACLD|200 people with compensated advanced chronic liver disease who have not undergone liver transplant
3482350|NCT03778411||cACLD-post transplant|100 people with compensated advanced chronic liver disease who have previously undergone liver transplant
3482351|NCT03778359||Gonadotropin-releasing hormone agonist treatment|Endometriosis post-operative Gonadotropin-releasing hormone agonist treatment
3482352|NCT03778359||Intrauterine device treatment|Endometriosis post-operative intrauterine device treatment
3179628|NCT00675038||1|Study participants will be patients who are cared for by the St. Jude Hematology Division and have developed iron overload and require liver biopsy.
3482353|NCT03778359||Hormone therapy|Endometriosis post-operative hormone therapy
3482354|NCT03778359||Oral contraceptive|Endometriosis post-operative oral contraceptive
3482355|NCT03778281|Experimental|Baclofen group|Treatment of Chemotherapy-related Hiccups With Baclofen
3482356|NCT03778281|Other|Methoxyclopramide group|Treatment of Chemotherapy-related Hiccups With Methoxyclopramide
3482357|NCT03778281|Experimental|Baclofen group 2|After 3 days, if the metoclopramide treatment is ineffective, it will cross into the baclofen group 2.
3482358|NCT03778281|Other|Methoxyclopramide group 2|After 3 days, if the baclofen treatment is ineffective, it will cross into the metoclopramide group 2.
3482359|NCT03778320|Experimental|CTP-692|
3482360|NCT03778320|Active Comparator|D-Serine|
3482361|NCT03778515||Cases - Ankylosing Spondylitis Cohort|20 patients with ankylosing spondylitis (AS). Fifteen of these patients will be recruited from the Ankylosing Spondylitis clinic at the University of California, San Francisco. Five patients will be recruited from the Rheumatology clinic at the Cleveland Clinic. Observational with MRI.
3482362|NCT03778515||Controls - w/o Ankylosing Spondylitis|5 patients without AS and with no history of any arthritis or lower back pain in this study. These 5 patients will make up the control group of the study, which means that they will provide a benchmark of comparison for the results investigators obtain from the active AS group. 2 of these 5 patients will be recruited from Cleveland Clinic, and 3 will be recruited from UCSF. Observational with MRI
3482363|NCT03778528||Down syndrome|Individuals with Down syndrome undergoing cataract surgery.
3482364|NCT03778528||Control|Age-matched controls undergoing cataract surgery.
3482365|NCT03778567|Other|lamivudine + nucleotide analogue|At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued
3482366|NCT03778541|Experimental|CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
3482367|NCT03778541|Active Comparator|RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
3482368|NCT03778580|Experimental|pyridoxamine|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year
3482369|NCT03778580|Placebo Comparator|identical placebo|identical placebo po bid for one year
3482370|NCT03778372||study|pediatric patients undergoing outpatient strabismus surgery, and receiving methadone
3482371|NCT03778372||control|pediatric patients undergoing outpatient strabismus surgery, and not receiving methadone
3127700|NCT03104985|Experimental|Conventional therapy and combined LLLT|"Conventional therapy and combined LLLT (LASMIK device) was performed. External exposure was conducted on the 1-4 affected area during one session for 2 minutes per zone in pulsed mode, light pulse duration - 100-130ns, wavelength - 635nm, by a matrix emitter consisting of eight laser diodes with a surface area of 8cm2, at a distance of up to 7cm, with pulsed power of 40W. ILBI was conducted in continuous mode with wavelength between 365-405nm (UV-spectrum) and 520-525nm (green spectrum) alternately, during 12 daily treatment sessions according to the scheme:~- 365-405nm, power 1-2mW, exposure 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min;~- 365-405nm, 1-2mW, 2 min;~- 520-525nm, 1-2mW, 5 min"
3482372|NCT03778593|Experimental|mFOLFIRINOX|D1 Oxaliplatin 65 mg/m2 + 5% dextrose water (5DW) 200 mL mix IV over 2 hours followed by, D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1 liter (1L) continuous IV over 23 hours repeat every 2 weeks
3482373|NCT03778216|Experimental|FBT-ARFID|Family Based Treatment of child ARFID
3482374|NCT03778216|No Intervention|Usual Care|Continued usual care for ARFID with the exception of any Family Based Treatment
3482375|NCT03778437|Active Comparator|landmark techniques|Subclavian vein catheterization is performed without the guidance of ultrasound. The needle was inserted 1 cm inferior and 1 cm lateral to the junction of the middle and medial thirds of the clavicle (infraclavicular approach)
3482376|NCT03778437|Experimental|ultrasound-guided with aiming method|Subclavian vein catheterization is performed with our newly proposed aiming method with the guidance of ultrasound.
3482377|NCT03778437|Experimental|ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique.
3482378|NCT03778164|Experimental|Fast Track Intervention|This arm refers to the new Partner Services-Sexual Health intervention offered to contacts by the Partner Services program
3482379|NCT03778164|Active Comparator|Standard of Care|This arm refers to the current standard practice for partners contacted by the Partner Services program
3127701|NCT03105297|Experimental|All participants (Baseline phase)|All the participants were applied nasal dilator strip during the sleep laboratory night on Day 1.
3482380|NCT03778385|Experimental|Isometric Exercise|Submaximal isometric resistance exercise of the arm.
3127702|NCT03105297|Experimental|All Participants (Active Phase)|All the participants wore nasal dilator strip over a 1 month in-home use period and returned for sleep laboratory nights after 7 (Day 8) and 28 days (Day 29) of treatment
3127703|NCT03105297|Experimental|All Participants (Nasal Resistance Phase)|The participants were randomized to receive a sequence of either 'strip'/' no strip' or 'no strip'/'strip' on 2 sleep laboratory nights (on Day 30 and Day 31) based on the randomization schedule
3482381|NCT03778385|Experimental|Dynamic Exercise|Submaximal dynamic resistance exercise of the arm.
3482382|NCT03778268|Experimental|Undergoing sentinel lymph node biopsy|This group of patients will undergo sentinel lymph node biopsy.
3127704|NCT03105362|Experimental|Amino Acid-ORS arm|Patients consumed an amino acid based oral rehydration solution (enterade®) as part of their oral rehydration care plan. Enterade® oral rehydration solution volumes varied from patient to patient depending on baseline clinical need.
3482383|NCT03778554|Experimental|Beta blocker treatment|"Treatment with beta blockers plus standard of care. Type and dosage according to treating cardiologist choice~Bisoprolol up to a total dose of 10 mg daily~Carvedilol up to a total dose of 50 mg daily~Metoprolol succinate up to a total dose of 200 mg daily~Nebivolol up to a total dose of 10 mg daily"
3482384|NCT03778554|No Intervention|No beta blocker treatment|Standard care without beta blocker treatment
3482385|NCT03778008|Experimental|Recombinant bovine basic fibroblast growth factor|
3482386|NCT03778008|Active Comparator|Quadruple mixture|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition
3482387|NCT03778255|Experimental|Undergoing sentinel lymph node biopsy|
3482388|NCT03778242|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1 gm tranexamic acid ( 2 ampoules) in 100 ml saline by slow infusion
3482389|NCT03778242|Active Comparator|oxytocin plus placebo to TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus2 placebo ampoules to tranexamic acid(TA) in 100 ml saline by slow infusion
3482390|NCT03778112|Experimental|Negative mpMRI Prostate Scan|SBRT to the whole prostate
3482391|NCT03778112|Experimental|Positive mpMRI Prostate Scan|IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions
3482392|NCT03778047|Experimental|enzalutamide|160mg
3482393|NCT03778047|Experimental|HC-1119|To be determined
3482394|NCT03778060|Experimental|Transcutaneous stimulation|Participants in the clinical study will consist of subjects with essential tremor who are scheduled more than 3 months in advance to undergo deep brain stimulation surgery for treatment of essential tremor at Mayo Clinic. Subjects will wear a Cala TWO stimulator to reduce hand tremors.
3482395|NCT03778021|Experimental|Intervention Group|Students in the intervention group will receive the curriculum and school garden during the second academic school year (Year 2)
3482396|NCT03778021|Active Comparator|Delayed Intervention Group|For the delayed intervention group schools, students will receive the intervention at the beginning of Year 3
3482397|NCT03778177|Experimental|Trigeminal Neuralgia Pain Diagnosis|Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
3482398|NCT03778034||Female with forward head posture|post-pubertal females suffering from (FHP) with Craniovertebral angle (CVA) less than 49 degrees(study group)
3482399|NCT03778034||healthy female without (FHP)|post-pubertal females expected to exhibit an average normal CVA within 10degrees range from 49 to 59 (control group)
3482400|NCT03778138|Experimental|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
3482401|NCT03778086||cataractous eyes|eyes of children with unilateral or bilateral cataract
3482402|NCT03778086||fellow eyes|fellow eyes of children with unilateral cataract
3482403|NCT03777956|Active Comparator|Lacosamide|Lacosamide (50 mg) are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
3482404|NCT03777956|Placebo Comparator|Placebo|Placebo are given as capsules, same as lacosamide, and taken orally twice a day, without active ingredient.
3482405|NCT03778151|Active Comparator|TRANSCRANIAL MAGNETIC STIMULATION|repetitive TRANSCRANIAL MAGNETIC STIMULATION (rTMS) will be applied over the precuneus to modulate DMN activity. The rTMS treatment will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
3482406|NCT03778151|Sham Comparator|SHAM TRANSCRANIAL MAGNETIC STIMULATION|SHAM TMS will be applied over the precuneus. The SHAM protocol will consist of two phases: an intensive phase and a maintenance phase. The intensive phase will involve 2 weeks of treatment, 5 days per week (10 sessions, 1.600 pulses per day for a total of 16.000 pulses). The maintenance phase will consist of 1 session of treatment every week for 5 months (21 sessions, 100.800 pulses in total).
3482407|NCT03778099|Experimental|Cinnamon Group|Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
3127705|NCT03105479|Experimental|Part A / Cohort A|Subjects from 12 years to 18 years old (exclusive) will receive cadazolid 500 mg per day for 10 days. The dose may be adjusted based on the pharmacokinetic (PK) and safety data reviewed for the first 3 subjects.
3482408|NCT03778099|Placebo Comparator|Placebo Group|"Placebo capsules will contain 450 mg of starch and 50 mg of cinnamon powder (to improve blindness regarding taste and odor). Color, shape, and size of placebo capsules will be exactly the same as the cinnamon capsules.~2g/day along with clomiphene citrate"
3482409|NCT03777852|Experimental|Pre-surgery First Breast Q|Women with proven breast cancer diagnosis. Respond to the First Breast Q questionnaire..
3482410|NCT03777852|Active Comparator|Post-surgery Second Breast Q|The Second Breast Q questionnaire will be applied to this group that will be composed of the women of the first group submitted to reconstructive breast cancer surgery.
3482411|NCT03777943||Cytoreductive surgery (CRS)|In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
3482412|NCT03777878|Active Comparator|Carbetocin plus placebo to TA and placebo to oxytocin|100 μg carbetocin ampoule or separate placebo ampoule was diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby plus two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion
3482413|NCT03777878|Active Comparator|oxytocin plus TA|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 1gm TA in 100ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
3482414|NCT03777878|Active Comparator|oxytocin plus placebo to TA and placebo to carbetocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby plus 2 placebo ampoules to TA in 100 ml saline by slow infusion plus placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
3482415|NCT03777904||Children with high serum ferritin|Children with very high serum ferritin levels and confirmed iron toxicity will have a urine sample and blood sample drawn at the same time. Both samples will have ferritin levels and iron content measured and compared for correlation.
3482416|NCT03777813|Experimental|Arm A|"Concomitant administration of durvalumab (dose: 1500 mg):~Every 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)~Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
3482417|NCT03777813|Active Comparator|Arm B|"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:~50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)~45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node~FOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):~IV oxaliplatin 85 mg/m² in 2 h on D1~IV Leucovorin 200 mg/m² in 2 h on D1, followed by~IV 5-FU 400 mg/m² in 10 minutes on D1 followed by~IV continuous infusion 5-FU 2400 mg/m² in 46 h"
3482418|NCT03777891|Experimental|group A|received Silicone gel phonophoresis: Silicone gel (strataderm) was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes. The Ultrasound Device is Sonopulse 590: Nonius, sonopuls 590, S.NO.03-202 type 14663.900 was a therapeutic ultrasound device manufactured by Enraf Holland.
3482419|NCT03777891|Experimental|group B|received Contractubex phonophoresis: Contractubex (Merz Pharma, Frankfurt, Germany was applied to the scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes.
3482420|NCT03777891|Experimental|group C|received Corticosteroid phonophoresis: A thin film of coupling medium (gel) was put on the hypertrophic scar and sufficient quantity of Triamcinolone was put by a syringe over the whole scar then the ultrasound was implemented by the therapist. The ultrasound parameters were set as following, frequency: 1 MHz, intensity: 0.5 W/cm2 and the treatment time was 5 minutes
3482421|NCT03777800|Experimental|Body Therapy|Participants in the intervention condition will be assigned to a 6-month body therapy treatment focused on 24 individual body treatments including conversations and direct physical treatment of the body combined with home-based daily practice of meditation.
3482422|NCT03777800|Active Comparator|Treatment As usual|Participants in the control condition will be offered treatment as usual, which is psychiatric medication and/or individual psychotherapy as deemed relevant by the psychiatrist.
3482423|NCT03777683|Experimental|Dietary Supplement (OLIGOPIN)|Intervention group will receive French maritime pine bark extract supplement (OLIGOPIN) in the form oral capsules containing 50 mg French maritime pine bark extract plus 130 mg Microcrystalline Cellulose. OLIGOPIN powder of each capsule are dissolved in 10 ml deionized water and given to patients via gavage (3 capsule per day) for 10 days
3482424|NCT03777683|Placebo Comparator|Placebo|Control group will receive oral capsules containing 130 mg Microcrystalline Cellulose with 10 ml of deionized water via gavage (3 capsule per day) for 10 days.
3482425|NCT03777670||Cases|Infants with suspected sepsis
3482426|NCT03777670||Controls|Infants with no suspicion of sepsis
3482427|NCT03777748|Experimental|Two dental implants in the edentulous maxilla and mandible|Edentulous maxilla und mandible are treated with two diameter-reduced tissue level implants (Straumann, Basel) and anchored with CM LOC® and CM LOC Flex® attachments (Cendres+Métaux SA, Bienne).
3482428|NCT03777917|Experimental|Belotero Balance®|
3482429|NCT03777917|No Intervention|No treatment|
3482430|NCT03777930|Experimental|chemotherapy group|the patients were recepted chemotherapy alone
3482431|NCT03777930|Experimental|chemotherapy combined with TH and MG group|the patients were recepted chemotherapy combined with thalidomide and megestrol
3482432|NCT03777930|Experimental|the best supportive treatment group|the patients were recepted the best supportive without chemotherapy
3482433|NCT03777930|Experimental|the best supportive treatment combined with TH and MG group|the patients were recepted the best supportive combined with thalidomide and megestrol without chemotherapy
3127706|NCT03105479|Experimental|Part A / Cohort B|Subjects from 6 years to 12 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort A reviewed by the Independent Data Monitoring Committee (IDMC).
3127707|NCT03105479|Experimental|Part A / Cohort C|Subjects from 2 years to 6 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort B reviewed by the IDMC.
3482434|NCT03777774|Active Comparator|No subgaleal drains|Drains will be placed during closing stage of craniectomy but will be clamped so that no drainage takes place. Drains can be opened if needed
3482435|NCT03777774|Active Comparator|Passive subgaleal drains|Passive non-vacuum drains will be placed during closing stage of craniectomy
3482436|NCT03777774|Active Comparator|Vacuum subgaleal drains|Active vacuum drains will be placed during closing stage of craniectomy
3482437|NCT03777410||Vanguard|(CLOSED TO ENROLLMENT) Bone marrow (BM) from this cohort of up to 30 treatment naïve subjects with a diagnosis of multiple myeloma (MM) will first be used to define sample processing pipeline performance and optimal drug dosages before sites on the study proceed to mass accumulation rate (MAR) testing of BM from the relapsed/refractory MM (RRMM) subject cohort.
3482438|NCT03777410||Relapsed/Refractory MM|BM from this cohort of 100 relapsed subjects with a diagnosis of MM will be used to test the MAR assay's accuracy of condition by matching conditions tested in vitro to the patient's planned course of therapy. This is the main study cohort described in the Eligibility section.
3127708|NCT03105479|Experimental|Part A/ Cohort D|Subjects from 3 months to 2 years old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort C reviewed by the IDMC.
3482439|NCT03777579|Experimental|JS001 Plus Nab-Paclitaxel|Participants assigned to JS001 plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
3482440|NCT03777579|Placebo Comparator|Placebo Plus Nab-Paclitaxel|Participants assigned to placebo plus nab-paclitaxel will receive both agents until disease progression or unacceptable toxicity.
3482441|NCT03777696|Active Comparator|Misoprostol with TA|400 μg of buccal misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
3482442|NCT03777696|Active Comparator|Misoprostol with placebo to TA|400 μg of buccal misoprostol (two tablets) plus 110 ml saline by iv rout
3482443|NCT03777696|Placebo Comparator|placebo to Misoprostol and TA|placebo to misoprostol plus placebo to tranexamic acid
3482444|NCT03777423|Experimental|PEEK framework partial dentures|High performance ketone polymers introduced lately.These polymer-based frameworks provide better esthetics, higher elasticity, lighter in weight, have low water sorption and solubility, and are easily repaired and reproduced.
3482445|NCT03777423|Active Comparator|Cobalt-chromium framework partial dentures|it is considered the gold standard framework. These frameworks are less bulky with high strength, conduct heat and electricity well, and have good durability. some disadvantages include hypersensitivity, adverse tissue reactions and bad aesthetics.
3482446|NCT03777787|Experimental|Bitter|A single intragastric administration of denatonium benzoate (1 µmol/kg)
3482447|NCT03777787|Placebo Comparator|Placebo|A single intragastric administration of placebo (water)
3482448|NCT03777540||Age; timing of gastric resection|Patients 80-85 years; Patients > 85 years; Elective and urgent surgery.
3482449|NCT03777709|Experimental|Intervention|The FAITH! App intervention includes a 10-week core series of multimedia education modules with a LS7 focus and other features including interactive self-quizzes, self-monitoring (diet/physical activity), and social networking. Participants will follow a weekly schedule of each module concentrating on each LS7 component. Personalized messages will be delivered to each participant 3-4 times weekly over the intervention phase through the app dashboard, text message, or email. The sharing board will be moderated weekly to foster discussion on behavior change influences and participant successes/challenges to healthy lifestyle. Participants will maintain app access for the duration of the study.
3482450|NCT03777709|No Intervention|Delayed Intervention/Control|"The delayed intervention group will not receive additional materials while under the control time point (intervention group within intervention/maintenance phases)."
3482451|NCT03777462|Active Comparator|Group A of neoadjuvant chemotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And surgical resection is performed after completion of the whole chemotherapy.
3482452|NCT03777462|Experimental|Group B of neoadjuvant chemoradiotherapy|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of gemcitabine (1000mg/m2) and nab-paclitaxel (125 mg/m2) are initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
3482453|NCT03777462|Experimental|Group C of neoadjuvant chemoradiotherapy|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in this group. Intravenous administration of nab-paclitaxel (125 mg/m2) is initiated on day 1, 8 and 15 during each 4-week cycle, which will repeat for 3 cycles. And S-1 is orally administrated at a dose of 80 mg/m2 for 18 days followed by a 10-day rest during each 4-week cycle, which aslo continues for 3 cycles. After completion of the whole chemotherapy, patients will first receive PET-CT to exclude distant metastases and then undergo SBRT. The prescribed dose is 7.5-8Gy/f for 5 fractions. Dose constraints of normal tissues are referred to the American Association of Physicists in Medicine guidelines in TG-101. And surgical resection is performed 3 weeks after SBRT.
3482454|NCT03777722|Experimental|Aim 1: Active Intervention then Placebo|Tailored Lighting intervention (TLI). The active TLI will provide high circadian stimulation during the day produced by light sources that provide moderate light levels of spectra that are tuned to the sensitivity of the circadian system. The active lighting intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the placebo control intervention for 8 weeks.
3482455|NCT03777722|Experimental|Aim 1: Placebo Intervention then Active|The placebo lighting intervention is designed to have no effect on the circadian system. The control intervention will be in place for 8 weeks. Following an 8 week washout period, the participants will see the active tailored lighting intervention for 8 weeks.
3482456|NCT03777644|Experimental|TPVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with morphine
3482457|NCT03777644|Placebo Comparator|placebo TPVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with morphine
3482458|NCT03777449||Vertical bone loss|Infra-osseous defects
3482459|NCT03777449||Horizontal bone loss|Supra-osseous defects
3482460|NCT03777449||Combined bone loss|Combined supra-osseous and infra-osseous defects
3482461|NCT03777631|No Intervention|Standard medical therapy group|The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
3482462|NCT03777631|Active Comparator|Catheter ablation group|Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
3127709|NCT03105479|Experimental|Part A/ Cohort E|Subjects from birth to 3 months old (exclusive) will receive cadazolid for 10 days. The dose will depend on the PK and safety data from cohort D reviewed by the IDMC.
3127710|NCT03105479|Experimental|Part B / Cadazolid|Subjects from birth to 18 years old (exclusive) will receive cadazolid for 10 days, at the dose defined in the corresponding age cohort in Part A.
3127711|NCT03105479|Active Comparator|Part B / Vancomycin|Subjects from birth to 18 years old (exclusive) will receive vancomycin capsule (for subjects able to swallow) or vancomycin solution (for the others) during 10 days .
3127712|NCT03105518|Experimental|Analgesia options|Protocolized analgesia based on VAS degree of discomfort and time. Analgesic options include heating pad, acetaminophen, percocet (oxycodone), fentanyl 0.5-1 mcg/kg.
3127713|NCT03106077|Experimental|Cohort A (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unaccepted toxicity.
3127714|NCT03106077|Experimental|Cohort B (mirvetuximab soravtansine)|Patients receive mirvetuximab soravtansine IV over 2-3 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unaccepted toxicity.
3127715|NCT03106337|Experimental|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
3127716|NCT03106636|Active Comparator|KEEP-P|Caregivers are randomly assigned to one of two groups. The KEEP-P group completes a basic version of the curriculum. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
3482463|NCT03777657|Experimental|Tislelizumab (BGB-A317) + chemotherapy|Tislelizumab and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-Fluorouracil regimens are used as the backbone chemotherapy.
3482464|NCT03777657|Placebo Comparator|Placebo + chemotherapy|Placebo and chemotherapy. Oxaliplatin + capecitabine or cisplatin + 5-FU regimens are used as the backbone chemotherapy.
3482465|NCT03777553|Experimental|VETNET|Narrative Exposure Therapy for Justice-Involved Veterans
3482466|NCT03777592|Active Comparator|ESPB with local agent|ESPB will be performed using 20ml of 0.5% ropivacaine.
3127717|NCT03106636|Experimental|KEEP-P+|Caregivers are randomly assigned to one of two groups. The KEEP-P+ group completes an augmented version of the intervention with curriculum that includes the addition of information about recent findings in early brain development and a video coaching component based on the Filming Interactions to Nurture Development (FIND) program. The intervention content is delivered by a KEEP-P group facilitator in a 2-hour weekly group format. Duration of the program is 12 weeks.
3127718|NCT03106753|Active Comparator|Spinal anesthesia immediately for ECV.|The patient will have a spinal administered by the on call anesthesiologist using standard protocol (intrathecal bupivacaine 7.5 mg). The patient will then be administered 0.25 mg Terbutaline subcutaneously and the ECV will be attempted. Under ultrasound guidance the provider will attempt to lift the breech upward from the pelvis with one hand and guide the head with the other hand to produce a forward roll. If forward roll fails, a backward roll somersault may be attempted. ECV attempt will be abandoned if there is significant fetal bradycardia, discomfort to the patient, or if the procedure cannot be completed easily with these maneuvers. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
3482467|NCT03777592|Sham Comparator|ESPB with saline|ESPB will be performed using 20ml of saline.
3127719|NCT03106753|Experimental|Spinal anesthesia if no intervention fails for ECV.|The patient will be administered terbutaline 0.25 mg subcutaneously and the version will be attempted using the same procedure as above. If successful, the patient will be monitored for 30 minutes and discharged if fetal and maternal status is reassuring. If the attempt fails, the patient will be administered spinal anesthesia as above and the same maneuvers will be attempted. Once attempt is complete, whether successful or not, the patient will be monitored for a minimum of 30 minutes, and will be discharged once they are able to walk, void, and tolerate PO intake, only if fetal and maternal status is reassuring.
3127720|NCT03106844|Experimental|Treatment|All patients in this study will receive Fecal Microbiota Tranplantation
3482468|NCT03777605|Experimental|"NTG1523, rapid absorbable capsule"|"Nitroglycerine 0.4 milligram taken as ordinary tablets or NTG1523 rapid absorbable capsule once in the morning, and subsequently blood samples and observations for 2 hours are performed"
3482469|NCT03777475|Experimental|low dose|low oxaliplatin (85mg/m2)
3482470|NCT03777475|Active Comparator|high dose|high oxaliplatin (135mg/m2)
3482471|NCT03777501|Experimental|non-random whole body vibration group|Each participant will receive the non-random type whole body vibration treatment about one hour after the administration of medicine.
3127721|NCT03106870|Active Comparator|oral metformin and insulin|Intervention 'Insulin Mixtard' and Intervention 'metformin' had included
3127722|NCT03106870|Active Comparator|insulin therapy only|Intervention 'Insulin Mixtard' had included
3127723|NCT03107026|Experimental|dasotraline 4mg|dasotraline 4mg once daily
3127724|NCT03107026|Experimental|dasotraline 6mg|dasotraline 6mg once daily
3482472|NCT03777501|Active Comparator|conventional therapy group|For the conventional therapy group, participants will receive the occupational therapy including dynamic balance training and functional ambulatory training. Each session is 10 minutes.
3482473|NCT03777735||human bone graft screw|The patients will receive human bone graft screws surgically.
3482474|NCT03777761|Experimental|Treatment Sequence ABC|tucatinib + placebo + moxifloxacin (administered in sequential treatment periods)
3127725|NCT03107026|Placebo Comparator|Placebo|Placebo, once daily
3482475|NCT03777761|Experimental|Treatment Sequence CAB|moxifloxacin + tucatinib + placebo (administered in sequential treatment periods)
3482476|NCT03777761|Experimental|Treatment Sequence BCA|placebo + moxifloxacin + tucatinib (administered in sequential treatment periods)
3482477|NCT03777761|Experimental|Treatment Sequence CBA|moxifloxacin + placebo + tucatinib (administered in sequential treatment periods)
3179629|NCT00675064|Experimental|Anti-malarial experimental drug|After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules.
3179630|NCT00675064|Active Comparator|Matching placebo|After randomization subjects will receive matching placebo of GSK3697969.
3482478|NCT03777761|Experimental|Treatment Sequence ACB|tucatinib + moxifloxacin + placebo (administered in sequential treatment periods)
3482479|NCT03777761|Experimental|Treatment Sequence BAC|placebo + tucatinib + moxifloxacin (administered in sequential treatment periods)
3482480|NCT03777488|Experimental|Tranexamic acid Group 1|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Intramuscular Third Dose: Oral"
3482481|NCT03777488|Experimental|Tranexamic acid Group 2|"Participants will receive tranexamic acid in the following order:~First Dose: Intravenous Second Dose: Oral Third Dose: Intramuscular"
3482482|NCT03777488|Experimental|Tranexamic acid Group 3|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Intravenous Third Dose: Oral"
3482483|NCT03777488|Experimental|Tranexamic acid Group 4|"Participants will receive tranexamic acid in the following order:~First Dose: Intramuscular Second Dose: Oral Third Dose: Intravenous"
3482484|NCT03777488|Experimental|Tranexamic acid Group 5|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intravenous Third Dose: Intramuscular"
3482485|NCT03777488|Experimental|Tranexamic acid Group 6|"Participants will receive tranexamic acid in the following order:~First Dose: Oral Second Dose: Intramuscular Third Dose: Intravenous"
3482486|NCT03777514|Active Comparator|IV iron|"Ferumoxytol intravenous (IV) 1020 mg as - 2 vials of 510 mg (510 mg IV over 15 minutes) each given 2-7 days apart.~Participants in this group will also receive oral vitamin C as a placebo."
3482487|NCT03777514|Active Comparator|oral iron|Ferrous sulfate 325 mg (oral) tabs morning and evening. Participants in this group will also receive intravenous normal saline as a placebo.
3482488|NCT03777566||group A|35 patients with an indication for hysterectomy without gross uterine pathology
3482489|NCT03777566||group B|150 infertile patients in the childbearing age without gross uterine pathology
3482490|NCT03777111|Active Comparator|Single Task Training Group|"Gait and balance exercises will be applied in single task training group.~Semi-tandem, tandem stand with eyes open and close~One leg stance with eyes open and close~Gait exercises; walking forwards, backwards, sidewards, semi-tandem and tandem walking~Reaching forward and sidewards with eyes open and close"
3482491|NCT03777111|Experimental|Dual Task Training Group|"The exercises given in the single task training group will be combined with the cognitive tasks.~Semi-tandem, tandem stand with recall a sequence of numbers~One leg stance with writing pre-defined letters or words with other foot~Semi-tandem or tandem walking with saying previous number (one or two previous) from number that researcher has given before~Walking sidewards with collecting numbers that researcher has given~Walking backwards with counting forward by one (then two or three)~Reaching forward with counting backward one (then two or three)~Reaching sidewards with saying next number (one or two next) from number that researcher has given before"
3482492|NCT03777085|Experimental|TQB2303|
3127726|NCT03107052|Experimental|Fremanezumab 225 mg Monthly|Participants with ECH or CCH who received fremanezumab at 900 mg intravenous (IV) infusion at Week 0 and fremanezumab at 225 mg subcutaneous (SC) injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056 or TV48125-CNS-30057, and participants with CCH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab at 225 mg SC injection monthly (approximately every 4 weeks, administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 milliliter {mL}] at Week 0 and 36; and 2 placebo SC injections at Weeks 0, 12, 24, and 36 for blinding in participants rolled over from Study TV48125-CNS-30056; fremanezumab at 225 mg as a single SC injection (225 mg/1.5 mL) at Week 0, 12, 24, and 36; 2 SC injections of placebo at Week 0 for blinding in participants rolled over from Study TV48125-CNS-30057) through Week 36 in this study.
3127727|NCT03107052|Experimental|Fremanezumab 675/225 mg Monthly|Participants with CCH who received placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30057; will receive fremanezumab 675 mg SC injection as loading dose (administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Week 0) followed by monthly (approximately every 4 weeks) fremanezumab at 225 mg SC injection (administered as single SC injection of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 12, 24, and 36) through Week 36.
3179631|NCT00675077|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3179632|NCT00675090|Experimental|GSK239512|GSK239512 oral tablets
3179633|NCT00675090|Placebo Comparator|Placebo|Placebo to match tablets
3482493|NCT03777085|Active Comparator|Rituximab|
3482494|NCT03777124|Experimental|SHR-1210 +apatinib|subject will receive SHR-1210 200mg every 2 weeks, apatinib 250mg every day
3482495|NCT03777124|Active Comparator|chemotherapy|Pemetrexed 500mg/m2, Day 1 of each 21 day, 4 cycles carboplatin AUC 5 on Day 1 of each 21 day, 4 cycles followed by pemetrexed 500mg/m2 until progression Q3W
3482496|NCT03777150|Experimental|Group ICU|Group ICU:patients are admitted directly into the ICU for postoperative care
3482497|NCT03777150|Experimental|Group Ward|Group Ward:patients are admitted directly into the standard ward for postoperative care
3482498|NCT03777293|Experimental|training cohort|ultrasound viscoelasticity
3482499|NCT03777293|Other|testing cohort|ultrasound viscoelasticity
3482500|NCT03777254|Experimental|RC28-E|"·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E~Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"
3482501|NCT03777358||Three-dimensional transvaginal ultrasonography (3D-TVS)|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then, hysteroscopy will be performed.
3482502|NCT03777176|Experimental|Standard of Care + dasiglucagon|8 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
3482503|NCT03777176|Other|Standard of Care|4 weeks of standard of care + 4 weeks of dasiglucagon treatment as sc infusion starting at 10 µg/hr on top of standard of care
3482504|NCT03777202|Experimental|High-flow nasal oxygen during sleep endoscopy|High-flow nasal oxygen will be applied to the patients through nasal openings using Optiflow system during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
3482505|NCT03777202|Active Comparator|Low-flow nasal oxygen during sleep endoscopy|Low-flow nasal oxygen will be applied to the patients through nasal openings using conventional nasal cannula during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
3482506|NCT03777189|Experimental|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
3482507|NCT03777241|Active Comparator|Behavioral Intervention Team|The participants in this arm will receive the Behavioral Intervention Team.
3482508|NCT03777241|Active Comparator|Standard of Care|The participants in this arm will receive the standard of care.
3482509|NCT03777280|Experimental|peek framework Removable partial denture|polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
3482510|NCT03777280|Active Comparator|cobalt chromium framework Removable partial denture|it's the gold standard framework which has many benefits such as they are used in thin sections and are less bulky,provide high strength and stiffness,and some disadvantages include hypersensitivity,metal display and oral galvanism,
3482511|NCT03777163|Other|Butantan Trivalent Influenza Vaccine|"Butantan Institute Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
3482512|NCT03777163|Other|Sanofi Trivalent Influenza Vaccine|"Sanofi Trivalent Seasonal Influenza Vaccine (IB-TIV): 15 μg influenza A/H1N1 antigen + 15 μg influenza A/H3N2 antigen + 15 μg influenza B antigen~Patients will receive one dose (0,5 ml) via intramuscular injection."
3482513|NCT03776981|No Intervention|Baseline Gait Comparisons of Groups|Determine if kinetic (time to first peak ground reaction force [T1] and second peak ground reaction force [F2], both in the sagittal plane) and kinematic (peak stance knee flexion angle [KFA] and external knee adduction moment [KAM]) gait variables, and speed, differ between patients with KOA and age and gender matched controls during self-selected paced ambulation, and determine which ones have predictive relationships with Knee Injury and Osteoarthritis Outcome Score (KOOS) scores in the patients with KOA.
3482514|NCT03776981|Experimental|Gait with core activation|Determine if volitional core activation alters gait kinetics (T1 and F2), kinematics (KFA and KAM), and speed in patients with and without KOA during self-selected paced ambulation when compared to ambulating without volitional core activation, and whether the subjective pain complaints are significantly changed in the group with KOA. Determine whether there are baseline differences in core activation between those with and without KOA.
3482515|NCT03776981|Experimental|Knee OA Gait After core stabilization|Determine if a six-week core stabilization program alters KOOS score, and the kinetics (T1 and F2), kinematics (KFA and KAM), and speed of gait in patients with KOA during self-selected paced ambulation as compared to their pre-intervention baselines. Determine if there is a predictive relationship between the number of completed intervention sessions performed and these observed changes.
3482516|NCT03777033|No Intervention|Control Group|Patients after thyroidectomy will be managed as usual. Oral or IV supplements of Calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia.
3482517|NCT03777033|Experimental|Study group|Intervention: the patients will be given prophylactically ca and vit D. Patients after thyroidectomy will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb Intervention: The patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. Afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days)
3482518|NCT03776903||endemic|Samples collected from areas endemic for zika. Subject specimens underwent testing with the study device and reference method.
3482519|NCT03776903||non-endemic|Samples collected from areas non-endemic for zika. Subject specimens underwent testing with the study device and reference method.
3482520|NCT03776851|Experimental|Erythropoietin|Erythropoietin plus standard of care (RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability)
3482521|NCT03776851|No Intervention|No Intervention|Standard of care: RBC transfusions if Hb ≤7 mg/dl and/or hemodynamic instability
3482522|NCT03777046|No Intervention|Screen fail subjects|Mothers and their babies that meet inclusion criteria for the study, but score less than 10 on the Edinburgh Postpartum Depression Scale (EPDS)
3482523|NCT03777046|Active Comparator|PPD Control subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
3482524|NCT03777046|Experimental|PPD Intervention subjects|Mothers and their babies that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
3482525|NCT03777020|Experimental|Service Dog Training Program (SDTP)|Veterans randomized to the SDTP will be paired with an experienced Warrior Canine Connection (WCC) Mission Based Trauma Recovery (MBTR)-Trainer (MBRT-T) and a service dog (SD). One hour training modules will be scheduled once a week for 8 weeks. Participants will come to WCC for all the weekly training modules. Participants will be paired with the same SD for the duration of the SDTP unless an unforeseen circumstance arises and the SD needs to be removed from the SDTP. The MBTR-T will deliver the prescribed SDTP modules created by WCC. Each session will be fully supervised by a WCC MBTR-T to address any concerns or safety issues that may arise.
3482526|NCT03777020|Other|Dog Training Education|Veterans randomized to Dog Training Education will participate in one hour online SD training modules (https://e-trainingfordogs.com) scheduled once a week for 8 weeks. The online training modules are delivered by experienced SD trainers and will employ parallel content to the WCC SDTP. Participants will come to the WCC site for all the weekly online training modules. Members of the WLCI group will have education about dog training, but NO interaction with a SD. The online training modules for the DTE group are intended to keep the veterans who are not immediately assigned to the SDTP engaged in the study. They will participate in the SDTP after conclusion of participation in the 8 week study.
3482527|NCT03776916|Experimental|Group 1|"Simethicone administration 20-30 min before the procedure:~Patients intake simethicone solution 20-30 min before the procedure."
3482528|NCT03776916|Experimental|Group 2|"Simethicone administration 31-60 min before the procedure:~Patients intake simethicone solution 31-60 min before the procedure."
3179634|NCT00675129|Experimental|1|Dialectical behavioral therapy
3179635|NCT00675129|Active Comparator|2|Enhanced Usual Care (standard care plus monitoring and patient safety protocol implemented)
3482529|NCT03776916|Experimental|Group 3|Simethicone administration >60 min before the procedure; Patients intake simethicone solution >60 min before the procedure.
3482530|NCT03776968|Experimental|HC1119|Fasting state:40 mg, 80 mg, 160 mg; After meal: 160mg;
3179636|NCT00675142|Experimental|1|IUI 36 hours after ovulation induction
3482531|NCT03776838|Experimental|SoC+NOL analgesia guided fentanyl administration|"A bolus of 2 mcg/kg of IV Fentanyl will be given at the induction of the anesthesia. A bolus of 1 mcg/kg of IV Fentanyl will be given at the time of incision. During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administered following a pre determinate algorithm based on NOL index + heart rate + mean arterial blood pressure variations.~Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery."
3482532|NCT03776838|Active Comparator|SoC analgesia guided group|"A bolus of IV Fentanyl at the discretion of a physician will be given at the induction of the anesthesia. A bolus of IV Fentanyl at the discretion of a physician will be given at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.~Intervention will be here to use Heart rate and blood pressure to administer intraoperative intravenous fentanyl."
3482533|NCT03777007|Experimental|Experimental|The application used is build upon the company's category-defining, SPARTA Platform and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
3482534|NCT03777345|Active Comparator|cobalt-chromium framework partial dentures|It's the gold standard biocompatible metal alloy used in thin sections, provide high strength and stiffness ,conduct heat and cold for a more natural experience, and is resistant to corrosion but their disadvantages include esthetic issues with metal display, oral galvanism, adverse tissue reactions,and osteolysis of abutment teeth.
3482535|NCT03777345|Experimental|PEEK framework partial dentures|It's a promising polymer-based framework has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
3482536|NCT03776721|Experimental|Active treatment|
3482537|NCT03776721|Placebo Comparator|Placebo treatment|
3482538|NCT03776617|Experimental|Group Ropivacaine|general anesthesia + scalp block with 20 ml xylocaine 1% and 20ml ropivacaine 0.5%
3482539|NCT03776617|Experimental|Group Ropivacaine-Dexmedetomidine|general anesthesia + scalp block with 20 ml xylocaine 1%, 20ml ropivacaine 0.5% and 1mcg/kg dexmedetomidine
3482540|NCT03776617|No Intervention|Group control|general anesthesia
3482541|NCT03776617|Sham Comparator|Group sham|general anesthesia + Scalp block with 40ml Normal Saline
3482542|NCT03776864|Experimental|Treatment (pembrolizumab, umbralisib)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive umbralisib PO daily on days 1-21 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3482543|NCT03776734|Experimental|cryotherapy application|effect of cold application
3482544|NCT03776890|Experimental|DeStress for Health Program Participants|Rural residents 18 years and older of Granville and Vance counties (n=30) will be recruited to participate.
3482545|NCT03776825||Perianal Crohn's Disease|Permacol Paste injection
3482546|NCT03776747|Experimental|Group One: Prone MRI Scans|Subjects will have vitals, pulmonary function tests, initial proton MRI scan, prone hyperpolarized 3 helium gas scan
3482547|NCT03776747|Active Comparator|Group Two: Supine MRI scans|Subjects will have vitals, pulmonary function tests, initial protocol MRI scan, supine hyperpolarized 3 helium gas scan
3482548|NCT03776708|Experimental|Spinal manipulation|The spinal manipulation is located between the fifth and eighth thoracic vertebrae, on a level and a side pain-free to a light palpation. The maneuver is of high velocity and low amplitude, oriented posterior to anterior, on the transverse process area of the chosen thoracic vertebrae.
3482549|NCT03776708|Sham Comparator|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires."
3482550|NCT03776786|Experimental|Safety Arm - 0.5 mg/kg|Subject will be administered with 0.5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
3482551|NCT03776786|Placebo Comparator|Safety Arm - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
3482552|NCT03776786|Experimental|Safety Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes.
3482553|NCT03776786|Experimental|Safety Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes.
3482554|NCT03776786|Experimental|Safety Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes.
3179637|NCT00675142|Experimental|2|IUI 42 hours after ovulation induction
3179638|NCT00675142|Experimental|3|IUI 48 hours after ovulation induction
3482555|NCT03776786|Experimental|Safety Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes.
3179639|NCT00675155|Experimental|1|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
3482556|NCT03776786|Experimental|Efficacy Arm - 2 mg/kg|Subject will be administered with 2 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482557|NCT03776786|Placebo Comparator|Efficacy Arm - 2 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482558|NCT03776786|Experimental|Efficacy Arm - 5 mg/kg|Subject will be administered with 5 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482559|NCT03776786|Placebo Comparator|Efficacy Arm - 5 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482560|NCT03776786|Experimental|Efficacy Arm - 10 mg/kg|Subject will be administered with 10 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482561|NCT03776786|Placebo Comparator|Efficacy Arm - 10 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482562|NCT03776786|Experimental|Efficacy Arm - 20 mg/kg|Subject will be administered with 20 mg/kg of TY014 via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482563|NCT03776786|Placebo Comparator|Efficacy Arm - 20 mg/kg Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes 24 hours post-YF vaccination.
3482564|NCT03776773|Active Comparator|patients AR (+) and sleep apnea (+)|Patients with AR and obstructive sleep apnea (OSA) will have sleep and pollution exposure recordings
3482565|NCT03776773|Active Comparator|AR (-) and sleep apnea (+)|Patients without allergic rhinitis (+ sleep apnea) will have sleep and pollution exposure recordings
3482566|NCT03776773|Active Comparator|AR (+) and sleep apnea (-)|Patients with allergic rhinitis but no sleep apnea will have sleep and pollution exposure recordings
3127728|NCT03107052|Experimental|Fremanezumab 675 mg Quarterly|Participants with ECH who received fremanezumab at 675 mg SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study; or placebo IV infusion and SC injection at Week 0 and placebo SC injection at Weeks 4 and 8, respectively in the pivotal study TV48125-CNS-30056; will receive fremanezumab at 675 mg SC injection quarterly (approximately every 12 weeks, administered as 3 SC injections of fremanezumab at 225 mg [225 mg/1.5 mL] at Weeks 0 an 36; and single placebo SC injections at Weeks 4, 8, 16, 20, 28, and 32 for blinding) through Week 36.
3127729|NCT03107091|Experimental|Terlipressin acetate continuous infusion|Continuous infusion of terlipressin starting at 2 mg/day over 7 days in-house and if tolerated continue treatment in the ambulatory setting for 21 days
3482567|NCT03776773|Sham Comparator|AR (-) and sleep apnea (-)|Volunteers without allergic rhinitis and no sleep apnea will have sleep and pollution exposure recordings
3482568|NCT03776578||Head and neck Cancer surgery not treatment and rehabilitation|The patients with oral cavity cancer who weren't treated by radical operation and free flap reconstruction,and can't provide them with preventive swallowing rehabilitation
3482569|NCT03776578||Head and neck Cancer surgery treatment and rehabilitation|Head and neck cancer treatment has developed over the last decade, with improved mortality and survival rates, It is well accepted that pre-treatment swallow function is indicative of post-treatment status and is helpful in identifying patients with high risk of aspiration and dysphagia.Preventive swallowing rehabilitation including evaluation patient's swallowing function and propose rehabilitation and adaptive maneuver or change in food texture. The aim is to ensure safe swallowing and prevent deglutitive muscles from deconditioning. Investigators include patients with advanced oral cavity cancer who were treated by radical operation and free flap reconstruction, and provided them with preventive swallowing rehabilitation.Investigators then analyze the swallowing function, oral intake status, and nasogastric tube dependence rate and tracheostomy tube dependence rate.
3482570|NCT03776955|Experimental|Oral Carvedilol|6.25 mg or 12.5 mg if tolerated
3482571|NCT03776955|Placebo Comparator|Oral Placebo|
3482572|NCT03776669|Active Comparator|LSG alone|"Intervention: laparoscopic sleeve gastrectomy alone.~LSG will be performed laparoscopically via a 5-port technique. The greater omentum is dissected by using the 5-mm laparoscopic LigaSure or Harmonic from 4 cm proximal to the pyloric ring to the angle of His. Sleeve calibration is done by a 36-French bougie inserted along the lesser curvature. Then the stomach is transected with sequential firings of linear green, gold, and blue 60 mm staplers starting about 4 cm proximal to the pylorus and ending approximately 2 cm distal to the left of the esophagus. The staple-line of the remnant gastric tube is oversewn with 3-0 V-Loc to prevent leakage and hemorrhage."
3482573|NCT03776669|Experimental|LSG + HHR|"Intervention: concomitant laparoscopic sleeve gastrectomy + hiatal hernia repair.~The surgical detail of LSG is the same as described in LSG alone arm, and the surgical detail of HHR is described as below.~The hiatus is approached from the right side of the EGJ, through the lesser omentum. The hiatal defect is repaired by 1-0 Surgilon interruptedly, and then a commercialized U-shaped Biodesign Hiatal Hernia Graft is placed to the EGJ to cover the posterior side but spare the anterior side of the hiatus. Care must be taken to avoid direct contact of mesh to the esophagus to avoid any unnecessary complication. After the mesh is appropriately placed and oriented, 2 ml of TISSEEL solution for sealant is applied all over the mesh for fixation."
3482574|NCT03776877||Arterial Ischemic Stroke (AIS)|"All patients (prospective and retrospective) included will have to present an Arterial Ischemic Stroke (AIS) from a large cerebral vessel occlusion.~The participation in the study will consist in:~Plasmatic collection at the time of AIS, for study of plasma biomarkers~Additional standardized blinded clinical evaluation at three months after the thrombectomy realized during a phone call, particularly via an assessment of the modified Rankin score."
3482575|NCT03776929|No Intervention|Standard Care|No intervention - Standard care only. Group of 32 subjects
3127730|NCT03107377|Active Comparator|EVO100|A pH-buffering, acidity-maintaining gel (pH 3.5), containing three active compounds: lactic acid, citric acid, potassium bitartrate. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
3127731|NCT03107377|Placebo Comparator|Placebo|An isotonic, non-buffering gel, pH adjusted to 4.5, containing 2.7% hydroxyethylcellulose, sorbic acid, sodium hydroxide, sodium chloride and purified water. 5 g intravaginally applied at least one hour prior to vaginal intercourse.
3127732|NCT03107611|Experimental|Test|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
3127733|NCT03107611|Active Comparator|Reference Standard|Pimecrolimus Cream, 1%, topical, thin layer applied to all affected skin areas twice daily for 14 days
3127734|NCT03107611|Placebo Comparator|Placebo|Placebo cream, topical, thin layer applied to all affected skin areas twice daily for 14 days
3127735|NCT03107715|Active Comparator|Breastfeeding Champion|The Breastfeeding Champion Intervention (Intervention A) utilizes information about Breastfeeding Champions from the Coffective™ program: participants will be guided to tap and scroll through the content and will receive a follow up handout and encouragement to select a Champion.
3127736|NCT03107715|Active Comparator|Positive Messaging|The Positive Messaging Intervention (Intervention B) utilizes positive messaging from several sources and is modelled on the WIC Loving Support™ approach: participants will click on (istock-purchased) photographs which each reveal an informational statement about exclusive breastfeeding benefits and tips, followed by receipt of a summary handout.
3179640|NCT00675181|Active Comparator|A, 1|A, 1 = Melatonin
3179641|NCT00675181|Placebo Comparator|A, 2|A,2 = Placebo
3482576|NCT03776929|Experimental|Dialectical Behavioral Therapy|Dialectical Behavioral Therapy in addition to standard care. Four hour and a half group sessions (or one-on-one sessions, if not enough for a group session) commencing after surgery while still inpatient. Each session is designed to stand-alone, allowing for enrolling patients on a rolling basis.
3482577|NCT03776695|Experimental|2 mg/kg|Subject will be administered with 2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
3482578|NCT03776695|Placebo Comparator|2 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
3482579|NCT03776695|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
3482580|NCT03776695|Placebo Comparator|5 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
3482581|NCT03776695|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
3482582|NCT03776695|Placebo Comparator|10 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
3482583|NCT03776695|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
3482584|NCT03776695|Placebo Comparator|20 mg/kg - Placebo|Subject will be administered with 0.9% saline via IV infusion over a period of 30 minutes.
3482585|NCT03776656|Experimental|Allopurinol|Oral administration of Allopurinol (Zyloric®) for 12 months without exceeding 400 mg / day in children and 900 mg / day in adults, with dosage adjustment in case of renal failure
3482586|NCT03776591|Experimental|Open D3|Right colectomy Open surgery Central lymphadenectomy and vascular ligation
3482587|NCT03776591|Active Comparator|Laparoscopic CME with CVL|Right colectomy Laparoscopic surgery Central lymphadenectomy and vascular ligation
3482588|NCT03776604|Experimental|PEG-rhG-CSF|"Jin Youli(PEG-rhG-CSF): The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
3482589|NCT03776526||Postoperative Hip fracture patients|The target population will include patients aged 65 years or older admitted with hip fracture to the orthopedic ward at the Juravinski Hospital, a site of Hamilton Health Sciences Corporation in Ontario, Canada.
3482590|NCT03776994|Experimental|Group 1A 2 µg VEE Vaccine Alone|"Subgroup 1A, 2 µg VEE VLP Vaccine Alone Venezuelan equine encephalitis VLP Vaccine candidate~Vaccinations on Day 0, Day 28, and Day 140"
3482591|NCT03776994|Experimental|Group 2A 10 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 2A, 10 µg VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
3482592|NCT03776994|Experimental|Group 3A 20 µg VEE Vaccine Alone|"Venezuelan equine encephalitis VLP Vaccine candidate Subgroup 3A, 20 µg VEE VLP Vaccine Alone~Vaccinations on Day 0, Day 28, and Day 140"
3482593|NCT03776994|Experimental|Group 1B 2 µg VEE Vaccine and Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 1B, 2 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
3482594|NCT03776994|Experimental|Group 2B 10 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 2B, 10 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
3482595|NCT03776994|Experimental|Group 3B 20 µg VEE Vaccine with Adjuvant|"Venezuelan equine encephalitis VLP Vaccine candidate with Adjuvant Subgroup 3B, 20 µg VEE VLP Vaccine with Adjuvant (Adjuvant - Aluminum hydroxide, 5 mg/mL)~Vaccinations on Day 0, Day 28, and Day 140"
3482596|NCT03776565||Operative hysteroscopy|women with an operative hysteroscopy planned
3482597|NCT03776565||Planned caesarean section|Pregnant women with a planned caesarean section
3482598|NCT03776682||Acute inflammation|Patients with RA and active inflammation (by exam or inflammatory markers)
3482599|NCT03776682||Chronic remission|Patients with RA who are in remission (clinically)
3482600|NCT03776422|Experimental|Mobile self-help intervention|This study uses automated self-help interventions designed as a kit of smartphone tools.
3482601|NCT03776409||vancomycin plus piperacillin/tazobactam|Critically ill patients who received the combination of VAN (vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and PTZ were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
3482602|NCT03776409||vancomycin plus other beta-lactams|Critically ill patients who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours during an ICU (intensive care unit) admission, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics. This is an observational study without any intervention.
3482603|NCT03776448|Experimental|Sativa Nigra oil arm|A total of 15 subjects randomly allocated to the treatment arm will receive 2000mg a day of 'Sativa Nigra oil' softgels for 30 consecutive days. The total daily dose is divided in 4 doses taken 6 hourly (each softgel contains 500mg). This supplement is manufactured by [Bioextract Ltd, Sri Lanka] and is available commercially.
3482604|NCT03776448|Placebo Comparator|The charcoal arm|Subject randomly allocated to the control arm will receive 1040mg a day of activated charcoal softgels for 30 consecutive days. The total daily dosage is divided in 4 doses taken 6 hourly (each softgel contains 260mg). This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially.
3482605|NCT03776383|Active Comparator|Antibiotic use feedback letter 1|Antibiotic use feedback letter 1 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic prescribing for acute respiratory conditions
3482606|NCT03776383|Active Comparator|Antibiotic use feedback letter 2|Antibiotic use feedback letter 2 provides physicians with information on their antibiotic use plus change ideas on appropriate antibiotic durations for common infections
3482607|NCT03776383|No Intervention|Control|Controls will not receive a letter
3482608|NCT03776487|Experimental|Treatment (chemotherapy, immunotherapy, IMRT)|"INDUCTION CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours and fluorouracil IV over 48 hours on day 1. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Treatment with nivolumab repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients also receive fluorouracil IV continuously for 5 days per week and undergo 25 fractions of IMRT for 5 weeks. Patients undergo surgical resection 5-7 weeks after completing radiation therapy.~Within 8-12 weeks post-surgery, patients with residual disease may receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 courses (16 weeks) then every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity."
3482609|NCT03776357|Experimental|Experimental|The application used is build upon the company's category-defining, FDA- cleared Virtual Exercise Rehabilitation Assistant (VERA™) and create a platform that streamlines the performance and management of post-acute care physical therapy. The rehab tool will provide us with functional outcome score.
3482610|NCT03776370|Experimental|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
3482611|NCT03776370|Active Comparator|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery
3482612|NCT03776500|Experimental|Panel A - Active|N = 6, 150 mg twice daily of PBTZ169
3482613|NCT03776500|Placebo Comparator|Panel A - Placebo|N = 2, 150 mg twice daily of PBTZ169 matching placebo
3482614|NCT03776500|Experimental|Panel B - Active|N = 6, 300 mg twice daily of PBTZ169
3482615|NCT03776500|Placebo Comparator|Panel B - Placebo|N = 2, 300 mg twice daily of PBTZ169 matching placebo
3127737|NCT03107754|Placebo Comparator|Standard paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine, which is our standard office protocol
3127738|NCT03107754|Experimental|Buffered lidocaine paracervical block|A paracervical block will be administered with 20 cc of 1% lidocaine buffered with 8.4% sodium bicarbonate
3127739|NCT03107793|Experimental|All Participants|At Week (Wk) 0, all eligible participants will initiate intravenous (IV) induction treatment with ustekinumab (UST) on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg). At Week 8, all participants will receive a 90 milligram (mg) subcutaneous (SC) injection of ustekinumab. At Week 16, participants who do not achieve a Crohn's Disease Activity Index (CDAI) improvement of greater than or equal to (>=) 70 points versus Week 0 (CDAI 70) will leave the study. Remaining participants will be randomized in a 1:1 ratio to either one of two arms for open label maintenance treatment up to Week 48: the treat to target arm or the routine care arm. From Week 48, participants will continue ustekinumab treatment in the study extension period, up to Week 104. Dosing frequency will be adjusted in the extension period for the participants failing to meet the treatment target.
3482616|NCT03776500|Experimental|Panel C - Active|N = 6, 600 mg once daily of PBTZ169
3179642|NCT00675207|Active Comparator|1|Brimonidine purite 0.15%
3179643|NCT00675207|Active Comparator|2|Dorzolamide 2%
3482617|NCT03776500|Placebo Comparator|Panel C - Placebo|N = 2, 600 mg once daily of PBTZ169 matching placebo
3482618|NCT03776500|Experimental|Panel D - Active|N = 6, 600 mg twice daily of PBTZ169
3482619|NCT03776500|Placebo Comparator|Panel D - Placebo|N = 2, 600 mg twice daily of PBTZ169 matching placebo
3482620|NCT03776435||CT-exposed group|
3482621|NCT03776435||CT-unexposed group|
3482622|NCT03776552|Active Comparator|Low energy diet (LED)|8-week LED (<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks <1300 kcal/day and 4 weeks <1500 kcal/day)
3482623|NCT03776552|Active Comparator|Gradual weight loss (GWL)|16-week standard GWL-course (controls)
3482624|NCT03776474||Allergic|Minors allergic to cow's milk and/or eggs
3482625|NCT03776474||Non-allergic|Minors without history of allergy to cow's milk and/or eggs
3482626|NCT03776474||Acquired tolerance|Minors formerly allergic to cow's milk and/or eggs
3482627|NCT03776331||Myeloma Patients|
3482628|NCT03776331||Controll group|
3482629|NCT03776812|Experimental|Continuous Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, once daily every day in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
3179644|NCT00675207|Active Comparator|3|Brinzolamide 1%
3179645|NCT00675220||A|
3482630|NCT03776812|Experimental|Intermittent Relacorilant Dosing|Patients will be treated with relacorilant, administered orally, on the day before (excluding Cycle 1, Day -1), the day of, and the day after nab-paclitaxel, in combination with nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
3482631|NCT03776812|Active Comparator|Nab-paclitaxel Comparator|Patients will receive nab-paclitaxel on Days 1, 8, and 15 of each 28-day cycle.
3482632|NCT03776513|Experimental|experimental group|Thirty obese boys (12-17 years old) undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
3482633|NCT03776513|Other|control group|Thirty healthy boys (12-17 years old) paired for pubertal stage, level of education and socio-economic level undergoing an MRI, a clinical and psychological examination and a series of cognitive tests
3482634|NCT03776110|Experimental|GRT9906 80-mg dose group|"In one period, 80 mg GRT9906 (2 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4.~In the second period, a total of 7 doses of placebo (2 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
3482635|NCT03776110|Experimental|GRT9906 120-mg dose group|"In one period, 120 mg GRT9906 (3 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on the day before Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (3 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
3482636|NCT03776110|Experimental|GRT9906 160-mg dose group|"In one period, 160 mg GRT9906 (4 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 80 mg was administered on Day T. The dose administration on Day T was also performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (4 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
3482637|NCT03776110|Experimental|GRT9906 200-mg dose group|"In one period, 200 mg GRT9906 (5 GRT9906 PR tablets) were administered twice daily at 12 hours apart with non-carbonated water. A total of 7 doses were administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4. A 'titration dose' of 120 mg was administered on Day T. The dose administration on Day T was performed twice daily with 12 hours apart and with non-carbonated water.~In the other period, a total of 7 doses of placebo (5 tablets per dose) was administered with the first administration in the morning of Day M1 and the last administration in the morning of Day M4."
3482638|NCT03776097||Defect Fill.|Observational study of the patients that were treated with biomaterials at the surgery in the previous study
3482639|NCT03776097||No defect Fill.observational|Observational study of the patients that were not treated with biomaterials at the surgery of te previous study
3482640|NCT03776149|Experimental|Beetroot juice (dietary nitrate)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of beetroot juice (Beet It (HeartBeet Ltd.), Ipswich, UK). During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
3482641|NCT03776149|Placebo Comparator|Black currant juice (placebo control)|Over the 7 days preceding each testing session, participants will consume 140 ml per day of a nitrate-depleted placebo. During this time participants will be asked to abstain from use of antiseptic mouthwash as this has been shown to temporarily kill the bacteria that facilitate the reduction of nitrate to nitrite. All participants will be asked to refrain from consuming any antioxidant (e.g., Vit E or Fish Oil) supplements during the course of the study as these may impact the study findings.
3482642|NCT03776227|Experimental|Sotagliflozin Test|One tablet of sotagliflozin administered orally under fasting conditions
3482643|NCT03776227|Active Comparator|Sotagliflozin Reference|Two tablets of sotagliflozin administered orally under fasting conditions
3482644|NCT03776292||supine position group= Group (S)|1st group of 20 patients will undergo urinary bladder cystectomy and orthotopic urinary diversion lying supine with ring abdominal retractors
3482645|NCT03776292||lateral position group = Group (L)|2nd group of 20 patients will undergo surgical open nephrectomy lying lateral position with self retaining abdominal retractors
3482646|NCT03776279|Experimental|Mitoxantrone Hydrochloride Liposome Injection|4 weeks is a treatment cycle, and the first day of each cycle is administered.
3482647|NCT03776136|Experimental|lenvatinib plus pembrolizumab|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
3132721|NCT03447314|Experimental|Part 1b: 250ng GSK1795091 + 80mg GSK3359609|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with GSK3359609 80 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with GSK3359609 80 mg at Q3W interval.
3179646|NCT00675233|Experimental|Treatment PDT|Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
3482648|NCT03776162|Active Comparator|ACL Reconstruction(BPTB Graft)|Procedure/Surgery ACL Reconstruction (Bone Patellar Tendon Bone Graft): Standard of care surgical procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
3482649|NCT03776162|Experimental|Bridge Enhanced ACL Repair|Procedure/Surgery Bridge Enhanced ACL Repair (BEAR): The surgical repair of the ACL using the BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to group into.
3482650|NCT03776305|Experimental|Imipenem ECMO|1-h infusion of 0.5 g of imipenem, q6h
3482651|NCT03776240|Experimental|HD201|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
3482652|NCT03776240|Active Comparator|EU-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
3482653|NCT03776240|Active Comparator|US-licensed Herceptin|Trastuzumab Single-dose 6mg/kg body weight by 90 minute intravenous infusion
3482654|NCT03776344|Experimental|Virtual Reality|Patients randomized to the experimental group will benefit from the usual standard care following surgery and during the second day the opportunity to use virtual reality for 15 minute. Along VR, they will complete the psychological and physiological measures.
3482655|NCT03776344|No Intervention|Non-VR condition (Standard of Care)|Patients randomized to the control group will benefit from the usual standard care following surgery and during the second day will complete the psychological and physiological measures.
3179647|NCT00675246|Experimental|A|Antenatal corticoid therapy
3179648|NCT00675272|Active Comparator|1|hydrocortisone treatment 50mg iv x4
3482656|NCT03776253|Experimental|Supportive care (CFS)|"Patients attend CFS psychosocial intervention consisting of 7 nurse-led sessions (session 1 in-person and sessions 2-7 via video conferencing) over 45 minutes each for 8 weeks. Patients also complete home practice assignments comprising attention training technique and mindfulness practice after each session.~Patients complete self-report questionnaires at baseline (T1), 8 weeks (T2) and 12 weeks (T3)."
3482657|NCT03776058|Experimental|Cinacalcet|Participants received 65 mg cinacalcet orally twice a day for 4 weeks.
3179649|NCT00675272|Placebo Comparator|2|Placebo iv every 6 hours
3179650|NCT00675285|Active Comparator|1|
3482658|NCT03776058|Placebo Comparator|Placebo|Participants received placebo to cinacalcet orally twice a day for 4 weeks.
3482659|NCT03776318||Safety Group|STX-015-18-01 Clonidine Micropellet long-term safety follow-up
3482660|NCT03776318||Sham Control|STX-015-18-01 Sham control long-term safety follow-up
3482661|NCT03776019|Experimental|Modulated|modulated music
3482662|NCT03776019|Sham Comparator|Typical|typical music
3482663|NCT03776045|No Intervention|Standard care|This group did not receive any supervised exercise or were not given any specific exercise recommendations during the trial period. However, patients in this group were offered the exercise intervention after completing the study.
3482664|NCT03776045|Experimental|Standard care plus exercise|This group received standard care in addition to a 3-month exercise intervention upon initiating androgen deprivation therapy.
3482665|NCT03776084||Patients SAHS with CPAP|Continuous Positive Airway Pressure treatment
3482666|NCT03776032|Experimental|Darbepoetin alfa|Participants received once a week darbepoetin alfa, administered by subcutaneous injection at a starting dose of 2.25 µg/kg for up to 12 weeks. The dose of darbepoetin alfa may have been adjusted based on hemoglobin levels to a maximum dose of 4.5 µg/kg /week.
3482667|NCT03776032|Placebo Comparator|Placebo|Participants received once a week placebo, administered by subcutaneous injection for up to 12 weeks.
3127740|NCT03107793|Experimental|Routine Care Arm|In the routine care arm, assessment visits will be scheduled according to the timing of maintenance treatment injections up to Week 48, which will be in compliance with the EU SmPC for ustekinumab for the treatment of Crohn's disease, in which dosing every 12 weeks is recommended. At Week 16, (that is, 8 weeks after the first SC dose) participants continuing in the study will have demonstrated a CDAI-70 response. Nonetheless, participants who have not shown adequate response based on the investigator's judgment may receive a second SC dose at Week 16. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
3179651|NCT00675285|Placebo Comparator|2|
3482668|NCT03776006||TPLA|
3482669|NCT03775993|Active Comparator|GHD|
3482670|NCT03775993|Placebo Comparator|Placebo|
3482671|NCT03775616|Experimental|Supportive (financial navigation program)|Participants receive financial navigation program intervention consisting of a financial navigation video, monthly one-one financial counselling session, monthly phone or email consultation with patient navigators for 6 months and complete surveys at baseline, 3, 6, and 12 months.
3482672|NCT03775889|Experimental|Behavioral|Behavioral Gardening Exposure
3482673|NCT03775629|Experimental|Polmacoxib and Tramadol combination|Tramadol HCl 300mg once/day + 2 mg Polmacoxib capsule once/day for 14 days
3482674|NCT03775629|Active Comparator|Polmacoxib|Polmacoxib 2mg 14days
3132722|NCT03447314|Experimental|Part 1c: 50ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 50 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 50 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 50 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
3179652|NCT00675298||1|Men with chronic prostatitis/chronic pelvic pain syndrome
3482675|NCT03775629|Active Comparator|Tramadol|Tramadol hydrochloride (HCl) 150mg 5days
3482676|NCT03775876|Active Comparator|Propofol|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Propofol. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 2mg/Kg/h and modified to a maximum of 4 mg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four.
3482677|NCT03775876|Active Comparator|Dexmedetomidine|Patients programmed for elective Shoulder arthroscopy surgery will receive a continuous intravenous infusion of Dexmedetomidine. Infusion will be started after regional block (interscalene) being performed and will be continued to the end of wound closure. Infusion will be started at 1mcg/kg over 10 minutes then 0.2 mcg/Kg/h and modified to a maximum of 0.7 mcg/Kg/h in order to achieve a bispectral index (BIS) between 60 and 90 and a Ramsay sedation score between two and four with a maximum.
3482678|NCT03775759|Experimental|Study arm|Tricuspid valve ring annuloplasty or replacement at the time of LVAD implantation plus medical therapy
3482679|NCT03775759|Active Comparator|Control arm|LVAD implantation plus medical therapy
3482680|NCT03775668|Experimental|1 µCi of 14C-AAI101 + 500 mg AAI101|14C-AAI101 + 500 mg AAI101 iv infusion
3482681|NCT03775863||Latin American multicenter Cohort|Transplanted patients with HCC in LATAM from 2005-2011
3482682|NCT03775863||French mutlicenter Cohort|Transplanted patients with HCC in France from 2003-2005
3179653|NCT00675298||2|Women with painful bladder syndrome/interstitial cystitis
3179654|NCT00675298||3|Children with overactive bladder
3482683|NCT03775863||Italian multicenter Cohort|Transplanted patients with HCC in Italy from 2005-2011
3482684|NCT03775707|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3482685|NCT03775902|Experimental|Healthy subjects|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
3482686|NCT03775902|Experimental|Pre and/or type 2 diabetics|Three experimental day where the effect of Nicorandil (20mg), Glibenclamide (3,5mg) or placebo will asses the function of the ATP sensitive potassium pumps role in the development of fatigue.
3482687|NCT03775772|Other|Oral Health - Test Group|- study population is randomly assigned to control and test group
3482688|NCT03775772|Other|Bite Force/Chewing Efficacy-Test Group|- study population is randomly assigned to control and test group
3482689|NCT03775577||HFpEF|Participants with Heart Failure with Preserved Ejection Fraction
3482690|NCT03775577||HFrEF|Participants with Heart Failure with Reduced Ejection Fraction
3482691|NCT03775577||Hypertensive Subjects|Participants with Hypertension
3482692|NCT03775577||Healthy Subjects|Participants without heart failure and without commodities
3482693|NCT03775551|No Intervention|Control|The participants belonging to the hospitals assigned to the control group the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC following usual practice.
3482694|NCT03775551|Experimental|Improvement cycle|In participants belonging to the hospitals assigned to the intervention group,the health providers will give feedback on their health condition and will advise on how to follow up their care after discharge or referral back to PHC using innovative intervention to assure continuity of care and assistant level approach. This innovations will be crafted from the rapid improvement cycles considering the environment and key aspects of the every day care at the participating centers.
3482695|NCT03775642|Experimental|Intervention video|The intervention video will employ debiasing strategies to correct women's misinformation about the safety of the IUD and implant safety.
3482696|NCT03775642|Placebo Comparator|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration.
3482697|NCT03775824||MTX start|Patients with active rheumatoid arthritis who are either naive to methotrexate, or have not used this medicine in the last year and who are about to start therapy with methotrexate i.v. or s.c.
3482698|NCT03775824||TNF start|Patients with active rheumatoid arthritis who are either naive to TNF-inhibitors, or have not used this medicine in the last year and who are about to start therapy with any of the following (biosimilars included); infliximab, adalimumab, etanercept, certolizumab or golimumab
3482699|NCT03775655|Active Comparator|LD-DEX|This group will receive 7mg hyperbaric bupivacaine (about 1.4 ml of hyperbaric bupivacaine 0.5%) and 10μg dexmedetomidine (10 unit by U-100 insulin syringe using a preservative free dexmedetomidine 100μg/ml).
3482700|NCT03775655|No Intervention|Control group|This group will receive 12 mg hyperbaric bupivacaine (about 2.2 ml of hyperbaric bupivacaine 0.5%).
3482701|NCT03775720|Experimental|Low genetic risk group|Dietary advice to maintain salt intake to 6g/day
3482702|NCT03775720|Experimental|High genetic risk group|Dietary advice to reduce salt intake to 4g/day
3482703|NCT03775564|Experimental|REMEDRUGBY|TAU + RemedRugby Program
3482704|NCT03775564|Active Comparator|TAU + TOUCH RUGBY|TAU + Touch Rugby Program
3482705|NCT03775590|Active Comparator|Water|Subjects will bathe at least twice a week in a water bath for 6 months and keep a record of their bathing regimen
3132723|NCT03447314|Experimental|Part 1c: 100ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 100 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 100 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 100 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
3482706|NCT03775590|Active Comparator|Bleach|Subjects will bathe at least twice a week in a water + dilute bleach bath for 6 months and keep a record of their bathing regimen
3482707|NCT03775590|Active Comparator|Acetic acid|Subjects will bathe at least twice a week in a water bath + vinegar for 6 months and keep a record of their bathing regimen
3482708|NCT03775746|Experimental|Clopidogrel with Rivaroxaban|Clopidogrel 75mg o.d. and Rivaroxaban 2.5mg b.i.d.
3482709|NCT03775746|Active Comparator|Clopidogrel|Clopidogrel 75mg o.d.
3482710|NCT03775746|Active Comparator|Ticagrelor|Ticagrelor 90mg b.i.d.
3482711|NCT03775928|Experimental|Apatinib + Capecitabine|Apatinib 425mg d1-21+ capecitabine 1000mg/m2 bid d1-14, q21d
3482712|NCT03775928|Active Comparator|Capecitabine|capecitabine 1000mg/m2 bid d1-14, q21d
3482713|NCT03775733|Experimental|Hydrolysed red ginseng extract|Hydrolysed red ginseng extract 2.4g/day for 12 weeks
3482714|NCT03775733|Placebo Comparator|Placebo|Placebo for 12 weeks
3482715|NCT03775525|Experimental|Experimental: monotherapy|GZ17-6.02 given orally on a daily x 28 day schedule. This will be a dose escalation study.
3482716|NCT03775837|Experimental|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
3482717|NCT03775837|Placebo Comparator|Placebo group|This group takes placebo for 8 weeks
3482718|NCT03775538|Experimental|CDNF mid-dose (400 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to mid-dose (400 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
3482719|NCT03775538|Experimental|CDNF high-dose (1200 micrograms)|Patients randomized to this group will receive 6 monthly-intermittent intracerebral doses of Cerebral Dopamine Neurotrophic Factor (CDNF) titrated to high-dose (1200 micrograms) administered via the Renishaw Drug Delivery System (DDS) to the bilateral putamen.
3482720|NCT03775434|Experimental|B244|B244 suspension in 30ml/bottle
3482721|NCT03775460|Placebo Comparator|control|Participants will receive placebo+ prednisolone. Participants will start receiving 4 dummy tablets per week, than participants weighing less than 60 kg will receive 6 dummy tablets from week 8. The placebo will be prescribe weekly. Participants weighing 60 kg or more will receive 8 dummy tablets from week 8. Participants will receive dummy tablets for 52 weeks. Along with prednisolone. The start dose of prednisolone will be 40 mg per day decreasing dosage for 20 weeks.
3482722|NCT03775460|Experimental|intervention|Participants will receive Methotrexate(MTX)+prednisolone. All participants in intervention arm will receive an initial dose of MTX 10 mg. The MTX will be increased to 15 mg the following week. Participants weighing less than 60 kg will continue to receive 15 mg of MTX weekly thereafter. Individuals weighing 60 kg or more will receive MTX 20 mg from week 8. At week 48 the MTX will be reduced to 10 mg for two weeks followed by 5 mg for two weeks and then stopped. In total participants will receive 52 weeks of MTX along side prednisolone, which will be the same as the control arm.
3482723|NCT03775330|Experimental|SRS|Stereotactic radiosurgery
3482724|NCT03775330|Experimental|SRS plus WBRT|Stereotactic radiosurgery plus whole brain radiation
3482725|NCT03775447||Parkinson's Disease Patients|"A diagnosis of Parkinson's disease in the opinion of the enrolling investigator~Disease duration: any~Male or female age 18 years or older at time of PD diagnosis."
3482726|NCT03775447||Healthy Control (HC) Subjects|• Male or female age 18 years or older at Screening.
3482727|NCT03775278|Experimental|Experimental|PHP-303, multiple oral dose, up to 5 ascending dose cohorts
3482728|NCT03775278|Placebo Comparator|Placebo|Placebo, multiple oral dose, up to 5 ascending dose cohorts
3482729|NCT03775200|Experimental|Low dose|Low dose Psilocybin
3482730|NCT03775200|Experimental|Medium dose|Medium dose Psilocybin
3482731|NCT03775200|Experimental|High dose|High dose Psilocybin
3482732|NCT03775317|Experimental|Video Laryngoscopy|
3482733|NCT03775317|Active Comparator|Direct Laryngoscopy|
3482734|NCT03775135||Children with neuromuscular diseases|Questionnaires will be administered by children with neuromuscular disease between 12 and 25 years and their parents
3482735|NCT03775161|Experimental|V-LAP™ System|Percutaneous implantation of the V-LAP™ implant by right heart catheterization (RHC) approach and daily LAP measurements at home
3482736|NCT03775122|Placebo Comparator|Group 1 sedation group|"Elderly patients under colonoscopy with sedation, but no real TAES neiguan(pc6)~sedation is using the typical protocol for the following: Slowly peripheral intravenous injection(0.5ml/s) of fentanyl 50μg, then followed with 1.5-2.5mg/kg propofol until loss of eyelash reflex, the Observer's Assessment of Alertness/Sedation Scale (OAAS) score Level3-5."
3482737|NCT03775122|Experimental|Group 2 sedation+TAES group|"Elderly patients under colonoscopy both have TAES neiguan(pc6) and sedation.~sedation is begun followed TAES. sedation is same as group2 do. TAES is same as group3 do."
3482738|NCT03775109|Active Comparator|Canakinumab 150mg/ml solution for injection|150mg/ml solution for injection
3482739|NCT03775109|Placebo Comparator|Dextrose|
3482740|NCT03775369|Active Comparator|Endurance training|"Endurance Training (warm-up; endurance on bike; brisk walking; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
3482741|NCT03775369|Active Comparator|Resistance training|"Resistance Training (warm-up; resistance training units; cooling down; group sessions; supervised; moderate and individualized exercising load):~6 weeks, 2 sessions/week, 40-60min/session"
3482742|NCT03775369|Active Comparator|Control condition|"Control condition (individualized counselling, but not intended as a bona fide intervention, that is to say: not intended to actively improve participants' well-being):~6 weeks, social support and counseling,1-2 sessions/week; 30 min/session"
3482743|NCT03775291||Low pre-test likelihood for sleep apnea|Subjects at low risk for having sleep apnea due to lack of known risk factors and no complaints of symptoms related to sleep apnea (e.g., excessive daytime sleepiness)
3482744|NCT03775291||High pre-test likelihood for sleep apnea|Suspected sleep apnea patients who are undergoing sleep tests as part of normal medical care or are also known to be non-compliant with therapy.
3482745|NCT03775382|Placebo Comparator|Placebo|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
3482746|NCT03775382|Active Comparator|Ascorbic Acid|"Ascorbic acid will be measured into sterile syringes by the research nurse and infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline or lactated ringers followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
3482747|NCT03775343||General Anesthesia|"General anesthesia:~25 patients older than 65 years, undergoing elective eye surgery under general anesthesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative.~Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
3482748|NCT03775343||Local anesthesia with sedoanalgesia|"25 patients older than 65 years, undergoing elective eye surgery under local anesthesia in combination with sedoanalgesia.~Intervention: neurocognitive testing (Neurocognitive Test Battery) preoperative, 6 and 24 hours postoperative Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery."
3482749|NCT03775343||Control Group|"25 patients, not undergoing any operative intervention. To determine a normal reference value of cognitive functions, a group of 25 individuals without an operative intervention will be recruited as a control group.~Intervention: neurocognitive testing (Neurocognitive Test Battery) at 3 determined time points (0, 6 and 24 hours)"
3482750|NCT03775031|Active Comparator|Fraxel 1927nm|Treatment setting for Fraxel 1927 nm: 20 mJ, Treatment level 8, 6 passes
3482751|NCT03775031|Active Comparator|Fraxel 1550nm|Treatment setting for Fraxel 1550 nm: 70 mJ, Treatment level 6, 6 passes
3482752|NCT03775031|Active Comparator|25% TCA Peel|25% TCA on 5 x 5 cm of sun exposed back
3482753|NCT03775031|Placebo Comparator|Control|Patient serves as their own control
3482754|NCT03775252|Experimental|Ketogenic diet|Group of patients treated with ketogenic diet after the first neurophysiological screening.
3482755|NCT03775239|Other|Treatment-as-usual|Those who are randomly selected to treatment-as-usual will receive a minimum of 6 sessions at Sexological Clinic.
3482756|NCT03775239|Other|Treatment-as-usual + MSIR|Those who are randomly selected to receive Mindfulness in Sex Therapy and Intimate Relationships (MSIR) will first receive 6 weeks of mindfulness followed by treatment-as-usual. The intervention will take place at Sexological Clinic.
3482757|NCT03775044|Experimental|Experimental: Medherent Device|All participants get the Medherent device. There is only one arm to this study.
3482758|NCT03775226|Experimental|Single are|This study is designed as an early feasibility, prospective, open label, single arm study. 30 patients with infra-inguinal peripheral arterial disease appropriate for treatment with a femoro-popliteal stent will be treated with ChampioNIR® SFA stent implantation.
3482759|NCT03775096|Experimental|carvedilol therapy|The dosage of carvedilol will be gradually increased from the initial recommended starting dose of 3.125 mg twice/daily, the target dose will be 25mg twice daily (50 mg/day) and participants will take 50 mg/day carvedilol for 6 months.Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose.
3482760|NCT03775395|Experimental|HAIC plus Lenvatinib|
3482761|NCT03775395|Active Comparator|HAIC plus Sorafenib|
3482762|NCT03775499|Other|Period 1: Placebo - Period 2: BL NCC 2705|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
3482763|NCT03775499|Other|Period 1: BL NCC 2705 - Period 2: Placebo|For the 2 populations (Celiac and Non-Celiac Gluten Sensitivity)
3482764|NCT03775057|Experimental|MyDose Coach app intervention|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
3482765|NCT03775148|Experimental|TranS-C Group|Transdiagnostic Sleep and Circadian Treatment
3482766|NCT03775148|No Intervention|CAU Group|Care-As-Usual group
3482767|NCT03775356|No Intervention|1 - Blinded|EEG and Entropy will be blinded. The anesthesiological management will be performed by the anesthetist according to clinical standard operations.
3482768|NCT03775356|Active Comparator|2 - Unblinded|EEG and Entropy will be unblinded. The intervention starts with the start of a positive burst suppression rate. In the case of a concurrent hypotension the anesthetist treats the hypotension according to clinical standard operations in the first step. Hypotension means blood pressure values blow the baseline value which is defined by the lowest, preoperatively measured value. If after this treatment and a reevaluation of the BSR, BSR remains positive, the anesthetist is going to reduce the concentration of anesthetics in a second step. In case of positive BSR and a blood pressure value ≥ the baseline value, the concentration of anesthetics will be reduced as a first measure. The aim is to figure out whether one or both of these interventions can reduce to total, cumulative BSR.
3482769|NCT03775473|Other|progastrin|anyone who will participate in colon screening at the Princess Grace Hospital in Monaco and who has signed the informed consent document
3482770|NCT03775070|Experimental|Simvastatin|Simvastatin, 0.5mg/kg/d(maximum 20mg), once daily
3482771|NCT03775018|Experimental|Transversus abdominis plain blockade|The patients will undergo Transversus abdominis plain blockade, associated with intravenous analgesia
3482772|NCT03775018|Active Comparator|Intravenous analgesia|The patients will receive intravenous analgesia with Acetaminophen (1g/6h)
3482773|NCT03775005|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fraction
3482774|NCT03775005|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
3482775|NCT03774940|Experimental|fever|patients that have fever after PNL
3482776|NCT03774940|Active Comparator|No fever|Patients without fever after PNL
3482777|NCT03774992|Experimental|Orthokeratology|Subjects randomized to OKL in the CONTROL-study
3482778|NCT03774992|Experimental|Cross over|Subjects randomized to SVS in the CONTROL-study
3482779|NCT03774901|Experimental|avelumab maintenance|Avelumab will be administered at a dose of 10 mg/kg every 2 weeks with appropriate supportive care
3482780|NCT03774797||Pre-Implementation Patients|Enrolled patients will take online surveys following a prenatal or a postpartum visit.
3482781|NCT03774797||Post-Implementation Patients|All enrolled patients will take online surveys following a prenatal or a postpartum visit. A subset will be interviewed after the postpartum survey.
3482782|NCT03774797||Post-Implementation Providers|All enrolled providers will take online surveys at 6-12 months after program implementation, and a subset will be interviewed.
3482783|NCT03774849|Experimental|Picoway™ 532nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 532nm fractional handpiece
3482784|NCT03774849|Experimental|PicoWay™ 730nm wavelength|PicoWay™ 730nm wavelength. Subjects will receive up to four study treatments with the PicoWay™ 730nm wavelength.
3482785|NCT03774849|Experimental|PicoWay ™1064nm fractional handpiece|Subjects will receive up to four study treatments with the PicoWay™ 1064nm fractional handpiece
3482786|NCT03774979|Experimental|SHR-1701|intravenous infusion
3482787|NCT03774537|Experimental|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs.
3482788|NCT03774537|Other|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
3482789|NCT03774732|Experimental|Pembrolizumab+ Chemotherapy + Radiotherapy|"In the experimental arm, patients will receive the same treatment as the control arm (chemotherapy plus pembrolizumab) in addition with conformal 3D radiotherapy (3D-CRT) or stereotactic ablative radiotherapy (SABR) that will be delivered at C2D1, 21 days after the beginning of pembrolizumab using photons/electrons with standard field encompassing tumour.~Irradiation technique (3D-CRT or SABR) will be at physician discretion. Ideally, oligometastatic patient (defined by the presence of less than 6 metastases) should be treated with SABR and those with non-oligometastatic disease should be treated with 3D-CRT.~Radiotherapy will be delivered a dose of at least 18 Gy in 3 X 6 Gy for 3D-CRT (cf. protocol for possible schemes and volumes restriction).~Irradiated tumor size will be ≤5 cm (GTV <65 mL sphere); partial tumor irradiation should be delivered if larger tumor size while respecting dose constraints."
3482790|NCT03774732|Active Comparator|Pembrolizumab+ Chemotherapy|"Squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin + paclitaxel or nab paclitaxel every 3 weeks for 4 cycles then pembrolizumab every 3 or 6 weeks (according to the current version of the SmPC )~Non squamous-cell lung carcinoma:~Pembrolizumab every 3 weeks and carboplatin or cisplatin + pemetrexed every 3 weeks for 4 cycles, and then pemetrexed plus pembrolizumab every 3 weeks (according to the current version of the SmPC)~Pembrolizumab treatment may be continued as long as patient is experiencing clinical benefit, as assessed by an investigator, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression after an integrated assessment of radiographic data, biopsy results (if available) and clinical status."
3482791|NCT03774719|Experimental|Hand-carried ultrasound arm|This is the only arm of the study. It will be comprised of 154 inpatients who had a renal ultrasound ordered or performed within the past 4 hours. The intervention will be performing hand-carried ultrasound to evaluate for presence and degree of hydronephrosis.
3482792|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort A, non-ALL)|This cohort is for patients without refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
3482793|NCT03774654|Experimental|CD19.CAR-aNKT cells (cohort B, ALL).|This cohort is for patients with refractory/relapsed B-cell NHL or leukemia (ALL). Three dose levels will be evaluated. Patients will also receive lymphodepletion chemotherapy consisting of cyclophosphamide and fludarabine followed by the CD19.CAR-aNKT cell infusion.
3482794|NCT03774953|Experimental|Intervention group|protein and vitamin supplementation
3482795|NCT03774953|No Intervention|Control group|No supplementations
3482796|NCT03774628|Experimental|Chengdu Kanghua (one booster shot)|one dose, A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
3482797|NCT03774628|Experimental|Chengdu Kanghua (two booster shots)|two doses at 0 and 3 days, on A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd.
3482798|NCT03774706|Active Comparator|Misoprostol with TA|two tablets sublingual misoprostol plus IgM tranexamic acid in 100 ml saline by slow iv
3127741|NCT03107793|Experimental|Treat to Target (T2T) Arm|UST maintenance treatment assignment will be based on centrally-read colonoscopy (at Wk16). Participants with <25% improvement in SES-CD score at Wk16 will be assigned to Q8 (8-weekly) treatment and will receive UST 90mg SC at Wk16. In contrast, participants with >=25% improvement in SES-CD score at Wk16 will be assigned to Q12 treatment and will receive next UST dose (90 mg SC) at Wk20. At assessment visits (from Wk24 for participants assigned to the Q8 regimen or from Wk20 for the Q12 group) UST maintenance treatment (up to Wk 48) will be directed by T2T assessments. Participants meeting target will continue with same UST dosing frequency. The dosing frequency will be optimized for all participants failing to meet the target at assessment visit. Those previously on Q12 regimens will be adjusted to Q8 dosing; those previously on Q8 regimens will be adjusted to Q4 dosing. Participants subsequently failing to meet the target will not be able to adjust further and will leave the study.
3179655|NCT00675298||4|Bulgarian cohort with chronic prostatitis/chronic pelvic pain syndrome, painful bladder syndrome/interstitial cystitis and children with overactive bladder
3482799|NCT03774706|Active Comparator|Misoprostol with placebo to TA|two tablets sublingual misoprostol plus placebo to tranexamic acid ( 110 ml saline) by slow iv
3482800|NCT03774771|Placebo Comparator|Placebo|In Part 1 participants received placebo capsules orally once a day for 6 weeks. In Part 2 participants received placebo capsules twice a day for 15 days.
3482801|NCT03774771|Experimental|Cinacalcet 50 mg QD|In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
3482802|NCT03774771|Experimental|Cinacalcet 75 mg QD|In Part 1 participants received 75 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 40 mg cinacalcet capsules twice a day for 15 days.
3482803|NCT03774771|Experimental|Cinacelcet 100 mg QD|In Part 1 participants received 100 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 50 mg cinacalcet capsules twice a day for 15 days.
3127742|NCT03107793|Experimental|Exploratory Extension period: From Week 48 to Week 104|At Week 48, dose de-escalation will be implemented for participants with both endoscopic remission (SES-CD score <=2) and corticosteroid-free clinical remission of at least 16 weeks duration. Participants receiving 12 weekly dosing frequency (Q12) ustekinumab will maintain this dosing frequency. Participants with either clinical remission or endoscopic remission, but not both, at Week 48 will continue with same dosing frequency or de-escalate provided maintenance of corticosteroid-free clinical remission and biomarker remission at 2 consecutive visits. Participants with neither corticosteroid-free clinical remission nor endoscopic remission will escalate dose or leave study if already on 4 weekly dosing frequency (Q4) dose. If neither clinical remission nor biomarker remission is evident at the next visit, participant will leave study. Later in the extension period, only those who achieve corticosteroid-free clinical remission and biomarker remission will undergo dose de-escalation.
3482804|NCT03774667||Placenta Previa|Pregnant women is diagnosed with placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
3482805|NCT03774667||None-Placenta Previa|Pregnant women is diagnosed without placenta previa after delivery. Placenta previa is diagnosed by experienced ultrasonologists based on a transabdominal ultrasonic finding of placental tissue covering the internal cervical os before delivery, and further confirmed by obstetricians at delivery.
3482806|NCT03774758||Cohort 1A: Benign nodule on screening CT|"High-risk patients eligible for lung cancer screening but with negative radiographic findings on CT screening (Lung RADS ≤2).~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
3127743|NCT03108027|Experimental|Sequence 1|Patients will receive in a sequential order the following interventional treatments: A,B and C.
3482807|NCT03774758||Cohort 1B: Incidental benign nodule|"Patients with lung nodules ≥ 6 mm on routine (non-lung cancer screening) CT evaluation deemed suspicious for malignancy by initial physician judgment but not malignant by ≥2 years of radiographic stability and consensus clinical opinion.~1- Age ≥40 years."
3482808|NCT03774758||Cohort IC: Presumed lung cancer|"Patients with lung cancer (histologically proven or presumed by consensus opinion of tumor board); prior to definitive therapy.~1- Age ≥40 years."
3482809|NCT03774758||Cohort 2A: Suspicious nodule|"High-risk patients with newly diagnosed suspicious nodule of Lung RADS ≥3 on CT screening.~≥30 pack-year history of cigarette smoking~≥55 years of age~Current smoker or quit within the past 15 years"
3482810|NCT03774758||Cohort 2B: Suspicious incidental nodule|"Patients with newly diagnosed incidentally-found lung nodules ≥ 6 mm on routine CT evaluation deemed suspicious for malignancy by physician judgment.~1- Age ≥40 years."
3482811|NCT03774758||Cohort 2C: Post-treatment lung cancer|"Patients with previously treated lung cancer (histologically proven or by consensus opinion); status-post completion of definitive therapy (resection +/- chemotherapy or SBRT with curative intent) within the previous year with no current evidence of disease.~1- Age ≥40 years."
3482812|NCT03774927|Experimental|10 Hz treatment group|In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
3482813|NCT03774927|Experimental|20 Hz treatment group|In active rTMS, 20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
3482814|NCT03774927|Sham Comparator|Control Group|In sham rTMS, all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
3482815|NCT03774693|Active Comparator|GS [General anesthesia]|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.
3482816|NCT03774693|Active Comparator|GR [General anesthesia + regional block]|"Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1.~Also patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block. Fentanyl boluses of 0.5 mcg.Kg-1 will be given when needed to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1."
3482817|NCT03774836|Active Comparator|Tramadol 50 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
3482818|NCT03774836|Active Comparator|Morphine 4 mg|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
3482819|NCT03774836|Placebo Comparator|Placebo|Given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
3482820|NCT03774914||Lemtrada|Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
3482821|NCT03774680|Active Comparator|Cetuximab nanoparticles goup|A group of volunteers infected colon cancer or colorectal cancer received cetuximab in the formulated nanoparticles
3127744|NCT03108027|Experimental|Sequence 2|Patients will receive in a sequential order the following interventional treatments: B, A and C.
3127745|NCT03108027|Experimental|Sequence 3|Patients will receive in a sequential order the following interventional treatments: C, B and A.
3127746|NCT03108027|Experimental|Sequence 4|Patients will receive in a sequential order the following interventional treatments : C, A and B.
3482822|NCT03774680|Placebo Comparator|Oral approved anticancer drug|A group of volunteers infected with colon cancer or colorectal cancer received placebo anticancer drug.
3127747|NCT03108027|Experimental|Sequence 5|Patients will receive in a sequential order the following interventional treatments: A, C and B.
3127748|NCT03108027|Experimental|Sequence 6|Patients will receive in a sequential order the following interventional treatments: B, C and A.
3179656|NCT00675298||5|Asymptomatic healthy controls
3482823|NCT03774966|Active Comparator|Adductor Canal Block + Catheter|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine
3482824|NCT03774966|Experimental|Adductor Canal Block + Catheter & IPACK|Adductor canal block: 15 mL of 0.25% ropivicaine, adductor canal catheter: 6 mL/hr of 0.2% ropivacaine, IPACK block: 15 ml of 0.25% ropivacaine.
3482825|NCT03774615|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
3482826|NCT03774602|Experimental|MCSP package of interventions|MCSP package of interventions for health promotion and provision of RMNCH services
3482827|NCT03774810|Experimental|Continuous|Nightly active dose (QHS). The intervention is zolpidem tartrate 5 mg or 10 mg.
3482828|NCT03774810|Experimental|Partial Reinforcement 1|1 active dose per week with 6 placebos interspersed between the active dose. The intervention is zolpidem tartrate 5 mg or 10 mg.
3482829|NCT03774810|Experimental|Partial Reinforcement 3|3 active doses per week with 4 placebos interspersed between the active doses. The intervention is zolpidem tartrate 5 mg or 10 mg.
3482830|NCT03774810|Experimental|Low Frequency Intermittent Dosing|1 to 3 active doses per week PRN. The intervention is zolpidem tartrate 5 mg or 10 mg.
3482831|NCT03774589|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
3482832|NCT03774589|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
3482833|NCT03774511|Active Comparator|Study group 1|High Intensity Interval Excercise
3482834|NCT03774511|Active Comparator|Study group 2|Moderate Intensity Interval Exercise
3482835|NCT03774511|No Intervention|Control group|No Intervention
3127749|NCT03108157|Experimental|GROUP A: intervention group|Patients will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before the embryo transfer and then they will follow the conventional preparation protocol to receive embryos coming from an egg donation treatment.
3127750|NCT03108157|No Intervention|GROUP B: no intervention group|Patients will receive the conventional preparation protocol to receive embryos coming from an egg donation treatment.
3127751|NCT03108469|Active Comparator|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
3127752|NCT03108469|Placebo Comparator|Placebo|Those randomized to placebo will receive subcutaneous injections containing 1.00 mL (200mg) weekly for weeks 1-16.
3482836|NCT03774498|Active Comparator|Sensodyne repair and protect|NovaMin & fluoride toothpaste
3482837|NCT03774498|No Intervention|Sensodyne Daily Care Toothpaste 0.315%|Sodium fluoride toothpaste
3482838|NCT03774524|Active Comparator|Misoprostol with TA|400 μg of sublingual misoprostol (two tablets) plus 1 gm tranexamic acid in 100 ml saline by iv rout
3482839|NCT03774524|Active Comparator|Misoprostol with placebo to TA|400 μg of sublingual misoprostol (two tablets) plus 110 ml saline by iv rout
3482840|NCT03774524|Placebo Comparator|placebo to Misoprostol with placebo to TA|placebo to misoprostol plus placebo to tranexamic acid
3482841|NCT03774342||CABG-patients|We will study one group of patients all scheduled for a Coronary Artery Bypass Grafting-procedure. This observational study consists of one group.
3482842|NCT03774329|Experimental|physical activity program|Child with an adapted physical activity program
3482843|NCT03774329|Other|Usual care|
3482844|NCT03774407|Other|urogenital symptoms|To evaluate the efficiency of vaginal estriol, as a treatment for urogenital symptoms in female patients with RRMS.
3482845|NCT03774407|Experimental|remyelination|To evaluate the potential role of vaginal estriol in re-myelination in RRMS patients.
3482846|NCT03774290|Experimental|PBF-680 10 mg|10 mg of PBF-680 once a day
3127753|NCT03108482|Experimental|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two tablets of 100 mg every 12 hours. The total daily dose will be 400 mg of Co-crystal E-58425.
3127754|NCT03108482|Active Comparator|Tramadol (Ultram®)|Tramadol: One tablet of 50 mg every 6 hours. The total daily dose will be 200 mg of tramadol.
3482847|NCT03774290|Placebo Comparator|Placebo oral capsules|Placebo once a day
3482848|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - PRP Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to undergo platelet rich plasma injection
3127755|NCT03108482|Active Comparator|Celecoxib (Celebrex®)|Celecoxib: One capsule of 100 mg every 12 hours. The total daily dose will be 200 mg of celecoxib.
3127756|NCT03108482|Placebo Comparator|Placebo|Placebo: One or two tablets of 100 mg every 6 hours.
3127757|NCT03108521|Experimental|Sitagliptin group|Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.
3482849|NCT03774251|Active Comparator|Greater Trochanter Pain Syndrome - ESWT Arm|Individuals with Greater Trochanter Pain Syndrome with MRI evidence of gluteus medius or gluteus minimus tendinopathy, assigned to extracorporeal shock wave therapy
3482850|NCT03774277|Experimental|Intervention Communities|Packed Promise for a Healthy Heart intervention, free Tribal Wellness Center membership, a Fitbit, and the AYA culturally based mobile walking app.
3482851|NCT03774277|No Intervention|Control Communities|Free Tribal Wellness Center membership, Fitbit, and the AYA culturally based mobile walking app
3482852|NCT03774303|Experimental|mobile intervention|families to be prepared for day surgery with a mobile application
3482853|NCT03774303|Active Comparator|control group|families to be prepared for day surgery with current practice
3482854|NCT03774212|Experimental|Group A|On study night 1, participants will receive standard care (no headphones provided). On study night 2, these patients will wear Active Noise Cancelling headphones playing white noise.
3482855|NCT03774212|Experimental|Group B|Patients will spend night 1 wearing Active Noise Cancelling headphones playing white noise. On Study night 2, these patients will receive standard care (no headphones provided).
3482856|NCT03774485||Healthy controls|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in healthy controls. The investigator does not change the routine medical care of study participants.
3482857|NCT03774485||Crohn's disease (remission state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (remission state). The investigator does not change the routine medical care of study participants.
3482858|NCT03774485||Crohn's disease (flare state)|Record gastrointestinal motility by G-Tech Gutcheck Myoelectric recording device in subjects with Crohn's disease (flare state). The investigator does not change the routine medical care of study participants.
3482859|NCT03774368|Other|Website about emergency contraception|Subjects are randomly assigned to view an existing website about emergency contraception. The website contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
3482860|NCT03774368|Other|Video about emergency contraception|Subjects are randomly assigned to view an existing video about emergency contraception. The video is two minutes in length and contains information about the three methods of emergency contraception: the copper IUD, ulipristal pill, and levonorgestrel pill. It includes information about their relative effectiveness and where to access emergency contraception.
3482861|NCT03774238|Experimental|COPD patients|FMD analysis Endothelial progenitors Exercise test Exercise training
3482862|NCT03774238|Experimental|Healthy subject|FMD analysis Endothelial progenitors Exercise test
3127758|NCT03108521|No Intervention|non-T2DM group|Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.
3482863|NCT03774472|Experimental|Treatment (hydroxychloroquine, palbociclib, letrozole)|"PHASE I: Patients with advanced, metastatic (stage IV) breast cancer receive hydroxychloroquine PO QD, palbociclib PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients with early stage (stage I-III) breast cancer receive hydroxychloroquine PO QD on days 15-28 of cycle 1 and on days 1-28 of subsequent cycles. Patients also receive palbociclib PO QD, and letrozole PO QD on days 1-28, followed by standard of care surgery at week 5. If there is a proliferative benefit with CCCA by biopsy at 4 weeks, cycles may repeat every 28 days for up to 20-24 weeks in the absence of disease progression or unacceptable toxicity, followed by standard of care surgery during weeks 20-24."
3482864|NCT03774459|Experimental|High dose ANAVEX2-73|High dose ANAVEX2-73
3482865|NCT03774459|Experimental|Mid dose ANAVEX2-73|Mid dose ANAVEX2-73
3482866|NCT03774459|Placebo Comparator|Placebo oral capsule|Placebo oral capsule
3482867|NCT03773952|Experimental|Oral 5-ASA + PBF-677 200 mg|Oral Mesalazine (5-ASA) (4g) + PBF-677 (200mg)
3482868|NCT03773952|Placebo Comparator|Oral 5-ASA + Placebo oral Capsules|Oral Mesalazine (5-ASA) (4g) + Placebo oral capsules
3482869|NCT03774017|Other|Traditional microsurgery group|Patients receive only traditional microsurgical operations in traditional operating theaters or the one-staged hybrid operation theater. No endovascular intervention technique or intraoperative digital subtraction angiography(DSA) will be performed. The DSA will be performed in 3 days after the operation.
3482870|NCT03774017|Experimental|Hybrid operation group|Patients receive microsurgical operation under the assistance of intraoperative DSA, endovascular embolization and/or balloon occlusion in the one-staged hybrid operating theater.
3127759|NCT03108924|Experimental|Moderate RI|Participants with moderate renal insufficiency (RI) are treated with a single 50 mg dose of gefapixant
3127760|NCT03108924|Experimental|Severe RI|Participants with severe RI are treated with a single 50 mg dose of gefapixant
3482871|NCT03773991||Maintenance Hemodialysis Patients|"Patients on chronic hemodialysis therapy due to end-stage renal disease.~Proton Lung MRI~Sodium MRI of the leg~Chest CT~Transthoracic Echocardiography~Fractional Exhaled Nitric Oxide~Six-Minute Walk Test~Pulmonary Function Tests~Blood sampling~Self-administered dyspnea questionnaires"
3482872|NCT03774030|Experimental|hearing impaired participants|Hearing impaired participants with mild or severe hearing loss
3482873|NCT03773939||Derivation cohort|Prospective cohort study based on the 'Simple Intensive Care Studies' (SICS) registry (NCT02912624, NCT03577405, and NCT03553069)
3482874|NCT03773939||External validation cohort|We will create a multicenter cohort based on prospectively collected data derived from the Dutch National Intensive Care Evaluation (NICE) registry
3482875|NCT03774199|Other|Pulse oximeter calibration population|
3482876|NCT03773900|Experimental|Chitin-Glucan supplementation|
3482877|NCT03773900|Placebo Comparator|Placebo supplementation|
3482878|NCT03774043|Experimental|Single session of Acute Intermittent Hypoxia (AIH)|
3482879|NCT03774043|Placebo Comparator|Single session of Sham Acute Intermittent Hypoxia (Sham AIH)|
3482880|NCT03774043|Experimental|Two successive sessions of AIH|
3482881|NCT03774043|Placebo Comparator|Two successive sessions of Sham AIH|
3482882|NCT03774069|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
3482883|NCT03774069|Active Comparator|Control group- medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
3482884|NCT03774056|Experimental|dose group|Drug name L:HC-1119 Dosage: 40 mg, 80 mg, 160 mg, and 200 mg
3482885|NCT03774355|Experimental|CG1801|Dosing 'CG1801' followed by dosing 'CGL1802'
3482886|NCT03774355|Experimental|CGL 1802|Dosing 'CGL1802' followed by dosing 'CG1801'
3482887|NCT03774134||CME group|The CME group consisted of patients, who underwent elective CME for sigmoid colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2014.
3482888|NCT03774134||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for sigmoid adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
3482889|NCT03774225|Experimental|Manual and verbal guidance (MVG)|The MVG Group will be done by experimental group with the manual and verbal guidance of a physiotherapist using four games of X-Box Kinect system®
3127761|NCT03108924|Other|Healthy Matched Controls|Healthy, participants matched for age and body weight are treated with a single 50 mg dose of gefapixant
3127762|NCT03108924|Experimental|ESRD Requiring HD|Participants with end stage renal disease (ESRD) requiring hemodialysis (HD), are treated in Period 1 with a single 50 mg dose of gefapixant immediately after the scheduled HD, followed in Period 2 with a single 50 mg dose of gefapixant two hours prior to HD. Between the Periods 1 and 2 MK-7264 dose administrations there was approximately a 7-day washout period with 3 dialysis sessions.
3127763|NCT03109015|Active Comparator|Schedule 4/2|
3127764|NCT03109015|Experimental|Schedule 2/1|
3127765|NCT03109184|No Intervention|Waitlist Control|Parents and teens enrolled in the study and randomized to the control condition wait until they complete their 3-month and 9-month follow-up surveys before completing the web-based program.
3127766|NCT03109184|Experimental|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
3127767|NCT03109262|Experimental|Yttrium Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans|All participants receive both Y-90 PET/CT vs 99mTc-MAA SPECT/CT Scans
3127768|NCT03109769|Experimental|Mobile phone application|Subjects in this group received a mobile phone application that sends active reminder notifications of oral hygiene 3 times a day.
3127769|NCT03109769|Active Comparator|Verbal oral hygiene instructions|Subjects in this group received verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
3127770|NCT03109951|Other|Diabetes group|Type 2 diabetes patients undergoing colonoscopy with preparation with 2L of polyethylene glycol.
3127771|NCT03110003|Active Comparator|10 mg Bupivacaine|Subjects will receive 10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl.
3482890|NCT03774225|Experimental|No manual and verbal guidance (NMVG)|The NMVG Group will be done by experimental group using four games of X-Box Kinect system® in the presence of a physiotherapist that will care about the safety of the participants without interfere in their moviment pattern.
3482891|NCT03774225|Active Comparator|Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
3482892|NCT03774173|Experimental|Aramchol 300 mg|Aramchol 300 mg twice daily (every 12 hours)
3482893|NCT03774173|Experimental|Aramchol 600 mg|Aramchol 600 mg once daily (every 24 hours)
3482894|NCT03774160|Experimental|Generacion Actual|Generacion Actual includes Community-based and a Health Systems Components. This multi-level intervention reaches out to all MSM/trans by mobilizing them to encourage friends to reduce risk behavior and increase HIV testing, and for HIV+ friends, encourage them to link, stay in care, and take medications regularly. The community based component includes a leadership group, community space, community mobilization events, and group sessions to address a variety of psychosocial issues as well as HIV literacy. The Health Systems component includes sensitization of the HIV testing and care staff to working with MSM and trans, Navigators to help MSM/trans to navigate the complex health system; and positive prevention training of providers; all evidence-based approaches.
3127772|NCT03110003|Active Comparator|5 mg Bupivacaine|Subjects will receive 5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
3127773|NCT03110029|Active Comparator|Efinaconazole 10 % and Nail Polish|Subject will have Efinaconazole 10% solution application and nail polish
3127774|NCT03110029|Placebo Comparator|Efinaconazole 10% without Nail Polish|Subject will have only Efinaconazole 10% application and no nail polish
3482895|NCT03774160|No Intervention|Comparison|No intervention is implemented in the comparison arm.
3482896|NCT03774108|Experimental|Metformin Experimental Arm|Metformin 850mg/12 hours, oral, 8 weeks
3482897|NCT03774108|Placebo Comparator|Placebo Comparator Arm|Placebo pills/12hours, oral, 8 weeks
3482898|NCT03774121|Experimental|CRYO|Subjected to Cryoneurolysis treatment and Neuromuscular training (GLA:D).
3482899|NCT03774121|Sham Comparator|SHAM|Subjected to similar procedures as CRYO, but without freezing temperatures. Subjected to Neuromuscular training (GLA:D).
3482900|NCT03773913||Four facilities in Kozah District|Baseline estimated population of 33,412 served by four public sector facilities in Kozah District.
3482901|NCT03774446|Experimental|Seliciclib|Up to 800 mg/day oral seliciclib for 4 days each week for 4 weeks
3482902|NCT03774095|No Intervention|No oil|6-hour oral glucose tolerance test
3482903|NCT03774095|Active Comparator|Hydrolyzed pine nut oil|6g hydrolyzed pine nut oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
3482904|NCT03774095|Active Comparator|Hydrolyzed pine nut oil and olive oil|3g hydrolyzed pine nut oil and 3g olive oil in delayed release capsules given 30 min prior to an 6-hour oral glucose tolerance test
3127775|NCT03110185|Other|delirium|Patients in the cardiothoracic ICU diagnosed with postoperative delirium. Subjects will wear a diffuse optical tomography device in addition to the normal monitors. A non-contrast functional MRI will be performed.
3127776|NCT03110185|Other|no delirium|Patients in the cardiothoracic ICU not diagnosed with postoperative delirium. Subjects will be monitored in the same way as the delirium arm
3482905|NCT03773887|Other|acute alcoholic hepatitis|collection of liver biopsies collection of blood samples in patients with acute alcoholic hepatitis (group A)
3482906|NCT03773887|Other|Alcoholic cirrhosis|collection of liver biopsies collection of blood samples in patients with alcoholic cirrhosis (group B1)
3482907|NCT03773887|Other|Without chronic liver disease|collection of liver biopsies collection of blood samples in patients without chronic liver disease (group B2)
3482908|NCT03773926|Experimental|Neuro-feedback therapy|"EEG headset is placed on the patients head and the electrodes record the brain activity from F3, F4, FC1 and FC2 (on the 10-10 international localization system of EEG electrodes) and generate feedback.~Each session is composed of 6 blocks of 3 minutes in which the patient is incited to practice a specific cognitive strategy. During the 4 first session, 8 strategies are explored. Then through the therapy, the best cognitive strategies are gradually selected through an automatized process taking in account objective performances and subjective feedback."
3482909|NCT03774381|Experimental|Bifidobacterium breve B-3 group|160 mg mg of Bifidobacterium breve B-3 was orally administered per day for 12 weeks.
3127777|NCT03110380|Experimental|B/F/TAF|B/F/TAF + DTG placebo + F/TAF placebo for 48 Weeks
3127778|NCT03110380|Active Comparator|DTG + F/TAF|DTG + F/TAF + B/F/TAF placebo for 48 Weeks
3482910|NCT03774381|Placebo Comparator|Control group|160 mg of placebo was orally administered per day for 12 weeks.
3482911|NCT03773861|Other|Participants|Active BLS- Instructors at the Bern Simulation and CPR- Center (BeSiC), at the Bern University Hospital, Bern, Switzerland. Participants have to oversee a BLS instructional session, where standardized errors are performed by trained volunteers.
3482912|NCT03773718||Russkoe pole|400 patients
3482913|NCT03773835|Experimental|HSK3486|0.15mg/kg, 0.40mg/kg, 0.60mg/kg, 0.90mg/kg,
3482914|NCT03773679|Experimental|Exercise Group|"Daily exercise program involved Range of Motion (ROM) exercises against extremity resistances and extension and flexion in upper and lower extremities. Exercises were implemented on wrists, elbows, shoulders, ankles, knees, and hip joints of the infants by the same researcher (YSE). The daily exercise program was repeated 5-8 times, 1 session/day (a similar time of the day), for 30 days. Each session continued for 7-10 minutes."
3482915|NCT03773679|No Intervention|Control Group|The preterm infants in the control group did not receive the daily exercise program, only the standard clinical routine.
3482916|NCT03773523|Experimental|Experimental: active tDCS|Subjects that are randomly assigned to this arm will undergo 5 sessions of tDCS.
3482917|NCT03773523|Sham Comparator|Sham Comparator: sham tDCS|Subjects randomly assigned to sham-tDCS will receive very low current stimulation at the beginning and end of the session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function. There will be a total of 5 sham tDCS sessions.
3482918|NCT03773822|Placebo Comparator|Placebo of hydrocortisone and placebo of fludrocortisone|Placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of enteral fludrocortisone given once a day for seven days
3482919|NCT03773822|Experimental|Combination of hydrocortisone + fludrocortisone|Hydrocortisone will be given as 50 mg iv bolus every 6 hours for seven days and a tablet of 50 µg of fludrocortisone will be given once a day enterally for seven days
3482920|NCT03773744|Experimental|Arm 1: Intravenous Dosing|Low dose cyclophosphamide (300mg/ m2) at Day -3, then a fixed dose of Ad-MAGEA3 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-MAGEA3 administered as 2 intravenous (IV) doses at Day 15 and Day 18 and fixed dose pembrolizumab (200mg) beginning at either Week 6 or Day 1, depending on the cohort.
3132724|NCT03447314|Experimental|Part 1c: 150ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 150 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 150 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 150 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
3482921|NCT03773744|Experimental|Arm 2: Intravenous followed by Intratumoral Dosing|A fixed dose of Ad-MAGEA3 administered IM followed by Pembrolizumab on Day 1. MG1-MAGEA3 administered as an intravenous (IV) dose at Day 15, followed by intratumoral (IT) MG1-MAGEA3 on Day 22, Day 29, and Day 36. IT MG1-MAGEA3 booster injections may be continued every 3 weeks beginning at Day 43 (Week 6).
3482922|NCT03773783|Active Comparator|Twin Block|Twin Block appliance
3482923|NCT03773783|Experimental|Button and Bead|Button and Bead appliance
3482924|NCT03773562|Other|Erenumab|All participants receive erenumab 140mg by subcutaneous injection at baseline and again 4 weeks later.
3482925|NCT03773536|Experimental|ASAQ + SLD Primaquine|Artesunate + amodiaquine (WHO prequalified Artesunate/Amodiaquine Winthrop®) was administered orally as a fixed dose combination, at a dose of approximately artesunate 4 mg/kg + amodiaquine 10mg/kg once daily for 3 consecutive days. Primaquine was administered orally, as a single dose (0.25 mg/kg) together with the first artesunate + amodiaquine dose. All doses of medicine were administered under direct supervision. Any patient who vomited within a 30 minute observation period was re-treated with the same dose of medicine and observed for an additional 30 minutes. If the patient vomited again after the second study drug administration, he/she was withdrawn and offered rescue therapy (Artesunate IV).
3482926|NCT03773640|Experimental|The study group|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
3482927|NCT03773640|Active Comparator|The control group|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
3482928|NCT03773848|Experimental|A- hook plate|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with hook plate. X-ray was applied to check the grade of reduction before the operation is completed.
3482929|NCT03773848|Experimental|B- tightrope|All participants will have an Open Reduction Internal Fixation (ORIF). The affected upper limb will be temporarily fixed by a sling after admission. The patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with tightrope. X-ray was applied to check the grade of reduction before the operation is completed.
3482930|NCT03773809|Placebo Comparator|Group A0|Vitamin D3 deficient ACO patients with placebo at day 0.
3482931|NCT03773809|Placebo Comparator|Group A90|Vitamin D3 deficient ACO patients with placebo at day 90.
3482932|NCT03773809|Active Comparator|Group B0|Vitamin D3 deficient ACO patients with vitamin D3 at day 0.
3482933|NCT03773809|Active Comparator|Group B90|Vitamin D3 deficient ACO patients with vitamin D3 at day 90.
3482934|NCT03773653|Experimental|BMT to be combined with BAT|Participants in this group will receive bilateral robotic priming and bilateral arm training or mirror therapy within the 90-minute training sessions.
3482935|NCT03773653|Experimental|BMT to be combined with MT|Participants in this group will receive bilateral robotic priming and mirror therapy within the 90-minute training sessions.
3482936|NCT03773653|Active Comparator|BMT to be combined with IOT|Participants in this group will receive bilateral robotic priming and impairment-oriented training within one 90-minute training session.
3482937|NCT03773549||Body dysmorphic disorder|Meet DSM-5 criteria for principal body dysmorphic disorder, assessed via the Structured Clinical Interview for the DSM-V Axis I Disorders (SCID)
3482938|NCT03773549||Healthy control|Individuals who do not have a current psychiatric diagnosis, assessed via the Mini-International Neuropsychiatric Interview (MINI)
3482939|NCT03773601|Experimental|Athletes|Athletes will undergo a 4-days sleep monitoring with the use of the Sleep Profler. At the same time, they will fill the Total Quality of Recovery (TQR) scale and the Pittsburgh Sleep Quality Index (PSQI).
3482940|NCT03773705|Active Comparator|Electrocautery group|Electrocautery used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
3482941|NCT03773705|Active Comparator|Scalpel group|Scalpel used to raise pediclued nasoseptal flaps to repair skull based defects following endoscopic transphenoidal surgery.
3482942|NCT03773757|Experimental|IN-PEACE Dementia Care Coordination|In-PEACE intervention arm will have monthly contact with a dementia care coordinator (DCC) to to identify symptoms the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors.
3482943|NCT03773757|No Intervention|Usual Care|The usual care arm will have access to education and informational materials from the local chapter of the Alzheimer's Association and other community resources and will be reminded of these resources throughout the study.
3482944|NCT03773731|Experimental|High intensity interval training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: intensive cycling bouts of 60s interspersed with 60s of recovery intervals. Power output will be 90% (week 1-6) or 95% (week 7-12) of the maximal power output of the exercise test during the intensive cycling bouts. During recovery intervals, subjects will pedal with a power output of 30% (week 1-6) or 35% (week 7-12) of the maximal power output of the exercise test.~10 minutes with 30% of maximal power output."
3482945|NCT03773731|Active Comparator|Moderate intensity continuous training|"3x/week the following 45 min training protocol on bicycle ergometer for 12 weeks:~5 minutes warm-up phase with a power output of 40% of the maximal power output achieved in an incremental exercise test~30 minutes: Continuous training with 60% (week 1-6) or 65% (week 7-12) of maximal power output~10 minutes with 30% of maximal power output."
3482946|NCT03773588|Active Comparator|Closed-Loop propofol Target control infusion|Closed loop target controlled infusion(TCI) TIVA with propofol using BD TCI pumps guided by entropy and SPI
3482947|NCT03773588|Active Comparator|Open-loop propofol target control infusion|Open-loop target controlled infusion of propofol using BD TCI pumps based on Schnider effect site algorithm
3482948|NCT03773692|Experimental|Passive feedback and JITAI|"Passive feedback and JITAI~Second Phase - PA Level Feedback Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)"
3482949|NCT03773510|Active Comparator|Trabectedin continuation|All the patients who will complete 6 cycles of trabectedin without disease progression, will continue trabectedin until progressive disease, unacceptable toxicity, patient or investigator decision
3482950|NCT03773510|Experimental|Trabectedin discontinuation|"All the patients who will complete 6 cycles of trabectedin without disease progression , will discontinue trabectedin.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
3482951|NCT03773497|Other|Common snack combination|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of a combination of common snack foods (pretzels, potato chips, and popcorn).
3482952|NCT03773497|Other|Cheese broccoli|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli.
3482953|NCT03773497|Other|Cheese broccoli with Daikon radish powder|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder.
3482954|NCT03773497|Other|Uncooked broccoli with ranch-type dip|Subjects will consume a self-chosen, low-carotenoid diet, and on the first day, with breakfast, will consume a snack of uncooked, freeze-dried broccoli with ranch-type dip.
3482955|NCT03773432|Other|Men|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
3482956|NCT03773432|Other|Women|In two separate days a probe meal (290 stewed beans, 35 g bread, 100 mL water; 549 Kcal) will be served at conventional and unconventional time.
3127779|NCT03110380|Experimental|Open-Label Extension Phase|After Week 48, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants in a country where B/F/TAF FDC is not available will be given the option to receive open-label B/F/TAF for up to 96 weeks, or until the product becomes accessible through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.
3127780|NCT03110458|Experimental|SENS-111 100mg|SENS-111 100mg: 2 Oral Dispersible Tablets (1 SENS-111 100 mg and 1 placebo)
3127781|NCT03110458|Experimental|SENS-111 200mg|SENS-111 200mg: 2 Oral Dispersible Tablets (SENS-111 100 mg)
3127782|NCT03110458|Placebo Comparator|Placebo|Placebo: 2 placebo Oral Dispersible Tablets
3482957|NCT03773484|Experimental|Clinical Decision Support nudges|"Clinical decision support nudges within the electronic health record to discourage unnecessary opioid prescribing through the application of behavioral insights-empirically-tested social and psychological interventions that affect choice. Participating clinicians will receive any of three nudges when eligibility criteria are met within a patient's chart."
3482958|NCT03773458|Other|Eligible patients for AI test.|Device: An artificial system for the screening of scoliosis
3482959|NCT03773198|Experimental|ERCS Group|
3482960|NCT03773198|Placebo Comparator|Control Group|
3482961|NCT03773146|No Intervention|Control|No airtime incentive was given for completing the survey
3482962|NCT03773146|Experimental|1X Incentive|1X Airtime Incentive
3482963|NCT03773146|Experimental|Lottery|Lottery Airtime Incentive
3482964|NCT03773406|Active Comparator|Offline tDCS-before therapy|Participants will receive 20 minutes of tDCS prior to the 40 minute speech-language therapy session.
3482965|NCT03773406|Active Comparator|Offline tDCS-after therapy|Participants will receive 20 minutes of tDCS after the 40 minute speech-language therapy session.
3482966|NCT03773406|Active Comparator|Online tDCS|tDCS will be applied at the beginning of the 40 minute speech-language therapy session and will last for 20 minutes.
3482967|NCT03773406|Sham Comparator|Sham tDCS|Sham tDCS will be applied at the beginning of the 40 minute speech-language therapy session.
3482968|NCT03773367|Experimental|Treatment with chemotherapy pre- and postoperative.|
3482969|NCT03773211|Experimental|Renaparin|Solution administered once to kidney ex-vivo
3482970|NCT03773211|Placebo Comparator|Placebo|Placebo administered once to kidney ex-vivo
3482971|NCT03773393|Experimental|CK0801|All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
3482972|NCT03773419|Experimental|Texting Intervention (T-WRITE)|Computer-based treatment targeting written language via texting (90 minutes a day, 5 days a week for 4 weeks)
3482973|NCT03773419|Active Comparator|HandWriting Intervention (ORLA+WTG)|Computer-based treatment targeting written language via handwriting (90 minutes a day, 5 days a week for 4 weeks)
3482974|NCT03773172|Placebo Comparator|Placebo Control Group|Subjects will receive placebo treatment to mimic active treatment.
3482975|NCT03773172|Active Comparator|Active treatment|IV push loading dose of 300 mg MEDI6012 followed by a 150 mg maintenance dose of MEDI6012 at 48 hours.
3482976|NCT03773315|Experimental|UMH group|This group takes UMH extract for 12 weeks
3482977|NCT03773315|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
3482978|NCT03773354|Experimental|Intervention|There is no control group for this study, and all participants receive the intervention. Although a few participants will be asked to give additional information during the intake and after the study concludes for quality improvement purposes. Effects of these additional interview questions will be considered during analysis
3482979|NCT03773328|Experimental|CK0801, 50ml|"All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801. Subjects will receive one 50mL intravenous dose of CK0801 (Treg cells) on study Day 0. A total of three cohorts will be evaluated.~Cohort dosing will be as follows:~Dose level 1 = 1x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 2 = 3x10e6/kg Treg cells per kg recipient ideal body weight (IBW); Dose level 3 = 1x10e7/kg Treg cells per kg recipient ideal body weight (IBW)."
3482980|NCT03773263|Experimental|sequential oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. COCs were removed from aspirated follicular fluid and transferred into HEPES-buffered collection medium. The immature oocytes will be cultured in sequential IVM medium 1 for 6 hours (37℃, 5% CO2), and removed into sequential IVM medium 2 for further cultivation. After 24 and 40 hours cultivation, the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle.
3482981|NCT03773263|Active Comparator|traditional oocyte IVM group|From day 7~9 of the menstrual cycle, 225 IU HMG (Menotrophins for Injection) per day will be administrated for 3 days. On the day of ovulation, COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed and the mature oocytes will be fertilized by intracytoplasmic sperm injection (ICSI). Two of the D3 embryos (if available) which graded as top-quality embryo will be vitrified and the rest of embryos will be cultivated extendedly. Thawed embryo transfer (TET) will give preference to D3 embryos and carried out with a hormone replacement cycle. If biochemical pregnancy is not achieved, thawed blastocysts transfer will be performed.
3482982|NCT03773237|Active Comparator|SMOFLipid|SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
3482983|NCT03773237|Active Comparator|IntraLipid|Intralipid is a lipid emulsion that contains soybean oil
3482984|NCT03773250|Experimental|Behavioral Intervention|Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
3482985|NCT03773250|No Intervention|Control|No intervention will be provided.
3482986|NCT03773107|Experimental|Phase I|Cohort 1) 5mg ruxolitinib, Cohort 2) 10mg ruxolitinib, Cohort 3) 15mg ruxolitinib
3482987|NCT03773107|Other|Phase II|Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen
3482988|NCT03773094|Experimental|Guava leaves extract|A natural product that is prepared as a mouthwash
3482989|NCT03773094|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
3482990|NCT03773224|Active Comparator|Irrigation|Layer by layer irrigation of the surgical wound with gentamicin-saline solution
3482991|NCT03773224|No Intervention|Control|The surgical wound is closed layer by layer without irrigation
3482992|NCT03773159||Patients|Patients with von Willebrand disease or major constitutional thrombopathy or patients on antiplatelet drugs
3482993|NCT03773159||Controls|Blood donors at the French blood establishment in Burgundy Franche-Comté
3482994|NCT03773068|Experimental|Group 1 - BAY1817080 Dose 1|Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
3482995|NCT03773068|Experimental|Group 2 - BAY1817080 Dose 2|Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg [13C715N]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
3482996|NCT03773068|Experimental|Group 3 - BAY1817080 Dose 3|Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence
3482997|NCT03773055|Active Comparator|NPC-06 (High dosage)|18 mg (iv) in Day 1 as an induction dosage and 9 mg (iv) in Day 2 - 7 as a maintenance dosage
3482998|NCT03773055|Active Comparator|NPC-06 (Low dosage)|15 mg (iv) in Day 1 as an induction dosage and 6 mg (iv) in Day 2 - 7 as a maintenance dosage
3482999|NCT03773055|Placebo Comparator|Placebo|Saline will be administered intravenously
3483000|NCT03773042|Experimental|HSK3486|0.1mg/kg, 0.2mg/kg, 0.3mg/kg, 0.4mg/kg, 0.5mg/kg
3483001|NCT03773042|Active Comparator|Propofol|1.0mg/kg, 2.0mg/kg
3483002|NCT03773081|Other|Magmaris implantation|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice.
3483003|NCT03773029|Active Comparator|isoflavone|100 mg soy isoflavone (as 2 capsules)
3483004|NCT03773029|Placebo Comparator|control|2 capsules of placebo
3483005|NCT03772665|Experimental|Emixustat|10 mg
3483006|NCT03772665|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
3483007|NCT03772756|Experimental|EUS-RFA group|Patients in EUS-RFA group will undergo endoscopic ultrasound guided radiofrequency ablation(EUS-RFA ) and chemoradiotherapy
3483008|NCT03772756|Active Comparator|control group|the control group will receive chemoradiotherapy only
3483009|NCT03772769|Experimental|Subjects with advanced deep space odontogenic infection|Subjects will be diagnosed via two methods: 1. Target Enriched Multiplex PCR (TEM- PCR) and 2. Standard microbial culture.
3483010|NCT03772860||Healthy volunteers|Healthy volunteers will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
3483011|NCT03772860||Left headache|Migraine patients with mostly left sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
3483012|NCT03772860||Right headache|Migraine patients with mostly right sided headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
3483013|NCT03772860||Bilateral headache|Migraine patients without a dominant side headache will be exposed to pain stimulation, visual stimulation, auditory stimulation and mental stress
3483014|NCT03772652||Peri-implantitis|Subjects who were diagnosed with peri-implantitis and received treatment at least five years ago at the Graduate Periodontics Clinic at University of Michigan with sufficient baseline data. Soft tissue measurements (observation) of the implant will be completed.
3483015|NCT03772834|Experimental|Group I (methylphenidate, resistance training, walking)|Patients receive methylphenidate PO BID and undergo exercise program consisting of resistance training BIW and walking 15- 40 minutes a day 4 days a week for 12 weeks.
3483016|NCT03772834|Active Comparator|Group II (placebo, resistance training, stretching)|Patients receive a placebo PO BID and undergo exercise program consisting of resistance training BIW and walking 15-40 minutes a day for 4 days a week for 12 weeks.
3483017|NCT03772834|Active Comparator|Group III (methylphenidate, stretching)|Patients receive methylphenidate PO BID and undergo stretching for 4 days a week for 12 weeks.
3483018|NCT03772834|Active Comparator|Group IV (placebo, stretching)|Patients receive a placebo PO BID and undergo stretching for 4 days a week for 12 weeks.
3483019|NCT03772847|Experimental|ginkgolide group|ginkgolide plus alteplase
3483020|NCT03772847|No Intervention|control|alteplase
3483021|NCT03772886|Experimental|Peanut Ball Arm|Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
3483022|NCT03772886|No Intervention|Control Arm|Study participants randomized to the Control Arm will labor without the peanut ball.
3483023|NCT03772808|Experimental|Lycocomfort|The once-daily supplement LycoComfort™ is a combination of lycopene and beta-sitosterol, a chemically defined extract of phytosterols with beta-sitosterol as the main component,
3483024|NCT03772977|Experimental|Brain Health Champion (BHC)|"A health coach intervention with weekly phone calls"
3483025|NCT03772977|No Intervention|Standard of Care (SOC)|The current physician/provider counseling on brain health to reduce cognitive decline or incidence of cognitive impairment that occurs, per providers' own practice
3483026|NCT03773016|Experimental|Art apps - Group 1 (A-B)|Cross-over use of two different visual art apps on touchscreen tablets (App A and App B)
3483027|NCT03773016|Experimental|Art apps - Group 2 (B-A)|Cross-over use of two different visual art apps on touchscreen tablets (App B and App A)
3127783|NCT03110471||Glangarnant Care Home|This is a 'before and after' observational study involving 10 care homes, listed below as groups. The investigators will observe the changes in detection and management of adverse drug reactions between usual care and with administration of the West Wales ADR Profile. Usual care will be provided before and during the intervention period.
3483028|NCT03772795|Active Comparator|Group 1- Alignment with fixed appliance|"A pre-adjusted edgewise fixed appliance (3M Gemini Uniteks, 0.022 Roth prescription brackets.Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
3483029|NCT03772795|Experimental|Group 2- Alignment with clear aligners|Clear aligner orthodontic appliance (EON, Eon Dental NV, Belgium). Teeth alignment with clear aligners.
3483030|NCT03772951|Active Comparator|Cognitive Remediation Therapy|The study group received antipsychotic drugs Clozapine combined with Computerized Cognitive Remediation Therapy for 4 times/week for 45 minutes each time. For a total of 12 weeks. Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
3483031|NCT03772951|Placebo Comparator|Clozapine|Clozapine, dosage, dosage form, and frequency :300~600 mg/d; po; duration: 12 week.
3483032|NCT03772678|Placebo Comparator|Placebo|0.9% Saline For SAD and MAD arms.
3483033|NCT03772678|Experimental|Single Ascending Dose - Low Dose|LSALT peptide (1mg/mL in 0.9% saline) Single escalating dose - 0.01mg, 0.1mg, 0.3mg, 0.5mg intravenously Escalation to 2.5mg and 5mg doses in next cohorts if no adverse effects are seen after 10-14 days.
3483034|NCT03772678|Experimental|Single Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Single dose - 1mg intravenously over 2h Escalation to next dose in next participant every 72h if no adverse effects are seen.
3483035|NCT03772678|Experimental|Multiple Ascending Dose|LSALT peptide (1mg/mL in 0.9% saline) Dose will be determined based on results of SAD arm. LSALT will be administered intravenously once or twice daily for 3 days.
3127784|NCT03110471||Fieldbay Care Homes|All groups are having identical intervention, so the above text applies to all.
3127785|NCT03110471||Neuadd Drymmau Care Home|As above
3483036|NCT03772964|Experimental|500mg exposure|Subjects will be exposed to 500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
3483037|NCT03772964|Experimental|1000mg exposure|Subjects will be exposed to 1000mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
3483038|NCT03772964|Experimental|1500mg exposure|Subjects will be exposed to 1500mg of daily MetFORMIN Hydrochloride ER for up to 90 days.
3483039|NCT03772639|Experimental|Experimental group|The experimental group received a standard medical and pharmacological care in a daily format and shared decision making (SDM). The general framework of SDM was developed focusing on self-management goals which include education that addresses continuous use of medication, behavioral change, breathing training, learning to interpret changes in the disease and its consequences, and use of medical and community resources.
3483040|NCT03772639|No Intervention|Control Group|The control group received standard care and pharmacological care including systemic steroids, antibiotics, inhaled bronchodilators, and oxygen therapy.
3127786|NCT03110471||Monkstone House,|As above
3127787|NCT03110471||Danygraig House|As above
3127788|NCT03110471||Ty Coch|As above
3127789|NCT03110471||Swn y mor|As above
3127790|NCT03110471||Hengoed court|As above
3127791|NCT03110471||Hengoed park|As above
3127792|NCT03110471||Cefn Lodge care home|As above
3127793|NCT03110562|Active Comparator|selinexor+bortezomib+dexamethasone (SVd)|Selinexor will be given on Days 1, 8, 15, 22, and 29 of each 35-day cycle. Bortezomib will be given Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
3127794|NCT03110562|Active Comparator|bortezomib+dexamethasone (Vd)|Bortezomib will be given Days 1, 4, 8, and 11 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, bortezomib will be given on Days 1, 8, 15, and 22 of each 35-day cycle. Dexamethasone will be given on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle for the first 8 cycles. For cycles ≥ 9, dexamethasone will be given on Days 1, 2, 8, 9, 15, 16, 22, 23, 29, and 30 of each 35-day cycle.
3483041|NCT03772938|Active Comparator|Stem/progenitor cells transplantation|Intervention: A single intravitreal injection of autologous bone marrow-derived stem/progenitor cells will be performed.
3483042|NCT03772938|Sham Comparator|Standard treatment of degenerative disease of retina|Symptomatic treatment of degenerative disease of retina without biologic cell-based treatment
3483043|NCT03772912||Total Knee Arthroplasty Patients|Patients undergoing primary or revision total knee arthroplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
3483044|NCT03772613|Active Comparator|Low ACT Target|ACT target range of 225 to 275 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
3483045|NCT03772613|Active Comparator|Medium ACT Target|ACT target range of 275 to 325 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
3483046|NCT03772613|Active Comparator|High ACT Target|ACT target range of 325 to 375 seconds is achieved prior to PCI if no planned glycoprotein IIb/IIIa inhibitor used
3483047|NCT03772990|Experimental|Calcium chloride|Participants randomly assigned to the experimental group will receive 15 mg/kg of calcium chloride (bolus) intravenously during separation from cardiopulmonary bypass
3483048|NCT03772990|Placebo Comparator|0,9% Sodium Chloride|Participants randomly assigned to the placebo group will receive equivalent amount of placebo intravenously during separation from cardiopulmonary bypass
3483049|NCT03773003|Active Comparator|Arm 1: Tumor disease w/o fatigue|Group receiving probiotics.
3483050|NCT03773003|Placebo Comparator|Arm 2: Tumor disease w/o fatigue|Group receiving placebo (corn starch)
3483051|NCT03773003|Active Comparator|Arm 3: Healthy control group|Group receiving probiotics
3483052|NCT03773003|Placebo Comparator|Arm 4: Healthy control group|Group receiving placebo (corn starch)
3483053|NCT03772626|Experimental|Heated humidified high-flow|Heated Humidified High-flow Nasal Cannula
3483054|NCT03772496|Experimental|circulating tumor cells|circulating tumor cells test and FNAB will be performed at the same time
3483055|NCT03772600|Experimental|Dexcom G6|Use a Dexcom G6 CGM for 36 months
3483056|NCT03772600|No Intervention|FreeStyle Libre|"Keep using their FreeStyle Libre for 6 months. Before the 6 month time point is reached, patients will wear a blinded Dexcom G6 for 28 days, together with their FreeStyle Libre.~Cross-over to Dexcom G6 for 30 months."
3127795|NCT03110601|Active Comparator|Control - Conventional SCS|Conventional SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
3127796|NCT03110601|No Intervention|Washout Period|1 day where no stimulation is provided
3483057|NCT03772535|No Intervention|Control Group|Subjects in this arm will receive the standard postoperative pain prescription protocol.
3483058|NCT03772535|Active Comparator|Pharmacogenomics Guided Group|Subjects in this group will receive postoperative pain prescriptions based on the results of pharmacogenomic testing.
3483059|NCT03772418|Placebo Comparator|Cream base|A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.
3483060|NCT03772418|Active Comparator|Pomegrante and Ginkgo biloba group|A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.
3483061|NCT03772548||Patients with spinal cord injury|
3483062|NCT03772548||Healthy subjects|
3483063|NCT03772275|Active Comparator|New york Heart Association Class II-IV|New york Heart Association Class II-IV heart failure
3483064|NCT03772275|Active Comparator|New york Heart Association Class I|New york Heart Association Class I with no heart failure
3483065|NCT03772574|Experimental|THRIVE|THRIVE preoxygenation (tidal volume breathing with the OptiFlow system applied at 100% oxygen).
3483066|NCT03772574|Active Comparator|Facemask|Facemask preoxygenation (tidal volume breathing via a face mask set at 100% oxygen).
3483067|NCT03772483|Active Comparator|Control group|Local anesthesia with conventional syringe
3483068|NCT03772483|Active Comparator|Virtual reality group|Local anesthesia with conventional syringe + VR device
3483069|NCT03772366||Warfarine|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Warfarine
3483070|NCT03772366||Fluindione|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Fluindione
3483071|NCT03772366||Rivaroxaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Rivaroxaban
3483072|NCT03772366||Apixaban|Women in childbearing age treated for a venous thromboembolic disease with oral coagulant : Apixaban
3483073|NCT03772366||Control|Women in childbearing age with superficial venous insufficiency without treatment oral anticoagulant or antiplatelet.
3483074|NCT03772561|Experimental|AZD5363+Olaparib+Durvalumab|"A traditional 3+3 design will be used during the dose escalation part of the study.~Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities."
3483075|NCT03772353|Experimental|Pyrotinib Combined with Letrozole and SHR6390|Data from phase Ib showed the triplet of pyrotinib, SHR6390, and letrozole had an acceptable safety profile and encouraging efficacy, potentially offering a chemotherapy-sparing treatment option for patients with HER2-positive/HR-positive MBC. Based on DLTs and clinical efficacy, pyrotinib 320mg/d, SHR6390 125mg/d, and letrozole 2.5mg/d was declared as RP2D. The pharmacokinetic analysis had not yielded conclusive results and would involve more samples in phase II trial.
3483076|NCT03772184|Active Comparator|cervical inversion|
3483077|NCT03772184|No Intervention|no cervical inversion|
3483078|NCT03772470|No Intervention|Control|No airtime incentive was given for completing the survey
3483079|NCT03772470|Experimental|1X Incentive|1X airtime incentive
3483080|NCT03772470|Experimental|2X incentive|2X airtime incentive
3483081|NCT03772470|Experimental|Lottery Incentive|Lottery airtime incentive given to one in 20 participants
3483082|NCT03772314|Active Comparator|Modafinil|Participants in this study arm will take modafinil.
3483083|NCT03772314|Experimental|Amphetamine-dextroamphetamine|Participants in this study arm will take amphetamine-dextroamphetamine (amphetamine salts).
3483084|NCT03772431|Experimental|Male Informational|Male voice, informational introduction
3483085|NCT03772431|Experimental|Male Motivational|Male voice, motivational introduction
3483086|NCT03772431|Experimental|Female Informational|Female voice, informational introduction
3483087|NCT03772431|Experimental|Female Motivational|Female voice, motivational introduction
3483088|NCT03772249|Experimental|Cohort A1 DCR-HBVS|Single dose, Subcutaneous injection of 0.1mg/kg of DCR-HBVS (HV)
3483089|NCT03772249|Placebo Comparator|Cohort A1 Placebo|Single dose, Subcutaneous injection of 0.1mg/kg of Placebo for DCR-HBVS (HV)
3483090|NCT03772249|Experimental|Cohort A2 DCR-HBVS|Single dose, Subcutaneous injection of 1.5mg/kg of DCR-HBVS (HV)
3483091|NCT03772249|Placebo Comparator|Cohort A2 Placebo|Single dose, Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS (HV)
3483092|NCT03772249|Experimental|Cohort A3 DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of DCR-HBVS (HV)
3483093|NCT03772249|Placebo Comparator|Cohort A3 Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (HV)
3483094|NCT03772249|Experimental|Cohort A4 DCR-HBVS|Single dose, Subcutaneous injection of 6mg/kg of DCR-HBVS (HV)
3483095|NCT03772249|Placebo Comparator|Cohort A4 Placebo|Single dose, Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS (HV)
3483096|NCT03772249|Experimental|Cohort A5 DCR-HBVS|Single dose, Subcutaneous injection of 12mg/kg of DCR-HBVS (HV)
3483097|NCT03772249|Placebo Comparator|Cohort A5 Placebo|Single dose, Subcutaneous injection of 12mg/kg of Placebo for DCR-HBVS (HV)
3483098|NCT03772249|Experimental|Cohort B DCR-HBVS|Single dose, Subcutaneous injection of 3mg/kg of for DCR-HBVS (NUC naïve, CHB)
3483099|NCT03772249|Placebo Comparator|Cohort B Placebo|Single dose, Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS (NUC naïve, CHB)
3483100|NCT03772249|Experimental|Cohort C1 DCR-HBVS|4 doses- Subcutaneous injection of 1.5mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483101|NCT03772249|Placebo Comparator|Cohort C1 Placebo|4 doses- Subcutaneous injection of 1.5mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483102|NCT03772249|Experimental|Cohort C2 DCR-HBVS|4 doses- Subcutaneous injection of 3mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483103|NCT03772249|Placebo Comparator|Cohort C2 Placebo|4 doses- Subcutaneous injection of 3mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483104|NCT03772249|Experimental|Cohort C3 DCR-HBVS|4 doses- Subcutaneous injection of 6mg/kg of DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483105|NCT03772249|Placebo Comparator|Cohort C3 Placebo|4 doses- Subcutaneous injection of 6mg/kg of Placebo for DCR-HBVS administered every 28 days (NUC experienced, CHB)
3483106|NCT03772249|Experimental|Cohort 4C DCR-HBVS|"1 dose- Subcutaneous injection of 100mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 200mg (NUC experienced, CHB)~1 dose- Subcutaneous injection of 400mg (NUC experienced, CHB)"
3127797|NCT03110601|Experimental|Test - Stimgenics SCS|Stimgenics SCS parameters for 4 days plus/minus 1 day using an external SCS modulator.
3127798|NCT03110692|No Intervention|Usual practice (control)|The usual practice group will rollover to the intervention arm after 3 months.
3483107|NCT03772249|Experimental|Cohort 5C1 DCR-HBVS|4 doses- Subcutaneous injection of 200mg administered every 4 weeks (NUC experienced, CHB)
3483108|NCT03772249|Experimental|Cohort 5C2 DCR-HBVS|2 doses- Subcutaneous injection of 200mg administered every 8 weeks (NUC experienced, CHB)
3483109|NCT03772249|Experimental|Cohort 5C3 DCR-HBVS|2 doses- Subcutaneous injection of 400mg administered every 12 weeks (NUC experienced, CHB)
3483110|NCT03772444|Active Comparator|Beetroot juice|
3483111|NCT03772444|Placebo Comparator|Control group 1|
3483112|NCT03772444|Sham Comparator|Control group 2|
3483113|NCT03772262|Experimental|Control|Study subjects will be administered a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one rosuvastatin tablet (10 mg) by mouth. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
3483114|NCT03772262|Experimental|Treatment|Study subjects will be administered goldenseal 2 capsules (500 mg each) three times daily for 5 days. On day 6, subjects will be administered goldenseal 2 capsules (500 mg each), a single dose of midazolam syrup (2.5 mg), metformin solution (50 mg), furosemide solution (1 mg), and one tablet (10 mg) rosuvastatin. Goldenseal 2 capsules (500 mg each) will be administered approximately 4 and 8 hours later. Plasma will be collected from 0-96 hours. Urine will be collected from 0-24 hours.
3483115|NCT03772379|Experimental|tooth borne hyrax expander group|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars .
3483116|NCT03772379|Experimental|tooth borne hyrax expander with microosteoperforation|patients of this group will receive a tooth borne hyrax expander anchored to the first premolars and first permanent molars and microosteoperforation .
3483117|NCT03772405|Experimental|Nascum Plus and ACC|In a cross-over design, patients are exposed to pollen in the ACC twice for 4 hours each 3 weeks apart. Subjects will receive treatment with Nascum Plus either 5 minutes before the first or the second 4 hour pollen challenge.
3483118|NCT03772340|Experimental|Tradipitant|
3483119|NCT03772340|Placebo Comparator|Placebo|
3483120|NCT03772288|Experimental|Dose Escalation: TAK-659 + NKTR-214|TAK-659 tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 in a 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participant. The dose escalation phase will determine the MTD or RP2D of TAK-659. Dose escalation of TAK-659 will be based on available safety and tolerability data.
3483121|NCT03772288|Experimental|Safety Expansion: TAK-659 + NKTR-214|TAK-659, tablet, orally, once daily along with NKTR-214, infusion, intravenously, once on Day 1 of 21-day treatment cycle, until disease progression, unacceptable toxicities, or discontinuation by participants. TAK-659 and NKTR-214 MTD/RP2D will be determined from the dose escalation phase.
3483122|NCT03772132|Experimental|Chemotherapy|The patients wil receive conventional chemotherapy FORFIRINOX
3483123|NCT03772223|Experimental|Treatment sequence 1 (ABC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027) , Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3127799|NCT03110692|Experimental|Intervention|Default initiation: Introduce a default prescription template in the palliative setting in order to reduce unnecessary daily image guided radiation.
3127800|NCT03110770|Experimental|Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 injections|Zika virus wildtype (ZIKVwt) DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered intramuscularly (IM) by a needle-free injection device
3127801|NCT03110770|Experimental|Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
3127802|NCT03110770|Experimental|Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 4 limbs (both arms and legs) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 8 mg of vaccine administered IM by a needle-free injection device
3483124|NCT03772223|Experimental|Treatment sequence 2 (BCA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3483125|NCT03772223|Experimental|Treatment sequence 3 (CBA)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), and Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3483126|NCT03772223|Experimental|Treatment sequence 4 (ACB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3127803|NCT03110770|Experimental|Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 injections|ZIKVwt DNA vaccine (VRC-ZKADNA090-00-VP), in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 4 mg of vaccine administered IM by a needle-free injection device
3127804|NCT03110770|Placebo Comparator|Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 injections|Sterile phosphate-buffered saline (PBS) (VRC-PBSPLA043-00-VP), the placebo, in 2 limbs (both arms) on Day 0, Day 28 (+/-7 days), and Day 56 (-7/+14 days); 1 mL of placebo administered IM by a needle-free injection device
3483127|NCT03772223|Experimental|Treatment sequence 5 (BAC)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3483128|NCT03772223|Experimental|Treatment sequence 6 (CAB)|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence consist of Treatment C (Albuterol Sulfate metered dose inhaler [AS MDI] - PT007), Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler [BDA MDI] - PT027), and Treatment B (Budesonide metered dose inhaler [BD MDI] - PT008). Each randomized participant will receive a single-dose (2 inhalations) on Day 1 of this Treatment Period.
3483129|NCT03772119||Surgical treatment of hemivertebra|cohort of children with a vertebral malformation treated by surgical resection
3483130|NCT03772210|Active Comparator|Current Intensity 1 mA|tDCS will be administered at an intensity of 1 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
3483131|NCT03772210|Sham Comparator|Sham 1 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1 mA tDCS.
3483132|NCT03772210|Active Comparator|Current Intensity 1.5 mA|tDCS will be administered at an intensity of 1.5 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
3483133|NCT03772210|Sham Comparator|Sham 1.5 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 1.5 mA tDCS.
3483134|NCT03772210|Active Comparator|Current Intensity 2 mA|tDCS will be administered at an intensity of 2 mA to locations F3-F4, and fMRI response during performance of a 3-back/0-back memory task will be assessed.
3483135|NCT03772210|Sham Comparator|Sham 2 mA|Determine fMRI response during performance of a 3-back/0-back memory task with sham 2 mA tDCS.
3483136|NCT03772210|Experimental|Structural, Diffusion and MREIT Imaging|"Structural and High angular resolution diffusion weighted imaging will be performed.~Magnetic Resonance Electrical Impedance Tomography imaging will be performed using electrode locations F3-F4."
3483137|NCT03772106|Experimental|Group P|Group P : Propolipid 1% dose : variable to keep BIS between 40 and 60
3483138|NCT03772106|Experimental|Group S|Group S : Sevoflurane dose : variable to keep BIS between 40 and 60
3483139|NCT03772509|Experimental|CATI|Introduction and consent via computer assisted telephone interview
3483140|NCT03772509|No Intervention|IVR|Introduction and consent via interactive voice response
3483141|NCT03772054|Active Comparator|Propofol|After spinal anesthesia, patients in this arm will receive an intravenous target controlled infusion to site effect (TCI/Ce) infusion of propofol to achieve hypnosis guided to a bispectral index (BIS) level of 40-60 during surgery.
3483142|NCT03772054|Experimental|Sevoflurane|After spinal anesthesia, patients in this arm will receive an inhalation induction with sevoflurane to achieve hypnosis guided to 0.7-0.9 minimum alveolar concentration (MAC) during surgery.
3483143|NCT03771820|Experimental|NC-6004 +pembrolizumab|"NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.~In phase IIa portion, NC-6004 dose goes up from 90 mg/m2 up to 135 mg/m2. In phase IIb portion, the dose should be the determined RPII dose in phase IIa portion."
3483144|NCT03771820|Active Comparator|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
3483145|NCT03771833|Other|Main MARIA scan visit|For Arm 1, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 1 participants will receive study information that they will be sent home with and informed that they will be approached via a telephone call in 2-3 days (or the closest working day to that date) to enquire if they would like to schedule an appointment for the study visit. If so, this will be scheduled to occur around 7 days from the date of the phone call.
3483146|NCT03771833|Other|Same-day MARIA scan visit|"For Arm 2, participants will be identified in clinic as having a suitable symptomatic breast and approached about the study. They will have the study design explained to them and will be informed that they are under no obligation to participate. Arm 2 participants will receive study information and as much time as possible to consider their involvement with the study (at least 1 hour). If the patient agrees to participate, they will be scheduled to have their MARIA scans at a time that suits their commitments that day.~This arm also includes the 2b group, who can optionally consent to a dielectric constant reading of their routinely-aspirated cyst fluid before this is disposed of as per usual site process."
3483147|NCT03771846|Experimental|Hepatic artery infusion chemotherapy|Participants received hepatic artery infusion chemotherapy of irinotecan, oxaliplatin, 5-fluorouracil and leucovorin
3483148|NCT03771846|Active Comparator|Systemic chemotherapy|Participants received systemic chemotherapy of gemcitabine and oxaliplatin
3483149|NCT03771911|Other|AED guided|"Laypeople will be guided by an Automatic External Defibrillator's (AED) voice instructions during the cardiopulmonary resuscitation.~No other help is available."
3483150|NCT03771911|Other|Telephone guided|"Laypeople will be guided by telephone assistance (from an Emergency Call Center) during the cardiopulmonary resuscitation.~AED voice instructions are also available."
3483151|NCT03771755|Active Comparator|Ibuprofen group|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
3483152|NCT03771755|Placebo Comparator|Acetaminophen group|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
3483153|NCT03771950|Experimental|Intervention group|Early team based neuro-rehabilitation after Traumatic Brain Injury
3483154|NCT03771950|No Intervention|Control group|Treatment as usual.
3483155|NCT03771742|Active Comparator|transverse TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
3483156|NCT03771742|Experimental|paramedian sagittal TMQLB|Patients in this group will receive the transmuscular quadratus lumborum block before surgery using the para-sagittal scan, in-plain, caudal to cephalic approach.0.6ml 0.375% ropivocaine was injected when the correct needle location is confirmed.
3483157|NCT03771898|Experimental|SHP611|Participants will receive 150 milligrams (mg) of SHP611 intrathecally (IT) via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once weekly for 210 weeks.
3483158|NCT03771989|Active Comparator|Intervention|Patients are treated with an intra articular injection with autologous, micro-fragmented adipose tissue.
3483159|NCT03771989|Placebo Comparator|Control|Patients are treated with an intra articular injection with saline (placebo).
3483160|NCT03771729|Experimental|LCZ696 treatment|LCZ696 200mg twice daily
3127805|NCT03111108|Experimental|Arm 1: EBR/GZR for 8 Weeks|Treatment-naïve participants with stage 0-2 fibrosis (F0-F2) receive FDC of EBR/GZR (50 mg/100 mg) for 8 weeks, with 24 weeks of follow-up.
3127806|NCT03111108|Experimental|Arm 2: EBR/GZR for 12 Weeks|Treatment-naïve participants with F0-F2 stage fibrosis, treatment-naïve participants with F3-F4 stage fibrosis, and treatment-experienced participants with F0-F4 stage fibrosis receive FDC of EBR/GZR (50 mg/100 mg) for 12 weeks, with 24 weeks of follow-up.
3127807|NCT03111316|Other|Foley Catheter & Dinoprostone Insert|transcervical Foley catheter and an intravaginal dinoprostone controlled release insert
3483161|NCT03771976||Over 35 years of age|Primiparous women over 35 years of age.
3483162|NCT03771976||Between 20-34 years of age|Primiparous women between 20 and 34 years of age.
3483163|NCT03771937|Experimental|Intervention|Intervention group received a telephone follow-up intervention, which consisted of a pre-discharge education program and three telephone follow-up sessions based on the RAM.
3483164|NCT03771937|No Intervention|Control group|the control group received routine care.
3483165|NCT03772067|Experimental|MBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will contain 38 g protein mostly from milk and dairy products.
3483166|NCT03772067|Active Comparator|OBdiet|This arm consist on 3 month on Bdiet with high energy and protein breakfast (660 +/-20 kcal), medium sized lunch (580+/-20 kcal) and dinner reduced in energy (300+/-20 kcal), with distribution of calories: breakfast 44%, lunch 37% and dinner 19%. The breakfast will 38 g protein without milk or dairy products mostly from other proteins, i.e. eggs, tuna, soy, oatmeal. Milk product will be avoided in this diet also in other meals along the day.
3483167|NCT03771794|Active Comparator|Active Comparator: ReguRate RR2 active|Device: ReguRate neurostimulation device
3483168|NCT03771794|Sham Comparator|Sham Comparator: ReguRate RR2 sham.|Device: Sham ReguRate neurostimulation - mock sham stimulation mode
3483169|NCT03771716|Experimental|African Dance|This is the experimental group. Dance classes will be held 3 times per week for 1 hour. Participants will learn traditional Africana dance moves and sequences.
3483170|NCT03771716|Active Comparator|African Cultural Immersion|This is the active control group. Participants will participate in a variety of educational activities related to African Culture, including traditional cooking, lectures, crafts, music and films. They will meet 3 times per week for the same duration as the Dance group. However, they will not participate in aerobic activity during the classes, and most activities will be conducted in a seated position.
3483171|NCT03771807|Placebo Comparator|Placebo & facial cleansing|"Maltodextrin and food coloring~Subjects will clean the right side of their face with a cosmetic instrument daily"
3483172|NCT03771807|Active Comparator|Beauty From Within & facial cleansing|"Study Product contains collagen hydrolysate, ceramide wheat extract oil and lutein~Subjects will clean the right side of their face with a cosmetic instrument daily"
3483173|NCT03771677|Active Comparator|Active Comparator:NAs group|"Active Comparator:nucleotide analogues(NAs)~patients continue to use NAs"
3127808|NCT03111316|Other|Foley Catheter Alone|a Foley catheter alone
3127809|NCT03111381|Experimental|Intervention Group|The intervention group in this study will receive a one-time dose of Ketorolac 30mg intravenously after undergoing general anesthesia. Because the participants will be under general anesthesia, they will not know if they received the medication. The surgeon will also be blinded to this. The anesthesiologist will not be blinded as he/she will deliver the agent and because the use of Toradol may alter their usage of other intra-operative agents and post-operative agents
3127810|NCT03111381|No Intervention|Non-Intervention Group|In the no-treatment group, participants will not receive a dose of intra-operative Ketorolac.
3483174|NCT03771677|Experimental|Experimental:PEG-IFN group|"Experimental: peg-interferon alfa-2a~patients switch to sequential peg-interferon α-2a"
3483175|NCT03771690|No Intervention|Control 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
3483176|NCT03771690|No Intervention|Control 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00).
3483177|NCT03771690|Experimental|Standardised meal 1|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
3483178|NCT03771690|Experimental|Standardised meal 2|After a 13 h overnight fast, participants will rest in the laboratory for the duration of the trial (09:00-11:00). A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
3483179|NCT03772015||Study|"Patients who had the operation of laparoscopic lateral mesh suspension for apical prolapse will have magnetic resonance imaging preoperatively and at postoperative 6th month"
3483180|NCT03772015||Control|Multiparous, sexually active participants who have grade 0 or 1 (asymptomatic if exists) prolapse will have magnetic resonance imaging as a control group
3483181|NCT03772028|No Intervention|conventional surgery|Primary cytoreductive surgery without HIPEC
3483182|NCT03772028|Experimental|HIPEC|Primary cytoreductive surgery with HIPEC with cisplatin
3483183|NCT03772002|Experimental|HCV screening|
3483184|NCT03771924|Experimental|inorganic phosphate|"Experimental intervention:~Single dose of orally administered 700 mg inorganic phosphate as sodium phosphate in combination with a standardized meal and blood sampling"
3483185|NCT03771924|Placebo Comparator|Placebo|Single dose of Sodium chloride in combination with a standardized meal and blood sampling
3483186|NCT03771781|Other|Empagliflozin Tablets|The test formulation is manufactured by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd.During the study session,subjects will be administered a single does of Empagliflozin Tablets 25mg after fasting and fed conditions.
3483187|NCT03771781|Other|Empagliflozin Tab 25 MG|The reference formulation is manufactured by Boehringer Ingelheim International GmbH.During the study session,subjects will be administered a single does of Empagliflozin Tab 25 MG after fasting and fed conditions.
3483188|NCT03771768|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide 0.1% 5 gm adhesive paste 4 times / day for 1 month.
3483189|NCT03771768|Experimental|Diode laser|Diode laser 980 nm & 100mWatt.
3483190|NCT03772080|Experimental|Early counseling of prematurity in high-risk pregnancies|
3483191|NCT03772080|No Intervention|Standard counseling of prematurity in high-risk pregnancies|
3483192|NCT03771872|Experimental|Virtual Prism Adaptation Therapy|This group will be provided with real virtual prism adaptation therapy. In the real therapy session, the hand trajectory will deviate to the right side in the virtual reality. The deviation angle will be adjusted according to the subject's adaptation. 20min-session will be provided twice a day for 5 days, then the total 10 sessions of therapy will be provided.
3483193|NCT03771872|Sham Comparator|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
3483194|NCT03771599|Active Comparator|Control group|"Routine physical therapy~[Time Frame: Twelve weeks]"
3483195|NCT03771599|Experimental|Intervention group|"Traditional massage + Routine physical therapy~[Time Frame: Twelve weeks]"
3483196|NCT03772093|Active Comparator|Patients with manual massage therapy|30 patients were randomly assigned to massage therapy. The procedures were performed for ten days, with weekend break. Manual massage of lumbar area was performed by certified massage therapist with the typical course of the procedure. The technique was consisted of stroking, kneading, grinding, patting and shaking. The procedure lasted twenty minutes.
3483197|NCT03772093|Active Comparator|Patients with Trabert current therapy|30 patients were randomly assigned to Trabert current therapy. The Trabert current was administered by 143 frequency, time of 2 ms impulse, time of break 5 ms. The current was generated by Pulsotronic ST-6D device (ZAMED©). The electric pads were placed on the lumbar area, in the middle part of spine. The anode in the lower part, near to buttocks. The intensity of current was regulated between 15-25 mA. The time of procedure lasted fifteen minutes.
3483198|NCT03771638|Experimental|DOT Diary Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
3483199|NCT03771638|Other|DOT Diary Control|Standard of care for Emtricitabine / Tenofovir Disoproxil Oral Tablet (once daily)
3483200|NCT03771404|Other|Operable (stages I-IIIA) NSCLC|For Operable (stages I-IIIA) NSCLC Patients, blood sampling and tissue samples of the primary tumor as well as the regional involved lymph nodes and, in selected patients, from biopsies from metastasis
3483201|NCT03771443|Experimental|gluten free toothpaste|experimental gluten free toothpaste with natural ingredients prepared for the study to be used 3 times per day for six months
3483202|NCT03771482|Active Comparator|Opioid module first then fluid|The providers in this arm will first receive daily information and questions related to opioid use for eight weeks and then daily information and questions related to intravenous fluid prescribing for five weeks.
3483203|NCT03771482|Active Comparator|Fluid module first then opioid|The providers in this arm will first receive daily information and questions related to intravenous fluid prescribing for five weeks and then daily information and questions related to opioid use for eight weeks.
3483204|NCT03771508||PillCam SB3 procedure|Subjects with normal/abnormal PillCam SB3 procedure
3483205|NCT03771378|Experimental|Effective of rhTPO|After enrollment, all subjects receive rhTPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
3483206|NCT03771378|Active Comparator|Effective of eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
3483207|NCT03771430|Experimental|Non-surgical group|Osteoarthritis education, exercise and eCBT
3483208|NCT03771430|Experimental|Combined group|Total knee arthroplasty + osteoarthritis education, exercise and eCBT
3483209|NCT03771430|Active Comparator|Surgery only (standard care)|Total knee arthroplasty + standard physiotherapy
3127811|NCT03111407|Other|iAssist group|patients will have primary total knee arthroplasty with the iAssist. The iAssist Knee System is a computer assisted stereotaxic surgical instrument system to assist the surgeon in the positioning of orthopedic implant system components intra-operatively. It involves surgical instruments and position sensors to determine alignment axes in relation to anatomical landmarks and to precisely position alignment instruments and implant components relative to these axes.
3483210|NCT03771469|Experimental|Questionnaires and sleep studies|Caregivers of patients meeting eligibility criteria will be invited to participate. If they agree to participate, baseline SRBD-PSQ, OSA-18, and PedsQL questionnaires along with written informed consent forms will be mailed to them along with their standard scheduling paperwork. Caregivers will be asked to review the consent form and complete the questionnaires and bring the paperwork to clinic on the day of their visit. Sleep study testing will also be ordered prior to their visit so that it can be scheduled within a month of the initial clinic visit and again three months later.
3483211|NCT03771365||Standard-PCNL|Perform PCNL with ≥24 Fr access tract for the treatment of ≥2 renal stones
3483212|NCT03771365||Mini-PCNL|Perform PCNL with 12-20 Fr access tract for the treatment of ≥2 renal stones
3483213|NCT03771365||Super-mini PCNL|Perform SMP for the treatment of ≥2 renal stones
3483214|NCT03771547||More 80|The first group included ERCP patients aged 80 and above.
3483215|NCT03771547||Less 80|The second group included those ERCP patients younger than 80.
3483216|NCT03771573|Experimental|Home based intervention|will be submitted to a total of 24 sessions of an unsupervised Cardiovascular Physical Therapy protocol, composed of the following steps: warm up, proper training (aerobic training + muscle training for upper and lower limbs with theraband in 5 series with 10 repetitions) often three times a week for eight weeks.
3483217|NCT03771573|Placebo Comparator|Control group|Will not be submitted to the Cardiovascular Physiotherapy Rehabilitation protocol for unsupervised domiciliary, only monitorization of cardiovascular variables.
3483218|NCT03771573|Active Comparator|Professional seupervision based|eight weeks of supervised activities by professional. Each day and for 20 days (20 sessions), volunteers will undergo exercises on cycle ergometer during 30 minutes for upper and lower limbs
3483219|NCT03771586|Experimental|SAGE-718|
3483220|NCT03771586|Placebo Comparator|Placebo|
3483221|NCT03771534|Experimental|Oxygen gas|10-15 L/min of oxygen by face mask for up to 45 minutes for the MRI and up to 30 minutes for the echocardiogram.
3483222|NCT03771287|Experimental|OpenSound Navigator (OSN) Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the OpenSound Navigator algorithm enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
3483223|NCT03771287|Active Comparator|omni-directional Hearing Aid|Participants will be fit with Oticon OPN™ behind-the-ear hearing aids with the Omni-directional microphone system enabled. Participants are to use the hearing aids at least an average of 8 hours per day over the course of 6-8 months.
3483224|NCT03771248|Active Comparator|Co-cr telescopic partial denture|A removable partial denture, that gains retention from a telescopic crown made of cobalt chromium
3483225|NCT03771248|Experimental|PEEK telescopic partial denture|A removable partial denture, its attachment is a telescopic crown made of PEEK
3483226|NCT03771300|Experimental|Mindfulness condition|90-minute group sessions, held once a week over a space of 6 weeks, and is offered as an extra-curricular activity.
3483227|NCT03771300|Experimental|Mindfulness condition complemented by VR|This condition is equivalent to the mindfulness condition (group sessions, held once a week over a space of 6 weeks and offered as an extra-curricular activity), unlike the time of each session, which is reduced from 90 to 75 minutes of duration.
3483228|NCT03771300|Active Comparator|Relaxation condition|90-minute group sessions, held once a week over a space of 6 weeks, and will be offered as an extra-curricular activity.
3483229|NCT03771222|Experimental|Prophylactic DLI|The scheduled time of the first prophylactic DLI was +30 ~ +60 days after transplantation for HLA-matched sibling donors (MSD)-PBSCT recipients and +60 ~ +90 days after transplantation for HLA-haploidentical sibling donors (HID)-PBSCT recipients.
3483230|NCT03771222|No Intervention|No prophylactic DLI|
3483231|NCT03771339|Active Comparator|Continuous Epidural Analgesia|Continuous epidural analgesia using ropivacaine 0.375% 3 mL boluses followed by ropivacaine 0.2% with rate 6 mL per hour for 24 hours
3483232|NCT03771339|Experimental|Bilateral Quadratus Lumborum Block|Bilateral Quadratus lumborum block using ropivacaine 0.2% 20 mL each injection after surgery
3483233|NCT03771170|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
3483234|NCT03771170|Active Comparator|Ringer lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
3127812|NCT03111407|Other|conventional instrumentation|patients will have primary total knee arthroplasty with the conventional instrumentation.
3127813|NCT03111550|Other|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Tecnis Model ZHR00
3483235|NCT03771105|Experimental|Patients with hereditary hypophosphatemic rickets with HHRH|Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)
3483236|NCT03771105|Active Comparator|Patients with X-linked Hypophosphatemia|Patients with X-linked hypophosphatemia
3483237|NCT03771105|Active Comparator|15 Patients with X-linked Hypophosphatemia|15 Patients with X-linked Hypophosphatemia that will receive phosphate treatment for 30 days.
3127814|NCT03111550|Other|Investigational Lens Device #2|Investigational Intraocular Lens Device #2: Tecnis Model ZQR00
3127815|NCT03111550|Other|Control Device|Control TECNIS Symfony® Extended Range of Vision Intraocular Lens: Model ZXR00
3483238|NCT03771105|Active Comparator|15 Patients Hereditary hypophosphatemic rickets with HHRH|15 patients withHereditary hypophosphatemic rickets with hypercalciuria (HHRH) that will receive phosphate treatment for 30 days.
3483239|NCT03771261|Placebo Comparator|WL-Control|Weight loss intervention (WL-Control; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, protein~0.8g/g/d.
3483240|NCT03771261|Active Comparator|WL-Protein|High-protein weight loss intervention (WL-Protein; n = 20): Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of high quality protein at each meal. Intakes of > 30g of protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal sources (high quality) and 60-70% of animal protein from eggs or egg protein powder that will be provided to WL-Protein participants.
3127816|NCT03111628|Other|Omalizumab|Omalizumab 300mg every month for 3 doses
3483241|NCT03771235|Experimental|Mindfulness-based Intervention for Tics|8-week group-based mindfulness-based program
3127818|NCT03111940|Experimental|PCI optimisation|Post PCI FFR below 0.9
3127819|NCT03111940|No Intervention|No PCI optimisation|Post PCI FFR 0.9 or higher
3483242|NCT03771235|Active Comparator|Tic Information and Coping Strategies|8-week group-based educational and supportive therapy program
3483243|NCT03770988|Experimental|poziotinib single arm study|Single Arm study
3483244|NCT03770897|Experimental|3D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed with 3d technology device by young surgeons, tutored by an expert assistant.
3483245|NCT03770897|Active Comparator|2D laparoscopic appendectomy.|Laparoscopic appendectomy will be performed by young surgeons (tutored by an expert assistant) with the standard 2D viewing method.
3483246|NCT03771144|Experimental|Experimental|
3483247|NCT03771131|Experimental|Experimental group|Group receiving the multi-domain cognitive training
3483248|NCT03771131|No Intervention|Control group|Passive control group
3483249|NCT03771196|Experimental|Bioactive-Restorative material|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
3483250|NCT03771196|Active Comparator|Resin Modified Glass Ionomer (RMGI)|Fuji II Lc, fluoride-releasing restorative system that combines fluoride release of glass ionomer cement and acceptable esthetics a wear-resistant, self-adhesive, light-cured resin coating.
3483251|NCT03771040|Experimental|Masitinib (titration to 6.0 mg/kg/day)|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
3483252|NCT03771040|Placebo Comparator|Placebo|Participants receive matched placebo
3483253|NCT03771157|Experimental|Shingrix shingles vaccine treatment|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
3483254|NCT03770910|Placebo Comparator|Placebo+placebo|Saline infusions
3483255|NCT03770910|Active Comparator|GIP+placebo|GIP(1-42), receptor agonist
3483256|NCT03770910|Experimental|GIP+dose 1|GIP(1-42) and lowest dose of GIP(3-30)NH2
3483257|NCT03770910|Experimental|GIP+dose 2|GIP(1-42) and dose of GIP(3-30)NH2
3483258|NCT03770910|Experimental|GIP+dose 3|GIP(1-42) and dose of GIP(3-30)NH2
3483259|NCT03770910|Experimental|GIP+dose4|GIP(1-42) and highest dose of GIP(3-30)NH2
3127820|NCT03112473|Active Comparator|Bilateral TENS (Bi-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral electrical stimulation
3483260|NCT03770962|Experimental|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will observe the birth or give any assistance needed."
3483261|NCT03770962|No Intervention|One midwife|This is standard care. One midwife is responsible for the care of the woman and her unborn baby during labor and birth.
3483262|NCT03771014|Experimental|Early mobility|Patients will receive standard physiotherapy regimen plus 2 x 30 minute rehabilitation sessions 5 days per week.
3483263|NCT03771014|No Intervention|Standard care|Patients will receive standard physiotherapy regimen
3483264|NCT03771066|Experimental|Diet plus bisphenol A|Participants will receive a 4-day diet plus bisphenol A at 50 ug/kg body weight.
3127821|NCT03112473|Placebo Comparator|Unilateral TENS (uni-TENS) group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with unilateral electrical stimulation on paretic side and sham electrical stimulation on the non-paretic side
3127822|NCT03112473|Placebo Comparator|Placebo group|All subjects will undergo 20 sessions of their assigned intervention (60 minutes, thrice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented upper limb training (TOT) with bilateral sham electrical stimulation
3483265|NCT03771066|Placebo Comparator|Placebo|Participants will receive a 4-day diet plus no bisphenol A.
3483266|NCT03771092|Experimental|Patients with non-severe anemia treated with SunActive®Fe|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with SunActive®Fe micronized
3483267|NCT03771092|Experimental|Patients with non-severe anemia treated with Lipofer®|Patients with non-severe anemia Hb> 10 g/dl (Hb <12 g/dl for women and Hb <13 g/dl for men), treated with Lipofer®
3483268|NCT03771092|Experimental|Patients with severe anemia with Lipofer®|Patients with severe anemia (Hb <10 g/dl) treated respectively with Lipofer®
3483269|NCT03771092|Experimental|Patients with severe anemia with SunActive®Fe|Patients with severe anemia (Hb <10 g/dl) treated respectively with SunActive®Fe micronized
3483270|NCT03771092|Experimental|Patients with severe anemia with intravenous ferric gluconate|Patients with severe anemia (Hb <10 g/dl) treated respectively with intravenous ferric gluconate according to departmental protocols
3483271|NCT03771326|Experimental|obese men|To the 7 obese men, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
3483272|NCT03771326|Experimental|Normal men|To the 7 normal BMI mean, kisspeptin-10 was intravenously administered (0.5µg/kg BW, prepared under sterile conditions), as a bolus in a volume of 1ml. Blood samples from all the individuals were collected for 30 minutes pre and 120 minutes post-KP-10 administration, at 30 minutes interval. The obtained blood was centrifuged and the plasma insulin was measured by ELISA.
3483273|NCT03771001|Other|Convenience sample participants|In this feasibility study all participants will receive the intervention.
3483274|NCT03771209|Experimental|ultrasound assessment|The aim of this study is the creation of a five-step ultrasound examination to evaluate and monitor HF patients during hospitalization and short follow-up.
3127823|NCT03112473|No Intervention|Control group|No Active intervention
3127824|NCT03112863|Experimental|Bakuchiol|Bakuchiol 0.5% applied to face twice daily
3127825|NCT03112863|Active Comparator|Retinol|0.5% retinol applied to face nightly
3127826|NCT03112993|Experimental|Sugammadex group|2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
3483275|NCT03771495|Experimental|Hip Joint Mobilization|passive accessory movement on femur in anterior/posterior direction, grade III for four minutes and passive physiological movement of the most restricted hip joint movement, grade III for one minute (without pain), and a verbal education of hypothesized underlying effect mechanisms.
3483276|NCT03771495|Sham Comparator|Laying on of Hands|grade I, very small amplitude without encountering any tissue resistance for five minutes, thus effectively a Laying on of Hands, with a verbal education of hypothesized underlying effect mechanisms.
3483277|NCT03771651|Experimental|Aspirin|Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
3127827|NCT03112993|Active Comparator|Neostigmine group|"50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight."
3127828|NCT03113656|Experimental|Weighted Blanket First|This group will receive the Weighted Blanket first and then the Non-weighted blanket
3127829|NCT03113656|Experimental|Non-weighted Blanket First|This group will receive the Non-weighted Blanket first and then the Weighted blanket
3127830|NCT03113916|Experimental|Behavioral|26 weekly behavioral intervention sessions 6 monthly behavioral intervention sessions Sessions focused on diet, physical activity, behavior change
3127831|NCT03113916|No Intervention|Enhanced usual care|Printed materials
3127832|NCT03114124|Active Comparator|Bipolar Ablation Catheter|Subjects will be randomized by random computer programming to receive standard ablation catheter for their procedure.
3127833|NCT03114124|Experimental|MIFI Ablation Catheter|Subjects will be randomized by random computer programming to receive an ablation with MIFI technology. MIFI Catheter contains tightly spaced multielectrode pattern
3127834|NCT03114488|Experimental|Anodal Stimulation|
3127835|NCT03114488|Sham Comparator|Sham Stimulation|
3127836|NCT03114657|Placebo Comparator|Placebo|Participants received intravenous (IV) infusion of Placebo every 4 weeks (Q4W) for 100 weeks.
3127837|NCT03114657|Experimental|Crenezumab|Participants received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W) for 100 weeks.
3127838|NCT03114683|Experimental|IBI308|
3127839|NCT03114969||Subjects using RELVAR ELLIPTA|Subjects with a fixed dose combination of inhaled corticosteroids/ long-acting beta agonists (ICS/LABA) via a single DPI of RELVAR ELLIPTA for treatment of COPD will be included.
3127840|NCT03114969||Subjects using SYMBICORT TURBUHALER|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SYMBICORT TURBUHALER for treatment of COPD will be included.
3127841|NCT03114969||Subjects using SERETIDE DISKUS|Subjects with a fixed dose combination of ICS/LABA via a single DPI of SERETIDE DISKUS for treatment of COPD will be included.
3127842|NCT03114969||Subjects using SPIRIVA HANDIHALER|Subjects with a fixed dose monotherapy of long-acting muscarinic antagonists (LAMA) via a single DPI of SPIRIVA HANDIHALER for treatment of COPD will be included.
3483278|NCT03770923|No Intervention|No intervention|No intervention
3483279|NCT03770923|Active Comparator|Rupatadine|Rupatadine 10 mg once daily.
3483280|NCT03770923|Active Comparator|Montelukast|Montelukast 10 mg daily
3483281|NCT03770819|Placebo Comparator|Placebo group|Application of placebo gel followed by sham Photodynamic therapy
3483282|NCT03770819|Active Comparator|Zinc oxide gel group|Application of Zinc oxide gel followed by sham Photodynamic therapy.
3179657|NCT00675311|Active Comparator|DM-Standard|The conventional disease management group will receive management under the site's usual program offering, which includes, but is not limited to, compliance with the prescribed treatment regimens, dietary management, exercise programs, and other measures recommended by the American Diabetes Association (ADA) and the Association of American Endocrinologists (AACE).
3483283|NCT03770819|Experimental|PDT group|Application of placebo gel followed by Photodynamic therapy.
3483284|NCT03770819|Experimental|Zinc oxide and PDT group|Application of Zinc oxide gel followed by Photodynamic therapy.
3483285|NCT03770975|Active Comparator|Delayed implant placement with immediate provisionalization|Single delayed implant placement in the esthetic zone with placing an immediate temporary crown placed within 48 hours after the surgery
3483286|NCT03770975|Experimental|Implant with immediate temporization and soft tissue graft|Single delayed implant placement in the esthetic zone with placing a subepithelial connective tissue graft buccal to the implant and immediate temporary crown within 48 hours after the surgery
3483287|NCT03771625||single-group studies|All the patients received chemotherapy and radiotherapy.
3127843|NCT03114969||Subjects using INCRUSE ELLIPTA or ANORO ELLIPTA|Subjects with a fixed dose monotherapy of LAMA via a single DPI of INCRUSE ELLIPTA or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ANORO ELLIPTA for treatment of COPD will be included.
3127844|NCT03114969||Subjects using SEEBRI BREEZHALER or ULTIBRO BREEZHALER|Subjects with a fixed dose monotherapy of LAMA via a single DPI of SEEBRI BREEZHALER or subjects taking a fixed dose combination of LAMA/LABA via a single DPI of ULTIBRO BREEZHALER for treatment of COPD will be included.
3483288|NCT03770858||Crisaborole and wearable sensor|Subjects will apply topical crisaborole twice daily to the affected atopic dermatitis areas for three weeks.
3483289|NCT03770871|Active Comparator|IPT using Dycal (TM )|Indirect pulp treatment; IPT using Dycal (TM ); (2 paste system) by partial caries removal
3483290|NCT03770871|Experimental|IPT using Vitrebond (TM )|Indirect pulp treatment; IPT using Vitrebond (TM );(powder and liquid) by partial caries removal
3483291|NCT03770936|No Intervention|Control group|No intervention
3483292|NCT03770936|Active Comparator|Candesartan|Candesartan 8 mg/day
3127845|NCT03114969||Subjects using RELVAR ELLIPTA with HANDIHALER/ INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via RELVAR ELLIPTA along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
3127846|NCT03114969||Subjects using TURBUHALER with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SYMBICORT TURBUHALER along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
3127847|NCT03114969||Subjects using DISKUS with HANDIHALER/INCRUSE ELLIPTA|Subjects with a fixed dose combination of ICS/LABA via SERETIDE DISKUS along with a fixed dose of LAMA via SPIRIVA HANDIHALER or INCRUSE ELLIPTA will be included.
3127848|NCT03114995|Experimental|Group A (high platelet reactivity - tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban administered dose: 0.4 μg/kg/min continuous infusion for 30 min and then 0.10 μg/kg/min continuous infusion for 12 h
3483293|NCT03770936|Active Comparator|Ramipril|Ramipril 1.25 mg/day
3483294|NCT03770806|Experimental|Femoral Nerve Block|Standard Ultrasound-guided femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
3483295|NCT03770806|Experimental|Adductor Canal Nerve Block|Standard Ultrasound-guided adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg. These subjects will also receive the standard multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg.
3483296|NCT03770806|Experimental|No Block|For subjects who choose to have medication alone with no block for their routine care, there will be no changes to their care, which includes receiving the multimodal oral premedication of Celebrex 300-400mg, Tylenol 1000mg, and Oxycontin 10mg. They will be in an observational group only with no randomization.
3483297|NCT03770754|Experimental|Control group|"Control Group (n= 15): the root canals were prepared manually with K-files (Dentsply-Maillefer, Ballaigues, Switzerland) and step back technique up to size #35."
3483298|NCT03770754|Experimental|Group 1|Group 1 (n= 15): the root canals were instrumented with rotary LightSpeed LSX instruments (Discus Dental, Culver City, CA, USA). They were used to complete the canal preparation to a size #50 for the anteriors and molar teeth to size #40.
3483299|NCT03770754|Experimental|Group 2|Group 2 (n= 15): root canals were instrumented with ProTaper Next (Dentsply Maillefer, Ballaigues, Switzerland) using X1, X2 to X3. 0.5% NaOCl was used for irrigation.
3483300|NCT03771027|Experimental|Low FODMAP diet group|four weeks of the low FODMAP diet based on Monash University low FODMAP diet App.
3483301|NCT03771027|Active Comparator|Control group|four weeks of the diet based on NICE guidelines and contained products with different FODMAP content
3483302|NCT03771053|Experimental|Ezetimibe with simvastatin group|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
3483303|NCT03771053|Active Comparator|Simvastatin group|simvastatin 40mg everyday for 12 months after PCI
3483304|NCT03770780|Experimental|SAGE-718|
3483305|NCT03770780|Placebo Comparator|Placebo|
3483306|NCT03770793|Experimental|Lung-sono guided|Before starting one-lung ventilation, alveolar recruitment is performed under the examination with ultrasound. Find the minimal airway pressure that actually starts to resolve the observed atelectasis. Repeat alveolar recruitment with the minimal pressure untill the atlelectasis is not visible.
3483307|NCT03770793|No Intervention|Conventional|Before starting one-lung ventilation, alveolar recruitment is performed with the pressure of 30mmHg for 10 seconds which is a conventional method.
3483308|NCT03770429|Experimental|AZD6738|Patients will receive AZD6738 orally on a 28-day cycle
3127849|NCT03114995|No Intervention|Control C1 (high platelet reactivity - no tirofiban)|Patients with high platelet reactivity unit (230 or higher) Tirofiban was not administered
3483309|NCT03770416|Experimental|Cohort A|Patients receive ibrutinib PO daily on days 1-28. Beginning course 1, patients also receive nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
3483310|NCT03770416|Experimental|Cohort B|Patients receive ibrutinib PO daily on days 1-28 and nivolumab IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve at least a partial response after 6 courses may continue therapy for up to 2 years.
3483311|NCT03770702|No Intervention|Control group|No intervention
3483312|NCT03770702|Active Comparator|Angiotensin receptor blockers|ARB ( Angiotensin receptor blockers) + Traditional therpy.
3483313|NCT03770702|Active Comparator|Statins|Statin + Traditional therapy.
3483314|NCT03770572|Experimental|Open-label, single-dose, dose-escalation study of AT-GTX-502|"Cohort 1: AT-GTX-502 Low-Dose~Cohort 2: AT-GTX-502 High-Dose"
3483315|NCT03770520|Experimental|QFR-guided|This group will be performed a CABG surgery based on CAG and QFR, whether graft the moderate stenosis vessels will be based on the result of QFR.
3483316|NCT03770520|Active Comparator|Angio-guided|This group will be performed a CABG surgery only based on CAG, the final surgery strategy will be decided after the discussion of heart team.
3483317|NCT03770403|Experimental|ARGX-113|
3127850|NCT03114995|No Intervention|Control C2 (low platelet reactivity - no tirofiban)|Patients with low platelet reactivity unit (less than 230) Tirofiban was not administered
3127851|NCT03115112|Active Comparator|Bexagliflozin|Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
3127852|NCT03115112|Active Comparator|Sitagliptin|Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.
3483318|NCT03770559|Active Comparator|Open-RAMPS|Patients with pancreatic cancer treated by traditional open surgery
3483319|NCT03770559|Experimental|MI-RAMPS|Patients with pancreatic cancer treated by laparoscopic surgery
3483320|NCT03770585|Active Comparator|Group 1(Fluoroscopy guided group)|IN Fluoroscopy guided group, with x-ray beam, after cleaning and drapping and administration of local anesthesia, a22-g spinal needle is inserted in line till bony contact is felt under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.
3483321|NCT03770585|Active Comparator|Group2 (Ultrasound guided group)|In Ultrasound guided group, with Ultrasound guidance, , a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml(20mg) methylprednisolone acetate is administered intra-articular (until resistance was encountered) and injected around the posterior facet joint capsule.
3127853|NCT03115177|Active Comparator|Cefazolin|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The control group will not receive any further antibiotic treatment.
3127854|NCT03115177|Active Comparator|Doxycycline+Cefazolin Group|All patients will receive standard perioperative antibiotics with 2g of cefazolin within 1 hour of incision. The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision.
3483322|NCT03770455|Experimental|Avelumab + 2nd generation ADT|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
3483323|NCT03770481|Experimental|Assess the NLCS' feasibility|"Hypothesis: No significant differences will be observed in recruitment and attrition between NLCS intervention and control groups.~Approach: Determine rates of enrollment and drop-outs between groups."
3483324|NCT03770481|Experimental|Assess the NLCS' acceptability|"Hypothesis: More surrogates agree that the NLCS is suitable, appropriate, effective and willing to adhere versus treatment as usual (TAU) communication.~Approach: Assess outcome using the validated instrument, Client Satisfaction Questionnaire (CSQ-8)."
3127855|NCT03115411|Experimental|Winged stent|Placement of Winged stent for management of biliary obstruction. Stent to be placed for 90 days, with laboratory studies and clinical evaluation during this period to assess for stent potency.
3483325|NCT03770481|Experimental|Assess the NLCS' preliminary effects|Hypothesis: NLCS improves communication and decreases surrogates' psychological distress (e.g., anxiety and depression) Approach: Compare pre- and post-intervention scores of the Quality of Communication (QOC) questionnaire, Hospital Anxiety and Depression Scale (HADS), and Decisional Conflict Scale (DCS) between intervention and control groups.
3483326|NCT03770533|Other|MR-proADM guided|
3483327|NCT03770533|No Intervention|Standard Care|
3483328|NCT03770663|Experimental|European strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day"
3127856|NCT03115476|Experimental|Ingenol disoxate gel 0.018%|
3127857|NCT03115476|Experimental|Ingenol disoxate gel 0.037%|
3127858|NCT03115476|Placebo Comparator|Vehicle gel|
3127859|NCT03115580|Active Comparator|Rotational atherectomy|Rotational atherectomy (RA)
3127860|NCT03115580|Active Comparator|CBA/PTCA|Cutting Balloon Angioplasty (CBA) or Percutaneous transluminal coronary angioplasty (PTCA)
3127861|NCT03115801|Active Comparator|Arm A - immunotherapy alone|"Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64."
3127862|NCT03115801|Active Comparator|Arm B - Radiation & immunotherapy|Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.
3127863|NCT03115827|Experimental|Arm 1|Droxidopa 600mg by mouth twice a day and carbidopa 200mg by mouth twice a day for 4 weeks
3127864|NCT03116152|Experimental|IBI308|IBI308 200mg Intravenous drip every three weeks
3483329|NCT03770663|Experimental|American strategy|"3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12~In association with:~Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL."
3483330|NCT03770442|Experimental|Cycling with FES|"Ten sessions of 14 days in patients consented within 48 hours of arriving in critical care who are sedated and mechanically ventilated with a diagnosis of sepsis from any source.~Sessions last a maximum of 30 minutes (with an ideal minimum of 20 minutes), using the Restorative Therapies (RT) 300 Supine with the Sage 12-channel stimulator. Stimulation will provided to the quadriceps, hamstrings, calves and abdomen. Both legs and both sides of the abdomen will be stimulated. Stimulation current settings are individualised for each patient and each muscle group.~These patients will also receive their routine physiotherapy that they would have received if they were in the control group (or not in the trial at all)."
3483331|NCT03770442|Active Comparator|Control - routine physiotherapy|Usual daily physiotherapy, consisting of limb care and mobilisation, and respiratory care and exercises as appropriate.
3483332|NCT03770650|Experimental|IVUS-guided DK crush stenting|"In the IVUS-guided DK crush stenting group, IVUS will be before side branch stenting, after rewiring side branch, after 1st kissing balloon inflation, after rewiring side branch, after 2nd kissing balloon inflation.~For LM bifurcation lesions involving ostial LAD and LCX: minimum stent are (MSA) should be ≥10mm2 (LM), 7 mm2 (LAD), and 6 mm2 (LCX), with stent expansion index ≥90% (CSA≥90% of distal reference lumen area in LCX) and symmetry index >0.8.~For non-LM bifurcation lesion involving the MSA should be ≥6 mm2 in the main vessel; and the MSA in the ostial side branch should be ≥5 mm2 and ≥90% of distal reference lumen area; and symmetry index should be >0.8."
3483333|NCT03770650|Active Comparator|Angiography-guided DK crush stenting|In the Angiography-guided DK crush stenting group, stent diameter and length will be selected by visual estimation with a stent/artery ratio of 1.1:1.0. Post-dilation with a noncompliant balloon (balloon/stent diameter=1.0:1.0) inflated at >18 atm will be performed for all lesions. Angiographic success is defined as Thrombolysis In Myocardial Infarction (TIMI) grade 3, residual stenosis <20%, and the absence of ≥Type B dissection.
3483334|NCT03770611|Active Comparator|Probiotic|Subjects receiving probiotic supplementation: 2x108 CFU probiotic bacteria + prebiotic placebo per day during 3 months
3483335|NCT03770611|Active Comparator|Prebiotic|Subjects receiving prebiotic supplementation: 20 g of prebiotic fiber + probiotic placebo per day during 3 months
3483336|NCT03770611|Experimental|Symbiotic|Subjects receiving probiotic and prebiotic supplementation: 2x108 CFU probiotic bacteria + 20 g of prebiotic fiber per day during 3 months
3483337|NCT03770611|Placebo Comparator|Placebo|Subjects receiving placebo of probiotic and prebiotic per day during 3 months
3483338|NCT03770624|Experimental|200 mg QD|Tablet QL-007 will be administered orally daily (200 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
3483339|NCT03770624|Experimental|400 mg QD|Tablet QL-007 will be administered orally daily (400 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
3483340|NCT03770624|Experimental|600 mg QD|Tablet QL-007 will be administered orally daily (600 mg QD) over the 28 days under fasted state. Patients fast for 10h before administration and 1h after administration.
3483341|NCT03770624|Experimental|100 mg BID|Tablet QL-007 will be administered orally daily (100 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
3483342|NCT03770624|Experimental|200 mg BID|Tablet QL-007 will be administered orally daily (200 mg BID) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
3483343|NCT03770624|Active Comparator|TDF 300 mg QD|TDF will be administered orally daily (300 mg QD) over the 28 days not request fast .
3483344|NCT03770637|Experimental|Glucagon RTU (glucagon injection)|Glucagon Ready-to-Use (RTU); 60 μL injection (0.3 mg glucagon)
3483345|NCT03770637|Placebo Comparator|Placebo|Non-active vehicle for Glucagon RTU; 60 μL injection
3483346|NCT03770767|Experimental|Intervention with insulin Fiasp|Women randomized to insulin Fiasp
3127865|NCT03116152|Active Comparator|paclitaxel/irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
3127866|NCT03116230|Experimental|Experimental Treatment A then B|Subjects will receive two treatments: (1) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject and (2) a commercially-available knee sleeve, separated by a washout period.
3179658|NCT00675311|Active Comparator|DM-Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology that includes mobile phone client software with web-based companion software, Bluetooth glucose meter cradle, and web-based clinical management software for the clinical management team. The core of the system is the patient's cell phone which is used as an input device and which enables patients to maintain an electronic diary of information such as meal times, blood glucose, insulin use, weight, blood pressure, and exercise. The device is customizable to collect only the information relevant to the patient with diabetes and their healthcare provider. The patient with diabetes enters diary information on his or her mobile phone. No immediate or real-time information is provided to patients as part of this study.
3179659|NCT00675324|Active Comparator|A|Traditional bowel preparation with Laxabon
3179660|NCT00675324|Active Comparator|B|Bowel preparation with nutritional drinks
3483347|NCT03770767|Active Comparator|Control (insulin Novorapid)|Women randomized to insulin NovoRapid
3483348|NCT03770676|Experimental|Flavour 1|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 1. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
3483349|NCT03770676|Experimental|Flavour 2|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 2. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits biscuit for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
3483350|NCT03770676|Experimental|Flavour 3|Selenium-fortified biscuits These participants will be assigned to biscuit flavour 3. If possible, there will be an equal number of low, medium and high selenium-status participants. They will consume this flavour of selenium-fortified biscuits for 14 consecutive days at home, providing approximately 60 mcg selenium per day.
3483351|NCT03770377|Experimental|Stroke without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
3483352|NCT03770377|Experimental|Stroke with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
3483353|NCT03770377|Experimental|SCA6 without Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
3483354|NCT03770377|Experimental|SCA6 with Dysarthria|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
3483355|NCT03770377|Active Comparator|Age-Matched Controls|Examine laryngeal adaptation across all study groups: (1) baseline measures of speech or swallowing , (2) a clinical examination of disease/condition severity and (3) the experimental paradigm.
3483356|NCT03770507|Experimental|Treadmill Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
3483357|NCT03770507|Experimental|Cyclo Ergometer Exercise in Adolescents and Adults|Comparison of gas exchange kinetics between treadmill and cyclo ergometer exercises
3483358|NCT03770338|No Intervention|Control|Recruitment for fusion surgery as usual
3483359|NCT03770338|Experimental|Teriparatide|Preoperative 1 month use of teriparatide, before lumbar fusion surgery
3483360|NCT03770221|Experimental|Financial Incentive|"Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.~Additionally, participants in this arm will receive $20 for every week they maintain contact with CATCH service providers, as required by their care plan. Contact can be by phone, text, email, or in person with CATCH service providers over 6 months of follow up, or until they are successfully transitioned to longer-term supports (for up to $80/month per participant)."
3483361|NCT03770221|Active Comparator|Usual Care|Participants will receive usual brief, intensive case management to connect them to health and social services and supports in the community.
3483362|NCT03770143||Group 1|Infants feeding predominantly with palm olein free formula if presence in addition to breast milk for 8 weeks of life
3483363|NCT03770143||Group 2|Infants feeding with other formulas including palm olein if presence in addition to breast milk for 8 weeks of life
3483364|NCT03770143||Group 3|Having similar demographical properties with infants feeding with breast milk (gender, age, weight, height)
3483365|NCT03770156||Subjects who contacted CUMP by phone|Subjects who contacted CUMP (Medical Psychological Emergency Cell) by phone from Paris November 13th, 2015, London 11th,2017 ; Barcelone 17-18th, 2017 ; Strasbourg 11th, 2018.
3483366|NCT03770195||Abdominoplasty Patients|Patients undergoing full abdominoplasty procedures in which the surgeon elects to use HEMOBLAST Bellows to control minimal, mild, or moderate bleeding for which conventional means of hemostasis are ineffective or impractical
3127867|NCT03116230|Experimental|Experimental Treatment B then A|Subjects will receive two treatments: (1) a commercially-available knee sleeve and (2) a non-invasive external Cutaneous Stimulation device placed on the leg of the subject consisting of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback (vibration) to the subject, separated by a washout period.
3127868|NCT03116698|Experimental|Low dose DFD07 once daily|
3127869|NCT03116698|Experimental|High dose DFD07 once daily|
3127870|NCT03116698|Experimental|High dose DFD07 twice daily|
3127871|NCT03116698|Placebo Comparator|Placebo twice daily|
3127872|NCT03116828|Experimental|eslicarbazepine acetate (arm 1)|eslicarbazepine acetate (as first add-on)mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
3127873|NCT03116828|Experimental|eslicarbazepine acetate (arm 2)|eslicarbazepine acetate (as later add-on)
3127874|NCT03116841|Experimental|Vonoprazan 20 mg|Vonoprazan 20 mg orally administered once daily
3127875|NCT03117140|Active Comparator|Plain Ropivacaine|Plain Ropivacaine 0.75%, (225 mg) total volume 32 cc for interscalene block given pre-operatively
3127876|NCT03117140|Experimental|Ropivacaine + Buprenorphine|A mixture of 0.75% ropivacaine with 300 mcg buprenorphine, total volume 32 cc for interscalene block given pre-operatively
3127877|NCT03117140|Experimental|Ropivacaine + Clonidine|A mixture of 0.75% ropivacaine with 75 mcg clonidine, total volume 32 cc for interscalene block given pre-operatively
3127878|NCT03117140|Experimental|Ropivaciane + Dexamethasone|A mixture of 0.75% ropivacaine with and 8 mg dexamethasone, total volume 32 cc for interscalene block given pre-operatively
3127879|NCT03117361|Experimental|Experimental|"Plitidepsin + bortezomib + dexamethasone~Plitidepsin will be administered as a 3-hour intravenous (i.v.) infusion on Day(D) 1 and 15 , every four weeks (q4wk)~Bortezomib will be administered as a bolus subcutaneous (s.c.) injection on D 1, 4, 8 and 11,q4wk~Dexamethasone will be taken orally on D1,8,15 and 22, q4wk"
3127880|NCT03117517|Experimental|Metformin|Drug intervention: Metformin 500 mg tablet twice orally for 3 months
3127881|NCT03117517|Active Comparator|Metformin, pioglitazone|Drugs intervention: Combination of Metformin (1000 mg) and pioglitazone (30 mg) tablets will be given orally for 3 months
3127882|NCT03117569|Other|Standard monitoring schedule|Participants will have on-treatment clinic visits at weeks 4 and 8. Participants have also phone contact-based visits at weeks 4 and 8 (1-2 days prior to scheduled clinic visits).
3483367|NCT03770247|Experimental|intraoperative group (IOCPN group)|Intraoperative celiac plexus neurolysis Before closure of the abdomen the surgeon will expose the aorta at the level of the celiac trunk.With the stomach retracted inferiorly, the index and second finger of the surgeon's left hand straddle the aorta with the index finger placed on the splenic artery and the second finger on the common hepatic artery. we will use of a 20- gauge spinal needle (in contrast to the usual short intravenous needle) allows better visualization and access to this area, especially in deep patients, while a 10 ml syringe permits the surgeon to control the injection with the right hand alone.(10) Twenty ml of 90 % alcohol, five ml lidocaine 2%, five mg dexamethasone will be injected in each side of the aorta after aspiration to exclude intravascular or subarachnoid injection.
3483368|NCT03770247|Active Comparator|CT group (CTCPN group)|CT guided celiac plexus neurolysis After one week of the operation and the patient completely awake, the patient will be transferred to CT lab. The procedure will be done after attachment of basic monitors and transfusion of 500 ml saline in 20 G cannula before starting the procedure and the patient will be given 5 mg midazolam as a sedation. The procedure will be done by anesthetist and radiologist who had a good experience in celiac plexus neurolysis. In our study we will use the classic posterior bilateral approach. The patient will be in the prone position. After sterilization of the back by chlorohixidine 10 % , subcutaneous injection of 5 ml lidocaine as a local anaesthesia until a wheel will be formed then the procedure will be done. We will use 20 G Chiba needle under guidance of CT. Twenty ml of 95% alcohol , five ml lidocaine 2 % and five mg dexamethasone in each side of the aorta after aspiaration to exclude intravascular injection and subarachnoid injection
3483369|NCT03770234|Experimental|Treatment A: Transtec patch application for 96 hours|Transtec 35 µg/hour transdermal patch wearing period of 96 hours, with application of patch on Study Day 1 and removal on Study Day 5.
3483370|NCT03770234|Experimental|Treatment B: Transtec patch application for 72 hours|Transtec 35 µg/hour transdermal patch wearing period of 72 hours, with application of patch on Study Day 1 and removal on Study Day 4.
3483371|NCT03770117||Prehabilitation|"In this arm of the study, participants will undergo prehabilitation prior to surgery. This is intended to increase the participants overall health prior to surgery to try and increase their general well-being during and after surgery.~Prehabilitation is multimodal therapy comprising:~Assessment for malnutrition and nutritional support dependent on the outcome~Optimisation of management of pancreatic exocrine insufficiency~Assessment of muscle mass and strength~Individually tailored, goal directed exercise regimen under the care of physiotherapy"
3483372|NCT03770117||Standard Procedure|In this arm, participants will not receive any Rehabilitation prior to the surgery. This is the current standard care and will act as the control data for this study.
3483373|NCT03770208|Placebo Comparator|Control: Standard Care + Placebo|"Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV placebo (Lactated Ringers). Lactated Ringers will be delivered as a initial bolus and then run as a continuous infusion to mimic the volume (as per Kg) of study drug for 72-96 hours. Standard care will be determined by the care team with no limitations introduced by the research team. Medications utilized and dosing regimes will be recorded after the intervention."
3483374|NCT03770208|Experimental|Intervention: Lidocaine|Standard care (acetaminophen, NSAIDs, opioids, gabapentin) as directed by MRP care team plus IV lidocaine. IV lidocaine will be administered as a bolus dose of 2 mg/kg (maximum dose 100 mg) followed by a 2 mg/kg/hr infusion for 72-96 hrs.
3483375|NCT03770065||Group A|
3483376|NCT03770065||Group B|
3127883|NCT03117569|Experimental|Simplified monitoring schedule|Participants will have no on-treatment clinic visits at weeks 4 and 8. Participants have phone contact-based visits at weeks 4 and 8.
3127884|NCT03117634|Active Comparator|Fixed dosing group (2Q8)|Fixed Dosing with Aflibercept 2mg will be administered at a fixed regime at 8 week intervals through to week 52.
3127885|NCT03117634|Experimental|Treat and Extend group (T&E)|Reassessment at week 12 (month 3) by repeat examination for disease activity by OCT and indocyanine green angiography (ICGA). Subsequent treatment regime of Treat and Extend with Aflibercept 2mg will depend on disease activity at this point.
3483377|NCT03770325|Experimental|Berberine|berberine (500 mg orally twice a day)
3127886|NCT03117738|Experimental|AstroStem|
3127887|NCT03117738|Placebo Comparator|Placebo-Control|
3127888|NCT03118297|Experimental|Ulipristal Acetate|15mg ulipristal acetate (capsule) daily for 7 days
3483378|NCT03770325|Placebo Comparator|Placebo|placebo (500 mg orally twice a day)
3483379|NCT03770000|Experimental|Tenalisib+Romidepsin|Participants receive Tenalisib in escalating doses daily Orally BID and Romidepsin in escalating doses intravenously on day 1, 8 and 15
3483380|NCT03770312|Active Comparator|Low intensity statin group|Taking low intensity statin
3483381|NCT03770312|Active Comparator|Moderate intensity statin group|Taking moderate intensity statin
3483382|NCT03770299|Experimental|Arm A|Nivolumab + SOC (chemotherapy in eligible participants or observation)
3483383|NCT03770299|Active Comparator|Arm B|SOC (chemotherapy in eligible participants or observation)
3483384|NCT03770273|Active Comparator|placebo|8 SC injections of placebo
3483385|NCT03770273|Active Comparator|sarilumab|8 (SC) injections of 200 mg/1.14 mL of sarilumab over 16 weeks
3179661|NCT00675337|Active Comparator|perineum|infants maintained at the level of the perineum until umbilical cord clamping
3179662|NCT00675337|Experimental|abdomen|infants placed on the maternal abdomen prior to cord clamping
3179663|NCT00675350|Experimental|Homoharringtonine|
3179664|NCT00675363|Active Comparator|PS|Nurse-directed protocols for administering sedation and/or analgesia by continuous infusion.
3127889|NCT03118297|Placebo Comparator|Placebo|Identical placebo (capsule) daily for 7 days
3127890|NCT03118466|Experimental|Lenalidomide and MEC chemotherapy|Lenalidomide is taken orally on a daily basis days 1-10. Mitoxantrone, Etoposide, and Cytarabine are administered intravenously on a daily basis for days 4 through 8 of the treatment. There is only one cycle of treatment in this study.
3179665|NCT00675363|Active Comparator|PS + DI|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
3179666|NCT00675389|Experimental|A|Peer Health Workers Intervention
3483386|NCT03770130|Experimental|Dexmedetomidine treatment group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an initial loading dose of dexmedetomidine of 1μg/kg over 10 min after the induction of anaesthesia followed by a continuous infusion of 0.5μg/kg/h until the end of surgery.
3483387|NCT03770130|Placebo Comparator|Control group|Anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Muscle relaxation will be maintained with rocuronium or cisatracurium. Analgesia will be maintained with remifentanil (administered via continuous infusion), sufentanil (administered via continuous infusion or intermittent injection), or fentanyl (administered via intermittent injection). In addition to this, patients will receive an equal volume initial loading dose of 0.9% saline over 10 min after the induction of anaesthesia followed by an equal volume continuous infusion until the end of surgery.
3483388|NCT03770104|Experimental|Intervention Group (5.5 plus weight)|ETT insertion depth using Spanish recommendations Patients included in the intervention group arm who are included in the study will be intubated using Spanish recommendations (5.5 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
3483389|NCT03770104|Experimental|Control Group (6 plus weight)|ETT insertion depth using international recommendations Patients included in the intervention group arm who are included in the study will be intubated using international recommendations (6 plus weight) to estimate insertion endotracheal tube depth. In addition, every arm will be divided into 2 subgroups depending on gestational age (under 32 weeks or equal/over 32 weeks' gestation).
3127891|NCT03118518|Active Comparator|Anti-arrhythmic drug|
3127892|NCT03118518|Experimental|Cryoablation|
3127893|NCT03118596|Active Comparator|I-gel|Fibreoptic guided tracheal intubation through I-gel
3127894|NCT03118596|Active Comparator|LMA Protector|Fibreoptic guided tracheal intubation through Protector
3127895|NCT03118739|Experimental|Verinurad 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
3179667|NCT00675389|Experimental|B|Peer Health Workers and Mobile Phone Intervention
3179668|NCT00675389|No Intervention|C|Control
3483390|NCT03770078|Experimental|Study period|First the subjects will use the comparator (SenSura Mio) and then the test products (Test Product A)
3483391|NCT03770052|Experimental|0.25mg robeglitazone add-on group|0.25mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
3127896|NCT03118739|Placebo Comparator|Placebo|Capsule administered orally, once daily for 24 weeks
3127897|NCT03118765|Experimental|Test Treatment T1: GSP304 Inhalation Solution|
3483392|NCT03770052|Active Comparator|0.5mg robeglitazone add-on group|0.5mg robeglitazone once daily in patients with type 2 diabetes with inadequate control on metformin and DPP-4 inhibitor therapy
3483393|NCT03770039|Experimental|2-period, fixed sequence|fixed sequence with 2 treatment period
3483394|NCT03770026|Active Comparator|Clomiphene citrate only|Infertile women (30 women) with prior clomiphene citrate failure (ovulation was documented without conception), with thin endometrium (<7mm) in at least 3 cycles. Saline cervical flushing will be done at cycle day 8 and 10 to convince patient-blinded procedure.
3483395|NCT03770026|Experimental|Platelet-rich plasma plus Clomiphene|Women who did not conceive on the Clomiphene citrate-only cycle will receive Clomiphene citrate 100 mg/ day starting from the third day of the cycle. Intrauterine Autologous platelet-rich plasma will be done on the cycle days 8 and 10.
3483396|NCT03770013|Active Comparator|bupivacaine 0.25% and Dexmedetomidine|bupivacaine 0.25% + Dexmedetomidine 0.5 mcg/kg (a total volume of 40 ml (20 ml each side) was used for the TAP block.)
3483397|NCT03770013|Active Comparator|bupivacaine and clonidine|20 ml bupivacaine+1ug/kg clonidine bilaterally (a total volume of 40 ml (20 ml each side) was used for the TAP
3483398|NCT03770013|Placebo Comparator|bupivacaine and placebo|bupivacaine 0.25% + placebo (a total volume of 40 ml (20 ml each side) was used for the TAP
3127898|NCT03118765|Experimental|Test Treatment T2: GSP304 Inhalation Solution|
3483399|NCT03769974|Experimental|Motor imagery|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-person kinesthetic motor imagery training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of motor imagery will be 2 series of 30 seconds for each of the 12 manual positions to remember
3483400|NCT03769974|Experimental|Action observation|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which a first-personaction observation training will be conducted on a sequence of manual motor gestures of increasing complexity for four consecutive days. The tasks of action observation will be 2 series of 30 seconds for each of the 12 manual positions to remember in video format.
3483401|NCT03769974|Placebo Comparator|Placebo group|A group of healthy subjects who meet the inclusion and exclusion criteria established for the study to which an imagery training and placebo observation, inspired by a rural landscape, will be given for four consecutive days. This group will carry out the observation and imagination of a landscape during 2 series of 30 seconds for each manual motor sequence to remember.
3127899|NCT03118765|Experimental|Test Treatment T3: GSP304 Inhalation Solution|
3127900|NCT03118765|Placebo Comparator|Test Treatment T4: GSP304 Placebo Inhalation Solution|
3483402|NCT03769961||ET (DBS-, Ataxia+)|Essential Tremor without DBS with Ataxia on examination
3483403|NCT03769961||ET (DBS-, Ataxia-)|Essential Tremor without DBS and without Ataxia on examination
3127901|NCT03118765|Active Comparator|Test Treatment T5: Spiriva® Respimat® inhalation spray|
3127902|NCT03118843|Experimental|SOF/VEL/VOX|SOF/VEL/VOX for 12 weeks
3483404|NCT03769961||ET (DBS+, Ataxia+)|Essential Tremor with DBS with Ataxia on examination
3483405|NCT03769961||ET (DBS+, Ataxia-)|Essential Tremor with DBS without Ataxia
3127903|NCT03118934|Experimental|AOA MF|Lotrafilcon B multifocal contact lenses worn bilaterally (in both eyes) for 10 ± 3 days
3483406|NCT03769935|Experimental|experimental arm|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
3483407|NCT03769935|Active Comparator|active comparator|cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.
3483408|NCT03769922|Experimental|Extensive mesenteric resection|Mesenteric is resected avoiding the root region, i.e. 1 cm from the root of ileocolic artery and vein.
3483409|NCT03769922|Active Comparator|Limited mesenteric excision|"Mesentery is retained, i.e. Close shave or 3 cm from the border of bowel (using whatever approach - clips, or haemostatic vessel sealing device)."
3483410|NCT03769883|Experimental|Dietary control (DCON)|The macro-nutrient distributions are in line with the current guidelines from the national Diabetes Association and Canadian guidelines, where individualization in macronutrient distribution should lie within the range of 45-60E% carbohydrate, 15-20E% protein and 20-35E% fat. The dietary plan will aim at reducing saturated fat intake <7E% aiming at a caloric deficit of 500 kilo calories/day
3483411|NCT03769883|Experimental|Moderate Exercise Dose (MED)|Two aerobic training sessions per week of 45-60 min duration and one session per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
3483412|NCT03769883|Experimental|High Exercise Dose (HED)|Four aerobic training sessions per week of 45-60 min duration and two sessions per week with combined aerobic (30-35 min) and resistance (30 min) training and a dietary intervention (as above)
3483413|NCT03769883|No Intervention|Control|No intervention
3483414|NCT03769870|Other|Teneligliptin|
3483415|NCT03769870|Other|Atorvastatin|
3483416|NCT03769870|Other|Teneligliptin + Atorvastatin|
3483417|NCT03769857|Experimental|NEM® + BIOCURC®|"NEM® + BIOCURC®~NEM, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS BIOCURC, 350 mg, #10 oval softgel, once daily orally for 2 weeks"
3483418|NCT03769857|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks PLUS Placebo, 350 mg, #10 oval softgel, once daily orally for 2 weeks
3483419|NCT03769844|Experimental|IV GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the intravenous (IV) route at a dose of 125 mcg/m2/day for 7 consecutive days.
3483420|NCT03769844|Experimental|SQ GM-CSF 125 mcg/m2/dose|Subjects in this arm who demonstrate immunoparalysis will receive GM-CSF by the subcutaneous (SQ) route at a dose of 125 mcg/m2/day for 7 consecutive days.
3483421|NCT03769844|Experimental|IV GM-CSF 250 mcg/m2/dose|If the IV 125 mcg/m2/dose arm is not successful in the first cohort of subjects, we will transition to 250 mcg/m2/day via the IV route for 7 consecutive days in a subsequent cohort.
3483422|NCT03769844|Experimental|SQ GM-CSF 250 mcg/m2/dose|If the SQ 125 mcg/m2/dose arm is not successful in a cohort of subjects (or if the IV dose had to be escalated to 250 mcg/m2/dose), we will transition to 250 mcg/m2/day via the SQ route for 7 consecutive days in a subsequent cohort.
3483423|NCT03769831|Experimental|SHR2285|Up to 7 cohorts of healthy subjects will receive a single dose of oral SHR2285 tablet.
3127904|NCT03118934|Experimental|DACP MF|Nelfilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
3127905|NCT03118934|Experimental|DT1 MF|Delefilcon A multifocal contact lenses worn bilaterally for 10 ± 3 days
3483424|NCT03769831|Experimental|Placebo|Up to 7 cohorts of healthy subjects will receive a single dose of oral placebo.
3483425|NCT03769818|Active Comparator|bupivacaine and dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
3483426|NCT03769818|Active Comparator|bupivacaine and placebo to dexamethasone|Bilateral ESP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
3483427|NCT03769818|Placebo Comparator|control group|Bilateral ESP block with placebo to bupivacaine bilaterally plus placebo to dexamethasone
3483428|NCT03769805|Experimental|Anlotinib Arm|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
3483429|NCT03769792|Experimental|Impedance spectroscopy|"24 women will be included in the study and divided into two subgroups.~12 of them (first subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 1 or 2 in OASIS classification.~Remaining 12 (second subgroup) came from patients within 6 to 8 weeks after natural delivery, that had a perianal tear of grade 3 or 4 in OASIS classification.~The planned interventions are:~Blood and faeces tests~Impedance spectroscopy test~Full gynecological and proctological examination~Transanal ultrasonography~Anorectal manometry"
3483430|NCT03769779|Experimental|Treatment|Lutein (FloraGLO™) in safflower oil
3483431|NCT03769779|Placebo Comparator|Placebo|safflower oil
3483432|NCT03769766|Active Comparator|Curcumin|"Other names for the supplement: BCM-95 CG (Biocurcumax),Tumeric~Manufacture- DolCas Biotech, LLC.~Classification - type of agent: Supplement~Protocol dose: 500 mg twice"
3483433|NCT03769766|Placebo Comparator|Placebo|"Drug: placebo~placebo orally twice a day Other Names: •sugar pill"
3483434|NCT03769753|Experimental|intraoperative use of IRE|Patients with intraoperatively determined advanced unresectable PHC will be treated with IRE during the same surgical exploration session (N=20). Electrodes will be placed using ultrasound guidance. All electrodes will be placed by hepatopancreatobiliary surgeons with experience using IRE.
3127906|NCT03118947|Experimental|Pimavanserin 20 mg OR 34 mg per day|
3127907|NCT03119025|Experimental|Autologous DC-vaccines|Thirty patients with chronic hepatitis C (genotype 1) will receive the initiating and maintaining courses of autologous of autologous monocyte-derived dendritic cells, generated in the presence of IFN-α/GM-CSF and pulsed with recombinant HCV Core (1-120) and NS3 (1192-1457) proteins.
3127908|NCT03119168|Experimental|Simethicone solution + Polyethylenglycol|This arm of the study will include the patients assigned to take simethicone solution with their colon preparations ( 4L Polyethyleneglycol)
3483435|NCT03769740||CPR Group|
3483436|NCT03769714|Active Comparator|Saline Solution for Injection|Group A (control, n=26) to receive 20ml of saline while prepping. The syringe will covered as to disguise the contents of the syringe.
3127909|NCT03119168|Active Comparator|Polyethylenglycol|This arm of the study will include the patients assigned to take a regular bowel preparation (4L Polyethylenglycol)
3483437|NCT03769714|Experimental|Exparel|Group B (study, n=26) to receive 20ml of liposomal bupivacaine (EXPAREL) into the stroma of the cervix at the 4 and 8 o'clock positions (innervation insertion points of the cervix).
3483438|NCT03769675|Experimental|Spinal Cord Stimulator Implant|Spinal Cord Stimulator implant
3483439|NCT03769662|Experimental|High dose from study XT-150-1-0201|Open label administration of the highest dose in the earlier study, in which all doses were well tolerated
3483440|NCT03769623|Experimental|Biolimus|BA9 Drug-eluting Coronary Artery Balloon Catheter
3483441|NCT03769623|Active Comparator|Powerline|Balloon dilated catheter
3127910|NCT03119181|Experimental|Active Tymbion Iontophoresis|Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
3127911|NCT03119181|Sham Comparator|Sham Tymbion Iontophoresis|The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.
3483442|NCT03769610|Active Comparator|Inpatient Foley catheter|Subjects will be admitted to a room on labor and delivery and will be monitored with the external fetal monitor (EFM) and tocometer (a device to monitor contractions). If she is contracting less than every 2 minutes, intravenous (IV) Pitocin will be started at 2 milliunits/minute and increased per hospital protocol. While on pitocin, she will remain on continuous EFM and tocometer. She will also be kept on a clear liquid diet with intravenous fluids per standard protocol. If the Foley catheter has not been expulsed in 24 hours, it will be removed. After expulsion or removal of the Foley catheter, induction may proceed as deemed clinically appropriate by the managing physician. No further cervical ripening will be performed after the Foley catheter is expulsed/removed, or after 24 hours.
3127912|NCT03119389|Experimental|Donning Non-Sterile Gloves without HH|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves is NOT necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3127913|NCT03119389|No Intervention|HH before donning Non-Sterile Gloves|In this arm, entire units will be assigned education that hand hygiene before donning non-sterile gloves IS necessary. For Aim A, observations will be made on compliance at entry and exit with hand hygiene and glove use. For Aim B, samples will be obtained from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3483443|NCT03769610|Experimental|Outpatient Foley catheter|Subjects are asked to return to the hospital ~12 hours after placement. Subjects are to return to the hospital if they develop heavy vaginal bleeding, decreased fetal movement, rupture of membranes, or increasingly painful or frequent contractions requiring an epidural or pain relief. Once admitted, subjects will be evaluated for expulsion of the catheter. If the catheter is in place IV Pitocin will be started. If the catheter has been expulsed, the induction will proceed as deemed clinically appropriate. After 24 hours, if the Foley catheter is still in the cervix it will be removed and the induction will proceed as deemed clinically appropriate.
3483444|NCT03769597|Experimental|Iohexol administration|After injecting a loading dose of 5ml of Iohexol Inj 300 MG/ML bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
3483445|NCT03769571|Other|parental coaching program at ESDM (P-ESDM)|
3483446|NCT03769571|No Intervention|CONTROL|
3483447|NCT03769558||JIA patients prescribed abatacept|
3483448|NCT03769532|Experimental|Pembrolizumab + Azacitidine|"Pembrolizumab (IMP): 200 mg i.v. (fixed dose) / Azacitidine (SOC): 75 mg/m2 s.c.~maximum duration of treatment: up to 24 weeks"
3483449|NCT03769506|Active Comparator|ASP-1929 Photoimmunotherapy|Use of ASP1929 PIT therapy
3483450|NCT03769506|Active Comparator|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, paclitaxel
3483451|NCT03769493|Experimental|Mobile After-Care Support (MACS) app|All participants will download the MACS app to their mobile phone (or a study provided phone, as needed). The app runs through the third-party platform, mEMA, designed by Ilumivu. It is designed to prompt engagement through questions and tailored responses at multiple times throughout the day and provide brief interventions.
3483452|NCT03769480||Study Group|Study Group=Athletes with Disability
3483453|NCT03769480||Control Group|Control Group=Healthy Athletes
3483454|NCT03769467|Experimental|tabelecleucel in combination with pembrolizumab|Tabelecleucel will be administered initially to 12 subjects at a dose of 2 x 10^6 cells/kg intravenously (IV) on Day 1, Day 8, and 15 of a 21-day cycle. For Cohort 1, if there is a dose-limiting toxicity, the dose of tabelecleucel will be reduced to 1 x 10^6 cells/kg. Pembrolizumab will be administered to adult subjects at 200 mg or to pediatric subjects (12 to < 18 years of age) at 2 mg/kg IV every 3 weeks.
3483455|NCT03769454|Experimental|PP-001 low dose group|
3483456|NCT03769454|Placebo Comparator|Placebo low dose group|
3483457|NCT03769454|Experimental|PP-001 mid dose group|
3483458|NCT03769454|Placebo Comparator|Placebo mid dose group|
3483459|NCT03769454|Experimental|PP-001 high dose group|
3483460|NCT03769454|Placebo Comparator|Placebo high dose group|
3483461|NCT03769441|Active Comparator|Ferric(III) carboxymaltose|The intervention group will be treated with four dosages of 500 mg iron in the form of 10 mL ferric(III) carboxymaltose dissolved in 240 mL of NaCl 0.9%, with interval periods of six weeks.
3483462|NCT03769441|Placebo Comparator|Placebo|The placebo-controlled group will receive four dosages of 250 mL of NaCl 0.9% solution with interval periods of six weeks.
3483463|NCT03769428|Active Comparator|group B:ESP block|"Patients in the experimental arm will receive an erector spinae plane block prior to induction of general anesthetic :- 150 mg of Ropivacaine : 40cc of Ropivacaine (3.75mg/cc)~An intravenous patient controlled analgesia device will be given to the patients postoperatively"
3483464|NCT03769428|Placebo Comparator|group P: Sham ESP block|"Patients allocated to the placebo-control arm will receive a sham erector spinae plane block .they will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block:- 40 cc of normal saline will be injected~-An intravenous patient controlled analgesia device will be given to the patients postoperatively"
3483465|NCT03769415|Experimental|Intrinsic subtyping of Primary Breast Cancer|Intrinsic subtype of primary breast tissue from metastatic breast cancer subject will be determined
3483466|NCT03769402|Active Comparator|Citric acid|Citric acid PH1 and concentration 50% was used for 30 seconds on bone surface before washing it off and filling the defect with xenograft
3483467|NCT03769402|Placebo Comparator|Control|Control test
3483468|NCT03769389|Experimental|assessing the GI + GL of Birhi + YEO 0% fat yoghurt|47g of total carbohydrate in which contains 43.6g of Freeze-dried of Birhi powder+ 150g of 0% fat yoghurt
3483469|NCT03769389|Experimental|assessing the GI + GL of Khassab + YEO 0% fat yoghurt|47g of total carbohydrate in which contains34.6g of freeze-dried Khassab powder+ 150g of 0% fat yoghurt
3483470|NCT03769389|Experimental|assessing the GI + GL of 50g of Glucose in 100 ml of water|50g of pure glucose dissolved in 100ml of water
3483471|NCT03769350|Experimental|Smartphone-delivered CBT for MDD|8-week Smartphone delivered CBT for MDD.
3483472|NCT03769350|Other|8 Week Waitlist Control|8-week waitlist control. (Note: participants will be crossed over to 8-week Smartphone-delivered CBT for MDD following the 8-week waitlist control).
3483473|NCT03769337||Infected|Serum biomarkers in patients with diagnosis of prosthetic joint infection
3483474|NCT03769337||Not Infected|Serum biomarkers in patients with implant failure not caused by infection
3127914|NCT03119571|Experimental|Initial CCL admission|Admission to the CCL to evaluate the coronary artery disease
3127915|NCT03119571|Active Comparator|Initial ICU admission|Admission to the ICU to be evaluated by clinical team and the clinical treatment will be decided by the admitting/attending team.
3483475|NCT03769324||Normal Eye Group|Normal eye receiving Osmolarity Test
3483476|NCT03769324||DED Group|Dry Eye Disease receiving Osmolarity Test
3483477|NCT03769311|Experimental|Pre-Operative Cetuximab Therapy|Two weekly doses of pre-operative cetuximab during the interval between diagnostic HNSCC biopsy and surgery (~14 days), ensuring that no delay in standard of care (SOC) will occur. For dose #1, participants will receive cetuximab 400 mg/m2 via intravenous infusion over 2 hours (maximum infusion rate 10 mg/min) as per the standard of care loading regimen for cetuximab monotherapy. For dose #2, participants will receive cetuximab 250 mg/m2 via intravenous infusion over 1 hour (maximum infusion rate 10 mg/min) as per the standard of care dosing regimen for cetuximab monotherapy.
3483478|NCT03769298|Experimental|Envarsus XR|Envarsus XR (extended release) will be administered orally, once-daily, for 6 months.
3483479|NCT03769285|Experimental|Nicotinamide|
3483480|NCT03769285|Placebo Comparator|Placebo|
3483481|NCT03769272||Echocardiographic targeting|
3483482|NCT03769272||Electrogram targeting|
3127916|NCT03119610|Experimental|Oxytocin nasal spray|Oxytocin (Syntocinon), intranasal, 24IU, 4x a day for 8 weeks, self administered
3127917|NCT03119610|Experimental|Placebo nasal spray|Placebo nasal spray, 4x a day for 8 weeks, self administered
3127918|NCT03119649|Experimental|Cohort A: GLPG2222 50 mg once daily (QD)|Participants received a single GLPG2222 50 mg tablet and two matching placebo tablets orally, QD for 29 days.
3483483|NCT03769259|Experimental|Brief Cognitive Behavioral Therapy|
3483484|NCT03769259|Active Comparator|Present-Centered Therapy|
3483485|NCT03769246|Experimental|Upright Go Device Group|"Patients receiving the Upright device will have a brief training on the use of the device and proper posture. They will be asked to download the Upright app on their phone from the Playstore.~Patients will wear the device once daily for training. They will attach the device applying an adhesive on their upper back, as instructed, and the device will be attached to the adhesive by velcro. Once completed they should remove adhesive."
3483486|NCT03769246|Active Comparator|Control Group|The control group will receive a 15-20 minute instruction on proper posture by the physician and will receive an ergonomic handout.
3483487|NCT03769233|Experimental|Mindfulness-based Intervention|5 week, manual-based group MBI treatment for depressive and anxious symptoms
3483488|NCT03769181|Experimental|Phase 1: cHl/DLBCL/PTCL|Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose
3483489|NCT03769181|Experimental|Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
3483490|NCT03769181|Experimental|Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
3483491|NCT03769181|Experimental|Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
3483492|NCT03769181|Experimental|Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve|Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose
3483493|NCT03769168|Experimental|Group 1 - Secukinumab 75 mg|Group 1 - Secukinumab (AIN457) 75 mg/0.5mL
3483494|NCT03769168|Experimental|Group 2 - Secukinumab 150 mg|Group 2 - Secukinumab (AIN457) 150 mg/1.0mL
3483495|NCT03769129|Experimental|Microwave ablation|Firstly, microwave ablation performed at our department by interventional radiologist, then Pembrolizumab will be administered at a dose of 2 mg/kg every three weeks.
3483496|NCT03769129|Other|Pembrolizumab|Firstly, pembrolizumab was administered intravenously at a dose of 2 mg/kg. Then microwave ablation will be performed if there is no immune-related adverse reactions. Pembrolizumab will also be continuously administered every three weeks until the imaging evaluation of the disease progress.
3483497|NCT03769103|Active Comparator|SRS + Osimertinib|Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.
3483498|NCT03769103|Experimental|Osimertinib alone|Osimertinib 80mg PO daily
3483499|NCT03769090|Experimental|BDA MDI (PT027) 80/180 μg|BDA MDI (PT027) low dose
3483500|NCT03769090|Experimental|BDA MDI (PT027) 160/180 μg|BDA MDI (PT027) high dose
3127919|NCT03119649|Experimental|Cohort A: GLPG2222 100 mg QD|Participants received a single GLPG2222 100 mg tablet and two matching placebo tablets orally, QD for 29 days.
3127920|NCT03119649|Experimental|Cohort B: GLPG2222 200 mg QD|Participants received two GLPG2222 100 mg tablets and one matching placebo tablet orally, QD for 29 days.
3127921|NCT03119649|Experimental|Cohort B: GLPG2222 400 mg QD|Participants received two GLPG2222 150 mg tablets and one GLPG2222 100 mg tablet orally, QD for 29 days.
3127922|NCT03119649|Placebo Comparator|Cohort A Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
3483501|NCT03769090|Active Comparator|AS MDI (PT007) 90 µg|
3483502|NCT03769077|Experimental|Exergaming (Case) Group|"Participants assigned to the exergame condition will play the exergames for 30 minutes, 5 days a week for 3 weeks (15 exergame sessions). Outcomes will be acquired at baseline (before intervention), and at the end of every week during the 3 week intervention phase. Participants will also receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
3483503|NCT03769077|No Intervention|Comparison Group|"Participants will receive the current standard PT care at the Specialized Orthopedic and Developmental Rehab (SODR) inpatient unit at Holland Bloorview Kids Rehabilitation Hospital and will complete questionnaires and assessments at the same time points during study participation.~The research participants will be asked to complete the following self-report questionnaires: Patient Reported Outcome Measurement Information System Pediatric Pain Interference Scale (PROMIS-PI), the KIDSCREEN-27, Faces Pain Scale-Revised (FPS-R) and the Self-Reported Experiences of Activity Settings (SEAS)."
3483504|NCT03769064|Experimental|Qualification Phase (Part A)|Placebo/Methylphenidate (60 mg) on days 1 and 3
3483505|NCT03769064|Experimental|Qualification Phase (Part B)|Methylphenidate (60 mg)/Placebo on days 1 and 3
3483506|NCT03769064|Experimental|Treatment Phase Sequence 4213|Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg
3127923|NCT03119649|Placebo Comparator|Cohort B Placebo|Participants received three matching placebo tablets, orally, QD for 29 days.
3127924|NCT03119688|Other|Test product|0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.
3127925|NCT03119688|Other|Positive Control|Soap bar (positive control) will be applied on the allocated site on forearm by topical dermal administration of towel moistened with sterile water that had been rubbed onto the 100 g bar of soap for 6 seconds to generate a lather.
3483507|NCT03769064|Experimental|Treatment Phase Sequence 2134|Methylphenidate 60 mg/Placebo Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg
3483508|NCT03769064|Experimental|Treatment Phase Sequence 1342|Placebo/Placebo Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo
3483509|NCT03769064|Experimental|Treatment Phase Sequence 3421|Methylphenidate 60 mg/Naltrexone 50 mg Methylphenidate 60 mg/Naltrexone 100 mg Methylphenidate 60 mg/Placebo Placebo/Placebo
3483510|NCT03769038|Other|Chronic Total Occlusion and Restenosis|contemporary antegrade or retrograde dissection and re-entry (ADR or RDR) to open CTO
3483511|NCT03769025|Experimental|Remote Observed Dosing|One group will be assigned to Remote Observed Dosing (ROD) and will have all of their Suboxone® doses remotely observed. The intervention is remote observed dosing
3483512|NCT03769025|Active Comparator|Attention Control|The attention control (AC) group will not have their dosing observed but will send a text message confirming they have taken their study medication to the study team daily matching contact with the study team. Text message confirming that they have taken their study medication is the intervention
3179669|NCT00675402||1|Patients referred to the vascularsurgeon with complaints of claudication for their first time, will be asked to participate with the study, with respect toward the in- and exclusion criteria.
3179670|NCT00675467||Group 1|Early cancer group-children ages 10-13 years
3483513|NCT03769012|Experimental|Treatment|Beta-Glucan
3483514|NCT03769012|Placebo Comparator|Placebo|Placebo
3483515|NCT03768999||Study group|All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
3483516|NCT03768986|Active Comparator|Treatment Group A|Standard referral for HIV testing and online HIV risk reduction training
3483517|NCT03768986|Experimental|Treatment Group B|Standard referral for HIV testing and online HIV risk reduction training plus reinforcement
3483518|NCT03768973||Group T2DM|Patients with diabetes mellitus undergoing elective cardiac surgery
3483519|NCT03768973||Group Ctrl|Control patients undergoing elective cardiac surgery without T2DM
3127926|NCT03119688|Other|Negative Control|0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.
3179671|NCT00675467||Group 2|Early cancer group-children ages 14 to 18 years
3483520|NCT03768934|No Intervention|Control|No airtime incentive for completing the survey
3483521|NCT03768934|Experimental|1X Incentive|1X airtime incentive
3483522|NCT03768934|Experimental|2X incentive|2X airtime incentive
3483523|NCT03768934|Experimental|Lottery Incentive|Lottery airtime incentive where odds of winning lottery are 1 out of 20
3483524|NCT03768921|Experimental|PEEP Titriation|patients with respiratory distress syndrome will undergo alveolar recruitment in the mechanical ventilator and will have their final positive mechanical ventilator pressure determined by ventilator evaluation by the electrical impedance tomograph. The increase of the peep in the mechanical ventilator to perform the alveolar recruitment will be of 2 in 2 cmH2O every 2 minutes until the pressure reaches 25 cmH20, after the pressure was reduced in the same way being evaluated in the tomograph what will be the point with greater alveolar recruitment, having greater ventilation, without alveolar hyperdistension or alveolar collapse.
3483525|NCT03768908|Active Comparator|Treatment with artesunate + amodiaquine|Co-administration of a daily dose of artesunate (Arsumax) 4mg/kg and amodiaquine (Flavoquine) 10mg/kg for 3 days, under direct observation. Children <12months <10kg: artesunate (Arsumax) 50mg - 0.5tab/day + amodiaquine (Flavoquine) 153mg - 0.5tab/day; Children 12-59months 10-20kg: artesunate (Arsumax) 50mg - 1 tab/day + amodiaquine (Flavoquine) 153mg 1 tab/day.
3483526|NCT03768908|Active Comparator|Treatment with artemether-lumefantrine (Coartem®)|Artemether-lumefantrine (Coartem®) - artemether 1.3mg/kg + lumefantrine 4mg/kg administered twice daily, both doses under direct observation either in the clinic or in the patient's home. Children <60 months, 5-14kg: 1 tab/dose; Children <60 months >14kg: 2 tabs/dose.
3483527|NCT03768895||MRI group|The criteria for patient inclusion were: Age > 18 years old, who had realised a pelvis MRI for any cause at MRI Center. Exclusion criteria included age < 18 years old, inadequate imaging quality, medical history likely to affect pelvic and hip morphometry: pelvic oncological disease, infection or inflammatory arthritis, postsurgical change disruptions, soft tissue abnormality, avascular necrosis, or pelvic and hip fracture.
3483528|NCT03768882|Experimental|Paracetamol|Experimental: Paracetamol 1000 mg of paracetamol (parol 10mg/ml solution Mefar,Turkey ) intravenous (IV) was given 102 patients
3483529|NCT03768882|Experimental|dexketoprofen|Dexketoprofen Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay-Menarini,Turkey) intravenous (IV) was given 98 patients
3483530|NCT03768869|Experimental|Low Risk: Oupatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
3483531|NCT03768869|Active Comparator|Low Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
3483532|NCT03768869|Active Comparator|High Risk: Inpatient Management|Patients will be categorized according to risk of serious bacterial infection per risk stratification system, which is based on demographic, clinical history and physical findings that have been shown to be predictive of risk.
3483533|NCT03768843|Other|traumatic odontoid fracture|C1 C2 fusion screws
3483534|NCT03768830|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
3483535|NCT03768830|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
3483536|NCT03768830|Experimental|Healthy Exercise|Healthy individuals that will exercise-group (HE). Intervention is exercise training.
3483537|NCT03768830|No Intervention|Healthy Control (no-Exercise)|Healthy individuals that will not exercise (HC).
3483538|NCT03768817||Patients treated with triheptanoin|Patients with LC-FAOD treated with triheptanoin before 01 September 2018 under eIND
3483539|NCT03768804|Other|SyncAV algorithm on|"Device randomised to have SyncAV on, with delta programmed to the value which gives the narrowest QRS duration at rest and pseudo left ventricular (LV) only pacing"
3483540|NCT03768804|Other|SyncAV algorithm off|"Device randomised to have SyncAV off, with a fixed sensed atrioventricular (AV) delay of 120ms or shorter if necessary to prevent fusion, and biventricular (BiV) pacing"
3483541|NCT03768791|Experimental|SCS off|
3483542|NCT03768791|Experimental|SCS on|
3483543|NCT03768778|Other|Debridement|
3483544|NCT03768765||Long Term Medication Usage|Patients who have been on medication for over a year for benign prostatic hyperplasia (BPH)
3179672|NCT00675467||Group 3|Early cancer group-parents of patients ages 10-18 years
3483545|NCT03768765||Short Term Medication Usage|Patients who have been on medication for under a year for benign prostatic hyperplasia (BPH)
3483546|NCT03768739||CICU extubated patients|Participants will undergo a Fiberoptic Endoscopic Evaluation of Swallowing (FEES)
3483547|NCT03768713|Experimental|Drug (Suvorexant)|20 mg of Suvorexant daily (taken orally ~1 hour before bedtime)
3483548|NCT03768713|Placebo Comparator|Placebo|20 mg of Placebo daily (taken orally ~1 hour before bedtime)
3483549|NCT03768700||Cohort|Hospitalization in a Post-Resuscitation Rehabilitation Care Units (SRPR)
3483550|NCT03768674||Inpatient cohort (Target group)|"Inpatient at mental health centre/ psychiatric hospital due to severe self-harm. Duration > 4 weeks and/or > five admissions last year.~Assessment of diagnoses, functioning and health services"
3483551|NCT03768674||Outpatient comparison cohort|"Admitted to treatment within Norwegian Network of personality-focused treatment during 2017-2018.~Assessment of diagnoses, functioning and health services"
3483552|NCT03768661||SILC Group|patients with symptomatic cholelithiasis submitted to a single-incision laparoscopic cholecystectomy
3483553|NCT03768661||Laparoscopy Group|patients with symptomatic cholelithiasis submitted to a standard three trocar laparoscopic cholecystectomy
3483554|NCT03768648|Experimental|patient|RRMS diagnosis according to McDonald criteria (Polman et al.,2005);
3483555|NCT03768648|Active Comparator|Control|40 Healthy controls (HC)
3483556|NCT03768635||Necrotizing external otitis|description of necrotizing external otitis
3483557|NCT03768609|Experimental|Group 1: Sequence AB|Participants will receive Treatment A (pimodivir 600 milligram [mg] orally as two tablets of 300 mg each) on Day 1 in Period 1 followed by Treatment B (pimodivir 600 mg as two tablets of 300 mg each plus cyclosporine 400 mg orally as four capsules of 100 mg each) on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
3483558|NCT03768609|Experimental|Group 2: Sequence BA|Participants will receive Treatment B on Day 1 in Period 1 followed by Treatment A on Day 1 in Period 2. Study drug intake in subsequent treatment periods will be separated by a washout period of at least 14 days.
3483559|NCT03768596|Experimental|Nudge|receiving nudge and form
3483560|NCT03768596|Active Comparator|No nudge|receiving the same form without nudge (only questions about their opinion/attitudes about vaccination)
3483561|NCT03768596|No Intervention|No intervention|receiving no nudge nor form
3483562|NCT03768583|Experimental|Group TSM ICT sneakers|"ICT with sneaker~five weeks~twice a week~half hour."
3127927|NCT03119688|Other|No Treatment|An area of the forearm that remained unwashed and was included in the study as a reference for the treated areas.
3179673|NCT00675467||Group 4|Advanced cancer group-children ages 10-13 years
3483563|NCT03768583|Experimental|Group TSM ICT barefoot|"ICT barefoot~five weeks~twice a week~half hour."
3483564|NCT03768583|Experimental|Group TSM health barefoot|"Health with sneaker~five weeks~twice a week~half hour."
3483565|NCT03768583|Experimental|Group TSM health sneakers|"Health barefoot~five weeks~twice a week~half hour."
3483566|NCT03768557|Experimental|Minocycline|single dose of minocycline (200mg)
3483567|NCT03768557|Placebo Comparator|Placebo|lactose pills (400mg)
3483568|NCT03768531|Experimental|Arm A: Nivolumab|
3483569|NCT03768531|Experimental|Arm B: Nivolumab and Cabrilizumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes, a 30 minute rest, followed by cabiralizumab every 2 weeks. (Cycle length 2 weeks).
3483570|NCT03768505|Experimental|Zandelisib (ME-401) open label|Subjects with relapsed/refractory FL or MZL will be administered 60 mg of ME-401 orally, once a day on an intermittent schedule (IS).
3483571|NCT03768492|Experimental|Caffeine Based Cream|caffeine based cream during and for 4 weeks following radiation
3483572|NCT03768492|Placebo Comparator|Placebo|placebo cream during and for 4 weeks following radiation
3483573|NCT03768479|Experimental|FES-Fulvestrant|Patients with ER positive breast cancer receive Fulvestrant as the first line treatment enrolled in the study would receive 18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant.
3483574|NCT03768466|Experimental|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
3483575|NCT03768440|Experimental|continuous erector spinae block|An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
3483576|NCT03768440|Active Comparator|continuous paravertebral block|A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
3483577|NCT03768427|Experimental|EZ 10 mg/Ator 10 mg|Single oral dose of EZ10mg/Ator10mg FDC tablet once daily (QD) for 84 days
3483578|NCT03768427|Active Comparator|Atorvastatin 20 mg|2 atorvastatin 10 mg tablets administered orally, QD for 84 days
3483579|NCT03768427|Experimental|EZ 10 mg/Ator 20 mg|Single oral dose of EZ10mg/Ator20mg FDC tablet QD for 84 days
3483580|NCT03768427|Active Comparator|Atorvastatin 40 mg|2 atorvastatin 20 mg tablets administered orally, QD for 84 days
3483581|NCT03768401|Experimental|Educational Seminars and Wellness Clinics|"I. Community outreach educational seminars about wellness and exercise while living with a neurological physical disability and measurement of the effects of these seminars for training individuals with neurological physical disabilities and their care givers (family, therapists, community personal trainers and community funders such as Lions or Rotary Clubs) about how to create a safe cost-effective exercise program .~II. Creation and measurement of the effects of a wellness clinic for those with a neurological physical disability."
3483582|NCT03768388|Other|Fasting State|A single 600 mg dose of levoketoconazole administered in a fasting state.
3483583|NCT03768388|Other|Fed State|A single 600 mg dose of levoketoconazole administered in a fed state.
3483584|NCT03768375|Experimental|target therap|The patients wil receive conventional chemotherapy(FORFIRINOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
3483585|NCT03768375|Experimental|FORFIRINOX|The patients wil receive conventional chemotherapy(FORFIRINOX)
3483586|NCT03768362|Experimental|Undergoing plication strabismus surgery|
3483587|NCT03768362|Active Comparator|Undergoing resection strabismus surgery|
3483588|NCT03768349|Experimental|PET/CT Ga-68 PSMA|Ga-68 labeled PSMA-11 (or PSMA-HBED-CC) PET/CT
3483589|NCT03768349|Experimental|PET/CT F-18 Labeled PSMA 1007|F-18 Labeled PSMA 1007 PET/CT
3127928|NCT03119701|Experimental|FP-1201-lyo 10 µg|"FP-12-lyo 10 µg (Interferon Beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.~Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection."
3127929|NCT03119701|Placebo Comparator|FP-1201-lyo Placebo|"FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.~Investigational placebo is lyophilisate for solution for injection which will be reconstituted in water for injection"
3483590|NCT03768323|No Intervention|Control|No airtime incentive was given for completing the survey
3483591|NCT03768323|Experimental|1X incentive|1X airtime incentive
3483592|NCT03768323|Experimental|2X incentive|2X airtime incentive
3483593|NCT03768310|Experimental|CD19.CAR-multiVST for Group A|"Group A: Patients with no evidence of disease after having a bone marrow transplant.~T cells will be given at the specified dose on or after day 30 after the bone marrow transplant. Three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
3483594|NCT03768310|Experimental|CD19.CAR-multiVST for Group B|"Group B: Patients with evidence of disease before bone marrow transplant OR have relapsed after bone marrow transplant.~Patients in Group B will receive the T cells at the earliest feasible time point after the detection of disease, but no earlier than day 30 after the transplant. The three dose levels will be studied in both groups of patients (Group A and Group B). The lowest dose level will be 2 x 10^7cells/m2 and the highest will be 10 x10^7cells/m2."
3483595|NCT03768297|Experimental|immediate implant with dual zone therapeutic concept|
3483596|NCT03768297|Active Comparator|immediate implant with buccal bone fill|
3483597|NCT03768245|Experimental|Behaviour|Physical activity and the Health Education programs are applied.
3483598|NCT03768245|Active Comparator|Nutrition|In this Arm, the the Physical activity, the Health education and Nutrition program are applied.
3483599|NCT03768219|Experimental|Stage 1 (SAD) Cohort 1|6 subjects will receive 2 mcg/kg of APVO210 2 subjects will receive placebo
3483600|NCT03768219|Experimental|Stage 1 (SAD) Cohort 2|6 subjects will receive 5 mcg/kg of APVO210 2 subjects will receive placebo
3127930|NCT03119831|Experimental|C31G (Group A)|C31G
3127931|NCT03119831|Experimental|Alcohol-free Chlorhexidine (Group B)|Alcohol-free Chlorhexidine Gluconate 0.12%
3127932|NCT03119831|Experimental|Alcohol-based Chlorhexidine (Group C)|Alcohol-based Chlorhexidine Gluconate 0.12%
3127933|NCT03120013|Experimental|Real tDCS|10 days anodal cerebellar and cathodal spinal tDCS
3483601|NCT03768219|Experimental|Stage 1 (SAD) Cohort 3|6 subjects will receive 10 mcg/kg of APVO210 2 subjects will receive placebo
3483602|NCT03768219|Experimental|Stage 1 (SAD) Cohort 4|6 subjects will receive 20 mcg/kg of APVO210 2 subjects will receive placebo
3483603|NCT03768219|Experimental|Stage 1 (SAD) Cohort 5|6 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
3483604|NCT03768219|Experimental|Stage 1 (SAD) Cohort 6|6 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
3483605|NCT03768219|Experimental|Stage 1 (SAD) Cohort 7|6 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
3483606|NCT03768219|Experimental|Stage 1 (SAD) Cohort 8|6 subjects will receive 320 mcg/kg of APVO210 2 subjects will receive placebo
3483607|NCT03768219|Experimental|Stage 2 (MAD) Cohort 9|8 subjects will receive 40 mcg/kg of APVO210 2 subjects will receive placebo
3483608|NCT03768219|Experimental|Stage 2 (MAD) Cohort 10|8 subjects will receive 80 mcg/kg of APVO210 2 subjects will receive placebo
3483609|NCT03768219|Experimental|Stage 2 (MAD) Cohort 11|8 subjects will receive 160 mcg/kg of APVO210 2 subjects will receive placebo
3483610|NCT03768219|Experimental|Stage 2 (MAD) Cohort 12|8 subjects will receive 360 mcg/kg of APVO210 2 subjects will receive placebo
3483611|NCT03768219|Experimental|Expansion Cohort (Psoriasis)|"12 subjects will receive the starting dose for the Psoriasis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
3483612|NCT03768219|Experimental|Expansion Cohort (Ulcerative Colitis)|"12 Subjects will receive the starting dose for the Ulcerative Colitis Patients Expansion Cohort portion of the study will be the recommended dose from Stage 2 of the study of APVO210. It will be a dose that has been demonstrated to be safe and well tolerated by the Safety Monitoring Committee.~8 subjects will receive placebo"
3483613|NCT03768193|Experimental|Deep serratus anterior plane block|Ultrasound-guided deposition of 40mls of 2mg/ kg levobupivacaine into the deep serratus anterior plane space, in the mid axillary line, at the level of the 4th/5th rib. Insertion of a continuous local anaesthetic infusion catheter(Portex™) and continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
3483614|NCT03768193|Active Comparator|Surgically-placed paravertebral block|Surgical placement of paravertebral local anaesthetic infusion catheters (Portex™) prior to closure. Bolus of levobupivacaine as per protocol. Continuation of an infusion of 0.125% levobupivacaine at a rate of 8-12mls/ hour for 48 hours.
3483615|NCT03768167|Other|patients with metastatic spinal lesions|corpectomy
3483616|NCT03768154|Experimental|study arm|all patients will receive all four intervention in the same sequential method
3483617|NCT03768141||Liver surgery|Any type of liver surgery
3483618|NCT03768089|Experimental|Part A: VX-121 in Healthy Subjects (HS)|Single dose escalation.
3483619|NCT03768089|Placebo Comparator|Part A: Placebo|
3483620|NCT03768089|Experimental|Part B: VX-121 in HS|Multiple-dose escalation.
3483621|NCT03768089|Placebo Comparator|Part B: Placebo|
3483622|NCT03768089|Experimental|Part C: VX-121 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-121 in TC with TEZ/IVA.
3483623|NCT03768089|Placebo Comparator|Part C: Placebo|
3483624|NCT03768089|Experimental|Part D: VX-121 in TC with TEZ/IVA in subjects with CF|VX-121 in TC with TEZ/IVA in subjects with CF.
3483625|NCT03768089|Placebo Comparator|Part D: Placebo|
3483626|NCT03768050|Active Comparator|Advanced care for frail elderly|Integrated care program for frail elderly covering Home Hospitalization/Early Discharge; geriatric residences and; home-based case management done by dedicated teams specialised in geriatric medicine
3483627|NCT03768050|No Intervention|Standard care|Usual care at the community and geriatric residences by primary care physicians
3483628|NCT03768037|Experimental|Anlotinib plus Pemetrexed|Anlotinib plus Pemetrexed
3483629|NCT03768037|Other|Pemetrexed|Pemetrexed
3483630|NCT03768024|Experimental|Treatment A: GRT0151Y 100 mg|Treatment A: GRT0151Y 100 mg free base: 2 × GRT0151Y 50 mg capsules and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483631|NCT03768024|Experimental|Treatment B: GRT0151Y 200 mg|Treatment B: GRT0151Y 200 mg free base: 4 × GRT0151Y 50 mg capsules and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483632|NCT03768024|Experimental|Treatment C: GRT0151Y 400 mg|Treatment C: GRT0151Y 400 mg free base: 8 × GRT0151Y 50 mg capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483633|NCT03768024|Experimental|Treatment D: Matching placebo|Treatment D: Matching placebo to GRT0151Y and hydromorphone IR: 8 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483634|NCT03768024|Experimental|Treatment E: Hydromorphone IR 4 mg|Treatment E: Hydromorphone IR 4 mg: 1 × hydromorphone IR 4 mg tablet (encapsulated) and 7 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483635|NCT03768024|Experimental|Treatment F: Hydromorphone IR 8 mg|Treatment F: Hydromorphone IR 8 mg: 2 × hydromorphone IR 4 mg tablet (encapsulated) and 6 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483636|NCT03768024|Experimental|Treatment G: Hydromorphone IR 16 mg|Treatment G: Hydromorphone IR 16 mg: 4 × hydromorphone IR 4 mg tablet (encapsulated) and 4 placebo capsules. A single dose comprised 8 capsules in total which will be taken with water and in a fasted state.
3483637|NCT03767998|Experimental|IMST group|Interventions: Respiratory muscle training for IMST. Inspiratory muscle training for patients with inspiratory muscle weakness (MIP less than 70% of normal range). IMT will commence from 30% to 60 % of MIP and then adjust one level of training loading according to the tolerance of continuously breathing through a respiratory trainer for two sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week.
3483638|NCT03767998|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
3483639|NCT03767998|Experimental|EMST group|Intervention: Respiratory muscle training for EMST. For patients with only swallowing disturbance. Training resistance will be adjusted accordingly. The loading will be performed with the previous resistance setting or even lower if training load is not tolerated or not completed.
3483640|NCT03767985|Active Comparator|Occlusion therapy|Participants are prescribed 2 hours of occlusion therapy per day, 7 days a week.
3483641|NCT03767985|Experimental|Dichoptic video game therapy|Participants receive dichoptic video game therapy: 1 hour per week at the out-patient clinic under direct supervision.
3483642|NCT03767972|Experimental|Rejuvenation|Adults requiring rejuvenation of either the face, neck/décolletage, hands, upper and lower extremities, trunk and/or vagina will receive energy-based treatment (Fraxel Restore, Helios III, PicoWay, Halo, ThermiVa or DiVa) based on the investigators' assessment and discretion. The treating physician will decide which energy-based device is best-suited to addressing the patients' aging concerns; although patient preference will be taken into account, ultimately the treating physician will be responsible for the correct assessment of patients' rejuvenation needs and use of appropriate energy-based devices for the final treatment.
3127934|NCT03120013|Sham Comparator|Sham tDCS|10 days sham cerebellar and sham spinal tDCS
3127935|NCT03120351|Experimental|Lidocaine patch 5%|1) Group I: Patients will receive topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl repeated clinician boluses, later oxycodone will be given 5-10 mg q4-6 hours as needed for pain.
3127936|NCT03120351|Placebo Comparator|Placebo Patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off. They will also receive opioids as needed after the surgery. Initially, they may receive IV fentanyl clinician boluses, later oxycodone will be given in doses from 5-10 mg q4-6 hours as needed for pain.
3127937|NCT03120520|Experimental|Plecanatide 0.5 mg|Taken orally once daily in the morning for 8 weeks
3127938|NCT03120520|Experimental|Plecanatide 1.0 mg|Taken orally once daily in the morning for 8 weeks
3127939|NCT03120520|Experimental|Plecanatide 1.5 mg|Taken orally once daily in the morning for 8 weeks
3127940|NCT03120520|Placebo Comparator|Matching placebo|Taken orally once daily in the morning for 8 weeks
3127941|NCT03120832|Experimental|PAN-301-1 (SNS-301) Vaccine|PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
3127942|NCT03121144|Experimental|Masimo Centroid System|Single-arm study. All subjects are enrolled into the test group wherein the noninvasive positional monitoring device will be administered.
3179674|NCT00675467||Group 5|Advanced cancer group-children ages 14-18 years
3483643|NCT03767959|Experimental|Chen's U-Suture|Patients in this group will treated by Chen's U-suture technique in pancreaticojejunostomy.
3483644|NCT03767959|Active Comparator|Classic pancreatic duct to mucosa|Patients in this group will treated by classic pancreatic duct to mucosa technique in pancreaticojejunostomy.
3483645|NCT03767946||Group 1|"Children both genders according to age:~*1-year old children (12 months -1/+4 months); n=125 at the date of recruitment."
3483646|NCT03767946||Group 2|"Children both genders according to age:~*2-year-old children (24 months -1/+4 months); n=125 at the date of recruitment."
3483647|NCT03767946||Group 3|"Children both genders according to age:~*5-year old children (60 months +/- 6 months); n=125 at the date of recruitment."
3483648|NCT03767946||Group 4|"Children both genders according to age:~*12-years old children (12 years old +/- 6 months); n=125 at the date of recruitment."
3127943|NCT03121365|Active Comparator|Standard/Board Book Arm|Parent-infant dyads randomized to the standard/board book arm will receive developmentally appropriate early reader board books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
3127944|NCT03121365|Experimental|Digital/E-Book Arm|Parent-infant dyads randomized to the digital/e-book arm will receive developmentally appropriate e-books at the time of their infant's 6, 9, and 12 month well visits. In addition to the books, parent-infant dyads will be provided information on the importance of early parent-child reading activity by pediatric clinicians using the Reach Out and Read framework.
3483649|NCT03767920|Active Comparator|bupivacaine and dexamethasone|Bilateral TAP block with 20 ml of 0.25% bupivacaine + 4 mg/kg dexamethasone diluted with isotonic saline.
3483650|NCT03767920|Active Comparator|bupivacaine and placebo to dexamethasone|BilateralTAP block with 20 ml of 0.25% bupivacaine bilaterally plus placebo to dexamethasone
3483651|NCT03767881|Experimental|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
3483652|NCT03767855|Experimental|CK-3773274 for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of CK-3773274
3483653|NCT03767855|Placebo Comparator|Placebo for SAD Cohorts|Subjects will be assigned to one of 8 planned dose cohorts and receive single doses of placebo
3483654|NCT03767855|Experimental|CK-3773274 for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of CK-3773274
3483655|NCT03767855|Placebo Comparator|Placebo for MAD Cohorts|Subjects will be assigned to one of 3 planned dose cohorts and receive multiple doses of placebo
3483656|NCT03767855|Experimental|CK-3773274 for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of CK-3773274
3483657|NCT03767855|Placebo Comparator|Placebo for CYP2D6 Cohort|Subjects with CYP2D6 poor metabolizer phenotype will be assigned to receive a single dose of placebo
3483658|NCT03767855|Experimental|Food Effect|Subjects will be administered CK-3773274 with and without food in a randomized cross-over fashion
3483659|NCT03767855|Experimental|Relative Bioavailability|Subjects will be administered CK-3773274 as granules in a capsule and as a tablet in a randomized cross-over fashion.
3483660|NCT03767829|Experimental|Part A: SAD: ALN-AAT02|Participants will be administered a single dose of ALN-AAT02.
3483661|NCT03767829|Placebo Comparator|Part A: SAD: Placebo|Participants will be administered a single dose of matching placebo.
3483662|NCT03767829|Experimental|Part B: MAD: ALN-AAT02|Participants will be administered multiple doses of ALN-AAT02.
3483663|NCT03767829|Placebo Comparator|Part B: MAD: Placebo|Participants will be administered multiple doses of matching placebo.
3483664|NCT03767816|Experimental|Group R : Rectus sheath block group|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision
3483665|NCT03767816|Active Comparator|Group RE: Rectus sheath block and erector spinae plane block|ultrasound guided Rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml before surgical incision and ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml
3483666|NCT03767803||Positive Preeclampsia group|A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery
3483667|NCT03767803||Study Cohort|A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.
3483668|NCT03767790|Experimental|Automated Insulin Delivery|Participants will use the Automated Insulin Delivery (AID) iAPS system for 2 weeks in the outpatient setting. During AID use, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
3483669|NCT03767790|No Intervention|SAP/PLGS|Participants will use their home pump with a CGM sensor (sensor augmented pump) or in Predictive Low Glucose Suspend (PLGS) mode if their home pump supports this mode, for 2 weeks in the outpatient setting. During these 2 weeks, subjects will consume 6 study meals (3 meals of each meal type in assigned random order, 1-2 portions per meal,) at dinner time over the 2-week period in a pre-assigned random order, and document on the study meal forms when they consume each numbered meal.
3483670|NCT03767777|Experimental|Intervention arm|Participants will be treated with Artery Stent Graft System Intervention: Device: Artery Stent Graft System
3483671|NCT03767764||HCC|Patients with diagnosis of Hepatocellular carcinoma
3483672|NCT03767764||Cirrhosis|Patients with the diagnosis of cirrhosis who is following a screening program for diagnosis of HCC
3483673|NCT03767764||Chronic liver diseases|Patients with the diagnosis of Chronic liver diseases without cirrhosis
3483674|NCT03767764||Control|Normal human serum from donors without liver disease
3127945|NCT03121612|Experimental|Dolphin CPAP|CPAP machine with oxygen intake and an on-board air compressor, and integrated blender and humidifier, delivering heated humidified blended gases through a Fisher-Paykel nasal mask. [Also includes built-in Massimo pulse oximeter, though this is not used for this study, to prevent differential measurement error in SpO2 measurement]
3127946|NCT03121612|Active Comparator|Fisher-Paykel CPAP|Fisher-Paykel (F&P) CPAP machine with separate oxygen and medical air intakes, with third-party FP-compliant blender, and F&P blender, delivering heated humidified blended gases through a Fisher-Paykel nasal mask.
3483675|NCT03767725|Experimental|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART19 cells.
3127947|NCT03121820|Experimental|Memantinol tablets, 20 mg|"Treatment A: a single oral dose of memantin 20 mg film-coated tablet (JSC GEROPHARM, Russia - test)"
3127948|NCT03121820|Active Comparator|Akatinol Memantine® tablets, 20 mg|Treatment B: a single oral dose of memantin 20 mg film-coated tablet (Merz Pharma GmbH & Co. KGaA, Germany - reference)
3483676|NCT03767673|Experimental|Patients after esophageal atresia|Patients older than 12 years following surgical repair of congenital esophageal atresia will be included after written informed consent. Patients will be subjected to spirometry to determine their age, weight (determined by Kilogram (kg) on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
3483677|NCT03767673|Active Comparator|Control group|Age and sex matched adolescents will be recruited as control group and will be included after written informed consent. Adolescents will be subjected to spirometry to determine their age, weight (determined by Kilogram on a medical weight scale) and Vital Capacity before (initial Spirometry) and after (final Spirometry) exercise performance testing. Bicycle ergospirometer will be applied to determine the Maximum Oxygen Uptake and the Maximum Performance. Thereafter deep induced sputum will be harvested for measurements of the pulmonary microbiome (Pulmonary Microbiome 16S rDNA profiling).
3483678|NCT03767660|Experimental|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
3483679|NCT03767647|Experimental|Intervention group|Receives 6 lessons in 6 different weeks on Emotional Intelligence
3483680|NCT03767647|No Intervention|Control group|Receives no intervention.
3483681|NCT03767634||Neonatal population (Project A)|Neonates born between 1st January 2012 and 31st December 2017 and admitted to a neonatal unit in England, Scotland and Wales).
3179675|NCT00675467||Group 6|Advanced cancer group-parents of children ages 10-18 years
3179676|NCT00675467||Group 7|End of life group - parents of children ages birth to 18 years of age at time of death
3483682|NCT03767634||No PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who did not receive any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
3483683|NCT03767634||PN use (Project B)|All neonates born between 30 and 33 weeks postmenstrual age in England, Wales and Scotland and admitted to a NHS neonatal unit between 1st January 2012 and 31st December 2017 who received any parenteral nutrition (for any duration, by any intravenous route) in the first seven postnatal days.
3483684|NCT03767621||Patients with intermediate lesions.|Patients with intermediate lesions (stenosis in angiography between 25% and 60%) in LMCA.
3179677|NCT00675480|Experimental|T|Patients treated with thrombectomy: T
3179678|NCT00675480|Active Comparator|P|Patients treated with standard PCI with stent implantation
3483685|NCT03767595|Experimental|ProACT Adjustable Continence Therapy for Men|Patients implanted with ProACT Adjustable Continence Therapy for Men
3483686|NCT03767582|Experimental|Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist|
3483687|NCT03767582|Experimental|Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist|
3483688|NCT03767582|Experimental|Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist|
3483689|NCT03767569|Experimental|Myo-inositol|Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology)
3483690|NCT03767569|Other|Folic acid|Folic acid 0.4 mg daily during 12 weeks before start of ART
3483691|NCT03767556|No Intervention|Control|This group will not receive intervention
3127949|NCT03121950|Experimental|Dance in dementia|examine if participating in a dance class improves mobility and/or cognition in individuals with dementia.
3127950|NCT03121950|Active Comparator|Music and dementia|examine if listening to music improves mobility and/or cognition in individuals with dementia.
3127951|NCT03122145|Experimental|Healthy Volunteers - Experiment 1|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo voluntary and reflexive cough testing. The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
3179679|NCT00675493||A|
3179680|NCT00675519|Experimental|BI|
3179681|NCT00675532|Experimental|1|Primary Care Counseling
3179682|NCT00675532|Experimental|2|Cognitive-behavioral psychotherapy (CBT)
3179683|NCT00675545|Experimental|docetaxel and prednisolone|"Patients in study will receive both chemotherapeutic agents on day 1 and day 8 of every 21-day cycle as described below:~Docetaxel 30 mg/m2 over 1 hour IV infusion, followed by~Carboplatin (AUC 2) over 1 hour IV infusion~Additonal medication required: IV Dexamethasone 10 mg followed by PO dexamethasone 4 mg 8 hourly x 4 doses, starting 12 hours after starting iv docetaxel."
3179684|NCT00675610|No Intervention|usual care|providers are not trained and patients are not coached
3179685|NCT00675610|Experimental|intervention arm|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
3179686|NCT00675623|Experimental|A|Dimebon, 5 mg orally three times daily
3179687|NCT00675623|Experimental|B|Dimebon 20 mg orally three times daily
3483692|NCT03767556|Experimental|Inspiratory Muscle Training|This group, for inspiratory muscle training, will use the Powerbreathe® K5 device. This device will be adjusted with a load of 55% of previously assessed MIP. The volunteer will be instructed to inhale with sufficient force to overcome the resistance of the equipment and subsequently perform a normal expiration. During the 4-week period of respiratory muscle training volunteers will be instructed to perform 2 sets with 30 inspiratory efforts, 5 days a week. The training load will be readjusted on the first day of training each week, after a new reassessment of the PIMax in order to guarantee the overload during inspiratory muscle training.
3483693|NCT03767543|Experimental|iGlarlixi DAILY|Titration Group 1: Addition of 1 unit per day until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
3132725|NCT03447314|Experimental|Part 1c: 200ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 200 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 200 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 200 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
3179688|NCT00675623|Placebo Comparator|C|Placebo orally three times daily for six months
3483694|NCT03767543|Active Comparator|iGlarlixi WEEKLY|Titration Group 2: Algorithm of weekly adjustment until pre-stated fasting self-monitoring plasma glucose (SMBG) level is reached
3483695|NCT03767530|Experimental|Mibo Thermoflo (thermal device)|3 sessions at 2 weeks interval (basal, week 2, week 4)of 11 minutes per eye of thermal therapy with Mibo Thermoflo.
3483696|NCT03767530|Active Comparator|Warm compresses and eyelid massage|2 times per day, 11 minutes per eye.
3483697|NCT03767517|Experimental|Active Intervention|Usual Care + Tele-consult Intervention
3483698|NCT03767517|Active Comparator|Usual Care|Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
3483699|NCT03767504|Experimental|Musclin|Thymol based dietary supplement
3179689|NCT00675649|Experimental|001|
3179690|NCT00675649|Placebo Comparator|002|
3179691|NCT00675662|Experimental|1|Stratification by angiotensin converting enzyme (ACE) genotype
3179692|NCT00675662|Placebo Comparator|2|Waiting list controls
3483700|NCT03767491|Experimental|Smartphone-delivered CBT for OCD|12-week Smartphone delivered CBT for OCD.
3483701|NCT03767491|Other|12 Week Waitlist Control|12-week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for OCD following the 12-week waitlist control).
3483702|NCT03767478|Sham Comparator|Control group|Best Medical Therapy + Sham Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
3483703|NCT03767478|Active Comparator|Intervention group|Best Medical Therapy + Revitive Medic Coach Neuromuscular Electrical Stimulation Device for 6 months
3483704|NCT03767452|Experimental|Single-Arm|Xiaflex® 0.58 mg, 2 injections separated by 1 to 3 days, repeated after 6 weeks for up to 4 treatment cycles.
3483705|NCT03767439|Experimental|Nivolumab, Vismodegib, Ipilimumab|"Patients will receive a two week run-in of Vismodegib 150 mg PO daily followed by concurrent Nivolumab 480 mg IV every 4 weeks and Vismodegib 150 mg PO daily.~In an exploratory fashion, patients will have the option to receive combination Ipilimumab 1 mg/kg IV every 6 weeks and Nivolumab 360 mg IV every 3 weeks at the time of disease progression."
3483706|NCT03767426|No Intervention|Overnight sleep|Subjects are permitted a night of polysomnograph-recorded sleep before participating in training and testing sessions the next day
3483707|NCT03767426|Active Comparator|Sleep deprivation|Subjects sleep deprived before participating in training and testing sessions the next day
3483708|NCT03767426|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
3483709|NCT03767413|Active Comparator|PNF group|It will be consisted of 15 -25 healthy subjects receiving only proprioceptive nueromuscular facilitation training for 5 weeks with 17 days follow up after completion of program.
3483710|NCT03767413|Experimental|PNFMP|It will be consisted of 15 -25 healthy subjects receiving proprioceptive nueromuscular facilitation training and mental practice technique for 5 weeks with 17 days follow up after completion of program.
3179693|NCT00675675|Active Comparator|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training (HRT) plus functional assessment/intervention designed to identify and ameliorate environmental triggers for and consequences to tics that might serve to maintain and/or generalize these symptoms
3179694|NCT00675675|Other|Minimal Contact Waitlist|Bimonthly phone check-in to assess illness severity and maximize subject retention
3483711|NCT03767400||Group A - Young skin (18 - 30 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
3483712|NCT03767400||Group B - Aged skin (55 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
3483713|NCT03767400||Group C - Atrophic acne scars (18 - 75 years old)|Assessments will be made after facial cleansing on areas being imaged utilizing VivoSight Dynamic Optical Coherence Tomography (D-OCT). Post-study D-OCT images will be processed with VivoSight software. Assessments of participant's overall photodamage and participant's appearance of fine lines/wrinkles will be measured.
3483714|NCT03767387|Active Comparator|Prehabilitation + standard care|Trimodal Prehabilitation consisting on motivation, personalisation and supervision of physical activity before major surgery
3483715|NCT03767387|No Intervention|Standard care|Standard care before major surgery
3483716|NCT03767374||Main study group (HIV-negative)|"2000 HIV-negative individuals seeking care at the STI clinic of Saint-Antoine Hospital~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
3483717|NCT03767374||Exposure-matched group (HIV-positive)|"500 HIV-positive men who have sex with men from the Infectious Diseases Unit of Saint- Antoine Hospital. These individuals will be compared to 500 HIV-negative MSM from the main study group, matching on age (+/-5 years).~Inguinal swab sample~Anal swab sample~Fecal sample~Risk factor assessment"
3483718|NCT03767361|Active Comparator|Fresh PRBCs|Neonates will receive fresh packed red blood cells transfusion within 7 days of donation
3483719|NCT03767361|Active Comparator|Old PRBCs|Neonates will receive fresh packed red blood cells transfusion older than 7 days yet within the standard range accepted universally will be transfused to this group.
3483720|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in superficial tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors
3179695|NCT00675688|Experimental|A|
3179696|NCT00675688|Active Comparator|B|
3179697|NCT00675688|Placebo Comparator|C|
3179698|NCT00675701|Placebo Comparator|A|Placebo by mouth
3179699|NCT00675701|Experimental|B|lixivaptan
3483721|NCT03767348|Experimental|Dose escalation of RP1 by intratumoral (IT) injection in deep/visceral tumors|Dose escalation of RP1 alone in 3 cohorts with IT injections in deep/visceral tumors
3483722|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in superficial tumors|Doses of RP1 (IT) in superficial tumors with nivolumab (IV)
3483723|NCT03767348|Experimental|Dose expansion of RP1 and nivolumab (IV) in deep/visceral tumors|Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)
3483724|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma
3483725|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors
3483726|NCT03767348|Experimental|RP1 (IT) and nivolumab (IV) in NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer
3483727|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1 Failed Cutaneous Melanoma|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy
3483728|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NMSC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non-melanoma skin cancer who have been previously treated with anti-PD1/PD-L1 therapy
3483729|NCT03767348|Experimental|RP1(IT) and nivolumab (IV) in anti-PD1/PD-L1 Failed NSCLC|Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with non small cell lung cancer who have been previously treated with anti-PD1/PD-L1 therapy
3483730|NCT03767335|Experimental|MEN1611|MEN1611 + Trastuzumab +/- Fulvestrant
3483731|NCT03767322|Active Comparator|Allopurinol group|The intervention group will receive 300 mg of allopurinol 12 hours before and 12 hours after the coronary intervention.
3483732|NCT03767322|Placebo Comparator|Placebo group|The placebo group will receive 300 mg of placebo 12 hours before and 12 hours after the coronary intervention.
3127952|NCT03122145|Experimental|Healthy Volunteers - Experiment 2|This study will involve a single 60-minute visit. All women under the age of 62 will be asked to complete a pregnancy test as part of the screening process during to radiation exposure. Eligible participants will then undergo a instrumental swallowing evaluation (videofluoroscopy). The entire duration of the exam will be under 60 minutes and the participant will be free to leave at any point during the examination.
3127953|NCT03122171|Experimental|Prosthesis|
3483733|NCT03767322|Active Comparator|Febuxostat group|The intervention group will receive 80 mg of febuxostat 12 hours before and 12 hours after the coronary intervention
3483734|NCT03767309|Experimental|Test group|SCTG will be harvested from the palate in the intervention group (coronally advanced flap and abrasively de-epithelialized free gingival graft)
3483735|NCT03767309|Active Comparator|Control group|SCTG will be harvested from the palate using Zucchilli's technique (zucchelli, 2010) in the control group (coronally advanced flap and conventionally de-epithelialized free gingival graft)
3483736|NCT03767296|Experimental|Dose Bolus of E-P-E|Ephedrine Hydrochloride 3 MG/ML- Phenylephrine - Ephedrine Hydrochloride 3 MG/ML
3483737|NCT03767296|Experimental|Dose Bolus P-E-P|Phenylephrine- Ephedrine Hydrochloride 3 MG/ML - Phenylephrine
3483738|NCT03767296|Experimental|Dose Bolus E-E-E|Ephedrine Hydrochloride 3 MG/ML- Ephedrine Hydrochloride 3 MG/ML - Ephedrine Hydrochloride 3 MG/ML
3483739|NCT03767296|Experimental|Dose Bolus P-P-P|Phenylephrine-Phenylephrine-Phenylephrine
3127954|NCT03122184|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
3127955|NCT03122184|Active Comparator|Motivational Interviewing Health Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior (physical activity, medication adherence, diet, stress reduction) and assign an activity related to one health behavior each week. Motivational interviewing techniques will be used throughout to facilitate health behavior changes.
3483740|NCT03767270|Experimental|MRT5201|Single Ascending Low, Mid, and High doses of MRT5201
3483741|NCT03767270|Placebo Comparator|Placebo|Placebo comparator using 5% dextrose in water at the same administration rate as study drug.
3483742|NCT03767257|Experimental|Participants with Myeloma|Individuals with Myeloma on lenalidomide maintenance who experience grade 2 or more diarrhea
3483743|NCT03767231|Experimental|HCV POC VL Group|This group will receive the POC HCV viral load testing via fingerstick using the novel Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid) in addition to the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
3127956|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/MF59 + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL100 mcg Protein/MF59 and 0.75 mL placebo injection in the right deltoid on Months 3 and 6.
3179700|NCT00675701|Active Comparator|C|moxifloxacin
3179701|NCT00675714|Experimental|1|Humatrope subcutaneous(SQ) 0.05-0.2 mg/kg/day for up to 2 years post burn
3483744|NCT03767231|No Intervention|Reference Group|This group will receive the standard-of-care whole-blood conventional laboratory-based HCV PCR viral load testing only. Participants in this group will also fill out a short survey regarding participant's socio-demographic information as well as participant's experience, attitudes, and perceptions regarding HCV testing and care.
3483745|NCT03767218|Experimental|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
3483746|NCT03767218|Active Comparator|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
3483747|NCT03767205|Experimental|stroke patients|All participants perform overground walking and treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot).
3483748|NCT03767192|Experimental|Active Stimulation|Device: The Ischemic Stroke System SPG stimulation and standard of care
3483749|NCT03767192|Sham Comparator|Sham Stimulation|Device: Sham control Sham stimulation and standard of care
3483750|NCT03767179||Study Group|The study group consisted of 30 fertile, under 35 years old women who were included in the study for the first time missed abortus diagnosis.
3483751|NCT03767179||Control Group|30 cases with the same trimester, fertile, and under 35 years old who were referred to Obstetrics clinic, who had no systemic disease, were included in the study.
3483752|NCT03767140|Experimental|Verum acupucnture|Real acupuncture treatment
3483753|NCT03767140|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
3483754|NCT03767114|Experimental|cases of psoriasis|group of 25 cases of psoriasis subjected to skin biopsy for detection of lesional and non lesional expression of ERAP1 by RT-PCR
3483755|NCT03767114|Experimental|normal controls|group of 30 age and sex matched healthy controls o subjected to skin biopsy from normal skin for detection of expression of ERAP1 by RT-PCR
3127957|NCT03122223|Active Comparator|ALVAC-HIV + 100mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL100 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
3127958|NCT03122223|Active Comparator|ALVAC-HIV + 20mcg Protein/AS01(B) + Placebo|50 participants will receive 1 mL ALVAC-HIV injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.75 mL 20 mcg Protein/AS01(B) and 0.5 mL placebo injection in the right deltoid on Months 3 and 6.
3127959|NCT03122223|Placebo Comparator|Placebo|10 participants will receive 1 mL of the placebo injection in the left deltoid on Months 0, 1, 3, and 6. They will receive 0.5 mL of the placebo injection and 0.75 mL of a separate placebo injection in the right deltoid on Months 3 and 6.
3127960|NCT03122457|Experimental|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combo|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination gel; daily use for 99 days
3127961|NCT03122535|Active Comparator|FS-LASIK 70 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
3127962|NCT03122535|Active Comparator|FS-LASIK 110 degree side-cut angle|Each patient will be masked as to which angle of cut is used in which eye. Each patient will receive a 70 degree cut in one eye and a 110 degree cut in the fellow eye.
3132726|NCT03447314|Experimental|Part 1c: 250ng GSK1795091 + 200mg Pembrolizumab|Participants will be administered GSK1795091 250 ng IV on Days 1 and 8 followed by once weekly administration of GSK1795091 250 ng IV in combination with pembrolizumab 200 mg administered at Q3W via the IV route until Week 12. From Week 12 onwards, GSK1795091 250 ng IV will be administered in combination with pembrolizumab 200 mg at Q3W interval.
3483756|NCT03767101|Experimental|TAU + Positive mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented positive mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a happy, positive situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities and feelings in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
3483757|NCT03767101|Active Comparator|TAU + Neutral mental imagery|In all conditions the first eight sessions of treatment are focused. All sessions start with a brief, audio-tape presented neutral mental imagery intervention (duration about six minutes). In this intervention patients are guided to imagine a all-day, non-emotional provoking situation within the last seven days. Patients get the instruction to imagine from a field perspective, exploring various sensory modalities in that specific moment. Patients perform this task in the rooms of the treatment center together with their therapists. The text of the mental imagery intervention is standardized and spoken by Prof. Dr. Ulrike Willutzki. Directly before and after the imagination patients are asked on their mood with a single-item. After the short intervention patients are instructed to communicated the content of their imagination with their therapists for about one minute. After completion the regular cognitive behavioral therapy session begins.
3483758|NCT03767101|Other|Treatment as usual|In all conditions the first eight sessions of treatment are focused. No additional intervention is conducted at the start of therapy sessions. Standard cognitive behavioral therapy is conducted during the whole treatment sessions.
3483759|NCT03767088|Active Comparator|WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 8 muscle groups (legs, gluteal region, core, arms) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
3483760|NCT03767088|Active Comparator|partial WB-EMS|1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session stimulation of 2 muscle groups (legs, gluteal region; lower extremities) while performing slight eccentric pronounced physiological movement patterns parameters: 85 Hz, 350ms, intermittent, 4 s load vs 4 s regeneration
3483761|NCT03767088|Sham Comparator|control|active sham comparator: 1.5 sessions per week; in total: 6 training sessions training duration: 20 min per session performing slight eccentric pronounced physiological movement patterns
3483762|NCT03767075|Experimental|Module 1 Arm 1 - atezolizumab|"Genomically selected populations will all receive the same drug (6 groups of mutation will be evaluated)~Arm 1A: BRCA1 or BRCA2 mutations~Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations~Arm 1C: tumors with POLE mutation, POLD1 mutation.~Arm 1D: hypermutated tumors~Arm 1E: tumors with other mutations in DNA-repair genes.~Arm 1F: tumors with amplified PDL1~Subjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 100 patients in part B of module 1."
3483763|NCT03767049||Lung transplant patients readmitted in ICU|
3483764|NCT03767036|Active Comparator|Tramadol|Each participant received an oral dose of tramadol hydrochloride 25 mg (A1, one capsule) under fasting conditions with 250 milliliters (mL) of water.
3483765|NCT03767036|Active Comparator|Ketorolac|Each participant received an oral dose of ketorolac 10 mg (A2, one tablet) under fasting conditions with 250 mL of water.
3483766|NCT03767036|Experimental|Tramadol and ketorolac|Each participant received an oral dose of tramadol hydrochloride 25 mg and ketorolac 10 mg simultaneously (A3 = one capsule of A1 + one tablet of A2, test medication) under fasting conditions with 250 mL of water.
3483767|NCT03767023||Stable AAA|"= patients with a small abdominal aortic aneursym diameter < 55 mm "
3483768|NCT03767023||instable AAA|"=patients with a large abdominal aortic aneursym diameter > 55 mm and/or AAA with rapid growth who needs open surgery or EndoVascular Aneurysm Repair EVAR"
3483769|NCT03767010|Experimental|Control (no PLM)|Control: Pre, post, delayed test Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
3483770|NCT03767010|Experimental|Experimental (PLM)|Experimental: PLM group (pre, post, delayed test, PLM) Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
3483771|NCT03766997|Experimental|local injection|Compound betamethasone injection (Each injection contains betamethasone dipropionate at 5 mg for betamethasone and betamethasone sodium phosphate at 2 mg for betamethasone) was local injected to the breast by the patient once a week for one to four times followed by Hydrocortisone butyrate cream(0.1%) topical use twice a day until the termination of treatment.
3483772|NCT03766997|Active Comparator|topical|Hydrocortisone butyrate 0.1% cream was applied to the breast by the patient twice a day until the termination of treatment.
3483773|NCT03766984|Experimental|Diclofenac 25 mg|Participants receive 1 tablet of diclofenac sodium 25 mg with 250 milliliters of purified water.
3483774|NCT03766984|Experimental|Tramadol 25 mg|Participants receive 1 tablet of tramadol hydrochloride 25 mg with 250 milliliters of purified water.
3483775|NCT03766984|Experimental|Diclofenac/Tramadol 25 mg/25 mg FDC|Participants receive 1 fixed-dose combination tablet of diclofenac sodium 25 mg/tramadol hydrochloride 25 mg with 250 milliliters of purified water.
3483776|NCT03766971|Experimental|Early-onset Cigarette Smokers|Participants who began smoking cigarettes earlier in life (<16 years old) will be randomized to 7 or 21 days of tobacco cessation.
3483777|NCT03766971|Experimental|Late-onset Cigarette Smokers|Participants who began smoking cigarettes later in life (>16 years old) will be randomized to 7 or 21 days of tobacco cessation.
3483778|NCT03766932||Blood culture candida positive group|
3483779|NCT03766932||Tracheal aspiration candida culture positive group|
3483780|NCT03766932||Urine candida culture positive group|
3483781|NCT03766932||Other aseptic humoral candida positive group|
3483782|NCT03766919|Experimental|INVICTA lead|All patients eligible for enrolment in whom the INVICTA lead is attempted (Implant of the INVICTA lead)
3127963|NCT03122548|Experimental|CRS-207 + Pembrolizumab|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
3127964|NCT03122587|Sham Comparator|Active Sham (Session 1 and Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Session 2
3483783|NCT03766906|Experimental|Talk STEM Familia App|This arm will test the feasibility of the Talk STEM Familia app to improve English language acquisition and family engagement and promote long-term educational and health outcomes among first- and second-generation Latino families.
3483784|NCT03766893|Experimental|Pharmacy based opioid use disorder care|A single-arm pilot study to test the collaborative pharmacy practice agreement for MAT (using the medications buprenorphine or injectable naltrexone) care model with up to 12 patients with opioid use disorder, assessing feasibility of medication dispensing, administration, and monitoring in the pharmacy, and determining patient acceptability of this model.
3483785|NCT03766880|Experimental|Single arm study|Participants will receive MR imaging, transjugular HVPG measurement, and analysis per protocol.
3179702|NCT00675714|Experimental|2|Ketoconazole by mouth (PO) given twice a day throughout hospitalization for up to 2 years post burn
3179703|NCT00675714|Experimental|3|Oxandrolone PO given daily throughout hospitalization for up to 2 years post burn
3483786|NCT03766867|Experimental|Vortioxetine|
3483787|NCT03766867|Placebo Comparator|Placebo|
3483788|NCT03766854|Experimental|Insulin 287 followed by insulin glargine U100|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin 287 once a week (OW) for 8 weeks and subsequent 4 weeks of terminal pharmacokinetic (PK) sampling where subjects are treated with once daily (OD) insulin glargine.~After insulin 287 treatment, participants will receive insulin glargine U100 OD for 2 weeks."
3483789|NCT03766854|Experimental|Insulin glargine U100 followed by insulin 287|"Run-in period (2 days to 7 weeks): The basal insulin glargine dose for each subject will be established and optimised.~After run-in, participants will receive insulin glargine U100 OD for 2 weeks followed by 1-14 days (at least 1 day is mandatory) of continued insulin glargine treatment.~After insulin glargine treatment, participants will receive insulin 287 OW for 8 weeks and subsequent 4 weeks of terminal PK sampling."
3483790|NCT03766841|Experimental|Facilitated Enrollment|Patients will be aided in the account creation and usage of a consumer informatics tool to collect and report patient-contextual data within the electronic health record
3483791|NCT03766841|No Intervention|Usual Care|Patients will be invited to use the patient contextual data tool as per usual care, but will not receive additional assistance in account creation and usage.
3483792|NCT03766828||inside-out-access technique with inside-out access device|
3483793|NCT03766828||access technique including Sharp recanalization|
3483794|NCT03766815|Placebo Comparator|Placebo|Fiber supplement mixed with jelly will be ingested for 18 days with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
3127965|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 10 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 10 Hz during Session 2
3132727|NCT03447314|Experimental|Part 2a: GSK1795091 + 24 mg GSK3174998|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3174998 24 mg.
3483795|NCT03766815|Experimental|BCAA 200mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (200mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
3483796|NCT03766815|Experimental|BCAA 400mg/kg/day|Branched-chain amino acid supplement mixed with jelly will be ingested for 18 days. The amount of supplement provided will be based on body weight (400mg/kg/day) with participants performing elbow eccentric contractions as a muscle damaging exercise on the 12th-day of supplementation.
3483797|NCT03766802|Active Comparator|Wearable watch training group.|"Aerobic exercises Strengthening exercises Stretching exercises Balance exercises Dose was increased as person is able to tolerate. Form:intervention is trackable and notifiable if patients don't exercise with smartwatch.~Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
3483798|NCT03766802|Active Comparator|Mobile application training group.|"Aerobic exercises Strengthening exercises Stretching exercises~Balance exercises Form:intervention is trackable and notifiable if patients don't exercise with smartphone Dose was increased as person is able to tolerate. Frequency:3/week Duration:12 weeks Dosage:Dose was increased as person is able to tolerate."
3483799|NCT03766802|Sham Comparator|Supervised exercise training group|Aerobic exercises Strengthening exercises Stretching exercises supervised by a physical therapist
3483800|NCT03766789|Active Comparator|Intervention|They will receive the cell phone application, as reminder of medications time and dose.
3483801|NCT03766789|No Intervention|Control|Patients will receive standard of care recommendations.
3483802|NCT03766776|Experimental|Anlotinib Arm|
3483803|NCT03766763|Experimental|ARM A VENETOCLAX|VENETOCLAX
3483804|NCT03766750|Experimental|LIMA|
3483805|NCT03766750|Active Comparator|Tradjenta®|
3483806|NCT03766750|Active Comparator|Forxiga®|
3483807|NCT03766737|Other|Eligible patients for AI test.|Device: An intelligent visual acuity diagnostic system for children. An artificial intelligence to evaluate children's vision.
3483808|NCT03766724|Experimental|Group A|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin
3483809|NCT03766724|Experimental|Group B|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin
3483810|NCT03766724|Experimental|Group C|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin
3483811|NCT03766724|Experimental|Group D|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
3483812|NCT03766711|Experimental|Actual - Augmented|Reaching task as a physical therapy intervention. First with 1:1 visual feedback, then with augmented forward symmetry.
3483813|NCT03766711|Experimental|Augmented - Actual|Reaching task as a physical therapy intervention. First with augmented forward symmetry, then with 1:1 visual feedback.
3483814|NCT03766672||Intervention Arm|Identify the genetic profile of type 2 endometrial carcinomas in Martinique from tumor sample for extraction of tumor DNA .
3483815|NCT03766659|Other|MOSE|EUS-FNB with MOSE
3483816|NCT03766659|Other|ROSE|EUS-FNA with ROSE
3483817|NCT03766633||Living liver donors|This is a group of living liver donors that underwent a CT prior to donating their partial liver to a recipient.
3483818|NCT03766607|Experimental|Trastuzumab with Ramucirumab and Paclitaxel|Single arm study of trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) every 21 days + ramucirumab (8 mg/kg) on days 1 & 15 every 28 days + paclitaxel (80 mg/m2) on days 1, 8, and 15 every 28 days
3483819|NCT03766594|Active Comparator|Sildenafil group|Includes 45 women who received Sildenafil citrate (Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
3483820|NCT03766594|Active Comparator|Control group|Includes 45 women who received placebo oral tablets (apparently identical to Respatio(R) 25mg tablets, four times daily for 24 days preconceptionally starting first day of previous period) and folic acid (Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally).
3483821|NCT03766581|Placebo Comparator|BMS-986177 Placebo|Specified Dose on Specified Days
3483822|NCT03766581|Experimental|Dose 1: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483823|NCT03766581|Experimental|Dose 2: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483824|NCT03766581|Experimental|Dose 3: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483825|NCT03766581|Experimental|Dose 4: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483826|NCT03766581|Experimental|Dose 5: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483827|NCT03766581|Experimental|Dose 6: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483828|NCT03766581|Experimental|Dose 7: BMS-986177 + Aspirin + Clopidogrel|Specified Dose on Specified Days
3483829|NCT03766568|Experimental|Diagnostic with JGG endoscope|
3483830|NCT03766555|Experimental|Microwave Ablation|Microwave ablation (MWA) will be performed in patients randomized to this arm.
3483831|NCT03766555|Active Comparator|Liver Resection|Liver resection will be performed in patients randomized to this arm.
3483832|NCT03766542|Active Comparator|CPAP|Oronasal CPAP therapy applied as per current international guidelines
3483833|NCT03766542|Experimental|Bi-level|Oronasal Bi-level therapy + supplemental oxygen (if necessary) applied as per current international guidelines
3483834|NCT03766516||Cohort|"Any patient planning to administer BrentuximabVedotin to treat the target disease.~Any patient administering BrentuximabVedotin to treat the target disease.~Any patient tracing BrentuximabVedotin after treating the target disease.~Any patient administering another salvage option for cancer as the target disease has relapsed after terminating treatment using BrentuximabVedotin."
3483835|NCT03766503|Other|Intervention|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
3483836|NCT03766490|Experimental|Anlotinib Hydrochloride plus gefitinib or icotinib|
3483837|NCT03766477||Individuals with sleep bruxism|"Individuals with sleep bruxism evaluated in three different methods regarding their sleep quality:~Pittsburgh Sleep Quality Index (IQSP) and Johansson~Smartphone APP~Polysomnography"
3483838|NCT03766464||with sleep bruxism, apnea and DTM|"Patients who will undergo analysis of:~Evaluation of TMD and pain sensitivity Evaluation of SB Evaluation of AB"
3483839|NCT03766438|Experimental|Intervention|The intervention group will view the 12-minute digital storytelling intervention that has been previously pilot-tested, in addition to usual clinical care.
3483840|NCT03766438|No Intervention|Control|The comparison group will receive usual clinical care.
3483841|NCT03766425|Experimental|Aflibercept|Aflibercept applied intraoperatively as a subconjunctival injection at a dose of 0.05 ml (40 mg / ml) and one week after the operation at the same dose, also subconjunctival.
3483842|NCT03766425|Active Comparator|Mitomycin|Mitomycin applied during a surgery at a concentration of 0.3mg / ml for 3 min. on a soaked sponge.
3483843|NCT03766412||School start time 8:30 AM or later|These are high schoolers with migraine who attend a school that begins at 8:30 AM or later (i.e. follows AAP recommendation re: high school start time).
3483844|NCT03766412||School start time earlier than 8:30|These are high schoolers with migraine who attend a school that begins earlier than 8:30 AM (i.e. does not follow AAP recommendation re: high school start time).
3483845|NCT03766399|Experimental|Part 1a (SAD) Cohort 1|6 participants will receive inhaled dose 1 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483846|NCT03766399|Experimental|Part 1a (SAD) Cohort 2|6 participants will receive inhaled dose 2 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483847|NCT03766399|Experimental|Part 1a (SAD) Cohort 3|6 participants will receive inhaled dose 3 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483848|NCT03766399|Experimental|Part 1a (SAD) Cohort 4|6 participants will receive inhaled dose 4 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483849|NCT03766399|Placebo Comparator|Part 1a (SAD) Cohort 5|6 participants will receive inhaled dose 5 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483850|NCT03766399|Experimental|Part 1a (SAD) Cohort 6|6 participants will receive inhaled dose 6 of AZD0449 nebulized suspension and 2 participants will receive inhaled placebo.
3483851|NCT03766399|Experimental|Part 1b (IV cohort 1)|All 6 participants will receive single IV dose of AZD0449 solution.
3483852|NCT03766399|Experimental|Part 2a (MAD) Cohort 1|6 participants will receive inhaled dose 7 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
3483853|NCT03766399|Experimental|Part 2a (MAD) Cohort 2|6 participants will receive inhaled dose 8 of AZD0449 nebulized suspension and 3 participants will receive inhaled placebo.
3483854|NCT03766399|Experimental|Part 2b (MAD/healthy volunteers) Cohort 3|18 healthy volunteers will receive inhaled dose 9 of AZD0449 nebulized suspension and 12 healthy volunteers will receive inhaled placebo.
3483855|NCT03766399|Experimental|Part 3a (DPI/PoM)|18 participants will receive inhaled dose 10 of AZD0449 DPI and 6 participants will receive inhaled placebo.
3483856|NCT03766399|Experimental|Part 1b (IV cohort 2)|6 healthy volunteers will receive single IV dose of AZD0449 solution.
3483857|NCT03766399|Experimental|Part 3b (DPI/healthy volunteers)|Part 3b is optional. 8 healthy volunteers; 6 volunteers will receive AZD0449 DPI and 2 volunteers will recieve placebo.
3483858|NCT03766386||Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are currently alive (including patients who may or may not have undergone heart transplantation).
3483859|NCT03766386||Deceased Danon Disease Patients|Patients with a confirmed diagnosis of Danon disease who are deceased (including patients who may or may not have undergone heart transplantation).
3483860|NCT03766360|Experimental|FAP Intervention Group|All of the clients in the FAP intervention group will begin treatment at the same time and complete 3 assessments.
3483861|NCT03766360|No Intervention|Control Group|The clients in the control group will take their assessments at the same time as those in the FAP intervention group.
3483862|NCT03766347||Pediatric Neuromyelitis Optica|Participants under the age of 18 that are positive for Aquaporin-4 antibody.
3483863|NCT03766334|Experimental|Diabetes Diet+Highland Barley Diet|Diabetes Diet+Highland Barley Diet(20g, thrice-daily)
3483864|NCT03766334|No Intervention|Diabetes Diet|only Diabetes Diet
3483865|NCT03766321|Active Comparator|Fecal microbiota transplantation (FMT)|"Fecal microbiota transplantation will be performed during two endoscopic procedures (at baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum. Fecal microbiota will be diluted in saline solution 200 ml and infused at 30 ml/minute speed. Every endoscopic procedure will be performed with sedation of the patient.~Feces for FMT will be obtained by known healthy donors for C. difficile infection according to standard selection procedures."
3483866|NCT03766321|Placebo Comparator|Placebo|"ALS patients will undergo upper GI endoscopy with small-intestine biopsies at baseline and after 6 months. Patients in the placebo arm will not receive any treatment during these procedures, but will undergo intestinal biopsy.~Every endoscopic procedure will be performed with sedation of the patient."
3483867|NCT03766308|Experimental|Highland barley diet|highland barley diet(20g, thrice-daily) +Metformin sustained-release tablets(500mg, thrice-daily)
3483868|NCT03766308|Active Comparator|ADA diet|ADA diet + Metformin sustained-release tablets(500mg, thrice-daily)
3483869|NCT03766295|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
3483870|NCT03766295|Active Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
3483871|NCT03766282||Animal study|Critically ill animal on ECMO. PK data from critically ill animal on ECMO will be compared with data from controls and healthy animal on ECMO.
3127966|NCT03122587|Experimental|Active Sham (Session 1) and tACS at 40 Hz (Session 2)|Active sham transcranial alternating current stimulation (tACS) during Session 1 and Transcranial Alternating Current Stimulation at 40 Hz during Session 2
3127967|NCT03122860|Experimental|0.03 mg SM04690|Single intra-articular injection of 0.03 mg SM04690 in 2 mL vehicle
3127968|NCT03122860|Experimental|0.07 mg SM04690|Single intra-articular injection of 0.07 mg SM04690 in 2 mL vehicle
3127969|NCT03122860|Experimental|0.15 mg SM04690|Single intra-articular injection of 0.15 mg SM04690 in 2 mL vehicle
3127970|NCT03122860|Experimental|0.23 mg SM04690|Single intra-articular injection of 0.23 mg SM04690 in 2 mL vehicle
3483872|NCT03766282||Clinical study|To describe variation of plasma concentration of drugs in patients receiving ECMO, as compared with patients without ECMO.And develop population PK model for ECMO patients.
3483873|NCT03766269|Other|Baseline Opioid|One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.
3483874|NCT03766256|Experimental|Shared decision-making with pharmacists|Pharmacist-coordinated shared decision making about treatment for history of gestational diabetes mellitus (lifestyle change and/or metformin), using a decision tool
3483875|NCT03766243|Experimental|Brochure and DVD plus nursing training|"In addition to the control intervention, see below, the experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. The nurse provided theoretical explanations on the exercises, watched the explanatory DVD with the patients, answering questions and commenting relevant points, and then had the patients repeat the exercises in front of a mirror under direct observation, so that any errors could be pointed out and corrected."
3483876|NCT03766243|Active Comparator|Brochure and DVD only|"After recruitment, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use. At the same time, she contacted the research nurse to obtain the random allocation to one of the study groups for that patient.~These exercises had to be done every day for the entire duration of the program (12 months) and registered in the diary with any comments."
3483877|NCT03766217|Experimental|Mesenchymal stem cells associated with biomaterials|Mesenchymal stem cells obtained from autogenous deciduous dental pulp associated with biomaterials. The stem cells will be obtained by enzimatic digestion in GMP laboratory and will be seed into the biomaterial (hydroxyapatite/collagen).
3483878|NCT03766217|Active Comparator|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest. The prepare of the receptor area will be the same in both arms and will follow current recommendations.
3483879|NCT03766204||ARDS patients|137 patients were enrolled consecutively over a two-year time period (2017-2018) and identified as ARDS prospectively according to the Berlin definitions of the European Society of Intensive Care Medicine and American Thoracic Society on ARDS. Exclusion criteria were an age of less than 18 years, pregnancy, chronic obstructive pulmonary disease according to medical history and failure to obtain informed consent.
3483880|NCT03766204||Healthy volunteers|Forty healthy volunteers recruited from the general population who had no significant medical history and no medications were categorized as control patients.
3483881|NCT03766191|Active Comparator|Food Ads and fMRI|
3127971|NCT03122860|Placebo Comparator|Placebo|Single intra-articular injection of 0 mg SM04690 in 2 mL vehicle
3179704|NCT00675714|Experimental|4|Propranolol PO given daily throughout hospitalization for up to 2 years post burn
3483882|NCT03766191|Sham Comparator|Non-Food Ads and fMRI|
3483883|NCT03766191|Active Comparator|Food Ads and TV show|
3483884|NCT03766191|Sham Comparator|Non-Food Ads and TV show|
3483885|NCT03766178|Experimental|Nimotuzumab + SHR-1210|Nimotuzumab + SHR-1210
3483886|NCT03766152|Other|Adhear|Patients will be fitted with an adhesive bone conduction device for three weeks
3483887|NCT03766139|Experimental|SUPERCELL GLUE(STEM CELLS AND PRFM)|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites .
3483888|NCT03766139|Active Comparator|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites
3483889|NCT03766126|Experimental|Treatment Arm|CART123 cells; cyclophosphamide; fludarabine
3483890|NCT03766113|Other|Healthy volunteer|"50 subjects~A single neurofeedback coupling electroencephalogram and functional MRI in time actual ."
3483891|NCT03766113|Other|Patients at the early stage after stroke|"30 subjects~Effectiveness of an electroencephalogram-neurofeedback"
3483892|NCT03766113|Other|Patients at the chronic stage after stroke|"36 subjects~Effectiveness of a neurofeedback coupling electroencephalogram and functional MRI in time actual"
3483893|NCT03766100|Experimental|Intervention group|Cognitive Behavioural Therapy for Insomnia (CBT-i).
3483894|NCT03766100|No Intervention|Control group|Insomnia is untreated.
3483895|NCT03766087|Experimental|surgery group|Decompressive craniectomy associated with optimal medical management of intracranial pressure.
3483896|NCT03766087|No Intervention|conservative group|Optimal medical management of intracranial pressure only.
3483897|NCT03766074|Experimental|Intervention|vitamin D supplement every other week
3483898|NCT03766074|Placebo Comparator|control|Placebo every other week
3483899|NCT03766061|Active Comparator|Onlay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with onlay mesh hernioplasty in which we placed mesh on the anterior rectus sheath
3483900|NCT03766061|Active Comparator|Sublay Mesh Hernioplasty|In this group patients with paraumbilical hernia are treated with sublay mesh hernioplasty in which we placed mesh in the retromuscular space
3127972|NCT03122860|Sham Comparator|Sham|Single intra-articular injection of 0 mg SM04690 in 0 mL vehicle
3127973|NCT03122886|Experimental|Group I (fat emulsion)|Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3483901|NCT03766048|Experimental|Single-Anterior-Mesh, SAM|
3483902|NCT03766048|Sham Comparator|Double-Mesh, DM|
3179705|NCT00675714|Experimental|5|Oxandrolone and propranolol PO to be given daily for up to 2 years post burn
3179706|NCT00675714|Experimental|6|Humatrope SQ and Propranolol PO to be given daily for up to 2 years post burn
3483903|NCT03766022|Experimental|Heavy smoker patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
3483904|NCT03766022|Active Comparator|non Smokers patients|Marginal bone changes after 1 year after implant installation using Neo dental implant Alpha Bio Tec. Ltd.
3127974|NCT03122886|Placebo Comparator|Group II (placebo)|Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3127975|NCT03123055|Experimental|B-701 (vofatamab)|B-701 (vofatamab, 25 mg/kg) will be administered via IV infusion on Cycle 0 Day 1 for a single 14-day cycle.
3483905|NCT03765983|Experimental|Cohort A: single-arm, two stage, phase II cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter
3483906|NCT03765983|Experimental|Cohort B: a pre-surgical window cohort|GDC-0084 45 mg administered orally once daily Trastuzumab administered at a dose of 8 mg/kg intravenously (IV) loading dose; followed by 6 mg/kg IV every 3 weeks thereafter Surgical brain metastasis resection
3127976|NCT03123055|Experimental|B-701 (vofatamab) plus pembrolizumab|B-701 (vofatamab, 25 mg/kg [or the recommended Phase 2 dose if different than 25 mg/kg]) plus pembrolizumab (200 mg) will be administered by IV infusion on Cycle 1 Day 1 once every 3 weeks.
3127977|NCT03123068|Active Comparator|Active treatment group - Group A|Participants will receive a daily oral dose of 1,000 mg cocoa flavanol (CocoaVia®) for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
3127978|NCT03123068|Placebo Comparator|Placebo treatment group - Group B|Participants will receive a daily oral dose of a placebo for 5 days before surgery. The daily dose will consist of 8 capsules in divided doses throughout the day.
3127979|NCT03123120|Experimental|Spesolimab|1200 milligrams (mg) of Spesolimab (BI 655130) were administered every 4 weeks (q4w) via intravenous infusion over 12 weeks of treatment (3 injections of Spesolimab 1200 mg in total during the 12 weeks: at Week 0, 4, and 8 respectively).
3127980|NCT03123120|Placebo Comparator|Placebo|Matching placebo was administered via intravenous infusion over 12 weeks of treatment.
3483907|NCT03765957|Experimental|Mesenchymal Stem Cells|The mesenchymal stem cells will be derived from human umbilical cord. After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjects of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment.
3483908|NCT03765944|Active Comparator|NPC-12 granule|NPC-12 granules (1.0g: 2mg sirolimus)
3483909|NCT03765944|Active Comparator|NPC-12T tablet|NPC-12T 2 tablets (2mg sirolimus)
3483910|NCT03765931|Active Comparator|subjects treated with doxycycline|The participants treated by doxycycline 100 mg will have one dose but followed 5 days
3483911|NCT03765931|Placebo Comparator|subjects treated with amoxycilline|The participants treated with amoxycilline 500 mg will have 2 doses per days during 5 days treatement and follwed during these 5 days
3483912|NCT03765905||PCOS diagnosis area|The study group consisted of 40 reproductive age women between 18th and 35th years old women who were PCOS diagnosis (according to the 2003 Rotherdam criteria)
3483913|NCT03765905||PCOS is not diagnosed|Forty patients who did not have any complaints between the ages of 18-35 who applied to the gynecology policlinic as a control group but who had no PCOS orany other systemic problems and were similar in terms of age group and body mass index were included in the study after being approved for participation in the study
3483914|NCT03765892||Adult Case Group|Adults with type 1 narcolepsy according to the ICSD3
3483915|NCT03765892||Adult Control Group|Parents, cousins and / or friends of included narcoleptic adult patients, at least 18 years old and not suffering from narcolepsy.
3483916|NCT03765892||Children Case Group|Children with type 1 narcolepsy according to the OCSD3
3483917|NCT03765892||Children Control Group|Close friends and cousins of included narcoleptic children, minor and not suffering from narcolepsy.
3483918|NCT03765879|Experimental|Verum VGAIT Group|Participants in this group will receive verum (real) acupuncture and verum video-guided acupuncture imagery treatment (VGAIT).
3127981|NCT03123354|Experimental|Test group|All subjects are enrolled in the test group and receive an O3 regional oximeter sensor during their scheduled, general cardiac catheterization procedure.
3127982|NCT03123471|Experimental|Apremilast 30 mg BID|Apremilast 30 mg tablets orally twice daily (BID) during Weeks 0 to 32
3483919|NCT03765879|Placebo Comparator|Sham VGAIT Group|Participants in this group will receive sham acupuncture and sham VGAIT.
3483920|NCT03765866|No Intervention|Massive Transfusion Protocol Guided|Clinicians will only transfuse patients according to standard massive transfusion protocol (MTP)
3483921|NCT03765866|Experimental|Thromboelastometry guided transfusion|Clinicians will transfuse patients according to ROTEM results.
3132728|NCT03447314|Experimental|Part 2b: GSK1795091 + 80 mg GSK3359609|Participants will be administered GSK1795091 at a dose identified in Part 1 along with GSK3359609 80 mg.
3483922|NCT03765853|Other|Stretching Postural®|
3483923|NCT03765853|No Intervention|Control|
3483924|NCT03765840||POCD group|patients occur cognitive decline after surgery according to scores in this group.
3483925|NCT03765840||NO POCD group|patients do not occur cognitive decline after surgery according to scores in this group.
3483926|NCT03765827|Experimental|Vitamin E acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
3483927|NCT03765827|Sham Comparator|Control group|No ointment will be applied
3483928|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fed)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
3483929|NCT03765801|Experimental|GRTA9906 60 mg PR tablet (fasting)|Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
3483930|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fed)|Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
3483931|NCT03765801|Experimental|GRTA9906 60 mg IR capsule (fasting)|Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
3483932|NCT03765788|Experimental|Secukinumab|Participants will receive secukinumab at a dose of 300 milligrams (mg) as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
3483933|NCT03765788|Placebo Comparator|Placebo|Participants will receive placebo as subcutaneous (s.c.) injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to week 48 along with a 26-week prednisolone tapering regimen.
3483934|NCT03765775|Experimental|Anlotinib Hydrochloride+Sintilimab|Participants receive Sintilimab (IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle , Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD
3483935|NCT03765749||Community onset 3rd generation cephalosporin resistant entero|Patient with Community onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received inappropriate Antibiotic
3483936|NCT03765749||Nosocomial onset 3rd generation cephalosporin resistant ente|Patient with Nosocomial onset third generation cephalosporin resistant enterobacteriaceae bacteremia who received appropriate Antibiotic
3483937|NCT03765710|Experimental|Recommended protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 13% protein, 54% carbohydrate, and 33% fat.
3483938|NCT03765710|Experimental|Elevated protein intake|Subjects consumed a mixed meal with a macronutrient distribution of 26% protein, 44% carbohydrate, and 30% fat.
3483939|NCT03765697|Experimental|Lidocaine 5% medicated plaster|Up to 3 plasters were applied per day.
3483940|NCT03765671|Experimental|Mild Child-Pugh A|Single oral dose of elafibranor 120mg
3483941|NCT03765671|Experimental|Moderate Child-Pugh B|Single oral dose of elafibranor 120mg
3483942|NCT03765671|Experimental|Severe Child-Pugh C|Single oral dose of elafibranor 120mg
3483943|NCT03765671|Experimental|Healthy|Single oral dose of elafibranor 120mg
3483944|NCT03765658|Experimental|GRT0151Y dose escalation|GRT0151Y will be administered to participants as 50 mg capsules in a dose escalation range of 150, 200, 250, 300, 350 and 400 mg. Dose levels were increased by increments of 50 mg to a maximum of 400 mg, only after the previous dose level was found to be well-tolerated. During each treatment period, participants randomly received either GRT0151Y or matching placebo, in a manner that no participant received placebo in two consecutive periods.
3483945|NCT03765645|Active Comparator|3 doses on intra venous antibiotics|Patients will receive 3 doses of intra venous antibiotics. (1 dose preoperative, 1 intra operative and 1 post-operative)
3483946|NCT03765645|Active Comparator|9 doses of intra venous antibiotics|Patients will receive 9 doses of intra venous antibiotics. (1 dose preoperative, rest 8 doses at equal intervals)
3483947|NCT03765619|Experimental|Aspirin|250 patients will be randomized to receive Aspirin postoperatively.
3483948|NCT03765619|No Intervention|Non-Aspirin|250 patients will be randomized to not receive Aspirin postoperatively.
3483949|NCT03765606|Placebo Comparator|Cocoa Flavanol beverage mix|Cocoa Flavanol beverage mix (flavanols, 566mg; caffeine, 11mg & theobromine, 93mg)
3483950|NCT03765606|Experimental|De-xanthinated Cocoa Flavanol beverage mix|De-xanthinated Cocoa Flavanol beverage mix (flavanols, 583mg; caffeine, 0.6mg & theobromine, 0.2mg)
3483951|NCT03765593||Study group 1|Immunopositive primary SS (Anti-SSA +/anti-Ro+) will receive salivary gland biopsy.
3483952|NCT03765593||Study group 2|Immunonegative primary SS (Anti-SSA -/anti Ro-, biopsy Chisholm-Mason 3-4) will receive salivary gland biopsy.
3483953|NCT03765593||Study group 3|Non-autoimmune sicca syndrome (Anti-SSA/anti Ro-, biopsy Chisholm-Mason 2 o less) will receive salivary gland biopsy.
3483954|NCT03765593||Control group|Patients who have sicca syndrome but do not meet the classification criteria of Sjögren's syndrome, therefore, at the time of evaluating these patients to determine whether or not they have the disease are what will serve as controls since according to the usual diagnostic process, the same studies will be carried out as for patients with the proposed disease. Will receive salivary gland biopsy.
3483955|NCT03765580|Placebo Comparator|Control group|No fish
3127983|NCT03123471|Placebo Comparator|Placebo|Placebo tablets BID during weeks 0 to 16; at week 16, placebo participants were switched to apremilast 30 mg tablets BID for 16 weeks (from Week 16 to Week 32)
3483956|NCT03765580|Experimental|1 portion of fish per week|140g fish/week
3483957|NCT03765580|Experimental|2 portions of fish per week|280g fish/week
3483958|NCT03765554|Experimental|PF-06700841: IR followed by MR|Participants receive PF-06700841 Immediate release tablets (IR) followed by PF-06700841 Modified release tablets (MR)
3483959|NCT03765554|Experimental|PF-06700841: MR followed by IR|Participants receive PF-06700841 Modified release tablets (MR) followed by PF-06700841 Immediate release tablets (IR)
3483960|NCT03765541|Experimental|Standard salvage therapy + dexamethasone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness in combination with dexamethasone
3483961|NCT03765541|Active Comparator|Standard salvage therapy alone|Intensive chemotherapy amsacrine-cytarabine or azacitidine according to the investigator's willingness
3483962|NCT03765515|Experimental|Q-Fix|"Q-Fix has the advantages of all-suture implant and has the same or better performance than the traditional anchor.~Consistent activation effect~Excellent performance~Streamlined technique Q-fix is an experimental Arm."
3483963|NCT03765515|Active Comparator|Twinfix Ti|The Smith & Nephew's marketed Twinfix Suture Anchor is selected as the control product. This product is composed of anchor, suture, suture needle and inserter. The anchor is made of Ti6Al4V titanium alloy conforming to ISO5832-3. The Durabraid suture is made of polyester (Polyethylene terephthalate) conforming to YY 0167. Ultrabraid suture is made of two materials of UHMWPE and polypropylene monofilaments conforming to GB/T 19701.1. The suture needle is made of Type 420B stainless steel conforming to YY/T 0726. The stem portion of inserter that comes into contact with the body is made of Type 630B stainless steel conforming to YY/T 0726.
3483964|NCT03765489|Experimental|electrical muscle stimulation|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al. plus electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction"
3483965|NCT03765489|Active Comparator|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
3483966|NCT03765476|Active Comparator|TAU|treatment as usual
3483967|NCT03765476|Experimental|TAU plus SALIENCE|"treatment as usual plus computer-based intervention SALIENCE"
3483968|NCT03765463|Experimental|Habit Reversal Training|Habit Reversal Training (HRT) is a multi-component evidence-based treatment for tics. It will be delivered over 4 two-hour sessions in an intensive format.
3483969|NCT03765450||Single Group Study|Patients with Acute Severe Ulcerative Colitis who are either a) biologic-naïve or b) biologic-experienced without a known history of anti-infliximab antibodies requiring infliximab infusion therapy as a part of standard of care.
3179707|NCT00675714|Placebo Comparator|7|Placebo PO to be given for up to 2 years post burn
3179708|NCT00675714|Experimental|8|Exercise--hospital supervised intensive exercise program
3483970|NCT03765437|Experimental|Quadrivalent Influenza Vaccine|Quadrivalent Influenza Vaccine (split-virion, inactivated) Northern hemisphere seasonal formulation 2018-2019
3127984|NCT03123588|Experimental|Group A : Ruxolitinib and anagrelide placebo|Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
3127985|NCT03123588|Active Comparator|Group B : Anagrelide and Ruxolitinib PLacebo|Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.
3179709|NCT00675714|Experimental|9|Exercise--home or community based exercise program
3179710|NCT00675740|Experimental|1|
3483971|NCT03765424||GCA cases|"GCA cases were patients with a clinical diagnosis of GCA based on a rheumatologists evaluation of history taking, physical examination, laboratory screening and initial PET report (reporting potential large vessel inflammation but not considering cranial artery inflammation).~GCA was considered large vessel (LV) and/or cranial (c) GCA cases:~LV-GCA cases were patients with a clinical diagnosis of GCA and verified LV inflammation by 18F-FDG PET/CT with or without concomitant c-GCA.~C-GCA cases, for the exploratory analysis of the performance of US and PET in c-GCA, were patients with a clinical diagnosis of GCA fulfilling the 1990 American College of Rheumatology (ACR) criteria, with or without concomitant LV-GCA."
3127986|NCT03123614|Active Comparator|Loteprednol Etabonate 0.5% Oph Gel|Group 1 will use loteprednol 0.5% gel in both eyes, starting at a frequency of four times per day for the first week and then tapered off based on clinical judgement of the corneal healing response.
3127987|NCT03123614|Active Comparator|Prednisolone acetate 1% Oph Susp|Group 2 will use prednisolone acetate 1% suspension in both eyes, starting at a frequency of four times per day for the first week, then tapered down to a regimen of fluorometholone 0.1% suspension, which will then be tapered off based on clinical judgement of the corneal healing response.
3127988|NCT03123848|Experimental|Darunavir/Cobicistat FDC (Prezcobix)|Participants will receive one darunavir/cobicistat fixed-dose combination (FDC) tablet, containing 800 milligram (mg) of darunavir (DRV) and 150 mg of cobicistat (COBI) in the morning on Day 1.
3127989|NCT03123861|Active Comparator|Gabapentin|Participants will take 300 mg Gabapentin for the first 3 days after surgery, then dose escalate to 300 mg twice a day (BID) for an additional 11 days.
3127990|NCT03123861|Placebo Comparator|Placebo oral capsule|Participants will take placebo for the 2 weeks after surgery.
3127991|NCT03123874|Experimental|Sterile pump set-up first|Participants will pump with sterile pump set-ups first. Approximately 3 hours later, participants will pump with their own pump set-ups.
3127992|NCT03123874|Experimental|Mother's Own pump set-up first|Participants will pump with their own pump set-ups first. Approximately 3 hours later, participants will pump with sterile pump set-ups.
3127993|NCT03123939|Experimental|CTL019|CTL019 transduced T cells were given as a single dose of 0.2 to 5.0 × 10^6 autologous CTL019 transduced viable T cells per kg body weight (for patients ≤ 50 kg) and 0.1 to 2.5 × 10^8 CTL019 transduced viable T cells (for patients > 50 kg)
3483972|NCT03765424||controls|Controls were GCA suspected patients in whom GCA diagnosis was dismissed.
3483973|NCT03765411||Open Proctectomy Patients|Patients who underwent Proctectomy through an open approach
3483974|NCT03765411||Laparoscopic Proctectomy Patients|Patients who underwent Proctectomy through a Laparoscopic approach
3483975|NCT03765411||Robotic Proctectomy Patients|Patients who underwent Proctectomy through a Robotic approach
3483976|NCT03765398|Experimental|VR Cognitive-motor-balance training|Virtual reality based cognitive-motor balance (VR-CogMoBal) training will be delivered using the commercially available Wii-Fit Nintendo in conjunction with cognitive training. All participants will undergo 12 sessions of training in a tapering manner for four weeks with 90 minutes of training per session, i.e., 5 sessions for the first week, 3 sessions for the second week, and 2 sessions for the third and fourth week. Each session will be divided into 3 sub-sessions, where each sub-session will consist of playing 4 games in conjunction with cognitive task. All the games will be performed using a Wii-Fit balance board in front of a TV screen.
3127994|NCT03124069|Experimental|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
3127995|NCT03124108|Placebo Comparator|Placebo|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
3483977|NCT03765385|Experimental|High-intensity training|Each high-intensity training (HIT) session will consist of 10 repeated 6-seconds regulated high intensity cycling sprints against an individualized load set to reach a supramaximal exercise intensity (i.e. power output is higher than power output at maximum oxygen uptake). Session duration for HIT is 20 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
3483978|NCT03765385|Active Comparator|Moderate-intensity continuous training|Each moderate-intensity continuous training (MICT) session will consist of aerobic training regulated against an individualized load set to reach a moderate submaximal exercise intensity (i.e. power output is lower than power output at maximum oxygen uptake). Session duration for MICT is 40 min, including warm-up and cool-down. The protocol enables controlled and systematic adjustments of training intensity by means of standardized criteria.
3483979|NCT03765346|Experimental|Oxycodone IR ADF and placebo to match oxycodone API|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of manipulated oxycodone IR ADF (mass of 540 mg, containing oxycodone hydrochloride 30 mg).
3483980|NCT03765346|Active Comparator|Oxycodone API and placebo to match oxycodone IR ADF|Participants receive a single intranasal dose of oxycodone API powder (mass of 30 mg, containing oxycodone hydrochloride 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
3483981|NCT03765346|Placebo Comparator|Placebo to match oxycodone API and to match oxycodone IR ADF|Participants receive a single intranasal dose of placebo to match oxycodone API powder (mass of 30 mg) followed by a single intranasal dose of placebo to match manipulated oxycodone IR ADF (mass of 540 mg).
3483982|NCT03765307|Experimental|SyMap Bronchial Ablation Group|The experimental group is treated using SyMap Bronchial Radiofrequency Ablation system, including disposable bronchial radiofrequency ablation catheter (Model: BA125T) and Bronchial radiofrequency ablation instrument (Model: ELATION S3).
3483983|NCT03765307|Active Comparator|Boston Scientific Bronchial Thermoplasty Group|The control group is treated using Boston Scientific Alair System, including Bronchial radiofrequency ablation catheter Alair (Model: ATS2-5 ) and Bronchial radiofrequency ablation instrument (Model: ATS200)
3483984|NCT03765294|Experimental|Treatment A: ACT-541468|50 mg once daily from Day 1 to Day 5 of Period A
3483985|NCT03765294|Placebo Comparator|Treatment B: Placebo|Matching placebo once daily from Day 1 to Day 5 of Period B
3483986|NCT03765281|Experimental|Navigation|Navigation intervention plus Resource List
3127996|NCT03124108|Active Comparator|Elafibranor 80 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
3483987|NCT03765281|Active Comparator|Self-Navigation|Resource List intervention
3483988|NCT03765268|Active Comparator|Neurectomy|In this group we did mesh hernioplasty of inguinal hernia with neurectomy of iliohypogastric and ilioinguinal nerve
3483989|NCT03765268|Active Comparator|Nerve Sparing|In this group we did mesh hernioplasty of inguinal hernia with preservation of iliohypogastric and ilioinguinal nerve
3483990|NCT03765255|Experimental|In the Know (ITK): sexual health education|Cohorts/participants in the experimental (treatment) arm receive an intervention that combines 6 hours of in-person sexual health and adolescent development education with an app that includes a resource locator, text message reminders (for one month), goal setting, and other resources.
3483991|NCT03765255|No Intervention|Control: do not receive ITK intervention|Cohorts/participants in the no intervention arm do not receive either the in-person education or the app. However, after completing the 10 month survey, they will have access to the app and will be invited to participate in the in-person program after the study implementation phase is completed (years 4 and 5).
3483992|NCT03765242||Patient initiating warfarin|
3483993|NCT03765242||Patient initiating apixaban|
3483994|NCT03765229|Experimental|Single Arm: Entinostat + Pembrolizumab|Subjects in this trial will be administered entinostat, 5mg PO, once weekly (D1, D8, D15 of a 21-day cycle) starting on day 1 of study treatment. Pembrolizumab, 200 mg will be administered intravenously (IV) every 3 weeks and initiated at cycle 2 after the mandatory research tumor biopsy in the end of cycle 1, beginning of cycle 2 (day 21±2 days),. Combination therapy with both agents will continue if subject is receiving clinical benefit from therapy for up to 27 weeks (8 cycles of combination therapy or approximately 6 months). Study therapy will be discontinued for intolerable toxicity, disease progression or for other reasons at the discretion of the investigator.
3483995|NCT03765216|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
3483996|NCT03765216|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
3483997|NCT03765203|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to Natera's dd-cfDNA test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
3483998|NCT03765203|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to Natera's dd-cfDNA test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
3483999|NCT03765190|Experimental|Radiation: Proton Therapy+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
3484000|NCT03765177|Experimental|CLIC-1901|A single Intravenous infusion of CLIC-1901 will be given.
3484001|NCT03765151|Experimental|LLLT group|Low-level laser therapy and orthodontic retention
3484002|NCT03765151|Placebo Comparator|control group|orthodontic retention and no laser treatment.
3484003|NCT03765125|Experimental|collagen peptide test|1 x daily consumption of 1 blister package of the collagen-peptide test powder dissolved in water over a period of 90 days
3484004|NCT03765125|Placebo Comparator|collagen peptide placebo|1y daily consumption of 1 blister package of the placebo powder dissolved in water over a period of 90 days
3484005|NCT03765112|Experimental|OCTA|Patients with diabetes and healthy controls will be imaged with optical coherence tomography (OCT) angiography, Spectral domain OCT and ultra wide-field imaging.
3484006|NCT03765086|Active Comparator|Karydakis procedure|Karydakis Procedure: In this procedure the pilonidal sinus will be excised by semilunar incision so that the incision line closure will be away from midline.
3484007|NCT03765086|Active Comparator|Limberg Flap|Limberg Flap: In this procedure the pilonidal sinus will be excised by diamond shaped incision and the defect will be closed by random pattern flap.
3484008|NCT03765073|Experimental|Stage 1 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
3127997|NCT03124108|Active Comparator|Elafibranor 120 mg|Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
3127998|NCT03124121|Other|Induction cohort|Golimumab induction therapy
3179711|NCT00675740|Active Comparator|2|physical exercise
3179712|NCT00675740|No Intervention|3|control
3127999|NCT03124121|Other|Maintenance cohort|Golimumab maintenance therapy
3128000|NCT03124199|Experimental|Rifaximin|Patient with Helicobacter pylori infection with standard triple therapy prescribed by clinical practice.
3128001|NCT03124342|Experimental|VANDERBILT ICU RECOVERY PROGRAM (VIP)|Patients assigned to the Vanderbilt ICU Recovery Program (VIP) group will receive the components of the ICU Recovery Program intervention.
3484009|NCT03765073|Experimental|Stage 1 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 1 Nonpregnant women
3484010|NCT03765073|Experimental|Stage 2 - Lowest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3132729|NCT03447314|Experimental|Part 2c: GSK1795091 + 200 mg Pembrolizumab|Participants will be administered GSK1795091 at a dose identified in Part 1 along with pembrolizumab 200 mg.
3132730|NCT03447353|Experimental|"Sober or Double Placebo"|Subject receives two tablets, both containing placebo
3132731|NCT03447353|Experimental|Active Xanax, Active Norco|Subject receives two tablets, one containing Xanax and one containing Norco
3132732|NCT03447353|Experimental|Active Xanax, Placebo Norco|Subject receives two tablets, one containing Xanax and one containing placebo
3179713|NCT00675753||Preterm group|Preterm (36 6/7 weeks gestation or earlier) mothers and their newborns.
3179714|NCT00675753||Term group|Term (> 37 weeks gestation) mothers and their newborns.
3179715|NCT00675779|Experimental|2|oral contraceptive + atorvastatin
3179716|NCT00675779|Active Comparator|1|oral contraceptive
3484011|NCT03765073|Experimental|Stage 2 - Lowest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3484012|NCT03765073|Experimental|Stage 2 - Middle dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3484013|NCT03765073|Experimental|Stage 2 - Middle dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3484014|NCT03765073|Experimental|Stage 2 - Highest dose formulation a|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3484015|NCT03765073|Experimental|Stage 2 - Highest dose formulation b|Multivalent group B streptococcus vaccine - Stage 2 Pregnant women
3484016|NCT03765073|Experimental|Stage 3 - Selected dose and formulation|Multivalent group B streptococcus vaccine - Stage 3 Pregnant women
3484017|NCT03765073|Placebo Comparator|Stage 1 Placebo|Saline control
3484018|NCT03765073|Placebo Comparator|Stage 2 Placebo|Saline control
3484019|NCT03765073|Placebo Comparator|Stage 3 Placebo|Saline control
3484020|NCT03765060|Experimental|Small Stitch|"Patients requiring an urgent emergency laparotomy. The Small Stitch closure technique will be perform using a Monomax® 2/0 HR26 (Half-circle Round body):~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle (Half-circle Round body).~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
3484021|NCT03765060|Active Comparator|Large Stitch|"The intervention will be the classic large Stitch closure technique using a Monomax® 1 HR48 (Half-circle Round body).~It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle (Half-circle Round body).~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
3484022|NCT03765047|Experimental|Intervention Arm|"This study arm includes the schools where the School Team (school teachers, coordinator) receives the physical activity intervention. The intervention consists of four parts:~School Engagement and Assessment~Training~Physical Activity Equipment and Resources~Ongoing Assessment and Technical Assistance"
3484023|NCT03765047|No Intervention|Control Arm|The control arm includes the schools where the School Team does not receive any intervention but all the necessary data will be collected.
3484024|NCT03765034|Experimental|Constraint-induced Movement Therapy|A passive constraint cast is applied to the participant's unaffected arm to prevent use for 8 weeks.
3132733|NCT03447353|Experimental|Placebo Xanax, Active Norco|Subject receives two tablets, one containing Norco and one containing placebo
3484025|NCT03765034|Active Comparator|Usual Occupational Therapy|Usual and standard care occupational therapy is administered for 8 weeks.
3484026|NCT03765021|Experimental|Tranexamic acid injection (Kapron)|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
3484027|NCT03765021|Active Comparator|Fractional CO2 laser resurfacing|The other side of the face will be randomly assigned to do low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
3484028|NCT03765008|Active Comparator|High Water intake|5-days of High water intake according to IOM guidelines
3484029|NCT03765008|Experimental|Low Water Intake|5-days of Low water intake of 500 mL/day
3484030|NCT03764969|Active Comparator|standard smoking cessation program (SCP)|standard smoking cessation program
3484031|NCT03764969|Experimental|SCP + CRT|SCP plus cognitive remediation treatment (CRT)
3484032|NCT03764969|Experimental|SCP + ICHT|SCP plus an implicit computer-based habit-modifying training (ICHT)
3132734|NCT03447730|Experimental|Part 1: SYNB1020|Part 1 comprised a sentinel open-label cohort of subjects enrolled sequentially to receive SYNB1020, which was administered orally at a dose of 5 × 10^11 colony-forming units (CFU) 3 times daily (TID) given immediately after meals from Days 1 through 6.
3484033|NCT03764956|Experimental|Low Glycemic Index therapy|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only
3484034|NCT03764956|Active Comparator|Modified Atkins Diet|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio
3484035|NCT03764891||Uphold|Patients who underwent Uphold procedure
3484036|NCT03764891||Perigee|Patients who underwent Perigee procedure
3484037|NCT03764878||Normal weight|BMI 18.5-24.9 kg/m^2 low risk pregnancy
3484038|NCT03764878||Pregestational diabetes mellitus|Type 1 or Type 2 diabetes mellitus diagnosed prior to the pregnancy or in the first trimester
3484039|NCT03764878||Obese|Pre-pregnancy BMI ≥ 30.0 kg/m^2
3484040|NCT03764865|Experimental|day 3 embryo transfer|embryo transfer 3 days after fertilization
3484041|NCT03764865|Experimental|day 5 embryo transfer|embryo transfer 5 days after fertilization
3484042|NCT03764852|Experimental|outpatient laparoscopic|Patients will have laparoscopic outpatients. The procedure is identical to that performed in hospital. What changes is that the patient will return home at night if her condition allows it.
3484043|NCT03764839|No Intervention|Active Control Group (Digital Health Education)|"Demographics survey~Baseline surveys~Participants receive a digital information sheet on nutrition and exercise that are relevant for people recovering from surgery. Participants are encouraged to incorporate healthy lifestyle choices into their daily routines as they recover from surgery~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Patients receive 30 second booster videos at 7, 14, and 21 days after surgery~Follow-up surveys (4, 8, and 12 weeks after surgery)"
3484044|NCT03764839|Experimental|"My Surgical Success Treatment Group"|"Demographics survey~Baseline surveys~Intervention:~45-minute digital behavioral pain medicine intervention My Surgical Success that emphasized cognitive and emotional regulation of pain and downregulation of physiologic arousal.~downloadable app with an audio file~personalized plan that allows learners to incorporate the treatment information~Post-video survey (detailed above)~Post-surgery:~Pain check-ins (2 times per week) (detailed above)~Follow-up surveys (4, 8, and 12 weeks after surgery) Intervention: Behavioral: Perioperative Digital Behavioral Pain Medicine My Surgical Success"
3484045|NCT03764826|Experimental|CAABT|CAABT(Cochleural Alternating Acoustic Beam Therapy) is an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
3484046|NCT03764826|Active Comparator|TMT|TMT(tinnitus masking therapy) is a traditional tinnitus intervention. The masking sound is mainly white noise, and the intensity just covers tinnitus.
3484047|NCT03764787|Experimental|Radiation+PD-1 Ab|proton radiotherapy concurrent with immunotherapy(ie. PD-1 Ab for 1 year)
3484048|NCT03764774|Experimental|LY3463251 Single dose|Single dose of LY3463251 administered subcutaneously (SC)
3484049|NCT03764774|Placebo Comparator|Placebo Single dose|Single dose of placebo administered SC
3484050|NCT03764774|Experimental|LY3463251 Multiple Dose|Multiple doses of LY3463251 administered SC
3484051|NCT03764774|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered SC
3484052|NCT03764761|Experimental|AAC Intervention|Participants will use AAC technology of different designs delivered on iMacs or Surface tablets
3484053|NCT03764748|Experimental|mini-FMT|Participants will receive 200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
3484054|NCT03764735|Placebo Comparator|SkQ1 Vehicle|SkQ1 (Vehicle)
3484055|NCT03764735|Active Comparator|Low Dose - SkQ1|Low-dose ophthalmic solution
3484056|NCT03764735|Active Comparator|High Dose - SkQ1|High-dose ophthalmic solution
3484057|NCT03764722|Experimental|Levosimendan|
3484058|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The experimental arm will wear wireless monitoring for 5 days after transfer in subacute care unit"
3484059|NCT03764709|Active Comparator|Control arm GROUP A|"GROUP A clinical hypothesis: reduction in the number of exacerbations in stable inpatients who transit towards subacute managed care unit.~The active comparator arm will be monitored by nursing staff."
3484060|NCT03764709|Experimental|Vital signs wireless monitoring system GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The experimental arm will wear wireless monitoring for 5 days after discharge at home"
3484061|NCT03764709|Active Comparator|Control Arm GROUP B|"GROUP B clinical hypothesis: non-inferiority in the number of major clinical complications that, if treated at an earlier stage, can improve outcomes in stable patients who are selected for earlier discharge and are followed by a remote wireless monitoring at home.~The active comparator arm will perform usual checks by caregivers at home."
3484062|NCT03764683|Experimental|Drug-Drug|This arm will receive the active drug in the first and second phase of the study.
3484063|NCT03764683|Other|Placebo-Drug|This arm will receive placebo in the first phase of the study and the active drug in the second phase.
3484064|NCT03764683|Placebo Comparator|Placebo-Placebo|This arm will receive placebo in the first phase and second phase of the study.
3484065|NCT03764657||"16 patients, named Hot group"|"We considered 16 sinus excision by diathermy as a case group (named Hot group)"
3484066|NCT03764657||"13 patients, named Cold group"|"13 procedures performed by knife as control group (named Cold group)."
3484067|NCT03764644|Experimental|Combined ABMT and CBT|9 sessions of Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
3484068|NCT03764644|Sham Comparator|Combined Sham ABMT and CBT|9 sessions of Sham Attention Bias Modification Treatment (dot-probe based of 160 trials) followed by individual Cognitive Behavioral Therapy via FRIENDS program
3484069|NCT03764631||subjects with Type 2 Diabetes mellitus|
3484070|NCT03764605|Experimental|Metformin|"Patients will take metformin starting from 500 mg a day. They will up-titrate every week, if tolerating IMP, adding one 500 mg dose 8 hours after the former, till reaching 500 mg thrice a day.~The minimum tolerated dose requested in order to be admitted to the study is 500 mg twice a day.~Those reaching eGFR<45 ml/min will reduce the dose by one third. Those reaching eGFR<30 will drop out the study."
3484071|NCT03764605|Active Comparator|Tolvaptan|Patient will start Tolvaptan in a split dose regimen 45 mg as first dose, followed by 15 mg 8 hours later. Those tolerating this dose will uptitrate to 60/30 mg and then to 90/30 mg a day. Those not tolerating 45/15 mg a day will drop out.
3484072|NCT03764592||VF BrS/ERS patients|Only patients that diagnosed with BrS or ERS based on ECG criteria
3484073|NCT03764579|Active Comparator|sleep and diet intervention|
3484074|NCT03764579|Active Comparator|diet intervention|
3484075|NCT03764566||Trauma control group|Individuals with adverse childhood experiences (e.g.childhood abuse or neglect) will be included as the experimental group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
3484076|NCT03764566||Healthy control group|Individuals with no trauma history will be added as the healthy control group of participants. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
3484077|NCT03764566||Clinical control group|Individuals with Borderline Personality Disorder (BPD) will be added as a clinical control group. Individuals will fill out the designated questionnaires (e.g. Childhood Trauma Questionnaire, Rejection Sensitivity Questionnaire, Loneliness questionnaires), will participate in a multimodal emotion recognition experiment as well as a virtual reality (VR) task.
3484078|NCT03764553|Experimental|Liposomal irinotecan, leucovorin and 5FU|IV Nal-IRI 80 mg/m² (expressed as irinotecan hydrochloride (HCl) salt), folinic acid 400 mg/m², fluorouracil 2400 mg/m² over 46 h, every 2 weeks.
3484079|NCT03764553|Experimental|Carboplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and carboplatin area under the curve (AUC5), every three weeks.
3484080|NCT03764553|Experimental|oxaliplatin and capecitabine|IV and PO Capecitabine 1000 mg/m2 and oxaliplatin 130 mg/m2, every three weeks.
3484081|NCT03764540|Experimental|Cabazitaxel plus prednisone|"Cabazitaxel: Single-dose vial, containing a total of 60 mg of cabazitaxel expressed as anhydrous and solvent-free basis, per 1.5 mL of solution. Cabazitaxel will be administered by IV route Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
3484082|NCT03764540|Active Comparator|Docetaxel plus prednisone|"Docetaxel is formulated in polysorbate 80 and commercially available as 80 mg/2.0 mL single-dose vials with accompanying diluent (13% ethanol in water for injection) for IV use.~Prednisone will be administered orally, 5 mg twice daily (10 mg per day total dose).~Prednisone will be administered by oral route"
3484083|NCT03764527|Active Comparator|Artemether-lumefantrine (AL)|One tablet of artemether-lumefantrine (Coartem®) was administered twice daily for 3 days to children with a body weight of 9 to <15 kg, and 2 tablets were administered twice daily for 3 days to children with a body weight of >15 to 25 kg. All doses were taken under direct observation.
3484084|NCT03764527|Active Comparator|Artesunate + Amodiaquine (AA)|Artesunate + amodiaquine (ASAQ) was administered as follows: 4 mg/kg body weight of artesunate plus 10 mg/kg body weight of amodiaquine once daily for 3 days under direct observation.
3484085|NCT03764514||Spinal Cord Stimulator - Permanent Implantation|
3484086|NCT03764501|Active Comparator|Image fusion group (Image fusion)|Use image fusion system during surgery (Image fusion, ZedTrauma, LEXI Co., Ltd.)
3484087|NCT03764501|No Intervention|Control group (ZedTrauma)|only use 3D preoperative planning (Zed Trauma, LEXI Co., Ltd.)
3484088|NCT03764488|Experimental|BIIB067 High Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 milliliter (mL) artificial cerebrospinal fluid (aCSF).
3484089|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 15 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 15 mL aCSF.
3484090|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in 5 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in 5 mL aCSF.
3484091|NCT03764488|Experimental|BIIB067 Low Dose + 99mTc-MAG3-BIIB067 in up to 20 mL aCSF|Participants will receive intrathecal injection consisting of unlabeled BIIB067 and 99mTc-MAG3-BIIB067 in up to 20 mL aCSF.
3484092|NCT03764475|Other|Long-term Safety of ARQ-151|Open Label Long-term Safety of ARQ-151
3484093|NCT03764462|Experimental|Raloxifene 60mg to AD-101 45mg|Period 1: Raloxifene 60mg, 1 tab, QD, Per oral / Period 2: AD-101 45mg, 1 tab, QD, Per oral
3484094|NCT03764462|Experimental|AD-101 45mg to Raloxifene 60mg|Period 1: AD-101 45mg, 1 tab, QD, Per oral / Period 2: Raloxifene 60mg, 1 tab, QD, Per oral
3484095|NCT03764436|Experimental|LEAPS-NCHD Program - Group 1|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
3484096|NCT03764436|Experimental|LEAPS-NCHD Program - Group 2|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
3484097|NCT03764436|Experimental|LEAPS-NCHD Program - Group 3|Participants will receive the LEAPS-NCHD Program, a youth-led community-based preschool program for children aged 3.5 - 5 years.
3484098|NCT03764423|Experimental|Salmon fishmeal|7,5 g fishmeal and 7,5 g microcrytalline cellulose per day in capsules by mounth for 8 weeks
3484099|NCT03764423|Placebo Comparator|Microcrystalline cellulose|7,5 g microcrystalline cellulose per day in capsules by mounth for 8 weeks
3484100|NCT03764410|Experimental|Diabetic group DG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
3484101|NCT03764410|Active Comparator|No diabetic group NG|Non-surgical periodontal treatment with scaling and root coronary planing, oral hygiene instructions and removal of biofilm retention factors
3484102|NCT03764397|Experimental|Prehabilitation group|A 4-week prehabilitation educational programme (i.e., a behavioral change intervention) and to pilot that prehabilitation in combination with a 6-week gentle self-paced walking programme (with weekly telephone support) in people with FM.
3484103|NCT03764358|Active Comparator|Arteriovenous fistula|
3484104|NCT03764358|Experimental|Tunneled Cuffed Catheter|
3484105|NCT03764345|Experimental|Sofosbovir/Ledipasvir Daily|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
3484106|NCT03764332|Other|Stabilometry|The Podoprint pressure platform was used as a measuring device. The Podoprint platform is a low profile floor platform consisting of 1.4 sensors / cm2 with a sampling frequency of 40Hz.
3484107|NCT03764319|Active Comparator|Intervention group|Ultra-protective ventilator settings in patients with ARDS and ECMO.
3484108|NCT03764319|Active Comparator|Control group|Standard ventilator settings in patients with ARDS and ECMO.
3484109|NCT03764306|Active Comparator|Carotid Artery Stenting|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent with a proximal protection system Mo.Ma
3484110|NCT03764306|Active Comparator|Endarterectomy carotid artery|Subjects will undergo carotid endarterectomy
3484111|NCT03764293|Experimental|SHR-1210|SHR-1210+Apatinib
3484112|NCT03764293|Active Comparator|Control|Sorafenib
3484113|NCT03764280|No Intervention|MDI with Physician Adjusted Basal-Bolus Parameters|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Participants will undergo their conventional multiple daily injection (MDI) therapy.
3484114|NCT03764280|Experimental|MDI with Basal-Bolus Optimization Algorithm|Participants will be wearing the Freestyle Libre glucose sensor (Abbott Diabetes Care). Once daily, the data from the glucose sensor and injection information will be entered into a computer and the optimization algorithm will be run. Once daily, participants' parameters may be changed based on the algorithm's recommendations.
3484115|NCT03764267|Active Comparator|remifentanil|MAC group
3484116|NCT03764267|Active Comparator|general anesthetic|TIVA group
3484117|NCT03764241|Experimental|Rivaroxaban|rivaroxaban will be added in addition to dual antiplatelet therapy
3484118|NCT03764241|Active Comparator|Vitamin K Antagonist|warfarin will be added in addition to dual antiplatelet therapy
3484119|NCT03764228|Experimental|hAECs|Infusion of hAECs at the day before HSCT and 7th days after HSCT. The dose is 1×10^6, 2×10^6, 5×10^6 cell/kg, successively.
3484120|NCT03764215|Experimental|Group 1|Ten (10) participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If Nilotinib 150 mg per mouth daily dose is tolerated by the 1st group of 10 participants for 3 months, another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
3484121|NCT03764202|Other|CSEA，1μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
3484122|NCT03764202|Other|CSEA，1.5μg/kg•d|"The puerpera received combined spinal epidural anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
3484123|NCT03764202|Other|GA，1μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1 μg/kg•d"
3484124|NCT03764202|Other|GA，1.5μg/kg•d|"The puerpera received general anesthesia~The dosage of sufentanil intravenous analgesia was 1.5 μg/kg•d"
3484125|NCT03764202|Other|CSEA，Epidural analgesia|"The puerpera received combined spinal epidural anesthesia~Postoperative analgesia was performed with epidural analgesia~Speed of epidural analgesia pump ：6ml/h（0.1% ropivacaine , 0.5μg/ml sufentanil）"
3484126|NCT03764189|No Intervention|en masse retraction only|anterior segment retraction on miniscrews without microosteoperforation
3484127|NCT03764189|Active Comparator|en masse retraction with alveocentesis|anterior segment retraction on miniscrews with microosteoperforation
3484128|NCT03764176|Active Comparator|Conventional impression|"The intervention of this arm will be conventional impression: polyether impression will be taken with a customized tray."
3484129|NCT03764176|Experimental|Digital impression|"The intervention of this arm will be digital impression: digital impression will be taken using a CS 3600 intraoral scanner ."
3484130|NCT03764163|Experimental|Study Participants|Pulmonary Function Test, Questionnaires, CT scans, perfusion scan, ventilation scan, Xenon gas ventilation CT scan with hyperpolarized 3-Helium MRI Scan.
3484131|NCT03764150||PaCO2> 45 mmHg|Diurnal hypercapnia defined by PaCO2> 45 mmHg
3484132|NCT03764150||PaCO2 <45 mmHg|PaCO2 diurnal within the limits of normal (PaCO2 <45 mmHg)
3484133|NCT03764124||Kidney recipients|Kidney recipients aged over 18 and of all sexes recruited between 2007 and 2020 from the Centre Hospitalier Universitaire de Liege, who have e-GFR follow-up and data from protocol and for cause biopsies available at 1-year post transplant. PET/CT imaging will be performed with patient's approval for protocol and per cause biopsies we performed. Data will be collected in the follow up such as clinical, biological and histological data.
3484134|NCT03764111||large mobile ultrasound system|the ultrasound transducer is based on piezoelectric technology.
3484135|NCT03764111||handheld ultrasound machine|The handheld device utilizes Capacitive micro-machined ultrasound transducers (CMUTs) instead of piezoelectric technology
3484136|NCT03764098|Experimental|Guanfacine ER|Guanfacine extended release (6mg/day ER). Administered orally twice daily at 8:00 AM and 8:00 PM while titrating to the full dose. Titration schedule: Days 1-3 1mg/day; 0.5mg/dose, Days 4-6 2mg/day; 1mg/dose, Days 7-9 3mg/day; 1.5mg/dose, Days 10-12 4mg/day; 2mg/dose; Days 13-15 5mg/day; 2.5mg/dose and Days 16-23 6mg/day; 3mg/dose. Once at steady state, administration is orally once per day at 8:00 PM.
3484137|NCT03764098|Placebo Comparator|Placebo|Administered orally twice a day at 8:00 AM and 8:00 PM Days 1-23, then orally once a day at 8:00 PM.
3484138|NCT03764085|Experimental|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours).The period of the treatment with the study drug lasts 3 days.
3484139|NCT03764085|Active Comparator|Ringer's Lactate|Ringer's Lactate is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours).The period of the treatment with the active comparator lasts 3 days.
3484140|NCT03764072|Experimental|VX-150|
3484141|NCT03764072|Placebo Comparator|Placebo|
3484142|NCT03764059|Experimental|Interventional|The experimental group (Filtek Bulk fill posterior restoration) .After restoration,subjects will return to site for follow up visit at 1 week and 1 year postoperative for further clinical assessments.
3128002|NCT03124342|No Intervention|Usual care|Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
3484143|NCT03764059|Active Comparator|observational|The control group (Filtek™ Z350XT Universal Restorative which was approved by CFDA in 2010 and has been in the market for 5 years with some validated clinical data).After restoration,subjects will return to the site for follow up visits at 1 week and 1 year postoperative for for further clinical assessments.
3484144|NCT03764033|Experimental|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
3484145|NCT03764033|Active Comparator|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
3484146|NCT03764020|Experimental|Melatonin|"Intervention group1:~Melatonin,capsule,3 mg, one dose one hour before bedtime, three weeks"
3484147|NCT03764020|Placebo Comparator|Placebo|"Intervention group2 :~Placebo, capsule, 3 mg, one dose one hour before bedtime, for three weeks"
3128003|NCT03124368|Experimental|Group 1: Danicopan 100 mg TID (Sentinel)|All participants received 100 milligrams (mg) of danicopan three times per day (TID) during the Treatment Period.
3128004|NCT03124368|Experimental|Group 2: Danicopan up to 200 mg TID|All participants received not more than 200 mg of danicopan TID depending on the available safety, pharmacokinetic, and pharmacodynamic data from Group 1 (Sentinel) during the Treatment Period.
3128005|NCT03124381|Active Comparator|Acne Mask|Cleanser, Acne Mask
3128006|NCT03124381|Experimental|Gel-Cream + Acne Mask|Cleanser, Gel-Cream, Acne Mask
3128007|NCT03124407|Active Comparator|Once daily-Active|40 subjects receiving once daily application of complete drug product (contains 0.25% capsaicin) to the knee
3484148|NCT03763981|Active Comparator|prolene seton|Prolene thread will be used as seton treatment for perianal fistulas
3484149|NCT03763981|Active Comparator|silk seton|Silk thread will be used as seton treatment for perianal fistulas
3484150|NCT03763955||PD patients|PD patients at 1-5 H&Y stage undergoes 4week Multidisciplinary Intensive Rehabilitation Treatment
3484151|NCT03763942|Experimental|HealthMindr App|Participants in the intervention arm will receive access to all HealthMindr app capabilities. The app information will cover the importance of testing, links to HIV prevention resources, resources to locate HIV testing and PrEP services, the Substance Abuse and Mental Health Services Administration (SAMHSA) substance abuse treatment resource locator, and other prevention information specific to their area.
3484152|NCT03763942|Placebo Comparator|Control App|Participants in the control arm will be directed to download a study app that allows study staff to interact with them.
3484153|NCT03763916|Active Comparator|Intra operative ureteric dissection|midline abdominal incision extending supraumbilical, incision of the SC tissue, dissection and splitting of the recti, classic midline incision of the uterus [above the site of placental insertion], delivery of the fetus , avoid traction of the placenta, quick closure of the uterus [in presence of the placenta] in one layer, clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
3484154|NCT03763916|Active Comparator|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter.
3484155|NCT03763903|Other|3D training|Basic laparoscopic skills (FLS tasks) training using 3D visualization
3484156|NCT03763903|Other|2D training|Basic laparoscopic skills (FLS tasks) training using 2D visualization
3484157|NCT03763864|Other|Inherited disorders|
3484158|NCT03763851|Experimental|Cannabis group|"Delta-9 Tetrahydrocannabidiol (THC) /Cannabidiol (CBD) ratio 1:1 capsule~These capsules contain different cannabis formulations with low-dose and high-dose preparations according to the treatment group:~Cannabis group low-dose capsule contains THC 1mg CBD 1mg~Cannabis group high-dose capsule contains THC 2.5mg CBD 2.5mg"
3484159|NCT03763851|Placebo Comparator|Placebo group|"The placebo capsule will have no cannabis, it will look identical to the active treatment capsule, and it will also be prepared in low-dose and high-dose presentations."
3128008|NCT03124407|Placebo Comparator|Once daily-Vehicle|20 subjects receiving once daily application of drug product vehicle (i.e., with no capsaicin) to the knee
3484160|NCT03763825|Experimental|Intervention group|Patient will receive the Mini-AFTERc intervention after completion of primary breast cancer treatment.
3484161|NCT03763825|No Intervention|Control group|Patients will receive usual care after completion of primary breast cancer treatment.
3484162|NCT03763812|Other|Endovascular Aneurysm Repair (EVAR)|Patients scheduled for EVAR will be included and blood samples at 7 time points will be taken.
3484163|NCT03763812|Other|Endovascular Aneurysm Sealing (EVAS)|Patients scheduled for EVAS will be included and blood samples at 7 time points will be taken.
3484164|NCT03763799|Experimental|multiplex PCR strategy|FilmArray® Pneumonia Panel plus
3484165|NCT03763799|Active Comparator|standard strategy|
3484166|NCT03763786|Experimental|No GnRH antaogonist|Cetrorelix Acetate (NOT given) Daily 0.25mg Subcutaneous injection for 7 days
3484167|NCT03763786|Active Comparator|Standard GnRH antoagonist|Cetrorelix Acetate (control) Daily 0.25mg Subcutaneous injection for 7 days
3128009|NCT03124407|Active Comparator|Twice daily-Active|40 subjects receiving twice daily application of complete drug product (contains 0.25% capsaicin) to the knee
3484168|NCT03763760|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
3484169|NCT03763760|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
3128010|NCT03124407|Placebo Comparator|Twice daily-Vehicle|20 subjects receiving twice daily application of drug product vehicle (i.e., with no capsaicin) to the knee
3128011|NCT03124459|Experimental|Part 1 Cohort 1|ACE-083 150 mg intramuscular (IM) (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
3484170|NCT03763734|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
3484171|NCT03763734|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
3484172|NCT03763721|Experimental|iOCT optimized protocol (iOCT-p)|In the iOCT optimized protocol (iOCT-p) group, graft apposition will be assessed with special detail for graft orientation, interface fluid, and any peripheral folds as described by Xu et al. Potential tissue manipulations will be therefore based on the iOCT image. Apposition of the graft will be obtained using a complete filling of the anterior chamber with 20% sulphur hexafluoride (SF6) endotamponade for 1-2 minutes, whilst the OCT image is assessed and any graft manipulation can be performed if deemed necessary. After this period, the gas is partly exchanged for BSS (Balanced Salt Solution, Alcon) to achieve a bubble with a diameter of approximately the same size of the graft (i.e. 8.5mm)
3484173|NCT03763721|Active Comparator|current practice protocol (CP-p)|In the current practice protocol (CP-p), graft apposition will be obtained using a complete and pressurized (approx. 65mmHg) filling of the anterior chamber with 20% SF6, for 8 minutes. Tissue manipulations, such as corneal swiping, will be performed as deemed necessary by the surgeon, based on the en face view from the conventional microscope image. The intraocular pressure is normalized by exchanging the SF6 gas for BSS, to achieve a gas bubble approximately the size of the graft (i.e 8.5mm). Now, the graft apposition is assessed using iOCT, to ensure all trial patients eventually undergo advanced iOCT imaging. Should this iOCT image reveal improper graft adherence or any other irregularity, the surgeon will perform additional manipulations or interventions as deemed necessary
3484174|NCT03763708|Experimental|Spinal Cord Stimulation|Each subject will be programmed to different settings.
3484175|NCT03763695||Retrospective control group|Patients admitted in our PICU before the implementation of the protocol for VAP prevention (from 01/01/2016 to 12/31/2017)
3484176|NCT03763695||Prospective group|Patients admitted to our PICU since the VAP bundle has been introduced in the clinical practice (from 01/01/2018)
3484177|NCT03763682|Experimental|Genio(TM) system therapy|Genio(TM) bilateral hypoglossal nerve stimulation system
3484178|NCT03763669|Experimental|Intervention|Pregnant women randomly assigned to receive (n. 40) diet and folic acid (400 mcg per day) and myo-inositol supplementation
3128012|NCT03124459|Experimental|Part 1 Cohort 2|ACE-083 200 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
3128013|NCT03124459|Experimental|Part 1 Cohort 3|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 5 doses.
3484179|NCT03763669|Placebo Comparator|Control|Pregnant women randomly assigned to receive (n. 40) only diet and folic acid (400 mcg per day)
3484180|NCT03763656|Experimental|Open Label|Novel oral solution formulation of hydroxyurea
3484181|NCT03763630|Active Comparator|Intervention arm|House dust-mite SLIT
3484182|NCT03763630|Placebo Comparator|Control arm|Normal saline
3484183|NCT03763630|No Intervention|Observation cohort|ITEC observational cohort, no intervention administered
3484184|NCT03763617|Active Comparator|Test group|A d-ptfe membrane will be placed between the buccal bone and periosteum of an extraction socket during a 4 months healing time before it is surgically removed.
3484185|NCT03763617|No Intervention|Control group|The extraction socket will be left to heal naturally without a socket preservation intervention.
3484186|NCT03763591|Experimental|Psychological Skills Group (e.g., Active Intervention)|10-week Psychological Skills Group.
3484187|NCT03763578|Experimental|Licorice|licorice is one of the natural products that is listed by the Food and Drug Administration (FDA) as GRAS (generally regarded as safe) when used as food flavoring and sweetening agent which has an antimicrobial, anti-inflammatory and antiviral activity.
3484188|NCT03763578|Active Comparator|Chlorhexidine|"The gold standard of oral therapeutics is Chlorhexidine due to its prolonged broad- spectrum antimicrobial effect."
3484189|NCT03763578|No Intervention|Control Group|Participants in this group will follow only the standard preventive measures which is brushing twice a day after breakfast and before bed time and daily flossing interdentally before bed time. (No Mouthwash is used)
3484190|NCT03763565||Vaccinated group|Thai women who received at least one dose HPV vaccination at least 5 years ago, either by Bivalent or Quadrivalent HPV vaccines when they were 20-45 years old
3484191|NCT03763565||Control group|Thai women who did not receive HPV vaccination, either by bivalent or quadrivalent HPV vaccine but have received Pap smear at their ages 20-45 years at least 5 years ago from the current enrollment time
3484192|NCT03763539|Active Comparator|Ultraslow shock wave lithotripsy (SWL)|"SWL at ultraslow rate of 30 SW/min. Power ramping at the first 100 SW from 6 to 18 kv followed by safety pause for two minutes then power ramping from 18 to 22kv during the second 100 SW followed by safety pause for another two minutes.~The rest of the session at 22kv (full power)."
3484193|NCT03763539|Active Comparator|Slow power-ramping SWL|SWL at a slow rate of 60 SW/min. Power ramping from 6 - 10 kv during the first 500 SW then from 11 - 14 kv during the second 500 SW then from 15 - 18 kv during the following 500 SW then from 19 - 22 kv during the remaining 1000 - 1500 SW.
3484194|NCT03763513|Active Comparator|ESWT|the first group:The group that will receive Extra corporeal shock wave therapy
3484195|NCT03763513|Experimental|ESWT+KT|the second group:The group that will receive Extra corporeal shock wave therapy + Kinesiotaping application
3484196|NCT03763500|No Intervention|Care as usual|"Regular care at participating hospitals:~Extended written information and education of patients with atrial fibrillation."
3128014|NCT03124459|Experimental|Part 2 (double-blind placebo controlled)|ACE-083 up to 250 mg IM (tibialis anterior muscle) or placebo, once every 3 weeks for up to 9 doses
3179717|NCT00675805|Active Comparator|Group I|IVIG infusion with filter
3484197|NCT03763500|Active Comparator|Internet-based education|Patients randomized in this arm receive an Internet-based educational program in addition to extended written information. This includes 6 steps with detailed information on background, symptoms, investigations, treatment options, life-style as well as one part with guides to self management.
3128015|NCT03124459|Experimental|Part 2 (open label)|ACE-083 up to 250 mg IM (tibialis anterior muscle), once every 3 weeks for up to 8 doses
3484198|NCT03763487|Experimental|Patients|Ultrasound examination: scaled to spleen size (spleen volumetry) Methodology of laboratory tests: venous blood sampling
3484199|NCT03763487|No Intervention|healthy blood donors|No intervention in this group.
3484200|NCT03763474|Experimental|Euglyca|Patients randomized to the Euglyca group were advised to download the Euglyca application on their smartphones and they were asked to use the application for the calculation of the bolus insulin dose.
3484201|NCT03763474|No Intervention|Control|
3484202|NCT03763461|Experimental|HFNC|HFNC will be started at flow of 40 L/min and FiO2 of 40%.
3484203|NCT03763461|Other|Oxygen Mask|Standard non-humidified oxygen therapy via an oxygen mask at 6 l/min will be performed.
3484204|NCT03763448|Experimental|Infrapatellar Fat Pad Preservation|The IPFP retention of more than 80% in actual operation shall be regarded as IPFP retention.
3484205|NCT03763448|Active Comparator|Infrapatellar Fat Pad Resection|In the clinical practice, more than 80% of IPFP volume is commonly resected by surgeons during total knee arthroplasty. The investigators hereby define resection of more than 80% IPFP volume as IPFP excision.
3484206|NCT03763435||Antenatal Classes Received|Women who are involved into at least 3 comprehensive session of Antenatal pregnancy classes (educational) during the prenatal period.
3484207|NCT03763435||Without education|Groups are not randomized for not to give rise to ethical problems in order to maximize the community health care. Only women who are not involved into the educational classes due to their inaccessibility related to their own conditions or wishes.
3484208|NCT03763409|Experimental|losartan|50 mg single-dose oral losartan
3484209|NCT03763409|Placebo Comparator|placebo|microcellulose placebo in identical capsule
3128016|NCT03124537|Experimental|App Control Condition|The control group will just have the App with the accelerometer program to set step goals and to count and record steps for 1 month
3128017|NCT03124537|Experimental|App Experimental condition|The experimental condition will set step goals and have the schedule, map, and social components for 1 month.
3484210|NCT03763396|Experimental|Ketoconazole (KCZ) Single Dose Group|Single dose 400mg oral tablets 4-24 hours prior to surgery
3484211|NCT03763396|Experimental|Ketoconazole (KCZ) Repeated Dose Group|400mg oral tablets twice a day (BID) for 2-5 days prior to surgery
3484212|NCT03763396|Experimental|Posaconazole (PCZ) Single Dose group|Single dose 300 mg delayed release oral tablets 4-24 hours prior to surgery
3484213|NCT03763396|Experimental|Posaconazole (PCZ) Repeated Dose group|300 mg delayed release oral tablets twice a day (BID) for day 1; every day thereafter is a single dose of 300 mg delayed release oral tablets. Total treatment time is 7-10 days prior to surgery.
3484214|NCT03763383||Free lateral arm flap|included patients who had free lateral Arm flap
3484215|NCT03763383||pedicled lateral arm flap|included patients who had pedicled lateral arm flap
3484216|NCT03763357|Experimental|Heat Therapy|Subject will dress in water-circulating trousers that are connected to a Heat Therapy (HT) pump. Warm water (42-43 degrees C) will be perfused through the pants for 90 minutes.
3484217|NCT03763344|Experimental|Cohort C|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (Baseline),~intervention is fourteen sessions of Perceptual Cognitive Training (PCT) for seven weeks,~a post-treatment cognitive assessment (Week 7), and~a follow up cognitive assessment (Week 11)"
3484218|NCT03763344|No Intervention|Cohort D|"Older adults over the age of 60 years old with subjective memory complaints that underwent:~the first cognitive assessment (baseline),~seven weeks of no intervention,~a post-treatment cognitive assessment (week 7), and~a follow up cognitive assessment (week 11)"
3484219|NCT03763331|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 91.4 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks..
3484220|NCT03763331|Active Comparator|Heat Therapy|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 110 degrees F will be circulated through the pants for 90 minutes daily for 8 weeks.
3484221|NCT03763318|Experimental|EQ001 Dose Escalation (Part A)|Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses.
3484222|NCT03763318|Experimental|EQ001 (Part B)|EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses.
3484223|NCT03763318|Placebo Comparator|EQ001 Placebo (Part B)|Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses.
3484224|NCT03763305|Experimental|Total intravenous anesthesia (TIVA)|Study participants are anesthetized by total intravenous anesthesia (TIVA) using propofol continuous infusion and remifentanil continuous infusion. During induction of general anesthesia, participants receive 3~5mcg/mL Propofol Fresenius and 3~5ng/mL and Remifentanil [Ultiva] as initial effect site concentrations. The effect site concentration is controlled with target-controlled infusion to maintain bispectral index (BIS) values between 40 and 60.
3484225|NCT03763305|Experimental|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, sevoflurane inhalant solution [Sojourn] is used to maintain 1 age-related minimum alveolar concentration (MAC).
3484226|NCT03763305|Experimental|Desflurane|Study participants receive fentanyl 1mcg/kg and propofol bolus injection 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane [Suprane] is used to maintain 1 age-related minimum alveolar concentration (MAC).
3484227|NCT03763292|Experimental|Information brochure|Intervention: The parents are given a specific information brochure that describes the procedures that the child is going through during anesthesia when it has been decided that the child is going to have the surgery.
3179718|NCT00675805|Placebo Comparator|Group II|IVIG infusion without filter
3484228|NCT03763292|No Intervention|Information as usual|Information as usual, i.e. oral information about the procedures to parents when they arrive at the hospital with the child that is going to have the surgery.
3484229|NCT03763279|Experimental|Triclosan-coated barbed suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone barbed suture
3484230|NCT03763279|Experimental|Triclosan-coated monofilament suture|Abdominal wall closure will be performed using a Triclosan-coated Polydioxanone monofilament suture
3484231|NCT03763279|Sham Comparator|Monofilament suture|Abdominal wall closure will be performed using a monofilament suture
3484232|NCT03763266|Experimental|1 day low residue diet|Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
3484233|NCT03763266|Active Comparator|3 days low residue diet|Patients are instructed to complete a low residue diet three days prior the colonoscopy.
3484234|NCT03763253|Active Comparator|Control Arm: Standard of Care (SOC)|"Standard of Care (SOC) treatment as determined by treating physician (positive control) (androgen deprivation with or without docetaxel chemotherapy or other systemic standard of care treatment including but not limited to Abiraterone or Enzalutamide).~Radiotherapy to the prostate in this arm is defined as cytoreductive (for symptom control) in high volume (>/=4) metastases or to mirror current accepted local radiotherapy dose regimens for men with low volume metastases (<4 metastases).~Metastases directed therapy will not be permitted in the control arm. Palliative radiotherapy for symptom control or for prevention of fracture will be permitted as standard clinical practice."
3484235|NCT03763253|Active Comparator|Intervention Arm 1: Minimally Invasive Ablative Therapy (MIAT)|"MIAT to prostate in form of cryotherapy or high intensity focused ultrasound (HIFU), in addition to SOC systemic treatment. No local prostate radiotherapy will be given as part of this intervention. Radiotherapy can be given subsequently for palliative reasons.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
3484236|NCT03763253|Active Comparator|Intervention Arm 2: Radical Therapy|"Radical therapy in form of prostatectomy (any approach) or external beam radiotherapy (radical dose) in addition to SOC systemic treatment. Modality based on physician and patient preference and patient co-morbidities.~For patients undergoing radical prostatectomy no local prostate radiotherapy will be given as part of the intervention. Radiotherapy can be given subsequently for palliative reasons.~Radical radiotherapy doses in this arm will be higher than SOC.~Metastatic directed therapy will be available for use in this arm (if declared at randomisation)."
3484237|NCT03763240|Active Comparator|BSE|Sulforaphane-containing broccoli sprout extract (BSE). The study product is BSE with standardized amounts of sulforaphane. BSE contains a mixture of maltodextrin as a bulking agent and copper chlorophyllin (E 141) as a food additive. BSE is a dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane.
3484238|NCT03763240|Placebo Comparator|Placebo|A mixture of maltodextrin and copper chlorophyllin will be used as placebo. The active compound and the placebo are the same except BSE. The placebo will look similar to the BSE-containing mixture.
3484239|NCT03763227|Active Comparator|Carbonic Anhydrase Inhibitor (CAI) Arm|Patients who have received carbonic anhydrase inhibitor (CAI) therapy namely oral acetazolamide or topical brinzolamide
3484240|NCT03763227|Experimental|Intravitreal ranibizumab (IVR) arm|"Intravitreal ranibizumab (IVR) injection administered to patients who have not shown adequate response or who have not tolerated CAI therapy~IVR therapy = Three 0.5mg IVR injection at monthly intervals"
3484241|NCT03763214|Experimental|Stenting with PTFE-coated stent (HILZO)|The bile duct is stented with a PTFE-coated stent by duodenoscopy to allow bile duct flow
3128018|NCT03124550|Experimental|Exergame Experience|Participants will use the exergame for 6 weeks, during which time game telemetry data (all interactions with the software) will be automatically logged by the system. The participants will be asked to use the game at least every other day. Caregivers will be sent an email or text message to remind them to use the system if they have not done so within three days. Utilizing two-way text messaging, an experience sampling protocol will be employed: once per week, participants will be sent brief questions probing their level of satisfaction with the exergame and their level of perceived connectedness to the community of other caregivers using the exergame.
3132735|NCT03447730|Experimental|Part 2: SYNB1020|Subjects randomized to receive SYNB1020 in Part 2 received SYNB1020 administered orally at a dose of 5 × 10^11 CFU TID given immediately after meals from Days 1 through 6.
3484242|NCT03763214|Active Comparator|Stenting standard silicone coated stent|The bile duct is stented with a standard silicone-coated stent by duodenoscopy to allow bile duct flow
3484243|NCT03763201||rheumatoid arthritis|recently diagnosed rheumatoid arthritis patients in whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum and synovial fluid (if clinically determined knee effusion)
3484244|NCT03763201||control group|age and sex matched healthy volunteers whom we measure Glucocorticoid-induced Tumour Necrosis Factor Receptor Related Protein (GITR) in their serum.
3484245|NCT03763188||the group BEFORE|Retrospective group. The daily urinary urea excretion was unknown.
3484246|NCT03763188||the group AFTER|Prospective group. Use the daily urinary urea excretion to guide the renal replacement therapy weaning.
3484247|NCT03763162|Experimental|Treatment (daratumumab, bortezomib, dexamethasone, ixazomib)|Patients receive daratumumab IV over 3.5-6.5 hours on days 1, 8, and 15, bortezomib SC on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and PO on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3484248|NCT03763136|Experimental|hPSC-CM Therapy|Procedure: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
3484249|NCT03763136|Sham Comparator|Control|Procedure: Coronary artery bypass grafting surgery only.
3128019|NCT03124563|Experimental|Control group|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
3128020|NCT03124563|Experimental|Implementation Intention Condition|Participants will wear a Fitbit Zip to record their daily activity data, which will be deidentified and aggregated with an online platform called Fitabase. Participants in this arm will receive all components of the intervention: scheduling, maps, and activity goals.
3128021|NCT03124602|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
3484250|NCT03763123|Experimental|Sevacizumab +Chemotherapy Combined chemotherapy drug including|Investigators selected single-agent chemotherapy on an individual patient basis from the following options, with appropriate premedication according to local standards: paclitaxel 80mg/m2 intravenously (IV)on days 1, 8, 15, and 22 every 4 weeks; or topotecan 4 mg/m2 IV on days 1, 8, and 15 every 4 weeks.
3484251|NCT03763110|Experimental|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
3484252|NCT03763110|Active Comparator|Antibiotic paste|Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation
3484253|NCT03763097||participants|Patients who are scheduled for single-incision needleless (Contasure-needleless®) mini-sling for their stress urinary incontinence. They will be assessed by Pelvic floor ultrasound
3484254|NCT03763084|Experimental|acetaminophen|For patients randomized to OVA group, OVA 500mg was given every 8 hours for the first 48 hours postoperatively. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
3484255|NCT03763084|Active Comparator|Sufentanil|Sufentanil injection 500μg /10ml in normal saline, total volume 50 ml.Constant infusion dosage is 0.05μg/kg/h. Numeric Pain Rating Scale pain score is assessed every 15 minutes during the 1 hour of ICU stay and when needed.
3484256|NCT03763071||Participants|Pregnant women in the 2nd or 3th trimester Patient-reported scales to measure sleep disorders
3128022|NCT03124693|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received the Rainbow DCI pulse oximeter sensor.
3484257|NCT03763045|Experimental|Sildenafil 25|Twenty hemodialysis patients will receive a dose of 25mg sildenafil daily for 3 months.
3484258|NCT03763045|Experimental|Sildenafil 50|Twenty hemodialysis patients will receive a dose of 50mg sildenafil daily for 3 months.
3484259|NCT03763045|Placebo Comparator|Placebo|Twenty hemodialysis patients will receive a placebo tablet daily for 3 months.
3484260|NCT03763032|Experimental|Stepped Interventions|Patient navigation intervention, plus various psychosocial interventions
3484261|NCT03763019|Active Comparator|Respiratory rehabilitation|"Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.~Respiratory exercises 30 minutes, once daily, (incentive spirometric trainer, forced expiration, percussion, postural drainage etc.)"
3484262|NCT03763019|Placebo Comparator|Conventional rehabilitation|Conventional rehabilitation program aiming to normalize movement patterns and minimize spasticity. Including static and dynamic control of position, balance skills, weight shift, and activities of daily living. 45 minutes, once daily.
3484263|NCT03763006|Experimental|Ocudox lid wiped|
3484264|NCT03763006|Active Comparator|Povidone Iodine|
3484265|NCT03762980|Experimental|Right hemiplegic patients|
3484266|NCT03762980|Experimental|Left hemiplegic patients|
3128023|NCT03124758|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all subjects received the Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI, DCIP)
3128024|NCT03124771|Experimental|Rainbow Resposable Adhesive Sensors|All subjects are enrolled into the test group and all subjects received the Rainbow Resposable Adhesive Sensors.
3484267|NCT03762967|Experimental|Lipoaspiration and SVF introduction I.|Patients with azoospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
3128025|NCT03124784|Experimental|RD Disposable Sensors|All subjects are enrolled into the test group and all subjects received the RD Disposable Sensors
3128026|NCT03124797|Experimental|RD DCI Sensor|All subjects are enrolled into the test group and all subjects received the RD DCI Sensor
3128027|NCT03124823|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Rainbow DCI Sensor
3128028|NCT03124836|Experimental|R2-25 Sensor|All subjects will be enrolled in the test group and will receive R2-25 Pulse Oximeter Sensor
3484268|NCT03762967|Active Comparator|Standard therapy I.|Patients with azoospermia that introduce with Standard therapy only.
3484269|NCT03762967|Experimental|Lipoaspiration and SVF introduction II|Patients with oligospermia that introduce with standard treatment and Lipoaspiration and SVF introduction.
3484270|NCT03762967|Active Comparator|Standard therapy II.|Patients with oligospermia that introduce with Standard therapy only.
3484271|NCT03762954||Research Subjects|All adults aged 60 years or older scheduled to undergo outpatient ERCP and/or EUS at Vanderbilt University Medical Center (VUMC) will be invited to participate in the study. Invited patients who consent to participate as study subjects will undergo neurocognitive and functional assessment pre-procedure and at 90 days post-procedure.
3484272|NCT03762928|Experimental|midazolam/efavirenz|
3484273|NCT03762928|Experimental|PF-06651600/midazolam/efavirenz|
3484274|NCT03762915|Experimental|SRP with minocycline HCl microspheres|The intervention of minocycline HCl microspheres, 1 mg will be administered in the experimental group at baseline and the three month periodontal maintenance visit.
3484275|NCT03762915|No Intervention|SRP without minocycline HCl microspheres|The control group will not have minocycline HCl microspheres, 1 mg administered.
3484276|NCT03762889|Experimental|Eyeprotx™ Group|This group of participants will use the Eyeprotx™ General Anesthesia Protective Goggles when intubated perioperatively under general anesthesia.
3484277|NCT03762889|Active Comparator|Eyelid Tape Group|This group of participants will be receiving the eyelid tape as the preventative measure when intubated perioperatively under general anesthesia.
3484278|NCT03762889|Active Comparator|Eye Ointment Group|This group of participants will be receiving the ointment application when intubated perioperatively under general anesthesia.
3484279|NCT03762863|Experimental|Appropriate application of a CAT tourniquet|All study subjects attended an American College of Surgeons Stop the Bleed Basic course with live training by approved instructors. 6 months after participation in the Stop the Bleed class volunteers study subjects are randomly solicited to return for a refresher session. During this refresher session the volunteer study subjects are observed to determine if they have retained tourniquet application skills and to what degree they have retained them. A 10 point check list will be used to evaluated tourniquet application skill retention.
3128029|NCT03124901|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
3128030|NCT03124927|Experimental|Test Group|All subjects are enrolled into the test group and all subjects receive DCI pulse oximeter sensor.
3484280|NCT03762850|Experimental|sparsentan|Sparsentan will be administered daily as a 200-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 200 mg after 2 weeks will increase their dose to 400 mg and continue treatment to Week 110.
3484281|NCT03762850|Active Comparator|irbesartan|Irbesartan will be administered daily as a 150-mg oral tablet, over-encapsulated (blinded) size 00 capsule for the first 2 weeks of the study following randomization. For patients who tolerate the initial dose of 150 mg after 2 weeks will increase their dose to 300 mg and continue treatment to Week 110.
3128031|NCT03124966|Experimental|Noninvasive Hemoglobin Sensor|All subjects are enrolled into the test group and all will receive the pulse oximeter sensor.
3128032|NCT03124979|Other|Test Subject|All subjects are enrolled into the test group and all subjects received the LNCS DBI Sensor.
3128033|NCT03125005|Experimental|Rainbow Universal Pulse Oximeter Sensor|All subjects will be enrolled in the test group and will receive Rainbow Universal Pulse Oximeter Sensor.
3128034|NCT03125018|Experimental|Test Subject|All subjects are enrolled into the test group and receive the LNCS ADTX Sensor.
3128035|NCT03125031|Experimental|Group- Sensor 1|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/pediatric sensors.
3128036|NCT03125031|Experimental|Group- Sensor 2|All subjects are enrolled into the test group and receive the Rainbow adhesive adult/neonatal sensors.
3128037|NCT03125200|Experimental|ADCT-502|"Part 1 (dose escalation): Participants received an infusion of ADCT-502, at escalating doses. Part 1 continued until the maximum tolerated dose or the recommended dose(s) and schedule(s) for expansion were determined.~Part 2 (expansion): Participants were due to be assigned to the recommended dose level of ADCT-502 as identified in Part 1 by the Dose Escalation Steering Committee."
3128038|NCT03125226|Experimental|Supportive care (TracelT hydrogel)|Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.
3128039|NCT03125395|Experimental|LUM/IVA|LUM/IVA granules or tablets were administered orally every 12 hours (Participants aged 2 through 5 years received LUM 100 mg/IVA 125 mg granules or LUM 150 mg/IVA 188 mg granules based on body weight. Participants ≥6 years of age were to receive LUM 200 mg/IVA 250 mg tablets). Doses were adjusted upward for changes in weight and age.
3128040|NCT03125629|Experimental|18F-FDG PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 18F-FDG.
3128041|NCT03125629|Experimental|18F-FDG PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 18F-FDG.
3484282|NCT03762837||Exposure group：Benign gallbladder disease|Patients with benign gallbladder diseases, such as gallbladder polyps, gallstones, etc.
3484283|NCT03762837||Non-exposed group: healthy people|Patients without benign gallbladder diseases
3484284|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated patients|Patients with different inflammatory rheumatic diseases are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
3484285|NCT03762824|Active Comparator|PCV13+PPV23 vaccinated controls|Healthy controls are immunized with one dose 13-valent pneumococcal conjugate vaccine 0.5 ml i.m., followed by one dose 23-valent pneumococcal polysaccharide vaccine 0.5 ml i.m. after 8 weeks.
3128042|NCT03125629|Experimental|68Ga-DOTA-TATE PET/CT Scan|Participants will undergo a PET/CT scan with radiolabel 68Ga-DOTA-TATE.
3128043|NCT03125629|Experimental|68Ga-DOTA-TATE PET/MRI Scan|Participants will undergo a PET/MRI scan with radiolabel 68Ga-DOTA-TATE.
3484286|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
3128044|NCT03125902|Placebo Comparator|Placebo and Paclitaxel|Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
3128045|NCT03125902|Experimental|Atezolizumab and Paclitaxel|Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.
3128046|NCT03125915|Active Comparator|CHTC as usual|Participants receive couples HIV testing and counseling following the CDC approved protocol.
3128047|NCT03125915|Experimental|CHTC + communication skills videos|The couple views communication skills training videos together prior to participating in a CHTC session following the CDC approved protocol.
3128048|NCT03125915|Experimental|CHTC + substance use module|The couple completes a CHTC session which includes the substance use calendar and structured debriefing activity. This is administered following Step 5 in the standard CDC protocol, just prior to delivery of HIV test results.
3179719|NCT00675818|Experimental|1|CVVH: Patients in this arm will receive CVVH at a replacement fluid rate of 35 mL/kg/h.
3128049|NCT03125915|Experimental|CHTC + video + substance use module|The couple views communication skills training videos together prior to participating in a CHTC session which includes administration of the substance use calendar and structured debriefing activity.
3128050|NCT03125941|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative
3484287|NCT03762824|Active Comparator|PCV13 to previous PPV23-vaccinated patients|Patients with different inflammatory rheumatic disease previously immunized with one dose PPV23 within another study (see VACCIMIL), are immunized with one dose PCV13 0.5 ml i.m.
3484288|NCT03762824|Active Comparator|PPV23-booster to previous PCV-vaccinated controls|Healthy controls previously immunized with one dose PCV7 or PCV13 within another study (see VACCIMIL), are immunized with one dose PPV23 0.5 ml i.m.
3484289|NCT03762811|Other|NanoFUSE® PMCF|NanoFUSE® Bioactive Matrix will be implanted according to labeling and the intended surgical treatment plan of the surgeon.
3484290|NCT03762798|Experimental|Treatment|All participants will receive the Bridge device.
3484291|NCT03762785|Active Comparator|nebulized dexmedetomidine 2ug/kg|inhalation of dexmedetomidine in the dose of 2ug/kg by nebulization
3484292|NCT03762785|Active Comparator|nebulized dexmedetomidine 3ug/kg|inhalation of dexmedetomidine in the dose of 3ug/kg by nebulization
3484293|NCT03762772|Experimental|TAF/EVG vaginal insert|Post-dose sampling at 4 and 48 hours or at 24 and 72 hours, per randomization
3128051|NCT03125941|Active Comparator|Dexamethasone 24 mg|Dexamethasone 24 mg pre-operative
3128052|NCT03126227|Active Comparator|AR101 Powder Provided in Capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
3128053|NCT03126227|Placebo Comparator|Placebo powder|Placebo formulation in pull-apart capsules containing only excipients color-matched to AR101 study product.
3128054|NCT03126344|Experimental|King Vision video laryngoscope|
3484294|NCT03762759|Experimental|Arm I (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 IV and undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
3484295|NCT03762759|Active Comparator|Arm II (68Ga-PSMA, PET/CT)|Patients receive gallium Ga68-labeled PSMA-11 IV, wait 60 minutes, then undergo positron emission tomography (PET)/computed tomography (CT) over 30 minutes.
3484296|NCT03762746|Active Comparator|Active|Intervention with transcranial magnetic stimulation (TMS) low frequency 1 Hz , 1000-pulse train, 20 minutes, 90% motor threshold in left temporo-parietal cortex for 10 consecutive days for 20 schizophrenia patients with auditory hallucination
3484297|NCT03762746|Sham Comparator|Control|Control group is received treatment as usual
3484298|NCT03762720|Experimental|Physium treatment|Patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for a month
3484299|NCT03762694|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|12 sessions acupuncture treatment (EA+AA) will be given twice a week for 6 weeks after randomization.
3484300|NCT03762694|No Intervention|Wait-list control|No treatment except routine care will be given at the first 6 weeks, followed by 12 sessions treatment as Acupuncture group.
3484301|NCT03762642||Mastectomy|
3484302|NCT03762642||Breast-Conserving Surgery|
3484303|NCT03762629|Experimental|Obese intervention group|Obese children were received exercise and diet intervention for 6 weeks.
3484304|NCT03762629|No Intervention|Normal weight control group|Normal weight children were recruited as a control group without any intervention.
3484305|NCT03762603|Experimental|robotic exoskeleton device|Patients who are scheduled to be discharged to a ECF will be asked if they would want to use the exoskeleton device ( for which safety and comfort has been established) instead of going for ECF.
3484306|NCT03762577|Experimental|Training Group|Training group will attend ground-based walking training under the supervision of a physiotherapist for 2 days and 30 minutes a week. Patients will walk for 1-2 days in a week without supervision.
3484307|NCT03762577|No Intervention|Control Group|Patient education will be given and no intervention will be made.
3484308|NCT03762564|Experimental|Arm A (Paclitaxel + Ramucirumab)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 plus Ramucirumab 8 mg/kg as 1 hour intravenous infusion on day 1 and 15 qd 28
3484309|NCT03762564|Active Comparator|Arm B (control arm)|Paclitaxel 80 mg/m2 as 1 hour intravenous infusion on day 1, 8, 15 qd 28
3484310|NCT03762551|Experimental|vitiligo|assess the level of JAK1 in vitiligo patients before and after treatment with NB-UVB
3484311|NCT03762551|Active Comparator|psoriasis|assess the level of JAK1 in psoriasis patients before and after treatment with NB-UVB
3484312|NCT03762551|Other|controls|assess the level of JAK1 in controls
3484313|NCT03762538||G/G group|Patients who are determined to be G/G genotype.
3484314|NCT03762538||G/A A/A group|Patients who are determined to be G/A or A/A genotypes.
3484315|NCT03762525|Other|ECG gated CTA pre and post operative at Gore IBE|To prospectively enroll 15 patients that are scheduled for endovascular aneurysm repair using the Gore IBE device in conjunction with its dedicated self expanding Internal Iliac component. Each patient will have an ECG gated CTA scan before the operation and 6-8 weeks after operation, in stead of a regular CT scan.
3484316|NCT03762525|Other|ECG gated CTA post operative at Gore IBE and Cook IBD|To compare 15 patients that have been treated in the period October 2006- July 2016 with the Cook IBD with a non-dedicated IIA component (Advanta-V12 or Fluency) and 15 matched patients treated with Gore IBE device. Each patient will have an ECG gated CTA after the operation, at the first doctor's appointment, in stead of a regular CT scan.
3484317|NCT03762499|Active Comparator|Prospective participants|250 participants will be recruited prospectively during the hypertension clinic, where a full set of data will be collected from each participant as part of their standard hypertension clinical service. An additional echocardiography scan will be performed for this cohort by the study team, if the scan has not been performed as a part of the clinical care service
3484318|NCT03762499|No Intervention|Retrospective participants|500 participants will be recruited retrospectively, and no additional echocardiography scan will be required for them.
3484319|NCT03762486|Active Comparator|TENS to around the incision|The Patient Controlled Analgesia infusion was started right after the surgery. TENS was applied to around the incision.
3484320|NCT03762486|Active Comparator|TAES to the acupuncture points|The Patient Controlled Analgesia infusion was started right after the surgery. TAES was applied to acupuncture points.
3484321|NCT03762486|No Intervention|No stimulation|No stimulation was performed to the patients in the control group.
3484322|NCT03762473|Experimental|Study Group|Post transplant patients (kidney transplant alone) with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, and negative BK screening at month 1, whom have a concentration/dose of < 1 and a steady state therapeutic level will be eligible. Patients will be converted to envarsus at 20% reduction in dose.
3484323|NCT03762473|Active Comparator|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
3484324|NCT03762460|Experimental|Online eHealth Tool|Participants randomized to this group will use a personally-owned smartphone, tablet, or computer to access the online eHealth tool.
3484325|NCT03762460|Placebo Comparator|Informational website (control)|Participants randomized to this group will receive information about online resources for mental health
3484326|NCT03762447|Experimental|INCB086550|
3484327|NCT03762434|Active Comparator|mobile app|Mobile app: The participants will receive a Life style Modification Program with the support of mobile application (MetS app). The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area of the Mets app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the app installment and briefing.
3128055|NCT03126344|Experimental|McGrath MAC video laryngoscope|
3128056|NCT03126344|Active Comparator|Macintosh|
3179720|NCT00675818|Active Comparator|2|CVVHD: Patients in this arm will receive CVVHD at a dialysate flow rate of 35 mL/kg/h.
3484328|NCT03762434|Active Comparator|booklet|The participants will receive the Life Style Modification programme with the support of a Hong Kong version Metabolic Syndrome (MetS) booklet to take home and use for 3 months. The booklet had been modified from a booklet of a Life Style Intervention Programme (LIP) in China and the principal investigator of this proposal was the core team members of the previous project . The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management . The major component of the booklet for the change is the language translated from simplified Chinese to traditional Chinese and slight adjustment about the advice on vegetable choice due to difference in type of available vegetables in Hong Kong.
3484329|NCT03762421|Experimental|Psychosocial skills development workshops based on PM plus|A number of psycho-social skills development workshops will be conducted for newly inducted civil servants, based on the problem management plus intervention. Problem Management Plus is a brief low-intensity, trans-diagnostic psychological intervention that helps with existing psychological problems as well as building resilience against future adversity. It addresses a range of psychological and practical problems that participants identify as relevant to their lives, including common mental health problems (WHO, 2016; Dawson, et al., 2015). The workshops will be integrated into the routine induction sessions for trainee civil servants.
3484330|NCT03762421|Active Comparator|Control Arm|The control group will receive 5 routine training induction sessions.
3484331|NCT03762408|Experimental|ENKO 1|ENKO 1 administered by single intra-articular injection.
3128057|NCT03126370|Experimental|TAF with a boosted PI and LDV/SOF|"Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide (TAF) 25 mg/emtricitabine (FTC) 200 mg (Descovy) with a boosted protease inhibitor for the next 12 weeks.~After taking TAF/FTC for 12 weeks, participants will then start taking ledipasvir 90mg/sofosbuvir 400mg (LDV/SOV, Harvoni) in combination with TAF/FTC and a boosted protease inhibitor for 4 weeks.~Participants will then return to taking TAF/FTC with a boosted protease inhibitor for the final 12 weeks of the study."
3484332|NCT03762408|Active Comparator|Durolane|Durolane administered by single intra-articular injection.
3484333|NCT03762395|Experimental|CXA-10|Administered orally, continuously, and daily for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Drug will be dispensed at Visit 4.
3484334|NCT03762395|Placebo Comparator|Matching Placebo|Administered orally, daily, and continuously for at least 6 weeks. Dispensed at Visit 1. Washout period of at least 4 weeks and then enter crossover phase of an additional 6 weeks. Placebo will be dispensed at Visit 4.
3484335|NCT03762382|Experimental|TFV/LNG IVR (10mg/20μg) (Continuous)|Tenofovir/Levonorgestrel Intravaginal Ring
3484336|NCT03762382|Experimental|TFV IVR (10mg) (Continuous)|Tenofovir Intravaginal Ring
3484337|NCT03762382|Placebo Comparator|Placebo IVR (Non-eluting)|Placebo Intravaginal Ring
3484338|NCT03762369|Experimental|CKD-351|Latanoprost+D930
3484339|NCT03762369|Active Comparator|Latanoprost|
3484340|NCT03762369|Active Comparator|D930|
3484341|NCT03762343|Experimental|Greater occipital nerve block group (group GONB)|Patient in this group will receive 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
3484342|NCT03762343|Placebo Comparator|Control group (group C):|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
3484343|NCT03762330|Active Comparator|COPD structured self-management plan|Participants will receive usual care for COPD and in addition, a structured self-management education plan.
3484344|NCT03762330|No Intervention|Usual care|COPD participants receiving only usual care
3484345|NCT03762317|Active Comparator|clonidine|Clonidine is started at 6mcg/kg/day and increased to 12 mcg/kg/d for the duration of the study period
3484346|NCT03762317|Placebo Comparator|Placebo|Placebo solution will be given for the duration of the study period
3484347|NCT03762304||Intervention group|The intervention group consists of individuals with a measured blood pressure just above the hypertensive cut-off of 140 mmHg systolic or 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact upper bound on blood pressure will be determined empirically. Individuals in the intervention group were told that that their blood pressure was high, that high blood pressure can lead to life threatening consequences, that blood pressure control can reduce these negative consequences, and that they should seek follow-up care for their blood pressure.
3484348|NCT03762304||Control group|The control group consists of individuals with a measured blood pressure just below the hypertensive cut-off of 140 mmHg systolic and 90 mmHg diastolic blood pressure who have never previously been diagnosed as hypertensive and are not taking medication to lower their blood pressure. The exact lower bound on blood pressure will be determined empirically. These individuals were not given the care encouragement intervention.
3484349|NCT03762278|Experimental|Immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the uni-laterally immobilised leg.
3484350|NCT03762278|Active Comparator|Non-immobilised leg and leucine|Participants consuming leucine supplementation with measures obtained from the non-immobilised leg.
3484351|NCT03762278|Placebo Comparator|Immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the uni-laterally immobilised leg.
3484352|NCT03762278|Placebo Comparator|Non-immobilised leg and placebo|Participants consuming placebo supplementation with measures obtained from the non-immobilised leg.
3484353|NCT03762252|Experimental|Dry needling|Patients will receive dry needling over active trigger points in the scalene muscles
3484354|NCT03762252|Active Comparator|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the scalene muscles
3484355|NCT03762239|Active Comparator|Purified air|Purifying the air with a Pure Airbox device (Zonair 3D). Use of air purifier (Pure Airbox, Zonair 3D) in the classroom 30 minutes before the participants enter the room and during the 2 hours of the experiment.
3484356|NCT03762239|Sham Comparator|Normal air|Using a sham air purifier (same device without filters). Use of the same air purifier but without filters, so that it only recirculates the air without purifying it. Used for the same time period than the other arm.
3484357|NCT03762226||Patient with Macular edema|Patients with clinically significant macular edema due to diabetes or retinal vein occlusion, undergoing at least 4 monthly intravitreal anti-VEGF injections.
3484358|NCT03762187|Experimental|Self-affirmation|Participants completed a written self-affirmation manipulation before completing the standard counseling provided by the clinic.
3484359|NCT03762187|Active Comparator|Positive living counseling|Participants completed the standard counseling provided by the clinic (treatment as usual control condition).
3484360|NCT03762161|Experimental|Intervention TAS-102|
3484361|NCT03762148|Experimental|ferrous fumarate|labelled iron as ferrous fumarate
3484362|NCT03762148|Experimental|ferrous sulphate|labelled iron as ferrous sulphate
3484363|NCT03762148|Experimental|ferric pyrophosphate|labelled iron as ferric pyrophosphate
3484364|NCT03762148|Experimental|ferrous fumarate + 3.5 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 3.5 g GOS
3484365|NCT03762148|Experimental|ferrous fumarate + 7 g GOS|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS
3484366|NCT03762148|Experimental|ferrous sulphate + 15 g GOS|labelled iron as ferrous sulphate + prebiotics in the form of 15 g GOS
3484367|NCT03762148|Experimental|ferrous fumarate + Vitamin C|labelled iron as ferrous fumarate + Vitamin C
3484368|NCT03762148|Experimental|ferric pyrophosphate + 15 g GOS|labelled iron as ferric pyrophosphate + prebiotics in the form of 15 g GOS
3484369|NCT03762148|Experimental|ferrous fumarate + 7 g GOS + Vitamin C|labelled iron as ferrous fumarate + prebiotics in the form of 7 g GOS + Vitamin C
3484370|NCT03762122|Experimental|Rogaratinib|Rogaratinib is given at a dose of 600 mg twice daily in continuous 28-days cycles, without treatment breaks (except for toxicity management). Trial treatment is continued until evidence of tumor progression, unacceptable toxicity, consent withdrawal or withdrawal by the investigator.
3484371|NCT03762109|Experimental|Dantrolene Group|Patients will receive 25 mg of Dantrolene orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
3484372|NCT03762109|Placebo Comparator|Placebo Oral Tablet Group|Patients will receive a 25 mg of a placebo pill orally at four different time points: immediately before surgery, as well as at 12, 24 and 36 hours after surgery.
3484373|NCT03762096|Experimental|Resveratrol|
3484374|NCT03762096|Placebo Comparator|Placebo|
3484375|NCT03762083|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of BV.
3484376|NCT03762057||Surgical patients|All postoperative patients admitted to surgical ICU with foley catheter in place
3484377|NCT03762044|Experimental|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|10 sessions of 30 minutes, twice a week in a total 5 week period of Activity-oriented Proprioceptive Antiedema Therapy (TAPA in Spanish)
3484378|NCT03762044|Active Comparator|Complete Decongestive Therapy (CDT)|10 sessions of 30 minutes, twice a week in a total 5 week period of complete decongestive therapy (CDT).
3484379|NCT03762031|Experimental|GC4711 30mg|
3484380|NCT03762031|Experimental|GC4711 60mg|
3484381|NCT03762031|Experimental|GC4711 90mg|
3484382|NCT03762031|Experimental|GC4711 120mg|
3484383|NCT03762031|Placebo Comparator|Placebo|
3484384|NCT03762031|Experimental|GC4711 75mg|
3484385|NCT03762031|Experimental|GC4711 105mg|
3484386|NCT03762018|Active Comparator|Bevacizumab plus chemotherapy|Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
3484387|NCT03762018|Experimental|Atezolizumab plus bevacizumab plus chemotherapy|Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks
3484388|NCT03762005|Experimental|CRT guided resuscitation|Fluid resuscitation will be aimed at normalizing capillary refill time (CRT) during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of CRT until achieving normal values, or the patient becomes fluid unresponsive, or a safety issue develops.
3484389|NCT03762005|Active Comparator|Lactate guided resuscitation|Fluid resuscitation will be aimed at normalizing or decreasing lactate levels by more than 20% every 2 hours during the intervention during the intervention period. Fluid challenges will be administered at a rate of 500 ml of crystalloids over 30 minutes, with reassessment of lactate every 2 hours until reaching target, or the patient becomes fluid unresponsive, or a safety issue develops.
3484390|NCT03761992|Active Comparator|Gingko Biloba Extract|Gingko Biloba Extract 240 mg.
3484391|NCT03761992|Placebo Comparator|Placebo|Placebo Pill
3484392|NCT03761979|Active Comparator|Strontium dose of 170 mg|The Sponsor provided each 170 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
3484393|NCT03761979|Active Comparator|strontium dose of 340 mg|The Sponsor provided each 340 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
3484394|NCT03761979|Active Comparator|Strontium dose of 680 mg|The Sponsor provided each 680 mg dose of strontium as strontium L-lactate dry powder packaged in individual vials. The powder was prepared for consumption by adding 10 mL of distilled water to the vial and stirring until dissolution was complete. This liquid was then poured into an administration cup. An additional 10 mL of distilled water was used to rinse the remaining SrLac into the administration cup. Then 80 mL of distilled water was added directly into the administration cup. Following consumption of the 100 mL solution of SrLac, another 100 mL of distilled water was added into the administration cup, swirled, and consumed by the subject.
3484395|NCT03761966||Pregnant women|"Pregnant women older than 18 years old atended at the Mónica Pretelini Sáenz Maternal-Perinatal Hospital (HMPMPS), Health Institute of the State of Mexico (ISEM)."
3484396|NCT03761953|Experimental|Oritavancin|Single IV infusion of 1200mg of oritavancin
3484397|NCT03761940||Disease free|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires are disease free.
3484398|NCT03761940||Local recurrences|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with local recurrence and may be undergoing treatment for this.
3484399|NCT03761940||Distant disease|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have been diagnosed with distant disease and may be undergoing treatment for this.
3484400|NCT03761940||Mastectomy|Women who have been treated for early breast cancer with breast conserving surgery and radiotherapy and at the time of completing study questionnaires have undergone a mastectomy.
3484401|NCT03761927|Active Comparator|Hearing Aid without NR enabled.|Hearing Aid without Noise Reduction (NR) enabled serves as reference condition.
3484402|NCT03761927|Experimental|Hearing Aid with NR(1)|Hearing Aid with Noise Reduction I (NR) enabled.
3484403|NCT03761927|Experimental|Hearing Aid with NR(2)|Hearing Aid with Noise Reduction II (NR) enabled.
3484404|NCT03761914|Experimental|Colorectal Cancer (CRC)|"N=20;~Metastatic CRC priorly Rxed with ≥2 lines of ChemoRx (3rd/4th line); must have documented disease progression post last administration of or intolerance to standard therapies, which must have included a fluoropyrimidine, oxaliplatin, irinotecan, bevacizumab, and, if KRAS wild-type, cetuximab or panitumumab. Prior regorafenib or trifluridine/tipiracil is allowed, but not mandated;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
3484405|NCT03761914|Experimental|Ovarian Cancer (OvC)|"N=20;~Metastatic OvC priorly Rxed with ≥1 line of platinum-containing ChemoRx (2nd/3rd line) with either relapse or disease refractoriness; interval surgery permitted, as long as subjects have measurable disease by imaging and concomitant CA-125 increase, and/or biopsy showing OvC; must have either received (or been offered) bevacizumab therapy; those with BRCA germline mutations (gBRCA mut) must have been offered therapy with poly-ADP ribose polymerase (PARP) inhibitors.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
3484406|NCT03761914|Experimental|Small Cell Lung Cancer (SCLC)|"N=20;~Advanced SCLC priorly Rxed with 1 line of ChemoRx (2nd line); must have measurable disease by imaging after they progressed or were resistant to 1 prior systemic therapy; asymptomatic or treated brain metastases are allowed;~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
3484407|NCT03761914|Experimental|Triple Negative Breast Cancer (TNBC)|"N=15;~TNBC priorly Rxed with 1 line of ChemoRx with residual or recurrent disease (2nd line); estrogen (ER) and progesterone receptor (PgR) negative, and HER2(-) by IHC AND HER2 non-amplified by fluorescence in situ hybridization; weak IHC positivity for ER or PgR (i.e., < 5%) eligible; must have undergone 2nd line therapy after 1st line Rx could include: neoadjuvant Rx if macroscopic disease still present after surgery OR adjuvant Rx but only if relapse occurred > 6 months from the start of pembrolizumab (P);~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
3484408|NCT03761914|Experimental|Acute Myelogenous Leukemia (AML)|"N=15;~Pts with AML who are not eligible for allogeneic stem cell transplant and have been able to achieve morphological partial remission (PR) as their best ever response at the time of completion of their 4th cycle of upfront Rx with HMA; prior initial upfront hydroxyurea or leukapheresis Rx or history of induction early failure after up to 2 cycles of ChemoRx (7+3 or similar regimen) with seamless immediate transitioning to HMA Rx eligible; must remain on HMA therapy throughout the trial.~PFS and OS to be assessed in all;~GM-CSF before each galinpepimut-S (GPS) vaccine injection; first 2 GPS injections (monotherapy) Q3 wks, followed by GPS co-administered with pembrolizumab (P) Q3wks x 4. After that, there will be 1 unpaired administration of P, and GPS will be resumed Q3wks x 6. After a 12-wk interval where 3 unpaired administrations of P will occur, GPS will resume Q12wks x 4. After 84 wks, non-progressors will continue in the study on P alone."
3484409|NCT03761901||Patients with EGFR mutation positive NSCLC|
3484410|NCT03761888||Labetalol|Patients who will receive labetalol in IV route in first intention
3484411|NCT03761888||Nicardipine|Patients who will receive nicardipine in IV route in first intention
3484412|NCT03761875|Other|CHB patients|a blood sample is done during a follow-up visit
3484413|NCT03761875|Other|Control group|a blood sample
3484414|NCT03761862||Control|The control group with bilateral tubal ligation
3484415|NCT03761862||Neural Therapy|The treatment group
3484416|NCT03761836|Experimental|ShangRing|Males aged 13 years and above will undergo circumcision through ShangRing procedure, with regular follow-up visits to evaluate pain, wound healing and incidence of adverse events. The ShangRing will be removed after 7 days, with a last follow-up visit at 60 days.
3484417|NCT03761797||Subjects with type 2 Diabetes Mellitus|
3484418|NCT03761771||colonoscopy withdrawal with the ADS monitoring|The ADS automatically initiated once the ileocecal valve was pictured by the colonoscopist or the colonoscopist recorded any image of colon during the insertion. When colonoscopists withdrew the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the ADS, which made it feasible to identify and classify lesions in real time.
3484419|NCT03761758|Experimental|Lens Design 1|Spectacle lenses design 1, fitted into spectacle frames
3484420|NCT03761758|Experimental|Lens Design 2|Spectacle lenses design 2, fitted into spectacle frames
3484421|NCT03761758|Experimental|Lens Design 3|Spectacle lenses design 3, fitted into spectacle frames
3484422|NCT03761732|Experimental|PTSD lay-led group treatment program|The group will go through the Islamic Trauma Healing Program
3128058|NCT03126448|Other|Group 1: Closed Index Fractures|Group 1 is clean, closed fractures undergoing index open reduction internal fixation (ORIF), intramedullary nailing (IMN) where the fracture site is accessible, or staged treatment of a pilon or plateau that was initially treated by joint spanning external fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
3484423|NCT03761706|Experimental|Intervention Cohort|This is a one-arm intervention study that includes assessments and questionnaires at several time points as early stage breast cancer patients undergo chemotherapy and at 6 months post-chemotherapy. Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits to evaluate engagement in physical activity. Study participants will complete questionnaires, an exercise log, and submit blood samples as multiple time points.
3484424|NCT03761693|Experimental|Severe/classical MCADD|"Severe MCADD will be defined by ACADM mutations associated with clinical ascertainment or residual MCAD enzyme activity < 10 %, as defined previously (Touw et al., 2012).~Interventions include fasting challenges at two and six months of age."
3484425|NCT03761693|Experimental|Mild MCADD|"Mild MCADD will be defined by the remaining ACADM genotype variants and residual MCAD enzyme activity ≥ 10%.~Interventions include fasting challenges at two and six months of age."
3484426|NCT03761667|Experimental|NBI|The group of NBI inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
3484427|NCT03761667|No Intervention|White light endoscopy (WLE)|The group of WLE inspection on resection margin for surveillance of remnant tissue of SSA/P right after the endoscopic resection. If the remnant tissue is detected using NIB inspection, additional endoscopic resection should be performed.
3484428|NCT03761654||"Patients with a non-severe subarachnoid hemorrhage"|
3484429|NCT03761628|Experimental|pHyph, Gedea Pessary|Clinical performance, tolerability, safety and user experience of Gedea Pessary, a slow-release vaginal tablet for the treatment of VVC.
3484430|NCT03761615||type 1 diabetes and pregnancy|Pregnant women with T1D on insulin pumps (CSII/SAP/PLGS) will be offered enrollment in a prospective study that will capture: 1) Dexcom G6 CGM data, 2) self-monitoring of blood glucose (SMBG), 3) insulin pump settings, 4) insulin delivery records, and 5) maternal and fetal outcomes.
3128059|NCT03126448|Other|Group 2: Hardware Removal from Healed Fractures|Group 2 will include patients having a plate removed from a healed fracture without clinical evidence of infection and excluding history of open fracture. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
3132736|NCT03447730|Placebo Comparator|Part 2: Placebo|Subjects randomized to receive control in Part 2 received matching placebo (100 mL masking solution) administered orally TID given immediately after meals from Days 1 through 6.
3484431|NCT03761602||Proper selenium and iodine condition|"The subjects should have proper dietary intake of selenium and iodine, according to Chinese Dietary Reference Intakes (DRIs) (intake of selenium 65μg/d and iodine 230 μg/d).~The Serum iodine concentration are 45-92μg/L，and the urinary I/Cr 150-249μg/g Cr.~The Serum selenium concentrations are 18-40μg/L."
3484432|NCT03761602||Excessive selenium or iodine condition|"The subjects have excessive dietary intake of selenium and iodine, usually more than 2 times of DRIs. The Serum iodine concentration are more than 100μg/L，and the urinary I/Cr more than 300μg/g Cr.~The Serum selenium concentrations are more than 40μg/L."
3484433|NCT03761602||Insufficient selenium or iodine condition|"The subjects have insufficient dietary intake of either selenium or iodine, compared with DRIs. The Serum iodine concentration are less than 45μg/L，and the urinary I/Cr less than150μg/g Cr.~The Serum selenium concentrations are less than 18μg/L."
3484434|NCT03761589|Experimental|AFL Intervention Group|The AFL intervention consisted of twice a week physical activity and nutrition sessions for children and twice a week educational and physical activity sessions for parents. Each session lasted 90 minutes and all sessions were conducted in a municipal recreation center. The child program was delivered in English while the parent program was delivered in separate English-only or Spanish-only classes.
3484435|NCT03761589|Other|Wait-List Control Group|The wait-list control group received the 12-week AFL intervention after all follow-up data had been completed.
3484436|NCT03761550||Stage 2|The Process Implementation Stage
3484437|NCT03761524|Experimental|Customized V plate fixation|Computed tomography (CT) scan of the Facial bones (Axial cuts, DICOM file, Gantry tilt zero and minimal thickness of 1mm )is taken for the patients and a customized V pattern plate
3484438|NCT03761524|Active Comparator|Conventional miniplates fixation|Conventional superior-inferior miniplates fixation of mandibular angle fixation
3484439|NCT03761511|Active Comparator|Treatment arm|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
3484440|NCT03761511|Placebo Comparator|Placebo arm|Matching Placebo (capsules) once daily
3484441|NCT03761498||Normal Growth|Require less than or equal to 110 kcal/kg/day to maintain growth curve
3484442|NCT03761498||Slow Growth|Require more than 110 kcal/kg/day to maintain growth curve
3484443|NCT03761485|Experimental|Dentifrice 750 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
3484444|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF neutral|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
3484445|NCT03761485|Active Comparator|Dentifrice 1.100 ppm of NaF acidulated|Use of Dentifrice Fluoride Use of few of dentifrice on brushing for 12 months
3484446|NCT03761472|Active Comparator|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2 ml solution, once initially.
3484447|NCT03761472|Active Comparator|Platelet-rich plasma injection|Platelet-rich plasma 5 ml, once initially
3484448|NCT03761472|No Intervention|Unaffected side Hyaluronic acid|Unaffected sides of the patients will be controls for hyaluronic acid group, no intervention.
3484449|NCT03761472|No Intervention|Unaffected side Platelet-rich plasma|Unaffected sides of the patients will be controls for Platelet-rich plasma group, no intervention.
3484450|NCT03761433||SPI group|All patients who received the liver resection surgery will receive surgical pleth index
3484451|NCT03761407|Experimental|Group 1 (100 mg GRT0151Y)|"The dose of 100 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 100 mg. On Day 5 the last dose of 100 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group."
3484452|NCT03761407|Experimental|Group 2 (125 mg GRT0151Y)|"The dose of 125 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 125 mg. On Day 5 the last dose of 125 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
3484453|NCT03761407|Experimental|Group 3 (150 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the treatment regimen will be changed to a triple daily (t.i.d) medication with 150 mg. On Day 5 the last dose of 150 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
3484454|NCT03761407|Experimental|Group 4 (225 mg GRT0151Y)|"The dose of 150 mg will be administered twice (b.i.d.) on Day 1 (titration day). On Days 2, 3 and 4, the dose of 225 mg will be administered twice (b.i.d.). On Day 5 the last dose of 225 mg will be administered in the morning.~Matching placebo using the same dosing regimen as defined in the treatment group"
3484455|NCT03761381||Early Dementia|This group will consist of adults with suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
3179721|NCT00675831|Experimental|CD25+ Treg depleted DLI dose schema|"Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema:~Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*))~Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*))~Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg"
3484456|NCT03761381||Dementia-Free Controls|This group will consist of adults without suspected dementia/Alzheimer's Disease. OCTA and NRAI data will be gathered in two study visits, with each visit about 10 days apart.
3484457|NCT03761342|No Intervention|Control|A control arm that mirrors a traditional web-grocery store with no but with no FOP labels.
3484458|NCT03761342|Experimental|Multiple Traffic Light Labels|Similar to Arm 1, with Multiple Traffic Light labels displayed on all products FOP. A 60-second introductory video briefly explaining the MTL scheme will be shown before each shop in this Arm.
3484459|NCT03761342|Experimental|Nutri-Score|Similar to Arm 2, with Nutri-Score labels instead of MTL labels displayed on all products FOP. A 60-second introductory video briefly explaining the NS scheme will be shown to shoppers in this condition.
3484460|NCT03761329|Active Comparator|Bier's block|Upperarm intravenous regional anesthesia (Bier's block) with lidocaine 0.5% 40ml
3484461|NCT03761329|Experimental|Mini-Bier's block|Forearm intravenous regional anesthesia (mini-Bier's block) with lidocaine 0.5% 25ml
3484462|NCT03761316||FBSS patients|patients with Failed Back Surgery Syndrome, eligible for SCS
3484463|NCT03761303|Active Comparator|active rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
3484464|NCT03761303|Sham Comparator|sham rTMS|Patients in the control group receive sham rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
3484465|NCT03761264|Experimental|Intra-canal Odontopaste®|Single visit placement of Odontopaste®
3484466|NCT03761264|Active Comparator|Intra-canal Pulpdent|Single visit placement of Pulpdent
3484467|NCT03761264|Active Comparator|Oral Amoxicillin|Amoxicillin 15mg/kg tds for 5 days
3484468|NCT03761251|Experimental|Pet Fish|Participants will be instructed to partner thrice daily and once weekly fish care activities with diabetes care activities for 3 months
3484469|NCT03761238|Experimental|Standard medical treatment + MARS|Patients assigned to the control arm will receive standard medical treatment (SMT) and liver dialysis using Molecular Adsorbent Recirculating System (MARS).
3484470|NCT03761238|Active Comparator|Standard medical treatment|Patients assigned to the control arm will receive standard medical treatment (SMT) as specified in the study protocol.
3484471|NCT03761225|Experimental|Masitinib & docetaxel|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
3484472|NCT03761225|Placebo Comparator|Placebo & docetaxel|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus docetaxel 75 mg/m2 by intravenous infusion during 1 hour, once every 3 weeks (1 cycle = 21 days) for 6 cycles (8 to 10 cycles can be performed according to patient's tolerance) plus prednisone according to usual practice.
3484473|NCT03761212||Patient with ankylosing spondylitis or axial spondyloarthritis|No intervention - observational study
3484474|NCT03761212||Healthy controls|Age and sex matched healthy controls
3484475|NCT03761199|Experimental|a group of patients with AD|15 people with clinically diagnosed atopic dermatitis (AD), established on the basis of criteria Hanifin and Rajka
3484476|NCT03761199|Other|control group|15 healthy persons which will form the control group
3484477|NCT03761186|Active Comparator|traditional diabetes diet|Participants in this arm will follow a diet with carbohydrate intake 50-60% of total energy intake
3484478|NCT03761186|Experimental|moderately low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 30-40% of total energy intake
3484479|NCT03761186|Experimental|strictly low carbohydrate diet|Participants in this arm will follow a diet with carbohydrate intake 15-20% of total energy intake
3484480|NCT03761134|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
3484481|NCT03761134|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
3484482|NCT03761134|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
3484483|NCT03761121|Experimental|Primary Testing Group|"This scan is in the same imaging session as the participant's scheduled clinical MRI and is no longer 15 minutes~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
3484484|NCT03761121|Experimental|Software Testing Group|"Participants will receive hour research-only scan~Wave-CAIPI will be use to enable a 40-60 s acquisition per contrast at 0.9-mm isotropic resolution~Wave-CAIPI will be used to acquire a 4-echo GE-SE time-series at 1.5-mm isotropic resolution"
3484485|NCT03761056|Experimental|Axicabtagene Ciloleucel|Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, axicabtagene ciloleucel
3128060|NCT03126448|Other|Group 3: Index Treatment of Fracture Nonunions|Group 3 will be patients that are undergoing an index procedure for fracture nonunion at a site where prior surgery has been undertaken for the fracture. Exclusions include bone grafting of 'critical' defects, active clinical infection, or < 3 months from index fracture fixation. Tissue obtained at the time of surgery will be sent to the research laboratory for culture and performance of the two highly sensitive assays.
3484486|NCT03761043|No Intervention|Pre-Intervention Arm|The nurses will have not been exposed to the behavior change intervention.
3484487|NCT03761043|Experimental|Post-Intervention Arm|The nurses will have been exposed to the behavior change intervention.
3128061|NCT03126539|Experimental|Group A|Sulforaphane will be applied topically to both sites for up to 7 consecutive nights. Biopsies will be obtained prior to, and immediately after this intervention, on standard photoprotected and photoexposed sites.
3128062|NCT03126539|Experimental|Group B|Two photoprotected sites will be identified. Sulforaphane will be applied topically to a single selected site for up to 7 consecutive nights. Both site will be exposed to UV. Biopsies of both sites will be obtained prior to, and 24 hours after UV exposure.
3484488|NCT03761030|Experimental|L-DOPA Arm|Those assigned to L-DOPA will begin taking 37.5mg carbidopa/150 mg levodopa once daily (with placebo twice daily) for one week, then increase to 75mg carbidopa/300mg levodopa (37.5 mg carbidopa/150mg levodopa twice daily and placebo once daily) for one week, and finally increase to 112.5mg carbidopa/450mg levodopa (37.5 mg carbidopa/150mg levodopa three times daily and no placebo) for the final six weeks. Each subject assigned to the L-DOPA arm will be titrated to 450mg L-DOPA unless they cannot tolerate higher doses, in which case subjects will have their dosage reduced to the maximum tolerable dose
3484489|NCT03761030|Placebo Comparator|Placebo Arm|Subjects assigned to the placebo arm will take placebo oral tablet three times daily throughout the study.
3484490|NCT03761017|Experimental|MGD019|Bispecific DART protein binding PD-1 and CTLA-4
3484491|NCT03761004|Experimental|WD-1603 single dose|"WD-1603 single dose:~A single WD-1603 tablet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
3484492|NCT03761004|Experimental|WD-1603 BID dose|"WD-1603 BID dose:~A single WD-1603 tablet after breakfast, and a second WD-1603 tablet approximately 3 hours after completing lunch.~Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 4.5, 5, 6, 7, 7.25, 7.5, 7.75, 8, 8.5, 9, 10, 10.5 11, 12, 16 and 24 hours post-dose."
3484493|NCT03761004|Active Comparator|Sinemet single dose|"Sinemet single dose:~A single oral dose of Sinemet after breakfast. Plasma samples for PK analysis will be collected at pre-dose (baseline) and 10 min, 30 min, 45 min and 1, 1.5, 2, 3, 4, 6, 7, 8, 10, 12, 16 and 24 hours post-dose."
3128063|NCT03126682|Active Comparator|Wellbutrin during ECT 1|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 1
3128064|NCT03126682|Active Comparator|Wellbutrin during ECT 2|Drug - Wellbutrin SR 300Mg Extended-Release Tablet during ECT session 2.
3128065|NCT03126760|Experimental|Acthar Gel|Participants receive Acthar Gel under the skin once a day for 14 consecutive days
3128066|NCT03126760|Placebo Comparator|Placebo|Participants receive Placebo under the skin once a day for 14 consecutive days
3128067|NCT03126786|Active Comparator|Active|Treatment will consist of IVT injection of Aflibercept followed by an SC injection of CLS-TA
3128068|NCT03126786|Sham Comparator|Control|Treatment will consist of IVT aflibercept injection followed by a sham SC procedure
3128069|NCT03127228|Other|Standard mechanical debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with dental scalers.
3484494|NCT03760991|Experimental|Insulin glargine (U300)|Insulin glargine (U300) (Gla-300) once daily for 26 weeks on top of any other antidiabetic treatment except other basal insulin
3484495|NCT03760978||dex group|Critically ill patients <18 year-old receiving prolonged sedation with endovenous dexmedetomidine (dosage 0.2 mcg/Kg/hour to 1.8 mcg/Kg/hour) more than 24 hours
3484496|NCT03760965|Experimental|Sotagliflozin dose 1|Sotagliflozin dose 1, given as two (2) dose 2 tablets, once daily, before the first meal of the day
3179722|NCT00675844|Experimental|elvucitabine|Subjects currently receiving elvucitabine will continue elvucitabine as part of their ART regimen for an additional 48 months.
3179723|NCT00675857|Placebo Comparator|A|
3484497|NCT03760965|Experimental|Sotagliflozin dose 2|Sotagliflozin dose 2, given as 1 sotagliflozin dose 2 tablet and 1 sotagliflozin-matching placebo tablet (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
3484498|NCT03760965|Placebo Comparator|Placebo|Two sotagliflozin-matching placebo tablets (identical to sotagliflozin dose 2 in appearance), once daily, before the first meal of the day
3484499|NCT03760939|Experimental|Ambulatory care|Colorectal surgery in ambulatory care
3484500|NCT03760939|Other|Standard hospitalization|Colorectal surgery with standard hospitalization for retrospective patients who benefit from the ERAS program, selected by statistical matching.
3484501|NCT03760926|Experimental|AblaCare Procedure|AblaCare Procedure performed with use of the AblaCare Kit intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to polycystic ovary syndrome.
3484502|NCT03760900|Experimental|infusion group|Autologous Umbilical Cord Blood Stem Cells Therapy
3484503|NCT03760887|Sham Comparator|No Home Sensory training|Patients who perform a home exercise program only
3484504|NCT03760887|Experimental|Home sensory training|Patients who perform home exercise and home sensory training
3484505|NCT03760874||Non Vitamin K Oral Anticoagulant|Dabigatran, Rivaroxaban, Apixaban, Edoxaban
3484506|NCT03760874||Vitamin K Oral Anticoagulant|Warfarin, Acenocoumarol.
3484507|NCT03760861|Experimental|Prototype Microcapsule Treatment Arm|Intervention by placement of prototype weight-loss microcapsule in the stomach. Subjects will have a weight-loss microcapsule deployed endoscpically in the stomach. The intragastric balloon in the capsule will be inflated using an external magnet..
3484508|NCT03760848|Other|Midazolam, Atorvastatin / Aramchol, Midazolam, Atorvastatin|Midazolam 2 mg -atorvastatin 40 mg /Aramchol 600mg -midazolam 2 mg-atorvastatin 40 mg (MA/MAA)
3484509|NCT03760835|Experimental|Dual-release hydrocortisone|
3484510|NCT03760835|Active Comparator|Conventional glucocorticoids|
3484511|NCT03760822|Experimental|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
3484512|NCT03760822|Active Comparator|Ramucirumab + Paclitaxel|IV ramucirumab at 8 mg/kg on D1 and D15 IV paclitaxel at 80 mg/m² on D1, D8 and D15
3484513|NCT03760809|Experimental|group A|Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
3484514|NCT03760809|Experimental|group B|Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia
3484515|NCT03760783|Other|Effect of microgravity on human sperm|Simulated microgravity flight
3484516|NCT03760770|Experimental|Riboflavin at 4ºC|patients treated with Riboflavin at 4ºC in crosslinking (cases).
3484517|NCT03760770|Experimental|Riboflavin at room temperature|patients treated with Riboflavin at room temperature in crosslinking (controls)
3484518|NCT03760757|Experimental|PCSO-524® (no krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. Amounts per day equal to 800 mg olive oil, 400 mg lipid extract (~58 mg EPA and 44 mg DHA) and 1.8 mg vitamin E (d-alpha-tocopherol).
3484519|NCT03760757|Experimental|ESPO-572® (75% PCSO-524®, 25% krill oil)|Four total capsules per day (2 in the morning; 2 at night) for 29 days. ESPO-572®, a 75/25% PCSO-24®/Krill oil blend. Each capsule of the ESPO-572® contains green lipped mussel oil, krill oil, olive oil and vitamin E.
3484520|NCT03760744|Experimental|CDT with Negative Pressure|CDT with LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
3179724|NCT00675857|Active Comparator|B|
3179725|NCT00675870|Experimental|1|
3179726|NCT00675883||Prospective|500 patients who will be enrolled in the MS Alliance program will be consented to participate in this study.
3179727|NCT00675883||Retrospective|500 patient chart reviews will be completed for patients who were enrolled in the MS Alliance program between two (2) to three (3) years ago.
3179728|NCT00675896|Experimental|1|Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
3179729|NCT00675896|Placebo Comparator|2|Placebo
3484521|NCT03760744|Active Comparator|CDT alone|CDT alone without LymphaTouch for 6 weeks, total of 9 therapy visits (75minutes duration)
3484522|NCT03760731|Experimental|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
3484523|NCT03760731|Active Comparator|Present Centered Therapy|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right. PCT could provide another treatment option that might be preferable to some Veterans and promote patient choice. Additionally, PCT would require less clinician training and specialization than ACT-MI. Using PCT as an active comparison condition will determine whether it is necessary to train clinicians in ACT-MI or if therapists with exposure to supportive problem-solving therapy approaches can lead a group that impacts functioning among Veterans reporting moral injury-related distress.
3484524|NCT03760705||Coronary Artery Disease|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
3484525|NCT03760705||Heart Failure|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
3128070|NCT03127228|Experimental|Er:YAG laser-assisted debridement|Debridement and surface detoxification of the implant surface and removal of the inflamed tissue with the aid of the laser treatment.
3484526|NCT03760705||Atrial Fibrillation|"Clinical data collected by Singapore Cardiac Data Bank (SCDB)~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by the Ministry of Health"
3484527|NCT03760692|Active Comparator|Group i-gel|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
3484528|NCT03760692|Experimental|Group Ambu Auragain|Insertion of the airway device. The size of the airway device used is based on the manufacturers' recommendations and evaluation of its clinical performance
3484529|NCT03760679|Active Comparator|Laryngeal mask Supreme|Device: Laryngeal mask Supreme
3484530|NCT03760679|Experimental|i-gel|Device: i-gel
3484531|NCT03760666|Experimental|Brequinar|Brequinar dosed orally. Multiple doses.
3484532|NCT03760666|Other|Brequinar + Ribavirin|Subjects in Cohort 2 may roll over to add ribavirin dosing; subjects in Cohort 3 will start with brequinar alone then add ribavirin dosing.
3128071|NCT03127358|Experimental|AiCure App|Participants will use a-DOT technology called AiCure (a Smartphone App) to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks.
3128072|NCT03127358|No Intervention|Treatment As Usual|Participants will receive treatment for ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks without using the AiCure app.
3484533|NCT03760653|Experimental|Physical Exercise and probiotic group|The subjects will receive 3 weekly sessions of combined exercise supervised by professionals in a specialized gym (60 minutes each one). The exercise will consist of a combination of aerobic and strength exercises involving the main muscle groups. They will take the probiotic supplementation at the established dose, 3 capsules/day before bedtime. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
3484534|NCT03760653|Experimental|Probiotic group|Participants will follow their usual sedentary lifestyle (i.e to practice less than 3 days a week of physical exercise, as is specified in the inclusion criteria). They will take the probiotic supplementation at the established dose. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum
3484535|NCT03760653|Placebo Comparator|Placebo group|They will follow their sedentary lifestyle. Placebo probiotic will consist of a maltodextrin capsule.
3484536|NCT03760614|Experimental|Entinostat + FOLFOX|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks. Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle. Entinostat dose will vary between 2mg and 5mg depending on time of enrollment and observed toxicities. Dosing will begin at 3mg.
3484537|NCT03760601|No Intervention|Baseline phase ('A')|Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.
3484538|NCT03760601|Experimental|Intervention phase ('B')|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task selfguided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma).
3484539|NCT03760588|Experimental|Sacubitril/valsartan|Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: Sacubitril/valsartan 24/26 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by sacubitril/valsartan 49/51 mg b.i.d. for 2-4 weeks. Provided blood pressure > 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to sacubitril/valsartan 97/103 mg b.i.d. will be performed.
3484540|NCT03760588|Placebo Comparator|Placebo|Matched to the comparator.
3484541|NCT03760549||Extension of NasoVAX high dose|A serum sample will be collected from each eligible subject who received NasoVAX at the 1×10(11th) vp dose in Study ALT-103-201 for evaluation of influenza hemagglutination assay against influenza A/California/07/2009(H1N1), a strain homologous to the one used for NasoVAX (monovalent AdcoCA09.HA). Ad5 antibody neutralization assay may also be performed.
3484542|NCT03760536||16-week Exercise Program|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
3484543|NCT03760497|Experimental|CIV Group|Temporary Restoration with Glass Ionomer (Equia Forte® - GC Corporation, Tokyo, Japan) for 30 days + Restoration in Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA).
3128073|NCT03127358|Active Comparator|AiCure with gamification|Sub-group of participants will use a-DOT technology called AiCure (a Smartphone app) with gaming to track ingestion of fixed-dose Elbasvir and Grazoprevir, 1 tablet, 50mg-100mg of each drug, respectively, daily for 12 weeks. The gaming feature is to test whether competition encourages engagement and helps to increase adherence to the HCV medication.
3128074|NCT03127384|Experimental|No-treatment control|
3128075|NCT03127384|Experimental|Treatment|Intradermal injection Restylane Lidocaine
3484544|NCT03760497|Experimental|Composite Resin Group|Restoration with Composite Resin (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, United States).
3484545|NCT03760497|Experimental|Composite Resin Group + Laser|Composite Resin Restoration (Filtek® Resin Z350 XT - 3M Corporate Headquarters, St. Paul, USA) + Application of Diode Laser.
3484546|NCT03760484|Experimental|fecal transplant with fidaxomicin|FMT per rectum x 3 days in conjunction with fidaxomicin (dificid) PO 200 mg bid x 7-10 days
3484547|NCT03760471|Experimental|Collaborative palliative and oncology care|
3484548|NCT03760445|Experimental|Part 1 - first line (1L) AML|1L acute myeloid leukemia (AML) subjects receiving HDM201 in various doses/schedules in combination with cytarabine/anthracyclines
3128076|NCT03127514|Placebo Comparator|Placebo|Placebo administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
3484549|NCT03760445|Experimental|Part 1 - relapsed/refractory (R/R) AML|R/R AML subjects receiving HDM201 in various doses/schedules in combination with cytarabine
3484550|NCT03760445|Experimental|Part 2 - Expansion Cohort 1|1L de novo AML subjects without documented FLT3 mutation receiving HDM201 at the recommended dose of expansion (RDE) in combination with cytarabine/anthracyclines
3484551|NCT03760445|Experimental|Part 2 - Expansion Cohort 2|1L de novo AML subjects with documented FLT3 mutation status receiving HDM201 at RDE in combination with cytarabine/anthracyclines and midostaurin
3484552|NCT03760445|Experimental|Part 2 - Expansion Cohort 3|1L secondary AML subjects receiving HDM201 at RDE in combination with liposomal cytarabine/daunorubicin
3484553|NCT03760445|Experimental|Part 2 - Expansion Cohort 4|R/R AML subjects receiving HDM201 at RDE in combination with cytarabine
3484554|NCT03760445|Experimental|Part 3 - DDI Cohort 1|R/R AML subjects receiving HDM201 at adjusted recommended Phase 3 dose (RP3D) determined in Part 2 in combination with cytarabine and posaconazole added in Cycle 1
3484555|NCT03760445|Experimental|Part 3 - DDI Cohort 2|R/R AML subjects receiving HDM201 at RP3D in combination with cytarabine and midazolam
3484556|NCT03760432|Experimental|Surgery|OCT-guided custom laser CXL
3484557|NCT03760419|Active Comparator|Intervention Arm|Effectiveness of the EHR-based antibiotic decision support application for promoting guideline-concordant antibiotic prescribing in children presenting for emergency care will be evaluated in a pragmatic, cluster randomized crossover study conducted over a period of 18 months that includes two respiratory seasons. The antibiotic decision support application will be provided to those randomized to the intervention arm. Due to the nature of the intervention, blinding of treating providers will not be possible. All children will receive standard of care management. All treatment decisions will be made by the clinical providers and will not be restricted or altered in any way.
3484558|NCT03760419|No Intervention|Control Arm|The investigator will conduct a randomized controlled trial comparing a prognostic tool (intervention arm) to usual care (control arm) over a period of 24 months. Randomization will occur at the patient level. Allocation to intervention or control will be based on medical record number (even vs. odd) and will be assigned automatically once a provider confirms the diagnosis of pneumonia via the radiology alert tool. All standard of care treatment options will be available and decision-making will not be restricted in any way in either group.
3128077|NCT03127514|Experimental|AMX0035|AMX0035 administered by mouth or via feeding tube for 24 weeks: once daily for first 3 weeks and then twice daily for remainder of study if participant tolerating
3128078|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
3484559|NCT03760406|Experimental|Severe essential tremor treated by DBS|
3484560|NCT03760393|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
3484561|NCT03760393|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
3484562|NCT03760380|Experimental|Phase 1 Short Term|Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
3128079|NCT03127644|Experimental|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
3128080|NCT03127644|Placebo Comparator|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
3128081|NCT03127943|Active Comparator|Buffered 1% lidocaine|"In week One, Each subject would be injected intraorally with either anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
3128082|NCT03127943|Active Comparator|Non-buffered 1% lidocaine|"In week Two, Each subject would be injected intraorally with the alternate anesthetic (Buffered 1% lidocaine with 1/100,00 epinephrine) or (Non-buffered 1% lidocaine with 1/100,00 epinephrine to block the Inferior alveolar, Lingual and Buccal nerves.~At least a week later injections for the same nerves would involve the alternate anesthetic. Mandibular molar and canine tested for pulpal anesthesia."
3128083|NCT03127956|Experimental|Olumacostat Glasaretil Gel, 5.0%|Olumacostat Glasaretil Gel, 5.0%, applied twice daily to the face
3128084|NCT03128008|Experimental|Carboplatin/Paclitaxel with radiation therapy|Single arm, non randomized, open label study. Eligible subjects will receive standard of care Carboplatin IV once a week, Paclitaxel IV once a week given concurrently with daily hyperfractionated radiation therapy (RT). RT will be delivered as 6 fractions weekly.
3128085|NCT03128086|Experimental|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation: performing a spontaneous breathing trial through a T-tube and after that to assess the patient's capacity to maintain airway. In case of reach a score the patient will extubated.
3179730|NCT00675935|Experimental|1|One high-risk medical unit at each hospital will be randomly assigned to receive the fall prevention toolkit
3484563|NCT03760380|Experimental|Phase 2 Long Term|Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
3484564|NCT03760367|Experimental|Blue Covarine Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste containing blue covarine (Pepsodent White Now Gold, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
3484565|NCT03760367|Active Comparator|Control Toothpaste|After a short video introduction to the bass technique, participants brush their teeth once with a silica toothpaste (Colgate Advanced Whitening, 1 g) for 2 min, starting with the upper front teeth. Thereafter, participants rinse their mouth with of tap water.
3179731|NCT00675935|No Intervention|2|One high-risk medical unit at each hospital will be randomly assigned to receive usual care as it relates to fall prevention; i.e., receives no intervention.
3484566|NCT03760354|Experimental|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
3484567|NCT03760354|Placebo Comparator|Placebo (no corticosteroid treatment)|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
3484568|NCT03760341|Active Comparator|cold adenoidectomy group|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - cold method
3484569|NCT03760341|Active Comparator|hot method adenoidectomy|this group of patient will undergo adenoidectomy by the cold method intervention: adenoidectomy - hot method
3484570|NCT03760328|Active Comparator|therapeutic stimulation|Therapeutic Stimulation: optimal therapy setting for home use
3484571|NCT03760328|Sham Comparator|sham stimulation|Sham Stimulation (Control Group): stimulation voltage programmed at 0.1 volts
3484572|NCT03760315||targeted treatment by mNGS|In the mNGS targeted treatment group，Clinicians figure out sepsis patients' microbe by mNGS and alter or confirm targeted treatment.
3484573|NCT03760315||targeted treatment by Culture|In the Culture targeted treatment group，Clinicians figure out sepsis patients' microbe by Culture and alter or confirm targeted treatment.
3484574|NCT03760315||Experience treatment|In the experience treatment group，Clinicians didn't figure out sepsis patients' microbe even with Culture and mNGS of the plasm and other secretion to alter or confirm targeted treatment.
3484575|NCT03760302||Patient given analgesics or hypnotics|All patients treated with any kind of analgesics or hypnotics are analyzed and compared.
3484576|NCT03760276|Experimental|Voriconazole TBD mg tablet orally, every 12 hours for 7 days|
3484577|NCT03760263|Active Comparator|Envarsus|Once-daily extended-release tacrolimus
3484578|NCT03760263|Active Comparator|Prograf|twice-daily tacrolimus
3128086|NCT03128086|No Intervention|Conventional weaning|A control group of weaning from mechanical ventilation according to the usual procedure: performing a spontaneous breathing trial through a T-tube and then extubation if the patient success this trial.
3179732|NCT00675961|Experimental|1|Behavioral Counseling Intervention (BCI) plus treatment as usual (TAU) (i.e. standard referral to and management by an addictions specialist)
3484579|NCT03760237||Acute Leukemia|Observation only. Patients newly diagnosed with acute leukemia who are scheduled to start treatment with chemotherapy will be enrolled and followed serially with blood collection, echocardiogram, arterial applanation tonometry, and questionnaires for 1 year.
3484580|NCT03760224|Experimental|Intervention|WhatsApp group will receive at least 3 messages each week and allow real-time group discussion for the intervention period (8 weeks).
3484581|NCT03760224|Active Comparator|Control|The control group will receive 3 mobile phone text messages each week in the 8 weeks after recruitment. This will be a one way message and no real-time discussion will be available.
3484582|NCT03760211|Experimental|Multilevel Gaming Adherence|Participants in the intervention arm will receive Multilevel Gaming Adherence Intervention. Participants receive Battle Viro on their mobile phones, an electronic pill monitoring device, and, for 24 weeks, game-related text messages guided by medication adherence data (collected from an electronic pill monitoring device).
3484583|NCT03760211|Active Comparator|Treatment as Usual +|TAU+ participants will receive the Treatment As Usual + intervention, which includes receiving a non-HIV related mobile game and an electronic pill monitoring device.
3484584|NCT03760198|Experimental|botulinum toxin type A|
3484585|NCT03760198|Placebo Comparator|Placebo|
3484586|NCT03760185|Experimental|All patients|All patients in this arm will receive eye drops to be applied to one eye only. The alternative eye will not receive any eye drops and as such will serve as the control.
3484587|NCT03760172||Prevalence of NAFLD in patients with IMID|To analyze the global prevalence of NAFLD in patients with an immune-mediated inflammatory disease IMID
3484588|NCT03760172||Prevalence of High-risk NASH in patients with IMID|To evaluate the prevalence of high-risk NASH (NASH with advanced fibrosis) in patients with IMID through clinical, radiological and histological evaluation
3484589|NCT03760172||Immunophenptypic characterization|To investigate the existence of common and differential immunophenotypes between the subjects with NASH with and without IMID, and patients with IMID without liver involment
3484590|NCT03760172||Genetic and Molecular characterization|Liver molecular characterization of NASH associated to IMID
3484591|NCT03760159||Group RESPIRATORY SIMUL (Study A)|In 46 healthy subjects, a computer program will generate random instructions of periods of normal breathing, voluntary end-expiratory breathing cessation periods (as surrogate of central apnoea) and Muller's manœuvre (as surrogate of obstructive apnoea). Meanwhile, the KCG will record the parameters of biological interest. ECG, heart rate, beat to beat non-invasive blood pressure (Finometer), ventilation, end-tidal CO2 (AD instruments), O2 saturation (Nellcor), cardiac output (CO) (Philips) will also be recorded.
3484592|NCT03760159||Group SDB (Study B)|In patients suspected of sleep apnoea and admitted to the sleep unit of the Erasme hospital to perform sleep test as required by their medical condition, the investigators will simultaneously record KCG and PSG and qualitatively compare the data (Bland-Altman plots).
3484593|NCT03760159||Group nCPAP (Study C)|In patients with a diagnosis of sleep apnea, the investigators will determine if KCG is capable to reliably assess the efficacy of the nCPAP therapy in comparison to simultaneous PSG recording. Ongoing adjustment in the CPAP therapy pressure during the night, and its effect on cardiovascular haemodynamic assessed by the KCG, will be taken into account as well.
3484594|NCT03760159||Group UNSELECTED (Study D)|After validation of the three previous steps, the investigators plan to extend the recordings on 100 unselected consecutive patients, without recruitment restrictions, which will undergo PSG recordings because of complains of sleep apnoea.
3484595|NCT03760133|Active Comparator|with Probiotics|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
3484596|NCT03760133|No Intervention|without Probiotics|Participants included in this group will not be taken probiotics for 1 month after bowel preparation for colonoscopy.
3484597|NCT03760120|Active Comparator|PEP standard|
3484598|NCT03760120|Sham Comparator|PEP sham|
3484599|NCT03760107|Experimental|Incentive Level High, Call|
3484600|NCT03760107|Experimental|Incentive Level High, No Call|
3484601|NCT03760107|Experimental|Incentive Level Medium, Call|
3484602|NCT03760107|Experimental|Incentive Level Medium, No Call|
3484603|NCT03760107|Experimental|No Incentive, Call|
3484604|NCT03760107|Experimental|No Incentive, No Call|
3484605|NCT03760094|Experimental|Study group|patients with lymphadenopathy
3484606|NCT03760055||Glaucoma and glaucoma suspects|Patients with at least two consecutive and reliable standard automated perimetry (SAP) examinations with either a pattern standard deviation (PSD) outside the 95% normal limits or a glaucoma hemifield test (GHT) result outside the 99% normal limits. Patients considered suspects for glaucoma must have an intraocular pressure (IOP) greater than 21 millimeters of mercury (mmHg) or suspicious appearance of the optic nerve head but with reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
3484607|NCT03760055||Age-related macular degeneration|"Patients will be considered as having AMD if one or more of the following are present on posterior biomicroscopy (fundoscopy), indirect ophthalmoscopy or Optical Coherence Tomography (OCT) exams:~Presence of at least intermediate-size drusen (63µm or larger in diameter)~Retinal pigment epithelium (RPE) abnormalities such as hypopigmentation or hyperpigmentation~Reticular pseudodrusen (also called sub retinal drusenoid deposit)~Presence of any of the following features: geographic atrophy of the RPE, choroidal neovascularization (exudative, wet), polypoidal choroidal vasculopathy, or retinal angiomatous proliferation."
3484608|NCT03760055||Other eye diseases|Patients with other retinal degenerations such as retinitis pigmentosa or with other diseases affecting the visual pathways such as tumors, ischemic neuropathy or optic neuritis may also be included. Their diagnosis will be extracted from their clinical visits.
3484609|NCT03760055||Healthy subjects|To be considered healthy, subjects have to have IOP < 22 mmHg with no history of elevated IOP and with at least two reliable normal visual fields, defined as a PSD within 95% confidence limits and a GHT result within normal limits.
3484610|NCT03760042|Other|Group A (Crisaborole RIGHT SIDE / Vehicle LEFT SIDE)|Crisaborole ointment 2% applied to sensitive skin locations on right side of body. Crisaborole placebo vehicle ointment applied to sensitive skin locations on left side of body
3484611|NCT03760042|Other|Group B (Crisaborole LEFT SIDE / Vehicle RIGHT SIDE)|"Crisaborole placebo vehicle ointment applied to 7 sensitive skin sites on right side of body.~Crisaborole ointment 2% applied to 7 sensitive skin locations on left side of body"
3484612|NCT03760029|Other|Study arm|All subjects in this study will be observed for 24-30 months.
3484613|NCT03760016|Active Comparator|Moderate-Intensity Aerobic Training|
3484614|NCT03760016|Experimental|High-Intensity Interval Training|
3484615|NCT03760003|Experimental|ABX464|ABX464 will be administrated orally (Capsules) and daily for 16 weeks
3484616|NCT03760003|Placebo Comparator|Matching Placebo|Matching placebo will be adminstrated orally (Capsules) and daily for 16 weeks
3132737|NCT03447821|Active Comparator|400 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Four of the six daily tablet taken in this group were placebos.
3484617|NCT03759990|Active Comparator|insertion time|
3484618|NCT03759990|Active Comparator|intubation time|
3484619|NCT03759977|Experimental|Adapted Physical Activity group|This group will receive 3 sessions per week of specific physical activity.
3484620|NCT03759977|No Intervention|Usual accompaniment group|This group will continue to follow the usual accompaniment of the nursing home.
3484621|NCT03759964|Active Comparator|Ferric Carboxymaltose group|Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
3484622|NCT03759964|Placebo Comparator|Placebo group|Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery
3484623|NCT03759938|Experimental|Early initiation of DOAC|Early initiation of any direct oral anticoagulant (DOAC) at a dose licensed for stroke prevention in AF, within four days (96hrs) of onset of acute ischaemic stroke
3484624|NCT03759938|Active Comparator|Standard Initiation of DOAC|Standard initiation of any DOAC at a dose licensed for stroke prevention in AF, no sooner than day 7 and no later than day 14 after the onset of acute ischaemic stroke (i.e. between 144hrs and 336hrs from onset).
3484625|NCT03759925|Experimental|Nutritional Support|The intervention consists of home delivery of medically-appropriate food support (DASH and diabetic diet compliant) in the form of prepared meals and/or groceries and monthly individual nutritional counseling with a Registered Dietician.
3484626|NCT03759925|No Intervention|Standard of Care|The control group will receive standard of care follow up care after their hospitalization for acute decompensated heart failure.
3484627|NCT03759912||PVI using Ultra-High-Resolution Mapping|The paroxysmal atrial fibrillation patients who received pulmonary vein antral catheter ablation for electrical isolation of pulmonary veins using ultra-high-resolution mapping system (Rhythmia High Density mapping system).
3484628|NCT03759886||Oral Antibiotics|The patients get mechanical bowel preparation and oral antibiotic prophylaxis with 4g Paromomycin (Paromomycin Sulfate Powder) and 1 g Metronidazole p.o. and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
3484629|NCT03759886||iv Antibiotics|The patients get mechanical bowel preparation and perioperative i.v. antibiotic prophylaxis with Ertepanem 1g i.v.
3484630|NCT03759860|Experimental|Selective Retina Therapy and ranibizumab combination therapy|"Perform R:GEN laser (SRT) on the 6,000 microns diameter region including macular edema, while excluding the 500 microns diameter region from the fovea, with the appropriate treatment energy determined.~Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) injection into the vitreous cavity at 3.5-4.0 mm posterior to the corneal limbus, towards the center of the eye, avoiding horizontal meridians. Then, 0.05 mL of the injection solution is slowly injected.~In study group and the control group, ranibizumab is administered 5 times in total from the baseline to month 4."
3484631|NCT03759860|Sham Comparator|Sham Selective Retina Therapy and ranibizumab monotherapy|"For the participants assigned to the control group, sham procedures are performed in Sham Mode. All procedures except for the absence of laser light emission at the laser irradiation stage are the same with the study group.~Sham SRT is performed three times in total, one time for each visit for month 1, 3, and 5. At the time of month 1 and 3, Sham SRT should be performed before administration of ranibizumab."
3484632|NCT03759847|Experimental|Vanguard|Participants in this arm will use the fluid intake app and take a survey to test the fluid intake monitoring app for both safety and design issues.
3484633|NCT03759834|Experimental|Testing Arm|"There will only be one arm. The patient and investigator will initially be blinded to the on-off status of the electrode. The patient will thus serve as an internal control for testing. Once device integrity and possible benefit is confirmed, the patients will undergo non-tactile electrical stimulation to the bone of the inner ear (cochlear promontory) for short term relief of tinnitus via Cochlear promontory stimulation."
3484634|NCT03759821|Experimental|Nutrition, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
3484635|NCT03759821|Experimental|Nutrition, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. The CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition-related behavior change. Group sessions will last between 1.5-2 hours and the groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
3484636|NCT03759821|Experimental|Nutrition+parenting, mothers|Community health workers (CHWs) will facilitate peer group sessions with mothers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
3484637|NCT03759821|Experimental|Nutrition+parenting, mothers and fathers|Community health workers (CHWs) will facilitate peer group sessions with mothers and fathers of children aged 0-18 months at enrollment. CHWs will deliver key messages and facilitate problem-solving and skill-building activities to promote nutrition and parenting-related behavior change. The group sessions will last between 1.5-2 hours and groups will meet biweekly for a period of 12 months. Due to the COVID pandemic, group sessions were paused for three months (March-June 2020). The intervention resumed in July 2020 with delivery via home visits rather than peer groups, and concluded in September 2020.
3484638|NCT03759821|No Intervention|Standard of care control|Local standard of care
3484639|NCT03759795|Experimental|Intervention Group|Acceptance and Commitment Training (ACTr)
3484640|NCT03759795|No Intervention|Wait-list control|No intervention during trial. Participants in this group will be offered the training once the study is complete.
3484641|NCT03759782|Experimental|Group 1|Tenofovir (TDF) 300 mg po once a day (OD)
3484642|NCT03759782|Active Comparator|Group 2|Tenofovir 300 mg po OD + Ribavirin 400 mg twice a day (BID) if <70kg / 600 mg every (q) in the morning (AM) and 400 mg q in the evening (PM) if ≥70kg
3484643|NCT03759769|Experimental|simulator|Practice at home all activities of the wheelchair simulator, at least 20 minute per session, at least one session every second day
3484644|NCT03759769|Active Comparator|control|Practice on a computer video game, at least 20 minute per session, at least one session every second day
3484645|NCT03759756||AI visible group|the endoscopic novices analyzing the images can see the automatic diagnosis of AI during the process
3179733|NCT00675961|Experimental|2|Naltrexone/ Brief Behavioral Compliance Enhancement Treatment (BBCET) plus TAU
3179734|NCT00675961|Experimental|3|BCI + Naltrexone/BBCET plus TAU
3484646|NCT03759756||AI invisible group|the endoscopic novice analyzing the images can not see the automatic diagnosis of AI during the process
3484647|NCT03759743|Experimental|Probiotics|
3484648|NCT03759743|Placebo Comparator|Placebo|
3484649|NCT03759704||Hyperpolarized 13CPyruvate and gadolinium|Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.
3484650|NCT03759691||Stroke patients|Structured interviews of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
3484651|NCT03759691||Bystander|Structured interviews of bystanders of patients with stroke, admitted at the Department of Neurology, Aarhus University hospital and Regional Hospital West Jutland (Holstebro)
3179735|NCT00675961|Active Comparator|4|Treatment as Usual (TAU)
3179736|NCT00675974|Experimental|1|Pressure garment therapy
3484652|NCT03759678|Experimental|Treatment with IB1001|"6-weeks treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)~After the 6-week treatment period, patients will enter a 6-week post-treatment washout period."
3128087|NCT03128099|Experimental|Low dose VR social skills training|In the low dose condition, participants play the video game for one hour per session. This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
3128088|NCT03128099|Experimental|High dose Low dose VR social skills training|In the high dose condition, participants play the same video game twice per session (it takes them two hours). This is a behavioral intervention study. The intervention is playing the social skills virtual reality game to exercise social skills with avatar characters.
3128089|NCT03128099|No Intervention|Healthy Control Participants|23 healthy control participants were recruited and consented to yield baseline comparison data. These participants did not undergo VR training. Only baseline comparison data were collected.
3128090|NCT03128372|Experimental|Desaturation|Volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3484653|NCT03759678|No Intervention|Post-Treatment Washout|After the 6-week treatment period, patients will enter a 6-week post-treatment washout period.
3484654|NCT03759665|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
3484655|NCT03759665|No Intervention|Post-Treatment Washout|After the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
3484656|NCT03759652||infected, before-after studyt: 2003|neurosurgical patients; 2003: the beggining of active and target HAI surveillance
3484657|NCT03759652||infected, before-after studyt: 2017|neurosurgical patients; 2017: the effective of active and target HAI surveillance
3484658|NCT03759639|Experimental|Treatment with IB1001|"Parent Study: 6-weeks treatment with IB1001 administered orally. Extension Phase: 1-year treatment with IB1001 administered orally.~Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day).~Patients 6-12 years old will receive weight-tiered doses:~Patients aged 6-12 years weighing 15 to <25 kg will take 2 g per day: 1 g in the morning and 1 g in the evening.~Patients aged 6-12 years weighing 25 to <35 kg will take 3 g per day: 1 g in the morning, 1 g in the afternoon, and 1 g in the evening.~Patients aged 6-12 years weighing ≥35 kg will take 4 g per day: 2 g in the morning, 1g in the afternoon and 1 g in the evening (as per adults)"
3484659|NCT03759639|No Intervention|Post-Treatment Washout|After both the Parent Study 6-week treatment period, and Extension Phase one-year treatment period, patients will enter a 6-week post-treatment washout period.
3128091|NCT03128411|Experimental|Bosutinib|Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
3484660|NCT03759626|Active Comparator|pupils benefiting from the impulsive intervention|Secondary school pupils from general secondary schools
3484661|NCT03759626|Active Comparator|pupils benefiting from the reflective intervention|Second year students from general high schools.
3484662|NCT03759613|Experimental|Experimental Group|Thirty subjects with unilateral upper burn injury will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. Their evaluations will be made within 5 days following burn injury.
3484663|NCT03759613|Active Comparator|Control Group|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, they will be asked to walk their natural walking.
3484664|NCT03759613|Sham Comparator|Control Grup (Restricted arm swing)|Thirty healthy subjects will be included in this study. GAITRite system for gait analysis, Tampa kinesiophobia scale for kinesiophobia level, visual analog scale for pain and a scale that developed by us for arm swing will be used. When their gait analysis made, their arms will be fixed with a bandage on their bodies. Their arm swing will be restricted.
3484665|NCT03759574||Orthostatic intolerant (OI)|Patients that experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
3484666|NCT03759574||Orthostatic tolerant (OT)|Patients that do not experience symptoms of orthostatic intolerance (dizziness, nausea, vomiting, blurry vision or syncope) or orthostatic hypotension (fall in systolic pressure > 20 mmHg and/or diastolic pressure > 10 mmHg) during mobilisation
3484667|NCT03759561|Active Comparator|Videolaryngoscope group|In the videolaryngoscope group, tracheal intubation was performed using videolaryngoscop under cervical collar application.
3484668|NCT03759561|Active Comparator|Fiberoptic bronchoscope group|In the fiberoptic bronchoscope group, tracheal intubation was performed using fiberoptic bronchoscope via oral cavity under cervical collar application.
3179737|NCT00675974|No Intervention|2|No pressure garment therapy
3484669|NCT03759548||Breast Cancer|Breast Cancer's patients undergoing pharmacological treatments prior or after surgery.
3484670|NCT03759548||Colorectal Cancer|Colorectal Cancer's patients undergoing pharmacological treatments prior or after surgery.
3128092|NCT03128723|Experimental|Acne Mask|The light therapy acne mask is applied to the face once in the evening for a duration of 10 minutes. The cleanser is used twice daily, once in the morning and once in the evening.
3484671|NCT03759535||Control group and Case group|"Control group:~The allograft kidneys function normally. The rejection of allograft kidneys are excluded. The patients have no infectious complications.~Case group:~There is obvious evidence for acute rejection of the allograft kidneys. The patients have no infectious complications."
3128093|NCT03128892|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects received the Noninvasive Oxygen Reserve Index - RD Lite Sensors
3128094|NCT03128931|Experimental|Test Group|The subjects will be enrolled in the test group and will receive the Pediatric SedLine forehead EEG sensor.
3128095|NCT03129100|Experimental|Ixekizumab (IXE) 80Q4W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
3128096|NCT03129100|Experimental|Ixekizumab (IXE) 80Q2W|Participants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
3484672|NCT03759509|Experimental|aerobic exercise training|three times a week, a total of twenty-four times in eight weeks
3484673|NCT03759509|No Intervention|control|routine activity
3128097|NCT03129100|Placebo Comparator|Placebo|Participants received subcutaneous dose of placebo.
3128098|NCT03129178|Experimental|Beetroot juice then nitrate depleted beetroot juice|Participants will be asked to consume 140ml of beetroot juice prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
3179738|NCT00676000|Active Comparator|1|Interrupted vaginal closure
3484674|NCT03759496|Experimental|Durvalumab treated patients|Subjects will receive up to 1000mg durvalumab (MEDI4736) via weekly intravesical administration, for up to a maximum of 6 weeks or until confirmed progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
3484675|NCT03759483||AI group|The visual field reports in this group will be evaluated by the convolutional neural network.
3484676|NCT03759483||Human group|The visual field reports in this group will be evaluated by 3 ophthalmologists independently.
3484677|NCT03759470||Evaluation of different methods for diagnosis of meningitis|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperaturetemperature.Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.."
3484678|NCT03759457|Experimental|High Flow Nasal Cannula|High Flow Nasal Cannula is a relatively new technique able to deliver both oxygen and high flow in order to improve oxygenation and waking out CO2 from the upper airways
3484679|NCT03759444||women with eating disorders|"women with eating disorders (age: M = 26.88; SD = 5.82)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
3484680|NCT03759444||healthy female controls.|"healthy female controls (age: M = 24.27; SD = 6.49)~The three measures applied in this group were: the Time Metaphors Questionnaire by Sobol-Kwapinska (2007), the Time Perspective Inventory by Zimbardo (1999), and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al. (1990)."
3484681|NCT03759431|Experimental|Vocal-cord Radiotherapy|
3484682|NCT03759431|Active Comparator|Complete Larynx Radiotherapy|
3484683|NCT03759405|Experimental|Chronic heart failure treatment group|One case of CHF caused by coronary heart disease, one case of CHF caused by dilated heart disease and one case of CHF caused by Keshan disease were selected and treated with autologous iPS differentiated cardiomyocyte intravenous transplantation.
3484684|NCT03759392|Experimental|Omecamtiv Mecarbil|
3484685|NCT03759392|Placebo Comparator|Placebo|
3484686|NCT03759353|Active Comparator|Lactoferrin Group|Includes 49 pregnant women receiving lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin (R) , Hygint pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
3484687|NCT03759353|Active Comparator|Ferrous Sulfate Group|Includes 49 pregnant women receiving 200 mg of dried ferrous sulfate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset (Feosol (R) , Meda pharmaceuticals). Baseline ferritin level will be obtained and compared to follow up ferritin level after 30 days of treatment.
3484688|NCT03759301|Active Comparator|Growth Hormones Somatropin Recombinant|Growth hormone (Somatropin) 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup for the treatment group which consists of 70 women.
3484689|NCT03759301|Placebo Comparator|Placebo saline solution|Control group consisting of 70 women who will receive subcutaneous placebo injection in the same dosing as the treatment group
3484690|NCT03759275||Stage 1|For the Baseline Investigation and Technical Preparation Stage
3484691|NCT03759262|Experimental|Vitamin D (Cholecalciferol)|All subjects will be enrolled to this arm. A single dose of ultra-high-dose vitamin D will be given.
3128099|NCT03129178|Experimental|Nitrate depleted beetroot juice then beetroot juice|Participants will be asked to consume 140ml of placebo prior to their first experimental visit. Participants will then be asked to consume 70ml a day for 2 weeks and final visit the investigators once more following another 140ml drink.
3128100|NCT03129321|Experimental|Test|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
3484692|NCT03759249|Experimental|Treatment group|Standard Treatment of Sleep disorder according to applicable guideline
3484693|NCT03759249|No Intervention|Waiting list|Continuation of former treatment, after completing the study standard treatment of Sleep disorder according to applicable guidelines
3484694|NCT03759236|Experimental|Health Messaging via SMS|Clinics randomized to this arm will receive the health messaging via SMS intervention. Flyers and information cards will be made available in all exam rooms and the waiting room, which contain information about the health messaging program. Patients must voluntarily elect to enroll in the program using their mobile device. Patients who enroll will receive a variety of health messages on topics including HPV Vaccine, Cervical Cancer screening, Birth Control options, Menstrual Problems, diet and exercise. Text messages are sent out using a third party interface, Twilio, at a frequency of 2 times each week for a duration of 1 year. These are one-way messages which only allow for texts to be sent to the participant.
3484695|NCT03759236|Active Comparator|CDC Pamphlets|The clinic randomized to this control arm will receive standard Center for Disease Control health pamphlets about the HPV Vaccine. Flyers are posted in the clinic waiting room and exam room.
3484696|NCT03759223|Experimental|E-PST|Enhanced Problem-Solving Training (E-PST) arm. E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
3484697|NCT03759223|Active Comparator|Control|Healthy Living Messages (Control) arm. Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
3484698|NCT03759197|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
3484699|NCT03759197|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
3484700|NCT03759171|Experimental|Immediate Entry Group|Following the baseline interview, veterans randomized to the immediate entry group directly engaged in the Guitars for Vets Intervention and were interviewed at the end of the intervention period, roughly 6 weeks later. The intervention content and duration (6 weeks) was the same across both groups.
3484701|NCT03759171|Experimental|Delayed Entry Group|Those randomized to the delayed entry group had their baseline interview repeated at the end of the delayed entry period (4 weeks) prior to receiving the 6-week Guitars for Vets Intervention as well as after intervention completion. The intervention content and duration (6 weeks) was the same across both groups.
3484702|NCT03759158|Experimental|NAC Arm|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
3484703|NCT03759158|Placebo Comparator|Placebo|
3484704|NCT03759145|Experimental|Intervention arm, usual rehabilitation + Jintronix exergame|On top of the usual out-patient rehabilitation sessions planned for the participant, participants attend sessions to use the Jintronix system for up 30 minutes up to 3 times per week
3484705|NCT03759145|Other|Control group|Participants continue their prescribed rehabilitation sessions
3484706|NCT03759132|Experimental|Anodal tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes"
3484707|NCT03759132|Sham Comparator|Sham tDCS|"Bihemispheric tDCS applied over primary motor cortex.~Dose: 2mA, 20 minutes (30s ON)"
3484708|NCT03759119|Experimental|Tummy Time and Parent Education|This group will receive tummy time and parent education and be encouraged to perform tummy time on their own. They will utilize the PT Pal application to record their tummy time adherence. The primary investigator performs the intervention to the participants two times a day for 10 minutes for 4 weeks.
3484709|NCT03759119|No Intervention|Parent education|This group will receive parent education only and utilize the PT Pal application to record their adherence. The primary caregiver will be encouraged to perform the same dosage of tummy time (2x/day, 10 minutes each, 4 weeks) and record their adherence on the PT Pal application.
3128101|NCT03129321|Active Comparator|Reference Standard|Econazole Nitrate Cream, 1%, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
3484710|NCT03759106|Other|No Intervention: Usual care|All study participants in the control group will receive an 8-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
3128102|NCT03129321|Placebo Comparator|Placebo|Placebo Cream, topical, sufficient amount to cover all affected areas on the feet once daily for 28 days
3128103|NCT03129568|Experimental|CDC infusion|CDCs infusion by coronary intervention.
3484711|NCT03759106|Experimental|Experimental: Telerehabilitation system|Participants in the experimental group will receive 8 weeks home exercise program using a virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and synchronously and the program adapted to ensure it remains at an appropriate level for the patient.
3484712|NCT03759093|Active Comparator|Standard of Care|Dosing of VCD(bortezomib, cyclophosphamide, dexamethasone) or VTD (bortezomib, thalidomide, dexamethasone) combinations according to standard of care
3484713|NCT03759093|Experimental|CURATE.AI-guided dosing|CURATE.AI optimized modulation of bortezomib and cyclophosphamide dosages in the VCD (bortezomib, cyclophosphamide, dexamethasone) or bortezomib and thalidomide in the VTD (bortezomib, thalidomide, dexamethasone) combinations
3484714|NCT03759080|Active Comparator|intervention of PNF|PNF group: 30 individuals, these subjects received proprioceptive neuromuscular facilitation training.
3484715|NCT03759080|Experimental|MP|PNFMP group:30 individuals, these subjects received mental practice.
3484716|NCT03759067|Active Comparator|LD group|clopidogrel 600 mg once loading, usually 2-24 h before the procedure
3484717|NCT03759067|Experimental|MD group|After randomization, the routine therapy using daily clopidogrel 75mg
3484718|NCT03759067|Active Comparator|RL group|After randomization, additional clopidogrel 300 mg reloading for patients who were taking a maintenance dose.
3484719|NCT03759028|Experimental|Ibuprofen|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed ibuprofen for breakthrough pain (liquid oral medication, 10mg/kg/dose every 8 hours as needed, max dose 40mg/kg/day).
3484720|NCT03759028|Active Comparator|Oxycodone|This group is given acetaminophen (liquid oral medication, 15mg/kg/dose every 6 hours as needed, max 90mg/kg/day) as the first-line pain medication, and as needed oxycodone for breakthrough pain (liquid oral medication, 0.1mg/kg/dose every 6 hours as needed).
3484721|NCT03759015|Other|Health education|This arm's subjects are tasked to create an original 10-minute theater that is required to use the guidelines about physical activity and diet/nutrition.
3484722|NCT03759002||Patients|Children with end stage renal disease
3484723|NCT03759002||Controls|Healthy sex- and age adjusted children
3484724|NCT03758989|Experimental|Baseline PET|R-CHOP
3484725|NCT03758963|Experimental|Active Laser|"Once the energy to be applied for the treatment is determined through the laser irradiation testing, conduct laser therapy after selecting T corresponding to treatment laser on GUI.~At irradiation, excluding the circle area with a 100 μm radius (200 μm diameter) from the center of the fovea, irradiate laser in the form of surrounding the leakage site with an interval of 0.5-1 spot diameter (fovea = 1 spot size). As for the test spots, the serial number needs to be given for each treatment spot with the order of irradiation, as described above.~If pigment epithelial detachment (PED) occurs at the leakage site, irradiate laser around the PED (excluding the circle area with a 100 μm radius (200 μm diameter) from the center), not to the leakage site.~Within 2 hours after therapy, perform tests for efficacy evaluation (color fundus photography and fluorescein angiography)."
3484726|NCT03758963|Sham Comparator|Sham Laser procedure|"Select C corresponding to Sham Therapy on GUI of the laser device, and then perform Sham therapy.~During Sham therapy, for patient's blinding, both light from the slit lamp and sound from laser oscillation are same as laser irradiation, and no laser oscillation will occur for treatment.~Perform subsequent procedures in the same manner as the procedure of study group."
3484727|NCT03758950|Placebo Comparator|Placebo|Once daily inhaled placebo
3484728|NCT03758950|Active Comparator|Mometasone|Inhaled Mometasone Furoate 220 mcg DPI
3484729|NCT03758937|Active Comparator|volume-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
3484730|NCT03758937|Active Comparator|pressure-controlled ventilation group|During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
3484731|NCT03758924|Experimental|Active arm|Week 0-7: Take 1 ml orally of the product daily (solution of ANAVEX2-73)
3484732|NCT03758924|Placebo Comparator|Placebo arm|Week 0-7: Take 1 ml orally of the product daily (placebo)
3128104|NCT03129945|Active Comparator|Nifedipine|Participants will be given this medication orally
3484733|NCT03758911||bone marrow/blood stem cell donors|Participants underwent a one time semi-structured telephone interview to understand the perspectives of bone marrow/stem cell donors experience, including how family dynamics impacted participants' decision to donate and identifying unique supportive care needs of bone marrow/stem cell donors.
3484734|NCT03758898|Experimental|Treatment|Chest physiotherapy and mobilisation were applied on the patients for 4 days. The treatment of the patients was started on the first postoperative day and continued until the postoperative 4th day.
3484735|NCT03758898|Placebo Comparator|Group 2|only mobilisation was applied to the patients in the second group
3484736|NCT03758885|Experimental|Nolasiban 900 mg|Nolasiban dispersible tablets for single oral administration
3484737|NCT03758885|Placebo Comparator|Placebo|Placebo dispersible tablets for single oral administration
3484738|NCT03758872||historical comparaison whithout cuff|517 patients included in 2017 without CUFF and 517 patients will be included in 2018 with CUFF for polyp detection
3484739|NCT03758859|Experimental|sodium hyaluronate eye drops|the randomly allocated eye will receive sodium hyaluronate drops, followed by a repeat OCT scan; images are then evaluated for clarity by the masked assessor.
3128105|NCT03129945|Active Comparator|Indomethacin|Participants will be given this medication orally
3128106|NCT03130257|Active Comparator|Clinic Blood Pressure Measurement|Participants will be asked to check their blood pressure at their clinic once within the subsequent three weeks.
3179739|NCT00676000|Active Comparator|2|Continuous vaginal closure
3484740|NCT03758846|Experimental|Cognitive-motor Exergaming|A total of 6 Wii-fit games: Bubble balance, Table Tilt, Tightrope walking, Soccer head, Basic Run and Basic Step. A total of 6 cognitive tasks namely Digit recall, repeated letter, word list generation (category and alphabets), mental arithmetic, analogies. Each session was divided into 3 sub-sessions. Every Wii-fit game was played with any 3 cognitive tasks. The combination of games with cognitive tasks was randomized in such a manner that all the cognitive tasks were played with the Wii-fit games in that session. Breaks were provided after each sub-session or when the participant demanded one or when the research personnel noticed any discomfort of the participant.
3484741|NCT03758846|Active Comparator|Conventional balance Training for people with Chronic stroke|The sessions were divided into 10 minutes of warm-up that involved active movements of the body (arm movements, trunk twists, lunges). Next 15 minutes consisted of functional strengthening exercises like high stepping, lunges, squats, resistance training using therabands and weights. Following 35 minutes included balance training exercises like one leg standing, tandem standing, sit to stand exercises, reach outs and step-ups. Last 10-15 minutes were spent treadmill walking. Breaks were provided in between the exercise training as and when needed by the participant.
3484742|NCT03758846|Experimental|Dance Therapy for Stroke|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
3484743|NCT03758846|Experimental|Dance Therapy for Older Adults|"Virtual-reality based dance training - Participants received Virtual-reality based dance training for 6 weeks using the commercially available Kinect dance game (Microsoft Inc., Redmond, WA, U.S.A.) Just Dance 3. The six week session consisted of 5 sessions/week, next two weeks of 3 sessions/week and last two weeks of 2 sessions/week, for a total of 20 sessions. Participants played on 10 songs for the first 2 weeks, progressing to 12 songs during the 3nd and 4th weeks with an addition of 2 more songs of their choice during the last two weeks. Participants played on alternating slow- and fast-paced songs (each maximum of 4 minutes in duration) with a five minutes break after a set of one slow and fast song."
3484744|NCT03758846|Active Comparator|Conventional therapy - Home education for Older adults|Participants received a one-hour education on conventional physical exercises and fall prevention.
3484745|NCT03758833|Active Comparator|SET|patients receiving the elective single embryo transfer
3484746|NCT03758833|Experimental|SET+NGS|patients receiving the elective single embryo transfer evaluated genetically by NGS
3484747|NCT03758833|Active Comparator|DET|patients receiving the elective double embryo transfer
3484748|NCT03758833|Experimental|DET+NGS|patients receiving the elective double embryo transfer evaluated genetically by NGS
3484749|NCT03758820|Experimental|BCT group|"Intervention : Behavorial Cognitive Therapy (BCT) will be delivered by two psychologists at six once-weekly sessions of 90 minutes (with homework activities between the sessions) + 4 booster sessions at week 6, 12, 18 and 36 after the end of the programme.~It was designed for groups of 8 to 10 people. The programme is standardised: PowerPoints presentations support each session and a detailed facilitator manual and companion patient workbook. accompany the programme."
3484750|NCT03758820|No Intervention|Control group|Usual local practice
3484751|NCT03758807|Sham Comparator|Passive treatment|Passive treatment will consist of Manual Therapy with biomechanical explanation of the technique.
3484752|NCT03758807|Experimental|Active Treatment|Active treatment will consist of Manual Therapy with a neuroplasticity explanation of the technique.
3484753|NCT03758794|Active Comparator|interactive lecture module|interactive lecture
3484754|NCT03758794|Active Comparator|online educational module|online educational using a special link
3484755|NCT03758781|Experimental|IRX-2 Regimen combined with Nivolumab|IRX-2 Regimen (4 ml) combined with Nivolumab (240 mg)
3484756|NCT03758768|Experimental|Blue monochromatic light|Three consecutive mornings of one hour exposure to monochromatic light (20 lx, irradiance = 49.65 µW/cm2) with peak wavelength of 455 nm (blue light), with equal photon flux as the control condition.
3484757|NCT03758768|Active Comparator|Full spectrum light control condition|"Three consecutive mornings of one hour exposure to full spectrum light (2500 Kelvin, irradiance = 37.72 µW/cm2) with equal photon flux as the blue light.~We will adjust the light intensity to make sure that the photon energy is the same across the two conditions."
3484758|NCT03758755|Experimental|BFR Therapy|This group will undergo physical therapy exercises per the standard of care, with the addition of Blood Flow Restriction (BFR) utilizing a wide pressure cuff. BFR exercises will be initiated two weeks post-op, and continued for 16 weeks.
3484759|NCT03758755|Active Comparator|No BFR|This group of patients will undergo physical therapy exercises per the current standard of care after their ACL reconstruction without BFR
3484760|NCT03758729|Experimental|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
3484761|NCT03758703|Experimental|Pre-recorded music intervention group|The experimental group will be receiving the pre-recorded music care intervention. The intervention is to be delivered once a day for 30 minutes, over one week, on a portable Bluetooth speaker system. Participants will select their own music from the list of pre-recorded songs playlist and are free to switch to another playlist within their treatment arm should they desire. This music was specifically designed for use in palliative care. Specifically, all songs are played at 60 beats per minute to mimic resting heart rate. Instrumentation was specifically chosen to be soothing and calming
3484762|NCT03758703|Active Comparator|Pre-recorded soothing poetry group|The control group will be provided pre-recorded soothing poetry which they will self-select. Participants are allowed to switch playlists within their treatment arm each day should they desire. This control group is designed to control time, attention, and placebo effect. Thus, the soothing poetry will be offered the identical time duration of listening to recorded soothing poetry readings and played at the same time the intervention group receives the pre-recorded music.
3484763|NCT03758690|Experimental|Treatment Group|Treatment with the investigational device - High-Intensity Focused Electromagnetic (HIFEM) Field Device
3128107|NCT03130257|Active Comparator|Home Blood Pressure Measurement|Participants will receive a validated upper-arm home blood pressure monitor and asked to take two measurements in the morning and two in the evening for at least 5 days over three weeks.
3484764|NCT03758677|Experimental|Patients who progressed after EGFR-TKI without T790M mutation|Single arm; Plan to enroll 30 cases; Patients who progressed after EGFR-TKI treatment without T790M mutation
3484765|NCT03758664|Experimental|ICP-192|The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.
3128108|NCT03130257|Active Comparator|Kiosk Blood Pressure Measurement|Participants will be asked to use a validated blood pressure kiosk in their clinic or local pharmacy to measure their blood pressure three times on three separate days over three weeks.
3128109|NCT03130738|Active Comparator|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
3484766|NCT03758651||Williams syndrome - Onsite participation|Individuals with Williams syndrome who will participate in the study at Massachusetts General Hospital (MGH)
3484767|NCT03758651||Williams syndrome - Convention participation|Individuals with Williams syndrome (WS) who will have a more limited evaluation at a convention focusing on WS, such as the WS Association convention.
3484768|NCT03758651||Williams syndrome - Remote participation|Individuals with Williams syndrome (WS) who will participate in the study remotely by filling out a questionnaire and providing information by mail.
3128110|NCT03130738|Active Comparator|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day of treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
3128111|NCT03130738|Placebo Comparator|14-Day Placebo - Oil Vehicle|14 days of 2x per day of treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
3128112|NCT03130959|Experimental|Module A|nivolumab
3128113|NCT03130959|Experimental|Module B|nivolumab plus ipilimumab
3128114|NCT03131167|Experimental|SHP639 Ophthalmic Solution Arm (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 participants. In each cohort 5 out of 7 participants will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study participants will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
3128115|NCT03131167|Placebo Comparator|Vehicle Ophthalmic Arm (n=24)|In each cohort 2 out of 7 participants will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study participants will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
3484769|NCT03758651||Healthy Controls|Healthy individuals without Williams syndrome who will participate in the study at the Massachusetts General Hospital
3484770|NCT03758638|Experimental|Healthy Eating & Active Living Taught at Home|"PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum (implementation strategy).~Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits."
3484771|NCT03758638|Active Comparator|Usual Care|Participants at usual care PAT sites will receive PAT as usual
3484772|NCT03758625|Experimental|ARM A|a1DC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
3484773|NCT03758625|Experimental|ARM B|a1DC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
3484774|NCT03758625|Active Comparator|ARM C|a1DC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
3484775|NCT03758625|Experimental|ARM D|pgDC + inactivated whole autologous HIV vaccine given as six monthly doses of approximately 10e7 DC per dose
3484776|NCT03758625|Experimental|ARM E|pgDC + conserved HIV peptides vaccine given as six monthly doses of approximately 10e7 DC per dose
3484777|NCT03758625|Active Comparator|ARM F|pgDC + no antigen vaccine given as six monthly doses of approximately 10e7 DC per dose
3484778|NCT03758612|Active Comparator|Cohort 1 (sentinel group) - Active|Single dose of TBI-223 50 mg (n=2) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
3484779|NCT03758612|Placebo Comparator|Cohort 1 (sentinel group) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1) dosed at least 24 hours before the Cohort 1 (remainder of cohort).
3484780|NCT03758612|Active Comparator|Cohort 1 (remainder of cohort) - Active|Single dose of TBI-223 50 mg (n=4).
3484781|NCT03758612|Placebo Comparator|Cohort 1 (remainder of cohort) - Placebo|Single dose of Placebo for TBI-223 50 mg (n=1).
3484782|NCT03758612|Active Comparator|Cohort 2 - Cohort 7 - Active|Single dose of TBI-223 100, 300, 600, 1200, 2000, 2600 mg; n=3 per dosing group.
3484783|NCT03758612|Placebo Comparator|Cohort 2 - Cohort 7 - Placebo|Single dose of matching Placebo for TBI-223 100, 300, 600, 1200, 2000, 2600 mg, n=1 per dosing group.
3484784|NCT03758612|Active Comparator|Cohort 3b - Active - Oral Capsule|Single dose of 300 mg in oral enteric capsule, n=4 per dosing group.
3484785|NCT03758612|Placebo Comparator|Cohort 3b - Placebo - Oral Capsule|Single dose of placebo for 300 mg in oral enteric capsule, n=1 per dosing group.
3484786|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 1|Single dose of TBI-223 sustained-release (SR) tablet prototype 1, 3 x 600 mg, n=6 per cohort.
3484787|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 2|Single dose of TBI-223 SR tablet prototype 2, 3 x 600 mg, n=6 per cohort.
3484788|NCT03758612|Active Comparator|Cohort 8 - Prototype Tablet 3|Single dose of TBI-223 SR tablet prototype 3, 2 x 900 mg, n=6 per cohort.
3484789|NCT03758612|Active Comparator|Cohort 8 - IR Tablet fasted|Single dose of TBI-223 immediate-release (IR) tablet prototype 4, 2 x 1000 mg, n=6 per cohort; fasted prior to dose.
3484790|NCT03758612|Active Comparator|Cohort 9 - IR Tablet with meal|Single dose of TBI-223 immediate-release (IR) tablet, 2 x 1000 mg, n=6 per cohort; fed prior to dose.
3484791|NCT03758599|Experimental|Climbing Exercise Group|At the beginning of each session, a standardized body-centered, mind-setting warmup of ten minutes will take place. The general warm-up will be followed by climbing specific warm-up, which will consist of bouldering (20-30 minutes). Afterwards the rope climbing session will start. Climbing sessions also contain several sport-specific skill-development training sessions to familiarize the participants with gear and rope management, to acquire footwork and route finding, and to locate good belay spots and resting positions while climbing. At the end of the climbing session a short cool-down of five minutes will be executed.
3484792|NCT03758599|Experimental|Aerobic Exercise Group|As the climbing exercise group, the aerobic exercise group will start with a ten minutes body-centered, mind-setting warm-up, followed by 60 minutes of Nordic walking and five minutes cool down. A physiotherapist or sport scientist will instruct and guide the group. Nordic walking will be performed at a moderate pace at varying paths.
3484793|NCT03758599|Active Comparator|Social Contact Control Group|Patients allocated to the social contact control group will receive the same amount of social interaction as the exercise groups. A physiotherapist or sport scientist will be present while participants watch movies with relevant content to disease followed by interactive group discussions. This group is required to control for the impact of social contact/support on AD/PTSD and secondary outcomes.
3484794|NCT03758586|Active Comparator|Study group|Surgical residents undergoing spatial skill training.
3484795|NCT03758586|Sham Comparator|Control group|Surgical residents not undergoing spatial skill training.
3484796|NCT03758573|Experimental|Inspiratory Muscle Training (IMT)|IMT by means of the Powerbreath equipment (Classic, London, UK), according to the following parameters: initial loading of 40% of MIP, 3 sets of 10 repetitions with interval of 1 minute between each sets, 7 days a week, 2 times a day , with the patients in the bed with the angulation of 45 °. The IMT load settings will be adjusted according to the values evaluated weekly. If there is need for addition of supplemental oxygen will be performed to perform the IMT.
3484797|NCT03758573|Active Comparator|Intensive Physiotherapy (IPT)|IPT will be to individualized and supervised intervention program consisting of any of the following procedures: passive, assisted, active or resisted mobilization, sedation and orthostasis depending on the functional level of the patient, as well as bronchial hygiene therapy and pulmonary expansion therapy.
3484798|NCT03758547|Experimental|in-exufflator and percussion technique|"assess the physiological effects, of a common daily practice of secretion removal in intubated patients, that are: in-exufflator technique and percussion technique"
3484799|NCT03758521||BCH Cohort|Patients enrolled at BCH will travel to BCH every 2 years at a minimum for comprehensive evaluation taking place over a 48 hour period. Visits to BCH may occur within ± 2 months of the scheduled visit date. Electronic surveys will be sent out every 6 months.Visits will consist of clinical assessments (demographics, medical history, physical examination, neurological exam, medication history, neuropsychological assessments, and clinical severity score), neurophysiological assessments (Brain Magnetic resonance imaging [MRI/MRS/DTI], Electroencephalogram [EEG], and Transcranial magnetic stimulation [TMS]), and yearly bio-specimen collection.
3484800|NCT03758521||iNTD Cohort|Patients enrolled at iNTD sites will travel to their iNTD site according to standard of care requirements. Data collection includes clinical history and relevant laboratory-chemical, therapeutic, instrumental and neuropsychological parameters by the study centers. Data collection takes place within the framework of elective outpatient visits. The collected parameters are congruent with the current standard investigations. Electronic surveys will be sent out every 6 months. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the site's ongoing research. Yearly bio-specimen collection will be attempted after consent is obtained from the family.
3484801|NCT03758521||Standard of Care Cohort|Patients enrolled at other sites will attend their visit at their regular clinical site as mandated by standard of care. Data collection includes medical history, family history, medications, and all clinical and neuropsychological assessments listed. Imaging and neurophysiological data will be collected if performed during the clinical visit or if performed as part of the clinical site's ongoing research. Yearly bio-specimen collection will be attempted.
3484802|NCT03758508|Active Comparator|HFO|Continuous high flow oxygen through nasal cannula for 45 hours; longer if the clinical need persists
3484803|NCT03758508|Active Comparator|NIV/HFO|Alternating noninvasive ventilation (3 hours) and high flow oxygen through nasal cannula (3 hours) for 45 hours; longer if the clinical need persists
3484804|NCT03758495||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
3132738|NCT03447821|Active Comparator|800 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. Two of the six daily tablet taken in this group were placebos.
3484805|NCT03758495||Patients with Major Depressive Disorder|Individuals who have been previously diagnosed with major depressive disorder and meet our research criteria for symptoms indicative of major depressive disorder within their lifetime.
3484806|NCT03758495||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
3484807|NCT03758482|Other|Men|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
3484808|NCT03758482|Other|Women|The probe meal consists of: 50 g fatty liver duck, 15 g toasts, 50 g cheese, 25 g potato chips, 10 g salted peanuts and 140 mL soft drink.
3132739|NCT03447821|Active Comparator|1200 mg Rifamycin SV dosage|Two enteric coated, modified release tablets, each containing 200 mg Rifamycin SV, taken three times daily. None of the six daily tablet taken in this group were placebos.
3484809|NCT03758469|Experimental|HSK3486|0.4 mg/kg
3484810|NCT03758469|Experimental|rifampin , HSK3486|600 mg;0.4 mg/kg
3484811|NCT03758456|Placebo Comparator|HAL-MRE1 0 AUeq|15 subjects will receive placebo. Subjects will receive 7-9 incremental weekly injections. All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
3128116|NCT03131206|Experimental|Phase 1 RP2D of alectinib|"The investigators are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have NSCLC, not everyone who participates in this research study will receive the same dose of the study drug. The dosage will depend on the number of participants who have been enrolled in the study and how well the dosage has been tolerated.~Alectinib~Oral, BID~A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days."
3128117|NCT03131206|Experimental|Cohort A|"Participants with RET-rearranged NSCLC with no previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
3128118|NCT03131206|Experimental|Cohort B|"Participants with RET-rearranged NSCLC with previous history of RET-TKI therapy.~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
3128119|NCT03131206|Experimental|Cohort C|"Participants with RET-rearranged thyroid cancer~Alectinib~Oral, BID, participants will receive the RP2D identified during Phase 1.~Each treatment cycle will be defined as 28 consecutive days."
3484812|NCT03758456|Experimental|HAL-MRE1 5,000 AUeq|10 subjects will receive HAL-MRE1 5,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 5,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
3484813|NCT03758456|Experimental|HAL-MRE1 10,000 AUeq|10 patients will receive HAL-MRE1 10,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 10,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 weeks). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
3484814|NCT03758456|Experimental|HAL-MRE1 20,000 AUeq|10 patients will receive HAL-MRE1 20,000 AUeq. Subjects will receive 6-8 incremental weekly injections until reaching the maximum dose of 20,000 AUeq. Subsequently, 1 repeated maximum dose injection will be given 1 week later (total treatment period will be approximately 7-9 year). All doses will be subcutaneously injected in a double-blind fashion in the upper arm.
3484815|NCT03758430||Combined Diabetes Management Data|Participants with type 1 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their continuous glucose monitor and insulin pump. Combined data will be used for diabetes management.
3484816|NCT03758404|Experimental|Low dose AAV - CNGA3|Subretinal administration of a single low dose of range AAV - CNGA3
3484817|NCT03758404|Experimental|Intermediate dose AAV - CNGA3|Subretinal administration of a single intermediate dose of range AAV - CNGA3
3484818|NCT03758404|Experimental|High dose AAV - CNGA3|Subretinal administration of a single high dose of range AAV - CNGA3
3484819|NCT03758391|No Intervention|Traditional Didactic Education|Education will be provided to fellows using the traditional didactic approach (lecture-based).
3484820|NCT03758391|Experimental|Flipped Classroom Education|Education will be provided to fellows using the flipped classroom approach.
3484821|NCT03758378|Experimental|Dietary intervention|
3128120|NCT03131219|Experimental|Ravulizumab|
3484822|NCT03758352|Experimental|intervention group (rIC)|The rIC procedure will be applied on seated patients, who have been resting for at least five minutes. The active rIC procedure consists of four five-minute inflations of a pneumatic tourniquet to 100 mmHg above the patient's systolic blood pressure separated by five-minute periods of complete deflation. Placement of the pneumatic tourniquet will be unilaterally on a lower limb (right thigh)
3484823|NCT03758352|Other|control group (non-rIC)|The control group will be a retrospective group, who have undergone a liver transplantation and meet the inclusion criteria.
3484824|NCT03758339|Experimental|Tucatinib|
3484825|NCT03758326|Other|Eating disorder|Measurement of body image via Body App and relationship to body measurement
3128121|NCT03131453|Experimental|CNP520 50 mg|50 mg capsule taken orally once daily
3128122|NCT03131453|Experimental|CNP520 15 mg|15 mg capsule taken orally once daily
3484826|NCT03758326|Other|Healthy comparison|Measurement of body image via Body App and relationship to body measurement
3484827|NCT03758300|Experimental|Radiofrequency group|In this group patients will receive in a sterile fashion continuous radiofrequency for 4 minutes to the 3 genicular nerves in the operative knee as well as Pulsed Radiofrequency at 42 degrees celsius, for 4 minutes (60-70 volts) to the saphenous nerve and the nerve to the Vastus Medialis, at the level of the adductor canal. The procedure is done under local anesthesia on an ambulatory basis. After the radiofrequency, Ropivacaine 0.5% 5 ml is injected to each one of the nerves, along with 5 milligrams of Methylprednisolone to each nerve. Once the procedure is completed (takes about 20 minutes), patients will be observed in the preoperative program facility for 30 minutes and then discharged home.
3484828|NCT03758300|Sham Comparator|Control (Sham Radiofrequency) group|In this group patients will receive injections of the local anesthetic and steroids in the same anatomical locations, without activating the radiofrequency generator.
3128123|NCT03131453|Placebo Comparator|Placebo|Matching placebo to 15 and 50 mg CNP520 taken orally once daily
3128124|NCT03131479|Experimental|Mild|Patients with mild renal impairment (Group 1) received LIK066 50 mg qd before breakfast for 7 days.
3128125|NCT03131479|Experimental|Moderate A|Patients with moderate renal impairment grade A (Group 2) received LIK066 50 mg qd before breakfast for 7 days.
3128126|NCT03131479|Experimental|Moderate B|Patients with moderate renal impairment grade B (Group 3) received LIK066 50 mg qd before breakfast for 7 days.
3128127|NCT03131479|Experimental|Severe|Patients with severe renal impairment (Group 4) received LIK066 50 mg qd before breakfast for 7 days.
3128128|NCT03131479|Experimental|Normal|Patients with normal renal function (Group 5) received LIK066 50 mg qd before breakfast for 7 days.
3128129|NCT03131570|Experimental|Group 1|6 months of Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period.
3484829|NCT03758287|Experimental|CT053PTSA +Gefitinib|"Patients will receive CT053PTSA and gefitinib over a 28-day cycle until progressive disease, intolerable toxicity or subject's withdrawal from treatment.~CT053PTSA will be administered daily, at a dose of 30 mg/40mg/60mg orally .~Gefitinib will be administered daily, at a dose of 250 mg orally ."
3484830|NCT03758261|Other|Erector Spinae Nerve Block|Erector Spinae nerve block
3484831|NCT03758261|Other|Paravertebral Nerve Block|Paravertebral nerve block
3484832|NCT03758235|Experimental|Incobot/A 100 U|Incobot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
3484833|NCT03758235|Experimental|Incobot/A 200 U|Incobot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered in patients performin intermittent catheterization.
3484834|NCT03758235|Active Comparator|Onabot/A 100 U|Onabot/A 100 U diluted in 10 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (20 injections, 0.5 ml of solution for each injection) will be administered in patients able to perform spontaneous micturitions
3484835|NCT03758235|Active Comparator|Onabot/A 200 U|Onabot/A 200 U diluted in 30 ml of sodium chloride solution 0.9% by endoscopic detrusor injections (30 injections, 1 ml of solution for each injection) will be administered to patients performing intermittent catheterization
3484836|NCT03758222|Experimental|Arm-1: Device implantation for 1 month|Treatment group receives intervention with the XFLO Expander System implantation for 1 month, and then retrieved.
3484837|NCT03758222|Experimental|Arm-2: Device implantation for 6 months|Treatment group receives intervention with the XFLO Expander System implantation for 6 months, and then retrieved.
3484838|NCT03758222|Experimental|Arm-3: Device implantation for 12 months|Treatment group receives intervention with the XFLO Expander System implantation for 12 months, and then retrieved.
3484839|NCT03758209|Experimental|Prehabilitation + ERAS|"Patients receiving a formal preoperative preparation on:~Physical status (walking, respiratory training)~Nutrition (nutritional supplements)~Mental status (weekly groups led by clinical psychologist on anxiety and depression management).~Each patient will be treated in an ERAS program preoperatively."
3484840|NCT03758209|Active Comparator|ERAS|Each patient will be treated in an ERAS program preoperatively. No specific preoperative training will be involved apart from nutritional status assessment and nutritional supplements.
3484841|NCT03758196|Experimental|Renal sympathetic denervation from the adventitia|Renal sympathetic denervation from the adventitia of renal artery and optimized medication regimen
3484842|NCT03758196|No Intervention|optimized medication regimen|optimized medication regimen
3484843|NCT03758183||two-stage algorithm|Prolotherapy injections (PrT) combined with rehabilitation protocol (RP) prior to total knee arthroplasty (TKA)
3484844|NCT03758183||one-stage algorithm|total knee arthroplasty (TKA)
3484845|NCT03758170|Experimental|High dose Dexamethasone|An intravenous bolus dose of Dexamethasone 1 mg/kg bodyweight administered preoperatively before surgery.
3484846|NCT03758170|Active Comparator|Medium dose Dexamethasone|An intravenous bolus dose of Dexamethasone 0,3 mg/kg bodyweight administered preoperatively before surgery.
3484847|NCT03758144|Active Comparator|study|
3484848|NCT03758144|No Intervention|CONTROL GROUP|
3484849|NCT03758131|Experimental|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. Mi is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
3484850|NCT03758131|Active Comparator|Motivational Interviewing|In the Motivational Interviewing (MI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use.
3484851|NCT03758131|Placebo Comparator|Waitlist Control|Those dyads randomized to the Waitlist Control (WC) condition willl be offered teh PMI intervention at month 2 post-intervention for the PMI arm.
3484852|NCT03758118|Active Comparator|NAION patients OS-Citicoline treated|In a group of patients with NAION, OS-Citicoline will be administered (500 mg/day) for 6 months followed by three months of suspension
3484853|NCT03758118|No Intervention|NAION patients untreated|In one group of patients with NAION no type of treatment will be performed during 9 months of observation
3484854|NCT03758105|Experimental|Usual care and tDCS (Arm A)|Arm A patient receives a first tDCS treatment in association with usual care (medication, psychotherapy...). If the patient is responding to tDCS, he can have other tDCS treatments in case of relapse.
3484855|NCT03758105|Active Comparator|Usual care without tDCS (Arm B)|Arm B patient receives usual care: medication management and psychotherapy.
3484856|NCT03758079|Active Comparator|Doxepin|10 mg Doxepin daily for 4 weeks
3484857|NCT03758079|Active Comparator|Gabapentin|Gabapentin 100mg after each dialysis session
3484858|NCT03758066|Other|PlusCare|Patients and case managers who work with them will be given access to a web-/mobile-based application, PlusCare, to support various case management activities for one year.
3484859|NCT03758053||Individuals with alcohol use disorder + ACE|Individuals with AUD and varying levels of adverse childhood experiences (ACE)
3484860|NCT03758053||Healthy controls|Healthy individuals without AUD
3128130|NCT03131570|Placebo Comparator|Group 2|Placebo followed by Secukinumab. 3 months of placebo followed by 3 months of Secukinumab at a dose of 300 mg with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period.
3132740|NCT03448068|Experimental|Ketamine Therapy|"Ketamine 0.3 mg/kg (IBW) bolus with induction.~Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion will not be titrated.~Remaining care will be identical to standard therapy group."
3484861|NCT03758053||Individuals with alcohol use disorder, no ACE|Individuals with AUD and no adverse childhood experiences (ACE)
3484862|NCT03758040|Experimental|Slips on Turns|Slips administered during walking on a curved paths of radii 1.0, or 2.0 meters in early, middle or late stance to the inside or outside foot.
3484863|NCT03758040|Experimental|Slips on Slopes|Slips administered during walking on sloped ground of 5.0 or 10.0 degrees mediolaterally or anteroposteriorly, or flat ground, in early middle or late stance. For mediolateral slopes, slips will be administered to the uphill or downhill foot.
3484864|NCT03758027|Experimental|CARESS|"The proposed intervention for this study has three stages: communicate alternatively (CA), release endorphins (RE), and self-soothe (SS) (CARESS)~CARESS is a combined skill of three activities. Each section is timed and has specific activities:~CA - will last eight (8) minutes, and will be expression of emotion with drawing with crayons.~RE - will last six (6) minutes, and will be a butterfly hug with a blanket. SS - will last six (6) minutes, and will be a pre-recorded music selection."
3484865|NCT03758027|Active Comparator|ISOMETRIC|This is a one time five-minute isometric circuit involving contracting muscles in different parts of the body. In order to be equivalent in time spent with the experimental intervention, this circuit will be performed three times with a five-minute break between each instance
3484866|NCT03758014|Experimental|Chlorogenic Acid for Injection|3 mg/kg per day, injection for 28 days，5 weeks per circle; max. 8 circles
3484867|NCT03758014|Active Comparator|Lomustine|110 mg/m2 taken as a single oral dose every 6 weeks; max. 4 circles
3484868|NCT03758001|Experimental|IBI101|IBI101 will be administrated intravenously. 3+3 dose escalation design will be used with eight dose levels being tested.
3484869|NCT03758001|Experimental|IBI101 in combination with Sintilimab|"IBI101 and Sintilimab will be administrated intravenously. 3+3 dose escalation design will be used with 4 dose levels of IBI101 being tested.~Two dose levels of IBI101 in combination with Sintilimab will be expanded to 10 patients each."
3484870|NCT03757975||TAH|patients before and after total abdominal hysterectomy (TAH)
3484871|NCT03757975||TLH|patients before and after total laparoscopic hysterectomy (TLH)
3484872|NCT03757975||TVH|patients before and after total vaginal hysterectomy (TVH)
3484873|NCT03757975||SAH|patients before and after abdominal supracervical hysterectomy (SAH)
3484874|NCT03757975||SLH|patients before and after supracervical laparoscopic hysterectomy (SLH)
3484875|NCT03757962|Experimental|Dietary intervention|
3484876|NCT03757949|Experimental|Arm I (SIM)|Patients receive SIM PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
3484877|NCT03757949|Placebo Comparator|Arm II (placebo)|ARM II: Patients receive placebo PO TID on days -5 to -1 and 1-5. Patients undergo standard of care surgery on day 0.
3484878|NCT03757936|Experimental|HLX04+HLX10|HLX10, at three dose levels (1, 3, 10 mg/kg), to be intravenously injected once every two weeks; HLX04, at a fixed dose of 5 mg/kg, intravenously injected once every two weeks; Study drugs given in combination for up to 2 years or until the disease gets worse, whichever comes first.
3484879|NCT03757923|Experimental|metformin|TAB METFORMIN 500mg TDS
3128131|NCT03131596|Experimental|IUB dilatation therapy|The patient will have Foley-catheter intrauterine balloon dilatation 2 weeks and 6 weeks after hysteroscopic adhesiolysis. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
3128132|NCT03131596|No Intervention|control group|Patient will not undergo any balloon therapy. A second-look hysteroscopy will be carried out in the early proliferative phase 4 weeks after the surgery and third-look hysteroscopy will be carried out 8 weeks after the surgery.
3484880|NCT03757923|Experimental|pioglitazone|TAB PIOGLITAZONE 30 mg OD
3484881|NCT03757910|Experimental|DPPOS Exposed to Metformin|DPPOS participants with exposure to metformin will be scanned with 18F-MK-6240 and 11C-PIB.
3484882|NCT03757910|Active Comparator|DPPOS Exposed to Placebo|DPPOS participants with no exposure to metformin but only placebo will be scanned with 18F-MK-6240 and 11C-PIB.
3484883|NCT03757897|Experimental|Dexmedetomidine induced sleep patients|All subjects will be measured for CSF volume, diffusion parameters and mechanical 'stiffness' of the brain during wakefulness and during sleep-induced with dexmedetomidine (DEXM).
3484884|NCT03757884|Experimental|Virtual Pod|Mindfulness breathing, privacy screen, noise cancelling headphones, diagnostic checklist, diagnostic support on-line application
3484885|NCT03757871|Experimental|Laser Stimulation|laser pen acupuncture projecting an infrared beam with a wavelength of 905nm bilaterally for 30 seconds on each point.
3484886|NCT03757871|Placebo Comparator|Placebo|The placebo group will have an application of the pen according to the same extinguished laser criteria.
3484887|NCT03757858|Experimental|HT+ACT|
3484888|NCT03757858|Experimental|HT+ACT+PD-1|
3484889|NCT03757858|Experimental|HT+ACT+CT|
3128133|NCT03131648|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks."
3484890|NCT03757858|Active Comparator|HT+CT|
3484891|NCT03757845|No Intervention|Control diet|
3484892|NCT03757845|Experimental|Mediterranean diet|
3484893|NCT03757819|Experimental|Before Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
3484894|NCT03757819|Experimental|During Walking|To investigate the effects of tDCS applied before walking versus during to evaluate effectiveness of the intervention.
3484895|NCT03757806|Experimental|Experimental group|The experimental group will receive the LiFE4D in addition to usual care (e.g., pharmacologic treatment).
3484896|NCT03757806|No Intervention|Control group|The control group will receive usual care only.
3484897|NCT03757793||Reliability of NIRS in DIEP flap surgery|In patients who underwent DIEP flap surgery, monitoring of postoperative tissue oxygen saturation of the flap by use of the FORE-SIGHT Elite monitor will be compared to standard of care physical examination.
3484898|NCT03757780||Pregnant ladies who are caffeine using|ladies who uses caffeine during pregnancy
3484899|NCT03757767|Experimental|Intervention arm|Fasting for 26-hours.
3484900|NCT03757754|Experimental|HPPH 2.5 mg/m2|HPPH 2.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3484901|NCT03757754|Experimental|HPPH 3 mg/m2|HPPH 3 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3484902|NCT03757754|Experimental|HPPH 3.5 mg/m2|HPPH 3.5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3484903|NCT03757754|Experimental|HPPH 4 mg/m2|HPPH 4 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3484904|NCT03757754|Experimental|HPPH 5 mg/m2|HPPH 5 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3484905|NCT03757754|Experimental|HPPH 6 mg/m2|HPPH 6 mg/m2, Freeze-dried powder injection, intravenous infusion once daily, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
3128134|NCT03131648|Placebo Comparator|Initial treatment period - Placebo Q2W|"Week 0 to Week 16:~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks."
3484906|NCT03757741||AF-SG 01|Study subjects with atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
3484907|NCT03757741||AF-SG 02|Study subjects without atrial fibrillation recurrence after ablation: Blood sampling (assessment of complete blood count, biochemistry, inflammatory biomarkers), 2D transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance, and complex left and right atrium analysis, Pulmonary vein isolation radiofrequency ablation
3484908|NCT03757728|Other|open haemorrhoidectomy|Open haemorrhoidectomy is performed using an anal retractor, exposed haemorrhoids at 3 - 7- 11 hours are excised using cautery. The arteries are ligated or cauterized. Open or closed technique is used (the choice of the surgeon). The Spongostan plug is then introduced
3484909|NCT03757728|Other|Haemorrhodal pedicle ligation|Haemorrhodal pedicle ligation is performed using operating proctoscope. The pedicle of symptomatic haemorrhoid is suture ligated with absorbable Vycril 2/0. Mucopexy is performed simultaneously if the prolapse is noticed. No tissue removal is performed
3484910|NCT03757728|Other|Intrahaemoroidal laser coagulation|Intrahaemoroidal laser coagulation is performed using disposable THD kit [Biolitec Co]. The haemorrhoidal pedicle is sutured. 1mm opening is created at the external haemorrhoid (skin level). Laser is then introduced up to pedicle and coagulation performed. This is repeated to all the piles. The procedure is finished with placing Spongostan plug into anal canal
3484911|NCT03757715|Experimental|Treatment Group|20 mL of 1.3% bupivacaine with 2 mg dexamethasone injected locally in the location for sensory nerves of the sinus cavities and face during the functional endoscopic sinus surgery (FESS) procedure
3484912|NCT03757715|No Intervention|Control Group|No regional anesthetic of any kind during the functional endoscopic sinus surgery (FESS) procedure
3484913|NCT03757702||Fibromiyalgia group|women with FMS between 18-65 years of age and being volunteered.
3484914|NCT03757702||Healthy group|healthy women and being volunteereed
3128135|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks."
3484915|NCT03757689|Experimental|Neoadjuvant Pembrolizumab|Subjects will receive one dose of pembrolizumab 200 mg. Approximately 3 weeks after the initial dose of pembrolizumab, subjects will undergo wide excision and sentinel lymph node (SLN) biopsy. Post-operatively, subjects will receive up to 1 year of adjuvant pembrolizumab 200 mg every 3 weeks.
3484916|NCT03757676|Experimental|No Play|This 'no play' group functioned as the control group.
3484917|NCT03757676|Experimental|At Will Play|This group functioned as 1 of the 2 play groups.
3484918|NCT03757676|Experimental|Goal Oriented Play|This group functioned as 1 of the 2 play groups.
3484919|NCT03757663|Experimental|UV Dosimeter|UV Dosimeter will measure participants' UV exposure for two separate 3-week periods.
3484920|NCT03757650|Active Comparator|HP eradication therapy positive-HP positive|who has HP positive endoscopic biopsy will take HP eradication therapy one month before the surgery
3484921|NCT03757650|Active Comparator|HP eradication therapy negative-HP positive|who has HP positive endoscopic biopsy and will not take any medication about HP
3484922|NCT03757650|No Intervention|HP negative-Control group|who has HP negative endoscopic biopsy and will not take any medication. (control group)
3484923|NCT03757637|No Intervention|General module|"Control group will be case manager care only group. Eligible patients will also invite and receive their first time assessment as baseline during hospitalization. The usual cancer care group will receive routine cancer care in the inpatient wards through OPD visits."
3484924|NCT03757637|Experimental|NLSCP|NLSCP group will receive 5 section of NLSCP. Contents of scheduled intervention will be developed baed on the literature mentioned above. Ex 1 group, patients will receive at least 3 times face-to-face NLSCP, and two times by telephone calls for following up.
3484925|NCT03757637|Experimental|ICT supported HAP|The ICT supported HAP group will receive information or counseling through mobile phone App as the schedule intervention time. For this group, patients will receive two face to face interventions in the first two sections (pre-discharge from hospital and 5th week post-op). It will be delivered by research nurse to intervene patients and help them to build up the App system. Research nurse will also help patients to be familiar with the operation system. The rest parts of the intervention will all through Apps in the scheduled time. Patients can raise their questions and concerns through APPs. Patients in the HAP can raise their concerns or questions through APP and receive interventions or answers through App interactively.
3484926|NCT03757624|Active Comparator|Gastric specimen measurements after 24 hours from % 10 formol|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after formol solution
3484927|NCT03757624|Active Comparator|Gastric specimen measurements after surgery in operating room|Gastric specimens of patients who will undergo to Laparoscopic Sleeve Gastrectomy ,will examine after surgery in operating room peroperatively
3484928|NCT03757611|Experimental|tabetri|Tabetri capsule will be administered orally twice daily for 12 weeks
3484929|NCT03757611|Placebo Comparator|Placebo|Placebo capsule will be administered orally twice daily for 12 weeks
3484930|NCT03757598|No Intervention|Paper Partograph|The comparison group used the standard WHO Standard Paper Partograph approved in Kenya to monitor labor. Copies of the partograph were made available to the facilities.
3484931|NCT03757598|Experimental|ePartogram|ePartogram use by skilled birth attendant providers in health facilities. The intervention arm used the novel ePartogram or electronic partogram. The interface was of the same WHO approved partograph on an Android tablet. There were reminders to spur provider actions and alerts that were programmed in an algorithm.
3484932|NCT03757585|Experimental|Omega-3 Fatty Acids + Inositol|Subjects will be treated with 1020mg QAM + 1020mg QPM of omega-3 fatty acids and inositol based on weight (subjects under 25kg: 1000mg QD; Subjects weighing 25kg or more: 2000mg QD).
3484933|NCT03757585|Experimental|N-acetylcysteine|Subjects will be treated with N-acetylcysteine capsules (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2400 mg QD) or effervescent tablets (subjects ages 5-12: 1800mg QD; subjects ages 13-17: 2700 mg QD) based on age.
3484934|NCT03757572|Experimental|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Alginate dressings with silver and high-G cellulose, which combine increased absorption properties, antimicrobial action and high coherence will be used. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials for latent breathing of the skin with dressing dimensions based on the wound size, will be also placed.~Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
3484935|NCT03757572|Active Comparator|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy.~Wound care will be performed with the application of simple gauze dressings. Wound care will be performed in a specific way each time that the dressings will be removed. The wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
3484936|NCT03757559|Experimental|Cebranopadol 200 micrograms (Treatment A)|"Cebranopadol 200 micrograms (low dose): Participants took 2 tablets (cebranopadol 100 micrograms) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
3484937|NCT03757559|Experimental|Cebranopadol 400 micrograms (Treatment B)|"Cebranopadol 400 micrograms (medium dose): Participants took 2 tablets (cebranopadol 400 micrograms plus matching placebo) as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
3484938|NCT03757559|Experimental|Cebranopadol 800 micrograms (Treatment C)|"Cebranopadol 800 micrograms (high dose): Participants took 2 tablets containing cebranopadol 400 micrograms as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
3484939|NCT03757559|Active Comparator|Hydromorphone IR 8 milligrams (Treatment D)|"Hydromorphone immediate-release (IR) 8 milligrams: Participants took 4 capsules (2 capsules of hydromorphone hydrochloride 4 mg plus 2 placebo capsules) as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
3484940|NCT03757559|Active Comparator|Hydromorphone IR 16 milligrams (Treatment E)|"Hydromorphone immediate-release (IR) 16 milligrams: Participants took 4 capsules of hydromorphone hydrochloride 4 mg as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
3484941|NCT03757559|Placebo Comparator|Placebo (Treatment F)|"Placebo: Participants took 4 placebo capsules matching hydromorphone capsules as a single dose.~In addition, participants took 2 placebo tablets matching cebranopadol tablets as a single dose."
3484942|NCT03757559|Placebo Comparator|Placebo (Treatment G)|"Placebo (following Treatment C): Participants took 2 placebo tablets matching cebranopadol tablets as a single dose.~In addition, participants took 4 placebo capsules matching hydromorphone capsules as a single dose."
3484943|NCT03757533|Experimental|Health Coaching|Participants in the Health Coaching (HC) arm will be assigned to a health coach for a period of 5 months along with receiving usual care (UC). An initial telephone call with the coach will include a discussion about the participant's self-assessment of health perceptions and goals. This self-assessment creates the foundation for the personalization of the behavioral intervention. From this point, the participant schedules the remaining 9 biweekly sessions (30-45 minute in length), for a total of 10 coaching calls over 5 months. Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record.
3484944|NCT03757533|Other|Control|Participants in the control arm will receive usual care (UC). Sociodemographic, behavioral, and psychosocial data will be collected over a period of 24 months by surveys and from the medical record. To enhance recruitment, those subjects randomized to the usual care control group will be offered to participate in the health coaching arm of the study as well after a period of 6 months. If they refuse, they will continue in the usual care control group.
3484945|NCT03757520|Active Comparator|Regular user group|Their number: 300; female and male students, will earn 39 points or less of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
3128136|NCT03131648|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52:~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Subjects in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks."
3128137|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo Q2W|"Week 16 to Week 52:~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks."
3484946|NCT03757520|Active Comparator|Heavy user group|Their number: 300; female and male students, will earn 40 points or more of Smartphone Addiction Proneness Scale. Pain Pressure Threshold and Hand Grip Force will Measured for them.
3484947|NCT03757507|Experimental|Optoacoustic imaging|Optoacoustic Imaging before and after tracer administration
3484948|NCT03757494|Experimental|Use of Alpha Stim|Use of Alpha Stim Device
3484949|NCT03757481|Other|no intervention|patients with history of PE (pulmonary embolism) with acute DVT (deep veinous thrombosis) treated with heparin plus edoxaban or heparin plus warfarin
3484950|NCT03757468|Active Comparator|RME (rapid maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with the standard hyrax expansion screw anchored on second deciduous molars
3484951|NCT03757468|Experimental|Leaf (leaf maxillary expander)|Intervention orthodontic - maxillary expansion : crossbite or transversal maxillary deficiency correction with Leaf Expander appliance anchored on second deciduous molars.
3484952|NCT03757429||RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU with verified or suspected RS-virus infection that are mechanically ventilated.
3484953|NCT03757429||Non-RS-virus infection with mechanical ventilation|Patients admitted to the pediatric ICU due to a cause other than a verified or suspected respiratory tract infection.
3484954|NCT03757416||Flexor tenosynovectomy surgery|Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.
3484955|NCT03757403|Experimental|RDD1609 followed by Placebo|Application on the perianal area BID
3484956|NCT03757403|Experimental|Placebo followed by RDD1609|Application on the perianal area BID
3484957|NCT03757390|Experimental|Sequence 1|"period 1: receive Exforge® tab 5/160mg, Crestor® tab 10mg~period 2: receive CJ-30060 5/160/10mg"
3484958|NCT03757390|Experimental|Sequence 2|"period 1: receive CJ-30060 5/160/10mg~period 2: receive Exforge® tab 5/160mg, Crestor® tab 10mg"
3484959|NCT03757377|Active Comparator|BackBeat Moderato System (PHC ON)|Eligible patients randomized after optimization phase to PHC ON (PHC algorithm active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
3484960|NCT03757377|Placebo Comparator|BackBeat Moderato System (PHC OFF)|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF or PHC algorithm not active) for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
3484961|NCT03757364||19 patients with Ps|19 patients with Ps with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
3484962|NCT03757364||13 patients with PsA|13 patients with PsA with psoriatic changes in nails treated at the Dermatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy who were started on methotrexate during the study and the treatment continued for 6 months
3484963|NCT03757351|Experimental|DNL747 First, Placebo Second|
3484964|NCT03757351|Experimental|Placebo First, DNL747 Second|
3484965|NCT03757351|Experimental|Open-Label Extension|Conducted in the Netherlands only.
3484966|NCT03757338|Active Comparator|Fingolimod Reference Formulation|0.5 mg Fingolimod capsule (manufactured by Novartis, Batch No. S0099), orally administered as a single dose of 3 x 0.5 mg capsules.
3484967|NCT03757338|Experimental|Fingolimod Test Formulation|0.5 mg Fingolimod capsule (manufactured by manufactured by Asofarma S.A.I. y C. on behalf of Tolmar, Batch No. 22264), orally administered as a single dose of 3 x 0.5 mg capsules.
3484968|NCT03757325|Experimental|DNL747 First, Placebo Second|Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
3484969|NCT03757325|Experimental|Placebo First, DNL747 Second|Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods.
3484970|NCT03757286|Experimental|FSF with CAD\CAM customized cutting guide|Maxillary reconstruction using free scapular flap with CAD/CAM customized osteotomy guide.
3484971|NCT03757286|Active Comparator|FSF without customized cutting guide|maxillary reconstruction using free scapular flap without customized osteotomy guide. CAD/CAM 3D model for maxilla will be used.
3484972|NCT03757273|Experimental|FFF with CAD/CAM customized cutting guide|Mandibular reconstruction using free fibular flap with CAD/CAM customized osteotomy guide.
3484973|NCT03757273|Active Comparator|FFF without customized cutting guide|Mandibular reconstruction using free fibular flap without customized osteotomy guide. CAD/CAM 3D model for mandible will be used.
3484974|NCT03757260|Experimental|Treatment Group|Antimicrobial photodynamic therapy with methylene blue applied to test site after mechanical debridement.
3484975|NCT03757260|Placebo Comparator|Placebo Group|Photodynamic therapy laser is not activated with saline water in the test site after mechanical debridement.
3128138|NCT03131648|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52:~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks."
3484976|NCT03757221|Experimental|Combination ixazomib + daratumumab without dexamethasone|Elderly Relapse Refractory Multiple Myeloma Patients treated by Combination ixazomib + daratumumab without dexamethasone
3484977|NCT03757208|No Intervention|Fasting group|
3484978|NCT03757208|Active Comparator|Carbohydrate rich drink (CHD) group|
3484979|NCT03757195|Experimental|augmentation by xenograft|xenograft mixed with plasma extracted from blood
3484980|NCT03757182||Wearable activity monitor|Continuous activity monitoring with Fitbit Charge HR from baseline to up to 1 year from end-of-study.
3484981|NCT03757169|Active Comparator|Control group|Verbal informations about the disease, and exercise behavior, and nutrition.
3484982|NCT03757169|Active Comparator|Hand grip group|Three supervised sessions por week: 4 series (2 at each arm) of two minutes of isometric hand grip contraction at 30% of maximal voluntary contraction. Between series there will be two minutes to rest.
3484983|NCT03757156|No Intervention|Aspirin maintenance group|People who are taking aspirin continue to take aspirin.
3128139|NCT03131648|Experimental|Open-label treatment - Tralokinumab + optional TCS|"Week 16 to Week 52:~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered Tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W.~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS* regimen Q2W.~*TCS = topical corticosteroids."
3128140|NCT03131648|Experimental|Open-label short-term- Tralokinumab + optional TCS|"Week 52 to Week 68 [Short term extension (Japan only)] :~Japanese subjects who were transferred to the open-label tralokinumab Q2W arm at Week 16 continued an additional 16 weeks (Week 52 to Week 66) of open-label treatment to receive 52 weeks of active therapy."
3128141|NCT03131687|Placebo Comparator|Placebo|Tirzepatide placebo and dulaglutide placebo administered subcutaneously (SC) once weekly.
3128142|NCT03131687|Experimental|1 mg Tirzepatide|1 milligrams (mg) tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
3484984|NCT03757156|Experimental|Aspirin withdrawal group|People who are taking aspirin stop to taking aspirin.
3484985|NCT03757143|Active Comparator|PVI et Insyte|Groupe A: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) InsyteTM AutoguardTM BC Winged, BD
3484986|NCT03757143|Experimental|CHG et Insyte|Groupe B: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) InsyteTM AutoguardTM BC Winged, BD
3484987|NCT03757143|Experimental|PVI et Nexiva|Groupe C: (1) 5% (w/v) PVI-69% (v/v) ethanol (Bétadine alcoolique™, MEDA Pharma SAS); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, , PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
3484988|NCT03757143|Experimental|CHG et Nexiva|Groupe D: (1) 2% (w/v) CHG-70% (v/v) isopropanol (ChloraPrep™, CareFusion); (2) NexivaTM single port catheter, MaxZeroTM needleless connector, PureHub™ Desinfecting Caps, PosiflushTM prefilled saline syringes, all from BD
3484989|NCT03757117|Experimental|Intervention|Feminizing hormone therapy and peer navigation
3484990|NCT03757104|Experimental|micro-incentives|micro-incentives only (8 communities)
3484991|NCT03757104|Experimental|EPIC-HIV|Empowered through informed choice for HIV [male sensitive HIV specific decision support app] (males only in 8 communities)
3484992|NCT03757104|Experimental|micro-incentive and EPIC-HIV|micro-incentives as well as EPIC [male sensitive HIV specific decision support app] (8 communities)
3128143|NCT03131687|Experimental|5 mg Tirzepatide|5 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
3128144|NCT03131687|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
3128145|NCT03131687|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly. Dulaglutide placebo administered SC once weekly.
3484993|NCT03757104|No Intervention|control|standard of care
3484994|NCT03757091|Active Comparator|Arm A (flexible intubation scope)|Patients undergo flexible scope intubation up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
3484995|NCT03757091|Experimental|Arm B (flexible intubation scope,video laryngoscope)|Patients undergo flexible scope intubation and video laryngoscopy up to 2 attempts following induction of general anesthesia and adequate manual ventilation. In case of failed 2 attempts, patients undergo a third attempt utilizing another technique or device.
3484996|NCT03757078||Patients with acute hemorrhoids|Patients with acute hemorrhoids of 1-2 stage were prescribed Fluocortolone + Lidocaine by a physician. No drug will be provided to Patient by the Investigator, only prescription order, based on International Nonproprietary name (Fluocortolone + Lidocaine)
3484997|NCT03757052|Experimental|Skin testing and Graded Oral Challenge|Penicillin skin testing as described in the intervention section, followed by amoxicillin graded oral challenge as described in the intervention section
3484998|NCT03757026|Active Comparator|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
3128146|NCT03131687|Active Comparator|1.5 mg Dulaglutide|1.5 mg Dulaglutide administered SC once weekly. Tirzepatide placebo administered SC once weekly.
3484999|NCT03757026|Experimental|Slip training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine intervention sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
3485000|NCT03757026|Experimental|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
3485001|NCT03757000|Experimental|YY-20394|"YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).~YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day."
3485002|NCT03756987|Experimental|ESPB group|Patient will receive a single shot of Ropivacaine injection 0.5% 25 mL injected at the erector spinae plane.
3485003|NCT03756987|Placebo Comparator|Control Group|Patient will receive a single shot of normal saline 25 mL injected at the erector spinae plane.
3485004|NCT03756974|Experimental|BX-1 (dronabinol)|BX-1
3485005|NCT03756974|Placebo Comparator|Placebo|Placebo of BX-1
3485006|NCT03756961|Active Comparator|Control|"Control group: The patients receive the routine based anesthesiological treatment during bariatric surgery (Gastric By-Pass or Sleeve Gastrectomy). It consists of:~General anesthesia induction: TCI Remifentanil Cpt 6 ng/ml/ Cp 3.2 ng/m, Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) adjusted via BIS (40-60) and Remifentanil Cp 4-10 ng/ml.~Post-operative pain management: Oxycodone 2.5 mg iv if the pain is rated by patient NRS ≧3. Paracetamol 1 g/6 h and Diclofenac 80 mg/24 h."
3485007|NCT03756961|Experimental|Intervention|"Induction: Dexmedetomidine 0.2 micrograms/kg/h iv 5 min, Esketamine 0.1mg/kg + Propofol 1.5-2 mg/kg iv, Desflurane MAC (0.6-0.8).~Maintained by Desflurane MAC (0.6-0.8) BIS (40-60), Dexmedetomidine 0.2 micrograms/kg/h, Esketamine 0.1-0.3mg/kg/h och 0.1 mg/kg in case of hypertension. At the end of surgery, Lidocaine 1 mg/kg iv (max 4 mg/kg /4 h)~Post-operative: Dexmedetomidine (0.1-0.2 micrograms/kg/h up to 4 h post-operative). If the pain is rated NRS ≧3: Transcutaneous Nerve Stimulation (TENS) with high intensive 40-50 mA for 1 minute, if the patient still NRS ≧3, the TENS treatment is repeated one more time. If pain NRS ≧3 after two treatments with TENS: Esketamine 0.1mg/kg iv + Lidocaine 0.5 mg/kg iv (max 4 mg/kg /4 h) If pain NRS still ≧3 within 30 minutes after both TENS and Esketamine/Lidocaine, 2.5 mg Oxycodone iv, with a 10 minutes intervals until NRS < 3. Perioperative and at discharge, PCC will be used for the second half of the intervention."
3485008|NCT03756948|Active Comparator|Usual Care (Before)|No Thromboelastometry No Synthetic Factor Concentrates Usual Care
3485009|NCT03756948|Experimental|Thromboelastometry-Guided Therapy (After)|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates
3485010|NCT03756922|Experimental|Part 1|To receive a single dose of FDL176 on Day 1, followed by FDL169 TID for 28 days starting on Day 29; and another single dose of FDL176 on Day 42.
3128147|NCT03131713|No Intervention|Control|The control group will receive usual perioperative care including patient education on diagnosis, treatment and prognosis of skin cancer, encouragement of food and fluid intake prior to and during the surgery as needed, and acetaminophen per patient request.
3128148|NCT03131713|Experimental|Intervention|The intervention group, in addition to usual care, will receive Acetaminophen 1000mg and commercially available carbohydrate drink (two pouches of Gatorade Prime Sports Fuel drink containing 50gm carbohydrate in approximately 250ml fluid total) at the beginning of the surgery.
3128149|NCT03131895|Experimental|Part 1, Sequence 1 (Regimen A, B)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
3128150|NCT03131895|Experimental|Part 1, Sequence 2 (Regimen B, A)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
3128151|NCT03131895|Experimental|Part 2, Sequence 3 (Regimen C, D)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 2 following a 10-hour fast.
3128152|NCT03131895|Experimental|Part 2, Sequence 4 (Regimen D, C)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once on Day 1 of Period 1 following a 10 hour fast, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regiment C [test]), orally, once on Day 1 of Period 2 following a 10-hour fast.
3128153|NCT03131960|Experimental|VNS + Rehabilitation (1)|Study treatment is vagus nerve stimulation (VNS) delivered during rehabilitation.
3128154|NCT03131960|Active Comparator|Control VNS|Active control treatment is rehabilitation (standard-of-care treatment) with only a minimal amount of VNS at the start of each session intended to support blinding.
3485011|NCT03756922|Experimental|Part 2|To receive FDL169 TID for 3 days from Day 1, followed by FDL176 QD for 19 days starting on Day 8; and FDL169 TID for 3 days from Day 24.
3485012|NCT03756922|Experimental|Part 3|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
3485013|NCT03756922|Experimental|Part 4|FDL169 and FDL176 for 28 days and 4 weeks of follow-up
3128155|NCT03131999|Experimental|Imatinib Mesylate 400mg capsule|56 days of Imatinib mesylate 400 mg oral daily with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction to 200 mg daily is allowed for toxicity.
3485014|NCT03756896|Experimental|Carfilzomib, pomalidomide, dexamethasone|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3485015|NCT03756870|Experimental|CTO PCI|Patients will receive optimal medical therapy, with percutaneous coronary intervention of the chronic total occlusion.
3485016|NCT03756870|No Intervention|OMT|Patients will receive optimal medical therapy, without percutaneous coronary intervention of the chronic total occlusion.
3485017|NCT03756857|Experimental|Afterload transfer|First, an empty catheter passes to the level of the lower uterine segment under ultrasound guidance to a point where the inner catheter enters the endometrial cavity. The inner sheath is removed slowly, leaving the outer sheath just beyond the internal os. After verifying the catheter's position on the TA ultrasound scan, the physician gives the signal to the embryologist to start the embryo loading. The embryologist brings the loaded inner catheter and inserts it into the outer sheath, which is maintained in its position by the physician.
3485018|NCT03756857|Experimental|Trial Followed by Transfer|First a trial transfer is performed using both the inner catheter and outer sheath connected together in standard configuration, just before the actual embryo transfer. It is passed up to and just through the the internal os. When it appears that the actual transfer will be possible without great difficulty ,the trial catheter is withdrawn. An embryo transfer catheter is loaded and the actual transfer is performed
3485019|NCT03756844|Experimental|Just Right Challenge Food Club Protocol|There was only one arm in this study. All participants received the Just Right Challenge Food Club Protocol and single subject (time series) data was collected.
3485020|NCT03756831|Active Comparator|Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
3485021|NCT03756831|Active Comparator|Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
3128156|NCT03131999|Placebo Comparator|Placebo Capsule|56 days of Placebo with or without co-administration of an mTOR inhibitor for 28 days. A dose reduction is allowed for toxicity.
3485022|NCT03756831|Active Comparator|Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg//m^2)). Core Stability Assessment will be performed for them using Prokin system.
3485023|NCT03756818|Experimental|Treatment (TAK-659 and paclitaxel)|Patients receive spleen tyrosine kinase inhibitor TAK-659 PO QD and paclitaxel IV over approximately 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3485024|NCT03756805|Active Comparator|Group 1 (CPAP)|Patient, who are receiving a CPAP
3485025|NCT03756805|Experimental|Group 2 (UAS)|Patient, who are receiving a device for upper airway stimulation
3485026|NCT03756779|Experimental|Low Saturated Fat Diet|Goal will be to attain <7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
3128157|NCT03132220|Active Comparator|Book Club Active Control|"The subject will participate in 16 in-person hours that are broken into sessions for the book club active control intervention. This club will be facilitated by 1-2 instructors. The club will be described as a fun activity to do outside of work to help reduce work-related stress. The club will be structured similarly to the intervention with respect to time, and homework expectations. Nurses will be prohibited from talking about work stress."
3485027|NCT03756779|Active Comparator|High Saturated Fat Diet|Goal will be to attain 15% of daily calories from saturated fat. Decrease intake of monounsaturated fat.
3485028|NCT03756766||RSV positive ARTI|"RSV point of care testing will be performed (if result not already available) to confirm RSV positive status. Individuals with confirmed acute respiratory tract infection (ARTI) secondary to RSV (Group 1- active) will have nasopharyngeal swabs, blood samples, urine samples and stool samples taken at the time of recruitment and again at 7 weeks (convalescence).~Group 1 participants are categorised into 4 groups as follows:~Group 1a and 1b participants are healthy infants with an RSV infection either requiring hospitalisation for at least 12 hours or not requiring hospitalisation respectively.~Group 1c & 1d are infants with an RSV infection with any co-morbidity that would exclude them from Group 1a and 1b either requiring hospitalisation for at least 12 hours or not respectively."
3485029|NCT03756766||Healthy controls|"This group will include healthy infants (Group 2) who do not have an RSV positive respiratory tract infection and have been asymptomatic in the week preceding and following recruitment.~This group will have nasopharyngeal swabs, a blood test and a stool and urine sample taken at enrolment only."
3485030|NCT03756727|Experimental|Ascorbic acid group|the patients received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery.
3485031|NCT03756727|Placebo Comparator|Control comparator group|the patients received 10ml saline at the night before surgery, during the surgery and five days after surgery.
3485032|NCT03756701|Experimental|Group 1|Initial participants in the 10 mind body sessions
3485033|NCT03756701|Active Comparator|Group 2|10 week no intervention groups - receives the mind body interventions after group 1 has completed.
3128158|NCT03132220|Experimental|MBCT Intervention|The subject will participate in 16 in-person hours that are broken into sessions for the Mindfulness-Based Cognitive Therapy intervention. The intervention will be facilitated by 1-2 instructors who are trained in clinical psychology/ social work and are also trained in MBCT. This intervention will include mindfulness activities, didactic learning, homework assignments and group dialogue. This adapted MBCT intervention will follow the empirically-based MBCT intervention for depression structure with fidelity.
3485034|NCT03756675||haplotype PBSCT group|"Subjects in this group will receive haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system in the treatment of acute leukemia."
3485035|NCT03756649||Control Group|Subjects without inflammatory bowel disease (IBD) will have samples collected of blood, urine and stool
3485036|NCT03756649||Inflammatory bowel disease (IBD)|Subjects with known inflammatory bowel disease will have samples collected of blood, urine and stool
3485037|NCT03756636|Other|"Underwater mucosectomy"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
3485038|NCT03756623|Experimental|Drug: Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
3485039|NCT03756623|Experimental|Drug: Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
3485040|NCT03756623|Placebo Comparator|Drug: Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
3485041|NCT03756610|Active Comparator|Active tACS & active boosting group|The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.
3485042|NCT03756610|Other|Active tACS & sham boosting group|The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
3485043|NCT03756610|Sham Comparator|Sham tACS & sham boosting group|The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.
3485044|NCT03756597||Cases Pathway A|"Case pathway A - Intention to diagnose population~Only patients with a very high clinical suspicion based on imaging are scheduled for surgical procedures.Subjects with a confirmed diagnosis of cancer after clinical work-up will be labelled cases. of the study.~Patients with Gastric or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy."
3485045|NCT03756597||Clinical Controls|"Clinical controls represent subjects that:~Are suspected of the same cancer or part of an at risk-group~Have undergone full per-guideline diagnostic work-up, resulting in confirmation the subject does not have cancer (see section 6)~Is matched to the case for age, gender and known risk-factors specific to that tumour type (section 5.4)"
3485046|NCT03756597||Healthy volunteers|Healthy volunteers will be recruited from the clinical research facility at Addenbrooke's Hospital (Cambridge) or from the Cambridge BioResource. These subjects will be selected to have a similar age and sex distribution as the overall PAN-study cases.
3485047|NCT03756597||Substudy Cases|Patients with a confirmed diagnosis of cirrhosis and providing up to 6 samples will be labelled as the washout substudy cases
3485048|NCT03756597||Cases Pathway B|"Case pathway B - Confirmed malignancy population~Patients with a Gastric, Liver or Oesophageal cancer will be recruited after confirmation of their diagnosis but prior to initiation of therapy. Patients will be recruited by research staff at the clinic they are referred to for diagnosis and/or treatment"
3485049|NCT03756584|Experimental|Intermittent theta-burst stimulation|iTBS will be performed on the left lateral parietal cortex
3485050|NCT03756584|Active Comparator|Control stimulation|iTBS will be performed on the vertex
3485051|NCT03756558|Experimental|Cross-Seal System|The Cross-Seal System will be used in all subjects enrolled in the study
3485052|NCT03756519|Experimental|Exercise|Participants in the exercise intervention arm will receive the usual care protocol plus a standardized, evidence informed exercise intervention provided by trained physiotherapy students. The exercise intervention will begin with a brief assessment to rule out contraindications to exercise and to identify any directional preferences (e.g. pain with lumbar flexion and relief with extension). The PT will then be taught four standardized exercises: the pelvic tilt exercise, a rotational exercise, a tailored graded walking program taking into account the current abilities of the patient, and an exercise based on the directional preference of the individual. These will be re-enforced with a handout including the rationale, instructions and dosage recommendations for the exercises.
3485053|NCT03756519|Active Comparator|Usual care|Our usual care protocol was developed based on 30 responses to an 18 item survey of Queen's Department of Emergency Medicine physicians. Three themes emerged as interventions most commonly used. Each of these strategies has evidence for small, but positive treatment effects and low risk of harms: 1) advice to stay active and engaged in usual activities, 2) use of ice or heat to manage pain, and 3) recommendation for analgesia using NSAIDs if needed and appropriate.
3485054|NCT03756493|Experimental|OFD+ABG+L-PRF treated patients|Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures.
3179740|NCT00676039|Active Comparator|1|"Crossover Effexor / NOVO-Venlafaxine~Examination of the bioequivalence of Effexor (Wyeth Pharmaceuticals) and NOVO-Venlafaxine (NOVOPHARM).~Both drugs will be given at the dose of 75 mg/day (one capsule per day) for 4 consecutive days. A washout period (corresponding to 10 half-life of the active metabolite desmethylvenlafaxine) will be respected after receiving each medication."
3485055|NCT03756493|Active Comparator|OFD+ABG treated patients|Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
3485056|NCT03756493|Active Comparator|OFD treated patients|Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures.
3485057|NCT03756480||Case Group|"Clinical or surgical diagnosis of Endometriosis, patients undergoing surgical management~100 participants"
3485058|NCT03756480||Control Group|"No diagnosis of Endometriosis, Patients undergoing Laparoscopic Tubal Ligation~35 participants"
3485059|NCT03756467|No Intervention|Arm 1|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff
3485060|NCT03756467|Experimental|Arm 2|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up
3485061|NCT03756467|Active Comparator|Arm 3|1) the Girl Empower life skills curriculum, facilitated by local mentors; 2) caregiver discussion group, facilitated by IRC staff; and 3) savings account start-up.
3485062|NCT03756441|Experimental|Experimental: Mindfulness group|This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion protocol. They will group with have eight meetings, one per week, during a half hour and will learn the techiques to practice everyday during the week.
3485063|NCT03756441|Active Comparator|Psychotherapy group|This group will learn group problem solving techniques during eight weeks
3485064|NCT03756428|Experimental|Deep dry needling in tibialis posterior|Deep dry needling will be applied in the tibialis posterior myofascial trigger point
3485065|NCT03756428|Placebo Comparator|Sham technique in tibialis posterior|Placebo tibialis dry needling
3485066|NCT03756415|Experimental|mask plus CO2 removal device|"a traditional mask with inserted a new CO2 removal device that is called DiMax Zero Total face mask R,"
3485067|NCT03756415|Active Comparator|traditional face mask|Traditional mask without a CO2 clearance device inserted
3128159|NCT03132246||Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group went on to develop an infection."
3128160|NCT03132246||Not Infected|"Trauma patients that were considered at risk for infection after fracture fixation. Inclusion criteria included open fractures, proximal tibia fractures, pilon fractures, and calcaneus fractures treated with surgical fixation. Each patient enrolled in the study provided 1-3 blood samples. These blood samples were tested using basic science techniques to determine the level of exposure to a staphylococcal biofilm each patient has experienced over a period of time.~The only intervention patients experience are non-standard of care blood draws. The blood is then tested in a basic science laboratory.~Patients were enrolled if presented as high risk but later separated into the Infected Group or the Not Infected Group based on whether or not they went on to develop an infection post surgery. All patients in this group did not go on to develop an infection."
3179741|NCT00676039|Active Comparator|2|"Crossover Celexa/Gen-citalopram~Examination of the bioequivalence of Celexa (Lundbeck, Brand Name) and Gen-Citalopram (Genpharm, Generic). Both drugs will be given at the dose of 40 mg/day (one tablet per day) for 8 consecutive days. A washout period (corresponding to 10 half-life of citalopram) will be respected after receiving each medication."
3485068|NCT03756389|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Rosacea of the face.
3485069|NCT03756389|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Rosacea of the face.
3485070|NCT03756363|Experimental|Non-solvent|Non-solvent use of a rotary retreatment system
3485071|NCT03756363|Experimental|Solvent|Solvent use in combination with a rotary retreatment system
3485072|NCT03756350|Experimental|Treatment subjects|Single group of subjects which will have the treatment of a 1060nm diode laser administered to them.
3485073|NCT03756324|Experimental|CHPM (Chinese Herbal Patent Medicine )|"CHPM (Chinese Herbal Patent Medicine ): Pugongying (Herba Taraxaci) Granules, 15g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
3485074|NCT03756324|Experimental|CHPM & Antibiotics Cefdinir Capsules|"CHPM (Chinese Herbal Patent Medicine): Pugongying (Herba Taraxaci) granules, 15g/tid for 3 days, follow-up for 7 days.~Antibiotics: Cefdinir Capsules, 0.1g/tid for 2 days, follow-up for 7 days.~Education, basic medical order."
3485075|NCT03756324|Active Comparator|Antibiotics Cefdinir Capsules|"Antibiotics: Cefdinir Capsules, 0.1g/tid for 3 days, follow-up for 7 days.~Education, basic medical order."
3485076|NCT03756298|Experimental|Combination|Atezolizumab + capecitabine combination arm
3485077|NCT03756298|Active Comparator|Control|Capecitabine alone arm
3485078|NCT03756272|Experimental|Stellate ganglion bupivacaine block|Nervus Sympathicus block. Stellate ganglion anaesthetic block in which 7 ml of 0.5% bupivacaine will be injected next to the stellate ganglion
3485079|NCT03756272|Placebo Comparator|Placebo ganglion block|Sham Nervus Sympathicus block. Stellate ganglion sham anaesthetic block using 7 ml of 0.9 % natrium chloride (NaCl)
3485080|NCT03756259|Other|Pneumonia perception arm|Caregivers of children under five will be interviewed qualitatively to understand in depth on perception of pneumonia. These will be mothers, fathers and grandmothers of these children. Once the formative research is done, it will inform design of an intervention whereby the caregivers will be recruited to be counselled by Lady health workers on pneumonia and its prevention via an audiovisual user friendly android based mobile application. Additionally, one text and one voice message will also be sent to the caregivers cell phones on the same subject. The LHWs will also be trained on pneumonia case finding which they will manage at their end and refer if required while doing daily field visits.
3485081|NCT03756246|Experimental|Depression Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
3485082|NCT03756246|Active Comparator|Healthy Subjects: Influenza Vaccine|Subjects will receive a quadrivalent inactivated influenza vaccine, for the appropriate season/year of enrollment. The vaccine will be administered by the PI or similarly trained clinician, into the deltoid muscle as directed
3485083|NCT03756233|Active Comparator|Remifentanil gradually withdrawal group|20 minutes before the end of the operation, remifentanil was gradually decreased by 25% every 5 minutes.
3179742|NCT00676104|Experimental|Treatment|
3179743|NCT00676104|Sham Comparator|Control|
3179744|NCT00676117|Experimental|1|
3485084|NCT03756233|Active Comparator|Remifentanil immediately stop group|The control group stopped remifentanil 10 minutes before the end of the operation.
3485085|NCT03756220|Experimental|Treatment|Combination therapy of vitamin C and thiamine for 2 days.
3485086|NCT03756220|Placebo Comparator|Control|Normal Saline Solution
3128161|NCT03132298|Experimental|Implicit Theories of Personality Program|"This program is self-administered, computer-based, and 30 minutes in length. Content is designed to maximize relevance for youths with internalizing distress. The program includes 5 elements: 1. An introduction the concept of neuroplasticity; 2. Testimonials from older youths describing beliefs that people's traits are malleable, given the brain's capacity for change; 3. Further vignettes by older youths describing times when they used growth mindsets to cope with peer rejection, hopelessness, and feared embarrassment; 4. A worksheet describing strategies for applying these principles to participants' lives; 5. An exercise wherein participants write notes to younger children, using newly-gleaned information about the malleability of personal traits to help them to cope with setbacks"
3485087|NCT03756207|Experimental|Multidisciplinary Therapy|Multidisciplinary bladder-preservation therapy: Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
3485088|NCT03756194|Experimental|Experimental|"Participants will utilize the socially-assistive robot with a CARESSES cultural competence solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
3485089|NCT03756194|Other|Control arm 1|"Participants will utilize the socially-assistive control robot with an alternative CARESSES solution during 6 sessions (3 times per week, e.g., Monday, Wednesday, and Friday; for a total of 2 weeks) of 3 hours at a time.~Baseline and follow-up assessments will be conducted prior to the beginning of the trials and shortly after the end of the last session accordingly."
3485090|NCT03756194|No Intervention|Control arm 2|"Participants will be receiving conventional human care with no robot intervention.~Baseline assessments will be conducted as soon as participants are recruited and allocated to the study arm. Follow-up assessments will be conducted in two weeks after the baseline data collection."
3485091|NCT03756181|Experimental|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of compassion: self-kindness, mindfulness, and common humanity, and will work on soothing the processes of self-criticism, self-neglect and perfectionism that are believed to withhold upon experiencing psychological distress. There will also be sessions dedicated to incorporating self-compassion in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
3485092|NCT03756181|Active Comparator|Five-week Mindfulness-based Stress Reduction program (MBSR5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator will perform a brief check-in and may discuss the student's experience within the course of the session. These discussions will reinforce the guiding principles of meditation: awareness, non-judgment and acceptance and will work on automatic mental processes that are believed to be at the root of experiencing psychological distress. There will also be sessions dedicated to incorporating mindfulness into daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
3485093|NCT03756168|Experimental|Treatment subjects|Single group of subjects with will have the treatment of a 1060 nm diode laser administered to them
3179745|NCT00676117|Active Comparator|2|
3179746|NCT00676156|Active Comparator|A|This arm involves a 1-day pharmacokinetics study of three different formulations of oral lipoic acid.
3179747|NCT00676156|Active Comparator|B|This arm will examine the pharmacokinetics of LA with and without fish oil supplement in a cross over design.
3485094|NCT03756155|Experimental|Group 1|Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30%-40% value.
3485095|NCT03756155|Experimental|Group 2|Group 2 will complete a protocol with 5 sets of 20 second isometric holds followed by 20 second rest intervals between sets. Each repetition will be performed as closely to the targeted 30% value.
3485096|NCT03756142||Multiple sclerosis patients|Analysis of orthostatic posture, initiation of walking and walking in MS patients with an EDSS between 0 and 4 (included) by a motion analysis system
3485097|NCT03756142||Healthy volunteers|Analysis of orthostatic posture, initiation of walking and walking in a group of healthy volunteers
3485098|NCT03756116|Experimental|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
3485099|NCT03756116|Active Comparator|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope; followed by octreotide.
3485100|NCT03756090|Experimental|Experimental group|Arm I: Palbociclib combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
3485101|NCT03756090|Placebo Comparator|Control group|Arm II: Placebo combined with Dose-Dense neoadjuvant chemotherapy for total 16 weeks.
3485102|NCT03756077||Primary diagnosis and staging|Patients suspected of or diagnosed with prostate cancer who want a differential diagnosis and staging by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT before treatment
3485103|NCT03756077||Evaluation of recurrence|Patients with a history of prostate cancer and elevated PSA level after treatment, who need to determining whether or not there are recurrences/metastatic lesions and its locations by 68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT
3485104|NCT03756064|Experimental|Experimental group|Pyrotinib+Trastuzumab+Docetaxel +Carboplatin
3485105|NCT03756064|Placebo Comparator|Control group|Placebo Oral Tablet+Trastuzumab+Docetaxel +Carboplatin
3485106|NCT03756051||Cohort|This study will collect prospective longitudinal data to characterize rates and identify correlates of a) physical harms due to follow-up tests, b) financial harms, and c) inappropriate screening using electronic medical record data and manual chart review. The study will also use surveys and semi-structured interviews to characterize rates and identify correlates of screening-related psychological harms, e.g. cancer specific worry, situational anxiety, mood disturbances, and decisional regret. Lastly, investigators will create and disseminate a balance sheet of benefits and harms to inform patients, providers, healthcare organizations, payers, and policymakers about the role of hepatocellular carcinoma screening in patients with cirrhosis.
3485107|NCT03756025|Experimental|Vitro Molar® (DFL, Rio de Janeiro, Brazil)|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Vitro Molar® (DFL, Rio de Janeiro, Brazil).
3179748|NCT00676156|Active Comparator|C|This arm will include the study of a single dose of R enantiomer lipoic acid.
3485108|NCT03756025|Active Comparator|Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).|ART restorations of a face with one of the two high-viscosity conventional glass ionomer cements-Ketac Molar Easy Mix® (3M ESPE, St Paul, MN, USA).
3485109|NCT03755999|Experimental|PIOMI treat group|Preterm infant receive oral massage using the premature infant oral motor intervention (PIOMI)
3485110|NCT03755999|No Intervention|Routine care group|Preterm infant receive routine care of neonatal intensive care unit(NICU)
3485111|NCT03755986|Other|ATOMO Diagnostic Test|All patients will receive an ATOMO diagnostic test to use. There is no comparative arm.
3485112|NCT03755973|Experimental|CFA plus step-down rFSH (1A)|"A single dose of 150 IU of CFA followed by daily rFSH will be administered. The initial rFSH administration will be dosed between 100 IU and 200 IU according to the following criteria:~200 IU: <3 follicles above 13 mm visible on transvaginal ultrasound;~150 IU, >2 follicles above 13 mm and circulating day-8 follicle-stimulating hormone (FSH) levels ≤20 IU/mL.~100 IU, >2 follicles above 13 mm and circulating day-8 FSH levels >20 IU/mL;~Subjects will perform a step-down daily rFSH dose (fixed decreases in the dosing of 25 IU/day) until the triggering criteria are met or a minimum of 50 IU/day is reached. Subjects with <3 follicles above 13 mm visible will maintain 200 IU/day of rFSH until this criterion is met, initiating a fixed 25 IU/day stepdown protocol only from then onwards."
3485113|NCT03755973|Experimental|CFA plus fixed daily dose rFSH (1B)|A single dose of 150 IU of CFA followed by a fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
3485114|NCT03755973|Active Comparator|Fixed daily dose rFSH only|A fixed daily rFSH dosing protocol of 200 IU will be administered as ovarian stimulation
3485115|NCT03755960|Experimental|acupuncture plus routine care|12 session of semistandardized acupuncture together with pharmacological routine care
3485116|NCT03755960|Active Comparator|routine care alone|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
3485117|NCT03755947|Experimental|IGV|"Cytoreduction 3 cycles (I) Ibrutinib, [Imbruvica, Janssen]~Induction 6 cycles (G) Obinutuzumab, [Gazyva, Roche]~Consolidation 12 cycles (V) Venetoclax, [Venclexta, Abbvie]."
3485118|NCT03755921|Experimental|Brief and intensive therapy|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, daily
3485119|NCT03755921|Active Comparator|Therapy Weekly|exercises for swallowing (strength and mobility of oral and pharyngeal muscles) controlling the number of series according to each participant, weekly
3485120|NCT03755908||asthmatic children|Children with the diagnosis of asthma and normal spirometry results. Each subject will undergo evaluation including: asthma control questionnaire, spirometry, FOT and Fractional exhaled nitric oxide (FeNO).
3485121|NCT03755895|Experimental|experimental|patients to benefit from brachytherapy detachment under KALINOX and formal hypnosis
3485122|NCT03755895|Active Comparator|active comparator|patients to benefit from brachytherapy detachment under KALINOX
3179749|NCT00676169||Observational|Pa negative or concurrently enrolled in the EPIC Clinical Trial
3179750|NCT00676234|No Intervention|1|
3179751|NCT00676234|Experimental|2|Administration of intravenous rhu Epo on Day 0
3179752|NCT00676247||preterm|Very-low-birth-weight preterm infants with brain lesion
3179753|NCT00676247||full-term|Healthy fullterm infants
3485123|NCT03755869|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
3485124|NCT03755830|Active Comparator|vitiligo patients|Two skin biopsies (lesional and non-lesional) will be taken from every patient.
3485125|NCT03755830|Experimental|healthy controls|A skin biopsy will be taken from each control subject.
3485126|NCT03755817|Experimental|Scenar application|Application of SCENAR device on
3485127|NCT03755817|Placebo Comparator|Scenar application with the device off|Application of SCENAR device off
3485128|NCT03755804|Experimental|Low-Risk|Participants receive 2 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
3485129|NCT03755804|Experimental|Intermediate-Risk|Participants receive 3 cycles of BEABOVP: bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine and prednisone. For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
3485130|NCT03755804|Experimental|High-Risk|Participants receive 2 cycles of AEPA: Adcedris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxorubicin) and 4 cycles of CAPDac: cyclophosphamide, Adcetris® (brentuximab vedotin), prednisone and Dacarbazine® (DTIC). For patients with an AR after 2 cycles of therapy, steroids will be omitted from their subsequent cycles of therapy. Filgrastim may be given as clinically indicated. Dexrazoxane may be given at the discretion of the treating investigator. Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy. Quality of Life measurements will be done.
3485131|NCT03755791|Experimental|Experimental arm|Subjects with advanced HCC will receive cabozantinib 40 mg oral, qd + atezolizumab 1200 mg infusion, q3w
3485132|NCT03755791|Active Comparator|Control arm|Subjects with advanced HCC will receive sorafenib 400 mg bid (twice a day)
3128162|NCT03132298|Active Comparator|Control Program|The Control Program is a computer-based session of supportive therapy (ST), designed to encourage youths to identify and express feelings. ST does not teach specific skills or beliefs and has been shown to be less effective than cognitive-behavioral interventions in reducing youth internalizing distress. Here, ST was designed to control for nonspecific intervention elements (eg. completing an interactive computer program) and to encourage youths to share emotions with others. ST included the same number of reading/writing activities as the experimental program and took the same amount of time (30 mins.) to complete.
3128163|NCT03132571|Experimental|Naltrexone with Bupropion|Oral Naltrexone taken once a day and Oral Bupropion taken once a day for 16 weeks.
3128164|NCT03132571|Placebo Comparator|Placebo with Bupropion|Oral placebo capsule and Oral Bupropion taken once a day for 16 weeks.
3485133|NCT03755791|Other|Single-Agent Cabozantinib arm|Subjects with advanced HCC will receive cabozantinib 60 mg qd
3485134|NCT03755778|Experimental|EDP-938 and itraconazole interaction (Part 1)|
3485135|NCT03755778|Experimental|EDP-938 and rifampin interaction (Part 2)|
3485136|NCT03755778|Experimental|EDP-938 and quinidine interaction (Part 3)|
3485137|NCT03755765|Placebo Comparator|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12) and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
3485138|NCT03755765|Experimental|BB-12|Bifidobacterium animalis subsp. lactis BB-12 (BB-12)-supplemented yogurt and Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
3485139|NCT03755752|Experimental|Phacoemulsification with Trypan Blue|Phacoemulsification with Trypan Blue capsule staining of the anterior lens capsule in patients with diabetic retinopathy
3485140|NCT03755752|Experimental|Phacoemulsification without Trypan Blue|Phacoemulsification without Trypan Blue capsule staining of the anterior lens capsule in patients with
3485141|NCT03755739|Experimental|Pembrolizumab via localized infusion|"This group dividied into two subgroups:~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a dose of 1-2mg/kg via sustained (10min) micro-pump infusion via artery, every 3 weeks.~Checkpoint inhibitor (CPI) such as Pembrolizumab ± Ipilimumab is administrated with a total dose of 150mg via intra-tumor fine needle injection in 5 min, every 3 weeks."
3128165|NCT03132753|Experimental|SUPPORT Group|Subjects enrolled in the intervention.
3128166|NCT03132753|No Intervention|Treatment as Usual|Subjects enrolled in standard services.
3485142|NCT03755739|Active Comparator|Checkpoint inhibitor (CPI) Pembrolizumab via vein infusion|Checkpoint inhibitor (CPI) such as Pembrolizumab is administrated with a total dose of 2mg/kg via vein infusion (30 min), every 3 weeks.
3485143|NCT03755700|Placebo Comparator|Placebo|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with the placebos of both vitamin E and NAC (i.e. the placebo of vitamin E as a soft gel capsule and the placebo of NAC as an effervescent tablets along with a glass of water with the same consumption order used in the groups 2 and 3, respectively).
3485144|NCT03755700|Active Comparator|Vitamin E|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention plus the placebo of NAC with a consumption order similar to group 3.
3179754|NCT00676260|Experimental|Pioglitazone QD|
3485145|NCT03755700|Active Comparator|NAC|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization combined with NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention plus the placebo of vitamin E with the consumption order similar to group 2.
3485146|NCT03755674|Experimental|CHRONOTYPE-ADJUSTED DIET|Patients that undergo a chronotype adjusted diet
3485147|NCT03755674|No Intervention|CONTROL|Patients following a traditional or conventional hypocaloric diet
3485148|NCT03755648|Experimental|Treadmill training|Group A: received treadmill training along with traditional physiotherapy.. The motorized treadmill was used keeping treatment parameters as 50 Hertz, 10 Ampere and 220 Volts The treadmill training was provided by giving instructions first and then warm up was given for 5 minutes prior to the training. The children were upright with the feet flat on treadmill platform. The height of handrails was adjustable according to every child thus keeping their gaze forward. The training was ended at cool down period of 5 minutes
3485149|NCT03755648|Other|traditional physical therapy|Traditional therapy includes use of hot packs for 15 minutes and stretching for 20 minutes which will be applied to both groups prior to actual intervention
3485150|NCT03755648|Experimental|Delorme Resistance exercise|Group B received delorme resistance exercise with traditional physiotherapy. Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
3485151|NCT03755635|No Intervention|Standard of care|Continuously monitoring of neonatal sepsis under standard of care at one site
3485152|NCT03755635|Experimental|Hand hygiene|The WHO multimodal hand hygiene strategy is implemented at one site
3485153|NCT03755622|Active Comparator|Group C (Conventional)|Group C consists of patients who receive Transplatal Arch (TPA) fabricated from conventionally made stone working model.
3485154|NCT03755622|Experimental|Group 3D ( Three Dimensional)|Group 3D consists of patients who receive Transpalatal Arch (TPA) made from 3D recontructed model.
3485155|NCT03755609|Active Comparator|patients with oxycodone|
3485156|NCT03755609|Sham Comparator|patients with fentanyl|
3485157|NCT03755596|Experimental|Treatment|Oral treatment with single-dose 160mg Z. officinale extract in tablet form.
3485158|NCT03755583|Other|EEN group|Received exclusive enteral nutrition after enrollment.
3485159|NCT03755570||CRT: Main Arm|"Cardiac Resynchronisation Therapy (CRT): Main Arm ~98 participants~Prior to CRT Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning, Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
3485160|NCT03755570||ICD and PPM: Control Arm|"Implantable Cardioverter-Defibrillator (ICD) and Permanent Pacemaker (PPM): Control Arm ~98 participants~Prior to ICD or PPM Implantation & Post-Implant 6-Month Device Follow-Up Clinic:~- Battery of 5 questionnaire-based cognitive tests, including the Test of Premorbid Functioning Repeatable Battery for the Assessment of Neuropsychological Status, Hospital Anxiety and Depression Scale, Frontal Assessment Battery and Trail Making Test Part A and B~Please note, the Test of Premorbid Functioning will only be performed ONCE at Pre-Assessment as results reflect IQ prior to disease onset."
3485161|NCT03755557|Placebo Comparator|Placebo|Application of a placebo nasal spray once daily for 8 days Nasal Sprays
3485162|NCT03755557|Active Comparator|Rhinocort|"Nasal Sprays Application of Rhinocort Aqua 64 micrograms, nasal spray once daily for 8 days. Daily dosage 256 µg/d"
3485163|NCT03755557|Experimental|Budesolv|Application of a Budesolv 10 micrograms, nasal spray once daily for 8 days. Daily dosage 40 µg/d Nasal Sprays
3485164|NCT03755531|Experimental|Carbetocin|One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection after labor of the baby at once.
3485165|NCT03755531|Active Comparator|Oxytocin|One ml of Oxytocin (10 IU), was given as a bolus intravenous injection after labor of the baby at once.
3485166|NCT03755518|Experimental|Administration of Fedratinib 400mg/day|Self-administered Investigational Product (IP) (400 mg/day) on an outpatient basis, once daily preferably with food during an evening meal at the same time each day in consecutive 4-week (28-day) cycles.
3485167|NCT03755518|Experimental|Administration of Luspatercept 1.33 mg/kg|Administered as a subcutaneous injection concomitantly with Fedratinib at 3-week (21 day) cycles
3485168|NCT03755505||Healthy Smoker|Healthy smoker with normal spirometry value
3485169|NCT03755505||COPD|Patients with smoking history at least 10 pack-year Patients with persistent airflow limitation that was not fully reversible (e.g. post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7)
3485170|NCT03755492||Group 1 (Provided absorbent pads)|Patients will receive a 6 month supply (as needed) of absorbent pads for urinary incontinence.
3485171|NCT03755492||Group 2 (not provided absorbent pads)|Patients enrolled in the control arm will not receive absorbent pads.
3485172|NCT03755479||Single Arm Group|Patient on multiple daily injections will start Hybrid Closed Loop System Insulin Pump Minimed 670G
3485173|NCT03755466|Active Comparator|BARI|
3485174|NCT03755466|Active Comparator|Bio|
3485175|NCT03755466|Active Comparator|Tofa|
3485176|NCT03755453|Active Comparator|Audéo B-Direct fitted with fitting method A|Traditional standard fitting method which do not include adjustments from the participants.
3485177|NCT03755453|Experimental|Audéo B-Direct fitted with fitting method B|Alternative fitting method which includes additional adjustments from the participants.
3485178|NCT03755440|Experimental|PD-1 antibody|SHR-1210, 200mg, ivdrip, d1, every two weeks.
3485179|NCT03755427|Experimental|15μg H7N9 Vaccine|Participants will be inoculated with 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
3485180|NCT03755427|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will be first inoculated with one dose of seasonal influenza vaccine and followed with one dose of aluminum hydroxide adjuvant at 21-day intervals.
3485181|NCT03755414|Experimental|Pilot Study: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
3485182|NCT03755414|Experimental|Expansion Phase: Itacitinib|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy~Stem cell transplantation on Day 0~Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently~To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure."
3485183|NCT03755388|Experimental|Episealer group|Subjects with a focal cartilage lesion of the distal femur in which biological surgical methods have failed or are not eligible
3485184|NCT03755375|Active Comparator|E-stim Group|The E-stim Group will start treatment after the assessment. Interventions:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
3485185|NCT03755375|Active Comparator|Postural Group|The Postural Group will star treatment after the assessment. The interventions will be: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
3485186|NCT03755375|Placebo Comparator|E-stim Control Group|The E-stim Control Group will start treatment 3 months after the assessment: 10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and transcutaneous electrostimulation. SEMG Biofeedback device will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The e-stim will be applied during 20 minutes on the sites of pelvic pain to decrease the pain and discomfort (analgesia). Parameters:F=100Hz; Pulse width = 70-100 us and the intensity varies according to the sensitivity of the patient.
3485187|NCT03755375|Placebo Comparator|Postural Control Group|The Postural Control Group will start treatment 3 months after the assessment:10 sessions of physiotherapeutic treatment, once a week, using SEMG Biofeedback , myofascial trigger points release and postural exercises. SEMG Biofeedback device: It will be applied with vaginal sensors, to assess pelvic floor tenderness and to treat pelvic floor muscles disorders. The myofascial trigger points release will be applied using manual myofascial stretching and relaxation techniques to release the trigger points.The postural exercises will be used to increase the pelvic mobility and stability. Patients will be asked to move the pelvic area in different postures.(lay down, sit down and standing positions).
3128167|NCT03133481|Active Comparator|Adductor Canal Nerve Block|Participants will be randomized using block randomization.
3128168|NCT03133481|Active Comparator|Femoral Nerve Block|Participants will be randomized using block randomization.
3485188|NCT03755362|Active Comparator|Standard treatment (control)|Dental evaluation and dental prophylaxis at baseline, 3, 6, and 9 months and standard oral hygiene instruction.
3485189|NCT03755362|Experimental|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
3485190|NCT03755349|Experimental|Intervention group|Both burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes of the intervention side are covered by burr-hole covers.
3485191|NCT03755349|Active Comparator|Control group|None of the burr-holes are covered by burr-hole covers in patients with unilateral cSDH. In patients with bilateral cSDH, both burr-holes on the control side are left uncovered.
3485192|NCT03755310|Experimental|Suvorexant|10mg tabs during the first week, 10-20 mg tabs on the second week.
3485193|NCT03755310|Placebo Comparator|Placebo|Equivalent dosage, route of administration and dose regimen.
3485194|NCT03755297|Other|Rheumatoid arthritis|Patients responding to ACR/EULAR 2010 criteria and Blood sample analysis of patients treated as standard care
3485195|NCT03755297|Other|Osteoarthritis|Control patients and Blood sample analysis of patients treated as standard care
3485196|NCT03755297|Other|Rheumatoid arthritis with JAK/STAT inhibitors|Standard use of JAK/STAT inhibitors and Blood sample analysis of patients treated as standard care
3485197|NCT03755284|Experimental|sacral Massage Group|"The massage was applied only to the pregnant women in the intervention group at every phase of labour. There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~For the pregnant women included in the experimental group:~In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour."
3485198|NCT03755284|No Intervention|Control Group|"There was no intervention in the control group except for routine hospital applications. The steps taken in this study are discussed below.~One-on-one interviews were conducted with the pregnant women, and the voluntary disclosure forms, which explained the purpose of the study, were completed.~The prepared questionnaire form was applied. Routine nursing/midwifery care was applied. The state-trait anxiety inventory (STAI FORM TX-I) was applied and evaluated in the active (5-7 cm) phase.~The Visual Analogue Scale (VAS) was evaluated once in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases.~Birth action follow-up form and postpartum interview forms were applied"
3485199|NCT03755258|Experimental|GCK 100 mg group|GCK 100 mg+ Placebo 200 mg GCK tablet 100 mg + Placebo tablet 100 mgX2 tablets, once daily for 12 weeks (oral)
3485200|NCT03755258|Experimental|GCK 200 mg group|GCK 200 mg + Placebo 100 mg GCK tablet 100 mg X 2 tablets+ Placebo tablet 100 mg once daily for 12 weeks (oral)
3485201|NCT03755258|Experimental|GCK 300 mg group|GCK tablet 300 mg GCK tablet 100 mgX3 tablets once daily for 12 weeks (oral)
3485202|NCT03755258|Placebo Comparator|Placebo of GCK group|Placebo 300 mg Placebo tablet 100 mgX3 tablets, once daily for 12 weeks (oral)
3485203|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Intravenous 140 MBq bolus injection of [68Ga]Ga-DOTA-Siglec-9 radiopharmaceutical
3485204|NCT03755232|Experimental|scFOS treatment #1|Phase 1: 10g of scFOS Phase 2: 50g dextrose +15g scFOS Phase 3: 50g avCHO from white bread +15g scFOS
3485205|NCT03755232|Experimental|scFOS treatment #2|Phase 1: n/a Phase 2: 35g Dextrose +15g scFOS Phase 3: 35g avCHO from white bread +15g scFOS
3485206|NCT03755232|Active Comparator|Control #1|Phase 1: Water control (negative control) Phase 2: 35g Dextrose control 1 Phase 3: 35g avCHO from white bread (control 1)
3485207|NCT03755232|Active Comparator|Control #2|Phase 1: 10g Dextrose (positive control) Phase 2: 50g Dextrose control 2 Phase 3: 50g avCHO from white bread (control 2)
3485208|NCT03755219||StdPPM|Standard pure polypropylene mesh
3485209|NCT03755219||LWM|Lightweight mesh: Either a pure polypropylene mesh, or a polypropylene-based composite mesh
3485210|NCT03755219||Tacks, metal|Metal staples or tacks
3485211|NCT03755219||Tacks, absorbable|Absorbable synthetic staples or tacks
3485212|NCT03755219||Tacks, uncategorized|Staples or tacks were in SHR 2005-2011 not further categorized
3485213|NCT03755219||Fibrin glue|Biologic glue/sealant produced from human donor blood
3485214|NCT03755219||Non-fixation|Mesh is deployed without fixation
3485215|NCT03755206|Other|Intervention|Interrupted time series design
3485216|NCT03755193|Active Comparator|SERM plus ELD|To examine the effects of SERM plus ELD in osteoporosis patients
3128169|NCT03133676|Experimental|KA34 Active Drug|KA34 active drug in the dose range of 50 - 400 ug per knee
3128170|NCT03133676|Placebo Comparator|Placebo|Placebo is the formulation for KA34.
3128171|NCT03133767|Experimental|Lactated ringers solution|Participants in this arm will receive two liters of IV Lactated Ringer's solution during their emergency department stay
3485217|NCT03755193|Active Comparator|BP plus ELD|To examine the effects of BP plus ELD in osteoporosis patients
3485218|NCT03755193|Active Comparator|ELD alone|To examine the effects of ELD alone in osteoporosis patients
3485219|NCT03755180|Experimental|Group 1|Exercise Group
3485220|NCT03755180|Active Comparator|Group 2|Compression Group
3128172|NCT03133767|Experimental|Normal saline solution|Participants in this arm will receive two liters of IV 0.9% sodium chloride solution during their emergency department stay
3179755|NCT00676260|Placebo Comparator|Placebo QD|
3179756|NCT00676273|Active Comparator|1|TVTO
3179757|NCT00676273|Active Comparator|2|TVTS
3485221|NCT03755167|Experimental|IPL344|IV IPL344 administered once a day
3485222|NCT03755154|Experimental|S65487 - initial scheme|
3485223|NCT03755154|Experimental|S65487 - alternative scheme|
3485224|NCT03755141|Experimental|Herzuma|Herzuma + TPC
3485225|NCT03755115|Experimental|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, D1,30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
3485226|NCT03755102|Experimental|Cohort 1: Participants treated with dacomitinib alone|Participants in this cohort have a somatic activating mutation in EGFR in a tumor biopsy or plasma cfDNA liquid biopsy.
3485227|NCT03755102|Experimental|Cohort 2: Participants treated with dacomitinib in combination with osimertinib|Participants in this cohort have a secondary acquired EGFR mutation in addition to the sensitizing mutation
3485228|NCT03755089|Active Comparator|Oral Phenazopyridine|Patients randomized to the oral phenzopyridine arm will receive 200mg phenazopyridine to take by mouth 1-2 hours before their scheduled procedure.
3485229|NCT03755089|Active Comparator|Intravesical Lidocaine|Patients randomized to the intravesical lidocaine arm will have the bladder back-filled with 30mL 2% lidocaine for the 20 minutes immediately preceding their procedure.
3485230|NCT03755076|Experimental|Perceptual cuing|Two perceptual cues will be provided: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context. The effect of the two cues on bimanual coordination will be determined.
3485231|NCT03755063|Experimental|Treatment arm|Tablet with speech therapy apps
3485232|NCT03755063|No Intervention|Standard of Care|The standard care provided by speech language therapists.
3485233|NCT03755050||Sleigh Accident|Accident while using a sleigh
3485234|NCT03755050||Climbing Accident|Accident occurred while climbing (rock, ice)
3485235|NCT03755050||Cycle Accident|Accident occurred while using any form of cycle in the mountains (e.g. bike, mountainbike, e-bike)
3485236|NCT03755050||Canyoning Accident|Accident occurred while doing canyoning
3485237|NCT03755050||Hiking Accident|Accident occurred while hiking in mountainous area.
3485238|NCT03755050||Snowshoeing Accident|Accident occurred while doing Snowshoeing
3485239|NCT03755050||Mountainous Water-sport Accident|Accident occurred while doing any type of Water-sport (e.g. canoeing, kayaking, tubing, swimming) in mountainous environment.
3485240|NCT03755050||Skiing/Snowboarding|Accident occurred while using ski or a snowboard either in backcountry or on ski slope
3485241|NCT03755037|Active Comparator|Estradiol and cc|"Group 1 received estradiol, cc and placebo simillar to sildenafil for induction of ovulation.~CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient then ethinyl estradiol 0.05mg orally twice daily on the 8th day of same cycle till 11th day."
3485242|NCT03755037|Active Comparator|Sildenafil and cc|Group 2 received CC 50 mg (clomid) orally twice daily from 3rd day to 7th day of menstrual cycle of the patient, sildenafil citrate (Respatio) 20 mg tab orally 3 times daily from8th day of same cycle till 11th day and placebo simillar to estradiol.
3485243|NCT03755037|Placebo Comparator|Placebo and cc|Group 3 received cc and placebo similar to sildenafil and placebo similar to estradiol with the same doses.
3485244|NCT03755024||normal group|fetuses with normal growth
3485245|NCT03755024||Growth retardation group|fetuses with retarded growth
3485246|NCT03755011|Experimental|patients exposed to white noise|Six patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined; pausing will be at nurse, provider, and patient discretion during routine care and conversations with the patients.
3485247|NCT03755011|Placebo Comparator|usual care|Six patients exposed to normal ICU activity noise.
3485248|NCT03754998|Experimental|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
3485249|NCT03754985||Hyperbaric Oxygen Therapy|The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.
3485250|NCT03754972|Experimental|Lumbar spinal stenosis surgery candidate|Patients with lumbar spinal stenosis and spondylolisthesis that have previously consented to surgical treatment. After recording the initial surgical plan, the Sagittal plane shear index (SPSI) will be provided to the surgeon. The surgeon may change the initial surgical plan based on the stability metric.
3485251|NCT03754959|Experimental|Dose Group 1|
3485252|NCT03754959|Experimental|Dose Group 2|
3485253|NCT03754959|Experimental|Dose Group 3|
3128173|NCT03134092|No Intervention|Generalized Risk Communication (GRC)|Generalized Risk Communication (GRC): Participants in this arm will receive standard discharge instructions similar to instructions they would receive during usual care. This arm represents a standardized way of communicating post-discharge risk-benefit information about treatment options for patients with back pain and renal colic. The GRC, includes a standardized discharge information sheet about the clinical condition of interest and a written overview of population based evidence describing comparative benefits and side effects of alternative classes of medication acute pain.
3179758|NCT00676312|Experimental|1|Cross-over treatment with increasing doses of PTH134, placebo and active comparator.
3485254|NCT03754959|Experimental|Dose Group 4|
3485255|NCT03754959|Experimental|Dose Group 5|
3485256|NCT03754933|Experimental|Ad/PNP + fludarabine phosphate, 5 cycles|
3485257|NCT03754920|Experimental|prolonged fasting|Participants fast for five days, without any food, except unlimited mineral water, and do some fitness regimen(such as meditation and mild physical exercise ).
3485258|NCT03754907|Experimental|stapled anastomosis group|Following the first side-to-side anastomosis at the antimesenteric border in both intestinal limbs, the staple lines are oversewn to reinforce the crotch. Thereafter, the stapler is again fired across the joined intestinal limbs to close the enterotomies. The suture line of the side-to-side anastomosis should not overlap, and the staple lines are oversewn to reinforce the double-stapled areas.
3485259|NCT03754907|Active Comparator|hand-sewn anastomosis group|Patients chose HA group will performed in an end-to-end manner using absorbable suture material.
3485260|NCT03754894|Experimental|goup 1(with readymade plastic stent )|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
3485261|NCT03754894|Experimental|group 2 (control)|Will include 10 patients where combined full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement then suturing the flap in place.
3485262|NCT03754855||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria
3485263|NCT03754842|Placebo Comparator|Placebo|
3485264|NCT03754842|Experimental|Nicotinamide Riboside + Pterostilbene|
3485265|NCT03754829|Experimental|HSKA - Web Group|The first experimental group will receive direct access to the web version of HSKA.
3485266|NCT03754829|Experimental|HSKA - Mobile Group|The second experimental group will receive direct access to the mobile app of HSKA as well as automated supportive text messages based on PST.
3485267|NCT03754829|No Intervention|Control Group|The control group consists of a wait-list and for ethical reasons, participants in this group will gain access to the intervention (either web or mobile application) four months after the baseline.
3485268|NCT03754816|Experimental|Experimental group|The combination of PECS II and parasternal block performed by injecting Levobupivacaine 0.375% 40 ml, injected between minor and major pectoralis muscles, between minor and serratus muscles and between major and intercostal muscles
3485269|NCT03754803||Treatment naïve subjects with HIV infection|Treatment naïve HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included
3485270|NCT03754803||Pre-treated subjects with HIV infection|Pre-treated HIV-1 positive subjects for whom DTG+3TC is indicated according to local label will be included.
3128174|NCT03134092|Active Comparator|Probabilistic Risk Communication (PRT)|Probabilistic Risk Communication (PRT): The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
3128175|NCT03134092|Active Comparator|Narrative Enhanced Risk Tool (NERT)|Narrative Enhanced Risk Tool (NERT): Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale related to prolonged opioid use. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded.
3128176|NCT03134144|Experimental|First without exoskeleton then with exoskeleton|"Subject will perform the conditions as described under model description first without the exoskeleton and then with the exoskeleton."
3485271|NCT03754777|Experimental|Modified ERAS protocol group|"Laparoscopic appendectomy with modified ERAS protocol group Preadmission. Not available due to the emergency setting. Preoperative care.~1) Patient brochure with a detailed description of the type of pathology, surgery procedure, rehabilitation process, possible complications, and other.~Surgery.~Low pressure (8-9 mmHg) pneumoperitoneum.~Routinely remove of appendix mesentery in presence of any signs of its inflammation.~Additional local anesthesia with 0.25% ropivacaine.~Abdominal cavity draining only in patients with perforated appendicitis and diffuse peritonitis (Gomes 5).~Postoperative care.~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery)"
3485272|NCT03754777|Placebo Comparator|Standard care group|"Standard care laparoscopic appendectomy. Preadmission. Not available due to emergency setting. Preoperative care. 1) Patient oral informing about the type of pathology, surgery procedure and possible complications. No brochure.~Surgery.~Standard pressure (12-14 mmHg) pneumoperitoneum~Abdominal draining for patients with perforated and not perforated appendicitis complicated by abscess, local or diffuse peritonitis (Gomez ≥ 3A).~Appendix mesentery removing in the appearance of its necrotic changes.~No intraabdominal anesthesia. Postoperative care.~1) Mobilization in 4-6 h after surgery 2) Fluid intake in 6 hours 3) Liquid food intake in 12 hours"
3485273|NCT03754751|Experimental|Modified ERAS program group|Laparoscopic cholecystectomy with the implementation of modified ERAS program
3485274|NCT03754751|Active Comparator|Conventional care group|Laparoscopic cholecystectomy with standard perioperative treatment
3485275|NCT03754738|Experimental|Balloon guide catheter group|mechanical thrombectomy with a balloon guide catheter group
3485276|NCT03754738|Active Comparator|Non-balloon guide catheter group|mechanical thrombectomy with a non-balloon guide catheter group
3485277|NCT03754725|Experimental|Deferiprone|This is the drug arm (deferiprone). Patients will receive oral deferiprone
3485278|NCT03754725|Placebo Comparator|Control|this group will only receive the placebo (sugar pill)
3485279|NCT03754712|Active Comparator|Intervention Vitamin D3 along with SSRIs|One tablet of vitamin D3 (2000IU) per day for 8 weeks
3128177|NCT03134144|Experimental|First with exoskeleton then without exoskeleton|"Subject will perform the conditions as described under model description first with the exoskeleton and then without the exoskeleton."
3179759|NCT00676325|Active Comparator|1|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction were eligible for participation.traditional colporrhaphy in this group.
3485280|NCT03754712|No Intervention|SSRIs|Patients treated with SSRIs
3485281|NCT03754699|Experimental|Patients with a therapeutic educational intervention|Arm 1 : Interventional group: A therapeutic educational intervention is performed following pre-anesthesia assessment
3485282|NCT03754699|Active Comparator|Patients without therapeutic educational intervention|Arm 2 : Control group: standard information on pain is performed following pre anesthesia assessment
3485283|NCT03754686|Active Comparator|Oseltamivir|best medical care and oral oseltamivir 75 mg twice daily for five days.
3485284|NCT03754686|Active Comparator|Paracetamol|best medical care and oral paracetamol twice daily for five days.
3485285|NCT03754647|No Intervention|Patients receiving SSRIs|This group will be receive SSRIs only
3485286|NCT03754647|Active Comparator|Patients receiving Vitamin C with SSRIs|This group will be receive vitamin C (500mg) twice daily with SSRIs for 8 weeks
3485287|NCT03754634|Experimental|drugs|Eltrombopag and Diacerein
3485288|NCT03754621||Pregnants|400 pregnant women with a singleton pregnancy, free of pre-existing thyroid disease, that do not use thyroid interfering medication, that did not undergo IVF treatment and are TPOAb negative. Serum thyroid functions tests will be obtained on the first visit.
3485289|NCT03754608||Diabetics/No cognitive impairment|These are individuals with diabetes who do not have vascular cognitive impairment as determined by VASCOG criteria.
3485290|NCT03754608||Diabetics with vascular cognitive impairment|These are individuals with diabetes who have vascular cognitive impairment as determined by VASCOG criteria.
3485291|NCT03754595|Active Comparator|2D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 2D Laparoscopic pancreatoduodenectomy
3485292|NCT03754595|Experimental|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
3485293|NCT03754569|Experimental|Peritoneal biopsies|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
3485294|NCT03754543|Active Comparator|Testmeal A|A new, whole-grain infant cereal fortified with ferrous fumarate
3485295|NCT03754543|Active Comparator|Testmeal B|An alternative new whole-grain infant cereal recipe fortified with ferrous fumarate
3128178|NCT03134183|Experimental|Vaginal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within cocoa butter suppository
3128179|NCT03134183|Experimental|Buccal Misoprostol|Intervention is misoprostol versus placebo 400mcg misoprostol formulated within mint flavored powder
3485296|NCT03754543|Placebo Comparator|Testmeal C|An existing, refined grain infant cereal fortified with ferrous fumarate
3485297|NCT03754543|Active Comparator|Testmeal D|An existing, whole-grain infant cereal fortified with ferrous fumarate
3485298|NCT03754543|Active Comparator|Testmeal E|An existing, whole-grain infant cereal fortified with ferrous bisglycinate
3485299|NCT03754530|Experimental|Icotinib|icotinib is administered orally three times per day. Until emerge the progression of the intracranial disease, then is given radiotherapy(>3 with WBRT or <=3 with SRS) after PD
3485300|NCT03754530|Experimental|Icotinib plus radiation therapy|Standard whole brain radiotherapy (WBRT) is given with 30GY/10 times(>3), or SRS(<=3) plus concurrent icotinib, which was administered orally three times per day. Until the disease progresses.
3485301|NCT03754517||Serofast status|The syphilitic patients who remain in a serologically positive state after therapy
3485302|NCT03754517||Untreated|untreated syphilis cases
3485303|NCT03754517||Serological cure|"In the early syphilis patients, at 6 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer.~In the late syphilis patients, at 12 months following treatment, a serological cure was defined as either a negative RPR or ≥2 dilution (4-fold) decrease in the RPR titer."
3485304|NCT03754504|Experimental|Cranberry|Whole Cranberry Powder Supplements
3485305|NCT03754504|Placebo Comparator|Placebo|Placebo
3485306|NCT03754491|Experimental|One stage stone removal in mild cholangitis|one-stage stone removal at the first session of ERCP in mild cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
3485307|NCT03754491|Experimental|One stage stone removal in moderate cholangitis|one-stage stone removal at the first session of ERCP in moderate cholangitis patients. The indomethacin 100mg anal route will be administered for all patients without allergy history
3128180|NCT03134209|Experimental|Zipper surgical skin closure|Zipper surgical skin closure device applied to the most superficial layer of skin following a joint arthroplasty
3128181|NCT03134209|Active Comparator|Monocryl + Dermabond|Monocryl suture plus Dermabond is a commonly used combination of wound closure techniques today.
3485308|NCT03754478||overweight subjects|Overweight male and females referred to a physical activity program by their primary care physician Intervention is being included in a 3-month physical activity training program
3485309|NCT03754465|Experimental|ALLO-ASC-DFU|Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
3485310|NCT03754465|Placebo Comparator|Hydrogel SHEET(Vehicle control)|Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells
3485311|NCT03754439||Inborn|"Infants born within Nottingham University hospitals~< 32 weeks gestational age~< 72 hours old"
3485312|NCT03754439||Transported|- Infants born outside of Nottingham University Hospitals or transferred between units Phase 1 < 32 weeks gestational age and <72 hours old Phase 2 any gestation and age
3485313|NCT03754413|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
3485314|NCT03754413|Other|Comparator device|No-treatment
3485315|NCT03754400|Experimental|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
3485316|NCT03754400|Active Comparator|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment.
3485317|NCT03754387|Active Comparator|Antibiotic therapy group|Ceftazidime will chosen as the antibiotic for this study because of its efficacy as a monotherapy for serious intraabdominal infections, requiring only a single, daily dose. Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) is administered for 3 days to patients in the AT group, with the first dose given in the emergency department. The clinical status of patients in the AT group is reevaluated within 12 to 24 hours after admission by the surgeon on call. If the surgeon suspected progressive infection, perforated appendicitis, or peritonitis, the patient will underwent appendectomy. Intravenous antibiotic treatment will followed by 7 days of oral cefuroxime (250mg twice daily).
3485318|NCT03754387|Experimental|Laparoscopic Appendectomy group|Laparoscopic appendectomy will performed using. Prophylactic antibiotics (ceftazidime sodium 50mg/kg/dose ) will administered approximately 30 minutes before the incision was made. No further antibiotics will given to patients in the surgical group unless a wound infection was suspected postoperatively.
3485319|NCT03754361|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment
3485320|NCT03754361|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent hemodialysis treatment 3-4 times per week,2-4 hours each time.
3485321|NCT03754348|Experimental|NT1 group|hypothalamus neuroinflammation evaluation in Narcoleptic patients
3485322|NCT03754348|Other|Control group|hypothalamus neuroinflammation evaluation in control patients (patients without hypersomnia or inflammatory pathology)
3485323|NCT03754348|Experimental|KLS group|hypothalamus neuroinflammation evaluation in Kleine-Levin syndrome patients
3485324|NCT03754335|Experimental|Lumbar puncture|Lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
3485325|NCT03754335|Active Comparator|Sham lumbar puncture|Sham lumbar puncture in addition to a predefined analgesic protocol Patients will be randomized between the 3rd and 5th days following aneurismal rupture.
3485326|NCT03754322|Active Comparator|Standard of care|One third of individuals get allocated to the standard of care arm. At each antenatal visit as per Ethiopian guidelines, pregnant women enrolled in the study will be submitted to the standard of care for malaria in pregnancy. If the pregnant mothers are symptomatic for malaria, they receive microscopy (blood smear for Plasmodium detection) and then are treated with anti-malarial therapy if microscopy is positive for Plasmodium. If it is negative they receive no treatment. If they are asymptomatic, they do not receive any further investigations or treatment in relation to malaria.
3485327|NCT03754322|Experimental|Intervention arm|The remaining two-thirds of participants will be actively screened (symptomatic and asymptomatic) for Plasmodium infection at each antenatal visit, using both LAMP and conventional techniques (microscopy and RDT). If either is positive, participants will be treated with antimalarial therapy according to Ethiopian Ministry of Health guidelines. If both are negative then they receive no treatment.
3485328|NCT03754309|Experimental|KY1005 lower dose|Low dose KY1005
3485329|NCT03754309|Experimental|KY1005 higher dose|High dose KY1005
3128182|NCT03134209|Active Comparator|Polyester mesh + Dermabond|The polyester plus Dermabond closure techniques combines the OCA topical skin adhesive with a flexible, self-adhesive polyester mesh that has proven to reduce wound cosure times and have a significant greater skin holding strength than skin staples or subcuticular sutures in one study
3128183|NCT03134222|Experimental|Lanraplenib 30 mg|Lanraplenib + filgotinib placebo for 48 weeks
3485330|NCT03754309|Placebo Comparator|Placebo|Matched placebo
3485331|NCT03754296||CATCHVIEW stent retriever|
3485332|NCT03754283|Experimental|Silicone|Indirect bonding performed with the silicone trays
3485333|NCT03754283|Active Comparator|Vacuum formed|Indirect bonding performed with the vacuum formed trays
3485334|NCT03754270|Active Comparator|Lifestyle advice|Patients receive instructions and advice on lifestyle according to current clinical practice.
3485335|NCT03754270|Experimental|Lifestyle advice and cervical collar|"Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it."
3485336|NCT03754257|Experimental|High-frequency Electrical Stimulation|High-frequency Electrical Stimulation for 40 minutos + conventional physiotherapy, during seven days.
3485337|NCT03754257|Sham Comparator|Sham Electrical Stimulation|Sham Electrical Stimulation for 40 minutes + conventional physiotherapy, during seven days.
3485338|NCT03754244|Experimental|TQB3456|p.o. qd
3485339|NCT03754231|Experimental|Aingeal|All recruited patients will wear the Aingeal device as a form of heart rate monitoring and respiratory rate monitoring in a paediatric outpatient clinic setting.
3485340|NCT03754218|Experimental|Amnion membrane product treatment area|The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.
3485341|NCT03754218|Active Comparator|SOC Wound Covering treatment area|The donor wound site (Site B) will be covered per SOC (Standard of care).
3485342|NCT03754205|Experimental|Laser Group|"Microablative Fractional CO2 laser therapy at monthly intervals.~The laser parameters that will be used are the following: (1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode."
3128184|NCT03134222|Experimental|Filgotinib 200 mg|Filgotinib + lanraplenib placebo for 48 weeks
3128185|NCT03134222|Placebo Comparator|Placebo|Filgotinib placebo + lanraplenib placebo for 12 weeks
3128186|NCT03134222|Experimental|Placebo to Lanraplenib 30 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.
3128187|NCT03134222|Experimental|Placebo to Filgotinib 200 mg|After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.
3485343|NCT03754205|Placebo Comparator|Placebo Group|"Placebo CO2 laser therapies at monthly intervals.~The laser parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode."
3485344|NCT03754192|Other|perfusion computed tomography|Will be realsed before liver surgery
3485345|NCT03754179|Experimental|Arm A phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
3485346|NCT03754179|Active Comparator|Arm B phase 2|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily until disease progression. At disease progression, add-on of hydroxychloroquine 200 mg twice daily. Treatment until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment"
3485347|NCT03754179|Experimental|Phase 1|"Patients are eligible if they are diagnosed with BRAF V600 mutant unresectable AJCC (American Joint Committee on Cancer) stage III or IV melanoma and are documented with progression of disease following treatment with a BRAF with or without MEK inhibitor and treatment with an immune checkpoint inhibitor (at least an anti-PD1 [programmed cell death 1] antibody). Patients will be considered for study participation not earlier than 12 weeks after the last dosing of the prior BRAF with or without MEK inhibitor therapy and 4 weeks after the last dosing of immune checkpoint inhibitor therapy.~Upfront treatment with dabrafenib 150 mg twice daily, trametinib 2 mg once daily and hydroxychloroquine 200 mg twice daily upfront until disease progression, unacceptable treatment related toxicity or patient's refusal to continue study treatment."
3485348|NCT03754166|Experimental|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
3485349|NCT03754166|No Intervention|Usual care|Usual care of the neurovascular unit. = No constraint, no cueing, and same physiotherapy intervention as experimental arm.
3485350|NCT03754140|Experimental|Polidocanol Injection|Polidocanol (3%) 0.1ml intralesional injection per 10mm diameter lesion
3485351|NCT03754114|Active Comparator|ICP only|ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
3485352|NCT03754114|Active Comparator|ICP + PbtO2|ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
3128188|NCT03134248|Experimental|MyDay Toric|Participants were randomized to wear a new pair of MyDay Toric lenses each day for one week during the cross over study
3128189|NCT03134248|Active Comparator|1-Day Acuvue Moist for Astigmatism|Participants were randomized to wear a new pair of 1-Day Acuvue Moist Toric lenses each day for one week during the cross over study
3485353|NCT03754075||CME group|The CME group consisted of patients, who underwent elective CME for right-sided colon adenocarcinoma at Nordsjaellands Hospital Hillerød from 1 June 2008 to 31 December 2013.
3485354|NCT03754075||Non-CME group|The non-CME group comprised patients having a elective conventional colon cancer resection for right-sided adenocarcinoma at the other three colorectal centers in the Capital Region of Denmark from 1 June 2008 to 31 December 2013.
3485355|NCT03754062|Placebo Comparator|Placebo|Placebo control
3485356|NCT03754062|Experimental|Haloperidol 3mg|Haloperidol
3485357|NCT03754062|Experimental|L-Dopa 150 mg & Domperidone 10mg|L-Dopa
3485358|NCT03754049|Experimental|TLC599 12 mg|12 mg DSP with 100 μmol phospholipid via IA injection;
3485359|NCT03754049|Experimental|TLC599 6 mg|6 mg DSP with 50 μmol phospholipid via IA injection.
3485360|NCT03754049|Active Comparator|DSP 4mg|Dexamethasone Sodium Phosphate (DSP): 4 mg/mL, 1 mL via IA injection.
3485361|NCT03754036|Experimental|Sleep Extension|Increase in time in bed of 1.5 hours per night for one week
3128190|NCT03134248|Active Comparator|Dailies Aquacomfort Plus Toric|Participants were randomized to wear a new pair of Dailies Aquacomfort Plus Toric lenses each day for one week during the cross over study
3128191|NCT03134313|Experimental|R1-25 Sensor|All subjects will be enrolled in the test group and will receive Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor
3485362|NCT03754036|Experimental|Sleep Restriction|Decrease in time in bed of 1.5 hours per night for one week
3485363|NCT03754010|Placebo Comparator|Scaling and root planning (SRP)|Under local anesthesia, full-mouth SRP was performed within 24 h in a single or two sessions using ultrasonic and hand instruments (Gracey, Hu-Friedy, Chicago, IL, USA) by a single investigator (DA). Immediately after the SRP, HA gel (Gengigel, Hyaluronic acid, gingival gel, Ricefarma S.R.L, Italy) or mouthrinse was performed according to the groups' procedure. In Group 1, the periodontal sulcus was irrigated with saline solution after SRP.
3485364|NCT03754010|Experimental|Hyaluronic acid gel (HA) and SRP|Group 2, after SRP was performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA was applied intrasulcular.
3485365|NCT03754010|Experimental|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse (Gengigel, Hyaluronic acid, Hydrogel moutrinse for gums, Ricefarma S.R.L, Italy) were used as an irrigator after SRP.
3485366|NCT03754010|Experimental|HA mouthrinse+gel and SRP|In Group 4, after SRP was performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel was applied.
3485367|NCT03753997|No Intervention|Conventional therapy|Patiens´s will come to the clinic for regular contact with a diabetes nurse.
3485368|NCT03753997|Experimental|Treatment by a Psychologist|Patients will meet with a diabetes educated psychologist over 9 months and will come to the clinic for regular contact with a diabetes nurse
3128192|NCT03134326|Experimental|Test group|All subjects will be enrolled in the test group and will receive both R1-25 and R2-25 Pulse Oximeter Sensors
3128193|NCT03134599|Active Comparator|etafilcon A|
3128194|NCT03134599|Active Comparator|methafilcon A - Interozzo|
3128195|NCT03134599|Active Comparator|methafilcon A - CVI|
3485369|NCT03753984|Experimental|Healthy group|The protocol consists of Low-level laser therapy (LLLT) application in the dominant side brachialis muscle in healthy subjects prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, electromyography associated with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration by means of the lactimeter, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
3485370|NCT03753984|Experimental|Post stroke group|The protocol consists of Low-level laser therapy (LLLT) application in the hemiparetic side brachialis muscle post stroke individuals prior to performing the Isometric Maximum Voluntary Contraction (IMVC) for 50 seconds in the isokinetic dynamometer and will be analize Visual Analog Pain Scale, surface electromyography with the evaluation of the muscular torque through the isokinetic dynamometer, local infrared thermography and blood lactate concentration, which will be measured at four different times, prior to the application of the laser (basal collection) and 3, 15 and 25 minutes after IMVC. All the participants will pass for three groups: Control group (not will be applicate LLLT), Placebo group (laser will be off) and LLLT group (will be applicate LLLT).
3485371|NCT03753971|Experimental|Apneas with and without intervention|Each patient will be his own control.
3485372|NCT03753958|Experimental|Control group|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
3485373|NCT03753958|Experimental|aPDT group|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
3485374|NCT03753945|Experimental|DBS electrode placement|"Participants in this study will be patients who have already undergone surgery for implantation of DBS electrodes.~Patients who have already undergone surgery for implantation of DBS electrodes and patients for whom the treating physicians recommends (based on clinical grounds) a spine MRI (cervical, thoracic or lumbar) shall be recruited for the study.This eligible patient population is broad but unified by the fact that they have undergone DBS to treat specific circuit dysfunctions. Patients with internalized leads and IPG may be included. Patients will undergo routine clinical MRI sequences used for the spine (structural in axial and sagittal planes). The choice of imaging the cervical, thoracic or lumbar will depend on the requisition from the treating physician."
3485375|NCT03753932|Experimental|Intervention|Dentures (fixed oral prosthesis) compared with standard treatment (removable oral prosthesis).
3485376|NCT03753919|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.
3485377|NCT03753906|Experimental|Osmed® hydrogel expander implantation|Implantation of Osmed® hydrogel expander was done in subperiosteal positions using the pouch technique in the mandibular anterior region.
3485378|NCT03753880|Experimental|Hemopatch|Hemopatch used to cover the resection surface after LR
3485379|NCT03753867|Experimental|Acitretin treatment|
3485380|NCT03753854|Active Comparator|SS patients|"Homozygous sickle cell patients~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
3485381|NCT03753854|Experimental|SS patients apneic|"Homozygous sickle cell patients after one year of continuous positive airway pressure treatment~Each patient will undergo the following:~polysomnography and oxygen saturation exam~calculation of VOC rate within the two previous years~Blood samples~Physiological measurements"
3128196|NCT03134703|Experimental|Methadone Treatment Group|NAS infants treated for withdrawal symptoms with methadone
3128197|NCT03134703|Active Comparator|Comparison Group|NAS infants treated for withdrawal symptoms with morphine (standard of care at Johns Hopkins All Children's Hospital)
3128198|NCT03134911||anticoagulation controlled patients|Treated with DOAC or VKA
3128199|NCT03134911||anticoagulation non controlled patients|Treated with VKA
3128200|NCT03134963||Mild cognitive impairment|"MCI Patient-specific Inclusion Criteria~Clinical diagnosis of MCI made by a specialist* in a patient who fulfils the established clinical consensus criteria for MCI [NIA/AA 2011] specifically:~Concern regarding a change in cognition compared to the person's previous level, by the patient and/or informant~Objective evidence of impairment of one or more cognitive domains, greater than expected for age, and educational background, over time if repeated measures are available.~Preserved independence of functional abilities and minimal to no impairment on complex instrumental functions~Not demented"
3485382|NCT03753841|Active Comparator|Adjustment of oral diet|Patients who need a change in their diet regime, in whom FEES shows that they have not the adequat diet.
3485383|NCT03753841|No Intervention|No adjustment of oral diet|Patients who have the adequat diet based on FEES findings.
3485384|NCT03753815|Active Comparator|19G FNA needle|Patients referred for EUS-guided tissue acquisition of AIP
3485385|NCT03753815|Active Comparator|20G FNB needle|Patients referred for EUS-guided tissue acquisition of AIP
3485386|NCT03753802|Experimental|Treated|The treated group will receive chest physiotherapy treatment using slow extended and passive expiratory maneuvers.
3485387|NCT03753802|Placebo Comparator|Control|The control group will not receive physiotherapy treatment.
3485388|NCT03753776|Placebo Comparator|Radium bromatum placebo group|Placebo group will receive placebo pills of Radium bromatum during radiotherapy
3485389|NCT03753776|Experimental|Radium bromatum group|Radium bromatum group will receive homeopathic Radium bromatum pills during radiotherapy
3485390|NCT03753776|Placebo Comparator|Radium bromatum/Apis mellifica/Belladonna placebo group|Placebo group will receive Radium bromatum/Apis mellifica/Belladonna placebo pills to treat grade 2 or higher radiodermatitis
3485391|NCT03753776|Experimental|Radium bromatum/Apis mellifica/Belladonna group|Radium bromatum/Apis mellifica/Belladonna group will receive homeopathic Radium bromatum/Apis mellifica/Belladonna pills to treat grade 2 or higher radiodermatitis
3485392|NCT03753750|Experimental|Actual stimulation|Subjects enrolled in the
3485393|NCT03753750|Sham Comparator|Sham stimulation|
3485394|NCT03753737||Chemsex|Men who have Sex with Men (MSM) attending an addiction care center for past or present mild, moderate or severe substance-related disorder(s) according to DSM-V criteria, occurring in a sexual context and concerning cathinones, GHB/GBL, methamphetamine, cocaine and/or ketamine.
3485395|NCT03753737||Control|Men who have Sex with Men (MSM) consulting for a PrEP (HIV Pre-Exposure Prophylaxis) prescription who have never used cathinones, GHB/GBL, methamphetamine, cocaine or ketamine before or during sex.
3128201|NCT03134963||Alzheimer disease|"NIA/AA criteria~Meets the criteria for dementia~o The memory impairment and cognitive deficits cause significant impairment functioning, a significant decline from a previous level of functioning, Impairment of at least two cognitive domains~Insidious or gradual onset~Clear history of worsening cognition by report or observation~The initial and most prominent cognitive deficits are evident on history and examination in one of the following domains:~Amnestic: impaired learning and recall of recently learned information~Non amnestic: language/visuospatial/executive dysfunction"
3128202|NCT03134963||Vascular dementia|"NINDS-AIREN criteria for VascD, specifically:~Cerebrovascular disease defined by the presence of focal signs on neurological examination consistent with stroke and evidence of cerebrovascular disease on brain imaging.~One or more of:~Onset of dementia within 3 months of a diagnosed stroke~Abrupt deterioration in cognitive function~Fluctuating, stepwise progression of cognitive deficits"
3485396|NCT03753724||Group 1|On review of the scans by an expert, no further follow up or investigation is required, as the nodule(s) has been categorised as benign. As the patient was unaware the scan was being reviewed and no further investigations are required. Patient is invited to take part in the study (by telephone).
3485397|NCT03753724||Group 2|On review, the nodule is indeterminate and further scanning at a later date is required. The patient is informed of this, usually via a telephone call from either the doctor or nurse specialist working in the Lung Nodule Clinic (LNC) or site equivalent. This LNC is usually a virtual clinic - no physical interaction with the patient - and the follow up scan is reviewed and the patient contacted again via the virtual clinic. Patient is invited to take part in the study (by telephone, by post or in clinic if appropriate).
3128203|NCT03134963||Healthy controls|"Healthy Controls-specific Inclusion Criteria~No evidence of subjective or objective memory impairment on cognitive testing~No major medical co-morbidity (outlined in detail in the exclusion criteria) or medication use that could adversely affect cognition"
3128204|NCT03134989|Other|Cochlear implant recipients|Study group is comprised of cochlear implant patients already identified as candidates and undergoing surgery.
3485398|NCT03753724||Group 3|On review, the nodule is regarded as potentially malignant and further scans and a clinic appointment is made for the patient. Patient is invited to take part in the study (in clinic if appropriate).
3485399|NCT03753711|Experimental|LDH (lumbar disc hernia)|
3485400|NCT03753698|Experimental|eCoin|Neuromodulation of posterior tibial nerve
3485401|NCT03753685|Experimental|X-396(Ensartinib) Capsule|
3485402|NCT03753672||preload responsive|defined as an increase in Velocity time integral of the sub-aortic flow greater or equal to 10%
3485403|NCT03753672||preload unresponsive|defined as an increase in Velocity time integral of the sub-aortic flow lower than 10%
3485404|NCT03753659|Experimental|Pembrolizumab with local ablation|"Pembrolizumab 200mg IV Q3W on day 1 of cycle 1 and 2~Radio Frequency Ablation (RFA) / Microwave Ablation (MWA) / brachytherapy or combination of TACE with RFA, MWA or brachytherapy will be performed on day 1 of cycle 3~Pembrolizumab 200mg IV administration 2 days after local ablation~Pembrolizumab 200mg IV Q3W for up to 12 months total treatment duration"
3485405|NCT03753646|Experimental|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
3485406|NCT03753646|No Intervention|Only lactating allowance|Mothers will receive only lactating allowance
3485407|NCT03753633|Experimental|Speech therapy Group|25 patients will be treated with speech therapy, once a week, during 40 minutes for 12 weeks. Oropharyngeal exercises will be performed under the supervision of a speech therapist. Patients will perform the oropharyngeal exercises at home every day.
3128205|NCT03135015|Other|Lean Participants|Participants with BMI >18.5 and <25.0kg/m²
3485408|NCT03753633|Sham Comparator|Control Group|25 patients will perform inspiratory and expiratory exercises recruiting diaphragmatic muscle.
3485409|NCT03753620|Experimental|Music listening|The participants listens to their favorite emotional musical extracts. While listening, their Hemodynamic activity (with fMRI), their cerebral electric activity (with EEG) and their peripheral physiological parameters are recorded simultaneously
3485410|NCT03753594||H group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.5% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests at 5 min were assessed before the block and at 5-min intervals till 30 min after the block.
3128206|NCT03135015|Other|Overweight/Obese Participants|Participants with BMI ≥25.0 and <35.0kg/m²
3128207|NCT03135028|Experimental|ENTO monotherapy (Group A)|Participants with relapsed or refractory hematologic malignancies will receive ENTO twice daily of every 28-day cycle until participants meet treatment discontinuation criteria or do not experience clinical benefit.
3485411|NCT03753594||L group|Patients scheduled for elective knee arthroscopy with peripheral nerve block will receive ultrasound-guided femoral nerve block with 0.25% ropivacaine. Regional tissue oxygenation saturation of the nerve innervation area and pinprick sensory tests were assessed at 5 min before the block and at 5-min intervals till 30 min after the block.
3485412|NCT03753581|Experimental|Care protocol plus microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Intervention with microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer."
3485413|NCT03753581|Placebo Comparator|Care protocol plus placebo microcurrents|"Standardized protocol of nursing care: postural treatment plus standardized cure.~Placebo microcurrents: application of 2 electrodes (Mc Patch, Newmark USA) around the ulcer previously handled that do not emit current."
3485414|NCT03753568|Experimental|Study group|The participants use either direct oral anticoagulants or oral diabetic medication.
3485415|NCT03753555|Active Comparator|Routine-dose statin group|Routine-dose statin group will be gaven the treatment of atorvastatin 20mg Qd for 12 months
3485416|NCT03753555|Experimental|high-dose statin group|high-dose statin group will be gaven the treatment of atorvastatin 40-80mg Qd till 6 months at the moment the subjects will be followed up to determine plaques status by HRMRI examination, among which the subjects presenting culprit plaque progression with the significant increasing of plaque burden including intraplaque hemorrhage will be again randomized into two groups at a ratio of 1:1 as followed: atorvastatin-probucol group will be administrated atorvastatin 40-80mg Qd plus probucol 0.5g Bid till 12 months, the other group will maintain the original scheme till 12 months.
3485417|NCT03753542|Experimental|Intervention|The Intervention group will received multimedia education, booklet and weekly tele-nursing follow-up about chemotherapy and side effects management
3485418|NCT03753542|No Intervention|Control|The Control group will receive routine care
3485419|NCT03753529|Experimental|deep friction massage group|
3485420|NCT03753529|Experimental|pressure release group|
3128208|NCT03135028|Experimental|ENTO + cytarabine + daunorubicin (Group B)|"Lead-in (Cycle 0): Participants with previously untreated AML will receive ENTO twice daily for 14 days.~Induction (Up to 2 cycles): ENTO in combination with daunorubicin and cytarabine for up to two 28-day cycles.~Post-remission chemotherapy (at least 2 cycles, up to 4 cycles): Some participants (who have achieved complete remission [CR] or morphologic complete remission with incomplete blood count recovery [CRi] and do not require or cannot proceed to allogeneic stem cell transplantation [SCT] and participants who are awaiting a donor or transitioning to allogeneic SCT per investigator discretion) will have the option to receive post-remission chemotherapy with ENTO twice daily in combination with high-dose cytarabine (Hi-DAC) for up to four 28-day cycles."
3128209|NCT03135210|Active Comparator|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
3485421|NCT03753529|Experimental|control group|
3485422|NCT03753516|Active Comparator|Laparoscopic - Vaginal Cuff Closure|
3128210|NCT03135210|Experimental|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
3485423|NCT03753516|Active Comparator|Vaginal - Vaginal Cuff Closure|
3485424|NCT03753503|Experimental|PD-TR|"Intervention:~exercise, dose: 8-week HIIT program (three times a week) & conventional physical therapy"
3485425|NCT03753503|Active Comparator|PD-NTR|conventional physical therapy
3485426|NCT03753503|No Intervention|Healthy controls|healthy controls without any kind of therapy
3485427|NCT03753477|Experimental|Test Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)
3485428|NCT03753477|Active Comparator|Reference Drug|Sevikar and Crestor
3485429|NCT03753464||Peri-implantitis|Patients undergoing surgical treatment for peri-implantitis. Gingival and blood samples will be collected during the treatment for peri-implantitis.
3485430|NCT03753464||Healthy|Healthy patients undergoing treatment for either wisdom tooth extraction or gingivectomy. Gingival and blood samples will be collected during either wisdom tooth extraction or gingivectomy.
3485431|NCT03753451|No Intervention|Group 1|20 patients without periodontal disease and coronary artery disease
3485432|NCT03753451|No Intervention|Group 2|20 patients without periodontal disease and with coronary artery disease
3485433|NCT03753451|Active Comparator|Group 3|20 patients with periodontal disease and with coronary artery disease received treatment of periodontal disease
3485434|NCT03753451|Active Comparator|Group 4|20 patients with periodontal disease and without coronary artery disease received treatment of periodontal disease
3485435|NCT03753438||Intragastric Balloon|Intragastric Balloon will be placed for 6 months
3485436|NCT03753425||PEG4L, four liters polyethylene glycol|PEG4L, four liters polyethylene glycol
3485437|NCT03753425||PEG2L, two liters polyethylene glycol with ascorbic acid|PEG2L, two liters polyethylene glycol with ascorbic acid
3485438|NCT03753425||Pico, sodium picosulfate|Pico, sodium picosulfate
3485439|NCT03753425||NaP, sodium phosphate|NaP, sodium phosphate
3485440|NCT03753425||MPS, sodium, magnesium and potassium sulphates|MPS, sodium, magnesium and potassium sulphates
3485441|NCT03753399|Experimental|High-dose acupuncture|Acupuncture for 7 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
3485442|NCT03753399|Experimental|Low-dose acupuncture|Acupuncture for 3 times every 3 weeks (a cycle of chemotherapy) for 9 weeks
3485443|NCT03753399|No Intervention|Usual care|Chemotherapy without acupuncture
3485444|NCT03753386|Experimental|Healthy subjects|Subjects not presenting any pulmonary pathology that will follow the intervention Oxygen therapy simulation.
3485445|NCT03753360|Other|Intervention Group|internet-based mindfulness meditation program
3485446|NCT03753360|Other|Active Control Group|relaxing music
3485447|NCT03753347|Experimental|influenza vaccine recipients|Participants of an earlier clinical trial (TITRE I) to receive one dose of the 2018-19 quadrivalent inactivated influenza vaccine
3485448|NCT03753334|Experimental|MAG-EPA group|5g/day of omega-3-rich fish oil capsules, which include 4g of purified EPA, to be taken once a day, for 12 months.
3485449|NCT03753334|Placebo Comparator|Placebo group|5g/day of high-oleic sunflower oil capsules, to be taken once a day, for 12 months.
3485450|NCT03753321|Experimental|Whey protein|Whey protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
3485451|NCT03753321|Experimental|Soy protein|Soy protein isolate supplementation (7 day pre-loading phase and 3 day training phase). The protein dose will be individually adjusted to reach a total protein intake of 1.5 g protein/kg body mass/day.
3485452|NCT03753321|Placebo Comparator|Placebo (maltodextrin)|Isoenergetic, maltodextrin (7 day pre-loading phase and 3 day training phase)
3485453|NCT03753308||1a, HBV patients / no scheduled biopsy|"Intervention : Blood Sampling~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral"
3485454|NCT03753308||1b, HBV patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~HBsAg positive for more than 6 months~known status of HBeAg (positive or negative)~Treated or not with an antiviral~Patient with a liver biopsy indication as part of the treatment within 3 months."
3485455|NCT03753308||2, NASH patients / with scheduled biopsy|"Intervention : Liver biopsy~Eligibility criteria :~Male or female, Age of 18 or older, Weight over 40kg~Surveyed as part of their usual care in Hepato-Gastroenterology clinic at CHUGA~Patients who signed a non-opposition~Patient affiliated to social security insurance~The existence of at least one element of metabolic syndrome~Steatosis detected by non-invasive tests (echo, CAP, MRI)"
3485456|NCT03753308||3, Blood samples from healthy donors|"No subject will be included in this group, the samples have been already collected at EFS from healthy donors who had previously given their informed consents for using their blood samples in the research.~The blood samples have been collected in sufficient quantity to carry out the analyzes (20mL from each donor)."
3485457|NCT03753295||Group I (normal subjects)|30 individuals (15 male, and 15 female students) with (BMI<25 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
3485458|NCT03753295||Group II (overweight subjects)|30 individuals (15 male, and 15 female students) with (BMI, 25-30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
3485459|NCT03753295||Group III (obese subjects)|30 individuals (15 male, and 15 female students) (BMI>30 kg/m2). Hand grip force will measured using Baseline Hydraulic Hand Dynamometer.
3485460|NCT03753282||Population 1|Patients with a first AVN-related contact (initial or confirmed diagnosis) at the Universitätsspital Basel (USB) or Kantonsspital Basel-Liestal (KSBL) in the years between 1999-2006 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
3485461|NCT03753282||Population 2|Patients with a THA because of AVN in the years 2000-2007 (being assessed by questionnaires for patient reported outcome and questionnaire for course of the disease)
3485462|NCT03753269|Experimental|Fasudil Hydrochloride|Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
3485463|NCT03753269|Placebo Comparator|Placebo saline|Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
3485464|NCT03753256|Active Comparator|Transbond XT|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive a bonding primer (Transbond XT) The investigators will evaluate in this arm~the development of demineralization~its adverse effects after application"
3485465|NCT03753256|Experimental|Protecto®CaF2Nano|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Protecto®CaF2Nano).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
3485466|NCT03753256|Experimental|Pro Seal®|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Pro Seal®).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
3485467|NCT03753256|Experimental|Opal® Seal|"Application of different orthodontic surface sealants to participants:~Randomly assigned quadrants in this arm will receive an orthodontic surface sealant (Opal®Seal).~The investigators will evaluate in this arm~its abrasion behavior and the development of demineralization~its adverse effects after the application"
3485468|NCT03753243|Experimental|Intervention|Treatment will be planned for a total of 14 to 16 weeks. Pembrolizumab will be administered every 3 weeks via IV infusion with a dose of 200 mg per infusion. Enzalutamide will be given orally and dispensed to the patient on the date of their first infusion. The dosage of Enzalutamide will be 160 mg, administered once daily for approx. 16 weeks. GNRH agonist therapy will be administered as a standard of care therapy and will follow a standard dosage to maintain castrate levels.
3485469|NCT03753230|Experimental|EEG Device 1|Participants are listening to music while their neural activity is recorded with Emotiv Epoc+
3485470|NCT03753230|Experimental|EEG Device 2|Participants are listening to music while their neural activity is recorded with g.tec
3485471|NCT03753230|Active Comparator|High density EEG|Participants are listening to music while their neural activity is recorded with high density 256 electrodes EEG Geodesic
3485472|NCT03753217|Experimental|qCON Monitor|Simultaneous measurement of BIS and qCON
3485473|NCT03753191|Experimental|People with Dementia|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. A 2mA direct current for active tDCS (current density : .057 mA/cm2) with a 20 mins stimulation period
3485474|NCT03753191|Sham Comparator|Health Control|Twenty subjects each group will be randomized to receive either anodal tDCS or shame tDCS over the Right iFG or Left DLPFC. After a fade in period of 10s to mimic initial tDCS peripheral skin sensations, the stimulator will be turned off in order to prevent the induction of any neuromodulatory effect.
3485475|NCT03753165|Experimental|High Intensity Interval Exercise group|Patients suffering from chronic low back pain perform 12 sessions of high intensity interval exercise (HIIE) over a period of 6 weeks at an intensity of 80% of their maximal Heart rate. In addition they also receive conventional physiotherapy in the form of hot pack or TENS
3485476|NCT03753165|No Intervention|Conventional physiotherapy|Patients suffering from chronic low back pain will receive conventional physiotherapy such as TENS and hot packs applied over appropriate areas over a period of 6 weeks
3485477|NCT03753152|Experimental|Investigational medical device|Neuramis® Deep Lidocaine
3485478|NCT03753152|Active Comparator|Comparator device|YVOIRE® Volume Plus
3485479|NCT03753139||Atrial fibrillation|Patients with atrial fibrillation as recorded by Holter
3485480|NCT03753139||Sinus rhythm|Patients with sinus rhythm as recorded by Holter
3485481|NCT03753126|Other|Cardiac CT imaging|
3485482|NCT03753100|Active Comparator|Periprosthetic BMD; anterolateral approach|Periprosthetic bone mineral density will be measured using a DXA scanner from GE Lunar Prodigy. The initial scan was performed post-operatively during hospitalization
3485483|NCT03753100|Active Comparator|Periprosthetic BMD; lateral approach|Periprosthetic bone mineral density will be measured using DXA scanner from GE Lunar Prodigy.The initial scan was performed post-operatively during hospitalization.
3485484|NCT03753087|Experimental|Empagliflozin|Patients will receive standard care for Heart Failure and Diabetes Mellitus + Empagliflozin 10mg once daily
3485485|NCT03753087|Active Comparator|Control|Patients will receive standard care for Heart Failure and Diabetes Mellitus with no SGLT-2 inhibitors
3485486|NCT03753061|Experimental|Aspiration Catheter|Mechanical thrombectomy with Aspiration Catheter.
3485487|NCT03753061|Active Comparator|Stent Retriever (Solitaire FR)|Mechanical thrombectomy with Solitaire FR.
3485488|NCT03753048|Active Comparator|Y-Graft|The group includes patients who underwent CABG in Y-Graft Configuration.
3485489|NCT03753048|Active Comparator|In-Situ|The group includes patients who underwent CABG in In-Situ Configuration.
3485490|NCT03753035||epileptic children|Completion of questionnaire, during medical consultation, on compliance and quality of life
3485491|NCT03753022|Sham Comparator|Group G5|Patients submitted to CABG and peep 5
3485492|NCT03753022|Experimental|Group G10|Patients submitted to CABG and peep 10
3485493|NCT03753022|Experimental|Group G15|Patients submitted to CABG and peep 15
3485494|NCT03753009||iontophoretic transepithelial corneal cross-linking (I-ON CXL)|Twenty eyes of 15 patients with keratoconus (mean age 13±3.5 [SD] years, range 9 to 18) underwent Iontophoresis epi-on CXL
3132741|NCT03448068|Active Comparator|Standard Therapy|"Calculation ideal body weight (IBW)~Pre-op dexamethasone~Pre-op midazolam at discretion of anesthesiologist~Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~Other post-op care as per usual surgical routine"
3485495|NCT03753009||epithelium-off collagen cross-linking (epi-off CXL)|Twenty eyes of 13 patients with keratoconus (14±4 [SD] years, range 10 to 18) underwent standard epi-off CXL
3485496|NCT03752996|Experimental|ACURATE TF™ Aortic Valve System|ACURATE TF™ Aortic Valve System is intended for subjects with severe symptomatic Aortic Stenosis and considered high risk for surgical conventional Aortic Valve Replacement .
3485497|NCT03752983||cases|patients with SLE
3485498|NCT03752983||controls|Healthy people
3485499|NCT03752944|Experimental|prebent plate|fixation of le fort I osteotomy using prebent plate
3485500|NCT03752944|Active Comparator|Conventional four miniplates|fixation of le fort I osteotomy using conventional four miniplates
3485501|NCT03752931|Active Comparator|Celiprolol|receiving 1 tablet per day of celiprolol (Celiprol®) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
3485502|NCT03752931|Active Comparator|Diltiazem|receiving 1 capsule per day of diltiazem (Monotildiem® LP) 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobectomy for 2 weeks.
3485503|NCT03752918|Experimental|MDMA|MDMA (1.5mg/kg)
3485504|NCT03752918|Placebo Comparator|Niacin|Niacin (250mg)
3485505|NCT03752905|Experimental|PTR-01 0.1 mg/kg|Three intravenous infusions of PTR-01 at 0.1 mg/kg with doses 2 weeks apart.
3485506|NCT03752905|Experimental|PTR-01 0.3 mg/kg|Three intravenous infusions of PTR-01 at 0.3 mg/kg with doses 2 weeks apart.
3485507|NCT03752905|Experimental|PTR-01 1.0 mg/kg|Three intravenous infusions of PTR-01 at 1.0 mg/kg with doses 2 weeks apart.
3485508|NCT03752905|Placebo Comparator|Normal Saline|Saline control to mimic PTR-01.
3485509|NCT03752905|Experimental|PTR-01 3.0 mg/kg|Three intravenous infusions of PTR-01 at 3.0 mg/kg with doses 2 weeks apart.
3485510|NCT03752892|Experimental|intervention -1-leg cycle training|Primary aerobic training component one-legged, partitioned, cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity one-legged exercise progressing to continuous duration of the target duration of 15 min for each leg and then restarting the cycle at a higher intensity.
3485511|NCT03752892|Active Comparator|usual care - 2-leg cycle training|Primary aerobic training component conventional two-legged cycle training. A progressive approach to combined intensity and duration will be taken. A cycle starting with intermittent high intensity exercise progressing to continuous duration of 30 min and then restarting the cycle at a higher intensity.
3485512|NCT03752879||Case (Kristaller Group)|Group of kristeller maneuver applied in the second stage of labor due to clinical necessity.
3485513|NCT03752879||Control (no Kristaller Group)|The control group not required to kristeller maneuver
3485514|NCT03752853|Experimental|iCBT for depression - behavioral activation first (BAF)|internet-based intervention for mild to moderate depression: patients receive behavioral activation first, followed by cognitive restructuring
3485515|NCT03752853|Experimental|iCBT for depression - cognitive restructuring first (CRF)|internet-based intervention for mild to moderate depression: patients receive cognitive restructuring first, followed by behavioral activation
3485516|NCT03752840|Experimental|Screening|
3485517|NCT03752840|Active Comparator|Case detection|
3485518|NCT03752827|Experimental|Adipose Derived Regenerative Cells|Adipose-derived regenerative cell injection into the area of the supraspinatus tendon tear
3485519|NCT03752827|Active Comparator|Corticosteroid|Subjects in the active control arm will receive a corticosteroid injection into the subacromial space using ultrasound (US) guidance.
3485520|NCT03752814|Experimental|SYNOSTE Nitinail System|The intended purpose of the SNS in this trial is lengthening of the femur by callotasis.
3485521|NCT03752788|Experimental|Dual-task Training Fixed Priority|"Dual-task Training with fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
3485522|NCT03752788|Active Comparator|Dual-task Training Variable Priority|"Dual-task Training with variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
3485523|NCT03752775|Experimental|subacute device assisted group|
3485524|NCT03752775|Active Comparator|subacute conventional group|
3485525|NCT03752775|Other|chronic device assisted group|
3485526|NCT03752762|No Intervention|Standard Care|Participants will receive standard health care services provided by the Health Secretary
3485527|NCT03752762|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive SQ-LNS supplement from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits and group sessions. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
3485528|NCT03752749|Experimental|Prednisolone + Acute Intermittent Hypoxia|
3485529|NCT03752749|Placebo Comparator|Placebo + Acute Intermittent Hypoxia|
3485530|NCT03752736|Active Comparator|Extended intervention|"Upon completion of the two-week baseline period and two-week standard intervention period, the two classrooms assigned to the Extended intervention condition will receive the I wear sunscreen everyday song-based video intervention daily for two additional weeks."
3485531|NCT03752736|No Intervention|Maintenance|"The two classrooms assigned to the Maintenance condition will continue to receive a two- minute window for sunscreen application, but no I wear sunscreen everyday song-based video instruction.~Change trajectories from Time 3-Time 4 (two-week follow up) will be compared by follow-up assignment condition and will provide preliminary information about dosing and maintenance effects."
3485532|NCT03752723|Experimental|combination with CPA, GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: CPA, GX-I7 and pembrolizumab"
3485533|NCT03752723|Experimental|combination with GX-I7, and pembrolizumab|"Experimental: combination~Assigned interventions: GX-I7 and pembrolizumab (without CPA)"
3485534|NCT03752697||Neurological injury|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
3485535|NCT03752697||Healthy control|Paper and pencil/computerized assessments of cognitive functioning and metacognitive performance will be administered.
3485536|NCT03752671|Experimental|the IntraSPINE® device associated with discectomy|
3485537|NCT03752671|Active Comparator|discectomy alone|
3485538|NCT03752658||Tenofovir alafenamide (TAF)|Male or female HBeAg positive or negative patients (above 18 years of age) who were mono-infected with HBV, either NA treatment-naïve or treatment-experienced, but TAF naïve will be enrolled in this study, and they will be treated with TAF, alone or in combination with anti-HBV agents.
3485539|NCT03752645|Experimental|intervention|Transverse Many Channels Laser Instrument
3485540|NCT03752645|No Intervention|control|
3485541|NCT03752632|Experimental|Veinplicity with tourniquet (treatment)|Veinplicity with tourniquet
3485542|NCT03752632|Active Comparator|Tourniquet (control)|Control: Tourniquet
3485543|NCT03752606|Active Comparator|TACHOSIL GROUP|Surgical procedures were performed by four doctors with extensive experience in oncological gynecology. A TachoSil® absorbable patch of 4.8x4.8 cm was attached, once, intraoperatively to one side of the obturator fossa (study group). Specific drainage of the retroperitoneum was performed.
3485544|NCT03752606|No Intervention|GROUP WITHOUT TACHOSIL|The same patient constituted also control group, because no TachoSil® absorbable patche was used on the second side of lymphadenectomy. Specific drainage of the retroperitoneum was performed.
3485545|NCT03752593||Obese|Patients with a BMI of greater than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
3485546|NCT03752593||Non-Obese|Patients with a BMI of less than 30 who are presenting to the hospital for any surgical procedure requiring general anesthesia
3485547|NCT03752580|Experimental|Arm|Experimental: User Instructions of a Novel Nasal Mask Participants to interpret user instructions in a one hour daytime visit.
3485548|NCT03752541|Experimental|BCMA-UCART|Each subject will accept one of the following dosages of BCMA-UCART cells intravenously (IV) on day 0: 0.5-1*10~6/KgBW, 1-2*10~6/KgBW,2-3*10~6/KgBW.
3132742|NCT03448224|Experimental|Group I (web-based Indoor Tanning intervention)|Participants receive intervention, weekly text messages about IT reduction, and personalized booster intervention. Participants then receive text messages twice weekly for 4 weeks.
3132743|NCT03448224|Active Comparator|Group II (wait-list)|Participants are placed on wait-list and may receive full intervention after follow-up.
3485549|NCT03752515||case|
3485550|NCT03752515||control|
3132744|NCT03448406|Experimental|Empagliflozin|
3132745|NCT03448406|Active Comparator|Placebo|
3485551|NCT03752502|Experimental|Cerebral stimulation|"Active transcranial direct current stimulation~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
3485552|NCT03752502|Experimental|Combined stimulation|"Active transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
3485553|NCT03752502|Sham Comparator|Sham cerebral stimulation|"Sham transcranial direct current stimulation combined with active peripheral electrical stimulation (PES)~tDCS: 20 minutes (30s ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
3485554|NCT03752502|Experimental|Peripheral stimulation|"Active peripheral electrical stimulation (PES).~PES: 20 minutes, 10Hz (frequency), 100µs (pulse duration), intensity at sensorial level."
3485555|NCT03752489|Experimental|Fluid treatment-specific algorithm|The experimental arm will involve patients monitored by the fluid treatment-customized version of InSight.
3485556|NCT03752489|Active Comparator|Standard InSight|The control arm will involve patients monitored with the standard, non-treatment specific version of InSight.
3485557|NCT03752476||case|Patients are colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
3485558|NCT03752476||control|Patients aren't colonized patient by antimicrobial bacteria hospitalized in intensive care during the fist hospitalization in intensive care during 2016-2017.
3485559|NCT03752463|Experimental|DAOI-A group|
3485560|NCT03752463|Experimental|DAOI-B group|
3485561|NCT03752463|Experimental|DAOI-C group|
3485562|NCT03752463|Placebo Comparator|Placebo group|
3485563|NCT03752437|Experimental|Real Weight|Injection of 300 IU of heparin based on REAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
3485564|NCT03752437|Experimental|Ideal Weight|Injection of 300 IU of heparin based on IDEAL weight. This injection will be controlled by an ACT (activated clotting time) one minute after the injection.
3128215|NCT03135379|Experimental|Heated gel|Patient undergoes ultrasound study using the intervention of heated ultrasound gel.
3485565|NCT03752424|Active Comparator|Silver nanoparticles group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms.
3485566|NCT03752424|Placebo Comparator|Topical approved anti-microbial gel|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream.
3128216|NCT03135379|Placebo Comparator|Room temperature gel|Patient undergoes ultrasound study using the intervention of room temperature gel.
3128217|NCT03135431|Experimental|Salpingectomy|Bilateral salpingectomy following cesarean delivery
3128218|NCT03135431|Active Comparator|Tubal Ligation|Bilateral tubal ligation following cesarean delivery via Parkland or modified Pomeroy methods.
3128219|NCT03135522|Active Comparator|Zinc Acetate 50 mg oral capsule|50 mg zinc acetate oral capsules, over-encapsulated, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
3485567|NCT03752411|Experimental|Research Bottle|This group will have medication dispensed in a research bottle.
3485568|NCT03752411|Placebo Comparator|Regular prescription Bottle|This group will have medication dispensed in a regular prescription bottle
3485569|NCT03752398|Experimental|XmAb®23104 Monotherapy|XmAb®23104 administered by IV dosing on Days 1 and 15 of each 28-day cycle x 2 cycles
3132746|NCT03448419|Experimental|Empagliflozin|
3132747|NCT03448419|Placebo Comparator|Placebo|
3485570|NCT03752398|Experimental|XmAb®23104 Combination Therapy with Ipilimumab|XmAb®23104 administered by IV on Days 1 and 15 of each 28-day cycle x 2 cycles + Yervoy® (ipilimumab)
3485571|NCT03752385|No Intervention|Control Group|No intervention
3485572|NCT03752385|Experimental|Intervention Group|"Will cut their smartphone screen time in half, sleep without phone in bedroom, and have a bedtime for their phone use."
3485573|NCT03752372||HSCT cohort|IL10RA-deficient patients who received hematopoietic stem cell transplantation
3485574|NCT03752359|Experimental|whey protein group|Participants received a dose of 35 grams of whey protein after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
3485575|NCT03752359|Placebo Comparator|placebo group|Participants received a dose of 35 grams of maltodextrin after resistance training (RT). Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps push-down, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
3485576|NCT03752346|No Intervention|control group|Control group maintained their regular lifestyle and received the routine care
3485577|NCT03752346|Experimental|exercise group|Participants in the exercise group (EG) were instructed to engage performed exercise at least 3 times per week (30-50 minutes) or 10-15 minutes per section every day to accumulate 150 minutes per week for 8 weeks using disc (DVD) at home. Main exercise was moderate intensity aerobic exercise, an intensity of 55-70% of the heart rate reserve (HR max).
3485578|NCT03752333|Experimental|Pembrolizumab|All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
3485579|NCT03752320||POP+ and POP-|POP+: patients with postoperative pneumonia POP-: patients without postoperative pneumonia
3485580|NCT03752307|Experimental|Corticosteroid & Isoxsuprine HCL|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive days and Isoxsuprine Hydrochloride one 10 mg Capsule 3 times daily for 5 consecutive days
3485581|NCT03752307|Placebo Comparator|Corticosteroid & Placebo|Corticosteroid pulse of either daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon for 3 to 5 consecutive day and placebo one Capsule 3 times daily for 5 consecutive days
3485582|NCT03752294|Active Comparator|Dabigatran|Participants will receive 150mg dabigatran daily for a total of 9-months.
3485583|NCT03752294|Placebo Comparator|Placebo|Participants will receive placebo daily for a total of 9-months.
3485584|NCT03752294|Active Comparator|Open Label|All study participants are assigned to receive 150mg dabigatran daily for a total of 12 months (study month 9 through month 21)
3485585|NCT03752281||Health and activity|The cohort consists of long-term social assistance recipients where there is need to investigate the health status and working ability.
3485586|NCT03752268|No Intervention|Enhancing Cancer Pain Management Part 1|"Will collect information from participants via self-report assessment at two time points: at baseline (i.e. study enrollment) and approximately 8 weeks post-baseline~Will then use MEMS to monitor LA opioid intake over approximately 8 weeks~A subset of enrolled participants (n=20) will be invited to participate in an optional one-time qualitative exit interview with a study staff member trained in conducting qualitative interviews"
3485587|NCT03752268|Experimental|Enhancing Cancer Pain Management Part 2|"Enhancing Cancer Pain Management will consist of 3 individual manualized sessions~The 3 individual manualized sessions will be conducted (approximately 20 minutes each), led by a nurse practitioner, to provide sufficient dose for change in adherence behaviors.~Learning and practicing skills for managing cancer-related pain and adhering to prescribed LA opioid regimens.~Study staff will provide participants with MEMS caps and bottles at time of enrollment, to monitor LA opioid intake over approximately 14 weeks."
3485588|NCT03752255|Experimental|Anxiety measurement method|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). Then patients will watch a video about impacted tooth. This video will include the complications that patients may face and what should be done after the procedure. After the watching the video, patients will fill the both DAS and STAI.
3485589|NCT03752255|Placebo Comparator|Control|Before the operation, patients in the experimental group will fill the anxiety scales (DAS and STAI). The verbal information in detail will be given to the patients by the surgeon.This verbal information will include the complications that patients may face and what should be done after the procedure.
3485590|NCT03752242|Experimental|BMX-010 0.03%|Approximately 30 subjects will receive BMX-010 0.03% for 7-28 days to be applied topically to Acne of the face.
3485591|NCT03752242|Experimental|BMX-010 0.1%|Approximately 30 subjects will receive BMX-010 0.1% for 7-28 days to be applied topically to Acne of the face.
3485592|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 610|
3485593|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 553-556|
3485594|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 430|
3485595|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 420|
3485596|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 520|
3485597|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 450|
3485598|NCT03752229|Experimental|HTL-STREFA S.A.safety lancet type 545-549|
3485599|NCT03752229|Experimental|Owem Mumford lancet|
3485600|NCT03752229|Experimental|Medicore lancet|
3485601|NCT03752229|Experimental|Arkray lancet|
3485602|NCT03752229|Experimental|Medipurpose lancet|
3485603|NCT03752229|Experimental|Sterilance lancet|
3485604|NCT03752229|Experimental|Dynarex lancet|
3485605|NCT03752229|Experimental|Ypsomed lancet|
3485606|NCT03752229|Experimental|Promismed lancet|
3485607|NCT03752229|Experimental|Cambridge Sensors lancet|
3485608|NCT03752216|Experimental|NIRAPARIB|Oral Niraparib Daily
3485609|NCT03752203|Experimental|Sodium-Fluorescein Resection|This study will employ the use of sodium fluorescein and an FDA approved operative microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
3485610|NCT03752190|Experimental|Intravenous and intramuscular administration|Subjects will receive intravenous and intramuscular ACTH on different days
3485611|NCT03752164|Experimental|Yoga and Mindfulness|An intervention consisting of one session lasting 30 minutes where a certified yoga instructor teaches the children gentle yoga and mindfulness skills.
3485612|NCT03752138|Experimental|Group 1 Part 1 TK216: Days 1-7|Patients receive TK216 IV continuously on days 1-7 every 21 days.
3485613|NCT03752138|Experimental|Group 2 Part 1 TK216: Days 1-7 and 15-28|Patients receive TK216 IV on days 1-7 and 15-21 every 28 days.
3485614|NCT03752138|Experimental|Part 2 TK216 + Decitabine 10mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
3485615|NCT03752138|Experimental|Part 2 TK216 + Decitabine 20 mg/m2|Patients receive recommended dose of TK216 from Part 1 plus Decitabine.
3485616|NCT03752138|Experimental|Expansion Phase: TK216 + Decitabine|All patients in the expansion cohort will receive the RP2D of TK216 and Decitabine.
3485617|NCT03752125|Experimental|Flavonoid, caffeine|Flavonoid, caffeine capsules
3485618|NCT03752125|Placebo Comparator|Placebo|Placebo capsules
3485619|NCT03752112|Experimental|Cefixime|cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection.
3485620|NCT03752112|Other|Benzathine penicillin|To benchmark the performance of benzathine penicillin in the study population being used for cefixime, the investigators will include a contemporary arm of participants that will receive standard of care treatment with benzathine penicillin according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.
3485621|NCT03752086|Experimental|Greater omentum binding|Bind greater omentum to pancreatic stump after distal pancreatectomy
3485622|NCT03752086|Experimental|Pancreatic stump exposed|pancreatic stump exposed without binding greater omentum after distal pancreatectomy
3485623|NCT03752073|Experimental|Trans-cervical cervical balloon|17 F non-latex Foley catheter will be placed and balloon filled with 30 cc of sterile normal saline.
3485624|NCT03752073|Experimental|Hygroscopic cervical dilators|Dilapan-S hygroscopic dilators will be placed into the cervix at the level of the internal os.
3485625|NCT03752060|Experimental|Resistance Training Group|These participants will participate in a progressive resistance training program three times per week on non-consecutive days for 16 weeks. During each session, participants will perform the following exercises: supine bench press, lat pulldown, lateral raise, seated row, leg press, leg extension, leg curl, biceps curl, and triceps extension. The exercises will be completed such that upper body and lower body exercises are alternated throughout each session. During the Weeks 1-4 of training, the subjects will complete two sets of 15 repetitions for each exercise at approximately 50% of their one-repetition maximum (1RM). During Weeks 5-8 of training, the subjects will complete three sets of 12 repetitions at approximately 60% 1RM. During Weeks 9-12, the subjects will complete four sets of 12 repetitions at approximately 60% 1RM. During Weeks 13-16 of training, the subjects will complete 4 sets of 10 repetitions at approximately 70% 1RM.
3485626|NCT03752060|Active Comparator|Aerobic Training Group|Women randomized to the AT group will engage in aerobic exercise training that complies with ACSM recommendations10. Specifically, women will complete walking or stationary cycling sessions 5 times per week for 16 weeks. Heart rate data from the pre-intervention VO2peak tests (described below) will be used to estimate each participant's target training heart rate. Like the RT regimen, the AT intervention will be progressive in nature. During the first half of the intervention period, duration will increase by 5 minutes every 2 weeks, from 30 min to 45 min. In the second phase of the intervention, duration will remain constant at 45 min, but intensity will increase from 50% to 65% of heart rate reserve (HRR). Exercise sessions will take place on a treadmill and/or cycle ergometer.
3485627|NCT03752060|No Intervention|Control Group|The control group will complete all baseline and post-testing, but will not complete any training for the 16 weeks between the baseline and post-testing sessions. These participants will also be instructed to maintain their current dietary and physical activity habits (see Lifestyle Controls section). All participants in the control group will also be provided an opportunity to come to the laboratory for two weeks after they have completed the study to receive instruction regarding resistance and/or aerobic training exercise prescription, and to complete supervised resistance and/or aerobic exercise training.
3485628|NCT03752034|Experimental|Muscle Fiber Fragments (MFF)|Participants undergoing rotator cuff repair will have autologous muscle tissue harvested. The tissue will be processed to obtain Muscle Fiber Fragments (MFFs) and administered via direct injection into the supraspinatus muscle belly.
3485629|NCT03752021||Laboring Subjects|Subjects with a planned cesarean delivery who labor prior to their scheduled date or those who are in labor and require an unplanned but non-emergent cesarean delivery. These subjects will be approached upon admission to the study facility by the researcher for potential enrollment to allow adequate time to consider participation, ask questions, provide consent, and prior to procedure (Myometrial Sampling).
3485630|NCT03752021||Non Laboring Subjects|Subjects with a planned cesarean delivery will be approached by the researcher during prenatal visits or at the study facilities prior to planned procedure (Myometrial Sampling)
3485631|NCT03752008|Experimental|Active Play (AP)|This arm received the Active Play curriculum intervention (described in following section).
3485632|NCT03752008|Experimental|Outdoor Play (OP)|This arm received the Outdoor Play curriculum intervention (described in following section).
3128220|NCT03135522|Placebo Comparator|Placebo oral capsule|Placebo matched to zinc acetate 50 mg oral capsule active arm, administered starting at 1 capsule/day and escalated to 3 capsules/day by Day 8 post-randomization (if tolerated)
3128221|NCT03135535|Experimental|Avex Footbeat|Subjects will receive a new pair of diabetic shoes with BOA shoelace closure and a pair of AVEX Footbeat insoles, which include a micro-mobile compression pump. The entire system is named 'intervention shoes' for simplicity. They will be instructed to wear the intervention shoes on daily basis for 4 weeks for duration of at least 4 hours per day.
3485633|NCT03751995|No Intervention|Control|Participants from medical centers assigned to the control arm will receive usual care.
3485634|NCT03751995|Experimental|Intervention|Participants from medical centers assigned to the intervention arm will receive access to their choice of a mindfulness app or a webinar-based mindfulness course for 6 weeks.
3485635|NCT03751982|Active Comparator|Open-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is not synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
3485636|NCT03751982|Experimental|Closed-Loop|In this arm of this repeated measures (within subjects) design, the participants receive electrical neuromodulation (TES) that is synchronized to their slow waves of sleep. The Transcranial Electrical Stimulation (TES) is 2 mA applied in 100 ms pulses at 0.75 Hz.
3485637|NCT03751969|Experimental|HSK3486|"0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg)~."
3485638|NCT03751956|Experimental|HSK3486|0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection
3485639|NCT03751943|Other|NanoFuse® PL Gutter|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%) within one posterolateral gutter (unilateral)
3485640|NCT03751930||Patients with Autism Spectre Disorders|Taken biological samples on patients with Autism Spectre Disorders
3485641|NCT03751930||Healthy volunteers|Taken biological samples on patients healthy volunteers
3485642|NCT03751917||APL patients|The study will be conducted using multinational data from disease registries for APL. The study participants will consist of patients with newly diagnosed, low-to intermediate-risk APL.
3485643|NCT03751904|Other|AcoustiCare|Single Arm
3485644|NCT03751891|Experimental|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
3485645|NCT03751891|Active Comparator|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_A which will be fitted to the participants individual Hearing loss.
3485646|NCT03751891|Active Comparator|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid with direct connectivity functionality from manufacturer_B which will be fitted to the participants individual Hearing loss.
3128222|NCT03135548|Experimental|Spesolimab (low dose)|
3128223|NCT03135548|Experimental|Spesolimab (high dose)|
3485647|NCT03751878|Experimental|Intervention arm|Evaluation of reporting inconsistencies between the CONSORT checklist and the information reported in the manuscript. Feedback is provided to authors.
3485648|NCT03751878|Other|Control arm|Standard peer review process.
3485649|NCT03751865|Experimental|CBT group|This intervention aims for distress reduction, symptom coping, and life quality enhancement. It is a gender-specific CBT tailor-made for the at-risk population. The intervention is delivered by a registered clinical psychologist.
3485650|NCT03751865|Active Comparator|Psychoeducation group|The content of the psycho-education program will be related to healthy living content and mental health knowledge, such as food hygiene, psychological well-being, knowledge about psychosis and common mental disorder and food nutrition. In addition, a weekly call to remind the subject about healthy living will also be provided to the subjects. The intervention is delivered by a registered social worker.
3485651|NCT03751852|Experimental|Exercise coaching group|This intervention is an integration of aerobic exercise, yoga, mindfulness and exercise coaching. Exercise class and coaching will be provided weekly in the first 8 weeks. In the next 8 week, exercise class will be provided weekly while exercise coaching will be provided bi-weekly. The exercise class includes aerobic exercise coached by a well-trained intervention officer, and the yoga and mindfulness coached by a certified yoga instructor. The exercise coaching session followed by some stretching and aerobic exercise session. Both motivational coaching and aerobic exercise will be coached by a well-trained intervention officer.
3485652|NCT03751852|Active Comparator|Psychoeducation group|This group is similar with the exercise coaching group while exercise coaching session will be substituted by psychoeducation session.
3485653|NCT03751839|Experimental|Diagnostic|The investigators will examine all participants in the same way by performing biochemical tests, clinical tests, osteodensitometry, HRQCT and HRpQCT measurements.
3485654|NCT03751826|Experimental|Incentivised network delivery HIV-ST|Peer-navigators will use respondent-driven sampling to distribute HIV-ST kits through 'seeds'. Each 'seed' (female aged 18-24 years) will receive a session on HIV prevention, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. Seeds will be asked to recruit females aged 18-24 years and given 5 uniquely numbered incentivized recruitment coupons with HIV-ST kits to pass on to their peers. Individual who return the coupons will undergo the same procedure as the seeds above and the individual who handed out the coupon will receive a sum of $1.5 in airtime per friend who returns the coupon. The packs include referral slips with information on how to link to HIV community-based confirmatory testing, HIV treatment and PrEP.
3485655|NCT03751826|Experimental|Peer Navigator distributed HIV-ST|Peer navigators will directly distribute HIV-ST kits to females aged 18-24 years over a period of six months. Each person recruited will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV-ST. The packs include referral slips with information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
3485656|NCT03751826|Active Comparator|Standard of care|Peer navigators will encourage females aged 18-24 years to test for HIV at clinics, and link to services/care. Each female aged 18-24 approached by a peer navigator will receive a session from the peer-navigator on the HIV prevention services available, the importance of sexual health, the benefits of HIV testing PrEP and ART, and a demonstration of HIV self-screening. They will then be given a referral slip for HIV testing through the clinic. The referral slips include information on how to link to community-based HIV confirmatory testing, HIV treatment and PrEP.
3485657|NCT03751813|Placebo Comparator|Placebo|placebo supplement
3128224|NCT03135548|Placebo Comparator|Placebo|
3128225|NCT03135899|Experimental|BI 443651|
3485658|NCT03751813|Experimental|Supplement|actual supplement
3485659|NCT03751800||Women with HMB|Women with a diagnostic of HMB according to medical criteria and based on clinical judgment that have freely chosen a chronic hormonal treatment under therapeutic indication of HMB in Spain
3485660|NCT03751787|Experimental|cranial osteopathy|The group will receive treatment with osteopathic cranial osteopathy
3485661|NCT03751787|Placebo Comparator|comfort massage|The group will benefit from a placebo manipulation by an osteopathic student who has not yet been trained in cranial osteopathy.
3485662|NCT03751774|Experimental|MAMAACT|Training of midwives in intercultural communication. A 6 hours course and 2 one hour booster sessions. Distribution of health education materials on warnings signs of pregnancy and health system navigation to pregnant women during antenatal care visits.
3485663|NCT03751774|No Intervention|Control|Care as usual
3485664|NCT03751761|Experimental|durvalumab, tremelimumab, paclitaxel|
3485665|NCT03751748|Sham Comparator|Control arm|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
3485666|NCT03751748|Experimental|AFR arm|Implantation of Occlutech atrial flow regulator (AFR) device
3485667|NCT03751735|Experimental|Dose 1|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up
3128226|NCT03135899|Placebo Comparator|Placebo|
3128227|NCT03136068|Experimental|Digoxin|Subjects assigned to the intervention arm will receive a 1 mg intrafetal digoxin injection under ultrasound guidance
3485668|NCT03751696|Experimental|Group coaching|There will be a total of 4 sessions of group coaching intervention within 8 weeks. Each session is in a group of 5-6 women and lasts for approximately 1-1.5 hours. The sessions will be conducted by experienced social workers online.
3485669|NCT03751696|Active Comparator|SMS Self-help tips|The participants in the control group will receive four self-help tips on mental well-being on the same schedule as the group coaching group.
3128228|NCT03136068|Placebo Comparator|Placebo|Subjects assigned to the control arm will receive an ultrasound-guided intrafetal saline injection of the equivalent volume
3128229|NCT03136107|Experimental|Test product|This arm will include all the test sites on the participants back where test product (Physiogel Daily Defence Protective Day Cream Light) will be applied.
3485670|NCT03751670|Experimental|PR+conventional treatment|Patients will be treated with daily medication prescribed by the physician. Additionally, patients will receive 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). PR will include breathing retraining and airway clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training, education and psychosocial support.
3485671|NCT03751670|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician.
3485672|NCT03751644|Experimental|Electrical stimulation|After local antisepsis, 4 electrodes will be placed at the proximal and distal extremities of the lateral and vastus medialis muscles of dominant limb. A positive, single-phase pulsating (intermittent) current with a rectangular waveform will be delivered with a duty cycle of 10 to 15 seconds shutdown at a frequency of 60 Hertz with a pulse width of 400 microseconds for 30 minutes. To control the degree of muscle activation, electrical stimulation will be administered at an intensity that will consistently produce a target torque equal to 15% of maximal voluntary contraction, as monitored in real time through torque output. The desired intensity of stimulation and intensity adjustments throughout the treatment will be evaluated in all patients.
3485673|NCT03751644|No Intervention|Placebo|Patients will not submitted to electrical stimulation.
3485674|NCT03751631|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
3485675|NCT03751631|Active Comparator|Phenylephrine|Phenylephrine 2.5% ophthalmic solution administered using a microdose dispenser
3128230|NCT03136107|Active Comparator|Reference product|This arm will include all the test sites on the participants back where reference product (ISO 24444:2010 P3 standard sunscreen) will be applied.
3128231|NCT03136107|No Intervention|Negative control|This arm will include all the test sites on the participants back which will be left unprotected.
3485676|NCT03751631|Active Comparator|Tropicamide|Tropicamide 1% ophthalmic solution administered using a microdose dispenser
3485677|NCT03751618|Experimental|Capsular suture|Capsular suture at the end of hip arthroscopy
3485678|NCT03751618|Active Comparator|No capsular suture|No capsular suture at the end of hip arthroscopy
3485679|NCT03751592|Experimental|Chlorogenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
3128232|NCT03136159|Experimental|Silver-impregnated antimicrobial dressing|All participants undergoing primary cesarean section will receive a silver impregnated antimicrobial wound dressing (Mepilex Border AG), postoperative.
3128233|NCT03136198|Experimental|LUS-guided strategy-of-care|Patients randomized to the LUS strategy of care arm will be treated according to protocol. This protocol only involves therapies used in everyday AHF clinical practice.
3128234|NCT03136198|Placebo Comparator|Usual care|Patients randomized to the usual care arm will also undergo lung ultrasound assessments. However, these results will not be revealed to the care team. Patients will receive treatment per usual, standard care.
3128235|NCT03136328|Experimental|68Ga-DOTATOC PET/CT|Study participants will receive 68Ga-DOTATOC and undergo a PET/CT imaging study.
3485680|NCT03751566|Active Comparator|Regimen A|Regimen A (control regimen): standard support treatment of adverse events of the radiotherapy.
3485681|NCT03751566|Experimental|Regimen B|Regimen B (acupuncture regimen): standard support treatment of adverse events of the radiotherapy and acupuncture.
3485682|NCT03751553|Experimental|obstetric gel group|they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel.
3485683|NCT03751553|No Intervention|no intervention group|they will receive the standard care during labor and delivery without the use of the obstetrical gel
3128236|NCT03136367|Experimental|Arm 1: Option Grid|Patients in this arm will receive the Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
3128237|NCT03136367|Experimental|Arm 2: Picture Option Grid|Patients in this arm will receive the Picture Option Grid for breast cancer surgery, an encounter decision aid, when they first meet with the breast surgeon to discuss their surgical options for breast cancer treatment.
3128238|NCT03136367|No Intervention|Arm 3: Usual Care|In the usual care arm, surgeons provided their standard information about breast cancer
3485684|NCT03751540||OSTAP|Data of patients (performed oblique subcostal transversus abdominis plane-OSTAP- block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
3485685|NCT03751540||SIPB plus rectus sheath block|Data of patients (performed serratus intercostal plane block-SIPB- plus rectus sheath block for postoperative analgesia in laparoscopic cholecystectomy) will be collected.
3485686|NCT03751527|Experimental|ZENFLEX stent Group|subjects applying ZENFLEX peripheral stent system
3485687|NCT03751514|Experimental|Phase A - SI|"Phase A aims to determine a 'standard inoculum' dose (SI), which results in safe colonisation of 70% of volunteers.~The SI will be identified in a dose escalating or de-escalating experiment commencing at 10-3 colony forming units B. pertussis administered intranasally. Each group of volunteers will be inoculated at half log-fold increasing/decreasing doses until the endpoint is reached. The experiment will be continued until the SI yields 10 subjects who are colonised at day 14.~Intervention to be administered: Bordetella Pertussis B1917"
3485688|NCT03751514|Experimental|Phase B Inoculum|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence. The final protocol for phase B will be presented as a protocol amendment, it will be based on the SI and colonisation period identified in Phase A.~The SI determined in phase A will be used for all volunteers and eradication therapy will be given after the colonisation period based on the data of phase A. Approximately 30 individuals will receive the intranasal SI and will be treated with azithromycin for three days at the end of the colonisation period.~Intervention to be administered: Bordetella Pertussis B1917"
3485689|NCT03751514|Experimental|Phase B Sham|"Phase B, using study data from phase A, will be used to design a more practical model - if possible conducted partially in an outpatient setting, which will be conditional on safety and transmission evidence.~Approximately 15 individuals will not receive the Bordetella Pertussis B1917, instead they will be given an intranasal sham of sterile saline and will be treated with azithromycin 500mg for three days at the end of the 'colonisation' period."
3485690|NCT03751501|Experimental|Experimental Group|Indocyanine green-Guided Targeted Laser photocoagulation combines routine procedures, that are, the detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT. Indocyanine green-Guided Targeted Laser photocoagulation is administered in combination with anti VEGF treatment
3485691|NCT03751501|Sham Comparator|Control Group|Sham laser is administered at randomization visit and repeated if needed 3 month later in combination with anti VEGF treatment
3485692|NCT03751488|Experimental|LY03010 351mg|LY03010 at 351 mg
3485693|NCT03751488|Experimental|LY03010 156 mg|LY03010 at 156 mg
3485694|NCT03751488|Experimental|LY03010 117mg|LY03010 at 117mg
3485695|NCT03751488|Active Comparator|INVEGA SUSTENNA|INVEGA SUSTENNA 156mg
3485696|NCT03751475|Experimental|OptiMA|The enrolled subjects will follow the nutritional Optima strategy.
3485697|NCT03751475|Active Comparator|Control|The enrolled subjects will follow the standard nutritional protocol currently in use in the Democratic Republic of Congo
3128239|NCT03136380|Experimental|Part 1: Group A|Subjects will receive GSK1325756H 10 mg in P-1, GSK1325756H 50 mg in P-2 and placebo in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
3485698|NCT03751462|Experimental|Pseudoexfoliation syndrome|Patients with pseudoexfoliation syndrome or traumatic cataract will be examined using the Purkinjemeter device concerning IOL wobble, tilt and decentration
3485699|NCT03751449|Experimental|Group I (active treatment)|Participants complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
3485700|NCT03751449|Active Comparator|Group II (waitlist)|Participants are placed on a waitlist for 12 weeks and then complete a home-based aerobic and resistance exercise program and receive nutrition education for 12 weeks.
3485701|NCT03751436|Experimental|Treatment (venetoclax, enzalutamide)|Patients receive venetoclax PO QD and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3485702|NCT03751423|Active Comparator|PO Morphine & IV Placebo|One third of study participants will be randomized to this local standard of care arm.
3485703|NCT03751423|Active Comparator|IV Fentanyl & PO Placebo|One third of study participants will be randomized to this current gold standard of care arm.
3485704|NCT03751423|Experimental|IV Ketamine & PO Placebo|One third of study participants will be randomized to this experimental arm.
3485705|NCT03751384|Experimental|Capsules|Dietary Supplement: Möllers Omega-3 Ekstra Sterk
3485706|NCT03751384|Active Comparator|Drink|Dietary Supplement: Nutrifriend Cachexia
3485707|NCT03751371|Experimental|Walking Training with the HWA Device|Training with HWA device
3485708|NCT03751371|Other|Usual Care|Usual Care
3485709|NCT03751358|Experimental|Unilateral Erector spinae plane block|Thoracic unilateral Erector spinae plane block performed on the volunteer and analyse of the spread of local anesthetic by magnetic resonance imaging
3485710|NCT03751345|No Intervention|Treatment As Usual (TAU)|The TAU condition consists of the standard treatment elements offered to all Gateway (study site) patients, and will be received by patients in both the PW and the TAU-only condition. TAU services during the adolescent's treatment are typically eclectic and mainly entail meeting with the adolescent alone to provide support and psychoeducation, with occasional family therapy sessions. Medication management is offered as needed.
3485711|NCT03751345|Experimental|Parenting Wisely (PW)|In addition to TAU services, the PW arm includes in-person sessions where parents complete computer-administered PW sessions, in-person session including therapist coaching to reinforce PW material and personalize treatment by applying PW skills to individual issues, and access to PW material remotely so parents can access information and skills from home as needed.
3485712|NCT03751332|Other|Conversion from either CSA or TAC|Tacrolimus with modified galenic (tacrolimus MR4; Advagraf®) once daily. In patients treated with ciclosporin A, the initial dose will be 0.1 - 0.12 mg tacrolimus MR4 per kg of body weight per day with oral morning administration. In patients who are already treated with Prograf, the conversion to Advagraf will be performed in a 1:1 ratio.
3485713|NCT03751319|Active Comparator|Standard Emergency Care + CGA|Standard Care is provided for the acute condition as usual by the ED personnel. Besides the standard care provided by ED personnel, patients are systemically screened and assessed by physician trained for geriatrics or geriatric emergency medicine. Geriatric multi-discipline treatment plan and recommendations are given if suitable for the case.
3485714|NCT03751319|No Intervention|Standard Emergency Care|Standard Care is provided for the acute condition as usual by the ED personnel.
3485715|NCT03751306|Active Comparator|Control-Cardiorespiratory Rehabilitation|These individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
3485716|NCT03751306|Placebo Comparator|Transcranial Photobiomodulation Placebo|In this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
3485717|NCT03751306|Experimental|Transcranial Photobiomodulation|In this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
3485718|NCT03751293|Experimental|C-CAR088|Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene
3485719|NCT03751267|Experimental|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
3485720|NCT03751267|No Intervention|Wait-list control|This group of patients will receive Tuina (massage) 4 weeks after baseline assessments.
3485721|NCT03751254|Experimental|Myopic patients|In myopic patients with axial length over 25.0 mm during surgery of the first eye the Stellaris platform will be used and during surgery of the second eye the Stellaris Elite platform will be used
3485722|NCT03751241|Experimental|Intraocular lens types|Patients with different types of IOLs (EROV, monofocal, minimonovision) are tested for their reading quality using the EyeTracker device
3485723|NCT03751228|Experimental|BMS-986165 taste evaluation|BMS-986165 taste evaluation using Active Pharmaceutical Ingredient (API) and Prototypes of the API containing various flavors and sweeteners
3485724|NCT03751215|Experimental|Monofocal IOL|Patients will be implanted with two different monofocal lenses (Clareon and AcrySof) during cataract surgery
3485725|NCT03751202|Experimental|Test product|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
3485726|NCT03751202|Active Comparator|Reference product|ADVAIR DISKUS® 500/50
3485727|NCT03751176|Experimental|FOLFIRI + panitumumab|"Patients received panitumumab plus FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
3485728|NCT03751176|Active Comparator|FOLFIRI|"Patients received FOLFIRI in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Irinotecan: 180 mg/m2 as IV infusion over 90 min on day 1~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
3485729|NCT03751163|Active Comparator|Study|Tranexamic acid 250 mg po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
3485730|NCT03751163|Placebo Comparator|Control|Placebo po bid 12 weeks 4% Hydroquinone cream qhs 12 weeks sunscreen spf 30 qam 24 weeks
3485731|NCT03751150|No Intervention|Control|Normal training, no intervention
3485732|NCT03751150|Experimental|Intervention INT|The intervention consists of an exercise program developed by a team specialised in orthopaedics, physiotherapy and biomechanics, based on the results from a recent prospective study in Gothenburg, Sweden. The exercises included cover muscle control training for the core, abductors, quadriceps and foot pronators, as well as foamrolling for the abductors, quadriceps, hamstrings, calf muscles and gluteal muscles. The runners will be instructed to perform the training program twice a week for the entire intervention period.
3485733|NCT03751111|Experimental|Naloxone|Naloxone at an sublingual dose of 40 mg daily will be given to each subject.
3485734|NCT03751111|Placebo Comparator|Placebo|Sublingual placebo will be given to each subject.
3485735|NCT03751098|Experimental|Phenylephrine-tropicamide|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered using a microdose dispenser
3485736|NCT03751098|Placebo Comparator|Placebo|Eyewash solution administered using a microdose dispenser
3485737|NCT03751085|Experimental|AW frame|AW frame biopsy
3485738|NCT03751072||Relapse/Refractory|
3485739|NCT03751072||MRD positive|
3485740|NCT03751059|Active Comparator|NSAID|Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op
3485741|NCT03751059|Active Comparator|Steroid|Dexamethasone: used from one week post-op to three months post-op
3485742|NCT03751046|Experimental|Intervention group. Trial-Based Cognitive Therapy|Participants with therapeutic failure. Fourteen sessions of psychotherapy in group format, using Trial-Based Cognitive Therapy. Frequency: Bi-weekly meetings for seven months. Intervention arm comprises 10 psychotherapy groups with five participants in each group.
3485743|NCT03751046|Experimental|Control group. Standard healthcare.|Participants with therapeutic failure, receiving standard healthcare in the HIV/AIDS Program, which includes at least half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each). The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV.
3485744|NCT03751033|Experimental|BSS and DisCoVisc|Following lens removal and removal of all OVD from the anterior chamber during cataract surgery, the chamber will be filled with BSS and the main incision hydrated with BSS. Intraoperative aberrometry, using the Optiwave® Refractive Analysis with VerifEye+ (ORA), will be performed, and the results of aphakic refraction and suggested IOL power will be recorded in triplicate. Immediately following, the BSS will be replaced with DisCoVisc; and, triplicate readings will be measured under the same conditions.
3485745|NCT03750981|Other|A 12-week pilot intervention study introducing a high-intensi|
3485746|NCT03750968|Experimental|Carotenoid group|The Carotenoid group will receive a commercially available prenatal vitamin/mineral tablet plus a softgel containing lutein/zeaxanthin, vitamin E and docosahexaenoic acid (DHA).
3485747|NCT03750968|Active Comparator|Control group|The Control group will receive the same prenatal vitamin/mineral tablet plus a softgel containing only vitamin E and DHA.
3485748|NCT03750942|Experimental|Adhesix® monofilament polypropylene mesh (Bard Davol) group|The intervention arm will receive a mesh surrounding the stoma at the time of creation of the stoma.
3485749|NCT03750942|No Intervention|Control group|The control group will not receive a mesh and the stoma will be created according local protocol.
3485750|NCT03750929|No Intervention|Non physical exercises|Patients will not be submmitted to combined acute physical exercises (strength and aerobic)
3485751|NCT03750929|Experimental|Physical exercises|Patients will be submmitted to combined acute physical exercises (strength and aerobic) that consist on: supine, paddling, leg press 45º, knee extensor, flexor knee (two sets of 15 to 20 repetitions, with loads between 30% and 40% of a maximum repetition, with 30 seconds of interval). We will perform in the first exercise for upper and lower limbs, for heating, after starting the training where 4 series of 8 to 12 maximum repetitions will be performed, using the load between 70% and 80% of 1 maximum repetitions, already evaluated. The recovery between sets will be 90 seconds and between exercises will be 120 seconds.
3485752|NCT03750916|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1) Drug: Anlotinib Hydrochloride plus Docetaxel
3485753|NCT03750877|Active Comparator|median approach|Spinal anesthesia will be performed with a conventional median approach
3485754|NCT03750877|Active Comparator|paramedian approach|Spinal anesthesia will be applied with a paramedian approach.
3128240|NCT03136380|Experimental|Part 1: Group B|Subjects will receive GSK1325756H 10 mg in P-1, placebo in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
3128241|NCT03136380|Experimental|Part 1: Group C|Subjects will receive placebo in P-1, GSK1325756H 50 mg in P-2 and GSK1325756H 100 mg in P-3 after a high fat meal. There will be a washout period of at least 7 days between each treatment period.
3128242|NCT03136380|Experimental|Part 2: Group D|Subjects will receive GSK1325756H 50 mg after a low fat meal and fasted state respectively. There will be a washout period of at least 7 days between each treatment period.
3485755|NCT03750864|Experimental|ACT-LCS Therapy|Intervention is psychosocial counseling utilizing Acceptance and Commitment Therapy for Lung Cancer Stigma (ACT-LCS) as a patient-focused intervention to reduce the self-blame, guilt and inhibited disclosure associated with lung cancer stigma.
3485756|NCT03750851|Placebo Comparator|GPlacebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
3485757|NCT03750851|Experimental|GCPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
3485758|NCT03750851|Experimental|GLaser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
3485759|NCT03750851|Experimental|GLaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
3485760|NCT03750838|Experimental|Text Messaging Intervention Group|Participants in the TM Intervention condition will be provided a predetermined number of messages per week (based partially on responses from Phase 2 focus group) for 6 weeks delivered on Thursdays, Fridays, and Saturdays, which are the most common days of the week that heavy drinking occurs as well as other days and times that focus group participants indicated would be the most helpful.
3485761|NCT03750838|Active Comparator|Active Control|Participants in the attention only control condition will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
3128243|NCT03136380|Experimental|Part 2: Group E|Subjects will receive GSK1325756H 50 mg after a fasted state and a low fat meal respectively. There will be a washout period of at least 7 days between each treatment period.
3485762|NCT03750812|Active Comparator|Highly fit older adults - Exercise|This will receive an aerobic exercise intervention
3485763|NCT03750812|Active Comparator|Poorly fit older adults - Exercise|This arm will receive an aerobic exercise intervention
3485764|NCT03750812|Active Comparator|Highly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
3485765|NCT03750812|Active Comparator|Poorly fit young adults - Exercise|This arm will receive an aerobic exercise intervention
3485766|NCT03750812|Active Comparator|Highly fit older adults - TV|This arm will sit at rest and watch television
3128244|NCT03136484|Experimental|Semaglutide + canagliflozin placebo|
3485767|NCT03750812|Active Comparator|Poorly fit older adults - TV|This arm will sit at rest and watch television
3485768|NCT03750812|Active Comparator|Highly fit young adults - TV|This arm will sit at rest and watch television
3485769|NCT03750812|Active Comparator|Poorly fit young adults - TV|This arm will sit at rest and watch television
3128245|NCT03136484|Active Comparator|Canagliflozin + semaglutide placebo|
3128246|NCT03136861|Experimental|Secukinumab 150 mg (Group A)|Treatment Period 1: Secukinumab 150 mg (1 x 1.0 mL) s.c. administered at Baseline, Week 1, 2, 3 and 4
3485770|NCT03750799|Experimental|Experimental group|Whole body vibration was applied on the right lower extremity.
3128247|NCT03136861|Placebo Comparator|Placebo (Group B)|Treatment Period 1: Placebo (1 x 1.0 mL) s.c. administered at Baseline and Week 1, 2, 3 and 4
3128248|NCT03136861|Active Comparator|Arm A1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
3485771|NCT03750799|Sham Comparator|Sham group|Unlike the experimental group, sham vibration was applied to the control group.
3485772|NCT03750786|Experimental|Group A|ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab
3485773|NCT03750786|Active Comparator|Group B|mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab
3485774|NCT03750773|Active Comparator|Subjects receiving gabapentin drug|Administration of Gabapentin 600mg orally every 8 hours. Women will receive gabapentin for a total of 48 hours after cesarean
3485775|NCT03750773|Placebo Comparator|Subjects receiving placebo oral capsule|Administration of identical placebo capsule orally every 8 hours. Women will receive placebo for 48 hours after cesarean
3485776|NCT03750760|Active Comparator|Alirocumab (enhanced care)|"Alirocumab (150 mg) administered by subcutaneous injection, every two weeks for 7 weeks.~Atorvastatin (80 mg), oral administration daily."
3485777|NCT03750760|Active Comparator|Atorvastatin (standard care)|Atorvastatin (80 mg), oral administration daily. Ezetimibe (10 mg), oral administration daily, from week 4 if LDL-C is ≥ 70 mg/dL (1.8mmol/L) at week 4.
3485778|NCT03750747|Experimental|Intervention (Pulse Oximeter)|The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
3485779|NCT03750747|No Intervention|Comparison|The comparison facilities will continue providing routine IMCI services as per the existing guidelines. In routine IMCI services, IMCI service providers classify and treat children presenting with cough and difficult breathing based on history and clinical signs only. In routine IMCI services in Bangladesh, PO has not been introduced. Therefore, in the comparison facilities all children clinically classified as 'Pneumonia' will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day)
3485780|NCT03750734||Idiopathic bronchiectasis|Idiopathic bronchiectasis participants
3485781|NCT03750734||COPD|Chronic obstructive pulmonary disease participants
3485782|NCT03750734||Cystic fibrosis|Cystic fibrosis participants
3485783|NCT03750734||Healthy volunteers|Healthy volunteers
3485784|NCT03750721||Role of rifampin in staphylococcal PJI|retrospective cohort study in 4 hospitals : patients with staphylococcal acute post-operative (< 1 month) PJI treated with DAIR in 2011-2016 period
3485785|NCT03750708|Other|Ara® KOLIBREE toothbrush|The Ara® KOLIBREE tooth brush is given to the child at the usual consultation one month before alveolar bone graft.
3485786|NCT03750708|No Intervention|Without Ara® KOLIBREE tooth brush|Usual consultation one month before alveolar bone graft.
3485787|NCT03750682|Active Comparator|Physical Activity Intervention (PA)|The PA intervention will consist of a twice per week group-based moderate-intensity program that includes aerobic, strength, flexibility, and balance training.
3485788|NCT03750682|Placebo Comparator|Health Education Intervention (HE)|The HE intervention will consist of bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics including relevance to older adults, including nutrition, understanding the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services, information on resources, etc.
3485789|NCT03750669|Experimental|Neoadjuvant Chemotherapy|Patients receive the sequential neoadjuvant chemotherapy of AG regimen (nab-paclitaxel plus gemcitabine) and mFOLFIRINOX before resection.
3485790|NCT03750669|No Intervention|control|Patients receive surgical treatment without any neoadjuvant treatments.
3485791|NCT03750656|Active Comparator|Hyoscyamine|Hyoscyamine 0.125 mg tab sublingual every 4 hours as needed for discomfort
3485792|NCT03750656|Active Comparator|Tamsulosin|0.4 mg tab orally daily
3485793|NCT03750643|Experimental|LY3454738 - Part A|Escalating doses of LY3454738 administered intravenously (IV) or subcutaneously (SC) to healthy participants
3485794|NCT03750643|Placebo Comparator|Placebo - Part A|Placebo administered IV to healthy participants
3485795|NCT03750643|Experimental|LY3454738 - Part B|LY3454738 administered IV to healthy participants
3485796|NCT03750643|Placebo Comparator|Placebo - Part B|Placebo administered IV to healthy participants
3485797|NCT03750643|Experimental|LY3454738 - Part C|LY3454738 administered IV to participants with atopic dermatitis (AD)
3485798|NCT03750643|Placebo Comparator|Placebo - Part C|Placebo administered IV to participants with AD
3485799|NCT03750617|Experimental|pre-endoscopic screening risk assessment|
3485800|NCT03750617|No Intervention|routine screening|
3485801|NCT03750604|Active Comparator|patients with OAB|"Patients were asked to fill (OABSS) for more accurate evaluation of bothersome degree. Waist Circumference is evaluated. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to CT detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
3128249|NCT03136861|Active Comparator|Arm A2|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
3128250|NCT03136861|Active Comparator|Arm A3|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
3128251|NCT03136861|Active Comparator|Arm B1|Treatment Period 2: Secukinumab 150 mg (1 x 1.0 mL) plus placebo (1 x 1.0 mL) administered at Week 8, 12, 16 and 20
3128252|NCT03136861|Active Comparator|Arm B2|Treatment Period 2: Secukinumab 300 mg (2 x 1.0 mL) administered at Week 8, 12, 16, and 20
3128253|NCT03136913|Active Comparator|Closed Flap Technique|Healing by primary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200 ) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in primary coverage.
3128254|NCT03136913|Active Comparator|Open Flap Technique|Healing by secondary intention: Extraction and ridge preservation, utilizing non-resorbable membrane (Cytoplast® TXT-200) and freeze dried bone allograft (MinerOss® Cortical and Cancellous Chips (FDBA)), with flaps in position for healing by secondary intention.
3128255|NCT03137069|Placebo Comparator|Cohort 1: Placebo|Participants received matching placebo twice daily from Day 1 to 56.
3485802|NCT03750604|Placebo Comparator|normal variants healthy without symptoms|"WC is evaluated crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels. Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL. And in males:VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL"
3485803|NCT03750591||Integrative Korean medicine treatment group|"Observation of pain, function, quality of life, satisfaction, and adverse events in inpatients with lumbar intervertebral disc herniation hospitalized at 4 Korean medicine hospitals~Interventions:~Drug: Herbal medicine Procedure/Surgery: Chuna manual therapy Procedure/Surgery: Bee venom pharmacopuncture Procedure/Surgery: Pharmacopuncture Procedure/Surgery: Acupuncture Procedure/Surgery: Electroacupuncture Procedure/Surgery: Cupping Other intervention(s)"
3485804|NCT03750578|Experimental|Virtual Reality Group|Patients in this group will be offered virtual reality distraction through the use of OR in addition to standard of care.
3485805|NCT03750578|No Intervention|Standard of care group|Patients in this group will receive standard care, including the proposition to use topical anesthetic cream prior to venipuncture attempt, usual distraction and positioning proposed by the treating nurse.
3485806|NCT03750565|Experimental|Cohort 1|Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
3128256|NCT03137069|Experimental|Cohort 1: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
3128257|NCT03137069|Placebo Comparator|Cohort 2: Placebo|Participants received matching placebo up to twice daily from Day 1 to 56.
3485807|NCT03750565|Experimental|Cohort 2|Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
3485808|NCT03750565|Experimental|Cohort 3|Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
3485809|NCT03750565|Experimental|Cohort 4|Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days.
3485810|NCT03750552|Experimental|ampreloxetine|Participants randomized to ampreloxetine will receive a single, oral, daily dose of active drug for 4 weeks.
3128258|NCT03137069|Experimental|Cohort 2: GDC-0853 50mg QD|Participants received GDC-0853 50mg once daily from Day 1 to 56.
3128259|NCT03137069|Experimental|Cohort 2: GDC-0853 150mg QD|Participants received GDC-0853 150mg once daily from Day 1 to 56.
3485811|NCT03750552|Placebo Comparator|Placebo|Participants randomized to Placebo will receive a single, oral, daily dose of placebo for 4 weeks.
3485812|NCT03750539|Active Comparator|Standard Treatment|External Beam pelvic radiation therapy daily dose of 1.8-2 Gray (Gy) per session for 25 sessions to accomplish 45 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
3485813|NCT03750539|Experimental|hypofractionated treatment|External Beam pelvic radiation therapy daily dose of 1.8-2gy per session for 15 sessions to accomplish 37.5 Gy Chemotherapy ( cisplatin 40mg/m2), intravenous administration of chemotherapy once a week in an hour infusion Type II or type III open radical hysterectomy after 4-6 weeks after completion of external beam radiation
3485814|NCT03750526|Experimental|rTMS and AR group|Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
3485815|NCT03750526|Active Comparator|Sham rTMS and AR group|Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
3128260|NCT03137069|Experimental|Cohort 2: GDC-0853 200mg BID|Participants received GDC-0853 200mg twice daily from Day 1 to 56.
3128261|NCT03137121|Experimental|Olanzapine|Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.
3128262|NCT03137121|Placebo Comparator|Placebo|Patients will receive a placebo orally for 1 to 7 days daily.
3128263|NCT03137173|Experimental|ceftobiprole medocaril|Patients treated with ceftobiprole medocaril 500 mg q8h (with dose adjustment for renal impairment).
3128264|NCT03137173|Active Comparator|vancomycin+aztreonam|Patients treated with vancomycin 1000 mg (or 15 mg/kg) q12h plus aztreonam 1000 mg q12h (both with dose adjustment for renal impairment).
3132748|NCT03448536|Experimental|Naproxen Sodium : Acetaminophen|Subjects received one single oral dose of 440 mg naproxen sodium in treatment period 1, followed by one single oral dose of 1000 mg acetaminophen in treatment period 2
3485816|NCT03750526|Active Comparator|AR group|Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
3485817|NCT03750526|Active Comparator|Conventional physiotherapy group|Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
3485818|NCT03750513|Experimental|Treatment (LET optimized IMPT)|Patients receive LET optimized IMPT for up to 6 weeks.
3485819|NCT03750500|Experimental|Experimental|Participants included in this arm will benefit from a 12-week exercise program using the novel biofeedback rehabilitation device, under remote monitoring from a physical therapist
3485820|NCT03750500|Placebo Comparator|Standard of Care|Patients included in this arm will benefit from the standard of care currently in place in the Primary Care facility: education on risk factors for falls, medication review, visual and auditory acuity screening.
3485821|NCT03750487|Experimental|e-screening & brief intervention (e-SBI)|A two-session (20 minutes each) computer-delivered screening and brief motivational intervention targeting alcohol and drug use. Computerized screening is conducted using the ASSIST. Session 1 of the BI includes personalized feedback, readiness to change interventions, and goal setting around substance use. Session 2 will contain motivational content reinforcing engagement in home visiting and information around other challenges mothers may experience including tobacco use, postpartum depression, and intimate partner violence.
3128265|NCT03137303|Placebo Comparator|Patient Subject Usual Care|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit. The following will be performed.~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Subjects will be advised to go to their clinics and be managed by their PCP thereafter.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry and undergo the same spirometry protocol as the intervention group."
3485822|NCT03750487|Sham Comparator|Control|The control group will receive a similar 2-session brief motivational intervention. Session 1 focuses on nutrition and healthy eating, session 2 focuses on exercising while pregnant or in the postpartum period.
3485823|NCT03750474|Experimental|patient with chronic low back pain|magnetic resonance elastography and shear wave elastography of the back muscles
3128266|NCT03137303|Experimental|Patient-Subject Intervention|"On the day of the outpatient visit, subjects will be advised to arrive 90 minutes prior to their clinic visit in the same building as the clinic site. The following information will be collected and procedures will be performed:~Subject demographic and contact information~Co-morbid conditions~Smoking history~Medication history from patient and also from pharmacy used by subjects~A respiratory exacerbation history in the past year~Modified Medical Research Counsel (mMRC) dyspnea scale~Quality of life measures~Pre and post-bronchodilator using Albuterol (BD) spirometry"
3128267|NCT03137459|Experimental|TTM|Participants enrolled at the intervention site will receive four contacts, at baseline, two, four and six months. Each of the first three contacts consists of an integrated assessment and intervention feedback report, using an expert system.
3128268|NCT03137459|Active Comparator|Usual Care|Participants enrolled in control sites will receive four assessment contacts on the same schedule and in the same manner as the participants enrolled in intervention sites.
3485824|NCT03750474|Other|healthy controls|magnetic resonance elastography and shear wave elastography of the back muscles
3485825|NCT03750461|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
3485826|NCT03750448|Active Comparator|Telerehabilitation|Patients randomized to this group will receive interactive virtual rehabilitation using a mobile app. The telerehabilitation is based on sensor technology, developed by ICURA. This technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patient with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. This technology has already been successfully implemented in several different rehabilitation facilities across Denmark, and, hence, reflects current clinical practice.
3485827|NCT03750448|Active Comparator|No intervention|This group of randomised patients will not be given any physical rehabilitation intervention. This means no physical activity or exercise designed and prescribed for restoring normal function or reducing pain cause by disease, injury or surgery. The no intervention group will be encouraged to stay active and continue life as usual, gradually returning to their activities of daily living when they feel ready for it.
3485828|NCT03750448|Active Comparator|Unsupervised rehabilitation|This group will be instructed in similar exercises as patients allocated to telerehabilitation. However, this group will receive a written exercise-program with instructions to perform these exercises at home. The home-based exercise program will be created using exercise templates from Exorlive. Using a link provided in the exercise-program, the patients will be able to see short instruction-videos of the individual exercises.
3485829|NCT03750435|Experimental|Ablation for AF or left-sided AT|The patient will be admitted in hospital as for a standard ablation procedure and discharged the next day. The procedure will be carried out without using fluoroscopy and relying on the visualization of the electroanatomical mapping system.
3485830|NCT03750422|Active Comparator|Stratacel|medical grade silicone gel following Picoway Laser treatment
3485831|NCT03750422|Sham Comparator|Vehicle|Clear ultrasound gel following Picoway Laser treatment
3485832|NCT03750409|Active Comparator|Helmet Active Device|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
3485833|NCT03750409|Sham Comparator|Helmet Sham|Patients will be randomized 2:1 ratio to receive either the helmet active device or the helmet sham matched device. EACH device will be delivered with a highly visible tag with either an 'A' or 'B' respective to the study group the patient was randomized to.
3485834|NCT03750396|Experimental|Endocrine and local treatments|"Endocrine therapy is a standard-of-care for 1st line treatment in the patients with ER+/HER2- metastatic breast cancer.~Endocrine options included aromatase inhibitors, aromatase inhibitors with CDK4/6 inhibitors, fulvestrant, fulvestrant with CDK4/6 inhibitors, everolimus with exemestane, tamoxifen. For premenopausal women, agents for ovarian function suppression using GnRH agonists or surgical ovarian ablation including bilateral salpingo-oophorectomy are allowed.~Local treatments for metastatic lesions will be added in this group.~Local treatments include modalities described below:~i) Surgical resection: the achievement of tumor-free margin is not obligatory. ii) Stereotactic body radiotherapy iii) Radiofrequency ablation"
3485835|NCT03750383|Experimental|EDP-938 and cyclosporine interaction (Part 1)|
3485836|NCT03750383|Experimental|EDP-938 and prednisone interaction (Part 2)|
3485837|NCT03750357|Experimental|Primary Relief v 2.0 with Paracetamol|Group A will be treated with Primary Relief v 2.0(1 - 100Hz) sweep stimulation with increase in power of the stimulation for fixed interval of time.
3485838|NCT03750357|No Intervention|Only Paracetamol|Group B will be treated with paracetamol drug.
3485839|NCT03750344|Experimental|ChroniSense Polso Respiratory Rate|
3485840|NCT03750318|Experimental|Aingeal|All patients will wear the Aingeal device as part of the vital sign monitoring with opioid delivery system at ward setting.
3485841|NCT03750305|Active Comparator|psychoeducation/TAU|TAU consists of psycho-education for a period of 12 weeks, consisting of 6 2-hour sessions. Psycho-education is offered in groups,
3485842|NCT03750305|Experimental|imCT intervention|For a period of 12 weeks, 12 1-hour sessions of imagery-focused Cognitive Therapy delivered weekly by a trained therapists, divided in an in depth identification (4 sessions) of images followed by imagery interventions, (6 sessions) and a consolidation phase (2 sessions).
3485843|NCT03750266||Congenital Diaphragmatic Hernia referred for fetal MRA|
3485844|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy to relieve pain after arthroscopy for osteochondral lesions of talus
3128269|NCT03137693|Other|Change in Procedure Scheduling|Pre-Surgery SABR: Treatment with Stereotactic Ablative Body Radiation Therapy (SABR) followed by breast-conserving surgery. The usual treatment for patients with early-stage breast cancer who have breast-conserving treatment (BCT) is to receive radiotherapy AFTER surgery, targeting either the whole breast or part of the breast.
3485845|NCT03750240|Experimental|12 Triple Negative Breast Cancer Patients|scanned 4 times to assess breast cancer response to NACT with the proposed method.
3485846|NCT03750227|Active Comparator|Arm A (Post-operative SRS)|Patients undergo surgery on day 1. Within 2 weeks, patients undergo stereotactic radiosurgery.
3485847|NCT03750227|Experimental|Arm B (Pre-operative SRS)|Patients undergo stereotactic radiosurgery on day 1. Within 4 weeks, patients undergo surgery.
3485848|NCT03750214|Experimental|Biop Coplposcopy System|Biop Colposcopy system procedure
3485849|NCT03750201|Experimental|Direct Selective Trabeculoplasty|Treatment by the investigational device.
3485850|NCT03750201|Active Comparator|Selective Trabeculoplasty|Treatment by the comparator device.
3485851|NCT03750175||Colorectal cancer patients|"Clinical utility of ctDNA analysis for treatment decision~Use of ctDNA for KRAS, NRAS and BRAF testing prior to potential anti-EGFR monoclonal antibody treatment for metastatic colorectal cancer"
3485852|NCT03750162|Experimental|Passive Ultrasonic irrigation|Irrigation solution was ultrasonically activated in the canal for 1 minute by using IrriSafe tip coupled to an ultrasonic device with VDW Ultra .
3485853|NCT03750162|Experimental|Manuel dynamic activation|Irrigation solution was activated with a well-fitting a ProtaperNext X3 gutta-percha point placed to working length was then moved in push - pull motions at a rate of 100 strokes/per minute
3485854|NCT03750162|Experimental|Photodynamic Therapy|Root canal was filled by 0.5 mL of 0.01% methylene blue (MB) solution for 5 minutes, then radiated by the light supply of a diode laser AMD picasso with a wavelength of 810 nm for 40 seconds (0.2 W).
3485855|NCT03750149|Experimental|Ophthalmologic Disease|Patients with glaucoma, AMD, diabetic maculopathy, epiretinal membranes, and healthy patients will undergo a reading analysis using the EyeTracker
3485856|NCT03750136|Experimental|high-dose furosemide & hypertonic saline|furosemide i.v., 3% NaCl
3485857|NCT03750136|Active Comparator|high-dose furosemide|furosemide i.v.
3485858|NCT03750123||Kawasaki Disease (KD)|Children 5 years after Kawasaki Disease
3485859|NCT03750123||Healthy controls (HC)|Age- and sexmatched healthy siblings of children after Kawasaki Disease
3485860|NCT03750110|Active Comparator|Usual Care|Smoking Cessation NICE PH48 Guidelines
3485861|NCT03750110|Active Comparator|Intervention|Smoking Cessation NICE PH48 Guidelines plus personalised feedback from Lung Scan
3485862|NCT03750097|Experimental|Walking protocol|Walking for 250 steps with comfortable walking velocity (CWV), slow walking velocity (SWV: CWV - 20%) and fast walking velocity (FWV: CWV + 20%) with sufficient rest between conditions.
3485863|NCT03750071|Experimental|VXM01/Avelumab|Combination of VXM01, Ty21a transformed with a eukaryotic expression cassette encoding VEGFR-2, and anti-PD-L1 Checkpoint Inhibitor Avelumab
3128270|NCT03137784|Other|1(NVA237 50 ug/NVA237 25 ug/placebo)|Treatment sequence: NVA 237 50 ug, 25 ug and placebo
3485864|NCT03750058|Experimental|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
3485865|NCT03750045|Experimental|Experimental group|For the tests, the volunteers used the access device (Leap Motion) and a computer that were previously installed. The intervention was composed by 8 sessions of 15 minutes each, where the volunteers used a virtual environment attached it to a Leap Motion, which is a sensor that allows to capture the movements that are produced by the hands and reproduce them in a computer through a 3D virtual environment in order to stimulate the execution of their finer movements. The strength (Jamar) and motor coordination (wooden box) evaluations were made in the first, fourth and eighth sessions with the objective of checking the gain progression or not of motion coordination and grip strength.
3485866|NCT03750032|Experimental|Stapler appendectomy|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using a stapler.
3485867|NCT03750032|Experimental|Endoloop|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using endoloop.
3485868|NCT03750032|Experimental|Hem-O-Lock|A total of 40 study subjects undergoing appendectomy will be randomized into the group with appendicular stump closure using Hem-O-Lock.
3485869|NCT03750019|Experimental|Satisfying rehearsal|Participants completed the satisfying rehearsal task where they rehearsed the satisfying aspects of the lunchtime meal.
3485870|NCT03750019|Experimental|Dissatisfying rehearsal|Participants completed the dissatisfying rehearsal task where they rehearsed the dissatisfying aspects of the lunchtime meal.
3485871|NCT03750019|Active Comparator|Neutral rehearsal|Participants completed the neutral rehearsal task where they rehearsed their journey to campus that day.
3485872|NCT03750006|Experimental|HIIT intervention|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
3128271|NCT03137784|Other|2(NVA237 50 ug/placebo/NVA237 25 ug)|Treatment sequence: NVA 237 50 ug, placebo and 25 ug
3128272|NCT03137784|Other|3 (NVA237 25 ug/NVA237 50 ug/placebo)|Treatment sequence: NVA237 25 ug, 50 ug and placebo
3128273|NCT03137784|Other|4 (NVA237 25 ug/placebo/NVA237 50 ug)|Treatment sequence: NVA 237 25 ug, placebo and 50 ug
3128274|NCT03137784|Other|5 (placebo/NVA237 50 ug/ NVA237 25 ug)|Treatment sequence: Placebo, NVA237 50 ug and 25 ug
3485873|NCT03749993|Other|Screening Arm|Screening
3485874|NCT03749967|Experimental|Dose 1|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485875|NCT03749967|Experimental|Dose 2|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is ten sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485876|NCT03749967|Experimental|Dose 3|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifteen sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485877|NCT03749967|Experimental|Dose 4|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485878|NCT03749967|Experimental|Dose 5|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is twenty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485879|NCT03749967|Experimental|Dose 6|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485880|NCT03749967|Experimental|Dose 7|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is thirty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485881|NCT03749967|Experimental|Dose 8|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485882|NCT03749967|Experimental|Dose 9|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is forty-five sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485883|NCT03749967|Experimental|Dose 10|All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is fifty sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds.
3485884|NCT03749954||Overall eligible participants|Eligible participants will receive standard esophagogastroduodenoscopy and magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
3128275|NCT03137784|Other|6 (placebo/ NVA237 25 ug/NVA237 50 ug)|Treatment sequence: placebo, NVA237 25 ug and 50 ug
3485885|NCT03749928|Experimental|OstiSense biosensor - active|Participants will wear the biofeedback tool for 1 week with biofeedback turned off. After checking, for 3 more weeks the biofeedback will stay turned off. At 4-week recall the biofeedback mechanism will be turned on. Subjects will be instructed how to use the vibration mechanism. Participants will wear the tool with biofeedback turned on during the night/sleep for 8 more weeks. They will be asked to return for a check after the first week with biosensor turned on (5-week recall). At the end of 8 weeks, participants will be invited for a final recall visit (12-week recall). At points a questionnaire will be provided, and feedback questions will be asked. All data about bruxism episodes will be collected from the smart device.
3485886|NCT03749928|Placebo Comparator|OstiSensor biosensor - not activated|Participants in the control group will be treated, asked for feedback and receive questionnaires identical to the subjects in the active treatment group. The only difference will be that the biofeedback mechanism in the biofeedback night guard tool will always stay turned off. At the 1-week recall a check for any comfort issues will occur and accurate data recording will be confirmed. After three weeks the participant will be checked on, feedback will be requested and any wear issues will be identified, and the data recording function will be checked (4-week recall). At the end of additional 8 weeks participants will be invited for a final recall visit (12-week recall). A questionnaire will be provided, and feedback questions will be asked, data from the smart device about bruxism episodes will be collected.
3128276|NCT03137992|Experimental|Test Product (tiotropium bromide inhalation powder)|Once daily administration of test product (tiotropium bromide inhalation powder), 18 mcg for open-label extension (device robustness).
3485887|NCT03749915|Active Comparator|Comparator: Ametop only|Ametop Gel applied as sole topical anesthetic.
3485888|NCT03749915|Experimental|Intervention: Pain Ease Cold Spray|Pain Ease Cold spray applied immediately before IV insertion, as an adjunct to Ametop Gel.
3485889|NCT03749902|Other|Oxytocin infusion|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
3485890|NCT03749902|Other|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
3485891|NCT03749889|Experimental|100 g carbs|100 grams of carbohydrate allowance for the day
3485892|NCT03749889|Active Comparator|MyPlate|Carbohydrate suggestions based on standard MyPlate. 45-65% kcal intake from carbs.
3485893|NCT03749876|Active Comparator|Study Group 1|Study Group 1 will begin the first treatment period with the provided Unfiltered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Filtered Cigarette intervention for two weeks.
3485894|NCT03749876|Experimental|Study Group 2|Study Group 2 will begin the first treatment period with the provided Filtered Cigarettes intervention for two weeks, followed by a three-week wash-out period, before switching to the provided Unfiltered Cigarette intervention for two weeks.
3485895|NCT03749863|Experimental|Serial PRP injections|This arm will receive experimental intervention of serial monthly platelet-rich plasma (PRP) injections to a unilateral vocal fold mucosa for a total of 4 injections.
3485896|NCT03749850|Experimental|Study treatment|"LTLD in combination with MR-HIFU induced hyperthermia and cyclophosphamide~Single arm study"
3485897|NCT03749837|Experimental|C- MAC VS|Intubation with C- MAC VS
3485898|NCT03749837|Active Comparator|Video Endoscope|Intubation with standard fiberoptic scope
3485899|NCT03749824|Experimental|Omega-3|Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure.
3485900|NCT03749824|Placebo Comparator|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
3485901|NCT03749811|Experimental|Pupillometry group|A group of participants who receive remifentanil infusion under pupillometry monitoring.
3485902|NCT03749811|No Intervention|Conventional group|A group of participants who receive remifentanil infusion without pupillometry monitoring; their analgesic dose is mainly determined via hemodyamic change.
3485903|NCT03749798|Experimental|Intraoperative wavefront measurement|Patients will be measured with an intraoperative wavefront device during cataract surgery
3485904|NCT03749785|Active Comparator|Regular carbohydrate feeding|Ingestion of 75 g sucrose, given in regular doses for the first 75 minutes of exercise during a time to exhaustion run
3485905|NCT03749785|Active Comparator|Single carbohydrate bolus|Ingestion of 75 g sucrose, given in a single bolus after 75 minutes of exercise, during a time to exhaustion run
3485906|NCT03749772|Experimental|Cognitive|The participants of the COGNITIVE group performed cognitive training during 12 sessions during the 3 months of hypocaloric treatment. The training was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
3128277|NCT03137992|Active Comparator|Reference Product (Spiriva®)|Single dose of reference product (Spiriva®) 18 mcg
3128278|NCT03137992|Placebo Comparator|Placebo|Single dose of placebo inhalation powder
3128279|NCT03138382|Experimental|Treatment then sham|20 subjects will be randomised to first receive active vestibular nerve stimulation during indirect calorimetry. Then 2 weeks later they will return for sham stimulation during indirect calorimetry.
3179760|NCT00676325|Active Comparator|2|The NAZCA TC™ POP REPAIR SYSTEM (polypropylene mesh repair),promedon™ , cordoba, argentina, is used to repair anterior vaginal prolapse by a transobturator and pre pubic approach . Helical needles are used to anchor graft to the pelvic sidewall at two points transobturator, the other two arms pre pubic needles is used. We designed this randomized control trial to compare the anatomic success rates, effect on quality of life and sexual symptom scores, and rates of adverse events of the procedure with polypropylene mesh with that of anterior colporrhaphy, with planned follow-up of 1 years.
3179761|NCT00676351|Other|A|body plethysmography Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
3179762|NCT00676377|Experimental|1|Neostigmine
3179763|NCT00676377|Placebo Comparator|2|Placebo
3179764|NCT00676390|Other|1|Congestive Heart failure patients
3179765|NCT00676416||1|Propofol general anesthesia for asthmatic patients
3179766|NCT00676416||2|Propofol general anesthesia for non-asthmatic patients
3179767|NCT00676429|Experimental|1|Ziprasidone Hydrochloride oral solution with individual titration from 5 mg to 40 mg per day
3179768|NCT00676429|Placebo Comparator|2|Placebo oral solution
3179769|NCT00676442|Other|1|PN400 administered after meal
3128280|NCT03138382|Experimental|Sham then treatment|20 subjects will be randomised to first receive sham stimulation during indirect calorimetry. Then 2 weeks later they will return for active vestibular nerve stimulation during indirect calorimetry.
3128281|NCT03138577|Other|Dose Cohort 7|5 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3485907|NCT03749772|No Intervention|Control|As a control group, we used nutrition education sessions of approximately the same duration (30 min) where we simply reinforced the knowledge that was already provided during the sessions with the patient, such as concepts about the balanced diet, nutrient composition and micronutrients, etc. The objective of this control group was to avoid the effect of time with the researcher.
3485908|NCT03749759|Experimental|Biofeedback measurement|A Biofeedback measurement will be done during cataract surgery of both eyes
3485909|NCT03749733|Experimental|Test Product|"Participants will receive a single film-coated tablet of the test formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
3128282|NCT03138577|Other|Dose Cohort 6|10 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3128283|NCT03138577|Other|Dose Cohort 5|15 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3485910|NCT03749733|Active Comparator|Reference Product|"Participants will receive a single film-coated tablet of the marketed reference formulation containing estradiol 1.5 mg/nomegestrol acetate 2.5 mg.~The tablet will be taken with water and in a fasting condition."
3485911|NCT03749720|Other|Cervical cancer patients|Baseline- and follow-up blood samples are collected from the cervical cancer patients at time of diagnosis and during treatment and clinical follow-up. HPV DNA is measured in these samples.
3485912|NCT03749707|Other|SLNs from early-stage cervical cancer patients|Tissue from SLNs removed from early-stage cervical cancer patients are analyzed for HPV.
3485913|NCT03749655|No Intervention|PR+CBT|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy
3485914|NCT03749655|Experimental|PR+CBT+PA Promotion.|Standard care Pulmonary rehabilitation will be given alongside cognitive behavioural therapy and physical activity promotion.
3485915|NCT03749642|Experimental|trazodone/gabapentin 2.5/25 mg|One capsule, three times a day, for 8 weeks. The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
3485916|NCT03749642|Experimental|trazodone/gabapentin 5/50 mg|One capsule, three times a day, for 8 weeks.
3485917|NCT03749642|Experimental|trazodone/gabapentin 10/100 mg|One capsule, three times a day, for 8 weeks.
3485918|NCT03749642|Placebo Comparator|placebo|Two capsules, three times a day, for 8 weeks.
3485919|NCT03749642|Active Comparator|Gabapentin|"according to the following scheduling dosage regimen:~100 mg (2 capsules) 3 times a day, from day 0 to day 6 (±1);~300 mg (1 capsule) 3 times a day, from day 7 (±1) to day 13 (±1);~400 mg (1 capsule) 3 times a day, from day 14 (±1) to day 20 (±1);~300 mg (2 capsules) 3 times a day, from day 21 (±1) to day 55 (±2)."
3485920|NCT03749629|Active Comparator|CANMAT + GeneSight Psychotropic Test guided tx|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) and the pharmacogenomic test GeneSight®. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
3485921|NCT03749629|Placebo Comparator|CANMAT alone|Participant treatment will be guided by the Canadian Network for Mood and Anxiety Treatments (CANMAT) alone.
3485922|NCT03749603|Experimental|TIBAY meter|Non-invasive measurement of red blood cell Zinc Protoporphyrin (ZnPP/haem ratio-µmol/mol haem) fluorescence in the microcirculation of the lower lip.
3485923|NCT03749590|Experimental|Magnesium|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~With each infusion 10 ml magnesium sulfate (4930 mg magnesium sulfate = 20 mmol magnesium) are administered (total dose: 9860 mg magnesium sulfate)."
3179770|NCT00676442|Other|2|PN400 administered prior to meal
3179771|NCT00676442|Other|3|PN400 administered prior to meal
3179772|NCT00676442|Other|4|PN400 followed by fast
3179773|NCT00676468|Other|1|Active Montelukast + Fish Oil Placebo
3179774|NCT00676468|Other|2|Active Fish Oil + Montelukast Placebo
3179775|NCT00676468|Other|3|Active Montelukast + Active Fish Oil
3179776|NCT00676481|Active Comparator|1|Phase III participants who are educated about risk of HIV infection before receiving a rapid HIV test
3179777|NCT00676481|No Intervention|2|Phase III participants who are not educated about risk of HIV infection before receiving a rapid HIV test
3179778|NCT00676507|Experimental|Treatment|Treatment Arm: This course of therapy is Best Support Care (BSC) plus monthly intradermal (ID) injections of Lucanix™ (belagenpumatucel-L) consisting of 25,000,000 cells in a volume of 0.40 mL.
3485924|NCT03749590|Placebo Comparator|Placebo (NaCl 0,9%)|"Patients receive 2 infusions of 500 ml NaCl 0,9%: the first one 60 min before ERCP and the second one 6 hours after ERCP.~To each infusion 10 ml NaCl 0.9% (Placebo) will be added ."
3485925|NCT03749577|Experimental|L-citrulline|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
3485926|NCT03749577|Experimental|Beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
3485927|NCT03749577|Placebo Comparator|L-citrulline placebo|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
3485928|NCT03749577|Placebo Comparator|Denitrated beetroot juice|"Six cycles will be conducted over two consecutive winters. One cycle will consist of two 2-week supplementation periods.~A 7 days wash-out period will be imposed between treatment periods (placebo and treatment)."
3485929|NCT03749564|Experimental|SMT Only|All patients receive 2 SMT sessions in the first week.
3485930|NCT03749564|Experimental|SMT extended|All patients receive 2 SMT sessions in the first week. This arm also involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
3485931|NCT03749564|Experimental|SMT with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm receives 6 additional sessions of activation exercises."
3485932|NCT03749564|Experimental|SMT with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additional sessions of mobilizing exercise."
3485933|NCT03749564|Experimental|SMT with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm involves 6 additions sessions including both activation and mobilizing exercises."
3485934|NCT03749564|Experimental|SMT extended with Mobilizing Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and mobilizing exercises."
3485935|NCT03749564|Experimental|SMT extended with Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including both SMT and activation exercises."
3128284|NCT03138577|Other|Dose Cohort 4|20 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3128285|NCT03138577|Other|Dose Cohort 3|Supraclavicular Block: 25 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3485936|NCT03749564|Experimental|SMT extended with Mobilizing and Activation Exercises|"All patients receive 2 SMT sessions in the first week.~This arm includes 6 additional sessions including SMT, activation and mobilizing exercises."
3485937|NCT03749551||Participants|diagnostic test - patients serving as their own controls
3485938|NCT03749538|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation session: the energy of the anode (transcranial current stimulation) will have as its source a battery-powered DC generator and will be exerted by two electrodes measuring 5x7cm and attached to the head. The electrodes will be located of the primary motor cortex. The electrode with positive charge (anode) will be positioned at contralateral to the dominant limb and the negative charged electrode will be positioned in the supraorbital region ipsilateral to the dominant limb. The active current of direct transcranial stimulation will be applied with the intensity of electric current of 2mA and density of 0.057 mA/cm2 with duration of 20 minutes. During the session, patients will remain seated. Number of sessions: three times, once per day.
3485939|NCT03749538|Placebo Comparator|Placebo|This group will not receive a transcranial direct current stimulation session.
3485940|NCT03749525|Placebo Comparator|placebo group|5% GS solution
3485941|NCT03749525|Active Comparator|control group|shenfu injection
3485942|NCT03749512||Observational Group|Group of patients with lung tumor qualified for thoracic surgery intervention with routine, preoperative complete blood count test and routine postoperative histopathological examination of lung tumor.
3485943|NCT03749486|Experimental|ArcScan|High resolution immersion ultrasound measurement before Cataract surgery
3485944|NCT03749473|Active Comparator|Control|Participants receive a daily message with their step count on the prior day to serve as an active control for 24 weeks (daily performance feedback). No other interventions during the 24-week study
3485945|NCT03749473|Experimental|Choice + Immediate|Participants choose a step goal between 1000-3000 steps greater than their baseline (choice). They are asked to reach their full step goal upon intervention start (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
3128286|NCT03138577|Other|Dose Cohort 2|30 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3128287|NCT03138577|Other|Dose Cohort 1|35 mL of 2:1 mixture of 1.5% mepivacaine and 0.5% bupivacaine Ultrasound Imaging Bedside Negative Inspiratory Force Meter
3128288|NCT03138590|Experimental|Active tDCS|Active transcranial Direct Current Stimulation targeting the trigeminal nerve
3128289|NCT03138590|Sham Comparator|Sham tDCS|Sham transcranial Direct Current Stimulation targeting the trigeminal nerve
3128290|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 100 mg|Participants with UC having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128291|NCT03138655|Experimental|UC: <30 kg Participants, Vedolizumab 200 mg|Participants with UC having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128292|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 100 mg|Participants with CD having baseline weight of <30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128293|NCT03138655|Experimental|CD: <30 kg Participants, Vedolizumab 200 mg|Participants with CD having baseline weight of <30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128294|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 150 mg|Participants with UC having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3485946|NCT03749473|Experimental|Choice + Gradual|Participants are asked to choose a step goal between 1000-3000 steps greater than their baseline (choice). They will be asked to increase their step goal by even increments of 12.5% each week for the 8 weeks of the ramp-up period (gradual). After the 8-week ramp-up period, they will be asked to maintain the step goal for the study. They may change their goal within the range at anytime. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
3485947|NCT03749473|Experimental|Assigned + Immediate|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to reach their full step goal as soon as the intervention begins (immediate). They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
3485948|NCT03749473|Experimental|Assigned + Gradual|Participants in this arm will be assigned a step goal 2000 steps greater than their baseline (assigned). They will be asked to achieve their step goal of 2000 steps incrementally over the 8 weeks of the ramp-up period (gradual). After the first 8 weeks, they will be asked to maintain their full step goal of 2000 for the the study. They will be in a gamification intervention for the first 16 weeks and then receive only daily feedback during the 8-week follow-up
3485949|NCT03749460|Experimental|Treatment (nivolumab, ipilimumab, SBRT)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 courses and then every 4 weeks for an additional 8 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 60 minutes on day 1. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning week 3, patients undergo 3 fractions of stereotactic body radiation therapy every other day in the absence of disease progression or unacceptable toxicity.
3485950|NCT03749421||Prosigna Assay|"Biopsy specimen will be subject to molecular profiling via the Prosigna PAM-50 assay~The results of Prosigna assay will be provided to the study team in a standardized report.~This report will include the patient's intrinsic subtype, ROR score, and general risk (high, intermediate, low)."
3485951|NCT03749408|Active Comparator|bupivacaine plus mannitol|0.5% bupivacaine with 1:200,000 epinephrine plus 1.5 ml of 0.5 mol/L mannitol
3485952|NCT03749408|Experimental|bupivacaine alone|0.5% bupivacaine with 1:200,000epinephrine alone
3485953|NCT03749395|Active Comparator|Erector Spinae Plane Block group|"The Erector Spinae Plane block will be done as follow,the patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.~All patients will receive general anesthesia as described in conventional group"
3485954|NCT03749395|No Intervention|Conventional group|"Nothing will be injected~All patients will receive pre-oxygenation with O2 100% for 3 min. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and atracurium 0.5 mg/kg will be used for muscle relaxation. Anesthesia will be maintained by controlled ventilation with oxygen and air (50:50) with target of EtCo2≈ 35-40 mmHg, isoflurane 1:1.5 minimum alveolar concentration (MAC), 0.5μg/kg fentanyl will be given intraoperative when either heart rate or Non Invasive Blood Pressure report an increase by more than 20% of the basal records. Anesthesia will be discontinued and tracheal extubation will be done once patient fulfilled the extubation criteria."
3485955|NCT03749382|Experimental|Intervention Neutral instructions|Appearance based intervention group delivered with neutral instructions from the investigator alongside general stop smoking intervention leaflet.
3485956|NCT03749382|Experimental|Intervention Additional instructions|Appearance based intervention group delivered with neutral instructions with additional reassuring messages from the investigator alongside general stop smoking intervention leaflet.
3485957|NCT03749382|No Intervention|Control|Neutral task plus the general stop smoking intervention in the form of a leaflet, administered by the investigator.
3485958|NCT03749369|Active Comparator|SRP plus salvadora persica root|Subjects receiving salvadora gel in addition to scaling and root planing
3485959|NCT03749369|Placebo Comparator|SRP only|Subjects receiving scaling and root planing only
3485960|NCT03749356|Experimental|Once-Daily Tacrolimus|One arm: TacroBell SR Cap.
3128295|NCT03138655|Experimental|UC: >=30 kg Participants, Vedolizumab 300 mg|Participants with UC having baseline weight of >=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128296|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 150 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3485961|NCT03749317|Experimental|Treatment|IVIEW-1201; four times per day (QID) for 7 days
3485962|NCT03749317|Placebo Comparator|Placebo|Placebo; four times per day (QID) for 7 days
3485963|NCT03749304|Experimental|ANI monitor|
3485964|NCT03749291|Experimental|Obemat2.0 Intervention Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
3485965|NCT03749291|Active Comparator|Control Group|Obese children (BMI >97th percentile of the Spanish curves from Hernández 1988) Ages: 8 to 13 at baseline (9 to 15y at the end of the intervention)
3485966|NCT03749278|Experimental|ALMA Intervention Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention after baseline assessment.
3485967|NCT03749278|Active Comparator|ALMA Delayed Intervention Control Group|Latina Friends Motivating the Soul (ALMA). This group receives the intervention six months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
3485968|NCT03749252|Experimental|CNS Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing CNS contrast-enhanced MRI
3485969|NCT03749252|Experimental|CNS Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing CNS contrast-enhanced MRI
3485970|NCT03749252|Experimental|CNS Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing CNS contrast-enhanced MRI
3485971|NCT03749252|Experimental|Body Cohort 2-6 years|Pediatric patients aged 2-6 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
3485972|NCT03749252|Experimental|Body Cohort 7-11 years|Pediatric patients aged 7-11 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
3485973|NCT03749252|Experimental|Body Cohort 12-17 years|Pediatric patients aged 12-17 years undergoing contrast-enhanced MRI of other body organs (head and neck, thorax, abdomen, pelvis or musculoskeletal system)
3485974|NCT03749239|Experimental|Effects of collagen protein.|Non-hydrolized collagen protein
3485975|NCT03749226|Active Comparator|AZLI group|Patients assigned to study group will receive nebulized Aztreonam lysine (AZLI 75 mg-dose) three times /day during 5 days by mean of the ultrasonic nebulizer (Aeroneb solo®) plus Combihaler® spacer adapted of the ventilator
3485976|NCT03749226|No Intervention|Control group|Patients assigned to control group will no receive any intervention for heavy Gram negative colonization
3485977|NCT03749213|Experimental|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib as neoadjuvant therapy before surgery and adjuvant therapy or till progressive disease or unaccepted toxicity.
3485978|NCT03749200|Experimental|Obemat2.0 Intervention Group|Intervention: Obemat2.0 therapy (11 Motivational Interview Visits, 3 Workshops) Duration: 12 months (+3 months). Setting: Primary care centers Providers: pediatritians and nurses trained to perform motivational interview Visits description: The interviews follow a structure: 1. Checking the accomplishment of objectives to congratulate and motivate the patient. 2. A specific topic per visit is explained to the participant and family. 3. A task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight and physical activity are defined to be accomplished until the next visit. The follow-up of the structure is ensured by means of a printed material that the therapists provide each visit to participants.
3485979|NCT03749200|Active Comparator|Control Group|Control Intervention: regular practise in primary care (11 individual monthly visits) Duration: 12 months (+3 months). Setting: Primary care centers. Providers: standard pediatritians and nurses Children and their families receive the usual recommendations conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity. At visits, the family receive explanations about carrying out a balanced diet, divided into 5 meals, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports regular practise is recommended. Monthly visits are organized in which weight and height are measured and compliance with advice is reviewed.
3485980|NCT03749174|Active Comparator|Long acting anesthetic block/plaster|Intervention 1: Blockade will be given supraclavicularly with Long acting local Anesthetic (n=30) combined with post operative plaster immobilization.
3485981|NCT03749174|Active Comparator|Short acting anesthetic block/plaster|Intervention 2: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) combined with plaster immobilisation postoperatively
3485982|NCT03749174|Active Comparator|Short acting anesthetic block/orthotic|Intervention 3: Blockade will be given supraclavicularly with Short acting local anesthetic (n=30) and combined with orthosis for postoperative immobilisation
3485983|NCT03749174|Active Comparator|General Anesthesia and plaster|Intervention 4: General anesthesia wil be administered for surgical procedure combined with postoperative plaster immobilisation (n=30),
3485984|NCT03749161|Experimental|Lentis comfort|Patient will receive the low-add multifocal IOL during cataract surgery
3485985|NCT03749161|Experimental|Lentis L-313|Patient will receive the monofocal IOL Lentis L-313 during cataract surgery
3485986|NCT03749148|Active Comparator|Dupilumab|Dupilumab, s.c. administration 2 injections (600mg) as loading dose, 1 injection (300mg) every 14 days for a total of 16 weeks
3485987|NCT03749148|Placebo Comparator|Placebo|matching Placebo, s.c. administration 2 injections as loading dose, 1 injection every 14 days for a total of 16 weeks
3485988|NCT03749135|Active Comparator|Dupilumab|Dupilumab (anti-IL4Ra), s.c. administration
3485989|NCT03749135|Placebo Comparator|Placebo Comparator|matching Placebo, s.c. administration
3128297|NCT03138655|Experimental|CD: >=30 kg Participants, Vedolizumab 300 mg|Participants with CD having baseline weight of >=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
3128298|NCT03138798|Experimental|Laboraide TM dental support device|Receive Laboraide
3485990|NCT03749109|Experimental|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg, with daily target release rate of 13.5 µg.
3485991|NCT03749109|Placebo Comparator|Placebo|Vaginal ring containing matching placebo
3485992|NCT03749096|Active Comparator|Intravenous immunoglobulin|IVIg dose will be 2g/kg ideal body weight every 4 weeks (in 2 divided doses on consecutive days) for 12 weeks (3 cycles total).
3485993|NCT03749096|Placebo Comparator|Placebo|
3485994|NCT03749083||Tumor Sequencing|"Quality of life assessments will be collected using The Functional Assessment of Cancer Therapy- Colorectal~Blood for circulating tumor DNA will be collected"
3485995|NCT03749070|Active Comparator|Silymarin|Patients will receive 2 capsules containing a total of 700mg of silymarin, 8mg of vitamin E and 50mg of phosphatidylcholine, in addition to the excipient, which should be ingested daily for 12 weeks.
3128299|NCT03138798|No Intervention|Control Group|Patients will give consent in the first stage of labor. Subsequently, randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group B will not receive a Laboraide TM dental support device. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment.
3485996|NCT03749070|Placebo Comparator|Placebo|Patients will also receive similarly 2 capsules per day, but without the bioactive principle tested (silymarin). Therefore, the capsules in the control group will contain only 700 mg of maltodextrin, a neutral food component derived from starch, in addition to the excipient and the same amount of vitamin E and phosphatidylcholine to balance the two groups.
3485997|NCT03749057|Other|rivaroxaban|15-20 mg rivaroxaban daily
3485998|NCT03749044|Experimental|Patient Educational Tool|At the baseline visit, after having responded to the questionnaire, participants in the education arm will be given the patient educational tool.
3485999|NCT03749044|No Intervention|Standard of Care|Subjects in the standard of care arm will not receive the patient educational tool. If participants ask specific questions on pregnancy complications and/or preeclampsia, the clinicians will provide relevant information as they judge appropriate, but without handing out the patient educational tool.
3486000|NCT03749031|Placebo Comparator|Orange juice only|16 oz. orange juice per day for 4 weeks
3486001|NCT03749031|Experimental|orange juice + orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
3486002|NCT03749031|Placebo Comparator|Apple juice only|16 oz. apple juice per day for 4 weeks
3486003|NCT03749031|Experimental|Apple Juice + Apple Pomace|16 oz. apple juice + apple Pomace per day for 4 weeks
3486004|NCT03749018|Experimental|Treatment (nivolumab, DA-REPOCH)|Patients receive rituximab IV and nivolumab IV over 60 minutes on day 1. Patients also receive etoposide, vincristine sulfate and doxorubicin hydrochloride IV continuously over 96 hours, cyclophosphamide IV bolus, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After course 6, patients receive nivolumab IV over 60 minutes on day 1 every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3486005|NCT03748966|Experimental|Adults with XLH|Adults with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
3486006|NCT03748966|Experimental|Children with XLH|Children (age 6-17) with X-linked hypophosphatemia will be treated with optimized doses of calcitriol (without phosphate supplementation) for one year
3486007|NCT03748940|Placebo Comparator|Part A: Placebo|Placebo administered subcutaneously (SC)
3486008|NCT03748940|Experimental|Part A: LY3074828|LY3074828 administered SC
3486009|NCT03748940|Placebo Comparator|Part B: Placebo|Placebo administered SC
3486010|NCT03748940|Experimental|Part B: LY3074828|LY3074828 administered SC
3486011|NCT03748940|Experimental|Part B: LY900021|LY900021 (LY3074828 + LY9999QS) administered SC
3486012|NCT03748914|Experimental|Intervention Group|Milking the cut umbilical cord once towards the Infant at a speed of 10cm/second.
3486013|NCT03748914|Active Comparator|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
3486014|NCT03748888|Experimental|Exercise group|An antenatal physical activity (APA) programme will be designed for participants in the exercise group.
3486015|NCT03748888|No Intervention|Control Group|Sedentary participants.
3486016|NCT03748875|Experimental|Intervention group|an 8-session mindfulness-based relapse prevention program
3486017|NCT03748875|No Intervention|Control group|treatment as usual
3486018|NCT03748862||Cases|"Patients who were receiving high-dose, long-term opioid therapy at study entry and achieved a sustained taper during the follow-up period.~A Taper Plan is a plan to reduce or discontinue use of opioids discussed with the primary care provider. Evidence of a taper plan is found in the prescription notes or medical encounter notes in the electronic health record."
3486019|NCT03748862||Controls|Patients who were receiving high-dose, long-term opioid therapy at study entry and didn't achieve a sustained taper during the follow-up period.
3486020|NCT03748849||Low back pain group|Males and females who have had low back pain lasting between 12 weeks - 5 years without any other health problems (physical or psychological). Following baseline measurements, all subjects are offered individualized physiotherapy. The interventions mainly consist of exercises targeting their functional limitations. These are supplemented by a thorough explanation of their pain condition. This is done within the boundaries of the current understanding of musculoskeletal pain. This is supplemented with encouragement to do regular exercise and with manual therapy if needed/indicated.
3128300|NCT03138876|Other|EEG Cap|Single arm study, where every participant gets assessed by EEG cap and then standard EEG. Some subjects may be treated with anti-seizure medications before standard EEG, due to ethical responsibility, if clear NCSE is identified on cap EEG. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
3128301|NCT03138967|Experimental|Sugammadex|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade."
3128302|NCT03138967|Active Comparator|Standard of Care - Neostigmine/Glycopyrrolate|"Participants to have cystoscopy with bladder tumor resection.~Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.~Neostigmine/Glycopyrrolate administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. Once T1 is at 10% or greater, a dose of 70 mcg/kg of Neostigmine with 14 mcg/kg Glycopyrrolate administered simultaneously over a period of one minute up to 5 mg."
3128303|NCT03139032|Experimental|APD334|APD334 active treatment for 12 weeks.
3128304|NCT03139240|Experimental|Gestational age <7 weeks|Women with a gestational age <7 weeks will be randomized to oxycodone 10mg oral vs placebo
3128305|NCT03139240|Experimental|Gestational age 7-10w0d|Women with a gestational age 7-10w0d will be randomized to oxycodone 10mg oral vs placebo
3486021|NCT03748849||Control group|"Healthy males and females who have no current musculoskeletal pain problem (specific to the low back and/or in general). Likewise, they cannot have a previous history of on-going musculoskeletal pain. On-going pain is defined as a condition that limited their function for 3 months or more.~Participants in the control group take part in the baseline measurement and then another measurement after 6-8 weeks"
3486022|NCT03748836|Active Comparator|Single Ascending Dose ALPN-101|
3486023|NCT03748836|Placebo Comparator|Single Dose Placebo|
3486024|NCT03748836|Active Comparator|Multiple Ascending Dose ALPN-101|
3486025|NCT03748836|Placebo Comparator|Multiple Dose Placebo|
3486026|NCT03748797|Experimental|Exercise group|8-week moderate intensity exercise training under supervision
3486027|NCT03748797|No Intervention|Control group|No supervised exercise training given. Participants were advised to continue their routine daily activities and self exercises if they have
3486028|NCT03748745|Experimental|Cohort A|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
3486029|NCT03748745|Experimental|Cohort B|SH229 (600 mg) once daily, Daclatasvir dihydrochloride (60 mg) once daily.
3486030|NCT03748719|Experimental|Stereotactic Body Radiation Therapy, followed by Prostatectomy|Patients will receive 6 Gy per day of Stereotactic Body Radiation Therapy (SBRT) per day for 5 days, followed by prostatectomy in 3 weeks.
3128306|NCT03139279|Experimental|Dexmedetomidine and propofol|Intravenous dexmedetomidine 0.3 ug/kg followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
3128307|NCT03139279|Placebo Comparator|Saline placebo and propofol|Intravenous saline placebo followed by propofol. Titrated doses of propofol will be given at the discretion of the anesthesiologist based on a target BIS range between 60-70.
3486031|NCT03748693||POP Group|Women with POP undergoing surgery in our OB/GYN department.
3486032|NCT03748693||Non-POP Group|Women undergoing hysterectomy for other indications.
3486033|NCT03748680|Active Comparator|A|Intensified follow-up schedule
3486034|NCT03748680|Experimental|B|Adjuvant chemotherapy + intensified follow-up schedule
3486035|NCT03748667||Patients with colorectal polyps|Patients with non-pedunculated type 0 lesions in Paris classification (not obvious cancers) larger than 10 mm
3486036|NCT03748654|Experimental|Single Arm|Patients will perform visual field testing with the Humphrey Field Analyzer and with the Virtual Reality Headset
3486037|NCT03748628|Experimental|Single arm EDP-305|
3486038|NCT03748615|Experimental|Computer Guided ridge splitting in posterior mandible|fabrication of a computer aided surgical guide and performing ridge splitting in posterior mandible using piezosurgery
3486039|NCT03748602|Experimental|TOD|Thoracic Outlet Decompression (TOD)
3486040|NCT03748602|No Intervention|Conservative therapy|Physiotherapy and pain relief
3486041|NCT03748589|Experimental|airway type 1|The children weighed between 2-5kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1
3486042|NCT03748589|Experimental|airway type 1.5|The children weighed between 5-12kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 1.5
3486043|NCT03748589|Experimental|airway type 2|The children weighed between 10-25kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2
3486044|NCT03748589|Experimental|airway type 2.5|The children weighed between 25-35kg are assigned into this group,they are allocated with i-gel laryngeal mask airway type 2.5
3486045|NCT03748576|Experimental|Mobile technologies group|m-health group (Intervention Group) participants were managed continuously through WeChat group chat during prenatal clinic interval.
3128308|NCT03139448|Active Comparator|Oxygen via nasal cannula (Standard of Care)|The anesthesia provider will supply oxygen via nasal cannula at oxygen flow rates as per standard of care routine at Vanderbilt University Medical Center.
3128309|NCT03139448|Experimental|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
3128310|NCT03139552|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
3128311|NCT03139552|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
3128312|NCT03139552|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item (apple crisp, tea and oatmeal). The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
3486046|NCT03748576|No Intervention|control group|Standard Clinic Prenatal Care (Control Group): regular routine prenatal care following Chinese standard.
3486047|NCT03748563|Experimental|ds-MCE and EGD|All the enrolled participants will undergo the examination of detachable string magnetically controlled capsule endoscopy (ds-MCE) first, followed by EGD within 48 hours.
3486048|NCT03748550|No Intervention|Control|Participants will receive standard of care treatment for their breast cancer.
3486049|NCT03748550|Experimental|Exercise|Participants will receive standard of care treatment for their breast cancer plus be given a 12-week home based aerobic exercise program.
3486050|NCT03748537|Experimental|Hydrocortisone|Hydrocortisone will be administered intravenously at 200 mg every 24 hours for 5 days, then tapered to a 50 mg intravenous bolus every 12 hours for days 6 to 8 and 50 mg every 24 hours for days 9 to 11, and then stopped.
3486051|NCT03748537|No Intervention|No Hydrocortisone|In control group, patient will not receive any corticosteroids for seven day after inclusion.
3486052|NCT03748524|Experimental|Single Influenza Vaccine|Single Influenza Vaccine,Quadrivalent
3486053|NCT03748511||fatty liver disease 0-1F|20 patients with uncomplicated liver disease, with fibrosis stage 0-1F.
3486054|NCT03748511||fatty liver disease 2F|20 patients with liver disease, fibrosis stage 2F.
3486055|NCT03748511||fatty liver disease 3-4F|20 patients with advanced liver disease, fibrosis stage 3-4F.
3486056|NCT03748498|Experimental|laser group|Low level laser was applied for 60 second per tooth using Nd-YAG laser.
3486057|NCT03748498|Placebo Comparator|placebo group|The same procedures as in the laser group were performed, been completed but the laser was not activated in this group.
3486058|NCT03748485|Experimental|wait and watch group|clinical local advanced colorectal cancer (cTxN1/2M0) following pre-operational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) without adjuvant chemotherapy
3486059|NCT03748485|Active Comparator|adjuvant chemotherapy group|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0) with adjuvant chemotherapy
3486060|NCT03748472|Experimental|Bolus feeding|
3486061|NCT03748472|Experimental|continuous gavage feeding|
3486062|NCT03748459||Permanent suture|Subjects will have skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
3128313|NCT03139578|Experimental|C 8.5\C 9.0\T 8.5\T 9.0|Subjects randomized to this sequence received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
3128314|NCT03139578|Experimental|C 9.0\C 8.5\T 9.0\T 8.5|Subjects randomized to this sequence received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
3128315|NCT03139578|Experimental|T 8.5\T 9.0\C 8.5\C 9.0|Subjects randomized to this sequence received Test lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the first period and then received Control lens (base curve 8.5 on the left eye and 9.0 on the right eye) during the second period.
3486063|NCT03748459||Resorbable suture|Subjects will have skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty
3486064|NCT03748446|Active Comparator|X-TAU (xenon)|"Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug.~- xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)"
3486065|NCT03748446|Placebo Comparator|N-TAU (nitrogen-placebo)|Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)
3128316|NCT03139578|Experimental|T 9.0\T 8.5\C 9.0\C 8.5|Subjects randomized to this sequence received Test lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the first period and then received Control lens (base curve 9.0 on the left eye and 8.5 on the right eye) during the second period.
3128317|NCT03139604|Experimental|Itacitinib|Itacitinib plus corticosteroids
3128318|NCT03139604|Placebo Comparator|Placebo|Matching placebo plus corticosteroids
3128319|NCT03140254|Active Comparator|comparator|Chlorhexidine gluconate
3128320|NCT03140254|Experimental|experimental|BDIP-0001
3128321|NCT03140254|Placebo Comparator|placebo|Vehicle
3128322|NCT03140631|No Intervention|Control|Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of <200s or return to pre-procedural baseline prior to sheath removal.
3128323|NCT03140631|Active Comparator|Protamine|Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of <200s or return to preprocedural baseline prior to removal of vascular sheaths.
3128324|NCT03140722|Experimental|vadadustat|Vadadustat daily oral dose, adjustable based on Hb level
3486066|NCT03748433|Experimental|Continuous Glucose Monitoring (CGM)|The RT CGM group will receive a Dexcom G6 transmitter and sensors, as well as a structured education refresher focusing on hypoglycaemia avoidance, recognition, and management.
3486067|NCT03748433|No Intervention|Self Monitoring Blood Glucose (SMBG)|The SMBG group will additionally undergo blinded CGM at weeks 1 and 2, weeks 4 to 6 and weeks 9 to 12 using the Dexcom G6 system. Participants in this group will be shown how to insert the Dexcom G6 at the first clinic visit and sensors provided so they can do this at home.
3486068|NCT03748433|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|All participants will be re-consented with the choice to continue using RT-CGM for a further 16 weeks or be re-randomised to either receive the Tandem t:slim X2 insulin pump or RT-CGM. Participants randomised to the Tandem t:slim X2 group will be proficiently trained to safely use the Tandem t:slim X2 insulin pump. All participants (Tandem t:slim X2 and RT-CGM) will be provided with Dexcom G6 real time CGM transmitters and sensors for the 16-week second extension phase.
3486069|NCT03748420|No Intervention|Usual Care|Basic clinical decision support alone
3486070|NCT03748420|Experimental|ReachOut Adherence intervention|Adherence-enhanced clinical decision support plus pharmacist-based adherence outreach
3486071|NCT03748407|Other|dosages in Healthy volunteers|"Only one arm : healthy volunteer blood donors. Performing a blood test for the determination of parameters that explore thyroid status : only once.~Absence of other healthy volunteers group all healthy volunteers have a blood test performed in the same way."
3128325|NCT03140722|Active Comparator|epoetin alfa|Epoetin alfa, dose adjustable based on Hb level, as clinically indicated throughout the study
3486072|NCT03748394|Experimental|Work-directed rehabilitation|Work-directed, person-centered plan using modules of occupational therapy and physical therapy
3486073|NCT03748394|Active Comparator|Physical activity|Physical activity according to national health recommendations
3486074|NCT03748381|Experimental|Trifocal IOL|The patients will receive two different diffractive trifocal IOLs in each eye (AT Lisa tri vs. Rayner trifocal) during cataract surgery
3486075|NCT03748368|Active Comparator|Cataract presentation|Cataract presentation prior to surgery
3486076|NCT03748368|Placebo Comparator|Placebo presentation|Placebo presentation prior to surgery
3486077|NCT03748355|Other|Pharmacogenetic Analysis|A pharmacogenetic analysis will be completed for each participant upon inclusion into the study
3486078|NCT03748342|No Intervention|Standard Endotracheal Tube|
3486079|NCT03748342|Active Comparator|Second-Generation LMA|
3486080|NCT03748303|Experimental|Allo IM cohort|Allopregnanolone 4-18mg IM, weekly, for 12 weeks.
3128326|NCT03141086|Experimental|Group 1|LML134, then placebo
3486081|NCT03748290|Experimental|People with a SCI who will receive Lyrica 75mg for 12 weeks|
3486082|NCT03748290|Placebo Comparator|People with a SCI who will receive Placebo for 12 weeks|
3486083|NCT03748277|Experimental|Minimally invasive fusion|Bilateral decompression using unilateral approach, MIS TLIF + screw fixation percutaneous
3486084|NCT03748277|Active Comparator|Open Fusion|Bilateral decompression, open fusion + screw fixation
3486085|NCT03748251|Experimental|Short fermented pizza|the patients ate a pizza that fermented for 8 hours
3486086|NCT03748251|Experimental|Long fermented pizza|the patients ate a pizza that fermented for 24 hours
3486087|NCT03748238|Experimental|Injury group|Endometrial injury with hysteroscopy
3486088|NCT03748238|No Intervention|Control group|No hysteroscopy
3128327|NCT03141086|Experimental|Group 2|Placebo, then LML134
3128328|NCT03141151|Experimental|COACH: Healthy Bodies|This will be a staged intensity behavioral intervention. The intensive phase will last 15 weeks and consist of weekly, 90 minute, skills-building sessions. The content will focus on diet, physical activity, sleep, media use, and parenting. Behavior change techniques will include goal-setting, self-monitoring, and problem solving. Following the intensive phase, participants will enter a maintenance phase, consisting of monthly phone calls from a health coach for 3 months.
3128329|NCT03141151|Active Comparator|COACH: Strong minds|This will be a school-readiness intervention for the 3-5 year old children involved, which will meet twice a month for 3 months. Group sessions will focus on building social support around literacy skills for parents and children, as well as school advocacy.
3128330|NCT03141242|Active Comparator|ENACT Group Visit|Participants will engage in two 2-hour group visits related to advance care planning, including printed advance care planning resources.
3128331|NCT03141242|Placebo Comparator|Mailed Resources|Participants will receive printed advance care planning resources by mail.
3128332|NCT03141281|Experimental|BrainHQ|Participants will be provided with a laptop computer and enrolled in a commercial web-based cognitive training program, BrainHQ, trained on how to access it, and instructed to complete a fixed number of sessions in 20 hours.
3128333|NCT03141281|Experimental|Rise of Nations|Participants will be provided with a laptop computer with the Rise of Nations video game, be trained in game play, and instructed to play the game for 20 hours
3132749|NCT03448536|Experimental|Acetaminophen : Naproxen Sodium|Subjects received one single oral dose of 1000 mg acetaminophen in treatment period 1, followed by one single oral dose of 440 mg naproxen sodium in treatment period 2
3486089|NCT03748212|Active Comparator|Group 1|D935 Cap. 1T
3486090|NCT03748212|Experimental|Group 2|CKD-385 Tab. 1T
3486091|NCT03748199|Experimental|POL6014|multiple ascending doses: 80, 160 and 40 mg once or twice daily
3486092|NCT03748199|Placebo Comparator|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
3486093|NCT03748173|Experimental|Treatment|Subjects randomized to the aerosol surfactant evaluation will occur at the end of 60 minutes, with the aerosol continued if the bronchiolitis score is > 4 or there has been less than a 2-point improvement in the bronchiolitis score. Similar evaluation will be performed, if necessary, at 30-minute intervals (maximum 2 hours) with stoppage of the aerosol for an improved bronchiolitis score (≤ 4 or 2-point improvement) at any of the time points. The aerosol would be stopped at any time for significant sustained deterioration in clinical status or any serious adverse event felt related to the treatment. Retreatment can be given at > 4 but < 24 hours if the initial response was positive and there has been subsequent deterioration.
3486094|NCT03748173|No Intervention|Usual Care|The only difference in care between treatment and usual care will be treatment with up to two doses of aerosolized Infasurf®.
3486095|NCT03748160|No Intervention|Control|There is no intervention (letter) in the control arm. There is no control arm in the city of Espoo. 1/3 of subjects in all other municipalities are assigned to the control arm.
3486096|NCT03748160|Active Comparator|Mailing|This treatment arm consists of a standard letter reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
3486097|NCT03748160|Active Comparator|Herd|This treatment arm consists of a letter that highlights the herd immunity effects of vaccination and reminds elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers.
3486098|NCT03748147|Active Comparator|Control|Standard of care, misoprostol 25 mcg po every four hours
3486099|NCT03748147|Experimental|Intervention|Misoprostol 50 mcg po every four hours
3486100|NCT03748121|Experimental|Pranayama assisted Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|To prepare patients for the TF-CBT, they received 5-10 minutes of pranayama at the begin of each of the 10 TF-CBT units.
3486101|NCT03748121|Active Comparator|Trauma-focused Cognitive Behavioral Therapy (TF-CBT)|Patients wait for 10 TF-CBT units and then are offered to learn pranayama.
3486102|NCT03748108|Experimental|lidocaine|A bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
3486103|NCT03748108|Placebo Comparator|Placebo|A bolus intravenous dose of a saline placebo over 15 s just before the induction of general anesthesia.
3486104|NCT03748082|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Test gas administration will commence at the onset of CPB and last for 24 hours.
3486105|NCT03748082|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
3132750|NCT03449030|Experimental|Part A Escalation Stage: TAK-164 Q3W|TAK-164 0.004 milligram per kilogram (mg/kg) starting dose, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. Dose escalation will be performed to determine the MTD and/or RP2D.
3486106|NCT03748069||Influenza positive CAPIV|All consecutive patients older than 18 years, admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
3486107|NCT03748069||Influenza negative CAPIV|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza
3486108|NCT03748056|Experimental|Targeted incentives arm|The interventions received by the experimental group include: 1) weekly emails with targeted coupons for healthier products, 2) weekly emails with targeted nutrition education, and 3) and a nominal discount on grocery purchases for using their loyalty card
3486109|NCT03748056|Active Comparator|Usual care arm|"The interventions included under usual care include 1) untargeted nutrition education, 2) occasional untargeted coupons for healthier products, and 3) a nominal discount on their grocery purchases for using their loyalty card. These interventions are only received by participants randomized to the usual care arm (rather than the entire population of shoppers), and will allow for testing whether targeting discounts and nutrition education improves the diet quality of purchases in comparison to untargeted approaches."
3486110|NCT03748043|Experimental|lactoferrin+ferric hydroxide polymaltose|lactoferrin 100 mg /day plus ferric hydroxide polymaltose 6 mg /kilogram body wight for 3 months
3486111|NCT03748043|Experimental|ferric hydroxide polymaltose|6 mg /kilogram body wight of ferric hydroxide poly maltose per day for 3 months
3486112|NCT03748030||Confirmed Left-Sided Breast Cancer|T1/T2 N0, T1/T2 N1, T3/T4 and/or N2/N3 Left-Sided Breast Cancer Patients receiving standard radiation therapy will receive PET/MRI, ECG/EKG, and bloodwork before, within a month, and within a year post treatment.
3486113|NCT03748017|Placebo Comparator|Placebo-Control Supplement|12 participants will receive a placebo-control supplement per daily oral feeding.
3486114|NCT03748017|Active Comparator|Streptococcus-Containing Probiotic Supplement|12 participants will receive a powdered probiotic containing 7.77 billion colony-forming units (CFU) of L. acidophilus, 8.25 billion CFU of B. lactis, and 2 billion CFU of S. salivarius bacteriocin-like inhibitory substance (BLIS) K12 per daily oral feeding.
3486115|NCT03748004|Experimental|Adults living in the DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
3486116|NCT03748004|Placebo Comparator|Individuals 19 yrs or older settled in DTES|"36 out of the 72 recruited participants who live in the DTES will be randomly assigned to the intervention group (IPS & Peer Support). The IPS and Peer Support will actively work and support with each of the 36 participants in seeking employment and education for 16 weeks. IPS/SP will help participants identify their employment and educational goals, identify potential employers, help prepare their resumes and for interviews, and provide ongoing support during the 16 weeks.~36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services."
3486117|NCT03747978|Experimental|Perindopril and Amlodipine|Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
3128334|NCT03141281|Experimental|IADL training|Participants will be enrolled in American Association of Retired Persons' web-based driver training course, trained on how to access it, and asked to complete the course, estimated to take approximately 6-8 hours. They will also be provided with web-based access to a finance and fraud avoidance training tutorial, instructed on how to access it, and be asked to complete the course, estimated to take approximately 5-7 hours. The two courses combined are estimated to take about 15 hours.
3128335|NCT03141281|Active Comparator|Active Control|Participants will be provided with a laptop computer and asked to complete 20 hr of training with Sudoku, crossword puzzles, and word search
3128336|NCT03141307|Active Comparator|Intervention|The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure.
3128337|NCT03141307|Placebo Comparator|Control|This group will receive the standard of care currently used (paper-based brochure)
3486118|NCT03747978|Active Comparator|Perindopril-Indapamide|Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks
3486119|NCT03747965|Experimental|Mesothelin-directed CAR-T cells infusion|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation."
3486120|NCT03747913|Experimental|Antioxidative Supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
3486121|NCT03747900|Experimental|BTX-A|Patients underwent 200 U BTX-A injections in biceps brachii muscle.
3486122|NCT03747900|Active Comparator|BTX-A+Dry needling|Dry needling was administered for 4 times in total after the BTX-A injection.
3486123|NCT03747887|Active Comparator|School as Usual|School as usual comparison condition.
3486124|NCT03747887|Experimental|Daily Report Card|A coach will establish a Daily Report Card based on IEP goals and objectives with the parents/teachers of the child in this arm.
3486125|NCT03747874|Other|past medical history of sudden hearing loss|sleep examination and ventilatory polygraphy device for 1 night
3486126|NCT03747861|Other|Arm for HRV monitoring|For monitoring HRV each subject will put Wristband for registration of ECG RR intervals for one hand, SenceBand in the left wrist and Holter monitor electrodes will be placed in standard configurations places.
3486127|NCT03747848|Experimental|CBT group|Subjects will participate in group treatment sessions (once a week for six weeks).
3486128|NCT03747835|Active Comparator|Exposure and Response Prevention|Inpatients will be provided three 90-minute sessions of Exposure and Response Prevention therapy each week.
3486129|NCT03747835|Active Comparator|Motivational Interviewing|Inpatients will be provided two 60-minute sessions of Motivational Interviewing each week.
3486130|NCT03747822|Active Comparator|autogenous fat|autogenous fat augmentation in deficient chin will be harvested from lower abdomen,inner or outer thigh
3486131|NCT03747822|Active Comparator|PEEK|Will use onlay PEEK augmentation in deficient chin.Virtual planning will be done using mimics software. A virtual osteotomy of the chin will be performed at the inferior border of the mandible same alignments as sliding genioplasty, then segmentation of the chin area will be done and according to the soft tissue analysis adjustment will be performed.
3486132|NCT03747822|Other|Osseous sliding genioplasty|Under general anesthesia, the preparation and the incision line will be performed same as PEEK augmentation .After complete exposure of the bone repositioning of the chin will be performed. Finally fixation will be obtained using x shape titanium plate.
3486133|NCT03747809||Patients with CIEDs having Remote Monitoring|
3486134|NCT03747809||Patients with CIEDs having no Remote Monitoring|
3486135|NCT03747796|Active Comparator|supine position|The children will be in the supine position after ingestion of a standard volume of clear fluid.
3128338|NCT03141372|Active Comparator|Autofill Void Trial|"Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL, the void trial will be considered failed and a Foley catheter will be replaced."
3128339|NCT03141372|Active Comparator|Backfill Void Trial|"About 300 mL of fluid will be instilled into the bladder and the Foley will then be removed. The participant will be given up to 1 hour to urinate and the amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR > 100 mL or if the patient is unable to void within the hour, the void trial will be considered failed and a Foley catheter will be replaced."
3128340|NCT03141528|Active Comparator|Instructor-led learning|This group will train their technical CPR-skills with supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
3128341|NCT03141528|Experimental|Self-learning|This group will Train alone without supervision and without communicating with the other participants.
3128342|NCT03141788|Other|3M Clear Aligner|Clear Aligner for Orthodontic Treatment
3128343|NCT03141905|Active Comparator|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVRSDRS weekly remote monitoring
3128344|NCT03141905|Placebo Comparator|Usual Care|Standard clinical care
3128345|NCT03141931|Experimental|Supplement|Combination of flaxseed oil, borage oil and fish oil omega-3 fatty acids
3128346|NCT03141931|Placebo Comparator|Placebo|Polyethylene glycol, Oleic acid, Propylene glycol
3486136|NCT03747796|Experimental|Semi-sitting position|The children will be in the semi-sitting position after ingestion of a standard volume of clear fluid.
3486137|NCT03747783||Survival Group|status from radical operation to follow-up
3128347|NCT03142438|Experimental|F&P Seal Improvement Project|participants will be placed on this arm for a total of 14 +- 4 days from visit 1. participants will be using the trial mask during this treatment arm
3128348|NCT03142451|Experimental|FMX103 1.5%|Participants will apply the assigned FMX103 minocycline foam 1.5% topically once daily for 12 weeks as directed.
3128349|NCT03142451|Placebo Comparator|Vehicle foam|Participants will apply the assigned vehicle foam topically once daily for 12 weeks as directed.
3486138|NCT03747783||Non-Survival Group|status from radical operation to follow-up
3486139|NCT03747770|No Intervention|Cross-sectional baseline survey|This are will collect behavioral questionnaire and urine in Grade 10 high school and Year 1 vocational school and Grade 12 high school and Year 3 Vocational school female students
3486140|NCT03747770|Active Comparator|Single Dose HPV vaccination|Grade 8 female students from Udon Thani Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Single Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
3486141|NCT03747770|Active Comparator|Two-dose HPV vaccination|Grade 8 female students from Buriram Province This arm will collect behavioral questionnaire and blood prior vaccination Intervention: Two-Dose HPV Vaccination with CERVARIX®(Glaxo Smith Kline, GSK, Rixensart, Belgium)
3486142|NCT03747770|No Intervention|Cross-sectional survey at Year 2|This arm will collect behavioral questionnaire, urine and blood in Grade 10 high school and Year 1 vocational school female students
3486143|NCT03747770|No Intervention|Cross-sectional survey at Year 4|Cross-sectional survey at Year 4 post vaccination
3486144|NCT03747757|Experimental|Supportive Care (CBT)|Patients undergo CBT consisting of 7 counseling sessions, up to 45 minutes each over the phone.
3486145|NCT03747744|Experimental|CD1c (BDCA-1)+ myDC|CD1c (BDCA-1)+ myDC
3486146|NCT03747731||Resistive Index and Peep Titration|"Enrolled patients will receive a sequential, step-wise increase in PEEP from 0 cmH2O to 12 cmH2O. The inter-lobar arterioles will be sampled at each PEEP increment and the IR will be measured as the average of three values recorded at the upper and lower pole and at the mesorenes in each kidney.~Gas exchanges, HR, systolic, diastolic and mean PA, Pmax, P1 and P2 airway, total resistance and ohmic resistance and static respiratory compliance indexed for body weight (RRSmaxI, RRSminI, CrsI) will be measured at each Peep Level.~The physiologic measurements will be obtained at regular intervals (within 15 minutes at each PEEP level) throughout the PEEP titration period."
3486147|NCT03747718|Experimental|Fecal Microbiota Follow up Enemas|In this arm subjects will receive 3 fecal microbiota transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
3486148|NCT03747718|Placebo Comparator|Placebo Enemas|In this arm subjects will receive 3 placebo transplants at 1 monthly intervals at 1.5, 2.5 and 3.5 months (+/- 2 weeks) after transplant
3486149|NCT03747692|Experimental|study group|patient put in dorsal postion , insertion of a speculum , sterilization of the cervix then intracervical injection of 5 ml mepicaine hydrochloride a local anasthetic as Carbocaine3%54 mg at site 3 and 9 using a 10 cm syringe
3486150|NCT03747692|Placebo Comparator|control group|patient receives one tablet of NSAIDs (diclofenac sodium 50 mg )15 minutes before procedure then 5 ml of normal saline will be injected intracervical using 10 cm syringe then wait for 5 minutes before the procedure
3128350|NCT03142750|Experimental|Enrolled subjects|There is only one arm to this study. The intervention includes providing one week supply of each of two gastrostomy tube dressing prototypes to try at home.
3128351|NCT03142932|Active Comparator|Control|A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute (NCI) 5 A's model.
3128352|NCT03142932|Experimental|COach2Quit|"A certified smoking cessation interventionist (SCI) will deliver standardized smoking cessation counseling using the National Cancer Institute's 5 A's model.~Participants in the COach2Quit arm will be provided with an individualized carbon monoxide (iCO) monitor along with instructions on the use of the monitor and the COach2Quit application."
3128353|NCT03143101|Experimental|FluMist trivalent (2015-2016)|Participants will receive intranasal spray of 0.2 milliliter (mL) (total dose in both nostrils) FluMist trivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain. Strains included in the trivalent vaccine were: A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), and B/Phuket/3073/2013 (B/Yamagata-lineage).
3128354|NCT03143101|Experimental|FluMist Quadrivalent (2015-2016)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were A/H1N1 (A/Bolivia/559/2013), A/H3N2 (A/Switzerland/9715293/2013), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
3128355|NCT03143101|Experimental|FluMist Quadrivalent (2017-2018)|Participants will receive intranasal spray of 0.2 mL (total dose in both nostrils) FluMist quadrivalent vaccine on Days 1 and 28. Each 0.2 mL dose contained 10^7±0.5 FFU of each vaccine strain. Strains included in the vaccine were the new A/H1N1 (A/Slovenia/2903/2015), A/H3N2 (A/New Caledonia/71/2014), B/Phuket/3073/2013 (B/Yamagata-lineage), and B/Brisbane/60/2008 (B/Victoria-lineage).
3128356|NCT03143166|Experimental|All participants|Dabigatran etexilate given without rabeprazole and then Dabigatran etexilate given without rabeprazole.
3128357|NCT03143569|Active Comparator|aPTT nomogram|aPTT guided heparin management
3128358|NCT03143569|Experimental|Anti-factor Xa nomogram|Anti-factor Xa guided heparin management
3128359|NCT03143855|Experimental|Lorcaserin|
3128360|NCT03143855|Placebo Comparator|Control Group|
3128361|NCT03143894|Active Comparator|Active tDCS first|2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
3128362|NCT03143894|Sham Comparator|Sham tDCS first|Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.
3132751|NCT03449030|Experimental|Part B Expansion Stage: TAK-164 Q3W|TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 RP2D dose to be decided based on safety, PK, pharmacodynamics and antitumor response data observed in Part A escalation stage.
3486151|NCT03747679|Experimental|A- Bosutinib in water|200 Mg of bosutinib (50 mg capsule x4) in Water solution
3486152|NCT03747679|Experimental|B- bosutinib in sorbitol|200 Mg of bosutinib sorbitol base in water solution
3486153|NCT03747679|Experimental|C- - bosutinib mannitol|200 Mg of bosutinib powder mannitol base in water solution
3486154|NCT03747679|Experimental|D - bosutinib in mannitol low sweet|200 Mg of bosutinib mannitol low sweet solution
3486155|NCT03747679|Experimental|E- - bosutinib in mannitol high sweet|200 Mg of bosutinib High % sweet mannitol solution
3486156|NCT03747679|Experimental|F- - bosutinib low flavour|Taste assessment of 200 Mg of bosutinib low % Flavour
3486157|NCT03747679|Experimental|G- bosutinib high flavour|Taste assessment of 200 Mg of bosutinib high percentage of flavor in water
3486158|NCT03747679|Experimental|H- - bosutinib capsules in low sweet|Taste assessment of 200 Mg of bosutinib (50 mg x4 capsules) low % sweet
3486159|NCT03747679|Experimental|I - bosutinib capsules high sweet|200 Mg of bosutinib (4 X 50 mg capsules)in high % sweetener
3486160|NCT03747679|Experimental|J- - bosutinib capsules low flavour|Taste assessment of 200 Mg of bosutinib (50 mg X4 capsules) in Low % flavour Water solution
3486161|NCT03747679|Experimental|K - bosutinib capsules high flavour|Taste assessment of 200 Mg of bosutinib (50 mg X 4 capsules) in high % flavour
3486162|NCT03747679|Experimental|L - bosutinib capsules applesauce|200 Mg of bosutinib (50 mg x 4 capsules) in applesauce
3128363|NCT03144089|Active Comparator|Guedel oral airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Guedel oral airway first and measurements were taken during breaths 6 through 10. After its removal the Articulated Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
3128364|NCT03144089|Experimental|Articulated Oral Airway|Each participant in the study will have both devices (GOA or AOA). The participants reported in this arm were randomized to receive the Articulated oral airway first and measurements were taken during breaths 6 through 10. After its removal the Guedel Oral Airway was inserted and measurements were repeated again during breaths 6 through 10.
3128365|NCT03144180|No Intervention|Control|The Q-cup will not be used to collect umbilical cord blood.
3486163|NCT03747679|Experimental|M - bosutinib capsules full fat yougurt|200 Mg of bosutinib (50 mg x 4 capsules) in full fat yogurt
3486164|NCT03747679|Experimental|N - bosutinib capsules in water (retest)|200 Mg of bosutinib (50 mg x 4 capsules) in Water (retest)
3486165|NCT03747666|Experimental|Locking miniplate|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
3486166|NCT03747666|Experimental|Non-locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 two non-locking miniplates and the fractured segments of the angle will be fixed conventionally using 2.0 single non-locking miniplate placed on the external oblique ridge.
3486167|NCT03747653||Arm 1|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a low dose.
3486168|NCT03747653||Arm 2|Participants will receive a single intravenous (i.v.) injection of ADVATE followed by a single intravenous (i.v.) injection of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection (FRSW107) at a high dose.
3128366|NCT03144180|Active Comparator|Study Group|The Q-cup will be used to collect umbilical cord blood.
3128367|NCT03144518|Experimental|Experimental|Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
3128368|NCT03144518|Active Comparator|Active Control|Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.
3128369|NCT03144635|Experimental|Grazoprevir plus Elbasvir|Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.
3128370|NCT03144687|Experimental|Cohort A|Participants with MF who were tolerating a ruxolitinib dose of less than 20 milligrams (mg) daily with no dose increase or no dose modification in the 8 weeks before screening visit received a combination of the itacitinib at the dose of 200 mg, orally, once daily (QD) and ruxolitinib, orally, twice daily (BID) at their previous stable dose (must had been < 20 mg daily). Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
3128371|NCT03144687|Experimental|Cohort B|Participants with MF who progressed after initial reduction in spleen with ruxolitinib treatment, progressed or discontinued for hematologic toxicities received treatment with itacitinib alone at the dose of 600 mg QD. Participants continued study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or other Protocol-specified criteria to stop treatment are met.
3128372|NCT03144804|Experimental|Lamivudine|"Lamivudine administered orally every 4 weeks~Treatment cycles will last 28 consecutive days~The dosage will be determine by the PI"
3128373|NCT03145064|Experimental|Zanubrutinib|Participants received zanubrutinib BID.
3128374|NCT03145207|Other|name brand patch|name brand lidocaine patch
3128375|NCT03145207|Other|generic patch|generic lidocaine patch
3128376|NCT03145207|Other|name brand patch-early|name brand lidocaine patch-early
3128377|NCT03145207|Other|name brand patch-late|name brand lidocaine patch-late
3128378|NCT03145207|Other|generic patch-early|generic lidocaine patch-early
3128379|NCT03145207|Other|generic patch-late|generic lidocaine patch-late
3128380|NCT03145207|Other|both patches|brand name and generic lidocaine patch
3128381|NCT03145259|Other|Diclofenac patch|Study Session 1: diclofenac epolamine patches (PK) [51 h study duration]
3128382|NCT03145259|Other|Diclofenac solution|Study Session 2: diclofenac sodium solution (PK) [47 h study duration]
3486169|NCT03747640|Experimental|tDCS with mindfulness-based meditation|Self Transcranial Direct Current Stimulation (tDCS) with Mindfulness-Based Meditation
3486170|NCT03747640|Sham Comparator|sham tDCS with sham meditation|Sham self Transcranial Direct Current Stimulation (tDCS) with sham Meditation
3486171|NCT03747614|Experimental|Dry eye group|The recruitment of subjects met the criteria of DEWS. Each subject received treatment based on increasing severity according to the expert consensus for the treatment of DE inflammation. For moderate levels of severity, topical anti-inflammatory agents (0.1% Fluorometholone) were administered twice daily and then gradually less frequently until inflammation was controlled. For severe DE, the approach was similar to that of the moderate level but with an increased concentration and treatment frequency of the anti-inflammatory agents (0.1% Fluorometholone, 4 times daily). Topical 0.05% tacrolimus twice daily when DE was extremely severe. Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
3486172|NCT03747614|Experimental|Control group|Normal health subject without drug intervention, Functional Slit-Lamp Biomicroscopy were administrated to collected data from this group.
3486173|NCT03747601|Experimental|Temporal Interference (TI) Stimulation|Temporal Interference stimulation applied to the head via standard electrodes
3486174|NCT03747588|Experimental|Laparoscopic Pancreaticoduodenectomy|LPD
3486175|NCT03747588|Placebo Comparator|Open Pancreaticoduodenectomy|OPD
3128383|NCT03145259|Other|Diclofenac patch and solution|Study Session 3: diclofenac epolamine patch pieces and diclofenac sodium solution (no PK, for skin tape stripping) [51 h study duration]
3128384|NCT03145766|Experimental|Group 1: VRVg-2 Formulation 1|VRVg-2 formulation 1, intramuscular (IM) injection on Days 0, 3, 7, 14 and 28. Concomitant administration of human rabies immunoglobulins (HRIG) on Day 0.
3486176|NCT03747575|Experimental|Treatment|Participants will receive MSTT1041A
3486177|NCT03747575|Placebo Comparator|Placebo|Participants will receive placebo matched to MSTT1041A
3486178|NCT03747562|Experimental|Experimental group|"Patients randomised to the experimental group will receive a prescription for a gabapentin starting dose of 100 mg three times a day (ter in die, t.i.d) /day per orally, additional to the analgesics according to standard local practices.~Gabapentin dosage may be gradually increased based on individual patient response and tolerability, and as per standard practice in accordance with the drug label. The dose can be further increased in 300 mg/day increments (dose increments of 50% - 100%) every two to three days, up to a maximum dose of 3600 mg/day. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of two weeks, and to reach 3600 mg/day is a total of three weeks."
3486179|NCT03747562|Placebo Comparator|Control group|Patients randomised to the control group will receive a prescription for a matching placebo. The starting dose will be the same as in the experimental group (100 mg three times a day per orally), additional to the analgesics according to standard local practices. Placebo can optionally follow the same dose scheme as described in the experimental arm.
3486180|NCT03747549|Experimental|Acupuncture and Home Exercise|Acupuncture and home exercise.
3486181|NCT03747549|Active Comparator|Home Exercise Alone|The prescribed home exercise program alone.
3486182|NCT03747536|Experimental|Intervention|ipratropium bromide administered via metered dose spray (21 micrograms per spray). 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
3128385|NCT03145766|Experimental|Group 2: VRVg-2 Formulation 2|VRVg-2 formulation 2, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
3128386|NCT03145766|Experimental|Group 3: VRVg-2 Formulation 3|VRVg-2 formulation 3, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
3486183|NCT03747536|Placebo Comparator|Placebo|normal saline administered via metered dose spray. 1-2 spray sublingual or to buccal mucosa every 6 hours up to 4 times a day
3486184|NCT03747523|Experimental|Healthy Group|40 Healthy individuals will receive a single dose of ergocalciferol (200,000 units)
3486185|NCT03747523|Experimental|ADTKD-MUC1 Group|40 individuals with ADTKD-MUC1 (Autosomal Dominant Tubulo-Interstitial Kidney Disease- a rare disease caused by mutation in MUC1) will receive a single dose of ergocalciferol (200,000 units)
3486186|NCT03747510|Experimental|CarpX Device|Transverse carpal ligament release with CarpX Device
3486187|NCT03747471|Experimental|Experimental Arm|Intervention: Diabetic Conversation Map x 4 Sessions
3486188|NCT03747471|No Intervention|Control Arm|No intervention
3486189|NCT03747458|Active Comparator|OPN-375 186 μg BID|"Double-Blind Treatment Phase: OPN-375 186 μg BID x 16 weeks~Open-Label Extension Phase: OPN-375 186 μg BID x 12 weeks"
3486190|NCT03747458|Placebo Comparator|Placebo|Double-Blind Treatment Phase: Matching Placebo BID x 16 weeks
3128387|NCT03145766|Experimental|Group 4: VRVg-1|VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
3128388|NCT03145766|Active Comparator|Group 5: Imovax Rabies|Imovax Rabies, IM injection on Days 0, 3, 7, 14 and 28. Concomitant administration of HRIG on Day 0.
3486191|NCT03747445||Roux-en-Y gastric bypass patients|severely obese non-diabetic adult female patients scheduled for RYGB
3486192|NCT03747445||Normal weight controls|normal weight healthy non-diabetic adult females
3486193|NCT03747445||Obese controls|Severely obese non-diabetic adult female patients not scheduled for RYGB
3486194|NCT03747432|Experimental|Propofol|Conscious sedation with propofol during the TAVR procedure (anticipated around 2 hours), dosage: 0,5-2,5 mg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
3486195|NCT03747432|Experimental|Dexmedetomidine|Conscious sedation with dexmedetomidine during the TAVR procedure (anticipated around 2 hours), dosage: bolus of 0,5 mcg/kg during 10 minutes, then continuous infusion of 0,2-1 mcg/kg/h for appropriate level of sedation - Ramsay sedation score 3-4)
3486196|NCT03747419|Experimental|Avelumab and Bladder-Directed Radiation|"Avelumab will be administered every 2 weeks intravenously for 6 doses unless there is unacceptable toxicity~Two radiation dose regimens are allowed, and the regimen selected is at the discretion of the treating radiation oncologist"
3486197|NCT03747406|Experimental|ESP group|The patient rolled to his side, the level between T9 and T10 identified using ultrasound. An 8-14 MHz curved array probe (Siemens ACUSON X300 Ultrasound System) will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced inplane until contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration confirmed. The same procedure will be repeated in the contralateral side.
3486198|NCT03747406|Experimental|TAP group|The patient in supine position. Under complete aseptic conditions, a linear array transducer 5-12 MHz (Siemens ACUSON X300 Ultrasound System) will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge, 8 cm Tuohy needle (Perifix Epidural Needle) will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
3486199|NCT03747406|No Intervention|opioid group|will receive intravenous morphine with general anesthesia and total opioid consumption will be calculated
3486200|NCT03747393|Active Comparator|DoD/VA CPG Core Set|The standard core set of interventions recommended by the DoD/VA clinical practice guidelines for non-surgical management of knee OA.
3486201|NCT03747393|Experimental|DoD/VA CPG Core Set + PT|In addition to DoD/VA clinical practice guidelines, patients will be referred to physical therapy (PT). Physical therapy will consist of evidence-based interventions that can be provided by a PT (exercise, manual therapy, education).
3486202|NCT03747380|Experimental|inspiratory muscle program|Inspiratory muscle training preoperative with standard of care
3486203|NCT03747380|Other|no inspiratory muscle program|standard of care: postoperative spirometry with enhanced recovery program in thoracic surgery
3486204|NCT03747367|No Intervention|Baseline|8 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab. Repeated for visit 1 and visit 2.
3486205|NCT03747367|Experimental|Insufficient Sleep|3 days with 3 hour sleep opportunities in lab, immediately following baseline on both visit 1 and visit 2.
3486206|NCT03747354|Active Comparator|complete blood count|blood samples will be taken from patient and complete blood count is done early morning
3486207|NCT03747354|Active Comparator|erythrocyte sedimentation rate|blood samples will be taken from patient and erythrocyte sedimentation rate is done
3486208|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine Low|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=low dose buprenorphine + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
3486209|NCT03747341|Experimental|Part A (Healthy Participants): Placebo-Buprenorphine High|"Three treatment periods consisting of 3 days each of investigational treatment~1=placebo + fentanyl,~2=high dose buprenorphine + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
3486210|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine Low-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=low dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=low dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
3486211|NCT03747341|Experimental|Part A (Healthy Participants): Buprenorphine High-Placebo|"Three treatment periods consisting of 3 days each of investigational treatment~1=high dose buprenorphine + fentanyl,~2=placebo + fentanyl,~3 (optional)=high dose buprenorphine only~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.075, 0.15, 0.25 and 0.35 mg/70 kg.~Each dosing period was followed by 10-17 days of washout."
3486212|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Low|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=low dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
3128389|NCT03145818||Veterans|Veterans will be the primary group for whom the VD-HCBS Program is implemented. Veterans enrolled in VD-HCBS will be functionally impaired
3128390|NCT03145818||Caregivers|Caregivers support Veterans independence in their home and community
3128391|NCT03145818||VHA Coordinators|VHA VD-HCBS Coordinators allow the program to operate within the VA
3128392|NCT03145818||ADNA Coordinators|ADNA Coordinators engage with the Veteran, Caregivers, and VA Coordinators to ensure the Veteran is able to maintain independence
3128393|NCT03146403|Experimental|GEN-003|60μg of each GEN-003 antigen with 50μg Matrix-M2 adjuvant, administered as a 0.5mL intramuscular (IM) injection
3128394|NCT03146403|Placebo Comparator|Placebo|0.9% normal saline administered as a 0.5mL intramuscular (IM) injection
3128395|NCT03146585||Patients on artificial ventilation|
3128396|NCT03146585||Patients on renal replacement therapy|
3128397|NCT03146585||Patients with targeted temperature management|
3128398|NCT03146663|Experimental|Arm A|NUC-1031 500 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
3128399|NCT03146663|Experimental|Arm B|NUC-1031 750 mg/m2 administered on Days 1, 8, and 15 of 28-day cycles
3128400|NCT03146741|Experimental|Zepatier (grazoprevir 100mg and elbasvir 50 mg)|
3128401|NCT03146806|Experimental|Intranasal ketamine treatment|Study participants who are receiving intranasal ketamine treatments.
3486213|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine Mid|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=mid dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
3486214|NCT03747341|Experimental|Part B (Opioid-Tolerant): Placebo-Buprenorphine High|"Opioid-tolerant participants in Part B undergo a washout of their own opioids during which these were replaced with oral oxycodone, and continue at stable doses of oxycodone from at least 48 hours before Period 1 to the end of Period 2.~Two treatment periods:~1=placebo (Day 1),~2=high dose buprenorphine + fentanyl (Day 3)~Fentanyl was administered as a bolus over 90 seconds in escalating doses of 0.25, 0.35, 0.5 and 0.7 mg/70 kg."
3486215|NCT03747328|Experimental|ABI-009|nanoparticle albumin bound sirolimus (ABI-009). Dose levels 1, 2.5, 5 and 10 mg/m2 given weekly for 8 cycles of ABI-009 (each cycle is weekly dosing for 2 weeks followed by a week of rest (qw2/3))
3486216|NCT03747315||Familial Mediterranean Fever (patients)|Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)
3486217|NCT03747315||Control group (patients)|Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.
3486218|NCT03747315||Healthy donors|Patients without symptoms (anonymous blood donors)
3486219|NCT03747302|Experimental|HPV Messaging|Subjects are randomized to receive one of five messages on one of the four themes about HPV vaccination.
3486220|NCT03747302|Other|Control Message|Subjects are randomized to receive one of five messages about electronic cigarettes.
3486221|NCT03747289|Experimental|weight bearing group|performing exercises in a weight bearing posture
3486222|NCT03747289|Active Comparator|non-weight bearing group|performing exercises in a non- weight bearing posture
3486223|NCT03747276|Other|Clinical Trial Kiosk|
3486224|NCT03747263|Experimental|Individual Freeze-Catheter ablation|"The individualized time-to-effect protocol utilizing the AFA-Pro applies a freeze-cycle until documentation of PVI based on continuous real-time recordings from the Achieve catheter inside the PV. After documentation of PVI the freeze-cycle is prolonged for additional 90 seconds. If no PVI is achieved after 90 seconds or a temperature of -<30° is not reached after 40 seconds the freeze cycle is stopped, the cryoballoon will be repositioned to possibly achieve a better position. Afterwards the freeze-cycle will be restarted. If no real-time PV signal recording can be obtained, a standard freeze-cycle of 180 seconds is applied. No bonus-freeze-cycle is applied in this protocol."
3486225|NCT03747263|Active Comparator|Fixed Freeze-Catheter ablation|The fixed-freeze-cycle protocol utilizing the AFA-Pro comprises a fixed freeze-cycle duration of 180 seconds. If PVI is not achieved with the first freeze-cycle, another 180 seconds freeze-cycle will be applied until documented PVI. After PVI no bonus freeze-cycle is applied.
3486226|NCT03747250|Experimental|Videolaryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of videolaryngoscope
3486227|NCT03747250|Active Comparator|Direct laryngoscopy|Pediatric patients undergoing elective surgery with planned tracheal intubation for airway management. The tracheal intubation will be performed with the use of direct laryngoscopy
3486228|NCT03747237|Experimental|1. method, Edema measurement methods|"The surgeon will measure from three different places on the patient's face with the help of a paper ruler to measure the edema.~Tragus-Pogonion Tragus-Labial Comissura Angulus Mandible-Latheral Cantus Measurements will be made preoperative, postoperative 2. and 7. days and saved as milimetre."
3486229|NCT03747237|No Intervention|2. method, Edema measurement methods|Patients will be given edema scale.With the help of the edema scale, the patients will be evaluated the edema by themselves. When the patient stand in front of the mirror, they will be assessed the edema on their face. And a value between 0 and 5 will be pointed on the scale postoperative 2. and 7. days.
3486230|NCT03747224|Experimental|ARO-ANG3|
3486231|NCT03747224|Placebo Comparator|Placebo|
3486232|NCT03747211|Experimental|Aerobic exercise intervention|Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
3486233|NCT03747211|No Intervention|Control group|No intervention for 12 weeks
3486234|NCT03747198|Experimental|methylsulfonylmethane|Subjects will be given 2 g/day of methylsulfonylmethane (MSM). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points (ovulation, menstruation).
3128402|NCT03147248|Active Comparator|Cohort 1: CT-P13 IV 3 mg/kg|CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
3128403|NCT03147248|Experimental|Cohort 2: CT-P13 SC 90 mg|CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
3128404|NCT03147248|Experimental|Cohort 3: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
3128405|NCT03147248|Experimental|Cohort 4: CT-P13 SC 180 mg|CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
3128406|NCT03147248|Experimental|Arm 1: CT-P13 SC 120 mg|CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
3128407|NCT03147248|Active Comparator|Arm 2: CT-P13 IV 3 mg/kg|CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
3128408|NCT03147495||the study group|The participants with medial compartment knee osteoarthritis and without lateral compartment knee osteoarthritis according to the Ahlbäck classification.
3128409|NCT03147495||the control group|The healthy volunteers without knee osteoarthritis according to the American College of Rheumatology criteria for the classification and reporting of OA of the knee joint. Radiographic evidence of the knee with Ahlbäck classification grade 0.
3179779|NCT00676507|Placebo Comparator|Control Arm|Control Arm: This course of therapy is Best Support Care (BSC) plus a placebo injection that consists of 0.15% Intralipid® in solution composed of the cryopreservation formulation minus the gene modified cells and dimethyl sulfoxide (DMSO) in a volume of 0.40 mL.
3486235|NCT03747198|Placebo Comparator|Placebo|Subjects will be given 2 g/day placebo (rice flour). Salivary estrogen will be measured around ovulation and menstruation each month for 3 months. Knee laxity will be measures 2 times per month at the same time points as the intervention arm (ovulation, menstruation).
3486236|NCT03747185|Experimental|Lumbopelvic stiffening technique|Hamstring muscle stretching with lumbopelvic stiffening technique.
3486237|NCT03747185|Active Comparator|Lumbopelvic relaxing technique|Hamstrings muscle stretching with lumbopelvic relaxing technique.
3486238|NCT03747159|Experimental|BLM+RTX treatment arm|"Intervention 1 Belimumab injection: subcutaneous weekly injections with 200mg belimumab (BML) for the duration of the entire study period of two years.~Intervention 2 Rituximab infusion: Two intravenously infusions of 1000mg rituximab (RTX) at week 4 and week 6 after the start of belimumab.~Intervention 3: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L."
3486239|NCT03747159|No Intervention|Standard of Care treatment arm|"Intervention 1: Standard of care: induction therapy with three intravenously infusions methylprednisolone of 1000mg (or 500mg if weight is below 60kg), oral prednisolone 60mg with a quick tapering scheme to reach 5mg in 10 weeks and mycofenolate mofetil start dosis 500mg twice daily with maximum dosis of 2000mg twice daily depending on tolerance and area under curve (AUC) aimed at 60mg*hour/L.~Optional intervention: (if patients flare or are non-responders on mycofenolate mofetil + prednisolone) : Two intravenously infusions of 1000mg rituximab at week 4 and week 6 after the start of belimumab."
3128410|NCT03147690|Experimental|All Study Participants|All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL
3486240|NCT03747146|Active Comparator|Continuous Adductor Canal Catheter (ACC)|Patients will receive a combined spinal epidural, PAI, IPACK, and a continuous adductor canal catheter
3486241|NCT03747146|Sham Comparator|Adductor Canal block with sham catheter|Patients will receive a combined spinal epidural, PAI, IPACK, and an adductor canal block. The patient will also receive a sham catheter.
3486242|NCT03747133|Experimental|Stereotactic Ablative Radiotherapy|Adult patients with Kidney mass (either primary or metastasis) amenable to SABR
3486243|NCT03747120|Active Comparator|Arm A: THP|"Arm A: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
3486244|NCT03747120|Experimental|Arm B: THP-K|"Arm B: Paclitaxel weekly x12 + Trastuzumab + Pertuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
3486245|NCT03747120|Experimental|Arm C: TH-K|"Arm C: Paclitaxel weekly x12 + Trastuzumab + Pembrolizumab~All subjects may receive standard of care systemic therapy after surgery per their treating physician's discretion."
3486246|NCT03747094|Active Comparator|Fentanyl group|
3486247|NCT03747094|Experimental|Ketamine group|
3486248|NCT03747081|Experimental|Rivoroxaban|Patients would be administered Enoxaparine (60 mg/SC/BID)in first day, after dicontinuing Enoxaparin in second day, Rivoroxaban 20 mg per day will use. .it would be given once a day.The total duration of Rivoroxaban would be 3 months.
3128411|NCT03148067||Patients|Patients with closed or open diaphyseal femoral and tibial fractures treated through intramedullary nailing for fracture fixation
3128412|NCT03148236|Active Comparator|Vitamin C|
3128413|NCT03148236|Placebo Comparator|Placebo|
3128414|NCT03148262|Experimental|The high flow nasal cannula|The Comfort Flo system will be used for the high flow nasal cannula during colonoscopy
3128415|NCT03148262|Placebo Comparator|The standard nasal cannula|The Salter nasal cannula will be used during the colonoscopy
3128416|NCT03148470|Experimental|intermittent theta burst stimulation|intermittent theta burst stimulation (iTBS) + Sham iTBS
3128417|NCT03148470|Experimental|continuous theta burst stimulation|continuous theta burst stimulation (cTBS) + Sham cTBS
3128418|NCT03148691|Placebo Comparator|Vehicle|Vehicle Topical Solution
3128419|NCT03148691|Active Comparator|A-101 Low Dose|A-101 Low Dose Topical Solution
3128420|NCT03148691|Active Comparator|A-101 High Dose|A-101 High DoseTopical Solution
3128421|NCT03148756|Experimental|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
3128422|NCT03148756|Active Comparator|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
3128423|NCT03148795|Experimental|Talazoparib|Talazoparib 1 mg daily
3128424|NCT03149042||CCTA|Patients who are scheduled for clinically mandated elective invasive coronary angiography (ICA) at Buffalo General Hospital.
3128425|NCT03149055|Experimental|Isavuconazole prophylaxis|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose. The minimum duration of prophylaxis with isavuconazole will be through D +60. Beyond day +60 discontinuation is at the discretion of the treating physician.
3128426|NCT03149172|Experimental|Equimatrix®|Equimatrix® + Mucograft or alternatives
3128427|NCT03149172|Experimental|Bio-Oss®|Bio-Oss® + Mucograft or alternatives
3128428|NCT03149172|Experimental|Endobon®|Endobon® + Mucograft or alternatives
3128429|NCT03149328|Experimental|Northern Alberta Renal Program (NARP)|Provide in NARP (intervention group), 1) an electronic tool (ePRO) that facilitates real time PRO data collection and feedback in clinical practice, and 2) educational support to multidisciplinary home dialysis clinicians about how to use PROs routinely in their practice.
3128430|NCT03149328|No Intervention|Southern Alberta Renal Program (SARP)|In SARP (comparator group), clinicians will not receive PRO feedback or education sessions.
3128431|NCT03149848|Experimental|Treatment A|Participants will be administered a single oral dose of CAB 30 mg after an overnight fast of at least 6 hours for 14 days in Period 1. Dosing of study medication on non-PK days may be with or without food.
3179780|NCT00676533|Experimental|Arm 1|
3179781|NCT00676559|Experimental|Group 1|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
3486249|NCT03747081|Active Comparator|warfarin|Patients would be administered Warfarin with overlap of Enoxaparine utill INR adjust to 2-3 then enoxaparine will disconstinue.it would be given once a day.The total duration of Warfarin would be 3 months
3128432|NCT03149848|Experimental|Treatment B|Participants will be administered a single dose of RBT 300 mg and a single dose of CAB 30 mg after an overnight fast of at least 6 hours once daily for 14 days in Period 2. Dosing of study medication on non-PK days may be with or without food.
3128433|NCT03149887|Experimental|Experimental|Injection of liposomal bupivacaine in surgical field at end of arthroscopic rotator cuff repair.
3486250|NCT03747068||anti-TNF|UC patients treated with maintenance anti-TNF therapy who underwent IPAA surgery
3486251|NCT03747068||CONTROL GROUP|UC patients who were not exposed to anti-TNF therapy
3486252|NCT03747055|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
3486253|NCT03747055|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
3486254|NCT03747042|Experimental|Treatment|"Drug: letrozole Take by mouth at a dose of 2.5 mg on days 7-56~Other: Blood Collection Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction~Procedure: biopsy/lumpectomy/mastectomy Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis"
3486255|NCT03747029||Patients with hyperparathyroidism|Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
3486256|NCT03747029||Patients with hypoparathyroidism|"Patients aged between 18-90 years old with diagnosed hypoparathyroidism. No intervention is provided.~."
3486257|NCT03747029||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~No intervention is provided."
3486258|NCT03747016|Experimental|High energy 2|In the second step, the experimental group (Group E2) was given high energy digestible food 300ml before the time of gastric emptying found in the first step before surgery.
3486259|NCT03747016|Active Comparator|Glucose 2|In the second step, Group G2 is given 5% glucose injection 300ml before the time of gastric emptying found in the first step before surgery.
3486260|NCT03747016|Placebo Comparator|Normal saline 2|In the second step, Group N2 is given normal saline 300ml before the time of gastric emptying found in the first step before surgery.
3486261|NCT03747016|No Intervention|Control 2|In the second step, the control group (Group C2) was not given any diet before surgery.
3486262|NCT03747016|Experimental|High energy 1|In the first step,The experimental group (Group E1) is treated with high energy digestible food 300ml.
3486263|NCT03747016|Active Comparator|Glucose1|In the first step, Group G1 is given 5% glucose injection 300ml
3486264|NCT03747016|Placebo Comparator|Normal saline 1|In the first step, Group N1 is given normal saline 300ml.
3486265|NCT03747003||HIV-infected male patients|Male patients (age 18-50 years) with HIV-infection and ongoing HAART therapy No intervention is provided
3486266|NCT03746977|Active Comparator|energy restriction and protein supplementation|Energy restriction of 500 kcal/d and total Protein Uptake (including Supplementation) of 1.2 g/kg body mass/d
3486267|NCT03746977|Active Comparator|Energy restriction, walking and protein|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d) and total protein uptake (including supplementation) of 1.5 g/kg body mass/d
3486268|NCT03746977|Active Comparator|Energy restriction, walking, protein and WB-EMS|Energy restriction of 250 kcal/d, increased energy consumption by walking (250 kcal/d), total protein uptake (including supplementation) of 1.5 g/kg body mass/d and WB-EMS application 1,5x 20 min/week
3486269|NCT03746951|Active Comparator|Fascia iliaca compartment block (FICB)|FICB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the groin.
3486270|NCT03746951|Active Comparator|Lumbar plexus block (LPB)|LPB is a local anesthetic nerve block, a type of local anesthesia, used for the hip, thigh, and knee. It is performed by inserting the needle into the back.
3486271|NCT03746938|Experimental|VB-C01|Surgical technique: Via left lateral thoracotomy, the heart is lifted and supported on two deep pericardial points with 4-0 or 5-0 Prolene double arrmed suture. Each suture is passed through the reinforced frame of the collagen membrane containing the stem cells (VB-C01) and then tied, while the upper part of the patch is held with forceps. After securing the lower part of the pericardial layer, the heart is allowed to slowly recover its position with the pericardial cavity while the collagen membrane is mobilized to cover all of the target area. If necessary, some sutures can be used to fix the patch VB-C01 to the epicardial surface of the heart. Each suture is likewise passed through the reinforced frame of the membrane.
3486272|NCT03746925|Active Comparator|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
3486273|NCT03746925|Experimental|SuperPATH|SuperPATH approach surgery to replace the hip.
3486274|NCT03746886||Breast-feeding women|A single breast-milk sample will be collected from 20 women who breast-feed their child (0-6 months old).
3486275|NCT03746847||Patients with Suspected Cardiac Sarcoidosis|patients with biopsy proven or suspected sarcoidosis (based on standard clinical imaging findings).
3486276|NCT03746834|Experimental|Treatment arm|Patients are given NASHA/Dx as a perianal injection
3486277|NCT03746821|Other|Biotin|Volunteers to take biotin suppliment
3486278|NCT03746808|Placebo Comparator|EMA only|Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults with an AUD who are receiving shelter-based treatment.
3486279|NCT03746808|Active Comparator|EMA + App/Treatment Messages|Phase III will pilot test the newly developed app for utility, satisfaction, and preliminary effectiveness in a group of 40 homeless adults with an AUD who are receiving shelter-based treatment. The investigators will compare Phase III participants (i.e., received Metrocare, EMAs, and tailored treatment messages) to Phase I participants (i.e., received Metrocare and EMAs only) to examine the preliminary effectiveness of the app.
3486280|NCT03746795|No Intervention|Standard spirometry|Standard spirometry measurement with a pneumotachograph alone.
3486281|NCT03746795|Experimental|EIT alone|Spirometric examinations realized using the EIT
3486282|NCT03746795|Experimental|Simultaneous standard spirometry and EIT|Simultaneous measurement by spirometer and EIT
3486283|NCT03746782||ACS using clopidogrel + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of clopidogrel + aspirin
3486284|NCT03746782||ACS using ticagrelor + aspirin|Apixaban combined with blood specimens (in vitro) from Acute Coronary Syndrome participants prescribed a regimen of DAPT in the form of ticagrelor + aspirin
3486285|NCT03746782||Healthy Donors|Apixaban combined with blood specimens (in vitro) from healthy participants
3486286|NCT03746769|Experimental|Single Arm Study|
3486287|NCT03746756|Experimental|SBIRT as Usual|The follow-up team will (a) contact participants within 24-48 hours to collect additional locator information and mailing a schedule card for the next interview, (b) receipt information in a management information system (MIS), (c) assign each case to a follow-up case tracker, (d) verify locator data, (e) conduct outreach for unverified cases and discussing them at weekly meetings, (f) mail thank-you cards to participants and collaterals, (g) schedule follow-up appointments, (h) mail 3 and 6 week post-enrollment flyers, (i) implement returned-mail procedures, (j) call participants 6 weeks before appointment to confirm date and location (phone vs. research office), (k) conduct outreach for unconfirmed cases and review them at weekly meetings, (l) complete follow-up interviews and scheduling next appointments, and (m) implement a no-show protocol.
3486288|NCT03746756|Experimental|SBIRT + RMC-PC|Patients will receive SBIRT plus the RMC protocol. The Linkage Manager (LM) will: 1) provide personalized feedback to participants about the status of their condition based on responses from the Global Appraisal of Individual Needs Quick version 3 (GAIN-Q3), 2) help participants resolve ambivalence about their dependence and moving them toward a commitment to change by accessing additional care, 3) address existing barriers to treatment, 4) schedule an assessment, and 5) facilitate reentry and engagement. The LM will stay in contact 2-3 times per week for two weeks to ensure that individuals both initiate and remain engaged in treatment.
3486289|NCT03746743||Preterm neonates|Neonates born between 32 and 37 weeks gestation
3179782|NCT00676559|Experimental|Group 2|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
3179783|NCT00676559|Experimental|Group 3|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks in combination with ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
3179784|NCT00676624||Uveitis|Patients suffering from uveitis, who have vitrectomy performed for diagnostic purpose
3128434|NCT03149887|Active Comparator|Control|Injection of inert placebo solution in surgical field at end of arthroscopic rotator cuff repair.
3128435|NCT03149991|Active Comparator|Ketamine/Brexpiprazole Arm|brexpiprazole up to 3 mg/day for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
3486290|NCT03746743||Fullterm neonates|Neonates born at or after 37 weeks gestation
3486291|NCT03746717|Experimental|Prineo|Skin closure with Dermabond Prineo occlusive wound closure system
3486292|NCT03746717|Active Comparator|Staples|Skin closure with staples
3486293|NCT03746691|Experimental|Citalopram, 20 mg, IV|After placement of a high resolution impedance manometry catheter (transnasally), citalopram will be administered IV over 30 minutes (20 mg in 100ml saline). Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
3128436|NCT03149991|Placebo Comparator|Ketamine/Placebo Arm|placebo for four weeks in combination with bi-weekly administration of intranasal ketamine (40 mg) for two weeks, followed by weekly administration of intranasal ketamine (40 mg) for two weeks
3128437|NCT03150043|Other|All Participants|All patients who agree to participate in the study will have the Masimo Rainbow Pulse CO-Oximeter non-invasive hemoglobin monitor placed on their finger during cesarean delivery. A CBC will be drawn immediately prior to delivery and this value will be compared to the values obtained from the monitor. The patients will be separated into quartiles based on total drop in hemoglobin (pre-op to post-op day 1) and the values from the monitor compared between quartiles.
3128438|NCT03150056|Experimental|GSK525762 + Abiraterone (+ Prednisone) (Arm A)|
3128439|NCT03150056|Experimental|GSK525762 + Enzalutamide (Arm B)|
3128440|NCT03150082|Experimental|Treatment sequence: A/B|Eligible subjects will be randomized to receive a single dose of Treatment A (GR37547 500 mg tablet) followed by Treatment B (ciprofloxacin 500 mg reference tablet) administered orally on Day 1 in each treatment period. The washout period will be of at least 7 days and not more than 14 days.
3179785|NCT00676624||Control group|"Patients suffering from either Epiretinal fibrosis og Macula hole who have vitrectomy performed for curative reasons"
3179786|NCT00676637||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
3486294|NCT03746691|Placebo Comparator|Placebo, IV|After placement of a high resolution impedance manometry catheter (transnasally), placebo (saline 100ml) will be administered IV over 30 minutes. Thereafter, the investigators will wait for 20 minutes, after which the volunteers will receive 10 wet swallows (5ml saline), to investigate esophageal peristalsis. Thereafter, a standard meal (1000kcal) will be given to the volunteers and recordings will continue for another 2 hours.
3486295|NCT03746678||C-Care Mobile Application|
3486296|NCT03746665|Experimental|meningococcal serogroup A conjugate|mothers will be vaccinated with meningococcal serogroup A conjugate vaccine between 28 - 34 weeks gestation
3486297|NCT03746665|No Intervention|control|serological samples from 100 control mother-infant pairs already recruited as part of the PROPEL trial, (SCC1433), NCT02628886
3486298|NCT03746652|Experimental|DId|Daratumumab, Ixazomib, Dexamethasone
3486299|NCT03746639|Active Comparator|therapeutic ultrasound group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy and therapeutic ultrasound over the paravertebral low back region.
3486300|NCT03746639|Other|therapeutic ultrasound untreated group|The patients will be treated with superficial heating, transcutaneous electrical nerve stimulation, exercise therapy over the paravertebral low back region.Therapeutic ultrasound will not be applied to this group.
3486301|NCT03746626||Hospice 1|Strathcarron Hospice, Scotland. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
3486302|NCT03746626||Hospice 2|Arthur Rank Hospice, England. All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
3486303|NCT03746626||Hospice 3|All consenting patients will either see chaplain or not as many times as per their choice, over eight week stay in day care at the hospice.
3486304|NCT03746613|Experimental|Minimally invasive robotic cochlear implantation with HEARO|
3486305|NCT03746574|Experimental|Intervention Clinics|Participants in the intervention clinics experienced a 12 session compassion curriculum intevention offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
3486306|NCT03746574|No Intervention|Control Clinics|Completed baseline, end of curriculum, and 6 month follow up survey. Otherwise no intervention
3486307|NCT03746561||spinal stenosis|Spinal stenosis is a narrowing of the spaces within your spine, which can put pressure on the nerves that travel through the spine. Spinal stenosis occurs most often in the lower back and the neck.
3486308|NCT03746548|Other|CM-ADHEAR|First patients use the Contact Mini (conventional bone conduction device used with a soft band or headband) then ADHEAR (adhesive bone conduction device)
3486309|NCT03746548|Other|ADHEAR - CM|First patients use ADHEAR (adhesive bone conduction device) then CM (conventional bone conduction device used with a soft band or headband)
3486310|NCT03746535|Active Comparator|patients without endometriosis|Control subjects will be healthy women, with regular menses every 26-34 days. Subjects will be excluded if they have any symptoms of endometriosis, including severe dysmenorrhea or progressive cyclic pelvic pain or prior surgery showing evidence of endometriosis
3486311|NCT03746535|Experimental|patients with endometriosis|Endometriosis will be diagnosed by history of the disease seen at the time of prior surgery or will be diagnosed by classic clinical symptoms of the disease (cyclic progressive pelvic pain) using prior surgical report reviewed by Dr. Taylor.
3486312|NCT03746522|Experimental|Setmelanotide|Dosage form: Subcutaneous injection Dosage: 3 mg Frequency: daily
3128441|NCT03150082|Experimental|Treatment sequence: B/A|Eligible subjects will be randomized to receive a single dose of Treatment B (ciprofloxacin 500 mg reference tablet) followed by Treatment A (GR37547 500 mg tablet) administered orally. The washout period will be of at least 7 days and not more than 14 days.
3128442|NCT03150108|Experimental|Non-Hispanic Caucasians|Subjects will receive single dose of 100 microgram (mcg) rhPTH(1-84) subcutaneous (SC) injection on Day 1.
3486313|NCT03746522|Placebo Comparator|Placebo|Dosage form: Subcutaneous injection Dosage: 3 mg equivalent volume Frequency: daily
3486314|NCT03746509|Experimental|Low-High Treatment|Participants in the low-high treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
3128443|NCT03150108|Experimental|Participants of Japanese Descent|Subjects will receive single dose of 100 mcg rhPTH(1-84) SC injection on Day 1; On days 4 and 7, either 25 mcg or 50 mcg SC injection. A washout period of 73 hours will be maintained between each single doses (100 mcg, 50 mcg and 25 mcg) in a cross-over fashion.
3128444|NCT03150199|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
3128445|NCT03150199|Active Comparator|MI-Based Health Education Intervention|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet) and will use motivational interviewing techniques to facilitate the consideration of behavior change.
3128446|NCT03150485|Experimental|etafilcon A Toric Multifocal|
3128447|NCT03150485|Active Comparator|etafilcon A Multifocal|
3128448|NCT03150589|Experimental|SB11 (Proposed ranibizumab biosimilar)|
3128449|NCT03150589|Active Comparator|Lucentis (ranibizumab)|
3128450|NCT03150719|Placebo Comparator|Placebo|Participants received placebo matched to TEZ/IVA fixed-dose combination tablet orally once daily in the morning followed by placebo matched to IVA tablet orally once daily in the evening for 56 days.
3128451|NCT03150719|Experimental|TEZ/IVA|Participants received TEZ 100 milligram (mg)/IVA 150 mg fixed-dose combination tablet orally once daily in the morning and IVA 150 mg tablet orally once daily in the evening for 56 days.
3128452|NCT03150758|Experimental|Electrical Stimulation|Each participant will be given 4 electrical stimulants with an amplitude ranging from 1mA to 30mA. The maximum stimulus without causing an erection will be recorded
3128453|NCT03150875|Experimental|IBI308|injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
3486315|NCT03746509|Experimental|High-Low Treatment|Participants in the high-low treatment group will receive Laryngeal Vibration (Treatment) at 100Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 100Hz frequency once a week for a duration of 4 weeks (low intensity).
3486316|NCT03746509|Active Comparator|Low-High Comparator|Participants in the low-high comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency once a week for a duration of 4 weeks (low intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency every second day of the week (high intensity) for a duration of 4 weeks.
3486317|NCT03746509|Active Comparator|High-Low Comparator|Participants in the high-low comparator group will receive Laryngeal Vibration (Comparator) at 5Hz frequency every second day of the week for a duration of 4 weeks (high intensity). Then they will switch and receive laryngeal vibration at 5Hz frequency once a week for a duration of 4 weeks (low intensity).
3128454|NCT03150875|Active Comparator|docetaxel|injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria
3128455|NCT03151083|Active Comparator|Phase 1: Implementation As Usual (Implementation Through Research Team)|SHUTi digital CBTi Program was implemented in VACT primary care using implementation activities executed by the research team between June 2017 and January 2018 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), Single Referral Pathway Not Integrated Primary Care Workflow (Primary care provider contact research team for patient referral over email).
3128456|NCT03151083|Experimental|Phase 2: Primary Care Coached Digital CBTi Implementation (Implementation through primary Care)|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams June 2018 and January 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders (information pamphlets in treatment rooms), Patient Advertising/Information (information pamphlets in treatment rooms), patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a primary care nurse trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Single Referral Pathway Not Integrated Primary Care Workflow.
3486318|NCT03746496||pre-hospital emergency patients|Patient in a need of an IO-access. Patient in a need of point-of-care laboratory analysis. Over 18 years. Alive (no Cardiac arrest.)
3486319|NCT03746470|Experimental|insertion preserving|ACL reconstruction preserving insertion
3486320|NCT03746470|Active Comparator|insertion detaching|ACL reconstruction detaching insertion
3486321|NCT03746457|No Intervention|Control ART Center|Control arm with no intervention throughout the course of the study
3128457|NCT03151083|Experimental|Phase 3: Primary Care Mental Health Collaborative Care Implementation|SHUTi digital CBTi Program implemented in VACT primary care using implementation activities executed by primary care teams April 2019 and November 2019 (8-months). Implementation activities included: Provider Education by the research team, Provider Reminders, Patient Advertising/Information, patient education and motivational support supplied through a digital CBTi coach, the digital CBTi coach was a peer support specialist working on the primary care mental health collaborative care team, the digital CBTi coach was trained by the research team, technical support and oversight of the digital CBTi coach by the research team. Additional members primary care mental health collaborative care team were educated to provide education about digital CBTi. Multiple referral pathways to digital CBTi: consults to the digital CBTi Coach, warm handoffs to primary care mental health collaborative care team. Digital CBTi coach consults integrated Primary Care Workflow.
3128458|NCT03151148|Experimental|TMT Lotion|The targeted microbiome transplant (TMT) lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to active TMT will apply 2 grams of TMT to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
3128459|NCT03151148|Placebo Comparator|Placebo Lotion|Placebo lotion will be provided in single-dose sealed packets. The lotion should be stored at 4°Celsius (=39.2 degrees Fahrenheit). Participants randomized to placebo will apply 2 grams of placebo to each ventral aspect of their arm (wrist to upper humerus). Frequency of lotion application: topical application administered twice daily for one week.
3128460|NCT03151265|Experimental|Low Back Pain Group|"Low Back Pain (LBP) group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a Baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
3179787|NCT00676702|Experimental|001|Pancrelipase in combination with Ensure Plus 3 pancrelipase MT 21 capsules containing a total of 63 000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
3486322|NCT03746457|Active Comparator|Control and Cycle 3 integrated package|Control arm in Cycles 1 and 2 and in Cycle three converts to experimental
3486323|NCT03746457|Experimental|GI + CA + IC|Receives one alternative sequence of three interventions
3486324|NCT03746457|Experimental|IC + GI + CA|Receives a second alternative sequence of three interventions
3486325|NCT03746457|Experimental|CA + IC + GI|Receives a third alternative sequence of three interventions
3486326|NCT03746444|Active Comparator|General Anesthesia|"The patients in this group will undergo unilateral total knee arthroplasty under general anesthesia. Following vascular access and monitorization (non-invasive blood pressure, saturation, electrocardiography).~Epidural chateterisation will be performed and test dose will be applied. Induction will be carried out using propofol (3mg/kg), fentanyl (1cmg/kg) and rocuronium (0.6 mg/kg). Maintenance will be carried out using sevoflurane (%2-3) and 50-50% mixture of nitrous oxide and oxygen. Epidural analgesia will be initiated after the end surgery."
3486327|NCT03746444|Active Comparator|Regional Anesthesia|The patients in this group will undergo unilateral total knee arthroplasty under combined spinoedpidural anesthesia . Following vascular access and monitorization (noninvasive blood pressure, oxygen saturation and electrocardiography), spinal anesthesia will be performed using 12,5 mg marcaine given to the subarachnoid space and epidural analgesia will be initiated at the end of surgery following negative test dose. The patients will be given nasal oxygen supplementation.
3486328|NCT03746431|Experimental|[225Ac]-FPI-1434 Single-Dose Escalation|
3486329|NCT03746431|Experimental|[225Ac]-FPI-1434 Multi-Dose Escalation|
3486330|NCT03746431|Experimental|FPI-1175 Cold Antibody|
3486331|NCT03746418|Placebo Comparator|Group I|received 20 ml of 0. 25% bupivacaine plus one mL normal saline bilaterally.
3486332|NCT03746418|Active Comparator|Group II|received 20 ml of 0.25% bupivacaine with supplementation of 1 mL containing 100µg dexmedetomidine bilaterally
3486333|NCT03746392|Experimental|Jumpstart Intervention|
3486334|NCT03746392|No Intervention|Usual Care|
3486335|NCT03746366|Experimental|Alcohol use disorders|[C-11]Pittsburgh Compound B (PiB) PET scan
3128461|NCT03151265|Experimental|Active in Sport Group|"Sport group will be assessed on two consecutive days. The first day will have no ThermaCare intervention applied, and is for a baseline assessment of flexibility, muscle relaxation and low back pain.~The second day will have the ThermaCare Low Back Heat Wrap intervention applied, and will have the same assessments as the Baseline day."
3128462|NCT03151395|Other|Total Group|Moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) patients with at least 1 documented moderate or severe Acute exacerbation of COPD (AECOPD) in the year before enrolment and for whom sputum and blood samples are collected during specified visits
3486336|NCT03746366|Experimental|Healthy controls|[C-11]Pittsburgh Compound B (PiB) PET scan
3486337|NCT03746353|Experimental|Early closure of ileostomy|Early clousure of ileostomy before 30 days
3486338|NCT03746353|Active Comparator|Conventional closure of ileostomy|Conventional closure of ileostomy after 30 days
3486339|NCT03746340||Anesthetic|Sevoflurane Group Propofol Group
3486340|NCT03746327|Experimental|Sivextro arm|200 mg milligram per day during 4 weeks
3486341|NCT03746288|Experimental|Treatment Group|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
3486342|NCT03746288|Active Comparator|Control Group|The dose is 2.0 Gy/d, 5 times/week, with a total planned radiation dose of 36 Gy.
3128463|NCT03151434|Active Comparator|Group #1|US Guided Single Shot Paravertebral Block
3128464|NCT03151434|Active Comparator|Group #2|US Guided Paravertebral Catheter
3128465|NCT03151434|Active Comparator|Group #3|Thoracic Epidural
3128466|NCT03151551|Experimental|Ixekizumab|"160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants.~80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps.~80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps."
3128467|NCT03151551|Active Comparator|Adalimumab|"80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps.~40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps."
3128468|NCT03152019|Active Comparator|Protopic® 0.1% (Tacrolimus) ointment|Protopic® 0.1% ointment, packed in blinded tube of 30g.
3128469|NCT03152019|Placebo Comparator|Placebo ointment|Same formulation as the Protopic® 0.1% ointment but without tacrolimus, packed in blinded tube of 30g.
3128470|NCT03152084|Experimental|Arm 1|T2DM subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
3128471|NCT03152084|Experimental|Arm 2|T2DM subjects with an eGFR (CKD-EPI) between >90 and ≤130 mL/min/1.73m2 for patients aged 59 or younger, between >85 and ≤130 mL/min/1.73m2 for patients aged 60 to 69, and between >75 and ≤130 mL/min/1.73m2 for patients aged 70 or older at the Screening Visit.
3128472|NCT03152084|Experimental|Arm 3|Non-diabetic subjects with an eGFR (CKD-EPI) between ≥25 and ≤50 mL/min/1.73m2 at the Screening Visit.
3128473|NCT03152110|Experimental|HIIT|Exercise sessions will be 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
3128474|NCT03152136|Experimental|TAPS|Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.
3128475|NCT03152136|Sham Comparator|Sham|Subjects will receive a Cala ONE device that delivers sham stimulation.
3128476|NCT03152136|No Intervention|No Intervention|Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.
3128477|NCT03152552|Experimental|LIK066 2.5mg|Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
3128478|NCT03152552|Experimental|LIK066 10mg|Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
3486343|NCT03746275||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) from Europe, Asia, Latin America and Canada, who are treated with a combination of rivaroxaban and acetylsalicylic acid to prevent atherothrombotic events
3486344|NCT03746249|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3486345|NCT03746223|Experimental|R2-R/IV-MTX（methotrexate）|experimental arm will be treated rituximab plus lenalidomide (R2) regimen for 6 cycles and followed by lenalidomide maintenance for 2 years, meanwhile intravitreal methotrexate will be given as protocol
3486346|NCT03746197|Experimental|Project EVO Multi- Treatment|Treatment group receives video game device treatment. Participant plays the game for 30 minutes a day, at least five days a week for four weeks.
3486347|NCT03746197|No Intervention|Control|No contact control
3486348|NCT03746184||Knee osteoarthritis|Treatment course
3486349|NCT03746171||Patients with rectosigmoid colonic polyps|Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy in the frame of the FOBT based screening program, in which at least one diminutive (<5 mm) rectosigmoid polyp is detected.
3486350|NCT03746158|Experimental|Curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
3486351|NCT03746145|Experimental|Bifidobacterium longum 1714|Participants consume one 2g sachet containing 10e11 colony-forming units Bifidobacterium longum 1714 strain with maltodextrin and magnesium stearate on a daily basis over 1 year.
3486352|NCT03746145|Experimental|Placebo|Participants consume one 2g placebo sachet containing maltodextrin and magnesium stearate.
3486353|NCT03746132|Active Comparator|Transdermal Continuous Oxygen Therapy|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the Treatment arm which provides Transdermal Continuous Oxygen Treatment (TCOT) (as delivered by EPIFLO device), in addition to standard of care for the surgical wound
3486354|NCT03746132|No Intervention|Control|Subjects who satisfy the inclusion/exclusion conditions will be randomly assigned to the control arm which provides standard of care for the surgical wound.
3486355|NCT03746119|Active Comparator|Nicotine-free e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine-free vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
3128479|NCT03152552|Experimental|LIK066 50mg|Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
3128480|NCT03152552|Active Comparator|Empagliflozin|Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
3486356|NCT03746119|Active Comparator|Nicotine e-cigarette|Subjects will undergo baseline assessments, then actively inhale nicotine containing vapor from an e-cigarette prior to blood samples and various cardiovascular testing.
3486357|NCT03746106|Active Comparator|Thiamine only|5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
3486358|NCT03746106|Experimental|Trimethporim + thiamine combination|5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.
3486359|NCT03746106|Experimental|Metformin + thiamine combination|5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.
3486360|NCT03746093|Placebo Comparator|Control Group|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
3486361|NCT03746093|Experimental|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
3486362|NCT03746080|Experimental|Whole Brain Radiotherapy + Plerixafor +Chemoradiotherapy|After completion maximal safe surgical resection, patients undergo radiation therapy for 42 days, initiating whole brain radiation therapy at day 21 (dose 16 of radiation therapy) and receive temozolomide daily on days 1 to 42. Beginning 7 days before the completion of whole brain radiation therapy, patients receive plerixafor by continuous infusion on days to 1 to 28. Beginning 1 week after completion of plerixafor infusion and 35 days after completion of whole brain radiation therapy, patients receive temozolomide monthly for 6 to 12 courses in the absence of disease progression or unacceptable toxicity.
3486363|NCT03746067|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
3128481|NCT03152552|Placebo Comparator|Placebo|Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.
3128482|NCT03152591|Experimental|LIK066|LIK066 tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
3128483|NCT03152591|Placebo Comparator|Placebo|Placebo tablets received three times daily; before breakfast, lunch and dinner for 14 days and once on day 15 morning before meal test
3128484|NCT03153956|Experimental|Active Treatment Arm|Personally calibrated bio-mechanical device
3128485|NCT03153956|Placebo Comparator|Control Arm|sham-placebo device (similar shoes without bio-mechanical elements).
3128486|NCT03154047|Experimental|Open label|Open Label Study Drug NEOD001
3128487|NCT03154086|Experimental|Part A: Cohort 1: Placebo/GSK3352589 5mg/15mg/50mg|Subjects will receive single oral dose of placebo tablet in Period 1 followed by GSK3352589 5 milligrams (mg) tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128488|NCT03154086|Experimental|Part A:Cohort 1:GSK3352589 2mg/ Placebo/GSK3352589 15mg/50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by Placebo tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128489|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/Placebo/GSK3352589 50mg|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by Placebo tablet in Period 3 followed by GSK3352589 50 mg tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128490|NCT03154086|Experimental|Part A:Cohort 1: GSK3352589 2mg/5mg/15mg/Placebo|Subjects will receive single oral dose of GSK3352589 2 mg tablet in Period 1 followed by GSK3352589 5 mg tablet in Period 2 followed by GSK3352589 15 mg tablet in Period 3 followed by Placebo tablet in Period 4 of Cohort 1 in Part A of the study. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3179788|NCT00676702|Active Comparator|002|Ensure Plus A high-fat liquid meal of 500 ml of Ensure Plus
3179789|NCT00676728|Experimental|JNJ-26481585|
3179790|NCT00676741||A|
3486364|NCT03746067|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 4 cohorts. Within each cohort, 8 subjects will be randomized in a 3:1 ratio (6 active + 2 placebo) per cohort to receive TS-134 or placebo as a single oral dose solution. All cohorts will be dosed in a fasted state except for the 2nd and 4th (food effect) cohorts, which will be dosed first in a fasted state, and then in a fed state, in a single crossover design conducted with a washout between two periods. In the 3rd (CSF) cohort, the 8 subjects will receive one dose level of TS-134 as a single-blind dosing assignment; there will be no placebo dosing.
3486365|NCT03746054|Experimental|active prevention|optimal medical treatment
3486366|NCT03746054|Sham Comparator|usual clinical practice|usual clinical practice in each center
3486367|NCT03746041|Experimental|abaloparatide and bevacizumab treatment|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days. In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
3486368|NCT03746015|Experimental|Takeda's Tetravalent Dengue Vaccine Candidate (TDV) 0.5 mL|TDV 0.5 mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3) in flavivirus-naïve participants (Group 1) and dengue-immune participants (Group 2). TDV comprised of 1 molecularly characterized, attenuated dengue virus strain and 3 chimeric dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing not less than 3.3, 2.7, 4.0, and 4.5 log10 plaque forming units (PFU) respectively.
3486369|NCT03745989|Experimental|MK-8353 and Selumetinib Dose Escalation|Starting Dose (Dose Level [DL] 1): MK-8353 + selumetinib
3486370|NCT03745976||Group 1|a new long-term total articular prosthesis follow-up strategy by simple questionnaire and radiography (questionnaire and Xray for all patients)
3486371|NCT03745963|Experimental|Skin-to-skin contact|"Infants will be placed in full ventral skin-to-skin with their mother at least fifteen minutes prior to heel lance to allow time to settle and recover following transfer. Positioning will be determined based on individual maternal preference in order to optimize comfort as well as facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Skin to skin contact will continue until the procedure is completed.~In addition, infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) during SSC. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
3486372|NCT03745963|Active Comparator|24% Oral sucrose|"Infants will be placed in a cot or in an incubator, depending on their gestational age, for the duration of the blood collection. Administration of 0.12mls (0.04mls per drop) of 24 percent oral sucrose will occur two minutes prior to the heel lance.~The infants will be offered non-nutritive sucking using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose. Whether infants are actively sucking during the procedure will be recorded by the research coordinator."
3486373|NCT03745950|Experimental|Olaparib|"The Olaparib arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST (Response evaluation criteria in solid tumors) as assessed by the investigator, or unacceptable toxicity"
3486374|NCT03745950|Placebo Comparator|Placebo|"The placebo arm :~Patients will be administrated the randomized study treatment tablets orally at a dose of 300 mg twice daily until objective radiological disease progression as per RECIST as assessed by the investigator, or unacceptable toxicity"
3486375|NCT03745911|Experimental|Paclitaxel plus TAK-228|"Paclitaxel will be given on days 1, 8, and 15 of each 28 day cycle intravenously (every Monday or first day of business week if holiday), the day before the first TAK-228 dose. It should be given over approximately one hour.~TAK-228 will be given orally on Days 2-4, 9-11, 16-18 and 23-25 of each 28-day cycle."
3486376|NCT03745898|Active Comparator|Nocturnal Oxygen Therapy|Active nocturnal oxygen therapy
3486377|NCT03745898|Sham Comparator|Sham Nocturnal Oxygen Therapy|Sham nocturnal oxygen therapy (room air)
3486378|NCT03745885|Experimental|0.15mg Supaglutide or placebo|0.15 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
3486379|NCT03745885|Experimental|0.375mg Supaglutide or placebo|0.375 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
3486380|NCT03745885|Experimental|0.75mg Supaglutide or placebo|0.75 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
3486381|NCT03745885|Experimental|1.5mg Supaglutide or placebo|1.5 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
3486382|NCT03745885|Experimental|3.0mg Supaglutide or placebo|3.0 milligrams (mg) Supaglutide injection or placebo administered once subcutaneously（SC） to healthy participants
3486383|NCT03745872|Experimental|Testing|This is a preventative study model. All students who choose to participate will receive a pre and post test regarding their sun exposure behaviors and knowledge on sun exposure risk.
3486384|NCT03745846|Experimental|Composite Gel Containing Black Raspberry|Drug:Composite Gel Containing Black Raspberry 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
3486385|NCT03745846|Placebo Comparator|Composite Gel Containing Black Raspberry-placebo|Drug:Composite Gel Containing Black Raspberry-placebo 3,000mg Dosage and duration: 1 preparation every other day for 3 months.
3486386|NCT03745833|Experimental|Intervention|Participants will be shown a brief VR-based mindfulness intervention after meals.
3486387|NCT03745807|Experimental|Combination|NKTR-214 + nivolumab
3179791|NCT00676741||B|
3486388|NCT03745781|Experimental|open-label placebo|open-label placebo
3486389|NCT03745781|No Intervention|treatment as usual|
3486390|NCT03745768|Experimental|Active iTBS Treatment|Intermittent theta burst stimulation to the dorsolateral prefrontal cortex
3486391|NCT03745768|Sham Comparator|Sham Stimulation|Sham stimulation to the dorsolateral prefrontal cortex.
3486392|NCT03745742|Other|control|standard rehabilitation protocol according to the personal functional capacities (measured by a cardiopulmonary test on the beginning of the cardiac reeducation.
3486393|NCT03745742|Experimental|study strategy|individualization of the rehabilitation program according to the daily HRV measure and the personal functional capacity (measured by a cardiopulmonary test on the program beginning).
3128491|NCT03154086|Experimental|Part A:Cohort 2: GSK3352589 25mg Fasted/GSK3352589 25mg Fed|Subjects will receive single oral dose of GSK3352589 25 mg tablet in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing Period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128492|NCT03154086|Experimental|Part A: Cohort 2: Placebo Fasted/Placebo Fed|Subjects will receive single oral dose of placebo tablet matching GSK3352589 25 mg in Period 1 (fasted state) and Period 2 (fed state). Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128493|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150 mg/Placebo|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by placebo tablet matching GSK3352589 150 mg in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3486394|NCT03745716|Experimental|Experimental arm: APR-246 + azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
3128494|NCT03154086|Experimental|Part A:Cohort 3: Placebo/GSK3352589 400 mg|Subjects will receive single oral dose of placebo tablet matching GSK3352589 400 mg in Period 1 followed by single oral dose of GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3128495|NCT03154086|Experimental|Part A:Cohort 3: GSK3352589 150mg/GSK3352589 400mg|Subjects will receive single oral dose of GSK3352589 150 mg tablet in Period 1 followed by GSK3352589 400 mg tablet in Period 2 in Cohort 3 of Part A. Subjects will return for their next scheduled dosing period approximately 14 days (wash out period) after administration of the study drug during the prior dosing period.
3486395|NCT03745716|Experimental|Control arm: Azacitidine|Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):
3486396|NCT03745703|Experimental|MOCHA|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
3128496|NCT03154086|Experimental|Part B: GSK3352589|Subjects will receive repeat oral doses of GSK3352589 of 5 mg, 15 mg, 50 mg, 100 mg or 200 mg twice daily administered for 14 days.
3128497|NCT03154086|Placebo Comparator|Part B: Placebo|Subjects will receive repeat oral doses of placebo twice a day tablet administered for 14 days.
3486397|NCT03745703|Experimental|"MOCHA+, Stories Matter"|Behavioral: 12-week trial with 3 sessions per week with one small group discussion session of critical issues affecting African-American men's health each week combined with two aerobic exercise sessions each week
3486398|NCT03745703|No Intervention|Wait-list control|There is no intervention to be administered during the 12-week wait-list control period
3486399|NCT03745690|Experimental|Treatment (near-infrared image guided surgical resection)|Patients receive indocyanine green IV on day 0 and undergo near-infrared image guided surgical resection on day 1.
3486400|NCT03745677|Experimental|Phase I|Each study site has selected 1-2 units ideally suited for initial implementation of the Advanced and Integrated MicroSystems (AIMS) interventions (Phase I Implementation) and 1-2 units for later implementation of AIMS interventions (Phase II Implementation). During Implementation Phase I, AIMS interventions were implemented on the initial, phase I Implementation units. The phase II units serve as control units during phase I.
3128498|NCT03154333|Experimental|diacerein 1% ointment|diacerein 1% ointment will be used for 8 weeks
3128499|NCT03154333|Placebo Comparator|vehicle ointment|vehicle ointment will be used for 8 weeks
3128500|NCT03154476|Experimental|Sildenafil|Subjects randomized to this arm will receive sildenafil 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week, and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
3128501|NCT03154476|Placebo Comparator|Placebo|Subjects will receive placebo times per day for 12 months.
3128502|NCT03154658|Experimental|Sub-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
3128503|NCT03154658|Active Comparator|Supra-serratus regional block|A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.
3128504|NCT03154710|Experimental|Web-application follow up|Patients will have a clinical and biological exam every 3 months and a web-mediated follow up. Patients will have to connect to the MOOVCARE application every 14 days to complete a questionnaire about their symptoms. Imaging will be performed in the event of an alert or clinical problem
3128505|NCT03154710|No Intervention|Standard|Patients will have the usual follow up (Clinical and biological exam every 3 months and imaging every 6 months)
3128506|NCT03155178|Experimental|3M CHG/IPA Prep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
3128507|NCT03155178|Active Comparator|ChloraPrep|Apply topically for 30 seconds (abdominal site) or 2 minutes (inguinal site), and allow to dry for 3 minutes.
3128508|NCT03155269|Experimental|Group 1- Protein rich beverage powder fortified with MMN|Participants will be administered orally two doses of cereal based fortified beverage (30 grams powder made up in 200 milliliter (mL) water) daily in the morning and evening for 6 months.
3128509|NCT03155269|Other|Group 2 -Low protein non-fortified iso-caloric beverage powder|Participants will be administered orally two doses (in morning and evening) of low protein non fortified isocaloric beverage (30 grams powder made up in 200 mL water) daily for 6 months.
3128510|NCT03155724|Experimental|MultiPole Pacing|Traditional biventricular pacing CRT non-responders at the 3 or 6 month QP ExCELs study follow-up.
3179792|NCT00676741||C|
3179793|NCT00676767|Experimental|1|
3486401|NCT03745677|Experimental|Phase II|During Implementation Phase II, Advanced and Integrated MicroSystems (AIMS) interventions are being implemented on additional, phase II implementation units, leveraging lessons learned during phase I.
3486402|NCT03745664|Active Comparator|Treatment group|"Methylprednisolone Sodium Succinate (20mg/ml) will be given at the dose of 40 mg/day (20 mg x 2/day).~The treatment will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days)."
3486403|NCT03745664|Placebo Comparator|Placebo group|Saline Solution for Injection will be given ath the dose of 2 ml/day. The treatment placebo will last 7 days (or the time of hospitalization if the patient is discharged in a period less or more than 7 days).
3486404|NCT03745625|Experimental|HSK3486|First-stage: 1mg/kg/h, 0.4mg/kg/h; Second-stage:Single loading dose: 0.2mg/kg, maintenance dose: 0.35mg/kg/h,
3486405|NCT03745625|Active Comparator|Propofol|First-stage: 5mg/kg/h, 2mg/kg/h; Second-stage:Single load ing dose: 1mg/kg, maintenance dose: 1.75mg/kg/h
3486406|NCT03745612|Experimental|TRF|Time restricted feeding
3486407|NCT03745612|Active Comparator|CER|continuous energy restriction
3486408|NCT03745599|Experimental|Diclofenac|Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
3486409|NCT03745599|Experimental|Flurbiprofen|Flurbiprofen group, which received flurbiprofen 100 mg capsules and placebo sprays. Placebo sprays have consisted of a normal saline solution and peppermint flavor.
3486410|NCT03745599|Experimental|Benzydamine|Benzydamine group, which received benzydamine 0.045 g, 30 mL oral sprays (Tantum Verde) and placebo capsules. Placebo capsules contained starch.
3486411|NCT03745586|Experimental|All study participants|
3486412|NCT03745573|Experimental|Empateach Intervention|All teachers in intervention schools will be invited to participate. Participants in the intervention condition will receive Empateach, a 10-week group intervention. Groups meet 14 times for 1-1.5 hour length sessions, which are led by peers. The aim of the Empateach intervention is to improve 'student and teacher well-being; self-regulation; teacher classroom management and teacher's use of positive discipline techniques. The intervention uses cognitive behavioural therapy techniques to change negative thought and behaviour patterns related to corporal punishment. The teachers receive information on alternatives to corporal punishment, planning exercises and reinforcement SMS, and because the intervention is in a group setting, social support to change their behaviours. They discuss their experiences and challenges in group sessions.
3486413|NCT03745573|No Intervention|Wait-list control|Teachers in wait-list control schools will receive no specific interventions related to violence prevention during the study, but will receive the intervention after the study is over if it is shown to be effective (pending donor funding).
3486414|NCT03745521||X-linked Hypophosphatemia (XLH)|Hypophosphatemic Rickets/osteomalacia
3486415|NCT03745508|Active Comparator|Caffeinated Coffee (200 mg caffeine)|~200 mg of caffeine from instant coffee
3486416|NCT03745508|Active Comparator|Caffeinated Coffee (400 mg caffeine)|~400 mg of caffeine from instant coffee
3486417|NCT03745508|Placebo Comparator|Decaffeinated Coffee|Decaffeinated instant coffee
3486418|NCT03745482|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following application of the mobilisations outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
3486419|NCT03745482|No Intervention|Control|"The control condition will consist of the participant lying prone on a plinth for the same time if takes for intervention to be applied approximately 10 minutes.~Following the control condition outcome measures including hamstring strength, sEMG activity and 3D motion analysis will take place."
3128511|NCT03155945|Experimental|Olorinab 25 mg TID|Participants received olorinab 25 milligrams (mg) tablet by mouth, three times daily (TID) for 8 weeks
3128512|NCT03155945|Experimental|Olorinab 100 mg TID|Participants received olorinab 100 mg oral tablets TID for 8 weeks
3128513|NCT03155997|Experimental|150 mg Abemaciclib + Endocrine Therapy|Participants received Abemaciclib orally at 150 milligrams (mg) twice daily with at least 6 hours between doses for up to 2 years or until evidence of disease recurrence or other discontinuation criteria were met, whichever occurs first. Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
3128514|NCT03155997|Other|Endocrine Therapy|Endocrine therapy (physicians' choice) standard-of-care was administered according to package label until discontinuation criteria were met.
3128515|NCT03156270|Experimental|Vivaer Stylus Treatment|Thermal treatment of the submucosal tissue including cartilage in the internal nasal valve area
3128516|NCT03156543|Experimental|Group A|This group will have the jumpstart dressing pre-operatively and a standard dressing post operatively.
3128517|NCT03156543|Experimental|Group B|This group will have the jumpstart dressing pre-operatively and a jumpstart dressing post operatively.
3128518|NCT03156621|Experimental|Alirocumab SC Q2W|"Alirocumab SC every 2 weeks (Q2W) from baseline (day 1) through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
3128519|NCT03156621|Experimental|Placebo SC Q2W|"Matching placebo SC Q2W from baseline through week 10 during the double-blind treatment period~Starting at week 12, and continuing through week 22, participants will receive open-label alirocumab SC Q2W"
3128520|NCT03157089|Experimental|All patients|
3128521|NCT03157232|Experimental|Test Group|All subjects are enrolled into the test group and all subjects received both the Rainbow DCI and R1-25 sensor.
3128522|NCT03157531|Experimental|B-Laser™ Atherectomy System|B-Laser™ Atherectomy System
3128523|NCT03157583|Active Comparator|Reference product (for SPFi calculation)|This arm will include all the test sites on the participants back where reference product (P3 standard sunscreen) will be applied.
3128524|NCT03157583|Experimental|Test product 1|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 1 will be applied for SPF testing.
3179794|NCT00676767|Active Comparator|2|
3486420|NCT03745469||Young-age group|Patient between the age of 18 and 30 years old, with a confirmed diagnosis of chronic mechanical neck pain
3128525|NCT03157583|Experimental|Test product 2|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 2 will be applied for SPF testing.
3128526|NCT03157583|Experimental|Test product 3|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 3 will be applied for SPF testing.
3486421|NCT03745469||Middle-age group|Patients between 30 and 60 years old, with a confirmed diagnosis of chronic mechanical neck pain.
3486422|NCT03745456||Subarachnoid Hemorrhage patients|Patients with severe subarachnoid hemorrhage (Hunt and Hess 4-5, Fisher 3-4) will be included initially in the first 6 hours after the onset of symptoms.
3486423|NCT03745443|Experimental|Intervention group|Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
3486424|NCT03745443|No Intervention|Control|Ventilation with PEEP 3 during anesthesia and surgery
3486425|NCT03745417|Experimental|UCMSCs group|Umbilical cord mesenchymal stem cells intravenous injection at a dose of 2 million cells/kg at week 0,week 2,week 4,week 6,week 8 with a duration for treatment for 12 weeks.
3486426|NCT03745404|Experimental|Lido-Patch (Open-label Run-in Phase)|All participants applied up to 3 Lido-Patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area). Patches were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
3486427|NCT03745404|Experimental|Lido-Patch (Double-blind Phase)|Up to 3 patches (lidocaine 5% medicated plaster) per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
3486428|NCT03745404|Placebo Comparator|Placebo Patch (Double-blind Phase)|Up to 3 placebo plasters per day (depending on the size of PHN area) were applied topically for up to 12 hours per day (patch free interval: at least 12 hours) at the site of skin affected by painful PHN.
3128527|NCT03157583|Experimental|Test product 4|This arm will include all the test plates used for UVAPF testing and test sites on the participants back where test product 4 will be applied for SPF testing.
3128528|NCT03157583|No Intervention|Negative control (for SPFi calculation)|This arm will include all the test sites on the participants back which will be left unprotected.
3486429|NCT03745391|Active Comparator|MULTIMODAL MAGNETIC RESONANCE (MR)|Diagnostic test: Multimodal Neuroimaging Test: MR The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization be assigned to Multimodal MR, will be directedly transferred to MR. It will be performed a multimodal MR taking into account that after discard an intracerebral haemorrhage and confirm an ischemic lesion if the patient fulfill criteria to receive intravenous alteplase, the test will be paused just to administer the treatment and immediately put again into the machine to complete the MR images. With all the information vascular neurologist will be decide if it is necessary administer endovascular treatment.
3128529|NCT03157583|Active Comparator|Reference (for UVAPFi calculation)|This arm will include test plates treated with reference sunscreen formulation S2.
3128530|NCT03157583|Other|Blank control (for UVAPFi calculation)|This arm will include blank test plates treated with glycerin.
3128531|NCT03158012|Active Comparator|Active treatment|
3128532|NCT03158012|Placebo Comparator|Placebo treatment|
3128533|NCT03158038|Experimental|Monovalent Influenza Vaccine|Participants will receive a single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 fluorescent focus unit (FFU) of each of 1 cold adapted (ca), attenuated (att), temperature sensitive (ts) 6:2 reassortant influenza strain] by intranasal spray on Day 1.
3128534|NCT03158038|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching with monovalent influenza vaccine by intranasal spray on Day 1.
3128535|NCT03158116|Experimental|Treatment|All participants will be receiving the study drug
3128536|NCT03158220|Experimental|Adult Women 27- to 45-years Old|Adult women 27- to 45-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
3128537|NCT03158220|Active Comparator|Young Adult Women 16- to 26-years Old|Young adult women 16- to 26-years old will receive V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6.
3128538|NCT03158272|Experimental|Monotherapy|Cabiralizumab administered as a single agent intravenous formulation
3128539|NCT03158272|Experimental|Combination Therapy|Cabiralizumab will be administered in combination with Nivolumab as an intravenous formulation
3128543|NCT03158311|Experimental|QVM149 150/50/80 μg|QVM149 150/50/80 μg o.d. delivered via Concept1
3128544|NCT03158311|Experimental|QVM149 150/50/160 μg|QVM149 150/50/160 μg o.d. delivered via Concept1
3128545|NCT03158311|Active Comparator|Salmeterol/fluticasone 50/500 μg plus tiotropium 5 μg|Salmeterol/fluticasone 50/500 μg b.i.d. delivered via Accuhaler® plus tiotropium 5 μg o.d. delivered via Respimat®
3132535|NCT03435562|Experimental|electronic cigarette vs own brand use|Participants will come in for three session. During one session, participants will first complete a 10-puff product use bout with JUUL, and then a 90-minute ad lib product use bout with JUUL (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with IQOS, and then a 90-minute ad lib product use bout with IQOS (the session will be approximately 3 hours). During one session, participants will first complete a 10-puff product use bout with their own brand cigarettes, and then a 90-minute ad lib product use bout with their own brand cigarette (the session will be approximately 3 hours). The order of the sessions will be determined randomly and data about session will not be recorded or used in the analysis.
3486430|NCT03745391|Active Comparator|MULTIMODAL COMPUTED TOMOGRAPHY (CT)|Diagnostic test: Multimodal Neuroimaging Test: CT The group of patients with clinical suspicion of acute stroke and that fulfill the inclusion/exclusion criteria for the study that after randomization is assigned to Multimodal CT, will be directedly transferred to CT. If the patient fulfill criteria to receive intravenous alteplase after discard an intracerebral haemorrhage the CT will be paused to administer the treatment and immediately will continue with the test. At the end of the test the vascular neurologist will decide if it is necessary administer endovascular treatment.
3486431|NCT03745378||Cases|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, who experienced secondary cancer(s) diagnosed at presentation of MPN or during the course of the myeloproliferative disease.
3486432|NCT03745378||Controls|Patients with diagnosis of Myeloproliferative Neoplasms (MPN) including Polycythemia Vera, Essential thrombocytopenia or Myelofibrosis, exposed or not exposed to JAK2V617F mutation, without history of secondary cancer.
3486433|NCT03745365|Experimental|sleeve gastrectomy|"The greater omentum is divided 5 cm from the pylorus with an energy device. The antral pouch is measured 2-6cm from the pylorus along greater curve as risk benefit ratio is best within these limits.~Devascularization is continued up the greater curve of the stomach to the short gastric vessels with the help of the assistant who maintains traction and exposure during this process. Eventually, one reaches the left crus which is an important landmark of dissection. We selectively explore the hiatus of the symptomatic and endoscopically proven hiatus hernia , and the hernia should be reduced and repaired."
3486434|NCT03745365|Experimental|sleeve gastrectomy with loop bipartition|Sleeve gastrectomy is performed first, then a loop gastro-ileostomy 200-250 cm from doudeno-jejunal junction was created at the dependent part of the antrum with 2 layers of with stapler but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastro-ileostomy. The staple line and anastomosis was tested with methylene blue. A drain is inserted.
3128548|NCT03158714|Experimental|Couples Connecting Mindfully Curriculum|Receives the Couples Connecting Mindfully curriculum over a 6 week period.
3128549|NCT03158714|Experimental|ELEVATE Curriculum|Receives the ELEVATE curriculum over a 6 week period.
3128550|NCT03158714|No Intervention|Control|No programming is offered.
3128551|NCT03159091|Experimental|Rengalin|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
3128552|NCT03159091|Placebo Comparator|Placebo|Oral administration. Two tablets per intake. The tablet should be held in the mouth until complete dissolution. 2 tablets 3 times a day without food (i.e. 15-30 min prior to meal or 15-30 min after meal).
3128553|NCT03159143|Experimental|Docetaxel and Oxaliplatin|Docetaxel administered at a dose of 60mg/m^2 IV infusion, followed by oxaliplatin at a dose of 110mg/m^2 as a 2 hour IV infusion.
3128554|NCT03159195||Breast Cancer Patients|HR+/HER2- advanced/metastatic breast cancer patients across multiple countries.
3128555|NCT03159260|Experimental|Theraworx|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
3128556|NCT03159260|Placebo Comparator|Placebo|Subjects will receive two 3 ounce foam dispensers corresponding to their group assignment (Foam A or Foam B) and a 2-week Compliance and Symptom Log. The contents of these two foams will remain blind to the subjects and the data collectors until all 50 subjects complete the study protocol. One of the foams will contain Theraworx/[pH]uel (treatment) and the other will contain a physiologically inert substance (placebo control).
3128557|NCT03159299|Experimental|Yo Puedo|This group will receive the modified Yo Puedo + mHealth program.
3128558|NCT03159299|No Intervention|Wait-list Control|This group will not receive the Yo Puedo + mHealth program during the 6 month data collection period, but will be invited to participate in it after data collection has finished.
3128559|NCT03159455|Experimental|BI 1467335|
3128560|NCT03159455|Placebo Comparator|Placebo|
3128561|NCT03159468|Experimental|Cognitive Restructuring & Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
3128562|NCT03159468|Experimental|Mindfulness & Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume an alcoholic beverage in the lab.
3128563|NCT03159468|Experimental|Nutrition Information & Alcohol Condition|Participants will receive general information about nutrition. They will then consume an alcoholic beverage in the lab.
3128564|NCT03159468|Experimental|Cognitive Restructuring & No Alcohol Condition|Participants will receive a brief online training regarding the use of cognitive restructuring skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
3128565|NCT03159468|Experimental|Mindfulness & No Alcohol Condition|Participants will receive a brief online training regarding the use of mindfulness skills to cope with negative emotions. They will then consume a non-alcoholic beverage in the lab.
3128566|NCT03159468|No Intervention|Nutrition Information & No Alcohol Condition|Participants will receive general information about nutrition. They will then consume a non-alcoholic beverage in the lab.
3128567|NCT03159611|Experimental|Tenoten for children|
3128568|NCT03159611|Placebo Comparator|Placebo|
3128569|NCT03159624|Experimental|Treatment Group|2x3 cm Biodesign™ SIS graft placement + overlying Doyle silastic sheet placement over the resulting exposed septum cartilage/bone
3128570|NCT03159624|Active Comparator|Control Group|Thin Doyle silastic sheet placement alone over the resulting exposed septum cartilage/bone
3179795|NCT00676767|Placebo Comparator|3|
3486435|NCT03745352|Experimental|Arm A (pevonedistat, azacitidine)|Patients receive pevonedistat intravenously (IV) over 60 minutes on days 1, 3, and 5 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on either days 1-7, or days 1-5 and 8-9, or days 1-6 and 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3486436|NCT03745352|Active Comparator|Arm B (azacitidine)|Patients receive azacitidine IV or SC as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3486437|NCT03745326|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12D mTCR PBL + highdose aldesleukin
3486438|NCT03745326|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12D mTCR PBL + high-dose aldesleukin
3486439|NCT03745313|Experimental|Treatment|Treatment with the Edwards PASCAL Transcatheter Valve Repair System
3128571|NCT03160027|Experimental|Immediate PBM treatment|This arm will receive photobiomodulation (PBM), delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
3128572|NCT03160027|No Intervention|Delayed PBM treatment|This arm will maintain usual activities for 12 weeks. After the week 12 psychometric and MRI assessment, this arm will receive PBM, delivered with the Vielight Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes (the device automatically shuts itself off after 20 minutes) for 12 weeks.
3486440|NCT03745300|Active Comparator|GROUP 1|Scaling and root planing (SRP) followed by 1.2% atorvastatin gel local drug delivery
3486441|NCT03745300|Active Comparator|GROUP 2|Scaling and root planing (SRP) followed by 1.2% simvastatin gel local drug delivery
3128573|NCT03160170|Experimental|Use of Cobb device|Use of SISTER device during surgery
3128574|NCT03160170|No Intervention|Control|Standard exposure technique and instruments will be used during surgery
3128575|NCT03160287|Experimental|Motivational interview and text messages|Multidimensional, tailored intervention for sleep deficiency in for older adults with OA
3128576|NCT03160560|Active Comparator|Test-Unflavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution.
3128577|NCT03160560|Active Comparator|Test-Flavored Rinse|CloSYS Oral Rinse product containing 0.1% stabilized chlorine dioxide (sodium chlorite) in aqueous solution with mint flavoring.
3128578|NCT03160560|Placebo Comparator|Placebo|CloSYS Oral Rinse product (no chlorine dioxide)
3128579|NCT03160573|Active Comparator|Test-Unflavored Rinse then Placebo Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks,. After a washout period of 2 weeks, they will then receive Placebo unflavored rinse containing containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
3128580|NCT03160573|Active Comparator|Test-Flavored Rinse then Placebo Flavored Rinse|Participants will receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks. After a washout period of 2 weeks, they will then receive Placebo flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks.
3128581|NCT03160573|Placebo Comparator|Flavored Oral Rinse-Placebo then Test-Flavored Rinse|Participants will receive CloSYS mint flavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive CloSYS mint-flavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
3128582|NCT03160573|Placebo Comparator|Unflavored Oral Rinse-Placebo then Test-Unflavored Rinse|Participants will receive CloSYS unflavored rinse containing NO 0.1% stabilized chlorine dioxide for 3 weeks. After a washout period of 2 weeks, they will then receive unflavored rinse containing 0.1% stabilized chlorine dioxide (sodium chlorite) in an aqueous solution for 3 weeks.
3128583|NCT03160703|Experimental|Test dentifrice 1 (RDA~58)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
3128584|NCT03160703|Experimental|Test dentifrice 2 (RDA~77)|Participants will apply experimental dentifrice containing 0.454% SnF2 / 5% STP.
3128585|NCT03160703|Other|Reference dentifrice 1 (RDA~80)|Participants will apply dentifrice containing 1000 parts per million (ppm) fluoride as Sodium Monofluorophosphate (SMFP).
3128586|NCT03160703|Active Comparator|Reference dentifrice 2 (RDA~120)|Participants will apply dentifrice containing 0.454% SnF2.
3128587|NCT03160716|Other|Treatment|
3128588|NCT03160885|Experimental|Initial treatment period - Tralokinumab Q2W|"Week 0 to Week 16~Two subcutaneous (SC) injections of tralokinumab as a loading dose on Day 0, followed by a SC injection of tralokinumab Q2W regimen for 16 weeks"
3128589|NCT03160885|Placebo Comparator|Initial treatment period - Placebo|"Week 0 to Week 16 (Initial treatment period):~Two subcutaneous (SC) injections of placebo as a loading dose on Day 0 followed by a SC injection of placebo Q2W regimen for 16 weeks"
3128590|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q2W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q2W for 36 weeks"
3128591|NCT03160885|Experimental|Maintenance treatment period - Tralokinumab Q4W|"Week 16 to Week 52~Tralokinumab responders from the initial treatment period re-randomised at Week 16 and administered tralokinumab maintenance subcutaneous injection regimen Q4W for 36 weeks.~Participants in this group receive alternating doses of tralokinumab SC injection and placebo SC injection every 2 weeks"
3128592|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo|"Week 16 to Week 52~Tralokinumab responders from initial treatment period randomised at Week 16 and administered placebo subcutaneous maintenance injection for 36 weeks"
3486442|NCT03745300|Placebo Comparator|GROUP 3|Scaling and root planing (SRP) followed by placebo gel local drug delivery
3486443|NCT03745274|Experimental|GHB04L1|GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
3486444|NCT03745274|Placebo Comparator|Placebo|Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.
3486445|NCT03745261|Experimental|YCC capsule+conventional medicine|Patients in this group will be given Yong Chong Cao (YCC) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD,which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
3486446|NCT03745261|Experimental|BL capsule + conventional medicine|Patients in this group will be given Bailing (BL) capsule and conventional medicine based on the classes of medications recommended by 2017 GOLD and Chinese Treatment Guidelines for COPD, which are Group A patients: Salbutamol (Ventolin®),Group B and Group C patients: Tiotropium Bromide (Spiriva®),Group D patients: Salmeterol / fluticasone (Seretide®).
3486447|NCT03745248|Experimental|Aerobic Training|Participants will be given a stationary exercise bike for home use. They will be instructed to use the exercise bike five times a week for thirty-minute sessions. The exercise intensity prescription will be based on the subject's VO2max determined on pre-test day. The exercise program will start at 60% of intensity per session, and then will be increased by steps of 5% intensity every 2 sessions until participants reach 30 minutes of training at 80% intensity. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be instructed to log each training session. Subjects will record duration of exercise, perceived exertion, average heart rate, maximum heart rate, and distance.
3128593|NCT03160885|Placebo Comparator|Maintenance treatment period - Placebo (tralokinumab naive)|"Week 16 to Week 52~Placebo responders from the initial treatment period re-assigned at Week 16 and administered placebo maintenance subcutaneous injection regimen Q2W for 36 weeks"
3128594|NCT03160885|Experimental|Open-label treatment - Tralokinumab 300 mg Q2W + optional TCS|"Week 16 to Week 52~Subjects receiving initial treatment with tralokinumab Q2W or placebo Q2W assigned to open-label treatment at Week 16 and administered tralokinumab subcutaneous (SC) injection + optional TCS* regimen Q2W~OR~Subjects receiving maintenance treatment with tralokinumab Q2W/Q4W or placebo assigned to open-label treatment after Week 16 and administered tralokinumab SC injection + optional TCS regimen Q2W~• TCS = topical corticosteroids"
3128595|NCT03160898|Experimental|Reldesemtiv 150 mg twice daily|Patients in this arm took 1 reldesemtiv 150 mg oral tablet and 2 matching placebo tablets every 12 hours for 12 weeks.
3128596|NCT03160898|Experimental|Reldesemtiv 300 mg twice daily|Patients in this arm took 2 reldesemtiv 150 mg oral tablets and 1 matching placebo tablet every 12 hours for 12 weeks.
3128597|NCT03160898|Experimental|Reldesemtiv 450 mg twice daily|Patients in this arm took 3 reldesemtiv 150 mg oral tablets every 12 hours for 12 weeks.
3128598|NCT03160898|Placebo Comparator|Placebo|Patients in this arm took 3 placebo oral tablets every 12 hours for 12 weeks.
3128599|NCT03161158|Active Comparator|Ultrafiltration Group|Veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm.
3128600|NCT03161158|Other|Control group (Usual care IV diuretics)|Guideline-directed therapy including IV loop diuretics according to treatment algorithm.
3128601|NCT03161327|Other|ABI|ABI will be performed in patient
3128602|NCT03161405|Experimental|TAK-906 maleate 25mg;Itraconazole 200mg + TAK-906 maleate 25mg|TAK-906 maleate 25 milligram (mg), capsule, orally, once on Day 1 of First Intervention Period, followed by a minimum of 4-day washout period, further followed by Itraconazole 200 mg, solution, orally, once daily on Days 1 to 5 along with TAK-906 maleate 25 mg, capsule, orally on Day 4 of Second Intervention Period.
3128603|NCT03161483|Experimental|CC-220 0.45 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.45 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.45 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
3128604|NCT03161483|Experimental|C-220 0.3 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.3 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.30 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
3128605|NCT03161483|Experimental|CC-220 0.15 mg QD Placebo Controlled Phase|"At Weeks 0 to 24: CC-220 Placebo Controlled Phase: CC-220 0.15 mg once daily (QD)~At Weeks 24 to 52: CC-220 Active Treatment Phase: CC-220 0.15 mg once daily (QD)~Long-term Extension Phase (52 weeks to 104 weeks): At Week 52 all subjects who elect to continue in the Long-term Extension will stay on the same dose they were on at the conclusion of the randomized, double-blind, active treatment phase."
3128606|NCT03161483|Placebo Comparator|Placebo|Weeks 0 to 24: CC-220 Placebo Controlled Phase: placebo once daily (QD)
3128607|NCT03161938|Active Comparator|Dexamethasone 48 mg|Dexamethasone 48 mg pre-operative, single shot injection
3128608|NCT03161938|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg pre-operative, single shot injection
3128609|NCT03162055|Experimental|Experimental|glycopyrronium/formoterol fumarate 7.2/4.8 μg per actuation, twice daily
3128610|NCT03162055|Active Comparator|Active comparator|umeclidinium/vilanterol 62.5/ 25μg per inhalation, once daily
3128611|NCT03162328|Placebo Comparator|Powersleep Sham, PowerSleep Stim|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers. After 2 nights in the lab in the sham condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
3128612|NCT03162328|Experimental|Powersleep Stim, PowerSleep Sham|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night. After 2 nights in the lab in the stim condition participants will cross-over to the other arm of the trial the following week. Week 2 - Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
3128613|NCT03162354|Experimental|Intervention Sites|"At the four intervention sites, investigators will deploy active, multifaceted, implementation strategies designed to promote CDR acceptability and application as an AHT screening tool. These strategies will include physician training with onsite visits, monthly booster training emails, access to an AHT probability calculator, audit and site-specific feedback, and local information sharing sessions designed to address local barriers to CDR acceptance and application."
3128614|NCT03162354|No Intervention|Control Sites|"At the four matched control sites, physicians will engage in AHT screening as usual."
3128615|NCT03162458|Experimental|Anaferon for children|
3128616|NCT03162458|Placebo Comparator|Placebo|
3128617|NCT03162614|Active Comparator|AduFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and Month 1 and 1/5th of RTS,S/AS01B full dose at Month 7, and underwent sporozoite challenge.
3128618|NCT03162614|Experimental|2PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E double dose at Month 0 and Month 1, and 1/5th of double dose RTS,S/AS01E at Month 7, and underwent sporozoite challenge.
3128619|NCT03162614|Experimental|PedFx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01E full dose at Month 0 and Month 1, and 1/5th of RTS,S/AS01E full dose at Month 7, and underwent sporozoite challenge.
3128620|NCT03162614|Experimental|Adu2Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose at Month 1 and Month 7, and underwent sporozoite challenge.
3128621|NCT03162614|Active Comparator|Adu1Fx Group|Healthy subjects, between, and including, 18 and 55 years of age, who received RTS,S/AS01B full dose at Month 0 and 1/5th of RTS,S/AS01B full dose administered at Month 7, and underwent sporozoite challenge.
3128622|NCT03162614|Other|Control Group|Healthy subjects, between, and including, 18 and 55 years of age, who did not receive any immunization but underwent sporozoite challenge.
3128623|NCT03162796|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
3128624|NCT03162796|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
3128625|NCT03162796|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
3128626|NCT03163017|Experimental|2D Fluoroscopy then 3D Fluoroscopy|"Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system."
3128627|NCT03163134|No Intervention|No Lumbar Drain Group|Group of patients that did not receive a lumbar drain after surgery
3128628|NCT03163134|Experimental|Lumbar Drain Group|Group of patients that received a lumbar drain after surgery
3128629|NCT03163303|Experimental|Tobacco Status Project (TSP) + Alcohol Intervention|Tobacco and alcohol intervention on Facebook and 14-day nicotine patch
3128630|NCT03163303|Experimental|Tobacco Status Project Intervention|Tobacco intervention on Facebook and 14-day nicotine patch
3128631|NCT03163342|Other|Open label|Licensed seasonal influenza vaccine, intramuscular
3128632|NCT03163446|Experimental|CF-301|Patients will receive a single IV infusion of CF-301 in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
3128633|NCT03163446|Placebo Comparator|Placebo|Patients will receive a single IV infusion of placebo in addition to standard of care (SOC) antibacterial therapy selected by the investigator.
3128634|NCT03163472|Active Comparator|10 ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
3128635|NCT03163472|Experimental|30ml of lidocaine 2% with epinephrine|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
3128636|NCT03163758|Experimental|rTMS treatment group|The rTMS treatment group received a 10-day real repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
3128637|NCT03163758|Sham Comparator|sham group|The sham group received a 10-day sham repetitive transcranial magnetic stimulation (rTMS) treatment beginning within 1 week after stroke onset.
3128638|NCT03164538|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
3128639|NCT03164538|Active Comparator|Diabetes Education|Participants will speak on the telephone each week with a study trainer. During these calls, the trainer will provide education about a health behavior related to diabetes health (physical activity, medication adherence, diet).
3128640|NCT03164551|Active Comparator|GERI+ Incubator|
3128641|NCT03164551|Other|Conventional incubator|
3128642|NCT03164629|Experimental|3D Angiogram + Emboguide|Participants will receive cone-beam CT 3D Emboguide: cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
3486448|NCT03745248|Active Comparator|Balance Training|A physical therapist will tailor a home balance training program for each participant based on pre-training capabilities. Subjects will be asked to perform exercises five times a week for thirty-minute sessions. Both dynamic and static exercises will be performed in sitting and standing positions. Exercises will start with stabilizing in a challenging static position and progress to dynamic arm and leg movements in the same or modified position. Participants will be contacted weekly by e-mail or phone to answer any questions about the exercise protocol and will be required to log their exercise effort in terms of frequency and level of balance challenge. Individuals will be instructed to perform more difficult exercises if balance challenge scores are low.
3486449|NCT03745235|Experimental|"Mindfulness group"|
3486450|NCT03745235|Other|Control group|Treatment as Usual
3128643|NCT03164629|Active Comparator|No 3D Angiogram + Emboguide|Embolization will be guided by a standard of care CT.
3486451|NCT03745209|Experimental|Ultrasound-guided peripheral IV.|Ultrasound-guided peripheral IV cannulation
3128644|NCT03165045||patients treated with Spiolto® Respimat®|Patients with COPD
3128645|NCT03165058||Inflammatory Bowel Disease|Patients undergoing standard of care colonoscopy for inflammatory bowel disease (IBD) surveillance will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
3128646|NCT03165058||control|Patients undergoing standard of care colonoscopy for age appropriate screening will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa.
3128647|NCT03165110|Experimental|Users of the Onyx Blood Glucose Meter/ app System at home|Participants have a diagnosis of either type 1 or type 2 diabetes for at least 6 months and use insulin.
3128648|NCT03165175|Experimental|App + treatment as usual|The experimental group will be provided with the prescription drug-abuse education smartphone application in addition to treatment as usual. This educational mobile phone app focuses on helping military members reduce their risk for prescription drug misuse.
3128649|NCT03165175|No Intervention|Treatment as usual|The control group will be provided with treatment as usual, and will also receive a list of resources for help with prescription drug and other substance abuse issues.
3128650|NCT03165617|Experimental|QIVc (≥2 years to <18 Years of Age)|Cell-derived Seasonal Quadrivalent Influenza Vaccine
3128651|NCT03165617|Active Comparator|Non-Influenza Comparator Vaccine|Non-Influenza Comparator Vaccine
3128652|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/Wild-Type GIST|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Gastrointestinal stromal tumor (GIST)"
3128653|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/PHEO/PGL with SDH-deficient PHE|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Pheochromocytoma and Paraganglioma (PHEO/PGL) with succinate dehydrogenase (SDH)-deficient PHE"
3128654|NCT03165721|Experimental|Patients ≥ 12 Years of Age w/HLRCC-associated Renal Cell Ca|"SGI-110 administered subcutaneously at 45mg/m^2/day x 5 days on a 28-day cycle~Hereditary leiomyomatosis and renal cell carcinoma (HLRCC)-associated Renal Cell Ca"
3486452|NCT03745209|No Intervention|Traditional landmark technique|Traditional landmark technique
3486453|NCT03745196|Experimental|PC945|PC945 5mg once-daily, nebulized
3128657|NCT03165955|Experimental|Oraxol|Subjects will receive Oraxol 205 mg/m2 daily x 3 days weekly for up to 16 weeks.
3128658|NCT03165981|Other|Simultaneous vaccination arm|In the study arm, subjects will receive PCV13, DTaP and IIV vaccines during visit 1. Approximately 2 weeks later, subjects will receive a health education visit without vaccination during study visit 2.
3128659|NCT03165981|Other|Sequential vaccination arm|In the study arm, subjects will receive PCV13 and DTaP during study visit 1. Approximately 2 weeks later, subjects will receive the IIV vaccine during study visit 2.
3128660|NCT03166124|Experimental|Elderly Adults LY900014|Single, subcutaneous (SC) 15-U dose of LY900014 in the elderly adult group.
3128661|NCT03166124|Active Comparator|Elderly Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in in the elderly adult group.
3128662|NCT03166124|Experimental|Younger Adults LY900014|Single, SC 15-U dose of LY900014 in the younger adult group.
3128663|NCT03166124|Active Comparator|Younger Adults Insulin Lispro|Single, SC 15-U dose of insulin lispro (Humalog) in the younger adult group.
3128664|NCT03166215|Placebo Comparator|Part 1: Placebo|TAK-935 matching-placebo tablets, orally or through gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) from Days 1 to 30 in dose titration period.
3128665|NCT03166215|Experimental|Part 1: TAK-935|TAK-935 100 mg, tablet, orally or through G-tube/PEG tube, BID from Days 1 to 10 followed by TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 11 to 20 followed by TAK-935 100 mg tablets x3, orally or through G-tube/PEG tube, BID from Days 21 to 30 in dose titration period. The dose of TAK-935 was escalated or de-escalated during Part 1 as per investigator's discretion.
3128666|NCT03166215|Experimental|Part 2: TAK-935|TAK-935 100 mg tablets x2, orally or through G-tube/PEG tube, BID from Days 31 to 40 followed by TAK-935 100 mg tablets x1, x2 or x3, orally or through G-tube/PEG tube, BID from Days 31 to Day 85 as per investigator's discretion in the maintenance period. At the end of Part 2, the dose of TAK-935 was de-escalated until discontinuation.
3128667|NCT03166735|Experimental|BI 1467335 dose 1|
3128668|NCT03166735|Experimental|BI 1467335 dose 2|
3128669|NCT03166735|Experimental|BI 1467335 dose 3|
3128670|NCT03166735|Experimental|BI 1467335 dose 4|
3128671|NCT03166735|Placebo Comparator|Placebo|
3128672|NCT03167073|Experimental|BreastFeeding Friend (BFF)|BFF is a novel android app initially created in Microsoft PowerPoint with the results of a well-validated questionnaire administered to the target patient population, in which participants identified barriers preventing them from starting or continuing breastfeeding. The app was then modified by a multidisciplinary team of neonatologists, perinatologists, and certified lactation consultants. The finalized prototype was presented to three focus groups of test users sociodemographically similar to the target population. This approach allowed BFF to be adjusted to maximize the users' experience per their opinions. Once the focus groups' feedback was consistent, the app prototype was provided to a freelance coding team at Washington University of St. Louis, which built a native android app.
3128673|NCT03167073|Placebo Comparator|dummy app|The dummy app looks identical to BFF but is limited to a few pages of information on breastfeeding that is provided in hand-out form during routine prenatal care.
3486454|NCT03745196|Placebo Comparator|Placebo|Placebo, nebulized
3486455|NCT03745183|Experimental|Senna alata leaf decoction|The participants were instructed to take a bath once a day using a syndet bar and to towel dry their skin before applying the akapulko decoction. Fresh decoction was prepared by the patients every day. After a bath, the patient applied the fresh cooled decoction by hand on the whole body especially on the affected areas and left it to dry. Approximately one glassful (350ml) of akapulko decoction should be consumed for one whole body application. The total duration of daily application should be 4 weeks (28 days +3) until the next outcome assessment.The patients were given illustrated, laminated instructional materials and a tabulated checklist of instructions on how to prepare and apply the decoction which served as a monitoring sheet of each patient.
3486456|NCT03745170|Experimental|Sintilimab+ Oxaliplatin +capecitabine|
3486457|NCT03745170|Active Comparator|placebo +Oxaliplatin + Capecitabine|
3486458|NCT03745157||Patients with Type 2 Diabetes requiring insulin therapy|Patients with type 2 diabetes requiring insulin therapy in Japanese routine clinical practice previously treated with insulin glargine (IGlar)
3128674|NCT03167151|Experimental|Arm A Intravesical|"Intravesical Pembrolizumab (solution for infusion) 50-200 mg, given on D1, D8, D15, D22, D29, D36 & D64.~Dose to be decided after safety run-in."
3128675|NCT03167151|Active Comparator|Arm B Intravenous|Intravenous Pembrolizumab (solution for infusion), 200mg, given on D1, D22, D43, D64
3128676|NCT03167359|Experimental|Participants with Stage 0-III breast cancer|Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.
3128677|NCT03167411|Experimental|Bexagliflozin alone|
3128678|NCT03167411|Active Comparator|Bexagliflozin with exenatide injection|
3128679|NCT03167541|Experimental|1|Treatment Order: Test, Reference
3128680|NCT03167541|Experimental|2|Treatment Order: Reference, Test
3128681|NCT03168022|Experimental|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
3128682|NCT03168022|Experimental|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
3128683|NCT03168295|Experimental|Placebo first and then dapagliflozin|Renal transplant subjects with intact native kidneys with Type 2 Diabetes Mellitus receive dapagliflozin then placebo
3128684|NCT03168295|Active Comparator|Dapagliflozin first then placebo|Renal transplant subjects with intact native kidneys who are non-diabetic receive placebo then dapagliflozin
3128685|NCT03168295|Other|Control Group|Subjects who are type 2 diabetes mellitus who have not undergone renal transplant.
3128686|NCT03168308|Active Comparator|Neostigmine & Glycopyrrolate|Patients randomized to receive Neostigmine w/ Glycopyrrolate
3128687|NCT03168308|Active Comparator|Sugammadex|Patients randomized to receive Sugammadex
3128688|NCT03168321|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
3128689|NCT03168321|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
3128690|NCT03168334|Experimental|IDP-123 Lotion|Tazarotene 0.045% Lotion
3128691|NCT03168334|Placebo Comparator|IDP-123 Vehicle Lotion|Vehicle Lotion
3128692|NCT03168425|Experimental|Tailored|Participants will be prescribed an opioid based on a formula derived from inpatient opioid use
3128693|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg, which is the average prescription currently given to our population.
3128694|NCT03168542|Experimental|Toric Multifocal Contact Lens|JJVC Investigational Toric Multifocal Contact Lens for Presbyopia
3128695|NCT03168542|Experimental|Multifocal Contact Lens|1-Day Acuvue® Moist Brand Multifocal Contact Lens
3128696|NCT03168711|Experimental|Inosine|Subjects will be administered oral inosine daily. The dose of inosine will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
3128697|NCT03168711|Placebo Comparator|Placebo|Subjects will be administered oral placebo daily. The dose of placebo will be titrated to obtain serum urate levels of 7 - 8 mg/dL.
3128698|NCT03168841|Experimental|Intervention Group, receiving medication|Enrolled subjects with confirmed onychomycosis will be dispensed topical medication for treatment.
3128699|NCT03168919|Experimental|Chemoradiation with MRI assessment|This study has only one arm. The eligible subjects will receive standard of care fractionated radiation therapy along with concomitant temozolomide, which will NOT be changed based on the MRI scans obtained as a part of this study. There is no control or sham group.
3128700|NCT03169062|Experimental|All patients|Gated Stationary Chest Tomosynthesis
3128701|NCT03169153|Other|Lotrafilcon B, then senofilcon C|Lotrafilcon B contact lenses worn first, followed by senofilcon C contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
3132536|NCT03435614||Critically ill patients|Mechanically ventilated critically ill adults receiving regular opioids for more than 72 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opioids.
3179796|NCT00676832|Placebo Comparator|Group 1|
3179797|NCT00676832|Experimental|Group 2|
3486459|NCT03745131||Pre-exposure prophylaxis recipients|40 healthcare workers who provide specialist medical care to patients with monkeypox and who received vaccine as pre-exposure prophylaxis.
3486460|NCT03745131||Post-exposure prophylaxis recipients|40 healthcare workers who received vaccine as post-exposure prophylaxis following monkeypox-exposure risk assessments.
3486461|NCT03745131||Control Group 1|20 healthcare workers who provided specialist medical care to patients with monkeypox but declined the offer of vaccine as pre-exposure prophylaxis.
3486462|NCT03745131||Control Group 2|Healthcare workers not involved in the care of, and have not had known exposure to, patients with monkeypox and, therefore, were not offered vaccine.
3486463|NCT03745118|Other|Monitoring Device|Subjects will be asked to wear up to 4 different noninvasive seizure detection devices including EpiTel EpiLog, Byte Flies Sensor Dots, Empatica E4, Biovotion Everion, GeneActiv
3486464|NCT03745105|Experimental|dexamethasone|Pretreatment intraligamentary injection of 0.4 mL of 8 mg/2 mL dexamethasone (Dexamethasone, AMRIYA pharmaceutical, Egypt)
3486465|NCT03745105|Experimental|piroxicam|Pretreatment intraligamentary injection of 0.4 mL of 20 mg mL-1 piroxicam (Feldene, Pfizer, Egypt)
3486466|NCT03745105|Active Comparator|Mepivacaine HCL|Pretreatment Intraligamentary injection of 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml (Mepecaine - L, Alexandria Co.-Egypt)
3486467|NCT03745079||Group 1|"Participants' temperature measured at 3 places at the same time~Esophagus~Skin near to temporal artery~Skin near to carotid artery"
3486468|NCT03745053|Experimental|XLIMUS DES|Xlimus DES Implantation during coronary angioplasty
3486469|NCT03745053|Active Comparator|Synergy DES|Synergy DES Implantation during coronary angioplasty
3128702|NCT03169153|Other|Senofilcon C, then lotrafilcon B|Senofilcon C contact lenses worn first, followed by lotrafilcon B contact lenses, as randomized. Each product worn bilaterally (in both eyes) for a total duration of 30 (+ 3) days under a daily wear modality for the specific study period. The lenses will be removed every night and cared for with the subject's habitual lens care solution.
3486470|NCT03745040|Experimental|Group A: Exparel|"Standard of Care plus Liposomal bupivacaine (Exparel®). Dosage: Exparel® 20 mL single use vial, 1.3% (13.3 mg/mL), Maximum dose of 266 mg (20 mL).~Frequency: Single intraoperative administration"
3486471|NCT03745040|No Intervention|Group B: No Exparel|Standard of Care
3486472|NCT03745027|Experimental|In vitro fertilization|Paients undergoing in vitro fertilization with Gonadotropin-releasing Hormone agonist. Follicular fluid sialic acid levels will be measured.
3486473|NCT03745014|Active Comparator|Pheno|
3486474|NCT03745014|Active Comparator|Standard of Care|
3128703|NCT03169244|Active Comparator|Bupropion|Bupropion extended release
3128704|NCT03169244|Placebo Comparator|Placebo|Placebo oral tablet
3128705|NCT03169816|Experimental|Lorcaserin|10 mg capsule taken twice daily of lorcaserin
3128706|NCT03169816|Placebo Comparator|Placebo|a placebo comparator capsule taken twice daily
3128707|NCT03170154|Experimental|Clareon IOL|Clareon aspheric hydrophobic acrylic monofocal IOL implanted in one eye during routine small incision cataract surgery
3128708|NCT03170193|Experimental|AMG 529|Participants received a single dose of AMG 529 at ascending dose levels by either subcutaneous or intravenous injection.
3128709|NCT03170193|Placebo Comparator|Placebo|Participants received a single dose of placebo matching to AMG 529 by either subcutaneous or intravenous injection.
3128710|NCT03170219|Experimental|Subcutaneous Furosemide and sc2wear device|Subjects will receive device training and study materials (SQ pump device and up to a 7 day supply of SQ furosemide vials) on the day of randomization (study day 0) and discharged within 24 hours. Subjects will be discharged with planned treatment of 80 mg subcutaneous furosemide injection over 5-hours either QD or BID, depending on anticipated diuretic requirements.
3128711|NCT03170219|No Intervention|Usual Care|Subjects randomized to usual care will continue to receive inpatient therapy, eventual transition to oral diuretics, and discharge and post discharge care as per the discretion of the treating clinician and standard treatment guidelines.
3128712|NCT03170232|Experimental|Subjects receiving danirixin|Following screening and assessment of rescue medication use, subjects will receive one tablet of danirixin 35 mg (as hydrobromide hemihydrate salt) orally twice daily with food for 52 weeks during treatment period. Study treatment will be dispensed to subjects at the study visits.
3128713|NCT03170232|Placebo Comparator|Subjects receiving placebo|Following screening and assessment of rescue medication use, subjects will receive one tablet of placebo 35 mg orally twice daily with food for 52 weeks during treatment period. Placebo will be dispensed to subjects at the study visits.
3128714|NCT03170271|Experimental|Benralizumab (Medi-563)|Benralizumab (Medi563) Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
3128715|NCT03170271|Placebo Comparator|Placebo|Administered subcutaneously at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
3128716|NCT03170388|Experimental|IDP-126 Gel|Gel
3128717|NCT03170388|Active Comparator|IDP-126 Component A|Component A
3128718|NCT03170388|Active Comparator|IDP-126 Component B|Component B
3128719|NCT03170388|Active Comparator|IDP-126 Component C|Component C
3128720|NCT03170388|Placebo Comparator|IDP-126 Vehicle Gel|Vehicle Gel
3128721|NCT03170544|Experimental|Part 1, MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128722|NCT03170544|Experimental|Part 1, MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128723|NCT03170544|Experimental|Part 1, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128724|NCT03170544|Experimental|Part 1, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128725|NCT03170544|Experimental|Part 1, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128726|NCT03170544|Active Comparator|Part 1, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in healthy participants
3128727|NCT03170544|Experimental|Part 2, MK-1092, 8.0 nmol/kg + lispro, 1.2 nmol/kg|MK-1092, 8.0 nmol/kg dose selection based on Part 1 + lispro (Humalog®), 1.2 nmol/kg, as a single dose, in healthy participants
3128728|NCT03170544|Experimental|Part 3, MK-1092, 8.0 nmol/kg|MK-1092, (8.0 nmol/kg based on Part 1), SC, in participants with T1DM.
3128729|NCT03170544|Experimental|Part 3, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T1DM
3128730|NCT03170544|Active Comparator|Part 3, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T1DM
3179798|NCT00676832|Experimental|Group 3|
3486475|NCT03745001|Experimental|Single dose study part|there will be 7 cohorts of healthy volunteers dosed with single doses of EHP-101 (7 planned dose levels) or with placebo and 1 potential additional cohort (also dosed with single dose of EHP-101 or placebo)
3486476|NCT03745001|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of EHP-101 (3 planned dose levels) or placebo and 1 potential additional cohort (also dosed with multiple doses of EHP-101 or placebo)
3486477|NCT03744988||control group|serum androgen levels will be measured in 25 normotensive pregnant women
3486478|NCT03744988||mild preeclampsia|serum androgen levels will be measured in 25 mild preeclamptic patients
3486479|NCT03744988||severe preeclampsia|serum androgen levels will be measured in 25 severe preeclamptic patients
3486480|NCT03744949|Experimental|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
3486481|NCT03744949|Experimental|Remifentnil dose 1 ug/kg|Remifentanil will be given (dosage of 1.0 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
3486482|NCT03744949|Experimental|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
3486483|NCT03744949|Experimental|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus according to randomization) from an infusion pump over 30 seconds. The bolus of remifentanil will be programmed on an electronic pump which gives an auditory signal when each bolus is completed. When the pump will ring at the end of the remifentanil bolus, the chronometer on the Dräger Monitor (anesthesia machine, Dräger Perseus A500, Draeger Medical Canada Inc., Ontario, Canada) will be turned on.
3128731|NCT03170544|Experimental|Part 4, MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose, in participants with T2DM
3128732|NCT03170544|Experimental|Part 4, MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose, in participants with T2DM
3128733|NCT03170544|Experimental|Part 4, MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose, in participants with T2DM
3128734|NCT03170544|Active Comparator|Part 4, Glargine, 3.0 nmol/kg|Glargine, 3.0 nmol/kg, SC, as a single dose, in participants with T2DM
3128735|NCT03170609|Experimental|Lowest dose formulation a|Multivalent group B streptococcus vaccine
3128736|NCT03170609|Experimental|Middle dose formulation a|Multivalent group B streptococcus vaccine
3128737|NCT03170609|Experimental|Highest dose formulation a|Multivalent group B streptococcus vaccine
3128738|NCT03170609|Experimental|Lowest dose formulation b|Multivalent group B streptococcus vaccine
3128739|NCT03170609|Experimental|Middle dose formulation b|Multivalent group B streptococcus vaccine
3128740|NCT03170609|Experimental|Highest dose formulation b|Multivalent group B streptococcus vaccine
3128741|NCT03170609|Placebo Comparator|Placebo|Saline control
3128742|NCT03170661|No Intervention|Moderate neuromuscular block|Subjects will receive moderate neuromuscular block, aimed at 1-2 twitches train of four
3128743|NCT03170661|Experimental|Deep neuromuscular block|Subjects will receive deep neuromuscular block, aimed at 1-2 twitches post tetanic count
3128744|NCT03170882|Active Comparator|Pomalidomide 4 mg + Dexamethasone 40 mg|Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged >=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
3128745|NCT03170882|Experimental|Ixazomib 4 mg + Dexamethasone 20 mg|Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged >=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.
3128746|NCT03171051|Other|Lipolysis treatment|"The right flank of the abdomen will be treated with the 950nm LED device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes.~The left flank of the abdomen will be treated with the 1050nm diode laser device. The treatment area will be heated initially for 4 minutes at 41W followed by a duty cycle of 25 sec on and 10 sec off time at 29W for 16 minutes. Total treatment time will be 24 minutes."
3128747|NCT03171415|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into 8-36 sites (0.1mL per site):~40mg RZL-012 -administered at 8 sites~80mg RZL-012 - administered at 16 sites~120mg RZL-012 - administered at 24 sites~180mg RZL-012 - administered at 36 sited"
3128748|NCT03171415|Placebo Comparator|Placebo|A single-time injection, multiple subcutaneous injections of Placebo administered into 8-36 sites (0.1mL per site)
3128749|NCT03172130|Experimental|Straight CPAP|Patients randomized to straight CPAP will receive 10 cm of air pressure, or as determined by the results of polysomnography, for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
3128750|NCT03172130|Sham Comparator|Sham CPAP|Patients randomized to sham CPAP will receive 1-2 cm of air pressure for 6 weeks. Following the 6-week visit, patients will be placed on straight CPAP with equipment approved by insurance for an additional 6 weeks.
3128751|NCT03172325|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
3179799|NCT00676832|Experimental|Group 4|
3486484|NCT03744923|Active Comparator|Transmuscular QLB group|Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall Then, scan dorsally keeping the transverse orientation until observing that the transverse abdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia The needle (20G spinal needle) is inserted in-plane from posterior to anterior and the tip of the needle is advanced towards then through the QL muscle, penetrating the ventral proper fascia of the QL muscle. The target site for injection is the plane between quadratus lumborum and psoas major. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together.
3128752|NCT03172325|Active Comparator|AbbVie adalimumab|Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
3128753|NCT03172364|Experimental|Test product 1|All the participants in this arm will receive test product 1 (micellar cleanser) at home twice a day (morning and evening) for 21 (±2) days.
3128754|NCT03172364|Experimental|Test product 2|All the participants in this arm will receive test product 2 (micellar foaming cleanser) at home twice a day (morning and evening) for 21 (±2) days.
3128755|NCT03172481|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70 or 85 mg
3128756|NCT03172481|Placebo Comparator|Placebo Treatment|
3128757|NCT03172494|Experimental|Insulin degludec/liraglutide|
3128758|NCT03172494|Active Comparator|Insulin degludec|
3128759|NCT03172494|Active Comparator|Liraglutide|
3128760|NCT03172702|Experimental|Sodium Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
3128761|NCT03172780|Experimental|Diclofenac Sodium Gel|Diclofenac Sodium Gel, 1%
3128762|NCT03172780|Active Comparator|Voltaren® Gel|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%
3128763|NCT03172780|Placebo Comparator|Placebo gel|Placebo gel
3128764|NCT03172884|Experimental|BAY80-6946/Healthy subject|Healthy subjects
3128765|NCT03172884|Experimental|BAY80-6946/moderate hepatically impaired patients|Patients with Child-Pugh B (score 7-9) at the screening visit
3128766|NCT03172884|Experimental|BAY80-6946/severe renal impaired patients|Patients with eGFR 15-29 mL/min/1.73 m^2 at the screening visit based on the Modification of Diet in Renal Disease (MDRD) equation
3128767|NCT03172884|Experimental|BAY80-6946/severe hepatically impaired patients|Patients with Child-Pugh C (score 10-15) at the screening visit
3128768|NCT03173170|Experimental|TAK-954 0.2 mg + Itraconazole 200 mg and TAK-954 0.2mg|TAK-954 0.2 milligram (mg), infusion, intravenously, once on Day 1 of First Intervention Period, followed by a minimum of 7-day washout period, further followed by Itraconazole 200 mg, capsule, orally, once daily on Days 1 to 8 along with TAK-954 0.2 mg, infusion, intravenously on Day 4 of Second Intervention Period.
3128769|NCT03173313|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
3128770|NCT03173313|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
3128771|NCT03173547|Active Comparator|146-9251 cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
3128772|NCT03173547|Placebo Comparator|Vehicle cream|Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
3128773|NCT03173560|Experimental|Lenvatinib 14 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 14 mg once daily (QD) plus oral everolimus 5 mg QD as the starting dose for Cycle 1. If there are no intolerable Grade 2 or any >= Grade 3 treatment-emergent adverse events (TEAEs) that require dose reduction in the first 28-day cycle (that is, the first 4 weeks of treatment), the lenvatinib dose will be escalated to 18 mg QD (plus everolimus 5 mg) beginning in Cycle 2 or later (cycle length equal to [=] 28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
3128774|NCT03173560|Experimental|Lenvatinib 18 mg plus everolimus 5 mg|Participants will receive oral lenvatinib 18 mg QD plus oral everolimus 5 mg QD as the starting dose in Cycle 1 or later (cycle length =28 days) during randomization phase. After the data cutoff for the primary analysis, participants will receive study treatment as continuous 56-day cycles.
3128775|NCT03174132|Experimental|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine will be injected into one side of the nasolabial fold at day 1
3128776|NCT03174132|Active Comparator|Restylane Perlane|Restylane Perlane will be injected into the opposite side of the nasolabial fold on day 1
3128777|NCT03174158|Active Comparator|Brief advice|Usual care plus brief telephone advice to quit tobacco delivered by a clinical research coordinator who underwent Tobacco Treatment Specialist core training.
3128778|NCT03174158|Experimental|Text messaging|Patients randomized to the text messaging program are offered a 12-week text messaging. The text messaging intervention will use content from the National Cancer Institute's SmokeFreeTXT library, content for smokers not ready to quit from SmokeFreeTXT and a pilot feasibility study conducted by the PI, and new messages supporting nicotine replacement medication adherence. The text messaging program will be personalized using subject's first name, the telephone number for the Massachusetts General Hospital (MGH) tobacco cessation counseling services and the Massachusetts state quitline. Smokers receiving the intervention will be sent from 0 and 5 text messages per day.
3179800|NCT00676832|Experimental|Group 5|
3128779|NCT03174158|Experimental|Mailed nicotine replacement therapy|Subjects randomized to mailed nicotine replacement therapy will be offered a 2 week supply of nicotine replacement therapy mailed to their home address. Daily smokers planning to quit in the next 30 days will be offered nicotine patches (14 or 21 mg patches) and lozenges (2 or 4 mg lozenges) dosed according to package instructions. Non-daily smokers planning to quit will be offered a 2 week allotment of 2 mg lozenges alone. Smokers not planning to quit will be offered one box of lozenges (72 count box of 4 mg or 2 mg lozenges based on time to first cigarette as above per package instructions) to use when they are not smoking during their practice quit attempt.
3128780|NCT03174158|Experimental|Text messaging + mailed NRT|Subjects will be offered both the 12 week text message program and 2 weeks of mailed nicotine replacement therapy.
3128781|NCT03174366|Experimental|Intervention Group, receiving medication|Subjects in this group will be receiving medication (denosumab)
3128782|NCT03174925|Experimental|Tissue Stiffness by Elastography|Potentially cancerous thyroid nodules were assessed by elastrography, then a fine needle biopsy specimen or the surgically-excised nodule was assessed pathologically to determine cancer status.
3128783|NCT03175120|Experimental|Insulin degludec/liraglutide|
3128784|NCT03175120|Active Comparator|Insulin degludec|
3128785|NCT03175172|Experimental|Experimental|CRS-207 and pembrolizumab will be administered in 3-week cycles. For Cycle 1, pembrolizumab (200 mg) will be administered by intravenous (IV) infusion over 30 minutes on Day 1 and CRS-207 (starting dose 1 × 10e9 colony-forming units [CFU]) will be administered by IV infusion over 1 hour on Day 2. If the infusions are well tolerated, pembrolizumab and CRS-207 may be administered on the same day (Day 1) for subsequent cycles. After 4 cycles, pembrolizumab will continue to be administered on Day 1 at each treatment cycle (every 3 weeks); CRS-207 will be administered once every 6 weeks (every other cycle). Treatment will continue for up to 35 cycles as long as there is adequate safety and potential for clinical benefit.
3128786|NCT03175562|Experimental|Test product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
3128787|NCT03175562|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and waistline and away from the spinal mid-line.
3128788|NCT03175731|Experimental|Proton Pump Inhibitors|Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
3128789|NCT03175731|Placebo Comparator|Placebo|Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
3128790|NCT03176238|Experimental|everolimus + exemestane|Everolimus (10 mg) and exemestane (25 mg) tablets taken orally in combination once daily
3128791|NCT03176407|Experimental|HemoPill acute|"Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours.~Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days."
3128792|NCT03176459|Experimental|EXPAREL+bupivacaine TAP infiltration|Receive a single 20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL.
3128793|NCT03176459|Active Comparator|Active bupivacaine TAP infiltration|Receive 20 mL 0.25% bupivacaine expanded in volume with 40 mL normal saline for a total volume of 60 mL
3128794|NCT03176654|Experimental|HVLAT manipulation|An HVLAT manipulation is applied to the site of pain or restriction with the patient in supine. This technique uses both primary levers (pre-manipulation rotation - away (30 ° - 45 °) from the side of pain or limitation) and secondary levers (Side bending - towards coupled with lateral shift - away, and posterior-anterior (PA) shift (extension). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand is placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions the clinician performed the thrust with the arc of rotation dependent on the level of the target vertebrae.
3128795|NCT03176654|Sham Comparator|Sham HVLAT manipulation|Subjects in the control group were instructed to lay on a table in the same position as the HVLAT manipulation group. The clinician went through the same basic steps as the HVLAT manipulation, localizing the appropriate vertebral landmarks but without carrying out the final HVLA thrust procedure.
3128796|NCT03176784|Experimental|Varenicline + Patch Standard Duration|"Standard Condition Varenicline: 0.5 mg pill once daily (QD) on Days -7 to -5; 0.5 mg pill twice daily (BID) Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Nicotine Patches:~Patches (Nicotine): 14 mg Patches for 2 weeks prequit and then 10 weeks post-quit, then 7 mg patches for Weeks 11 and 12; Placebo patches weeks 13-24"
3128797|NCT03176784|Experimental|Varenicline Only Standard Duration|"Standard Condition Varenicline: 0.5 mg pill QD on Days -7 to -5; 0.5 mg pill BID Days -4 to -1; 1 mg pill BID Days 1 to Week 11; Placebo Pill weeks 12-23 BID~Standard Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
3128798|NCT03176784|Experimental|Varenicline + Patch Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Nicotine Patches:~14 mg Patches for 2 weeks prequit and then weeks 1-22 post-quit, then 7 mg patches for Weeks 23 and 24 post-quit."
3128799|NCT03176784|Experimental|Varenicline Only Extended Duration|"Extended Condition Varenicline: 0.5 mg pill QD on Days -7 to -5, 0.5 mg pill BID Days -4 to -1, and 1 mg pill BID Days 1 to Week 22~Extended Condition Placebo Patches:~Placebo patches for 2 weeks prequit and for weeks 1-24 post-quit"
3128800|NCT03177395|No Intervention|Acetylcysteine (N-acetylcysteine; NAC)|NAC infusion 100mg/kg in 200ml 'loading dose' at timepoint '0'. 12 hour NAC regime will be continued with the second dose: 200mg/kg NAC in 1000ml i.v. over 10hr as per standard care protocol in NHS Lothian.
3179801|NCT00676845|Placebo Comparator|1|A 3-week placebo run-in period.
3128801|NCT03177395|Experimental|PP100-01 (Calmangafodipir)+ NAC|"In addition to the standard care NAC regime, participants will be allocated into a dosing cohort to receive:~Group A: PP100-01 (2 umol/kg calmangafodipir) after the loading dose of NAC~Group B: PP100-01 (5 umol/kg calmangafodipir) after the loading dose of NAC~Group C: PP100-01 (10 umol/kg calmangafodipir) after the loading dose of NAC~PP100-01 treatment is administered intravenously over 5 minutes."
3128802|NCT03177512|Experimental|LYNX Mobile App|
3128803|NCT03177512|No Intervention|Control|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
3128804|NCT03177603|Experimental|GSK2586881 - 0.1 mg/kg|Eligible subjects will receive a single dose of 0.1 mg/kg GSK2586881. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
3128805|NCT03177603|Experimental|GSK2586881 - 0.2 mg/kg|Eligible subjects will receive a single dose 0.2 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
3128806|NCT03177603|Experimental|GSK2586881 - 0.4 mg/kg|Eligible subjects will receive a single dose of 0.4 mg/kg of GSK2586881 IV infusion. Dose escalation up to maximum dose of 0.8 mg/kg will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
3128807|NCT03177603|Experimental|GSK2586881 - 0.8 mg/kg|Eligible subjects will receive single dose of 0.8 mg/kg of GSK2586881 IV infusion. Dose escalation will occur after 4 subjects have been dosed per cohort and review of safety, tolerability, PK and hemodynamic data up to 24 hours post dose has taken place.
3128808|NCT03177798|Experimental|Icatibant then Placebo|"Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
3128809|NCT03177798|Experimental|Placebo then Icatibant|"Placebo will be intravenously infused at the same rate of Icatibant (50 ug/kg/h) for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)~1 week washout~Icatibant will be intravenously infused at a rate of 50 ug/kg/h for 1 hour prior to the initiation of dialysis and continue through hemodialysis (4 hours)"
3128810|NCT03178045||Team Monitoring|Team Monitoring is the current standard of care for patients at Josie Robertson Surgery Center (JRSC).
3128811|NCT03178045||Enhanced Feedback|The electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity.
3128812|NCT03178266||Zip Closure Device|Patients will receive the Zip Closure Device for final skin closure after knee arthroplasty.
3128813|NCT03178266||Metal Staples|Patients will receive Metal Staples for final skin closure after knee arthroplasty.
3128814|NCT03178344|Experimental|Sham Stimulation, then Alpha Stimulation|"Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS."
3128815|NCT03178344|Experimental|Alpha Stimulation, then Sham Stimulation|"Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.~Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.~Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham."
3128816|NCT03178487|Experimental|Upadacitinib 15 mg|Participants will receive 15 mg upadacitinib orally once a day for 14 weeks in Period 1 and continue to receive 15 mg upadacitinib orally once a day for an additional 90 weeks in Period 2.
3128817|NCT03178487|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 weeks in Period 1. In Period 2 participants will receive 15 mg upadacitinib orally once a day for 90 weeks.
3128818|NCT03178669|Experimental|Cobitolimod Dose 2x31 mg|Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions
3128819|NCT03178669|Experimental|Cobitolimod Dose 2x125 mg|Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions
3128820|NCT03178669|Experimental|Cobitolimod Dose 2x250 mg|Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions
3128821|NCT03178669|Experimental|Cobitolimod Dose 4x125 mg|Dose 125 mg of cobitolimod, at 4 occasions
3128822|NCT03178669|Placebo Comparator|Placebo|Placebo at four occasions
3128823|NCT03178773|Active Comparator|TExT-MED only|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) in traditional booklet form.
3128824|NCT03178773|Experimental|TExT-MED+FANS|Patients receive SMS-textmessage curriculum to improve self0-efficacy and self care for diabetes. A patient-identified family member receives a social support curriculum (FANS) by SMS-text-message synchronized by time and content.
3128825|NCT03178851|Experimental|Cohort A|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.
3128826|NCT03178851|Experimental|Cohort B|Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.
3179802|NCT00676845|Experimental|2|Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
3486485|NCT03744923|Active Comparator|unilateral posterior TAP block group|"under ultrasonographic guidance,the probe will be positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid-axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, the block was performed with the 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydro visualization of needle-tip position and confirming its correct positioning. This will be followed by injection of Bupivacaine 0.5 % (0.25ml/kg) and lidocaine 2% (0.15ml/kg) mixed together."
3486486|NCT03744923|No Intervention|control group|the patients will not receive any blocks
3486487|NCT03744910|Active Comparator|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.
3486488|NCT03744910|Placebo Comparator|Placebo|Physiologic saline solution that is administered subcutaneously.
3486489|NCT03744897|Experimental|Hypnotic analgesia|"Intervention:~- Subjects will receive hypnotic analgesia"
3486490|NCT03744897|Experimental|a-tDCS|"Intervention: transcranial direct current stimulation - tDCS~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
3128827|NCT03178851|Experimental|Cohort C|Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.
3128828|NCT03178942|Active Comparator|Reference: Elimite™ Cream|Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
3128829|NCT03178942|Experimental|Test: Permethrin Cream, 5%|Test: Permethrin Cream, 5% (Encube Ethicals)
3128830|NCT03179319|Experimental|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
3128831|NCT03179319|No Intervention|Standard of Care|Participants in this study arm will receive local standard of care for linkage to PrEP and HIV/STI testing.
3128832|NCT03179345|Active Comparator|Gralise® (gabapentin)|Gralise® 3 x 600 mg tablets (1800 mg total dose) administered once daily at 7:00 pm on Day 1 and Day 2 with one placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®. At other dosing times, treatment consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule.
3128833|NCT03179345|Active Comparator|Neurontin® (gabapentin)|Neurontin® 1 x 600 mg film-coated tablet administered 3 times daily at 7:00 pm on Day 1, at 8:00 am, 2:00 pm and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Neurontin® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
3128834|NCT03179345|Active Comparator|Lyrica® (pregabalin)|Lyrica® 1 x 150 mg capsule administered 2 times daily at 7:00 pm on Day 1, at 8:00 am and 8:00 pm on Day 2 and at 8:00 a.m. on Day 3. Each dose of Lyrica® was over-encapsulated and administered with 3 placebo tablets matching the appearance of Gralise®.
3128835|NCT03179345|Placebo Comparator|Placebo (sugar pill)|Each dose consisted of 3 placebo tablets matching the appearance of Gralise® and 1 placebo capsule matching the over-encapsulation of doses of Neurontin® and Lyrica®.
3128836|NCT03179410|Experimental|Neuroendocrine prostate cancer (NEPC)|Subjects with neuroendocrine prostate cancer (NEPC). Avelumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks.
3486491|NCT03744897|Sham Comparator|s-tDCS|"Sham comparator: transcranial direct current stimulation - tDCS~sham tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current: 0 milliamps~time: 20 minutes"
3486492|NCT03744897|Experimental|Hypnotic analgesia + a-tDCS|"Intervention:~hypnotic analgesia~active tDCS stimulation~montage: bilateral DLPFC anodal/left and cathodal/right~current:2 milliamps~time: 20 minutes"
3486493|NCT03744884|Experimental|CP intervention group|Force efforts with haptic feedback in virtual reality for participants with CP.
3128840|NCT03179891|Experimental|Interictal Period|All subjects received 12.5 mg DBF during the interictal state.
3128841|NCT03179891|Experimental|Ictal/Peri-ictal Period|All subjects received 12.5 mg DBF during the ictal/peri-ictal state.
3128842|NCT03180138|No Intervention|Controls|
3128843|NCT03180138|Active Comparator|Reminders alone|
3128844|NCT03180138|Active Comparator|Reminders + compliance-linked incentives|
3128845|NCT03180385|Experimental|Neurally-Adjusted Ventilatory Assist (NAVA)|Synchronized biphasic non-invasive respiratory support
3128846|NCT03180385|Active Comparator|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional non-invasive respiratory support
3128847|NCT03180489|Experimental|Dapagliflozin with dietary counseling|Daily oral administration of dapagliflozin tablet with dietary counseling to promote weight loss.
3128848|NCT03180489|Placebo Comparator|Placebo with dietary counseling|Daily oral administration of placebo tablet with dietary counseling to promote weight loss.
3128849|NCT03180515|Experimental|Activa PC+S Neurostimulator|All patients will complete motor testing on both continuous DBS and adaptive DBS during a study visit. The UPDRS rater and the patient will be blind to which type of stimulation they are on.
3128850|NCT03180528|Experimental|Treatment (remetinostat)|Patients receive topical remetinostat 1% gel applied TID directly to the lesion, for 6 weeks in the absence of disease progression or unacceptable toxicity.
3128851|NCT03180619|Experimental|Part A (Renal Impairment): Moderate or Severe Renal Impairment|Participants with chronic hepatitis B (CHB) and moderate or severe renal impairment who were virologically suppressed and taking tenofovir disoproxil fumarate (TDF), a TDF-containing anti-hepatitis B virus (HBV) regimen, or other oral antivirals (OAVs), will switch to tenofovir alafenamide (TAF) and receive TAF 25 milligram (mg) tablet once daily orally for 96 weeks.
3179803|NCT00676845|Experimental|3|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
3486494|NCT03744884|No Intervention|CP control group|Regular activity control group, for participants with CP.
3486495|NCT03744884|Experimental|TD intervention group|Force efforts haptic feedback in virtual reality. The intervention will be the same as the CP intervention group but for typically developing participants.
3486496|NCT03744884|No Intervention|TD control group|Regular activity control group, same as CP no intervention group, but for typically developing participants.
3486497|NCT03744871|Active Comparator|Respirator|Open label use of N95 respirators (worn outdoors) (active limb, n=100)
3486498|NCT03744871|No Intervention|No intervention|No respirators will be worn by the control group (control limb, n=100)
3486499|NCT03744858||Group A - Participants with CVD|Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
3486500|NCT03744858||Group B - Healthy Participants|Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
3486501|NCT03744845|No Intervention|Control group|Usual anesthetic care.
3128852|NCT03180619|Experimental|Part A (Renal Impairment): End Stage Renal Disease|Participants with CHB and end stage renal disease who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
3128853|NCT03180619|Experimental|Part B: Hepatic Impairment|Participants with CHB and moderate or severe hepatic impairment who were virologically suppressed and taking TDF, a TDF-containing anti-HBV regimen, or OAVs, will switch to TAF and receive TAF 25 mg tablet once daily orally for 96 weeks.
3128854|NCT03180645|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
3128855|NCT03180645|Other|Test product/ Positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
3128856|NCT03180645|Other|Positive control /No treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
3128857|NCT03180801|Placebo Comparator|Group 1 adjuvanted placebo|0.5ml adjuvanted placebo on Day -43 and on Day -22 followed by influenza challenge on day 0
3128858|NCT03180801|Experimental|Group 2 adjuvanted FLU-v one dose|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and adjuvanted placebo on Day -22 followed by influenza challenge on day 0
3128859|NCT03180801|Experimental|Group 3 adjuvanted FLU-v two doses|0.5ml (500mcg) adjuvanted FLU-v vaccine on Day -43 and on Day -22 followed by influenza challenge on day 0
3128860|NCT03181009|Experimental|Group A (300 mg maintenance dose)|After initial therapy with omalizumab Group A subjects will escalate their food flour allergens to 300 mg in 18 weeks.
3128861|NCT03181009|Active Comparator|Group B (1200 maintenance dose)|After initial therapy with omalizumab Group B subjects will escalate their food flour allergens to 1200 mg in 18 weeks.
3128862|NCT03181308|Experimental|TRC105 plus Nivolumab|
3128863|NCT03181451|Active Comparator|30 mg Ferric Maltol|12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 & Day 10.
3128864|NCT03181451|Active Comparator|16.6 mg Ferric Maltol|12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 & Day 10.
3128865|NCT03181451|Active Comparator|7.8 mg Ferric Maltol|12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 & Day 10.
3128866|NCT03181503|Placebo Comparator|Placebo|Participants received 3 subcutaneous injections of placebo (matched to nemolizumab) every 4 weeks (Q4W) up to Week 8.
3128867|NCT03181503|Experimental|Nemolizumab 0.5 mg/kg|Participants received 3 subcutaneous injections of nemolizumab 0.5 milligram per kilogram (mg/kg) Q4W up to Week 8.
3128868|NCT03181594|Experimental|Treatment with the ClariFix Device|Bilateral ablation of nasal tissue for treatment of chronic rhinitis
3128869|NCT03181724|Active Comparator|Decision Aid|Cohort that will receive a decision aid.
3128870|NCT03181724|No Intervention|No Decision Aid (control)|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
3128871|NCT03181789|Experimental|Group 1 (Treatment): p24CE1/2 pDNA + p55^gag pDNA + IL-12 pDNA|Participants will receive the p24CE1/2 pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Month 1. They will receive the p24CE1/2 pDNA vaccine plus the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Months 3 and 6.
3128872|NCT03181789|Placebo Comparator|Group 1 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
3128873|NCT03181789|Experimental|Group 2 (Treatment): p55^gag pDNA + IL-12 pDNA|Participants will receive the p55^gag pDNA vaccine and the IL-12 pDNA adjuvant at Day 0 and Months 1, 3, and 6.
3128874|NCT03181789|Placebo Comparator|Group 2 (Control): Placebo|Participants will receive placebo at Day 0 and Months 1, 3, and 6.
3128875|NCT03181932|Experimental|Double-blind vancomycin inhalation powder|Vancomycin inhalation powder 30 mg is administered twice daily (BID) during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
3128876|NCT03181932|Placebo Comparator|Double-blind placebo inhalation powder|Matching placebo is administered BID during the 24-week double-blind period (Period 1) by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
3128877|NCT03181932|Experimental|Open-label vancomycin inhalation powder|In the 24-week Period 2, all participants receive AeroVanc 30 mg BID by inhalation during three dosing cycles, each cycle being 28 days of treatment followed by 28 days of observation.
3128878|NCT03181958|Experimental|NHFOV|"neonates assigned to NHFOV will be started with the following boundaries:~a) Paw of 10 cmH2O (can be changed in steps of 1 cmH2O within the range range 5- 16cmH2O); Paw will be titrated (within the range) according to open lung strategy, performing alveolar recruitment, similar to what is done in endotracheal high frequency oscillatory ventilation targeting a FiO2≤25-30%. Maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90%-95%. b) frequency of 10Hz(can be changed in steps of 1Hz within the range 8-12Hz). c)Inspiratory time 50% (1:1).d)amplitude 25 cmH2O(can be changed in steps of 5 cmH2O within the range 25-50 cmH2o; amplitude will be titrated according to PaCO2."
3128879|NCT03181958|Active Comparator|NCPAP|Neonates assigned to the CPAP group were initiated on a pressure of 5 cmH2O. CPAP can be raised in steps of 1 cmH2O up to 8 cmH2O. If this is not enough to maintain SpO2 between 90% and 95%, FiO2 will be added up to 0.40.
3486502|NCT03744845|Experimental|Virtual Reality Intervention Group|Virtual Reality Distraction
3486503|NCT03744832|Experimental|Point of Care Testing|"Point of care testing using the Alere i™ Strep A assay for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. If test is positive, patients will be started on antibiotics prior to discharge from the ED. If test is negative, patients will not be started on antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
3128880|NCT03181958|Experimental|NIPPV|neonates assigned to the NIPPV group will be started with the following parameters: a) positive end-expiratory pressure (PEEP) of 4 cmH2O (can be raised in steps of 1 cmH2O to max 8 cmH2O, according to the oxygenation).b)Peak Inspiratory Pressure (PIP) of 15 cmH2O (can be raised in steps of 1 cmH2O to max 25 cmH2O, according to oxygenation,PaCO2 levels and the chest expansion); maximal allowed FiO2 will be 0.40 and SpO2 targets will be 90-95%. c) inspiratory time (IT) will be 0.45 - 0.5 sec(according to clinicians' evaluation of leaks and the appearance of the pressure curve: a small pressure plateau is required and flow may be set accordingly) and rate will be started at 30 bpm (can be raised in steps of 5 bpm to max 50 bpm, according to PaCO2 levels).
3128881|NCT03182582|Active Comparator|Week 1 - Erbium:Yttrium-Aluminum-Garnet Laser Debridement|"During the first treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized. During the second treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
3128882|NCT03182582|Active Comparator|Week 1 - Scalpel/Curette Debridement|"During the first treatment, sharp debridement will be performed via a scalpel/curette until punctate bleeding is visualized. During the second treatment, laser debridement will be performed at 200-um until punctate bleeding is visualized.~Tissue biopsies will then be obtained from the wounds prior to the first treatment, immediately after the first treatment, immediately prior to the subsequent treatment, and immediately after the second treatment. These will then be sent to Pathogenius for molecular analysis of wound microflora using polymerase chain reaction and sequencing.~Pain will be assessed during debridement by recording the Numerical Rating Scale for pain assessment."
3128883|NCT03182725|Placebo Comparator|Placebo|Patient will consume one placebo pill twice a day for one month.
3128884|NCT03182725|Experimental|Ivabradine|Patient will consume one dose of Ivabradine twice a day for one month.
3128885|NCT03182738|Experimental|Intervention|VIP app that delivers HIV-related symptom strategies
3128886|NCT03182738|Sham Comparator|Control|VIP app without HIV-related symptom strategies
3128887|NCT03182829||Factor Xa inhibitor|"Patients on treatment with Apixaban, Edoxaban or Rivaroxaban are included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Factor Xa inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
3128888|NCT03182829||Thrombin inhibitor|"Patients on treatment with Dabigatran are included included into the evaluation study at the outpatient care unit. Patients receive treatment for a specific clinical indication such as non-valvular atrial fibrillation or venous thromboembolism since one week or longer. During the study visit DOAC Dipstick test and liquid-chromatography mass-specrotmery are performed to identify absence or presence of Thrombin inhibitor in urine.~publication Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]"
3128889|NCT03182868|Experimental|Repeatability Group|Healthy participants perform goggle testing on two consecutive days to determine if the testing results are repeatable. Testing will be between 10 am and 2 pm and testing on the two sessions will be within 30 minutes of the same time. Sessions can be on two consecutive days or separated by up to 4 days.
3128890|NCT03182868|Experimental|Time of Day Group|Healthy participants perform goggle testing at two different times of day to determine if time of day affects goggle testing performance. One quarter of the participants in this arm will undergo one test at 8 am on the first session and 10 am on the second session. A second quarter will undergo the tests at 10 am on first session and 8 am on the second session. A third quarter will undergo one test at 3 pm on the first session and 10 am on the second session. The fourth quarter will undergo the tests at 10 am on first session and 3 pm on the second session. In all these cases the sessions can be on consecutive days or separated by up to 4 days.
3128891|NCT03182868|Experimental|Learning Affect Group|Healthy participants perform goggle testing back to back on the same day to determine if performance on second test changes from first test suggesting a learning affect.
3128892|NCT03182868|Experimental|MSQ Group|Healthy participants perform goggle testing and upon completion of each goggle testing session will complete a Motion Sickness Questionnaire (MSQ) to determine if they show any signs of motion sickness.
3128893|NCT03182868|Experimental|OKN Only Group|OKN Only Group is for exploratory aims only. Healthy participants will undergo goggle testing limited to Optokinetic Nystagmus (OKN) recordings at two stimulus speeds (20 and 60 deg/s) in both the counterclockwise and clockwise directions.
3128894|NCT03182920|Experimental|200 mg Lasmiditan (Group 1 Elderly)|200 milligrams (mg) lasmiditan on Day 1 of 1 of 2 dosing periods.
3128895|NCT03182920|Placebo Comparator|Placebo (Group 1 Elderly)|Placebo on Day 1 of 1 of 2 dosing periods.
3128896|NCT03182920|Experimental|200 mg Lasmiditan (Group 2 Young)|200 mg lasmiditan on Day 1.
3128897|NCT03182933|Experimental|Liposomal bupivacaine group|20ml 1.33% liposomal bupivacaine administered in adductor canal (a type of peripheral nerve block)
3128898|NCT03182933|Active Comparator|Standard bupivacaine group|20ml 0.5% standard bupivacaine in adductor canal (a type of peripheral nerve block)
3128899|NCT03183063|Experimental|4DCT and SPECT/CT|Anticipated 15 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. Both 4DCT scans will be obtained with normal breathing. Data will be analyzed for objectives 1, 4 and 5.
3486504|NCT03744832|Active Comparator|Standard Care|"Conventional testing using a standard bacterial throat culture for patients randomized to this study arm when presenting with suspected streptococcal pharyngitis and having their throat swabbed. Patients will be discharged with a post-dated prescription and will be contacted in approximately 3 days if their culture results are positive to fill/take the antibiotics.~At home, the patient family will be asked to complete an online survey and/or keep a written diary daily detailing their clinical course following discharge from the ED."
3486505|NCT03744806||treated with intravitreal bevacizumab.|
3486506|NCT03744806||control group|
3486507|NCT03744767|Experimental|Single treatment arm|
3179804|NCT00676845|Experimental|4|Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.
3486508|NCT03744754||Women with endometriosis|Women with endometriosis disease aged 18-36 years, with appropriate endometriosis diagnosis, based on transvaginal sonography, magnetic resonance imaging and/or previous surgery.Ovarian reserve was assessed by antral follicle counting (AFC) and measurement of serum anti-Mullerian hormone (AMH) levels Enrolled after preservation fertility procedure (vitrification of mature oocytes)
3179805|NCT00676871|Experimental|1|MEDI-538
3486509|NCT03744715|Experimental|Poziotinib|Poziotinib
3486510|NCT03744702|Experimental|Treatment|All patients will receive ascorbic acid as this is a pilot study.
3486511|NCT03744689|Active Comparator|Erector Spinae Plane Block|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine hydrochloride (20ml) will be used for blocks"
3486512|NCT03744689|Sham Comparator|Control Group|Sham block will be done with serum physiologic.
3486513|NCT03744676|Experimental|Lisocabtagene maraleucel|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.
3486514|NCT03744663|Active Comparator|Suboxone® SL|Patients assigned to this group will continue with their already established dose of Suboxone ® SL films for 24 weeks along with weekly therapy.
3486515|NCT03744663|Experimental|Sublocade®|Patients assigned to the Sublocade® group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy.
3486516|NCT03744650|Experimental|"Care4Heart programme"|The single group pretest and repeated posttest longitudinal study design is adopted in the main study. All the recruited participants received the study intervention
3486517|NCT03744637|Experimental|Panel A (Parts 1 and 2)|Participants will receive a single inhaled dose of MK-5475 120 µg or a matching placebo in Period 1, MK-5475 165 µg or a matching placebo in Period 2 and MK-5475 240 µg or a matching placebo in Period 3. Each dose will be separated by at least a 7-day washout. In Part 2, participants will receive a single inhaled dose of MK-5475 240 µg and undergo an right heart catheterization (RHC) and will receive a single inhaled dose of MK-5475 240 µg and undergo an functional respiratory imaging (FRI).
3486518|NCT03744637|Experimental|Panel B (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants receive a single inhaled dose of MK-5475 360 µg and have an RHC.
3486519|NCT03744637|Experimental|Panel C (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 300 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 360 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 360 µg and have an RHC.
3486520|NCT03744637|Experimental|Panel D (Part 2)|In Period 1, participants will receive a single inhaled dose of MK-5475 480 µg. In Period 2, participants will receive a single inhaled dose of MK-5475 120 µg and have an FRI. In Period 3, participants will receive a single inhaled dose of MK-5475 120 µg and have an RHC.
3486521|NCT03744624|Experimental|With 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing both 3D printed model and computed tomography (or/and magnetic resonance imaging)
3486522|NCT03744624|Active Comparator|Without 3D Model|Patients in this arm will undergo laparoscopic liver resection with prior planning utilizing only standard medical imaging computed tomography (or/and magnetic resonance imaging) without development of 3D printed model
3486523|NCT03744611|Experimental|CE|CE capsule administered orally twice daily for 12 weeks.
3486524|NCT03744611|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for 12 weeks.
3486525|NCT03744559|Experimental|R-E (Retrieval Extinction) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a lab-based smoking-related cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the R-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
3486526|NCT03744559|Experimental|R-E (Retrieval Extinction) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' smoking-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of smoking-related cues (e.g., pictures). Participants will also receive a smoking-related cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
3179806|NCT00676871|Experimental|2|MEDI-538
3179807|NCT00676871|Experimental|3|MEDI-538
3128900|NCT03183063|Experimental|4DCT with BiPAP and SPECT/CT|Anticipated 5 patients with segmental or lobar pulmonary emboli on CTA. Each will receive SPECT/CT and 4DCT imaging on the same day. The second of the two 4DCT scans will be obtained with positive airway breathing via BiPAP. Results in these patients will be analyzed for objective 6 only.
3128901|NCT03183063|Experimental|4DCT with CTA in suspected PE|Anticipated 124 participants with CTA ordered/performed for suspected PE will be enrolled to have 4DCT. Goal for analysis is 62 with positive CTA results for PE and 62 with negative CTA results for PE. Data will be analyzed for objectives 2 and 3.
3128902|NCT03183518|Experimental|Test Product|All the participants will have the test product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
3486527|NCT03744559|Other|NR-E (No R-E) with no fMRI|49 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a lab-based non-smoking or neutral cue-reactivity experience during the baseline assessment and 24-hour follow-up test that is equivalent to the task that the NR-E with fMRI arm receives in the fMRI scanner. This arm participates in the no functional magnetic resonance imaging (fMRI) intervention.
3486528|NCT03744559|Other|NR-E (No R-E) with fMRI|34 anticipated participants will undergo 3 sessions on consecutive days of the control Retrieval Extinction Training (RET) intervention consisting of a 5-minute 'retrieval' non-smoking or neutral-content video followed 10 minutes later by 1 hour of 'extinction' training consisting of four sequences of non-smoking or neutral cues (e.g., pictures). Participants will also receive a non-smoking or neutral cue-reactivity experience in an fMRI scanner during the baseline assessment and 24-hour follow-up test. This arm participates in the functional magnetic resonance imaging (fMRI) intervention.
3486529|NCT03744533|Experimental|head-down position treatment|
3486530|NCT03744533|Active Comparator|guideline-based treatment|
3486531|NCT03744520|Experimental|ESP block group|The patients who had paravertebral interfacial plane block for postoperative analgesia
3128903|NCT03183518|Other|Reference product|All the participants will have the reference product applied to the appropriate test sites by trained study staff. The test site will be designated on above the waist between the left scapula and the spinal mid-line.
3128904|NCT03183869|Active Comparator|Early Intervention|Fecal microbiota via enema at Month 1, 2, 3. 4, 5 and month 6 along with stool, urine and blood collection. At months 7, 8, 9, 10, 11 and 12 only stool, urine and blood collection.
3486532|NCT03744455||End of training|Anesthesia residents at the end of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
3486533|NCT03744455||Begin of training|Anesthesia residents at the begin of their training who will realize axillary plexus. The satisfaction of the patient will be registered.
3486534|NCT03744442|Active Comparator|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
3486535|NCT03744442|Active Comparator|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
3486536|NCT03744442|Active Comparator|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
3486537|NCT03744429|Experimental|Mediterranean Meal Plan|This is a single arm study in which participants will receive meals that follow a Mediterranean diet plan for 4 weeks. Breast milk samples will be collected before, during, and after the intervention period.
3486538|NCT03744416|Experimental|Intervention group|Counseling based on Epstein's active decision making on birth plan
3179808|NCT00676871|Experimental|4|MEDI-538
3486539|NCT03744416|No Intervention|Control group|The standard midwife's advice on birth plan during prenatal care.
3486540|NCT03744403|Experimental|CS1001 monoclonal antibody|
3179809|NCT00676871|Experimental|5|MEDI-538
3179810|NCT00676871|Experimental|6|MEDI-538
3179811|NCT00676871|Experimental|7|MEDI-538
3486541|NCT03744390|Experimental|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 - 100 mg.
3486542|NCT03744364|Active Comparator|Misoprostol|Group of women allocated to misoprostol induction.
3486543|NCT03744364|Active Comparator|Dinoprostone|Group of women allocated to dinoprostone induction.
3486544|NCT03744351|Other|Healthy volunteer|"45 subjects~A single visit"
3486545|NCT03744351|Other|Clinically Isolated Syndrome|• 35 subjects
3486546|NCT03744351|Other|Non-MS patients with neurological inflammatory disease|• 30 subjects
3486547|NCT03744351|Other|MS patients (remitting or progressive untreated)|"30 untreated remittent patients~30 progressive untreated patients"
3486548|NCT03744338||Group 1|
3486549|NCT03744325|Active Comparator|Hen's egg OIT|Daily intake of gradually increasing doses of egg white protein under a 32 weeks period, continued by regular, daily intake of 1000 mg egg white protein.
3486550|NCT03744325|No Intervention|Hen's egg avoidance|Hen's egg is avoidance diet is continued.
3486551|NCT03744312|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
3486552|NCT03744312|Active Comparator|No cognitive impairment|Healthy Controls
3486553|NCT03744299|Other|Intervention|Patients and caregivers are asked to complete a questionnaire
3179812|NCT00676884|Experimental|1|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
3179813|NCT00676884|Placebo Comparator|2|placebo control
3179814|NCT00676936|Experimental|Methylprednisolone|Methylprednisolone 16 mg twice daily
3486554|NCT03744247|Experimental|Lenvatinib Plus PD-1|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received 3mg/kg PD-1 antibody intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3486555|NCT03744247|Active Comparator|Lenvatinib alone|Participants received lenvatinib capsules 12 milligram (mg) based on the participant's body weight greater than or equal to (>=) 60 kilogram (kg) or 8 mg based on the participant's body weight less than (<) 60 kg at baseline, orally, once daily (QD) in continuous 14-day treatment cycles, and received placebo intravenously every 2 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
3486556|NCT03744234|Experimental|Platelet-Rich Plasma Injection|Autologous injection of platelet-rich plasma (PRP) in the sacroiliac joint
3486557|NCT03744234|Active Comparator|Steroid Injection|Steroid injection in the sacroiliac joint
3486558|NCT03744221|Experimental|Corn protein|Corn protein powder
3486559|NCT03744221|Experimental|Bovine plasma protein|Bovine plasma protein powder
3486560|NCT03744221|Active Comparator|control benchmark protein Whey|Whey protein powder
3486561|NCT03744208|Experimental|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3486562|NCT03744195|Experimental|Group I Experimental Kinesotaping|Application of kinesotaping along with conventional treatment
3179815|NCT00676936|Placebo Comparator|Placebo|Placebo capsules twice daily
3179816|NCT00676949|Experimental|1|cyclophosphamide dose escalation, level 1:150mg/m2,level 2: 300mg/m2, level 3: 300mg/m2x2, with 5 kinds o tumor specific antigen peptides followed by low dose IL-2, 6 patients will be enrolled for each level.
3179817|NCT00676962|Experimental|Facilitation|Therapists receive assistance with adopting CBT
3179818|NCT00676975|Active Comparator|Traditional Chinese Medicine|Traditional Chinese Medicine 17g herbal extract
3179819|NCT00676975|Placebo Comparator|Traditional Chinese Medicine Placebo|Placebo
3179820|NCT00676988||Observation|Subjects with Luminal Crohn's Disease receiving infliximab
3179821|NCT00677027|Experimental|1|
3179822|NCT00677027|Placebo Comparator|2|
3179823|NCT00677053|Experimental|TAK-442 10 mg BID|Added with standard care for recurrent ischemic events.
3179824|NCT00677053|Experimental|TAK-442 20 mg BID|Added with standard care for recurrent ischemic events
3179825|NCT00677053|Experimental|TAK-442 40 mg QD|Added with standard care for recurrent ischemic events
3179826|NCT00677053|Experimental|TAK-442 40 mg BID|Added with standard care for recurrent ischemic events
3179827|NCT00677053|Experimental|TAK-442 80 mg QD|Added with standard care for recurrent ischemic events
3179828|NCT00677053|Experimental|TAK-442 80 mg BID|Added with standard care for recurrent ischemic events
3179829|NCT00677053|Experimental|TAK-442 160 mg QD|Added with standard care for recurrent ischemic events
3179830|NCT00677053|Experimental|TAK-442 120 mg BID|Added with standard care for recurrent ischemic events
3179831|NCT00677053|Placebo Comparator|Placebo|Added with standard care for recurrent ischemic events
3486563|NCT03744195|Active Comparator|Group II conventional training group|Application of conventional treatment
3486564|NCT03744182|Experimental|HM15211|
3486565|NCT03744182|Placebo Comparator|Placebo|
3486566|NCT03744169||Children with acute respiratory failure|Point-of-care lung ultrasound on admission to the PICU to determine the cause of respiratory failure.
3486567|NCT03744143|Other|Group A (vaginal technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through vaginal technique
3486568|NCT03744143|Other|Group B (laparoscopic technique)|Patients undergoing surgical removal of vaginal endometriotic nodule through laparoscopic technique. Closure of the vagina with a transverse suture or a longitudinal suture.
3128905|NCT03183869|Active Comparator|Late Intervention|At months 1, 2, 3, 4, 5 and 6, stool, urine and blood collection. Fecal microbiota via enema at month 6, 7, 8, 9, 10, 11and 12 months along with stool, urine and blood collection.
3128906|NCT03183908|Active Comparator|Adjuvanted influenza vaccine (FLUAD®)|In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
3486569|NCT03744130|Experimental|patients with UC|"Patients with endoscopically proven UC with various extents of disease activity.~Diagnostic Test: Contrast-enhanced Ultrasound"
3179832|NCT00677066|Experimental|1|Children discharged home with oxygen
3179833|NCT00677066|No Intervention|2|Children remain in hospital for oxygen therapy
3179834|NCT00677079|Experimental|Iniparib|Iniparib, twice weekly on Days 1 and 4 of each week during 8-week cycles
3179835|NCT00677118|Experimental|Concurrent and adjuvant|Concurrent chemoradiotherapy plus adjuvant chemotherapy
3179836|NCT00677118|Active Comparator|Concurrent|Concurrent chemoradiotherapy
3179837|NCT00677131|Active Comparator|1|To read the package insert of the drug
3179838|NCT00677131|Active Comparator|2|To read the education information provided by the Pharmacy of NTUH
3179839|NCT00677131|Active Comparator|3|Oral education provided by the pharmacist
3486570|NCT03744130|Experimental|patients with CD|Patients with proven CD with various extents of disease activity Diagnostic Test: Contrast-enhanced Ultrasound
3486571|NCT03744117|Experimental|Intervention Arm|There is a single arm in this study. All patients will be assigned to receive the intervention, which is a palliative care consultation delivered by telemedicine.
3486572|NCT03744104|Experimental|Quadrivalent influenza vaccine|Quadrivalent influenza vaccine(containing 2 subtypes of B lineage)
3486573|NCT03744104|Active Comparator|Trivalent influenza vaccine A|Trivalent influenza vaccine (containing B/Victoria lineage)
3486574|NCT03744104|Active Comparator|Trivalent influenza vaccine B|Trivalent influenza vaccine (containing B/Yamagata lineage)
3486575|NCT03744091|Active Comparator|10 mg P1|10 mg of P1 will be administered and compared with an active dose of 20 mg P1 on crossover
3486576|NCT03744091|Active Comparator|20 mg P1|20 mg of P1 will be administered and compared with an active dose of 10 mg P1 on crossover
3486577|NCT03744078|Active Comparator|PGE2 with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
3486578|NCT03744078|No Intervention|PGE2 vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
3486579|NCT03744065|Active Comparator|Lumbar plexus block|Patients randomized to receive an ultrasound-guided lumbar plexus block
3486580|NCT03744065|Experimental|Suprainguinal fascia iliaca block|Patients randomized to receive an ultrasound-guided suprainguinal fascia iliaca block
3486581|NCT03744052|Experimental|Adult Participants|Messages regarding physical activity will be texted to participants.
3486582|NCT03744013|Active Comparator|Perforated|Fortiva® 1mm perforated ADM
3486583|NCT03744013|Active Comparator|Non-perforated|Fortiva® 1mm non-perforated ADM
3486584|NCT03744000|Placebo Comparator|Immediate stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate stenting group.
3486585|NCT03744000|Active Comparator|Deferred stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred for 3-7 days in the deferred stenting group.
3486586|NCT03743987|Sham Comparator|control group|Apical resection group. Only root resection was applied without any other interventions (like prf or mta)
3486587|NCT03743987|Experimental|MTA group|Root resection was applied and MTA was inserted through the apical foramen
3486588|NCT03743987|Experimental|PRF group|Root resection was applied and PRF was placed to the surgically prepared area
3486589|NCT03743987|Experimental|MTA + PRF group|Root resection was applied. MTA was inserted through the apical foramen and PRF was placed to the surgically prepared area
3486590|NCT03743974|Active Comparator|Interscalene block|Site of injection for ISB was the C6 plexus nerve root with a posterior in-plane approach, with neurostimulation control, and ultrasound-controlled of extra-plexus injection of the mixture posterior to the C6 root
3486591|NCT03743974|Experimental|Supraclavicular block|"Site of injection for SCB was superficial and lateral to the trunks of the brachial plexus, and not directly deep inside the corner pocket zone, with neurostimulation control and visualization of the lung"
3486592|NCT03743961||Group A : control group|"Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients with 14 Questions) and QoL EORTC Q30 (Quality Qf Life with 30 Questions)~for patients with G8 score > 14/17"
3486593|NCT03743961||Group B : geriatric intervention group|Evaluation of quality of life with the EORTC QoL ELD 14 (Quality Qf Life ELDerly patients) and QoL (Quality Qf Life) EORTC Q30 for patients with G8 score ≤14/17 ( in this arm there is two groups : patient who received geriatric intervention before treatment initiation (group A) and group of patient did not received geriatric intervention before treatment initiation( group B))
3486594|NCT03743948|Experimental|Expectant couple at risk of transmitting a monogenic disease.|Expectant couple (pregnant woman from 9 weeks of gestation and spouse) at risk of transmitting a monogenic disease among the genes included in the trusight one expanded sequencing kit (Illumina).
3486595|NCT03743922|Experimental|Oral calciferol group|Subjects will receive oral calciferol 20,000 iu per week during pregnancy until delivered
3486596|NCT03743922|Placebo Comparator|oral placebo group|Subjects will receive oral placebo 1 tab per week during pregnancy until delivered
3486597|NCT03743896|No Intervention|Control group|No intervention
3486598|NCT03743896|Experimental|Test group|single dose (2g), topical application of Transdermal Glucosamine Cream (containing 10% w/w of glucosamine sulfate)
3486599|NCT03743883||Low-dose ASA cohort|A person is identified as newly exposed to low-dose ASA, he/she will become member of new user low-dose ASA cohort and that date will be the start date for outcome follow-up.
3486600|NCT03743883||Comparison unexposed cohort|When a member of new user low-dose ASA cohort is confirmed, one comparison member will be confirmed also from the source population not yet censored on that day (start date) and with the same distribution of matching factors (age, sex, time interval since entry date and number of PCP visits in the year prior to start date) of its low-dose ASA pair with the only difference of being free of ASA on start date.
3486601|NCT03743870||levobupivacaine cohort|125 pregnant patients that will have to undergo spinal anesthesia with Levobupivacaine for elective caesarean section.
3486602|NCT03743870||bupivacaine cohort|Historical control group made of 125 patients underwent spinal anesthesia with Bupivacaine for elective cesarean section during the period between April 2017 and April 2018.
3486603|NCT03743857|Experimental|Manual Therapy|6 sessions of ankle manual therapy
3179840|NCT00677144|Experimental|OS (oxalipaltin+S-1)|OS (oxaliplatin + S-1): Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
3179841|NCT00677144|Active Comparator|XELOX (oxalipaltin+capecitabine)|XELOX (oxalipaltin+capecitabine): Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
3179842|NCT00677157||screening|participants evaluated for possible inclusion in a natural history or intervention protocol
3486604|NCT03743857|No Intervention|Control|No intervention
3486605|NCT03743844|Experimental|Compassion-focused psychoeducation group|Receiving 2-hours of group-based in-person psychoeducational sessions weekly for 6-weeks.
3486606|NCT03743844|No Intervention|Control group|Weight management treatment as usual
3486607|NCT03743831|Other|orotracheal intubation direct|
3486608|NCT03743831|Other|orotracheal intubation indirect|
3486609|NCT03743818|Experimental|dry needling|dry needling in trigger point in vastus medialis of quadriceps
3179843|NCT00677170|Experimental|1|MLN4924
3179844|NCT00677183||SN###.#1|All children in this cohort will have biopsy-proven NASH.
3179845|NCT00677183||SN###.#2|This cohort will be parents (mother and father when possible) of child subjects with biopsy-proven NASH.
3179846|NCT00677196|Active Comparator|1|The LMA StoneBreakerTM
3486610|NCT03743818|Active Comparator|standardized treatment protocol|in the standardized treatment protocol the investigators including ultrasound, tens, and isometric quadriceps contractions
3486611|NCT03743818|Active Comparator|hialuronic acid|infiltration of hyaluronic acid in the affected knee
3486612|NCT03743805|Experimental|Reversal drugs|Flumazenil and naloxone
3486613|NCT03743792|Experimental|Active|Freeze-dried red raspberry powder (25 g) in active breakfast meal
3486614|NCT03743792|Placebo Comparator|Placebo|Placebo breakfast
3486615|NCT03743779||Intervention|Participants enrolled in Mastering Diabetes.
3486616|NCT03743766|Experimental|Relatlimab|"Cycle 1: Relatlimab (BMS-986016) is supplied as a sterile 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV for the first 4 weeks (cycle 1).~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
3486617|NCT03743766|Experimental|Nivolumab|"Cycle 1: Nivolumab (BMS-936558) is supplied as a sterile 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV for the first 4 weeks.~Cycle 2+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV once every 4 weeks."
3486618|NCT03743766|Experimental|Relatlimab + Nivolumab|Cycle 1+: Combination therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV for the first 4 weeks (Cycle 1), then once every 4 weeks afterwards.
3486619|NCT03743740|Experimental|Group 1|"first, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.~then, exercises will be suspended for 4 weeks. then, patients will undergo home based program 3 days per week for 6 weeks."
3486620|NCT03743740|Experimental|Group 2|first, patients will undergo home based program 3 days per week for 6 weeks. then, exercises will be suspended for 4 weeks. then, patients will undergo spinal stabilization exercise and home based program 3 days per week for 6 weeks.
3486621|NCT03743727|Experimental|Combined Therapy LDV and SOF|
3486622|NCT03743714|Experimental|males|healthy, sedentary males
3486623|NCT03743714|Experimental|females|healthy, sedentary females
3486624|NCT03743701|Active Comparator|Transrectal ultrasound in В-mode|
3486625|NCT03743701|Experimental|Transrectal ultrasound examination using three-di|
3486626|NCT03743688||Influenza Vaccine Recipients (ccIIV-4)|All participants will receive one dose of FDA-approved inactivated influenza vaccine (Flucelvax Quadrivalent) via intramuscular injection (0.5 mL) as part of their standard of care.
3486627|NCT03743675|Experimental|Diet-Induced Weight Loss|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period.
3486628|NCT03743675|Experimental|Exercise Training|Subjects in this arm will undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
3486629|NCT03743675|Experimental|Diet Plus Exercise|Subjects in this arm will undergo 6-months of dietary counseling targeting 5-10% weight loss by the end of the intervention period. They will simultaneously undergo 6-months of supervised aerobic exercise training (3 days per week, moderate-to-vigorous intensity).
3486630|NCT03743675|No Intervention|Control|Subjects in this group will be asked to maintain their habitual physical activity, and will received counseling regarding a healthy, weight-maintenance diet.
3486631|NCT03743649|Experimental|Group I (haloperidol, placebo)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
3486632|NCT03743649|Experimental|Group II (lorazepam, placebo)|Patients receive lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed and placebo IV every 4 hours and then every hour as needed until discharge from palliative care unit.
3486633|NCT03743649|Experimental|Group III (haloperidol, lorazepam)|Patients receive haloperidol IV over 3-15 minutes every 4 hours and then every hour as needed and lorazepam IV over 3-15 minutes every 4 hours and then every hour as needed until discharge from palliative care unit.
3486634|NCT03743649|Experimental|Group IV (placebo, lorazepam)|Patients receive two different placebos IV every 4 hours. Patients then receive placebo IV and lorazepam IV over 3-15 minutes every hour as needed until discharge from palliative care unit.
3486635|NCT03743636|Active Comparator|Nicotinamide riboside + resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 1,000 mg of NR and 125 mg of reservatrol daily for six months.
3486636|NCT03743636|Active Comparator|Nicotinamide riboside + placebo|Participants randomized to the NR + placebo arm of the study will receive 1,000 mg of NR and a placebo daily for six months.
3486637|NCT03743636|Placebo Comparator|Placebo + placebo|Participants randomized to the placebo + placebo arm of study will receive placebo pills.
3486638|NCT03743623|Experimental|Treatment Group|Study treatment with Neurocytotron, which is a device is designed to generate a controlled beam of electromagnetic waves of certain frequencies in the presence of a magnetic field with pre-determined strength.
3486639|NCT03743623|Placebo Comparator|Placebo Group|The placebo control is a mock treatment in which a subject will go through the same procedures as subjects assigned to the treatment group, only without being actually exposed to electromagnetic waves and magnetic fields.
3486640|NCT03743610|Experimental|Effect of heart rate training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining >65% max heart rate during room air based maximal peak work.
3486641|NCT03743610|Experimental|Effect of saturation of oxygen training in simulated altitude|Participants will exercise in simulated altitude start at a minimum of 2,000ft and will increase to no greater than 16,400ft with each visit. The increase will be in accordance to maintaining 40-60% of max work rate during room air work rate and based upon saturation of oxygen of between 70-80%.
3486642|NCT03743610|Active Comparator|Effect of optimized training in simulated altitude|Participants will perform the more beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether it improves elite athlete's training status at altitude.
3486643|NCT03743610|Placebo Comparator|Effect of placebo training in non-simulated altitude|Participants will perform placebo beneficial intervention (heart rate or saturation of oxygen training) to evaluate whether the optimized protocol truely improves elite athlete's training status at altitude.
3486644|NCT03743597|Experimental|SOCKNLEG|"Group of participant who will conduct the examinations first with the SOCKNLEG compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
3486645|NCT03743597|Active Comparator|Sigvaris COTTON|"Group of participant who will conduct the examinations first with the Sigvaris COTTON compression stockings.~All examinations will be conducted in all participants and with both stockings one after the other."
3128907|NCT03183908|Active Comparator|High-dose influenza vaccine (Fluzone® HD)|In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
3128908|NCT03184077|Active Comparator|Polyglactin 910|
3179847|NCT00677196|Active Comparator|2|Pneumatic Lithotripsy
3128909|NCT03184077|Active Comparator|poliglecaprone 25|
3128910|NCT03184428||Implantation of IOL L313|Patients who have undergone a cataract surgery with implantation of the monofocal MICS IOL L313 more than 3 Years ago will be asked about the Treatment for Postoperative observation and survey.
3128911|NCT03184441|Experimental|Premie Pouch|All participants will receive the experimental treatment with the Premie Pouch device.
3179848|NCT00677209|Active Comparator|A|house dust mite allergics will undergo autovaccine immunization
3486646|NCT03743584|Experimental|Targeted temperature management at 33°C|Cooling and temperature control at 33°C, according to the study protocol of the TTM2-trial
3486647|NCT03743584|Active Comparator|Standard care, early treatment of fever|Standard of care and normothermia. If temperature 37,8 °C or above use of device for temperature control.
3486648|NCT03743571|Active Comparator|anodal tDCS during exposure|anodal transcranial direct current stimulation (2mA) will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
3486649|NCT03743571|Sham Comparator|sham tDCS during exposure|sham transcranial direct current stimulation will be applied over EEG coordinate FpZ during exposure therapy at a level that provides the physical sensations of tDCS but which is non-therapeutic
3486650|NCT03743558|Experimental|children with adenoamygdala hypertrophy|
3486651|NCT03743545|Active Comparator|conventional drilling with irrigation|
3486652|NCT03743545|Experimental|low speed without irrigation|
3486653|NCT03743519|Placebo Comparator|Placebo|
3486654|NCT03743519|Experimental|Cherry juice|
3128912|NCT03184519|Experimental|All patients|Patients will undergo 3 blood samples after IVF-ET (pregnancy test) to determine pregnancy.
3132752|NCT03449030|Experimental|Part C Imaging Substudy: 89Zr-TAK-164 and TAK-164|89Zr-TAK-164, intravenous infusion, followed by unlabeled TAK-164, intravenous infusion in combination with 89Zr-TAK-164, intravenous infusion, and further followed by unlabeled TAK-164, intravenous infusion, until PD, unacceptable toxicity or discontinuation by participant. TAK-164 recommended imaging dose (RID) or RP2D dose to be decided based on safety, PK, PD and antitumor response data observed in Part A escalation stage.
3486655|NCT03743506|Experimental|Volunteers without motor abnormalities.|The test was performed in a single, 30-minute session. The test is divided into two phases, with feedback and no feedback from the system. The order of phases was randomized. In each phase the volunteer will remain balanced on the wobble board for 15 seconds under the conditions of the phase. This test is repeated 3 times with a 30 seconds rest between them, then the next phase is performed. With feedback the volunteer can observe the system responses. Without feedback the volunteer can not observe the response of the system.
3486656|NCT03743480|No Intervention|standard care|Patients in this arm will receive standard hematological care and palliative care on demand
3486657|NCT03743480|Experimental|early palliative care|early palliative care: patients in this arm will receive integrated palliative care
3486658|NCT03743467||Control group|Health subjects
3486659|NCT03743467||PD patients Hoehn Yahr 1|Patients with Hoehn Yahr stage 1
3486660|NCT03743467||PD patients Hoehn Yahr 2-3|Patients with Hoehn Yahr stage 2 and 3
3486661|NCT03743454||Men|
3486662|NCT03743454||Women|
3486663|NCT03743441|Active Comparator|Exercise + Cryotherapy + LLLT|
3486664|NCT03743441|Sham Comparator|Exercise + Cryotherapy + Sham LLLT|
3486665|NCT03743428|Experimental|Apatinib-FOLFIRI|Apatinib Mesylate Tablets 250mg po qd Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
3486666|NCT03743428|Active Comparator|Bevacizumab-FOLFIRI|Bevacizumab Injection 5mg/kg IV,day 1 Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks.
3486667|NCT03743415|Experimental|Handbook|The Symptom Management and Survivorship Handbook is a self-care management handbook with each symptom chapter presented in an identical format: what the symptom is, how people describe the symptom, the causes of the symptom, strategies for managing the symptom and resources. The Handbook is available in English and Spanish. Each weekly call will begin with the symptom assessment. For each symptom rated at 4 or higher on a 0-10 scale of severity, the survivors will be referred for symptom self-management. During weeks 2-12, Handbook use since the last call (intervention enactment) and symptoms will be assessed. During weekly calls to caregivers, the caregivers will be notified of symptoms above threshold experienced by survivors and directed to the Handbook. During weeks 2-12, Handbook use and symptoms are assessed, a summary of survivors' symptoms provided. Calls will last about 10 minutes.
3486668|NCT03743415|Experimental|TIP-C plus Handbook|Each survivor and caregiver will receive one 40-minute telephone call per week for 12 weeks. The Telephone Interpersonal Counseling (TIP-C) intervention 8-week protocol is the same for both survivor and caregiver. During weekly contacts, the counselors target social support behaviors using interpersonal communications techniques. Counselors can personalize the counseling intervention for the specific needs or interests as expressed during sessions while still adhering to a structured protocol. The final 4 weeks will be Handbook only.
3486669|NCT03743389|Experimental|12G pigtail catheter|
3486670|NCT03743389|Active Comparator|16F chest tube|
3486671|NCT03743376|No Intervention|Standard ART|Subjects will receive standard ART for 48 weeks
3486672|NCT03743376|Experimental|UB-421(25mg/kg) Q2W add-on treatment|UB-421(25 mg/kg) Q2W plus standard ART for 48 weeks
3486673|NCT03743376|Experimental|UB-421(25mg/kg) Q4W add-on treatment|UB-421(25 mg/kg) Q4W plus standard ART for 48 weeks
3486674|NCT03743363|Experimental|Exergame 3/week|The group does active training for 8 weeks after not training.
3486675|NCT03743363|Experimental|Exergame 2/week|The group does active training for 8 weeks after not training.
3486676|NCT03743363|Experimental|Healthy control / Exergame 1/week|In the first 8 week-long only control group, The group will do 1 training/week for the next 8 weeks.
3486677|NCT03743324||BR group|Breast reconstruction without radiation therapy
3486678|NCT03743324||Immediate BR +post-op radiation|Immediate breast reconstruction followed by surgical site radiation therapy
3486679|NCT03743324||Radiation +delayed BR|previous post-mastectomy radiation followed by delayed breast reconstruction
3486680|NCT03743298|Experimental|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
3486681|NCT03743285|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
3486682|NCT03743272||Liver condition|Participants who have a history of of liver disease
3128913|NCT03184558|Experimental|Bemcentinib (BGB324) + pembrolizumab|Participants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
3128914|NCT03184701|Experimental|Experimental|Patients assigned to this arm receive the intervention in addition to routine standard of care. Telehealth based remote monitoring of symptoms and brain tests is the intervention in this study. A device with preloaded questionaires will be given to patients randomized to this group. The patients will respond on a daily basis for the 3 months of intervention phase.
3486683|NCT03743272||Healthy volunteers|Participants who have do not have a diagnosed liver condition and are in general good health
3486684|NCT03743259|Experimental|LuminoMark inj. 0.1mL|Injection LuminoMark inj. 0.1mL once in this study.
3486685|NCT03743259|Experimental|LuminoMark inj. 0.2mL|Injection LuminoMark inj. 0.2mL once in this study.
3486686|NCT03743259|Active Comparator|Charcotrace Inj.|Charcotrace Inj. about 0.3~1mL
3486687|NCT03743246|Experimental|Administration of JCAR017|Subjects will receive Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently, followed by JCAR017 cells infusion. Phase 1 will evaluate up to 5 JCAR017 cells dose levels and dose escalation/de-escalation will follow a modified toxicity probability interval (mTPI-2) algorithm. The declared RP2D in Phase 1 will be applied to the subjects enrolled in Phase 2
3486688|NCT03743233|Active Comparator|Hand file instrumentation|
3486689|NCT03743233|Active Comparator|Reciprocating instrumentation|
3486690|NCT03743207|Experimental|Room temperature|All of the infants in neonatal intensive care units are used to be fed with milk at 22-24°C which is close to room temperature.
3486691|NCT03743207|Experimental|Warmer temperature|The investigators decided to feed the infants in this group with warmer milk at to examine the effects of feeding temperature.
3486692|NCT03743194|Active Comparator|Bupi HCl plus liposomal bupi|"Pectoral fascial plane or serratus anterior plane blocks (PECSII/SAP blocks) with bupivacaine HCl plus liposomal bupivacaine.~An ultrasound guided pectoral fascial plane blocks (PECS I and II blocks) and Serratus anterior plane (SAP) block with injection of the local anesthetic."
3486693|NCT03743194|Placebo Comparator|Control Group|Standard parenteral analgesia technique with or without incisional local anesthetic infiltration: patients randomized to control group will be given parenteral opioids (such as fentanyl or hydromorphone) until they are converted to the enteral medications such as Percocet.
3486694|NCT03743181||intervention|will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
3486695|NCT03743181||control|will received standard care by physician in attendance
3486696|NCT03743168|Experimental|Intermittent stretching protocol|Intermittent stretching protocol including five sets at 1 minute and 15 second rest.
3486697|NCT03743168|Experimental|Continuous stretch|2 minutes continuous stretch
3179849|NCT00677222|Experimental|1|Treatment arm
3179850|NCT00677222|No Intervention|2|Registry Arm -standard of care
3486698|NCT03743155|Experimental|treatment with mesenchymal stem cells|xerostomy using mesenchymal stem cells adult autologous bone marrow
3486699|NCT03743142||Patients with AAA|Patients with AAA are eligible for participation and study screening. They will receive, once included, an endovascular repair of the AAA
3486700|NCT03743129|Experimental|Anlotinib|Anlotinib p.o, qd. Treatment from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) to disease progress or untolerated toxicity or consent withdrawal. The 2:1 ratio (Anlotinib to blank).
3486701|NCT03743129|No Intervention|Blank|No intervention from Day 1 of randomization(after concurrent chemoradiation 4-6 weeks) .The 2:1 ratio (Anlotinib to blank).
3486702|NCT03743103|Experimental|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
3486703|NCT03743103|Active Comparator|Nitroprusside, Sodium|0.5 mcg / kg / min every 3 minutes until reaching the pressure target
3486704|NCT03743090||CABG with ECC|Group of patients for whom CABG was performed under ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
3486705|NCT03743090||CABG without ECC|Group of patients for whom CABG was performed without ECC. A polysomnography will be performed to all of these patients the day before surgery and the third postoperative day.
3486706|NCT03743077|Experimental|Individuals with spinal cord injury|Volunteers will participate in the the spinal mobility fitness training program which includes exercise training with inspiratory muscle training.
3486707|NCT03743064|Experimental|100 mg anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
3486708|NCT03743064|Placebo Comparator|Placebo|Placebo oral tablet (administered as matching placebo tablets in the fasted condition)
3486709|NCT03743051|Experimental|100mg Anamorelin HCl|
3486710|NCT03743051|Placebo Comparator|placebo|
3486711|NCT03743025|Experimental|Dulaglutide Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 1 to 3 days prior to surgery
3486712|NCT03743025|Placebo Comparator|Placebo Arm|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 1 to 3 days prior to surgery
3486713|NCT03743012|Experimental|Integrated cardiac rehabilitation|Participants enrolled in integrated cardiac rehabilitation plus usual care
3486714|NCT03743012|Active Comparator|Usual Care|Participants receiving usual care only
3486715|NCT03742999|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
3486716|NCT03742999|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
3486717|NCT03742999|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
3486718|NCT03742986|Experimental|HER2-negative, including TNBC or HR-positive|
3486719|NCT03742986|Experimental|HER2-positive, independent of HR status|
3486720|NCT03742960|Experimental|Behavioral Sleep Restriction|Participants will be required to go to sleep half an hour later than their usual bedtime. Wake up time will be determined via their usual wake time.
3486721|NCT03742947|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
3486722|NCT03742947|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL)
3486723|NCT03742934|Experimental|Formula group|short peptide formula prior to capsule endoscopy
3486724|NCT03742934|Other|Control group|regular liquid diet
3486725|NCT03742921||Relapsed or Refractory T-Cell Lymphoma patients with Istodax|Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
3486726|NCT03742908|No Intervention|saline control|Implant immersion with 100 ml sterile saline (0.9%) for 10 minutes; Breast pocket irrigation (IRRI) with 100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards. No antibiotics is used.
3486727|NCT03742908|Experimental|Cefazolin/clindamycin immersion|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI) with100ml type III Anerdian for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards
3486728|NCT03742908|Experimental|Cefazolin/clindamycin immersion+ IRRI|Implant immersion: implant is immersed with 200mg cefazolin in 100 ml sterile saline (0.9%) for 10 minutes, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead for immersion; Breast pocket irrigation (IRRI): breast pocket is irrigated with100ml type III Anerdian plus 200mg cefazolin in 100 ml sterile saline (0.9%) for 30 seconds and washed with a total of 1000ml sterile distilled water twice afterwards, if the patient is allergic to cefazolin, 600mg clindamycin in 100ml sterile saline (0.9%) is used instead of cefazolin
3486729|NCT03742882|Experimental|Administration of CC-90001|Single oral dose of 200 mg of CC-90001
3486730|NCT03742869||Patients with HPV integration|The HPV integration status will be checked by GWAS.
3486731|NCT03742869||Patients without HPV integration|The HPV integration status will be checked by GWAS.
3486732|NCT03742843||Group of adenomyosis|Patients with adenomyosis with or without endometriosis
3486733|NCT03742843||Group of endometriosis|Patients with endometriosis without adenomyosis
3486734|NCT03742843||Group of control|Patients without adenomyosis or endometriosis
3128915|NCT03184987|Experimental|FF/UMEC/VI 100/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
3132753|NCT03449134|Placebo Comparator|Placebo|Participants receive dose-matched placebo tablets twice daily (BID) during the 12-week main study period and 40-week extension period.
3486735|NCT03742817|Experimental|Sweet-Flavor 4.5% Nicotine (Salt)|Participants will self-administer a sweet-flavored e-cigarette containing 4.5% nicotine by volume.
3486736|NCT03742817|Placebo Comparator|Sweet-Flavor 0 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 0 mg/mL nicotine.
3486737|NCT03742817|Experimental|Sweet-Flavor 6 mg/mL Nicotine (Free-Base)|Participants will self-administer a sweet-flavored e-cigarette containing 6 mg/mL nicotine.
3486738|NCT03742817|Active Comparator|Usual e-Cigarette|Participants will self-administer either their preferred brand combustible cigarette or e-cigarette with usual nicotine nicotine concentration.
3486739|NCT03742804|Experimental|G100 injections|All patients will receive 6 intratumoral G100 injections alone over 5 weeks. There will be a 4-week break for restaging. Patients will receive another 6 doses of G100 with either topical nitrogen mustard for 2 days before each dose or local radiotherapy (2 Gy daily x 2 days) prior to G100 to the injected lesion to assess the response to combination therapy. After the first 4 doses, nitrogen mustard is optional and can be omitted at the discretion of the investigator.
3486740|NCT03742791|Experimental|TS-134|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
3486741|NCT03742791|Placebo Comparator|Placebo|Healthy adult subjects will be prospectively assigned to 1 of 6 cohorts. Within each cohort, 10 subjects per cohort will be randomized in a 4:1 ratio (8 active + 2 placebo) to receive daily doses of TS-134 or placebo for 14 days in a fed state, with ascending titrated dose levels ranging from 5 mg to 80 mg, depending on the assigned cohort. The maximum daily dose shall not exceed 80 mg.
3486742|NCT03742778|Experimental|Incentivizing reflection|"Participants will receive three texts each week asking a question to reflect on their latest workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you felt right after your last workout? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
3486743|NCT03742778|Experimental|Incentivizing Exercise|"Participants will receive three texts each week asking a question for them to reflect on. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout). Example text: Which best describes how you are feeling now? 1-Energized, 2-Proud, or 3-Tired? Send your personal reply (e.g., 1)"
3486744|NCT03742765|Experimental|Incentivizing Planning|Participants will receive three texts each week asking a question to help plan for the next workout, and will receive 500 points for each text they answer. These bonus points are on top of points participants receive for each workout (200 points per workout).
3486745|NCT03742765|Experimental|Incentivizing Exercise|Participants will receive three texts each week asking a question about their workout. Regardless of whether or not they respond to the texts, participants receive 500 bonus points for their first three workouts during the week. These bonus points are on top of points participants receive for each workout (200 points per workout).
3486746|NCT03742752|Experimental|Enteral Nutrition (EN)|"To demonstrate the superiority of EN versus TPN in the treatment of postoperative upper GI anastomotic leak (PUGIAL) after upper GI surgery (including esophageal, gastric, duodenal, pancreatic and obesity surgery).~Patients will be randomized to receive EN through jejunostomy or nasojejunal tube until oral diet covering at least 60% of their daily requirement"
3486747|NCT03742752|Active Comparator|Parenteral Nutrition (TPN)|Patients will be randomized to receive TPN through central venous access, piccline or totally implantable venous access port tube until oral diet covering at least 60% of their daily requirement
3486748|NCT03742726|Experimental|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
3486749|NCT03742713|Experimental|CPC634 (CriPec® docetaxel)|CPC634 (CriPec® docetaxel) administered intra-venously every 21 days at 60 mg/m2
3486750|NCT03742700|Experimental|T-smokers|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
3486751|NCT03742700|Experimental|E-smokers|E-smokers were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
3486752|NCT03742700|Experimental|T/E-smokers|T/E-smokers (dual users) were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
3486753|NCT03742700|Placebo Comparator|Control subjects|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
3486754|NCT03742687|Experimental|A:Large target volume|The target volume for radiotherapy treatment volume is considered too large for a standard treatment of 66Gy in 33 fractions, considering the expected normal tissue toxicity with a standard treatment plan. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
3486755|NCT03742687|Experimental|B:Fragile patient|The patient is too fragile for standard long-course radiotherapy with 66 Gy. Heterogeneously Hypofractionated Radiotherapy plan ( 24 fractions )
3486756|NCT03742674||Cohort patients post stroke|
3486757|NCT03742661|Experimental|Treatment Group|SPEAC System
3486758|NCT03742661|No Intervention|Standard of Care|Standard of Care
3486759|NCT03742648|Active Comparator|Control physiotherapy group|Basic standard medical and nursing care along with standard chest physiotherapy involving steam inhalation and nebulization for 15-20 minutes and 10-15 cycles of incentive spirometry twice daily
3486760|NCT03742648|Experimental|Experimental physiotherapy group|Basic standard medical and nursing care along with chest physiotherapy involving any of the deep breathing exercises as per patients ease with 5-10 repetitions each, twice daily
3486761|NCT03742635|Experimental|GMA Assessment|"Conduct General Movements Assessment (GMA) in-person/via-telemedicne (real-time) and recorded (standard of care)"
3486762|NCT03742622|Experimental|Obese adolescents|18 adolescents with obesity are involved and will perform the three conditions
3486763|NCT03742609|No Intervention|Information only|provision of written information regarding consequences of using a hearing aid and not using a hearing. For example using a hearing aid will improve ability to hear others.
3486764|NCT03742609|Active Comparator|Physical reminder only|provision of written information regarding consequences of using a hearing aid and not using a hearing and physical reminder to use a hearing aid. For example, a hearing aid box as a physical reminder to use the hearing aids.
3486765|NCT03742609|Active Comparator|Behaviour Plan only|provision of written information regarding consequences of using a hearing aid and not using a hearing and creation of behaviour plan to use a hearing aid. For example, when and where to use the hearing aids.
3486766|NCT03742609|Experimental|Info, Reminder and Plan|provision of written information regarding consequences of using a hearing aid and not using a hearing, physical reminder and creation of behaviour plan to use a hearing aid
3486767|NCT03742596|Experimental|Probiotic Formula Capsule|In this intervention arm the patients will receive oral viable capsules of probiotic contain (1*10 10 colony forming unit (CFU)/g) of lactobacillus (Lactobacillus rhamnosus , Lactobacillus acidophilus , Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus gasseri, Lactobacillus plantarum) and bifidobacteria (Bifidobacterium lactis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium infantis) species three times a per day
3486768|NCT03742596|Other|Control|In this intervention arm, the control arm will receive normal treatment without any probiotic
3128916|NCT03184987|Experimental|FF/UMEC/VI 200/62.5/25 mcg closed triple therapy|Subjects will receive FF/UMEC/VI 200/62.5/25 mcg inhalation powder via ELLIPTA, once daily, 1 puff/time, in the morning. Subjects may receive salbutamol as a rescue medication when needed throughout the run-in and treatment period.
3486769|NCT03742583|Active Comparator|Square Knot|
3486770|NCT03742583|Active Comparator|Reversing Half-Hitch Alternating Post Knot|
3486771|NCT03742570||CBBDQ|A Questionnaire
3486772|NCT03742557|Active Comparator|Ketamine|"Ketamine 50 MG/ML - at a dose of 0.5 mg/kg IV diluted in 100cc of saline solution 0.9% over 40 minutes.~The intervention will be done twice weekly for 8 weeks."
3128917|NCT03185065|Experimental|Arm A|amantadine, placebo, modafinil, methylphenidate
3486773|NCT03742557|Placebo Comparator|Placebo|Saline solution 0.9% over 40 minutes. The intervention will be done twice weekly for 2 weeks, and then patients will receive intervention with ketamine as described above in the Active Comparator.
3486774|NCT03742531|Active Comparator|low dose group|oxytocin therapy starting with 2mU/min increased by 2 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
3486775|NCT03742531|Active Comparator|high dose group|oxytocin therapy starting with 4mU/min increased by 4 mU/min every 15 minutes. oxytocin will be stopped at the beginning of the active phase of labor.
3486776|NCT03742492|Experimental|Canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
3486777|NCT03742492|Placebo Comparator|Canned tuna + soybean oil|Meal containing canned tuna + soybean oil
3486778|NCT03742479|Experimental|Hyaluronic Acid Microinjection|
3486779|NCT03742466|Active Comparator|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
3486780|NCT03742466|Active Comparator|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
3486781|NCT03742453|Experimental|Hepatic nodule group|This group meets eligibility criteria, and undergo contrast-enhanced ultrasound (CEUS) and scheduled gadoxetic acid MRI (gadoxetic acid-enhanced liver MRI; EOB-MRI; Gd-EOB-MRI)
3486782|NCT03742401|Active Comparator|Surgery|Surgery
3486783|NCT03742401|Active Comparator|HIFU (Echopulse)|HIFU (Echopulse)
3486784|NCT03742375|Experimental|HPV genotyping|
3486785|NCT03742362|Experimental|Bone marrow fat fraction by MRI|MRI scans of distal radius will be performed to all participants to monitor the fat fraction in bone marrow
3486786|NCT03742336|Experimental|Arm 1|Single dose of dabigatran on Day 1 of Period 1 and Single dose of dabigatran + PF-04965842 on Day 1 of Period 2.
3486787|NCT03742336|Experimental|Arm 2|Single dose of dabigatran + PF-04965842 on Day 1 of Period 1 and Single dose of dabigatran on Day 1 of Period 2.
3486788|NCT03742323|Experimental|Idelalisib|
3486789|NCT03742310|Experimental|identical supplement group|"Take vitamin D supplements according to genotype. If the genotype result is high risk, we will give vitamin d 800 international unit(IU)/d, when the result is middle risk, we will give 600 international unit(IU)/d, when the result is low risk, we will give 400 international unit(IU)/d."
3486790|NCT03742310|No Intervention|control group|General dose. Whatever the result is, we all give 400 international unit(IU)/d.
3486791|NCT03742297|Active Comparator|VMP x 9 + Lenalidomida-dexamethasone x 9|Bortezomib-melfalán-prednisone. Melfalán: 9mg/m2D1-4. Prednisone: 60mg/m2D1-4. Bortezomib: 1.3mg/m2 One 6 week cycleD1, 4, 8, 11, 22, 25, 29 and 32; followed by eight4-week cycleD1, 8, 15 and 22 Lenalidomida-dexametasona at low dose
3486792|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethasone regimen|carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15.Lenalidomida: 25 mg, d1-21 Dexamethasone : 40 mg, d1, 8, 15, 2218 28-day cycle
3486793|NCT03742297|Experimental|Carfilzomib-lenalidomida-dexamethason with daratumumab|Carfilzomib: 1 st cycle: 20mg/m2 day 1 and 36 mg/m2 days 2, 8, 9 & 15, 16. 2nd cycle: 36 mg/m2 days 1, 2, 8, 9 & 15, 16. Cycles 3-18: 56 mg/m2 days 1, 8 & 15. Lenalidomida: 25 mg, d1-21 Dexamethasone: 40 mg, d1, 8, 15, 22. Daratumumab 1800mg SC Days 1, 8, 15, 22 of cycles 1-2; Days 1 and 15 of cycles 3 and 4; Day 1 of cycles 5 to 18
3486794|NCT03742284|Other|SoftOx Wound Irrigation Solution|SoftOx Wound Irrigation Solution is Medical Device that will be applied to rinse acute wounds.
3128918|NCT03185065|Experimental|Arm B|placebo, methylphenidate, amantadine, modafinil
3128919|NCT03185065|Experimental|Arm C|modafinil, amantadine, methylphenidate, placebo
3486795|NCT03742258|Experimental|Treatment (R-CHOP, TAK-659)|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV over 3-5 minutes, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning in course 2, patients also receive spleen tyrosine kinase inhibitor TAK-659 PO QD on days 1-21. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
3486796|NCT03742245|Experimental|Olaparib and Vorinostat|"Phase I: Olaparib and vorinostat will be orally administered for 4 28-day cycles. Dose levels (DLs) are as follows: DL -1, 100 mg twice daily (b.i.d.) olaparib and 300 mg for 5 consecutive days per week vorinostat; DL 0 (starting dose), 200 mg twice daily (b.i.d.) olaparib and 300 mg once daily (q.d.) vorinostat; DL 1, 300 mg b.i.d. olaparib and 300 mg q.d. vorinostat; and DL 2, 300 mg b.i.d. olaparib and 400 mg q.d. vorinostat.~Phase Ib: Olaparib and vorinostat will be administered at the maximum tolerated dose (MTD) determined in the Phase I portion of the study for 4 28-day cycles. Participants who derive clinical benefit (complete response, partial response, or stable disease) after 4 cycles will continue to receive study treatment until unacceptable toxicity or disease progression."
3486797|NCT03742232|Experimental|PLENVU|PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.
3128920|NCT03185065|Experimental|Arm D|methylphenidate, modafinil, placebo and amantadine
3128921|NCT03185182|Experimental|experimental group|"185 megabecquerel (MBq) of Ioflupane I-123 (DaTSCAN) will be administered IV to patients with suspected renal cell carcinoma, at a single occasion and followed by SPECT-analysis 5h after injection.The images from the DaTSCAN investigation will be analyzed and anatomically compared to CT-scan from the same the patient. Any adverse effects during the study will be reported.~This is a exploratory open single arm trial, including a small number of patients with suspected disseminated renal cell carcinoma."
3128922|NCT03185455|No Intervention|Standard of Care|Those randomized to the standard protocol for blood pressure monitoring will be scheduled for an office based nursing blood pressure visits 4-6 days postpartum. Care at this visit is based on a physician derived algorithm.
3132754|NCT03449134|Experimental|Gefapixant 15 mg BID|Participants receive a gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg BID during the 12-week main study period and 40-week extension period.
3486798|NCT03742232|Active Comparator|SELG-ESSE|SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.
3486799|NCT03742219|Experimental|Lifestyle Intervention|Impoverished communities in Lima, Peru will be offered free medical clinics. Four communities have been chosen initially for focus over the following 10 years. These communities will be made aware of their risk for chronic lifestyle related diseases. In conjunction with the communities, specific interventions focused on a plant-based diet, physical activity, stress management and control of unhealthy habits will be devised.
3179851|NCT00677248|Placebo Comparator|1|Ezetimibe and placebo
3179852|NCT00677248|Experimental|2|Eprotirome dose 1 and ezetimibe
3486800|NCT03742206|Experimental|Parasacral|Parasacral Transcutaneous Electrical Stimulation Group: participants in this group will receive two self-adhesive electrodes and will be instructed to position them in the sacral region. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
3486801|NCT03742206|Active Comparator|Posterior Tibial Nerve|Transcutaneous Posterior Tibial Nerve Stimulation Group: participants in this group will receive a neoprene ankle brace that will be connected to the electrostimulator. Current parameters will be: 10 hertz frequency, 700μs wavelength, 20 minute therapy duration, 3x frequency in the week. The treatment will be at home for 6 weeks.
3486802|NCT03742193|Experimental|Apatinib + GD group|Apatinib + GD regimen. For unilateral metastases,3 cycles before metastasectomy, and 4 cycles after. For bilateral metastases, 3 cycles before first metastasectomy, 1 cycle inbetween, and then second metastasectomy followed by 4 cycles. Apatinib monotherapy is then maintained until 1 year following complete resection.
3486803|NCT03742180|Experimental|intranasal dexmedetomidine|this group is planned for intranasal dexmedetomidine
3486804|NCT03742180|Active Comparator|sublingual ketorolac|this group is planned for sublingual ketorolac
3486805|NCT03742167|Experimental|Telemedicine|The telemedicine arm will have 2-way audiovisual connection with a pediatric medical control physician.
3486806|NCT03742167|No Intervention|Control|The control arm will receive pediatric medical control physician consultation via telephone.
3486807|NCT03742115|Experimental|Etoposide standard group|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
3486808|NCT03742115|Experimental|Etoposide reduction group|Etoposide 150 mg/m2 once a week; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
3486809|NCT03742115|Active Comparator|Corticosteroid group|dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering, with or without IvIG (0.5 g/kg IV, once every 4 weeks)
3179853|NCT00677248|Experimental|3|Eprotirome dose 2 and ezetimibe
3486810|NCT03742089||Treatment|Bone Anchored Hearing Surgery using a BHX implant manufactured by Oticon Medical
3486811|NCT03742076|Active Comparator|High-dose prebiotic|10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
3486812|NCT03742076|Active Comparator|Low-dose prebiotic|5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks
3486813|NCT03742076|Placebo Comparator|Placebo|2 gm powdered fiber daily for at least 6 weeks
3486814|NCT03742063||Huvos group I|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade I is 0% to 49%.
3486815|NCT03742063||Huvos group II|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade II is 50% to 89%.
3486816|NCT03742063||Huvos group III|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade III is 90% to 99%.
3486817|NCT03742063||Huvos group IV|Upon histopathological examination, the tumor response was assessed on the basis of the presence and extent of necrosis, which was assessed by a combination of gross and microscopic observations. Tumor necrosis was graded as per Picci et al. tumor histopathological response grading (Huvos classification), where grade IV is 100% necrosis.
3486818|NCT03742050|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents and modern techniques
3486819|NCT03742050|Placebo Comparator|Placebo percutaneous coronary intervention|Placebo percutaneous coronary intervention
3486820|NCT03742037|Experimental|Cenerimod 0.5 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
3486821|NCT03742037|Experimental|Cenerimod 1 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
3486822|NCT03742037|Experimental|Cenerimod 2 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
3486823|NCT03742037|Experimental|Cenerimod 4 mg|"Subjects will receive cenerimod once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will will be re-randomized in a double-blinded fashion in TP2 in a 1:1 ratio to placebo or cenerimod 2 mg."
3486824|NCT03742037|Placebo Comparator|Placebo|"Subjects will receive matching placebo once daily in addition to background SLE therapy and will enter a 6-month double-blind study treatment called Treatment Period 1 (TP1).~Subjects completing TP1 will continue their study double-blind treatment unchanged during TP2 for up to 6 additional months, or until last subject in TP1 completes the 6-month visit. This will trigger the end of treatment for all subjects."
3132755|NCT03449134|Experimental|Gefapixant 45 mg BID|Participants receive a gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the 12-week main study period and 40-week extension period.
3179854|NCT00677248|Experimental|4|Eprotirome dose 3 and ezetimibe
3179855|NCT00677261|Experimental|1|
3486825|NCT03741998|No Intervention|THRIVE|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction using jaw-thrust maneuver.
3486826|NCT03741998|Active Comparator|THRIVE with nasopharyngeal airway|Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) during induction with nasopharyngeal airway.
3486827|NCT03741985|Placebo Comparator|The handgrip exercise|Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
3486828|NCT03741985|Experimental|The dumbbell exercise|Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
3486829|NCT03741972||Treatment|Patients with diabetes and heart failure that are treated with iSGLT2
3132756|NCT03449147|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and the 28-week extension period.
3132757|NCT03449147|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID and placebo tablet to match gefapixant 45 mg BID during the 24-week main study period and the 28-week extension period.
3179856|NCT00677261|Experimental|2|
3179857|NCT00677261|Sham Comparator|3|
3128923|NCT03185455|Experimental|Remote (text based) surveillance|Those randomized to remote surveillance will be provided with electronic blood pressure monitors prior to discharge and instructed on their use. Every day, for two weeks post-discharge, patients will receive a standard text message in the morning from a HIPAA compliant automated monitoring system reminding them to text their blood pressure. They will be asked to send in one blood pressure a day at minimum. They may be asked to send in more depending on the blood pressure result and clinical algorithm. This system will provide timely responses to patient texts and create a physician derived response to elevated blood pressures based on a programmed algorithm. Additionally, for blood pressures that reach a dangerous threshold, a clinical provider will be alerted per the algorithm and contact the patient for further evaluation.
3128924|NCT03185481|Experimental|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
3486830|NCT03741959|Experimental|Experimental|The experimental group will undergo three groups of exercises: 1) active self-correction exercises (20 minutes) defined as the best possible trunk alignment the patient can achieved in the three-dimensional planes; 2) passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint and to counteract the evolution of the misalignment; 3) functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015).Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks.
3486831|NCT03741959|Active Comparator|Control|The control group will undergo strengthening exercises and gait training as the usual practice in Parkinson Disease. Training will consist of individualized treatment 60 mins/day, 2 days/week, for 5 consecutive weeks (Bartolo et. al., 2010).
3128925|NCT03185481|Experimental|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
3486832|NCT03741946|Other|Triangle of Sedillot identification using ultrasonography|USG probe placed upright at the top of triangle of Sedillot at cricoid level
3486833|NCT03741933|Experimental|Apremilast|30 mg twice daily to be administered for a period of 6 months
3486834|NCT03741920|Experimental|Personal KinetiGraph™ (PKG™) +|For subjects in the PKG+ Group, the study MDS will review and report on the PKG prior to the visit and use the information to guide the discussion with the subject during the clinical assessment. PKG results will be recorded in the PKG Reporting case report form (CRF). The study MDS will complete the MDS-Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures along with the PKG information.
3486835|NCT03741920|Active Comparator|Personal KinetiGraph™ (PKG™) -|For subjects in the PKG- Group (control group), the study Movement Disorder Specialist (MDS) will complete the MDS - Clinician Assessment CRF to denote patient-reported symptoms, treatable findings, and clinical management planning based on his/her routine clinical assessment procedures. The study Movement Disorder Specialist will be blinded to the PKG information until the second part of the 90-day follow-up visit.
3486836|NCT03741907|Experimental|FAUCS|French Ambulatory C-section
3486837|NCT03741907|Active Comparator|MLC|Gold Standard
3486838|NCT03741894|Placebo Comparator|Primary wound closure|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
3486839|NCT03741894|Experimental|Iodoform and wound closure|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture (Surgilon 3-0 non-absorbable) placements for a week.
3486840|NCT03741894|Experimental|Chlorhexidine and wound closure|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
3486841|NCT03741855|Experimental|Remote-Monitoring Program|Cloud Dx kit with remote-monitoring
3486842|NCT03741855|Experimental|Self-Monitoring Program|Cloud Dx kit with self-monitoring
3486843|NCT03741855|No Intervention|Standard of Care|Participants will not be provided with the Cloud DX kit or an action plan
3486844|NCT03741842|Experimental|COMBO-KEY group|"The participants in the intervention group will receive a home visiting and phone coaching self-management programme (Coaching Ongoing Momentum Building On stroKe rEcovery journeY COMBO-KEY) which is underpinned by Bandura's constructs of self-efficacy and outcome expectation."
3486845|NCT03741842|No Intervention|Usual care group|The participants in the usual care group will receive usual rehabilitation services offered, including services by a community rehabilitation network such as exercise training, physical rehabilitation, or activities organised by stroke support groups.
3486846|NCT03741816|Active Comparator|Biodentine|Indirect pulp capping with Biodentine in mature permanent molars with deep carious lesions and reversible pulpitis
3486847|NCT03741816|Experimental|TheraCal LC|Indirect pulp capping with TheraCal LC in mature permanent molars with deep carious lesions and reversible pulpitis
3486848|NCT03741803|Active Comparator|Delayed cord clamping|
3486849|NCT03741803|Active Comparator|Early cord clamping|
3486850|NCT03741777|Active Comparator|3 ml/kg of clear oral fluid|This group of patient will consume 3 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
3486851|NCT03741777|Active Comparator|5 ml/kg of clear oral fluid|This group of patient will consume 5 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
3486852|NCT03741777|Active Comparator|7 ml/kg of clear oral fluid|This group of patient will consume 7 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
3486853|NCT03741777|Active Comparator|10 ml/kg of clear oral fluid|This group of patient will consume 10 ml/kg of clear fluid by mouth at 2-hour period before surgical scheduled time
3486854|NCT03741764|Other|Vivosorb|Only arm in study
3486855|NCT03741751|Experimental|active rTMS with computerized cognitive training|Participants will receive 6 sessions of active rTMS followed by a computerized cognitive training session over 2 weeks.
3486856|NCT03741751|Sham Comparator|sham rTMS with computerized cognitive training|Participants will receive 6 sessions of sham rTMS followed by a computerized cognitive training session over 2 weeks.
3486857|NCT03741712|Experimental|SHR2554|Participants will receive SHR2554 orally
3486858|NCT03741712|Experimental|SHR2554+SHR3680|Participants will receive SHR2554 combined with SHR3680 orally
3486859|NCT03741699|Experimental|Arm 1 - experimental group|Treatment with 150 IU/day rLH, administered subcutaneously for 4 consecutive days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
3486860|NCT03741699|No Intervention|Arm 2 - control (no pre-treatment) group|The subjects assigned to this group will not receive any treatment in the four days prior to COS (with a starting dose of 225 IU/day rFSH and 75 IU/day rLH for 18 days maximum in a short antagonist protocol).
3486861|NCT03741686|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet.
3486862|NCT03741686|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet.
3486863|NCT03741673|Experimental|Group I (pre-operative SRS)|Patients undergo SRS within 15 days of randomization followed by surgery within 15 days. Patients may undergo additional SRS if disease returns after treatment.
3486864|NCT03741673|Active Comparator|Group II (post-operative SRS)|Patients undergo surgery within 15 days of randomization followed by standard of care SRS within 30 days. Patients may undergo additional SRS if disease returns after treatment.
3486865|NCT03741660|Experimental|Konjac-mannan|Konjac-mannan fiber-enriched biscuits with NCEP Step II metabolically controlled diet
3486866|NCT03741660|Placebo Comparator|Placebo|wheat bran fiber biscuits with NCEP Step II metabolically controlled diet
3486867|NCT03741634|Experimental|Intervention|Participants enrolled at one study location will receive the Multi-sectoral agricultural intervention as specified below under the intervention.
3128926|NCT03185481|Experimental|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
3128927|NCT03185481|Experimental|15 mg QD PF-06649751|15 mg QD PF-06649751 remains at 15 mg QD PF-06649751
3486868|NCT03741634|No Intervention|No intervention|During the study, participants enrolled at one study location will non receive the Multi-sectoral agricultural intervention. At the end of the study, participants in this arm will be eligible for education in financial management and sustainable farming practices and those who pay the loan down payment will be eligible for a small loan to purchase a human-powered water pump, seeds, fertilizers and, pesticides.
3486869|NCT03741621|Experimental|High Viscosity|viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
3486870|NCT03741621|Experimental|Medium Viscosity|Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
3486871|NCT03741621|Experimental|Low Viscosity|Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
3486872|NCT03741608|Active Comparator|Education, BP cuff & training|High blood pressure management education. Home blood pressure measurement
3486873|NCT03741608|Active Comparator|Education only|High blood pressure management education
3486874|NCT03741595|Experimental|Single Arm|
3486875|NCT03741582||Control - San Cristobal|"1000 individuals located in an area with no access to the intervention (TransMicable). The control area was defined by a 800-meter buffer around each projected station of the car, San Cristobal was an area with a projected but non financed Cable Car."
3128928|NCT03185481|Experimental|1 mg to 7 mg QD PF-06649751|Up titration from 1 to 7 mg QD PF-06649751 if de-escalated in parent study
3486876|NCT03741582||Intervention - Ciudad Bolviar|1000 individuals who live in the area of influence of TransMiCable. The area of influence of TransMiCable was defined by a 800-meter radial buffer around each station of the cable car.
3486877|NCT03741569|Other|parturients (gestational age ≥37 weeks).|
3486878|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material
3486879|NCT03741504|No Intervention|No micro-osteoperforations (No MOPs)|Canine Distalization without micro-osteoperforations Distalization of the upper canine in working phase with coil spring of 100 gr of force
3486880|NCT03741504|Experimental|Micro-osteoperforations (MOPs)|Canine Distalization with micro-osteoperforations at the start of the distalization Distalization of the upper canine in working phase with coil spring of 100 gr of force
3486881|NCT03741478|Experimental|Metabolic Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility.~This arm then includes the pancreatic euglycemic clamp procedure at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, 7.5mg on day 1, and 10mg on day 2.~Day 2 consists of the final dose of olanzapine (or placebo) and the pancreatic euglycemic clamp procedure and other assessment procedures.~On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) during the pancreatic euglycemic clamp procedure."
3486882|NCT03741478|Experimental|Cognitive and MRI Arm|"This arm includes a screening visit 1 and screening visit 2 to assess eligibility. This arm includes an MRI scan and cognitive testing at visits 1 to 4. Visits 1 to 4 each consist of 3 days (day 0, day 1, and day 2).~Olanzapine 2.5mg (or placebo) will be administered in doses of 5mg on day 0, and 10mg on day 1. Cognitive testing and MRI scanning then occur on day 2. On day 2, the participant is also randomized to and administered either intranasal insulin/Insulin Lispro 100 UNT/ML (or saline placebo) prior to conducting the MRI imaging and cognitive testing."
3179858|NCT00677274|Active Comparator|1|Epidural analgesia initiated at the cervix 0cm
3179859|NCT00677274|Active Comparator|2|Epidural analgesia initiated at the cervix 0.5cm
3128929|NCT03185481|Experimental|3 mg QD to 7 mg QD PF-06649751|Up titration from 3 to 7 mg QD PF-06649751 if de-escalated in parent study
3128930|NCT03185481|Experimental|7 mg QD to 7 mg QD PF-06649751|7 mg QD remains at 7 mg QD PF-06649751 if de-escalated in parent study
3179860|NCT00677274|Active Comparator|3|Epidural analgesia initiated at the cervix 1.0cm
3179861|NCT00677274|Active Comparator|4|Epidural analgesia initiated at the cervix 1.5cm
3179862|NCT00677274|Active Comparator|5|Epidural analgesia initiated at the cervix 2.0cm
3179863|NCT00677274|Active Comparator|6|Epidural analgesia initiated at the cervix 3.0cm
3486883|NCT03741465|Active Comparator|The SFP technique|In the SFP neuraxial positioning technique, fifty participants were planned to sit on the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs hanging freely, forearms on the lap and hand are on the knees. The position is completed with the back curved in the fetal position. Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
3486884|NCT03741465|Experimental|The ASP technique|In the ASP neuraxial positioning technique, the same fifty participants were planned to sit on the same part of the stretcher facing the wall of the sonography room and turned back to the consultant Radiologist with legs crossed, forearms of the participants are on the lap and hands are on the knees, and the position is completed with the back curved in the fetal position.Then the USG is performed by the consultant Radiology M.D. in maximum 2 hours time to each participant, and the 5-point NRS evaluation is done by each participant in maximum 30 minutes time until the study ends within 24 weeks.
3486885|NCT03741452|Experimental|Transversalis fascia plane block|The transversalis fascia plane block will be administrated to this group at end of the surgery under general anesthesia. An intravenous patient-controlled analgesia device within tramadol will be given to the patients postoperatively.
3486886|NCT03741452|No Intervention|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia with tramadol. No block will be performed.
3486887|NCT03741439|Experimental|Treatment arm|Receives real treatment according to manufactures instructions. 6 sessions of low intensity shockwave treatment with an electromagnetic emitter.
3486888|NCT03741439|Sham Comparator|Sham Arm|Receives sham treatment with same applicator, same sound, same time and number of shocks. But no real energy is delivered.
3486889|NCT03741426|Experimental|Arm 1- Cediranib|Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
3486890|NCT03741426|Experimental|Arm 2- Olaparib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy.
3486891|NCT03741426|Active Comparator|Arm 3- Olaparib and Cediranib|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy AND Cediranib tablet oral 20mg once daily for a minimum of 2 weeks up until 36 hours before nephrectomy.
3486892|NCT03741426|Experimental|Arm 4- Durvalumab|Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
3486893|NCT03741426|Active Comparator|Arm 5- Olaparib and Durvalumab|Olaparib tablet oral 300mg twice daily for a minimum of 2 weeks up until the morning of nephrectomy. Durvalumab 1500mg intravenous infusion once, a maximum of 4 weeks prior to nephrectomy.
3486894|NCT03741413|Experimental|Gain-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to save their lives. Thank you for your support. were send to donors in this group."
3486895|NCT03741413|Experimental|Loss-frame SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can offer a helping hand to prevent them from death. Thank you for your support. were send to donors in this group."
3486896|NCT03741413|Experimental|Control SMS|"SMS messages Dear Rh negative blood donors: Hello! As the Rh negative O/B blood stockpile is low now, but patients who are this blood type are in urgent need. If you are available, we hope that you can donate blood again. Thank you for your support. were send to donors in this group."
3486897|NCT03741413|No Intervention|Control group|Donors in this group were not received SMS reminders.
3486898|NCT03741400|Experimental|Standard Occupational Therapy + Smart Glove|Subjects randomized to this arm will be expected to use the Neofect Rapael Smart Glove for a minimum of 20-30 minutes per day, 5 days per week, in addition to prescribed occupational therapy.
3179864|NCT00677274|Active Comparator|7|Epidural analgesia initiated at the cervix 4.0cm
3486899|NCT03741400|No Intervention|Standard Occupational Therapy|Subjects in the control arm will undergo standard of care occupational therapy as prescribed by their care team.
3486900|NCT03741387|Experimental|Gain-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you save his life? Donors in this group will answer the questions about attitude of saving patients' lives."
3486901|NCT03741387|Experimental|Loss-frame questionnaire|"Questionnaire included a picture of a patient lying in bed entitled Will you prevent him from death? Donors in this group will answer the questions about the attitude of preventing patients from death."
3486902|NCT03741374|Experimental|Minimally-invasive non-surgical therapy|Intrabony defects treated with Minimally-invasive non-surgical therapy (MINST)
3486903|NCT03741361||Anxiety and Depression|Female patients scheduled for hysteroscopic surgery under propofol-based intravenous anesthesia will be recruited in this prospective cohort study.
3486904|NCT03741348|Active Comparator|ES|Erector Spinae Plane Block
3486905|NCT03741348|Placebo Comparator|control|the control group will not receive block
3486906|NCT03741335|Experimental|Strength Training|Participants wear a weighted vest while performing exercises using functional movement patterns used in everyday activities (chair rises, 90° squats, side-to-side squats, toe raises, lunges (forward, lateral, backward, walking), multi-directional step ups). Participants attend supervised, group-based moderate-intensity strength training program remotely 3 times per week for 60 minutes per session.
3486907|NCT03741335|Active Comparator|Stretching Control|Participants attend a supervised flexibility program where they will perform a series of whole body stretching exercises with a focus on developing and maintaining a healthy back. Participants attend a supervised, group-based supervised flexibility program remotely 3 times per week for 60 minutes per session.
3486908|NCT03741335|Experimental|Tai Ji Quan Training|An integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements. Participants attend a supervised, group-based tai ji quan program remotely where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session.
3486909|NCT03741309|Active Comparator|Group I|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
3486910|NCT03741309|Sham Comparator|Group II|dentifrice containing Calcium sodium phosphosilicate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
3486911|NCT03741309|Placebo Comparator|Group III|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks.
3486912|NCT03741296|Active Comparator|single stage revision|One surgery where the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided and washed out before a new artificial hip joint (prosthesis) is implanted. All the procedures will be done in a single surgery.
3486913|NCT03741296|Active Comparator|two-stage revision|"Patients will undergo 2 separated surgeries. In the first operation, the infected artificial joint will be removed along with all components, cement, and any potentially infected material. The surgical site will be debrided, washed out and a spacer will be placed in the hip (temporarily replace prosthesis).~A secondary surgery to re-implant the hip will be performed with an interval period of 4-10 weeks when the infection is cleared.~The site will be debrided and irrigated, and any component/spacer will be removed. A new artificial joint will then be implanted."
3486914|NCT03741283|Experimental|Optimisation of nutrition and medication|"N=approx.~65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition."
3486915|NCT03741283|No Intervention|Standard care|N= approx. 65 acutely admitted older medical patients with undernutrition or risk of undernutrition, and 35 without undernutrition or risk of undernutrition.
3486916|NCT03741270|Experimental|Vaccine|
3486917|NCT03741257|Active Comparator|Group A|Received Hypertonic saline 3% as resuscitation fluid.
3486918|NCT03741257|Active Comparator|Group B|Received Hypertonic saline 1.8% as resuscitation
3486919|NCT03741244|Experimental|Temozolomide and apatinib|"Patients have treated with postoperative concurrent chemoradiation. Then Temozolomide (150mg/m2/d d1-5 in the first cycle, followed by 200mg/m2/d d1-5 q28d) + apatinib (500mg/d QD).~After 6 cycles,apatinib single drug maintained until progress."
3486920|NCT03741244|Active Comparator|Temozolomide|Patients were treated with postoperative concurrent chemoradiation.Then Temozolomide alone chemotherapy 6 cycles(first cycle 150mg/m2/d d1-5, later 200mg/m2/d d1-5 q28d).
3486921|NCT03741218|Experimental|1|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast the placebo (PLA) the first time and grape (GRAP) the second time.
3486922|NCT03741218|Experimental|2|All subjects will receive a high-fat breakfast and a medium-fat lunch twice. They will consume together with the breakfast grape (GRAP) the first time and the placebo (PLA) the second time.
3486923|NCT03741205|Experimental|Treatment Group|SPEAC System
3486924|NCT03741205|No Intervention|Standard of Care|Standard of Care
3486925|NCT03741192|Experimental|Treatment Group|SPEAC System
3486926|NCT03741192|No Intervention|Standard of Care|
3486927|NCT03741179|Experimental|ASA-withdrawn group|ASA treatment will be withdrawn if patients present an sFlt/PlGF < 38 at 24+0-27+6 weeks of gestation.
3486928|NCT03741179|No Intervention|ASA group|ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio < 38 at 24+0-27+6 weeks of gestation.
3486929|NCT03741166||Subject aged 45-49 with Average CRC Risk|Subjects will be men and women, 45-49 years of age, who enroll in Exact Sciences Protocol 2018-10. Subjects will provide a blood sample at time of enrollment.
3486930|NCT03741153||study group|includes patients who will be diagnosed with Pseudoexfoliation syndrome
3128931|NCT03185481|Experimental|15 mg to 7 mg QD PF-06649751|15 mg QD de-escalated to 7 mg QD in parent study B7601003 remain at 15 mg QD PF-06649751
3179865|NCT00677274|Active Comparator|8|Epidural analgesia initiated at the cervix 5.0cm
3486931|NCT03741153||control group|age matched controls who do not have Pseudoexfoliation syndrome
3486932|NCT03741140|Other|medial frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the medial frontal lobe will be included in this arm, and will undergo motivation phenotyping.
3486933|NCT03741140|Other|lateral frontal stroke|20 patients (up to 10 patients can be replaced) with a stroke in the lateral frontal lobe will be included in this arm, and will undergo motivation phenotyping.
3179866|NCT00677287|Experimental|A|
3179867|NCT00677300|Experimental|Group A|Will receive Raltegravir (400mg twice daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
3486934|NCT03741140|Other|Healthy participants|20 healthy participants (up to 10 healthy participants can be replaced) will be included in this arm, and will undergo motivation phenotyping.
3486935|NCT03741127|Other|P-BCMA-101 treated|Patients who received previous treatment with P-BCMA-101. Rimiducid may be administered as indicated.
3486936|NCT03741114|Active Comparator|Foley's Catheter plus TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus 1 gm tranexamic acid in 100ml saline intravenous just before skin incision
3486937|NCT03741114|Active Comparator|Foley's Catheter plus placebo to TA|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus plus single injection of 100 ml intravenous saline before skin incision
3486938|NCT03741101|Experimental|single arm study|children treated with trametinib
3486939|NCT03741075|Active Comparator|BUAL plus placebo|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus 200 ml saline topical application to placental bed
3486940|NCT03741075|Experimental|BUAL plus topical tranexamic acid|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures plus topical application of 20ml saline contains 2 gm tranexamic acid
3486941|NCT03741049||Consultants|
3486942|NCT03741049||Trainee anaesthetists|
3486943|NCT03741049||Paramedics|
3486944|NCT03741049||Students|
3486945|NCT03741036|Active Comparator|autogenous bone graft as a space filling material|Autogenous bone from sub mental bone had been grafted in jumping gap between implant and freshely extracted socket
3486946|NCT03741036|Active Comparator|deproteinized bovine as a space filling material|Granules of deproteinized bovine bone of 0.25-1.0 mm diameter were used to fill the remaining defect when the distance of the defect wall to the implant surface was > 3 mm.
3486947|NCT03741036|Active Comparator|nano-hydroxyapatite alloplast as a space filling material|The patient was treated using alloplast material mixed with a nano-bone graft to fill gap between implant and freshely extracted socket
3486948|NCT03741023|Other|Trauma Patients|"During Hospitalization:~Patients routinely have blood drawn at time of admission and every 12 hours following admission up until 2 weeks post-admission or until discharge. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (2 blue-top tubes) per time point during their normal course of care for this study, for a total of 72.8 mL of blood drawn per week. In addition to the routine blood draws, a finger stick may also be obtained the same day. Approximately 3 drops of blood (100μL maximum) will be removed by the finger stick.. Finger sticks will not be collected in the pediatric population.~Follow-Up Visits Any complications resulting from traumatic injury will be documented at these routine care visits. These complications will be documented if they occur within 2 years of injury."
3486949|NCT03741023|Other|Invasive Elective Surgery Patients|"During Hospitalization:~Patients routinely have blood drawn pre-, intra- and post-operatively. Remnants of the blood draw will be stored in the Vanderbilt Lab core and retrieved for further analysis by key research personnel. Patients will have an additional 5.2ml of blood drawn (for patients 7 years of age or older) or 2mL of blood drawn (for patients under the age of 7 years old) immediately prior to surgery, every 30 minutes intraoperatively, every 6 hours for 3 days post-operatively, and every 12 hours from 3 days post-operative until discharge. Total blood volume drawn within one week will not exceed 150mL for patients ≥7 years of age and 55mL for patients <7 years of age (~3% total blood volume).~Follow-Up Visits Any complications resulting from surgery will be documented at these routine care visits. These complications will be documented if they occur within 2 years of surgery."
3486950|NCT03741023|Other|Healthy Volunteers|Blood will be taken from healthy, non-pregnant adults who weigh at least 110 pounds by research staff trained in venipuncture at a one-time study visit.
3486951|NCT03740997|Experimental|Patients with body weight ≥20 to ≤28 kg|In children weighing ≥20 to ≤28 kg, 0.1 or 0.2 mL of OPTISON per injection will be given in ascending order. The cumulative dose will not exceed 1.0 mL.
3486952|NCT03740997|Experimental|Patients with body weight >28 to ≤40 kg|If children weigh >28-≤40 kg, 0.2 or 0.3 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.5 mL.
3486953|NCT03740997|Experimental|Patients with body weight >40 kg|For children whose weight is >40 kg, 0.2 or 0.4 mL of OPTISON per injection will be administered in ascending order with total dose not to exceed 1.8 mL.
3486954|NCT03740971|Experimental|Guideline-based therapy+RIC|RIC is given twice a day with 200mmHg pressure.
3486955|NCT03740971|Active Comparator|Guideline-based therapy|
3486956|NCT03740958|Experimental|Argatroban combined with rt-PA|Drug: Argatroban combined with rt-PA Argatroban as a 100 ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
3486957|NCT03740958|Active Comparator|rt-PA|Drug: rt-PA Intravenous throbolysis with 0.9mg/kg rtPA.
3128932|NCT03185546|Experimental|Normal Nicotine Content (NNC) cigarette + moderate nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
3486958|NCT03740945|Placebo Comparator|Placebo|Placebo vaginal ovule daily for 12 weeks
3486959|NCT03740945|Experimental|Prasterone|Prasterone (DHEA) vaginal ovule daily for 12 weeks
3486960|NCT03740932||Study group (group A):|It will consist of 30 subjects who will have cyclic pelvic pain
3486961|NCT03740932||Study group (group B):|It will consist of 30 subjects who will have non cyclic pelvic pain.
3486962|NCT03740932||Control group (group C):|It will consist of 30 subjects normal women who will not having pelvic pain.
3486963|NCT03740919|Experimental|LY900014|LY900014 administered subcutaneously (SC).
3486964|NCT03740919|Active Comparator|Insulin Lispro|Insulin lispro (Humalog) administered SC.
3486965|NCT03740919|Experimental|LY900014 Open Label|LY900014 administered SC.
3486966|NCT03740893|No Intervention|Cohort A (standard care reference cohort)|
3486967|NCT03740893|Experimental|Cohort B (AZD6738 monotherapy)|
3486968|NCT03740893|Experimental|Cohort C (olaparib monotherapy)|
3486969|NCT03740893|Experimental|Cohort D (durvalumab monotherapy)|
3486970|NCT03740880|Active Comparator|Late trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 17 mm
3486971|NCT03740880|Experimental|Early trigger|dual trigger (10.000 IU hCG i.m. and 0.3 mg Deca) once the leading follicle is 14 mm
3486972|NCT03740867|Experimental|Group1|"Those with poor cognition (MOCA score<23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
3486973|NCT03740867|Experimental|Group2|"Those with good cognition (MOCA score≥23)~The patients will receive the Pulmonary Rehabilitation program for 3-months (2 days at hospital, 3 days at home). Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components."
3486974|NCT03740854|Active Comparator|Pressure Controlled Ventilation|Patients undergoing pressure controlled ventilation
3486975|NCT03740854|Active Comparator|Volume Controlled Ventilation|Patients undergoing volume controlled ventilation
3486976|NCT03740841|Other|LUNII|The interactive story teller LUNII is delivered to the child the day before surgery, during the usual pre-operative medical visit.
3486977|NCT03740841|No Intervention|Without LUNII|Usual pre-operative visit.
3486978|NCT03740828||Women undergoing IVF treatment|Device: KIDScore D3 study
3486979|NCT03740815|Experimental|Serratus plane block plus sedation|Serratus plane block plus intravenous sedation as anesthetic technique during axillary dissection procedure.
3486980|NCT03740763|Active Comparator|Spinal Cord Stimulation (SCS)|"Spinal Cord Stimulation (SCS)~Pharmacological analgetic treatment and treatment with SCS for 3 months~Add-on physiotherapy for 6 months to SCS and pharmacological analgetic treatment~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
3486981|NCT03740763|Active Comparator|Physiotherapy|"Physiotherapy~Pharmacological analgetic treatment for 3 months~Physiotherapy for 3 months and pharmacological analgetic treatment~Add-on SCS in combination with physiotherapy and pharmacological analgetic treatment for 3 months~Pharmacological analgetic treatment, SCS treatment and add-on self management physical activity for 12 months"
3486982|NCT03740750|Placebo Comparator|control|sham heat and sham TENS
3486983|NCT03740750|Experimental|heat only|heat applied to the back for 4 hours with sham TENS
3486984|NCT03740750|Experimental|Tens only|Tens applied for 4 hours with sham heat
3128933|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + tobacco flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
3486985|NCT03740750|Experimental|Heat and Tens continuous|Heat and Tens applied together for 4 hours
3486986|NCT03740750|Experimental|Tens 15|Tens applied only 15 minutes each hour for 4 hours, sham heat
3486987|NCT03740750|Experimental|Heat and Tens 15|Heat applied for 4 hours with tens only applied the last 15 minutes of each hour
3486988|NCT03740724|Experimental|FCX-013 + veledimex|Following the injection of FCX-013, subjects will initiate a 14-day course of veledimex to be taken orally daily
3486989|NCT03740711|Experimental|Early LA venting|When detect B-line on serial lung ultrasound, we will perform early LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
3486990|NCT03740711|Active Comparator|Conventional LA venting|When detect refractory pulmonary congestion on chest radiograph or inadequate AV opening on serial echocardiography, we will perform LA venting for improving LV distention in patients with refractory cardiogenic shock who received VA-ECMO support.
3486991|NCT03740698|No Intervention|SAP, open-loop|Sensor augmented pump (combination of insulin pump and continuous glucose monitoring) (open-loop system)
3486992|NCT03740698|Experimental|BiAP, fixed bolus calculator|Bio-inspired Artificial Pancreas (closed-loop system) with a fixed bolus calculator
3486993|NCT03740698|Experimental|BiAP, ABC4D|Bio-inspired Artificial Pancreas (closed-loop system) with the Advanced Bolus Calculator for Diabetes (ABC4D)
3486994|NCT03740685||Patients with acute pancreatitis|All patients will recive different lines of treatment {saline,antibiotics,dexamethasone}
3486995|NCT03740633|Experimental|Study group|Patients in the study group accept functional training and regular care.
3486996|NCT03740633|Active Comparator|Control group|Patients in the control group only accept regular care.
3486997|NCT03740620|Active Comparator|intervention group|In the intervention group, a nasotracheal tube is inserted into the nostril with the bevel of the tube facing the cephalad direction of the patient.
3486998|NCT03740620|Active Comparator|conventional group|In the conventional group, a nasotracheal tube is inserted in a usual way, i.e., with the bevel of the tube facing the left side of the patient.
3486999|NCT03740607|Experimental|Virtual reality during PIV placement|Randomized consented adult subjects will participate in a six-minute healthcare virtual reality software program via Samsung Gear virtual reality headsets while receiving 18 or 20-gauge peripheral intravenous catheter placement in peri-operative suite in preparation for surgery. They will be asked to rate their pain and discomfort afterwards using a graphic rating scale. They will be asked several questions about satisfaction, in order to elicit clinical significance of this intervention. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
3487000|NCT03740607|Placebo Comparator|Standard PIV placement|Adult control arm subjects will receive 18 or 20-gauge peripheral intravenous catheter placement according to current standard protocol, without virtual reality distraction .They will be asked to rate pain and discomfort afterwards using a graphic rating scale. Demographic information will be collected, and baseline vital signs upon arrival to OR will be abstracted retrospectively.
3487001|NCT03740594|Active Comparator|KMC 60 min group|
3487002|NCT03740594|Active Comparator|KMC 120 min group|
3487003|NCT03740594|Active Comparator|control group|
3487004|NCT03740581|Active Comparator|Intensive|New anti-diabetic drug regimen with (mandatory) Insulin >= 3 times per day
3487005|NCT03740581|No Intervention|Conventional|Old anti-diabetic drug regimen with or without Insulin (<3 times per day) to be continued as before
3487006|NCT03740568|Other|Normal Progesterone group|Progesterone level >10.64 ng/mL on day 4 of progesterone supplementation
3487007|NCT03740568|Experimental|Low Progesterone group|Progesterone level <10.64 ng/mL on day 4 of progesterone supplementation
3487008|NCT03740555|Experimental|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose,
3487009|NCT03740555|Placebo Comparator|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose
3487010|NCT03740555|Experimental|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route
3487011|NCT03740555|Placebo Comparator|Placebo, multiple ascending doses|Placebo, multiple ascending doses, Intravenous route,
3487012|NCT03740542|Active Comparator|Esophagectomy with Pyloroplasty|Esophagectomy with Pyloroplasty
3487013|NCT03740542|Experimental|Esophagectomy without Pyloroplasty|Esophagectomy without Pyloroplasty
3487014|NCT03740529|Experimental|Phase I Dose Escalation (LOXO-305) Monotherapy)|Dose Escalation and determination of MTD; multiple dose levels of LOXO-305 to be evaluated
3487015|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 3|CLL/SLL patients with no prior therapy.
3487016|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 1|Non-blastoid MCL patients treated with a prior BTK-inhibitor containing regimen.
3487017|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 4|CLL/SLL patients treated with prior therapy, BTK inhibitor naïve.
3487018|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 2|CLL/SLL patients treated with 2 or more prior regimens, including a BTK inhibitor-containing regimen.
3487019|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 5|WM patients treated with a prior BTK inhibitor-containing regimen.
3487020|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 6|MZL patients treated with a prior BTK inhibitor-containing regimen.
3128934|NCT03185546|Experimental|NNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
3128935|NCT03185546|Experimental|NNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with normal nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
3128936|NCT03185546|Experimental|Very Low Nicotine Content (VLNC) cigarette + moderate nicotine e-liquid + tobacco flavor|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
3487021|NCT03740529|Experimental|Phase 2 (LOXO-305 Monotherapy) Cohort 7|(Not otherwise specified) Defined as CLL/SLL or NHL not otherwise specified in Cohorts 1 through 6, inclusive of CLL/SLL, Richter's transformation, or low grade NHL with transformation, blastoid MCL, and patients with history of CNS involvement or primary CNS lymphoma. In the event the Sponsor electively closes Cohorts 2-4 prior to completion, patients with CLL/SLL who are ineligible to participate in or unable to access late Phase studies of LOXO-305 would remain eligible to enroll in this cohort.
3487022|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm A|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax
3487023|NCT03740529|Experimental|Phase 1b Dose Expansion (LOXO-305 Combination Therapy) Arm B|Relapsed/Refractory CLL will receive the recommended Phase 2 dose of LOXO-305 in combination with Venetoclax and Rituximab
3128937|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid +tobacco flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with very low or nicotine-free nicotine level e-liquid cartridges and can choose from tobacco e-liquid flavors.
3487024|NCT03740529|Experimental|Phase 1 Dose Expansion (LOXO-305 Monotherapy)|Patients to receive the recommended Phase 2 dose of LOXO-305.
3487025|NCT03740477|Experimental|Intrevention|Eligible participants will receive a 30-second smartphone-based ECG
3487026|NCT03740464|Experimental|Study group|Patients in study group accept long-acting granulocyte colony stimulating factor 48 hours from the chemotherapy and regular interventions for myelosuppression.
3487027|NCT03740464|Active Comparator|Control group|Patients in control group only accept regular interventions for myelosuppression rather than long-acting granulocyte colony stimulating factor.
3487028|NCT03740451|Experimental|Experimental group 1|Active mobilization of soft tissues
3487029|NCT03740451|Experimental|Experimental group 2|Passive mobilization
3487030|NCT03740451|No Intervention|Control group|No intervention
3487031|NCT03740425||Transfusion|Patients requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
3487032|NCT03740425||No Transfusion|Patients not requiring blood transfusion after transcatheter aortic valve implantation (TAVI)
3487033|NCT03740412|Experimental|Sedentary behaviour reduction (behaviour change techniques)|Intervention group attending visits 1, 2, 3, 4, 5
3487034|NCT03740412|No Intervention|Usual care|Will receive usual orthopaedic care, attending visits 1, 4, 5
3487035|NCT03740399|Active Comparator|Group sitting|we are performing spinal anesthesia in sitting position pregnant patients
3128938|NCT03185546|Experimental|VLNC cigarette + moderate nicotine e-liquid + variety flavors|Participants are provided with very low nicotine content tobacco Spectrum Cigarettes along with moderate nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors.
3128939|NCT03185546|Experimental|VLNC cigarette + low nicotine e-liquid + variety flavors|Participants are provided with very low or nicotine-free nicotine content tobacco Spectrum Cigarettes along with very low nicotine level e-liquid cartridges and can choose from tobacco and non-tobacco e-liquid flavors
3128940|NCT03186261|Experimental|Nano silver fluoride solution|Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
3128941|NCT03186261|Active Comparator|Cavity Cleanser|Chlorhexidine digluconate 2 % solution (Cavity Cleanser, Bisco, USA). Each tooth will receive two drops of cavity cleanser with a micro brush, equivalent to a dose of 10 mg of the solution.
3128942|NCT03186378|Experimental|Exposure Group|This group is open label and allows for up to 16 subjects with 21 or more molluscum lesions will be enrolled. They must complete all blood draws or will be replaced. Intervention Drug: Subjects will receive treatment to their molluscum contagiosum lesions per protocol with VP-102 using the VP-102 applicator.
3128943|NCT03186378|Experimental|Standard Group|This group is open label allowing up to 16 subjects with 20 lesions or less to be enrolled. Drug: Subjects will receive treatment to their molluscum lesions with VP-102 using the VP-102 applicator.
3487036|NCT03740399|Active Comparator|Group lateral decubitus position|we are performing spinal anesthesia in lateral decubitus position pregnant patients
3487037|NCT03740399|Active Comparator|Group Modified 45-degree head-up tilt|we are performing spinal anesthesia in Modified 45-degree head-up tilt position pregnant patients
3487038|NCT03740386|Experimental|lidocaine|lidocaine 2% 1:80000
3487039|NCT03740386|Experimental|articaine|articaine 4% 1:200000
3487040|NCT03740386|Experimental|bupivacaine|bupivacaine 0,5% 1:200000
3487041|NCT03740373|Experimental|Treatment Sequence 1|Subjects will receive BGF MDI with 10 s breath hold during Treatment Period 1 and BGF MDI with 3 s breath hold during Treatment Period 2
3487042|NCT03740373|Experimental|Treatment Sequence 2|Subjects will receive BGF MDI with 3 s breath hold during Treatment Period 1 and BGF MDI with 10 s breath hold during Treatment Period 2
3487043|NCT03740347||Juvenile idiopathic arthritis and chronic pain|Patients followed for juvenile idiopathic arthritis and chronic pain in Necker Hospital
3128944|NCT03186677|Experimental|Cohort 1|Single intravenous administration of BeneFIX (75 IU/kg) with 72 hours of observation, followed by single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
3487044|NCT03740334|Experimental|Ribociclib (RIBO) + Dexamethasone (DEX)|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15"
3487045|NCT03740334|Experimental|RIBO + Everolimus (EVE) + DEX|"Ribociclib administered daily for 21 consecutive days~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days"
3487046|NCT03740334|Experimental|RIBO + EVE+ DEX (dose expansion)|"Ribociclib administered daily for 21 consecutive days. Dosing at RDE~Dexamethasone administered intravenously on days 1-5 and again on days 11-15~Everolimus administered daily for 21 consecutive days. Dosing at RDE"
3487047|NCT03740321|Experimental|Embospheres 500-700 microns|Intervention.Embolization with 500-700 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
3487048|NCT03740321|Experimental|Embospheres 700-900 microns|Intervention.Embolization with 700-900 micron particles will be performed with 1 ml vials. Embolization procedure will be continued with vials until the stasis in SRAE will be achieved. Procedure will be performed only one time.
3487049|NCT03740308|Active Comparator|Locally Made Zirconia Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions.
3487050|NCT03740308|Experimental|ZR Zirconia Crwons NuSmile ® Crowns|One operator completes all the teeth preparing and restoring procedures. Local anesthesia is achieved using Lidocaine Hydrochloride 2% with Epinephrine 1:100,000. The teeth are then isolated using a rubber dam. After caries excavation, the teeth are prepared according to manufacturer instructions. (Same as Arm 1 Description)
3487051|NCT03740295|Placebo Comparator|Control Multiple Sclerosis|
3487052|NCT03740295|Experimental|Intervention Multiple Sclerosis|
3487053|NCT03740282|Experimental|Lapiplasty|All study participants receiving Lapiplasty procedure
3487054|NCT03740269||oral health educational program|poster for oral health education program for a group of egyptian school girls
3487055|NCT03740256|Experimental|Treatment Phase|"Seven dose levels will be evaluated using the BOIN design. Cohorts of size 3 will be enrolled at each dose level until 9 evaluable patients have been studied at a single dose. Each patient will receive an intratumoral injection of CAdVEC alone or combined with an injection of HER2.CAR.T cells 3 days later (Day 4), according to the following dose levels.~Dose Level 1 CAdVEC = 5.00E+9 HER2 specific CAR-T cells = 0~Dose Level 2 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 0~Dose Level 3 CAdVEC = 1.00E+10 HER2 specific CAR-T cells = 1.00E+06~Dose Level 4 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+06~Dose Level 5 CAdVEC = 1.00E+11 HER2 specific CAR-T cells = 1.00E+07~Dose Level 6 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+07~Dose Level 7 CAdVEC = 1.00E+12 HER2 specific CAR-T cells = 1.00E+08"
3487056|NCT03740243|Active Comparator|buprenorphine|"Buprenorphine 2 mg to 8 mg daily: Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine 8 mg to 16 mg daily: Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
3487057|NCT03740243|Experimental|buprenorphine/naloxone|"Buprenorphine/naloxone 4 mg/1 mg daily once daily or twice daily (BID): Light to moderate history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 5-24~Buprenorphine/naloxone 8 mg/2 mg daily once daily or twice daily (BID): Heavy history of opioid use (heroin, oxycodone, etc.) and/or Clinical Opioid Withdraw Scale (COWS) scores 25-36+"
3128945|NCT03186677|Experimental|Cohort 2|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation
3487058|NCT03740217|Other|Treatment A|Single oral dose of 400 mg GKT137831 administered as 4 x 100 mg capsules in fasting conditions.
3179868|NCT00677300|Active Comparator|Group B|Will receive Tenofovir (300mg once daily) + Emtricitabine (200mg once daily) + Ritonavir-boosted (100mg once daily) Darunavir (800mg once daily)
3179869|NCT00677313|Experimental|1|
3487059|NCT03740217|Other|Treatment B:|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fasting conditions.
3487060|NCT03740217|Other|Treatment C|Single oral dose of 400 mg GKT137831 administered as 1 x 400 mg tablets in fed conditions.
3487061|NCT03740191|Other|Proton Therapy of Prostate Cancer|"Patients with low and intermediate risk are included. The following interventions are performed:~'Expanded Prostate Cancer Index Composite' (EPIC) questionnaire~kV x-ray images~Conebeam CT"
3487062|NCT03740178|Experimental|Donepezil + MK-4334|Oral MK-4334 60/120 mg QD and open-label, oral donepezil 10 mg QD.
3487063|NCT03740178|Placebo Comparator|Donepezil + Placebo|Placebo to MK-4334 QD and open-label, oral donepezil 10 mg QD.
3128946|NCT03186677|Experimental|Cohort 3|Single intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) with 72 hours of observation, followed by single subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) with 120 hours of observation
3128947|NCT03186677|Experimental|Cohort 4|One subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) per day for 6 days with 240 hours of observation
3179870|NCT00677326|Experimental|A|Peptide administered
3487064|NCT03740165|Experimental|Pembrolizumab + Olaparib|Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
3487065|NCT03740165|Experimental|Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
3487066|NCT03740165|Active Comparator|Placebo for Pembrolizumab + Placebo for Olaparib|Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.
3128948|NCT03186677|Experimental|Cohort 5|One intravenous administration of ISU304/CB2679d/Dalcinonacog alfa (75 IU/kg) followed by subcutaneous administration of ISU304/CB2679d/Dalcinonacog alfa (150 IU/kg) once daily for 9 days with 312 hours of observation
3128949|NCT03186781|Experimental|Group 1: HA-F A/Sing (20 mcg), ages 18-47 Yrs|HA-F A/Sing injections (20 mcg) administered intramuscularly (IM) by Needle/Syringe (Day 0) in H2-naïve adults (adults with no pre-existing immunity to H2)
3487067|NCT03740139|Experimental|Intervention|"The Police-Mental Health Linkage System~In the case of an encounter between law enforcement and subjects randomized to this group, the officer will receive a notice disclosing that the participant receives services in a mental health clinic and that he/she has the opportunity to call to speak with a mental health professional."
3487068|NCT03740139|No Intervention|No Intervention|In the case of an encounter between law enforcement and subjects randomized to this arm of the study, the officer will not receive any notice.
3487069|NCT03740126|Experimental|Arm A, PET/CT|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography with computed tomography (FDG PET/CT) replacing computed tomography (CT) at months 6, 12, 18 and 24, otherwise as B with CT scan months 9, 15 and 21. Quality of life assessment and liquid biopsy every 3 months for later analysis.
3487070|NCT03740126|No Intervention|Control arm B|CT-scan and clinical evaluation every 3 months. Quality of life assessment and liquid biopsy at every 3 months for later analysis.
3487071|NCT03740113|Experimental|Kids SipSmartER|Kids SIPsmartER is a 12 session, 6-month program with an integrated two-way short service message (SMS) strategy to engage caregivers in SSB role modeling and supporting home SSB environment changes
3487072|NCT03740113|No Intervention|Control|Control arm receives no intervention
3487073|NCT03740100|Other|Open single arm|Bimiralisib capsules orally
3487074|NCT03740087|Experimental|Omnivorous diet|This group was assigned a meal containing beef (test meal) that consisted of 200 g roast beef with salad (lettuce, tomato, lentils) and a cup of rice.
3487075|NCT03740087|Active Comparator|Vegan diet|This group was assigned a control meal consisted of salad (lettuce, tomato, lentils) and a cup of rice.
3487076|NCT03740074|Experimental|PAI|Participants will utilize a MIO Slice wearable device to generate a PAI score, which will be utilized to provide feedback and incentive for physical activity.
3487077|NCT03740061||Antwerp|
3487078|NCT03740061||Barcelona|
3487079|NCT03740061||Istanbul|
3487080|NCT03740061||Oldenburg|
3487081|NCT03740061||Krakow|
3487082|NCT03740061||Bialystok|
3487083|NCT03740061||Rome|
3487084|NCT03740061||Madrid|
3487085|NCT03740061||Leuven|
3487086|NCT03740048|Experimental|Hemodialysis and Pharmacologic Therapy|Hemodialysis regimen at the initiation of dialysis treatment: Twice-weekly hemodialysis plus adjunctive pharmacologic therapy (loop diuretic, potassium-binding agent, and sodium bicarbonate) for six consecutive weeks, continued by thrice-weekly hemodialysis (intervention group)
3128950|NCT03186781|Experimental|Group 2: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
3487087|NCT03740048|Active Comparator|Conventional Hemodialysis Regimen|Hemodialysis regimen at the initiation of dialysis treatment: thrice-weekly hemodialysis
3487088|NCT03740035||Prostate Cancer Patients|Prostate cancer patients that who have been actively receiving care through Wake Forest Baptist Comprehensive Cancer Center and/or satellite clinics over the past two-year period will be using an eHealth for Sedentary Behavior.
3487089|NCT03740022|Active Comparator|ACL plasty|The surgical procedure consists of a ligamentoplasty of the antero crusader ligament (ACL) with the patellar tendon according to a conventional arthroscopic procedure.
3487090|NCT03740022|Experimental|ACL + ALL plasty|The surgical procedure consists of a hamstring ligamentoplasty (DIDT) of the antero crusader ligament (ACL) and anterolateral ligament (ALL) according to a published arthroscopic procedure.
3487091|NCT03739970|Experimental|Investigational Group- Silk Peptide|"Ingredient: Silk Peptide~Type: Yellow granule stick~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
3487092|NCT03739970|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
3487093|NCT03739957|Experimental|BPCO Media Kit|The kit is composed of a Bluetooth pulse oximeter and an APP for Android system downloadable from Google Play and installed on the Android smartphone of the patient from version 4.1 on.
3128951|NCT03186781|Experimental|Group 3A: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 18-47 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
3487094|NCT03739944|Active Comparator|Laparotomic radical hysterectomy|
3487095|NCT03739944|Active Comparator|Laparotomic radical trachelectomy|
3487096|NCT03739944|Active Comparator|Laparoscopic radical hysterectomy|
3487097|NCT03739944|Active Comparator|Laparoscopic radical trachelectomy|
3487098|NCT03739892|Other|stroke patients|stroke patients with upper limb motor deficit receiving standard care of rehab
3487099|NCT03739879|Experimental|Inspiratory muscle training (IMT)|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
3487100|NCT03739853|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice following international recommendations and National requirements for the prescription of biologic therapy[19-22]. Commonly Initial therapy will be with methotrexate alone (15mg/week rising to 25mg/week as tolerated by week 8 of therapy) unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (most commonly sulfasalazine or leflunomide) added or switched to. In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
3487101|NCT03739853|Experimental|Combination csDMARD|Arm 2 - Combination DMARD arm. All participants will be prescribed methotrexate with an additional DMARD (either sulfasalazine or leflunomide) at baseline. Response will be assessed after 12 weeks of therapy using the Minimal Disease Activity (MDA) criteria. Participants who achieve the MDA criteria by week 12 on this combination therapy will continue . Participants who show a significant response by in week 12 (a reduction in tender and swollen joint counts of at least 20%) but do not yet meet the MDA criteria should continue on this therapy for an additional 12 weeks before review. Participants failing to show significant response (reduction in joint counts by less than 20%) by week 12 on this combination therapy or those failing to meet MDA criteria by week 24 will be eligible for rescue therapy
3487102|NCT03739853|Experimental|Early TNF inhibition|Early biologic arm. All participants will be prescribed methotrexate (given weekly) with a TNF inhibitor (adalimumab given every two weeks) at baseline. Treatment with TNF inhibitor will be continued until week 24 at which time the TNF inhibitor will be tapered to week 32. The TNF inhibitor will be stopped completely after week 32 and participants will continue on methotrexate. In case of flare of disease, participants will be eligible for rescue therapy
3487103|NCT03739801|Experimental|Treatment (ramucirumab, liposomal irinotecan[MM-398])|Patients receive ramucirumab IV over 30 minutes and MM-398 IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3487104|NCT03739788|Experimental|BMS-986165|Oral and intravenous administration
3487105|NCT03739762|Experimental|i-STAND|i-STAND participants have a Baseline visit followed by their first Coaching visit. They are offered wristbands that vibrate every 15 minutes to prompt a standing break, standing desks, a workbook and 10 phone-based coaching sessions focused on sitting less and standing more. At 3 months they will participate in a measurement visit. The program ends at 6 months where they wear an activPAL and participate in a measurement. Their coach will provide feedback on their sitting time from the activPAL after all activPAL wears (Baseline, 3, 6 and 12 month). They may also opt in to wear an activPAL at 6 weeks and receive feedback. They will be re-randomized at 6 months, where half will be assigned to intervention boosters (5 more phone coaching sessions / one 9-month optional activPAL wear) before the 12 month time point for a final activPAL wear and final measurement visit. Those not randomized to receive boosters will have no further contact with the study team until the 12 month time point.
3487106|NCT03739762|Active Comparator|Healthy Living control|In this arm, participants have a phone-based Baseline visit followed by their first phone-based Coaching visit. They are not offered any prompting devices or desks, and their coaching sessions focus on a variety of topics related to healthy living, but without a focus on sitting less/standing more. They have 10 phone calls with a health coach. Participants are given a workbook. All content is from Kaiser Permanente Washington and is available to all members. Participants will select topics of interest and review them with their health coach. At 3 months, participants will participate in a measurement visit. The program ends at 6 months where participants will wear an activPAL and participate in a measurement visit. After that, they will not have contact with the study team until 12 months when they will again wear an activPAL and participate in their final measurement visit.
3487107|NCT03739749|Active Comparator|Fascia lata autograft|Arthroscopic superior capsular reconstruction using a fascia lata autograft
3487108|NCT03739749|Active Comparator|Fascia lata allograft|Arthroscopic superior capsular reconstruction using a fascia lata allograft
3487109|NCT03739749|Active Comparator|Achilles tendon allograft|Arthroscopic superior capsular reconstruction using an achilles tendon allograft
3487110|NCT03739749|Active Comparator|Bovine pericardium allograft|Arthroscopic superior capsular reconstruction using a bovine pericardium allograft
3487111|NCT03739749|Active Comparator|Swine dermal xenograft|Arthroscopic superior capsular reconstruction using a swine dermal xenograft
3487112|NCT03739749|Active Comparator|Collagen allograft|Arthroscopic superior capsular reconstruction using a collagen allograft
3128952|NCT03186781|Experimental|Group 3B: DNA A/Sing(4 mg)-HA-F A/Sing(60 mcg), ages 52-70 Yrs|DNA A/Sing injections (4 mg) administered IM by PharmaJet (Day 0); HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Week 16) in H2-exposed adults (may have some H2 immunity)
3128953|NCT03186781|Experimental|Group 4A: HA-F A/Sing (60 mcg), ages 18-47 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-naïve adults (adults with no pre-existing immunity to H2)
3179871|NCT00677339|Active Comparator|1|Active L-arginine plus active vitamin D
3487113|NCT03739736||Combination of TB/HIV prevention activities (A)|Communities in the intervention group (A) were exposed to a combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. In this arm, ART was initiated regardless of CD4 count
3487114|NCT03739736||Standard of care (C)|"The standard of care arm (C) communities have access to TB/HIV testing, care and treatment services (usually at the health facility) and according to national guidelines. TB case finding is passive i.e. relies on individuals to present with symptoms to the health facility."
3487115|NCT03739736||Combination of TB/HIV prevention activities (B)|The intervention in arm B was the same as in arm A, consisting in a package of combination of TB/HIV prevention activities, including active case finding (ACF) for TB and Universal Testing and Treatment for HIV delivered in the community. Differently to arm A, in arm B national guidelines on CD4 count were used for ART initiation. During the trial the thresholds for commencement of ART changed from 500 CD count to 350 CD count and then, in 2016, to universal ART regardless of CD4 count.
3487116|NCT03739697|Active Comparator|spontaneous breathing|spontaneous breathing after adminitration of anesthetics
3487117|NCT03739697|No Intervention|mechanical ventilation|mechanical ventilation after adminitration of anesthetics and neuromuscula blockade
3487118|NCT03739671|Placebo Comparator|Non-vitamin D supplementation|Group not receiving vitamin D supplementation
3487119|NCT03739671|Experimental|Vitamin D supplementation|Group receiving vitamin D supplementation
3487120|NCT03739658|Experimental|Cognitive Based Neuromuscular Education|It will be applied for one hour. There are individual and partner parts. For example, in this training, the athlete will throw the tennis ball up and down on one foot.
3487121|NCT03739658|Experimental|Game Based Education|It will be applied for one hour. There are individual and partner parts. The active game will be played using the Xbox game console and the kinect sensor.
3487122|NCT03739658|No Intervention|Control Group|You will not receive any training. Athletes who continue their training as athletes in the other group.
3487123|NCT03739632|Experimental|10 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10mg/day Study,5mg tablet is to be given orally, twice daily, for 6 weeks
3487124|NCT03739632|Experimental|20 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 20mg/day Study,10mg tablet is to be given orally, twice daily, for 6 weeks
3487125|NCT03739632|Experimental|40 mg of Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 40mg/day Study,20mg tablet is to be given orally, twice daily, for 6 weeks
3487126|NCT03739632|Placebo Comparator|comparator|Placebo tablets is to be given orally, twice daily, for 6 weeks
3487127|NCT03739619|Experimental|Gemcitabine, bendamustine, nivolumab|Patients receive gemcitabine IV over 30 minutes on day 1, bendamustine IV over 30 minutes on days 1 and 2, and nivolumab over 60 minutes IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive nivolumab IV over 60 minutes on day 1. Treatment with single agent nivolumab repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
3487128|NCT03739606|Experimental|Treatment (flotetuzumab)|Patients receive flotetuzumab IV continuously for 28 days. Patients who achieve partial response or stable disease or any clinical benefit (PR, SD) that did not meet CR, CRi, CRh or MLFS criteria receive a second 28-day continuous flotetuzumab IV infusion. Patients who achieve CR/CRi/CRh/MLFS after course 1 or course 2 receive flotetuzumab IV at a 4 days on-3 days off schedule. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3487129|NCT03739580|Experimental|drug-coating balloon|drug-coating balloon (Orchid) intervention
3487130|NCT03739580|Active Comparator|stent deployment|metal bare stent intervention
3487131|NCT03739554|Experimental|CYC065 and venetoclax|CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15 after the venetoclax ramp-up schedule is completed. Venetoclax will be taken daily at a dose that is deemed safe and tolerable after the ramp-up schedule. One cycle will be 28 days or 4 weeks.
3487132|NCT03739541|Experimental|[14C]-Benznidazole|A single dose of 100 mg [14C]-BNZ, orally administered on Day 1 following an overnight fast.
3179872|NCT00677339|Active Comparator|2|Placebo L-arginine plus active Vitamin D
3179873|NCT00677339|Active Comparator|3|Active L-arginine plus placebo vitamin D
3487133|NCT03739515|Experimental|HSCP team|Patients in this arm will receive comprehensive assessment and/or pre-discharge services by an ED-based HSCP team
3487134|NCT03739515|Active Comparator|Routine care|Patients in this arm will receive routine ED care
3487135|NCT03739502|Experimental|HBO arm|
3487136|NCT03739502|No Intervention|non-HBO arm|
3487137|NCT03739489|Active Comparator|rTMS-PSI|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the posterior superior insula right.
3487138|NCT03739489|Active Comparator|rTMS-M1|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the right primary motor cortex.
3487139|NCT03739489|Active Comparator|rTMS-F3|Participants allocated in this arm will receive active repetitive transcranial magnetic stimulation over the left pre frontal dorsolateral cortex.
3179874|NCT00677339|Placebo Comparator|4|placebo L-arginine plus placebo vitamin D
3179875|NCT00677378||EXPERIMENTAL|Children undergoing an endoscopy for retrosternal chest pain, epigastric pain, regurgitation, heart burn or dyspepsia.
3179876|NCT00677378||CONTROL|Children undergoing an endoscopy for reasons not stated in the experimental group condition (i.e. celiac disease, rectal bleeding, polyps, weight loss, malabsorption).
3179877|NCT00677391|Active Comparator|1|
3179878|NCT00677391|Placebo Comparator|2|
3179879|NCT00677404|Experimental|stem cell recipient|the patients with peripheral vascular disease who receive bone marrow derived mono nuclear cells
3487140|NCT03739476|Experimental|Interventional|Quetiapine 25 miligrames 1 hour after surgery and each 12 hours for 3 days
3487141|NCT03739476|Placebo Comparator|control|Placebo 1 hour after surgery and each 12 hours for 3 days
3487142|NCT03739463|Experimental|MAG-DHA|1500 MG of MAG-DHA per day until childbirth or for up to 2 weeks
3487143|NCT03739463|Placebo Comparator|Placebo|1500 MG of oleic acid per day until childbirth or for up to 2 weeks
3128954|NCT03186781|Experimental|Group 4B: HA-F A/Sing (60 mcg), ages 52-70 Yrs|HA-F A/Sing injections (60 mcg) administered IM by Needle/Syringe (Day 0 and Week 16) in H2-exposed adults (may have some H2 immunity)
3487144|NCT03739450|Experimental|Problem Solving Training + Education|Participants in this arm will receive the TBI-specific education intervention and the Problem Solving Training (PST) intervention.
3487145|NCT03739450|Active Comparator|Education|Participants in this arm will only receive the TBI-specific education intervention.
3487146|NCT03739437|Experimental|Mobile Contingency Management|
3487147|NCT03739437|Active Comparator|Standard Care|
3487148|NCT03739424|Experimental|Whole egg powder arm|The whole egg powder arm will be part of our food product intervention. Food products created using whole egg powder will be provided and consumed 10x/week for 9 months. Each food item will contain the equivalent of one whole egg.
3487149|NCT03739424|Active Comparator|Whole milk powder arm|The whole milk powder arm will be part of our food product intervention. Food products created using whole milk powder will be provided and consumed 10x/week for 9 months. These items will have the equivalent amount of protein as the whole egg group. They will be isocaloric in nature.
3487150|NCT03739424|Placebo Comparator|Gelatin arm|The gelatin food products will be a part of our food product intervention. Food products created using gelatin will be provided and consumed 10x/week for 9 months. These items will be isocaloric in nature to the other treatment arms but will not contain additional protein.
3128955|NCT03187002|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS)
3128956|NCT03187002|Active Comparator|Moderate IV Sedation|Fentanyl, versed
3128957|NCT03187119|Experimental|Pictorial Asthma Action Plan|Young people in the Pictorial Asthma Action Plan (PAAP) arm will receive a PAAP generated by their asthma provider using a software program developed for the study. The PAAP will be personalized according to the young person's gender, race, favorite sport/activity, provider's gender, provider's clinic contact details, and hospital in emergency situations. The PAAP contains minimal text, instead illustrating each participant's asthma regimen using pictures, such as color-coded daily controller and rescue inhalers. Each participant will receive multiple copies of their PAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the PAAP.
3128958|NCT03187119|Active Comparator|Written Asthma Action Plan|Young people in the Written Asthma Action Plan (WAAP) arm will receive a WAAP generated by their asthma provider using using the National Heart, Lung, and Blood Institute (NHLBI) template. The WAAP will be personalized according to the young person's treatment plan. Each participant will receive multiple copies of their WAAP, after receiving a brief education session with their provider, outlining the treatment summarized in the WAAP.
3487151|NCT03739411|Experimental|Cohort I (hyperpolarized C13, MRI)|Patients receive hyperpolarized carbon C 13 pyruvate intravenously IV and undergo MRI. The second hyperpolarized 13 C injection/imaging will be started approximately 15 to 60 minutes after the first injection for those who are willing to receive two 13 C injections
3487152|NCT03739411|Experimental|Cohort II (hyperpolarized C13, MRI, radiation, temozolomide)|Patients receive hyperpolarized carbon C 13 pyruvate IV and undergo MRI before standard treatment with radiation therapy and temozolomide and 4 weeks after completion of radiation therapy.
3487153|NCT03739398|Experimental|LUTRONIC GENUS laser with LASEMD laser|
3487154|NCT03739398|Active Comparator|LUTRONIC GENUS laser without LASEMD laser|
3487155|NCT03739385|Experimental|Intergenerational Group|Pre-school children and residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
3487156|NCT03739385|Active Comparator|Peer Group Children|Pre-school children will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
3487157|NCT03739385|Active Comparator|Peer Group Seniors|Residential seniors will receive two weekly exercise training sessions lasting 45 minutes each. All exercise training sessions are conducted by professional exercise coaches and are planned in a progressive and variable manner. The training sessions focus on balance and fundamental movement skills.
3487158|NCT03739385|No Intervention|Control Group Children|Pre-School children will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
3487159|NCT03739385|No Intervention|Control Group Seniors|Residential seniors will be assessed during pre-, post- and follow-up testing procedures but will receive no exercise intervention.
3487160|NCT03739359|Active Comparator|Gas flow 50 L/min|In this group, nasal cannula gas flow will be set at 50 L/min.
3487161|NCT03739359|Experimental|GF:IF=1|In this group, nasal cannula gas flow will be set at each individual patient's own inspiratory flow (GF:IF=1)
3487162|NCT03739359|Experimental|GF:IF=0.5|In this group, nasal cannula gas flow will be set at 50% of each individual patient's own inspiratory flow (GF:IF=0.5)
3487163|NCT03739346|Experimental|Control|Tell, show, do technique
3487164|NCT03739346|Experimental|Intervention|Hypnosis.
3487165|NCT03739333|Experimental|patients with glioblastoma|implementation of 11C-Methionine PET-MRI
3487166|NCT03739294|Experimental|PILOT: 4 puffs once|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms
3487167|NCT03739294|Experimental|PILOT: 4 puffs once a day for 7 days|4 puffs of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms for 7 days
3487168|NCT03739294|Experimental|LARGE: 4 puffs once|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) once
3487169|NCT03739294|Experimental|LARGE: 4 puffs once a day for 7 days|Supra-therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (4 puffs) daily for 7 days
3487170|NCT03739294|Experimental|LARGE: 1 puff once|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 micrograms (1 puff) once
3487171|NCT03739294|Experimental|LARGE: 1 puff once a day for 7 days|Therapeutic inhalation of Fluticasone Furoate/ Vilanterol Trifenatate 184/22 (1 puff) daily for 7 days
3487172|NCT03739281|Other|Nuclear medicine imaging|Patients undergo nuclear medicine imaging with PET/MR and PET/CT.
3128959|NCT03187132|Experimental|Digital Pain Reduction Kit|Participants in the experimental arm will be assigned the digital pain reduction kit consisting of a transcutaneous electrical nerve stimulation unit to be used as needed and a virtual reality headset to be used as needed or at least once a day. Remote clinical support is provided for patients who volunteer information to be viewed by clinicians.
3487173|NCT03739255|Experimental|Cacicol20|One drop of Cacicol20 will be applied 4-6 hours after the surgery, in one of the randomly chosen eye, and thereafter one drop daily until the reepithelialization is completed.
3487174|NCT03739255|Placebo Comparator|Placebo|One drop of conservative free artificial tear (Oculac, Thea Laboratories) will be applied to one eye at the same time when Cacicol20 is instilled to the other eye.
3487175|NCT03739229|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of study vaccine (total dose 0.50 ml at each study vaccine administration).
3487176|NCT03739229|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers at study entry (dose 1) and four weeks post-dose one (dose 2), subjects will receive two, 0.25 ml intranasal doses of placebo (total dose 0.50 ml at each placebo administration).
3487177|NCT03739216||Open label|Open label registry study of patients treated with the ClariFix device for chronic rhinitis.
3487178|NCT03739190|Experimental|Test Condom: Thin NRL Condom|Following randomisation each couple will be given one set of 7 condoms as per randomisation schedule. Couples will return to the clinic site for collection of their next set of condoms on two additional occasions. Each couple will test a maximum of 21 condoms during their participation in the investigation.
3487179|NCT03739190|Active Comparator|Reference condom A: Medium Thickness NRL Condom|
3487180|NCT03739190|Active Comparator|Reference condom B: Thick NRL Condom|
3487181|NCT03739151|Other|Behavioral Obesity Treatment|All participants will receive gold-standard behavioral obesity treatment
3487182|NCT03739138|Experimental|MK-4621/JetPEI™ Monotherapy (Arm 1)|Participants receive MK-4621/JetPEI™ once a week (Q1W) during each 21-day cycle for a maximum duration of 6 cycles.
3487183|NCT03739138|Experimental|MK-4621/JetPEI™ + Pembrolizumab (Arm 2)|Participants receive escalating doses of MK-4621/JetPEI™ Q1W during each 21-day cycle for a maximum duration of 6 cycles in combination with pembrolizumab at a fixed dose 200 mg every 3 weeks (Q3W) for a maximum duration of 6 cycles. Participants may continue on treatment with pembrolizumab after Cycle 6 for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
3487184|NCT03739138|Experimental|Intrahepatic MK-4621/JetPEI™ + Pembrolizumab (Arm 3)|Participants receive MK-4621/JetPEI™ as monotherapy on Day 1 only of the first 21-day cycle (run-in phase). After the run-in phase, participants receive escalating doses of MK-4621/JetPEI™ Q3W in combination with pembrolizumab at a fixed dose 200 mg Q3W for a maximum duration of 5 cycles (Cycles 2-6). Participants may continue on treatment with pembrolizumab for up to 35 cycles (Cycles 7-35, approximately 2 years) from the start of treatment. Dose escalation of MK-4621/JetPEI™ will be based on safety and tolerability.
3487185|NCT03739125|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
3487186|NCT03739125|Placebo Comparator|Placebo|Placebo
3487187|NCT03739112|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
3487188|NCT03739112|Active Comparator|Quadrivalent Comparator Vaccine|Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine
3487189|NCT03739060|Active Comparator|Active TENS group|Conventional transcutaneous electric nerve stimulation
3487190|NCT03739060|Placebo Comparator|Placebo TENS group|0 amperes transcutaneous electric nerve stimulation
3487191|NCT03739047|Experimental|Desensitization with flipped spoon|Children in this study will receive behavioral feeding treatment. This arm will include desensitization.
3487192|NCT03739047|Placebo Comparator|flipped spoon|Children in this study will receive behavioral feeding treatment.
3487193|NCT03739034|Experimental|Lifestyle Medicine|Patients presenting for lifestyle medicine treatment to prevent, arrest or reverse chronic lifestyle related diseases.
3487194|NCT03739021|Experimental|Group 1 (30 participants)|
3487195|NCT03739021|Experimental|Group 2 (30 participants)|
3487196|NCT03738982|Experimental|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
3487197|NCT03738969||Laparotomy group|Patients in this group accepted laparotomic radical hysterectomy for cervical cancer.
3487198|NCT03738969||Laparoscopy group|Patients in this group accepted laparoscopic or robotic radical hysterectomy for cervical cancer.
3487199|NCT03738956|Experimental|Open label clinical trial|NSAID refractory axial spondyloarthritis patients who are eligible after considering inclusion and exclusion crietria will be put on 5 mg tofacitinib BD ,at the end of 1st and 3rd month they will be assessed for safety and efficacy.Those who will not respond will be put on 10 mg tofacitinib BD.All patients will be assessed at the end of 6th month.If any adverse event occur they will be treated accordingly.
3487200|NCT03738943|Experimental|ATP, Ach, SNP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Acetylcholine: 1, 4, 8, and 16 μg/dl forearm volume/min for 3 minutes each.~Sodium Nitroprusside: 0.25, 0.5, 1, and 2 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
3487201|NCT03738943|Experimental|ATP, ADP, AMP|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine Diphosphate: 20, 40, 80, and 160 μg/dl forearm volume/min for 3 minutes each.~Adenosine Monophosphate: 25, 50, 100, and 200 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
3487202|NCT03738943|Experimental|ATP, UTP, Adenosine|"All drugs will be administered via intra-arterial (brachial artery) infusion, and the dosages below will be administered two times: once before administration of Vitamin B6 (pyridoxine) and once following administration of the Vitamin B6 (pyridoxine) loading dose.~Adenosine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Uridine Triphosphate: 1.25, 2.5, 5, and 10 μg/dl forearm volume/min for 3 minutes each.~Adenosine: 3.125, 6.25, 12.5, and 25 μg/dl forearm volume/min for 3 minutes each.~Vitamin B6 (pyridoxine): up to 200 mg of pyridoxine will be infused over 20 minutes. A maintenance dose of 2.5 mg/min may be used throughout the remainder of the protocol.~Pyridoxal-5-Phosphate (PLP) may be used as an alternative blocker instead of pyridoxine. It will be infused at doses up to 200 µg/dl forearm volume/min."
3487203|NCT03738930|No Intervention|normal follow-up group|normal follow-up in ACS patients after PCI
3487204|NCT03738930|Experimental|AI based mHealth system follow-up group|AI based mHealth system follow-up in ACS patients after PCI. ACS patients in this group will receive message to take more notice to bleeding events.
3487205|NCT03738917|Active Comparator|Dextromethorphan|Usual clinical practice + dextromethorphan (15 milligrams unit), one 15 mg-tablet t.i.d. up to a maximum of 14 days.
3487206|NCT03738917|Active Comparator|Ipratropium|Usual clinical practice + ipratropium bromide 20Micrograms Inhaler each puff), 2 puffs t.i.d. up to a maximum of 14 days.
3487207|NCT03738917|Active Comparator|Honey|Usual clinical practice + Honey 30 g (full tablespoon) t.i.d. up to a maximum of 14 days. Patients will be given two 750 milligram bottles of wildflower honey (the most frequent type of honey used in our country) and patients will be recommended to add the honey to a cup of lemon or thyme juice, milk herbal tea, yogurt, as a hot toddy, etc.
3487208|NCT03738917|Placebo Comparator|Usual clinical practice|Usual care.
3487209|NCT03738891|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the abdomen.
3487210|NCT03738878|Active Comparator|valsartan then LCZ696|"After four-week treatment with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
3487211|NCT03738878|Active Comparator|LCZ696 then valsartan|"After four-week treatment with LCZ696, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin.~Then, after three-week washout and four week therapy with valsartan, participants will receive intra-arterial infusions of bradykinin, substance P, and BNP in the presence and absence of sitagliptin."
3487212|NCT03738852|Experimental|Aim 3: Type 1 diabetes mellitus user unaware subjects 3 months|Continuous Glucose Monitor for 3 months duration
3487213|NCT03738852|Experimental|Aim 1: Impact of hypoglycemia on brain connectivity Type 1|Healthy controls, T1 aware, and T1 unawares
3487214|NCT03738852|Experimental|Aim 2: Impact of hypoglycemia on brain glucose transports in Type 1|Healthy controls, T1 aware, and T1 unawares
3487215|NCT03738839|Experimental|Direct Bonding|On the individual teeth Conventional bracket placement Use conventional composite
3487216|NCT03738839|Experimental|Indirect bonding|On the dental stone models Indirect bracket placement Use flowable composite Use transfer trays
3487217|NCT03738839|Active Comparator|Quantitative Light-Induced Fluorescence|Use special device and software Determination of the number and effect of caries
3487218|NCT03738813|Experimental|Treatment Group|"The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.~In Treatment Group, the movements will be performed using Gloreha ARIA. Gloreha Aria is a sensor-based therapy device designed for motor recovery of impaired upper limb. Gloreha Aria is equipped with sensors that can detect any movements in space: the software processes and displays them on the screen."
3487219|NCT03738813|Active Comparator|Participants Usual Care (PUC)|The specific hand intervention consisted of 30 sessions, lasting 60 min/ day, for 6 days/week. All patients will be educated by physiotherapist to perform the movements for wrist, hand and arm in complete autonomy.In Control Group, these activates will be performed without any device.
3487220|NCT03738800|Experimental|CD5789 Cream 200 µg/g|CD5789 200 µg/g, topical, 50g
3487221|NCT03738800|Experimental|CD5789 Cream 100 µg/g|CD5789 100 µg/g, topical, 50g
3487222|NCT03738800|Placebo Comparator|CD5789 Cream Vehicle|CD5789 Cream Vehicle, topical, 50g
3487223|NCT03738787|Experimental|Pancreatic duct occlusion|Patients considered at high risk for pancreatic fistula or oncological relapse due to introperative evaluation submitted to pancreatic duct occlusion with Neoprene-based glue.
3487224|NCT03738787|Active Comparator|Pancreato-Jejunal anastomosi|Patients considered at low risk for pancreatic fistula submitted to pancreato-jejunal anastomosis.
3487225|NCT03738761|Experimental|Amlessa® Arm|Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.
3487226|NCT03738761|Experimental|Co-Amlessa® Arm|Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.
3487227|NCT03738748|Experimental|Ultrasound-guided Percutaneous Neuromodulation|This group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L3 (1 times/ 4 weeks).
3487228|NCT03738748|Active Comparator|TENS therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region (1 times/ 4 weeks).
3487229|NCT03738735|No Intervention|Control|Patients will receive standard of care lactated ringer's solution for the arthroscopic irrigation during surgery.
3487230|NCT03738735|Experimental|Intervention|Patients will receive hyperosmolar saline for the arthroscopic irrigation during surgery.
3487231|NCT03738722|Experimental|High-flow-nasal-cannula-therapy (HFNCT)|100% Oxygen at 80 l/min with flow reductions of 20 l/min, jaw thrust, with opened and closed mouth, using different flow rates (80l/min, 60l/min, 40l/min, 20l/min, 1l/min) within each subject.
3487232|NCT03738709|Experimental|Occupational therapy group sessions|In the collective experimental group, the care includes 6 group sessions of one hour each, programmed over 2 weeks and progressive courses.
3487233|NCT03738709|Active Comparator|Individual Occupational therapy sessions|In the individual control group, care consists of 6 individual sessions of 45 minutes each, not programmed over 2 weeks and progressive courses.
3487234|NCT03738670|Experimental|RFA|Single-arm prospective observational study
3487235|NCT03738657||Screening|Olfactory screening
3487236|NCT03738657||On Study|Taste testing
3487237|NCT03738605|Experimental|Laser Group|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
3487238|NCT03738605|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
3128960|NCT03187132|Active Comparator|Active Control|Participants in the active control arm will receive standard of care as provided by their physician in addition to a transcutaneous electrical nerve stimulation unit.
3487239|NCT03738592|Experimental|cochlear implant children|18 cochlear implant children wil include in this study
3487240|NCT03738592|Other|normal hearing children|18 normal hearing children wil include in this study
3487241|NCT03738579|Active Comparator|Control Group|After standard of care debridement and irrigation (using normal saline), Mepilex foam dressing will be used. Foam dressing will be used throughout the study, including for mid-week dressing changes.
3487242|NCT03738579|Active Comparator|Antibacterial Control|After standard of care debridement and irrigation (using normal saline), Mepilex AG foam dressing will be used. This dressing will be used throughout the study, including for mid-week dressing changes.
3487243|NCT03738579|Experimental|Next Science Group|Standard of care debridement will be performed as well as irrigation using TorrentX Wound Wash,then BlastX Wound gel will be applied to the wound before covering treatment site with Mepilex foam dressing (no AG component). BlastX will re-applied again mid-week during mid-week dressing change.
3487244|NCT03738566|Other|Endoscopic Dilation|Patients randomized to the observation group will undergo repeat upper endoscopy with dilation as needed if their dysphagia relapses. A relapse will be considered if a patient developed solid food dysphagia at least once a week.
3487245|NCT03738566|Active Comparator|Esophageal Self Dilation|Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months.
3487246|NCT03738540|Experimental|Experimental|This is the experimental arm of the study. This includes 25 weekly then biweekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
3487247|NCT03738540|Active Comparator|Control|This is the control arm of the study. This includes This includes 25 weekly then biweekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
3487248|NCT03738527|Experimental|TXA arm|
3487249|NCT03738527|Placebo Comparator|Placebo arm|
3128961|NCT03187197||Cohort A|consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
3487250|NCT03738514|Active Comparator|Group 1|dentifrice containing 5% fluorocalcium phospho silicate prescribed and VAS score assessed at Baseline, 2 weeks, 6 weeks.
3487251|NCT03738514|Sham Comparator|Group 2|dentifrice containing 5% potassium nitrate prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
3128962|NCT03187197||Cohort B|patients being newly diagnosed with NVAF and initiated on Pradaxa®
3128963|NCT03187262|Experimental|Daratumumab|"Daratumumab will be administered in three phases: Induction, consolidation and maintenance~During induction, participants will receive daratumumab on days 1, 8, 15 and 22 of each 28-day~During consolidation, daratumumab will be administered on days 1 and 15 of each 28-day cycle~During maintenance, daratumumab will be administered on day 1 of each 28-day cycle"
3128964|NCT03187301|Experimental|APL-130277|APL-130277 at the dose determined in the dose titration phase
3128965|NCT03187301|Placebo Comparator|Placebo|Placebo
3128966|NCT03187301|Active Comparator|moxifloxacin|moxifloxacin at a single 400mg dose
3128967|NCT03187418|Experimental|Micropulse trans-scleral CPC|A treatment session of micropulse trans-scleral cyclophotocoagulation in the affected eye, using the MicroPulse® P3 Glaucoma Device (MP3) powered by the CYCLO G6™ Glaucoma Laser System (Iridex, Mountain View, CA, USA).
3487252|NCT03738514|Placebo Comparator|Group 3|dentifrice without the active ingredient prescribed and VAS score assessed at Baseline, 2weeks, 6 weeks .
3487253|NCT03738501|Experimental|Chest physiotherapy with SET|Chest physiotherapy will be provided by a single physiotherapist not involved in outcomes assessment. Airway clearance technique will be Slow Expiratory Technique (SET). SET is a slow modulation of airflow in order to remove bronchial secretions within infants lungs. Experimental group will also benefit for standard medical and non-pharmacological care (e.g Standard Treatment)
3487254|NCT03738501|Active Comparator|Standard treatment|Medical treatment, health education for parents, rhinopharyngeal clearance using isotonic saline solution, advices.
3487255|NCT03738488|Experimental|3D printing + images|Surgery planification with the combination of all the images available and a 3D biomodel printed from that images.
3487256|NCT03738488|Active Comparator|Images|Surgery planification with all the images available
3487257|NCT03738449|Experimental|Group 1|"Period 1: D484~Period 2: CKD-387"
3487258|NCT03738449|Experimental|Group 2|"Period 1: CKD-387~Period 2: D484"
3487259|NCT03738436|Active Comparator|traditional neuromuscular training, NMT|Eight-week physical therapy program consisted of neuromuscular training (NMT) starting from 4 weeks post-surgery. The NMT program includes re-position exercise, strengthening, stretching, landing and balance training.
3487260|NCT03738436|Experimental|modified visual feedback, MVF|Starting from 4 weeks post-surgery, eight-week physical therapy program consisted of traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles.
3487261|NCT03738423|Experimental|Treatment 1|
3487262|NCT03738423|Experimental|Treatment 2|
3487263|NCT03738423|Experimental|Treatment 3|
3487264|NCT03738423|Experimental|Treatment 4|
3487265|NCT03738423|Experimental|Treatment 5|Matching placebo
3487266|NCT03738397|Experimental|Participants administered with upadacitinib|Participants are administered with upadacitinib from baseline to week 24 and placebo pre-filled syringe at baseline visit (2 injections) followed by an injection every other week until week 22
3487267|NCT03738397|Experimental|Participants administered with dupilumab|Participants are administered with dupilumab (2 injections) at baseline followed by one every other week until week 22 and placebo tablets daily from baseline to week 24
3487268|NCT03738384|Experimental|TKR Patients|Any patient 3-6 weeks post-op from a TKR
3487269|NCT03738371||Team of health professionals|Team of health professionals involved in thrombectomy (including specialized nurses in anesthesiology, anesthesiologists, neuroradiologist and technicians specialized in electro-radiology) will participate to in situ simulation.
3487270|NCT03738358|Experimental|Trehalose|
3487271|NCT03738358|Placebo Comparator|Placebo|
3487272|NCT03738345|Experimental|Oxygenation on hypoxemia patients|Adult patients with hypoxemia will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then patients will be placed on high flow nasal cannula (HFNC), HFNC flow will be titrated based on the hospital's policy or protocol and patient's comfort, patient's clinical effects on oxygenation will be monitored and recorded during the titration process.
3487273|NCT03738345|Experimental|Lung expansion on healthy volunteer|Adult healthy volunteers will be recruited, their own breathing profiles (inspiratory flow, respiratory rates and tidal volume) will be measured. Then they will be placed on HFNC, HFNC flow will be increased sequentially by research protocol and their comfort, subjects' lung expansion effects in different flow will be quantified by Electrical impedance tomography (EIT), a noninvasive assessment tool. Their comfort will also be assessed using a visual scale.
3487274|NCT03738332|Other|Low-level laser therapy|Single arm
3487275|NCT03738319||HGSOC group|This group includes patients of high grade serous ovarian cancer (HGSOC).
3128968|NCT03187678|Experimental|Selexipag|Subjects with stable pulmonary arterial hypertension (PAH) and currently treated with a stable oral dose of Uptravi will be switched to i.v. selexipag from Day 2 to Day 3 (2 infusions on Day 2 and 1 infusion on Day 3). Otherwise, they will continue with their current oral selexipag treatment throughout the study.
3487276|NCT03738319||Control group|This group includes patients of benign gynecologic diseases as control.
3487277|NCT03738306|Experimental|Mezieres Method|The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
3487278|NCT03738306|Active Comparator|Conventional Physiotherapy|The treatment with conventional physiotherapy will include stretching of hamstrings, gluteus, (and others) hot pack, transcutaneous electrical nerve stimulation, ultrasound and some exercises of core performance.The time of treatment will be of 1 hour, two times a week, during 5 weeks.
3487279|NCT03738254|Active Comparator|Paper PRO|Participants in the Paper PRO arm completed daily patient reported outcome diaries on paper
3487280|NCT03738254|Active Comparator|ePRO|Participants in the ePRO arm completed daily patient reported outcome diaries online via a smartphone app.
3487281|NCT03738254|Experimental|Game-Motivated ePRO|Participants in the Game-Motivated ePRO arm completed daily patient reported outcome diaries online via a smartphone app. These participants were also given access to a game that rewarded the participant with an in-game reward that helped the participant complete various in-game quests.
3487282|NCT03738202|Experimental|Intervention|Multifaceted intervention package will be implemented at textile mills in the intervention arm.
3487283|NCT03738202|No Intervention|Control|No intervention will be provided to mills in the control arm.
3487284|NCT03738176|Experimental|sesame oil in orabase|20 gm sesame oil-80 gm CMC 3 times per day for one month
3487285|NCT03738176|Active Comparator|triamcinolone in orabase|140 gm triamcinolone-50 gm Na CMC 3 times per day for one month
3487286|NCT03738150|Experimental|Sotatercept|Each participant will receive standard of care (SOC) plus sotatercept at a dose of 0.3 mg/kg SC for Cycle 1. Dose will escalate to 0.7 mg/kg SC at Cycle 2 through the remainder of the treatment period. Dosing will be every three weeks during the 24 weeks Treatment Period and every three weeks during the 18 month Extension Period.
3487287|NCT03738137|Experimental|Narcotrend|After 0.1µg/kg sufentanil is applied, miidazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by the Narcotrend index stage C.
3487288|NCT03738137|Experimental|BIS|After 0.1µg/kg sufentanil is applied, midazolam is given by non-anaesthetist physicians to achieve moderate levels of sedation as assessed by bispectral index (BIS; between 70 and 85).
3487289|NCT03738137|Experimental|No monitoring|After 0.1µg/kg sufentanil is applied, midazolam iss given by non-anaesthetist physicians according to patient's tolerance .
3487290|NCT03738137|Experimental|Lidocaine|Only topical anesthesia was applied.
3128969|NCT03187730|Active Comparator|Intervention Arm|
3128970|NCT03187730|Placebo Comparator|Waitlist Control|
3487291|NCT03738124|Experimental|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA Thoracic Stent Graft System is administered.
3128971|NCT03187756|Experimental|Cyclophosphamide|
3487292|NCT03738111|Experimental|TG02 Citrate|TG02 citrate capsules given orally.
3487293|NCT03738072|Experimental|StiMic stimulation condition|StiMic stimulation condition will be evaluate during stereo-electro-encephalography and this condition will be compare to standard stimulation condition
3487294|NCT03738059|Placebo Comparator|group I (placebo)|will receive intravenous normal saline (NS)
3487295|NCT03738059|Experimental|group II (Dex 0.5)|will receive intravenous Dex 0.5 mcg/kg
3487296|NCT03738059|Experimental|group III (Dex 0.25)|will receive intravenous Dex 0.25 mcg/kg
3128972|NCT03188055|Experimental|Best Case/Worst Case communication tool|The patient's enrolled surgeon will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the patient.
3128973|NCT03188055|No Intervention|Usual Care|Usual care typically includes informed consent and a surgeon-directed deliberative phase in which surgeons present their own evaluation of the trade-offs and goals of the proposed intervention.Usual care also consists of daily updates with patient and family, describing each new problem as it arises and what will be done to treat it, regardless of how this fits into the patient's overall prognosis or health trajectory.
3487297|NCT03738059|Experimental|group IV (Dex 0.2)|will receive intravenous Dex 0.2 mcg/kg.
3487298|NCT03738046|Experimental|Pilot Treatment Arm|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules-will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module-Stress Coping-will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
3487299|NCT03738033||use of the educational platform|Before the hand-on practice and assessements, the participants use the platform for learning.
3487300|NCT03738033||without use of the educational platform|Before the hand-on practice and assessements, the participants did not use the platform for learning.
3487301|NCT03738007|Experimental|HA IDF II|
3487302|NCT03738007|Active Comparator|Perlane|
3487303|NCT03737968|Experimental|Durvalumab monotherapy Arm|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg.
3487304|NCT03737968|Active Comparator|Durvalumab + tremelimumab combination therapy Arm|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months until confirmed disease progression unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. The first durvalumab (MEDI4736) monotherapy dose at 1500mg Q4W will be within 8 weeks after the completion of adjuvant therapy.
3487305|NCT03737942||control group|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
3487306|NCT03737942||T2DM without neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
3487307|NCT03737942||T2DM with neuropathy|"Motor nerve conduction studies:~Were done on right ulner, right median, right common peroneal, and right anterior tibial nerves F-wave (for Median, Ulnar and common peroneal nerves) H-reflex study"
3487308|NCT03737929|Experimental|Hybrid ablation procedure|In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.
3487309|NCT03737929|Active Comparator|Percutaneous endocardial catheter ablation procedure|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).
3487310|NCT03737916|Experimental|dextrose group|"Procedure: Ultrasound-guided perineural injection with 5% dextrose. Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: 5% Dextrose 5% Dextrose could decrease the release of CGRP (Calcitonin Gene Related Peptide) and substance P to reduce the nerve inflammation"
3487311|NCT03737916|Placebo Comparator|control group|"Procedure: Perineural injection with normal saline Ultrasound-guided perineural injection with normal saline (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).~Drug: Normal Saline Normal saline is safe for perineural injection."
3487312|NCT03737890|Experimental|Inspiratory muscle Training|4 weeks of inspiratory muscle training
3487313|NCT03737890|Active Comparator|Hold Relax Pectoral Stretch|4 weeks of hold relax pectoral stretch
3487314|NCT03737877|Experimental|Diet modification|
3487315|NCT03737864|Active Comparator|Motivational Interview|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
3128974|NCT03188120||Spiriva Respimat group|
3128975|NCT03188185|Experimental|ALKS 5461|Sublingual tablets
3128976|NCT03188185|Placebo Comparator|ALKS 5461 Placebo|Sublingual tablets
3487316|NCT03737864|Experimental|Patient navigation and MI|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification plus patient navigation for 30 days, or until the patient is successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
3487317|NCT03737825|Active Comparator|Program 1|Computerized gaming rehabilitation Program 1.
3487318|NCT03737825|Placebo Comparator|Program 2|Computerized gaming rehabilitation Program 2.
3487319|NCT03737786|Active Comparator|GA with mild hypercarbia (GAH)|Controlled ventilation with target end-tidal CO2 levels 50 (±5%)
3487320|NCT03737786|Active Comparator|GA with normocarbia (GAN)|Controlled ventilation with target end-tidal CO2 levels 40 (±5%)
3487321|NCT03737773|Active Comparator|group prisms|Patients that receive active prismatic lenses
3487322|NCT03737773|Placebo Comparator|group placebo lenses|Patients that receive non-active prismatic lenses
3487323|NCT03737734|Experimental|DaRT Seeds|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seeds
3128977|NCT03188263|Experimental|Bright Light|Irradiance is 230 μW/m2 and lux is 500 lux.
3128978|NCT03188263|Placebo Comparator|Dim Light|irradiance is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
3487324|NCT03737721|Experimental|Avelumab and Radical radiotherapy|Single-arm combining Avelumab with radical radiotherapy.
3487325|NCT03737708|Experimental|tacrolimus + biologics|Participants will receive tacrolimus daily for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
3128979|NCT03188523|Experimental|MK-8504 100 mg (Panel A)|Participants receive a single oral dose of MK-8504 100 mg.
3128980|NCT03188523|Experimental|MK-8504 240 mg (Panel B)|Participants receive a single oral dose of MK-8504 240 mg.
3487326|NCT03737708|Active Comparator|methotrexate + biologics|Participants will receive methotrexate weekly for 12 weeks. In addition, each participant will be administered one of adalimumab, tocilizumab, or abatacept for 12 weeks.
3487327|NCT03737695||Ancillary-Correlative (biospecimen, clinical info collection)|Patients' archival and newly collected tissue and blood samples are collected periodically for genetic testing. Patients also undergo collection of clinical information within 30 days of biopsy procedure and every 4 months.
3487328|NCT03737682||hemostasis achievement|in which hemostasis at the exposure site was achieved in five minutes were included in group A
3487329|NCT03737682||No hemostasis achievement|in which hemostasis at the exposure site couldn't be achieved in five minutes where included in group B
3487330|NCT03737669|Experimental|Mirasol-treated Fresh Whole Blood|Standard Fresh Whole Blood, treated with Mirasol Pathogen Reduction Technology
3487331|NCT03737669|Placebo Comparator|Standard Fresh Whole Blood|Standard-issue fresh whole blood
3487332|NCT03737656|Experimental|Progesterone Vaginal Ring (Group A)|Insertion of the vaginal ring on Day 1 and continuous use until 91 days of treatment are completed. In this group, 28 participants will be included.
3128981|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel C)|Participants receive a single oral dose of MK-8504 ≤240 mg.
3128982|NCT03188523|Experimental|MK-8504 ≤240 mg (Panel D)|Participants receive a single oral dose of MK-8504 ≤240 mg.
3128983|NCT03188536||Multiple Myeloma (MM) Participants|Adult participants with a diagnosis of MM who received at least one previous treatment line (standard care of treatment) and experienced symptomatic relapse and/or refractory disease in the previous 6 months, who were followed-up at the time of the study visit. No intervention was administered in this study.
3128984|NCT03188718|Other|WatchPAT Intervention|Wearing the WatchPAT device simultaneously while receiving a clinically indicated sleep study (polysomnogram).
3128985|NCT03188991|Experimental|Dose Escalation: NanoPac® 6 mg/mL|Single intracystic injection of NanoPac® at a dose of 6 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
3128986|NCT03188991|Experimental|Dose Escalation: NanoPac® 10 mg/mL|Single intracystic injection of NanoPac® at a dose of 10 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
3128987|NCT03188991|Experimental|Dose Escalation: NanoPac® 15 mg/mL|Single intracystic injection of NanoPac® at a dose of 15 mg/mL in a volume sufficient to fill the cyst, at least equal to the amount of cyst fluid aspirated
3128988|NCT03188991|Experimental|Second Phase: NanoPac® at Best Dose|Intracystic injection of NanoPac®. The dose administered in the second phase will be determined during the dose escalation phase. Subjects will receive two NanoPac® injections, with the second injection administered 12 weeks after the first injection.
3128989|NCT03189134|Experimental|Imaging arm|Up to 5mL of 1:1000 dilute FLUORESCITE will be applied to cardiac tissue prior to imaging with Cellvizio 100 Series System with Confocal Miniprobes
3128990|NCT03189446|Experimental|Vaginal Cuff Brachytherapy + Chemotherapy|Vaginal cuff brachytherapy followed by Carboplatin (AUC 6) on day 1and Paclitaxel 80 mg/m2 IV over 1 hour days 1, 8, and 15 X 3 total cycles
3128991|NCT03189524|Experimental|Part I: 160 mg BID|"Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]) administered in the morning and at night, or 320 mg (once daily [QD]), and a 3+3 design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D)."
3128992|NCT03189524|Experimental|Part I: 320 mg QD|"Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a 3+3 design was adopted for Part I of the study to determine RP2D."
3128993|NCT03189524|Experimental|Part II: 160 mg BID|Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).
3128994|NCT03189589|Experimental|GSK2269557 500 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.
3128995|NCT03189589|Experimental|GSK2269557 750 µg receivers|Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.
3128996|NCT03189719|Experimental|Pembrolizumab + SOC|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) plus standard of care (SOC) chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
3132758|NCT03449147|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet BID and placebo tablet to match gefapixant 15 mg BID during the 24-week main study period and during the 28-week extension period.
3487333|NCT03737656|Experimental|Progesterone Vaginal Ring (Group B)|Insertion of the vaginal ring on Day 1, removal for 2 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
3487334|NCT03737656|Experimental|Progesterone Vaginal Ring (Group C)|Insertion of the vaginal ring on Day 1, removal for 4 hours on study Day 28, re-insertion on Day 28, and continuous use for 63 days until 91 days of treatment are completed. In this group, 6 participants will be included.
3487335|NCT03737630|Experimental|GExp|This group will perform the inspiratory muscle training with moderate load
3487336|NCT03737630|Active Comparator|GCon|This group will initiate inspiratory muscle training with low load
3487337|NCT03737617|Experimental|Active arm|Weekly subcutaneous immunoglobulin therapy (0.1g/Kg) Cuvitru 20% Injectable Solution for 1 Year
3487338|NCT03737617|No Intervention|Control|Standard Care arm without immunoglobulin replacement therapy
3487339|NCT03737604|Active Comparator|Ropivacaine Continuous Infusion Catheter|Ropivacaine Continuous Infusion Catheter: ultrasound guided TAP block and TAP catheter placement performed with 0.2% ropivacaine (2.5 mg/kg) and maintained with 0.2% ropivacaine infusion 8 ml/hour via catheter.
3487340|NCT03737604|Active Comparator|Single dose liposomal bupivicaine|Liposomal bupivacaine TAP block: ultrasound guided TAP block a performed with up to 12 ml 0.25% bupivacaine and prolonged with liposomal bupivacaine 133 mg diluted to total volume of 20 ml with preservative free saline.
3487341|NCT03737591||Healthy individuals|Healthy individuals
3487342|NCT03737591||Patients with Colorectal cancer|Stage I-IV colorectal cancer patients
3487343|NCT03737591||Patients with Colorectal Adenomas|Patients with Colorectal Adenomas
3487344|NCT03737578|Experimental|Daily hemodialysis patients|"Description: End stage renal disease patients starting daily hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
3487345|NCT03737578|Active Comparator|Conventional hemodialysis patients|"Description: End stage renal disease patients currently treated by conventional hemodialysis or starting conventional hemodialysis treatment.~Interventions: Delivery of a connected pedometer / accelerometer and Quality Of Life and Restless Leg Syndrome questionnaires."
3487346|NCT03737565||Coronary Artery Disease|
3487347|NCT03737552||Children and adolescents with ADHD|Children and Adolescents with ADHD children or Adolescents, male or female, ages 6-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
3487348|NCT03737552||Healthy control children and adolescent|children or Adolescents, male or female, ages 6-17,medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 1 night of polysomnography at sleep lab and a neuropsychological and quality of life assessment in the lab.
3487349|NCT03737539||Stage II colorectal cancer|Patients diagnosed with stage II colorectal cancer
3487350|NCT03737539||Stage III colorectal cancer|Patients diagnosed with stage III colorectal cancer
3487351|NCT03737500|Active Comparator|Standard silicone-based breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)
3487352|NCT03737500|Experimental|B-Lite® light weight breast implant|Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant
3487353|NCT03737474|Experimental|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
3487354|NCT03737448|Experimental|Group 1|"AD with serum creatinine ≥ 1 and < 2 mg/dL, OR~ACLF 1 with~liver failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~liver failure and West Haven grade 1-2 hepatic encephalopathy, or~coagulation failure and serum creatinine ≥ 1.5 and < 2 mg/dl, or~coagulation failure and West Haven grade 1-2 hepatic encephalopathy, OR~ACLF 2 with~liver failure and coagulation failure, or~liver failure and West Haven grade 3-4 hepatic encephalopathy."
3487355|NCT03737448|Experimental|Group 2|"ACLF 1 with renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), OR~ACLF 2 with~liver failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL), or~coagulation failure and renal failure (serum creatinine ≥ 2.0 and < 3.5 mg/dL)."
3132759|NCT03449342|Experimental|Turoctocog alfa|Previously treated moderate or severe haemophilia A patients will receive routine prophylaxis treatment and treatment of bleeding episodes.
3487356|NCT03737422|Active Comparator|hesperidin and flaxseed|
3487357|NCT03737422|Placebo Comparator|control|
3487358|NCT03737409|Experimental|Oxygen therapy with POC (AOT group)|Patients will receive ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
3487359|NCT03737409|Sham Comparator|Sham oxygen therapy with POC (air group)|Patients will receive sham ambulatory oxygen therapy provided by a portable oxygen concentrator and will be encouraged to use it at all times when they are moving about, including walking at home or in the community, during exercise or during other activities.
3487360|NCT03737396|Active Comparator|Electronic health screening|Self-administered electronic health screening on tablet
3487361|NCT03737396|No Intervention|Paper-based health screening|Routine-care nurse-administered, paper-based health screening
3487362|NCT03737383|Experimental|Feasibility and Preliminary Efficacy|We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes.
3487363|NCT03737370|Experimental|Dose escalation|"There are four dose cohorts (1, 1a, 2, 2a) in this arm and two dose levels of docetaxel (40mg/m^2 [level 1] and 50mg/m^2 [level 2]). Dosing of Radium 223 remains the same in all cohorts (55 KBq/kg given every 28 days for 6 cycles).~Maximum tolerated dose (MTD) of docetaxel will be assessed. MTD is defined as the highest dose-level, among those tested, associated with a rate of less than a 33% dose limiting toxicity (DLT)."
3487364|NCT03737370|Experimental|Dose expansion|If the maximum tolerated dose (MTD) of docetaxel is found in arm 1, this dose level will be expanded to include an additional 25 subjects to confirm the safety and explore the preliminary anti-cancer effect. If the MTD is not identified, the study will be stopped and the expansion cohort will not be accrued.
3487365|NCT03737357|Experimental|SLActive® implant|
3487366|NCT03737357|Active Comparator|SLA® implant|
3487367|NCT03737344|Active Comparator|IL-1Ra Kineret®|100mg doses of the trial drug Kineret® will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
3487368|NCT03737344|Placebo Comparator|IL-1Ra Placebo|100mg doses of the placebo will be administered subcutaneously (SC) twice daily (12 hourly) starting within 8 hours of symptoms onset for a maximum of 3 days from symptoms onset (or sooner if discharged from neurosurgical centre).
3487369|NCT03737331|Experimental|Fractal visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be fractal (i.e., pink noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
3487370|NCT03737331|Active Comparator|Periodic visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be periodic (i.e., invariant). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
3487371|NCT03737331|Sham Comparator|Random visual cueing|This stimulus will consist of a visual moving bar displayed on a small monitor attached to a pair of glasses. The temporal structure of the movement will be random (i.e., white noise). Participants will be asked to match their hell strikes of right foot with the top of the moving bar's path and their heel strikes of left foot to the bottom.
3487372|NCT03737331|No Intervention|Control|Natural walking.
3487373|NCT03737318|Experimental|Group 1|Traditional articulation treatment
3487374|NCT03737318|Experimental|Group 2|Biofeedback--visual-acoustic
3487375|NCT03737318|Experimental|Group 3|Biofeedback-ultrasound
3487376|NCT03737305|Active Comparator|Control Group|Control group of conventional therapy with manual distraction performed by the physiotherapist in the office (active comparator)
3487377|NCT03737305|Experimental|Distractor Test Group|Test group with manual distraction performed by the physiotherapist in the office and the condylar distraction performed by the patient with the condylar distraction device in an ambulatory basis.
3487378|NCT03737292|Experimental|Exparel|Intercostal injection of 266mg of Exparel diluted to 30 ml.
3487379|NCT03737292|Active Comparator|Bupivacaine|Intercostal injection of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml.
3487380|NCT03737279|Experimental|Meditation|"Intervention Group:~Routine care plus twice daily mindful meditation"
3487381|NCT03737279|Active Comparator|Routine care|"Control Group:~Routine care which includes ACOG educational pamphlets on day 1, 2 and 3 after randomization"
3487382|NCT03737266|Experimental|Sonographically assisted breast surgery|Sonography assisted breast surgery
3487383|NCT03737266|Active Comparator|Conventional breast surgery|Conventional breast surgery
3487384|NCT03737253|Active Comparator|Follitropin alpha|Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
3487385|NCT03737253|Active Comparator|Menotropin|Menotropin (Menopur, Ferring GmbH, Kiel, Germany), injections, dosage varying 1500-2500 IU, duration 2-5 days.
3487386|NCT03737240|Experimental|IDegLira|Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
3128997|NCT03189719|Placebo Comparator|Placebo + SOC|Participants receive placebo to pembrolizumab (saline) IV Q3W plus SOC chemotherapy with cisplatin 80 mg/m^2 IV Q3W and 5-FU 800 mg/m^2/day continuous IV infusion on Days 1 to 5 (120 hours) Q3W. All treatments will be administered on an outpatient basis beginning on Day 1 of each 3-week dosing cycle.
3128998|NCT03189745|Experimental|MenACWY-TT Booster|10 year booster dose of MenACWY
3128999|NCT03190005||group 1|placebo control without medication.
3129000|NCT03190005||group 2|hyper-reactive responser after clopidogrel.
3487387|NCT03737240|Active Comparator|Basal-Bolus Insulin|Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
3487388|NCT03737227|Other|Cinematographic recording|Cinematographic recordings of the asymptomatic participants during flexion and extension of the lumbar spine.Cinematographic recordings will be performed twice with an interval of two weeks.
3487389|NCT03737214|Experimental|Lucerastat|Dose will be based on subject's eGFR.
3487390|NCT03737201|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
3487391|NCT03737201|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
3487392|NCT03737201|Active Comparator|control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
3487393|NCT03737175|Experimental|Carotid Artery Stenting group|Carotid Artery Stenting
3487394|NCT03737175|Active Comparator|Carotid Endarterectomy group|Carotid Endarterectomy
3487395|NCT03737162|Experimental|Covered stent group|Covered stent
3487396|NCT03737162|Active Comparator|Bare-metal stent group|Bare-metal stent
3487397|NCT03737136|No Intervention|Plasmapheresis|5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375mg/m2 rituximab at the end of last session
3487398|NCT03737136|Active Comparator|Plasmapheresis plus Bortezomib|Drug 5 Sessions Plasmapheresis and 100 mg/kg Intra venous immunoglobulin at the end of each session and one dose 375ml/m2 rituximab at the end of last session plus bortezomib Injections 1.3mg/m2 intravenously on days 1, 4, 8, and 11
3487399|NCT03737123|Experimental|Chemotherapy and Atezolizumab|Subjects that received a PD 1 or PD-L1 inhibitor with no prior platinum chemotherapy for metastatic disease will be treated with atezolizumab + carboplatin + gemcitabine on trial. Subjects that received sequential or concurrent PD1/PDL1 inhibitor and carboplatin-based regimen will be treated with atezolizumab + docetaxel on trial.
3487400|NCT03737097|Experimental|Online Spaced Education|The intervention cohort will participate in an online spaced education on fall prevention education developed for patients with multiple sclerosis.
3487401|NCT03737097|Active Comparator|Brochure Education|The control cohort will receive the fall prevention education in bolus through a Brochure developed by the National Multiple Sclerosis Society. The brochure was translated to portuguese and will be used in the study with authorization of the Society.
3487402|NCT03737084|Experimental|CBCT Intervention|The compassion intervention (CBCT) will be performed during the period of hospitalization, in the hospital room, and will be applied simultaneously to the patient his caregiver. The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
3487403|NCT03737084|No Intervention|Control group|Control group participants will receive standard hospital care. Patients and caregivers of the control group will receive the same CBCT intervention at the end of the study.
3487404|NCT03737071|Experimental|Low Carbohydrate Diet|Low Carbohydrate Diet
3487405|NCT03737045|Other|Decision Aid Testing|Participants will have the opportunity to test the different decision aid prototypes while selecting new treatment/therapy.
3129001|NCT03190005||group 3|hypo-reactive responser after clopidogrel.
3129002|NCT03190005||group 4|normo-reactive responser after clopidogrel.
3129003|NCT03190005||group 5|reaction after OPC-13013
3129004|NCT03190005||group 6|reaction after AR-C
3129005|NCT03190005||group 7|reaction after simastatin
3129006|NCT03190083|Experimental|3-dimensional tomosynthesis mammogram|The patients assigned a Breast imaging-reporting and data system (BIRADS) 5 category at the time of diagnosis and all new diagnosed breast cancer patients, will undergo a separate 2-D plus DBT in addition to the standard 2-D mammogram
3129007|NCT03190213|Experimental|Pembrolizumab, all patients|
3129008|NCT03190369|Placebo Comparator|Placebo|Participants received a single IA injection of phosphate buffered saline on Day 1 and were observed for 26 weeks.
3129009|NCT03190369|Experimental|Hylan G-F 20|Participants received a single IA injection of 6 mL Hylan G-F 20 (Synvisc-One) on Day 1 and were observed for 26 weeks.
3129010|NCT03190460|Experimental|Intervention|
3129011|NCT03190460|Other|Education|
3129012|NCT03190993|Active Comparator|Sugar Sweetened Solid Treatment|A solidified food that is made with the SSB syrup concentrate and gelatin. It is equivalent to one 20 oz. soft drink.
3129013|NCT03190993|Active Comparator|Sugar Sweetened Beverage Treatment|20 oz. carbonated sugar sweetened beverage. Added ingredients include: ~2.1g whey protein powder.
3487406|NCT03737032|Experimental|Intermittent, Continuous, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Continuous theta burst stimulation, 3) Sham theta burst stimulation.
3487407|NCT03737032|Experimental|Intermittent, Sham, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Intermittent theta burst stimulation, 2) Sham theta burst stimulation, 3) Continuous theta burst stimulation.
3487408|NCT03737032|Experimental|Continuous, Intermittent, Sham Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Sham theta burst stimulation.
3487409|NCT03737032|Experimental|Continuous, Sham, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Continuous theta burst stimulation, 2) Sham theta burst stimulation, 3) Intermittent theta burst stimulation.
3487410|NCT03737032|Experimental|Sham, Intermittent, Continuous Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Intermittent theta burst stimulation, 3) Continuous theta burst stimulation.
3487411|NCT03737032|Experimental|Sham, Continuous, Intermittent Order|3 sessions of theta burst stimulation administered in the following order: 1) Sham theta burst stimulation, 2) Continuous theta burst stimulation, 3) Intermittent theta burst stimulation.
3487412|NCT03737019|Experimental|ACT in County Council of Kalmar|Group education with ACT in six primary health care centers in County Council of Kalmar
3487413|NCT03737019|Placebo Comparator|Control health care centers of County Council of Jönköping|Five primary health care centers of County Council of Jönköping that do not get education.
3487414|NCT03736993|Other|Additional blood sampling|non-small cell lung cancer (NSCLC)
3487415|NCT03736980|Experimental|Psilocybin Group 1|Group 1: randomized, placebo-controlled, double-blind, cross-over design
3487416|NCT03736980|Experimental|Psilocybin Group 2|Group 2: randomized, placebo-controlled, double-blind, cross-over design
3487417|NCT03736980|Experimental|Psilocybin Group 3|Group 3: randomized, placebo-controlled, double-blind, cross-over design
3487418|NCT03736980|Experimental|Psilocybin Group 4|Group 4: randomized, placebo-controlled, double-blind, matched group design
3487419|NCT03736954|Experimental|ICU doulas intervention|specially trained ICU doulas will provide critically ill intubated patients with early psychological support on a daily basis
3487420|NCT03736941|Experimental|Patients with venous leg|"After inclusion, the medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. Follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.~During the various visits, clinical data will be collected in the patient's medical file as well as the answers to the questionnaires."
3487421|NCT03736915|Active Comparator|1 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
3487422|NCT03736915|Active Comparator|3 cc syringe with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
3487423|NCT03736915|Active Comparator|5 cc needle with 26 G needle|comparing the pain from injection using syringe and needle combination i.e. 1) 1 cc syringe with 26G needle, 2) 3 cc syringe with 26 G needle, and 3) 5 cc needle with 26 G needle. The injection will be performed in any of at the second, third and fourth fingers of either subject's hand randomly. Injection using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
3487424|NCT03736889|Experimental|Tislelizumab (BGB-A317) Injection|
3487425|NCT03736876|Experimental|Treatment group|These students will receive About Us, an innovative, healthy relationship intervention. The program includes 10 lessons that blend group-based activities with online activities implemented in school-based health centers.
3487426|NCT03736876|No Intervention|Delayed intervention (control group)|These students will receive the business-as--usual condition (e.g., the standard health education that is provided by the school during the study period), and will receive the intervention once the study period has concluded.
3487427|NCT03736863|Experimental|Apatinib+SHR-1210（Camrelizumab）|Apatinib+SHR-1210（Camrelizumab）
3487428|NCT03736850|Experimental|CS3006|
3487429|NCT03736837|Experimental|Anlotinib Plus Icotinib|Anlotinib 12 mg once a day from day 1 to 14 of a 21-day cycle. Icotinib 125mg p.o, tid. It should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent.
3487430|NCT03736811|Active Comparator|Absorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyglactin 910 [Vicryl] or polydioxanone [PDS II] sutures.
3487431|NCT03736811|Experimental|Nonabsorbable suture|will undergo anterior colporrhaphy in a traditional manner using either 2-0 polyester [Ethibond Excel] or polypropylene [Prolene] sutures.
3487432|NCT03736772|Experimental|LY3090106|LY3090106 administered subcutaneously (SC)
3487433|NCT03736772|Placebo Comparator|Placebo|Placebo administered SC
3487434|NCT03736759|Experimental|Exercise and vaccine in same arm|20 min eccentric resistance exercise of deltoid and biceps brachii in non-dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
3487435|NCT03736759|Active Comparator|Exercise and vaccine in different arms|20 min eccentric resistance exercise of deltoid and biceps brachii in dominant arm, followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
3487436|NCT03736759|No Intervention|vaccine only|20 min rest followed immediately by intramuscular injection of seasonal quadrivalent influenza vaccine in non-dominant arm
3487437|NCT03736746|Experimental|Motivational Interviewing|"Will entail two-to-four Motivational Interviewing sessions per participant~Will include a battery of questionnaires~Investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs).~The investigator will elicit questions and goals that participants will be encouraged to discuss with their palliative care providers"
3487438|NCT03736733|Experimental|fibromyalgia patients with physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
3487439|NCT03736733|Other|fibromyalgia patients with physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
3487440|NCT03736720|Experimental|Treatment (liposomal irinotecan, leucovorin, fluorouracil)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin IV over 30 minutes, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 28 days for in the absence of disease progression or unacceptable toxicity.
3487441|NCT03736707|Experimental|Selective HFOV|Selective HFOV will be provided
3129014|NCT03191396|Experimental|Semaglutide|Half the study participants are randomised to receive semaglutide
3129015|NCT03191396|Active Comparator|Liraglutide|Half the study participants are randomised to receive liraglutide
3487442|NCT03736707|Active Comparator|CMV|CMV will be provided
3487443|NCT03736694|Experimental|CBTI Workshop|The first intervention group (Group 1) will attend one half-day CBTI workshop in the community setting. The workshop is subdivided into 4 sessions, covering topics regarding regulation of stimuli, limit of sleeping duration, relaxation, sleep hygiene and alteration of cognitive beliefs (Arnedt, Cuddihy, & Swanson, et al, 2014; Morin, Savard, Ouellet, & Daley, 2003). One workshop has the capacity of 30 participants.
3487444|NCT03736694|Experimental|Self-Help CBTI|The second intervention group (Group 2) will receive self-help CBTI. A CBTI webpage will be set up and the subjects are asked to review all the materials in it. The content is the same as that in Group 1.
3487445|NCT03736694|Active Comparator|SHE Workshop|The control group (Group 3) will receive SHE. To ensure uniformity of the therapy model, the participants will also need to attend one half-day face-to-face session, covering topics related to sleep hygiene only. The capacity is also 30 participants.
3487446|NCT03736668|Experimental|Patients with Type 2 diabetes|"One year after patient's inclusion, during the additional cardiology consultation, an echocardiography will be performed by the investigator to evaluate any changes.~Two years after the patient's inclusion, an investigator will contact by phone the general practitioner, cardiologist and / or diabetologist treating the patient to find out if any cardiovascular events occurred."
3487447|NCT03736642||restrictive anorexia nervosa with hunger|
3487448|NCT03736642||restrictive anorexia nervosa without hunger|
3487449|NCT03736642||constitutional thinness|
3487450|NCT03736642||control subjects without eating disorders|
3487451|NCT03736616|Experimental|Cohort A: Transplant eligible|"Patients receive RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin area under curve (AUC) 5 IV d2, Etoposide (VP16) 100mg/m2 IV d1-3 & Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~BEAM chemotherapy & autoHSCT: BEAM given as Carmustine (BCNU) 300mg/m2 IV day -6 respective to stem cell infusion, VP16 200mg/m2 IV BID day -5 to day-2, Cytarabine (Ara-C) 200mg/m2 IV BID day -5 to day -2, and Melphalan 140mg/m2 IV day -1. Autologous hematopoietic stem cell infusion on day 0. Only patients with CR/PR after RICE acalabrutinib will undergo BEAM and autoHSCT~Maintenance therapy: Post autoHSCT patients will receive Acalabrutinib 100mg oral BID starting on day +30 for 12 consecutive months or until progression or intolerance if occurs within those 12 months."
3487452|NCT03736616|Experimental|Cohort B: Transplant ineligible|"Patients receive RICE chemoimmunotherapy + Acalabrutinib Salvage therapy: RICE: Rituximab 375mg/m2 IV d1, Ifosfamide 5000mg/m2, Carboplatin AUC 5 IV d2, Etoposide 100mg/m2 IV d1-3. Acalabrutinib 100mg oral BID d1-21. Cycle is 21 days for up to 3 cycles of treatment.~Maintenance therapy: Patients will receive Acalabrutinib 100mg oral BID for 12 consecutive months or until progression or intolerance if occurs within those 12 months. Maintenance therapy will only be given to patients with stable disease or better response after 3 cycles of RICE+ acalabrutinib"
3487453|NCT03736603|Experimental|Pathway Intervention 1|Hospitals randomized to group 1 receive PIPA Intervention Bundle 1.
3487454|NCT03736603|Experimental|Pathway Intervention 2|Hospitals randomized to group 2 receive PIPA Intervention Bundle 2, which adds a mobile app.
3487455|NCT03736603|No Intervention|Control|Hospitals are in the control arm (usual care) after January 2017 until active implementation begins, which includes 3-6 months of implementation preparation (identifying local multidisciplinary champions, educational sessions/webinars for local champions, one teleconference with an external practice facilitator).
3487456|NCT03736590|Experimental|Intervention - Financial Coaching Plus Social Needs Screening|Families in this intervention arm will receive financial coaching at each well child visit, in addition to clinic-based social needs screening and referral.
3487457|NCT03736590|Active Comparator|Control - Social Needs Screening and Referral|Families in this active control arm will receive social needs screening and referral to community resources to address identified social needs.
3487458|NCT03736577|Experimental|NorGeP-NH|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend.~Intervention: Drug reviews with NorGeP-NH Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH) and they will do a structured drug review on the participants' drug charts."
3487459|NCT03736577|No Intervention|Control nursing home|"Initially, a three hours lecture on dementia, depression, anxiety and psychosis on the elderly will be held. Both physicians working in the facilities and selected personnel, i.e. specialized nurses, will attend. Physicians will not attend any lecture about drug reviews and they will keep treating participants as usual."
3487460|NCT03736564|Experimental|68Ga-DOTATATE PET/CT|Subjects will undergo imaging by 68Ga-DOTATATE PET/CT
3487461|NCT03736551|Experimental|Intervention|The intervention arm will involve standard care plus an intermittent modified fasting regimen consisting of a very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet). All dietary intake on modified fasting days will be from LighterLife foodpacks, (4 x 150 kcal portions/day presented as milkshakes, cereal bars, soups and modified meals such as spaghetti bolognese, or macaroni cheese) providing ~600 kcal/day and 100% of the RNI for vitamins and minerals.
3487462|NCT03736551|Active Comparator|Standard Care|Renal Weight management Programme - Patients will attend individual appointments with the specialist dietitian and physiotherapist once a month, for 6 months. Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure (9). In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
3487463|NCT03736525|Experimental|Design For Wellness (DWELL)|Intervention participants will: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
3487464|NCT03736525|Other|Wait list control group|After the close of the study, we will open the Facebook group to all, and wait list control group participants can receive a delayed form of the intervention, which includes: 1) consume scientific evidence and practical solutions of how to design the home environment for wellness; 2) be part of a community which encourage participants engagement; 3) be empowered to read and control cues in the environment by developing skills.
3487465|NCT03736473|Other|MEDI9447 monotherapy|Dose escalation of MEDI9447 monotherapy for patients with advanced solid malignancies
3487466|NCT03736460|Experimental|Mindfulness-based intervention|
3487467|NCT03736460|Active Comparator|Physical training|
3487468|NCT03736460|No Intervention|Wait-list|
3487469|NCT03736447|Active Comparator|AR101 powder (Peanut allergen formulation)|Subjects will be randomized to active arm of ARC005 and will be administered IP (AR101) in escalating doses for approximately 6 months.
3487470|NCT03736447|Placebo Comparator|Placebo powder|Subjects will be randomized to placebo arm of ARC005 and will be administered escalating doses of IP (placebo) for approximately 6 months.
3487471|NCT03736434|Experimental|Mindfulness plus DASH group|Receives Mindfulness and DASH Diet education once a week for 8 weeks (2.5-hour sessions)
3487472|NCT03736434|Active Comparator|Education Group|The sham intervention includes general education on non-health related topics such as fire-safety and learning how to dispose of medication properly, once a week for 8 weeks (2.5-hour sessions)
3487473|NCT03736434|No Intervention|Control Group|Continue care as usual without intervention.
3487474|NCT03736421||Control Cohort|"This cohort is recruited to help to define what a normal PIVA value should be during a state of presumed euvolemia."
3487475|NCT03736421||Infection Cohort|This cohort are subjects with suspected infection, enriched to contain sepsis patients.
3487476|NCT03736421||Acute Heart Failure|This cohort will have a diagnosis of CFH who are being admitted to the hospital. These patients will be followed during their hospital course.
3487477|NCT03736395|Active Comparator|Control|Schools in this condition will be provided a four-day training about Schoolwide Positive Behavioral Interventions and Supports, and bi-yearly feedback about progress monitoring and action planning.
3487478|NCT03736395|Experimental|I-RIM Intervention|Schools in this condition will be provided the same basic training as the control condition, plus the elements of the Idaho Rural Implementation Model (I-RIM).
3487479|NCT03736382|Experimental|Experimental Group|The experimental group is comprised of participants with OSA and hypertension [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be treated with mild IH and CPAP. In the present proposal, the mild IH protocol will be administered during wakefulness each day for 15 days over a 3-week period to participants that will also be treated with CPAP during sleep. The mild IH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve - two minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2) = 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The PETCO2 will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol.
3487480|NCT03736382|Sham Comparator|Control Group|The control group is comprised of hypertensive OSA participants [either able bodied (Aim 1) or with spinal cord injury (Aim 2)] that will be exposed to a sham protocol in addition to being treated with CPAP during sleep. The sham protocol will be administered during wakefulness for 15 days over a 3-week period. During the sham protocol the participants will be exposed to atmospheric levels of oxygen and carbon dioxide for the duration of the protocol.
3487481|NCT03736369|Experimental|DWP14012 40mg|Orally, once daily
3487482|NCT03736369|Active Comparator|Esomeprazole 40mg|Orally, once daily
3487483|NCT03736330|Experimental|Combinations treatment|Drug: Axitinib 5mg orally twice a day Combination Treatment：Anti-PD-1 Combinations of D-CIK Immunotherapy
3487484|NCT03736317|Sham Comparator|control group|Sham TBS delivered on left dlPFC or medial prefrontal cortex of amphetamine-dependent patients. Stimulation pulses are the same as the real group.
3487485|NCT03736317|Experimental|real mPFC cTBS group|The real cTBS stimulation pattern will be delivered on the medial prefrontal cortex.
3487486|NCT03736317|Experimental|real dlPFC iTBS group|The real iTBS stimulation pattern will be delivered on the left dorsal prefrontal cortex.
3487487|NCT03736317|Experimental|real dlPFC iTBS + real mPFC cTBS group|Combination therapy of real iTBS stimulation delivered on the left dorsal prefrontal cortex and real cTBS stimulation delivered on the medial prefrontal cortex.
3487488|NCT03736304|Placebo Comparator|Usual care|Patients will receive standard clinical care by the doctor in charge.
3487489|NCT03736304|Experimental|AKI alert|An AKI alert will send to the the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
3487490|NCT03736291|Active Comparator|active rTMS|"The Active rTMS: The magnetic head uses the Magro X100's 8-shaped coil, and the intervention site is the cerebellar vermis (1 cm below the occipital carina). The stimulation intensity is gradually increased by the 80%-100% exercise threshold according to the patient's tolerance. The total number of stimulation pulses per day is 600, the basic frequency is 5 Hz, and one short burst stimulus is given every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and every 10 short bursts are stimulated for 8 s. A total of 200 short bursts of stimulation. Intervention once a day, 5 times a week, intervention for 2 weeks, a total of 10 times."
3487491|NCT03736291|Sham Comparator|sham rTMS|"The sham rTMS: The sham stimulation method was to invert the 8 shaped coil, which was 180° to the scalp, and other intervention parameters were consistent with the study group."
3487492|NCT03736265|Experimental|Carvedilol+ Nucleos(t)ide Analogues|Based on nucleoside analogue (NUCs), carvedilol will added to the patients. Carvedilol is started at a dose of 6.25 mg once daily. After 1 week, this will increased to a dose of 12.5 mg once daily. Target dose of 12.5 mg once daily will be maintained if systolic blood pressure does not fall below 90 mm Hg and HR 50 beats per minute.
3487493|NCT03736265|No Intervention|Nucleos(t)ide Analogues|Continuing take nucleoside analogue (NUCs) including lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
3179880|NCT00677430||Questionnaire + Digital Imaging|A brief questionnaire packet will be completed. Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
3487494|NCT03736200|Active Comparator|Exergaming 1/day|Post stroke group that received 4 weeks of intensive therapy. (1/day)
3487495|NCT03736200|Active Comparator|physiotherapy|Post stroke group that received 4 weeks of traditional physiotherapy.
3487496|NCT03736200|Active Comparator|Exergaming 2/day|Post stroke group that received 4 weeks of intensive therapy. (2/day)
3487497|NCT03736187|Experimental|Cephalexin|Group a will receive cephalexin 1gm before skin incision intravenous
3487498|NCT03736187|Experimental|Cephalexin &metronidazole|Group b will receive cephalexin 1gm intravenous plus 1gm metronidazole rectally before skin incision
3487499|NCT03736174||Compartment Pressure Testing|Patients who present with symptoms of CECS will be consented and tested per protocol with compartment pressure testing. Concurrently, patients will undergo a high frequency ultrasound to observe any patterns in structure to assist future research in noninvasively diagnosing CECS. Evaluation of ultrasonographic findings will be dependent on tissue density as measured by hypoechoic versus hyperechoic signal as well as muscle compartment thickness at its largest dimension.
3487500|NCT03736174||Control|Control subjects will undergo exercise protocol and ultrasound, but will not have compartment pressure testing completed.
3487501|NCT03736161|Experimental|Group A- Tofacitinib|Tofacitinib 5mg twice daily orally. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD.
3487502|NCT03736161|Placebo Comparator|Group B- Methotrexate|Methotrexate in increasing dose starting from 15 mg weekly to a maximum dose of 25 mg weekly from the end of 1st month. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD.
3487503|NCT03736148|Experimental|Manual Manipulation|A single manual manipulation was applied to C3/C4 level, on the right side.
3487504|NCT03736148|Active Comparator|Instrument-assisted Manipulation|A single instrument-assisted manipulation was applied to C3/C4 level, on the right side.
3487505|NCT03736148|Placebo Comparator|Placebo|A placebo manipulation was applied on C3/C4 level, on the right side. The neck of th subject was placed in the pre manipulative position but no thrust was made. Then, the cervical was replaced in neutral position.
3487506|NCT03736148|No Intervention|Control|No contact was given to the subject.
3487507|NCT03736122|Experimental|BSG-001|Inhalation route, daily
3487508|NCT03736109||Group I:|Thirty patients with knee osteoarthritis taking topical Copper-Albumin Complex cream
3487509|NCT03736109||Group II:|Thirty patients with knee osteoarthritis taking oral chondroprotective drugs
3487510|NCT03736083|Active Comparator|Freestyle Libre Group|Freestyle Libre Group: Participants will use the Freestyle Libre flash glucose monitoring system throughout the study for 2-3 months.
3487511|NCT03736083|No Intervention|Control Group (standard diabetes care)|This group will receive standard care. At the around 1 week and 2 month visits, control group subjects will use a blinded Freestyle Libre Pro to provide data that can be used to compare glucose variability between groups. The Libre sensor will allow the study team to measure glucose values but the subjects will not have access to this information for management/treatment decisions and usual diabetes care will be unaffected. The Freestyle Libre Pro last 14 days, can be activated in clinic, and the sensor can be returned in person or via mail where the investigators will download the data.
3487512|NCT03736044|Experimental|TNF-blockers withdrawal|Patients on treatment with TNF-blockers plus DMARDs in which a withdrawal of anti-TNF therapy was made.
3487513|NCT03736044|No Intervention|DMARDs control group|Patients treated with DMARDs only (Methotrexate/Leflunomide), never treated with anti-TNF.
3487514|NCT03736018|Active Comparator|CTCA + ICA|Computed Tomography Cardiac Angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
3487515|NCT03736018|No Intervention|ICA only|Invasive coronary angiogram (ICA) performed only.
3487516|NCT03736005||General ICU admissions|Non- major trauma ICU admission Exposure to significant period of critical illness
3487517|NCT03736005||Major Trauma admissions|Exposure to Major Trauma Exposure to significant period of critical illness
3129016|NCT03191552|Experimental|SPIO 2 hours|"All children will be hospitalized for 2 weeks and will receive conventional exercise therapy including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks 2 hours a day.~SPIO 2 hours group will receive conventional exercise therapy with the garment on for 2 hours."
3487518|NCT03735992|Experimental|Mind-body medicine group program|Patients recieve an 11-week mind-body medicine group program including elements of mindfullness based stress reduction (MBSR), yoga, and education + treatment as usual.
3487519|NCT03735992|No Intervention|Wait list|Treatment as usual.
3487520|NCT03735979|Experimental|Argatroban|100µg/kg bolus followed by 3µg/kg per minute for 12 hours
3487521|NCT03735979|Experimental|Eptifibatide|135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours
3487522|NCT03735979|Placebo Comparator|Placebo|
3487523|NCT03735966|Experimental|Pyrotinib plus trastuzumab and docetaxel and carboplatin|Pyrotinib + trastuzumab + docetaxel+carboplatin
3487524|NCT03735953|Experimental|Retroflexion arm|Retroflexion in the total colon and slow withdrawal to the rectum and record all visible colon polyps and other colon related diseases
3487525|NCT03735953|No Intervention|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the the rectum have a forward view and record all visible colon polyps and other colon related diseases
3487526|NCT03735940|No Intervention|Control phase|no intervention, i.e. care as usual
3487527|NCT03735940|Experimental|Intervention phase|experimental intervention: spot monitoring device, i.e. use of DeltaScan
3487528|NCT03735927|No Intervention|Control phase|no intervention, i.e. care as usual
3487529|NCT03735927|Experimental|Intervention phase|experimental intervention: spot monitoring device (excl. sham), i.e. use of DeltaScan
3487530|NCT03735914|Experimental|neuralgic patients|MRI experimentation
3487531|NCT03735901|Active Comparator|Experimental Intervention|White Investigational Medicinal Product (IMP)- capsules of a combination of IMP Levodopa 100mg/Carbidopa 25mg.
3487532|NCT03735901|Placebo Comparator|Control Intervention|Matching placebo, identical in aspect, texture, and taste when compared to the IMP. Procedures regarding route of administration, study treatment duration and treatment phases will be identical in the IMP- and the placebo-group.
3487533|NCT03735875|Experimental|Treatment (venetoclax, quizartinib)|Patients receive quizartinib PO QD on days 1-28 and venetoclax PO QD beginning on day 8 of cycle 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment beyond 24 cycles at the discretion of the treating physician.
3487534|NCT03735849|Experimental|Group 1: VRC07-523LS|Participants will receive 10 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
3487535|NCT03735849|Experimental|Group 2: VRC07-523LS|Participants will receive 30 mg/kg of VRC07-523LS at Weeks 0, 16, and 32.
3487536|NCT03735836|Experimental|MaxSimil 2 capsules daily|Subjects will receive two (2) capsules per day of MAG-EPA/MAG-DHA omega-3 oils for a total of 600mg of MAG-EPA and 260mg of MAG-DHA daily during 20 consecutive weeks of treatment.
3487537|NCT03735836|Experimental|MaxSimil 3 capsules daily|Subjects will receive two (3) capsules per day of of MAG-EPA/MAG-DHA omega-3 oils for a total of 900mg of MAG-EPA and 390mg of MAG-DHA daily during 20 consecutive weeks of treatment.
3487538|NCT03735810|Experimental|SAD - Cohort 1|50 mg LBS-008 or placebo
3487539|NCT03735810|Experimental|SAD - Cohort 2|100 mg LBS-008 or placebo
3487540|NCT03735810|Experimental|SAD - Cohort 3|200 mg LBS-008 or placebo
3487541|NCT03735810|Experimental|SAD - Cohort 4|400 mg LBS-008 or placebo
3487542|NCT03735810|Experimental|SAD - Cohort 5|25 mg LBS-008 or placebo
3487543|NCT03735810|Experimental|MAD - Cohort 1|10 mg LBS-008 or placebo
3487544|NCT03735810|Experimental|MAD - Cohort 2|25 mg LBS-008 or placebo
3487545|NCT03735810|Experimental|MAD - Cohort 3|5 mg LBS-008 or placebo
3487546|NCT03735810|Experimental|MAD - Cohort 4|12 mg LBS-008 or placebo
3487547|NCT03735784|Experimental|AWARE condition|AWARE is a four-session Motivational Interviewing (MI)-informed group risk reduction intervention that incorporates education, skills building and personalized feedback.
3487548|NCT03735784|No Intervention|Standard Care condition|"Participants in the Standard Care condition have access to usual care at the drop-in center where the study is being conducted."
3487549|NCT03735771|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
3487550|NCT03735771|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
3487551|NCT03735771|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
3487552|NCT03735771|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml. A PCEA bolus of 2.5mL of 0.25% Bupivacaine plus fentanyl 8mcg/ml will also be available.
3487553|NCT03735758|Experimental|Pazopanib|Pazopanib; 800 mg; daily; oral
3129017|NCT03191552|Experimental|SPIO 6 hours|SPIO 6 hours group will receive conventional exercise therapy with the garment on for 2 hours and worn SPIO 4 hours more in addition to 2 hour of wear during exercise therapy.
3487554|NCT03735758|Active Comparator|Chemotherapy|Guideline-conform chemotherapy
3487555|NCT03735732||weight status|
3487556|NCT03735732||mindset|
3487557|NCT03735706|Active Comparator|Control group - 120 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW and a tube voltage of 120 kV.~The intervention is the application of a standard contrast media volume and a standard tube voltage of 120 kV."
3487558|NCT03735706|Experimental|90 kV - 0.521 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media injection protocol with a standard dosing factor of 0.521 g I/kg of TBW.~A radiation dose reduction from 120 to 90 kV.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention; contrast media volume, is unchanged compared to group 1."
3487559|NCT03735706|Experimental|100 kV - 0.417 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.417 g I/kg of TBW. A radiation dose reduction from 120 to 100 kV compared to group 1.~The intervention is a change in tube voltage to 100 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.417 g I/kg."
3487560|NCT03735706|Experimental|90 kV - 0.365 g I/kg|"Weight is measured prior to the scan. Before performing the contrast enhanced CT scan(s), an unenhanced slice through the liver, at the level of the portal vein, is performed.~Contrast media volume reduction with a dosing factor of 0.365 g I/kg of TBW. A radiation dose reduction from 120 to 90 kV compared to group 1.~The intervention is a change in tube voltage to 90 kV, compared to group 1. The other intervention is a change in contrast media volume, which is adapted to the tube voltage used and therefore lowered to 0.365 g I/kg."
3487561|NCT03735641||postoperative|Expanded Pedicled Deltopectoral Flap is a type of surgical flap that has been cut away from surrounding areas for transplantation.The postoperative patients are studied . Tested sensory recovery,skin color and Skin elasticity
3487562|NCT03735615|Experimental|chronic obstructive lung disease|
3487563|NCT03735615|Experimental|healthy control|
3132760|NCT03449433|Experimental|LY900014|T1DM participants received a single, individualized, subcutaneous (SC) dose of LY900014.
3487564|NCT03735602|Experimental|perceptual training|Orientation discrimination task, which is a cognitive task. Patients were trained for 1 hour per day, 15 days in total.
3487565|NCT03735576|Experimental|LLD-adapted cognitive behavioural therapy (CBT)|manualized 15-session individually-delivered cognitive behavioural therapy (CBT) specific for late life depression (LLD)
3487566|NCT03735576|Active Comparator|supportive unspecific intervention (SUI)|manualized 15-session individually-delivered supportive unspecific intervention (SUI)
3487567|NCT03735563|Experimental|Ketamine|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
3487568|NCT03735563|Experimental|Fentanyl|Individuals needing the LISA will receive premedication as follows: caffeine (in case of gestational age <32 weeks and not already given), glycopyrrolate, and randomly either ketamine or fentanyl.
3487569|NCT03735550||Group A age: 18-49|Women aged 18-49 who had breast ultrasound performed with a result of BI-RADS 4b, 4c or 5. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to breast ultrasound. The planned number of participants in the group: n=700 people.
3487570|NCT03735550||Group B age: 50 and above|Women aged 50 and above who had mammography and/or breast ultrasound performed (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa). Women were recruited if they had a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques. The planned number of participants in the group: n=2100 people.
3487571|NCT03735550||Group C 18-49; 50 and above|"Subgroup C1 (n=100 people): women aged 18-49 years, who underwent breast ultrasound with a result of BI-RADS 1 or 2.~Sub-group C2 (n=100 people): women aged 50 and above, who had mammography or breast ultrasound performed; with a result of BI-RADS 1 or 2 (both examinations are obligatory, i.e. if the subject was recruited based on mammography, then ultrasound must be performed and vice-versa).~Thermography examination was performed with the use of contact thermographic breast examination device as a complementary tool to the aforementioned techniques."
3487572|NCT03735537|Active Comparator|Teriparatide and zoledronic acid|Teriparatide (TPTD) 20mcg daily using Teriparatide Pen Injector, given subcutaneously using a self-administered injection device for two years (24 months) followed by a single intravenous 5mg infusion of zoledronic acid.
3487573|NCT03735537|No Intervention|Standard Care|Continuation of existing bone modifying treatment (i.e. bisphosphonate treatment) or no active bone modifying treatment according to the clinical judgement of the local investigator.
3487574|NCT03735524|Experimental|Exercise|Conventional rehabilitation
3487575|NCT03735498|Experimental|Psychological Intervention|"Qualitative interview will be conducted~7-item Generalized Anxiety Disorder measure will be completed by participants via mail correspondence or online~A psychoeducational component to address preparedness, manage expectations, and develop caregiving skills~A psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~A self-care component to promote caregiver health and well-being"
3487576|NCT03735485|Experimental|Group I|The control group. Participants in this group received only conventional physiotherapy. Number of the participants were 14.
3487577|NCT03735485|Experimental|Group II|The shoulder mobilization group. Participants in this group received conventional physiotherapy and shoulder joint mobilization techniques. Number of the participants were 15.
3487578|NCT03735485|Experimental|Group III|The Proprioceptive Neuromuscular Facilitation (PNF) group. Participants in this group received conventional physiotherapy and PNF exercises. Number of the participants were 15.
3487579|NCT03735472||Aneurysm/Dissection|Thoraflex™ Hybrid
3487580|NCT03735459|Experimental|Patient reminder|"Patient Oriented SCORAD (PO-SCORAD): Assess severity of eczema.~Adherence Questionnaire (AQ): Assess adherence to eczema treatment plan provided to them by their healthcare provider.~Family Dermatology Life Quality Index (FDLQI): Assess impact of the participant's eczema on the family's quality of life.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 1, 2, and 4: Participants will complete PO-SCORAD and AQ.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
3132761|NCT03449433|Active Comparator|Insulin Lispro (Humalog®)|T1DM participants received a single, individualized, SC dose of insulin lispro.
3487581|NCT03735459|No Intervention|No patient reminder/control|"Participants in arm 2 are not sent text messages, and will not be asked to complete questionnaires 1, 2, and 4 weeks post enrollment. Participants will be asked to complete questionnaires during enrollment and 6 weeks post enrollment.~Enrollment: Participants will complete FDLQI and PO-SCORAD.~Week 6: Participants will complete FDLQI, PO-SOCRAD, and AQ."
3487582|NCT03735446|Experimental|Prexasertib+MEC|"Cytarabine is administered intravenously on days 1-5.~Etoposide is administered intravenously on days 1-5.~Mitoxantrone is administered intravenously on days 1-5.~Prexasertib is administered intravenously on days 1, 3, and 5."
3487583|NCT03735433|No Intervention|81 mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive recommended 81mg ASA
3487584|NCT03735433|Active Comparator|162mg daily aspirin dose|obese women >30 BMI at risk for preeclampsia will receive increased dose of 162mg ASA
3487585|NCT03735420|Experimental|Xanthohumol|Participants will receive 24 mg of 98% pure xanthohumol in a rice protein vehicle by mouth once daily with the first daily meal.
3487586|NCT03735420|Placebo Comparator|Placebo oral capsule|Participants will receive vehicle (rice protein) by mouth once daily with the first daily meal.
3487587|NCT03735407|Experimental|C-Scan procedure|Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
3179881|NCT00677443|Experimental|S-1 and Oxaliplatin|"S-1 and Oxaliplatin~S-1 : 80 mg/m2/day D1-14 Oxaliplatin : 130 mg/m2/day D1 Repeated every 3 weeks"
3179882|NCT00677443|Active Comparator|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin
3487588|NCT03735394|Experimental|Gingival Biotype|A Periodontal probe was used to differentiate between thick and thin biotypes and patients were classified into 3 possible categories of Gingival Biotype (A1, A2 and B) according to Müller & Eger (https://doi.org/10.1034/j.1600-051x.2000.027009621.x). On each group two measurements were taken on the most protruded lower and upper central incisor: 1/ a tangential radiographic film and 2/ an ultrasonic probe measurement with the PIROP Biometric scanner (G-scan) form Echoson
3179883|NCT00677456|Active Comparator|1|Patients will receive R-Y reconstruction after total gastrectomy as intervention
3487589|NCT03735381|Active Comparator|Intervention 1: pedometer|"Minimum intervention:~Use of pedometer watch from 12 to 32 GW~Recommendations of physical activity"
3487590|NCT03735381|Experimental|Intervention 2: pedometer+goal+reminds|"Maximum intervention:~Use of pedometer from 12 to 32 GW~Recommendations of physical activity~Information about get a goal of 11000 steps/day~Reminds the goal every two weeks."
3487591|NCT03735381|No Intervention|Control: without pedometer|Women receive some recommendations of physical activity during pregnancy. They do not use the pedometer during pregnancy
3487592|NCT03735368|Placebo Comparator|Control|placebo oral capsule+ dexmedetomidine+topical anesthesia
3487593|NCT03735368|Active Comparator|Dexmedetomidine- Pregabalin|Pregabalin Oral Capsule +Dexmedetomidine Injection+topical anesthesia
3487594|NCT03735355|Experimental|Balloon dilation|TTS balloon dilation
3487595|NCT03735355|Active Comparator|Surgery|Resection of the fibrostenotic area
3487596|NCT03735342|Experimental|Audio Recording|Participants receive a verbal discharge discussion with a provider, written discharge instructions and a re-playable audio recording of the discharge discussion with the discharging provider.
3487597|NCT03735342|No Intervention|Usual care|Participants receive a verbal discharge discussion with a provider and written discharge instructions.
3487598|NCT03735329|Experimental|Pulse oximetry monitoring|
3487599|NCT03735316|Experimental|B12a|Subjects will receive Hydroxocobalamin marketed as Cyanokit®, 5g, IV
3487600|NCT03735316|Placebo Comparator|Placebo|Subjects will receive placebo
3487601|NCT03735303|Experimental|VD3 group|dietary supplement : VD3 group treated with 50000 IU VD3/ week for 8 weeks
3487602|NCT03735303|Experimental|omega 3- FA group|dietary supplement : omega 3- FA group 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
3487603|NCT03735303|Experimental|VD3 and omega 3 FA group|dietary supplement : VD3 and omega-3FA 50000 IU VD3/week for 8 weeks and 1000 mg wild salmon and fish oil complex (contain 300 mg of omega 3-FA) once daily for 8 weeks
3487604|NCT03735303|Experimental|control group|no intervention was given
3487605|NCT03735290|Experimental|Phase 1b: Cohort 1, ilixadencel + pembrolizumab|3 x 10⁶ DCs (Dendritic Cells) of ilixadencel, 2x over 4 weeks (w). Pembrolizumab I.V. q3w
3487606|NCT03735290|Experimental|Phase 1b: Cohort 2, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 2x over 4 weeks. Pembrolizumab I.V. q3w
3487607|NCT03735290|Experimental|Phase 1b: Cohort 3, ilixadencel + pembrolizumab|10 x 10⁶ DCs of ilixadencel, 3x over 10 weeks. Pembrolizumab I.V. q3w
3487608|NCT03735290|Experimental|Phase 1b: Cohort 4, ilixadencel + pembrolizumab|Ilixadencel 3 times over 10 weeks: 1st dose 20 x 10⁶ DCs ilixadencel; 2nd dose 10 x 10⁶ DCs; 3rd dose 10 x 10⁶ DCs. Pembrolizumab I.V. q3w
3487609|NCT03735290|Experimental|Phase 2 exp. cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric or gastroesophageal junction (GEJ) adenocarcinoma. ilixadencel administered intra-tumorally up to 3 times over 10 weeks; dose determined after Phase 1b. Pembrolizumab I.V. q3w according to currently approved doses and indications.
3487610|NCT03735290|Active Comparator|Phase 2 comparator cohorts HNSCC/NSCLC/Gastric/GEJ|Subjects with HNSCC, NSCLC, gastric/GEJ adenocarcinoma receiving active treatment with pembrolizumab I.V. q3w according to currently approved doses and indications.
3487611|NCT03735277|Experimental|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters.
3487612|NCT03735264|Experimental|Anlotinib Hydrochloride plus Docetaxel|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Docetaxel (75mg/m2 IV d1)
3487613|NCT03735251||Left Ventricular Diastoic Dysfunction Classification|normal diastole pattern：E/A>1，DT 160~220 ms，S/D >1，AR 0.22-0.32m/sec，E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern：E/A< 1，DT > 220 ms，S/D > 1，AR 0.21-0.28 m/sec，E/e'<10 Pseudo-normalization pattern：E/A> 1，DT 150~210 ms，S/D < 1，AR ≥0.35m/sec，E/e'≥ 10 Restrictive pattern：E/A ≥ 2，DT < 150 ms，S/D <1，AR ≥0.25m/sec，E/e'≥10
3487614|NCT03735238||Lupus Patients|All lupus patients, regardless of if they are having an active flare
3487615|NCT03735225|Experimental|IV Dasiglucagon|Dasiglucagon 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
3487616|NCT03735225|Experimental|SC 0.6 mg Dasiglucagon|Dasiglucagon 0.6 mg administered SC as a single dose
3487617|NCT03735225|Placebo Comparator|IV Placebo|Placebo 0.1, 0.3, 0.6, 1.5 or 2.0 mg administered IV as a single dose
3487618|NCT03735212|Experimental|Program Group|Participants in this group receive enhanced services as the intervention. These services include Motivational Enhancement, Incredible Years, and Contingency Management. Participants also receive case management services to support referrals to substance use.
3487619|NCT03735212|No Intervention|Control Group|Participants in this group receive services as usual.
3487620|NCT03735199|Experimental|PCL-TCP scaffold|During the surgery, the PCL-TCP scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A Geistlich Bio-Gide collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
3487621|NCT03735199|Active Comparator|Geistlich Bio-Gide collagen membrane|"No space filler will be inserted in the extraction socket but similar to the test group, a Geistlich Bio-Gide collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.~denture overlying the extraction site will be completely relieved."
3487622|NCT03735186|No Intervention|Control|Participants will rest in the laboratory on day 1 and day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
3487623|NCT03735186|Experimental|Exercise|Participants will complete 60 min of treadmill exercise on day 1 (14:30-15:30). Participants will rest in the laboratory for the remainder of day 1 and throughout day 2 (08:00-17:00). A high fat breakfast and lunch will be consumed on both days at pre-determined intervals.
3487624|NCT03735173|Active Comparator|Pegged through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through a Subscapularis Peel (SP) manipulation.
3129018|NCT03191552|Active Comparator|Control(conventional exercises)|Control group will only receive conventional exercise therapy (for two hours a day) including range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills during hospital inpatient stay throughout 2 weeks
3179884|NCT00677456|Active Comparator|2|Patients will receive P-Y reconstruction after total gastrectomy as intervention
3487625|NCT03735173|Active Comparator|Pegged through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene pegged glenoid component through subscapularis tenotomy (ST) manipulation.
3487626|NCT03735173|Active Comparator|Keeled through SP|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through a Subscapularis Peel (SP) manipulation.
3487627|NCT03735173|Active Comparator|Keeled through ST|Primary anatomic shoulder arthroplasty with implantation of a cemented all-polyethylene keeled glenoid component through subscapularis tenotomy (ST) manipulation.
3487628|NCT03735160||Nasal intubation with pressure sensor|anesthetized patient with nasotracheal intubation
3487629|NCT03735147|Experimental|All children|Administration of live attenuated influenza vaccine (LAIV)
3487630|NCT03735134|Active Comparator|Control Group|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment
3487631|NCT03735134|Active Comparator|Early colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI
3487632|NCT03735134|Active Comparator|Late colchicine loading dose|Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI
3487633|NCT03735108||pregnancy loss group|the times of pregnancy loss more than or equal to twice
3487634|NCT03735108||normal control group|no history of pregnancy loss
3487635|NCT03735095|Experimental|Treatment (porfimer sodium, EBUS, and photodynamic therapy)|Patients receive porfimer sodium IV over 20 minutes 2-4 hours prior to the delivery of I-PDT. Patients then undergo EBUS-TBN guided I-PDT over 30-45 minutes.
3487636|NCT03735082|Experimental|apatinib+Paclitaxel+Carboplatin|apatinib 250mg, d1-14,14day/cycle; Paclitaxel 175mg/m2,d1,14days/cycle; Carboplatin AUC=4,d1,14day/cycle
3487637|NCT03735069|Experimental|IPT (Indirect pulp treatment) group|In this group, complete caries excavation from the dentin-enamel junction will be done. Caries near the pulp will be removed with caution until the remaining dentin shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material will be placed (Vitrebond; St.Paul, MN), followed by resin-modified glass ionomer (RMGI) build-up material (Vitremer; St. Paul, MN), and the final restoration of choice for MIH involved teeth; a preformed Stainless Steel Crown (SSC).
3487638|NCT03735069|Experimental|Cvek/partial pulpotomy group|"In this group, partial pulpotomy will be attempted first, inflamed pulp tissue will be removed until healthy pulp tissue is reached (2-4mm depth), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated twice if required; otherwise, cervical pulpotomy will be done.~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be placed in the pulp chamber (2-3mm thickness), a moist cotton pellet will be placed and Intermediate Restorative Material (IRM) to ensure setting. Patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
3487639|NCT03735069|Experimental|Cervical pulpotomy group|"In this group, a cervical pulpotomy procedure will be done where all pulp chamber tissue shall be removed until healthy pulp tissue is reached, as indicated by bleeding from all canals and arrest of hemorrhage upon pressure (for maximum 6 minutes).~Gray MTA (Mineral Trioxide Aggregate, Dentsply, Canada) will be mixed according to manufacturer instructions and will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with Intermediate Restorative Material (IRM), the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGI (Vitremer; St. Paul, MN) and stainless steel crown will be placed , and a post-op radiograph will be taken."
3487640|NCT03735056|No Intervention|Group 1 (Usual care)|Receives usual care only.
3487641|NCT03735056|Experimental|Group 2 (Usual care plus Support 1)|Receives usual care plus Support 1 (MS Nurse Support) which includes one one-to-one, face-to-face session with an MS Nurse Specialist in a hospital setting (or via Skype). The session will include answering newly diagnosed patients' questions about MS, providing psychoeducation and teaching Acceptance and Commitment strategies (Hayes, Strosahl & Wilson, 1999), and referring to other services (based on needs). Participants will also be given a self-help workbook ('Better living with a diagnosis of MS: Patient Workbook') by the nurses. This session will take place within 2 weeks of diagnosis and last up to 90 minutes. It will be supplemented by phone calls (depending on participant needs). MS Nurses will receive training and on-going supervision from experienced clinical psychologists.
3487642|NCT03735056|Experimental|Group 3 (Usual care plus Support 2)|Receives usual care plus Support 2 (i.e. MS Nurse Support plus Peer Support). In addition to receiving the MS Nurse Support (i.e. Support 1, as described in Group 2), this group will also receive peer support which will be provided by Peer Support Workers who are patients/carers with lived experience and who are recruited and trained to deliver peer support under supervision from experienced clinical psychologists. It will be delivered one-to-one, face-to-face (in a community setting or via Skype, based on participants' preferences). Patients in this group will be triaged to a Peer Support Worker by the MS Nurse during the 2-week MS Nurse Support session. The sessions will be scheduled to a convenient time between weeks 2-6 after diagnosis and each session will last up to 60 minutes.
3487643|NCT03735043|Experimental|ccNexfin ©|
3487644|NCT03735030|Experimental|human hCG|
3487645|NCT03735030|Active Comparator|recombinant hCG|
3487646|NCT03735004|Experimental|TES 60 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 60 Hz) current
3487647|NCT03735004|Active Comparator|TES 100 Hz DC:AC|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC, 100 Hz) current
3487648|NCT03735004|Sham Comparator|TES with DC current|Transcranial electrostimulation (TES) with direct current (DC) only
3487649|NCT03734978||A blood group|prematurity with sepsis
3487650|NCT03734978||O blood group|prematurity with sepsis
3487651|NCT03734978||B blood group|prematurity with sepsis
3487652|NCT03734978||AB blood group|prematurity with sepsis
3487653|NCT03734952|Experimental|Group A|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program+Postoperative radiotherapy program
3487654|NCT03734952|Other|Group B|Neoadjuvant Radiotherapy Program+Neoadjuvant chemotherapy Program+ Esophagectomy program
3487655|NCT03734926|Experimental|Part 1|Participants with advanced solid tumors including hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
3487656|NCT03734926|Experimental|Part 2 Cohort A|Participants with hepatocellular carcinoma.
3487657|NCT03734926|Experimental|Part 2 Cohort B|Participants with gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumor.
3487658|NCT03734913|Experimental|Part 1|Participants with advanced solid tumors including basal cell carcinoma and medulloblastoma, regardless of SMO or Gli1 alteration status.
3487659|NCT03734913|Experimental|Part 2 Cohort A|Participants with Adenocarcinoma of Esophagogastric Junction with SMO or Gli1 protein overexpression alteration.
3487660|NCT03734913|Experimental|Part 2 Cohort B|Participants with basal cell carcinoma, small cell lung cancer, neuroendocrine neoplasm and glioblastoma with SMO or Gli1 protein overexpression alteration.
3129019|NCT03191630|Experimental|Control|This arm includes participants randomized to the control group who will use activity trackers (Fitbits) only, and not receive the SystemCHANGE intervention.
3129020|NCT03191630|Experimental|Intervention|This are includes participants randomize to the intervention group who will receive the combination of the SystemCHANGE TM and activity tracker intervention
3487661|NCT03734900|Placebo Comparator|Saline injection|Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections
3487662|NCT03734900|Experimental|PRP injection|PRP injection into the study knee joint every 4 weeks for a total of 3 injections
3487663|NCT03734900|Experimental|PL injection|PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.
3487664|NCT03734887|Active Comparator|Private Feedback|Participants will receive a smart pill bottle that will collect data on their medication usage and provide real-time data about adherence to study staff. Study staff will provide participants with private feedback about adherence in the form of meeting with a pharmacist. Feedback will be provided at the start of the study. A semi-structured interviews will be performed among a random sub-sample of participants afterwards.
3487665|NCT03734887|Experimental|Social Network Intervention|Participants will receive the same treatment as the Private Feedback arm but they will additionally have Social Network Feedback. A biweekly feedback text messages will be sent to both the participant and a designated loved-one or friend of the participants for 12 weeks.
3487666|NCT03734874|Active Comparator|hesperidin|
3487667|NCT03734874|Placebo Comparator|control|
3487668|NCT03734861|Experimental|BreatheSmart System|"BreatheSmart mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor real-time adherence and to provide targeted outreach to children with low adherence (intervention arm)"
3487669|NCT03734861|Active Comparator|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
3487670|NCT03734848|No Intervention|Group 1|patients did not receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
3487671|NCT03734848|Active Comparator|Group 2|patients receive Bilateral Ultrasound Guided Pectoralis Nerve Block (control group).
3487672|NCT03734835|Active Comparator|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
3487673|NCT03734835|Placebo Comparator|control|no supplementation
3487674|NCT03734835|Active Comparator|flaxseed|30 grams flaxseed
3487675|NCT03734835|Active Comparator|hesperidin|1000 mg hesperidin as two capsules
3487676|NCT03734809|Experimental|pembrolizumab|"Total 51 weeks for 17 doses of pembrolizumab:~Neoadjuvant pembrolizumab-chemotherapy: 6 weeks (2 doses of pembrolizumab)~Concurrent pembrolizumab-chemoradiation: 9 weeks (3 doses of pembrolizumab~Maintenance pembrolizumab: 36 weeks (12 doses of pembrolizumab)"
3487677|NCT03734796||suspected NSTEMI|Patients aged 18-75 years old and highly suspected NSTEMI without Left bundle branch block (LBBB) will be included. Patients will be excluded if who is STEMI, underwent surgical operation within four weeks, medium and several kidney dysfunction (Ccr<30ml/min), anemia, acute myocarditis, chronic cardiac dysfunction (NYHA III-IV), serious cardiac arrhythmias, with history of intravenous drug, oncosis and recent thrombolysis treatment, or pregnant.
3487678|NCT03734770|Active Comparator|Subcutaneous progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
3487679|NCT03734770|Active Comparator|Vaginal progesterone|After standard stimulating protocol for IVF, beginning on the day of oocyte retrieval allocated patients receive micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours) for at least 8 gestational weeks or confirmation of a negative pregnancy test performed 14 days after oocyte retrieval.
3487680|NCT03734757|Experimental|Trimodality|PET-CT with fluorocholine and MRI
3487681|NCT03734744|Experimental|Adults with Cystic Fibrosis|CF adults with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
3487682|NCT03734744|Experimental|Non-CF Controls with Low vitamin D|Non-CF controls with vitamin D insufficiency or deficiency will receive 300,000-600,000 IU vitamin D3 (cholecalciferol)
3487683|NCT03734718|Active Comparator|Glucose-Dependent Insulinotropic Polypeptide|6-day continuous infusion of Glucose-Dependent Insulinotropic Polypeptide
3487684|NCT03734718|Placebo Comparator|Placebo|Saline
3487685|NCT03734705|Experimental|Imaginal Exposure Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about their worst-case scenario regarding discarding a possession (i.e., imaginal exposure).
3487686|NCT03734705|Sham Comparator|Neutral Writing|People with hoarding disorder will write for 20 minutes on each of 3 consecutive days about what they would do if they had a day off work or school.
3129021|NCT03191799|Experimental|1.5 mg/kg Emicizumab QW|Participants will receive initial weekly doses of prophylactic emicizumab subcutaneously for 4 weeks, followed by maintenance doses consisting of half the initial dose, administered subcutaneously for the remainder of the 2-year treatment period
3129022|NCT03192137|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
3129023|NCT03192137|Placebo Comparator|Vehicle|DuraSite® 2 Vehicle
3487687|NCT03734692|Experimental|cisplatin + rintatolimod + pembrolizumab|Intraperitoneal (IP) cisplatin 50mg/m^2 solution with IP rintatolimod 200 mg solution and IV pembrolizumab 200 mg solution.
3487688|NCT03734679|Experimental|Surveil drug coated balloon|
3487689|NCT03734653|Experimental|Square Wave Testosterone Therapy + SOC|All patients will receive transdermal testosterone. All patients will also receive standard of care enzalutamide. Patients will alternate between the two therapies.
3487690|NCT03734640|Placebo Comparator|Guideline recommended standard monitoring|vital signs (HR, BP) and neurological assessment (GCS and NIHSS) 15-30mins x 2 hours, 30mins x 6 hours, 1hourly x 16 hours in usual care monitoring environment
3129024|NCT03192150|Experimental|ISV-305|0.1% dexamethasone in DuraSite® 2
3129025|NCT03192150|Placebo Comparator|Vehicle|DuraSite® 2 vehicle
3129026|NCT03192176|Placebo Comparator|Placebo|Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
3487691|NCT03734640|Active Comparator|Low-intensity monitoring strategy|vital signs (HR, BP) and neurological assessment (GCS and/or NIHSS) 15-30mins x 2 hours, 2hourly x 8 hours, 4hourly x 14 hours in a non-ICU ward
3487692|NCT03734627||Upper Gastrointestinal Surgery - Transit|
3487693|NCT03734627||Control - Transit|
3487694|NCT03734627||Upper Gastrointestinal Surgery - Gut Function|
3487695|NCT03734627||Control - Gut Function|
3129027|NCT03192176|Experimental|Fezolinetant 15 mg|Participants received fezolinetant 15 mg capsules orally, BID for a period of 12 weeks.
3129028|NCT03192176|Experimental|Fezolinetant 30 mg|Participants received fezolinetant 30 mg capsules orally, BID for a period of 12 weeks.
3179885|NCT00677456|Active Comparator|3|Patients will receive Pouch reconstruction after total gastrectomy as intervention.
3179886|NCT00677456|Active Comparator|4|Patients will receive P-I reconstruction after total gastrectomy as intervention.
3487696|NCT03734614||Patients with adjuvant aspirin|After surgery, patients would use low-dose aspirin (100mg) longer than 1 year
3487697|NCT03734614||Patients without adjuvant aspirin|After surgery, patients would not use low-dose aspirin or use asprin shorter than 1 year
3487698|NCT03734588|Experimental|SPK-8016|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8016.
3487699|NCT03734575|Experimental|ClariCore System|Biopsy tissue, correlative spectral data, T2-weighted MR scans and ultrasound images acquired with the ClariCore System will be collected and recorded during standard practice transperineal biopsy.
3487700|NCT03734562|Experimental|Ablation|Substrate-based radiofrequency catheter ablation
3487701|NCT03734562|Active Comparator|Antiarrhythmic drug therapy|Antiarrhythmic drug therapy; amiodarone or sotalol
3129029|NCT03192176|Experimental|Fezolinetant 60 mg|Participants received fezolinetant 60 mg capsules orally, BID for a period of 12 weeks.
3129030|NCT03192176|Experimental|Fezolinetant 90 mg|Participants received fezolinetant 90 mg capsules orally, BID for a period of 12 weeks.
3487702|NCT03734549||technical success group|Technical success was defined as crossing the CTO and placement of a guidewire in the distal true lumen confirmed by angiography.
3487703|NCT03734549||technical failure group|Technical failure was defined that guidewire could not crossing through the CTO nor reture to the true lumen by angiography.
3487704|NCT03734549||had adverse events group|Patients had one of the adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization or amputation.at 12 months after procedures.
3129031|NCT03192176|Experimental|Fezolinetant 30 mg + Placebo|Participants received fezolinetant 30 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
3129032|NCT03192176|Experimental|Fezolinetant 60 mg + Placebo|Participants received fezolinetant 60 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
3129033|NCT03192176|Experimental|Fezolinetant 120 mg + Placebo|Participants received fezolinetant 120 mg capsules orally, QD and matching placebo QD for a period of 12 weeks.
3129034|NCT03192306|Active Comparator|Merlin|glycolic acid and ethanol mixture
3129035|NCT03192306|Placebo Comparator|Ethanol|
3129036|NCT03192475|Active Comparator|Group Lifestyle Balance plus phone contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using an in-person group format. The active comparator receives 8 additional sessions of group interactive telephone contact delivered from 5-12 months
3129037|NCT03192475|Placebo Comparator|Group Lifestyle Balance plus newsletter contacts|Group Lifestyle Balance is the core behavioral lifestyle intervention delivered from 0-4 months using in-person group format. The placebo comparator receives 4 additional educational newsletters delivered from 5-12 months.
3129038|NCT03192488|Experimental|Cetirizine/Hypoxia|Subjects orally ingested 10 mg of Cetirizine 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
3129039|NCT03192488|Placebo Comparator|Placebo/Normoxia|Subjects orally ingested a 10 mg gelatin Placebo 60 min before exercising in a normoxic (room-air) environment (20.9% oxygen).
3129040|NCT03192488|Placebo Comparator|Placebo/Hypoxia|Subjects orally ingested a 10 mg Placebo 60 min before exercising in a normobaric hypoxic environment (14.3% oxygen simulating an altitude of 3,000m/9,000ft).
3129041|NCT03192826|Active Comparator|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
3129042|NCT03192826|Active Comparator|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
3487705|NCT03734549||had no adverse events group|Patients had none adverse events such as all-cause death, nonfatal myocardial infarction, repeat revascularization and amputation at 12 months after procedures
3487706|NCT03734536|Other|REGENETEN™ Bioinductive Implant|Surgical treatment of partial-thickness rotator cuff tears with the REGENETEN Bioinductive Implant system.
3487707|NCT03734536|Other|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
3487708|NCT03734523||Pilot Group: 12 week study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for 12 weeks. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
3487709|NCT03734523||Study Group: 6 month study|"Premenopausal women between 18 and 52 who have been diagnosed with BV at least once within the past year will be invited to enroll. They will be followed longitudinally for six months. As this is an observational study, there is no control group.~Exclusions: pregnant women, those with allergies/sensitivities to product ingredients or to Diflucan or metronidazole, anyone who is immunocompromised, anyone with known vaginal infection other than BV or yeast, those who may be mentally/emotionally triggered by VSQ questions. We will exclude vulnerable populations: adults unable to consent, individuals too young to consent, prisoners, and pregnant women."
3487710|NCT03734510|Active Comparator|hesperidin and flaxseed|
3487711|NCT03734510|Placebo Comparator|control|
3487712|NCT03734510|Active Comparator|flaxseed|
3487713|NCT03734510|Active Comparator|hesperidin|
3487714|NCT03734497|Active Comparator|Group Control|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
3487715|NCT03734497|Experimental|Group Preloading|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
3487716|NCT03734497|Experimental|Group Carotis FTc|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
3487717|NCT03734484|Experimental|Gram type infection-specific algorithm|The experimental arm will involve patients monitored by the Gram type infection-customized version of InSight.
3487718|NCT03734484|No Intervention|Standard treatment protocol|The control arm will involve patients treated with the regular diagnosis and treatment protocol for gram-type infection, where fluid cultures are run to determine infection type.
3487719|NCT03734471|Active Comparator|Traditional|
3487720|NCT03734471|Experimental|Reactor Device|
3487721|NCT03734458|Experimental|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun 1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube and one 10ml sterile plastic tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane. For the AFG, the liquid will be separated from the red blood cells from the plastic tube using a sterile syringe.
3487722|NCT03734458|Experimental|Group B - PRF only with a CAF|Group B - PRF only with a CAF: The PRF will be prepared according to the protocol outlined by Choukroun1. Prior to the surgical procedure, venous blood will be collected via venipuncture from the antecubital vein using one 10 ml sterile glass tube. The tubes will be immediately centrifuged at 1300 rpm for 8 minutes to obtain PRF. The fibrin clot formed in the middle part of the tube will be collected. The clot will be transferred to the PRF box and compressed to form a membrane.
3487723|NCT03734458|Active Comparator|Group C - CTG with a CAF|Group C - CTG with a CAF: Sup-epithelial connective tissue harvest: The palatal donor site should be at least 3mm in thickness. A horizontal incision will be made on the palate 3mm from the maxillary canine to the first molar using a 15 blade. A sub-epithelial connective tissue graft will be harvested with adequate dimensions based on the recipient site. The graft will be sutured over the recipient site with 5-0 chromic gut sutures using a continuous mattress suturing technique.
3487724|NCT03734445|Experimental|Vitamin supplement|Effervescent tablets containing Vitamin C, Vitamin D and zinc
3487725|NCT03734445|Placebo Comparator|Placebo|Effervescent tablets not containing Vitamin C, Vitamin D and zinc
3487726|NCT03734432|Experimental|Patients|IGAR-Breast TeleOp
3487727|NCT03734406|Experimental|Video group|"All subjects enrolled in the study group will be showed during the discharge process the video related to patient's condition (DVT vs AF), using it as a graphic support to doctor's verbal explanation of the diagnosed pathology and its possible complications.~For the purposes of the study we have selected two 3D videoclips, available on various internet sites and not covered by any copyright restrictions; these have been modified and shortened to make them suitable to use in our study setting.~The images contained show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.~The SIs will show the videos to patients on the institutional computer or, alternatively, on their personal smartphone / tablet. The videos were purposely left without audio content."
3487728|NCT03734406|No Intervention|Control group|"Patients of the control group will receive discharge explanations without the aid of any video.~The communication strategy in these cases won't be standardized, in order to leave the treating doctors free to express themselves in the way they are used to in their clinical practice, which is based solely on doctor's verbal and non-verbal communication skills."
3487729|NCT03734393|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 40
3487730|NCT03734393|No Intervention|HIVD-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and are randomized to participate in the full study arm, which includes research sample collection -enrollment 40
3129043|NCT03192826|Placebo Comparator|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
3129044|NCT03192904|Experimental|Energy Instruments Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use energy instruments dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
3487731|NCT03734393|No Intervention|HIVD-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group with limited data collection - enrollment 120
3487732|NCT03734380|Experimental|Laboratory-based gait retraining (LGR)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they walk at a self-selected speed on the instrumented staircase. The training time will be progressively increased from 15 to 30 minutes over the six sessions. The auditory feedback will be gradually removed in the last three sessions.
3487733|NCT03734380|Experimental|Sensor-based gait retraining (SGR)|Subjects will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. The training schedule, duration, and intensity will be identical to those of the LGR group.
3487734|NCT03734380|Experimental|Walking exercise control (Ctrl)|Subjects will attend 6 weekly sessions of stair ascent and descent exercise over six consecutive weeks. In each session, they will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups.
3132762|NCT03449433|Active Comparator|Insulin Aspart (NovoRapid®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
3132763|NCT03449433|Active Comparator|Insulin Aspart (Fiasp®)|T1DM participants received a single, individualized, SC dose of insulin aspart.
3132764|NCT03449433|No Intervention|Healthy Participants|Healthy participants who received no study drug.
3487735|NCT03734367|Active Comparator|Emotional abilities training program|Intervention program on emotional abilities that will be carried out for 10 hours distributed over 5 weeks, in two and a half hour session. The work methodology will be eminently practical, working in groups including real case analysis and interactive simulation
3487736|NCT03734367|No Intervention|Control group|Control group that will not receive the training program on emotional abilities but usual care.
3487737|NCT03734354|Experimental|1 mg dosing group|Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets
3487738|NCT03734354|Experimental|2 mg dosing group|Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets
3132765|NCT03449446|Experimental|Selonsertib (SEL)|Participants will receive SEL + placebo to match firsocostat 20 mg tablet + placebo to match cilofexor 30 mg tablet orally once daily for 48 weeks.
3132766|NCT03449446|Experimental|Firsocostat (FIR)|Participants will receive placebo to match SEL 18 mg tablet + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
3487739|NCT03734354|Experimental|4 mg dosing group|Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets
3487740|NCT03734341|Experimental|EZ START Titration|"CPAP titration test performed with an auto CPAP device preset on incremental fixed pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with EZ START pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: auto-adjusting pressure (no wash-out period)."
3487741|NCT03734341|Active Comparator|APAP Titration|"CPAP titration test performed with an auto CPAP device preset on auto-adjusting pressure modality. If the titration pressure is achieved (in a 14-day maximum period) the device will be immediately and remotely preset in CPAP modality with APAP pressure (if any) for a 14-day period to check the titration pressure performance in a short-time period.~Afterwards, the device will be remotely preset on the next modality: incremental fixed pressure (no wash-out period)."
3487742|NCT03734328|Active Comparator|connective tissue graft|"Drug:local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~5/0 silk suture"
3487743|NCT03734328|Experimental|connective tissue graft&PRF|"Drug: local anesthesia (2% lidocaine with 1:100,000 epinephrine/ultracaine ds ampule)~Other names:~-5/0 silk suture"
3487744|NCT03734302|Experimental|Multiple dose oral administration|1mg Once Daily (QD) , oral administration,14 consecutive days
3487745|NCT03734276|Experimental|High intensity exercise|
3487746|NCT03734276|Active Comparator|Control|
3487747|NCT03734237|Active Comparator|Egg based influenza vaccines|Quadrivalent egg-based vaccines, which contain an inactivated form of the virus. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. All egg-based vaccines are FDA licensed for use in the United States.
3487748|NCT03734237|Active Comparator|Recombinant influenza vaccines|FluBlok, recombinant HA influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flublok Quadrivalent is a quadrivalent recombinant influenza vaccine that has been licensed by the FDA for use in the United States.
3487749|NCT03734237|Active Comparator|Cell-culture based influenza vaccines|Flucelvax, Madin-Darby canine kidney (MDCK)-cell-culture based inactivated influenza vaccine. Vaccines will be given to the participant in accordance with standard clinical practices for those in the US military. Flucelvax quadrivalent, the only cell-based flu vaccine FDA licensed for use in the United States.
3487750|NCT03734224|Active Comparator|Group1: Adhesix|This group gets the Adhesix mesh in a normal open hernia operation.
3487751|NCT03734224|Active Comparator|Group 2: Progrip|This group gets the Progrip mesh in a normal open hernia operation.
3487752|NCT03734211|Experimental|Evolocumab|Evolocumab (Repatha®) will be administered subcutaneously once monthly in the abdomen, thigh, or upper arm for the duration of the treatment period (one year). The 420 mg evolocumab/placebo will be administered by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
3487753|NCT03734211|Placebo Comparator|Placebo|The placebo is presented in an identical prefilled autoinjector. It is supplied as a sterile, single-use, preservative-free solution for subcutaneous injection in a disposable, spring-based prefilled autoinjector. The prefilled autoinjector contains a 1.0 mL deliverable volume of 1.1% (w/v) sodium carboxymethylcellulose, 250 mM proline, 10 mM acetate, and 0.01% (w/v) polysorbate 80, pH 5.0.
3487754|NCT03734198|Experimental|Ibrutinib + daratumumab|"Prephase (D-27 to D0): ibrutinib 420 mg/day~Cycle 1 (4 weeks): ibrutinib 420 mg/day from D1 to D28 + daratumumab 8 mg/kg D1 and D2, then 16 mg/kg at D8, D15, D22.~Cycle 2 (4 weeks): ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1, D8, D15 and D22.~Cycles 3 to 6 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1 and D15.~Cycles ≥ 7 (4 weeks) : ibrutinib 420 mg/day D1 to D28 + daratumumab 16 mg/kg at D1."
3487755|NCT03734185|Experimental|Learning and Coping|A health pedagogical strategy that builds on inductive teaching with high involvement of the participants. Characteristics of Learning and Coping are that 'experienced patients' plan, teach and evaluate, in cooperation with health professionals.
3487756|NCT03734185|Active Comparator|Usual Cardiac Rehabilitation|The theoretical frameworks used in some of these local healthcare services are empowerment, self-efficacy and self-management
3487757|NCT03734172||Paediatric diagnostic group|Paediatric diagnostic group
3487758|NCT03734159|Experimental|parasternal block|preoperative parasternal block by ropivacaine injection
3487759|NCT03734159|Placebo Comparator|physiological serum|sodium chloride injection
3487760|NCT03734146|Experimental|Aerobic exercise (AE)|Engage in supervised aerobic exercise for 60 minutes on 3 days per week for 8 weeks. Exercise is performed on a recumbent bike or treadmill at 50-80% of their heart rate reserve.
3487761|NCT03734146|Experimental|Resistance exercise (RE)|Engage in supervised resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 3 sets of 8-12 repetitions of 12 exercises for the major muscle groups.
3487762|NCT03734146|Experimental|Combined Resistance and Aerobic Exercise|Engage in supervised aerobic resistance exercise for 60 minutes on 3 days per week for 8 weeks. Exercise consists of 30 min aerobic exercise at 50-80% heart rate reserve and 30 min of resistance exercise comprising 2 sets of 8-12 repetitions of 9 exercises for the major muscle groups.
3487763|NCT03734146|No Intervention|No training control|No exercise training. Participants will refrain from any moderate-vigorous exercise or resistance training for 8 weeks.
3487764|NCT03734133|Experimental|Foot orthoses|Different foot orthoses
3487765|NCT03734120||men|men undergoing routine semen analysis for infertility
3487766|NCT03734094|Experimental|Ceramic Barrier|The use of a ceramic barrier to induce bone formation during GBR
3487767|NCT03734094|Active Comparator|Titanium mesh|The use of a titanium mesh to induce bone formation during GBR
3487768|NCT03734081|Experimental|Gastric electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
3487769|NCT03734081|Experimental|Electrical stimulation with type 2 ODC|Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
3487770|NCT03734081|Experimental|Electrical stimulation with type 1 ODC|Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
3487771|NCT03734068||Chemoembolization|Chemoembolization Using LifePearl and Doxorubicin
3487772|NCT03734055|Experimental|Peer Mentoring|The program will consist of 12 sessions of peer mentoring that will include one standard educational session by telephone or video for approximately 60 minutes every 2 weeks. Additional interaction will be discouraged, but mentees and mentors will be asked to report any additional social interaction should it occur. The bi-weekly educational session will be generally structured in three parts: introduction, structured education, and problem solving. 60-minute calls are necessary for the delivery of educational content and mentors and mentees to be able to discuss their own experiences and potential solutions.
3487773|NCT03734055|Active Comparator|Social Support Group|Mentees randomized to the social support control group will be enrolled in a lupus support group designed specifically for this project.
3487774|NCT03734029|Experimental|Trastuzumab deruxtecan|HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a
3487775|NCT03734029|Active Comparator|Physician's Choice|"HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:~Capecitabine~Eribulin~Gemcitabine~Paclitaxel~Nab-paclitaxel"
3487776|NCT03734003|Experimental|Controllable infrared bioeffect system for cutaneous warts|"Controllable infrared bioeffect system at 44±2℃ for 30 mins on target lesion, at days of 1, 2, 3, 15, 16, 23, 30.~Common warts, plantar warts, and condyloma acuminata"
3487777|NCT03734003|Active Comparator|Liquid nitrogen cryotherapy for cutaneous warts|Liquid nitrogen crytotherapy at days 1, 15, 30.
3487778|NCT03733964|Experimental|Manual therapy|A group of 50 people using manual therapy as a treatment method.
3487779|NCT03733964|Experimental|PNF|A group of 50 people using PNF (Proprioceptive Neuromuscular Facilitation) as a treatment method.
3487780|NCT03733964|Experimental|Manual therapy + PNF|A group of 50 people using combination therapy - manual therapy and PNF.
3487781|NCT03733964|Experimental|Kinesiotherapy|A group of 50 people using traditional kinesiotherapy (exercises) as a treatment method.
3487782|NCT03733951|Experimental|KN046|
3487783|NCT03733938||teeth with failed root canal treatement|endodontic microsurgery will be performed for teeth with failed root canal treatment
3487784|NCT03733912||Pregnancy|Infertile women undergoing in vitro fertilization cycle got pregnancy successfully. The pregnancy persisted over 12 weeks.
3487785|NCT03733912||Non-pregnancy|Infertile women undergoing in vitro fertilization cycle failed to reach pregnancy.
3179887|NCT00677469|Experimental|I|Cholestyramine 2g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3487786|NCT03733886|Active Comparator|Burst SCS|"In the active comparator the burst SCS system will be turned on according to randomisation.~A treatment period is a 2-week period where the patient receives either active treatment or sham. Each patient will go through 6 treatment periods (in total 12 weeks). A treatment cycle is a 4-week period with two treatment periods, one of active treatment and one of sham. Each patient will go through three treatment cycles."
3487787|NCT03733886|Sham Comparator|Sham|In the sham comparator the burst SCS system will be turned off according to randomisation.
3487788|NCT03733873|Experimental|desmopressin plus Suoquan|Drug1. name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months Drug2 name:Suoquan mixture form:liquid dosage:10ml/time frequence:bid duration:3 months
3487789|NCT03733873|Active Comparator|desmopressin|name:desmopressin form:tablet dosage:2-4mg frequency:qn duration:3 months
3487790|NCT03733860|Active Comparator|Cavernous sparing group|
3487791|NCT03733860|Other|Conventional technique group|
3487792|NCT03733834||SD therapy|SD therapy is definited as the treatment regimen must follow NCCN guildline and chemotherapy intensity could not be reduced.
3487793|NCT03733834||NSD therapy|Non-standard (NSD) therapy is definited as patients receiving reduced-intensity therapy or only supporting care.
3487794|NCT03733821||CUD patients on HF-rTMS treatment|Patients fulfilling the Diagnostic and Statistical Manual of Mental Disorders - 5 (DSM 5) criteria for Cocaine Use Disorder undergoing a High Frequency rTMS protocol stimulating over the left dorsolateral prefrontal cortex (DLPFC).
3487795|NCT03733808|Active Comparator|Active rTMS treatment|Active High frequency rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. The stimulation protocol parameters will be set as follow: frequency of 15 Hz, of 100% of resting motor threshold (rMT), 40 trains, 60 pulses per train, 15 s intertrain-interval, 2400 pulses per session.
3487796|NCT03733808|Sham Comparator|Sham rTMS treatment|Sham rTMS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same procedures of active High frequency rTMS will be used.
3487797|NCT03733795||Control|'Healthy babies' to establish 'normal' blood flow in neonates.
3487798|NCT03733795||ECMO|Children undergoing extracorporeal membrane oxygenation for acute respiratory failure.
3487799|NCT03733795||Conventional|Neonates undergoing conventional treatment for acute respiratory failure.
3487800|NCT03733782|Active Comparator|Modular enteral protein - Prosource|Subjects are patients admitted to the surgical intensive care unit and identified by one of the investigators as being appropriate for protein supplementation. Guidelines required that patients were: 1. Deemed ready to start enteral nutritional support by the attending physician within 72 hours of admission to the intensive care unit, 2. No contraindications to full enteral support, 3. No history of chronic liver disease, 4. Serum creatinine < 2.0 mg/dl.
3487801|NCT03733782|No Intervention|Control group|The investigators used the electronic medical record to identify control subjects. These were patients admitted to the surgical intensive care unit who were in the ICU long enough to undergo testing of 24 hour urine nitrogen excretion from January to December 2016.8 As part of standard clinical practice, measurement of urine nitrogen excretion is performed in patients who are in the ICU and receiving nutritional support for more than one week.
3487802|NCT03733769|Experimental|TQL group|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
3487803|NCT03733756|Experimental|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
3487804|NCT03733756|Active Comparator|POEM involving longitudinal muscle|participants are operated POEM involving the whole layer of muscle, both circular and longitudinal muscle
3487805|NCT03733743|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
3487806|NCT03733717|Experimental|Isatuximab|Administered intravenously every week in Cycle 1 (4 weeks) followed by every 2 weeks (Q2W) in subsequent cycles.
3487807|NCT03733704|Experimental|Healthy volunteers|Healthy volunteers
3487808|NCT03733691|Experimental|Ixazomib Only|The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.
3487809|NCT03733691|Experimental|Ixazomib + Lenalidomide|"The prescribed dose administration of ixazomib in this study is 3mg orally on Days 1, 8, and 15 of a 28-day cycle.~The prescribed dose administration of lenalidomide in this study is the same as the dose of the patient's front-line treatment taken in the last treatment cycle unless otherwise clinically indicated per investigator's discretion, taken orally on days 1-28 of a 28-day cycle. If patient was receiving lenalidomide at a higher dose than 10 mg, then the dose of lenalidomide on this study will be adjusted to 10 mg daily on days 1-28 of a 28-day cycle"
3487810|NCT03733678|Experimental|Free SARC, Free LARC, Recommendation|Free SARC, Free LARC, Sequential recommendation
3487811|NCT03733678|Experimental|Free SARC, LARC=500, Recommendation|Free SARC, LARC=500 CFA, Sequential recommendation
3487812|NCT03733678|Experimental|Free SARC, LARC=1000, Recommendation|Free SARC, LARC=1000 CFA, Sequential recommendation
3487813|NCT03733678|Experimental|Free SARC, LARC=2140, Recommendation|Free SARC, LARC=2140 CFA, Sequential recommendation
3129045|NCT03192904|Experimental|Stapling Device Group|All enrolled patients will accept robot-assisted or uniportal segmentectomy. After cutting off the relevant segmental arteries and veins, we clamp the segmental bronchus, and then the diseased lung will be ventilated to identify the border of segment according to the collapse region. We use stapling device to dissect intersegmental plane along the determined border. If fast-frozen pathology confirms lung cancer, we will do lymphadenectomy. At last, a drainage tube will be placed.
3487814|NCT03733678|Experimental|Free SARC, LARC=5000, Recommendation|Free SARC, LARC=5000 CFA, Sequential recommendation
3487815|NCT03733678|Experimental|Regular SARC, Free LARC, Recommendation|Regular price SARC, Free LARC, Sequential recommendation
3487816|NCT03733678|Experimental|Regular SARC, LARC=500, Recommendation|Regular price SARC, LARC=500 CFA, Sequential recommendation
3487817|NCT03733678|Experimental|Regular SARC, LARC=1000, Recommendation|Regular price SARC, LARC=1000 CFA, Sequential recommendation
3487818|NCT03733678|Experimental|Regular SARC, LARC=2140, Recommendation|Regular price SARC, LARC=2140 CFA, Sequential recommendation
3487819|NCT03733678|No Intervention|Regular SARC, LARC=5000, Recommendation|Regular price SARC, LARC=5000 CFA, Sequential recommendation
3129046|NCT03193021|Experimental|Cardiva Mid-Bore VVCS|Cardiva Mid-Bore VVCS will be used to close all femoral venous access sites at the end of the case.
3129047|NCT03193021|Active Comparator|Manual Compression|Direct manual compression to the access sites will be used to close all femoral venous access sites at the end of the case.
3487820|NCT03733678|Experimental|Free SARC, Free LARC, No Recommendation|Free SARC, Free LARC, Simultaneous recommendation
3487821|NCT03733678|Experimental|Free SARC, LARC=500, No Recommendation|Free SARC, LARC=500 CFA, Simultaneous recommendation
3487822|NCT03733678|Experimental|Free SARC, LARC=1000, No Recommendation|Free SARC, LARC=1000 CFA, Simultaneous recommendation
3487823|NCT03733678|Experimental|Free SARC, LARC=2140, No Recommendation|Free SARC, LARC=2140 CFA, Simultaneous recommendation
3129048|NCT03193047|Experimental|bempedoic acid|Bempedoic acid 180mg tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
3487824|NCT03733678|Experimental|Free SARC, LARC=5000, No Recommendation|Free SARC, LARC=5000 CFA, Simultaneous recommendation
3487825|NCT03733678|Experimental|Regular SARC, Free LARC, No Recommendation|Regular Price SARC, Free LARC, Simultaneous recommendation
3487826|NCT03733678|Experimental|Regular SARC, LARC=500, No Recommendation|Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
3129049|NCT03193047|Placebo Comparator|placebo|Matching placebo tablet taken orally, once daily plus evolocumab (Repatha) 420mg injection once monthly
3487827|NCT03733678|Experimental|Regular SARC, LARC=1000, No Recommendation|Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
3487828|NCT03733678|Experimental|Regular SARC, LARC=2140, No Recommendation|Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
3487829|NCT03733678|Experimental|Regular SARC, LARC=5000, No Recommendation|Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
3487830|NCT03733665||Heart failure patients|All patients in NICOR's National Heart Failure Audit will be matched to those in NHS Digital's HES database who have a 4-character primary diagnosis of I50.0-I50.9.
3487831|NCT03733652|No Intervention|Tenofovir|Patents are treated with oral tenofovir 300mg once per day for 48 weeks. Then, tenofovir will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be continued if HBsAg is positive.
3487832|NCT03733652|Active Comparator|Interferon alfa|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
3487833|NCT03733639|Active Comparator|Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm Tisseel® surgeon dispenses the product all over the anastomosis. The rest of the surgical procedure is as usual."
3487834|NCT03733639|Other|no Tisseel®|"Once the esophagojejunal anastomosis is done the patient is randomized (Tisseel® vs no product). In the arm  noTisseel® surgeon performs the surgical procedure as usual."
3487835|NCT03733613||Healthy adults|Subjects will receive pre and post-test, in order to verify the test-retest reliability of the Somatosensory detector
3487836|NCT03733600||Glaucoma|All patients followed for either early or moderate forms of primary or secondary open-angle glaucoma who had undergone surgery for Xen alone or in combination with cataract surgery for phacoemulisation of the lens.
3487837|NCT03733587|Experimental|Cyclophosphamide and GX-I7|Cyclophosphamide and determined dose of GX-I7 of each cycle
3487838|NCT03733574|Experimental|LY03005 cross-over to Pristiq® (Desvenlafaxine)|Subjects in this group will receive an 80 mg oral dose of LY03005. After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®).
3487839|NCT03733574|Experimental|Pristiq® (Desvenlafaxine) cross-over to LY03005|Subjects in this group will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005
3487840|NCT03733561|Experimental|LY03003|LY03003
3487841|NCT03733561|Active Comparator|Neupro transdermal patch|Neupro transdermal 4 mg patch
3487842|NCT03733548|Experimental|Regulating Emotions Like An eXpert (RELAX)|Families at the Virginia Commonwealth University Center for Psychological Services and Development or Clark-Hill Institute for Positive Youth Development
3129050|NCT03193398|Experimental|BTRX-246040|40 mg administered orally as 1 capsule QD for 1 week, followed by 80 mg as 2 capsules QD for 7 weeks.
3129051|NCT03193398|Placebo Comparator|Placebo|administered orally as 1 capsule QD for 1 week, followed by 2 capsules QD for 7 weeks.
3487843|NCT03733535|Experimental|Treatment|Benralizumab 30mg subcutaneous injection on study days 0, 28 and 56 and 1.0 L 129-Xenon/4-Helium mixture, twice per visit, on days 0, 14, 28 and 112.
3487844|NCT03733522|Active Comparator|Rubber dam isolation|"Absolute isolation~local anesthesia~use of dental clamp and rubber dam~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
3487845|NCT03733522|Experimental|Relative isolation|"Relative isolation~no local anesthesia~use of cotton roll and saliva ejector~restoration using Universal Adhesive in a self etch mode (Single Bond Universal - 3M ESPE) and bulkfill composite resin (Filtek Bulkfill - 3M ESPE)"
3487846|NCT03733509|Experimental|Intraoperative Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of Bupivacaine 0.25%.~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml of saline solution (NaCl 0.9%)."
3487847|NCT03733509|Active Comparator|Ultrasound Block|"Before skin closure, blunt suprapatellar dissection proximal to medial femoral condyle towards adductor canal. Nerve block at this level with 20ml of of saline solution (NaCl 0.9%).~Postoperatively, mid-thigh ultrasound guided standard adductor canal nerve block with 20ml Bupivacaine 0.25%."
3179888|NCT00677469|Experimental|II|Cholestyramine 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3129052|NCT03193593|Placebo Comparator|Placebo Injections|"Intervention: Drug: Placebo~Single Saline Injection into the Pectoralis Muscle"
3179889|NCT00677469|Placebo Comparator|III|Placebo powder 1g BID, Methimazole 10mg TID, and Propranolol 20mg BID
3487848|NCT03733457|Experimental|TASC Intervention|All participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
3487849|NCT03733444|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
3129053|NCT03193593|Active Comparator|EB-001 Dose 1|"Intervention: Drug: EB-001~1st Dose in escalation paradigm. Single Injection of active drug into the pectoralis muscle"
3129054|NCT03193593|Active Comparator|EB-001 Dose 2 (1.6X)|"Intervention: Drug: EB-001~2nd Dose in escalation paradigm, 1.6X Dose 1. Single Injection of active drug into the pectoralis muscle"
3487850|NCT03733444|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
3487851|NCT03733444|Experimental|Placebo|Placebo to match will be administered as matching film-coated tablets for oral use once daily.
3487852|NCT03733431|Active Comparator|Standard dose vagal stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
3129055|NCT03193593|Active Comparator|EB-001 Dose 3 (3.3X)|"Intervention: Drug: EB-001~3rd Dose in escalation paradigm, 3.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
3129056|NCT03193593|Active Comparator|EB-001 Dose 4 (6.7X)|"Intervention: Drug: EB-001~4th Dose in escalation paradigm, 6.7X Dose 1. Single Injection of active drug into the pectoralis muscle"
3487853|NCT03733431|Active Comparator|High dose vagal stimulation|A total of 7 consecutive 2-minute trains applied at every 10 minutes for one hour that is followed by an additional 7 consecutive 2-minute trains interspersed at every 10 minutes applied 3 hours after completion of the initial scheme (n=20)
3487854|NCT03733431|Sham Comparator|Sham stimulation|A total of 7 consecutive 2-minute trains at every 10 minutes for one hour (n=20)
3487855|NCT03733405|Experimental|Postpartum Visit 6 Weeks|Participants will have a postpartum visit scheduled 6 weeks after birth
3487856|NCT03733405|Experimental|Postpartum Visit 2 and 6 Weeks|Participants will have postpartum visits scheduled 2 and 6 weeks after birth
3487857|NCT03733379|Placebo Comparator|Control|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
3487858|NCT03733379|Experimental|Probiotic|Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.
3487859|NCT03733379|Experimental|Antibiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.
3487860|NCT03733379|Experimental|Antibiotic + probiotic|Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.
3487861|NCT03733340|Experimental|Imipenem prophylaxis group|Imipenem: 1g q8h i.v. daily for 5 consecutive days before the onset of conditioning of allo-HSCT
3487862|NCT03733340|No Intervention|Blank control group|Without antibacterial prophylaxis at the onset of condition of all-HSCT
3487863|NCT03733327|Experimental|BUCYE|For PCNSL patients undergoing auto-HSCT，BUCYE conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/ day on days -3 and -2.
3487864|NCT03733288|Experimental|SLAMM|Multi-component intervention (Education and training sessions, Support emails, Team leader training)
3487865|NCT03733288|Experimental|SLAMM+|Multi-component intervention (Education and training sessions, Support emails, Team leader training, Height-adjustable workstation)
3487866|NCT03733275|Experimental|local anesthetic group|local aensthetic group receive preopetaive lidocaine spray and lidocaine-bupivacine mixture-soaked nasal pacing after nasal reduction surgery
3487867|NCT03733275|Placebo Comparator|control group|control group receive preoperative normal saline spray and normal saline-soaked nasal packing after nasal reduction surgery
3487868|NCT03733262||Hemodialysis Patients|There will be approximately 1,200 patients in the outpatient HD units from Toronto (300), Vancouver (200), Winnipeg (400) and Halifax (300). Based on a previous pilot study, it is assumed that 80% of patients have been prescribed at least one of the nine target drugs (i.e., n=960). Of those, it is assumed that 50% will be eligible for the study (i.e., n=480). Of eligible individuals, it is assumed 88% will initiate a De-prescribing Trial (Intervention Group), resulting in an anticipated cohort of n=420.
3487869|NCT03733249|Experimental|Rimiducid and Rivogenlecleucel|"Rimiducid: to treat uncontrolled GVHD in patients who have received rivogenlecleucel Rimiducid will be given at 0.4 mg/kg weight (intravenous infusion)~No further rivogenlecleucel infusions are planned. Patients who received rivogenlecleucel in the BP-004 study will be evaluated for long-term safety and efficacy."
3487870|NCT03733236|Experimental|Active Stimulation|The Implant will be implanted using a minimal invasive approach. Following implantation, a CT localization imaging should be performed as soon as possible following the implant procedure. ISS (Ischemic Stroke System) stimulation of the SPG (Sphenopalatine Ganglionduring) for 5 consecutive days.
3487871|NCT03733223||experimental group|The patients who were treated with Ateptidase had intracranial haemorrhage adverse reactions
3487872|NCT03733223||control group|The patients who were treated with Ateptidase did not have intracranial haemorrhage adverse reactions.
3129057|NCT03193593|Active Comparator|EB-001 Dose 5 (10X)|"Intervention: Drug: EB-001~5th Dose in escalation paradigm, 10X Dose 1. Single Injection of active drug into the pectoralis muscle"
3129058|NCT03193593|Active Comparator|EB-001 Dose 6 (13.3X)|"Intervention: Drug: EB-001~6th Dose in escalation paradigm, 13.3X Dose 1. Single Injection of active drug into the pectoralis muscle"
3129059|NCT03193736|Experimental|implant|
3129060|NCT03194217|Experimental|BEN-2001, 0.5mg|Experimental treatment
3487873|NCT03733210|Experimental|Lymph Node-positive Tumor|Participants whose lymph nodes are positive for cancer
3487874|NCT03733210|Experimental|Lymph Node-negative Tumor|Participants whose lymph nodes are negative for cancer
3487875|NCT03733197|Experimental|Culture specific|"The culture-specific arm may entail FIT kits plus barbers as motivational interviewers."
3487876|NCT03733197|Experimental|Control|Distribution of CRC screening brochures & FIT (Fecal Immunochemical Test) kits by barbers
3487877|NCT03733184||The Christie NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at The Christie NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
3487878|NCT03733184||Hampshire Hospitals NHS FT|Patients treated by Cytoreduction and Heated Intraperitoneal Surgery at Hampshire Hospitals NHS Foundation Trust (one of the two initial, primary treatment centres) for Colorectal Peritoneal Metastasis.
3487879|NCT03733171|Active Comparator|Platelet rich plasma|endoscopic injection of PRP
3129061|NCT03194217|Placebo Comparator|Placebo|Placebo comparator
3129062|NCT03194217|Experimental|BEN-2001, 1.0mg|Experimental treatment
3487880|NCT03733171|Placebo Comparator|CONTROL GROUP|diluted epinephrine
3487881|NCT03733158|Experimental|Normal airway|intubation in normal aurway condition
3487882|NCT03733158|Experimental|Tongue edema|intubation in Tongue edema condition
3487883|NCT03733158|Experimental|Pharyngeal obstruction|intubation in Tongue edema condition
3129063|NCT03194217|Experimental|BEN-2001, 3.0mg|Experimental treatment
3129064|NCT03194334|No Intervention|Control|continued their omnivorous diet throughout the entire study
3487884|NCT03733158|Experimental|Manual cervical inline stabilization|intubation in Manual cervical inline stabilization condition
3487885|NCT03733158|Experimental|Cervical collar stabilization|intubation in Cervical collar stabilization condition
3487886|NCT03733158|Experimental|Cervical collar stabilization and pharyngeal obstruction|intubation in Cervical collar stabilization and pharyngeal obstruction condition
3487887|NCT03733145|Experimental|Participants on ACE inhibitors|Participants taking ACE inhibitors (angiotensin-converting enzyme inhibitors)will be placed into this group. Intervention: Drug: Angiotensin II.
3487888|NCT03733145|Experimental|Participants on ARBs|Participants taking ARBs (angiotensin-receptor blockers) will be placed into this group. Intervention: Drug: Angiotensin II.
3487889|NCT03733145|Experimental|Other Classes of Antihypertensive Agents|Participants taking any other class of Antihypertensive Agents will be placed into this group. Intervention: Drug: Angiotensin II.
3487890|NCT03733106|Experimental|digital breast tomosynthesis|Tomosynthesis and two dimension digital mammography
3487891|NCT03733106|Active Comparator|control|standard two dimension digital mammography
3487892|NCT03733054||Men|Men with lower limb amputation
3487893|NCT03733054||Women|Women with lower limb amputation
3487894|NCT03733041|Active Comparator|rTMS|This group will be randomized to receive rTMS
3487895|NCT03733041|Sham Comparator|Sham|This group will be randomized to receive sham treatment
3487896|NCT03733041|Other|No intervention|This group will receive no intervention
3487897|NCT03733028|Experimental|Mobile Intervention for Reducing Anger (MIRA)|Participants in this arm will be provided with a device that has the MIRA application (app) and asked to use the app for a period of 4 weeks.
3487898|NCT03733028|Active Comparator|Mindfulness Intervention|Participants in this arm will be provided with a device that has the Mindfulness application (app) and asked to use the app for a period of 4 weeks.
3487899|NCT03733015|Active Comparator|cTBS group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. TBS refers to a rTMS protocol where pulses are applied in bursts of three, delivered at a frequency of 50 Hz and an inter-burst interval of 200 ms (5 Hz)."
3487900|NCT03733015|Active Comparator|High frequenct rTMS group|High frequency refers to a rTMS protocol where pulses are applied in at 10Hz frequency
3487901|NCT03733002|Experimental|AngongNiuhuang|Drugs: AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
3487902|NCT03733002|Placebo Comparator|Placebo of AngongNiuhuang|Drugs: Placebo of AngongNiuhuang pill. The other treatments will be provided according to guidelines for standard treatment of acute ischemic stroke.
3487903|NCT03732989|Active Comparator|Control group: Non-interactive toy prototype|30 children will be given the same toy as participants in the experimental group, but without the interactive features (haptic feedback).
3487904|NCT03732989|Experimental|Experimental: Interactive toy prototype|30 children will be given the same toy as participants in the control group, but with the interactive features (haptic feedback).
3487905|NCT03732976|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
3487906|NCT03732976|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
3487907|NCT03732963|Placebo Comparator|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
3487908|NCT03732963|Active Comparator|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
3129065|NCT03194334|Experimental|Veg+Pla|vegetarian + placebo: switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with placebo pills instead of beta-alanine and creatine
3487909|NCT03732937||Control group|Pregnant ladies with no medical disorders from 16 weeks till term
3487910|NCT03732937||case group|Pregnant ladies with medical disorders from 16 weeks till term
3487911|NCT03732924|Experimental|Five minute rest|
3487912|NCT03732924|Active Comparator|Zero minute rest|
3487913|NCT03732911|Experimental|Intervention|Intervention arm
3487914|NCT03732885|Experimental|densah burs drilling group|maxillary sinus floor elevation during implant placement using Densah burs
3487915|NCT03732885|Experimental|Summers osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
3487916|NCT03732872||Patient with habits and having OSMF|Patients who had history of arecanut chewing habit in any form and composition and who were not undergone any treatment for their current condition i.e, OSMF
3487917|NCT03732872||Patients with habits and had no clinical symptoms of OSMF|Patients who had history of arecanut chewing habit in any form and composition and had no symptoms of OSMF clinically
3487918|NCT03732872||Healthy human volunteers|patients who reported no history of areacnut chewing habits and had no clinical symptoms of OSMF
3487919|NCT03732846|Experimental|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
3487920|NCT03732833|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3487921|NCT03732833|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the LCL and MT10109L Dose 2 into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3487922|NCT03732833|Placebo Comparator|Placebo|Placebo will be injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3487923|NCT03732820|Experimental|olaparib plus abiraterone|"Olaparib is available as a film-coated tablet containing 100 milligrams (mg) or 150 milligrams (mg) of olaparib. Subjects will be administered olaparib orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
3487924|NCT03732820|Placebo Comparator|placebo plus abiraterone|"Placebo to match olaparib is available as a film-coated tablet in 100 milligrams (mg) or 150 milligrams (mg). Subjects will be administered placebo orally at a dose of 300 milligrams (mg) twice daily (bid). The initial dosage of 300 milligrams (mg) twice daily will be composed of 2 x 150 milligrams (mg) tablets per dose. The 100 milligrams (mg) and 150 milligrams (mg) tablets will be used to manage dose reductions during the study.~Abiraterone acetate with prednisone or prednisolone will be sourced locally as commercially available materials. Subjects will be administered abiraterone orally at a dose of 1000 milligrams (mg) once daily, in combination with prednisone or prednisolone 5 milligrams (mg) administered orally twice daily."
3487925|NCT03732807|Experimental|Sequence A|Induction dose given once daily (QD) for 4 weeks followed by maintenance dose #1 given QD for 44 weeks
3487926|NCT03732807|Experimental|Sequence B|Induction dose given QD for 4 weeks followed by maintenance dose #2 given QD for 44 weeks
3487927|NCT03732807|Experimental|Sequence C|Maintenance dose #1 given QD for 48 weeks
3487928|NCT03732807|Experimental|Sequence D|Maintenance dose #2 given QD for 48 weeks
3487929|NCT03732807|Experimental|Sequence E|Maintenance dose #3 given QD for 48 weeks
3129066|NCT03194334|Experimental|Veg+ creatine and beta-alanine|switch to a lacto-ovo-vegetarian diet for 6 months and are supplemented with 1 g of creatine monohydrate (2 capsules of 500 mg) and 0.8 g of beta-alanine (1 Carnosyn® tablet) each day
3487930|NCT03732807|Experimental|Sequence F|Placebo given QD for 24 weeks followed by induction dose given QD for 4 weeks then maintenance dose #1 given QD for 20 weeks
3487931|NCT03732807|Experimental|Sequence G|Placebo given QD for 24 weeks followed by maintenance dose #1 given QD for 24 weeks
3487932|NCT03732794|Experimental|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
3487933|NCT03732781|Experimental|Radspherin|
3487934|NCT03732768|Experimental|Radspherin|
3487935|NCT03732755|Experimental|Active|PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
3487936|NCT03732742|Experimental|TOF repair with preservation of PV|Surgical intervention by repair of Tetralogy of Fallot with preservation of pulmonary valve, recently interested has shifted to preserving the integrity of the pulmonary valve.
3487937|NCT03732742|Experimental|TOF repair with trans-annular patch|Surgical intervention by repair of Tetralogy of Fallot with trans-annular patch, right ventricular hypertrophy, right ventricular dilatation and pulmonary vavle regurgitation has been recognized as one of the most important risk factors for both right and left ventricular performance after the repair of Tetralogy of Fallot.
3487938|NCT03732729|Experimental|Massage chair|lifestyle modification education(once)+ Using massage chair
3487939|NCT03732729|No Intervention|Control|lifestyle modification education(once)
3487940|NCT03732716||Elderly with sarcopenia|50 patients aged 75 or older with sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
3487941|NCT03732716||Elderly without sarcopenia|50 patients aged 75 or older without sarcopenia Intervention: Each patient's supine and standing blood pressures will be measured.
3487942|NCT03732703|Experimental|Sub-Protocol A1|Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487943|NCT03732703|Experimental|Sub-Protocol B1|Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487944|NCT03732703|Experimental|Sub-Protocol C1|Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487945|NCT03732703|Experimental|Sub-Protocol D1|Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487946|NCT03732703|Experimental|Sub-Protocol E1|Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
3487947|NCT03732703|Experimental|Sub-Protocol Y1|Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487948|NCT03732703|Experimental|Sub-Protocol Y2|Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487949|NCT03732703|Experimental|Sub-Protocol Y3|Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)
3487950|NCT03732690|Other|Diet High Protein (HP)|Diet High Protein (HP) : 30% protein, 40% carbohydrate and 30% fat
3487951|NCT03732690|Other|Diet Low Protein (LP)|Diet Low Protein (LP) : 10% protein, 55% carbohydrate and 35% fat
3487952|NCT03732677|Experimental|Arm 1|Chemotherapy + Durvalumab
3487953|NCT03732677|Active Comparator|Arm 2|Chemotherapy alone
3487954|NCT03732651|Experimental|non-pulsatile blood flow|
3487955|NCT03732651|Experimental|pulsatile blood flow|
3487956|NCT03732625|Experimental|Raltegravir|Raltegravir (RAL) x 2 600mg QD (Total 1200mg QD)
3487957|NCT03732612||Control patients|"Control patients (n=20): In individuals undergoing vascular surgery that is not associated with vascular disease (e.g. knee replacement surgery, trauma, etc), a piece of healthy vessel must sometimes be removed in order to facilitate the surgical process. The vessel biopsies from this group will be categorized as healthy vessels in our study."
3487958|NCT03732612||Study patients|"Study patients (n=150): In individuals undergoing vascular surgery associated with peripheral arterial diseases, aneurysm and/or other manifestations of atherosclerosis, vascular tissue is sometimes excised to facilitate the surgery. Biopsies from these individuals will be categorized as vessels with vascular dysfunction."
3487959|NCT03732599|Active Comparator|Standard DALK|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
3487960|NCT03732599|Active Comparator|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
3487961|NCT03732586|Experimental|Omega 5 fatty acid supplement|20 patients will be assigned to traditional treatment with prednisone 40 mg per day plus dietary supplement with omega 5 fatty acid
3487962|NCT03732586|Placebo Comparator|PLACEBO|20 patients will be assigned to traditional treatment (prednisone 40 mg per day) plus placebo
3487963|NCT03732573|Experimental|Intervention Group|This group will receive 9 text messages over 3 weeks. Messages will be based on goal-setting in the first week, goal-operating in the second week, and self-monitoring in the third week.
3487964|NCT03732573|No Intervention|Control Group|Participants in this group will receive no messages during the intervention period.
3487965|NCT03732560||Patients undergoing treatment with nivolumab and ipilimumab|
3487966|NCT03732560||Patients undergoing treatment with nivolumab|
3487967|NCT03732547|Experimental|'PolyIC plus PD-1 mAb' and 'PD-1 mAb'|"'PolyIC plus PD-1 mAb' group: PolyIC, 2mg, i.m., every other day, for three weeks. PD-1 mAb, 200mg, i.v., every three weeks.~'PD-1 mAb' group: PD-1 mAb, 200mg, i.v., every three weeks."
3487968|NCT03732534|Experimental|NBI-98854|NBI-98854 administered once daily for up to 96 weeks
3487969|NCT03732521|Experimental|Intervention group|educational therapy
3487970|NCT03732521|No Intervention|Control group|usual clinical practice
3487971|NCT03732508|Experimental|Irinotecan liposome plus SHR1316 plus fluorouracil|
3487972|NCT03732495|Experimental|Trial arm|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met."
3487973|NCT03732482|Placebo Comparator|RT groups|participants was given radiotherapy only,50Gy in 10 fractions over 2 weeks to metastases synchronously with 25Gy WBRT
3487974|NCT03732482|Experimental|Drug plus RT groups|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
3487975|NCT03732469|Experimental|Fentanyl/propofol + acetaminophen|In addition to the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol, one dose of 1300 mg of solid base rectal acetaminophen suppository (2 suppositories) will be administered at the end of oocyte retrieval.
3487976|NCT03732469|Active Comparator|Fentanyl/propofol only|Participants in this arm will receive the weight-based intraoperative IV dose of propofol and fentanyl per standard TGH Anesthesiology protocol.
3487977|NCT03732443||Critical Ill Patients|Critically ill patients with a RASS ≥ 3. FAM-CAM and CAM-ICU will be administered.
3487978|NCT03732430|Experimental|Anti-PD-1 antibody|IBI308 200mg intravenous drip every three weeks following adaptive radiation therapy.
3487979|NCT03732417||Stroke patients|Control group included people with ischemic or haemorragic stroke in Terres de l'Ebre, Spain.
3487980|NCT03732417||Telematic model treatment of patients with Stroke|The intervention group included control and education for the patient's health to promote self-care and empowerment, and enhance pharmacological compliance. The telematic model has been developed through clinical practice guides of primary care and the most recent publications on the subject referenced.
3487981|NCT03732404|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
3487982|NCT03732404|Placebo Comparator|Placebo|The control group will receive plain water with the same volume and timing of treatment
3487983|NCT03732391|Experimental|single arm|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will come continued with the same schedule until unacceptable toxicity or disease progression
3487984|NCT03732378|Experimental|Omega-3|one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given to treatment group along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time)
3487985|NCT03732378|Placebo Comparator|Placebo|one capsule of 500 mg corn oil, along with already taking anti depressant drugs( citalopram, escitalopram, paroxetine 1 tablet at night time) were given to placebo group
3487986|NCT03732365|Experimental|Investigational Group|Patients who are randomized to the investigational regimen will receive Ultrasonic Drug Delivery, which includes infusion of up to 2 grams of cefazolin in 100 mL saline followed by external ultrasound in addition to standard of care antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
3487987|NCT03732365|Active Comparator|Comparator Group|Patients who are randomized to the comparator regimen will receive antibiotic according to the antibiotic package insert instructions for standard of care for the particular gram-positive pathogen over a period of no more than 14 days as well as standard of care adjunct therapy.
3487988|NCT03732339|Experimental|GILUPI CellCollector®|
3487989|NCT03732313|Active Comparator|Central toenail resection|Under local ring anaesthesua using xylocaine injection in base of big toe ,Surgical resection of the central part of toenail with underlying germinal matrix.the defect is sutures by prolene.
3487990|NCT03732313|Active Comparator|wedge toenail resection|Under local ring anaesthesiausing xylocaine injection around the base of big toe. Resect lateral wedge of toenail with removal of ingrown toenail and periungual skin. The wound is then sutured.
3487991|NCT03732300|Experimental|ASSIP + TAU goup|ASSIP psychotherapy intervention + treatment as usual (TAU)
3487992|NCT03732300|No Intervention|TAU|Treatment as usual
3487993|NCT03732287|Experimental|-5 degrees Celsius for 10 seconds|
3487994|NCT03732287|Experimental|-5 degrees Celsius for 20 seconds|
3487995|NCT03732287|Experimental|-10 degrees Celsius for 10 seconds|
3487996|NCT03732287|Experimental|-10 degrees Celsius for 20 seconds|
3129067|NCT03194373|Experimental|Palbociclib and Carboplatin|"Treatment with Palbociclib and Carboplatin for up to 6 cycles:~Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days~Maintenance Palbociclib after 6 cycles Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
3487997|NCT03732274|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Durvalumab administration.
3487998|NCT03732261|Experimental|Intervention|Intervention Group: Women randomized to the intervention group will be given a 3month membership to a community based exercise program, a pedometer and individual dietary recommendations. They will be asked to attend a minimum of three 45 minute to 60 minute exercise sessions per week but no more than five and will gradually build to walk 10,000 steps per day. Childcare and breastfeeding support will be provided. Trained research assistants will lead all group sessions. Weekly workout volume will be calculated and weekly steps will be monitored by research assistants. For the dietary intervention, the women will be provided 6oz of plain yogurt fortified with vitamin D post workout for the 12-week intervention. If any yogurt is out of date (expired), we will dispose of the expired yogurt. Weekly monitoring for the consumption of the yogurt and energy intake will be conducted by face-to-face or telephone interviews by research assistants.
3487999|NCT03732261|No Intervention|Control|Minimal Care Group: Women randomized into the minimal care group will be asked not to participate in any structured exercise or make any changes in their diet. They will be permitted to walk their infants in strollers at a leisurely pace (no faster than 2 mph) for no more than 30 minutes per day. After the endpoint measurements of the 12-wk intervention, the minimal care group will be asked to join the community based program provided to the intervention group. The participants will be given the pedometer, individual dietary recommendations and yogurt. Additionally, support by the PI and research assistants for exercise and diet will be provided until the one-year postpartum laboratory measurement.
3488000|NCT03732235||TACE+ systemic Bevacizumab|"TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.~Bevacizumab (5 mg/kg) therapy was initiated 15 days after first round of TACE and was repeated every two weeks, for a total of 8 cycles."
3488001|NCT03732235||FOLFIRI+Bevacizumab|FOLFIRI consists of 5-FU administered as a 48-hour continuous infusion to a total dose of 3,200 mg/m2 without a bolus, leucovorin 200 mg/m2, irinotecan 165 mg/m2 Bevacizumab (5 mg/kg) therapy was repeated every two weeks, for a total of 8 cycles.
3488002|NCT03732235||TACE|TACE was performed, using 2 ml of LifePearl® with 100 micron diameter (Terumo Europe NV, Leuven, Belgium) loaded with Irinotecan (100 mg), diluted in 5 ml of non-ionic contrast solution and 5 ml of distilled water, infused at fixed speed of 1ml/minute for a median time of 12 minutes (range 8-16 minutes). A second TACE was performed after 30 days if needed according to physician choice.
3488003|NCT03732222|Experimental|Stretching the diaphragm muscle|The interventor places his hands on the last costal cartilages and the subject makes an inspiration and keeps his hands resisted in the expiration.
3488004|NCT03732222|Experimental|Impulse technique in rotation of cervical level 3 and 4|The thumbs position the head in a double chin and then place it with neutral flexion-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
3488005|NCT03732222|Experimental|Combined technique of diaphragm muscle stretch and cervical ro|combine both previous techniques.
3488006|NCT03732183|Experimental|Podcast SMART-3RP|"The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new podcast session will be delivered every day."
3488007|NCT03732170|Experimental|TotalFill® Bioceramic sealer|It will be used in conjunction with TotalFill® bioceramic impregnated gutta percha points for the obturation of root canals. It is dispensed through a fine disposable syringe into the root canals during obturation.
3488008|NCT03732170|Active Comparator|AH plus® sealer|It consists of 2 pastes that are mixed together in equal amounts before it is used in conjunction with gutta percha points for obturation during root canal treatment.
3488009|NCT03732157||outpatient management of parathyroidectomy|
3488010|NCT03732157||conventional management of parathyroidectomy|
3129068|NCT03194464|Experimental|Task-failure, Extended Session|Repeated sub-maximal gripping exercise with the less affected hand to task-failure - followed by repeated measurements (5) during recovery period
3488011|NCT03732144|Experimental|Connect Staff-based PA intervention|Sites receiving the Connect physical activity intervention will involve three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum.
3488012|NCT03732144|Other|Connect Health Curriculum Control|Sites receiving the general health curriculum control will also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff.
3488013|NCT03732118||Minimal hepatic encephalopathy|
3488014|NCT03732118||No hepatic encephalopathy (minimal or clinical)|
3488015|NCT03732105|Experimental|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization. After radiotherapy, patients on the control arm will be actively monitored.
3488016|NCT03732105|Experimental|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence,death, patient withdrawal or unacceptable toxic effects.
3488017|NCT03732105|Experimental|Radiotherapy and apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg/qd until recurrence,death,patient withdrawal or unacceptable toxic effects.
3488018|NCT03732105|No Intervention|Control group|Patients on the control arm will be actively monitored after randomization.
3488019|NCT03732092||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
3488020|NCT03732079||Research group|Women with early postpartum hemorrhage.
3488021|NCT03732079||Control group|Postpartum women without abnormal bleeding.
3488022|NCT03732066|Experimental|Intervention Group|The intervention group will receive usual text messages, personalized reminders and interactive responses.
3488023|NCT03732066|Other|Control Group|The control group will receive usual text messages only.
3488024|NCT03732053|Experimental|GPR Intervention Research group|A total of 135 subjects with AD in the mild or moderate phase participated in the study from which 90 pertain to research group.The intervention implemented to the patients with AD was the Global Postural therapy which lasted about 30-40 min in repeated sessions of 2 meetings per week by making 48 sessions in total during a six month period.
3488025|NCT03732053|No Intervention|Control Group|45 subjects of the study belongs to the control group which has not received the same treatment .
3488026|NCT03732040|Sham Comparator|standerd preventive measures|tooth brushing twice daily with fluoride tooth paste and dental flossing and mouthwash
3488027|NCT03732040|Experimental|miswak stick|use of miswak stick twice daily
3488028|NCT03732040|Experimental|Use of Miswak plus tooth brushing and tooth paste|use of miswak stick and tooth brush with fluoride toothpaste twice daily
3488029|NCT03732027|Active Comparator|Transversus Abdominis Block [TB] group|Patients will receive Surgical Transversus Abdominis Plane Block
3488030|NCT03732027|Active Comparator|Rectus Sheath Block [RB] group|Patients will receive Surgical Rectus Sheath Block
3488031|NCT03732001|Experimental|Anlotinib combined Docetaxel|patients treated with Anlotinib and Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
3488032|NCT03732001|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until disease progress or toxicity cannot be tolerated or patients withdraw consent
3488033|NCT03731988|Experimental|5.5% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 5.5%, 350 µm ablation depth, level 1 coagulation and a single pulse
3488034|NCT03731988|Experimental|11% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 11%, 350 µm ablation depth, level 1 coagulation and a single pulse
3488035|NCT03731988|Experimental|22% density AFL-PDT|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at laser density of 22%, 350 µm ablation depth, level 1 coagulation and a single pulse
3488036|NCT03731975|Active Comparator|CTZ Paste|Endodontic treatment with CTZ paste.
3129069|NCT03194490|Experimental|The combined intervention group|The combined intervention group will receive the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).
3488037|NCT03731975|Experimental|GP Paste|Endodontic treatment with Guedes-Pinto paste.
3488038|NCT03731962|Active Comparator|Developed Contrast Induced Nephropathy|Coronary Angiography
3488039|NCT03731962|Other|Without CIN|Coronary Angiography
3488040|NCT03731936||Model establishment and test group|Patients undergoing coronary angiography or coronary computer tomography angiography will be enrolled. Patients data will be used to establish the facial based diagnostic model of coronary artery diseases, and to prospectively validate the diagnostic effectiveness of the model.
3488041|NCT03731897|Experimental|prolotherapy|"Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain."
3488042|NCT03731897|Placebo Comparator|control|"Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc.~Procedure: Plantar fascia will be injected to the places where it adheres to the bone.~Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection."
3488043|NCT03731884||Elapsed time of onset-of-pain-to-PCI <3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) prior to 3 hours from the onset of symptoms
3129070|NCT03194490|Active Comparator|The standard intervention|The standard intervention group will receive cervical mobilization and home program (ROM exercises).
3129071|NCT03194503|Active Comparator|Attendings|Study intervention is a VL coaching training for site neonatology attendings. Each site leader/key educator will be trained remotely by expert co-investigators. Site leaders and key educators will train their attendings. The quality of VL coaching skills will be verified by randomly auditing 20% of attending providers at each site for their skill assessment by remote simulation during the transition/post-intervention phase.
3129072|NCT03194503|No Intervention|Trainees|Trainees will be coached as usual by attendings during their supervised intubation events
3488044|NCT03731884||Elapsed time of onset-of-pain-to-PCI >3 hours|Patients with AMI undergoing percutaneous coronary intervention (PCI) after at least 3 hours from the onset of symptoms
3129077|NCT03194698|Experimental|MGX and Intense Pulsed Light Treatment (IPL)|Treatment with 4 visits and 4 treatments of IPL and Meibomian Gland Expression (MGX)
3488045|NCT03731845|Experimental|patient|
3129078|NCT03194698|Active Comparator|Meibomian Gland Expression (MGX)|Treatment with 4 visits and 4 treatments of MGX only
3129079|NCT03194737|Experimental|UroLift System procedure|All eligible,enroled subjects will undergo a UroLift procedure.
3488046|NCT03731832|Experimental|PId|Treatment of eligible patients with combination of Pomalidomide, Ixazomib, Dexamethasone for all patients until disease progression.
3488047|NCT03731832|Experimental|PICd|Treatment of patients showing an isolated biochemical relapse at disease progression with combination of Pomalidomide, Ixazomib, Dexamethasone plus Cyclophosphamide.
3488048|NCT03731819|Experimental|Follow-up participants|Patients who met eligibility criteria. Participants are going to undergo Abbreviated PB MRI.
3488049|NCT03731793|Placebo Comparator|Placebo Group|Placebo. For 90 days one capsule/day.
3488050|NCT03731793|Experimental|Intervention Group|600 mg/day of non-animal Chondroitin Sulphate. One capsule/day for 90 days.
3488051|NCT03731780|Experimental|Personalized Treatment|Intervention by (standard preventive measures + targeting individual caries risk factors)
3488052|NCT03731780|Experimental|Chlorhexidine and Rremineralization|Intervention is (chlorhexidine + Remineralizing agent + standard preventive measures)
3488053|NCT03731780|Active Comparator|Control|standard preventative measures (tooth brushing, fluoride tooth paste, interdental cleaning)
3488054|NCT03731767|Other|Subject group|Distraction thrust manipulation of the talocural joint in supine position
3129080|NCT03194737|No Intervention|Retrospective Arm|Chart review will be performed on all invasive BPH surgeries (TURP, Holmium Laser Enucleation of the prostate (HoLEP), etc) performed by the site from June 1, 2015 to December 31, 2015
3129081|NCT03194776|Experimental|LLG783|Patients will receive LLG783 i.v. infusion every 4 weeks for 12 weeks.
3129082|NCT03194776|Placebo Comparator|Placebo|Patients will receive placebo to LLG783 i.v. infusion every 4 weeks for 12 weeks.
3179890|NCT00677482||1|Solid organ transplant recipients with both asymptomatic CMV viremia, and symptomatic CMV disease are eligible for inclusion in the study. THis includes liver, kidney, heart, pancreas, lung, intestinal and combined transplant recipients.
3488055|NCT03731754|Active Comparator|Traditional Closure|Patients receive primary closure discontinuously for reconstruction of APR perineal wound
3488056|NCT03731754|Experimental|"Cross Closure"|"Patients receive cross closure for reconstruction of APR perineal wound"
3488057|NCT03731741|Experimental|treatment group|Group I: 29 patients (25 completed the study) that received the study agent (400mg of oral pentoxifylline daily for 6 months.), besides the appropriate weight-based dose of ESA (60-150I.U/kg/wk).
3488058|NCT03731741|No Intervention|control group|Group II: 28 patients (25 completed the study) who did not receive pentoxifylline but they received the appropriate dose of ESA. They were used as a control group and compared to group1 concerning the primary and the secondary outcomes.
3488059|NCT03731728|Experimental|Group CBT plus TAU|"Participants enrolled in the group CBT plus TAU arm of the study will receive a 2-hour session of group CBT every week for 14 weeks in addition to being wait-listed to receive treatment as usual."
3488060|NCT03731728|Experimental|Group Exercise plus TAU|"Participants enrolled in the group exercise plus TAU arm of the study will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks in addition to being wait-listed to receive treatment as usual."
3488061|NCT03731728|No Intervention|Wait-listing for TAU|"Participants enrolled in the wait-listing for treatment as usual or TAU arm of the study will be wait-listed to receive individual therapy or counselling from an Addiction and Mental Health therapist as per current standard protocol for managing patients with MDD at Addiction and Mental Health Clinics of Edmonton Zone."
3488062|NCT03731715|Experimental|Cohort I|Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.
3488063|NCT03731715|Experimental|Cohort II|Subjects 12 to <18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.
3488064|NCT03731715|Experimental|Cohort III|Subjects 6 to <12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.
3488065|NCT03731715|Experimental|Cohort IV|Subjects 2 to <6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.
3488066|NCT03731689|No Intervention|Control group|Control group( Intrauterine patients) do not apply intrauterine lavage therapy or intrauterine gel-injection therapy after surgery.
3488067|NCT03731689|Experimental|Intrauterine lavage therapy group|Intrauterine lavage therapy group apply intrauterine lavage therapy after surgery.
3488068|NCT03731689|Experimental|Intrauterine gel-injection therapy group|Intrauterine gel-injection therapy group apply intrauterine gel-injection therapy after surgery.
3488069|NCT03731689|No Intervention|Healthy control group|Healthy control group 1)have regular menstrual cycles,diagnostic hysteroscopy with endometrial biopsy and laparoscopy as part of their infertility diagnostic work-up prior to IVF, hysteroscopy and subsequent pathological results having shown no abnormality in the uterine cavities and abdominal cavity.2) had male partners who were infertile and diagnosed with defective sperm function,such as asthenozoospermia, oligoasthenozoospermia, severe oligoasthenozoospermia and azoospermia, defined according to guidelines published by the World Health Organization.
3488070|NCT03731676|Active Comparator|Rotating platform total knee arthroplasty|These patients were randomly assigned to receive a rotating platform total knee arthroplasty.
3488071|NCT03731676|Active Comparator|Fixed bearing total knee arthroplasty|These patients were randomly assigned to receive a fixed bearing total knee arthroplasty.
3488072|NCT03731663|Experimental|Appetizing Food exposure group|Participants allocated to this group will watch a 3-minute video presenting a series of pictures of appetizing foods eaten in facilities in a tourist destination. An audio of a young adult describing herself eating these foods during a trip to London will be played.
3488073|NCT03731663|Sham Comparator|Control content watching group|Participants allocated to this group will watch a 3-minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
3132767|NCT03449446|Experimental|Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
3488074|NCT03731650|Experimental|active comparator|
3488075|NCT03731650|Experimental|placebo|
3488076|NCT03731637||New-onset diabetes|Subjects with biochemically-defined new-onset diabetes
3488077|NCT03731624||SLK|
3488078|NCT03731624||GVHD|
3488079|NCT03731624||Dry eye|
3488080|NCT03731624||Control|
3488081|NCT03731611|Active Comparator|Group A|umbilical cord milking will be done for preterm infants <34 gestational age without placental insufficiency
3488082|NCT03731611|Active Comparator|Group B|umbilical cord milking will be done for preterm infant <34 gestational age with placental insufficiency
3488083|NCT03731611|No Intervention|Group C|Immediate cord clamping for preterm infants <34 gestational age with placental insufficiency
3488084|NCT03731585|Experimental|Group I (psychological intervention)|Patients participate in 5 psychological sessions and complete training on mindfulness, compassion, emotional processing, social support, generating positive emotions, and proactive coping strategies once a week for up to 5 weeks. Patients also complete questionnaires over 35 minutes and participate in video-based group sessions weekly for 5 weeks.
3488085|NCT03731585|Experimental|Group II (educational intervention)|Patients participate in 5 information sessions and receive education on lung cancer, symptom management, communication, and practicing self-care once a week for up to 5 weeks. Patients also complete questionnaires and participate in group sessions as in group I.
3488086|NCT03731572|Experimental|Power Training|Hip abductor-adductor resistance exercises at 75% maximum strength and maximum execution speed, 3, 1-hour training sessions per week for 12 weeks.
3488087|NCT03731572|Active Comparator|Strength Training|Hip muscle abductor-adductor resistance exercises at maximum strength at reduced execution speed (2s concentric/3s eccentric), 3, 1-hour training sessions per week for 12 weeks.
3488088|NCT03731559|Active Comparator|DTG 50 mg OD with food|DTG 50 mg OD with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
3488089|NCT03731559|Active Comparator|DTG 50 mg BID|DTG 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
3488090|NCT03731546|No Intervention|Group A|Placental insufficiency and ICC : Immediate cord clamping after delivery of the fetus in preterm infants with placental insufficiency
3488091|NCT03731546|Active Comparator|Group B|Placental insufficiency and DCC: Cord clamping 60 seconds after delivery of fetus in preterm infants with placental insufficiency
3488092|NCT03731546|Active Comparator|Group C|Normal placenta with DCC:Cord clamping 60 seconds after delivery of fetus in preterm infants without placental insufficiency
3488093|NCT03731533|Experimental|WellStart|WellStart is a 12-week virtual intensive therapeutic lifestyle program utilizing web-based encounters with physicians, dietitians, health coaches and additional resources.
3488094|NCT03731533|No Intervention|Usual Care|The control group will continue with usual care.
3488095|NCT03731520|Experimental|Assessing exercise behavior|determining exercise behaviour in patients with JIA by using specific scales
3488096|NCT03731507|Experimental|Range of motion in upper extremity|Assessment of shoulder: flexion/extension, abduction/adduction, internal/external rotation, elbow flexion/extension, hip: flexion/extension, abduction/adduction, internal/external rotation, knee: flexion/extension, ankle: dorsal flexion/plantar flexion
3488097|NCT03731494||Nickel oral hyposensitization treatment|The patients take capsules at different doses in nickel content until reaching the maximum dose of 1.5 mcg per week for a total of 12 months.
3179891|NCT00677495|Experimental|Gluten-free diet|Gluten-free diet
3488098|NCT03731481|Experimental|CHIP - Urban|Participants randomized by urban location of residence to receive CHIP Lifestyle Medicine program intervention.
3488099|NCT03731481|Experimental|CHIP - Rural|Participants randomized by rural location of residence to receive CHIP Lifestyle Medicine program intervention.
3488100|NCT03731481|Experimental|FPD2- Urban|Participants randomized by urban location of residence to receive FPD2 Lifestyle Medicine program intervention.
3179892|NCT00677508||C FR|Children with constipation and fecal incontinence.
3179893|NCT00677508||C|Children with constipation but without fecal incontinence.
3179894|NCT00677508||P-C FR|Parents of children with constipation and/or fecal incontinence.
3179895|NCT00677521|Experimental|1|
3179896|NCT00677547||1|Kidney transplant recipients
3179897|NCT00677547||2|Healthy volunteers
3488101|NCT03731481|Experimental|FPD2 - Rural|Participants randomized by rural location of residence to receive FPD2 Lifestyle Medicine program intervention.
3488102|NCT03731468|Active Comparator|dexmethasone group|8 mg dexamethasone will be added to local anaesthetics
3488103|NCT03731468|Sham Comparator|control group|isobaric bupivacaine will be given on each side
3488104|NCT03731455|Experimental|Investigational and Comparator devices|Investigational (WISE Cortical Strip, WCS) and comparator (Subdural Strip Electrode, Ad-Tech Medical Instruments Corporation) devices will be used together.
3488105|NCT03731442|Experimental|Involved field irradiation|Patients after R0 surgery whose recurrence lesion larger than 5cm in diameter, or largest diameter was less than 5cm but with skip metastasis far from primary tumor or their time-to-recurrence longer than 16 months were assigned to involved field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 60Gy/2Gy/30f, and for lesions close to the thoracic stomach, the prescribed dose is 59.4-61.2Gy/1.8Gy/33-34f. Chest CT scan is planned at 50Gy. Radiation field should be modified according to the tumor response. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF (3-6mg) should be given after 48 hours of chemotherapy.If patients received postoperative chemotherapy of paclitaxel and platinum and went through local-regional recurrence within six months, it is allowed to deliver chemotherapy regimens in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
3488106|NCT03731442|Experimental|Elective field irradiation|Patients after R1/R2 surgery or R0 surgery with the recurrence lesion whose diameter was less than 5cm without skip metastasis far from primary tumor and time-to-recurrence shorter than 16 months were assigned to elective field irradiation group. For lesions far from the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a simultaneously integrated boost up to 59.92-62.16Gy/2.14-2.22Gy/28f. For lesions close to the thoracic stomach, the prescribed dose is 50.4Gy/1.8Gy/28f with a sequential boost of 10-12Gy/1.8-2Gy/5-7f. For patients whose planned thoracic stomach V50>50%, the dose should be lowered to 45Gy/1.8Gy/25f. Concurrent chemotherapy of paclitaxel and platinum was delivered every 3 weeks. PEG-rhG-CSF should be given in need. If patients received postoperative chemotherapy of TP and went through local-regional recurrence within 6 months, chemotherapy regimens delivered in the second line. Consolidate chemotherapy were adjusted to the patients after radiation therapy.
3488107|NCT03731429|Experimental|Intervention|Group that receives a 1 mg/kg single bolus of 2% IV lidocaine
3488108|NCT03731429|Placebo Comparator|Placebo|group that receives 0.9% saline solution
3488109|NCT03731416|Placebo Comparator|GBR by xenograft|"Patients of both groups will be subjected to CBCT (diagnostic for upper arch).~Intra operative procedures (for both groups) followed by CBCT will be taken for every patient.~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, anorganic bovine bone derived mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~• The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
3488110|NCT03731416|Active Comparator|GBR by xenograft ,autogenous bone|Intervention In the control group:first crestal incision then two vertical incisions by blade 15c,full thickness flap reflection, bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area(atrophic maxilla) then covered by a native collagen membrane which will be stabilized by tacks.Then The flap will then be closed using interrupted 4/0 resorbable sutures.
3488111|NCT03731403|Experimental|MI Varnish|
3488112|NCT03731403|Active Comparator|Profluorid Varnish|
3488113|NCT03731390|Experimental|GR1405 injection 3 mg/kg|According to the patient's weight, the dose of this group is 3mg/kg.
3488114|NCT03731390|Experimental|GR1405 injection 10 mg/kg|According to the patient's weight, the dose of this group is 10mg/kg.
3488115|NCT03731390|Experimental|GR1405 injection 20 mg/kg|According to the patient's weight, the dose of this group is 20mg/kg.
3488116|NCT03731390|Experimental|GR1405 injection 30 mg/kg|According to the patient's weight, the dose of this group is 30mg/kg.
3488117|NCT03731377|Experimental|Intubated group|Patient in this group will receive general anesthesia with endotracheal tube intubation to perform one lung ventilation. Patient will be paralyzed and controlled ventilation will be implied.
3488118|NCT03731377|Experimental|Non-intubated group|Patient in this group will receive general anesthesia with laryngeal mask insertion. Patients in this group will not be paralyzed and keep spontaneous breathing to maintain one lung ventilation.
3488119|NCT03731364|Active Comparator|CA-008 - Pilot Stage|
3488120|NCT03731364|Placebo Comparator|Placebo - Pilot Stage|
3488121|NCT03731325|Experimental|Episodic Future Thinking Group|The experimental group (N=20 families; N=40 total) will receive the Episodic Future Thinking (EFT) intervention. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now [Atance].
3488122|NCT03731325|Placebo Comparator|Healthy Thinking Group|The placebo group (N=20 families; N=40 total) will receive the Healthy Thinking (HT) intervention. HT encourages individuals to focus on the nutritional characteristics of food and the healthy benefits of physical activity.
3129083|NCT03195010|Experimental|Group I (lower dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 30 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
3129084|NCT03195010|Experimental|Group II (higher dose platelet transfusion)|Patients undergo platelet transfusion on all days when the morning platelet count is below the threshold 50 x 10^9/L for up to 30 days or until the platelet count spontaneously recovers to > 50 x 10^9 for 3 consecutive days in the absence of transfusions.
3132768|NCT03449446|Experimental|Selonsertib (SEL) + Firsocostat (FIR)|Participants will receive SEL + FIR + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
3488123|NCT03731312||Study group|We will collect two repeated spot urine samples, a DBS sample and obtain weight in all 600 study participants. In a randomly selected subsample (n=200) a third repeat spot urine sample and one 24 h urine will additionally be collected.
3488124|NCT03731286|Active Comparator|Alpinia galanga|EnXtra: 2 capsules to be taken twice daily after breakfast and evening.
3488125|NCT03731286|Active Comparator|Composite (Alpinia galanga + Caffeine)|Composite: 2 capsules to be taken twice daily after breakfast and evening.
3488126|NCT03731286|Placebo Comparator|Placebo|Microcellulose crystalline: 2 capsules to be taken twice daily after breakfast and evening.
3488127|NCT03731221|Experimental|Bupi HCl plus liposomal bupi|PECSII/SAP blocks with bupivacaine HCl plus liposomal bupivacaine
3488128|NCT03731221|Active Comparator|Bupi HCl plus saline|PECSII/SAP blocks with bupivacaine HCl plus preservative free normal saline
3488129|NCT03731208|Experimental|Intervention group|The patient assign to this arm receive the telerehabilitation program for 8-week after a knee operation
3488130|NCT03731169|Active Comparator|TDM Only|This is the standard of care trial arm. Patients receive voriconazole dosages according to the product monograph. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
3132769|NCT03449446|Experimental|Selonsertib (SEL) + Cilofexor (CILO)|Participants will receive SEL + placebo to match FIR 20 mg tablet + CILO orally once daily for 48 weeks.
3179901|NCT00677573|Active Comparator|UrFSH|
3488131|NCT03731169|Experimental|Genotyping + TDM|After ascertaining CYP2C19 genetic status, the participants will be categorized as having either the ultra-rapid metabolizer (URM), extensive metabolizer (EM), heterozygous extensive metabolizer (HEM) or poor metabolizer (PM) phenotype. They will receive an experimental dosage regimen based on their phenotype. receive the following dosing regimen until TDM is conducted on day 4. After day 4, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
3488132|NCT03731143|Experimental|study arm|surgical opening the lower punctum using the pig tail probe and a scalpel followed by insertion of self retaining bicanalicular stent (FCI®; Paris, France).
3488133|NCT03731130||neoadjuvant short term radiation|Treatment with neoadjuvant short term radiation therapy (5x5 Gy) followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire.
3488134|NCT03731130||neoadjuvant long-term chemoradiation|Treatment with neoadjuvant Long-term chemoradiation followed by surgery. Quality of life will be assessed using the EORTC QLQ C30 and EORTC QLQ CR 29 questionaire
3488135|NCT03731117|Experimental|FST|FUROSEMIDE STRESS TEST
3488136|NCT03731091|Experimental|Calcipotriene/ betamethasone dipropionate topical foam|Topical foam once daily for 4 weeks (28 days)
3488137|NCT03731091|Active Comparator|Enstilar®|Topical foam once daily for 4 weeks (28 days)
3488138|NCT03731091|Placebo Comparator|Placebo|Topical foam once daily for 4 weeks (28 days)
3488139|NCT03731078||Motor Functional Neurological Disorder|The cohort will consist of patients with clinically-established motor functional neurological disorder, which includes individuals with functional movement disorders and functional limb weakness. Individuals with functional movement disorders and/or functional limb weakness who also have psychogenic nonepileptic seizures will be included. Patients will receive CBT informed PT intervention. The physical therapy intervention will be usual care in FND and based on consensus recommendations, clinical trials and good practices.
3488140|NCT03731065|Active Comparator|Fructose-maltodextrin ingestion|Ingestion of fructose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
3179902|NCT00677586|Experimental|1|simultaneous resection of liver metastasis and the colorectal primary tumor
3488141|NCT03731065|Experimental|Fructose-maltodextrin hydrogel ingestion|Ingestion of fructose and maltodextrin (glucose polymers) encapsulated in alginate-pectin hydrogel, drinks at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
3488142|NCT03731065|Active Comparator|Glucose-maltodextrin ingestion|Ingestion of glucose and maltodextrin (glucose polymers) at a rate of 90 g carbohydrate per hour during two hours of treadmill running at 60%VO2peak.
3488143|NCT03731052|Experimental|Drug: 188-0551 Spray|188-0551 Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
3488144|NCT03731052|Placebo Comparator|Vehicle Spray|Vehicle Spray applied topically twice daily to psoriatic lesions within the assigned treatment area for up to four (4) weeks
3488145|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SLIGHT TISSUE DAMAGE|
3488146|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH MODERATE TISSUE DAMAGE|
3488147|NCT03731039||SURGICAL PROCEDURES ASSOCIATED WITH SUBSTANTIAL TISSUE DAMAGE|
3488148|NCT03731026|Other|Group 1|Patient will receive an IV injection of up to 200MBq 68Ga-RM2. Each patient will have torso PET/CT imaging at 2 timepoints. Alternate patients will have imaging at 1 and 2h post-injection then the next patientat 1 and 3h post-injection, with axillary gamma probe measurements (using a collimator) of 68Ga-RM2 at the same time points.
3488149|NCT03731026|Experimental|Group 2|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 2 scans will acquire LightPath® images of both intact and incised cancer specimens with varying parameters to optimise imaging.
3488150|NCT03731026|Experimental|Group 3|WLE will be performed as per standard of care but will also include Intraoperative LightPath® Imaging with 68Ga-RM2. Group 3 scans will acquire LightPath® images of intact and incised cancer specimens using a final and consistent imaging procedure.
3488151|NCT03731013|Experimental|Mediterranean diet (MedDiet)|
3488152|NCT03731013|Experimental|Physical activity (PA)|
3488153|NCT03731013|Experimental|Mediterranean diet and physical activity|
3488154|NCT03731013|No Intervention|Control|
3488155|NCT03731000|Experimental|PHIL® device|Using device
3488156|NCT03730935|Experimental|Intervention|Respiratory muscle endurance training (30 minutes of volitional hyperpnoea at a target ventilation of 60-70% of the individual maximal voluntary ventilation for 5 days per week for 4 weeks).
3488157|NCT03730935|Sham Comparator|Sham|Sham training will be performed 5 times a week for 4 weeks using a mock asthma inhaler filled with 5.5 mg lactose powder. Subjects will be instructed to inhale the powder according to inhaler instructions and to then perform one full inspiration to total lung capacity using custom-made, low resistance tubing, which elicits minimal resistance to breathing.
3488158|NCT03730922|Experimental|A: Delayed-immediate reconstruction|"Primary Surgery: Skin sparing mastectomy (nipple sparing if appropriate) and axillary surgery according to guidelines or protocol. Reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix.~Delayed reconstruction: Final reconstruction with any reconstructive procedure - being it autologous or implant-based (one- or two-stage, +/- acellular dermal matrix (ADM)) - is performed 6-12 months after completion of chemotherapy and PMRT. Any contralateral procedure is allowed when doing the delayed surgery, but not in relation to the initial cancer surgery."
3488159|NCT03730922|Active Comparator|B: Delayed reconstruction|"Primary surgery: Total mastectomy and axillary surgery according to guidelines or protocol.~Delayed reconstruction: 6-12 months after completion of PMRT: final recon-struction with any reconstructive procedure - being it autologous or implant-based (one-or two-stage, +/- ADM). Any contralateral procedure is allowed at any time point after PMRT has been delivered"
3488160|NCT03730909|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
3488161|NCT03730909|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
3488162|NCT03730896|No Intervention|standard care group|Normal manual therapy interventions Clinician will decide normal course of treatment
3488163|NCT03730896|Experimental|Dry needling|Dryneedling group Clinician will decide normal course of treatment and dry needling of the Sternocleidomastoid muscle (SCM) muscle will be added to that treatment
3488164|NCT03730883|Experimental|Central line removal at 100ml/kg/day.|"In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant. After central line removal, infants in this group may continue to receive parenteral nutrition via peripheral venous access, depending on the decision of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
3488165|NCT03730883|Active Comparator|Central line removal at 140 ml/kg/day.|"In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake (full enteral intake). In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake. Central lines will be removed after 3 well tolerated consecutive feedings (assessed by the physician) with no contraindications for central line removal present.~Assessment of feedings tolerance will be at discretion of the physician taking care for the infant.~Parenteral nutrition will be prescribed according to the local protocol. Enteral nutrition will be initiated during the first days of life and advanced gradually at the discretion of the neonatologist."
3488166|NCT03730870|Experimental|Pharmacogenomics report|Clinician reviews pharmacogenomics report for subject prior to prescribing FDA-approved medications.
3488167|NCT03730870|No Intervention|Control|"Clinician prescribes FDA-approved medications as customarily performed without additional guidance from pharmacogenomics report (treatment-as-usual)."
3488168|NCT03730857|Active Comparator|olanzapine|olanzapine has a dose of 10 to 20 mg daily for 12 weeks
3488169|NCT03730857|Active Comparator|risperidone|risperidone at a dose of 4 to 6 mg daily for 12 weeks
3129085|NCT03195517|Experimental|Physical Exercise|"The exercise program was performed at C.U.R.I.A.Mo. Institute of Università degli Studi di Perugia. Twenty-four exercise sessions were provided, carried out twice a week for three months. Each session was supervised by two graduated trainers and two medical doctors with a maximum attendance of 5 patient/group.~Each session lasted 45 minutes divided into 15 minutes of aerobic activity and 30 minutes of weight-bearing and resistance activities.~This latter section was specifically projected for adults and older adults with increased risk of fractures and was intended to improve muscle strength and flexibility, balance and, as a result, to prevent the risk of falls."
3129086|NCT03195517|No Intervention|No additional physical exercise|Usual recommendations for prevention of fractures in adults and elderly.
3488170|NCT03730857|Active Comparator|paliperidone|paliperidone at a dose of 6 to 12 mg daily for 12 weeks.
3488171|NCT03730831|Experimental|Intervention|Narrative Exposure Therapy The Narrative Exposure Therapy (NET) is a brief manualized trauma-focussed treatment and will be performed according to the manual of Schauer et al., 2011. In the NET the experiences experienced as traumatic are worked on and placed in the context of the entire life story.
3488172|NCT03730831|No Intervention|Control|Waiting List
3488173|NCT03730818|Experimental|Water-based Exercise Group|"The Water-based Exercise Group will compromise participants attending a 2 weekly exercise intervention each session lasting 1 hour for 12 weeks.~Each session will consist of:~10 minutes of warm-up: general mobilisation, walking, active stretching~40 minutes of global training: 20 minutes of endurance exercise and 20 minutes of resistance exercises targeting large main muscle groups involved in daily life activities (squats, lateral hip abduction, row, etc.) using body weight and elastic bands~10 minutes of cooling down: stretching, breathing exercises and relaxation Intensity will be monitored with the modified Borg Scale to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
3488174|NCT03730818|Active Comparator|Land-based Exercise Group|"The land-based exercise group will attend as well 2 weekly sessions lasting 1 hour each for 12 weeks.~Each session will consist of the same structure as the Water-based Exercise Group including:~10 minutes warm up~40 minutes of global training (20 minutes of endurance exercise and 20 minutes of resistance training)~10 minutes cool down. The exercises will be adapted from the water-based exercise group to match the requirements on the water-based exercise group. Intensity will be monitored with the Perceived Rate of Exertion Scale (modified Borg Scale, Borg 1982) to maintain a 5 - 6 level of exertion during the first 5 weeks and progressively increase to a 6 - 7 level for the following weeks."
3488175|NCT03730805|Experimental|Intervention + open mindset|ASSIST-linked Brief Intervention plus prior induction of deliberative mindset
3129087|NCT03196076|Experimental|Perflutren Lipid Microsphere (Healthy subjects)|Healthy subjects will be imaged using contrast-enhanced ultrasound (perflutren) for image optimization prior to enrolling clinical patients.
3129088|NCT03196076|Experimental|Perflutren Lipid Microsphere (patients with kidney lesions)|Patients with kidney lesions will be imaged using contrast-enhanced ultrasound with perflutren.
3488176|NCT03730805|Experimental|Intervention + closed mindset|ASSIST-linked Brief Intervention plus prior induction of closed mindset
3488177|NCT03730805|Experimental|Intervention alone|ASSIST-linked Brief Intervention without prior induction of any mindset
3488178|NCT03730805|Experimental|Control + open mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of an open mindset is conduced.
3488179|NCT03730805|Experimental|Control + closed mindset|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) with prior induction of a closed mindset is conduced.
3488180|NCT03730805|No Intervention|Control alone|In stead of intervention, a neuropsychological assessment (Raven's Standard Progressive Matrices; SPM; Raven, 1940) without prior induction of any mindset is conduced.
3488181|NCT03730792|Experimental|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
3488182|NCT03730792|No Intervention|Usual Practice Control|"Participants experience standard or Usual Practices in new employee onboarding processes at their workplace."
3488183|NCT03730779|Experimental|O2 recieving|Patients who receive hyperoxia
3488184|NCT03730766|Experimental|Bismuth Plus triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
3488185|NCT03730753|Active Comparator|Control group|Continuous infusion + patient controlled epidural analgesia
3488186|NCT03730753|Experimental|Study group|Programmed intermittent epidural bolus + patient controlled analgesia
3488187|NCT03730740|Experimental|Lenalidomide|Administer the study drug in the following way with 28 days as one cycle. Lenalidomide 25mg Days 1-21 Dosing continues until disease progression is confirmed.
3488188|NCT03730727|Active Comparator|Control|A liquid meal replacement shake containing 500 kcal (55% kcals from carb, 30% fat, 15% protein) will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Two-hours after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
3488189|NCT03730727|Experimental|Immediate prior to meal|At approx. 8 am following an 8-10 hour overnight fast, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]). Immediately after completion of this bout, a liquid meal replacement shake containing 500 kcal will be administered. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion.
3488190|NCT03730727|Experimental|Immediate post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Immediately after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
3488191|NCT03730727|Experimental|30-minutes post-meal|A liquid meal replacement shake containing 500 kcal will be administered at approx. 8 am following an 8-10 hour overnight fast. Postprandial blood glucose responses will be assessed for 2-hours post-ingestion. Thirty-minutes after ingestion of the meal, participants will complete a bout of physical activity (either 30-mins of standing still, 30-mins of walking at a self selected brisk pace on a treadmill, or 3-sets of circuit-exercises [10 squats, 10 push-ups, 10 lunges, 10 sit-ups]).
3488192|NCT03730714|Active Comparator|Ggroup LAM|Patients will receive local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg) instilled into the assigned areas according to the technique.
3488193|NCT03730714|Active Comparator|Ggroup LAMG|Patients will receive the same mixture in LAM-group to soak the surgicel according to the previous planned technique.
3488194|NCT03730714|Active Comparator|Group CG|Patients will receive normal saline 0.9% to soak the surgicel according to the planned technique.
3488195|NCT03730701|Experimental|Prevention treatment group|Prevention program with 10 week blended intervention utilizing both a digital health app, group-sessions with peers and a interprofessional team of health-care workers chairing 5+1 themed group-sessions as support to change lifestyle habits in to a pattern of activities (behaviors and actions) in everyday life that can promote health and wellbeing and decrease risk for stroke. Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
3488196|NCT03730701|No Intervention|Standard treatment group|Usal care in Swedish primary health care. In addition a Lifestyle analysis and stroke risk screening before, at follow up and 12 months after the prevention program.
3488197|NCT03730688|Experimental|Conventional and experimental compartment pressure measurement|Compartment pressure in the patients in this group will be measured using the conventional Intra-Compartmental Pressure Monitor System (Stryker) and using the newly-developed measuring device.
3488198|NCT03730675|Experimental|irradiation stent plus TACE|Portal irradiation stent placement will be performed before TACE procedures.
3488199|NCT03730675|Active Comparator|Sorafenib plus TACE|TACE will be performed in patients randomized to Arm B, with sequential sorafenib.
3488200|NCT03730662|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3488201|NCT03730662|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3488202|NCT03730662|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3488203|NCT03730662|Active Comparator|Insulin Glargine|Insulin glargine administered SC once a day.
3488204|NCT03730649|Active Comparator|Sulforaphane without light challenge|Participants with moderate photodamage and moderate intrinsic skin aging will apply sulforaphane (broccoli sprout extract) in jojoba oil nightly (without any UV or visible light irradiation) for up to 6 months and have up to 9 biopsies taken just before treatment and occurring at regular intervals during the study
3488205|NCT03730649|Active Comparator|Sulforaphane with light challenge|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments and biopsies taken before and within 7 days after UV or visible light irradiation; one of the UV/visible light treated areas will be pre-treated with sulforaphane (broccoli sprout extract) for up to 28 consecutive nights and the other UV/visible light treated areas will be pre-treated with jojoba oil.
3488206|NCT03730623|No Intervention|Control group|Usual care. Conservative management of IC
3488207|NCT03730623|Experimental|Intervention|Supervised exercise
3488208|NCT03730610|Experimental|Exercise intervention|Six months of exercise training
3488209|NCT03730597|Active Comparator|glenosphere 42|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 42. reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
3488210|NCT03730597|Active Comparator|glenosphere 38 ECC|patients receiving a reverse shoulder arthroplasty with a glenosphere sized 38 ECC reverse shoulder prosthesis implantation X-Ray analysis to detect scapular notch
3488211|NCT03730584|Experimental|Patient with Hereditary Epidermolysis Bullosa|
3488212|NCT03730571|Experimental|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
3488213|NCT03730545|Experimental|EIN group|Enteral formula including not only basic energy components, but also immune components such as omega-3 fatty acids, glutamine (Gln), arginine (Arg), and nucleotide.
3488214|NCT03730545|Active Comparator|SEN group|Enteral formula including only basic energy components.
3488215|NCT03730532|Experimental|Randomised CBT|Cognitive Behavioural Therapy Guided Self Help
3129089|NCT03196076|No Intervention|Controls: No interaction|Patients with kidney lesions will be included as control subjects. These patients will be followed, but will not receive any study intervention.
3129090|NCT03196193|Experimental|ZNN CM Asia with AS2 technique|"Open Reduction and Internal Fixation with AS2 Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail.~Bone fragment will be stabilized by additional screw fixation (Anterior Support Screw)."
3129091|NCT03196193|Active Comparator|ZNN CM Asia without AS2 technique|Trochanteric Fracture treated by Open Reduction and Internal Fixation using with ZNN CM Asia nail without additional screw fixation.
3488216|NCT03730532|Experimental|Randomised CAT|Cognitive Analytic Therapy Guided Self Help
3488217|NCT03730532|Experimental|Preference CAT|Cognitive Analytic Therapy Guided Self Help
3488218|NCT03730532|Experimental|Preference CBT|Cognitive Behavioural Therapy Guided Self Help
3488219|NCT03730519|Active Comparator|Patients with refractory hypertension|Patients with refractory hypertension which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
3129092|NCT03196232|Experimental|Treatment (epacadostat, pembrolizumab)|Participants receive oral epacadostat BID on Days 1 to 21 and pembrolizumab IV over 30 minutes on Day 1, with cycles repeating every 21 days for up to 24 months, in the absence of disease progression or unacceptable toxicity.
3129093|NCT03196284|Experimental|Concizumab|Concizumab administered in both the main phase and extension phase, with eptacog alfa administered on-demand during bleeding episodes
3488220|NCT03730519|Active Comparator|Patients with highly variable BP|Patients with symptomatic highly variable blood pressure due to afferent baroreceptor failure which cannot be controlled with drug therapy in the hands of hypertension specialists will be treated with Baroreflex Activation Therapy with Barostim Neo and followed up for a period of up to 3 years
3488221|NCT03730506|Experimental|CBCT|
3129094|NCT03196284|Active Comparator|Eptacog alfa and concizumab|Eptacog alfa administered on-demand during bleeding episodes as the only intervention during the main phase. Concizumab given in the extension phase
3488222|NCT03730506|Experimental|IOS|
3488223|NCT03730506|Active Comparator|desktop scanner|
3488224|NCT03730493|Experimental|Pictorial flashcard|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). Time was noted and kept for observation till 72 hours or removal in between.
3488225|NCT03730493|No Intervention|Comparison Group|In control group, standard care was given as per the hospital protocol.Time was noted and kept for observation till 72 hours or removal in between.
3488226|NCT03730454|Experimental|Group A. Transanastomotic Tube|Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.
3488227|NCT03730454|Experimental|Group B. No Transanastomotic Tube|Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.
3488228|NCT03730415|Experimental|Viscoelastic (VE) guided transfusion|The intervention made in the VE guided transfusion group is that the VE results will be available to the treating physicians to guide transfusions based on VE results during their burn excision.
3488229|NCT03730415|No Intervention|Standard practice transfusion|The standard practice transfusion group will receive the current standard transfusion practice during their burn excision, which is based solely on physician preference using standard lab values.
3488230|NCT03730402|Active Comparator|bupivacaine block|laparoscopic assisted plane block of standardized dose of bupivacaine plain
3488231|NCT03730402|Active Comparator|liposomal bupivacaine block (Exparel 266 milligram Per 20 ML)|laparoscopic assisted plane block of standardized dose of bupivacaine plain
3488232|NCT03730402|Placebo Comparator|saline block|laparoscopic assisted plane block with placebo saline injection
3488233|NCT03730389|Experimental|EPVL Group|In treatment group, patients were given one to three sessions of External Physical Vibration Lithecbole therapy in two weeks. These patients were also instructed to drink a minimum of 2500 ml water daily and take more exercise.
3488234|NCT03730389|No Intervention|Traditional Group|patients with 4-10mm ureteral stone, were treated by traditional treatment methods, including drinking a minimum of 2500 ml water daily and taking more exercise.
3488235|NCT03730376|No Intervention|Control|Participants in the control group will be given a hypothetical scenario about carpal tunnel syndrome and asked to make a treatment decision for that hypothetical patient.
3488236|NCT03730376|Experimental|Intervention|Participants in the intervetion group will be given a hypothetical scenario about carpal tunnel syndrome as well as information about the cost of treatment and asked to make a treatment decision for that hypothetical patient.
3488237|NCT03730363|Experimental|Pentamidine + ICE|Pentamidine, Ifosfamide, Carboplatin, and Etoposide (ICE) by IV Infusion.
3488238|NCT03730350|Experimental|Hypnosis|Prior to surgery, a member of the pain psychology team will guide patients through a clinical hypnosis session aimed at preparing for surgery by reducing anxiety and introducing relaxation and self-soothing strategies that can be used after surgery for adaptive coping. They will also be provided with a recording of this hypnosis script to use at home, and it will be recommended that they listen to the recording on the two days prior to surgery. Following surgery, a clinician from the pain psychology team will visit the patient in hospital on post-operative day one or whenever they are able to be seen prior to hospital discharge, in order to guide them through a clinical hypnosis session targeted at increasing comfort and pain relief.
3488239|NCT03730350|No Intervention|Standard Care|This control group will receive standard care pre- and post-surgery. After the completion of their one-month trial, control participants will be offered access to the hypnosis recordings, as well as an in-person hypnosis session.
3488240|NCT03730311|Experimental|Elpida 120 mg once weekly|elsulfavirine 120mg or placebo orally once weekly for 4 weeks
3488241|NCT03730311|Experimental|Elpida 200 mg once weekly|elsulfavirine 200mg or placebo orally once weekly for 4 weeks
3488242|NCT03730311|Experimental|Elpida 280 mg once weekly|elsulfavirine 280mg or placebo orally once weekly for 4 weeks
3488243|NCT03730298|Experimental|American Ginseng|American Ginseng, cpr 700 mg (500 mg of Panax Quinquefolius 5%): 1 cpr twice a day orally for 3 months
3488244|NCT03730298|Placebo Comparator|Placebo|Placebo: 1 cpr twice a day orally for 3 months
3488245|NCT03730285|Active Comparator|Telemedicine|Discharge with telemedicine contact to emergency nurse, doctor, and municipality
3488246|NCT03730285|No Intervention|Control|Standard care with 24-48 h observation at emergency unit
3488247|NCT03730259|Experimental|WebTIPS|A Tailored Program for Perioperative Anxiety and Pain (WebTIPS) aims at reducing perioperative anxiety and pain in children via an internet and mobile platform with short message service (SMS) two-way communication between a healthcare provider and patient/parent. The Web-based Tailored Intervention Preparation for Surgery (WebTIPS) program is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent surgical experience, and reduced resource utilization during the surgical episode.
3488248|NCT03730259|No Intervention|Control|Subjects in this attention control group, the Web-based Information (WebINFO) group will not be provided tailored content or access to two-way communication. Instead, this group will only receive basic information regarding the management of perioperative anxiety and postoperative pain via the internet and/or mobile platform.
3129095|NCT03196297|Experimental|Concizumab|Daily administration of concizumab to both on-demand and prophylaxis patients
3129096|NCT03196349|Active Comparator|Warfarin|Subjects randomized to Warfarin will have warfarin administered daily in order to maintain a target INR of 2-3
3488249|NCT03730233|Active Comparator|Tension-free|Hiatal hernia repair by tension-free mesh closure
3488250|NCT03730233|Active Comparator|Suturing|Hiatal hernia repair by simple suturing of the diaphragmatic
3488251|NCT03730207|Experimental|Xpede™ Bone Cement|The subjects in this group will be injected the Xpede™ Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
3488252|NCT03730207|Active Comparator|Mendec Spine Bone Cement|The subjects in this group will be injected the Mendec Spine Bone Cement into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body.
3488253|NCT03730194|Experimental|Melatonin Only|Participants in this arm will take 3 mg of melatonin 30 minutes before bedtime.
3488254|NCT03730194|Experimental|Bedtime Bank Only|Participants in this arm will utilize the Bedtime Bank, a behavioral sleep intervention.
3488255|NCT03730194|Experimental|Combination (Melatonin+Bedtime Bank)|Participants in this arm will take 3 mg melatonin 30 minutes before bedtime and utilize the Bedtime Bank, a behavioral sleep intervention.
3488256|NCT03730181|Experimental|Single Arm Rifapentine and Isoniazid|Single arm, open label and exposure-controlled. Intervention is rifapentine given in a new fixed dose combination once-weekly, in combination with isoniazid for 12 weeks, in HIV-infected and HIV-uninfected children aged 0-12 years in whom LTBI treatment is indicated. The protocol allows for parallel enrolment of children into cohorts 1 and 2, simultaneously, using a predetermined modeled initial dose for each cohort, separately. Similarly, cohorts 3 and 4 will be enrolled in parallel, using modeled doses for each cohort, based on data from cohorts 1 and 2 and historical data from TBTC trials.
3488257|NCT03730168|Experimental|study group and control group|"Two groups; study group included 30 diabetic male patients who where trained by circuit weight training program in the form of sets of resistance exercises (in the form of dumbbells and sand bags) for the muscles of lower limb and upper limb .The training sessions were performed 3 days per week for a period of 12 weeks. All patient were on their prescribed routine medications .~The control group were on there prescribed medications only ."
3488258|NCT03730155|Experimental|CCT intervention|CCT intervention. 8 weeks with 2 hours session every week. Homework approx. 25 min. of meditation daily.
3488259|NCT03730155|No Intervention|Control waitlist|No treatment given. Participants only answer questionnaire packages.
3488260|NCT03730142|Experimental|WXFL10030390 tablet|"WXFL10030390 continuous oral dosing (0.1 mg once a day)~WXFL10030390 continuous oral dosing (0.2 mg once a day)~WXFL10030390 continuous oral dosing (0.4 mg once a day)~WXFL10030390 continuous oral dosing (0.7 mg once a day)~WXFL10030390 continuous oral dosing (1.1 mg once a day)~WXFL10030390 continuous oral dosing (1.4 mg once a day)~WXFL10030390 continuous oral dosing (1.7 mg once a day)"
3488261|NCT03730129|Experimental|Ig replacement|Subjects will receive Hizentra 0.4 mg/kg subq once weekly.
3488262|NCT03730077|Experimental|18F-MISO PET/CT Test Retest|Up to 5 of the 30 intended subjects will participate in a test-retest group that will undergo a second 18F-FMISO scan. Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
3488263|NCT03730077|Experimental|18F-MISO PET/CT|The investigators anticipate enrolling up to 30 subjects who will undergo 18F-FMISO PET/CT.Subjects will undergo biopsy as part of their clinical care. Subjects will be asked to consent to allow archived excess tissue to be accessed for the purposes of this study
3488264|NCT03730064|Experimental|Bipolar depressed|
3488265|NCT03730051|Active Comparator|Gadoterate meglumine contrast|0.2 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection at a rate of 2 mL/second. The FDA-approved product labeling provides weight-adjusted dose volumes as follows: 30 kg: 6 mL; 40 kg: 8 mL; 50 kg: 10 mL; 60 kg: 12 mL; 70 kg: 14 mL; 80 kg: 16 mL; 90 kg: 18 mL; 100 kg: 20 mL; 110 kg: 22 mL; 120 kg: 24 mL; 130 kg: 26 mL; 140 kg: 28 mL; 150 kg: 30 mL.
3488266|NCT03730051|Experimental|Gadobutrol contrast|0.1 mL/kg (0.1 mmol/kg) administered as a single IV bolus injection by power injector. Imaging may begin after administration and then repeat sequentially to determine peak intensity and wash-out. The manufacturer provides weight-based dose volumes as follow: 35 kg: 3.5 mL; 40 kg: 4 mL; 45 kg: 4.5 mL; 50 kg: 5 mL; 60 kg: 6 mL; 70 kg: 7 mL; 80 kg: 8 mL; 90 kg: 9 mL; 100 kg: 10 mL; 110 kg: 11 mL; 120 kg: 12 mL; 130 kg: 13 mL; 140 kg: 14 mL.
3488267|NCT03730038|Experimental|Pitavastatin treatment|Treatment of pitavastatin 4 mg qd for 12 weeks
3488268|NCT03730038|Active Comparator|Life-style modification|
3488269|NCT03730025|Experimental|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
3179903|NCT00677586|Active Comparator|2|staged resection of the liver metastasis and the colorectal primary tumor
3179904|NCT00677599|Active Comparator|Intervention A|Experimental arm enriched with flavonoids
3179905|NCT00677599|Placebo Comparator|Intervention B|
3488270|NCT03730025|Active Comparator|Auscultation without NeoTapAS|Pediatric resident responsible for HR assessment will mentally calculate the HR based on auscultation (by counting the number of beats in 6 seconds and multiplying by 10) and will verbally communicate the calculated HR.
3129097|NCT03196349|Active Comparator|Apixaban|Subjects randomized to Apixaban will have apixaban administered study drug of 2.5mg twice daily
3129098|NCT03196349|Active Comparator|Rivaroxaban|Subjects randomized to Rivaroxaban will have rivaroxaban administered study drug of 10 mg daily
3179906|NCT00677612|Experimental|A|
3179907|NCT00677625||Liver Disease (LD)|These child subjects have some form of liver disease (including those who need a liver transplant) or have already had a liver transplant.
3179908|NCT00677638|Experimental|1|Embracer implantation
3179909|NCT00677651||1|Five caucasian women
3179910|NCT00677651||2|Five caucasian men
3179911|NCT00677664|Active Comparator|A|Group which received Copaxone
3488271|NCT03730012|Experimental|Gilteritinib plus Atezolizumab|Participants will be treated with gilteritinib once daily for the phase 1 portion of the study to establish the recommended dose for the phase 2 portion. In the phase 2 portion, the participants will be treated with gilteritinib once daily at dose determined by the phase 1 portion of the study. Atezolizumab will be administered once every 2 weeks for the phase 1 and 2 portions of the study. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet 1 of the discontinuation criteria; whichever occurs first.
3488272|NCT03729999|Experimental|Ultrasonography|Patients requiring single lung ventilation for a surgical procedure will have a bedside ultrasound to evaluate lung isolation.
3488273|NCT03729986||Healthy adults|Healthy subjects without exercise habit that can cooperate with the measurements of this study, loaded inspiratory muscle test.
3488274|NCT03729973|Active Comparator|Group (K)|"Group (K) (n=25): patients nebulized ketamine 50 mg(milgram) (1ml) plus 4ml normal saline.So total volume (5ml).~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized 1ml ketamine (Ketalar 50mg/VI Solution for Injection) by compressor nebulizing for 15 minutes."
3129099|NCT03196505|Active Comparator|Liposomal Bupivacaine|Liposomal bupivacaine (Exparel) 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
3129100|NCT03196505|Active Comparator|Control|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
3488275|NCT03729973|Active Comparator|Group (M)|"Group M(n=25) : patients nebulized isotonic magnesium sulfate 250mg (3ml)( 50% Magnesium Sulfate Injection)plus 1ml normal saline.~In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
3488276|NCT03729973|Active Comparator|Group (L)|"Group (L) (n=25): patients nebulized lidocaine 2% 100mg .So total volume (5ml). In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
3488277|NCT03729973|Active Comparator|Group (C)|"Group (C) (n=25): patients nebulized normal saline(0.9%). 5ml .In preparation room an I.V line was secured ,and stranded monitoring was connected to patient.~Patients nebulized by compressor nebulizing for 15 minutes."
3488278|NCT03729947|Active Comparator|Drain placed|Subfascial drain at end of procedure
3488279|NCT03729947|Placebo Comparator|No drain placed|No drain left at the end of study
3488280|NCT03729934|No Intervention|Control|This arm receives no treatment control.
3179912|NCT00677664|Placebo Comparator|B|Group which received Mannitol
3179913|NCT00677703|No Intervention|Standard Care|Participants will receive standard care without daily reminders.
3488281|NCT03729934|Experimental|Ketone Ester|This arm receives 25 g ketone ester.
3488282|NCT03729934|Experimental|Ketone Salt|This arm receives 25 g ketone salt.
3488283|NCT03729921|Active Comparator|gastric variceal obturation|gastric variceal obturation
3488284|NCT03729921|Experimental|gastric variceal ligation|gastric variceal ligation
3488285|NCT03729908|Experimental|Animal assisted mindfulness based intervention|"The intervention is the AAMI. Trained animals that live in the Therapie-Tiergarten of REHAB Basel will function as therapy animals. Trained psychologists will lead the AAMI."
3488286|NCT03729908|Active Comparator|Anti-stress program|The active control intervention consists of the same program, however without the inclusion of animals (Anti-Stress program, ASP).
3488287|NCT03729895|Experimental|patients with OSAS in different degrees|OSAS patients will be treated with an adjustable oral appliance and evaluated with cone-beam computed tomography and polysomnography.
3488288|NCT03729882|Other|EUS-guided gallbladder drainage|"In one arm, Endoscopic Ultrasound-Gallbladder Drainage (EUS-GBD) will be performed by using a 3,8 mm therapeutic echoendoscope and a lumen apposing metal stent ( Hot AXIOS™ Stent and Electrocautery Enhanced Delivered System; Boston Scientific Corporation, Natick, MA, USA) after conventional biliary drainage with self-expandable metallic stents during endoscopic retrograde cholangiopancreatography (ERCP).~All procedures will be performed under general anesthesia."
3488289|NCT03729882|Other|Non EUS-guided gallbladder drainage|"In the other arm, patients will undergo conventional biliary drainage with self-expandable metallic stent placement during ERCP evaluation without prophylactic EUS-GBD and will be considered as a Non EUS-guided gallbladder drainage.~All procedures will be performed under general anesthesia."
3488290|NCT03729869|Experimental|Progesterone Males|35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
3488291|NCT03729869|Placebo Comparator|Placebo Males|35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
3488292|NCT03729869|Experimental|Progesterone Female|35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
3488293|NCT03729869|Placebo Comparator|Placebo Females|35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
3488294|NCT03729856|Experimental|B5 week,intervention,follow-up|Participants will undertake their usual activities for the 5 week baseline period. Participants will begin the 16 week intervention period at week 6 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 22, participants will have no contact with intervention personnel during the 5 week follow-up period.
3179914|NCT00677703|Experimental|Text Messages|Participants will receive a daily text message reminder for 6 months
3179915|NCT00677716|Experimental|131I-chTNT-1/B MAb (Cotara)|
3179916|NCT00677729|Active Comparator|1|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline (NaCl)
3179917|NCT00677729|Placebo Comparator|2|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl)
3179918|NCT00677742|Experimental|1|enhanced initial supply of oral contraception
3179919|NCT00677742|Active Comparator|2|conventional initial supply of oral contraception
3488295|NCT03729856|Experimental|B8 week,intervention,follow-up|Participants will undertake their usual activities for the 8 week baseline period. Participants will begin the 16 week intervention period at week 9 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 25, participants will have no contact with intervention personnel during the 5 week follow-up period.
3488296|NCT03729856|Experimental|B11 week,intervention,follow-up|Participants will undertake their usual activities for the 11 week baseline period. Participants will begin the 16 week intervention period at week 12 during which time they will participate in 12 sessions with an accredited exercise physiologist. Beginning week 28, participants will have no contact with intervention personnel during the 5 week follow-up period.
3488297|NCT03729843||CBCT and intraoral digital radiography|simulated bone defects will be detected and measured by 2 techniques using CBCT and using intraoral digital radiography and the all measurements will be compared with the gold standard real measurements on the dry jaws
3488298|NCT03729804|Experimental|KRD Arm|Patients assigned to this group will receive a combination of carfilzomib, lenalidomide, and dexamethasone in 28 day cycles. Doses will vary
3129101|NCT03196635|Experimental|All Study Participants|All subjects will undergo their regularly scheduled full-field digital mammogram, consisting of bilateral, 2-view (craniocaudal [CC] and mediolateral oblique [MLO]) image acquisition. In addition, a study-specific, unilateral 2-view image set will obtained, utilizing the PA breast compression mode.
3488299|NCT03729804|Experimental|VRD Arm|Patients assigned to this group will receive a combination of Bortezomib, lenalidomide and dexamethasone in 21-day cycles. Doses will vary
3488300|NCT03729791|Experimental|actual tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
3129102|NCT03196791|Experimental|Deep neuromuscular block group|Sugammadex sodium 4mg/kg/IV after operation
3129103|NCT03196791|Experimental|Moderate neuromuscular group|Sugammadex sodium 2mg/kg/IV after operation
3488301|NCT03729791|Active Comparator|sham tDCS|sham direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
3488302|NCT03729778|Active Comparator|HIV+|One time administration of Prevnar-13 vaccine to HIV+ participants
3488303|NCT03729778|Active Comparator|HIV Negative Controls|One time administration of Prevnar-13 vaccine to HIV Negative Control participants
3488304|NCT03729765|Experimental|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
3488305|NCT03729765|No Intervention|standard care|The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.
3488306|NCT03729752|Active Comparator|Healthy Volunteer|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
3488307|NCT03729752|Experimental|Viremic HIV-infected|Four serial PET-MR scans over 120 hours following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
3488308|NCT03729752|Experimental|Suppressed HIV-infected|A PET-MR scan following a single, bolus injection of [89]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).
3488309|NCT03729726|Experimental|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model will include: a mandatory school-year program that offers after-school programming 4 days a week, including 120 hours of education (direct instruction & homework support), 30 hours of health (social emotional learning & sexual health), and 15 hours of student advocacy; an optional, 4-week summer program that offers 120 hours of programming each summer, including 16 hours of health (social emotional learning - service learning), 104 hours of project-based learning and enrichment (project-based learning in STEM - 64 hours) and enrichment (i.e., field trips, career speakers, and arts and crafts opportunities- 40 hours); and an optional parent engagement program, which will offer monthly parent workshops and quarterly events.
3488310|NCT03729726|No Intervention|Control|
3488311|NCT03729713|Experimental|Intervention|Computerized Cognitive Rehabilitation
3488312|NCT03729713|Sham Comparator|Placebo|Video game
3488313|NCT03729700|Experimental|Almond supplementation|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
3488314|NCT03729700|No Intervention|Control snack|The control snack will be a typical western diet snack. The calorie-matched control snack will be commercially available individually wrapped food products.
3179920|NCT00677755|Experimental|Mf+Ms|The women in mifepristone combined misoprostol group (Mf+Ms) received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
3488315|NCT03729687|Experimental|LARCT-US|Short Course Radiation Therapy (5 x 5 Gy in 1 week, scRT) followed by 4 cycles of Pre-operative Chemotherapy using capecitabine and oxaliplatin (CAPOX) and Surgery in High-risk Rectal Cancer
3488316|NCT03729674||Biosimilar|Exposed group
3488317|NCT03729674||Originator (legacy) drug|Reference group
3488318|NCT03729661|Experimental|Breath hold|Patients who receive a breathhold CT- and treatment
3488319|NCT03729635|Experimental|PIFB performed to treat PSP|Pectoral-intercostal fascial plane block (PIFB) is performed on patients with severe post-sternotomy pain (PSP) after coronary artery bypass graft surgery (CABG).
3488320|NCT03729622|Active Comparator|Immediate Intervention|Participants in this arm will receive an immediate low FODMAP dietary intervention on their second visit after they have been screened, consented and enrolled during visit 1.
3129104|NCT03196973|Experimental|DF289 plus DF277|Otic solution
3129105|NCT03196973|Active Comparator|DF289|Otic solution
3129106|NCT03196973|Active Comparator|DF277|Otic solution
3129107|NCT03197025|Experimental|1/Arm 1 - Dose Escalation|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at escalating doses) + aldesleukin
3488321|NCT03729622|Placebo Comparator|Delayed Intervention|Participants in this arm will receive a delayed Low FODMAP dietary intervention during their third visit after they have been been screened, consented and enrolled during visit 1.
3488322|NCT03729609||Brentuximab vedotin 1.2 mg/kg (body weight)|Brentuximab vedotin 1.2 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every two weeks (up to 12 times). The dose should be adjusted depend on the participant's condition. Participants received interventions as part of routine medical care.
3129108|NCT03197025|Experimental|2/Arm 2 - Maximum Tolerated Dose (MTD)|Patients will undergo leukapheresis, then treatment with E6 T Cell Receptor (TCR) cells (at the MTD) + aldesleukin
3132770|NCT03449446|Experimental|Firsocostat (FIR) + Cilofexor (CILO)|Participants will receive placebo to match SEL 18 mg tablet + FIR + CILO orally once daily for 48 weeks.
3132771|NCT03449446|Experimental|Placebo|Participants will receive placebo to match SEL 18 mg + placebo to match FIR 20 mg tablet + placebo to match CILO 30 mg tablet orally once daily for 48 weeks.
3488323|NCT03729583|Active Comparator|Control group|The control group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme without breathing retraining All patients were medically stable and referred by their caring respiratory consultant
3488324|NCT03729583|Experimental|Active group|The active group consisted of 15 patients with a diagnosis of ILD. They received a 12-week Pulmonary Rehabilitation (PR) programme with breathing retraining exercises. All patients were medically stable and referred by their caring respiratory consultant
3488325|NCT03729570|Experimental|ePrEP|Participants will receive the ePrEP home care system for telemedicine PrEP, permitting initiation and persistence in PrEP care. The ePrEP home care system consists of: a smartphone application (app) for video-based telemedicine PrEP consultations with a clinician; secure messaging; a system to track shipments to & from participants; and behavioral risk surveys that are complemented by home specimen kits. Self-collected specimens will be mailed to laboratories for routine, guideline-based testing for PrEP care. Home specimen collection will be used to determine the primary study outcome of tenofovir-diphosphate levels.
3488326|NCT03729570|No Intervention|Standard of care|Participants will be referred to a publicly available website that geolocates the nearest PrEP provider. They will receive standard of care, defined as what a member of the general public would be able to access for PrEP services. Home specimen self-collection will be used to determine the primary study outcome of tenofovir-diphosphate levels. Additional research assessments will include quarterly surveys.
3488327|NCT03729544|Experimental|Alert|On-screen computerized decision support alert during the outpatient clinical encounter that notifies the provider that the patient should be screened for CTEPH
3488328|NCT03729544|No Intervention|No Alert|No provider notification
3488329|NCT03729531|Active Comparator|Conventional|The perivascular tissue is stripped off when harvesting the vein, and saline will be used to distend the vein to check for leakage.
3488330|NCT03729531|Experimental|No-touch|The vein will be harvested by frequency electrotome and the perivascular tissue will be preserved, the vein will not be distended.
3488331|NCT03729505|Active Comparator|Pyloric injection of magnesium sulfate and lidocaine mixture|After sleeve gastrectomy, the pylorus is injected with a mixture of magnesium sulfate and lidocaine
3488332|NCT03729505|Active Comparator|Pyloric injection of saline|After sleeve gastrectomy, the pylorus is injected with normal saline
3488333|NCT03729492|Other|CTEPH/CTED work-up|
3488334|NCT03729479|Experimental|Experimental: DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
3488335|NCT03729479|Experimental|Experimental: very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
3488336|NCT03729479|Experimental|Experimental: DASH diet and extra support|"Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
3488337|NCT03729479|Experimental|Experimental: very low carb, ketogenic diet and extra support|"Participants will be taught to follow a very low-carbohydrate, ketogenic diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).~They will also be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior."
3488338|NCT03729466|No Intervention|Control group|There will be no intervention for 8 weeks
3488339|NCT03729466|Experimental|Intervention group|clinical pilates will be given to the intervention group for 8 weeks
3488340|NCT03729440||corrosive patients|
3488341|NCT03729427|Experimental|Treatment Arm|ESP Block
3488342|NCT03729427|No Intervention|Control Arm|Standard of Care
3488343|NCT03729414|Active Comparator|mucopexy with Doppler artery ligation|Doppler guided hemorrhoidal artery ligation and mucopexy: Group of patients with III degree hemorrhoids treated by THD or AMI device is introduced into the anal canal. The terminal branches of the rectal artery are detected by the Doppler 2-3 cm above the dentate line. The tip of the instrument is tilted and arteries ligated with a figure-of-eight suture inserted using a special needle-holder. After the haemorrhoid artery ligation, the suture is continued with 3/5 sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all artery ligations (6 ligations
3488344|NCT03729414|Experimental|mucopexy without Doppler artery ligation|Non Doppler guided hemorrhoidal artery ligation and mucopexy: A lubricating gel is applied to the tip of the THD or the AMI device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. the mucopexy will start at two o'clock and repeated at 4, 6 8, 10, 12, in clockwise direction
3488345|NCT03729401|Active Comparator|DAPT - Aspirin and Ticagrelor|As per results of the PEGASUS trial, patients will be treated with aspirin 81mg daily and ticagrelor 60mg twice daily
3488346|NCT03729401|Experimental|Ticagrelor Monotherapy|Patients will only receive ticagrelor 60mg twice daily.
3488347|NCT03729401|Experimental|Personalized Therapy Arm|Patients allocated to the personalized arm (PA) will have a DAPT score calculated. For those with a score of < 2, only aspirin at 81 mg daily will be prescribed. For those with a score of ≥ 2, P2Y12 inhibitor choice will be dependent on carrier status of CYP2C19 LOF alleles. Heterozygous or homozygous carriers will receive be prescribed ticagrelor 60mg twice daily and non-carriers with will be prescribed clopidogrel 75mg daily.
3488348|NCT03729375|Experimental|10cc Patients|Intervention: Group 1 will receive 10cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
3488349|NCT03729375|Active Comparator|20cc Patients|Intervention: Group 2 will receive 20cc of intra-operative intra-carpal tunnel anesthetic injection (bupivacaine/Marcaine). Postoperatively, patients will also be prescribed an opioid pain medication in congruence with current standard medical practice. Patients will be contacted at 24-hours, 48-hours, 72-hours, and at 2-week clinic follow-up by research staff and evaluated for pain levels through the LIKERT scale.
3488350|NCT03729336|Experimental|PEEZY specimen|All subjects will use PEEZY to give a urine specimen.
3488351|NCT03729336|Placebo Comparator|CATHETER specimen|All subjects will use CATHETER (performed by their clinician) to give a urine specimen, following PEEZY use.
3488352|NCT03729323|Experimental|Experimental: Motivational Interviewing|INTERVENTION GROUP: In this group, Diabetics and Hypertensives will attend two Nursing Consultation sessions based on the assumptions and techniques of Motivational Interviewing with a certified nurse with specific 20-hour theoretical and practical training for this approach style.
3488353|NCT03729323|Active Comparator|Nursing Consultation|CONTROL GROUP: In this group, Diabetics and Hypertensives will attend two conventional nursing consultation sessions aimed at self-care, with a untrained nurse for the use of motivational interviewing, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in Diabetes Mellitus and Arterial Hypertension and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
3488354|NCT03729310|Other|Propel Implant|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
3488355|NCT03729310|Other|Nasopore soaked with triamcinolone|"This packing' is a sponge-like material which dissolves while releasing triamcinolone, which is another type of steroid. Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA."
3488356|NCT03729297|Experimental|cabozantinib|cabozantinib 60 mg tablets OD
3179921|NCT00677755|Experimental|Ms-alone|The control group (Ms-alone) patients were only administered 0.8 mg of misoprostol orally on day 3.
3179922|NCT00677768||Early ALS|
3488357|NCT03729284|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
3488358|NCT03729284|Active Comparator|Cymbalta|Duloxetine hydrochloride hard gelatinous capsule 60 mg by mouth on Day 1 of period 1 or 2
3488359|NCT03729219|Experimental|ETVAX|Contains inactivated Tetravalent ETEC vaccine, 10 ug Double-mutant heat-labile toxin (dmLT) and effervescent power for oral solution administered twice 14 (plus minus 7) days intervals.
3488360|NCT03729219|Placebo Comparator|Placebo|Effervescent power for oral solution administered wice 14 (plus-minus 7) days intervals
3488361|NCT03729206|Experimental|Sublingual microscopy|
3488362|NCT03729193||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 soccer players.
3488363|NCT03729193||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 basketball players.
3488364|NCT03729193||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 volleyball players.
3488365|NCT03729193||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 archers.
3488366|NCT03729193||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 kickboxers.
3488367|NCT03729193||table tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 table tennis athletes.
3488368|NCT03729193||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 runners.
3488369|NCT03729193||field tennis athletes|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 20 field tennis athletes.
3488370|NCT03729180|Other|Pain Cohort|Patients with a post-operative pain consult will be included in a pain sub-analysis to assess pain scores, pain therapy administration, and rate of opioid-induced adverse events.
3488371|NCT03729180|Experimental|Pharmacogenomic (PGx) Arm [Randomization Arm 1]|All patients will undergo preemptive genotyping prior to their surgical procedure, and all patients will have pharmacogenomic results made available to providers.
3488372|NCT03729180|Other|Control Arm [Randomization Arm 2]|All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
3488373|NCT03729167|Experimental|Scaling and root planing|Teeth that have been given a prognosis of hopeless and treatment planned for extraction will be scaled and root planed with various non-surgical instruments prior to extraction. The teeth will then be photographed and assessed for remaining hard accretion deposits to determine the effectiveness of the instruments.
3179923|NCT00677768||Suspected ALS|
3488374|NCT03729154|Experimental|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
3488375|NCT03729154|No Intervention|Treatment as Usual|Participants in the Treatment as Usual condition will receive behavioral and counseling services typically provided by their preschool.
3488376|NCT03729141|Experimental|Added Cholesterol|
3488377|NCT03729141|Active Comparator|No Added Cholesterol|
3488378|NCT03729128|Experimental|dextromethorphan and memantine (DM+MM)|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on dextromethorphan 30mg/day and memantine 5mg/day combination (DM+MM) for 12 weeks.
3488379|NCT03729128|Placebo Comparator|Placebos|The patients with Amphetamine-type stimulants use disorder will be recruited and received treatment of add-on placebos for 12 weeks.
3488380|NCT03729115|Other|Screening Arm|Enrolled patients will undergo Magnetic Resonance Imaging (MRI) every 6 months (2x/year) in addition to an annual screening mammogram.
3488381|NCT03729102|Active Comparator|Control group|Persons who had received primary immunization
3488382|NCT03729102|Experimental|Study group|Persons who had received primary immunization and later received booster vaccination for at least 3 times
3488383|NCT03729089|Experimental|Modified Biophysical Profile scan|Participants randomized to intervention group (modified biophysical profile scanning) will receive scans starting from 34 weeks at enrollment then every 3 weeks thereafter until 40 weeks of amenorrhea.
3488384|NCT03729089|No Intervention|Current standard of care|The participants randomized to this control group will receive the current standard of care recommended by World Health Organization implemented by the attending Doctor. they may receive the modified biophysical profile scanning or not but at non specified time during their pregnancy.
3488385|NCT03729076|Experimental|Crystalloid|Patients will receive rapid co-load of plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia.
3488386|NCT03729076|Active Comparator|Colloid|Patients will receive rapid co-load of 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia.
3488387|NCT03729063|Experimental|Twice daily expired CO measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
3488388|NCT03729063|Active Comparator|Control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
3488389|NCT03729050|Experimental|Intervention with rehabilitation coordinator|
3488390|NCT03729050|No Intervention|Control|
3488391|NCT03729037|Experimental|Serious game|Intervention: CPR self-training with serious game.
3488392|NCT03729037|Active Comparator|Training video|Intervention: CPR self-training with Keynote presentation with the addition of voice-over narration.
3488393|NCT03729011|Active Comparator|Volatile anesthesia group|
3129109|NCT03197038|Experimental|Home-based walking exercise|Home-based exercise program: The exercise training group will participate in an educational session on exercise for CKD. Participants will receive a packet of information with an exercise prescription and a heart rate monitor that monitors the exercise. Participants will be asked to exercise (a brisk walk) at home, 3 times per week, for 30-60 minutes for 24 weeks. Participants will be contacted via phone biweekly or more frequently if they are behind the exercise routine, and the investigators will meet with them monthly to provide encouragement and progression of exercise, and to download the heart rate monitor.
3179924|NCT00677768||Disease Mimics of ALS|
3179925|NCT00677768||Healthy Controls|
3488394|NCT03729011|Active Comparator|TIVA group|
3488395|NCT03728998|Other|PLR & Clearsight measurements|All patients 16years or older presenting to the ED with uncomplicated sepsis (see inclusion and exclusion criteria) will undergo a Passive Leg Raise (PLR, non-invasive) and multiple measurements by the Clearsight non-invasive hemodynamic monitoring system. Followed by a fluid challenge (common practice; non interventional)
3488396|NCT03728959|Experimental|Liquid meal (Nutridrink)|Liquid meal (Nutridrink)
3488397|NCT03728959|Experimental|GIP|Glucose-dependent insulinotropic polypeptide
3488398|NCT03728959|Experimental|GLP-2|Glucagon-like peptide-2
3488399|NCT03728959|Experimental|Placebo (saline)|Placebo (saline)
3488400|NCT03728946|Experimental|Liposomal Bupivacaine Interscalene Block|Liposomal bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
3488401|NCT03728946|No Intervention|Bupivacaine Interscalene Block|Bupivacaine anesthetic will be administered as an interscalene block during rotator cuff repair surgery and total shoulder arthroplasty.
3488402|NCT03728933|Experimental|2 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 2 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
3488403|NCT03728933|Experimental|3 milligram/24 hours rotigotine|Subjects randomized to this arm will be initiated on 1 milligram (mg)/24 hours (h) rotigotine and up-titrated to a maximum of 3 mg/24 h rotigotine, which is the assigned dose level throughout the 12-week Maintenance Period.
3488404|NCT03728933|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching placebo patches to maintain the blinding.
3488405|NCT03728907|Active Comparator|Audiologist-adjusted first|This arm will complete the field trial with the audiologist-adjusted fitting first, followed by the user-adjustment fitting.
3488406|NCT03728907|Experimental|User-adjusted first|This arm will complete the trial with the user-adjusted fitting first followed by the audiologist-adjusted fitting.
3179926|NCT00677781||F64|We investigate a cohort of 20 consecutive patients undergoing hepatic or pancreatic surgery (Pilot study)
3488407|NCT03728894|Active Comparator|A: Midazolam-hydroxyzine with 100% O2|Midazolam-hydroxyzine with 100% O2 was administrated to 30 children. Drug: Oral Medication (midazolam 7.5 mg and hydroxyzine 10 mg) and Inhalation Gas 100% O2 Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
3488408|NCT03728894|Experimental|Midazolam-hydroxyzine with 50% N2O/ O2|children received Midazolam-hydroxyzine with 50% N2O/O2, one tablet of oral midazolam 7.5 mg and one tablet of hydroxyzine 10 mg with 50% N2O/O2. Drug: Oral Medication and Inhalation Gas Patients were randomly assigned to received one of two regimens (A,B) in across over design, Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
3488409|NCT03728881|Experimental|Group I (Cervarix)|Participants 9-14 years old receive Cervarix IM at baseline.
3129110|NCT03197038|Active Comparator|Control|The control group will receive standard instructions on exercise for patients with kidney disease similar to what is commonly done in clinical practice. The control group will not receive an exercise prescription or heart rate monitor. Participants will be contacted via phone biweekly to answer any questions and ensure continued study participation. The control group will not meet with the investigators monthly.
3129111|NCT03197129|Experimental|SADE waiting room|children that will wait in the SADE waiting room
3488410|NCT03728881|Active Comparator|Group II (Gardasil)|Participants 18-25 years old receive Gardasil IM at baseline and at 2 and 6 months in the absence of unacceptable toxicity.
3488411|NCT03728868|Placebo Comparator|Placebo|One capsule containing placebo (identical to the capsule with active product (F. prausnitzii and D. piger) in taste and appearance but without the active component) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
3488412|NCT03728868|Active Comparator|High dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E9-5x1E9 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
3488413|NCT03728868|Active Comparator|Low dose F. prausnitzii and D. piger|One capsule (containing F. prausnitzii and D. piger at a dose of 1E8-5x1E8 colony forming units per bacterial strain) taken orally once a day (morning), one hour before breakfast on empty stomach, for 8 consecutive weeks.
3488414|NCT03728855|No Intervention|Standard care|Based on an (electronic) order placed by a physician, nurses collect medication and provide patients with the ordered medication in a timely matter. Nurses document the administration either in an electronic medical record or on paper.
3488415|NCT03728855|Experimental|Self-administration of medication (SAM)|During SAM medication is stocked at the patient's bedside. When medication is scheduled to be administered, patients collect those form their own stock, administer, and document the administration by themselves. Once daily nurses check whether patients succeeded in administration for all prescriptions of the last 24 hours. Each day, patients are qualified for SAM. In the case patients do not meet the criteria of SAM, they will be excluded from SAM.
3488416|NCT03728842||Spontaneous regression|Patients must have metastatic melanoma or renal cell cancer with spontaneous regression.
3488417|NCT03728829||Trastuzumab+TP neoadjuvant chemotherapy|100 cases of patients with stage II-III HER2+ breast cancer will be assigned participants to neoadjuvant treatment regimen, including Trastuzumab combined with Docetaxel and Carboplatin. 5-10 ml peripheral blood will be collected from each patient and formalin fixed paraffin embedded (FFPE) blocks/sections or fresh tumor tissues/biopsies will be obtained from the hospitals before and after neoadjuvant therapy. The genomic characteristics between patients achieved pCR and non-pCR will be analyzed. The clinically actionable mutations for future therapy instructions will be identified.
3488418|NCT03728816||SCAP groups|all the SCAP patients who meet the inclusion criteria
3488419|NCT03728803|Sham Comparator|Sham inspiratory muscle training|"Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. For sham IMT the valve will be removed, creating a low resistance.~The participants will perform the sham IMT twice a day during 15 minutes for a period of 8 weeks."
3129112|NCT03197129|No Intervention|Traditional waiting room|children that will wait in the traditional waiting room
3129113|NCT03197324|Active Comparator|Digoxin Alone first, then Digoxin With Bexagliflozin|
3129114|NCT03197324|Active Comparator|Digoxin with Bexagliflozin, then Digoxin alone|
3129115|NCT03197376|Experimental|Pneumosil Lot 1|Pneumosil Lot 1
3129116|NCT03197376|Experimental|Pneumosil Lot 2|Pneumosil Lot 2
3129117|NCT03197376|Experimental|Pneumosil Lot 3|Pneumosil Lot 3
3129118|NCT03197376|Active Comparator|Synflorix|Synflorix
3129119|NCT03197389|Other|Cohort A1|Cohort A1 will include patients with a triple negative breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3129120|NCT03197389|Other|Cohort A2|Cohort A2 will include patients with ER/PR negative and Her2 positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3129121|NCT03197389|Other|Cohort B1|Cohort B1 will include patients with a triple negative breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3129122|NCT03197389|Other|Cohort B2|Cohort B2 will include patients with a ER/PR negative and Her2 positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3179927|NCT00677794|Active Comparator|1|Clear fluids only after lunch.
3129123|NCT03197389|Other|Cohort A3|Cohort A3 will include patients with ER positive breast tumor. Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3488420|NCT03728803|Active Comparator|Active inspiratory muscle training|Commercially available threshold IMT trainers (Threshold IMT, Philips Respironics) for inspiration will be used. After the sham IMT, the participants will perform an active inspiratory muscle training during 8 weeks with the same training schedule. The resistance will gradually be increased in the first couple of weeks until the intended resistance (30% of MIP) is reached.
3488421|NCT03728777|Placebo Comparator|Placebo|
3488422|NCT03728777|Experimental|Resveratrol|Over the counter supplement
3488423|NCT03728764|Other|single arm|
3488424|NCT03728751|Experimental|study group|Study group receiving dry needling and pupil diameter will be studied up to 23 minutes after needle placement.
3488425|NCT03728738|Experimental|Zero Degree HOB|Randomization to zero degree head of bed positioning until the time of initiation of thrombectomy
3488426|NCT03728738|Active Comparator|Thirty Degree HOB|Randomization to thirty degree head of bed positioning until the time of initiation of thrombectomy
3488427|NCT03728725||TB case detection Group|Patients with pulmonary TB symptoms and at least one DR-TB risk factor will be screened by Xpert MTB/RIF or Ultra. Patients with a clear TB-positive and RIF-resistant or RIF-sensitive result by Xpert MTB/RIF or Ultra and who consent to study procedures will be tested by Xpert MTB/XDR.
3488428|NCT03728725||RIF-resistance MTB Group|"An anticipated 316 additional RIF-resistant patients, as detected by Xpert MTB.~/RIF, will be enrolled in this study to evaluate sensitivity and specificity of the Xpert MTB/XDR test against strains with other potential drug-resistance mutations."
3488429|NCT03728712||Never smokers|Participants with no history of cigarette smoking
3488430|NCT03728712||Active smokers|Participants with an active history of cigarette smoking AND at least 10 pack-years total smoking history
3488431|NCT03728686|Experimental|3mins|Different given time: Fentanyl 2mcg/kg was given at either time 3 minutes before intubation
3488432|NCT03728686|Active Comparator|2mins|Different given time: Fentanyl 2mcg/kg was given at either time 2 minutes before intubation
3488433|NCT03728686|No Intervention|control|Different given time: Fentanyl 2mcg/kg was given at either time 1 minute before intubation
3488434|NCT03728673|Experimental|escitalopram|
3488435|NCT03728660|Experimental|LVES 2 first LEGACY second|Virtual bioptic magnification with large field of view (LVES 2) followed by 22-week washout period and then Full field magnification with small field of view (LEGACY)
3488436|NCT03728660|Active Comparator|LEGACY first LVES 2 second|Full field magnification with small field of view (LEGACY) followed by 22-week washout period and then Virtual bioptic magnification with large field of view (LVES 2)
3488437|NCT03728647|Experimental|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
3488438|NCT03728647|Active Comparator|regular health education|The regular (traditional) education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
3488439|NCT03728634|Experimental|AKCEA-TTR-LRx|Single and multiple doses of AKCEA-TTR-LRx administered subcutaneously
3488440|NCT03728634|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator administered subcutaneously
3129124|NCT03197389|Other|Cohort B3|Cohort B3 will include patients with a ER positive breast tumor who received neoadjuvant chemotherapy and who have clear signs of residual tumor on imaging after finishing neoadjuvant chemotherapy (i.e. on imaging estimated residual tumor size of at least 10 mm). Patients will be treated with one injection of Pembrolizumab (Keytruda®) administered intravenously at 200 mg 10 +/- 4 days before surgery.
3179928|NCT00677794|Active Comparator|2|Two sachets of picosalax the evening prior to Video Capsule Endoscopy (VCE).
3129125|NCT03197558|Other|Tube insertion using Tube Delivery System (TDS)|Active Tymbion iontophoresis and tube insertion using the TDS
3179929|NCT00677794|Active Comparator|3|Polyethylene glycol, 2 liters the evening prior to Video Capsule Endoscopy (VCE).
3488441|NCT03728621|Experimental|Individual-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
3488442|NCT03728621|Experimental|Group-based lifestyle intervention|Promotion of normocaloric & balanced diet and physical activity
3488443|NCT03728608|Active Comparator|Group 1--Short Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 0-48 hours for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
3488444|NCT03728608|Active Comparator|Group 2--Long Dwell|Premature VLBW (very low birth weight) male and female infants will be randomly assigned to have their feeding tubes removed at 7 days for the first 4 weeks of life.The feeding tube lumen, interluminal liquid and hub will be analyzed for level of contamination.
3488445|NCT03728595||Patients with lung disease having HAST|"Patients with chronic respiratory diseases who had a hypoxic altitude simulation test (HAST) for clinical purposes will have for research purposes:~venepuncture~spirometry."
3488446|NCT03728582|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be verb naming therapy in a sentence context. This will be followed by sham tDCS plus speech-language therapy after a 2 month washout period.
3488447|NCT03728582|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. Language therapy will be verb naming therapy in a sentence context. This will be followed by active tDCS plus speech-language therapy after a 2 month washout period.
3488448|NCT03728569|Other|Subjects over the age of 70 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
3488449|NCT03728569|Other|Subjects between 18 and 30 yrs receiving Vanicream|Subjects will be instructed to apply a moisturizer over the entire skin surface from the neck down twice daily. Subjects will also be required to use a bar soap (Vanicream Cleansing Bar) once daily and avoid application of other soaps or cleaners to the body for the duration of the study.
3488450|NCT03728556|Experimental|CS1001monoclonal antibody|
3488451|NCT03728556|Placebo Comparator|CS1001 Placebo|
3488452|NCT03728543|Experimental|Children 0-2yo|Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
3488453|NCT03728543|Active Comparator|Children 2-18yo|Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV
3488454|NCT03728530|Experimental|Experimental Group|Deep /breathing exercises including Purse lip, diaphragmatic breathing and powered breathing
3488455|NCT03728530|No Intervention|Control Group|The participants from control group did not perform any exercise.
3488456|NCT03728504|Experimental|ASN002 40 mg|40 mg ASN002
3488457|NCT03728504|Experimental|ASN002 80 mg|80 mg ASN002
3488458|NCT03728504|Placebo Comparator|Placebo oral tablet|Matching placebo for ASN002 doses
3488459|NCT03728491|Experimental|Healthy Figurant|Hands-on training on healthy figurants for gaining competence in TUS
3488460|NCT03728491|Experimental|Simulator|Hands-on training on US Mentor simulator for gaining competence in TUS
3488461|NCT03728491|No Intervention|Controls|Controls with no hands-on training
3179930|NCT00677846||3|Patients with symptoms of deep venous thrombosis less than for 2 weeks, with thrombus occluding without any reperfusion in color mode in the common femoral vein (CFV), the femoral vein (FV) or the popliteal vein (PV)
3488462|NCT03728478|No Intervention|Treatment arm 1: Step-up|JIA patients managed with a Treat-To-Target strategy (T2T)
3488463|NCT03728478|Experimental|Treatment arm 2: Step-down|JIA patients treated with an early combined therapy
3488464|NCT03728465|Experimental|Treatment Phase|"Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only ."
3488465|NCT03728439|Experimental|Before|LED applications at the beginning, with a dose of 8 J/cm2, will be performed shortly after the blood collections, with a maximum period of 10 minutes, in which the participants of the other groups should remain in rest passive. At the end of these 10 minutes, a 5 minute warm up will be performed and then the tests will be started.
3488466|NCT03728439|Experimental|Interval|The LED therapy applied in the tests interval will be performed after the first block of tests, with a maximum duration of 10 minutes and dose of 8 J/cm2. Then the second block of maximum tests will be performed.
3488467|NCT03728439|Experimental|After|LED applications at the end will be performed 10 minutes after the second battery of tests, also with 8 J/cm2 and in the same muscles irradiated in the other moments of application.
3488468|NCT03728439|No Intervention|Baseline|On that day, participants will not receive any intervention.
3488469|NCT03728426|Experimental|Letermovir|Open label letermovir will be administered daily for up to 12 weeks. The study allows an optional additional 12 weeks of treatment for secondary prophylaxis if clinically indicated.
3488470|NCT03728413|Other|Elderly Non-smoking|RSV A Memphis 37 will be given as intra-nasal drops.
3488471|NCT03728413|Other|Elderly ex and current smokers|RSV A Memphis 37 will be given as intra-nasal drops.
3488472|NCT03728413|Other|Young non-smokers|RSV A Memphis 37 will be given as intra-nasal drops.
3488473|NCT03728387|Experimental|osteoarthritis and clinical pilates exercise|34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section.
3488474|NCT03728374|Experimental|Anlotinib|
3488475|NCT03728361|Experimental|Treatment (nivolumab, temozolomide)|Patients receive nivolumab IV on day 1 of a 28 day cycle. Patients also receive temozolomide PO on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3488476|NCT03728335|Experimental|Treatment (enasidenib mesylate)|Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3488477|NCT03728322|Experimental|iHSCs treatment group|
3488478|NCT03728296|Experimental|islet body treatment group|
3488479|NCT03728283|Active Comparator|Conventional Implant placement|conventional implant placement following the manufacturer's instructions
3488480|NCT03728283|Experimental|Implant and Connective tissue grafting|implant placement in combination with connective tissue grafting
3488481|NCT03728270|Experimental|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl sutures."
3488482|NCT03728270|Active Comparator|Inlay Autogenous Bone Graft|"A safety distance of 5 mm will be maintained from the apex of the mandibular incisor and inferior mandibular border, the mental foramen, and permanent canine follicle.~One corticocancellous bone block with a maximum depth of 4 mm will be removed by mallet and chisel based on the recommendation that bone from the chin should be harvested at this maximum depth, compatible with the course of the mandibular incisive nerve canal on CT scans.~After removal of bone from the chin, the intervening bone struts will be removed using rongeur forceps and used as an additional bone graft.~The bone removed will be trimmed and contoured in a wedge form to be used as an inter-positional graft in the previously down fractured articular eminence to act as an obstacle in front of the mandibular condyle to prevent its hyper movement."
3488483|NCT03728257|Experimental|LTGO-Home Based Exercise|The lung transplant recipient will receive LTGO- Home Based Exercise, a behavioral exercise intervention that consists of in-home exercise training integrated with behavioral coaching using tele-rehabilitation.
3488484|NCT03728257|Active Comparator|Enhanced Usual Care|Enhanced Usual Care (EUC) will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including food safety, environmental health, flu, mental health, etc. and the provision of a self-monitoring device.
3488485|NCT03728244|Experimental|test group Hyaluronic acid|Patients scheduled for free gingival graft harvesting will receive Hyaluronic acid gel 0.2%
3488486|NCT03728244|Experimental|test group MEBO ointment|Patients scheduled for free gingival graft harvesting will receive MEBO ointment
3488487|NCT03728244|No Intervention|negative control group|Patients scheduled for free gingival graft harvesting
3488488|NCT03728231||Fifty patients with RA.|"-CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* Disease activity Score(DAS)(17)"
3488489|NCT03728231||Fifty patients with SLE.|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16). :* SLE Disease activity Index(SLEDAI)(18)"
3488490|NCT03728231||Fifty apparently healthy controls|"CBC with assessment of NLR and PLR. Immumological tests (RF, ANA, anti-ds DNA).~Functional Performance Tests:(12)~Fatigue severity scale (13).~Short-Form Health Survey 36 (SF-36) (14).~the short version of the International Physical activity Questionnaire (s-IPAQ) (15).~frequency intensity time (FIT) index of kasari (16)."
3488491|NCT03728218|Experimental|Orthokeratology Contact lenses|
3488492|NCT03728218|Experimental|Soft Multifocal Contact lenses|
3488493|NCT03728205|Experimental|Observational|All 10 pilot subjects will be taking yoga
3488494|NCT03728192|Experimental|Mangosteen treated group|"HeLa and H357 cell lines were procured and were further subdivided into 2 subdivisions and were assigned interventions:~Mangosteen group- cells treated with mangosteen extract and Camptothecin group - cells treated with standard anticancer drug camptothecin(25 micro mole)"
3488495|NCT03728192|No Intervention|Untreated group|H357 and HeLa cell line without any drug intervention.
3488496|NCT03728179|Experimental|Cohort 1|0,5 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
3488497|NCT03728179|Experimental|Cohort 2|1 Gy of RT + Cyclophosphamide + Nivolumab + Ipilimumab + Aspirin
3488498|NCT03728179|Experimental|Cohort 3a|1 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
3488499|NCT03728179|Experimental|Cohort 4a|2 Gy of RT + Cyclophosphamide + Nivolumab + Celecoxib
3488500|NCT03728179|Experimental|Phase I b|Recommended Phase Ib RT dose (RP1bD) + Nivolumab + Ipilimumab or Cyclophosphamide + Celecoxib
3488501|NCT03728179|Experimental|Cohort 3b|1 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
3488502|NCT03728179|Experimental|Cohort 4b|2 Gy of RT + Ipilimumab + Nivolumab + Celecoxib
3179931|NCT00677859|Experimental|Single dose Arm|There will be six cohorts of three patients each. Three escalating doses of MultiStem will be evaluated.
3179932|NCT00677859|Experimental|Repeat Dose Arm|There will be six cohorts of three patients each. Four dosing regimens will be evaluated,varying doses at three times weekly or five times weekly.
3179933|NCT00677872|Experimental|1|
3488503|NCT03728166|Experimental|Alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
3488504|NCT03728166|No Intervention|No Alert|No notification to the provider.
3488505|NCT03728153|Experimental|20mg dose|Fluoxetine 20 MG Oral Tablet
3488506|NCT03728127|Experimental|DicaBr group and nuts (DCBN)|Brazilian cardioprotective diet plus 30g/day of mixed nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
3488507|NCT03728127|Active Comparator|DicaBr group (DCB)|Brazilian cardioprotective diet
3488508|NCT03728114|Experimental|High Altitude RIC group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device (patent number ZL200820123637.X, China)
3488509|NCT03728114|Sham Comparator|High Altitude Sham group|Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
3488510|NCT03728114|Experimental|Low Altitude RIC group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude RIC group. They will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days. The treatment was carried out using an electric auto-control device.
3488511|NCT03728114|Sham Comparator|Low Altitude Sham group|Thirty young healthy males from the altitude of 42 meters will be allocated to the Low Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
3488512|NCT03728101|Experimental|Single arm|"Dabigatran etexilate~Simvastatin + Dabigatran etexilate"
3488513|NCT03728075|No Intervention|Control group|standard protocol for cardiac rehabilitation
3488514|NCT03728075|Experimental|Intervention group|standard protocol for cardiac rehabilitation plus neuromuscular electrical stimulation (NMES)
3488515|NCT03728062|Experimental|Mindfulness meditation during lunch break|"Participants performed mindfulness meditation during lunch break at work place for a month, beginning with 15 minutes and ending with 30 minutes. They had available a quiet room and mp3 audios with guided meditations based on the MBSR program."
3129126|NCT03197883|Experimental|Group 1|Participants will apply a pea-sized quantity of test product (approximately 0.6-1 grams (g)) topically onto the fingertips and will apply twice daily (morning and evening) to the full face after cleansing. All participants will be instructed to continue using the facial cleanser twice-daily during the morning and evening and to apply the sunscreen in the morning (after application of test product) and at lunchtime.
3129127|NCT03197883|Other|Group 2|Participants will wet face with water and work a small amount of facial cleanser (approximately 0.6-1 g) into lather. Massage topically onto wet skin and rinse with water twice daily (morning and evening). After cleansing, participants will apply a pea-sized quantity (approximately 0.6-1 g) of the sunscreen in the morning and at lunchtime.
3488516|NCT03728062|Experimental|Physical exercise during lunch break|Participants performed physical exercises during lunch break at a gym for a month, beginning with 15 minutes and ending with 30 minutes. They were instructed to do cardio exercise such as running through a park or going to the gym for running, rowing, cycling or elliptical exercise. 20-140 beats per minute must be reach.
3179934|NCT00677937|Experimental|1|Intervention to include education and ongoing support
3179935|NCT00677937|No Intervention|2|Control to receive standard care
3179936|NCT00677950|Experimental|1|OP-1 Putty
3179937|NCT00677950|Active Comparator|2|Autograft
3488517|NCT03728062|No Intervention|Control group|Participants continue their normal lunch routine.
3488518|NCT03728049|Experimental|CT-ADP group|PVR assessment with the standard methods and with the CT-ADP that will be provided to the operator in real-time during TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator and based on the results of the CT-ADP on top of the standard methods of PVR assessment.
3488519|NCT03728049|Other|Control group|PVR assessment with standard methods only (at discretion of the operator excluding CT-ADP and transesophageal echocardiography). CT-ADP will not be provided to the operator at the time of TAVI. The decision to undertake corrective procedure will be left at the discretion of the operator according to the results of the standard methods of PVR assessment.
3488520|NCT03728023|Experimental|AZD4205|Single ascending dose: 5mg, 20mg, 50mg, 100mg, 150mg Multiple ascending dose: low, medium and high dose once daily X 14 days
3488521|NCT03728023|Placebo Comparator|Placebo|placebo single dose in SAD and once daily for 14 days
3179938|NCT00677963|Other|1|Patients with symptomatic 70-99% carotid stenosis who are operated on.
3179939|NCT00677976||IBS|Children between the ages of 10 and 18 who meet Rome III criteria for IBS as determined by a pediatric gastroenterologist.
3488522|NCT03728010||One-Lung Ventilarion|Thoracic surgery cases with one-lung ventilation strategy.
3488523|NCT03727971|Active Comparator|omalizumab arm|The treatment is initiated with one injection with weight and serum-Immunoglobulin E balanced omalizumab one time per cyclus
3488524|NCT03727971|Placebo Comparator|placebo arm|Participants will be administered placebo (NaCl), one time per cyclus
3488525|NCT03727958|Active Comparator|Lung and coronary CT assessment|Subjects will undergo simultaneous CT assessment of both coronary arteries and thoracic area
3179940|NCT00677976||Control|Healthy children between the ages of 10 and 18.
3488526|NCT03727958|Active Comparator|Coronary CT assessment|Subjects will undergo CT assessment of coronary arteries only
3488527|NCT03727945|Experimental|abdominopelvic exercise and posture|N=21 received supervised physiotherapy abdominopelvic exercise previous postural correction.
3488528|NCT03727945|Experimental|abdominopelvic exercise|N=21 received supervised physiotherapy abdominopelvic exercise.
3488529|NCT03727932|Other|VioOne HIV Profile|HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2. It is intended as an additional, more specific test to confirm the presence of antibodies to HIV-1 and HIV-2 for specimens repeatedly reactive in diagnosis or screening procedures, including pediatric patients (ages 2-20).
3488530|NCT03727919|Experimental|Early Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided within the first 6 weeks post-stroke
3488531|NCT03727919|Experimental|Delayed Experimental Group|N = 20 Intervention = 1-hour sessions of exoskeleton-assisted gait training, using the Ekso GT (Ekso Bionics, CA, USA) in addition to standard care Frequency = 4 times per week for 4 weeks, provided between week 8 and week 12 post-stroke
3488532|NCT03727919|No Intervention|Control Group|N = 20 Intervention = standard care including conventional physiotherapy
3488533|NCT03727906|Other|Non-insomnia Group|"Non-insomnia participants will not meet criteria for current DSM-5 Insomnia Disorder or have a past history of insomnia.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
3488534|NCT03727906|Other|Insomnia Group|"Insomnia Group participants will have to meet DSM-5 criteria for current Insomnia Disorder.~Interventions (order is randomly assigned):~no pre-sleep arousal manipulation night;~pre-sleep arousal down-regulation night~pre-sleep arousal up-regulation night."
3488535|NCT03727893|Active Comparator|Roller-based intervention Group (IG)|A group participating in a high-intensity exercise on a roller-based system.
3488536|NCT03727893|Placebo Comparator|Control Group (CG)|A group participating in an independent workout program at an accessible community-based fitness facility.
3488537|NCT03727880|Experimental|Arm A - Pembrolizumab and Defactinib|
3488538|NCT03727880|Experimental|Arm B - Pembrolizumab|
3488539|NCT03727867|Placebo Comparator|Drug group|Participants were under prescription of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) at the beginning and continued until disease progressed.
3488540|NCT03727867|Experimental|Drug plus SBRT group|After the first month of EGFR TKI orally, participants were given Stereotactic Body Radiation Therapy (SBRT) in dose of 50 Gy/5 F or 60 Gy/8 F for peripheral and central primary tumor, respectively, combined with oral EGFR TKI continually until the primary end point.
3488541|NCT03727828||Patients with heart failure|Patients with heart failure (HF) who are followed in the hospital or clinic setting, with optimization of medical therapy and blood collection.
3488542|NCT03727828||healthy control|
3488543|NCT03727815|Experimental|Mindfulness Pain Management Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target pain management through mindfulness.
3488544|NCT03727815|Experimental|Mindfulness Self Esteem Arm|Mindfulness meditation intervention - pain management module: patients will be asked to complete a guided mindfulness meditation phone application intervention that was designed to target self esteem through mindfulness.
3488545|NCT03727815|No Intervention|Non-intervention Arm|Patients assigned to the non-intervention arm will not be instructed to use a mindfulness meditation phone application and instead will listen to educational materials.
3488546|NCT03727802|Experimental|TRK-250|
3488547|NCT03727802|Placebo Comparator|Placebo|
3488548|NCT03727776|Experimental|H.P. Acthar ®|Subjects will self-administer subcutaneous injections of 80 units of adrenocorticotropic hormone analog starting on post-operative day 1 for twice a week until week 8.
3488549|NCT03727776|No Intervention|Controls|Subjects will be managed per the standard of care.
3488550|NCT03727763|Experimental|FIVC group|Irinotecan 180mg/m2 iv gtt (14 days per course) leucovorin 400mg/m2 iv gtt (14 days per course) 5-fluorouracil 400mg/m2 iv (14 days per course) 5-fluorouracil 2400 mg/m2 46h (14 days per course) vemurafenib 960mg po bid cetuximab 500mg/m2 iv gtt (14 days per course)
3488551|NCT03727750|Experimental|Gemtuzumab Ozogamicin (GO)|Patients will receive three doses of Gemtuzumab Ozogamicin (GO) 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
3488552|NCT03727737|No Intervention|Sham|Patients with mild and moderate TBI will be assigned randomly to this arm and will not receive treatment
3488553|NCT03727737|Active Comparator|ACTIVE|Patients with mild and moderate TBI will be assigned randomly to this arm and will receive treatment
3488554|NCT03727711|Experimental|Home Treatment|Participants will be taught home treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
3488555|NCT03727711|Active Comparator|Hospital Treatment|Participants will receive hospital treatment with TPTNS - twice weekly, 30 minute sessions for 6 weeks
3488556|NCT03727698|Experimental|Radiotherapy delivered on the MR Linac|MR Guided radiotherapy treatment
3488557|NCT03727685|No Intervention|Usual care|Patients admitted to the hospital will not receive information about Our Care Wishes.
3488558|NCT03727685|Active Comparator|Intervention: Our Care Wishes|Patients admitted to the hospital during the intervention phase will receive information from registration representatives regarding Our Care Wishes.
3488559|NCT03727659|Experimental|SHADE therapy + CONNECT FaceBook support|SHADE is a 10-week, 10-session, computerized CBT/MET intervention for Cannabis Use Disorder and depression. At each visit, a study clinician meets with participants for a 'check-in' session, which includes: review of homework; plans for completing homework; suicide risk and mood assessment. The CONNECT FB intervention component will facilitate social support for between-session homework and CBT skills practice for managing depression and preventing relapse, and bolstering motivation to change. Daily posts will be delivered. Only those participating in the study will know about the existence of this group and will be able to access it. A weekly real-time, Facebook chat session will be held to provide feedback concerning homework practice or answer questions.
3488560|NCT03727646|Experimental|Open-label nicotinamide riboside|"Participants scheduled to receive an LVAD will be prescribed nicotinamide riboside (NR) according to the following administration schedule:~Dose Escalation Day 1: 250 mg (1 capsule) twice daily (total daily intake = 500 mg) Day 2: 500 mg (2 capsules) twice daily (total daily intake = 1000 mg) Day 3: 1000 mg (4 capsules) twice daily (total daily intake = 2000 mg)~Dose Maintenance Day 4: 1000 mg (4 capsules) twice daily Day 5-14 as applicable thru Day Before Surgery: 1000 mg (4 capsules) twice daily~Washout Day of LVAD Surgery and/or Day 15: None"
3488561|NCT03727646|No Intervention|Baseline controls|Patients previously receiving LVADs, in whom blood and myocardial tissue assays for NAD+ levels and mitochondrial function were performed.
3488562|NCT03727620|Experimental|doxycycline group|Drug Longamycine 200 mg the first day , then 100 mg per day for 14 days
3488563|NCT03727620|Active Comparator|amoxicillin plus metronidazole group|Drug Dispamox 500 mg, 3 times a day for 7 days Flagyl 250 mg, 3 times a day for 7 days
3488564|NCT03727607|Active Comparator|Gass|DESFLURANE ANESTHESIA
3488565|NCT03727607|Active Comparator|TIVA|TOTAL INTRAVENOUS ANESTHESIA
3488566|NCT03727568|Experimental|Cryobiopsy: longer freezing time|Group nº1: A total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and a freezing time from ≥5 seconds for the following biopsies.
3488567|NCT03727568|Experimental|Cryobiopsy: shorter freezing time|Group nº 2: A total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and a freezing time from <5 seconds for the following biopsies.
3488568|NCT03727555|Experimental|Lentivirus-mediated delivery of ABCD1 to the CNS.|Intracerebral injection with lentiviral TYF-ABCD1 vector carrying the functional gene
3488569|NCT03727542|Experimental|Short AV-delay pacing|Participants will be their own control. Serum samples will be collected at baseline while the participants were in sinus rhythm and after 3 weeks of short AV-delay pacing serum samples will be recollected to measure matrix metalloproteinase levels .
3488570|NCT03727529|Experimental|Intervention group|
3488571|NCT03727529|Active Comparator|Control group|
3179941|NCT00677989||LA|LA group: patients with perforated appendicitis treated by laparoscopic operation intentionally
3488572|NCT03727503|Other|group/cohort|operated patients from cardiac surgery. Once they arrived in the ICU, we will measure PPV with the capstesia and the PICCO device at baseline, and after a volume expansion of 500 ml of crystalloid.
3488573|NCT03727490|Active Comparator|Control|This group will have the subscapularis left un-repaired, which is the standard of care for our institution for reverse shoulder arthroplasty.
3488574|NCT03727490|Experimental|Study|This group will have the subscapularis tendon repaired through a bone to bone repair that will add approximately 5 minutes to the surgical procedure.
3488575|NCT03727464|Experimental|Propofol Abstract Priming|Patients undergoing propofol general anesthesia and stimulation with a list of abstract words
3488576|NCT03727464|Experimental|Propofol Concrete Priming|Patients undergoing propofol general anesthesia and stimulation with a list of concrete words
3488577|NCT03727464|Active Comparator|Propofol Controls|Patients undergoing propofol anesthesia without any intraoperative priming
3488578|NCT03727464|Experimental|Sevoflurane Abstract Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of abstract words
3488579|NCT03727464|Experimental|Sevoflurane Concrete Priming|Patients undergoing sevoflurane general anesthesia and stimulation with a list of concrete words
3488580|NCT03727464|Active Comparator|Sevoflurane Controls|Patients undergoing sevoflurane general anesthesia without any intraoperative priming
3488581|NCT03727451|Experimental|PH-Pulmonary Fibrosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional open label long term extension at the optimal dose as identified in Part 1"
3488582|NCT03727451|Experimental|PH-Sarcoidosis|"Part 1: 1st 4 subjects will be treated with iNO 30, 45, 75 mcg/kg IBW/hr~2nd 4 subjects will be treated with iNO 45, 75, 125 mcg/kg IBW/hr~Part 2: Optional Open label long term extension at the optimal dose as identified in Part 1"
3488583|NCT03727412|Active Comparator|Naproxen Group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking preoperatively naproxen (Naprosyn, tab 500 mg twice/day for 4 days)
3488584|NCT03727412|Placebo Comparator|Control group|patients with an abdominal aortic aneurysm undergoing endovascular epair and taking placebo
3488585|NCT03727386|Experimental|Coconut oil|A dietary intervention that relies on the administration of 30 ml of extra virgin coconut oil per day for six months will be utilized in this study. Coconut oil administered will replace the cooking/vegetable oil usually used by the participants. .
3488586|NCT03727386|Placebo Comparator|Sunflower oil|A dietary intervention that relies on the administration of 30 ml of sunflower oil per day for 6 months will be utilized in this study. The oil administered will replace the cooking/vegetable oil usually used by the participants.
3488587|NCT03727360|Experimental|Exercise Training|Group exercise and treadmill walking
3488588|NCT03727360|Active Comparator|Flexibility Control|Group exercise and flexibility exercise
3488589|NCT03727334|Experimental|Treatment|For the treatment arm, the participants will complete the intervention protocol following the first in-person study visit 6 months post-injury. The intervention involves 16 weeks of online, in-home spatial navigation training. During the 16 weeks, the participant will complete exercises for 1 hour/day, every other day.
3488590|NCT03727334|No Intervention|Control|The control arm participants will receive their typical standard of care; they will not complete the intervention but will complete all of the in-person visits at the same post-injury time-points as the treatment group.
3488591|NCT03727321|Placebo Comparator|Placebo|Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
3488592|NCT03727321|Experimental|Fecal Microbial Transplant and cellulose|"Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.~Cellulose x 6weeks"
3488593|NCT03727321|Experimental|Fiber|Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
3179942|NCT00677989||OA|OA group:patients with perforated appendicitis treated by open approach
3179943|NCT00678002||QOL###|All child subjects in this cohort will be listed for or already have received a solid organ transplant (kidney, heart, or liver).
3488594|NCT03727321|Experimental|Fecal Microbial Transplant and Fiber|"Fecal Microbial Transplant~Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS)."
3488595|NCT03727308||Women recruited from pharmacies|"Investigators will enroll women seeking medical abortion pills without prescription from pharmacies.~- Medical abortion pills sourced from pharmacies"
3488596|NCT03727308||Women recruited from health clinics|"Investigators will enroll women seeking medical abortion pills from clinics.~- Medical abortion pills sourced from health clinics"
3488597|NCT03727295|Experimental|The control group 1|60 cases, idebenone 180mg/d, 3 times / day, oral
3179944|NCT00678054|Experimental|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
3179945|NCT00678067|Placebo Comparator|Placebo|12 hypercholesterolemic children 3-13 years of age
3488598|NCT03727295|Experimental|The control group 2|60 cases, idebenone 360mg/d, 3 times / day, oral
3488599|NCT03727295|Placebo Comparator|The placebo group|60 cases, placebo, 3 times / day, oral
3488600|NCT03727282|Other|Liberal strategy|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the attending physician
3488601|NCT03727282|Experimental|ejection volume index|Initiate dobutamine at 5 mcg/kg/min and adjust dobutamine according to the ejection volume index
3488602|NCT03727269|Experimental|Wii Fit Training Experimental Group|receiving Wii fit based abdomino-pelvic training
3488603|NCT03727269|Active Comparator|Conventional Training Control Group|receiving conventional pelvic floor exercises.
3488604|NCT03727256|Active Comparator|Group 1 patients|Patients have grade 2 or 3 knee osteoarthritis ultrasound therapy
3488605|NCT03727256|Active Comparator|Group 2 patients|Patients have grade 2 or 3 knee osteoarthritis neuromuscular electrical stimulation application
3488606|NCT03727243||Septic/septic shock patients|Patients with underlying confirmed or probable cause of infection leading to sepsis or septic shock will form the active group of interest.
3488607|NCT03727243||Non-septic/sterile inflammation patients|Patient with severe trauma, severe burns and patients admitted to ICU after major surgery or pancreatitis. Active comparator group.
3488608|NCT03727243||Healthy control patients|Active comparator group.
3488609|NCT03727230|Other|"Asia type DEL recipients"|"To identify Asia type DEL patients by phenotyping and gentoyping methods in the Chinese recipients and then blood transfusion of D+ blood rather than the rare D negative blood to the identified Aisa type DEL recipients."
3488610|NCT03727217|Experimental|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative.
3488611|NCT03727204||Aarhus University Hospital|100 patients undergoing on-pump cardiac surgery at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
3488612|NCT03727204||Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand|50 patients undergpoing on-pump cardiac surgery at at Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand
3488613|NCT03727191|Active Comparator|Control Group|Nutritional education, guidelines for the consumption of a completed shreded diet and recommendations for physical activity.
3488614|NCT03727191|Experimental|Experimental Group|Nutritional education and guidelines for the consumption of a completed shreded diet including: 2 packets of 90 grams every day (One salted packet for lunch/dinner and one sweet packet for breakfast/afternoon snack) and recommendations for physical activity for one month.
3488615|NCT03727165|Active Comparator|Continuous infusion|Patients with continuous infusion enteral nutrition in the intensive care unit at San Ignacio University Hospital
3488616|NCT03727165|Experimental|Cyclic infusion|Patients formulated with cyclic enteral nutrition infusion, administrated at night hours, from 4pm until 7am.
3488617|NCT03727152|Other|generic single tablet regimen of tenofovir alafenamide/e|HIV infected adults currently on protease inhibitor/ritonavir will switch to use generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir to see if the single tablet can continue to suppress viral replication and be used as a maintenance regimen
3488618|NCT03727126|Experimental|Robotic esophagectomy|Esophagectomy performed for esophageal cancer using the da Vinci robotic surgical system
3488619|NCT03727126|Active Comparator|Thoracolaparoscopic esophagectomy|Esophagectomy performed for esophageal cancer using conventional thoracoscopic and laparoscopic techniques
3488620|NCT03727113||Control cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
3488621|NCT03727113||Optimization cohort|Patients receiving an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
3488622|NCT03727100|Active Comparator|Clonidine Micropellets|single dose injection into the lumbar epidural space
3488623|NCT03727100|Sham Comparator|Sham Control|non-epidural needle placement
3488624|NCT03727087||Melanoma|Subjects with clinically confirmed melanoma or high suspicion of a primary malignancy of melanoma based on skin exam or imaging and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
3488625|NCT03727074|Experimental|5-FU Cream|topical cream
3488626|NCT03727074|Active Comparator|Efudex®|topical cream
3488627|NCT03727074|Placebo Comparator|Vehicle|topical cream
3488628|NCT03727061|Active Comparator|Arm A (standard of care chemotherapy at doctor's discretion)|Patients receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion
3488629|NCT03727061|Experimental|Arm B(porfimer sodium, I-PDT, SoC chemotherapy)|Patients receive porfimer sodium IV over 3-5 minutes and undergo I-PDT approximately 48 hours later. Patients also receive SoC chemotherapy (cisplatin, carboplatin, fluorouracil, cetuximab, nivolumab, pembrolizumab) at the oncologist's discretion at either 7 days, 14 days, or 28 days later.
3488630|NCT03727048|Active Comparator|Control|To the control group post ankle fracture surgery, per subject 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
3488631|NCT03727048|Experimental|Intervention|To the treatment group post ankle fracture surgery, per subject 30mg of IV ketorolac intraoperatively; 20 tablets of 10mg ketorolac with instructions to take every 6 hours, and 30 tablets of 5/325 oxycodone-acetaminophen with instructions to take 1 or 2 tabs every 4 to 6 hours as needed for pain
3488632|NCT03727035||Group I|Group I :40 Generalized chronic periodontitis subjects without type II diabetes mellitus
3488633|NCT03727035||Group II|Group II: 40 Generalized chronic periodontitis subjects diagnosed with type II diabetes mellitus
3179946|NCT00678067|Experimental|DHA+EPA group|12 hypercholesterolemic children 3-13 years of age
3179947|NCT00678067|Experimental|DHA Group|12 hypercholesterolemic children 3-13 years of age
3179948|NCT00678093|Experimental|SNAG|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
3488634|NCT03727022|Experimental|0.07 mg SM04690|Intra-articular injections of 0.07 mg SM04690 in 2 mL vehicle
3488635|NCT03727022|Placebo Comparator|Vehicle|Intra-articular injections of 0 mg SM04690 in 2 mL vehicle
3488636|NCT03727009||Hematologic Malignancy|Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
3488637|NCT03726983|Experimental|eHMP experimental group|"The experimental group received health management support and counseling,including:~GDM health care knowledge~self-awareness of health~self-monitoring of health status (i.e., recording weight and measurement data of metabolic syndrome risk factors and monitoring changes in data trends)~participation in discussions or browsing forums~healthy lifestyle guidance and counseling~reminder systems~a token system of earning points in exchange for prizes."
3488638|NCT03726983|No Intervention|Control group|only received usual care
3488639|NCT03726970|Experimental|Tube Potential difference|Different kVp values of the CBCT machine 70, 80 ,90 kVp
3488640|NCT03726970|Experimental|MAR tool|MAR option in the software off and on
3488641|NCT03726957|Experimental|Intervention group|The intervention arm included households which received improved cookstoves
3488642|NCT03726957|No Intervention|Control group|The control group included households, which did not receive improved cookstoves, and cooked in their usual traditional cookstoves.
3488643|NCT03726944|Other|Group 1 - Meditation1+Meditation2|8 weeks in total; 4 weeks of unnamed consumer-based meditation app + 4 weeks of Calm meditation app
3488644|NCT03726944|Other|Group 2 - Meditation2+Meditation1|8 weeks in total; 4 weeks of Calm meditation app + 4 weeks of unnamed consumer-based meditation app
3488645|NCT03726944|Other|Group 3 - Control+Meditation1|8 weeks in total; 4 weeks of educational control + 4 weeks of unnamed consumer-based meditation app
3129130|NCT03198000|Experimental|Formula # 13418-148|
3488646|NCT03726944|Other|Group 4 - Control+Meditation2|8 weeks in total; 4 weeks of educational control + 4 weeks of Calm meditation app
3129131|NCT03198000|Experimental|Formula # 13418-158|
3129132|NCT03198000|Active Comparator|Control Formula # PF004390|
3129133|NCT03198221|Active Comparator|Group A|Participants in Group A will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes. Participants must finish drinking the bowel preparation by 7:00 PM, and may continue to drink clear liquids until midnight.
3129134|NCT03198221|Active Comparator|Group B|Participants in Group B will begin drinking the bowel preparation Golytely (4 liter Polyethylene glycol based preparation) at 4:00 PM on the day before colonoscopy - an 8-ounce glass of the bowel preparation every 10 minutes for a total of 8 glasses, and must complete drinking the bowel preparation by 5:30 PM. Participants may continue to drink clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will be asked to drink an 8 ounce glass of bowel preparation every ten minutes for a total of 8 glasses over no more than 1.5 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
3179949|NCT00678106|Experimental|1|
3488647|NCT03726931|Experimental|[18F]FES|All patients will receive an additional PET/CT scan: [18F]FES PET/CT scan.
3488648|NCT03726918||Osteoarthritis|Surgery for implantation of a prosthesis in case of Osteoarthritis
3488649|NCT03726918||Non Osteoarthritis|Surgery for implantation of a prosthesis fon non Osteoarthritis cases
3488650|NCT03726905|Experimental|respiratory muscles training|4 weeks guided respiratory muscles training followed by 12 weeks guided aerobic training - (treadmill walking)
3488651|NCT03726905|Sham Comparator|sham respiratory muscles training|"4 weeks sham respiratory muscles training (THRESHOLD® IMT breathing trainer with 0 pressure level) followed by 12 weeks guided aerobic training - (treadmill walking)"
3488652|NCT03726892|Active Comparator|The SYNERGY stent|
3488653|NCT03726892|Active Comparator|Xience|
3488654|NCT03726866|Experimental|Sequence 1|Sequence 1
3488655|NCT03726866|Experimental|Sequence 2|Sequence 2
3488656|NCT03726866|Experimental|Sequence 3|Sequence 3
3488657|NCT03726866|Experimental|Sequence 4|Sequence 4
3488658|NCT03726866|Experimental|Sequence 5|Sequence 5
3488659|NCT03726866|Experimental|Sequence 6|Sequence 6
3488660|NCT03726853|Experimental|CKD-497 200mg|CKD-497 200mg
3488661|NCT03726853|Experimental|CKD-497 300mg|CKD-497 300mg
3488662|NCT03726853|Active Comparator|Active Comparator|compartor
3488663|NCT03726853|Placebo Comparator|Placebo|CKD-497 placebo and comparator placebo
3488664|NCT03726840|No Intervention|Driving performance no fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with no fragrance
3488665|NCT03726840|Experimental|Driving performance Fragrance|healthy young (ages 24-35 years) and older (ages 60-85 years) with fragrance
3488666|NCT03726827||population|self selected members of the general population who perceive a value in having a Fibroscan screening test of their liver
3488667|NCT03726814|Experimental|EPC treatment group|
3488668|NCT03726801|Experimental|Stratum C|"N 32 C~Women who are going to be mastectomized, conservate surgery and ostomy who attend the health education together with their immediate family member prior to surgery"
3488669|NCT03726801|Placebo Comparator|Stratum E|"N 32 E~Patients who are going to be subjected to a mastectomized, conservate surgery and ostomy who come alone to the health education prior to surgery"
3488670|NCT03726788|Experimental|Botulinum Toxin Type A 100U|one intra-articular injection in the painful knee 30 days after the inclusion visit
3488671|NCT03726788|Experimental|Botulinum Toxin Type A 200U|one intra-articular injection in the painful knee 30 days after the inclusion visit
3488672|NCT03726788|Active Comparator|Triamcinolone Hexacetonide 20 MG/ML|one intra-articular injection in the painful knee 30 days after the inclusion visit
3488673|NCT03726775|Experimental|RT-durvalumab|durvalumab at fixed dose of 1120 mg on Day1 of RT and every 3 weeks during the RT. Durvalumab with be continued at a fixed dose of 1500 mg every 4 weeks during 6 months following RT.
3488674|NCT03726762|Experimental|Diet Beverages|'Diet beverages' after the main meal
3488675|NCT03726762|Experimental|Water|'Water' after the main meal
3129135|NCT03198221|Active Comparator|Group C|Participants in Group C will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM. At 10:00 PM, participants will drink another 5 ounces of the bowel preparation, and will then be asked to drink at least three (3) additional glasses of clear liquids by midnight.
3132537|NCT03435692|Experimental|Lumbar Plexus Catheter|"Children undergoing pediatric hip surgery will have a lumbar plexus catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
3488676|NCT03726749|Experimental|Tocilizumab and prednisone|"TCZ 162 mg administered by subcutaneous injection weekly for 52 weeks.~Prednisone taper over 8 weeks with a starting dose between 20 and 60 mg."
3488677|NCT03726736|Experimental|Anlotinib combined Docetaxel|patients treated with anlotinib and Docetaxel (21 days for 1 cycle) until PD (progressive disease)
3488678|NCT03726736|Active Comparator|Docetaxel|patients treated with Docetaxel (21 days for 1 cycle) until PD (progressive disease)
3488679|NCT03726710|Experimental|Blood Pressure measurement and pharmacy|Blood Pressure measurement performed by barber and Blood pressure measurement and management visits with study pharmacist in person and through Telemedicine.
3488680|NCT03726697|Experimental|Tahneek|Infants receiving a single dose of soft date, prepacked by the pharmacy containing glucose equivalent to 200mg/kg at 1 hour after birth in the nursery.
3488681|NCT03726697|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
3488682|NCT03726684|Experimental|Coding strategy for cochlear implants|Measure neural responses of cochlear implant recipient Use measured values of refractoriness, spread of excitation and facilitation as parameters for a bioinspired coding strategy perform listening tests to compare new coding strategy with standard clinical coding strategy
3488683|NCT03726658|Experimental|AGN-241751 3mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
3488684|NCT03726658|Experimental|AGN-241751 10mg|AGN-241751, oral administration, once per day
3488685|NCT03726658|Experimental|AGN-241751 25mg|AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B
3488686|NCT03726658|Placebo Comparator|Placebo|Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B
3488687|NCT03726645|Active Comparator|Study group|Allogeneic fecal microbiota transplantation (from donor)
3488688|NCT03726645|Placebo Comparator|Control group|Autologous fecal microbiota transplantation (own stool)
3488689|NCT03726619|Experimental|e-CHEC-uP|Group 1 will receive the education study intervention after the first baseline questionnaire. Participants will be asked to take part in a one-time, 1 to 1.5-hour online education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker to help address any barriers in order to help receive a mammogram or a Pap test.
3488690|NCT03726619|Active Comparator|CHEC-uP|Group 2 will receive a similar education intervention but the education is offered face-to-face instead. Participants will be asked to take part in a one-time, 1 to 1.5-hour face-to-face education on breast and cervical cancer prevention followed by monthly phone calls and navigation assistance by a community health worker.
3488691|NCT03726606|Experimental|Extended depth of focus intraocular lens|Bilateral implantation of extended depth of focus intraocular lenses.
3488692|NCT03726606|Active Comparator|Trifocal intraocular lens|Bilateral implantation of trifocal intraocular lenses.
3488693|NCT03726593|Experimental|ASPY|Artesunate-pyronaridine, once daily for three days, following standard weight-based dosing per drug label. All volunteers with P.f monoinfection will receive single dose of primaquine (PQ) (15 mg) for transmission blocking.
3488694|NCT03726593|Experimental|AP+ASPY|Atovaquone-Proguanil (AP) + Artesunate-Pyronaridine (ASPY), once daily for three days, following standard weight-based dosing per drug label for each drug. All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking
3488695|NCT03726593|Experimental|AP+ASMQ|Atovaquone-Proguanil (AP) + Artesunate-Mefloquine (ASMQ); ASMQ once daily for three days (D0, D1, D2), following standard weight-based dosing per drug label. Subsequently, volunteers continue their treatment with AP once daily starting on day 3, for three additional days (D3, 4, 5). All volunteers with P.f monoinfection receive single dose of PQ (15 mg) for transmission blocking.
3488696|NCT03726580||control group|regional anesthesia
3488697|NCT03726580||general anesthesia(S)|general anesthesia with sevoflurane
3488698|NCT03726580||general anesthesia(I)|general anesthesia with isoflurane
3488699|NCT03726580||total intravenous anesthesia|total intravenous anesthesia with propofol.
3488700|NCT03726567|Active Comparator|Bariatric surgery group|Patients who are undergoing bariatric surgery for weight loss
3488701|NCT03726567|No Intervention|Non bariatric surgery group|Patients who are undergoing abdominal surgery for non-weight loss reasons
3488702|NCT03726541|Experimental|Early physiotherapy group|breathing exercise incentive spirometry training ambulation coughing
3488703|NCT03726515|Experimental|CART-EGFRvIII + Pembrolizumab|
3488704|NCT03726502|Active Comparator|ureteroscopy with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
3488705|NCT03726502|Placebo Comparator|ureteroscopy alone|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
3488706|NCT03726502|Active Comparator|with safety guide-wire|ureteroscopy is done with use of safety guide-wire, this is a one procedure that we use safety guide wire (as a device) during ureteroscopy
3488707|NCT03726502|Placebo Comparator|without safety guide-wire|"ureteroscopy is done without use of safety guide-wire, this is a one procedure that we dont use safety guide wire (as a device) during ureteroscopy"
3179950|NCT00678119|Experimental|1: AGS-003+sunitinib|Single arm study AGS-003 plus sunitinib
3179951|NCT00678145|Experimental|Healthy|Healthy individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
3488708|NCT03726489|Other|Office Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a clinical setting via narrow band phototherapy clinic units.
3488709|NCT03726489|Active Comparator|Home Based Phototherapy|Patients randomized to this arm will receive narrow band phototherapy in a home setting via Daavlin 7 series 3 panel narrow band phototherapy home units.
3488710|NCT03726476|Experimental|Patient Centered pre-op education|Patient centered pre-operative education and patient centered post-operative care.
3129136|NCT03198221|Active Comparator|Group D|Participants in Group D will begin drinking the bowel preparation Clenpiq (sodium picosulfate, magnesium oxide, and citric acid) at 4:00 PM on the day before colonoscopy. Participants will be asked to drink 5 ounces of the bowel preparation and at least five (5) additional 8-ounce glasses of clear liquids by 9:00 PM, and may continue drinking clear liquids until midnight. The next day, 4 hours before the scheduled time of colonoscopy, participants will drink another 5 ounces of the bowel preparation and at least three (3) 8 ounce glasses of clear liquids within the next 2 hours. Participants may continue to drink clear liquids until 2 hours before the scheduled time of colonoscopy.
3129137|NCT03198507|Experimental|RHB-105|RHB-105 is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin, Omeprazole and Rifabutin; as well as separate Riboflavin
3488711|NCT03726476|Active Comparator|Routine Pre-op education|Participants will receive routine pre-operative education and post-op will receive a standardized number of narcotics
3488712|NCT03726463||polycystic kidney disease|patients with polycystic kidney disease who receive kidney transplantation at Asan Medical Center
3488713|NCT03726450|Experimental|Andrositol Plus|all the patients will be treated for three months with a dietary supplement containing Myo-inositol, NAC, Folic acid, selenium, vitamin E, L-Arginine and L-Carnitine
3488714|NCT03726437|Experimental|RealConsent|A 3-hour web-based program designed to teach female college freshmen strategies to reduce their risk of sexual violence victimization.
3129138|NCT03198507|Active Comparator|Active Comparator|Active comparator is an 'all-in-one' combination oral capsule consisting of combination therapy of Amoxicillin and Omeprazole; as well as separate Riboflavin
3488715|NCT03726437|Placebo Comparator|Stress and Mood Management|A 3-hour general mental health web-based program.
3488716|NCT03726424||mutation|patients carrying one or more specific pathogenic mutations
3488717|NCT03726424||control|patients not carrying the pathogenic mutation(s)
3488718|NCT03726411|Experimental|periodontitis group|in this group, prolactin in GCF will be assessed at baseline and after 3 months of receiving non-surgical periodontal treatment
3488719|NCT03726411|No Intervention|control group|in this group of systemically and periodontally healthy participants, prolactin in GCF will be assessed at baseline only
3488720|NCT03726398|Experimental|Opsumit|Opsumit 10 mg tablet by mouth once daily
3488721|NCT03726372|Experimental|deep neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given by continuous infusion at a dose that reaction to train of four (TOF) stimulation is depressed to zero
3179952|NCT00678145|Experimental|Type 1 Diabetes|T1D individuals will receive drug (naloxone, morphine sulfate, epinephrine) and placebo comparator.
3179953|NCT00678158|Experimental|1|Patients with metastatic disease to soft tissue.
3179954|NCT00678158|Experimental|2|Patients with metastatic disease to lymph nodes.
3488722|NCT03726372|Experimental|moderate neuromuscular blockade|Rocuronium, a neuromuscular blocking agent will be given at a dose by intermittent injection that reaction to train of four (TOF) stimulation is kept 1 to 2
3488723|NCT03726359|Experimental|Fractionated Stereotactic Radiation Therapy|This study is unique in that it employs a continuous reassessment methodology (CRM) to determine the Maximum Tolerated Dose. Information for the proper dose level for each subsequent patient enrolled will be determined based on DLTs from previous patients enrolled in the trial.
3488724|NCT03726346|Experimental|Toffee Full Face Mask|Participants will be placed on this arm for a total of 14+- 4 days from visit 2. Participants will be using the Toffee mask during this treatment arm.
3488725|NCT03726333|Active Comparator|Group A1 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
3488726|NCT03726333|Active Comparator|Group A2 Normal hepatic function|continued daily administration of lorlatinib in patients with normal hepatic function
3179955|NCT00678158|Experimental|3|Patients with metastatic disease to the bone.
3179956|NCT00678171|Experimental|OP-1 Putty|Patients randomized to the OP-1 Putty Spinal System arm will receive OP-1 Putty with AVS™TL PEEK Spacer System and XIA® Spinal System.
3488727|NCT03726333|Experimental|Group B mild hepatic impairment|continued daily administration of lorlatinib in patients with mild hepatic imapirment
3179957|NCT00678171|Active Comparator|Autograft|Patients randomized to the Autograft Spinal System arm will receive iliac crest autograft with AVS™TL PEEK Spacer System and XIA® Spinal System.
3179958|NCT00678197|Experimental|A|
3179959|NCT00678197|Experimental|B|
3179960|NCT00678197|No Intervention|C|
3179961|NCT00678236|Active Comparator|1|Refobacin Bone Cement R
3488728|NCT03726333|Experimental|Group C moderate hepatic impairment|continued daily administration of lorlatinib in patients with moderate hepatic impairment
3488729|NCT03726333|Experimental|Group D severe hepatic impairment|continued daily administration of lorlatinib in patients with severe hepatic impairment
3488730|NCT03726307|Experimental|DCreg: 0.5 million cells/kg+SOC|"N=3 participants will receive 0.5 (± 0.1) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
3488731|NCT03726307|Experimental|DCreg: 1.2 million cells/kg+SOC|"N=3 participants will receive 1.2 (± 0.2) million cells/kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
3488732|NCT03726307|Experimental|DCreg:2.5 to 5.0 million cells/kg+SOC|"N=8 participants will receive 25 to 5.0 million cells /kg body weight as a single infusion.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
3488733|NCT03726294|Experimental|NBM-BMX|
3488734|NCT03726281|Experimental|single-arm trial of Nivolumab|Multi-institutional, single arm phase II trial with Simon's optimal two-stage design, to evaluate the clinical benefit of Nivolumab monotherapy in patients with platinum-recurrent or platinum-refractory metastatic GCT. No randomization or blinding is involved.
3488735|NCT03726268|Active Comparator|IV methadone|Intraoperative and post-operative IV methadone
3488736|NCT03726268|Active Comparator|IV fentanyl, sufentanil, morphine or hydromorphone|Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion
3488737|NCT03726255||Stromal Vascular fraction|31 patients were treated with one injection of Stromal Vascular Fraction from adipose tissue obtained by liposuction. Procedure: curettage, closure of the internal opening (IO) and SVF injection in IO (50%) and fistula tract (50%)
3488738|NCT03726255||Autologous mesenchymal stem cells|9 patients were treated with one injection of autologous mesenchymal stem cells from adipose tissue. Procedure: curettage, closure of the internal opening (IO) and autologous cell injection in IO (50%) and fistula tract (50%)
3488739|NCT03726255||Allogenic mesenchymal stem cells|12 patients were treated with one injection of allogenic mesenchymal stem cells of healthy donors: Procedure: curettage, closure of the internal opening (IO) and allogenic cell injection in IO (50%) and fistula tract (50%)
3488740|NCT03726242|Active Comparator|Levcromakalim|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of 150 ug/ml levcromakalim after baseline time 0."
3488741|NCT03726242|Placebo Comparator|Saline|"To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.~To give 0,05 ml intradermal and 0.2 intramuscular of saline after baseline time 0."
3488742|NCT03726229||Fontan patient|Cholate assay will be administered once to Fontan patients and blood specimens will be collected to analyze cholate clearance.
3488743|NCT03726216||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in France
3488744|NCT03726203|Experimental|trocars of type MiniLap|Patients benefiting from the use of trocars of type MiniLap of Teleflex during the realization of their coelioscopy scheduled in ambulatory
3488745|NCT03726203|Active Comparator|trocars classics|Patients benefiting from the use of trocats classics during the realization of their coelioscopy scheduled(programmed) in ambulatory.
3488746|NCT03726190||OLLIF|Patients who underwent Oblique Lateral Lumbar Interbody Fusion
3488747|NCT03726177|Active Comparator|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
3488748|NCT03726177|Active Comparator|aspirin 81 mg plus placebo|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3488749|NCT03726151|No Intervention|Usual Care|
3488750|NCT03726151|Experimental|Parent Reminders|
3488751|NCT03726151|Experimental|Multicomponent clinic-system strategies|
3488752|NCT03726151|Experimental|Combined Condition|
3488753|NCT03726125|Experimental|LY3374849 - SC (Part A)|Single subcutaneous (SC) dose of LY3374849
3488754|NCT03726125|Experimental|Insulin Degludec - SC (Part A)|Single SC dose of insulin degludec
3488755|NCT03726125|Experimental|LY3374849 - SC (Part B)|Single dose of LY3374849 administered SC in up to three of three study periods
3488756|NCT03726125|Experimental|LY3374849 - IV (Part B)|Single dose of LY3374849 administered intravenously (IV) in up to one of three study periods
3488757|NCT03726125|Experimental|LY3374849 - IV (Part C)|Single IV dose of LY3374849 in one of two study periods
3488758|NCT03726125|Experimental|Insulin Degludec - IV (Part C)|Single IV dose of insulin degludec in one of two study periods
3488759|NCT03726112|Active Comparator|SpotOn Specs|Eyeglasses with Neuro-Balance Active (NBA) Spots
3488760|NCT03726112|Sham Comparator|Sham Specs|Eyeglasses with spots placed in peripheral zones previously identified as neutral
3129139|NCT03198520|Other|Polymer Removable Partial Denture|Evaluate the change in patient Oral Health-related Quality of Life while wearing the Solvay Dental 360™ polymer Removable Partial Denture (RPD)
3129140|NCT03198715|Experimental|DS-1040b 0.6 mg|Participants receive DS-1040b 0.6 mg by intravenous infusion over six hours
3129141|NCT03198715|Experimental|DS-1040b 1.2 mg|Participants receive DS-1040b 1.2 mg by intravenous infusion over six hours
3129142|NCT03198715|Experimental|DS-1040b 2.4 mg|Participants receive DS-1040b 2.4 mg by intravenous infusion over six hours
3129143|NCT03198715|Experimental|DS-1040b 4.8 mg|Participants receive DS-1040b 4.8 mg by intravenous infusion over six hours
3129144|NCT03198715|Placebo Comparator|Placebo|Participants receive saline by intravenous infusion over six hours
3488761|NCT03726099|Experimental|14d concomitant therapy|Patients will receive a 14-day concomitant therapy containing esomeprazole, amoxicillin, tetracycline and furazolidone.
3488762|NCT03726073|Experimental|Intervention group|Electrical stimulation will be given 30min before anesthesia and during surgery, auricular acupressure will be given in postoperative 3 days
3488763|NCT03726073|Sham Comparator|Non-intervention group|Usual care
3488764|NCT03726060|Other|splint therapy|"Alginate impressions will be taken and the plaster models of the dental arches will be made.~The splint will be subsequently delivered to the patient with the relative indications of use.~The splint therapy consist in the use of neuromuscoral splint every the night for 6 months."
3488765|NCT03726060|Other|physical therapy with splint therapy|"The treatment consists of a series of interventions: advice on self-treatment techniques to be performed at home and administering manual therapy techniques addressed to: temporomandibular district, cervical and cervico-thoracic junction.~Each session will be carried out individually and will last for 45 minutes. This duration will be divided as follows: 25 minutes dedicated to the temporomandibular district, 15 minutes to the cervical and cervico-thoracic junction, 5 minutes to teaching self-treatment techniques to be carried out at home and to verify the correct way of performing them.~The cycle will consist of 10 sessions distributed over 3 months."
3488766|NCT03726047|No Intervention|Control|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately after and 24 hours later (without visual feedback).
3129145|NCT03198754|Experimental|PEI Experimental Light|Ambient light fixture installed in the patient's hospital room
3129146|NCT03198754|Active Comparator|Comparison Light|Ambient light fixture installed in the patient's hospital room
3488767|NCT03726047|Experimental|Exercise|Subjects will complete learning of a new walking pattern through distorted visual feedback and retention will be tested immediately without visual feedback. This will be followed immediately by 5 minutes of high intensity exercise. Retention without visual feedback will them be tested again 24 hours later.
3488768|NCT03726034|Experimental|Life story book training|The migrant caregivers will receive training (six weekly 1.5-hour sessions) about life story approach by a part-time trained interventionist with psychology or social work background with at least three years of working experience working with older people and have basic knowledge about the life story work. After training, the migrant caregivers will be asked to produce the life story book individually at home with the older adults
3488769|NCT03726034|Active Comparator|Communication skills training|The migrant caregivers who have randomly assigned into the control group will receive communication skills training (two 1.5-hour sessions) offered by another trained interventionist with psychology or social work background with at least three years of working experience working with older people. They would not receive any additional training on life story work.
3488770|NCT03726021|Experimental|experimental arm|Treatment consists of treatment with Irinotecan 165mg/m2, Oxaliplatin 85mg/m2 on day 1, and S1 40mg orally on day 1-14, every 21 days each cycle. Treatment will be administered until untolerable toxicities or progression or subject death, or either the subject or sponsor discontinues the study.
3488771|NCT03726008|Experimental|Experimental group|The experimental group will receive the perinatal health promotion program and regular prenatal care
3488772|NCT03726008|No Intervention|Control group|The control group will receive the regular perinatal care
3488773|NCT03725995|Active Comparator|A (Midazolam)|21 children received 0.5 mg/kg intranasal medication (midazolam), with a maximum dose of 10 mg, via a spray of 0.2 ml per puff, administering the drug was alternated between the two nostrils of the child.
3488774|NCT03725995|Experimental|B (Lidocaine-Midazolam)|21 children received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg intranasal medication (midazolam),administering the drug was alternated between the two nostrils of the child, with a maximum dose of 10 mg via a spray of 0.2 ml per puff.
3488775|NCT03725995|Placebo Comparator|C (Placebo)|21 children received intranasal medication (saline 9% as placebo), 0.5 mg/kg, with a maximum dose of 10 mg via a spray of 0.2 ml per puff,administering the drug was alternated between the two nostrils of the child.
3488776|NCT03725969|Experimental|Healthy individuals (camel milk)|
3488777|NCT03725969|Experimental|Healthy individuals (cow milk)|
3488778|NCT03725956|Experimental|endoscopic sinus surgery|Single group of patients with nasal polyposis eligible for endoscopic sinus surgery
3488779|NCT03725943|Experimental|Healthy adults|Dreem
3179962|NCT00678236|Active Comparator|2|Refobacin Plus Bone Cement
3179963|NCT00678275|Other|A|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, RECEIVING ATG in conditioning regimen
3488780|NCT03725930|Active Comparator|Clonidine|This arm will receive intra nasal Clonidine as a premedication before surgery
3488781|NCT03725930|Placebo Comparator|Placebo|This arm will receive intra nasal Placebo as a premedication before surgery
3488782|NCT03725917|Experimental|Experimental Group|The intervention will be a progressive physiotherapy protocol formed by therapeutic exercise and manual therapy
3488783|NCT03725917|No Intervention|Control Group|The control group will not receive physiotherapy treatment.
3488784|NCT03725904|Experimental|IVF/FET|
3488785|NCT03725891|Active Comparator|Aspirin 162 mg|Aspirin 81mg tow tablet once a day from recruitment until 37 weeks or labor whichever comes first
3129147|NCT03198767|Experimental|Part A: LIK066 + P1: 50% CHO / P2: 25% CHO / P3: 0% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 50% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 25% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 0% carbohydrate
3129148|NCT03198767|Experimental|Part A: LIK066 + P1: 25% CHO / P2: 0% CHO / P3: 50% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 25% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 0% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 50% carbohydrate
3488786|NCT03725891|Active Comparator|Aspirin 81 mg plus placebo|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first plus placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
3179964|NCT00678275|Other|B|Hematopoeitic Stem Cell Transplantation from HLA-identical sibling, NOT RECEIVING ATG in conditioning regimen
3488787|NCT03725878|Experimental|Interventional|Standard tertiary interventions of birth defects; Additional preconception health care; Additional health care procedures during and after pregnancy.
3488788|NCT03725878|Active Comparator|Control|Standard tertiary interventions of birth defects; Additional health care procedures during and after pregnancy.
3488789|NCT03725865|Experimental|iNSC treatment group|
3488790|NCT03725839|Experimental|Arm|F&P Interface will be used by OSA participants in-home for 2 weeks.
3488791|NCT03725813|Experimental|Person-centred inpatient care|Person-centred inpatient care
3488792|NCT03725787|Experimental|CuroCell S.A.M. ® pro mattress|Mattresses of eligible participants will be replaced by a static air pressure redistribution mattress (CuroCell S.A.M. ® Pro).
3129149|NCT03198767|Experimental|Part A: LIK066 + P1: 0% CHO / P2: 50% CHO / P3: 25% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 0% carbohydrate (CHO) Period 2 (Day 9-11): Daily dose of 50 mg LIK066 + 50% carbohydrate Period 3 (Day 17-19): Daily dose of 50 mg LIK066 + 25% carbohydrate
3129150|NCT03198767|Experimental|Part A: LIK066 + P1: 8% CHO|Period 1 (Day 1-3): Daily dose of 50 mg LIK066 + 8% carbohydrate (CHO) PROTOCOL DEVIATION: subjects received 8% CHO in error and were discontinued after Period 1.
3488793|NCT03725774|Experimental|Quasi-experimental uncontrolled, before-and-after|The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action
3488794|NCT03725761|Experimental|IMMU-132 Treatment|Subjects enrolled in this study will receive IMMU-132 as treatment for Castrate-Resistant Prostate Cancer. Dose will be calculated per protocol in milligrams based on the subject's body weight at the beginning of each cycle or more frequently if weight changes >10%. Subjects will be treated on days 1 and 8 in a 21-day cycle, minimum 3 cycles.
3488795|NCT03725748|No Intervention|no irrigation group|nothing used for irrigation of cs scar
3129151|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: NS / P2: PS / P3: CC|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC)
3488796|NCT03725748|Placebo Comparator|saline irrigation group|saline used for irrigation the cs scar before closure
3488797|NCT03725748|Experimental|betadine irrigation group|betadine used for irrigation of cs scar
3488798|NCT03725735|Experimental|CBT for PG with emotion regulation|A new treatment protocol for problem gamblers, CBT for problem gambling with emotion regulation, has a focus on emotion regulation, a component that has been lacking in current published research.
3488799|NCT03725709||All patients|spinal anesthesia
3488800|NCT03725696||Observational group|Patients who are booked for RYGB gastric bypass surgery and enroll in the study will undergo semen analysis, sexual health questionnaire (IIEF survey), and a blood hormonal panel before and after surgery.
3488801|NCT03725683|Experimental|Incrementing groups|Each of the Increased caliber balloon capsules was predilated one by one, and the order of the increased balloon capsules was as follows: Balloon 2 diameter = target lesion reference vessel diameter minus 1; Balloon 3 diameter = target lesion reference vessel diameter;
3488802|NCT03725683|Experimental|matching groups|Pre-dilatation of the matched caliber balloon, whose diameter = the target lesion's diameter as a reference vessel, was applied.
3488803|NCT03725670|Experimental|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral injection with lentiviral TYF-ARSA vector carrying the functional gene
3488804|NCT03725644|Experimental|parent-training program|Parents in the treatment group received the parent-training program based on the DIR model. The parent-training program encouraged child-initiated activities according to the functional developmental levels. The treatment intensity and duration were the same for both groups including 3-week courses and 11-week home programs. The investigators in this study are two registered pediatric occupational therapists who have at least five years of early intervention experience and had studied the DIR model.
3488805|NCT03725644|Experimental|traditional program|Parents in the control group received the traditional program based on the developmental approach. The traditional program provided parent-lead activities that fit child's developmental stage.
3488806|NCT03725631|Experimental|Biopsy proven NAFLD patients|150 subjects who are diagnosed with NAFLD with biopsy from September 2016 to October 2018.
3488807|NCT03725618|Experimental|One-fifth fractional dose|One-fifth fractional dose (0.1 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
3488808|NCT03725618|Experimental|One-half fractional dose|One-half fractional dose (0.25 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
3488809|NCT03725618|Experimental|Full dose|Full dose (0.5 ml) of Yellow Fever 17DD Vaccine administered subcutaneously
3488810|NCT03725605|Experimental|LTX-315 plus TIL infusion|LTX-315 intratumoural 5mg per injection time point (number of injections per dosing days is dependent upon lesion size), TILs expansion and infusion.
3488811|NCT03725592|Active Comparator|Standard Treatment|Receives arsenic removal device and written instructions and phone calls on how to use the device (Arsenic Removal Device)
3488812|NCT03725592|Experimental|Intensive Education|Receives the Standard Treatment plus in-person visits and phone calls for follow-up (Community Participatory Arsenic Mitigation)
3488813|NCT03725579|Experimental|mepivacaine hydrochloride|2% Mepivacaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
3488814|NCT03725579|Active Comparator|articaine hydrochloride|4 % Articaine hydrochloride with 1:100,000 epinephrine anaesthetic solution. Each patient received two inferior alveolar nerve block injections of the tested anesthetic solution by using a side loading aspirating syringe and 27-gauge long needle
3488815|NCT03725566|Experimental|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
3488816|NCT03725553|Experimental|Intramyometrial Vasopressin|the experimental group received a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
3488817|NCT03725553|Placebo Comparator|Placebo|the placebo group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)immediately after delivery, as soon as the umbilical cord was clamped.
3488818|NCT03725540||I-gel group|Patients will be anesthetized using an appropriate sized I-gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
3488819|NCT03725540||BASKA Group|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
3488820|NCT03725527|Active Comparator|Rectus sheath catheter block|Patients will receive ultrasound-guided rectus sheath block with catheter insertion performed after induction of general anesthesia and before surgery.
3488821|NCT03725527|Active Comparator|Epidural Catheter block|Patients will receive thoracic epidural at the level of T7 performed before anesthesia induction.
3488822|NCT03725514|Active Comparator|conventional|Conventional blood clot technique
3488823|NCT03725514|Experimental|PRF|Platelet Rich Fibrin Technique
3129152|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: PS / P2: CC / P3: NS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS)
3129153|NCT03198767|Experimental|Part B: LIK066 + 50% CHO + P1: CC / P2: NS / P3: PS|Period 1 (Day 1-3): Daily dose of 50 mg LIK066+50% carbohydrate +1g calcium carbonate (CC) Period 2 (Day 9-11): Daily dose of 50 mg LIK066+50% carbohydrate + no supplement (NS) Period 3 (Day 17-19): Daily dose of 50 mg LIK066+50% carbohydrate + 6 g psyllium (PS)
3129154|NCT03198871|Experimental|Acetaminophen Injectable Product|Acetaminophen group: Half of subjects enrolled will be randomized to the acetaminophen group
3129155|NCT03198871|Placebo Comparator|Sodium Chloride 0.9%, Intravenous|Sodium Chloride 0.9% group: Half of subjects enrolled will be randomized to the acetaminophen group
3129156|NCT03199079||Group 1: Non-pregnant women|Non-pregnant women with normal pelvic floor
3129157|NCT03199079||Group 2: Pregnant women|Pregnant women; 22-29 weeks of pregnancy
3179965|NCT00678314|Active Comparator|Group A|
3179966|NCT00678314|Active Comparator|Group B|
3129158|NCT03199118|Experimental|CAF+SCTG+PRF|The patients suffering from class I or II gingival recession in the intervention group will receive a subepithelial connective tissue graft (SCTG) covered by platelet rich fibrin membrane (PRF) followed by a coronally advanced flap (CAF)
3488824|NCT03725501|Experimental|Ranibizumab + ALS-L1023 600mg|"ALS-L1023 600 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
3488825|NCT03725501|Experimental|Ranibizumab + ALS-L1023 1200mg|"ALS-L1023 1200 mg - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
3488826|NCT03725501|Placebo Comparator|Ranibizumab + Placebo|"Placebo - Take 2 tablets orally twice a day.~Ranibizumab (Lucentis®)~Loading Phase (3 months): Intravitreally inject 0.5 mg of Ranibizumab/0.05 mL monthly.~PRN Phase (9 months): It should only be administered to subjects who meet the re-administered criteria."
3488827|NCT03725488||Active|Evaluate stress among dental students by Questionnaire
3488828|NCT03725488||the present level of stress, comfort zone & coping with stress|Evaluate how stress was coped, the coping mechanisms used through Questionnaire
3488829|NCT03725462|Experimental|Cardioskin|Subjects performed a monitoring with Cardioskin. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Cardioskin, either by an opinion of an expert.
3488830|NCT03725462|Experimental|Neuronaute|Subjects performed a monitoring with Neuronaute. The performance is evaluated either by a comparison with a gold standard, either by a comparison with anterior version of Neuronaute, either by an opinion of an expert.
3488831|NCT03725449|Experimental|Phase I (user testing)|Participants complete telephone-based usability testing of the online program. Participants complete between 1-5 user testing sessions of the mySmartCheck program (about 45-60 minutes per session) to provide feedback on acceptability, satisfaction, comprehension, and usability.
3488832|NCT03725449|Experimental|Phase II Group I (mySmartCheck)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive access to mySmartCheck program, and continue to receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
3488833|NCT03725449|Experimental|Phase II Group II (standard of care)|Participants are asked to complete a baseline survey. After completing the baseline survey, participants receive standard of care. Participants are asked to complete another survey 13 weeks post-baseline.
3488834|NCT03725436|Experimental|Treatment (paclitaxel, ALRN-6924)|Patients receive paclitaxel IV over 1 hour and MDM2/MDMX inhibitor ALRN-6924 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3488835|NCT03725423|Experimental|experimental group|Oral administration of 250mg of apatinib daily, with or without chemotherapy
3488836|NCT03725410|Active Comparator|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
3488837|NCT03725410|Placebo Comparator|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
3488838|NCT03725397|Experimental|Outpatients with a transcervical Foley catheter|Women with a transcervical Foley catheter in place that will spend the night at home.
3488839|NCT03725397|Active Comparator|Inpatients with a transcervical Foley catheter|"Women to be admitted to the hospital overnight which has been a standard of care."
3488840|NCT03725358|Experimental|Control: no training, low subsidies|No provider training and low (status quo) subsidies received: business as usual
3488841|NCT03725358|Experimental|No training, medium-level subsidies|No provider training, but receiving medium-level PBF payments for contraceptive methods provided
3488842|NCT03725358|Experimental|No training, high-level subsidies|No provider training, but receiving high-level PBF payments for contraceptive methods provided
3488843|NCT03725358|Experimental|Training, low-level subsidies|Providers being trained on modern contraception, but receiving low-level (status quo) PBF payments for contraceptive methods provided
3488844|NCT03725358|Experimental|Training, medium-level subsidies|Providers being trained on modern contraception, but receiving medium-level (status quo) PBF payments for contraceptive methods provided
3488845|NCT03725358|Experimental|Training, high-level subsidies|Providers being trained on modern contraception, but receiving high-level (status quo) PBF payments for contraceptive methods provided
3488846|NCT03725358|Experimental|Training+App, low-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving low-level (status quo) PBF payments for contraceptive methods provided
3488847|NCT03725358|Experimental|Training+App, medium-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving medium-level (status quo) PBF payments for contraceptive methods provided
3488848|NCT03725358|Experimental|Training+App, high-level subsidies|Providers being trained on modern contraception and receiving a tablet-based decision-support tool (app), but receiving high-level (status quo) PBF payments for contraceptive methods provided
3488849|NCT03725306|Experimental|Librata|Librata Endometrial Ablation Device
3488850|NCT03725293|Active Comparator|Angiodynamics BioFlo Midline Catheter|Placement of clinically indicated Angiodynamics BioFlo midline catheter.
3488851|NCT03725293|Active Comparator|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of clinically indicated Teleflex Arrowg+ard Blue Advanced Midline Catheter
3129159|NCT03199118|Active Comparator|CAF+SCTG|Control group patients with class I or II gingival recession will receive treatment that consists of CAF+SCTG only
3129160|NCT03199872|Experimental|RV001V|RV001 Vaccine 0.1 mg/mL (RV001V). RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51.
3488852|NCT03725280||Transgender men I|Transgender men after testosterone treatment
3179967|NCT00678314|Placebo Comparator|Group C|
3488853|NCT03725280||Transgender men II|Transgender men before testosterone treatment
3488854|NCT03725280||IVF- PCOS|IVF- PCOS patients with high testosterone levels
3488855|NCT03725280||Egg donors|IVF- egg donors patients
3488856|NCT03725267|Experimental|Melatonin|Patients will receive 1 pill each day with 30 mg of Melatonin during polymyxin B treatment for a maximum of 14 days.
3488857|NCT03725267|Placebo Comparator|Placebo|Patients will receive 1 pill each day with Placebo during polymyxin B treatment for a maximum of 14 days.
3488858|NCT03725254|Active Comparator|radical surgery|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical surgery.
3488859|NCT03725254|Experimental|radical chemoradiotherapy|In this arm, patients with retroperitoneal or paraaortic lymph node recurrence will receive radical chemoradiotherapy.
3488860|NCT03725241|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
3488861|NCT03725241|Experimental|Experimental: Glutathione|Intervention: Dietary Supplement: Glutathione supplement
3488862|NCT03725228|Active Comparator|Magnesium Sulfate|Continuous intravenous infusion of 15mg/kg/h of magnesium sulfate, starting just after spinal anesthesia infusion until the end of surgery
3179968|NCT00678327|Active Comparator|Arm I|Patients receive ABVD chemotherapy comprising doxorubicin hydrochloride IV, bleomycin IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3488863|NCT03725228|Experimental|Lidocaine|Continuous intravenous infusion of 1.5mg/kg/h of lidocaine, starting just after spinal anesthesia infusion until the end of surgery
3488864|NCT03725215|Experimental|Split-Belt Treadmill Training 1:2|Split-Belt Training with a steady ratio of 1:2.
3488865|NCT03725215|Experimental|Split-Belt Treadmill Training 3:4|Split-Belt Training with a steady ratio of 3:4.
3488866|NCT03725215|Experimental|Split-Belt Treadmill Training Changing|Split-Belt Training with changing ratios between 3:4 to 1:2.
3488867|NCT03725215|Active Comparator|Split-Belt Treadmill Training Tied-Belt|Split-Belt Training with tied belts.
3488868|NCT03725189|Experimental|PPG Group|Testing of PPG device in healthy adult population doing cardiovascular exercise
3488869|NCT03725163|Experimental|Treatment|This arm will begin treatment immediately after completing the initial intake assessment.
3488870|NCT03725163|Other|Waitlist Control|Participants assigned to the waitlist control condition will begin a 12-week waiting period after completing the initial intake assessment before starting treatment.
3488871|NCT03725137||Group A (young stroke)|Young stroke patients (≤ 55); Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), cognitive tests; structural MRI
3488872|NCT03725124||Patients|Women with inflammatory bowel disease (IBD.
3488873|NCT03725124||Partners|Partners of women with IBD.
3488874|NCT03725124||Healthcare Professionals|Healthcare professionals working with women with IBD.
3488875|NCT03725111|Experimental|arterio venous leg ulcers|
3488876|NCT03725072|Experimental|Evobrutinib|
3488877|NCT03725046|No Intervention|Usual information transmission after ED admission|The emergency department (ED) sends to the referring doctor a letter to inform him about the reason of consultations in the emergency department (mail currently realized as part of the care process).
3488878|NCT03725046|Experimental|Optimized information transmission after ED admission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
3488879|NCT03725020|Experimental|Fluoride varnish|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply the test varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The NFV test varnish has mint flavour and the active ingredient is ammonium fluoride dissolved in ethanol, water and an acrylate polymer.
3488880|NCT03725020|Placebo Comparator|Varnish without Fluoride|During the course of the orthodontic treatment, the patients are regularly checked every 6th week. At the end of each such occasion, the clinical staff will apply either the placebo varnish with a small brush in a thin layer around the base of the braces on the maxillary teeth. The varnish is let to dry and the subjects are instructed not to eat or drink within 60 minutes after the application. The placebo varnish has an identical composition as the test varnish except for the ammonium fluoride. Thus, taste, colour and handling properties are the same.
3488881|NCT03724994||Study cohort|All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö and Lund
3488882|NCT03724955|Experimental|Treatment Group|The treatment group will receive Estradiol 2 mg oral daily for 6 months. Medication will be mailed to patient. All study drugs will be dispensed by the Investigational Drug Pharmacy.
3488883|NCT03724955|Placebo Comparator|Placebo Group|The placebo group will receive placebo oral daily for 6 months. Medication will be mailed to patient. Placebo will be dispensed by the Investigational Drug Pharmacy.
3488884|NCT03724942|Experimental|Brexpiprazole|
3488885|NCT03724929|Experimental|Ulcerative Colitis patients|"To determine if the best cut-off points of vedolizumab (VDZ) trough levels measured at W6 capable to identify UC patients who will achieve a clinical response at week 10 with VDZ and also the best cut-off points of VDZ trough levels measured at W14 capable to identify UC patients who will achieve a clinical remission to maintenance therapy with VDZ :~Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.~Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52, to evaluate treatment efficacy.~In cases of loss of response, rectosigmoidoscopy will be performed before and four weeks after optimization."
3488886|NCT03724903|Experimental|Ductal lavage|Ductal lavage and breast massage for two weeks.
3488887|NCT03724903|Active Comparator|Corticosteroids therapy|Oral corticosteroids therapy for 6 months.
3488888|NCT03724864|Experimental|Stevia snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
3488889|NCT03724864|Active Comparator|Maltitol snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
3488890|NCT03724864|Placebo Comparator|Sugared snacks|Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks.
3488891|NCT03724851|Experimental|Dose Escalation of TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) and Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
3488892|NCT03724838|Active Comparator|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of Sildenafil Citrate 40mg orally every 8 hours
3488893|NCT03724838|Active Comparator|Esomeprazole alone plus placebo to Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
3488894|NCT03724838|Placebo Comparator|placebo to Esomeprazole plus placebo to Sildenafil Citrate|Patients will take placebo identical in shape and consistency with esomeprazole single dose of 40 mg orally once a day plus three doses of placebo identical in shape and consistency withSildenafil Citrate 40mg orally every 8 hours
3488895|NCT03724825||obese men|Adult obese men (BMI ≥ 30 kg/m2)
3488896|NCT03724825||normal men|normal weight men (18.5 ≤ BMI < 25 kg/m2 )
3488897|NCT03724799|Experimental|single arm|Intravenous low level laser therapy
3488898|NCT03724786|Experimental|Calculated collection|"Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the 6-hour collection will be multiplied by four, and the result will serve as the calculated collection, for pregnancy management. The additional 18 hour collection will serve for: 1. Patient blinding. 2. Calculation of the total 24-hour protein collection for reference."
3488899|NCT03724786|No Intervention|Control collection|Patients in this arm will collect urine for protein for 6 hours, and then an additional 18 hours. The result of the total 24-hour collection will serve for pregnancy management. The initial 6-hour collection will serve for patient blinding.
3488900|NCT03724773|Active Comparator|Long-Arm Cast|Reduction and long-arm cast application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
3488901|NCT03724773|Active Comparator|Sugar-Tong Splint|Reduction and sugar-tong splint application will be performed by PGY-1 and up residents with adequate training and/or supervision in the required techniques.
3488902|NCT03724760|Experimental|Feedback|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve feedback regrding the number of steps taken by them at two time points.
3488903|NCT03724760|No Intervention|Control|Patients in this arm will wear a pedometer for two days following cesarean delivery. During this period, they will recieve no feedback regrding the number of steps taken by them.
3488904|NCT03724734|Experimental|Adaptive DBS|We will use our custom-built externalized research system (ERS) to deliver adaptive stimulation to the subthalamic nuclei.
3488905|NCT03724734|Active Comparator|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous stimulation to the subthalamic nuclei.
3488906|NCT03724721|Experimental|pneumothorax drainage|Pneumothorax drainage with vacuum bottle plus intercostal catheter
3488907|NCT03724708|Experimental|Hang up technique|"where the enrolled patients will have the IUD applied in the middle of the uterine cavity and then attached to the fundus of the uterus by an absorbable suture Hang up technique"
3488908|NCT03724708|Active Comparator|Postpartum insertion|will include patients where IUD will be inserted after 6 weeks post-partum.
3488909|NCT03724708|Active Comparator|Control|will serve as our control group where the enrolled patients will have the IUD just applied into the middle of the uterine cavity at the level of the fundus without attachment
3488910|NCT03724695|No Intervention|Control|Usual Care
3488911|NCT03724695|Experimental|AHCAH Nudge|"The investigators have developed methods for sending nudges to clinicians via secure text messages to primary teams to alert them that their patient was identified as high-risk for 6-month mortality and that an AHCAH liaison would visit their patient to discuss the AHCAH program and to facilitate enrollment if the patient was amenable. The investigators propose that these secure text messages would be sent to the teams of patients randomized to the intervention by the AHCAH liaison within 72 hours of eligibility identification (to allow for the liaison not being available over the weekend). The investigator team will track all aspects of messaging and timing. Clinicians can choose to opt out a patient from the liaison visit and AHCAH enrollment within a two-hour timeframe."
3488912|NCT03724682|Experimental|Single arm|Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,
3488913|NCT03724669|Placebo Comparator|waiting list|
3488914|NCT03724669|Experimental|Benzodiazepines and Z-drugs knowledge|
3488915|NCT03724656|Experimental|acupuncture treatment|"Patients in the TAES treatment group received Transcutaneous Acupoint Electrical Stimulation(TAES) 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
3488916|NCT03724656|Sham Comparator|Sham acupuncture treatment|"The control group was treated with non-acupoint shallow acupuncture method. The needle was inserted 5 cm beside the acupoint and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
3129161|NCT03199911|Experimental|Topical Antibiotic Ointment|Intervention: 200 patients in the antibiotic arm will receive either erythromycin or bacitracin, based on allergies, surgeon preference, and antibiotic availability. If neither antibiotic is obtainable by the patient, bacitracin polymyxin will be prescribed instead. Antibiotic ointment is to be applied to the surgical incision(s) 4 times daily for 1 week.
3488917|NCT03724643|Experimental|Protocolized Wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
3488918|NCT03724643|No Intervention|Usual Care|In the UC group, the SBT type and extubation decision was determined by the attending intensivist on service based upon neurologic status, airway competence (gag, cough, suction requirements), and negative inspiratory force (NIF) or RSBI measurements.
3129162|NCT03199911|Placebo Comparator|Topical Non-Antibiotic Ointment|Intervention: 200 patients in the placebo group will receive mineral oil/petrolatum-based artificial tear ointment to be applied to the surgical incision(s) 4 times daily for 1 week.
3129163|NCT03199963|Experimental|BHR-700 (0.2% 4-OHT gel)|The gel formulation contains 2 mg/mL 4-OH tamoxifen (0.2%) in a clear, colorless, absorptive hydro-alcoholic gel base formulated to provide continuous release of 4-OH tamoxifen. A total of 8 mg/day (4 mg/breast) of 4-OH tamoxifen will be administered daily for 52 weeks.
3129164|NCT03199963|Placebo Comparator|Matching Placebo Gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
3129165|NCT03200366|Active Comparator|Tailored DVD|Tailored digital video disc (DVD)
3129166|NCT03200366|Active Comparator|Tailored DVD + Patient Navigation|Tailored digital video disc (DVD) plus Patient Navigation by a population health nurse in the healthcare system
3488919|NCT03724617|Experimental|stem cell therapy|
3488920|NCT03724604||high NAR|Neuron-Specific Enolase to Albumin Ratio is higher than 3.2×10-7
3488921|NCT03724604||low NAR|Neuron-Specific Enolase to Albumin Ratio is lower than 3.2×10-7
3488922|NCT03724591|Experimental|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
3488923|NCT03724591|Active Comparator|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
3488924|NCT03724578|Sham Comparator|standard preventive measures|the participants will only follow standard preventive measure twice a day brushing with fluoride toothpaste and flossing once a day
3488925|NCT03724578|Active Comparator|antimicrobial and fluoride mouth wash|participants will use mouth wash contains both chlorhexidine and fluoride in addition to standard preventive measures
3488926|NCT03724578|Experimental|grape seeds extract mouth wash|the intervention is grape seeds extract mouth wash
3488927|NCT03724565||Endoscopic procedural area|air quality check of endoscopic procedural room
3129167|NCT03200366|No Intervention|Usual Care|Care normally provided by a nurse in the endoscopy department of the healthcare system
3129168|NCT03200535|No Intervention|Usual care|Usual care
3129169|NCT03200535|Active Comparator|"Electronic health record gaps"|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
3488928|NCT03724565||Recovery area for patients|air quality check of recovery area for patients in endoscopic unit
3488929|NCT03724565||Cleansing area for equipments|air quality check of cleansing area for equipments in endoscopic unit
3488930|NCT03724552|Experimental|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
3488931|NCT03724539|Experimental|STRIPA intervention|"GPs in the intervention group will perform a STRIPA analysis for each of their 8-10 patients after the recruitment of the patient into the OPTICA trial, so that the results can be discussed in the next consultation and a shared decision-making can be performed.~STRIPA is a structured method to perform pharmacotherapy optimization. The STRIPA intervention in the OPTICA trial consists of 4 steps:~recording medication and diagnoses in STRIPA (upload from data from the 'Family medicine ICPC Research using Electronic medical records' (FIRE) database)~structured drug review through the GP based on the STRIPA with the integrated STOPP/START criteria~shared decision-making between GP and patient with possible adaptation of the recommendation~follow-up through study team"
3488932|NCT03724539|Sham Comparator|Sham intervention|Patients in the control group will receive a sham intervention, which consists of a usual medication review by their GP as well as a shared decision making of the latter.
3488933|NCT03724526|Experimental|Intervention-Text messaging|Participates will receive regular 6 text messages per week for 12 months. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week. Each message will be sent on 6 of 7 randomly selected weekdays and arrived at random times the day during working hours.
3488934|NCT03724526|No Intervention|Control|Participates in control group will not receive text messages.
3129170|NCT03200535|Active Comparator|Bulk outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent
3488935|NCT03724487|Experimental|Coachman|The first study condition, A COmmunity and Tech-Based ApproaCh for Hypertension Self-MANagement (COACHMAN) will be exposed to three Technology-based Interventions (TBI) accessible via smartphone and counseling from a local community nurse organization for hypertension self-management support.
3488936|NCT03724487|Experimental|Enhanced Usual Care|The second study condition, Enhanced Usual Care (EUC) will be exposed to routine and standard hypertension education materials and one session on self-monitoring blood pressure.
3488937|NCT03724474|Experimental|Be SMART Condition|"Subjects randomly assigned to the Be SMART condition (n=30) will first meet with a credentialed health coach to help create personally relevant weekly, short-term (6-weeks) and long-term (12-weeks) PA and sleep goals, and an initial action and coping plan. At 6- weeks (study mid-point), Be SMART subjects will complete a short telephonic booster session with the health coach. Throughout the 12-week intervention, our agent-based feedback system will communicate weekly messages via short message service (SMS) based on their weekly goal achievement, informed by the continuous collection of their Fitbit data. In addition, subjects in the Be SMART condition will also take their morning blood pressure using a blue-tooth enabled device that wirelessly sends this data to the Be SMART server."
3488938|NCT03724474|Active Comparator|Fitbit Only Condition|Subjects who are randomly assigned to the active control condition (n=30) will receive a Fitbit device and wireless blood pressure monitor (same as Be SMART condition). However, subjects in the Fitbit Only condition will not meet with a health coach for establishing SMART goals and creating an action/coping plan, nor will Fitbit Only subjects receive any feedback messages or prompts from the Be SMART server, although data from their Fitbit devices will be continuously collected throughout the q12 week intervention.
3488939|NCT03724461|Active Comparator|High intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg is established as control.
3488940|NCT03724461|Active Comparator|Light intensity vs Control (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes light-moderate intensity resistance training (12 weeks) and the other leg is established as control.
3488941|NCT03724461|Experimental|High vs Light intensity (12 weeks)|8 weeks of baseline period plus an exercise program where one leg undergoes High Intensity resistance training (12 weeks) and the other leg undergoes light-moderate intensity resistance training.
3488942|NCT03724461|Experimental|High intensity (Acute)|Analysis of the effects of one High Intensity resistance training session, with a crossover design.
3488943|NCT03724461|Experimental|Light intensity (Acute)|Analysis of the effects of one Light-moderate Intensity resistance training session, with a crossover design.
3488944|NCT03724448|Experimental|ALEOZEN group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
3488945|NCT03724448|Placebo Comparator|placebo group|Clinical information will be collected on a standardized card specifying general data on the patient, his antecedents, his telephone number, the circumstances of the traumatic event and the score of PDI, PDEQ and L-CROCQ, score PCL-5 to 10 days, 1 month and 6 months.
3488946|NCT03724422|No Intervention|Control|This group will receive the standard of care treatment for their distal humerus fracture only.
3488947|NCT03724422|Experimental|Intervention|This group will receive the prophylactic radiation therapy in addition to the standard of care treatment of their distal humerus fracture.
3488948|NCT03724409|Experimental|Cohort 1|Subject will be administered 2.96 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488949|NCT03724409|Experimental|Cohort 2|Subject will be administered 3.33 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488950|NCT03724409|Experimental|Cohort 3|Subject will be administered 3.7 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488951|NCT03724409|Experimental|Cohort 4|Subject will be administered 4.17 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488952|NCT03724409|Experimental|Cohort 5|Subject will be administered 4.44 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488953|NCT03724409|Experimental|Cohort 6|Subject will be administered 5.18 gigabecquerels of [90]Y-DOTATOC intra-aterially to the liver
3488954|NCT03724383|No Intervention|Control|Participants in the control arm will receive standard care.
3488955|NCT03724383|Experimental|Intervention|Participants in the intervention group will receive risk factor management consultations and take part in 1-hour biweekly diet classes and stress management classes for the first 3 months. This will be followed by 3 months of 1-hour biweekly high intensity interval training exercise classes. At the 6-month time point, participants will be prescribed a home based exercise program and will have the option of participating in weekly group walking sessions. During the final 6 months, participants will use a step/activity tracker to track their steps and heart rate.
3488956|NCT03724370|Experimental|TES+ VHA-SRM|Telehealth monitoring system (TES) will be added to the VA suicide risk management system (VHA-SRM)
3488957|NCT03724370|Active Comparator|VHA-SRM|VHA-SRM will be active comparator
3488958|NCT03724357|Experimental|Vaccination with Oral Cholera Vaccine (Vaxchora)|Volunteers receive immunization with Vaxchora cholera vaccine. Blood draws are performed at subsequent visits.
3488959|NCT03724344||Dimensions with Behavioral and psychological symptoms|
3488960|NCT03724331|Experimental|Light Physical Activity 1|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital.
3488961|NCT03724331|Experimental|Light Physical Activity 2|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light (mild) physical activity program that begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital.
3488962|NCT03724331|Active Comparator|Support Education Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will participate in a supportive cancer-related education activity each week for 6-weeks after returning home from the hospital.
3488963|NCT03724318|Active Comparator|Closure|Patients randomized to the active Group will undergo closure of the left atrium appendage during Heart surgery by means of commercial clips
3488964|NCT03724318|No Intervention|Control|The left atrium appendage will remain open in patients randomized to the control group
3488965|NCT03724305|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
3488966|NCT03724305|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
3488967|NCT03724292|Placebo Comparator|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
3488968|NCT03724292|Experimental|VTP-43742 Dose 1|VTP-43742 administered as oral capsule(s) once daily
3488969|NCT03724292|Experimental|VTP-43742 Dose 2|VTP-43742 administered as oral capsule(s) once daily
3488970|NCT03724292|Experimental|VTP-43742 Dose 3|VTP-43742 administered as oral capsule(s) once daily
3488971|NCT03724292|Experimental|VTP-43742 Dose 4|VTP-43742 administered as oral capsule(s) once daily
3488972|NCT03724292|Experimental|VTP-43742 Dose 5|VTP-43742 administered as oral capsule(s) once daily
3488973|NCT03724279|Experimental|ByCross Atherectomy and Thrombectomy|Percutaneous intervention including ByCross atherectomy and Thrombectomy potentially followed with PTA and/or stent placement
3129171|NCT03200535|Active Comparator|Personalized outreach|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient; in addition a bulk letter or email will be sent and patients will receive a personalized call by a registered dietitian
3129172|NCT03200860|Active Comparator|Empagliflozin|Empagliflozin 10 mg daily, oral, 30 days
3488974|NCT03724266|Experimental|chitosan|chitosan as intracanal medication 0.2% in form of gel
3488975|NCT03724266|Active Comparator|calcium hydroxide|intracanal medication
3488976|NCT03724240|Placebo Comparator|Placebo solution|Placebo Comparator: Placebo The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 containing sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml. The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks. The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
3488977|NCT03724240|Experimental|gpASIT+™ (Grass Pollen-ASIT+™)|Experimental: gpASIT+™ The product will be supplied as ready-to-use vials containing 1.5 mL of aqueous buffered solutions at pH 7.4 with a grass pollen peptide concentration of 100 µg/mL. Excipients are sodium phosphate, NaCl, mannitol and trehalose. the dosage is100 µg/ml.The treatment schedule will consist in a subcutaneous injection over four visits during 3 consecutive weeks.The patient will receive two injections (1 per arm)with an interval of 30 minutes between both.
3488978|NCT03724214|No Intervention|Pre-intervention|Patients presenting with simple gastroschisis during the pre-intervention phase will receive the current care provided by the study sites (no intervention).
3488979|NCT03724214|Active Comparator|Post-intervention|Patients presenting with simple gastroschisis during the post-implementation phase will receive the interventional care bundle if consent for participation is provided.
3129173|NCT03200860|Placebo Comparator|Placebo|Matching Placebo 10 mg daily, oral, 30 days
3129174|NCT03200912|Active Comparator|Picato|Picato® (ingenol mebutate) gel, 0.15% (Leo Pharma Inc.) [Reference Listed Drug (RLD)]
3488980|NCT03724175|Experimental|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks to treat pouchitis in ulcerative colitis patients with antibiotic refractory or antibiotic dependent pouchitis
3488981|NCT03724136|Active Comparator|Arm 1|Intravenous Bone Marrow Stem Cell (BMSC) Fraction
3488982|NCT03724136|Active Comparator|Arm 2|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Near Infrared Light exposure .
3488983|NCT03724136|Active Comparator|Arm 3|Intravenous Bone Marrow Stem Cell (BMSC) Fraction combined with Intranasal topical Bone Marrow Stem Cell (BMSC) Fraction.
3129175|NCT03200912|Experimental|Generic Ingenol Mebutate|Generic ingenol mebutate gel, 0.15% [Test]
3488984|NCT03724110||Pre-Telestroke|Retrospective collection of defined metrics for all TIA patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
3488985|NCT03724110||Post-Telestroke|Prospective collection of defined metrics for all TIA patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
3488986|NCT03724097||Group 1|Patients receiving target drugs with the score value above 0,1 as monotherapy or in combination
3488987|NCT03724097||Group 2|Patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination
3488988|NCT03724097||Group 3|Patients receiving palliative care
3488989|NCT03724084|Experimental|Treatment (pinometostat)|"Patients receive pinometostat IV continuously on days 1-35, daunorubicin hydrochloride IV over 10-30 minutes on days 8-10 and cytarabine IV continuously on days 8-14 in the absence of disease progression or unacceptable toxicity.~Patients who do not achieve CR/CRi after treatment receive pinometostat IV continuously on days 1-28, daunorubicin hydrochloride IV over 10-30 minutes on days 1 and 2 and cytarabine IV continuously on days 1-5 in the absence of disease progression or unacceptable toxicity."
3488990|NCT03724071|Experimental|Phase 1, Arm A - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with repeated administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
3488991|NCT03724071|Experimental|Phase 1, Arm B - Dose escalation and safety of TG6002 and flucytosine combination|Dose escalation with closer administrations of TG6002 in combination with flucytosine in patients with advanced gastro-intestinal (GI) tumors.
3488992|NCT03724071|Experimental|Phase IIa - Efficacy of TG6002 and flucytosine combination|Repeated administrations of TG6002 in combination with flucytosine in patients with colorectal cancer and liver metastases
3488993|NCT03724058|Experimental|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty using Trident II Clusterhole HA Acetabular Shells
3488994|NCT03724058|Active Comparator|Trident® Hemispherical Acetabular Shell|Hip arthroplasty using Trident Hemispherical Acetabular Shell
3488995|NCT03724045|Experimental|Back Side of the Moon|"Patients will be screened and enrolled at the ICU. Extraordinary measurements concerning nutritional status will be performed, to investigate whether patients at the ICU actually meet their nutritional needs. The same patients as above will be followed up, once discharge from ICU to a low-care ward has taken place. From there, they will be followed up until discharge from the hospital. The procedures are the same as in the ICU. The results obtained at the low-care ward will be compared to those from the ICU. 6 months after hospital discharge, morbidity and mortality will be assessed.~A substudy of included COVID-19 positive patients will be analysed and compared to non COVID-19 patients."
3488996|NCT03724019||Group Q|20 milliliter of ketamine (0.5mg / kg ideal body weight) at induction of anesthesia.
3488997|NCT03724019||Group S|20 milliliter of sodium chloride at induction of anesthesia.
3488998|NCT03724006|Experimental|INTERVENTION group (I)|Group I will be composed by parents of children with the diagnosis of CHD who will receive a psychoeducational intervention plus usual routines of the Service.
3488999|NCT03724006|No Intervention|CONTROL group (C)|Group C will be composed by parents of children with the diagnosis of CHD who will receive the usual routines of the Service. After completing the data collection, the possibility of receiving the psychoeducational intervention under study will be offered to this group.
3489000|NCT03723993|Placebo Comparator|Control group|control group will have non inflated cuff around the arm.
3489001|NCT03723993|Active Comparator|RIPC group|Inflated cuff will be done systematically and regularly
3489002|NCT03723967|Experimental|Durvalumab with Carboplatin/Paclitaxel|Combination of Durvalumab with Carboplatin/Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
3489003|NCT03723941|Experimental|A - adjuvant therapy|adjuvant therapy with four cycles of cisplatin plus etoposide +/- mitotane according to investigator's preference versus
3489004|NCT03723941|Other|B - observation or mitotane alone|observation or mitotane alone according to the investigator's preference
3489005|NCT03723902|Experimental|Strength training + protein supplement|Heavy-load strength training, Protein supplementation
3489006|NCT03723902|No Intervention|Control|No intervention
3489007|NCT03723876|Active Comparator|Intervention group|Twelve occasions of Basic body awareness therapy, administered once a week, alongside treatment as usual (such as structured everyday support, medicine, contact with social worker).
3489008|NCT03723876|No Intervention|Control group|No extra intervention except treatment as usual.
3489009|NCT03723863|Experimental|Supportive care (Occupational therapy)|Patients receive in-person occupational therapist-led work consultation
3489010|NCT03723837|Active Comparator|Study Arm A|Children {Age > 24 months and who received a single dose Inactivated Polio Vaccine (IPV) at the time of routine immunization} in this arm will receive an IPV (0.5ml) intramuscularly at the time of enrolment in the trial
3489011|NCT03723837|Active Comparator|Study arm B|Children {Age 7-12 months and have not received any IPV till date of enrolment} in this arm will receive an Inactivated Polio Vaccine, IPV (0.5 ml) intramuscularly at the time of enrolment in the trial and a repeat dose of IPV (0.5 ml) after 1 month
3489012|NCT03723824|Experimental|Zepatier therapy|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
3489013|NCT03723811|Experimental|1|SJP002 BID
3489014|NCT03723811|Experimental|2|SJP002 QID
3489015|NCT03723811|Placebo Comparator|Placebo 1|SJP002 Placebo 1
3489016|NCT03723811|Placebo Comparator|Placebo 2|SJP002 Placebo 2
3489017|NCT03723798|Experimental|1|SA001 Low dose
3489018|NCT03723798|Experimental|2|SA001 Mid dose
3489019|NCT03723798|Experimental|3|SA001 High dose
3489020|NCT03723798|Placebo Comparator|Placebo|SA001 Placebo
3489021|NCT03723785|Experimental|Participants with normal renal function|Participants with normal renal function (glomerular filtration rate [GFR] of greater than or equal to 90 ml/min) will receive single dose of insulin 287 on Day 1.
3489022|NCT03723785|Experimental|Participants with mildly decreased renal function|Participants with mildly decreased renal function (GFR of 60 to less than 90 ml/min) will receive single dose of insulin 287 on Day 1.
3489023|NCT03723785|Experimental|Participants with moderately decreased renal function|Participants with moderately decreased renal function (GFR of 30 to less than 60 ml/min) will receive single dose of insulin 287 on Day 1.
3129176|NCT03200912|Placebo Comparator|Vehicle Foam|Vehicle gel of the test product
3489024|NCT03723785|Experimental|Participants with severely decreased renal function|Participants with severely decreased renal function (GFR of less than 30 not requiring dialysis) will receive single dose of insulin 287 on Day 1.
3489025|NCT03723785|Experimental|Participants with end-stage renal disease|Participants with end-stage renal disease requiring haemodialysis will receive single dose of insulin 287 on Day 1.
3489026|NCT03723759|Experimental|Group A|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E.~The dosing visits will be separated by wash-out periods (2-21 days)."
3489027|NCT03723759|Experimental|Group B|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL.~The dosing visits will be separated by wash-out periods (2-21 days)."
3489028|NCT03723759|Experimental|Group C|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D.~The dosing visits will be separated by wash-out periods (2-21 days)."
3489029|NCT03723759|Experimental|Group D|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B.~The dosing visits will be separated by wash-out periods (2-21 days)."
3179969|NCT00678327|Active Comparator|Arm II|Patients receive AVD chemotherapy comprising doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3489030|NCT03723759|Experimental|Group E|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C.~The dosing visits will be separated by wash-out periods (2-21 days)."
3489031|NCT03723759|Experimental|Group F|"Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence:~formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A.~The dosing visits will be separated by wash-out periods (2-21 days)."
3489032|NCT03723746|Experimental|Cohort 1: Dose 1 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (single day [SD] Dose 1) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
3489033|NCT03723746|Experimental|Cohort 2: Dose 2 or Placebo (Part 1 - SD)|Participants will receive a single oral dose (Dose 2) of either JNJ-67670187 or placebo capsules after an overnight fast on Day 1 of Part 1.
3489034|NCT03723746|Experimental|Cohort 3: Dose 1 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Multiple Day [MD] Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days without antibiotic pretreatment after an overnight fast in Part 2.
3489035|NCT03723746|Experimental|Cohort 4:Antibiotic + Dose 1 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 1) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
3489036|NCT03723746|Experimental|Cohort 5: Dose 2 or Placebo (Part 2 - MD)|Participants will receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily without antibiotic pretreatment for 14 days after an overnight fast in Part 2.
3489037|NCT03723746|Experimental|Cohort 6:Antibiotic + Dose 2 or Placebo (Part 2 - MD)|Participants will receive pretreatment with an oral antibiotic, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2.
3489038|NCT03723746|Experimental|Cohort 7 (Optional): Laxative + Dose 2 or Placebo (Part 3)|Participants may receive pretreatment with an oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 7 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
3489039|NCT03723746|Experimental|Cohort 8 (Optional):Antibiotic+Laxative+Dose 2/Placebo(Part 3)|Participants may receive pretreatment with an oral antibiotic and oral laxative, followed by an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. Cohort 8 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
3489040|NCT03723746|Experimental|Cohort 9 (Optional): Dose 2 or Placebo (Part 3) + Biopsy|Participants may receive an oral dose (Dose 2) of either JNJ-67670187 or placebo capsules once daily for 14 days after an overnight fast in Part 2. After final dosing collection of sigmoid biopsies will be performed. Cohort 9 (Part 3) will only be conducted if the strains are not detected in microbial analysis of Parts 1 and 2.
3489041|NCT03723720||Patients after colonoscopy over 50 years|All colonoscopies in patients over 50 years of age (screening, surveillance, diagnostic) excluding therapeutic, IBD, management of complications and sigmoidoscopies
3489042|NCT03723707|Experimental|Intervention (INT)|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
3489043|NCT03723707|Placebo Comparator|Control (CON)|During training the CON providers will be encouraged to do cognitive screening as well as follow the guidelines in general.
3489044|NCT03723694|Active Comparator|650 mg of Cocoapro flavanols|Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.
3489045|NCT03723694|Placebo Comparator|0mg Cocoapro flavanols|Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.
3489046|NCT03723655|Experimental|Group 1|Active Treatment for participants with base target trough concentration
3489047|NCT03723655|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
3489048|NCT03723655|Experimental|Group 3|Active Treatment for participants dose titrated to clinical response
3489049|NCT03723642|Active Comparator|OAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
3489050|NCT03723642|Active Comparator|LAE group|All patients will undergo measurements of oxydative stress (initial serum malondialdehyde level and final serum malondialdehyde level), White blood cell count (initial differential white blood cell count and final differential white blood cell count), c-reactive protein measurements (initial c-reactive protein serum level and final c-reactive protein serum level) as well as volatile organic compound (VOC) sampling (initial VOC, VOC 5min, VOC 15min, VOC 30min, VOC 45min and final VOC).
3489051|NCT03723629||pulmonary GGO|Patients with pulmonary GGO.
3489052|NCT03723616|Active Comparator|Hookah Tobacco Smokers|Young adults, ages 18-34, who smoke hookah tobacco
3489053|NCT03723616|Active Comparator|Open to Smoking Hookah Tobacco|Young adults, ages 18-34, who do not smoke hookah tobacco but are open to trying
3489054|NCT03723577|Experimental|Fibrillar Collagen Powder Dressing|
3489055|NCT03723564|Experimental|Amnioinfusion|Lactated Ringers Solution for Injection --- Serial ultrasound-guided amnioinfusion procedures will be performed on fetuses having severe LUTO or bilateral renal agenesis that are diagnosed between 18 0/7-25 6/7 weeks.
3489056|NCT03723525|Experimental|Package of HIV care|Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI), Rapid antiretroviral therapy (ART) initiation and Enhanced adherence support.
3489057|NCT03723525|Experimental|Standard HIV care|Screening and management of common OIs, basic health assessment (CD4, viral load and other tests), ARV drugs and follow up.
3489058|NCT03723499||endoscopic treatment|Patient with endoscopic treatment will be included. Some medical data collection by medical record will be collected.
3489059|NCT03723460||Households|Household here means a family unit comprising of at least both parents (mother and father) and a child under 5 years of age or an adolescent child.
3489060|NCT03723434|Active Comparator|Healthy Participants|Healthy participants without disorders or medications influencing brain function will be scanned with MRI and undergo single-pulse TMS and PAS during several visits, each with a different asynchrony, while EEG and MEPs are recorded.
3489061|NCT03723434|Experimental|Patients|Participants with stroke, traumatic brain injury (TBI), or multiple sclerosis (MS) will be scanned with MRI and undergo single-pulse TMS and paired associative stimulation during several visits while EEG is recorded.
3489062|NCT03723421|Experimental|Rapid Injection Group Without Aspiration|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position by rapid injection technique without aspiration.
3489063|NCT03723421|Experimental|Control|The tetanus vaccine was applied into the deltoid muscle of the left arm in the sitting position with the standard injection technique.
3489064|NCT03723408|Other|Single Arm post-approval study|Single Arm post-approval study.
3489065|NCT03723395|Experimental|Part A|Tucatinib plus Itraconazole
3489066|NCT03723395|Experimental|Part B|Tucatinib plus Rifampin
3489067|NCT03723395|Experimental|Part C|Tucatinib plus Gemfibrozil
3489068|NCT03723395|Experimental|Part D|Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam
3489069|NCT03723395|Experimental|Part E|Tucatinib plus Digoxin
3489070|NCT03723382||Patients with stroke with structured management|Patients with the Acute Brain injury, Transient Ischemic Attack, Acute and Chronic Ischemic and Hemorrhagic Stroke, Subarachnoid hemorrhage, and cerebral venous thrombosis from pre-hospitalization, hospitalization (in-patient) and post hospitalization (clinic) data
3489071|NCT03723382||Patients with stroke without structured management|Control subject who have stroke and did not managed according to the SECRET 6 level metrics
3489072|NCT03723356||MS Patients|Definite diagnosis of RRMS
3489073|NCT03723356||Healthy Controls|gender aged match healthy
3489074|NCT03723343||Experimental: GP+IMRT|Test group: GP-induced chemotherapy (Gemcitabine 1000 mg/m2 d1, 8+Cisplatin 80 mg/m2 d1, once every 3 weeks, 4/6 course) + IMRT radiotherapy alone
3489075|NCT03723343||Active Comparator: TPF+IMRT|Control group: TPF-induced chemotherapy (Docetaxel: 75 mg/m2d1, Cisplatin 75 mg/m2, d1~d5, 5-fluorouracil 750 mg/m2/dd1~d5, 4/6 course) + IMRT radiotherapy alone
3489076|NCT03723330|Experimental|Plant sterol with a healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided with specific instructions to consume plant sterols-enriched food (contains 2 g plant sterols).
3489077|NCT03723330|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
3489078|NCT03723317||Training liver transplantation|Patients consecutively transplanted in four European collaborative LT Centres (Ancona, Brussels, Rome Sapienza, and Padua) (N=1,262)
3489079|NCT03723317||Validation liver transplantation|Patients consecutively transplanted in the Karolinska Institute (N=520)
3489080|NCT03723304||Direct liver transplant|All the cases listed for liver transplantation and then transplanted/dropped-out without undergoing any neo-adjuvant loco-regional treatment
3489081|NCT03723304||Bridging followed by transplant|All the cases listed for liver transplantation and then transplanted/dropped-out after undergoing at least one neo-adjuvant loco-regional treatment
3489082|NCT03723291|Active Comparator|Arm A|The current best standard of care [rehabilitation exercises]
3489083|NCT03723291|Experimental|Arm B|The current best standard of care [rehabilitation exercises] + the experimental intervention
3489084|NCT03723252|Experimental|Dapagliflozin group|Participants will receive dapagliflozin 10mg po qd.
3489085|NCT03723252|Placebo Comparator|Placebo group|Participants will receive placebo po qd.
3489086|NCT03723226|Active Comparator|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 6 weeks of single-legged low load (25%) resistance exercise. Their contralateral leg will serve as within subject control.
3489087|NCT03723226|Experimental|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 6 weeks of single-legged low load (25%) resistance exercise plus blood flow restriction. Their contralateral leg will serve as within subject control.
3489088|NCT03723187|Experimental|experimental group|use Normal saline
3489089|NCT03723187|Active Comparator|comparator group|use Heparin
3489090|NCT03723174||Single Arm|baseline data will be calculated before the oral health educational program using gingival index and after 3 months from the intervention
3489091|NCT03723161||Treatment|Bone Anchored Hearing surgery using a BHX implant manufactured by Oticon Medical
3489092|NCT03723122|Experimental|DCRI program|Patient-caregiver dyads will immediately attend the Dyadic communication reinforcement intervention. For both groups, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 2 weeks post-intervention. Pre-post assessments consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
3489093|NCT03723122|No Intervention|Waiting List|Patient-caregiver dyads are in a waiting condition for 6 weeks. They will attend the Intervention after the second assessment time if they want to. For both group, first assessment time take place just after the enrollment, before the randomization. For this group, second assessment time take place 6 weeks after first assessment time. First and second assessment consist in self-reported scales assessing emotional distress, individual coping, cancer-related dyadic communication frequency, satisfaction, self-efficacy and coping.
3489094|NCT03723044|Experimental|healthy volunteers|
3489095|NCT03723031|Active Comparator|rectal misopristol|will receive 400 microgram misoprostol rectally preoperatively with urinary catheter insertion.
3489096|NCT03723031|Active Comparator|intrauterine misopristol|will receive 400 microgram misoprostol inserted intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta.
3489097|NCT03723018|Experimental|Meditation - Headspace|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by the commercially available app/website Headspace (provided to participants for free). Participants in this arm will have access to the other meditation arm once they finish the study.
3489098|NCT03723018|Experimental|Meditation - Respite|Participants in this arm will be asked to meditate daily for 10 minutes for 8 weeks. Meditation instruction will be provided by Respite, a website created by the investigators for this study. Participants in this arm will have access to the other meditation arm once they finish the study.
3489099|NCT03723018|No Intervention|Observational|Participants in this arm will not receive any intervention. Their only study activity will be taking online surveys. They will have access to the two meditation arms once they finish the study.
3489100|NCT03723005||Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
3489101|NCT03723005||Standard-of-Care Phototherapy|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
3489102|NCT03722992|Other|Mindfulness Cohort|Mindfulness-based stress reduction (MBSR) treatment group
3489103|NCT03722979|Other|All patients|
3489104|NCT03722940|Active Comparator|Magnesium sulphate|Group M
3489105|NCT03722940|Placebo Comparator|Na CL 0.9%|group C
3489106|NCT03722927|Experimental|Bupivacaine Group|Participants will be randomized to the Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
3489107|NCT03722927|Experimental|Liposomal Bupivacaine Group|Participants will be randomized to the Liposomal Bupivacaine Group and receive a bilateral mastectomy with immediate implant based breast reconstruction
3489108|NCT03722914|Active Comparator|benzonatate soft capsules group|
3489109|NCT03722914|Placebo Comparator|control group|
3489110|NCT03722901||Late preterm infants|34 weeks and 0-6 days gestational age
3489111|NCT03722901||Moderate preterm infants|32 weeks and 0-6 days gestational age
3489112|NCT03722901||Reference|Term infants 9m/39-40
3489113|NCT03722888|Experimental|adolescents who have previously smoked|Adolescents given a pre-post survey to measure the effect of the game and building that into the smokeSCREEN video game to anonymously collect information on players' perspectives, beliefs, behaviors around smoking, and collaborating with youth programs to pilot test how the game can be implemented in real world settings.
3489114|NCT03722875|Experimental|SHR-1210+ apatinib|"SHR-1210 (200mg fixed dose every 3 weeks, one cycle is three weeks, total~1 year ) will be administered as an intravenous infusion over 30 minutes.~apatinib 250 mg qd ， one cycle is three weeks, total 1 year"
3489115|NCT03722862|Placebo Comparator|Control Arm|Healthy volunteers will continue normal healthy diet with a placebo.
3489116|NCT03722862|Experimental|Low fiber|Healthy volunteers will be randomized to receive 3 grams of Sunfiber.
3489117|NCT03722862|Experimental|High fiber|Healthy volunteers will be randomized to receive 6 grams of Sunfiber.
3129177|NCT03200925|No Intervention|Group A - no video group|"Group A will be asked a short survey:~their intention to practice skin to skin at the time of delivery~if they participated in skin to skin in a previous pregnancy~if they had any formal education about skin to skin~if they did have formal education was it either~a.) Provided at a prenatal appointment,~b.) A formal class led by either a nurse or a lactation consultant.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
3489118|NCT03722849|Experimental|Chronic cough participant|"Twenty-five (25) Idiopathic chronic cough patients, defined as refractory to disease modifying therapies (eg anti-asthma medications), will be recruited.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of Adenosine Triphosphate (ATP; 0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo functional brain imaging (fMRI) for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
3489119|NCT03722849|Experimental|Healthy control participant|"Twenty-five (25) appropriately age and sex matched healthy non-smoking individuals will be recruited as the comparison group.~Participants will attend two sessions. In the first they will inhale in a single breath a nebulized solutions of increasing doses of ATP (0.2-300 microM) and capsaicin (0.5-125 microM) to determine their individual cough and urge-to-cough thresholds. In the second session, participants will undergo fMRI for 1 hour while inhaling over 24 seconds randomly administered nebulized solutions of saline, or threshold doses of ATP or capsaicin."
3489120|NCT03722823|Active Comparator|Group 1: Healthy|Match-controlled healthy subjects with normal hepatic function
3489121|NCT03722823|Experimental|Group 2: Mild Hepatic Impairment|Subjects with Mild hepatic impairment (Child-Pugh Class A, score of 5 or 6)
3489122|NCT03722823|Experimental|Group 3: Moderate Hepatic Impairment|Subjects with Moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9)
3489123|NCT03722823|Experimental|Group 4: Severe Hepatic Impairment|Subjects with Severe hepatic impairment (Child-Pugh Class C, score of 10 to 14)
3489124|NCT03722797||Unilateral Transtibial Amputation|Individuals with a unilateral, transtibial amputation.
3489125|NCT03722797||Controls|Healthy adults without a lower-limb amputation who have been matched to participants in the Unilateral Transtibial Amputation group based on age, sex, and body mass index.
3489126|NCT03722771|Experimental|lavender oil group (A)|"100 % pure, high strength lavender oil inhalation in a separate room for 3 minutes, prior to surgery.~Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)"
3489127|NCT03722771|Sham Comparator|control group (B)|No application of lavender oil, prior to surgery. Anxiety questionnaires 1 (MDAS) Anxiety questionnaires 2 (STAI-S) Vital signs 1 (Blood pressure) Vital signs 2 (respiratory rate,) Vital signs 3 (heart rate) Vital signs 4 (saturation)
3489128|NCT03722758|Active Comparator|Spectrum TPH3, tooth restoration|Restoration with micro hybrid resin composite
3489129|NCT03722758|Active Comparator|Riva LC, restorative material|Restoration with resin-modified glass ionomer cement
3489130|NCT03722745|Experimental|Study group 1|Juvenile offenders will attend 4-session Trauma Affect Regulation: Guide for Education & Treatment (TARGET) groups led by one or two juvenile staff members
3489131|NCT03722745|Active Comparator|study group 2|Juvenile offenders will receive treatment-as-usual (TAU).
3489132|NCT03722732|Active Comparator|Open pancreaticoduedenectomy|will include all the patients who will undergo open pancreaticoduodenectomy
3489133|NCT03722732|Active Comparator|Laparoscopic pancreaticoduodenectomy|will include all the patients undergoing laparoscopic pancreaticoduodenectomy
3489134|NCT03722719|Experimental|Group I (the Knack)|
3489135|NCT03722719|Active Comparator|Group II (PFMT)|
3489136|NCT03722719|Active Comparator|Group III (the Knack + PFMT)|
3489137|NCT03722706|Experimental|Handbook|handbook provided as an adjunct to standard AD management with a healthcare provider at BCH
3489138|NCT03722706|No Intervention|Control|standard management alone
3489139|NCT03722680|Experimental|Riluzole|The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).
3489140|NCT03722680|Placebo Comparator|Placebo|Posology, administration and duration of treatment will be equivalent to riluzole group.
3489141|NCT03722667|Placebo Comparator|Technology-Based Component|A Technology-based interventions comprised of three technolgy components accessible via smartphone to support self-managing hypertension.
3489142|NCT03722667|Experimental|TechSupport|A Technology-based interventions comprised of three technolgy components plus positive psychological training accessible by smartphone to support self-managing hypertension.
3489143|NCT03722654|Experimental|MTFS|MTFS-I Installation
3489144|NCT03722654|No Intervention|Control|
3489145|NCT03722641|Placebo Comparator|Bread reference|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread.
3489146|NCT03722641|Experimental|Product 1: Milk|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on milk.
3489147|NCT03722641|Experimental|Product 2: Full fat milk + oat|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on full fat milk and oat with high fiber content.
3489148|NCT03722641|Experimental|Product 3: Skim milk + oat, high fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with high fiber content.
3489149|NCT03722641|Experimental|Product 4: Skim milk + oat, low fibre|A standardized (50 grams carbohydrates) breakfast meal will be provided based on bread and a test product based on skim milk and oat with low fiber content.
3489150|NCT03722628||HCC with TTT|Blood sample from all HCC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
3489151|NCT03722628||HCC without TTT|Blood sample from all HCC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
3489152|NCT03722628||LC with TTT|Blood sample from all LC patients who recieved antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
3489153|NCT03722628||LC without TTT|Blood sample from all LC patients who didnot recieve antiviral treatment for HCV will be taken to detect the MMP1-genotype polymorphism in those patients and the effect of treatment on this polymorphism.
3489154|NCT03722628||Healthy control|MMP1-genotype polymorphism will be applied on those healthy people to detect which type of mutation occur in healthy rather than diseased.
3489155|NCT03722602|Experimental|Rehabilitation group|Patients with stroke receiving standard inpatient rehabilitation for five weeks
3489156|NCT03722589|Active Comparator|Flublok (Recombinant)|Flublok® Quadrivalent by Sanofi Pasteur, 45µg of HA per strain
3129178|NCT03200925|Experimental|Group B - video group|"Group B will be asked the same short survey as group A.~The patient would then immediately watch Jumping into Kangaroo Care, and then immediately take the post survey which would ask if they intended to practice skin to skin at the time of delivery.~We will also look at patient's medical record number, age, gestational age, any pregnancy complications, race, type of insurance, and the number of times the patient has been pregnant. We will also examine data that is already collected by this hospital after delivery regarding skin to skin. This includes gestational age in weeks at the time of delivery, 5 minute APGAR, delivery date/time, skin to skin initiation time, skin to skin end time, delivery to skin to skin duration (minutes), and skin to skin duration (minutes)."
3489157|NCT03722589|Active Comparator|Flucelvax (Cell-based)|Flucelvax™ Quadrivalent by Seqirus, Inc., 15µg of HA per strain
3489158|NCT03722589|Active Comparator|Fluarix (Egg-based)|Fluarix® Quadrivalent by GlaxoSmithKlein, 15µg of HA per strain
3489159|NCT03722589|Active Comparator|Fluzone (Egg-based)|Fluzone® Quadrivalent by Sanofi Pasteur, 15µg of HA per strain
3489160|NCT03722589|Active Comparator|Fluzone (Egg-based) High-Dose|Fluzone® Trivalent High-Dose by Sanofi Pasteur, 60µg of HA per strain
3489161|NCT03722563|Active Comparator|TLHS|total laparoscopic hysterectomy with sacrocolpopexy will be performed
3489162|NCT03722563|Experimental|TLHLS|total laparoscopic hysterectomy with lateral suspension will be performed
3489163|NCT03722537|Active Comparator|Ligament Reconstruction Tendon Interposition (LRTI)|Selected randomly, 100 patients will receive this treatment. During the LRTI (standard of care procedure), the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
3489164|NCT03722537|Experimental|Osteochondral Allograft|Selected randomly,100 patients will receive this treatment. In this procedure, the arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface, known as the 'Cartibend©' .
3489165|NCT03722511|Active Comparator|NET with carcinoid syndrome|Participants with NET and carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
3489166|NCT03722511|Active Comparator|NET w/o cardinoid syndrome|Participants with NET w/o carcinoid syndrome will be instructed to drink two 8 oz. bottles of Amino Acid Based Medical Food/Drink (Enterade®) per day.
3489167|NCT03722498|Experimental|HAIC of FOLFOX|Hepatic arterial infusion chemotherapy with oxaliplatin, leucovorin, and 5-fluorouracil
3489168|NCT03722498|Active Comparator|Sorafenib|Sorafenib 400 mg orally twice a day
3489169|NCT03722485|Experimental|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|V.A.C. VeraFlo Cleanse Choice Dressing, V.A.C.Ulta Therapy Unit and saline solution
3489170|NCT03722485|Active Comparator|Collagenase Ointment|Collagenase Ointment
3489171|NCT03722472|Experimental|Single-vial ID93 + GLA-SE|Single-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
3489172|NCT03722472|Active Comparator|Two-vial ID93 + GLA-SE|Two-vial presentation of ID93 + GLA-SE. Participants will receive two intramuscular (IM) injections of the vaccine on Days 0 and 56. 2 mcg ID93 and 5 mcg GLA-SE in 0.5 mL volume will be given per injection.
3489173|NCT03722459|Experimental|All participants|All participants will receive the investigational MR Fingerprinting sequence.
3489174|NCT03722433|Experimental|probiotic plus 14-day sequential therapy|D1-D56: probiotics 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
3489175|NCT03722433|Placebo Comparator|placebo plus 14-day sequential therapy|D1-D56: placebo 1 pack bid for 56 days D1-D7: (esomeprazole + amoxicillin bid) for 7 days D8-D14: (esomeprazole + clarithromycin + metronidazole bid) for another 7 days
3489176|NCT03722420|Experimental|Radotinib 300mg|Oral adminstration of Radotinib 300mg BID (600mg/day) for 12months
3489177|NCT03722420|Active Comparator|Imatinib 400mg|Oral administration of Imatinib 400mg QD (400mg/day) for 12months
3489178|NCT03722407|Experimental|Ruxolitinib|All patients will be given their first dose of oral Ruxolitinib, 20 mg at first scheduled visit. After that dose and on all other days patients will self-administer oral Ruxolitinib at a dose of 40 mg daily divided into two equal doses approximately 12 hours apart. Patients will be treated for a total of 16 weeks. After treatment, patients will be followed monthly.
3489179|NCT03722394|Experimental|Pain Neuroscience Education|Subjects received a 15-minute verbal, one-on-one Pain Neuroscience Education (PNE) session
3489180|NCT03722368|Experimental|RCHC|Participation in the Resilience and Coping of the Healthcare Community Intervention.
3489181|NCT03722368|Experimental|RCHC+|Participation in the Resilience and Coping of the Healthcare Community Intervention, support groups and one on one counseling.
3489182|NCT03722368|Other|Waitlist Control|This group will receive treatment as usual and will be offered services once the study is complete.
3489183|NCT03722355|Active Comparator|Arm 1: Conventional RT + Carmustine|Conventional RT: 60.0 Gy/30 fractions/2.0 Gy once daily + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT then every 8 weeks for 6 cycles
3489184|NCT03722355|Experimental|Arm 2: Hyperfractionated RT + Carmustine|Hyperfractionated RT: 72.0 Gy/60 fractions/6 weeks/1.2 Gy BID + carmustine 80 mg/m2 IV on Days 1, 2, 3 of RT and then every 8 weeks for 6 cycles
3489185|NCT03722342|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
3489186|NCT03722329|Experimental|SB12|SB12 (proposed eculizumab biosimilar)
3129179|NCT03201003|Active Comparator|AR101|AR101 powder provided in capsules & sachets
3129180|NCT03201003|Placebo Comparator|Placebo|Placebo powder provided in capsules & sachets
3489187|NCT03722329|Active Comparator|EU Soliris|EU sourced Soliris (eculizumab)
3489188|NCT03722329|Active Comparator|US Soliris|US sourced Soliris (eculizumab)
3489189|NCT03722316|Experimental|MCI/Mild Dementia|"Twenty participants will be allocated to this arm if they demonstrate mild impairments in cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
3489190|NCT03722316|Active Comparator|Healthy Older Adults|"Participants are allocated to this arm if they demonstrate healthy cognition based on a cognitive screening phase. Participants enrolled in this arm will be arranged in groups of 5. They will attend a paperwork visit and two video-viewing sessions (order is randomized) held approximately one week apart: (1) brief immersive nature-based video experience + group discussion and (2) comparison condition that includes presentation of a relatively neutral, un-arousing documentary + group discussion. Each video lasts approximately 15 minutes. Using a semi-structured group discussion guide, participants will be prompted to talk about what they saw in the video and relate video content to their own lives and experiences."
3489191|NCT03722303|Active Comparator|Steroid Injection|Subjects with CTS will receive steroid injection.
3489192|NCT03722303|Experimental|Fat Injection|Subjects with CTS will receive fat injection.
3489193|NCT03722290|Experimental|Metformin|Metformin 500mg twice a day per os for 9 weeks
3489194|NCT03722277|Experimental|Variable load training|"The participants will be training two times per week in 10 weeks. Training will consist of variable load training in knee flexion- and extension.~Training will be based on symptoms in isometric strength at five different angles of flexion- and extension."
3489195|NCT03722277|Active Comparator|Conventional strength training|The participants will be training two times per week in 10 weeks. Training will consist of a training programme consisting of strength training with rubber bands for hip and knee.
3489196|NCT03722251|Experimental|Glucose Beverage|50 g of glucose in solution
3489197|NCT03722251|Experimental|Control Beverage|Sucralose in solution
3489198|NCT03722251|Experimental|Glucose beverage and active video game playing|50 g of glucose in solution and 30 min of active video game playing
3489199|NCT03722251|Experimental|Control Beverage and active video game playing|Sucralose in solution and 30 min of active video game playing
3129181|NCT03201211|Experimental|10-10-10-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, PE-PilA and UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
3489200|NCT03722225|Experimental|Descriptive, single arm, interventional study|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during physical exercise and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
3489201|NCT03722212|Other|Patients for METAglut1|"The METAglut1 test is performed on all patients included in the study. In parallel, patients included prospectively (based on a clinical suspicion) benefit from the reference diagnostic strategy through the current practice, starting with a lumbar puncture for glycorrhachia dosage.~Already diagnosed patients are included retrospectively."
3489202|NCT03722199|Experimental|Healthy persons|In this interventional study the investigators ask the patient (healthy persons) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
3489203|NCT03722199|Experimental|Persons with essential hypertension|In this interventional study the investigators ask the patient (persons with essential hypertension) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
3489204|NCT03722199|Experimental|Persons with type 2 diabetes|In this interventional study the investigators ask the patient (persons with type 2 diabetes) to come twice. One time they get capsules (6 or 8) with real flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances) and the other time they get capsules with a placebo
3489205|NCT03722186|Experimental|SHR-1603|Multiple escalating doses of SHR-1603
3489206|NCT03722173|Experimental|All subjects|Period 1:Treatment R (BI 894416 alone) followed by Period 2:Treatment T (BI 894416 + itraconazole)
3489207|NCT03722160|Other|Solo Tympanostomy Tube Device|The Solo Tympanostomy Tube Device is a disposable surgical tool designed to deliver a tympanostomy tube (grommet) into the tympanic membrane of patients undergoing a tympanostomy tube placement procedure
3489208|NCT03722147|Experimental|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
3489209|NCT03722134|Experimental|MOCA|The refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
3489210|NCT03722134|Active Comparator|EVLA|The refluxing GSV was treated with endovenous laser ablation.
3489211|NCT03722134|Active Comparator|RFA|The refluxing GSV was treated with radiofrequency ablation.
3489212|NCT03722082|Experimental|Enhancing cognitive reserve intervention|This intervention focuses in the improvement of academic skills, the increase of leisure activities and the improvement of neurocognitive functions with the ultimate goal of improving daily functioning. This intervention is based on ecological tasks that will be carried out in two areas, both in the hospital and at home. Most of the techniques are based on: pencil and paper tasks, with audiovisual and virtual reality support, telephone applications and group activities. The groups will be made with parents and children, adolescents and young adults separately being the content of the sessions the same but adapted to the age of the attendees.
3489213|NCT03722082|Placebo Comparator|Supportive Intervention|The participants will not receive any structured intervention focused to enhance cognitive reserve. The therapists will adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise.
3489214|NCT03722069|Other|Low sodium diet|22 patients were randomized to receive 3 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
3489215|NCT03722069|Other|Normal sodium diet|22 patients were randomized to receive 7 g/day of dietary sodium chloride and a limit of fluid intake of 1000 ml/day.
3489216|NCT03722056||gastric GIST|patients with suspected gastric GIST with size > 2cm are subjected for laparoscopic resection.
3489217|NCT03722043|Experimental|Parenting Program|"All study participants will receive our parenting program curriculum. There will not be a control group.~The parenting program will include the topics of mindful parenting strategies, emotional regulation, positive discipline, and positive parenting/attachment. Participants will be provided skills to develop strategies for each of the modules. Each session will contain elements of group troubleshooting and practice in-session. Practice at home will be assigned so that participants can continue to practice and implement these skills and strategies in their homes.~The program is taken from a published, empirically based program called Everyday Parenting: A Professional's Guide to Building Family Management Skills written by Thomas Dishion, Elizabeth Stormshak, and Kathryn Kavanagh."
3489218|NCT03722004|Active Comparator|mOPV1 + fIPV 6 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at 6 weeks.
3489219|NCT03722004|Active Comparator|mOPV1 + fIPV 10 weeks|mOPV1 administered at 6, 10, and 14 weeks and fIPV at10 weeks.
3129182|NCT03201211|Experimental|10-10-3-AS|Subjects who received two doses of the AS01E adjuvanted GSK Biologicals' NTHi-Mcat investigational vaccine, containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2, and administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974), and were enrolled in the study.
3489220|NCT03722004|Active Comparator|mOPV1 only|mOPV1 administered at 6, 10, and 14 weeks.
3489221|NCT03722004|Active Comparator|bOPV only|bOPV administered at 6, 10, and 14 weeks.
3489222|NCT03721991|Active Comparator|GABA|gamma Amino butyric acid (GABA) food supplement with 6 g per day
3489223|NCT03721991|Placebo Comparator|PLACEBO|Matching placebo capsules to GABA
3489224|NCT03721965|Experimental|Itacitinib + Corticosteroids|
3489225|NCT03721939|Experimental|FLEX Scoring Catheter plus DEB|The target lesion is prepared by the FLEX Scoring Catheter® with a 30° rotation between each passage. Angioplasty is performed during 3 minutes with paclitaxel-coated balloon(s) (PCB), all along the target lesion.
3129183|NCT03201211|Placebo Comparator|PLACEBO|Subjects who received two doses of placebo (saline solution), administered at Month 0 and Month 2 in NTHi-Mcat-001 study (NCT02547974) and were enrolled in the study.
3129184|NCT03201419|Experimental|FE 201836 500 μg (Randomized Treatment Period)|FE 201836 500 μg oral solution and placebo orally disintegrating tablet (ODT), administered once daily
3489226|NCT03721926|Experimental|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
3489227|NCT03721926|Active Comparator|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
3489228|NCT03721913|Experimental|Intervention group|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
3489229|NCT03721913|No Intervention|Control group|The control group will not receive the intervention during the study.
3489230|NCT03721900|Experimental|SHX-001 Active Low Dose|Ketamine transdermal patch
3489231|NCT03721900|Placebo Comparator|Placebo|placebo transdermal patch
3489232|NCT03721900|Experimental|SHX-001 Active high dose|ketamine transdermal patch
3489233|NCT03721887|Experimental|real tDCS|In transcranial direct current stimulation, the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 mins.
3489234|NCT03721887|Sham Comparator|sham tDCS|In transcranial direct current stimulation, the sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
3489235|NCT03721874|Active Comparator|Dapagliflozin 10 mg|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 14 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 14 days."
3489236|NCT03721874|Placebo Comparator|Placebo matching to dapagliflozin 10 mg|"Patients will receive matching placebo in tablet for a maximum of 14 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 14 days"
3489237|NCT03721848|Experimental|Healthy Community Clinic: NCD+MH|The arm of this study consists of a 28 session intervention, which are 45 minutes and meet 2-3 times a month providing health awareness on non-communicable diseases diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking; traumatic stress reactions, individual strategies for coping with stress and traumatic events and collective strategies for coping with stress and trauma.
3489238|NCT03721848|Active Comparator|Healthy Community Clinic: NCD|The arm of this study consists of a 24 session intervention, which are 45 minutes and meet 2 times a month providing health awareness on non-communicable disease diabetes, hypertension, obesity, reproductive health, cardiovascular diseases, allergies; smoking.
3489239|NCT03721848|No Intervention|Treatment as usual|This is treatment as usual where there is no intervention, but patients attend the clinic for treatment of non-communicable diseases.
3489240|NCT03721835|Other|Control femoral neck fracture system|This is a single arm study of subjects who are to be implanted with the CONQUEST FN™Femoral Neck Fracture System for treatment of a trauma related femoral neck fracture
3489241|NCT03721822|Experimental|Traditional Cigarette Smokers|Reported current cigarette smoking of at least 5 cigarettes per day, 5 days per week for the past 1 year with no history of e-cigarette use (cannabis or nicotine) or cannabis smoking during the 30 days prior to study enrollment
3489242|NCT03721822|Experimental|Non-Smokers|Reported non-smoking history or < 100 lifetime cigarettes, < 100 e-cigarette use episodes and < 100 lifetime cannabis use episodes
3129185|NCT03201419|Experimental|FE 201836 350 μg (Randomized Treatment Period)|FE 201836 350 μg oral solution and placebo ODT, administered once daily
3489243|NCT03721822|Experimental|Nicotine Vapers|Reported current e-cigarette use of nicotine at least 5 days per week for the past year with no current combustible cigarette use, cannabis vaping or cannabis smoking during the 30 days prior to study enrollment
3489244|NCT03721822|Experimental|Cannabis Vapers|Reported current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking or nicotine vaping during the 30 days prior to study enrollment
3489245|NCT03721822|Experimental|Dual Smokers/Vapers|Reported current e-cigarette use of cannabis and/or nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 days prior to study enrollment
3489246|NCT03721809|Other|macrophage activation syndrome secondary to bacterial sepsis|Patients hospitalized in medical intensive care for macrophage activation syndrome secondary to bacterial sepsis
3489247|NCT03721809|Other|bacterial sepsis/septic shock|Patients hospitalized in medical intensive care for sepsis / septic shock
3489248|NCT03721796||Arm 1 Physician/APP|Surgical, medical, and radiation oncologists and/or Advanced Practice Provider (APP)
3489249|NCT03721796||Arm 2 Patients|For each participating oncologist, we will may enroll up to three adult cancer patients presenting for consultation, since certain disease sites have a higher incidence in the HIV population.
3489250|NCT03721783||children with soft tissue lesions|All children who undergo cryoablation therapy for benign soft tissue lesions
3489251|NCT03721770||Relatives|Relative or adult companion (age <18 years) of a patient who died of cardiac arrest after organ removal request. A parent is defined as a close relative of the first degree: husband-wife, father-mother, son-daughter. Only one loved one is included per patient. Inclusion order of priority is husband-wife / father-mother / son-daughter.
3489252|NCT03721757|Other|Nivolumab, Surgery, Radiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with low risk criteria following surgery will be assigned to radiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and commencement of radiotherapy (1-2 weeks prior).~Radiotherapy will be administered over 30 fractions i.e. over 30 days (Monday to Friday for 6 consecutive weeks).~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals"
3489253|NCT03721757|Other|Nivolumab, Surgery, Chemoradiotherapy|"Patients will be treated with a single dose of nivolumab (240mg flat dose), followed by surgery to remove their tumour within 1-2 weeks.~Based on pathological risk factors determined following surgery, patients will be assigned to undergo adjuvant radiotherapy or chemoradiotherapy. Patients with high risk criteria following surgery will be assigned to chemoradiotherapy.~A single dose of nivolumab (240mg flat dose) will be given between surgery and chemoradiotherapy (1-2 weeks prior).~Chemoradiotherapy will be administered over 30 fractions i.e. over 30 days with concomitant Cisplatin (100mg/m2) on day 1 and 21.~Following completion of radiation (within 1-2 weeks), patients will commence adjuvant nivolumab, with a total of 6 doses (480mg flat dose) given at 4 weekly intervals."
3129186|NCT03201419|Experimental|FE 201836 250 μg (Randomized Treatment Period)|FE 201836 250 μg oral solution and placebo ODT, administered once daily
3129187|NCT03201419|Experimental|FE 201836 150 μg (Randomized Treatment Period)|FE 201836 150 μg oral solution and placebo ODT, administered once daily
3129188|NCT03201419|Experimental|FE 201836 100 μg (Randomized Treatment Period)|FE 201836 100 μg oral solution and placebo ODT, administered once daily
3489254|NCT03721744|Experimental|Napabucasin+Paclitaxel+Gemcitabine|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose).Paclitaxel 80 mg/m^2 will be administered intravenously. Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion. This regimen will be repeated on Days 1, 8 and 15 of every 28-day cycle. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on RECIST 1.1 criteria
3129189|NCT03201419|Experimental|FE 201836 50 μg (Randomized Treatment Period)|FE 201836 50 μg oral solution and placebo ODT, administered once daily
3129190|NCT03201419|Experimental|Placebo (Randomized Treatment Period)|Placebo oral solution and placebo ODT, administered once daily
3129191|NCT03201419|Experimental|Desmopressin 25 μg (Randomized Treatment Period)|Desmopressin 25 μg ODT and placebo oral solution, administered once daily (female subjects)
3129192|NCT03201419|Experimental|Desmopressin 50 μg (Randomized Treatment Period)|Desmopressin 50 μg ODT and placebo oral solution, administered once daily (male subjects)
3129193|NCT03201562|Experimental|Aceclidine+tropicamide combination|Aceclidine+tropicamide combination single dose (PRX-100 Ophthalmic Solution)
3129194|NCT03201562|Active Comparator|Aceclidine|Aceclidine single dose
3129195|NCT03201562|Sham Comparator|Vehicle|Vehicle single dose
3129196|NCT03201809|Experimental|On-Q Catheter|On-Q catheters placed within the implant pocket; infusion of 0.2% Ropivacaine at 4 mL/h for a total of 400 mL (about 4 days).
3129197|NCT03201809|Active Comparator|Ultrasound Guided Pectoral Nerve Block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the pecs 2 injection
3129198|NCT03201900|Experimental|E2007|The Treatment Phase consists of the 4 milligrams (mg) Treatment Phase (the Titration Period [6 weeks] and the Maintenance Period [26 weeks]) and the 8 mg Treatment Phase (the Titration Period [4 weeks] and the Maintenance Period [26 weeks]) if participants require a higher dose. In the 4 mg Titration Period (6 weeks), participants will initiate 2 mg perampanel once daily (QD) for 2 weeks and then will be up-titrated to 4 mg QD and will continue this dose for 4 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 4 mg Maintenance Period for 26 weeks. Participants will only need the higher dose if they are having seizures. In the 8 mg Titration Period (4 weeks), participants will be administered 6 mg perampanel QD for 2 weeks and then will be up-titrated to 8 mg QD and will continue this dose for 2 weeks. If participants have no safety issues at the end of the Titration Period, they will start the 8 mg Maintenance Period for 26 weeks.
3489255|NCT03721744|Active Comparator|Standard of care treatment options|Patients will receive standard of care treatment options treatment, including Fluorouracil and Leucovorin, Gemcitabine, Onivyde plus Fluorouracil and Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region), or best supportive care (BSC) alone, one of which will be assigned by the investigator for each patient.
3489256|NCT03721718|Experimental|GLS-5300 with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
3489257|NCT03721718|Experimental|GLS-5300 at 0.3mg DNA/dose with ID Cellectra electroporation|GLS-5300 at 0.3mg DNA/dose
3489258|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (3 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
3489259|NCT03721718|Experimental|GLS-5300 at 0.6mg DNA/dose (2 dose regimen)|GLS-5300 at 0.6mg DNA/dose with ID Cellectra electroporation
3489260|NCT03721705|Experimental|Treatment Arm|The first four sessions will be the escalation phase using the Renew NCP-5. There will be a 5-minute ramp up period where the pressure is increased 1 psi/min until the desired pressure is reached. The goal for the treatment group will be at least 2.5 psi for the first treatment, and then escalate the pressure gradually through the fourth session with an average goal of 3 psi/session. After the fourth session, the pressure will be slowly increased to reach the maximum level the subject can tolerate with a goal of reaching 3-6 psi.
3489261|NCT03721705|Sham Comparator|Sham Arm|The subjects will receive the same initial and maintenance treatment regimen on the Renew NCP-5. The pressure will not exceed an average of 0.5 psi over all treatments.
3129201|NCT03202134||opioid free anesthesia (OFA)|The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.
3489262|NCT03721692|Experimental|RIC group|The patients will accept cardio-cerebrovascular disease secondary prevention treatment and use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
3489263|NCT03721692|No Intervention|non-RIC group|The patients will only accept cardio-cerebrovascular disease secondary prevention treatment.
3489264|NCT03721679|Experimental|Poly-ICLC treatment combination aPD-1or aPD-1L1|"Weeks 1 and 2: Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM ONLY twice a week with a 48-72 hour interval between the two injections~Weeks 3-25:~Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND~ONLY 1 of the following regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows:~Nivolumab (Opdivo), OR~Pembrolizumab (Keytruda), OR~Cemiplimab (Libtayo) OR~Atezolizumab (Tecentriq) OR~Durvalumab (Imfinzi) Follow up: After completion of treatment subjects may be contacted by telephone at least twice over 12 months, or longer with patient consent, in order to inquire on their health status (e.g., in remission, progressive disease, on new cancer treatment)."
3489265|NCT03721653|Active Comparator|FOLFOXIRI + Bevacizumab|"(to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
3489266|NCT03721653|Experimental|FOLFOXIRI + Bevacizumab + Atezolizumab|"Atezolizumab 840 mg iv over 30 minutes(60 minutes at the first infusion) day 1 followed by Bevacizumab 5 mg/kg iv over 30 minutes day 1, followed by Irinotecan 165 mg/sqm iv over 60 minutes day 1, followed by Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with L-Leucovorin 200 mg/sqm iv over 2 hours day 1, followed by 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 (to be repeated every 2 weeks for a maximum of 8 cycles)~If no progression occurs during FOLFOXIRI plus bev plus atezolizumab, patients will receive maintenance 5-FU/LV plus bev plus atezolizumab at the same dose used at the last cycle of the induction treatment. 5-FU/LV plus bev plus atezolizumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal.~The prosecution of bev and atezolizumab until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
3489267|NCT03721640||Preterm neonates (< 33 weeks GA)|Preterm neonates requiring in the first week of life, an elective tracheal intubation for surfactant administration by INSURE or LISA methods.
3489268|NCT03721627|Experimental|Treatment group|Ledipasvir/sofosbuvir fixed dose combination tablet (90 mg ledipasvir, 400 mg sofosbuvir) once daily for 12 weeks for those 12-18 years, Wt 35 kg or more and half the dose (45 mg ledipasvir, 200 mg sofosbuvir) once daily for 12 weeks for those 6-11 years, Wt Less than 35 kg.
3489269|NCT03721614|Experimental|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|
3489270|NCT03721614|Active Comparator|Xience family Everolimus Coronary Stent Systems|
3489271|NCT03721601||Atrial fibrillation|Patients in atrial fibrillation as recorded by 3-lead Holter.
3489272|NCT03721601||Sinus rhythm|Patients in sinus rhythm as recorded by 3-lead Holter.
3489273|NCT03721588||Major depressive disorder|MDD; patients with diagnosis of major depressive disorder, Clinical interviews, psychometric scales were applied.
3489274|NCT03721588||MDD and ADHD|MDD; major depressive disorder ADHD; attention deficit hyperactivity disorder, Clinical interviews, psychometric scales were applied.
3129202|NCT03202134||opioid anesthesia (OA)|OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.
3129203|NCT03202264||TAPERMD|80 Long term care residents on 5 or more medications aged over 70 from 2 long term care facilities
3129204|NCT03202472|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo mammogram or ultrasound for image-guided placement of the radiofrequency tag within 30 days of surgery and then undergo radiofrequency-guided localization during surgery.
3129205|NCT03202511|Active Comparator|Control|The control phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) on day 1 (2 tablets) followed by 300/200 mg (1 tablet) doses on days 2 and 3.
3489275|NCT03721575|Active Comparator|Scarpa's preserving hernio-abdominoplasty|Hernio-abdominoplasty is performed with preservation of Scarpa's fascia.
3489276|NCT03721575|Active Comparator|Classical hernio-abdominoplasty|Hernio-abdominoplasty is performed with removalof Scarpa's fascia.
3489277|NCT03721536|Active Comparator|low-flow anesthesia|Patients in low-flow anesthesia receive a fresh gas flow of 4 L/min for the first 10 minutes and were then maintain with a fresh gas flow of 0.75 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
3489278|NCT03721536|Active Comparator|normal-flow anesthesia|Patients in normal-flow anesthesia received a fresh gas flow of 4 L/min for the first 10 minutes and were then maintained with a fresh gas flow of 1.5 L/min. Patients will be monitored for hemodynamic parameters during the perioperative period. Arterial blood gase will be analyzed for the oxygenation.
3489279|NCT03721510|Active Comparator|Group 1A|HIV-uninfected volunteers receiving one IV infusion
3489280|NCT03721510|Active Comparator|Group 1B|HIV-uninfected volunteers receiving one IV infusion
3489281|NCT03721510|Active Comparator|Group 2|HIV-infected volunteers on ART receiving three or six IV infusions
3489282|NCT03721497|Active Comparator|Testosterone Undecanoate|Inj. Testosterone undecanoat (Nebido®), 1000 mg im preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
3489283|NCT03721497|Placebo Comparator|Placebo|Inj. placebo preoperative (baseline, weeks 6, 18 and 30 depending on time to surgery) and postoperative (weeks 4, 16, 28, 40)
3489284|NCT03721471||Frail, non-frail|"Frail Group: Those individuals identified as frail by low hand-grip-strength and/or the Clinical Frailty Scale.~Non-frail Group: Those individuals identified as not frail by hand-grip-strength and/or the Clinical Frailty Scale."
3489285|NCT03721445||CPAP opponent|CPAP opponent: moderate to severe OSA patients who refused CPAP therapy after PSG study and CPAP titration test.
3489286|NCT03721445||CPAP acceptor|CPAP acceptor: moderate to severe OSA patients who accepted CPAP therapy after PSG study and CPAP titration test and had purchased a PAP at home for long term use.
3489287|NCT03721432|Experimental|Pregabalin group (P)|received pregabalin 150 mg capsules (Lyrica®,Pfizer) sixty minutes prior to the epidural insertion.
3489288|NCT03721432|Placebo Comparator|Control group (C)|received placebo capsules sixty minutes prior to epidural insertion.
3489289|NCT03721419|Experimental|High Flow High Humidity device|High Flow High Humidity device arm subjects will be placed on a High Flow Airvo device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen. This device has its own flow generator built in.
3489290|NCT03721419|Active Comparator|Low Flow High Humidity Device|Low Flow High Humidity device arm patients will be placed on a Low Flow device post tracheostomy with oxygen bled into system which maintains a safe level of patient blood oxygen.
3489291|NCT03721406|Other|Ropivacaine|"25 ml single dose of 0.5% ropivacaine~continuous infusion of ropivacaine 0.2% with a constant infusion rate of 14 ml/h"
3489292|NCT03721380|Experimental|BDRC|At the time of assignment to the counseling intervention arm of the study, there will be an initial meeting between the subject and the assigned counselor. As described in the counseling manual, this initial session is designed to introduce the counselor, review the purpose and expectations of counseling, review the rules of confidentiality, agree on attendance times and rescheduling rules, and to begin to collect information from the participant on their drug use and risk behaviors. Behavioral contracting is a key component to this counseling approach.
3489293|NCT03721380|Other|TAU|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs.
3489294|NCT03721367||Urea Cycle Disorders|
3489295|NCT03721354|Experimental|NAVA vs PSV -TCCD|Ultrasound evaluation, using trans cranial doppler technique will be performed to evaluate the cerebral blood flow speed (average/systolic speed) near the point of emergency, in the middle tract and at the bifurcation of M1 bilaterally, at the end of every ventilation trial (NAVA and PSV).
3489296|NCT03721315|No Intervention|Control|This group will receive the standard of care for this condition.
3489297|NCT03721315|Experimental|Intervention|This group will receive additional education along with their designated health support person prior to hospital discharge. This intervention does not include drugs/or devices.
3489298|NCT03721302||Main Study Clinical Sepsis|Clinical and Antimicrobial Assessments
3489299|NCT03721302||Microbiology Sub study|Clinical and Antimicrobial Assessments
3129206|NCT03202511|Experimental|Treatment|The treatment phase will consist of subjects taking 600/400 mg oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) (2 tablets) along with a 2 gram oral probenecid (PRO) dose (4 tablets, 500 mg each) on day 1.
3489300|NCT03721289||Cohort 1|All registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the participant institution during one year (from Jan 1st 2017 to Dec 31st 2017).
3489301|NCT03721289||Cohort 2|All EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st 2017 to Dec 31st 2017)
3489302|NCT03721263|Experimental|ASLAN004 Single Ascending Dose|"Up to 10 dose levels are planned.~ASLAN004 by IV route: 0.1 mg/kg (Cohort 1), 0.3 mg/kg (Cohort 2), 1 mg/kg (Cohort 3), 3 mg/kg (Cohort 4) and 10 mg/kg (Cohort 5), 20 mg/kg (Cohort 6 [optional]).~ASLAN004 SC route: 75 mg (Cohort 7), 150 mg (Cohort 8), 300 mg (Cohort 9), and 600 mg (Cohort 10 [optional])."
3489303|NCT03721250||thoracic epidural|patients receiving thoracic epidural
3489304|NCT03721237|Experimental|EBC-assisted|A nasogastric tube, equipped with esophageal and gastric balloons, will be inserted in each patient enrolled in the study. After definitive catheter positioning has been obtained, Esophageal ballon calibration will be run in volume-controlled ventilation, pressure support ventilation and sigh + pressure support ventilation.
3489305|NCT03721224||Children with psychogenic cough|children who were examined by Pediatric Respiratory Disease specialist and diagnosed as having a psychogenic cough.
3489306|NCT03721224||control subjects|children who were referred to pediatrics clinics and do not have a chronical disease.
3489307|NCT03721211|Experimental|[11C]Martinostat|"Subjects will be administered [11C]Martinostat, which is synthesized on site at the MGH Martinos Imaging Center~All subjects will undergo an MR-PET scan of the thorax, including the breasts, to determine tumor uptake~All subjects will be scanned using [11C]Martinostat during an imaging session on a Siemens Biograph mMR integrated MR-PET scanner~PET imaging will begin concomitant with radiotracer administration"
3129207|NCT03202550|Placebo Comparator|Placebo Arm|Two oral placebo pills (microcrystalline cellulose capsules)
3129208|NCT03202550|Active Comparator|Active Drug Arm: Lorazepam and Oxycodone|1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
3129209|NCT03203291|Experimental|Tethered Pelvic Assist Device (TPAD) Treatment|All participants will receive 5 consecutive days of training with the TPAD (tethered pelvic assist device) with testing completed before training, on completion of training and at a 1-week follow up.
3489308|NCT03721198|Active Comparator|Acidulated phosphorous flouride|Acidulated phosphorous flouride used once at the first of the study
3489309|NCT03721198|Experimental|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish (CLINPRO XT ) is used once at the first of the study only
3489310|NCT03721185|Active Comparator|LC|Lypolitic cream with hypocaloric diet and physicial activity in 51 patients
3489311|NCT03721185|Placebo Comparator|NLC|Hypocaloric diet and physicial activity alone in 51 patients
3129210|NCT03203447|Active Comparator|Active|Lucentis (0.5 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection or Avastin (1.25 mg/0.05 mL), IVT injection + CLS-TA (4 mg/0.10 mL), SC injection
3129211|NCT03203447|Sham Comparator|Control|Lucentis (0.5 mg/0.05 mL), IVT injection + sham SC procedure or Avastin (1.25 mg/0.05 mL), IVT injection + sham SC procedure
3489312|NCT03721159||Group I|30 Generalized chronic periodontitis subjects diagnosed with Coronary heart disease.
3489313|NCT03721159||Group II|30 Generalized chronic periodontitis subjects without coronary heart disease.
3489314|NCT03721159||Group III|30 Systemically healthy patients with no chronic periodontitis or coronary heart disease.
3489315|NCT03721133|Other|circulating tumor cell|Recurrent predictive power of circulating tumor cell in non small cell lung cancer patients who receive curative
3489316|NCT03721107|Experimental|Cohort C Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-C
3489317|NCT03721107|Placebo Comparator|Cohort C Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-C
3489318|NCT03721107|Experimental|Cohort D Active|two capsules Blautix administered twice daily to subjects diagnosed with IBS-D
3489319|NCT03721107|Placebo Comparator|Cohort D Placebo|two capsules placebo administered twice daily to subjects diagnosed with IBS-D
3489320|NCT03721094|Other|Immersive virtual reality|Completing the procedures in immersive virtual reality
3489321|NCT03721094|No Intervention|Conventional virtual reality|Completing the procedures in conventional virtual reality
3489322|NCT03721081|Placebo Comparator|Na Cl 0.9%/Epi 1:200000|Subcutaneous infiltration of Na Cl 0.9%/Epi 1:200000
3489323|NCT03721081|Active Comparator|Lidocaine 1%/Epi 1:200000|Subcutaneous infiltration of Lidocaine 1%/Epi 1:200000
3129212|NCT03203564|Active Comparator|Modufolin® for injection, 200, 350 and 500 mg/m2|Three cohorts, 8 subjects will be randomised to Modufolin ® for injection 100 mg
3129213|NCT03203564|Placebo Comparator|0.9% NaCl sterile solution|Three cohorts, 3 subjects will be randomised to placebo
3129214|NCT03203681|Other|Natesto|Participants in this group will receive Natesto for a 24 consecutive weeks treatment course.
3489324|NCT03721055|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
3489325|NCT03721042|Experimental|exhaled air|exhaled air analysis of patients
3489326|NCT03721029|Experimental|Intraoperative nerve monitoring|Patients that undergo robotic-assisted radical prostatectomy with the use intraoperative nerve monitoring, via electromyography, to identify the exact location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function
3489327|NCT03721029|Active Comparator|Control Cohort|Patients that undergo standard of care robotic-assisted radical prostatectomy.
3489328|NCT03721016|Experimental|MT10109L Dose 1 + Placebo|MT10109L Dose 1 will be injected into the GL and Placebo into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3489329|NCT03721016|Experimental|MT10109L Dose 1 + MT10109L Dose 2|MT10109L Dose 1 will be injected into the GL and MT10109L Dose 2 into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3489330|NCT03721016|Placebo Comparator|Placebo|Placebo will be injected into the GL and into the LCL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period.
3489331|NCT03720990|Experimental|Cholic acid|Participants will be treated with cholic acid 10 mg/kg body weight.
3489332|NCT03720964||presbycusis affected patients|affected by a more severe age related hearing loss than expected according to the norm ISO 7029
3489333|NCT03720964||controls|not affected by age related hearing loss according to the norm ISO 7029
3489334|NCT03720951|Experimental|Group I(Pudendal n.)|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
3489335|NCT03720951|Experimental|Group II(Sacral n.)|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
3489336|NCT03720925|Experimental|TDI treatment|"The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and from between 3 to 6 months after the TDI treatment ."
3489337|NCT03720912|Experimental|Online Family Education Modules|Patients will receive online family education modules.
3489338|NCT03720912|No Intervention|Control|Patients will not receive any intervention.
3489339|NCT03720899|Experimental|NicoBloc|NicoBloc participants will be provided with NicoBloc to use during counseling sessions and will test smoking their conventional cigarette with NicoBloc.
3489340|NCT03720899|Active Comparator|Nicotine Lozenge|Participants who receive nicotine lozenge will use the lozenge in session and will discuss the effects of using the lozenge in session.
3489341|NCT03720886|Experimental|rhPTH（1-34） 28.2μg|Participants received 28.2μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
3489342|NCT03720886|Experimental|rhPTH（1-34） 56.5μg|Participants received 56.5μg rhPTH（1-34）administered by subcutaneous injection once a week for 24 weeks.
3489343|NCT03720886|Active Comparator|teriparatide acetate(Teribone™)|Participants received 56.5μg teriparatide acetate(Teribone™) administered by subcutaneous injection once a week for 24 weeks.
3489344|NCT03720873|Experimental|EGFR-TKIs and Anlotinib|Experimental:EGFR-TKIs and Anlotinib EGFR-TKIs:erlotinib 150mg QD or gefitinib250mgQD or icotinib 125 mg TID , Anlotinib 12mg po qd d1-14 q21d
3489345|NCT03720860||Sepsis|Patients admitted to the intensive care unit with sepsis
3489346|NCT03720860||Surgery|Patinets subjected to major surgery and then admitted to the intensive care unit
3489347|NCT03720860||Non-inflamed|Otherwise healthy patients admitted to the intensive care unit because of intoxication.
3489348|NCT03720834||Patients|Questionnaire on risk perception
3489349|NCT03720834||Clinicians|Questionnaire on risk perception
3489350|NCT03720821|Experimental|Cognitive Training + fMRI|"Participants will complete Trail Making Test (TMT) A & B (both electronic and paper-pencil), the paper-pencil Color-Word Matching Stroop Test (CWMST), and its electronic version called Color Match, and a computer-based subset of NCPT (Neurocognitive Performance Test). In addition, participants will also complete Brief Pain Inventory (BPI), Hospital Anxiety and Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and the Resilience Scale questionnaires at baseline.~Participants will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.~Participants will be asked to undergo 2 functional magnetic resonance imaging (fMRI) sessions. One prior to, and one after the 5-week cognitive training period."
3489351|NCT03720808|Experimental|Balloon Blowing|Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
3489352|NCT03720808|Experimental|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
3489353|NCT03720808|Experimental|Coughing|Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
3489354|NCT03720808|Experimental|Control|No intervention was performed to reduce pain and fear in the control group.
3489355|NCT03720795|Other|Stepped Care CBT|Stepped Care CBT consists of two main steps. Step One involves 4 parent-led, therapist-assisted treatment sessions, up to 45 minutes each, over an 8-week period. Participants who do not show significant improvement in symptom severity at the end of Step One, are then 'stepped up' to receive Step Two, which involves 12 weekly, therapist-led, parent-assisted treatment sessions, up to 60 minutes each.
3489356|NCT03720769|Experimental|Step-by-Step|
3489357|NCT03720769|Active Comparator|Enhanced care as usual|
3489358|NCT03720756|Experimental|Subjects WITH nickel-sensitivity|Subjects on nickel-free diet who have a positive patch-test result, indicating nickel-sensitivity.
3489359|NCT03720756|Active Comparator|Subjects WITHOUT nickel-sensitivity|Subjects on nickel-free diet who have a negative patch-test result, indicating they do NOT have nickel-sensitivity.
3489360|NCT03720743|Experimental|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
3489361|NCT03720743|No Intervention|Control Group|The study allowed control group subjects to participate in Biodanza sessions after the follow-up period.
3489362|NCT03720717|Experimental|Opioid Tolerant - baclofen|
3489363|NCT03720717|Placebo Comparator|Opioid Tolerant - placebo|
3489364|NCT03720717|Experimental|Opioid Naive - baclofen|
3489365|NCT03720717|Placebo Comparator|Opioid Naive - placebo|
3489366|NCT03720704||GORE VIABAHN VBX Balloon Expandable Endoprosthesis|The GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted according to the institution standard of practice in patients needing preservation of peripheral vessels due to multiple pathologies and conditions.
3489367|NCT03720691|Active Comparator|Real rTMS Supplementary motor area|Real rTMS will be applied over the supplementary motor area
3489368|NCT03720691|Sham Comparator|Sham rTMS Supplementary motor area|Sham rTMS will be applied over the supplementary motor area
3489369|NCT03720678|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The RDE of etrumadenant will be determined in this part with escalating doses of etrumadenant in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal or colorectal cancer.
3489370|NCT03720678|Experimental|Dose Expansion-GE|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with gastroesophageal cancer
3489371|NCT03720678|Experimental|Dose Expansion-CRC|The RDE of etrumadenant will be determined from the dose escalation part. Etrumadenant will be given in combination with the standard mFOLFOX chemotherapy regimen in participants with colorectal cancer
3489372|NCT03720665|Active Comparator|Caffeine group|"200mg caffeine tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
3489373|NCT03720665|Placebo Comparator|Placebo group|"Non-active tablet~transcranial alternating current stimulation (140 Hz tACS) at 1 mA~transcranial alternating current stimulation (140 Hz tACS) at 0.4 mA~transcranial alternating current stimulation (140 Hz tACS) sham~paired associative stimulation (PAS 25)"
3489374|NCT03720639|Active Comparator|Abbott, Inc Confirm Rx™|Every other consenting subject will receive the Abbott Inc. Confirm Rx™ device.
3489375|NCT03720639|Active Comparator|Medtronic, Inc Reveal LINQTM|Every other consenting subject will receive the Medtronic, Inc. Reveal LINQTM.
3489376|NCT03720613||Naldemedine|Patients with chronic non-cancer pain who initiated naldemedine treatment for opioid-induced constipation.
3489377|NCT03720613||Lubiprostone|Patients with chronic non-cancer pain who initiated lubiprostone treatment for opioid-induced constipation.
3489378|NCT03720613||Naloxegol|Patients with chronic non-cancer pain who initiated naloxegol treatment for opioid-induced constipation.
3489379|NCT03720600|Experimental|MAB Intervention|Participants in this condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will watch a voice-guided PowerPoint on MAB strategies for coping with discrimination. For the following two weeks, they will be asked to complete multiple momentary assessments daily for two weeks. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires and complete a qualitative exit-interview.
3489380|NCT03720600|Other|Waitlist-Control|"Participants in the waitlist-control condition will be asked to come into the laboratory twice. At Time 1 (T1), participants in this condition will complete an initial set of questionnaires. For the following two weeks, they will be asked to complete multiple daily momentary assessments daily. After two weeks, participants will return to the laboratory to complete a final battery of questionnaires, watch a voice-guided PowerPoint on MAB strategies for coping with discrimination, and complete a qualitative exit-interview."
3489381|NCT03720600|No Intervention|No-EMA Control|"Participants in the No-EMA Control condition will only complete questionnaires at T1 and T2."
3489382|NCT03720574|Experimental|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening
3489383|NCT03720574|Placebo Comparator|Matching Placebo BID|Matching Placebo tablet each morning and evening
3129215|NCT03204279|Experimental|Netupitant 1.33 mg/kg plus Palonosetron|Single oral dose of Netupitant 1.33 mg/kg up to a maximum of 100 mg (for patients < 3 months of age the netupitant dose will be 0.8 mg/kg) administered with single oral dose of 20 μg/kg palonosetron up to a maximum of 1.5 mg.
3129216|NCT03204279|Experimental|Netupitant 4 mg/kg plus Palonosetron|Single oral dose of Netupitant 4 mg/kg up to a maximum of 300 mg (for patients < 3 months of age the netupitant dose will be 2.4 mg/kg) administered with single oral dose 20 μg/kg palonosetron up to a maximum of 1.5 mg.
3489384|NCT03720548|Experimental|LY3372993 (Part A)|LY3372993 administered intravenously (IV) to healthy participants.
3489385|NCT03720548|Placebo Comparator|Placebo (Part A)|Placebo administered IV to healthy participants.
3489386|NCT03720548|Experimental|LY3372993 (Part B)|LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.
3489387|NCT03720548|Placebo Comparator|Placebo (Part B)|Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.
3489388|NCT03720522||Group 1: Patients suffering from acute myocardial infarction|Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
3489389|NCT03720522||Group 2: Patients suffering from chronic myocardial infarction|Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
3489390|NCT03720522||Group 3: Patients suffering from stunned neurogenic myocardium|"Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.~These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.~Patients with normal (< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3."
3489391|NCT03720522||Group 4: Control|Patients with normal (< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
3489392|NCT03720496|Experimental|CD19-TriCAR-T|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
3129217|NCT03204526|Experimental|low frequency stimulation (LFS)|Low-frequency deep brain stimulation of the subthalamic nucleus
3489393|NCT03720483|Experimental|N-acetyl cysteine then placebo|This arm will receive NAC followed by placebo
3489394|NCT03720483|Experimental|Placebo then N-acetyl cysteine|This arm will receive placebo followed by NAC
3129218|NCT03204643|Experimental|BH-VPN|A bundle of usual care components applied consistently and completely, plus access to mental health trained patient navigators and navigation services.
3489395|NCT03720457|Experimental|Human CD19 targeted T Cells Injection|
3489396|NCT03720444||MDT (mechanical diagnosis and therapy) method|
3489397|NCT03720431|Experimental|TTAC-0001 and pembrolizumab|TTAC-0001 and pembrolizumab combination therapy will be administered.
3489398|NCT03720418|Experimental|OXB-102 Dose Level 1|OXB-102 Dose Level 1 Single Administration (Part A: open-label)
3489399|NCT03720418|Experimental|OXB-102 Dose Level 2|OXB-102 Dose Level 2 Single Administration (Part A: open-label)
3489400|NCT03720418|Experimental|OXB-102 Dose Level 3|OXB-102 Dose Level 3 Single Administration (Part A: open-label)
3489401|NCT03720418|Experimental|OXB-102 Selected Dose|Selected Dose of OXB-102 Single Administration (Part B: double-blind)
3489402|NCT03720418|Sham Comparator|Imitation Surgical Procedure|General anesthesia with bilateral skin incisions (Part B: double-blind)
3129219|NCT03204643|No Intervention|Usual Care|The standard intervention (Control - Usual Care) is given in this population. May contain some of the BH-VPN components.
3489403|NCT03720379|Active Comparator|Fluoride Varnish - Fluor PROTECTOR S|"Fluor Protector S - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor, 1.5% ammonium fluoride (7700 ppm fluoride), additional ingredients~APPLICATION OF Fluor Protector S will be performed AT BASELINE, after 3,6 months (control 1) and after 9 and 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
3489404|NCT03720379|Placebo Comparator|PLACEBO|"- Placebo - manufacturer: Ivoclar Vivadent Composition: ethanol, water, polymer, saccharin, mint flavor.~APPLICATION OF PLACEBO will be performed AT BASELINE, after 3,6 months (control 1) and after 9 AND 12 months (control 2). Preliminary(AT BASELINE) and control dental exams after 12 months will include an interview and a physical examination, radiological and Diagnodent examination, a 6 months follow-up -a physical examination, Diagnodent examination and interview."
3489405|NCT03720366|Experimental|Arm 1: Administration of enasidenib and Arm 1 probes|Part 1: Subjects will receive prescribed doses of Arm 1 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 1 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
3489406|NCT03720366|Experimental|Arm 2: Administration of enasidenib and Arm 2 probes|Part 1: Subjects will receive prescribed doses of Arm 2 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 2 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination
3489407|NCT03720366|Experimental|Arm 3: Administration of Enasidenib and Arm 3 probes|Part 1: Subjects will receive prescribed doses of Arm 3 probes on Day -1, followed by the first enasidenib dose on Day 1. Subjects will continue to take enasidenib once daily for 27 more days. On Day 28, subjects will receive the Arm 3 probes again together with the Day 28 dose of enasidenib. Part 2: the subjects continue to receive daily doses of enasidenib for the next 28 days (equivalent to a cycle). The subject will continue in subsequent cycles until the end of the study (28 months) or termination.
3489408|NCT03720353|Active Comparator|Active H|Participants will take SAS2094AL and SAS2094BH for 3 days, then SAS2094AH and SAS2094BH for 7 days.
3489409|NCT03720353|Active Comparator|Active L|Participants will take SAS2094AL and SAS2094BL for 10 days
3489410|NCT03720353|Placebo Comparator|Placebo|Participants will take placebo for 10 days.
3489411|NCT03720340|Active Comparator|Recombinant human interleukin-11|Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.
3489412|NCT03720340|Placebo Comparator|Saline|Only 10ml 0.9% NS was administered twicely to patients through respiratory tract.
3489413|NCT03720327|Active Comparator|Get FIT|The Get FIT intervention
3489414|NCT03720327|Experimental|Get FIT+|The Get FIT+ intervention, which includes push-only personalized text messages from a health coach.
3489415|NCT03720314||IBS|Irritable bowel syndrome patients
3489416|NCT03720314||control|healthy controls
3489417|NCT03720301|Experimental|Treatment|Study arm who will receive pre operative and intraoperative treatments intended to effect POST severity.
3489418|NCT03720301|Sham Comparator|Sham|Sham are who will receive a preoperative treatment not intended to effect POST outcomes.
3489419|NCT03720288|Experimental|Acetazolamide|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the acetazolamide group, he / she will start using the adjuvant medication as acetazolamide drug capsule at the daily dose of 250 mg / day (oral) during the first three days of treatment.
3489420|NCT03720288|Experimental|Placebo|All patients will receive an initial dose of intravenous furosemide of 1mg / kg, subsequently descaled to 0.5mg / kg of 6 / 6h, associated with oral hydrochlorothiazide 25mg / day and spironolactone 25mg / day orally. When the patient is randomized to the placebo group, he / she will start using the placebo drug capsule during the first three days of treatment.
3129220|NCT03204942|Active Comparator|PRF on DRG|Patients will receive Pulsed Radiofrequency (PRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 42°C for 480 sec.,2 active cycles per second of 20 milliseconds each , with a voltage output 40 to 60-V range, impedance ranges between 150 and 400 Ohms at all levels using Fluroscopic guidance (FG).
3489421|NCT03720275|Experimental|patients with chronic neuropathy of unknown aetiology|For the 130 patients with chronic neuropathy of unknown aetiology, the diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
3489422|NCT03720262|Experimental|Mesh reinforcement|Retro muscular mesh at the stoma site.
3489423|NCT03720262|Placebo Comparator|No reinforcement|Standard closure of the abdominal wall
3489424|NCT03720249|Experimental|supplementation of compound nutrients|Betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc are provided as a 800mg tablet. And the tablet is orally taken once a day, four tablets at a time for 12 weeks.
3129221|NCT03204942|Active Comparator|TRF on DRG|Patients will receive Thermal Radiofrequency (TRF) on Dorsal root ganglion(DRG) of the selected metastatic painful dorsal vertebrae, with temperature 80°C for 90 sec.,2 cycles, using Fluoroscopic guidance (FG) .
3129222|NCT03204942|Active Comparator|Control group|The control group will have identical needle placement and preparation like the 2 previous groups without the RF lesion, but with the injection of particulate Betamethasone steroids and local anesthetic on DRG of the selected metastatic painful dorsal vertebrae, using Fluoroscopic guidance (FG).
3489425|NCT03720249|Placebo Comparator|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of betaine、(6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc supplement.
3129223|NCT03204981|Experimental|Intramural Needle Ablation|
3129224|NCT03205046|Experimental|Part 1 continuous dose for vistusertib|acalabrutinib daily + vistusertib daily
3129225|NCT03205046|Experimental|Part 1 intermittent dose for vistusertib|acalabrutinib daily + vistusertib 5 days on and 2 days off
3129226|NCT03205150|Experimental|LIK066 30 mg|Film coated tablet of LIK066 30 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
3489426|NCT03720236|Experimental|Full preparation|Group A: the complete milling protocol indicated by the manufacturer for the 3.75x10 mm BLX implant will be performed.
3489427|NCT03720236|Experimental|Partial preparation|Group B: the partial / under milling protocol for the 3.75x10 mm implant, indicated by the manufacturer, will be carried out.
3489428|NCT03720236|Experimental|Deferred loading|Code 2: for implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. Impressions will be taken at 6 weeks to place the provisional prosthesis at 8 weeks. At 6 months the final impressions will be taken for the definitive load.
3489429|NCT03720236|Experimental|Immediate load|The code 1: to the implants with this random code, the prosthetic prosthesis SRA of 2.5 mm and its corresponding healing plug of 5.1 mm will be placed. The impression will be made in the same surgery and the placement of the provisional prosthesis before 7 days. At 6 months the final impressions will be taken for the definitive load.
3489430|NCT03720223|Experimental|Liposomal Bupivacaine|20ml Liposomal Bupivacaine 1.3% (13.3mg/mL), injected to the buccal mucosal graft harvest site.
3489431|NCT03720223|No Intervention|Control|No local anesthetics injected to the buccal mucosal graft harvest site
3489432|NCT03720197||Participants aged less than 14 years old|
3489433|NCT03720197||Participants aged 14 years old and older|
3489434|NCT03720184|Experimental|HAR group|Treated group is exposed to an haematic antegrade autologous repriming of the MiECC CLass IV circuit, reducing the haemodilution related to CPB initiation to a fix amount of 300ml
3489435|NCT03720184|No Intervention|Control Group|Control group is not exposed to HAR. The extracorporeal circuit is a MiECC primed with 1000ml of Isofundin (crystalloid balanced solution) as an standard circuit
3129227|NCT03205150|Experimental|LIK066 150 mg|Film coated tablet of LIK066 150 mg was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84
3129228|NCT03205150|Experimental|Placebo|LIK066 0 mg film-coated tablet(Placebo matching tablets) was mostly administered once daily before lunch, except on Day 56 when it was administered before breakfast and in fasted state on Day 84.
3129229|NCT03205163|Experimental|Low Dose Cohort: Advate 25 IU/kg Then BIVV001 25 IU/kg|Participants received a single intravenous (IV) dose of Advate 25 international units per kilogram (IU/kg) on Day 1 of Advate treatment period (3 days) followed by a single IV dose of BIVV001 25 IU/kg in BIVV001 treatment period (BTP) (28 days). Advate treatment period (ATP) consisted of a washout of at least 72 hours which was started from the time of Advate dosing.
3489436|NCT03720171|Experimental|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb.
3489437|NCT03720158|Experimental|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
3489438|NCT03720158|Placebo Comparator|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
3489439|NCT03720145|Experimental|Treatment Group|lifestyle medicine group
3179970|NCT00678327|Experimental|BEACOPP-14 chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride and oral prednisolone on days 1-7; and bleomycin IV and vincristine IV on day 8. Patients also receive filgrastim (G-CSF) subcutaneously (SC) on days 8-13 OR pegfilgrastim SC once on day 8. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3129230|NCT03205163|Experimental|High Dose Cohort: Advate 65 IU/kg Then BIVV001 65 IU/kg|Participants received a single IV dose of Advate 65 IU/kg on Day 1 of ATP (4 days) followed by a single IV dose of BIVV001 65 IU/kg in BTP (28 days). ATP consisted of a washout of at least 96 hours which was started from the time of Advate dosing.
3129231|NCT03205358|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine.
3129232|NCT03205358|Active Comparator|Group 2: NIMENRIX®|Healthy, meningococcal-vaccine naive toddlers aged 12 to 23 months received a single dose of NIMENRIX® vaccine.
3129233|NCT03205371|Experimental|South Korea(Group1):MenACYW Conjugate + MMR+ Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
3489440|NCT03720145|No Intervention|CAU group|Care-As-Usual group
3489441|NCT03720132|Experimental|Patients with port catheter: flushing|In patients with a catheter-related blood stream infection (CRBSI) and a port catheter, being treated with vancomycin intravenously, we will flush the catheter with 30 ml of sodium chloride 0.9 % prior to blood sampling to determine vancomycin concentrations, in order to decrease residuel vancomycin in the port.
3489442|NCT03720106|Other|treatment arm|In this arm the GOAL therapy plan is used.
3489443|NCT03720080||670G/OpenAPS|Participants with Type 1 Diabetes wearing a Medtornic Minimed 670G hybrid closed loop system in parallel with a non-insulin injecting, self-constructed OpenAPS system.
3129234|NCT03205371|Experimental|South Korea (Group 2): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
3489444|NCT03720067|Active Comparator|Phase 1: Propranolol (PPL)|Hepatic venous pressure gradient (HVPG) will be measured before and after 120 minutes of a loading dose of Propranolol (PPL) 80 mg PO. Thereafter, patients will receive maintenance therapy with Propranolol (40 to 320 mg / day) adjusted according to blood pressure and heart rate. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
3489445|NCT03720067|Active Comparator|Phase 1: Carvedilol (CVD)|HVPG will be measured before and after 120 minutes of a loading dose of Carvedilol (CVD) 12.5 mg PO. Thereafter, patients will receive maintenance therapy with Carvedilol (6.25 - 25 mg / day) adjusted according to blood pressure. After 28 days of reaching the maximum tolerated dose, a new HVPG measurement will be performed.
3489446|NCT03720067|Active Comparator|Phase 2: PPL non-responders/rosuvastatin|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
3489447|NCT03720067|Placebo Comparator|Phase 2: PPL non-responders/placebo|Patients treated with PROPRANOLOL (PPL) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
3489448|NCT03720067|Active Comparator|Phase 2: CVD non-responders/rosuvastatin|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of ROSUVASTATIN 20 mg /day PO. HVPG will be measured again after 56 days.
3489449|NCT03720067|Placebo Comparator|Phase 2: CVD non-responders/placebo|Patients treated with CARVEDILOL (CVD) who do not reach HVPG fall below 12 mmHg will be randomized to receive the addition of PLACEBO 1 tablet PO. HVPG will be measured again after 56 days.
3489450|NCT03720054|Experimental|MapTrek|Veterans in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, veterans are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so veterans can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
3489451|NCT03720054|Active Comparator|Fitbit Only|Veterans randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the veterans a Fitbit.
3489452|NCT03720041|Active Comparator|R1: IRD induction therapy (reactive)|In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol.
3489453|NCT03720041|Experimental|R1: IRD induction therapy (adaptive)|In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail.
3489454|NCT03720041|Active Comparator|R2: Lenalidomide plus placebo maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus placebo maintenance.
3489455|NCT03720041|Experimental|R2: Lenalidomide + ixazomib maintenance|Participants randomised to this arm at Randomisation 2 will receive lenalidomide plus ixazomib maintenance.
3489456|NCT03720028||Child w Angelman/Rett syndrome|Children with Angelman or Rett syndrome, up to 14 years of age
3489457|NCT03720028||Parent|Parents of Children with Angelman or Rett syndrome
3489458|NCT03720015|Experimental|Concurrent training|Three sessions per week of concurrent training during radiotherapy period. Each session will begin with warm-up (5-min cardiovascular activity at low-moderate intensity, joint mobility and one set of resistance exercises circuit at 30-40% 1RM). Resistance training will follow the warm-up, including 9 standard exercises involving major muscle groups of the lower and upper body: vertical bench press, parallel bar dip for triceps, seated rowing, standing dumbbell curl for biceps, leg press, deadlift and shoulder press. All these exercises will be realized following circuit training with 4 sets of 8-12 repetitions, using a training load of 70-80% RM. When patient will able to complete more than 12 repetitions, load will be increased progressively 10%. Cardiovascular training will be completed 20-30 min after resistance training, and it will include High-Intensity Interval Training (HIIT) of 3 min near to the second ventilatory threshold and 2 min near to the first ventilatory threshold.
3489459|NCT03720015|Experimental|Nutritional management|Prescribed diet controlling macronutrients according to patient body weight (~4g/kg/day for carbohidrates, ~2g/kg/day for proteins, and ~1g/kg/day for fats). Patient will take one single dosage per day of probiotics (Arkoprobiotics® Defenses), 1 or 2 capsules of omega-3 fish oil concentrate (Solgar®, 600-1200mg depending on fat sources intake during the day), and a combine ingestion of 3g beta-hydroxybeta-methylbutyrate (HMB), 14g arginine, and 14g glutamine (HSN Raw Series®, all pure ingredients and making the ingestion adding each of them individually in a solution with 300-400 ml of water). During concurrent training sessions, between resistance exercise and HIIT, patient will also take 6g of BCAA's (HSN Raw Series®, 2:1:1) along with a banana. Additionally, patient could take whey isolated protein (Amix® IsoPrime CFM) to meet with some of the prescribed proteins intakes.
3489460|NCT03719989|Experimental|Treatment arm|This study is sing-arm study. Therefore, all enrolled patients will be treated with azacitidine plus R-GDP regimen
3489461|NCT03719976|Experimental|Healthcare navigation workshops|All enrolled caregivers and parents will partake in the group-based educational intervention.
3179971|NCT00678327|Experimental|BEACOPP-escalated chemotherapy|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; etoposide IV on days 1-3; oral procarbazine hydrochloride on days 1-7; oral prednisolone on days 1-14; and bleomycin IV and vincristine IV on day 8. Patients also receive G-CSF SC beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3179972|NCT00678340|Active Comparator|1|WACA and PVI
3179973|NCT00678340|Active Comparator|2|PVAC
3129235|NCT03205371|Active Comparator|South Korea (Group 3): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
3129236|NCT03205371|Experimental|Thailand (Group 10):MenACYW Conjugate +MMR+Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
3129237|NCT03205371|Experimental|Thailand (Group 11):MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
3179974|NCT00678353||1|Follow-up to S01-01US, conducted to expand information
3489462|NCT03719963||cochlear implant|Cochlear implantation is a powerful tool for helping children with severe to profound sensorineural hearing loss to gain the ability to hear, and to achieve age appropriate communication skills. Evaluating the development of auditory, speech, language skills and the personality of implanted child is useful for the parent, the teacher, the therapist, and the subsequent rehabilitation progress
3489463|NCT03719937|Experimental|anterior chest wall weight|moderate to severe ARDS patients in whom prone positioning is contraindicated. Patients will have a 100 g/kg weight placed on the anterior chest wall, while in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
3489464|NCT03719911|Experimental|Live diabetes coaching program|Live diabetes coaching program
3489465|NCT03719898|Experimental|Brigatinib|90 mg daily orally for 7 days, then 180 mg daily orally during first cycle; 180 daily orally thereafter during every subsequent cycle. Each cycle has 28 days
3489466|NCT03719872||Participants undergoing laparoscopy|Participants undergoing laparoscopic abdominal surgery with surgical insufflation receiving pre-operative transabdominal ultrasound and post-operative transabdominal ultrasound.
3489467|NCT03719859|Experimental|Physical Therapy (PT) Group|Subjects will attend formal physical therapy after surgery.
3489468|NCT03719859|Active Comparator|Home Therapy (HT) Group|Subjects will receive instruction from clinical staff regarding home therapy exercises after surgery.
3489469|NCT03719833||1-control group-T1-T2 N0 M0|"Breast cancer patients in T1 N0 M0 stage at time of diagnose who initial undergo surgical treatment (quadrantectomy/mastectomy + sentinel lymph node biopsy).~All patients will be followed for 5 years after surgery"
3489470|NCT03719833||2-T2-T3 N0 M0|"Breast cancer patients in T2-T3 N0 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by surgery (quadrantectomy/mastectomy + sentinel lymph node biopsy). For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made.~All patients will be followed for 5 years after surgery"
3489471|NCT03719833||3-T1-T3 N1-N2 M0|"Breast cancer patients in T1-T3 N1-N2 M0 stage at time of diagnose who undergo neoadjuvant oncological treatment followed by ultrasound reevaluation of axillary lymph nodes that indicate complete clinical axillary remission. Surgical procedure that would be performed is quadrantectomy/mastectomy + sentinel lymph node biopsy.~Before initiating neoadjuvant treatment biopsy (FNA) proven positive node will be marked with titanium clip and at the time of surgery removed and pathological examined regardless presenting as a sentinel node or not.~For presence of any residual tumor in lymph node(s) at final pathology report, ALND would be made All patients will be followed for 5 years after surgery"
3489472|NCT03719820||Intracranial Atherosclerosis|First-ever stroke patients attributed to intracranial artery stenosis (> 50% or occlusion) who receive aggressive medical management
3489473|NCT03719807|Active Comparator|Control Group|Usual Care No routine outpatient physiotherapy following discharge home post-operatively in line with standard care.
3489474|NCT03719807|Experimental|Intervention Group|12 x Exercise//Rehabilitation sessions Begin at 6 weeks. 6 x weekly sessions Followed by 6 x bi-weekly sessions In line with Accelerated Rehabilitation protocol
3489475|NCT03719794|Active Comparator|Probiotics arm|The active comparator arm will be of a 12-week probiotic supplement regimen (one capsule daily, containing 20 x 109 CFU of Bifidobacterium animalis ssp. Lactis Lafti®B94 and Lactobacillus plantarum R1012)
3489476|NCT03719794|Placebo Comparator|Placebo arm|The placebo comparator arm will be of a 12-week placebo supplement regimen.
3489477|NCT03719781||Group1|patients undergoing pituitary tumor removal surgery will be tested with standardized minimental testing.
3489478|NCT03719755|Active Comparator|50% dextrose|Cystoscopic distention of 40 cc of 50% dextrose plus 300 cc of normal saline washout
3489479|NCT03719755|Placebo Comparator|Normal Saline|Cystoscopic distention media of normal saline.
3489480|NCT03719742|Experimental|Sponsor Test Products|"Baby Bee Foaming Cleanser(at least once daily)~BB Baby Ultra Gentle Lotion (twice daily)"
3489481|NCT03719729|Experimental|Single|Each subject will receive rifaximin 550 mg twice a day for up to one year.
3489482|NCT03719716|Experimental|Early support group|This group receive the Anticipatory care planning letter to take to their GP and the GP receives a copy of the Scottish Anticipatory Care Planning information leaflet and a short communication guide about ACP.
3489483|NCT03719716|No Intervention|Usual care group|No change to standard care from oncology services and primary care
3489484|NCT03719703||Case 1|Children conceived by frozen embryo transfer
3489485|NCT03719703||Case 2|Children conceived by fresh embryo transfer
3489486|NCT03719703||Control|Naturally conceived children
3179975|NCT00678366|Experimental|1|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
3179976|NCT00678366|Active Comparator|2|pure carbon dioxide pneumoperitoneum
3179977|NCT00678405|Active Comparator|WLm / WLnm|Best supportive care
3179978|NCT00678405|Experimental|FTm / FTnm|Breathlessness Intervention Service
3179979|NCT00678431|Placebo Comparator|Arm 1|Liquid placebo
3489487|NCT03719690|Experimental|AIM-HN|Tipifarnib, Oral Tablet. Dose Level 1 orally, bid on days 1-7 and 15-21 of 28-day treatment cycles
3489488|NCT03719690|No Intervention|SEQ-HN|To obtain historical information of first line therapy in subjects enrolled in AIM-HN, in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
3489489|NCT03719664|Experimental|Cohort 1: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks
3489490|NCT03719664|Experimental|Cohort 2: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 2 g every 4 weeks
3489491|NCT03719664|Active Comparator|Control Arm 1: Baseline ART|Subjects continuing on baseline ART
3489492|NCT03719664|Experimental|Cohort 3: albuvirtide & 3BNC117|albuvirtide 0.32 g and 3BNC117 0.8 g every 4 weeks
3489493|NCT03719664|Experimental|Cohort 4: albuvirtide & 3BNC117|albuvirtide 0.16 g and 3BNC117 0.8 g every 4 weeks
3489494|NCT03719664|Experimental|Optimal Dose: albuvirtide & 3BNC117|albuvirtide and 3BNC117 every 2 or 4 weeks
3489495|NCT03719664|Active Comparator|Control Arm 2: Baseline ART|Subjects continuing on baseline ART
3489496|NCT03719651|Experimental|Intervention|"When clinics join the intervention arm, leaders will receive leadership training through the Leadership and Organizational Change for Implementation (LOCI) intervention.~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
3489497|NCT03719651|Active Comparator|Control|"Clinics that are not yet included in the intervention arm, the leaders will not receive any leadership training (LOCI).~Therapists will receive training in evidence-based practices for treatment of Post-Traumatic Stress Symptoms (EMDR, CT-PTSD, TF-CBT)"
3489498|NCT03719638|Active Comparator|D-blade group|Intubation will be done using D-blade of videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
3489499|NCT03719638|Active Comparator|Macintosh group|Intubation will be done using Macintosh videolaryngoscope in a simulated difficult airway Difficult airway will be simulated with collar.
3489500|NCT03719625|Experimental|norepinephrin group|The patients of this group will recieve 0.5 micro gr/kg of norepinephin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
3489501|NCT03719625|Experimental|Ephedrin group|The patients of this group will recieve 0,3mg/kg of Ephedrin intravenously, the infusion will start during the intrathecal injection and during 10 minutes
3129238|NCT03205371|Active Comparator|Thailand (Group 12): MMR + Varicella Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
3179980|NCT00678431|Experimental|Arm 2|Liquid Resveratrol with Glucose, and Malate
3489502|NCT03719573|Experimental|Geriatric intervention|A comprehensive geriatric assessment and intervention, including exercise program.
3489503|NCT03719573|No Intervention|control.|Usual treatment and care.
3489504|NCT03719560|Experimental|CNS prophylaxis protocol|Patients will receive central nervous system prophylaxis protocol using high-dose methotrexate and cytarabine.
3489505|NCT03719547|Experimental|Robot-assisted radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
3489506|NCT03719547|Active Comparator|Abdominal radical hysterectomy|Total radical hysterectomy with Sentinel lymph node biopsy followed by completion pelvic lymphadenectomy
3489507|NCT03719534|Active Comparator|Haplo-SCT|people enrolled in this arm will receive a typical haplo-identical donor SCT
3489508|NCT03719534|Experimental|Haplo-cord SCT|people enrolled in this arm will receive a co-infusion of cord blood unit in addition to a typical haplo-identical donor SCT
3489509|NCT03719521|Experimental|Intervention Arm|"Community-based provision of an integrated package of services over a 24 month period.~For all those aged 16-24 years residing in the intervention clusters: HIV testing, Sexual and reproductive health services (condoms, menstrual hygiene management, contraception, syndromic sexually transmitted infection (STI) treatment, referral for voluntary medical male circumcision, cervical screening), General health information and counselling. For those who are aged 16-24 years and test HIV-positive (or known HIV positive) within the intervention clusters: ART initiation and community-based treatment, adherence support."
3489510|NCT03719521|Active Comparator|Control Arm|Routine existing services
3489511|NCT03719495||Cohort 1|Pre-menopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
3489512|NCT03719495||Cohort 2|Postmenopausal women as healthy controls will be recruited on Duke University Campus and Duke University Hospital.
3489513|NCT03719495||Cohort 3|Pre-menopausal women initiating tamoxifen after standard of care local-regional therapy after surgery +/- radiation.
3489514|NCT03719495||Cohort 4|Pre-menopausal women initiating ovarian suppression plus aromatase inhibition after surgery +/- radiation.
3489515|NCT03719495||Cohort 5|Postmenopausal women initiating endocrine therapy with aromatase inhibition after standard of care surgery +/- radiation.
3489516|NCT03719482|Experimental|[18F]MNI-1054|To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.
3489517|NCT03719469||Green tea group|A total of 100 subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity at the division of rheumatology and clinical immunology at Mansoura University,After starting green tea supplement (4 to 6 cups/day; 60 to 125 mg catechins), patients were evaluated for therapeutic response at baseline and 12, and 24 weeks.
3489518|NCT03719469||control group|fifty healthy normal subjects were included in this study as controls.
3489519|NCT03719443|Experimental|VIS649|A single dose of VIS649 will be administered IV over approximately 1 hour on Day 1, at doses ranging from 0.5 mg/kg up to but not to exceed 20 mg/kg. No other doses will be administered during the study.
3489520|NCT03719443|Placebo Comparator|Placebo|Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
3489521|NCT03719417|Active Comparator|Unicompartmental Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty only
3489522|NCT03719417|Active Comparator|Extensive Biologic Arthroplasty|Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.
3129239|NCT03205371|Experimental|Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
3129240|NCT03205371|Experimental|Mexico (Group 5): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
3489523|NCT03719404|Experimental|sodium hypochlorite group|sodium hypochlorite and EDTA are used in endodontic retreatment cases
3489524|NCT03719404|Experimental|chlorhexidine group|chlorhexidine and citric acid are used in endodontic retreatment cases
3489525|NCT03719391|Experimental|JUUL 5% Virginia Tobacco ENDS|Treatment with JUUL Virginia Tobacco flavored 5.0% ENDS product.
3489526|NCT03719391|Experimental|JUUL 5% Cool Mint ENDS|Treatment with JUUL Cool Mint flavored 5.0% ENDS product.
3489527|NCT03719391|Experimental|JUUL 5% Mango ENDS|Treatment with JUUL Mango flavored 5.0% ENDS product.
3489528|NCT03719391|Experimental|JUUL 5% Creme Brulee ENDS|Treatment with JUUL Creme Brulee flavored 5.0% ENDS product.
3489529|NCT03719391|Active Comparator|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine product.
3489530|NCT03719391|Active Comparator|Nicotine Gum|Treatment with nicorette white ice mint 4mg nicotine polacrilex gum product.
3489531|NCT03719391|Active Comparator|Usual Brand Combustible Cigarette|Treatment with usual brand combustible cigarette.
3489532|NCT03719365|Experimental|NAVAPSV|Each patient enrolled in the study will be submitted to 3 ventilation trials during PSV and NAVA ventilation modes, assigned in a randomized order.
3489533|NCT03719352|Experimental|Deep dry needling|Deep dry needling will be applied in the upper trapezius myofascial trigger point
3489534|NCT03719352|Experimental|Superficial dry needling|Superficial dry needling will be applied in the upper trapezius myofascial trigger point
3489535|NCT03719352|Placebo Comparator|Placebo Gastrocnemius dry needling|A technique simulating dry needling will be applied in the gastrocnemius myofascial trigger point with a needle guard guide tube, without any therapeutic manoeuvre will be applied.
3489536|NCT03719326|Experimental|Dose Escalation-Arm A|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
3489537|NCT03719326|Experimental|Dose Escalation-Arm B|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
3129241|NCT03205371|Active Comparator|Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
3129242|NCT03205371|Experimental|Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
3129243|NCT03205371|Experimental|Russian Federation (Group 8): MenACYW Conjugate Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
3179981|NCT00678457|Experimental|ondansetron/olanzapine|"ondansetron (4 μg/kg b.i.d.)~olanzapine (9 μg/kg)"
3179982|NCT00678457|Placebo Comparator|placebo|placebo
3179983|NCT00678483|Experimental|1|10 mg
3489538|NCT03719326|Experimental|Dose Escalation-Arm C|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period.
3179984|NCT00678483|Experimental|2|20 mg
3179985|NCT00678509|Experimental|A|
3179986|NCT00678548|Experimental|guided imagery|CD
3179987|NCT00678548|Active Comparator|pain diary|Pain diary
3179988|NCT00678600|Active Comparator|Standard (static) Computer Alerts|Participants in this arm will be assigned to standard care. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Provider computer alerts will be posted on the participant's electronic health record summary page.
3179989|NCT00678600|Experimental|Enhanced Computer Alerts|Participants in this arm will be assigned to the enhanced alert arm. Participants will be monitored for new laboratory toxicity, suboptimal follow up, and virologic failure. Providers will receive population and asynchronous computer alerts with improved functionality.
3179990|NCT00678613|Placebo Comparator|1, Primary prophylaxis|"Patients with liver cirrhosis with ascites having ascitic fluid protein <1 gm/dl will be included in this arm.~They will be randomized between probiotics and placebo."
3489539|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 1|The dose given will be determined from the dose escalation part (Arm A).
3489540|NCT03719326|Experimental|Dose Expansion-Ovarian Cancer-Arm 2|The dose given will be determined from the dose escalation part (Arm A).
3489541|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 3|The dose given will be determined from the dose escalation part (Arm B). .
3489542|NCT03719326|Experimental|Dose Expansion-TNBC-Arm 4|The dose expansion will be determined from the dose escalation part (Arm C).
3489543|NCT03719313|Experimental|Group 1|Lonafarnib 50 mg BID + Ritonavir 100 mg BID
3489544|NCT03719313|Experimental|Group 2|Lonafarnib 50 mg BID + Ritonavir 100 mg BID + PEG IFN alfa-2a 180 mcg QW
3489545|NCT03719313|Active Comparator|Group 3|placebo Lonafarnib + placebo Ritonavir + PEG IFN-alfa-2a 180 mcg QW
3489546|NCT03719313|Placebo Comparator|Group 4|placebo Lonafarnib + placebo Ritonavir
3489547|NCT03719287||Hospital #1|Patients who meet inclusion criteria in the first of three participating Brazil hospitals
3489548|NCT03719287||Hospital #2|Patients who meet inclusion criteria in the second of three participating Brazil hospitals
3489549|NCT03719287||Hospital #3|Patients who meet inclusion criteria in the third of the three participating Brazil hospitals
3489550|NCT03719274|Experimental|non-surgical vitamin c depigmentation|locally injected vitamin c is used to depigment the hyperpigmented gingival tissues
3489551|NCT03719274|Active Comparator|surgical depigmentation|the conventional scalpel surgical technique is used to depigment the hyperpigmented gingival tissues
3489552|NCT03719261|Active Comparator|sodium hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
3489553|NCT03719261|Experimental|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
3489554|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR alone(n=10)|HTEA Group + N(LVMI)+ AVR alone(n=10)
3129244|NCT03205371|Active Comparator|Russian Federation (Group 9): PCV13 Vaccine|Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
3489555|NCT03719248|Active Comparator|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)|HTEA Group + ↑ (LVMI)+ AVR alone(n=10)
3489556|NCT03719248|Active Comparator|HTEA Group + N(LVMI)+ AVR + CABG(n=10)|HTEA Group + N(LVMI)+ AVR + CABG(n=10)
3489557|NCT03719248|Active Comparator|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)|HTEA Group +↑ (LVMI)+ AVR + CABG(n=10)
3489558|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)|Control(GA) Group+ N(LVMI)+ AVR alone(n=10)
3489559|NCT03719248|No Intervention|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)|Control(GA) Group+ ↑ (LVMI)+ AVR alone(n=10)
3489560|NCT03719248|No Intervention|Control(GA) Group+ N(LVMI)+ AVR + CABG(n=10)|(GA) Group+ N(LVMI)+ AVR + CABG(n=10)
3489561|NCT03719248|No Intervention|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)|Control(GA) Group+↑ (LVMI)+ AVR + CABG(n=10)
3489562|NCT03719235|Other|column|ultra-low dose CBCT versus digital panoramic radsiography
3489563|NCT03719209|Placebo Comparator|Standard Practice|Patients and families will be shown images of their endoscopic procedure per standard practice.
3489564|NCT03719209|Experimental|Virtual Reality|Patients and families will be showed the results of their endoscopic procedure via a virtual reality application called HealthVoyager, in addition to standard practice images.
3489565|NCT03719196|Experimental|Reading glass provided|"Randomization took place after conducting the census survey. Participants were selected based on the inclusion criteria.~423 random households were surveyed at the baseline. These households have been given reading glasses free of cost."
3489566|NCT03719196|No Intervention|Non-reading glass|A total of 824 households were surveyed at the baseline survey. Among them, 423 households have been provided reading glasses. The 401 remaining households were not given reading glasses during the baseline survey. The endline survey will be conducted in March 2018. Upon completing the endline survey, the non-reading glasses group will be provided reading glasses.
3489567|NCT03719183||Acute Myeloid Leukemia (AML) group|"Patients who are diagnosed as Acute Myeloid Leukemia based on peripheral blood, bone marrow aspiration and immunophenotyping and fulfill WHO criteria for diagnosis.~Fluorescent in Situ Hybridization (FISH) Panels for AML, Multiplex FISH (M-FISH) and Conventional Cytogenetics Studies will be performed for AML patients."
3489568|NCT03719157|Active Comparator|Unilateral ESP Block|Before general anaesthesia, Ultrasound guided unilateral ESP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
3129245|NCT03205488|Active Comparator|Cohort 1|Moderate to Advanced PD Population Randomized 1:1:1
3129246|NCT03205488|Active Comparator|Cohort 2|Early/de novo Randomized 2:1
3489569|NCT03719157|Active Comparator|Unilateral OSTAP block|Under general anaesthesia, Ultrasound guided unilateral OSTAP block will perform with 15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
3489570|NCT03719157|Active Comparator|Injection of Local Anesthetic to Trocar Insertion|After the laparoscopic surgery was completed, the trocar incision sites were closed. Following the infiltration rules, local anesthetic (15 ml of 0.5% bupivacaine and 5 ml 2% lidocaine) was applied to the trocar sites of skin, fascia, muscle, and preperitoneal area by the surgical team after the operation. A total of 20 mL of local anesthetic was used, with 6 mL for trocar sites of 10 mm, and 4 mL for trocar sites of 5 mm .Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
3489571|NCT03719157|Sham Comparator|multimodal analgesia|Perioperative and postoperative routine analgesic protocol will be performed with no additional regional anesthesia method.Patient controlled analgesia (PCA) with tramadol will apply to the all patients. Postoperative pain assessment and opioid consumption will record till the postoperative 24 th hours.
3489572|NCT03719144||Patients|Patients registered on ResearchMatch.org with Atrial Fibrillation as a medical condition; or who participate in afib-related social media platforms and confirm a diagnosis of afib, will be invited to participate in this study. Patients will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
3489573|NCT03719144||Providers|Providers who have contributed at least 25 Atrial Fibrillation patients to the Symphony pharmacy claims dataset will be contacted to participate. Interested providers will be consented using an online consent form and then will be asked to complete 1 survey that contains scenarios and ranking questions.
3129247|NCT03205566|Active Comparator|Arm A Raltegravir, then Raltegravir/Lamivudine|7 days Raltegravir 400mg bd followed by minimum 4 weeks wash out and then 7 days Raltegravir 400mg/lamivudine 150mg (oral tablets) bd.
3489574|NCT03719131|Active Comparator|Arm A (standard of care)|This is standard of care arm: induction with 4 cycles (21 days each) of Ipilimumab and nivolumab followed by continuation with nivolumab alone every month X1 year (13 doses).
3489575|NCT03719131|Experimental|Arm B (rituximab, hyaluronidase human)|This includes induction with 4 cycles of ipilimumab and nivolumab X 4 cycles followed by continuation with nivolumab alone every month for 1 year as in standard of care arm. Each induction cycle is 21 days and includes ipilimumab on day 1 plus nivolumab on day 1. In addition, patients will receive 4 weekly doses of Rituxan (first dose intravenously and then 3 weekly doses subcutaneously). First dose of Rituxan will be administered one week following the start of cycle 1 of ipilimumab and nivolumab. All treatments will have a +/-3 business day window for administration.
3489576|NCT03719118|Experimental|Genotyping group|The patients undergo pretreatment of genotyping for three genes (TPMT, NUDT15 and FTO)
3489577|NCT03719118|Active Comparator|Non-genotyping group|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping.
3489578|NCT03719105|Experimental|Cohort 1|"Patients with aggressive NK cell leukemia or stage III or IV extranodal NK/T-cell lymphoma, nasal type.~Chemotherapy Regimen:~mSMILE: Methotrexate Day 1, Ifosfamide Days 2-4, Dexamethasone Days 2-4, Etoposide Days 2-4, calaspargase pegol Day 8. For patients in CR and no available allogeneic SCT can receive up to 2 additional cycles of mSMILE.~Pembrolizumab: For patients in PR/MR/NR/PD after 2 cycles of mSMILE.~Allogeneic Stem Cell Transplant if donor available and not in PD."
3489579|NCT03719105|Experimental|Cohort 2|"Patients with stage III or IV peripheral T-cell lymphoma-NOS, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, or enteropathy-associated T-cell lymphoma (other histologies will be considered after case-by-case discussion with Study Chairs and Executive Vice-Chairs).~Chemotherapy Regimen:~Cycle 1 & 2: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 3 & 5: Brentuximab vedotin Day 1, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Cycle 4 & 6: Pralatrexate Days 1, 8, and 15, cyclophosphamide Day 1, DOXOrubicin Day 1, predniSONE days 1-5 Allogeneic Stem Cell Transplant if donor available and not in PD."
3489580|NCT03719092|Experimental|Prevention (vitamin A compound)|Participants receive vitamin A compound PO or enterally once prior to stem cell transplant.
3489581|NCT03719079||Heart Failure Patients|Patients with primary diagnosis as heart failure
3489582|NCT03719066|Active Comparator|DIG 1 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered two weeks after the first dose.
3489583|NCT03719066|Experimental|DIG 2 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 6 months after the first dose.
3489584|NCT03719066|Experimental|DIG 3 (dose interval group)|This group will receive two doses of killed whole cell oral cholera vaccine. The second dose being administered 11 months after the first dose.
3489585|NCT03719053|Experimental|Truvada|single oral dose of Truvada® (300 mg tenofovir disoproxil fumarate)
3489586|NCT03719027|Experimental|Study population|Patients followed-up after the diagnosis of pulmonary embolism (PE) Patients who survived after a PE and who consent to participate to the prospective interventional phase of the PREVA-CTEPH study have dyspnea assessment, EKG, and echocardiography to investigate the diagnosis of CTEPH
3489587|NCT03719014|Experimental|NovaCross|the NovaCross is a guidewire positioning and support micro-catheter for improving chronic total occlusion (CTO) crossability. The NovaCross gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extandable segment, both at its distal tip.
3489588|NCT03719001|Experimental|Phenylephrine|Phenylephrine (100 ug/ml) infusion will be used to increase blood pressure by 20 mmHg
3489589|NCT03719001|Experimental|Dexmedetomidine|Dexmedetomidine infusion will be used to increase blood pressure by 20 mmHg
3489590|NCT03719001|Experimental|Clevidipine|Clevidipine infusion will be used to increase blood pressure by 20 mmHg
3489591|NCT03719001|Experimental|Calcium Chloride|Calcium Chloride will be administered to increase blood pressure and to increase blood calcium concentration
3129248|NCT03205566|Active Comparator|Arm B Raltegravir/Lamivudine, then Raltegravir|Raltegravir 400mg + Lamivudine 150mg tablet, taken twice a day for 7days followed by a minimum of 4 weeks wash out and then 7 days Raltegravir 400mg bd.
3129249|NCT03206073|Experimental|1/Arm A1 Pexa-Vec + Durvalumab|Pexa-Vec escalation dose levels + Durvalumab
3489592|NCT03719001|Experimental|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be used to increase peripheral vascular tone
3489593|NCT03719001|Experimental|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm.
3489594|NCT03718988|Experimental|Meat Phase first|Participants will be asked to consume traditional meat products for 8 weeks, then switch to plant-based meat alternative products for another 8 weeks.
3489595|NCT03718988|Experimental|Plant Alternative Phase first|Participants will be asked to consume plant-based meat alternative products for 8 weeks, then switch to traditional meat products for another 8 weeks.
3489596|NCT03718975|Experimental|Successor of Phonak Audéo B90|The successor of the Phonak Audéo B90 is a Receiver-in-the-canal Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss.
3489597|NCT03718975|Active Comparator|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
3489598|NCT03718962|Active Comparator|needling|needling + phototherapy
3129250|NCT03206073|Experimental|2/Arm A2 Pexa-Vec +Durvalumab|Maximum tolerated dose (MTD) of Pexa-Vec after the MTD is established +Durvalumab
3489599|NCT03718962|Placebo Comparator|phototherapy|phototherapy
3129251|NCT03206073|Experimental|3/Arm B1 Pexa-Vec + Durvalumab +Tremelimumab|Pexa-Vec escalation dose levels + Durvalumab +Tremelimumab
3129252|NCT03206073|Experimental|4/Arm B2|MTD of Pexa-Vec after the MTD is established+Durvalumab + Tremelimumab
3129253|NCT03206749|Experimental|VX-150|
3129254|NCT03206749|Active Comparator|Hydrocodone Bitartrate/Acetaminophen (HB/APAP)|
3489600|NCT03718884|Experimental|Drug Cocktail|Drug cocktail administered orally once in Period 1
3489601|NCT03718884|Experimental|Mirikizumab + Drug Cocktail|Drug cocktail administered orally once in Period 2 (day 116). Mirikizumab administered subcutaneously (SC) on multiple occasions in Period 2.
3489602|NCT03718845||Peer Counselors|Mind-Body Medicine Curriculum
3489603|NCT03718832|Experimental|Treatment Group-Begin Now|"Group 1- Will be randomized to the treatment (Begin Now) group for the Fresh Food Farmacy program. Subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program right away when the program opens in their geographic area. Data will be collected during the first 12 months of subject participation and EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total)."
3129255|NCT03206749|Placebo Comparator|Placebo|
3489604|NCT03718832|No Intervention|Control Group-Begin Later|"Group 2- Will be randomized to the control (Begin Later) group for the FFF program. These subjects will be consented to join the FFF study prior to learning their program start date. They will join the FFF program approximately 6 months after the program opens in their geographic area. Data will be collected during the first 6 months of subject participation and used as control data for the study. EHR and claims data may be analyzed for an additional 12 month follow-up period (24 months in total from the start of the trial)."
3489605|NCT03718806|Experimental|Regimen A|3 g zoliflodacin oral suspension; oral administration after an overnight fast
3489606|NCT03718806|Experimental|Regimen B|3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
3489607|NCT03718806|Experimental|Regimen C|4 g zoliflodacin oral suspension; oral administration after an overnight fast
3489608|NCT03718806|Experimental|Regimen D|4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast
3129256|NCT03206788|Experimental|Losartan group|Participant will receive the Losartan intervention and will take 50 mg losartan orally once daily for week 1, followed by 50 mg orally twice daily on weeks 2-12 (unless weight adjustment needed).
3129257|NCT03206788|Placebo Comparator|Placebo group|Participant will receive the placebo intervention, matching the Losartan intervention, once daily for week 1, followed by twice daily on weeks 2-12.
3129258|NCT03206918|Experimental|Zanubrutinib|
3489609|NCT03718780|Experimental|A1: Patient in intensive care|"Patient in intensive care (n=10):~in patients in the intensive care unit of the Centre Hospitalier Metropole Savoie (Chambéry, France), where repeated arterial blood gas analysis is routinely performed (Patients equipped for their usual care with an arterial catheter, enabling repeated arterial blood gas determination ).~PaCO2 and Pt CO2 will be measured simultaneously at rest, and during conditions inducing PaCO2 modifications (ventilator settings modifications, or exercise as per routine rehabilitation) Comparison will be done between arterial PaCO2 and PtCO2"
3489610|NCT03718780|Experimental|A2: Healthy subjects|"Healthy subjects performing a voluntary hyperventilation, in the laboratory room where routine exercise testing is usually done.~Comparison will be done between arterialized PaCO2 and PtCO2, at rest, and during an induced voluntary hyperventilation."
3489611|NCT03718780|Experimental|B1: Healthy subject|"Subjects, referred for exercise diagnostic testing, and whose results indicate normal cardiac and pulmonary exercise physiology.~Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points."
3489612|NCT03718780|Experimental|B2: Chronic Obstructive Pulmonary Disease|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
3489613|NCT03718780|Experimental|B3: Interstitial Lung Disease (ILD)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
3129259|NCT03206970|Experimental|Zanubrutinib|Zanubrutinib (160 milligrams) administered orally twice daily
3129260|NCT03207022|Active Comparator|lidocaine 2% with normal saline|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with 2 ml of 0.9% normal saline.
3129261|NCT03207022|Experimental|lidocaine 2% with clonidine|Patients will receive ultrasound guided axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine mixed with clonidine 1µg/kg in 2 ml of 0.9% normal saline.
3129262|NCT03207035|Active Comparator|20 ml of lidocaine 2% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 2% with epinephrine.
3129263|NCT03207035|Experimental|40 ml 0f lidocaine 1% with epinephrine|Patients will receive axillary brachial plexus block with 20 ml of lidocaine 1% with epinephrine diluted with 20 ml of nacl 0.9% ( total 40 ml)
3129264|NCT03207074|Other|All patients|Single study arm. All patients who participate in the study will receive conventional histological diagnosis and diagnosis with the new technology (iKnife)
3129265|NCT03207243|Experimental|Subjects receiving GSK3772847|Eligible subjects will receive GSK3772847 once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
3489614|NCT03718780|Experimental|B4: Chronic heart failure (CHF)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
3489615|NCT03718780|Experimental|B5: Pulmonary Arterial Hypertension (PAH)|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
3489616|NCT03718780|Experimental|B6: inappropriate hyperventilation syndrome|Measurement, throughout these exercise tests, of the alveolar dead space, and its kinetics, up to peak VO2, then during recovery, in the different conditions listed above. Alveolar dead space will be calculated using the continuous Pt CO2 values observed, and also with some intermittent PaCO2 measurement, done as per routine modus operandi (arterialized earlobe capillary drawn at rest, at ventilatory threshold, and at peak exercise). The values measured through PtCO2 and PaCO2 will be compared at these 3 time points.
3489617|NCT03718741|Experimental|Adiuvant Radiotherapy +/- CT|"The radiation treatment will be delivered with two possible schedules, according to the presence of positive margins on the pathology specimen:~R0: PTVb + PTVn 50 Gy in 25 fractions~R1-2: PTVn 50 Gy in 25 fractions. PTVb (including cystectomy bed and residual tumor when present) 55 Gy in 25 fractions with simultaneous integrated boost (SIB).~Considering an alfa/beta of 10 for bladder tumor and 3 for healthy tissues the equivalent doses will be respectively:~BED10: 60/67.1; EQD2: 50/55.92 Gy BED3: 83.33/95.33; EQD2: 50/57.20 Gy~Patients with ECOG PS<2, good haematological, hepatic and renal function (haemoglobin, neutrophil count, platelets, creatinine, glycaemia, Bilirubin, AST, ALT values within the limits of normal), will be submitted to concurrent cisplatin based weekly chemotherapy, 20-30 mg/m2, if they have not received neoadjuvant chemotherapy before surgery."
3489618|NCT03718728|Active Comparator|Standard group|A personalized diet and physical exercise recommendations.
3129266|NCT03207243|Placebo Comparator|Subjects receiving placebo drug|Eligible subjects will receive placebo once every 4 weeks via IV route along with 500/50 mcg FP/Sal twice daily for first 2 weeks and dose of FP was reduced by approximately 50 percent at every 2 weeks until complete FP discontinuation.
3129267|NCT03207386|Experimental|Youth VIP|Youth VIP is a youth-led set of prevention strategies. Youth and their adult mentors are trained in evidence based sexual assault primary prevention strategies at a three day youth summit. The summit is followed by participation in working groups in which youth and their adult mentors will adapt best practices for sexual assault prevention to the Rapid City community and diffuse these strategies through both their own social networks and more formally in work in Rapid City middle and high schools.
3489619|NCT03718728|Experimental|Mind&Life (standard + intervention) group|A personalized diet and physical exercise recommendations plus the acceptance and mindfulness-based group intervention program.
3489620|NCT03718715||prospective cohort|All participants receive Metformin in accordance to the ordinary therapy practice. They will be part of one subject group/cohort. After onset of metformin treatment the subjects who develop gastrointestinal side effects will be compared with cases without gastrointestinal side effects.
3489621|NCT03718702|Experimental|Intervention group|ePain will be accessible by the intervention group.
3489622|NCT03718702|No Intervention|Control group|No intervention will be applied to control group and they can download an educational pamphlet only.
3489623|NCT03718689|Experimental|Group L|The second group of teeth (Group L) were etched with Er:YAG laser.
3489624|NCT03718689|Experimental|Group A+L|The third group of teeth (Group A+L) were etched with both Er:YAG laser and phosphoric acid.
3489625|NCT03718689|No Intervention|Group A|The first group of teeth (Group A) were not etched with Er:YAG laser.
3489626|NCT03718676|Other|Ferric sulphate|Group FS. Teeth in this goup will pulpotomized with ferris-sulphate.
3489627|NCT03718676|Experimental|Orto-mta|Group O-MTA.Teeth in this goup will pulpotomized with Ortho-mta.
3489628|NCT03718676|Experimental|Retro-mta|Group R-MTA. Teeth in this goup will pulpotomized with Retro-mta.
3489629|NCT03718663||Knee OA patients (part 1)|Painful knee OA patients signed up for standardized exercise therapy
3489630|NCT03718663||Healthy subjects (part 2)|Healthy subjects (age 18-28) signed up military service in Defence Command Denmark
3489631|NCT03718650|Experimental|Scans, Surgical Resection and Assessment|Pre-surgery scans, surgical resection and post-surgery pathological assessment. All patients will receive standard of care imaging and blood tests. If suitable, non-standard of care abdominal MRI imaging will be done. 16-24 hours prior to surgery, patients will be administered a single dose of 0.5 g/m^2 pimonidazole (HydroxyProbe).
3489632|NCT03718637|Active Comparator|Control|Surgical treatment alone, consisting of tendon debridement and repair. Ultrasounds preoperatively and 6 months postoperatively.
3489633|NCT03718637|Experimental|Experimental|Identical surgical treatment plus Smith & Nephew bio-inductive patch implant. Ultrasounds preoperatively and 6 months postoperatively.
3489634|NCT03718624|Experimental|paclitaxel,apatinib and S-1|
3489635|NCT03718611|Experimental|Sequence 1|BR900A - Wash out - BR9001
3489636|NCT03718611|Experimental|Sequence 2|BR9001 - Wash out - BR900A
3489637|NCT03718598||Carpal tunnel syndrome|Patients with mild and moderate carpal tunnel syndrome
3489638|NCT03718598||normal|Patients without mild and moderate carpal tunnel syndrome
3489639|NCT03718585||nocturnal group|Chronic kidney disease patients with nocturnal hypertension
3489640|NCT03718585||non-nocturnal group|Chronic kidney disease patients without nocturnal hypertension
3489641|NCT03718585||non-CKD group|patients without chronic kidney disease
3489642|NCT03718572||Scoring factors|
3489643|NCT03718572||Difficulty criteria|
3489644|NCT03718559|Experimental|Edoxaban alone|
3489645|NCT03718559|Active Comparator|Combination of edoxaban plus single antiplatelet|
3489646|NCT03718546||Sibling pediatric donors|
3489647|NCT03718546||Sibling recipients and caregivers|
3489648|NCT03718546||Non-donor sibling|From the donor-recipient families
3489649|NCT03718546||Non-donor siblings|Of patients receiving unrelated transplants
3489650|NCT03718546||Healthy comparison|A matched sample
3489651|NCT03718533|Experimental|Eltrombopag|Patients will receive eltrombopag orally once daily up to 36 weeks.
3489652|NCT03718507|Active Comparator|GROUP Fentanyl|patients will receive atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes) before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
3489653|NCT03718507|Experimental|GROUP Sucrose|patients will be given atropine (0.01-0.02 mg/kg i.v. bolus) and oral sucrose 24% (0.5 ml) 2 minutes before LISA in addition to standard care (wrapping). NIRS will be monitored during the whole procedure, which will be video-recorded.
3489654|NCT03718494|Experimental|Follow up|Subjects will receive F-18 Florbetapir PET
3489655|NCT03718494|Experimental|Follow up - Mayo Clinic Sites only|Subjects will receive F-18 AV-1451 PET and F-18 Florbetapir PET
3489656|NCT03718481||Surgical Trainees|Trainee membership of the Association of Surgeons in Training (ASiT) in the UK and the Republic of Ireland
3489657|NCT03718468|Experimental|GC Flu Quadrivalent|
3489658|NCT03718468|Active Comparator|Fluarix tetra|
3489659|NCT03718442||Breast cancer patients - lumpectomy|Women who are 18 years or older, have Ductal carcinoma in situ (DCIS) or invasive breast-conserving surgery, have not had previous chest radiotherapy. 20 patients who meet above study population criteria will be enrolled in this study.Shaved margins for each lumpectomy site will be excised with either Bovie (3 sides) or PhotonBlade (3 sides) for each patient. The effect of PhotonBlade vs Bovie on pathology assessment of lumpectomy shaved surgical margins will be compared.
3489660|NCT03718429|Experimental|aspirin|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
3489661|NCT03718429|Experimental|aspirin and clopidogrel|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
3489662|NCT03718429|Experimental|aspirin and ticagrelor|Patients will be treated with adjunctive low-dose rivaroxaban (2.5 mg/bid) for 7-10 days, after which aspirin therapy will be suspended for 7-10 days.
3489663|NCT03718429|No Intervention|rivaroxaban|A control cohort of subjects with atrial fibrillation on full dose rivaroxaban (20 mg/qd) as per standard of care will be recruited and will undergo a single PD assessment.
3129268|NCT03207399|Other|Epclusa|Epclusa (sofosbuvir 400mg/velpatasvir 100mg) 1 tablet oral or via tube daily for 12 weeks, taken with or without food.
3489664|NCT03718403|Experimental|Single arm open labeled intervention study|Subjects with PHP will be given theophylline to decrease the end organ resistance by increasing levels of cAMP, a second messenger. Theophylline will be dosed twice a day for a period of 52 weeks.
3489665|NCT03718390|Experimental|Sentinel Group 1 LYN-PLT|Sentinel dosing in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
3489666|NCT03718390|Experimental|Sentinel Group 2 LYN-PLT|Sentinel dosing (second) in endoscopy center of one of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized randomized, observer blind) and evaluation of gastric retention by MRI
3489667|NCT03718390|Experimental|Group 3 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind). and evaluation of gastric retention by MRI
3129269|NCT03207438|Experimental|Quetiapine XR 50mg|Quetiapine XR 50mg OD for 6 weeks
3489668|NCT03718390|Experimental|Group 4 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI
3489669|NCT03718390|Experimental|Group 5 LYN-PLT|Dosing in clinic of two of each formulation (A, B, C, D, E) in a 1:1:1:1:1 ratio (centralized, randomized, observer blind) and evaluation of gastric retention by MRI.
3489670|NCT03718377|Experimental|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
3489671|NCT03718377|Active Comparator|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
3489672|NCT03718351|Active Comparator|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
3489673|NCT03718351|Experimental|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
3489674|NCT03718338||Clinical Evaluations|Patients undergo clinical evaluations over 12 months including physical exam and vital signs, waist to hip circumference, medical history and events, laboratory evaluations, imaging evaluations, cognitive function evaluations, gait assessment, and quality of life questionnaires.
3489675|NCT03718312|Experimental|Arm 1|Patients with aortic clamping withpre-conditioning
3129270|NCT03207438|Placebo Comparator|Placebo 1|Placebo OD for 6 weeks
3129271|NCT03207438|Experimental|Quetiapine XR 150-300mg|Quetiapine XR 150-300mg OD for 6 weeks
3129272|NCT03207438|Placebo Comparator|Placebo 2|Placebo OD for 6 weeks
3489676|NCT03718312|No Intervention|Arm 2|Patients with aortic clamping without pre-conditioning
3489677|NCT03718286|Experimental|Alirocumab|
3489678|NCT03718286|Sham Comparator|Sham Control|
3489679|NCT03718273|Active Comparator|Digoxin|Digoxin 0,25 mg. The initial dose will be based on whether there are factors such as age over 80 years, weight under 60 kg and creatinine clearance <60ml / min,
3489680|NCT03718273|Experimental|Ivabradine|Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.
3489681|NCT03718234|Experimental|Subcutaneous Hydrocortisone via Infusion Pump|Patients will receive a subcutaneous injection of hydrocortisone (HC). Each patient's total daily dose (TDD) of oral tablet hydrocortisone to determine the doses to be delivered of the study drug. The 24-hr schedule and percentage of the TDD of HC will be as follows: approximately 60% of the TDD of HC will be delivered in 3 equal pulses at 0300, 0600 and 0900. Another 35% will be delivered in 3 equal pulses at 1200, 1500 and 1800 and the remaining 5% at 2100 and 2400.
3489682|NCT03718234|Active Comparator|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
3489683|NCT03718208|Experimental|Paediatric formula|"Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake."
3489684|NCT03718195|Other|Pediatric formula|"Each child will receive a new formula for a period of seven days. The new formula is a nutritionally complete standard enteral tube feed, with ingredients derived from real food. The formula is a food for special medical purposes for use under medical supervision.~The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube"
3489685|NCT03718182|Active Comparator|Arm A - Cholecalciferol 400iu|Vitamin D3 (Cholecalciferol) 400 iu. Daily oral capsule. To be taken for 24 weeks (6 months)
3489686|NCT03718182|Experimental|Arm B - Cholecalciferol 3200iu/800iu|"Vitamin D3 (Cholecalciferol) supplement 3,200iu daily oral capsule. To be taken for 12 weeks (3 months).~Then switch to vitamin D3 supplement 800iu daily oral capsule. To be taken for 12 weeks (3 months)."
3489687|NCT03718169||Hong Kong female smokers|Hong Kong female smokers will be invited to fill in questionnaires about their current smoking situation and quit intention.
3489688|NCT03718156|Experimental|PREPARED Trial Intervention|Participating nursing staff will be trained to apply the PREPARED Trial interventions, and will apply this knowledge to modify the therapeutic nursing plans of residents under their care who are enrolled in the study, accordingly.
3489689|NCT03718156|No Intervention|Care as Usual|Participating nursing staff will only be provided with general information about delirium, but will not be trained or instructed to modify the therapeutic nursing plans that are in place for residents enrolled in the study. However, at the end of the follow-up period, nursing staff in the control arm will be provided with the PREPARED Trial intervention training program (including bedside coaching), which they can then use after the study has ended at their facility.
3489690|NCT03718130|Experimental|Group 1: 0.6 mg HTNV - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489691|NCT03718130|Experimental|Group 2: 3.0 mg HTNV - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489692|NCT03718130|Experimental|Group 3: 0.6 mg PUUV - Intradermal (ID)|0.1 mL 6.0 mg/mL PUUV DNA + 0.1 mL 0.9% saline (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489693|NCT03718130|Experimental|Group 4: 3.0 mg PUUV - Intramuscular (IM)|0.5 mL 6.0 mg/mL PUUV DNA + 0.5 mL 0.9% saline (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489694|NCT03718130|Experimental|Group 5: 1.2 mg HTNV/PUUV (0.6 mg each) - Intradermal (ID)|0.1 mL 6.0 mg/mL HTNV DNA + 0.1 mL 6.0 mg/mL PUUV DNA (ID) The HTNV and PUUV DNA vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489695|NCT03718130|Experimental|Group 6: 6.0 mg HTNV/PUUV (3.0 mg each) - Intramuscular (IM)|0.5 mL 6.0 mg/mL HTNV DNA + 0.5 mL 6.0 mg/mL PUUV DNA (IM) The HTNV and PUUV DNA vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
3489696|NCT03718104||Naltrexone|Pregnant women with opioid use disorder on prescribed oral or extended-release naltrexone and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This group will also receive safety and efficacy interventions.
3489697|NCT03718104||Buprenorphine/Naloxone|Pregnant women with opioid use disorder on prescribed buprenorphine/naloxone and their infants. Biospecimens collected from this group will undergo genetic and epigenetic analysis and the group will also receive safety and efficacy interventions.
3489698|NCT03718104||Naltrexone - alcohol use disorder|Pregnant women with alcohol use disorder on prescribed naltrexone (oral or extended-release) and their infants. Biospecimens collected from this group will undergo pharmacokinetic analysis, genetic and epigenetic analysis, and breast milk analysis. This exploratory group will also receive safety and efficacy interventions.
3489699|NCT03718091|Experimental|Cohort T1: ATRX-mutant Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489700|NCT03718091|Experimental|Cohort T2: Truncating ATM Mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489701|NCT03718091|Experimental|Cohort T3: Other HR Gene Mutations|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489702|NCT03718091|Experimental|Cohort 1A: Osteosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489703|NCT03718091|Experimental|Cohort 1B: Leiomyosarcoma|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489704|NCT03718091|Experimental|Cohort 2: Truncating ATM mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489705|NCT03718091|Experimental|Cohort 3A: Germline BRCA mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489706|NCT03718091|Experimental|Cohort 3B: Other HR Alteration|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489707|NCT03718091|Experimental|Cohort 4A: MYC amplification, FBXW7 mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489708|NCT03718091|Experimental|Cohort 4B: Cyclin E amplification|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489709|NCT03718091|Experimental|Cohort 5: ARID1A mutation|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489710|NCT03718091|Experimental|Cohort T4: SDH-Mutant GIST|M6620 will administered intravenously on days 1,4, 8, 11, 15, 18, 22, 25 on a 28-day cycle.
3489711|NCT03718078|Experimental|Confocal Laser Endomicroscopy|lt includes patients will undergo probe-based Confocal Laser Endomicroscopy during laparoscopic hepatic masses resection.
3489712|NCT03718065|Experimental|Lofexidine Men|Men will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
3489713|NCT03718065|Experimental|Lofexidine Women|Women will receive lofexidine (Lucemyra) for 5 weeks. Titration schedule is as follows: 0.36 mg on the first two evenings, 0.36 mg in the morning and evening on days 3 and 4; 0.36 mg in the morning, afternoon, and at bedtime on days 5 and 6; 0.36 mg in the morning and afternoon and 0.72 mg at bedtime on days 7 and 8; 0.36 mg in the morning and 0.72 mg in the afternoon and at bedtime on days 9 and 10, and 0.72 mg in the morning, afternoon and at bedtime on Day 11 and throughout the rest of the study.
3489714|NCT03718065|Placebo Comparator|Placebo Men|Men will receive matching placebo for five weeks.
3489715|NCT03718065|Placebo Comparator|Placebo Women|Women will receive matching placebo for five weeks.
3489716|NCT03718052|Experimental|Early valve surgery (EVS)|Cardiac surgery as soon as possible within 72 hours of randomization
3489717|NCT03718052|Active Comparator|Conventional care|Conventional care according to the 2015 European guidelines.
3489718|NCT03718039|Experimental|Treatment Group 1|HTX-011
3489719|NCT03718039|Experimental|Treatment Group 2|aprepitant
3179991|NCT00678613|Active Comparator|2, secondary prophylaxis|"Patients with liver cirrhosis with ascites having history of prior SBP will be included in this arm.~They will be randomized between probiotics and norfloxacin."
3489720|NCT03718039|Experimental|Treatment Group 3|HTX-011 and a scheduled multimodal analgesic regimen (oral ibuprofen and acetaminophen).
3489721|NCT03718026||Patients with Multiple Sclerosis|"The timed 360° turn test~Berg Balance Scale~Timed Up and Go test~Functional Reach Test~One-leg stance test~Four square step test"
3489722|NCT03718026||Healthy Controls|-The timed 360° turn test
3489723|NCT03718013|Experimental|accelerated dTMS|
3489724|NCT03718013|Active Comparator|standard dTMS|
3489725|NCT03717987|Active Comparator|Botulinum toxin A injection|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
3489726|NCT03717987|Active Comparator|Zinc supplementationj prior to Botulinum toxin A injection|"Patients in the intervention group will take zinc supplement tablets to increase zinc levels for 4 days before botulinum toxin injections. While patients in the control group will take placebo tablets 4 days prior to the injections. All tablets will be placed in envelopes for blinding the operator, and numbered by a supervisor to allocate patients again in their groups for statistical results. Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women."
3489727|NCT03717974|Experimental|telemedecine's follow-up|Telemedecine follow-up after an intervention at home of the mobile team
3489728|NCT03717974|Active Comparator|mobile team's follow-up|Mobile team follow-up after an intervention at home of the mobile team
3179992|NCT00678626|Experimental|Arm A|combination of CP-751,871 + docetaxel administered
3179993|NCT00678626|Active Comparator|Arm B|chemotherapy
3489729|NCT03717961|Experimental|" BTX-A group"|"BOTOX® solution~Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~BOTOX 100 UNITES (Allergan, Courbevoie, France, and São Paulo, Brazil) Single injection schedule of BOTOX® in both hands, diluted in 2 ml of sterile serum saline, with a dosage of 50 UI (1 ml) by hand. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site)~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
3489730|NCT03717961|Placebo Comparator|Placebo group|"Saline serum~lidocaine/prilocaine cream~Nitrous oxide/oxygen (50%/50%)~Intervention Description :~Sterile saline solution Single injection schedule of 2 ml (1 ml by hand) of serum saline, in both hands. Injections will be performed at the level of the distal palmar crease, targeting the neurovascular bundles in the 4 web spaces (0.25 ml/injection site).~between 2 to 3 hours before the procedure, application of lidocaine/prilocaine cream under an occlusive dressing (polyurethane film) in each palmar crease of the patients (1/2 tube/hand), according to the recommendations of the manufacturer of the lidocaine cream.~inhaled nitrous oxide/oxygen (50% / 50%) may be used, if needed"
3179994|NCT00678678|Active Comparator|I - Spirometer|
3179995|NCT00678678|Active Comparator|II - Kit Epap®|Device with Spring load by mask,produced by Brazil (critical med)
3489731|NCT03717948|Experimental|CTL - BFR|CTL Exercise then BFR Exercise
3489732|NCT03717948|Experimental|BFR - CTL|BFR Exercise then CTL Exercise
3129273|NCT03207750|Experimental|HRV PCV-free Liq Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in PCV-free liquid formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4). PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
3129274|NCT03207750|Active Comparator|HRV Lyo Group|Healthy female or male subjects, between and including 6 and 12 weeks (42-90 days) of age at the time of the first study vaccination who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, according to a 0, 2-month schedule, co-administered with one dose of each Pediarix, Hiberix and Prevnar-13 at three timepoints (day 1, month 2 and month 4).
3489733|NCT03717935|Experimental|Essential Amino Acid (EAA) Supplement|4 weeks: Essential Amino Acid Supplement- 15g 2/day
3489734|NCT03717935|Placebo Comparator|Placebo|4 weeks: Placebo- 15g 2/day
3489735|NCT03717922|Experimental|MRI ultrasound sonication|Low Intensity focused ultrasound pulsation will be administered to participants while they are in the fMRI scanner. Functional and perfusion MR data will be collected before and after the sonication to allow for comparisons and investigation of pre and post sonication functional activation and connectivity.
3489736|NCT03717922|Sham Comparator|Sham Ultrasound|While in the fMRI scanner, participants will have the ultrasound transducer attached to their head in the same manner as during the actual ultrasound sonication. However, during this portion of the experiment, the transducer will not be turned on. Previous, published experiments indicate that participants are unable to differentiate between when the transducer is on and off.
3489737|NCT03717909|Experimental|Experimental Group|Sodium Valproate 200Mg E/C Tablet (active treatment)
3489738|NCT03717909|Placebo Comparator|Control Group|Sodium Valproate matched placebo (inactive treatment)
3489739|NCT03717883||Healthy subjects|
3489740|NCT03717883||Subjects with ADPKD|
3129275|NCT03207763|Experimental|Cohort 1|Participating infants and children will receive Microneedle Formulation 1. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
3489741|NCT03717870|Experimental|Surgery|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
3489742|NCT03717870|Active Comparator|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
3489743|NCT03717857||Caregiver InDepth Interviews|Caregivers who have a child between the ages of 11-13, who attends 6th-8th grades in one the targeted schools, and who resides in one of the targeted public school districts identified by zip code. In RI , caregivers will identity as Latino . Caregivers will participate in a one time in-depth qualitative interview regarding their child's sleep.
3179996|NCT00678704|Placebo Comparator|Arm 3|
3179997|NCT00678704|Experimental|Arm 1|
3489744|NCT03717857||Focus Groups|"Three focus groups with middle school students [N = 5], caregivers [N =5], and school staff [N = 5] will be conducted to inform the development of the intervention.~Criteria for caregiver and middle school student selection is similar to the in-depth interviews and the pilot clinical trial. Inclusion criteria specify that participants must 1) be between the ages of 11-13 , 2) be in 6th-8th grades, or have a child that meets that criteria 3) reside in one of the targeted public school districts identified by zip code, 4) attend one of the schools within these districts.In RI, caregivers will have to identify as Latino.~The school staff focus group will include school personnel from the targeted schools."
3489745|NCT03717831||Healthy|Healthy subjects will be enrolled as age and activity matched controls for muscle power assessment at one time-point to establish normative values.
3179998|NCT00678704|Experimental|Arm 2|
3179999|NCT00678717|Active Comparator|Healthy|Healthy volunteers
3489746|NCT03717831||ICU|Observational, subjects enrolled initially in the ICU and followed for six months after hospital discharge. ICU subdivided based on diagnosis
3489747|NCT03717818|Experimental|Good Psychiatric Management-Brief|
3489748|NCT03717818|Placebo Comparator|Treatment as Usual-Brief|
3489749|NCT03717805|Experimental|Intervention group|Participating couples of the intervention group will receive care as usual and will watch the preparatory information movie on oocyte aspiration (POAM) 1-3 days before their oocyte aspiration. Their gynecologist or midwife will empower them to watch the movie when they call them to plan the oocyte aspiration and will send them the secured link to the movie via email.
3489750|NCT03717805|No Intervention|Control group|Participating couples of the control group will receive care as usual (as will participating couples of the intervention group) and will not get access to the preparatory information movie on oocyte aspiration (POAM).
3489751|NCT03717779||HF/HFpEF|patients with heart failure with a preserved ejection fraction(HFpEF) perform LUS
3489752|NCT03717779||HF/HFrEF|patients with heart failure with a reduced ejection fraction(HFrEF) perform LUS
3489753|NCT03717766||Patients|Intraaxial brain tumors that are tributary to surgical treatment. Prospective observational study of the use and effectiveness of intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology in the resection of intracranial supratentorial tumors.
3489754|NCT03717753|No Intervention|Before Group|We plan to have 70 patients studied prior to initiation of a pathway.
3489755|NCT03717753|Experimental|After Group|We plan to have 70 patients studied after initiation of a pathway.
3489756|NCT03717740|Experimental|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
3489757|NCT03717740|Placebo Comparator|Placebo|Patients will take Placebo Oral Tablet once a daily oral tablet from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy,
3489758|NCT03717714|Active Comparator|Glucosamine 1500mg|Glucosamine 1500 mg per day for 12 weeks
3489759|NCT03717714|Experimental|Polycan & Glucosamine 750mg|Polycan 50 mg + Glucosamine 750 mg per day for 12 weeks
3489760|NCT03717714|Experimental|Polycan & Glucosamine 1500mg|Polycan 50 mg + Glucosamine 1500 mg per day
3489761|NCT03717701|Experimental|metformin and esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day plus single dose of metformin 1000mg orally single dose once a day
3489762|NCT03717701|Placebo Comparator|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
3129276|NCT03207763|Experimental|Cohort 2|Participating infants and children will receive Microneedle Formulation 2. At least 4 infants or children must complete Day 8 without halting criteria having been met before subjects will be enrolled into the next younger age group within a Cohort. At least the first 2 children will have a microneedle patch initially applied to the skin overlying the shoulder blade. If this site is well tolerated without halting criteria having been met additional microneedle patches may be applied to the same participants and in subsequent participants to the upper arm, forearm, wrist and/or thigh.
3129277|NCT03207776|Other|Control|Treatment of patients in the usual manner based on their diagnosis and resources available at that site (Usual Care).
3129278|NCT03207776|Other|Intervention|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services (COPD Clinical Pathway).
3129279|NCT03208088|Experimental|Sequence 1|etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental)
3129280|NCT03208088|Experimental|Sequence 2|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator)
3489763|NCT03717688|Placebo Comparator|Placebo|No treatment. Participants are subjected to a standardized meal
3489764|NCT03717688|Active Comparator|Entrestro as single dose|194 mg sacubitril / 206 mg valstartan (entresto) as one single dose followed by a standardized meal
3489765|NCT03717688|Active Comparator|Sitagliptin as single dose|200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
3489766|NCT03717688|Active Comparator|Entrestro + sitagliptin as single dose|194 mg sacubitril / 206 mg valstartan (entresto) + 200mg sitagliptin (100mg the night before and 100mg on the study day) as one single dose followed by a standardized meal
3489767|NCT03717675|Experimental|Interventional|Interventional arm, where the NovaCross™ CTO micro-catheter will be placed in study subjects during the Total Occlusion opening procedure.
3489768|NCT03717662|Experimental|Brief counseling and NRT|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers (including all types of tobacco products such as shisha, electronic cigarettes and heat-not-burn (HNB) which are available in the market) who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
3489769|NCT03717649|Active Comparator|Conventional 2-stage venous cannulation|The two-stage venous cannula 36Fr and 51Fr (size) for each of the two stages (91251C, Medtronic)
3489770|NCT03717649|Active Comparator|Conventional 3-stage venous cannula|The standard three-stage cannula (91437C, Medtronic) is 29Fr, 46Fr and 37Fr for each of the three stages.
3129281|NCT03208088|Experimental|Sequence 3|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental)
3129282|NCT03208088|Experimental|Sequence 4|etafilcon A Test Lens 4 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental)
3129283|NCT03208088|Experimental|Sequence 5|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 3 (experimental)
3129284|NCT03208088|Experimental|Sequence 6|etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental / etafilcon A Test Lens 1 (experimental)
3129285|NCT03208088|Experimental|Sequence 7|etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental)
3489771|NCT03717649|Experimental|Fenestrated 3-stage venous cannula|The fenestrated three-stage cannula (MC2X, Medtronic) is 29Fr, 29Fr and 29Fr for each of the three stages.
3489772|NCT03717636|Experimental|Hospital Day|Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.
3489773|NCT03717636|Other|Outpatient clinic|The patients in control group will return for medical evaluation 30 days at the outpatient clinic.
3489774|NCT03717623|Experimental|Posaconazole prophylaxis|Blood samples will be taken from participants undergoing cancer treatment and receiving Posaconazole prophylaxis. The samples will be used for Posaconazole pharmacokinetics study.
3489775|NCT03717610|Experimental|Complete cytoreductive surgery plus HIPEC with cis-platinum100mg/m2 for 90 min|
3489776|NCT03717597|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
3489777|NCT03717571||Control group|age and sex matched healthy control persons
3489778|NCT03717571||isolated tear|patients with isolated complete supraspinatus muscle tear
3489779|NCT03717571||combined tear|patients with complete supraspinatus muscle tear and either partial infraspinatus muscle tear or partial subscapularis muscle tear
3489780|NCT03717558|Active Comparator|Stromectol R|Stromectol R = ivermectin 3mg (tablet)
3489781|NCT03717558|Experimental|ivermectin T1|T1= ivermectin low grade particle Size Distribution
3489782|NCT03717558|Experimental|ivermectin T2|T2= ivermectin medium grade particle Size Distribution
3489783|NCT03717558|Experimental|ivermectin T3|T= ivermectin high grade particle Size Distribution
3489784|NCT03717545|Experimental|intervention arm|second allogeneic stem cell transplantation
3489785|NCT03717532|Experimental|Patients with Patellopain syndrome with Cuff|Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises
3489786|NCT03717532|Placebo Comparator|Patients with Patellopain syndrome with Placebo Cuff|
3489787|NCT03717519||s-CRLM|Patients with synchronous colorectal liver metastases who underwent surgical resection
3489788|NCT03717493|Experimental|Affect Regulation Training (ART)|Affect Regulation Training (ART; Berking & Whitley, 2014) is a transdiagnostic, group-based intervention aiming to enhance general affect regulation skills in individuals who meet criteria for mental disorders or are at-risk of developing mental-health problems.
3129286|NCT03208088|Experimental|Sequence 8|etafilcon A Test Lens 1 (experimental) / etafilcon A Control Lens (Active Comparator) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental / etafilcon A Test Lens 3 (experimental)
3129287|NCT03208088|Experimental|Sequence 9|etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 1 (experimental) / etafilcon A Test Lens 3 (experimental / etafilcon A Control Lens (Active Comparator) /etafilcon A Test Lens 4 (experimental)
3489789|NCT03717493|No Intervention|Waitlist Control Condition (WLC)|In order to control for the effects of time, we compared changes during ART with changes during WLC. Participants in the WLC condition received no treatment within the study but were offered to participate in ART after completing all assessments.
3489790|NCT03717480|Experimental|TCR α/β Reagent System|"The stem cell apheresis product will be depleted of TCRαβ T cells by negative selection using the automated CliniMACS® Plus device.~CD34+ stem cell counts will be obtained before and after processing with the Miltenyi ClinicMACs device"
3489791|NCT03717467|Placebo Comparator|S group|Isotonic saline as placebo will be given.
3489792|NCT03717467|Active Comparator|M group|Magnesium sulfate will be given
3129288|NCT03208088|Experimental|Sequence 10|etafilcon A Test Lens 3 (experimental) / etafilcon A Test Lens 2 (experimental) / etafilcon A Test Lens 4 (experimental) / etafilcon A Test Lens 1 (experimental / etafilcon A Control Lens (Active Comparator)
3129289|NCT03208166|Experimental|Ischemic Conditioning|Doctormate device is used daily.
3489793|NCT03717454|Experimental|Drug treatment|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.
3489794|NCT03717454|Experimental|Surgery|Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.
3129290|NCT03208166|Other|Usual Care|Standard medical care.
3129291|NCT03208192|Experimental|ErbeJet|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon) and water-jet dissector (ERBEJET 2).
3129292|NCT03208192|Experimental|Misonix|liver resection using a bipolar dissector (Erbe), ultracision harmonic scalpel (Ethicon), and ultrasonic aspirator (Misonix/SonaStar Ultrasonic Surgical Aspiration System)
3129293|NCT03208530|Experimental|Intervention Arm|This is a single arm study with all enrolled patients receiving the same brief motivational interview intervention.
3489795|NCT03717428|Experimental|Daily Weighing Group|This group will be weighed and height measured in our metabolic unit at the beginning and end of the two year experimental period. In addition, the intervention in Daily Weighing Group is that they will be given an internet based scale and asked to weigh themselves immediately after rising from bed every morning for the duration of the two year experimental period.
3489796|NCT03717428|Active Comparator|Control Group|The only intervention for the control group is that they will be weighed and height measured at the beginning and end of the experimental period in our metabolic unit.
3489797|NCT03717415|Experimental|Part 1|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks
3489798|NCT03717415|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin~Triple-negative breast cancer~Platinum-sensitive Ovarian cancer~Mesothelioma"
3489799|NCT03717363|Active Comparator|Control group|Educational talk: an educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
3489800|NCT03717363|Experimental|Interventional group|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
3489801|NCT03717350|Placebo Comparator|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously
3489802|NCT03717350|Active Comparator|Antibiotic|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously
3489803|NCT03717337|Experimental|Single visit pulp regeneration|Regenerative endodontic procedure not involving placement of intracanal medicament will be done in single visit
3489804|NCT03717337|Active Comparator|Two visit pulp regeneration|Regenerative endodontic procedure involving placing intracanal medicament will be done in two visit
3489805|NCT03717324||First evaluation group (survey_1)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA)
3489806|NCT03717324||Co-creation group|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA) who want to participate in the co-creation workshop
3489807|NCT03717324||Second evaluation group (survey_2)|Patients/caregivers attended in the Emergency Department Elder Friendly Area (EFA), after improvements are made
3489808|NCT03717311|Experimental|13C enriched bran biscuit|The volunteers will consume 5 biscuits (100g) enriched with 13C bran with a 200 ml hot beverage in 15 minutes
3489809|NCT03717285|Experimental|Group 1:Under direct vision|Patients in Group 1 insert the UAS under direct vision.In this procedure,the investigators will insert the ureteroscope into urinary bladder beside the guidewire to observe the process of uas insertion into the ureter.
3489810|NCT03717285|Active Comparator|Group 2:Under non direct vision|Patients in Group 2 insert the UAS under non direct vision.In this procedure,the investigators will insert the UAS under fluoroscopy control.
3489811|NCT03717272|Experimental|AEF0117|AEF0117 capsules ; dose range 0.02 to 1.2mg by mouth, once a day for 5 consecutive days.
3489812|NCT03717272|Placebo Comparator|Placebo oral capsule|corn oil capsules once a day for 5 consecutive days.
3489813|NCT03717259|Active Comparator|Open nephrectomy|These patients will undergo an open nephrectomy.
3489814|NCT03717259|Active Comparator|Hand-assisted laparoscopic nephrectomy|These patients will undergo a hand-assisted nephrectomy.
3489815|NCT03717259|Active Comparator|Laparoscopic nephrectomy|These patients will undergo a pure laparoscopic nephrectomy.
3489816|NCT03717246|Experimental|Sleep Smart Latino|Sleep Smart Latino is a sleep hygiene intervention culturally tailored to be consistent with the beliefs, behaviors and needs of urban Latino middle school children and families. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting, and 2 60-minute long home based sessions that involve the student and their caregiver. The intervention focuses on sleep education, including effective sleep hygiene practices, use of electronics and caffeine and their impact on sleep.
3489817|NCT03717246|Active Comparator|Basic Sleep Education and Child Health|The basic sleep education and child health condition includes education regarding sleep hygiene , and the effects of sleep on child functioning integrated with additional child health topics such as nutrition, physical activity and safety. It consists of 4 60-minute sessions delivered in a group format in an urban middle school setting
3489818|NCT03717246|No Intervention|No treatment control|Students randomly assigned to this arm, will receive standard of care , which is no treatment and will not participate in any group sessions.
3489819|NCT03717233|Experimental|Primary Arm|Participants will be used as their own controls. Participants will be evaluated using exo-skeletons with non-motorized spring elements in parallel to the Achilles tendon. Up to 5 different levels of spring force will be evaluated to evaluate the impact upon plantar pressure and measures of fall risk.
3489820|NCT03717220|Other|flaps|flap transferring is used for reconstruction of multiple small-to-moderate soft-tissue defects
3489821|NCT03717207||type 2 diabetes mellitus (T2DM) patients|T2DM patients affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
3489822|NCT03717207||patients without T2DM|Patients without T2DM affected by vaso vagal syncope. All these patients received before to perform and Head upTilt test and ecg Holter monitoring.
3489823|NCT03717194|Experimental|Ertugliflozin|Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
3489824|NCT03717194|Placebo Comparator|Control group|Placebo in addition to their preexisting metformin and/or DPP4 inhibitor
3489825|NCT03717168|Active Comparator|Recombinant human growth hormone|Patients who received growth hormone immediately after tracheostomy.
3489826|NCT03717168|Active Comparator|Control|Patients who did not receive growth hormone and followed the conventional weaning trials
3489827|NCT03717142|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients, in each indication, to measure baseline tissue fluorescence. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3489828|NCT03717142|Experimental|1st Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3489829|NCT03717142|Experimental|2nd Tier Dose Level|3 patients, in each indication, will be administered a single dose of LUM015 at 2.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3489830|NCT03717142|Experimental|3rd Tier Dose Level|After an interim analysis, the dosing for the 3 patients, in each indication, will be administered a single dose of LUM015 of no greater than 3.0 mg/kg. Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
3489831|NCT03717116||control-normocalcemia group|
3489832|NCT03717116||hypocalcemia group|
3489833|NCT03717103|Experimental|IBI188|
3489834|NCT03717090||Patients with PJI|
3489835|NCT03717077|Experimental|Learned resourcefulness intervention|The learned resourcefulness program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
3489836|NCT03717077|No Intervention|Usual home care service|The control group maintains home care service
3489837|NCT03717038|Experimental|Arm A (Sym004)|Sym004 will be administered as a loading dose of 9 mg/kg on Cycle 1 Day 1, followed by weekly doses of 6 mg/kg beginning Cycle 1 Day 8.
3489838|NCT03717038|Active Comparator|Arm B (TAS-102)|TAS-102 is commercially available and will be administered as per local prescribing instructions.
3489839|NCT03717025|Active Comparator|Mini Punch Grafting|
3489840|NCT03717025|Active Comparator|Suction Blister Epidermal Grafting|
3489841|NCT03717025|Active Comparator|Non Cultured Epidermal Cell Suspension|
3489842|NCT03716999||Palliative Care Patients|Palliative care Patients meeting criteria will receive Starlight Therapy
3489843|NCT03716986|Other|SatO2|
3489844|NCT03716973|Experimental|High density programming|High density programming of spinal cord stimulator for paraesthesia-free therapy.
3489845|NCT03716960|Experimental|Pumpkin Seed Oil|This arm involved 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner). Likewise,
3489846|NCT03716960|Placebo Comparator|Placebo|This arm involved 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
3489847|NCT03716947|Active Comparator|ORBIT Mechanical disc prosthesis|"Surgical procedure with total disc replacement using mechanical disc prosthesis device, ORBIT, Globus Medical"
3489848|NCT03716947|Experimental|ZACK viscoelastic disc prosthesis|"Surgical procedure with total disc replacement using viscoelastic disc prosthesis device, ZACK, FH Orthopaedics"
3489849|NCT03716947|Active Comparator|ORBIT SASCA|Surgical procedure with total disc replacement (TDR) using ORBIT disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
3489850|NCT03716947|Experimental|ZACK SASCA|Surgical procedure with total disc replacement (TDR) using ZACK disc prostheses device combined with adjacent level anterior intracorporal fusion (ALIF) with intracorporal device SASCA.
3489851|NCT03716934|Experimental|Cryoablation|Cryoablation for bidirectional block of all pulmonary veins
3489852|NCT03716934|Active Comparator|Antiarrythmics|The drug will be chosen based on the preference of the researcher based on clinical practice guidelines.
3489853|NCT03716921|Experimental|Short antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 3 weeks
3489854|NCT03716921|No Intervention|Long antibiotics treatment|patients will receive effective antibiotic treatment (IV and oral) for 6 weeks according to standard care
3489855|NCT03716882||Infant at the birth|"Infant at the birth will be included. Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights.~At every cry, parent should answer the questionnaire of cry in infant."
3180000|NCT00678717|Experimental|Chronic Visceral Pain|Chronic Visceral Pain patients. Participants will be tested before and after implantation of a Spinal Cord Stimulator (implantation of the Spinal Cord Stimulator is done as usual care and is not a study procedure)
3489856|NCT03716869|No Intervention|Targeted Screening Arm (Current Process)|Students randomized to the targeted screening arm will complete their routine school-based health screenings. Students will be followed through the academic year for referrals to the Student Assistance Program (SAP). SAP currently exists in all Pennsylvania (PA) schools and functions like a triage service. If a student exhibits behavior concerning for MDD (raised by any contact, e.g. teachers, nurse, parent, peer, or even self-referral), SAP will triage the student and based on the initial assessment provide recommendations for school or community-based services.
3489857|NCT03716869|Experimental|Universal Screening Arm (Intervention)|"Students randomized to the universal screening arm will complete the Patient Health Questionnaire (PHQ-9) during the academic year. This screening tool includes nine close-ended questions with a scoring system ranging from 0 to 27. Scores >10 are considered a positive screen. Students with a positive PHQ-9 result will then proceed to SAP triage as per the current process for those referred via the targeted screening arm."
3489858|NCT03716856|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
3489859|NCT03716843||Pressure monitoring system for AIS|"Adolescent idiopathic scoliosis (AIS) patients~(1) all target subjects are aged 10 to 15 years old with immature skeletons (Risser grade 0-2); (2) they are diagnosed with AIS with a Cobb angle between 25-45° and high risk for curve progression; (3) the types of scoliosis are classified by the Lenke classification system; and (4) the subjects have received rigid brace treatment."
3489860|NCT03716830|Experimental|verum acupuncture + real tDCS|
3489861|NCT03716830|Experimental|sham acupuncture + real tDCS|
3489862|NCT03716830|Experimental|verum acupuncture + sham tDCS|
3489863|NCT03716830|Sham Comparator|sham acupuncture + sham tDCS|
3489864|NCT03716817|Experimental|Tetric CAD Crown|Tetri CAD crowns will hand polished and cemented with a dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
3489865|NCT03716804|Experimental|Intervention group|"Intervention:~To the prescribers- Educational intervention about guideline and present sensitivity trend.~To the Patients- Tablet Nitrofurantoin(100 mg), two times daily at 12 hours interval for 7 days."
3489866|NCT03716804|Active Comparator|Control Group|"Intervention:~To the Patients- Tablet Ciprofloxacin, 500 mg or,Tablet Cefixime 200 mg or,Tablet Cefuroxime 250 mg (According to physician's personal choice)."
3180001|NCT00678730|Active Comparator|1|"Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or joint.~Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or joint.~Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or joint."
3489867|NCT03716791|Placebo Comparator|Placebo Control Group|pill capsules containing white rice flour
3489868|NCT03716791|Active Comparator|Methylsulfonylmethane Group|pill capsules containing MSM
3489869|NCT03716778|Other|Classical exercise training modality in concentric mode (CON)|Description: Control group, usual medical care according to the rehabilitation recommendations
3489870|NCT03716778|Experimental|experimental, active group (ECC)|Patients perform a mixed program combining eccentric pedalling session with the usual sessions
3489871|NCT03716765|Experimental|non-surgical periodontal regeneration|non-surgical periodontal regeneration using locally injected vitamin d to treat the infrabony defect
3129294|NCT03208673|Experimental|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep. The treatment regimen will be used for one month.
3489872|NCT03716765|Active Comparator|surgical peridoontal regeneration|surgical periodontal regeneration using bone graft and collagen barrier
3489873|NCT03716752|Active Comparator|bone graft and collagen barrier|peridoontal regeneration using bone graft and collagen barrier as treatment of vertical bony defects with recession defect
3489874|NCT03716752|Experimental|Modified connective tissue graft wall with wing technique|peridoontal regeneration using bone graft and modified connective tissue graft wall with wing as treatment of vertical bony defects with recession defect
3489875|NCT03716739|Active Comparator|Treatment Arm|Weekly IM administration of 100 mg testosterone cypionate for 12 weeks.
3489876|NCT03716739|Placebo Comparator|Control Arm|Weekly IM administration of placebo for 12 weeks.
3489877|NCT03716713|Experimental|CeraShield Endotracheal Tube|Subjects who are expected to require mechanical ventilation for 24 hours or longer will be intubated with the CeraShield ETT.
3489878|NCT03716700||Cohort 1|Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.
3489879|NCT03716700||Cohort 2|Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.
3489880|NCT03716700||Cohort 3|Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.
3489881|NCT03716687|Experimental|ciNPWT|"Prophylactic negative pressure wound dress (Hartmann) is set up for 5 days right after operation.~Continous -90 Hgmm negative pressure mode selected. No change of wound dress until 5 days completed."
3489882|NCT03716687|No Intervention|Traditional wound dressing|Control group with traditional, dry laparotomy wound dressing.
3489883|NCT03716674|Experimental|Parkinson's Disease patients|
3489884|NCT03716661|No Intervention|Control|Arm 1/control group: Participants who are treated with conservative plaster following National Clinical Guidelines.
3489885|NCT03716661|No Intervention|Conservative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 2: Patients randomized to conservative plaster treatment"
3489886|NCT03716661|Other|Operative|"Arm 2 and 3 consist of participants fulfilling the criteria for operative treatment following National Clinical Guidelines.~Arm 3: Patients randomized to operative treatment (ORIF)"
3180002|NCT00678730|Placebo Comparator|2|small amount of ethanol, (quarter teaspoon), with no THC
3489887|NCT03716648|Active Comparator|Subjective titration|After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
3489888|NCT03716648|Experimental|DISE-assisted titration|Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated.
3489889|NCT03716648|Experimental|PSG-guided titration|An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced.
3489890|NCT03716635|Experimental|cryotherapy|2.5c cold saline as a final flush after chemicomechanical debridement
3489891|NCT03716635|Other|normal saline|room temperature saline is used as a final flush after chemicomechanical preparation
3489892|NCT03716622|Active Comparator|bismuth-clarithromycin-containing group|Patients in bismuth-clarithromycin-containing group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and clarithromycin (Klacid) 500mg po bid for 14d
3489893|NCT03716622|Experimental|bismuth-furazolidone-containing quadruple group|patients in bismuth-furazolidone-containing quadruple group will receive lansoprazole (Takepron) 30mg po bid, amoxicillin 1000mg po bid, bismuth subcitrate (Colloidal Bismuth Pectin) 240mg po bid, and furazolidone (Liteling) 100mg po bid for 14d
3489894|NCT03716609|Experimental|Magnesium supplement group|Subjects receive citrate acid drinks with additional magnesium citrate (300mg magnesium)
3489895|NCT03716609|Placebo Comparator|placebo group|Subjects receive citrate acid drinks without additional magnesium
3489896|NCT03716596|Experimental|SBRT and PD-1|Stereotactic body radiotherapy, radiation dose is 40-50 Gy in total. Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
3489897|NCT03716583|Experimental|Melatonin/DMSO|25 mg melatonin in 1 g cream twice daily for the duration of the radiation therapy
3489898|NCT03716583|Placebo Comparator|Placebo|1 g of cream once daily
3489899|NCT03716570|Experimental|Cohort 1: BIIB054 Dose A|Participants will receive IV infusion of BIIB054 Dose A (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
3489900|NCT03716570|Experimental|Cohort 2: BIIB054 Dose B|Participants will receive IV infusion of BIIB054 Dose B (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
3489901|NCT03716570|Experimental|Cohort 3: BIIB054 Dose C|Participants will receive IV infusion of BIIB054 Dose C (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
3489902|NCT03716570|Placebo Comparator|Cohorts 1-3: Placebo|Participants will receive a single IV infusion of BIIB054 matching placebo (single infusion on Day 1 followed by an observation period; with subsequent doses for 48 weeks)
3489903|NCT03716557|Experimental|Spinal Cord Stimulation 4000Hz|Patients will trial Spinal Cord Stimulation 4000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
3489904|NCT03716557|Experimental|Spinal Cord Stimulation 10000Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
3489905|NCT03716557|Active Comparator|Spinal Cord Stimulation 40Hz|Patients will trial Spinal Cord Stimulation 10,000Hz for 4 weeks. PET/CT scan will be conducted at the end of this period.
3489906|NCT03716544|No Intervention|Waiting list control group|There will be no treatment for 12 months.
3489907|NCT03716544|Experimental|Hearing aid group|Participants will receive amplification with hearing aids. Bilateral open-fit hearing aids will be fitted. Participants will be required to use the hearing aids for at least 2 hours daily for 12 months.
3489908|NCT03716544|Active Comparator|Customized music group|Customized music according to participants hearing level will be made available in an iPod. The iPod will deliver ear-specific therapeutic sound for asymmetrical hearing profile. Participants will have to listen to the therapeutic sound at a comfortable volume for two hours daily for 12 months.
3489909|NCT03716531|Experimental|IORT|"IORT will be administered as determined to be best practice by the treating radiation oncologist,~Electron beam intraoperative radiation therapy will occur in a hybrid operating room with a portable linear accelerator"
3489910|NCT03716518|Experimental|TCM group|Tonifying Spleen and Kidney Sequential Regimen(TSKSR) will be prescribed to the participants in each course of chemotherapy.
3489911|NCT03716518|Placebo Comparator|Placebo group|Placebo of Tonifying Spleen and Kidney Sequential Regimen(TSKSR)similar in color,smell and texture with TSKSR will be prescribed to participants in each course of chemotherapy.
3129295|NCT03208933|Experimental|Pirfenidone|Participants will be administered pirfenidone 2403 milligram per day (mg/d) orally for 26 weeks in participants with IPF.
3129296|NCT03209050|Other|Central Venous Access Placement|Central venous access placement
3489912|NCT03716505|Active Comparator|gammaCore Sapphire active|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
3489913|NCT03716505|Sham Comparator|gammaCore Sapphire Sham|"Treatment 3 times per day, every day for the 12-week treatment period~Each of the 3 daily treatments comprises 2 consecutive 120-second stimulations on 1 side, ipsilateral (2 stimulations) to the side of predominate pain, upon waking, lunch time (i.e., between 11:00 AM and 2:00 PM), and prior to sleep, for a total of 6 stimulations per day"
3129297|NCT03209362|Experimental|SI-613|
3489914|NCT03716479|Experimental|0 fiber|0 grams fiber added to orange juice
3489915|NCT03716479|Experimental|low fiber|20 grams of acacia gum added to orange juice
3489916|NCT03716479|Experimental|high fiber|40 grams of acacia gum added to orange juice
3129298|NCT03209362|Placebo Comparator|Placebo|
3129299|NCT03209492||Leuprorelin acetate|Usually, for adults, 22.5 mg of leuprorelin acetate is subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants will receive interventions as part of routine medical care.
3129300|NCT03209505|Other|Eye 1: Low coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 1 will be fit in a contact lens with a low coefficient of friction, Acuvue Oasys.
3489917|NCT03716466||Endotracheal intubation|Cases with prophylactic endotracheal intubation during urgent endoscopy procedure for upper gastrointestinal bleeding .
3489918|NCT03716466||No airway intervention|Cases without airway intervention during urgent endoscopy procedure for upper gastrointestinal bleeding
3489919|NCT03716453|Placebo Comparator|Control group|Intraoperative fentanyl administration will be guided by standard protocol
3489920|NCT03716453|Experimental|ANI group|Intraoperative fentanyl administration will be guided by ANI protocol
3489921|NCT03716440|Experimental|Nature group|Nature exposure intervention.
3489922|NCT03716440|Active Comparator|Non-nature group|Non-nature exposure intervention.
3489923|NCT03716427|Experimental|Active Treatment- CT1812 560 mg|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole)
3489924|NCT03716414||Experimental SLN arm|"Experimental SLN arm~Intra-operative sentinel lymph node (SLN) mapping with indocyanine green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceed to a total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy including complete pelvic lymphadenectomy and aortic lymph node dissection.~If only unilateral SLN or non SLN are detected, surgeons will proceed to complete pelvic lymphadenectomy and aortic lymph node dissection."
3489925|NCT03716401||Bari: Biopsy Arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bari site will have an additional renal biopsy at baseline."
3489926|NCT03716401||Bordeaux: MRI Follow-up arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Bordeaux site will have an additional ultrasound US and MRI in Follow-up year 2."
3489927|NCT03716401||Exeter: Microvascular arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Participants at the Exeter site will undergo microvascular measurements including estimating glycocalyx thickness at baseline and at 2 years follow-up."
3489928|NCT03716401||Leeds: Microstructure MRI arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection.~Participants at the Leeds' site will have an extended MRI scan at baseline including novel microstructure MRI measurements."
3489929|NCT03716401||Turku: PET arm|"All study participants will undergo a baseline MRI and US and corresponding blood and urine sample collection. This will be followed up annually for additional blood and urine samples.~Additionally, participants at the Turku site will undergo a renal Positron Emission Tomography (PET) scan at the baseline timepoint."
3489930|NCT03716388|Experimental|FMT Vs Placebo|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus placebo granules (4g/day)
3489931|NCT03716388|Active Comparator|FMT Vs Mesalamine|Fecal microbiota transplantation (fresh sample, colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
3489932|NCT03716388|Active Comparator|Placebo Infusion Vs Mesalamine|Placebo infusion (colonoscopic administration at weeks 0,2,6,10,14) plus mesalamine granules (4g/day)
3489933|NCT03716375|Experimental|use of fibrinolytic agent|Chest tube drainage with intrapleural urokinase instillation 1000 IU/ml
3489934|NCT03716375|No Intervention|no use of any drug|Chest tube drainage
3489935|NCT03716362||Neonates who will be admitted at Neonatal Intensive Care Unite|
3489936|NCT03716336|Other|aerobic exercise|walking on treadmill
3489937|NCT03716336|Other|resistive exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs
3489938|NCT03716323|Experimental|immediate premolar implant with xenograft and allograft|Immediate Implant Placement in Maxillary Premolar zone with grafting the jumping gap using xenograft and allograft
3489939|NCT03716310||septic shock patients|Inclusion criteria of the study were diagnosis of septic shock and a platelet count >150*103/mcL.
3489940|NCT03716245|Experimental|supraclavicular lymph node dissection and raidiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular lymph node dissection and supraclavicular area radiotherapy
3489941|NCT03716245|Active Comparator|supraclavicular area radiotherapy|breast cancer patients with supraclavicular lymph node metastasis receive supraclavicular area radiotherapy
3489942|NCT03716232|Active Comparator|Multiple plastic stents|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
3489943|NCT03716232|Experimental|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
3489944|NCT03716219|Other|Healthy Subjects|Healthy control group which received the same exercise training intervention as the experimental group
3489945|NCT03716219|Experimental|Subjects with Asthma|Subjects with asthma who received exercise training
3489946|NCT03716206|Experimental|exergames group|The exergames intervention is one hour per day, four or five days per week for three weeks.
3489947|NCT03716206|Active Comparator|conventional group|The conventional group intervention is one hour per day, four or five days per week for three weeks.
3489948|NCT03716193|Experimental|Cohort 1|Patients who will receive definitive surgery for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
3489949|NCT03716193|Experimental|Cohort 2|Patients who will receive definitive radiation (+/- concurrent systemic therapy) for a primary malignancy of the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
3489950|NCT03716193|Experimental|Cohort 3|Patients who will receive palliative radiation (+/- concurrent systemic therapy) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
3489951|NCT03716193|Experimental|Cohort 4|Patients who will receive systemic therapy alone (without radiation) for any tumor involving the skin, will have their tumor injected with India ink for tumor marking and will be given oxygen during the measurement sessions.
3489952|NCT03716180|Experimental|Paclitaxel+Trastuzumab+Pertuzumab|Paclitaxel is administered intravenously on days 1, 8, and 15 of each 21-day cycle Trastuzumab is administered intravenously on day 1 of each 21-day cycle Pertuzumab is administered intravenously on Day 1 of each 21-day cycle
3489953|NCT03716167|Experimental|Laser Treatment|Summus Laser treatment with infrared light
3180003|NCT00678769|Experimental|Group A (temsirolimus on days 15 and 22 course 1)|Patients receive temsirolimus IV over 30 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
3489954|NCT03716167|Sham Comparator|Sham treatment|Sham Summus Laser treatment with no infrared light
3489955|NCT03716154|Experimental|SRP and diode laser|In a split mouth design either left or right sites randomly treated by SRP and diode laser as an adjunct
3489956|NCT03716154|No Intervention|SRP alone|The other sites in the other side will be treated by SRP alone
3489957|NCT03716141|Active Comparator|Autologous Platelets Rich Plasma|In this group we will be managing diabetic wounds with platelet rich plasma treatment.
3489958|NCT03716141|Active Comparator|Conventional Saline dressing|In this group we will be managing diabetic wounds with normal saline dressing.
3489959|NCT03716128||Low turnover bone disease|PTH<150 pg/ml
3489960|NCT03716128||High turnover bone disease|PTH>300 pg/ml
3489961|NCT03716128||Normal renal function|Patients under examination for prostate cancer
3489962|NCT03716115|Experimental|Colostrum|Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
3489963|NCT03716115|Experimental|GInNAC|N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
3489964|NCT03716115|Experimental|Teduglutide|Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
3489965|NCT03716115|Experimental|Budenoside|Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
3489966|NCT03716115|No Intervention|Standard care|Standard care following WHO guidelines for management of SAM.
3489967|NCT03716102|Experimental|Svelte DES|Stent: A mounted Cobalt Chromium (Co-Cr) alloy based stent Polymer coating: Polyesteramide (PEA) Sirolimus drug
3489968|NCT03716089||Group A (Study group)|Group for laparoscopic resection of GIST with unfavorable group (Unfavorable group)
3489969|NCT03716089||Group B (Control group)|Group for laparoscopic resection of GIST with favorable group (favorable group)
3489970|NCT03716063|Experimental|test group|The test group will oral Jianpi Huatan dispensing granule , once a day in the morning and evening, once a month for a course of treatment, a total of three courses.
3489971|NCT03716063|Placebo Comparator|control group|The control group will oral drug:low-dose control granules (containing 1/10 of the dose of the experimental group) , once a day in the morning and evening, once a month for a course of treatment, a total of three courses
3489972|NCT03716037|Experimental|Physical Activity|Physical Activity for Life (PAL) is an 8-week exercise program, meeting three times per week for one hour sessions.
3489973|NCT03716037|No Intervention|Contact Control|those in the attentional contact control group will receive a phone call from research personnel three times per week asking them about their physical exercise routines.
3489974|NCT03716011|Other|DAPT 3M or DAPT 12M|After stent implantation in DAPT 3M or DAPT 12M
3489975|NCT03715998|Experimental|Group 1: firibastat 50 mg|Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks.
3489976|NCT03715998|Experimental|Group 2: firibastat 250 mg|Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks.
3489977|NCT03715998|Active Comparator|Group 3: ramipril 2.5 mg|Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks.
3489978|NCT03715985|Experimental|NeoPepVac|Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
3489979|NCT03715972||Anemia Observation|The study will enroll 90 adult subjects with transfusion independent sickle cell disease (70 SS, 10 SC, 10 Sβ0) and 60 patients with transfusion-dependent sickle cell disease. It will also include 10 transfusion independent thalassemia patients and 20 transfusion dependent thalassemia patients. Diamox (acetazolamide) will be administered during MRI.
3489980|NCT03715972||Anemia Intervention|"Most patients will already be prescribed hydroxyurea as part of their standard of care. Since hydroxyurea could impact brain blood flow, there is also a small pilot study (20 patients, nonrandomized, open label) where MRI imaging will be performed prior to and following administration of hydroxyurea up to maximum tolerated dose.~non transfusion dependent sickle cell disease patients not already receiving hydroxyurea will be placed on hydroxyurea following their baseline exam and titrated to maximal tolerated dose. They will then undergo a repeat MRI within two months of reaching that dose and be given the option to continue on hydroxyurea or stop."
3489981|NCT03715972||Healthy Controls|40 control subjects recruited from first degree relatives of the sickle cell disease population. Diamox (acetazolamide) will be administered during MRI.
3489982|NCT03715946|Experimental|Radiotherapy (RT) + Nivolumab Injection|RT of 45 or 50 Gy in 25 daily fractions, 6 fractions per week. Nivolumab will be administered at 240 mg every 2 weeks during radiotherapy, and at 480 mg every 4 weeks for 6 doses after radiotherapy.
3489983|NCT03715933|Experimental|Dose Escalation|INBRX-109 will be escalated (3+3 design) in subjects with locally advanced or metastatic solid tumors including sarcomas.
3489984|NCT03715933|Experimental|Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
3489985|NCT03715933|Experimental|Expansion Gastric Adenocarcinoma|Subjects with gastric adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
3489986|NCT03715933|Experimental|Expansion Colorectal Adenocarcinoma|Subjects with colorectal (CRC) adenocarcinoma will be treated with single-agent INBRX-109 at either the MTD or RP2D.
3489987|NCT03715933|Experimental|Expansion Sarcomas|Subjects with certain sarcoma subtypes will be treated with single-agent INBRX-109 at either the MTD or RP2D.
3489988|NCT03715933|Experimental|Combination Expansion Malignant Pleural Mesothelioma|Subjects with malignant pleural mesothelioma will be treated with INBRX-109 in combination with chemotherapies (carboplatin, cisplatin, carboplatin and pemetrexed, or cisplatin and pemetrexed)
3489989|NCT03715933|Experimental|Combination Expansion Pancreatic Adenocarcinoma|Subjects with pancreatic adenocarcinoma will be treated with INBRX-109 in combination with 5FU/irinotecan based chemotherapy
3489990|NCT03715933|Experimental|Combination Expansion Ewing Sarcoma|Subjects with Ewing sarcoma will be treated with INBRX-109 in combination with irinotecan/temozolomide based chemotherapy
3489991|NCT03715920|Active Comparator|High Voltage Pulsed Galvanic Current|HVPG current is a new form of neuromuscular electrical stimulation.The total output voltage of the device ranged from 0 to 500 volts and the current intensity was increased until the sensible contraction of the applied muscle was achieved without causing too much sense of discomfort
3489992|NCT03715920|Placebo Comparator|Russian Current|"Russian currents are a high frequency current of 2500 Hz and reduce the resistance of the skin and it would penetrate deeper and reach deeper motor nerves.Russian movement, a protocol developed by Kots, also known as Russian Technique, was used in the literature. There were 10 muscle contractions per treatment session in this protocol. Each contraction lasted for 10 seconds and a resting time of 50 seconds were given for the next contraction (transition: rest ratio was 1/5)."
3489993|NCT03715920|Sham Comparator|Isometric Exercise|"Isometric or static strength training is exercises performed without joint movement and changing muscle length during muscle contraction.~The body and knee of the participants in the isometric exercise group were positioned and stabilized at 75 ° flexion and 60 ° flexion angle, respectively as in the stimulation groups. Participants were asked to do 10 repetitions as 10 seconds of maximum voluntary contractions and 10 seconds of rest."
3489994|NCT03715907|No Intervention|Control: W34|Members receiving the Control intervention for the W34 (3- to 6-year-old well visit) gap will not receive a mailer.
3129301|NCT03209505|Other|Eye 2: High coefficient of friction|Subjects will be fit in a different contact lens brand in each eye. Assignment of the contact lens to each eye will be randomized. Eye 2 One eye will be fit in a contact lens with a high coefficient of friction, Air Optix Night & Day Aqua
3489995|NCT03715907|Experimental|Information only: W34|Members receiving the Information Only intervention for the W34 care gap will receive a mailer informing them of that gap, but not of financial incentives for closing the care gap.
3489996|NCT03715907|Experimental|Incentives: W34|Informational W34 mailer and incentive to close gap
3489997|NCT03715907|No Intervention|Control: LSC|Members receiving the Control intervention for the LSC (lead screening in children) gap will not receive a mailer.
3489998|NCT03715907|Experimental|Information only: LSC|Informational LSC mailer and incentive to close gap
3489999|NCT03715907|Experimental|Incentives: LSC|Members receiving the Incentives intervention for the LSC care gap will receive a mailer informing them of the gap and eligibility for a gift card if they close the gap.
3490000|NCT03715907|No Intervention|Control: IMA|No mailer for IMA (immunizations) gap
3180004|NCT00678769|Experimental|Group B (cixutumumab on days 15 and 22 of course 1)|Patients receive cixutumumab IV over 60 minutes on days 15 and 22 for course 1 and on days 1, 8, 15, and 22 for all subsequent courses. Patients also receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22.
3490001|NCT03715907|Experimental|Information only: IMA|Informational IMA mailer
3490002|NCT03715907|Experimental|Incentives: IMA|Informational IMA mailer and incentive
3490003|NCT03715907|No Intervention|Control: CDC|No mailer for CDC (clinical diabetes care) gap
3129302|NCT03209518||Leuprorelin acetate|Usually, for adults, 22.5 mg of Leuprorelin acetate was subcutaneously administered once every 24 weeks. Refer to the Precautions section of the package insert. Participants received Leuprorelin as part of routine medical care.
3129303|NCT03209570|Experimental|TENA Identifi with sensor wear data|All individuals in this arm will receive care planning using TENA Identifi sensor wear data
3490004|NCT03715907|Experimental|Information only: CDC|Informational CDC mailer
3490005|NCT03715907|Experimental|Incentives: CDC|Informational CDC mailer and incentive
3490006|NCT03715907|No Intervention|Control: CCS|No mailer for CCS (cervical cancer screening)
3490007|NCT03715907|Experimental|Information only: CCS|Informational CCS mailer
3490008|NCT03715907|Experimental|Incentives: CCS|Informational CCS mailer and incentive
3490009|NCT03715907|No Intervention|Control: AWC|No mailer for AWC (adolescent well-care visit) gap
3490010|NCT03715907|Experimental|Information only: AWC|Informational AWC mailer
3490011|NCT03715907|Experimental|Incentives: AWC|Informational AWC mailer and incentive
3490012|NCT03715894||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI
3490013|NCT03715881|Active Comparator|Oral prednisolone administration|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
3490014|NCT03715881|Active Comparator|Intravenous Erythropoietin injection|2. 1000 units of erythropoietin every 12 hours for three days
3490015|NCT03715868|Active Comparator|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
3490016|NCT03715868|No Intervention|Milked derived protein source formula diet|Formula diet based on a milked derived protein source
3490017|NCT03715842|Experimental|Tub shaped design|The tub-shaped preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
3490018|NCT03715842|Active Comparator|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
3490019|NCT03715829|Experimental|Cohort 1|Induction dose 1 given once a day(QD) for 4 weeks followed by maintenance dose A given QD for 20 weeks
3490020|NCT03715829|Experimental|Cohort 2|Induction dose 2 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
3490021|NCT03715829|Experimental|Cohort 3|Maintenance dose A given QD for 24 weeks
3490022|NCT03715829|Experimental|Cohort 4|Maintenance dose B given QD for 24 weeks
3490023|NCT03715829|Experimental|Cohort 5|Maintenance dose C given QD for 24 weeks
3490024|NCT03715829|Placebo Comparator|Cohort 6|Placebo given QD for 24 weeks
3490025|NCT03715829|Experimental|Extension Cohort 1|4 week drug holiday (no drug given) followed by PF-06700841 oral tablet QD for 20 weeks
3490026|NCT03715829|Experimental|Extension Cohort 2|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks in conjunction with narrow band UVB phototherapy
3490027|NCT03715829|Experimental|Extension Cohort 3|Induction dose 1 given QD for 4 weeks followed by maintenance dose A given QD for 20 weeks
3490028|NCT03715829|Experimental|Extension Cohort 4|Maintenance dose A given QD for 24 weeks
3490029|NCT03715829|Experimental|Extension Cohort 5|Maintenance dose B given QD for 24 weeks
3490030|NCT03715829|No Intervention|Extension Cohort 6|Observation period for 24 weeks
3490031|NCT03715816|No Intervention|No breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory.
3490032|NCT03715816|Experimental|Passive breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they can have a rest.
3490033|NCT03715816|Experimental|Active breaks|Subjects will simulate a 90-min laparoscopic activities in the laboratory, and after 30 and 60 min of work, they will be provided a 2.5-min break during which they will be performing some mobilisation exercises for the back, shoulder, and neck.
3490034|NCT03715777|Experimental|BoNTA Injection|"Patients diagnosed with chronic pelvic floor pain, without contraindications for the administration of BoNTA.~Name of each active substance (INN or proposed INN if available):~Botulinum toxin type A Clostridium botulinum type A (BoNTA) Pharmaceutical form (use standard terms): Powder and solution for solution for injection Route of administration (relevant to the maximum dose): Intramuscular use Specify total dose : 80 U"
3490035|NCT03715751|Active Comparator|ASV|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted to target the same minute ventilation achieved prior to any change in Vt. Patients will then be switched to ASV mode. The percentage minute volume (%minVol) will be adjusted to target the same minute ventilation as was achieved before the change. Settings will be maintained for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
3490036|NCT03715751|Active Comparator|Lung Protective Ventilation|Patients in this arm will have the ventilator adjusted per results of recent arterial blood gas. Esophageal balloon placement will be confirmed. Study team will measure several tidal breaths, end-expiratory and end-inspiratory ventilator holds. Then PEEP will be adjusted to achieve desired end-expiratory transpulmonary pressures, Fraction of Inspired Oxygen (FiO2) adjusted as needed to achieve SpO2>95%, and Tidal Volume (Vt) adjusted to 6cc/kg (IBW). Respiratory Rate (RR) will be adjusted (while leaving the Vt at 6cc/kg) to achieve the same minute ventilation. Patients will then be maintained on their current lung protective ventilation settings for approximately 1-2 hours, after which breath hold measurements will be repeated and another blood gas drawn.
3490037|NCT03715738|Experimental|arm 1 : Creaform3D + MyotonPRO|"A clinical questionnaire is completed by the investigator (chest circumference, thorax turn, breast measurements).~The breast density is assessed by the surgeon and scored from 1 to 5 (Likert scale) and then by the MyotonPRO The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair during 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~Intraoperatively, the weight of tissues removed is weighed (in grams), recorded in the observation notebook.~In post-operative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete"
3490038|NCT03715725||Registry cohort|Registries in Norway are nation-wide and provision of the information is mandatory, which eliminates the risk of both selection and re-call bias. The large and detailed dataset also makes it possible to adjust for other risk factors on which information is available.
3490039|NCT03715725||Electronic Medical Records (EMR) cohort|Patients with NVAF diagnosis will be identified through extraction of patient-level data from EMRs from a number of hospitals in Norway, in order to describe these patients more closely regarding their clinical characteristics that are not available in nation-wide registers (e.g., in-patient treatments, anthropometric data and laboratory test results).
3490040|NCT03715712|Experimental|Standard|Standardized blood pressure management with a target of mean blood pressure greater than 65mmHg and systolic blood pressure lower than 160mmHg
3490041|NCT03715712|Active Comparator|Individualized|Individualized blood pressure management of 20% within the preoperative ward blood pressure
3490042|NCT03715699|Experimental|Group 1|Patients treated with single glucocorticoid
3129304|NCT03209570|Active Comparator|TENA Identifi without sensor wear data|All individuals in this arm will receive care planning without using TENA Identifi sensor wear data
3129305|NCT03209882|Experimental|One TILS, one sham, and then five TILS interventions|Participants first received a TILS intervention, followed by a sham session one week later. Then, participants received another five weekly TILS interventions.
3490043|NCT03715699|Experimental|Group 2|Patients treated with Leflunomide and glucocorticoid
3490044|NCT03715673||Cases:Active IBD patients|23 patients with active inflammatory bowel disease for whom von willlebrand antigen and activity will be done
3129306|NCT03209882|Experimental|One sham, then six TILS interventions|Participants first received a sham session, followed by six weekly TILS sessions.
3129307|NCT03209973|Experimental|Tislelizumab|Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)
3180005|NCT00678769|Experimental|Group C (temsirolimus on days 1, 8, 15, and 22)|Patients receive temsirolimus IV over 30 minutes and cixutumumab IV over 60 minutes on days 1, 8, 15, and 22.
3490045|NCT03715673||Control:Inactive IBD patients|23 patients with inactive inflammatory bowel disease; VWF antigen and activity will be done for them
3490046|NCT03715660|Experimental|Xpert monitor- evaluated patients|Xpert Bladder Cancer Monitor performance shall be established in recurrence patients relative to cystoscopy (for disease negative patients) or histology (for disease positive patients)and relative to a currently used diagnostic assay (urine cytology)which is the standard of care used for detecting recurrent bladder cancer at the site. In this study, clinical sensitivity shall be established in patients who have been previously diagnosed with bladder cancer and are scheduled for a standard of care (SOC) surveillance cystoscopy.
3490047|NCT03715647||Sepsis|"The puerperal / postpartum women who evolved with sepsis, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
3490048|NCT03715647||HELLP Syndrome|"The puerperal / postpartum women who evolved with HELLP syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
3490049|NCT03715647||Respiratory Distress Syndrome, Adult|"The puerperal / postpartum women who evolved with Adult Respiratory Distress Syndrome, needing support by invasive mechanical ventilation, were evaluated and monitored with Electrical Impedance Tomography for ventilatory therapy. In order to obtain the images and quantification of the regional ventilatory distribution, two strips with 16 electrodes were connected around the thorax to capture an imperceptible and harmless electric current to the patient, generating, according to the pulmonary dynamics, an impedance power of variation. A flow sensor was positioned between the endotracheal tube and the Y of the ventilator circuit and was responsible for capturing information about ventilatory mechanics. Data were sent simultaneously to a system (computer) with specific softwear in order to measure and quantify the regional distribution of pulmonary ventilation and perfusion, as well as their correlation."
3490050|NCT03715634|Experimental|Depot buprenorphine (INDV-6200)|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive depot buprenorphine
3490051|NCT03715634|Placebo Comparator|Placebo|Period 1 subjects will receive SL buprenorphine to confirm tolerance to product Period 2 subjects will receive volume-matched placebo
3490052|NCT03715608|No Intervention|Control group|Patients in the control group received routine TKA surgery and perioperative management without any other interventions.
3490053|NCT03715608|Experimental|Intervention group|The patients in the intervention group received professional psychological interventions include psychological counseling and corresponding medication after the operation. Other perioperative treatments were the same as the patients in the control group. Psychotherapy was based on the clinical expertise of the psychosocial specialist, who selected the most appropriate plan for each patient.
3490054|NCT03715595|Experimental|SSDM group|The patients in will use the SSDM at home every month for one year.
3490055|NCT03715595|No Intervention|Control group|The patients will receive the conventional therapy for half a year. After half a year, all the patients will use the SSDM at home monthly for half a year.
3490056|NCT03715582|Experimental|trimetazidine|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When the patient is randomized to the trimetazidine pill group, he / she will initiate the medication at 70 mg oral dose (2 tablets of Vastarel ® MR 35 mg single dose) 2 hours before the procedure.
3490057|NCT03715582|Experimental|placebo|The randomization will be done with a list generated by the central pharmacy of the Hospital das Clínicas, Medical School, USP. When randomized to the placebo oral tablets group, the patient will receive placebo (orally, 2 single dose tablets) also 2 hours prior to PCI.
3490058|NCT03715569||Cohort with CNS infections|"Otoacoustic emissions (OAE), Wide Band Tympanometry (WBT), Vestibular function tests. Audiometry. MOCA, eGOS are cognitive tests.~Biomarker is a protein found in the inner ear examined in the cerebral fluid."
3490059|NCT03715569||OAE/WBT control: Healthy individuals|Otoacoustic emissions in normal position with head. Otoacoustic emission in different head positions.
3490060|NCT03715569||OAE/WBT control: Systemic infection|Otoacoustic emission during admission
3180008|NCT00678847|Placebo Comparator|B|
3490061|NCT03715569||OAE/WBT control: ICP changes|Otoacoustic emission on patients without an CNS infection before and after elective lumbare puncture with measurement of intracranial pressure (ICP).
3490062|NCT03715569||Biomarker control|Inner ear biomarkers in patients without CNS infection. Inner ear fluid examination from patients that underwent elective cochlea implantation.
3490063|NCT03715556|Active Comparator|Amiodarone|Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated. Administration of the drug will be blinded within the first hour to the principal investigator.
3490064|NCT03715556|Placebo Comparator|No intervention|The Liberal group will receive only 0.9% physiological solution, also blinded to the principal investigator.
3490065|NCT03715543|Experimental|Surgical Resection Arm|Surgical Resection of the Greater Splanchnic Nerve
3490066|NCT03715517|Experimental|Intrathecal morphine|"Spinal anesthesia with intrathecal morphine~Bolus (pre-induction): High-spinal anesthesia with 0.25 mg⋅kg-¹ hyperbaric bupivacaine 0.75% plus 3 mcg⋅kg-¹ intrathecal morphine (preservative-free)~Postoperative analgesia: IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)"
3490067|NCT03715517|Active Comparator|Thoracic epidural analgesia|"Continuous thoracic epidural analgesia~Bolus (pre-induction): 0.25 mg⋅kg-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹ hydromorphone (0.1 mL⋅kg-¹)~Infusion (initial): 0.25 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 1 mcg⋅kg-¹⋅h-¹ hydromorphone (0.1 mL⋅kg-¹⋅h-¹)~Infusion (range): 0.19-0. 3 mg⋅kg-¹⋅h-¹ bupivacaine 0.25% plus 0.75-1.25 mcg⋅kg-¹⋅h-¹ hydromorphone (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹)~Postoperative analgesia: (1) Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL-¹, infusion range as above (0.075-0.125 mL⋅kg-¹⋅h-¹) (3-10 mL⋅h-¹), continued for a maximum of 72 h postoperatively; (2) IV-PCA hydromorphone (bolus: 0.2 mg [range: 0.1-0.4 mg]; 5 min lockout; no infusion)."
3490068|NCT03715478|Experimental|GSK2857916 with Pomalidomide and Dexamethasone|This will be a single arm study of GSK2857916 administered with pomalidomide and dexamethasone. GSK2857916 will be administered intravenously either on Day 1 of each 28 day cycle (Single Dose) or on Days 1 and 8 (Split Dose) and up to 4 dose levels will be evaluated during the phase I portion. Pomalidomide will be administered orally on Days 1-21 at 4 mg. Dexamethasone will be administered orally at 40 mg for patients ≤ 75 years old or 20 mg for patients older than 75 on days 1, 8, 15, 22.
3490069|NCT03715439||Leucocyte- and Platelet-rich Fibrin|Dental implant placed into post-extraction sites preserved with leucocyte- and platelet-rich fibrin
3490070|NCT03715439||Control|Dental implant placed into non-preserved post-extraction sites
3490071|NCT03715413|Other|Tamoxifen group|they was received Tamoxifen 10 mg daily.
3490072|NCT03715413|Active Comparator|Tamoxifen and pulsed radiofrequency group|they was received Tamoxifen 10 mg daily and pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.
3490073|NCT03715400|No Intervention|Control|The control group will not undergo the positive virtual reality training program. Instead, they will complete all self-report and behavioral measures and have the option to experience the positive virtual reality training program upon the conclusion of the study.
3490074|NCT03715400|Experimental|Positive Virtual Reality Training Intervention|The experimental group will undergo the positive virtual reality training program, which consists of 7 virtual reality (VR) sessions to be completed at home after orientation to the program, in addition to all self-report and behavioral measures.
3490075|NCT03715387|Experimental|Tacrolimus Treatment|Tacrolimus Topical 0.1% Topical Ointment
3490076|NCT03715387|Placebo Comparator|Control|Patients will be self matched controls with one cheek receiving the study ointment and the other receiving a control ointment (polysporin ointment).
3490077|NCT03715374|Experimental|PRF+ABB treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A prf membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
3490078|NCT03715374|Active Comparator|Collagen Membrane + ABB treated patients|Periodontal surgery with collagen membrane is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Anorganic bovine bone material will be applied to the entire root surfaces ; then, A collagen membrane is positioned above the filling material. Finally the flap will be positionated and sutures completed by interrupted sutures.
3490079|NCT03715361||Patients|Patients (500 patients ≤ ) who undergo out- or inpatient treatment and who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
3490080|NCT03715361||Control Group|Fifty volunteers who did a 12lead-ECG measurement, repeat the procedure using the hand-held diagnostic tool (SL-ECG).
3490081|NCT03715348|Active Comparator|Fresh Frozen Plasma (FFP)|"Patients randomised to the comparator arm will receive Fresh Frozen Plasma (FFP)~FFP will be provide as a solution for intravenous administration, once thawed.~The dose of the FFP will be ~ 15 mL/kg.~Subjects may receive multiple doses of FFP as required if bleeding continues, as per usual care"
3490082|NCT03715348|Experimental|Prothrombin Complex Concentrate (PCC)|"Patients randomised to the experimental arm will receive PCC at ~15 IU/kg. PCC will be reconstituted into a solution for intravenous administration.~Subjects will receive a single dose of PCC, and if bleeding continues, standard treatment will be administered"
3490083|NCT03715322|Active Comparator|tobramycin inhalation|300mg tobramycin dissolved in 5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
3490084|NCT03715322|Placebo Comparator|natural saline inhalation|5ml saline will be nebulized with an ultrasonic nebulizer within 15-20 minutes.
3490085|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
3490086|NCT03715309|Experimental|Revlimd|
3129308|NCT03210155|Active Comparator|Active Comparator|About the size of a smart phone, the Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The active intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
3490087|NCT03715283|Experimental|Home Lower Extremity Strengthening|Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing.
3490088|NCT03715283|Experimental|No intervention|In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs.
3490089|NCT03715270||breast reconstruction surgery patients|Patients will be imaged with imaging device (Presygen™/si-1) during surgical procedure. Image surgical area. Surgical procedure will follow standard of care. No clinical decisions will be made on device readings. A surgeon will complete a survey regarding his assessment of the imaging device.
3490090|NCT03715257|Active Comparator|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
3490091|NCT03715257|Active Comparator|Tube changing catheter|"Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
3490092|NCT03715244||Study group 1|n=220 patients for routine data of spinal anesthesia with short-acting local anesthetics
3490093|NCT03715244||Study group 2|n= 220 patients for routine data of general anesthesia (current standard)
3490094|NCT03715244||No intervention: Control group postoperative cognitive deficit|n= 90 control subjects aged 18 years or older (without surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
3490095|NCT03715218|Experimental|Mother Touch Program|Post natal care provided by trained carer after the birth. 6 weeks of care included massage, special diet, physical and mental relaxations.
3490096|NCT03715218|Other|Usual care Program|Usual care and supervision was provided as usual.
3490097|NCT03715205|Experimental|Cohort A: Melanoma|Participants with unresectable or metastatic melanoma receive 200 mg of pembrolizumab as an intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 cycles.
3490098|NCT03715205|Experimental|Cohort B: NSCLC|Participants with NSCLC who are either treatment naïve or have progressed after prior treatment receive 200 mg of pembrolizumab as an IV infusion every Q3W for up to 35 cycles.
3490099|NCT03715192|Experimental|LY3462817 - IV|Escalating doses of LY3462817 administered as a single intravenous (IV) infusion in healthy participants
3490100|NCT03715192|Placebo Comparator|Placebo|Normal saline administered as a single IV infusion in healthy participants
3490101|NCT03715192|Experimental|LY3462817 - SC|Single dose of LY3462817 administered as subcutaneous (SC) injections in healthy participants
3490102|NCT03715179||Standard of Care|Individuals living with an ostomy and their caregivers. Participants use their own ostomy pouching systems per their clinician's standard of care
3490103|NCT03715166|Experimental|Bumetanide/S95008|
3490104|NCT03715166|Placebo Comparator|Placebo|
3490105|NCT03715153|Experimental|BUMETANIDE/S95008|
3490106|NCT03715153|Placebo Comparator|PLACEBO|
3490107|NCT03715140|Experimental|Patients who will recieve crucumin|patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.
3129309|NCT03210155|Sham Comparator|Sham Comparator|The Alpha-Stim® AID CES sham device is identical in appearance to the active device but is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham intervention is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
3180009|NCT00678847|Active Comparator|A|
3490108|NCT03715140|Placebo Comparator|Patients who will receive placebo|Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.
3490109|NCT03715127|Placebo Comparator|Placebo|one oral dose of 100% mannitol (placebo)
3490110|NCT03715127|Active Comparator|Psilocybin|one oral dose of 0.215mg/kg psilocybin (verum)
3490111|NCT03715114|Experimental|GV-971 900 mg|900 mg oral
3490112|NCT03715114|Experimental|GV-971 1200 mg|1200 mg oral
3490113|NCT03715114|Experimental|GV-971 1500 mg|1500 mg oral
3490114|NCT03715114|Placebo Comparator|Placebo|Oral placebo
3490115|NCT03715101|Experimental|Rosuvastatin 20 mg PO|Rosuvastatin 20 mg daily for 21 days
3490116|NCT03715088|Experimental|Older Adults (BMI ≥30 kg/m2)|Individuals aged 65-75 living with obesity will perform the Resistance Training Intervention.
3490117|NCT03715088|Experimental|Younger Adults (BMI ≥30 kg/m2)|Individuals aged 18-30 living with obesity will perform Resistance Training Intervention.
3490118|NCT03715075||Post-caesarean section group|This single cohort observational study shall recruit women undergoing elective caesarean section within the Simpson's Centre for Reproductive Health (SCRH).
3490119|NCT03715062|Experimental|Intervention group|Receives education in diagnosing urinary tract infection and use of observation, reflection and communication tool.
3490120|NCT03715062|No Intervention|Control group|No intervention
3490121|NCT03715049|Other|Fraxel Laser Treatment|Using the energy and density settings within the FDA approved limits (5-40mJ at 30-100% density) that were narrowed down by the pre-clinical portion of the study, and analysis of abdominal and facial tissue treated in Objective 1, up to thirty (30) subjects will be recruited and treated one (1) time in the perioral region of the upper lip and followed for 6 months (study design below). The acute effects of the laser application will be determined by subjective analysis using the wrinkle severity scores.
3129310|NCT03210220|Experimental|pecs group|Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .
3490122|NCT03715036|No Intervention|Fundal height|Patients will have routine fundal height measurement
3490123|NCT03715036|Experimental|Point-of-care US|Patients will receive POC US for DVP and AC.
3490124|NCT03715023|Experimental|Active + SoC|Daily doses of PC786 for 3 days + SoC
3490125|NCT03715023|Placebo Comparator|Placebo + SoC|Daily doses of Placebo for 3 days + SoC
3490126|NCT03715010|Active Comparator|Brain Chain Amino Acid (BCAA)|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
3490127|NCT03715010|Placebo Comparator|Placebo|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa, cross-over design
3129311|NCT03210220|No Intervention|control group|There is no block.
3129312|NCT03210259|Experimental|BI 695501|
3129313|NCT03210259|Active Comparator|Humira®|
3490128|NCT03714997|Experimental|High Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates close to 80% of heart rate reserve.
3490129|NCT03714997|Active Comparator|Low Intensity Locomotor Training|High Intensity Locomotor Training will consist of 30 sessions of walking related activities in variable contexts (i..e, on a treadmill, overground, and on stairs), with a primary goal to achieve 40 minutes of walking within 1 hour sessions while achieving heart rates from 30% to 40% of heart rate reserve.
3129314|NCT03210337|Experimental|Active|A-101 Topical Solution
3129315|NCT03210337|Placebo Comparator|Vehicle|Vehicle
3490130|NCT03714984|Experimental|Pre operative exercise|The educational pelvic floor intervention group will receive one months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction. Patients and care giver will receive a daily exercise diary to fill at home and will be advised to follow the exercise program.
3490131|NCT03714984|Active Comparator|Control group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
3490132|NCT03714971|Experimental|Receiving WhatsApp messages|Among patients applying to the smoking cessation outpatient clinic between March and October 2017, >18-year old volunteers who smoked at least one cigarette/day, using WhatsApp at least on four days of the week, accepting the 3-month follow-up were included In receiving WhatsApp messages group.
3490133|NCT03714971|No Intervention|Not receiving WhatsApp messages|"In not receiving WhatsApp messages group; Stratification and randomization were both used to randomly allocate participants to both arms of the study. The intervention and control groups were first stratified according to physician and then gender, and later allocated in a simple random manner. Randomization was conducted using a computer spreadsheet. Allocation according to gender was conducted regarding the 2:3 female to male ratio in the routine cessation services and stratification according to physician aimed to have a balanced distribution among the different physicians working in the same cessation unit. As the target number of participants was small, further stratification was not applied. Simple random sampling was then used to allocate participants to each group."
3490134|NCT03714958|Experimental|combination HDM201 - Trametinib|"HDM201: Therapeutic class HDM2 inhibitor, given Per Os every D1 and D8 over a 28 day cycle. Four dose-levels possible in dose escalation part: 40 mg, 80mg, 100 mg, 120mg.~Trametinib: Therapeutic class Protein kinase inhibitor of MEK1 and MEK2 activation and kinase activity. Administrated daily, countinous dosing , twodose-level possible in dose escalation: 1.5 mg and 2mg"
3490135|NCT03714945||Case Group with Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years, diagnosed with allergic rhinitis on basis of screening instruments, medical history, clinical assessment (by general ORL examination including nasal endoscopy)~Chinese in ethnicity~Positive skin prick test with wheal diameter >= 3mm~Ability to understand the nature, scope, and possible consequences of the study~Capability and willingness to comply with the requirements of the protocol"
3490136|NCT03714945||Control Group without Allergic Rhinitis|"- Inclusion Criteria~Both genders of 11-14 years~Chinese in ethnicity~Subjects who have not been diagnosed with a long term medical or psychiatric problem~Subjects who are not currently undergoing any long term medical treatment."
3490137|NCT03714906|Experimental|Treatment|Patients randomized to the Treatment arm will be assigned to receive a stellate ganglion block. While in the hospital after surgery, patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
3129316|NCT03210376|Experimental|Deep Neuromuscular Blockade (NMB) + Sugammadex|"Deep Neuromuscular Blockade (NMB) given during surgery.~Sugammadex intravenously as a single bolus injection after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
3129317|NCT03210376|Experimental|Moderate Neuromuscular Blockade (NMB) + Neostigmine|"Moderate Neuromuscular Blockade (NMB) given during surgery.~Neostigmine intravenously slowly over a period of at least 1 minute after surgery.~Pain assessment done at about 15, 45, and 90 minutes after surgery."
3129318|NCT03210519|Experimental|Eleutherococcus senticosus|Acanthopanax senticosus-mono formula (30mg/vial) and Fructus Ziziphi Jujube concentrated juice15ml/vial
3129319|NCT03210519|Placebo Comparator|Placebo|Fructus Ziziphi Jujube concentrated juice15ml/vial
3490138|NCT03714906|No Intervention|Control|Patients assigned to the Control arm will receive no pre-operative intervention. While in the hospital after surgery, these patients will be given a regimen of scheduled acetaminophen 650 milligrams every 6 hours. Planned treatment of post-operative pain will include the option of requesting oxycodone on an as-needed basis every four hours and IV morphine for breakthrough pain.
3490139|NCT03714880|Experimental|Mifepristone|Participants ingest mifepristone 200 mg oral medication once 18-24 hours prior to dilator placement
3490140|NCT03714880|Placebo Comparator|Placebo|Participants ingest placebo oral medication once 18-24 hours prior to dilator placement
3490141|NCT03714867|Experimental|Treatment|Treatment arm intervention consists of patients who will be administered a single enteral dose of concealed over-encapsulated Pregabalin 150mg in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
3490142|NCT03714867|Placebo Comparator|Control|Treatment arm consists of patients who will be administered a single enteral dose of concealed over-encapsulated placebo capsules in the pre-operative holding area. Patients will be given a post-operative regimen of 650 mg enteral acetaminophen every 6 hours and as needed oxycodone and intravenous morphine for breakthrough pain.
3490143|NCT03714841|Experimental|CRP value|The patients point of care CRP value is known by the treating physician
3490144|NCT03714841|Active Comparator|CRP value unknown|The patients point of care CRP value is not known by the treating physician
3490145|NCT03714828|Experimental|Treatment (talimogene laherparepvec)|The subject participation period will be approximately 48 weeks. This will include a screening visit, 4 injection visits and 5 follow up visits. Total length of study/patient is 8.5 to 10.5 months. TVEC will be administered by injection with a needle directly into one or more tumors.
3490146|NCT03714802|Experimental|Szabo T-Stenting Technique|Patients received 2-stents implantation guided with Szabo technique in bifurcation lesion.
3490147|NCT03714802|Placebo Comparator|T-Stenting Technique|Patients received 2-stents implantation guided with T-stenting technique in bifurcation lesion.
3490148|NCT03714789||Meropenem|Patients requiring dialysis and receiving meropenem for infection or suspended infection.
3490149|NCT03714789||Vancomycin|Patients requiring dialysis and receiving vancomycin for infection or suspended infection.
3490150|NCT03714789||Ceftriaxone|Patients requiring dialysis and receiving ceftriaxone for infection or suspended infection.
3129320|NCT03210701|Other|Patients requesting a HIV screening test|
3129321|NCT03210961|Experimental|PF-06826647 tablet|
3490151|NCT03714776|Experimental|IONIS-AGT-LRx|IONIS-AGT-LRx injected subcutaneously once-weekly
3490152|NCT03714776|Placebo Comparator|Placebo|Placebo matching solution injected subcutaneously once-weekly
3490153|NCT03714763|Experimental|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.
3490154|NCT03714763|Experimental|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.
3490155|NCT03714750|Active Comparator|DK crush|Percutaneous revascularization of true coronary bifurcation stenosis (Medina 1,1,1 or 0,1,1) with double kissing and crush technique
3490156|NCT03714750|Experimental|Reverse TAP|Percutaneous revascularization of true coronary bifurcation Stenosis (Medina 1,1,1 or 0,1,1) with reverse T and protrusion technique
3490157|NCT03714737|Experimental|Experimental 1|Experimental vaccine of 0.5ml in 300 children aged 2-5 years at day 0.
3490158|NCT03714737|Active Comparator|Positive control 1|Positive control vaccine 1 of 0.5ml in 300 children aged 2-5 years at day 0.
3490159|NCT03714737|Experimental|Experimental 2|Experimental vaccine of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
3490160|NCT03714737|Experimental|Experimental 3|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0.
3490161|NCT03714737|Active Comparator|Positive control 2|Positive control vaccine 2 of 0.5ml in 150 children aged 12-23 months at day 0 and 28.
3490162|NCT03714737|Experimental|Experimental 4|Experimental vaccine of 0.5ml in 150 children aged 2-5 years at day 0 and 28, and boost at 18 months.
3129322|NCT03210961|Placebo Comparator|Placebo tablet|
3490163|NCT03714737|Active Comparator|Positive Control 3|Positive control vaccine 2 of 0.5ml in 150 children aged 6-11 months at day 0 and 28.
3490164|NCT03714737|Experimental|Experimental 5|Experimental vaccine of 0.5ml in 300 children aged 3-5 months at day 0, 28, 56, and boost at 18 months.
3490165|NCT03714737|Active Comparator|Positive Control 4|Positive control vaccine 1 of 0.5ml in 300 children aged 3-5 months day 0, 28, 56.
3490166|NCT03714724|Active Comparator|Group 4|"Patients who received 0-4 cmH2O PEEP in mechanical ventilation were referred to as Group 4.~Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded."
3490167|NCT03714724|Active Comparator|Group 8|Patients who received 5-8 cmH2O PEEP in mechanical ventilation were referred to as Group 8. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
3490168|NCT03714724|Active Comparator|Group 12|Patients who received 9-12 cmH2O PEEP in mechanical ventilation were referred to as Group 12. Intraabdominal, central venous, arterial blood pressures, pulse rates, peripheric oxygen saturation, body temperature, instant fluid balances and amounts of urine (in ml/kg/hour unit) of the patients were measured on the 0. 6. 12. 18. and 24. hours and recorded.
3490169|NCT03714698|Active Comparator|Pilates Exercise Group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
3490170|NCT03714698|Placebo Comparator|Control Group|the control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
3490171|NCT03714685|Experimental|Firibastat prototype tablet formulations|Firibastat (QGC001) 500 mg modified release prototype tablet formulations or immediate release capsule formulation - 1 tablet or 1 capsule administered per period
3129323|NCT03210961|Experimental|PF-06826647 oral suspension|
3129324|NCT03210961|Placebo Comparator|Placebo oral solution/suspension|
3129325|NCT03211117|Experimental|Cohort A (pembrolizumab, surgery, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients undergo surgery. Within 42 days of surgery, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
3490172|NCT03714646|Placebo Comparator|Placebo|
3180010|NCT00678873|Experimental|Surgical group|Patients with ultrasound proven symptomatic cholelithiasis (gallstones).
3490173|NCT03714646|Active Comparator|beta glucan|
3490174|NCT03714646|Experimental|beta glucan and Resistant Starch|
3490175|NCT03714620|Active Comparator|0.15 mg/kg IV Ketamine|
3490176|NCT03714620|Active Comparator|0.3 mg/kg IV Ketamine|
3490177|NCT03714607|Experimental|Laser|Erbium Yttrium Aluminum Garnet (Er:YAG) laser therapies
3490178|NCT03714607|No Intervention|Control|No intervention
3490179|NCT03714594|Active Comparator|Dapagliflozin 10mg|Dapagliflozin inhibits SGLT2 promoting the excretion of glucose in the urine,and lowers the plasma glucose concentration. This class of drugs has been shown to effectively reduce the HbA1c at all stages of T2DM and can be used in combination of all other anti-diabetic agents including insulin.
3490180|NCT03714594|Active Comparator|Saxagliptin 5mg|Saxagliptin is a DPP4 inhibitor.In patients with type 2 diabetes,administration of saxagliptin led to inhibition of DPP4 enzyme activity.After an oral glucose load,this DPP4 inhibition resulted in a increase in circulating levels of active incretin hormones include GLP-1 and GIP, decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness,which resulted in higher insulin and C-peptide concentrations.The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.Saxagliptin improves glycaemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.
3490181|NCT03714594|Active Comparator|Saxagliptin 5 mg + dapagliflozin 10 mg|Please see Arm 1 and 2
3490182|NCT03714581|Experimental|Laser|Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.)
3490183|NCT03714581|Placebo Comparator|Placebo|Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode.
3490184|NCT03714568|Experimental|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
3490185|NCT03714568|Experimental|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
3490186|NCT03714555|Active Comparator|Nab-Paclitaxel/Gemcitabine + DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
3490187|NCT03714555|Active Comparator|FOLFIRINOX +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
3490188|NCT03714555|Active Comparator|Single-Agent Gemcitabine +DSF/Cu|Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
3490189|NCT03714542|Other|Pre- and postoperative MRI|All patients will undergo a preoperative MRI and will have a postoperative follow-up with CT and MRI.
3490190|NCT03714529|Experimental|Treatment arm|"The vaccine consists of 500µl of 100µg PD-L1 peptide, dissolved in DMSO and PBS reconstituted with 500 µl Montanide ISA-51.~Patients will be vaccinated Q2W for 10 weeks, and a further 12 weeks if a clinical response is measured."
3490191|NCT03714503|Other|One day post-operative head positioning|patients will be assigned to remain a one-day post operative head positioning following retina re-attachment surgery
3490192|NCT03714490|Experimental|Experimental group|The intervention of Experimental group includes: Radiotherapy, followed by chemotherapy with capecitabine, oxaliplatin, and then surgery. The detail of procedure: 1, short-course preoperative radiotherapy(SCPRT) , which consists of SCPRT, 5 Gray(Gy) x 5, 4Gy for boost on the gross tumour volume(GTV) with MRI-simulation alone; 2,then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy.
3490193|NCT03714490|Active Comparator|Control group|The intervention of Control group includes:Radiotherapy, capecitabine, and surgery. The detail of procedure: 1, long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively; 2, 6-8 weeks after chemoradiation, total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends.
3490194|NCT03714477|Active Comparator|Treatment Arm|immediate extracorporeal shock wave lithotripsy - subject will have SWL arranged in the next available list
3490195|NCT03714477|No Intervention|Control Arm|delayed extracorporeal shock wave lithotripsy - subject will have SWL done 6 months later
3490196|NCT03714464|Experimental|Whole Apple|"Participants will be given 350g of whole apple and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
3490197|NCT03714464|Experimental|Apple Puree|"Participants will be given 384g of apple puree and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes."
3490198|NCT03714464|Experimental|Apple Juice|"Participants will be given 338g of apple juice and 150 mls water to be consumed in 20 minutes.~Serial MRI of gastrointestinal tract is done every 45 minutes from baseline until 315 minutes"
3490199|NCT03714451|Experimental|Onyx Group|Patients with T2DM will receive food products containing onyx sorghum (Onyx Group).
3180011|NCT00678912|Experimental|1|Children are mechanically ventilated with Smartcare/PS
3490200|NCT03714451|Active Comparator|Wheat Flour Group|Patients with T2DM will receive food products with wheat flour.
3490201|NCT03714438|Experimental|Medicago sativa|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
3490202|NCT03714438|Placebo Comparator|Placebo|1,500 mg unique dose, 30 min before the oral glucose tolerance test.
3490203|NCT03714425|Active Comparator|High frequency device|Subjects will use high frequency Quell devices.
3490204|NCT03714425|Sham Comparator|Low frequency device|Subjects will use low frequency Quell devices.
3490205|NCT03714412|Experimental|Implantation|Eligible patients will undergo implantation with the Cardiovalve system
3490206|NCT03714386|Experimental|expanded hemodialysis (HDx)|HDx therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
3490207|NCT03714386|Active Comparator|online hemodiafiltration (HDF-OL)|OL-HDF therapies must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
3490208|NCT03714373|Experimental|DCCR|75 - 450 mg DCCR
3490209|NCT03714360|Experimental|TXA tranexamic acid|a single dose of 10 mg/kg of TXA, with a maximum dose of 1g. Administered as IV injection and marked as 'project-drug' and amount (mL) in the medical record.
3490210|NCT03714360|Placebo Comparator|Sodium Chloride 0,9%|an equivalent volume 0.9 % Sodium Chloride.
3490211|NCT03714347|Active Comparator|Group Control|routine monitoring will be applied to this group
3490212|NCT03714347|Active Comparator|Group Oxygen|cerebral oxygen monitoring is applied to this group
3490213|NCT03714334|Experimental|DNX-2440 injection|all the patients included will be treated with the experimental agent
3490214|NCT03714321|Experimental|Mechanical insufflation-exsufflation arm|MIE will be given as prescribed by physician responsible at the intermediate care unit, typically every 4 hours. MIE will be administered with standard settings of insufflation 20 cm H2O and exsufflation 20 cm H2O, with possible individual changes from 10/-10 H2O up to 40/-40 H2O, and oxygen flow up to 15 l/min. The standard settings will be set to five cycles of 2 seconds insufflation, 3 seconds exsufflation with a three second pause between each cycle. Every treatment session consists of five rounds of five cycles, in all 25 insufflation/exsufflation, with time between each cycle of 30 seconds, meant used for suction.
3490215|NCT03714321|No Intervention|CPAP arm|CPAP will be given as prescribed by the physician responsible at the intermediate care unit, typically every 4 hours. CPAP will be administered with standard settings of H2O and an oxygen flow of 15L/min.
3490216|NCT03714295||Use of interdental brushes|The group use interdental brushes one time each day and wash teeth with a classical brush two times a day
3490217|NCT03714295||No use of interdental brushes|The group wash teeth with a classical brush two times a day
3490218|NCT03714282|Experimental|Noninvasive Spinal Stimulation with Gait Training|May receive up to 50 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
3490219|NCT03714282|Active Comparator|Conventional Gait Training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
3490220|NCT03714282|Other|Healthy Control Group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
3490221|NCT03714269|Experimental|Children with cerebral palsy of the spastic type|
3490222|NCT03714243|Experimental|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
3490223|NCT03714217|Experimental|Intervention|Telenutrition counseling
3490224|NCT03714204|Experimental|Transcendental Meditation Group|Participants assigned to this group each received the intervention of 5 initial class instructions in the Transcendental Meditation technique, followed by 6 additional classes over the 4-month study period. Group participants were expected to practice the technique for 20 minutes twice per day for 4-months.
3490225|NCT03714204|No Intervention|Control Group|Participants assigned to this group served as wait-list controls
3180012|NCT00678912|No Intervention|2|Children are mechanically ventilated with usual care
3180013|NCT00678925|Active Comparator|1|Choline supplement given from 18-weeks pregnancy through 90 days postpartum
3490226|NCT03714191||Improved outcomes|
3490227|NCT03714191||Regulatory reminder|
3490228|NCT03714191||Billing and documentation|
3490229|NCT03714178|Experimental|FARAPULSE Endocardial Ablation|Subjects who are treated with the FARAPULSE Endocardial Ablation System for paroxysmal atrial fibrillation.
3129326|NCT03211117|Experimental|Cohort B (pembrolizumab, chemoradiation)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
3129327|NCT03211156|Placebo Comparator|Placebo arm|Placebo 2 capsules PO twice a day for 7 days, n=49
3490230|NCT03714152|Experimental|ABI-H2158|ABI-H2158 in varying doses of tablets by mouth without and with food for 1 day or 10 days
3490231|NCT03714152|Placebo Comparator|Matching Placebo for ABI-H2158|Matching Placebo in varying doses of tablets by mouth without and with food for 1 day or 10 days
3490232|NCT03714139|Experimental|Immediate implant Loading|Immediate loading is defined as the placement of the implant and immediate prosthetic restoration
3490233|NCT03714139|No Intervention|non implant loading|there is not immediate prosthetic restoration
3490234|NCT03714126||HF patients|HF patients will use the Cordio Medical app to record in their hospital visits and at home.
3490235|NCT03714113|Experimental|Kidney transplant recipients.|Patients who undergo kidney transplant in 2018 or 2019.
3490236|NCT03714100|Experimental|MFBB intervention|All participants will attend Tai Ji Quan: Moving for Better Balance classes twice a week for 16 weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
3490237|NCT03714087|Experimental|T1 Conventional treatment before aligner|T1 before aligner: Conventional orthodontic treatment patients before the essix aligner
3490238|NCT03714087|Experimental|T2 After essix aligner|T2 after the aligner: Essix aligner appliance with setup for 3 weeks full time
3490239|NCT03714087|Active Comparator|Historic control group|Conventional orthodontic treatment without finishing protocol UdeA2
3490240|NCT03714074|Experimental|PEEK abutment|PEEK abutment restored with PEEK superstructure
3490241|NCT03714074|Experimental|Zirconia abutment|zirconia abutment restored with PEEK superstructure
3490242|NCT03714061|Experimental|Pain Neuroscience Education (PNE)|The PNE will be administered following Explaining Pain concepts (Butler and Moseley, 2013), initially contextualizing the importance of the program. The program will be administered as interactive workshops lasting 50 minutes. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
3490243|NCT03714061|Active Comparator|Self-Management Education (SME)|The SME education will be administered as an interactive workshop lasting 50 minutes. The program is based on the Back-book material (Roland et al, 2011), focusing on concepts targeting change of behavior and beliefs. In addition, the participants were oriented to perform at home a group o motor control exercises during three weeks, twice a week.
3490244|NCT03714048||Perioperative|
3490245|NCT03714048||Cardiogenic shock minus arrest|
3490246|NCT03714048||Cardiogenic shock plus arrest|
3490247|NCT03714048||Preventive|
3490248|NCT03714009|Active Comparator|Fasting group|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. They should take adequate water and non calorie beverages intake daily (2-3 liters)"
3490249|NCT03714009|Other|Non fasting group|no fasting, patients will have usual balanced diet as 3 meals and 2 snacks all over the day. They should take adequate water and non calorie beverages intake daily (2-3 liters)
3490250|NCT03713996|Experimental|CBT-I intervention|The intervention includes several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components.
3490251|NCT03713996|Active Comparator|Diabetes Education|Sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity will be delivered for the Health Education group. During all sessions, subjects will be encouraged to engage in the discussion through open questions about their experience in diabetes, lifestyle, and understanding about provided materials.
3490252|NCT03713970|Experimental|Celtra duo press|Celtra duo press ingot 20g for three laminate veneers
3490253|NCT03713970|Active Comparator|IPS e.max press|IPS e.max press ingot 20g for three laminate veneers
3129328|NCT03211156|Experimental|Treatment arm|Amoxicillin 2 x 250 mg capsules PO twice a day for 7 days, n=49
3490254|NCT03713957|Experimental|GRF6021|Subjects will receive GRF6021 for 5 consecutive days at Week 1 and Week 13.
3490255|NCT03713957|Placebo Comparator|Placebo|Subjects will receive Placebo for 5 consecutive days at Week 1 and Week 13.
3490256|NCT03713944|Experimental|Carboplatin, Pemetrexed, Atezolizumab plus Bevacizumab|"Carboplatin (AUC 5) i.v. day 1 plus pemetrexed (500 mg/m2) i.v. day 1 plus atezolizumab 1200 mg i.v. day 1 plus bevacizumab 15 mg/kg i.v. day 1 every 3 weeks for up to 4 cycles.~Patients with non-PD after 4 cycles will be permitted to continue with maintenance therapy with pemetrexed plus atezolizumab plus bevacizumab every 3 weeks until the time of disease progression or intolerable toxicities."
3490257|NCT03713918|Experimental|Reinforced lithium silicate endocrown|Device: Endocrown restoration
3490258|NCT03713918|Active Comparator|Reinforced lithi silicate crn e post|Device: Post retained reinforced lithium silicate crowns
3490259|NCT03713892|Experimental|CKD-504|investigational Drug
3490260|NCT03713892|Placebo Comparator|Placebo|investigational Drug
3490261|NCT03713879|Experimental|indomethacin|rectal indomethacin 100 mg to be administered before or after ERCP
3490262|NCT03713879|Experimental|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
3490263|NCT03713879|Experimental|indomethacin plus pancreatic stenting|"[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire]"
3490264|NCT03713866|Experimental|EP Imaging and Testing|MRI images,120 lead body surface mapping and NIPS testing will be completed to correlate areas of VT scar.
3490265|NCT03713853||Total hip arthroplasty + ORIF|Patients will receive acute primary total hip arthroplasty (THA) with open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
3490266|NCT03713853||Surgical Fixation (ORIF)|Patients will receive open reduction internal fixation (ORIF) as a treatment for their acetabular fracture
3490267|NCT03713840|Experimental|Healthy Beverages in Child Care|Child care centers in the experimental arm received 12-week intervention that promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
3490268|NCT03713840|No Intervention|Control|Child care centers in the control arm received access to intervention materials at a later date.
3490269|NCT03713827|Active Comparator|"composite resin, Ceram-x One Universal"|"tooth restoration with nano-ceramic composite resin Ceram-x one Universal"
3490270|NCT03713827|Active Comparator|"glass ionomer cement, Equia Forte"|"Tooth restoration with glass ionomer cement (Glass hybrid restorative system) Equia Forte"
3490271|NCT03713814|Experimental|Experimental Group|8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.
3490272|NCT03713814|No Intervention|Control group|After the 8 weeks of intervention, the pilots will receive explanation and handbook demonstration of the same exercises.
3490273|NCT03713801|Experimental|Metformin|Dosage is increased over the first 3 weeks up to three 500 mg tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
3490274|NCT03713801|Placebo Comparator|Placebo|Placebo tablet dosage is increased over the first 3 weeks up to three tablets a day at 3 weeks, then continued on 3 tablets daily for a further 9 weeks.
3490275|NCT03713788|Experimental|Experimental pain group|subjects in the pain group were instructed to immerse their non-dominant hand into a container with circulating water at 1˚C to 4˚C and keep it there for 2 minutes. They were instructed to immerse it to wrist-level and keep the hand open.
3490276|NCT03713788|No Intervention|Control group|Participants rested in a seated position for 5 minutes.
3129329|NCT03211234|Experimental|2.0 mg DE-122|2.0 mg DE-122 and Lucentis ® 0.5 mg
3129330|NCT03211234|Experimental|4.0 mg DE-122|4.0 mg DE-122 and Lucentis ® 0.5 mg
3129331|NCT03211234|Sham Comparator|Sham|Sham and Lucentis ® 0.5 mg
3490277|NCT03713775|Experimental|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Weight Loss Programme with behavioural support. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counsellors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients. The programme conventionally includes the 3 phases (meal replacement phase, transition phase, and weight maintenance phase) but the Consultant will have full discretion to modify and tailor this programme to suit each individual participant.
3490278|NCT03713775|Active Comparator|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min at the John Radcliffe Hospital, Oxford) together with supporting written information (i.e. a copy of the booklet 'Facts not fads - Your simple guide to healthy weight loss.')
3490279|NCT03713762|Experimental|Group 1 LB|Peribulbar block 1 was performed received 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml
3490280|NCT03713762|Experimental|Group 2 LBF|Peribulbar block 2 was performed received 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
3490281|NCT03713749|Experimental|Robot Esophagectomy (RE)|Patients in the RE group will receive robotic-assisted esophagectomy with standard total two-field lymphadenectomy.
3490282|NCT03713749|No Intervention|Video-assisted thoracoscopic esophagectomy (VATE)|Patients in the VATE group will receive thoracoscopic esophagectomy with standard total two-field lymphadenectomy.
3490283|NCT03713736|Other|Female patients with spondyloarthritis or rheumatoid arthritis|Female patients (18 to 65 years old) with spondyloarthritis or rheumatoid arthritis will undergo HPV screening and a have a close gynecologic follow-up.
3490284|NCT03713723||Patients undergoing IVF treatment with hemodynamic monitoring|Fifty health women aged 18-45 undergoing their first, second or third cycle of IVF treatment will be monitored with the non invasive NICaS bioimpedance
3490285|NCT03713710|Experimental|Pap testing|Women assigned to this arm will be scheduled a Pap testing appointment at the local health department
3490286|NCT03713710|Experimental|Choice|Women assigned to this arm will be given a choice between scheduling an appointment for a Pap testing at the health department or engage in self-sampling for HPV testing at home
3490287|NCT03713697|Experimental|Pap testing|Women assigned to this arm were invited to get a Pap testing at the Basic Health Unit
3490288|NCT03713697|Experimental|Self-Collection for HPV testing|Women assigned to this arm were provided with a kit to engage in self-collection for HPV testing
3490289|NCT03713697|Experimental|Choice|Women assigned to this arm were given a choice between a Pap testing at the local Basic Health Unit or self-collection for HPV testing
3490290|NCT03713658|Experimental|Oral Risperidone|Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
3490291|NCT03713658|Experimental|Paliperidone Palmitate Once Monthly (PP1M)|Participants will receive 50, 75, 100 or 150 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
3490292|NCT03713658|Experimental|Paliperidone Palmitate Every 3 Months (PP3M)|Participants will receive 175, 263, 350 or 525 mg eq. ([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
3490293|NCT03713645|Experimental|Tacrolimus extended-release 0.13mg/kg/day|Tacrolimus extended-release is initiated within post-operative day 3 of kidney transplant
3490294|NCT03713606||Overall eligible participants|Eligible participants will receive HVPG measurement by catheterization of a hepatic vein with a balloon catheter and run blood tests.
3490295|NCT03713567|Placebo Comparator|Experimentally induced plaque|Induced inflammation by suspension of oral hygiene
3490296|NCT03713567|Experimental|Experimentally induced plaque GAP|Induced inflammation by suspension of oral hygiene in patients with history of Generalized Aggressive periodontitis
3490297|NCT03713541||Patients with Anorexia nervosa (AN)|Female patients with Anorexia nervosa (AN, ICD-10: F50.0/1) of 14 years and older, receiving an initial treatment due to their AN (start of initial treatment no longer than 3 months ago, inpatient care: at least 7 days inpatient; outpatient care: at least 5 sessions with the same therapist) with sufficient language skills and no serious organic or psychiatric illnesses and no acute suicidality will be consecutively included in the study. No intervention.
3490298|NCT03713541||Carers of patients with AN|Significant caregivers in AN patients aged 14 to 15 years: parents; in AN patients aged 16 years and over: parents or other significant carer. No intervention.
3490299|NCT03713541||Physicians of patients with AN|Resident general practitioner, pediatrician, internist or gynecologist with at least one medical patient contact within the last 12 months. No intervention.
3490300|NCT03713528|Other|Treatment Group|The treatment group includes any patient with an acute perioperative periprosthetic infection, acute hematogenous infection, or unresectable infection with a gram positive organism sensitive to vancomycin and treated with intraoperative intraosseous vancomycin. Additionally, patients will be treated with at least 4 weeks of IV antibiotics under guidance of an infectious disease specialist, and indefinite antibiotic chronic suppression.
3490301|NCT03713489|Experimental|Platelet transfusion group|Besides standard medical treatment, up to 9 units of platelets will be transfused per protocol within 4 weeks
3490302|NCT03713489|No Intervention|standard medical treatment group|standard medical treatment
3490303|NCT03713476|Experimental|Robot-assisted training|The participants will receive 20 minutes of robot assisted tenodesis-grip therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
3490304|NCT03713476|Active Comparator|Traditional occupational therapy|The participants will receive 20 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
3490305|NCT03713463||Oral Nutritional Supplement (ONS)|2 servings per day ONS
3490306|NCT03713450|Experimental|Control with imaging guidance|
3490307|NCT03713450|Active Comparator|Control without imaging guidance|
3490308|NCT03713437||Cystic Fibrosis|Serum sample will be drawn once
3490309|NCT03713437||Healthy, age-matched controls|Serum sample will be drawn once
3490310|NCT03713424|Active Comparator|Clav|4-day 125 bid oral capsule administration
3129332|NCT03211858|Experimental|SAR341402|SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
3180014|NCT00678925|Placebo Comparator|2|Placebo capsules given from 18 weeks pregnancy through 90 days postpartum
3490311|NCT03713424|Placebo Comparator|Placebo|4-day, twice-daily oral capsule administration
3490312|NCT03713411|No Intervention|No-catheter|after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones, patients in whom a urethral catheter wasn't placed
3490313|NCT03713411|Active Comparator|Catheter|urethral catheter placement after semirigid or flexible ureteroscopy + double J stent placement for ureteral or kidney stones
3490314|NCT03713385||Aged group (n =49)|Determined the optimal endotracheal tube size according to age of the child (internal diameter [ID] in mm = [age in years + 16] /4) suggested by Cole
3490315|NCT03713385||Subglottic diameter group (n =49)|The subglottic transverse diameter was estimated with ultrasonography on the middle of the anterior region of the neck at the level of cricoid cartilage
3490316|NCT03713385||Epiphyseal diameter group (n =49)|The epiphyseal transverse diameter of the distal radius was estimated with ultrasonography.
3490317|NCT03713372|Experimental|Anti-EGFR monoclonal antibody|6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3490318|NCT03713359|Active Comparator|Trial arm (MRVAC)|"Measles and Rubella combined vaccine (lyophilized) MRVAC produced by POLYVAC is live attenuated measles vaccine. Each vial of 10 doses of measles-rubella combined vaccine is reconstituted with 5.5 mL of water for injection. Each single dose 0.5 mL contains the following components:~Live, attenuated strain AIK-C measles virus not less than 1000 PFU Live, attenuated strain Takahashi rubella virus not less than 1000 PFU Subcutaneous injection"
3490319|NCT03713359|Active Comparator|Control arm|"Measles and Rubella combined vaccine produce by Serum Institute, India (lyophilized) is live attenuated Measles and Rubella vaccines being used in the Vietnam expanded immunization program was used as control arm.~Subcutaneous injection"
3490320|NCT03713346|Other|Lactose digester|
3490321|NCT03713346|Other|Lactose maldigester|
3490322|NCT03713333|Experimental|Technology-Enabled Visitations|Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.
3490323|NCT03713333|No Intervention|Standard-Care Visitations|Standard-care is defined as the range of services available during usual patient care. Handheld Imaging and digital health screening will be performed in the control group after the patient-physician encounter. As such, patients and physicians will be blinded to the diagnostic findings unless an abnormal finding is detected that requires physician review and triage for further care.
3490324|NCT03713320|Experimental|Cobomarsen|
3490325|NCT03713320|Active Comparator|Vorinostat|
3490326|NCT03713268||Healthy (ocular health) participants|"Adult subjects with normal, ocular health will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system for reproducibility testing in humans, provide feedback to engineers, and verify that the system functions to produce high quality images of the desired areas of the eye after ex vivo development before surgical use.~Each healthy subject will be imaged by the MIOCT system. There will be no surgery or intervention on these healthy volunteer subjects. We anticipate that a portion of the volunteer subjects would have repeat imaging (e.g. for reproducibility testing)."
3490327|NCT03713268||Surgeons as research subjects|Duke Eye Center surgical trainees (residents and fellows), attending surgeons, and surgeons from other medical institutions will be enrolled as subjects as we will test their performance with and without microscope integrated optical coherence tomography and with and without advances in 4D MIOCT in model surgeries in the research wet lab to better understand the utility of specific aspects and of this next generation MIOCT as a whole for specific anterior segment and retinal surgical tasks.
3490328|NCT03713268||Surgical patients|Adult and minor (> 4 months of age) surgical patients will be enrolled to evaluate and obtain multiple images from the microscope integrated optical coherence tomography system during clinically indicated vitreoretinal and anterior segment surgical procedures.
3490329|NCT03713255|Active Comparator|PVB group|paravertebral blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
3490330|NCT03713255|Experimental|MTP block group|MTP blocks with 0.5% ropivacaine and epinephrine 2.5 mcg/mL
3490331|NCT03713255|Sham Comparator|control group|local anesthetic infiltration subcutaneous 1% lidocaine
3490332|NCT03713242|Experimental|Group A: ACT-541468 in subjects with mild hepatic impairment|Single oral dose administered on Day 1.
3490333|NCT03713242|Experimental|Group B: ACT-541468 in subj. with moderate hepatic impairment|Single oral dose administered on Day 1.
3490334|NCT03713242|Experimental|Group C: ACT-541468 in subjects with severe hepatic impairment|Single oral dose administered on Day 1.
3490335|NCT03713242|Experimental|Group D: ACT-541468 in healthy subjects.|Single oral dose administered on Day 1.
3490336|NCT03713229||HIV-infected men who have sex with men|HIV-infected male patients who refer to conducting sexual risk practices that enable HPV transmission
3490337|NCT03713229||HIV-infected men|HIV-infected male patients who neglect conducting sexual risk practices that enable HPV transmission
3490338|NCT03713229||HIV-infected women|HIV-infected female patients disregarding sexual risk practices
3490339|NCT03713216|Experimental|Naldebain|Subjects will receive one dose of Naldebain before surgery.
3490340|NCT03713216|Active Comparator|Morphine|Subjects will receive morphine after surgery.
3490341|NCT03713203|Experimental|Pagetex PDT|"PAGETEX medical device for photodynamic therapy (PDT). Composed of the association: Laser source + optical fiber + diffuser support incorporating luminous textiles + drug photosensitizer (Metvixia®)"
3129333|NCT03211858|Active Comparator|NovoLog/NovoRapid|NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.
3180015|NCT00678938|Experimental|1|
3490342|NCT03713190|Active Comparator|Empagliflozin|SGLT-2 inhibitor
3490343|NCT03713190|Placebo Comparator|placebo|A substance without specific pharmacology principles.
3490344|NCT03713177||Ministry of health - Cairo|Dentists working for Egyptian ministry of health - Cairo
3490345|NCT03713177||Interns|Dental interns of Cairo University
3490346|NCT03713164|Active Comparator|Pomegranate Juice (PJ)|single dose of 8oz Pomegranate Juice (PJ)
3490347|NCT03713164|Active Comparator|Ellagic Acid (EA)|500 mg Ellagic Acid (EA) capsules
3490348|NCT03713151|Experimental|Dividat FIT: Computer based exercise|One arm with 10-15 Haemophilia patients and 10-15 Myositis patients.
3490349|NCT03713138|Experimental|Intervention Flaxseed powder|"Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Intervention/ Dietary Supplement:~Flax seed powder~Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.~Other Name: intervention"
3490350|NCT03713138|No Intervention|Control group; Comparison group|"The controlled group was given no intervention. No intervention was done to this group.~Three different quantities of white flour were intervened to the subjects. One group was given 15 grams of white flour a day. Second group was given 20 grams and third group was given 25 grams of white flour a day."
3490351|NCT03713125|Active Comparator|Reading Tutoring Intervention|20 hours of one-on-one reading tutoring administered over 6 weeks
3490352|NCT03713125|No Intervention|Business as Usual|Instruction as usual within schools
3490353|NCT03713112|Active Comparator|Weekly MDT deprescribing rounds|Weekly MDT deprescribing rounds for certain drugs will be performed on top of usual care.
3490354|NCT03713112|No Intervention|Control (Usual Care)|"Usual Care includes the following:~De-prescribing at the discretion of the ward doctors~Initial medication reconciliation by pharmacist on admission~Ward rounds to be conducted 3 weekdays per week for rehabilitative patients and daily on weekdays for sub-acute patients."
3490355|NCT03713099|Experimental|Microwave Ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach performed by an interventional pulmonologist or thoracic surgeon.
3490356|NCT03713073|Experimental|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
3490357|NCT03713073|Active Comparator|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
3490358|NCT03713060|Other|Women with RYGB and fetus/ child|20 pregnant women with previous gastric bypass surgery. During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
3490359|NCT03713060|Other|Matched controls and fetus/ child|20 pregnant women matched on age, prepregnancy-BMI and parity (n = 20). During pregnancy the women will be tested with mixed meal test and continuous glucose monitoring for the diagnosis of hypoglycemia. Ultrasounds of fetal growth will be performed and after birth anthropometrics of the newborn will be meaured including a DXA-scan to estimate bodycomposition.
3490360|NCT03713034|Experimental|Active Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
3490361|NCT03713034|Active Comparator|Control Game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
3490362|NCT03713021|Experimental|TraceIT Tissue Marker|"Following successful tumor resection, TraceIT Tissue Marker will be applied in 0.2 to 0.5 mL injections at 5 locations to mark the tumor bed: superiorly, inferiorly, laterally, medially, and center of resection. The marginal injections will be within 3 mm of the resection edge and within 5 mm deep. The center of the resection bed will be injected within 5 mm deep if possible.~Within 6 weeks after surgery, a CT simulation scan will be performed per normal protocol for patients receiving surgery followed by adjuvant therapy. This scan will be used to generate the IMRT treatment plan~Two treatment plans will be performed per patient using the simulation CT scan. One will be the standard of care treatment plan and will be the basis of the actual radiation treatment they receive. The second treatment plan will be based on utilizing the TraceIT hydrogel markers as a guide for the resection bed."
3490363|NCT03713008|Experimental|Fluid bolus|Patients included in the study will receive fluid bolus.
3490364|NCT03712995|Experimental|Cutler-Beard modified with graft|Reconstruction of Upper Eyelid With a Newly Modified Cutler-Beard Technique With Tarsoconjunctival Graf
3490365|NCT03712969|Experimental|Intervention group|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
3490366|NCT03712969|No Intervention|Control group|Patients receive conventional adjuvant chemotherapy.
3490367|NCT03712956|Experimental|Caelyx® for 8 courses|Caelyx® administered intravenously at a dose of 20 mg/m2 once every two weeks for 8 courses.
3490368|NCT03712904|Experimental|A. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy over 5 fractions every other week day during days 1-10. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
3180016|NCT00678938|Experimental|2|
3180017|NCT00678938|No Intervention|3|
3180018|NCT00678964|Experimental|A|
3180019|NCT00678964|Active Comparator|B|
3490369|NCT03712904|Experimental|B. Stereotactic body radiation therapy, ziv-aflibercept|Patients undergo stereotactic body radiation therapy as in arm A. Patients then receive ziv-aflibercept IVI on the last day of radiation therapy and then every 4 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
3490370|NCT03712891|Experimental|Patients receiving coffee postoperatively|Patients who self-identify as coffee drinkers and receive coffee postoperatively
3490371|NCT03712891|No Intervention|Patients not receiving coffee postoperatively|Patients who self-identify as coffee drinkers and do not receive coffee postoperatively
3490372|NCT03712878|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT, tacrolimus, MMF)|"Description CONDITIONING REGIMEN: Participants undergo TBI BID on days -9 to -6.~TRANSPLANT: Participants receive donor lymphocytes IV on day -6 after the last dose of TBI.~CONDITIONING REGIMEN: Participants receive cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Participants undergo hematopoietic stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Participants receive tacrolimus IV beginning on day -1 with taper beginning on day 42 in the absence of GVHD, a suspicion of GVHD, or previous history of GVHD requiring a taper delay. Participants also receive mycophenolate mofetil IV BID beginning on day -1 through day 28 in the absence of GVHD."
3490373|NCT03712839||Acquired Brain Injury group with anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. To determine the presence of anosognosia, patients must present an overestimation value of their capacities greater than 5 (>5) in the discrepancy index on the Patient Competency Rating Scale (PCRS) (Prigatano et al., 1998).
3490374|NCT03712839||Acquired Brain Injury group without anosognosia|People with presence of an acquired brain damage and cognitive deficits relative to executive functions and memory. These patients must present a score of < 5 on the PCRS Scale.
3490375|NCT03712839||Control group|Healthy participants matched in age, gender and educational level with the others two groups.
3490376|NCT03712826|Experimental|anti TNF|Crohn patient with antiTNF treatment
3490377|NCT03712826|Experimental|Ustekinumab|Crohn disease with ustekinumab treatment
3490378|NCT03712813|Experimental|Macrodyne LivMD plate|
3490379|NCT03712813|No Intervention|Wait-Listed Control|
3180020|NCT00678977|Experimental|Arm A|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, and 1000 mg/m2 gemcitabine. Intermediate dose levels may also be explored. Intravenous gemcitabine will be given on Day 1 and 8 of Cycle 1 and each subsequent cycle.~Cohort expansion phase - patients will receive gemcitabine alone, at the OTR dose starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR beginning on Day 2 Cycle 1 after the last blood sample for gemcitabine analysis is collected, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib. On Day 1 of Cycle 2 patients will receive the simultaneous administration of gemcitabine and pazopanib"
3490380|NCT03712800|Experimental|Rhythmical massage|Participants who receive rhythmical massage for three months.
3490381|NCT03712800|Experimental|HRV biofeedback|Participants who perform HRV biofeedback for three months.
3490382|NCT03712800|No Intervention|Control group|Participants who do not receive an intervention during the three-month intervention period but are advised to stay with their usual care during menstrual pain. For ethical and compliance reasons, these participants receive a series of rhythmical massage treatments after the initial three-month intervention/control period.
3490383|NCT03712774||neoadjuvant chemoradiation|Patient with esophageal Cancer treated by neoadjuvant chemoradiation followed by surgery will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
3490384|NCT03712774||definitive chemoradiation|Patient with esophageal Cancer treated by definitive chemoradiation will be longitudinally evaluated by questionaires EORTC QLQ C30, EORTC QLQ OES-18 and EORTC OG-25
3490385|NCT03712761||Supplementation with Enriched Protein®|Participants will consume a low protein containing breakfast and 2 hours later will consume the enriched protein supplement
3490386|NCT03712761||Low protein breakfast|No supplementation
3490387|NCT03712761||High protein breakfast|No supplementation
3490388|NCT03712748|Experimental|Imaginal Exposure Session|
3129334|NCT03212261|Experimental|3RP-Lymphoma|-An adapted version of the 3RP (3RP-Lymphoma) for lymphoma survivors recently completing cancer treatment. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks.
3129335|NCT03212326|Experimental|Definity|Perflutren echo contrast is infused to enhance intracardiac echo imaging recorded during catheter ablation of ventricular tachycardia. We will compare areas that appear to be myocardial scar on ultrasound with areas of abnormal electrical signals obtained by direct catheter mapping.
3490389|NCT03712735|Active Comparator|Group A|"Bupivacaine 0.08% - fentanyl 2mcg on the following pump settings:~PIEB flow rate = high; interval = 60 min"
3490390|NCT03712735|Experimental|Group B|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = high; interval = 45 min
3490391|NCT03712735|Experimental|Group C|Bupivacaine 0.08% - fentanyl 2mcg on the following pump settin PIEB flow rate = low; interval = 45 min
3490392|NCT03712722||rCDI|Adult patients with recurrect Clostridium difficile infection
3490393|NCT03712709||Case Detection Group|Clinical suspicion of pulmonary TB (including cough ≥2 week and at least 1 other symptom typical of TB). Only participants who have not received any form of TB treatment within the prior 60 days will be enrolled
3490394|NCT03712709||Drug Resistant TB Group|In addition to the criteria of the Case Detection Group, participants should also meet the following conditions: Non-converting pulmonary TB cases (category I and category II failures).
3490395|NCT03712696|Experimental|DIGNICAP™|DigniCap® System
3490396|NCT03712683|Experimental|Sub clinical hypothyroid women|"Levothyroxine sodium(Euthyrox 50µg and 25 µg MerckSerono) treatment was initiated and the women were followed in a combined clinic of endocrinologist and Gynecologist.~2.5 µg of Thyroxine daily was prescribed to women with TSH more than 2.5 mIU/L. Women with TSH more than 4mIU/L were given 50 µg daily . When pregnancy was confirmed Thyroxine was continued till 13 weeks gestation ."
3490397|NCT03712670|Active Comparator|AM group|Intravitreal aflibercept monotherapy
3129336|NCT03212365|Other|Fixed Dose|Participants will receive 40 mg enoxaparin twice daily
3490398|NCT03712670|Experimental|AP group|Intravitreal aflibercept along with 0.1% pranoprofen
3490399|NCT03712670|Experimental|AN group|Intravitreal aflibercept plus daily supplementation of nutraceutical tablets
3490400|NCT03712657|Experimental|ERAS group|interventions: 1.preoperative pain control; 2.avoiding application of ureter; 3.avoiding application of gastric tube; 4.avoiding application of irrigation; 5.avoiding application of drainage; 6.early exercising postoperatively; 7.early oral feeding postoperatively; 8.early discharging.
3490401|NCT03712657|No Intervention|conservative group|normal treatment
3490402|NCT03712644|No Intervention|Conservative|Patients will receive primarily optimal medical therapy alone and followed, according to protocol. Any further cardiologic investigation will be performed only in case of clinical suspicion of myocardial ischemia related symptoms.
3490403|NCT03712644|Experimental|Invasive|"In the Invasive group in addition to optimal medical therapy elective coronary angiography will be performed. Coronary catheterization is preferably scheduled within a maximum of 14 days after peripheral revascularization~All lesions of 50-90% diameter stenosis in a major coronary artery will be evaluated by fractional flow reserve (FFR) and intervened by percutaneous coronary intervention (PCI) if FFR≤0.80 or left for medical therapy if FFR>0.80. All lesions of ≥90% diameter stenosis in a major coronary artery will be intervened. This includes also efforts to recanalize chronic total occlusions (CTO) of large supplied viable myocardial territory.~For complex cases revascularization by coronary artery bypass surgery might be considered, however PCI is preferred whenever possible."
3129337|NCT03212365|Experimental|Variable Dose|Participants will receive 0.5mg/kg enoxaparin twice daily
3129338|NCT03212521|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 weeks.
3129339|NCT03212638|Experimental|Baricitinib T1 (Part A)|4 mg (milligram) baricitinib suspension test formulation (TF) administered orally (PO) without water following a 10 hour fast. (Baricitinib T1)
3490404|NCT03712631|Active Comparator|bone without a collagen membrane|not covering bone with collagen membrane
3490405|NCT03712631|Experimental|bone with collagen membrane|covering bone with collagen membrane
3490406|NCT03712618|Active Comparator|Group A|Group A: Long Transfusion followed by Short Transfusion in the first block
3490407|NCT03712618|Active Comparator|Group B|Group B: Short Transfusion followed by Long Transfusion in the first block
3490408|NCT03712592|Experimental|160km|
3490409|NCT03712592|Experimental|40km|
3490410|NCT03712592|Experimental|100km|
3490411|NCT03712592|Experimental|4x40km|
3490412|NCT03712579|Experimental|SFA-Rich Meal|Participants will consume a SFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
3490413|NCT03712579|Experimental|MUFA-Rich Meal|Participants will consume a MUFA-rich test meal (75g test fat) and sequential blood and white adipose tissue samples will be collected
3490414|NCT03712566||MASST|Patients with a histological or cytological confirmed diagnosis of Squamous Cell Cancer of the Head & Neck, Esophagus or Anal Canal who have radiologically confirmed recurrent or metastatic disease and are commencing on a new treatment or either first-line platinum based chemotherapy or any line immunotherapy.
3129340|NCT03212638|Experimental|Baricitinib T2 (Part A)|4 mg baricitinib suspension formulation (TF) administered PO prior to 240 mL water following a 10 hour fast (Baricitinib T2)
3490415|NCT03712553|Active Comparator|A1: Opt-In, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of an opt-in message encouraging participants to contact their primary care provider for Hepatitis C screening.
3490416|NCT03712553|Experimental|A2: Opt-Out, UC Letter|Behavioral: Opt-In vs. Opt-Out The usual care (UC) letter consists of a message and a written laboratory order from primary care provider to complete Hepatitis C screening.
3490417|NCT03712553|Experimental|B1: Active MPM User, UC Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
3490418|NCT03712553|Experimental|B2: Active MPM User, BE Letter|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive a letter with behavioral economic (BE) principles encouraging them to contact their primary care provider for Hepatitis C screening.
3490419|NCT03712553|Active Comparator|B3: Active MPM User, UC MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic usual care (UC) message on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
3490420|NCT03712553|Experimental|B4: Active MPM User, BE MPM Message|Behavioral: Letter vs. Electronic Messaging Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are active MyPennMedicine (MPM) users receive an electronic message with behavioral economic principles on the MyPennMedicine patient portal encouraging them to contact their primary care provider for Hepatitis C screening.
3129341|NCT03212638|Experimental|Baricitinib R (Part A)|4 mg baricitinib tablet administered PO, taken with 240 mL water following a 10 hour fast (baricitinib R)
3129342|NCT03212638|Experimental|Baricitinib TF Fasted (Part B)|4 mg baricitinib suspension test formulation (TF) administered after 10 hour fast. (TF fasting)
3129343|NCT03212638|Experimental|Baricitinib TF Fed (Part B)|4 mg baricitinib suspension TF administered after a high fat meal.(baricitinib TF Fed)
3490421|NCT03712553|Active Comparator|B5: Non-MPM User, UC Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a usual care (UC) letter consisting of a message encouraging them to contact their primary care provider for Hepatitis C screening.
3490422|NCT03712553|Experimental|B6: Non-MPM User, BE Letter|Behavioral: Usual Care Messaging vs. Behavioral Economic Messaging Participants who are non-MyPennMedicine (non-MPM) users receive a letter with behavioral economic principles (BE) encouraging them to contact their primary care provider for Hepatitis C screening.
3490423|NCT03712540|Experimental|BMS-986278 + Rifampin|Treatment period A: BMS-986278 alone Treatment period B: Rifampin followed by BMS-986278
3490424|NCT03712501|Experimental|Exercise|Participants will walk for 60 minutes at 60% maximal oxygen uptake on day 1. Participants will return the following day and consume a high fat breakfast and lunch.
3490425|NCT03712501|No Intervention|Control|Participants will rest on day 1. Participants will return the following day where they will consume a high fat breakfast and lunch.
3490426|NCT03712475|Experimental|Phudialin Hard Capsules|Phudialin Hard Capsules Dosing Regimen: Single dosing
3490427|NCT03712475|Active Comparator|Lyrica Hard Capsule|Lyrica Hard Capsule Dosing Regimen: Single dosing
3490428|NCT03712462|Experimental|ABBT Weight Loss Therapy for BED|Acceptance-Based Behavioral Weight Loss Therapy for BED
3490429|NCT03712462|Active Comparator|Standard Behavior Therapy|Standard Behavioral Weight Loss Therapy
3490430|NCT03712436|Experimental|patients receiving palliative care|Patients receiving standard oncologic care plus palliative care.
3490431|NCT03712436|Active Comparator|patients receiving standard oncological care|Patients receiving standard oncologic care.
3490432|NCT03712423|Experimental|Patients [89Zr]-Df-CriPec® docetaxel|Day 1 of the Run-in a low dose of [89Zr -Df-CriPec® docetaxel (corresponding to 0.1- 2 mg docetaxel). On Cycle 1 Day 1, the patients will receive unlabelled CriPec® docetaxel of a variable dose up to 60mg/m2 followed < 2 h by a second low dose of [89Zr]-Df-CriPec® docetaxel. On day 1 of each subsequent cycle, patients will only receive unlabelled CriPec® docetaxel . The dose will be the same as was given on Cycle 1 Day 1. For the following patients the dose of unlabelled CriPec® docetaxel combined with the low dose of [89Zr]-Df- CriPec® docetaxel will be variable but never exceed the highest dose of unlabelled CriPec® docetaxel that was determined to be safe in the phase I NAPOLY trial (CT-CL01).
3490433|NCT03712397|Experimental|nal-IRI in Head & Neck cancer|nal-IRI 80 mg/m2 for 90 minutes in sequence at day 1, every 14 days counted as one cycle
3490434|NCT03712384||Young adult with severe anorexia|Young adult with severe Anorexia hospitalized during adolescence at Institut Mutualiste Montsouris
3129344|NCT03212690|Experimental|Mechanically ventilated subjects|Subjects receiving invasive mechanical ventilation (Duration of ventilation <=48 hours) will be evaluated using standard care investigations.
3490435|NCT03712358|Experimental|Cohort 0 (PVSRIPO)|A single dose of PVSRIPO into a single lesion.
3490436|NCT03712358|Experimental|Cohort 1 (PVSRIPO)|A single dose of PVSRIPO into 2 different lesions, 21 days apart, when applicable per dose escalation guidelines.
3490437|NCT03712358|Experimental|Cohort 2 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
3490438|NCT03712358|Experimental|Cohort 3 (PVSRIPO)|A single dose of PVSRIPO into 3 different lesions, 21 days apart, when applicable per dose escalation guidelines.
3490439|NCT03712358|Experimental|Cohort 4 (PVSRIPO)|A single dose of PVSRIPO into a single lesion, followed by PVSRIPO injected into up to 6 lesions at Day 10 and every 21 days thereafter.
3490440|NCT03712345|Experimental|Group A|Will receive IFX-1 low dose regimen diluted in sodium chloride solution
3490441|NCT03712345|Experimental|Group B|Will receive IFX-1 high dose regimen diluted in sodium chloride solution
3490442|NCT03712345|Placebo Comparator|Group C|Will receive placebo
3490443|NCT03712332|Experimental|Distress Tolerance Group|6 session inpatient distress tolerance group intervention twice a week for 1.5 hours for up to three weeks.
3490444|NCT03712319|Experimental|Group 1: App.|"Participants use application REM Volver a casa on their cell phones during 8 weeks. Codes are provided to the students in order to unlock the different stages of the training free of charge. The application provides short videos and audios for training. Students practice on their own, in accordance with the instruction of completing a stage a week."
3490445|NCT03712319|Active Comparator|Group 2: MBSR.|Participants attend a presence-based training during 8 weeks. The Mindfulness-Based Stress Reduction program involves a session of two and a half hours each week.
3490446|NCT03712319|No Intervention|Group 3: Waiting list.|Participants do not receive any intervention during the study. At the end of the study (16 weeks), they are provided with the codes so they can unlock the app and use it like participants from Group 1.
3490447|NCT03712306|No Intervention|Control group|No intervention. Participants will only receive a brochure on general healthy eating habits.
3490448|NCT03712306|Experimental|Dietary advice|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products.
3490449|NCT03712306|Experimental|Dietary advice and advice on timing|Personalized nutritional advice from a registered dietician or nutritionist aimed at increasing protein intake to at least 1.2 g/kg adjusted body weight/d, through intake of regular protein rich food products and provided protein-enriched food products, as well as advice regarding the consumption of protein rich food products in close proximity of usual physical activity.
3490450|NCT03712293|Experimental|BBB Disruption with Chemotherapy Arm|All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
3490451|NCT03712241|Experimental|Treatment A|K-285 dose/application method A
3490452|NCT03712241|Experimental|Treatment B|K-285 dose/application method B
3490453|NCT03712241|Experimental|Treatment C|K-285 dose/application method C
3490454|NCT03712241|Active Comparator|Treatment D|Indomethacin capsule
3129345|NCT03213210|Other|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
3129346|NCT03213366|Experimental|E-PrEP- Peer-Led Intervention about PrEP|8 Peer Leaders (PLs) will be randomly assigned to the E-PrEP arm. Each of the PLs will recruit at least 15 participants into a private social media group on one of several social media platforms. PLs will then deliver a behavioral intervention over a 6 week period, posting information and engaging participants in a discussion about PrEP, PrEP access, and other related health issues. All contents will be formatted to be both mobile device accessible.
3490455|NCT03712215|Experimental|Experimental Group 1|synchronized FES mode, according to the parameters based on the Gueddes et al., (1991): current frequency (F) 30 Hz; pulse width (T) 0,4 ms; upload time (Rise) 1s; time of muscle contraction (On time) 1 s; down time (Decay) 2s e muscle relaxation time (Off time) 1 s.
3490456|NCT03712215|Experimental|Experimental Group 2|the same apparatus will be used, differing in the parameters that will be based on the studies of Cancelliero et al., (2012) for the EDET procedure, being used in synchronized FES mode, with frequency of 30 Hz; pulse width (T) 0,4 ms, climb (ramp) of 0,7 s (maximum value). The support was of 0.4 s, already standardized and fixed in the apparatus
3490457|NCT03712215|No Intervention|Control Group|The control group (CG) with the same characteristics of the experimental groups will perform conventional physiotherapy
3490458|NCT03712176||Cohort 1 : chemotherapy and radiotherapy|50 women aged between 18 and 65 with first non-metastatic breast cancer treated by surgery and adjuvant therapy (chemotherapy and radiotherapy)
3490459|NCT03712176||Cohort 2 : radiotherapy only|150 women aged between 18 and 65 with first non-metastatic breast cancer treated with surgery and adjuvant therapy (radiotherapy only).
3490460|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 1)|
3490461|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 2)|
3490462|NCT03712163|Experimental|Norketotifen or Placebo (Cohort 3)|
3490463|NCT03712163|Experimental|Norketotifen or Placebo (Multiple Dose)|
3490464|NCT03712150||Healthy|"Healthy adults~- Participants will receive single session of tdcs after application"
3490465|NCT03712137|Experimental|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional maintenance treatment at Month 12.
3490466|NCT03712137|Experimental|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
3490467|NCT03712124|Experimental|CNSA-001|Patients will receive CNSA-001 (sepiapterin) 20 mg/kg/day (10 mg/kg twice daily) for 14 days as an oral suspension.
3490468|NCT03712124|Placebo Comparator|Placebo|Patients will receive a placebo oral suspension twice daily for 14 days.
3490469|NCT03712111|Experimental|Norepinephrine 6 mcg|Mothers in this group will receive a bolus of Norepinephrine 6 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
3490470|NCT03712111|Active Comparator|Norepinephrine 10 mcg|Mothers in this group will receive a bolus of Norepinephrine 10 mcg for management of hypotensive episode after spinal anesthesia using Bupivacaine hydrochloride under prophylactic Norepinephrine infusion
3490471|NCT03712085|Active Comparator|Treatment Group A|Abdominal acupuncture and upper limb rehabilitation training
3490472|NCT03712085|Sham Comparator|Treatment Group B|Sham abdominal acupuncture and upper limb rehabilitation training
3490473|NCT03712085|No Intervention|Control Group|Upper limb rehabilitation only
3490474|NCT03712072||Children with Cerebral Palsy|Data from the participants with Cerebral Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
3490475|NCT03712072||Children with BPBP|Data from the participants with Brachial Plexus Birth Palsy will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the TMS session.
3490476|NCT03712072||Typically Developing Children|Data from the typically developing participants will be collected over the course of four visits: (i) the recording session for the Magnetoencephalography (MEG), (ii) the recording session for the Electroencephalography (EEG), (iii) the Magnetic Resonance Imaging (MRI) scanning session, and (iv) the Transcranial Magnetic Stimulation (TMS) session.
3490477|NCT03712059||Screening group|All patients receive FIT test and colonoscopy, whose age, sex, family history, smoking history, body mass index (BMI), diabetes and other risk factors are collected by researchers through pad, equipped with a specially designed database and app. Using colonoscopy results as the gold standard, the diagnostic value of risk prediction model for the Chinese population is explored, and the optimal strategy of colonoscopy practice for the Chinese established initially.
3490478|NCT03712059||Adenoma resection group|During the polypectomy of 2000 patients, for all pathologically confirmed or NBI-predicted adenomas with size<10mm, 1-2 biopsies were randomly performed on the edge after resection to determine the completion rate of the polypectomy.
3490479|NCT03712059||Identification and classification group|For 12000 patients regardless of cancer diagnosis or polypectomy, if there is polyp, NBI (magnification) observation is required, with 4 white light and NBI images collected and reserved, respectively. If there is magnifying endoscopy, another 4 endoscopic images of magnification are also required. Endoscopists are invited to predict the pathology of polyps according to the NICE classification principle and endoscopic images, and upload the pathological results and endoscopic images within 2-4 week after colonoscopy.
3490480|NCT03712046|Experimental|Main arm|PET-CT imaging of the ankles and feet following injection of 18F-FDG
3490481|NCT03712033||TEC4Home Stroke Cohort|"All participants or caregiver involved will be instructed to measure BP per the TEC4Home BP Telemonitoring Protocol. Participants will measure their BP daily, 4x/day, for the first week. After the first week, all weekly BP measurements will be done 3 days/week with 4 measurements a day. All readings must be taken before administration of antihypertensive medications, twice in the morning, 5 minutes apart and twice in the evening, 5 minutes apart.~The TEC4Home telemonitoring nurse will review the BP measurements and contact the participant on a weekly basis until the end of the 6-month monitoring period. The telemonitoring nurse will adjust the antihypertensive medication doses as per the TEC4Home Stroke - Hypertension Management Algorithm."
3490482|NCT03712007|Experimental|MAMP therapy with MARPE expander|The experimental group will comprise 20 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-bone-borne expander as anchorage in the maxillary arch. The miniscrew assisted rapid palatal expander (MARPE) will be used.
3490483|NCT03712007|Active Comparator|MAMP therapy with Hyrax expander|The active comparator group will comprise 15 patients submitted to miniscrew anchored maxillary protraction (MAMP) with a tooth-borne expander as anchorage in the maxillary arch. The conventional hyrax expander will be used.
3490484|NCT03711994|No Intervention|Repeat C/S Control|Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
3490485|NCT03711994|Active Comparator|Repeat C/S Treatment|Repeat C/S done with spinal with Alkantis ice pack.
3490486|NCT03711994|No Intervention|Primary C/S - Control|Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
3490487|NCT03711994|Active Comparator|Primary C/S Treatment|Primary C/S done with Epidural with Alkantis ice pack.
3490488|NCT03711981|Active Comparator|TAP block of 10cc Liposomal bupivacaine|Patients in this arm of the study would receive a bilateral Laparoscopic Assisted TAP block with 10cc Liposomal bupivacaine, 10cc 0.25% bupivacaine and 10cc normal saline each bilaterally at the beginning of their surgery.
3490489|NCT03711981|No Intervention|Routine pre-incisional injections at trocar incision sites|The patients in the control arm of the study would receive routine pre-incisional injections at the trocar incision sites using a total of 20cc 0.25% bupivacaine.
3490490|NCT03711968|Active Comparator|Treatment group|"Rehabilitative treatment protocol:~Therapeutic exercise 8 mono-weekly sessions, 5 patients per group, duration 60 minutes and two sessions of single treatment, duration 60 minutes (duration of treatment about two months, considering also any recovery sessions)"
3490491|NCT03711968|No Intervention|Waiting list|Intervention: The WL patients will be taken into the same treatment at the end of the experimental protocol, after T2 evaluation. In this period they act like a control group.
3490492|NCT03711955|Experimental|Aerobic training group (AET)|Each AET sessions are to last one hour, with 40 minutes being allocated to the aerobic exercise training component, 10 minutes allocated to warm-ups, 5 minutes allocated to cool-downs, and one 5 minute rest period between the 20 minutes spent on each machine (20 minutes of cycling, 5 minute rest, 20 minutes seated row). The AET program consists of 20 minutes of cycling on the stationary bicycle and 20 minutes of seated row on the kinesis Technogym machine. This is to be preceded by 10 minutes of static stretching during warm up, and 5 minutes of post-exercise recovery (dynamic stretches).
3490493|NCT03711955|Experimental|Instability training group (IRT)|Each IRT sessions are to last one hour, with time being allocated to a 10 minute warm up, consisting of static stretches, a 5 minute cool down, consisting of dynamic stretches, and a series of IRT exercises performed in a circuit setting over the duration of 40 minutes. In the sessions, five resistance exercises will be performed. A linear periodization will occur, in which the training load will progress from high-volume low-intensity to low-volume high-intensity loads over the duration of eight weeks to maximize training adaptations. Additionally, there will be a progressive increase in load/resistance by 1-2 lbs and the degree of instability of each exercise during the course of the eight week program. Unstable devices will be changed from the least unstable to the most unstable device throughout the program, but only when participants showed a considerable decrease in body sway/movement and force production increased when performing exercises.
3490494|NCT03711942|Active Comparator|Periodontally Healthy IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar.
3490495|NCT03711942|Experimental|Periodontally Healthy Base|2mm thick base was applied in periodontally health teeth.
3490496|NCT03711942|Experimental|Periodontally healthy control|coronal access was restored with composite resin without any base.
3490497|NCT03711942|Active Comparator|Periodontally diseased IOB|Intra orifice barrier (IOB) was placed in periodontally healthy molar
3490498|NCT03711942|Active Comparator|Periodontally diseased Base|2mm thick Base of GIC was applied under composite restoration
3490499|NCT03711942|Active Comparator|Periodontally diseased control|coronal access was restored with composite resin without any base
3490500|NCT03711916|Experimental|Breast flap creation with PlasmaBlade|During participant's scheduled bilateral mastectomy, breast flap on one breast will be created using low thermal dissection device (PlasmaBlade) on one breast and standard Bovie cautery in the contralateral breast.
3490501|NCT03711916|No Intervention|Breast flap creation with Bovie Cautery|During participant's scheduled bilateral mastectomy, breast flap will be created using standard Bovie cautery on the breast contralateral to the one that was created using PlasmaBlade.
3490502|NCT03711903|Experimental|Treatment arm|The study drug, CN-105, will be administered at 1.0 mg/kg every 6 + 2 hours. The calculated volumes of study agent will be removed from the vials and transferred to 250 mL of normal saline (0.9% sodium chloride injection, USP). The recorded weight at baseline will be used to determine the appropriate amount of CN-105 drug product to administer. Each dose of CN-105 or placebo will be administered as a slow IV bolus over 30 minutes.
3490503|NCT03711903|Placebo Comparator|Placebo arm|The Placebo arm will be given 0.9% NaCL
3490504|NCT03711890|Experimental|Diagnostic (resection, OCT)|Participants undergo resection. Resected tissues are analyzed via ultra-high resolution OCT.
3490505|NCT03711864|Experimental|IM21 CAR-T cells|IM21 CAR-T cells
3490506|NCT03711851|Experimental|Web-based|Self-help Acceptance and commitment therapy (Web-based)
3490507|NCT03711851|Experimental|Bibliotherapy|Self-help Acceptance and commitment therapy (bibliotherapy)
3490508|NCT03711851|Active Comparator|Education pamphlets on pain|Self-help Education on Chronic pain (pamphlet style pdf documents)
3490509|NCT03711838|Experimental|N-Acetylcysteine|N-Acetylcysteine supplementation: Orally, 40 mg/kg per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 40mg/kg per day in 3 doses (250 ml each).
3490510|NCT03711838|Active Comparator|Placebo|Placebo administration: Orally 750 ml per day in 3 doses (250 ml each) for 7 consecutive days and immediately post-exercise. The remaining 8 days, 750 ml per day in 3 doses (250 ml each).
3490511|NCT03711825|Experimental|Sentinel/Main|Sentinel dosing of two subjects in clinic of LYN-057 (50 mg), followed by Main, i.e. remaining 6 subjects, for total of 8 subjects doses; followed by imaging assessment (MRI/abdominal U/S)
3490512|NCT03711812|Active Comparator|Serratus Anterior Plane Catheter|
3490513|NCT03711812|Placebo Comparator|Thoracic Epidural|
3490514|NCT03711799|No Intervention|Resource Only Group|Families randomized to the resource only condition will have access to training materials in web-based and paper formats. The will receive the internet address to access web-based trainings, handouts and materials, including instructions for each activity and they will receive a binder that includes the information that is available on line so they can access the information even if they do not have internet access. Families in the resource only condition will not have access to a peer coach through the program. They will not have access to the on-line support community.
3490515|NCT03711799|Experimental|Peer Coaching Group|Families randomized to peer coaching will receive assistance with navigating the training program and accessing the system from a trained peer parent coach. Peer coaches will, as much as possible, be culturally and language-matched with the participant family.
3490516|NCT03711786|Active Comparator|Basic implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
3490517|NCT03711786|Experimental|Enhanced implementation package|Ten Malawi non-communicable diseases clinics will be randomized 1:1 to one of two implementation strategies to be used for two years followed by a 12-month follow-up period.
3490518|NCT03711773|Experimental|Group Physical Therapy Class|Group Physical Therapy Classes. Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
3490519|NCT03711760|Experimental|intervention|telepsychology treatment
3490520|NCT03711760|No Intervention|usual care|standard of care
3490521|NCT03711734|Experimental|Acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally with electrostimulation at Shen men and Hypothalamus at 30 hz."
3490522|NCT03711734|No Intervention|No acupuncture + Standard of Care|"Patients will receive spinal anesthesia (4 cc Mepivacaine) with IV sedation. Intraoperative anti-emetics will consist of IV odansetron and IV dexamethasone. Intra-operative analgesics will include IV Ketamine, IV Ketorolac, and IV Acetaminophen.~Patients will not have ATP acupuncture (8 ear points - Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) bilaterally."
3490523|NCT03711721|Experimental|Food basket|
3490524|NCT03711721|Experimental|Ready-to-Use Therapeutic Food|
3490525|NCT03711708|Experimental|Zoloft Oral Solution|50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water.
3490526|NCT03711708|Active Comparator|Zoloft Tablets|Zoloft 50 mg tablet.
3490527|NCT03711695||Group A|Subjects presenting for catheter ablation for cardiac arrhythmias (e.g. atrial fibrillation, supraventricular tachycardia, or ventricular tachycardia)
3490528|NCT03711695||Group B|Subjects judged based on the clinical evaluation of high, greater than 75%, atrial pacing or ventricular pacing burden or known pacing dependence with planned device interrogation for: 1) pacemaker (single or dual chamber), 2) implantable cardioverter-defibrillator (single or dual chamber), or 3) cardiac resynchronization therapy with or without defibrillator (single or dual chamber plus left ventricular pacing).
3490529|NCT03711695||Group C|Subjects for clinically indicated defibrillation threshold testing (DFT) (with a transvenous or subcutaneous implantable cardioverter defibrillator (ICD) lead system)
3490530|NCT03711682|Experimental|Cinnamon (Intervented)|
3490531|NCT03711682|Placebo Comparator|Wheat Flour (Placebo)|
3490532|NCT03711656|Experimental|isCGM and Physical exercise tracker|"Participants will perform CGM during 12 weeks using an isCGM (intermittently scanned Continuous Glucose Monitoring), Freestyle Libre, (Abbott Diabetes Care, Witney, Oxon, UK). Insulin dose (rapid-acting and long acting), carbohydrates and Self-monitoring blood glucose (SMBG) per day will be recorded by the patient in the reader or in the App (LibreLink, Abbott Diabetes Care, Witney, Oxon, UK). Moreover, participants will be instructed to collect data about moderate or high intensity exercise, illness and other disturbances occurring during the study period at home.~Patients will wear a physical exercise tracker (Fitbit Alta HR® wristband (Fitbit, Inc., San Francisco, California, USA)) to track physiological variables such as heart rate, steps, activity level and sleep quality."
3490533|NCT03711643|Experimental|Optimizing pain management|An experimental group receive a standard pain management and benefit the hypnotic mask (Hypnos pro).
3490534|NCT03711643|Active Comparator|standard pain management|
3490535|NCT03711630|Experimental|Meditation|The study cohort will participate in self-guided meditation practice over the course of eight weeks.
3490536|NCT03711565|Active Comparator|Regular Nasal CPAP using a conventional ventilator|Regular nasal CPAP for management of respiratory distress Patient will have regular nasal CPAP placed via nasal prongs with level of pressure adjusted and level of oxygen adjusted as needed for acceptable oxygenation and ventilation
3129347|NCT03213366|Active Comparator|BxNow - General Health Campaign|BxNow is an attention-matched control. Eight of the 16 PLs will be randomly assigned to the BxNow arm. The BxNow campaign will be a 6-week long social media intervention about general health wellness topics chosen and administered by the PLs assigned into this arm. Similarly to the intervention group, PLs in the BxNow arm will create private social media groups and recruit participants into these private groups. General health information in the BxNow arm will be posted with the same frequency as in the intervention arm.
3490537|NCT03711565|Active Comparator|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation
3490538|NCT03711552||Quality of recovery|All enrolled patients will be asked to complete the ObsQoR-11 and QoR-15 questionnaires pre-surgery if feasible and at 24 and 48 hours post-surgery.
3490539|NCT03711539||Lifelong Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
3490540|NCT03711539||Late-onset Endurance Athletes|i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (> 5 pack years) or diabetes, ii) they have a history of smoking (> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.
3490541|NCT03711539||Healthy Non-athletes|Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than >3 hours / week, ii) have a history of smoking (> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.
3490542|NCT03711513|Experimental|Exposure only|Psycho-education (PE) (plus homework) + 4 x Exposure (EX) (plus homework): 20 participants will receive four exposure group sessions after the psycho-education session. In the four sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
3490543|NCT03711513|Experimental|Cognitive restructuring plus exposure|PE (plus homework) + Cognitive Restructuring (CR) (plus homework) + CR (plus homework) + EX (plus homework) + EX: 20 participants will receive two cognitive restructuring group sessions after the psycho-education session. In these two session they will practice identifying dysfunctional cognitions and formulating more functional (alternative/helping) cognitions. After the cognitive sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
3490544|NCT03711513|Experimental|Relaxation plus exposure|PE (plus homework) + Relaxation (RE) (plus homework) + RE (plus homework) + EX (plus homework) + EX: 20 participants will receive two relaxation exercises group sessions after the psycho-education session. In these two session they will practice muscle relaxation and breathing exercises. After the relaxation sessions they will receive two exposure group sessions. In these two sessions they will move up in their fear hierarchy by practicing public speaking/performance tasks.
3490545|NCT03711500|Experimental|D-serine|
3490546|NCT03711500|Placebo Comparator|Placebo|
3490547|NCT03711487|Experimental|Ironing therapy|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, 4 times daily from 12 hours after surgery and last for 2 days. The medicine bag can be heated and reused after it cool down.
3490548|NCT03711487|No Intervention|No intervention|No intervention.
3490549|NCT03711474|Experimental|Treatment 1; Dexamethasone|"Drug: Treatment 1; Dexamethasone. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10 and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the single dose steroid administration group or the single dose saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of incision."
3490550|NCT03711474|Placebo Comparator|Treatment 0; Placebo|"Drug: Treatment 0; Saline placebo. Patients undergoing elective anterior cervical spine surgery will be seen by spine surgeons. After consent the Bazaz, EAT 10, and Dysphagia Short Questionnaire will be administered at baseline prior to surgery, Day 1, Day 2, 1 week, 2 weeks, 1 month, 3 months, 6 months, and 12 months after surgery.~Patients will be randomized to either the steroid administration group or the saline administration group. Patients randomized to the experimental (steroid) group will receive a single dose, 0.3 mg/kg of body weight of intravenous dexamethasone within one hour of the incision. Patients in the control(saline) group will receive a single dose of saline, 0.3 mg/kg of body weight within one hour of the incision."
3490551|NCT03711461|Active Comparator|nonintubated|patients received nonintubated during thoracoscopy
3490552|NCT03711461|Experimental|intubated|patients receiving intubated during thoracoscopy
3490553|NCT03711448|Active Comparator|Control group|
3490554|NCT03711448|Experimental|Experimental group|
3490555|NCT03711435||control group|15 subjects was enrolled in the control group，they are healthy controls
3490556|NCT03711435||training IPF group|30 subjects was enrolled in the training IPF group，they are IPF patients，the group is designed to identify differential metabolites between IPF and control groups.
3490557|NCT03711435||Validation group|15 subjects was enrolled in the Validation IPF group，they are IPF patients，the group is designed to validate differential metabolites identified in the previous groups.
3490558|NCT03711422|Experimental|Part A|Standard dose oral afatinib. If patients in Part A do not benefit from the regimen, they can be enrolled into Part B
3490559|NCT03711422|Experimental|Part B|Intermittent high dose oral afatinib
3490560|NCT03711409|Experimental|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of the muscles around the shoulder. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
3490561|NCT03711409|Experimental|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. The patient receives treatment 45 minutes per times and 2 times per week for 6 weeks.
3129348|NCT03213405|Active Comparator|Conventional BCG full dose|Participants will receive one full dose of the Conventional BCG vaccine administered as an intradermal injection at study entry.
3129349|NCT03213405|Experimental|rBCG-N-hRSV 1/100 dose|Participants will receive one 1/100 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
3490562|NCT03711383|Placebo Comparator|Placebo|isocaloric maltodextrin the day before CIDs
3490563|NCT03711383|Active Comparator|Inulin|12 g of inulin + isocaloric maltodextrin the day before CID
3490564|NCT03711383|Experimental|Inulin and Resistant Starch|12 g inulin + 7.5 g resistant starch the day before CID
3490565|NCT03711370|Experimental|Opaque Bottle Group|This group will be given a set of opaque bottles that are to be used during infant feedings for a full 12-week period.
3129350|NCT03213405|Experimental|rBCG-N-hRSV 1/10 dose|Participants will receive one 1/10 dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
3129351|NCT03213405|Experimental|rBCG-N-hRSV full dose|Participants will receive one full dose of the rBCG-N-hRSV vaccine administered as an intradermal injection at study entry.
3490566|NCT03711370|Active Comparator|Clear Bottle Group|This group will be given a set of clear bottles that are to be used during infant feedings for a full 12-week period.
3490567|NCT03711357|Active Comparator|laser|980 nm diode laser (maximum output of 3 watts and coupled with a fiber optic tip of 200 µm diameter) will be used for four irradiations, of 5 seconds each, after chemo-mechanical preparation procedures.
3490568|NCT03711357|Placebo Comparator|Placebo|After chemo-mechanical preparation procedures, the diode laser fiber optic tip will be inserted inside the root canals but not activated.
3490569|NCT03711344|Experimental|Culturally adapted Cognitive Behavioral therapy|The experimental group will receive the culturally adapted version of cognitive behavioral therapy.
3490570|NCT03711344|Active Comparator|Non-adapted Cognitive Behavioral therapy|The control group will receive the original (non-adapted) version of cognitive behavioral therapy.
3490571|NCT03711331|Experimental|FilmArray® Pneumonia panel plus strategy|patients benefiting from the new strategy based on the system Unyvero ®
3490572|NCT03711331|Sham Comparator|Standard care|patients benefiting from usual standard care
3490573|NCT03711318|Experimental|Short-term treatment with buprenorphine|Short-term treatment with buprenorphine
3490574|NCT03711305|Experimental|SHR-1316 + carboplatin + etoposide|Participants will receive SHR-1316 intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) SHR-1316 until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
3490575|NCT03711305|Active Comparator|Placebo + carboplatin + etoposide|Participants will receive placebo intravenously in combination with carboplatin and etoposide during the induction phase (Cycles 1-4 or 6). Thereafter, participants will receive maintenance (after induction phase) placebo until persistent radiographic PD, intolerable toxicity or withdrawal of consent.
3490576|NCT03711292|Experimental|Stepped Wedge Cluster Randomized|Antibiotic stewardship intervention
3490577|NCT03711279|Experimental|SHR-1210 plus Apatinib|
3490578|NCT03711279|Active Comparator|ADM Plus IFO or IFO Alone|
3490579|NCT03711266|Experimental|PE-PC|Eligible participants who present to participating CHCs and screen positive for PTSD will be offered PE-PC via telepsychiatry.
3490580|NCT03711253|Other|Biktarvy|All participants get Biktarvy Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg in this single arm study
3490581|NCT03711240|Experimental|bevacizumab+mFOLFOXIRI|
3490582|NCT03711227||Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level. These patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the Emergency Department and while an inpatient. Then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qSOFA score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.
3490583|NCT03711201|Active Comparator|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
3129352|NCT03213457|Placebo Comparator|Placebo|Placebo for elagolix administered twice daily (BID) plus placebo for estradiol/norethindrone acetate (E2/NETA) administered once daily (QD) for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
3129353|NCT03213457|Experimental|Elagolix / Elagolix + E2/NETA|Elagolix 200 mg BID alone for the first 6 months of the 12-month placebo-controlled Treatment Period and elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the second 6 months, followed by elagolix 200 mg BID+E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
3129354|NCT03213457|Experimental|Elagolix + E2/NETA|Elagolix 200 mg BID + E2/NETA 1 mg/0.5 mg QD for the 12-month placebo-controlled Treatment Period, followed by elagolix 200 mg BID plus E2/NETA 1 mg/0.5 mg QD for the remaining 36 months of the Treatment Period.
3129355|NCT03213509||Perinatal Death With Pause Point(s) Observed, Intervention Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the intervention arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
3129356|NCT03213509||Perinatal Death With Pause Point(s) Observed, Control Arm|"Any perinatal death where one or more pause points was observed by BetterBirth staff (FADA) at 2 months or 6 months post-intervention launch, in the control arm of the BetterBirth Trial.~The study involves administering verbal and social autopsies to the mother or family member of a baby who is in this cohort."
3129357|NCT03213626|Experimental|Cabozantinib + erlotinib|
3490584|NCT03711201|No Intervention|Group NoIORE|The patient's hemodynamic data will be measured in the evening service before surgery. The patient will be brought to the operating room by the anesthesiologist on the day of surgery and hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured in the preop unit. The hemodynamic data and the ST-STAI scale will measure the anxiety level in the operating room.
3490585|NCT03711188|Experimental|IMM-101 (and nivolumab or ipilimumab)|IMM-101 given in combination with nivolumab. Patients in cohort B who fail to respond to treatment with IMM-101 and nivolumab, and who meet certain criteria, have the option to change treatment on study to IMM-101 and ipilimumab.
3490586|NCT03711175|Other|Group A|The subscapularis is repaired. Receives device
3490587|NCT03711175|Other|Group B|The subscapularis is not repaired. Receives device
3490588|NCT03711162|Experimental|GLPG1690 Dose A|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
3490589|NCT03711162|Experimental|GLPG1690 Dose B|GLPG1690 (ziritaxestat) will be administered as film-coated tablets for oral use once daily.
3490590|NCT03711162|Placebo Comparator|Placebo|Placebo to match will be administered as film-coated tablets for oral use once daily.
3129358|NCT03213938|Experimental|Acupuncture|The participants in the acupuncture group will receive treatment that consists of 20 acupuncture sessions over an 8-week (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks) period after baseline, each for 30 minutes. Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Sanyinjiao (SP6), Zhongliao (BL33), Shenshu (BL23), and Huiyang (BL35), were selected as acupoints protocol. SP6 is on the tibial aspect of the leg, posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus; BL32 is in the sacral region, in the second posterior sacral foramen; BL33 is in the third posterior sacral foramen; BL35 is in the buttock region, 0.5 cun lateral to the extremity of the coccyx.
3129359|NCT03213938|Sham Comparator|Sham acupuncture|The participants in the sham acupuncture group will receive shallow needling at bilateral sham BL23, BL33, BL35 and SP6. The protocol includes the same duration and frequency of sessions as for the acupuncture treatment, but the treatment was delivered superficially at non-acupuncture points 10-15 mm to the lateral of corresponding acupuncture and not above a meridian line (15mm to BL23, BL33 and BL35; 10mm to SP6). The Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be inserted with a depth of 2-3 mm without any manipulation.
3490591|NCT03711149|Experimental|Intervention Arm|Intervention: Activity monitor feedback loop: (1) Subjects will receive activity monitor with feedback on daily step count from the in-room TV screen, and (2) access to the Art Tour application
3490592|NCT03711149|No Intervention|Standard-of-care Arm|"Subjects in the control arm will receive a blinded activity monitor post-op (without feedback on step count) and the usual standard of care. Nurses and doctors will not monitor ambulation with the activity monitor, they will use standard methods of observation."
3490593|NCT03711136||Frozen elephant trunk surgery|
3490594|NCT03711136||Standart surgery|
3490595|NCT03711123|Experimental|Group metacognitive therapy (GMCT)|10 weekly sessions of GMCT With 90 minutes duration
3490596|NCT03711123|Active Comparator|Clinical Management|10 weekly individual sessions with up to 60 minutes duration
3490597|NCT03711110|Experimental|Primary prevention strategy|Intensive cardiovascular monitoring focused on prevention and early diagnosis and treatment of cardiotoxicity based in cardio-onco-hematology teams involved in cancer patient care.
3129360|NCT03214081||Vonoprazan 10 mg or 20 mg|Usually, for adults, 10 mg of vonoprazan administered orally once daily. If that dosing proved insufficient, the dosage may have been increased up to 20 mg once daily. Participants received vonoprazan as part of a routine medical care.
3129361|NCT03214094||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
3129362|NCT03214198||Vonoprazan 10 mg|The usual adult dosage for oral use is 10 mg of Vonoprazan administered once daily. Participants will receive interventions as part of routine medical care.
3490598|NCT03711110|Other|Secondary prevention strategy (control)|Current clinical practice: cardiac care is based on the onco-hematologist criteria.
3490599|NCT03711097|No Intervention|Control|Upper left or right central and lateral incisor
3490600|NCT03711097|Experimental|Varnish Intervention|Upper central and lateral incisor contralateral to control upper central and lateral incisor
3490601|NCT03711084|Placebo Comparator|Water|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
3129363|NCT03214224|Experimental|remote PFT (rPFT) validation|Subjects in this arm perform both standard and remote PFT assessments in order to validate the procedure.
3129364|NCT03214367|Experimental|LY900014|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
3129365|NCT03214367|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
3490602|NCT03711084|Experimental|Natural high potency sweetener from leaf extract|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
3490603|NCT03711084|Experimental|Glucose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
3490604|NCT03711084|Experimental|Sucrose|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
3490605|NCT03711084|Experimental|Maltodextrin|Beverage containing either water, glucose, sucrose, maltodextrin or a natural high potency sweetener from leaf extract
3490606|NCT03711071|Experimental|Intervention Group|The Intervention Group is allocated to a Workshop of communication training before data collection covering theoretical background and clinical implementation of ICE communication in association with frequent consultation contents.
3490607|NCT03711071|No Intervention|Control Group|This group will not get the intervention before data collection.
3490608|NCT03711058|Experimental|Phase I - Copanlisib and Nivolumab (De-Escalation)|
3490609|NCT03711058|Experimental|Phase II - Copanlisib and Nivolumab|
3490610|NCT03711045||Suicide Risk Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) also have a history of suicide attempt in the past 6 months.
3490611|NCT03711045||Disorder Control Group|patients with affective disorders(eg. bipolar disorder, major depression disorder) and without suicide ideation or behavior.
3490612|NCT03711045||Healthy Control Group|
3490613|NCT03711006|Experimental|FMT treated patients|Seven patients with active Ulcerative Colitis treated with 25 multi-donor FMT Capsules daily.
3129366|NCT03214367|Experimental|LY900014 Postmeal (Open Label)|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3490614|NCT03710980||Healthy Adult Volunteer|
3490615|NCT03710967|Experimental|Bilateral TMS|
3490616|NCT03710967|Active Comparator|Unilateral TMS|
3490617|NCT03710954|Experimental|Experimental Group|All the volunteers were evaluated through numerical evaluation of pain that assumes a subjective condition, the researcher showed the numerical scale of pain, being 0 without pain, 1 to 4 mild pain, 5 moderate pain, 6 to 9 severe pain and 10 worse pain possible pain, which was interpreted by the volunteer. In the Fuzzy Pain Scale, the evaluation of the range of motion was done where the evaluator used the goniometer (plastic instrument that verifies the angulation of the joint movement) and supplied the Fuzzy system with these data.
3490618|NCT03710941|Experimental|REGN2477+REGN1033|Single, sequential, repeat-dose IV or matching placebo
3490619|NCT03710941|Experimental|Placebo|Single, sequential, repeat-dose IV
3490620|NCT03710915|Experimental|HG146 capsule treat multiple myeloma|"Experimental: 5/10/15/20 mg HG146 capsule 5 mg starting dose taken orally on Day 1, 3, 5, 7, 9, 11, 13 of each cycle, and off drug for 8 days (3 weeks).~Intervention: Drug: HG146 capsule"
3129367|NCT03214367|Experimental|LY900014 - Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
3129368|NCT03214367|Active Comparator|Insulin Lispro (Humalog)-MEE|Insulin lispro given SC 0-2 minutes before each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Preprandial insulin doses were individualized and titrated according to protocol-defined targets.
3490621|NCT03710902|Experimental|Intervention|
3490622|NCT03710902|No Intervention|Control|Standard diagnostic work-up, follow-up, and treatment of hypertension.
3490623|NCT03710863|Experimental|CM082 Tablet|Code Name: CM082 Tablet Other Name: X-82 Dosage and Administration: 25/50mg BID, P.O., two-week on/two-week off in four-week cycles until disease progression or unacceptable toxicity
3490624|NCT03710850|Experimental|Responders|Responders in terms of fecal butyrate production after acute inulin test.
3490625|NCT03710850|Experimental|Non-responders|Non-responders in terms of fecal butyrate production after acute inulin test.
3490626|NCT03710837|Experimental|Pain neuroscience education|Intervention: Pain neuroscience education group. One-off, 70 minute duration session delivered by Dr Cormac Ryan.
3490627|NCT03710837|Experimental|Red flag education|Intervention: Red flags education group. One-off 70 minute duration session delivered by Dr Cormac Ryan.
3490628|NCT03710811||Type 2 Diabetes|drug naive Type 2 Diabetes received insulin therapy
3490629|NCT03710811||normal control|healthy volunteers as normal control
3490630|NCT03710798|Experimental|Low carbohydrate high fat diet|Low carbohydrate high fat (LCHF) diet
3129369|NCT03214367|Experimental|LY900014 Postmeal (Open Label)-MEE|LY900014 given SC 20 minutes after the start of each meal with either basal insulin glargine given SC once or twice daily or insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3129370|NCT03214380|Experimental|LY900014|LY900014 given subcutaneously (SC) with each meal with either 100 U/mL (U-100) basal insulin glargine given SC once or twice daily or U-100 or 200 U/mL (U-200) insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3490631|NCT03710772|Experimental|Group I (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as described in part I.~COMBINATION CHEMOTHERAPY: Patients receive rituximab IV over 6 hours on day 1, dexamethasone PO or IV on days 1-4, cyclophosphamide IV over 3 hours BID on days 2-4, and doxorubicin hydrochloride IV over 24 hours and vincristine sulfate IV over 15-30 minutes on day 5 of odd-numbered cycles (1 and 3). Patients also receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours BID on days 3-4 of even-numbered cycles (2 and 4). Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ibrutinib and venetoclax PO QD on days 1-28, and rituximab IV over 4-8 hours on day 1 of every other month. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3490632|NCT03710772|Experimental|Group II (ibrutinib, rituximab, venetoclax, chemotherapy)|"Patients receive ibrutinib, rituximab, and venetoclax as in part I.~Patients receive combination chemotherapy as in group I. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive maintenance therapy as in group I."
3490633|NCT03710772|Experimental|Group III (ibrutinib, rituximab, venetoclax)|Patients receive ibrutinib, rituximab, venetoclax as in part I. Patients then receive maintenance therapy as in group I.
3490634|NCT03710759|Experimental|Assistive Autogenic Drainage|Autogenic drainage (AD) is a breathing technique that uses controlled breathing and least amount of coughing to clear secretions from your chest. It involves you hearing and feeling your secretions as you breathe out and controlling the urge to cough until secretions are high up and easily cleared with little effort.
3490635|NCT03710746|Experimental|Mixed Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the food-focused response and attention training intervention.
3490636|NCT03710746|Experimental|Mixed Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in mixed-sex groups and will complete the generic response and attention training intervention.
3321252|NCT02017548|Experimental|Comfort default|Subjects in this group will receive an advance directive form that defaults to an overall goal of care directed towards comfort and relief of pain and suffering (vs. life extension) unless the subject specifies otherwise. The form also states 4 specific life extending interventions (cardiopulmonary resuscitation, mechanical ventilation, hemodialysis, and feeding tube insertion) will be not provided unless patients specifically opts into such selections. It also will state that upon discharge from the hospital, hospice care (vs. long-term care) will be provided unless the patient chooses otherwise.
3129371|NCT03214380|Active Comparator|Insulin Lispro (Humalog)|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3129372|NCT03214380|Experimental|LY900014 Maximum Extended Enrollment (MEE)|LY900014 given subcutaneously (SC) with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3490637|NCT03710746|Experimental|Female Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the food-focused response and attention training intervention.
3490638|NCT03710746|Experimental|Female Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in female-only groups and will complete the generic response and attention training intervention.
3490639|NCT03710746|Experimental|Male Group, Food Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the food-focused response and attention training intervention.
3490640|NCT03710746|Experimental|Male Group, Generic Response Training|Participants in this arm will be assigned to receive Project Health in male-only groups and will complete the generic response and attention training intervention.
3490641|NCT03710733|Active Comparator|Sequential boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus sequential boost 10 Gy/4 fx (2.5 Gy/fx) to lumpectomy cavity
3490642|NCT03710733|Experimental|Concomitant boost|Hypofractionated whole breast irradiation 40 Gy/15 fx (2.67 Gy/fx) plus concomitant boost 8 Gy/15 fx (0.53 Gy/fx) to lumpectomy cavity
3490643|NCT03710707|Experimental|DNL201 low dose|
3490644|NCT03710707|Experimental|DNL201 high dose|
3490645|NCT03710707|Placebo Comparator|Placebo|
3490646|NCT03710694|Experimental|DAV132 group|Patients randomized to the DAV132 arm will be administered DAV132 concomitantly with fluoroquinolones.
3321253|NCT02017548|No Intervention|Standard advance directive|Subjects in the standard advance directive (AD) group will receive an AD that will have no options pre-selected.
3490647|NCT03710694|No Intervention|No DAV132 group|Patients randomized to the No DAV132 arm will receive only fluoroquinolones, according to local standard of care.
3490648|NCT03710681|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 at 160mg every two weeks
3490649|NCT03710681|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 at 240mg every two weeks
3490650|NCT03710655|Experimental|treatment group|skin test, dose escalation, final dose of 1.5mg weekly over 16 weeks of Apitox pure honeybee toxin
3490651|NCT03710655|Placebo Comparator|placebo group|histamine placebo administered intradermally in dose escalation, final dose of 1.5mg weekly over 16 weeks
3490652|NCT03710642|Active Comparator|Treatment (Prazosin)|"Eligible participants will be randomized using a 2:1 schedule to prazosin or placebo and stratified by site and gender, and will follow a fixed titration scheme for the first 15 days, followed by a flexible does titration from days 15-29, then a maintenance phase stable dose from days 29 to the end of the 12 weeks study period.~Prazosin Fixed titration dose schedule for Days 1 to 14 1 mg QHS for Days 1 to 3~1 mg QAM and 1 mg QHS for days 4 to 7~mg QAM and 2 mg QHS for days 8 to 10~mg QAM and 2 mg QHS for days 11 to 14~Prazosin Flexible titration dose schedule for Days 15 to 29. 3 mg QAM and 3 mg QHS on day 15, 4 mg QAM and 4 mg QHS on day 22, 4 mg QAH and 6 mg QHS on day 29,~Dose increases will be allowed only during the fixed and flexible dosing periods."
3490653|NCT03710642|Placebo Comparator|Placebo oral capsule|Placebo medication will be administered in a titration schedule mimicking the active comparator treatment.
3490654|NCT03710629||NSCLC patients with driver genes|NSCLC patients and driver genes
3490655|NCT03710603|Active Comparator|Velcade Lenalidomide dexamethasone (VRd)|VRd: subjects will receive VRd for induction and consolidation, followed by lenalidomide (R) maintenance until disease progression or unacceptable toxicity.
3490656|NCT03710603|Experimental|Daratumumab + VRd (D-VRd)|D-VRd: Subjects will receive D-VRd for induction and consolidation followed by daratumumab and lenalidomide maintenance until disease progression or unacceptable toxicity. Minimal residual disease (MRD)-negative subjects in Arm B will stop therapy with daratumumab after sustained MRD negativity for 12 months and after a minimum of 24 months of maintenance therapy. These subjects will continue lenalidomide maintenance therapy until disease progression or unacceptable toxicity. After stopping daratumumab therapy, subjects with sustained MRD negativity should restart therapy with daratumumab if there is a recurrence of MRD or a confirmed loss of Complete Response (CR) without International Myeloma Working Group (IMWG)-defined disease progression. After reinitiating daratumumab, the subject will continue daratumumab and lenalidomide therapy until disease progression or unacceptable toxicity.
3490657|NCT03710551|Experimental|Experimental Infant Formula|Experimental Infant Formula with a new fat blend plus L. reuteri
3490658|NCT03710551|Active Comparator|Standard Infant Formula|Standard bovine milk-based infant formula.
3321254|NCT02017561|Active Comparator|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
3490659|NCT03710538|No Intervention|[Placebo + Sedentary]|1) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women; Sedentary activities throughout the study
3490660|NCT03710538|Experimental|[Snack effect + Sedentary]|2) Consumption of 200ml of soy beverage + 90g of carbohydrate (CHO) breakfast for men and 80g for women; Sedentary activities throughout the study
3490661|NCT03710538|Experimental|[Placebo + Exercise]|3) Consumption of 200ml of water (flavored) + breakfast of 90g of carbohydrates (CHO) for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5);
3129373|NCT03214380|Active Comparator|Insulin Lispro (Humalog) MEE|Insulin lispro given SC with each meal with either U-100 basal insulin glargine given SC once or twice daily or U-100 or U-200 insulin degludec given SC once daily. Prandial insulin doses were individualized and titrated according to protocol-defined targets.
3129374|NCT03214406|Experimental|Arm & Hammer Advance White Brilliant Sparkle (Test product)|2X daily brushing for 12 weeks with Arm & Hammer Advance White Brilliant Sparkle (Test product). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
3129375|NCT03214406|Active Comparator|Crest Cavity Protection Regular Toothpaste (Negative Control)|2X daily brushing for 12 weeks with Crest Cavity Protection Regular Toothpaste (Negative Control). Return to pre-study hygiene regimen for 4 weeks and final evaluation at 16 weeks.
3490662|NCT03710538|Experimental|[Snack + Exercise]|4) Consumption of 200ml of soy beverage + breakfast of 90g of carbohydrate (CHO) breakfast for men and 80g for women + physical activity practice (3min walk at 60% VO2max every 30 minutes, x5).
3490663|NCT03710525|Experimental|Own-Price Elasticity|"The price of vegetables will vary (own-price elasticity) while the price of all other foods in the mock grocery store will remain constant."
3490664|NCT03710525|Experimental|Cross-Price Elasticity|"The price of vegetables will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
3490665|NCT03710512||hydroset|patients receiving hydroset at osteotomy site
3490666|NCT03710512||Control|patients not receiving hydroset at osteotomy site
3490667|NCT03710499|Experimental|Physical activity|The program comprises the practice of resistance exercises for the main muscular groups, with free weights and with their own body weight against the action of gravity, the proposal consists of 3 weekly sessions, for 8 consecutive weeks.
3490668|NCT03710486||Cohort 1: Vedolizumab|Participants diagnosed with UC or CD, who have initiated vedolizumab treatment between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index vedolizumab treatment initiation during the eligibility period, and then from date of index vedolizumab treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when vedolizumab treatment was initiated.
3490669|NCT03710486||Cohort 2: Other Biologic|Participants diagnosed with UC or CD, who have initiated other biologic treatment (infliximab, adalimumab, or golimumab [UC only]) between January 2017 until date of site initiation from the 25 participating sites will be observed from the date of UC or CD diagnosis until one day prior to the date of index other biologic treatment initiation during the eligibility period, and then from date of index other biologic treatment initiation until the earliest of 6 months (post-index treatment discontinuation, death of participant, lost-to-follow up, or date of chart abstraction). Index date is defined as the date when other biologic treatment was initiated.
3490670|NCT03710460|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
3490671|NCT03710460|Experimental|Dapagliflozin plus metformin XR|Dapagliflozin plus metformin XR capsules, 10/1000 mg, one per day before breakfast during 12 weeks.
3490672|NCT03710460|Experimental|Metformin XR|Metformin XR capsules, 1000 mg, one per day before breakfast during 12 weeks.
3490673|NCT03710447|Experimental|HIIT + WB-EMS|High-intensity interval training (HIIT) combined with whole-body electromyostimulation (WB-EMS) Sequence of application: HIIT - WB-EMS
3490674|NCT03710447|Experimental|WB-EMS + HIIT|Whole-body electromyostimulation (WB-EMS) combined with High-intensity interval training (HIIT) Sequence of application: WB-EMS - HIIT
3129376|NCT03214588|Placebo Comparator|Placebo|TAK-831 placebo-matching tablets, orally, twice daily for up to 12 weeks.
3490675|NCT03710447|Experimental|HIIT + CST|High-intensity interval training (HIIT) combined with conventional low-volume strength training (CST) Sequence of application: HIIT - CST
3490676|NCT03710447|Experimental|CST + HIIT|Conventional low-volume strength training (CST) combined with high-intensity interval training (HIIT) Sequence of application: CST - HIIT
3490677|NCT03710434|Experimental|Part A - nano-suspension|Subjects will receive single dose of AZD4635 50mg nano-suspension (reference) in the fasted state.
3490678|NCT03710434|Experimental|Part A - solid oral formulation|Subjects will receive single dose of AZD4635 50mg solid oral formulation, in the fasted state.
3490679|NCT03710434|Experimental|Part B-solid oral formulation with food|Subjects will receive a single dose AZD4635 solid oral formulation after high fat meal.
3490680|NCT03710434|Experimental|Part B - solid oral formulation with PPI|Subjects will receive 30 mg lansoprazole BID and a single dose of AZD4635 solid oral formulation in the fasted state.
3490681|NCT03710434|Experimental|Part B - dose exploration 1|If dose adjustment is required, subjects will receive a different single dose (XX mg) of AZD4635 solid oral formulation, in the fasted state.
3490682|NCT03710434|Experimental|Part B - dose exploration 2|If dose adjustment is required, subjects will receive a different single dose (YY mg) of AZD4635 solid oral formulation, in the fasted state.
3490683|NCT03710434|Experimental|Part B - variant 1|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state and optional [14C] AZD4635 IV microtracer.
3490684|NCT03710434|Experimental|Part B - variant 2|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
3490685|NCT03710408|Experimental|Subcutaneous hydration|
3490686|NCT03710408|Active Comparator|Intravenous hydration|
3490687|NCT03710395|Active Comparator|Wild homozygous for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as wild homozygous for ABCG2 c.421C>A.
3129377|NCT03214588|Experimental|TAK-831 75 mg|TAK-831 75 mg, tablets, orally, twice daily for up to 12 weeks.
3129378|NCT03214588|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, twice daily for up to 12 weeks.
3490688|NCT03710395|Experimental|Variant genotypes for ABCG2 c.421C>A|Chronic hypertensive breastfeeding women (18-45 years old) genotyped as heterozygous or mutant homozygous for ABCG2 c.421C>A.
3490689|NCT03710382|Experimental|Walking epidural|Parturients will receive a lower concentration of bupivacaine in their epidural infusion and will be encouraged to walk during labor.
3490690|NCT03710369|Sham Comparator|Normoxia|Exercise in room air (normoxia). Sildenafil
3490691|NCT03710369|Active Comparator|Hypoxia|Exercise in hypoxic air (reduced O2 concentration) that simulates 2500m elevation for 30-40 minutes with Sildenafil. Placebo
3490692|NCT03710356|Experimental|Danazol|Danazol
3490693|NCT03710343|Experimental|Metformin|Metformin oral tablet will be taken by mouth, once or twice a day for 16 weeks.
3490694|NCT03710343|Placebo Comparator|Placebo|The placebo oral tablet will be taken by mouth once or twice a day for 16 weeks.
3490695|NCT03710330|Placebo Comparator|normal saline|the patients receives 110 ml normal saline IV just before skin incision
3490696|NCT03710330|Active Comparator|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
3490697|NCT03710330|Active Comparator|0.5 gm tranexamic acid|0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
3490698|NCT03710317|Active Comparator|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
3490699|NCT03710317|Experimental|Tranexamic acid plus misoprostol|400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision in addition to 1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
3490700|NCT03710304|Active Comparator|oxytocin|20 IU oxytocin ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal(ranitidine) plus 110 ml saline iv
3129379|NCT03214640|Active Comparator|Palpation with spinal block (Group C-P)|insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest) for placement of spinal block for cesarean delivery
3490701|NCT03710304|Active Comparator|Tranexamic acid plus misoprostol|400 μg misoprostol (2 tablets of 200 μg) or two placebo tablets were given buccally after spinal anesthesia and few minutes before skin incision; then 1 gm TA will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision, plus 500 ml normal saline intravenous solution infusion over 15 min after delivery of the baby
3490702|NCT03710291|Experimental|TRC101|
3490703|NCT03710291|Placebo Comparator|Placebo|
3490704|NCT03710278||LPat Device|Performing Lumbar Puncture assisted by LPat
3490705|NCT03710252|Experimental|Single|Ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) + databuvir (DSV) +/- ribavirin (RBV)
3490706|NCT03710239|Active Comparator|Dilapan-S|Synthetic osmotic dilator
3490707|NCT03710239|Active Comparator|Laminaria|Seaweed-based osmotic dilator
3490708|NCT03710226||cases|women with recurrent miscarriage (two or more consecutive miscarriages)
3490709|NCT03710226||controls|women without recurrent miscarriage and delivered at least once before
3490710|NCT03710213|No Intervention|Usual Care|Usual care includes (1) bowel preparation instructions that are delivered via mail or through a secure online messaging portal, (2) a phone call from the endoscopy staff in the week prior to colonoscopy, and (3) the option to call the endoscopy staff during business hours to have any questions answered on demand.
3490711|NCT03710213|Experimental|Text Message-based Intervention|In addition to usual care, the text message-based intervention consists of the subject receiving text messages per a pre-determined protocol starting 7 days prior to the date of scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program. Of note, if a patient in the intervention arm cancels or reschedules their colonoscopy after randomization, they will not receive any additional protocol text messages as part of this trial.
3490712|NCT03710200|Active Comparator|Bologna 00+S. cerevisiae yeast|Bread made with Bologna flour (type 00) (modern variety)+S. cerevisiae yeast
3490713|NCT03710200|Experimental|Bologna 1+S. cerevisiae yeast|Bread made with Bologna flour (type 1) (modern variety)+S. cerevisiae yeast
3490714|NCT03710200|Experimental|Bio2+S. cerevisiae yeast|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+S. cerevisiae yeast
3490715|NCT03710200|Experimental|ICARDA+S. cerevisiae yeast|Bread made with Icarda mix (type 1) (heritage mix varieties)+S. cerevisiae yeast
3490716|NCT03710200|Experimental|Bologna 1+sourdough|Bread made with Bologna flour (type 1) (modern variety)+sourdough
3490717|NCT03710200|Experimental|Bio2+sourdough|Bread made with mix Bio2 flour (type 1) (heritage mix varieties)+sourdough
3129380|NCT03214640|Active Comparator|Palpation with neuraxial block (Group L-P)|the needle insertion site for the neuraxial block will be identified with palpation for labor analgesia, using the spinous process and iliac crest for reference
3490718|NCT03710200|Experimental|ICARDA+sourdough|Bread made with mix Icarda flour (type 1) (heritage mix varieties)+sourdough
3490719|NCT03710200|Experimental|Grossi+sourdough|Bread made with mix Grossi flour (type 1) (heritage mix varieties)+sourdough
3490720|NCT03710174|No Intervention|Control group|Without bruxism and no intervention. They will be submitted to electromyographic assessment and evaluation of salivary cortisol and dopamine.
3490721|NCT03710174|Experimental|LED group|The volunteers in Group 2 will be submitted to the initial evaluation of the morphological and psychosocial variables. During the same appointment, red LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of 650 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later. They will be submitted before and after LED to electromyographic assessment and evaluation of salivary cortisol and dopamine.
3490722|NCT03710174|Experimental|Occlusal splint group|They will be treated using the standard protocol of a rigid occlusal splint. After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
3490723|NCT03710174|Placebo Comparator|Placebo group|Subjects with bruxism. The same procedures as LED group, but the device will be turn off.
3490724|NCT03710122|Experimental|Vancomycin|
3490725|NCT03710122|Placebo Comparator|Placebo|
3490726|NCT03710109||Concussion|Individuals who have sustained a recent concussion
3490727|NCT03710109||Control Healthy Volunteers|No Intervention
3490728|NCT03710096|Experimental|Mac grath group|
3490729|NCT03710096|Active Comparator|Macintosh Group|
3490730|NCT03710070|Experimental|Intervention|In the presence of a significant coronary artery stenosis and randomization to the intervention group: Catheter-based permanent occlusion of the ipsilateral (to the culprit coronary lesion) IMA will be performed at the projected height of inferior vena cava confluence and right atrium using a dedicated occlusion device (Amplatzer vascular plug 4, CE0086).
3490731|NCT03710070|Sham Comparator|Sham-Control|In the presence of a significant coronary artery stenosis, and randomization to the sham-procedure: IMA will be selectively intubated using an appropriate catheter. Angiography of the IMA and the pericardiacophrenic branch will be performed.
3490732|NCT03710044|Experimental|Cyclosporine A treatment|Oral cyclosporine A treatment
3490733|NCT03710031||HSCT Survivors|PNS tracking will occur through blood and stool samples to track the interplay among psychoneurologic symptoms (PNS) as they relate to diminished QOL among survivors of HSCT.
3490734|NCT03710018||A Patient who underwent open cavity BCS|Patients undergoing Open cavity Breast Conservative Surgery
3490735|NCT03710018||B Patient who underwent close cavity BCS|Patients undergoing Close cavity Breast Conservative Surgery
3490736|NCT03710018||C Patient who underwent oncoplasty|Patients undergoing oncoplasty for breast cancer
3490737|NCT03710005|Experimental|Ascent Intervention Treatment|Interventional treatment arm will receive Ascent dehydrated cell and protein concentrate injection
3490738|NCT03710005|Active Comparator|Standard Treatment|Standard treatment arm will receive a standard Corticosteroid injection
3490739|NCT03709992|Active Comparator|Trospium|Patients will receive 30 mg of Trospium chloride tablet twice daily
3490740|NCT03709992|Active Comparator|Tamsulosin|Patients will receive 0.4 mg of Tamsulosin tablet once daily
3490741|NCT03709979|Active Comparator|C-MAC with folded towel position|Children will be intubated by C-MAC videolaryngoscope with placing a folded towel under the shoulder.
3490742|NCT03709979|Placebo Comparator|C-MAC with flat position|Children will be intubated by C-MAC videolaryngoscope with flat position (non-inserted a folded towel)
3490743|NCT03709966|Experimental|FitBit|Portable technological support to monitor physical activity, similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status.
3490744|NCT03709966|Active Comparator|Routine|Physical activity promotion supported by a kinesiologist
3490745|NCT03709953|Experimental|apatinib|apatinib, 500 mg, po, QD; 28 days every cycle
3490746|NCT03709940|Experimental|Placebo, MPH|"Dose order: placebo, methylphenidate (MPH)~Participants receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 and a clinically effective dose of short-acting MPH (20 mgs) on DAY 2."
3490747|NCT03709940|Experimental|MPH, Placebo|"Dose order: methylphenidate (MPH), placebo~Participants receive a clinically effective dose of short-acting MPH (20 mgs) on DAY 1 and a placebo tablet (ascorbic acid 50 mgs) on DAY 2."
3490748|NCT03709927|Experimental|Therapeutic ZTI-01 6 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 6g
3490749|NCT03709927|Experimental|Supra-therapeutic ZTI-01 12 g IV|intravenous fosfomycin (only antibiotic in phosphonic acid derivative class) 12g
3490750|NCT03709927|Active Comparator|moxifloxacin 400 mg PO|oral moxifloxacin 400mg film coated tablets - Avelox(TM)
3490751|NCT03709927|Placebo Comparator|Placebo IV|IV 0.9% normal saline solution
3490752|NCT03709914|Experimental|ZTI-01 Cohort 1 ≥ 6 to <12 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
3490753|NCT03709914|Experimental|ZTI-01 Cohort 2 ≥ 2 to <6 years of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
3490754|NCT03709914|Experimental|ZTI-01 Cohort 3a Birth to < 3 mos of age|ZTI-01 (fosfomycin IV) 75 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
3490755|NCT03709914|Experimental|ZTI-01 Cohort 3b ≥ 3 to < 6 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
3490756|NCT03709914|Experimental|ZTI-01 Cohort 3c ≥ 6 to < 24 mos of age|ZTI-01 (fosfomycin IV) 100 mg/kg (single dose) Subjects weighing within the 3rd to < 97th percentile for age
3490757|NCT03709901|Experimental|Active Allograft|Injection of viable allograft
3490758|NCT03709901|Placebo Comparator|Placebo|Injection of saline
3490759|NCT03709901|No Intervention|Conservative Care|Continued conservative care treatment
3490760|NCT03709888||Observation Group|Subjects will be identified from patients with chemotherapy induced peripheral neuropathy (CIPN) that are planning to be treated with memantine XR-pregabalin combination therapy.Patients who agree to participate will be asked to complete study questionnaires prior to the start of their CIPN treatment and once per week for six weeks during their treatment.
3490761|NCT03709875|Experimental|TR Treatment|TR will be delivered by means of an advanced video-conferencing system, and patients will be provided with low-cost monitoring devices, able to collect data about the health status and QoL. All treatments from remote are based on scheduled videoconferences between the patient's home and the Clinical Units, and therapists can control and modify the exercises. A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech and cognitive exercises will be delivered from the two Research Institutes to the patient's home.
3129381|NCT03214640|Experimental|Rivanna Accuro Ultrasound Device with spinal block (Group C-R)|insertion will be identified with Rivanna Accuro U/S device for placement of spinal block for cesarean delivery
3129382|NCT03214640|Experimental|Rivanna Ultrasound Device with neuraxial block (Group L-R)|insertion will be identified with Rivanna Accuro U/S device for placement of neuraxial block (combined spinal epidural) for labor analgesia
3490762|NCT03709875|Other|Conventional Treatment|"In this group patients will be treated with conventional physiotherapy and speech training, adjusted in reason of the clinical needs, as usually. Treatments for motor limbs activity will be focused on functional active-assistive and active exercises. Conventional paper and pencil training will be used to improve cognitive function."
3490763|NCT03709862||Syphilis|Patients with syphilis and detectable Treponema pallidum DNA in a routinely collected clinical sample
3490764|NCT03709849|Experimental|experimental group|Intervention, dosage and frequency: drug: Bushen Culuan Decoction 13g tid and Clomiphene Citrate Tablets placebo 50mg qd; Dosage form: Bushen Culuan Decoction is dissolved medicine and Clomiphene Citrate Tablets placebo is tablets; Duration: the medicine will be taken from 5th day of a menstrual cycle, Bushen Culuan Decoction is taken for 14 days while Clomiphene Citrate Tablets placebo being taken for 5 days. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
3490765|NCT03709849|Active Comparator|control group|Intervention, dosage and frequency: drug: Clomiphene Citrate Tablets 50mg qd and Bushen Culuan Decoction placebo 13g tid; Dosage form: Clomiphene Citrate Tablets is tablet and Bushen Culuan Decoction placebo is dissolved medicine; Duration: the medicine will be taken from 5th day of a menstrual cycle, Clomiphene is taken for 5 days while Bushen Culuan Decoction placebo being taken for 14 days while. Then patients stop taking the medicine until the 5th day of next menstrual cycle. If the patient doesn't have a regular menstrual cycle, the medicine will be taken from 5th day from vaginal bleeding caused by taking progesterone. Each treatment cycle contains 3 menstrual cycle. If the patient regains normal ovulation at the end of the first treatment cycle, she will reach the end of the whole treatment, and if not she will start the second treatment cycle. All treatment will be terminated after 2 treatment cycles.
3490766|NCT03709797|Experimental|Experimental group|Experimental group will receive dry needling treatment.
3490767|NCT03709797|Sham Comparator|Control group|Control group will receive sham dry needling treatment.
3490768|NCT03709771||VEGF inhibitor alone|
3490769|NCT03709771||Immune Checkpoint Inhibitor (ICI) alone|
3490770|NCT03709771||Combination (VEGF inhibitor + ICI, or combination of ICI)|
3490771|NCT03709771||No treatment|
3490772|NCT03709745|Active Comparator|Aflibercept|Aflibercept is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given aflibercept according to a treat-and-extend regimen.
3490773|NCT03709745|Active Comparator|Ranibizumab|Ranibizumab is given monthly (at least 3 times) until resolution of macular edema after which the patient is observed monthly. If there is recurrence of macula edema, the patient is given ranibizumab according to a treat-and-extend regimen.
3490774|NCT03709732||Spinal cord injury|Persons with a spinal cord injury. No intervention
3490775|NCT03709732||Caregivers spinal cord injury|Caregivers for persons with a spinal cord injury. No intervention
3490776|NCT03709732||Controls for patients|Control group for patient cohort. No intervention
3490777|NCT03709732||Controls for caregivers|Control group for caregivers cohort. No intervention
3490778|NCT03709719|Experimental|blinatumomab|
3490779|NCT03709706|Experimental|Arm A: lete-cel monotherapy|In Arm A, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel monotherapy. Participants who subsequently progress by Week 25 will be offered pembrolizumab.
3490780|NCT03709706|Experimental|Arm B: lete-cel plus pembrolizumab|In Arm B, participants with NSCLC (lacking actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
3490781|NCT03709706|Experimental|Arm C: lete-cel plus pembrolizumab|In Arm C, participants with NSCLC (with actionable genetic aberrations) will receive lete-cel followed by pembrolizumab.
3490782|NCT03709693||SternaLock Blu|All patients will receive SternaLock Blu for closure of full mid-line sternotomy.
3321255|NCT02017561|Experimental|Metformin + Lifestyle Counseling|Metformin: maximum dose of 1000mg twice daily. Lifestyle counseling: Written and individualized information during the interview in all clinic visits, emphasizing the importance of regular moderate-intensity physical activity and healthy diet.
3490783|NCT03709667|Experimental|EX|Participants in this arm of the study will be randomized in to the exercise intervention.
3490784|NCT03709667|Placebo Comparator|CON|The control condition is a health-education intervention.
3490785|NCT03709641|Experimental|Restylane Defyne receiver|Participants will receive Restyane Defyne injected into punctum of one eye.
3129383|NCT03214952||Vonoprazan 20 mg|The usual adult dosage for oral use is 20 mg of vonoprazan administered orally once daily. An 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer. For reflux esophagitis, the usual adult dosage for oral use was administered for a total of 4 weeks of treatment, and if that dosing proved insufficient, the administration may have been extended, but for no longer than 8 weeks of treatment. Participants received vonoprazan as part of a routine medical care.
3490786|NCT03709628|Experimental|Patients with active Crohn's disease|EB8018: 3000 mg for the single dose in Part 1 (2 sentinel patients) and 1500 mg BID for multiple dose administration over 13 days in Parts 1 and 2 (2 sentinel patients and 6 remaining patients), oral.
3490787|NCT03709615|No Intervention|Wait list|Wait list condition with no active treatment, length of 10 weeks, with weekly measurements.
3490788|NCT03709615|Experimental|Intervention- active treatment|Internet delivered CBT for social anxiety disorder
3490789|NCT03709589||Group-A|Patients with Modified Early Warning Score of ≥ 5
3490790|NCT03709589||Group-B|Patients with Modified Early Warning Score of < 5
3490791|NCT03709563|Active Comparator|Oral Nutraceutical Supplement|
3490792|NCT03709563|Placebo Comparator|Placebo|
3490793|NCT03709550|Experimental|Treatment (decitabine, enzalutamide)|Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3490794|NCT03709537|Experimental|Mental Health Peer Workforce Support|Sites assigned to this group will engage in Co-Learning Collaborative, several trainings, and the creation of Implementation Teams--all part of the intervention and designed to support their peer workforce.
3490795|NCT03709537|No Intervention|Control Group|Sites assigned to this group will continue practice as usual and not receive any additional peer worker training or technical assistance.
3490796|NCT03709524|Active Comparator|insertion time|1 minute Airtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
3490797|NCT03709524|Active Comparator|intubation time|2 minutesAirtraq, nasotracheal Airtraq + styletted tube and airtraq + fiberoptic
3490798|NCT03709485|Experimental|prostate biopsy patients|a cohort o consecutive patients referred to prostate biopsies. In all patients, a rectal swab will be taken prior to biopsy and antimicrobial treatment. The swab will be cultured and analyzed in the lab for characterization of the microbiome.
3129384|NCT03215667|Experimental|Device treatment|easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
3129385|NCT03215706|Experimental|Module A|Chemotherapy/Biologics combined
3490799|NCT03709472|Experimental|Computer Assisted CIFFTA|CA CIFFTA (Computer Assisted Culturally Informed and Flexible Family Based Treatment for Adolescents) consists of a hybrid intervention utilizing office-based CIFFTA and technology-delivered material. Over 16 weeks CIFFTA participants receive 45 minutes of face-to-face sessions plus approximately 45 minutes of web-based intervention per week. During the continuing care phase participants access website resources and receive targeted messages (e.g., handling family conflicts). CA CIFFTA will: 1) deliver psycho-educational modules (e.g., depression, emotion regulation), 2) collect diary-card information, and 3) provide additional resources. During videos parents and adolescents can report symptoms and information that is automatically transmitted to therapists and used in the next session
3490800|NCT03709472|Active Comparator|Behavioral: Traditional face-to-face treatment-no technology|Participants randomized to Treatment-As-Usual (TAU) work over a 16-week period with their community agency. They may receive individual or family treatment. The team coordinates with the TAU agencies to minimize the overlap of data collected. The team will refer out to service locations that are most convenient for the participant. A great deal of thought has gone into the selection of the Treatment as Usual condition. The investigators wanted to compare CA CIFFTA's ability to retain and bring about change in participants with what is typically done in the community. Although running an in-house comparison condition gives more control of the delivery of services and tracking of clients, it is difficult to know how that compared to the services that are typically provided in the community
3490801|NCT03709433|Experimental|ACT groups and mobile app|Participants will receive six two-hour weekly sessions of acceptance and commitment therapy (ACT) in a group format. They will also access the ACT Daily mobile app, which helps participants practice ACT skills in the moment, for the duration of the study (10-14 weeks depending on when the participant completes the baseline assessment.) Sessions use metaphors, experiential exercises, and discussion to target core ACT skills: acceptance, defusion, present-moment awareness, self-as-context, values, and committed action. The mobile app includes metaphors and experiential exercises to aid with all of these skills except self-as-context. Participants will be asked to use the app to practice these skills and to complete behavioral commitments linked to their values between sessions.
3129386|NCT03215706|Active Comparator|Module B|Chemotherapy Combination
3129387|NCT03215758|Active Comparator|QAW039|QAW039 once daily
3490802|NCT03709420|Placebo Comparator|Placebo|Matching placebo capsule
3490803|NCT03709420|Experimental|FOR-6219|"Part I (SAD): Single oral doses of 2 mg, 10 mg, 25 mg, 50 mg, 100 mg and 175 mg.~Part II (MAD): Multiple oral doses of 50 mg QD, 75 mg BID and 150 mg BID.~Part III: Multiple oral doses of 10 mg, 25 mg, 75 mg and 150 mg BID"
3490804|NCT03709407|Experimental|cervical stimuli|Godoy´s maneuver with traction-sliding in supraclavicular fossa
3490805|NCT03709407|Experimental|terminus|Vodder´s maneuver with medial and anterior traction in supraclavicular fossa
3490806|NCT03709407|Sham Comparator|placebo|maneuver with sliding ON clavicular
3490807|NCT03709407|No Intervention|Control group|only lying down
3129388|NCT03215758|Placebo Comparator|Placebo|Placebo once daily
3129389|NCT03215771|Experimental|MyoPro + Motor Learning-Based Therapy|Subjects received 9 weeks of motor learning-based therapy in combination with use of MyoPro myoelectric elbow wrist hand orthosis, followed by 9 weeks of home use with a customized exercise program.
3490808|NCT03709394|Active Comparator|Group A: Full utrasound guidance|Full utrasound guidance of cathether insertion. Intervention: Ultrasound portable device used for the identification of the target vein and for the ultrasound control of proper catheter placement during the procedure of peripheral venous cannula insertion.
3490809|NCT03709394|Active Comparator|Group B: Partial ultrasound guidance|Catheter insertion under partial ultrasound guidance. Intervention: Ultrasound portable device used only for the identification of the target vein, the catheter placement will be done by conventional approach.
3490810|NCT03709394|Active Comparator|Group C: No ultrasound guidance|Catheter insertion by conventional approach, without ultrasound guidance
3490811|NCT03709381|Experimental|ACTH stim test arm|Cosyntropin 1 mcg IV (low dose) will be given to subjects at t=0 minutes, and Cosyntropin 250 mcg (high dose) IV will be given to subjects at t=60 minutes. (All subjects were in the same arm and had the same protocol).
3490812|NCT03709368|Experimental|RANAS|Hardware CLTS+PHAST RANAS (contextualized)
3490813|NCT03709368|Experimental|Mini-RANAS|Hardware CLTS+PHAST mini-RANAS (norms)
3490814|NCT03709368|Active Comparator|Control|Hardware CLTS+PHAST Placebo
3490815|NCT03709355|Active Comparator|Elpida®|Single dose of Elpida® (capsule 20 mg)
3490816|NCT03709355|Experimental|Rifampin & Elpida®|Single dose of Rifampin (capsule 150 mg), Rifampin + Elpida® 20mg single dose
3490817|NCT03709355|Experimental|Rifabutin & Elpida®|Single dose of Rifabutin capsule 150 mg, Rifabutin + Elpida® 20mg single dose
3490818|NCT03709355|Experimental|Clarithromycin & Elpida®|Single dose of Clarithromycin capsule 250 mg, Clarithromycin + Elpida® 20mg single dose
3490819|NCT03709355|Experimental|Omeprazole & Elpida®|Single dose of Omeprazole capsule 20 mg, Omeprazole + Elpida® 20mg single dose
3490820|NCT03709355|Experimental|Atorvastatin & Elpida®|Single dose of Atorvastatin tablet 80 mg, Atorvastatin + Elpida® 20mg single dose
3490821|NCT03709355|Experimental|Levonorgestrel+Ethinylestradiol & Elpida®|Single dose of Levonorgestrel 150 µg + Ethinylestradiol 150 µg tablet, Levonorgestrel + Ethinylestradiol + Elpida® 20mg single dose
3490822|NCT03709342|Experimental|All Patients|
3129390|NCT03215901|Experimental|A Beautiful Future Video|Participants randomized to intervention will view intervention video.
3129391|NCT03215901|Sham Comparator|Active Control Video|Participants randomized to control will watch a video of similar length as the intervention video on a different topic.
3129392|NCT03215901|No Intervention|Pure Control|Participants view no video.
3129393|NCT03216200|Experimental|Experimental|5 Subjects with 20-75% Distal Subungual Onychomycosis (mild to moderate DSO) infection of their big toe (hallux) nail infected by the dermatophytes Trichophyton (T.) rubrum or T. mentagrophytes will be enrolled. All Subjects will receive three 45-minute plasma treatments performed over a week.
3490823|NCT03709329|Experimental|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
3490824|NCT03709329|Active Comparator|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
3490825|NCT03709316|Experimental|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
3490826|NCT03709316|Placebo Comparator|Placebo|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
3490827|NCT03709303||SCD patients|Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
3321256|NCT02017587||Chronic HBV|chronic HBV strata: HBV tolerant, Chronic active HBe+ or HBe-, suppressed with antiviral therapy
3490828|NCT03709290||1st group|30 patients were diagnosed with MS according to revised MacDonald's criteria 2017 & collected from Neuropsychiatry department in Assuit university hospital
3490829|NCT03709290||2nd group|30 healthy volunteers subjects matched with age, sex & education level were recruited from outpatient clinic neuropsychiatry department and included only if they had no current or previous history of any neurological illness and their neurological examination was free
3129394|NCT03216226|Experimental|dasiglucagon (ZP4207)|Repeated single fixed doses (s.c.injection) of dasiglucagon
3129395|NCT03216226|Experimental|GlucaGen|Repeated single fixed doses (s.c.injection) of GlucaGen
3129396|NCT03216265|Other|Test product/ No treatment|Participants randomized to this arm will apply Test product at allocated sites and leave other sites untreated.
3490830|NCT03709277|Experimental|Pharmacist-Driven Intervention|The study group will receive a targeted, pharmacist-driven intervention(s) to overcome patient-specific barriers to adherence. Each patient in the study group will be intervened upon using a protocol that is based on their reason for non-adherence.
3490831|NCT03709277|No Intervention|Standard of Care|The Standard of Care Group will receive the standard of care provided to all patients that utilize Vanderbilt Specialty Pharmacy.
3490832|NCT03709251|Experimental|High Intensity Walking|HIW (70-80% Heart Rate max)
3490833|NCT03709251|Experimental|Casual Speed Walking|Self selected pace
3490834|NCT03709238||Alzheimers diseased patients|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
3490835|NCT03709238||Healthy participants|Behavioral: Different thermal stimulation. Recording of facial expression during thermal stimulation.
3490836|NCT03709225|Experimental|Music-based meditation|"The music therapy intervention consists of four in-person sessions (45 minutes) over twelve weeks. Content includes:~Introduction to music therapy and mindfulness~Music-based meditation~Using personal music to shift energy, mood, and support relaxation~Mindfulness through active music making~Discuss bringing mindfulness to daily activities"
3490837|NCT03709212||Individual semi-structured interview|"20 participants will undergo individual semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.~Participants will be recruited from three ethnic backgrounds; Black African/ Caribbean, South Asian and White Caucasian."
3490838|NCT03709212||Focus Group 1|10 participants female black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3490839|NCT03709212||Focus Group 2|10 participants male Black African/ African Caribbean ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3490840|NCT03709212||Focus Group 3|10 participants female South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3490841|NCT03709212||Focus Group 4|10 participants male black South Asian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3490842|NCT03709212||Focus Group 5|10 participants female White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3129397|NCT03216265|Other|Test product/positive control|Participants randomized to this arm will apply Test and positive product at allocated sites.
3490843|NCT03709212||Focus Group 6|10 participants male White Caucasian ethnicity will undergo group semi-structured interviews to explore perceptions of living with Chronic Kidney Disease, attitudes and understanding of exercise and physical activity and any cultural influences that may influence attitudes or decisions regarding this.
3490844|NCT03709173||Premanifest HDGEC participants|
3490845|NCT03709173||Early-manifest HDGEC participants|
3490846|NCT03709173||Companions of Premanifest HDGEC|
3490847|NCT03709173||Companions of Early-manifest|
3490848|NCT03709160|Experimental|BUMETANIDE|we will administrated bumetanide at dosis: oral, 2mg each 8hours for seven day.
3490849|NCT03709160|Active Comparator|INDAPAMIDE|we will administrated indapamide at dosis:oral,1.5MG each 8hours for seven day.
3490850|NCT03709147|Experimental|FAME arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg~every-three week, 5-day Fasting-mimicking diet (FMD), up to a maximum of 4 cycles"
3490851|NCT03709147|Experimental|MERCY arm|"cisplatin 75 mg/mq every three weeks OR carboplatin (CBDCA) at an area under the curve (AUC) of 5 every three weeks, up to a maximum of 4 cycles~pemetrexed 500 mg/mq every three weeks~pembrolizumab 200 mg flat dose every three weeks~metformin hydrochloride up to a daily dosage of 1500 mg"
3490852|NCT03709147|No Intervention|BORN arm|Standard clinical approach.
3490853|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
3490854|NCT03709121|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
3490855|NCT03709121|Placebo Comparator|Vehicle Ophthalmic Solution|
3490856|NCT03709108|Other|Experimental-Control|Subjects randomized to this Arm would go through the Experimental Admission (SI-informed bolus calculator) first and Control Admission (regular bolus calculator) second
3490857|NCT03709108|Other|Control-Experimental|Subjects randomized to this Arm would go through the Control Admission (regular bolus calculator) first and Experimental Admission (SI-informed bolus calculator) second
3490858|NCT03709095|Active Comparator|Moderate Intensity Continuous Training|Training was performed three times a week for five weeks. Each session began with a 2 minute warm up, and concluded with a 3 minute cool down. Following the warm-up, participants performed 20 minutes of arm cycling at a self-selected cadence at 45-65% of their peak power output. Total training duration was 25 mins.
3490859|NCT03709095|Experimental|Sprint Interval Training|"The SIT protocol was adopted from Gillen and colleagues (See Ref), and consisted of 3 x 20 second all-out efforts at ≥ 100% of an individuals peak power output. Each sprint was interspersed by 120 seconds of active recovery at 10% of an individuals peak power output. Total training duration was 10 mins."
3490860|NCT03709082|Experimental|Phase 1: Palbociclib 75 mg|Palbociclib 75 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
3490861|NCT03709082|Experimental|Phase 1: Palbociclib 100 mg|Palbociclib 100 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
3490862|NCT03709082|Experimental|Phase 1: Palbociclib 125 mg|Palbociclib 125 milligrams (mg) by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
3490863|NCT03709082|Experimental|Phase 2: RP2D|Recommended Phase 2 dose (RP2D; determined during Phase 1 Safety Run In) Palbociclib by mouth (PO) daily Letrozole 2.5 mg PO Daily Ado-trastuzumab Emtansine (T-DM1) 3.6 milligrams per kilograms (mg/kg) intravenous (IV) Day 1
3490864|NCT03709069|No Intervention|Traditional Group|"Traditional group receives diet from hospital kitchen quantity of which calculated depending on calorie requirement per kg body weight. This diet is same for all burn patients fulfilling the inclusion criteria of the study and it will be labelled as routine diet.~Wounds of patients will be managed by closed dressing to be changed on every third day."
3490865|NCT03709069|Experimental|Albumin Group|Interventional group receiving enteral supplemental albumin 2mg per kg body weight along with routine hospital kitchen diet same as group A and same wound management with closed dressing to be changed on every third day similar to group A.
3129398|NCT03216265|Other|Positive control /no treatment|Participants randomized to this arm will apply Positive product at allocated sites and leave other sites untreated.
3321257|NCT02017600|Experimental|Induction Chemotherapy DCF followed by Surgery|All eligible patients will receive ND-420, Cisplatin and fluorouracil every 3 weeks for 2 cycles. After induction chemotherapy, patients will be planned to receive Surgery.
3490866|NCT03709056|Experimental|HSK3486 0.4/0.2mg/kg ，0.5mg/kg/0.15mg/kg|
3490867|NCT03709056|Active Comparator|Propofol 2.0/1.0mg/kg group|
3490868|NCT03709043|Experimental|Kudzu|Standardized kudzu
3490869|NCT03709043|Placebo Comparator|Control|Placebo
3490870|NCT03709030|No Intervention|Standard Care|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with abdominal ultrasound as first line imaging, as per standard care
3129399|NCT03216382|Experimental|Attention Training Technique|Participants in this arm will listen to the Attention Training Technique. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
3490871|NCT03709030|Experimental|Direct MRCP|Patients with suspected acute gallstone disease and deranged liver function tests/amylase will be investigated with magnetic resonance cholangiopancreatography (MRCP) as first-line imaging
3490872|NCT03709004|Experimental|Pacifier|Mother given a pacifier during birth hospitalization, along with other baby items
3490873|NCT03709004|No Intervention|Control|Mother not given a pacifier, just the other baby items
3490874|NCT03708991||IVF combined with PGT-A|5000-10000 motile sperm will be added to the oocyte
3490875|NCT03708991||ICSI combined with PGT-A|1 motile sperm will be injected into the oocyte
3490876|NCT03708978||mammography group|women who receives mammography because of suspected breast lesion(s)
3490877|NCT03708965|Experimental|JR-141|"Subjects will be assigned to 1.0, 2.0 or 4.0 mg of JR-141 per kg of body weight once every week (the same dose taken during the previous study) in the beginning of the study.~During the study, the dose of all subjects will be switched to the selected one."
3490878|NCT03708939|Experimental|glucose|
3490879|NCT03708939|Experimental|aspartame|
3490880|NCT03708939|Experimental|sucralose|
3490881|NCT03708939|Experimental|saccharin|
3490882|NCT03708939|Experimental|Stevia|
3490883|NCT03708939|Experimental|No supplement control|
3490884|NCT03708926|Experimental|abaloparatide|abaloparatide 80 mcg subcutaneously once daily for 90 days
3129400|NCT03216382|Placebo Comparator|Control Condition|Participants in this arm will listen to the control condition recording. Participants will listen to the recording once in the lab, followed by a week of once/day listening at home for a week. For a week before the intervention, and for the week during the intervention, participants will respond to questions every evening, about their worry and attention that day.
3490885|NCT03708926|Placebo Comparator|placebo|placebo formulated similarly but without active abaloparatide injected subcutaneously once daily for 90 days
3490886|NCT03708913|Experimental|Open-Label Lateral Hypothalamic DBS Stimulation|Open-label lateral hypothalamic DBS stimulation for 1 year.
3490887|NCT03708900|Experimental|LCI699 (osilodrostat)|Subjects with cushing's disease taking LCI699 (osilodrostat)
3490888|NCT03708887|Experimental|Low dose group|Low dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 1 gram per day for 1 year.
3490889|NCT03708887|Experimental|High dose group|High dose omega-3 fatty acid supplementation, omega-3 fatty acids capsules, 3 gram per day for 1 year.
3490890|NCT03708887|Placebo Comparator|Control group|Control drug, matching placebo capsules, 1 gram per day for 1 year.
3490891|NCT03708874||Group 1.Intraoperative bupivacaine|intraperitoneal bupivacaine wash-emergency laparoscopic cholecystectomy
3490892|NCT03708874||Group 2.Intravenous paracetamol|intravenous paracetamol-emergency laparoscopic cholecystectomy
3490893|NCT03708861|Experimental|MVC + ATV/r|maraviroc (300 mg tablet, 300 mg per day every 24 hours) + atazanavir/ritonavir (300 and 200 mg capsule, 300 and 200 mg per day every 24 hours / 100 mg capsule, 100 mg per day every 24 hours)
3490894|NCT03708848|Experimental|Tailored Therapy|Medications will be adjusted according to clarithromycin，metronidazole and levofloxacin sensitivity. All drugs will be prescribed for 14 days.(1) When three of them or clarithromycin and metronidazole are sensitive, esomeprazole 20mg bid, clarithromycin 0.5g bid and metronidazole 0.4g bid will be prescribed. (2) When two of them (levofloxacin and clarithromycin or metronidazole) are sensitive, esomeprazole 20mg bid, levofloxacin 0.5g qd plus clarithromycin 0.5g bid or metronidazole 0.4g bid will be prescribed. (3) When one of them (clarithromycin or levofloxacin) is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus clarithromycin 0.5g bid or levofloxacin 0.5g qd will be prescribed.(4) When only metronidazole or none of them is sensitive, esomeprazole 20mg bid, bismuth Potassium Citrate 600mg bid, metronidazole 0.4g qid plus tetracycline 0.4g qid will be prescribed.
3490895|NCT03708835|Experimental|Transitional Care Model is applied|Types of interventions that are applied to stroke caregivers and patient based on Transitional Care Model are hospital interview, home visit, telephone interview and web-based training. Multiple interventions including at least three face-to-face interviews at the hospital, distance education via Web and telephone communication for three months,and one home visit within seven days after discharge will be performed in order to increase health literacy levels and caregiving competence of the caregivers and to reduce burnout. In pre-tests and post-tests to be applied to the caregivers. Rate of return to the hospital, risk of pressure sore, and time of access to home health services will be assessed in stroke patients
3490896|NCT03708835|No Intervention|Routine hospital schedule|In the first interview after the admission to the hospital, the pretest will be applied to intervention and control groups and the posttest would be applied to the groups at the end of three months after discharge. After taking the posttest, the website will be made available to the control group.
3490897|NCT03708822|Experimental|Docetaxel and Cisplatin and Nimotuzumab|
3490898|NCT03708783|Experimental|No. 10 Lymph Node Dissection group|Patients with locally advanced upper or middle third gastric cancer will receive laparoscopic total gastrectomy and D2 lymphadenectomy with spleen-preserving No.10 lymph node dissections
3490899|NCT03708757|Experimental|Post isometric relaxation - Group I|"Group I will receive post isometric relaxation techniques in order to reduce hamstring spasticity. This technique induces relaxation and decreases spasticity in muscles~Post isometric relaxation (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercises (10 reps 3sets) hold for 2 sec"
3490900|NCT03708757|Active Comparator|Eccentric Muscle contraction - Group II|"Eccentric Muscle contraction lengthens the spastic muscles and enhance joint flexibility.~Hot Pack for (10 MINTS) Eccentric stretching (3 sets of 10 repetitions ,1 session in a day, 30 minutes, 4 days a week for 6 weeks.) Stretching Exercise(10 reps 3sets) hold for 2 sec In both experimental groups PIR and Eccentric stretching is applied on hamstring to"
3490901|NCT03708718|Active Comparator|Prednisolone|"Prednisolone 5mg enteric-coated tablets, over-encapsulated in a hard gelatine capsule and filled with lactose BP. The prednisolone will be self-administered, orally with water before or after a meal once a day. Dosing will be continuous for a total of 6 months.~The total dose prescribed will be equivalent to approximately 0.3mg/kg/day. The minimum dose prescribed will be 10mg per day (2 capsules) and a maximum of 30mg per day (6 capsules).~From August 2020: The prednisolone is no longer over-encapsulated. Prednisolone 5mg enteric-coated tablets will be prescribed and taken as above."
3490902|NCT03708718|Placebo Comparator|Placebo oral capsule; From August 2020 - 'no additional treatment'|"The placebo will be a hard gelatine capsule filled with lactose BP and identically matched to the prednisolone capsules. The placebo will be self-administered once a day, orally with water before or after a meal. Dosing will be continuous for a total of 6 months.~From August 2020 - no placebo capsule will be administered."
3490903|NCT03708705||Relapse|Relapse of tumor within two years after liver transplantation
3490904|NCT03708705||Non-relapse|Non-relapse of tumor within two years after liver transplantation
3490905|NCT03708692||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
3490906|NCT03708692||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
3490907|NCT03708679||Group F|Patients with menstrual cycle between 8-12 days were called Group F (Follicular phase)
3490908|NCT03708679||Group L|Patients with menstrual cycle between 20-24 were called Group L (Luteal phase)
3490909|NCT03708666|Other|Telemonitoring of blood pressure|Patients measure their blood pressure and register their results on the app or website.
3490910|NCT03708653||PHN(+)|Patients who have persistent pain more than three months after the onset of herpes zoster.
3490911|NCT03708653||PHN(-)|Patients whose pain disappear within three months.
3490912|NCT03708640|Placebo Comparator|Physical Activity Counseling|"Group receives baseline physical activity counseling.~Group does not receive personalized, health coaching via smart text messages."
3490913|NCT03708640|Experimental|Digital Activity Tracker/Smart Text Messaging|"Group receives baseline physical activity counseling.~Group receives personalized, health coaching via smart text messages informed by digital activity tracker."
3490914|NCT03708627|Experimental|Bimatoprost in more proptotic eye|Patients instill Bimatoprost in their more proptotic eye one nightly
3490915|NCT03708627|No Intervention|Control|Bimatoprost is not instilled in the patient's fellow eye
3129401|NCT03216499|Experimental|Treatment (HIF-2 alpha inhibitor PT2385)|"Patients receive HIF-2 alpha inhibitor PT2385 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis~Pharmacogenomic Study"
3129402|NCT03216512|Experimental|Noise cancelling headphone first, then sham control headphone|This group will use the noise cancelling headphone during the first experimental session as they complete study assessments. They will then return within a week, for experimental session day 2, to complete the same assessments this time using a sham control headphone.
3490916|NCT03708614|Other|Controlled energy intake with elevated protein intake|Dietary intervention - Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks.
3490917|NCT03708588|Experimental|Experimental: Chewed ticagrelor|Drug: Ticagrelor chewed pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will be asked to chew, but not swallow, allowing for sublingual absorption. (Loading dose 180mg)
3490918|NCT03708588|Active Comparator|Active Comparator: Integral pill|Drug: Ticagrelor integral pills. The loading dose will be administered as soon as possible by Catheterization Lab staff after a baseline PRU level is drawn and before the end of the PCI. Patients will swallow the loading dose followed by 25-50mL of water. (180mg)
3129403|NCT03216512|Experimental|Sham control headphone first, then noise cancelling headphone|This group will use the sham control headphone during the first experimental session as they complete study assessments. They will then return within a week for experimental session day 2, to redo the same assessments this time using a noise cancelling headphone.
3129404|NCT03216746|Experimental|Oral orientation and App for smartphone|The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
3321258|NCT02017613|Experimental|Single arm|RP6530 administered orally
3490919|NCT03708536|Experimental|bevacizumab plus s-1|
3490920|NCT03708536|Active Comparator|bevacizumab plus capecitabin|
3490921|NCT03708510|Experimental|Filtek Silorane-Er,Cr:YSGG Laser|
3490922|NCT03708510|Experimental|Filtek Silorane- Diamond Bur|
3490923|NCT03708510|Experimental|Kalore- Er,Cr:YSGG Laser|
3490924|NCT03708510|Experimental|Kalore- Diamond Bur|
3490925|NCT03708497|Active Comparator|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
3490926|NCT03708497|Experimental|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
3490927|NCT03708497|Active Comparator|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
3490928|NCT03708484|Active Comparator|Aerobic Interval Training|Aerobic Interval Training is active comparator
3490929|NCT03708484|Experimental|Aerobic + Resistive Interval Training|Aerobic + Resistive Interval Training is experimental
3490930|NCT03708471|Experimental|Two-stage hybrid abltaion|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will receive percutaneous catheter ablation and recommendations about cardiovascular risk control.
3490931|NCT03708471|Active Comparator|Thoracosopic surgical ablation|After thoracoscopic surgical ablation and 3 months of blanking-period, patients in this group will only receive recommendations about cardiovascular risk control.
3490932|NCT03708458|Active Comparator|Control group|Control group - patients receiving 100 mg indomethacin suppository immediately post ERCP
3180021|NCT00678977|Experimental|Arm B|"Dose Escalation - Patients will be entered into dose cohorts of three patients. Each cohort will be assigned to a dose level for the duration of the study. There will be no intra-patient dose-escalation. The starting dose will be 400 mg daily of pazopanib, 1000 mg/m2 gemcitabine and 60 mg/m2 cisplatin. Doses of gemcitabine may range from 600 to 1250 mg/m2. Doses of cisplatin may range from 60 to 80 mg/m2. Intermediate dose levels may also be explored. Pazopanib administered starting on Day 1 of Cycle 1, gemcitabine co-administration on Day 1 and 8, and cisplatin on Day 1 in each 21-day cycle.~Cohort expansion - patients will receive gemcitabine and cisplatin alone, at the OTR doses, starting on Day 1 of Cycle 1. Pazopanib will be administered at the OTR dose beginning on Day 2 of Cycle 1, and pazopanib administration will continue for the duration of the study. Patients will return to the clinic on Day 8 of Cycle 1 for simultaneous administration of gemcitabine and pazopanib"
3180022|NCT00678990|Experimental|Open, single arm|Transplantation of islets with heparin coating.
3490933|NCT03708458|Active Comparator|Group A|Group A - patients receiving N-acetylcysteine (NAC) 600 mg before performing ERCP and indomethacin suppository 50 mg before and after performing ERCP
3490934|NCT03708458|Active Comparator|Group B|Group B - patients receiving indomethacin suppository 50 mg before and 50 mg after ERCP
3490935|NCT03708445|Experimental|Bile duct stenosis|This arm includes patients with bile duct stenosis. Endobiliary brushing cytology specimens will be obtained with endoscopic retrograde cholangiopancreatography (ERCP) of patients with bile duct stenosis. Cytology staining will be performed in the cytology specimens.
3490936|NCT03708432||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
3490937|NCT03708419|Experimental|Optimal diet|Participants will follow a diet for a total duration of 12 weeks, optimal for their metabolic phenotype. For participants with muscle insulin resistance (MIR) this will be a diet high in monounsaturated fatty acids, for participants with liver insulin resistance (LIR) this will be a diet high in protein and fiber and low in fat.
3490938|NCT03708419|Experimental|Suboptimal diet|Participants will follow a diet for a total duration of 12 weeks, suboptimal for their metabolic phenotype. For participants with liver insulin resistance (LIR) this will be a diet high in monounsaturated fatty acids, for participants with muscle insulin resistance (MIR) this will be a diet high in protein and fiber and low in fat.
3180023|NCT00679003|Experimental|1|Social learning and cognitive behavioral therapy (SLCBT)
3490939|NCT03708406||Children with Cleft lip and palate|Children with Cleft lip and palate
3490940|NCT03708406||Children with Cleft palate|Children with Cleft palate
3490941|NCT03708380|Experimental|Dietary intervention|Community-based dietary intervention to Black and African American barbers identified as having previously undiagnosed diabetes and prediabetes
3490942|NCT03708354|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
3490943|NCT03708354|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
3490944|NCT03708341|Experimental|Melatonin|Patients will be administered melatonin 5 mg at a fixed time every day during their ICU stay (from day of admission till day of discharge from ICU)
3490945|NCT03708341|Placebo Comparator|Placebo|Patients will be administered a placebo pill that is identical in shape and color to the melatonin pill, at a fixed time every day during their ICU stay
3490946|NCT03708315|Active Comparator|Order 1|Subjects will be given a sublingual formulation of BXCL501 (dexmedetomidine)
3490947|NCT03708315|Placebo Comparator|Order 2|Subjects will be given a sublingual film of placebo.
3490948|NCT03708302|Active Comparator|Study Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.2% ropivacaine.
3129405|NCT03216746|Experimental|Oral orientation|The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
3129406|NCT03216746|Experimental|Video orientation and App for smartphone|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
3490949|NCT03708302|Sham Comparator|Control Group|Ultrasound guided bilateral serratus plane block and bilateral parasternal infrapectoral block with 0.9% saline.
3490950|NCT03708276|Experimental|My MS Toolkit|20 Participants asked to use My MS Toolkit.
3490951|NCT03708263|Active Comparator|532nm KTP Laser|Cutera® Excel V 532 nm Application of light spots 5 to 7 mm for a pulse duration of 8 to 20 ms and a fluence of 7.4 to 10 J / cm2.
3490952|NCT03708263|Experimental|585 nm yellow laser|PHOTOLASE PLV 585 nm Application of light spots 1.4mm for a pulse duration of 10 to 100 ms and a fluence of 0 to 65 J / cm2.
3490953|NCT03708237|Placebo Comparator|Placebos|Placebo Dose: Not Applicable Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
3490954|NCT03708237|Experimental|Ropinirole|Drug: ropinirole Dose: 0.25 - 2 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
3490955|NCT03708237|Experimental|Gabapentin|Drug: gabapentin Dose: 100 - 300 mg as tolerated Route: Mouth Regimen: Daily 2 hours before bed Duration: 6 months
3490956|NCT03708224|Experimental|Atezolizumab Monotherapy|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery.
3490957|NCT03708224|Experimental|Atezolizumab (Adjuvant)|Participants will receive 840mg of atezolizumab over 15 days prior to definitive surgery. The first 9 participants in Arm A (atezolizumab monotherapy) will also receive adjuvant atezolizumab 16 weeks after standard of care surgery and radiation, or chemoradiation therapy, at a fixed dose of 1200 mg IV every 3 weeks for an additional 12 cycles.
3490958|NCT03708224|Experimental|Atezolizumab + Tiragolumab|Participants will receive 840 mg of atezolizumab IV and 600 mg of Tiragolumab during the 15-day neoadjuvant period prior to definitive surgery.
3490959|NCT03708224|Experimental|Atezolizumab + Tocilizumab|Participants will receive 840 mg of atezolizumab IV and 6 mg/kg of Tocilizumab during the 15-day neoadjuvant period prior to definitive surgery.
3490960|NCT03708198|Other|Intercostal Nerve Block|The study participants will be given a standard 266 mg single dose injection of liposomal bupivacaine by the surgeon at the start of the surgery.
3490961|NCT03708185|Experimental|HIIT + beta-alanine|Participants will ingest an active supplement containing beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
3490962|NCT03708185|Experimental|HIIT + placebo|Participants will ingest a placebo supplement containing no beta-alanine for a period of 12 weeks. During the last 8 weeks of that period, participants will take part in a structured program of high-intensity interval training.
3490963|NCT03708172|Active Comparator|rTMS + Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive active cognitive training (CT) which consists of completing computer-based tasks designed to enhance executive function.
3490964|NCT03708172|Sham Comparator|rTMS + Sham Cognitive Training|Participants will receive repetitive transcranial magnetic stimulation (rTMS) in an open label fashion. In addition, participants will receive sham cognitive training (CT) which consists of completing computer-based tasks.
3490965|NCT03708159|Experimental|active tDCS + mindfulness meditation|Participants randomized to this group will receive active tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
3490966|NCT03708159|Sham Comparator|sham tDCS + mindfulness meditation|Participants randomized to this group will receive sham tDCS 3 times a week for approximately 3 months and then weekly for 3 months. After completing baseline procedures they will be trained how to apply the tDCS device themselves. The first 3-6 treatments will be completed at the hospital to ensure proper and safe application. Prior to taking the tDCS device home, they will pass the self-application scale adequately 3 times. Each treatment session lasts 30 minutes, during which, they will engage in mindfulness meditation.
3129407|NCT03216746|Experimental|Video orientation|The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.
3129408|NCT03216850||Patients in ICU requiring parenteral nutrition|
3129409|NCT03216902|Placebo Comparator|Placebo (Vehicle of DE-126) followed by high dose of DE-126|
3129410|NCT03216902|Experimental|Ultra-low dose 0.0005% DE-126|
3490967|NCT03708146|Experimental|Cohort 1 (BIA 5-1058 /50 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490968|NCT03708146|Experimental|Cohort 2 (BIA 5-1058 /25 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 25 mg (as 1 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490969|NCT03708146|Experimental|Cohort 3 (BIA 5-1058 /100 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3129411|NCT03216902|Experimental|Low dose 0.001% DE-126|
3129412|NCT03216902|Experimental|Medium dose 0.002% DE-126|
3490970|NCT03708146|Experimental|Cohort 4 (BIA 5-1058 /50 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 50 mg (as 2 x 25 mg tablet) or matching placebo 12 active and 3 placebo)
3490971|NCT03708146|Experimental|Cohort 5 (BIA 5-1058 /150 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 150 mg (as 1 x 100 mg and 2 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490972|NCT03708146|Experimental|Cohort 6 (BIA 5-1058 /75 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 75 mg (as 3 x 25 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490973|NCT03708146|Experimental|Cohort 7 (BIA 5-1058 /200 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490974|NCT03708146|Experimental|Cohort 8 (BIA 5-1058 /100 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 100 mg (as 1 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490975|NCT03708146|Experimental|Cohort 9 (BIA 5-1058 /400 mg/fasted)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490976|NCT03708146|Experimental|Cohort 10 (BIA 5-1058 /200 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 200 mg (as 2 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490977|NCT03708146|Experimental|Cohort 11 (BIA 5-1058 /400 mg/fed)|15 Subjects: 12 active and 3 placebo; BIA 5-1058 Tablet 400 mg (as 4 x 100 mg tablet) or matching placebo tablet (12 active and 3 placebo)
3490978|NCT03708133|Experimental|Test Treatment + Reference Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Test treatment~Reference treatment"
3490979|NCT03708133|Experimental|Reference Treatment + Test Treatment|"Male and female subjects with Chagas' disease will be give treatment follow below Crossover Sequence:~Reference treatment~Test treatment"
3490980|NCT03708120|Experimental|Consumer Dose and Tick Repellency|Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
3490981|NCT03708107|Experimental|Percutaneous Microelectrolysis (MEP)|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP.~MEP® will be applied with a 0,30 x 25 mm acupuncture needle. The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
3490982|NCT03708107|Experimental|Ischemic compression|"Principal MTrP will be detected by digital palpation in the upper trapezius. Algometry will be used to determine if the Pain Pressure Threshold (PPT) is equal or less than 3 KgF/cm2. If not, the patient will be not included. A mark will be done in the MTrP with a marker.~Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.~Algometry will be done immediately finished the intervention, after 10 minutes and at 24 hs."
3490983|NCT03708094||molecular diagnosis confirmed|Whole exome sequencing is applied to children and the molecular diagnosis was identified before renal transplantation.
3490984|NCT03708094||molecular diagnosis unconfirmed|Whole exome sequencing is applied to children and the molecular diagnosis was not identified before renal transplantation.
3490985|NCT03708081||Group 1|Root canal treatments will be completed by ProTaper Next instruments with rotational motion
3490986|NCT03708081||Group 2|Root canal treatments will be completed TF Adaptive instruments with adaptive motion.
3490987|NCT03708055|Experimental|Prevention (weight bearing exercise program)|Participants undergo a weight bearing exercise program in a group 2 days a week and at home 5 days a week for 8 weeks.
3490988|NCT03708042|Experimental|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day.
3490989|NCT03708042|Active Comparator|Neoadjuvant Radiochemotherapy|Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
3490990|NCT03708029|Experimental|Intervention Treatment|Will receive Revita allograft for wound treatment
3490991|NCT03708029|No Intervention|Control|Will receive current standard of care for wound treatment
3129413|NCT03216902|Experimental|High dose 0.003% DE-126|
3129414|NCT03216902|Active Comparator|0.005% Latanoprost|
3490992|NCT03708016|Experimental|Robot gait training with brain stimulation|Lokomat robot training and anodal transcranial direct current stimulation (tDCS) on the leg motor areas
3490993|NCT03708016|Active Comparator|Robot gait training without brain stimulation|Lokomat robot training and sham tDCS on the leg motor areas
3490994|NCT03707990|Experimental|NNC0165-1875|Participants will receive NNC0165-1875 alone in cohorts 1-5 (part 1) and NNC0165-1875 along with semaglutide in cohorts 6-11 (part 2).
3490995|NCT03707990|Placebo Comparator|Placebo|Participants will receive placebo alone in cohorts 1-5 (part 1) and placebo along with semaglutide in cohorts 6-11 (part 2).
3490996|NCT03707977|Experimental|Group PK-A: ART + VRC01LS|In the PK Step, participants will continue ART and receive VRC01LS at Weeks 0, 4, and 8 as a single intravenous (IV) dose (30 mg/kg load then 10 mg/kg maintenance).
3490997|NCT03707977|Experimental|Group PK-B: ART + 10-1074|In the PK Step, participants will continue ART and receive 10-1074 at Weeks 0, 4, and 8 as a single IV dose (30 mg/kg).
3490998|NCT03707977|Experimental|Steps 1-3 Participants (ART + 10-1074 + VRC01LS)|In Step 1, eligible participants will continue to receive ART and will receive both 10-1074 and VRC01LS at Weeks 0, 4, and 8. Following a recommendation from the study team and Safety Monitoring Committee (SMC) to increase the maintenance dosing based on the PK Step, a VRC01LS loading dose of 30 mg/kg will be given at the start of Step 1, followed by 15 mg/kg dosing at each 4-weekly visit, and 10-1074 dosing will be at 30 mg/kg at each 4-weekly visit. In Step 2, participants with ongoing viral suppression throughout Step 1 will undergo withdrawal of ART and will continue maintenance 10-1074 (30 mg/kg) and VRC01LS (15 mg/kg) treatment for up to 24 weeks. In Step 3, both 10-1074 and VRC01LS will be discontinued and ART will be re-started.
3490999|NCT03707964|Placebo Comparator|Control|Subjects allocated to the control arm will receive standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles, as part of their regular teaching schedule.
3491000|NCT03707964|Experimental|Intervention|Subjects allocated to the intervention arm will receive education on crisis resource management (CRM) and teaching targeting the cognitive skills required to monitor and challenge a superior's decision, and conflict resolution tools, in addition to standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
3491001|NCT03707951|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks; administered orally
3491002|NCT03707951|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 8 weeks; administered orally
3491003|NCT03707938|Experimental|Treatment (brigatinib, LCT)|Patients receive brigatinib PO QD on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo LCT for up to 3 weeks in the absence of disease progression or unacceptable toxicity. Within 7 days after completion of LCT, patients receive brigatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3491004|NCT03707899|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 5 mg, rosuvastatin 5 mg)
3491005|NCT03707899|Active Comparator|Group II (Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 80 mg, amlodipine 5 mg) and Crestor(rosuvastatin 5 mg)
3491006|NCT03707886|Experimental|Pain SMART (Intervention Arm)|The Intervention Arm will be invited to participate in a one-time group intervention, Pain SMART
3491007|NCT03707886|Placebo Comparator|Minimally Enhanced Usual Care|The Minimally Enhanced Usual Care group will receive educational information via mail.
3491008|NCT03707873|Experimental|In-person education|Education will be given on a regular basis via predefined consultation visits. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
3129415|NCT03216954|Placebo Comparator|Placebo|Subjects will receive oral placebo capsules two times daily.
3491009|NCT03707873|Experimental|Online education|Education will be given on a regular basis via a special designed online platform. Medication adherence (oral anticoagulation) will also be measured using a special cap that fits on a medication bottle. If adherence is low, the patient will get additional feedback when he does not take this medication as prescribed.
3491010|NCT03707873|No Intervention|Standard Care|This group of AF patients will serve as a control group and no extra focused educational reinforcements will be provided beyond standard care (i.e. information of the treating physician and a brochure).
3491011|NCT03707860||head and neck radiotherapy patients|(Single arm); Patients receiving radiotherapy for head and neck cancers can report their symptoms through the mobile app.
3491012|NCT03707847|Experimental|Crizotinib + etoposide capsule+Auto-HSCT|"Crizotinib and etoposide capsule followed by autologous hematopoietic stem cell transplantation.~Crizotinib: 250mg, bis in die （BID）, PO.~Etoposide capsule:50mg, quaque die （QD）, PO, d1-10，21days for one cycle.~Patients will receive the treatment of crizotinib and etoposide capsule, and those who have achieved CR（complete response）or VGPR（very good partial response）will undergo the Auto-HSCT."
3491013|NCT03707834|No Intervention|WIC Standard Care (SC)|Participants assigned to the WIC standard care arm will receive usual care offered to pregnant women at WIC.
3491014|NCT03707834|Experimental|Antenatal Obesity Treatment (AO)|The AO arm consists of a multi-component, theory- and evidence-based intervention and includes weight-related behavior change through goal setting and self-monitoring, behavioral skills training, interpersonal support, and social modeling strategies.
3491015|NCT03707795|Experimental|Arm 1 - Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
3491016|NCT03707795|Active Comparator|Arm 2 - Familial Amyotrophic Lateral Sclerosis|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
3491017|NCT03707782||Individuals with immune deficiencies|aged 18 years or older and have an immune deficiency
3491018|NCT03707782||Family members|aged 18 years or older and are related to a person who has an immune deficiency
3491019|NCT03707769|Experimental|Fistula treatment|Treatment of fistula with TIPS microspheres
3491020|NCT03707730|Experimental|AGY|capsule containing egg yolk with AGY
3491021|NCT03707730|Placebo Comparator|placebo|capsule containing plain egg yolk
3491022|NCT03707717|Experimental|Bimekizumab-SS|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a prefilled syringe.
3491023|NCT03707717|Experimental|Bimekizumab-AI|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with an auto-injector.
3129416|NCT03216954|Experimental|Low Dose n-Acetylcysteine|Subjects will receive 0.6 g oral n-acetylcysteine two times daily.
3129417|NCT03216954|Experimental|High Dose n-Acetylcysteine|Subjects will receive 1.2 g oral n-acetylcysteine two times daily.
3129418|NCT03217968|Experimental|Active|120 minutes of Cefaly® Abortive Program device stimulation as abortive treatment of an early stage migraine attack
3491024|NCT03707717|Experimental|Bimekizumab-TN|Subjects randomized to this arm will receive bimekizumab administered subcutaneously with a reference device.
3491025|NCT03707704||SCI patients in primary rehabilitation|
3491026|NCT03707691|Experimental|Cochlear implant users|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
3180024|NCT00679003|Active Comparator|2|Education and support (ES)
3491027|NCT03707691|Experimental|Participants with Congenital Amusia|In both arms a pitch training protocol and a visuo-spatial training protocol are applied.
3491028|NCT03707691|Experimental|Control Participants|
3491029|NCT03707678|Experimental|Subjects receiving GSK2245035|Eligible subjects will be administered 20 nanograms (ng) of GSK2245035 nasal spray solution using a metered Valois VP7 pump (1 spray=10 ng per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol metered dose inhaler (MDI) will be given for symptom relief from screening to the end of the study.
3491030|NCT03707678|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be administered placebo nasal spray solution using a metered Valois VP7 pump (1 spray per actuation per nostril) once weekly for 8 weeks. Subjects will also receive tapering doses of FP-DPI 100-500 mcg twice daily during the treatment period. Albuterol/Salbutamol MDI will be given for symptom relief from screening to the end of the study.
3491031|NCT03707652|Experimental|Cohort A (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
3491032|NCT03707652|Experimental|Cohort A (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
3491033|NCT03707652|Experimental|Cohort A (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
3491034|NCT03707652|Experimental|Cohort A (oral supplement A)-1 or 4 capsules|Oral supplement A (1 or 4 capsules) administered daily for 3 days
3491035|NCT03707652|Experimental|Cohort A (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
3491036|NCT03707652|Experimental|Cohort A (oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
3491037|NCT03707652|Experimental|Cohort B (oral supplement B)-4 capsules|Oral supplement B (4 capsules) administered daily for 3 days
3491038|NCT03707652|Experimental|Cohort B (oral supplement C)-2 capsules|Oral supplement C (2 capsules) administered daily for 3 days
3491039|NCT03707652|Experimental|Cohort B (oral supplement A)-2 capsules|Oral supplement A (2 capsules) administered daily for 3 days
3491040|NCT03707652|Experimental|Cohort B (oral supplement C)- 1 or 4 capsules|Oral supplement C (1 or 4 capsules) administered daily for 3 days
3491041|NCT03707652|Experimental|Cohort B (oral supplement D)-1 or 2 tablets|Oral supplement D (1 or 2 tablets) administered daily for 3 days
3491042|NCT03707652|Experimental|Cohort B(oral supplement D) or combination with supplement C|Oral supplement D (1 or 2 tablets) or combination with oral supplement C (2 or 4 capsules) administered daily for 3 days
3180025|NCT00679068|Experimental|1|treatment with Bosentan
3491043|NCT03707639|Experimental|Experimental: Apatinib plus POF|Apatinib (500 mg qd p.o.) plus POF until disease progression or intolerable toxicity or refused by the patients.
3491044|NCT03707626||LAD with collaterals with and without wellens sign|
3491045|NCT03707613|Experimental|DWT learning curve|Initial cannulation is performed with a wire-guided sphincterotome by a trainee. If the cannulation proves difficult (cannulation time >10min, cannulation attemtps >5 or inadvertent PD cannulation >1) and PD is inadvertently entered, DWT will be performed by one of the two trainees. If DWT fails within 5min or 5 attempts, a trainer will take over and continue the cannulation. To prevent PEP, all patients receive prophylactic PD stent and post-ERCP rectal indomethacin. Aggressive hydartion will be administrated at the discretion of endoscopists.
3491046|NCT03707600|Sham Comparator|Sham|The sham coil setting is designed to mimic the auditory artifact and scalp sensations evoked by the real coil without stimulating the brain.
3491047|NCT03707600|Active Comparator|TMS|Active TMS
3491048|NCT03707561||Group 1 - IPAH and heritable PAH|Idiopathic pulmonary arterial hypertension (IPAH) and heritable PAH Diagnostic Test: Right Heart Catheterization (RHC)
3491049|NCT03707561||Group 2- PAH associated with CHD|Pulmonary arterial hypertension associated with congenital heart disease Diagnostic Test: Right Heart Catheterization (RHC)
3491050|NCT03707561||Group 3- PAH associated with CTD|Pulmonary Arterial Hypertension associated with Connective Tissue Diseases Diagnostic Test: Right Heart Catheterization (RHC)
3129419|NCT03218397|Active Comparator|Standard blood culture and AST|Standard blood culture and antimicrobial susceptibility testing (AST), and antimicrobial stewardship.
3129420|NCT03218397|Active Comparator|Rapid organism identification and AST|Rapid organism identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX), and antimicrobial stewardship. The blood sample will also undergo standard culture and AST in addition to the rapid testing.
3491051|NCT03707561||Group 4- portoPH|Portopulmonary hypertension
3491052|NCT03707561||group 5- PAH-HIV|Pulmonary arterial hypertension associated with HIV infection
3491053|NCT03707561||group 6- operable CTEPH|Operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
3491054|NCT03707561||group 7- non-operable CTEPH|Non operable chronic thromboembolic pulmonary hypertension Diagnostic Test: Right Heart Catheterization (RHC)
3491055|NCT03707548|Experimental|Group BPT|"Six group BPT sessions (using a waiting-period comparator and pre-/post design)~A nested randomized controlled trial (RCT) is included to evaluate the short-term efficacy of smartphone-triggered bodily interventions compared with the smartphone triggered control intervention of audio-typed fairy tales."
3491056|NCT03707535|Experimental|CT-P13|
3491057|NCT03707535|Active Comparator|China-approved Remicade|
3491058|NCT03707509|Experimental|Camrelizumab + Gemcitabine + Cisplatin|subject will receive camrelizumab 200mg every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
3491059|NCT03707509|Active Comparator|Placebos + Gemcitabine + Cisplatin|subject will receive placebos every 3 weeks, cisplatin 80mg/m2 on Day 1 of each 21 day, at most 6 cycles, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles
3491060|NCT03707496||DeWinterCohort|Patients with de Winter syndrome pattern ECG
3491061|NCT03707483|Experimental|Intervention|250 μM of vitamin C will be used with the platelet rich fibrin
3491062|NCT03707483|Active Comparator|Comparator|using platelet rich fibrin alone
3491063|NCT03707470|Experimental|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
3491064|NCT03707470|Active Comparator|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 15 mmHg at both the ankle and thigh)
3491065|NCT03707470|Sham Comparator|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
3491066|NCT03707457|Experimental|Arm A: Nivolumab + anti-GITR|Patients receive nivolumab intravenously (IV) over 30 minutes and anti-GITR intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3491067|NCT03707457|Experimental|Arm B: Nivolumab + IDO1 inhibitor|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1 and IDO1 inhibitor daily by mouth. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3491068|NCT03707457|Experimental|Arm C: Nivolumab + Ipilimumab|Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab intravenously (IV) over 90 minutes on Day 1. Courses repeat every 21 days for up to 4 doses. After ipilimumab is discontinued, courses of nivolumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3491069|NCT03707444||Scrambler Therapy|All participants get the same device treatment with the Scrambler Therapy device, up to 10 treatments.
3491070|NCT03707431|Experimental|Web-based CBT (WebMAP)|Receives access to WebMAP
3491071|NCT03707431|Active Comparator|Pain Education (WebED)|Receives access to WebED
3491072|NCT03707418|Active Comparator|Bivalirudin Injection (Angiomax)|This arm will receive intravenous Bivalirudin for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
3491073|NCT03707418|Active Comparator|Heparin Sodium|This arm will receive intravenous Heparin Sodium for ECMO anticoagulation for the extent of ECMO support or 7 days whichever comes first
3491074|NCT03707405|Active Comparator|ROC-sit|Ride-On Cars with Sitting Posture (ROC-sit) The 2-hour training session is composed of a 70-minute driving session and a 40-to-50-minute natural play session, with a 10-mintue break if necessary. The natural play session can be divided into two 20-to-25 sessions depending on the participant's condition. Training will concentrate on building the concept of casual-effect on the switch and car motion, practicing goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person) in public spaces (e.g., hallways, convenient stores, garden, museum) and upper limb use in functional tasks with driving, facilitating hand use in functional tasks for exploration and applying motor skills for mobility and socialization in natural play session. All the programs will be discussed by the family, the treating therapist and the research team.
3491075|NCT03707405|Active Comparator|ROC-sit45 and stand25|Ride-On Cars with 45-min Sitting and 25-min Standing Postures (ROC-sit45 and stand25) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 45-minute driving with sitting posture and then transfers to the standing posture for driving 25 minutes.
3491076|NCT03707405|Active Comparator|ROC-sit25 and stand45|Ride-On Cars with 25-min Sitting and 45-min Standing Postures (ROC-sit25 and stand45) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute driving session begins with a 25-minute driving with sitting posture and then transfers to the standing posture for driving 45 minutes.
3491077|NCT03707405|Active Comparator|ROC-stand|Ride-On Cars with Standing Postures (ROC-stand) The training guidelines and time are the same as the ROC-sit group, except for the posture of driving. The 70-minute standing session can be divided into two 30-minute sessions with 10-minute break, depending on the child's condition with the standing posture.
3491078|NCT03707392|Active Comparator|Control|Standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
3491079|NCT03707392|Experimental|Treatment|Ostomy care educational video combined with standard preoperative and postoperative stoma teaching including ostomy nurse teaching and educational materials
3491080|NCT03707379||common care group|diabetic patients under common care group
3491081|NCT03707366|Experimental|FHF-T Intervention Group|9 months of 1:1 youth mentoring by graduate-student mentors; workshops; educational advocacy
3491082|NCT03707366|No Intervention|Control group|Services as usual
3491083|NCT03707353|Experimental|Group 1|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by ChAd63 ME-TRAP vaccination intravenously.
3491084|NCT03707353|Experimental|Group 2|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
3491085|NCT03707353|Experimental|Group 3|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by ChAd63 ME-TRAP vaccination intravenously.
3491086|NCT03707353|Experimental|Group 4|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, followed by MVA ME-TRAP vaccination intravenously. 4 weeks after the last vaccine dose, all vaccinated volunteers will undergo malaria challenge by mosquito bite.
3491087|NCT03707353|No Intervention|Group 5|6 Volunteers will receive no vaccinations but will undergo malaria challenge infection by mosquito bite at the same time as groups 1-4.
3491088|NCT03707353|No Intervention|Group 6|6 Volunteers will be used as infectivity controls if any volunteers from Groups 1-4 are rechallenged 5 - 7 months after the initial CHMI.
3491089|NCT03707353|Experimental|Group A|Volunteers will receive ChAd63 ME-TRAP vaccination intramuscularly, then MVA ME-TRAP vaccination intramuscularly followed by MVA ME-TRAP vaccination intravenously.
3491090|NCT03707340||Breast Cancer Pts with hyposexual desire disorder/HSDD|
3491091|NCT03707327|Experimental|Game Ready group|the participants performed cryotherapy by compression with Game Ready
3491092|NCT03707327|Experimental|Ice pack|the participants performed cryotherapy for ice pack
3491093|NCT03707314|Other|Group A: Immediate angiography|Immediate angiography with follow-on revascularisation if indicated
3491094|NCT03707314|Other|Group B: Standard of care angiography|Standard of care angiography with follow-on revascularisation if indicated (within 3-4 days, but will vary depending on recruiting centre)
3491095|NCT03707301||Cancer patients performing sophrology sessions|Cancer patients performing sophrology sessions will be recruited in this study, and will complete questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
3491096|NCT03707288|Other|Spine exercise program|"The preclinical second year medical students will be prospectively randomized into two (2) groups, a control group (Group A) and an intervention group (Group B) that will be given a standardized spine exercise program. They will be asked to complete a Questionnaire B to evaluate changes in knowledge, attitude and practice towards musculoskeletal problem of the back and neck pain after intervention; the numeric rating scale (NRS), and the Cornell Musculoskeletal Discomfort Questionnaire (CMDQ) at eight (8) weeks.~The standardized spine exercise program will be provided in a handout and given only to the intervention Group B subjects, these are basic low back exercises to be done three (3) times per week for 20mins, as well as a few very brief stretching exercises to be done during periods of sitting for greater than sixty (60) minutes."
3491097|NCT03707275|Experimental|Alexa+ Arm|
3491098|NCT03707275|Other|Standard of Care Arm|
3491099|NCT03707262|Experimental|Donor CD34+ and CD3+ cell infusion|"The investigational products are (1) an intravenous infusion of granulocyte colony-stimulating factor (GCSF)-mobilized, Miltenyi-enriched CD34+ cells (≥ 5 million cells per kilogram) followed by (2) an infusion of CD3+ cells (5 million cells per kilogram) from an HLA-identical sibling living donor.~The cells are infused around Day 11 post-transplant after the following pre-conditioning regimen:~5 doses of rATG (1.5 mg/kg IV per day for 5 days, starting on the day of transplant)~10 doses of TLI (120 centigray [cGY] x 10 fractions, starting the day after transplant)"
3491100|NCT03707249|Experimental|Iron|Received a blinded single 15 mg/kg dose of iv ferric carboxymaltose (Ferinject) up to a maximum off 1g total dose 2 weeks prior to ascent to very high-altitude.
3491101|NCT03707249|Sham Comparator|Saline control|Received a blinded single dose of iv normal saline 2 weeks prior to ascent to very high-altitude.
3491102|NCT03707236|Experimental|Treatment arm|Patients in the treatment arm will have monthly office visits for weeks 0-4 and then have monthly teledermatology visits during weeks 8-20 with a final office visit at week 24. Standardized baseline photographs including 3 facial images (front, left, and right) as well as 2 truncal images of the chest and back (if affected) will be taken in the office at treatment week 0 and 24 for all patients. All patients will be required to take photos in front of a white wall to facilitate blinding.
3491103|NCT03707236|No Intervention|Control arm|Patients in the control arm will have the same series of photographs taken at each monthly visit. These patients will also be required to fill out a monthly survey assessing acne severity, quality of life, cost of attending appointment, time missed from school/work, satisfaction with treatment (only to be reviewed by study staff) and will be screened for adverse events by their provider. Every patient will be counseled about isotretinoin and contraception (if applicable) by their provider in order to adhere with iPledge requirements. All photographs will be uploaded into the patient's medical record. The physician will be required to document a progress note in the electronic medical record after each visit as per standard hospital protocol.
3491104|NCT03707223|Experimental|experimental|"The interfaces Program"
3491105|NCT03707223|Active Comparator|control group|supported employment using the individual placement and support (IPS) model
3491106|NCT03707210|Experimental|Intervention|The experimental group uses the VR program to training chemotherapy skill. Use VR software to make a training education program.
3491107|NCT03707210|No Intervention|usual care|Chemotherapy training as usual care (for training chemotherapy skill).
3491108|NCT03707197|Experimental|Meditation Group|The intervention group will be assigned to a digitally-based meditation intervention (Headspace app- Basic + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
3491109|NCT03707197|No Intervention|Wait-list Control Group|Wait-list control group participants will continue their normal activities and not engage in any form of meditation during the study period
3491110|NCT03707184|Experimental|Diagnostic (fluciclovine F18, PET/CT)|Patients receive fluciclovine F18 intravenously (IV) over 30 seconds and undergo PET/CT scan over 60 minutes at baseline, 3 months and at approximately 6 months of radium-223 therapy.
3129421|NCT03218566|Other|Single Arm|Single Arm - Use of Indigo Aspiration System (mechanical thrombectomy) to treat pulmonary embolism
3129422|NCT03218592|Experimental|Maraviroc|12 Healthy subjects will dose with Maraviroc Pill and we will collect blood and hair over all three phases
3491111|NCT03707171|Active Comparator|Liraglutide|12 weeks of liraglutide treatment at adjusting dose, up to 1.8mg/day Drug: liraglutide
3491112|NCT03707171|Placebo Comparator|Placebo|12 weeks of Placebo treatment at adjusting dose Drug:Placebo
3491113|NCT03707158|Active Comparator|Web-based CBT|The online, multimedia suite of Cool Kids CBT web-based programs for youth anxiety is a supported, largely self-administered online digital cognitive-behavioral therapy anxiety management intervention, with adjunctive therapist phone support. Treatment content runs directly parallel to that included in the therapist-led Cool Kids face-to-face suite of interventions. The online suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
3491114|NCT03707158|Active Comparator|Face-to-Face CBT|The Cool Kids suite of face-to-face (office-based or telehealth) CBT-based programs for youth anxiety is a well-supported therapist-led, clinic-based anxiety management intervention. The face-to-face cognitive-behavioral therapy treatment content runs directly parallel to that included in the Cool Kids online suite of interventions. The face-to-face suite of interventions is comprised of two developmentally tailored programs, depending on the age of the child.
3491115|NCT03707145|Active Comparator|Professional led with online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
3129423|NCT03218592|Experimental|Dolutegravir|12 Healthy volunteers will dose with Dolutegravir Pill and we will collect blood and hair over all three phases
3129424|NCT03218592|Experimental|Truvada|12 healthy volunteers will dose with Truvada Pill and we will collect blood and hair over all three phases
3491116|NCT03707145|Active Comparator|Professional led without online support|"The consultation is led by the professional and lifestyle recommendations are based on ViviFrail recommendations and personal experience of the professional.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
3491117|NCT03707145|Experimental|Patient empowered with online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~The 12-week intervention includes access to an online monitoring platform. The online platform provides the lifestyle recommendations and consists of a diary of activities, examples of exercises, general advice and instructions for monitoring and self-assessment."
3180026|NCT00679094|Experimental|Arm I|Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
3180027|NCT00679107|Experimental|1|autogenous bone graft with the addition of OP-1 Putty
3129425|NCT03218787|Experimental|XIENCE|Subjects will receive XIENCE family stents and if a subject was DAPT compliant and event free, then took 3 month DAPT, following with aspirin mono-therapy until 12 month
3129426|NCT03219216|Experimental|Arm A: Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeks|Arm A: Hepatitis C virus (HCV) genotype (GT) 1 to GT6 participants without cirrhosis (fibrosis stage F2 to F3) received glecaprevir (GLE)/pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
3129427|NCT03219216|Experimental|Arm B: GLE/PIB for 12 Weeks|Arm B: HCV GT1 to GT6 participants with compensated cirrhosis (F4) received GLE/PIB 300 mg/120 mg QD for 12 weeks.
3491118|NCT03707145|Active Comparator|Patient empowered without online support|"The consultation is led by the participant, and started with the questions 'What matters to you', and 'What are your goals'. The professional based the lifestyle recommendations based on these responses.~There is no access to the online monitoring platform, and lifestyle recommendations were provided on paper to the participant."
3491119|NCT03707132||Tourniquet Group|'Tourniquet: Folley catheter in the low segment of the uterus
3491120|NCT03707132||Control Group|Standard hysterectomy is performed
3129428|NCT03219294|Active Comparator|Moderate Neuromuscular Blockade (NMB)|Intubating dose of Vecuronium 0.1 mg/kg (IBW) and re-dosing with 0.0125 to 0.05 mg/kg as needed to achieve and maintain 1 to 2 train-of-four (TOF) contractions. Redosing in this manner is a current clinical practice.
3129429|NCT03219294|Active Comparator|Deep NMB|Deep NMB: Intubating dose of Vecuronium 0.2 mg/kg (IBW) and re-dosing with 0.025 to 0.1 mg/kg to achieve and maintain zero twitches in the TOF, and post tetanic count (PTC) of 1 to 2 contractions. This level of blockade is new to the practice since approval of the drug for use at Maine Medical Center (MMC) but is in common use since the advent of Sugammadex.
3491121|NCT03707119||S4BE|"The intervention consisted of the use of Student 4 Best Evidence blog to teach EBP competence. The section S4BE about has been used to teach the EBP principles and their key steps and the section S4BE topics has been used to teach critical thinking and the clinical practice in rehabilitation for a total of 24 training hours."
3491122|NCT03707106|Experimental|VR based cue exposure smoking cessation|an established CBT intervention for smoking cessation supported by cue exposure in virtual reality
3491123|NCT03707106|Active Comparator|PMR supported smoking cessation|an established CBT intervention for smoking cessation supported supported by specific stress reduction (Progressive Muscle Relaxation, Jacobson)
3491124|NCT03707093|Experimental|ADG106 Dose escalation|
3491125|NCT03707080||Prospective|"The prospective DAA-PASS cohort will include a subset of HCV RNA positive participants in the TARGET-HCC study who meet entry criteria including hepatitis C (with no prior history of DAA therapy) and newly diagnosed Barcelona Clinic Liver Cancer (BCLC) Stage A HCC.~Participants will be enrolled in the countries participating in TARGET-HCC which will include: United States (US), France, Germany, Italy, and Spain."
3491126|NCT03707080||Historical|The historical cohort will be derived from the ITA.LI.CA database, which includes data on all consecutive patients with HCC who were managed within participating centers in Italy. The historical cohort will include patients from the ITA.LI.CA database who have active HCV infection who were not treated for HCV (IFN-based or DAA-based regimens) during the followup period, with initial HCC diagnosis BCLC Stage A, and subsequent successful treatment of HCC with curative therapy.
3491127|NCT03707067|Experimental|Custom fitted compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
3129430|NCT03219320|Placebo Comparator|Placebo Oral Capsule|Up to 300 subjects: Placebo
3129431|NCT03219320|Experimental|NYX-2925|Up to 300 subjects: Multiple dose levels of NYX-2925 daily for 28 days
3129432|NCT03219723||Vonoprazan 20 mg|For adults, the following three-drug regimen will be administered orally at the same time twice daily for 7 days: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 200 mg (potency) dose of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg (potency)/dose twice daily. If H. pylori eradication with a three-drug regimen comprising vonoprazan or proton pump inhibitor + amoxicillin hydrate + clarithromycin has been unsuccessful, as an alternative treatment, the following three drugs will be administered orally twice daily for 7 days to adults: 20 mg dose of vonoprazan, 750 mg (potency) dose of amoxicillin hydrate, and 250 mg dose of metronidazole. Participants will receive interventions as part of routine medical care.
3129433|NCT03219840|Experimental|CPC + Xylitol chewing gum, then Xylitol only chewing gum|Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum and then Xylitol only chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Xylitol only chewing gum will be used for the last 21 days.
3129434|NCT03219840|Experimental|Xylitol only chewing gum, then CPC + Xylitol chewing gum|Xylitol only chewing gum and then Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated. Xylitol only chewing gum will be used for the first 21 days, then there will be a washout period of 21 days, and finally Cetylpyridinium Chloride (CPC) 0.09% + Xylitol chewing gum will be used for the last 21 days.
3491128|NCT03707067|Sham Comparator|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
3491129|NCT03707054|Experimental|Study Arm|Measurements of optic nerve diameter, Urine and plasma osmolality, Serum vasopressin.
3491130|NCT03707028|Experimental|Rivoceranib (apatinib) with Paclitaxel|Oral daily doses of rivoceranib (as its mesylate salt) with a fixed dose of paclitaxel given intravenously on day 1, day 8, and day 15.
3491131|NCT03707002|Active Comparator|scFOS|scFOS consumed at 5g/day for 6 weeks
3491132|NCT03707002|Placebo Comparator|Placebo|maltodextrin consumed at 5g/day for 6 weeks
3491133|NCT03706989|Experimental|EEG for cardiac surgery patients|Patients who undergo elective cardiac surgery with cardiopulmonary bypass, from 18 to >75 years old.
3491134|NCT03706976|Experimental|CTOM|
3129435|NCT03219866|Experimental|Nebulizers|Subjects will receive a long-acting B2-agonist (LABA; Brovana, twice daily), corticosteroid (ICS; Pulmicort, twice daily), and a short-acting anti-cholinergic (SAMA; Atrovent, three times a day).
3180028|NCT00679107|Active Comparator|2|autogenous bone graft alone
3180029|NCT00679120|Active Comparator|1|Cemented single pegged femur with standard tibial bearing tray
3491135|NCT03706950||Elpida® + 2 NRTIs|Elpida® 20mg qd in the first line of therapy for HIV-1 infected patients with a background standard ART.
3491136|NCT03706937||Paramedical professionals|Paramedical professionals of the Lucien Neuwirth Cancer Institute
3491137|NCT03706924|Experimental|VM-1500FDC|VM-1500FDC (tenofovir 300 mg/elsulfavirine 20 mg/emtricitabine 200 mg), once daily fasting
3491138|NCT03706924|Active Comparator|Elpida® & Truvada®|Elpida®, 20 mg + Truvada® (tenofovir 300 mg / emtricitabine 200 mg), once daily fasting
3491139|NCT03706898|Experimental|Elpida® fasting|Elpida® 20 mg single dose fasting
3491140|NCT03706898|Experimental|Elpida® after meal|Elpida® 20 mg single dose after meals
3491141|NCT03706898|Experimental|Elpida® (in subjects with mild hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with mild hepatic impairment (Child - Pugh Class А)
3491142|NCT03706898|Experimental|Elpida® (in subjects with moderate hepatic impairment)|Elpida® 20 mg single dose fasting - subjects with moderate hepatic impairment (Child - Pugh Class B)
3491143|NCT03706898|Experimental|Elpida® & sofosbuvir & daclatasvir|Drug-drug interactions of sofosbuvir 400 mg + daclatasvir 60 mg and Elpida® 20 mg, single dose fasting
3129436|NCT03219866|Experimental|Dry Powder Inhaler|Subjects will receive a LABA/ICS (Advair Diskus, twice daily) plus a long-acting anticholinergic (LAMA; Spiriva Handihaler, once daily).
3129437|NCT03219892|Experimental|High-frequency rTMS|Patients randomized to this group will receive rTMS delivering over the supplementary motor area (SMA). Each treatment consists 1000 pulses (5-second burst of 10Hz rTMS, repeated 20 times at every minute ).Stimulus intensity is 90% of resting motor threshold. A figure-of-8 coil is connected to a biphasic magnetic stimulator, and the induced current is perpendicular to the midline.
3491144|NCT03706898|Experimental|Elpida® & dolutegravir|Drug-drug interactions of dolutegravir 50 mg and Elpida® 20 mg, single dose fasting
3491145|NCT03706872|Experimental|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care.
3491146|NCT03706872|No Intervention|Control Group|Provision of usual prenatal care
3491147|NCT03706859|Experimental|Tourniquet inflation pressure method 1|the pneumatic tourniquet inflation pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Unver B. et al.,: (AOP=[SBP+10]/KTP)
3491148|NCT03706859|Active Comparator|Tourniquet inflation pressure method 2|the pneumatic tourniquet inflateion pressure at 20 mmHg above the arterial occlusion pressure which will be estimated using the equation of Hong-yun Liu et al.,: (AOP = 17.986 + 3.158X1 + 0.408X2)
3491149|NCT03706846|Other|Fasting 2 hours|Fasting 2 hours
3491150|NCT03706846|Other|Fasting 6 hours|Fasting 6 hours
3491151|NCT03706820||normal rest and exercise hemodynamics|
3491152|NCT03706820||normal rest and abnormal exercise hemodynamics|
3491153|NCT03706820||resting pulmonary hypertension|
3491154|NCT03706820||abnormal wedge pressure at exercise|
3491155|NCT03706807|Experimental|Mindfulness-Based Intervention|"This group will be included in the eight-week mindfulness program following the Mindfulness-Based Health Promotion (MBHP) protocol. The group will have a weekly meeting of an hour and thirty minutes for eight weeks to perform the mindfulness-based interventions accompanied by plus four one-hour meetings through a maintenance group after conclusion of the program, totaling 16 hours. The training will be lead by a certified instructor and he will introduce practices such as mindfulness in breathing, body scan, mindful walking, mindful movements and 3-minutes of mindfulness and the concepts of first and second suffering and the Hi-Thanks-Bye."
3491156|NCT03706807|Active Comparator|Cognitive Stimulation|The basic workshop is considered a cognitive stimulation and the participants will receive an hour and thirty minutes class once a week during four months. The abilities learned at the workshop will be basic computer functions from development of the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks. The activities of the workshop are elaborated according to the development of each class and is participants.
3491157|NCT03706807|No Intervention|Naïve|It's a waiting list group which will receive no intervention.
3491158|NCT03706794|Experimental|Clinical Decision Support Tool|Tailored education provided via a smartphone application
3129438|NCT03219892|Sham Comparator|Sham rTMS|Patients randomized to this group will receive the sham rTMS. The procedure is same as used in patients receiving experimental rTMS, except that the coil is angled 90° away.
3129439|NCT03220048|Other|Cohort A: Sentinel Group|Sentinel group in which subjects received a challenge virus inoculum volume of 100uL on Day 0.
3129440|NCT03220048|Experimental|Cohort B: PrEP-001|PrEP-001 6400μg dose administered equally over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
3129441|NCT03220048|Experimental|Cohort B: Placebo|Nasal dose of placebo Comparator equally divided over both nostrils and on 2 consecutive days, using a single dose nasal powder device, as per randomisation schedule.
3491159|NCT03706794|Active Comparator|Headache Education|Non-tailored education provided via a smartphone application.
3491160|NCT03706781|Experimental|Test product CTP/BNZ with mucus adhesive polymer|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) + mucus adhesive polymer is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
3491161|NCT03706781|Active Comparator|Reference product CTP/BNZ - Tantum Verde Bocca|A multiple dose of the Cetylpyridinium Chloride 0.05%+Benzydamine HCl 0.15% (CTP/BNZ) Tantum Verde Bocca is administered to healthy subjects twice a day for 7 days, under fasting conditions in two subsequent periods according to the randomised cross-over design.
3491162|NCT03706768|Other|Glycocalyx|degree of glycocalyx breakdown in patients with aSAH
3491163|NCT03706755|Active Comparator|A|group A: will receive 1 mcg/Kg of Norepinephrine intravenously
3491164|NCT03706755|Active Comparator|B|group B: will receive 0.5 mcg/Kg of Norepinephrine intravenously
3491165|NCT03706742|No Intervention|Usual Care|Patients randomized to Group 1 will receive visit-based HCV screening, as offered by clinic providers as part of usual care. Providers must identify at-risk patients who are eligible for HCV screening, understand the benefits of screening in this population, and enter orders for HCV Ab testing. If the HCV antibody is abnormal, providers must order appropriate follow-up tests including HCV viral load to confirm HCV infection. Once HCV is confirmed, providers must refer the patients for fibrosis assessment and treatment evaluation. These efforts are augmented by an established best practice alert and health maintenance reminders.
3491166|NCT03706742|Active Comparator|Mailed outreach|Patients randomized to Group 2 will receive low literacy, written materials about HCV screening among baby-boomers in English and Spanish. The invitation will include patient-centered educational materials that discuss the risk of HCV in baby boomers and the benefits and risks of HCV screening. The invitation will include a phone number to schedule the HCV antibody blood test. Written materials will be developed and validated in Spanish using the Spanish Language Translation Resource. Once a potential subject is identified and randomized in Group 2, an outreach invitation will be mailed out. Shortly after the letter, a bilingual patient navigator will place a follow-up call to this potential subject. These follow-up calls will occur in the 2nd - 4th week after mailing invitations; up to three attempts in total will be made to reach the patient to facilitate HCC screening completion.
3129442|NCT03220204|Experimental|PP-based health behavior intervention|Participants will undergo a 12-week, Positive Psychology (PP)-based health behavior intervention. Each weekly session will include (a) a review of the week's PP exercise, (b) a discussion of the rationale of the next week's PP exercise through a guided review of the PP manual, and (c) assignment of the next week's PP exercise. Additionally for the goal-setting portion, participants will (a) review their goals and behaviors from the prior week, (b) discuss techniques for improving health behavior adherence (e.g., monitoring physical activity, reading nutrition labels), and (c) set goals for the next week.
3491167|NCT03706729|Experimental|Spraino intervention group|Participants will use Spraino® as a measure to prevent future lateral ankle sprains during all training sessions and games.
3491168|NCT03706716|Other|Intervention with use of decision aid in the consultation|With use of developed decision aid for pelvic organ prolapse / At the beginning of the consultation the IF will be opened within the patients electronic journal. The conversation will take its starting point from the generated IF which should define the area of interest rather for the patient.
3491169|NCT03706716|No Intervention|Control with no use of decision aid in the consultation|Without decision aid / The conversation during the consultation will follow the general standard for consultation conversations in the department.
3491170|NCT03706703|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with docetaxel/carboplatin or pemetrexed/carboplatin
3491171|NCT03706677|Active Comparator|CRYO group|"Within the CRYO arm the ablation will be performed using the Arctic Front Advance Cardiac CryoAblation Catheter, including next generation systems as applicable and approved by Medtronic for the trial.~Intervention performed: Cryoballoon ablation; Cryoballoon (Arctic Front Advance Cryoballoon)"
3491172|NCT03706677|Active Comparator|RF group|"Within the RF arm the ablation will be performed using a catheter out of the ThermoCool Smarttouch catheter family, including next generation contact force systems as applicable.~Intervention performed: Radiofrequency ablation; Radiofrequency Catheter (ThermoCool Smarttouch)"
3491173|NCT03706664|Other|Training of machine learning algorithm|113 MR Enterography images labelled by Radiologists will be used to develop a machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal.
3491174|NCT03706664|Other|Testing of machine learning algorithm|"113 MR Enterography images labelled by Radiologists will be used to test the accuracy of the machine learning algorithm to (1) localise the terminal ileum, (2) classify the terminal ileum as normal or abnormal compared to Radiologists opinion.~Cross Validation analysis will be used for data analysis."
3129443|NCT03220204|Experimental|MI-based educational control condition|Participants will undergo 12 weekly phone sessions to learn about a different health behavior topic related to cardiac health. This Motivational Interviewing (MI)-based educational control condition will introduce these participants to motivational interviewing topics in concert with the health behavior education topics.
3129444|NCT03220204|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment as Usual (TAU) group will not receive any interventions between the baseline visit and follow-up visits.
3491175|NCT03706651||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
3180030|NCT00679120|Active Comparator|2|Cemented twin pegged femur with standard tibial bearing tray
3180031|NCT00679120|Active Comparator|3|Cementless tibial bearing tray and femur (porous coated and HA coated)
3180032|NCT00679133|Experimental|1|
3180033|NCT00679146|Active Comparator|1|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
3180034|NCT00679146|Active Comparator|2|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
3180035|NCT00679159|Experimental|1|24 children (5 x 10^7pfu)
3491176|NCT03706651||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
3491177|NCT03706638|Other|Daily|Patients randomized to this arm will take ferrous sulfate 325 mg every day.
3491178|NCT03706638|Other|Intermittent (Every other day)|Patient's randomized to this arm will take ferrous sulfate 325 mg every other day.
3491179|NCT03706625||Non-Hodgkin-Lymphoma (after transplantation)|Immune-suppressed patients suffering from Non-Hodgkin-Lymphoma (after transplantation) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
3491180|NCT03706625||Non-small cell lung cancer|Immune-suppressed patients suffering from HIV-related non-small cell lung cancer, followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
3491181|NCT03706625||Primary Central Nervous System Lymphoma|Patients suffering from primitive cerebral lymphomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
3491182|NCT03706625||Gliomas|Patients suffering from Gliomas and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
3491183|NCT03706625||Non-Hodgkin-Lymphoma with HIV infection|Immune-suppressed patients (during HIV infection) and followed in the four centers of reference for rare cancers (KVirogref, CANCERVIH, LOC and POLA)
3491184|NCT03706599|Experimental|Fever therapeutic education session|Therapeutic education session on fever
3491185|NCT03706599|Placebo Comparator|Control therapeutic education session|Control therapeutic education session (on household accidents)
3491186|NCT03706586|Active Comparator|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
3491187|NCT03706586|Experimental|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
3491188|NCT03706547|Experimental|anti-CD19/BCMA CAR-T cells|"Chemotherapy with a classic combination with fludarabine and cyclophosphamide;~Administration with anti-CD19/BCMA CAR-T cells in the BCMA-positive multiple myeloma patients."
3491189|NCT03706534|Active Comparator|Manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored. Radiologists also make assessment decision without any intervention from artificial intelligence. 10 radiologists review manually.
3491190|NCT03706534|Experimental|Review by S-Detect for Breast|The same images will be separately processed by the artificial intelligence system (S-Detect for Breast) by Samsung. The two results, one by the radiologists and the other by artificial intelligence system, will be compared to statistically quantify equivalence (CADe).
3491191|NCT03706534|Experimental|Review with assistance of S-Detect for Breast|Second, the images will be reviewed by the radiologists with the help of artificial intelligence system, which is an interactive tool automatically providing recommendations on BIRADS descriptor choices that can be modified by the radiologists. The radiologists, after selecting all the descriptors of BIRADS, will decide the assessment categories. These decisions will be compared with the ground truths generated from the biopsy results or a 24-month follow-up (CADx).
3491192|NCT03706495|Experimental|The Group I|The Group I Postural exercise will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
3491193|NCT03706495|Experimental|The Group II|The Schroth method three-dimensional exercise therapy program consists of individual exercise programs combined with correction patterns. It is based on sensorimotor and kinesthetic principles. Goals of this exercise are to facilitate the correction of the asymmetric posture and to maintain the correct posture in the daily activities of the patient. The Group II receive Schroth method based on three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
3491194|NCT03706443|Active Comparator|Systane® Complete|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Complete, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
3491195|NCT03706443|Active Comparator|Systane® Ultra|All subjects are randomly assigned to arm one or arm two. Subjects are assigned to be treated with one drop of Systane® Ultra, and the tear lipid layer thickness is to be measured at 15 minutes, 1, 2, 4, and 6 hours after instillation of the eye drop. Following a minimum of a 2-day washout, the same subjects will proceed to the second arm.
3491196|NCT03706404|Experimental|Point-of-care Testing and Ultrasound pathway|
3180036|NCT00679159|Experimental|2|36 infants (2.5 x 10^7pfu)
3180037|NCT00679159|Experimental|3|36 infants (5 x 10^7 pfu)
3180038|NCT00679159|Experimental|4|36 infants (1 x 10^8pfu)
3180039|NCT00679159|Placebo Comparator|5|36 infants (Prevenar vaccine)
3180040|NCT00679185|Experimental|Experimental-EW|four emotion focused writing assignments
3180041|NCT00679185|Active Comparator|control group|non-emotional writing control
3491197|NCT03706404|No Intervention|Classical pathway|
3491198|NCT03706391||ALS and PMA Reversals|
3491199|NCT03706378|Other|Glucose Reference 1|50g glucose dissolve in 250 ml of water
3491200|NCT03706378|Other|Glucose Reference 2|50g glucose dissolve in 250 ml of water
3491201|NCT03706378|Other|Glucose Reference 3|50g glucose dissolve in 250 ml of water
3491202|NCT03706378|Experimental|Wheat Yellow Noodle|Boiled 170.6g of wheat yellow noodle
3491203|NCT03706378|Experimental|Beta-glucan Yellow Noodle|Boiled 230.4g of beta-glucan yellow noodle.
3491204|NCT03706378|Experimental|Rice Roll|Steamed 197.6g of rice roll
3491205|NCT03706378|Experimental|Rice Roll with resistant starch|Steamed 232.6g of rice roll fortified with resistant starch
3491206|NCT03706378|Experimental|Sucrose jelly|Jelly made with 25g of sucrose and 48g of wheat white bread
3491207|NCT03706378|Experimental|Isomaltulose jelly|Jelly made with 25g of isomaltulose and 48g of wheat white bread
3491208|NCT03706352|Experimental|tunneling group|Epidural Catheter Insertion and fixation by subcutaneous tunneling procedure.
3491209|NCT03706352|Active Comparator|taping group|Epidural Catheter Insertion and fixation by use of adhesive tape without tunneling.
3491210|NCT03706339|Placebo Comparator|normal saline arm group|they received 110 ml saline infusion or placebo (110 normal salines) by slow intravenous injection at an approximate rate of 1 mL per min plus Throughout the operation irrigation was done by120 ml saline
3491211|NCT03706339|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus100 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
3491212|NCT03706339|Experimental|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 100 ml normal saline applied on the placental bed after Cesarean section plus110 ml normal saline IV just before skin incision
3491213|NCT03706326|Experimental|Treatment with Anti-MUC1 CAR-T cells|Anti-MUC1 CAR-T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
3491214|NCT03706326|Experimental|Combination Therapy: CAR-T combining PD-1 knockout T Cells|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
3491215|NCT03706326|Experimental|Treatment with PD-1 knockout Engineered T cells|PD-1 knockout Engineered T cells will be prepared ex vivo using the T cells from the patients and infused back to the patients.
3491216|NCT03706300|Experimental|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets|Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets 1200/120 mg of Dr. Reddy's Laboratories Limited
3491217|NCT03706300|Active Comparator|Mucinex D|Mucinex D extended-release bi-layer tablets 1200/120 mg of Reckitt Benckiser Inc., USA
3491218|NCT03706287|Experimental|Anlotinib + AP/PC|
3491219|NCT03706274|Experimental|CX-188 Escalation|
3180042|NCT00679198|Experimental|1|We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers
3180043|NCT00679198|No Intervention|2|Standard care
3180044|NCT00679224||ambrisentan prescribed subjects|ambrisentan prescribed subjects
3491220|NCT03706274|Experimental|CX-188 Alternative Dosing Schedule|
3491221|NCT03706261|Experimental|Offspring Cohort|Racially/ethnically diverse subjects with or without a positive family history of Alzheimer's disease (AD) will have one PET scan with 18F-MK-6240 over a 30 to 60-minute scanning period, and one PET scan with 18F-Florbetaben over a 20-minute scanning period.
3491222|NCT03706248||No recurrence|"CT scan has confirmed that subjects are without recurrence. Blood can be drawn up to 4 weeks after scan.~Effective Feb 28, 2019, this group is closed to accrual as it has reached the goal."
3129445|NCT03220217|Experimental|5-20μg/40-80 MBq, 30-45μg/100-140 MBq|Subjects will receive a first intravenous (i.v.) injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 40 to 80 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 100 to 140 MBq.
3180045|NCT00679237|Active Comparator|Multifactorial intervention|Smoking cessation betablocker, diuretics, ACEI, ARB, statins, ezetimibe training influenza vaccine weight reduction metformin, glimepiride, insulin
3180046|NCT00679237|No Intervention|Control|no intervention
3180047|NCT00679250|Experimental|Levocetirizine|Active drug
3491223|NCT03706248||Recurrence|CT scan has confirmed that subjects are have recurrence of their colorectal cancer. Blood can be drawn prior to any treatment for the recurrent disease.
3180048|NCT00679250|Placebo Comparator|placebo|placebo to levocetirizine
3491224|NCT03706235||No recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging. Imaging documents no recurrence.
3491225|NCT03706235||Recurrence|Subjects at least 30 days from end of primary treatment for colorectal cancer in a clinically indicated surveillance program (e.g. ASCO, NCCN) provide a blood sample before the next clinically indicated surveillance scan/imaging or imaging has confirmed recurrence. Imaging documents recurrence.
3491226|NCT03706222||Drug interaction of Elbasvir/Grazoprevir|Patients treated with elbasvir/grazoprevir will be enrolled. DDI will be evaluated.
3491227|NCT03706209|Experimental|150 mg MP1032 bid|3 × 50 mg (150 mg) MP1032 plus 3 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
3491228|NCT03706209|Experimental|300 mg MP1032 bid|6 × 50 mg (300 mg) MP1032 hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
3491229|NCT03706209|Placebo Comparator|Placebo bid|6 × placebo hard gelatin capsules (per dosage) are provided twice daily over a period of 12 weeks.
3491230|NCT03706196||high incidence crohn's disease area|subjects living in high incidence crohn's disease area coming in dentist for dental extraction linked to medical indication
3491231|NCT03706196||low incidence crohn's disease area|subjects living in low incidence crohn's disease area coming in dentist for dental extractionlinked to medical indication
3491232|NCT03706183||Study Group|The IMA levels will be determined and the association of the IMA and Hearing thresholds will be evaluated.
3491233|NCT03706183||Control Group|The IMA levels will be determined.
3180049|NCT00679276||1|Patients having surgical repair of a vaginal prolapse .
3180050|NCT00679315|Experimental|Alpha blocker|alfuzosin hydrochloride XL 10mg
3491234|NCT03706170|Experimental|Vegetative State|For patients in vegetative state (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
3491235|NCT03706170|Experimental|Minimally Conscious State|For patients in minimally conscious state (n = 15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
3491236|NCT03706170|Experimental|Acquired Brain damaged patients without DOC|Acquired Brain damaged patients without disorder of consciousness (patients without DOC) For patients with acquired brain damage without disorder of consciousness (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography
3491237|NCT03706170|Experimental|Healthy subjects|For healthy subjects (n=15), three experiments will be performed during 2 days in order to assess emotions and consciousness with physiological variables and electroencephalography.
3491238|NCT03706157|Active Comparator|Iodinate contrast|Doxorubicin solution reconstituted in 5 mL iso-osmolar ionic iodinated contrast media
3491239|NCT03706157|Active Comparator|Normal saline|Doxorubicin solution reconstituted in 5 mL normal saline
3491240|NCT03706144|Experimental|Prodigy Intervention Group|Teachers will use the Prodigy Math Training with their students in school for at least 20 minutes per day, 3 days per week, from August to December 2018.
3491241|NCT03706144|No Intervention|Control Group|Instruction as usual = TAU
3491242|NCT03706131|Experimental|experimental group|one session 15 minutes cervical mobilisation and home exercise
3491243|NCT03706131|No Intervention|control grup|no intervention
3491244|NCT03706118|Experimental|MRI and Neuropsychologic testing|"102 healthy controls will be examined by magnetic resonance imaging (MRI) of brain, spinal and thoracic cord at month 0, 12, 24 and 36.~102 healthy controls will be examined by neuropsychological and walking testing designed for patients with multiple sclerosis at month 0, 12, 24 and 36."
3491245|NCT03706105|Experimental|Intervention - Cardiac Rehabilitation|
3491246|NCT03706092||Before|Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
3491247|NCT03706092||After|Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
3491248|NCT03706066||PanOptix|Cataract surgery with implantation of Acrysof IQ PanOptix IOL
3491249|NCT03706053|Placebo Comparator|Placebo|Investigational pharmacy formulated placebo. In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group)
3491250|NCT03706053|Experimental|Midodrine Hydrochloride 10 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
3491251|NCT03706053|Experimental|Midodrine Hydrochloride 20 mg TID|In early phase patients will be randomized to placebo, 10mg TID midodrine or 20 mg TID midodrine. (15 per group). After the first 45 patients are enrolled, interim safety and efficacy analysis will dictate which experimental group is continued/open to further enrollment (either 10 mg midodrine TID or 20 mg midodrine TID).
3491252|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 3 fractions|
3491253|NCT03706027|Active Comparator|Stereotactic body radiotherapy- 5 fractions|
3491254|NCT03706014|Experimental|SIBS Program|The program condition includes 12 weekly 90-minute afterschool group sessions for siblings. Sessions are structured as psycho-educational groups and include social interactional activities, role-playing, discussion, and didactic presentation. The focus is on sibling relationship skills, cognitions, and activities. During a total of 3 family nights, parents attend with their children. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children. Family Nights promote parents' understanding of sibling relationships, review concepts, provide strategies for parental support of siblings, and teach parents skills for dealing with sibling problems. Family Nights include dinner and last 2 hours.
3491255|NCT03706014|Placebo Comparator|Contact-Equivalent Attention Control|The Contact-Equivalent Attention Control condition includes 12 weekly 90-minute afterschool group sessions for siblings led by two co-leaders. Students work on educational games and activities. Groups begin with an icebreaker and continue with games and projects. This condition also includes 3 family nights, where parents attend with their children. Activities of the Family Nights include children showing their parents the activities they have been engaging in during the sessions. Family Nights include dinner and last 2 hours. Part of the family night session involves parents and children together. Another part of the session involves parents being separated from children; during this part, parents will break out with one group leader, and siblings will work with the other group leader.
3491256|NCT03706001|Experimental|Experimental Arm|Participants will receive psychotherapy for once a week.
3491257|NCT03706001|No Intervention|Control Arm|Participants will not receive any treatment for depression.
3180051|NCT00679315|Placebo Comparator|Placebo|Placebo
3491258|NCT03705988|Experimental|Intervention Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted continuously from 500 μA~2mA.
3491259|NCT03705988|Sham Comparator|Sham Arm|Participants will receive 40 sessions in 4 weeks, for twice daily on weekdays from Monday to Friday. Each session will be performed for 30 minutes. The current intensity will be adjusted lower than 100 μA.
3180052|NCT00679328|Experimental|1|Surgical implantation of OP-1
3180053|NCT00679328|Active Comparator|2|Surgical implantation of bone graft material
3180054|NCT00679393|Other|Fix|Open reduction internal fixation of severely comminuted calcaneal fracture (Sanders IV)
3129446|NCT03220217|Experimental|5-20μg/100-140 MBq, 30-45μg/160-200 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 100 to 140 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 160 to 200 MBq.
3129447|NCT03220217|Experimental|5-20μg/160-200 MBq, 30-45μg/40-80 MBq|Subjects will receive a first i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 5 to 20 μg and a radioactivity dose range 160 to 200 MBq. After 15 to 21 days the subjects will receive a second i.v. injection of satoreotide trizoxetan with a peptide mass dose range of 30-45 μg and a radioactivity dose range 40 to 80 MBq.
3129448|NCT03220412|Experimental|Experimental Condition|Intervention was guns in movies. Participants in this condition viewed a movie with guns, as it was filmed and distributed. The actual scenes in the movie (National Treasure or The Rocketeer) was not edited, but the same scenes were used as the Experimental Condition Intervention is m
3129449|NCT03220412|No Intervention|Control Condition|Participants in this condition viewed a movie without guns. The movie (National Treasure or The Rocketeer) was edited to remove guns from scenes.
3491260|NCT03705975|Active Comparator|edit arms|classical physiotherapy and manual treatment. Classical physiotherapy consisting of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Manual treatment is consist of scapular mobilization, glenohumeral joint inferior and posterior mobilization. Treatment modality is implemented by physical therapist three times a week for 8 weeks.
3491261|NCT03705975|Active Comparator|edit arm/intervention cross|classical physiotherapy and proprioceptive neuromusculer fasilitation. Classical physiotherapy consist of hotpack and ultrason. Hotpack duration is 20 minutes and ultrason duration is 5 minutes in one session. Scapular PNF and upper extremity PNF (flexion-abduction-external rotation) pattern. Treatment programme was implemented by physical therapist three times a week for 8 weeks.
3491262|NCT03705962|Experimental|Antibiotic|Subjects will be injected locally at the wound cavity (i.e. fracture site, surrounding soft tissue which include muscle, and subcutaneous space) with 80mg/40mL of tobramycin after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
3491263|NCT03705962|Placebo Comparator|Normal Saline|Subjects will be injected locally with 40 mL 0.9% NS after wound closure. Systemic antibiotic will not be withheld and will be done along side the intervention.
3491264|NCT03705949|Active Comparator|Study group|Sodium Hyaluronate 0.1% drops
3491265|NCT03705949|Active Comparator|Control group|Sodium Hyaluronate 0.2% drops
3491266|NCT03705936|Sham Comparator|Sham 1Hz rTMS--5Hz rTMS|Participants will receive sham 1Hz rTMS, then immediately followed by 5Hz rTMS.
3491267|NCT03705936|Experimental|1Hz rTMS--5Hz rTMS|Participants will receive 1Hz rTMS, then immediately followed by 5Hz rTMS.
3491268|NCT03705936|Experimental|1Hz rTMS--30-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 30 minutes break, then followed by 5Hz rTMS.
3491269|NCT03705936|Experimental|1Hz rTMS--60-minute break--5Hz rTMS|Participants will receive 1Hz rTMS, then followed by 60 minutes break, then followed by 5Hz rTMS.
3491270|NCT03705936|Sham Comparator|Sham 5Hz rTMS--1Hz rTMS|Participants will receive sham 5Hz rTMS, then immediately followed by 1Hz rTMS.
3129450|NCT03220581|Active Comparator|Referral for care|Referral for mental health issues and family support services
3180055|NCT00679393|Other|Fuse|Primary subtalar fusion of severely comminuted calcaneal fractures (Sanders IV).
3491271|NCT03705936|Experimental|5Hz rTMS--1Hz rTMS|Participants will receive 5Hz rTMS, then immediately followed by 1Hz rTMS.
3491272|NCT03705936|Experimental|5Hz rTMS--45-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 45 minutes break, then followed by 1Hz rTMS.
3491273|NCT03705936|Experimental|5Hz rTMS--90-minute break--1Hz rTMS|Participants will receive 5Hz rTMS, then followed by 90 minutes break, then followed by 1Hz rTMS.
3491274|NCT03705923|Experimental|Bariatric surgery|Subjects undergoing laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy.
3491275|NCT03705910|Active Comparator|Perceptive Rehabilitation (PR-group)|"This treatment will include small latex cones with different resistance. In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture."
3491276|NCT03705910|Active Comparator|Mobilisation Techniques (Mob-group)|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
3491277|NCT03705910|No Intervention|Control Group (C-group)|This group will not receive any intervention during this period. C-group will attend assessments.
3491278|NCT03705897|Other|Screening|Employ innovative methods for assessing personalized guideline-based screening in the clinic setting to evaluate guideline-based, over- and under-screening. Interventions include Computerized Risk Stratification Tool, Algorithmic Risk Stratification Tool, and Step completion assessment.
3491279|NCT03705884|Other|Cardiac Sarcoidosis|Patients with an established diagnosis of cardiac sarcoidosis.
3491280|NCT03705884|Other|Healthy volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
3491281|NCT03705871|Experimental|Differential Expansion Group|The experimental group will be comprised 24 patients treated with a rapid maxillary expansion using the expander with differential opening. The expander is composed by two screws, one posteriorly and the other anteriorly positioned on the palate.
3491282|NCT03705871|Active Comparator|Fan-Fype Expander Group|The active comparator group will be comprised by 24 patients treated with rapid maxillary expansion using the the fan-type expander. The expander is composed by one screw anteriorly positioned on the palate.
3491283|NCT03705858|Experimental|Ac-lintuzumab|Subjects with AML will receive Ac-lintuzumab.
3129451|NCT03220581|Experimental|Behavioral therapy|8-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors
3491284|NCT03705845|Placebo Comparator|Control|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
3491285|NCT03705845|Active Comparator|Intervention|One 430 mg tocotrienol softgel daily for 24 weeks. Each tocotrienol softgel (DeltaGold® Tocotrienol 70%) contains 430 mg tocotrienol (90% δ-tocotrienol+10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
3491286|NCT03705832|Experimental|Active drug|Subjects assigned to the intervention will receive 2 grams daily of Ginger Extract for 56 days.
3491287|NCT03705832|Placebo Comparator|Placebo|Subjects assigned to the placebo group will receive a matching placebo for 56 days.
3491288|NCT03705819|Experimental|Healthy Volunteers|In Stage 1, five healthy volunteers will receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate [11C]-NOP46 biodistribution and derive dosimetry estimates.
3491289|NCT03705819|Experimental|Individuals with Focal Pain|In Stage 2, up to 30 subjects with focal pain will receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
3491290|NCT03705780|Other|the short OSAS scale|In preoperative interview，distributing the short OSAS screening scales to children's parents，and the scale was completed preoperative，calculate the score of the scale
3491291|NCT03705780|Experimental|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
3491292|NCT03705754|Active Comparator|Tattoo arm|Tattoo will be placed by endoscopic submucosal injection of carbon black suspension
3491293|NCT03705754|No Intervention|Control arm|Tattoo will not be placed but case will follow standard procedure
3491294|NCT03705741|Experimental|Exercise group|Resistance exercise twice a week
3491295|NCT03705741|No Intervention|Control group|
3491296|NCT03705728|Experimental|Intravenous group|"Propofol & remifentanil administration using the closed-loop controller with the Easy-TIVA platfrom."
3491297|NCT03705728|Active Comparator|volatile anesthesia group|Sevoflurane will be administered manually according to the BIS values. Remifentanil will be administered manually using a Target Controlled Infusion pump using the Minto model.
3491298|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning.
3491299|NCT03705715|Experimental|PET with radiotracer [11C]PBR-28 or [11C]ER176 and affective challenge|PET with radiotracer [11C]PBR-28 or [11C]ER176 will be performed. [11C]PBR-28 or [11C]ER176 will be injected into subjects' veins during PET scanning. Affective challenge (e.g. induction of mood, affective pain) will be presented to the patient during the PET scanning period.
3491300|NCT03705702|Active Comparator|Intervention Group (IG)|The intervention of active comparator will be education program plus behavioral intervention through physical activity counseling program combined with a monitoring-and-feedback tool.
3491301|NCT03705702|Sham Comparator|Control Group (CG)|The intervention of sham comparator will be an education program in asthma and physical activity recommendations.
3491302|NCT03705676|Active Comparator|Healthy controls - control condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
3491303|NCT03705676|Experimental|Healthy controls - fear condition|Assesses EMG and EEG activity of healthy controls during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
3491304|NCT03705676|Active Comparator|RLBP - control condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
3491305|NCT03705676|Experimental|RLBP - fear condition|Assesses EMG and EEG activity of RLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
3491306|NCT03705676|Active Comparator|CLBP - control condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. No painful stimuli are administered, only non-painful vibrotactile stimuli.
3491307|NCT03705676|Experimental|CLBP - fear condition|Assesses EMG and EEG activity of CLBP subjects during a rapid arm task after a warning and go cue. Half of the trials are no threat trials, the other half are threat trials. A painful stimulus is administered during arm movement in 25% of the threat trials in order to evoke anticipation of pain during the 75% other threat trials.
3491308|NCT03705663||Women interested in HIV PrEP|Cis-gender women at high risk for HIV interested in or initiating HIV PrEP
3491309|NCT03705650|Experimental|Medicare Primary Care Provider (PCP) Patients|This is a non-randomized study of non-significant risk (NSR) that will be conducted at Northwestern's Central Dupage Hospital. Medicare patients > 65 years who are scheduled for a routine physical exam with their PCP that meet inclusion and exclusion criteria will be asked to participate in this study. Consenting patients will be scheduled for 2 back to back ultrasound scans including 5 standard 2D echocardiogram views each. The first scan will be performed by a non-ultrasound specialist using EchoGPS experimental guidance technology and the second control exam will be performed by a trained sonographer using a cleared conventional ultrasound platform.
3491310|NCT03705637|Experimental|Exparel Arm|20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.
3491311|NCT03705624|No Intervention|Standard of Care|Standard of care with passively monitored malaria incidence at health centers that receive appropriate diagnostic and clinical supplies and Seasonal Malaria Chemoprevention (SMC) for children less than 5 years of age
3491312|NCT03705624|Experimental|CCM|Standard of care supplemented with enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with artemether-lumefantrine (AL) according to national guidelines
3491313|NCT03705624|Experimental|CCM+MSAT|Standard of Care supplemented with CCM and Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
3129452|NCT03220737|Experimental|Cohort 1 (active, 12-17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
3129453|NCT03220737|Placebo Comparator|Cohort 1 (placebo, 12 - 17 yrs)|Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
3129454|NCT03220737|Experimental|Cohort 2 (active, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
3180056|NCT00679406|Experimental|1|Brief Behavioral Treatment for Insomnia
3180057|NCT00679419||Group 0 (Controllgroup)|eGFR >= 90 ml/min/1.73m^2 and no proteinuria
3180058|NCT00679419||Group 1|eGFR >= 90 ml/min/1.73m^2 and proteinuria
3180059|NCT00679419||Group 2|eGFR 60 - 89 ml/min/1.73m^2
3180060|NCT00679419||Group 3|eGFR 30 - 59 ml/min/1.73m^2
3180061|NCT00679419||Group 4|eGFR 15 - 29 ml/min/1.73m^2
3180062|NCT00679419||Group 5|eGFR < 15 ml/min/1.73m^2 or requiring dialysis
3491314|NCT03705611|No Intervention|Standard of care|Provide personalised clinic invitation slips (letters) to partners to come for HIV testing, and to access post-test services
3491315|NCT03705611|Experimental|HIV self-testing only|HIV self-testing only
3491316|NCT03705611|Experimental|HIV self-testing secondary accuracy|HIV self-testing secondary accuracy
3491317|NCT03705598|Placebo Comparator|Light physical exercise|Normal walking, light intensity resistance exercise and stretching, and health education discussions.
3491318|NCT03705598|Active Comparator|Tai Chi|Joint rotations and balance games, Tai Chi walking drills and the 8 forms.
3491319|NCT03705585|Experimental|Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine prior to routine endoscopic examination. During endoscopy, small bowel biopsies will be obtained to examine immune responses and microbiota at the mucosal level; brushings might also be obtained.
3491320|NCT03705585|Experimental|Endoscopy, Vaccination, Endoscopy|Individuals receive immunization with Vivotif typhoid vaccine and/or Vaxchora cholera vaccine after initial endoscopic exam and specimen collection and prior to a routine follow up endoscopic examination during which additional specimens will be collected.
3180063|NCT00679445|Experimental|A|Device: NeoVista Ophthalmic System A single procedure using the NeoVista Ophthalmic System plus an injection of Lucentis.
3491321|NCT03705585|No Intervention|Endoscopy Without Vaccination|Individuals do not receive immunization but consent to collection of specimens during endoscopy. The specimens to be collected in all three groups include stool, saliva, and small bowel biopsies (terminal ileum if colonoscopy performed, duodenum if EGD performed).
3491322|NCT03705572|Active Comparator|Dietary Supplement: Phospholipid drink.|Participant in an intervention parallel group consumed a drink with added phospholipids (Lacprodan PL20).
3491323|NCT03705572|Placebo Comparator|Dietary Supplement: Placebo milk drink.|Participant in an intervention parallel group consumed a drink without added phospholipids.
3491324|NCT03705559|Experimental|Vaporized Marijuana|Participants will receive non-therapeutic, experimental doses of active or placebo. vaporized marijuana. Active marijuana/placebo will be administered once per session and will be administered via a vaporizer.
3491325|NCT03705559|Experimental|Opioid Agonist|Participants will receive non-therapeutic, experimental doses of an active opioid agonist or placebo. Active opioid agonist/placebo will be administered once per session and will be administered intranasally (snorting).
3491326|NCT03705559|Experimental|Opioid Agonist/Marijuana Combination|Participants will receive non-therapeutic, experimental doses of active opioid/placebo in combination with non-therapeutic, experimental doses of active vaporized marijuana/placebo. Opioid/placebo and marijuana/placebo doses will be administered once during each session. It is possible to receive both active drugs on the same day. Opioid doses will be administered intranasally; marijuana doses will be administered via vaporizer.
3180064|NCT00679458|Experimental|1.|Study drug: buprenorphine and ultra-low-dose naloxone
3180065|NCT00679458|Active Comparator|2.|Study drug: buprenorphine
3491327|NCT03705533|Other|Sequence ABAB|Subjects assigned to sequence ABAB will receive a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 1 and 3 and a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
3491328|NCT03705533|Other|Sequence BABA|Subjects assigned to sequence BABA will receive a single 80 mg dose of the reference product Micardis (1 x 80 mg tablet) marked as B in the sequence in periods 1 and 3 and a single 80 mg dose of the test product Telmisartan (1 x 80 mg tablet) marked as A in the sequence in Periods 2 and 4. These treatments will be administered orally with approximately 240 mL of water at ambient temperature, in the morning, following a 10-hour overnight fast. The tablet must be swallowed whole and must not be chewed or broken.
3180066|NCT00679471||Pre-Term|Infants born pre-term with birthweight less than 1KG
3180067|NCT00679471||Full-Term Infants|Well infants who are born full-term
3180068|NCT00679484|Experimental|1|
3180069|NCT00679484|Experimental|2|
3180070|NCT00679497|Experimental|1|MVA HIV-B
3180071|NCT00679497|Placebo Comparator|2|Placebo
3491329|NCT03705520||Cross-Sectional|This cohort is composed of only medicated PD subjects and their spouse or 1st degree relative.
3491330|NCT03705520||Logitundinal|This cohort is composed of only non-medicated PD subjects and their spouse or first degree relative.
3491331|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group A (18 years and above)|Patients will receive the adult cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
3491332|NCT03705507|Experimental|Selumetinib + Dexamethasone - Group P (under 18 years)|Patients will receive the paediatric cohort specified dose of selumetinib by mouth, as a single dose on cycle 1 day 1, then twice daily continuously from cycle 1 day 4 onwards. Combined with pulsed doses of dexamethasone at 6mg/m2/day on days 2-4 and 8-11 then at 4mg/m2/day on days 15-18 and 22-25 divided into two doses (as per local practice) by mouth during cycle 1, then on days 1-4 at 4mg/m2/day at the start of cycle 2, then on days 1-5 at 6mg/m2/day during subsequent cycles.
3129455|NCT03220737|Placebo Comparator|Cohort 2 (placebo, 6 - 11 yrs)|Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
3180072|NCT00679510|Active Comparator|rosuvastatin|Rosuvastatin Patients were randomly allocated rosuvastatin (crestor) 10 mgs. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
3180073|NCT00679510|Placebo Comparator|Placebo|Placebo. Patients were randomly allocated placebo. The drugs (rosuvastatin and placebo) were provided by Astra Zeneca Ltd.
3180074|NCT00679523|Experimental|Group 1|AN2690 Solution, 5.0%
3180075|NCT00679523|Experimental|Group 2|AN2690 Solution, 7.5%
3180076|NCT00679536|Experimental|A|All patients on this trial will receive a conditioning regimen of Busulfan, Fludarabine, Anti-Thymocyte Globulin and Total Body Irradiation (400 cGy)
3180077|NCT00679562|Experimental|1|
3180078|NCT00679562|Placebo Comparator|2|
3180079|NCT00679575||1|Cases : Patients with a first myocardial infarction
3180080|NCT00679575||2|Referents : Patients recruited by a GP during a routine consultation
3321259|NCT02017626|Experimental|group 1|5 patients will receive 10 single rising doses of mCyp c 1 (modified allergen)from 0.6 ng to 6 ug and two maintenance doses, and 2 patients will receive placebo
3491333|NCT05177692|Active Comparator|Intervention group - Vguard|Intervention group will be fitted with a Vguard system Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
3491334|NCT05177692|No Intervention|Control group - regular intra-ventricular drainage|Control group will be fitted with a standard system for drainage of ventricular fluid Patients will have double ICP monitoring using the intraventricular drainage and and intraparenchymal ICP monitoring device
3491335|NCT05177679|Experimental|Active Supplement|The active supplementation group participants will be asked to consume a daily carotenoid supplement for 9 months.
3491336|NCT05177679|Placebo Comparator|Placebo Control|The placebo control group participants will be asked to consume a placebo supplement for 9 months.
3491337|NCT05177653|Experimental|GIPRA|
3491338|NCT05177653|Experimental|GLP-1RA|
3491339|NCT05177653|Experimental|GIPRA + GLP-1RA|
3129456|NCT03220737|Experimental|Cohort 3 (active, 2 - 5 yrs)|Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
3129457|NCT03220737|Placebo Comparator|Cohort 3 (placebo, 2 - 5 yrs)|Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
3491340|NCT05177653|Placebo Comparator|Saline|
3491341|NCT05177640|Experimental|99mTC-duramycin|single dose of 99mTc-duramycin in healthy volunteers who will undergo SPECT-Ct scanning at different time points
3491342|NCT05177627|Experimental|Fundamental of Care Framework implementation|Educational interventions related to introduction of FoC framework and taking charge of patients and their fundamental needs will be realized during theoretical, simulation and internship learning.
3491343|NCT05177627|No Intervention|No Fundamental of Care Framework implementation|the participants of no intervention group will receive the standard training as scheduled on the curriculum
3491344|NCT05177614|Experimental|Upper-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
3491345|NCT05177614|Experimental|Lower-level multiple micronutrient-fortified bouillon cube|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with six micronutrients
3491346|NCT05177614|Placebo Comparator|Control (iodine-fortified bouillon cube)|10 gram shrimp-flavoured bouillon cube, consumed ad-lib, fortified with one micronutrient
3491347|NCT05177601|Active Comparator|TMS+DCS|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
3491348|NCT05177601|Active Comparator|TMS+Placebo|"The Transcranial Magnetic Stimulation (TMS) involves magnetic stimulation of the brain to the left medial prefrontal cortex (mPFC) daily for four weeks. The stimulation is intermittent Theta-Burst (iTBS).~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
3491349|NCT05177601|Sham Comparator|shamTMS+DCS|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule containing 100mg of the antibiotic d-cycloserine (DCS) daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
3491350|NCT05177601|Placebo Comparator|shamTMS+placebo|"Sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered to the brain.~Participants will orally ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 4 weeks of rTMS treatment (20 sessions) one hour prior to rTMS treatment."
3129458|NCT03220737|Other|Historical Control: Adult Bridging Population|This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118
3180081|NCT00679588|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery (placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind)
3491351|NCT05177588|Experimental|Metformin|Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
3491352|NCT05177588|No Intervention|Standard of Care|Patients in the control arm will continue the SOC medications
3491353|NCT05177562||PCOS|No intervention.
3491354|NCT05177562||PCOS surgery|No intervention
3491355|NCT05177562||Surgery control|No intervention
3491356|NCT05177562||IVF PCOS|No intervention
3491357|NCT05177562||IVF control|No intervention
3491358|NCT05177562||Investigations, fertility PCOS|No intervention
3491359|NCT05177562||Investigations, fertility control|No intervention
3491360|NCT05177562||Pregnancy - gestational diabetes mellitus|No intervention
3491361|NCT05177562||Pregnancy - Intrahepatic cholestasis of pregnancy|No intervention
3491362|NCT05177562||Pregnancy - control|No intervention
3491363|NCT05177549|Experimental|on estrogen-progestin contraception|
3491364|NCT05177549|Experimental|under micro-progestational contraception|
3491365|NCT05177549|Experimental|without hormonal contraception|
3491366|NCT05177536|Experimental|Iberdomide|Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle
3491367|NCT05177523||MS patient group|Recruitment of 200 MS patients at the MS Clinic of the Department of Neurology (Neurologische Klinik und Poliklinik), University Hospital Basel (Universitätsspital Basel)
3491368|NCT05177523||control group (HC)|Recruitment of 100 healthy controls (HC) by public announcements (i.e. advertisement/flyer) on the University Hospital's and the University's notice board.
3491369|NCT05177510|Experimental|Mifepristone and standard of care|Mifepristone 300mg once only and standard of care
3491370|NCT05177510|Placebo Comparator|Placebo|Placebo 300mg once only and standard of care
3491371|NCT05177497|Experimental|treatment arm|
3491372|NCT05177484|Experimental|Ferric maltol|
3491373|NCT05177484|No Intervention|Standard Care|
3491374|NCT05177471||SSc-ILD patients with JAK inhibitors|
3491375|NCT05177458|Experimental|Moderate Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of moderate intensity (70-75% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
3491376|NCT05177458|Active Comparator|Control - Low Intensity Exercise|"Visit 1: Participants will complete study screening, PTSD assessments, and provide written narrative for a traumatic event and a neutral control event.~Visit 2: Participants will complete eight trials of imaginal exposure (blocks of four neutral and four trauma narrative trials presented as text and sound) with heart rate monitoring and skin conductance. Anxiety will be measured at baseline and after each imagery trial. Participants will then complete 30 minutes of light intensity (40-50% maximum heart rate) exercise on a treadmill.~Visit 3: Participants will complete eight more imaginal trials with heart rate and anxiety ratings as per visit 2."
3491377|NCT05177445|Experimental|Intervention group with phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction ) positive for coronavirus-19 will receive the phototherapy intervention. It consists of the introduction of the nasal probe of the phototherapy device in the nasal cavity of the patient. A mixture of ultraviolet light A, ultraviolet light B and red light will be applied between 2 and 3 minutes. The patient will receive a maximum of 10 interventions. Furthermore both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
3491378|NCT05177445|Active Comparator|Intervention group (corticosteroids + OT) without Phototherapy|Patients that present loss of smell 4 weeks after their coronavirus-19 infection and that have had a real-time polymerase chain reaction (reverse transcriptase polymerase chain reaction )and both oral corticosteroids (prednisone 40mg) and olfactory training will be applied, in the intervals of daily for 10 days and daily for the duration of the study respectively.
3491379|NCT05177432|Experimental|QPOP-based drug screen assay using patient tumour-derived organoids|"Patients with Histological confirmed breast carcinoma of any subtype (any estrogen receptor, progesterone receptor and HER2 receptor status) with at least 1 tumour lesion (primary or metastatic) amendable to fresh biopsy and measurable based on RECIST 1.1 criteria will undergo biopsy to obtain a sample of cancer tissue that will be used to generate Patient Derived Organoids (PDOs).~Patients' cells will be subjected to testing with 10-12 anti-cancer drugs and a table for treatment sensitivity to each drug will be derived after 4 to 6 weeks of treatment in the laboratory. Results will be reviewed at an expert panel discussion to decide on the most suitable anti-cancer drug treatment"
3491380|NCT05177419|Experimental|High-dose LSD|High dose of lysergic acid diethylamide
3491381|NCT05177419|Active Comparator|Low-dose LSD|Low dose of lysergic acid diethylamide
3491382|NCT05177406||Full cohort|patients newly initiating Aimovig therapy
3491383|NCT05177393||Participants with Esophageal Cancer|Participants with esophageal cancer will be administered questionnaires, and medical charts will be accessed to collect study related data.
3491384|NCT05177380|Experimental|Personalized rehabilitation program of facial involvement in systemic sclerosis|"3 sessions of 2 hours of facial rehabilitation in hospital over 2 weeks including:~Physiotherapy with facial and endo-oral massages, self-massages, active and passive exercises of the face and mouth, tongue exercises~Speech therapy with mobilization of the orofacial sphere applied to swallowing and speech difficulties~Individual workshop on the theme of dry mouth, dry mouth, swallowing disorders, and oral care~Individual therapeutic makeup workshop~A motivational interview~A patient notebook with a personalized protocol for self-rehabilitation of the face~A video tutorial for self-rehabilitation of the face Facial self-rehabilitation sessions at home"
3491385|NCT05177380|Other|Routine care|Delivery of a standard prescription for facial rehabilitation
3491386|NCT05177367|Experimental|Sequential Variety, Small Portion|3 courses each consisting of a different food served in a small portion.
3491387|NCT05177367|Experimental|Sequential Variety, Large Portion|3 courses each consisting of a different food served in a large portion.
3491388|NCT05177367|Experimental|Simultaneous Variety, Small Portion|3 courses each consisting of 3 foods served in small portions.
3491389|NCT05177367|Experimental|Simultaneous Variety, Large Portion|3 courses each consisting of 3 foods served in large portions.
3491390|NCT05177367|Experimental|Single Food, Small Portion|3 courses each consisting of the same food served in a small portion.
3491391|NCT05177367|Experimental|Single Food, Large Portion|3 courses each consisting of the same food served in a large portion.
3491392|NCT05177354|Experimental|Treatment|
3491393|NCT05177341||Amputees with acceptable phantom sensation|
3491394|NCT05177341||Amputees with no phantom sensation|
3491395|NCT05177341||Control group|
3491396|NCT05177328|Experimental|ShA9 dominant and placebo non-dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of ShA9 applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of placebo applied to their contralateral arm (i.e. left arm for a right handed participant).
3321260|NCT02017626|Experimental|Group 2|6 patients will receive 10 single rising doses of mCyp c 1 from 6 ng to 60 ug and two maintenance doses, and two patients will receive placebo.
3491397|NCT05177328|Experimental|ShA9 non-dominant and placebo dominant|The ShA9 product and placebo will be provided in single dose dispensers. Dispensers will be stored at -80°Celsius (= -112 degrees Fahrenheit) and thawed to 4°Celsius (=39.2 degrees Fahrenheit) prior to administration. Participants will have a single application of placebo applied by clinic staff to their dominant arm (i.e. right arm for a right handed participant) and a single application of ShA9 applied to their contralateral arm (i.e. left arm for a right handed participant).
3491398|NCT05177302||Individuals with hip and/ or groin pain|The young to middle-aged physically active individuals with hip and/ or groin pain, which symptoms lasting for 2 to 6 month.
3491399|NCT05177289|Experimental|Treatment group|Patients allocated to the treatment group will receive scalp cooling combined with thrice weekly PBM sessions during the CTx course and until one month after the end of CTx.
3491400|NCT05177289|Active Comparator|Control group|Patients allocated to the control group will receive scalp cooling during their CTx course.
3491401|NCT05177276|Experimental|Dose Level -1|Selinexor 12mg po twice weekly (Monday & Wednesday or Tuesday & Thursday); Irinotecan 50mg/m2 IV once daily on days 1, 8 & 15
3491402|NCT05177276|Experimental|Dose Level 1|Selinexor 15mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
3491403|NCT05177276|Experimental|Dose Level 2|Selinexor 20mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 100mg/m2 IV once daily on days 1, 8 & 15.
3491404|NCT05177276|Experimental|Dose Level 3|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 75mg/m2 IV once daily on days 1, 8 & 15.
3491405|NCT05177276|Experimental|Dose Level 4|Selinexor 30mg po twice weekly (Monday & Wednesday or Tuesday and Thursday); Irinotecan 125mg/m2 IV once daily on days 1, 8 & 15.
3491406|NCT05177263|Placebo Comparator|Supportive Positions+Sterile Water+Non-Nutritive Sucking|The enrolled premature infants will be administered 1ml of the sterile water a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of sterile water a second time.
3491407|NCT05177263|Active Comparator|Supportive Positions+10% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 10% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 10% oral dextrose solution a second time.~(%10 oral dextrose solution: osmolarity= 550 mOsm/L, pH= 3.5-6.5, calorie=400 kcal/L)"
3491408|NCT05177263|Active Comparator|Supportive Positions+20% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 20% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 20% oral dextrose solution a second time.~(%20 oral dextrose solution: osmolarity= 1010 mOsm/L, pH= 3.2-6.5, calorie= 680 kcal/L)"
3491409|NCT05177263|Active Comparator|Supportive Positions+30% Oral Dextrose+Non-Nutritive Sucking|"The enrolled premature infants will be administered 1ml of the 30% oral dextrose solution a first time 2 minutes before the procedure. After 2 minutes, heel-stick sampling (with an auto lancet for premature infants) will be performed immediately after administering 1 ml of 30% oral dextrose solution a second time.~(%30 oral dextrose solution: osmolarity= 1515 mOsm/L, pH= 3.2-6.5, calorie= 1020 kcal/L)"
3491410|NCT05177250|Other|Case group|50 cases with type 2 DM.
3491411|NCT05177250|Other|Control group|50 subjects not diabetics.
3491412|NCT05177237|Experimental|Endostar combined with Methylprednisolone|Endostar combined with Methylprednisolone lasts for 10 weeks
3491413|NCT05177224|Experimental|Participants with dual mobility cup|
3491414|NCT05177211|Experimental|Treatment with Fedratinib|Participants will taken Fedratinib by mouth once a day every day of each 28 day cycle.
3491415|NCT05177198|Experimental|Test group (M-MIST + Clindamycin augmented PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with Clindamycin (at concentration of 150 mg/ml) augmented platelet-rich fibrin.
3491416|NCT05177198|Experimental|Control group (M-MIST + PRF)|Patients will be selected with probing pocket depth PD ≥ 5 mm and clinical attachment level (CAL) ≥ 5 mm, with vertical defects as detected in periapical radiographs will be treated with modified minimally invasive surgical technique with platelet-rich fibrin alone .
3491417|NCT05177185|Experimental|SRS with hippocampal-sparing|Stereotactic radiosurgery with hippocampal-sparing
3491418|NCT05177172|Placebo Comparator|Control|White wheat flour bread
3321261|NCT02017639|Experimental|Sarilumab SAR153191 (REGN88)|Single dose of simvastatin before and after sarilumab administration
3321262|NCT02017652||Preterm Infants|Preterm infants 32 to 36 weeks will be eligible for this study
3491419|NCT05177172|Experimental|High betaglucans|White wheat flour bread included beta glucans with the highest amounts in this study
3491420|NCT05177172|Experimental|Low beta glucans|White wheat flour bread included beta glucans with the lowest amounts in this study
3491421|NCT05177172|Experimental|Low beta glucans + low polar lipids|White wheat flour bread included a combination of the lowest amounts of beta glucans and polar lipids
3491422|NCT05177172|Experimental|low polar lipids|White wheat flour bread included polar lipids
3491423|NCT05177159||Postoperative delirium|
3491424|NCT05177159||Non postoperative delirium|
3491425|NCT05177146|Experimental|Intravenous Ketamine (IV)|
3491426|NCT05177133|Experimental|Capecitabine, oxaliplatin and retifanlimab|IV and PO Capecitabine 1000 mg/m2, oxaliplatin 130 mg/m2, every three weeks (up to 2 cycles) IV retifanlimab 500mg, every four weeks
3491427|NCT05177120||FMF patients|Patients with diagnosed FMF
3491428|NCT05177107|Experimental|Group 1: Phage Therapy|Bacteriophage therapy will be personalized for each patient dependent on phage susceptibility testing
3491429|NCT05177107|Placebo Comparator|Group 2: Placebo|Placebo (normal saline) will be administered using the same schedule and techniques as for Group 1 (phage therapy).
3491430|NCT05177094|Experimental|LY3526318|Participants will be administered LY3526318 orally.
3491431|NCT05177094|Placebo Comparator|Placebo|Participants will be administered placebo orally.
3491432|NCT05177081|Experimental|Home BIA Monitoring group|Preemptive management by Body fluid monitoring system (BWA ON + App + Web)
3491433|NCT05177081|No Intervention|Control group|Usual heart failure management (Outpatient follow-up and medical treatment)
3129459|NCT03220854|Experimental|A: SBRT (body) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
3491434|NCT05177068|Experimental|Experimental|fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)
3491435|NCT05177055|Experimental|n=17, sleep-school 6 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep-school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3491436|NCT05177055|Experimental|n=18, sleep-school 6 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3129460|NCT03220854|Experimental|B: Patients receiving SBRT and SRS (body and brain) irradiation|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
3321263|NCT02017678|Experimental|JX-594 IV Infusion|Patients with peritoneal carcinomatosis of ovarian origin that are not eligible for curative treatments will receive 5 weekly IV infusions of JX-594
3491437|NCT05177055|Active Comparator|n=35 Six-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3491438|NCT05177042|Experimental|Oral tablet(s) in combination with abiraterone and a corticosteroid.|ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles.
3491439|NCT05177029|Experimental|Part A: Lu AG06466 or Placebo|Participants will receive single dose of Lu AG06466 capsule or matching placebo orally on Day 1.
3491440|NCT05177029|Experimental|Part B: Lu AG06466 or Placebo|Participants will receive starting dose of Lu AG06466 capsule or matching placebo orally once daily from Day 1 to Day 4 followed by Lu AG06466 capsule or matching placebo at a titrated treatment dose orally once daily from Day 5 until Day 8. Participants will then receive LuAG06466 capsule or matching placebo at a higher assigned dose orally once daily from Day 9 to Day 15.
3491441|NCT05176977|Experimental|Peer Specialist - Whole Health Coaching (PS-WHC)|Participants will meet with a Peer Specialist for 18 sessions over 24 weeks. The essential elements of this intervention include 1) general support provided via the core functions of a Peer Specialist, and 2) a structured Whole Health Coaching curriculum.
3491442|NCT05176977|No Intervention|Enhanced Usual Care (EUC)|Usual PACT care plus Hot Spotter Analytics (consists of access to field-based dashboard that allows PACTS to identify homeless Veterans on their panels who were super-utilizers, and the hot spotter manual).
3491443|NCT05176964||SBRT with concurrent chemotherapy and immunotherapy|CAPOX chemotherapy plus tislelizumab treatment plus split-course SBRT
3491444|NCT05176951|Experimental|Treprostinil Palmitil|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be titrated up to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
3491445|NCT05176951|Placebo Comparator|Placebo|Participants will be administered a placebo matching treprostinil palmitil (TPIP) once daily.
3491446|NCT05176938|Experimental|Ultrasound guided Thoracic Interfascial plane Block (TIFB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected in the serratus intercostal space at 6 ribs midaxillary line and (20ml) in pecto-intercostal space at 2 ribs parasternal.
3491447|NCT05176938|Experimental|Ultrasound guided Erector Spinae plane Block (ESPB)|Patients will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the fourth thoracic segment (T4).
3491448|NCT05176938|No Intervention|General anesthesia|Patients will receive general anesthesia only without blocks.
3491449|NCT05176925|Experimental|Tislelizumab combined with sitravatinib|
3491450|NCT05176912|Experimental|Experimental Exercise Group|Reformer Pilates exercises will given for 8 weeks, 3 days in a week.
3491451|NCT05176912|No Intervention|Control Group|Nothing given to the control group, will be told to continue their normal life for 8 weeks.
3491452|NCT05176873|Experimental|Single dose of DZD8586|Single dose of DZD8586
3491453|NCT05176873|Placebo Comparator|Single dose of Placebo|Single dose of Placebo
3491454|NCT05176860|Experimental|High-performance CBCT imaging|Two additional study imaging sets are acquired.
3491455|NCT05176847|Experimental|Gamified mLIFE app group|Participants allocated to this group will be provided with elements of social gaming and healthy competition within the mLIFE app.
3491456|NCT05176847|Active Comparator|standard mLIFE app|Participants in this group will receive the same intervention as the experimental group, but some features of the APP will not facilitate gaming or competition.
3491457|NCT05176834|Experimental|B-Cure laser pro|In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.). In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
3491458|NCT05176821|Experimental|High-dose dual therapy group|esomeprazole 20mg qid plus amoxicillin 750mg qid were used in the high-dose dual therapy group
3491459|NCT05176821|Active Comparator|Furazolidone-based quadruple therapy|furazolidone 100mg bid + amoxicillin 1000mg bid + esomeprazole 20mg bid + bismuth potassium citrate 1000mg(220mg of bismuth) bid were used in the Furazolidone-based quadruple therapy
3491460|NCT05176808|Active Comparator|Telehealth Parent Coaching (TC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting the child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is 12 weeks with 2 sessions per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Trained study coaches will join families in their homes remotely via Kennedy Krieger Institute's secure Zoom password-protected account to provide coaching."
3491461|NCT05176808|Active Comparator|In-person Coaching(IPC)|"A family-centered, collaborative coaching approach, Practice-Based Coaching (Snyder et al., 2015), will be used. Coaches will use an NDBI coaching curriculum to support parents in targeting child social-communication skills during interactions with their toddlers with ASD. The duration of the coaching period is12 weeks with sessions 2 times per week. Parents will be coached to implement NDBI strategies during daily routines with their young child with ASD following the coach and parent NDBI manuals developed in the Landa lab.~Coaching will be delivered in families' homes by trained study coaches to support parent implementation of NDBI strategies during daily life activities with their toddler with ASD."
3491462|NCT05176795||Experimental|Child under 10 years old newly diagnosed with JIA, IBD or T1DM
3491463|NCT05176795||Active Comparator: Healthy control|Brother/sister of child with pediatric onset inflammatory disease (same age category - same environment: food, living space)
3491464|NCT05176782|Active Comparator|Group A (HTK cardioplegia)|will receive HTK cardioplegia in volume 30 ml/Kg given by antegrade route through an aortic route cannula.
3491465|NCT05176782|Active Comparator|Group B ( Cold Cardioplegia)|will receive group cold Blood Cardioplegia in volume 20mL/kg given by antegrade route through an aortic route cannula and repeated 10mL/kg/dose every 25minutes at 8-12°C for maintenance. This technique considered the standard management in this age.
3491466|NCT05176756|Active Comparator|Attention Control|In addition to using a wearable device, participants in this arm will receive a daily notification of their step count from the previous day. This notification serves as an 'attention control' and allows us to better isolate the impact of the gamification with social support. It may also help to reduce differential attrition across arms.
3491467|NCT05176756|Experimental|Gamification and Social Support|Participants in this arm will receive the same devices and daily messaging as control. They will also be entered into a game designed using behavioral economic principles for 6 months. This intervention has been adapted from our prior successful pilot studies. The game runs automatically and does not require any effort on the part of the participant to 'play' the game other than to strive for physical activity goals. Participants in this arm will also select a family member or friend who will serve as a support partner to encourage the participant to meet their step goals. The gamification and social support interventions will end after 6 months at which point participants will receive the same treatment as the attention control arm for the 3-month follow-up period.
3491468|NCT05176743|Other|Usual Care|"Referral to services~Nutrition pamphlets~One-time payment of $300 paid 4 months after baseline"
3491469|NCT05176743|Experimental|Unconditional Cash Transfer Intervention|"Three monthly payments of $100~Referral to services~Nutrition pamphlets"
3491470|NCT05176730|Experimental|Patients with hemodialysis receiving mindfulness meditation|The ABC standardized version of mindfulness meditation was used. The experimental group received 30-minute mindfulness meditation sessions 3 times a week for 5 weeks (450 minutes). An additional two-hour educational workshop about the rationale and procedures of intervention was provided before the actual training sessions. To ensure the consistent delivery of the intervention, the researcher recorded the intervention instructions in Arabic based on the intervention protocol and sent the audio-recorded instructions to the participants via WhatsApp or email. The audio-recorded intervention contents were validated by two psychologists and experts in meditation. The recorded intervention instructions were accessed by the participants during the sessions using their cell phones and headsets, as recommended. This method allowed for up to 3-5 participants to listen to the instructions and perform the intervention simultaneously.
3491471|NCT05176730|No Intervention|Control group|The participants in the control group were instructed to sit with their eyes closed and relaxed for 30 minutes 3 times a week for 5 weeks during hemodialysis sessions to control for the nonspecific effects of social interaction and environment. The timings of the control group sessions were similar to those of the experimental group, whereby if a given experimental group intervention lasted for 30 minutes, the control group participants would be asked to sit with their eyes closed and relax for 30 minutes also.
3491472|NCT05176717|Experimental|QR-421a 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
3491473|NCT05176717|Experimental|QR-421a 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
3491474|NCT05176717|Sham Comparator|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
3491475|NCT05176704||CDR = 0.5|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Questionable/very mild dementia (CDR = 0.5)
3491476|NCT05176704||CDR = 1|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Mild dementia/MCI (CDR = 1)
3491477|NCT05176704||CDR = 2|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Moderate dementia (CDR = 2)
3129461|NCT03220854|Experimental|C: Patients receiving SRS (brain) irradiation only|Patients will receive a standard treatment regimen of SRT (refer to Section 6.3). The term SRT encompasses all radiotherapy using a stereotactic setup, both stereotactic radiosurgery (SRS) for metastatic lesions in the brain and stereotactic body radiotherapy (SBRT) for SRT delivered to all other locations
3129462|NCT03220958|Experimental|Metoclopramide|Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
3129463|NCT03220958|Placebo Comparator|Placebo|Normal saline, administered as an intravenous drip
3129464|NCT03221192||Subjects participating in CE and CD interviews|Twenty adult subjects from the US and 10 adult subjects from Germany with severe recurrent nasal polyps who have received nasal polyp surgery in the past 10 years prior to screening will be asked to participate in CE and CD interviews
3491478|NCT05176704||CDR = 3|50 Alzheimer's Disease (AD) patients including predominant AD with mixed vascular and MCI due to AD based on their CDR score. Severe dementia (CDR = 3)
3491479|NCT05176704||Healthy Control|50 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
3491480|NCT05176691|Experimental|Part 1 Dose Escalation Cohorts|Approximately 18 DLT evaluable patients will receive ascending oral doses of HMPL-760
3491481|NCT05176691|Experimental|Part 2 Dose Expansion Cohorts|Approximately 150 patients will receive HMPL-760 daily at MTD and/or RP2D for 28 day cycles
3491482|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence A|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 4 gram/day.
3491483|NCT05176678|Active Comparator|Escalating dose of natural protein hydrolysate - sequence B|Participants will consume escalating doses of natural protein hydrolysate: Week 1-2: 1 gram/day, Week 3-4: 2 gram/day, Week 5-6: 8 gram/day.
3491484|NCT05176665|Experimental|Phase Ib and Phase II|"In phase 1b part of the study, the study will recruit approximate 6 patients to each of the 4 GI cancer groups (gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer) to characterize PK profile of EMB-01 at the RP2D (1600 mg QW) in GI cancers and evaluate the safety and tolerability of EMB-01 at the RP2D.~In the Phase 2part of the study, additional patients will be enrolled into each of the 4 GI cancer groups (gastric cancer, hepatocellular cancer, cholangiocarcinoma, and colorectal cancer) until a total of 24 patients are treated at the RP2D."
3491485|NCT05176639|Experimental|Phase 1 MAD study part|Healthy participants and participants with TED will be randomized to receive two intravenous infusions of VRDN-001 or placebo with an interval of 3 weeks.
3491486|NCT05176639|Experimental|Phase 2 extension study part|Participants with TED will be randomized to one of two VRDN-001 doses/dosing regimens or placebo. The doses/dosing regimens may include doses up to 20 mg/kg with the dosing interval and duration to be defined based on the results of the MAD study part.
3491487|NCT05176626|Experimental|Phentermine|Participants randomized to active treatment in LEAP will be provided with phentermine hydrochloride 8 mg scored tablets. This formulation of the drug is commercially available and marketed as Lomaira TM.
3491488|NCT05176626|Placebo Comparator|Placebo|Participants randomized to the control arm of LEAP will be provided with placebo tablets consisting of cellulose and corn starch and manufactured to have the same characteristics of the active drug, including size, shape, weight, and sensory perceptions.
3491489|NCT05176613|Experimental|HF-rTMS and ML|High frequency Repetitive Transcranial Magnetic Stimulation and Motor Learning(Experimental group)
3491490|NCT05176613|Sham Comparator|Sham-rTMS and ML|Sham Repetitive Transcranial Magnetic Stimulation and Motor Learning
3491491|NCT05176600|Experimental|Bimanual group|In this group, patients will perform a robotic rehabilitation based on bimanual serious games
3491492|NCT05176600|Active Comparator|Unimanual group|In this group, patients will perform a robotic rehabilitation based on unimanual serious games
3491493|NCT05176587||Integrated group (SPOC)|
3491494|NCT05176587||Control group|
3491495|NCT05176574||Physicians|Physicians from 12 different specialties (i.e. General Medicine, Endocrinologists, Neurologists, Cardiologists, Orthopedists, Pathologists, Rheumatologists, Phytochemists-Pneumonologists, Vascular Surgeons, Oncologists-Pathologists, Psychiatrists, Neurologists-Psychiatrists) who manage patients with non-communicable diseases.
3491496|NCT05176561|Experimental|Treatment: Auditory-Cognitive Training|Behavioral: AR Group will complete sessions in their home or office via internet. Sessions will include independent work using computer software two hours per week and one hour meeting with the clinician each week. One half of the training is devoted to auditory training and one half to auditory cognitive activities. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
3129465|NCT03221192||Subjects participating in interview and real-time data capture|Ten subjects from the US with severe recurrent nasal polyps who are participating in CE and CD interviews will be asked to complete the real-time data capture app task.
3129466|NCT03221387|Other|Nasal high flow with oxygen|While in the clinic High Flow Nasal Cannula oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience. The subject will be discharged to home and instructed to use the high flow nasal cannula system at night and during the daytime while at home and resting.
3129467|NCT03221595|Experimental|Operative|Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
3491497|NCT05176561|Sham Comparator|Control: Non-auditory Cognitive Training|Behavioral: The CT Group will complete two hours of training in their home or office via internet. Sessions will include independent work using computer software two hours per week. Training exercises will be chosen from: Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Differences. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with cochlear implant.
3491498|NCT05176548||Group 1|Patients in whom Cardiac Amyloidosis is confirmed
3491499|NCT05176548||Group 2|Patients in whom Cardiac Amyloidosis is ruled out
3491500|NCT05176535|Experimental|FertyBiotic Balance|Participants received FertyBiotic Balance one capsule a day
3491501|NCT05176509|Experimental|Intervention/treatment|
3491502|NCT05176496||Cohort 1|Women with a continuous observation of 365 days after January 1st, 2000 and before December 31, 2020.
3491503|NCT05176496||Cohort 2|Women diagnosed with HMB.
3491504|NCT05176483|Experimental|XL092 + Nivolumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
3491505|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
3491506|NCT05176483|Experimental|XL092 + Nivolumab + Bempegaldesleukin Dose-Escalation Cohorts|"Approximately 12 subjects will accrue across 1-2 dose levels of XL092 following the rolling 6 design."
3491507|NCT05176483|Experimental|XL092 + Nivolumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in genitourinary cancers.
3491508|NCT05176483|Experimental|XL092 + Nivolumab + Ipilimumab Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in genitourinary cancers.
3491509|NCT05176483|Experimental|XL092 + Nivolumab + Bempegaldesleukin Expansion Cohorts|The recommended dose from the dose-escalation stage may be further explored in genitourinary cancers.
3491510|NCT05176483|Experimental|Nivolumab + Bempegaldesleukin Expansion Cohorts|
3491511|NCT05176483|Experimental|Nivolumab + Ipilimumab Expansion Cohorts|
3491512|NCT05176483|Experimental|XL092 Single-Agent Expansion Cohorts|
3491513|NCT05176470|Experimental|Treatment (pembrolizumab, lifileucel)|"Patients receive pembrolizumab IV on day -14, cyclophosphamide IV QD on days -7 to -6, fludarabine IV over 30 minutes QD on days -5 to -1, and lifileucel IV infusion on day 0. Patients also receive pembrolizumab IV on day 28 and 70, and undergo surgery on day 80.~MAINTENANCE: Patients receive pembrolizumab IV every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
3491514|NCT05176457|No Intervention|BEFORE PICT'REA introduction|Patients will have the usual communication tools (pen and paper, hands gestures...)
3491515|NCT05176457|Experimental|AFTER PICT'REA introduction|Patients will be given a tablet to communicate with the caregivers whenever needed
3491516|NCT05176444|Experimental|Music therapy intervention|Music therapy
3491517|NCT05176444|No Intervention|Control group - standard care|Standard care for residents with cognitive impairment. Staff will not receive music therapy training.
3491518|NCT05176431|Active Comparator|Focused extracorporeal shock wave therapy|
3491519|NCT05176431|Active Comparator|Radial extracorporeal shock wave therapy|
3491520|NCT05176431|Sham Comparator|Sham extracorporeal shock wave therapy|
3491521|NCT05176418|Active Comparator|delivery rate for nicotine dose 1mg/70kg|delivery rate 50,35, 16.6 and 12.5 ug per second
3491522|NCT05176418|Active Comparator|Delivery rate for nicotine dose 0.2mg/70kg|delivery rate 10,5, 3.3 and 2.5
3491523|NCT05176405|Experimental|Elissa's EE Song|Participants will have to click on the watch button to start the YouTube video as it is without manipulation. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
3491524|NCT05176405|Active Comparator|Standard of Care|Participants will be assigned to read general infographic messages adopted from the Saudi Ministry of Health (MOH) in the breast cancer early screening context in Arabic/English. Right after exposure, the first and second arms will be asked if they have seen either of the presented materials before.
3491525|NCT05176405|No Intervention|Control Group|The third arm of this trial is the control group who will not be exposed to any preventative messages.
3491526|NCT05176392|Active Comparator|Active rTMS with telehealth headache management therapy|Participants receive both active rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
3491527|NCT05176392|Other|Active rTMS with telehealth headache education control|Participants receive active rTMS treatment at the left dorsolateral prefrontal cortex and headache education
3491528|NCT05176392|Other|Sham rTMS with telehealth headache management therapy|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and therapy for headache management
3491529|NCT05176392|Sham Comparator|Sham rTMS with telehealth headache education control|Participants receive sham rTMS treatment at the left dorsolateral prefrontal cortex and headache education
3491530|NCT05176379|Experimental|fluconazole|fluconazole tablet/pill 150 mg, single acute dose
3491531|NCT05176379|Placebo Comparator|Placebo|250 mg pill microcrystalline Cellulose, single acute dose
3491532|NCT05176366|Experimental|15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 8 weeks after that to week 46|IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 8 weeks thereafter to week 46 (n=5), (total # doses = 10).
3129468|NCT03221595|No Intervention|Non-operative|Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
3491533|NCT05176366|Experimental|15ml of ExoFlo at Day 0, 2, 4 Week 2, 6, and every 4 weeks after that to week 46|IV administration of study agent at Day 0, Day 2, Day 4, Week 2, Week 6 and every 4 weeks thereafter to week 46 (n=5), (total # doses = 15).
3491534|NCT05176353|Experimental|VAP diagnostic stewardship|
3491535|NCT05176340|Experimental|Intervention group|Participants in the experimental group were provided an education program through the Care Action Module during their hospitalization period, and follow-up was conducted one and two months after discharge.
3491536|NCT05176340|No Intervention|Control group|The control group received no intervention, except for the regular care followed by the nurses in general in the rehabilitation ward.
3491537|NCT05176327|Experimental|Intervention|Subjects will receive 2 consecutive courses of exoskeleton training with twelve 45-minute sessions, each to be completed in 6 to 8 weeks. The total period of training will be 12 to 16 weeks.
3491538|NCT05176327|Active Comparator|Control|Subjects will receive twelve 45-minute sessions of usual physiotherapy treatment, consisting of maintenance exercise in the first 6 to 8 weeks, and then one course of exoskeleton training with twelve 45-minute sessions in the following 6 to 8 weeks.
3491539|NCT05176314|Experimental|Rosuvastatin + Pirtobrutinib|Rosuvastatin administered orally on day 1 followed by rosuvastatin administered with pirtobrutinib on day 6 orally. Pirtobrutinib alone administered orally from days 7 to 12 followed by rosuvastatin administered with a single dose of pirtobrutinib on day 13. Pirtobrutinib alone administered from days 14 to17.
3491540|NCT05176288|Experimental|Axitinib, Avelumab and Palbociclib|"During each 28 day (+/- 3 days) study cycle, all participants will receive:~Axitinib: 2x Daily until it is determined participant must stop the drug~Palbociclib: Taken 1x time per day on days 8-28 of each cycle until it is determined participant must stop the drug.~Avelumab: Once every 2 weeks continued for up to 2 years or earlier if it is determined participant must stop the study drug"
3491541|NCT05176275|Experimental|68Ga-NOTA-RP25|Intravenous injection
3491542|NCT05176236|Experimental|Pictographic group|Participants received the pictographic handouts on tracheostomy care
3491543|NCT05176223|Experimental|Treatment (68GA PSMA PET/CT)|Patients undergo 68GA PSMA PET/CT scans at baseline, and after 3, 6, 9, and 12 cycles of standard of care immunotherapy in the absence of disease progression or unacceptable toxicity.
3491544|NCT05176210|Experimental|SAD portion - Cohort 1 (100mg)|An eligible subject will receive a single dose of 100 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
3491545|NCT05176210|Experimental|SAD portion - Cohort 2 (200mg)|An eligible subject will receive a single dose of 200 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
3491546|NCT05176210|Experimental|SAD portion - Cohort 3 (400mg)|An eligible subject will receive a single dose of 400 mg of PS1 or Placebo tablets in a fed condition on Day 1 and be followed for 14 days.
3491547|NCT05176210|Experimental|FE portion - Cohort 4 (100mg)|An eligible subject will receive a single dose of 100 mg PS1 or Placebo tablets in a fasted condition on Day 1 and be followed for 14 days.
3491548|NCT05176210|Experimental|MAD portion - Cohort 5 (50mg)|An eligible subject will receive 50 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 14 days.
3491549|NCT05176210|Experimental|MAD portion - Cohort 6 (100mg)|An eligible subject will receive 100 mg PS1 or Placebo tablets once daily in a fed condition for 28 days and be followed for additional 14 days.
3491550|NCT05176197|Experimental|Almond Group|Participants will consume almonds every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
3491551|NCT05176197|Experimental|Control Group|Participants will consume pretzels every day for 16 weeks, but will not be allowed to consume any other nuts or nut products.
3491552|NCT05176171|Experimental|Photorefractive Keratectomy with Corneal Cross-Linking|For correction of refractive error
3491553|NCT05176158|Experimental|Morning dosage|Dexketoprofen pill at morning; Placebo at night
3491554|NCT05176158|Experimental|Night dosage|Placebo pill at morning; Dexketoprofen at night
3491555|NCT05176145|Other|single arm|Only one arm. The urine collection from each patient will be used for VisioCyt® test and conventional cytology
3491556|NCT05176132||OBESE (BMI>30)|BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.
3491557|NCT05176132||CONTROL Normal weight (BMI 20-25)|100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age
3491558|NCT05176132||CONTROL Overweight (BMI 25-30)|100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age
3491559|NCT05176119|Active Comparator|Nalbuphine arm|0.1 mg /kg nalbuphine was given to 30 patients
3491560|NCT05176119|Active Comparator|Ketamine arm|0.25 mg /kg ketamine was given to 30 patients
3491561|NCT05176119|Placebo Comparator|Saline arm|an equivalent volume of normal saline was given to 30 patients
3491562|NCT05176106|Experimental|Intervention-Randomized Parishes|Parishes will be randomized in Masindi District to receive the intervention (i.e., an incentives package). VHTs who are active in that parish will thereby receive the incentives intervention.
3491563|NCT05176106|No Intervention|Control-Randomized Parishes|Non-intervention randomized parishes will be the control parishes. Active VHTs in the control parishes will not receive the incentives intervention.
3491564|NCT05176093|Active Comparator|Engensis|Active Comparator: Engensis 64 mg Engensis per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
3491565|NCT05176093|Placebo Comparator|Placebo|Placebo Comparator: Placebo 32 mL of Placebo per Treatment Cycle, with each of 3 cycles composed of 2 days of 128 injections each to the right and left target muscles, spaced 2 weeks apart
3491566|NCT05176080|Experimental|Treatment group|Famitinib Plus SHR6390 and Endocrine therapy
3491567|NCT05176067|No Intervention|drug therapy group|targeted therapy, immune, chemotherapy
3491568|NCT05176067|Experimental|drug therapy concurrent radiotherapy|drug therapy(targeted therapy, immune, chemotherapy ) combined with thoracic tumor concurrent radiotherapy
3491569|NCT05176054|Experimental|Experimental group|Researchers will conduct the health service program for the experimental group.
3491570|NCT05176054|No Intervention|Contrast group|The contrast group will be receiving the routine care only.
3491571|NCT05176028|Experimental|Control group|conventional physiotherapy
3491572|NCT05176028|Experimental|Intervention group|conventional physiotherapy and fascial release
3491573|NCT05176015|Experimental|Frenzel Lens with Diagnostic Algorithm|"Frenzel lens will be applied on patients' eyes during different diagnostic manoeuvre to assess if a nystagmus is present and if present describe its main characteristic.~Without mentionning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
3491574|NCT05176015|Experimental|Frenzel Lens without Diagnostic Algorithm|Frenzel lens will be applied on patients' eyes during different diagnostic manoeuvres to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.
3491575|NCT05176015|Experimental|No Frenzel Lens with Diagnostic Algorithm|"Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens.~Without mentionning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging"
3491576|NCT05176015|No Intervention|No Frenzel Lens and No Diagnostic Algorithm|The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.
3491577|NCT05176002|Experimental|Neoadjuvant Camrelizumab combined with radiotherapy group|
3491578|NCT05175963||High Risk|"Nurses (auxiliary nurses, enrolled nurses and professional nurses), medical doctors (interns, medical officers, registrars and consultants) and auxiliary/para-medical staff involved in the care of patients admitted for respiratory illnesses at Chris Hani Baragwanath Academic Hospital (CHBAH). This will include staff that have been assigned to work in:~Internal Medicine: Staff working in the Ambulatory and Emergency Department, staff in the pneumonia-admission ward (ward 24), and staff in the COVID-19 confirmed case wards.~Paediatrics: Staff involved in-hospital care of patients admitted to the dedicated pneumonia ward and COVID-19 cases wards.~Intensive Care Unit: All medical staff working in the intensive care unit."
3491579|NCT05175963||Low Risk|Nursing and medical-doctor staff that are working in the neonatal high-care and intensive care unit; who are likely to be at lower risk from SARS-CoV-2 acquisition in the health-care facility compared to their peers listed in Group 1.
3129469|NCT03221660|Experimental|F-Composite 2 system|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the F-Composite 2 system.
3491580|NCT05175963||Intermediate Risk|"A third group, with a likely intermediate risk for hospital-facility based SARS-CoV-2 infection, are:~VIDA staff involved in sample collection related to COVID-19, and laboratory personnel that will be involved in sample collection at VIDA.~Nurses and medical doctors from the Obstetrics & Gynaecology."
3491581|NCT05175963||Mixed Risk|In 2021 with an eminent 3rd wave spreading across the country an additional group will be included comprising of any person working at CHBAH even if not in direct contact with patients.
3491582|NCT05175963||TND group|Any person working at CHBAH or Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital (HJH) even if not in direct contact with patients.
3491583|NCT05175950|Experimental|Test group 1: primary vaccination completed with ChAdOx1 nCOV-19|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
3491584|NCT05175950|Placebo Comparator|Placebo group 1: primary vaccination completed with ChAdOx1 nCOV-19|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
3491585|NCT05175950|Experimental|Test group 2: primary vaccination completed with BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
3491586|NCT05175950|Placebo Comparator|Placebo group 2: primary vaccination completed with BNT162b2(Pfizer)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
3491587|NCT05175950|Experimental|Test group 3: primary vaccination completed with mRNA-1273(Moderna)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
3491588|NCT05175950|Placebo Comparator|Placebo group 3: primary vaccination completed with mRNA-1273(Moderna)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
3491589|NCT05175950|Experimental|Test group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
3491590|NCT05175950|Placebo Comparator|Placebo group 4: primary vaccination completed with Ad26.COV2.S(Janssen)|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
3491591|NCT05175950|Experimental|Test group 5: primary vaccination completed with ChAdOx1 nCOV-19(AZ)-BNT162b2(Pfizer)|GBP510 adjuvanted with AS03 (Receptor Binding Domain (RBD) 25μg/dose), 1 dose on Days 0
3491592|NCT05175950|Placebo Comparator|Placebo group 5: primary vaccination completed with ChAdOx1 nCOV-19-BNT162b2|Participants will receive intramuscular (IM) injections of Normal saline on Days 0
3491593|NCT05175937||APP group|Patient wearing ICD with Bluetooth® technology and smartphone APP based remote monitoring
3491594|NCT05175937||Bedside transmitter group|Patient wearing ICD monitored remotely through a bedside transmitter
3491595|NCT05175924|Experimental|Virtual reality|In the Aquarium VR group, virtual reality headset compatible with iPhone 7 (Apple) was used to distract attention. Before use, the headsets were tested on five children for face fit and visibility of the application used. Written and verbal consent of the children and their parents was obtained to test the headsets. The children who tested the headsets were not included into the study. The headset offered a soft and comfortable experience in contact with the skin due to its leather and pad covering. It also had a wide viewing angle and an optical zoom button. Due to its noise isolation function, it did not disturb anyone or make noise.
3491596|NCT05175911||premature infants|premature infants less than 31 weeks of gestation or weighting less than 1300 g
3491597|NCT05175898||VA-ECMO|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) during cardiac arrest.
3491598|NCT05175898||ECMELLA|Patients who were treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella® micro-axial pump.
3491599|NCT05175885|Experimental|Experimental group|Ex vivo normothermic perfusion (EVNP) of the graft with the Ark Kidney System
3491600|NCT05175885|Active Comparator|Historical control group|Nonrandomized historical control group formed by patients transplanted without ex vivo normothermic perfusion (EVNP) in the period Sept 2015-Sept 2020, selected by retrospective matching.
3491601|NCT05175859||Early tracheostomy|Tracheostomy time before day 10 following endotracheal airway management and invasive ventilation.
3491602|NCT05175859||Late tracheostomy|Tracheostomy time after day 11 following endotracheal airway management and invasive ventilation.
3491603|NCT05175846||Normal volunteers|Participants with negative COVID-19 test
3491604|NCT05175846||COVID-19|Participants with positive COVID-19 test and severe symptoms of disease
3129470|NCT03221738|Experimental|App-Based Cognitive Behavioral Therapy|12-week Smartphone-delivered CBT for BDD.
3129471|NCT03221764|Experimental|Amiodarone with CoSeal administered with CO2 driver|Lung Transplant Recipients who receive Intraoperative application of an Amiodarone containing hydrogel at the time of transplant.
3129472|NCT03222037|Experimental|TEST/SCR|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (TEST/SCR) sequentially
3129473|NCT03222037|Experimental|SCR/TEST|Subjects who are current soft contact lens wearers between the ages of 18 and 35 will be randomized to the two different treatments (SCR/TEST) sequentially
3491605|NCT05175833|Experimental|Oral probiotics|oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli). During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
3491606|NCT05175833|Placebo Comparator|Oral placebo|oral gel containing placebo. During the trial, the oral gel was applied in the mouth every 8 hours for 7 days
3491607|NCT05175820||Dentists|"Graduated from the Faculty of Dentistry,~Continuing/not continuing dental education (master, doctor, doctorate) after graduation,~Working in practice or outpatient clinic, private or public hospital, private polyclinic or public health or university hospital,~Dentists who registered in Turkish Dental Association"
3491608|NCT05175807|Experimental|Mindfulness Group_1|The intervention will be characterized by be based on Mindfulness exercises (e.g. body scan, gentle yoga, sitting, grounding and walking meditation), relaxation techniques and cognitive rehabilitation exercises. walking), relaxation techniques and cognitive rehabilitation exercises. The objective is to provide specific practical skills to learn how to deal with difficult and/or stressful situations managing emotions and intercurrent thoughts. The intervention is proposed to last for a total of 5-6 sessions lasting 45 minutes each, two sessions per week, for a three-week commitment. In addition, between sessions, reflection materials, readings or exercises will be offered. The intervention will be conducted in telemedicine by a Psychologist, who has experience in conducting these interventions and who receives regular supervision. The sessions will be conducted through special platform and audio-recorded to ensure the reliability of the data collected, prior consent.
3491609|NCT05175807|No Intervention|Waiting List Group_2|"In both groups the usual care or usual treatment, will consist of the usual daily medical examinations of the department, respiratory and motor physiotherapy sessions. The Group 2, therefore, will not be submitted to other type of treatment outside of that previewed near O.U. for the course of the first three weeks, during which they will be placed on the waiting list. Once the Once the assessment is carried out after 3 weeks, we will proceed to implement the intervention proposed to the Group 1. If the participant has already been discharged from the structure, it will still be possible to proceed with the intervention, since it is online. If the participant has already been discharged from the structure, you can still proceed with the intervention, since this is in telemedicine, in order to promote the continuity hospital-territory."
3491610|NCT05175794||Cohort 1|Participants that test positive for Mycobacterium tuberculosis (M.tb) with rifampicin resistance will be enrolled in Cohort 1 (n=880).
3491611|NCT05175794||Cohort 2|Participants that test positive for M.tb that are rifampicin susceptible with isoniazid mono-resistance will be enrolled in Cohort 2 (n=400).
3491612|NCT05175781|Active Comparator|Dexmedetomidine|"patients will receive two NIV sessions during which intravenous continuous infusion of dexmedetomidine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. Dexmedetomidine will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions accounting for 1-h contextual half-life of dexmedetomidine. Patients received neither tested drug nor NIV during this 6-h interval."
3491613|NCT05175781|Active Comparator|Ketamine|"patients will receive two NIV sessions during which intravenous continuous infusion of ketamine will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, infusion of ketamine will be at the dose of 0.20 mg/kg/h (or 3.3 mg/kg/min). to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two NIV sessions . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of the infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
3491614|NCT05175781|Placebo Comparator|Placebo|"patients will receive two NIV sessions during which intravenous continuous infusion of placebo (0.9% sodium chloride solution) will be given.~The infusion was initiated 60 min prior to NIV at the same rate for all treatments, corresponding to 0.7 mcg/kg/h of dexmedetomidine without a loading dose. will then titrate by 0.2 mcg/kg/h every 60 min (up to a maximum dose of 1.3 mcg/kg/h) to maintain a RASS score between 0 and 3. A 6-h washout period was observed between two . Patients received neither tested drug nor NIV during this 6-h interval.~Following the start of any infusion, the patient could have a morphine dose if the 10-cm Visual Analog Scale (VAS) exceeded 3."
3491615|NCT05175768|Active Comparator|Nicotinamide Mononucleotide|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
3491616|NCT05175768|Active Comparator|Nicotinamide Mononucleotide with L-Leucine|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
3491617|NCT05175768|Placebo Comparator|Placebo|Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
3491618|NCT05175755|Experimental|Patients|The procedure involves taking a total of 12 ml of blood.
3491619|NCT05175742|Experimental|40µg PTX-COVID19-B Open-label|Participants, 10-15 healthy adults 18 to 64 years of age will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
3491620|NCT05175742|Experimental|40µg PTX-COVID19-B|Participants, 350 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 40µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28. Participants will receive a placebo dose on Day 21.
3491621|NCT05175742|Active Comparator|Pfizer-BioNTech COVID-19 vaccine|Participants, 175 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of Pfizer-BioNTech COVID-19 vaccine on Day 1, followed by a placebo dose on Days 21. Participants will receive a placebo dose on Day 28.
3491622|NCT05175742|Other|60 µg PTX-COVID19-B|Exploratory arm - Participants, 175 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 60µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
3491623|NCT05175742|Other|80 µg PTX-COVID19-B|Exploratory arm - Participants, 175 healthy adults 18 to 64 years of age, will receive 1 intramuscular (IM) injection of 80µg PTX-COVID19-B vaccine on Day 1, followed by a second dose on Day 28.
3491624|NCT05175729||Pregnant Group|First trimester pregnant group would be included and will be followed up in second, third trimesters and after pregnancy
3129475|NCT03222141|Experimental|SAPIEN 3™ valve|
3129476|NCT03222349|Experimental|Interictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
3129477|NCT03222349|Experimental|Ictal/Peri-ictal Period|Each subject received a single dose of DBF based on the subject's age and weight.
3129478|NCT03222414|Experimental|Arm A: Conical then Cylindrical|BP recording with noninvasive conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring; then with traditional cylindrical BP cuff and direct invasive arterial pressure monitoring
3491625|NCT05175729||Control group|Age-, sex-matched healthy volunteers
3491626|NCT05175703|Other|the infrainguinal arteries disease group|Actual patient group with any atherosclerotic change in the infrainguinal arteries
3491627|NCT05175690||Trial Population|The trial population will be enrolled from adults presenting for elective, outpatient COVID-19 testing at a single center, potentially with multiple testing locations (subject to local needs at the time of the trial). The investigational device will be provided to Participants via a cell phone preloaded with Common off-the-shelf original equipment manufacturer (COTS OEM) software and the investigational Dx SaMD. The investigational device will be evaluated during a single encounter in which an FCV-SDS will be collected. No follow-up visits or participant contacts will be involved in this trial.
3491628|NCT05175664||MCI|Patients suffering from mild cognitive impairment (MCI) due to Alzheimer's disease.
3491629|NCT05175664||AD|Patients diagnosed with mild to moderate Alzheimer's disease (AD)
3491630|NCT05175664||NDD|Patients under investigation of a neurodegenerative disease (NDD)
3491631|NCT05175664||DLB|Patients diagnosed with Dementia with Lewy Bodies (DLB)
3491632|NCT05175664||VaD|Patients with vascular dementia (VaD)
3491633|NCT05175664||FTD|Frontotemporal dementia (FTD)
3491634|NCT05175664||NPH|Normal pressure hydrocephalus (NPH)
3491635|NCT05175664||Healthy Controls|Healthy Controls without brain disease
3491636|NCT05175651|Experimental|Subjects identified by Optum Health|10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.
3491637|NCT05175638||Control|A total of 20 term newborn infants with a median gestational age of 40 weeks (range: 37-42 weeks) will be selected from the Gynecology and Obstetrics Hospital (Assiut University). All control infants should have an Apgar score of > 9 at 1, 5, and 10 minutes.
3491638|NCT05175638||Study group|"Thirty newborn infants born for Covid-19 positive mothers will be prospectively included in this study. The diagnosis of hypoxia will made based on Apgar score, clinical signs present during the first hours of life and acid-base status.~The following inclusion criteria will be used (all necessary): Covid-19 positive mothers, term newborn (>37 completed gestational weeks), free from severe malformations. All infants will be examined generally, systemically and neurologically at birth for clinical assessment of HIE if present and for detection of outcome of these neonates."
3491639|NCT05175625|Experimental|SpikoGen COVID-19 Vaccine|
3491640|NCT05175625|Placebo Comparator|Saline Placebo|
3491641|NCT05175599|No Intervention|Land Birth|Women in the land birth group will labor and give birth according to standard of care procedures.
3491642|NCT05175599|Experimental|Water Birth|Women in the water birth group will give birth in the water. During the first stage of labor, women may enter or leave the water at any point.
3129479|NCT03222414|Active Comparator|Arm B: Cylindrical then Conical|BP recording with noninvasive traditional cylindrical BP cuff and direct invasive arterial pressure monitoring; then with conical Ultracheck Curve BP cuff and direct invasive arterial pressure monitoring
3129480|NCT03222427|Experimental|LY3314814|Single 50 milligram (mg) dose of LY3314814 administered orally
3491643|NCT05175586|Experimental|Group 1|15 patients in the experimental group of percutaneous neuromodulation together with orthopaedic manual therapy (Maitland and Mulligan)
3491644|NCT05175586|Active Comparator|Group 2|15 patients in the experimental group of orthopaedic manual therapy (Maitland and Mulligan).
3491645|NCT05175573|Experimental|SuperNO2VA Et|Continuous positive airway pressure with end-tidal CO2 monitoring
3491646|NCT05175573|Active Comparator|Supplemental Oxygen Face Mask|
3491647|NCT05175547|Active Comparator|Intensive blood pressure management group|Target blood pressure of 90-120mmHg (Intensive BP management group)
3491648|NCT05175547|Active Comparator|Standard blood pressure management group|Target blood pressure of 90-160mmHg (Standard BP management group)
3491649|NCT05175521|Placebo Comparator|Eucalyptus Oil Scent|Eucalyptus oil diluted in mineral oil 1:20
3491650|NCT05175521|Active Comparator|Isopropyl Alcohol Vapors|Isopropyl Alcohol 70%
3491651|NCT05175508|Experimental|Azacytidine Combined With ARTA|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle with ATRA 20mg tid by po on days 1-21 of every cycle 28 days
3491652|NCT05175508|Experimental|Azacytidine|Azacytidine 75mg/m2/d by IV on days 1-7 of every cycle
3491653|NCT05175495||Normal young|Aged less than 45 years old,no underlying heart disease
3491654|NCT05175495||Young people diagnosed with coronary heart disease|Aged less than 45 years old,Diagnosed coronary heart disease;Confirmed by coronary angiography;Diagnosed myocardial infarction;Typical symptom of ischemic chest pain with positive stress test;
3491655|NCT05175495||Coronary heart disease|Older than 65 years, diagnosed with coronary heart disease
3491656|NCT05175482|Experimental|Education received group|Health belief model based education on HPV infection and vaccination
3129481|NCT03222427|Experimental|[13C415N3] LY3314814|Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion.
3491657|NCT05175482|No Intervention|Control Group|No virtual education
3129482|NCT03222505|Experimental|Treadmill|
3491658|NCT05175456|Experimental|Bedjet arm|All participants will complete a baseline study period of 4 weeks and then will be provided the Bedjet system.
3491659|NCT05175443|Experimental|Exercise Intervention|"Wall Angels:Stretching tight anterior shoulder musculature Participants will assume this position and slide their arms up and down the wall for 2 minutes.~Cervical Spine Mobility: will be accomplished by having the participant stabilize their shoulders and side bend their head in various positions to stretch each side of theiir next for 2 minutes with 10-15 second holds in each position.~Posterior shoulder strengthening: will be performed with shoulder externally rotating and squeezing the scapular with 5 second holds for 2 minutes.~Thoracic Spinal mobility: to improve thoracic extension participants will use a strap or tennis ball and perform thoracic extension with 10 second holds for 2 minutes."
3491660|NCT05175430|Active Comparator|Pretreatment with paroxetine|Pretreatment with paroxetine (10 mg daily for 1 week followed by 20 mg daily for 5 weeks, per os), followed by administration of LSD (0.1 mg, per os) on the study day
3491661|NCT05175430|Placebo Comparator|Pretreatment with placebo|Pretreatment with placebo for 6 weeks (mannitol, per os), followed by administration of LSD (0.1 mg, per os) on the study day
3491662|NCT05175417||Case|Patients being considered for functional neurosurgical procedures, such as deep brain stimulation (DBS), radiofrequency ablation (RFA), gamma knife radiosurgery (GKR), or magnetic resonance-guided focused ultrasound (MRgFUS).
3491663|NCT05175417||Control|Healthy control volunteers.
3491664|NCT05175391|Active Comparator|Meat based protein, no spice|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, with whole wheat crackers and grapes as side items.
3491665|NCT05175391|Experimental|Meat based protein, spice added|Test meal will be a chicken salad entree consisting of shredded skinless chicken breast, mayonnaise, lemon juice, celery, salt and pepper, onion powder, garlic powder, dill and ground mustard seed, served with whole wheat crackers and grapes as side items.
3491666|NCT05175391|Active Comparator|Plant based protein, no spice|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, served with whole wheat crackers and grapes as side items.
3491667|NCT05175391|Experimental|Plant based protein, spice added|Test meal will be a chick pea and rice salad entree consisting of chick peas, brown rice, mayonnaise, yogurt, lemon juice, celery, soy protein powder, salt and pepper, onion powder, garlic powder, cumin, parsley, dill, oregano, ground rosemary and ground mustard seed, served with whole wheat crackers and grapes as side items.
3491668|NCT05175378|Active Comparator|Intervention arm|In the intervention group, MS women received a personalized daily eating plan (specific meals, recipes, food portions) together with nutritional consultation on the Meditteranean dietary pattern, as well as physical activity guidelines. All essential aspects of the dietary plan e.g. daily energy expenditure, classification of physical activity based on the concept of metabolic equivalent (MET), caloric adjustment according to nutritional status, and macronutrient distribution were calculated by a Clinical Decision Support System (CDSS). Body mass index (BMI) was also calculated, as the ratio of reported weight (kg) to the square of height (m2). Co-existed health issues, such as constipation or esophageal reflux, were taken into consideration. All MS patients acquired personal login passwords that allowed them to get access to their personal CDSS account and track their progress in regards to body weight, physical activity, and healthy food choices consumption.
3491669|NCT05175378|Sham Comparator|Control arm|"Patients of the control group received general dietary advice and physical activity recommendation that was in accordance with the National Dietary Guidelines for Greek adults"
3491670|NCT05175365|Experimental|Dance|Patients allocated to this group will attend dance classes for patients with Parkinson's desease given once a week over a 4-month period for a total of 16 dance sessions.
3491671|NCT05175365|No Intervention|Control|The control group will receive its rehabilitation care.
3491672|NCT05175352|Experimental|Administration of Cendakimab and Cytochrome P450 (CYP) substrates|
3491673|NCT05175313||normal people|people who don't complain of respiratory diseases will be examined by chest ultrasound and pulmonary function test.
3491674|NCT05175313||obstructive respiratory diseases|the patients who are diagnosed with either COPD or asthma.
3491675|NCT05175313||restrictive respiratory diseases|patient with either ILD
3491676|NCT05175300|Experimental|Group 1|Prosthesis with a second-generation ceramic-on-highly cross-linked polyethylene (CoPXE) couple.
3491677|NCT05175300|Active Comparator|Group 2|Prosthesis with ceramic-on-ceramic (CoC) torque.
3491678|NCT05175274|Experimental|Intervention Group|colchicine 0.5mg every 24 hours for 12 months
3491679|NCT05175274|Placebo Comparator|Control Group|1 placebo tablet every 24 hours for 12 months
3491680|NCT05175248|Experimental|Plant-based Intervention Group|Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
3491681|NCT05175248|No Intervention|Control Group|Control group participants will be asked to maintain their usual diet for the duration of the 12-week study period. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant. At the conclusion of the 12 weeks, control group participants will be offered instruction in the plant-based diet.
3491682|NCT05175235|Experimental|CURATE.AI|"Participants will undergo two treatment periods: selection period and CURATE.AI modulation period. During the selection period, baseline ctDNA measurements and CT scans will be performed. Subsequently, participants will receive Standard of Care (SOC) doses of nivolumab and have their ctDNA measured at the end of the third cycle together with other SOC monitoring.~After the first ctDNA measurement and CT scan, selected patients who responded to treatment through both ctDNA and CT scan may continue into the CURATE.AI modulation period. Non-responders will receive SOC doses of nivolumab for 2 cycles before having their ctDNA measured and CT scan at the end of the 2 cycles. Subsequent responders through both ctDNA and CT scans may then continue into the CURATE.AI modulation period.~Only the dose of nivolumab will be modulated with CURATE.AI, based on measurements of the response marker (ctDNA)."
3491683|NCT05175222|Experimental|Laser|Patients receive low-level laser therapy with LightWalker laser from the first day of conditioning chemotherapy till +2 day post hematopoietic stem cell transplantation. Additionally, standard supportive care is introduced.
3491684|NCT05175222|No Intervention|Control|Patients are observed and receive standard supportive care.
3491685|NCT05175209|Other|Electromyelography|
3491686|NCT05175196|Experimental|Pediatric Participants with GAS|"Children age 5-17 years old diagnosed via standard Rapid Antigen Detection Test with acute pharyngitis caused by Group A Streptococcus (GAS), along with their parent or legal guardian (aka caregiver)."
3491687|NCT05175170|Experimental|Decision-aid|Participants will spend up to one hour freely navigating the web-based decision aid. They will complete pre- and post-test measures to determine if using the decision-aid website increased knowledge and impacted decision self-efficacy regarding fertility and fertility preservation.
3491688|NCT05175157||General practitioner|Answer the Gut Fellings questionnaire
3491689|NCT05175157||Internal|Answer the Gut Fellings questionnaire
3491690|NCT05175131|Experimental|Mebeverine+Simethicone combination|three times a day per os
3491691|NCT05175131|Active Comparator|mebeverine|three times a day per os
3491692|NCT05175131|Active Comparator|simethicone|80 mg (2 capsules 40 mg) three times a day per os
3491693|NCT05175118|Other|Minimally invasive fixation|Minimally Invasive Surgical Fixation for Unstable Fractures of the distal end Radius in Adults
3491694|NCT05175105|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
3491695|NCT05175105|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 12 weeks in the fixed-dose period.
3491696|NCT05175105|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the open-label extension period will receive both mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment.
3491697|NCT05175092|Experimental|Intent to Treat: LDLT|Living Donor Liver Transplantation
3491698|NCT05175092|No Intervention|Control Group|Enrolled but does not receive LDLT
3491699|NCT05175079|Experimental|Accupressure group|"acupressure band apply to P6 (nei guan) point which located three fingers below the skin wrinkles of the anterior wrist.~Acupressure band wear 3 times daily before breakfast, lunch and dinner for at least 10 minutes"
3491700|NCT05175079|Placebo Comparator|Control group|
3491701|NCT05175066|Experimental|Bisoprolol|40 patients who were given bisoprolol at a dose of 1.25 mg daily, and in the absence of clinical symptoms and heart rate above 60 and systolic blood pressure above 100, 1.25 mg was added to the therapeutic dose every 2 weeks to reach 5 mg daily.
3491702|NCT05175066|Placebo Comparator|Placebo|Two placebo tablets in similar shape and color to bisoprolol were given on a daily basis to each of the 40patients as the control group.
3491703|NCT05175053|Experimental|Early RRT group|Patients who will undergo renal replacement therapy (RRT) within 6 hours of diagnosis of stage 2 acute kidney injury (AKI).
3491704|NCT05175053|Active Comparator|Delayed RRT group|Patients who will undergo renal replacement therapy (RRT) if one of the absolute indications for RRT is present.
3491705|NCT05175040|Experimental|Prophylactic manual rotation|Prophylactic manual rotation involves a vaginal examination performed with an obstetric provider's hands to turn the baby from a position in which the baby's face is looking up in the direction of the ceiling (occiput posterior) or to the side (occiput transverse) to a position in which the baby's face is looking down in the direction of the mother's spine (occiput anterior). Prophylactic manual rotation will occur at the initiation of pushing once the individual achieves complete cervical dilation.
3491706|NCT05175040|Sham Comparator|Sham rotation|Sham rotation involves a vaginal exam that obstetric providers commonly do with their hands to assess cervical dilation and fetal position during routine labor, and will occur at the initiation of pushing once the individual achieves complete cervical dilation.
3491707|NCT05175027|Active Comparator|Hypochlorosis|Hypochlorosis was used as an antiseptic for the patients
3491708|NCT05175027|Active Comparator|Povidone iodine|Povidone iodine was used as an antiseptic for the patients
3491709|NCT05175014|Experimental|Single full dose of PCV 10|27 clusters randomized to receive a vaccination campaign with the full dose.
3491710|NCT05175014|Experimental|Single fractional dose of PCV10 (1/5)|27 clusters randomized to receive a vaccination campaign with the fractional dose (1/5).
3129483|NCT03222505|Experimental|Overground Walking|
3129484|NCT03222583|Experimental|Glecaprevir/Pibrentasvir|"Participants received oral glecaprevir/pibrentasvir (300 mg/120 mg) once daily with food for 8 or 16 weeks during the double-blind (DB) treatment period.~Participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
3491711|NCT05175014|No Intervention|Control Group|9 clusters randomized to the control arm.
3491712|NCT05175001|Placebo Comparator|Group R|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine in saline was administered under real-time ultrasound monitoring
3491713|NCT05175001|Experimental|Group RD|The patient is placed in lateral decubitus position with the operative side facing up, and the thoracic paravertebral nerve block will be performed under ultrasound. We select T4-5,T6-7and T8-9 intervertebral spaces for puncture.A 30-mL bolus of a solution of 0.33% ropivacaine plus 4.67mg Diprospan in saline was administered under real-time ultrasound monitoring
3491714|NCT05174988|Experimental|Angle stitch|"If the allocation corresponds to Angle stitch, surgeon will use 0 polyglactin 910 suture on a tapered needle to place figure of 8 sutures on both (left and right) apexes. Knot tying technique (intra-corporeal vs extracorporeal) will be up to surgeon preference. After this is completed, barbed suture will be used to re-approximate the remainder of the vaginal cuff from right to left, backtracking once at the end for reinforcement."
3491715|NCT05174988|No Intervention|control|"If the subject's group corresponds to Control group, the surgeon will re-approximate the cuff in a standard fashion, using a running-barbed suture (2-0 V-LOC 90 with tapered needle), starting at the right apex, moving towards the left, and then back-tracking once to further reinforce the closure."
3491716|NCT05174975|Experimental|App-based Positive Psychological Intervention group|The intervention will be conducted on the app, including 2-week PPI, diabetes-related health education, physical records, and online consultation.
3491717|NCT05174975|No Intervention|control group|usual care which will educated by certificated educators in terms of self-management
3491718|NCT05174949|Experimental|Anodal stimulation|Anodal stimulation targeting hemisphere
3491719|NCT05174949|Experimental|Cathodal stimulation|Cathodal one at the contralesional hemisphere
3129485|NCT03222583|Experimental|Placebo / Glecaprevir/Pibrentasvir|"Participants received placebo to glecaprevir/pibrentasvir for 8 or 16 weeks during the DB treatment period followed by glecaprevir/pibrentasvir (300 mg/120 mg) once daily for 8 or 16 weeks during the open-label (OL) treatment period.~In each period participants received treatment for 8 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks."
3129486|NCT03223246|No Intervention|Usual care|
3129487|NCT03223246|Experimental|Additional teaching|
3129488|NCT03223272|Experimental|Reserpine|Subjects will receive open-label reserpine 0.1 mg daily for 4 weeks.
3491720|NCT05174949|Experimental|Sham stimulation|Sham stimulation to the brain
3129489|NCT03223337|Experimental|Subjects with moderate hepatic impairment: Part 1|Approximately 8 subjects with moderate hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 7, one with a score of 8 and one with a score of 9. The group will also include at least one female and at least one male subject.
3129490|NCT03223337|Active Comparator|Matched Healthy controls: Part 1|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with moderate hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
3180082|NCT00679588|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium (placebo for Semuloparin sodium 8 hours after surgery to maintain the blind)
3491721|NCT05174936|Experimental|PLWH intervention sessions|The PLWH in this arm will receive five 2-hour intervention sessions delivered over five weeks (one session per week) in the clinics. Two trained facilitators will deliver the materials through interactive trainings that include multimedia presentations, group discussions, role-play, personal testimonies, and/or games. The same two facilitators will deliver all five sessions within a clinic to increase group cohesion and rapport with PLWH. The goal of this intervention is to assist PLWH in identifying and developing internal and external resilience resources to aid in coping HIV stigma.
3491722|NCT05174936|Experimental|Family member intervention|The intervention sessions for family members will be similar to PLWH sessions in terms of format and content and will be led by trained facilitators. Family member intervention sessions will emphasize supporting PLWH to cope with HIV-related stigma and to improve their clinical outcomes. The goal of this intervention is to provide social support for PLWH's resilience building as well as foster resilience at the family level.
3491723|NCT05174936|Experimental|Health care provider intervention|The HCP intervention curriculum consists of four 1.5-hour sessions (e.g., one per week) that will be delivered in small groups in the clinic setting by trained facilitators (e.g., health educators from Guangxi CDC). The delivery schedule and format will be flexible and individually tailored (e.g., four sessions can be given one per week or consolidated into two longer sessions). The goal of this intervention is to reduce the institutional stigmatizing attitudes and practices toward PLWH and other social identities, such as MSM, sex workers, and drug users, and improving the provider-patient relationships.
3491724|NCT05174923||Age Range 45 to </= 60|
3491725|NCT05174923||Age Range 61 to </= 75|
3491726|NCT05174923||Age >/= 76|
3491727|NCT05174910|Active Comparator|With Obsidian ASG|Anastomosis treatment using standard procedure and Obsidian ASG
3491728|NCT05174910|No Intervention|Without Obsidian ASG|Anastomosis treatment using standard procedure
3491729|NCT05174897|No Intervention|Control Group|The child for whom an intravenous catheter will be applied will be placed on a stretcher and pain and fear will be evaluated before the procedure. Afterwards, an intravenous catheter will be applied. Pain and fear scores will be evaluated during and after the procedure.
3491730|NCT05174897|Experimental|Experimental group|The child to whom an intravenous catheter will be applied is placed on a stretcher. After evaluating the pain and fear score before the procedure, emotional liberation technique (EFT) is performed for 10 minutes. followed by an intravenous catheter. Pain and fear scores are evaluated during and after the procedure.
3491731|NCT05174884|Experimental|Single Casea S pellet|In Part 1 of this study, four women will each have a single Casea S pellet (22.2 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
3491732|NCT05174884|Experimental|Two Casea S pellets|In Part 2 of this study, eight women will each have two Casea S pellets (44.4 mg ENG) inserted into the inner aspect of the non-dominant upper arm.
3491733|NCT05174884|Experimental|Variable Casea S pellets|Based on PK modeling from Parts 1 and 2, the investigator will select one or more doses of Casea S for Part 3. In Part 3 of this study, approximately 18 women will each have Casea S pellets (range 1-3 pellets) inserted into the inner aspect of the non-dominant upper arm.
3491734|NCT05174871|Active Comparator|Active control|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months
3491735|NCT05174871|Experimental|Time-Restricted Feeding|Participants in this arm will receive the usual treatment for obesity at our hospital, based on lifestyle changes (encouraging a healthy diet and physical activity) for 2 months. During this time, participants will have their feeding time restricted to 8 hours per day.
3491736|NCT05174858|Experimental|Device under investigation|intra-alveolar placement of ETIK COLLAGENE immediately after tooth extraction.
3491737|NCT05174858|Other|Comparator|the alveolus is left empty after tooth extraction.
3491738|NCT05174832|Active Comparator|Cisplatin+ Nab-paclitaxel + Pembrolizumab followed by Pembrolizumab monotherapy|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab monotherapy as maintenance therapy
3491739|NCT05174832|Experimental|Cisplatin+Nab-paclitaxel+Pembrolizumab followed by Pembrolizumab+Olaparib|4~6 cycles combination therapy of Cisplatin, Nab-paclitaxel and Pembrolizumab as induction therapy; Pembrolizumab plus Olaparib as maintenance therapy
3491740|NCT05174806|Experimental|MBN-101 topical|MBN-101 at a dose of 2.5 mg/mL will be applied directly to the infected wound and covered with an appropriate non-antimicrobial dressing. Dosing will be daily for the first week followed by 3 times per week for an additional 11 weeks.
3491741|NCT05174806|Other|Standard of Care|Standard of care treatment without administration of any topical drugs.
3491742|NCT05174793|Experimental|dehydration to rehydration|subjects were rehydrated following 2% dehydration
3491743|NCT05174793|Experimental|euhydration to dehydration|subjects were dehydrated by 2% with exercise in the heat
3491744|NCT05174767|Experimental|Acute DeBakey Type I Dissection|
3491745|NCT05174754|Experimental|Inflammatory Bowel Disease Exercise Group|The exercise group will be randomized to a 20-week physician-prescribed exercise programme following the principles of Frequency, Intensity, Time, and Type (FITT) in addition to best medical therapy with the aim of increasing physical fitness levels, inflammatory response, quality of life/fatigue improvements and favorable body composition changes.
3491746|NCT05174754|Other|Inflammatory Bowel Disease Control Group|The IBD control group will be randomized to best medical therapy alone.
3491747|NCT05174754|No Intervention|Healthy Control Group|A group of healthy controls without inflammatory bowel disease will be included in the study for comparison of inflammatory markers including cytokine analysis and body composition.
3491748|NCT05174741|Active Comparator|Conventional Chest Physiotherapy|Diaphragmatic Breathing exercise 15 repetition ACBT *3 sets/session*TD Walk (10-15 minutes) * BD
3491749|NCT05174741|Experimental|Aerobic Training group|"Supervised Conventional chest physiotherapy+ Aerobic training Conventional chest physiotherapy supervised (1st week) Then non supervised for 2nd to 6th week Warm-up (5 minutes) Breathing exercise and stepping Diaphragmatic Breathing exercise *15 Reps* TD~Aerobic training on cycle ergometer:~between 50% and 70% Vo2max, perceived exertion up to 11 on Borg scale 20-30 min/session/day Cool down (5 minutes) AROM +Body stretch"
3491750|NCT05174702||Percutaneous surgery|Patient will have a percutaneous hallus valgus surgery
3491751|NCT05174702||conventional surgery|Patient will have a conventional hallus valgus surgery
3491752|NCT05174689|Other|EIA wih house dust mite|Patients with EIA and house-dust mite allergy and an eNO > 30 ppb
3491753|NCT05174689|Other|EIA without sensitization|Patients with EIA without allergic sensitization and an eNO < 20 ppb
3491754|NCT05174689|Other|Healthy controls|Healthy controls without allergic sensitization or known asthma
3491755|NCT05174676|Experimental|Intervention|The participant will receive 6 therapy sessions of approximately 25 minutes each WITH the application of error enhancement.
3491756|NCT05174676|Sham Comparator|Control|The participant will receive 6 therapy sessions of approximately 25 minutes each WITHOUT the application of error enhancement.
3491757|NCT05174663|Experimental|Almond-enriched diet dose 1|Participants will be instructed to ingest 1.5 oz of almonds daily for 16 weeks. The 1.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take their missed dose as soon as they remember.
3491758|NCT05174663|Experimental|Almond-enriched diet dose 2|Participants will be instructed to ingest 2.5 oz of almonds daily for 16 weeks. The 2.5 oz of almonds can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of almonds daily. If a dose is missed, participants should take their missed dose as soon as they remember.
3491759|NCT05174663|Other|Nut-free diet|Participants will be instructed to ingest the control snack (Iso-caloric [to 1.5 oz of almonds] control snack of chocolate chip cookies or Oreo cookies) daily for 16 weeks. The control snack can be split into a morning and afternoon snack. Participants will be advised not to exceed 2 doses of snack daily. If a dose is missed, participants should take their missed dose as soon as they remember.
3491760|NCT05174650|Experimental|Combined treatment with Atezolizumab and Derazantinib|Treatment with Atezolizumab 1200 mg i.v. every 3 weeks and Derazantinib 300 mp p.o. once daily for a maximum of 96 weeks or until disease progression or unacceptable toxicity or study termination
3491761|NCT05174637|Experimental|FDA018-ADC 2.5mg/kg|Subjects will receive FDA018-ADC 2.5 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3491762|NCT05174637|Experimental|FDA018-ADC 5.0mg/kg|Subjects will receive FDA018-ADC 5.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3491763|NCT05174637|Experimental|FDA018-ADC 7.5mg/kg|Subjects will receive FDA018-ADC 7.5 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3491764|NCT05174637|Experimental|FDA018-ADC 10.0mg/kg|Subjects will receive FDA018-ADC 10.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3180083|NCT00679614|Experimental|1|Group A oral tramacet 2 tablets preoperatively, 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. Naloxone infusion starting preop at 0.25ug/kg/hr and continuing during hospital stay (an equivalent of 400ug over 24 hours in a 70 kg man). The infusion will be discontinued 1 hour before patient discharge.
3491765|NCT05174637|Experimental|FDA018-ADC 12.0mg/kg|Subjects will receive FDA018-ADC 12.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle(Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3491766|NCT05174637|Experimental|FDA018-ADC15.0mg/kg|Subjects will receive FDA018-ADC 15.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3129491|NCT03223337|Experimental|Subjects with either mild or severe hepatic impairment: Part 2|Approximately 8 subjects with mild or severe hepatic impairment will receive 6 mg of daprodustat as a single oral dose in the fasted state. This group will include at least one subject with a Child-Pugh score of 5 and one with a score of 6 for mild hepatic impairment and at least one subject with a Child-Pugh score of 10 or 11 and one with a score of 12 or 13 for severe hepatic impairment. The group will also include at least one female and at least one male subject.
3180084|NCT00679614|Active Comparator|2|Group B will receive oral tramacet 2 tablets preoperatively and then 2 tablets every 6 hours for five days. ( or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). This group will also receive saline infusion at 4-6mls / hour for the duration of the hospital stay.
3491767|NCT05174637|Experimental|FDA018-ADC 18.0mg/kg|Subjects will receive FDA018-ADC 18.0 mg/kg of body weight via intravenous (IV) infusion on Day 1, 15 and 22 of a 35-Day cycle (Cycle 1) and on Day 1 and 8 of a 21-day cycle (Cycle 2 ~ Cycle 5) in dose escalation phase, and on Day 1 and 8 of a 21-day cycle (Cycle 1 ~ Cycle 6) in dose expansion phase, and Day 1 and 8 of a 21-day cycle in follow-up period until disease progression, unacceptable toxicity or death.
3491768|NCT05174624||FAMILY Cohort|This Cohort was part of a prospective population-based study in 2007, consisting of 46,001 participants in Hong Kong. It was the first large-scale programme to understand the determinants of physical, mental, and social wellbeing in Hong Kong. The Cohort has an excellent (99.8%) coverage of the neighbourhoods in Hong Kong and represents roughly 1% of all households, which enables detailed studies linking the social environment to physical and mental health.
3491769|NCT05174611|Experimental|Treatment group|Subject in treatment group will receive one capsule of 2000IU Vitamin D3 supplement per day with the duration of 16 weeks.
3491770|NCT05174611|Placebo Comparator|Placebo group|Subject in placebo group will receive one capsule of placebo per day which looks exactly same as the Vitamin D3 capsule with the duration of 16 weeks.
3491771|NCT05174598|Experimental|Calcipotriol/AKVANO, 50 μg/g cutaneous solution|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
3491772|NCT05174598|Active Comparator|Calcipotriol Ointment 50 micrograms/g, Sandoz|Ointment applied topically, twice daily, for the duration of 8 weeks.
3491773|NCT05174598|Placebo Comparator|Placebo|Spray formulation applied topically, twice daily, for the duration of 8 weeks.
3491774|NCT05174585|Experimental|Arm A, JAB-BX102 monotherapy, Phase 1, Dose Escalation|Dose escalation of JAB-BX102 will be administered as monotherapy to determine the MTD and RP2D.
3491775|NCT05174585|Experimental|Arm B, JAB-BX102 combination with pembrolizumab, Phase 2a, Dose Expansion|JAB-BX102 will be administered in combination with pembrolizumab in specific solid tumor patients to evaluate the preliminary antitumor activity.
3491776|NCT05173506||Adolescent Depression Screening|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10:G40)~Age > 12 years at last visit (before CHICA-CN)~Computer assistant depression screening and management"
3491777|NCT05173506||Genetic Testing|"> 3 visits to clinic~Diagnosis of global developmental delay - International Classification of Diseases, Tenth Revision - autistic disorder (ICD-10: F84)~Age < 6 years at last visit (before CHICA-CN)~Computer reminders to test for genetic disorders"
3491778|NCT05173506||Rescue seizure therapy|"> 3 visits to clinic~Diagnosis of epilepsy - International Classification of Diseases, Tenth Revision - Epilepsy and recurrent seizures (ICD-10: G40)~Age < 18 years at last visit (before CHICA-CN)~Computer reminders to prescribe and adjust rescue anti-seizure medications"
3491779|NCT05173506||Adolescent Transition|"> 3 visits to clinic~Age > 13 years at last visit (before CHICA-CN)~Computer supported screening and counseling regarding transition to adult care"
3491780|NCT05173441|Experimental|High Dose Group|Standard of care (SOC)+high dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
3491781|NCT05173441|Experimental|Low Dose Group|Standard of care (SOC)+low dose COVID-HIG. COVID-HIG will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
3491782|NCT05173441|Placebo Comparator|Control Group|Standard of care (SOC)+placebo (0.9% sodium chloride). Placebo will be administered via intravenous infusion. once a day, for three consecutive days (Day 0, day 1, and Day 2). And it could be administered again for 1-2 days according to the clinical improvement of subjects, and the total number of infusions should not exceed5 times.
3491783|NCT05173428|Experimental|Interventional Gruop|Online motivational interviews based on the transtheoretic model with the intervention group will be held via zoom. Data collection forms will be applied to the intervention group at the first interview, at the 3rd month as an interim monitoring, and at the 6th month as the final monitoring.
3491784|NCT05173428|No Intervention|Control Gruop|No intervention will be made to the control group, and data collection forms will be applied at the first interview and 6 months after the first interview.
3491785|NCT05172492|Experimental|Endocare|
3491786|NCT05172492|Active Comparator|Digital control|
3491787|NCT05172271|Sham Comparator|Sham TEST|Anesthesia alone
3491788|NCT05172271|Experimental|Transcranial Electric Stimulation Therapy (TEST)|TEST involves bifrontal electrical brain stimulation at a dose below the seizure threshold, applied in the same manner as standard electroconvulsive therapy (ECT), with scalp electrodes, under anesthesia, using a standard ECT device (modified or unmodified) that can deliver a range of doses below seizure threshold.
3491789|NCT05170919|Experimental|Olanzapine|
3491790|NCT05170919|Experimental|Mirtazapine|
3491791|NCT05170425||Cohort 1|
3491792|NCT05170425||Cohort 2|
3491793|NCT05170412||Patients|outpatient adults with the diagnosis of Sickle Cell Disease
3129492|NCT03223337|Active Comparator|Matched healthy controls: Part 2|Approximately 8 healthy controls, matched in gender, age and BMI to subjects with mild or severe hepatic impairment, will receive 6 mg of daprodustat as a single oral dose in the fasted state. The group will include at least one female and at least one male subject.
3129493|NCT03223649|Experimental|Sedentary|(Control intervention) Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
3180085|NCT00679614|Active Comparator|3|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay.
3180086|NCT00679640||1|Outpatients to whom candesartan has been initiated for less than 30 days or during the consultation to treat heart failure
3491794|NCT05170399|Experimental|CLL -1|Treatment Naive
3491795|NCT05170399|Experimental|CLL-2|Not Receiving Active Treatment
3491796|NCT05170399|Experimental|CLL-3|Treatment with BTKi (n=25)
3491797|NCT05170399|Experimental|CLL-4|Treatment Break for BTKi Therapy (n=25)
3491798|NCT05170399|Experimental|CLL-5|Treatment with B-cell lymphoma 2 (BCL-2) Inhibitor (n=25)
3491799|NCT05170399|Experimental|FL-1|Treatment Naive
3491800|NCT05170399|Experimental|FL-2|Treatment with Targeted Therapies (n=25)
3491801|NCT05170399|Experimental|Other NHL and WM Arms-1|Treatment Naive
3491802|NCT05170399|Experimental|Other NHL and WM Arms-2|Treatment with Targeted Therapies (n=25)
3491803|NCT05170399|Experimental|Pfizer-COVID-19 Vaccine|Treatment with Targeted Therapies (n=25
3491804|NCT05170386|Experimental|study group|receive cognitive training combined with instructive conventional treatment for sleeping disorder
3491805|NCT05170386|Experimental|control group|receive instructive conventional treatment for sleeping disorder
3491806|NCT05169710|Experimental|SEP-4199 CR 200 mg|SEP-4199 CR 200 mg/day
3491807|NCT05169710|Experimental|SEP-4199 CR 400 mg|SEP-4199 CR 400 mg/day
3129494|NCT03223649|Experimental|Walking bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
3129495|NCT03223909|Experimental|PRO-087 PF|Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
3491808|NCT05169710|Placebo Comparator|Placebo|Placebo
3491809|NCT05167305||liver disease without COVID-19 infection-April-May 2019|
3491810|NCT05167305||liver disease without COVID-19 infection -April- May 2021|
3491811|NCT05166252|Experimental|Experimental group|"Installation of the study app.~At the beginning of the meal, participants press a button within the App to start a time out from the smartphone at the beginning of a meal (i.e. calls and message are blocked and participants need to press an extra button in order to leave the app). The app instructs all other family members to turn off their phones and to put them away. Then, the participants are instructed to take a picture with their smartphone from the meal table.~A time out from the smartphone starts, meaning that all functions of the phone are locked. The time-out is over as soon as the participant presses the stop button.~A short questionnaire about the meal is sent via App to the participating family member when the smartphone is used again.~During the whole period of the study the App tracks the smartphone behavior (i.e., frequency and duration of smartphone use and the specific applications used). Active comparator: control group"
3491812|NCT05166252|Active Comparator|Control group|Control points in time include all parts as in the experimental group except for number 3.
3491813|NCT05165160|Experimental|Eligible patients|
3491814|NCT05163184||Laparotomy|Patients undergoing laparotomy
3491815|NCT05160584||Participants with Relapsed/Refractory Multiple Myeloma|Participants with relapsed/refractory multiple myeloma (RRMM) receiving antimyeloma treatment as standard of care (SOC) under routine clinical practice will be observed. The primary data source will be medical records of each participant.
3491816|NCT05160142|Experimental|Intervention|Participate in the DICE program, which entails culinary and diabetes educational programming delivered weekly for 10 consecutive weeks.
3491817|NCT05158855|Experimental|neutralizing antibody booster for vaccinated participants|participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract
3491818|NCT05157724||PLASMA|This technique consists of an endoscopic intervention, through the natural route (urethra).
3491819|NCT05157724||HOLEP|"This is a recent and difficult technique of endoscopic prostate enucleation, requiring a greater learning curve for the operators compared to PLASMA. The principle remains the same technically as the PLASMA procedure, the energy used is not electrical energy, but a laser.~Once the adenoma has been enucleated, it can only be removed by a morcellator (additional material) which can lead to complications such as bladder perforation. This is a blade that rotates in a tube that has to cut the adenoma once it has been freed from the prostate when it is in the bladder and it can happen that this blade catches on the bladder wall and causes a bladder wound or even a perforation."
3491820|NCT05156684|Experimental|placebo group|Control group: oral rehydration salts (ORS, Poursina, Tehran, Iran), two times daily
3491821|NCT05156684|Experimental|pentoxifylline group|Intervention group 1: received pentoxifylline (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily)
3491822|NCT05156684|Experimental|Zinc group|Intervention group 2: received zinc ( Zinc Sulfate 220mg Capsules,One time daily)
3491823|NCT05156684|Experimental|pentoxifylline+ zinc group|Intervention group 3: received pentoxifylline+ zinc (TRENTAL 400 mg modified release tablets, OSPS; 400 mg ,two times daily + Zinc Sulfate 220mg Capsules,One time daily )
3491824|NCT05156619||Cohort#1|new annual breast cancer cases and cases of recurrence at Hadassah University hospital between 2018-2021 (700)
3491825|NCT05156619||Cohort#2|Retrospective study - all clinical trial patients in the Sharett institute of oncology between 1.1.12-30.6.21 (300)
3491826|NCT05156619||Cohort#3|all newly diagnosed recurrent/metastatic disease during the study period (200)
3491827|NCT05156398|Active Comparator|Rimegepant / BHV3000|Rimegepant 75mg or 50mg (2 X 25mg) ODT
3491828|NCT05156398|Placebo Comparator|Matching Placebo|Matching placebo 75mg or 50mg (2 X 25mg) ODT
3491829|NCT05156047|Active Comparator|Pitolisant|"Dose Optimization Period:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 6: 17.8 to 35.6 mg pitolisant administered once daily in the morning.~Stable Dose Period:~Weeks 7 through 8: Stable dose of 17.8 or 35.6 mg pitolisant administered once daily in the morning.~Double-Blind Randomized Withdrawal Phase:~Weeks 9 through 12: Stable dose of 17.8 or 35.6 mg pitolisant administered once daily in the morning."
3491830|NCT05156047|Placebo Comparator|Matching Placebo|"Double-Blind Randomized Withdrawal Phase:~Weeks 9 through 12: Matching placebo tablets."
3491831|NCT05156034|Experimental|SRK-001- Dose 1|Participants will receive intravenous (IV) SRK-001 every 2 weeks (Q2W) for 4 doses.
3180087|NCT00679653|Active Comparator|1|verapamil/trandolapril
3491832|NCT05156034|Experimental|SRK-001- Dose 2|Participants will receive IV SRK-001 every 4 weeks (Q4W) for 2 doses.
3491833|NCT05156034|Experimental|SRK-001- Dose 3|Participants will receive IV SRK-001 Q2W for 4 doses.
3491834|NCT05156034|Placebo Comparator|Placebo|Participants will receive IV placebo Q2W for 4 doses or Q4W for 2 doses.
3491835|NCT05155709|Experimental|Arm 1: Unfit adult participants with AML who responded sub-optimally to standard of care|Unfit adult participants with AML who responded sub-optimally to at least 2 and not more than 4 cycles ( 1 cycle=28 days) of first-line venetoclax plus azacitidine therapy
3491836|NCT05155709|Experimental|Arm 2: Newly diagnosed unfit adult participants with high high-risk AML|Unfit adult participants with newly diagnosed AML and with adverse genetic risk stratification (according to ELN 2017)(Except TP53 mutation positive participants).
3491837|NCT05155540|Active Comparator|Direct mechanical thrombectomy|Direct mechanical thrombectomy performed within 4.5 of stroke onset without giving intravenous recombinant tissue plasminogen activator.
3491838|NCT05155540|Active Comparator|Bridging therapy|Mechanical thrombectomy performed within 4.5 of stroke onset after giving intravenous recombinant tissue plasminogen activator at a dose of 0.9 mg/Kg
3491839|NCT05155384|Experimental|biopsychosocial model-based treatment|Biopsychosocial model-based management will be applied including pain neuroscience education, functional exercises, and relaxation training.
3491840|NCT05155384|Active Comparator|Conventional physiotherapy|Conventional physiotherapy will be applied including standard exercises and electrical stimulation.
3491841|NCT05155254|Experimental|IO102-IO103 + pembrolizumab|"IO102-IO103 subcutaneous injections (85µg) every 3 weeks for a maximum 35 cycles. Additional dose given during the induction period on Day 8 of cycles 1 and 2. Each patient can be treated for a maximum of 37 administrations in total.~Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles."
3491842|NCT05155254|Active Comparator|pembrolizumab|Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles.
3491843|NCT05155059|Sham Comparator|Control|Sham TMS stimulation using a sham coil
3491844|NCT05155059|Experimental|Treatment|Active TMS stimulation using an active TMS coil
3491845|NCT05155046|Experimental|18F-DCFPyL imaging|18F-DCFPyL imaging with routine imaging (mpMRI)
3491846|NCT05155033|Experimental|1 - Pembro and IL-2|Course 1: pembrolizumab (200 mg IV) on Day 1 of each cycle with aldesleukin (600,000 IU/kg intravenous bolus every eight hours) continuing for up to 4 days (maximum 10 doses) for 2 cycles (each 21 days). Course 2: pembrolizumab (200 mg IV) on Day 1 of each cycle for 2 cycles (each 21 days).
3491847|NCT05154864||SBUF-SMUF|All patients underwent standard of care cardiac surgery, cardiopulmonary bypass and SBUF-SMUF with effluent removal of 30 ml/kg/hr and physiologic solution replacement of 25ml/kg/hr.
3491848|NCT05154669|No Intervention|Standard Smoking Cessation Coaching|Participants will receive 5 counseling sessions over approximately 8 weeks as per standard smoking cessation programs. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
3491849|NCT05154669|Experimental|Integrated Financial-Smoking Cessation Coaching|The integrated intervention will provide 5 counseling sessions over approximately 8 weeks that integrates financial coaching into the smoking cessation program. Participants will receive 8 weeks of nicotine replacement therapy (patches, gum, and/or lozenges).
3180088|NCT00679653|Active Comparator|2|metoprolol/HCT
3180089|NCT00679653|Active Comparator|3|felodipine/ramipril
3491850|NCT05154526|Experimental|Exercise Group|Exercise Program only
3491851|NCT05154526|Active Comparator|Manual Therapy Group|Manual Therapy only
3491852|NCT05154526|Active Comparator|Manual Therapy and Exercise Group|Manual Therapy + exercise program
3491853|NCT05153850||Cases|Patients diagnosed with inflammatory bowel disease with the complete vaccination regimen.
3129496|NCT03223909|Active Comparator|Systane Ultra|"Systane Ultra ophthalmic solution, Dropper bottle, Multidose.~1 drop every 4 hours for 90 days."
3491854|NCT05153655|Experimental|Ischemic post-conditioning group|The safety and tolerability of ischemic post-conditioning will be investigated using 3+3 dose-escalation trial design.
3491855|NCT05153642|Experimental|Microsurgical intervention|Microsurgical intervention will be used for treatment of acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment
3491856|NCT05153642|No Intervention|Standard treatment|Acute symptomatic occlusion of middle cerebral artery (in M1 or M2 segment) with or without intracranial ICA occlusion in patients who failed to reach recanalization using standard treatment - intravenous thrombolysis and/or mechanical thrombectomy
3491857|NCT05153525|Experimental|Intermittent boluses group|Thirty children with ARDS will be managed with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).
3491858|NCT05153525|Experimental|Intravenous infusion for 24 hours|Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.
3491859|NCT05153434|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
3491860|NCT05153096|Experimental|Experimental: solid tumors|"Dose-escalation stage: Patients will receive NBL-015 once every two or three weeks, starting at a dose of 1 mg/kg.~Cohort-expansion stage: Patients will receive NBL-015 at selected dose as per the results of dose-escalation stage."
3129497|NCT03223909|Active Comparator|Systane Ultra PF|"Systane Ultra, preservative free ophthalmic solution, single-use vials.~1 drop every 4 hours for 90 days."
3491861|NCT05152706|Experimental|Intervention aerobic (IAER)|Patients assigned to the IAER participated in fourty-eigth aerobic exercise therapy sessions over the course of six months.
3491862|NCT05152706|Experimental|Intervention photobiomodulation (IPBM)|Patients assigned to the IPBM participated in fourty-eigth transcraneal photobiomodulation (PBM) theraphy sessions, using a therapeutic laser console, over the course of six months.
3129498|NCT03224130|Experimental|Nurse Phone Call|Families in this arm will receive a phone call within 96 hours of discharge
3129499|NCT03224130|Active Comparator|Standard of Care|This arm will receive standard of care.
3180090|NCT00679666|Sham Comparator|Sham treatment|Subjects are randomized to control (sham) group or a treatment group with the control group crossed over to the treatment group at the 3 month visit.
3491863|NCT05152706|Experimental|Intervention aerobic and photobiomodulation (IAER+PBM9|Patients assigned to the IAER+PBM participated in the aerobic exercise therapy and the PBM one at the same time, during six months.
3491864|NCT05152706|No Intervention|Control (CO)|Patients assigned to the control (CO) did not participated in any kind of therapy, they just followed their usual weekly routine during six months
3491865|NCT05151380|Other|Women with CO2 laser MonaLisa Touch ® sessions|Women with 3 sessions of CO2 laser MonaLisa Touch ®
3491866|NCT05151146|Experimental|ANJ900 in the fasted state|Single dose (1800 mg) of ANJ900
3491867|NCT05151146|Experimental|ANJ900 in the fed state|Single dose (1800 mg) of ANJ900
3491868|NCT05151146|Active Comparator|Metformin IR in the fasted state|Single dose (1000 mg) of metformin IR
3491869|NCT05150678|Experimental|removal of cs scar|gruop 1 will remove the scar
3491870|NCT05150678|Experimental|non removal of the scar|gruop2 will not remove the scar
3491871|NCT05149781||patients with EH|patients with endocrine hypertension
3491872|NCT05149781||patients with PH|patients with primary hypertension
3491873|NCT05148637|Active Comparator|Group I|anesthesia maintained by sevoflurane
3491874|NCT05148637|Active Comparator|Group II|anesthesia maintained by desflurane
3491875|NCT05148637|Active Comparator|Group III|anesthesia maintained by TIVA
3491876|NCT05148286|Active Comparator|Treatment|For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1~2h for initial fluid resuscitation.
3491877|NCT05148286|Placebo Comparator|Control|For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice.
3491878|NCT05148234|Experimental|escalating dose of treatment for HR-MDS|escalating doses of BMS-986253 + DNMTi
3491879|NCT05148234|Experimental|escalating doses of treatment for LR-MDS|escalating doses of BMS-986253
3491880|NCT05148234|Experimental|phase II dose of BMS-986253 for HR-MD|phase II dose of BMS-986253 + DNMTi
3491881|NCT05148234|Experimental|phase II dose of BMS-986253 for LR-MDS|phase II dose of BMS-986253
3491882|NCT05148091|Experimental|18~59 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
3491883|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B ,0.5mL) on Day 0 and Day 28
3491884|NCT05148091|Placebo Comparator|18~59 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
3491885|NCT05148091|Experimental|≥60 yrs. low dosage (20 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of low dosage (20 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
3491886|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
3491887|NCT05148091|Placebo Comparator|≥60 yrs. low dosage (20 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
3491888|NCT05148091|Experimental|18~59 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of 18~59 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
3491889|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
3491890|NCT05148091|Placebo Comparator|18~59 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of 18~59 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
3491891|NCT05148091|Experimental|≥60 yrs. high dosage (40 μg) - SCTV01C VACCINE|20 participants in Phase I and 120 participants in Phase II at the age of ≥60 years old will receive two doses of high dosage (40 μg/0.5mL) SCTV01C VACCINE on Day 0 and Day 28
3491892|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Adjuvant (SCT-VA02B )|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of study adjuvant (SCT-VA02B, 0.5mL) on Day 0 and Day 28
3491893|NCT05148091|Placebo Comparator|≥60 yrs. high dosage (40 μg) - Saline|4 participants in Phase I and 20 participants in Phase II at the age of ≥60 years old will receive two doses of saline (0.5mL) on Day 0 and Day 28
3491894|NCT05147922|Experimental|Booster Training Group|Participants randomized to intervention will undergo booster training sessions with the RQI cart (including audiovisual feedback) at 3, 6 and 9 months post instructor-led training session. Following each of these booster sessions, the participants will undergo 1 minute assessments, without feedback.
3491895|NCT05147922|No Intervention|No Booster Training Group|Participants randomized to the control group will undergo 1 minute assessments, without feedback, at 6 and 9 months. Participants will not be able to access the RQI cart outside of their assessment.
3491896|NCT05147558|Experimental|Pembrolizumab With Lenvatinib|Lenvatinib (20mg once daily orally) in combination with Pembrolizumab (200mg every 3 weeks, intravenously)
3491897|NCT05147389||Neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm neoplastic bile duct lesion and the type: pCCA or dCCA, local extension of iCCA, hepatocarcinoma mixed CCA/hepatocarcinoma, gallbladder cancer, pancreas cancer, or any other neoplastic bile duct lesion. Based on follow-up, videos from patients with confirmed non-neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
3491898|NCT05147389||Non-neoplastic bile duct lesions|This group is confirmed by DSOC videos from patients with DSOC-confirmed non-neoplastic bile duct lesions, coming from each participating group. Each DSOC video corresponds to a complete DSOC procedure in a single patient. The non-neoplastic bile duct criteria are in accordance with the two following tools: the Robles-Medranda et al and the Mendoza classification. A further follow will be necessary to confirm non-neoplastic bile duct lesion and the type, when available: acute or chronic cholangitis secondary to stones or parasite's location, autoimmune cholestatic liver diseases as autoimmune sclerosant cholangitis, and primary biliary cholangitis. Based on follow-up, videos from patients with confirmed neoplastic bile duct lesions will be re-assessed and re-classified or finally excluded by an expert blinded to clinical records and who do not participate in videos classification.
3129500|NCT03224182|Experimental|Qapzola|Participants were randomized to receive a single dose of Qapzola 8 mg by intravesical administration into the bladder at 60 ± 30 minutes post transurethral resection of bladder tumor (TURBT) on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
3129501|NCT03224182|Placebo Comparator|Placebo|Participants were randomized to receive a single dose of Qapzole-matching placebo by intravesical administration into the bladder at 60 ± 30 minutes post TURBT on Day 1 via an indwelling 100% Silicone Foley catheter and retained in the bladder for 60 ± 5 minutes.
3129502|NCT03224234|Experimental|Insulclock with feedback (Group A)|Participants will use the Insulclock and receive daily information on their smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses. At midpoint (week 12), patients will be converted to the alternate arm.
3129503|NCT03224234|Active Comparator|Insulclock without feedback (Group B)|Participants will use the Insulclock, but will not receive feedback on insulin administration. At midpoint (week 12), patients will be converted to the alternate arm.
3491899|NCT05147116|Experimental|Hypoxia - 15% O2|Participants will sleep in a tent for 10 nights.
3491900|NCT05147116|Sham Comparator|Sham - room air 21% 02|Participants will sleep in a tent for 10 nights.
3491901|NCT05146596|Experimental|LLLT group|use low level light therapy,The Dr.Tai's energy cap
3491902|NCT05146596|No Intervention|control group|routine care.
3491903|NCT05146440|Experimental|PM14 in monotherapy and in combination with radiotherapy in STS and other solid tumors|"Cohort A : Phase I. PM14 24-h IV 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort B: Phase I. PM14 3-h IV infusion 3 d 21-d cycles, up to PD or toxicity. Dexamethasone recommended.~Cohort E: PM14 at RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort F: PM14 at the RP2D. Dexamethasone recommended. 21-d cycles up to PD or toxicity.~Cohort C: Phase I: PM14 at the RP2D, 21-d cycles in combination with radiotherapy, up to PD or toxicity. Dexamethasone recommended. Radiation therapy 3Gy/f 10 d. Phase II: PM14 at RP2D with radiation therapy.~Cohort D: Phase I: PM14 at the RP2D, 3 x 21-d cycles in neoadjuvant setting, in combination with radiotherapy. Dexamethasone recommended. Radiation therapy 1.8Gy/f 25 d. Phase II: PM14 at RP2D with radiation therapy."
3491904|NCT05145738|Experimental|C-Raven + Avatar|Computer delivered intervention with Avatar as virtual counselor plus linkage to community health worker
3491905|NCT05145738|Active Comparator|C-Raven|Computer-delivered intervention without virtual counselor, with linkage to community health worker
3491906|NCT05145686|Experimental|Comparing MMP-2, -8, -9 in reversible and irreversible pulpitis|The coronal pulp samples from both reversible and irreversible groups were placed in an eppendorf tube containing TriPure Reagent transport medium. The MMP-2, -8 and -9 expression levels were determined with specific primers by real time polymerase chain reaction method (RT-PCR).
3491907|NCT05145686|Active Comparator|Comparing the clinical success of MTA and Biodientine in primary molar pulpotomy treatments|In reversible pulpitis group MTA (ProRoot MTA,white) was used in 21 teeth and Biodentine was used in the other 21 teeth for pulpotomy treatments. Final restorations were performed with stainless steel crowns in both group. At the end of 3, 6 and 9 months, all teeth were evaluated clinically and radiographically based on AAPD criteria: (1) absence of spontaneous pain and/or sensitivity to pressure; (2) absence of sinus, fistula, edema, and/or abnormal mobility; (3) absence of radiolucency at the interradicular and/or periapical regions; (4) absence of internal or external root resorption.
3491908|NCT05145530|Active Comparator|Group C|selective anterior cervical discectomy and fusion (ACDF)
3491909|NCT05145530|Experimental|Group SNRB|US-guided selective nerve root block (SNRB) then selective anterior cervical discectomy and fusion (ACDF)
3491910|NCT05145127|Experimental|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
3491911|NCT05144984|Experimental|2.4 mg semaglutide + 2.4 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
3129504|NCT03224299|Experimental|Investigational Product #1 (IP1)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - clear
3129505|NCT03224299|Experimental|Investigational Product #2 (IP2)|octenidine dihydrochloride in isopropyl alcohol in a single-use applicator - tinted
3129506|NCT03224299|Active Comparator|Active Control|ChloraPrep® - Hi-Lite Orange® applicator
3491912|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
3129507|NCT03224299|Placebo Comparator|Negative Control|sterile 0.9% saline applied with single use applicator
3129508|NCT03224325|Other|Placebo (Pooled)|TAK-831 placebo-matching suspension, orally, once daily (QD) for up to Day 16.
3129509|NCT03224325|Experimental|TAK-831 100 mg|TAK-831 100 mg, tablets, orally, QD on Days 1 and 3 to 16.
3129510|NCT03224325|Experimental|TAK-831 300 mg|TAK-831 300 mg, tablets, orally, QD on Days 1 and 3 to 16.
3129511|NCT03224325|Experimental|TAK-831 600 mg|TAK-831 600 mg, tablets, orally, QD on Days 1 and 3 to 16.
3129512|NCT03224325|Experimental|TAK-831 15 mg|TAK-831 15 mg, suspension, orally, multiple doses (MD) daily, on Days 1 and 3 to 16.
3129513|NCT03224325|Experimental|TAK-831 800 mg|TAK-831 800 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
3129514|NCT03224325|Experimental|TAK-831 1200 mg|TAK-831 1200 mg, suspension, orally, QD on Day 1, MD on Days 3 to 16.
3491913|NCT05144984|Experimental|2.4 mg semaglutide + 7.2 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
3491914|NCT05144984|Experimental|2.4 mg semaglutide + 12.0 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
3491915|NCT05144984|Experimental|2.4 mg semaglutide + 21.6 mg NNC0480-0389|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
3491916|NCT05144984|Experimental|NNC0480-0389 + placebo (semaglutide)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
3491917|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
3491918|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
3491919|NCT05144984|Placebo Comparator|Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
3129515|NCT03224351|Placebo Comparator|Part 1: Placebo|Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
3491920|NCT05144984|Experimental|Semaglutide 2.4 mg + placebo (NNC0480-0389)|subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.
3491921|NCT05144932|Experimental|StrokeAlarm use|This is a single arm study. All participants will be instructed to use the StrokeAlarm medical device for 1 month.
3491922|NCT05144620|Experimental|Preoperative Imaging|
3491923|NCT05144256|Experimental|Mitapivat|Double-Blind Period: Participants will receive mitapivat orally, at doses based on age and weight, for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
3491924|NCT05144256|Placebo Comparator|Placebo|Double-Blind Period: Participants will receive mitapivat-matching placebo orally for 8 weeks in the dose titration period and for 24 weeks in the fixed-dose period.
3491925|NCT05144256|Experimental|Mitapivat (OLE period)|Participants who have completed the double-blind period will be eligible to receive mitapivat for up to 5 years in the OLE period. Participants entering the OLE period will receive both mitapivat and placebo for 8 weeks to maintain the double-blind treatment assignment.
3491926|NCT05144178||Mild and moderated COVID -19 patient treated out side the hospital sitting|Reviewing files of such group that had been received Sotrovimab
3491927|NCT05144061|Experimental|Single Arm|HRS2398 Tablets
3491928|NCT05143775|Experimental|new surgical plan group|The investigators use a monopolar stimulator to determine and retain the tumor margin within 5mm in the sensitive area which is posterior superior longitudinal fasciculus or posterior arcuate fasciculus.
3491929|NCT05143775|Active Comparator|traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified, those points would be retained to avoiding language function impairment after the tumor resection.
3491930|NCT05142761||Posterior component separation|Patients undergoing posterior component separation
3491931|NCT05142644||Early / growth restriction|Intrauterine growth restriction with onset before 32 weeks of gestation
3491932|NCT05142644||Late growth restriction|Intrauterine growth restriction with onset after 32 weeks of gestation
3491933|NCT05142553|Experimental|COVID-19 Vaccine HIPRA|40 ug/0.5 ml
3491934|NCT05142553|Active Comparator|Cominarty (Pfizer-BioNtech)|30 micrograms/dose concentrate for dispersion for injection
3491935|NCT05141227|Experimental|two stage ORIF|Two-stage Open reduction and internal fixation
3491936|NCT05141227|Experimental|single stage Ex. Fix|Single-stage external fixation with minimal internal fixation if needed
3491937|NCT05140837||cross-sectional study|
3491938|NCT05140837||real-world cohort study|
3491939|NCT05140252|Experimental|Breast cancer decision aid|Participants receive a breast cancer decision aid.
3491940|NCT05139602|Experimental|Lutikizumab Dose A|Lutikizumab Dose A every week
3129516|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Low Dose|Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
3491941|NCT05139602|Experimental|Lutikizumab Dose B|Lutikizumab Dose B every other week
3491942|NCT05139602|Experimental|Lutikizumab Dose C|Lutikizumab Dose C every other week
3491943|NCT05139602|Placebo Comparator|Placebo|Placebo every week
3491944|NCT05139550|Experimental|Smartphone Rehabilitation Application|"Upper Limb Exercise Protocol:~Passive Exercises ROMs for shoulder, ROMs for elbow, ROMs for wrist,fingers and thumb~Active/Assisted Exercises bilateral shoulder flexion with both hands interlocked, Elbow pronation and supination, Wrist flexion and extension with the help of unaffected hand, Forearm to box, Extend elbow (side), Hand to box (front)~Functional Activities Lift can, Lift pencil, Lift paper clip, Stack checkers, Flip cards, Fold towel, drinking water from a glass, lifting a glass of water to a level of 90° shoulder flexion with an extended elbow, moving 5 crystals from the table to a box, wiping the table with a towel with the elbow extended, grasping and releasing a 6 cm in diameter tennis ball, combing their hair, Eating with affected hand, opening and closing jars"
3491945|NCT05138094|Active Comparator|Minimally invasive two-stage resection|Minimally invasive resection of the primary colorectal carcinoma and liver metastases in two stages. The liver metastases or the colorectal carcinoma can be resected during the first surgical procedure.
3180091|NCT00679666|Active Comparator|Treatment Arm|After randomization, the active arm will have the collagen crosslinking intervention.
3491946|NCT05138094|Experimental|Minimally invasive simultaneous resection|Minimally invasive resection of both the primary colorectal carcinoma and the liver metastases in one procedure.
3491947|NCT05137665||Amyotrophic Lateral Sclerosis ALS|Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
3491948|NCT05137665||Healthy|Healthy participants (family or friends) will have a neurologic exam to confirm non-neurologic disease status and will participate in 2 longitudinal visits; Screening/baseline Visit 1, and one (1) follow-up which will occur at approximate 12-month interval. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
3491949|NCT05135988||Children in vital distress|
3491950|NCT05135988||Health care givers|Experts in vital distress care Non experts in vital distress care
3491951|NCT05135871|Experimental|Cohort 1: Mavacamten 15 mg|Cohort 1: 15 mg capsules × 1 on Day 1
3491952|NCT05135871|Experimental|Cohort 2: Mavacamten 25 mg|Cohort 2: 10 mg capsules x 1 and 15 mg capsules x 1 on Day 1
3491953|NCT05135871|Experimental|Cohort 3: Mavacamten 15 mg|Cohort 3: 15 mg capsules × 1 on Day 1
3491954|NCT05135871|Experimental|Cohort 4: Mavacamten 15 mg|Cohort 4: 15 mg capsules × 1 on Day 1
3491955|NCT05133310|No Intervention|Standard Care Group|Patients will receive the standard chemotherapy regimen assigned for their treatment and, they will be followed and monitored until the end of treatment and hospitalization.
3491956|NCT05133310|Experimental|Simvastatin Treatment Group|Patients will combine the standard CALGB treatment scheme plus Simvastatin 10mg orally every 24 hours during the first 7 days of treatment and then continue with 20mg every 24 hours until the end of treatment and hospitalization.
3491957|NCT05132088|Experimental|oral semaglutide 50 mg once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
3491958|NCT05132088|Placebo Comparator|oral semaglutide placebo once daily|All participants will get semaglutide or placebo tablets, 1 tablet every morning.
3491959|NCT05129982|Experimental|Intervention|The reflex response will be recorded during whole-body vibration.
3491960|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Doses TBD|Subjects will crossover across 3 dosing periods in which they will receive placebo and two experimental dose levels
3491961|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300|LYT-300, Dose TBD with and without food, separated by 7-day washout
3491962|NCT05129865|Experimental|LYT-300, Dose TBD QAM every 24 h for 7 days|
3491963|NCT05129865|Placebo Comparator|Placebo QAM every 24 h for 7 days|
3491964|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD QAM or QHS every 24 h for 7 days|Subjects will crossover across 2 dosing periods in which they will receive LYT-300 Dose TBD QAM or QHS every 24 h for 7 days
3491965|NCT05129865|Placebo Comparator|Placebo QAM or QHS every 24 h for 7 days|Subjects will crossover across 2 dosing periods in which they will Placebo QAM or QHS every 24 h for 7 days
3491966|NCT05129865|Experimental|LYT-300 in healthy volunteers LYT-300, Dose TBD BID every 12 h for 7 days|
3491967|NCT05129865|Placebo Comparator|Placebo BID every 12 h for 7 days|
3491968|NCT05128994|Experimental|Non-invasive FES|Wearable FES sleeve with non-invasive user controls
3491969|NCT05126537||health volunteers|
3491970|NCT05126537||ICU non-sepsis patients|
3491971|NCT05126537||sepsis patients|
3491972|NCT05125562|Placebo Comparator|Placebo|100ml normal saline
3491973|NCT05125562|Experimental|10ml ExoFlo|10ml ExoFlo + 90ml normal saline
3491974|NCT05125562|Experimental|15ml ExoFlo|15ml ExoFlo + 85ml normal saline
3491975|NCT05122559|Active Comparator|N-acetyl cysteine|N-acetyl cysteine (NAC) 1200mg t.i.d.
3491976|NCT05122559|Placebo Comparator|Placebo|Placebo 1200mg t.i.d.
3129517|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - Medium Dose|Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
3491977|NCT05118776|Experimental|Team ASC40|ASC40 tablets 100mg/m^2 and bevacizumab 10mg/kg for 6 months.
3491978|NCT05118776|Placebo Comparator|Team Placebo|Placebo and bevacizumab 10mg/kg for 6 months.
3491979|NCT05117294|Experimental|ASP0367: Severe Renal Impairment|Participants with severe renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
3491980|NCT05117294|Experimental|ASP0367: Moderate Renal Impairment|Participants with moderate renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
3491981|NCT05117294|Experimental|ASP0367: Mild Renal Impairment|Participants with mild renal impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
3491982|NCT05117294|Experimental|ASP0367: Normal Renal Function|Participants with normal renal function will receive a single dose of ASP0367 under fasting conditions on day 1.
3491983|NCT05117164|No Intervention|control group|Patients will receive enteral feeding based on the practice of the leading physician.
3491984|NCT05117164|Experimental|intervention|"Infants will receive enteral feeding based on the following protocol.~Enteral nutrition Minimal enteral nutrition (MEN) will begin within 72 hours life at 10 to 20. mL/kg/day, via bolus gravity breast milk/donor human milk. MEN will not be included in the caloric goals.~Advancements in feeding will be set at 20-30 mL/kg/day, but not more than 10ml per feeding portion to reach a goal of 150ml/kg/day, but not than 120ml/kg/day cases of fluid restriction).~The goal will be to reach an overall daily caloric intake of minimum 100kcal/kg/d."
3491985|NCT05116189|Experimental|Pembrolizumab + paclitaxel ± bevacizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
3491986|NCT05116189|Placebo Comparator|Placebo + paclitaxel ± bevacizumab|Participants receive placebo via IV infusion for eighteen 6-week cycles (approximately 2 years) PLUS paclitaxel 80 mg/m^2 via IV infusion on Days 1, 8, and 15 of each 3-week cycle until intolerance or disease progression. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m^2 every 3 weeks [Q3W]) after Sponsor consultation. Participants may also receive bevacizumab 10 mg/kg via IV infusion of each 2-week cycle until intolerance, disease progression, or at the Investigator's discretion.
3491987|NCT05113069|Experimental|Treatment group|SHR-A1912
3491988|NCT05112952|Experimental|Part A: Group 1: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single oral dose of lazertinib.
3491989|NCT05112952|Active Comparator|Part A: Group 2: Normal Hepatic Function|Participants with normal hepatic function who qualify for the control group will receive a single oral dose of lazertinib.
3491990|NCT05112952|Experimental|Part B: Group 3 (Optional): Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single oral dose of lazertinib.
3491991|NCT05112952|Experimental|Part B: Group 4 (Optional): Severe Hepatic Impairment|Participants with severe hepatic impairment will receive a single oral dose of lazertinib.
3491992|NCT05109975|Experimental|Part 1: Dose Escalation|Participants will receive Debio 0123 orally in escalating dose cohorts during each 21-day treatment cycle until progression of disease, unacceptable toxicity, participant's withdrawal, or Investigator's decision, whichever occurs first.
3491993|NCT05109975|Experimental|Part 2: Expansion|Debio 0123 at the RP2D established in Part 1.
3491994|NCT05109520||investigational group|Participants of the FUTURE study who switched during the study to Gla-300
3491995|NCT05109520||control group|Participants of the FUTURE study who did not switch to Insulin Gla-300
3491996|NCT05108909||mild to moderate traumatic brain injury|patients diagnosed with mild to moderate traumatic brain injury within 1 week after onset of TBI.
3491997|NCT05108909||isolated orthopaedic trauma patients|Patients with isolated orthopaedic trauma were identified and enrolled using the same process as that for patients with TBI.
3491998|NCT05108909||healthy non-injury control|Healthy non-injured controls were recruited either via a relationship with a TRACK-TBI participant or through public advertisement within TRACK-TBI institutions, and were able to provide informed consent.
3491999|NCT05106595||Traditional Occupational Therapy|participants receiving traditional occupational therapy treatments and interventions provided in the inpatient rehabilitation setting. This includes, but is not limited to , therapeutic activity, therapeutic exercise, neuromuscular re-education. This group is retrospectively collected, and will not include participants who had access to the BAT.
3492000|NCT05106595||Bimanual Arm Trainer|Participants who are prospectively enrolled, who are appropriate for BAT use. Participants will receive additional traditional occupational therapy interventions, as deemed appropriate by treating therapists.
3492001|NCT05105789|Experimental|BinaxNOW Test + Lollipop PCR|"If a symptomatic participant's initial at-school BinaxNOW test was positive, then their study participation is complete after providing the lollipop swab for PCR testing.~If a symptomatic participant's initial at-school BinaxNOW test was negative, then they will be asked to complete an at-home BinaxNOW test approximately 24 hours later.~For the at-home BinaxNOW testing, the participant will schedule a follow-up virtual visit with the study coordinator. If they are unable to complete a virtual visit, they will schedule an in-person home visit. They will also be sent home with a BinaxNOW testing kit."
3492002|NCT05104983|Experimental|Sirolimus|Sirolimus
3492003|NCT05104983|Placebo Comparator|Placebo|Placebo
3492004|NCT05104736|Experimental|PT-112|PT-112 will be administered intravenously on Days 1, 8 and 15 of a 28-day cycle at a dose of 360 mg/m2 until disease progression, development of intolerable adverse events, or until 8 years after an individual participant has been on study
3492005|NCT05104723|Experimental|XELJANZ (tofacitinib)|Tofacitinib is self-administered orally at 5 mg twice per day for 3 months.
3492006|NCT05102292|Experimental|HLX208|Participants receive HLX208 450mg bid po
3492007|NCT05100641|Experimental|AV-GBM-1|Autologous dendritic cells loaded with autologous tumor antigens cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
3492008|NCT05100641|Placebo Comparator|Autologous monocyte control (MC)|Autologous monocytes cryopreserved in CryoStor 5, and admixed 500 mcg GM-CSF diluted in saline
3492009|NCT05098743|Experimental|Participants using the medication adherence mobile application.|Participants in this arm will use the Medisafe app to receive medication reminders for thirty days.
3129518|NCT03224351|Experimental|Part 1: VX-659/TEZ/IVA TC - High Dose|Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
3492010|NCT05098743|Active Comparator|Participants using a printed copy of their medication list.|Participants in this arm will use a printed out copy of their medication list for thirty days.
3492011|NCT05098340||AIS group|This group includes patients with acute ischemic stroke (AIS).
3492012|NCT05098340||HC group|This group includes healthy controls (HC).
3492013|NCT05097027|Experimental|Blood flow restriction recovery (Experimental I)|Active recovery program with blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
3492014|NCT05097027|Experimental|Non-Blood flow restriction recovery (Experimental II)|Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
3492015|NCT05095831||Suspicion of solid neoplastic lesion|Patients with high suspicion of solid pancreas neoplasia: carcinoma, intrapapillary mucinous neoplasia (IPMN), neuroendocrine tumor, lymphoma, or intrapancreatic metastasis; based on CT/MR.
3492016|NCT05095831||Suspicion of a solid inflammatory lesion|Patients with high suspicion of solid inflammatory lesions: acute, chronic, or autoimmune pancreatitis; based on CT/MR.
3492017|NCT05095831||Control group|Patients without a history of any type of solid or hematologic malignancy, hepato-pancreato-biliary disease (including fatty liver and pancreas disease), tobacco/alcohol habits, or morbid obesity with bariatric surgery criteria; who require EUS evaluation (e.g., suspicious of a subepithelial lesion in the context of chronic dyspepsia).
3492018|NCT05095350|Experimental|Probiotic powder|The probiotic powder contains 10 strains from Lactobacillus and Bifidobacterium genus. Participants will orally take two sachets daily and last for 8 weeks.
3492019|NCT05095350|Placebo Comparator|Placebo powder|The placebo powder consists of maltodextrin and contains no probiotics. Participants will orally take two sachets daily and last for 8 weeks.
3492020|NCT05095272|Experimental|Healthy malaria-naive US adults|A single dose of cryopreserved inoculum containing blood-stage P. vivax will be administered IV
3492021|NCT05094115|No Intervention|Training as usual|Training as Usual for the 3rd SFAB is the U.S. Army Master Resilience Trainer (MRT). It focuses on teaching resilience skills and is one of the foundational pillars of the Comprehensive Soldier Fitness program. MRT course is intended to impart training resilience skills, designed to introduce other resilience concepts that soldiers will likely encounter through their careers. Key focus of course are (1) resilience, (2) building mental toughness, (3) identifying character strengths, and (5) strengthening relationships. The 3rd SFAB uses a a team training grounded in strengths-based leadership. The Small Team Development Consultant and Brigade Behavioral Health Provider serves as a consultant to units conducting their own resiliency training as usual. No booster sessions will be offered to Training as Usual.
3492022|NCT05094115|Active Comparator|Training as usual with psychological flexibility training|"Training as usual, with psychological flexibility training delivered during a 2-day workshop.~Day 1 provides an overview of the training and describes the posture or stance to prepare for response to challenging situations in a psychologically flexible manner.~Day 2 provides common coping strategies."
3492023|NCT05094050|Experimental|Arm 1: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).
3492024|NCT05094050|Experimental|Arm 2: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).
3492025|NCT05094050|Experimental|Arm 3: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).
3492026|NCT05094050|Experimental|Arm 4: ABBV-951|Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).
3492027|NCT05092971|Other|Clinic|Tasks to be completed in OP4 clinic
3492028|NCT05092971|Other|fMRI|Tasks to be completed in fMRI
3492029|NCT05092815|Experimental|HLX208|Participants receive HLX208 450mg bid po
3492030|NCT05092802|Experimental|HLX208|
3492031|NCT05085405|Experimental|Clinician Notification only|
3129519|NCT03224351|Active Comparator|Part 2: TEZ/IVA|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
3129520|NCT03224351|Experimental|Part 2: VX-659/TEZ/IVA TC|Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
3129521|NCT03224351|Placebo Comparator|Part 3: Placebo|Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
3492032|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation only|
3492033|NCT05085405|Experimental|Clinician Notification / Patient Activation|
3492034|NCT05085405|Experimental|Clinician Notification with Nurse Facilitation / Patient Activation|
3492035|NCT05084248|Active Comparator|Low-dose|400 IU Per Orem
3492036|NCT05084248|Experimental|High-dose|4000 IU Per Orem
3492037|NCT05083845|Active Comparator|Erector Spinae Plane Block with 20 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine was injected into the area.
3492038|NCT05083845|Active Comparator|Erector Spinae Plane Block with 30 ml %0.25 Bupivacaine|Following the visualization of the anatomical structures, the nerve block needle was advanced via the in-plane technique beneath the erector spinae muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 30 ml 0.25% bupivacaine was injected into the area.
3492039|NCT05083169|Experimental|Arm A: Teclistamab-daratumumab (Tec-Dara)|Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
3129522|NCT03224351|Experimental|Part 3: VX-659/TEZ/VX-561 TC|Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.
3129523|NCT03224390|Experimental|Encouragement Arm|Women randomized to the encouragement arm will receive an invitation via SMS to try the new digital family planning screening and referral service.
3492040|NCT05083169|Experimental|Arm B:Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Bortezomib, Dexamethasone (DVd)|In DPd treatment (28-day cycle), participants will receive daratumumab SC 1800mg weekly on Cycles 1 and 2, every 2 weeks on Cycles 3 to 6, every 4 weeks on Cycle 7 and beyond; oral pomalidomide 4 mg on Days 1 to 21 of every 28-day cycle, dexamethasone 40 mg (less than or equal to [<=] 75 years) or 20 mg (greater than [>] 75 years) orally or intravenously (IV) weekly on every cycle. In DVd treatment (21-day cycle from Cycles 1 to 8 and 28-day cycle from Cycle 9 and beyond), daratumumab SC injection 1800 mg weekly on Cycles 1 to 3 and on Day 1 (Cycle 4 and beyond); bortezomib 1.3 milligrams per meter square (mg/m^2) on Days 1, 4, 8 and 11 (Cycles 1 to 8), and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8).
3492041|NCT05083078|Experimental|Part 1: Healthy Participants|Healthy participants will receive risankizumab and guselkumab subcutaneously (SC) on Day 1.
3492042|NCT05083078|Experimental|Part 2: Psoriatic Arthritis (PsA) Participants|Participants with PsA will receive either risankizumab or guselkumab SC on Day 1 and Day 29.
3492043|NCT05082584|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
3129524|NCT03224390|No Intervention|Control Arm|Women randomized to the control arm will receive a different set of SMS messages that do NOT include a special encouragement try the new digital family planning screening and referral service.
3492044|NCT05082571|Experimental|Vadadustat|Cohort 1: participants with ≥12 years to <17 years; Cohort 2: participants with ≥6 years to <12 years; Cohort 3(a): participants with ≥2 years to <6 years; and Cohort 3(b): participants with ≥4 months to <2 years
3492045|NCT05081622|Experimental|ICC-T|5 days with 9 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
3492046|NCT05081622|No Intervention|Monitoring condition|No intervention
3492047|NCT05081609|Experimental|Part 1 Dose Escalation: TransCon IL-2 β/γ|TransCon IL-2 β/γ in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D
3492048|NCT05081609|Experimental|Part 2 Dose Escalation: TransCon IL-2 β/γ with Pembrolizumab|TransCon IL-2 β/γ with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D
3492049|NCT05081609|Experimental|Part 3 Dose Expansion: TransCon IL-2 β/γ with SOC Chemotherapy|TransCon IL-2 β/γ with SOC Chemotherapy using the RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination
3492050|NCT05081206|Experimental|Manually controlled|
3492051|NCT05081206|Experimental|Target controlled|
3492052|NCT05080842|Experimental|AC682|This arm will evaluate AC682 monotherapy administered in 28-day cycles. Up to 30 participants will participate in this dose escalation arm.
3180092|NCT00679679|Experimental|Metformin|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
3180093|NCT00679679|Placebo Comparator|Placebo|Every patient will be given diet and exercise counseling in both arms. Intervention arm will receive metformin
3180094|NCT00679692||3:|three arms for study
3180095|NCT00679705|Experimental|1|Ritodrine (Pre-Par)
3492053|NCT05080699|Experimental|Peptamen Intense in obese home enteral nutrition patients after stroke|Subjects currently enrolled in Mayo Clinic Home Enteral Nutrition (HEN) program and anticipated to require tube feedings to provide 90% or more of feeding needs will be placed on a Peptamen Intense VHP for up to 12 weeks.
3492054|NCT05078905||Individuals Receiving Vaccine|Individuals receiving a vaccination for an emerging infection, like SARS-CoV-2
3492055|NCT05078892||Adolescents (12-17)|Adolescents 12-17 with Turner Syndrome
3492056|NCT05078892||Parents of Adolescents (12-17)|Parents of Adolescents (12-17)with Turner Syndrome
3492057|NCT05078892||Young Adults (18-25)|Young Adults (18-25)with Turner Syndrome
3492058|NCT05078736|Experimental|moderate intensity intermittent training|baseline physical therapy treatment along with moderate intensity intermittent training
3492059|NCT05078736|Experimental|moderate intensity continuous training|baseline physical therapy treatment along with moderate intensity continuous training
3492060|NCT05078047|Experimental|Experimental arm|"Reduced dose intensity of IO:~IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision"
3492061|NCT05078047|No Intervention|Control arm|"Standard IO:~Continuation of IO at the same dose levels and rhythmicity until disease progression, unacceptable toxicity, death or patient's choice."
3492062|NCT05076877|Experimental|Lazertinib + Probe Substrates of Midazolam, Rosuvastatin, and Metformin|Participants will receive a single oral dose of probe substrates of midazolam, rosuvastatin, and metformin on Day 1 under fasted conditions followed by a single oral dose of lazertinib under fed conditions from Day 5 to Day 14 except Day 13 which is under fasted conditions and co-administered with probe substrates under fasted conditions on Day 13.
3492063|NCT05074862|Experimental|Ketone monoester (3-OHB)|Weight-adjusted dose of 3-OHB Monoester (KetoneAID KE4, Virginia, US). Bolus of 200 mg/kg followed by a 2-hour continuous enteral infusion with a dosing of 150 mg/kg/hour (maximal total dose 50 grams). There is a 1-hour lag between the bolus and the continuous infusion.
3492064|NCT05074862|Placebo Comparator|Placebo Treatment|Maltodextrin- and fatbased placebo in isocaloric, isovolemic dose to the experimental arm.
3492065|NCT05073887|Experimental|3 nerve|3 genicular nerve blockade and radio frequency ablation
3492066|NCT05073887|Active Comparator|5 nerve|3 genicular nerve blockade and radio frequency ablation 2 genicular nerve blockade and pulse radio frequency
3492067|NCT05072483||Healthy controls|Healthy controls for exploratory analyses, where the measurements were not commonly performed previously in other populations, for qualitative comparison with CADASIL population
3492068|NCT05072483||Subjects with CADASIL|Adult genetically-confirmed patients with a wider range of CADASIL disease duration and debility
3492069|NCT05072028|Experimental|[14C]DBPR108|Subjects will receive a single oral 100 mg (radioactivity of 150 µCi) dose of [14C]DBPR108 on Day 1.
3492070|NCT05071664|Experimental|Group 1: Guselkumab and Golimumab|Participants will receive subcutaneous (SC) guselkumab and golimumab.
3492071|NCT05071664|Active Comparator|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab and placebo.
3492072|NCT05071027|Experimental|App Medication Reminder Group|Patients in this group will receive dual antiplatelet medication reminders.
3492073|NCT05071027|No Intervention|Non-app Using Group|Patients in this group receive the same standard of care [i.e. endovascular stent-based treatment of unruptured aneurysms] as the other group, but do not receive app dual antiplatelet reminders.
3492074|NCT05070663||Participants with severe asthma|Adolescents, for whom initiation of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was decided by the investigator before the inclusion in the study.
3492075|NCT05069714|Experimental|MTX 1 week hold|Patients who will hold MTX for 1 week after an influenza vaccine.
3492076|NCT05069714|Active Comparator|MTX 2 week hold|Patients who will hold MTX for 2 weeks after an influenza vaccine.
3492077|NCT05069701|Experimental|Healthy volunteers|SVV test will be done.
3180096|NCT00679705|Experimental|2|Atosiban (Tractocile)
3492078|NCT05068024|Experimental|Treatment of NSCLC patients with EGFR genetic alterations|
3492079|NCT05065801|Experimental|GABRINOX|"D1, D8 and D15 GEMBRAX: Albumin bound paclitaxel 125mg / m² followed by Gemcitabine 1000mg / m² followed by 2 weeks of rest~D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400 mg / m², 5-fluorouracil 400mg / m² in bolus followed by continuous administration over 46h at 2400mg / m² followed by 2 weeks of rest"
3492080|NCT05065801|Active Comparator|FOLFIRINOX|D1, D15, D29 and D43 FOLFIRINOX: Oxaliplatin 85mg / m², Irinotecan 180mg / m², Folinic acid 400mg / m², 5-fluorouracil 400mg / m² as a bolus followed by continuous administration over 46h at 2.400mg / m² followed by 2 weeks of rest.
3492081|NCT05064254|Active Comparator|Treatment as usual|All participants allocated to the control group will have access to standard care.
3492082|NCT05064254|Experimental|Mindful Adaptive Practice in Pregnancy Therapy|"Participants allocated to the intervention group will have access to treatment as usual in addition to synchronous virtual MAPP.~MAPP draws upon existing integrative principles of structured psychotherapies (mindfulness-based, cognitive, behavioural and relational psychotherapy)"
3492083|NCT05062083|Other|One arm|All particpants will receive the same tests
3492084|NCT05060783||Renal Call Carcinoma|Patrients with renal cancer
3492085|NCT05060783||Oncocytoma|Patients with oncocytoma
3492086|NCT05060783||Healthy persons|Patients with CT scan shows no renal cancer
3492087|NCT05057364|Experimental|Heart Smart Group|Receives Heart Smart Intervention
3492088|NCT05057000|Experimental|Group A|DIET PROGRAM IN ADDITION TO AEROBIC EXRCISES
3492089|NCT05057000|Other|Group B|DIET PROGRAM
3492090|NCT05054569|Experimental|10-week eHealth intervention|Weekly video conference groups led by a trained facilitator
3492091|NCT05054530|Experimental|GMA106|6 different dosages will be subcutaneously injected into the abdomen.
3492092|NCT05054530|Placebo Comparator|Matching placebo|6 different dosages will be subcutaneously injected into the abdomen.
3492093|NCT05053490|Experimental|Static Stretching|Participants will perform static stretching on day 1 and dynamic stretching after the switching.
3492094|NCT05053490|Experimental|dynamic stretching|Participants will perform dynamic stretching on day 1 and static stretching after the switching.
3492095|NCT05053139|Experimental|no PPX- no PPX - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 1, participants will be randomised to continue no prophylaxis (on-demand treatment with their Standard of Care FVIII concentrates) in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen
3492096|NCT05053139|Experimental|no PPX - Mim8 PPXQW - Mim8 PPXQW|Participants not receiving prophylaxis will not enter the run-in period. In arm 2, participants will be randomised to Mim8 once-weekly prophylaxis in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen
3492097|NCT05053139|Experimental|PPX - Mim8 PPXQW|Patients on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 3, participants will be randomised to once-weekly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-weekly Mim8 prophylaxis regimen.
3492098|NCT05053139|Experimental|PPX- Mim8 PPXQM|Patients on coagulation factor prophylaxis prior to enrolment will preferably continue the same product type and dosing frequency in the run-in period for at least 26 weeks before they can be randomised into the main part of the study. These participants will only be allowed to receive coagulation factor prophylaxis. In arm 4, participants will be randomised to once-monthly Mim8 prophylaxis regimen in the main part of the study (26 weeks). After the main part, participants will continue in the extension part of the study (26 weeks) on once-monthly Mim8 prophylaxis regimen.
3492099|NCT05052307||Fully vaccinated with BNT162b2 COVID-19 vaccine|Defined as 2 doses of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥7 days between receipt of the 2nd dose and acute respiratory illness (ARI) symptom onset. This group will serve as the 'exposed' group evaluated in the primary objective.
3492100|NCT05052307||Ever vaccinated with BNT162b2 COVID-19 vaccine|defined as ≥1 dose of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
3492101|NCT05052307||Partially vaccinated with BNT162b2 COVID-19 vaccine|Defined as 1 dose (only) of Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
3492102|NCT05052307||Fully vaccinated with other available COVID-19 vaccines|Defined as fully vaccinated with available COVID-19 vaccines other than the BNT162b2 according to the manufacturer recommendations.
3492103|NCT05052307||Never vaccinated|Defined as never received any COVID-19 vaccine. This group will serve as the reference exposure group (i.e., 'unexposed' group) in all vaccine effectiveness analyses.
3492104|NCT05052307||Fully vaccinated plus booster dose of BNT162b2 COVID-19 vaccine|Defined as fully vaccinated with available COVID-19 vaccines according to the manufacturer recommendations plus booster dose of BNT162b2 COVID-19 vaccine received with ≥14 days between receipt of the 1st dose and ARI symptom onset.
3492105|NCT05052216||NORM|healthy children
3492106|NCT05052216||OSA|children with obstructive sleep apnea
3492107|NCT05051436|Experimental|Mirabegron (M)|Drug will be administered for 12 weeks after baseline procedures.
3492108|NCT05051436|Experimental|Tadalafil (T)|Drug will be administered for 12 weeks after baseline procedures.
3492109|NCT05051436|Experimental|Mirabegron and Tadalafil (MT)|Both drugs will be administered for 12 weeks after baseline procedures.
3492110|NCT05051436|Placebo Comparator|Placebo (P)|
3492111|NCT05050994|Experimental|Microwave ablation|Patients receiving microwave ablation of splenomegaly
3492112|NCT05050916|Experimental|1/High Dose Vitamin D|Deficient women will be randomized to either the IOM recommended RDA, 4,200 IU/week, or the Endocrine Society recommendation for deficiency, 50,000 IU/week.
3492113|NCT05050916|Experimental|2/Low Dose Vitamin D|Deficient women will be randomized to either the IOM recommended RDA, 4,200 IU/week, or the Endocrine Society recommendation for deficiency, 50,000 IU/week.
3129525|NCT03224403|Experimental|Test acetaminophen|Test acetaminophen 1000 mg dose
3492114|NCT05050916|Placebo Comparator|3/Placebo|Sufficient women who will receive placebo instead of Vitamin D supplementation.
3492115|NCT05050097|Experimental|Treatment Regimen A: Talquetamab + Carfilzomib|Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.
3492116|NCT05050097|Experimental|Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib|Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.
3492117|NCT05050097|Experimental|Treatment Regimen C: Talquetamab + Lenalidomide|Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.
3492118|NCT05050097|Experimental|Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide|Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.
3492119|NCT05050097|Experimental|Treatment Regimen E: Talquetamab + Pomalidomide|Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.
3492120|NCT05049798||Cohort 1: Guselkumab|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of Psoriatic Arthritis (PsA) who are starting guselkumab as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice.
3492121|NCT05049798||Cohort 2: Interleukin-17 inhibitor (IL-17i)|Data as available from participant's source medical records will be collected for adult participants with a confirmed diagnosis of PsA who are starting IL-17i as a first, second, third, or fourth line of PsA biologic therapy either as monotherapy or with other medications per routine clinical practice.
3492122|NCT05049343|Experimental|SAGE-904 then Placebo|SAGE-904 in combination with ketamine, followed by a washout period, followed by placebo in combination with ketamine.
3492123|NCT05049343|Placebo Comparator|Placebo then SAGE-904|Placebo in combination with ketamine, followed by a washout period, followed by SAGE-904 in combination with ketamine.
3492124|NCT05048199|Experimental|pressure regulated volume-controlled mode of ventilation (PRVC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
3492125|NCT05048199|Active Comparator|volume-controlled mode of ventilation (VC group)|The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
3492126|NCT05047172|Experimental|Experimental Arm: Ticagrelor and Aspirin|Ticagrelor (180mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
3492127|NCT05047172|Active Comparator|Standard of Care Arm: Clopidogrel and Aspirin|Clopidogrel (600mg loading dose, then 75mg once daily) and aspirin (81mg daily)
3492128|NCT05047172|Experimental|Experimental Arm: Rivaroxaban and Aspirin|Rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
3492129|NCT05044780||Cohort 1/COVID19 positive|Participants with molecular testing positive for COVID19
3492130|NCT05044780||Cohort 2/COVID19 negative|Participants with molecular testing negative for COVID19
3492131|NCT05044507|Sham Comparator|BQ 2.0 sham stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
3492132|NCT05044507|Active Comparator|BQ 2.0 active stimulation group|45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.
3492133|NCT05042882|Experimental|Early enteral nutrition|Intervention group: enteral nutrition from the first postoperative night until 50% of caloric requirements are covered by oral nutrition. Enteral nutrition will start at a flow of 250 ml/12h. If tolerated, enteral nutrition will be increased to 500 ml/12h on postoperative day 1, 750 ml/12h on postoperative day 2, and 1000 ml/12h on postoperative day 3. A hypercaloric enteral nutrition will be used (Isosource Energy Fibre or similar).
3492134|NCT05042882|No Intervention|Oral nutrition|Control group: patients will receive standardized oral nutrition. The night after the operation, patients will be allowed to have free drinks. On postoperative day 1, they will receive bouillons, creams, yogurts, and drinks >2 l. On postoperative day 2, they will receive a light diet. On postoperative day 3, they will receive half portion of normal diet and on postoperative day 4 normal diet.
3492135|NCT05041842|Experimental|Tucatinib plus systemic treatment with or without hormone therapy|Addition of tucatinib (300 mg orally twice daily) to the systemic treatment (pertuzumab and trastuzumab) with or without hormone therapy
3492136|NCT05041387||1|patients, male or female, who are age 18 or older, diagnosed or suspected of having a neuromuscular disorder or neurodegenerative disorder.
3492137|NCT05041374||Study Cohort|Patients with known or suspected gastrointestinal disease
3492138|NCT05041075|Active Comparator|WB:UC|Weighted Blanket 2nd infusion Usual Care 3rd infusion
3492139|NCT05041075|Active Comparator|UC:WB|Usual Care 2nd infusion Weighted Blanket 3rd infusion
3492140|NCT05040971|Experimental|Semaglutide|Participants will receive subcutaneus (s.c.) semaglutide 2.4 mg once weekly for 52 weeks
3492141|NCT05040971|Placebo Comparator|Placebo (semaglutide)|Participants will receive subcutaneus (s.c.) placebo (semaglutide) once weekly for 52 weeks
3492142|NCT05038904|Experimental|Acalabrutinib|Participants will be given acalabrutinib (four doses of 100 mg of acalabrutinib to be taken orally twice daily).
3129526|NCT03224403|Active Comparator|Commercial acetaminophen|Commercial acetaminophen 1000 mg dose
3492143|NCT05037786|Active Comparator|Powerpoint group|In the control group, there will be a face-to-face intervention of 15 minutes of education on pain explained by Verbal form with supporting Powerpoint presentation. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
3492144|NCT05037786|Experimental|Infographic group|In the intervention group, the same pain education will be carried out, explained verbally but with the support of an infographic instead of a Powerpoint. The educational intervention will be carried out by one of the Unicaja Baloncesto Physiotherapists (research assistant), previously instructed by the research team.
3492145|NCT05035420|Experimental|Healthy Volunteer|Healthy Volunteer
3492146|NCT05035407|Experimental|Treatment at dose levels 1 through 7|Non-myeloablative, lymphocyte depleting preparative regimen, followed by KK-LC-1 TCR T cells plus aldesleukin at escalating doses
3492147|NCT05035290|Experimental|Negative pressure ventilation|Negative pressure application after extubation
3492148|NCT05035290|No Intervention|Standard approach|Standard approach - oxygentherapy based on patients need
3492149|NCT05035277|Active Comparator|Acetylsalicylic acid|Patients in the active control arm will receive 75 mg acetylsalicylic acid once daily indefinitely.
3492150|NCT05035277|Experimental|Direct oral anticoagulation (DOAC)|Patients in the experimental arm will receive an anti Xa-type DOAC (apixaban, rivaroxaban or edoxaban) in approved therapeutic dose for 12 months. The choice of DOAC agent will be made by the treating clinician after discussion with the patient. After 12 months, these patients will abort DOAC therapy. Acetylsalicylic acid, 75 mg once daily will be started after DOAC discontinuation and continued indefinitely.
3492151|NCT05035264|Active Comparator|Neutral head position|Laryngeal mask will be inserted after anaesthesia induction in neutral head position
3492152|NCT05035264|Active Comparator|Sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
3492153|NCT05035264|Experimental|Beyond sniffing position|Laryngeal mask will be inserted after anaesthesia induction in sniffing head position
3492154|NCT05035095|Experimental|Oral semaglutide|Participants will receive once daily semaglutide tables in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68)
3492155|NCT05035095|Placebo Comparator|Oral semaglutide placebo|All participants are given once daily dose for 68 weeks
3492156|NCT05035082|Experimental|oral semaglutide|All participants are given tablets used in addition to metformin.
3129527|NCT03224403|Active Comparator|Commercial ibuprofen|Commercial ibuprofen, 400 mg dose
3129528|NCT03224403|Placebo Comparator|Placebo|Placebo
3492157|NCT05035082|Active Comparator|other oral glucose lowering medication|All participants are given tablets used in addition to metformin.
3492158|NCT05033886|Experimental|fezolinetant|Participants will receive 2 tablets of fezolinetant once daily for 24 weeks.
3129529|NCT03224520|Experimental|Fully enhanced|Peer recruitment and recommender CTHC
3492159|NCT05033886|Placebo Comparator|placebo fezolinetant|Participants will receive 2 tablets of matching placebo once daily for 24 weeks.
3492160|NCT05033717|Experimental|Group A|Tissue Flossing Technique
3129530|NCT03224520|Experimental|Recommender CTHC only|Recommender CTHC and standard online recruitment
3492161|NCT05033717|Active Comparator|Group B|Static Stretching exercises
3492162|NCT05031806|Experimental|iNexin™ (0.08% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
3492163|NCT05031806|Experimental|iNexin™ (0.4% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
3492164|NCT05031806|Experimental|iNexin™ (2.0% aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
3492165|NCT05031806|Placebo Comparator|Vehicle (eye drop formulation without aCT1)|36 eligible subjects will be randomized to Vehicle or one of three concentrations of iNexin™ to be administered bilaterally BID for 15 days (from Visit 2 to the evening of Visit 4). Subjects will be randomized 2:1 for each active concentration to Vehicle. During a 7-day study run-in period prior to randomization, all subjects will receive Vehicle eye drops (Vehicle) bilaterally BID (from Visit 1 to the evening before Visit 2).
3492166|NCT05031507||1|Subjects with rare skeletal disorders
3492167|NCT05030597|Experimental|68Ga-DOTA-FAPI and 18F-FDG PET/CT|Investigators recruit patients whom are clinically highly suspected oral cancer or recurrence after treatment. Patients undergo 68Ga-DOTA-FAPI and 18F-FDG PET/CT imaging within one week.
3129531|NCT03224520|Experimental|Peer recruitment only|Peer recruitment and standard CTHC
3129532|NCT03224520|Experimental|Standard|Standard online recruitment and standard CTHC
3129533|NCT03224585|Experimental|Anakinra|100 mg subcutaneous injection
3129534|NCT03224585|Placebo Comparator|Placebo|100 mg NaCl 0.9% subcutaneous injection
3492168|NCT05030038||Aromatase inhibitor for breast cancer treatment|Participants will receive their standard of care for breast cancer treatment which includes an aromatase inhibitor. Pre-study assessments will be done at baseline as well as stool and blood samples at baseline, then again at 4 weeks and at 12 weeks during the course of the trial.
3129535|NCT03224598|Experimental|No medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
3129536|NCT03224598|Experimental|Medically abrading|A-101 40% with the identified DPN lesions medically abraded prior to treatment
3129537|NCT03224598|Experimental|Initial cohort - no medical abrading|A-101 40% without medically abrading the identified DPN prior to treatment
3492169|NCT05028972|Experimental|Intervention: Personal Amplifier|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
3492170|NCT05028972|Other|Control: No Personal Amplifier|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
3492171|NCT05028621|Experimental|Genomic analysis|When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.
3492172|NCT05027958|Other|1|TST+ IGRA+
3492173|NCT05027958|Other|2|TST- IGRA-
3492174|NCT05027945|Experimental|Arm A|Reduced intensity regimen (Fludarabine, busulfan)+HSCT+GVHD prophylaxis
3492175|NCT05027945|Experimental|Arm B|Reduced intensity regimen (Fludarabine, low dose cyclophosphamide, 200cGY TBI, busulfan)+HSCT+GVHD prophylaxis
3129538|NCT03225001|Experimental|Failing surgical valve|Patients with a failing surgical bioprosthetic valve in the aortic position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN XT transcatheter valve.
3129539|NCT03225313|Placebo Comparator|control group|normal saline will be injected in the rectus sheath
3129540|NCT03225313|Active Comparator|Rectus block group|bupivicaine will be injected in the rectus sheath
3129541|NCT03225313|Experimental|Field block group|bupivicaine will be injected locally in a circular fashion surrounding the site of the hernia
3180097|NCT00679705|Placebo Comparator|3|Placebo
3180098|NCT00679731|Experimental|A|ABT-874
3492176|NCT05027932|Experimental|Group A|15 participants receiving IM BPL1357 &amp; IN Placebo
3492177|NCT05027932|Experimental|Group B|15 participants receiving IN BPL1357 &amp; IM Placebo
3492178|NCT05027932|Sham Comparator|Group C|15 participants receiving IM and IN placebo
3492179|NCT05027685||Renal Denervation Treatment|Patients candidate for treatment or already treated within 6 months prior to consent, as per the sites normal practice with the commercially available Paradise Ultrasound Renal Denervation System, will be enrolled in this single arm registry.
3492180|NCT05026944|Experimental|Group A|Percussive massage and static stretching exercises
3492181|NCT05026944|Other|Group B|Static stretching exercises
3492182|NCT05026931|Experimental|Group A|Foam Rolling
3492183|NCT05026931|Active Comparator|Group B|Stretching exercises
3492184|NCT05026138||Biological relatives without HPV|Biological relatives without current HPV disease serving as controls to be compared with those from affected participants for evaluation of the differences between people with HPV and without.
3492185|NCT05026138||Participants with HPV|Patients with recurrent HPV related diseases refractory to standard-of-care medical or surgical interventions.
3492186|NCT05023876|Experimental|IASTM group|
3492187|NCT05023876|Experimental|Control Group|
3492188|NCT05022147|Experimental|Alternating-Frequency DBS|In this single-arm study, all participants will receive all interventions in a crossover fashion.
3492189|NCT05022082|Experimental|Chest Physiotherapy- Aspiration- Inhaler drugs group|The study group (n=26) will first receive chest physiotherapy (tapotement or vibration) and aspiration, followed by inhaler drug therapy.
3492190|NCT05022082|Other|Inhaler drugs- Chest Physiotherapy- Aspiration group|The control group (n=26) will be administered the inhaler drug routinely administered in the intensive care unit where the study is conducted and then receive chest physiotherapy (tapotement or vibration), then nasopharyngeal and oropharyngeal aspiration
3492191|NCT05022004|Experimental|BRIN-20-01|
3492192|NCT05022004|Active Comparator|Azopt®|
3129542|NCT03225599|Experimental|Procedure|
3129543|NCT03225859|Experimental|Self-Management Program|Patients in this arm will receive the therapist assisted self-management intervention following completion of trauma-focused therapy for PTSD.
3180099|NCT00679731|Active Comparator|B|Methotrexate
3321264|NCT02017691|Experimental|Near Infrared Spectroscopy|crSO2 measurements in addition SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
3492193|NCT05021835|Experimental|ziltivekimab 15 mg|Participants will receive ziltivekimab 15 mg for up to 4 years.
3492194|NCT05021835|Placebo Comparator|Placebo (ziltivekimab)|Participants will receive placebo (ziltivekimab) for up to 4 years.
3492195|NCT05015751||Hydrocephalus Patients|Hydrocephalus patients with an existing ventriculoperitoneal shunt and symptoms of a shunt malfunction.
3492196|NCT05014815|Experimental|Arm A: Ociperlimab + tislelizumab histology-based chemotherapy|
3492197|NCT05014815|Placebo Comparator|Arm B: Placebo + tislelizumab + histology-based chemotherapy|
3492198|NCT05014360|Experimental|JNJ-64251330|Participants will receive oral dose of JNJ-64251330 twice daily for 24 Weeks.
3492199|NCT05013554|Experimental|SAR443216-Dose Escalation|Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive an IV infusion administration of SAR443216
3492200|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort A|Participants with metastatic breast cancers with HER2 high expression will receive an IV infusion administration of SAR443216
3492201|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort B|Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
3492202|NCT05013554|Experimental|SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort C|Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive an IV infusion administration of SAR443216
3492203|NCT05013554|Experimental|SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort D|Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive an IV infusion administration of SAR443216
3492204|NCT05012098|Experimental|1/Arm 1|Treatment with Bintrafusp alfa
3492205|NCT05011994|Experimental|Maintenance intervention|Participants will receive a 12-week mobile health (mHealth) intervention that consists of action planning, text messages, and coordinator support.
3492206|NCT05011188|Experimental|Does Escalation|Up to two dose levels of FOR46 will be evaluated. Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
3492207|NCT05011188|Experimental|Dose Expansion|Participants will receive a lead-in treatment period of enzalutamide monotherapy for 14 days (day -14 to day -1), followed by addition of FOR46 on Cycle 1 Day 1, at the maximum tolerated dose (MTD) as determined in Phase 1b. If participants are on enzalutamide at the time of study entry, and remain on continuous dosing at 160 mg daily, the lead-in treatment period will not be required.
3492208|NCT05009979|Experimental|1/Baseline and Post-treatment Imaging|18F-DCFPyL PET/CT imaging, CT and/or MRI and standard of care local ablative treatment
3492209|NCT05007990||Active|Participants include individuals who are caregivers of an individual with a chronic medical condition, OR individuals who support caregivers of an individual with a chronic medical condition.
3492210|NCT05007990||Bereaved|Participants include individuals who were caregivers of an individual with a chronic medical condition who has died, OR individuals who support the caregiver.
3492211|NCT05006040|Experimental|Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase|Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.
3492212|NCT05005559|Experimental|Vaccine candidate|
3492213|NCT05005559|Placebo Comparator|Saline placebo|
3492214|NCT05005221|Active Comparator|Unidirectional Text Reminders|"Participants in the unidirectional text reminder arm will receive automated text messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection.~N=15"
3492215|NCT05005221|Experimental|Bidirectional Text Communication|"Participants in the bidirectional text communication arm will also receive automated messages to remind them to collect blood samples 48 hours before, 12 hours before, and the morning of the planned sample collection but they will be asked to confirm the planned day or reschedule. On the day of sample collection participants will also reply with the time the samples are collected to trigger future reminder messages for each of the 4 samples.~N=30"
3492216|NCT05003804|Experimental|STMC-103H Part A1|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
3492217|NCT05003804|Placebo Comparator|Placebo Part A1|Once daily dosing with one capsule of placebo mixed with milk, formula, or a milk product for 28 days
3492218|NCT05003804|Experimental|STMC-102H Part A2|Once daily dosing with one capsule of STMC-103H mixed with milk, formula, or a milk product for 28 days
3492219|NCT05003804|Placebo Comparator|Placebo Part A2|Once daily dosing with one capsule of placebo mixed with milk, formula or a milk product for 28 days
3492220|NCT05003804|Experimental|STMC-103H Part B|Once daily dosing with one capsule of STMC-103H mixed with breastmilk, formula or a milk product for 28 days
3492221|NCT05003804|Placebo Comparator|Placebo Part B|Once daily dosing with one capsule of placebo mixed with breastmilk, formula or a milk product for 28 days
3492222|NCT05003336|Experimental|Xiangshao Granules|dissolve 1 sachet (4 g) of Xiangshao Granules in water to be drank 3 times a day after meal for 8 weeks
3492223|NCT05003336|Placebo Comparator|Xiangshao Granules Placebo|dissolve 1 sachet (4 g) of Xiangshao Granules placebo in water to be drank 3 times a day after meal for 8 weeks
3492224|NCT05003037|Experimental|Wild-type Genotype|
3492225|NCT05003037|Experimental|EGFR mutation|
3492226|NCT05003024|Active Comparator|TOF scan train of four ratio monitoring|Recovery of train of four ratio after sugammadex administration
3492227|NCT05003024|Experimental|ITF device tetanus stimulation monitoring|Recovery of tetanus 100 Hz ratio after sugamamdex administration
3492228|NCT05000931|Experimental|To demonstrate the safety of the Osia 2 System in a pediatric population aged 5 - 11 years.|
3492229|NCT05000515|Experimental|High-resistance inspiratory muscle strength training|Using a handheld device, participants will perform 30 breaths a day at 75% of maximal inspiratory pressure, six days a week, for three months.
3492230|NCT05000515|Active Comparator|Aerobic exercise|Participants will walk for 25 minutes a day, six days a week, for three months at a target heart rate of 40-60% heart rate reserve. Heart rate will be monitored with a heart rate monitor.
3492231|NCT04996771|Experimental|Surufatinib Combined With Toripalimab and Chemotherapy|
3492232|NCT04996771|Experimental|Surufatinib Combined With Chemotherapy|
3492233|NCT04994717|Experimental|Safety Run-in: Blinatumomab alternating with low-intensity chemotherapy|"The safety run-in will be performed prior to initiating the phase 3 randomized part of the study. This safety run-in is to evaluate the safety and tolerability of blinatumomab alternating with low-intensity chemotherapy.~The safety run-in also evaluates a shorter dose step interval from (4 days instead of 7 days) and a 1-week (instead of 2-week) drug free interval between blinatumomab cycles. Blinatumomab will be infused at a lower dose for 4 days and increase to a higher dose on Day 5 of the infusion for the remainder of the infusion."
3492234|NCT04994717|Experimental|Phase 3: Blinatumomab alternating with low-intensity chemotherapy|Participants will receive blinatumomab alternating with low-intensity chemotherapy.
3492235|NCT04994717|Active Comparator|Phase 3: Standard of care (SOC) chemotherapy|Participants will receive 1 of 2 SOC chemotherapy regimens (GMALL or HyperCVAD) per investigator's choice.
3492236|NCT04994665|Active Comparator|Sleeve gastrectomy|realization of a sleeve gastrectomy alone
3492237|NCT04994665|Experimental|sleeve gastrectomy with omentopexy|realization of a sleeve gastrectomy followed by an omentopexy
3492238|NCT04993664|Experimental|Pelacarsen group (TQJ230)|The first group will receive 80 mg of pelacarsen every month subcutaneously for 6 months.
3492239|NCT04993664|Placebo Comparator|Placebo group|The first group will receive 80 mg of placebo every month subcutaneously for 6 months.
3492240|NCT04993443|Experimental|Active Comparator: Drug :LQ036|Experimental, Single and Multiple Oral escalating dose
3492241|NCT04993443|Placebo Comparator|Placebo Comparator: Matching Placebo for LQ036|Matching Placebo for LQ036: Matching Placebo
3492242|NCT04991740|Experimental|Part 1: Dose Escalation|Participants with renal cell carcinoma (RCC), ovarian cancer, colorectal cancer (CRC), and other tumor types with sponsor approval will receive JNJ-78306358. The dose will be escalated sequentially based on the decisions of the study evaluation team until the recommended phase 2 dose (RP2D) regimen(s) have been identified.
3492243|NCT04991740|Experimental|Part 2: Dose Expansion|Participants with RCC, ovarian cancer, CRC and other types of tumors will receive JNJ-78306358 at the RP2D regimen(s) determined in Part 1.
3492244|NCT04990427|Experimental|CLBS201|CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
3492245|NCT04988295|Experimental|Arm A: LACP (Lazertinib, Amivantamab, Carboplatin, and Pemetrexed)|Participants will receive Lazertinib orally along with Amivantamab, Pemetrexed, and Carboplatin as intravenous (IV) infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Lazertinib, Pemetrexed, and Amivantamab as maintenance until disease progression.
3492246|NCT04988295|Active Comparator|Arm B: CP (Carboplatin and Pemetrexed)|Participants will receive Pemetrexed in combination with Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Pemetrexed as maintenance until disease progression.
3492247|NCT04988295|Experimental|Arm C: ACP (Amivantamab, Carboplatin and Pemetrexed)|Participants will receive Amivantamab, Pemetrexed, and Carboplatin as IV infusion for up to 4 cycles (each cycle consists of 21 days). After 4 cycles, participants will receive Amivantamab and Pemetrexed as maintenance until disease progression.
3492248|NCT04988087|Experimental|SjS participants: MHV370|SjS participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
3492249|NCT04988087|Placebo Comparator|SjS participants: Placebo|SjS participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
3492250|NCT04988087|Experimental|MCTD participants: MHV370|MCTD participants randomized in the MHV370 arm will be treated with MHV370 for 24 weeks. Double-blind supply will be used.
3492251|NCT04988087|Placebo Comparator|MCTD participants: Placebo|MCTD participants randomized in the placebo arm will be treated with placebo for 24 weeks. Double-blind supply will be used.
3492252|NCT04988035|Experimental|Remdesivir + Danicopan (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
3492253|NCT04988035|Experimental|Remdesivir + Danicopan (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan, followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan participants, N=100.
3492254|NCT04988035|Active Comparator|Remdesivir + Placebo (< 70 years)|For participants < 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized, and 400 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) loading dose danicopan matching placebo, followed by 250 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 250 mg 3 times daily (TID) for 2 days, followed by 250 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
3492255|NCT04988035|Active Comparator|Remdesivir + Placebo (>/= 70 years)|For participants >/= 70 years, 200 mg intravenous (IV) loading dose of Remdesivir on Day 1, followed by a 100 mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 300 mg oral (PO) (or via nasogastric [NG] or gastrostomy [G] tube) of loading dose danicopan matching placebo followed by 200 mg 4 times daily (QID) for the duration of the hospitalization up to a 14-day total course. End of danicopan matching placebo treatment tapered as 200 mg 3 times daily (TID) for 2 days, followed by 200 mg twice daily (BID) for 2 days, until complete cessation (total treatment duration up to 18 days or 4 days after discharge). Total danicopan matching placebo participants, N=100.
3492256|NCT04984876|Experimental|ligelizumab 240 mg|ligelizumab 240 mg subcutaneous injection for 52 weeks
3321265|NCT02017691|Other|Pulse-oximetry|Only SpO2 measurements will be visible to guide supplemental oxygen support and respiratory support according predefined interventions depending on the infants breathing efforts and the heart rate during the first 15 minutes after birth
3129544|NCT03226223|Placebo Comparator|Naltrexone 0 mg|This aim assess the effects of pretreatment with 0 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
3129545|NCT03226223|Experimental|Naltrexone 50 mg|This aim assess the effects of pretreatment with 50 mg of naltrexone on laboratory measures of the abuse potential of methamphetamine (30mg/70 kg).
3129546|NCT03226249|Experimental|Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)|See Detailed Description
3129547|NCT03226275|Experimental|Fasting: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
3129548|NCT03226275|Experimental|Fasting: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fasting conditions. The two periods were separated by a washout period of 14 days.
3492257|NCT04984876|Experimental|ligelizumab 120 mg|ligelizumab 120 mg subcutaneous injection for 52 weeks
3492258|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 120 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 120 mg subcutaneous injection for 44 weeks
3492259|NCT04984876|Experimental|Placebo 16 weeks and ligelizumab 120 mg/240 mg|Placebo subcutaneous injection for first 16 weeks and ligelizumab 120 mg OR 240 mg subcutaneous injection for 36 weeks
3492260|NCT04984876|Experimental|Placebo 8 weeks and ligelizumab 240 mg|Placebo subcutaneous injection for first 8 weeks and ligelizumab 240 mg subcutaneous injection for 44 weeks
3492261|NCT04983251||U3 Women|Women in under-studied, under-represented, and under-reported (U3) populations.
3492262|NCT04982029|Experimental|Cannabidiol 600mg|All subjects will receive 600mg of oral cannabidiol in a double-blind fashion. Cannabidiol will be provided using Epidiolex™ oral solution 100mg/mL. Following administration, a battery of tests will be conducted to examine reward- and stress-related neurocognitive processes.
3492263|NCT04982029|Placebo Comparator|Placebo|All subjects will receive a matching placebo in a double-blind fashion. Following administration, a battery of tests will be conducted to examine the impact on reward- and stress-related neurocognitive processes.
3492264|NCT04980846|Experimental|Intervention group|Intervention: Other: Driving under the influence of alcohol with a driving simulator
3492265|NCT04980820|Experimental|FFP2|This arm starts with a FFP2 mask and switches to a FFP3 mask.
3492266|NCT04980820|Experimental|FFP3|This arm starts with a FFP3 mask and switches to a FFP2 mask.
3492267|NCT04978519|Experimental|Cryotherapy|Cryotherapy achieves a temperature averaging -40°C. Through the transperineal insertion of treatment probes, it exerts its effect through freezing of tissue and vascular injury, leading to destruction of cancer tissue.
3492268|NCT04977986|Experimental|ZYN002 - transdermal gel|Pharmaceutically manufactured. Cannabidiol is formulated as a clear gel for transdermal delivery.
3492269|NCT04977986|Placebo Comparator|Placebo transdermal gel|Placebo is formulated as a clear gel for transdermal delivery.
3492270|NCT04977466||Group #1 / Pregnant Female NIH Participants|Female NIH study participants.
3492271|NCT04977466||Group #2 / Male and Female Partners|Male or female partners of women who participated in NIH intramural clinical trials and that became pregnant.
3492272|NCT04977466||Group #3 / Pregnant Female Partners of Male or Female NIH Clinical Trial Partici|Female partners of NIH intramural clinical trial participants who became pregnant while their partner was or within 1 year after the last day of intervention after their partner was on a study.
3492273|NCT04977466||Group #4 / Neonate or Offspring of a Pregnant Female Participant or Pregnant Fe|Offspring from birth to 12 months of age and born to female participants / female partners.
3321266|NCT02017704|Active Comparator|IMRT and Capecitabine (potentially randomized to this arm)|"Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
3492274|NCT04977232|Experimental|Escitalopram + game intervention|Escitalopram treatment and game intervention are given in combinations for 8 weeks.
3492275|NCT04977232|Active Comparator|Escitalopram|Escitalopram treatment for 8 weeks
3492276|NCT04976790|Experimental|Chinese Tuina group (CTG)|The participants in Chinese Tuina group will receive the traditional Chinese Tuina therapy on the basis of health education and home-exercise. All the treatment will cost 20-25 minutes. Patients in this group received 4 treatments over 14 days.
3492277|NCT04976790|Active Comparator|Flurbiprofen Cataplasms group (FCG)|The FCG group received flurbiprofen gel on the basis of the health education and home-exercise, twice daily, for 14 days.
3492278|NCT04976218|Experimental|Experimental arm|Enrolled patients in this arm will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner.
3492279|NCT04975815||Non-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores0 will place the participants in Non-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
3492280|NCT04975815||Pre-frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores1-2 will place the participants in Pre-frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
3492281|NCT04975815||Frail group|"Participants will be assessed using five criteria from the Fried Frailty Index. Index scores3-5 will place the participants in Frail group.~Fried Frailty Index scale determines frailty phenotypes through the assessment of five criteria including walking speed, weight loss, weakness (grip strength), and self-reports of physical activity and exhaustion."
3492282|NCT04974996|Experimental|Part 1: Dose Escalation|Participants will receive escalating doses of loncastuximab tesirine (initial dose of 60 μg/kg and highest dose possibly tested of 150 µg/kg) in combination with R-CHOP (rituximab 375 mg/m^2, cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, and prednisone 100 mg/day) according to a standard 3+3 dose escalation design. The dose escalation part will be completed once the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) has been identified.
3492283|NCT04974996|Experimental|Part 2: Dose Expansion|Participants will receive the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of loncastuximab tesirine in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as determined in Part 1.
3492284|NCT04973930|Active Comparator|Tele-Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy is a time-limited, affect-focused treatment of repeatedly demonstrated efficacy for major depression in the general population. It was also helpful to patients with comorbid depression and breast cancer in our prior randomized controlled trial. IPT focuses on the connection between upsetting life circumstances (e.g., diagnosis of breast cancer) and their effect on mood, and vice versa. We have considerable experience, enhanced by the Covid-19 lockdown, in delivering IPT as a HIPAA-secure tele-therapy.
3492285|NCT04973930|Active Comparator|Tele-Serotonin Reuptake Inhibitor|Both venlafaxine and escitalopram are FDA-approved treatments with demonstrated efficacy in treating major depression in the general population. Although little formal research has been done in treating patients with depression and breast cancer, these two are the favored treatments among serotonin reuptake inhibitors due to minimal interference with oncotherapy. The choice between prescribing these two study medications will depend upon prior treatment history. Venlafaxine XR will be serially titrated under expert psychopharmacologist tele-guidance from 75 mg to 300 mg daily, depending on clinical response and tolerance. Escitalopram will similarly be dosed between 5 mg and 30 mg daily.
3492286|NCT04973670|Experimental|Sivelestat sodium|Sivelestat sodium 0.2mg/kg.h
3492287|NCT04973670|Active Comparator|placebo|The same amount of NS containing only sivelestat sodium excipients
3492288|NCT04971655|Experimental|Music therapy group|When individuals with diabetes apply to diabetes education after their polyclinic examination, music therapy will be applied in addition to routine monitoring and applications throughout the education. Turkish Folk, Classical, Turkish Art and Sufi Music genres will be offered as options to the individuals in the intervention group and will be listened to throughout the process. During the training, the selected music will be played over the loudspeaker. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
3492289|NCT04971655|No Intervention|Control group|When individuals apply to diabetes education after their polyclinic examinations, routine monitoring and application will be made throughout the education. Before the training, this group; Patient Description Form and Spielberger State-Trait Anxiety Scale will be applied. After the training, Visual Analogue Scale and State Anxiety Scale will be applied.
3492290|NCT04969913||19 + years|Healthy adults over the age of 19 years
3492291|NCT04969913||Ages 11 - 18 years|Healthy children between the ages of 11 and 18 years
3180100|NCT00679744|Active Comparator|4 dose levels|Pyrimethamine at 6.25, 12.5, 25 and 37.5 mg/day will be evaluated sequentially, starting from 6.25 mg/day. Escalation from 6.25 mg/day to 12.5 mg/day, and from 12.5 mg/day to 25 mg/day, will not perform until all patients in the previous dose cohort have been treated for 4 weeks and until results obtained 4 weeks after treatment initiation do not reveal toxicity. Additionally, escalation from 25 mg/day to 37.5 mg/day will not perform until all patients in the 25-mg/day cohort have been treated for 8 weeks, and until results obtained 4 weeks after the 8-week treatment do not reveal toxicity. Dose escalation is considered complete, if 2 patients experience a Grade 3 Adverse Event (AE) or if 1 patient experiences a Grade 4 AE at a particular cohort.
3492292|NCT04969913||Ages 5 - 10 years|Healthy children between the ages of 5 and 10 years
3492293|NCT04969913||Ages 6 months - 4 years|Healthy infants between the ages of 6 months and four years
3492294|NCT04969718|Experimental|LEADS Plus educational posters|A total of six group sessions with students using presentations and videos.
3492295|NCT04969718|Experimental|Question, Persuade, and Refer (Teachers) Plus educational posters|It is a manualised programme for gatekeepers (teachers). This includes both presentations and videos.
3492296|NCT04969718|Experimental|Screening by Professionals programme Plus educational posters|This is an indicated or selective intervention by health professionals who will review assessments (done using structured questionnaires) and refer students where necessary.
3492297|NCT04969718|Active Comparator|Educational poster|The control group will be exposed to the six educational posters.
3492298|NCT04969718|Experimental|Question, Persuade, and Refer (Parents) Plus educational posters|It is a manualised programme for gatekeepers (parents). This includes both presentations and videos.
3492299|NCT04969198|Experimental|Nicotine Patch + Nicotine Mini Lozenge|"No medication for 1 Week after Target Quit Day (TQD). Medication started 1 Week after TQD.~Patches (Nicotine): 14 mg Patches for 4 weeks postquit (Week 1-5), then 7 mg patches for 4 weeks (Week 6-9)~Mini Lozenge (Nicotine): 2 mg Mini Lozenges 5x per day (up to 20x day max) for 8 weeks post quit (Week 1-9)"
3492300|NCT04968184|Placebo Comparator|Placebo|All eligible participants will receive KBP-5074 matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period, then up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period, and thereafter for 4 weeks, during the randomized Double-blind withdrawal period.
3129549|NCT03226275|Experimental|Fed: First Bisoprolol-Amlodipine FDC, Then Both Separately|Participants received a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 1 in treatment period 1 followed by a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
3129550|NCT03226275|Experimental|Fed: First Bisoprolol and Amlodipine Separately, Then FDC|Participants received a single oral dose of 5 mg bisoprolol and a single oral dose of 5 mg amlodipine given concomitantly on Day 1 in treatment period 1 followed by a single oral dose of 5 mg/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) on Day 15 in treatment period 2 under fed conditions. The two periods were separated by a washout period of 14 days.
3492301|NCT04968184|Experimental|KBP-5074|All eligible participants will receive KBP-5074, for up to 24 weeks during the Double-blind treatment Period and during the Open-label treatment period. Thereafter, eligible participants will continue current dose of KBP-5074 at the end of the Open-label treatment period.
3129551|NCT03226353|Experimental|somofilcon A 1-day soft contact lenses|Habitual and refitted wearers of omafilcon A were refit into somofilcon A for a week
3129552|NCT03226366||Pre-implementation (intervention site)|Adult patients age ≥18 years who received usual care after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
3492302|NCT04967274|Experimental|Spinal cord injured subjects|
3492303|NCT04963166||Cohort 1|2 - 6 year olds
3492304|NCT04963166||Cohort 2|7 - 11 year olds
3492305|NCT04963166||Cohort 3|12 - 17 year olds
3492306|NCT04962646|Experimental|Intervention|Once the thoracic cavity os opened during surgery, carbon dioxide flooding using a diffusor will be instigated with a flow of 5L/min. The flooding will be terminated once the aorta and the heart have no open contact with surrounding air.
3492307|NCT04962646|No Intervention|Control|No intervention. No sham will be used as the staff performing the surgery would have been able to detect the lack of carbon dioxide in the surgical wound.
3492308|NCT04962633|Experimental|Probiotic Pasta Group|Subjects in the Probiotic Pasta group will consume 80 g per day of a probiotic pasta for 4 weeks
3492309|NCT04962633|Active Comparator|Control Pasta Group|Control Pasta Subjects in the Control Pasta group will consume 80 g per day of conventional pasta for 4 weeks.
3492310|NCT04959188||Bereaved caregivers|Parents of patients with dyskeratosis congenita or a related telomere biology disorder who has passed away.
3492311|NCT04959188||Caregivers|Family and/or caregivers of patients with dyskeratosis congenita or a related telomere biology disorder.
3492312|NCT04959188||Patients|Patients with dyskeratosis congenita or a related telomere biology disorder.
3492313|NCT04957719|Experimental|Selatogrel|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
3492314|NCT04957719|Placebo Comparator|Placebo|Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
3492315|NCT04955314|Experimental|PA mobilizations on their main painfull vertebral segment|Patients who will be treated with PA mobilizations on their main painfull vertebral segment.
3492316|NCT04955314|Experimental|PA mobilizations on an adjacent vertebral segment from the most painful|Patients who will be treated with PA mobilizations on an adjacent vertebral segment from the most painful.
3492317|NCT04954287|Experimental|Young adult cohort (age 18-55), low dose|CVXGA1 administered as a single dose of 1 x 10^6 PFU by intranasal route on Day 1
3492318|NCT04954287|Experimental|Young adult cohort (age 18-55), high dose|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1
3492319|NCT04954287|Experimental|Older adult cohort (age 56-75), low dose|CVXGA1 administered as a single dose of 1 x 10^6 PFU by intranasal route on Day 1
3180101|NCT00679770|Experimental|Group 1|AN2690 Solution: 2.5%
3180102|NCT00679770|Experimental|Group 2|AN2690 Solution: 5%
3492320|NCT04954287|Experimental|Older adult cohort (age 56-75), high dose|CVXGA1 administered as a single dose of 1 x 10^7 PFU by intranasal route on Day 1
3492321|NCT04952402|Experimental|mRNA-based COVID-19 vaccine|To be administered intramuscularly (IM) at Day 0 and Day 28.
3492322|NCT04951492|Experimental|Treatment (Olaparib)|Patients receive olaparib orally (PO) twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3492323|NCT04950309|Experimental|OPM Array studies|Testing of a final 49-61 channel OPM MEG system and any interim arrays
3492324|NCT04949399|Experimental|BOTOX|BOTOX will be injected into the platysma muscle on Day 1
3492325|NCT04949399|Placebo Comparator|Placebo|Placebo will be injected into the platysma muscle on Day 1
3492326|NCT04948931|Experimental|Lavender aromatherapy|As an intervention to this group, lavender application will be made by inhalation. Participants will apply lavender oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
3492327|NCT04948931|Experimental|Rosemary aromatherapy|As an intervention to this group, rosemary application will be made by inhalation. Participants will apply rosemary oil in half an hour before going to bed every night for a month under the supervision of a relative. The application will be done by dripping three drops on cotton, holding it 5-10 cm away from the nose for five minutes and breathing normally.
3492328|NCT04948931|Placebo Comparator|Control|Distilled water will be used for the application to this group. The application will be made every night for a month, half an hour before going to bed, under the supervision of a relative. Participants will apply distilled water by dropping three drops on cotton, holding it 5-10 cm away from the nose, for five minutes and breathing normally.
3492329|NCT04947579|Experimental|Administration of CC-99677 150 mg QD PO|49 participants will be randomized to CC-99677 150 mg in biologic naive main study
3129553|NCT03226366||Post-implementation (intervention site)|"Adult patients age ≥18 years eligible to receive immediate evaluation by multidisciplinary team (swarming) after presenting to the ED of the intervention hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017"
3180103|NCT00679770|Experimental|Group 3|AN2690 Solution: 7.5%
3492330|NCT04947579|Experimental|Administration of CC-99677 60mg QD PO|49 participants will be randomized to CC-99677 60 mg in biologic naive main study
3492331|NCT04947579|Placebo Comparator|Administration of Placebo QD PO|49 participants will be randomized to placebo in biologic naive main study
3492332|NCT04947579|Experimental|Administration of CC-99677 150 mg QD PO.|20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
3180104|NCT00679770|Placebo Comparator|Group 4|AN2690 Solution Vehicle
3492333|NCT04947579|Experimental|Administration of CC-99677 60mg QD PO.|20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
3180105|NCT00679796||Group A|Subjects with PCR confirmed varicella
3180106|NCT00679796||Group B|Age- and practice-matched control subjects
3180107|NCT00679822||Heart Failure|Heart Failure Out Patients at OSU
3492334|NCT04947579|Placebo Comparator|Placebo additional dose cohort|10 participants will be randomized to placebo in biologic-failure substudy
3492335|NCT04947007|Active Comparator|Group 1|In this group, US guided suprascapulary and axillary nerve block will be performed with 15cc+15c local anesthetic.
3492336|NCT04947007|Active Comparator|Group 2|In this group, US guided suprascapulary and axillary nerve block will be performed with 10cc+10c local anesthetic.
3492337|NCT04947007|Active Comparator|Group 3|In this group, US guided suprascapulary and axillary nerve block will be performed with 5cc+5c local anesthetic.
3492338|NCT04947007|Active Comparator|Group 4|In this group, US guided suprascapulary and axillary nerve block will be performed with serum physiologic.
3492339|NCT04945330||Gastrointestinal (GI)|Participants with GI cancer.
3492340|NCT04945330||Head and neck (H&N)|Participants with H&N cancer.
3492341|NCT04945330||Lung|Participants with lung cancer.
3492342|NCT04945330||Soft tissue sarcoma (STS)|Participants with STS cancer.
3492343|NCT04945330||Primary central nervous system (CNS)|Participants with CNS cancer.
3492344|NCT04945330||Melanoma|Participants with Melanoma cancer.
3492345|NCT04945330||Pediatrics|
3492346|NCT04945330||Others|
3492347|NCT04944368|Experimental|Vaccine candidate|
3492348|NCT04944368|Placebo Comparator|Saline placebo|
3492349|NCT04942028|Experimental|Internet-delivered exposure-based treatment|10 weeks of therapist-guided exposure-based treatment delivered via the Internet.
3492350|NCT04942028|Active Comparator|Internet-delivered standardized education and prolonged assessment|10 weeks of therapist-guided intervention based on prolonged assessment and routine care educational material delivered via the Internet.
3492351|NCT04940338|Experimental|Bromfenac|Group 1 will receive topical bromfenac (0.9 mg/mL) 2x daily, 7 days before the surgery
3492352|NCT04940338|Experimental|Dexamethasone|Group 2 will receive topical dexamethasone (1mg/mL) 3x daily before the surgery
3492353|NCT04940338|Placebo Comparator|Placebo|Group 3 will receive topical placebo (artificial tears substitute) 2x daily before the surgery
3129554|NCT03226366||Pre-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2015 and April 15, 2016
3492354|NCT04939428|Experimental|Molnupiravir|Participants take molnupiravir 800 mg every 12 hours (Q12H) on Days 1 to 5.
3492355|NCT04939428|Placebo Comparator|Placebo|Participants take placebo Q12H on Days 1 to 5.
3492356|NCT04939064||ART Infertile|Women that are part of a couple diagnosed with unexplained infertility that conceived on the first embryo transfer (ET) attempt
3492357|NCT04939064||Early Implantation Failure (EIF)|Infertility defined by a failure to conceive after: a) three or more failed transfers of high-quality blastocyst(s) (grade 3BB or higher); or b) two or more transfers of euploid blastocyst
3492358|NCT04939064||Early Pregnancy Failure (EPF)|defined by two or more biochemical pregnancies after transfer of a high-quality or euploid blastocyst with a positive hCG 12 days after ET but without subsequent clinical signs of pregnancy
3492359|NCT04939064||Normal Fertile|Women with proven parity based on spontaneous conception without fertility treatment or prior diagnosis of infertility, normal uncomplicated pregnancy, birth of at least one healthy baby
3492360|NCT04939064||Recurrent Pregnancy Loss (RPL)|defined as the loss of two or more pregnancies after transfer of a high-quality or euploid blastocyst with a positive HCG 12 days after ET and subsequent clinical signs of pregnancy
3492361|NCT04937166|Experimental|DSP107 monotherapy and in combination with azacitidine or azacitidine plus venetoclax.|"DSP107 will be administered by intravenous infusion once weekly during each 28-day cycle to all patients in this study.~Azacitidine (75 mg/m2/day) will be administered subcutaneously or intravenously for the first 7 days of every cycle.~Patients enrolled in Part B only will also receive venetoclax. During Cycle 1, venetoclax will be dose escalated daily to the goal dose of 400 mg daily. Patients will receive 100 mg on Day 1, 200 mg on Day 2 and 400 mg on Day 3 and onwards."
3492362|NCT04937088|Placebo Comparator|Placebo|Soy Bean Oil identical packaging as the active arm, taken once daily by mouth for 30 days.
3492363|NCT04937088|Active Comparator|Liquid ASA|Aspirin 150 mg liquid formulation (2.5%w/w) taken once daily by mouth for 30 days
3492364|NCT04936308|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.
3492365|NCT04936308|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
3492366|NCT04936308|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive guselkumab SC.
3129555|NCT03226366||Post-implementation (control site)|Adult patients age ≥18 years who received usual care after presenting to the ED of a non-intervention study hospital with sepsis or septic shock between May 16, 2016 and February 15, 2017
3129556|NCT03226392|Active Comparator|QAW039|QAW039 once daily
3492367|NCT04934540||Patients undergoing ERBT|Patients who are diagnosed with bladder tumors and planning for ERBT.
3492368|NCT04933617|Experimental|1- Dose Escalation|Copanlisib (IV) per dose level (30 mg, 45 mg, or 60 mg) on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R to determine RP2D and MTD of copanlisib. Up to 6 cycles total.
3492369|NCT04933617|Experimental|2 - Dose Expansion|Copanlisib (IV) at the RP2D or MTD on days 1 and 5 of each 21-day cycle in combination with standard dosing DA-EPOCH-R. Up to 6 cycles total.
3492370|NCT04933539|Experimental|Arm 1|Daratumumab SC (Cycles 1-2: Days 1, 8, 15, 22; Cycles 3-6: Days 1, 15; Cycles =7: Days 1 of the 28-day cycle); Carfilzomib IV (Days 1, 8, 15 of the 28-day cycle); Dexamethasone PO/IV (Days 1, 8, 15, 22 of the 28-day cycle)
3492371|NCT04930874|Experimental|ICU patients with COVID-19|NIRS monitoring will be performed for approximately 90 minutes at 2 mean blood pressure levels (MAP, ie 65-70 mmHg and 95-100 mmHg) within 12-48 hours and 60-84 hours after admission to the ICU for severe COVID-19 infection. Autoregulation will be assessed using Tissue Oxygenation Index values and mean arterial pressure values in a regression analysis and will be considered sufficient if the relative Pearson correlation coefficient is less than 0.3. Cerebral blood flow will be assessed by blood flow index determination after intravenous infusion of 5 mg indocyanine.
3492372|NCT04929041|Experimental|Arm A (immunotherapy, +/- chemotherapy)|See Detailed Description
3492373|NCT04929041|Experimental|Arm B ( immunotherapy, +/- chemotherapy, SBRT)|Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of SBRT every other day.
3492374|NCT04927442||Covid-19 patients|Patients, male or female, 18 to 65 years old, who tested positive for COVID-19 (PCR or rapid test) =5 days before enrollment.
3492375|NCT04927429||Affected participants|Participants with a clinically indicated referral for cardiac MRI
3129557|NCT03226392|Placebo Comparator|Placebo|Placebo once daily
3129558|NCT03226457|Active Comparator|Empagliflozin/Placebo|Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks, minimum of a 2 week washout period, then 6 weeks placebo
3180108|NCT00679835|Experimental|Group 1|8 mg/kg over a one hour infusion
3492376|NCT04927429||Healthy participants|Healthy individuals of various ethnicities to serve as reference ranges
3492377|NCT04927390|Experimental|Mycophenolate Mofetil (MMF) Arm|Participants will receive mycophenolate mofetil (MMF) for up to 96 weeks, in addition to their background Standard of Care medication for systemic sclerosis related symptoms. They will receive 500mg twice daily over the first 4 weeks following their randomisation, and if tolerated the dose will be increased to a target dose of 1g twice daily starting from week 5 until their Final visit.
3492378|NCT04927390|No Intervention|Control Arm|Standard of Care (no immunosuppression) for systemic sclerosis related symptoms.
3492379|NCT04927325|Other|central line with a reddened exit site|A standardized set of photos will be taken of 10 central lines with an erythema at exit site (visible to the naked eye)
3492380|NCT04927325|Other|Control Group: central line without a reddened exit site|A standardized set of photos will be taken of 10 newly inserted CVC (as a control over time to evaluate the in-patient redness and the impact of irritation of a CVC)
3492381|NCT04926922||HONOR participants at Month 12|Adult participants who agree to participate and meet the study-specific eligibility criteria at their Month 12 HONOR study visit
3492382|NCT04926818|Experimental|ofatumumab - 20 mg injection/ placebo|Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
3129559|NCT03226457|Active Comparator|Placebo/Empagliflozin|Placebo for 6 weeks, minimum of a 2 week washout period, followed by Empagliflozin (SGLT2 inhibitor) 25mg capsules once daily for 6 weeks
3129560|NCT03226652||Patients with clinically suspected sleep disordered breathing (SDB)|Patients referred for Sleep disordered breathing assessment.
3129561|NCT03226691|Experimental|Single Cohort - Plerixafor|Plerixafor at a single dose of 240 microgram/kg
3129562|NCT03226769|Active Comparator|Thermalon|Participants received application of Thermalon dry eye compress on Days 0 and 7 followed by daily use as per label instructions.
3129563|NCT03226769|Experimental|TrueTear™|Participants received TrueTear™ device intranasally for approximately 8 minutes on Day 0, for approximately 3 minutes on Day 7 followed by daily use of TrueTear™ per participant guide.
3129564|NCT03226899|Active Comparator|Lesinurad + XOI|lesinurad 200 mg oral tablet QD plus a stable, medically appropriate dose of an XOI
3129565|NCT03226899|Placebo Comparator|Placebo + XOI|placebo tablet QD plus a stable, medically appropriate dose of an XOI
3129566|NCT03227029|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants received a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
3129567|NCT03227029|Experimental|RSV 276 vaccine|Participants received a single dose of the RSV 276 vaccine at study entry (Day 0).
3129568|NCT03227029|Placebo Comparator|Placebo|Participants received a single dose of placebo at study entry (Day 0).
3492383|NCT04926818|Experimental|siponimod - 0.5 mg, 1 mg or 2 mg/ placebo|Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
3492384|NCT04926818|Active Comparator|fingolimod - 0.5 mg or 0.25 mg/ placebo|Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
3492385|NCT04926376|Experimental|EYE90 Microspheres Treament|Radioembolization with Eye90 Microspheres
3492386|NCT04924842||Children|Hospitalized children, 0 to 17 years of age, 30 subjects, consecutive sample survey, recruitment in quotas of five age ranges.
3492387|NCT04924842||Adults|Hospitalized adults, 18 years and above, 60 matched subjects
3492388|NCT04923893|Experimental|Arm A: VRd+Rd (Standard Therapy)|Participants will receive bortezomib, lenalidomide, and dexamethasone (VRd) regimen for 6 cycles before randomization. Following randomization, participants in Arm A will receive 2 more cycles of VRd. In VRd treatment, participants will receive bortezomib 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each cycle (Cycles 1 to 8), oral lenalidomide 25 mg on Days 1 to 14 of each cycle (Cycles 1 to 8) and oral dexamethasone 25 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle (Cycles 1 to 8). Each cycle will consist of 21 days. After 8 cycles of VRd, treatment will continue with lenalidomide and dexamethasone (Rd) maintenance therapy. In Rd treatment, participants will receive oral lenalidomide 25 mg on Days 1 to 21 of each cycle and oral dexamethasone 40 mg on Days 1, 8, 15, and 22 of each cycle. Each cycle will consist of 28 days. Participants will continue to receive Rd until confirmed progressive disease or unacceptable toxicity.
3492389|NCT04923893|Experimental|Arm B: VRd+Ciltacabtagene Autoleucel (Cilta-cel)|Participants will receive VRd regimen for 6 cycles before randomization. Following randomization, participants in Arm B will undergo apheresis and receive two more cycles of VRd as bridging therapy. In VRd treatment, participants will receive bortezomib 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each cycle for Cycles 1 to 8; oral lenalidomide 25 mg on days 1 to 14 of each cycle for Cycles 1 to 8 and oral dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle for Cycles 1 to 8. Each cycle will consist of 21 days. After 8 cycles of VRd, participants will receive a conditioning regimen (cyclophosphamide 300 mg/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily for 3 days) and Cilta-cel infusion 0.75*10^6 chimeric antigen receptor (CAR)-positive viable T cells/kilogram (kg).
3492390|NCT04923178||1/Non-invasive urothelial cancer|Participants with high-grade and, low-grade non-invasive bladder cancer
3492391|NCT04923178||2/Muscle invasive bladder and high-grade upper tract urothelial cancer|Participants with muscle invasive bladder and invasive upper tract urothelial cancer
3492392|NCT04923178||3/Variant urothelial cancer|Participants diagnosed with a urothelial variant histologies at any stage
3492393|NCT04923178||4/Metastatic Urothelial cancer|Participants diagnosed with urothelial cancer who cannot be placed in cohorts 1-3
3492394|NCT04923178||5/Localized rare genitourinary tumors|Participants with localized rare genitourinary tumors treated with curative intent
3129569|NCT03227445|Experimental|Treatment sequence A|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
3129570|NCT03227445|Experimental|Treatment sequence B|Eligible subjects will use ELLIPTA DPI QD for 28 days in Period 1 followed by DISKUS BID with HandiHaler QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
3180109|NCT00679835|Experimental|Group 2|10mg/kg over a one or two hour infusion
3129571|NCT03227445|Experimental|Treatment sequence C|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 1 at Visit 3 (Day 56).
3129572|NCT03227445|Experimental|Treatment sequence D|Eligible subjects will use DISKUS BID with HandiHaler QD for 28 days in Period 1 followed by ELLIPTA DPI QD use for 28 days in Period 2. These subjects will then be asked to complete preference questionnaire 2 at Visit 3 (Day 56).
3492395|NCT04923178||6/Locally advanced and metastatic rare genitourinary tumors|Participants with locally advanced and metastatic rare genitourinary tumors
3492396|NCT04919707|Experimental|Older Adolescent Soccer Players|10 male, 10 female soccer players, grades 11-12, age 16-18 Neurocognitive measures, physical measures, header session, MRI
3492397|NCT04919707|Experimental|Younger Adolescent Soccer Players|10 male, 10 female soccer players, grades 6-7, age 12-13 Neurocognitive measures, physical measures, header session, MRI
3492398|NCT04919512|Experimental|Cohort 1: TAR-200 + Cetrelimab|Participants will receive TAR-200 in combination with cetrelimab.
3492399|NCT04919512|Experimental|Cohort 2: Cetrelimab|Participants will receive cetrelimab.
3129573|NCT03227692|Experimental|Persona with iASSIST Knee|Having total knee arthroplasty (Persona Knee System) surgery with the use of a navigation system iASSIST Knee.
3492400|NCT04919031|Experimental|study|Inspiratory muscle trainer plus diaphragmatic release and traditional medications
3492401|NCT04919031|Active Comparator|control|inspiratory muscle trainer plus traditional medications
3492402|NCT04915183|Other|1|randomization to either placebo or atorvastin
3492403|NCT04915183|No Intervention|2|observational
3492404|NCT04914429|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligrams (mg) by subcutaneous (SC) injection at Weeks 0, 4, and then every 8 weeks (q8w) through Week 44. Participants will receive matching placebo at Week 16.
3492405|NCT04914429|Placebo Comparator|Group 2: Placebo|Participants will receive placebo SC injection for guselkumab at Weeks 0, 4, and 12, and then cross over at Week 16 to receive guselkumab 100 mg SC injection at Weeks 16 and 20 and q8w thereafter through Week 44.
3492406|NCT04913961|Experimental|Supine Daoyin|During hospitalization, the rehabilitation group will receive conventional western medicine treatment and supine guidance therapy which consists of training and patient education. They will be evaluated with some tests for the study.
3492407|NCT04913961|Active Comparator|Control|The control group will get the western medicine conventional therapy with some additional tests for the study.
3492408|NCT04911361|Active Comparator|Topical loteprednol suspension in both eyes|25 subjects will be randomized to receive treatment loteprednol etabonate 0.5% suspension QID for 2 weeks.
3492409|NCT04911361|Experimental|Lower eyelid canaliculi DEXTENZA insertion (study group)|25 subjects will be randomized to receive treatment of OTX-DED
3492410|NCT04910607||Patient|Participating patients will be recruited from the Specialised Obesity Centres =CSO (CHU and Follow-up and rehabilitation care (SSR), as well as patient associations) to fill in a questionnaire and take part in an interview (varied panel representative of the target population in terms of place of residence, socio-professional category, sex and age).
3492411|NCT04910607||Professional|Medical and paramedical staff involved in the partner CSOs will also be asked to participate in a semi-structured interview.
3492412|NCT04910048|Active Comparator|Standard of Care|The first arm consists of UAMS standard of care (SOC), including providing a brochure with information (contact information, brief educational information) for the patient to consult with a nutritionist to help with self-directed weight loss.
3180110|NCT00679848|Experimental|1|Transoral Suturing
3180111|NCT00679861|Experimental|3|A practitioner delivered counselling and an expert system intervention is implemented in practices allocated to this arm
3492413|NCT04910048|Experimental|Intervention (POPOP)|The second arm is a specified 2-month POPOP focused on weight loss administered by the external partner, 20Lighter. The program includes customized meal plans; vitamin, mineral and nutritional supplementation; and daily engagement via a smartphone app with a 20Lighter health care provider. Video conferencing appointments will occur approximately every 3 weeks. The program does not require any exercise or physical engagement but does necessitate that patients have a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection. During the first 40 days the customized meal plans are adhered to, then from days 41-60 patients will transition back to a normal dietary lifestyle via a customized plan based on considerations including, food preferences, physical engagement and height.
3492414|NCT04908761|Experimental|Transmuscular quadratus lumborum block group|Patients assigned to the Transmuscular Quadratus Lumborum (TQL) block group receive the Transmuscular Quadratus Lumborum block in a lateral decubitus position with the surgical site facing up before recovery of general anesthesia after surgery. For the block, 30cc of 0.375% ropivacaine is used.
3492415|NCT04908761|Placebo Comparator|Control group|For patients assigned to the control group, 30cc of 0.9% normal saline is used for Transmuscular Quadratus Lumborum block.
3492416|NCT04908475|Experimental|Arm 1: Risankizumab|Participants will receive risankizumab Dose A in Period A and Period B.
3492417|NCT04908475|Experimental|Arm 2a: Apremilast/Risankizumab|Participants will receive apremilast Dose A in Period A followed by risankizumab Dose A in Period B.
3492418|NCT04908475|Active Comparator|Arm 2b: Apremilast|Participants will receive apremilast Dose A in Period A and Period B. Non-responders at Week 28 and Week 40 will be offered to receive risankizumab Dose A.
3492419|NCT04906993|Experimental|camrelizumab combined with famitinib malate|
3492420|NCT04906993|Active Comparator|platinum-based chemotherapy|
3492421|NCT04903821|Experimental|Group A (Child- Pugh A)|Participants with mild impaired hepatic function (Child-Pugh A), including at least 2 female participants.
3492422|NCT04903821|Experimental|Group B (Child-Pugh B)|Participants with moderate impaired hepatic function (Child-Pugh B), including at least 2 female participants
3180112|NCT00679861|Experimental|1|A practitioner delivered counselling intervention was implemented in practices allocated to this arm
3180113|NCT00679861|Experimental|2|A computer expert system intervention was implemented in practices allocated to this arm
3180114|NCT00679874||I|Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.
3492423|NCT04903821|Experimental|Control A match controls for group A|Matched control participants for Group A with normal hepatic function.
3492424|NCT04903821|Experimental|Control B match controls for group B|Matched control participants for Group B with normal hepatic function
3492425|NCT04903626|Experimental|Participants Treated With Glecaprevir/Pibrentasvir for 8 weeks|Participants treated once daily with oral tablets of glecaprevir/pibrentasvir for 8 weeks.
3492426|NCT04901689|Experimental|Leronlimab (700 mg)|Leronlimab 700 mg intravenously once a week (up to 4 doses) until hospital discharge
3492427|NCT04901689|Placebo Comparator|Placebo|Placebo intravenously once a week (up to 4 doses) until hospital discharge
3492428|NCT04901676|Experimental|Leronlimab|Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.
3492429|NCT04901676|Placebo Comparator|Placebo|Placebo subcutaneously once a week (up to 4 doses) until hospital discharge
3492430|NCT04901195|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
3492431|NCT04901195|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.
3492432|NCT04899193|Experimental|Sequence 1: First Reference, Then Test 1, Then Test 2|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492433|NCT04899193|Experimental|Sequence 2: First Test 1, Then Test 2, Then Reference|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492434|NCT04899193|Experimental|Sequence 3: First Test 2, Then Reference, Then Test 1|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492435|NCT04899193|Experimental|Sequence 4: First Reference, Then Test 2, Then Test 1|Participants will receive single dose of Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 1 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 2 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492436|NCT04899193|Experimental|Sequence 5: First Test 1, Then Reference, Then Test 2|Participants will receive single dose of Test 1 drug (Pergoveris FD) on Day 1 in investigation period 1 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 2 followed by Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492437|NCT04899193|Experimental|Sequence 6: First Test 2, Then Test 1, Then Reference|Participants will receive single dose of Test 2 drug (Pergoveris Liquid) on Day 1 in investigation period 1 followed by Test 1 drug (Pergoveris FD) on Day 1 in investigation period 2 followed by Reference drug (Gonal-f/Luveris injection) on Day 1 in investigation period 3. A washout period of 6 days will be maintained between period 1 and 2 and washout period of 17 days will be maintained between period 2 and 3.
3492438|NCT04899141||Coronary Artery Disease|
3492439|NCT04896073|Experimental|1/Minnelide|Minnelide 2mg Days 1-21 of 28 day cycle (x12)
3492440|NCT04896060||Ecological Momentary Assessment (EMA) volunteers|Volunteers with access to mobile device with Wi-Fi and data recruited for an additional 1-week daily assessment study utilizing EMA to examine COVID-19 related stress and eating behavior in real-time
3492441|NCT04896060||General global population volunteers|Newly recruited volunteers 18 and above from the general global population that agree to participate in the COVID study
3492442|NCT04896060||NIDDK-Phoenix study volunteers|Previous research participants, who signed consents that allow data sharing that agree to participate in the COVID study
3492443|NCT04895280|Other|Group 1 (marcaine)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine
3492444|NCT04895280|Experimental|Group 2 (ketorolac)|will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
3492445|NCT04895280|Other|Group 3 (kenalog)|4 cc 0.25% Marcaine without epinephrine and 40 mg triamcinolone x 1. Group 3 is standard of care
3492446|NCT04895072|Active Comparator|Standard group|standard injection rate will be applied
3492447|NCT04895072|Active Comparator|Long group|long injection rate will be applied
3129574|NCT03227692|Active Comparator|Persona without iASSIST Knee|Having total knee arthroplasty surgery (Persona Knee System) with the use of conventional surgical instruments, and without a navigation system iASSIST Knee.
3492448|NCT04893343||Neonatal infection with antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated with antibiotics
3492449|NCT04893343||Neonatal infection without antibiotics|In-patient neonates with ICD-10 infectious disease diagnosis, treated without antibiotics
3492450|NCT04891133|Experimental|Active arm|4mg Baricitinib up to 14 days + SoC
3492451|NCT04891133|Placebo Comparator|Comparator|Matching placebo up to 14 days + SoC
3492452|NCT04890093|Experimental|1/Dose Escalation|Dose escalation of PEN-866 along with fixed doses of vincristine and temozolomide
3492453|NCT04890093|Experimental|2/MTD/RP2D|PEN-866 at the MTD or RP2D from phase 1 plus vincristine and temozolomide
3492454|NCT04889716|Experimental|Cohort 1|Participants receive mosunetuzumab 60 mg for cycles 1 and 2 (although fractionated for cycle 1), and 30 mg for all subsequent cycles after standard-of-care therapy with CD19-directed CAR T-cells
3492455|NCT04889716|Experimental|Cohort 2|Participants receive obinutuzumab (1000 mg for each subject) and glofitamab after standard-of-care therapy with CD19-directed CAR T-cells. The dose of glofitamab for each subject will be 30 mg, other than for cycle 1, which will be 12.5 mg glofitamab fractionated over two weeks.
3492456|NCT04888936||NCI RASopathies Clinical Center Cohort|includes Proband, Other carriers in family, Family Controls
3492457|NCT04888936||NCI RASopathies Field Cohort|includes Proband, Other carriers in family, Family Controls
3492458|NCT04883398||Breast cancer survivors|Breast cancer survivors ages 50-70 with AJCC stages 0-3 breast cancer who are at least 1 year post-treatment (including surgery, radiation, and chemotherapy, with or without current endocrine therapy)
3492459|NCT04883398||Healthy controls|Healthy controls ages 50-70 with no history of cancer.
3492460|NCT04882124|Experimental|CSJ117 8mg|Intervention: Drug: CSJ117
3492461|NCT04882124|Experimental|CSJ117 4mg|Intervention: Drug: CSJ117
3492462|NCT04882124|Placebo Comparator|CSJ117 Placebo|Intervention: Drug: Placebo
3492463|NCT04882098|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind. Participants who have not discontinued will be eligible to enter a long-term extension (LTE) and will receive guselkumab and placebo SC. After the study is unblinded to the investigative sites, participants will receive guselkumab and no longer be required to dose with placebo to maintain the blind.
3492464|NCT04882098|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
3492465|NCT04882098|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive placebo SC and will cross over to receive SC guselkumab. Participants who have not discontinued will be eligible to enter an LTE and will receive guselkumab SC.
3492466|NCT04877977||Healthy Volunteers|Individuals who previously signed consent for ETPB research as healthy volunteers
3129576|NCT03227861|Experimental|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing Darunavir 800 milligram (mg)/ Cobicistat 150 mg/ Emtricitabine 200 mg/ Tenofovir Alafenamide 10 mg (D/C/F/TAF) fixed-dose combination (FDC) once daily within 24 hours of the screening/baseline visit.
3492467|NCT04877977||Mood Disorder Patients|Individuals with mood disorders who previously signed consent for ETPB research
3492468|NCT04874155|Active Comparator|Active neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver active stimulation
3492469|NCT04874155|Sham Comparator|Sham neurostimulation|Noninvasive peripheral nerve stimulation device programmed to deliver non-therapeutic (sham) stimulation.
3492470|NCT04870034|Experimental|Treatment (palbociclib, binimetinib)|Patients receive palbociclib PO QD and binimetinib PO BID for 14 days in the absence of disease progression or unacceptable toxicity. Within 1 week after last dose of study medication, patients undergo surgery.
3129577|NCT03228017|Other|Psoriatic Disease Patients|Moderate to severe psoriatic disease
3492471|NCT04869514|Active Comparator|either lumbar manipulation (LMANIP)|LMANIP will consist of high velocity low amplitude (HVLA) SMT at the L4/L5 motion segment. LMANIP consists of two HVLA impulses, applied in side-posture on the right and left side (order pseudorandomized).
3492472|NCT04869514|Active Comparator|thoracic manipulation (TMANIP)|TMANIP will consist of high velocity low amplitude (HVLA) SMT at the T4/5 motion segment. TMANIP consists of supine SMT to the right and left (order pseudorandomized) using a thenar contact at facet joint level T4/5
3129578|NCT03228017|No Intervention|Healthy Control|
3129579|NCT03228212|Experimental|TEST/CONTROL/CONTROL|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (TEST/CONTROL/CONTROL)
3492473|NCT04869514|Sham Comparator|lumbar mobilisation (LMOB)|LMOB will be applied with the same positioning as in the LMANIP procedure, but instead of a thrust, a slow, a slow, passive mobilization without impulse will be applied
3492474|NCT04869514|No Intervention|No intervention|A natural history arm will serve to further control for potential specific and non-specific effects of TMANIP and LMOB. Subject will rest in side-lying position for the same duration as during the active interventions.
3492475|NCT04869371|Experimental|Androgen Deprivation Therapy with Docetaxel|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus docetaxel and prednisone, as per standard of care. Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks. Docetaxel (75 mg/m2 body surface area) will be administered as intravenous drip every 3 weeks for 6 cycles. Robot assisted radical prostatectomy will be followed in 2 weeks when 24-week treatment cycle is finished.
3492476|NCT04869371|Active Comparator|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robot assisted radical prostatectomy. Triptorelin Pamoate 15mg will be administered once per 12 weeks.
3492477|NCT04869124|Active Comparator|Dapagliflozin|Dapagliflozin tablet (10mg/tablet), orally, once daily for 12 weeks.
3492478|NCT04869124|Placebo Comparator|Placebo|Placebo tablet, matching Dapglilflozin, orally, once daily for 12 weeks.
3492479|NCT04868279|Experimental|Interventional Gruop|"Web-based interactive nurse support program with the intervention group will continue for 3 months, the implementation will last 6 months in total. Individuals in the intervention group will be able to access the training content by accessing the website designated for the study from devices such as computers or mobile phones.~Data collection forms will be applied to the intervention group 3 times in total, before starting the Web-based interactive nurse support program, at the end of the Web-based interactive nurse support program (in the 3rd month) and in the 6th month."
3492480|NCT04868279|No Intervention|Control Group|Web-based interactive nurse support program will not be opened to the control group, only access to data collection tools will be provided.
3492481|NCT04867837|Experimental|Octaplex Low-dose|Participants to receive 1 Octaplex infusion intravenously
3492482|NCT04867837|Experimental|Octaplex High-dose|Participants to receive 1 Octaplex infusion intravenously
3492483|NCT04867070||LLDN with ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
3492484|NCT04867070||LLDN without ESPB|The patient will be interviewed for participation in the study, and the pain scores of the patients who will participate in the study will be recorded according to the NAS and W-BAS scores at the first, 2nd, 12th, and 24th hours. At the end of the 24th hour, analgesic consumption will be recorded.
3492485|NCT04866810|Experimental|1|High-fiberr, plant-based diet + exercise prescription with act sessions
3492486|NCT04866810|No Intervention|2|Control
3129580|NCT03228212|Experimental|CONTROL/TEST/TEST|Enrolled subjects will be habitual wearers of spherical contact lenses between the ages of 18 and 49 years old. Subjects will wear the Test and Control contact lenses bilaterally for approximately 2 weeks each on a daily wear basis. Subjects will be randomly assigned to one of the two lens wear sequences, (CONTROL/TEST/TEST)
3129581|NCT03228420|Active Comparator|HF10 therapy plus CMM|The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
3492487|NCT04865432|Experimental|UVB treatment|The treatment group will first undergo an evaluation of each individual's sensitivity to the Solius Photobiological System UVB using the device titration system for the first 5 weeks. Once determined after the 5 weeks, the subjects will be enrolled in a 4-week study where they will be exposed to their individualized titration evaluation.
3492488|NCT04862390||Normal Pregnancy|Pregnant women with no diabetes
3492489|NCT04862390||Gestational diabetes on diet alone|
3492490|NCT04862390||Gestational diabetes on diet + Metformin therapy|
3492491|NCT04861766|Experimental|Treatment group Stylage L ®|"Each subject will receive STYLAGE® L in both NLFs.~STYLAGE® L will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
3492492|NCT04861766|Active Comparator|Control group Active Comparator|"Each subject will receive the Active Comparator in both NLFs.~Active Comparator will be injected in the NLFs by the Treating Investigator with optional touch-up injections on Month 1."
3492493|NCT04860518|Experimental|IV IFN beta-1a|Patients receiving active drug: will receive two separate bolus injections one containing IFN-beta -1a and another injection containing Saline.
3492494|NCT04860518|Active Comparator|IV Dexamethasone|Patients receiving active comparator: will receive two separate bolus injections one containing saline and another injection containing Dexamethasone.
3492495|NCT04859231|Active Comparator|Control|
3492496|NCT04859231|Experimental|Investigational|
3492497|NCT04859231|No Intervention|Mother's-own Breast Milk|
3492498|NCT04858542|Experimental|Mask-wearing healthcare workers|All participants in this arm will view the educational health modules and their subjective/objective outcomes will be measure pre/post module viewing.
3492499|NCT04852289||>=65 Female|Older Females
3492500|NCT04852289||>=65 Male|Older Males
3492501|NCT04852289||18-64 Female|Young Females
3492502|NCT04852289||18-64 Male|Young Males
3492503|NCT04845191|Experimental|Experimental: Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
3492504|NCT04845191|Experimental|Experimental: Cohort 2: hAd5-S-Fusion+N-ETSD Subcutaneous and Oral|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Oral on Day 1
3129582|NCT03228420|Other|CMM Alone|Conventional Medical Management
3129583|NCT03228433|Experimental|Cohort 1: TAK-418 5 mg|TAK-418 5 milligram (mg), capsule, orally, once on Day 1.
3492505|NCT04844944||Heart Failure|Hospitalized patients diagnosed with Heart Failure. No Intervention.
3492506|NCT04844944||Coronary Artery Disease|Hospitalized patients diagnosed with Coronary Artery Disease. No Intervention.
3492507|NCT04844944||Atrial Fibrillation|Hospitalized patients diagnosed with Atrial Fibrillation. No Intervention.
3492508|NCT04843722|Experimental|Cohort 1: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous|Cohort 1 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous on Day 1
3492509|NCT04843722|Experimental|Cohort 2: hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual|Cohort 2 (n=20): hAd5-S-Fusion+N-ETSD at 5 × 10e10 IU/dose Subcutaneous and 1 × 10e10 IU/dose Sublingual on Day 1
3492510|NCT04837196|Experimental|Phase 1 ASP7517 Monotherapy Dose Escalation|Participants will receive ASP7517 on day 1 of each 28-day cycle for up to 6 doses.
3492511|NCT04837196|Experimental|Phase 1 ASP7517 + Pembrolizumab Dose Escalation|Participants will receive ASP7517 on day 1 of each 28-day cycle for up to 6 doses in combination with 4 doses of Pembrolizumab administered every 6 weeks starting from Cycle 1 Day 1. An additional 13 doses of Pembrolizumab may be available for qualifying participants.
3492512|NCT04837196|Experimental|Phase 2 ASP7517 Monotherapy Dose Expansion|Participants will receive RP2D of ASP7517 on day 1 of each 28-day cycle for up to 6 doses
3492513|NCT04837196|Experimental|Phase 2 ASP7517 + Pembrolizumab Dose Expansion|Participants will receive RP2D of ASP7517 on day 1 of each 28-day cycle for up to 6 doses in combination with 4 doses of Pembrolizumab administered every 6 weeks. An additional 13 doses of Pembrolizumab may be available for qualifying participants.
3492514|NCT04835415|Active Comparator|group T|Group (T) (n=26): will receive ultrasound guided thoracic epidural analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
3492515|NCT04835415|Active Comparator|group R|Group (R) (n=26): will receive bilateral ultrasound guided retrolaminar block analgesia: 20 ml of bupivacaine 0.25 % plus 5ug/ml adrenaline (1:200000).
3129584|NCT03228433|Experimental|Cohort 2: TAK-418 15 mg|TAK-418 15 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
3129585|NCT03228433|Experimental|Cohort 3: TAK-418 30 mg Fasted + TAK-418 30 mg Fed|TAK-418 30 mg, capsule, in fasted state, orally, once on Day 1, followed by a 28-day washout period, further followed by TAK-418 30 mg, capsule, in fed state, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
3492516|NCT04834635|Experimental|FundoRingOAGB group|laparoscopic one anastomosis gastric bypass with the total wrapping of the fundus of gastric excluded part (and suture cruroplasty if present hiatal hernia).
3492517|NCT04834635|Active Comparator|OAGB group|laparoscopic one anastomosis gastric bypass (and suture cruroplasty if present hiatal hernia).
3492518|NCT04833361||Mothers|Mothers of children with coloboma.
3492519|NCT04831021|Experimental|Patients issued from dialysis units (clinic)|
3492520|NCT04828733|Experimental|Antireflux OAGB group|Antireflux laparoscopic one anastomosis gastric bypass with suture cruroplasty and the total wrapping of the fundus of the gastric excluded part.
3492521|NCT04828733|Active Comparator|Standard OAGB group|laparoscopic one anastomosis gastric bypass with only suture cruroplasty.
3492522|NCT04822610|Experimental|Study group: interscalene block + IV PCA|preop usg guided interscalene block and IV PCA
3492523|NCT04822610|Experimental|Study group: suprascapular block + axillary block + IV PCA|preop usg guided suprascapular block + axillary block and IV PCA
3180115|NCT00679887|Experimental|A|Ischemic compression on trigger points located around the shoulder. Active comparator. Ischemic compression, 5 weeks
3180116|NCT00679900|Experimental|1|
3492524|NCT04822610|No Intervention|Control group: IV PCA|no block + IV PCA
3492525|NCT04820426||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of neuropathic pain and its effect on the quality of life, at their admission.
3492526|NCT04818632|Experimental|AZD9833 monotherapy dose escalation|
3492527|NCT04818632|Experimental|AZD9833 monotherapy dose expansion|
3492528|NCT04818632|Experimental|AZD9833 with palbociclib dose expansion|
3492529|NCT04818632|Experimental|AZD9833 with everolimus dose expansion|
3492530|NCT04818112|Experimental|Behavioral ATVV intervention|A multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
3492531|NCT04818112|Active Comparator|Attention control|An attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
3492532|NCT04817254|Experimental|Arm 1|Nivolumab + Ipilimumab 1mg/kg + TMZ
3180117|NCT00679900|Active Comparator|2|
3492533|NCT04817254|Experimental|Arm 2|Nivolumab + Ipilimumab 3mg/kg + TMZ
3492534|NCT04815356|Experimental|Experimental therapy: Dose Escalation|Escalating doses of autologous anti-CD22-CAR T-cells in subjects to determine the MTD
3492535|NCT04815356|Experimental|Experimental therapy: Dose Expansion|Autologous anti-CD22-CAR T-cells at the MTD
3492536|NCT04814368|Experimental|LNA043|Placebo to canakinumab + LNA043
3492537|NCT04814368|Placebo Comparator|Placebo|Placebo to canakinumab
3492538|NCT04814368|Experimental|canakinumab + LNA043|canakinumab + LNA043
3492539|NCT04814368|Experimental|canakinumab|canakinumab
3492540|NCT04813926||Patients diagnosed with PAH|
3492541|NCT04813549||Rheumatoid Arthritis patients|Rheumatoid arthritis patients will be evaluated in terms of the presence of secondary fibromyalgia and its effect on the quality of life, at their admission.
3492542|NCT04811560|Experimental|JNJ-75276617|Participants in Part 1 (dose escalation) will receive JNJ-75276617 orally on a 28-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Food effect cohort participants in Part 1 will receive JNJ-75276617 orally on Cycle 2 Day 1 under fasted condition and on Cycle 2 Day 2 under fed condition. Participants in Part 2 (dose expansion) will receive JNJ-75276617 orally at one of the RP2D(s) determined in Part 1.
3492543|NCT04809805|Experimental|Dose escalation of BAY2666605|Approximately 7 or 8 dose levels are planned.
3492544|NCT04809805|Experimental|Dose expansion of BAY2666605|Participants will receive BAY 2666605 at the dose and regimen declared safe in the dose escalation part.
3492545|NCT04808427|Experimental|1/Arm 1|Ultrasound ablation of focal prostate cancer
3492546|NCT04808011|Experimental|Treatment|Each subjects will be treated with his prescribed dialysis device for 14 days, followed by a treatment period of 30 days with the investigational IDA system, and concluding with additional 14 days of treatment with the prescribed dialysis device.
3492547|NCT04807907|Experimental|Infant Directed Speech (IDS) Video + IDS Calendar|The participant will be shown a 3-minute video describing the value of IDS and how the participant can use IDS with their child. The participant will receive an IDS-themed wall calendar.
3492548|NCT04807907|No Intervention|Control|No intervention. The participant will receive a regular wall calendar with an image of Stanford.
3492549|NCT04805489|Experimental|stress test with masks|Within the framework of this research, an additional stress test is performed. This stress test, consisting of 3 periods, will follow a cardiovascular assessment requested as part of a health check-up, a license application, for risk factor assessment.
3492550|NCT04804358|Other|Anorexic women|Anorexic women with or without history of psychological trauma will perform study procedure : sociodemographic and clinical assessments, measurement of cardiac variability and salivary cortisol changes, before, during and after the exposition test.
3492551|NCT04804293|Experimental|Operative treatment (surgical decompression) for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated at 3 and 6 months post-operatively. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. This imaging will be done before the treatment. We will repeat the imaging study at 3 and 6 months after the treatment. Each ultrasound imaging session will take about less than 10 min. The investigators do not expect any discomfort during the imaging.
3492552|NCT04804293|Experimental|Corticosteroid injection treatment for carpal tunnel syndrome|Shear wave elastography (SWE) will be used to assess the stiffness of tissue. Patients will be revaluated after 6 weeks following corticosteroid injection. Patient will sit done in a chair. The investigators will scan the wrist area of both arms to acquire SWE map. The investigators do not expect any discomfort during the imaging.
3180118|NCT00679965|Experimental|Group 1|AN2690 Solution, 2.5%
3180119|NCT00679965|Experimental|Group 2|AN2690 Solution: 5%
3180120|NCT00679965|Experimental|Group 3|AN2690 Solution, 7.5%
3180121|NCT00679965|Placebo Comparator|Group 4|AN2690 Solution Vehicle
3180122|NCT00679978||A|A: etidronate
3492553|NCT04803383|Experimental|Tele-Yoga Group|Patients in the tele-yoga group will participate in tele-yoga sessions with a maximum of 5 people in each group by video-conference method for 8 weeks, 3 days a week. Assessments will perform just before starting to study and after the 8-week tele-yoga program
3492554|NCT04803383|No Intervention|Control group|Patients in the waiting list control group will be asked to continue their normal physical activities during the 8-week study, not to start a new exercise program, and to report any changes in the drug or dosage used. Control group's assessments will be performed when they are included in the study and at the end of 8 weeks. After these assessments, patients who wish will participate in the tele-yoga program.
3492555|NCT04803227|Active Comparator|Emricasan|Emricasan
3492556|NCT04803227|Placebo Comparator|Placebo|Placebo
3129586|NCT03228433|Experimental|Cohort 4: TAK-418 40 mg|TAK-418 40 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
3180123|NCT00679991|Active Comparator|PRT-201|
3492557|NCT04799301|Experimental|Diet with 20% of carb intake from soda|This group will receive a weight-maintaining diet with 20% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
3492558|NCT04799301|Experimental|Diet with 50% of carb intake from soda|This group will receive a weight-maintaining diet with 50% of carbohydrates provided as soda. The carbohydrates from sources other than corn and sugar cane will be reduced accordingly to meet the total carbohydrate supply.
3492559|NCT04799301|Experimental|Diet with no soda|This group will receive a weight-maintaining diet without soda. All 50% of carbohydrates will originate from sources other than corn and sugar cane.
3492560|NCT04799288|Experimental|Teriflunomide|Teriflunomide 14 mg daily
3492561|NCT04799249|Experimental|Trilaciclib + gemcitabine + carboplatin|Trilaciclib (240mg/m2) + gemcitabine (1000 mg/m2) and carboplatin (AUC 2)
3492562|NCT04799249|Placebo Comparator|Placebo + gemcitabine + carboplatin|The subjects in the placebo arm will follow the same schedule as the trilaciclib arm, but will receive placebo instead of trilaciclib.
3492563|NCT04799054|Experimental|Part 1 Dose Escalation: TransCon TLR7/8 Agonist|TransCon TLR7/8 Agonist in escalating doses to evaluate safety/tolerability and to determine the MTD and RP2D.
3492564|NCT04799054|Experimental|Part 2 Dose Escalation: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab in escalating doses to evaluate safety/tolerability and determine the MTD and RP2D.
3492565|NCT04799054|Experimental|Part 3 Dose Expansion: TransCon TLR7/8 Agonist with Pembrolizumab|TransCon TLR7/8 Agonist with Pembrolizumab using RP2D from Part 2 to evaluate safety/tolerability and anti-tumor activity of the combination.
3492566|NCT04797065|Experimental|6-minute then 9-minute withdrawal|"Patients in 6-minute then 9-minute withdrawal group will first be carefully observed in 6 minutes then in 9 minutes during the segmental withdrawal.~At 6-minute withdrawal, the left colon, transverse colon and right colon will take 2 minutes each. Then at 9-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 3 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
3492567|NCT04797065|Active Comparator|9-minute then 6-minute withdrawal|"Patients in 9-minute then 6-minute withdrawal group will first be carefully observed in 9 minutes then in 6 minutes during the segmental withdrawal.~At 9-minute withdrawal, the left colon, transverse colon and right colon will take 3 minutes each. Then at 6-minute withdrawal, the observation of the left colon, transverse colon and the right colon will be maintained for 2 minutes each.~A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included."
3492568|NCT04796649|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
3492569|NCT04796649|Active Comparator|Standard treatment + Sham laser|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
3492570|NCT04793698|Experimental|Compassion meditation|Compassion meditation is a contemplative meditation practice that fosters compassion through contemplation of common humanity.
3492571|NCT04793698|Active Comparator|Applied relaxation|Veteran.calm is an applied relaxation program that exposes participants to a variety of relaxation strategies and their application.
3492572|NCT04792190|Active Comparator|Intervention Management Arm (Dapagliflozin)|A block randomization method will be use to randomize subjects to treatment with dapagliflozin 10 mg once daily. Subjects will take 1 blinded tablet of study drug (dapagliflozin) dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
3492573|NCT04792190|Placebo Comparator|Control Arm (Placebo)|Subjects will take 1 blinded tablet of placebo drug dosed once daily, per the randomization scheme, for 12 months. Each subject will be dispensed 35 blinded doses per month, during each month of participation in the trial. Quarterly pill counts will be performed to track compliance.
3492574|NCT04790370|Active Comparator|Anticoagulation|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)
3492575|NCT04790370|Active Comparator|Anticoagulation and EkoSonicTM Endovascular System|Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System [ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg]
3492576|NCT04788628|Experimental|Epilepsy inpatients|Epilepsy inpatients with implanted hippocampal electrodes and continuous scalp EEG monitoring
3492577|NCT04788615|Experimental|ofatumumab|Oftatumumab 20mg auto injector syringes for subcutaneous injection on Day 1, Week 1 and 2, followed by subsequent monthly dosing, starting at Month 1.
3492578|NCT04788615|Active Comparator|First line DMT|"Glatiramer acetate minimum dose 20mg or maximum dose 40mg twice a day or three times a week or~Interferon minimum dose 22µg or maximum dose of 0.25mg 3 times a week or once a week or Every second week depending on preparation or~Teriflunomide 14 mg once a day or~Dimethyl fumarate minimum dose of 240mg or maximum dose of 480mh twice a day"
3492579|NCT04788251|Experimental|Exercise-based fall prevention intervention|To receive 7 weeks of exercise-based programme
3492580|NCT04788251|Other|Wait-list controls|To receive fall prevention resources while waiting for programme
3180124|NCT00679991|Placebo Comparator|2|
3492581|NCT04777357|Placebo Comparator|Placebo|Participants will receive Placebo over a 6 week treatment period.
3492582|NCT04777357|Experimental|Cariprazine|Participants will receive flexible dose Cariprazine over a 6 week treatment period.
3492583|NCT04773522|Experimental|Talquetamab|Participants will receive talquetamab injection subcutaneously (SC) in 3 cohorts: Cohort 1 and Cohort 2 as 2 step-up doses and Cohort 3 as 3 step-up doses followed by a treatment dose.
3129587|NCT03228433|Experimental|Cohort 5: TAK-418 60 mg|TAK-418 60 mg, capsule, orally, once on Day 1. Actual dose of TAK-418 may vary based on safety, tolerability and PK data from previous Cohorts.
3492584|NCT04772170||Current Challenge Study Participant|Current participation in a respiratory virus challenge study at the NIH CC
3129588|NCT03228433|Placebo Comparator|Cohorts 1-5: Placebo|TAK-418 placebo-matching, capsule, orally, once on Day 1.
3129589|NCT03228680|Experimental|Follitropin delta|FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
3492585|NCT04770935|Experimental|efanesoctocog alfa (BIVV001)|A single IV dose of BIVV001 will be administered to each patient
3492586|NCT04769323|Experimental|Group 1|Group 1 use virtual reality.
3492587|NCT04769323|Experimental|Group 2|Group 2 do traditional home exercises.
3492588|NCT04769323|Experimental|Group 3|Group 3 do traditional home exercises and virtual reality.
3492589|NCT04765969||Severe COPD patients|GOLD C and D group patients
3492590|NCT04765280||Patients with chronic musculoskeletal pain|Patients with any musculoskeletal pain for at least 3 months
3492591|NCT04764331|Other|Intervention|Caps will be provided for each subjects will use the cap once daily for10-minute treatment regimen
3492592|NCT04763941||Memory consultation patient|The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.
3492593|NCT04763928|Experimental|VenDec|Patients will receive a combination of VENETOCLAX (400 mg per day orally on days 1 to 28 of 28-days courses) and DECITABINE (20 mg/sqm intravenously on days 1 to 5 of 28-days courses)
3492594|NCT04763915|Experimental|GeneSHARE|Access to GeneSHARE, a web-based toolkit including interactive and narrative components to enhance FC of genetic test results.
3492595|NCT04763915|Experimental|LivingLabReport|Access to LivingLabReport, a website containing multiple resources including a summary of the patient's genetic test results, condition-specific information, recommended CRM, and information on accessing CRM services.
3492596|NCT04763915|Active Comparator|Standard-of-care|Receive standard-of-care from their treating healthcare provider.
3492597|NCT04761822|Experimental|Moderna COVID-19 Vaccine|The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart.
3129590|NCT03228680|Active Comparator|Follitropin beta|FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.
3129591|NCT03228836|Experimental|Sintilimab (IBI308)|
3180125|NCT00680004||1|Preoperative patients planned for a CT prior to an endograft implantation procedure
3492598|NCT04761822|Experimental|Pfizer-BioNTech COVID-19 Vaccine|The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart.
3492599|NCT04761822|Experimental|Placebo +Moderna COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.5 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Moderna COVID-19 Vaccine, with the first dose administered 1 month later. The Moderna COVID-19 Vaccine (0.5 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.5 mL each) administered 1 month (28 days) apart."
3492600|NCT04761822|Experimental|Placebo+Pfizer-BioNTech COVID-19 Vaccine|"Participants will receive placebo as a first dose followed by two doses of their assigned active vaccine at subsequent visits. 0.3 mL of placebo will be administered intramuscularly in the deltoid.~The placebo dose will be followed by two doses of Pfizer-BioNTech COVID-19 Vaccine, with the first dose administered 1 month later. The Pfizer-BioNTech COVID-19 Vaccine (0.3 mL) will be administered intramuscularly in the deltoid, as a series of two doses (0.3 mL each) administered 3 weeks (21 days) apart."
3492601|NCT04759066|Experimental|Experimental|Participants will wear HEALiX device
3492602|NCT04755660|Experimental|Exercise behavior change group (EBCG)|Behavior Change Theory-based intervention + Resistance Exercise
3492603|NCT04755660|Active Comparator|Elastic band resistance exercise group( EBRG)|Elastic Band Resistance Exercise
3492604|NCT04755660|Sham Comparator|Usual care (UC)|usual care: exercise education
3492605|NCT04755465|Experimental|Resistance Exercise Group|The lower extremity resistance exercise (REx) program was designed by reviewing the exercise principles recommended by the ACSM and the literature on physical activity and hematological cancer patients. The patients were treated for 40-60mins, 3 days/week,4 weeks. The exercise program includes active movements of the upper and lower extremities, stretching exercises, and resistance exercises for the lower extremities. REx to be applied with resistance bands of different resistance or with the patient's body weight. Clinical force generation of therapy bands follows a progression. Our proposed training protocol includes 4-6 different exercises for each extremity. Intensity, sets, and reps were adjusted to a target score of 12 to 14 using the Borg scale. Patients performed 1-2 sets of 8-10 repetitions of each REx based on their fatigue level. Resistance increased every three rounds.
3492606|NCT04755465|Experimental|NMES Training Group|In addition to resistance exercises, NMES will be applied to the quadriceps muscles in both legs of the patients in this group. The application will be made with a portable device using disposable electrodes. One of the electrodes will be placed proximally, that is, at the midpoint of the quadriceps muscle, while the second electrode will be placed on the distal part. Stimulation intensity will be adjusted individually for each limb to achieve the maximum tolerated intensity. In order to ensure that the patients get used to the device, low-intensity current with a frequency range of 5 Hz, 10-30 minutes. Afterwards, the treatment program will continue with a high frequency current with a frequency range of 50 Hz, 15 minutes. The duration of treatment will likewise be increased as adaptation is made to the patient.
3492607|NCT04755205||Cohort 1|Subjects with confirmed olfactory neuroblastoma.
3492608|NCT04754100|Experimental|Allogeneic iNKT cell therapy|3+3 dose escalation of agenT-797 will be administered by Intravenous (IV) infusion every 2 weeks (each cycle is 14 days [2 weeks]).
3492609|NCT04752904|Experimental|ClearSight group|Non-invasive, continuous blood pressure is monitored using ClearSight Sytem, with a finger cuff around the middle finger, and the anesthesiologist manages blood pressure based on this.
3492610|NCT04752904|No Intervention|Control group|The blood pressure is measured at 1-minute intervals by non-invasive blood pressure monitor using the arm cuff, and the anesthesiologist in charge manages the blood pressure based on the measured blood pressure.
3492611|NCT04749108|Experimental|Experimental: Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization."
3492612|NCT04749108|Active Comparator|RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy."
3492613|NCT04748224|Active Comparator|group A (bupivacaine only)|Group A will be injected with 20 ml of 0. 25% bupivacaine in each side
3492614|NCT04748224|Active Comparator|group B (bupivacaine plus dexmedetomidine)|Group B will be injected with 20 ml of 0. 25% bupivacaine in each side added to it dexmedetomidine 0.5 μg/kg; (Precedex 100 μg/ml (Hospira, inc, lake forest, USA).
3492615|NCT04744116|Active Comparator|Arm 1 (ruxolitinib)|Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
3492616|NCT04744116|Experimental|Arm 2 (ruxolitinib, lower dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
3492617|NCT04744116|Experimental|Arm 3 (ruxolitinib, higher dose ds-MSCs)|Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
3492618|NCT04742387||1|Medical records of subjects enrolled on various studies conducted by HAMB/CCR from 1/1/2005 to 12/1/2020
3492619|NCT04742270|Experimental|SIMEOX+ respiratory physiotherapy telecare|Use the device for 3 months in addition to usual care
3492620|NCT04739969|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
3492621|NCT04739969|Sham Comparator|Sham TBS-DLPFC|The sham group will receive sham theta-burst TMS stimulation.
3492622|NCT04735913|Other|Fasting group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®) orally on an empty stomach and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
3492623|NCT04735913|Experimental|Postprandial group|Subjects will take abiraterone acetate tablets (250 mg, produced by Patheon Ich, trade name: Zytiga®)orally after meals and their blood and plasma samples, urine and faeces samples in 72h will be collected for detection.
3492624|NCT04725825|Experimental|Dry needling|"A single dry needling session will be performed on the dominant painful trapezius muscle, with the patient lying in prone position. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down (fast-in, fast-out technique) in three different directions.~In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct."
3180126|NCT00680004||2|Patients who underwent a complicated endograft implant and/or with increased risk of complications
3180127|NCT00680030||1|
3492625|NCT04725825|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
3492626|NCT04724980|Experimental|Dose Levels|Adjuvant PRGN-2012 at escalating doses
3492627|NCT04724668|Other|Morning light version+ Melatonin|Morning light version and melatonin 3mg capsule (3hrs before DLMO)
3492628|NCT04724668|Other|Morning light version+ Placebo|Morning light version and placebo capsule (3hrs before DLMO)
3492629|NCT04723667|Experimental|Intervention|13-week multimodal intervention
3492630|NCT04723667|Active Comparator|Active control|5-week health education programme
3492631|NCT04722848|Experimental|Ponatinib+Blinatumomab|patients will receive induction with ponatinib followed by at least 2 cycles of blinatumomab
3492632|NCT04722848|Active Comparator|Chemotherapy+Imatinib|patients will receive a combination of imatinib and chemotherapy.
3492633|NCT04722666|Experimental|MIJ821 (mg/kg) - very low dose|MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
3492634|NCT04722666|Experimental|MIJ821 (mg/kg) - low dose|MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
3492635|NCT04722666|Experimental|MIJ821(mg/kg) - high dose|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
3492636|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
3492637|NCT04722666|Placebo Comparator|Placebo|40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
3492638|NCT04722666|Experimental|MIJ821 (mg/kg) - high dose/Placebo|MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
3492639|NCT04722666|Experimental|MIJ821 (mg/kg) - very high dose/Placebo|MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1/0.9% sodium chloride for 40 minutes IV infusion on Day 15 and Day 29
3492640|NCT04722276|Active Comparator|fraction of inspired oxygen 80%|
3492641|NCT04722276|Experimental|Fraction of inspired oxygen 80% with positive end expiratory pressure|
3492642|NCT04722146|Experimental|Treatment Regimen A: Teclistamab + Daratumumab + Pomalidomide|Participants will receive teclistamab plus daratumumab plus pomalidomide.
3492643|NCT04722146|Experimental|Treatment Regimen B: Teclistamab + Daratumumab + Lenalidomide + Bortezomib|Participants will receive teclistamab plus daratumumab plus lenalidomide plus bortezomib.
3492644|NCT04722146|Experimental|Treatment Regimen C: Teclistamab + Nirogacestat|Participants will receive teclistamab plus nirogacestat.
3492645|NCT04722146|Experimental|Treatment Regimen D: Teclistamab + Lenalidomide|Participants will receive teclistamab plus lenalidomide.
3492646|NCT04722146|Experimental|Treatment Regimen E: Teclistamab + Daratumumab + Lenalidomide|Participants will receive teclistamab plus daratumumab plus lenalidomide.
3492647|NCT04722003|Experimental|4CMenB|Participants will receive two doses (0.5 mL each) of 4CMenB vaccine on Day 1 and Day 29. Each single dose of vaccine will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=40
3492648|NCT04722003|Placebo Comparator|Placebo|Participants will receive two doses (0.5 mL each) of placebo injections (saline) on Day 1 and Day 29. Each single dose of placebo will be administered via intramuscular (IM) injection into the deltoid muscle of the preferred arm. N=10
3492649|NCT04718545|Active Comparator|Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a conventionally prepared recipient site and sutured to cover the mucosal recession
3492650|NCT04718545|Experimental|Modified Free Gingival Graft|A mucogingival surgery where a gingival graft harvested from the palate is placed on a modified recipient site and sutured to cover the mucosal recession
3492651|NCT04716959|Experimental|Prepectoral Prosthetic Breast Reconstruction|
3492652|NCT04716959|Active Comparator|Subpectoral Prosthetic Breast Reconstruction|
3492653|NCT04716153|Experimental|Interventional|"Patients in the interventional arm will follow a multifactorial sensory rehabilitation program focused on smell and taste that integrates several non-drug interventions, which are part of the current recommendations: program of workshops at the technical center, hydration of the mucous membranes with daily (3 times a day) liposomal sprays (LipoSaliva® and LipoNasal) between V0 and V1, presentation of visual dishes.~The workshops will take place at the frequency of one session of 2 hours per week and will last for 3 weeks. Each session will accommodate 6 to 10 participants. The program will include 3 workshops on olfactory rehabilitation and taste rehabilitation.~Exercises (taking up the themes discussed) will be carried out at home between 2 workshops."
3492654|NCT04716153|Other|Control|"The control group only receives the usual care provided for as part of routine care. It consists of a nutritional assessment at home by a dietician, with monitoring of intake and weight, in order to readjust nutritional support. A systematic search for oral mycosis is carried out in order to treat.~The foods that the patient prefers, identified from a list of authorized foods, are preferred or even fortified."
3492655|NCT04716127|Experimental|Women 50 to 65 years with no regular cervical cancer screening|Women aged 50 to 65 years with no cervical smear or no gynecological examination for more than three years, attending the mobile unit for breast cancer screening in the Department of Hérault, or the Medical and Social Care Center in the Department of Aude.
3492656|NCT04715646|Experimental|Brivaracetam|"Study participants who completed a brivaracetam (BRV) core study (N01263 [NCT00422422], N01349 [NCT03325439], EP0065 [NCT03405714]) and continued to N01266 [NCT01364597], as well as study participants directly from N01349, will enroll as long-term follow-up (LTFU) study participants in EP0156. Each LTFU study participant begins treatment in EP0156 at the individualized BRV dose he/she was maintained on at the completion of the core study. EP0156 will also enroll Japanese pediatric study participants with partial-onset seizure (POS) recruited in Japan.~LTFU study participants: Up to 5mg/kg/day (for study participants weighing 11kg to less than 20kg) and up to 4mg/kg/day (for study participants weighing 20kg to less than 50kg) and no more than 200mg/day Directly enrolled (DE) study participants: 1mg/kg/day to 4mg/kg/day and no more than 200mg/day."
3492657|NCT04714892||Healthy control|BMI of 18.5-29.9 kg/m2
3492658|NCT04714892||Obese|BMI of 30-39.9 kg/m2
3492659|NCT04714671|Experimental|Euthymics patients with history of suicide attempt (suicide attempters)|Euthymics patients with a lifetime history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
3492660|NCT04714671|Experimental|Euthymics patients without any history of suicide attempt (affective controls)|Euthymics patients without history of suicide attempt will be evaluated using the Structured interview for psychiatric disorder; Columbia-Suicide severity rating scale; Inventory of Depressive Symptoms (IDSC); Young Mania Rating Scale (YMRS).
3492661|NCT04712669|Experimental|Rodatristat Ethyl 300 mg BID|Rodatristat ethyl 300 mg tablet BID + standard of care medication(s) taken for 24 weeks
3492662|NCT04712669|Experimental|Rodatristat Ethyl 600 mg BID|Rodatristat ethyl 600 mg tablet BID + standard of care medication(s) taken for 24 weeks
3492663|NCT04712669|Placebo Comparator|Placebo|Matching placebo tablet + standard of care medication(s) taken for 24 weeks
3492664|NCT04707846|Experimental|Bright Light Therapy|Individuals will receive bright blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Bright blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total). Bright blue light treatment has been previously identified as an efficacious treatment for fatigue. It has also been shown in a number of studies that the blue wavelength of light is a key component to the shift of fatigue measures in patient reported outcomes.
3492665|NCT04707846|Active Comparator|Dim Light Therapy|Individuals will receive dim blue light therapy using glasses developed by AYO. During treatment blocks for bright blue light therapy, participants will receive a text message within an hour of their self-reported wake time instructing them to use their designated light therapy device for 30 minutes. Dim blue light therapy will be administered in 2 treatment periods each 2 weeks in length (4 weeks total).
3492666|NCT04707846|No Intervention|Usual Care|During usual care periods, participants will be instructed to abstain from use of AYO light therapy devices, and instructed to treat their fatigue as they normally would. Usual care will be presented in 2 periods each 2 weeks in length (4 weeks total).
3492667|NCT04707469|Experimental|Oral semaglutide 50 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12), 25 mg (week 13-16) and 50 mg (week 17-68).
3492668|NCT04707469|Experimental|Oral semaglutide 25 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8), 14 mg (week 9-12) and 25 mg (week 13-68).
3492669|NCT04707469|Active Comparator|Oral semaglutide 14 mg|Participants will receive once daily semaglutide tablets in a dose escalating manner for 68 weeks: 3 mg (week 1-4), 7 mg (week 5-8) and 14 mg (week 9-68).
3492670|NCT04704843|Experimental|Module A (Without Gluten-Challenge): Guselkumab or Placebo|Participants in Module A (without gluten-challenge) will receive intravenous (IV) infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by subcutaneous (SC) injection of guselkumab or matching placebo at Week 12.
3492671|NCT04704843|Experimental|Module B (With Gluten-Challenge): Guselkumab or Placebo|Participants in Module B (with gluten-challenge) will receive IV infusion of guselkumab or matching placebo as induction dose at every 4 weeks through Week 8 followed by SC injection of guselkumab or matching placebo at Week 12.
3492672|NCT04704193|Experimental|Electronic Decision Aid|Participants in this arm will complete an electronic decision aid for genetic testing.
3492673|NCT04702581|Experimental|PCV alone|Administration of 6 cycles of PCV chemotherapy alone.
3492674|NCT04702581|Active Comparator|RT + PCV|Radiotherapy followed by administration of PCV chemotherapy.
3492675|NCT04699890||preserved ejection fraction|Patients with a preserved ejection fraction (HF / FEp)
3492676|NCT04699890||reduced ejection fraction|Patients with a reduced ejection fraction (HF / FEr)
3492677|NCT04699890||without heart failure|Patient without heart failure
3492678|NCT04693377|Active Comparator|Arm A (SBRT)|Patients undergo stereotactic body radiation therapy for 1 fraction.
3492679|NCT04693377|Experimental|Arm B (cryoablation, SBRT)|Patients undergo cryoablation. Within 10 days after cryoablation, patients undergo stereotactic body radiation therapy for 1 fraction.
3492680|NCT04693325|Experimental|Prolonged normothermic machina perfusion|Eligible and consenting patients who will receive a donor kidney will be included for participation in this study. Current practice is to preserve donor kidneys on hypothermic machine perfusion (HMP). In this study, donor kidneys (n=18) will be taken off the HMP after arrival in the transplant center. These will then be perfused with oxygenated perfusate using the NMP device following an optimised NMP protocol.
3492681|NCT04693039|Experimental|FLZ-150mg|Drug：Phenlarmide；Dosage：150mg；
3492682|NCT04693039|Experimental|FLZ-300mg|Drug：Phenlarmide；Dosage：300mg；
3492683|NCT04693039|Experimental|FLZ-600mg|Drug：Phenlarmide；Dosage：600mg；
3492684|NCT04693039|Experimental|FLZ-900mg|Drug：Phenlarmide；Dosage：900mg；
3492685|NCT04693039|Placebo Comparator|Placebo-150mg|Drug：Placebo；Dosage：150mg；
3492686|NCT04693039|Placebo Comparator|Placebo-300mg|Drug：Placebo；Dosage：300mg；
3492687|NCT04693039|Placebo Comparator|Placebo-600mg|Drug：Placebo；Dosage：600mg；
3492688|NCT04693039|Placebo Comparator|Placebo-900mg|Drug：Placebo；Dosage：900mg；
3492689|NCT04692675|Experimental|AS + mpMRI|Active surveillance (AS) with the following: a) Initial PSA and DRE screen; then, PSA screening every 12 months, with DRE every year mpMRI or prostate biopsy is performed; b) Initial mpMRI and then prior to all biopsies; c) Initial systemic prostate biopsy and MRI/US fusion-guided prostate biopsy of all suspicious lesions; then, every 2 years for 5 years and then every 3 years
3492690|NCT04691206|Other|standardized step-wise operative curriculum|"General surgery residents at Mayo Clinic will complete surveys measuring resident autonomy, performance, confidence and case complexity at baseline and postoperatively following laparoscopic cholecystectomy to serve as a pre-intervention baseline.~A standardized step-wise operative curriculum will then be implemented Residents will follow and graduate through this curriculum by initiating a perioperative model of briefing objectives, intraoperative teaching, and debriefing feedback (BID). The effectiveness of the intervention will then be measured by comparing survey results pre and post intervention."
3492691|NCT04690829||control|control with non-inflammatory related eye disease
3492692|NCT04690829||control (healthy participant)|healthy volunteer
3492693|NCT04690829||uveitis|patients with a diagnosis of uveitis or ocular inflammation
3492694|NCT04690218||Mastalgia|"Mastalgia group will consist of women with confirmed mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
3492695|NCT04690218||Controls|"Controls group will consist of women attending to general surgery clinic for reasons other than mastalgia. The patients will be asked to fulfill the forms of Hospital Anxiety and Depression Scale and Pittsburgh Sleep Quality Index. Additionally patients will be asked to inform the frequency and amount of consumption of certain nutritional elements by a questionnaire."
3492696|NCT04686903|Experimental|Epiduroscopy|Epiduroscopy in patients with FBSS
3492697|NCT04686903|Experimental|Racz catheter epidural procedure|Racz catheter epidural procedure in patients with FBSS
3492698|NCT04686903|Experimental|Caudal epidural block|Caudal epidural block treatment of FBSS
3492699|NCT04686175|Experimental|INZ-701|The study design is a MAD 3+3 with 3 dose cohorts. The planned doses will be 0.2 mg/kg, 0.6 mg/kg, and 1.8 mg/kg administered via subcutaneous injection twice weekly.
3492700|NCT04686136|Experimental|Atogepant 60 mg|Taken once daily
3492701|NCT04685200||Controls|90 controls to collect epidemiological data as well as blood samples, nasal swabs, salivary samples and stool samples from family members and cohabitants of subjects affected with PSC.
3492702|NCT04685200||PSC Pariticipants|40 patients with PSC diagnosed by standard clinical, biochemical, or imaging features (including up to 30 with a known diagnosis of IBD)
3492703|NCT04684823|Experimental|Use of Patch Cap and Patch App|Subjects will use Patch Technologies to track their medication regimen compliance
3492704|NCT04684511|Experimental|TRM-201 (Rofecoxib)|1 TRM-201 tablet taken orally once daily for 12 weeks in Part I and orally once daily for an additional 52 weeks in Part II
3492705|NCT04684511|Placebo Comparator|Placebo|1 placebo tablet (to match TRM-201) taken orally once daily for 12 weeks in Part I and then 1 TRM-201 tablet taken orally once daily for an additional 52 weeks in Part II
3492706|NCT04683029|Experimental|Group A: Guselkumab|Participants will receive intravenous (IV) injection of Guselkumab Dose 1 at Week 0, 4, and 8 followed by subcutaneous (SC) injection of Dose 2 Guselkumab every 4 weeks (Q4W) from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Guselkumab Dose 2 and IV injection of placebo at long-term extension (LTE) Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
3492707|NCT04683029|Placebo Comparator|Group B: Placebo|Participants will receive IV injection of matching placebo at Week 0, 4, and 8 followed by SC injection of matching placebo Q4W from Week 12 to Week 48 (end of maintenance phase). Participants will receive SC injection of Placebo and IV injection of Guselkumab Dose 1 at LTE Weeks 52, 56, and 60 followed by SC injection of Guselkumab Dose 2 Q4W from LTE Week 64 until Week 100.
3492708|NCT04682860|Placebo Comparator|Placebo|In the placebo arm, patients will be slowly injected with 2 ml of normal saline within 30 seconds
3492709|NCT04682860|Active Comparator|Hyoscine N butylbromide|In the treatment arm, the patient will be injected intravenously with 1ml 20 mg of Hyoscine butylbromide and 1 ml of normal saline intravenously within 30 seconds.
3492710|NCT04681339||Pneumonia with antibiotics|Children with non-severe community acquired pneumonia and fever: managed with antibiotics
3492711|NCT04681339||Pneumonia without antibiotics|Children with non-severe community acquired pneumonia and fever: managed without antibiotics
3492712|NCT04680936|Active Comparator|low dose dextrose arm (5% dextrose)|Prolotherapy injection will be made with 5% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
3492713|NCT04680936|Active Comparator|high dose dextrose arm (15% dextrose)|Prolotherapy injection will be made with 15% dextrose solution for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
3492714|NCT04680936|Active Comparator|Isotonic saline arm (0.9% NaCl)|Prolotherapy injection will be made with isotonic saline for 3 sessions with 3 weeks intervals. 1ml solution will be given with 27 Gauge 1/2 inch needles in the sessions. Before the treatment, the examination and questionnaire data of the patient will be recorded.
3492715|NCT04676724|Experimental|GSK3228836 for 24 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 24 weeks, followed by up to 24 weeks of PegIFN.
3492716|NCT04676724|Experimental|GSK3228836 for 12 weeks + PegIFN for up to 24 weeks|Eligible participants on stable NA therapy will receive GSK3228836 for 12 weeks, followed by up to 24 weeks of PegIFN.
3492717|NCT04674319|Experimental|Brain engagement while using compesatory modes for walking|Brain engagemnent (recruitment of attention) is measured during four walking conditions
3492718|NCT04671251|Experimental|AEVI-007|
3129592|NCT03228914|Active Comparator|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
3180128|NCT00680069|Experimental|High Dose Group|Volunteers will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart
3492719|NCT04669041|Experimental|Single pill combination (SPC)|Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks
3492720|NCT04669041|Active Comparator|Rosuvastatin|Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks
3492721|NCT04668638|Other|Control group|Group 1 (Control Group) will not immediately receive respiratory rehabilitation but between the 2nd and 4th months postdiagnosis.
3492722|NCT04668638|Other|Intervention group|Group 2 (Intervention Group) will immediately receive rehabilitation between the diagnosis and the 2nd month postdiagnosis.
3492723|NCT04667494|Experimental|Sonotherapy|All participants will undergo sonotherapy
3492724|NCT04667481|Experimental|Arm I (aerobic exercise)|Patients participate in AE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders participate in combined AE and RE sessions for an additional 12 weeks, while responders continue participating in the AE sessions alone for an additional 12 weeks.
3492725|NCT04667481|Experimental|Arm II (resistance exercise)|Patients participate in RE sessions 3 times per week for 12 weeks. After 12-weeks, non-responders may participate in a further 12-weeks of combined AE and RE sessions, while responders continue participating in the RE sessions alone for an additional 12 weeks.
3492726|NCT04667481|Experimental|Control Group (digital exercise interventions)|After 24 weeks, patients receive a digital copy of the 12-week AE sessions and 12-week RE sessions and an outline of sessions for 24 weeks.
3492727|NCT04666636|Placebo Comparator|Placebo|Participants in the group will receive placebo.
3492728|NCT04666636|Experimental|Mirabegron|Participants in this group will receive Mirabegron for 16 weeks.
3492729|NCT04666610|Experimental|Brivaracetam 200 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to brivaracetam (BRV) 200mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
3492730|NCT04666610|Experimental|Placebo to 200 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 200mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 200mg/day (or equivalent dose) during the AT period."
3492731|NCT04666610|Experimental|Brivaracetam 100 mg|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to BRV 100mg/day (or equivalent dose) will receive these doses during the 2-week PC period and subsequent 11-week AT period."
3492732|NCT04666610|Experimental|Placebo to 100 mg brivaracetam|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 1: Study participants randomized to 'placebo to BRV 100mg/day' (or equivalent dose) will receive placebo during the PC period followed by BRV 100mg/day (or equivalent dose) during the AT period."
3492733|NCT04666610|Experimental|Optimal dose of BRV (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment Period (AT):~Stage 2: Study participants will be randomized in Stage 2 to receive a fixed dose of the optimal dose of brivaracetam (defined following Stage 1). Study participants randomized to the BRV optimal dose will receive this dose during the 2-week PC period and subsequent 11-week AT period."
3492734|NCT04666610|Experimental|Placebo to BRV optimal dose (defined following Stage 1)|"Placebo-Controlled (PC) and Active Treatment (AT) Period:~Stage 2: Study participants will be randomized in Stage 2 of the study to 'placebo to BRV optimal dose'. Study participants randomized to placebo to brivaracetam (BRV) optimal dose will receive placebo during the PC period followed by BRV optimal dose during the AT period."
3129593|NCT03228914|Active Comparator|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
3129594|NCT03229109|Experimental|Group 1|Age 18-25, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
3129595|NCT03229109|Experimental|Group 2|Age 26-35, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
3129596|NCT03229109|Experimental|Group 3|Age 36-45, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
3129597|NCT03229109|Experimental|Group 4|Age 46-50, males and females, Spectrophon dehydration body monitor was attached to subject's wrist
3129598|NCT03229252|Placebo Comparator|Placebo|Placebo Inhalation solution twice daily for 28 days.
3129599|NCT03229252|Experimental|SPX-101 Low Dose|Inhalation solution twice daily for 28 days.
3129600|NCT03229252|Experimental|SPX-101 High Dose|Inhalation solution twice daily for 28 days.
3129601|NCT03229486|Experimental|Sugammadex Injection [Bridion]|reversal of neuromuscular blockade with sugammadex
3129602|NCT03229486|Active Comparator|Neostigmine+Glycopyrronium|reversal of neuromuscular blockade with neostigmine & glycopyrrolate
3129603|NCT03229759|Experimental|Investigational Product|Polyester cloth impregnated with investigational product
3129604|NCT03229759|Placebo Comparator|Vehicle Control (VC)|Polyester cloth impregnated with the vehicle control
3129605|NCT03229759|Placebo Comparator|Saline Control (SC)|Saline applied wtih polyester cloth
3129606|NCT03230175|Experimental|TTAX01 plus standard care|Eligible consenting subjects will undergo a baseline aggressive debridement in the operating room to remove infected and devitalized bone and soft tissue. A six week course of systemic antibiotics will be used to resolve baseline infection. TTAX01 will be applied to the debrided wound bed at baseline, and if healing is not evident, it will be applied again at 4 week intervals. At each weekly visit the wound will be further debrided as necessary.
3129607|NCT03230864|Experimental|Prospective Confirmation (PC) Period|Single (patient)-blinded treatment period with risperidone or olanzapine for 6 weeks
3129608|NCT03230864|Experimental|Double-blind treatment (DBT) period, Lu AF35700 10 mg|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks
3129609|NCT03230864|Experimental|DBT Period, Continued treatment from PC Period|Eligible patients from PC period (based on criteria to which investigator and patient are blinded ), will be randomly assigned (1:1) double-blind treatment in DBT period, 8 weeks. Patients in this arm will continue with the same treatment and dose as at the last visit of the PC Period
3129610|NCT03231228|Active Comparator|Cefazolin 1 g Infusion|Pediatric surgical subjects weighing at least 25 kg to less than 60 kg will receive a single 30-minute infusion of 1 g cefazolin.
3129611|NCT03231228|Active Comparator|Cefazolin 2 g Infusion|Pediatric surgical subjects weighing at least 60 kg will receive a single 30-minute infusion of 2 g cefazolin.
3129612|NCT03231345|Experimental|US guided IJ|A physician placed ultrasound-guided IV in the internal jugular vein
3129613|NCT03231371|Experimental|Study Arm|
3129614|NCT03231709|Experimental|Trelagliptin 100 mg + Alogliptin 25 mg|Trelagliptin preceding group (T-A group): Trelagliptin 100 mg, tablets, orally, once a week for 8 weeks, followed by alogliptin, 25 mg, tablets, orally, once a day for 8 weeks.
3129615|NCT03231709|Experimental|Alogliptin 25 mg + Trelagliptin 100 mg|Alogliptin preceding group (A-T group): Alogliptin, 25 mg, tablets, orally, once a day for 8 weeks, followed by trelagliptin, 100 mg, tablets, orally, once a week for 8 weeks.
3129616|NCT03231800|Experimental|Dasotraline|Dasotraline capsule 2mg/day
3129617|NCT03231800|Placebo Comparator|Placebo|Placebo capsule
3129618|NCT03231917|Experimental|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
3129619|NCT03231917|Experimental|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion.
3129620|NCT03231943|Experimental|Subjects in cohort 1-2: Part 1|Eligible subjects will participate in cohort 1 or 2 and each of these two cohorts will contain up to four escalating doses of GSK3640254. In each cohort, 6 subjects will be randomized to receive single oral dose of GSK3640254 and 2 subjects will be randomized to receive placebo. Hence, each subject in cohort 1 and 2 will receive up to 3 escalating doses of GSK3640254 and one placebo in crossover manner.
3129621|NCT03231943|Experimental|GSK3640254 receivers (cohort 3-6 and expansion): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 6 subjects will be randomized to receive a once-daily oral dose of GSK3640254 for 14 days. After the safety data of cohort 3-6 is available, 18 eligible subjects will be randomized to receive once daily oral dose of GSK3640254 for 14 days in expansion cohort.
3492735|NCT04666610|Experimental|Brivaracetam received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Participants who are randomized to this arm will continue on the Brivaracetam dose they were receiving in the AT period."
3492736|NCT04666610|Experimental|Placebo received during RDW|"Randomized Withdrawal (RDW) Period:~Only study participants who are absence seizure-free based on the outcome of the 24h EEG of Visit 5 will enter the RDW Period. Study participants who are randomized to the placebo arm in the RDW Period will be tapered down to 0 mg and receive 0 mg for 2 weeks."
3492737|NCT04666389|Placebo Comparator|Control group|No statins being used for prevention
3492738|NCT04666389|Active Comparator|Low-dose statin therapy|Atorvastatin 40 mg
3492739|NCT04666389|Active Comparator|High-dose statin therapy|Atorvastatin 80 mg
3492740|NCT04665856|Experimental|Tiragolumab + Atezolizumab + Carboplatin and Etoposide|Induction treatment with tiragolumab plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with tiragolumab plus atezolizumab for 21-day cycles.
3129622|NCT03231943|Placebo Comparator|Subjects receiving placebo (cohort 3-6): Part 2|Eligible subjects will participate in one of the 4 cohorts (3,4,5,6). In each cohort, 2 subjects will be randomized to receive a once-daily oral dose of placebo for 14 days. After the safety data of cohort 3-6 is available, 6 eligible subjects will be randomized to receive once daily oral dose of placebo for 14 days in expansion cohort.
3129623|NCT03231969|Experimental|Bilastine 0.2%|"Bilastine Ophthalmic solution 0.2%~1 drop in each eye at 3 separate times during a 25 day period."
3492741|NCT04665856|Placebo Comparator|Placebo + Atezolizumab + Carboplatin and Etoposide|Induction treatment with placebo plus atezolizumab and CE will be administered on a 21-day cycle for 4 cycles. Following the induction phase, participants will continue maintenance therapy with placebo plus atezolizumab for 21-day cycles
3492742|NCT04664985|Active Comparator|Mucogyne®|The dosage during the study will be 1 Mucogyne® ovule per day at bedtime for 10 days and then 1 ovule every 2 days until the end of the 3-month follow-up.
3492743|NCT04664985|No Intervention|Control|No treatment for this arm.
3492744|NCT04664946|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug/min.
3492745|NCT04664933|Experimental|Intra-arterial administration of 3-n-butylphthalide|Intra-arterial administration of 3-n-butylphthalide for 16 to 24 hours during and after the operation at 17.36 to 26.04 ug/min.
3129624|NCT03231969|Experimental|Bilastine 0.4%|"Bilastine Ophthalmic solution 0.4%~1 drop in each eye at 3 separate times during a 25 day period."
3129625|NCT03231969|Experimental|Bilastine 0.6%|"Bilastine Ophthalmic solution 0.6%~1 drop in each eye at 3 separate times during a 25 day period."
3129626|NCT03231969|Placebo Comparator|Bilastine 0%|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 3 separate times during a 25 day period."
3129627|NCT03232281|Experimental|Triptorelin pamoate PR 3-month|Subjects received 15 mg triptorelin pamoate per injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections, at baseline and Week 12).
3492746|NCT04662710|Experimental|Lenvatinib + Pembrolizumab + Chemotherapy|Participants receive lenvatinib administered orally (PO) every day (QD) in combination with pembrolizumab intravenously (IV) every 6 weeks (Q6W) plus chemotherapy with either capecitabine and oxaliplatin (CAPOX) or chemotherapy with 5-FU, leucovorin, and oxaliplatin (mFOLFOX6). Induction with lenvatinib 8 mg QD plus pembrolizumab (400 mg Q6W) plus chemotherapy (CAPOX or mFOLFOX6) will be administered for 2 cycles (approximately 12 weeks), followed by consolidation with lenvatinib 20 mg QD plus pembrolizumab (400 mg Q6W) for 16 cycles. A cycle is 6 weeks (42 days).
3492747|NCT04662710|Experimental|Chemotherapy|Participants receive chemotherapy with either CAPOX Q3W or mFOLFOX6 Q2W. A cycle is 6 weeks (42 days).
3492748|NCT04661033|Experimental|Isatuximab Part A/Cohort 1|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
3492749|NCT04661033|Experimental|Isatuximab Part A/Cohort 2|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
3492750|NCT04661033|Experimental|Isatuximab Part A/Cohort 3 (optional)|Isatuximab dose subcutaneous (SC) every 2 weeks x 2 doses
3492751|NCT04661033|Experimental|Isatuximab Part B|Isatuximab dose subcutaneous (SC) every 2 weeks x 6 doses
3492752|NCT04660201|Experimental|Group 1|AV7909 liquid formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
3492753|NCT04660201|Active Comparator|Group 2|AV7909 lyophilized formulation will be administered 0.5mL intramuscularly in a 2-dose schedule, 2 weeks apart (on Day 1 and Day 15). N=20
3492754|NCT04658862|Experimental|TAR-200 + Cetrelimab|Participants will receive intravesical TAR-200 every 3 weeks (21 days indwelling) for first 18 weeks and thereafter from Week 24 every 12 weeks through study Year 3 in combination with Cetrelimab.
3492755|NCT04658862|Active Comparator|Chemotherapy (cisplatin or gemcitabine) + Radiation Therapy|Participants will receive chemotherapy based on investigator's choice from either cisplatin intravenously once weekly for 6 treatment weeks or gemcitabine intravenously twice weekly for 6 treatment weeks as Standard of Care (SOC) along with radiation therapy from either conventional radiotherapy (64 Gray [Gy], bladder only) for up to 6.5 treatment weeks or hypo-fractionated radiotherapy (55 Gy, bladder only) for up to 4 weeks.
3492756|NCT04654052|Other|VerifyNow® PRUTest ≤30 (De-escalated Prasugrel Ticagrelor )|Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will be de-escalated to Clopidogrel 75 mg q.d during 11 months.
3492757|NCT04654052|Other|VerifyNow® PRUTest ≤30 (Prasugrel or Ticagrelor )|Active comparator: Patients with ACS on Prasugrel or Ticagrelor and PRU ≤ 30 at the end of the first month will continue with these previous treatment during 11 months.
3492758|NCT04652960|Experimental|Treatment (duvelisib, nivolumab)|Patients receive duvelisib PO QD or BID on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3492759|NCT04647526|Experimental|[Lu-177]-PNT2002 (Arm A)|[Lu-177]-PNT2002 (6.8 GBq (±10%) every 8 weeks for 4 cycles)
3492760|NCT04647526|Active Comparator|Control Arm (Arm B)|Abiraterone (1000 mg orally qd with: 5 mg bid prednisone or 0.5 mg qd dexamethasone) or enzalutamide (160 mg orally qd).
3492761|NCT04647162|Active Comparator|medical group|Patients receive only medical treatment including active life support, nutritional support, homeostasis maintenance of the internal environment, and other symptomatic treatment.
3492762|NCT04647162|Experimental|surgical group|Patients receive intervention such as the evacuation of hematoma under craniotomy or by stereotactic puncture or neuroendoscopy.
3492763|NCT04645160|Experimental|1/ Phase I|Tivozanib, P.O. daily at 0.89 mg (given on Days 1-21 of every 28-day cycle) with intra-patient escalation to 1.34 mg daily (given on Days 1-21 of every 28-day cycle) and possible dose de-escalation to 0.89 mg every other day (without interruption for a 28-day cycle) if needed to determine RP2D
3492764|NCT04645160|Experimental|2/ Phase II|Tivozanib at the RP2D established in Phase I
3492765|NCT04645147|Experimental|EBV gp_350 Ferritin Vaccination|Adult participants with or without prior EBV infection will receive 3 doses of vaccine
3492766|NCT04644068|Experimental|Module 1: AZD5305 Monotherapy|AZD5305 Monotherapy
3492767|NCT04644068|Experimental|Module 2: AZD5305 + Paclitaxel|AZD5305 + Paclitaxel
3492768|NCT04644068|Experimental|Module 3: AZD5305 + Carboplatin with or without Paclitaxel|AZD5305 + Carboplatin with or without Paclitaxel
3492769|NCT04644068|Experimental|Module 4: AZD5305 + Trastuzumab Deruxtecan|AZD5305 + T- Dxd
3492770|NCT04644068|Experimental|Module 5 AZD5305 + Datopotamab Deruxtecan|AZD5305 + Dato-DXd
3492771|NCT04640909|Other|CAR T Cells generation|CAR T Cells generation at baseline and after 6 and 12 months of treatment
3492772|NCT04640792|No Intervention|Common Colonoscopy (Group A)|Patients will be examined with Conventional Colonoscopy (CC)
3492773|NCT04640792|Experimental|Magentiq Eye Assisted Colonoscopy (Group B)|Patients will be examined with Magentiq Eye Assisted Colonoscopy (MEAC)
3492774|NCT04640623|Experimental|Cohort 1: TAR-200 and Cetrelimab|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Study Year 2). In addition, Cetrelimab will be dosed every 3 weeks (Q3W) through Week 78 (18 months).
3492775|NCT04640623|Experimental|Cohort 2: TAR-200|TAR-200 is placed into the bladder through a urinary placement catheter on Day 0 and will be dosed every 21 days for up to the first 24 weeks (6 months), then every 12 weeks through Week 99 (Study Year 2).
3492776|NCT04640623|Experimental|Cohort 3: Cetrelimab|Participants will receive Cetrelimab which will be dosed Q3W through Week 78 (18 months).
3129628|NCT03232281|Active Comparator|Triptorelin acetate PR 1-month|Subjects received 3.75 mg triptorelin acetate per injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections, at baseline and Weeks 4, 8, 12, 16 and 20).
3129629|NCT03232333||MIRODERM|Biologic wound graft
3492777|NCT04639843|Experimental|1- Experimental Treatment: Dose Escalation|Duvelisib (PO BID) at escalating doses of 25, 50 and 75 mg/BID on days -14 to 14 of C1 and days 1-14 of all other cycles of each 21- day cycle (max 8 cycles) with CC-486 (5-azacitidine) (PO) at 300mg/day on days 1-10, romidepsin at 12mg/m2 (IV) on Days 1 and 8 of each cycle and doxorubicin (IV) at 25 mg/ m2 on Day 1 of cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy), to determine RP2D of duvelisib and doxorubicin
3492778|NCT04639843|Experimental|2 - Experimental Treatment: Dose Expansion|Duvelisib (PO BID) at RP2D on days -14 to 14 of C1 and days 1-14 of all other 21-day cycle (max 8 cycles) with CC-486 (5-azacitidine) at 300mg/day (PO) on days 1-10, romidepsin at 12mg/m2 (IV) on days 1 and 8 of each cycle, and doxorubicin at 25 mg/m2 on day 1 of Cycles 3-8 (Cycles 3-6 for patients with prior anthracycline-based therapy
3492779|NCT04634552|Experimental|Part 3: Cohort A (Talquetamab)|Cohort A will enroll participants with multiple myeloma who have previously received greater than or equal to (>=) 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
3492780|NCT04634552|Experimental|Part 3: Cohort B (Talquetamab)|Cohort B will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have been exposed to T cell redirection therapies. Participants will receive talquetamab subcutaneously (SC) at a recommended Phase 2 dose (RP2D) selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
3492781|NCT04634552|Experimental|Part 3: Cohort C (Talquetamab)|Cohort C will enroll participants with multiple myeloma who have previously received >= 3 prior lines of therapy and have not been exposed to T cell redirection therapies. Participants will receive talquetamab SC biweekly at a RP2D selected after review of safety, efficacy, PK, and pharmacodynamic data from Part 1 and Part 2 of this study.
3492782|NCT04633447|Experimental|Guselkumab|Participants will receive guselkumab dose 1 intravenously (IV) at week 0, 4, and 8 and guselkumab dose 2 subcutaneously (SC) every 4 weeks (q4w) from week 12 through week 48. This will be in combination with a protocol specified 26-week GC taper. Participants of the long-term extension (LTE) period will continue to receive subcutaneous (SC) injections q4w starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a Giant cell arteritis (GCA) flare, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
3492783|NCT04633447|Experimental|Placebo|Participants will receive matching placebo IV at week 0, 4 and 8 and matching placebo SC q4 weeks from week 12 through week 48. This will be in combination with a protocol-specified 26-week GC taper. Participants of the LTE period will continue to receive SC injections q4w starting at Week 52 (LTE Week 0) through Week 100 (LTE Week 48) or until the participants have a GCA flare, or the participants discontinues treatment due to unblinding after the Week 60 DBL for the Main study, or until a decision is made not to continue clinical development in this GCA population, whichever occurs first.
3492784|NCT04631042||impulsive compulsive|Individuals between 6 and 80 years of age with a wide range of impulsivity/compulsivity behaviors - ranging from normal to mildly/extremely impaired.
3492785|NCT04630613||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.
3492786|NCT04626128|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of 0.03 mg CLS-AX
3492787|NCT04626128|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of 0.10 mg CLS-AX
3492788|NCT04626128|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of 0.30 mg CLS-AX
3129630|NCT03232567|Experimental|NasoVAX low dose|NasoVAX administered by intranasal spray at a single dose of 1×10(9th) viral particles (vp) versus placebo
3129631|NCT03232567|Experimental|NasoVAX medium dose|NasoVAX administered by intranasal spray at a single dose of 1×10(10th) viral particles (vp) versus placebo
3129632|NCT03232567|Experimental|NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
3129633|NCT03232567|Placebo Comparator|Placebo|Normal saline administered by intranasal spray at a single dose
3492789|NCT04624204|Experimental|Group A - Pembrolizumab 200 mg|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg every 3 weeks (Q3W) concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg every 6 weeks (Q6W) plus olaparib matching placebo twice daily (BID) for 12 months or until specific discontinuation criteria are met.
3492790|NCT04624204|Experimental|Group B - Pembrolizumab 200 mg plus Olaparib 300 mg BID|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab 200 mg Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab 400 mg Q6W plus olaparib 300 mg BID for 12 months or until specific discontinuation criteria are met.
3492791|NCT04624204|Placebo Comparator|Group C (Pembrolizumab and Olaparib Matching Placebos)|Participants will receive 4 cycles of standard-of-care chemotherapy (etoposide/platinum) plus pembrolizumab placebo (saline) Q3W concurrently with standard thoracic radiotherapy, followed by 9 cycles of pembrolizumab placebo (saline) Q6W plus olaparib matching placebo for 12 months or until specific discontinuation criteria are met.
3492792|NCT04623671|Active Comparator|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
3492793|NCT04623671|Placebo Comparator|Placebo|Matching placebo solution
3492794|NCT04621786|Experimental|Experimental arm|All subjects enrolled will receive amplitude titration for their first treatment. The remainder of the ECT series will be completed with traditional (800mA) pulse amplitude with right unilateral electrode placement. This investigation only includes the single open-label arm.
3492795|NCT04621500|Other|Open label|All enrolled subjects will receive vitamin D3 at 4,000 IU daily for approximately one year.
3492796|NCT04620733|Experimental|Seladelpar 10 mg|
3492797|NCT04620733|Placebo Comparator|Placebo|
3492798|NCT04620733|Experimental|Seladelpar 5 mg|
3492799|NCT04617353|Experimental|Plasma|(the treatment of sterno-mediastinitis was carried out using a combined method of air-plasma flow and NO therapy)
3492800|NCT04617353|Other|Standard therapy|(patients who were treated for sterno-mediastinitis according to clinical guidelines, the main method of which is a permanent irrigation and aspiration flow drainage method, as well as a Vacuum Assisted Closure (VAC) system of dressings for vacuum drainage)
3492801|NCT04617093|Experimental|Total Patient Population|The planned PrismaLung+ treatment period for this study is 24 hours. Neuromuscular blockade and sedation will be required for the first 24 hours of ECCO2R treatment and thereafter, will be used at the discretion of the attending physician. Patients will require systemic anticoagulation with heparin during ECCO2R treatment. Blood warming during ECCO2R treatment will occur using the TherMax blood warmer.
3492802|NCT04614467|Experimental|GCSF-mobilized autologous CD34+ cells|
3492803|NCT04614467|Placebo Comparator|Placebo|
3492804|NCT04613453|Experimental|Ketamine Infusion|Participants will receive four Ketamine infusions over two weeks, each 0.5mg/kg over 40 minutes.
3492805|NCT04613453|Active Comparator|Midazolam Infusion|Participants will receive four Midazolam infusions over two weeks, each 0.045mg/kg over 40 minutes.
3129634|NCT03232580|Experimental|rhAnnexin V-128|All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
3129635|NCT03232645|Other|Rhythmia HDx and DirectSense technology|"Subjects will undergo ablation treatment of the pulmonary veins with the Rhythmia HDx mapping system with DirectSense technology. Subjects indicated for ablation treatment of de-novo PAF will be selected based on the inclusion/exclusion criteria and if deemed to be eligible for participation, will be asked to sign the Informed Consent Form.~For all enrolled subjects who undergo the ablation procedure, the subjects will be treated with the commercial Rhythmia HDx System with commercially available Software Version 2.0 with DirectSense technology (or any commercially available updates that are released during the course of the study); the IntellaMap Orion mapping catheter and the IntellaNav MiFi OI ablation catheter."
3129636|NCT03232736||Healthy Control|
3129637|NCT03232736||LVAD Group w/Pacemaker|
3129638|NCT03232749|Other|symptomatic primary osteoarthritis of the shoulder|Subjects enrolled into the study will be those who have failed previous treatment including over-the-counter analgesics and activity modification, and have elected to receive a medically-indicated, ultrasound-guided IACSI in the shoulder
3129639|NCT03232827|Active Comparator|Flavored-sweetened|Flavored-sweetened (FS) WP tobacco will be associated with longer and more frequent puffing resulting in the greatest overall levels of smoke inhalation (mL of smoke inhaled), highest abuse potential, and greatest levels of exposure to nicotine and carbon monoxide (CO). , followed by unflavored-sweetened WP, and lastly unflavored-very low sweetened WP. (H1d) A majority of WP smokers will report having initiated WP smoking with flavored-sweetened tobacco and report flavoring as an important reason for trying WP.
3129640|NCT03232827|Active Comparator|Unflavored-sweetened|Unflavored-sweetened (US) WP will be associated with the second longest and slightly less frequent puffing than FS resulting in the second greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
3180129|NCT00680069|Experimental|Low Dose Group|Volunteers will receive 15 mcg intramuscularly (IM). Subjects who received previous clade 1 vaccine will get 1 dose, clade 1 vaccine-naive subjects receive 2 doses 28 days apart.
3129641|NCT03232827|Active Comparator|Unflavored very low sweetened|Unflavored-very low sweetened (UU) WP will be associated with the shortest and the least frequent puffing resulting in the least overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
3129642|NCT03232827|Active Comparator|Flavored-very low sweetened waterpipe|Flavored-very low sweetened WP will be associated with the third longest and slightly less frequent puffing than US resulting in the third greatest overall levels of smoke inhalation (mL of smoke inhaled), abuse potential, and levels of exposure to nicotine and carbon monoxide (CO).
3492806|NCT04612738|Active Comparator|Group 1:Advance care planning conversation game, 'Hello'|"The 'Hello' game is a commercially available serious game that consists of 32 questions prompting players to share their values, goals, and beliefs about end-of-life issues. The game is played with 4 - 5 players, with each receiving a game booklet and chips. A play reads the first question in the book. Then each player writes down their answers individually and takes turns sharing their answers with the group. Players control what they share, how long they share and when to move to the next questions. During the conversation, plays can acknowledge others for a thoughtful, poignant or even funny comments by giving them a chip. A pre-game coin flip determines whether the player with the most chips wins the game (heads) or player with the least chips win (tails) the game.~Other names; previously name My Gift of Grace"
3492807|NCT04612738|Active Comparator|Group 2: The Conversation Project (CP) Starter Kit|The 'CP Starter Kit' (available for free online) is an 11-page workbook with open- ended prompts to consider one's values and preferences for end-of-life care, who to talk with about one's wishes, and suggestions on how to do so.
3492808|NCT04612738|Placebo Comparator|Group 3: Control Arm (Placebo control game, 'Table Topics')|A placebo/attention control l conversation game called 'Table Topics' will be used. Table Topics is a general conversation starter game that is unrelated to advance care planning. It involves answering open-ended questions in a group setting about a variety of topics.
3492809|NCT04610528|Experimental|U3-1402|U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
3492810|NCT04609644|No Intervention|Passive|"Passive arm participants will be sent two devices, at no cost-an Apple Watch and a Beddit Sleep Monitor. These are commercially available and have not been modified for this study. Participants will be asked to use these devices regularly throughout study Year 1. Participants can optionally continue to use devices during Year 2, if they have met requirements during Year 1 to keep study devices. To be eligible to keep devices, participants must meet pre-specified levels of adherence to study procedures.~Access to the Study App will be provided to all participants. It will be used to administer informed consent and electronic patient reported outcome (ePRO) measures, and for other study purposes. However, passive participants will not have access to the Study App features designed to support asthma self-management."
3129643|NCT03232983|Experimental|LY900014 (SC Abdomen)|Single dose of 15-U of LY900014 administered subcutaneously (SC) into the abdomen in one period
3129644|NCT03232983|Experimental|LY900014 (SC Thigh)|Single dose of 15-U of LY900014 administered SC into the thigh in one period
3492811|NCT04609644|Experimental|Active|"Active arm participants will be sent the same devices, also at no cost, and asked to use them in the same manner.~Only the active arm will have access to Study App features for asthma self-management, including:~Smart nudges that may promote proactive asthma self-management~Asthma symptom and trigger tracking~Evidence-based asthma education~The ability to photograph and easily reference an asthma action plan from a healthcare provider.~A 90-day summary of self-reported asthma symptoms/triggers and device-recorded heart rate and respiratory rate. This summary can be shared with providers.~In-app viewing of active asthma medications, refills available, and phone numbers to call for refills (subject to prescription benefits).~Active participants can, but are not required to, use the Study App in Year 2. Those who choose to may keep using study devices in Year 2, provided they meet requirements to keep devices. These requirements are the same for both arms."
3492812|NCT04609085||Participants with Rare Diseases|Participants with history of rare disease
3492813|NCT04609072||Healthy volunteers|Up to 200,000 men and women aged 40 to 65 years, with no personal history of cancer, and patients or members of participating integrated health care systems.
3492814|NCT04604197|Experimental|Angiography and Clinical Follow up|After PCI. The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
3492815|NCT04604197|Active Comparator|Clinical Follow up|After PCI. The patient is randomized to a Clinical Follow to 36 months
3492816|NCT04603482|Experimental|Self-Management|
3129645|NCT03232983|Experimental|LY900014 (SC Arm)|Single dose of 15-U of LY900014 administered SC into the arm (deltoid) in one period
3129646|NCT03232983|Active Comparator|LY900014 (IV)|Single dose of 15-U of LY900014 administered intravenously (IV) in one period
3492817|NCT04603482|Active Comparator|Attention Control Condition|
3492818|NCT04602507|Experimental|Intervention|50 patients with the routine care offered in the hospital plus ivermectin 400 µg/kg (2 drops per kg) orally in a single dose.
3492819|NCT04602507|Placebo Comparator|Control|50 patients with routine care offered in the hospital plus placebo orally (2 drops per kg) in a single dose.
3492820|NCT04601831|Experimental|Radiation Therapy to all residual FDG-avid sites*|"All patients enrolled in the trial will receive focal radiation therapy (RT) to all* residual FDG-avid sites per Lugano criteria (Lugano 4-5) as noted on day 30 post-CAR-T PET/CT scan.~*If >5 distinct sites, physician discretion will be allowed as to how many sites are treated, with recommendation that at least all symptomatic and bulky (>=7.5 cm in largest dimension) sites be treated."
3492821|NCT04598152|Experimental|Transcranial Direct Current Stimulation during fMRI|Each subject will undergo transcranial direct current stimulation twice while completing a task in the functional magnetic resonance imaging scanner.
3492822|NCT04596631|Experimental|Semaglutide - max. tolerated dose|Participants will receive semaglutide tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
3129647|NCT03233009|Experimental|Test Product 1|Participants will topically apply test product 1 via semi occlusive patch.
3180130|NCT00680082||1|Patients to whom a statin was initiated or switched between 3 and 6 months before consultation
3180131|NCT00680095|Experimental|A|AN2690 Solution, 2.5%
3180132|NCT00680095|Experimental|B|AN2690 Solution, 7.5%
3492823|NCT04596631|Placebo Comparator|Placebo (semaglutide)|Participants will receive semaglutide placebo tablets once daily in addition to background treatment with metformin or basal insulin or both, in addition to diet and exercise.
3492824|NCT04595045|Experimental|patients with spastic lower limb paresis|patients with spastic lower limb paresis secondary to Multiple Sclerosis
3492825|NCT04592445|Active Comparator|Axon Treatment Arm|Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
3492826|NCT04592445|Sham Comparator|Sham Control Arm|Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
3492827|NCT04591483||Affected|Patients with Stargardt-like macular dystrophy 3 who are >= 10 years of age.
3492828|NCT04588298|Experimental|Stage 1: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 1 of the study.
3492829|NCT04588298|Experimental|Stage 1: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 1 of the study.
3492830|NCT04588298|Experimental|Stage 2: AZD9833 Dose A|Post-menopausal participants will receive once daily oral dose A of AZD9833 in stage 2 of the study.
3492831|NCT04588298|Experimental|Stage 2: AZD9833 Dose B|Post-menopausal participants will receive once daily oral dose B of AZD9833 in stage 2 of the study.
3492832|NCT04588298|Experimental|Stage 2: AZD9833 Dose C|Post-menopausal participants will receive once daily oral dose C of AZD9833 in stage 2 of the study.
3492833|NCT04586426|Experimental|Part 1: Dose Escalation|Participants will receive tec+tal with or without daratumumab in 28-day cycles following initial step-up doses.
3492834|NCT04586426|Experimental|Part 2: Dose Expansion|Participants will receive treatment doses (combination of tal+tec and dara+tal+tec regimens) which will be determined by the RP2R(s) of the study treatment identified in Part 1.
3492835|NCT04585100|Experimental|Bioequivalent test of FM101 oral solution and FM101 tablet|
3492836|NCT04585100|Experimental|Phase 2a|
3492837|NCT04583956|Active Comparator|Remdesivir + Placebo|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab placebo infusion (300-mg x 4 vials) once on Day 1. N=100.
3492838|NCT04583956|Experimental|Remdesivir + Risankizumab|200-mg intravenous (IV) remdesivir loading dose on Day 1, followed by a 100-mg once-daily IV maintenance dose up to a 10-day total course while hospitalized and 1200-mg IV risankizumab infusion (300-mg x 4 vials) once on Day 1. N=100.
3129648|NCT03233009|Experimental|Test Product 2|Participants will topically apply test product 2 via semi occlusive patch.
3129649|NCT03233009|Experimental|Test Product 3|Participants will topically apply test product 3 via semi occlusive patch.
3492839|NCT04582916|Other|One Arm|All subject receive the same tests
3492840|NCT04578314|Experimental|Relating module + Treatment as usual|Participants in this arm will receive 16 weekly sessions with Relating Therapy (RT) over 5 months in addition to their treatment as usual.
3492841|NCT04578314|Active Comparator|Treatment as usual|Treatment as usual will include medication management, supportive brief counselling sessions and various types of psychosocial (e.g. social work guided support, peer support) and monitoring provided by Mental Health Services, with individual and family psychological therapies offered occasionally. Individual therapies may include Cognitive Behavior Therapy or psychodynamic interventions.
3492842|NCT04577833|Experimental|Treatment Sequence ABD|Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
3129650|NCT03233009|Experimental|Test Product 4|Participants will topically apply test product 4 via semi occlusive patch.
3129651|NCT03233009|Sham Comparator|Reference Product|Participants will topically apply Reference product via semi occlusive patch.
3129652|NCT03233217|Experimental|Cohort 1: QIV-HD by IM|Participants were randomized to receive a single 0.7-milliliter (mL) injection of QIV-HD by IM route on Day 0.
3129653|NCT03233217|Experimental|Cohort 1: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
3129654|NCT03233217|Experimental|Cohort 2: QIV-HD by IM|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by IM route on Day 0.
3129655|NCT03233217|Experimental|Cohort 2: QIV-HD by SC|Participants were randomized to receive a single 0.7 mL injection of QIV-HD by SC route on Day 0.
3180133|NCT00680095|Experimental|C|AN2690 Solution, 5.0%
3180134|NCT00680095|Active Comparator|D|AN2690 Solution, Vehicle
3180135|NCT00680095|Active Comparator|E|Sodium Lauryl Sulfate, 0.5%
3180136|NCT00680134|Experimental|Group/Cohort 1|AN2690 1% Solution (30 subjects)
3180137|NCT00680134|Experimental|Group/Cohort 2|AN2690 5% Solution (30 subjects)
3180138|NCT00680147|Experimental|Brief HPV vaccine informational intervention|Because we anticipated that knowledge and awareness of the HPV vaccine would be low in our study population, our CASI survey included a brief, informational overview of key facts concerning HPV vaccination prior to assessing vaccine acceptance, perceived barriers to vaccination, and intentions to vaccinate. The overview lasted approximately 3 minutes and consisted of a brief overview of key HPV vaccination facts that were presented visually (on the computer screen) and read aloud using a digital recording. HPV and vaccine knowledge, awareness, and attitudes items were administered prior to participants hearing the informational overview.
3180139|NCT00680173|Active Comparator|A|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin achieve a sustained virological response
3180140|NCT00680173|Active Comparator|B|15 patients with HCV genotype 1 infection receiving peginterferon plus ribavirin did not achieve a sustained virological response
3180141|NCT00680199||1|Primary Insomnia
3492843|NCT04577833|Experimental|Treatment Sequence ADB|Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
3492844|NCT04577833|Experimental|Treatment Sequence CBD|Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
3129656|NCT03233217|Active Comparator|Cohort 2: QIV-SD by SC|Participants were randomized to receive a single 0.5 mL injection of QIV-SD by SC route on Day 0.
3129657|NCT03233230|Placebo Comparator|Placebo|
3492845|NCT04577833|Experimental|Treatment Sequence CDB|Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension Phase all participants will continue to receive treatment with niraparib and AAP or AAP alone.
3492846|NCT04576000||Open-Label Group|Eligible patients will include those who will be prescribed Janus Kinase inhibitor as part of their routine medical care.
3492847|NCT04574583|Experimental|1/Sequential Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN M7824 +CV301
3492848|NCT04574583|Experimental|2/Combination Dose Escalation|Escalating doses of SX-682 for 2 weeks THEN Escalating doses of SX-682 + M7824 + CV301
3492849|NCT04574583|Experimental|3/Disease-Specific Expansion|RP2D of SX-682 + M7824 + CV301
3492850|NCT04573062||Post COVID patients|Individuals whom have previously had COVID -19 infection.
3492851|NCT04571658||NEPTUNE Match Participants|"Approximately 375 participants will be consented from the NEPTUNE observational study with age and demographic groups representing the patient population in the NEPTUNE study site geographical areas.~NEPTUNE observational cohort eligibility includes: participants in NEPTUNE observational cohort A are of any age and have a biopsy-confirmed diagnosis of Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), or Membranous Nephropathy (MN). Participants in NEPTUNE observational cohort B have documented NS based on proteinuria, serum albumin, and/or edema with age of onset less than 19 years."
3492852|NCT04570943|Experimental|Gabrinox followed by stereotactic radiotherapy|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
3492853|NCT04569591|Experimental|1|patients aged 8 or older with Cushing's Disease who are surgical candidates for resection of ACTH producing pituitary adenoma within 12 weeks of PET imaging
3492854|NCT04566445|Experimental|GT005 Medium Dose|Approximately 60 subjects are planned, with subjects randomised to GT005 Medium Dose.
3492855|NCT04566445|Experimental|GT005 High Dose|Approximately 60 subjects are planned, with subjects randomised to GT005 High Dose.
3492856|NCT04566445|No Intervention|Untreated control|Approximately 60 subjects are planned, with subjects randomised to untreated control.
3492857|NCT04566133|Experimental|1/Arm 1|Trametinib + hydroxychloroquine (HCQ)
3492858|NCT04565834||Suicidal patients|Patients who have made at least one attempt to commit suicide.
3492859|NCT04565834||Control group|"This group will consist of two types of people:~75 healthy subjects (i.e. those who have no mental disorders and have never attempted to commit suicide) and~150 patients suffering from depression but have never attempted to commit suicide."
3492860|NCT04565158||Women with bilateral salpingo-oophorectomy (BSO)|
3492861|NCT04565158||Women without bilateral salpingo-oophorectomy (BSO)|
3129658|NCT03233230|Experimental|M2951 25 mg QD|
3129659|NCT03233230|Experimental|M2951 75 mg QD|
3492862|NCT04557098|Experimental|Part 3: Teclistamab|Participants in all cohorts will receive teclistamab SC at an RP2D.
3492863|NCT04557059|Active Comparator|Interventional Cohort (Group 1): RT+ LHRHa|Participants who are PSMA-PET-positive will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization.
3492864|NCT04557059|Experimental|Interventional Cohort (Group 2): RT+LHRHa + Apalutamide|Participants who are PSMA-PET-positive receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days.
3129660|NCT03233230|Experimental|M2951 50 mg BID|
3129661|NCT03233308|Experimental|Netarsudil Ophthalmic Solution 0.02%|Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
3129662|NCT03233308|Placebo Comparator|Placebo Comparator|Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye
3129663|NCT03233438|Active Comparator|New Critical Pathway|The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
3129664|NCT03233438|Active Comparator|Usual Care|Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
3129665|NCT03233529|Experimental|Crisaborole ointment|
3129666|NCT03233529|Placebo Comparator|Placebo ointment (vehicle)|
3180142|NCT00680199||2|Good Sleepers
3180143|NCT00680212|Other|1|dietary carotenoids
3180144|NCT00680238|No Intervention|A|Embryo selection for transfer based on a Day 3 score only.
3492865|NCT04557059|No Intervention|Observational Cohort(Group3) PSMA-PET Negative Participants|Participants who are PSMA-PET-negative at screening, will be enrolled in the Observational Cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year.
3492866|NCT04556916|Experimental|Men over 40 being suspicious of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent and performing before the 1st prostate biopsy
3492867|NCT04556916|Experimental|Men over 40 with no suspicion of prostate cancer|Per patient 49 ml of peripheral blood sample after signing consent
3492868|NCT04554277|No Intervention|Control|Usual management of heart failure. The sST-2 level will be blunted.
3492869|NCT04554277|Experimental|Biomarker guided therapy|Guided therapy using sST-2 monitoring at the discharge from initial hospitalisation, 6, 12, 18 and 24 months of following.
3492870|NCT04552197|Experimental|Part 1: Treatment A (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), once daily for 5 days under fasting conditions.
3492871|NCT04552197|Experimental|Part 1: Treatment B (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 1), twice daily for 5 days under fasting conditions.
3492872|NCT04552197|Experimental|Part 1: Treatment C (JNJ-64251330)|Participants will receive JNJ-64251330 (dose 2), twice daily for 5 days under fasting conditions.
3492873|NCT04552197|Active Comparator|Part 1: Treatment D (JNJ-64251330)|Participants will receive tofacitinib tablet twice daily for 5 days under fasting conditions.
3492874|NCT04552197|Experimental|Part 2: Treatment EF (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
3492875|NCT04552197|Experimental|Part 2: Treatment FE (JNJ-64251330)|Participants will receive a single dose of JNJ-64251330 (dose 2), on Day 1 once with high fat breakfast (Treatment F) in Period 1 followed by a single dose of JNJ-64251330 (dose 2), on Day 1 once under fasting conditions (Treatment E) in Period 2. There will be a minimum of 5 days washout between dosing in the two treatment periods.
3129667|NCT03233737|Experimental|Stage II: One spray CTY-5339-A, then one spray CTY-5339-CB|A single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session. Used in Stage II of the study only.
3129668|NCT03233737|Active Comparator|Stage II: One spray of CTY-5339-CB, then one spray CTY-5339-A|A single spray of CTY-5339-CB Anesthetic Spray (14.0% benzocaine) tested over a 60 minute session, followed by a 4-14 day washout period, followed by a single spray of CTY-5339-A Anesthetic Spray (14.0% benzocaine and 2.0% tetracaine HCl) tested over a 60 minute session. Used in Stage II of the study only.
3492876|NCT04551846|Experimental|Oligomeric enteral feeding group|Oligomeric enteral nutrition will be administered according to the study protocol
3492877|NCT04551846|Active Comparator|Polymeric enteral feeding group|Polymeric enteral nutrition will be administered according to the study protocol
3129669|NCT03233737|Experimental|Stage I: One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
3492878|NCT04546399|Experimental|Arm G (dexamethasone, blinatumomab, nivolumab,MTX) DS patients|Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1 only, blinatumomab IV via continuous infusion on days 1-28, nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2, and MTX IT, cytarabine IT, or ITT IT on days 1,15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start this cycle 1), MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2, and leucovorin calcium IV or PO q6h for 2 doses on days 2, 16 and 37 of cycle 1 and q6h for 2 doses on days 16 and 37 of cycle 2.
3492879|NCT04546399|Experimental|Group 1, Arm A (dexamethasone, blinatumomab, MTX)|ARM A: Patients receive dexamethasone PO or IV on days 1 and 8 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1-2, MTX IT, cytarabine IT, or ITT IT on days 1, 15, and 36 of cycle 1 (MTX, cytarabine, and ITT on day 1 may be omitted if intrathecal therapy was given < 7 days prior to the start of this cycle), and MTX IT, cytarabine IT, or ITT IT on days 15 and 36 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
3492880|NCT04546399|Experimental|Group 1, Arm B (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX, cytarabine, or ITT as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
3492881|NCT04546399|Experimental|Group 2, Arm C (dexamethasone, blinatumomab, MTX)|Patients receive dexamethasone PO or IV on day 1 of cycle 1, blinatumomab via continuous IV infusion on days 1-28 of cycles 1 and 2, and methotrexate IT on days 1 and 15 of cycles 1 and 2 (day 1 may be omitted from cycle 1 if intrathecal therapy is given < 7 days prior to the start of this cycle). Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
3492882|NCT04546399|Experimental|Group 2, Arm D (dexamethasone, nivolumab, blinatumomab, MTX)|Patients receive dexamethasone, blinatumomab, and MTX as in Arm C. Patients also receive nivolumab IV over 30 minutes on days 11 and 25 of cycle 1 and days 1 and 15 of cycle 2. Treatment repeats every 36 days for 2 cycles in the absence of disease progression or unacceptable toxicity. NOTE: Patients with MRD < 0.01% after cycle 1 may stop study treatment or may choose to continue to cycle 2. Patients with MRD >= 0.01% after cycle 1 proceed to cycle 2.
3492883|NCT04546399|Experimental|Group 3, Arm E (dexamethasone, blinatumomab, MTX)|See Outline section
3129670|NCT03233737|Active Comparator|Stage I: One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
3492884|NCT04546399|Experimental|Group 3, Arm F (dexamethasone, blinatumomab, nivolumab)|See Outline section
3492885|NCT04545385|Experimental|TEV-48574|The patients will receive the investigational medicinal product (IMP) loading dose on the day of randomization and the subsequent corresponding IMP maintenance dose every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
3492886|NCT04545385|Placebo Comparator|Placebo|Matching Placebo
3492887|NCT04544436|Experimental|Ocrelizumab Higher Dose|Participants will be randomized to receive a minimum of 5 higher treatment doses (1200 mg or 1800 mg) of ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the double blind treatment (DBT) phase. During the optional open-label extension (OLE) phase, participants will continue with their assigned dose of ocrelizumab (either 1200 or 1800 mg) for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
3129671|NCT03233737|Placebo Comparator|Stage I: One spray CTY-5339-P|Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (placebo: vehicle control). Administered in a single anesthetic spray. Tested over a 60 minute session. Used in Stage I of the study only.
3180145|NCT00680238|Active Comparator|B|Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
3492888|NCT04544436|Active Comparator|Ocrelizumab Approved Dose|Participants will be randomized to receive a minimum of 5 treatment doses of 600 mg ocrelizumab administered by intravenous (IV) infusion every 24 weeks in the DBT phase. During the optional OLE phase, participants will be offered a higher dose of ocrelizumab (either 1200 or 1800 mg), based on their body weight at OLE baseline, for approximately 96 weeks (4 doses in total). Mandatory methylprednisolone (or equivalent) and antihistaminic drug (e.g., diphenhydramine or equivalent) will be administered approximately 30-60 minutes prior to the start of each ocrelizumab infusion.
3492889|NCT04538664|Experimental|Arm A: Amivantamab + Chemotherapy|"Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles.~Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3."
3492890|NCT04538664|Experimental|Arm B: Chemotherapy Alone|"Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression.~Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles."
3492891|NCT04537793|Experimental|Part A: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
3492892|NCT04537793|Experimental|Part B: ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening with the dose(s) to be based on the outcome of Part A.
3492893|NCT04537013|Active Comparator|Control Arm|Patients with small chondral lesions of the knee
3492894|NCT04537013|Experimental|Investigational Group|Patients with large chondral lesions of the knee
3492895|NCT04535635|Experimental|Active Release Techniques®|The ART® procedure will consist of identifying and treating manipulatable lesions as per their protocols, while the sham group will receive a passable version of this technique. This information is under copyright and cannot be copied or outlined specifically in any form, including a research paper. The overarching procedure used by ART® will be explained however specific details referring to each protocol cannot be described. Muscles are shortened, and the therapist applies sufficient digital pressure to be in contact with the tissue in question. Directional tension is applied proximally along the muscle fiber direction, and then the structure is lengthened while the contact remains as described.
3492896|NCT04535635|Placebo Comparator|Sham Active Release Techniques®|"For the sham treatment, the muscle(s) in question will be taken from a lengthened to a shortened position (opposite of the protocol direction as per the ART® manual) with a broad light contact on the skin - the treating therapist will not achieve tissue depth as specified by ART® and will not attempt to take tension as is outlined in the ART® manual."
3492897|NCT04535414|Experimental|1/ Arm 1|Bethesda protocol (investigational)
3492898|NCT04535414|Active Comparator|2/ Arm 2|Cambridge method (control) with confocal endomicroscopy
3492899|NCT04533568|Experimental|ibuprofen|400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
3492900|NCT04533568|Experimental|dexketoprofen|50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
3492901|NCT04530110|Experimental|Fremanezumab|The dose of Fremanezumab to be administered will be confirmed or adjusted, as appropriate, based on the participant's weight every 3 months.
3492902|NCT04526613||'healthy' LTBI+ controls who are negative for all of the below|'healthy' LTBI+ controls who are negative for all of the below conditions
3492903|NCT04526613||healthy LTBI negative controls with none of the above conditio|healthy LTBI negative controls with none of the above conditions
3492904|NCT04526613||LTBI+ and helminth infection (positive stool qPCR and/or serol|LTBI+ and helminth infection (positive stool qPCR and/or serology
3492905|NCT04526613||LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)|LTBI+ and severe to moderate malnutrition (BMI <17 kg/m2)
3492906|NCT04526613||LTBI+ and uncontrolled DM (HbA1c >8%)|LTBI+ and uncontrolled DM (HbA1c >8%)
3492907|NCT04526613||LTBI+ with more than one of the conditions defined in groups 1|LTBI+ with more than one of the conditions defined in groups 1-3
3492908|NCT04523207|Experimental|Apalutamide + Androgen Deprivation Therapy (ADT)|In the main study, participants will receive apalutamide 240 milligram (mg) once daily orally along with ADT for 12 cycles (Each cycle is of 28 days). Participants who enrolled in the sub-study will receive apalutamide 240 mg once daily along with relugolix (a type of ADT) 120 mg once daily following a loading dose of 360 mg relugolix orally. Sub-study participants will be receiving relugolix up to Day 28 after which they will be transitioned into the main study from Cycle 2 Day 1 and will continue to receive conventional or oral ADT.
3492909|NCT04519619||Aflibercept (Eylea, BAY86-5321)|Decision of Eylea treatment is made by attending investigators according to the Japanese Package Insert
3492910|NCT04518228|Experimental|Component 1: Arm 1.1: Bictegravir (BIC) 50 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving bictegravir (BIC) 50 mg once daily (q.d.), and their infants
3492911|NCT04518228|Experimental|Component 1: Arm 1.2: Doravirine (DOR) 100 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving doravirine (DOR) 100 mg q.d., and their infants
3492912|NCT04518228|Experimental|Component 1: Arm 1.3: Tenofovir alafenamide (TAF) 10 mg q.d.|Women ≥ 20 weeks gestation not receiving TB drugs and receiving tenofovir alafenamide (TAF) 10 mg q.d. boosted with cobicistat, and their infants
3492913|NCT04518228|Experimental|Component 1: Arm 1.4: TAF 25 mg q.d. without boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. without boosting, and their infants
3492914|NCT04518228|Experimental|Component 1: Arm 1.5: TAF 25 mg q.d. with boosting|Women ≥ 20 weeks gestation not receiving TB drugs and receiving TAF 25 mg q.d. boosted with cobicistat or ritonavir, and their infants
3492915|NCT04518228|Experimental|Component 2: Arm 2.1: CAB LA|Women ≥ 24 weeks gestation who received at least one dose of long-acting injectable formulation of cabotegravir (CAB LA) any dose during pregnancy, and their infants
3492916|NCT04518228|Experimental|Component 3: Arm 3.1: Dolutegravir (DTG) 50 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving dolutegravir (DTG) 50 mg twice daily (b.i.d.) when combined with RIF or 50 mg q.d. if RIF is not part of the TB regimen, and their infants
3492917|NCT04518228|Experimental|Component 3: Arm 3.2: ATV/r or DRV/r|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving atazanavir/ritonavir (ATV/r) ≥ 300/100 mg q.d. or darunavir/ritonavir (DRV/r) ≥ 600/100 mg b.i.d., and their infants
3492918|NCT04518228|Experimental|Component 3: Arm 3.3: Lopinavir/ritonavir (LPV/r) 800/200 mg|Women ≥ 20 weeks gestation receiving first-line TB treatment with at least two of the following TB treatment drugs: isoniazid (INH), rifampin (RIF), rifabutin (RFB), ethambutol (EMB), pyrazinamide (PZA), moxifloxacin (MFX), and receiving lopinavir/ritonavir (LPV/r) 800/200 mg b.i.d., and their infants
3492919|NCT04518228|Experimental|Component 4: Arm 4.1: Second-line TB treatment drugs|"Women ≥ 20 weeks gestation receiving at least one of the following second-line TB treatment drugs, and their infants:~Levofloxacin (LFX) 750mg - 1000mg q.d.~Clofazimine (CFZ) 100mg q.d.~Linezolid (LZD) 300mg - 600mg q.d.~Bedaquiline (BDQ) 200mg three times per week (t.i.w.)~Delamanid (DLM) 100mg b.i.d.~Moxifloxacin (MFX) 400mg or 800mg q.d., and at least one other second-line TB treatment drug under study"
3492920|NCT04518228|Experimental|Component 5: Arm 5.1: ATV/r|Women post-delivery receiving ATV/r, and their infants
3492921|NCT04518228|Experimental|Component 5: Arm 5.2: DRV/r|Women post-delivery receiving DRV/r, and their infants
3492922|NCT04518228|Experimental|Component 5: Arm 5.3: LPV/r|Women post-delivery receiving LPV/r, and their infants
3492923|NCT04518072||Biopsy prostatic group|positive biopsy (100) negative biopsy (100)
3492924|NCT04518072||Control group|No prostate cancer (50)
3492925|NCT04511078|Experimental|Panitumumab-IRDye800|50 mg infusion of panitumumab-IRDye800 given over 60 minutes
3492926|NCT04510636|Experimental|Pembrolizumab and Bendamustine|"The study drugs will be given in 3 week periods called cycles.~Pembrolizumab is available in powder form or as a liquid for infusion. Pembrolizumab at a dose of 200 mg will be given over 30 minutes, once every cycle for up to 35 cycles (approximately 24 months).~Bendamustine is available in powder form for injection. Bendamustine at a dose of 90 mg/m2 will be given over 60 minutes, on Days 1 and 2 of every cycle for up to 6 cycles."
3492927|NCT04510350||MS CIS+|
3492928|NCT04510350||Healthy volunteers|
3492929|NCT04508634|Experimental|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
3492930|NCT04508634|Active Comparator|Metformin Group|Metformin Group
3492931|NCT04507373|Placebo Comparator|Placebo|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
3492932|NCT04507373|Active Comparator|Simvastatin 40mg|Following the baseline period, subject will be randomized to receive either simvastatin or an identical placebo at a dose of 40 mg/day for a period of 10 weeks.
3492933|NCT04504435|Experimental|Participants in Cohort 1|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with 20 milligram (mg) and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
3492934|NCT04504435|Experimental|Participants in Cohort 2|Participants will receive a maximum of 3 ascending dose levels of GSK3494245 starting with dose level (DL) 5 and 1 placebo dose orally on Day 1 of each treatment period under fasted conditions. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
3492935|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fasted then fed)|Participants will receive the selected dose level (DLX) of GSK3494245 in the fasted state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fed state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
3492936|NCT04504435|Experimental|Cohort 3: Participants receiving GSK3494245 (fed then fasted)|Participants will receive the DLX of GSK3494245 in the fed state on Day 1 in Period 1 followed by a single dose of GSK3494245 in the fasted state in Period 2. There will be a washout period of at least 48 hours or 5-half-lives (whichever is longer) between each dose for an individual participant.
3129672|NCT03234036|Experimental|Treatment sequence ABC: Part 1|"A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 2 in Part 1A.~Both these treatments in Part 1A will be administered with RTV in fed state with a washout of 10 days.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
3129673|NCT03234036|Experimental|Treatment sequence BAC: Part 1|"A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation will be administered under fed conditions (treatment B) in period 1 in Part 1A.~A single dose of GSK2838232 200 mg (as 4 x 50 mg) capsule formulation will be administered under fed conditions (treatment A) in period 2 in Part 1A.~A single dose of GSK2838232 200 mg (as 2 x 100 mg) tablet formulation (with RTV) will be administered under fasted conditions (treatment C) in period 3 in Part 1B.~There will be a wash out of 15 days between Part 1A and Part 1B."
3129674|NCT03234036|Experimental|GSK2838232 tablet without RTV: Part 2|In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
3129675|NCT03234036|Placebo Comparator|Placebo without RTV: Part 2|In Part 2, subjects will receive a Placebo given as single daily doses for 11 days.
3492937|NCT04504357|No Intervention|Arm A- No intervention|Participants randomized to Arm A will receive no research intervention.
3492938|NCT04504357|Experimental|Arm B- U=U app|"Participants randomized to Arm B will receive controlled exposure to the tablet-based U=U app."
3492939|NCT04504357|Active Comparator|Arm C- clinical exposure demonstration|Participants randomized to Arm C will be shown U=U videos in clinic waiting rooms and the tablet-based app will be integrated into routine counseling
3129676|NCT03234374|Experimental|INL-001|3 x 100 mg INL-001 (bupivacaine HCl collagen implants). Total bupivacaine HCl dose 300 mg.
3129677|NCT03234374|Active Comparator|Marcaine 0.25% infiltration|Marcaine 0.25% infiltration (bupivacaine HCl 175 mg).
3492940|NCT04501653|Experimental|Psilocybin first|Participants will receive 25 mg of psilocybin at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the control drug (methylphenidate) at their second drug exposure neuroimaging session.
3492941|NCT04501653|Active Comparator|Methylphenidate first|Participants in this group will be randomized to receive 40 mg of methylphenidate at the first of two neuroimaging sessions, taken orally in capsule form. Participants in this arm will receive the active comparator (psilocybin) at their second drug exposure neuroimaging session.
3492942|NCT04500171|Active Comparator|English Original Assessment Tools|Short-Test of Functional Health Literacy in Adults ColoCARE Instruction Sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
3492943|NCT04500171|Active Comparator|Samoan Original Assessment Tools|Samoan Short-Test of Functional Health Literacy in Adults ColoCARE Instruction sheet CDC Colorectal Cancer Screening for Life Brochure ColoCARE Reply Card
3492944|NCT04500171|Experimental|English Modified Assessment Tools|Short-Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
3492945|NCT04500171|Experimental|Samoan Modified Assessment Tools|Samoan Short Test of Functional Health Literacy in Adults Modified ColoCARE Instruction Sheet Modified Colorectal Cancer Screening Brochure ColoCARE Reply Card
3492946|NCT04499963|Experimental|Open Label Arm|The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
3492947|NCT04499963|No Intervention|Healthy Control Arm|We will seek to enroll 50 healthy control participants. We will attempt to enroll one control subject from each enrolled primary participant's home, preferably a spouse or partner of similar age if possible. We plan to use this data to compare the microbiome of control participants to that of the ALS participants at baseline, week 4 and month 6. We will not conduct further follow-up or collect additional samples with the control subjects.
3129678|NCT03234465|Experimental|AG013: three mouth rinses/day|Subjects will rinse three times per day with AG013 mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
3492948|NCT04497844|Experimental|Niraparib with Abiraterone Acetate plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: niraparib 200 milligrams (mg), abiraterone acetate (AA) 1000 mg plus prednisone 5 mg once daily.
3492949|NCT04497844|Experimental|AA plus Prednisone (AA-P)|Participants will receive the following in each 28-day treatment cycle: matching placebo for Niraparib along with AA 1000 mg plus prednisone 5 mg once daily.
3492950|NCT04493645|Active Comparator|Standard of Care (SOC)|Participants will be randomized to receive standard of care rehabilitation (SOC) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the SOC group for 24 months following completion of their assigned SOC intervention.
3492951|NCT04493645|Experimental|Foot Intensive Rehabilitation (FIRE)|Participants will be randomized to receive foot intensive rehabilitation (FIRE) for a period of 6 weeks.The investigators will prospectively follow participants assigned to the FIRE group for 24 months following completion of their assigned SOC intervention.
3492952|NCT04487080|Experimental|Treatment Arm A (Open-label): Amivantamab and Lazertinib|Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.
3492953|NCT04487080|Active Comparator|Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib|Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.
3129679|NCT03234465|Placebo Comparator|Placebo: three mouth rinses/day|Subjects will rinse three times per day with placebo mouth rinse beginning from the start of radiotherapy until 2 weeks following its completion. The active treatment phase lasts for 7 to 9 weeks, depending on the duration of radiotherapy.
3492954|NCT04487080|Experimental|Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib|Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.
3492955|NCT04481009|Experimental|YH003 with Toripalimab after PD-1/L1 +/- CTLA-4 treatment|YH003 in combination with Toripalimab in subjects with unresectable /metastatic melanoma after having failed PD-1/L1 +/- CTLA-4 treatment.
3492956|NCT04481009|Experimental|YH003 with Toripalimab in subjects with PDAC|YH003 in combination with Toripalimab in subjects with unresectable/ metastatic pancreatic ductal adenocarcinoma (PDAC) as 2nd line treatment.
3492957|NCT04481009|Experimental|YH003 with Toripalimab plus standard chemotherapy|YH003 in combination with Toripalimab plus standard chemotherapy (Nab-paclitaxel + Gemcitabine) in subjects with unresectable/metastatic PDAC as 1st line treatment
3129680|NCT03234608|Experimental|AASPIRE Healthcare Toolkit|Patients will use the AASPIRE Healthcare Toolkit and will share a copy of their Autism Healthcare Accommodations Report with their primary care provider.
3492958|NCT04477161|Experimental|Ketone Intervention|Subjects will take the Ketone Ester Elite Endurance Nutrition Drink. They will drink 1 bottle 4 times daily for 4 weeks
3492959|NCT04476030|Experimental|Experimental: SAGE-217 + Assigned ADT|Participants will receive SAGE-217 capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
3492960|NCT04476030|Active Comparator|Active Comparator: Placebo + Assigned ADT|Participants will receive SAGE-217-matching placebo capsules, orally, daily with an assigned ADT (sertraline, escitalopram, citalopram, duloxetine, or desvenlafaxine administered per labeled prescribing information), daily from Day 1 through 14, followed by the same ADT, per labeled prescribing information, daily for up to 42 days, with fat-containing food.
3492961|NCT04475731|Experimental|Experimental arm|"MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).~Patients will receive the study drug until disease relapse or progression."
3492962|NCT04473742|Experimental|Patients exposed to silica|
3492963|NCT04473742|Active Comparator|Patients exposed to asbestos fibres|
3492964|NCT04469491|Experimental|Inhaled IFN arm|IFN (Interferon) pulmonary (Inhalation) + routine care (+/- antibiotics; +/- dexamethasone; + appropriate O2 support)
3492965|NCT04469491|Active Comparator|Control Arm:|Aerosol (WFI water and routine care (+/- antibiotics;+/- dexamethasone; + appropriate O2 support).
3492966|NCT04469465|Experimental|Danicopan + C5 Inhibitor|Participants will receive danicopan, in addition to their C5 inhibitor therapy, for 24 weeks (12 weeks in Treatment Period 1, followed by 12 weeks in Treatment Period 2).
3492967|NCT04469465|Placebo Comparator|Placebo + C5 Inhibitor|Participants will receive placebo, in addition to their C5 inhibitor therapy, for 12 weeks during Treatment Period 1. At Week 12, participants randomized to receive placebo will be switched to danicopan for an additional 12 weeks (Treatment Period 2).
3492968|NCT04464707|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
3492969|NCT04464707|Placebo Comparator|Placebo|Matching placebo
3492970|NCT04459507||Participants With Palmoplantar pustulosis (PPP)|Participants treated with a new systemic therapy for their PPP, having had an inadequate response to a prior PPP therapy either as their first systemic therapy or as a switch from, or addition to, a previous systemic therapy will be observed. Participants will be treated in accordance with routine clinical practice in Japan in the outpatient specialist care setting. The primary data source for this study will be the medical records of each participant.
3492971|NCT04459338|Placebo Comparator|Saline|Saline infused during the hyperglycemic clamp with escalating doses of glucagon
3492972|NCT04459338|Active Comparator|Exendin-9,39|Exendin-9,39 infused during the hyperglycemic clamp with escalating doses of glucagon
3492973|NCT04459156|Experimental|Healthy Participants|healthy control subjects
3492974|NCT04459156|Experimental|Chronic Obstructive Pulmonary Disease patients|Established diagnosis of Chronic Obstructive Pulmonary Disease
3492975|NCT04459156|Experimental|Healthy Young Participants|healthy young subjects with age 18-30 years old
3492976|NCT04458857|Experimental|Fremanezumab|Participants weighing ≥ threshold will receive Dose A subcutaneously monthly Participants weighing < threshold will receive Dose B subcutaneously monthly subcutaneously monthly, for 3 months.
3492977|NCT04458857|Placebo Comparator|Placebo|Matching placebo
3492978|NCT04456400||Derivation cohort|"The derivation sub-cohort will be used to derive optimum reconstruction algorithm parameters of MSOT images.~Primary objective of the derivation cohort is to derive Multispectral Optoacoustic Tomography (MSOT) thresholds maximizing receiver operating characteristic (ROC) to distinguish endoscopic remission from active disease.~As secondary objective, performance of the Multispectral Optoacoustic Tomography (MSOT) device will be analyzed."
3492979|NCT04456400||Validation cohort|Objective of the validation cohort is to confirm the performance of Multispectral Optoacoustic Tomography (MSOT) using prescribed thresholds from the derivation cohort.
3492980|NCT04452825|Experimental|Cancer and Aging: Reflections for Elders (CARE) Intervention|Session content and timing was developed and confirmed in our qualitative work (Expert Panel) and the CARE pilot study. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
3492981|NCT04452825|Experimental|Social Work and Supportive Counseling (SWSC)|The SWSC will include a social work assessment and follow-up augmented with additional components of supportive psychotherapy that have been shown to be an effective form of treatment for patients with cancer. Five sessions (45-60 minutes each) will be delivered over an 8-week period (+4 weeks). Following these sessions, four brief booster sessions (20-30 minutes each) will be delivered at a rate of approximately one per month to extend the interventions to 6 months (+3 months).
3129681|NCT03234608|No Intervention|Usual Care|Patients will receive usual care.
3129682|NCT03235050|Experimental|MEDI0382 low dose + Metformin|Drug: MEDI0382 low dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
3492982|NCT04449588|Experimental|Treatment group|
3129683|NCT03235050|Experimental|MEDI0382 mid dose + Metformin|Drug: MEDI0382 mid dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
3492983|NCT04449588|Experimental|Control group|
3129684|NCT03235050|Experimental|MEDI0382 high dose + Metformin|Drug: MEDI0382 high dose Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
3492984|NCT04441905|Experimental|Cohort 1|0.3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
3492985|NCT04441905|Experimental|Cohort 2|1 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
3492986|NCT04441905|Experimental|Cohort 3|3 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
3492987|NCT04441905|Experimental|Cohort 4|10 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
3492988|NCT04441905|Experimental|Cohort 5|20 mg/kg of SAR440894 (n=6) or placebo (n=2) administered once during a 60-minute intravenous (IV) infusion. 2 sentinel subjects will receive dosing for review of safety data (SAR440894 n=1, placebo n=1) before remainder of cohort.
3492989|NCT04438538||Patients with Dizziness|All trial participants are within this group. All trial participants will either have a diagnosis or a suspected diagnosis of Ménière's Disease in order to take part.
3492990|NCT04436640|Experimental|Bimekizumab|Subjects will receive bimekizumab throughout the Treatment Period.
3492991|NCT04432597|Experimental|1/Arm 1A|HPV vaccine at 1x10(11) Viral Particles (VP) (DL1) and at 5x10(11) VP (DL2)
3492992|NCT04432597|Experimental|2/Arm 1B|HPV vaccine at RP2D plus M7824 at 1200 mg
3492993|NCT04432597|Experimental|3/Arm 2A|HPV vaccine at RP2D given as neoadjuvant or induction therapy
3492994|NCT04432597|Experimental|4/Arm 2B|HPV vaccine at RP2D plus M7824 at 1200 mg given as neoadjuvant or induction therapy
3492995|NCT04427488|Experimental|Morning Chronotype (MC) Group|In the MC group, exercises were applied in the morning hours for the first 6 weeks and in the evening hours for the next 6 weeks.
3492996|NCT04427488|Experimental|Evening Chronotype (EC) Group|The EC exercises were applied in the evening hours for the first 6 weeks and in the morning hours for the next 6 weeks
3492997|NCT04420403|Experimental|Manual therapy plus cervical stabilization exercise group|The patients diagnosed with chronic neck pain (CNP) with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
3492998|NCT04420403|Active Comparator|Only manual therapy group|The patients diagnosed with CNP with 18-55 years of age followed by routine controls and who were volunteered will be included in the study.
3492999|NCT04416711|Active Comparator|Services As Usual|Participants assigned to the SAU condition will receive services as usual at their university, which include required programming related to heavy episodic drinking and sexually aggressive behavior either online or through new-student orientation.
3493000|NCT04416711|Experimental|Personalized Feedback and Cognitive Training|The prevention program will target heavy episodic drinking, sexually aggressive behavior, and risky sexual behavior through 2 sessions that integrate personalized feedback and cognitive training components.
3493001|NCT04415151|Experimental|Tofacitinib|Tofacitinib will be administered in a dose of 10 mg PO BID until return to their clinical baseline (as defined by supplementary oxygen requirement), and then will continue to be administered at 5 mg PO BID for a total treatment duration of 14 days.
3493002|NCT04415151|Placebo Comparator|Placebo|Matching placebo will be administered.
3493003|NCT04414514|Experimental|Open-label|Topical Ruxolitinib 1.5% Cream, twice daily for 16 weeks
3493004|NCT04411472|Experimental|active|recombinant human alkaline phosphatase 1.6mg/kg 3 daily 1 hour infusions
3493005|NCT04411472|Placebo Comparator|placebo|matching placebo
3493006|NCT04410445|Experimental|Combination of bempegaldesleukin (NKTR-214) + nivolumab|Arm A: Participants will receive bempegaldesleukin (NKTR-214) IV in combination with nivolumab every 3 weeks.
3493007|NCT04410445|Active Comparator|Nivolumab|Arm B: Participants will receive nivolumab IV alone every 4 weeks.
3493008|NCT04408963|Experimental|Group 1|5 mg/kg IV
3493009|NCT04408963|Experimental|Group 2|5 mg/kg SC
3493010|NCT04401748|Experimental|Arm 1: Venetoclax + Azacitidine (AZA)|Participants will receive venetoclax once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
3493011|NCT04401748|Active Comparator|Arm 2: Placebo + Azacitidine|Participants will receive placebo once daily (QD) (Days 1-14) in combination with AZA QD (7 days of the first 9 days) of each 28 day cycle.
3493012|NCT04401449||Acutely illl subjects|COVID-19 subjects treated at the Clinical Center, followed through recovery and into convalescence
3129685|NCT03235050|Placebo Comparator|Placebo + Metformin|Drug: Placebo Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
3129686|NCT03235050|Active Comparator|Liraglutide + Metformin|Drug: Liraglutide Drug: Metformin tablets, total daily dose of ≥1500 mg (unless only tolerated at a lower dose)
3493013|NCT04401449||Recovered subjects|COVID-19 subjects who were treated at other hospitals, followed through recovery and into convalescence
3493014|NCT04398524|Experimental|single arm|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
3493015|NCT04397354|Active Comparator|Group 1|intracochlear dexamethasone application during cochlear implantation
3493016|NCT04397354|Active Comparator|Group 2|intratympanic dexamethasone application during cochlear implantation
3493017|NCT04397354|Sham Comparator|Group 3|No drugs during cochlear implantation
3493018|NCT04396366|Placebo Comparator|placebo|Placebo controlled arm
3129687|NCT03235089|Active Comparator|Test lens|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
3129688|NCT03235089|Active Comparator|nelfilcon A lens (control)|Each subjects will wear a test lens in one eye and the control lens in the other as an unmatched pair, per predetermined randomization schedule (to determine which eye receives test/control lens).
3493019|NCT04396366|Active Comparator|QBW251|Active comparator drug arm
3129689|NCT03235115|Active Comparator|Methafilcon A IV|Subjects are randomized to wear Methafilcon A IV for 1 hour during the cross over study.
3129690|NCT03235115|Active Comparator|Ocufilcon B|Subjects are randomized to wear Ocufilcon B for 1 hour during the cross over study.
3493020|NCT04395586||Culture-proven infected patients|
3493021|NCT04394481|Experimental|DMD|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection Dexmedetomidine: IV injection (1µg/kg)
3493022|NCT04394481|Active Comparator|Control|Ropivacaine: perinervous injection (interscalene block) Dexamethasone: IV injection
3493023|NCT04389333|Experimental|Non-contact MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the study subject positions himself (herself) on the examination bed in Room A, while the operating doctor sits in Room B at the remote control workstation instructing her to swallow the capsule via the audio-visual exchange system. After the capsule entering the stomach, the doctor manipulated the two joysticks on the remote control workstation, mobilizing the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric examination. In order to simplify the examination procedure, the data recorder was put on the examination bed. The patient lay down after swallowing the capsule under the remote guidance of the endoscopist.
3493024|NCT04389333|Active Comparator|MCE examination|After an overnight fasting and drinking 1000 mL water and simethicone for gastric dilatation and preparation, the subjects put on the data recorder with the help of an endoscopist. Then, the endoscopist activated the capsule with the capsule locator. The patient was instructed to assume the supine or left lateral decubitus position and to swallow the capsule with a small amount of water to effectively observe the esophagus and dentate line. Then, under the guidance of the endoscopist face to face, the subject turned over on the bed to complete the examination.
3493025|NCT04387656||Observational Cohort (data collection, biospecimen collection)|Patients undergo collection of medical information about COVID-19 symptoms, treatments/cancer treatments and outcomes, and results from laboratory tests and imaging scans performed as part of routine care for up to 2 years. Patients also undergo collection of blood samples at the same times they receive routine bloodwork up to 9 times for adults and up to 6 times for children. Patients who are hospitalized for COVID-19 undergo collection of blood samples at up to 6 additional times for adults and up to 3 additional times for children. Adult patients also complete quality of life questionnaire.
3129691|NCT03235115|Active Comparator|Omafilcon A|Subjects are randomized to wear Omafilcon A for 1 hour during the cross over study.
3493026|NCT04383431|Experimental|Standard CXL|Standard epithelium-off CXL, 30 minutes soaking time with riboflavin, 30 minutes UVA corneal irradiation continuous mode.
3493027|NCT04383431|Experimental|Accelerated CXL|Accelerated epithelium-off CXL, 12 minutes soaking time with riboflavin, 8 minutes UVA corneal irradiation continuous mode.
3493028|NCT04379596|Experimental|Arm 1A|T-DXd and 5-fluorouracil (5-FU)
3493029|NCT04379596|Experimental|Arm 1B|T-DXd and capecitabine
3493030|NCT04379596|Experimental|Arm 1C|T-DXd and durvalumab
3493031|NCT04379596|Experimental|Arm 1D(a)|T-DXd, 5-FU, and oxaliplatin
3493032|NCT04379596|Experimental|Arm 1D(b)|T-DXd, capecitabine, and oxaliplatin
3493033|NCT04379596|Experimental|Arm 1E(a)|T-DXd, 5-FU, and durvalumab
3493034|NCT04379596|Experimental|Arm 1E(b)|T-DXd, capecitabine, and durvalumab
3493035|NCT04379596|Active Comparator|Arm 2A|Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
3493036|NCT04379596|Experimental|Arm 2B|T-DXd monotherapy
3493037|NCT04379596|Experimental|Arm 2C|T-DXd, 5-FU or capecitabine, and oxaliplatin
3493038|NCT04379596|Experimental|Arm 2D|T-DXd, 5-FU or capecitabine, and pembrolizumab
3493039|NCT04379596|Experimental|Arm 2E|T-DXd and pembrolizumab
3493040|NCT04378751|Experimental|Decision aid video|Participants receiving the intervention will complete a pretest, watch the decision aid video, and complete posttest via tablet computer facilitated by Patient Navigators.
3129692|NCT03235154|Other|Treatment Arm|In this open label, single arm study, all subjects will receive the intervention as prescribed by psychiatrists in the office based opiate addition treatment program.
3493041|NCT04378751|Active Comparator|Genetic counseling informational brochure|Participants receiving the control will complete pretest, review a genetic counseling brochure with the Patient Navigators, and complete posttest via tablet computer facilitated by a Patient Navigator.
3493042|NCT04376827|Experimental|Guselkumab+Standard of Care|Participants will receive guselkumab Dose 1 intravenously (IV) at Weeks 0, 4 and 8 and guselkumab Dose 2 subcutaneous (SC) every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Participants who complete the assessments at Week 52 and have achieved complete renal response (CRR) may have the option to participate in the long-term extension (LTE).
3493043|NCT04376827|Placebo Comparator|Placebo+Standard of Care|Participants will receive placebo IV at Weeks 0, 4 and 8 and placebo SC q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who complete the assessments at Week 52 and have achieved CRR may have the option to participate in the LTE of the study.
3493044|NCT04370847||Lung Ultrasound (LUS) Examination|Ultrasonographic assessment of fluid status through scanning the lungs would be performed in all included patients
3493045|NCT04370795|Active Comparator|Group 1|Patients will be treated with Total Body Irradiation (TBI)
3493046|NCT04370795|Active Comparator|Group 2|Patients will not be treated with Total Body Irradiation (TBI)
3493047|NCT04367246||Affected Patients|Eligible subjects have a confirmed germline TP53 mutation or variant, OR have a family history of LFS and clinically managed as a LFS patient, OR meet LFS diagnostic criteria including Classic, Chompret, and LFL (Birch and Eeles) criteria. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a blood sample for plasma and a stool sample every six months, as well as access to their residual clinical tissues.
3493048|NCT04367246||Family Members|Biological relative of subjects with germline TP53 mutation or variant (LFS), including first degree (siblings, parents) and second degree (grandparents, aunts, uncles) relatives. Negative for germline TP53 mutation or variant. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time DNA sample, a stool sample, as well as access to their residual clinical tissues.
3129693|NCT03235180|Experimental|Crohn's Disease Subjects|"Subjects will receive ultrasound exams of the bowel with 2 different machines (Ultrasound Elastography and Ultrasound Vascularity) at three time points: baseline, 4 weeks, and 6 months. The ultrasound exams will be performed at first with no contrast agent, and then ultrasound measurements will be repeated with 1-2 ml of Sulfur Hexafluoride, a contract agent.~Subjects also will receive Magnetic Resonance Enterography (MRE) exams at baseline and 6 months as part of their clinical care."
3493049|NCT04367246||Household Members|Household member of subjects with germline TP53 mutation or variant (LFS), sharing a living space (apartment or free-standing home) for at least 6 months prior to study enrollment. Medical information contribution is required for participation in the study. Subjects also have options to contribute a one-time stool sample.
3493050|NCT04362865||COVID-19 infection|Patients with confirmed or suspected COVID-19 infections
3493051|NCT04362865||No COVID-19 infection|Patients without confirmed or suspected COVID-19 infections (i.e., normal donors)
3493052|NCT04360369|Active Comparator|Goldmann Applanation Tonometer|Measurement of IOP with Goldmann Applanation Tonometer. All subjects will participate in this arm.
3493053|NCT04360369|Active Comparator|ORA G3 and ic100|Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers. All subjects will participate in this arm.
3493054|NCT04360369|Experimental|Tono-Vera Tonometer|Measurement of IOP with Tono-Vera Tonometer. All subjects will participate in this arm.
3493055|NCT04358458|Experimental|Monotherapy Arm|
3493056|NCT04358458|Experimental|Combination Arm|
3129694|NCT03235284|Active Comparator|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
3129695|NCT03235284|Active Comparator|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
3493057|NCT04356430|Experimental|ADT with Abiraterone and prednisone|All subjects in this arm will receive luteinizing hormone releasing hormone analogue (LHRHa) plus abiraterone acetate and prednisone, as per standard of care. Goserelin 10.8 mg will be used once per 12 weeks. Abiraterone acetate will be administered orally as 1000 mg once daily along with 5 mg of oral prednisone once per day. Subjects will continue to take abiraterone acetate and prednisone for 24 weeks before robotic assisted radical prostatectomy
3493058|NCT04356430|Experimental|ADT alone|All subjects in this arm will receive LHRHa alone for 24 weeks before receiving robotic assisted radical prostatectomy. Goserelin 10.8 mg will be administered once per 12 weeks.
3493059|NCT04354233|Experimental|Physical activity intervention with connected devices|Women randomized to the intervention arm will follow a 6-month physical activity intervention using a connected device that includes an activity tracker, a smartphone and a mobile application. Patients will also receive physical activity international recommendations
3493060|NCT04354233|No Intervention|Standard care|Women will receive stardard care and physical activity international recommendations, without further intervention
3493061|NCT04354168|Experimental|Nthabi mHealth Application|Twenty women from each of the ten district hospitals will be recruited for a total of 200 participants. Each district hospital will have a separate administrative page on the Nthabi server where women will be enrolled with a unique username and password. Upon enrollment, the women will be asked to engage with Nthabi for two months to discuss the relevant content areas they are interested in learning more about.
3493062|NCT04353271|Experimental|Hydroxychloroquine|Subjects in this arm will receive the study drug
3493063|NCT04353271|Placebo Comparator|Placebo|Subjects in this arm will take placebo for 6 days
3493064|NCT04350138|Experimental|Group 1|Bexsero vaccine will be administered as an intramuscular injection in 1 mL single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
3493065|NCT04350138|Placebo Comparator|Group 2|Placebo will be administered as an intramuscular injection in single-dose prefilled syringe in two doses with a two-month apart (at enrollment/Visit 1 and Visit 3). N=1100.
3493066|NCT04349189||Group 1|50 Men and Women with sickle cell disease and VTE
3493067|NCT04349189||Group 2|50 Men and Women with sickle cell disease but no VTE
3493068|NCT04349189||Group 3|50 Men and Women with sickle cell trait
3493069|NCT04349189||Group 4|50 ethnically matched Men and Women without sickle cell disease, sickle cell trait or VTE
3493070|NCT04347603|Experimental|General Anesthesia|- General anesthesia : After pre-anesthetic preparation (25-50 mg Hydroxizine orally), the anesthesia induction will be performed by IV perfusion of Propofol 1 to 2 mg/kg, Sufentanyl for analgesia 0,2 to 0,4 µg/kg, curarisation with Atracurium 0,15 mg/kg. The anaethesia depth will be monitored by the bispectral index (BIS). Orotracheal intubation will be performed, the patient will be ventilated to controlled volume with 6-8 mL/kg of current volume based on expected body weight (PBW). The respiratory rate will be adjusted to have an ETCO2 between 35 and 45 mmHg. The anesthesia will be maintained through the Sevorane at 0.7-1 MAC, the average blood pressure will be controlled through a pressure cuff with a target between 60 and 80 mmHg. The Fio2 will be adapted to obtain saturation > 94% with 5 cmH2O PEEP.
3493071|NCT04347603|Active Comparator|Local Anesthesia|Local anesthesia at the device introduction site will be obtained by infiltration of Naropein.
3493072|NCT04340180|Experimental|Subjects with enhancing breast lesions|
3493073|NCT04339920||Chinese patients with clinical suspicious of prostate cancer|Chinese patients with clinical suspicious of prostate cancer, due to elevated serum PSA or abnormal digital rectal examination, will be recruited for the study from the Prince of Wales Hospital and North District Hospital.
3493074|NCT04339777|Active Comparator|Arm A|Low Intensity, Intermediate Intensity and High Intensity Conditioning with or without alemtuzumab
3493075|NCT04339777|Active Comparator|Arm B|Intermediate Intensity Conditioning with or without Alemtuzumab
3493076|NCT04339751|Experimental|single center, prospective pilot study|effectiveness of vorinostat to reduce midnight ACTH levels in patients with Cushing s Disease
3493077|NCT04338815|Experimental|Determine optimal assistance pattern|
3493078|NCT04338815|Experimental|Determine effects on endurance|
3493079|NCT04338399|Experimental|Buparlisib & Weekly Paclitaxel|"Drug: Patients will receive 100 mg (2 x 50 mg) buparlisib hard gel capsule administered orally, once daily starting on Day 1 of Treatment Cycle 1, Drug: Paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle.~Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason."
3493080|NCT04338399|Active Comparator|Weekly Paclitaxel|Patients will receive weekly paclitaxel (80 mg/m2) administered intravenously (IV) on Days 1, 8, and 15 of a 21-day treatment cycle. Treatment will continue until disease progression, unacceptable toxicity, death or discontinuation for any other reason.
3493081|NCT04335669|Active Comparator|Arm A (Platinum-based dose dense EC):|Two-weekly epirubicin/cyclophosphamide (EC) x 4 (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2), followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
3129696|NCT03235284|Experimental|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
3493082|NCT04335669|Experimental|Arm B (Platinum-based with capecitabine):|Three-weekly cyclophosphamide/epirubicin/capecitabine (CEX) (epirubicin 75 mg/m2, cyclophosphamide 600 mg/m2 and capecitabine 900 mg/m2) x 4, followed after a three-week interval by three-weekly carboplatin x 4 (AUC = 5) together with weekly paclitaxel x 12 (80 mg/m2).
3493083|NCT04327999|Experimental|Preservative free artificial tears|Day 1, patients will self-administer artificial tears every 15 minutes for 2 hours followed by every 30 minutes for at least 4 hours or until bedtime at night. On Day 2, patients will self-administer artificial tears every 1 hour for 12 hours. On Day 3, patients will self-administer artificial tears four times that day. On Day 4, patients will self-administer tears twice that day. Patients will be instructed to wear their contact lenses throughout their waking hours.
3493084|NCT04327687|Experimental|remote ischemic conditioning|remote ischemic conditioning is a physical strategy performed by an electric auto-control device with cuffs placed on bilateral arms: five cycles of 5-min inflation and 5-min deflation one or two times per day. The duration of the treatment is six months.
3493085|NCT04327687|Active Comparator|conventional therapy|conventional therapy
3493086|NCT04327219|Experimental|CDED diet|The CDED will be divided into 3 stages: 0-6 weeks- induction phase (phase 1), weeks 7-12 step-down phase (phase 2), week 13 -24 maintenance phase (phase 3). During these weeks the diet is structured and contains a list of allowed/disallowed foods, and mandatory foods with specific daily/weekly amounts. Patients will be asked to progress with the diet if they respond to the diet clinically. Patients who do not improve, but show a clinicaly significant trend in symptoms, may be asked to prolong a dietary phase until reaching clinical reaction.
3493087|NCT04327219|No Intervention|standard diet|The control standard diet will be personally tailored for nutritional needs according to patient's daily recommended intake (DRI) for calories and protein intake (25kcal/kg and 0.8-1gr/kg per day respectivlly), and will follow the clinical guidelines for dietary therapy of patients with IBD.
3493088|NCT04323189|Other|Crossover AB|Subjects in arm A will first receive placebo daily for 7 days in the first intervention followed by sitagliptin 100mg/d for 7 days in the crossover intervention.
3493089|NCT04323189|Other|Crossover BA|Subjects in arm B will first receive sitagliptin 100mg/d for 7 days in the first intervention followed by placebo for 7 days in the crossover intervention.
3493090|NCT04318925||1|Persons with diagnosed or suspected tick-borne disease age >=18 years
3493091|NCT04316559|Placebo Comparator|Placebo|Placebo capsule
3493092|NCT04316559|Experimental|TRV734|TRV734 at different doses vs. oxycodone for withdrawal suppression
3493093|NCT04316546|Experimental|ARQ 092 (miransertib)|This is a single arm study. All study participants will be taking the experimental drug, ARQ 092 (miransertib).
3493094|NCT04316130|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
3493095|NCT04316130|Active Comparator|Exercise using brochure|brochure
3493096|NCT04313153|Experimental|Vadadustat once daily|
3493097|NCT04313153|Experimental|Vadadustat three times weekly|
3129697|NCT03235349|Experimental|Glecaprevir/Pibrentasvir|Participants received oral glecaprevir/pibrentasvir 300 mg/120 mg once daily (QD) for 12 or 16 weeks. Participants received treatment for 12 weeks with the exception of treatment-experienced, genotype 3-infected participants who received treatment for 16 weeks.
3129698|NCT03235414|Experimental|Normals|Will receive an MRI and a blood draw
3493098|NCT04313153|Active Comparator|Darbepoetin alfa|
3129699|NCT03235479|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3129700|NCT03235479|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3129701|NCT03235726|Experimental|Cohort A, Part 1: Active|60 milligrams (mg) single dose of CCI15106 will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered twice daily (BID) on Days 6-19 to healthy subjects.
3129702|NCT03235726|Placebo Comparator|Cohort A, Part 1: Placebo|60 mg single dose of placebo will be administered by inhalation route on Day 1; 120 mg single dose will be administered on Day 3; and then 30 mg dose will be administered BID on Days 6-19 to healthy subjects.
3129703|NCT03235726|Experimental|Cohort B, Part 1: Active|60 mg of CCI15106 BID will be administered by inhalation route for 14 days to healthy subjects.
3129704|NCT03235726|Placebo Comparator|Cohort B, Part 1: Placebo|60 mg of placebo BID will be administered by inhalation route for 14 days to healthy subjects.
3129705|NCT03235726|No Intervention|Cohort C, Part 1: bystanders|Healthy subjects will be enrolled to follow bystander exposure and will be studied concomitantly with Cohort B.
3129706|NCT03235726|Experimental|Cohort A, Part 2: Active|60 mg single dose of CCI15106 will be administered by inhalation route to subjects with COPD.
3493099|NCT04304079|Experimental|ARssist system|The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist system used by the patient side surgeon.
3493100|NCT04301089|Experimental|Experimental intervention|Experimental VR Intervention, Survey or Questionnaire Completion and Sample Submission
3493101|NCT04297345|Experimental|hemodialysis group|"The active group will include patients with acute ischemic stroke who, in addition to conventional treatment (best possible medical treatment in patients admitted to a stroke unit), will undergo two hemodialysis sessions for a period of about 3 hours each session in the acute phase of stroke.~The investigators will perform a conventional and heparin-free hemodialysis using high-flow dialyzers to avoid possible adverse (allergic) reactions with polysulfones containing other dialyzers."
3493102|NCT04297345|No Intervention|control group|The control group will be composed of patients with similar clinical and demographic characteristics to whom only conventional medical treatment will be applied.
3493103|NCT04297150||Patients that satisfy inclusion criteria|Patients who satisfy the inclusion criteria and sign the informed consent.
3493104|NCT04289571|Experimental|Participants|Participants with retinal disease, healthy volunteers
3493105|NCT04286295|Experimental|Cytisine|Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.
3493106|NCT04286295|Active Comparator|NRT+|The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.
3493107|NCT04282811||cohort group|Patients who have received at least one dose of venetoclax
3493108|NCT04279197|Experimental|FZHY Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~Fuzheng Huayu tablets"
3493109|NCT04279197|Placebo Comparator|Placebo Group|"usual treatment (respiratory function rehabilitation training + Vitamin C tablets)~placebo"
3493110|NCT04278690|No Intervention|Usual Care|Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.
3493111|NCT04278690|Experimental|HELPix|HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.
3493112|NCT04278690|Experimental|HELPix+Tech|After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app
3129707|NCT03235726|Placebo Comparator|Cohort A, Part 2: Placebo|60 mg single dose of placebo will be administered by inhalation route to subjects with COPD.
3129708|NCT03235726|Experimental|Cohort B, Part 2: Active|60 mg BID dose of CCI15106 will be administered by inhalation route for 14 days to subjects with COPD.
3129709|NCT03235726|Placebo Comparator|Cohort B, Part 2: Placebo|60 mg BID dose of placebo will be administered by inhalation route for 14 days to subjects with COPD.
3493113|NCT04278417|Experimental|Brolucizumab Arm|Intra-vitreal injection
3493114|NCT04278417|Active Comparator|Panretinal photocoagulation laser Arm|laser
3493115|NCT04274426|Active Comparator|Control arm with Platinum-based chemotherapy|"Carboplatin (AUC5, d1) combined with pegylated liposomal doxorubicin (PLD) (30 mg/m², d1) q28d~Carboplatin (AUC4, d1) combined with gemcitabine (1000 mg/m2, d1 & d8) q21d~Carboplatin (AUC5, d1) combined with paclitaxel (175 mg/m², d1) q21d"
3493116|NCT04274426|Experimental|Carboplatin + Mirvetuximab soravtansine (IMGN853)|Carboplatin (AUC5, d1) + Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV d1 x 6 cycles q21d, followed by subsequent monotherapy of Mirvetuximab soravtansine (IMGN853) 6 mg/kg IV q3w until disease progression.
3129710|NCT03235817|Experimental|Spontaneous ventilation|
3129711|NCT03235817|Experimental|Pressure support ventilation|
3129712|NCT03235817|Active Comparator|Pressure control ventilation|
3493117|NCT04272242|Experimental|Arm 1: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally twice daily (~12 hours apart). Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. Participants will take non-study supply of DTG for morning doses, and will take study-supplied DTG for evening doses."
3493118|NCT04272242|Experimental|Arm 2: DTG + INH + RPT|"Participants will receive 50 mg of DTG orally each morning. Participants will receive 300 mg of INH and 600 mg of RPT orally each morning for 4 weeks.~Participants will also receive 25 or 50 mg of pyridoxine (vitamin B6) with each dose of INH.~Participants will remain on once-daily DTG-based ARV treatment with 2 NRTIs (excluding TAF) during the study. DTG will be from non-study ARV supply.~NOTE: Arm 2 will only open based on assessment of DTG pharmacokinetics (PK) data from participants in Arm 1."
3493119|NCT04268823|Experimental|QBW251|Oral use, one capsule twice daily.
3493120|NCT04268823|Placebo Comparator|Placebo|Oral use, one capsule twice daily.
3493121|NCT04268628||Participants with mCRPC|Participants with metastatic castration resistant prostate cancer (mCRPC) will be evaluated for genetic polymorphism and pharmacodynamic parameters from serum and plasma samples collected during the Abira-DES study (NCT02217566). Serum and plasma samples were collected after use of diethylstilbestrol (DES) and subsequent abiraterone acetate therapy. Peripheral blood samples were collected prior to initiation of abiraterone acetate therapy, after 12 weeks of therapy, and at the time of disease progression (evaluated by prostate specific antigen [PSA] response).
3493122|NCT04267939|Experimental|Dose escalation of BAY1895344 and fixed dose of Niraparib|"In participants with all solid tumor(excluding prostate cancer) and positive for DDR deficiency.~DDR: DNA-Damage Repair"
3493123|NCT04267939|Experimental|Participants PARPi naïve|"Participants with ovarian cancer, PARPi naïve and with a platinum resistant/refractory disease and DDR deficiency.~DDR: DNA-Damage Repair"
3493124|NCT04267939|Experimental|Participants with disease progression on PARPi|Participants with ovarian cancer and disease progression on PARPi
3493125|NCT04262596|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
3493126|NCT04262596|Active Comparator|Traditional decision aid booklet|A traditional patient decision aid bookelet that includes provide standard general information, quantitative risk information on the possible outcomes of cataract surgery and value clarification exercise.
3493127|NCT04258566|Experimental|Suspected hepatic malignancy|Malignancy determination of new onset hepatic lesion
3493128|NCT04256421|Experimental|Tiragolumab + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
3493129|NCT04256421|Active Comparator|Placebo + Atezolizumab + CE|Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3.
3493130|NCT04251065|Experimental|Daratumumab-GDP|"This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of diagnosis of PTCL-NOS, AITL or nodal lymphoma of TFH cell origin and a central evaluation of immunohistochemical positivity of CD38 on bioptic material used to perform local diagnosis of relapsed disease, or that used for the more recent biopsy in the case of refractory patients. A core needle biopsy is considered sufficient for review and CD38 evaluation. Evaluation at central laboratory can be performed in bone marrow sections in those patients with only bone marrow lymphoma infiltration.~Only patients with confirmed eligible diagnosis and a percentage of CD38 positive tumor cells ≥ 5% will be considered eligible for study treatment.~The treatment consists of an induction phase and a maintenance phase."
3493131|NCT04247516|No Intervention|Standard Control Group|The standard control group (CG) will not have access to the self-regulatory (SR) intervention program.
3129713|NCT03236168|Other|Intervention Arm|This study consists of a single treatment arm. Patients will receive Ivermectin or where contraindicated (Pregnancy, Breastfeeding, Weight <15kg) Permethrin Cream and Malathion shampoo
3493132|NCT04247516|Experimental|Online-intervention group I (IGI)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration."
3129714|NCT03236246|Experimental|Group 1|KRX-0502 1 tablet thrice daily (TID) with meals
3129715|NCT03236246|Experimental|Group 2|KRX-0502 2 tablets twice daily (BID) with the largest 2 daily meals
3493133|NCT04247516|Experimental|Online-intervention group II (IGII)|"Online-intervention group will receive on a 6-week long online intervention program. The program includes:~i) a narrative with SR competences embedded worked on a weekly basis during an online session; ii) weekly tasks/activities will be delivered to promote the SR reflected with the narrative exploration; iii) the program includes gamification strategies with the purpose of promoting engagement in participants."
3493134|NCT04246346|Experimental|Interactive Q&A chatbot|A chatbot of patient decision aid embedded into a mobile application which is able to bidirectionally interact with patients and provide standard general information, quantitative risk information on the possible outcomes of cataract surgery.
3129716|NCT03236311|Placebo Comparator|Placebo|Matching placebo for 4 weeks.
3129717|NCT03236311|Experimental|SAR407899|SAR407899 with dose titration over 4 weeks administration (3 week titration phase + 1 week maintenance phase).
3129718|NCT03236506|Experimental|Daily observed therapy|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a daily, observed basis by either the nurse or a community pharmacist.
3129719|NCT03236506|Active Comparator|Fortnightly pick-up|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse.
3129720|NCT03236506|Active Comparator|Fortnightly pick-up +psych intervention|Patients with active hepatitis C infection genotype 1 will receive 12 weeks treatment with Zepatier at one tablet per day. Patients with active hepatitis C infection genotype 3 will receive 8 weeks treatment with Zepatier pill plus Sofosbuvir pill at one of each tablets per day. These tablets will be given to patients on a fortnightly basis by the nurse. In addition, this group will receive a one-off interview with the researcher to complete a psychological intervention designed to improve adherence to the medication regimen.
3493135|NCT04246177|Experimental|Lenvatinib plus Pembrolizumab plus TACE|Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight <60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years [~35 cycles] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
3493136|NCT04246177|Active Comparator|Oral Placebo plus IV Placebo plus TACE|Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).
3493137|NCT04246021|Experimental|Ferric carboxymaltose (ferrinject)|"Patients will receive one or two doses of Ferric carboxymaltose (ferrinject), based on the body weight and Hb level.~Ferric carboxymaltose will be administered as a single infusion if the needed dose is 1000 mg as a short IV infusion~If the needed Ferric carboxymaltose dose is > 1000 mg, an initial dose of 1000 mg will be given as a short IV infusion and the remaining dose will be given the week after in a similar fashion"
3493138|NCT04245085|Active Comparator|Arm A|"Atezolizumab (1200 mg) Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Carboplatin (AUC5) Q3W, 4-6 cycles~Paclitaxel (175-200 mg/m2), Q3W, 4-6 cycles"
3493139|NCT04245085|Active Comparator|Arm B|"Atezolizumab (1200 mg), Q3W, until PD~Bevacizumab (15 mg/kg), Q3W, until PD~Pemetrexed (500 mg/m2), Q3W, until PD"
3493140|NCT04243070|Other|3-channel Holter ECG recording for EPS patient|Patients participating in an EPS will undergo a 3-channel Holter ECG recording in parallel to the standard 12-channel Holter ECG recording during the EPS followed by an optional 24 h observation period
3493141|NCT04243070|Other|12-channel Holter ECG recording for non-EPS patients|Patients scheduled for a follow-up for their heart disease will undergo a 12-channel Holter ECG recording while participating in a Body Motion test followed by a 24 h observation period
3129721|NCT03236779|Experimental|Dry needling (DN) arm|Once the clinician locates the MTrP, he will insert the needle over it and he will do a quick entry of the needle. The chosen technique to manipulate the needle will be Hong technique, which consist of quick entry and exit of the needle (fast in/fast out) to get local twitch response (LTR), it will be repeated 5 times with a rhythmic movement of 1Hz/sec. LTRs will be counted and registered.
3493142|NCT04243044|Experimental|Intensity 1 (0.8x resting threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
3493143|NCT04243044|Experimental|Intensity 2 (0.8x resting threshold, dual-site, 30 minute duration)|Transcutaneous spinal stimulation will be applied continually at 0.8x resting threshold at two sites as determined from baseline testing of posterior root muscle reflexes.
3493144|NCT04243044|Experimental|Intensity 3 (burst 0.8x rest threshold, 30 minute duration)|Transcutaneous spinal stimulation will be applied in bursts at 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
3493145|NCT04243044|Experimental|Frequency 1 (30 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 30 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
3493146|NCT04243044|Experimental|Frequency 2 (50 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 50 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
3493147|NCT04243044|Experimental|Frequency 3 (80 Hz, 30 minute duration)|Transcutaneous spinal stimulation will be applied at a frequency of 80 Hz and an intensity of 0.8x resting threshold as determined from baseline testing of posterior root muscle reflexes.
3493148|NCT04242446|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
3493149|NCT04242446|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
3493150|NCT04242446|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
3493151|NCT04242446|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
3493152|NCT04242264|Experimental|Group 1|Vaccine: 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
3493153|NCT04242264|Experimental|Group 2|Placebo+Vaccine: 30 ml of Placebo administered orally on Day 1 and 1 ml of saline containing 10^6 cfu of the WRSs2 vaccine in 30 ml of sterile normal saline administered orally on Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
3493154|NCT04242264|Placebo Comparator|Group 3|Placebo: 30 ml of Placebo administered orally on Day 1 and Day 29. N=8 Challenge: 1 ml of S. sonnei 53G challenge administered orally on Day 57. N=6
3493155|NCT04239573|Experimental|Arm I (low intensity surveillance)|Patients undergo MRI or CT at the beginning of the trial and again in 1 year. Following the first year, patients with no abnormalities repeat MRI or CT every 2 years. Patients with positive imaging features on MRI and CT at 1 or 2 years and with negative EUS, repeat MRI or CT in 1 year. Patients with negative imaging repeat MRI or CT in 2 years.
3493156|NCT04239573|Experimental|Arm II (high intensity surveillance)|Patients undergo MRI or CT. Patients with 1-2 cm cyst undergo MRI or CT every 6 months for 1 year, then every 12 months for 2 years, and then every 24 months thereafter. Patients with 2-3 cm cyst undergo EUS within 6 months, and if EUS is negative, patients repeat MRI or CT in 1 year. If second EUS is negative, patients undergo alternate MRI or CT and EUS every 12 months. Patients with cyst > 3 cm undergo EUS within 6 months, and if EUS is negative, patients undergo alternate MRI or CT with EUS every 3-6 months.
3493157|NCT04239274|Experimental|Transcranial Direct Current Stimulation (tDCS)|
3493158|NCT04239274|Experimental|Transcranial Pulsed Stimulation tPCS|
3493159|NCT04239274|Sham Comparator|No Stimulation|
3493160|NCT04235855|Experimental|Endoscopic USG guided Liver biopsy|Olympus linear echo endoscope (GF -UCT 180, Olympus Ltde, Tkyo, Japan) will be used. 19 Gz EUS Acquire needle Boston ©Scientific Corp will be used for liver tissue acquisition.
3493161|NCT04235855|Active Comparator|Percutaneous Liver biopsy|All liver biopsies done in the Institute as routine procedure by percutaneous route would be compared with the EUS guided biopsy in respect to safety , tissue quality and diagnostic yield .
3180146|NCT00680264||Operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level Curve >40 degrees on sitting film, A spinal fusion is being undertaken and the patient/family is proceeding with the spinal fusion (with any level of distal fusion).
3180147|NCT00680264||Non-operative|Diagnosis of Cerebral Palsy (standard definition of any brain injury before the age of 3) with total body involvement - any functional level, Curve >40 degrees on sitting film, A spinal fusion is not being undertaken either because the family has refused surgery or because it is not recommended at this point.
3180148|NCT00680277|Experimental|1|
3180149|NCT00680277|Experimental|2|
3180150|NCT00680290|Experimental|1|Exercise group
3493162|NCT04235335|Other|Wait List Control|Participants receive intervention after 12 week delay
3493163|NCT04234945|Experimental|study|Group A will be the study group and will be given oral Doxycycline capsule 100mg bd for 3/7.
3493164|NCT04234945|Placebo Comparator|control|Group B will be the study group and will be given oral Multivitamin capsule i bd for 3/7
3493165|NCT04234906|Active Comparator|Stage 1, Group 1 - Dexmedetomidine|Dexmedetomidine: 1 mcg/kg administered at end of cardiopulmonary bypass, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
3493166|NCT04234906|Active Comparator|Stage 1, Group 2- Magnesium|Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day.
3493167|NCT04234906|Active Comparator|Stage 2, AMIODARONE|AMIODARONE I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
3493168|NCT04234906|Active Comparator|Stage 2, PROCAINAMIDE|PROCAINAMIDE IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
3493169|NCT04232540|Experimental|Patients with undetectable viral load for at least 2 years|Patient and provider will view and discuss results of the MedViewer test.
3129722|NCT03236779|Active Comparator|Percutaneous needle electrolysis (PNE) arm|The electrotherapy equipment used (Enraf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3, 1.5 mA for 5 seconds conveyed to the muscle will be applied. It will be done exactly the same way as in the DN group with the only difference that the needle will be transmitting the electrical current.
3180151|NCT00680303|Experimental|1|The child will receive the Lidcombe Program 2x per week
3180152|NCT00680303|Experimental|2|The child will receive the Lidcombe Program once every 2 weeks (fortnightly visits)
3180153|NCT00680303|Other|3|The child will receive the standard Lidcombe Program once per week (control)
3493170|NCT04232540|Experimental|Patients with detectable viral load once in past 2 years|Patient and provider will view and discuss results of the MedViewer test.
3493171|NCT04229901|Experimental|HepaStem|Patients in the HepaStem arm will receive 2 infusions of HepaStem (i.v) at 1.0 millions of cells/kg (7 day interval)
3493172|NCT04229901|Placebo Comparator|Placebo|Patients in the placebo arm will receive 2 infusions of placebo (i.v) (7 day interval)
3493173|NCT04227821||Hemodynamically instable pediatric patients|Pediatric patients admitted to the pediatric intensive care unit with the need of vasopressor and/or inotrope therapy due to hemodynamic instability
3493174|NCT04225117|Experimental|Cohort 1: HR+/HER2- breast cancer|"Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.~HR+/HER2- = Hormone receptor-positive/ human epidermal growth factor receptor 2-negative"
3493175|NCT04225117|Experimental|Cohort 2: Triple negative breast cancer (TNBC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493176|NCT04225117|Experimental|Cohort 3: Squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493177|NCT04225117|Experimental|Cohort 4: Non-squamous non-small cell lung cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493178|NCT04225117|Experimental|Cohort 5: Head and neck cancer|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493179|NCT04225117|Experimental|Cohort 6: Gastric; GEJ or esophageal cancer|"Participants enrolled into Cohort 6 will be reallocated based on disease type and histology into Cohorts 7 or 8.~GEJ= gastroesophageal junction"
3493180|NCT04225117|Experimental|Cohort 7: Gastric adenocarcinoma or esophageal carcinoma (EAC) or GEJ adenocarcinoma|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493181|NCT04225117|Experimental|Cohort 8: Esophageal squamous cell carcinoma (ESCC)|Participants will receive enfortumab vedotin as an intravenous (IV) infusion on days 1, 8 and 15 of each 28-day cycle.
3493182|NCT04222205|Active Comparator|Crossover sequence 1|"Cluster-randomization crossover sequence 1:~T-piece during odd-numbered months and inspiratory pressure augmentation during even-numbered months."
3493183|NCT04222205|Experimental|Crossover sequence 2|"Cluster-randomization crossover sequence 2:~T-piece during even-numbered months and inspiratory pressure augmentation during odd-numbered months."
3493184|NCT04221269|Active Comparator|Enhanced Treatment as Usual|Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
3493185|NCT04221269|Experimental|Coping Long-term with Active Suicide Program for Schizophrenia|Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
3493186|NCT04220840||Study Group|All consecutive patients who underwent damage control surgery (DCS) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers
3493187|NCT04220840||Control group|All consecutive patients who underwent other than DCS surgery (resection with primary anastomosis, Hartmann´s procedure, laparoscopic lavage) for perforated diverticulitis of the sigmoid colon with generalized Peritonitis in one of the participating centers which do not apply DCS routinely.
3493188|NCT04210219|Experimental|JNJ-64264681: Dose Escalation and Expansion|Participants will receive oral administration of JNJ-64264681 capsule at a dose assigned by the sponsor Study Evaluation Team (SET), based on the available safety, pharmacokinetics, and pharmacodynamics data in dose escalation treatment group (Part 1); and recommended Phase 2 dose (RP2D) determined in Part 1 in cohort expansion treatment group (Part 2).
3493189|NCT04209543|Experimental|Estetrol 15 mg -Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
3493190|NCT04209543|Experimental|Estetrol 20 mg -Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
3493191|NCT04209543|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for a minimum of 12 weeks and not longer than 13 weeks
3493192|NCT04209543|Experimental|Estetrol 20 mg + P4 100 mg - Safety Part|Estetrol (E4) 20 mg and Progesterone (P4) 100 mg will be administered once daily for up to 53 weeks
3493193|NCT04206332|Experimental|Group 1|5 mg/kg IV
3493194|NCT04206332|No Intervention|Group 10|Control
3493195|NCT04206332|Experimental|Group 11|1 mg/kg IV
3493196|NCT04206332|Experimental|Group 12|5 mg/kg IV
3493197|NCT04206332|Experimental|Group 13|5 mg/kg SC
3493198|NCT04206332|Experimental|Group 14|10 mg/kg IV
3493199|NCT04206332|Experimental|Group 15|10 mg/kg SC
3493200|NCT04206332|No Intervention|Group 16|Control
3493201|NCT04206332|Experimental|Group 2|5 mg/kg SC
3493202|NCT04206332|Experimental|Group 3|20 mg/kg IV
3493203|NCT04206332|Experimental|Group 4a|40 mg/kg IV
3493204|NCT04206332|Experimental|Group 4b|40 mg/kg IV
3493205|NCT04206332|Experimental|Group 5|Control
3493206|NCT04206332|Experimental|Group 6|5 mg/kg SC
3493207|NCT04206332|Experimental|Group 7|20 mg/kg IV
3493208|NCT04206332|No Intervention|Group 8|No additional study product
3493209|NCT04206332|Experimental|Group 9|40 mg/kg IV
3493210|NCT04206319|Experimental|1|Participants will receive radium-223 treatment every 4 weeks for up to 6 cycles. 18F-NaF PET scans will be used to assess response in bone.
3493211|NCT04203134|Experimental|Treatment Group|Patients in the randomly assigned treatment group will receive a mouthguard at first visit along with standard treatment of BMS.
3493212|NCT04203134|No Intervention|Control Group|Control group will proceed through treatment for BMS in an otherwise standard treatment protocol and will not receive a mouthguard.
3493213|NCT04200456|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
3493214|NCT04200456|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
3493215|NCT04199104|Experimental|Pembrolizumab with Lenvatinib|Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
3493216|NCT04199104|Active Comparator|Pembrolizumab with Placebo|Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months).
3493217|NCT04196803|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
3493218|NCT04196803|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
3493219|NCT04196803|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
3493220|NCT04196803|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
3493221|NCT04193189|Experimental|Group A, Arm 1: HEPLISAV-B (two injections)|Participants will receive 0.5 mL of HEPLISAV-B by intramuscular (IM) injection at Weeks 0 and 4.
3493222|NCT04193189|Experimental|Group A, Arm 2: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
3493223|NCT04193189|Experimental|Group A, Arm 3: ENGERIX-B (three injections)|Participants will receive 1 mL of ENGERIX-B by IM injection at Weeks 0, 4, and 24.
3493224|NCT04193189|Experimental|Group B: HEPLISAV-B (three injections)|Participants will receive 0.5 mL of HEPLISAV-B by IM injection at Weeks 0, 4, and 24.
3493225|NCT04192370|Experimental|Cannabidiol|As this is a single-arm, open-label study, all subjects will receive the interventional arm, specifically 600mg of oral cannabidiol once daily for 3 consecutive days.
3493226|NCT04188509|Experimental|Voxelotor|All participants will receive voxelotor once daily (QD), administered orally as tablets, dispersible tablets, or a stick pack formulation (powder blend formulation packaged as stick packs). Participants aged ≥ 12 years and/or ≥ 40 kgs will receive a voxelotor dose of 1500 mg QD. Participants aged < 12 years and < 40 kgs will receive weight based dosing of voxelotor. The participant's weight at study entry will be used to determine the starting voxelotor dose in this study. Participants may receive study drug as long they continue to receive clinical benefit that outweighs risk as determined by the investigator and/or until the participant has access to voxelotor from an alternative source.
3493227|NCT04188028|Experimental|CYP2D6 gene score 0|CYP2D6 gene score 0: carrier of two non-functional alleles
3493228|NCT04188028|Experimental|CYP2D6 gene score ≥1|CYP2D6 gene score ≥1: carrier of one fully-functional and one non-functional allele of CYP2D6 , one fully-functional and one reduced-function of CYP2D6, two fully-functional alleles of CYP2D6 or more than two functional alleles alleles
3493229|NCT04183218||Observational (cardiac monitoring)|Patients receive cardiac monitor implants then undergo standard of care RT or CRT at the discretion of the treating physician. Patients also undergo blood sample collection at baseline, 4 weeks, 3, 9, and 12 months.
3493230|NCT04179591|Experimental|Exercise|Exercises will be performed three times per week for six weeks.
3493231|NCT04179591|Experimental|Insole|Customized arch support insoles will be worn for six weeks.
3493232|NCT04179591|Experimental|Exercise plus Insole|Exercises will be performed three times per week, and customized arch support will be worn for six weeks.
3493233|NCT04174612|Active Comparator|Standard clinical treatment|"Patients will complete 3+7 + Midostaurin induction course."
3493234|NCT04174612|Experimental|Experimental treatment|"The experimental arm will provide 2 main modifications compared to standard:~i) immediate switch to intensified induction with high-doses Cytarabine (on days 5, 6 and 7 of induction) ii) early allocation to high-risk disease category to be refined according to ELN stratification and post induction MRD status"
3493235|NCT04172675|Experimental|Cohort 1: Erdafitinib|Participants with high-risk non-muscle-invasive bladder cancer (NMIBC) presenting as papillary tumor only (carcinoma in situ [CIS], absent), with disease recurrence after bacillus Calmette- Guerin (BCG) therapy will receive treatment with erdafitinib.
3493236|NCT04172675|Active Comparator|Cohort 1: Investigators Choice|Participants with high-risk NMIBC presenting as papillary tumor only (CIS, absent), with disease recurrence after BCG therapy will receive the investigator's choice of either intravesical gemcitabine or intravesical mitomycin C (MMC)/hyperthermic MMC. Participants who are randomized to gemcitabine or MMC/hyperthermic MMC in Cohort 1 and demonstrate a recurrence via investigator disease assessment will have the opportunity to cross over to treatment with erdafitinib.
3493237|NCT04172675|Experimental|Cohort 2|Participants with high-risk, BCG- unresponsive NMIBC presenting as CIS with or without concurrent papillary tumor will receive treatment with erdafitinib.
3132772|NCT03449758|Experimental|Sarilumab|Sarilumab 200 milligram (mg) subcutaneous (SC) injection every 2 weeks (q2w) from Day 1 of Week 0 up to Week 24 as monotherapy and/or in combination with methotrexate (MTX) or other csDMARD during the randomized 6-month (24 weeks) core treatment period. Participants completing 24 weeks period entered in a long-term extension treatment period and received sarilumab 200 mg q2w from Week 25 until the commercial availability of sarilumab in the country or maximum of up to Week 39.7.
3493238|NCT04172675|Experimental|Cohort 3|Marker lesion study in intermediate-risk NMIBC presenting as papillary disease only. All enrolled participants will receive treatment with erdafitinib.
3493239|NCT04168502|Experimental|Experimental arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~Maintenance with glasdegib 100 mg daily for one year or until toxicity/relapse"
3493240|NCT04168502|Active Comparator|Standard arm|"Induction:~Gemtuzumab 3 mg/m2 day 1,4,7 Daunorubicin 60 mg/m2 day 1-3 Cytosine arabinoside 200 mg/m2 day 1-7~Consolidation:~Gemtuzumab 3 mg/m2 day 1 Daunorubicin 50 mg/m2 day 4-6 Cytosine arabinoside 500 mg/m2 twice a day, day 1-6~Allogeneic transplantation or Autologous transplantation according to MRD level~clinical observation"
3493241|NCT04159740||Endometriosis - Cases|Premenopausal women with suspected endometriosis, planning to undergo laparoscopic surgery.
3493242|NCT04159740||Controls|Premenopausal women without endometriosis, planning to undergo laparoscopic surgery for non-cancer indications including elective salpingectomy, tubal ligation or surgical procedures for abnormal uterine bleeding
3493243|NCT04157088|Experimental|Participants treated with darolutamide|
3493244|NCT04157088|Experimental|Participants treated with enzalutamide|
3493245|NCT04154800|Experimental|Part A:SAD|Single Ascending Dose
3493246|NCT04154800|Experimental|Part B: MAD|Multiple Ascending Dose
3493247|NCT04154800|Experimental|Part C: DDI|Drug-Drug Interaction
3493248|NCT04154800|Experimental|Part A (SAD) Placebo|
3493249|NCT04154800|Experimental|Part B (MAD) Placebo|
3493250|NCT04149574|Experimental|Arm A: nivolumab|
3493251|NCT04149574|Placebo Comparator|Arm B: placebo +BCG|
3493252|NCT04147195|Experimental|Cohort 1, Arm 1|LYS006
3493253|NCT04147195|Experimental|Cohort 1, Arm 2|LYS006 + Tropifexor (LJN452)
3493254|NCT04146441|Experimental|SonoVue|SonoVue + chemotherapy
3493255|NCT04146441|Active Comparator|control|chemotherapy
3493256|NCT04141696|Experimental|Ketamine|Given intravenously over 40 minutes
3493257|NCT04141696|Active Comparator|Midazolam (Placebo)|Given intravenously over 40 minutes
3493258|NCT04140266|Experimental|Group A: Dapivirine (DPV) Vaginal Ring (VR)-004|Mothers will use one DPV VR continuously for approximately one month, replacing the DPV VR each month for approximately three months.
3493259|NCT04140266|Experimental|Group B: Truvada Tablet|Mothers will take one Truvada oral tablet daily for approximately three months.
3493260|NCT04137757|Experimental|Lower Body Negative Pressure (LBNP)|Participants complete mental tasks and imaging while undergoing lower body negative pressure (LBNP).
3493261|NCT04137757|Sham Comparator|Sham Pressure|Participants complete mental tasks and imaging with pressure noise but no pressure.
3180154|NCT00680329||Travalert with DuoTrav|One drop in study eye(s) once daily in the evening for four months
3180155|NCT00680342|Placebo Comparator|1|Placebo (lactose pill)
3493262|NCT04137692|Experimental|Red Blood Cell Transfusion|Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.
3493263|NCT04135300|Experimental|Arm of BBM-H901|Subjects will be dosed with single dose of BBM-H901 at 5x10·12 vg/kg via intravenous infusion.
3493264|NCT04130191||Participants with hereditary angioedema (HAE)|Participants who initiate treatment with lanadelumab according to current product labelling will be enrolled and followed for up to 24 or 36 months (depending on their enrollment date).
3493265|NCT04127968|Experimental|intervention group|Septic children with vitamin A deficiency who will receive vitamin A supplementation.
3493266|NCT04127968|Placebo Comparator|control group|Septic children with vitamin A deficiency who will receive placebo.
3493267|NCT04123366|Experimental|Olaparib+Pembrolizumab|Participants receive olaparib 300 mg via oral tablet 2 times each day PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 21-day cycle. Participants may receive olaparib+pembrolizumab for up to approximately 2 years.
3493268|NCT04112693|Experimental|Esophageal biopsies during POEM|"In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies for histopathological analysis will be analyzed in Full Field Optical Coherence Tomographie (FFOCT) before that. The FFOCT analysis take place for patient inclued after than 10 nov 2020.~The biopsies are taken by the gastroenterologist who performs the POEM assisted by an endoscopy-specialized nurse."
3493269|NCT04112602||Patients with MPS|In this cohort are included patients under 18 years old with MPS (all types). The objective is to be representative of the diversity of MPS, and of this evolution.
3493270|NCT04112602||Non-MPS patients|In this control group are included patients under 18 years old, with no respiratory problems, no MPS.
3493271|NCT04109846|Experimental|Non-euploid Transfer|Patients desiring pregnancy who have no acceptable euploid embryos available for transfer who chose to undergo embryo transfer of a non-euploid embryo (either aneuploid or mosaic).
3493272|NCT04109846|Active Comparator|Euploid Transfer|Patients desiring pregnancy who are undergoing euploid embryo transfer
3493273|NCT04104776|Experimental|Phase 2 Cohort M1|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M1: Open to patients with urothelial carcinoma (with known ARID1A mutation)"
3493274|NCT04104776|Experimental|Phase 2 Cohort M2|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M2: Open to patients with ovarian clear cell carcinoma (with known ARID1A mutation)"
3493275|NCT04104776|Experimental|Phase 2 Cohort M3|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M3: Open to patients with endometrial carcinoma (with known ARID1A mutation)"
3493276|NCT04104776|Experimental|Phase 2 Cohort M4|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M4: Open to patients with peripheral T-cell lymphoma (PTCL) and patients with diffuse large B-cell lymphoma (DLBCL), including patients with documented germinal center B cell like diffuse large B-cell lymphoma (GCB-DLBCL) with at least 1 EZH2 hotspot mutation"
3493277|NCT04104776|Experimental|Phase 2 Cohort M5|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M5: Open to patients with relapsed or refractory malignant pleural or peritoneal mesothelioma with known BAP1 loss"
3493278|NCT04104776|Experimental|Phase 2 Cohort M6|"CPI-0209 will be dosed once per day orally in 28 day cycles.~• Cohort M6: Open to patients with castration-resistant prostate cancer(mCRPC) with measurable soft tissue disease"
3493279|NCT04101331|Experimental|Cohort A|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥10%
3493280|NCT04101331|Experimental|Cohort B|PTCL (peripheral T cell lymphoma) patients with CD30 expression ≥1% to <10%
3493281|NCT04101331|Experimental|Cohort C|TMF (transformed mycosis fungoides) patients with CD30 expression ≥1%
3493282|NCT04098497|Experimental|ACT-based microintervention delivered by mobile app|"At every time-point of the study, participants will complete self-reports of mania (as measured by the shortened YMRS), depression (as measured by the shortened SIGH-D ), medication adherence, and activity through the mobile app Lorevimo. After completing these assessments, participants will be randomly assigned to either receive one additional ACT-based microintervention question or receive no additional question.~The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action).~The ACT-based questions were developed by the research team as a unique intervention for the current study. They are based upon core themes of acceptance and commitment therapy: engagement, awareness, and openness."
3493283|NCT04097184|Active Comparator|"active tDCS group"|Patients will benefit from a series of 10 double-blind effective tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
3493284|NCT04097184|Sham Comparator|"sham tDCS group"|Patients will benefit from a series of 10 double-blind placebo tDCS stimulation sessions over a period of 5 days (Monday to Friday): each stimulation series will include two daily stimulation sessions spaced 3 hours apart for 5 days.
3180156|NCT00680342|Experimental|2|700mg of Legalon (silymarin) three times daily
3180157|NCT00680342|Experimental|3|420mg Legalon (silymarin) three times daily
3180158|NCT00680355|Other|Golden rice meal with 10g fat|10 g corn oil in the Golden Rice meal
3180159|NCT00680355|Other|Golden Rice with 0g fat|0g corn oil eating with the Golden Rice meal
3180160|NCT00680355|Other|Golden Rice meal with 5 g fat|5 g corn oil in the Golden Rice meal
3493285|NCT04095676|Experimental|VATS / surgical group|The VATS procedure must be completed as soon as possible and no later than 48 hours after randomisation. The surgery is performed with the patient in a 90 degree sideways position, using general anesthesia. Access is obtained through one to three ports, followed by purification and possibly decortication, and insertion of one pleural drain (sizes 24 - 32F) at the end of surgery. 20 ml Marcain is used as local analgetic and applied at the incision sites or as a nerve block. In the VATS group, suction on drain (- 15 cm H20) is applied in the first day after the procedure. Operator must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be registered and approved by the steering committee.
3493286|NCT04095676|Active Comparator|Drain and intrapleural therapy group|"Pigtail is applied as soon as possible and within 48 hours after randomisation. Drain placement is carried out using ULS. Operators (conductors of the procedure) must have relevant training and competencies corresponding to the specialist level within the relevant specialty and be approved by the steering committee to conduct the procedure. A pigtail catheter (minimum 10F) is inserted. Operator determines the size of drain and whether drain placement is done with one-step or Seldinger technic.~The intrapleural therapy consists of treatment with the following two drugs:~intrapleural Actilyse® (alteplase) 10 mg twice daily for three days~intrapleural Pulmozyme® (DNase) 5 mg twice daily for three days"
3493287|NCT04095078|Experimental|SIMEOX|Use the device for 3 months in addition to usual care
3493288|NCT04095078|No Intervention|Control|Usual care
3132773|NCT03449979|Experimental|alpha stimulation in participants in a depressive episode|Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
3493289|NCT04094792|Experimental|Intervention|For the intervention group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later). Intervention group subjects will use the Breather app twice daily, five minutes each time, for a period of 21 days.
3493290|NCT04094792|No Intervention|Control|For the control group, baseline measures on depression and heart rate variability will be obtained at baseline and post-test (21 days later).
3493291|NCT04089969|Experimental|Evaluation of Standard of care followed by CTA/FFRct|Patient received clinical recommendation based on the Standard of Care i.e 2 D echocardiogram, plus ECG, plus, pharmacological stress test followed by re-evaluation of clinical recommendation with addition of CTA/FFRct
3493292|NCT04088136|Experimental|Everyday Metacognitive Memory|Training in techniques for managing memory demands in everyday life
3493293|NCT04088136|Active Comparator|Memory Strategy Control|Trains the use of memory strategies for learning new associations and concepts
3493294|NCT04086485|Experimental|1/Lu-177-DOTATATE + Olaparib escalation|Lu-177-DOTATATE and escalating doses of olaparib to determine the maximum-tolerated dose (MTD)
3493295|NCT04086485|Experimental|2/Lu-177-DOTATATE + Olaparib fixed dose|Lu-177-DOTATATE and olaparib at the MTD
3493296|NCT04085458|Other|Severe hemophilia A patients|Prophylactic treatment regimens should be guided by clinical judgement based on individual patient characteristics and treatment response.
3493297|NCT04077463|Experimental|Phase 1 (monotherapy dose escalation): Lazertinib|Participants will receive Lazertinib monotherapy orally once daily (QD) in 21-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. The subsequent doses of Lazertinib will be assigned by the Study Evaluation Team (SET) according to the dose escalation strategy by Bayesian logistic regression model (BLRM).
3180161|NCT00680381|Active Comparator|1|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly therapist phone calls for eight weeks.
3493298|NCT04077463|Experimental|Phase 1b (combination): Lazertinib and Amivantamab|Participants will receive Lazertinib and Amivantamab, after the safety of RP2D of Lazertinib is confirmed in the Phase 1, in 28-day cycles until documented evidence of disease progression, unacceptable toxicity, noncompliance, or withdrawal of consent, or the investigator decides to discontinue treatment, whichever comes first. This phase will start enrolling participants after the safety of Amivantamab is confirmed in Japanese participants in Study 61186372EDI1001 (NCT02609776).
3493299|NCT04077463|Experimental|Phase 1b (combination): Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP)|Participants will receive Lazertinib starting dose administered orally once daily (QD) in combination with Amivantamab, and doses of platinum-based chemotherapy (carboplatin and pemetrexed) per standard of care according to local guidance in a 21-day cycle for 4 cycles followed by maintenance with Lazertinib, Amivantamab and pemetrexed until disease progression or unacceptable toxicities.
3493300|NCT04077463|Experimental|Phase 1b (expansion) Cohort A: Lazertinib and Amivantamab|"This cohort A will further characterize the safety, tolerability, and preliminary antitumor activity of Lazertinib and Amivantamab based combinations within specific NSCLC population who have progressed after osimertinib and subsequent platinum-based chemotherapy, and platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR TKI is allowed if administered prior to osimertinib. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter."
3493301|NCT04077463|Experimental|Phase 1b (expansion) Cohort B: Lazertinib and Amivantamab|This Cohort B will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants previously treated with advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
3493302|NCT04077463|Experimental|Phase 1b (expansion) Cohort C: Lazertinib and Amivantamab|This Cohort C will further characterize the safety, tolerability and preliminary antitumor activity of Lazertinib and JNJ-61186372 combination in participants with uncommon EGFR mutations. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
3493303|NCT04077463|Experimental|Phase 1b (expansion) Cohort D: Lazertinib and Amivantamab|Cohort D will seek to validate one or both potential biomarker strategies (next generation sequencing [NGS] and Immunohistochemical [IHC]), previously identified in Cohort E of Study 61186372EDI1001, in participants with osimertinib-relapsed, but chemotherapy-naive, EGFR Exon19del or L858R mutated NSCLC. Participants will receive at the RP2CD of Lazertinib orally QD and Amivantamab, every 7 days for the first 28 days cycle and every 2 weeks thereafter.
3493304|NCT04076059|Experimental|Double-blind treatment: Enzalutamide plus androgen deprivatio|Participants will receive enzalutamide once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) will be maintained during study treatment as per standard of care (SOC ) and provided by the site's pharmacy stock.
3493305|NCT04076059|Placebo Comparator|Double-blind treatment: Placebo plus androgen deprivation ther|Participants will receive placebo once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) will be maintained during study treatment as per SOC and provided by the site's pharmacy stock.
3129723|NCT03237013|No Intervention|Control (Treatment as Usual only)|"Following baseline assessment, all participants were given health literature on tanning behavior from the U.S. Centers for Disease Control and Prevention (CDC). These materials included informational pamphlets addressing common myths regarding tanning behaviors, including Tanned skin is not healthy skin, and A base tan is not a safe tan. These misconceptions were accompanied by burning truth, scientific data debunking these myths. Additionally, all participants received a packet on sun protective practices for oneself and family, which include skin cancer statistics and information on UV rays."
3493306|NCT04076059|Experimental|Open-Label Phase: Enzalutamide|Participants who will receive placebo in double-blind phase and remain on study treatment until confirmed radiographic disease progression will receive enzalutamide in open-label phase.
3493307|NCT04072887|Active Comparator|QBW251 450 mg|QBW251 450 mg
3493308|NCT04072887|Active Comparator|QBW251 300 mg|QBW251 300 mg
3493309|NCT04072887|Active Comparator|QBW251 150 mg|QBW251 150 mg
3493310|NCT04072887|Active Comparator|QBW251 75 mg|QBW251 75 mg
3493311|NCT04072887|Active Comparator|QBW251 25 mg|QBW251 25 mg
3493312|NCT04072887|Placebo Comparator|QBW251 Placebo|QBW251 Placebo
3493313|NCT04071626|Experimental|Ertugliflozin Treatment Arm|Ertugliflozin 5 mg tablet once a day for 12 weeks
3493314|NCT04071626|Placebo Comparator|Placebo|Placebo tablet once a day for 12 weeks
3493315|NCT04069585|Experimental|RHA®1 with new anesthetic agent|"Split-face injection of RHA®1 with new anesthetic agent in the perioral rhytids on one side of the mouth and RHA®1-Lidocaine in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
3493316|NCT04069585|Experimental|RHA®1-Lidocaine|"Split-face injection of RHA®1-Lidocaine in the perioral rhytids on one side of the mouth and RHA®1 with new anesthetic agent in the perioral rhytids in the other side of the mouth.~Up to 3 mL injected per side."
3493317|NCT04057339|Placebo Comparator|SOC (Standard of Care)|Everyone in this arm will receive standard of care nutritional behavioral counseling and will be required to log their caloric intake through the use of a smartphone app.
3493318|NCT04057339|Experimental|TRE + SOC|Everyone in this arm will receive standard of care nutritional behavioral counseling and will implement a daily 8-10-hour window within which they must consume their calories. They will also be required to log their caloric intake through the use of a smartphone app.
3493319|NCT04056962|Experimental|patients treated with Tacrolimus ointment|
3493320|NCT04056247||Newly diagnosed NSCLC stage IV|Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
3493321|NCT04056247||NSCLC stage IV 2nd line and further of immunotherapy|Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.
3493322|NCT04056247||Malignant melanoma stage IV|Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.
3493323|NCT04056247||Malignant melanoma stage IIIb-d|Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.
3493324|NCT04056247||SCLC stage IV|Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.
3493325|NCT04054752|Experimental|1/Arm 1|NT-I7 administered at 720 and 960g/kg to select the OBD of NT-I7
3493326|NCT04054752|Active Comparator|2/Arm 2a|Administration of 4 vaccines according to Sequence 1 + NT-I7 administration at OBD to assess vaccine response
3493327|NCT04054752|Active Comparator|3/Arm 2b|Administration of 5 vaccines according to Sequence 2 + NT-I7 administration at OBD to assess vaccine response
3493328|NCT04051268|Experimental|Vi-DT TCV Batch 1|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 1
3493329|NCT04051268|Experimental|Vi-DT TCV Batch 2|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 2
3493330|NCT04051268|Experimental|Vi-DT TCV Batch 3|1 dose of 0.5 ml of Vi-DT TCV vaccine batch 3
3493331|NCT04051268|Active Comparator|PQed Typhoid Conjugate Vaccine (subjects 6 mo-45 yo)|1 dose of 0.5 ml of PQed TCV Vaccine
3493332|NCT04051268|Active Comparator|Vi Polysaccharide Vaccine (subjects 46-60 years old)|1 dose of 0.5 ml of Vi Polysaccharide Vaccine
3493333|NCT04047303|Experimental|Administration of CC-90010|During the preoperative period, all subjects will be given a course of orally administrated CC-90010 at 30 mg once daily for 4 consecutive days on Cycle 1 Day 1 to Day 4. The last CC-90010 dose (Day 4) will be administrated 6-24 hours prior to brain tumor resection. Following recovery from surgery and a minimum of 4 weeks from the first CC-90010 dose (Cycle 1 Day 1), subjects who are fit to continue study treatment my restart CC-90010 on Day 1 of Cycle 2 at 45 mg given orally once daily for 4 consecutive days followed by 24 consecutive days off (4 days on/24 days off), in each 28 day cycle.
3493334|NCT04045665|Active Comparator|Antiplatelet Therapy|Antiplatelet-only strategy
3493335|NCT04045665|Active Comparator|Oral Anticoagulant|OAC-based strategy
3493336|NCT04045223||Epidural analgesia and fever|Group 1 will be patients with vaginal delivery and having an epidural analgesia that develop fever during delivery.
3493337|NCT04045223||Epidural analgesia and no fever|Group 2 will be patients with vaginal delivery and having an epidural analgesia that do not develop fever during delivery.
3493338|NCT04045223||No epidural analgesia|Group 3 serves as additional control group and consists of patients having no epidural analgesia and no fever.
3493339|NCT04041284|Experimental|fremanezumab|monthly 225 mg. In the open-label extension phase starting at week 12, all patients will receive active treatment with a quarterly dose of 675 mg sc
3493340|NCT04041284|Placebo Comparator|Placebo|
3493341|NCT04038515|Experimental|E-liquid Order 'A'|Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
3493342|NCT04038515|Experimental|E-liquid Order 'B'|Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
3493343|NCT04038515|Experimental|E-liquid Order 'C'|One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
3493344|NCT04038515|Experimental|E-liquid Order 'D'|One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.
3493345|NCT04034095||Cohort 1: ADT alone/ ADT + Bicalutamide|Participants with diagnosis of metastatic hormone-naive prostate cancer (mHNPC) receiving androgen-deprivation therapy (ADT) alone or ADT plus bicalutamide (combined androgen blockade [CAB]) under routine clinical practice will be observed.
3493346|NCT04034095||Cohort 2: ADT + AAP/Docetaxel/Enzalutamide/Apalutamide|Participants with diagnosis of mHNPC receiving ADT plus abiraterone plus prednisolone (AAP) or Docetaxel or Enzalutamide or Apalutamide under routine clinical practice will be observed.
3493347|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 1|Participants will receive guselkumab dose 1 intravenously (IV) in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
3493348|NCT04033445|Experimental|Induction Study 1: Guselkumab Dose 2|Participants will receive guselkumab dose 2 IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
3493349|NCT04033445|Placebo Comparator|Induction Study 1: Placebo IV|Participants will receive matching placebo IV in Induction Study 1. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
3493350|NCT04033445|Experimental|Induction Study 2: Guselkumab IV|Participants will receive guselkumab IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12.
3493351|NCT04033445|Placebo Comparator|Induction Study 2: Placebo IV|Participants will receive matching placebo IV in Induction Study 2. Subsequent study treatment will be determined by the participant's clinical response status at Week 12. Clinical nonresponders will be administered guselkumab IV.
3129724|NCT03237013|Experimental|Treatment as Usual + Facial Morphing|"In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the UV exposure setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the UV exposure setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles."
3132774|NCT03449979|Placebo Comparator|sham stimulation in participants in a depressive episode|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.
3493352|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 1|Participants will receive guselkumab maintenance dose regimen 1 subcutaneously (SC) every 4 weeks (q4w).
3493353|NCT04033445|Experimental|Maintenance Study: Maintenance Dose Regimen 2|Participants will receive guselkumab maintenance dose regimen 2 SC every 8 weeks (q8w).
3493354|NCT04033445|Placebo Comparator|Maintenance Study: Placebo SC|Participants will receive matching placebo SC q4w.
3180162|NCT00680381|Active Comparator|2|Following 12 weeks of FFT, weekly one-hour group therapy for eight weeks
3493355|NCT04031508|Experimental|Omega 3|The experimental group will receive a parenteral emulsion containing soy oil, MCT, olive oil and n-3 LCPUFA in fish oil
3493356|NCT04031508|Sham Comparator|Control group|The Control group will receive a parenteral emulsion containing soy oil and MCT
3493357|NCT04027946|Experimental|1|LMB-100 + Pembrolizumab
3493358|NCT04024631|Other|Phenotyping|"All participants will undergo a four-hour frequently sampled oral glucose tolerance test in which they will ingest a 75g glucose beverage (intervention) within five minutes and have samples collected at baseline and for four hours after.~They will also undergo a whole body DXA (intervention) during the study day."
3493359|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 10 mg/kg|Participants will receive azacitidine 75 milligram per meter square (mg/m^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
3493360|NCT04023526|Experimental|Azacitidine 75 mg/m^2 and Cusatuzumab 20 mg/kg|Participants will receive azacitidine 75 mg/m^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle in Part 1. Part 1 findings will be reviewed by a data review committee.
3493361|NCT04019444|Experimental|Arm A|One dose (1 ml (5x10^10 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
3493362|NCT04019444|Experimental|Arm B|One dose (1 ml (1x10^11 vp)) of ChAd155-RG vaccine administered intramuscularly on Day 1, and 1 ml of matching placebo administered intramuscularly on Days 8, 15, 22. N=14 (3 sentinel, 11 non-sentinel)
3493363|NCT04019444|Experimental|Arm C|Two doses (1 ml (1x10^11 vp) each) of ChAd155-RG vaccine administered intramuscularly on Day 1 (first dose) and Day 15 (second dose), and 1 ml of matching placebo administered intramuscularly on Days 8 and 22. N=10
3493364|NCT04019444|Active Comparator|Arm D|Three doses (1 ml each) of RABAVERT vaccine administered intramuscularly on Day 1 (first dose), Day 8 (second dose), and Day 22 (third dose), and 1 ml of matching placebo administered intramuscularly on Day 15. N=12 (2 sentinel, 10 non-sentinel)
3493365|NCT04017832|Experimental|Oral semaglutide 3 mg and placebo (sitagliptin)|Oral semaglutide tablets 3 mg and sitagliptin placebo tablets for 26 weeks
3493366|NCT04017832|Experimental|Oral semaglutide 7 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 4 weeks, after which the target dose of 7 mg is taken for 22 weeks
3493367|NCT04017832|Experimental|Oral semaglutide 14 mg and placebo (sitagliptin)|Oral semaglutide tablets and sitagliptin placebo tablets. The dose of oral semaglutide will be escalated over 8 weeks, after which the target dose of 14 mg is taken for 18 weeks
3493368|NCT04017832|Experimental|Sitagliptin 100 mg and placebo (oral semaglutide)|Sitagliptin tablets and oral semaglutide placebo tablets for 26 weeks
3493369|NCT04012216||The study population|Patients consulting for persistant, moderate-to-severe rhinitis and meeting eligibility criteria.
3493370|NCT04006522|Experimental|Cohort 1|Patients with Localized RCC prior to nephrectomy.
3493371|NCT04006522|Experimental|Cohort 2|Patients with Unresectable/Metastatic RCC prior to treatment with an immune checkpoint inhibitor.
3493372|NCT04003961||Moderate/high risk for OSA with EDS|All clinical data of the patients who has moderate/high risk for OSA with excessive daytime sleepiness (EDS) will be assessed with statistical methods.
3493373|NCT04003961||Moderate/high risk for OSA without EDS|All clinical data of the patients who has moderate/high risk for OSA without excessive daytime sleepiness(EDS) will be assessed with statistical methods.
3493374|NCT04003961||Low risk for OSA|All clinical data of the patients who has low risk for OSA will be assessed with statistical methods.
3493375|NCT04002947|Experimental|1|Acalabrutinib 100 mg orally twice a day for 14 days; Following window: patients with > or = to 25% tumor reduction, treat with DA-EPOCH-R or R-CHOP + acalabrutinib 100mg orally twice a day for the first 10 days, for 6 cycles; whereas, patients with <25% tumor reduction, treat with DA-EPOCH-R or R-CHOP alone for 6 cycles
3493376|NCT04002908||In-facility Observations|Mothers and their LBW babies will be observed starting within 6 hours of birth until the baby is discharged from the health facility.
3493377|NCT04002908||Prospective cohort study - Quantitative|Mothers and their low-birth weight babies will be enrolled 72 hours after birth and followed through 12 months postpartum. The prospective cohort survey (which includes anthropometric measurements and feeding observations) occurs at multiple time points over this 12-month period.
3493378|NCT04002908||Prospective cohort study - Qualitative|"Research specialists at each site will be speaking to key informants (includes doctors, nurses, midwives, community health workers (CHWs), Ministry of Health (MOH) officials, supply chain & milk bank experts) who are knowledgeable about breastfeeding policy, supply chain, or milk banks. Clinicians in study health facilities who work on labor and delivery, postnatal, newborn and neonatal ICU wards. They participate in In-depth interviews. Mothers, family members and health care workers of LBW babies, as well as community leaders (including religious leaders) who are knowledgeable about infant feeding in their communities will participate in focus group discussions. Focus group discussion will take up to 2 hours. In-depth interviews will take up to 1 hour.~Mothers (6-month extension): Mothers chosen and consented for IDIs will include those currently enrolled in the prospective cohort. Additionally, their infants need to be between 9 and 12 months of age."
3493379|NCT04002908||Retrospective Chart review|The retrospective chart review is a review of secondary data of mothers and their LBW babies who were born in the study health facilities prior to the start of the study.
3493380|NCT04002908||Donor Human Milk Readiness Assessment|"Key stakeholders in the area of newborn health who determine policy and procedures or who are directly involved with the provision of care. This includes clinicians, nurses, lactation/nutrition specialists, hospital leadership and/or Ministry of Health officials present in the study health facilities.~This is a one-time data collection exercise in the form of either: (1) a largely qualitative facility readiness assessment tool with some qualitative questions for facility staff or (2) a facility tool observing the flow of milk along with key informant interviews in the study facilities. This could take anywhere from 1hr to a day depending on the tool administered, key informants involved and size of the study facility."
3493381|NCT04002583|Experimental|Early-onset Alzheimer's disease (EOAD) subjects|Subjects with mild cognitive impairment due to EOAD will undergo a 48 hour computer assisted ambulatory electroencephalogram
3493382|NCT03998683|Experimental|Guselkumab Group|Participants will receive guselkumab 100 mg SC injections at Weeks 0, 4, 12 and placebo subcutaneous (SC) injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injections at Weeks 20, 28, 36, and 44 in open-label phase.
3493383|NCT03998683|Placebo Comparator|Placebo Group|Participants will receive placebo SC injection at Weeks 0, 4, 12 and guselkumab 100 mg SC injection at Week 16 in double-blind phase followed by guselkumab 100 mg SC injection at Week 20, 28, 36, and 44 in open-label phase.
3493384|NCT03998618|Experimental|Acceptance and Commitment Therapy|Patients in the ACT arm will learn new and more adaptive ways to respond to fatigue.
3493385|NCT03998618|Active Comparator|Education/Support|Patients in the education/support arm will discuss their cancer-related concerns and receive education on services available in their medical center and community.
3493386|NCT03994510|Other|Patients with Borderline Personality Disorder|At each visit, these patients will have an interview that will allow for a clinical evaluation, as well as completing the hetero-questionnaires and self-questionnaires
3493387|NCT03986957||Hypertensive patients|Patients with SBP: 140-159; DBP: 90-99
3493388|NCT03968172|Experimental|EBBC programme|Participants in the intervention group will receive access to evidence-based patient information (EBPI) about lifestyle factors in MS combined with a complex behaviour change programme (EBBC programme), an online tool that was developed in line with principles of patient empowerment and cognitive behavioural therapy (CBT) approaches, including acceptance and mindfulness oriented techniques.
3493389|NCT03968172|Active Comparator|Control group programme|Participants randomized to the active control group will receive access to an information platform with optimized standard care consisting of information compiled from the German Multiple Sclerosis Society (DMSG) information material to reflect current practice.
3493390|NCT03966248|Experimental|Chinese Tuina group (CTG)|The participants in CT group will receive the traditional Chinese Tuina therapy on the basis of KOA health education and home-exercise.
3493391|NCT03966248|Active Comparator|Physical Manual group (PMG)|The participants in PM group will receive the modern physical manual therapy on the basis of KOA health education and home-exercise.
3493392|NCT03965091|Experimental|Fremanezumab - Dose A|
3493393|NCT03965091|Experimental|Fremanezumab - Dose B|
3493394|NCT03965091|Placebo Comparator|Placebo|
3493395|NCT03964506|Experimental|Hyperbaric Oxygen Therapy|Patients will receive HBO therapy one time on day 0 of the transplant. The treatment consists of exposure to hyperbaric oxygen at 2.5 atmospheric absolutes (ATA) for a total of 90 minutes after compression to 2.5 atmosphere absolutes (ATA) in a monoplace hyperbaric chamber (Model 3200/3200R, Sechrist Industries, Inc., USA), breathing 100% oxygen. The subjects will be in the chamber for a total of 120 minutes as approximately 10-15 minutes were spent during the compression and decompression phases and subjects had 10 minute room air breaks every 30 minutes of hyperbaric oxygen treatment.
3493396|NCT03964090|Experimental|1|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
3493397|NCT03964090|Experimental|2|Temozolomide, etoposide, doxil, dexamethasone, and rituximab without ibrutinib (TEDD-R) or TEDD-R with ibrutinib Days 1-10 (TEDDI-R), concurrent with cytarabine and isavuconazole, based upon response to 14-day ibrutinib window
3493398|NCT03957213|Experimental|Active IH + CT|Acute intermittent hypoxia will be provided to the subject by delivering 15 brief exposures (~60 seconds) of hypoxic air alternated with 15 brief exposures (~60 seconds) of room air. The amount of oxygen delivered during hypoxic exposures may range from 15%-9% fraction of inspired oxygen, compared to 21% oxygen in normal atmospheric air. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training.
3493399|NCT03957213|Sham Comparator|Sham IH + CT|A sham protocol will be administered in which 21% fraction of inspired oxygen will be delivered by the hypoxicator during hypoxic intervals, and room air will be delivered through the four-way valve during room air intervals. This is followed by a 30 minute rest period and then 60 minutes of computerized cognitive training (Posit; Brain HQ).
3493400|NCT03954067|Experimental|Dose Escalation - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
3493401|NCT03954067|Experimental|Dose Escalation - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles to determine the recommended phase 2 dose. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
3493402|NCT03954067|Experimental|Dose Expansion - cutaneous or subcutaneous lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
3493403|NCT03954067|Experimental|Dose Expansion - visceral lesions|Participants will receive ASP9801 on days 1 and 15 of 28 day cycles at the dose recommended by the dose escalation phase. After cycle 2, participants who have not met any discontinuation criteria and receiving clinical benefit may be treated on continuous cycles until treatment discontinuation criteria are met.
3493404|NCT03952624||Control|FNS <= 3
3493405|NCT03952624||Fatigued|FNS >= 4
3493406|NCT03949647||1|Healthy males and females aged 18 years and older
3493407|NCT03947684|Experimental|TMS|Paired-pulse transcranial magnetic stimulation during active contraction to determine the influence of sex hormone fluctuations on cortical excitability in naturally cycling women.
3180163|NCT00680381|Active Comparator|3|Following 12 weeks of FFT, an eight-week, customized series of therapist visits with the adolescent, family, teachers, coaches and others who can support the adolescent's reduced level of drug use.
3493408|NCT03946098|Experimental|iCBT for Gambling Disorder|Treatment will consist of a 1+10 module internet delivered CBT program targeting problem gambling, newly developed. A bottom-up procedure was used to develop the treatment protocol, inspired by Clark's (2004) method for developing novel CBT treatments. We developed a clinical model delineating what factors contribute to the persistence of problem gambling behavior, and aligned these with targeted treatment interventions; based on behavioral upon research on the learning and maintenance processes of gambling behavior (Ramnerö et al, in press), theoretical models of gambling and comorbidity (Blaszczynski & Nower, 2002); as well as qualitative interviews with treatment seeking gamblers with or without comorbidity.
3180164|NCT00680394|Experimental|mifepristone+misoprostol|200 mg mifepristone+ 800 mcg buccal misoprostol
3180165|NCT00680394|Experimental|misoprostol|800 mcg buccal misoprostol+placebo
3180166|NCT00680433|Experimental|Active|Ketamine
3180167|NCT00680433|Placebo Comparator|Placebo|Saline (placebo)
3180168|NCT00680446|Experimental|1|
3180169|NCT00680472|Active Comparator|A,1 HKT-500 Ketoprofen Topical Patch|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects with Acute Shoulder Pain
3493409|NCT03945825|Experimental|Group 1|0.5 mL of 2018/2019 Fluzone QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
3493410|NCT03945825|Experimental|Group 2|0.5 mL of 2018/2019 Fluzone QIV + 0.25 mL of AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Fluzone QIV intramuscular injection on Day 90, n=40
3493411|NCT03945825|Experimental|Group 3|0.5 mL of 2018/2019 Fluzone QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 2019/2020 of Fluzone QIV intramuscular injection on Day 90, n=40
3493412|NCT03945825|Experimental|Group 4|0.5 mL of 2018/2019 Flublok QIV intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
3493413|NCT03945825|Experimental|Group 5|0.5 mL of 2018/2019 Flublok QIV + 0.25 mL AF03 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
3493414|NCT03945825|Experimental|Group 6|0.5 mL of 2018/2019 Flublok QIV + 0.5 mL of Delta Inulin-CpG55.2 (admixed with vaccine) intramuscular injection on Day 1 and 0.5 ml of 2019/2020 Flublok QIV intramuscular injection on Day 90, n=40
3493415|NCT03942419|Experimental|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered daily in both eyes using a microdose dispenser
3493416|NCT03942419|Experimental|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered daily in both eyes using a microdose dispenser
3493417|NCT03942419|Placebo Comparator|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered daily in both eyes using a microdose dispenser
3493418|NCT03937141|Experimental|ADU-S100 and pembrolizumab|All eligible subjects will receive intravenous (IV) infusions of pembrolizumab and intratumoral injections of ADU-S100.
3493419|NCT03930745|Experimental|Arm 1|TOL-463 insert administered vaginally twice a week for twelve weeks. N=125
3493420|NCT03930745|Placebo Comparator|Arm 2|Matching placebo insert administered vaginally twice a week for twelve weeks. N=125
3493421|NCT03928639||Cohort 1|All patients undergoing consultation for structural and valve interventional procedures are invited to participate in this registry protocol.
3493422|NCT03926143|Experimental|Cancer patients|Adult patients with solid cancer who received anetumab-ravtansine treatment in a completed Bayer study
3493423|NCT03924479|Experimental|Breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
3493424|NCT03924479|Sham Comparator|Sham breathing muscle training|The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing ~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.
3493425|NCT03922724|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
3493426|NCT03922724|Experimental|2/IOC Arm|Immunosuppression Only Conditioning, plus allogeneic HCT with GVHD prophylaxis
3493427|NCT03922724|No Intervention|3/Donor Arm|Donors for Recipients in Arm 1, Arm 2, Arm 4, or Arm 5
3493428|NCT03922724|Experimental|4/mRIC Arm|modified Reduced Intensity Conditioning Arm, plus allogeneic HCT with GVHD prophylaxis
3493429|NCT03922724|Experimental|5/ATL-RIC Arm|modified Reduced Intensity Conditioning Arm for ATL patients, plus allogeneic HCT with GVHD prophylaxis
3493430|NCT03922698||Case Group|Patients who undergo surgical intervention of carotid trombo-endo-arterectomy at the Department of Vascular Surgery of the IRCCS Neuromed, with specific inclusion/exclusion criteria
3493431|NCT03921515|Other|1|Blister Induction
3493432|NCT03921515|Other|2|Skin Biopsies
3493433|NCT03915379|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-67571244. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
3493434|NCT03915379|Experimental|Part 2: Dose Expansion|Participants in 2 expansion cohorts of acute myeloid leukemia (AML) or either high-risk myelodysplastic syndromes (MDS) or very high-risk MDS will receive JNJ-67571244 at the RP2D determined in Part 1.
3493435|NCT03911778||Sacrospinofixation|Patients with apical symptomatic prolapse ≥ II in the POP-Q classification and for whom sacrospinofixation with posterior isthmic BSC Mesh is planned
3493436|NCT03908788|Experimental|Intplex test|In vitro diagnostic device
3493437|NCT03908632||Step 1|Subjects 14 years or older diagnosed with Community Acquired Pneumonia (CAP) and positive serology for primary pulmonary coccidioidomycosis (PPC) will enroll in Step 1 within 14 days of symptom onset, n=1000
3493438|NCT03908632||Step 2|Subjects with a diagnosis of primary pulmonary coccidioidomycosis (PPC) confirmed by positive serologic testing during Step 1 will enter Step 2 within 21 days of their test collection date, n=200
3493439|NCT03907488|Experimental|Arm I (chemotherapy, nivolumab, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and nivolumab IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.
3493440|NCT03907488|Experimental|Arm II (chemotherapy, brentuximab vedotin, radiation)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, dacarbazine IV, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Patients may receive pegfilgrastim SC on days 2 and 16, or filgrastim SC or IV on days 6-10 and 21-25. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 6, patients may receive radiation therapy 5 days per week for approximately 4 weeks at the discretion of the treating physician.
3180170|NCT00680472|Placebo Comparator|A,2 Placebo Patch|Treatment with placebo patch
3180171|NCT00680498|Active Comparator|1|
3180172|NCT00680498|Active Comparator|2|
3493441|NCT03907046|Active Comparator|Apixaban|Apixaban dosing will be 5 mg tablet in morning and 5 mg tablet in evening. A reduced dose of 2.5 mg tablet in morning and 2.5 mg tablet in evening will be used if: (1) ≥2 of the following are present: age ≥80 years, body weight ≤60 kg, or serum creatinine 1.5-2.4 mg/dL, or (2) Patient is taking a strong CYP3A4/pGP inhibitor (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin).
3493442|NCT03907046|Placebo Comparator|Aspirin|Aspirin dose will be 81 mg tablet once daily.
3493443|NCT03905889|Experimental|Experimental Abemaciclib and Sunitinib|For the dose escalation phase, Subjects will receive a 21-day cycle of continuous oral daily Sunitinib in combination with Abemaciclib every 12 hours for 14 days followed by 7 days off. Using a traditional 3 x 3 study design assessing dose limiting toxicity, if the initial prescribed dosing of these 2 medications (Dose Level 1) is tolerated by the first 3 subjects, the study will pause for a 30 day time period between cohorts to assess toxicity. If no dose limiting toxicity is identified, the next cohort of 3 new subjects will be treated at the next higher dose level (Dose Level 2). If the original cohort treated at Dose Level 1 do not tolerate the combination of medications, the medication regimen will be modified to a lower dose (Dose Level - 1). A dose expansion phase is included which will evaluate the combination of Abemaciclib in combination with Sunitinib when given at the maximum tolerated dose as determined from the from dose escalation phase.
3493444|NCT03904524|Experimental|SET-to-MEET|This is a single arm, open trial that will be conducted in parallel in 3 separate ICUs. Each site will receive the SET-to-MEET intervention.
3493445|NCT03902431|No Intervention|Control|CVD risk prior to the patient and clinician training
3493446|NCT03902431|Experimental|Training|CVD risk after the patient and clinician training
3493447|NCT03902028|Experimental|Reinforced multidisciplinary follow-up|"Entrance medication reconciliation performed by a pharmacist~Patient compliance evaluation~Patient quality of life evaluation~Pharmaceutical analysis with focus on medication optimization with a specific check-list (according to ESC 2016 recommendations)~Hospitalisation discharge medication reconciliation~Patient pharmaceutic interview at the hospitalisation discharge~Transmission of informations to the general practitioner and the pharmacist's patient~Multidisciplinary consult at 1 month after hospitalisation discharge"
3493448|NCT03902028|No Intervention|Standard care|"Drug review by a paramedic or a pharmacist~Pharmaceutical analysis~Therapeutic optimisation based on the usual practices care of the cardiologic department~Writing of the prescription given on leaving hospital based on the usual care of the department~Treatments explanations and support to the patient on the usual care~Transmission of the hospitalisation report to the patient general practitioner as the usual practice~Medical consult in usual time frames (an average of 1 month after hospitalisation discharge) at the patient location of choice"
3493449|NCT03901963|Experimental|Daratumumab + Lenalidomide|Participants will receive 1800 milligram (mg) daratumumab by subcutaneous (SC) injection in combination with lenalidomide (orally) as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
3493450|NCT03901963|Active Comparator|Lenalidomide|Participants will receive lenalidomide (orally) alone as maintenance therapy for a maximum of 36 cycles. Each cycle is of 28 days.
3493451|NCT03900598|Experimental|Part 1 (Dose Escalation): JNJ-67856633|Participants will receive JNJ-67856633 until disease progression, intolerable toxicity, withdrawal of consent, or the investigator or sponsor decision. Subsequent dose levels will be assigned by the sponsor using an adaptive dose escalation strategy based on all available safety, pharmacokinetic (PK), and biomarker data.
3493452|NCT03900598|Experimental|Part 2 (Cohort Expansion): JNJ-67856633|Participants will receive JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
3493453|NCT03895658|Experimental|ECT|ECT treatment, Within subject cross-over
3493454|NCT03895658|Experimental|MRI|Structural and functional neuroimaging pre and post ECT treatment
3493455|NCT03895658|Experimental|TMS|Transcranial magnetic stimulation measurements of cortical excitability pre and post ECT treatment
3493456|NCT03895645||Study Participants|Participants on the studies' samples that are transferred to this protocol
3493457|NCT03891329|Other|Acticor/Rivacor ICDs/CRT-Ds|Implant of the new Cor Family ICDs and Plexa ProMRI S DX lead (if applicable). Device measurements, pre-defined programming and Adverse Event Reporting
3493458|NCT03889418|Active Comparator|Electronic medical recorded clinical decision support|Usual care only
3180173|NCT00680511|Active Comparator|1|Family therapy combined with methamphetamine-specific group treatment.
3180174|NCT00680511|Active Comparator|2|Family Therapy.
3493459|NCT03889418|Active Comparator|stepped opioid collaborative care model|Usual care AND collaborative care with behavioral health integration
3493460|NCT03885765||Test group|The first 60 patients recruited.
3493461|NCT03885765||Validation group|The last 100 patients recruited.
3493462|NCT03884985|Experimental|Normal Vision|This study examines high-acuity vision, oculomotor behavior recorded using high-resolution eyetracking. Healthy participants are asked to perform different types of visual tasks, ranging from letter identification to judging facial expressions while their eye movements will be recorded with high-precision together with their behavioral performance in the task.
3493463|NCT03878823|Experimental|ODM-209 Part 1 Dose escalation|
3493464|NCT03878823|Experimental|ODM-209 Part 2 Dose expansion|
3493465|NCT03877354||Paediatric patients anaesthesia|Paediatric patients who underwent diagnostic or surgical procedure under general anaesthesia with the need for mechanical ventilation in the selected time period.
3493466|NCT03877354||Paediatric patients intensive care|Paediatric patients admitted to the paediatric intensive care unit with the need for mechanical ventilation in the selected time period
3493467|NCT03877094|Active Comparator|Nature Virtual Reality Video|After signing the Informed Consent Form, the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy. In the end of the procedure, the patient you will receive a Ipad (specific to the study and blocked for other functions) to respond a demographic questionnaire to characterize the sample and the likerts questionnaire to measure their pain, comfort, well-being, stress and anxiety during the procedure.
3493468|NCT03877094|No Intervention|Control group|This control group will not receive an intervention.
3493469|NCT03874754|Experimental|The iHBE program group|an intervention group
3493470|NCT03874754|No Intervention|Usual Care (Control group)|A control group
3493471|NCT03873636|Experimental|Active Stimulation|Active stimulation of targeted brain regions involved in task-switching and dual-tasking.
3493472|NCT03873636|Sham Comparator|Sham Stimulation|Sham stimulation of targeted brain regions involved in task-switching and dual-tasking.
3493473|NCT03873194|Experimental|Meditation group|Patients who are going to practice meditation and will receive only the usual outpatient care, with the aim of observing reduction of systemic blood pressure in this period.
3493474|NCT03873194|Other|conventional treatment|Patients that will receive only the usual outpatient care, with the aim of observing the systemic blood pressure in this period.
3493475|NCT03871829|Active Comparator|Arm A: Carfilzomib+Dexamethasone (Kd)|Participants will receive carfilzomib 20 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Cycle 1 and then 70 mg/m^2 on Days 8 and 15 of Cycle 1 and thereafter on Days 1, 8, 15 of Cycle 2 onwards. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
3493476|NCT03871829|Experimental|Arm B: Dara-SC in combination with Kd (DKd)|Participants will receive daratumumab subcutaneous (Dara-SC) 1800 mg by SC injection on Days 1, 8, 15, 22 for Cycle 1 and 2, Days 1 and 15 for Cycle 3-6, Day 1 for Cycle 7 onwards. Participants will receive carfilzomib 20 mg/m^2 IV on Cycle 1 Day 1 and then 70 mg/m^2 on Day 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2. Participants will receive dexamethasone 20 mg on Cycle 1 Day 1, a second dose of 20 milligram (mg) will be given on Cycle 1 Day 2 and 40 mg IV or orally on Days 8, 15, 22 for Cycle 1. Patients will then receive dexamethasone 40mg on days 1, 8, 15 and 22 for cycles 2-9, then on Days 1, 8, 15 for Cycle 10 onwards, until death, intolerable toxicity, start of a new treatment for multiple myeloma, withdrawal of consent, or end of the study. The total duration of each cycle is 28 Days.
3493477|NCT03871816||Participants with Metastatic Prostate Cancer|Participants with metastatic prostate Cancer (PC) will be evaluated for the prevalence of DNA-repair gene defects (DRDs) and will be assessed for biomarker eligibility status for niraparib interventional studies. Participants will be consented to saliva, blood, and/or archival tumor tissue testing for the presence or absence of DNA-repair gene defects.
3493478|NCT03839745|Other|Power level 10, 15, or 20 watts|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
3493479|NCT03839745|Other|1 of the other 2 remaining power levels|Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
3493480|NCT03839745|Other|Remaining power level|Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level
3493481|NCT03834779|Other|DOORS-CHW Intervention|"The type of intervention is behavioral.~Participants randomized to the intervention arm will meet with the Community Health Worker (CHW) and a staff member from Unlocking DOORS. The Unlocking DOORS broker will complete a needs assessment, generate an individualized re-entry plan and make referrals to providers in the extensive Unlocking DOORS network. The CHW will assist the participant in navigating these referrals, specifically with regards to HIV care, substance use treatment and mental healthcare."
3493482|NCT03834779|No Intervention|Treatment As Usual|TAU participants will receive standard of care, which involves passive referral by jail medical staff to the outpatient HIV clinic.
3493483|NCT03831958||Family member|Family member of survivor of pediatric Cushing disease
3132775|NCT03449979|Experimental|alpha stimulation in healthy participants|Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
3493484|NCT03831958||Subjects|survivor of pediatric Cushing disease
3493485|NCT03828201|Experimental|Investigational: DRAMATIC-16 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 16 weeks levofloxacin 1000 mg PO QD, 16 weeks clofazimine 100 mg PO QD, 16 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
3180175|NCT00680537|No Intervention|1|Control group
3493486|NCT03828201|Experimental|Investigational: DRAMATIC-24 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 24 weeks levofloxacin 1000 mg PO QD, 24 weeks clofazimine 100 mg PO QD, 24 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
3493487|NCT03828201|Experimental|Investigational: DRAMATIC-32 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 32 weeks levofloxacin 1000 mg PO QD, 32 weeks clofazimine 100 mg PO QD, 32 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
3493488|NCT03828201|Experimental|Investigational: DRAMATIC-40 weeks|delamanid 300 mg orally, by mouth (PO) once a day (QD), 40 weeks levofloxacin 1000 mg PO QD, 40 weeks clofazimine 100 mg PO QD, 40 weeks bedaquiline 200 mg PO QD x 8 wk then 100 mg PO QD remainder linezolid 1200 mg PO QD, Initial 8 weeks only
3493489|NCT03818035|Experimental|Part 1: Guselkumab|Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.
3493490|NCT03818035|Experimental|Part 2: Guselkumab q8w and Guselkumab q16w|Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder [SRe]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score >5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.
3493491|NCT03818035|Experimental|Part 2: Guselkumab q8w|Participants (Non SRe) in group 2c with a PASI score greater than (>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.
3180176|NCT00680537|Experimental|2|Exercise group
3180177|NCT00680563|Experimental|1|
3493492|NCT03818035|Experimental|Part 3: Guselkumab Withdrawal|Participants from groups 2a and 2b with a PASI score <3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 116 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to [>=] 3) at week 68 or PASI >5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.
3493493|NCT03813238|Experimental|Deutetrabenazine|administered as oral tablets at a starting dose of 6 mg once daily
3493494|NCT03813238|Placebo Comparator|Placebo|Matching placebo
3493495|NCT03811015|Experimental|Arm A (cisplatin, IMRT, nivolumab)|Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions. Within 4 weeks after completion of concurrent therapy, patients receive nivolumab IV once weekly over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
3493496|NCT03811015|Active Comparator|Arm B (cisplatin, IMRT, observation)|"Patients receive cisplatin IV over 60 minutes weekly and IMRT 5 days a week for 7 weeks for a total of 35 fractions, and then go on observation.~Patients will be offered the option to cross-over to Arm C if they have clearly documented progression within 12 months from the end of cisplatin/radiation therapy."
3493497|NCT03811015|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
3493498|NCT03811002|Experimental|Arm I (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1. Cycles repeat every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D-CRT or IMRT BID for approximately 3 weeks or QD for approximately 6-7 weeks in the absence of disease progression or unacceptable toxicity.
3493499|NCT03811002|Active Comparator|Arm II (etoposide, cisplatin, carboplatin, radiation therapy)|Patients receive treatment as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 or 2 of each chemotherapy cycle. Cycles repeat every 3 weeks for 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
3493500|NCT03805919||Cohort 1|Participants with germline pathogenic or likely pathogenic variants in prostate cancer-related risk genes
3493501|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Not Refractory)|
3493502|NCT03801525|Experimental|Phase 2: Previously Treated CLL (BTK-Refractory)|
3493503|NCT03801525|Experimental|Phase 2: Treatment Naïve CLL|
3493504|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
3493505|NCT03801525|Experimental|Phase 3: Treatment Naïve CLL/SLL: Ublituximab + Umbralisib (U2)|
3493506|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib + Venetoclax (U2-V)|
3493507|NCT03801525|Experimental|Phase 3: Previously Treated CLL/SLL: Ublituximab + Umbralisib (U2)|
3493508|NCT03794089|Experimental|Brief anxiety intervention|Modular anxiety intervention designed for PC-MHI, up to six 30-minute sessions occurring approximately every 2 weeks, patients select modules of interest to them to complete, emphasis on psycho-education and cognitive-behavioral coping strategies for self-management
3493509|NCT03794089|Active Comparator|Usual PC-MHI care|Appointment with PC-MHI provider at local primary care clinic, providers delivers whatever interventions they deem appropriate and collaboratively decides with patients whether and when to meet again as in routine PC-MHI care
3493510|NCT03789240|Experimental|1|Window of treatment with Copanlisib 60mg via IV for a single 28 day cycle, once weekly for the first 3 weeks and then a 1 week break followed by induction therapy with copanlisib and rituximab. Induction therapy will be 6 cycles (28 days) of: copanlisib dose and administration same as window, rituximab 375mg/m2 via IV, once weekly for the first 4 weeks during cycle 1, subsequent cycles (cycles 2-6), rituximab will be dosed only once on day 1 of the cycle.
3493511|NCT03768544|Experimental|Self-help guided by a lay provider|
3493512|NCT03768544|Other|Waiting list where participants wait for delayed treatment|
3493513|NCT03767244|Experimental|Apalutamide + ADT|Participants will receive androgen deprivation therapy (ADT) plus oral administration of apalutamide 240 milligram (mg) (4 tablets of 60 mg each) daily in each cycle (each cycle of 28 days). Participants will receive six cycles of treatment, followed by radical prostatectomy (RP) with pelvic lymph node dissection (pLND), followed by an additional six cycles of treatment.
3493514|NCT03767244|Experimental|Placebo + ADT|Participants will receive ADT with oral administration of matching placebo treatment daily in each cycle (each cycle of 28 days). Participants will receive six cycles of placebo treatment, followed by RP with pLND, followed by an additional six cycles of placebo treatment.
3493515|NCT03764696|No Intervention|air, the first and second stage of labor|"Patients randomized to the group will receive room air.~The therapy will continue until after delivery"
3493516|NCT03764696|Experimental|oxygen, the first and second stage of labor|"Patients randomized to the group will receive oxygen administered by high flow facemask oxygen at 10 L/min oxygen.~The therapy will continue until after delivery"
3493517|NCT03762733||Patient Relatives|Biological relatives (1st-3rd degree) of participants with histologically confirmed malignancy
3493518|NCT03762733||Patients|Participants with histologically confirmed malignancy
3493519|NCT03759184|Experimental|1|DOSE ESCALATION: IL-15 by civ infusion at escalating doses of 0.5, 1, and 2 mcg/kg/day on days 1-5 of each 4-week cycle (max 6 cycles), with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle, to determine the MTD
3129725|NCT03237013|Placebo Comparator|Treatment as Usual + Mindfulness|In addition to the health literature, participants completed the Mindfulness Intervention. Participants listened to a 10-minute self-guided mindfulness audio exercise. The audio file is a scripted reading of an established, brief mindfulness exercise (Erisman & Roemer, 2010). During this guided session, participants learned what mindfulness was, when it can be used, and benefits from practice. Listeners were led through steps, focusing on the physical sensations, breathing, and thoughts. After the exercise, participants were provided a handout highlighting key points about mindfulness and how to incorporate informal mindfulness practice into their daily life.
3493520|NCT03759184|Experimental|2|DOSE EXPANSION: 3 to 6 patients to receive IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with obinutuzumab by IV infusion at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of the first cycle; then 1,000 mg on day 4 of each subsequent cycle (Total 9 patients at MTD)
3129726|NCT03237065|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
3493521|NCT03748641|Experimental|Cohort 1: Participants with mCRPC and HRR Gene Alteration|Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
3493522|NCT03748641|Experimental|Cohort 2: Participants with mCRPC and No HRR Gene Alteration|Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
3493523|NCT03748641|Experimental|Cohort 3 (Open-label): Participants with mCRPC|Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg.
3493524|NCT03745339||Abstinent OUD|Men and women with history of OUD, but abstinent for at least 3 weeks and not in agonist treatment
3493525|NCT03745339||Controls|Men and women with no history of a substance-use disorder (except nicotine, for matching purposes) and not using any drug for nonmedical purposes
3493526|NCT03745339||In-treatment OUD|Men and women with opioid use disorder (OUD) being treated with an agonist (buprenorphine or methadone)
3493527|NCT03739996|Experimental|CAB LA + VRC07-523LS|"Step 1: CAB administered orally as one 30 mg tablet once daily, plus two NRTIs, for 5 weeks.~Step 2: CAB LA loading dose (600 mg) administered as one IM injection at Step 2 entry study visit, and maintenance dose (400 mg), starting at 4 weeks after CAB LA loading dose, and then every 4 weeks through Week R2+44.~VRC07-523LS (40 mg/kg) administered as an IV infusion starting at Step 2 entry and then every 8 weeks through Week R2+40.~Step 3: SOC oral ART regimen for approximately 48 weeks."
3493528|NCT03733925|Experimental|Golimumab|Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
3493529|NCT03733314|Experimental|E6011|
3493530|NCT03733314|Placebo Comparator|Placebo|
3493531|NCT03733067|Experimental|abatacept|Adult and pediatric dosing will be based on weight per protocol
3493532|NCT03733067|Placebo Comparator|placebo|will be given as the same IV volume as abatacept
3493533|NCT03729349||Participants with Diagnosis of Rheumatoid Arthritis|Participants will not receive any intervention as a part of this study. All Rheumatoid Arthritis (RA) participants treated with golimumab in a clinical practice setting will be observed.
3493534|NCT03720561||Group: Ibrutinib Treatment|Participants will not receive any intervention as a part of this study. This study will collect retrospective and prospective real-world data to describe retention rates for participants of chronic lymphocytic leukemia (CLL) receiving ibrutinib in routine Italian clinical practice over a 2-year follow-up period. Participants with CLL who have started ibrutinib treatment within 3 months before enrollment visit or in case ibrutinib was prescribed before or on the enrollment day as per routine clinical practice within the 30 days after enrollment visit will be included in the study. The primary data source for this observational study will be the medical records of each enrolled participant, as well as questionnaires concerning quality of life and treatment adherence. Data will be collected every 3 months for the first year and every 6 months for the second year during prospective period.
3493535|NCT03719599||Children|Children 6 -12 months of age presenting for routine clinic visits
3493536|NCT03719599||Pregnant Women|Pregnant Women 18 years and older presenting for routine clinic visits
3493537|NCT03712605|Experimental|Arm A (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1.
3129727|NCT03237065|Active Comparator|Ferric carboxymaltose|Administered IV
3493538|NCT03712605|Active Comparator|Arm B (standard of care observation, radiation therapy)|Patients receive standard of care observation every 3 months for 1 year, and then every 6 months for 5 years. Patients may also undergo standard of care radiation therapy within 14 days of day 1, cycle 1.
3493539|NCT03712527|Experimental|Platelet-Rich Plasma|
3493540|NCT03712527|Placebo Comparator|Placebo|
3493541|NCT03705169|Experimental|Arm A, Cohort 1A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single intravenous (IV) infusion on Day 0.
3493542|NCT03705169|Experimental|Arm A, Cohort 1B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
3493543|NCT03705169|Experimental|Arm A, Cohort 2A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
3493544|NCT03705169|Experimental|Arm A, Cohort 2B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
3129728|NCT03237156|Experimental|TAK-906 50 mg; Cohort 1|TAK-906 50 milligram (mg) capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 50 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
3493545|NCT03705169|Experimental|Arm A, Cohort 3A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0.
3493546|NCT03705169|Experimental|Arm A, Cohort 3B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single IV infusion on Day 0.
3493547|NCT03705169|Experimental|Arm A, Cohort 4A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 30 mg/kg of SAR441236, administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
3493548|NCT03705169|Experimental|Arm A, Cohort 4B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as an IV infusion on Day 0 and then every 12 weeks (at weeks 12, 24, and 36) for a total of four doses.
3493549|NCT03705169|Experimental|Arm B, Cohort 5: SAR441236|Participants will receive 1 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
3493550|NCT03705169|Experimental|Arm B, Cohort 6: SAR441236|Participants will receive 3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
3493551|NCT03705169|Experimental|Arm B, Cohort 7: SAR441236|Participants will receive 10 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
3493552|NCT03705169|Experimental|Arm B, Cohort 8: SAR441236|Participants will receive 30 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
3493553|NCT03705169|Experimental|Arm B, Cohort 9: SAR441236|Participants will receive 0.3 mg/kg of SAR441236, administered as a single IV infusion on Day 0. Antiretroviral treatment will be initiated or re-initiated by Day 28.
3493554|NCT03705169|Experimental|Arm C, Cohort 10A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 0.3 mg/kg of SAR441236, administered as a single subcutaneous (SC) injection on Day 0.
3493555|NCT03705169|Experimental|Arm C, Cohort 10B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection on Day 0.
3493556|NCT03705169|Experimental|Arm C, Cohort 11A: SAR441236|In addition to continuing non-study-provided ART, participants will receive 1 mg/kg of SAR441236, administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
3493557|NCT03705169|Experimental|Arm C, Cohort 11B: Placebo for SAR441236|In addition to continuing non-study-provided ART, participants will receive placebo administered as a single SC injection or divided into multiple SC injections of a maximum of 2 mL per each syringe on Day 0.
3493558|NCT03702751|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
3129729|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 1|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
3180178|NCT00680576|Active Comparator|1|Eight weeks of individual CBT for adolescents who have completed six weeks of group therapy and continue to use drugs.
3180179|NCT00680576|Active Comparator|2|Eight weeks of FFT for adolescents who have received six weeks of group therapy and continue to use drugs.
3180180|NCT00680589|Experimental|1|Injection of mouse TYRP2 DNA in patients with highrisk melanoma.
3129730|NCT03237156|Experimental|TAK-906 100 mg; Cohort 2|TAK-906 100 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 100 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
3493559|NCT03702751|Active Comparator|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
3493560|NCT03697148|Experimental|Diagnostic (mpMRI)|Patients undergo mpMRI within 3 months prior to schedule surgery.
3493561|NCT03693365||Patients undergoing surgeries|"Patients undergoing surgery with general anesthesia and controlled mechanical ventilation with indication of invasive arterial blood pressure.~Classification ASA 2-4"
3493562|NCT03689530|Experimental|Peer Support Arm.|Participants randomized to peer support will be matched with a peer supporter.
3493563|NCT03689530|Active Comparator|Enhanced Usual Care|Participants randomized to enhanced usual care will receive brief education and folder of information and resources.
3493564|NCT03689478|Experimental|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
3493565|NCT03678402|Experimental|Palarum Fall Prevention System|The Study site, the OSU Wexner Center Brain and Spine Hospital, is located on three contiguous floors with each floor being made up of two units or Pods designated East and South. Following commencement of the study, and throughout its duration, Pods assigned to the Study will only utilize the Palarum Fall Prevention System and a monitored PUP™ sock, i.e., (Patient is Up) System as the standard of care intervention for fall prevention in accordance with its operating instructions and procedures.
3493566|NCT03670628|Active Comparator|720 shockwave therapy Group|Participants in this group will receive a total of 5 daily sessions of shockwave therapy within a week. Each therapy session will consist of 720 shockwave therapy applied to the penis and to the left and right crus (shaft near the base)
3493567|NCT03670628|Sham Comparator|Sham shockwave therapy|Participants in this group will receive a total of 5 daily sessions of sham shockwave therapy within a week. Sham therapy will be applied to the penis and to the left and right crus (shaft near the base).
3129731|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 2|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period. Cohort 2 will be conducted after Cohort 1.
3129732|NCT03237156|Experimental|TAK-906 10 mg; Cohort 3|TAK-906 10 mg capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 10 mg capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
3180181|NCT00680602|Experimental|1|Group Cognitive Behavior Therapy
3180182|NCT00680602|Active Comparator|2|Selective Serotonin Reuptake Inhibitor
3180183|NCT00680615|Experimental|Usual Care|
3180184|NCT00680615|Experimental|Enhanced|
3180185|NCT00680641|Active Comparator|A|Simvastatin 40mg
3180186|NCT00680641|Placebo Comparator|B|Placebo
3493568|NCT03670355|Experimental|Tenofovir (TFV) Intravaginal Ring (IVR)|The TFV IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
3493569|NCT03670355|Placebo Comparator|Placebo IVR|The placebo IVR will be inserted during the enrollment visit (Day 0) and used continuously for approximately 91 days.
3493570|NCT03670069|Experimental|Treatment (itacitinib)|Patients receive itacitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3493571|NCT03668392|Experimental|Patients on Oncospar|
3493572|NCT03666871|Experimental|Arm 1|Arm 1 (n=20) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have been transduced with a zinc finger nuclease designed to cleave CCR5.
3493573|NCT03666871|Active Comparator|Arm 2|Arm 2 (n=10) will be pretreated with cyclophosphamide 1 g/m2 and will receive a single intravenous infusion of 0.5 to 4x1010 ex vivo expanded autologous CD4+ T cells that have not been modified by zinc finger nucleases.
3493574|NCT03662542|Experimental|Combination Therapy|Participants will receive guselkumab Dose 1 as intravenous (IV) infusion and Dose 2 as subcutaneous (SC) injection; and golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
3493575|NCT03662542|Experimental|Monotherapy: Guselkumab|Participants will receive guselkumab Dose 1 as IV infusion, Dose 2 as SC injection and placebo to maintain the blind.
3493576|NCT03662542|Active Comparator|Monotherapy: Golimumab|Participants will receive golimumab Dose 1 and Dose 2 as SC injection and placebo to maintain the blind.
3493577|NCT03661320|Active Comparator|Arm A|Chemotherapy alone followed by radical cystectomy
3493578|NCT03661320|Experimental|Arm B|BMS-986205 Placebo + Nivolumab + Chemotherapy followed by BMS-986205 Placebo + Nivolumab post radical cystectomy
3493579|NCT03661320|Experimental|Arm C|BMS-986205 + Nivolumab + Chemotherapy followed by Nivolumab plus BMS-986205 post radical cystectomy
3180187|NCT00680654|Experimental|Arm 1|
3180188|NCT00680667|Experimental|Trametes Versicolor|Females with Stage I-III infiltrating ductal adenocarcinoma of the breast being treated with Trametes versicolor capsules for 6 weeks after receiving radiation therapy.
3493580|NCT03659578|Experimental|Thymosin α1|Patients are treated with subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
3493581|NCT03652064|Active Comparator|Bortezomib + Lenalidomide + Dexamethasone (VRd) and Rd|Participants will receive bortezomib 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 (cycle of 28 days); dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond (each cycle is of 28 days) followed by lenalidomide-dexamethasone (Rd) until disease progression or unacceptable toxicity.
3493582|NCT03652064|Experimental|Daratumumab + VRd (D-VRd) and DRd|Participants will receive daratumumab 1800 mg as SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3 through 8 and every 4 weeks for Cycle 9 and beyond; bortezomib 1.3 mg/m^2 as SC injection twice weekly on Days 1, 4, 8, 11 for Cycles 1 through 8 (each cycle is of 21 days); lenalidomide 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9; dexamethasone 20 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, 12 for Cycles 1 through 8 and 40 mg on Days 1,8, 15 and 22 during Cycle 9 and beyond followed by daratumumab-lenalidomide-dexamethasone (DRd) until disease progression or unacceptable toxicity.
3493583|NCT03650114|Experimental|Ofatumumab|Subcutaneous injection
3493584|NCT03649971|Experimental|Guselkumab Dose 1|Participants will receive guselkumab Dose 1 subcutaneous (SC), 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
3493585|NCT03649971|Experimental|Guselkumab Dose 2|Participants will receive guselkumab Dose 2 SC, 6 doses every 4 weeks from Week 0 to Week 20. Participants who respond to guselkumab may continue treatment at the same dose level through Week 48.
3493586|NCT03649971|Placebo Comparator|Placebo|Participants will receive placebo SC, 6 doses every 4 weeks from Week 0 to Week 20.
3493587|NCT03648892|Other|Main|Healthy volunteers, within three BMI strata, under controlled overnight fasting conditions following a period of dietary stabilization
3129733|NCT03237156|Placebo Comparator|TAK-906 Placebo; Cohort 3|TAK-906 Placebo capsules, orally, once daily on Day 1 as Single Dose Period followed by TAK-906 Placebo capsules, orally, twice daily from Day 3 to 7 as Multiple Dose Period.
3129734|NCT03237234|Sham Comparator|Motor Training + Sham tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training while receiving sham transcranial direct current stimulation (tDCS).
3129735|NCT03237234|Experimental|Motor Training + tDCS|Individuals will participate in 3 consecutive sessions of lower extremity motor skill training combined with transcranial direct current stimulation (tDCS) delivered at 2mA to the motor cortex.
3129736|NCT03237481|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
3129737|NCT03237481|Active Comparator|Treatment Group 2: Bupivacaine HCI|Bupivacaine HCl
3129738|NCT03237481|Placebo Comparator|Treatment Group 3: Saline Placebo|Saline placebo
3180189|NCT00680693|Experimental|1|Mindfulness-based stress management 8-week program
3180190|NCT00680693|Active Comparator|2|Psycho-educational support group for women with IBS
3180191|NCT00680719|Active Comparator|1|Family Therapy plus HIV prevention
3180192|NCT00680719|Active Comparator|2|Family Therapy only.
3180193|NCT00680732|Experimental|A1|Multiple micronutrients supplements (MMS) and weekly chloroquine (CQ)
3180194|NCT00680732|Experimental|A2|Multiple micronutrients supplements (MMS) and intermittent suplphadoxyne-pyrimethamine (SP)
3180195|NCT00680732|Experimental|B1|Iron and folic acid (IFA) and weekly chloroquine (CQ)
3180196|NCT00680732|Experimental|B2|Iron and folic acid (IFA) and intermittent sulphadoxyne-pyrimethamine (SP)
3180197|NCT00680758|Experimental|Therapeutic Intervention|
3180198|NCT00680784|Experimental|HKT-500 Ketoprofen Topical Patch|Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
3493588|NCT03641937|Experimental|INVSENSOR00011 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00011 investigational sensor.
3493589|NCT03637660|Active Comparator|1|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly on Day 1, n=280
3493590|NCT03637660|Experimental|2|2.4 million units (MU) of Benzathine penicillin G (BPG) intramuscularly weekly for three successive weeks, n=280
3493591|NCT03614364|Experimental|nanoxel and herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
3493592|NCT03614260|Experimental|Renal Denervation|Renal Angiogram and Renal Denervation (Paradise Renal Denervation System)
3493593|NCT03614260|Sham Comparator|Sham Control|Renal Angiogram
3493594|NCT03610750|Active Comparator|Specialty Care|Psychiatric medications and evidence-based psychotherapies to be provided at a specialty mental clinic facilitated by psychiatric technicians, the mental health specialty workforce already in place in Mozambique.
3129739|NCT03237845|Experimental|Rimegepant 75 mg|Participants were administered a single oral dose of 75 mg of rimegepant tablet on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3129740|NCT03237845|Placebo Comparator|Placebo|Participants were administered a single oral dose of matching placebo tablet for rimegepant (75 mg) on occurrence of migraine that reached moderate or severe intensity up to 45 days after randomization.
3493595|NCT03610750|Experimental|Integrated Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers.
3493596|NCT03610750|Experimental|Community Clinic Stepped Care|Psychiatric medications and evidence-based psychotherapies to be provided by primary care providers and community health workers, respectively.
3493597|NCT03610516|Experimental|CFZ533|Investigational drug CFZ533 will be administred as multiple doses
3493598|NCT03610516|Placebo Comparator|Placebo|Investigational drug matching placebo will be administered as multiple doses
3493599|NCT03610438|Experimental|Cohort 1|Cohort 1 will entroll 38 Ph+ patients
3493600|NCT03610438|Experimental|Cohort 2|Cohort 2 will enroll 38 Ph- patients
3493601|NCT03608865|Experimental|experimental group|Drug:Durvalumab + tremelimumab Dose/Potency:Durvalumab 1500mg(up to 4cycle) / tremelimumab 75mg(up to 13 cycle) Dose Frequency:Q4W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 4 week cycle Use:Experimental
3493602|NCT03604991|Experimental|Arm A (carboplatin, paclitaxel, radiation therapy)|Patients receive carboplatin IV and paclitaxel IV once weekly and undergo radiation therapy once daily (Monday-Friday) beginning on day 1. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
3493603|NCT03604991|Experimental|Arm B (carboplatin, paclitaxel, radiation therapy, nivolumab)|Patients receive carboplatin, paclitaxel, and radiation therapy as in Arm A. Patients also receive nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every week for up to 5 weeks in the absence of disease progression or unacceptable toxicity.
3493604|NCT03604991|Experimental|Arm C (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3493605|NCT03604991|Experimental|Arm D (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm C and receive ipilimumab IV over 90 minutes on day 1 of cycles 1, 4, 7, and 10. Treatment repeats every 2 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3493606|NCT03602599||Healthy-controls Longitudinal Cohort|( Cohort HL ; approximate n=20) includes subjects who will participate in up to 4 study visits across 1 year.
3493607|NCT03602599||Healthy-controls Short-term Cohort|( Cohort HS ; approximate n=80) will participate in a single baseline visit.
3493608|NCT03602599||New Transplant Cohort|( Cohort NT ; approximate n=300) consists of patients who are scheduled to undergo allogeneic HSCT (under another protocol at the NIH).
3493609|NCT03602599||Prior Transplant Cohort|( Cohort PT ; approximate n=100) consists of patients who have already undergone allogeneic HSCT.
3493610|NCT03602235|Experimental|Low dose melphalan + high dose ascorbate acid (HDAA)|"Patients will receive a test dose of 15g of HDAA prior to starting treatment dose. This will be mainly to rule out allergic reactions.~HDAA + Melphalan:~HDAA on day 1 and day 4 in combination with melphalan 12.5 mg/m2, followed by 2 additional doses of HDAA on day 2 and day 5.~A 3 + 3 cohort method will be used for this study. After successfully completing the test dose, subjects will receive 50gms, 75gms and 100gms of ascorbate per infusion in 3 different cohorts. Dose modifications are not made for weight or body surface area."
3493611|NCT03584542||Patients in general practitioners' offices|No interventional study. Only one questionnaire will be done
3129741|NCT03237871|Experimental|Survey and informational text messages|Text-message survey and informational text messages
3129742|NCT03238001|Experimental|All qualified participants|Participants received DCTclock, Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and a battery of other traditional pen and paper neuropsychological assessments.
3493612|NCT03584542||Patients of specialized centers for drug addict patients|No interventional study Only one questionnaire will be done
3493613|NCT03584542||General practitioners|No interventional study Only one questionnaire will be done
3493614|NCT03583333|Experimental|IMI/REL FDC|Imipenem/cilastatin/relebactam (IMI/REL) administered intravenously (IV) as a fixed-dose combination (FDC) at a dosage of 500 mg IMI/250 mg REL/500 mg Cilastatin, once every 6 hours for a minimum 7 days, up to 14 days. At the start of IMI/REL treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
3129743|NCT03238352|Experimental|Test Product|Participants will rinse twice daily (morning and evening) with 10 milliliters (mL) of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
3493615|NCT03583333|Active Comparator|PIP/TAZ FDC|Piperacillin/tazobactam (PIP/TAZ ) administered IV as a FDC at a dosage of 4000 mg PIP/500 mg TAZ once every 6 hours for a minimum 7 days, up to 14 days. At the start of PIP/TAZ treatment, participants will be treated empirically with 600 mg open-label linezolid administered IV every 12 hours until methicillin-resistant Staphylococcus aureus (MRSA) is ruled out. Participants with confirmed MRSA infection will continue to receive 600 mg linezolid every 12 hours for a minimum of 7 days, up to 14 days total.
3493616|NCT03583307|Experimental|Sirolimus|
3493617|NCT03580083|Experimental|Dose 1; 1x10^10 GC/g brain mass of RGX-111|
3493618|NCT03580083|Experimental|Dose 2; 5x10^10 GC/g brain mass of RGX-111|
3493619|NCT03573739|Experimental|Low group|"Patients randomized in the low group will receive a low-calorie low-protein nutrition regimen during the acute phase."
3493620|NCT03573739|Active Comparator|Standard group|"Patients randomized in the standard group will receive a standard-calorie/standard-protein nutrition regimen during the acute phase."
3493621|NCT03573310|Experimental|Part 1: Dose escalation and RP2D Selection|Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
3493622|NCT03573310|Experimental|Part 2:Dose Confirmation and Expansion|Participants with myelodysplastic syndromes (MDS) will receive JNJ-64619178 at a dose less than or equal to the RP2D selected in Part 1 for 24 weeks, or longer if there is evidence of clinical benefit. The dose level of JNJ-64619178 may be adjusted based on observed toxicities.
3493623|NCT03572244|Experimental|Laser-Lok|A Laser-Lok microgrooved implant will be placed.
3493624|NCT03572244|Active Comparator|Machine|A machined implant will be placed.
3493625|NCT03566082||Post Approval Study|"The PAS cohort consisted of 137 subjects who were implanted with the R3 delta Ceramic Acetabular System (DoD) in the pivotal study. These patients will continue to be followed to 10 years post-operatively.~The primary endpoint for the PAS study is implant survivorship at 10 years post study procedure."
3493626|NCT03562767|Experimental|Group-based Cognitive Behavioral Intervention|Subjects receiving the group-based CT-CB intervention
3493627|NCT03562767|Experimental|Web-based Cognitive Behavioral Intervention|Subjects receiving the web based CT-CB intervention
3493628|NCT03562767|Placebo Comparator|Usual Care|Subjects receiving usual care from their primary care providers
3493629|NCT03560193|Experimental|Chlorhexidine Group|
3493630|NCT03560193|Active Comparator|Povidone Iodine Group|
3493631|NCT03559699|Experimental|AG-348|Participants received AG-348 tablets, administered orally, at a starting dose of 5 milligrams (mg), twice daily (BID), followed by two sequential dose level increases to 20 mg and 50 mg BID, for a period of 16 weeks in Part 1. This was followed by optimized dose BID, as determined by the investigator in Part 1, for a period of 24 weeks in Part 2.
3493632|NCT03557281|Experimental|Subjects receiving GSK3036656|Eligible subjects will receive sequential doses of GSK3036656 at a starting dose of 5 milligrams given orally during treatment period.
3493633|NCT03557281|Active Comparator|Subjects receiving RIFAFOUR e-275|Eligible subjects will receive RIFAFOUR e-275 tablet given daily orally as standard-of-care therapy.
3493634|NCT03557242|Other|Warfarin plus Aspirin|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to warfarin plus low dose aspirin for 30-45 days
3493635|NCT03557242|Other|Aspirin Monotherapy|100 subjects will be randomized electronically through the Electronic Data Capture System in a 1:1 fashion to low dose aspirin monotherapy for 30-45 days
3493636|NCT03557242|Other|Registry Arm|Upto an additional 100 subjects with preexisting indication for anti coagulation (e.g. atrial fibrillation, deep venous thrombosis, pulmonary embolism) or who are not eligible for randomization after TAVR due to development of a new indication for anti coagulation will be enrolled in the registry arm of the study.
3129744|NCT03238352|Other|Negative Control|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
3180199|NCT00680784|Placebo Comparator|Placebo Patch|Treatment with placebo patch
3180200|NCT00680849||1|Treatment condition from first study. This is a follow-up study.
3493637|NCT03545256|Other|T1-N0 or T2-N0 cancers of the oral cavity|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search
3493638|NCT03540420|Experimental|Atezolizumab|atezolizumab after completed chemo-radiotherapy and non-progression
3493639|NCT03540420|No Intervention|Observation|standard care after completed chemo-radiotherapy and non-progression
3493640|NCT03538821|Experimental|Intact cod protein from fillet|Dietary supplement: intact cod protein from fillet, 8 g protein daily for 8 weeks
3493641|NCT03538821|Experimental|Intact cod protein from residual material|Dietary supplement: intact cod protein from residual material, 8 g protein daily for 8 weeks
3493642|NCT03538821|Experimental|Control|Control group receive tablet containing fillers and no proteins
3493643|NCT03538652|Placebo Comparator|EMA only|Randomized control group undergoing mobile assessment without JITAI
3493644|NCT03538652|No Intervention|Formative Interviews|First stage, before content of mobile intervention is finalized
3493645|NCT03538652|Active Comparator|JITAI|Group receiving microrandomized active intervention: JITAI with both CBT and ACT
3493646|NCT03538587|Active Comparator|1/EMI Group|Participate in an in-person session followed by a series of at-home assignments, and two booster sessions.
3493647|NCT03538587|Active Comparator|2/Control Group|Participants will briefly meet with a member of the research team who will assess parent and child coping, and provide the child- caregiver dyad educational material about coping with cancer
3493648|NCT03536884|Experimental|Bimekizumab dosage regimen 1|Subjects randomized to this arm will receive bimekizumab dosage regimen 1. At Week 16 subjects will be re-randomized and continue to receive bimekizumab regimen 1 or to switch to bimekizumab regimen 2. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
3493649|NCT03536884|Experimental|Bimekizumab dosage regimen 2|Subjects randomized to this arm will receive bimekizumab dosage regimen 2 starting at Week 16 after initial treatment on bimekizumab regimen 1 for 16 weeks. Placebo will be administered at pre-specified time-points to maintain the blinding over the double-blind Treatment Period. Subjects allowed to enroll in the open-label extension (OLE) Period will receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
3493650|NCT03536884|Active Comparator|Secukinumab|Subjects will receive secukinumab. Subjects allowed to enroll in the open-label extension (OLE) Period will be re-randomized to receive bimekizumab dosage regimen 1 or bimekizumab dosage regimen 2.
3493651|NCT03531814|Experimental|1/Intervention|Questionnaires and use of the medication event monitoring system (MEMS)
3493652|NCT03529344|Active Comparator|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
3493653|NCT03529344|Placebo Comparator|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
3493654|NCT03520660|Experimental|Phase I|Phase I treatment
3493655|NCT03520660|No Intervention|Phase II after Phase I|Participants who achieved SVR12 in Phase I
3493656|NCT03520660|No Intervention|Phase II without Phase I|Participants who achieved SVR 24 previously
3493657|NCT03518034|Active Comparator|Arm A|Participants receiving topical testosterone
3493658|NCT03518034|Placebo Comparator|Arm B|Participants receiving placebo
3129745|NCT03238352|Placebo Comparator|Placebo|Participants will rinse twice daily (morning and evening) with 10 mL of oral rinse for 60 timed seconds and expectorate. No further rinsing with water will be permitted after use of the oral rinse.
3180201|NCT00680849||2|Control condition from first study.
3493659|NCT03517228|Experimental|total laparoscopic or robotic-assisted hysterectomy|All patients who are consented for a total laparoscopic or robotic-assisted hysterectomy will be eligible for the trial, unless the surgeon does not plan to use a uterine manipulator.
3493660|NCT03516279|Experimental|Treatment (pembrolizumab, dasatinib, imatinib, nilotinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and dasatinib, imatinib mesylate, or nilotinib PO as clinically indicated per the treating physician. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients with detectable MRD after course 18 continue pembrolizumab and dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity. Patients with UMRD at any time before course 18 discontinue pembrolizumab after course 18 and continue dasatinib, imatinib mesylate, or nilotinib every 21 days for up to an additional 18 courses in the absence of disease progression or unacceptable toxicity.
3493661|NCT03515083|Experimental|Experimental|"In the experimental group, each patient will be issued an AliveCor Kardia electrocardiogram monitor that is compatible with their smartphone. Patients will be instructed on the use of the monitor at the initial visit with the study nurse. The patient will submit daily electrocardiogram transmission via on online portal. The study nurse may contact them via text message to remind them to submit their recordings, if they forget.~The remainder of the treatment of the experimental group will be identical to the control group. At the conclusion of the study, the patient will complete their final atrial fibrillation symptom assessment scale. Their smartphone electrocardiogram monitor will be reviewed to ensure that all of the recordings were retrieved successfully."
3493662|NCT03515083|No Intervention|Control|"Patients in the control group would receive the standard of care treatment for atrial fibrillation, including cardioversion and ablation as indicated. At monthly visits with the study nurse, a smartphone electrocardiogram monitor will be used to record patient's heart rhythm. No other intervention would be performed during the monthly visit. It is necessary to meet the subject at least once per month to receive the previous month's supply of pills and provide them with the next month's supply of pills. If these subjects were met less frequently, it is possible that the previous month's supply of pills might be lost by the end of the study.~During the study, if the patient is taken off anticoagulation due to medical contraindication or after an ablation, they will continue to be followed monthly but will not receive apixaban medication."
3493663|NCT03510442||adult-onset Still's disease (AOSD)|Composed of patients with known or suspected AOSD as defined by Yamaguchi criteria.
3493664|NCT03510442||family members|Composed of family members of patients with systemic juvenile idiopathic arthritis, adultonset Still's disease and related conditions.
3493665|NCT03510442||healthy volunteers|Composed of healthy adults and children (above the age of 6 years) who volunteer to participate in this protocol.
3180202|NCT00680875|Experimental|Intervention|5th and 6th grade students who attend schools randomly assigned to the intervention condition.
3493666|NCT03510442||related inflammatory conditions|Composed of patients with suspected inflammatory disease as indicated by thepresence of episodic fever and/ or arthritis.
3493667|NCT03510442||systemic juvenile idiopathic arthritis (sJIA)|Composed of patients with known or suspected sJIA as defined by the international league of Associations for Rheumatology (ILAR) criteria
3493668|NCT03509012|Experimental|HNSCC Arm 1|Durvalumab + cisplatin with radiation in patients with locally advanced squamous cell carcinoma of the head and neck (HNSCC)
3493669|NCT03509012|Experimental|NSCLC Arm 1|Durvalumab + cisplatin and etoposide with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
3493670|NCT03509012|Experimental|NSCLC Arm 2|Durvalumab + carboplatin and paclitaxel with radiation in patients with locally advanced, unresectable (Stage III) non-small-cell lung cancer (NSCLC)
3493671|NCT03509012|Experimental|NSCLC Arm 3|Investigator's choice of carboplatin and pemetrexed OR cisplatin and pemetrexed
3493672|NCT03509012|Experimental|SCLC Arm 1|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
3493673|NCT03509012|Experimental|SCLC Arm 2|Patients with limited-stage small-cell lung cancer (SCLC) should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin
3493674|NCT03509012|Experimental|SCLC Arm 3|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin. Note: Arm 3 will only be opened if the regimen in SCLC Arm 1 is safe and tolerable.
3493675|NCT03509012|Experimental|SCLC Arm 4|Patients should start with cisplatin, but if cisplatin is not tolerated, they have the option to switch to carboplatin Note: Arm 4 will only be opened if the regimen in SCLC Arm 2 is safe and tolerable.
3493676|NCT03508739|Experimental|ARM 1: randomization order AB|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order AB). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
3493677|NCT03508739|Experimental|ARM 2: randomization order BA|Subjects will present for a baseline mixed meal study day 1 (no medication). Next they will be randomized to sacubitril/valsartan 200mg po and then valsartan 160 mg po with each medication given on study day 2 and 3, respectively (order BA). At each study day, subjects will present after fasting and receive blinded study medication on study days 2 and 3. After an IV is placed, neprilysin activity will be measured at baseline. Two hours later, subjects will have neprilysin activity collected again as well as baseline insulin, glucose, GLP-1, and triglycerides. Following this, subjects will ingest a mixed meal. Blood samples for insulin, glucose, GLP-1, and triglycerides will be collected after the meal for four hours total. Blood pressure and heart rate will be monitored.
3493678|NCT03494933|Experimental|CRT-P group|Intervention: CRT-P implantation
3493679|NCT03494933|Active Comparator|CRT-D group|Intervention: CRT-D implantation
3493680|NCT03484819|Experimental|Treatment (copanlisib hydrochloride, nivolumab)|Patients receive copanlisib hydrochloride IV over 1 hour on days 1, 8 and 15 of cycles 1-8 and days 1 and 15 of subsequent cycles. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 of cycles 1-8 and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3493681|NCT03481829||Children|Children of mothers enrolled in the study
3493682|NCT03481829||Pregnant women and mothers|Pregnant women/mothers
3493683|NCT03474679|Experimental|Ibrutinib|Participants will receive 420 milligram (mg) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
3132776|NCT03449979|Placebo Comparator|sham stimulation in healthy participants|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.
3132777|NCT03450070|Experimental|Test Panel|Light Therapy Mask Cream
3493684|NCT03473743|Experimental|Phase 1b: Dose Escalation|Two dosing cohorts (erdafitinib and cetrelimab; and erdafitinib, cetrelimab and cisplatin/carboplatin) are explored in Phase 1b of the study. Participants will receive erdafitinib orally followed by cetrelimab intravenously (IV) and carboplatin/cisplatin IV as a part of platinum chemotherapy. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
3493685|NCT03473743|Experimental|Phase 2: Dose Expansion|The participants will be randomized in a 1:1 manner to receive either erdafitinib alone (orally) or the identified RP2D of Phase 1b for erdafitinib (orally) in combination with cetrelimab (IV).
3493686|NCT03473561|Experimental|Racecadotril plus standard treatment oral rehydration solution|Racecadotril Infants Granules for Oral Suspension 10 mg (in addition to standard treatment i.e. oral rehydration solution) Racecadotril Children Granules for Oral Suspension 30 mg (in addition to standard treatment i.e. oral rehydration solution)
3493687|NCT03459534|Experimental|Radotinib HCl|"Enrolled subjects will continue to administer Radotinib 400mg twice daily (800mg/day) orally every 12 hours at regular dosing hours for 12 months.~Dose modification is allowed if the subject cannot comply with the protocol-defined dosing schedule due to hematologic or non-hematologic toxicities and toxicities resolve within 28 days (within 42 days for hematologic toxicities). For radotinib, maximum 2 dose reductions will be allowed by stage to 600mg and to 400mg."
3493688|NCT03458728|Experimental|Dose escalation of BAY806946 in Phase 1|It is estimated that 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Safety and MTD/RP2D dose will be evaluated in 2 age groups (< 1 year old and ≥ 1 year old).
3493689|NCT03458728|Experimental|Patients with Neuroblastoma in Phase 2|Recommended Phase 2 dose (RP2D) for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
3493690|NCT03458728|Experimental|Patients with Osteosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
3493691|NCT03458728|Experimental|Patients with Rhabdomyosarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
3493692|NCT03458728|Experimental|Patients with Ewing sarcoma in Phase 2|RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
3493693|NCT03455517|Experimental|Veritas|"Step 1. All patients: venetoclax 5-weeks dose-titration phase with weekly increases in the dose of venetoclax.~Step 2. All patients will receive 6 courses of the VR combination.~Step 3. After 6 courses of VR combination:~3a. Patients with no response will be off treatment; 3b. Patients with clinical response (CR or PR) after 6 courses of VR combination will receive venetoclax as a single agent for 6 months. Then, patients will be observed clinically until disease progression or until month 36."
3493694|NCT03451851|Experimental|Part 1 Group 1: Guselkumab|Participants in Part 1a (age greater than or equal to (>=) 12 - less than (<) 18 years) will receive a weight-based dose of guselkumab subcutaneously (SC) at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of guselkumab until they lose >=50% of their Week 16 PASI response, then they receive 1 dose guselkumab, followed by a dose 4 weeks later, and every 8 weeks (q8w) thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a placebo injection at Week 16 and continue to receive guselkumab q8w from Week 20 through Week 52. Participants who are eligible and willing to continue guselkumab may enter the Long Term Extension (LTE) and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
3132778|NCT03450083|Active Comparator|Benralizumab treatment group|Benralizumab Active treatment group delivered subcutaneously
3129746|NCT03238417|Experimental|Evidence-Based Quality Improvement (EBQI)|EBQI represents a multilevel stakeholder engaged top-down/bottom-up research-clinical partnership approach to systematically improving the design and implementation of local innovations adapted to local contexts. The EBQI contractor will (1) convene facility-level stakeholder meetings, (2) facilitate local facility-level QI team design meetings, (3) provide external practice facilitation through within and across facility QI collaboration calls, (4) provide formative QI data feedback and (5) provide QI training/education to local teams.
3180203|NCT00680875|No Intervention|Usual Curriculum|5th and 6th grade students attending schools randomly assigned to the usual curriculum control condition.
3180204|NCT00680888||1|Children and adolescents with psychosis in outpatients setting on treatment with quetiapine started from january 2003 to june 2006
3129747|NCT03238417|No Intervention|Waitlist Controls|Waitlist controls will continue naturalistic routine care implementation of VHA directives and other guidance related to comprehensive women's health care.
3493695|NCT03451851|Placebo Comparator|Part 1 Group 2: Placebo for Guselkumab|Participants in Part 1a (age >= 12 - <18 years) will receive placebo for guselkumab administered SC at Weeks 0, 4, and 12. Participants who are PASI 90 responders at Week 16 will not receive any additional doses of study intervention until they lose >=50% of their Week 16 PASI response, at which time they will receive a weight-based guselkumab SC dose, followed by a dose 4 weeks later, and q8w thereafter through Week 52. Participants who are PASI 90 non-responders at Week 16 will receive a weight-based guselkumab dose at Weeks 16 and 20, followed by q8w dosing thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
3493696|NCT03451851|Active Comparator|Part 1 Group 3: Etanercept|Participants in Part 1a (age >= 12 - <18 years) will receive weight-based etanercept dose up to 50 milligram SC weekly through Week 15. Participants who elect to continue in the study will receive a weight-based guselkumab dose at Weeks 20 and 24, followed by q8w dosing thereafter through Week 48. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab until drug approval for pediatric psoriasis or discontinuation of drug development. Part 1b (age >= 6 - <12 years) will follow the same dosing and commence after Part 1a data review.
3493697|NCT03451851|Experimental|Part 2: Guselkumab|Participants will receive a weight-based dose of open-label guselkumab SC at Weeks 0, 4 and q8w thereafter through Week 52. Participants who are eligible and willing to continue guselkumab treatment, may enter the LTE of the study and continue to receive guselkumab at Week 52 and q8w thereafter until drug approval for pediatric psoriasis or discontinuation of drug development.
3493698|NCT03446170|Experimental|Loss-framed, branded|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on branded packages.
3493699|NCT03446170|Experimental|Loss-framed, plain|Participants assigned to this arm use cigarette packs with loss-framed graphic warnings communicating the risks of smoking on plain or standardized packages.
3493700|NCT03446170|Experimental|Gain-framed, branded|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on branded packages.
3493701|NCT03446170|Experimental|Gain-framed, plain|Participants assigned to this arm use cigarette packs with gain-framed graphic warnings communicating the benefits of quitting smoking on plain or standardized packages.
3493702|NCT03446170|No Intervention|Control|Participants assigned to this arm use their regular cigarette packs and complete study measures only.
3493703|NCT03436901|Other|Testicular cancer st. II-III|MRI with DWI vs CT
3493704|NCT03433339|Experimental|Active Treatment|Thoracic anodal transcutaneous spinal direct current stimulation 2.5mA for 20 min/ three times per week for 8 weeks.
3493705|NCT03433339|Sham Comparator|Sham Treatment|Thoracic anodal transcutaneous spinal direct current sham stimulation session of 20min/ three times per week for 8 weeks.
3493706|NCT03428009||Dystonia group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
3129748|NCT03238651|Experimental|Dose Escalation Part Schedule A: TAK-659 60 mg in Cohort 1|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 60 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema . If 60 mg, once daily is safe and tolerable, then the dose will be escalated to 80 mg, once daily and subsequently in 20 mg increments until MTD and/or RP2D is determined. Based on emerging safety, tolerability, PK data, a lower dose will be permitted.
3132779|NCT03450083|Placebo Comparator|Placebo group|Placebo treatment group delivered subcutaneously
3180205|NCT00680940|Active Comparator|Chemotherapy|Paclitaxel + Cisplatin
3493707|NCT03428009||Control Group|Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.
3493708|NCT03422003|Experimental|Arm 1: Hypofractionation|16 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 15 fractions to the supraclavicular (with or without axillary) lymph nodes.
3493709|NCT03422003|Active Comparator|Arm 2: Conventional Radiation Therapy|25 fractions of radiation therapy (daily, Monday through Friday) to the chest wall with or without internal mammary nodes, and 23-25 fractions to the supraclavicular (with or without axillary) lymph nodes.
3493710|NCT03419234|Experimental|Arm A (abiraterone acetate, prednisone, cabazitaxel)|Patients receive abiraterone acetate PO QD on days 1-21, prednisone PO BID on days 1-21. Courses of abiraterone acetate and prednisone repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients receive cabazitaxel IV over 1 hour on day 1, and treatment with cabazitaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
3129749|NCT03238651|Experimental|Dose Escalation Part Schedule B: TAK-659 80 mg in Cohort 1|TAK-659, tablet, orally, once daily as 7 days on and 7 days off treatment (dosing on 7 days followed by 7 days of rest) in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, with a starting dose of 80 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. An alternative intermittent regimen may be evaluated if deemed necessary per the emerging data.
3180206|NCT00680940|Experimental|Chemoimmunotherapy|Paclitaxel + Cisplatin + Mycobacterium w
3180207|NCT00680966|Experimental|TX1|Functional Family Therapy (FFT) followed by Adolescent Coping With Depression (ACWD)
3493711|NCT03419234|Active Comparator|Arm B (abiraterone acetate, prednisone)|Patients receive abiraterone acetate and prednisone as in Arm A. Patients also receive standard of care antiandrogen therapy with either LHRH agonist or antagonist, or surgical castration with bilateral orchiectomy.
3493712|NCT03410407||AML patients|AML patients according to the French-American-British (FAB) criteria, previously enrolled in GIMEMA Studies for AML treatment. AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
3493713|NCT03405311|Active Comparator|Palpation|The control group (Group 2: Epidural) will receive the 'Blind/standard approach', which is the current standard of care using palpation in administering labor epidural analgesia. Additionally, an anesthesiologist will scan patient's back with Accuro device in turn off mode.
3493714|NCT03405311|Experimental|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device.
3493715|NCT03396081|Experimental|PRADO-IC|
3493716|NCT03396081|Other|Usual care|
3493717|NCT03393078|Active Comparator|Real Stimulation|The repetition transcranial magnetic stimulation(rTMS) lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT) . MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
3493718|NCT03393078|Sham Comparator|Sham Stimulation|The procedure of this protocol was performed by a placebo coil, lasted 30 mins and delivered at 1 Hz with 1s duration, a total of 1800 pulses at 110% of the rest motor threshold (RMT). No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first rTMS session and after the last rTMS session.
3493719|NCT03390504|Experimental|Cohort 1 (Arm 1A): Erdafitinib|Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events [AEs]).
3493720|NCT03390504|Experimental|Cohort 1 (Arm 1B): Vinflunine or Docetaxel|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-PD-[L] 1 agent) will receive vinflunine 320 milligram per meter square (mg/m^2) as a 20-minute intravenous infusion once every 3 weeks or docetaxel 75 mg/m^2 as a 1 hour intravenous infusion every 3 weeks. Treatment with either agent (choice of investigator) will be administered until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
3493721|NCT03390504|Experimental|Cohort 2 (Arm 2A): Erdafitinib|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 mg, once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on phosphate level and observed toxicity (AEs).
3493722|NCT03390504|Experimental|Cohort 2 (Arm 2B): Pembrolizumab|Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-[L] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities.
3493723|NCT03388619|Experimental|1/Prostate bed with integrated boost|Dose to prostate bed with integrated boost
3180208|NCT00680966|Experimental|TX 2|ACWD (Adolescent Coping With Depression) followed by FFT (Functional Family Therapy)
3493724|NCT03388619|Experimental|2/Prostate bed irradiation only|Dose to prostate bed irradiation only
3493725|NCT03384654|Experimental|Cohort 1: B-Cell Acute Lymphoblastic Leukemia (ALL)/LL|Cohort 1 will include participants with B cell ALL/LL in second or greater relapse or refractory to at least 2 prior induction regimens. Participant will receive daratumumab in combination with vincristine and prednisone.
3493726|NCT03384654|Experimental|Cohort 2: T-Cell ALL/LL|Cohort 2 will include participants with T-cell ALL/LL in first relapse or refractory to at least 1 prior induction/consolidation regimen. Participant will receive daratumumab in combination with vincristine, prednisone, doxorubicin and peg-asparaginase in Cycle 1 and daratumumab in combination with cyclophosphamide, cytarabine, 6- mercaptopurine and methotrexate in Cycle 2.
3493727|NCT03383679|Experimental|Arm 1 Darolutamide|Darolutamib: 600 mg (2 tablets of 300 mg) twice daily with food (equivalent to a daily dose of 1200 mg) will be administered orally, continuously until disease progression
3493728|NCT03383679|Other|Arm 2 Capecitabine|"according to the 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC3) capecitabine monotherapy is one of the recommended options even in first line (Cardoso et al, 2017).~According to each center policy (minimum 1000 mg/m²) twice daily for 2 weeks followed by 1-week rest period, until progression or unacceptable toxicity"
3493729|NCT03382145||postmenopausal bleeding women|Retrospective review on outcome of One stop Postmenopausal bleeding clinic in New Territorial Eastern Cluster, Hong Kong. Single group study, no intervention.
3493730|NCT03377491|Experimental|NovoTTF-100L(P)|Patients receive TTFields using the NovoTTF-100L(P) System together with gemcitabine and nab-Paclitaxel
3493731|NCT03377491|Active Comparator|Best Standard of Care|Patients receive best standard of care with gemcitabine and nab-Paclitaxel
3493732|NCT03375320|Experimental|Arm I (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3493733|NCT03375320|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3493734|NCT03375307|Experimental|Cohort I (olaparib)|Patients that have cancer-associated DNA-repair gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3129750|NCT03238651|Experimental|Expansion Part: TAK-659 MTD/RP2D|TAK-659, tablet, orally, once daily, in a 28-day treatment cycle until disease progression or unacceptable toxicity in participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL) who are relapsed and/or refractory. Dose and dosing schedule for this part will be MTD/RP2D determined from results of dose escalation part.
3493735|NCT03375307|Experimental|Cohort II (biospecimen collection)|Patients that do not have cancer-associated DNA-repair gene mutations undergo blood sample collection at baseline.
3493736|NCT03367299|Experimental|Chemotherapy + Blinatumomab|Treatment sequence consists of eight chemotherapy courses and two blinatumomab courses. Patients not in CR after chemotherapy course 2 will go off-study.
3493737|NCT03366116|Experimental|1|Aza-TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
3493738|NCT03360396|Experimental|Endobronchial Coils|Treatment with PneumRx Endobronchial Coil System
3493739|NCT03360396|No Intervention|Control|Medically-managed control group
3493740|NCT03350269|Experimental|Intervention|Kidney transplant recipient candidates who are informed that their living donor candidates can receive reimbursement for lost wages incurred during the evaluation, donation surgery and recuperation
3493741|NCT03350269|No Intervention|Control|Kidney transplant recipient candidates who receive standard of care (donors are not offered wage reimbursement)
3493742|NCT03341806|Experimental|Patients with Recurrent Glioblastoma|Part A - Avelumab Part B - Avelumab + MRI-guided LITT therapy
3493743|NCT03333057|Experimental|NOV03 4 times daily (QID)|Perfluorohexyloctance solution 4 times daily (QID)
3129751|NCT03238781|Placebo Comparator|Placebo|Participants randomized to Placebo were administered 6 subcutaneous (SC) injections on day 1 and weeks 2, 4, 6, 8 and 10 during the 12 week double-blind treatment period.
3129752|NCT03238781|Experimental|AMG 301 210 mg Q4W|Participants randomized to AMG 301 210 mg every fourth week (Q4W) received a total of 3 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) plus 3 matching placebo injections on day 1 and weeks 4 and 8. Participants also received 6 SC placebo injections on weeks 2, 6, and 10 during the 12 week double-blind treatment period.
3129753|NCT03238781|Experimental|AMG 301 420 mg Q2W|Participants randomized to AMG 301 420 mg every second week (Q2W) received a total of 6 AMG 301 subcutaneous (SC) injections (70 mg/mL in each injection) on day 1 and weeks 2, 4, 6, 8, and 10 during the 12 week double-blind treatment period.
3129754|NCT03238911|Experimental|Iron isomaltoside/ferric derisomaltose|Administered IV
3129755|NCT03238911|Active Comparator|Ferric carboxymaltose|Administered IV
3129756|NCT03238924|Experimental|Oxytocin|40 IU intranasal oxytocin spray
3129757|NCT03238924|Placebo Comparator|Placebo|Placebo is matching saline nasal spray
3129758|NCT03238963|Experimental|BI 1467335|
3129759|NCT03238963|Placebo Comparator|Placebo|
3129760|NCT03239106|Experimental|open label|All participants will receive Apremilast 30 mg BID.
3493744|NCT03333057|Experimental|NOV03 2 times daily (BID)|Perfluorohexyloctance solution 2 times daily (BID)
3493745|NCT03333057|Placebo Comparator|Placebo 4 times daily (QID)|Saline solution (0.9% sodium chloride solution) 4 times daily (QID)
3493746|NCT03333057|Placebo Comparator|Placebo 2 times daily (BID)|Saline solution (0.9% sodium chloride solution) 2 times daily (BID)
3493747|NCT03331094||surgery with graft|The procedure is to place a metal instrumentation (rods and screws) in contact with the spine to correct the deformity. Added to this is a graft between the vertebrae that will allow a bone bridge of ankylosis making the spine completely rigid.
3493748|NCT03331094||surgery without graft|Adult scoliosis surgery is performed with instrumentation without grafting: the teams use variable stiffness rods made of metal or PEEK.
3493749|NCT03328988|Experimental|Quadratus lumborum block|Single shot bilateral QLB, ropivacaine 75 mg (20 mL) per side, placed under ultrasound control, at the end of surgery. 22 patients will be allocated in this group.
3129761|NCT03239470|Experimental|Cohort 1: 1.0 x 10^8 PolyTregs|A single intravenous infusion of 1.0 x 10^8 PolyTregs will be administered.
3129762|NCT03239470|Experimental|Cohort 2: 2.5x10^8 PolyTregs|A single intravenous infusion of 2.5x10^8 PolyTregs will be administered.
3129763|NCT03239483|Experimental|Dapivirine gel|Participants will receive a single dose of dapivirine gel rectally, followed by 7 daily doses of dapivirine gel to be administered under direct observation in the clinic.
3180209|NCT00680966|Experimental|TX 3|Combination of an augmented FFT and ACWD - Integrated treatment
3493750|NCT03328988|No Intervention|Epidural|"Epidural catheter (placed before anesthesia induction), ropivacaine 75 mg in 50 mL isotonic saline (1,5 mg/mL), induction bolus after surgery 1 mL/10 kg ideal weight and there on continuous infusion 2-8 mL/h according to analgesic need. 22 patients will be allocated in this group.~This is the current standard for postoperative pain relief in cystectomy patients in our hospital"
3493751|NCT03316872|Experimental|Pembrolizumab and Stereotactic Body Radiotherapy (SBRT)|"Pembrolizumab, intravenously, at a dose of 200 mg, once every 3 weeks~SBRT starting Day 2 of Cycle 1 of pembrolizumab treatment, given in 5 fractions over 10-15 days."
3129764|NCT03239483|Placebo Comparator|Placebo gel|Participants will receive a single dose of placebo gel rectally, followed by 7 daily doses of placebo gel to be administered under direct observation in the clinic.
3129765|NCT03239496|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
3129766|NCT03239496|Experimental|Group B|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
3493752|NCT03314272|No Intervention|Sliding scale protocol|"Consists of giving insulin every 30 minutes based on the blood glucose readings as follows:~<150 mg/dl: 0 units of insulin~150-220 mg/dl: 2 units of insulin~201-250 mg/dl: 4 units~251-300 mg/dl: 6 units~301-350 mg/dl: 8 units~351-400 mg/dl: 10 units~> 400 mg/dl: inform the MD on call"
3493753|NCT03314272|Experimental|Space Glucose Control|"Automated protocol consisting of an insulin infusion pump named The Space Glucose Control System.~Intervention:~For glucose measurement, a sample of blood gas will be taken every 30 minutes. Actrapid HM will be used in a 4IU/ ml concentration for infusion in a 50 ml syringe.~The range of glucose will be recorded throughout the intra-operative period. The number of hypoglycemic (<70mg/dl) and hyperglycemic (> 200mg/dl) events will be recorded."
3493754|NCT03305016|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
3493755|NCT03304691||Bandiagara, Mali|Children of both sexes between 6 months and 10 years of age.
3493756|NCT03304691||Yirimadio, Bamako, Mali|Children and adults of both sexes 6 months and older.
3493757|NCT03301532|Experimental|Patients on a ketogenic diet|This is a one arm study were patients will be receiving an oil called triheptanoin. Patients will be consuming triheptanoin 4 times over the course of one day. The triheptanoin oil will take up 45% of their daily calories on the day the day they are taking the oil.
3493758|NCT03301506|Experimental|Seladelpar 5 mg Capsules|
3493759|NCT03301506|Experimental|Seladelpar 10 mg Capsule|
3493760|NCT03301415|Experimental|Confirmed congenital CMV without baseline SNHL|Valganciclovir 16 mg/kg/dose orally twice daily for four months, n=229
3493761|NCT03300336|Experimental|Intervention|Implementation of STRIDE program
3493762|NCT03300336|No Intervention|Usual Care|Pre-implementation before STRIDE program
3493763|NCT03291470|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
3493764|NCT03291470|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
3493765|NCT03291067|Experimental|MT-8554 1mg|
3493766|NCT03291067|Experimental|MT-8554 5mg|
3493767|NCT03291067|Experimental|MT-8554 10mg|
3493768|NCT03291067|Placebo Comparator|Placebo|
3129767|NCT03239496|Experimental|Group C|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 14, 18 & 40 weeks.
3129768|NCT03239496|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
3493769|NCT03290794||Decision to treat with intravitreal aflibercept for wet AMD|Adult patients with a diagnosis of wet AMD, as an indication approved by the local health authorities for use with intravitreal aflibercept.
3129769|NCT03239522|Experimental|All participants receiving treatment|Each participant will receive a single 6 milligram (mg) oral dose of daprodustat on Day 1 of period 1. After approximately 1 hour, participants will receive 50 microgram (µg) of [14C]-GSK1278863 by IV infusion over 1 hour. On Day 1 of period 2, each participant will receive 25 mg [14C]-GSK1278863 as an oral solution.
3129770|NCT03239574|Experimental|MightySat Test group|The subjects will be enrolled into the test group and will receive the MightySat investigational pulse oximeter.
3129771|NCT03239665|Active Comparator|Pharmacist-led Intervention (PHARM)|In the PHARM intervention group, participants will be given a 60-minute formal presentation on vaccine-preventable diseases to address knowledge and beliefs related to zoster, pneumonia, and influenza and to address barriers to receiving vaccination. In several studies, it has been demonstrated that those who believe it is wise to receive vaccinations and those that have discussed vaccination with their healthcare provider are more likely to receive a vaccine.
3129772|NCT03239665|Experimental|Peer-led Intervention (PEER)|A pharmacist will train the peer educators about vaccine-preventable diseases over the course of two didactic sessions. Following this training, a third session will be held to train the peer educators on the script that they will deliver to participants. The script will include the key learning points to be taught by the peer educators to participants about vaccine preventable diseases and vaccination. The script will also include role-play exercises. In the role-play exercises, 3 vaccination-related scenarios (one for each disease- zoster, pneumonia, and influenza) will be delivered to illustrate situations participants might encounter when interacting with healthcare providers or friends/family.
3129773|NCT03239873|Experimental|VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II®|VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
3129774|NCT03239873|Active Comparator|VARIVAX® 2016 Commercial Process + M-M-R II®|VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
3493770|NCT03288207||Mobile Health|African-American female; age of 25-75 years oldMust be overweight or obese (Body Mass Index (BMI) greater than or equal to 25 kg/m^2)Must live in Washington DC Wards (5, 7, or 8)
3493771|NCT03277105|Experimental|Dara SC|Participants will receive a fixed dose of daratumumab as 1800 milligram (mg) subcutaneously (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Unit per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks.
3129775|NCT03240081|Active Comparator|50mcg estradiol cream|Subjects randomized to 50mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
3129776|NCT03240081|Active Comparator|100mcg estradiol cream|Subjects randomized to 100mcg of study medication will be issued a pump that will dispense 0.5gm of cream with each pump
3493772|NCT03277105|Active Comparator|Dara IV|Participants will receive daratumumab for intravenous infusion (Dara IV) 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks on Day 1 in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study. The duration for each cycle is 4 weeks. For Participants still receiving treatment with Dara-IV at the time of Protocol Amendment 4 the duration of infusion may be shortened to a 90-minute infusion or participants will have the option to switch to Dara 1800 mg subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
3493773|NCT03276221|Active Comparator|Abstinent|This group of cannabis users are agree to remain abstinent from cannabis use for 30 days.
3493774|NCT03276221|No Intervention|Monitoring|This group of cannabis users are not asked to change their cannabis use behavior.
3493775|NCT03276221|No Intervention|Non-Users|This is a group of adolescents with little to no cannabis use history and is non-randomized.
3493776|NCT03273907|Experimental|CyPass System|CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery
3493777|NCT03271047|Experimental|Phase 1b / Arm 1A|binimetinib + nivolumab
3129777|NCT03240133|Experimental|Part1: BCX7353 750 mg|
3129778|NCT03240133|Experimental|Part 2: BCX7353 500 mg|
3493778|NCT03271047|Experimental|Phase 1b / Arm 1B|binimetinib + nivolumab + ipilimumab
3493779|NCT03271047|Experimental|Phase 2 / Arm 2A|binimetinib + nivolumab
3493780|NCT03271047|Experimental|Phase 2 / Arm 2B|binimetinib + nivolumab + ipilimumab
3493781|NCT03262610|Experimental|Setmelanotide daily subcutaneous injection|Up to 18 weeks setmelanotide treatment.
3493782|NCT03258593|Experimental|1/ Run In|Durvalumab + Vicineum, escalating doses. Up to 2 dose levels will be evaluated in the first 6 - 12 subjects
3493783|NCT03258593|Experimental|2/ Expansion|Durvalumab + Vicineum, at the MTD. Up to 24 subjects
3493784|NCT03257436|Other|Single Arm|General population who receive a Boston Scientific Resonate family of CRT-D device in accordance with its labeled indication for use.
3493785|NCT03257150|Experimental|Study Treatment|Single arm trial of irreversible electroporation using the NanoKnife system for locally advanced pancreatic ductal adenocarcinoma.
3493786|NCT03253848||Observational (simplified guidelines and support)|Patients receive standard of care treatment for APL. Patients? doctors regularly discuss with an APL expert to identify and mange treatment.
3493787|NCT03248154|No Intervention|Immunocompetent with 2-14% TBSA|Immunocompetent with 2-14% TBSA thermal burn subjects. Does biofilm infection result in conversion of partial-thickness burn wounds to full-thickness?
3493788|NCT03248154|Experimental|Immunocompromised with >=20% TBSA|Immunocompromised patients with large thermal burn >=20% TBSA. Higher bacterial burden with biofilm infection will result in higher rates of graft loss. Does application of a wireless electroceutical dressing (Procellera) lower biofilm burden compared to burn subjects receiving standard of care therapy?
3493789|NCT03248154|No Intervention|Peripheral blood - all subjects|All subjects enrolled in arms 1 and 2. Do children have a more robust innate immune response to prevent biofilm infection?
3493790|NCT03239899|Experimental|Pembrolizumab arm|Pembrolizumab 200mg will be administered as a one-time intravenous infusion over 30 minutes during the treatment phase of the study.
3493791|NCT03234972|Experimental|Arm A: Daratumumab, Velcade, and Dexamethasone (DVd)|Participants will receive daratumumab weekly for the first 3 cycles, every 3 weeks (q3w) on Day 1 of Cycles 4-9 as an intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) or will have the option to switch to daratumumab subcutaneously (SC) on Day 1 of any cycle, and then every 4 weeks (q4w) thereafter, Velcade at a dose of 1.3 milligram per square meter (mg/m^2) subcutaneous (SC) on Days 1, 4, 8 and 11 of each 21-day cycle (up to 8 treatment cycles) and dexamethasone (Dex) orally (PO) at 20 milligram (mg) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the 8 Velcade treatment cycles.
3493792|NCT03234972|Experimental|Arm B: Velcade and Dexamethasone (Vd)|Participants will receive Velcade SC at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle and Dex 20 mg PO on Days 1, 2, 4, 5, 8, 9, 11, 12 (up to 8 cycles). Participants who have sponsor-confirmed disease progression while being treated with Vd or on observation, will be offered the option for treatment with daratumumab monotherapy (16 mg/kg weekly for Cycles 1 and 2, every other week for Cycles 3 to 6, and every 4 weeks for Cycles 7 and onwards until disease progression, unacceptable toxicity, pregnancy, loss of follow-up, withdrawal of consent, or death [each cycle is 28 days]), if recommended by the site investigator.
3493793|NCT03213678|Experimental|Treatment (samotolisib)|Patients receive samotolisib PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unexpected toxicity.
3493794|NCT03212794|Experimental|Experimental|Subjects randomized to the experimental arm will be assigned to a recovery coach.In addition to being linked to a community buprenorphine or methadone treatment program, the recovery coach will work to meet weekly with the subject following discharge from the hospital to provide support.
3493795|NCT03212794|No Intervention|Control|Subjects randomized to the control arm will receive treatment as usual. This means subjects are linked to ongoing outpatient treatment with buprenorphine or methadone.
3493796|NCT03208036|Experimental|TDCS|TDCS offered concurrent with working memory focused cognitive training
3129779|NCT03240133|Experimental|Part 3: BCX7353 250 mg|
3129780|NCT03240133|Placebo Comparator|Parts 1, 2 and 3: placebo|
3129781|NCT03240575|Experimental|Tiotropium + Olodaterol fixed dose combination|
3129782|NCT03240575|Active Comparator|Fluticasone propionate + Salmeterol fixed dose combination|
3129783|NCT03241030|Experimental|Experimental Group|Subjects will receive sucralfate
3129784|NCT03241030|Placebo Comparator|Placebo Group|Subjects will receive a placebo
3129785|NCT03241342|Active Comparator|1 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
3129786|NCT03241342|Active Comparator|3 mg GTx-024|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
3129787|NCT03241342|Placebo Comparator|matching placebo|Study drug will be provided as softgel capsules in blister packaging, labeled and designed to protect study blinding. All subjects will take 2 softgel capsules orally, once daily.
3493797|NCT03208036|Sham Comparator|Sham|Sham stimulation offered concurrent with working memory focused cognitive training
3493798|NCT03187860|Experimental|Non-smoking controls|"Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)"
3493799|NCT03187860|Experimental|Smokers without COPD|"Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture"
3493800|NCT03187860|Experimental|Smokers with COPD|"Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture"
3493801|NCT03187860|Experimental|Severe asthma|"Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture"
3493802|NCT03182907|Experimental|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
3493803|NCT03182907|Placebo Comparator|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose
3493804|NCT03181867|Experimental|Biochemical recurrence (BCR)|18F-DCFPyL PET/CT imaging
3493805|NCT03181867|Experimental|Localized High risk|18F-DCFPyL PET/CT imaging and possible prostatectomy
3493806|NCT03180554|Other|tVNS version 1|Transcutaneous vagus nerve stimulation (tVNS) version 1 will be delivered non-invasively via a portable take-home stimulation device which attaches to the concha of the outer ear. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
3493807|NCT03180554|Other|tVNS version 2|Transcutaneous vagus nerve stimulation (tVNS) version 2 will be delivered non-invasively via a portable take-home stimulation device which attaches to the center of the left ear lobe. Intensity, pulse duration, and frequency is optimised by the participant. Participants will receive a 15-minute stimulation twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
3493808|NCT03180554|Other|MNRB version 1|Motivational nondirective resonance breathing (MNRB) version 1 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a deep breathing session. Participants will practice MNRB version 1 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
3493809|NCT03180554|Other|MNRB version 2|Motivational nondirective resonance breathing (MNRB) version 2 will be delivered via a take-home guided breathing apparatus. Participants will be guided through a paced breathing session. Participants will practice MNRB version 2 for 15-minutes twice a day (once in the morning upon waking and once in the evening before bed) for 2 weeks.
3493810|NCT03176134|Experimental|Cohort 1: Tedizolid phosphate 6 to <12 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
3493811|NCT03176134|Active Comparator|Cohort 1 Comparator: 6 to <12 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
3493812|NCT03176134|Experimental|Cohort 2: Tedizolid phosphate 2 to <6 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
3493813|NCT03176134|Active Comparator|Cohort 2 Comparator: 2 to <6 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
3493814|NCT03176134|Experimental|Cohort 3: Tedizolid phosphate 28 Days to <2 Years|Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to <50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to <30 kg), by IV and/or oral suspension for 6 to 10 days.
3493815|NCT03176134|Active Comparator|Cohort 3: Comparator: 28 Days to <2 Years|Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days
3493816|NCT03176134|Experimental|Cohort 4: Tedizolid phosphate Birth to <28 Days Neonates|Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study covering the age range.
3493817|NCT03176134|Active Comparator|Comparator: Birth to <28 Days (Term and preterm neonates)|Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days
3493818|NCT03171480|Experimental|Monoket pill|Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris[1] and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur,
3493819|NCT03171480|Placebo Comparator|Placebo pill|The pharmacy has compounded an identical appearing placebo
3493820|NCT03164655|Experimental|HAI oxaliplatin combined with I.V. FOLFIRI + target therapy|"HAI oxaliplatin 100 mg/m² on D1~I.V. cetuximab 500 mg/m² or panitumumab 6 mg/kg or bevacizumab 5 mg/kg D1 according to RAS status and prior response/tolerance to systemic induction CT~modified FOLFIRI regimen without fluorouracil bolus~I.V. irinotecan 180 mg/m² D1~I.V. bolus 5-Fluorouracil (5-FU): 0~I.V. leucovorin 400 mg/m² in 2 hours D1~I.V. continuous infusion 5-FU 2400 mg/m² in 46 hours"
3493821|NCT03164655|Active Comparator|conventional systemic CT|"Response to systemic induction CT~Toxicity and duration of the systemic induction CT~RAS status~Current guidelines/standard of care"
3493822|NCT03162627|Experimental|Selumetinib + Olaparib|"Dose Escalation Phase: Participants take both Selumetinib and Olaparib by mouth 2 times each day, about 12 hours apart at the Starting Dose Level. Treatment cycle is 28 days.~When maximum tolerated dose reached, Dose Expansion Phase begins."
3493823|NCT03162627|Experimental|Ovarian Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
3493824|NCT03162627|Experimental|Endometrial Cancer with RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
3493825|NCT03162627|Experimental|Ovarian Cancer-Progression-prior PARP Treatment|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
3493826|NCT03162627|Experimental|Solid Tumors that Harbor Somatic RPA|Dose Expansion Phase: Selumetinib + Olaparib taken at the maximum tolerated dose from Dose Escalation Phase.
3129788|NCT03241368|Other|MRE, Patency Capsule (if needed), CE, and IC|Single-arm study, which includes MRE procedure, Patency Capsule Procedure (if needed), PillCam Crohn's Capsule Endoscopy Procedure and Ileocolonoscopy procedure.
3129789|NCT03241485|Placebo Comparator|Placebo|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal saline.
3129790|NCT03241485|Active Comparator|Intrathecal morphine|60 patients will be randomly assigned to this arm. The patients in this arm will receive intrathecal morphine.
3493827|NCT03160794|Experimental|[18F] DCFPyL PET/MRI|"[18F] DCFPyL PET/MRI scans for patients with recurrent disease after radical prostatectomy and adjuvant/salvage radiotherapy.~Lesions identified through [18F] DCFPyL PET/MRI will be treated with stereotactic ablative radiotherapy (SABR) or surgery."
3493828|NCT03158285|Experimental|Group 1: Guselkumab|Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 100.
3493829|NCT03158285|Experimental|Group 2: Guselkumab and Placebo|Participants will receive SC guselkumab 100 mg at Weeks 0 and 4 then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92, and 100) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88, and 96) to maintain the blind.
3493830|NCT03158285|Experimental|Group 3: Placebo Followed by Guselkumab|Participants will receive SC placebo q4w from Week 0 to Week 20 and will cross over at Week 24 to receive SC guselkumab 100 mg q4w from Week 24 through Week 100.
3493831|NCT03152773|Experimental|1|Open label
3493832|NCT03139370|Experimental|KITE-718|"Phase 1A: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718.~Phase 1 B: Participants will receive cyclophosphamide and fludarabine conditioning chemotherapy followed by the investigational treatment, KITE-718, at a dose selected based on Phase 1A."
3493833|NCT03115424|Placebo Comparator|Sleeve Gastrectomy Placebo|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
3493834|NCT03115424|Active Comparator|Sleeve Gastrectomy Saxenda|Subjects undergoing Sleeve Gastrectomy (SG) will be randomized 1:1 at the time of 3 month visit after bariatric surgery.
3493835|NCT03115424|Sham Comparator|RYGB|Twenty five subjects will be recruited from the Nutrition Clinic at Mayo Clinic Rochester prior to undergoing RYGB surgery.
3493836|NCT03113253|Experimental|Tranexamic Acid|"Patient will receive:~1g of tranexamic acid by slow intravenous injection~1g of tranexamic acid by syringe pump during 8 hours"
3493837|NCT03113253|Placebo Comparator|Placebo|"Patient will receive:~10 mL of 0.9% sodium chloride by slow intravenous injection~48 mL of 0.9% sodium chloride by syringe pump during 8 hours"
3493838|NCT03104517|Experimental|AMDC-USR|AMDC-USR is the study product (autologous muscle derived cells for urinary sphincter repair).
3493839|NCT03104517|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
3493840|NCT03094052|Experimental|Neratinib Monotherapy|Patients will receive up to 240mg neratinib once a day for up to 55 weeks on study. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity
3493841|NCT03094052|Experimental|Neratinib and Trastuzumab|Patients will receive up to 240mg orally while receiving standard of care maintenance adjuvant trastuzumab (duration of maintenance trastuzumab up to the treating physician) for up to 55 weeks . After the completion of trastuzumab maintenance therapy (determined by treating physician), neratinib can continue as monotherapy to complete a maximum of 55 weeks. Neratinib is to be taken continuously in 21-day cycles with no rest between cycles unless related to toxicity
3493842|NCT03074240|Active Comparator|TAPB Group|Compare the instance in the TAPB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing TAPB to anesthetize the abdominal wall.
3493843|NCT03074240|Active Comparator|RSB Group|Compare the instance in the RSB group of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia when undergoing RSB to anesthetize the abdominal wall.
3493844|NCT03073122||TGA Case|Brain MRI, Neurocognitive and psychological testing
3493845|NCT03060473|Experimental|Azithromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 500 mg PO every 8 hours with Azithromycin 1 gm PO once at randomization.
3493846|NCT03060473|Active Comparator|Erythromycin|Ampicillin 2 gm IV every 6 hours followed by amoxicillin 250 mg PO every 8 hours for 5 days with erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
3493847|NCT03051217|Placebo Comparator|Placebo|Placebo subcutaneous (sc) injection every two weeks (Q2W)
3493848|NCT03051217|Experimental|CZP 200 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg at Weeks 0, 2, 4, followed by Certolizumab Pegol subcutaneous (sc) injection 200 mg every two weeks (Q2W) with PBO administered to maintain the blind, starting at Week 6
3493849|NCT03051217|Experimental|CZP 400 mg|Certolizumab Pegol subcutaneous (sc) injection 400 mg every two weeks (Q2W).
3493850|NCT03039296||One side endoscopic rhizotomy|Endoscopic rhizotomy will be provided only on one back side according pain
3129791|NCT03241810|Experimental|Arm A|"Seribantumab~Fulvestrant"
3129792|NCT03241810|Active Comparator|Arm B|"Placebo~Fulvestrant"
3129793|NCT03241862|Experimental|Restylane® Silk|All subjects enrolled in the study will undergo lip rejuvenation treatment with Restylane® Silk.
3180210|NCT00681005|Active Comparator|Rabeprazole|Rabeprazole 1 # qd
3493851|NCT03039296||Both sides endoscopic rhizotomy|Endoscopic rhizotomy will be provided on both back sides according pain
3493852|NCT03032250|Experimental|Group I Supportive Care (Prepare to Care kit)|Caregivers watch introduction video on a DVD over 10 minutes at baseline. Caregivers receive Prepare to Care kit including 8 workbook modules and complete at least 1 module over 30-45 minutes each week. Caregivers also attend interventionist session over 10-30 minutes weekly.
3493853|NCT03032250|Experimental|Group II Control Group|Caregivers received standard of care throughout course of intervention, with option to receive study intervention at end of study
3493854|NCT03027388|Experimental|1/LB100|Treatment with LB100
3493855|NCT03025542|Experimental|Treatment Arm 1|Subjects randomized in this arm will receive a combination of Bimekizumab and Placebo injections.
3493856|NCT03025542|Experimental|Treatment Arm 2|Subjects randomized in this arm will receive Bimekizumab injections.
3493857|NCT03017573|Experimental|Tumor and blood sampling|Patients will have a biopsy or a surgery and blood sampling at different time points.
3493858|NCT03008382|Other|Double-Blind Randomized Drug|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
3493859|NCT03008382|Other|Double-Blind Randomized Placebo|"Participants with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and/or Myofascial Pelvic Pain (MPP) will be randomized to take 8 weeks of Metoprolol Tartrate Oral Tablet or Placebo Oral Tablet, followed by a 4-Week washout period, and then 8 weeks of Placebo or Metoprolol.~This intervention aims at finding if subjects with IC/BPS have higher baseline HR compared to HCs. After 4 weeks baseline, subjects will receive a bottle with capsules containing 25 mg of metoprolol tartrate or placebo distributed in a double-blind manner by each site's investigational pharmacy. Subjects will start at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week, if HR has not decreased below 55 bpm at rest. Subjects will report daily rest HR for the first week. The subjects will then washout for 4 weeks and enter crossover in similar manner."
3493860|NCT02992080|Other|Cystic fibrosis Patients|
3493861|NCT02992080|Other|Patients without fibrosis cystic|
3493862|NCT02992080|Other|Cystic fibrosis Patients (secondary use of samples)|
3493863|NCT02988401|Experimental|Intranasal insulin 20 international units|Subjects will administer 20 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
3493864|NCT02988401|Experimental|Intranasal insulin 10 international units|Subjects will administer 10 I.U. of insulin in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
3493865|NCT02988401|Placebo Comparator|Intranasal saline|Subjects will administer a sterile diluent containing inactive ingredients in the nostrils using a ViaNaseTM controlled particle dispersion nasal device two times/day (BID) for 24 weeks.
3493866|NCT02987530|Experimental|Dolutegravir + Emtricitabine/Tenofovir|Patients will take Dolutegravir 50 mg (= Tivicay, 1 tablet per day) with Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
3493867|NCT02987530|Active Comparator|Darunavir/Cobicistat + Emtricitabine/Ténofovir|Patients will take Darunavir 800 mg / Cobicistat 150 mg (=Rezolsta, 1 tablet per day) + Emtricitabine 200 mg / Ténofovir 245 mg (=Truvada, 1 tablet per day) for 48 weeks
3493868|NCT02986620||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
3493869|NCT02982915|Experimental|Pilot Phase- Cohort A|Single dose of 20 million Longeveron Mesenchymal Stem Cells (LMSCs) will be delivered followed by vaccination with Fluzone High-Dose at 1 week post-infusion.
3493870|NCT02982915|Experimental|Pilot Phase Cohort B & C|Single dose of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) followed by vaccination with Fluzone High-Dose at either 1 week (Cohort B) or 4 weeks (Cohort C) post infusion.
3493871|NCT02982915|Experimental|Double-Blind,Randomized,Placebo Phase|2 cohorts to receive a single infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort A: 30 subjects) or placebo (Cohort B:30 subjects) followed by vaccination with Fluzone High-Dose.
3493872|NCT02965690|Active Comparator|Zimmer Biomet NexGen CR|Patients receive a Zimmer Biomet NexGen Total Knee Replacement
3493873|NCT02965690|Active Comparator|Medacta International GMK Sphere|Patients receive a Medacta International, GMK Sphere Total Knee Replacement
3493874|NCT02964182|Experimental|Arm I (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks."
3493875|NCT02964182|Experimental|Arm II (usual cigarettes, VLNCC, ECIG-Hi, ECIG-Lo)|"PHASE I: Patients smoke their usual cigarettes brand during week 1.~PHASE II: Patients smoke VLNCC cigarettes provided during weeks 2-4.~PHASES III-IV: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks."
3493876|NCT02963025|Other|THE HIGHER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 10 cmH2O with lung recruitment maneuvers
3493877|NCT02963025|Other|THE LOWER PEEP LEVEL|Mechanical ventilation with VT of 5 ml/kg PBW and the level of PEEP at 5 cmH2O without lung recruitment maneuvers
3493878|NCT02958319||Anti P Carb negative RA patients|RA patients negative for antibodies against the carbamylated proteins
3493879|NCT02958319||Anti P Carb positive RA patients|RA patients positive for antibodies against the carbamylated proteins
3493880|NCT02938689|Experimental|Lumbar extension exercise|Exercise education based on Mckenzie lumbar extension exercise for 4 weeks
3493881|NCT02938689|Active Comparator|Lumbar flextion exercise|Exercise education based on Wilillams lumbar flexion exercise for 4 weeks
3493882|NCT02933255|Experimental|Lead-in mCRPC Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F every 2 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo sigmoidoscopies on week 9 and restaging scans on week 12. If no PD, option to continue treatment every 2 weeks until intolerance or progression. Option to extend nivolumab interval to 4 weeks after 1 year
3493883|NCT02933255|Experimental|Neoadjuvant Cohort|PROSTVAC-V on week 0 followed by booster injection called PROSTVAC-F on 2, 4 and 8 weeks. When administered on the same day, the preferred order of administration is PROSTVAC first followed by nivolumab. Participants will undergo prostatectomy on week 9.
3493884|NCT02929069|Experimental|ESTEEM|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive ESTEEM. ESTEEM is a 10-session intervention based on the Unified Protocol,an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
3493885|NCT02929069|Active Comparator|Community Mental Health Treatment (CMHT)|Participants in all arms will receive Voluntary Counselling and Testing (VCT). Participants randomized to this arm will receive Community Mental Health Treatment (CMHT). CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
3493886|NCT02929069|Active Comparator|Voluntary Counselling and Testing (VCT)|Participants randomized to the VCT only arm will not receive any further intervention. VCT will be based on on CDC guidelines and the control arms of large community-based RCTs (e.g., Projects RESPECT, EXPLORE, AWARE). VCT will consist of one 45-minute session given that 1-session VCT is as effective as 2-session VCT for GBM.
3180211|NCT00681005|Active Comparator|pantoprazole|Pantoprazole 1# qd
3180212|NCT00681018|Experimental|1|Liquid human milk fortifier
3129794|NCT03241927|Experimental|Pembrolizumab|200 mg IV infusion every 3 weeks
3180213|NCT00681018|Active Comparator|2|Powder human milk fortifier
3493887|NCT02923570|Experimental|Photon intensity modulated radiation therapy (IMRT)|IMRT to standard dose of 60-66Gy
3493888|NCT02923570|Experimental|Proton beam radiotherapy (PBRT)|PBRT to standard dose of 60-66Gy
3493889|NCT02912559|Experimental|Arm I (combination chemotherapy, atezolizumab)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive atezolizumab IV over 30-60 minutes starting on day 1 of cycle 1 or 2. Treatment repeats every 14 days for up to 25 cycles in the absence of disease progression or unacceptable toxicity.
3493890|NCT02912559|Active Comparator|Arm II (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV as a bolus on day 1, then continuously over 46 hours on days 1-3. Treatment repeats every 14 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3493891|NCT02909868|Experimental|RV location|All included subjects will undergo the PV loop test with 'BackBeat PHC' ON and OFF
3493892|NCT02907398||ADHERE|This group will include 250 patients who have been implanted with the Inspire therapy system, enrolled in the ADHERE Registry, and are willing to complete a follow-up home sleep apnea test (HSAT).
3493893|NCT02907398||CONTROL|This group will include 100 patients who have been denied insurance coverage of the Inspire therapy system implant by their provider, have had no intervention (Inspire), and are willing to complete a HSAT and provide information about their OSA treatment after denial.
3493894|NCT02902250|Experimental|Decompression|bone marrow decompression at fractured vertebral body
3493895|NCT02902250|Active Comparator|vertebroplasty|vertebroplasty for compression fracture
3493896|NCT02889809|Experimental|Fluticasone furoate 50 mcg|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled FF 50 mcg administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >= 6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
3493897|NCT02889809|Placebo Comparator|Placebo|During run-in period, subjects will receive inhaled placebo for 16 weeks using ELLIPTA inhaler. Followed by treatment period where subjects will receive inhaled placebo administered once daily in the morning for 52 weeks using ELLIPTA inhaler. Subjects will also receive open-label montelukast (4 milligrams [mg] for subjects who are 5 years old and 5 mg for subjects who are >=6 years old) to be administered as one tablet of montelukast each evening for the duration of the study. Each subject will receive a SABA (albuterol/salbutamol [inhalation aerosol or nebuliser]) to be used as needed throughout the entire study period as rescue medication for symptomatic relief of asthma symptoms.
3493898|NCT02884648|Experimental|Bevacizumab|Participants receive Bevacizumab by vein on Day 1 of every 21-day study cycle, for as long as study doctor thinks it is in participant's best interest.
3493899|NCT02881814|Experimental|Lung ultrasound and clinical decision|Clinical assessment and choice of chest physiotherapy treatmetn performed by the clinical physiotherapist, followed by a comprehensive lung and diaphragm ultrasonography. After ultrasonography, the clinical physiotherapist is asked what CPT treatment he was going finally to implement, and explain the reasons for change, if any.
3493900|NCT02881814|Experimental|Mechanically ventilated patients|In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
3493901|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|"For patients whose clinician is randomized to the decision aid arm:~The study coordinator will provide the decision aid for the parent/clinician dyad.~The study coordinator will provide a color-printed copy of the decision aid to the clinician prior to the clinician having the antibiotics discussion with the parents.~The study coordinator will offer to provide the treating clinician a concise refresher of the content included in the decision aid in the context of the trial.~The clinician will then, using the decision aid as a tool to facilitate discussion regarding the natural course of AOM, pain control, antibiotics exposure and deeper infections.~The clinician will then engage the parents in a shared decision regarding the use of immediate antibiotics versus a wait and watch prescription that is consistent with both the parent's values and preferences and the clinician's level of comfort."
3129795|NCT03241927|No Intervention|Healthy Donors|
3129796|NCT03242018|Placebo Comparator|Placebo|Following a 2-week run-in phase, participants received two placebo tablets (identical to sotagliflozin 200 milligrams [mg] in appearance) orally once daily for up to 56 weeks.
3129797|NCT03242018|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in phase, participants received two tablets, one sotagliflozin 200 mg tablet and one placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily for up to 56 weeks.
3129798|NCT03242018|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in phase, participants received sotagliflozin 400 mg, administered as 2 sotagliflozin 200 mg tablets, orally once daily for up to 56 weeks.
3493902|NCT02872558|Other|Usual Care|the clinician will discuss management options with the parent in the clinician's usual fashion.
3493903|NCT02859558|Experimental|Arm 1: Fiebig I/II|Participants enrolled during Fiebig stages I or II (non-reactive HIV-1 antibody).
3129799|NCT03242148|Experimental|Toffee Nasal Pillows Mask|Participants will be placed on this arm for a total of 14 +- 5 days from visit 2. participants will be using the Toffee mask during this treatment arm
3129800|NCT03242252|Placebo Comparator|Placebo|Following a 2-week run-in period, participants received two placebo tablets (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 54 weeks.
3129801|NCT03242252|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, participants received two tablets, 1 sotagliflozin 200 mg tablet and 1 placebo tablet (identical to sotagliflozin 200 mg in appearance), orally once daily, before the first meal of the day for up to 58 weeks.
3493904|NCT02859558|Experimental|Arm 2: Fiebig III/IV|Participants enrolled during Fiebig stages III or IV (reactive HIV-1 antibody and negative or indeterminate results on the Western blot or Geenius HIV-1/HIV-2).
3129802|NCT03242252|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, participants received sotagliflozin 400 mg, administered as two 200 mg sotagliflozin tablets, orally once daily, before the first meal of the day for up to 60 weeks.
3129803|NCT03242408|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 150 mg TU three times a day
3493905|NCT02859558|Experimental|Arm 3: Fiebig V|Participants enrolled during Fiebig stage V (reactive HIV-1 antibody and positive Western blot or Geenius HIV-1/HIV-2 without p31 band).
3493906|NCT02849587|Placebo Comparator|Placebo Cannabis|Subjects will smoke cannabis with placebo THC (.02%) ad libitum
3493907|NCT02849587|Experimental|Cannabis with 5.9% THC|Subjects will smoke cannabis cigarettes with 5.9% THC ad libitum
3493908|NCT02849587|Experimental|Cannabis with 13.4% THC|Subjects will smoke cannabis cigarettes with 13.4% THC ad libitum
3493909|NCT02839551|Experimental|Simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
3493910|NCT02837445|Active Comparator|Treatment|Eligible patients randomized after optimization phase to PHC ON for 6 months Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
3493911|NCT02837445|Placebo Comparator|Control|Eligible patients randomized after optimization phase to pacemaker only (PHC OFF) for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
3129804|NCT03242434|Other|Healthy controls|Approximately 15 healthy participants of age 18 years or above will be included in the study and will receive STM intermittently via oral route. The total duration of study for healthy participants will be approximately 2 weeks.
3129805|NCT03242434|Other|Thermal injury participants|Approximately 25 thermally injured participants having TBSA more than or equal to 15 percent and who are co-consented to the SIFTI-2 and HESTIA studies will be included in the study and will receive STM intermittently via oral route. The total duration of study for thermal injury participants will be approximately 6 months.
3129806|NCT03242590|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate, LPCN 1021 225 mg TU two times a day.
3129807|NCT03242759||patients with idiopathic pulmonary fibrosis (IPF)|
3129808|NCT03242863|Experimental|Control|Baseline proportions of high and low energy dense foods.
3129809|NCT03242863|Experimental|Addition|Increased portion of low energy dense foods.
3129810|NCT03242863|Experimental|Substitution|Increased portion of low energy dense foods substituted for equal portion of foods higher in energy density.
3129811|NCT03242928|Placebo Comparator|Placebo|Matching tablet of placebo taken orally BID
3180214|NCT00681070|Active Comparator|Arm1: Non-absorbable sutures|use of non-absorbable sutures in facial laceration in this arm
3493912|NCT02835911||Lymphoma|Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
3493913|NCT02835443|Experimental|Electrical Stimulation|This is a single arm study and all subjects will receive electrical stimulation.
3493914|NCT02823730||Synergy Stent Cohort|Retrospective registry of 500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
3493915|NCT02823730||Xience V Cohort|500 patients that are propensity matched to the 500 patients that underwent PCI with a Synergy stent, eligible for similar time points of follow-up following the PCI.
3493916|NCT02821767||1|Individuals with various diagnosed and undiagnosed ocular conditions
3493917|NCT02818023|Experimental|Pembrolizumab plus vemurafenib and Cobimetinib|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ), and vemurafenib/cobimetinib will be given at 480 mg twice daily/20 mg daily, 720 mg twice daily/40 mg daily, or 960 mg twice daily/60 mg daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
3493918|NCT02815540|Other|Observational|This study looks at participants already receiving CBD from the state of MN. We are not providing the CBD. We are looking at heart function with ECGs and Holter monitoring before and after CBD is taken by the participant. We are also looking at dysautonomia signs and symptoms and seizure frequency before and after CBD is taken by the participant.
3493919|NCT02814708|Experimental|Dose Group 1|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 1
3493920|NCT02814708|Experimental|Dose Group 2|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 2
3493921|NCT02814708|Experimental|Dose Group 3|rTSST-1 Variant Candidate Vaccine 10µg Number of Immunizations: 3
3493922|NCT02814708|Experimental|Dose Group 4|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 1
3493923|NCT02814708|Experimental|Dose Group 5|rTSST-1 Variant Candidate Vaccine 100µg Number of Immunizations: 2
3493924|NCT02814708|Experimental|Dose Group 6|rTSST-1 Variant Candidate Vaccine 100 µg Number of Immunizations: 3
3493925|NCT02814708|Placebo Comparator|Dose Group 7|Al(OH)3 Adjuvant, 1mg Number of Immunizations: 3
3493926|NCT02808572|Experimental|Cardiovascular risk evaluation|Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
3493927|NCT02785224||Vasopressin Steroids Epinephrine (VSE)|Patients with in-hospital cardiac arrest treated with vasopressin, methylprednisolone, and epinephrine during cardiopulmonary resuscitation, and also with stress-dose hydrocortisone for postresuscitation shock.
3493928|NCT02785224||Control|Patients with in-hospital cardiac arrest treated with normal saline placebo, normal saline placebo, and epinephrine during cardiopulmonary resuscitation, and also with normal saline placebo for postresuscitation shock.
3493929|NCT02784210|Experimental|Methylprednisolone|3 day course of intravenous methylprednisolone 1000 mg/day
3493930|NCT02784210|Experimental|prednisone|3-day course of oral prednisone 1250 mg/day
3493931|NCT02781883|Experimental|Untreated AML|BP1001 in combination with Ventoclax plus decitabine
3493932|NCT02781883|Experimental|Refractory/Relapsed AML|BP1001 in combination with Ventoclax plus decitabine
3129812|NCT03242928|Experimental|AFQ056|Mavoglurant was up titrated on a bid regimen followed by fixed-dose bid regimen: 50 mg bid from Day 1 to Day 7, 100 mg bid from Day 8 to Day 14, and then fixed-dose 200 mg bid for 84 days
3129813|NCT03242941|Experimental|Persistent and Paroxtmal AF Patients|Patients with either paroxymal or persistent AF already referred to the center for Pulmonary Vein Ablation will be stimulated delivering a novel dual-stage pacing protocol to terminate atrial fibrillation usinf a ring of electrodes positioned on the septum.
3493933|NCT02781883|Experimental|Refractory/Relapsed AML (ventoclax-intolerant or resistant)|BP1001 + decitabine combination in patients who are resistant or intolerant of venetoclax-based treatment, or considered not optimal candidates for a venetoclax-based therapy.
3493934|NCT02781727|Experimental|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
3493935|NCT02781727|Active Comparator|human growth hormone (Genotropin)|Once daily subcutaneous injection of Genotropin
3493936|NCT02780583|Placebo Comparator|placebo|methylprednisolone intravenously, placebo shots every 6 hours
3493937|NCT02780583|Experimental|anakinra (Kineret)|methylprednisolone intravenously, anakinra shots every 6 hours
3493938|NCT02778204|Experimental|Cohort 1 Stratum 1A|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; without in utero exposure to maternal efavirenz.
3493939|NCT02778204|Experimental|Cohort 1 Stratum 1B|Infants in this cohort received a single dose of 8 mg/kg maraviroc solution within 3 days of birth and at Week 1 (7-14 days) of life; with in utero exposure to maternal efavirenz.
3493940|NCT02778204|Experimental|Cohort 2 Stratum 2A|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; without in utero or breast milk exposure to maternal efavirenz.
3493941|NCT02778204|Experimental|Cohort 2 Stratum 2B|Infants in this cohort received 8 mg/kg maraviroc solution twice daily starting within 3 days of birth and continuing up to Week 6 (35-42) days of life; with in utero and breast milk exposure to maternal efavirenz
3493942|NCT02755584||Healthy Volunteers|between the ages of 20-39 years and 70 years old and older
3493943|NCT02750865|No Intervention|Control Usual Care|In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
3493944|NCT02750865|Experimental|Embodied Conversational Agent (ECA)|In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment.
3493945|NCT02745002|Experimental|navigated bronchoscopy|
3493946|NCT02743364|Experimental|Arm I (simvastatin)|Patients receive simvastatin PO QD for 6 months.
3493947|NCT02743364|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
3129814|NCT03242954|Active Comparator|Adolescents: Consent Condition 1|Autonomous minor consent
3129815|NCT03242954|Active Comparator|Adolescents: Consent Condition 2|Adult permission required
3129816|NCT03242954|Active Comparator|Adolescents: Consent Condition 3|Parental permission required
3129817|NCT03242954|Active Comparator|Parents: Consent Conditions 1-3|Autonomous minor consent, adult permission required, and parental permission required
3493948|NCT02741440||Affected Participants|Twenty-five (25) participants with molecularly-confirmed SCA7
3493949|NCT02725853|Experimental|tDCS + personalized practice|Transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
3493950|NCT02725853|Active Comparator|tDCS + non-personalized practice|Transcranial direct current stimulation and non-personalized arm motor training spanning both active control and spasticity zones, 1 hour per day, 5 days per week for 2 weeks
3129818|NCT03243084|Sham Comparator|Sham tACS|Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.
3129819|NCT03243084|Active Comparator|Active 10 Hz tACS|Participants will receive 2mA of alternating current stimulation at a frequency of 10Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
3493951|NCT02725853|Sham Comparator|sham tDCS + personalized practice|Sham transcranial direct current stimulation and personalized arm motor training limited to active control zones, 1 hour per day, 5 days per week for 2 weeks
3493952|NCT02706639||SVAS group|Children or adults must:be between the ages of 0-85; have clinical features of SVAS; SVAS-like condition; have genetic testing results that imply affected status (SVAS has decreased penetrance)
3493953|NCT02706639||WS group|Children or adults must: be between the ages of 0 and 85 have a presumed or confirmed diagnosis of WS; have a parent/guardian available to provide consent and assist in answering medical questions
3493954|NCT02701907|Other|breast cancer|In this study, we aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. We will focus our analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
3493955|NCT02701907|Other|non-small cell lung cancer|"In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies.~The investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed"
3493956|NCT02701907|Other|kidney cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
3493957|NCT02701907|Other|colorectal cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
3493958|NCT02701907|Other|ovarian cancer|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
3493959|NCT02701907|Other|skin cutaneous melanoma|In this study, the investigators aim to assess whether tumors characterized by a low level of genomic alterations (mutation, amplification or deletion) are associated with unexpected and exceptional responses across targeted anticancer therapies. the investigators will focus analyses on tumor types for which molecular targeted anticancer agents are frequently prescribed
3493960|NCT02699606|Experimental|Erdafitinib|Participants will receive a 8 milligram (mg) starting dose once daily with option to up-titrate to 9 mg on a 28-day cycle. The dose of study drug may be modified, delayed, or terminated based on guidelines provided in the protocol.
3493961|NCT02692924||NICHD Fetal Growth Studies Singletons and NICHD Fetal Growth Studies Dichor|Analysis of stored ultrasound data collected from the NICHD Fetal Growth Studies - Singletons and NICHD Fetal Growth Studies - Dichoronic Twins
3493962|NCT02677896|Experimental|Enzalutamide + Androgen Deprivation Therapy (ADT)|Participants received enzalutamide orally once daily. ADT (either bilateral orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
3493963|NCT02677896|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants received matching placebo orally once daily. ADT (either bilateral orchiectomy or LHRH agonist/antagonist) was maintained during study treatment as per standard of care and provided by the site's pharmacy stock.
3493964|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 40mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
3493965|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 600mg + Cobi 40mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
3493966|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 800mg + Cobi 40mg)|Participants received Venetoclax 800mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 40mg daily on Days 1-21 of each 28-day treatment cycle.
3493967|NCT02670044|Experimental|Dose Escalation: Arm A (Venetoclax 400mg + Cobi 60mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Cobimetinib 60mg daily on Days 1-21 of each 28-day treatment cycle.
3493968|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 200mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
3493969|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 150mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
3493970|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 600mg + Ida 200mg)|Participants received Venetoclax 600mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 200mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
3493971|NCT02670044|Experimental|Dose Escalation: Arm B (Venetoclax 400mg + Ida 400mg)|Participants received Venetoclax 400mg daily on Days 1-28 of each 28 day treatment cycle and Idasanutlin 400mg daily or twice daily on Days 1-5 of each 28 day treatment cycle.
3493972|NCT02670044|Experimental|Dose Optimisation: Arm B (Ven 600mg (Day 1 to 21) + Ida 150mg)|Participants received Venetoclax 600mg daily on Days 1-21 of each 28 day treatment cycle and Idasanutlin 150mg daily on Days 1-5 of each 28 day treatment cycle.
3493973|NCT02669251|Experimental|Phase 1b|Phase Ib dose escalation
3493974|NCT02669251|Experimental|Phase 2|MTD po bid on days 1-28
3129820|NCT03243305|Experimental|Interventional|This is a single-arm, open-label, Phase III study of AMPHORA , a non-hormonal contraceptive, at approximately 100 sites in the United States (US) over seven cycles of use in women aged 18 to 35 years who are at risk of pregnancy.
3493975|NCT02648997|Experimental|Cohort 1 (original cohort): Nivolumab Monotherapy|Nivolumab monotherapy (240 mg every 2 weeks)
3493976|NCT02648997|Experimental|Cohort 2: Nivolumab in Combination with Ipilimumab|"External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy)~Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks)~Followed by Nivolumab monotherapy (480 mg every 4 weeks)."
3493977|NCT02640664|Experimental|Ranibizumab 0.1 mg|Ranibizumab 0.1 mg
3129821|NCT03243630|Placebo Comparator|Menthol e-liquid|Menthol Flavor + IV saline Menthol Flavor + IV nicotine (0.25mg/70kg) Menthol Flavor + IV nicotine (0.5mg/70kg)
3129822|NCT03243630|Active Comparator|green apple e-liquid|Green apple + IV saline Green apple + IV nicotine (0.25mg/70kg) Green apple + IV nicotine (0.5mg/70kg)
3129823|NCT03243630|Active Comparator|green apple and menthol e-liquid|Green apple and menthol + IV saline Green apple and menthol + IV nicotine (0.25mg/70kg) Green apple and menthol + IV nicotine (0.5mg/70kg)
3493978|NCT02640664|Experimental|Ranibizumab 0.2 mg|Ranibizumab 0.2 mg
3129824|NCT03243981|Experimental|Open label study-- single arm|All patients will receive Skintyte treatment as well as Skintyte plus broadband light
3493979|NCT02640664|No Intervention|Laser therapy|Laser therapy
3493980|NCT02639780||healthy young female|
3129825|NCT03244618|Experimental|CSSP Toothpaste|Toothpaste containing Calcium Silicate and Sodium Phosphate
3129826|NCT03244618|Placebo Comparator|Fluoride Toothpaste|Toothpaste containing Sodium monofluorphosphate
3493981|NCT02639780||healthy young male|
3493982|NCT02639780||healthy older female|
3493983|NCT02639780||healthy older male|
3493984|NCT02639780||obese older female|
3493985|NCT02639780||obese older male|
3129827|NCT03244800|Placebo Comparator|Placebo Cohort 1|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
3129828|NCT03244800|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 7 days, followed by Dose 2 for 7 days, Dose 3 for 7 days, and Dose 4 for 28 days
3493986|NCT02639325||Patients|Patients who have solitary primary or recurrent brain tumor with associated seizures.
3493987|NCT02639299||Healthy volunteer|healthy, malaria-na(SqrRoot) ve US adults
3493988|NCT02639273|Experimental|Drug|single dose nalmefene
3493989|NCT02639273|Placebo Comparator|Placebo|single dose placebo
3493990|NCT02632721|Experimental|Dose Escalation Cohorts (Phase I)|Combination treatment of decitabine with escalating doses of BI 836858
3493991|NCT02632721|Experimental|Extension Cohorts (Phase I)|Combination treatment of decitabine with BI 836858 at MDT (Maximum Tolerated Dose)
3493992|NCT02632721|Experimental|Arm 1 (Phase II)|Combination treatment of decitabine with BI 836858 at R2PD (Recommended Phase II dose)
3493993|NCT02632721|Other|Arm 2 (Phase II)|Monotherapy treatment with decitabine (standard of care treatment)
3493994|NCT02625441|Experimental|Short anti-HER2 treatment|Pertuzumab 840 mg, i.v., then 420 mg i.v., 3-weekly for 3 cycles; Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles
3493995|NCT02625441|Active Comparator|Standard anti-HER2 treatment|Trastuzumab 8 mg/kg, i.v., then 6 mg/kg, 3-weekly for 3 cycles; Docetaxel 75 mg/m2, i.v., 3-weekly for 3 cycles; Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
3493996|NCT02617966||Affected|Participants with retinal disease
3493997|NCT02617966||Unaffected|Healthy volunteers
3493998|NCT02610465||1|Computed Tomography (CT) images
3493999|NCT02609776|Experimental|Part 1:Amivantamab Monotherapy+Combination Dose Escalations|The first cohort of participants will receive intravenous (IV) infusions of Amivantamab 140 milligram (mg) as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level. Dose escalation will continue until maximum tolerated dose is reached or all planned doses are administered. Participants will receive IV infusion of Amivantamab once weekly during cycle 1 and once every 2 weeks during subsequent cycles (duration of each treatment cycle is 28 days). Participants will receive lazertinib and Amivantamab on Cycle 1 Day 1 (C1D1) prior to initiation of Amivantamab (C1D1) at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily thereafter, on 28-day Amivantamab treatment cycle. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with standard of care carboplatin and pemetrexed.
3494000|NCT02609776|Experimental|Part 2:Amivantamab Monotherapy+Combination Dose Expansion|Participants will receive IV infusion of Amivantamab as monotherapy at Phase 2 dose (RP2D) regimen or in combination lazertinib at the recommended Phase 2 combination dose (RP2CD) regimen as determined in Part 1. The purpose of dose expansion is to further evaluate safety, tolerability, pharmacokinetic, and to assess preliminary efficacy in monotherapy and combination therapy cohorts.
3494001|NCT02575794|Experimental|Treatment (terameprocol)|"Patients receive terameprocol PO QD on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Pharmacological Study"
3494002|NCT02564991||Healthy Controls|125 non-substance abusing controls (NSAC)
3494003|NCT02564991||Individuals with Alcohol Use Disorder|This group includes individuals who enrolled NIAAA alcohol treatment.
3494004|NCT02564978|Experimental|Minocycline|Oral administration of minocycline.
3494005|NCT02564380|Experimental|Arm A: Pembrolizumab|Pembrolizumab 200 mg every three weeks until disease progression (maximum 2 years)
3494006|NCT02564380|Placebo Comparator|Arm B: Placebo|Placebo i.v. every three weeks until disease progression (maximum 2 years)
3494007|NCT02560298|Experimental|Arm A (cisplatin, fluorouracil or capecitabine)|Patients receive cisplatin IV over 1-4 hours on day 1 and fluorouracil IV continuously over 24 hours on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients with complications associated with the central venous access which prevent further infusion of fluorouracil and only after discussion with the Chief Investigator receive capecitabine BID on days 1-4.
3494008|NCT02560298|Experimental|Arm B (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3494009|NCT02551991|Experimental|nal-IRI + 5-FU/LV + oxaliplatin|
3494010|NCT02547493|Active Comparator|pneumococcal polysaccharide vaccine|Patients are vaccinated vith Peumo23/Pneumovax on the first day. Abatacept started on frst day.
3494011|NCT02547493|Active Comparator|pneumococcal conjugate vaccine|"Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.~Abatacept started on frst day."
3494012|NCT02545517|Experimental|Conv-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 and JE primary series regimen on days 1 and 29 in the parent study V49_23 were enrolled in the Conv-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
3494013|NCT02545517|Experimental|Acc-R/JE Group|Subjects who completed the Rabies PrEP regimen on days 1, 4 and 8 and JE primary series regimen on days 1 and 8 in the parent study V49_23 were enrolled in the Acc-R/JE Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
3494014|NCT02545517|Experimental|Conv-R Group|Subjects who completed the Rabies PrEP regimen on days 1,8 and 29 in the parent study V49_23 were enrolled into the Conv-R Group and received a single booster dose of the PCEC rabies vaccine in this extension study.
3129829|NCT03244800|Placebo Comparator|PLacebo Cohort 2|Participants will receive placebo matching with MEDI0382 subcutaneously once daily for 49 days.
3494015|NCT02544022||1/Phase 1 Focus Group|Patients with NF1 who have PNs and report experiencing PN related pain and parents of these patients. (completed)
3494016|NCT02544022||2/Phase 1 Patients|Patients with NF1 who have PNs
3494017|NCT02544022||3/Phase 1 Parent|Parents of patients in cohort 2
3494018|NCT02544022||4/Phase 2 Patients|Patients with NF1 who have PNs
3180215|NCT00681070|Active Comparator|Arm 2: Absorbable sutures|use of absorbable sutures in this arm
3494019|NCT02544022||5/Phase 2 Parents|Parents of patients enrolled in cohort 4
3494020|NCT02544009||1|16 subjects who previously participated in the Biggest Loser study
3180216|NCT00681122||1|Standard therapy
3494021|NCT02543983|Experimental|1|Participants will be administered open-label intravenous ketamine.
3494022|NCT02537613|Experimental|Arm A- obinutuzumab -> ibrutinib|Participants enrolled in Arm A will receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6. Participants will begin to take ibrutinib daily starting cycle 2 and will continue with daily ibrutinib until the end of treatment.
3494023|NCT02537613|Experimental|Arm B- ibrutinib -> obinutuzumab|Participants enrolled in Arm B will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. Participants will begin to receive obinutuzumab weekly starting cycle 2, and will receive obinutuzumab monthly during cycles 3-7
3494024|NCT02537613|Experimental|Arm C- obinutuzumab/ibrutinib|Participants enrolled in Arm C will begin to take ibrutinib daily starting cycle 1 and will continue with daily ibrutinib until the end of treatment. At the same time, participants will begin to receive obinutuzumab weekly starting cycle 1, and will receive obinutuzumab monthly during cycles 2-6.
3494025|NCT02531893||Irritable youth|Participants meet full DMDD criteria for IBT and either full DMDD or one of two core DMDD criteria for CBT.
3494026|NCT02531516|Experimental|Apalutamide|Participants will receive apalutamide (240 mg), by mouth, once daily for overall 30 months, plus bicalutamide placebo, by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
3494027|NCT02531516|Active Comparator|Control group|Participants will receive apalutamide placebo, by mouth, once daily for overall 30 months, plus bicalutamide (50 mg), by mouth, once daily, for four months from randomization. All participants are treated with gonadotropin releasing hormone (GnRH) agonist for 30 months from randomization and radiation therapy to the prostate started at about 8 weeks after randomization.
3494028|NCT02525432|Experimental|Autologous BMMNC Infusion|Subjects randomized to the treatment group will undergo a bone marrow harvest and then receive an autologous infusion of BMMNC's starting with the lowest dose (6 x 10^6 cells/kg body weight) and progressing to the high dose of 9 x 10^6 cells/kg body weight using a Bayesian adaptive dose escalation design.
3494029|NCT02525432|Placebo Comparator|Placebo Infusion|"Subjects randomized to the placebo control group will undergo a sham bone marrow harvest."
3494030|NCT02520609||Healthy volunteers|Healthy volunteers
3494031|NCT02520609||Patients with metabolic syndrome without NAFLD|Patients with metabolic syndrome without NAFLD
3494032|NCT02520609||Patients with NAFLD|Patients with NAFLD
3494033|NCT02511028|Experimental|ferumoxytol|A 510 mg dose (17 mL) of ferumoxytol diluted in 50 mL of 0.9% normal saline will be intravenously infused over 17 minutes
3494034|NCT02511002||1|Post influenza infection
3494035|NCT02501226|Other|Control group|Treatment as usual
3494036|NCT02501226|Experimental|Interventional group|ENVIE psychoeducational program
3494037|NCT02496611|Placebo Comparator|Weight Loss Maintenance without Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve ≥5% BMI reduction. A selection of these participants are then randomized to receive treatment with placebo.
3494038|NCT02496611|Active Comparator|Weight Loss Maintenance with Pharmacotherapy|Individuals who, after a short-term (1-3 month) meal replacement induction period, achieve a >/= 5% BMI reduction. A selection of these participants are then randomized to receive treatment with GLP-1RA.
3494039|NCT02476097|Placebo Comparator|Sudden discontinuation|placebo for 7 days
3494040|NCT02476097|Active Comparator|Progressive discontinuation|Esomeprazole: Nexium® 20mg, Astra Zeneca , for 7 days
3494041|NCT02464553|Experimental|Group A|1x periradicular therapy in one intervertebral space, corresponding with pain radiating dermatome
3494042|NCT02464553|Experimental|Group B|2x periradicular therapy in two intervertebral spaces, the first corresponding with pain radiating dermatome the second according magnetic resonance visualization where stenosis is situated
3494043|NCT02459392|Other|Epiduroscopy mechanical lysis - failed back surgery syndrome|Epiduroscopy only mechanical lysis
3494044|NCT02459392|Experimental|Epiduroscopy combination - failed back surgery syndrome|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
3494045|NCT02459392|Other|Epiduroscopy mechanical lysis - chronic low back pain without previous spine surgery|Epiduroscopy only mechanical lysis
3129830|NCT03244800|Experimental|MEDI0382 Cohort 2|Participants will receive subcutaneous injection of MEDI0382 once daily for 49 days as Dose 1 for 14 days, followed by Dose 2 for 14 days, Dose 3 for 14 days, and Dose 4 for 7 days.
3180217|NCT00681122||2|Standard therapy + educational material
3494046|NCT02459392|Experimental|Epiduroscopy combination - chronic low back pain without previous spine surgery|Epiduroscopy together mechanical lysis of epidural adhesions together with epidural drug administration Hyaluronic acid 150 IU and Depo-Medrol 80mg
3494047|NCT02455479|Other|Cohort 1: 100µg|Subjects will receive 100µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3494048|NCT02455479|Other|Cohort 2: 316 µg|Subjects will receive 316 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3494049|NCT02455479|Other|Cohort 3: 1000µg|Subjects will receive 1000 µg dAd5GNE vaccine or placebo at weeks 0, 4, 8, 12, 16 and 20.
3494050|NCT02446626|Active Comparator|1|Patients with Lyme disease, post treatment
3494051|NCT02446626|Active Comparator|2|Patients with post-Lyme disease complaints at least 12 months from initial treatment
3180218|NCT00681135|Experimental|1|
3494052|NCT02446626|Active Comparator|3|Acute erythema migrans patients (possible positive control)
3494053|NCT02446626|Active Comparator|4|Lyme Arthritis patients (possible positive control)
3494054|NCT02446626|Active Comparator|5|Healthy Volunteers (negative control)
3494055|NCT02428985||Riociguat|Riociguat treatment group
3494056|NCT02423070||Cohort 1|Heart and Lung Transplant patients
3494057|NCT02422524|Experimental|Child-Pugh A (Mild hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
3494058|NCT02422524|Experimental|Child-Pugh B (Moderate hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
3494059|NCT02422524|Experimental|Child-Pugh C (Severe hepatic impairment)|6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
3494060|NCT02422524|Experimental|Non-hepatically impaired controls|18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
3494061|NCT02417766||Family Members|Family members to the patients
3494062|NCT02417766||Patient|Patients here at NIH
3494063|NCT02417272|Experimental|Total disc replacement (TDR)|Total disc replacement with preserved segmental motion decreasing load on adjacent levels.
3494064|NCT02417272|Experimental|Anterior Cervical Decompression and Fusion (ACDF)|Interbody fusion by replacing disc space with a cage packed with bone substitute, and inserted into the anterior portion of the interspace.
3494065|NCT02413736|Experimental|Imatinib|Imatinib 400 mg/day for 24 months.
3494066|NCT02413736|No Intervention|No imatinib|No further imatinib.
3494067|NCT02408549|Experimental|Lacosamide|"Start dose~SP982 completers at V1:~LCM 10 mg/kg/day for pediatric subjects weighing <30 kg~LCM 8 mg/kg/day for pediatric subjects weighing ≥ 30kg to <50 kg~LCM 400 mg/day (200 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~SP982 Baseline failures at V1:~LCM 2 mg/kg/day for pediatric subjects weighing <50 kg~LCM 100 mg/day (50 mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50 kg~Oral solution (pediatric subjects <50 kg):~Minimum LCM dose: 4 mg/kg/day~Maximum LCM dose: 12 mg/kg/day~Tablets (pediatric subjects ≥50kg):~Minimum LCM dose: 200 mg/day~Minimum LCM dose: 600 mg/day~Tablets (adult subjects):~Minimum LCM dose: 200 mg/day~Maximum LCM dose: 800 mg/day"
3494068|NCT02394964||Systemic Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
3494069|NCT02394964||Subacute Cutaneous Lupus Erythematosus|Blood, stool, and swab samples will be collected at baseline, week 4, and week 8 and compared with control samples
3494070|NCT02394964||Control|Blood, stool, and swab samples will be collected for comparison to each disease group
3494071|NCT02394964||Cutaneous T-Cell Lymphoma|Blood and swab samples will be collected for comparison to each disease group
3494072|NCT02394964||Autoimmune Disorders|Blood, stool, and swab samples will be collected for comparison to each disease group
3494073|NCT02390765||All participants|All participants in the study will be evaluated as one group
3494074|NCT02367040|Experimental|Copanlisib + Rituximab|Combination of the Copanlisib and rituximab
3494075|NCT02367040|Placebo Comparator|Placebo + Rituximab|Combination of Copanlisib placebo and rituximab
3494076|NCT02361125|Experimental|Methylphenidate|"Participants given a 7 day supply of 5 mg methylphenidate tablets (to take a maximum of 20 mg/day, for total of 28 tablets). Directions for use are to take one 5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue (maximum of 4 tablets/day).~Evaluation of fatigue, ability to sleep, and general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment."
3494077|NCT02359084|Experimental|Family Navigation|Families will work one-on-one with the navigator who provides off-site support - e.g. home visits or accompanying families to appointments. The goal of FN during the diagnostic evaluation period is to ensure timely completion of the evaluation. The focus of these interactions is to understand the structure and purpose of the evaluation, gather and complete required materials, and address logistic barriers related to the diagnostic visit. The navigator will continue to work with the family after the diagnostic evaluation to access recommended services and support the family's engagement in treatment.
3494078|NCT02359084|Active Comparator|Conventional Care Management|Families will be assigned to a care manager for the diagnostic evaluation and for 100 days thereafter. Consistent with a high quality medical home, the care manager will be responsible to ensure that the referral for the diagnostic evaluation has been made. She is also available for family-initiated support. The care manager will be responsible for ensuring that referrals are made and continue to provide family-initiated, clinic-based support to families for up to 100 days after the completion of diagnostic evaluation.
3494079|NCT02352896|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 15 milligrams/kilogram (mg/kg) up to a total 200 mg 3 times daily (TID) orally with meal or by using nasogastric (NG) or gastrostomy feeding tubes with liquid food for at least 36 months.
3494080|NCT02339012||20-34|healthy individuals ages 20-34 years
3494081|NCT02339012||35-49|healthy individuals ages 35-49 years
3494082|NCT02339012||50-64|healthy individuals ages 50-64 years
3494083|NCT02339012||65-79|healthy individuals ages 65-79 years
3494084|NCT02339012||80+|healthy individuals ages 80 years and older
3494085|NCT02338921|Active Comparator|Glimepirde, Metformin, Sitagliptin|"Dipeptidyl peptidase-4 (DPP4) inhibitor~Sitagliptin"
3494086|NCT02338921|Active Comparator|Glimepirde, Metformin, Dapagliflozin|"Sodium-glucose cotransporter 2 (SGLT2) inhibitors~Dapagliflozin"
3494087|NCT02338921|Active Comparator|Glimepirde, Metformin, Lobeglitazone|"Peroxisome proliferator-activated receptor gamma agonist~Lobeglitazone"
3494088|NCT02326116|Experimental|Group 1|Trachael Traction Exercises
3129831|NCT03244865||Pregnant Females|"All patients admitted to the Labor & Delivery Suite at UF Health, will be eligible for inclusion in the study except minors and those unable to consent for themselves.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus. No longitudinal follow-up is planned or indicated."
3494089|NCT02326116|Placebo Comparator|Group 2|Trachael Massage
3494090|NCT02320994||stroke patients|post-rehabilitation stroke patients
3494091|NCT02312401|Experimental|Multiparametric MRI|Patients undergo baseline standard (clinical) MP-MRI prior to therapy (ADT or RT). After completion of radiotherapy, follow-up MRIs will be obtained using the same 3T Philips MRI unit at approximately 3, 6, 12, 18 & 24 (+/- 4 weeks) months after radiotherapy. A standard post-tx biopsy will be performed at 24 months (+/- 4 weeks) after therapy which will serve to define the local control status after therapy. Local control based on this biopsy will be interpreted as negative or adenoca with severe tx effect; a positive biopsy will be a specimen which demonstrates adenocarcinoma that can be classified with a Gleason score as we have previously reported.
3132780|NCT03450369|Experimental|NB01|"NB01 is a live probiotic containing a single strain of P. acnes, frozen, on a pad, in a single use pouch, for topical application.~Open label and dose escalation of a single application of NB01 to subjects with moderate acne, with approximately 5 subjects assigned to lower bound dose before escalation to upper bound dose."
3494092|NCT02312193||Case|Hypertensive subjects
3494093|NCT02312193||Control|Normotensive subjects
3494094|NCT02311335||1|Dyslipidemia patients
3494095|NCT02310217||1|Hypertensive
3494096|NCT02310217||2|Normotensive
3494097|NCT02306161|Experimental|Regimen A (VDC/IE)|See Design Details.
3494098|NCT02306161|Experimental|Regimen B (VDC/IE + ganitumab)|"INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.~LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.~CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A.~METASTATIC SITE IRRADIATION: Patients with lung metastases undergo definitive SBRT or EBRT over 5 days."
3494099|NCT02257853|No Intervention|Control Group|No intervention group
3494100|NCT02257853|Experimental|Intervention|Receives stress reduction intervention introduction with daily practice
3494101|NCT02245308|Experimental|ART|Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.
3494102|NCT02245308|Active Comparator|Control Group|Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.
3494103|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 1 (brentuximab 1.2mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.2mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
3494104|NCT02227199|Experimental|Phase I: Dose Escalation, Dose Level 2 (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
3494105|NCT02227199|Experimental|Phase II: Dose Expansion (brentuximab 1.5mg/kg, ifosfamide, carboplatin, etoposide)|Patients receive brentuximab vedotin 1.5mg/kgIV over 30 minutes on days 1 and 8; ifosfamide IV over 24 hours and carboplatin IV over 1 hour on day 2; and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients planning to go on to consolidative HDT and ASCT may undergo PBSC mobilization following the 2nd course of study therapy at the discretion of the treating physician.
3494106|NCT02223208|Experimental|Ro-CHOEP-21|During the Phase I It will administered Romidepsin (dose escalation) and the combination of CHOEP-21. During the Phase II It will administered Romidepsin (dose according to phase I) and the combination of CHOEP-21.
3494107|NCT02211768|Experimental|1/FDG and FLT PET scans|Subjects will undergo FDG-PET and FLT-PET scans at least one day apart
3129832|NCT03244917|Experimental|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education.
3129833|NCT03244917|No Intervention|CONTROL|Facility randomized to the control arm will employ usual care for the management for suspected infections in advanced dementia,
3494108|NCT02211768|Other|2/FDG-PET scan|Subjects will undergo FDG-PET scan
3494109|NCT02198794|Experimental|Part A: SD-809|Participants will receive SD-809 orally twice daily (BID) starting at 12 mg/day, which will be titrated based on dyskinesia control and tolerability up to a maximum total dose of 48 mg/day. Participants who decline to participate in Part B, will continue at their stable dose of SD-809 BID up to Week 158.
3494110|NCT02198794|Placebo Comparator|Part B: Placebo|Participants will receive placebo matched to SD-809 for 1 week in randomized withdrawal period and thereafter will receive SD-809 (stable dose) for 12 weeks.
3494111|NCT02198794|Active Comparator|Part B: SD-809|Participants will receive SD-809 (stable dose) for 1 week in randomized withdrawal period and will continue to receive the same dose of SD-809 for an additional 12 weeks.
3494112|NCT02198794|Experimental|Part C: SD-809|EU participants who complete Part B and willing to continue in the study will continue treatment with SD-809 for 52 weeks at the dose administered during the 12-week open-label period of Part B.
3494113|NCT02177695|Experimental|Gemcitabine & Cisplatin|Gemcitabine, 1000 mg/m2, IV, Days 1&8, q 21 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1, q 21 days x 4 cycles
3494114|NCT02177695|Experimental|Dose Dense MVAC|Methotrexate, 30 mg/m2, IV, Day 1, q 14 days x 4 cycles Vinblastine, 3 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Doxorubicin, 30 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Cisplatin, 70 mg/m2, IV, Day 1 or 2, q 14 days x 4 cycles Filgrastim, 5 mcg/kg, SubQ/IV, Days 3-7, q 14 days x 4 cycles
3494115|NCT02176148||Lupus control standard-of-care|Each person enrolled will be given fluocinonide 0.05% cream to apply twice daily to active areas.
3494116|NCT02167022|Experimental|Intense Physiotherapy (Group 1)|30 minutes each of physical and occupational therapy each weekday for 12 weeks (intense physiotherapy) followed by the same therapies administered once a week for 36 weeks (the current standard of care).
3494117|NCT02167022|Experimental|Delayed Intense Physiotherapy (Group 2)|30 minutes each of physical and occupational therapy once a week for 36 weeks (the current standard of care) followed by the same therapies administered each weekday for 12 weeks (intense physiotherapy).
3129834|NCT03245372|Active Comparator|Standard care|Basic intraoperative hemodynamic objectives
3129835|NCT03245372|Experimental|Goal directed therapy|Target value is a cardiac index equal or superior to 2.2 l/min/m2.
3132781|NCT03450915|Experimental|M-001|Participants will be vaccinated with 1mg dose of M-001 twice: Once at Day 0, and once at Day 21.
3494118|NCT02145403|Experimental|Carfilzomib|Carfilzomib will be administered IV over 30 minutes, starting at dose level 1 (20 mg/m2 IV) on Day +1, +2, +6 and +7.
3494119|NCT02134574||hematologic malignancy|hematologic malignancy with a sampling of blood
3494120|NCT02107976|Experimental|Stage 1|Upon admission, diabetic subjects maywill discontinue their oral hypoglycemic medications and/or insulin regimen per investigators discretion. Oral hypoglycemic agents and/or insulin doses will be adjusted and may be supplemented with a correction scale and/or and transitioned to a basal-bolus insulin regimen. In order to achieve optimal glycemic monitoring and for safety reasons, subjects may be fitted with a Dexcom continuous glucose monitor (CGM) upon inpatient admission. CGM will be used to supplement, rather than replace, fingerstick glucose measurements. CGM monitoring will include a sensor fitted subcutaneously, a wireless transmitter that allows for remote glucose monitoring by the research team.
3494121|NCT02107976|Experimental|Stage 2|Subjects may be considered for arm stage 2 inpatient study no less than 8 weeks duration from arm stage 1 study. Once the RBC vitamin C concentrations are optimal (>30 uM), subjects may be re-admitted to Clinical Center metabolic unit and undergo the same protocol as described above in arm stage 1. Oral vitamin C and E supplementation may be discontinued on admission. The inpatient diet, glucose monitoring and sampling scheme will be the same as described for the first inpatient study.
3494122|NCT02105636|Experimental|Arm A: Nivolumab|Nivolumab 3mg/kg intravenous (IV) Solution for Injection every 2 weeks until disease progression
3494123|NCT02105636|Active Comparator|Arm B: Cetuximab/Methotrexate/Docetaxel|"Cetuximab intravenous (IV) Solution for Injection 400 mg/m2 (first dose) then 250 mg/m2 weekly until disease progression~OR~Methotrexate intravenous (IV) Solution for Injection 40 or 60 mg/m2 weekly until disease progression~OR~Docetaxel intravenous (IV) Solution for Injection 30 or 40 mg/m2 weekly until disease progression"
3494124|NCT02091245|Experimental|KPT-330|KPT-330 will be administered twice a week on Days 1 and 3 for four weeks. Starting dose 30 mg/m2.In the dose-escalation cohort, three patients will initially be enrolled at each dose level and will be monitored for a DLT during the 28-day treatment cycle before dose escalation may occur.
3494125|NCT02076009|Experimental|Daratumumab + lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
3494126|NCT02076009|Active Comparator|Lenalidomide + dexamethasone|During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.
3494127|NCT02061423|Experimental|HER-2 Pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months.
3494128|NCT02038946|Experimental|Arm 1: Nivolumab|Nivolumab 3 mg/kg injection by Intravenous for every 2 weeks until disease progression or discontinuation due to toxicity
3494129|NCT02027948|Experimental|nutritional management|The proposed study will be a prospective feasibility study of a nutritional management algorithm with risk-based guidelines in older adults (n=50) with newly diagnosed locally advanced esophageal cancer receiving preoperative or definitive chemoradiotherapy with an induction chemotherapy approach. Eligible patients must be age ≥ 65 years old. While all patients with esophageal cancer may benefit from this intervention, we wish to target the most vulnerable population (older patients who are at highest risk of malnutrition) in this pilot study.
3494130|NCT02016872|Experimental|18F-FMISO PET/CT|All enrolled patients will undergo a baseline 18F-FDG PET scan as part of their standard clinical treatment for NSCLC. Dynamic 18F-FMISO PET scans will be performed on one of the GE PET/CT scanners in 3D mode, at least one day after the baseline 18F-FDG PET scan. The dynamic baseline 18F-FMISO studies may precede the 18F-FDG study if the patient had a CT or PET/CT scan within the last 30 days that would permit the investigators to localize the tumor of interest during the 18F-FMISO study. In a group of 5 patients, the feasibility of simultaneous imaging of 18F-FMISO and 18F-FDG will be assessed. The patient will have an IV line placed for radiotracer injection and for venous blood sampling. All dynamic PET scans will be performed over one PET FOV centered at the lesion position. The 18F-FDG mid-treatment PET/CT scan will be performed over only one bed position.
3494131|NCT02016599||Initial cohort|Initial cohort used to develop a series of multivariate clinical deterioration indices using monitoring modalities and biospecimen collection
3494132|NCT02016599||Validation cohort|Separate cohort of infants used to validate the clinical deterioration indices using monitoring modalities and biospecimen collection
3494133|NCT01989585|Experimental|Arm I (dabrafenib, trametinib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3494134|NCT01989585|Experimental|Arm II (dabrafenib, trametinib, and navitoclax)|Patients receive navitoclax PO QD days -7 to -1 of cycle 1 only. Patients also receive dabrafenib PO BID, trametinib PO QD, and navitoclax PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3494135|NCT01988571|Active Comparator|Arm 1 - Atorvastatin|One 40 mg Atorvastatin tablet each morning by mouth for 24 months
3494136|NCT01988571|Placebo Comparator|Arm 2 - Placebo|One placebo tablet each morning by mouth for 24 months.
3494137|NCT01979367|Experimental|Anodyne|To evaluate the efficacy treatment of lower extremity pathologies from neurological ischemia disorders using the Monochromatic Infrared Photo Energy (MIRE)
3129836|NCT03245398|Active Comparator|Single dose of mebendazole|In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
3494138|NCT01974440|Placebo Comparator|Treatment Arm A|Treatment Arm A = background immune-chemotherapy (bendamustine and rituximab [BR] or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) for 6 cycles + placebo.
3494139|NCT01974440|Experimental|Treatment Arm B|Treatment Arm B = background immune-chemotherapy (BR or R-CHOP) for 6 cycles + PCI-32765 (Ibrutinib).
3129837|NCT03245398|Active Comparator|Multiple dose of mebendazole|In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).
3494140|NCT01974206|Experimental|ASP0113|Participants received 1 mL of 5 mg/mL of ASP0113 via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
3494141|NCT01974206|Placebo Comparator|Placebo|Participants received 1 mL of 5 mg/mL of placebo via injection in the deltoid muscle alternating sides with each dose on days 30, 60, 90, 120 and 180 in relation to the day of transplant (Day 0).
3494142|NCT01973452|Experimental|Dexmedetomidine|continuous infusion of 0.4 mcg/kg/hr
3494143|NCT01973452|Placebo Comparator|Placebo|continuous infusion of 0.4 mcg/kg/hr
3494144|NCT01964560|Experimental|Lacosamide|"In the first week after enrollment into EP0034 subjects will be dosed according to their weight:~Lacosamide (LCM) 10 mg/kg/day (oral solution) for subjects weighing <30 kg~LCM 6 mg/kg/day (oral solution) for subjects weighing ≥30 kg to <50 kg~LCM 300 mg/day (tablets) for subjects weighing ≥50 kg~After 1 week the investigator may adjust the LCM dose during the Treatment Period based on clinical judgment within a range of 2 mg/kg/day to 12 mg/kg/day for the oral solution and 100 mg/day to 600 mg/day for the tablets."
3494145|NCT01961778|Active Comparator|Radio-Frequency Ablation|Patients in this arm will receive treatment with radio-frequency ablation.
3180219|NCT00681135|Experimental|2|
3494146|NCT01961778|Active Comparator|Cryothearpy|Patients in this arm will receive treatment with cryotherapy.
3494147|NCT01933958||Group 1|Patients treated with Regorafenib under practical manner for gastrointestinal stromal tumors progressed after cancer chemotherapy.
3494148|NCT01927783||Group 1|Healthy Volunteer
3494149|NCT01927783||Group 2|Focus Group- Neighborhood and Physical Activity
3494150|NCT01927783||Group 3|Focus Group
3494151|NCT01927783||Group 4|Focus Group- Mobile App
3494152|NCT01927783||Group 5|Consent for Cooking Survey Focus Group
3494153|NCT01927783||Group 6|Community Organization Survey focus Group
3494154|NCT01878617|Experimental|Stratum W1: Low Risk|Participants in stratum W1 will undergo reduced dose Craniospinal Irradiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494155|NCT01878617|Experimental|Stratum W2: Atypical|Participants in stratum W2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494156|NCT01878617|Experimental|Stratum W3: High Risk|Participants in stratum W3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494157|NCT01878617|Experimental|Stratum S1: Standard Risk|Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
3494158|NCT01878617|Experimental|Stratum S2: High Risk|Participants in stratum S2 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
3494159|NCT01878617|Experimental|Stratum N1: Standard Risk|Participants in stratum N1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494160|NCT01878617|Experimental|Stratum N2: Intermediate Risk|Participants in stratum N2 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494161|NCT01878617|Experimental|Stratum N3: High Risk|Participants in stratum N3 will undergo high dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive standard chemotherapy (cisplatin, vincristine, cyclophosphamide) for 4 cycles intermixed with an additional 3 cycles of chemotherapy with pemetrexed and gemcitabine in absence of unacceptable toxicity. Some participants will complete aerobic training and/or neurocognitive remediation.
3494162|NCT01863550|Experimental|Arm A (bortezomib, lenalidomide, dexamethasone)|Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3180220|NCT00681135|Experimental|3|
3494163|NCT01863550|Experimental|Arm B (carfilzomib, lenalidomide, dexamethasone)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
3494164|NCT01863550|Experimental|Arm C (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
3494165|NCT01863550|Experimental|Arm D (lenalidomide)|Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3494166|NCT01841736|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3129838|NCT03245463|Active Comparator|Teaching Method A|Patient will receive an educational handout on self-management strategies. Patient will be asked to take the handout home to read and to call the office if he/she has any questions.
3129839|NCT03245463|Active Comparator|Teaching Method B|Patient will receive an educational handout on self-management strategies. A provider will review the handout with the patient (approximately 5 minutes including a question-and-answer session).
3494167|NCT01841736|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progressive disease, patients may cross-over to Arm I.
3494168|NCT01824875|Experimental|Arm A (temozolomide)|Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3494169|NCT01824875|Experimental|Arm B (temozolomide and capecitabine)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3494170|NCT01817192|Active Comparator|Observation|Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
3494171|NCT01817192|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
3494172|NCT01805869||1|Data and surgical waste tissue for research purpose in subjects undergoing clinically indicated wisdom teeth extraction at the NIH NIDCR Dental clinic
3494173|NCT01804686|Experimental|Ibrutinib|
3494174|NCT01792583||Prospective Cohort|Prospective is defined per protocol: prospective data of pregnancy exposure are data acquired prior to the knowledge of the pregnancy outcome or prior to the detection of a congenital malformation at prenatal examination (e.g. fetal ultrasound, serum markers).
3494175|NCT01792583||Retrospective Cohort|Retrospective is defined per protocol: retrospective data of pregnancy exposure are data acquired after the outcome of the pregnancy is known or after the detection of a congenital malformation on prenatal test.
3494176|NCT01776840|Placebo Comparator|Treatment Arm A|
3494177|NCT01776840|Experimental|Treatment Arm B|
3494178|NCT01755975|Experimental|Romidepsin and Lenalidomide|This will be a multicentered, open label, phase Ib/IIa trial of romidepsin and lenalidomide in patients with relapsed or refractory lymphomas or multiple myeloma. Lenalidomide will be provided in accordance with the Celgene Corporation's Revlimid REMS® program. Per standard Revlimid REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, and all research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the Revlimid REMS® program. Only enough lenalidomide for one cycle of therapy will be supplied to the patient each cycle.
3494179|NCT01747213|Experimental|BNC|Bisnorcymserine tartrate
3494180|NCT01747213|Placebo Comparator|Placebo|microcrystalline celluose
3494181|NCT01737827|Experimental|INC280|The protocol consists of two independent parts (Dose-Determining Part and Dose Expansion Part). Approximately 6 patients will be treated with INC280 300 mg twice a day in the Dose-Determining Part. Approximately 50 patients will be treated with INC280 in the Dose Expansion Part. The dose for the Expansion Part can be lower, equal or higher than in the Dose-Determining Part will be determined after the Dose Determining Part at the dose decision analysis.
3494182|NCT01715285|Experimental|Abiraterone acetate + Prednisone + ADT|Participants will receive abiraterone acetate tablet at a total dose of 1000 milligram (mg) along with 5 mg capsule of prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of androgen deprivation therapy (ADT) will be administered.
3494183|NCT01715285|Placebo Comparator|Placebo + Androgen Deprivation Therapy (ADT)|Participants will receive placebo matched to abiraterone acetate and prednisone orally once daily until disease progression, withdrawal of consent or unacceptable toxicity. Stable regimen of ADT will be administered.
3494184|NCT01702883|No Intervention|Control|Randomization occurs after enrollment survey has been completed. This group will not receive the internet intervention for the twelve months. They will be asked to complete the final survey.
3494185|NCT01702883|Experimental|Intervention Group A|Randomization occurs after enrollment survey has been completed. Upon secondary randomization at week eight, this group will continue to receive weekly internet surveys for the entire twelve months. They will be asked to complete the final survey.
3494186|NCT01702883|Experimental|Intervention Group B|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, this group will begin to receive monthly internet surveys. They will be asked to complete the final survey.
3494187|NCT01702883|Experimental|Intervention Group C|Randomization occurs after enrollment survey has been completed. This group will complete weekly internet surveys for eight weeks. Upon secondary randomization at week eight, the group will not receive any more internet surveys. They will be asked to complete the final survey.
3494188|NCT01670409|Experimental|SMART combined with PF chemotherpay|SMART-base IMRT with concurrent and adjuvant chemotherapy(cisplatin and 5-fluorouracil)
3494189|NCT01659606|Experimental|alemtuzumab/fludarabine conditioning|alemtuzumab/fludarabine conditioning; cyclosporins/mycophenolate mofetil GVHD prophylaxis
3494190|NCT01617408||1|Neurologically normal subjects aged 18 to 50 years old
3132782|NCT03450915|Placebo Comparator|Saline|Participants will be vaccinated with saline twice: Once at Day 0, and once at Day 21.
3132783|NCT03451071|Experimental|Gardasil9|
3494191|NCT01572493|Experimental|Arm A1 (Dose Escalation, 10-day Dosing)|MTD determination in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
3494192|NCT01572493|Experimental|Arm A2 (Dose Expansion, 10-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 10 consecutive days
3494193|NCT01572493|Experimental|Arm B1 (Dose Escalation, 5-day Dosing)|MTD determination in subjects with metastatic unresectable cancers receiving rhIL-15 IV for 5 consecutive days
3494194|NCT01572493|Experimental|Arm B2 (Dose Expansion, 5-day Dosing)|Clinical activity evaluation in subjects with metastatic cancers receiving rhIL-15 IV for 5 consecutive days
3494195|NCT01571752||CMU|Current marijuana users
3494196|NCT01571752||Cohort|HIV positive adults
3494197|NCT01571752||Cohort 1|HIV negative adults
3129840|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohorts 1 to 8. In each cohort, six subjects will be randomized to receive alternating and escalated doses of GSK3335065.
3494198|NCT01571752||Cohort 2 Seeds-Wave 0|HIV positive adults
3494199|NCT01571752||Cohort 2 Wave 1|HIV negative adults or HIV positive adults
3494200|NCT01571752||Cohort 2 Wave 2|HIV negative adults or HIV positive adults
3494201|NCT01571752||COSU|Current opioid/stimulant users
3494202|NCT01571752||COSU-NTS|Non-treatment seekers
3494203|NCT01571752||COSU-TS|Treatment seekers
3494204|NCT01571752||NDU|Non-drug-users
3494205|NCT01571752||Unclassified|Unclassified
3494206|NCT01570465||All patients enrolled in the GIMEMA AML1310 study.|"All patients enrolled in the GIMEMA AML1310 study;~Signed written informed consent according to ICH/EU/GCP and national local laws."
3494207|NCT01568697||Healthy Volunteers|Healthy volunteers (with/without periodontal disease)
3494208|NCT01568697||Immune deficient patients|Subjects with known genetic immune deficiency
3494209|NCT01568697||Subjects with severe periodontitis of suspected genetic etiology|Subjects with severe periodontitis of suspected genetic etiology and their family members
3494210|NCT01563874||Cohort 1|This study involves a broad panel of lymphoma and lymphoid samples, which were previously procured under multiple protocols at the NIH, and for which there is excess tissue available for research.
3494211|NCT01534598|Experimental|Single Arm|FdCyd + THU administered on an intermittent schedule in 21-day cycles per dose escalation table. THU will be administered orally at a fixed dose of 3000 mg 30 minutes prior to FdCyd.
3494212|NCT01532310||Pregnant women taking belimumab|Any women with belimumab exposure within the 4 months prior to and/or during pregnancy
3129841|NCT03245619|Experimental|Subjects receiving Placebo (Cohorts 1 to 8) in Part A|Male subjects will be assigned to Cohort 1 and 2. In each cohort, two subjects will be randomized to receive placebo.
3494213|NCT01532310||Infants|Infants through the first year of life whose mothers were exposed to belimumab during pregnancy
3129842|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, six subjects will be randomized to receive GSK3335065. In all cohorts each dose level will consist of an IV bolus on Day 1 subsequently followed by a continuous IV infusion for seven days.
3132784|NCT03451084|Experimental|Part 1: Dose Level 1|
3494214|NCT01526135|Active Comparator|Arm A GEMCITABINE|Arm A : Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
3494215|NCT01526135|Experimental|Arm B mFOLFIRINOX|"Arm B : mFOLFIRINOX every 14 days, 12 cycles, 24 weeks. Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
3494216|NCT01524822||Artillery personnel|exposure to a significant number of concussive evolutions, specifically, exposure to 400 or more within a career, will be considered experienced by the investigators.
3494217|NCT01524822||Breachers|exposure to a significant number of breaching blasts, specifically, exposure to 400 breaching blasts or more within a career, will be considered experienced by the investigators
3494218|NCT01524822||Companions|The criterion is met by a person who has both some historical knowledge of the participant and routine interactions outside a work environment.
3494219|NCT01524822||Unexposed|People not exposed to repeated blasts
3494220|NCT01500447||Central Precious Puberty|CPP subjects
3494221|NCT01500447||Hypogonadotropic Hypogonadism|IHH, KS, GnRH Deficiency, BAM syndrome (arhinia), HA, CDP subjects
3494222|NCT01496625||Cohort 1|Participants with age-related macular degeneration (AMD), diabetic retinopathy, and other retinal diseases.
3494223|NCT01496625||Cohort 2|Participants without any retinal diseases.
3494224|NCT01495598|Experimental|1/Phase 1|Up to six subjects will initially be treated with pomalidomide 5mg daily for 21 days of a 28 day cycle
3494225|NCT01495598|Experimental|2/ Phase 2|15 HIV positive and 10 HIV negative subjects evaluable for response will be treated with Pomalidomide 5mgdaily for 21 days of a 28 day cycle
3494226|NCT01475110||Study cohort group|"Adult patients with Imatinib resistant (failure + suboptimal) or intolerant chronic myeloid leukaemia in all phases, who started treatment with Nilotinib between January 2005 and December 2012 in Italy.~Adult pts treated with Nilotinib as second line therapy after Dasatinib."
3494227|NCT01468246||Young Women|Young women with newly diagnosed breast cancer
3494228|NCT01445509|Experimental|Arm 1|Group 1 will receive dasatinib and bevacizumab together at the start of study in a dose escalation fashion
3494229|NCT01445509|Experimental|Arm 2|Group 2 will be randomized as to which agent they receive for cycle one. Cycles 2 and beyond are treated using both agents.
3494230|NCT01443910||behavior, supportive|receiving information about behavior with supportive provider communication
3494231|NCT01443910||behaviors, directive|receiving information about behavior with directive provider communication
3494232|NCT01443910||genetics, directive|receiving information about genetics with directive provider communication
3494233|NCT01443910||genetics, supportive|receiving information about genetics with supportive provider communication
3494234|NCT01434368||children age 8-17 years admitted to pilot brain imaging studies|children age 8-17 years admitted to pilot brain imaging studies
3494235|NCT01434368||healthy adults|healthy adults ages 25 - 35 years at the time of enrollment
3494236|NCT01434368||typically developing children (with evidence of advanced bone|typically developing children (with evidence of advanced bone age relative to chronologic age); age 8 or ages 12-13
3494237|NCT01434368||typically developing children ages 12/13- 17 years|typically developing children ages 12 or 13 - 17 years
3129843|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 9 to 12) in Part B|Male subjects will be assigned to one of four cohorts (9, 10, 11 or 12). In each cohort, two subjects will be randomized to receive placebo.
3129844|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Six subjects will be randomized to receive a single IV dose of GSK3335065.
3494238|NCT01434368||typically developing children ages 8 - 17 years|typically developing children ages 8 - 17 years
3494239|NCT01432847||Affected|Participants affected by ocular diseases/conditions.
3494240|NCT01432847||Healthy Volunteers|Age, gender, and ethnicity-matched to participants with ocular conditions.
3129845|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 13) in Part C|WONCBP will be assigned to cohort 13. Two subjects will be randomized to receive placebo.
3129846|NCT03245619|Experimental|Subjects receiving GSK3335065 (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Six subjects will be randomized to receive a continuous IV infusion over 7 days of GSK3335065.
3129847|NCT03245619|Experimental|Subjects receiving Placebo (Cohort 14) in Part C|WONCBP will be assigned to cohort 14. Two subjects will be randomized to receive placebo.
3180221|NCT00681135|Active Comparator|4|
3494241|NCT01425892||incomplete sjogren's|patients who meet criteria as incomplete sjogren's
3494242|NCT01425892||primary sjogren's|patients who meet criteria for classification for primary sjogren's
3494243|NCT01425892||secondary sjogren's|patients who meet classification criteria for secondary sjogren's
3494244|NCT01422694||Healthy control|Healthy volunteers will be recruited to serve as controls
3494245|NCT01422694||Other Inflammatory Diseases|Subjects with Other Inflammatory Diseases
3494246|NCT01422694||Patients with Spondyloarthritis|Subjects with confirmed or probable SpA will be identified predominantly by physician referral.
3494247|NCT01415752|Experimental|Arm A|Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm E.
3494248|NCT01415752|Experimental|Arm B|Patients receive induction therapy comprising bortezomib IV subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm F.
3494249|NCT01415752|Experimental|Arm C|Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm G.
3494250|NCT01415752|Experimental|Arm D|Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then proceed to arm H.
3494251|NCT01415752|Experimental|Arm E|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3494252|NCT01415752|Experimental|Arm F|Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3494253|NCT01415752|Experimental|Arm G|Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3494254|NCT01415752|Experimental|Arm H|Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
3494255|NCT01399385|Experimental|Group 1|will consist of subjects with a 10-year total CHD risk <10% (low)
3494256|NCT01399385|Experimental|Group 2|will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)
3494257|NCT01399385|Experimental|Group 3|will consist of subjects with a 10-year total CHD risk 10-20% (intermediate)
3494258|NCT01399385|Experimental|Group 4|no known risk factors (control subjects)
3494259|NCT01398852|Experimental|CXL Treatment|All eyes to be treated with riboflavin and UV light
3494260|NCT01391962|Experimental|Part I|Patients will be randomized to receive cediranib (30 mg) or sunitinib malate (37.5 mg) orally, once a day in 28-day cycles
3494261|NCT01391962|Experimental|Part II|At the time of disease progression patients will cross over to the other treatment arm after a 2-week wash-out period.
3494262|NCT01375530||1|Healthy adults 18 years old or older
3494263|NCT01370447|Experimental|EPI-743|Participants will receive EPI-743 at a dose of 50 milligrams (mg) at Day 1, 50 mg twice daily for 13 days, 100 mg on Day 15, and 100 mg twice daily until Day 28; either by mouth with a meal or via their G-tube with feeds. In the absence of clinical or laboratory indications of any safety concerns, participants will receive 100 mg EPI-743 three times daily until end of study.
3494264|NCT01352962|Experimental|Arm 1|Standard of Care plus escalating doses of Lenalidomide
3494265|NCT01352962|Experimental|Arm 2|Lenalidomide Lead for 14 days + standard of care +lenalidomide MTD
3494266|NCT01332266|Active Comparator|Active Comparator; Phase 1b: Cohort 1,2,and 3|"Phase 1b:~Cohort 1; 200 mg E7050 + 250 mg/m2 cetuximab Cohort 2; 300 mg E7050 + 250 mg/m2 cetuximab Cohort 3; 400mg E7050 + 250mg/m2 cetuximab~Phase 2: Arm 1; MTD E7050 + 250 mg cetuximab Arm 2; 250 mg cetuximab~Interventions: Drug cetuximab"
3494267|NCT01332266|Active Comparator|Phase 2|"Phase 2:~Arm 1; MTD E7050 + 250 mg/m2 cetuximab Arm 2; 250 mg/m2 cetuximab"
3494268|NCT01328808|Experimental|group 2 Pain management|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute"
3129848|NCT03245723|Active Comparator|Preterm|"Participants born premature either registered on the National Lung Project (currently in their late twenties) or not registered on the National Lung Project Cohort (current age ranges 18-35 years).~All the participants in this group will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging."
3129849|NCT03245723|Placebo Comparator|Term - Healthy Controls|Healthy individuals that were not born premature. Individuals are ages 18-35. Subjects will undergo Pulmonary Function Testing, Electrocardiogram, Positron Emission Tomography, and Magnetic Resonance Imaging.
3494269|NCT01326715|Active Comparator|mangafodipir|see protocol
3129850|NCT03245736|Experimental|Tisotumab Vedotin|All patients will be administered tisotumab vedotin (HuMax-TF-ADC) in 21 day treatment cycles.
3129851|NCT03245762|Active Comparator|Intranasal oxytocin|Intervention: 4 IU/day of intranasal oxytocin via a nasal spray device each morning.
3129852|NCT03245762|Placebo Comparator|IN-placebo|Intervention: 4 IU/day of placebo via nasal spray device each morning.
3494270|NCT01325805|Experimental|Structured Weight Loss|Women randomized to this arm will meet with a registered dietician regularly for review of calorie recommendations and food diary. As well as regular clinic visits to measure patients weight.
3494271|NCT01325805|Active Comparator|Routine Weight Loss Counseling|Patients are counseled by a physicians about the impact of maternal weight on fertility and pregnancy outcomes.
3494272|NCT01323322||HANDLS|A fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009.
3494273|NCT01319565|Experimental|1/ACT|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin
3494274|NCT01319565|Experimental|2/ACT + TBI|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young TIL + highdose aldesleukin + TBI
3494275|NCT01306084||1|NIH campus employees who have recently recovered from COVID-19
3494276|NCT01306084||2|Clinical Center health care workers and ancillary staff who have close patient contact and possible exposures to SARS-CoV-2
3494277|NCT01306084||3|Healthy and immunocompromised subjects who have or are suspected to have a viral infection
3494278|NCT01306084||4|Healthy and immunocompromised subjects exposed to someone who has a viral infection or is suspected of having a viral infection
3494279|NCT01306084||5|Healthy subjects who grew up in dengue endemic areas.
3494280|NCT01306084||6|Healthy subjects with a history of viral hepatitis
3494281|NCT01294332|Experimental|Excercise|Aerobic exercise performed for 12 weeks
3494282|NCT01287156||1|Subjects with diagnosed or suspected TBI or postconcussive syndrome
3494283|NCT01282021||Region 1|Northern part: Gonder, Gojam, Tigray
3494284|NCT01282021||Region 2|Southern Ethiopia: Bale, Sidamo, Gambela
3494285|NCT01282021||Region 3|Northeastern and Southeastern Ethiopia
3494286|NCT01264549|Experimental|PCT guided arm|
3494287|NCT01264549|No Intervention|Control|Standard treatment
3494288|NCT01261728|Experimental|Gemcitabine and Cisplatin|This is a Phase II Study of Gemcitabine and Cisplatin (GC) as neoadjuvant chemotherapy in patients with upper tract high-grade urothelial carcinoma who are candidates for radical nephroureterectomy or distal ureterectomy.
3494289|NCT01251900||Patients|Hispanic women, over the age of 18, with breast cancer will be eligible.
3494290|NCT01231932||Cancer survivors|Individuals recently completed primary treatment for cancer
3494291|NCT01231932||Individuals receiving cancer treatment|Individuals receiving cancer treatment
3494292|NCT01231932||Individuals with cancer|Individuals with cancer
3494293|NCT01224691||Asmathics|Asmathics
3494294|NCT01224691||Non-Asmathics|Non-Asmathics
3494295|NCT01222754|Experimental|1|Radiation with Lenalidomide
3494296|NCT01222741||Healthy Voluntary|Healthy Voluntary
3494297|NCT01222741||Patients|affected patient
3494298|NCT01222741||relatives|family member to patient
3494299|NCT01212003||Active TB|subjects with active TB as determined by smear, culture, or biopsy or have appropriately documented clinically suspicious active TB without definitive microbiology confirmation
3494300|NCT01212003||Latent TB|subjects with documented evidence of a positive PPD skin test or Interferon Gamma Release Assays (IGRA) test meeting American Thoracic Society (ATS)/CDC guidelines for latent TB
3494301|NCT01209000||FSGS/MCD Cohort (Cohort A)|"Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3494302|NCT01209000||MN Cohort (Cohort A)|"Membranous Nephropathy (MN) Cohort~Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3494303|NCT01209000||Other glomerulopathies cohort|"Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.~Eligible participants must be scheduled for a clinically indicated renal biopsy."
3494304|NCT01209000||cNEPTUNE (Cohort B)|Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.
3494305|NCT01191853||Healthy volunteers|Healthy volunteers will have blood drawn before and after seasonal flu vaccination
3494306|NCT01150890|Placebo Comparator|Placebo|Participants received placebo intravenously at baseline and week 4.
3494307|NCT01150890|Experimental|Brodalumab 210 mg|Participants received 210 mg brodalumab intravenously at baseline and week 4.
3494308|NCT01150890|Experimental|Brodalumab 350 mg|Participants received 350 mg brodalumab intravenously at baseline and week 4.
3494309|NCT01150890|Experimental|Brodalumab 700 mg|Participants received 700 mg brodalumab intravenously at baseline and week 4.
3494310|NCT01148381||controls|healthy non-smoking, participants with no substance use disorders
3494311|NCT01148381||psychiatric disorders|individuals with other psychiatric disorders
3494312|NCT01148381||smokers|healthy individuals with nicotine use disorder
3129853|NCT03246061|Active Comparator|BVN Ablation|BVN ablation with continued standard care
3494313|NCT01148381||substance use disorders|healthy individuals with other substance use disorders
3494314|NCT01148381||treatment seeking individuals|treatment seeking individuals with substance use disorders
3494315|NCT01143779|Experimental|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
3494316|NCT01143480||ABCA1|SNP or allele of interest
3494317|NCT01143480||APOE|SNP or allele of interest
3494318|NCT01143480||APOL1|SNP or allele of interest
3494319|NCT01143480||CD14|SNP or allele of interest
3494320|NCT01143480||CD44|SNP or allele of interest
3494321|NCT01143480||IRGM|SNP or allele of interest
3494322|NCT01143480||ITIH3|SNP or allele of interest
3494323|NCT01143480||ITIH4|SNP or allele of interest
3494324|NCT01143480||MyD88|SNP or allele of interest
3494325|NCT01143480||TIRAP|SNP or allele of interest
3494326|NCT01143480||TLR4|SNP or allele of interest
3494327|NCT01143480||TLR5|SNP or allele of interest
3494328|NCT01143480||TNFa|SNP or allele of interest
3494329|NCT01143454||1. Adult index cases and relatives|Enrolled with a known or suspected pathology that may be associated w/cardiovascular dysfunction or risk w/suspected atypical presentation, heritable disorder, or genetic predisposition.
3494330|NCT01143454||2. Child index case and child relatives|Children over 1 year of age who is affected with diseases/disorders (index cases), or who is a relative of a person who is affected with diseases/disorders.
3494331|NCT01143454||3. Healthy adult volunteers|Healthy adult volunteers must be 18 years of age or older, and must agree to have blood or tissue samples studied, and potentially stored for future research.
3494332|NCT01140867|Experimental|1|
3494333|NCT01139476||AHS BEEA participants|A subset of 1990 AHS cohort members who are male private pesticide applicators, living and over 50 years of age at the time contact, cancer free, and who completed AHS Phases IIII.
3494334|NCT01139476||Non-AHS BEEA participants|A group of 225 age-, race-, and countymatched, non-AHS controls, who have not lived or worked on a farm as an adult, or held a job applying pesticides.
3494335|NCT01137773|Experimental|Intensive IV Insulin|Patients will receive IV insulin to maintain target glucose levels of 80-110 mg/dl
3494336|NCT01137773|Active Comparator|Conventional Insulin Treatment|Patents will receive conventional IV insulin treatment with target glucose levels of 150-170 mg/dl
3494337|NCT01132898||cross-sectional TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 5 years from injury. Seen at only one visit.
3129854|NCT03246061|Active Comparator|Standard Care Control|Continue with non-surgical standard care
3494338|NCT01132898||HV|Healthy Volunteer with no history of TBI
3494339|NCT01132898||Prospective TBI|Participants with a mild, moderate, or severe Traumatic Brain Injury enrolled within 1 year from injury.
3494340|NCT01132898||Remote Select Exposure Samples|Participants who are unable to travel to the NIH Clinical Center to participate can remote consent, answer questionnaires remotely, and have biospecimens sent to our lab for analysis.
3494341|NCT01132898||Select Exposure Group|US government associated personnel experiencing TBI-like symptoms arising after possible exposure to a non-natural energy source
3494342|NCT01132898||Select Exposure Matched Unaffected|a longitudinal control group comprised of unaffected volunteers matched to the Select Exposure group
3494343|NCT01127256|Experimental|1|
3494344|NCT01127256|Active Comparator|2|
3494345|NCT01087307||1|Biologic and environmental samples anonymously obtained from adult volunteers for use in laboratory assay evaluation
3494346|NCT01079728||ischemic stroke patients|patients with an ischemic stroke in the anterior (ACA, MCA) and posterior flow area (PCA, BA) of any severity in the last 36h
3494347|NCT01051635|Experimental|Cohort A|LMP400 administered IV daily for 5 days per dose escalation table.
3494348|NCT01051635|Experimental|Cohort B|LMP776 administered IV daily for 5 days per dose escalation table.
3494349|NCT01031160||U.S. high school students|U.S. high school students who were in 10th grade in the 2009-2010 school year.
3494350|NCT01019343|Placebo Comparator|Healthy Volunteers|Healthy Volunteers
3494351|NCT01019343|Active Comparator|Movement Disorder|Subjects diagnosed with movement disorder
3494352|NCT01005654||1/ Cohort 1|Subjects with endocrine neoplasm or pre or potentially malignant condition of the endocrine system, scheduled to have surgery or biopsy
3494353|NCT01004861|Experimental|PLX3397|
3494354|NCT00978458|Active Comparator|Arm I|Patients undergo 3-dimensional conformal or intensity-modulated radiotherapy once daily 5 days a week for 5½ weeks (28 fractions).
3494355|NCT00978458|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive concurrent oral temozolomide once daily for 5½ weeks. Beginning 28 days after completion of chemoradiotherapy, patients receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3494356|NCT00942981||healthy volunteers|healthy volunteers
3494357|NCT00942981||patients|patients with schizophrenia, schizoaffective disorder or other psychotic disorders aged18-60
3494358|NCT00923221||1/Patient samples|blood samples from patients with diagnosed prostate cancer
3494359|NCT00923065||Consults|Individuals being seen as a consult.
3494360|NCT00923065||Donors|Donors of cellular products.
3494361|NCT00923065||Genetic Follow-Up|Individuals with a known/suspected germline genomic research incidental pathogenic or likely pathogenic variant, and/or who require CLIA confirmation.
3494362|NCT00923065||Patients|Individuals being enrolled for the treatment or follow-up of their disease.
3494363|NCT00923026||A/Gene Therapy|Patients who have received gene therapy
3494364|NCT00923026||B/Non-Gene Therapy|Patients who have not received gene therapy
3494365|NCT00912223|Experimental|Hematopoietic Stem Cell Transplant|Participants will undergo a non-myeloablative allogeneic hematopoietic stem cell transplant.
3494366|NCT00887939||1|Affected physical urticaria
3494367|NCT00887939||2|Healthy volunteer
3494368|NCT00887939||3|Unaffected relative
3494369|NCT00852111||Patients|Prostate cancer patients
3494370|NCT00774254|Experimental|A|
3494371|NCT00739362|Experimental|Active|Active tDCS stimulation
3494372|NCT00739362|Sham Comparator|Sham|Sham/no-stimulation
3494373|NCT00720785|Experimental|1|NK Cell Infusion (cell /kg pt wt)
3494374|NCT00720785|Experimental|2|1.3 mg/m2/dose administered as a 3 to 5 second bolusintravenous injection
3494375|NCT00678821|Experimental|1|Patients with PH will be randomized to either aerobicexercise training plus education (AET) or education only (Ed-only) treatments
3494376|NCT00678821|Active Comparator|2|A comparison group of patients with ILD who do not have secondary PH (ILD- only) will also undergo the AET arm
3494377|NCT00589654||1|
3494378|NCT00572481|Other|Sentinel Lymph Node Biopsy Only|Axillary Reverse Mapping
3494379|NCT00572481|Other|Full Axillary Lymph Node Dissection|Axillary Reverse Mapping
3494380|NCT00523627||Healthy Volunteers with normal glucose regulation|Healthy volunteers with normal glucose regulation
3494381|NCT00491842||At-risk|Individuals at-risk for HD
3494382|NCT00491842||Presymptomatic|Presymptomatic carriers of HD
3494383|NCT00482833|Experimental|ARM A - ATO/ATRA|
3494384|NCT00482833|Active Comparator|ARM B - ATRA|
3494385|NCT00471302||1|Healthy adults in a malaria endemic area in Mali
3129855|NCT03246152|Experimental|Bevacizumab group|Monthly intravitreal injection of 2.5 mg of Bevacizumab for at least 3 consecutive months. This is followed by treat and extend regimen after resolution of macular edema.
3129856|NCT03246646|Experimental|Coaching + VA CRAFT|Telephone coaching along with web-based CRAFT course
3129857|NCT03246646|Other|Treatment as usual|Treatment as usual matched comparison
3129858|NCT03246672|Experimental|maintenance|behavioral intervention to increase adherence to lifestyle recommendations
3129859|NCT03246724|Experimental|Cataract Procedures|"The following ocular procedures will fall under this arm of the study:~• Cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
3494386|NCT00428987||lean|Normal weight men and women over the age of 18 years with BMI greater than 18.5 and less than 25, who are reasonably healthy
3494387|NCT00428987||obese|Obese men and women over the age of 18 years with BMI greater than 30, who are reasonably healthy
3494388|NCT00428987||overweight|Overweight men and women over the age of 18 years with BMI greater than 25 and less than 30, who are reasonably healthy
3129860|NCT03246724|Experimental|Retina Procedures|"The following ocular procedures will fall under this arm of the study:~Pars plana vitrectomy~Pars plana vitrectomy with cataracts, epiretinal membrane peel, pars plana lensectomy, and/or endolaser, silicone oil removal~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
3494389|NCT00381381|Experimental|1|
3494390|NCT00381121||Kidney disease cohort|Individuals with a clinically indicated biopsy are recruited and/or surplus tissue that remains from past clinical interventions is obtained.
3129861|NCT03246724|Experimental|Cornea Procedures|"The following ocular procedures will fall under this arm of the study:~Descemet Stripping Endothelial Keratoplasty (DSEK)~Cataracts with Descemet Stripping Endothelial Keratoplasty (DSEK)~Descemet Membrane Endothelial Keratoplasty (DMEK)~Cataracts with Descemet Membrane Endothelial Keratoplasty (DMEK)~Conjunctival and/or corneal lesion excisions~Pterygium~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
3132538|NCT03435692|Active Comparator|Lumbar Epidural Catheter|"Children undergoing pediatric hip surgery will have an epidural catheter placed (with bolus and continuous infusion of ropivacaine) intraoperatively for perioperative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
3132785|NCT03451084|Experimental|Part 1: Dose Level 2|
3494391|NCT00353158|Active Comparator|A|Subjects currently on or previously on chronic voriconazole or subjects who are scheduled to begin voriconazole
3494392|NCT00353158|Experimental|B|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
3494393|NCT00352573||Normal Volunteers|Adults over 21 years old
3494394|NCT00344331||Patients with a diagnosis of Niemann-Pick type C (NPC) of either sex and any age|Participants may range from neurologically asymptomatic to severe and may have liver disease or unrelated comorbidities, but must be stable enough to safely travel and tolerate medical evaluations.
3494395|NCT00341679||Family Members|Family members need to be blood relatives of the proband with the diagnosis of an autoimmune disease
3494396|NCT00341679||IIM Patient|Adult and pediatric patients with diagnosis of myositis or a related autoimmune or rheumatic disorder (by Bohan and Peter criteria, American College of Rheumatology, or other criteria).
3494397|NCT00341679||Normal volunteers|gender and race-matched to a subset of autoimmune subjects as controls. Should be without any autoimmune disease.
3494398|NCT00341237||polymorphisms|Specimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.
3494399|NCT00340028||Women in Early Pregnancy|Women enrolled in the University of North Carolina's Right from the Start study are followed while trying to become pregnant and through 9 weeks of pregnancy
3494400|NCT00314119||1|Men and women between 20 and 50 years of age diagnosed with NF1 and their biological parents are eligible for this study.
3129862|NCT03246724|Experimental|Glaucoma Procedures|"The following ocular procedures will fall under this arm of the study:~Ahmed valve~Ahmed valve with cataracts~Trabeculectomy~Trabeculectomy with cataracts~Baerveldt~Baerveldt with cataracts~Endocyclophotocoagulation~Endocyclophotocoagulation with cataracts~Istent~Cataracts with istent~Kahook~Cataracts with kahook~Cypass~Cypass with cataracts~Each subject will receive a capsule and an intravenous injection; however, they will not know which one is administering the sedation. Each patient will be randomized to one of the two groups listed below within this arm of the study:~Triazolam oral sedation with sodium chloride 0.9% intravenous placebo~Microcrystalline cellulose oral placebo with midazolam intravenous sedation"
3129863|NCT03247322|Experimental|mHealth Group|Patients in the intervention cohort will have enhanced medication safety monitoring utilizing a Pharmacist-led medication therapy using mHealth application. The application will provide patients a useful tool to conduct self-care monitoring and management, including timely reminders to take medications, automated messages when patients miss multiple medication doses, tracking of medication side effects and reporting trends in blood pressures and glucoses (when applicable).
3132786|NCT03451084|Experimental|Part 1: Dose Level 3|
3494401|NCT00302146||Asymptomatic|Unaffected at-risk individuals with or without a first degree family member with parkinsonism, GD with and without a family history of PD, Gaucher carriers with and without a family history of PD.
3494402|NCT00302146||Control|Controls will include subjects without GBA mutations, with sporadic PD and healthy volunteers who do not have a family history of parkinsonism or Gaucher disease.
3494403|NCT00302146||PD|Subjects with parkinsonism to better characterize the parkinsonian phenotype (e.g.,GD/PD, Sporadic PD, Gaucher carrier PD).
3494404|NCT00250159||1/CAH Patients Managed at the NIH|Patients with Congenital Adrenal Hyperplasia (CAH).
3494405|NCT00250159||2/CAH Patients Managed by Outside Physicians|Patients with Congenital Adrenal Hyperplasia (CAH) followed by home physician post visit at NIH.
3494406|NCT00250159||3/Relatives of Patients|Relatives (mostly parents) of patients will be genotyped. This is often necessary to establish the genotype of the patient.
3494407|NCT00250159||4/FMPP Patients|Patients with Familial Male-Limited Precocious Puberty (FMPP).
3494408|NCT00250159||5/Patients with Androgen Excess of Unknown Etiology|Patients with Androgen Excess of Unknown Etiology followed by home physician post visit at NIH.
3494409|NCT00102648|Experimental|Treatment (temozolomide and lonafarnib)|Patients receive temozolomide PO QD on days 1-7 and 15-21 and lonafarnib PO BID on days 8-14 and 22-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3494410|NCT00102544|Experimental|All cohorts (prostate biopsy percutaneous biopsy and ablation)|This study will consist of comparison of tracked imaging with near-simultaneous actual imaging .
3494411|NCT00078078||Methylmalonic Acidemia|Individuals with methylmalonic acidemia
3494412|NCT00071045||1|patients undergoing allogeneic stem cell transplantation
3494413|NCT00071045||2|HLA compatible donors
3494414|NCT00068003||1/Cancer Patients|Patients with a current diagnosis of cancer
3494415|NCT00068003||2/Healthy Volunteers|Healthy volunteers
3494416|NCT00055172||Non-sibling relative|18 years of age or older
3494417|NCT00055172||Patients (index cases)|Patients (index cases), 6 months of age or older
3494418|NCT00055172||Siblings|Siblings, 6 months of age or older
3494419|NCT00051857||1/Healthy Controls|Subjects 5 years old and up with musculoskeletal impairment, pathology, or variant.
3494420|NCT00051857||2/Healthy Volunteers|Subjects 5 years old and up without musculoskeletal impairment, pathology, or variant.
3494421|NCT00047853|Experimental|Acoustic startle|loud noises with MEG only
3494422|NCT00047853|Experimental|Threat of shock|threat of electric shock
3494423|NCT00046189||1|Patients with XP
3494424|NCT00046189||2|Family members from XP families with known DNA repair gene mutations
3494425|NCT00038675|Experimental|Imatinib|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily.
3494426|NCT00023049||1|patients with known SNHL and/or peripheral vestibular dysfunction
3494427|NCT00023023||Adults and children subjects|The NIH and SH components will enroll and follow only adult (age (Bullet)18) blood donor or recipient subjects. CNMC will enroll and follow children between the ages of 6 months and 18 years.
3494428|NCT00001876||Combo|Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.
3494429|NCT00001876||pulmonary fibrosis|Patients with biobsy-proven idiopathic pulmonary fibrosis only.
3494430|NCT00001876||rheumatoid arthritis|Patients with rheumatoid arthritis only.
3494431|NCT00001711||Healthy Volunteers and Patients|Healthy volunteers and patients age 18 and older.
3494432|NCT00001645||Diarrhea GI Parasite|Subjects infected with a GI parasite
3494433|NCT00001645||Echinococcus|Subjects infected with echinococcus
3494434|NCT00001645||Intestinal Worm|Subjects infected with parasitic intestinal worm
3494435|NCT00001645||Malaria|Subjects infected with malaria
3494436|NCT00001645||Parasitic Infection|Subjects infected with a parasitic infection that is not included in the other cohorts
3494437|NCT00001604||1|Subjects with a family history of stuttering
3494438|NCT00001595||Patients with pituitary tumors or hypothalamic defects|Patients with pituitary tumors or hypothalamic defects
3494439|NCT00001594||Children with OI|Children with OI
3494440|NCT00001506||Patients|With dermatologic diseases and systemic diseases with cutaneous manifestations
3494441|NCT00001481|Placebo Comparator|Group 1, Hormone and Placebo Group|8 weeks of hormonal addback plus 4 weeks of placebo
3494442|NCT00001481|Active Comparator|Group 2, Continued Replacement Group|12 weeks of hormone addback
3494443|NCT00001452||1|families with PPNAD and/or Carney complex
3494444|NCT00001405||Healthy Volunteers|Healthy Adult Volunteers
3494445|NCT00001405||Patients|Pts with PID or other blood disorder or clinical history consistent with PID or other blood disorder. Pts are able to volunteer as patient for research collection only per PI discretion.
3494446|NCT00001393||Subjects|Individuals with focal segmental glomerulosclerosis (FSGS)
3494447|NCT00001367||family members|Family Members who are 2 years old or older of people with a neurological disorder
3494448|NCT00001367||healthy volunteers|healthy volunteers age 18 and older
3494449|NCT00001367||patients|subjects with neurological disorders who are 2 years old or older
3129864|NCT03247322|No Intervention|Usual Care Group|Subjects in the control group will receive the usual standard of follow up care for kidney transplant patients.
3129865|NCT03247517|Placebo Comparator|Placebo|Placebo, qd, oral capsule
3129866|NCT03247517|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
3129867|NCT03247517|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
3129868|NCT03247530|Placebo Comparator|Placebo|Placebo, qd, oral capsule
3129869|NCT03247530|Experimental|100mg SPN-812|100mg SPN-812, qd, oral capsule
3129870|NCT03247530|Experimental|200mg SPN-812|200mg SPN-812, qd, oral capsule
3129871|NCT03247543|Placebo Comparator|Placebo|Placebo, qd, oral capsule
3129872|NCT03247543|Active Comparator|200mg SPN-812|200mg SPN-812, qd, oral capsule
3129873|NCT03247543|Active Comparator|400mg SPN-812|400mg SPN-812, qd, oral capsule
3129874|NCT03247556|Placebo Comparator|Placebo|Placebo, qd, oral capsule
3129875|NCT03247556|Experimental|400mg SPN-812|400mg SPN-812, qd, oral capsule
3129876|NCT03247556|Experimental|600mg SPN-812|600mg SPN-812, qd, oral capsule
3129877|NCT03247673|Experimental|CT-P16|CT-P16 will be administrated once in IV infusion of 5mg/KG to healthy male subjects
3129878|NCT03247673|Active Comparator|EU-approved Avastin|EU-approved Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
3129879|NCT03247673|Active Comparator|US-licensed Avastin|US-licensed Avastin will be administrated once in IV infusion of 5mg/KG to healthy male subjects
3129880|NCT03247686|Placebo Comparator|Placebo|Placebo
3129881|NCT03247686|Active Comparator|RSLV-132|Experimental drug
3129882|NCT03247738|Experimental|Cangrelor|Cangrelor will be administered as 30 μg/kg bolus followed by 4 μg/kg/min infusion for 2 hours
3129883|NCT03247738|Placebo Comparator|Placebo|Normal saline bolus and infusion for 2 hours
3129884|NCT03247790|Experimental|Lasmiditan (Period 1)|200 mg Lasmiditan tablet given once orally during migraine attack.
3129885|NCT03247790|Experimental|Lasmiditan (Period 2)|200 mg Lasmiditan tablet given once orally during inter-ictal period.
3129886|NCT03247985|Active Comparator|PROLENE Polypropylene Tacking Mesh|Participants will be randomized to Tacking Mesh for their inguinal hernia surgery.
3129887|NCT03247985|Active Comparator|ProGrip Self-fixating Mesh|Participants will be randomized to Self-fixing mesh for their inguinal hernia surgery
3129888|NCT03248037|Experimental|Netarsudil|Netarsudil ophthalmic solution 0.02%, dosed topically once a day for 9 months
3129889|NCT03248037|Placebo Comparator|Placebo|Placebo eye drop, dosed topically once a day for 9 months
3129890|NCT03248440|Experimental|SUN-131 1.5% TDS|
3129891|NCT03248440|Placebo Comparator|Placebo TDS|
3129892|NCT03248492|Experimental|DS-8201a Low Dose|T-DM1 resistant/refractory (R/R) patients in the low dose treatment group
3129893|NCT03248492|Experimental|DS-8201a Medium Dose|T-DM1 resistant/refractory (R/R) patients in the medium dose treatment group
3129894|NCT03248492|Experimental|DS-8201a High Dose|T-DM1 resistant/refractory (R/R) patients in the high dose treatment group
3129895|NCT03248492|Other|Exploratory Arm|In Part 2b- Continuation Stage, about 10 T-DM1 Intolerant patients will receive the DS-8201a recommended dose (RD) as an exploratory arm
3129896|NCT03248882|Placebo Comparator|Placebo|Double-Blind, PF-05221304-matching Placebo
3129897|NCT03248882|Active Comparator|PF-05221304 - 2 mg|PF-05221304 - 2 mg, once-daily
3129898|NCT03248882|Active Comparator|PF-05221304 - 10 mg|PF-05221304 - 10 mg, once-daily
3129899|NCT03248882|Active Comparator|PF-05221304 - 25 mg|PF-05221304 - 25 mg, once-daily
3129900|NCT03248882|Active Comparator|PF-05221304 - 50 mg|PF-05221304 - 50 mg, once-daily
3129901|NCT03248947|Other|Pharmacy opioid use disorder care|A single-arm study to evaluate the feasibility and acceptability of transitioning office-based buprenorphine treatment of adult patients with opioid use disorder from physicians to pharmacists.
3129902|NCT03249116|Active Comparator|Control - interaction with a stuffed dog|Active control - interaction with a stuffed dog
3129903|NCT03249116|Experimental|Therapy dog - social|animal-assisted intervention - social interaction only with therapy dog during stress task.
3129904|NCT03249116|Experimental|Therapy dog - Social + physical|animal-assisted intervention - Social interaction and physical interaction with therapy dog during stress task.
3129905|NCT03249272|Active Comparator|Hypertrophic cardiomyopathy|
3129906|NCT03249272|Active Comparator|Non-ischemic dilated cardiomyopathy|
3129907|NCT03249272|Active Comparator|Control|
3132787|NCT03451084|Experimental|Part 1: Dose Level 4|
3180222|NCT00681148|Experimental|A|Botox injection
3129908|NCT03249454|Experimental|Anode, then Cathode, then Anode, then Sham, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129909|NCT03249454|Experimental|Sham, then Cathode, then Anode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129910|NCT03249454|Experimental|Anode, then Cathode, then Sham, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129911|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Anode, then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129912|NCT03249454|Experimental|Anode, then Anode, then Sham, then Cathode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129913|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Cathode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129914|NCT03249454|Experimental|Cathode, then Anode, then Cathode, then Sham, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3132788|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level -1 & Azacitidine|
3129915|NCT03249454|Experimental|Sham, then Anode, then Cathode, then Anode, then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129916|NCT03249454|Experimental|Cathode, then Cathode, then Sham, then Anode, then Anode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129917|NCT03249454|Experimental|Anode, Then Cathode, Then Anode, Then Cathode Then Sham tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129918|NCT03249454|Experimental|Sham, Then Anode, Then Anode, Then Cathode, Then Cathode tsDCS|5 tsDCS sessions were performed for each subject, with at least a 1 week washout period between tsDCS sessions. For each session, the subject was randomly assigned to cathodal, anodal or sham tsDCS. Each subject who completed the study received 2 cathodal, 2 anodal and 1 sham tsDCS session.
3129919|NCT03249584|Other|OsteoCool™ RF Ablation|Subjects will undergo a single OsteoCool™ RF Ablation procedure.
3132789|NCT03451084|Experimental|Part 2:ASLAN003 at Optinum Dose Level & Azacitidine|
3129920|NCT03249779|Experimental|Scrambler|All participants will receive electrical stimulation applied to the lower extremities using the Scrambler.
3129921|NCT03249909|Other|Exufiber Ag +|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
3129922|NCT03249909|Other|Exufiber|Gelling fibre dressing without silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
3129923|NCT03249909|Other|Aquacel® Ag Extra|Gelling fibre dressing with silver to treat chronic wounds, acute wounds, and pressure ulcers. Data from these groups were analyzed separately with no comparative analysis.
3129924|NCT03249935|Experimental|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
3180223|NCT00681148|Placebo Comparator|B|Saline injection
3180224|NCT00681161|Other|A|
3129925|NCT03250182|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol per protocol. Administered as 2 inhalations per use as instructed in the protocol.
3129926|NCT03250234|Other|Adequate Carbohydrate|Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
3129927|NCT03250234|Other|Low Carbohydrate|Non-nutritive control beverage. Low carbohydrate diet 1.2 g/kg/d
3129928|NCT03250689|Experimental|Danirixin 35 mg|Eligible subjects will receive danirixin 35 mg tablet with food twice daily for 14 Days.
3129929|NCT03250689|Experimental|Placebo Comparator|Eligible subjects will receive placebo tablet with food twice daily for 14 Days.
3129930|NCT03251482|Experimental|Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3129931|NCT03251482|Experimental|Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3180225|NCT00681174|Active Comparator|Control|Control intervention will be intraoperative i.v. morphine administration 30 minutes before the end of anesthesia.
3180226|NCT00681174|Experimental|CROxy|The intervention group will receive controlled-release oxycodone 1 h pre-operatively
3129932|NCT03251482|Experimental|Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3129933|NCT03251482|Experimental|Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3129934|NCT03251482|Experimental|Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3129935|NCT03251482|Experimental|Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban)|Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.
3129936|NCT03251482|Experimental|Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
3129937|NCT03251482|Experimental|Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
3129938|NCT03251482|Experimental|Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
3129939|NCT03251482|Experimental|Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo|Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.
3129940|NCT03251482|Experimental|Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg|Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.
3129941|NCT03251937|Experimental|Spinal Cord Stimulation|Spectra WaveWriter SCS System
3129942|NCT03251963|Experimental|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
3129943|NCT03251963|Experimental|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose.
3129944|NCT03252015|Experimental|Probe Drug Cocktail (Cohort 1a)|Probe Drug Cocktail administered orally on Day -3.
3129945|NCT03252015|Experimental|200 milligrams (mg) Lasmiditan+Probe Drug Cocktail (Cohort 1)|200 mg lasmiditan administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
3129946|NCT03252015|Placebo Comparator|Placebo+Probe Drug Cocktail (Cohort 1b)|Placebo administered alone, orally, on Days 1-6 and concurrently with probe drug cocktail on Day 7.
3129947|NCT03252015|Experimental|400 mg Lasmiditan (Cohort 2a)|400 mg lasmiditan administered orally for 7 days.
3129948|NCT03252015|Experimental|Placebo (Cohort 2b)|Placebo administered orally for 7 days.
3129949|NCT03252145|Experimental|Negative Pressure|PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
3129950|NCT03252145|Active Comparator|Manual Lymph Drainage|Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb
3180227|NCT00681200|Active Comparator|Enhanced health education program|This active treatment group consists of classes in health education and a social support group to enhance participant motivation and positive reinforcement to make healthier lifestyle choices (e.g. wholesome diet, increased exercise, reduced salt intake, and decreased use of alcohol and smoking). Note that is comparison group does not have a stress management component.
3180228|NCT00681200|Experimental|Transcendental Meditation program|Transcendental Meditation program plus health education. Basic AHA recommendations for lifestyle modification to reduce risk of heart disease will be given in a didactic classroom context.
3180229|NCT00681213|Experimental|A|Tacrolimus/Sirolimus
3129951|NCT03252353|Active Comparator|Octreotide capsules|Octreotide capsules
3129952|NCT03252353|Placebo Comparator|Matching Placebo|Matching placebo capsules
3129953|NCT03252431|Experimental|F-627|F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.
3129954|NCT03252431|Active Comparator|Neulasta|6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles
3129955|NCT03252964|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
3129956|NCT03253094|Active Comparator|Fluconazole|150 mg/day for 1 day
3129957|NCT03253094|Experimental|Ibrexafungerp 750mg|750mg QD for 1 day only
3129958|NCT03253094|Experimental|Ibrexafungerp 300mg|300mg BID for 1 day only
3129959|NCT03253094|Experimental|Ibrexafungerp 450mg|450mg BID for 1 day only
3129960|NCT03253094|Experimental|Ibrexafungerp 150mg|150mg BID for 3 days
3129961|NCT03253094|Experimental|Ibrexafungerp 300mg D1-D3|300mg BID for 3 days
3180230|NCT00681213|Experimental|B|Tacrolimus/MMF
3180231|NCT00681213|Experimental|C|Neoral/Sirolimus
3129965|NCT03254108|Experimental|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
3129966|NCT03254108|Experimental|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
3129967|NCT03254108|Experimental|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
3129968|NCT03254108|Experimental|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
3129969|NCT03254108|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
3129970|NCT03254134||Atrial Fibrillation|patients with atrial fibrillation
3129971|NCT03254147||patients prescribed with Oral Anti-coagulants|warfarin and non-vitamin K dependent oral anti-coagulants
3129972|NCT03254459|Experimental|Buprenorphine Sublingual Spray 0.5 mg|Buprenorphine Sublingual Spray 0.5 milligrams (mg) three times a day (TID) for 7 days.
3129973|NCT03254459|Active Comparator|Standard of Care Narcotic Therapy|Morphine intravenous (IV), 4 mg TID for 24 hours, followed by oxycodone hydrochloride tablet, 10 mg TID for 6 days.
3129974|NCT03254602|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound treatment applied along the length and width of the proximal Plantar Fascia. 1000 - 5 Joule pulses were applied twice, four weeks apart.
3129975|NCT03254719|Other|Treatment Arm|All participants enrolled in the study will receive chiropractic care consistent with the usual chiropractic procedures for the management of chronic low back pain at the Iowa City VA Health Care System. Participants will also complete study assessments as described in outcomes.
3129976|NCT03255187|Experimental|Fish oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of fish oil (marine-derived n-3 PUFA) for 4 consecutive months.
3129977|NCT03255187|Placebo Comparator|Sunflower seed oil supplementation|This group receive 2.5 g/day (two 1.25-g capsules daily) of placebo (sunflower seed oil) for 4 consecutive months.
3129978|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129979|NCT03255291|Experimental|Risk Display Format:Risk Ladder:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129980|NCT03255291|Experimental|Risk Display Format:Table:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129981|NCT03255291|Experimental|Risk Display Format:Table: Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129982|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Exercise|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down an exercise goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129983|NCT03255291|Experimental|Risk Display Format:Text:Imagery Behavior:Sleep|"With help from a research assistant, participants complete the Risk Assessment App. The App asks demographic & health questions. It then provides personalized risk estimates for participants' current activity level & how it would change with regular exercise.~Participants take Baseline Survey 1.~Participants listen to an audio recording that guides them through a mental imagery activity. They write down a sleep goal & are asked to practice the mental imagery twice a day for 3 weeks.~Participants take Baseline Survey 2.~Participants receive text messages reminding them to practice the mental imagery twice daily for 5 minutes each time (3 texts a week for 3 weeks).~Participants take surveys via text at the end of each week for 4 weeks.~90 days post-baseline, participants complete a survey sent through the mail.~Participants may be contacted for another survey 1 year later."
3129984|NCT03255382|Experimental|Risankizumab|Participants randomized to receive open-label risankizumab 150 mg by subcutaneous injection at Weeks 0, 4, and 16.
3129985|NCT03255382|Active Comparator|Fumaderm|Participants randomized to receive open-label Fumaderm 30 mg administered as a tablet orally once daily from Week 0 to Week 2 and then up to 240 mg, 3 times daily from Week 3 to Week 24 if 90% Improvement in Psoriasis Area and Severity Index (PASI90) is not achieved and if tolerability allows.
3129986|NCT03255655|Experimental|ITU Treatment|Intense Therapeutic Ultrasound (ITU) treatment applied along the length and width of the Plantar Fascia: 350 - 5 Joule pulses were applied twice, two weeks apart.
3129987|NCT03255655|Placebo Comparator|Sham ITU Treatment|Sham / Placebo Intense Therapeutic Ultrasound treatment (ITU) applied along the length and width of the Plantar Fascia: 350 - 0 Joule pulses were applied twice, two weeks apart.
3129988|NCT03255733|Experimental|Intense Therapeutic Ultrasound Treatment|Intense Therapeutic Ultrasound applied along and length and width of the Common Extensor Tendon. 80, 1 Joule pulses were applied twice, four weeks apart.
3129989|NCT03255824|Active Comparator|Propofol Group|Group of patients to be administered a standard Propofol, Midazolam, Fentanyl anesthesia combination.
3129990|NCT03255824|Experimental|Dexmedetomidine Group|Group of patients to be administered the Dexmedetomidine and Midazolam anesthesia combination.
3129991|NCT03255902|Experimental|Families attending parenting classes|Families attended 6 parenting sessions, filled out daily glucose screens, & questionnaires
3129992|NCT03255941|Active Comparator|Clinic Provider - Urban|Urban Clinic Provider providing DMPA or Sayana Press
3129993|NCT03255941|Active Comparator|Lay Provider - Urban|Urban Lay Provider providing DMPA or Sayana Press
3129994|NCT03255941|Active Comparator|Clinic Provider- Rural|Rural Clinic Provider providing DMPA or Sayana Press
3129995|NCT03255941|Active Comparator|Lay Provider- Rural|Rural Lay Provider providing DMPA or Sayana Press
3129996|NCT03255980|Experimental|Xonrid®|Xonrid® is a medical device for radiation dermatitis
3129997|NCT03255980|Active Comparator|Standard of Care|Standard of care suggested by MASCC guidelines
3129998|NCT03256136|Experimental|Nivolumab Plus Ipilimumab EGFR|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
3129999|NCT03256136|Experimental|Nivolumab Plus Ipilimumab ALK|Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
3130000|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed with EGFR Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
3130001|NCT03256136|Experimental|Nivolumab + Carboplatin + Pemetrexed ALK Chemo naive|Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
3130002|NCT03256162|Experimental|Ketamine|Participants will receive four once-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.
3130003|NCT03256162|Active Comparator|Midazolam|Participants will receive four once-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.
3130004|NCT03256253|Experimental|pregabalin|pregabalin up to daily dose of 600 mg
3132790|NCT03451721|Experimental|ImageReady™ MR Conditional Defibrillation System|"Subject is indicated to Class I/II indications per guidelines/consensus released by Chinese Society of Cardiac Pacing and Electrophysiology~Subject must have the ImageReady System as their initial (de novo) defibrillation system implant"
3130007|NCT03256526|Placebo Comparator|Placebo|
3130008|NCT03256526|Experimental|PF-06835919 Low Dose|75 mg once daily
3130009|NCT03256526|Experimental|PF-06835919 High Dose|300 mg once daily
3130010|NCT03256552|Active Comparator|GP MDI 28.8 micrograms|Glycopyrronium Metered Dose Inhaler 28.8 micrograms
3130011|NCT03256552|Active Comparator|GP MDI 14.4 micrograms|Glycopyrronium Metered Dose Inhaler 14.4 micrograms
3130012|NCT03256552|Active Comparator|GP MDI 7.2 micrograms|Glycopyrronium Metered Dose Inhaler 7.2 micrograms
3130013|NCT03256552|Placebo Comparator|Placebo MDI|Placebo Inhalation Aerosol
3130014|NCT03256578|Experimental|RFM visible|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants can see the information displayed on the New Life Box Respiratory Function Monitor screen.
3130015|NCT03256578|No Intervention|RFM masked|During resuscitation immediately following delivery the providers involved in the care of enrolled eligible infants cannot see the information displayed on the New Life Box Respiratory Function Monitor screen. Though the display is masked, data is collected in the background.
3130016|NCT03256695|Experimental|ABS eMDPI|Participants will receive 90 micrograms (mcg) of albuterol sulfate (ABS) via eMDPI (sitting on the upper part of the device for the purposes of detecting and storing usage information), 1 to 2 inhalations every 4 hours, as needed for 12 weeks. ABS eMDPI is a rescue/reliever agent that includes an eModule on top of the approved PROAIR RESPICLICK® inhaler. Participants will be allowed to continue use of other COPD and non-COPD medications as advised by their physician without changes unless deemed necessary by their physician.
3130017|NCT03256799|Experimental|Ivacaftor/Ataluren|
3130018|NCT03256851|Active Comparator|In-Person Delivered Exercise|"Participants in the in-person training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~complete one of their prescribed training sessions (lasting 1 hour total) each week with a physical therapist or trained member of the research team. Training sessions will focus on progression of aerobic and strength training exercises."
3130019|NCT03256851|Experimental|Telephone-Delivered Exercise|"Participants in the telephone-delivered training group will:~participate in a home exercise program including aerobic training 2x/week and strength training 3x/week.~receive a 60-minute, 1x/week telephone call from a trained research team member. Participants will report their progress from the prior week, discuss/troubleshoot any issues or problems, and receive progressions of both aerobic and strength training exercises for the upcoming week."
3130020|NCT03256968|Experimental|ataluren administration|dose of the drug administered (mg/kg body weight)
3130021|NCT03257189|Other|Single Arm|"This single arm consists of all subjects which will interact with the device under investigation as well as comparator devices.~This includes the Physiological signal monitor intervention, Heart rate and heart rate variability comparison device intervention, Respiration rate comparison device intervention, and Activity classification intervention."
3130022|NCT03257202|No Intervention|Control|No topical treatment
3130023|NCT03257202|Experimental|Clindamycin alone|topical clindamycin alone using Clindamycin 1% Gel
3130024|NCT03257202|Experimental|Benzoyl peroxide alone|topical benzoyl peroxide alone using Benzoyl Peroxide 5% Gel
3130025|NCT03257202|Experimental|Clindamycin and benzoyl peroxide|Topical clindamycin and topical benzoyl peroxide together using BenzaClin 5%-1% Topical Gel
3130026|NCT03257358|Other|Cohort 1|RMS patients who were newly prescribed commercially available fingolimod 0.5mg per day
3130027|NCT03257358|Other|Cohort 2|RMS patients who had been on commercially available fingolimod 0.5mg per day continuously for ≥ 2 years
3130028|NCT03257371||Post-traumatic knee OA|post-traumatic knee OA and requiring a tibial plateau and meniscus arthroplasty plus a femoral condyle arthroplasty
3130029|NCT03257410|Experimental|Theranova 400|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
3130030|NCT03257410|Active Comparator|Elisio-17H|Three (3) dialysis sessions per week in an in-center setting over 24-week period.
3130031|NCT03257631|Experimental|Pomalidomide|Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).
3130032|NCT03257657|Experimental|Observational Group|Intervention: Participants will receive usual WIC care plus they will be given a packet of written WIC materials on lifestyle recommendations at the baseline visit, and offered an appointment with a WIC Registered Dietitian (RD) at the 12 week visit.
3130033|NCT03257657|Experimental|Lifestyle Group|"Intervention: Visits with WIC staff at Baseline, 4 weeks, 8 weeks: Meet with WIC staff who will use motivational interviewing during visits. Participants will complete an iPad app that asks lifestyle questions. Responses are provided to WIC staff in an easy to read format to guide lifestyle counseling and informational handouts are provided to participants.~In-between visits: Participants receive text messages with informational and motivational content. They are invited to a Facebook private group providing informational and motivational content and encouraging cross-support amongst participants. They are asked to self-monitor activity and weekly weights and will be offered weekly phone coaching appointments with WIC staff."
3130034|NCT03257813|Other|Group A|In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
3130035|NCT03257813|Other|Group B|In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.
3130036|NCT03257865|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
3130037|NCT03257865|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind
3130038|NCT03257995|Experimental|Sequence 1|A-B-C
3130039|NCT03257995|Experimental|Sequence 2|B-C-A
3130040|NCT03257995|Experimental|Sequence 3|C-A-B
3130041|NCT03257995|Experimental|Sequence 4|A-C-B
3130042|NCT03257995|Experimental|Sequence 5|B-A-C
3130043|NCT03257995|Experimental|Sequence 6|C-B-A
3130044|NCT03258645||Acute ischemic stroke|Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke
3132791|NCT03451773|Experimental|1/ Arm 1-Gemcitabine + de-escalating dose of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + de-escalating dose of M7824
3130045|NCT03258710|Experimental|All subjects treated with Tenofovir Disoproxil Fumarate|Subjects with on-going ETV treatment will be switched to Tenofovir Disoproxil Fumarate treatment. Subjects will start TDF on the day ETV is discontinued, without having overlapping treatment periods. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
3130046|NCT03258762|Experimental|Healthy Japanese male subjects|Healthy Japanese male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
3180232|NCT00681239|Experimental|A|Patients will receive the modified Atkins diet in combination with a 10 oz KetoCal shake for the first month. The second month no shake will be given. Results at 1 month will be compared to 2 months, as well as to historical controls with the modified Atkins diet.
3130047|NCT03258762|Experimental|Healthy Caucasian male subjects|Healthy Caucasian male subjects will receive a single oral dose of Pyrimethamine 50 mg in the fasted state co-administered with calcium folinate 15 mg on Day 1. Oral calcium folinate will be administered once daily until Day 8. Blood samples for PK analysis will be collected prior to administering first dose of Pyrimethamine and over 22 days post dose. Each subject will participate in the study for a duration of approximately 2 months from screening to follow-up.
3130048|NCT03258814||Active Supervised Training (AST)|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive active supervised and standardized training (AST).
3130049|NCT03258814||Standard of Care (SOC) Physiotherapy|Participants with axSpA and treated with adalimumab (HUMIRA®) according to the local product label and local standard of care were to receive standard of care physiotherapy, according to the physiotherapist discretion.
3130050|NCT03259087|Experimental|Part 1: Mild Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
3130051|NCT03259087|Experimental|Part 1: Moderate Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
3130052|NCT03259087|Experimental|Part 1: Severe Renal Impairment|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
3130053|NCT03259087|Experimental|Part 1: Healthy Participants|Participants receive a single IV infusion of 200 mg MK-3866 over 30 minutes on Day 1.
3130054|NCT03259087|Experimental|Part 2: End-stage Renal Disease Undergoing Hemodialysis|End-stage renal disease (ESRD) participants received a single IV infusion of MK-3886 200 mg over 30 minutes on Day 1 just after hemodialysis (HD) in Period 1 and just before HD in Period 2. There was a washout of at least 6 days before dosing in Period 2.
3130055|NCT03259139|Experimental|Experimental: Violence with guns|Participants in this condition will play a video game with violent content which includes guns.
3130056|NCT03259139|Experimental|Experimental: Violence without guns|Participants in this condition will play a video game with violent content which does not include guns. Instead, the violence will include weapons such as swords.
3180233|NCT00681252|Experimental|A|
3130057|NCT03259139|Other|Control: No violence|Participants in this condition will play a video game which contains no violent content or weapons.
3130058|NCT03259308|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
3130059|NCT03259308|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab SC injection using PFS on Week 0, Week 4 and Week 8.
3130060|NCT03259308|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab SC injection using PFS on Week 0, Week 4, and Week 8.
3130061|NCT03259334|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligrams (mg) of ontamalimab (SHP647) subcutaneous (SC) injection using a prefilled syringe (PFS) on Week 0, Week 4 and Week 8.
3130062|NCT03259334|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
3130063|NCT03259334|Placebo Comparator|Placebo|Participants will receive placebo matched to ontamalimab (SHP647) SC injection using PFS on Week 0, Week 4 and Week 8.
3130064|NCT03259425|Experimental|Nivolumab and HF10, all participants|
3130065|NCT03259490|Experimental|Test Treatment|High dose empagliflozin/linagliptin/metformin XR fixed dose combination tablet
3130066|NCT03259490|Experimental|Reference Treatment|Single tablets of empagliflozin + linagliptin + metformin XR
3130067|NCT03259555|Experimental|Brexpiprazole|Participants received a starting dose of 2 milligrams (mg)/day brexpiprazole from Days 1 to 3, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
3130068|NCT03259555|Placebo Comparator|Placebo|Matching placebo was administered in the same way as brexpiprazole to maintain the blind.
3130069|NCT03259789|Active Comparator|Bexagliflozin tablets, 20 mg; Double-Blind|
3130070|NCT03259789|Placebo Comparator|Bexagliflozin tablets, Placebo; Double Blind|
3130071|NCT03259789|Experimental|Bexagliflozin Tablets, 20 mg; High Glycemic Group|
3130072|NCT03260205|Placebo Comparator|Placebo|Participant will receive placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
3130073|NCT03260205|Experimental|SPD489 (Lisdexamfetamine dimesylate)|Participants will be randomized to receive SPD489 capsule in a 5:5:5:5:6 ratio to SPD489 5, 10, 20, 30 milligram (mg) orally once daily for 6 weeks. Dosing will begin with the lowest strength of SPD489 (5 mg), and will be titrated until the randomly assigned fixed-dose is reached.
3130074|NCT03260426|Experimental|Clear Liquid Diet|Clear liquids on postoperative day zero and intestinal rate measured by Abstats
3130075|NCT03260426|Experimental|Regular Solid Diet|Regular diet from postoperative day zero and intestinal rate measured by Abstats
3130076|NCT03260595|Experimental|Crisaborole ointment 2%|
3130077|NCT03260595|Placebo Comparator|Vehicle|
3130078|NCT03260699|No Intervention|Control group|Subjects will receive two out-patient physical therapy (PT) visits per week for 2 weeks, followed by additional PT visits at clinician's discretion after TKA.
3132792|NCT03451773|Experimental|2/ Arm 2-Gemcitabine + Recommended Phase 2 Dose (RP2D) of M7824 (MSB0011359C)|Gemcitabine (dose based on genetic testing results) + RP2D of M7824
3132793|NCT03452033|Placebo Comparator|H-1337 Placebo|H-1337 Placebo
3132794|NCT03452033|Experimental|H-1337 [1]|H-1337 [1]
3132795|NCT03452033|Experimental|H-1337 [2]|H-1337 [2]
3130079|NCT03260699|Experimental|Bracing group|Subjects will be fitted with the Ongoing Care Solutions, Inc (OCSI) Rehabilitator brace prior to surgery. This brace will be worn for 6 weeks before surgery. The brace will be worn again after surgery ~10 days after surgery or when staples are removed until the end of the study. Participants will also have two PT visits per week for 2 weeks, followed by additional PT visits at clinician's discretion.
3130080|NCT03260790|Experimental|PCV13 and PPSV23|Participants randomized to receive PPSV23 primed with PCV13. Participants will receive PCV13 8 weeks prior to receiving PPSV23
3130081|NCT03260790|Active Comparator|PPSV23|Participants randomized to receive PPSV23 alone
3130082|NCT03260868|Experimental|Virtual|Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.
3130083|NCT03260868|Active Comparator|Traditional|Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.
3130084|NCT03260894|Experimental|Pembrolizumab + Epacadostat|
3130085|NCT03260894|Active Comparator|SoC (Sunitinib or Pazopanib)|Standard of care (SoC) (sunitinib or pazopanib monotherapy).
3130086|NCT03261037|Other|Participants With Suspicion of IPF/ILD|A participant will be eligible for inclusion if the Investigator has a suspicion that the participant may have IPF/ILD based on symptoms and radiological evidence.
3132796|NCT03452033|Experimental|H-1337 [3]|H-1337 [3]
3130087|NCT03261167|Experimental|Part 1: Subjects receiving 400 units of botulinum toxin A|Subjects will receive a total dose of 400 units of botulinum toxin A of which 240 units will be injected into the muscles that act on finger (including thumb flexors) and wrist flexors, and a total of 160 units will be injected into the muscles that act on the elbow flexors.
3130088|NCT03261167|Active Comparator|Part 1: Subjects receiving 240 units of botulinum toxin A|Subjects will receive 240 units of botulinum toxin A injected into the muscles that act on the finger (including thumb flexors) and wrist flexors. Placebo will be injected into the muscles that act on the elbow flexors.
3130089|NCT03261167|Experimental|Part 2,3,4: Subjects receiving 400 units of botulinum toxin A|Subjects will receive botulinum toxin A with a dose of 400 units injected in a divided doses.
3130090|NCT03261336|Experimental|Calcitriol, Ketoconazole, Hydrocortisone|Patients receive calcitriol (10mcg QD X3 weekly) in addition to ketoconazole (400mg QD) and hydrocortisone (20mg AM, 10 mg PM).
3130091|NCT03261947|Experimental|Western Safety Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, once daily (QD) for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 20 cycles. Participants with locally advanced or metastatic solid tumors with no standard therapeutic alternative in the United States were included in this cohort.
3130092|NCT03261947|Experimental|Pancreatic Cancer Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 4 cycles. Participants with metastatic pancreatic cancer who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
3130093|NCT03261947|Experimental|Metastatic CRC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 12 cycles. Participants with metastatic CRC who had progressed after at least 2 lines of previous standard chemotherapy were included in this cohort.
3130094|NCT03261947|Experimental|sqEC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 8 cycles. Participants with metastatic sqEC who had progressed after at least 1 line of standard chemotherapy were included in this cohort.
3130095|NCT03261947|Experimental|sqNSCLC Cohort|TAK-931 50 mg (2x25 mg or 5x10 mg), capsules, orally, QD for 14 days, followed by a 7-day washout period (14 days on and 7 days off study drug), in 21-day cycles until disease progression or unacceptable treatment-related toxicity up to 18 cycles. Participants with metastatic sqNSCLC who had progressed after at least 2 lines of standard treatment were included in this cohort.
3130096|NCT03261960|Experimental|Experimental Arm|BLI4700 Bowel Preparation
3130097|NCT03261960|Active Comparator|Control Arm|FDA Approved Bowel Preparation
3130098|NCT03261973|Other|DV8 esophageal deviation tool|This is a non-randomized one arm study.
3130099|NCT03261999|Experimental|Leuprolide Mesylate 25mg|"All subjects will be males with prostate cancer. They will be injected twice with a depot formulation containing 25 mg of Leuprolide Mesylate.~The first dose on day 0 and the second dose on day 84 (twelve weeks apart). Subjects will be followed until day 168."
3130100|NCT03262012|Experimental|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
3130101|NCT03262012|Experimental|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
3130102|NCT03262012|Experimental|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
3130103|NCT03262012|Active Comparator|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
3130104|NCT03262038|Experimental|Ondansetron IV|Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
3130105|NCT03262038|Placebo Comparator|Placebo|Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)
3130106|NCT03262233|Experimental|Active Deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
3130107|NCT03262233|Experimental|Active Non-deprived|"21 mg nicotine patches and 2 mg nicotine lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
3130108|NCT03262233|Active Comparator|Placebo Deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place 24 hours after start of quit attempt"
3130109|NCT03262233|Active Comparator|Placebo Non-deprived|"Placebo patches and placebo lozenges~+ First NPU task takes place during normal smoking prior to quit attempt"
3130110|NCT03262389|Experimental|Multiple Myeloma Patients|Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
3130111|NCT03262441|Experimental|Mycophenolate mofetil|Mycophenolate Mofetil 500mg Tablets once per day for one week as a lead in to limit drug-related side effects. Provided they are tolerating the drug at lower dose, they will then initiate Mycophenolate Mofetil 500mg Tablets twice daily orally for 22 months
3130112|NCT03263442|Experimental|Intervention|Thiamine 200 mg IV
3130113|NCT03263442|Placebo Comparator|Control|Normal saline IV
3130114|NCT03263702|Experimental|Computational Mapping Algorithm|AF mapping (utilizing CMA) will be performed and used to point the operator to regions within a heart chamber that should be interrogated further for suspicious electrogram activity, as measured by the St. Jude Ensite System, and ablated if the suspicious electrogram activity persists.
3130115|NCT03263780|Experimental|18F-Fluciclovine|10mCi +/-20% 18F-fluciclovine injection
3130116|NCT03264066|Experimental|Cohort 1 - SCCHN - Treatment Naive|In participants with recurrent or advanced / metastatic SSCHN who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130117|NCT03264066|Experimental|Cohort 2 - UC - Treatment Naive|In participants with advanced / metastatic UC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130118|NCT03264066|Experimental|Cohort 3 - RCC - Treatment Naive|In participants with metastatic RCC who are anti-PD-1 and anti-PD-L1 treatment naive, cobimetinib will be administered at the approved dose and schedule of 60 milligrams (mg) once daily (QD) for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130119|NCT03264066|Experimental|Cohort 4 - SCCHN - Previous Treatment Exposure|In participants with SCCHN whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130120|NCT03264066|Experimental|Cohort 5 - UC - Previous Treatment Exposure|In participants with UC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130121|NCT03264066|Experimental|Cohort 6 - RCC - Previous Treatment Exposure|In participants with RCC whose disease has progressed while receiving anti-PD-1 or anti-PD-L1 therapy, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle; and atezolizumab 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
3130122|NCT03264066|Experimental|Cohort 7 - Biopsy Cohort|In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
3130123|NCT03264092|Experimental|Wet suction|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the wet suction technique
3130124|NCT03264092|Experimental|Dry suction|This arm will include all the patients that will get and endoscopic ultrasound guided fine needle biopsy done with the dry suction technique
3130125|NCT03264092|Experimental|Slow pull|This arm will include all the patients that will get an endoscopic ultrasound guided fine needle biopsy done with the slow pull technique
3130126|NCT03264157|Experimental|BPL HRIG + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
3130127|NCT03264157|Active Comparator|Comparator HyperRab + RabAvert|20 IU/kg dose HRIG + active rabies vaccine
3130128|NCT03264248|Experimental|E-Scale|E-scale daily bodyweight system coupled with a standardized behavioral treatment weight-loss intervention for overweight or obese wheelchair users
3130129|NCT03264456|Experimental|[18F] Fluciclovine PET/MRI|[18F] Fluciclovine PET/MRI for pretreatment staging of high-risk prostate cancer
3130130|NCT03265119|Experimental|AEVI-001|
3130131|NCT03265119|Placebo Comparator|Placebo|
3130132|NCT03265132|Experimental|anakinra|2 mg/kg/day (max 100 mg/day) or 4 mg/kg/day (max 200 mg/day)
3130133|NCT03265132|Placebo Comparator|Placebo|Corresponding volume to anakinra 2 mg/kg/day or 4 mg/kg/day
3130134|NCT03265600|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
3130135|NCT03265600|Other|Low-dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group and allowed to receive behavioral and medical referrals and treatment as usual. All participants complete an action planning protocol during Week 7.
3130136|NCT03265938||Indirect laryngoscopy|Head and neck pathology patients undergoing indirect laryngoscopy. Patients with a past medical history of active or previously treated head and neck pathology.
3130137|NCT03266094|Other|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs Radio frequency (RF) energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
3130138|NCT03266107|Experimental|Treatment|BVN Ablation
3130139|NCT03266172|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 2, 4, 5 and 6) and GSK2982772 IR (Period 3)
3130140|NCT03266172|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR
3130141|NCT03266172|Experimental|Subjects in Part C|Subjects in Part C will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2)
3130142|NCT03266419|Experimental|Deep NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with deep NMB (post tetanic count 1-2) during operation
3130143|NCT03266419|Active Comparator|Moderate NMB using rocuronium|The abdomen is insufflated to 13 mmHg pneumoperitoneum with moderate NMB (train of four 1-2) during operation
3130144|NCT03266588|Experimental|Rimegepant|
3130145|NCT03267212|Active Comparator|Non-invasive Ventilation(NIV)|Subjects will perform FES-row testing while receiving bi-level positive airway pressure ventilation applied through a full face-mask.
3130146|NCT03267212|Sham Comparator|Sham Non-invasive ventilation(NIV)|Subjects will perform FES-row testing while receiving sham ventilation applied through a full face-mask.
3130147|NCT03267264|Experimental|Group 1|
3130148|NCT03267264|Experimental|Group 2|
3130149|NCT03267264|Experimental|Group 3|
3130150|NCT03267264|Experimental|Group 4|
3130151|NCT03267511|Experimental|Test Product 1|Participants will be instructed to apply experimental dentifrice containing 5% potassium nitrate (KNO3) / 0.2542% sodium fluoride (NaF) dentifrice with 0.5% spherical silica.
3130152|NCT03267511|Experimental|Test Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP.
3130153|NCT03267511|Active Comparator|Reference Product 1|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica.
3130154|NCT03267511|Active Comparator|Reference Product 2|Participants will be instructed to apply experimental dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP.
3132797|NCT03452176|Experimental|Scrambler|This arm will receive the Scrambler intervention for 1 hour daily x10 days.
3132798|NCT03452176|Sham Comparator|Sham-Control|This arm will receive the Sham-Control intervention for 1 hour daily x10 days.
3180234|NCT00681278||1|Hypertension patients with Type II Diabetes mellitus
3130155|NCT03267576|Experimental|Treatment Sequence AB|Participants will receive metformin monotherapy at stable doses (greater than or equal to [>=] 1500 milligram per day [mg/day]) orally once daily with canagliflozin 300 milligram (mg) tablet orally once daily (Treatment A) from Day 0 to 27 (treatment period 1), followed by sitagliptin 100 mg tablet orally once daily with metformin >=1500 mg/day (Treatment B) from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from Days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
3130156|NCT03267576|Experimental|Treatment Sequence BA|Participants will receive treatment B from Day 0 to 27 (treatment Period 1), followed by treatment A from Day 44 to 71 (treatment period 2), under fasted condition. A washout period of at least 16 days (from days 28 to 43) of metformin monotherapy will be maintained between each treatment period.
3130157|NCT03267940|Experimental|Run-in Portion: PEGCISGEM|Participants will receive 3.0 micrograms per kilogram (mcg/kg) PEGPH20 on Days 1, 8, and 15 in combination with 25 milligrams per meter square (mg/m^2) of CIS plus 1000 mg/m^2 of GEM administered on Days 2 and 9 of each 21-day cycle by intravenous (IV) infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130158|NCT03267940|Experimental|Run-in Portion: PEGCISGEMATEZO|After 6 participants from the PEGCISGEM arm are treated for at least 1 cycle without significant toxicities, new participants will be enrolled in this arm to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130159|NCT03267940|Experimental|Expansion Portion: PEGCISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130160|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Twice Weekly|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the Run-in portion safe and tolerable, new participants will be enrolled to receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130161|NCT03267940|Experimental|Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly|After the implementation of Protocol Amendment #3 and as communicated to the Investigators via a letter dated 22 March 2019, participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 4, 8, 11, 15 and 18 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 Cycle 1) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of Cycle 1 (cycle length = 21 days) by IV infusion. Participants will receive 3.0 mcg/kg PEGPH20 on Days 1, 8, and 15 in combination with 1200 mg ATEZO (administered 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle) plus 25 mg/m^2 of CIS and 1000 mg/m^2 GEM on Days 2 and 9 of each 21-day cycle from Cycle 2 and beyond by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130162|NCT03267940|Active Comparator|Expansion Portion: CISGEM|After the Investigators and the Sponsor considers the study treatment with PEGCISGEM during the run-in portion safe and tolerable, new participants will be enrolled to receive 25 mg/m^2 CIS and 1000 mg/m^2 GEM on Days 1 and 8 of each 21-day cycle by IV infusion. Treatment will continue until death, withdrawal of consent from the study, disease progression, or unacceptable toxicity.
3130163|NCT03268005|Experimental|Faster aspart + insulin degludec with or without metformin|
3180235|NCT00681304||1|Only one group of participants will be studies. There are no controls.
3180236|NCT00681317|Experimental|1|
3130164|NCT03268005|Active Comparator|NovoRapid/NovoLog + insulin degludec with or without metformin|
3130165|NCT03268343|Experimental|Schedule A: Fed Then Fasted|"Schedule A (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)."
3130166|NCT03268343|Experimental|Schedule B: Fasted Then Fed|"Schedule B (12 subjects):~Period 1: Cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state).~Period 2: Cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)."
3130167|NCT03268590|Experimental|All Study Participants|Breathing 21% oxygen via non-rebreather face mask followed by breathing 100% oxygen via non-rebreather face mask
3130168|NCT03268746|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
3130169|NCT03268941|Placebo Comparator|Part 1: Placebo|TAK-906 placebo-matching (4x0 mg), capsule, orally, twice daily (BID) on Days 1-8 and once on Day 9 under fasted conditions.
3130170|NCT03268941|Experimental|Part 1: TAK 906 Maleate 5 mg|TAK-906 maleate 1x5 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8, followed by TAK-906 maleate 1x5 mg, capsule, orally once on Day 9 under fasted conditions.
3130171|NCT03268941|Experimental|Part 1: TAK 906 Maleate 25 mg|TAK-906 maleate 1x25 mg, capsule, orally, BID and TAK-906 maleate placebo-matching (3x0 mg), capsules, orally, BID on Days 1-8 followed by TAK-906 maleate 1x25 mg, capsule, orally, once on Day 9 under fasted conditions.
3130172|NCT03268941|Experimental|Part 1: TAK 906 Maleate 100 mg|TAK-906 maleate 100 mg (4x25 mg), capsules, orally, BID on Days 1-8 and once a day on Day 9 under fasted conditions.
3130173|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fed Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (high fat breakfast), followed by a minimum 7- day washout.
3130174|NCT03268941|Experimental|Part 2: TAK-906 Maleate 25 mg Fasted Condition|TAK-906 maleate 1x25 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions.
3130175|NCT03268941|Active Comparator|Part 2: Metoclopramide 10 mg|Metaclopramide 10 mg, tablet, orally, once, 1 hour prior to breakfast on Day 1 in Part 2.
3130176|NCT03269435|Experimental|Greater Occipital Nerve Block|"Bilateral greater occipital nerve block with bupivacaine 0.5%~+ Normal saline IV"
3130177|NCT03269435|Active Comparator|Metoclopramide|"Metoclopramide 10mg IV~+ Bilateral greater occipital nerve block with normal saline"
3130178|NCT03269552|Experimental|Treatment (carfilzomib, rituximab)|Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve at least 25% M-protein reduction for Waldenstrom's macroglobulinemia or partial response for marginal zone lymphoma after 2 courses of carfilzomib, receive rituximab IV weekly on days 1, 8, 15, and 22 of course 3 and then monthly on day 1 of courses 4-6 in the absence of disease progression or unacceptable toxicity.
3130179|NCT03270085|Active Comparator|Colesevelam|"Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication."
3180237|NCT00681330|Experimental|A|
3180238|NCT00681343|Experimental|A|Thymoglobulin Induction
3180239|NCT00681343|Experimental|B|Campath-1H Induction
3130180|NCT03270085|Placebo Comparator|Placebo|"Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit & urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo."
3130181|NCT03270332|Experimental|Albuterol followed by placebo|Participants in this group will receive albuterol first followed by Placebo on the next visit
3130182|NCT03270332|Experimental|Placebo followed by albuterol|Participants in this group will receive placebo first followed by albuterol on the next visit
3130183|NCT03270436|Experimental|Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program|The Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program (WORD DPP) is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. The first 8 modules are intended to be delivered weekly. The last 8 modules are intended to be delivered every other week. Participants in the WORD DPP will be encouraged to maintain a daily weight, nutrition, physical activity and prayer log.
3130184|NCT03270436|Experimental|Partnership for Improving Lifestyle Intervention Diabetes Prevention Program|The Partnership for Improving Lifestyle Intervention Diabetes Prevention Program (PILI DPP) is a family and community based diabetes prevention curriculum that teaches participants to engage their social support (family and community) to have a healthy weight, eat healthy, and be physically active. The PILI DPP includes 14 modules that are intended to be delivered over a 24 week period and each module approximately 90 minutes in length. The first 4 modules are intended to be delivered weekly. The last 10 modules are intended to be delivered every other week. Participants will be encouraged to track their weight, physical activity, and their nutrition in a log on a daily basis.
3130185|NCT03270514|Experimental|Exparel Injectable Product|Liposomal Bupivacaine (Exparel) Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the liposomal bupivacaine (Exparel) group (~30).
3130186|NCT03270514|Active Comparator|Bupivacaine Hydrochloride|Bupivacaine Injection administered approximately 20 cc per inch of sternotomy wound. Half of subjects enrolled will be randomized to the bupivacaine group (~30).
3130187|NCT03270644|Experimental|Lasmiditan Reference|Single oral dose of lasmiditan 200 mg on Day 1 as reference treatment.
3130188|NCT03270644|Active Comparator|Propranolol Reference|Twice-daily oral doses of propranolol 80 mg on Days 4-10 as reference treatment.
3130189|NCT03270644|Experimental|Lasmiditan + Propranolol Test|Single oral dose of lasmiditan 200 mg + two oral doses of propranolol 80 mg on Day 9 as test treatment.
3180240|NCT00681343|Experimental|C|Daclizumab Induction
3180241|NCT00681356|Experimental|1|4975 - 15 mg
3130190|NCT03270657|Other|Intraoperative Recording During DBS Implant Surgery|Participants will be recruited and enrolled from individuals who have Parkinson's disease (PD) and who already are scheduled to undergo the planned deep brain electrode placement for treatment of their movement disorder. Intraoperative recordings of participants' neural signals will be made through the implanted deep brain electrode(s).
3130191|NCT03270943|Experimental|Mindful Self-Compassion (MFY)|An 8-week mindfulness self-compassion course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
3130192|NCT03270943|Active Comparator|Healthy Lifestyles (HLG)|An 8-week healthy lifestyles course for teens. 6 monthly continuation sessions will occur following completion of the 8-week course.
3130193|NCT03271021|Experimental|FMX101, 4% minocycline foam|FMX101, 4% minocycline foam applied topically once daily for 12 weeks
3130194|NCT03271021|Placebo Comparator|Vehicle foam|Vehicle foam applied topically once daily for 12 weeks
3130199|NCT03271307|No Intervention|AIm 1: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for outpatients in Aim 1. PITC guidelines recommend providers inform their OPD clients about HIV testing and refer them to HIV testing services at the facility.
3130200|NCT03271307|Experimental|Aim 1: Optimized standard of care|Facilities assigned to the optimized standard of care arm will receive additional guidance and support from the study team to adopt the Ministry of Health National HIV Guidelines for provider-initiated testing and counseling (PITC) for Aim 1.
3130201|NCT03271307|Experimental|Aim 1: Facility HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (PITC).
3130202|NCT03271307|No Intervention|Aim 2: Standard of care|Facilities assigned to the standard of care arm will receive no intervention and will continue with Ministry of Health National HIV Guidelines for index HIV testing for sexual partners of HIV-positive clients. Partner referral slips will be given to HIV-positive clients to encourage partner testing.
3130203|NCT03271307|Experimental|Aim 2: Index HIVST|Facilities assigned to the HIVST arm will implement HIVST procedures in lieu of recommendations provided by the Ministry of Health National HIV Guidelines (partner referral slips).
3130204|NCT03271424|No Intervention|Focus Group Discussions|Focus group discussions (FGD) with young women (n=2 FGDs) and young men (n=2 FGDs) in the study area to determine the best way to offer self-testing to study participants.
3130205|NCT03271424|Active Comparator|In Clinic Observation-Both|10 young women and 10 young men were assigned and conducted BOTH of the HIV self-tests. Participants tried two different self-testing kits, one that is oral fluid based (saliva), Oraquick HIV Self Test, and one that is blood based via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test and Atomo HIV Self Test - Both
3130206|NCT03271424|Active Comparator|In Clinic Observation-Subject Choice|20 young women and 20 young men were assigned and conducted EITHER of the HIV self-tests. Investigators asked them to choose which test they would prefer to use, one that is oral fluid based (saliva), Oraquick HIV Self Test, or one that requires the use blood via a finger prick, Atomo HIV Self Test. Oraquick HIV Self Test - Choice; Atomo HIV Self Test - choice
3130207|NCT03271528|Experimental|Lacosamide|Lacosamide titration was done to a target dose of 300mg. Participants took 100 mg of lacosamide once on day 1, 100 mg twice per day from day 2 through day 6 (200 mg daily total), on day 7 the lacosamide dose was increased to 150 mg twice daily (300 mg daily total), and on day 8 the participant took one dose of 150 mg.
3130208|NCT03271528|Placebo Comparator|Placebo oral capsule|Participants took a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
3130209|NCT03272139|Experimental|interscalene block (ISB)|The interscalene block will be done using an ultrasound-guided, in-plane approach. The anesthesiologists will target below the C5 nerve root. A 22 gauge 1.5-2 inch needle is advanced in-plane from lateral to medial through the middle scalene muscle until the needle tip is positioned in the interscalene groove between the C5 and C6 nerve roots. 15 20 ml of 0.5% bupivacaine will be injected.
3130210|NCT03272139|Experimental|superior trunk block (STB)|The superior trunk block will be performed at the point immediately distal to the roots when the c5-c6 form the superior trunk and lies anterior to the middle scalene muscle and below the deep cervical fascia, before the suprascapular nerve arises and goes into the omohyoid. A 22g 1.5-2inch needle will be advanced in-plane from lateral to medial. The needle tip will be placed lateral to the superior trunk and 15 20 ml of 0.5% bupivacaine will be injected just inferior to the deep cervical fasica. Local circumferential spread will be achieved both anterior and posterior to the superior trunk.
3130211|NCT03273153|Experimental|Cobimetinib and Atezolizumab|Participants will receive 60 mg of cobimetinib orally from Days 1 to 21 along with 840 mg of atezolizumab by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first. There will be no cobimetinib administration for 7 days (Days 22-28) in each cycle.
3130212|NCT03273153|Active Comparator|Pembrolizumab|Participants will receive 200 mg of pembrolizumab administered by IV infusion every 3 weeks (Q3W) until investigator-determined disease progression, unacceptable toxicity, death, patient or physician decision to withdraw, or pregnancy, whichever occurs first.
3130213|NCT03273166|Experimental|INVSENSOR00001 sensor|This is a nonrandomized single arm study wherein all subjects are enrolled into the experimental arm and receive both the INVSENSOR00001 sensor and the control sensor simultaneously on different fingers.
3130214|NCT03273257|Active Comparator|Riociguat|Patients will receive riociguat for 3 months followed by pulmonary endarterectomy.
3130215|NCT03273257|Placebo Comparator|Placebo|Patients will receive placebo for 3 months followed by pulmonary endarterectomy.
3130216|NCT03273270|Experimental|Active TMS|1 Hz repetitive transcranial magnetic stimulation
3130217|NCT03273270|Placebo Comparator|Sham TMS|No active stimulation
3130218|NCT03273283|Experimental|Intervention|Patients received a brief intervention on alcohol use. This brief intervention was a little chat based on motivational techniques to enhance motivation to reduce alcohol use or to initiate treatment. Patients were referred to specialized treatment when indicated.
3130219|NCT03273283|No Intervention|Control|Informative leaflets regarding alcohol use
3130220|NCT03273387|Placebo Comparator|Sugar pill|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
3130221|NCT03273387|Experimental|trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
3130222|NCT03273426|Experimental|Core needle Biopsy|Ultrasound-guided core needle biopsy (14G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
3130223|NCT03273426|Experimental|Vacuum-assisted biopsy|Vacuum-assisted biopsy (10G, ≥5 cores recommended) for complete clinical response (cCR) or near-cCR predicted by MRI.
3130224|NCT03273543|Experimental|Nasal Tip Projection|
3130225|NCT03273543|Experimental|Upper Lip Position|
3130226|NCT03273673|Experimental|Biofeedback Intervention|The 6-week biofeedback training program is focused on altering loading and movement asymmetry during biweekly sessions on non-consecutive days (12 sessions). The biofeedback training program will provide sensory (visual and tactile) feedback to the subject to heighten awareness of asymmetrical movement strategies (e.g. load shift, movement asymmetry) during a squat. The two exercises that will be completed during the biofeedback training program will be a visual feedback squat and a resisted squat (tactile feedback). Each of these tasks will be completed 30 (3 sets of 10 repetitions) times per session. We will provide a 20 second rest between trials, and a 10 minute break between the visual and tactile feedback exercises to decrease the effect of fatigue.
3130227|NCT03273673|No Intervention|Control|The 6-week attention control group program will focus on providing educational information to the participants related to the clinical and sports expectations as they are released to return to sport. These participants will be asked to meet 6 times during the 6-week intervention time period. Three of these visits will be completed in person and three will be completed using an online educational module (6 sessions). The online sessions will be completed in week 1, week 3, and week 5 while the in person sessions will be completed during week 2, week 4, and week 6.
3130228|NCT03273946||Subjects receiving fluticasone propionate|Eligible subjects will receive FP 50 µg twice daily inhaled via a pediatric pMDI with a face mask in clinical practice.
3130229|NCT03274076|Active Comparator|Tofacitinib|5mg Tofacitinib twice a day
3130230|NCT03274076|Placebo Comparator|Placebo|5mg Placebo twice a day
3130231|NCT03274440|Experimental|High THC/Low CBD Marijuana|This condition involves the ingestion of marijuana with a high THC (5-10%) and low CBD (<1%) content.
3130232|NCT03274440|Experimental|Low THC/High CBD Marijuana|This condition involves the ingestion of marijuana with a low THC (<1%) and high CBD (>10%) content.
3130233|NCT03274440|Placebo Comparator|No THC/No CBD|This condition involves the ingestion of a placebo control with no THC and no CBD content.
3130234|NCT03274453|Active Comparator|Ketamine Naive|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
3130235|NCT03274453|Placebo Comparator|Naive Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
3130236|NCT03274453|Placebo Comparator|Tolerant Placebo|Saline will be administered at the same rate as the ketamine infusion. Infusion will be maintained for 24 hours.
3130237|NCT03274453|Experimental|Tolerant Ketamine|"After an initial bolus of 0.2 mg/kg, the dose will be fixed at 0.12 mg/kg/hr of ketamine.~Infusion will be maintained for 24 hours."
3130238|NCT03274466|Experimental|Closed Incision Negative Pressure Therapy (ciNPT)|Prevena Peel & Place or Prevena Plus Customizable Dressing and ActiVAC Therapy Unit or Prevena Plus Therapy Unit
3130239|NCT03274466|Active Comparator|Standard of Care Dressing|Silver impregnated dressing
3130240|NCT03274518|Active Comparator|Online Hemodiafiltration|"The olHDF technique combines diffusion with high convection rates in which the dialysis fluid, free of toxins and pyrogens, is used to prepare the replacement fluid.~The online module of dialysis machine prepares the replacement fluid by a cold sterilization process. There is a cross-flow water preparation, in order to avoid the accumulation of possible contaminants. The addition of bicarbonate and acid solutions to water follows the process. Next, the ready-for-infusion dialysis solution is passed through another ultrafilter prior to being infused into patients."
3130241|NCT03274518|Experimental|Expanded Hemodialysis|More recently, membranes with high cutoff values, but with tight pore size distribution have been developed. The main concept is to keep both cutoff and retention onset values close to each other, but with a cutoff value lower than of albumin. This should allow removal of middle-to-high weight range uremic toxins, with very low albumin leak. Thus, these membranes, denominated high retention onset (HRO) membranes, allow performing both diffusive and convective processes in a conventional hemodialysis machine.
3130242|NCT03274804|Experimental|Single arm, prospective, open-label trial|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22) together with maraviroc administered perorally on day 1 to 21 of each cycle (d1-21; qd22).
3130243|NCT03274856|Other|Treatment Sequence 1|GLWL-01 (450mg) twice a day/ Placebo
3130244|NCT03274856|Other|Treatment Sequence 2|Placebo / GLWL-01 (450mg), twice a day
3130245|NCT03274986|Experimental|DFT015|ACRYSOF® IQ Extended Depth of Focus Intraocular lens (IOL), bilateral implantation
3130246|NCT03274986|Active Comparator|SN60WF|ACRYSOF® IQ Monofocal IOL, bilateral implantation
3130247|NCT03274999|Experimental|TrueTear™ Intranasal then Extranasal Application|TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 14.
3130248|NCT03274999|Experimental|TrueTear™ Extranasal then Intranasal Application|TrueTear™ device, extranasal (control) application, for approximately 3 minutes on Day 0 followed by TrueTear™ device, intranasal (test) application, for approximately 3 minutes on Day 14.
3130249|NCT03275246|Experimental|Total knee arthroplasty|Patients undergoing total knee arthroplasty
3130250|NCT03275389|Experimental|D-SUIV Adjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130251|NCT03275389|Experimental|D-SUIV Adjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1+AS03 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130252|NCT03275389|Experimental|D-SUIV Adjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1+AS03 vaccine at Day 1, one dose D-SUIV cH5/1N1+AS03 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS03 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130253|NCT03275389|Experimental|D-SUIV Adjuvanted Group 4|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130254|NCT03275389|Experimental|D-SUIV Adjuvanted Group 5|Subjects received one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130255|NCT03275389|Experimental|D-SUIV Adjuvanted Group 6|Subjects received one dose of D-SUIV cH8/1N1+AS01 vaccine at Day 1, one dose of D-SUIV cH5/1N1+AS01 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1+AS01 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130256|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 1|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH5/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130257|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 2|Subjects received one dose of D-SUIV cH5/1N1 vaccine at Day 1, one dose of Placebo at Day 57 and one booster dose of D-SUIV cH8/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130258|NCT03275389|Experimental|D-SUIV Unadjuvanted Group 3|Subjects received one dose of D-SUIV cH8/1N1 vaccine at Day 1, one dose of D-SUIV cH5/1N1 vaccine at Day 57 and one booster dose of D-SUIV cH11/1N1 vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130259|NCT03275389|Active Comparator|IIV4 Group|Subjects received one dose of Fluarix Quadrivalent (IIV4) vaccine at Day 1, one dose of Placebo at Day 57 and one dose of Fluarix Quadrivalent vaccine at Month 14. All doses were administered intramuscularly in the non-dominant arm.
3130260|NCT03275623|Active Comparator|Antibiotic treatment|Standard prenatal care with treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
3130261|NCT03275623|Active Comparator|No antibiotic treatment|Standard prenatal care without treatment for any urine culture with growth of 1- 100,000 CFU of any organism.
3130262|NCT03275766|Active Comparator|DLPFC facilitatory|"repetitive transcranial magnetic stimulation (rTMS) of 15 Hz over left DLPFC~usually effective in depression treatment, probably no specific effect on psychomotor slowing"
3130263|NCT03275766|Experimental|preSMA/SMA inhibitory|"repetitive transcranial magnetic stimulation (rTMS) of 1 Hz over preSMA/SMA~should inhibit overactive premotor cortices"
3130264|NCT03275766|Experimental|preSMA/SMA facilitatory|"intermittend theta burst stimulation (iTBS) over preSMA/SMA~should facilitate neural activity within premotor cortices"
3130265|NCT03275766|Sham Comparator|sham TMS|"sham rTMS with a placebo coil over occipital cortex~should have no effect at all (no transcranial magnetic stimulation, only sound)"
3130266|NCT03275870|Experimental|Hydroxychloroquine treatment|Hydroxychloroquine 200mg BID for 6 months
3130267|NCT03276026|Active Comparator|Control Group/Neostigmine|The control group will be the 63 patients who receive Neostigmine in a dose of 5mg, along with the anti-cholinergic glycopyrrolate 0.6mg.
3130268|NCT03276026|Active Comparator|Study Group/Sugammadex|63 patients will be given Sugammadex in a dose of 2mg/kg if the train of four twitch count is 2 and 4mg/kg if the twitch response has reached 1-2 post-tetanic counts with no twitch response to train of four.
3130269|NCT03276078|Experimental|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/Formoterol Fumarate 400/12μg inhalation powder twice-daily. Oral inhalation via Genuair® dry powder inhaler (DPI).
3130270|NCT03276494|Other|Intraosseous|Administration of intraosseous hypertonic saline
3132799|NCT03452189|Active Comparator|250mg of oral vancomycin First|After 3 months, initial experimental group will be switched to placebo for 3 months.
3130271|NCT03276637|Experimental|Healthy Active-Duty Airmen Cohort|Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.
3130272|NCT03276871|Active Comparator|Balloon Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a balloon dissection technique using the Spacemaker Balloon Dissector.
3130273|NCT03276871|Experimental|Telescopic Dissection|Patients will undergo laparoscopic TEP inguinal hernia repair and creation of the extraperitoneal space will be performed with a telescopic dissection technique.
3130274|NCT03276936|Experimental|Minocycline Foam 1.5%|FMX-103
3130275|NCT03276975|Active Comparator|Patching of CSF Leaks with Autologous Blood and Fibrin|CT fluoroscopy-guided blood and fibrin glue patching targeted to the site of CSF leak.
3130276|NCT03276975|Placebo Comparator|Simulated Patching Procedure|Instead of injection of blood and fibrin glue patching material through the needles, an equivalent volume of preservative free sterile Elliots B solution will be injected.
3130279|NCT03277274|Experimental|Group 1 Mild Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 milligram (mg), intravenous, administered as 60-minute infusion, once on Day 1.
3130280|NCT03277274|Experimental|Group 2 Moderate Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
3130281|NCT03277274|Experimental|Group 3 Severe Hepatic Impairment: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
3130282|NCT03277274|Experimental|Group 4 Healthy Participants: TAK-954 0.2 mg|TAK-954 0.2 mg, intravenous, administered as 60-minute infusion, once on Day 1.
3130283|NCT03277352|Experimental|INCAGN01876 + Pembrolizumab + Epacadostat|INCAGN01876 in combination with pembrolizumab and epacadostat
3130284|NCT03277378|Active Comparator|Group 1 (AB)|Group 1 (AB): anatomic lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
3130285|NCT03277378|Active Comparator|Group 2 (TB)|Group 2 (TB): targeted lead placement followed by BurstDR™ stimulation during an initial trial evaluation period
3130286|NCT03277794|Active Comparator|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
3130287|NCT03277794|Experimental|Full HOP-C Service|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
3130288|NCT03277846|Experimental|Accept ECT - TES|Accept ECT where subject is randomized to TES
3130289|NCT03277846|Placebo Comparator|Accept ECT - SHAM|Accept ECT where subject is randomized to a SHAM condition
3130290|NCT03277846|Experimental|Reject ECT - TES|Reject ECT where subject is randomized to TES
3130291|NCT03277846|Placebo Comparator|Reject ECT - SHAM|Reject ECT where subject is randomized to SHAM
3130292|NCT03278028|Experimental|Active|A-101 Topical Solutions
3130293|NCT03278028|Placebo Comparator|Vehicle|Vehicle
3180242|NCT00681356|Placebo Comparator|2|Placebo
3130294|NCT03278067||Vaccinated_Fluarix Tetra Group|Volunteered subjects who received GlaxoSmithKline's (GSK's) influenza vaccination (Fluarix Tetra) in 10 volunteer GP practices between 01 September and 30 November 2017.
3130295|NCT03278067||Vaccinated_Non GSK Group|Volunteered subjects who received non-GSK influenza vaccination in 10 volunteer GP practices between 01 September and 30 November 2017.
3130296|NCT03278067||Vaccinated_Unknown Group|Volunteered subjects who received influenza vaccination (GSK or non-GSK not known) in 10 volunteer GP practices between 01 September and 30 November 2017.
3130297|NCT03278106|Experimental|Treatment (TAS-102)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 orally PO BID on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3130298|NCT03278223|Active Comparator|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
3130299|NCT03278223|Active Comparator|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
3130300|NCT03278613|Experimental|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS treatment entails insertion of a 36 gauge needle electrode at a 60 degree angle 3-4 cm deep towards the tibial nerve, approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. The PTNS grounding electrode, placed near the calcaneus and the needle electrode will be connected to the ES-130 device pulse generator.
3130301|NCT03278613|Sham Comparator|Validated Sham|Sham treatment will use the Streitberger acupuncture placebo needle in the same location as the needle electrode for PTNS. The sham uses an active gel surface electrode pad placed on the bottom of the foot just below the fifth (smallest) toe. This location is not part of the acupuncture nerve pathway connected to the bladder, pelvis or any major organs. Electrical current is delivered to this pad via a TENS unit resulting in sensory stimulation.
3130302|NCT03278886|Experimental|Low dose naltrexone|Participants randomized to this group will receive low dose naltrexone (4.5 mg) for 8 weeks.
3130303|NCT03278886|Experimental|Nalmefene|Participants randomized to this group will receive nalmefene (18 mg) for 8 weeks.
3130304|NCT03279237|Experimental|FOLFIRINOX + pre-operative radiation|"FOLFIRINOX is a combination of 4 drugs that is administered twice per cycle~Oxaliplatin is administered intravenously~Leucovorin is administered intravenously~Irinotecan is administered intravenously~5-Fluorouracil is administered intravenously~Paclitaxel and Carboplatin will be given concurrently with radiation therapy every 7 days"
3130305|NCT03279458|Experimental|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform.
3130306|NCT03279458|Active Comparator|Ventilator|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted with the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air.The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
3130307|NCT03279731|Active Comparator|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg via subcutaneous injection. Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
3130308|NCT03279731|Placebo Comparator|Placebo|Pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg of placebo via subcutaneous injection. The placebo will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.The inactive ingredients include: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection.
3130309|NCT03280108|Experimental|Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
3130310|NCT03280108|Active Comparator|Monofocal IOL|AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
3130311|NCT03280121|Experimental|TIF using EsophyX ZR transoral device|Transoral incisionless fundoplication which is a minimally invasive treatment for gastroesophageal reflux disease (GERD) using EsophyX ZR transoral device
3130312|NCT03280264|Experimental|KHK7580|oral administration
3130313|NCT03280381|Experimental|NIFTY Feeding Cup First|Each caregiver/infant pair will first use the Nifty Feeding Cup for two feeds and then the standardized generic cup for two feeds.
3130314|NCT03280381|Experimental|Generic Medicine Cup First|Each caregiver/infant pair will first use the standardized generic cup for two feeds and then the Nifty Feeding Cup for two feeds.
3130315|NCT03280537|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
3130316|NCT03280537|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
3130317|NCT03280550|Experimental|Omalizumab|Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
3130318|NCT03280550|Placebo Comparator|Placebo|Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table. All participants were also treated during the entire study with intranasal corticosteroids (mometasone nasal spray) as background therapy.
3130319|NCT03280615|Experimental|Omega 3 fatty acids|Supplementation of 3.7 g of docosahexanoic and eicosapentanoic acids per day during 12 weeks
3130320|NCT03280615|Placebo Comparator|Corn oil|Supplementation of 3.7 g of corn oil per day during 12 weeks
3130321|NCT03281200||Anatomical main group:|
3130322|NCT03281200||Therapeutic subgroup|
3130323|NCT03281200||Pharmacological subgroup|
3130324|NCT03281200||Chemical subgroup|
3130325|NCT03281200||Chemical substance|
3130326|NCT03281304|Experimental|CP-690,550 5 mg|CP-690,550 5 mg tablet by mouth twice a day (BID)
3130327|NCT03281304|Experimental|CP-690,550 10 mg|CP-690,550 10 mg BID
3130328|NCT03281538|Experimental|CR845 0.5mcg/kg|CR845 0.5mcg/kg IV medication administered three times/week after dialysis
3130329|NCT03281577|Placebo Comparator|Placebo|TAK-954 placebo-matching, 60-minute infusion, intravenously (IV), once daily on Days 1 to 3.
3130330|NCT03281577|Experimental|TAK-954 0.1 mg|TAK-954 0.1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
3130331|NCT03281577|Experimental|TAK-954 0.3 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily for up to 3 days.
3130332|NCT03281577|Experimental|TAK-954 1 mg|TAK-954 1 mg, 60-minute infusion, IV, once daily on Days 1 to 3.
3130333|NCT03281668|Experimental|Intervention|Intervention consists of High Intensity Interval Training (HIIT) session which is af 3-5 minute warm up, followed by 10 repetitions of 1 minute bouts at individualized training intensity with 1 minute rest periods.
3130334|NCT03281876|Experimental|GSK3277511A Group|Healthy males and females, 40 to 80 years of age, who received two doses of the adjuvanted GSK3277511A investigational vaccine containing surface protein D (PD), protein E- type IV pilus assembly protein (PE-PilA,) and ubiquitous surface protein A2 (UspA2) at Day 1 and Day 61.
3130335|NCT03281876|Placebo Comparator|CONTROL Group|Healthy males and females, 40 to 80 years of age, who received two doses of placebo vaccine at Day 1 and Day 61.
3130336|NCT03282071|Experimental|Joyful Parenting Intervention|Subjects will participate in two-session interactive talks on joyful parenting (a core session intervention and booster intervention) and one family gathering activity; questionnaire evaluation will be conducted at baseline, post-session,1 month and 3 month after core session.
3130337|NCT03282071|No Intervention|Control|No intervention will be provided to control groups during study period.
3130339|NCT03282227|Experimental|M207 Microneedle System 3.8 mg|M207 Microneedle System 3.8 mg (1.9 mg/patch x 2 patches)
3130340|NCT03282240|Experimental|QIV-HD|Participants randomized to receive a single injection of 0.7 mL QIV-HD by intramuscular (IM) route at Day 0.
3130341|NCT03282240|Active Comparator|TIV-HD1 (Licensed TIV-HD1)|Participants randomized to receive a single injection of 0.5 mL licensed TIV-HD1 by IM route at Day 0.
3130342|NCT03282240|Active Comparator|TIV-HD2 (Investigational TIV-HD2)|Participants randomized to receive a single injection of 0.5 mL investigational TIV-HD2 by IM route at Day 0.
3130343|NCT03282357|Experimental|Radiesse|Subjects are randomized as to which of the two nasolabial folds is treated with Radiesse.
3130344|NCT03282357|Active Comparator|Restylane|Subjects are randomized as to which of the two nasolabial folds is treated with Restylane.
3130345|NCT03282591|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
3130346|NCT03282591|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
3130347|NCT03282682|Experimental|hypogonadal males without TRT|Strength training
3130348|NCT03282682|Experimental|hypogonadal males with TRT|Strength training and regular prescribed testosterone therapy given by participant urologist.
3130349|NCT03282682|Active Comparator|healthy eugonadal males|Strength training
3130350|NCT03283098|Placebo Comparator|Placebo|Intravenous (IV) administration of placebo three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
3130351|NCT03283098|Experimental|Etelcalcetide|5 mg intravenous (IV) dose of etelcalcetide three times a week (TIW) for 4 weeks for a total of 12 doses. Participants were followed for an additional 4 weeks.
3130352|NCT03283319|Experimental|3.75 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 plus AS03
3130353|NCT03283319|Experimental|7.5 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with AS03
3130354|NCT03283319|Experimental|15 ug Panblok H7 plus AS03|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with AS03
3130355|NCT03283319|Experimental|3.75 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 3.75 ug Panblok H7 adjuvanted with MF59
3130356|NCT03283319|Experimental|7.5 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 7.5 ug Panblok H7 adjuvanted with MF59
3130357|NCT03283319|Experimental|15 ug Panblok H7 plus MF59|Participants dosed intramuscularly (IM) on Days 1 and 29 with 15 ug Panblok H7 adjuvanted with MF59
3130360|NCT03283436|Experimental|Superior hypogastric plexus block|Prior to the laparoscopic hysterectomy and any additional procedures, the SHPB will be performed on patients in the treatment arm. The block will contain 10 mL of 0.25% bupivacaine hydrochloride (Bupivacaine; 2.5 mg/mL = 25 mg). The anesthetic works by blocking nerve conduction and the steroid by reducing inflammation. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
3130361|NCT03283436|No Intervention|No block|Patients in the control arm will undergo the hysterectomy with no intervention.
3130362|NCT03283553|Experimental|Multicomponent Intervention|1.) A one-page paper-pencil agenda setting checklist completed immediately before a regularly scheduled medical oncology visit to elicit and align patient and companion perspectives regarding issues to discuss with the provider, and to stimulate discussion about the role of the companion in the visit, 2.) facilitated registration for the patient portal (for patient and family member, as desired by the patient), and 3.) education (as relevant) on access to doctor's electronic visit notes.
3130363|NCT03283553|Placebo Comparator|Usual Care|Care as usual with the medical oncologist.
3130364|NCT03283696|Experimental|Olaratumab + Doxorubicin + Ifosfamide + Mesna|Olaratumab 15 milligrams per kilogram (mg/kg) on Days 1 and 8 of a 21-day cycle, in combination with doxorubicin and ifosfamide was administered. When the safety of the 15-mg/kg dose of olaratumab was established, a 20-mg/kg loading dose cycle of olaratumab on Days 1 and 8 of a 21-day cycle in Cycle 1 only, followed by 15 mg/kg on Days 1 and 8 of subsequent cycles in combination with doxorubicin and ifosfamide plus mesna, was administered.
3130365|NCT03283787|Active Comparator|Group 1|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
3130366|NCT03283787|Active Comparator|Group 2|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
3130367|NCT03283787|Active Comparator|Group 3|Negative Pressure Wound Therapy
3130368|NCT03284229|Experimental|Excimer Laser Coronary Atherectomy|ELCA® in patients with single or multivessel CAD either as a stand-alone modality or in conjunction with Percutaneous Transluminal Coronary Balloon Angioplasty (PTCA). The entire procedure will be carried out as per the site routine practice and the device will be used as per the 'Instruction for Use'. Treating physicians/study investigators will be trained by the study Sponsor on the study protocol and procedures prior to clinical investigation procedure. Subject preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted.
3130369|NCT03284359|Experimental|Pre-Consent Nudge Bundle|Arm 1 will be administered a novel pre-consent nudge bundle which incorporates several behavioral economic interventions within a brief survey. Participants will subsequently be asked by the same research personnel to participate in a simulated randomized control trial (RCT) comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive the standard consent form followed by a risk assessment and demographic survey.
3130370|NCT03284359|No Intervention|Standard Consent|Arm 2 will serve as the control arm. Participants will be approached by the research personnel to participate in a simulated RCT comparing two mechanical ventilation weaning protocols among mechanically ventilated patients. Participants will receive a standard consent form as detailed in the Study Instruments section. Following the consent process participants will conduct the same risk assessment survey and demographic survey.
3130371|NCT03284398||Parenteral nutrition bag type|Groups with different parenteral nutrition bags (3CBs or HCBs)
3130372|NCT03284411|Experimental|Spinal Cord Stimulation|Each subject was programmed to 4 different amplitude settings: 80%, 60%, 40% and 20% of perception threshold amplitude
3130373|NCT03284424|Experimental|R/M cSCC cohort|Participants with R/M cSCC receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
3130374|NCT03284424|Experimental|LA cSCC cohort|Participants with LA cSCC receive pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
3130375|NCT03284710|Active Comparator|Group 1: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120/MF59 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
3130376|NCT03284710|Active Comparator|Group 2: ALVAC-HIV + gp120/Al(OH)3|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
3130377|NCT03284710|Active Comparator|Group 3: ALVAC-HIV + gp120/MF59|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid and Bivalent Subtype C gp120/MF59 in the right deltoid at months 0, 1, 6, and 12. All injections are via needle and syringe.
3130378|NCT03284710|Active Comparator|Group 4: ALVAC-HIV + gp120|Participants will receive the ALVAC-HIV (vCP2438) vaccine in the left deltoid at months 0, 1, 3, 6, and 12, and Bivalent Subtype C gp120 in the right deltoid at months 3, 6, and 12. All injections are via needle and syringe.
3130379|NCT03285061|No Intervention|Standard Disposal Instructions|These patients will receive standard instructions on proper disposal of excess pain medication following orthopedic foot and ankle surgery. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
3130380|NCT03285061|Experimental|At Home Disposal|With patients' prescription for post operative pain medication, a Deterra portable drug deactivation system will be provided, along with instructions on proper use. They will be asked complete a survey at their 6 post operative follow-up on excess medication disposal.
3130381|NCT03285113|Experimental|Ultrahigh Frequency Stimulation|Patients with chronic lower limb pain will be treated with ultrahigh frequency stimulation via lead around DRG.
3132800|NCT03452189|Placebo Comparator|Placebo First|After three months, the control group will be crossed over to weekly oral vancomycin (250mg)
3130382|NCT03285295|Experimental|Screening|All subjects will be tested with at least one of the investigational Alinity s assays (Anti-HBc, Anti-HCV, HTLV I/II, Chagas, HBsAg, HBsAg Confirmatory, HIV Ag/Ab Combo) on Alinity s system.
3130383|NCT03285308|Placebo Comparator|Placebo|Following a 2-week placebo run-in, participants received placebo-matching relamorelin injected subcutaneously twice daily for up to 12 weeks.
3130384|NCT03285308|Experimental|Relamorelin 10 μg|Following a 2-week placebo run-in, participants received relamorelin 10 μg injected subcutaneously twice daily for up to 12 weeks.
3130385|NCT03285373||patients with NVAF|patients with Non Valvular Atrial Fibrillation
3130386|NCT03285477|Placebo Comparator|Placebo|Vehicle Ointment was applied topically once daily for 5 consecutive days on face or scalp
3130387|NCT03285477|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment 1% was applied topically once daily for 5 consecutive days on face or scalp
3130388|NCT03285490|Experimental|KX2-391 Ointment 1%|KX2-391 Ointment was applied once daily for 5 consecutive days on the face or scalp.
3130389|NCT03285490|Placebo Comparator|Placebo|The Vehicle Ointment was applied once daily for 5 consecutive days on the face or scalp.
3130390|NCT03285529|Active Comparator|STRATAFIX GROUP|STRATIFIX symmetric PDS Plus #1 will be used to close the capsule following total knee arthroplasty. The subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl) followed by the use of steri-strips and adhesive
3130391|NCT03285529|Placebo Comparator|CONTROL GROUP|The arthrotomy (deep layer) is repaired using Vicryl #1 followed by closure of the intermediate layer with a 2-0 Vicryl and a subcutaneous layer with a 2-0 Monocryl followed by steri-strips and adhesive, following total knee arthroplasty.
3130392|NCT03285542|Active Comparator|DERMABOND GROUP|For the active arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a STRATAFIX Spiral Knotless Tissue Control Device in addition to DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey) system for dermal closure.
3130393|NCT03285542|Placebo Comparator|CONTROL GROUP|For the control arm of the study, the arthrotomy (deep layer) is repaired using number 1 Vicryl, the subcutaneous layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by skin closure with staples
3130394|NCT03285555|Active Comparator|STRATAFIX GROUP|For the active arm of the study, wound closure will be performed similarly in 3 layers with the use of barbed equivalents at every layer: STRATIFIX symmetric PDS Plus #1 will be used to close the deep fascia and muscles . The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
3130395|NCT03285555|Placebo Comparator|CONTROL GROUP|For the control arm of the study, wound closure will be performed similarly in 3 layers with the use of vicryl to closure the deep fascia and muscles. The subcutaneous fat layer will be then closed with simple interrupted knots using number 2-0 braided absorbable sutures (Vicryl), followed by closure of the subcutaneous layer using a number 2-0 monofilament absorbable suture with inverted interrupted knots (Monocryl, Ethicon; Johnson & Johnson) followed by the use of steri-strips and glue
3130396|NCT03285594|Placebo Comparator|Placebo|Following a 4-week run-in period, participants were randomized to matching placebo to sotagliflozin 200 milligrams (mg) administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
3130397|NCT03285594|Experimental|Sotagliflozin 200 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 200 mg administered as 1 tablet and matching placebo as 1 tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
3130398|NCT03285594|Experimental|Sotagliflozin 400 mg|Following a 4-week run-in period, participants were randomized to sotagliflozin 400 mg administered as 2 tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 52 weeks. Background therapy with insulin glargine (with or without OADs) continued throughout the study.
3130399|NCT03285646|Experimental|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
3130400|NCT03285646|Experimental|Placebo|SC every 4 weeks
3180243|NCT00681356|Experimental|3|4975 - truncated for Phase 3
3130401|NCT03285711|Experimental|Lanraplenib 30 mg|"Participants receive lanraplenib 30 mg tablet + filgotinib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
3130402|NCT03285711|Experimental|Filgotinib 200 mg|"Participants receive filgotinib 200 mg tablet + lanraplenib placebo tablet orally once daily for 16 weeks in Blinded Treatment Phase. Participants who achieve ≥ 35% reduction in urinary protein excretion from baseline continue to receive same blinded study treatment for additional 16 weeks. Participants who did not achieve a ≥ 35% reduction in urinary protein excretion will switch treatment.~After 32 weeks of blinded treatment, participants who have ≥ 35% reduction in urinary protein excretion from baseline continue their assigned blinded treatment for additional 20 weeks in Extended Blinded Treatment Phase."
3130403|NCT03285711|Experimental|Lanraplenib 30 mg to Filgotinib 200 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive filgotinib 200 mg + lanraplenib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
3130404|NCT03285711|Experimental|Filgotinib 200 mg to Lanraplenib 30 mg|"At Week 16, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from baseline to Week 16 switch treatment and receive lanraplenib 30 mg + filgotinib placebo for additional 16 weeks.~At Week 32, participants who do not achieve a ≥ 35% reduction in urinary protein excretion from Week 16 to Week 32 can continue whichever treatment that lead to the greatest reduction in urinary protein excretion, or either treatment per investigator's discretion for additional 20 weeks in Extended Blinded Treatment Phase."
3130405|NCT03285724|Experimental|Harpoon Medical Transapical device TSD-5|This is a prospective, single arm, nonrandomized, early feasibility study to evaluate the safety and performance of the Harpoon Medical Device.
3130406|NCT03285958|Experimental|STEPS Intervention Group|Participants will receive a wearable physical activity monitor and will be asked to report their daily step count in 3 different ways (2 weeks each of SMS text messages, Interactive Voice Response calls (IVR), automatic upload) during the 6-week study period.
3130407|NCT03285958|No Intervention|STEPS Control Group|Participants in this group will not receive a wearable physical activity monitor and will not be asked to report their step count.
3130408|NCT03285984|Experimental|Test product 1|Participants will brush once (1.5g ± 0.05g of Test product 1), under supervision of study staff for one timed minute
3130409|NCT03285984|Experimental|Test product 2|Participants will brush once (1.5g ± 0.05g of Test product 2), under supervision of study staff for one timed minute
3130410|NCT03285984|Experimental|Test product 3|Participants will brush once (1.5g ± 0.05g of Test product 3), under supervision of study staff for one timed minute
3130411|NCT03285984|Experimental|Test product 4|Participants will brush once (1.5g ± 0.05g of Test product 4), under supervision of study staff for one timed minute
3130412|NCT03286218|Placebo Comparator|Placebo|Placebo was administered orally in one of five treatment periods
3130413|NCT03286218|Active Comparator|Alprazolam 2 milligram (mg)|2 mg of alprazolam was administered orally in one of five treatment periods
3130414|NCT03286218|Experimental|Lasmiditan 100 mg|100 mg of lasmiditan was administered orally in one of five treatment periods
3130415|NCT03286218|Experimental|Lasmiditan 200 mg|200 mg of lasmiditan was administered orally in one of five treatment periods
3130416|NCT03286218|Experimental|Lasmiditan 400 mg|400 mg of lasmiditan was administered orally in one of five treatment periods
3130417|NCT03286283|Experimental|J-Plasma|Each study subject will receive one procedure with J-Plasma at enrollment.
3130418|NCT03286400||CTAG Device with ACTIVE CONTROL|All consecutive patients meeting protocol selection criteria, consented, with an intention to be treated with CTAG Device with ACTIVE CONTROL.
3130419|NCT03286465|Experimental|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
3130420|NCT03286465|Active Comparator|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
3130421|NCT03286543|Experimental|Treatment Group (SPRINT Beta System)|Subjects in the treatment group will have up to 2 leads placed in their leg that underwent total knee replacement, will use the SPRINT Beta System, and will receive electrical stimulation in addition to the standard of care.
3130422|NCT03286543|No Intervention|Control Group|Subjects in the control group will receive the standard of care.
3130423|NCT03286751|Experimental|LY900014|Single dose of 7 units (U), 15 U, and 30 U of LY900014 administered subcutaneously (SC) in three of six periods.
3130424|NCT03286751|Active Comparator|Insulin Lispro (Humalog)|Single dose of 7 U, 15 U, and 30 U of insulin lispro administered SC in three of six periods.
3130425|NCT03286829|Experimental|"Tesomet High dose in fasted condition"|"A Tesomet FDC tablet (20 mg immediate release [IR] metoprolol, 1 mg tesofensine, 80 mg extended release [ER] metoprolol) in fasted condition (High dose)"
3130426|NCT03286829|Experimental|"Tesomet Low dose in fasted condition"|"Treatment B (Test 2): A Tesomet FDC tablet (5 mg immediate IR metoprolol, 0.2 mg tesofensine, 20 mg ER metoprolol) in fasted condition. (Low dose)"
3130427|NCT03286829|Active Comparator|Comperator|1 mg tesofensine (2 tablets of 0.5 mg), 25 mg commercial IR metoprolol (1 tablet of 25 mg), 75 mg commercial ER metoprolol (1 tablet of 25 mg ER metoprolol and 1 tablet of 50 mg ER metoprolol), fasted condition
3130428|NCT03286829|Experimental|"Tesomet High dose in fed condition"|"A Tesomet FDC tablet (20 mg immediate IR metoprolol, 1 mg tesofensine, 80 mg ER metoprolol in fed condition (High dose)"
3130429|NCT03287089|Active Comparator|Nitrofurantoin|Receives twice daily 100mg nitrofurantoin for 5 days following catheter removal
3130430|NCT03287089|Placebo Comparator|Placebo|Receives twice daily matching placebo for 5 days following catheter removal
3130431|NCT03287219|Active Comparator|150 mg Methylene Blue-MMX tablets|take 6 x 25mg Methylene Blue-MMX tablets equivalent to 150 mg
3130432|NCT03287219|Active Comparator|200 mg Methylene Blue-MMX tablets|take 8 x 25mg Methylene Blue-MMX tablets equivalent to 200 mg
3130434|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 1|Six subjects in Cohort 1 will receive a single SC dose of 2 mg GSK3511294.
3130435|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 1|Two subjects in Cohort 1 will receive a single SC dose of placebo.
3130436|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 2|Six subjects in Cohort 2 will receive a single SC dose of 10 mg GSK3511294.
3130437|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 2|Two subjects in Cohort 2 will receive a single SC dose of placebo.
3130438|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 3|Nine subjects in Cohort 3 will receive a single SC dose of 30 mg GSK3511294.
3130439|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 3|Three subjects in Cohort 3 will receive a single SC dose of placebo.
3130440|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 4|Nine subjects in Cohort 4 will receive a single SC dose of 100 mg GSK3511294.
3130441|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 4|Three subjects in Cohort 4 will receive a single SC dose of placebo.
3130442|NCT03287310|Experimental|Subjects receiving GSK3511294 in Cohort 5|Six subjects in Cohort 5 will receive a single SC dose of 300 mg GSK3511294.
3130443|NCT03287310|Placebo Comparator|Subjects receiving placebo in Cohort 5|Two subjects in Cohort 5 will receive a single SC dose of placebo.
3130444|NCT03287622|Experimental|Education Intervention + Nudge|This group will receive BOTH the scenario-tailored STOMP educational feedback AND the behavioral Nudge intervention
3130445|NCT03287622|Experimental|Standard of Care + Nudge|This group will receive routine, standard of care information AND the behavioral Nudge intervention
3130446|NCT03287622|Experimental|Educational Intervention no Nudge|This group will receive scenario-tailored opioid message (STOMP) feedback and NO behavioral nudge intervention.
3130447|NCT03287622|No Intervention|Standard of Care no Nudge|This group will receive only standard of care information and NO behavioral nudge intervention.
3130448|NCT03287635|Experimental|Acthar gel 80 U/ml|Patients who continue to experience clinically significant symptoms of dry eye disease even after utilizing traditional methods of treatment for dry eye including but not limited to artificial tears, warm compresses, topical anti-inflammatories like cyclosporine and/or lifitegrast. Patients will receive repository corticotropin intramuscular injections 80 u/ml 2-3 times weekly for up to 3 months as judged by the investigator.
3130449|NCT03287674|Experimental|Patient group|"All patients receive the same treatment. All patients are treated with one dose of Ipilimumab 14 days prior to surgical removal of tumor tissue for TIL expansion. Hospitalization for TIL treatment is approximately 3 weeks.~The patients are admitted to hospital on day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1. The first of 4 doses of Nivolumab is administered on day -2 and every 2 weeks for at total of 4 doses.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 13.~Interleukin-2 is administered as a daily low-dose subcutaneous injection for a total for 14 days."
3130450|NCT03287791|Experimental|Generic Azelaic Acid Foam|A thin layer of generic azelaic acid, 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
3130451|NCT03287791|Active Comparator|Finacea® (Azelaic Acid) Foam|A thin layer of Finacea (azelaic acid), 15% topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
3132801|NCT03452371|Active Comparator|Enhanced Traditional Care|Participants in this arm will receive usual care to help with smoking cessation offered to all patients who are smokers and some additional resources they can access for support.
3180244|NCT00681369||1|Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
3180245|NCT00681382||1|Asthma patients using inhaled steroids as maintenance treatment
3130452|NCT03287791|Placebo Comparator|Vehicle Foam|A thin layer of the vehicle topical foam was to be gently massaged into the entire facial area twice daily, once in the morning and once in the evening, for 12 weeks. Contact with the mouth, eyes, and other mucous membranes was to be avoided. Hands were to be washed following application of study drug. Participants were instructed not to bathe, shower, wash, or swim for at least 4 hours after application of study drug. Participants were provided with mild cleanser, a towel, sunscreen, and moisturizing lotion to be used on treated areas while participating in the study.
3130453|NCT03287804|Experimental|AUTO2|Relapsed or refractory Myeloma patients
3130454|NCT03287843|Experimental|Early surgery group|İn this arm patients will go under surgery before eight weeks, after neoadjuvant chemoradiation therapy.
3130455|NCT03287843|Experimental|Late surgery group|İn this arm patients will go under surgery after eight weeks, after neoadjuvant chemoradiation therapy.
3130456|NCT03287869|Experimental|Brexpiprazole|Brexpiprazole was administered in participants orally with flexible dosing from 2 mg/day from Days 1 to 3 regardless of treatment assignment in the previous double-blind trial, followed by titration to 3 mg/day on Day 4. Participants may have been titrated (or re-titrated) to a higher dose of brexpiprazole, up to a maximum of 4 mg/day, based on treatment response and at the investigator's discretion anytime at Day 7 or thereafter. Participants who were unable to tolerate their current dose could have been titrated down to a minimum of 2 mg/day any time after Day 4.
3130457|NCT03287947|Experimental|A|Nintedanib
3130458|NCT03288714|Experimental|Active sTMS|Synchronized Transcranial Magnetic Stimulation (sTMS) treatments to be administered using an active device 5 times per week for six treatment weeks.
3180246|NCT00681395|Experimental|1|ABT-143 capsules 20/135 mg
3130459|NCT03288714|Sham Comparator|Sham Stimulation|Sham treatments to be administered using a sham device 5 times per week for six treatment weeks.
3180247|NCT00681395|Active Comparator|2|ABT-335 135mg and rosuvastatin 20mg
3130460|NCT03288779|Other|Theta Burst Stimulation Arm|This is a pilot open label study.
3130461|NCT03288987|Experimental|Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (AryoGen) 5 mg/kg will be administered every 2 weeks.
3130462|NCT03288987|Active Comparator|Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)|Bevacizumab+FOLFIRI-3 (irinotecan, leucovorin, and 5-FU). Bevacizumab (Avastin®) 5 mg/kg will be administered every 2 weeks.
3130463|NCT03289052|Experimental|Restylane Volyme|Single injection and optional touch up injection with Restylane Volyme in Midface
3130464|NCT03289052|No Intervention|No intervention arm|No treatment
3130465|NCT03289208|Experimental|mild renal impairment|
3130466|NCT03289208|Experimental|moderated renal impairment|
3180248|NCT00681395|Experimental|3|ABT-143 capsules 5/45mg
3180249|NCT00681395|Active Comparator|4|ABT-335 45mg and rosuvastatin 5mg
3180250|NCT00681408|Active Comparator|Omega 3 recipient arm|
3130467|NCT03289208|Experimental|normal renal function|
3130468|NCT03289234|Experimental|mild hepatic impairment|
3130469|NCT03289234|Experimental|moderate hepatic impairment|
3130470|NCT03289234|Experimental|normal hepatic function|
3130471|NCT03289455|Experimental|AUTO3|Paediatric patients with relapse or refractory B-cell ALL
3130472|NCT03289481|Active Comparator|Active lozenge first|Subject will take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week, perform cardiac testing then take placebo lozenge for one week and perform cardiac testing.
3180251|NCT00681408|Placebo Comparator|Placebo|Placebo fish oil
3180252|NCT00681421|Experimental|A|
3180253|NCT00681434|Experimental|1|bilateral training
3180254|NCT00681434|Active Comparator|2|Unilateral training
3180255|NCT00681447|Other|Group I|Lumbar interlaminar epidural injection with local anesthetic only
3180256|NCT00681447|Other|Group II|Lumbar Interlaminar Epidural Injection with local anesthetic wiht 6 mg of non-particulate Celestone
3180257|NCT00681460|Active Comparator|1|gestational diabetes, insulin therapy
3180258|NCT00681460|Experimental|2|gestational diabetes, metformin therapy
3180259|NCT00681486|Active Comparator|A, 1|Ghrelin
3180260|NCT00681486|Active Comparator|A, 2|Ghrelin.
3180261|NCT00681499||malignant|eg. hepatocellular carcinoma, colorectal liver metastases
3180262|NCT00681499||benign|eg. liver cysts, traumatic liver injuries, adenoma etc
3180263|NCT00681525|Experimental|A|ABT-335 135 mg
3180264|NCT00681525|Experimental|B|Atorvastatin 80 mg and Ezetimibe 10 mg
3180265|NCT00681525|Experimental|C|ABT-335 135 mg, Atorvastatin 80 mg and Ezetimibe 10 mg
3180266|NCT00681551|Active Comparator|Arm 1|
3180267|NCT00681551|Experimental|Arm 2|
3130473|NCT03289481|Active Comparator|Placebo lozenge first|Subject will take placebo lozenge for one week, perform cardiac testing then take active lozenge (Vitamin C, Vitamin B12, Nitric Oxide Blend, L-citrulline, Sodium Nitrite) for one week and perform cardiac testing.
3130474|NCT03289533|Experimental|Experimental 1|Avelumab (MSB0010718C) in combination with axitinib (AG-013736)
3130475|NCT03289676|Experimental|Quitting Smoking Video|This arm will receive a storytelling narrative intervention by watching a video of women living with HIV taking about their success in quitting smoking.
3180268|NCT00681577|Experimental|A|
3130476|NCT03289676|Active Comparator|HIV Infection Video|This arm will watch an attention-control storytelling narrative intervention by watching a video of women living with HIV taking about their life after the diagnosis of HIV.
3180269|NCT00681603|Experimental|1|13 cases that accepted subconjunctival injection of bevacizumab
3180270|NCT00681616|Placebo Comparator|1|Compartment Monitoring System with Active Fluid Removal
3180271|NCT00681616|Active Comparator|2|Compartment Monitoring System (CMS) without fluid removal
3180272|NCT00681642||1|Corneal epithelial tissue with wound cultured in human autoserum
3180273|NCT00681642||2|Corneal epithelial tissue with wound cultured in umbilical cord serum
3180274|NCT00681655|Experimental|Responses to alcohol|Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur about 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.
3180275|NCT00681681||1|Men and women with 1 or more cardiovascular risk factors
3180276|NCT00681694||MRBT|MRI-assisted brachytherapy, the experimental arm
3180277|NCT00681694||USBT1|Standard ultrasound-guided brachytherapy performed by group 1 (control arm 1)
3180278|NCT00681694||USBT2|Standard ultrasound-guided brachytherapy performed by group 2 (control group 2)
3180279|NCT00681707||1|Hypertension patients recovering from stroke
3180280|NCT00681720|Experimental|1|
3180281|NCT00681733|Experimental|A|Pioglitazone
3180282|NCT00681733|Active Comparator|B|Pentoxifylline
3180283|NCT00681746|Experimental|1|
3180284|NCT00681759||1|Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).
3180285|NCT00681759||2|420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)
3180286|NCT00681759||3|Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.
3180287|NCT00681772|Experimental|Arm 1|
3180288|NCT00681785|Active Comparator|A|5000IE dalteparine
3180289|NCT00681785|Placebo Comparator|B|NaCL 0.9%
3180290|NCT00681798|Active Comparator|Dose level 1|Vandetanib 100mg/day plus Gemcitabine
3180291|NCT00681798|Active Comparator|Dose level 2|Vandetanib 300mg/day plus Gemcitabine
3180292|NCT00681798|Active Comparator|Dose level 3|Vandetanib 100mg/day plus Gemcitabine plus CapecitabineDose
3180293|NCT00681798|Active Comparator|Dose level 4|Vandetanib 300mg/day plus Gemcitabine plus CapectiabineDose
3180294|NCT00681837||1|children from 0 to 17 years old
3180295|NCT00681850||1|Control group
3180296|NCT00681850||2|Benchmarking group
3180297|NCT00681876|Experimental|1|Irinotecan+Avastin+Erbitux
3180298|NCT00681902|Experimental|1|Jet lidocaine
3180299|NCT00681902|Placebo Comparator|2|Jet saline
3180300|NCT00681915|Experimental|1|
3180301|NCT00681928||Breast Cancer patients receiving aromatase treatment|
3180302|NCT00681928||Healthy female controls age 60 and older|
3180303|NCT00681941|Experimental|1|Sevelamer Carbonate Tablets Dosed Three Times A Day
3180304|NCT00681954||1, 2, 3|
3130477|NCT03289858|Experimental|Exparel (Liposomal Bupivacaine)|"Exparel (liposomal bupivacaine) is FDA approved, with a labeled indication of single-dose infiltration into the surgical site to produce postsurgical analgesia."
3180305|NCT00681967|Experimental|Cohort 1|post operative combination of gefinib and RT
3180306|NCT00681967|Experimental|Cohort 2|combination of gefitinib with RT and Chemotherapy in non operated patients
3180307|NCT00681980|Experimental|A, 2, III|Patients with side effects to corticosteroids
3180308|NCT00681980|Experimental|B|patient with corticosteroids
3130478|NCT03289858|Placebo Comparator|Saline Control|Saline Solution (Sodium Chloride)
3130479|NCT03290027|Experimental|Active|DFD-03 (0.1% tazarotene) Lotion
3130480|NCT03290027|Placebo Comparator|Vehicle|Vehicle (0% tazarotene) Lotion
3180309|NCT00681980|Experimental|3|Valproic acid and corticosteroids
3180310|NCT00681993|Active Comparator|Standard ddAC chemotherapy with concurrent radiation therapy|Standard dose-dense Adriamycin and Cyclophosphamide (ddAC) chemotherapy and concurrent radiation therapy (RT)
3180311|NCT00681993|Active Comparator|Standard AC chemotherapy with concurrent RT|Standard Adriamycin and Cyclophosphamide (AC) chemotherapy and concurrent radiation therapy
3180312|NCT00681993|Active Comparator|Standard TCarbo H chemotherapy with concurrent RT|Standard Taxotere, Carboplatin and Herceptin (TCarbo H) chemotherapy and concurrent radiation therapy
3180313|NCT00681993|Active Comparator|Standard TAC chemotherapy with concurrent RT|Standard Taxotere, Adriamycin and Cyclophosphamide (TAC) chemotherapy with concurrent radiation therapy
3180314|NCT00681993|Active Comparator|Standard TC chemotherapy with concurrent RT|Standard Taxotere and Cyclophosphamide (TC) chemotherapy with concurrent radiation therapy
3180315|NCT00682006|Experimental|A|In this arm we recruited 2,400 subjects who received Intervention.
3180316|NCT00682006|Experimental|B|In this Arm, we recruited 2,400 subjects who received intervention.
3180317|NCT00682006|Experimental|C|In this Arm, we recruited 2,400 subjects who received intervention.
3180318|NCT00682006|No Intervention|D|In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.
3180319|NCT00682019|Experimental|Arm 1|
3180320|NCT00682019|Placebo Comparator|Arm 2|
3180321|NCT00682032|Experimental|AIM 2: subjects with suspected or definitive NSCLC diagnosis|1 (one) 250mg beta-glucan capsule 3 times a day for 14 days
3180322|NCT00682032|Experimental|AIM 3: subjects with resectable NSCLC|1 (one) 250mg beta-glucan capsule 3 times a day for 10 to 20 days
3180323|NCT00682045||T-SPOT.TB positive|T-SPOT.TB positive patients
3180324|NCT00682058||LABS patients|Bariatric surgery patients with 35>BMI kg/m2<60 prior to surgery will undergo follow-up post-bariatric surgery.
3180325|NCT00682071||1|transabdominal ultrasound (TAS) guided embryo transfer
3180326|NCT00682071||2|transvaginal ultrasound (TVS) guided embryo transfer
3180327|NCT00682084||1|Patients recently diagnosed with Cushing's syndrome
3180328|NCT00682097|Experimental|1|
3180329|NCT00682097|Experimental|2|
3180330|NCT00682097|Experimental|3|
3180331|NCT00682097|Experimental|4|
3180332|NCT00682097|Experimental|5|
3180333|NCT00682097|Experimental|6|
3180334|NCT00682097|Experimental|7|
3180335|NCT00682136|Active Comparator|1|Open Laparotomy Arm: All patients enrolled in the study who are undergoing elective open laparotomy surgery.
3180336|NCT00682136|Active Comparator|2|Laparoscopic Arm: All patients enrolled in the study who are undergoing elective laparoscopic abdominal surgery.
3180337|NCT00682149|Placebo Comparator|Group 1|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
3130481|NCT03290300||Long-Term Study Subjects|This cohort will consist of all subjects who were treated with the Vivaer Stylus in the 50-subject TP258 interventional study, who consent to continue to provide quality of life data.
3130482|NCT03290378|Active Comparator|AVE-901 50 mg|
3130483|NCT03290378|Active Comparator|AVE-901 25 mg|
3130484|NCT03290378|Placebo Comparator|Placebo|
3130485|NCT03290768|Experimental|Diabetes Management Educational Program|Subjects receive a CGM and activity tracker as part of a educational program to help manage their glucose levels.
3130486|NCT03291041|Experimental|tasimelteon|tasimelteon, administered as oral capsule(s)
3130487|NCT03291041|Placebo Comparator|Placebo|Placebo, administered as oral capsule(s)
3130488|NCT03291080|Experimental|Liquid|Oral liquid formulation of 13-Cis Retinoic Acid - test product.
3130489|NCT03291080|Experimental|Capsule|Isotretinoin capsules (13-CRA extracted per standard of care)- reference product.
3130490|NCT03291197|Experimental|Open label treatment|These patients will receive suprascapular and median nerve blocks for shoulder hand syndrome. Investigators will assess the tolerability of his procedure using pre-defined criteria (outlined elsewhere).
3130491|NCT03291288|Experimental|Pexidartinib|"Part 1 (Drug-drug Interaction Phase):~On Day 1, all participants will receive a single oral dose each of midazolam (2 mg) and tolbutamide (500 mg). On Day 3, pexidartinib (800 mg/d) in twice daily (400 mg BID) dosing will be initiated and continue throughout the remainder of Part 1 and into Part 2. On the first day of pexidartinib treatment (Day 3), a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning pexidartinib dose (400 mg). On Day 13, a single dose of midazolam (2 mg) and tolbutamide (500 mg) will be co-administered with the morning dose of pexidartinib (400 mg).~Part 2 (Efficacy and Safety Phase):~All participants will continue to receive pexidartinib 400 mg BID."
3130492|NCT03291379|Experimental|BTG-002814|Single arm: BTG-002814 (vandetanib-eluting radiopaque beads)
3180338|NCT00682149|Active Comparator|Group 2|We planned to compare a study group of 60 subjects with a placebo group of 60 subjects
3130493|NCT03291613|Experimental|Pinpoint App|Tablet application.
3130494|NCT03292016|Experimental|APL-130277, sublingual thin film|APL-130277, sublingual thin film, once daily
3130495|NCT03292016|Active Comparator|Subcutaneous APO-go|Subcutaneous APO-go, once daily
3130496|NCT03292016|Active Comparator|Subcutaneous APOKYN|Subcutaneous APOKYN, once daily
3130497|NCT03292406|Experimental|CD11301 Gel 0.06%|Participants applied 0.06% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
3130498|NCT03292406|Experimental|CD11301 Gel 0.03%|Participants applied 0.03% CD11301 gel (up to 500 mg per dose) topically once daily, 3 to 5 times per week, for cycle 1 and 2 i.e. 24 weeks.
3130499|NCT03292406|Experimental|Placebo|Participants applied placebo gel during cycle one followed by 0.03% CD11301 gel topically during cycle two once daily, 3 to 5 times per week, for 24 weeks.
3130500|NCT03292432|Active Comparator|Standard of Care (SOC)|Standard of Care for adherence support at Site
3130501|NCT03292432|Experimental|TERA Intervention (TERA)|Triggered, escalating, real-time adherence (TERA) intervention for 12 weeks.
3321267|NCT02017704|Experimental|Endo-HDR (potentially randomized to this arm)|"Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy~Followed by:~Oxaliplatin: 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~5-Fluorouracil (5-FU) bolus 400mg/m² following the oxaliplatin/FA infusions~5-FU continuous infusion 2400 mg/m², 46-h infusion following the 5-FU bolus~Cycle length: 14 days (2 weeks)~Duration of treatment: 12 cycles~Then: Surgical Resection"
3132802|NCT03452371|Experimental|Patient Navigation Intervention|Participants in this arm will meet with the trained patient navigator either in-person if she is available, or by telephone. They will receive up to ten hours of patient navigation over three months.
3130502|NCT03292562|Active Comparator|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
3130503|NCT03292562|Active Comparator|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
3130504|NCT03292614||Multifocal intraocular lens implantation|Patients who have undergone a cataract surgery with implantation of a multifocal intraocular lens LS313 MF30, Oculentis Berlin, will be invited for Measurements of the postoperative refraction
3130505|NCT03292640|Experimental|DFD-03 Lotion (0.1% tazarotene)|DFD-03 Lotion (0.1% tazarotene)
3130506|NCT03292640|Placebo Comparator|DFD-03 Vehicle (0% tazarotene)|DFD-03 Vehicle Lotion (0% tazarotene)
3130507|NCT03292653|Placebo Comparator|Placebo|Participants were randomized to matching placebo to sotagliflozin administered as two tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
3130508|NCT03292653|Experimental|Sotagliflozin 200 mg|Participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
3130509|NCT03292653|Experimental|Sotagliflozin 400 mg|Participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day in the double-blind treatment period for up to 14 days.
3130510|NCT03292692|Experimental|OurRelationship|Online Intervention
3130511|NCT03292692|No Intervention|Waitlist Control|2 month waiting period before couples can receive intervention
3321268|NCT02017730|Experimental|Part 1: [11C]BMT-136088 (Safety Study)|Single PET SCAN with single bolus injection of [11C]BMT-136088
3321269|NCT02017730|Experimental|Part 2: [11C]BMT-136088 (Test/Retest study)|Single PET SCAN with Intravenous (IV) bolus plus infusion of [11C]BMT-136088 followed by a re-test PET scan (approximately 6 hours apart) with IV bolus plus infusion of [11C]BMT-136088
3321270|NCT02017730|Experimental|Part 3: BMS-986020+[11C]BMT-136088 (Receptor Occupancy study)|BMS-986020 Tablets or Oral Solution of 4 dose levels from from the 6 dose levels of (50 mg, 150 mg, 300 mg, 600 mg, 1200 mg and 1500 mg) and 3 PET SCANS (Pre-Dose, Post-Dose1, Post-Dose2) with bolus plus infusion of [11C]BMT-136088
3130512|NCT03292809|Experimental|CyclASol Ophthalmic Solution|Cylclosporine A solution in vehicle
3130513|NCT03292809|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle only
3130514|NCT03292952|Experimental|Double-blind KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
3130515|NCT03292952|Placebo Comparator|Double-blind Placebo|Placebo oral capsule
3130516|NCT03292952|Experimental|Open-Label KP415|"KP415 (serdexmethylphenidate [SDX] Cl/ d-methylphenidate [d-MPH] HCl) oral capsule:~28/6 mg SDX/d-MPH (molar equivalent to 20 mg d-MPH HCl), 42/9 mg SDX/d-MPH (molar equivalent to 30 mg d-MPH HCl), 56/12 mg SDX/d-MPH (molar equivalent to 40 mg d-MPH HCl)"
3130517|NCT03293238|Active Comparator|Joint Line Ultrasound|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa aided by ultrasound guidance while sitting up.
3130518|NCT03293238|Sham Comparator|Joint Line Landmark|Patients assigned to this group receive a standard medial or lateral joint line injection of Euflexxa without ultrasound guidance while sitting up.
3130519|NCT03293238|Active Comparator|Suprapatellar Ultrasound Guided|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch aided by ultrasound guidance.
3180339|NCT00682162|Sham Comparator|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
3321271|NCT02017730|Experimental|Part 4: [11C]BMT-136088 (Tissue Distribution study)|Single PET SCAN with [11C]BMT-136088 to evaluate additional tracer uptake sites in humans other than the lung, such as heart, kidney, liver, gallbladder, etc.
3130520|NCT03293238|Sham Comparator|Suprapatellar Landmark|Patients assigned to this group receive an injection of Euflexxa while lying down into the suprapatellar pouch without ultrasound guidance.
3130521|NCT03293394|Experimental|Real tDCS|10 days anodal bilateral motor cortex and cathodal spinal tDCS
3130522|NCT03293394|Placebo Comparator|Sham tDCS|10 days sham bilateral motor cortex and sham spinal tDCS
3130523|NCT03293485|Experimental|Imipenem+Cilastatin/Relebactam|Participants with cIAI or cUTI will receive imipenem+cilastatin/relebactam intravenous (IV) infusion once every 6 hours for 5 to 14 days
3321272|NCT02017769||CIDP - treated|Patients diagnosed with CIDP and fulfilling the criteria by EFNS and PNS and in maintenance treatment with subcutaneous immunoglobulin
3321273|NCT02017769||Healthy controls|Healthy, gender and age matched controls
3321274|NCT02017769||CIDP - untreated|Patients newly diagnosed with CIDP and untreated are treated with immunoglobulin and re-examined after 4 months of treatment
3130524|NCT03293654|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3130525|NCT03293654|Active Comparator|US licenced Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3130526|NCT03293654|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3130527|NCT03294109|Experimental|study|liposomal bupivacain
3130528|NCT03294109|No Intervention|control|no intervention
3130529|NCT03294213||aScope 4 Broncho|The only data to be obtained are evaluation forms directly related to the users' perception of the aScope™ 4 Broncho
3130530|NCT03294317||His Bundle Pacing|Patient will be implanted per indications for single or dual chamber pacemaker. Lead for His bundle pacing will be implanted.
3130531|NCT03294538|Experimental|Generic Estradiol Vaginal Cream USP, 0.01%|Participants were to self-administer 2 grams (g) of generic Estradiol Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
3130532|NCT03294538|Active Comparator|Estrace Vaginal Cream USP, 0.01%|Participants were to self-administer 2 g of Estrace Vaginal Cream USP, 0.01% once daily at approximately the same time of the day for 7 consecutive days.
3130533|NCT03294538|Placebo Comparator|Vehicle Vaginal Cream|Participants were to self-administer 2 g of vehicle vaginal cream once daily at approximately the same time of the day for 7 consecutive days.
3130534|NCT03294629|No Intervention|APAP begins without SensAwake|Patients will receive CPAP treatment without SensAwake™ activation for two weeks, then crossed-over to CPAP treatment with SensAwake™ activation for additional two weeks.
3130535|NCT03294629|Experimental|APAP begins with SensAwake|"Patients will receive CPAP treatment with SensAwake™ activation for two weeks, then crossed-over to CPAP treatment without SensAwake™ activation for additional two weeks.~SensAwake™ modification: SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep."
3130536|NCT03294681||Cochlear Implant Recipients|
3130537|NCT03294850|Experimental|NASH group|These are individuals that have been identified as having NASH by MRE. Confirmation with liver biopsy required for continuation in the longitudinal study.
3130538|NCT03294850|Active Comparator|Non-NASH (NAFLD or normal) group|These are individuals that do not have NASH. They either have normal liver physiology or only have evidence of hepatic steatosis. This group will be studied up until the day of their bariatric surgery and will serve as a comparator population with respect to baseline measurements.
3130539|NCT03294941|Other|HepQuant SHUNT Liver Diagnostic Kit|All subjects receive HepQuant SHUNT test and DSI measurement. HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test and d4 Cholate 40mg is administered once orally for each test
3130540|NCT03295201|Experimental|Pulmonary rehabilitation+exercise group|Active cycle of breathing techniques (ACBT) and postural exercise program
3130541|NCT03295201|Active Comparator|Pulmonary rehabilitation group|Active cycle of breathing techniques (ACBT)
3130542|NCT03295266|Experimental|Moderate Hepatic Impairment (Panel A)|Participants with moderate HI (estimated glomerular filtration rate [eGFR] of ≤60mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
3130543|NCT03295266|Experimental|Severe Hepatic Impairment (Panel B)|Participants with severe HI (eGFR of ≤50 mL/min/1.73m^2) receive a single IV dose of MK-3866 (150 mg) on Day 1.
3130544|NCT03295266|Experimental|Healthy Matched Controls (Panel C)|Healthy participants receive a single IV dose of MK-3866 (150 mg) on Day 1.
3130545|NCT03295318|Experimental|Adjuvanted study formulation NmCV-5|"Subjects in this arm will receive adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
3132803|NCT03452527|Experimental|ICON-1 maintenance therapy|ICON-1 maintenance therapy after initial aflibercept treatment
3132804|NCT03452527|Experimental|ICON-1 combination therapy|ICON-1 combination therapy with aflibercept treatment
3130546|NCT03295318|Experimental|Non-adjuvanted study formulation NmCV-5|"Subjects in this arm will receive non-adjuvanted formulation of polyvalent conjugated vaccine against meningococcal serogroups A,C,Y,W & X.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
3130547|NCT03295318|Active Comparator|Menactra|"Subjects in this arm will licensed quadrivalent conjugated vaccine against meningococcal serogroups A,C,Y, & W viz. Menactra.~Dose to be administered is 0.5 mL intramuscularly in a two dose series separated by atleast 84 days."
3130548|NCT03295630|Other|Actigraph GT3X accelerometer|Ward based patients recovering from critical illness will wear two accelerometers placed on the thigh and ankle of the non-dominant leg
3130549|NCT03295721|Experimental|Treatment Group 1: HTX-011|HTX 011 (bupivacaine/meloxicam)
3130550|NCT03295721|Placebo Comparator|Treatment Group 2: Saline Placebo|Saline placebo
3130551|NCT03295721|Active Comparator|Treatment Group 3: Bupivacaine HCI|Bupivacaine HCl
3130552|NCT03296072|Experimental|Test product|Participants will apply a full ribbon of the test product (1.5 grams [g]) containing 0.254% w/w sodium fluoride and 5% KNO3.
3130553|NCT03296072|Active Comparator|Comparator Product|Participants will apply a full ribbon of the comparator product (1.5 g orally) containing 0.454% w/w stannous fluoride.
3130554|NCT03296072|Placebo Comparator|Placebo Product|Participants will apply a full ribbon of the placebo (1.5 g orally) containing 5% KNO3.
3130555|NCT03296163|Experimental|MB02 (Bevacizumab Biosimilar Drug)|MB02 (Bevacizumab Biosimilar Drug) + Carboplatin/Paclitaxel
3130556|NCT03296163|Active Comparator|EU-approved Avastin®|EU-approved Avastin® + Carboplatin/Paclitaxel
3130557|NCT03296280||Early Intervention|This cohort of 10 facilities will undergo early training by participating in the first 6 POCUS course sessions during FY17
3130558|NCT03296280||Late Intervention|This cohort of 10 facilities will undergo late training by participating in the last 6 POCUS courses during FY17.
3132805|NCT03452943|Experimental|TEV-50717|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 12 weeks
3132806|NCT03452943|Placebo Comparator|Placebo|Placebo matched to TEV-50717 BID for a total of 12 weeks
3132807|NCT03453060|Experimental|E-WE Thrombin Dose 1|Participants will receive a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
3132808|NCT03453060|Experimental|E-WE Thrombin Dose 2|Participants will receive a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
3130559|NCT03296345|Active Comparator|Intervention|"Prior to the second dose of IV opiates, the experiment was to give patients a single IV bolus of ketamine at the dose of 0.2 mg/kg. Pain scores were collected using the FACES scale currently in place. In consenting patients, chart review was performed with the following data collected: mg/kg/hour of morphine equivalents, pain scores on admission, during the encounter, and at discharge, the time to 50% pain reduction, and whether or not the patient was discharged.~In addition, a survey, which is attached, was given to patients/families at the time of drug administration to determine if they experienced a subjective improvement in their pain and if they suffered any undue side effects due to drug administration."
3130560|NCT03296345|No Intervention|Historical Control|"Patient data from at least one but up three patient encounters within the prior year were compared to their visit in which they were given adjuvant ketamine, using the outcome measures in the Intervention arm. Since this a historical control study, patients acted as their own controls in the above manner. Patients were allowed to re-enroll 4 weeks after presentation, which is typically considered a separate vaso-occlusive episode in the literature."
3130561|NCT03296527|Experimental|Follitropin delta|Recombinant follicle-stimulating hormone (rFSH). Follitropin delta for subcutaneous injection
3130562|NCT03296527|Active Comparator|Gonal-F|rFSH. Follitropin alfa for subcutaneous injection
3132809|NCT03453060|Experimental|E-WE Thrombin Dose 3|Participants will receive a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
3132810|NCT03453060|Experimental|E-WE Thrombin Dose 4|Participants will receive a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
3132811|NCT03453060|Placebo Comparator|Placebo|Participants will receive a single intravenous dose of placebo.
3130563|NCT03296566|Experimental|Patient Liaison Intervention|The participants randomized to the intervention group will be exposed to the patient liaison in receiving their colposcopy report results and recommendations. Rather than receive results from their referring/family physician, an experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients.
3132812|NCT03453151|Experimental|Regional nerve anesthesia|
3132813|NCT03453515|Experimental|HEART|Interactive website with five modules to address safer sex motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills. Program takes approximately 30-45 minutes to complete.
3130564|NCT03296566|No Intervention|Control|The control group will receive the standard of care for colposcopy results reporting via their referring physician. Following their colposcopy visit, control patients are given a slip of paper reminding them to call their family/referring physician for their colposcopy results in three weeks if they have not yet been contacted. Upon receipt of the final pathology, colposcopy reports are prepared by the colposcopists and forwarded to family/referring physicians typically within 2-3 weeks of the visit. Patients then receive the results of their colposcopy report from their family/referring physician by whatever method of communication preferred by that provider.
3130565|NCT03296787|Experimental|Group A TAK-954 0.2 mg: Healthy Participants|Participants with normal renal function receive TAK-954 0.2 milligram (mg), infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
3130566|NCT03296787|Experimental|Group B TAK-954 0.2 mg: Mild Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
3130567|NCT03296787|Experimental|Group C TAK-954 0.2 mg: Moderate Renal Impairment|Participants receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
3130568|NCT03296787|Experimental|Group D TAK-954 0.2 mg: Severe Renal Impairment|Participants without hemodialysis or End-stage Renal Disease (ESRD) receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 6-day period.
3130569|NCT03296787|Experimental|Group E TAK-954 0.2 mg: End-stage Renal Disease (ESRD)|Participants with hemodialysis receive TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period followed by a minimum 13-day washout period, further followed by TAK-954 0.2 mg, infusion, intravenously in fasted state, once on Day 1 of a 4-day period.
3130570|NCT03296800|Experimental|Bexagliflozin/probenecid|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or probenecid tablets, 500 mg, bid, in sequential order as follows: on Day 1 subjects took bexagliflozin; on Days 3 and 4 subjects took probenecid, bid; on Day 5 subjects took one bexagliflozin, and probenecid, bid; and on Day 6 subjects took probenecid tablets, 500 mg, bid.
3130571|NCT03296800|Experimental|Bexagliflozin/rifampin|Sixteen healthy subjects were dosed with bexagliflozin, qd and/or 600 mg of rifampin daily in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet; on Days 3 to 5, subjects took rifampin once daily; on Day 6 subjects took one bexagliflozin tablet and rifampin; and on Day 7 subjects took rifampin.
3321275|NCT02017782|Experimental|Dust, Ozone, Interaction Dust & Ozone|Dust (250-300µg/m3), Ozone (0,1ppm ozone),Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3). with at least 2 weeks between each exposure session
3130572|NCT03296800|Experimental|Bexagliflozin/verapamil|Sixteen healthy subjects were dosed with bexagliflozin, and/or verapamil tablets, 120 mg in sequential order as follows: on Day 1 subjects took one bexagliflozin tablet, on Day 4 subjects took one verapamil tablet, 1 hour before taking a bexagliflozin tablet.
3130573|NCT03297021|Placebo Comparator|Ondansetron 4mg Pre-emergence|
3130574|NCT03297021|Experimental|Ondansetron 8mg Pre-emergence|
3130575|NCT03297021|Experimental|Ondansetron Pre-Incision and Pre-emergence|4mg Ondansetron Pre-Incision and 4mg Ondansetron Pre-emergence
3130576|NCT03297112|Experimental|contrast-enhanced subharmonic ultrasound imaging|Patients receive perflutren lipid microspheres IV. After 15 minutes, patients receive perflutren lipid microspheres IV again over 5 minutes and undergo contrast-enhanced subharmonic ultrasound imaging over 60 minutes.
3130577|NCT03297216|Active Comparator|250 mg 17P|weekly intramuscular injection of 250mg 17P
3130578|NCT03297216|Placebo Comparator|Placebo|weekly intramuscular injection of indistinguishable placebo
3130579|NCT03297294|Experimental|EMA401|During the treatment epoch, patients will receive EMA401 for 12 weeks. During the treatment withdrawal epoch, patients will receive EMA401 or matching placebo for 1 week.
3130580|NCT03297294|Placebo Comparator|Placebo|Participants will receive matching placebo to EMA401 during both the treatment and treatment withdrawal epochs for a total of 13 weeks.
3130581|NCT03297398|Placebo Comparator|Other|Placebo Group
3130582|NCT03297398|Experimental|Drug Group 1|15mg, OPK-88004
3130583|NCT03297398|Experimental|Drug Group 2|25,mg OPK-88004
3130584|NCT03297944|Experimental|All Participants|All participants received each intervention with alprazolam, zolpidem and placebo.
3130585|NCT03298035|Active Comparator|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
3130586|NCT03298035|Experimental|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
3130587|NCT03298048|Active Comparator|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
3130588|NCT03298048|Active Comparator|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
3130589|NCT03298048|Active Comparator|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
3130590|NCT03298113|Experimental|Cavilon Advanced Skin Protectant|Product applicator contains liquid barrier and is applied according to the 3M manufacturer's instructions for use.
3130591|NCT03298113|Other|IAD Hospital Standard Care|Marketed products are applied according to the IAD hospital standard care routine.
3130592|NCT03298412|Experimental|Blinatumomab|"After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1).~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval."
3130595|NCT03298880|Other|Four VM's|Healthy volunteers undergo repeated VM's - Device: Supine VM VAD, Supine VAD manometer Modified VM VAD, Modified VM Manonmeter
3130596|NCT03298984|Experimental|Alvocidib and Cytarabine/Daunorubicin|The starting dose of alvocidib will be 20 mg/m2 as a 30-minute intravenous (IV) bolus followed by 30 mg/m2 over 4 hours as an IV infusion administered daily on Days 1-3 of Induction. Patients will have a one day drug holiday (Day 4) before initiation of the 7+3 regimen. Beginning on Day 5, cytarabine will be administered as a 100 mg/m2/day continuous IV infusion for seven consecutive days (Days 5-11) plus daunorubicin administered at a dosage of 60 mg/m2 IV on Days 5-7.
3130597|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 4 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q4W via intramuscular (IM) route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
3130598|NCT03299049|Experimental|Subjects in group 1 receiving study treatment once in 8 weeks|Group 1 will consist of subjects randomized from current ART SOC therapy. Subjects in group 1 will be randomized to receive CAB LA plus RPV LA Q8W via IM route. All subjects will receive oral therapy with CAB 30 mg + RPV 25 mg once daily prior to randomization.
3130599|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 4 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to continue CAB LA plus RPV LA Q4W administration via IM route.
3130600|NCT03299049|Experimental|Subjects in group 2 receiving study treatment once in 8 weeks|Group 2 will consist of subjects currently receiving CAB LA + RPV LA Q4W in ATLAS study. Subjects in Group 2 will be randomized to receive CAB LA plus RPV LA Q8W via IM route.
3130601|NCT03299101|Experimental|Prehabilitation|Prospective sample of patients anticipating cardiothoracic surgery.
3130602|NCT03299244|Active Comparator|Cinacalcet|Participants were randomized to receive oral cinacalcet once daily and placebo intravenous (IV) bolus injection at the end of each hemodialysis session three times per week (TIW) for 26 weeks. The starting dose of cinacalcet was 25 mg daily and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum parathyroid hormone (PTH) ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining corrected calcium (cCa) ≥ 8.3 mg/dL.
3321276|NCT02017782|Active Comparator|Interaction Dust & Ozone and placebo Filtered air|Dust+Ozone (250-300µg/m3 + 0,1 ppm ozone), Filtered air (<20µg/m3) with at least 2 weeks between each exposure session.
3130603|NCT03299244|Experimental|Etelcalcetide|Participants were randomized to receive etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session TIW and daily oral doses of placebo tablets for 26 weeks. The starting dose of etelcalcetide was 5 mg, and the dose may have been titrated at weeks 5, 9, 13, and 17 to target predialysis serum PTH ≤ 300 pg/mL but no lower than 100 pg/mL while maintaining cCa ≥ 8.3 mg/dL.
3130604|NCT03299686|Experimental|CJM112|Study treatment
3321277|NCT02017795|Experimental|SMS-Web eAAP group|electronic asthma action plan (eAAP) group
3321278|NCT02017795|Active Comparator|regular-care group|written asthma action plan (WAAP) group
3321279|NCT02017808||Copaxone|Patients with multiple sclerosis who are currently prescribed glatiramer acitate (Copaxone)
3130605|NCT03299686|Placebo Comparator|Placebo to CJM112|Placebo
3130606|NCT03299881|Experimental|Treatment|The Transcutaneous Nerve Stimulator (TENS) Elira wearable patch system will be applied to varying locations on the T6/T7 dermatone for 30 minutes three times a day after meals. Subjects will be instructed to follow a 1200 calorie healthy diet and record any changes in appetite.
3321280|NCT02017808||OCT|Healthy controls
3130607|NCT03299881|Active Comparator|Control|Open label diet and exercise counseling only. Subjects will be instructed to follow a healthy 1200 calorie diet and record any changes in appetite.
3130608|NCT03300050|Experimental|Group 1: cH8/1N1 LAIV and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
3321281|NCT02017821|Experimental|training group|high intensity aerobic training 3 weekly sessions for 8 weeks
3321282|NCT02017821|No Intervention|care as usual|
3321283|NCT02017834|Experimental|harmonic scalpel|
3321284|NCT02017834|Active Comparator|standard technique|
3321285|NCT02017847||Gen100|150 participants in the Generation 100 study with anticipated 3000 participants aged 70-75
3130609|NCT03300050|Experimental|Group 2: cH8/1N1 LAIV and cH5/1N1 IIV|Participants received 0.5 mL cH8/1N1 LAIV administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL cH5/1N1 IIV administered as an intramuscular injection on Day 85.
3130610|NCT03300050|Placebo Comparator|Group 3: Placebo|Participants received 0.5 mL of normal saline administered as 0.25 mL drops per nostril on Day 1 followed by 0.5 mL phosphate buffered saline (PBS) administered as an intramuscular injection on Day 85.
3130611|NCT03300050|Experimental|Group 4: cH8/1N1 IIV + adjuvant and cH5/1N1 IIV + adjuvant|Participants received 0.5 mL AS03-adjuvanted cH8/1N1 IIV administered as an intramuscular injection on Day 1 followed by 0.5 mL AS03-adjuvanted cH5/1N1 IIV administered as an intramuscular injection on Day 85.
3130612|NCT03300050|Placebo Comparator|Group 5: Placebo|Participants received 0.5 mL PBS administered as an intramuscular injection on Day 1 followed by 0.5 mL PBS administered as an intramuscular injection on Day 85.
3130615|NCT03300466|Experimental|GP0045|Treatment with GP0045
3130616|NCT03300466|Active Comparator|Comparator|Treatment with active comparator
3130617|NCT03300570|Experimental|Arm A (dolcanatide)|Participants receive dolcanatide PO QD for 7 days.
3130618|NCT03300570|Placebo Comparator|Arm B (placebo)|Participants receive placebo PO QD for 7 days.
3130619|NCT03300674|Active Comparator|Intravenous hydromorphone|Intravenous hydromorphone 1mg. A second dose can be administered at 30 minutes.
3130620|NCT03300674|Active Comparator|Intravenous lidocaine|Intravenous lidocaine 120 mg. A second dose can be administered at 30 minutes
3130621|NCT03300752|Experimental|BREATHE Intervention|The patient's primary care provider (PCP) will deliver the active intervention (shared decision-making discussion of asthma control status and treatment) - BREATHE Intervention.
3130622|NCT03300752|Active Comparator|Control Intervention|The patient's primary care provider (PCP) will deliver the control intervention (discussion of healthy lifestyles).
3130623|NCT03300843|Experimental|Peptide loaded dendritic cell vaccine|Peptide loaded dendritic cell vaccine on days 0, 14, 28, and 42
3132814|NCT03453515|Other|Growing Minds|Attention-matched control website with five modules to address an introduction to mindsets, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and an integrative summary. Program takes approximately 30-45 minutes to complete.
3130624|NCT03301155|Experimental|Anaferon for children|"Tablet for oral use. One tablet per intake, once daily (approximately at the same time).~The product is administered outside a meal (in the interval between meals or 15 min prior to meal or fluid intake), the tablets should be held in mouth until complete dissolution. For young children (aged 1 month to 3 years old), the tablet is recommended to be dissolved in a small amount (1 tablespoon) of drinking water of room temperature."
3130625|NCT03301155|Placebo Comparator|Placebo|Tablet for oral use. Placebo using Anaferon for children scheme.
3130626|NCT03301272|Experimental|Onabotulinumtoxin A Injection, then Placebo|Participants first receive Onabotulinumtoxin A Injection and following a 3-month washout, they receive Placebo
3130627|NCT03301272|Experimental|Placebo, then Onabotulinumtoxin A Injection|Participants first receive placebo injection and following a 3-month washout, they receive Onabotulinumtoxin A Injection.
3130628|NCT03301298|Experimental|SXC-2023, 50 mg|Single dose of 50 mg, given orally in capsule form.
3130629|NCT03301298|Experimental|SXC-2023, 100 mg|Single dose of 100 mg, given orally in capsule form.
3130630|NCT03301298|Experimental|SXC-2023, 200 mg|Single dose of 200mg, given orally in capsule form.
3130631|NCT03301298|Experimental|SXC-2023, 400 mg|Single dose of 400mg, given orally in capsule form.
3130632|NCT03301298|Experimental|SXC-2023, 800 mg|Single dose of 800mg, given orally in capsule form.
3130633|NCT03301298|Experimental|SXC-2023, 1600 mg|Single dose of 1600 mg, given orally in capsule form.
3130634|NCT03301298|Placebo Comparator|Placebo oral capsule|Placebo comparator, given once orally in matching capsule form.
3130635|NCT03301623|Experimental|Clinical Decision Support|Patients within the physicians randomized to the IDM arm will receive the Clinical Decision Support alerts via the EHR when certain order criteria are triggered appropriately.
3130636|NCT03301623|Experimental|Patient Education and Activation Tools|Patients within the physicians randomized to SDM will receive the PEAT materials via REDCap two days prior to their PCP office visit. They will receive these materials every time they have an office visit with their PCP.
3130637|NCT03301649|Experimental|Generic Ivermectin Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of generic ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
3321286|NCT02017873|Active Comparator|healthy patients bleaching|Healthy patients Peroxide Carbamide 10% - Dental bleaching treatment
3321287|NCT02017873|Experimental|Smokers bleaching|smokers patients Peroxide Carbamide 10% - Dental bleaching treatment
3321288|NCT02017886|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks.
3321289|NCT02017886|Placebo Comparator|Placebo|Placebo tablet twice daily for three weeks
3130638|NCT03301649|Active Comparator|Sklice (Ivermectin) Lotion 0.5%|Infested household participants will administer a single application of up to 117 grams (1 tube) of Sklice ivermectin 0.5% topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
3321290|NCT02017912|Active Comparator|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
3321291|NCT02017912|Placebo Comparator|Excipient|Combined intramuscular and intrathecal placebo administration
3321292|NCT02017925|Experimental|Arm I (early intervention)|Beginning within 2 weeks of starting chemoradiation, patients undergo an individualized rehabilitation program comprising aerobic exercise and strength training, including treadmill walking, stationary bicycle, NU-Step, upper body resistance training and breathing retraining, 3 times per week for 8 weeks (36 sessions).
3321293|NCT02017925|Experimental|Arm II (late intervention)|Beginning 1 month after completion of chemoradiation, patients undergo an individualized exercise rehabilitation program as in Arm I.
3132815|NCT03454048|Experimental|Group 1 (Cohort A) LD-PIP/LD-PIP2/PIP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 1 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg).
3130639|NCT03301649|Placebo Comparator|Vehicle Lotion|Infested household participants will administer a single application of up to 117 grams (1 tube) of vehicle topical lotion to the dry hair (avoiding contact with eyes) at home on Day 1, leave the lotion on the hair and scalp for 10 minutes, and then rinse off with warm water. Participants will be instructed to wash their hands after application of the study drug, allow hair to dry naturally (pat drying with decontaminated towel is permitted), and to leave hair uncovered after application of the study drug. Following application and rinsing of the study drug, participants are not to shampoo, wash, or rinse their hair or scalp until the Day 2 visit has been completed.
3130640|NCT03301714|No Intervention|Control: Standard of Care|Regular dental care under the standard clinic operation
3130641|NCT03301714|Experimental|Intervention 1: Group-based oral health education|Group based oral health education
3130642|NCT03301714|Experimental|Intervention 2: Individual-based oral health education|Individual-based motivational interviewing
3321294|NCT02017938|No Intervention|Stage 1: Health group|To establish non-invasive fatigue monitoring method via testing healthy individuals.
3130643|NCT03301740|Experimental|UF Profiling Phase First|"First treatment phase begins with linear UF profiling during HD.~Participants randomized to starting with the experimental UF profiling phase will receive 9 HD treatments with UF profiling (1st experimental phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 conventional HD treatments (1st control phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase)."
3321295|NCT02017938|Experimental|Stage 2: PD group|To find the optimal feedback variables for anti-fatigue training on individuals with PD.
3321296|NCT02017938|Experimental|Stage 2: Health group|Stage 2 controlled group
3321297|NCT02017938|Experimental|Stage 3: PD group|To evaluate the effect of four weeks of VR anti-fatigue ergo cycling training on various fatigue components and functional abilities in individuals with PD.
3130644|NCT03301740|Experimental|Conventional HD Phase First|"First treatment phase begins with conventional HD.~Participants randomized to starting with the control conventional HD phase will receive 9 conventional HD treatments (1st control phase). Following a 3 conventional HD treatment wash-out period, participants will then cross over to 9 HD treatments with UF profiling (1st experimental phase). Following a 2nd 3 conventional HD treatment wash-out period, participants will cross over to 9 conventional HD treatments (2nd control phase). Following a 3rd conventional HD treatment wash-out period, participants will cross over to 9 HD treatments with UF profiling (2nd experimental phase)."
3130645|NCT03301779|Experimental|Investigational Product|Blood product from these donors will be processed and stored using the Hemanext Red Blood Cell Processing System
3130646|NCT03301779|No Intervention|Control Product|Blood product from these donors will be stored in a Haemonetics Leukotrap Whole Blood System.
3130647|NCT03301831|Experimental|Resourcefulness Training Intervention|The intervention arm will receive an intervention that includes: a face-to-face session for teaching social (help-seeking) and personal (self-help) resourcefulness skills; ongoing access to video vignettes of caregivers of technology-dependent children describing resourcefulness skill application in daily life; 4 weeks of skills' reinforcement using daily journal writing; weekly phone calls for the first 4 weeks; and booster sessions at 2 and 4 months post enrollment.
3130648|NCT03301831|No Intervention|Attention Control|The Attention Control arm will receive weekly phone calls for the first 4 weeks and at 2 and 4 months post enrollment plus any usual care.
3321298|NCT02017938|No Intervention|Stage 3: PD controlled group|Stage 3 controlled group
3321299|NCT02017951||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people.
3130649|NCT03301844|Experimental|Study treatment|Blephapad Combo twice daily for one month. Blephapad is a disposable wet wipe containing Hy-Ter® solution (sodium hyaluronate acid and 4-terpineol), aloe, natural anti-inflammatories and antiseptics.
3130650|NCT03301844|Other|Standard treatment|Wet, warm gauze twice daily for one month.
3130651|NCT03302091|Experimental|BI 1467335 Normal (R)|Participants with normal renal function.
3130652|NCT03302091|Experimental|BI 1467335 Moderate (T)|Participants with moderate renal impairment.
3130653|NCT03302234|Experimental|Pembrolizumab + Ipilimumab|Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus 1 mg/kg of ipilimumab by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
3130654|NCT03302234|Active Comparator|Pembrolizumab + Placebo|Participants receive 200 mg of pembrolizumab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus placebo by IV infusion on Day 1 of each 6-week cycle for up to 18 cycles of treatment.
3130655|NCT03302416|Experimental|[C-11]NOP-1A PET Scan conditions|Baseline condition and Post-hydrocortisone (1 mg/Kg, intravenous) condition
3321300|NCT02017951||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people.
3321301|NCT02017951||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
3130656|NCT03302559|Experimental|Retinol Complex 0.5|During a 2-week washout period the participant used a basic skin care regimen (SkinMedica facial cleanser in the morning and in the evening, Cetaphil Fragrance Free Moisturizing Lotion in the morning and in the evening and SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen in the morning and as needed), followed by the same basic skin care regimen plus SkinMedica Retinol Complex 0.5 applied topically to the face in the evening for 12 Weeks. Assessments of the participant's facial skin were made utilizing investigator clinical grading, digital photography, a spectrophotometer and in vivo skin imaging.
3130657|NCT03302741|Active Comparator|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the IZs of the entire muscle.
3132816|NCT03454048|Experimental|Group 2 (Cohort A) LD-PIP/LD-PIP2/SP|Cohort A will be subjected to a standard controlled human malaria infection (CHMI) delivered by five Pf-infected mosquitoes. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 2(LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
3321302|NCT02017951||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3130658|NCT03302741|Experimental|3-dimensional innervation zone (3DIZ) guided injection|In the IZ-guided injection technique, IZ location obtained using the 3DIZ will be first marked over the skin surface of the muscle and the depth of the IZ will be also provided. The 3DIZ will be applied to the IZ-guided injection group 1 day prior to scheduled injection. The surface location and depth information of the IZ will be used to guide where the needle tip needs to go. Currently, patients commonly receive 1 to 2 injection sites, occasionally 3 sites for biceps muscles. To standardize the procedure, we will choose 2 sites for all patients.
3130659|NCT03302767|Experimental|Psychological and Social Consultation|Psychological and Social Consultation
3130660|NCT03302780|Experimental|Sham tDCS and BreEStim|This arm includes a 20-min sham tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
3130661|NCT03302780|Experimental|active tDCS (M1) and BreEStim|This arm includes a 20-min active tDCS to the current dominant primary motor cortex (M1), followed by a 20-min BreEStim to the median nerve (160 times) transcutaneously on the current dominant side.
3130662|NCT03302793|Experimental|BreEStim and tDCS sham, then combined BreEStim and tDCS|BreEStim is voluntary breathing controlled electrical stimulation.
3130663|NCT03302793|Experimental|Combined BreEStim and tDCS, then BreEStim and tDCS sham|BreEStim is voluntary breathing controlled electrical stimulation. tDCS is transcranial direct current stimulation.
3130664|NCT03302936|Experimental|Pyridium arm|Phenazopyridine 200mg tablet, once prior to surgery
3130665|NCT03302936|No Intervention|Control arm|No intervention in this group. Routine perioperative care.
3130666|NCT03302975|Experimental|Real time biofeedback|Real-time visual biofeedback of braking forces during a treadmill run.
3130667|NCT03303079|Experimental|TEV-48125 (675/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (675/225/225 mg).
3130668|NCT03303079|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/ placebo/placebo).
3130669|NCT03303079|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
3130670|NCT03303092|Experimental|TEV-48125 (225/225/225 mg) group|TEV-48125 will be subcutaneously administered once monthly for 3 months (225/225/225 mg).
3321303|NCT02017951||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more.
3130671|NCT03303092|Experimental|TEV-48125 (675 mg/placebo/placebo) group|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months (675 mg/placebo/placebo).
3130672|NCT03303092|Placebo Comparator|Placebo group|Placebo will be subcutaneously administered once monthly for 3 months (placebo/placebo/placebo).
3130673|NCT03303105|Experimental|TEV-48125 (225 mg/1 month) group|TEV-48125 will be administered subcutaneously once every 4 weeks for a total of 13 doses (at 225 mg once monthly [except for a loading dose of 675 mg in subjects with CM]).
3130674|NCT03303105|Experimental|TEV-48125 (675 mg/3 month) group|TEV-48125 will be administered subcutaneously once every 12 weeks for a total of 5 doses (at 675 mg once every 3 months).
3321304|NCT02017951||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more.
3321305|NCT02017951||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3321306|NCT02017951||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more.
3130675|NCT03303144|Experimental|Triferic via Hemodialysate|Triferic will be mixed with the liquid bicarbonate concentrate used in the preparation of the hemodialysate solution. This will result in a final Triferic iron concentration in the dialysate of 2 µM (110 µg/L). The patients will receive Triferic over 4 hrs at one hemodialysis session.
3130676|NCT03303144|Experimental|Triferic via IV infusion( pre-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via arterial blood line (pre-dialyzer)
3130677|NCT03303144|Experimental|Triferic via IV infusion (post-dialyzer)|Patients will receive a single 6.5-mg dose of Triferic iron administered IV over 3 hrs during hemodialysis via venous blood line (post-dialyzer)
3130678|NCT03303196|Experimental|Bihormonal bionic pancreas admission|Four day inpatient admission where participants will have blood sugar managed by the Bihormonal Bionic Pancreas. Blood sugars will be monitored for safety by study staff.
3321307|NCT02017951||Travel Time - see below|Travel time will be analysed as both a continuous and discrete variable.
3130679|NCT03303196|No Intervention|Standard care admission|Four day inpatient admission where participants will have blood sugar managed by the participant's home-glucose control regimen. Blood sugars will be monitored for safety by study staff.
3130680|NCT03303404|Experimental|Ambulatory (24-hour) Blood Pressure|
3130681|NCT03303417|Experimental|Kiwifruit|Participants asked to consume 2 kiwifruit twice a day for 3 days before undergoing MRI Scan
3130682|NCT03303417|Placebo Comparator|Control|Participants asked to consume a calorie-matched sugar drink twice a day for 3 days before undergoing MRI Scan
3130683|NCT03303521|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
3130684|NCT03303521|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
3130685|NCT03303794|Active Comparator|Bupivicaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
3130686|NCT03303794|Experimental|Bupivicaine + Exparel|0.25% bupivacaine and 1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
3321308|NCT02017977||Urban-Rural Classification 1: Large Urban Areas|Settlements of over 125,000 people
3130687|NCT03303911|Experimental|Cytisine 1.5 mg|"Multiple doses of 1.5 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
3321309|NCT02017977||Urban-Rural Classification 2: Other Urban Areas|Settlements of 10,000 to 125,000 people
3130688|NCT03303911|Experimental|Cytisine 3.0 mg|"Multiple doses of 3.0 mg cytisine administered per 25-day schedule:~Days 1-3 (6 times daily)~Days 4-12 (5 times daily)~Days 13-16 (4 times daily)~Days 17-20 (3 times daily)~Days 21-24 (2 times daily)~Day 25 (Once daily)"
3130689|NCT03303950|Experimental|Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)|Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
3130690|NCT03303989|Experimental|pegloticase + MMF|Participants randomized to this arm will receive pegloticase + mycophenolate mofetil.
3130691|NCT03303989|Placebo Comparator|pegloticase + placebo|Participants randomized to this arm will receive pegloticase + placebo
3130692|NCT03304054|Experimental|amifamapridine phosphate tablets|
3130693|NCT03304054|Placebo Comparator|placebo tablets|
3130694|NCT03304106|Experimental|Newly Implanted CI Recipients|Use of AI technology to assist in audiologist's evaluation and programming of new (standard of care-commercial) cochlear implant recipients
3130695|NCT03304106|Experimental|Existing CI recipients|Use of AI technology to assist in audiologist's evaluation and programming of existing cochlear implant recipients
3130696|NCT03304119||Patellar instability group|Group of patients with patellar instability stemming from a recurrent patellar dislocation
3130697|NCT03304119||Control group control|Group that has not been checked for patellar instability.
3130698|NCT03304184|Placebo Comparator|Photac-fil|Participants will have a restoration placed with photac-fil in the lesion near the gum line.
3130699|NCT03304184|Experimental|Biodentine|Participants will have a restoration placed with Biodentine in the lesion near the gum line.
3130700|NCT03304522|Experimental|VX-150|
3130701|NCT03304522|Placebo Comparator|Placebo|
3321310|NCT02017977||Urban-Rural Classification 3: Accessible Small Towns|Settlements of between 3,000 and 10,000 people and within 30 minutes drive of a settlement of 10,000 or more.
3130702|NCT03304626|Experimental|Study Group|"Budesonide EC 3 mg capsule. The dose will be as follows~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Budesonide 9 mg Days 31-45 SIS + Budesonide 6 mg Days 46-90 SIS + Budesonide 3 mg Days 90 onwards SIS1"
3130703|NCT03304626|Active Comparator|Control Group|"Standard of Care~Time post Liver Transplantation Immunosuppressive therapy Days 0-3 Standard immune suppression (SIS) + Intravenous corticosteroids Days 4-30 SIS + Prednisone 15-60 mg Days 31-45 SIS + Prednisone 10 mg Days 46-90 SIS + Prednisone 2.5 to 7.5 mg Days 90 onwards SIS"
3130704|NCT03304873|Experimental|Retapamulin|Thin layer of ointment applied twice a day for five days. Study drug will be applied to the nares and peri-rectal area twice a day for 5 consecutive days.
3130705|NCT03304873|Placebo Comparator|Placebo|The placebo used will be a triple purified pharmaceutical grade white petrolatum
3130706|NCT03305081|Experimental|Immediate or early placement|Immediate or early placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant (within 48 hours) postpartum
3130707|NCT03305081|Active Comparator|Interval placement|Interval (4-6 weeks) postpartum placement of levonorgestrel IUD, copper IUD, or etonorgestrel sub dermal implant
3130708|NCT03305159|Active Comparator|Control (Povidone Iodine)|Patients to receive povidone iodine for the surgical preparation of the vagina.
3130709|NCT03305159|Experimental|Intervention (4% Chlorhexidine gluconate)|Patients to receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
3130710|NCT03305419|Experimental|Subjects receiving treatment sequence ABC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABC in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
3130711|NCT03305419|Experimental|Subjects receiving treatment sequence ABP in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence ABP in Part A; A= GSK2982772 120 mg TID, B= GSK2982772 240 mg TID, and P= Placebo. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
3130712|NCT03305419|Experimental|Subjects receiving treatment sequence APC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence APC in Part A; A= GSK2982772 120 mg TID, P= Placebo and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
3180340|NCT00682162|Active Comparator|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
3180341|NCT00682175||Observation|Adult (age > 18 yrs) patients admitted to the Heart Failure Intensive Care Unit with Acute Heart Failure Syndrome requiring placement of a Pulmonary Artery catheter for hemodynamically guided therapy.
3180342|NCT00682188|Experimental|CI|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
3130713|NCT03305419|Experimental|Subjects receiving treatment sequence PBC in cohort 1: Part A|Eligible subjects will be randomized to receive treatment sequence PBC in Part A; P= Placebo, B= GSK2982772 240 mg TID and C= GSK2982772 360 mg BID. Subjects will receive oral capsule of GSK2982772 or placebo on Day 1 in each of the 3 treatment periods followed by a wash-out period of at least 7 days between dosing regimens.
3130714|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 2 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
3130715|NCT03305419|Experimental|Subjects receiving GSK2982772 120 mg TID in cohort 3 : Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 120 mg TID for 14 days in Part B.
3130716|NCT03305419|Experimental|Subjects receiving GSK2982772 240 mg TID in cohort 4: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 240 mg TID for 14 days in Part B.
3130717|NCT03305419|Experimental|Subjects receiving GSK2982772 360 mg BID in cohort 5: Part B|Eligible subjects will receive GSK2982772 oral capsule with a dose of 360 mg BID for 14 days in Part B.
3130718|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 2 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
3130719|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 3 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
3130720|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 4 : Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
3130721|NCT03305419|Placebo Comparator|Subjects receiving placebo in cohort 5: Part B|Subjects will receive placebo oral capsule for 14 days in Part B.
3130722|NCT03305575|Experimental|Chloroprocaine|Patients assigned to chlorprocaine will receive a single spinal injection of 40 mg of chloroprocaine PF. (other name: pure Nesacaine MPF 3% in a total volume of 2ml)
3130723|NCT03305575|Active Comparator|Bupivacaine|Patients assigned to bupivacaine will receive a single spinal injection of 7.5 mg of bupivacaine. (other name: pure Sensorcaine 0.75% diluted with normal saline to a total volume of 2ml).
3180343|NCT00682188|Active Comparator|II|Six individual sessions with the school nurse over 2 months to check weight and behavior changes and provide a series of six pamphlets on weight and weight management
3130724|NCT03305653|Experimental|Current/historical diagnosis of EoE|Subjects with current or historical diagnosis of EoE, or suspected of having EoE will complete the Esophageal String Test (EST) and EndoFLIP
3130725|NCT03305666|Active Comparator|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter will be placed in the subscapular space at the time of surgery, at infusion of 12 ml/hr of 0.25% bupivacaine, and left in place for a maximum of 120 hours
3130726|NCT03305666|Active Comparator|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine: mixture of 20 mL liposomal bupivacaine, 20 mL 0.25% bupivacaine, and 10 mL sterile saline (50 mL total), will be delivered in the intercostal space during VATS (with a 178 mm, 22 gauge needle, at ribs 3-8).
3130727|NCT03305731|Experimental|Activating Behavior for Lasting Engagement|Participants will engage in the ABLE intervention.
3130728|NCT03305770|Experimental|DD T2|Verofilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
3180344|NCT00682201||1|Healthy pregnant women
3130729|NCT03305770|Active Comparator|DT 1|Delefilcon A contact lenses worn in both eyes for 3 months in a daily wear, daily disposable modality. A new pair of study lenses will be inserted each day and discarded at the end of the day.
3130730|NCT03305809|Placebo Comparator|Placebo|Participants received placebo administered orally once a day (QD).
3130731|NCT03305809|Experimental|10 milligram (mg) LY3154207|Participants received 10 mg LY3154207 administered orally QD.
3130732|NCT03305809|Experimental|30 mg LY3154207|Participants received 30 mg LY3154207 administered orally QD.
3130733|NCT03305809|Experimental|75 mg LY3154207|Participants received 75 mg LY3154207 administered orally QD.
3130734|NCT03305822|Experimental|LY900014|Single, subcutaneous (SC) dose of 15 Units (U) LY900014 in one of two study periods
3130735|NCT03305822|Active Comparator|Insulin Lispro (Humalog)|Single SC dose of 15 U insulin lispro (Humalog) in one of two study periods
3130736|NCT03305887|Experimental|Barbed suture group|"The deep layer and the intermediate layer will be repaired and closed by using one STRATAFIX™ Symmetric Knotless Tissue suture respectively. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation."
3130737|NCT03305887|Active Comparator|Conventional suture group|VICRYL® Plus sutures will be used to close the deep and the intermediate layers with interrupted suturing manner. STRATAFIX Spiral sutures will be used to close the intradermal layer and the DERMABOND™ Advance™ Skin Closure System, a topical skin adhesive (TSA) will be applied to the skin surface to tissue approximation.
3130738|NCT03306043|Experimental|Subjects who received mepolizumab|Subjects who were part of study 200622 and were randomized to receive either placebo or mepolizumab will be enrolled in this study as per study eligibility criteria. In this study, subjects will receive 300 mg of mepolizumab SC (three 100 mg SC injections) every 4 Weeks for a total of 5 doses during 20-Week treatment period.
3130739|NCT03306277|Experimental|Onasemnogene Abeparvovec-xioi|One-time Intravenous administration of onasemnogene abeparvovec-xioi at the therapeutic dose.
3130740|NCT03306420|Experimental|Part IA Dose Escalation: M4112 100 mg|Participants received an oral dose of 100 milligrams (mg) M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
3130741|NCT03306420|Experimental|Part IA Dose Escalation: M4112 200 mg|Participants received an oral dose of 200 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
3130742|NCT03306420|Experimental|Part IA Dose Escalation: M4112 400 mg|Participants received an oral dose of 400 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
3180345|NCT00682214|Active Comparator|A, Choelcalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
3180346|NCT00682214|Placebo Comparator|B, Lactose|
3180347|NCT00682227|Experimental|1|
3180348|NCT00682240|Active Comparator|group 3|"Group 3: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation.~Intervention: All patients will receive a multi-session panretinal laser treatment according to the conventional protocol, using a conventional laser system."
3180349|NCT00682240|Active Comparator|group 2|"Group 2: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group 2.~Intervention: This group will receive multi-session panretinal laser treatment. The treatment will be performed using Pascal laser system."
3180350|NCT00682240|Active Comparator|group 1|"Group 1: 20 patients with proliferative retinopathy secondary to diabetes mellitus or venous occlusion) with need for panretinal photocoagulation randomized into group1.~Intervention: One group will receive a single-session panretinal laser treatment, performed using Pascal laser system."
3180351|NCT00682240|Active Comparator|group 4|"Group 4: 20 patients with persistent central or para-central diabetic macular edema receiving focal or grid laser treatment. As the treatment will be performed according to the conventional protocol (single spot), only the Pascal laser system will be used.~Intervention: focal or grid laser treatment"
3180352|NCT00682266|Experimental|Aerobic interval training|intensity-controlled interval training
3180353|NCT00682266|Experimental|MTG|multidisciplinary approach
3130743|NCT03306420|Experimental|Part IA Dose Escalation: M4112 600 mg|Participants received an oral dose of 600 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
3180354|NCT00682279|No Intervention|This is a single-arm, dose escalation|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
3180355|NCT00682292|Active Comparator|1, ATG|Thymoglobulin induction during 8 days (1.25 mg/kg per day) associated with tacrolimus, mycophenolate mofetil and steroids
3180356|NCT00682292|Active Comparator|2, Daclizumab|Dacluzamb induction (five infusions, 1 mg/kg per infusion) associated with tacrolimus, mycophenolate mofetil and steroids
3180357|NCT00682305|Other|Single-Arm|Single-Arm
3130744|NCT03306420|Experimental|Part IA Dose Escalation: M4112 800 mg|Participants received an oral dose of 800 mg M4112 twice daily in 28-day cycles, starting from Day 1 of each cycle until confirmed disease progression or unacceptable toxicity (up to 15 Months).
3130745|NCT03306433|Experimental|UDMA-K18|UDMA-K18 smooth surface sealant
3130746|NCT03306433|Placebo Comparator|UDMA-control|UDMA smooth surface sealant without K18
3130747|NCT03306433|No Intervention|Negative control|No intervention to provide baseline
3130748|NCT03306589|Experimental|Subjects receiving LPS: Part I and Part II|Eligible subjects will be randomized to receive LPS in a dose-escalation manner ranging from 0.5 nanogram (ng)/kg to 4 ng/kg. Subjects will be hydrated prior to administration of LPS with normal saline at a rate of 250 mL/hour for 4 hours prior to dosing and 8 hours after dosing.
3130749|NCT03306589|Experimental|Subjects receiving GM-CSF: Part I and Part II|Eligible subjects will be randomized to receive GM-CSF in a dose-escalation manner ranging from 5 to 15 microgram (µg)/kg.
3130750|NCT03306641|Active Comparator|Test Contact Lens|Per randomized schedule, subject will wear a pair of the test lens or control lens for one week and then cross-over with the control pair for 1 week.
3130751|NCT03306641|Active Comparator|nelfilcon A lens (control)|Per randomized schedule, subject will wear a pair of the control lens for one week and then cross-over with the test pair for 1 week.
3130752|NCT03307005|Experimental|Intervention|
3130753|NCT03307005|Placebo Comparator|Control|
3180358|NCT00682318|Experimental|Fish oil|Omega-3 polyunsaturated fatty acids (n-3 PUFA)
3180359|NCT00682318|Active Comparator|Safflower Oil|Omega-6 polyunsaturated fatty acids (n-6 PUFA)
3180360|NCT00682370|Experimental|A1|0.3 mg/kg heme arginate
3180361|NCT00682370|Experimental|A2|1 mg/kg heme arginate
3130754|NCT03307174|Active Comparator|Continuous epidural infusion|"At our institution, the most commonly utilized form of administration of medication through an epidural (our active comparator/control) is as follows:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl infused at a constant rate of 8ml/hr. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 15 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
3130755|NCT03307174|Experimental|Programmed intermittent epidural bolus|"For the programmed intermittent epidural bolus group:~Combination of 0.0625% bupivacaine with 2mcg/ml of fentanyl will be administered as a bolus of 4ml every 30 minutes. The patient has the ability to self administer patient controlled epidural analgesia of 2ml of the epidural medication with a lock out period of 10 min. The total maximum volume of epidural medication each hour is 16ml. These settings are managed and controlled by a epidural medication pump.~Additional oral and intravenous analgesia medications are available as scheduled and pro re nata."
3130756|NCT03307252|Experimental|Treatment Reference 1|
3130757|NCT03307252|Experimental|Treatment Reference 2|
3130758|NCT03307252|Experimental|Treatment Reference 3|
3130759|NCT03307252|Experimental|Treatment 1|
3130760|NCT03307252|Experimental|Treatment 2|
3130761|NCT03307252|Experimental|Treatment 3|
3130762|NCT03307252|Experimental|Treatment 4|
3130763|NCT03307252|Experimental|Treatment 5|
3130764|NCT03307252|Experimental|Treatment 6|
3130765|NCT03307785|Experimental|Part A: TSR-042 and niraparib 200 mg QD|Patients will receive TSR-042 500 milligram (mg), intravenous (IV) infusion on Day 1 of every cycle (every 3 weeks [Q3W]) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (every 6 weeks [Q6W]) beginning on Day 1 of Cycle 5 along with niraparib 200 mg, once daily (QD), orally on Days 1 to 21 repeated Q3W.
3180362|NCT00682370|Experimental|A3|3 mg/kg heme arginate
3180363|NCT00682370|Placebo Comparator|P|Placebo
3180364|NCT00682383|Other|ARM 1|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
3180365|NCT00682409|Other|1|Analysis of the value of the imaging of distribution and the late sequence to differentiate the cholesteatoma of the fibrosis in the follow-up operating post at the child
3180366|NCT00682422||Parent & Child Dyad|
3180367|NCT00682474|Experimental|CI|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
3180368|NCT00682474|Active Comparator|II|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
3180369|NCT00682487||1|patients admitted to the cardiology department with acute Myocardial infarction.
3180370|NCT00682487||2|patients admitted to an internal medicine department due to reasons other than an acute thrombotic event
3180371|NCT00682500|Experimental|1|Calfactant treatment
3180372|NCT00682500|Placebo Comparator|2|
3180373|NCT00682513||ATP1A3 Mutation|Those with RDP, AHC, unaffected carriers of ATP1A3 mutations, and non-carrying family members
3321311|NCT02017977||Urban-Rural Classification 4: Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 30 minutes to a settlement of 10,000 or more.
3180374|NCT00682526||Pre-study Period (Group 1 and Group 2).|"The TIME-MC study was conducted from June 2003 to June 2008 at NEMC (Figure 1) and from May 2005 to September 2008 at the six larger medical centers (Figure 2). Two groups were studied. Group 1 included patients at NEMC and Group 2 included patients at the other six medical sites. The study was divided into three periods:~Pre-study period (Group 1 and Group 2). No PH-ECG transmission system was available."
3130766|NCT03307785|Experimental|Part A: TSR-042 and niraparib 300 mg QD|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg, QD, orally on Days 1 to 21 repeated Q3W.
3321312|NCT02017977||Urban-Rural Classification 5: Very Remote Small Towns|Settlements of between 3,000 and 10,000 people and with a drive time of over 60 minutes to a settlement of 10,000 or more
3130767|NCT03307785|Experimental|Part B: TSR-042 and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 milligram per square meter (mg/m^2), IV infusion on Day 1 Q3W administered for 4 to 6 cycles.
3180375|NCT00682526||Study Period (Group 1 and Group 2)|Study period (Group 1 and Group 2). PH-ECG transmission to a cardiologist's hand-held device was attempted through pre-assigned EMS ambulances equipped with a wireless ECG transmission device in addition to a STEMI code system. In Group 1, this referred to the pilot study at NEMC from June 2003 to May 2005.
3180376|NCT00682526||Post-study period (Group 1)|Post-study period (Group 1). PH-ECG transmission and a STEMI code system implemented after the pilot study period.
3180377|NCT00682552|Experimental|1|"A cervico-vaginal cervical smear will be realized before every colposcopique examination.~A new cervical taking for the search(research) and the detection of the HPV 16 and 18 will be realized."
3180378|NCT00682578|Experimental|Artekin|Dihydroartemisinin+ Paperaquine (DHA+PPQ, Artekin)
3180379|NCT00682578|Active Comparator|Standard treatment|"The standard treatment for uncomplicated falciparum and vivax malaria are as follows:~Uncomplicated falciparum: artesunate-sulphadoxin/pyrimethamine Vivax malaria: chloroquine"
3130768|NCT03307785|Experimental|Part C: TSR-042, niraparib 200 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 200 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kilogram (kg), IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
3130769|NCT03307785|Experimental|Part C: TSR-042, niraparib 300 mg QD and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with niraparib 300 mg administered orally on Days 1 to 21 repeated Q3W and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
3180380|NCT00682630|Experimental|Study Group 1|Study Period 1: Treatment A (clinical trial reference tablets) 43 Days wash out Study Period 2: Treatment B (to-be-marketed tablets) 43 Days follow-up
3130770|NCT03307785|Experimental|Part D: TSR-042, carboplatin-paclitaxel and bevacizumab|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) for 4 cycles (each cycle is 21 days); followed by TSR-042 1000 mg, IV infusion on Day 1 of every other cycle (Q6W) beginning on Day 1 of Cycle 5 along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W administered for 4 to 6 cycles; and bevacizumab 15 mg/kg, IV infusion on Day 1 of every 21-day cycle Q3W for up to 15 months.
3130771|NCT03307785|Experimental|Part E: TSR-042 and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation) administered for 6 cycles (each cycle is 21 days).
3130772|NCT03307785|Experimental|Part F: TSR-042, TSR-022, and carboplatin-pemetrexed|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); and TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W administered for 5 cycles (each cycle is 21 days); and pemetrexed 500 mg/m^2, IV infusion on Day 1 Q3W (with vitamin supplementation).
3180381|NCT00682630|Experimental|Study Group 2|Study Period 1: Treatment B (to-be-marketed tablets) 43 Days wash out Study Period 2: Treatment A (clinical trial reference tablets). 43 Days follow-up
3130773|NCT03307785|Experimental|Part G: TSR-042 and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W) along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (every week [Q1W]) of every 3 week cycle for 4 to 6 cycles.
3130774|NCT03307785|Experimental|Part H: TSR-042, TSR-022, and carboplatin-nab-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days) and nab-paclitaxel 100 mg/m^2, IV infusion on Days 1, 8 and 15 (Q1W) of every 3 week cycle for 4 to 6 cycles.
3130775|NCT03307785|Experimental|Part I: TSR-042, TSR-022, and carboplatin-paclitaxel|Patients will receive TSR-042 500 mg, IV infusion on Day 1 of every cycle (Q3W); followed by TSR-022 900 mg, IV infusion on Day 1 Q3W along with carboplatin, IV infusion on Day 1 Q3W and paclitaxel 175 mg/m^2, IV infusion on Day 1 Q3W for 4 to 6 cycles (each cycle is 21 days).
3130776|NCT03307837|Active Comparator|CA-008 Cohort 1 0.5 mg|Intra-operative, local administration
3130777|NCT03307837|Active Comparator|CA-008 Cohort 2 1 mg|Intra-operative, local administration
3130778|NCT03307837|Active Comparator|CA-008 Cohort 3 2 mg|Intra-operative, local administration
3130779|NCT03307837|Active Comparator|CA-008 Cohort 4 3 mg|Intra-operative, local administration
3130780|NCT03307837|Active Comparator|CA-008 Cohort 5 4.2 mg|Intra-operative, local administration
3130781|NCT03307837|Placebo Comparator|Placebo|Intra-operative, local administration of saline (equivalent volume in active comparator arm)
3130782|NCT03308058|Experimental|Breastfeeding Computer education|Breastfeeding Computer education
3130783|NCT03308058|No Intervention|Printed Educational material|Printed educational material
3180382|NCT00682656|Active Comparator|A - N- methyl glucamine|Glucantime® , max day of 1,215 mg
3180383|NCT00682656|Experimental|B - Azithromycin|Zithromax ® , one dose 500 mg
3130784|NCT03308097|Experimental|PrEP Mobile Messaging Intervention|Participants from the STI/HIV testing clinic will receive Enhanced Standard of Care (described below) plus texted messages with the intervention content and follow-up questions over the next 4 weeks on their cell phones. Participants will receive approximately 8-16 interactive text messages with links to web content. Texts will be sent twice a week over the next 4 weeks. Participants will return for 2 more appointments over the next couple of months to fill out questionnaires.
3130785|NCT03308097|Active Comparator|Enhanced Standard of Care|As part of the enhanced standard of care, participants seen in the STI/HIV testing clinic are given feedback regarding PrEP eligibility and current risk behaviors. Participants are also given an informational handout about PrEP, shown a brief video, and given contact information for the PrEP Clinic Care Coordinator. Participants will return for 2 more visits over the next couple months to fill out questionnaires.
3130786|NCT03308669|Experimental|Lasmiditan Alone|Lasmiditan administered orally, alone
3130787|NCT03308669|Placebo Comparator|Placebo Alone|Placebo administered orally, alone
3130788|NCT03308669|Experimental|Topiramate + Lasmiditan|Topiramate administered orally, alone, and co-administered with oral lasmiditan
3130789|NCT03308669|Experimental|Topiramate + Placebo|Topiramate administered orally, alone, and co-administered with oral placebo
3130790|NCT03308799|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
3130791|NCT03308799|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
3130792|NCT03308799|Placebo Comparator|Cream vehicle|One application daily for 8 weeks.
3130793|NCT03308825|Experimental|Group 1: 6 to < 36 Months|Children aged 6 to < 36 months received a 0.25-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
3130794|NCT03308825|Experimental|Group 2: 3 to < 9 Years|Children aged 3 to < 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. For participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered on Day 28.
3130795|NCT03308825|Experimental|Group 3: 18 to < 65 Years|Adults aged 18 to < 65 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
3130796|NCT03308825|Experimental|Group 4: >= 65 Years|Adults aged >= 65 years received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
3130797|NCT03308942|Experimental|Stage 1 (Cohort 1): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/programmed death-ligand 1 (PD-L1) inhibitor treatment and whose tumors have high PD-L1 expression (tumor proportion score [TPS]: >= 50 percent [%]) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
3321313|NCT02017977||Urban-Rural Classification 6: Accessible Rural|Areas with a population of less than 3,000 people, and within a 30 minute drive time of a settlement of 10,000 or more
3130798|NCT03308942|Experimental|Stage 1 (Cohort 2): Niraparib plus Pembrolizumab|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; pembrolizumab.
3180384|NCT00682669|Experimental|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
3130799|NCT03308942|Experimental|Stage 1 (Cohort 3): Niraparib|Participants with locally advanced and metastatic squamous NSCLC who have been previously treated with both platinum and either PD-1 or PD-L1 inhibitor will receive single agent niraparib.
3130800|NCT03308942|Experimental|Stage 2 (Cohort 1A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have high PD-L1 expression (TPS: >= 50%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
3130801|NCT03308942|Experimental|Stage 2 (Cohort 2A): Niraparib plus TSR-042 (Dostarlimab)|Participants with locally advanced and metastatic NSCLC (all histologies) with no prior systemic chemotherapy or PD-1/PD-L1 inhibitor treatment and whose tumors have PD-L1 expression (TPS: 1% to 49%) will receive combination of niraparib and a PD-1 inhibitor; TSR-042 (Dostarlimab).
3130802|NCT03308968|Placebo Comparator|Placebo|Double-blind (DB) period: Participants with CM or EM will receive 3 injections of placebo 1.5 milliliters (mL) SC on Day 0 and single injection of placebo 1.5 mL SC on Days 28 and 56. Open-label (OL) period: Participants with CM or EM will receive fremanezumab (TEV-48125) 225 milligrams (mg) SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
3130803|NCT03308968|Experimental|Fremanezumab Quarterly|DB period: Participants with CM or EM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of placebo 1.5 mL for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
3130804|NCT03308968|Experimental|Fremanezumab Monthly|DB period: Participants with CM will receive fremanezumab 675 mg SC (3 injections of fremanezumab 225 mg/1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). Participants with EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL) on Day 0 followed by monthly SC administration of fremanezumab 225 mg (1 injection of fremanezumab 225 mg/1.5 mL) for 2 months (on Days 28 and 56). OL period: Participants with CM or EM will receive fremanezumab 225 mg SC (1 injection of fremanezumab 225 mg/1.5 mL) at Days 84, 112, and 140.
3130805|NCT03309020|Active Comparator|Control|Control with clinical need for cataract surgery
3130806|NCT03309020|Experimental|EVD Survivors|EVD survivors with need for cataract surgery
3130807|NCT03309072|Experimental|active tDCS|active tDCS with Face Name associate Memory task
3180385|NCT00682669|Active Comparator|HLC|A Healthy Living Course (HLC) consisting of an 8-week program of lectures and discussion on health-related topics.
3130808|NCT03309072|Sham Comparator|sham tDCS|sham tDCS with Face Name associate Memory task
3130809|NCT03309202|Experimental|Cohort 1_Without impairment|Single, 25 mg dose of PF-05221304
3130810|NCT03309202|Experimental|Cohort 2_Mild impairment|Single, 25 mg dose of PF-05221304
3130811|NCT03309202|Experimental|Cohort 3_Moderate impairment|Single, 25 mg dose of PF-05221304
3130812|NCT03309202|Experimental|Cohort 4_Severe impairment|Single, 25 mg dose of PF-05221304
3130813|NCT03309449|Other|Intramuscular administration|Participants in this arm will be provided with the training and supplies to administer intramuscular simulated naloxone using a syringe and needle to a simulated flesh pad on a mannequin.
3130814|NCT03309449|Other|Intranasal (Atomizer)|Participants in this arm will be provided with the training and supplies to administer atomized intranasal simulated naloxone to a mannequin via a syringe using an intranasal mucosal atomization device.
3130815|NCT03309449|Other|Intranasal (Spray)|Participants in this arm will be provided with the training and supplies to administer an intranasal spray simulated naloxone to a mannequin.
3130816|NCT03309605|Placebo Comparator|Placebo Comparator Arm|Placebo
3130817|NCT03309605|Experimental|ELX-02|ELX-02
3130818|NCT03309657|Experimental|Ceftolozane Tazobactam|Infected patients with external intraventricular drain will receive a single dose of Ceftolozane/ tazobactam (3000mg) over 1 hour and will undergo blood , csf and urine sampling at specific times over an 8 hour period.
3130819|NCT03309696|Experimental|tDCS and 1 Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC. .
3130820|NCT03309696|Experimental|tDCS and 10Hz rTMS delivered over TC|Participants receive sham and active 2mA tDCS over the temporal cortex (TC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
3130821|NCT03309696|Experimental|tDCS over DLFC and 1 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 1 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
3130822|NCT03309696|Experimental|tDCS over DLFC and 10 Hz rTMS over TC|Participants receive sham and active 2mA tDCS over the dorsolateral frontal cortex (DLFC) prior to receiving sham and active 10 Hz rTMS (900 rTMS pulses at 110% motor threshold) delivered to the TC.
3130823|NCT03309787||Amulet only|As per usual care participants will receive an eHealth (Amulet + videoconferencing) intervention over a 16 week period of time.
3130824|NCT03309787||Amulet/Fitbit|As per usual care participants will receive an eHealth (Amulet/Fitbit + videoconferencing) intervention over a 16 week period of time.
3130825|NCT03309787||Fitbit only|As per usual care participants will receive an eHealth (Fitbit + videoconferencing) intervention over a 16 week period of time.
3130826|NCT03309943|Experimental|Propranolol|Propranolol Capsule: 40 mg IR, administered 2x at separate laboratory sessions
3130827|NCT03309943|Placebo Comparator|Placebo|Placebo Capsule: No active ingredients, administered 2x at separate laboratory sessions
3130828|NCT03310021|Experimental|Cohort 1|Apixaban + low dose andexanet
3130829|NCT03310021|Experimental|Cohort 2|Rivaroxaban + high dose andexanet
3130830|NCT03310021|Experimental|Cohort 3|Edoxaban + high dose andexanet
3130831|NCT03310021|Experimental|Cohort 4|Edoxaban + high dose andexanet
3130832|NCT03310021|Experimental|Cohort 5|Apixaban + low dose andexanet
3130833|NCT03310021|Experimental|Cohort 6|Apixaban + high dose andexanet
3130834|NCT03310021|Experimental|Cohort 7|Edoxaban + low dose andexanet
3130835|NCT03310021|Experimental|Cohort 8|Apixaban + low dose andexanet
3130836|NCT03310021|Experimental|Cohort 9|Rivaroxaban + low dose andexanet
3130837|NCT03310021|Experimental|Cohort 10|Edoxaban + low dose andexanet
3130838|NCT03310268|Experimental|Test Product|Participants will be instructed to self administer experimental dentifrice containing 0.454% SnF2 and 0.072% sodium fluoride (NaF) (1450 parts per million [ppm] fluoride in total).
3130839|NCT03310268|Active Comparator|Negative Control|Participants will be instructed to self administer negative control dentifrice containing 1400 ppm fluoride as sodium monofluorophosphate (SMFP).
3130840|NCT03310268|Active Comparator|Positive Control|Participants will be instructed to self administer positive control dentifrice containing SnCl2 and 0.15% NaF (1450 ppm fluoride in total).
3130841|NCT03310411|Experimental|Lasmiditan + Sumatriptan (A)|Single oral dose of 200 milligram (mg) lasmiditan tablet and single oral dose of 100 mg sumatriptan tablet in one of four treatment periods.
3130842|NCT03310411|Experimental|Lasmiditan + Placebo (B)|Single oral dose of 200 mg lasmiditan tablet and single oral dose of placebo tablet in one of four treatment periods.
3130843|NCT03310411|Active Comparator|Sumatriptan + Placebo (C)|Single oral dose of 100 mg sumatriptan tablet and single oral dose of placebo tablet in one of four treatment periods.
3130844|NCT03310411|Placebo Comparator|Placebo + Placebo (D)|Oral doses of placebo tablets in one of four treatment periods.
3130845|NCT03310450||Group 140kms cycling|"Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
3130846|NCT03310450||Group 100kms cycling|"Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
3130847|NCT03310450||Group 240kms cycling|"Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.~Investigator did not give any intervention, just observed the cycling touring event that the subjects participated"
3130848|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
3130849|NCT03310580|Experimental|AR-13324 Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
3130850|NCT03310580|Placebo Comparator|Placebo Comparator|Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days
3130851|NCT03310723|Active Comparator|Standard Face Mask Preoxygenation|Tidal volume breathing for via a face mask set at 100% oxygen and a rate of 15L/min.
3130852|NCT03310723|Experimental|Optiflow Preoxygenation|Tidal volume breathing with the OptiFlow system applied at 100% oxygen and a flow rate of 30-70L/min.
3130853|NCT03310775|Experimental|case group|Behavioral: parent-assisted social skills training program for young adults with autism spectrum disorder The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
3130854|NCT03310775|Experimental|waitlist control group|"For this group, same intervention with the Experimental group will be provided after waiting for 16 weeks.~Behavioral: Delayed intervention Intervention is provided to Waitlist Control Group after waiting for 16 weeks"
3130855|NCT03310970|Active Comparator|Lidocaine 5% patch|Each subject will wear three generic Lidocaine 5% topical patches for 12 hours.
3130856|NCT03310970|Active Comparator|Lidoderm® 5% patch|Each subject will wear three Lidoderm® topical patches for 12 hours.
3130857|NCT03310970|Active Comparator|Intravenous lidocaine|A single intravenous dose of 0.5 mg/kg lidocaine hydrochloride will be administered to each subject.
3130858|NCT03311230|No Intervention|Control|Participants in this arm will receive no other interventions during the 9 month study period
3130859|NCT03311230|Experimental|Supportive social incentive|Participants will identify a family member or friend to support them during a gamification intervention.
3130860|NCT03311230|Experimental|Competitive social incentive|Participants will compete in a gamification intervention in groups of three.
3130861|NCT03311230|Experimental|Collaborative social incentive|Participants will collaborate in groups of three in a gamification intervention
3130862|NCT03311373|Experimental|Treatment Period 1|Test Formulation (Regimen B or D) or Reference Formulation (Regimen A or C)
3130863|NCT03311373|Experimental|Treatment Period 2|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
3130864|NCT03311373|Experimental|Treatment Period 3|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
3130865|NCT03311373|Experimental|Treatment Period 4|Test Formulation (Regimen (B or D) or Reference Formulation (Regimen A or C)
3130866|NCT03311646|Experimental|Nicotine Content Manipulation|All participants receive normal nicotine content (NNC) cigarettes during Baseline and all participants receive very low nicotine content (VLNC) cigarettes during the very low nicotine content condition.
3130867|NCT03311659|Experimental|dTpa group|Healthy female and male subjects with age 4 years and above and who received a single dose of Boostrix vaccine at Day 1.
3130868|NCT03311724|Experimental|4,8,12mg Tirzepatide|Participants received Tirzepatide by subcutaneous (SC) injection in three dose escalations starting with 4 milligrams (mg) for four weeks followed by 8mg for four weeks followed by 12mg for four weeks.
3130869|NCT03311724|Experimental|2.5,5,10,15mg Tirzepatide|Participants received Tirzepatide by SC injection in four dose escalations starting with 2.5mg for two weeks followed by 5mg for two weeks followed by 10mg for four weeks followed by 15mg for four weeks.
3130870|NCT03311724|Experimental|2.5,7.5,15mg Tirzepatide|Participants received Tirzepatide by SC injection in three dose escalations starting with 2.5mg for four weeks followed by 7.5mg for four weeks followed by 15mg for four weeks.
3130871|NCT03311724|Placebo Comparator|Placebo|Placebo administered by SC injection.
3130872|NCT03311841|Experimental|End Stage Renal Disease|Participants requiring hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). A washout period of at least 14 days will separate dosings.
3130873|NCT03311841|Experimental|Severe Impairment|Participants with <30 mL/min/1.73m^2 estimated glomerular filtration rate (eGFR) not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
3130874|NCT03311841|Experimental|Moderate Impairment|Participants with 30 to <60 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
3180386|NCT00682682|Experimental|1|all study participants will have 4 visits: VR alone, VR + opioid, opioid alone, and no VR/opioid
3130875|NCT03311841|Experimental|Mild Impairment|Participants with 60 to <90 mL/min/1.73m^2 eGFR not on hemodialysis. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
3321314|NCT02017977||Urban-Rural Classification 7: Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 30 minutes to a settlement of 10,000 or more
3130876|NCT03311841|Active Comparator|Healthy Control|Participants with ≥90 mL/min creatinine clearance. Period 1/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution). Period 2/Day 1: participants receive a single oral dose of the microdose cocktail (midazolam oral solution, dabigatran etexilate and pitavastatin oral solution, atorvastatin and rosuvastatin oral solution) and rifampin. A washout period of at least 14 days will separate dosings.
3130877|NCT03312023|Experimental|Group A (LDV/SOF for low replicative HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B in low replicative state.
3130878|NCT03312023|Experimental|Group B (LDV/SOF for viral suppressed HBV)|12 week treatment with ledipasvir/sofosbuvir (Harvoni) for chronic hepatitis B, virally suppressed.
3130879|NCT03312023|Experimental|Group C (SOF for low replicative HBV)|"12 weeks treatment with sofosbuvir (Sovaldi) for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group D."
3130880|NCT03312023|Experimental|Group D (LDV for low replicative HBV)|"12 weeks treatment with ledipasvir for chronic hepatitis B in low replicative state.~Randomized 1:1 with Group C."
3130881|NCT03312114|Experimental|Single arm|Avelumab and SABR
3130882|NCT03312218|Experimental|Intervention|Intervention site residents will receive alerts through an app to adaptively reinforce the learning of clinical content based on cases and test questions (spaced education).
3130883|NCT03312218|No Intervention|Control|Residents in the control group will receive the same app providing identical clinical cases and test questions-on-demand, but with alerts inactivated (no spaced education).
3130884|NCT03312231|Experimental|Group 1|3.75 mcg of H7N9 vaccine with PBS diluent plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
3130885|NCT03312231|Experimental|Group 2|7.5 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
3130886|NCT03312231|Experimental|Group 3|15 mcg of H7N9 vaccine plus AS03 adjuvant on days 1 and 22, n=100 (19-64 years old) and n=60 (65 and older)
3130887|NCT03312231|Experimental|Group 4|15 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
3130888|NCT03312231|Experimental|Group 5|45 mcg of unadjuvanted H7N9 vaccine on days 1 and 22, n=50 (19-64 years old) and n=30 (65 and older)
3130889|NCT03312348|Experimental|Infrared Imaging undertaken|Infrared imaging of Region Of Interest in study participants
3180387|NCT00682695||1|"Participants who have had a hemorrhagic stroke at University of Maryland, University of Cincinnati, Massachusetts General Hospital, Duke University, Columbia University and University of Chicago Illinois, age 18 years or greater. Ability of the patient or legal representative to provide informed consent. Racial/ethnic category meets one of the following: African American, Caucasian or Hispanic.~Healthy volunteers who are matched to the study cases with hemorrhagic stroke within +/- 5 years of age, same gender and same race."
3180388|NCT00682721|Active Comparator|2|Valacyclovir 1 gm daily x number of days active in the study
3180389|NCT00682721|Placebo Comparator|1|
3180390|NCT00682747|Experimental|HBO|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen)
3180391|NCT00682747|No Intervention|non HBO|
3180392|NCT00682760|Active Comparator|1|Korean botulinum toxin A treatment
3180393|NCT00682760|Placebo Comparator|2|Botox treatment
3180394|NCT00682773|No Intervention|1|Usual care, no educational intervention.
3180395|NCT00682773|Experimental|2|Usual care, nursing home nursing staff receive educational intervention on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
3180396|NCT00682812|Active Comparator|1|125 womens with normal cervix
3180397|NCT00682812|Other|2|105 womens with an intraepithelial lesion
3180398|NCT00682812|Other|3|105 womens with a cancer of the cervix
3180399|NCT00682825|Experimental|1|Bispectral index-guided protocol
3180400|NCT00682825|Active Comparator|2|End-tidal anesthetic gas-guided protocol
3180401|NCT00682877||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3180402|NCT00682877||Gastroparesis|Subjects with documented gastroparesis
3180403|NCT00682903|Experimental|1|This arm will benefit from the nonstop measure of the subcutaneous glucose during the hospitalization and the week on returning to the place of residence,
3130890|NCT03312517|Active Comparator|Suvorexant 10mg|Subjects will receive belsomra 10mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
3130891|NCT03312517|Active Comparator|Suvorexant 20mg|Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
3130892|NCT03312517|Sham Comparator|Placebo oral capsule|Subjects will receive placebo before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
3130893|NCT03312543|Experimental|Active Cell: Active Mask|Cleanser, Moisturizer, Active Mask
3130894|NCT03312543|Sham Comparator|Sham Cell: Sham Mask|Cleanser, Moisturizer, Sham Mask
3130895|NCT03312595|Other|Restrata TM Wound Matrix|Prospective, single armed, non-randomized study with direct assignment
3321315|NCT02017977||Urban-Rural Classification 8: Very Remote Rural|Areas with a population of less than 3,000 people, and with a drive time of over 60 minutes to a settlement of 10,000 or more
3321316|NCT02017977||Travel Time - see below|Travel time will be analysed as a continuous and discrete variable.
3130896|NCT03312933||Duration of boot >2 weeks|All patients who were placed into a CAM walker boot for >2 weeks were prospectively enrolled. Patients were placed by an orthopedic cast technician into either a tall or short CAM walker boot, based upon the appropriate boot type needed for treatment. Inclusion criteria included anticipated boot wear for at least two weeks, and weightbearing as tolerated weightbearing restrictions. Exclusion criteria included transitioning into a CAM walker boot as part of a postoperative protocol, injury requiring restricted weightbearing, or an additional acute injury to the lower back or lower extremity. Those who subsequently reported wearing the boot for less than two weeks or had a treatment plan change were removed from the study.
3130897|NCT03313037|Experimental|Multivalent|Pneumococcal conjugate vaccine
3130898|NCT03313037|Active Comparator|Control|Prevnar 13 and PPSV23
3130899|NCT03313050|Experimental|Stage 1 multivalent (ages 50-64 years)|multivalent
3130900|NCT03313050|Active Comparator|Stage 1 Tdap (ages 50-64 years)|Tdap
3130901|NCT03313050|Experimental|Stage 2 multivalent (ages 65-85 years)|multivalent
3130902|NCT03313050|Active Comparator|Stage 2 polysaccharide (ages 65-85 years)|polysaccharide
3130903|NCT03313076|Experimental|n-3 PUFA (O3FA) + Vitamin D3|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule
3130904|NCT03313076|Experimental|n-3 PUFA (O3FA) Placebo + Vitamin D3|4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule
3130905|NCT03313076|Experimental|n-3 PUFAs (O3FA) + Vitamin D3 Placebo|4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule
3130906|NCT03313076|Placebo Comparator|n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo|4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule
3130907|NCT03313310|Experimental|Employment Intervention|An employment intervention (iFOUR) that has been adapted from previous piloting work of focus groups, key informant interviews and a community advisory board.
3130908|NCT03314233|Experimental|DING intervention|Delayed Cord Clamping
3130909|NCT03314519|Experimental|Ultrasonography|Patients in this group receive lung ultrasonography to detect lung collapse after insert double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering pleural cavity.
3130910|NCT03314519|Active Comparator|Fiberoptic bronchoscopy|Patients in this group receive fiberoptic bronchoscope to detect lung collapse after inserting a double lumen tube and finally compare lung collapse by the surgeon's visual grading scale of lung collapse when entering the pleural cavity.
3130911|NCT03314662|Experimental|aQIV|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV) contains each of the 2 influenza type A strains and each of the two influenza type B strains in the vaccine.
3130912|NCT03314662|Experimental|aTIV-1|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1) contains each of the 2 influenza type A strains and one influenza type B strain in the vaccine.
3130913|NCT03314662|Experimental|aTIV-2|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine contains each of the 2 influenza type A strains and alternate influenza type B strain in the vaccine.
3130914|NCT03314753||Cryoballoon Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: Arctic Front® & Arctic Front Advance® Cardiac CryoAblation Catheter System.~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
3321317|NCT02017990||Renal transplant recipients|No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
3321318|NCT02018016||High volume hospitals|The hospitals in the upper tertile for procedural volume
3130915|NCT03314753||Radiofrequency Arm from FIRE AND ICE Trial|"No new/additional patients will be enrolled within this project. Only retrospective data will be collected on performed re-ablation procedures within the FIRE AND ICE Trial.~The FIRE AND ICE Trial collected data to compare efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus (Cryoballoon Arm) a radiofrequency ablation (RF Arm) with a ThermoCool catheter in patients with drug refractory symptomatic paroxysmal atrial fibrillation (AF).~Products Used within the FIRE AND ICE Trial: NaviStar® ThermoCool® Ablation Catheter (Radiofrequency Arm; Manufacturer Biosense Webster, Inc.).~The purpose of this retrospective data collection on re-ablations performed in both treatment arms (Cryo arm and Radiofrequency arm) of the FIRE AND ICE Trial."
3321319|NCT02018016||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
3130916|NCT03314857|Experimental|Patients with SAPIEN XT THV|Patients will be treated with Edwards SAPIEN XT™ Transcatheter Heart Valve and NovaFlex+ delivery system
3130917|NCT03315104|Experimental|FLU-IGIV High Dose|"Participants will receive a single infusion of high dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive standard of care (SOC) antiviral treatment for flu. Administered intravenously at a dose of 450 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
3321320|NCT02018016||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
3321321|NCT02018029||cardiac resynchronisation therapy|
3321322|NCT02018055|Active Comparator|Aspirin+Ticagrelor|A Group treated with Aspirin+Ticagrelor
3130918|NCT03315104|Experimental|FLU-IGIV Low Dose|"Participants will receive a single infusion of low dose of FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered intravenously at a dose of 225 mL of 65 g/mL FLU-IGIV diluted to 500 mL with normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~FLU-IGIV: Single dose, sterile liquid formulation for IV administration."
3321323|NCT02018055|Experimental|Aspirin+Clopidogrel|A Group treated with Aspirin+Clopidogrel
3130919|NCT03315104|Placebo Comparator|FLU-IGIV Placebo|"Participants will receive a single infusion of placebo for FLU-IGIV, administered over approximately 3 hours on Day 1. Participants will also receive SOC antiviral treatment for flu. Administered IV as 500 mL of normal saline. Participants also received standard of care (SOC) antiviral treatment for flu.~Placebo for FLU-IGIV: Single dose, normal saline solution for IV administration."
3130920|NCT03315208|Experimental|Unified Protocol + Treatment As Usual|Participants in this arm are offered 16 twice-weekly group UP sessions in addition to TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
3130921|NCT03315208|Active Comparator|Treatment As Usual Alone|Participants in this arm undergo TAU at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
3130922|NCT03315286|Experimental|Device: SHADE Ultraviolet Sensor|Patients will receive an Ultraviolet (UV) sensor that will quantify their UV exposure through a linked smartphone application. Patients will also receive clinical counseling by their dermatologist regarding sun protection and avoidance
3130923|NCT03315286|Active Comparator|Standard of Care Counseling|Patients will receive clinical counseling by their dermatologist regarding sun protection and avoidance
3130924|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 1|Eligible subjects will receive IV infusion of [14C] radiolabelled GSK2269557 with a single dose of 10 micrograms (µg) administered as single microtracer, concomitantly with an inhaled nonradiolabelled 1000 µg dose of GSK2269557. There will be a washout of at least 14 days after inhaled and IV dosing before subjects receive treatment 2.
3130925|NCT03315559|Experimental|Subjects receiving GSK2269557 in treatment period 2|Eligible subjects will receive [14C]-GSK2269557 with a single dose of 800 µg, administered as an oral solution.
3130926|NCT03315572||Pediatric subject/caregiver dyads-first interview set|The first interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
3130927|NCT03315572||Pediatric subject/caregiver dyads-second interview set|The second interview set will consist of eight pediatric subject/caregiver dyads including pediatric subjects with asthma currently using a maintenance inhaler and his or her caregiver. The pediatric subjects and their caregivers will be asked questions regarding ease of use of ELLIPTA inhaler.
3130928|NCT03315689|Placebo Comparator|Vehicle|Vehicle
3130929|NCT03315689|Experimental|Active|ATI-50002 Topical Solution
3130930|NCT03315702||control／mechanical ventilation|venous blood samples collected from patients twice，relatively before mechanical ventilation and 3rd hour after mechanical ventilation
3130931|NCT03315780|Experimental|Dulaglutide, Placebo|Dulaglutide 0.75 mg administered subcutaneously (SC) once weekly for 4 weeks in period 1 followed by placebo administered SC once weekly for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
3130932|NCT03315780|Experimental|Placebo, Dulaglutide|Placebo administered SC once weekly for 4 weeks in Period 1 followed by Dulaglutide 0.75 mg administered SC for 4 weeks in Period 2. There is a 4 to 6 week washout period between Period 1 and Period 2.
3130933|NCT03315793|Experimental|Duloxetine Hydrochloride|Duloxetine hydrochloride given orally.
3130934|NCT03315793|Placebo Comparator|Placebo|Placebo given orally.
3130935|NCT03315949|Experimental|Same-day dose group|Participants who ingest bowel cleanser on the day of colonoscopy. Participant will ingest the 4L PEG on the day of colonoscopy.
3130936|NCT03315949|Active Comparator|Split-dose group|Participants who ingest bowel cleanser by split dose. 2L PEG will be ingested 1 day before colonoscopy. Remaining 2L bowel cleanser will be ingested on the day of colonoscopy.
3130937|NCT03316131|Experimental|Treatment A|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin;"
3130938|NCT03316131|Experimental|Treatment B|"Randomized patients will receive orally once daily fixed dose of the following drugs:~verinurad + febuxostat + dapagliflozin matched placebo"
3132817|NCT03454048|Experimental|Group 3 (Cohort B) LD-PIP/LD-PIP2/PIP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 3 (LD-PIP/LD-PIP2/PIP) will be curatively treated with piperaquine (960mg)
3130939|NCT03316170|Experimental|Social Support + NRT Sampling|"The treatment group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,~a brief phone consult (10-15 minutes via phone) germane to smoking cessation,~a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and~a free, 2-week supply of nicotine patches and lozenges delivered via mail."
3130940|NCT03316170|Active Comparator|Social Support|"The control group will receive:~a brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs,~a written directory of a range of social support resources delivered via mail,"
3130941|NCT03316378|Experimental|Group with Achilles Tendinopathy|Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
3130942|NCT03316378|No Intervention|Group without Achilles Tendinopathy|The control group did not receive an injection between test repetitions
3130943|NCT03316547|No Intervention|Control|The control group received standard hospital care.
3130944|NCT03316547|Experimental|Intervention|Parents in the sensory-based intervention group were educated to provide daily sensory-based interventions across the length of hospitalization as outlined in the manualized intervention (the SENSE Program). A sensory support team completed the doses of sensory exposures when parents were unable.
3130945|NCT03316807|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
3130946|NCT03316807|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
3130947|NCT03316911|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
3130948|NCT03316911|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
3130949|NCT03316976|Experimental|Group 1: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
3130950|NCT03316976|Experimental|Group 2: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, delayed-release, capsule, orally, administered as single dose on Day 1.
3130951|NCT03317002|Experimental|AZD5718 Dose A|AZD5718 Dose A once daily
3130952|NCT03317002|Experimental|AZD5718 Dose B|AZD5718 Dose B once daily
3130953|NCT03317002|Placebo Comparator|Placebo|Matching placebo once daily
3130954|NCT03317288|Other|SCI subjects|The subject act as his or her own control. Each subject will undergo two procedures, intervention: alternating pressure overlay on top of standard operation room overlay, vs. control: operation room overlay.
3130955|NCT03317379|Experimental|Peer mentorship|Participants meet weekly with an adult peer mentor who has recovered from an eating disorder. The focus of meetings is on eating disorder symptoms and how to overcome them. The goal of this program is to reduce eating disorder symptoms directly by receiving support and guidance from someone who has been through it.
3130956|NCT03317379|Active Comparator|Social support mentorship|Participants meet weekly with an adult mentor who has not personally struggled with an eating disorder but who is dedicated to offering support. During weekly meetings, participants and mentors (and possibly 1-2 other mentees) engage in activities unrelated to the eating disorder. The goal of this program is to reduce eating disorder symptoms indirectly by exploring aspects of self outside the eating disorder.
3130957|NCT03317379|No Intervention|Wait list|Participants are on a wait list and then get matched with either type of mentor (of their choice) 6 months later
3130958|NCT03317431||ventilation|patients undergoing selective operation with general anesthesia(GA) and mechanical ventilation(MV)
3130959|NCT03317444|Experimental|TRC101|Administered once daily (QD) for 12 weeks
3130960|NCT03317444|Placebo Comparator|Placebo|Administered once daily (QD) for 12 weeks
3130961|NCT03318315|Experimental|Group 1|3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant and 0.5 ml dose of IIV4 vaccine, both administered intramuscularly within 15 minutes on day 1, and 3.75 mcg HA per 0.5 mL dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22, n=60
3130962|NCT03318315|Experimental|Group 2|0.5 ml dose of IIV4 vaccine intramuscularly on day 1 and 3.75 mcg HA per 0.5 ml dose of H7N9 vaccine in PBS diluent + GSK AS03 adjuvant intramuscularly on day 22 and day 43, n=60
3130963|NCT03318315|Active Comparator|Group 3|0.5 ml dose of IIV4 vaccine intramuscularly on day 1, n=30
3130964|NCT03318341|Other|Real then Sham|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies real stimulation in the first month. The device applies sham stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
3130965|NCT03318341|Other|Sham then Real|Participants are instructed to wear the TheraBracelet device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. After 2-week washout, participants are again instructed to wear the device on the affected wrist every day for at least 8 hours/day during their daily activity for 1 month. The device applies sham stimulation in the first month. The device applies real stimulation in the second month. The stimulation is imperceptible. Thus, participants do not perceive stimulation in either month.
3130966|NCT03318523|Placebo Comparator|Placebo|"Year 1: Participants will receive matching placebo to BIIB054 on Day 1 and then every 4 weeks.~Year 2: Participants who received placebo in year 1 will be randomized into one of the active treatment arms in year 2 and will receive BIIB054 intravenous (IV) infusion on Week 52 and then every 4 weeks."
3130967|NCT03318523|Experimental|BIIB054 250 mg|Participants will receive BIIB054 250 milligrams (mg) intravenous (IV) infusion on Day 1 and then every 4 weeks.
3130968|NCT03318523|Experimental|BIIB054 1250 mg|Participants will receive BIIB054 1250 mg IV infusion on Day 1 and then every 4 weeks.
3130969|NCT03318523|Experimental|BIIB054 3500 mg|Participants will receive BIIB054 3500 mg IV infusion on Day 1 and then every 4 weeks.
3130970|NCT03318783|Active Comparator|GSK2256294|10mg capsules of GSK2256294 will be administered in a single dose once daily enterally for a duration of 10 days.
3130971|NCT03318783|Placebo Comparator|Placebo|10mg matched placebo capsules will be administered in a single dose once daily enterally for a duration of 10 days.
3130972|NCT03318809|Experimental|Group 1: Severely Renal Impaired Participants|Participants with severely impaired renal function (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min/1.73 m^2) receive a single oral dose of 200 mg AMG 986.
3130973|NCT03318809|Active Comparator|Group 2: Healthy Participants|Participants with normal renal function (eGFR >= 90 mL/min/1.73 m^2 or above) receive a single oral dose of 200 mg AMG 986.
3130974|NCT03318861|Experimental|Dose Escalation: 3 x 10^7 KITE-585|Participants with relapsed/refractory multiple myeloma (RRMM), will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of KITE-585 autologous anti-B-cell maturation antigen (BCMA) CAR T cells at a dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
3130975|NCT03318861|Experimental|Dose Escalation: 1 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
3130976|NCT03318861|Experimental|Dose Escalation: 3 x 10^8 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 3 x 10^8 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
3130977|NCT03318861|Experimental|Dose Escalation: 1 x 10^9 KITE-585|Participants with RRMM, will receive conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day IV infusion for 3 days followed by a single infusion of KITE-585 anti-autologous BCMA CAR T cells at a dose of 1 x 10^9 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants will then have a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
3130978|NCT03318861|Experimental|Dose Expansion (Renal Impairment): 3 x 10^7 KITE-585|RRMM participants with moderate renal impairment (creatinine clearance 30 to 59 mL/min [Grade 2 chronic kidney disease]) will receive a conditioning chemotherapy consisting of cyclophosphamide 300 mg/m^2/day and fludarabine 24 mg/m^2/day IV infusion for 3 days followed by a single intravenous infusion of KITE-585 anti-autologous BCMA CAR T cells at a tolerable dose of 3 x 10^7 3e7 transduced cells on Day 0. Participants may also receive an optional bridging therapy at the investigator's discretion, up to 7 days before initiation of conditioning chemotherapy. Participants then had a post-treatment assessment period and long-term follow-up period from Week 2 to Month 3 and after Month 3 to Year 15, respectively.
3130979|NCT03319134|Experimental|active anodal HD-tDCS|Active anodal HD-tDCS stimulation applied during memory task
3130980|NCT03319134|Sham Comparator|sham HD-tDCS|Sham HD-tDCS stimulation during memory task for comparison
3130981|NCT03319134|Experimental|active cathodal HD-tDCS|Active cathodal HD-tDCS stimulation applied during memory task
3130982|NCT03319173|Experimental|Experimental group|"Dietary interventions for subjects in the experimental group include clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation. Subjects will consume 3 meals per day with the following approximate macronutrient breakdown per meal: 65% fat, 25% protein, 10% carbohydrate.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
3130983|NCT03319173|Active Comparator|Control group|"Dietary interventions for subjects in the control group include the subjects' current dietary protocol (Standard American Diet-SAD). Subjects will consume 4-6 small meals per day with the following approximate macronutrient breakdown per meal: 50% carbohydrate, 35% protein, 15% fat.~Both groups will play the Advanced PEAK brain training games on iPhone, iPad or Android devices for 75 minutes per week."
3130984|NCT03319212|Other|Active Comparator|Subjects that are between the ages 18-55 and are current spherical soft contact lens wearers will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.
3130985|NCT03319277|Active Comparator|Routine opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the standard amount of post-discharge opiate medications - 28 tablets of oxycodone 5mg.
3130986|NCT03319277|Experimental|Decreased opiate prescription|This arm will receive the standard post-discharge prescriptions of ibuprofen, docusate, acetaminophen, and polyethylene glycol. In addition, they will receive the decreased amount of post-discharge opiate medications - 5 tablets of oxycodone 5mg with a paper prescription for an additional 10 tablets of oxycodone 5mg as a backup for uncontrolled pain.
3130987|NCT03319719|Experimental|Belotero® Balance with integral lidocaine|Belotero® Balance with integral lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
3130988|NCT03319719|Active Comparator|Belotero Balance without lidocaine|Belotero Balance without lidocaine will be injected in one of the two NLF (split-face study design: treatment side will be randomized)
3130989|NCT03319810|Experimental|infusion of IVIG|
3130990|NCT03319953|Experimental|Treatment Sequence 1: TAK-041 40 mg/Placebo + Antipsychotics|TAK-041 40 milligram (mg), suspension, orally on Day 1 of Treatment Period 1, followed by 35 day Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
3130991|NCT03319953|Experimental|Treatment Sequence 2: Placebo/TAK-041 40 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 40 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received a stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
3130992|NCT03319953|Experimental|Treatment Sequence 3: TAK-041 160 mg/Placebo + Antipsychotics|TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
3130993|NCT03319953|Experimental|Treatment Sequence 4: Placebo/TAK-041 160 mg + Antipsychotics|TAK-041 placebo-matching, suspension, orally on Day 1 of Treatment Period 1, followed by 35 days Wash-out Period, followed by TAK-041 160 mg, suspension, orally on Day 1 of Treatment Period 2. All participants received stable dose of antipsychotics as per standard of care throughout the duration of the Treatment Period.
3130994|NCT03320057|Experimental|Medication abortion patients|Oral mifepristone 200 mg, followed by misoprostol 800 mcg administered buccally (at 24-48 hours following mifepristone) or vaginally (as soon as 6 hours following mifepristone)
3130995|NCT03320057|Other|Pharmacists|Pharmacists providing services at one of the study pharmacies during the study
3130996|NCT03320096|Experimental|Microfocused ultrasound with visualization|
3130997|NCT03320369|Other|Treatment|Elemental formula Intervention: Elemental Diet Therapy
3130998|NCT03320564|Experimental|Infiltration|Repeat F-18 FDG PET
3130999|NCT03320824|Experimental|New Dermal Filler|hyaluronic acid
3131000|NCT03320824|Active Comparator|Dermal Filler|hyaluronic acid
3131001|NCT03320850|Experimental|100U cohort - BOTOX® plus Hydrogel admixture|100U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131002|NCT03320850|Placebo Comparator|100U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131003|NCT03320850|Experimental|300U cohort - BOTOX® plus Hydrogel admixture|300U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131004|NCT03320850|Placebo Comparator|300U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131005|NCT03320850|Experimental|400U cohort - BOTOX® plus Hydrogel admixture|400U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131006|NCT03320850|Placebo Comparator|400U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131007|NCT03320850|Experimental|500U cohort - BOTOX® plus Hydrogel admixture|500U BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation on Day 1
3321324|NCT02018068|Experimental|Remote control|"For patient randomized in arm Remote Control, the communication with anesthesiologist will be done by teletransmission. The intervention Remote control is assigned to this arm. When evaluated pain values, sensory or motricity blockades are over the selected threshold then, the patient enters the data in the PCA (Patient Control Analgesia) pump, the physician in charge of the patient for the protocol is alerted by SMS on a specific smart phone and makes the necessary settings changes by Remote Control on the Micrel CareTM site."
3131008|NCT03320850|Placebo Comparator|500U cohort - Placebo plus Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation on Day 1
3131009|NCT03320941|Experimental|LIK066 2.5 mg|Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
3131010|NCT03320941|Experimental|LIK066 10 mg|Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
3131011|NCT03320941|Experimental|LIK066 25 mg|Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
3131012|NCT03320941|Experimental|LIK066 50 mg|Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
3131013|NCT03320941|Placebo Comparator|Placebo|Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
3131014|NCT03321006|Active Comparator|Antidepressant (AD) + full amplification hearing aids|Participant will be randomized to active comparator and will receive escitalopram or duloxetine + active hearing aid for 12 weeks.
3131015|NCT03321006|Sham Comparator|Antidepressant (AD) + Low amplification (sham) hearing aids|Participant will be randomized to sham comparator and will receive escitalopram or duloxetine + sham hearing aid for 12 weeks.
3131016|NCT03321097|Experimental|condensed RT group|Training session included 45 minutes RT, followed by 30-minute functional training. The condensed group will receive 4 sessions per week, for 6 weeks.
3131017|NCT03321097|Experimental|distributed RT Group|Training session included 45 minutes RT, followed by 30-minute functional training. The distributed group 2 sessions per week, for 12 weeks.
3131018|NCT03321253|Experimental|Nd: YAG laser posterior capsulotomy|Posterior capsulotomy was performed by using Nd: YAG laser and macular pigment optical density, intra ocular pressure, choroidal thickness, macular thickness and anterior chamber parameters were measured before Nd: YAG laser, at 1 week, 1 month and 2 months
3131019|NCT03321396|Experimental|Endoscopic submucosal dissection|All participants in the study received Endoscopic submucosal dissection with Sodium Alginate mixed with Calcium Lactate prior to endoscopic resection.
3131020|NCT03321721|No Intervention|conservative|patient fulfilling entry criteria will be randomized to the conservative arm - no suturing
3131021|NCT03321721|Active Comparator|suture|patient fulfilling entry criteria will be randomized to the suture arm for repair with nylon suture material
3321325|NCT02018068|Active Comparator|At bedside care|"For patient randomized in arm At bedside care, the communication with the anesthesiologist in charge of the patient will be done via the nurses and referent physician of the medical unit, as a routine procedures. The necessary changes of pump settings are doing by the anesthesiologist. The intervention at beside care is assigned to arm at bedside care."
3321326|NCT02018081|Experimental|Levofloxacin|Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin
3131022|NCT03322293|Active Comparator|A. Conventional arm|"This is considered the standard of care arm for photodynamic therapy for the treatment of actinic keratosis. This treatment arm includes: Acetone preparation, ALA topical application, 1 hour incubation, 16 minutes 40 seconds (16:40) BLU-U exposure, application of sunscreen.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
3131023|NCT03322293|Experimental|B. Combination arm|"This treatment arm combines standard of care BLU-U exposure and daylight exposure. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, 16:40 BLU-U exposure, application of sunscreen, 45 minute daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: BLU-U blue light phototherapy illuminator"
3321327|NCT02018094|Active Comparator|24 hour antibiotic course|24 hours of the stated antibiotics administered intravenously (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function)
3131024|NCT03322293|Experimental|C. Daylight arm|"This is the experimental arm. This treatment arm includes: Acetone preparation, ALA topical application, 15 minute incubation, application of sunscreen, 1 hour daylight exposure.~Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20% Device: none"
3131025|NCT03322423|Active Comparator|Test 1 Multifocal/Test 2 Multifocal OR Test 2 Alternative|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 1 Multifocal then Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power), for approximately 8-12 days of wear with an approximately 4-8 day washout period.
3131026|NCT03322423|Active Comparator|Test 2 Multifocal OR Test 2 Alternative/Test 1 Multifocal|Subjects who are habitual soft contact lens wearers, at least 40 years of age and no more than 70 years of age, will wear Test 2 Multifocal OR Test 2 Alternative (based on lens optimization- subject's lens power) then Test 1 Multifocal, for approximately 8-12 days of wear with an approximately 4-8 day washout period.
3131027|NCT03322462|Experimental|Flortaucipir PET Scan|
3131028|NCT03322514|Experimental|experimental group|10 g of Inulin-Propionate Esters will be administered per day
3131029|NCT03322514|Active Comparator|Inulin|10 g of Inulin will be administered per day
3131030|NCT03322540|Experimental|Pembrolizumab + Epacadostat|Participants received pembrolizumab 200 mg as an intravenous (IV) infusion, every three weeks (Q3W) starting on Day 1 of each cycle for up to 35 administrations in combination with epacadostat 100 mg orally, twice daily. Epacodostat administration was discontinued after the implementation of protocol amendment 05.
3131031|NCT03322540|Active Comparator|Pembrolizumab + Placebo|Participants received pembrolizumab 200 mg by IV infusion, Q3W starting on Day 1 of each cycle for up to 35 administrations in combination with matching placebo orally, twice daily. Placebo administration was discontinued after the implementation of protocol amendment 05.
3131032|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Epacadostat|Participant received pembrolizumab 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, twice daily (BID) in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
3131033|NCT03322566|Experimental|Pembrolizumab + Chemotherapy + Placebo|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat matching placebo tablets, orally, BID in each 21 day cycle for up to 35 cycles + platinum-doublet chemotherapy (pemetrexed 500 mg/m^2 IV infusion, Q3W + cisplatin 75 mg/m^2 IV infusion, Q3W or carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles followed by pemetrexed maintenance; or paclitaxel 200 mg /m^2 IV infusion, Q3W + carboplatin 5-6 mg/mL/min IV infusion Q3W for 4 cycles).
3131034|NCT03322566|Experimental|Pembrolizumab + Epacadostat|Participant received pembrolizumab 200 mg IV infusion, Q3W on Day 1 of each 21 day cycle for up to 35 cycles + epacadostat 100 mg tablets, orally, BID in each 21 day cycle for up to 35 cycles.
3131035|NCT03322657|Active Comparator|Neostigmine with glycopyrrolate|Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery
3131036|NCT03322657|Experimental|Sugammadex|Sugammadex 4 mg/kg at the end surgery
3131037|NCT03322930||Retinitis Pigmentosa|patients with a diagnosis of retinitis pigmentosa and reduced rod function on baseline testing
3131038|NCT03322930||Age-related Macular Degeneration|patients with a diagnosis of intermediate AMD and reduced rod function on baseline testing
3131039|NCT03323086|Experimental|Brief Intervention (BI) with Technology Extender|Participants assigned to BI condition will receive a face to face session lasting 45-60 minutes delivered by a health coach. Following the session, participants will be given access to a study website and receive texts-of-the day on study topics.
3131040|NCT03323086|Other|Brochure|Participants assigned to the Brochure condition will receive materials prepared by the Centers for Disease Control and Prevention on the study topics.
3131041|NCT03323164|Active Comparator|Timolol|Timolol maleate 0.5% ophthalmic solution Instillation of one drop in each eye, once.
3131042|NCT03323164|Active Comparator|Brimonidine|Brimonidine tartrate 0.2% Instillation of one drop in each eye, once.
3131043|NCT03323307|Experimental|OCT imaging|OCT device images retina
3131044|NCT03323723|Other|RS-2 SUI Device|Comparing use of device to non-treatment phase
3131045|NCT03323736|Other|Pivotal Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office.
3131046|NCT03323736|Other|Office Lead-In Cohort|Active Tymbion iontophoresis and tube insertion using the Tube Delivery System in-office. Physician initial in-office iontophoresis and tube insertion procedures (minimum of 2 subjects per investigator).
3131047|NCT03323736|Other|OR Lead-In Cohort|Tubes insertion using the Tube Delivery System in the operating room (OR). Physician initial tube insertion procedures in the OR (minimum of 2 subjects per investigator).
3131048|NCT03323749|Experimental|Part 1: Elamipretide|40 mg (0.5mL) elamipretide subcutaneous (SC) daily
3131049|NCT03323749|Placebo Comparator|Part 1: Placebo|Placebo SC daily
3131050|NCT03323749|Experimental|Part 2: Elamipretide open label|Elamepretide 40 mg (0.5 mL) SC daily
3131051|NCT03323801|Experimental|13-cis retinoic acid|20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks
3131052|NCT03323853|Experimental|CARS-SA Report|Emergency care providers for subjects in this group will receive a copy of the subject's CARS-SA summary results.
3131053|NCT03323853|Other|No CARS-SA Report|Emergency care providers for subjects in this group will not receive a copy of the subject's CARS-SA summary results.
3131054|NCT03324451|Experimental|Intervention arm|"The arm that receives TTM Intervention for Insulin Initiation. The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management"
3131055|NCT03324451|Placebo Comparator|Control arm|The arm that receives usual care from the hospital that hosts the control arm. Participants in the control arm receives regular patient education.
3131056|NCT03324581|Experimental|OPC-64005|During the titration period, participants received OPC-64005 two 10 milligram (mg) tablets, and one OPC-64005-matching placebo tablet along with two atomoxetine-matching placebo capsules, orally, once daily (QD), from Day 1 up to Day 4. During the treatment period, participants received OPC-64005 three 10 mg tablets, and two atomoxetine-matching placebo capsules, orally, QD, from Day 5 up to Day 56. The dose was reduced to 20 mg if the 30 mg dose in the treatment period was not tolerable.
3131057|NCT03324581|Active Comparator|Atomoxetine|"During the titration period, participants received atomoxetine one 40 mg capsule and one atomoxetine-matching placebo capsule along with three OPC-64005-matching placebo tablets, orally, QD, from Day 1 up to Day 4.~During the treatment period, participants received two atomoxetine 40 mg capsules and three OPC-64005-matching placebo tablets, orally, QD, from Day 5 up to Day 56. The dose was reduced to 40 mg if the 80 mg dose in the treatment period was not tolerable."
3131058|NCT03324581|Placebo Comparator|Placebo|Participants received three OPC-64005-matching placebo tablets and two atomoxetine-matching placebo capsules, orally, QD, from Day 1 up to Day 56.
3131059|NCT03324607|Experimental|single arm|glycopyrrolate/formoterol (Bevespi) 2 puffs twice a day taken for two weeks, started after completion of the study XeMRI. A follow up xeMRI occurs at the end of the two weeks of taking the Bevespi in a Pre-post study design.
3131060|NCT03325010|Placebo Comparator|Placebo|Participants received placebo (matching valbenazine) once daily for 12 weeks.
3131061|NCT03325010|Experimental|Valbenazine|Participants received valbenazine once daily for 12 weeks. The starting dose was 20 mg for participants <50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for subjects <50 kg and 80 mg for subjects ≥50 kg to achieve an optimal dose of valbenazine for each participant.
3131062|NCT03325556|Placebo Comparator|Placebo|
3131063|NCT03325556|Experimental|Drug - Pimavanserin|
3131064|NCT03325673|Experimental|TrueTear|TrueTear Device (Intranasal Tear Neurostimulator) was used intranasally on contact lens (CL) wear days; it was also used on non-CL wear days if the participant chose. The number of applications was determined by participant.
3131065|NCT03325673|Sham Comparator|TrueTear Sham Control|TrueTear sham device, which is not electrically active and has limited tip insertion depth, was used intranasally on CL wear days; it was also used on non-CL wear days if participant chose. The number of applications was determined by participant.
3131066|NCT03325816|Experimental|Phase II - Arm 1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~The Phase II dose of 177Lu-DOTA0-Tyr3-Octreotate will be the maximum tolerated dose as determined in the Phase I portion."
3131067|NCT03325816|Experimental|Phase I - Dose Level -1|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 3.7 GBq (100 mCi) every 8 weeks for 4 doses."
3131068|NCT03325816|Experimental|Phase I - Dose Level 0|"Nivolumab will be administered 240mg every 2 weeks. Nivolumab will be given until progressive disease, patient withdrawal, or toxicities.~177Lu-DOTA0-Tyr3-Octreotate dose will be 7.4 GBq (200 mCi) every 8 weeks for 4 doses."
3131069|NCT03325816|No Intervention|Phase II - Arm 2|Patients randomized to this arm will be followed (observation). Cross-over to Phase II Arm 1 at the time of disease progression will be allowed
3131070|NCT03325881|Experimental|SHP465|Participants will be randomized to receive SHP465 capsule 6.25 milligram (mg) orally once daily for 4 weeks.
3131071|NCT03325881|Placebo Comparator|Placebo|Participant will receive placebo matching to SHP465 capsule orally once daily for 4 weeks.
3131072|NCT03325894|Experimental|SHP465|Group A participants who have been rolled-over from antecedent SHP465 studies and Group B participants who will be newly enrolled into the study will receive SHP465 capsule 6.25 mg orally once daily for 360 days.
3131073|NCT03326323||Patients undergoing ANH during CABG|Patients undergoing Acute Normovolemic Hemodilution during CABG surgery.
3131074|NCT03326518|Experimental|Lumentin® 44|Contrast agent
3131075|NCT03326518|Active Comparator|Diluted Omnipaque®|Contrast agent
3131076|NCT03326518|Active Comparator|Movprep®|Contrast agent
3131077|NCT03326843|Experimental|Avatrombopag 60 mg|Open-label: oral avatrombopag
3131078|NCT03326856|Placebo Comparator|Vehicle|Vehicle
3131079|NCT03326856|Experimental|Dose 1|botulinum toxin, Type A, Dose 1
3131080|NCT03326856|Experimental|Dose 2|botulinum toxin, Type A, Dose 2
3131081|NCT03326856|Experimental|Dose 3|botulinum toxin, Type A, Dose 3
3131082|NCT03326856|Experimental|Dose 4|botulinum toxin, Type A, Dose 4
3131083|NCT03326895|Experimental|Group 1|Powered circular stapler used to complete anastomosis of colon
3131084|NCT03326986|Experimental|Panel A|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
3321328|NCT02018094|Active Comparator|5 day antibiotic Course|24 hours of IV antibiotics followed by 4 days of oral antibiotics (Augmentin and metronidazole. Teicoplanin and or gentamicin will be used if penicillin allergic and state of renal function. Clindamycin will be used as a an oral replacement for penicillin allergic patients)
3321329|NCT02018094|Active Comparator|Iodine|Skin Preparation used pre-operatively: Alcoholic Povidone
3321330|NCT02018094|Active Comparator|Chlorhexidine|Skin preparation to be used preoperatively: Alcoholic chlorhexidine
3321331|NCT02018120|Active Comparator|connective tissue graft|connective tissue graft harvested from palatum of subjects and placed under modified coronally advanced flap
3131085|NCT03326986|Experimental|Panel B|Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
3321332|NCT02018120|Experimental|Platelet rich fibrin|Autogenous platelet rich fibrin was obtained from subjects own blood samples after centrifugation. Platelet rich fibrin membranes were placed under modified coronally advanced flaps.
3131086|NCT03326986|Experimental|Panel C|Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods
3131087|NCT03326999|Experimental|Investigational arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with bupivacaine
3131088|NCT03326999|Sham Comparator|Control arm|Patients in this arm will receive adductor canal regional block with bupivacaine and obturator nerve regional block with saline
3131089|NCT03327051|Active Comparator|Omeprazole and VSL #3|Participants will receive a proton pump inhibitor (Omeprazole) and VSL #3 Probiotics
3131090|NCT03327051|Placebo Comparator|Placebo and VSL #3|Participants will receive placebo and VSL #3 Probiotics
3131091|NCT03327220|Experimental|iovera° Device Treatment Group|Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
3321333|NCT02018133||Vitamin D or Placebo|Take vitamin D for 2 weeks. 2mg daily before meal
3131092|NCT03327220|No Intervention|Standard of Care Treatment Group|All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.
3131093|NCT03327402|Experimental|SHP465|Participants will receive SHP465 capsule at a dose of 6.25 mg, orally once daily for 4 weeks.
3131094|NCT03327571||Group 1: cHL|Participants diagnosed with high-risk stage IIb-IV cHL, received frontline treatment with chemotherapy with or without radiotherapy between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for cHL, associated adverse events and resources used from the date of cHL diagnosis until the date of first documented relapse or disease progression after frontline therapy. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
3131095|NCT03327571||Group 2: RRHL|Participants diagnosed with RRHL, between 01 January 2010 and 31 December 2013 from the 13 participating countries will be observed for various treatments received for RRHL, detailed data on treatment pathways, clinical outcomes, associated adverse events and resources used from the date of RRHL diagnosis until the date death or data collection, whichever occurs first. Participants will be continue to be observed for overall survival until the date of death or data collection, whichever occurs first.
3131096|NCT03328182|Experimental|New oral endotracheal tube holder|Single Study Product Arm
3321334|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomized to nasopharyngeal airway placement and ventilation followed by mask ventilation
3131097|NCT03328208|Experimental|Comfort Talk® App Group|Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
3131098|NCT03328208|Active Comparator|White Noise Group|Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
3131099|NCT03328325|Experimental|Arm 1|0.5 mL dose of quadrivalent (IIV-4) vaccine administered once intramuscularly, n=240
3321335|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomized to mask ventilation followed by nasopharyngeal airway placement and ventilation
3321336|NCT02018159||Women treated with Menopur|Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
3321337|NCT02018172||Zomacton® treatment with Zomajet® Vision X device|
3131100|NCT03328624|Experimental|DVT Cuff users|Current or previous DVT cuff users
3131101|NCT03328832|Active Comparator|Combined topical TXA and Floseal|Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
3131102|NCT03328832|Active Comparator|Topical TXA alone|Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
3131103|NCT03328897|Experimental|Omalizumab 300mg|patients received a dose of omalizumab 300 mg which consisted of two injections of omalizumab 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
3131104|NCT03328897|Experimental|Omalizumab 150mg|patients received a dose of omalizumab 150 mg which consisted of one injection of omalizumab 150 mg vial and one injection of placebo 150 mg vial every 4 weeks (Day 1, Week 4 and Week 8)
3131105|NCT03328897|Placebo Comparator|Placebo|patients received placebo which consisted of two injections of placebo 150 mg vials every 4 weeks (Day 1, Week 4 and Week 8)
3131106|NCT03328949|Experimental|IVL Coronary Lithotripsy System|All enrolled patients will receive treatment from the IVL coronary lithotripsy system prior to coronary stent placement.
3131107|NCT03329196|Experimental|MT-6548|
3131108|NCT03329196|Active Comparator|Darbepoetin alfa|
3131109|NCT03329209|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, infusion, intravenously over 30-minutes, once on Day 1.
3131110|NCT03329352|Experimental|F&P Full-Face Mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial full-face mask during this treatment arm. Participants on the extension will use for a further six months after Visit 3.
3131111|NCT03329573|Experimental|AB treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fasting state.
3321338|NCT02018185|Active Comparator|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
3321339|NCT02018185|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation
3131112|NCT03329573|Experimental|BA treatment sequence receivers in fasting group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fasting state.
3131113|NCT03329573|Experimental|AB treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets A in Period 1 followed by Paroxetine IR tablets B in Period 2 in fed state.
3131114|NCT03329573|Experimental|BA treatment sequence receivers in fed group|Eligible subjects will receive a single dose of Paroxetine IR tablets B in Period 1 followed by Paroxetine IR tablets A in Period 2 in fed state.
3131115|NCT03329690|Experimental|Parallel: DS-8201a|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
3131116|NCT03329690|Active Comparator|Parallel: Physician's Choice|Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
3131117|NCT03329690|Other|Exploratory: Naïve HER2 IHC 2+/ISH-|A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
3131118|NCT03329690|Other|Exploratory: Naïve HER2 IHC 1+|A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.
3131119|NCT03329846|Active Comparator|Nivolumab + Placebo|"Specified dose on specified day~Participants will no longer receive BMS-986205 Placebo"
3131120|NCT03329846|Experimental|Nivolumab + BMS-986205|"Specified dose on specified day.~Participants have the option to discontinue BMS-986205, and continue nivolumab monotherapy, at investigator discretion"
3131121|NCT03329885|Experimental|Part A Single Ascending Dose (SAD) in Healthy Patients|Healthy patient will receive single escalating oral doses of BMS-986251 or placebo
3131122|NCT03329885|Experimental|Part B Multiple Ascending Dose (MAD) in Healthy Patients|Healthy patients will receive daily escalating oral doses of BMS-986251 or placebo
3131123|NCT03329885|Experimental|Part C Multiple Dosing in Psoriasis Patients|Psoriasis patients will receive daily escalating oral doses of BMS-986251 or placebo
3321340|NCT02018198||Acute Respiratory Infection|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices with a new onset, measured fever and new onset respiratory symptoms.
3131124|NCT03329911|Active Comparator|EU Avastin®|"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
3131125|NCT03329911|Experimental|BAT1706|"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.~Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles~Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles"
3131126|NCT03329937|Experimental|Participants with HER2-negative and BRCAmut breast cancer|Participants with HER2-negative and BRCAmut localized breast cancer (primary tumor >=1 cm) will receive niraparib (200 mg PO).
3131127|NCT03329989|Experimental|EN3835 Active|EN3835 0.84mg (Collagenase Clostridium Histolyticum)
3131128|NCT03330002||CE-marked MANTA vascular closure devices per IFU|Transcatheter Aortic Valve Replacement (TAVR), Endovascular aneurysm repair (EVAR), TEVAR, etc.
3131129|NCT03330041|Experimental|Fast absorbing gut suture placed 2 mm apart|Wound closed with sutures spaced 2 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
3131130|NCT03330041|Experimental|Fast absorbing gut suture placed 5 mm apart|Wound closed with sutures spaced 5 millimeters apart will be treated in a simple, interrupted cutaneous suture pattern
3131131|NCT03330119|Experimental|Alternate Management|
3131132|NCT03330119|Placebo Comparator|Control|The regular Lankenau cesarean section order set.
3131133|NCT03330236|Experimental|Study arm|"All patients in the study arm will receive the anesthetic care guided by the SedLine EEG Brain Function Monitor in addition to the conventional monitors. In addition to the conventional/standard interventions of anesthetic care, an additional intervention related to this trial is the anesthetic depth management via the titration of the propofol and remifentanil infusion rates to maintain SEF and PSI in the targeted ranges based on the SedLine EEG monitoring."
3131134|NCT03330236|No Intervention|Control arm|All patients in the control arm will receive the anesthetic care guided by the conventional monitors only. Patients in the control arm will be monitored using the SedLine EEG Brain Function Monitor; however, the screen of this monitor will be covered by an opaque cloth and blinded to the anesthesia team.
3131135|NCT03330262|Experimental|BALCAP prosthesis, then Control|Participants performed exercises daily at home wearing the BALCAP prosthesis for 6 weeks. After 6 weeks, participants performed the control condition (the same exercises without the BALCAP). Tests were performed before and after each 6-week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
3321341|NCT02018198||Asymptomatic Cohort|Study subjects will be 1 year of age and older presenting to emergency departments, urgent care centers and primary care offices without infection.
3321342|NCT02018211|Experimental|experimental group|All participants performed a modified version of the Loughborough Intermittent Shuttle Test (LIST; Nicholas et al, 2000), an exercise protocol designed to simulate the activity pattern characteristics of intermittent sports such as soccer. The LIST was performed on three occasions, at the same time of day, each separated by approximately four weeks. Following each exercise trial, one of three recovery interventions were applied, the order of which were randomly allocated.
3131136|NCT03330262|Experimental|Control, then BALCAP prosthesis|Participants performed exercises daily at home for 6 weeks without wearing the BALCAP prosthesis (control), followed by another 6 weeks of the same exercises with the BALCAP prosthesis (intervention). Tests were performed before and after each 6 week period. Exercises included: (1) standing on a firm surface with feet apart, eyes open and closed; (2) standing on a firm surface with feet together, eyes open and closed; (3) standing on thick footing (e.g., multiple pairs of socks) with feet apart, eyes open and closed; (4) standing on thick footing with feet together, eyes open and closed; (5) standing in a modified Romberg position on a firm surface, eyes open and closed; (6) standing in a Romberg position on a firm surface, eyes open and closed; (7) walking on a firm surface eyes open; (8) walking with thick footing, eyes open; (9) walking with head turns and tilts, eyes open; and (10) walking around a room, with turns and movements other than straight forward walking, eyes open.
3131137|NCT03330275|Experimental|Test/Control 1/Control 2|Subjects will be randomized to 1 of 3 lenses (Test/Control 1/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3131138|NCT03330275|Experimental|Test/Control 2/Control 1|Subjects will be randomized to 1 of 3 lenses (Test/Control 2/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3131139|NCT03330275|Experimental|Control 1/Test/Control 2|Subjects will be randomized to 1 of 3 lenses (Control 1/Test/Control 2). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3131140|NCT03330275|Experimental|Control 1/Control 2/Test|Subjects will be randomized to 1 of 3 lenses (Control 1/Control 2/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3321343|NCT02018224|Experimental|End-to-end suturation without augmentation|
3321344|NCT02018224|Experimental|End-to-end suturation with augmentation|
3131141|NCT03330275|Experimental|Control 2/Test/Control 1|Subjects will be randomized to 1 of 3 lenses (Control 2/Test/Control 1). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3131142|NCT03330275|Experimental|Control 2/Control 1/Test|Subjects will be randomized to 1 of 3 lenses (Control 2/Control 1/Test). Subjects will also be randomized to (1) Sequence of driving time (Day and Night) and (2) Driving Route (A, B, C). Hazard and pedestrian locations will be randomized for each driving route.
3131143|NCT03330288||Participants with Stage I-III Knee osteoarthritis (KOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
3131144|NCT03330288||Participants with Stage I-III Hip osteoarthritis (HOA)|Participants were receiving Theraflex not earlier than 2 weeks prior to enrollment
3321345|NCT02018237|Active Comparator|NAFLD|Subjects with nonalcoholic fatty liver disease (NAFLD) will complete baseline testing and then be assigned to either the high fructose corn syrup diet or the standard diet (low in high fructose corn syrup) for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
3131145|NCT03330457|Experimental|Cohort 1 Bertrixaban/Andexanet|Andexanet 800 mg, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
3131146|NCT03330457|Experimental|Cohort 1 Bertrixaban/Placebo|Placebo, administered as a slow IV bolus after having been dosed to steady-state with betrixaban 80 mg PO once daily (QD) for 7 days
3131147|NCT03330457|Experimental|Cohort 2 Bertrixaban/Andexanet|andexanet 800 mg administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
3131148|NCT03330457|Experimental|Cohort 2 Bertrixaban/Placebo|Placebo administered as a slow IV bolus at a target rate of approximately 30 mg/min followed by a continuous infusion of up to 8 mg/min for 120 min (960 mg) starting 4 h after the last dose of betrixaban
3131149|NCT03330834|Experimental|Single Arm|CAR-T cells to treat advanced lung cancer. This study has only one arm. All participators will attend the screening and meet the set criteria for the clinical treatment. PD-L1 CAR-T cells are infused on day 0 with 10%, day 3 with 30% and day 7 with 60% , (1-2)×10^6/kg PD-L1 CAR-T cells total.
3131150|NCT03331042|Experimental|Sequence 1|SM-1 (Treatment Period 1), D+Z (Treatment Period 2), D+L (Treatment Period 3), Placebo (Treatment Period 4).
3131151|NCT03331042|Experimental|Sequence 2|D+Z (Treatment Period 1), D+L (Treatment Period 2), Placebo (Treatment Period 3), SM-1 (Treatment Period 4).
3131152|NCT03331042|Experimental|Sequence 3|D+L (Treatment Period 1), Placebo (Treatment Period 2), SM-1 (Treatment Period 3), D+Z (Treatment Period 4).
3131153|NCT03331042|Experimental|Sequence 4|Placebo (Treatment Period 1), SM-1 (Treatment Period 2), D+Z (Treatment Period 3), D+L (Treatment Period 4).
3131154|NCT03331185|Active Comparator|Freeze Dried Bone Allograft|Socket filled with Mineralized Cortical Freeze Dried Bone Allograft
3131155|NCT03331185|Experimental|L-PRF Clot|Socket filled with L-PRF Clot
3131156|NCT03331315|Active Comparator|Ketorolac|Patients receiving scheduled ketorolac postoperatively
3131157|NCT03331315|Experimental|Celecoxib|Patients receiving celebrex preoperative and postoperatively for 7 days
3131158|NCT03331666|Active Comparator|Evolocumab|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 14 until Day 196.
3131159|NCT03331666|Placebo Comparator|Placebo|Subjects will start with placebo and will receive Evolocumab 140 mg every 14 days starting Day 28 until Day 196.
3131160|NCT03331835|Experimental|Brodalumab|Kyntheum® (brodalumab)> pre-filled syringe 210 mg/1.5 mL solution for subcutaneous injections.> First 3 injections are administered weekly, and hereafter every two weeks (Q2W).
3321346|NCT02018237|Active Comparator|Non-NAFLD|Subjects without nonalcoholic fatty liver disease (Non-NAFLD) will complete baseline testing and then be fed a high fructose corn syrup diet for 4 weeks. Post intervention testing will be completed after the subjects have completed the 4 week diet intervention.
3321347|NCT02018250|Experimental|0.6 mg/kg MMB4 DMS|0.6 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3321348|NCT02018250|Placebo Comparator|Placebo|5 mg benzyl alcohol USP/NF and 5 mg methanesulfonic acid adjusted to a pH 2.3 administered intramuscular (i.m.) to the anterior thigh.
3321349|NCT02018250|Experimental|0.9 mg/kg MMB4 DMS|0.9 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3321350|NCT02018250|Experimental|1.2 mg/kg MMB4 DMS|1.2 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3131161|NCT03331835|Active Comparator|Fumaric acid esters|"Fumaderm® initial dose tablets (30 mg dimethyl fumarate, 67 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)> Fumaderm® tablets (120 mg dimethyl fumarate, 87 mg ethyl hydrogen fumarate calcium salt, 5 mg ethyl hydrogen fumarate magnesium salt, 3 mg ethyl hydrogen fumarate zinc salt)>~> Fumaderm® tablets are administered orally up to 3 times daily in accordance with the dosing scheme in the label."
3321351|NCT02018250|Experimental|1.5 mg/kg MMB4 DMS|1.5 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3131162|NCT03331965|Experimental|Metoclopramide|A one-time dose of promotility agent (2 mL of Metoclopramide 5 MG/ML Injectable Solution in 8 mL saline IV) will be administered at the time of GJ placement. After administration of the pro-motility drug, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
3131163|NCT03331965|Placebo Comparator|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement. After administration of the placebo, the GJ placement procedure will be performed using conventional technique. An IR technologist observing the procedure will record the fluoroscopy time, air kerma, and chronological time will be recorded by an IR technologist at the following routine events during GJ tube placement procedures: 1) start of gastric insufflation, 2) needle access to the stomach, 3) wire intubation of the duodenum, 4) wire intubation of the jejunum, 5) and procedure completion.
3131164|NCT03332160|Active Comparator|Standard of Care|Standard home lymphedema care
3131165|NCT03332160|Experimental|Flexitouch head and neck lymphedema treatment system|Daily treatment with Flexitouch® pneumatic compression device for treatment of head and neck lymphedema and standard home lymphedema care
3131166|NCT03332212|Experimental|Cohort A (Empagliflozin + Placebo)|Heart Failure with Reduced Ejection Fraction
3131167|NCT03332212|Experimental|Cohort B (Empagliflozin + Placebo)|Heart Failure with Preserved Ejection Fraction
3321352|NCT02018250|Experimental|2.0 mg/kg MMB4 DMS|2.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3321353|NCT02018250|Experimental|3.0 mg/kg MMB4 DMS|3.0 mg/kg 1,1'-Methylenebis[4-[(hydroxyimino) methyl]-pyridinium] dimethanesulfonate (MMB4 DMS), intramuscular (i.m.) to the anterior thigh.
3131168|NCT03332459|Experimental|Lumicitabine|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing lumicitabine for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of lumicitabine, frequency and type of respiratory infections and medical resource usage.
3131169|NCT03332459|Placebo Comparator|Placebo|Participants who completed the last planned study-related visit in a feeding Phase 2 study (64041575RSV2004), in which they received a regimen containing placebo for the treatment of RSV infection, and who agree to participate in this follow-up study will be assessed for the incidence of the clinical diagnosis of asthma, frequency of wheezing, long-term safety of placebo, frequency and type of respiratory infections and medical resource usage.
3131171|NCT03332628|Other|Microneedle application|This is the only study arm, which all participants complete. Nine sites on the upper arm will be identified. Baseline measurements of transepidermal water loss, electrical resistance, hydration, and color will be made at each site. The 9 sites will be divided into clusters of 3 sites each. The first cluster will have small microneedle patches applied to at each site. This will only occur on the first study day. Transepidermal water loss and electrical resistance are re-measured immediately after microneedle application. The sites will be covered with a small patch secured with medical tape. The second cluster of sites will not receive microneedle application but will just be covered with patches. The last cluster of sites will not have microneedle application or patches. Electrical resistance will be re-measured at all sites for 4 days after microneedle application. Measurements from the 2nd and 3rd cluster of sites allow each subject to serve as their own control in data analysis.
3131172|NCT03332771|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, two Sotagliflozin 200 mg, tablets, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
3131173|NCT03332771|Experimental|Sotagliflozin 200 mg|Following a 2-week run-in period, one Sotagliflozin 200 mg, tablet and one Sotagliflozin-matching placebo tablet, and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
3131174|NCT03332771|Active Comparator|Glimepiride|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets, and combination of two Glimepiride capsules with adequate dose strengths per dose titration (titrated up to 6mg), taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
3131175|NCT03332771|Placebo Comparator|Placebo|Following a 2-week run-in period, two Sotagliflozin-matching placebo tablets and two Glimepiride-matching placebo capsules, taken orally once daily before the first meal of the day in the double-blind treatment period up to 52 weeks.
3131176|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 1)|TAK-925, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
3131177|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 2)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 2). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
3131178|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 3)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 3). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
3131179|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 4)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 4). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
3131180|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 1; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
3131181|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 2; Dose Level 6)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 6). Dose selected based on safety, tolerability and PK data from previous Cohorts. Healthy adults will be enrolled in double blind manner.
3131182|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 1-2)|TAK-925 Placebo, Intravenous single administration. Healthy adults will be enrolled in double blind manner.
3131183|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 3; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy elderly participants will be enrolled in double blind manner.
3131184|NCT03332784|Placebo Comparator|Part 1: Placebo (Cohort 3)|TAK-925 Placebo, Intravenous single administration. Healthy elderly participants will be enrolled in double blind manner.
3131185|NCT03332784|Experimental|Part 1: TAK-925 (Cohort 4; Dose Level 5)|TAK-925, Intravenous single administration. Dose level will be determined by targeted plasma level of TAK-925 (Dose level 5). Healthy adults will be enrolled in non-blinded manner.
3131186|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 5)|TAK-925, Intravenous single administration. Dose in Cohort 5 will be based on safety and tolerability in the Part 1. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
3131187|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 6)|TAK-925, Intravenous single administration. Dose in Cohort 6 TBD based on safety, tolerability, PK data, and results of the Maintenance Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
3321354|NCT02018263|Active Comparator|Cocaine Administration|Subjects self administer cocaine hydrochloride in both laboratory and outpatient settings
3131188|NCT03332784|Experimental|Part 2: TAK-925 TBD (Cohort 7)|TAK-925, Intravenous single administration. Dose in Cohort 7 TBD based on safety, tolerability, PK data, and results of the Maintenance of Wakefulness Test (MWT) from previous Cohorts. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
3131189|NCT03332784|Placebo Comparator|Part 2: Placebo (Cohort 5-7)|TAK-925 Placebo, Intravenous single administration. Patients with Narcolepsy will be enrolled in double blind manner (sponsor open).
3131194|NCT03333109|Experimental|AMG334 70 mg|AMG334 70 mg: one pre-filled syringe containing 70 mg of erenumab plus one pre-filled syringe of identical placebo administered subcutaneous every 28 days
3131195|NCT03333109|Experimental|AMG334 140 mg|AMG334 140 mg: two pre-filled syringe containing 70 mg each of erenumab administered subcutaneous every 28 days
3131196|NCT03333109|Placebo Comparator|Placebo|Two pre-filled syringes containing placebo identical in appearance to erenumab
3321355|NCT02018263|Active Comparator|Nicotine Administation|Subjects self administer nicotine in both laboratory and outpatient settings
3131197|NCT03333317|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 40 milligram per kilogram (mg/kg) loading dose (LD) (Dose 1) followed by nine 20 mg/kg maintenance doses (MDs) (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
3131198|NCT03333317|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 60 mg/kg LD (Dose 1) followed by nine 40 mg/kg MDs (Doses 2 to 10) of lumicitabine twice daily up to Day 5/6.
3131199|NCT03333317|Placebo Comparator|Regimen C (Placebo)|Participants will receive either a single 40 mg/kg placebo LD (Dose 1) followed by nine 20 mg/kg maintenance dose (MDs) (Doses 2 to 10) of placebo twice daily or single 60 mg/kg placebo LD (Dose 1) followed by nine 40 mg/kg placebo MDs (Doses 2 to 10), twice daily up to Day 5/6.
3131200|NCT03333577|Experimental|Experimental SoundArc study group|all subjects will receive the SoundArc intervention
3131201|NCT03333876|Active Comparator|Nasal Dilator|Nasal dilators have been used to treat snoring and sleep apnea. Many studies focus on external nasal dilators like Breathe Right Strips. These interventions largely were not effective in treating OSA. However, there is some evidence to suggest internal to the nose dilators (like Mute) may work to reduce snoring
3131202|NCT03333876|Active Comparator|Mandibular Advancement|Mandibular advancement devices have shown to be effective, but not necessarily acceptable to primary snorers.
3131203|NCT03333876|Active Comparator|Positional Therapy|Studies have shown mixed results for positional therapy as a whole. Braver and Block reported that foam wedges used to keep patients in a lateral position were not effective in reducing snoring in 20 individuals.
3131204|NCT03333941||RES (Regenerative Epithelial Suspension)|
3131205|NCT03334175|Experimental|Walnuts Now|Will receive and be instructed to consume 1-oz individually wrapped daily walnut supplement packages for 12 weeks during intervention.
3131206|NCT03334175|No Intervention|Walnuts Later|Will receive diet and exercise guidance at beginning of study. At end of study, will receive 12 weeks of a walnut supply to be consumed at their discretion after the study is complete.
3131207|NCT03334188|Other|Control|Patients will receive care-as-usual. The only study procedures patients will be exposed to will be a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment.This arm will include 'No Intervention--Usual Care'.
3131208|NCT03334188|Active Comparator|Intervention|Patients will receive the patient engagement video and HFrEF medication checklist by email one week prior to their next clinic appointment after enrollment. Patients in the intervention arm will also receive a baseline survey at time of enrollment about their sense of engagement around their HFrEF medication prescribing, as well as a follow-up survey with the same general content one month after their next clinic appointment. Medical record review will occur at baseline (enrollment), 1 month after the next clinic appointment post-enrollment, and at 12 months from enrollment. This arm will include the 'Intervention :Behavioral: Patient engagement materials.'
3131209|NCT03334214|Experimental|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
3131210|NCT03334214|Placebo Comparator|Placebo (sterile saline 0.9)|Calculated volume to match active comparator administered subcutaneously once weekly for 13 weeks
3131211|NCT03334396|Experimental|4 milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
3131212|NCT03334396|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
3131213|NCT03334396|Experimental|1 mg Baricitinib|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
3131214|NCT03334396|Placebo Comparator|Placebo|Placebo administered orally once daily.
3131215|NCT03334396|Experimental|4 mg Baricitinib Maximum Extended Enrollment Cohort|4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
3131216|NCT03334396|Experimental|2 mg Baricitinib Maximum Extended Enrollment Cohort|2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
3131217|NCT03334396|Experimental|1 mg Baricitinib Maximum Extended Enrollment Cohort|1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
3131218|NCT03334396|Placebo Comparator|Placebo Maximum Extended Enrollment Cohort|Placebo administered orally once daily.
3131219|NCT03334422|Experimental|4 Milligram (mg) Baricitinib|4mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match
3131220|NCT03334422|Experimental|2mg Baricitinib|2mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
3131221|NCT03334422|Experimental|1mg Baricitinib|1mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
3131222|NCT03334422|Placebo Comparator|Placebo|Placebo administered orally once daily.
3131223|NCT03334448|Experimental|LY900014-U200|Single subcutaneous (SC) dose of 15 units (U) LY900014 U-200 in two of four study periods
3131224|NCT03334448|Experimental|LY900014-U100|Single SC dose of 15 U LY900014 U-100 in two of four study periods
3131225|NCT03334630|Experimental|DiamondTemp Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using DiamondTemp temperature-controlled ablation catheter
3131226|NCT03334630|Active Comparator|TactiCath Quartz Ablation Catheter|Catheter ablation to treat paroxysmal atrial fibrillation using TactiCath Quartz contact-force sensing ablation catheter
3131227|NCT03334695|Experimental|Group 1: Ad26.RSV.preF|Participants will receive single intramuscular injection of 1*10^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.
3131228|NCT03334695|Placebo Comparator|Group 2: Placebo|Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.
3131229|NCT03334721|Experimental|Gabapentin, Then Placebo Oral Capsule|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
3321356|NCT02018263|Active Comparator|Exercise|Subjects complete a cardiovascular exercise session in both laboratory and outpatient settings
3321357|NCT02018276|Experimental|The effect of perioperative lidocaine infusion|
3321358|NCT02018276|Active Comparator|The effect of perioperative magnesium infusion|
3321359|NCT02018289|Experimental|Triclosan|Suture of the abdominal wall with triclosan coated suture
3321360|NCT02018289|Sham Comparator|No triclosan|Suture of the abdominal wall with the same suture, but without triclosan
3131230|NCT03334721|Experimental|Placebo Oral Capsule, Then Gabapentin|"Week 1: 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).~Week 2: 1-week condition will consist of an in-person study visit for assessment and dispensing of Gabapentin medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (days 1-5), MRI (Day 5), and medication washout (Days 5-7)."
3131231|NCT03334734|Experimental|PBTZ169, 160 mg|2 capsules 80 mg of PBTZ169 once a day for 14 days
3131232|NCT03334734|Experimental|PBTZ169, 320 mg|4 capsules 80 mg of PBTZ169 once a day for 14 days
3131233|NCT03334734|Experimental|PBTZ169, 640 mg|8 capsules 80 mg of PBTZ169 once a day for 14 days
3131234|NCT03334734|Active Comparator|Isoniazid, 600 mg|2 tablets 300 mg of Isoniazid once a day for 14 days
3131235|NCT03334747|Experimental|Treatment arm 1: KAE609 10 mg Single Dose (SD)|KAE609 10 mg once daily (QD) for 1 day
3131236|NCT03334747|Experimental|Treatment arm 2:KAE609 25 mg SD|KAE609 25 mg once daily (QD) for 1 day
3131237|NCT03334747|Experimental|Treatment arm 3:KAE609 10 mg 3 Days|KAE609 10 mg (QD) for 3 days
3131238|NCT03334747|Experimental|Treatment arm 4:KAE609 50 mg SD|KAE609 50 mg once daily (QD) for 1 day
3131239|NCT03334747|Experimental|Treatment arm 5:KAE609 25 mg 3 Days|KAE609 25 mg once daily (QD) for 3 days
3131240|NCT03334747|Experimental|Treatment arm 6:KAE609 75 mg SD|KAE609 75 mg once daily (QD) for 1 day
3131241|NCT03334747|Experimental|Treatment arm 7:KAE609 50 mg 3 Days|KAE609 50 mg once daily (QD) for 3 days
3131242|NCT03334747|Experimental|Treatment arm 8: KAE609 150 mg SD|KAE609 150 mg once daily (QD) for 1 day
3321361|NCT02018328|No Intervention|Triple therapy, helicobacter pylori|
3131243|NCT03334747|Active Comparator|Treatment arm 9: Coartem Control|Coartem® control
3131244|NCT03334812|Experimental|LNA043 20mg/ml|LNA043 20mg/ml single dose
3131245|NCT03334812|Placebo Comparator|Matching placebo to 20mg|Matching placebo to 20mg/3ml, single dose
3131246|NCT03334812|Experimental|LNA043 40mg/ml|LNA043 40mg/ml single dose
3131247|NCT03334812|Placebo Comparator|Matching placebo to 40mg|Matching placebo to 40mg/4ml, single dose
3131248|NCT03334825|Experimental|Enhanced housing placement assistance|
3131249|NCT03334825|Active Comparator|Standard housing placement assistance|
3131250|NCT03334903|No Intervention|Standard of Care|Standard of care includes one dose of 600 mg gabapentin in the immediate preoperative period (1-2 hours before surgery), then a dose of 600 mg each morning during postoperative admission.
3131251|NCT03334903|Experimental|Postoperative Gabapentin Regimen|Single preoperative dose of 600 mg, as described above, plus an additional postoperative regimen. Patients will take 300 mg gabapentin every 8 hours for 1 week after discharge, then a single nightly dose of 300 mg gabapentin for another month.
3131252|NCT03335150|Active Comparator|Supportive Care|Support Group for PD-MCI
3131253|NCT03335150|Experimental|CogSMART-PD|Cognitive Rehabilitation for PD-MCI
3321362|NCT02018328|Experimental|triple therapy+curcumin helicobacter pylori|Curcumin will be added to the regular triple therapy
3321363|NCT02018341|Experimental|homeopathic remedy in 30C potency|5 lactose globules containing a commonly used homeopathic remedy in the potency of 30C will be administered twice daily for 3 days
3321364|NCT02018341|Placebo Comparator|placebo|5 lactose globules without any homeopathic remedy will be administered twice daily for 3 days
3131254|NCT03335254|Experimental|Dose-Escalating Arm 1|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~Assigned Intervention: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131255|NCT03335254|Experimental|Dose-Escalating Arm 2|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 633 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131256|NCT03335254|Experimental|Dose-Escalating Arm 3|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 570 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3321365|NCT02018354|Active Comparator|ACL Reconstruction|Standard ACL reconstruction only.
3321366|NCT02018354|Experimental|ACL + LET|Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
3132818|NCT03454048|Experimental|Group 4 (Cohort B) LD-PIP/LD-PIP2/SP|Cohort B will be subjected to a standard blood stage challenge with ~2,800 Pf-infected erythrocytes by intravenous injection. All volunteers will be treated with a single oral subcurative low-dose of piperaquine (LD-PIP, 480 mg, T1). Volunteers will receive a second treatment (T2, LD-PIP2, 480mg) if a recrudescence of asexual parasitemia occurs before day 21 post challenge infection. Volunteers in group 4 (LD-PIP/LD-PIP2/SP) will be curatively treated with sulfadoxine-pyrimethamine (1000mg/50mg).
3321367|NCT02018367|Experimental|Proflavine, high resolution imaging|Proflavine hemisulfate will be used as a topical contrast agent in conjunction with the high resolution imaging device to visualize and image areas suspicious for neoplasia. Biopsies will be taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
3321368|NCT02018367|No Intervention|Standard of care|Standard of care examination of the upper GI tract using the standard high resolution endoscope with bipsies taken per Seattle biopsy protocol for Barrett's Esophagus surveillance.
3131257|NCT03335254|Experimental|Dose-Escalating Arm 4|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is <350 ng/dL, adjust dose to 570 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3321369|NCT02018380|Experimental|Shock Absorbing Insoles vs. Athletic shoes|
3131258|NCT03335254|Experimental|Dose-Escalating Arm 5|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131259|NCT03335254|Experimental|Dose-Escalating Arm 6|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 507 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131260|NCT03335254|Experimental|Dose-Escalating Arm 7|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 443 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131261|NCT03335254|Experimental|Dose-Escalating Arm 8|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is ≥350 ng/dL and <500 ng/dL, adjust dose to 443 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131262|NCT03335254|Experimental|Dose-Escalating Arm 9|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131263|NCT03335254|Experimental|Dose-Escalating Arm 10|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 443 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3132819|NCT03454581|Experimental|Photobiomodulation group (PBM)|"Gallium-aluminium-arsenide (GaAlAs) diode laser (MM Optics Recover, São Carlos, São Paulo, Brazil) with a wavelength of 808 nm, punctual contact mode,spot size of 0.03 cm2, power output of 100 mW, output density of 333 mW∕cm2, energy density of 13.3 J ∕cm2, 40 s exposure time per point, and 4 Joules (J) of total energy per point.~18 individuals"
3132820|NCT03454581|Experimental|Manual Therapy group (MT)|"At masticatory muscles were performed circular movements, slip and compression with fingers movements. At the temporomandibular joint (TMJ) was performed a caudal distraction with anterior projection, placing the thumb on the second or third molar.~16 individuals."
3132821|NCT03454581|Experimental|Combined therapy group (CT)|Applied the protocols of PBM group and immediately after, to MT group. 17 individuals.
3131264|NCT03335254|Experimental|Dose-Escalating Arm 11|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 380 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131265|NCT03335254|Experimental|Dose-Escalating Arm 12|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is 500 to 800 ng/dL, inclusive, maintain 380 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease TSX-011 dose to 317 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131266|NCT03335254|Experimental|Dose-Escalating Arm 13|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3132822|NCT03455218|Experimental|Nitric Oxide|20 ppm of Nitric Oxide delivered to the oxygenator via the INOmax device for the duration of the cardiopulmonary bypass time
3131267|NCT03335254|Experimental|Dose-Escalating Arm 14|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, increase dose to 380 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131268|NCT03335254|Experimental|Dose-Escalating Arm 15|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose 317 mg (TU) TSX-011 twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3132823|NCT03455218|Placebo Comparator|Placebo|INOmax device attached to the oxygenator, but no gas is delivered through the device
3131269|NCT03335254|Experimental|Dose-Escalating Arm 16|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Twice Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 317 mg (TU) TSX-011 twice daily.~Period 3, Day 26-30: Twice Daily Dose If Period 3 Day 19 total testosterone is >800 ng/dL, decrease dose to 253 mg TU twice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3132539|NCT03435692|Active Comparator|Patient Controlled Analgesia|"Children undergoing pediatric hip surgery will have patient controlled analgesia (with morphine) started in the post anesthesia care unit for post operative pain control.~An intraoperative pain protocol will dictate if the patient will receive intravenous fentanyl or morphine. Post operative side effects will be controlled with the administration of ondansetron for nausea and vomiting, diphenhydramine for itching, and lorazepam for muscle spasms. Post operative pain control will be managed with as needed (PRN) morphine and oxycodone as well as scheduled acetaminophen."
3132540|NCT03435783|Experimental|Intervention|
3132541|NCT03435783|Active Comparator|Attention-matched control|
3132542|NCT03436082||Data from a mHealth platform after bariatric surgery|Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.
3131270|NCT03335254|Experimental|Dose-Escalating Arm 17|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Thrice Daily Dose If Period 3 Day 19 total testosterone is <350 ng/dL, dose adjust subjects to 570 mg TSX-011 (TU) dosing thrice daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131271|NCT03335254|Experimental|Dose-Escalating Arm 18|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is ≥350 ng/dL and <500 ng/dL, dose adjust subjects on once-daily dosing from 507 mg TU daily to 570 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131272|NCT03335254|Experimental|Dose-Escalating Arm 19|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3 Day 19 total testosterone is 500 to 800 ng/dL inclusive, continue current dose of 507 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3132543|NCT03436082||Data from a mobile health platform after atrial fibrillation|Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.
3132544|NCT03436147||Vaginal Assisted Laparoscopic Sacrohysteropexy(VALH)|Patients who were performed vaginal assisted laparoscopic sacrohysteropexy (VALH)
3180404|NCT00682916|Active Comparator|1|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
3321370|NCT02018393||Prophylaxis group|Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of ≥50 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit
3321371|NCT02018393||On demand group|On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit.
3131273|NCT03335254|Experimental|Dose-Escalating Arm 20|"Period 1: Single Dose Ascending single-dose period: 190 mg TSX-011 (fed and fasted), 380 mg TSX-011 (fed), and 570 mg TSX-011 (fed).~Period 2: Twice Daily Dose 380 mg TSX-011 twice daily dosing period of 15 days in fed conditions. Period 3, Day 16-25: Once Daily Dose If Period 2 Day 8 total testosterone is >800 ng/dL, randomize half subjects to receive 507 mg (TU) TSX-011 once daily.~Period 3, Day 26-30: Once Daily Dose If Period 3, Day 19 total testosterone is >800 ng/dL, decrease dose to 380 mg TU daily.~TSX-011: TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient."
3131274|NCT03335566|Experimental|Sonazoid™|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 microliter (µL) microbubbles (MB)/kilogram (kg) body weight.
3131275|NCT03335566|Active Comparator|SonoVue®|Participants will receive single I.V bolus injection of SonoVue® 2.4 milliliter (mL).
3131276|NCT03335761|Experimental|Amplitude Setting #1|InterStim Therapy will be set to amplitude parameter #1.
3131277|NCT03335761|Experimental|Amplitude Setting #2|InterStim Therapy will be set to amplitude parameter #2.
3131278|NCT03335761|Experimental|Amplitude Setting #3|InterStim Therapy will be set to amplitude parameter #3.
3131279|NCT03335800|Experimental|Apple Heart Study App|
3131280|NCT03336450|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
3131281|NCT03336502|Experimental|Posaconazole|All participants will receive posaconazole 300 mg intravenous (IV) infusion twice on Day 1 followed by 300 mg IV infusion once daily on Days 2 to 10 (±1). At the discretion of the investigator, participants will received posaconazole 300 mg IV infusion once daily or 200 mg oral suspension three times daily for up to 18 additional days.
3321372|NCT02018406|Experimental|Intervention|Intervention Group
3321373|NCT02018406|Placebo Comparator|Control|Control Group
3131282|NCT03336645|Experimental|SHP615|Participants will receive a single age-specific dose (approximately 0.25 to 0.5 milligram per kilogram [mg/kg] as midazolam) of SHP615 oromucosal solution through buccal route upon onset of seizures.
3131283|NCT03336853|Experimental|HybenX ®|1 cc of mixture of hydroxybenzenesulfonic acid (37%) and hydroxymethoxybenzene acids (23%), sulfuric acid (28%), and water (12%) for 20 sec
3131284|NCT03336853|Placebo Comparator|Control|5 cc of sterile saline water for 20 sec
3131285|NCT03337139|Active Comparator|Lifestyle Modification|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
3131286|NCT03337139|Experimental|Lifestyle Modification + Share|Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
3131287|NCT03337152|Other|1A: primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1A. Participants in arm 1A will receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
3131288|NCT03337152|Other|1B: chloroquine + primaquine|Twelve males hemizygous for wildtype G6PD, 12 females homozygous for wildtype G6PD, and 12 females heterozygous for G6PD deficiency will be randomized to arm 1B. Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
3131289|NCT03337308|Experimental|BA 180 mg + EZE 10 mg FDC|Bempedoic acid (BA) + ezetimibe (EZE) fixed-dose combination (FDC) 180 mg/10 mg tablets taken orally once daily for 12 weeks
3131290|NCT03337308|Experimental|BA 180 mg|Bempedoic acid (BA) 180 mg tablets taken orally once daily for 12 weeks
3131291|NCT03337308|Active Comparator|EZE 10 mg|Ezetimibe (EZE) 10 mg overencapsulated tablets taken orally once daily for 12 weeks
3131292|NCT03337308|Placebo Comparator|Placebos|Placebos to match identical bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or identical bempedoic acid 180 mg tablet, or identical ezetimibe 10 mg capsule, taken orally, once daily for 12 weeks
3131293|NCT03337477|Experimental|ZS+insulin+glucose|ZS will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
3131294|NCT03337477|Placebo Comparator|Placebo+insulin+glucose|Placebo will be administered in addition to insulin and glucose. Insulin and glucose is the current standard of care to treat serum potassium ≥5.8mmol/L.
3131295|NCT03337490|Experimental|Ivermectin 0.5% Lotion|Ivermectin 0.5% lotion, topical, 117g, single dose
3131296|NCT03337490|Active Comparator|Ivermectin 0.5% Lotion [SKLICE]|Sklice 0.5% Lotion, topical, 117g, single dose
3131297|NCT03337490|Placebo Comparator|Placebo 0% Lotion|0% lotion, 117g, single dose
3131298|NCT03337542|Other|Treatment arm description|Subjects will receive maintenance dosing with AR101. Maintenance doses are provided in sachets, where each sachet contains 300 mg of peanut protein. Subjects are to ingest 300 mg orally once a day during maintenance.
3131299|NCT03338010|Experimental|LY2963016|Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
3131300|NCT03338010|Active Comparator|Lantus®|Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
3131301|NCT03338023|Experimental|LY2963016 + Insulin Lispro|Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
3131302|NCT03338023|Active Comparator|Lantus® + Insulin Lispro|Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
3131303|NCT03338036|Experimental|Heart Rate Variability/Neurofeedback|Participants in this arm of the study will receive HRV biofeedback and neurofeedback. HRV biofeedback will occur twice daily, using an android device and application. Additionally, three times per week they will have one-hour long neurofeedback sessions.
3321374|NCT02018419|Experimental|Dosing Schedule A|"the priming step with ID injection of AlloStim on Days 0, 7, and 14;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 21;~the activation step with an IV infusion of AlloStim on Day 28;~the booster step with intravenous booster infusion of AlloStim on Days 56 and 84;~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3131304|NCT03338036|No Intervention|Post-Concussed Control Group|Age-matched, previously concussed individuals that have completed the same concussion rehabilitation program (Brain Ex 90) will be recruited for this arm.
3131305|NCT03338036|No Intervention|Non-Concussed Control Group|Age-matched individuals who have not been diagnosed with a concussion in the previous two years
3131306|NCT03338062|Experimental|Theragnostic SBRT Planning|The theragnostic SBRT plan using the HIDA scan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
3321375|NCT02018419|Experimental|Dosing Schedule B|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous booster infusion of AlloStim on Days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3131307|NCT03338062|No Intervention|Standard SBRT Planning|The standard SBRT plan was chosen as the plan that reduced the dose of radiation to functional liver without compromising target coverage or tumor control.
3131308|NCT03338296|Experimental|Lorcaserin hydrochloride XR 20 mg QD|Participants will receive lorcaserin hydrochloride extended release (XR) 20 milligrams (mg) once daily (QD) for up to 52 weeks.
3131309|NCT03338296|Placebo Comparator|Placebo|Participants will receive placebo QD for up to 52 weeks.
3131310|NCT03338400|Active Comparator|Dexamethasone|Patients in the Dexamethasone arm will be administered the drug at the time of induction.
3131311|NCT03338400|Placebo Comparator|Normal Saline|The placebo arm patients will receive normal saline at the time of induction.
3131312|NCT03338556|Active Comparator|Cohort A - PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
3131313|NCT03338556|Placebo Comparator|Cohort A - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 7 and Day - 6 prior to intranasal challenge with HRV-16 (Day 0).
3131314|NCT03338556|Active Comparator|Cohort B- PrEP-001|PrEP-001 6400 μg/day, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
3131315|NCT03338556|Placebo Comparator|Cohort B - Placebo|Placebo matching PrEP-001, equally divided over both nostrils, on 2 consecutive days. Dosed Day - 4 and Day - 3 prior to intranasal challenge with HRV-16 (Day 0).
3131316|NCT03338569|Sham Comparator|Placebo|Placebo designed to mimic intervention
3131317|NCT03338569|Active Comparator|Intervention|6000 mg per day Vitamin C supplement
3131318|NCT03338673|Experimental|Dual Therapy First|Participants receive 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises (BrainHQ), followed by 10 hours of computerized cognitive exercises alone
3131319|NCT03338673|Experimental|Mono Therapy First|Participants complete 10 hours of computerized cognitive exercises (BrainHQ) alone, followed by 10 sessions of non-invasive brain stimulation (tDCS) plus 10 hours of computerized cognitive exercises
3131320|NCT03338686|Active Comparator|Free Gingival Graft|Free Gingival Graft (FGG)
3131321|NCT03338686|Experimental|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft (CTG) followed by Laser Gingivoplasty
3131322|NCT03338803||Patients with a written prescription for linagliptin|
3132545|NCT03436147||Vaginal Hysterectomy and Vaginal vault suspension (VAH+VVS)|Patients who were performed vaginal hysterectomy and vaginal vault suspension(VAH+VVS)
3131323|NCT03338816|Experimental|Givosiran/Givosiran|Givosiran 2.5 mg/kg administered subcutaneously (SC), monthly (QM), for 6 months during the 6-Month Double-blind (DB) Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the Open-label Extension (OLE) Period.
3131324|NCT03338816|Placebo Comparator|Placebo/Givosiran|Matching placebo (normal saline [0.9% NaCl]) was administered SC, QM, for 6 months during the 6-Month DB Period, followed by givosiran 2.5 mg/kg or 1.25 mg/kg SC, QM for 29 months during the OLE period.
3131325|NCT03338855|Active Comparator|Dapagliflozin|"Patients will receive dapagliflozin 10 mg in tablet for a maximum of 40 days based on randomization sequence in Period 1.~Patients that received 10 mg dapagliflozin in the first treatment period will receive matching placebo in the second treatment period for a maximum of 40 days."
3131326|NCT03338855|Placebo Comparator|Placebo matching to dapagliflozin|"Patients will receive matching placebo in tablet for a maximum of 40 days based on randomization sequence.~Patients who received placebo in the first treatment will receive 10 mg dapagliflozin in the second treatment period, for a maximum of 40 days"
3131327|NCT03338894|Other|Yoga group|Each subject will serve as their own control
3131328|NCT03338998|Experimental|BAF312|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally
3131329|NCT03338998|Placebo Comparator|Placebo|Days 1 - 7, IV up titration; days 8 - 14, 10 mg (5 x 2 mg tablets) taken daily orally - matching placebo
3132546|NCT03436420|Experimental|Gemcabene|Children receiving 12 weeks of treatment with gemcabene
3132547|NCT03436732|Experimental|1/Dose Escalation|Dose escalation - patients with mesothelioma treated with LMB-100+SEL-110 at escalating doses
3132548|NCT03436732|Experimental|2/Dose Expansion|Dose expansion - patients with mesothelioma treated with LMB-100+SEL-110 at recommended phase 2 dose (RP2D)
3132549|NCT03436810|Experimental|Experimental group|The experimental group will receive training programs of Motor imagery (MI) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration of program session will be 90 minutes. Training for 3 times a week over duration of 4 weeks.
3132824|NCT03455491|Experimental|XC221 100 mg|"XC221 100 mg orally.~1 tablet of XC221 100 mg +1 tablet of Placebo 100 mg (in total 2 tablets) once daily during 3 days of treatment period"
3131330|NCT03339206|Experimental|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
3131331|NCT03339206|Experimental|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
3131332|NCT03339206|Other|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
3131333|NCT03339219|Experimental|Cabozantinib 60 mg|Cabozantinib 60 mg, tablet, orally, once daily (QD) in the fasted state until unacceptable toxicity or need for subsequent systemic anticancer treatment up to 2.5 years.
3131334|NCT03339297|Experimental|Defibrotide Prophylaxis|Standard of Care Immunoprophylaxis + Defibrotide
3131335|NCT03339297|Active Comparator|Standard of Care|Standard of Care Immunoprophylaxis Alone
3131336|NCT03339453|Experimental|Nasal Glucagon|Single dose of Nasal Glucagon.
3131337|NCT03339453|Active Comparator|Intramuscular Glucagon|Single intramuscular (IM) dose of Glucagon.
3131338|NCT03339570||Orthopedic treatment|This is the prospective cohort which includes 20 patients presenting three-four proximal humeral fracture who were treated non-surgically and followed prospectively during 12 months.
3131339|NCT03339583|Experimental|zopiclone first group|underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy
3131340|NCT03339583|Experimental|BBT-I first group|received two-week brief behavioral therapy followed by medication therapy (zopiclone).
3131341|NCT03339713|Experimental|Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1|Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.
3131342|NCT03339713|Experimental|Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2|Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.
3131343|NCT03339726|Experimental|New Formulation Phenylephrine HCl|
3131344|NCT03339726|Active Comparator|Marketed Phenylephrine HCl|
3131345|NCT03339726|Placebo Comparator|Placebo|
3131346|NCT03339999|Placebo Comparator|Placebo|Placebo-matching AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
3131347|NCT03339999|Experimental|AGN-242428 Higher Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
3131348|NCT03339999|Experimental|AGN-242428 Medium Dose|AGN-242428 capsules, oral administration, once-daily for up to 12 weeks.
3131349|NCT03339999|Experimental|AGN-242428 Lower Dose|AGN-242428 capsule and placebo-matching AGN-242428 capsule, oral administration, once-daily for up to 12 weeks.
3131350|NCT03340025|Experimental|negative pressure wound therapy|PICO Single Use Negative Pressure Wound Therapy System
3131351|NCT03340025|Placebo Comparator|conventional dressing|traditional surgical wound dressing of xeroform gauze and padding
3131352|NCT03340337|Experimental|Neo-Russian Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Neo-Russian electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
3132550|NCT03436810|Active Comparator|Control group|The control group receives programs of Health education (HE) for 25 minutes and Task-Oriented Circuit Class Training (TOCCT) for 65 minutes. Overall duration will be 90 minutes. They will be trained for 3 times a week over duration of 4 weeks.
3131353|NCT03340337|Experimental|Aussie Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive Aussie electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
3131354|NCT03340337|Experimental|RBS Electrical Stimulation|"MVIC will be measured for data normalization. The subjects will receive RBS electrical stimulation. The Maximal Elicited Induced Contraction (MEIC) will be measured.~One week later, after a washout period, the fatigue will be measured with this type of current."
3131355|NCT03340350|Experimental|Minocycline|Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
3131356|NCT03340415|No Intervention|Control Rehab|Follow existing rehabilitation protocol of Non-weight bearing walking for 6 weeks followed by heel walking for 6 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
3131357|NCT03340415|Experimental|Accelerated Rehab|Accelerated rehabilitation protocol of non-weight bearing walking for 2 weeks followed by heel walking for 10 weeks; then the resumption of normal full weight-bearing walking in normal shoes at 12 weeks post-operation
3131358|NCT03340428|Experimental|Transition Community Adherence Club (TCAC)|Participants in this arm will be referred to join a facilitated group setting for HIV on release from incarceration. This arm will provide HIV care services in a facilitated group setting to provide medical and psychosocial needs of participants.
3131359|NCT03340428|No Intervention|Care as usual (CAU)|Care as usual participants will be referred to routine clinic HIV care on release from corrections.
3131360|NCT03340610|Other|Open Label Single Arm Trial|Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
3131361|NCT03340805|Experimental|Lactated Ringer's fluid (LR)|Lactated Ringer's (LR) fluid will be administered to patients randomized to the experimental arm. LR will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team.
3132551|NCT03437031|No Intervention|Latent-Control|Patients in the latent phase of labor who will receive no intervention.
3132552|NCT03437031|Experimental|Latent-Virtual Reality (VR)|Patients in the latent phase of labor who will receive the Virtual Reality (VR) intervention.
3131362|NCT03340805|Active Comparator|"0.9% normal saline fluid (NS)"|"0.9% normal saline (NS) fluid will be administered to patients randomized to the active comparator (control) arm. NS will be used for all fluid boluses and maintenance fluids (supplemental electrolytes are allowed) from time immediately after randomization through 11:59 pm of the next calender day. The determination of when to give fluid, how much fluid to give, how fast to give fluid, and what access to use to administer fluid will remain at the discretion of the treating team."
3131363|NCT03340883|Experimental|BION-1301|BION-1301 will be administered once every 2 weeks as an intravenous (IV) infusion.
3131364|NCT03340961|Experimental|DFD-29 Extended Release Capsules (40 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (40 mg) once per day for 16 weeks.
3131365|NCT03340961|Experimental|DFD-29 Extended Release Capsules (20 mg)|DFD-29 (minocycline HCl) Extended Release Capsules (20 mg) once per day for 16 weeks.
3131366|NCT03340961|Experimental|Oraycea® (doxycycline) Capsules|Oraycea® (doxycycline) Modified Release Hard Capsules (40 mg) once per day for 16 weeks.
3131367|NCT03340961|Placebo Comparator|Placebo Capsules|Placebo Capsules once per day for 16 weeks.
3131368|NCT03341273|Experimental|Azithromycin|500 mg of Azithromycin (2 capsules of 250 mg) administered orally as a single dose on Day 1, followed by 250 mg capsule of Azithromycin administered orally once daily for 4 days (Day 2 through Day 5). N=337
3131369|NCT03341273|Placebo Comparator|Placebo|2 capsules of Azithromycin placebo administered orally as a single dose on Day 1, followed by 1 capsule of Azithromycin placebo administered orally once daily for 4 days (Day 2 through Day 5). N=337
3131370|NCT03341299|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
3131371|NCT03341299|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
3131372|NCT03341299|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
3132553|NCT03437044|Experimental|Ticagrelor|180 mg loading dose (LD) followed by a 60 mg bid maintenance (MD) starting 12 h (± 1 h) after the LD
3131373|NCT03341299|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
3131374|NCT03341312|Experimental|LY900014 Before Meal|Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.
3131375|NCT03341312|Experimental|LY900014 After Meal|Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.
3131376|NCT03341312|Active Comparator|Insulin Lispro (Humalog) Before Meal|Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.
3131377|NCT03341312|Active Comparator|Insulin Lispro (Humalog) After Meal|Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.
3131378|NCT03341507|Experimental|laryngoscopy and tracheal intubation|Tracheal intubation with the rigid tube for laryngoscopy for patients with difficult airway. Prior the use of rigid tube for laryngoscopy, a classical laryngoscopy with a McIntosh laryngoscope will be performed.
3131379|NCT03341533|Experimental|Ice packs plus usual post-op analgesia|Ice pack applied to the abdomen and maintained continuously for the first 12 hours post-operatively. Standard standard post-operative analgesia orders will be followed in addition to use of ice.
3131380|NCT03341533|Active Comparator|Usual post-op analgesia|Standard post-operative analgesia only, no ice use.
3131381|NCT03341546||Patient cohort|20 patients referred to Ninewells Hospital radiology department for an anterior-posterior abdomen x-ray examination. All of these patients will have a measurement of their anterior-posterior depth before undergoing their x-ray examination. An estimate of their anterior-posterior depth will then be made from their x-ray image using the computational model.
3131382|NCT03341637|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose)
3131383|NCT03341637|Placebo Comparator|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
3131384|NCT03341728|Experimental|Intervention, then Control|Older adults will walk during exposure to optical flow perturbations
3131385|NCT03341728|Experimental|Control, then Intervention|Older adults will walk normally (without optical flow perturbations)
3131386|NCT03341910|Experimental|DFD-03 Lotion, 0.1%|DFD-03 Lotion, 0.1% to be applied twice daily approximately 12 hours apart, for 1 minute and rinsed off
3131387|NCT03341910|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% to be applied once in the evening and left overnight for approximately 12 hours
3131388|NCT03341910|Placebo Comparator|Vehicle Lotion|Vehicle Lotion to be applied twice daily for 1 minute and rinsed off
3131389|NCT03341910|Placebo Comparator|Vehicle Cream|Vehicle Cream to be applied once in the evening and left overnight for approximately 12 hours
3131390|NCT03341923|Other|DT1MF, then AMMF|Delefilcon A multifocal contact lenses, followed by etafilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
3131391|NCT03341923|Other|AMMF, then DT1MF|Etafilcon A multifocal contact lenses, followed by delefilcon A multifocal contact lenses. Each product worn in both eyes for 14 +/- 3 days.
3131392|NCT03341975|Experimental|Intervention|They will receive the same pamphlet as controls and the enhanced ED SexHealth intervention with the educator. Based on behaviors, CDS system recommendations (generated from screening survey responses only for intervention participants), and discussions, participants may be offered testing (for pregnancy, gonorrhea/chlamydia, and /or HIV), hormonal birth control, condoms, emergency contraception (for immediate or future use), treatment for previously diagnosed (yet untreated) infection with gonorrhea/chlamydia, and a scheduled appointment at Adolescent Clinic (for ongoing care, including repeat STI/HIV testing if needed). All services will be provided at point of care, costs will be covered by the study.
3131393|NCT03341975|No Intervention|Control|They will receive a printed health pamphlet and a list of local resources with the phone number for Adolescent Clinic. Participants will then be referred back to their ED provider, who will provide their standard care.
3131394|NCT03342001|Experimental|Treatment group, open label|calcitonin nasal spray, 200 mcg daily
3131395|NCT03342053|Experimental|RO7234292 Monthly|RO7234292 is administered every 28 days intrathecally for 14 months.
3131396|NCT03342053|Experimental|RO7234292 Bimonthly|RO7234292 is administered every 56 days intrathecally for 14 months following 2 monthly doses to serve as a loading dose.
3131397|NCT03342404|Experimental|Luspatercept (ACE-536) plus Best Supportive Care (BSC)|Arm Description: Luspatercept, subcutaneous(ly) (SC) once every 21 days
3131398|NCT03342404|Placebo Comparator|Placebo plus Best Supportive Care (BSC)|normal saline solution subcutaneous(ly) (SC) once every 21 days
3131399|NCT03342469|Experimental|ADHD- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
3132554|NCT03437044|Active Comparator|Clopidogrel|600 mg LD followed by a 75 mg od MD starting 24 hours (± 1 h) after the LD
3132825|NCT03455491|Experimental|XC221 200 mg|XC221 200 mg orally. 2 tablets of XC221 100 mg once daily during 3 days of treatment period
3131400|NCT03342469|Experimental|ADHD - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
3131401|NCT03342469|Experimental|Controls- Artificial food coloring, then placebo|Participants first received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday). After a 4-day washout period, they then received placebo of chocolate cookies and consumed them over three days.
3131402|NCT03342469|Experimental|Controls - Placebo, then artificial food coloring|Participants first received placebo of chocolate cookies and consumed them over three days. After a 4-day washout period, they then received 225 mg of the six most common artificial food colors (Red 40, Red 3, Yellow 5, Yellow 6, Blue 1, and Blue 2) mixed in chocolate cookies and consumed consecutively over three days (Monday, Tuesday, Wednesday).
3131403|NCT03342560|Experimental|30 Patients with known liver biopsy results|Patients with chronic liver disease with known biopsy results
3131404|NCT03342690||Eplerenone|Patients with CHF receiving Selara (eplerenone)
3132826|NCT03455491|Placebo Comparator|Placebo|Placebo orally. 2 tablets of Placebo 100 mg once daily during 3 days of treatment period
3132827|NCT03455543|Experimental|Active Group|Treatment with active Provant Therapy System
3131405|NCT03342898|Experimental|Group 1: YF-17D + Placebo/TDV/TDV|YF-17D vaccine, 0.5 mL injection, subcutaneously (SC) plus YF 17D + TDV placebo-matching 0.5 mL, injection, SC on Day 1, followed by TDV, 0.5 mL, injection, SC on Day 90 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 180 (second dose).
3131406|NCT03342898|Experimental|Group 2: TDV + Placebo/TDV/YF-17D|TDV, 0.5 mL, injection, SC plus TDV placebo-matching, 0.5 mL injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on Day 90 (second dose), followed by YF-17D vaccine, 0.5 mL, injection, SC on Day 180.
3131407|NCT03342898|Experimental|Group 3: TDV + YF-17D/TDV/Placebo|TDV, 0.5 mL, injection, SC plus YF-17D vaccine, 0.5 mL, injection, SC on Day 1 (first dose), followed by TDV, 0.5 mL, injection, SC on day 90 (second dose), followed by TDV + YF 17D placebo-matching, 0.5 mL, injection, SC on Day 180.
3131408|NCT03342963|Experimental|ASC-01 in period 1, Aripiprazole and sertraline in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting."
3131409|NCT03342963|Experimental|Aripiprazole and sertraline in period 1, ASC-01 in period 2|"At Day 1 in Period I, Aripiprazole 3 mg and sertraline 100 mg will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
3131410|NCT03342963|Experimental|Fasting in period 1, After breakfast in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast."
3131411|NCT03342963|Experimental|After breakfast in period 1, Fasting in period 2|"At Day 1 in Period I, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered 30 minutes after the start of breakfast.~At Day 1 in Period II, ASC-01 (aripiprazole 3 mg/sertraline 100 mg combination drug) will be administered after 10 or more hours of fasting."
3131412|NCT03343067|Experimental|Arm A|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 3 and continue treatment through Month 24"
3131413|NCT03343067|Experimental|Arm C|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
3132828|NCT03455543|Sham Comparator|Sham Group|Treatment with in-active (sham) Provant Therapy System
3131414|NCT03343067|Experimental|Arm D|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 6 and assigned to elagolix 200 mg BID plus E2/NETA 1/0.5 mg QD treatment group and continue treatment through Month 24."
3131415|NCT03343067|Experimental|Arm B|"Day 1 Through Month 3 (Open-Label): Open-Label elagolix 150 mg QD~Month 4 Through Month 6 (Double-Blind): Incomplete efficacy responders to elagolix 150 mg QD at Month 3 and randomized to elagolix 150 mg QD treatment group~Month 7 Through Month 24 (Double-Blind): Efficacy responders to elagolix 150 mg QD at Month 6 and continue treatment through Month 24."
3132829|NCT03456245||Vision device validation|In the single arm of this study, all members of this group were examined using a number of mobile eyesight assessment devices.
3132555|NCT03437265|Experimental|PLENVU powder for oral solution|"Dose 1: Oral administration of 1 sachet (115.96 g) PLENVU Dose 1, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 1.~Dose 2: Oral administration of 2 sachets (101.91 g) comprising PLENVU Dose 2, reconstituted with water and made up to 473 mL and 473 mL of additional water to be consumed; both to be consumed over a period of 60 min after the start of Dose 2.~Additional water was permitted ad libitum during and after each dose."
3131416|NCT03343080|Experimental|Buffered Lidocaine|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the buffered lidocaine arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with the study drug containing 1.8% lidocaine plus 0.76% sodium bicarbonate until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of solution instilled in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
3132556|NCT03437278|Experimental|Ligelizumab 120 mg|Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
3132557|NCT03437278|Experimental|Ligelizumab 24 mg|Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).
3132830|NCT03456427|Other|All Study Participants|All subjects will undergo standard of care imaging on one breast. The other breast will be imaged using Patient-Assisted Compression (PAC), followed by Technologist-controlled (TC) Compression.
3131417|NCT03343080|Placebo Comparator|Air|"At the induction of anesthesia, patients will be breathing 100% oxygen via a face mask and then, become anesthetized according to a standard protocol and at the discretion of the attending anesthesiologist.~For cardiac surgery patients randomized to the air arm, the operating room registered respiratory therapist (OR RRT) will inflate the endotracheal tube cuffs with air until abatement of the air leak at 20 cm of water.~The intervention will take place while in the operating room. The room nurse anesthetist (CRNA) or anesthesiologist will be aware of the amount of air in the ETT cuff. The patient will remain intubated after the surgery is complete and will be taken to the cardiac surgical ICU."
3131418|NCT03343639|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
3131419|NCT03343639|Placebo Comparator|Matching Placebo Tablets|Placebo Tablets
3131420|NCT03343704|Experimental|Group A - patients with uncontrolled or life-threatening bleeding|
3131421|NCT03343704|Experimental|Group B - patients not bleeding but requiring emergency surgery or invasive procedure|
3131422|NCT03344172|Experimental|PGHA|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine and Avelumab
3131423|NCT03344172|Experimental|PGH|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
3131424|NCT03344510|Experimental|Kinetic anesthesia device, then no intervention|In this arm of the crossover study, participants will receive lidocaine injection in conjunction with the kinetic anesthesia device, then will receive an injection without the kinetic anesthesia device intervention
3131425|NCT03344510|Experimental|No intervention, then kinetic anesthesia device|In this arm of the crossover study, participants will receive lidocaine injection without the kinetic anesthesia device intervention, then will receive an injection in conjunction with the kinetic anesthesia device.
3131426|NCT03344640|Experimental|secukinumab|AIN457 300 mg subcutaneously (s.c.) for 12 weeks
3131427|NCT03344640|Placebo Comparator|Placebo|Placebo subcutaneously for 12 weeks
3131428|NCT03344861|Experimental|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of porfimer sodium (Photofrin®) followed by illumination of the tumor using a fiber optic device during navigational bronchoscopy. Two days after the injection, the laser light will be applied to the tumor.
3131429|NCT03345108|Experimental|Test Denture Adhesive (Conventional Application)|Test denture adhesive will be applied to participants' dentures via conventional pattern of application.
3131430|NCT03345108|Experimental|Test Denture Adhesive (Continuous strip Application)|Test denture adhesive will be applied to participants' dentures via continuous strips pattern of application.
3131431|NCT03345108|Other|Negative Control|Participants will not apply any denture adhesive in this treatment arm.
3131432|NCT03345160|Experimental|Peanut Flour: Open label peanut OIT|This is an open label treatment for subjects who had previously received placebo treatment in a prior peanut OIT study
3131433|NCT03345394|Active Comparator|Standard Treatment|12 weeks of standard treatment offered by Unidade Recomeço Helvétia treatment program
3131434|NCT03345394|Experimental|Contingency Management|12 weeks of standard treatment offered at Unidade Recomeço Helvétia treatment program associated with Contingency Management
3131435|NCT03345407|Placebo Comparator|placebo once daily|Eligible subjects will receive placebo ELLIPTA dry powder (blended with lactose) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3131436|NCT03345407|Experimental|Nemiralisib 50 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3131437|NCT03345407|Experimental|Nemiralisib 100 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 100 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3132831|NCT03456700|Experimental|Treatment (auranofin, sirolimus)|Participants receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
3131438|NCT03345407|Experimental|Nemiralisib 250 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 250 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3131439|NCT03345407|Experimental|Nemiralisib 500 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 500 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3131440|NCT03345407|Experimental|Nemiralisib 750 µg once daily|Eligible subjects will receive nemiralisib ELLIPTA 750 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
3131441|NCT03345472|Experimental|Treated|Enrolled subjects who are implanted with a spinal cord stimulation system that is activated.
3131442|NCT03345914|Experimental|Group 1|Participants will receive dupilumab, dosing regimen 1
3131443|NCT03345914|Experimental|Group 2|Participants will receive dupilumab, dosing regimen 2
3131444|NCT03345914|Experimental|Group 3|Participants will receive matching placebo
3131445|NCT03345979|Experimental|Treatment Group 1|Regular injections
3131446|NCT03345979|Active Comparator|Treatment Group 2|Regular injections
3131447|NCT03346057|Experimental|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg administered as a single intravenous (IV) dose
3131448|NCT03346057|Experimental|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg administered as a single IV dose
3131449|NCT03346057|Experimental|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg administered as a single IV dose
3131450|NCT03346057|Active Comparator|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg (up to 5 mg maximum dose) plus glycopyrrolate 10 μg/kg (up to 1 mg maximum dose) administered as a single IV dose
3131451|NCT03346070|Experimental|Sugammadex 2 mg/kg ABW|Following administration of NMBA, participants received a single intravenous (i.v.) bolus of Sugammadex at 2 mg/kg as determined utilizing participant ABW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
3131452|NCT03346070|Experimental|Sugammadex 2 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 2 mg/kg as determined utilizing participant IBW. A treatment dose of 2 mg/kg was used for reversal of moderate NMB.
3131453|NCT03346070|Experimental|Sugammadex 4 mg/kg ABW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant ABW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
3131454|NCT03346070|Experimental|Sugammadex 4 mg/kg IBW|Following administration of NMBA, participants received a single i.v. bolus of Sugammadex at 4 mg/kg as determined utilizing participant IBW. A treatment dose of 4 mg/kg was used for reversal of deep NMB.
3131455|NCT03346070|Active Comparator|Neostigmine/Glycopyrrolate|Following administration of NMBA, participants received a single i.v. bolus containing both Neostigmine (50 µg/kg; up to 5 mg maximum dose) and Glycopyrrolate (10 µg/kg; up to 1 mg maximum dose) as determined utilizing participant ABW. Neostigmine/Glycopyrrolate was used for reversal of moderate NMB. Active comparator treatment for reversal for deep NMB was not available.
3132558|NCT03437278|Placebo Comparator|Placebo + Ligelizumab 120 mg|Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial.
3132559|NCT03437447|Experimental|First Cisticid, Then Biltricide, Then Biltricide|Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
3132560|NCT03437447|Experimental|First Biltricide, Then Cisticid, Then Biltricide|Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
3132561|NCT03437447|Experimental|First Biltricide, Then Biltricide, Then Cisticid|Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.
3132562|NCT03437512|Experimental|Active tDCS and fluency training|Participants will receive anodal tDCS at 2milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
3131456|NCT03346161|Experimental|Arm 1: BREASTChoice (Decision Tool)|Investigators recruited patients scheduled for a plastic/reconstruction consult. Investigators identified patients who completed a mastectomy, or were scheduled for one, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or offered them the option to complete pre-appointment procedures at home. Patients randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with the decision tool. They were asked to answer a survey. After the appointment, the team collected information consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes.
3132563|NCT03437512|Sham Comparator|Sham tDCS and fluency training|Participants will receive sham tDCS. Sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
3131457|NCT03346161|Active Comparator|Arm 2: Enhanced Usual Care (Surgical Care Booklet)|"Investigators recruited patients scheduled for plastic/reconstruction consultation. Investigators identified patients who completed or scheduled a mastectomy, and considering reconstruction, but didn't have an appointment with a plastic/reconstructive surgeon. A study team member called the patient to determine their interest and offered for them to come to their scheduled appointment 30 minutes early to meet a coordinator or to complete the pre-appointment procedures at home. Patients were randomized using computer random assignment. If the patient didn't have an appointment, she scheduled a convenient time to complete study procedures with research staff. Patients interacted with American Society of Plastic Surgeons booklet Breast Reconstruction. They were asked to answer a survey. After the appointment, the team collected information about consult duration, decision process quality, and measures of shared decision making. Patient participation was approximately 30 minutes."
3131458|NCT03346759|Experimental|Tampon A First|Subjects were provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
3131459|NCT03346759|Experimental|Tampon B First|Subjects were provided with 24 Playtex Gentle Glide 360 Regular Tampons (tampon B) to use exclusively for the first of two consecutive menstrual cycles. Subjects were then provided with 24 Tampax Pearl Regular Tampons (tampon A) to use exclusively for the second of two consecutive menstrual cycles. For the third menstrual cycle, subject used tampons of their choosing.
3131460|NCT03346850|Active Comparator|nasogastric tube (NGT) feeding|
3131461|NCT03346850|Active Comparator|nasoduodenal tube (NDT) feeding|
3131462|NCT03346902|Placebo Comparator|Placebo|"Drug: : Placebo: 0.9% Sodium Chloride Injection~Injection of Placebo into area of scarring (forehead)"
3131463|NCT03346902|Active Comparator|EB001|Drug: EB-001 Injection of EB-001 into area of scarring (forehead)
3131464|NCT03347188|Experimental|Fremanezumab|Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters [mL] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
3131465|NCT03347188|Placebo Comparator|Placebo|Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.
3131466|NCT03347279|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
3131467|NCT03347279|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
3131468|NCT03347695|Experimental|A new operation|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
3131469|NCT03347695|Other|A new operation (Selected pilot study)|Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
3131478|NCT03348683|Experimental|Propranolol|2mg of IV push
3131479|NCT03348683|Placebo Comparator|Placebo|an equivalent quantity in milliliters of normal saline
3131480|NCT03349034|Experimental|Test Group|Local Ropivicaine Infusion
3131481|NCT03349034|Placebo Comparator|Control Group|Local Saline Infusion
3131482|NCT03349060|Experimental|PF-04965842 100 mg|
3131483|NCT03349060|Experimental|PF-04965842 200 mg|
3131484|NCT03349060|Placebo Comparator|Placebo|
3131485|NCT03349099|Active Comparator|Cook Flexor|ureteral access sheath
3131486|NCT03349099|Active Comparator|Boston Scientific Navigator HD|ureteral access sheath
3131487|NCT03349333|Experimental|pralatrexate|Vitamin B12 and folic acid will be taken concurrently with pralatrexate
3131488|NCT03349437|Experimental|Vitabreath Device|The Philips Respironics investigational device VitaBreath is a handheld, battery powered, intermittent positive airway pressure device that is non-invasive, and provides positive airway pressure (PAP) of 18 cm water (H2O) during inspiration and 8 cm H2O on expiration, thus creating 10 cm H2O of pressure support. Pressure support is defined as the difference between inhalation pressure and exhalation pressure. The study device is intended as an adjunct therapy to relieve shortness of breath in COPD patients who experience exertion-related dyspnea to allow them to be more active. The air is delivered to the patient via a mouthpiece on the device.
3131489|NCT03349437|Active Comparator|Pursed Lip Breathing|Pursed lip breathing is a commonly used technique by COPD patients. That involves exhaling through tightly pressed lips and inhaling through the nose with the mouth closed.
3131490|NCT03349515|Active Comparator|Group A - povidone-iodine ophthalmic solution.|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first.
3131491|NCT03349515|Active Comparator|Group B - ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution, with the right eye to receive the drops first.
3131492|NCT03349567|Experimental|Audit-and-feedback|The experimental arm will consist of Emergency Department providers who do receive the intervention.
3131493|NCT03349567|No Intervention|Control|The control arm will consist of providers who do not receive the intervention.
3131494|NCT03349632|Other|DD T2/Oasys 1-Day|Verofilcon A contact lenses and senofilcon A contact lenses worn in both eyes, each product, for 1 week on a daily wear basis, as randomized
3131495|NCT03349632|Other|DD T2/MyDay|Verofilcon A contact lenses and stenfilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
3131496|NCT03349632|Other|DD T2/Moist|Verofilcon A contact lenses and etafilcon A contact lenses worn in both eyes, each product, for 1 week on a daily disposable basis, as randomized
3131497|NCT03349710|Experimental|Arm A|Cohort 1
3131498|NCT03349710|Experimental|Arm B|Cohort 1
3131499|NCT03349710|Experimental|Arm C|Cohort 2
3131500|NCT03349710|Experimental|Arm D|Cohort 2
3131501|NCT03349892|Experimental|Stereotactic Ablation Treatment Arm|This is a single-arm, non-blinded study.
3131502|NCT03350217|Active Comparator|Eleview|This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
3131503|NCT03350217|Active Comparator|Hetastarch|This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.
3131504|NCT03350256|Experimental|Microdosing group|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
3131505|NCT03350503|Experimental|Acrysof IQ Toric A-code IOL|IOL implanted during cataract surgery
3131506|NCT03350542|Experimental|SYNERGY 48 mm|SYNERGY 48 mm is a device/ drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating)
3132564|NCT03437564|Experimental|Vortioxetine one 20 mg tablet + two 10 mg tablets|Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.
3131507|NCT03350672|Experimental|Cohort 1a|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
3131508|NCT03350672|Experimental|Cohort 1b|"Age 18 or older at the time of signed informed consent~Not currently taking commercial FTC/TDF for PrEP or any other investigational, oral medication for the purpose of HIV PrEP~Willing and able to independently provide written informed consent~Tests HIV negative at time of screening using rapid HIV antibody test or serum antibody/antigen 4th generation HIV test"
3131509|NCT03350672|Active Comparator|Cohort 2|"Age 18 or older at the time of signed informed consent~Willing and able to independently provide written informed consent~Last viral load < 20 copies/mL within the last four weeks of screening~Must be on combination antiretroviral therapy that includes TAF/FTC for at least 6 months~Undetectable viral load, as defined by < 50 copies/ml, for at least 6 months"
3132565|NCT03437564|Experimental|Vortioxetine two 10 mg tablets + one 20 mg tablet|Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.
3131510|NCT03350724|Experimental|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
3131511|NCT03350724|Active Comparator|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
3131512|NCT03350919|Experimental|Training in the blind field|Training in the blind field using software
3131513|NCT03350919|Experimental|Training in the intact field|Training in the intact field using software
3132566|NCT03437577|Active Comparator|immediate-release tacrolimus|This is standard of care
3132567|NCT03437577|Experimental|extended release tacrolimus|replace standard of care
3131516|NCT03351101|Experimental|Senofilcon C|Senofilcon C Contact Lens
3131517|NCT03351101|Experimental|Samfilcon A|Samfilcon A Contact Lens
3131518|NCT03351114|Experimental|Crisaborole 2% ointment|Crisaborole 2% ointment applied to affected skin twice per day.
3131519|NCT03351231|Experimental|Dose Escalation|BMS-986242 administered in combination with Nivolumab
3131520|NCT03351231|Experimental|Dose Expansion|BMS-986242 administered in combination with Nivolumab
3131521|NCT03351335|Experimental|Ultherapy®, energy level 3|Group 1: Subjects will receive Ultherapy® treatment at energy level 3 (EL3).
3131522|NCT03351335|Experimental|Ultherapy®, energy level 4|Group 2: Subjects will receive Ultherapy® treatment at energy level 4 (EL4).
3131523|NCT03351335|Experimental|Ultherapy®, energy level 2|Group 3: Subjects will receive Ultherapy® treatment at energy level 2 (EL2).
3131524|NCT03351478|Experimental|Sotagliflozin 400 mg|Following a 2-week run-in period, sotagliflozin 400 mg (milligrams) administered as two 200 mg tablets and one placebo capsule (identical to the empagliflozin capsule in appearance), once daily before the first meal of the day for up to 26 weeks.
3132568|NCT03437733|Experimental|Intervention|Ablation with Multi-electrode Radiofrequency (RF) Balloon Catheter
3131525|NCT03351478|Active Comparator|Empagliflozin 25 mg|Following a 2-week run-in period, placebo matching sotagliflozin administered as two tablets (identical to sotagliflozin in appearance) and one capsule of empagliflozin 25 mg, once daily before the first meal of the day for up to 26 weeks.
3131526|NCT03351478|Placebo Comparator|Placebo|Following a 2-week run-in period, placebo was given as two placebo tablets (identical to sotagliflozin) and one placebo capsule (identical to empagliflozin) once daily before the first meal of the day for up to 26 weeks.
3131527|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part A)|Single intravenous (i.v.) bolus of sugammadex at 2 mg/kg.
3131528|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part A)|Single i.v. bolus of sugammadex at 4 mg/kg.
3131529|NCT03351608|Experimental|Sugammadex 2 mg/kg (Part B)|Single i.v. bolus of sugammadex at 2 mg/kg.
3131530|NCT03351608|Experimental|Sugammadex 4 mg/kg (Part B)|Single i.v. bolus of sugammadex at 4 mg/kg.
3131531|NCT03351608|Active Comparator|Neostigmine (Part B)|Single i.v. bolus containing neostigmine (50 μg/kg; up to 5 mg maximum dose) in combination with either glycopyrrolate (10 μg/kg) or atropine sulfate (20 μg/kg).
3131532|NCT03351699|Experimental|Panel A: MK-4250 150 mg|Participants will receive MK-4250 150 mg tablet by mouth on Day 1 after an 8-hour fast.
3131533|NCT03351699|Experimental|Panel B: MK-4250 600 mg|Participants will receive MK-4250 600 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel B and the dose selected (i.e., ≤600 mg) will be made based on evaluation of pharmacokinetics and 7-day safety and viral load data from Panel A.
3131534|NCT03351699|Experimental|Panel D: MK-4250 900 mg|Participants will receive MK-4250 900 mg tablet by mouth on Day 1 after an 8-hour fast. The decision to enroll Panel D will be made upon completion of Panels A and B and evaluation of safety and viral load data from those panels.
3131535|NCT03351699|Experimental|Panel E: MK-4250 ≤900 mg with a Low-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a low-fat meal. The decision to enroll Panel E will be made upon completion of Panel D and evaluation of safety and viral load data from that panel.
3131536|NCT03351699|Experimental|Panel F: MK-4250 ≤900 mg with a Moderate-fat Meal|Participants will receive MK-4250 ≤900 mg tablet by mouth on Day 1 with a moderate-fat meal. The decision to enroll Panel F will be made upon completion of Panel D and evaluation of safety and viral load data from that panel. The decision to enroll Panel F will be made based on evaluation of PK and safety data from other studies with MK-4250.
3131537|NCT03351738|Placebo Comparator|Placebo|Participants will receive subcutaneous (SC) dose of placebo (volume matched to MEDI5884) on Days 1, 31, and 61.
3131538|NCT03351738|Experimental|MEDI5884 50 mg|Participants will receive SC dose of MEDI5884 50 mg on Days 1, 31, and 61.
3131539|NCT03351738|Experimental|MEDI5884 100 mg|Participants will receive SC dose of MEDI5884 100 mg on Days 1, 31, and 61.
3131540|NCT03351738|Experimental|MEDI5884 200 mg|Participants will receive SC dose of MEDI5884 200 mg on Days 1, 31, and 61.
3131541|NCT03351738|Experimental|MEDI5884 350 mg|Participants will receive SC dose of MEDI5884 350 mg on Days 1, 31, and 61.
3131542|NCT03351738|Experimental|MEDI5884 500 mg|Participants will receive SC dose of MEDI5884 500 mg on Days 1, 31, and 61.
3131543|NCT03351933|Experimental|Immune Globulin (Human) GamaSTAN|The healthy subjects received a single IM dose of GamaSTAN (0.2 mL/kg), followed by a PK sampling period of 150 days.
3131544|NCT03352245|Experimental|Intervention Group|Prescribed Activity designed to improve patient participation and adherence to prescriptions to increase physical activity and will include: (1) an educational session at enrollment, (2) subject communication via tailored electronic messaging, and (3) a wrist-bound device (FitBit Flex 2).
3131545|NCT03352245|No Intervention|Control Group|Usual care group will receive standard of care management from their Oncologist.
3131546|NCT03352323|Experimental|oxymetazoline cream|
3131547|NCT03352414|Experimental|Alvimopan|alvimopan 12 mg PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
3131548|NCT03352414|Placebo Comparator|Placebo|Placebo pill PO twice daily, starting POD 1 for the earlier of 7 days or hospital discharge
3131549|NCT03352453|Experimental|Rapastinel 450mg|Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
3131550|NCT03352453|Placebo Comparator|Placebo|Placebo-matching rapastinel weekly IV injections.
3131551|NCT03352609|Experimental|Active rTMS|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
3131552|NCT03352609|Sham Comparator|Sham|5 session of sham rTMS delivered with Magpro (MagVenture) double blind rTMS system to mimic active intervention.
3131553|NCT03352713|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
3131554|NCT03353220|Experimental|Arm A|Participants receive lorcaserin (Belviq) 10 mg twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive placebo twice a day for 7 days.
3131555|NCT03353220|Experimental|Arm B|Participants receive placebo twice a day for 7 days followed by a 3 week washout period. These participants will then be crossed over to receive lorcaserin (Belviq)10 mg twice a day for 7 days.
3131556|NCT03353246|Experimental|InfraScanner 2000™|All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
3131557|NCT03353740|Experimental|Ga-68 labeled PSMA-11 PET|PSMA PET imaging: Patients will receive Ga-68 labeled PSMA-11 PET and then undergo PET/CT or PET/MRI approximately 55-70 minutes later.
3131558|NCT03353753|Active Comparator|Arm 1|150 mg QD DCC-2618
3131559|NCT03353753|Placebo Comparator|Arm 2|Placebo
3131560|NCT03353922|Experimental|Tolperisone HCl 150 mg|150 mg tolperisone tablets or cyclobenzaprine 10 mg oral tablet administered by mouth every 8 hours for 3 days
3131561|NCT03353922|Placebo Comparator|Placebo Oral Tablet|sugar pills administered by mouth every 8 hours for 3 days
3131562|NCT03353922|Active Comparator|Cyclobenzaprine 10 mg oral tablet|10 mg cyclobenzapine tablets administered by mouth every 8 hours for 3 days
3131563|NCT03354325|Active Comparator|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician (PCP) within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
3131564|NCT03354325|Experimental|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician (PCP). Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
3131565|NCT03354429|Experimental|TICAGRELOR|
3131566|NCT03354429|Placebo Comparator|TICAGRELOR PLACEBO|
3131567|NCT03354598|Experimental|Sulopenem-etzadroxil/probenecid|Sulopenem-etzadroxil/probenecid 500 mg PO twice daily for 5 days
3131568|NCT03354598|Active Comparator|Ciprofloxacin|Ciprofloxacin 250 mg PO administered twice daily for 3 days
3131569|NCT03354637|Active Comparator|ATI-50002 high dose Topical Solution|High dose active
3131570|NCT03354637|Active Comparator|ATI-50002 low dose Topical Solution|low dose active
3131571|NCT03354637|Placebo Comparator|Vehicle Topical Solution|placebo
3131572|NCT03354663|Experimental|TactiCath SE|Catheter ablation with the TactiCath SE ablation catheter to achieve pulmonary vein isolation.
3131573|NCT03354754|Experimental|LYS228|IV infusion every 6 hours for at least 5 days
3131574|NCT03354754|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
3131575|NCT03355326|Experimental|Glycerin Suppository Group|
3131576|NCT03355326|No Intervention|Non-suppository Group|
3131577|NCT03355742|Experimental|XIENCE|XIENCE + Short duration (1 month) of DAPT
3131578|NCT03355820|Experimental|HPV Group|Healthy Chinese female subjects, including and above 17 years of age at the time of enrollment, who received all three doses of the Cervarix vaccine in the HPV-058 (NCT00996125) primary study.
3131579|NCT03356145|Experimental|12 mL arm|"Intervention:~Syringe loaded with 12 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 10 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
3131580|NCT03356145|Active Comparator|20 mL arm|"Intervention:~Syringe loaded with 20 mL of 1% lidocaine (120 mg); 22-gauge spinal needle~2 mL injected at the tenaculum site, either 6 or 12 o'clock superficially into the cervix~The tenaculum is immediately placed at the previously injected site~The remaining 18 mL are slowly injected into the cervicovaginal junction in two equal aliquots at 4 and 8 o'clock; the injection is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal)~No wait time between injection and dilator insertion"
3131581|NCT03356977|Experimental|Crisaborole ointment 2%|Subjects will be dosed for 28 days. A thin layer of ointment will be applied to all areas designated for treatment.
3131582|NCT03357341||COPD cohort|Approximately 100 subjects with COPD identified through integrated EHR records will be enrolled.
3131583|NCT03357341||Asthma cohort|Approximately 100 subjects with asthma identified through integrated EHR records will be enrolled.
3131584|NCT03357393|Active Comparator|Midazolam and morphine-scopolamine|Sedation during bronchoscopy with midazolam and morphine-scopolamine as premedication.
3131585|NCT03357393|Experimental|PCS (propofol) with morphine-scopolamine|Sedation during bronchoscopy with propofol using PCS and morphine-scopolamine as premedication
3131586|NCT03357393|Experimental|PCS (propofol) with glycopyrronium bromide|Sedation during bronchoscopy with propofol using PCS and glycopyrronium bromide as premedication.
3131587|NCT03357471|Experimental|Certolizumab Pegol Q2W injection by e-Device|Subjects will self-inject Certolizumab Pegol 200 mg (1 x 200 mg injection) using the e-Device every 2 weeks.
3131588|NCT03357471|Experimental|Certolizumab Pegol Q4W injection by e-Device|Subjects will self-inject Certolizumab Pegol 400 mg (2 x 200 mg injection) using the e-Device every 4 weeks.
3131589|NCT03357614|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for a minimum of 5 days, followed by sulopenem-etzadroxil/probenecid 500 mg PO twice daily to complete 7-10 total days of treatment
3131590|NCT03357614|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for a minimum of 5 days, followed by ciprofloxacin 500 mg PO twice daily or amoxicillin-clavulanate 500 mg PO twice daily to complete 7-10 total days of treatment
3131591|NCT03357731|Experimental|Placebo/BMS-986231/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131592|NCT03357731|Experimental|Placebo/NTG/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131593|NCT03357731|Experimental|NTG/Placebo/BMS-986231|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131594|NCT03357731|Experimental|NTG/BMS-986231/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131595|NCT03357731|Experimental|BMS-986231/Placebo/NTG|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131596|NCT03357731|Experimental|BMS-986231/NTG/Placebo|administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
3131597|NCT03357952|Experimental|Part 1: JNJ-63723283 + Daratumumab|Participants in Safety Run-in cohort will receive daratumumab IV and JNJ-63723283 IV for 1 cycle (28 days). Participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
3131598|NCT03357952|Experimental|Part 2 and Part 3: Daratumumab/ JNJ-63723283 + Daratumumab|Participants in Treatment Arm A will receive daratumumab IV and in Treatment Arm B will receive daratumumab IV and JNJ-63723283 IV for cycles of 28 days each. All participants will continue to receive study treatment until confirmed disease progression, unacceptable toxicity, or any other treatment discontinuation criteria are met. Participants who were previously receiving JNJ-283 plus daratumumab have the opportunity to continue daratumumab therapy alone.
3131599|NCT03358147|Experimental|GP MDI 28.8 μg|GP MDI 14.4 μg per actuation taken as 2 inhalations BID
3131600|NCT03358147|Experimental|GP MDI 14.4 μg|GP MDI 7.2 μg per actuation taken as 2 inhalations BID
3321376|NCT02018419|Experimental|Dosing Schedule C|"the priming step with ID injection of AlloStim on Days 0 and 3 and an additional ID injection of AlloStim on Days 7 and 10;~the ablation step with cryoablation and intra-tumor injection of AlloStim on Day 14, and intra-tumor injection of AlloStim again into the same cryoablated lesion on Day 17;~the activation step with an IV infusion of AlloStim on Day 21;~the booster step with intravenous infusion of AlloStim on days 49 and 77.~Protocol follow-up procedures continue until day 168 and at investigator discretion thereafter."
3321377|NCT02018432|Experimental|Roflumilast escalation dosage|Roflumilast 250 μg qd (4 weeks) →500 μg qd
3131601|NCT03358147|Experimental|GP MDI 7.2 μg|GP MDI 3.6 μg per actuation taken as 2 inhalations BID
3131602|NCT03358147|Placebo Comparator|Placebo MDI|Taken as 2 inhalations BID
3131603|NCT03358147|Other|Spiriva Respimat 2.5 μg|Open Label Spiriva Respimat 2.5 μg
3321378|NCT02018432|Experimental|Roflumilast conventional dosage|Roflumilast 500 μg qd
3131604|NCT03358238|Placebo Comparator|No weekly review|Individuals will not review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
3131605|NCT03358238|Experimental|Weekly review|Individuals will review self-report and activity tracker data with an interviewer on a weekly basis over the phone.
3131606|NCT03358251|Other|SRP+Pocket-X Gel, split-mouth|This arm is a split-mouth arm, i.e., participants will receive conventional treatment for periodontitis (scaling and root planing) for the entire mouth, and, in addition, will receive experimental treatment (Pocket-X Gel) for periodontal pockets present in one/two mouth segments (quadrants), while the contralateral quadrants will serve as control and will not undergo any further intervention.
3131607|NCT03358290|Experimental|JTE-051 Dose 1|One dose of study drug by mouth daily for 12 weeks
3131608|NCT03358290|Experimental|JTE-051 Dose 2|One dose of study drug by mouth daily for 12 weeks
3131609|NCT03358290|Experimental|JTE-051 Dose 3|One dose of study drug by mouth daily for 12 weeks
3131610|NCT03358290|Experimental|JTE-051 Dose 4|One dose of study drug by mouth daily for 12 weeks
3131611|NCT03358290|Experimental|Placebo|One dose of study drug by mouth daily for 12 weeks
3131612|NCT03358329|Experimental|S8 Sinus Implant|corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
3131613|NCT03358355|Experimental|Intervention|Subcutaneous injection of unacylated ghrelin: Doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg
3131614|NCT03358407|Experimental|Part A: Cohort 1|Cohort 1 will be 5-way crossover with 5 treatment periods. Subjects will be randomized in the ratio 4:1 to receive either single dose of GSK2983559 or placebo.
3131615|NCT03358407|Experimental|Part A: Cohort 2 fasting|Cohort 2 will be 4-way crossover design with one additional period of open-label. Subjects will be randomized in the ratio 3:1 to receive either single dose of GSK2983559 or placebo in fasted conditions
3131616|NCT03358407|Experimental|Part A: Cohort 2 fed|In Cohort 2, treatment period 5 will be open-label period. This open-label period is to determine food effect and subjects will receive GSK2983559 under fed conditions.
3131617|NCT03358407|Experimental|Part B|Part B is repeat ascending dose sequential period. There will four cohorts (3-6) of 10 healthy subjects. In each cohort subjects will be randomized to receive GSK2983559 or placebo in ratio 4:1. Subjects will receive GSK2983559 or placebo QD and twice daily dose will be decided based upon the pharmacokinetic, safety and tolerability observed in Part A.
3131618|NCT03358472|Experimental|Pembrolizumab + Epacadostat|
3131619|NCT03358472|Experimental|Pembrolizumab|
3131620|NCT03358472|Active Comparator|EXTREME|EXTREME regimen includes cetuximab + cisplatin or carboplatin + 5-fluorouracil.
3131621|NCT03358576|Experimental|Sulopenem|Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment
3131622|NCT03358576|Active Comparator|Ertapenem|Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead
3131623|NCT03359395|Active Comparator|Alfentanil|
3131624|NCT03359395|Placebo Comparator|placebo|
3131625|NCT03359473|Experimental|Male subjects receiving GSK2881078-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 2 mg once daily by the oral route.
3131626|NCT03359473|Placebo Comparator|Male subjects receiving Placebo-Cohort 1|Male subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
3131627|NCT03359473|Experimental|Female subjects receiving GSK2881078-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 at a dose of 1 mg once daily by the oral route.
3131628|NCT03359473|Placebo Comparator|Female subjects receiving Placebo-Cohort 2|Post-menopausal female subjects between the age of 50 and 75 years will be administered GSK2881078 matching placebo once daily by the oral route.
3131629|NCT03359590|Experimental|Sitagliptin arm|Sitagliptin 100 mg
3131630|NCT03359590|Placebo Comparator|Placebo arm|Placebo comparator
3131631|NCT03359850|Experimental|Normal hepatic function (Group 1):|To evaluate the pharmocokinetics and safety of niraparib
3131632|NCT03359850|Experimental|Moderate hepatic impairment (Group 2):|To evaluate the pharmocokinetics and safety of niraparib
3131633|NCT03359889||patients administered with PraxbindTM|
3131634|NCT03360071|Experimental|Allergen Immunotherapy Group|
3131635|NCT03360071|Placebo Comparator|Control Group|
3131636|NCT03360110|Active Comparator|Test lens|Subjects randomized to wear pair of test lens either first or second
3131637|NCT03360110|Active Comparator|stenfilcon A lens (control)|Subjects randomized to wear pair of control lens either first or second
3131638|NCT03360344|Experimental|Kinesio Tape|"Dorsal application of Kinesio Tape to the affected extremity: Approximately 12 inches of Kinesio tape will be applied from the musculotendinous junction of the participant's forearm over digits 1 and 5. Two - 2 inch strips of Kinesio Tape will be applied to the participant's wrists over the volar and dorsal aspects. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application by the researchers four times during the course of the study.~A tape removal form will be provided should the participants want to remove it prior to the next visit."
3132569|NCT03437863|Experimental|Mobile application|Participants recruited from a self-management course are asked to use (single time) a mobile application to support reflection of personal strengths. The participant borrows an Ipad and uses the application to 1) reflect and identify their strengths by reviewing a list of examples, 2) define personal goals, and 3) link strengths to goals.
3131639|NCT03360344|Sham Comparator|Control group|Approximately 4 inch strip of Kinesio Tape will be applied to the scapular spine of the same side as the affected extremity. The Kinesio Tape will remain in place for three days, with the participants returning for skin check by the researchers and re-application four times during the course of the study by the researcher. A tape removal form will be provided should the participants want to remove it prior to the next visit.
3131640|NCT03360344|Active Comparator|Standard of Care|Currently, the standard of care is a general cock-up splint and lumbrical exercises. A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
3131643|NCT03360747|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received a subcutaneous (SC) injection of AKCEA-ANGPTL3-LRx, 20 milligrams (mg), weekly (QW) for 13-weeks of treatment period. Participants were followed up to Week 26.
3132570|NCT03438006||Cervarix group|Healthy female Chinese subjects aged between 9 and 45 years, vaccinated according to the Prescribing Information (PI) as per routine practice.
3321379|NCT02018471|Experimental|Pilot group|Forty-three patients who had to undergo one or more diagnostic tests (PET, TAC, fMRI, Mammography, Endoscopy, Colonoscopy) took part in the study. Most of the 43 patients had to undergo only one diagnostic test, and only 6 patients had more than one. They have attended a psychoeducative training.
3321380|NCT02018484|Experimental|Patient specific cutting guides|Unicompartmental knee replacement with patient specific cutting guides
3131644|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Surgery Not Performed Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled but did not have surgery. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
3132832|NCT03456856|Experimental|Ivabradine|The starting dose of ivabradine was 5 mg twice daily (BID), although investigators had the discretion to start participants at 2.5 mg BID if participant had a history of conduction defects, or bradycardia that could lead to hemodynamic compromise. Dose was adjusted at Day 15 (and at any other clinical visit) between 2.5 - 7.5 mg BID based on heart rate and signs/symptoms of bradycardia.
3132833|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin|One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
3131645|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
3131646|NCT03361137|Experimental|PwHA With Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) with inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
3131647|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: CVAD Removal Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for central venous access device (CVAD) removal. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
3131648|NCT03361137|Experimental|PwHA Without Inhibitors, Emicizumab: Simple Dental Extraction Cohort|This cohort included participants with Hemophilia A (PwHA) without inhibitors that were enrolled and had surgery for simple dental extraction. All participants received emicizumab via subcutaneous (SC) injection at a loading dose of 3 milligrams of medication per kilogram of body weight (mg/kg) once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as they continued to derive sufficient benefit. Participants must have received all loading doses prior to surgery and planned to continue emicizumab for a minimum of 1 month after surgery.
3131649|NCT03361176|Active Comparator|Control|Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
3131650|NCT03361176|Experimental|w/ Triamcinolone|Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
3321381|NCT02018497||Consecutive patients who consult a cardiologist|"Consecutive patients who consult a cardiologist - electrophysiologist since June 2006, regardless of the age or gender in the city of Medellin, Colombia. They could have consulted previously (considered as the enrollment date) if they had, at least, one measurement of their BP in supine position, and an immediate measurement of their BP in standing position that allows diagnosing their group of blood pressure. All patients have a record in paper and/or magnetic file and in OpenClinica.~No interventions."
3321382|NCT02018510|Experimental|Group 1A|"HIV-uninfected individuals~1 mg/kg, single dose IV administration of 3BNC117"
3131651|NCT03361293|Active Comparator|Cognitive Training and Active tDCS|5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus active tDCS (also 5 sessions).
3131652|NCT03361293|Sham Comparator|Cognitive Training and Sham tDCS|"5 sessions of computerized cognitive training on tasks of attention, concentration, set-shifting, and memory - plus sham tDCS (also 5 sessions) which consists of placebo stimulation with tDCS (ramp-up, but no actual stimulation)."
3131653|NCT03361423|Active Comparator|treatment of migraine with active device|Treatment of acute migraine with an active form of Nerivio migra-1 device
3131654|NCT03361423|Sham Comparator|treatment of migraine with sham device|Treatment of acute migraine with a sham form of the Nerivio Migra-1 device
3131655|NCT03361605|Experimental|Propofol Administration|
3131658|NCT03361917|No Intervention|Control Arm (Standard Colonscopy)|Standard colonoscopy with no device attachments
3131659|NCT03361917|Experimental|Endocuff Vision|Colonoscopy with Endocuff Vision attached to distal end of scope
3131660|NCT03362879||Participants with advanced Parkinson's disease|Participants with advanced Parkinson's disease on current treatment with levodopa-carbidopa intestinal gel (LCIG) for at least 12 months.
3131661|NCT03362944|Experimental|Active Music Therapy|
3131662|NCT03362944|Experimental|Passive Music Therapy|
3131663|NCT03362957|Experimental|GAE Procedure|Patients will be randomized to receive the Geniculate Artery Embolization Procedure
3131664|NCT03362957|Sham Comparator|Sham Procedure|Patients will be randomized to a sham procedure.
3131665|NCT03362957|Experimental|Crossover Arm|If after 1 month patients see no improvement, they will be unblinded and crossover to receive the Geniculate Artery Embolization Procedure
3131666|NCT03363321|Experimental|PF-06741086 (Cohort 1)|
3131667|NCT03363321|Experimental|PF-06741086 (Cohort 2)|
3131668|NCT03363321|Experimental|PF-06741086 (Cohort 3)|
3131669|NCT03363321|Experimental|PF-06741086 (Cohort 4)|
3131670|NCT03363321|Experimental|PF-06741086 (Cohort 5)|
3131671|NCT03363321|Experimental|PF-06741086 (Cohort 6)|
3131672|NCT03363776|Experimental|Monotherapy|BMS-986277 administered alone
3131673|NCT03363776|Experimental|Combination Dose Escalation Therapy|BMS-986277 administered in combination with Nivolumab
3131674|NCT03363776|Experimental|Combination Expansion Therapy|BMS-986277 monotherapy with option for subsequent Nivolumab therapy
3131675|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
3131676|NCT03363854|Experimental|Tralokinumab(initial)responders-> Tralokinumab(continuation B)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B."
3131677|NCT03363854|Experimental|Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
3131678|NCT03363854|Experimental|Placebo (initial)non-respon-> Tralokinumab(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A."
3131679|NCT03363854|Placebo Comparator|Placebo(initial)responders-> Placebo(continuation A)|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A."
3131680|NCT03363906|Experimental|Dulaglutide (Reference)|Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods
3131681|NCT03363906|Experimental|Dulaglutide (Test)|Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods
3131682|NCT03364023||Acute Ischemic Stroke Patients|Acute Ischemic Stroke (AIS) patients treated with Medtronic Market-Released Neurothrombectomy Device
3131683|NCT03364036|Experimental|Mavenclad®|
3131684|NCT03364049|Experimental|MK-7162 25 mg +Pembrolizumab (Pembro)|Participants receive MK-7162 25 mg via oral tablets once daily (QD) throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 25 mg orally QD PLUS pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (every 3 weeks [Q3W]).
3131685|NCT03364049|Experimental|MK-7162 50 mg + Pembro|Participants receive MK-7162 50 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-71625 50 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
3131686|NCT03364049|Experimental|MK-7162 100 mg + Pembro|Participants receive MK-7162 100 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 100 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
3131687|NCT03364049|Experimental|MK-7162 200 mg + Pembro|Participants receive MK-7162 200 mg via oral tablets QD throughout the 3-week cycle. Cycles 2 through 36: Participants receive MK-7162 200 mg orally QD PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle Q3W
3131688|NCT03364192|Experimental|Peer-delivered Whole Health Coaching|Whole Health Coaching is a Veterans Health Administration variation of integrative health coaching. For this study it will be administered by a peer support specialist.
3131689|NCT03364309|Experimental|Ixekizumab 80mg Q4W|Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.
3131690|NCT03364309|Experimental|Ixekizumab 80mg Q2W|Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.
3131691|NCT03364309|Placebo Comparator|Placebo|Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.
3321383|NCT02018510|Experimental|Groups 1B|HIV-uninfected individuals 3 mg/kg, single dose IV administration of 3BNC117
3131692|NCT03364335|Placebo Comparator|Placebo|Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.
3131693|NCT03364335|Experimental|Leu Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil
3131694|NCT03364335|Experimental|Leu Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil
3131695|NCT03364335|Experimental|Leu Met Sil 1.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil
3131696|NCT03364335|Experimental|Leu Met Sil 4.0mg|3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil
3131697|NCT03364608|Experimental|• AS MDI 90 µg|(2 actuations of 45 µg/actuation)
3131698|NCT03364608|Experimental|• AS MDI 180 µg|(2 actuations of 90 µg/actuation)
3131699|NCT03364608|Placebo Comparator|• Placebo MDI|(2 actuations)
3131700|NCT03364608|Active Comparator|• Proventil 90 µg|(1 actuation of 90 µg/actuation)
3131701|NCT03364608|Active Comparator|• Proventil 180 µg|(2 actuations of 90 µg/actuation)
3131702|NCT03364673|Experimental|Fitness Tracker + Social Incentive Intervention|Participants will enroll with a teammate (i.e. family or friend) and collaborate together. Teams will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive a social incentive intervention.
3131703|NCT03364738|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) subcutaneous (SC) injection in the thigh (alternate thigh every day) once daily (QD) of an escalating dose from 50 microgram (mcg) to a maximum of 100 mcg increased in increments of 25 mcg no more frequently than every 2 to 4 weeks, with the goal of achieving or maintaining albumin-corrected serum calcium (ACSC) levels in the range of 2-2.25 millimoles per liter (mmol/L) (8.0-9.0 milligrams per deciliter [mg/dL]). Once a participant achieves a stable ACSC (2-2.25 mmol/L [8.0-9.0mg/dL]) and has minimized supplement doses, they will be maintained at that dose of rhPTH(1-84). If ACSC is greater than (>) 2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be administered.
3131704|NCT03364751|Active Comparator|IQOS arm|~86 patients, switching from cigarette smoking to IQOS use.
3131705|NCT03364751|Active Comparator|Cigarette arm|~86 patients, continuing cigarette smoking.
3131706|NCT03365011|Placebo Comparator|Placebo|"Placebo was defined as 50% nitrogen and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
3131707|NCT03365011|Experimental|Nitrous oxide|"Nitrous oxide treatment was defined as 50% nitrous oxide and 50% oxygen for 40 minutes.~Participants are blinded to the order of interventions administered. Participants have been informed prior to consent that one session will contain the nitrous oxide gas mixture, and the other session will contain the placebo gas mixture."
3131708|NCT03365154|Experimental|Treatment Group|Patients with occlusive arterial disease who meet the study criteria and provide informed consent will receive atherectomy treatment with the investigational device.
3131709|NCT03365778|Active Comparator|Patient Educational Intervention group|Patients receive educational materials regarding selective laser trabeculoplasty (SLT) versus topical medication (ophthalmic eye drops) to lower eye pressure.
3131710|NCT03365778|Placebo Comparator|Usual care group|Patients receive standard of care.
3131711|NCT03365778|Other|Ophthalmologist Educational Intervention group|General ophthalmologists, ophthalmology residents, and glaucoma specialists in the Wills Eye Hospital physician contact database receive online survey and educational slide presentation regarding selective laser trabeculoplasty (SLT).
3131712|NCT03365791|Experimental|PDR001+LAG525|PDR001 and LAG525 administered via i.v. infusion over 30 minutes once every 3 weeks (Q3W). LAG525 was given first followed by PDR001.
3131713|NCT03365934|Experimental|ADHESIVE BANDAGE #1|bandage applied to wounded site.
3131714|NCT03365934|Experimental|ADHESIVE BANDAGE #2|bandage applied to wounded site.
3131715|NCT03365934|Experimental|ADHESIVE BANDAGE #3|bandage applied to wounded site
3131716|NCT03365934|Experimental|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied to wounded site
3131717|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
3131718|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded and no bandage applied, serving as a positive control site.
3131719|NCT03366207|Experimental|Ciprofloxacin|Ciprofloxacin for the treatment of uncomplicated urinary tract infection
3131720|NCT03366298|Active Comparator|1|Visit 1: Emerade 300mcg then Epipen 0.3mg Visit 2: Emerade 500mcg
3131721|NCT03366298|Active Comparator|2|Visit 1: Epipen 0.3mg then Emerade 300mcg Visit 2: Emerade 500mcg
3131722|NCT03366298|Active Comparator|3|Visit 1: Emerade 500mcg Visit 2: Emerade 300mcg then Epipen 0.3mg
3131723|NCT03366298|Active Comparator|4|Visit 1: Emerade 500mcg Visit 2: Epipen 0.3mg then Emerade 300mcg
3131724|NCT03366428|Experimental|All Participants|All participants will receive DS-8201a by intravenous infusion
3131725|NCT03367793|Experimental|Clinical, then Metric #1, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #1, and lastly the metric-derived #2.
3321384|NCT02018510|Experimental|Group 1C|HIV-uninfected individuals 10 mg/kg, single dose IV administration of 3BNC117
3131726|NCT03367793|Experimental|Clinical, then Metric #2, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the clinically derived prescription first, followed by the metric-derived #2, and lastly the metric-derived #1.
3131727|NCT03367793|Experimental|Metric #1, then Clinical, then Metric #2|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #2 prescription.
3131728|NCT03367793|Experimental|Metric #2, then Clinical, then Metric #1|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the clinically derived prescription, and lastly the metric-derived #1 prescription.
3131729|NCT03367793|Experimental|Metric #1, then Metric #2, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #1 prescription first, followed by the metric-derived #2 prescription, and lastly the clinically derived prescription.
3131730|NCT03367793|Experimental|Metric #2, then Metric #1, then Clinical|Each subject will receive all three spectacle prescription interventions dispensed in randomized order for 2 months of wear each. Subjects in this arm of the study will receive the metric-derived #2 prescription first, followed by the metric-derived #1 prescription, and lastly the clinically derived prescription.
3131731|NCT03368053|Experimental|GSKSB732461 Group|Healthy HIV uninfected volunteers who participated in study PRO HIV-002 between February 2003 and February 2005 and who were vaccinated with at least 3 doses of the GSKSB732461 vaccine candidate in the PRO-HIV-002 study.
3131732|NCT03368170|Experimental|Mesdopetam (IRL790)|Capsule 2.5 mg, oral administration
3131733|NCT03368170|Placebo Comparator|Placebo|Identical capsule, oral administration
3131734|NCT03368235|Experimental|AZD9567|oral suspension of 40 mg AZD9567 once daily (OD) for two weeks
3131735|NCT03368235|Active Comparator|Prednisolone|oral OD treatment of 20 mg prednisolone administered as capsules
3131736|NCT03368807||Blinded CGM (Continuous Glucose Monitoring)|Participants received Insulin lispro 100 U/mL (units per millilitre) injected via the pen and they were blinded to CGM device recording as directed in study period 1.
3131737|NCT03368807||Unblinded CGM|Participants received Insulin lispro 100 U/mL injected via the pen and they were unblinded to CGM device recording as directed in study period 2.
3131738|NCT03368859|Experimental|ABT-165 plus FOLFIRI|ABT-165 plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
3131739|NCT03368859|Active Comparator|Bevacizumab plus FOLFIRI|Bevacizumab plus FOLFIRI (irinotecan, leucovorin, fluorouracil).
3131740|NCT03368898||Estradiol valerate|Women who were treated with E2V for HMB for 3 months.
3131741|NCT03368898||LNG-IUD|Women who were treated with LNG-IUD for HMB for 4 years.
3131742|NCT03368898||Micronized Progesterone|Women who were treated with Micronized Progesterone for HMB for 3 months.
3131743|NCT03368937|Experimental|Tandem t:slim X2 with Control-IQ Technology|Subjects will use the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
3131744|NCT03369158|Experimental|MySpine|"Patients operated for spinal stabilization through patient specific pedicle screw guide MySpine"
3131745|NCT03369158|Active Comparator|Free hand technique|Patients operated for spinal stabilization through standard free hand technique
3131746|NCT03369236|Active Comparator|Danicopan (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Danicopan was administered at a starting dose of 100 milligrams (mg) 3 times daily (TID) for the first 2 weeks, then dosage was to be increased to 200 mg TID for the remainder of the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
3131747|NCT03369236|Placebo Comparator|Placebo (Double-blind Treatment Period), Followed by Danicopan (Open-label Extension Period)|"Placebo was administered TID during the 6-month treatment period.~All participants who completed the double-blind treatment period were enrolled in the open-label extension period and were to receive danicopan 200 mg TID."
3131748|NCT03369340|Active Comparator|Product Sequence 1|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4"
3131749|NCT03369340|Active Comparator|Product Sequence 2|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4"
3131750|NCT03369340|Active Comparator|Product Sequence 3|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4"
3131751|NCT03369340|Active Comparator|Product Sequence 4|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4"
3131752|NCT03369340|Active Comparator|Product Sequence 5|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4"
3131753|NCT03369340|Active Comparator|Product Sequence 6|"Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:~P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4"
3131754|NCT03369418|Active Comparator|Active|Subjects will be given an Alpha-Stim active device for daily treatment. The electrodes attached to the device will be active. The device frequency is preset to 0.5 Hz and 100 microampere and treatment is one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur.
3321385|NCT02018510|Experimental|Group 1D|HIV-uninfected individuals 10 mg/kg, two doses IV of 3BNC117
3131755|NCT03369418|Sham Comparator|Inactive|"Subjects will be given an Alpha-Stim inactive device for daily treatment. The electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive. The frequency on the device will state 0.5 Hz and 100 microampere but it will not actually emit anything. Subjects in this group will receive treatment one hour daily. The subjects will be instructed that the device is set to a low level so that the current is not detectable but should still be effective. The current will not be detectable in both active and sham devices in order for adequate blinding to occur."
3131756|NCT03369704|Experimental|Omalizumab|Eligible patients randomized to this arm received omalizumab subcutaneously for 12 weeks
3131757|NCT03369704|Placebo Comparator|Placebo|Eligible patients randomized to this arm received placebo subcutaneously for 12 weeks
3131758|NCT03369756|Other|Prontosan Solution and Gel|Treatment with Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel over 4 week period
3131759|NCT03369951|Experimental|Minocin® IV|200 mg minocycline hydrochloride IV infusion over approximately 60 minutes, n=50
3131760|NCT03370042|Active Comparator|Semilunar Coronally Positiones Flap + Free Gingival Graft|semilunar coronally positioned flap with free gingival graft for root coverage
3131761|NCT03370042|Sham Comparator|Semilunar Coronally Positioned Flap|semilunar coronally positioned flap alone without free gingival graft for root coverage
3131762|NCT03370289|Experimental|BLB-750 Qinghai RG strain|Two doses of BLB-750 Qinghai reverse genetics (RG) strain at a vaccination dose of 0.5 mL (HA antigen level of 7.5 µg per strain) will be injected into the upper arm muscle (the deltoid muscle) at 3-week intervals (Day 1 and Day 22) in a treatment period of 43 days.
3131763|NCT03370302|Experimental|TAK-228 Once Daily|TAK-228, milled capsule, orally, once daily, on an empty stomach in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 2 milligram (mg) in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 2 mg, once daily, is safe and tolerable, then the dose will be escalated to 4 mg, once daily, until RP2D is determined.
3131764|NCT03370302|Experimental|TAK-228 Once Weekly|TAK-228, milled capsule, orally, once weekly, on an empty stomach in Cycle 1 of a 28-day treatment cycle and following a light meal from Cycle 2 for up to 12 months or until disease progression or unacceptable toxicity or withdrawal of consent with a starting dose of 20 mg in Cohort 1. Dose escalation will follow a standard 3+3 schema. If 20 mg, once weekly, is safe and tolerable, then the dose will be escalated to 30 mg, once weekly, until RP2D is determined.
3131765|NCT03370419|Experimental|The Pick Two to Stick To|Participants are asked to participate in five health-coaching sessions and to return in Week 20 for follow-up data collection. The initial face-to-face coaching session lasts approximately 90 minutes with subsequent telephone sessions lasting approximately 20 minutes. Coaching sessions will include education about MetS, weight loss, dietary and physical activity recommendations, and the principles of habit development, guidance in forming implementation intentions for each self-selected habit, and identifying routines and contextual cues that could be modified to support habit development Coaching sessions are augmented with a participant workbook. Participants' also receive individually tailored study text messages to maintain their motivation.
3131766|NCT03370419|Other|Usual Care|Participants receive usual care only.
3131767|NCT03370471|Experimental|Healthy Older Adults|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
3131768|NCT03370471|Experimental|Individuals with Aphasia|"Participants complete all four interventions~Retrieval Practice + Moderate Intensity Exercise: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)~Retrieval Practice + Gentle Stretching: Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning using Retrieval Practice (active retrieval during learning)~Study Only + Moderate Intensity Exercise: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)~Study Only + Gentle Stretching: Subjects will engage in 30 minutes of gentle stretching prior to word learning using Study Only (no active retrieval during learning)"
3131769|NCT03370770||patients with EGFR mutation-positive NSCLC|(Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)
3131770|NCT03371355|Placebo Comparator|Pooled Placebo|Participants from each cohort received placebo at a dose-matched volume of study drug, subcutaneously (SC).
3131771|NCT03371355|Experimental|Cohort B: ISIS 703802, 40 mg Q4W|Participants received ISIS 703802, 40 milligrams (mg) SC once every 4 weeks for 6 doses.
3131772|NCT03371355|Experimental|Cohort C: ISIS 703802, 80 mg Q4W|Participants received ISIS 703802, 80 mg SC once every 4 weeks for 6 doses.
3131773|NCT03371355|Experimental|Cohort A: ISIS 703802, 20 mg QW|Participants received ISIS 703802, 20 mg once every week for 26 doses.
3131774|NCT03371381|Experimental|Nivolumab + JNJ-64041757|Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
3131775|NCT03371381|Active Comparator|Nivolumab|Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study.
3131776|NCT03371459|Experimental|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
3131777|NCT03371459|Active Comparator|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
3131778|NCT03371732|Other|Groupe 1|G1 : Motivational Intervention group
3131779|NCT03371732|Other|Groupe 2|G2 : Educational advises group
3131780|NCT03371836|Other|Clobazam|open label (single treatment arm)
3131781|NCT03372083|Experimental|Deferasirox|Crushed deferasirox (ICL670) FCT for oral use daily. Deferasirox FCT dosing was based on subject's weight.
3131782|NCT03372096|Experimental|All patients|Patients will receive the Prostatic Artery Embolization procedure.
3131783|NCT03372369|Active Comparator|CDC Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view CDC poster for contraceptive effectiveness.
3131784|NCT03372369|Experimental|Patient-Centered Poster|After collecting baseline contraceptive knowledge, method preference, if participant were to switch methods during the next year, and current perceived pregnancy risk, participants will view Patient-Centered poster for contraceptive effectiveness.
3131785|NCT03372382|Active Comparator|ibuprofen plus acetaminophen|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen
3131786|NCT03372382|Experimental|ibuprofen plus acetaminophen/hydrocodone|women that had a C-section will be discharged home with prescriptions for ibuprofen and acetaminophen/hydrocodone (Norco)
3131787|NCT03372434|Experimental|Investigational Lens Device #1|Investigational Intraocular Lens Device #1: Model ZFR00
3131788|NCT03372434|Experimental|Investigational Lens Device #2|Investigational Intraocular Lens Device #1: Model ZYR00
3131789|NCT03372434|Active Comparator|Control Device|Control TECNIS Multifocal Intraocular Lens Model ZLB00
3131790|NCT03372551|Experimental|somofilcon A 1 day test lens|Subjects wearing the somofilcon A 1 day test lens for one week, either randomized as the first or second pair.
3131791|NCT03372551|Active Comparator|somofilcon A 1 day control lens|Subjects wearing the somofilcon A 1 day control lens for one week, either randomized as the first or second pair.
3131792|NCT03372603|Experimental|Treatment Sequence AB|Subjects will receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days).
3131793|NCT03372603|Experimental|Treatment Sequence BA|Subjects will receive 4.8 mg (two tablets of 2.4 mg) GSK2798745 on Day 1, followed by 2.4 mg GSK2798745 tablets once daily for 6 days via oral route (treatment period of total 7 days). After a washout period of 14 to 21 days, subjects will then receive GSK2798745 matching placebo tablets (two tablets on Day 1 followed by one tablet once daily for 6 days), via oral route (treatment period of total 7 days).
3131794|NCT03372928|Experimental|Standard EAA Dose|EAA dose provided at 0.10 g/kg body mass
3131795|NCT03372928|Experimental|High EAA Dose|EAA dose provided at 0.30 g/kg body mass
3131796|NCT03373006|Experimental|Men with Gleason Score 7 prostate cancer|Men seeking focal therapy for Gleason Score 7 prostate cancer will receive Axumin PET/CT imaging to detect metastasis which will result in exclusion from laser focal therapy.
3131797|NCT03373110|Experimental|Online Mindfulness Based Cognitive Therapy +Fitbit|A central aspect of MBCT is the concept of awareness. Participants practice a variety of meditation types (e.g. breath awareness) and learn to bring mindfulness to everyday situations. Awareness will be directed to elements in participants' lives that interfere with living a more productive, physically active life (e.g. thoughts and feelings that interfere with becoming more physically active; stressful situations and circumstances that prevent them from engaging in exercise). Two hundred participants will be randomized into this group.
3131798|NCT03373110|Experimental|Online Cognitive Behavioral Therapy +Fitbit|1)identifying and setting realistic exercise-based goals and intermediate goals (to maximize success to increase motivation); (2) behavioral scheduling to optimize when to exercise, identify rewards for exercising, and problem solve obstacles to exercising; and (3) identify dysfunctional, maladaptive thoughts about exercise (which decrease motivation) and skills to identify more adaptive, positive thoughts (to overcome thoughts of being too tired or too stressed to exercise). Two hundred participants will be randomized into this group.
3131799|NCT03373110|Active Comparator|Fitbit Alone|Participants assigned to the Fitbit-only control study group you will not be receiving therapy. However, they will receive a Fitbit, which they will be asked to wear over the course of 16 weeks as well as to complete the same schedule of assessments as the therapy arms. One hundred participants will be randomized into this group.
3131800|NCT03373162|Experimental|MRI Scans Pre and Post-Botox Injection|Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.
3131801|NCT03373240|Experimental|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on learning and decision making.
3131802|NCT03373240|Placebo Comparator|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
3131803|NCT03373383|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
3131804|NCT03373383|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
3131805|NCT03373383|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
3131806|NCT03373383|Experimental|Padsevonil dosing regimen 4|Subjects will be randomized to receive a combination of tablets of Padsevonil and Placebo (as appropriate) to maintain the blinding.
3131807|NCT03373383|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several Placebo tablets to maintain the blinding.
3131808|NCT03373591|Experimental|Liposomal Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with liposomal bupivacaine (LB). The solution used to perform the TAP block with LB will comprise of 20mL of liposomal bupivacaine solution, 30mL of 0.25% bupivacaine, and 100mL of normal saline.
3131809|NCT03373591|Active Comparator|Regular Bupivacaine TAP block|Patients will be randomized to receive an intraoperative transverse abdominis peritoneal (TAP) block with regular bupivacaine (RB).The solution used to perform the TAP block with RB will comprise of 50mL of 0.25% bupivacaine and 100mL of normal saline.
3131810|NCT03373591|No Intervention|No TAP block|Patients will be randomized to receive no TAP block as a control group.
3131811|NCT03373890|Experimental|Short burst Interval Treadmill Training High Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
3131812|NCT03373890|Active Comparator|Short Burst Interval Treadmill Training Low Frequency|Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks
3131813|NCT03374176|Active Comparator|AMX-MET|"AMX-MET Amoxicillin 500 mg + Metronidazole 250 mg. Capsules.~1 capsule tid during 7 days."
3131814|NCT03374176|Experimental|Clindamycin|"Clindamycin Clindamycin 300 mg + placebo. Capsules.~1 capsule tid during 7 days."
3131815|NCT03374189|Experimental|EZ Close arm|EZ close used for port-site closure.
3131816|NCT03374189|Active Comparator|Carter Thomason arm|Carter Thomason used for port-site closure.
3131817|NCT03374358|No Intervention|No intervention arm.|Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).
3131818|NCT03374358|Experimental|Raltegravir arm.|Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).
3131819|NCT03374488|Experimental|Pembrolizumab 200 mg + Epacadostat 100 mg BID|Pembrolizumab + epacadostat
3131820|NCT03374488|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
3131821|NCT03374683|Experimental|RR Digital Tool|Participants in the RR digital tool were provided with a link to the web-based intervention (https://outsideplay.ca) to complete within one week.
3131822|NCT03374683|Active Comparator|RR In-Person Workshop|Participants in the in-person workshop attended the 45-90 minute in-person workshop.
3131823|NCT03374683|Sham Comparator|Position Statement on Active Outdoor Play|Participants in the control condition were provided with a web link to the Position Statement on Active Outdoor Play, which includes information on research and recommendations for action.
3131824|NCT03374995|Experimental|Group I (topical keratin)|Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).
3131825|NCT03374995|Active Comparator|Group II (standard of care)|Patients receive standard of care as directed by radiation oncologist until the end of radiation therapy (approximately 3-6 weeks).
3131826|NCT03375294|Experimental|Nitrous Oxide|PTSD patients in this arm will receive a single inhalation dose of 50% nitrous oxide and 50% oxygen for 1 hour
3131827|NCT03376061|Active Comparator|TA Topical|1 syringe of 50ml of topical Tranexamic Acid (5g) or placebo. The topical will be poured into the pericardial mediastinal cavities in 2 equal doses, 25ml when the pt comes off-pump and the other 25ml before sternotomy is closed.
3131828|NCT03376061|Active Comparator|TA Intravenous|2 syringes of 50ml (5mg) Tranexamic Acid for intravenous injection or placebo.
3131829|NCT03376256|Experimental|Phase A - Thoracic ES with LOR|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until loss of resistance (LOR) is perceived to identify the thoracic epidural space (ES). The Compuflo Epidural Instrument will be used to record pressure readings. The thoracic epidural procedure will then continue per standard of care.
3131830|NCT03376256|Experimental|Phase B - Thoracic ES with Compuflo|Patients will receive thoracic epidural anesthesia. The thoracic epidural needle will be introduced until the Compuflo Epidural Instrument indicates that pressure has decreased. The loss of resistance technique will then be used to identify the thoracic epidural space. The thoracic epidural procedure will then continue per standard of care.
3131831|NCT03376295||Subjects diagnosed with COPD|Chronic obstructive pulmonary disease
3321386|NCT02018510|Experimental|Group 1E|HIV-uninfected individuals 30 mg/kg, single dose IV administration of 3BNC117
3131832|NCT03376321|Experimental|Treatment Arm 1 (pimodivir + Standard-of-Care [SOC] treatment)|Participants will receive pimodivir 600 milligram (mg) orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in the protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment is determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of SOC cannot be changed (example, switching one influenza antiviral for another) during either treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in case of suspected adverse event (AE).
3131833|NCT03376321|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until morning of Day 6) along with SOC treatment. Participants who meet all treatment extension criteria as defined in protocol may receive an additional 5 day course of same treatment as received at study start. The SOC treatment determined by investigator based on local practice, may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than day of first study drug intake. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either treatment period/extension phase, with the exception that an influenza antiviral may be discontinued in case of a suspected AE.
3131834|NCT03376516|Experimental|All patients|All patients will receive Wilate for prophylactic treatment. Patients will also receive Wilate for treatment of breakthrough bleeding events as required
3131835|NCT03377127|Active Comparator|Standard of Care (SOC)|The control group patients will be managed by their assigned PCPs, per Standard of Care (SOC), per American Diabetes Association Guidelines. Management per standard of care includes referrals to ophthalmology for dilated eye exam, nephrology for nephropathy management, cardiology for macrovascular complications management, neurology for neuropathy or neurologic complications, diabetic education, laboratory studies, and vaccinations and will be ordered or performed at the discretion of each patient's PCP
3131836|NCT03377127|Experimental|SOC and PMDC|The intervention group patients will be managed by their assigned primary care physicians (PCPs), per American Diabetes Association Guidelines for Standard of Care (SOC) and will have scheduled six extra face-to-face visits with the pharmacists for the 6 month duration of the intervention. The pharmacy managed diabetes clinic (PMDC) visit encounters will focus on patient identified goals for the management of their diabetes. Pharmacists have the discretion to make medication adjustments and initiate new medications pertinent to the management of diabetic comorbidities. The model is a collaborative practice agreement between the pharmacist and the primary care physician.
3131837|NCT03377244|Experimental|HBHS|Participants in the Healthy Bodies Healthy Souls (HBHS) arm received the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) with the addition of church-level policy changes to support the individual behavioral intervention of the WORD DPP. The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length. Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
3131838|NCT03377244|Active Comparator|HBHS Policy|Participants in the HBHS Policy arm included members of churches enrolled in the HBHS study who did not receive the WORD DPP intervention (ie, these participants were exposed to only the church-level policy changes). Church-level changes to support healthier behaviors include improvements in food purchasing and preparation for events, physical activity programs, and increased congregational engagement in health promotion activities.
3131839|NCT03377244|Other|WORD DPP|Participants in the Wholeness, Oneness, Righteousness, Deliverance Diabetes Prevention Program Lifestyle Intervention (WORD DPP) arm included participants enrolled in a separate DPP study without the church-level policy changes (ie, these participants received only the WORD DPP intervention). The WORD DPP is a faith-based diabetes prevention curriculum that teaches participants to connect faith and health to have a healthy weight, eat healthy, and be physically active. The WORD DPP-LI includes 16 modules that are intended to be delivered over a 24 week period, each module approximately 90 minutes in length.
3131840|NCT03377556|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3131841|NCT03377634|Experimental|Intervention|Participants receive the MORPH intervention.
3131842|NCT03377634|No Intervention|Control|The wait list control participants receive usual care and are offered intervention materials on completion of the study.
3131843|NCT03378076|Experimental|FX006 32 mg|Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)
3131844|NCT03378076|Active Comparator|TAcs 40 mg|Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)
3131845|NCT03378635|Experimental|Dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
3131846|NCT03378635|Placebo Comparator|Placebo|Single fixed dose (s.c.injection) of placebo
3131847|NCT03378635|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
3131848|NCT03378921|Experimental|donors feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
3321387|NCT02018510|Experimental|Group 1F|HIV-uninfected individuals 30 mg/kg, two doses IV of 3BNC117
3131849|NCT03378921|Placebo Comparator|patients own feces|Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
3131850|NCT03378973|Experimental|High dose dexmedetomidine|Patients will receive dexmedetomidine 0.5 mcg/kg/hr plus propofol 50 mcg/kg/min
3131851|NCT03378973|Active Comparator|Low dose dexmedetomidine|Patients will receive dexmedetomidine 1.0 mcg/kg/hr plus propofol 25 mcg/kg/min
3131852|NCT03379259|Experimental|Phase 1A: BGB-A333 monotherapy dose escalation|
3131853|NCT03379259|Experimental|Phase 2A: BGB-A333 monotherapy dose expansion|
3131854|NCT03379259|Experimental|Phase 1B: BGB-A333 and BGB-A317 dose confirmation|
3131855|NCT03379259|Experimental|Phase 2B: BGB-A333 and BGB-A317 dose expansion|
3131856|NCT03379376|Experimental|Supportive Care (eMMB)|Participants receive a self-directed 20-minute eMMB video and are instructed to practice eMMB at least once before surgery and daily for 2 weeks after surgery. Participants may also request additional guidance from a yoga instructor via telephone and video conference before surgery and again 1 day after surgery or as soon as feasible.
3131857|NCT03379506|Experimental|EBR/GZR|Pediatric participants receive EBR/GZR as either FDC tablets or oral granules once daily for 12 weeks. A 24-week follow-up period will follow the 12-week treatment regimen.
3131858|NCT03379545|Other|3D MR and 3D CT Imaging|All shoulder arthroplasty candidates with glenohumeral osteoarthritis will be receiving both 3D computed tomography (CT) and 3D non-contrast magnetic resonance (MR) imaging.
3131859|NCT03379662|Experimental|Erchonia HLS Laser|The Erchonia HLS Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
3131860|NCT03379662|Placebo Comparator|Placebo Laser|The Placebo Laser is administered 8 times across 4 weeks for 5 minutes each time to the skull at the base of the brain and temporal areas.
3131861|NCT03379740|Experimental|Product Exposure Sequence 1|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%; P4M3-1.7%LA; P4M3-3%LA; and P4M3-4%LA"
3131862|NCT03379740|Experimental|Product Exposure Sequence 2|"Subjects will be randomized to follow a sequence of product exposure comprised of :~Subject's own e-cigarette; P4M3-1.7%LA; P4M3-1.7%; P4M3-3%LA; and P4M3-4%LA"
3131863|NCT03379753|Experimental|Intervention group|Those patients randomized to intervention group will be exposed to the diad of music and positive images in a private hospital room in addition to receiving standard care.
3131864|NCT03379753|No Intervention|Control group|Those patients randomized to control group will receiving standard care in a private hospital room with an un-modified post operative environment.
3131865|NCT03380000|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
3131866|NCT03380000|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
3131867|NCT03380026|Experimental|Valchlor 0.016% Topical Gel|0.016% w/w topical mechlorethamine gel applied over a minimum of 8 cm2, nightly, over a period of 4 months.
3131868|NCT03380026|Active Comparator|Valchlor plus Triamcinolone|0.016% w/w topical mechlorethamine gel (once, nightly) and Triamcinolone acetonide 0.1% ointment (up to three times daily) applied in over a minimum of 8 cm2, over a period of 4 months.
3131869|NCT03380091|Experimental|Metformin|Metformin 1000 mg PO bid
3131870|NCT03380091|Experimental|Vitamin D (Cholecalciferol)|Cholecalciferol 5,000 IU PO daily
3131871|NCT03380390|Experimental|Oxymetazoline + Energy-Based Therapy|Participants will receive energy-based therapy (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL]) plus once daily application of oxymetazoline hydrochloride (HCl) cream 1.0%.
3131872|NCT03380429|Experimental|Data on Maintenance use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone and to the subject's HCP via an online dashboard.
3131873|NCT03380429|Experimental|Data on Maintenance use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensor attached to RELVAR/BREO ELLIPTA will be fed back to the subject via an app on smart phone.
3131874|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject and HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to both subject and HCP. The data will be fed back to the subject through an app and to HCP through an online dashboard.
3131875|NCT03380429|Experimental|Data on Maintenance and Rescue use supplied to Subject|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Information from sensors attached to RELVAR/BREO ELLIPTA and salbutamol MDI will be fed back to subject through an app.
3131876|NCT03380429|Active Comparator|No data supplied to Subject or HCP|Eligible subjects will receive RELVAR/BREO maintenance therapy via ELLIPTA DPI and salbutamol rescue medication via MDI with sensors attached to both inhalers. Subjects will be provided with a home hub through which their data will be uploaded during the study but the subjects and their HCP will not be able to view the data.
3131877|NCT03380572|Experimental|Senhance Cholecystectomy|Cholecystectomy operation performed using Senhance robotic system
3131878|NCT03380572|Active Comparator|Laparoscopic Cholecystectomy|Cholecystectomy operation performed using standard laparoscopic instruments
3131879|NCT03380624|Experimental|Refresh Optive, then Refresh Optive MEGA-3|"Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.~."
3131880|NCT03380624|Experimental|Refresh Optive MEGA-3, then Refresh Optive|Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.
3131881|NCT03380780|Experimental|Emicizumab|
3131882|NCT03380845|Active Comparator|Fraxel Restore on one side of the face|"Fraxel Restore on one side of the face~Fraxel Restore: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
3131883|NCT03380845|Active Comparator|Fractora on the other side of the face|"Fractora on the other side of the face~Fractora: acne scar correction~Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned."
3131884|NCT03381196|Experimental|Treatment Arm 1 (pimodivir + SOC treatment)|Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).
3131885|NCT03381196|Placebo Comparator|Treatment Arm 2 (placebo + SOC treatment)|Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
3131886|NCT03381248|Experimental|Cooled Radiofrequency|Cooled radiofrequency energy will be delivered to study subjects' knees to ablate culprit sensory nerves and reduce knee pain
3131887|NCT03381248|Active Comparator|Hyaluronic Acid Injection|Hyaluronic acid injections will be administered to study subjects' knees to reduce knee pain
3131888|NCT03381339|Experimental|Powered toothbrush intervention|Subjects will be provided an oscillating rotating powered toothbrush as the experimental intervention, and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
3131889|NCT03381339|No Intervention|Manual toothbrush|Subjects will be provided a manual toothbrush as the control group and given written instructions on its proper use. Efficacy of overnight plaque reduction will be assessed at baseline and both gingivitis and plaque reduction will be assessed as change from baseline at 2, 4 and 12 weeks. Subjects will be given a standard fluoride toothpaste and asked to refrain from daily interproximal plaque control for the duration of the study.
3131890|NCT03381742|Experimental|ticagrelor 45mg bidpo.|To observe the efficacy and safety of ticagrelor 45mg bidpo. in patients with coronary artery disease.
3131891|NCT03381742|Experimental|ticagrelor 90mg qdpo.|To observe the efficacy and safety of ticagrelor 90mg qdpo. in patients with coronary artery disease.
3131892|NCT03381742|Active Comparator|ticagrelor 90mg bidpo.|To observe the efficacy and safety of ticagrelor 90mg bidpo. in patients with coronary artery disease.
3131893|NCT03381742|Active Comparator|clopidogrel 75mg qdpo.|To observe the efficacy and safety of clopidogrel 75mg qdpo. in patients with coronary artery disease.
3131894|NCT03381989|Experimental|Single arm: open-label treatment|The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
3131895|NCT03382262|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
3131896|NCT03382262|Active Comparator|TAcs 40 mg|Single intra-articular (IA) injection of TAcs 40 mg
3131897|NCT03382418|Experimental|Group 1: gp145 C.6980 (high dose)|Participants will receive 300 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
3131898|NCT03382418|Experimental|Group 2: gp145 C.6980 (low dose)|Participants will receive 100 mcg of the gp145 C.6980 vaccine admixed with aluminum hydroxide adjuvant at Day 0 and Months 2 and 6.
3131899|NCT03382418|Placebo Comparator|Group 3: Placebo|Participants will receive placebo at Day 0 and Months 2 and 6.
3131900|NCT03382509|Experimental|Single Dose Group|
3131901|NCT03382509|Experimental|Multiple Dose Group|
3131902|NCT03382821|Active Comparator|Transforaminal ESI with dexamethasone|Group 1: Transforaminal cervical ESI with dexamethasone sodium phosphate
3131903|NCT03382821|Active Comparator|Transforaminal catheter-targeted ESI with triamcinolone|Group 2: Catheter-targeted cervical ESI with triamcinolone acetonide
3131904|NCT03382834|Experimental|Arm A: Tamoxifen + Vorinostat|From Day 0 to Day 38, participants will receive tamoxifen orally once a day. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
3131905|NCT03382834|Active Comparator|Arm B: Vorinostat alone|Day 0 to Day 38 will be an observation period with no tamoxifen. On Days 35 and 38, participants will receive a single dose of vorinostat orally.
3131906|NCT03382847|Experimental|Intervention arm|HCV negative patients will receive a heart transplant from a HCV positive donor. Post-transplant, there will be surveillance for the development of viremia, and treatment of viremia. Following treatment, there will be surveillance for a sustained virologic response to HCV treatment.
3131907|NCT03382899|Experimental|Pegilodecakin + Pembrolizumab|"Participants received pegilodecakin subcutaneously (SQ) at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Pembrolizumab administered as an intravenous (IV) infusion at 200 mg on Day 1 of a 21-day cycle."
3131908|NCT03382899|Active Comparator|Pembrolizumab|Participants received pembrolizumab as an IV infusion at 200 mg on Day 1 of a 21-day cycle.
3131909|NCT03382912|Experimental|Pegilodecakin+Nivolumab|"Participants received Pegilodecakin subcutaneously at 0.8 milligrams (mg) (≤80 kilograms (kg) body weight) or 1.6 mg (>80 kg body weight) once daily (QD) in the abdomen, thigh or back of upper arm.~Nivolumab administered on day 1 of each 14 or 28 day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every 2 weeks (Q2W), or 480 mg every 4 weeks (Q4W)."
3131910|NCT03382912|Active Comparator|Nivolumab|Participants received Nivolumab on day 1 of each 14- or 28- day cycle over approximately 30 minutes intravenous (IV) infusion at 240 mg every two weeks (Q2W), or 480 mg every 4 weeks (Q4W).
3131911|NCT03383146|Placebo Comparator|Placebo|Placebo injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
3131912|NCT03383146|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to 52 weeks. De novo (New) participants, who did not participate in the previous relamorelin studies, began the study with a 2-week placebo run-in.
3131913|NCT03383198|Active Comparator|Liposomal Bupivacaine Left|Liposomal Bupivacaine left injection. Liposomal Bupivacaine is injected on the left, Bupivacaine plus Dexamethasone on the right
3131914|NCT03383198|Active Comparator|Liposomal Bupivacaine Right|Liposomal Bupivacaine right injection. Liposomal Bupivacaine injected on the right, Bupivacaine plus Dexamethasone on the left
3131915|NCT03383523|Experimental|Part 1a - treatment A|5 mg emodepside LSF, fasted
3131916|NCT03383523|Experimental|Part 1a - treatment B|5 mg emodepside IR-tablet #406, fasted
3131917|NCT03383523|Experimental|Part 1a - treatment C|5 mg emodepside IR-tablet #416, fasted
3131918|NCT03383523|Experimental|Part 1b - treatment D|5 mg emodepside IR-tablet #406, fed
3131919|NCT03383523|Experimental|Part 1b - treatment E|5 mg emodepside IR-tablet #416, fed
3131920|NCT03383523|Experimental|Part 2 - treatment F|2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
3131921|NCT03383523|Experimental|Part 2 - treatment G|2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
3131922|NCT03383588|Active Comparator|bupivacaine 0.25%|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25%
3131923|NCT03383588|Active Comparator|bupivacaine 0.25% + epinephrine|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous bupivacaine (Marcaine) 0.25% with Epinephrine
3131924|NCT03383588|Placebo Comparator|Saline Solution|standard intrathecal bupivacaine (Marcaine) 0.75% 1.5-1.7 ml, intrathecal morphine (Duramorph) 150mcg plus intrathecal fentanyl 10 mcg + 20 ml subcutaneous NACL 0.9% (placebo)
3131925|NCT03383614|Experimental|cohort 1 (8 subjects)|6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo
3131926|NCT03383614|Experimental|cohort 2 (8 subjects)|6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo
3131927|NCT03383614|Experimental|cohort 3 (8 subjects)|6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo
3131928|NCT03383627|Experimental|Continuous glucose monitoring|"If subjects meet inclusion criteria then they will return to the research site on Day 1 to place Freestyle Libre Pro device by the research staff for 14-day monitoring.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis. On Day 14, blood will be drawn for HbA1c and fructosamine, The blood drawn for this research will be approximately 10-15 milliliters.~There are no drug washout periods. Subjects will continue to take all their medications and/or insulins as prescribed by their doctor.~Baseline data including age, race, ethnicity, past medical history, home medication list, and diabetes related laboratory data will be collected."
3131929|NCT03383692|Experimental|Cohort 1: DS-8201a + Ritonavir|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Ritonavir twice daily (BID) on Day 17 of Cycle 2 until Day 21 of Cycle 3
3131930|NCT03383692|Experimental|Cohort 2: DS-8201a + Itraconazole|DS-8201a will be administered as an intravenous (IV) solution once every 3 weeks (Q3W) + Itraconazole BID on Day 17 of Cycle 2 followed by 200 mg daily (QD) until Day 21 of Cycle 3
3131931|NCT03383757|Experimental|SpO2 Sensor Application & Blood draw|All subjects will undergo the same study procedures of having their SpO2 levels measured with an external sensor applied to the skin and blood SpO2 level measured
3131932|NCT03383783|Other|Treatment Period 1|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
3131933|NCT03383783|Other|Treatment Period 2|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
3131934|NCT03383783|Other|Treatment Period 3|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
3131935|NCT03383783|Other|Treatment Period 4|0 ppm F (placebo, negative control), 250 ppm F as NaF (dose-response control), 500 ppm F as NaF (dose-response control), 1100 ppm F as NaF (positive control)
3131936|NCT03383887|Placebo Comparator|Placebo|Placebo capsule 30 minutes before sleep
3131937|NCT03383887|Active Comparator|DAW1033D|DAW1033D capsule 30 minutes before sleep
3131938|NCT03384173|Experimental|NIRS monitoring|These infants will be monitored with NIRS
3131939|NCT03384316|Experimental|1/Arm 1-Dose De-Escalation|Dose De-Escalation
3131940|NCT03384316|Experimental|2/Arm 2 - Dose Expansion|Dose Expansion
3131941|NCT03384329|Experimental|Resveratrol Pill|
3131942|NCT03384329|Placebo Comparator|Placebo|
3131943|NCT03384693|Experimental|Prophylactic Defibrotide|6.25mg/kg administered intravenously every 6 hours for 28 to 35 days, starting on the day before conditioning is initiated.
3131944|NCT03384745|Experimental|M1095 (Sonelokimab) 30mg|M1095, 30 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
3131945|NCT03384745|Experimental|M1095 (Sonelokimab) 60mg|M1095, 60 mg, given at Week 0, 2, 4, 8, 12 and every four weeks.
3131946|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 1|M1095, 120 mg, given at Week 0, 2, 4, 8, 12 and every eight weeks.
3131947|NCT03384745|Experimental|M1095 (Sonelokimab) 120mg - regimen 2|M1095, 120 mg, given at Week 0, 2, 4, 6, 8, 10, 12 and every four weeks.
3131948|NCT03384745|Placebo Comparator|Placebo / M1095 (Sonelokimab) 120mg|Placebo, given at Week 0, 1, 2, 3, 4, 6, 8 and 10, then M1095, 120mg, given at Week 12, 14, 16, and every four weeks.
3131949|NCT03384745|Active Comparator|Secukinumab|Secukinumab, 300mg, given at Week 0, 1, 2, 3, 4, 8, 12 and every four weeks.
3131950|NCT03384940|Experimental|DS-8201a Cohort A|Cohort A is comprised of participants with HER2-positive (IHC 3+ or IHC 2+/ISH +) who will receive DS-8201a once every 3 weeks
3131951|NCT03384940|Experimental|DS-8201a Cohort B|Cohort B is comprised of participants with HER2 IHC 2+/ISH - who will receive DS-8201a once every 3 weeks
3131952|NCT03384940|Experimental|DS-8201a Cohort C|Cohort C is comprised of participants with HER2 IHC 1+ who will receive DS-8201a once every 3 weeks
3131953|NCT03384953|Experimental|Clinical Hypnosis - Group Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in a group setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
3131954|NCT03384953|Experimental|Clinical Hypnosis - Individual Treatment|Subjects will receive 8 weeks of a manualized clinical hypnosis for chronic pain treatment in an individual, 1:1 setting. Assessments will be completed before, immediately after, and at 3- and 6- months post-treatment to assess for treatment gains.
3131955|NCT03384966|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
3131956|NCT03384966|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
3131957|NCT03384966|Placebo Comparator|Placebo|Placebo matching ACT-246475 is supplied in sealed glass vials for reconstitution with water for injection. Placebo will be given as a single subcutaneous dose matching selatogrel to be administered in a volume of 0.8 mL. Administration will performed at the investigational site by qualified personnel.
3131958|NCT03386032|Experimental|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
3131959|NCT03386032|Sham Comparator|Placebo Cream|Placebo Cream will be applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
3131960|NCT03386032|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
3131961|NCT03386110|Experimental|Couples Health Project (CHP)|The CHP intervention is a three session intervention that occurs once a week for three weeks. The CHP intervention will be delivered by MI-trained mental health counselors. The CHP intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
3131962|NCT03386110|Active Comparator|Education|The Education intervention is a attention-matched control three-session intervention that occurs once a week for three weeks. The education intervention will be delivered by trained health educators. The education intervention is comprised of 3 sessions. 25 couples will be allocated to this arm.
3131963|NCT03386344|Placebo Comparator|Placebo|Following a 2 week run-in period, participants were randomized to matching placebo to sotagliflozin administered as 2 tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 106 weeks.
3131964|NCT03386344|Experimental|Sotagliflozin 200 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 200 mg administered as 1 sotagliflozin tablet and 1 matching placebo tablet, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
3131965|NCT03386344|Experimental|Sotagliflozin 400 mg|Following a 2 week run-in period, participants were randomized to Sotagliflozin 400 mg administered as two 200 mg sotagliflozin tablets, once daily, before the first meal of the day, for up to 26 weeks in the Core Treatment Period. Participants were eligible to continue treatment in the Extension Period. The total treatment duration was planned for up to 104 weeks.
3131966|NCT03386435|Experimental|RIPC|intervention: RIPC groups receive remote ischaemic preconditioning after anaesthesia induction and before surgery started.
3131967|NCT03386435|No Intervention|Control|In the control group, the same maneuver was applied but without cuff inflation.
3131968|NCT03386448|Placebo Comparator|control|Participants will receive placebo medication
3131969|NCT03386448|Experimental|Active|participants will receive active medications scopolamine and naltrexone
3131970|NCT03386474|Experimental|Brolucizumab|Brolucizumab 6 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8, and Week 16 or Week 20
3131971|NCT03386474|Other|Aflibercept|Aflibercept 2 mg solution for IVT injection, single injection at Day 1 (baseline), Week 8 and Week 16 to maintain the masking of the extension trial only.
3131972|NCT03386994||Idiopathic Pulmonary Fibrosis patients|all IPF patients
3131973|NCT03387020|Experimental|Treatment (ribociclib, everolimus)|Patients receive ribociclib PO QD on days 1-21 of course 1 and subsequent courses and days 2-21 of course 2, and everolimus PO QD on days 3-28 of course 1 and days 1-28 of subsequent courses. Patients who are undergoing surgery also receive ribociclib PO QD on days 7-10 before surgery. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 13 courses may continue receiving ribociclib and everolimus every 28 days for up to 13 additional courses in the absence of disease progression or unacceptable toxicity.
3131974|NCT03387033|Experimental|VR intervention session|The patients will give a pain score as well as fill out GAD-7 and PHQ-9 scores initially. The VR intervention session consists of relaxation narration WITH Virtual Reality session for 20 minutes while wearing the VR device. They will then be again asked to give a pain score and fill out GAD-7, PHQ-9, and PGIC.
3131975|NCT03387046|Experimental|D-aspartate + IFN beta-1a + Methylprednisolone|Participants received D-aspartate 2660 milligrams (mg) once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
3131976|NCT03387046|Placebo Comparator|Placebo + IFN beta-1a + Methylprednisolone|Participants received placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks along with IFN beta-1a subcutaneously (sc) at a dose of 44 microgram (mcg) three times a week (TIW) in participants without relapse and IFN beta-1a sc TIW plus Methylprednisolone 1000 mg intravenously once daily for 5 consecutive days in participants with relapse.
3131977|NCT03387267|Other|single-arm Dysphagia Detection System|An operationally seamless single-arm, prospective, multicenter, single-blinded for central outcomes assessors trial to test DDS in assessing swallowing safety and efficiency in patients at risk of oropharyngeal dysphagia.
3131978|NCT03387319|Experimental|Racialized Stressful Event Recall|Participants in this study are recall a stressful event related to race.
3131979|NCT03387319|Experimental|Non-racialized Stressful Event Recall|Participants in this study arm recall a stressful event unrelated to race.
3131980|NCT03387462|Experimental|DOT Diary Optimization Intervention|DOT Diary mobile app and Emtricitabine / Tenofovir Disoproxil Oral Tablet
3131981|NCT03387683|Placebo Comparator|placebo|placebo tablets once daily
3131982|NCT03387683|Experimental|dapagliflozin 10mg|dapagliflozin 10mg tablets once daily
3131983|NCT03388008|Active Comparator|Standard of care|Tacrolimus + Mycophenolate mofetil + prednisone from day 0 through day 365
3131984|NCT03388008|Experimental|Belatacept-based immunosuppression|Belatacept + Tacrolimus + prednisone from day 0 through day 89, then Belatacept + Mycophenolate mofetil + prednisone from day 90 through day 365
3131985|NCT03388164|Active Comparator|Escitalopram + RT2CK17|10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.
3131986|NCT03388164|Placebo Comparator|Escitalopram + Placebo|10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.
3131987|NCT03388268|Active Comparator|Oral vancomycin|125mg of oral vancomycin four times per day
3131988|NCT03388268|Placebo Comparator|Placebo|Placebo four times per day
3131989|NCT03388294|Experimental|PC followed by SR|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention pre-linguistic (PC) domain to identify their child's pre-linguistic communication bids during daily routines and respond to those bids in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on sensory reactivity bids.
3131990|NCT03388294|Experimental|SR followed by PC|Parents will be coached for 6 weekly sessions in the Parents and Infants Engaged (PIE) intervention sensory reactions (SR) domain to identify their child's sensory reactions to daily activities and respond to those reactions or modify the environment in ways that optimize parent-child engagement. After posttest 1, they will be coached for 6 weekly sessions on pre-linguistic communication bids.
3131991|NCT03388645|Experimental|Low Dose 10^6.3 PFU of RSV A2|Single intranasal dose of 10^6.3 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
3131992|NCT03388645|Experimental|High Dose 10^7 PFU of RSV A2|Single intranasal dose of 10^7 plaque forming units (PFU) of respiratory syncytial virus A2 (RSV A2) using a nasal atomizer on Day 0
3131993|NCT03389308|Experimental|Treatment period|"Subjects with active lesions as determined Investigator's clinical assessment, will initiate a cycle of applying diacerein 1% ointment once-daily, study medication, at home to their EBS lesions for 8 weeks.~Following the Treatment Period, subjects will go Off Treatment for 8 weeks using only investigator approved bland, non-medicated emollient/moisturizer, routine cleansing products and sunscreens. As determined Investigator's clinical assessment, subjects may enter into another Treatment Period of 8 weeks.~The duration of a subject's participation in the extension study may be as short as 32 weeks or as long as 52 weeks depending on the cycle initiation schedule for each individual subject."
3131994|NCT03389555|Experimental|Vitamin C, Vitamin B1, Corticosteroids|"The combination of vitamin C, vitamin B1, hydrocortisone :~Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days~Vitamin B1 (thiamine) 100mg every 6 hours x 4-days~Hydrocortisone 50mg every 6 hours x 4-days"
3131995|NCT03389555|Placebo Comparator|Placebo|Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components
3131996|NCT03389854|Sham Comparator|Group 1 - Control|No treatment will be administered for the initial 3 months. This are is necessary as Peyronie's disease may result in changes in length and curvature as a function of the disease process. After the 3 month period of time, this group will enter an open label phase where they may utilize a penile traction device if desired.
3131997|NCT03389854|Experimental|Group 2 - PTT 1x daily x 3 months|Men will utilize penile traction therapy for 30 minutes once daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
3131998|NCT03389854|Experimental|Group 3 - PTT 2x daily x 3 months|Men will utilize penile traction therapy for 30 minutes twice daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
3131999|NCT03389854|Experimental|Group 4 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the initial 3 months. After this phase is completed, they will enter an open label phase for 3 months where they may utilize the device as much or as little as desired.
3132000|NCT03389893|Experimental|Dupilumab w/OLE|"Participants will receive a loading dose of dupilumab (two 300 mg subcutaneous (subcut) injections (total of 600 mgs)) on Day 0, followed by 300 mg dose of dupilumab by subcut injection every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of two subcut administered injections (one 300 mg dose of dupilumab and one dose of placebo, in order to protect prior masking/blind).Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
3132001|NCT03389893|Placebo Comparator|Placebo Comparator w/OLE|"Participants will receive a loading dose of placebo (two placebo subcutaneous (subcut) injections) on Day 0 followed by one dose of placebo by subcut injections every 2 weeks (Days 14 and 28).~Open Label Extension (OLE): Participants will begin a 10 week OLE on Day 42, beginning with a loading dose of dupilumab (two 300 mg subcut injections (total of 600 mgs)-protection of prior masking/blind maintained). Participants will then maintain a regimen of 300 mg of dupilumab by subcut injection every two weeks through Day 98.~The subcut injections will be administered in the abdomen (except for the 2 inches (5 cm) around the navel-not allowed), thighs, or upper arms. Injection sites will be rotated with each dose."
3132002|NCT03390101|Experimental|BCD-085 Q2W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 1 will be given BCD-085 every 4 weeks through Week 50."
3132003|NCT03390101|Experimental|BCD-085 Q4W|"Patients in this arm (85 subjects) will receive 120 mg BCD-085 (two SC injections, 60 mg in 1.0 mL each). Thus, the drug will be administered on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2 (induction), Day 1 of Week 6 and Day 1 of Week 10. For the purpose of blind design, patients will receive a placebo (2 injections) on day 1 of week 4 and week 8.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will continue BCD-085 every 4 weeks through Week 50."
3132004|NCT03390101|Placebo Comparator|Placebo|"Patients in this arm (43 subjects) will be given two SC injections of placebo (1.0 mL each) on Day 1 of Week 0, Day 1 of Week 1, Day 1 of Week 2, Day 1 of Week 4, Day 1 of Week 6, Day 1 of Week 8, and Day 1 of Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 on Day 1 of Week 12, Day 1 of Week 13, Day 1 of Week 14 (induction), then every 4 weeks through Week 50."
3132005|NCT03390114|Experimental|SHUTi Cognitive Behavioral Therapy|SHUTi (www.myshuti.com) is an evidence-based, cognitive-behavioral, online intervention for insomnia.
3132006|NCT03390114|No Intervention|Usual Care|Patients randomized to the Usual Care group will be encouraged to follow-up with their primary care or HIV provider. There will be no formal interaction with the participants between the Entry Visit and the Week 10 Visit. However, the participants will be encouraged to contact the study team for any changes in their condition. There will be no restrictions on the care that can be received, although we will assess changes in care during the trial.
3132007|NCT03390166|Active Comparator|GPO Tri Fluvac vaccine|630 volunteers will receive a single dose of the seasonal trivalent inactivated influenza vaccine (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) produced by GPO Thailand. To be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
3132008|NCT03390166|Active Comparator|Licensed Influenza vaccine|315 volunteers will receive acLicensed Influenza vaccine (seasonal trivalent inactivated split virion influenza vaccine recommended for Southern Hemisphere in 2017 (consisting of A/Michigan/45/2015 (H1N1)pdm-09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) 0.5 mL administered intramuscularly (IM) in the deltoid muscle of the non-dominant arm.
3132009|NCT03390257|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
3132010|NCT03390426|Experimental|Mepivacaine Block Group|Injection of local anesthetic (mepivacaine) above and beside the femoral artery.
3132011|NCT03390426|Placebo Comparator|Saline Sham Group|Injection of salt water (saline) above and beside the femoral artery.
3132012|NCT03390842|Experimental|TRC101|Administered once daily (QD) for 40 weeks
3132013|NCT03390842|Placebo Comparator|Placebo|Administered once daily (QD) for 40 weeks
3132014|NCT03390907|Experimental|Hybrid APC|Hybrid APC ( Erbe Hybrid APC) design for ablation of abnormal tissue in GI tract.
3132015|NCT03391115||Inpatient Participants|"Patients admitted to University of Colorado Hospital with at least one of the following diagnoses:~Heart Failure~COPD~Cancer"
3132016|NCT03391115||Nurse Participants|"Bedside nurses who provide care at the inpatient level for the following diseases:~Heart Failure~COPD~Cancer"
3132017|NCT03391765|Experimental|M15-562 ABBV-8E12 2000 mg/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
3132018|NCT03391765|Experimental|M15-562 ABBV-8E12 4000 mg/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1 and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength. Placebo IV infusion was administered on Day 15 in Study M15-563 (to maintain the blind in Study M15-562).
3132019|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 2000 mg|Intravenous (IV) infusions of 2000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
3132020|NCT03391765|Experimental|M15-562 Placebo/M15-563 ABBV-8E12 4000 mg|Intravenous (IV) infusions of 4000 mg ABBV-8E12 at Day 1, Day 15, and Day 29, then every 28 days for up to 5 years; administered at 300 mg/15 mL and 1000 mg/10 mL strength.
3132021|NCT03391986|Active Comparator|Pyonex needles|This arm will receive modified battlefield auricular acupuncture using SEIRIN® Pyonex™ Acupuncture Needles.
3132022|NCT03391986|Placebo Comparator|Placebo adhesives|This arm will receive placement of adhesives using the modified battlefield auricular acupuncture placement points using 12 mm Plasters.
3132023|NCT03391986|No Intervention|Routine Care|This arm will receive no intervention.
3132024|NCT03392168|Experimental|Cohort 1 - ARQ-151 cream 0.5%|Single-dose application of ARQ-151 cream 0.5% to 25 cm^2 of psoriatic plaque(s)
3132025|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.5%|ARQ-151 cream 0.5% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
3132026|NCT03392168|Experimental|Cohort 2 - ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
3132027|NCT03392168|Placebo Comparator|Cohort 2 - ARQ-151 vehicle cream|Vehicle cream applied daily for 28 days to all psoriatic plaques, not exceeding an application area of 5% BSA
3132028|NCT03392194|Experimental|Sleep hygiene & Yoga (SH+Y)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment. After completing the SH sessions, they will receive 10 weeks of the yoga intervention (8 in-person yoga sessions and 2 weeks of yoga home practice maintenance assessment).
3132029|NCT03392194|Active Comparator|Sleep hygiene (SH)|Participants will receive the sleep hygiene intervention, which includes 2 sleep hygiene sessions and 10 weeks of maintenance assessment.
3132030|NCT03392532|Other|AOHG toric, then AO toric|Lotrafilcon B toric contact lenses with HYDRAGLYDE, followed by lotrafilcon B toric contact lenses, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
3132031|NCT03392532|Other|AO toric, then AOHG toric|Lotrafilcon B toric contact lenses, followed by lotrafilcon B toric contact lenses with HYDRAGLYDE, as randomized. Each product worn in both eyes for approximately 30 minutes, with a 30-45 minute washout between the removal of Pair 1 and insertion of Pair 2.
3132032|NCT03392935|Experimental|All Subjects|All subjects will be treated with the laser at week 0 and week 4. Only assessors will be blinded and rate the dermatofibromas in photographs, they will not know which photos were taken pre-treatment vs. post-treatment to determine efficacy.
3132033|NCT03392974|Experimental|Valoctocogene Roxaparvovec Open Label|Single administration of valoctocogene roxaparvovec at a dose of 4E13 vg/kg
3132034|NCT03393000|Experimental|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
3132035|NCT03393000|Active Comparator|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
3132036|NCT03393208|Experimental|First Test GIR (Fasting), Then Reference GIR (Fasting)|Participants received a single oral dose of 500 milligram (mg) of test Glucophage Immediate Release (GIR) tablet Sino-American Shanghai Squibb (SASS)/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (Merck Santé in Semoy (MSS)/France) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
3132037|NCT03393208|Experimental|First Reference GIR (Fasting), Then Test GIR (Fasting)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fasting condition. There was a wash-out period of 7 days between each treatment period.
3132038|NCT03393208|Experimental|First Test GIR (Fed), Then Reference GIR (Fed)|Participants received a single oral dose of 500 mg of test GIR tablet (SASS/ China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GIR (MSS/France) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
3132039|NCT03393208|Experimental|First Reference GIR (Fed), Then Test GIR (Fed)|Participants received a single oral dose of 500 mg of reference GIR tablet (MSS/ France) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GIR (SASS/China) on Day 8 in treatment period 2 under fed condition. There was a wash-out period of 7 days between each treatment period.
3132040|NCT03393494|Experimental|Perrigo active|Test product
3132041|NCT03393494|Active Comparator|Reference active|RLD product
3132042|NCT03393494|Placebo Comparator|Perrigo placebo|placebo product
3132043|NCT03393754|Experimental|Sci-B-Vac® Hepatitis B Vaccination|Sci-B-Vac® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 10ug, IM injection at Days 0, 28, and 168.
3132044|NCT03393754|Active Comparator|Engerix-B® Hepatitis B Vaccination|Engerix-B® (hepatitis B vaccine) Hepatitis B Vaccination, Solution, 20ug, IM injection at Days 0, 28, and 168.
3132045|NCT03393806|Experimental|Participants receiving GSK3772847|Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks
3132046|NCT03393806|Placebo Comparator|Participants receiving placebo|Participants will be randomized to receive matching placebo as IV infusion
3132047|NCT03394391|Experimental|Intervention group|Daily ART-adherence SMS reminder
3132048|NCT03394391|Active Comparator|Control group|Standard adherence counselling/Patient experience group chat
3132049|NCT03394508|Placebo Comparator|Placebo|ALK diluent 0,3% human albumin'
3132050|NCT03394508|Experimental|Active treatment|Intervention: Drug ALK Alutard birch or 5-grasses. Grass pollen suspension or birch pollen suspension
3132051|NCT03394768||NICOM Cheetah®|Patients will be treated as per department protocols and no additional intervention will be performed. Each patient will have an arterial catheter inserted as per our usual practice. All patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The NICOM CO monitor involves the application of non-invasive sensor strips. In this study, it will be applied to patients receiving the FloTrac (standard of care), on top of the standard care of monitoring with Flotrac.
3132052|NCT03394768||FloTrac®|Same patient population as the NICOM Cheetah® group as described above as all patients will have the FloTrac® connected to the arterial catheter (standard of care in CGH SICU) and the NICOM Cheetah® electrodes placed on the skin across the anterior thoracic wall. The FloTrac CO monitor is the current standard of care for cardiac output monitoring in the SICU of CGH. All patients deemed to require cardiac output monitoring will receive the FloTrac (as per departmental practice).
3132053|NCT03394885|Experimental|Atezolizumab, Carboplatin, Paclitaxel (+Optional Bevacizumab)|"Atezolizumab administered over 90 (± 15) minutes (for the first infusion, shortening to 60 (± 15) minutes and 30 ± 15) minutes for subsequent infusions as described below) followed by~Paclitaxel 70-80mg/m2 IV administered over approximately one hour followed by~Carboplatin IV administered over 15-30 minutes to achieve an initial target AUC of 5-6 mg/mL/Min (Calvert formula dosing).~(Optional, Physician choice) Bevacizumab IV maintenance administered starting at cycle 5 of chemotherapy over 30-90 minutes. For those who receive bevacizumab, it will be given for a total duration of 16 cycles"
3132054|NCT03394924|Experimental|EDP-305 1 mg|Subjects will take 2 tablets once a day orally for 12 weeks
3132055|NCT03394924|Experimental|EDP-305 2.5 mg|Subjects will take 2 tablets once a day orally for 12 weeks
3132056|NCT03394924|Placebo Comparator|Placebo|Subjects will take two tablets once a day orally for 12 weeks
3132057|NCT03395353|Experimental|Duloxetine hydrochloride|Duloxetine hydrochloride administered orally.
3132058|NCT03395808|Other|AVE-901 50mg|IV Tramadol
3132059|NCT03395886||remifentanil group|Eligible patients will receive a continuous infusion of remifentanil starting with 0.05 μg/kg/min. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 0.12 μg/kg/min.
3132060|NCT03395886||dexmedetomidine group|Eligible patients will receive a continuous infusion of dexmiditomidine starting with 0.5 μg/kg/h. The doses will be adjusted according to the sedation satisfaction (sedation target is to achieve NIV-intolerance score 1-2), and the maximum dose is 1 μg/kg/h.
3132061|NCT03395990|Active Comparator|chloroprocaine|15 ml of 2% chloroprocaine via a femoral nerve block technique
3132062|NCT03395990|Sham Comparator|saline|15 ml of 0.9% saline via a femoral nerve block technique
3132063|NCT03396432|Active Comparator|Video Laryngoscopy for endotracheal (ET) Placement|"Device:~Storz C-MAC Video Laryngoscope"
3132064|NCT03396432|Active Comparator|Direct Laryngoscopy for ET Placement|"Device:~Miller Laryngoscope"
3132065|NCT03396835|Experimental|INVSENSOR00009 Sensor|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
3132066|NCT03396913|Experimental|IPL followed by Meibomian Gland Expression (MGX)|Subjects in the experimental arm with receive IPL followed by MGX: IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
3132067|NCT03396913|Sham Comparator|Sham IPL followed by MGX|Subjects in the sham comparator arm with receive Sham IPL followed by MGX: Sham IPL pulses will be administered on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and below the lower eyelids. Following Sham IPL therapy, subjects will undergo MGX of both eyelids in both eyes.
3132068|NCT03396952|Experimental|Treatment (pembrolizumab, ipilimumab, aspirin)|Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3132069|NCT03397121|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90 then every 6 months.
3132070|NCT03397121|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution on Day 1, Day 90 then every 6 months.
3132071|NCT03397394|Experimental|Rucaparib|Oral rucaparib (monotherapy)
3132072|NCT03397771|Experimental|Litoxetine oral capsules|oral experimental study medication litoxetine
3132073|NCT03397771|Placebo Comparator|Placebo oral capsules|oral comparator
3132074|NCT03398213|Experimental|Acupuncture|Acupuncture for treatment of COPD exacerbation + standard conventional care for COPD exacerbation
3132075|NCT03398213|Sham Comparator|Sham procedure|Ear stimulation with plaster + standard conventional care for COPD exacerbation
3132076|NCT03398213|No Intervention|Standard care|Standard conventional care for COPD exacerbation
3132077|NCT03398265|Experimental|Intervention|Initial discussion regarding opioid treatment options followed by 6 months of treatment navigation.
3132078|NCT03398265|Other|Control|Referrals to treatment from corrections staff.
3132079|NCT03398278|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
3132080|NCT03398278|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
3132081|NCT03398330|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 40 mg
3132082|NCT03398330|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 40 mg
3132083|NCT03398356|Other|group A|metformin dose 3 x 500 mg
3132084|NCT03398356|Other|group B|metformin dose 3 x 1000 mg
3132085|NCT03398356|No Intervention|group C|healthy volunteers who had basic parameters assessment and blood tests only at the beginning of the study
3132086|NCT03398421|Experimental|Subjects receiving nemiralisib and itraconazole|Eligible subjects will receive a single dose of 100 micrograms (mcg) nemiralisib on Day 1 in Period 1. Subjects will also receive a single dose of 200 milligrams (mg) itraconazole in the morning from Day 1 to Day 10 and single dose of 100 mcg nemiralisib on Day 5, one hour after the dose of itraconazole in Period 2. There will be a washout of at least 14 days between the administration of nemiralisib in Period 1 and Period 2.
3132087|NCT03398798|Active Comparator|".014 with twin brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
3132088|NCT03398798|Active Comparator|".016 with twin brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia Metal Twin brackets."
3132089|NCT03398798|Active Comparator|".014 with self-ligating brackets"|".014 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
3132090|NCT03398798|Active Comparator|".016 with self-ligating brackets"|".016 dimension CuNiTi orthodontic arch wires and .022 slot Ormco Insignia SL (self-ligating) brackets."
3132091|NCT03398928|Experimental|Acupuncture|Acupuncture for delirium treatment
3132092|NCT03398928|No Intervention|Standard care|Standard conventional delirium care at the discretion of the department medical staff
3132093|NCT03399370|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection on Day 1, Day 90, then every 6 months.
3132094|NCT03399370|Placebo Comparator|Saline Solution|Placebo will be administered as a SC injection of saline solution on Day 1, Day 90, then every 6 months.
3132095|NCT03399786|Experimental|evinacumab|
3132096|NCT03399786|Experimental|Placebo|
3132097|NCT03400033|Experimental|Daprodustat|Subjects randomized to this arm will receive daprodustat tablets titrated doses from 2 to 48 milligrams orally three-times weekly along with saline by IV route for the 52 weeks treatment period.
3132098|NCT03400033|Active Comparator|Epoetin alfa|Subjects randomized to this arm will receive matching placebo tablets to daprodustat orally three-times weekly and Epoetin alfa by IV route for the 52 weeks treatment period.
3132099|NCT03400163|Experimental|Treatment Group D:|Administered as specified on specified days
3132100|NCT03400163|Placebo Comparator|Treatment Group E:|Administered as specified on specified days
3132101|NCT03400449|Active Comparator|Video counseling|The video group watched a 13.75 minute video of a local Colombian counselor reading a script of the same information provided by conversational counseling and had a chance to ask questions at the end.
3132102|NCT03400449|Active Comparator|Conversational counseling|The conversation group participated in a structured, face-to-face conversation with a trained counselor.
3132103|NCT03400475|Experimental|Simvastatin group (Treatment)|Will receive 0.1 ml prepared Simvastatin in 1.2% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
3132104|NCT03400475|Placebo Comparator|Control group|Will receive a placebo of 0.1 ml 40% (W/V) Lecithin/isopropyl palmitate solution (Lipoil®), Poloxamer 407 gel (Polox Gel 20%®) applied topically into the peri-implant gingival sulcus using a plastic syringe with a blunt cannula.
3132105|NCT03400579|Experimental|Remote Ischemic Conditioning|RIC procedure (i.e., four cycles of alternating 5-min inflation and 5-min deflation) administered by the autoRIC® device
3132106|NCT03400748|Experimental|RF Ablation|Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
3132107|NCT03400787|Sham Comparator|Sham Control Arm|"Subjects in the Sham Control arm will undergo the same preoperative assessments as those in the Latera Treatment arm up to and including anesthesia for the implant, however, no implant will be placed.~Crossover - Subjects will be unblinded after the 3-month assessment is complete. Eligible subjects in the Sham Control arm will be treated with the Latera Implant if they still meet all eligibility criteria. Follow up will continue to 24 months post-implant. Subjects who no longer meet the eligibility criteria will exit the study."
3132108|NCT03400787|Experimental|Latera Treatment Arm|Subjects in the active treatment arm will receive the Latera Implant using standard techniques. Follow up continues for 24 months post-implant.
3132109|NCT03400800|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) (equivalent to 284 mg inclisiran) in 1.5 milliliters (mL) will be administered as a SC injection on Day 1, Day 90, and then every 6 months.
3132110|NCT03400800|Placebo Comparator|Saline Solution|Placebo (1.5 mL) will be administered as a SC injection of saline solution on Day 1, Day 90, and then every 6 months.
3132111|NCT03400852|Experimental|Period 1: MNK-1411|Participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 1
3132112|NCT03400852|Experimental|Period 1: Placebo|Participants receive placebo at a volume appropriate to body weight during Period 1
3132113|NCT03400852|Experimental|Period 2: MNK-1411|All participants receive MNK-1411 at a dosing volume appropriate to body weight during Period 2
3132118|NCT03400956|Experimental|Vilaprisan (A1)|Vilaprisan in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3132119|NCT03400956|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3132120|NCT03400956|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan in treatment period 1 for 12 weeks, and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3132121|NCT03401229|Experimental|Benralizumab 30mg SC + MF|SC - subcutaneously MF - Mometasone Furoate
3132122|NCT03401229|Placebo Comparator|Placebo SC + MF|
3132123|NCT03401450|Active Comparator|ACB within true AC with bupivacaine|The patients will receive an ultrasound-guided single injection adductor canal block with 20 mL of 0.5% bupivacaine
3132124|NCT03401450|Active Comparator|ACB proximal to true AC with bupivacaine|The patients will receive an ultrasound-guided single injection femoral triangle block with 20 mL of 0.5% bupivacaine
3132125|NCT03401671|Experimental|Japanese|Healthy subjects of Japanese descent will receive a single dose of 300 milligrams (mg) lanadelumab subcutaneous (SC) injection in the abdomen.
3132126|NCT03401671|Experimental|Non-Hispanic Caucasians|Healthy Non-Hispanic Caucasian subjects will receive a single dose of 300 mg lanadelumab SC injection in the abdomen
3132127|NCT03402126||TPD RAMWare Download|Subjects who qualify and consent to participate in the TPD study will have TPD RAMWare injected into their device to collect data.
3132128|NCT03402230|Experimental|Arm I (Avmacol lower dose, Avmacol higher dose)|Participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
3132129|NCT03402230|Experimental|Arm II (Avmacol higher dose, Avmacol lower dose)|Participants receive higher dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days. After 10-14 days, participants receive lower dose broccoli sprout/broccoli seed extract supplement PO daily for 10-14 days.
3132130|NCT03402243|Experimental|Menthol ban only for cigarettes|Participants will have available to them non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
3132131|NCT03402243|Experimental|Menthol ban for cigarettes and e-cigarettes|Participants will have available to them non-menthol cigarettes, tobacco flavored version of a cigarette-like e-cigarette, tobacco flavored version of a tank like e-cigarette and nicotine gum and lozenge
3132132|NCT03402243|Other|No Menthol Ban|Participants will have available to them menthol and non-menthol cigarettes, menthol and tobacco flavored versions of a cigarette-like e-cigarette, menthol and tobacco flavored versions of a tank like e-cigarette and nicotine gum and lozenge
3132133|NCT03402386|Experimental|MT-6548|
3132134|NCT03402659|Experimental|neflamapimod|40 mg hard gelatin capsules, taken twice daily with food.
3132135|NCT03402659|Placebo Comparator|placebo|hard gelatin capsules containing excipients only, weight- and size-matched; taken twice daily with food.
3132136|NCT03402750|Experimental|Meds to Beds|Patients receive medication in-hand at discharge from the hospital
3132137|NCT03402750|Active Comparator|Standard Care|Electronic prescription with patient pickup at the pharmacy
3132138|NCT03402893|Experimental|single arm Onexton gel application|Onexton gel will be supplied to all subjects and applied once daily to the face
3132139|NCT03402932|Experimental|Auditory Amplified-Visual|This arm is designed to test the contrast between auditory amplified and visual conditions.
3132140|NCT03402932|Experimental|Auditory Amplified-Unamplified|This arm is designed to test the contrast between auditory amplified and unamplified conditions.
3132141|NCT03402932|Experimental|Auditory Unamplified-Visual|This arm is designed to test the contrast between auditory unamplified and visual conditions.
3132142|NCT03402932|Other|Younger control group|This arm is designed to validate the visual version by comparing to the auditory version in a group of younger normal hearing controls.
3132143|NCT03403036|Experimental|Brodalumab|Brodalumab (210 mg) via subcutaneous injection using prefilled syringes
3132144|NCT03403192|Active Comparator|EZ-Blocker in the left lung|This arm will receive the EZ-Blocker in the left lung of their body, which functions as a bronchial blocker.
3132145|NCT03403192|Active Comparator|EZ-Blocker in right lung|This arm will receive the EZ-Blocker in the right lung of their body, which functions as a bronchial blocker.
3132146|NCT03403192|Active Comparator|DLT in left lung|This arm will receive the DLT in the left lung of their body, which functions as a bronchial blocker.
3132147|NCT03403192|Active Comparator|DLT in right lung|This arm will receive the DLT in the right lung of their body, which functions as a bronchial blocker.
3132148|NCT03403231|Active Comparator|Arm 1: Stock messages only|Participants will only receive the stock messages that encourage following recommended behaviors for reducing the risk for developing diabetes.
3132149|NCT03403231|Experimental|Arm 2: Urgency frame message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the urgency frame message strategy.
3132150|NCT03403231|Experimental|Arm 3: Social norm message strategy|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the social norm messaging strategy.
3132151|NCT03403231|Experimental|Arm 4: Urgency frame and social norm strategies|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the urgency frame and social norm messaging strategies.
3132152|NCT03403231|Experimental|Arm 5: Implementation Intentions and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and urgency frame messaging strategies.
3132153|NCT03403231|Experimental|Arm 6: Implementation Intentions and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the implementation intentions and social norm messaging strategies.
3132154|NCT03403231|Experimental|Arm 7: Implementation Intentions, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions, urgency frame, and social norm messaging strategies.
3132155|NCT03403231|Experimental|Arm 8: Implementation Intentions|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the implementation intentions messaging strategy.
3132156|NCT03403231|Experimental|Arm 9: Preference Checklists and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and urgency frame messaging strategies.
3132157|NCT03403231|Experimental|Arm 10: Preference Checklists and Social Norms|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the preference checklists and social norm messaging strategies.
3132158|NCT03403231|Experimental|Arm 11: Preference Checklists, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists, urgency frame, and social norm messaging strategies.
3132159|NCT03403231|Experimental|Arm 12: Preference Checklists|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the preference checklists messaging strategy.
3132160|NCT03403231|Experimental|Arm 13: Tailored Aspirations and Urgency Frame|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and urgency frame messaging strategies.
3132161|NCT03403231|Experimental|Arm 14: Tailored Aspirations and Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with both the tailored aspirations and social norm messaging strategies.
3132162|NCT03403231|Experimental|Arm 15: Tailored Aspirations, Urgency Frame & Social Norm|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations, urgency frame, and social norm messaging strategies.
3132163|NCT03403231|Experimental|Arm 16: Tailored Aspirations|Participants will receive messages that encourage following recommended behaviors for reducing the risk for developing diabetes integrated with the tailored aspirations messaging strategy.
3132164|NCT03403374|Experimental|Evolocumab|Evolocumab 420 mg subcutaneous (SC) once monthly (QM) or every 2 weeks (Q2W; for participants on apheresis).
3132165|NCT03403400|Experimental|VRWP Group|Vestibular Rehabilitation plus Walking with Pedometer Groupd
3132166|NCT03403400|Active Comparator|VRW Group|Vestibular Rehabilitation plus Walking without Pedometer Group
3132167|NCT03403400|No Intervention|VR Group|Vestibular Rehabilitation Only Group. The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
3132168|NCT03403413|Experimental|Muscle Vibration|Test feasibility of muscle vibration of tibialis anterior, rectus femoris, short head of biceps and tensor fasciae latae bilaterally during walking for 1 hour 3 times per week for 12 weeks to improve walking speed through improved coordination of hip, knee and ankle flexion.
3132169|NCT03403426|Experimental|Wingman Crossing Catheter|Use of the device to support CTO crossing
3132170|NCT03403491|Other|Sequence 1|Usual care for 2 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks.
3132171|NCT03403491|Other|Sequence 2|Usual care for 2 weeks followed by sham application (without digital scales or BP monitor) for 4 weeks followed by using patientMpower application [+digital weighing scales & BP monitor] for 4 weeks.
3132172|NCT03403504|Experimental|Oxycodone Tamper Resistant|Oxycodone Tamper Resistant (OTR) Tablet 10 mg
3132173|NCT03403504|Active Comparator|OXYCONTIN®|OXYCONTIN® Tablet 10 mg
3132174|NCT03403517|Experimental|Methylprednisolone|10 mg/kg, single preoperative infusion
3132175|NCT03403517|Active Comparator|Dexamethasone|8 mg dexamethasone, single preoperative infusion
3132176|NCT03403712|Experimental|Test group|"intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination, administered as a 30-minute infusion of a 50 mL solution, on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
3132177|NCT03403712|Active Comparator|Control group|"oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.~Oral dexamethasone will be administered on Day 1 of each cycle (12 mg)"
3321388|NCT02018510|Experimental|Group 2A|"HIV-infected individuals on or off ART~1 mg/kg, single dose IV administration of 3BNC117"
3321389|NCT02018510|Experimental|Group 2B|HIV-infected individuals on or off ART 3 mg/kg, single dose IV administration of 3BNC117
3132178|NCT03403725|Experimental|MEN1309 (Step 1-Solid Tumors)/(Step 2-NHL)|"Step1: Accelerated Titration Design with 1 single pt per cohort and double dose level per cohort until grade ≥ 2 drug related toxicity. Then, study reverts to 3+3 design. Any cohort in which 1 pt experiences a DLT (along ATD or 3+3) will be expanded up to 6 pts.~Step2: MTD defined in Step 1, 3 MEN1309 dose levels will be tested (MTD-2, MTD-1, and MTD), with 6 pts per each dose level. A further MTD-3 level will be explored if 2 DLTs occur at the MTD-2 dose level."
3132179|NCT03403751|Experimental|Reltecimod 0.5 mg/kg|Single IV infusion of Reltecimod 0.5 mg/kg
3132180|NCT03403751|Placebo Comparator|Placebo|Single IV infusion of 0.9% Sodium Chloride Injection (Normal Saline)
3132181|NCT03404167|Experimental|Zoliflodacin|4 g (2 sachets of 2 g) of zoliflodacin orally in the morning of Day 1 after 8 hours of fasting, n=8
3132182|NCT03404206|Experimental|Naproxen Sodium (Aleve, BAY117031)|Participants received one single dose of 440 mg naproxen sodium tablets (200 mg x 2 tablets, oral) after randomization
3132183|NCT03404206|Active Comparator|Ibuprofen (Advil)|Participants received one single dose of 400 mg ibuprofen tablets (200 mg x 2 tablets, oral) after randomization
3132184|NCT03404206|Placebo Comparator|Placebo|Participants received one single dose of matching placebo tablets (2 tablets, oral) after randomization
3132185|NCT03404219|Experimental|Intervention|Mobile intervention (i.e., Ecological momentary intervention [EMI]) addressing social motivation and social skills. Twice daily notifications sent to deliver EMI content. Social goal reminders and steps provided to support goal attainment. Social Skills Training content delivered via brief video clips.
3132186|NCT03404375|Other|Term patients|This study only has one arm: term pregnant patients scheduled for cesarean sections. The surgeon will clinically estimate blood loss and the research team will estimate blood loss using the Gauss Triton system. This will be done on all 242 patients.
3132187|NCT03404401|Experimental|BLI4700 Bowel Preparation|
3132188|NCT03404401|Active Comparator|FDA Approved Bowel Preparation|
3132189|NCT03404609|Experimental|Accelerated course of modified continuous theta-burst stimulation (cTBSmod)|Participants received 5 consecutive days of accelerated cTBSmod to the right frontal pole. Each cTBSmod session was comprised of 1800 pulses, delivered in a continuous train of 600 bursts. Each burst contained 3 pulses at 30 Hz, repeated at 6 Hz. Ten sessions were applied per day (18,000 pulses/day, hourly) (90,000 total pulses) using a Magventure Magpro X100. Stimulation was delivered at 90% resting motor threshold (depth corrected). Localite Neuronavigation System was used to position the TMS coil over the individualized stimulation target.
3132190|NCT03404648|Experimental|High Risk Prostate Cancer Patients|Subjects will receive C-11 choline PET Tracer and Gadobutrol prior to the one time Positron emission tomography (PET/MR scanner) imaging and Multiparametric Magnetic resonance imaging (mpMRI).
3132191|NCT03404674|Experimental|Group A1: CssBA 5 ug|Participants received an intramuscular injection of 5 ug CssBA on days 1, 22, and 43.
3132192|NCT03404674|Experimental|Group A2: DmLT 100 ng|Participants received an intramuscular injection of 100 ng DmLT on days 1, 22, and 43.
3132193|NCT03404674|Experimental|Group B: CssBA 5 ug + DmLT 100 ng|Participants received an intramuscular injection of 5 ug CssBA + 100 ng dmLT on days 1, 22, and 43.
3132194|NCT03404674|Experimental|Group C: CssBA 5 ug + DmLT 500 ng|Participants received an intramuscular injection of 5 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
3132195|NCT03404674|Experimental|Group D: CssBA 15 ug + DmLT 500 ng|Participants received an intramuscular injection of 15 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
3132196|NCT03404674|Experimental|Group E: CssBA 45 ug + DmLT 500 ng|Participants received an intramuscular injection of 45 ug CssBA + 500 ng dmLT on days 1, 22, and 43.
3132197|NCT03404843|Experimental|Fasudil hydrochloride|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of 60 mg of fasudil hydrochloride + saline prior to measurements of vascular function and ATP release.
3132198|NCT03404843|Placebo Comparator|Saline|Participants will receive a 100 mL intravenous infusion (in 60 minutes) of saline (placebo) prior to measurements of vascular function and ATP release.
3132199|NCT03405259|Experimental|Super Seal® Desensitizer|Professionally Applied
3132200|NCT03405259|Sham Comparator|Acclean® Fluoride Varnish|Professionally Applied
3132201|NCT03405363||new users of Olodaterol|COPD patients using Olodaterol for the first time
3132202|NCT03405363||new users of other LABAs|COPD patients using other long-acting beta2 agonists for the first time
3132204|NCT03405818|Experimental|Tavaborole 5% Topical Solution|All study participants apply study drug
3132205|NCT03405935|Experimental|B/F/TAF|B/F/TAF FDC for at least 96 weeks.
3132206|NCT03406260|Experimental|Lasmiditan 200 mg (milligrams)|Participants received 200 mg of Lasmiditan tablet orally in the fasted state with approximately 240 (milliliter) mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
3132207|NCT03406260|Experimental|Lasmiditan 100 mg|Participants received 100 mg of Lasmiditan tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
3132208|NCT03406260|Placebo Comparator|Placebo|Participants received placebo tablet orally in the fasted state with approximately 240 mL of room temperature water in the morning of Days 1, 3, and 5, while participants were in a sitting position.
3132209|NCT03406325||urticaria|Patients with this condition
3132210|NCT03406325||asthma|Patients with this condition
3132211|NCT03406325||eczema|Patients with this condition
3132212|NCT03406325||food allergy|Patients with this condition
3132213|NCT03406325||anaphylaxis|Patients with this condition
3132214|NCT03406325||mastocytosis|Patients with this condition
3132215|NCT03406325||mast cell activating syndrome|Patients with this condition
3132216|NCT03406377|Placebo Comparator|Placebo|Water for injection, Sorbitol, L-Methionine, Sodium Acetate Trihydrate
3132217|NCT03406377|Experimental|OPK-88003|70 mg/vial (extractable volume 1 mL) (20mg for 4 weeks, 40 mg for 4 weeks and 70 mg for 22 weeks)
3132218|NCT03406962|Experimental|MGTA-456|MGTA-456 is an expanded CD34+ cell therapy investigational product used in replacement of single umbilical cord blood transplantation.
3132219|NCT03407053|Active Comparator|Ultra-processed diet then unprocessed diet|Participants assigned to this arm will consume ultra-processed diet for two weeks followed by unprocessed diet for two weeks
3132220|NCT03407053|Active Comparator|Unprocessed diet then ultra-processed diet|Participants assigned to this arm will consume unprocessed diet for two weeks followed by ultra-processed diet for two weeks
3132221|NCT03407118|Experimental|LY900014|Single, 15 units (U)LY900014 administered subcutaneously (SC) in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus (T1DM).
3132222|NCT03407118|Active Comparator|Insulin Lispro (Humalog)|Single, 15 U insulin lispro administered SC in one of two study periods in Japanese Patients With Type 1 Diabetes Mellitus.
3132223|NCT03407170|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months
3132224|NCT03407313|Experimental|Rotational fractional resection (1.5mm diameter device)|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
3132225|NCT03407430|Experimental|Pregabalin, then Placebo|"Pregabalin in cycle 1; placebo in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg twice a day (BID) for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
3132226|NCT03407430|Experimental|Placebo, then Pregabalin|"Placebo in cycle 1; pregabalin in cycle 2.~Pregabalin or matching placebo will be administered at 75 mg BID for 4 days, to patients receiving pegfilgrastim for hematologic malignancies or breast cancer patients on myelosuppressive chemotherapy . Starting the day of pegfilgrastim, the dose of study medication will be increased to 150 mg PO BID provided the patient is tolerating the lower dose (ie, they are not experiencing any pregabalin associated toxicities >Grade 1). This will be determined by the research team on the day of pegfilgrastim administration."
3132227|NCT03407482|Experimental|GDC-0853 (200mg) BID|Participants previously enrolled in the parent GA30044 Study, now received GDC-0853 (200mg) orally twice daily (BID).
3132228|NCT03407612|Active Comparator|CPM|These subjects received a continuous passive motion (CPM) device and were instructed to use it for 4-6 hours daily throughout the first two postoperative weeks following their arthroscopic labral repair. They were provided adequate education on how to operate the device. The subjects recorded their average usage of the CPM, as well as their personal perception of the CPM, at the postoperative 2 day, 7 day, and 14 day marks.
3132229|NCT03407612|No Intervention|No CPM|No CPM was administered to these subjects.
3132230|NCT03407625|Experimental|Foley bulb plus Oral Misoprostol|Patients will received initial transcervical foley bulb, followed by oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
3132231|NCT03407625|Active Comparator|Oral Misoprostol|Patients will receive oral misoprostol 100 micrograms given every 4 hours for a maximum of 2 doses.
3132232|NCT03407651|Experimental|Part 1a|Coagulation Factor VIIa variant, 18 µg/kg by intravenous route
3132233|NCT03407651|Experimental|Part 1b|Coagulation Factor VIIa variant, 30 µg/kg by subcutaneous route
3132234|NCT03407651|Experimental|Part 2|Coagulation Factor VIIa variant, 30, 60, 90, 120 µg/kg by subcutaneous route
3132235|NCT03408171|Active Comparator|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
3132236|NCT03408171|Active Comparator|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
3132237|NCT03408392|Experimental|Test followed by Reference Formulation|Subjects will be randomized to receive single dose of Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 1 and Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
3132238|NCT03408392|Experimental|Reference followed by Test Formulation|Subjects will be randomized to receive single dose of Reference formulation (cefixime 200 mg/5 mL) on Day 1 of the treatment period 1 and Test formulation (SKF101804: cefixime 200 mg/ 5 mL) on Day 1 of the treatment period 2. There will be wash out period of 7-14 days between the two treatment periods.
3132239|NCT03408483|Experimental|quadratus lumborum block (QLB)|"Patients will be placed in the lateral decubitus position w/non-operative side recumbent. Pillow or blankets will be placed btw patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping will be applied to the area. Under ultrasound guidance, needle will be advanced to anterior border of quadratus lumborum muscle. After negative aspiration, a bolus of 30 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots.~After QLB is placed, patients will have THA under spinal anesthesia."
3132834|NCT03456960|Experimental|Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA|One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).
3321390|NCT02018510|Experimental|Group 2C|HIV-infected individuals on or off ART 10 mg/kg, single dose IV administration of 3BNC117
3132240|NCT03408483|Active Comparator|Standard of Care|"Patients will be placed in the lateral decubitus position with non-operative side recumbent. A pillow or blankets placed between patient's lower extremities. Standard noninvasive monitors applied, and oxygen administered via nasal cannula. Parenteral midazolam and fentanyl titrated to patient comfort.~Standard skin sterilization, prepping and draping applied to the area. Ultrasound probe used to identify quadratus lumborum muscle. No local anesthetic injected."
3132241|NCT03408639|Experimental|CinnaPoietin®|"The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.~In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients."
3132242|NCT03408639|Active Comparator|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response. In addition to main intervention, Nephrovit tablet/day and vitamine B12 100 mcg/month will be prescribed for patients.
3132243|NCT03408730|Experimental|Sci-B-Vac Lot A Hep B Vaccination|Sci-B-Vac Lot A Hepatitis B Vaccination
3132244|NCT03408730|Experimental|Sci-B-Vac Lot B Hep B Vaccination|Sci-B-Vac Lot B Hepatitis B Vaccination
3132245|NCT03408730|Experimental|Sci-B-Vac Lot C Hep B Vaccination|Sci-B-Vac Lot C Hepatitis B Vaccination
3132246|NCT03408730|Active Comparator|Comparator: ENGERIX-B Hep B Vaccination|Active Comparator: ENGERIX-B Hepatitis B Vaccination
3132247|NCT03408808|Active Comparator|Aspiration alone|The patients will have their dorsal wrist ganglion aspirated and then pressure dressing for 48 hours.
3132248|NCT03408808|Experimental|Aspiration plus platelet rich plasma|The patients will have their dorsal wrist ganglion aspirated, and then injected with platelet rich plasma (derived from a blood sample taken at the same visit) and then pressure dressing for 48 hours.
3132249|NCT03409107|Experimental|Daprodustat receivers|Participants will receive oral daprodustat once daily
3132250|NCT03409107|Placebo Comparator|Placebo receivers|Participants will receive oral placebo once daily
3132251|NCT03409731|Other|Absorb GT1 BVS|Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.
3132252|NCT03409796|Other|Group A: Gluten 3 gm|Gluten 3 gram (gm), powder, orally, once daily up to 14 days.
3132253|NCT03409796|Other|Group B: Gluten 10 gm|Gluten 10 gm, powder, orally, once daily up to 14 days.
3132254|NCT03410056|Placebo Comparator|Phase 1b: Placebo|Matching placebo administered via subcutaneous injection for a total of up to 12 weeks. Participants received placebo in 1 of 2 dosing schedules (i.e. dosing schedule A [less frequent] or schedule B [more frequent]).
3132255|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 1|A low dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
3132256|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 2|A high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule A (less frequent than schedule B) for a total of up to 12 weeks.
3132257|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 3|A medium dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
3132258|NCT03410056|Experimental|Phase 1b: Efavaleukin alfa Cohort 4|A medium/high dose of Efavaleukin alfa administered via subcutaneous injection using dosing schedule B (more frequent than schedule A) for a total of up to 12 weeks.
3132259|NCT03410056|Placebo Comparator|Phase 2a: Placebo|Matching placebo administered via subcutaneous injection, depending on the recommended phase 2 dose (RP2D) and dosing schedule as determined in phase 1b, for a total of up to 12 weeks.
3132260|NCT03410056|Experimental|Phase 2a: Efavaleukin alfa|Efavaleukin alfa administered via subcutaneous injection depending on the RP2D and dosing schedule determined in phase 1b, for up to a total of up to 12 weeks.
3132261|NCT03410628|Experimental|gammaCore Active Device|open label
3132262|NCT03410797|Other|Voice Disorder Requiring Voice Therapy|Individuals with a voice disorder such as muscle tension dysphonia (MTD), vocal fold atrophy or vocal fold lesions recommended for voice therapy as treatment.
3132263|NCT03410862|Experimental|Elderberry Extract|Patients will be supplied a liquid Elderberry Extract used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
3132264|NCT03410862|Placebo Comparator|Placebo|Patients will be supplied a liquid Placebo medication (similar in appearance and taste of Elderberry Extract) used to treat their confirmed human influenza. The dosage of the assigned medication will be 15 ml, or 1 tablespoon. Participants aged 5-12 will be asked to take the medication 2 times per day (morning/night) for a period of 5 days. Participants aged 13 and above will be asked to take the medication 4 times per day (morning/noon/afternoon/night) for a period of 5 days.
3132265|NCT03410914|Experimental|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery
3132266|NCT03410953|Experimental|Fendrix|"The primary immunisation consists of 4 separate 0.5 ml doses of FENDRIX administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
3132267|NCT03411902|Active Comparator|Risedronate|Experimental: Risedronate sodium,150 mg capsule once every 4 weeks for 24 weeks.
3132268|NCT03411902|Placebo Comparator|Placebo|Active comparator: Identical 150 mg placebo capsules once every 4 weeks for 24 weeks.
3132269|NCT03412019|No Intervention|Control group|baseline hemodynamics and anxiety screen; no music. Satisfaction will be measured.
3132270|NCT03412019|Experimental|Intervention group - Mozart|A study investigator will turn on a playlist of pre-selected Mozart music. Hemodynamics and anxiety screen. Satisfaction will be measured.
3132271|NCT03412084|Experimental|Stand up intervention|four week behavioral intervention based on self-regulation theory which is designed to facilitate the development of action plans to break up prolonged sitting
3132272|NCT03412084|No Intervention|Control|No behavioral intervention - the control group will go about their daily life, but come in for assessments at the same time points as the intervention group
3132273|NCT03412604|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.
3132274|NCT03412734|Experimental|Chlorhexidine group|
3132275|NCT03412734|Active Comparator|Iodine group|
3132276|NCT03412929|Experimental|Honey Impregnated Dressing|Honey Impregnated Dressing
3132277|NCT03413618|Experimental|Experimental: Rivaroxaban + Diosmin + Stockings|treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
3132278|NCT03413618|Active Comparator|Control: Rivaroxaban + Stockings only|standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings
3132279|NCT03414047|Experimental|Prexasertib Cohort 1|Participants received 105 milligram per square meter (mg/m²) prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, breast cancer susceptibility gene (BRCA) negative and have received ≥3 lines of prior therapy.
3132280|NCT03414047|Experimental|Prexasertib Cohort 2|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA negative and have received <3 lines of prior therapy.
3132281|NCT03414047|Experimental|Prexasertib Cohort 3|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum-resistant disease, BRCA positive and received a prior poly ADP ribose polymerase (PARP) inhibitor.
3132282|NCT03414047|Experimental|Prexasertib Cohort 4|Participants received 105 mg/m² prexasertib as an approximately 60 (+10) minute IV infusion on Day 1 and 15 of a 28-day cycle. Participants were with platinum refractory disease, BRCA positive or negative, no restriction on number of lines of prior therapy.
3132283|NCT03414359|Active Comparator|2% Lidocaine|Group LEBF received 20 ml of 2% lidocaine (combined with the following adjuncts [0.15 ml of 0.1% epinephrine, 2 ml of 8.4% sodium bicarbonate and 2 ml of 100 mcg fentanyl
3132284|NCT03414359|Experimental|3% Chloroprocaine|20 ml of 3% chloroprocaine with 4 ml 0.9% sodium chloride
3132285|NCT03415022|Experimental|4-week computer-based treatment|A 4-week (8-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks.
3132286|NCT03415022|Experimental|8-week computer-based treatment|An 8-week (12-sessions) course of computer-based treatment. Participants will receive treatment twice a week for four weeks, and then once a week for the subsequent four weeks.
3132287|NCT03415152||Omacor (Omega-3-acid ethyl esters)|Adult patients with history of myocardial infarction not earlier than 6 months ago and/or with diagnosis of hypertriglyceridemia who having been prescribed Omacor for at least 6 months.
3132288|NCT03415178|Experimental|Auto-Injector Device (AI)|Alirocumab 300 milligram (mg) subcutaneous (SC) injection on Week 0 (Day 1), self-administered using AI device, on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, participants switched to other arm of SYDNEY device to receive Alirocumab 300 mg, self- administered (unsupervised) using new auto-injector device (SYDNEY) every 4 weeks (Q4W) from Week 4 until Week 16 in the single arm treatment period added to lipid modifying therapy (LMT).
3132289|NCT03415178|Experimental|New Auto-injector Device (SYDNEY)|Alirocumab 300 mg SC injection on Week 0 (Day 1), self-administered using new auto-injector device (SYDNEY), on-site under supervision in the parallel arm treatment period of 4 weeks. From Week 4, same treatment (Alirocumab 300 mg) with the same device (SYDNEY) was self-administered, (unsupervised) Q4W until Week 16 in the single arm treatment period added to LMT. Duration of single arm treatment period was 12 weeks, i.e. from Week 4 to 16.
3132290|NCT03415243|Experimental|Treatment A Group|Participants will receive a single dose (1 sachet) of the investigational product (Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg).
3132291|NCT03415243|Experimental|Treatment B Group|Participants will receive a single dose (2 caplets) of the investigational product (Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg).
3132292|NCT03415581|Placebo Comparator|Doxazosin (Placebo First)|Maintenance on a daily dose of oral doxazosin (0 mg) for 4 weeks, followed by 4-week maintenance on active doxasozin (up to 16mg/day or the highest tolerated dose. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
3132293|NCT03415581|Active Comparator|Doxazosin (Active First)|Maintenance on a daily dose of oral doxazosin (16 mg, or the highest tolerated dose) for 4-weeks, followed by 4-week maintenance on placebo doxasozin. During this time subjects complete testing sessions (Self-administration, Cue session) assessing the abuse potential of intranasal oxycodone.
3132294|NCT03416127|Experimental|Propolis|Propolis capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
3132295|NCT03416127|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
3132296|NCT03416127|Placebo Comparator|Placebo|Placebo capsules, two times per day before break-fast and dinner during 12 weeks.
3132297|NCT03416179|Experimental|Arm A (Intensive Study)|Glasdegib + '7+3' Induction(s)
3132298|NCT03416179|Placebo Comparator|Arm B (Intensive Study)|Placebo + '7+3' Induction(s)
3132299|NCT03416179|Experimental|Arm A (Non-intensive study)|Glasdegib + azacitidine
3132300|NCT03416179|Placebo Comparator|Arm B (Non-intensive study)|Placebo + azacitidine
3132301|NCT03416621|Active Comparator|Experimental: Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
3132302|NCT03416621|Placebo Comparator|Placebo Comparator: Counseling and placebo drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
3132303|NCT03416621|Experimental|Active Comparator: Counseling and active drug intervention|enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
3132304|NCT03416946|Active Comparator|Custom Block Instrumentation|Patients-specific custom cutting blocks using the Smith and Nephew Visionaire system
3132305|NCT03416946|Active Comparator|Traditional Instrumentation|Traditional cutting methods for Total Knee Replacement
3132306|NCT03416985|Active Comparator|Manual Toothbrush|Patients will be asked to use a manual toothbrush for 30 days
3132307|NCT03416985|Active Comparator|Sonic Toothbrush|Patients will be asked to use a sonic toothbrush for 30 days
3132308|NCT03416985|Active Comparator|Pulsating Toothbrush|Patients will be asked to use a pulsating toothbrush for 30 days
3132309|NCT03417024||All Subjects|All subjects will undergo scanning with both Automated Breast Ultrasound and Digital Breast Tomosynthesis devices.
3132310|NCT03417141|Experimental|Valchor treatment of Lichen Planopilaris|Once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
3132311|NCT03417219|Experimental|Mobile Media Education and Skill-Building Rehabilitation Int|The investigators' ESBR-m intervention consists of four, 90-minute group (= 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
3132312|NCT03417219|Active Comparator|Usual Care|"Usual Care (plus supplemental educational materials). Participants randomized to the Usual Care (UC) group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
3132313|NCT03417466|Experimental|Study arm|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-4, or 6).
3132314|NCT03417505|Experimental|Treated followed by untreated|Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).
3132315|NCT03417505|Experimental|Untreated followed by treated|Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).
3132316|NCT03417557|Experimental|Comfilcon A lens (test)|Subjects are randomized to wear comfilcon A lens for up to 3 hours, either as first or second lens during this cross over study.
3132317|NCT03417557|Active Comparator|Omafilcon B Lens (control)|Subjects are randomized to wear omafilcon B lens for up to 3 hours, either as first or second lens during this cross over study.
3132318|NCT03417713||All Subjects|This group/cohort is expected to be representative of the general population that would require mobile fluoroscopic imaging with C-arm devices, such as OEC Elite.
3132319|NCT03417739|Experimental|BVD-523|BVD-523 is administered at the RP2D of 600mgs taken twice daily orally for 28 consecutive days (1 cycle). Planned does may modified based on toxicity.
3132320|NCT03417752|Experimental|Exposure to firearm safety Public Service Announcement (PSA)|Exposure to the firearm safety PSA (approx. 2.5 minutes long) once per week for 3 weeks.
3132321|NCT03417752|Experimental|Exposure to a mix of PSAs|Exposure to a general health promotion video (approx. 2 minutes long) 1 week post-randomization followed by exposure to firearm safety PSA at 2- and 3-weeks post-randomization.
3132322|NCT03417752|Active Comparator|Active control|Exposure to the general health promotion video once per week for 3 weeks.
3132323|NCT03417778|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
3132324|NCT03417778|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
3132325|NCT03417778|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment and matched healthy controls will receive a single dose of filgotinib on Day 1.
3132326|NCT03417830|Experimental|Subjects with ATTR-CM in Part A|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part A will participate in two anti-SAP dosing sessions approximately 26 days in duration. The first two subjects in Part A will have up to three 89Zr PET scans, while the remaining subject will undergo up to two 89Zr PET scans.
3132327|NCT03417830|Experimental|Subjects with ATTR-CM in Part B|Approximately 3 subjects with either wild type or inherited ATTR-CM will be included. Subjects in Part B will participate in one anti-SAP dosing session. Subjects will undergo up to two 89Zr PET scans.
3132328|NCT03418051|No Intervention|Control|Control group that will receive no intervention throughout the duration of the study (2-weeks).
3132329|NCT03418051|Experimental|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade III anterior-to-posterior talocrural joint mobilization with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
3132330|NCT03418051|Experimental|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage bouts with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
3132331|NCT03418064|Experimental|fanfilcon A toric|Subjects who wore fanfilcon A toric contact lens, either as the first or second lens in this cross-over study.
3132332|NCT03418064|Active Comparator|lotrafilcon B|Subjects who wore lotrafilcon B toric contact lens, either as the first or second lens in this cross-over study.
3132333|NCT03418324|Experimental|Arm A: TRC105 + Abiraterone|Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone
3321391|NCT02018510|Experimental|Group 2D|HIV-infected individuals on or off ART 30 mg/kg, single dose IV administration of 3BNC117
3132334|NCT03418324|Experimental|Arm E: TRC105 + Enzalutamide|Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide
3132335|NCT03418376|Experimental|MS beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
3132336|NCT03418376|Placebo Comparator|MS placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
3132337|NCT03418376|Experimental|HC beta-alanine supplementation|Subjects will perform a 6-month exercise intervention and receive beta-alanine supplements.
3132338|NCT03418376|Placebo Comparator|HC placebo group|Subjects will perform a 6-month exercise intervention and receive placebo tablets.
3132339|NCT03418545|Experimental|JUVÉDERM VOLBELLA® XC|JUVÉDERM® VOLBELLA™ XC injectable gel was injected into the infraorbital and adjacent area at Randomization as determined by the investigator. Participants were eligible to receive an optional touch-up treatment 1 month later and an optional repeat treatment 12 months after last treatment, if applicable. A maximum of 2.2 milliliter (mL) per side was injected for initial and touch-up treatments combined.
3321392|NCT02018510|Experimental|Group 2E|HIV-infected individuals off ART, VL 2,000-100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3132340|NCT03418545|No Intervention|No-treatment Control|Participants randomized to the No-treatment Control group completed a 3-month No-treatment Period. Participants were then eligible to receive optional treatment with JUVÉDERM® VOLBELLA™ XC injectable gel injected into the infraorbital and adjacent area followed by an optional touch-up treatment 1 month later.
3132341|NCT03418571|Experimental|ALX-0171 1.5 mg/kg|
3132342|NCT03418571|Placebo Comparator|Placebo|
3132343|NCT03418662|No Intervention|Control Arm (Standard Colonoscopy)|Standard colonoscopy with no device attachment.
3132344|NCT03418662|Experimental|EndoRings Colonoscopy|Colonoscopy with EndoRings device attached to the distal end of the scope.
3132345|NCT03418714|Experimental|Salvinorin A administration|All volunteers will be assigned to the salvinorin A administration arm.
3132346|NCT03419403|Experimental|Standard Steroids|Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days
3321393|NCT02018510|Experimental|Group 3|HIV-infected individuals off ART, VL < 2,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3321394|NCT02018510|Experimental|Group 4|HIV-infected individuals on ART, VL < 100,000 copies/ml 30 mg/kg, single dose IV administration of 3BNC117
3321395|NCT02018510|Experimental|Group 5A|HIV-infected individuals on ART, VL < 20 copies/ml 10 mg/kg, single dose IV administration of 3BNC117
3148657|NCT00153881|Experimental|1|Docetaxel/Carboplatin every 3 weeks for 2 cycles then concommitant chemotherapy and radiation Docetaxel weekly for 5 doses without premedication, then Capecitabine will be given orally, one dose prior to each fraction or irradiation (28 cycles).
3148658|NCT00153894|Active Comparator|Group A|Immediate Exercise
3148659|NCT00153894|Active Comparator|Group B|Delayed Exercise (delay by 16 weeks)
3132895|NCT03464383|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
3132896|NCT03464383|Active Comparator|Standard of Care|A psychiatry referral order placed by epileptologist under typical care circumstances (internal or external referral based on the participant's geographic preferences). Internal referrals will be processed by current clinic/institutional protocols. External referral orders will be printed and provided to the patient along with brief instructions on how to find a provider covered by the patient's insurance.
3132897|NCT03464383|Other|Survey Arm|This option will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are found to be ineligible for intervention arms of the study, or those who are eligible for the intervention arm but decline to participate in the intervention.
3132898|NCT03464422|Experimental|Young gay and bisexual men of color|Approximately 30 young MSM of color will take part in weekly 90-minute group treatment sessions over 10 weeks. All participants will complete outcome assessments at baseline and three months post-treatment, as well as an exit interview.
3132899|NCT03465436|Experimental|100 milligrams (mg) Lasmiditan|A single, PO dose of 100 mg lasmiditan administered on Day 1 in one of four treatment periods.
3132900|NCT03465436|Experimental|400 mg Lasmiditan|A single, PO dose of 400 mg lasmiditan administered on Day 1 in one of four treatment periods.
3132901|NCT03465436|Placebo Comparator|Placebo|Placebo for lasmiditan and placebo for moxifloxacin administered on Day 1 in one of four treatment periods.
3132902|NCT03465436|Active Comparator|Moxifloxacin|A single, PO dose of moxifloxacin administered on Day 1 in one of four treatment periods.
3132903|NCT03465709|Experimental|Pegcetacoplan Study Drug|
3132904|NCT03465722|Experimental|avapritinib|300 mg PO QD
3132905|NCT03465722|Active Comparator|regorafenib|160 mg PO QD
3132906|NCT03465878|Experimental|LY900014-Part A|Participants received single 0.2 U/kg of body weight subcutaneous (SC) bolus injection of 100 U/mL LY900014.
3132907|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part A|Participants received single 0.2 U/kg of body weight SC bolus injection of 100 U/mL of Humalog.
3132908|NCT03465878|Experimental|LY900014-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL LY900014 delivered using the continuous subcutaneous insulin infusion (CSII) pump.
3132909|NCT03465878|Active Comparator|Humalog (Insulin Lispro)-Part B|Participants received single 0.2 U/kg of body weight SC bolus infusion of 100 U/mL Humalog delivered using the CSII pump.
3132910|NCT03465904|Experimental|Verum|2-hour external trigeminal nerve stimulation with the Verum Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
3132911|NCT03465904|Sham Comparator|Sham|2-hour external trigeminal nerve stimulation with the Sham Cefaly® Abortive Program device, as abortive treatment of an early stage migraine attack
3132912|NCT03466047|Experimental|Protein stomach|Encapsulated protein released in the stomach
3132913|NCT03466047|Experimental|Protein distal small intestine|Encapsulated protein released in the distal small intestine
3132914|NCT03466047|Experimental|CHO stomach|Encapsulated CHO released in the stomach
3132915|NCT03466047|Experimental|CHO distal small intestine|Encapsulated CHO released in the distal small intestine
3132916|NCT03466047|Experimental|Fat stomach|Encapsulated Fat released in the stomach
3132917|NCT03466047|Experimental|Fat distal small intestine|Encapsulated Fat released in the distal small intestine
3132918|NCT03466060|Active Comparator|etafilcon A|Eligible subjects were randomized to the etafilcon A lens in both eyes throughout the entire duration of the study.
3132919|NCT03466060|Active Comparator|senofilcon A|Eligible subjects were randomized to the senofilcon A lens in both eyes throughout the entire duration of the study.
3132920|NCT03466060|Active Comparator|senofilcon C|Eligible subjects were randomized to the senofilcon C lens in both eyes throughout the entire duration of the study.
3132921|NCT03466073|Experimental|Single Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg v. placebo (NSS) in addition to standard of care
3132922|NCT03466073|Experimental|Multiple Dose 6 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 6 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
3132923|NCT03466073|Experimental|Multiple Dose 12 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 12 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
3132924|NCT03466073|Experimental|Multiple Dose 24 mg/kg|Intravenous administration of recombinant human plasma gelsolin at 24 mg/kg once per day for 3 days v. placebo (NSS) in addition to standard of care
3188719|NCT00769938|Active Comparator|Aspirin + clopidogrel + oral anticoagulation|
3132925|NCT03466086|Experimental|Test/Control|Subjects between the ages of 18-69 years of age will sequentially try the Test and Control eye drops in a random order
3132926|NCT03466086|Experimental|Control/Test|Subjects between the ages of 18-69 years of age will sequentially try the Control and Test eye drops in a random order.
3132927|NCT03466099|Experimental|KVD001 Injection (high dose)|
3132928|NCT03466099|Experimental|KVD001 Injection (low dose)|
3132929|NCT03466099|Sham Comparator|Sham Procedure|
3132930|NCT03466918|Experimental|Patients with SAPIEN 3 THV|Patients will be treated with Edwards SAPIEN 3 Transcatheter Heart Valve and Commander delivery system
3132931|NCT03467048|Experimental|McGrath videolaryngoscopy|Endotracheal intubation using McGrath videolaryngoscopy in an appropriate size (usually blade size 3 or 4)
3132932|NCT03467048|Active Comparator|Direct laryngoscopy|Endotracheal intubation using direct laryngoscopy with an appropriately sized Macintosh blade (usually size 3 or 4)
3132933|NCT03467217|Active Comparator|Losartan potassium capsule|Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to <150 kg.
3132934|NCT03467217|Placebo Comparator|Placebo losartan capsule|Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to <150 kg.
3132935|NCT03467412|Experimental|0.00625 μg FOL-005|50 μl solution (a total dose of 0.00625 μg FOL-005) injected intradermally three times per week for 12 weeks.
3188720|NCT00769938|Active Comparator|Oral anticoagulants + clopidogrel|
3188721|NCT00769990|Experimental|Genistein|Patients treated with Genistein who are going to undergo palliative radiation treatments for painful boney metastases.
3188722|NCT00770003|Experimental|1|
3188723|NCT00770003|Placebo Comparator|2|
3132936|NCT03467412|Experimental|0.025 μg FOL-005|50 μl solution (a total dose of 0.025 μg FOL-005) injected intradermally three times per week for 12 weeks.
3132937|NCT03467412|Experimental|0.050 μg FOL-005|50 μl solution (a total dose of 0.050 μg FOL-005) injected intradermally three times per week for 12 weeks.
3188724|NCT00770016|Experimental|1|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic - intramyocellular lipids in 12 adult patients, recently diagnosed with hypothyroidism
3188725|NCT00770042|Experimental|Group 1|Ketoconazole 400 mg qd for 5 days (Days 2-6) plus a single dose of 50 mg avanafil on Days 1 and 6
3188726|NCT00770042|Experimental|Group 2|Erythromycin 500mg every 12 hours for 5 days (Days 2-6) plus a single dose of 200 mg Avanafil on Days 1 and 6.
3188727|NCT00770042|Experimental|Group 3|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8) plus a single dose of 50 mg avanafil on Days 1 and 8
3188728|NCT00770068||Experimental group|All participants testing positive for tree and ragweed pollen allergies, as determined by levels of immunoglobulin E (IgE) antibodies
3132938|NCT03467412|Experimental|0.100 μg FOL-005|50 μl solution (a total dose of 0.100 μg FOL-005) injected intradermally three times per week for 12 weeks.
3132939|NCT03467412|Placebo Comparator|Placebo|50 μl solution (placebo) injected intradermally three times per week for 12 weeks.
3188729|NCT00770068||Control group|All participants testing negative for tree and ragweed pollen allergies, as determined by levels of IgE antibodies
3188730|NCT00770081|Experimental|1|50mg qd vildagliptin
3188731|NCT00770081|Active Comparator|2|sitagliptin (25mg qd)
3132940|NCT03467425|Experimental|TRELEGY ELLIPTA (FF/UMEC/VI: 100 mcg/62.5 mcg/25 mcg)|Eligible subjects will receive a blended combination of FF in the first strip (100 mcg per blister) and UMEC/VI in second strip (62.5 mcg UMEC per blister and 25 mcg VI per blister), a single inhalation once daily in the morning in the same TRELEGY ELLIPTA Dry Powder Inhaler (DPI) via inhalation route for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
3132941|NCT03467425|Active Comparator|Non-ELLIPTA MITT|Eligible subjects will receive the ICS/LAMA/LABA products twice daily and dosing regimens as prescribed by their physician for a period of 24 weeks. Study treatment may be augmented with other prescribed COPD medications such as including rescue medications, which will be prescribed and obtained according to usual practice.
3132942|NCT03467477|Experimental|Flortaucipir PET Scan|
3132943|NCT03467685|Placebo Comparator|VAD Off arm|This will be the group that has the VAD placed on their skin in the off mode, i.e. no vibration
3132944|NCT03467685|Experimental|VAD On arm|This will be the group that has the VAD placed on their skin in the on mode, i.e. vibration
3132945|NCT03467763|Active Comparator|Metformin Hydrochloride Extended Release|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of metformin extended release, followed by 500 mg metformin XR, 750 mg, and 1,000 mg metformin XR with each treatment period separated by a 2-week course of placebo.
3188732|NCT00770094|Active Comparator|Group 1|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the AMO/VISX CustomVue™ wavefront guided Excimer Laser System performed on the contralateral eye
3188733|NCT00770094|Active Comparator|Group 2|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment in one eye of the subject and the Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System performed on the contralateral eye
3148660|NCT00153933|Experimental|CC-5013 in combination with bortezomib|Participants will receive bortezomib intravenously on day 1,4,8 and 11 followed by 10 days of rest. CC-5013 will be given orally on days 1-14 followed by 7-days of rest. One cycle lasts 21 days.
3132946|NCT03467763|Placebo Comparator|Placebo|Patients will be assigned to take their baseline medication regimen plus 2 weeks of 250 mg per day of placebo, followed by 500 mg placebo, 750 mg, and 1,000 mg placebo with each treatment period separated by a 2-week course of metformin XR in the same increments of dosage.
3148661|NCT00153946|Active Comparator|A|The patients who are allocated to Argatroban monotherapy
3148662|NCT00153946|Active Comparator|B|The patients who are allocated to Edaravone-Argatroban combination therapy
3148663|NCT00153972|Active Comparator|Levodopa|Levodopa 300 mg per day orally.
3148664|NCT00153972|Active Comparator|Cabergoline|Cabergoline 3 mg per day orally.
3148665|NCT00153998|Active Comparator|1|Cetuximab and FOLFIRI
3148666|NCT00153998|Active Comparator|2|Cetuximab and FOLFOX
3148667|NCT00154076|Experimental|1|
3148668|NCT00154076|Active Comparator|2|
3148669|NCT00154089|Experimental|EM-1421|"Administration of EM-1421 intravaginally once per week for 3 weeks~Dose level of 45 mg/application (1% w/w) or 90 mg/application (2% w/w)"
3148670|NCT00154115|Experimental|1|Levosimendan
3148671|NCT00154115|Placebo Comparator|2|
3148672|NCT00154154|Active Comparator|A|General Psychiatric Management
3148673|NCT00154154|Experimental|2|Dialectal Behaviour Therapy
3148674|NCT00154180|Active Comparator|Arm 1|CEE 0.45 mg w/ Prometrium 200 mg patch 0.05 mg w/ Prometrium 200 mg
3148675|NCT00154180|Placebo Comparator|Arm 2|Placebo patch, placebo CEE, placebo Prometrium
3148676|NCT00154193|Active Comparator|Cyclosporine|
3148677|NCT00154258|Experimental|1|
3148678|NCT00154336|Active Comparator|Imatinib 400mmg OD +MTX|
3148679|NCT00154336|Placebo Comparator|Imatinib Placebo + MTX|
3148680|NCT00154349|Experimental|imatinib mesylate|
3148681|NCT00154622|No Intervention|pain/ disability survey|
3148682|NCT00154687|Experimental|A|
3148683|NCT00154778|Experimental|A|
3148684|NCT00154804|Experimental|A|
3148685|NCT00154843|Experimental|A|Lycopene 15 mg/day
3148686|NCT00154843|Experimental|B|Lycopene 30 mg/day
3148687|NCT00154882|Experimental|A|
3148688|NCT00155259|Experimental|A|
3148689|NCT00155311|Experimental|days after treatment|different days after orthodontic treament, samples will be taken.
3148690|NCT00155389|Active Comparator|H pylori eradication|All enrolled subjects received chemoprevention with Helicobacter pylori eradication
3148691|NCT00155402|Experimental|1|Use of fibrin glue after corneal surgery or transplantation
3148692|NCT00155454|Experimental|Study group|Group 1 had intravitreal long acting gas (10% C3F8) injection in the vitreous cavity at the end of surgery
3148693|NCT00155454|Sham Comparator|Control group|Group 2 did not receive intravitreal long acting gas (10% C3F8)
3132947|NCT03467945|Experimental|Treatment Sequence 1|Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
3148694|NCT00155545|No Intervention|Metformin|
3148695|NCT00155558|Experimental|A|
3132948|NCT03467945|Experimental|Treatment Sequence 2|Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
3148696|NCT00156026|Experimental|1|Immediate Treatment - LEEP - Loop electrosurgical excision procedure
3148697|NCT00156026|No Intervention|2|Colposcopic Follow-up
3132949|NCT03467945|Experimental|Treatment Sequence 3|Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
3148698|NCT00156052|Experimental|Hypofractionated whole breast radiation|Subjects treated with 4250 cGY in 16 fractions
3148699|NCT00156052|Active Comparator|Conventional whole breast radiation|Subjects treated with 5000 cGY in 25 fractions
3148700|NCT00156091|Active Comparator|1|Olanzapine 20 mg QD
3148701|NCT00156091|Experimental|2|Asenapine 5 or 10 mg BID
3132950|NCT03467945|Experimental|Treatment Sequence 4|Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
3132951|NCT03467971|Experimental|Metformin-Gliclazide (fasted), Then Metformin-Gliclazide (fed)|Participants received single dose of Metformin 1000 milligram (mg) and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 2. Each treatment period was separated by a 14-day wash-out period.
3132952|NCT03467971|Experimental|Metformin-Gliclazide (fed), Then Metformin-Gliclazide (fasted)|Participants received single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fed state in treatment period 1 followed by single dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting state in treatment period 2. Each treatment period will be separated by a 14-day wash-out period.
3132953|NCT03468075|Experimental|Gemcitabine + High-Dose Ascorbate|Subjects will receive ascorbate, 75g, on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Gemcitabine will be administered on Days 1, 8 and 15, after the infusion of ascorbate. Concomitant treatment will continue for 6 cycles. Patients whose disease has not progressed while receiving gemcitabine and ascorbate and who are tolerating therapy may continue either single agent gemcitabine or concomitant treatment beyond 6 cycles at the discretion of the investigator.
3132954|NCT03468179|Experimental|Oatmeal|Subjects will arrive for study fasting. IV access will be obtained, and baseline blood drawn. They will be fed 80gm/100kg oatmeal, and blood levels will be drawn at 30, 60, 90, and 120 minutes.
3132955|NCT03468543|Experimental|Cohort 1|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation A; then formulation B; following each administration MRI will be performed for up to 14 days
3132956|NCT03468543|Experimental|Cohort 2|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation C; then formulation D; following each administration MRI will be performed for up to 14 days
3132957|NCT03468543|Experimental|Cohort 3|Subjects will receive an oral administration of 50 mg of Memantine HCl prototype capsule formulation E; followed by MRI for up to 14 days
3132958|NCT03468816|Experimental|A-B-A|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant A, at next dressing change they received variant B, and on the third dressing change they received variant A again. No washout periods.
3132959|NCT03468816|Experimental|B-A-B|Investigational device is Absorbest moisture sensor in variant A and variant B, placed on the backside of the wound dressing DryMax Extra Soft. Participants performed three dressing changes. They first received variant B, at next dressing change they received variant A, and on the third dressing change they received variant B again. No washout periods.
3132960|NCT03468855|Experimental|ATI-50002 Topical Solution|ATI-50002 topical solution, high dose active, twice-daily, 24 weeks
3132961|NCT03468920|Experimental|Arm 1: IV Acetaminophen group|Patients randomized to Arm 1 will receive IV Acetaminophen 1000mg in 100mL NS once and a PO placebo pill preoperatively
3132962|NCT03468920|Active Comparator|Arm 2: PO Acetaminophen group|Patients randomized to Arm 2 will receive IV normal saline 100mL once and Acetaminophen 1000 mg PO once preoperatively
3188734|NCT00770094|Active Comparator|Group 3|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment in one eye of the subject and the Bausch and Lomb Planoscan™ Excimer Laser System performed on the contralateral eye
3188735|NCT00770107|Active Comparator|Thiamine|
3132963|NCT03468933|Active Comparator|Fibrinolytic therapy group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase) via chest tube.
3188736|NCT00770107|Placebo Comparator|Placebo|
2431072|NCT03359382|Experimental|exercise|
3188737|NCT00770159|Experimental|1|MK0822
3188738|NCT00770159|Placebo Comparator|2|Placebo to MK0822
3188739|NCT00770172|Experimental|Arm I|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
3132964|NCT03468933|Active Comparator|Medical Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
3132965|NCT03469336|Other|All subjects|All subjects will receive all six interventions/treatments applied to six different treatment fields.
3132966|NCT03469349|Experimental|Actovegin 1200 mg|Actovegin 1200 milligram (mg), intravenously, once daily for up to 2 weeks followed by actovegin 200 mg, tablets, orally, thrice daily (TID) (1200 mg/day) for up to 10 weeks.
3132967|NCT03469349|Placebo Comparator|Placebo|Actovegin placebo-matching, intravenously, once daily for up to 2 weeks and actovegin placebo-matching tablets, orally, TID for up to 10 weeks.
3132968|NCT03470012|Experimental|Treatment Arm|Investigational tape
3132969|NCT03470194|Active Comparator|Interpretation Modality: In person|Participants assigned to this group will use an in person interpreter for the duration of the UROGYN office visit
3188740|NCT00770172|Experimental|Arm II|Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.
3188741|NCT00770185|Experimental|Ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
3188742|NCT00770198||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biospy in our institution
3132970|NCT03470194|Active Comparator|Interpretation Modality: Telephonic|Participants assigned to this group will use a phone interpreter for the duration of the UROGYN office visit
3132971|NCT03470493|Experimental|Participants|ApneaLink Air
3132972|NCT03470545|Experimental|mavacamten (MYK-461)|
3132973|NCT03470545|Placebo Comparator|Placebo|
3132974|NCT03470740|Other|intervention group|An individualized rheumatoid arthritis self-management program for managing RA patients' physical behavioral problems was applied for the intervention group. The program was based on the self-efficacy theory and the four resources were incorporated to emphasize patients' knowledge, skill, and responsibility in managing their RA situations.
3132975|NCT03470740|No Intervention|control group|The control group received general information on rheumatoid arthritis care and follow-up.
3132976|NCT03471065|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
3132977|NCT03471078|Experimental|Avatrombopag|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
3132978|NCT03471078|Placebo Comparator|Placebo|Study is 2:1 randomization ratio (avatrombopag to placebo). Investigational product administered orally once daily for 5 days prior to chemotherapy and 5 days following chemotherapy treatment.
3132979|NCT03471832|Experimental|stenfilcon A lens|MyDay contact lens
2431073|NCT03359369||Septic Patients|
3132980|NCT03471832|Active Comparator|narafilcon A lens|1-Day Acuvue TruEye
3188743|NCT00770198||chronic HCV hepatitis|chronic HCV hepatitis patients undergoing a transjugular liver biopsy in our institution
3132981|NCT03471871|Experimental|HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg|Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
3148702|NCT00156091|Other|3|Double-Blind subjects randomized to only placebo medication for 6 weeks in the short-term 041021 or 041022 asenapine trials, were randomized (double-blind) Into the long-term 041512 asenapine extension trial and received asenapine 5 mg BID for Week 1. After Week 1, subjects received asenapine (either 5 mg BID or 10 mg BID) for the remainder of the 52 week trial.
3132982|NCT03471871|Experimental|HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo|Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
3148703|NCT00156104|Experimental|1|Asenapine 5 mg BID
3148704|NCT00156104|Experimental|2|Asenapine 10 mg BID
3148705|NCT00156104|Active Comparator|3|Haloperidol 4m mg BID
3148706|NCT00156104|Placebo Comparator|4|placebo
3148707|NCT00156117|Experimental|1|asenapine 5 mg BID and 10 mg BID
3148708|NCT00156117|Placebo Comparator|2|Placebo against olanzapine and asenapine
3148709|NCT00156117|Active Comparator|3|olanzapine 15 mgQD
3148710|NCT00156130||1|Accelerated whole breast irradiation
3148711|NCT00156130||2|Conventional whole breast irradiation
3148712|NCT00156156|Experimental|1|
3148713|NCT00156156|Experimental|2|
3148714|NCT00156182|Experimental|1|
3148715|NCT00156195|Experimental|1|
3148716|NCT00156195|Experimental|2|
3148717|NCT00156208|Experimental|1|
3148718|NCT00156208|Experimental|2|
3148719|NCT00156299|Experimental|Dexamethasone plus Choline Magnesium Trisalicylate|Dexamethasone plus Choline Magnesium Trisalicylate
3132983|NCT03471871|Experimental|HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg|Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period.
3132984|NCT03471871|Experimental|OSA Cohort, Sequence D: Placebo, Lemborexant 10mg|Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
3132985|NCT03471871|Experimental|OSA Cohort, Sequence E: Lemborexant 10mg, Placebo|Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period.
3132986|NCT03471975|Active Comparator|direct laryngoscope|teaching tracheal intubation using McGrath video laryngoscope as direct laryngoscope. Only trainer can see the monitor.
3132987|NCT03471975|Active Comparator|video laryngoscope|"teaching tracheal intubation using McGrath video laryngoscope using video function.~Trainer and Trainee both see the monitor."
3132988|NCT03472014|Experimental|IMVAMUNE®|Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals
2431074|NCT03359369||Non Septic Patients|
3132989|NCT03472287|Experimental|Cohort 1 (Adolescents, Adults)|Adolescent and adult subjects with EB (aged 12 years and older) received diacerein 1% ointment daily for 10 days.
3148720|NCT00156299|Experimental|Choline Magnesium Trisalicylate|Choline Magnesium Trisalicylate
3132990|NCT03472287|Experimental|Cohort 2 (Children)|Children with EB (aged 4 to 11 years, inclusive) received diacerein 1% ointment daily for 10 days.
3132991|NCT03472326|Experimental|Part 1 Sentinel Cohort 1: GS-9131 60 mg|Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
3148721|NCT00156338|Experimental|1|volume and sodium restriction
3148722|NCT00156338|Active Comparator|2|volume restriction
3132992|NCT03472326|Experimental|Part 1 Sentinel Cohort 2: GS-9131 180 mg|Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
3132993|NCT03472326|Experimental|Part 1: Randomized Cohort|Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
3132994|NCT03472326|Experimental|Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV|Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
3132995|NCT03472326|Experimental|Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF|Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA > 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
3148723|NCT00156338|Active Comparator|3|liberal fluid management
3148724|NCT00156416|Experimental|Meditation group|Participants received 8 weeks of mindfulness meditation instruction and support
3148725|NCT00156416|Active Comparator|Education group|Participants received 8 weeks of healthy living instruction
3148726|NCT00156507|Experimental|1|Parents of children in the experimental group receive asthma education prior to NICU discharge.
3148727|NCT00156637|Other|Arm 1|
3148728|NCT00156637|Active Comparator|Arm 2|Dosing & Side Effect Monitoring
3148729|NCT00156650|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (Depo-Medroxyprogesterone) (injected into muscle Day 0 & at Month 3)
3148730|NCT00156650|Active Comparator|2|T gel for 6 months + DMPA (Day 0 & Month 3) + Acyline 300 mcg/kg twice monthly for 12 weeks
3148731|NCT00156663|Other|Arm 1|
3148732|NCT00156676|Experimental|Arm 1|Cross over from body-weight support treadmill to Lokomat
3148733|NCT00156676|Experimental|Arm 2|Cross over from Lokomat to body-weight support treadmill
3148734|NCT00156702|Active Comparator|1|
3148735|NCT00156702|No Intervention|2|
3132996|NCT03472469|Active Comparator|Original MMPR - descending dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
3132997|NCT03472469|Active Comparator|MAST MMPR - escalating dose arm|Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.
3132998|NCT03472521|Experimental|Gabapentin|Gabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
3132999|NCT03472521|Placebo Comparator|Control|Matched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
3133000|NCT03472534|Other|study in healthy volunteers|diacerein 1% ointment
3133001|NCT03472547|Experimental|Single cohort (Healthy Volunteers)|diacerein 1% ointment
3133002|NCT03472885|Experimental|Group 1: 100 mg Danicopan TID + Eculizumab|Starting dose of 100 mg danicopan TID in combination with eculizumab.
3133003|NCT03472885|Experimental|Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab|Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
3133004|NCT03472885|Experimental|Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab|Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
3133005|NCT03472885|Experimental|Group 4: Optimal Dose of Danicopan TID + Eculizumab|Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.
3133006|NCT03473171|Experimental|Nasal non-invasive ventilation with RAM cannula|
3133007|NCT03473184|Experimental|Single Cohort (Healthy Volunteers)|Single cohort received diacerein 1% ointment
3133008|NCT03473197|Other|Single Cohort (Healthy Volunteers)|Diacerein 1% topical ointment Intra-subject photoallergy (photosensitization) test
3133009|NCT03473236|Experimental|Cohort 1A|Dose 1 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133010|NCT03473236|Experimental|Cohort 2A|Dose 2 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133011|NCT03473236|Experimental|Cohort 3A|Dose 3 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133012|NCT03473236|Experimental|Cohort 4A|Dose 4 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133013|NCT03473236|Experimental|Cohort 5A|Dose 5 Single Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133014|NCT03473236|Experimental|Cohort 1B|Dose 1 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133015|NCT03473236|Experimental|Cohort 2B|Dose 2 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133016|NCT03473236|Experimental|Cohort 3B|Dose 3 Multiple Ascending Dose Protocol: within the cohort, 6 participants receive active drug (GB002) and 2 participants receive placebo.
3133017|NCT03473301|Experimental|Allogeneic Umbilical Cord Blood|Subjects will receive a single intravenous infusion of a maximum of 10x107/kg allogeneic umbilical cord blood (CB) cells
3133018|NCT03473301|Experimental|Cord Tissue Mesenchymal Stromal Cells|Subjects will receive three intravenous infusions of 2x106/kg human umbilical cord tissue cells (hCT-MSC), manufactured from allogeneic umbilical cord donors
3133019|NCT03473301|Active Comparator|Natural History|Subjects will not receive any study product infusion until after the 12 month assessment. At the 12 month visit, they will receive an infusion of allogeneic umbilical cord blood cells so that all study participants will receive some type of cellular therapy.
3133020|NCT03473665|Active Comparator|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
3133021|NCT03473665|Active Comparator|Diclofenac|Diclofenac Delayed Release Oral Tablet 75mg by mouth, every 12 hours for 6 weeks
3133022|NCT03473665|Active Comparator|Meloxicam|Meloxicam tablet 7.5mg by mouth, every 12 hours for 6 weeks
3133023|NCT03473665|Active Comparator|Celecoxib|Celecoxib 200mg capsule by mouth, every 12 hours for 6 weeks
3133024|NCT03473808|Experimental|therapy + vibration|Imperceptible vibration applied to the wrist during a standardized hand task practice therapy program.
3133025|NCT03473886|Experimental|Intervention Arm: PP-MI|Participants will complete an 8-week group physical activity and positive psychology program, in which they will complete exercises related to increasing positive emotions and physical activity during and between the group sessions. They will track their activity (steps) and set personalized physical activity goals each week, as complete a group walk or indoor exercise during the group sessions. We will ask questions about participants' health and health behaviors, and ask them to wear a physical activity monitor at the beginning and end of the program.
3133026|NCT03473977|Experimental|Benralizumab|Subcutaneous dose of 30 mg of Benralizumab every 4 weeks
3133027|NCT03473977|Placebo Comparator|Placebo|Subcutaneous dose of Placebo every 4 weeks
3133028|NCT03474081|Experimental|Subjects receiving FF/UMEC/VI + Placebo to match tiotropium|Eligible subjects will receive FF/UMEC/VI at a dose of 100/62.5/25 microgram (mcg) administered once daily in the morning via ELLIPTA along with placebo to match tiotropium administered once daily in the morning via HANDIHALER. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via metered dose inhaler (MDI).
3133029|NCT03474081|Experimental|Subjects receiving Tiotropium + Placebo to match FF/UMEC/VI|Eligible subjects will receive Tiotropium at a dose of 18 mcg administered once daily in the morning via HANDIHALER along with placebo to match FF/UMEC/VI administered once daily in the morning via ELLIPTA. Subjects will self-administer 4 puffs of rescue medication (Albuterol/salbutamol) via MDI.
3133032|NCT03474172|Experimental|Genuine Tuina|Participants will receive genuine tuina manipulated on their skin in addition to the conventional therapy given by the doctors. The whole process of the Tuina, which may last for 15 minutes, should be completed under the Cloak Shape device. After that the parents and the observers may be required to fill out corresponding questionnaires. The outcomes assessors will ask the child the sense perception of the manipulation via a questionnaire if he is equal or older than 3 years old.
3133033|NCT03474172|Sham Comparator|Sham Tuina|Except for the conventional therapy given by doctors, participants in this group will receive sham Tuina. A cloak shape device will be adopted, while inside the cover the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead of childrens' hand or childrens' body. The acupoints and the manipulation time are the same as real Tuina group. Same questionnaires as those adopted in real Tuina group are also required to be completed.
3133034|NCT03474874|Other|Collagen Dressing and Comparator|NeoMatriX Collagen Dressing and Comparators - positive control and normal saline will be applied to the absorbent pad portion of the exclusive dressing.
3133035|NCT03475056|Experimental|Group 1: cAd3-Marburg vaccine (1x10^10 PU)|cAd3-Marburg vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
3133036|NCT03475056|Experimental|Group 2: cAd3-Marburg vaccine (1x10^11 PU)|cAd3-Marburg vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
3133037|NCT03475316|Experimental|Social Dancing|The program includes Fox-trot, Waltz, and Latin dances.
3133038|NCT03475316|Active Comparator|Treadmill Walking|The treadmill walking training protocol is based on the recommendations of the American College of Sports Medicine (ACSM) and American Heart Association (AHA) for older adults.
3133039|NCT03475875|Experimental|TEST/CONTROL/CONTROL|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
3133040|NCT03475875|Experimental|CONTROL/TEST/TEST|Subjects that are of 18 years or older and current spherical soft contact lens wearers will wear the Test and Control lenses for two weeks each in random order with one of the study lenses being worn twice for a total of 6 weeks per subject.
3133041|NCT03475992|Experimental|Pre-diagnosed breast cancer|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
3188985|NCT00772902|Experimental|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
3133042|NCT03475992|Experimental|Pre-diagnosed breast cyst|"Low-power microwave breast imaging system.~No prior biopsy"
3133043|NCT03475992|Experimental|Pre-diagnosed benign lesion|"Low-power microwave breast imaging system.~Core needle biopsy performed ≥14 days before the microwave breast investigation"
3133044|NCT03476135|Experimental|Group 1:MenACYW Conjugate Vaccine(Previous Exposed to MenACYW)|Participants who received a single dose of MenACYW conjugate vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
3133045|NCT03476135|Experimental|Group2:MenACYW Conjugate Vaccine(Previous Exposed to Nimenrix)|Participants who received a single dose of Nimenrix® vaccine 3 years earlier in a previous vaccine study (MET54), received a booster dose of MenACYW conjugate vaccine at Day 0 in this study (MET62).
3133047|NCT03476278||regional, questionnaire|patients who underwent surgery under regional anesthesia.
3133048|NCT03476798|Experimental|Bevacizumab + Rucaparib|
3133049|NCT03476850|Active Comparator|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
3133050|NCT03476850|Active Comparator|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
3133051|NCT03477006|Experimental|LTLR-WB|Receiving 2 units of low titer, leucocyte reduced, platelet replete whole blood initiated in the prehospital setting during air medical transport and continued (up to 6 units of whole blood followed by standard component resuscitation) thru the early in-hospital phase of care
3133052|NCT03477006|No Intervention|Standard Care|Receiving standard prehospital air medical care and standard of care component (1:1:1) trauma resuscitation thru the early in-hospital phase of care
3133053|NCT03477279|No Intervention|Individual (SOC)|HIV-infected pregnant women enrolled in the individual arm of the study will receive Standard of Care Option B+ procedures.
3148743|NCT00156949|Experimental|Epoetin alfa DT|
3133054|NCT03477279|Experimental|Couple (Intervention)|In addition to receiving standard of care procedures, HIV-infected pregnant women in the couple arm will be provided with an intervention aimed at recruiting their male partners, providing enhanced couple counseling and testing, engaging their male partners in their care, and supporting male partners to receive care and treatment services.
3133055|NCT03477279|No Intervention|HIV-Uninfected Cohort|HIV-uninfected pregnant women will be invited to participate in a cross-sectional study. No intervention will be provided and no follow-up will be conducted.
3133056|NCT03477838|Experimental|CGM Intervention arm|Patients eligible for care at the free clinic with diabetes and A1c greater than 8% on insulin therapy will be identified for CGM use.
3133057|NCT03478163|No Intervention|Control|The patient will not receive antibiotics as part of the study, though if at any time her provider chooses to administer antibiotics either prophylactically or for treatment she will not prohibited in any way from this or any other treatment as appropriate.
3133058|NCT03478163|Experimental|Antibiotics|The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.
3133059|NCT03478254||Vaccination adherence|All type 1 diabetes adults patients attended in Ciudad Real General University Hospital willl be checked for Influenza Vaccination status, Pneumococcal Vaccination status and Hepatitis B Virus (HBV) status.
3133060|NCT03478371|Sham Comparator|Marketed Tampon D|Regular absorbency tampon
3133061|NCT03478371|Sham Comparator|Marketed Tampon M|Regular absorbency tampon
3133062|NCT03478371|Sham Comparator|Marketed Tampon T|Regular absorbency tampon
3133063|NCT03478371|Sham Comparator|Marketed Tampon V|Regular absorbency tampon
3133064|NCT03478644|Experimental|Experimental Denture Wipe|Participants of this arm were instructed to use the experimental wipe to clean their dentures up to 4 times daily.
3133065|NCT03478644|Placebo Comparator|Tap Water|Participants of this arm were instructed to use running tap water to clean their dentures up to 4 times daily.
3133066|NCT03478657|Experimental|Subjects using placebo ELLIPTA DPI|Subjects in stratum 1 and stratum 2 will be of age group from 5 to 7 years and 8 to 11 years respectively. Subjects will take placebo ELLIPTA DPI once daily. During Visit 2 (Day 28) subjects will be randomized to receive questionnaire on ELLIPTA DPI usage either version A or B.
3133067|NCT03478683|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
3148744|NCT00156962|Active Comparator|Epoetin alfa RB|
3148745|NCT00156962|Experimental|Epoetin alfa DT|
3133068|NCT03478683|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
3133069|NCT03478696|Experimental|FF/UMEC/VI 100/62.5/25 mcg|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning plus placebo to match budesonide/formoterol via MDI, two inhalations twice daily plus placebo to match tiotropium via HandiHaler once daily in the morning for 84 days in the treatment period.
3133070|NCT03478696|Active Comparator|Budesonide/formoterol plus tiotropium|Subjects will receive budesonide/formoterol (320/9 mcg) twice daily plus tiotropium (18 mcg) once daily plus placebo via ELLIPTA during the 4-week run-in period. Subjects will be administered budesonide/formoterol 160/4.5 mcg via MDI, two inhalations twice daily plus tiotropium 18 mcg via HandiHaler once daily in the morning plus placebo via ELLIPTA once daily in the morning for 84 days in the treatment period.
3133071|NCT03478787|Experimental|Risankizumab|Participants randomized to risankizumab receive 2 injections of active risankizumab (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4, and then every 12 weeks (q12w) thereafter until the last dose at Week 40 (Week 64 for participants in France).
3133072|NCT03478787|Active Comparator|Secukinumab|Participants randomized to secukinumab receive 2 injections of active secukinumab (300 mg total dosage) SC at Weeks 0, 1, 2, 3, and 4, and then every 4 weeks (q4w) thereafter until the last dose at Week 48.
3133073|NCT03478891|Experimental|Group 1: 5 mg/kg IV|Group 1 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 5 mg/kg.
3133074|NCT03478891|Experimental|Group 2: 25 mg/kg IV|Group 2 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 25 mg/kg.
3133075|NCT03478891|Experimental|Group 3: 50 mg/kg IV|Group 3 subjects received a single IV infusion of a Human Monoclonal Antibody (MAb), VRC-EBOMAB092-00-AB (MAb114), on Day 0 at a dose of 50 mg/kg.
3133076|NCT03478904|Experimental|4x40mg Enzalutamide Capsule Followed by 160mg Enzalutamide Liquid|Enzalutamide capsule (Treatment A) followed by enzalutamide liquid (Treatment B)
3133077|NCT03478904|Experimental|160mg Enzalutamide Liquid Followed by 4x40mg Enzalutamide Capsule|Enzalutamide liquid (Treatment B) followed by enzalutamide capsule (Treatment A)
3133078|NCT03478930|Experimental|Cohort A: Study GA39688 Omalizumab|Participants who received omalizumab once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in Study GA39688 will continue to receive omalizumab at Week 24 at the same dosing schedule.
3133079|NCT03478930|Experimental|Cohort A: Study GA39688 Placebo|Participants who received placebo Q2W or Q4W in Study GA39688 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
3133080|NCT03478930|Experimental|Cohort B: Study GA39855 Omalizumab|Participants who received omalizumab Q2W or Q4W in Study GA39855 will continue to receive omalizumab at Week 24 at the same dosing schedule.
3133081|NCT03478930|Experimental|Cohort B: Study GA39855 Placebo|Participants who received placebo Q2W or Q4W in Study GA39855 will start receiving omalizumab Q2W or Q4W at Week 24 at the same dosing schedule.
3188744|NCT00770237|Experimental|Cues|Outcome Measures During cue trials, primary measures include craving (TCQ-SF, VAS), mood (mood form, VAS), and autonomic (heart rate, blood pressure, skin conductance and temperature) responsivity. During self-administration trials, primary measures include breakpoint (final ratio completed), total number of responses, and number of cigarette puffs earned and taken. Secondary measures include baseline smoking history, mood form, TCQ-SF, CO, FTND, and urinary cotinine and 3-hydroxycotinine (3-HC).
3133082|NCT03478956|Experimental|Etrolizumab Q4W|Etrolizumab 1.5 milligrams per kilogram of body weight (mg/kg) was administered by subcutaneous (SC) injection once every 4 weeks (Q4W) for a total of 4 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
3188745|NCT00770263|Experimental|Dose Level 1A|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 10 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 10 mg IV on days 8, 15, and 22 during subsequent cycles."
3133083|NCT03478956|Experimental|Etrolizumab Q8W|Etrolizumab 3.0 mg/kg was administered by subcutaneous (SC) injection once every 8 weeks (Q8W) for a total of 2 doses over the course of the 24-week randomized treatment phase (16-week treatment period plus 8-week safety follow-up). Participants were then given the option to participate in the 312-week open-label extension (OLE) treatment phase with etrolizumab 1.5 mg/kg SC Q4W followed by the 104-week safety surveillance phase (no etrolizumab treatment) to monitor for progressive multifocal leukoencephalopathy (PML). All participants who chose not to enter the OLE phase after the 24-week randomized treatment phase entered the 104-week PML monitoring phase.
3188746|NCT00770263|Experimental|Dose Level 1|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 15 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 15 mg IV on days 8, 15, and 22 during subsequent cycles."
3133084|NCT03478969|Experimental|Group A: Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with Accu-Chek® Solo Micropump system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
3133085|NCT03478969|Experimental|Group B: MDI, then Accu-Chek® Solo|Multiple daily injections (MDI) for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
3133086|NCT03478969|Experimental|Group C: mylife™ OmniPod®, then Accu-Chek® Solo|Continuous subcutaneous insulin infusion (CSII) with the mylife™ OmniPod® Insulin Management system for 26 weeks. From Week 26 until Week 39, all Groups will be using the Accu-Chek® Solo Micropump system for CSII therapy.
3133087|NCT03478982|Experimental|Staccato Alprazolam 1.0 mg|single dose for inhalation
3133088|NCT03478982|Experimental|Staccato Alprazolam 2.0 mg|single dose for inhalation
3133089|NCT03478982|Placebo Comparator|Placebo|single dose for inhalation
3133090|NCT03479216|Experimental|Precedex|5ml 0.25% Bupivacaine ve 50mcg Dexmetedomidin (diluted to 5ml with normal saline) intraarticularly at the end of surgery (total volume: 10 ml)
3133091|NCT03479216|Experimental|Magnesium Sulfate|5ml 0.25% Bupivacaine ve 5ml Magnesium Sulfate intraarticularly at the end of surgery (total volume: 10 ml)
3133092|NCT03479944|Experimental|FLACS|Femtosecond laser assisted cataract surgery (FLACS) in 1 eye, with manual conventional surgery in the fellow eye, as randomized
3133093|NCT03479944|Active Comparator|Conventional|Manual conventional surgery in 1 eye, with FLACS in the fellow eye, as randomized
3133094|NCT03480009|Experimental|Dextromethorphan, opted for narcotic prescription|Dextromethorphan hydrobromide and patient opts for narcotics (oxycodone or other standard narcotics)
3133095|NCT03480009|Placebo Comparator|Placebo, opted for narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) and patient opts for narcotics (oxycodone or other standard narcotics)
3133096|NCT03480009|Experimental|Dextromethorphan, declined narcotic prescription|Dextromethorphan hydrobromide and patient declines narcotic
3133097|NCT03480009|Placebo Comparator|Placebo, declined narcotic prescription|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding and patient declines narcotic
3133098|NCT03480022|Experimental|Liraglutide Pen Injector (Saxenda)|Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily
3133099|NCT03480022|Placebo Comparator|Placebo liraglutide pen injector|Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily
3133100|NCT03480048|Experimental|Breastfeeding and weight loss support|Participants receive a combination of in-person, phone, and online support for breastfeeding and postpartum weight management.
3133101|NCT03480048|No Intervention|Usual care|Participants receive usual care from their prenatal care provider.
3133102|NCT03480152|Experimental|1/Phase - Escalating doses of mRNA vaccine|Escalating doses of messenger ribonucleic acid (mRNA) vaccine
3133103|NCT03480152|Experimental|2/Phase II -MTD of mRNA vaccine established in Phase I|Maximum tolerated dose (MTD) of messenger ribonucleic acid (mRNA) vaccine established in Phase I
3133104|NCT03480243|Experimental|Padsevonil and Erythromycin|"Treatment Period 1 (Day 1 to Day 11):~Padsevonil 100 mg twice daily (bid) on Day 1 to Day 4~Padsevonil 100 mg single dose on Day 5~1 week of wash-out (from evening of Day 5 to Day 11)~Treatment Period 2 (Day 12 to 22):~Padsevonil 100 mg twice daily (bid) on Day 12 to Day 15~Padsevonil 100 mg single dose on Day 16~1 week of wash-out (from evening of Day 16 to Day 22)~Treatment Period 3 (Day 23 to Day 38):~Erythromycin 500 mg twice daily (bid) on Day 23 to Day 25~Padsevonil 100 mg bid and erythromycin 500 mg bid on Day 26 to Day 32~Padsevonil 100 mg single dose on Day 33~Erythromycin 500 mg twice daily (bid) on Day 33 to Day 36~Erythromycin 500 mg single dose on Day 37"
3133105|NCT03480425|Experimental|Esophageal then tracheal intubated patient|Esophagus is intentionally intubated with a cuffed endotracheal tube, the cuff inflated to >30cm water pressure, a force transducer attached, and force of extubation recorded. Then Trachea is intentionally intubated the cuff inflated to >30cm water pressure, and force of extubation recorded.
3133106|NCT03480685|Other|IVUS Imaging vs. OCT Imaging|A vessel segment will be imaged with intravascular ultrasound (IVUS). The same vessel segment will be imaged with optical coherence tomography (OCT).
3133107|NCT03480750|Experimental|trientine with chemotherapy|trientine dihydrochloride PO daily (in different dose levels) plus pegylated liposomal doxorubicin IV D1 plus carboplatin IV D1
3133108|NCT03480763|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
3133109|NCT03480763|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 12 (Vaccination 2)
3133110|NCT03480802|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
3180405|NCT00682916|Placebo Comparator|2|"Subjects will fast prior to the initial visit. Subjects' weight, blood pressure and heart rate will be recorded, waist and hip circumferences measured, and body composition determined. They will receive either the soluble fiber or placebo tablets, in a coded bottle. They will be instructed to take 2 tablets per fat containing meal, 3 times a day within one hour of consuming the meal. They will also be asked to keep records of missed doses and any gastrointestinal symptoms (e.g.: heartburn, indigestion, diarrhea, constipation). During the 4th week, they will be asked to record food intakes for 3 days.~After taking the supplement for 4 weeks, the participants will return to the clinic after an overnight fast. During this visit, they will turn in their 3-day dietary record. The studies performed during the initial baseline visit will be repeated. At this visit they receive the alternate supplement (placebo or active tablets) in a identical-looking coded bottle."
3180406|NCT00682955|Active Comparator|B|This group has been given Zinc Sulphate in Suspension Form.
3180407|NCT00682955|Active Comparator|A|This group has been given Tablets of Zinc Sulphate.
3133111|NCT03480802|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
3133112|NCT03480841|Experimental|LENA with Feedback|Mothers who will run the Language ENhancement Assessment/intervention system with their young children, and will receive initial feedback from researchers on LENA output and how to enhance the language the home language environment.
3133113|NCT03480919|Experimental|Shen Men acupuncture|Single acupuncture needles will be placed bilaterally onto the patient's Shen Men acupuncture point in the ear for a duration of 20 minutes.
3180408|NCT00682981|Experimental|Phase I A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
3133114|NCT03480919|Sham Comparator|Sham acupuncture|Single acupuncture needles will be placed bilaterally onto a sham location in the ear for a duration of 20 minutes.
3133115|NCT03480919|Placebo Comparator|Simulated acupuncture|Acupuncture will be simulated with a paper clip.
3180409|NCT00682981|Experimental|Phase I B|Obatoclax for 24 hours for 3 days with carboplatin/etoposide.
3133116|NCT03480932|Active Comparator|SOF+DAC+PEG|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) + Pegylated Interferon alfa-2a (180µg/weekly) for 4 weeks with a field-based DOT approach
3133117|NCT03480932|Active Comparator|SOF+DAC, DOT|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with a field-based DOT approach
3133118|NCT03480932|Active Comparator|SOF+DAC, standard|Sofosbuvir (400mg/daily) + Daclatasvir (60mg/daily) for 12 weeks with standard of care dispensation (4 monthly doses)
3133119|NCT03481270|Placebo Comparator|Discordant|Does not receive the concordant provider.
3133120|NCT03481270|Experimental|Concordant|The intervention is that the subject receives the concordant provider.
3180410|NCT00682981|Experimental|Phase II A|Obatoclax for 3 hours for 3 days with carboplatin/etoposide.
3180411|NCT00682981|Active Comparator|Phase II B|Carboplatin/etoposide without continued study treatment
3180412|NCT00682994|Other|Decision Making|Questionnaire + Interview
3180413|NCT00683007|Active Comparator|1|Crystalloid
3133121|NCT03481309|Active Comparator|anodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
3133122|NCT03481309|Active Comparator|cathodal tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
3133123|NCT03481309|Sham Comparator|sham tDCS|Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
3133124|NCT03481595|No Intervention|Group A|Group A will receive standard, routine medical care. If you are randomized to standard, routine medical care you will need to communicate with your Doctor and clinical care team through conventional methods such as over the phone or through MyChart.
3133125|NCT03481595|Experimental|Group B|Group B will be asked to use the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care. Patients randomized to use the Health Loop app will be able to communicate with their Doctor and clinical care team directly through the app. Patients will also participate in mobile and web-based surveys, receive reminders related to their healthcare, and receive information personalized to their treatment plan.
3133126|NCT03481725|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
3133127|NCT03481725|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
3133128|NCT03481816|Experimental|Arm 1/Dose De-Escalation|Subjects enrolled to dose de-escalation cohorts.
3133129|NCT03481816|Experimental|Arm 2/Dose expansion|Subjects enrolled at the maximum tolerated dose (MTD) after the MTD is established.
3133130|NCT03482011|Experimental|Mirikizumab|"Induction Period:~Participants received 250 milligrams (mg) mirikizumab administered subcutaneously (SC) every 4 weeks (Q4W).~Maintenance Period:~Participants received one of the four options below:~Placebo administered SC every 8 weeks (Q8W) for responders (≥PASI 90).~125 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q8W for non-responders (<PASI 90)."
3180414|NCT00683007|Active Comparator|2|Hypertonic Saline
3133131|NCT03482011|Placebo Comparator|Placebo|"Induction Period: Participants received placebo administered SC Q4W.~Maintenance Period:~Participants received one of the two options below:~Placebo administered SC Q8W for responders (≥PASI 90).~250 mg mirikizumab administered SC Q4W during week 16 to week 32 and Q8W during week 40 and 48 for non-responders (< PASI 90)."
3133132|NCT03482453|Experimental|Part 1 Cohort 1: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1.
3133133|NCT03482453|Experimental|Part 1 Cohort 2: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 1.
3180415|NCT00683033|Active Comparator|A|Brief counseling based on public health service guidelines.
3180416|NCT00683033|Experimental|B|Brief counseling based on public health service guidelines for quitting smoking plus prize-based contingency management
3133134|NCT03482453|Experimental|Part 1 Cohort 3: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 2.
3180417|NCT00683059|Experimental|Nab-paclitaxel|
3180418|NCT00683072||1|
3180419|NCT00683098||1|patients, who had a endoscopic total extraperitoneal repair of recurrent inguinal hernia between 1995 and 2008
3180420|NCT00683111|Active Comparator|1|oral esomeprazole 20 mg daily
3180421|NCT00683111|Active Comparator|2|oral famotidine 40mg daily
3180422|NCT00683124|Experimental|Losartan|Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.
3180423|NCT00683124|Experimental|Nebivolol|Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years.
3180424|NCT00683124|Experimental|Losartan+Nebivolol|"Losartan administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 100 mg/day for adults and 1,6 mg/kg/die for children minor than 16 years.~Nebivolol administered as maximal tolerated dosage, not to exceed the maximal theorical dosage of 10 mg/day for adults and 0,16 mg/kg/die for children minor than 16 years."
3180425|NCT00683137|Active Comparator|Arm 1|
3180426|NCT00683137|Active Comparator|Arm 2|
3180427|NCT00683137|Active Comparator|Arm 3|
3133135|NCT03482453|Experimental|Part 1 Cohort 4: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 3.
3133136|NCT03482453|Experimental|Part 1 Cohort 5: TAK-788|TAK-788, capsule, orally or TAK-788 matching placebo capsule, orally, once under fasted conditions on Day 1 following review of safety data from Cohort 4.
3133137|NCT03482453|Experimental|Part 2: TAK-788 Fed + TAK-788 Fasted|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fed conditions with low-fat meal (Treatment A), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fasted conditions (Treatment B). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
3180428|NCT00683150||Endothelial Function Test|Patients scheduled to have major abdominal or thoracic surgery.
3180429|NCT00683176|Active Comparator|1|
3180430|NCT00683176|Placebo Comparator|2|
3180431|NCT00683202|Active Comparator|1|Acetylsalicylic acid 100 mg daily perorally
3180432|NCT00683202|Placebo Comparator|2|Placebo daily perorally
3180433|NCT00683228|Other|Counseling|some caregivers will be provided counseling related to the hazards of secondhand smoke exposure
3133138|NCT03482453|Experimental|Part 2: TAK-788 Fasted + TAK-788 Fed|TAK-788, capsule, orally, once on Day 1 of Intervention Period 1 under fasted conditions (Treatment B), followed by at least 7 days washout period, further followed by TAK-788, capsule, orally, once on Day 1 of Intervention Period 2 under fed conditions with low-fat meal (Treatment A). TAK-788 dose will be determined based on review of safety and tolerability data from cohorts of Part 1.
3133139|NCT03482453|Experimental|Part 3: TAK-788 DiC (reference) + TAK-788 DiC (test)|TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC B (test), orally, under fasted condition, once on Day 1 of Intervention Period 2.
3133140|NCT03482453|Experimental|Part 3: TAK-788 DiC (test) + TAK-788 DiC (reference)|TAK-788 160 mg, DiC B (test), orally, under fasted condition, once, on Day 1 of Intervention Period 1, followed by at least 7 days washout period, further followed by TAK-788 160 mg, DiC A (reference), orally, under fasted condition, once on Day 1 of Intervention Period 2.
3133141|NCT03482583|Other|Cognitive Behavior Therapy with NRT|Cognitive Behavior Therapy (CBT) will be provided by a certified tobacco treatment specialist (CTTS) using vidyo, a HIPAA-compliant video based platform. Participants in this arm, if interested will be provided a 2 week supply of nicotine replacement therapy (NRT). The intervention in this arm would be NRT along with the CBT counseling.
3180434|NCT00683241|Experimental|1|Subjects with stage II to IV recurrent epithelial ovarian carcinoma or recurrent primary peritoneal cancer, from whom solid tumor, ascites or pleural effusion will be harvested and available and sufficient for lysate preparation; and whose largest tumor nodule is ≤ 2.5 cm. Subjects may have undergone chemotherapy or other therapy following tumor harvesting and prior to enrollment (apheresis).
3180435|NCT00683267|Experimental|1|Study treatment, 4975, is instilled directly into surgical site
3180436|NCT00683267|Placebo Comparator|2|Placebo is instilled directly into surgical site
3133142|NCT03482583|Other|Referral to Area Health Education Center|The Area Health Education Center (AHEC) is a locally available tobacco cessation program aimed at strengthening the capacity of Florida's healthcare system to deliver effective evidence based tobacco use treatment, and prevention services throughout the state. The intervention is education on the health effects related to tobacco use, and benefits of quitting and what to expect when quitting. A tobacco cessation specialist of trained facilitator guides participants as they identify triggers and withdrawal symptoms, and discuss ways to cope with them. The program offers free nicotine replacement therapy, educational materials, goodies for their quit day and follow up support.
3180437|NCT00683280|Active Comparator|Standard of Care|Medication (varenicline) for 12 weeks (Day 1 through 84) and brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35).
3180438|NCT00683280|Experimental|Standard of Care plus Contingency Management|Medication (varenicline) for 12 weeks (Day 1 through 84), brief counseling based on public health service guidelines for 5 weeks (Day 1 through 35), plus prize-based contingency management for carbon monoxide samples and urinary cotinine samples that meet smoking abstinence criteria.
3133143|NCT03482583|Other|Referral to Qutiline|"Quitline is a local program in the state where smokers can call a toll free number to talk to coach who can help them quit. There is also an option of online program if they prefer to engage in online help to quit tobacco use.~The intervention in this arm is counseling support by phone or online with an option of Nicotine replacement therapy. If participants prefer this option, our nurse will refer them to locally available quitline service using EPIC."
3133144|NCT03482635|Experimental|Group 1- Placebo Group|
3133145|NCT03482635|Experimental|Group 2- Small Dose Group|
3133146|NCT03482635|Experimental|Group 3- Medium Dose Group|
3133147|NCT03482635|Experimental|Group 4 - High Dose Group|
3133148|NCT03482713|Experimental|Gefapixant 45 mg|Participants will receive a gefapixant 45 mg film-coated tablet BID for 28 days.
3133149|NCT03482713|Placebo Comparator|Placebo|Participants will receive a film-coated placebo tablet matching gefapixant BID for 28 days.
3133150|NCT03482882|Experimental|Drug - pimavanserin|
3133151|NCT03482973|Experimental|Interventional Bupivacaine|20 cc of 0.25% bupivacaine on each side of the sternum at two time points after surgery and POD1
3133152|NCT03482973|Placebo Comparator|Interventional Placebo|20 cc of saline on each side of the sternum at two time points after surgery and POD1
3133153|NCT03483506|Experimental|All subjects|
3133154|NCT03483623|Experimental|NATO WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and WELP mattress combination
3133155|NCT03483623|Experimental|NATO FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on NATO litter and Fluid Immersion System (FIS) mattress combination
3133156|NCT03483623|Experimental|RAVEN WELP combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and WELP mattress combination
3133157|NCT03483623|Experimental|RAVEN FIS combination|Subjects will be their own control and have repeated measurements to compare baseline and supine transcutaneous oxygenation levels and interface pressures on Raven 90C litter and Fluid Immersion System (FIS) mattress combination
3133158|NCT03483675|Active Comparator|Arm I (discontinued IST)|Participants have their IST tapered and discontinued per the plan.
3133159|NCT03483675|Experimental|Arm II (continued IST)|Participants continue to receive a fixed dose IST for an additional 9 months with no taper.
3133160|NCT03483896|No Intervention|Control|At the 4 facilities in the control arm, participants received the usual care. During the period from 8:00 - 10:00 AM each day, the control group was taken to a similar sized area indoors (without daylight) for socialization under typical electrical lighting conditions.
3180439|NCT00683345|Active Comparator|Anakinra|Anakinra self-administered s.c. in a dose of 100mg daily
3180440|NCT00683345|Placebo Comparator|Placebo|Placebo self-adminsitered s.c in a dose 0.67ml daily
3180441|NCT00683358|Experimental|1|
3133161|NCT03483896|Active Comparator|Daylight Intervention|At the 4 facilities in the active light intervention arm, staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
3133162|NCT03483935|Experimental|Microwave energy treatment|The microwave treatment will be delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for this indication, will be used to deliver the microwave treatment. The microwave dose will be between 2 Watt and 4 Watt. The treatment will consist of 3, 2 to 3 second bursts delivered to the same lesion with 5-20 seconds between bursts.
3133163|NCT03483935|No Intervention|Control|No treatment will be given.
3133164|NCT03483961|Experimental|Group 1: 20 mcg/unadjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)
3133165|NCT03483961|Experimental|Group 2: 6 mcg/adjuvanted (Day 1 & 29)|6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
3133166|NCT03483961|Experimental|Group 3: 10 mcg/adjuvanted (Day 1 & 29)|10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
3133167|NCT03483961|Experimental|Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547)|20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)
3133168|NCT03483961|Experimental|Group 5: 6 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)
3133169|NCT03483961|Experimental|Group 6: 10 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)
3133170|NCT03483961|Experimental|Group 7: 20 mcg/adjuvanted (Day 15 & 29)|Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)
3133171|NCT03483961|Experimental|Group 8: 40 mcg/adjuvanted (Day 29)|Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)
3133172|NCT03483961|Experimental|Group 9: 20 mcg/adjuvanted (Day 1 & 29)|20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182
3133173|NCT03483961|Experimental|Group 10: 40 mcg/adjuvanted (Day 1)|40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.
3133174|NCT03484273|Experimental|Full Compression|The LifeWrap compression garment will be fully secured with all straps.
3133175|NCT03484273|Experimental|Abdominal and Pelvic Compression|The Lifewrap compression garment abdominal, pelvic and upper thigh straps only will be secured.
3133176|NCT03484273|Experimental|Lower Limb Compression|The Lifewrap compression garment calf and ankle straps only will be secured.
3133177|NCT03484273|No Intervention|No Compression|None of the LifeWrap compression garment straps will be secured.
3133178|NCT03484429|Experimental|Group 1|Standard medical therapy and 30 to 60 days of peripheral nerve stimulation starting within 7 days after surgery
3133179|NCT03484429|Active Comparator|Group 2|Standard medical therapy only
3133180|NCT03485222|Experimental|Empagliflozin|10mg once a day
3133181|NCT03485222|Placebo Comparator|Placebos|placebo once a day
3133182|NCT03485287|Experimental|MDMA and Psychotherapy|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
3133183|NCT03485495|Experimental|Divaza|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
3133184|NCT03485495|Placebo Comparator|Placebo|Tablet for oral use. Two tablets per intake 3 times a day (approximately at the same time), outside of meal (between meals or 15 minutes before eating or drinking). The tablets should be held in mouth until completely dissolved.
3180442|NCT00683371|Active Comparator|1|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery
3180443|NCT00683371|Placebo Comparator|2|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery.
3180444|NCT00683397||A|Patients with acute or previous venous thromboembolism >18 years of age
3180445|NCT00683423|Experimental|A|
3180446|NCT00683423|Placebo Comparator|B|
3180447|NCT00683436|Experimental|1|adipiplon 6 mg
3180448|NCT00683436|Experimental|2|adipiplon 9 mg
3180449|NCT00683436|Placebo Comparator|3|Placebo
3180450|NCT00683436|Experimental|4|Ambien CR 12.5 mg
3180451|NCT00683462|Placebo Comparator|1|
3180452|NCT00683462|Experimental|2|
3180453|NCT00683462|Experimental|3|
3133185|NCT03485911|Experimental|BCX7353 110 mg once daily|BCX7353 administered as oral capsules once daily
3133186|NCT03485911|Experimental|BCX7353 150 mg once daily|BCX7353 administered as oral capsules once daily
3133187|NCT03485911|Placebo Comparator|Placebo|Matching placebo administered as oral capsules once daily
3133188|NCT03485950|Experimental|Group I (ceftolozane-tazobactam)|Participants receive ceftolozane-tazobactam IV over 1 hour every 8 hours for up to 14 days in the absence of disease progression or unacceptable toxicity. After at least 3 days, participants may switch to different PO or IV antibiotics at the discretion of the study doctor.
3133189|NCT03485950|Active Comparator|Group II (standard of care antibiotic treatment)|Participants receive standard of care antibiotic treatment consisting of either cefepime IV over 30 minutes every 8 hours, meropenem IV over 30 minutes every 8 hours, or piperacillin-tazobactam IV over 1 hour every 6 hours for up to 14 days in the absence of disease progression or unacceptable toxicity.
3133190|NCT03485976|Experimental|Ixekizumab treatment arm|Ixekizumab 160 mg subcutaneous injection at week 0, followed by 80 mg subcutaneous injections at week 2, 4, 6, 8, 10, 12, 16, and 20
3133191|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 1|Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
3133192|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 2|Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
3133193|NCT03486392|Experimental|Double-Blind: JNJ-64565111 Dose Level 3|Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
3133194|NCT03486392|Placebo Comparator|Double-Blind: Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
3133195|NCT03486392|Active Comparator|Open-Label: 3.0 milligram (mg) Liraglutide|Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
3133196|NCT03486834|Experimental|V160 3-Dose Regimen|Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.
3133197|NCT03486834|Experimental|V160 2-Dose Regimen|Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.
3133198|NCT03486834|Placebo Comparator|Placebo|Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.
3133199|NCT03486990|Experimental|Part A, Cohort 1: 0.1 mg/kg|TIMP-GLIA 0.1 mg/kg, infusion, intravenously, once on Day 1.
3133200|NCT03486990|Experimental|Part A, Cohort 2: 0.5 mg/kg|TIMP-GLIA 0.5 mg/kg, infusion, intravenously, once on Day 1.
3133201|NCT03486990|Experimental|Part A, Cohort 3: 1.0 mg/kg|TIMP-GLIA 1.0 mg/kg, infusion, intravenously, once on Day 1.
3133202|NCT03486990|Experimental|Part A, Cohort 4: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Day 1.
3133203|NCT03486990|Experimental|Part A, Cohort 5: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Day 1.
3133204|NCT03486990|Experimental|Part A, Cohort 6: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Day 1.
3133205|NCT03486990|Experimental|Part B, Cohort 1: 2.0 mg/kg|TIMP-GLIA 2.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
3133206|NCT03486990|Experimental|Part B, Cohort 2: 4.0 mg/kg|TIMP-GLIA 4.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
3133207|NCT03486990|Experimental|Part B, Cohort 3: 8.0 mg/kg|TIMP-GLIA 8.0 mg/kg, infusion, intravenously, once on Days 1 and 8.
3133208|NCT03487276|Placebo Comparator|Cohort 1|Placebo
3133209|NCT03487276|Experimental|Cohort 2|Minimum Dose IFX-1 (400 mg Q4W)
3133210|NCT03487276|Experimental|Cohort 3|Low dose IFX-1 (800 mg Q4W)
3133211|NCT03487276|Experimental|Cohort 4|Medium Dose IFX-1 (800 mg Q2W)
3133212|NCT03487276|Experimental|Cohort 5|High Dose IFX-1 (1200 mg Q2W)
3180454|NCT00683488|Experimental|1|Focus groups with adolescents with SA (Substance Abuse) will be conducted at each site (one group with 5 to 6 adolescents per site) to provide information on the areas of the intervention in need of adaptation in order to reflect the context of HIV infection.
3133213|NCT03487445|Experimental|Selatogrel 8 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
3133214|NCT03487445|Experimental|Selatogrel 16 mg|Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
3133215|NCT03487549|Experimental|VP-102|Open label of VP-102 cantharidin topical film forming solution, using the VP-102 applicator.
3133216|NCT03487588|Experimental|A-101 Topical Solution|Open Label Arm
3133217|NCT03487718|Active Comparator|Control group|Under the effect of local anesthetic tooth will be extracted then a d-PTFE membrane will be used to cover the socket without any bone graft material to preserve the ridge.
3133218|NCT03487718|Experimental|Test group|Under the effect of local anesthetic tooth extraction will be followed by the collection of about 50 ml of the patient's venous blood, then without adding any anticougulant the blood will be spun to make a plug. The Leukocyte platelet rich fibrin plug + d-PTFE membrane will be used to preserve the ridge.
3133219|NCT03487848|Experimental|Daclatasvir with Sofosbuvir|Specified dose on specified days for specified duration
3133220|NCT03488030||All Participants|Participants diagnosed with moderate to severe UC or CD from the 7 participating sites will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years from the date of UC or CD diagnosis until Day 1 to assess the IBD treatments, medical history and comorbidities, treatment patterns and use of health resources.
3133221|NCT03488108|Experimental|Platelet Rich Plasma first, then Minoxidil Foam|Subjects will be randomized into the Platelet Rich Plasma group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Minoxidil Foam for 12 weeks.
3133222|NCT03488108|Experimental|Minoxidil Foam first, then Platelet Rich Plasma|Subjects will be randomized into the Minoxidil Foam group, treated for 12 weeks with a 2 month washout period in between treatments, then treated with Platelet Rich Plasma.
3133223|NCT03488225|Experimental|Treatment (hyper-CVAD, inotuzumab ozogamicin)|See detailed description.
3133224|NCT03488238|Experimental|ORi sensor|All subjects are enrolled in the test group and receive an ORi sensor during their scheduled, general surgery procedure
3133225|NCT03488849|Experimental|SureCRIC|SureCRIC-aided cricothyroid membrane identification
3133226|NCT03488849|Active Comparator|Freehand|Freehand cricothyroid membrane identification
3133227|NCT03488927|Experimental|Intervention|This arm will receive the intervention, followed by a six-month follow-up evaluation.
3133228|NCT03488927|No Intervention|Wait-list Control|This arm will receive the intervention after a six-month follow-up evaluation.
3133229|NCT03489304|Other|Zaleplon|Open-label zaleplon 5-10mg daily
3133230|NCT03489343|Experimental|Sym023 0.03 mg/kg|Sym023 was administered at a dose of 0.03 mg/kg by intravenous infusion
3133231|NCT03489343|Experimental|Sym023 0.1 mg/kg|Sym023 was administered at a dose of 0.1 mg/kg by intravenous infusion
3133232|NCT03489343|Experimental|Sym023 0.3 mg/kg|Sym023 was administered at a dose of 0.3 mg/kg by intravenous infusion
3133233|NCT03489343|Experimental|Sym023 1.0 mg/kg|Sym023 was administered at a dose of 1.0 mg/kg by intravenous infusion
3133234|NCT03489343|Experimental|Sym023 3.0 mg/kg|Sym023 was administered at a dose of 3.0 mg/kg by intravenous infusion
3133235|NCT03489343|Experimental|Sym023 10.0 mg/kg|Sym023 was administered at a dose of 10.0 mg/kg by intravenous infusion
3133236|NCT03489343|Experimental|Sym023 20.0 mg/kg|Sym023 was administered at a dose of 20.0 mg/kg by intravenous infusion
3133237|NCT03489369|Experimental|Sym022|Sym022 will be administered at up to 4 planned dose levels.
3133238|NCT03489551|Experimental|Oral Haldol in patients undergoing HSCT|Prior to stem cell transplant participants will receive 5mg of liquid or pill form, oral Haldol. Every other day visits will take place following the first administration of the study drug until 14 days after the transplant.
3133239|NCT03489720|Experimental|Arm A: Exercise intervention then usual exercise program|8 weeks of exercise intervention followed by 8 weeks of usual exercise program
3133240|NCT03489720|Active Comparator|Arm B: Usual Exercise Program then exercise intervention|8 weeks of usual exercise program followed by 8 weeks of exercise intervention
3133241|NCT03489850|Active Comparator|Ibudilast|20mg BID Days 1-2 50mg BID Days 3-14
3133242|NCT03489850|Placebo Comparator|Placebo|Matched to active
3133243|NCT03489863|Active Comparator|Prasugrel|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
3133244|NCT03489863|Active Comparator|Ticagrelor|Patients will be randomly (1:1) assigned to receive FDA approved doses of either prasugrel (60 mg loading dose - 10 mg/day maintenance dose) or ticagrelor (180 mg loading dose - 90 mg b.i.d maintenance dose).
3133245|NCT03489941|Experimental|EM-100|One drop of EM-100 in either the right or left eye once on Day 1.
3133246|NCT03489941|Experimental|Zaditor®|One drop of Zaditor® in either the right or left eye once on Day 1.
3133247|NCT03489941|Experimental|Vehicle|One drop of Vehicle in either the right or left eye once on Day 1.
3133248|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase I)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
3133249|NCT03490032|Experimental|Biochemically Recurrent Prostate Cancer (PCa-BR) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
3133250|NCT03490032|Experimental|Metastatic Prostate Cancer (mPCa) (Phase II)|All eligible participants received recommended dose of [68Ga]-PSMA-R2 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq].
3133251|NCT03490110|Experimental|State regulation skill training|This arm utilizes a training system designed to strengthen goal-directed cognitive-emotional state regulation skills. The emphasis is on practice and active application of skills across a range of challenge contexts. Digital scenarios provide experiential learning opportunities, allowing Veterans to apply skills to tackle challenges that are calibrated to maximize learning. Coaches guide learning for successful application of skills to challenges in personal life.
3133252|NCT03490110|Active Comparator|Treatment-as-usual|In this arm, participants receive clinical care as usual in VA and other clinics.
3133253|NCT03490942|Experimental|CSGI high infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
3133254|NCT03490942|Experimental|CSGI low infusion rate|Glucagon given as a continuous subcutaneous infusion for 28 days
3133255|NCT03490942|Placebo Comparator|Placebo high infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
3133256|NCT03490942|Placebo Comparator|Placebo low infusion rate|Placebo given as a continuous subcutaneous infusion for 28 days
3133257|NCT03490981|Other|Treatment as usual (TAU) only|Primary care treatment as usual
3180455|NCT00683488|Experimental|2|The first intervention trial will enroll 9 participants (3 participants per site). Exit interviews of participants will assess acceptability, feasibility, and relevance of the intervention. Quantitative assessments pre and post intervention using audio computer-assisted self-interviewing (ACASI) will document immediate changes in substance use, sexual risk, and adherence to medical care. Additional qualitative feedback from interviews with mental health providers and study coordinators will address feasibility, acceptability, and relevance of the intervention and its methods.
3133258|NCT03490981|Experimental|Treatment as usual (TAU) plus Brief Cognitive Behavioral Therapy for Chronic Pain (Brief CBT-CP)|Primary care treatment as usual and Brief CBT-CP
3133259|NCT03491150|Placebo Comparator|Parent Placebo|Participants (who were treated with Placebo in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
3133260|NCT03491150|Experimental|Parent Crenezumab|Participants (who were treated with Crenezumab in the BN29552/BN29553 Studies) received intravenous (IV) infusion of Crenezumab every 4 weeks (Q4W).
3133261|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-positive CHB Participants|Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
3133262|NCT03491553|Experimental|Selgantolimod 3 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3133263|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3133264|NCT03491553|Experimental|Selgantolimod 1.5 mg: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3133265|NCT03491553|Experimental|Placebo: HBeAg-positive CHB Participants|Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3133266|NCT03491553|Experimental|Placebo: HBeAg-negative CHB Participants|Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3133267|NCT03491800|Other|Question/Topic Prompt List|The Question/Topic Prompt List is provided to HF Patients and their family member (if applicable) for completion prior to being seen by the doctor.
3133268|NCT03491891||derivation cohort|no interventions will be administrated
3133269|NCT03491891||validation cohort|no interventions will be administrated
3133270|NCT03491917||DBT plus S-View|Breast images utilizing DBT plus S-View
3180456|NCT00683488|Experimental|3|The revised intervention will be implemented with 20 participants (6 to 8 at each site). Exit interviews with subjects and feedback from mental health providers and study coordinators will provide the same qualitative information as in the first intervention trial. Quantitative data on participant outcomes such as substance use, sexual risk, and adherence to medical care will be collected pre, post and 3 month post intervention through ACASI.
3180457|NCT00683501|Experimental|1|dosage X mg BID
3133271|NCT03491917||FFDM alone|Breast images using FFDM alone only
3180458|NCT00683501|Experimental|2|dosage Y mg BID
3180459|NCT00683501|Experimental|3|dosage Z mg BID
3180460|NCT00683501|Experimental|4|dosage 2Z mg BID
3133272|NCT03492099|Experimental|Buprenorphine Arm|This is the main and only arm of the study. All patients in this arm will undergo the steps outlined in the protocol to convert to buprenorphine treatment.
3133273|NCT03492281|Experimental|Vibegron + Placebo to match Tolterodine|
3133274|NCT03492281|Placebo Comparator|Placebo to match vibegron + Placebo to match Tolterodine|
3133275|NCT03492281|Active Comparator|Tolterodine + Placebo to match vibegron|
3133276|NCT03492398|Experimental|Cohort A HY209 0.05% gel|single dose of HY209 0.05% gel or single dose of placebo
3133277|NCT03492398|Experimental|Cohort A HY209 0.1% gel|single dose of HY209 0.1% gel or single dose of placebo
3133278|NCT03492398|Experimental|Cohort A HY209 0.3% gel|single dose of HY209 0.3% gel or single dose of placebo
3133279|NCT03492398|Experimental|Cohort A HY209 0.5% gel|single dose of HY209 0.5% gel or single dose of placebo
3133280|NCT03492398|Experimental|Cohort B HY209 0.1% gel|multiple dose of HY209 0.1% gel or multiple dose of placebo
3133281|NCT03492398|Experimental|Cohort B HY209 0.3% gel|multiple dose of HY209 0.3% gel or multiple dose of placebo
3133282|NCT03492398|Experimental|Cohort B HY209 0.5% gel|multiple dose of HY209 0.5% gel or multiple dose of placebo
3133283|NCT03492554|Other|Atrial fibrillation (AF)|Patient with a known history of AF who are in AF at the time of study screening.
3133284|NCT03492554|Other|Normal Sinus Rhythm (SR)|Patient with no known diagnosis of AF or other arrhythmia
3133285|NCT03493386|Experimental|Treatment Group A: Part 1|Subjects will be randomized to receive single dose of two tablets of 2 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
3133286|NCT03493386|Experimental|Treatment Group B: Part 1|Subjects will be randomized to receive single dose of 4 mg daprodustat in Period 1 and in Period 2 subjects will receive single dose of two tablets of 2 mg daprodustat. There will be a wash-out period of 5 days between the Periods.
3133287|NCT03493386|Experimental|Treatment Group C: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fed state during Period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fasted state. There will be a wash-out period of 5 days between the Periods.
3133288|NCT03493386|Experimental|Treatment Group D: Part 2|Subjects will be randomized to receive single dose of 4 mg daprodustat in fasted state during period 1 and in Period 2 subjects will receive single dose of 4 mg daprodustat in fed state. There will be a wash-out period of 5 days between the Periods.
3133289|NCT03493542|Experimental|Chinese Girls Aged 9 to 19 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
3133290|NCT03493542|Active Comparator|Chinese Young Women Aged 20 to 26 Years|Participants will receive V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
3133291|NCT03493607|Experimental|AMO-01|Intravenous Infusion
3133292|NCT03493698|Experimental|Treatment A: Midazolam|All subjects will receive a single oral dose of 2 mg Midazolam on Day 1
3133293|NCT03493698|Experimental|Treatment B and C: Inarigivir|All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18
3133294|NCT03493698|Experimental|Treatment D: Inarigivir with Midazolam|All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19
3133295|NCT03493815|Experimental|Transabdominal Ultrasound Guided IUD Insertion|Ultrasound Guided IUD Insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
3133296|NCT03493815|Active Comparator|Traditional Blind IUD Insertion|Traditional blind IUD insertion: Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
3180461|NCT00683501|Placebo Comparator|5|Placebo BID
3180462|NCT00683514|Other|A|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~cycle 3 & 4 (q 21 days) = chemotherapy : oral vinorelbine (60 mg/m2 d1, d8 for cycle 1, 80 mg/m2 d1 & d8 for cycle 2) and cisplatin (80 mg/m2 d1) plus Best Supportive Care"
3133297|NCT03493828|Active Comparator|TAP using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
3180463|NCT00683514|Other|B|"cycle 1 & 2 (q 28 days) = chemotherapy : oral vinorelbine (50 mg/m2 d1, d8, d15) and cisplatin (20 mg/m2/d from d1 to d4) combined with radiotherapy~Best Supportive Care only"
3180464|NCT00683527|Experimental|1|Starting oral iron at day 14 of life (Early Iron group)
3133298|NCT03493828|Active Comparator|TAP using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
3180465|NCT00683527|No Intervention|2|No iron supplementation till 60 days of life (Control group)
3180466|NCT00683553|Experimental|I5NP drug|
3180467|NCT00683553|Placebo Comparator|Placebo|
3133299|NCT03493828|Placebo Comparator|Placebo|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
3180468|NCT00683566|Experimental|1|A session in condition ON DOPAMINE and the other one in condition OFF DOPAMINE.
3180469|NCT00683579||1|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are initiating HAART with possibility of de-intensification (early treatment).
3133300|NCT03493854|Active Comparator|Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor [G-CSF] support as needed according to local guidelines) followed by paclitaxel Q1W for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab will be given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.
3180470|NCT00683579||2|Participants with CD4+ T cells above 350 cells/mm3 and HIV RNA >1,000 copies/ml who are not initiating treatment.
3180471|NCT00683579||3|Participants with CD4+ T cells < 350 cells/mm3 who are initiating treatment.
3180472|NCT00683579||4|Participants with CD4+ T cells < 350 cells/mm3 who are not initiating treatment.
3133301|NCT03493854|Experimental|Arm B: FDC of Pertuzumab and Trastuzumab SC + Chemotherapy|Participants will receive 8 cycles of investigator's choice of neoadjuvant chemotherapy. This will include either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab will be given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants will undergo surgery. Thereafter, participants will receive an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.
3133302|NCT03494725|Active Comparator|Lpc-37|"Lacticaseibacillus paracasei Lpc-37 (Lpc-37), formerly Lactobacillus paracasei Lpc-37~1x 1 capsule in the morning for 5 weeks"
3133303|NCT03494725|Placebo Comparator|Placebo|"Placebo capsule manufactured to mimic Lpc-37 capsule~1x 1 capsule in the morning for 5 weeks"
3133304|NCT03494816|Experimental|Axitinib|Axitinib - oral tablet twice daily for 8 weeks prior to surgery. Starting dose 5mg.
3133305|NCT03494985|Experimental|OralBalance moisturizing gel|All the participants in this arm used an experimental Oralbalance gel as instructed under the supervision of trained site staff on their visits.
3133306|NCT03494985|Experimental|Oral rinse|All the participants in this arm used an Oral rinse as instructed under the supervision of trained site staff on their visits.
3133307|NCT03494985|Experimental|Moisturizing mouth spray|All the participants in this arm used a moisturising mouth spray as instructed under the supervision of trained site staff on their visits.
3133308|NCT03494985|Sham Comparator|Water only use|All the participants in this arm used water as instructed under the supervision of trained site staff on their visits.
3133309|NCT03495102|Active Comparator|Dulaglutide 1.5 mg|Dulaglutide 1.5 mg administered subcutaneously (SC) once a week.
3133310|NCT03495102|Experimental|Dulaglutide 3 mg|Dulaglutide 3 mg administered SC once a week.
3133311|NCT03495102|Experimental|Dulaglutide 4.5 mg|Dulaglutide 4.5 mg administered SC once a week.
3133312|NCT03495648|Experimental|Walking Group (Low Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. Low engagers are defined as those participants who walked to the market two or fewer times during the program.
3133313|NCT03495648|Experimental|Walking Group (High Engagers)|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market. High engagers are defined as those participants who walked to the market three or more times during the program.
3188986|NCT00772902|Active Comparator|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
3133314|NCT03495817|Experimental|ATI-50002 Topical Solution|"This is an open-label phase 2 study designed to evaluate the safety and efficacy of ATI- 50002 Topical Solution, 0.46% in male and female subjects with androgenetic alopecia.~Subjects will be required to apply ATI-50002 study medication to their scalp twice a day for a total of 26 weeks."
3133315|NCT03495856|Experimental|Mindfulness Training For Chronic Pain|The intervention is adapted from the mindfulness-based stress reduction program. The adapted mindfulness training program consists of four, weekly 90 minute group sessions that focus on education on chronic pain and mindfulness, instruction and in-class mindfulness skills practice, and group discussion.
3133316|NCT03495869||Individuals with Cocaine Use Disorder|"This group will consist of individuals who are determined to have DSM5 diagnosis of Cocaine Use Disorder (n=50).~Individuals will be recruited from an existing registry (VCU IRB HMHM20000294, Keyser-Marcus, PI)"
3133317|NCT03495869||Individuals with Opioid Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Opioid Use Disorder (n=200).
3133318|NCT03495869||Individuals with Marijuana Use Disorder|This group will consist of individuals who are determined to have DSM5 diagnosis of Marijuana Use Disorder (n=50).
3133319|NCT03495869||Healthy Controls|This group will consist of individuals who are determined to be non-drug using healthy controls (n=100).
3133320|NCT03495908|Experimental|VGo with Regular Human Insulin|U-100 short-acting insulin, Regular, human insulin rDNA origin, including Humulin® R, Novolin® R, and ReliOn (Novolin R) delivered by V-Go
3133321|NCT03495908|Active Comparator|VGo with Rapid Acting Insulin|U-100 fast-acting insulin including Humalog® (insulin lispro, rDNA origin) or NovoLog® (insulin aspart, rDNA origin), which have both been tested by Valeritas, Inc. and found to be safe for use in the V-Go or Apidra® (insulin glulisine, rDNA origin) delivered by V-Go
3133322|NCT03496220|Experimental|Feedback|The ICU with feedback will be equipped with display device corresponding to each Angulus device with an interactive software interface which displays the patient's elevation.
3133323|NCT03496220|Other|No Feedback|The Angulus device will be on the patient but will NOT have the corresponding display data on patient elevation available to nurses.
3133324|NCT03496298|Placebo Comparator|Placebo|Participants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
3133325|NCT03496298|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
3133326|NCT03496298|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
3133327|NCT03496324|Active Comparator|Test (fed): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fed condition~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
3133328|NCT03496324|Active Comparator|Test (fasted): Nurofen for Children|"Nurofen for Children® 400 mg/10 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
3133329|NCT03496324|Experimental|Reference (fed): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fed condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
3133330|NCT03496324|Experimental|Reference (fasted): Algifor Junior|"Algifor® Junior 400 mg/20 ml by mouth under fasted condition.~Subjects participated in Treatment Sequence: BACD, DCAB, ADBC and CBDA."
3133331|NCT03496428|Other|Dental implant Impression Techniques|"Dental implant impressions- Different Techniques An customized impression coping will be created based on the provisional crown emergence profile which will be used to perform a silicone implant impression. A conventional cast will be created based on the silicone impression and an extra-oral scanner reading will be performed with a 3shape D2000.~An intra-oral scanner (Trios, 3Shape) will be used to scan the entire arch. The STL file created will be compared and tooth positions and soft tissues discrepancies will be determined"
3133332|NCT03496467|Active Comparator|Nepafenac PPDS|N-PPDS (Nepafenac Punctal Plug Deliver System) is an L-shaped, silicone punctal plug with a drug eluting core that contains nepafenac (active)
3133333|NCT03496467|Placebo Comparator|Placebo PPDS|p-PPDS (placebo Punctal Plug Delivery System) is an L-shaped, silicone punctal plug with a drug insert that contains no active ingredient (placebo).
3133334|NCT03496545|Active Comparator|Acetaminophen|Standard of care - acetaminophen 650mg every 4 hours PO/NG/FT (per oral, nasogastric tube, feeding tube) for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
3133335|NCT03496545|Experimental|Bromocriptine and Acetaminophen|Bromocriptine 5mg every 4 hours PO/NG/FT for 48 hours and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours, initiated within 1 hour after temperature reading ≥ 38.3ºC.
3133336|NCT03496701|Experimental|Stenfilcon A / Test lens|All subjects will first wear stenfilcon A contact lenses for one week, then refitted with test contact lenses to wear for one week.
3133337|NCT03496974|Experimental|Group A: 200 mg cohort|The dose of bermekimab for Group A is 200 mg (2ml of the 100 mg/ml formulation)
3133338|NCT03496974|Experimental|Group B: 400 mg cohort|The dose of bermekimab for Group B is 400 mg (2ml of the 200 mg/ml formulation) administered weekly by subcutaneous injection
3133339|NCT03496987|No Intervention|Manual Drainage|Patients undergo drainage of pleural fluid via manual (syringe) system
3133340|NCT03496987|Experimental|Vacuum Bottle Drainage|Patients undergo drainage of pleural fluid via a vacuum bottle system (evacuated cylinder)
3133341|NCT03497026|Experimental|Robotic Bronchoscopy|Robotic bronchoscopy with Robotic Bronchoscopy Platform
3133342|NCT03497039|Experimental|Active Treatment|In the active treatment arm, DDEA gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
3188747|NCT00770263|Experimental|Dose Level 2|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 20 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 20 mg IV on days 8, 15, and 22 during subsequent cycles."
3133343|NCT03497039|Placebo Comparator|Placebo Control|In the placebo control arm, placebo gel will be applied topically at a dose of 4 gram (g) on 400 square centimeter (cm^2) twice a day for 7 days to the target knee (the knee planned for arthroplasty surgery).
3133344|NCT03497130|Experimental|regimen group|After 1 week washout period using provided Dove® Soap without any moisturizer, participants in the skin care regimen group will receive Vaseline® Moisturizer, Dove® Soap, and application log. These participants will be asked to apply the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks. All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use.
3133345|NCT03497130|No Intervention|control group|"After 1 week washout period using provided Dove® Soap without any moisturizer, Individuals in the control group will continue with the provided Dove® Soap for 2 weeks.~All applications should be reported in the application log by the participants. A demonstration and verbal instructions for how and where to apply the products will be provided to the subjects along with the application log for daily use."
3133346|NCT03497429|Experimental|Cohort 1: Niraparib 200 mg|Niraparib 200 milligrams (mg), capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
3133347|NCT03497429|Experimental|Cohort 2: Niraparib 300 mg|Niraparib 300 mg, capsule, once orally on Days 1 - 21 of each 21-day treatment cycle.
3133348|NCT03497585||Activity Pacing Framework|Adult patients attending rehabilitation programmes underpinned by the activity pacing framework.
3133349|NCT03497845|Experimental|a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
3133350|NCT03497845|Experimental|b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
3133351|NCT03497845|Experimental|c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant|Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
3133352|NCT03497845|Experimental|d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant|Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
3188987|NCT00772980|Experimental|1|Drug: Neramexa mesylate Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
3133353|NCT03497845|Experimental|e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
3133354|NCT03497845|Experimental|f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant|Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
3188748|NCT00770263|Experimental|Dose Level 3|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
3133355|NCT03497845|Experimental|g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
3133356|NCT03497845|Experimental|h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
3133357|NCT03497845|Experimental|i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant|Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
3133358|NCT03497845|Experimental|j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant|Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
3188988|NCT00772980|Placebo Comparator|2|Drug: Placebo Double-blind treatment period of 17 weeks placebo
3188989|NCT00772993||1|Primary open angle glaucoma
3188990|NCT00772993||2|Normal Control
3188991|NCT00772993||3|Myopia with no evidence of glaucoma
3133359|NCT03497845|Experimental|k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
3133360|NCT03497845|Experimental|l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant|Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
3133361|NCT03498196|Experimental|Avelumab|Avelumab 10 mg/kg intravenously, over 60 minutes every 2 weeks for 3 cycles or 42 days.
3133362|NCT03498287|Experimental|Study Device|Small, non-invasive, stiff patch for the wrist
3133363|NCT03498287|Sham Comparator|Sham Device|Device that looks like the Study Device but modified to prevent or remove the main mechanism of action.
3188992|NCT00772993||4|Myopia with evidence og glaucoma
3133364|NCT03498300|Experimental|Experimental|A single dose of Tdap vaccine at GA 27 - 36 weeks
3133365|NCT03498300|No Intervention|Active comparator|dT vaccine as standard protocol
3133366|NCT03498560||MGH Surgery Patients|PSG data will be collected, and delirium assessments conducted, on patients undergoing surgery at MGH.
3133367|NCT03499028|No Intervention|Standard of Care Group|The Standard of Care Group will receive standard, routine medical care and will communicate with their surgeon and clinical care team through conventional methods such as phone.
3188993|NCT00773006||A|Stable/elective PCI patients
3188994|NCT00773006||B|NSTEMI PCI patients
3133368|NCT03499028|Experimental|Experimental (JointCOACH) Group|The Experimental Group will receive standard, routine medical care and utilize a web-based communication platform called JointCOACH to communicate with their care team via computer or smartphone throughout their episode of care. They will also receive information personalized to their treatment plan and will be asked to complete online questionnaires.
3188995|NCT00773006||C|STEMI PCI patients
3188996|NCT00773045||pain training program|ICU Patients treated with or without pain management protocol
3188749|NCT00770263|Experimental|Dose Expansion Phase|"Erlotinib 100 mg administered orally on a once daily schedule for 35 days for the first cycle.~Erlotinib 100 mg administered orally on a once daily schedule for 28 days for subsequent cycles.~Temsirolimus 25 mg IV on days 8, 15, 22, and 29 during the first cycle.~Temsirolimus 25 mg IV on days 8, 15, and 22 during subsequent cycles."
3133369|NCT03499067|Experimental|Test lens|Subjects wearing the test contact lens either as first or second pair during the cross-over study.
3133370|NCT03499067|Active Comparator|Control lens|Subjects wearing the control contact lens either as first or second pair during the cross-over study.
3133371|NCT03499353|Experimental|TALAZOPARIB|SINGLE ARM, NON-RANDOMIZED
3133372|NCT03499873|Experimental|Nepafenac 0.3% Opthalmic Suspension|Test product manufactured by Indoco Remedies, Ltd for Actavis LLC.
3133373|NCT03499873|Active Comparator|Ilevro 0.3% Opthalmic Suspension|Reference product manufactured by Alcon Laboratories Inc.
3133374|NCT03499873|Placebo Comparator|Placebo (vehicle) Opthalmic Suspension|Placebo (vehicle) manufactured by Indoco Remedies, Ltd for Actavis LLC.
3133375|NCT03500094|Experimental|migalastat HCl 150 mg|"One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as migalastat) was administered every other day for 12 months."
3133376|NCT03500198|Experimental|Investigational Device: Next Generation TECNIS IOL|Investigational Intraocular Lens Device #1: Next Generation TECNIS IOL
3133377|NCT03500198|Active Comparator|Control Device: TECNIS Monofocal IOL|Control Monofocal Intraocular Lens: TECNIS Monofocal IOL
3133378|NCT03500211|Experimental|Lidoderm 5% Topical Patch|5% lidocaine patch applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second 5% lidocaine patch applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
3188750|NCT00770276||Bariatric surgery|Bariatric surgery
3133379|NCT03500211|Sham Comparator|Sham Topical Patch|Sham patch containing no study medication applied at 12 hours after cesarean delivery and removed 24 hours after delivery. A second sham patch containing no study medication applied at 36 hours after cesarean delivery and removed at 48 hours after delivery.
3133380|NCT03500224|Experimental|[14C]-TAK-954 0.5 mg|[14C]-TAK-954 0.5 milligram (mg), (containing approximately 1.5 microcurie [µCi] of radioactive tracer), administered as 60-minute infusion, intravenously, once on Day 1.
3133381|NCT03500289|Experimental|Ketamine|
3133382|NCT03500289|Placebo Comparator|Midazolam|
3133383|NCT03500302|Experimental|Evolocumab|All enrolled patients will receive evolocumab sq once a month for a total of two doses
3133384|NCT03500419|Active Comparator|Control|No treatment will be administered for the initial 6 months post-prostatectomy. This is necessary as a measure to review post-prostatectomy penile length changes.
3133385|NCT03500419|Experimental|Group AB - PTT 1-2x daily x 5-7 days/week x 5 months|Men will utilize penile traction therapy for 30 minutes 1-2 times daily, 5-7 times a week, beginning 4 weeks post-prostatectomy. Men will remain in this phase for a period of 5 months.
3133386|NCT03500679|Experimental|Group 1: ExPEC4V (JNJ-63871860)|Participants will receive vaccination of ExPEC4V dose as an intramuscular (IM) injection into deltoid muscle on Days 1 and 181. The ExPEC4V doses contain polysaccharide antigen (4:4:4:8 microgram [mcg]) from the ExPEC4V serotypes O1A, O2, O6A, and O25B.
3133387|NCT03500679|Placebo Comparator|Group 2: Placebo|Participants will receive placebo matching to ExPEC4V as an IM injection on Days 1 and 181.
3133388|NCT03500692||MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
3133389|NCT03501043|Experimental|Dysport|Subjects will receive 1000 to 1500 units of Dysport to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors for one injection.
3188751|NCT00770276||conservative Therapie|diet and exercise
3188752|NCT00770354|Experimental|1|AS1402 plus letrozole
3133390|NCT03501069|Experimental|Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg|TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.
3133391|NCT03501069|Experimental|Non-Japanese Cohort 2: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.
3133392|NCT03501069|Experimental|Non-Japanese Cohort 3: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.
3188753|NCT00770354|Active Comparator|2|Letrozole
3188997|NCT00773058|Active Comparator|glucocorticoid+RAI|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test hints RAI
3133393|NCT03501069|Experimental|Non-Japanese Cohort 4: TAK-418 60 mg|TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.
3133394|NCT03501069|Experimental|Japanese Cohort 5: TAK-418 20 mg|TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.
3133395|NCT03501069|Experimental|Japanese Cohort 6: TAK-418 40 mg|TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.
3133396|NCT03501264|Experimental|Intervention group|This group receives the game
3133397|NCT03501264|Active Comparator|Control Group|This group receives LGBTQ resources only
3188998|NCT00773058|Placebo Comparator|placebo + RAI|no glucocorticoid But ATCH test hints RAI
3133398|NCT03501277|Experimental|Sequence I: ABCD|SYR-322-4833 BL (alogliptin 25 [milligram] mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 2 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 4 (Regimen D).
3133399|NCT03501277|Experimental|Sequence II: BCDA|Alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 1 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 3 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen A).
3188754|NCT00770380|Experimental|Hypnosis for relapse prevention|The hypnosis intervention was conducted in two face-to-face visits with hypnosis recorded for home practice. Learning, practicing, and employing hypnotic skills in resisting the urge to smoke are core components of this intervention.
3133400|NCT03501277|Experimental|Sequence III: CDAB|SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 1 (Regimen C), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 2 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 3 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 4 (Regimen B).
3133401|NCT03501277|Experimental|Sequence IV: DABC|Alogliptin 25 mg tablet and pioglitazone 30 mg tablet, orally, once, on Day 1 of Period 1 (Regimen D), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 15 mg) FDC tablet, orally, once, on Day 1 of Period 2 (Regimen A), followed by a 7-day washout period, followed by alogliptin 25 mg tablet and pioglitazone 15 mg tablet, orally, once, on Day 1 of Period 3 (Regimen B), followed by a 7-day washout period, followed by SYR-322-4833 BL (alogliptin 25 mg and pioglitazone 30 mg) FDC tablet, orally, once, on Day 1 of Period 4 (Regimen C).
3133402|NCT03501550|Experimental|CDI-31244 + SOF/VEL|CDI-31244 in combination with SOF/VEL
3133403|NCT03501693||DBT plus S-View|Breast images utilizing DBT plus S-View
3133404|NCT03501693||FFDM alone|FFDM alone images
3133405|NCT03502070|Other|Open-Label Placebo|One dose (4 capsules) of placebo
3188755|NCT00770380|Active Comparator|Behavioral relapse prevention counseling|In the behavioral relapse prevention counseling, participants were taught coping strategies for resisting the urge to smoke. This intervention focused on relapse prevention (i.e., maintenance stage of change) and was based on the theoretical concepts and treatment procedures advocated by Marlatt and Gordon and recent smoking relapse data.
3188756|NCT00770393|Experimental|1|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging.
3180474|NCT00683670|Experimental|Dendritic Cell Vaccine (First Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
3133406|NCT03502265|Experimental|Otteroo adjunct|A single-subject research design will be used: measures of infant development will be collected across a 4-week baseline period (standard care), 4 weeks of intervention (standard care and Otteroo use), and a 4 weeks of reversal/retention period (standard care). There is only one arm due to the study design. It is a within-subjects comparison, not a between-subjects comparison of different study arms.
3133407|NCT03502616|Experimental|Tofacitinib|
3188757|NCT00770393|Active Comparator|2|Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
3188758|NCT00770445|Experimental|Pioglitazone 15mg BID|Insulin therapy added
3133408|NCT03502616|Placebo Comparator|Placebo|
3133409|NCT03502681|Experimental|Maximum tolerated dose (MTD) cohort|"The initial 9-12 patients (MTD cohort) will be enrolled to determine safety of avelumab in combination with eribulin mesylate.~Upon determination of maximum tolerated dose (MTD), 12 additional patients will be enrolled in an expansion cohort (efficacy cohort) to determine objective response rate (ORR) at 6 months."
3133410|NCT03502798|Experimental|scanning a/LCI|
3133411|NCT03502915|Experimental|Nitrous Oxide|Patients will receive nitrous oxide during the version procedure.
3133412|NCT03502915|Placebo Comparator|Oxygen|Patients will receive placebo (100% oxygen) during the version procedure.
3133413|NCT03502941|Experimental|A single dose of EAAs/whey|Subjects will consume 6.3 g of EAAs/whey in ~12 oz water.
3133414|NCT03502941|Experimental|A double dose of EAAs/whey|Subjects will consume 12.6 g of EAAs/whey in ~12 oz water
3133415|NCT03502941|Experimental|Whey protein alone|Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
3133416|NCT03503162|Experimental|Colonoscopy with Pure-Vu System|Standard colonoscopy procedure with Pure-Vu System
3133417|NCT03503188|Experimental|All participants|
3133418|NCT03503292|Experimental|CYP2D6 rapid metabolizer|Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment
3133419|NCT03503292|Experimental|CYP2D6 normal metabolizer|Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment
3133420|NCT03503565||Moderate block group|maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery
3133421|NCT03503565||Deep block group|maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery
3133422|NCT03503578|Experimental|EEG Dynamics|EEG data will be collected on patients receiving sevoflurane, and sevoflurane and ketamine together.
3180475|NCT00683670|Experimental|Dendritic Cell Vaccine (Second Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 3 weeks for a total of 6 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 and dose #6 in order to collect PBMC for immune monitoring. Patients with stable disease or better after 6 doses will be eligible to receive additional vaccinations as maintenance therapy every 2 months until progression.
3188759|NCT00770445|Experimental|Pioglitazone 15mg + Metformin 850mg BID|Insulin Therapy Added
3188760|NCT00770445|Active Comparator|Metformin 850mg BID|Insulin therapy added
3133423|NCT03504189|Experimental|PregSense™|PregSense™ wearable device and the standard of care CTG (cardiotocography) will be applied for maternal-fetal monitoring
3133424|NCT03504839|Other|Intervention|S-ICD implantation.
3133425|NCT03504852|Experimental|Secukinumab 300 mg every 2 weeks (Q2W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.
3133426|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks (Q4W)|2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.
3188761|NCT00770458||Pregnant women|Pregnant women that will undergo standard of care procedures to evaluate fetus for Down Syndrome
3188762|NCT00770471|Experimental|Dose Escalation|
3188763|NCT00770497|Experimental|Pioglitazone 15 mg to 30 mg QD|
3188764|NCT00770497|Active Comparator|Pioglitazone 15 mg to 30 mg QD + Ramipril 2.5 mg to 5 mg QD|
3133427|NCT03504852|Active Comparator|Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)|2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).
3133428|NCT03504917|Experimental|Balovaptan|
3133429|NCT03504917|Placebo Comparator|Placebo|
3133430|NCT03505021|Experimental|Levosimendan|Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks
3133431|NCT03505021|Placebo Comparator|Placebo for levosimendan|Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
3133432|NCT03505190|Experimental|RO7062931 0.3mg/kg|Participants will receive subcutaneously (SC) 0.3 milligram per kilogram (mg/kg) of RO7062931.
3133433|NCT03505190|Experimental|RO7062931 1.0mg/kg|Participants will receive subcutaneously (SC) 1.0 milligram per kilogram (mg/kg) of RO7062931.
3133434|NCT03505190|Experimental|RO7062931 2.0mg/kg|Participants will receive subcutaneously (SC) 2.0 milligram per kilogram (mg/kg) of RO7062931.
3133435|NCT03505190|Experimental|RO7062931 4.0mg/kg|Participants will receive subcutaneously (SC) 4.0 milligram per kilogram (mg/kg) of RO7062931.
3133436|NCT03505190|Placebo Comparator|Placebo|Participants will receive matching placebo.
3133437|NCT03505593|Experimental|EFT placement using ENVUE System|Placement of the ENvizion Medical™ Enteral Feeding Tube (EFT) in the stomach or small intestine of adult patients who require feedings via the oro/ nasoenteric route, using the ENVUE™ System.
3188765|NCT00770497|Active Comparator|Ramipril 2.5 mg to 5 mg QD|
3188766|NCT00770536|Experimental|Part 1|In part 1, six subjects will be assigned to each cohort A or B. This is a dose escalation/de escalation study with a 6 + 3 design based on the incidence of DLTs (dose limiting toxicities) during the first 4 weeks of combined therapy [(cohort A: AMG 386 and pegylated liposomal doxorubicin) or (cohort B: AMG 386 and topotecan)].
3180476|NCT00683670|Experimental|Dendritic Cell Vaccine (Third Group)|Blood mononuclear cells will be collected for vaccine production through apheresis. Patients will be given cyclophosphamide 300mg/m2 IV 3 days prior to vaccine dose #1 in order to deplete regulatory T cells. Patients will receive mature DC for each dose of vaccine and will receive autologous dendritic cells. The DC vaccine will be given intravenously every 6 weeks for a total of 3 doses. Peripheral blood will be taken weekly to monitor the immune response. Apheresis is repeated after vaccine dose #3 in order to collect PBMC for immune monitoring.
3180477|NCT00683683|Other|Cooling|Cardiac arrest patients will be cooled to 32-34°C within 6 hours of ED arrival
3180478|NCT00683709||Counselling as Usual|Discussing Clozapine medication, diet and exercise as per clinical protocol potential weight changes
3180479|NCT00683709||Cognitive Behavoural Therapy|Counselling about Clozapine medication, diet and exercise in a structured fashion using Cognitive Behavioural Therapy about potential weight changes
3180482|NCT00683735|Active Comparator|Treatment A|sitagliptin and placebo
3133438|NCT03505749|Experimental|TI-MBRP|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
3180483|NCT00683735|Active Comparator|Treatment B|placebo and metformin
3180484|NCT00683735|Active Comparator|Treatment C|sitagliptin and metformin
3180485|NCT00683735|Placebo Comparator|Treatment D|placebo
3180486|NCT00683748||Kidney transplant|
3180487|NCT00683748||Liver transplant|
3180488|NCT00683761|Experimental|1|
3180489|NCT00683813|No Intervention|UC|usual care
3133439|NCT03505749|Active Comparator|Standard MBRP|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
3133440|NCT03506295|Other|Control|Standard of Care - Transbronchial cryobiopsies are obtained as a standard of care under fluoroscopy guidance
3180490|NCT00683813|Experimental|vCRP|
3133441|NCT03506295|Experimental|Intervention|In the intervention arm , radial ultrasound probe will be used in addition to standard of care described above to confirm adequate position of the cryoprobe before transbronchial cryobiopsy is obtained.
3180491|NCT00683839|Experimental|2|"Dental practitioners provide the following intervention:~5As plus nicotine replacement therapy The 5As consist of: Ask, Advise, Assess, Assist and Arrange."
3133442|NCT03506347|Active Comparator|Vancomycin 15mg/kg IV|Will receive 15mg/kg based on actual body weight (maximum of 2g) of vancomycin via the systemic route at a rate of 15mg/kg as per hospital guidelines. Systemic IV vancomycin is given via a forearm vein, given over an infusion timed to finish immediately prior to surgery.
3133443|NCT03506347|Experimental|Vancomycin 500mg Intraosseous|Will have the limb exsanguinated and an above knee tourniquet inflated to 300 mmHg. Immediately following tourniquet inflation, Group B will receive 500mg of vancomycin, via an EZ-IO intraosseous cannula. The vancomycin would be administered in 150ml of saline solution. The intraosseous cannula would be placed into the epiphysis of the proximal tibia. The tourniquet will be left inflated for 10 minutes following completion of the IORA injection then deflated.
3133444|NCT03506386||Multiple Myeloma Participants|Participants with multiple myeloma (MM) were observed retrospectively since the diagnosis up to death or lost to follow-up within the eligibility window of time (between January 1, 2008 and December 31, 2016), in this study.
3133445|NCT03506425|Experimental|Group 1|Standard care for 1 month, then standard care and Triheptanoin for 5 months.
3133446|NCT03506425|Experimental|Group 2|Standard care and Triheptanoin for 6 months.
3133447|NCT03506425|No Intervention|Group 3|Healthy controls for biomarkers
3133448|NCT03506477|Experimental|Enstilar® foam|Enstilar® foam - a combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%.
3133449|NCT03506477|Placebo Comparator|Vehicle foam|does not contain the active ingredient
3133450|NCT03506724|Other|Oral nifedipine|Oral medication 10mg and 20mg
3133451|NCT03506724|Other|Intravenous labetalol|intravenous medication 20mg, 40mg, 80 mg
3180492|NCT00683839|No Intervention|1|Usual Care Control: Patients receive treatment as usual.
3133452|NCT03507036|Experimental|Treatment|"All patients will undergo treatment with Profound system device. Using the radiofrequency and temperature setting within the FDA approved limits (460 +/- 5kHz and 65-75°C +/- 1°C), patients will be treated one time over the entire suprapatellar region bilaterally and followed for a 6 month period. The acute effect of the radiofrequency application will be determined by subjective and objective analysis using standard, close-up, 3D, cross-polarized, high resolution ultrasound, optical coherence tomography, transepidermal water loss measurements, and/or BTC 2000 measurements.~Biopsies will be taken using 0.33mm WellTech Rapid Core 0.33mm Biopsy Punch. Biopsies will allow investigators to correlate changes seen in skin measurements with histology and gene expression."
3133453|NCT03507569|Experimental|RO7017773|The first two participants of the first cohort are anticipated to receive a single dose of RO7017773 orally. The doses to be tested in the subsequent cohorts of participants will be determined by review of PET scan, PK, and safety results from the previous dose level.
3133454|NCT03508050|Experimental|Clamping double lumen tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
3180493|NCT00683865|Active Comparator|Arm 1|
3133455|NCT03508050|No Intervention|Not Clamping double lumen tube|Not Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
3133456|NCT03508609|Experimental|Autologous CD34 cells|Open label active treatment arm. Subjects receive autologous CD34 cells.
3133457|NCT03508661|Experimental|SPIN-SSLED Program|13-session SPIN-SSLED Program
3133458|NCT03508687|Experimental|Group 1: 300 mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.
3133459|NCT03508687|Experimental|Group 2: 600mg Gemcabene daily week 12-24|Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.
3133460|NCT03508830|Experimental|Liposomal Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation: 266mg (20cc) Liposomal Bupivacaine admixed with 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) and varied 0.9% normal saline volume for total volume of 60cc."
3133461|NCT03508830|Active Comparator|Standard Bupivacaine|"5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.~Drug Preparation - 0.25% (2.5mg/cc) Standard Bupivacaine (maximum dose of 2mg/kg) admixed with varied 0.9% normal saline volume for total volume of 60cc."
3133462|NCT03508843|Experimental|interactive virtual presence|install a car seat using advice from a remotely-located certified car seat technician communicating via interactive virtual presence
3180494|NCT00683865|Experimental|Arm 2|
3180495|NCT00683969|Experimental|1|
3180496|NCT00683969|Placebo Comparator|2|
3180497|NCT00683982|Active Comparator|1|This group will receive oral nitazoxanide preparation
3180498|NCT00683982|Active Comparator|2|This group will receive a mix combination of probiotics
3133463|NCT03509350|Experimental|Treatment Protocol|Participants randomized to the treatment protocol will receive the VICTAS Intervention, consisting of intravenous vitamin C, thiamine, and hydrocortisone for four days or until ICU discharge.
3133464|NCT03509350|Placebo Comparator|Control Protocol|A placebo to match the VICTAS intervention will be administered for four days or until ICU discharge. During the treatment period, if an indication for steroids exist, the treating physicians are permitted to initiate open-label corticosteroid therapy based on local practice and international guidelines. If this occurs, the hydrocortisone/placebo will be withheld and subjects will be started on open-label corticosteroids.
3133465|NCT03509675|Placebo Comparator|Placebo|Placebo suspension was compounded with the same taste as the active medication but without the active ingredient.
3133466|NCT03509675|Active Comparator|Active ingredient|The topical suspension of the topical NSAID was 100 mg per 5 ml concentration of ibuprofen, with similar ingredients as OTC children's ibuprofen and was compounded by an external drug service.
3133467|NCT03509766|Experimental|Skin testing|All subject both allergic and non-allergic will be tested. There is only one (1) arm.
3133468|NCT03509883|Experimental|Apixaban sprinkle capsules followed by apixaban tablets|Apixaban (BMS-562247) sprinkle capsules followed by apixaban tablets
3133469|NCT03509883|Active Comparator|Apixaban tablets followed by apixaban sprinkle capsules|Apixaban (BMS-562247) tablets followed by apixaban sprinkle capsules
3133470|NCT03509948|Experimental|Schedule A: Fed Then Fasted|"Schedule A (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)"
3133471|NCT03509948|Experimental|Schedule B: Fasted Then Fed|"Schedule B (6 participants):~Period 1: cytisine (2 x 1.5 mg tablets) will be administered after an overnight fast of at least 10 hours (fasting state)~Period 2: cytisine (2 x 1.5 mg tablets) will be administered 30 minutes after the start of a high fat breakfast (fed state)"
3133472|NCT03509974|Experimental|Bone Anchored Hearing Device (OSIA)|All subjects will receive the Bone Anchored Hearing Device (OSIA)
3133473|NCT03510182|Experimental|transcranial Direct Current Stimulation|tDCS will be given to all qualified patients with aphasia.
3133474|NCT03510195|Experimental|MEDICORP HO PREPARATORY MODULE|The participants that will have intervention which is the module
3133475|NCT03510273|Other|Thermocoagulation treatment|Acceptability of Liger Medical Thermocoagulator treatment
3133476|NCT03510455|Experimental|Single Arm (TIO Subjects)|Phase 2, open-label, non-randomized, single-arm, drug treatment trial. 10 subjects will be studied. Treatment duration of 6 months with 3 months off drug follow-up and optional extension phase.
3133477|NCT03510481|Experimental|Experimental arm 1: Dosing interval 0, 8, 16, and 54 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
3133478|NCT03510481|Experimental|Experimental arm 2: Dosing interval 0, 1, 4, and 42 weeks|Participants received 3 doses of PfSPZ Vaccine (9 x 10^5) via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd vaccination. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
3133479|NCT03510481|Placebo Comparator|Placebo comparator 3a: Dosing interval 0, 8, 16, and 54 weeks|Control for Arm 1. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 8, 16 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
3133480|NCT03510481|Placebo Comparator|Placebo comparator 3b: Dosing interval 0, 1, 4, and 42 weeks|Control for Arm 2. Participants received 3 doses of placebo saline injection via direct venous inoculation (DVI) at 0, 1, 4 weeks and a 4th dose at 38 weeks post 3rd injection. Oral antimalarial treatment with artemether 20mg/lumefantrine 120mg (AL) given orally with food with 4 tablets taken as a single initial dose, then 4 tabs again after 8hrs, then 4 tabs twice daily for the following two days for a total of 24 tabs, 2 weeks prior to 3rd and 4th injection.
3133481|NCT03510663|Experimental|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
3133482|NCT03510663|Experimental|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
3133483|NCT03510663|Active Comparator|Moxifloxacin|400mg tablet will be administrated once a week.
3133484|NCT03510663|Placebo Comparator|Placebo|Placebo will be intravenously administered once a week.
3133485|NCT03510715|Experimental|Alirocumab|"Participants with BW less than (<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to [>=] 50 kg.~Participants with BW >=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks."
3133486|NCT03510910|Experimental|Acetaminophen along with a reduced quantity of Percocet|
3133487|NCT03510910|Experimental|Percocet only|
3133488|NCT03511001|Experimental|E-Cigarette|6 weeks of JUUL electronic cigarettes
3133489|NCT03511001|Active Comparator|Assessment Only|6 weeks of smoking as usual
3133490|NCT03511053|Experimental|All participants|Epidural Lavage followed by Lumbar Epidural Steroid Injection
3133491|NCT03511105|Experimental|Subjects receiving GSK2798745|Eligible subjects will receive two tablets of 2.4 milligrams GSK2798745 on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose of a single tablet of 2.4 milligrams of GSK2798745 will be administered 10 hours after LPS and saline challenge.
3133492|NCT03511105|Placebo Comparator|Subjects receiving matching Placebo|Eligible subjects will receive two tablets of placebo on the morning of Day 1. Subjects will then undergo segmental challenge at 2 hours after first dose wherein LPS will be instilled into the right middle segment and saline control into the lingula segment of the contralateral side. The second dose placebo will be administered 10 hours after LPS and saline challenge.
3133493|NCT03511326|Experimental|Luxerm®|
3133494|NCT03511378|Experimental|Lupin's Pegfilgrastim|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
3133495|NCT03511378|Experimental|Neulasta®|6 mg, subcutaneous injection on day 2/3 of each 21 ± 3 day cycle. Number of cycles: 4.
3180499|NCT00683982|Placebo Comparator|3|This is the control group receiving only oral or systemic hydration solutions
3180500|NCT00683995|Experimental|1|KW-2246 (fentanyl citrate)
3188999|NCT00773058|Active Comparator|glucocorticoid|stress-dose glucocorticoid treatment, compared to placebo group and ACTH test does not hint RAI
3189000|NCT00773058|Placebo Comparator|placebo|no glucocorticoid But ATCH test does not hint RAI
3133496|NCT03511521|Experimental|NPH Insulin|"NPH will be given at the time of steroid administration to the patient in addition to standard basal/bolus insulin the patient may be receiving in the following doses:~Prednisone Dose (mg/day) - NPH dose (U=Units): 10-20 mg/day - 1.2U (units)/mg; 21-40 mg/day - 0.6U/mg; 41-60 mg/day - 0.45U/mg; 61-80 mg/day - 0.3U/mg; >80 mg/day - no additional NPH. Note that the amounts of NPH are added to each other for the various prednisone doses. For example, a dose of 75 mg/day of prednisone would come out to be (1.2U x 20mg = 24U) + (0.6U x 20mg = 12U) + (0.45U x 20mg = 9U) + 0.3U x 15 mg = 4.5U) for a total of 24 + 12 + 9 + 4.5 = 49.5U of NPH for 75 mg of prednisone."
3180501|NCT00684008|Experimental|I|"Single arm dose escalation study. Three successive cohorts of 3 patients each. Doses to be evaluated: 10, 20, and 30 mcg/kg/dose for 3 consecutive doses.~CYT107 is a recombinant protein belonging to the class of growth factors known as cytokines.~CYT107 is a heavily glycosylated and sialylated form of recombinant human Interleukin-7.~CYT107 is supplied as a sterile colorless liquid at a concentration of 4 mg/ml."
3180502|NCT00684034|Other|1|Volunteer healthy
3180503|NCT00684034|Other|2|Patient dialysis patient
3180504|NCT00684034|Other|3|Not dialysed chronic renal insufficient patient
3180505|NCT00684099|Experimental|1|
3180506|NCT00684112|Experimental|Gabapentin|Single dose preoperative gabapentin
3180507|NCT00684112|Placebo Comparator|Placebo Control|Single dose preoperative placebo control
3180508|NCT00684125|Experimental|1|mediastinal drainage will be accomplished using a 28F or 32F chest tube in the anterior mediastinum and a 19F Blake drain located in the posterior pericardial cavity.
3180509|NCT00684125|Active Comparator|2|mediastinal drainage will be accomplished using two 28F or 32F chest tubes located in the anterior mediastinum.
3180510|NCT00684151||1|Patients with high cardiovascular risk who have been treated with lipid-lowering drugs at least 3 months
3180511|NCT00684164|Experimental|1|Subjects in the treatment group will receive standard medical treatment plus Conivaptan administered as a 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
3180512|NCT00684164|Placebo Comparator|2|Subjects in the placebo control group will receive an equivalent volume loading dose of D5 followed by an infusion of D5 in the same manner as the experimental group.
3180513|NCT00684190|Experimental|1|AZD3355 150 mg
3180514|NCT00684190|Experimental|2|Esomeprazole 40mg
3180515|NCT00684190|Experimental|3|AZD3355 150mg/Esomeprazole 40mg
3133497|NCT03511521|Active Comparator|Basal/Bolus Insulin|"Basal insulin (glargine) and Bolus insulin (insulin aspart) will be increased (doses given in U [units]/kg) according to the Prednisone dose (mg/day) as follows:~Prednisone Dose (mg/day) - doses of insulin (U/kg): Prednisone 0 mg - Glargine 0.25U/kg, Bkfst Aspart 0.08U/kg, Lunch Aspart 0.08U/kg, Dinner Aspart - 0.08U/kg; Prednisone 10-20 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.15U/kg, Dinner Aspart - 0.2U/kg; Prednisone 21-40 mg - Glargine 0.25U/kg, Bkfst Aspart 0.1U/kg, Lunch Aspart 0.2U/kg, Dinner Aspart - 0.25U/kg; Prednisone 41-60 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.25U/kg, Dinner Aspart - 0.30U/kg; Prednisone 61-80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.30U/kg, Dinner Aspart - 0.35U/kg; Prednisone >80 mg - Glargine 0.30U/kg, Bkfst Aspart 0.15U/kg, Lunch Aspart 0.35U/kg, Dinner Aspart - 0.40U/kg."
3133498|NCT03511638|Experimental|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
3133499|NCT03511638|Active Comparator|Alcon VISCOAT®|Ophthalmic viscosurgical device
3133500|NCT03511937|Experimental|Sugar-Sweetened Beverage Health Warning Label|
3133501|NCT03511937|Other|Neutral Label|
3180516|NCT00684216|Active Comparator|1|capecitabine followed by hormonal treatment
3180517|NCT00684216|Active Comparator|2|hormonal treatment followed by capecitabine
3133502|NCT03512028|Experimental|Remote Limb Ischemic Conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-8.
3180518|NCT00684229|Active Comparator|Regional anesthesia and analgesia|Regional anesthesia and analgesia (either epidural or paravertebral anesthesia).
3133503|NCT03512028|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-8.
3133504|NCT03512041|Experimental|RLIC - 5 Cycles|Remote Limb Ischemic Conditioning (RLIC) is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 5 Cycles of RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
3133505|NCT03512041|Experimental|RLIC - 4 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 4 Cycles of RLIC requires 35 minutes and involves 4 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
3133506|NCT03512041|Experimental|RLIC - 3 Cycles|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the non-dominant arm. 3 Cycles of RLIC requires 25 minutes and involves 3 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
3133507|NCT03512041|Sham Comparator|Sham Conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the non-dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
3133508|NCT03512067|Experimental|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
3133509|NCT03512210|Experimental|MINMON 24 weeks with SOF/VEL 12 Weeks|Participants received Sofosbuvir/Velpatasvir (SOF/VEL [Tradename: Epclusa®]) tablet for 12 weeks with a minimal monitoring (MINMON) strategy for 24 weeks
3180519|NCT00684229|Active Comparator|general anesthesia followed by opioid analgesia|Subjects randomized to arm 2 will receive general anesthesia followed by opioid analgesia.
3133510|NCT03512288|Experimental|Multivalent|Pneumococcal conjugate vaccines
3133511|NCT03512288|Active Comparator|Control|13vPnC
3180520|NCT00684268|Experimental|on treatment nonresponders|naive patients with null response to peginterferon/ribavirin at week 12 or partial response at week 24
3180521|NCT00684268|Experimental|Nonresponders to previous antiviral combination therapy|Nonresponders defined by viral status at weeks 4,12, and 24 of previous peginterferon/ribavirin combination therapy
3180522|NCT00684281|Other|1|Subject control
3180523|NCT00684281|Experimental|2|40 patients before hand include in a program
3180524|NCT00684294|Experimental|TAG Vaccine 1 x 10^7 cells/ injection|TAG Vaccine 1 x 10^7 cells/injection
3180525|NCT00684294|Experimental|TAG Vaccine 2.5 X 10^7 cells/injection|TAG Vaccine 2.5 X 10^7 cells/injection
3180526|NCT00684333|Experimental|group 1|volunteers
3180527|NCT00684346|Experimental|1|
3180528|NCT00684437|Experimental|Factual Gain-Framed|Smoking Risk Message - Factual Gain-Framed (FGF)
3133512|NCT03512353|Experimental|Carfilzomib Plus Dexamethasone|"Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12.~Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12."
3133513|NCT03512457|Experimental|Intensive Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
3133514|NCT03512457|Active Comparator|Minimal Intervention|Participants receive brochure, card advising how to make an appointment with dermatology, and reminder in one week to perform SSE.
3133515|NCT03513588|Placebo Comparator|Placebo|
3133516|NCT03513588|Experimental|PF-06865571 100 mg|
3133517|NCT03513588|Experimental|PF-06865571 600 mg|
3180529|NCT00684437|Experimental|Factual Loss-Framed|Smoking Risk Message - Factual Loss-Framed (FLF)
3133518|NCT03513757|Active Comparator|propofol|Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
3133519|NCT03513757|Experimental|propofol dexmedetomidine|Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
3133520|NCT03513848|Experimental|Bright Light|
3133521|NCT03513848|Placebo Comparator|Dim Light|
3133522|NCT03514277|Active Comparator|Local infiltration of EXPAREL and Bupivacaine|
3133523|NCT03514277|Active Comparator|Local infiltration of Exparel|
3133524|NCT03514277|Active Comparator|Local infiltration of Bupivacaine|
3133525|NCT03514420|Experimental|AKCEA-ANGPTL3-LRx 20 mg|Participants received AKCEA-ANGPTL3-LRx 20 milligrams (mg) administered every week for 26 weeks by subcutaneous (SC) injection.
3133526|NCT03514641|Other|Sequence 1|Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
3133527|NCT03514641|Other|Sequence 2|Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
3133528|NCT03514641|Other|Sequence 3|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
3133529|NCT03514641|Other|Sequence 4|Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
3180530|NCT00684437|Experimental|Emotional Gain-Framed|Smoking Risk Message - Emotional Gain-Framed (EGF)
3133530|NCT03514966|No Intervention|Conventional group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the conventional group will receive no intervention. Thirty and 40 min after dimethicone administration, subjects will additionally take 200 ml and 800 ml water, respectively, and undergo MCE examination.
3180531|NCT00684437|Experimental|Emotional Loss-Framed|Smoking Risk Message - Emotional Loss-Framed (ELF)
3180532|NCT00684450|Active Comparator|1|in vivo protamine titration in cardiac surgery. The titration is done during administration of protamine each 3 minutes to reach 2 consecutive ACT defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds. .The protamine is stopped when this values are obtain. Follow-up is done 15 minutes and 3 hours post-protamine
3133531|NCT03514966|Experimental|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
3133532|NCT03515681|Experimental|Intervention|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
3133533|NCT03515681|No Intervention|Control|Subjects randomized to the control arm will receive the messages regarding their kiosk blood pressure levels currently provided by higi to kiosk users. These messages are provided at the kiosk at the time of the blood pressure measurement (no text messages).
3180533|NCT00684450|Active Comparator|2|standard protamine administration ACT is done during administration of protamine each 3 minutes the values are recorded but the totality of protamine is given. Follow-up is done 15 minutes and 3 hours post-protamine
3133534|NCT03515824|Experimental|Part A: MK-1696 20 mg|Participants received 20 mg of MK-1697 by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
3180534|NCT00684463|Experimental|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent
3180535|NCT00684489|Active Comparator|A; B|
3180536|NCT00684489|Active Comparator|2|Arm A is assignment to a clinical hypertension specialist Arm B is assigned renin-guided therapeutics
3133535|NCT03515824|Experimental|Part A: MK-1697 65 mg|Participants received 65 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
3133536|NCT03515824|Experimental|Part A: MK-1697 200 mg|Participants received 200 mg of MK-1697 by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
3133537|NCT03515824|Experimental|Part B: Expansion Cohort|Participants with select tumor types were to receive MK-1697 at the RP2D by IV infusion on Day 1 of each 21-day cycle for up to 35 administrations (up to approximately 2 years).
3133538|NCT03515941|Experimental|Arm 1: Adjuvant Chemotherapy|Three cycles of chemo with CAPEOX (Oxaliplatin:130 mg/m2 by IV and Capecitabine: 625 or 1000 mg/m2 by PO (BID) on 21 day-cycle or FOLFOX (Oxaliplatin:85 mg/m2 by IV, Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 2400 mg/m2 by IV) on 14 day-cycle
3133539|NCT03515941|Experimental|Arm 2: Adjuvant Chemoradiation|Three cycles of chemo with Capecitabine: 750 mg/m2 by PO BID on days 1-14 of a 28 day-cycle or 5-fluorouracil (Leucovorin:400 mg/m2 by IV,5-fluorouracil: 400 mg/m2 and 1200 mg/m2 by IV) on days 1 and 15 of a 28 day cycle After 1st chemo cycle above, chemoradiation for 5 weeks with 45 Gy in 1.8 Gy/fraction, 5 days a week, to the entire gastric bed (including anastomosis) and draining lymph nodes, and a single agent fluoropyrimidine, either capecitabine or 5-fluorouracil After 5 weeks chemoradiation, 2 cycles of chemo as described above.
3133540|NCT03516227|Experimental|HRVBF|Heart rate variability biofeedback
3133541|NCT03516227|No Intervention|Control|Usual Care
3133542|NCT03517436|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|
3180537|NCT00684489|Active Comparator|A is clinical hypertension specialist|Arm A is assigned to a clinical hypertension specialist
3133549|NCT03517566|Placebo Comparator|placebo|Placebo
3133550|NCT03517566|Experimental|ZPL389 3mg|ZPL389 3 mg oral powder
3133551|NCT03517566|Experimental|ZPL389 10 mg|ZPL389 10 mg oral powder
3133552|NCT03517566|Experimental|ZPL389 30mg|ZPL389 30 mg oral powder
3133553|NCT03517566|Experimental|ZPL389 50mg|ZPL389 50 mg oral powder
3133554|NCT03518008|Other|DD T2, then Clariti 1 Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second. Each product worn bilaterally (in both eyes) for 1 week in a daily disposable modality.
3133555|NCT03518008|Other|Clariti 1 Day, then DD T2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second. Each product worn bilaterally for 1 week in a daily disposable modality.
3133556|NCT03518125|Experimental|Age ≥ 66, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
3133557|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL AV7909.
3133558|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
3133559|NCT03518125|Experimental|Age ≥ 66, AV7909 (Days 1 and 29)|Subjects dosed on Days 1 and 29 with 0.5 mL AV7909 and on Day 15 with 0.5 mL placebo.
3133560|NCT03518125|Active Comparator|Age18-50, BioThrax (Days 1, 15, 29)|Subjects dosed on Days 1, 15, and 29 with 0.5 mL BioThrax.
3133561|NCT03518125|Active Comparator|Age 18-50, AV7909 (Days 1 and 15)|Subjects dosed on Days 1 and 15 with 0.5 mL AV7909 and on Day 29 with 0.5 mL placebo.
3133562|NCT03518658||Evaluation Group|Patients implanted with a pacemaker or CRT-P device who will be using remote monitoring via the MyCareLink Heart App
3133563|NCT03518658||Control Group|Patients with low power implantable devices and CareLink Monitor 2490 (Excluding wireless model 2490C)
3133564|NCT03518840|Other|Sacroiliac Joint Belt|All patients will receive and be fitted by the PI with an SIJ belt.
3133565|NCT03519087|Experimental|Interdisciplinary Evaluation|Participants will receive an Interdisciplinary Evaluation for Nonarthritic Hip Disease from a hip arthroscopist, followed by an examination from a physical therapist, and then will participate in a shared decision-making process with both providers to determine a plan of care.
3133566|NCT03519087|No Intervention|Standard Evaluation|Participants will receive a standard-of-care evaluation from a hip arthroscopist who will then determine the plan of care with the participant.
3133567|NCT03519087|Experimental|Posture and Movement Training|Participants will receive six training sessions with a physical therapist over a 3-week period.
3133568|NCT03519087|No Intervention|3-week Wait Period|Participants will undergo a 3-week wait period. They will be instructed to not receive any treatment (e.g. chiropractic services, physical therapy, medication, surgery, injections) for their hip symptoms during this time.
3133569|NCT03519087|Other|Observational Arm|Participants who refuse randomization to receive posture and movement training may continue participation in an observational group. These participants complete the same baseline and follow-up testing but proceed with their treatment-of-choice during the 3-week intervention period.
3133570|NCT03519204|Experimental|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips at Day 1. Participants were eligible to receive optional touch-up retreatment one month following initial treatment if applicable.
3133571|NCT03519204|Experimental|No-treatment Control|No-treatment was administered during control period. After 3 months, participants were eligible to receive treatment with JUVÉDERM® VOLBELLA® XC with lidocaine if applicable followed by an optional touch-up retreatment one month following initial treatment.
3133572|NCT03519243|Experimental|BCD-131 1,05 mcg/kg * conversion ratio|subcutaneously monthly
3133573|NCT03519243|Experimental|BCD-131 1,7 mcg/kg * conversion ratio|subcutaneously monthly
3133574|NCT03519243|Experimental|BCD-131 2,75 mcg/kg * conversion ratio|Subcutaneously monthly
3133575|NCT03519243|Active Comparator|Mircera|subcutaneously monthly
3133576|NCT03519282|Experimental|Test Multifocal Toric Lens|comfilcon A multifocal toric lens
3133577|NCT03519282|Active Comparator|omafilcon A Multifocal Toric Lens|Control multifocal toric lens
3133578|NCT03519516|Experimental|PRO-174|"Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period"
3133579|NCT03519516|Active Comparator|Sophixín Ofteno®|o Dosage: 1 drop in both eyes, 8 times a day during the waking period
3133580|NCT03519854|Placebo Comparator|Arm A. Placebo; given 3 minutes after Esmeron®|Placebo (single intravenous (IV) bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133581|NCT03519854|Experimental|Arm B. 1 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133582|NCT03519854|Experimental|Arm C. 2 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133583|NCT03519854|Experimental|Arm D. 4 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3180538|NCT00684489|Active Comparator|Arm B is renin-guided therapeutics|This group will be assigned to renin-guided therapeutics
3180539|NCT00684502|Experimental|1|Oral solution.
3180540|NCT00684502|Placebo Comparator|2|Oral solution
3133584|NCT03519854|Experimental|Arm E. 6 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3180541|NCT00684528|Active Comparator|a|This group will receive Metformin and placebo.
3180542|NCT00684528|Experimental|2|The second arm will receive Metformin and Januvia
3180543|NCT00684580||Observational Group|Data Collection
3180544|NCT00684606|Experimental|1|Transcervical Foley catheter with IV Oxytocin
3180545|NCT00684606|No Intervention|2|Transcervical Foley catheter only
3180546|NCT00684619|Experimental|Arm A|Nelarabine
3180547|NCT00684632|Experimental|1|KW-2246
3180548|NCT00684632|Placebo Comparator|2|Placebo
3180549|NCT00684658|Experimental|1|TeenCope: Internet-based Coping Skills Training
3180550|NCT00684658|Active Comparator|2|Managing Diabetes: Internet-based Diabetes Education
3180551|NCT00684684|Experimental|1|
3180552|NCT00684697|Placebo Comparator|1|low iron dose
3180553|NCT00684697|Active Comparator|2|intermediate iron dose
3180554|NCT00684697|Experimental|3|High Iron dose
3180555|NCT00684710|Experimental|PAZ-417|
3180556|NCT00684710|Placebo Comparator|Placebo|
3180557|NCT00684801||Usual care (control group)|Patients undergo usual care as determined by core cancer team.
3133585|NCT03519854|Experimental|Arm F. 8 mg/kg Sugammadex; given 3 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 3 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133586|NCT03519854|Placebo Comparator|Arm G. Placebo; given 5 minutes after Esmeron®|Placebo (single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133587|NCT03519854|Experimental|Arm H. 1 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133588|NCT03519854|Experimental|Arm I. 2 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133589|NCT03519854|Experimental|Arm J. 4 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133590|NCT03519854|Experimental|Arm K. 6 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133591|NCT03519854|Experimental|Arm L. 8 mg/kg Sugammadex; given 5 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 5 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133592|NCT03519854|Placebo Comparator|Arm M. Placebo; given 15 minutes after Esmeron®|Placebo (single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133593|NCT03519854|Experimental|Arm N. 1 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (1 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133594|NCT03519854|Experimental|Arm O. 2 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (2 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133595|NCT03519854|Experimental|Arm P. 4 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (4 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133596|NCT03519854|Experimental|Arm Q. 6 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (6 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133597|NCT03519854|Experimental|Arm R. 8 mg/kg Sugammadex; given 15 minutes after Esmeron®|Sugammadex (8 mg/kg; single IV bolus) administered 15 minutes after the bolus intubation dose of 0.6 mg/kg Esmeron®.
3133598|NCT03519867|Experimental|1) Zemuron® 0.6 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced neuromuscular blockade (NMB) reaches 1 to 2 PTCs.
3133599|NCT03519867|Experimental|2) Zemuron® 1.2 mg/kg + MK-8616 0.5 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 0.5 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133600|NCT03519867|Experimental|3) Zemuron® 0.6 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133601|NCT03519867|Experimental|4) Zemuron® 1.2 mg/kg + MK-8616 1.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 1.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133602|NCT03519867|Experimental|5) Zemuron® 0.6 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133603|NCT03519867|Experimental|6) Zemuron® 1.2 mg/kg + MK-8616 2.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 2.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133604|NCT03519867|Experimental|7) Zemuron® 0.6 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3180558|NCT00684801||DMP (experimental group)|Patients undergo a systematic approach regarding specific domains related to their disease focusing on supportive care and symptom management determined by a multidisciplinary team of providers to help patients and caregivers manage.
3180559|NCT00684827|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose"
3188767|NCT00770536|Experimental|Part 2|The decision on declaration of a safe and tolerable dose during part 1 will lead to part 2 (cohort A: liposomal doxorubicin + AMG 386 MTD (max tolerated dose) of part 1, cohort B: Topotecan + AMG 386 MTD (max tolerated dose) of part 1
3188768|NCT00770575|Experimental|Pioglitazone 30mg to 45 mg QD + Atorvastatin 20 mg to 40 mg QD|
3188769|NCT00770575|Active Comparator|Atorvastatin 20mg to 40 mg QD|
3133605|NCT03519867|Experimental|8) Zemuron® 1.2 mg/kg + MK-8616 4.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 4.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133606|NCT03519867|Experimental|9) Zemuron® 0.6 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 0.6 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133607|NCT03519867|Experimental|10) Zemuron® 1.2 mg/kg + MK-8616 8.0 mg/kg|Participants (ASA Class 1 to 3) will receive an iv bolus of Zemuron® 1.2 mg/kg followed by MK-8616 8.0 mg/kg iv during a single study session. MK-8616 will be administered once Zemuron®-induced NMB reaches 1 to 2 PTCs.
3133608|NCT03519919|Experimental|Somofilcon A multifocal lens|Habitual wearers of multifocal contact lenses will be refit to somofilcon A multifocal lens and provide a subjective assessment.
3133609|NCT03519932|Experimental|comfilcon A toric lens|Subjects who wear comfilcon A toric lens either as first or second pair during this cross-over study.
3133610|NCT03519932|Active Comparator|samfilcon A toric lens|Subjects who wear samfilcon A toric lens either as first or second pair during this cross-over study.
3133611|NCT03520283|Experimental|Supportive Care (MAP)|Participants complete MAP in-clinic over 60-90 minutes.
3133612|NCT03520348|Experimental|PRO-167|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom
3133613|NCT03520348|Active Comparator|Corneregel®|Dose: a strip approximately 1 cm long, 4 times a day during the period of vigil, in the bottom of the right eye sac.
3133614|NCT03520387|Experimental|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves
3133615|NCT03520387|Active Comparator|Simulated lumbar radiofrequency ablation (simulated LRFA)|Simulated radiofrequency ablation of the dorsal rami of the lumbar spinal nerves(simulated LRFA), with targeted steroid injections
3133616|NCT03520387|Experimental|AcTIVE-CBT|Activity-Tracker Informed Video-enabled Cognitive Behavioral Therapy (AcTIVE-CBT)
3133617|NCT03520387|Active Comparator|TBSCE|Telephone-based self-directed CBT and education (TBSCE)
3180560|NCT00684827|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. An AeroChamber Plus spacer will be utilized for each dose.
3133618|NCT03520400|Experimental|Exercise Intervention Group|Group receives one year of exercise and lifestyle intervention
3133619|NCT03520400|No Intervention|PCI group (usual care)|Group receives standard clinical care with no intervention
3133620|NCT03520920|Experimental|R/R Non-GCB DLBCL|Participants with non-GCB DLBCL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
3133621|NCT03520920|Experimental|R/R FL or MZL|Participants with R/R FL or MZL received zanubrutinib plus rituximab for up to progressive disease or intolerance.
3133622|NCT03520959|Placebo Comparator|Placebo|A sequential regimen of LV305-matching placebo and G305-matching placebo.
3133623|NCT03520959|Experimental|CMB305|A sequential regimen of LV305 and G305.
3133624|NCT03520998|Experimental|GRF6019 Low Dose|Subjects will receive a low dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
3133625|NCT03520998|Experimental|GRF6019 High Dose|Subjects will receive a high dose of GRF6019 for 5 consecutive days at Week 1 and Week 13.
3180561|NCT00684853|Active Comparator|1|
3180562|NCT00684853|Active Comparator|2|
3188770|NCT00770614|Active Comparator|1|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3188771|NCT00770614|Active Comparator|2|Isotonic Saline (0.9% sodium chloride) 1 mL/kg/h for 12 hours after the procedure
3188772|NCT00770614|Placebo Comparator|3|Placebo
3188773|NCT00770627|Placebo Comparator|Placebo caps|
3188774|NCT00770627|Active Comparator|Omega 3 caps|
3180563|NCT00684866|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (8 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (8 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects."
3180564|NCT00684866|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. Treatment will be administered with an AeroChamber Plus ™ spacer for the first cohort (spacer cohort) of subjects and without the AeroChamber Plus ™ spacer (non-spacer cohort) for the second cohort of subjects.
3180565|NCT00684892|Experimental|1|
3133626|NCT03521089|Active Comparator|Active tDCS|Active tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The active tDCS intervention include stimulation for 15 minutes at 1mA. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
3133627|NCT03521089|Sham Comparator|Sham tDCS|Sham tDCS uses the Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001. The sham tDCS intervention lasts for 15 minutes. The cathode electrode will be placed over the right dorsolateral prefrontal cortex with reference electrode (anode) over the left dorsolateral prefrontal cortex. Both electrodes are covered by saline-soaked sponges that are held against the scalp by a pair of large, adjustable head straps. Treatment sessions will last for 15 minutes. 5 consecutive treatment sessions will be completed within 1 week.
3133628|NCT03521115|Experimental|Smart Choices 4 Teens|A web-based intervention consisting of 3 main components (Communication, Alcohol, Relationships) provided to both parents and teens was completed by parents and teens individually. At the end of each component, discussion guidelines were given to promote communications and to offer skill building practices between parent and teen regarding the component topic. Both the parent and teen were required to complete the component and discussion before moving to the next component. Numbers are provided for the number of families
3133629|NCT03521115|No Intervention|Control condition|This group was provided with websites where information was available regarding the same topics.
3180566|NCT00684918|Experimental|Experimental|In the Pilot Schedule portion of the study 3 hour vs 24 hour infusion schedules of obatoclax.
3180567|NCT00684931|Experimental|1|patients with Attention Deficit Disorder with or without Hyperactivity
3133630|NCT03521141|Other|Guideline-Based Care (GBC)|GBC participants are 1) referred to the state quitline, 2) provided the NCI Clearing the Air smoking cessation program, and 3) asked to talk to their healthcare provider about potential lung cancer screening (LCS). Medication assignment is guided by standard guidelines and a conversation between the study tobacco counselor and the participant. Groups 1 and 2 also receive GBC counseling.
3133631|NCT03521141|Active Comparator|Nicotine Metabolite Ratio (PC-NMR)|Group 1, nicotine metabolism. Medication is guided by nicotine metabolism.
3133632|NCT03521141|Active Comparator|Respiragene (PC-Respiragene)|Group 2, genetically-informed lung cancer risk score. Medication assignment is guided by standard guidelines and a conversation between the study nurse and the participant.
3133633|NCT03521193|Experimental|Migraine evaluation in PFO patients|Patients symptomatic for migraine with/o aura and addressed to patent foramen ovale closure (Occlutech Figulla Flex II PFO occluder device) for a previous ischemic event, will receive dual antiplatelet therapy (DAPT) for 2 months after procedure and aspirin alone subsequently. Patients will undergo evaluation of platelet reactivity, serotonin and cytokines before PFO closure with a dedicated device and at 6 months follow-up and these results compared to those of a control, group of healthy subjects treated with aspirin alone
3180568|NCT00684931|Sham Comparator|2|healthy volunteer without Attention Deficit Hyperactivity Disorder
3133634|NCT03521193|No Intervention|healthy subjects on aspirin treatment|12 healthy subjects on 100 mg aspirin daily will be compared to PFO patients in terms of platelet reactivity, serotonin and cytokines
3133635|NCT03521479|Experimental|Group A|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 2% SADBE on the visits at week 3, week 6, week 9, and month 8.
3133636|NCT03521479|Experimental|Group B|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and with 0.5% SADBE on the visits at week 3, week 6, week 9, and month 8.
3133637|NCT03521479|Active Comparator|Group C|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0, month 3, and month 6.
3133638|NCT03521479|Active Comparator|Group D|Treated with 2% Squaric Acid Dibutyl Ester (SADBE) on day 0 and month 6.
3133639|NCT03521505|Experimental|Dexmedetomidine arm|Dexmedetomidine will be administrated for sedation of EBUS-TBNA
3133640|NCT03521505|Active Comparator|Propofol arm|Propofol will be administrated for sedation of EBUS-TBNA
3133641|NCT03521635|Experimental|Pramipexole SR|
3133642|NCT03521635|Active Comparator|Pramipexole IR|
3133643|NCT03521791|Experimental|PRO-155|Pro-155: 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac for 20 days
3133644|NCT03521791|Placebo Comparator|Placebo|Placebo 1 drop 2 times a day in the period of vigil in the conjunctival cul-de-sac
3133645|NCT03521817|Experimental|Alcohol|Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the ~240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila).
3133646|NCT03521817|Active Comparator|No Alcohol|No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat).
3133647|NCT03522350|Active Comparator|EmbryoScope|Standard of care embryo incubator.
3133648|NCT03522350|Experimental|EmbryoScope+|New experimental embryo incubator.
3133649|NCT03522441|Experimental|Clindamycin 1% gel (Akorn Pharmaceuticals)|
3133650|NCT03522441|Active Comparator|Clindamycin 1% gel (Greenstone LLC)|
3133651|NCT03522441|Placebo Comparator|Placebo|
3133652|NCT03522506|Experimental|TAK-925 Low Dose + Placebo + TAK-925 High Dose + Modafinil|TAK-925 low dose milligram (mg), intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
3133653|NCT03522506|Experimental|TAK-925 High Dose + TAK-925 Low Dose + Modafinil + Placebo|TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
3180569|NCT00684944|Active Comparator|1|30mg tid TRx0014
3180570|NCT00684944|Active Comparator|2|60mg tid TRx0014
3180571|NCT00684957|Active Comparator|1|Subject taking growth hormone
3180572|NCT00684957|Active Comparator|2|Subject taking recombinant human IGF-1
3180573|NCT00684970|Other|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118 (single arm)
3180574|NCT00685009||1|Women from the Women's Health Initiative study taking estrogen hormone therapy
3133654|NCT03522506|Experimental|Modafinil + TAK-925 High Dose + Placebo + TAK-925 Low Dose|Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by placebo once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
3180575|NCT00685009||2|Women from the WHI study taking estrogen plus progesterone hormone therapy
3180576|NCT00685009||3|Women from the WHI study taking placebo
3188775|NCT00770640|Experimental|Pioglitazone 30mg QD|(and variable insulin therapy)
3188776|NCT00770640|Placebo Comparator|Placebo QD|(and variable insulin therapy)
3133655|NCT03522506|Experimental|Placebo + Modafinil + TAK-925 Low Dose + TAK-925 High Dose|Placebo, once on Day 1 of Intervention Period 1, followed by a minimum of 7-days washout period, further followed by Modafinil 300 mg, tablet, orally, once on Day 1 of Intervention Period 2, followed by a minimum of 7-days washout period, further followed by TAK-925 low dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 3, followed by a minimum of 7-days washout period, further followed by TAK-925 high dose mg, intravenously, administered as 9-hour infusion, once on Day 1 of Intervention Period 4. TAK-925 dose will be decided based on the availability of safety, tolerability and PK data from ongoing study TAK-925-1001.
3133656|NCT03522675|Other|NeoMatriX and Two Comparators|NeoMatriX Wound Matrix Collagen Dressing 8mm disc Histamine positive control (0.1mL) Normal saline negative control (0.1mL)
3133657|NCT03522948|Experimental|Open pilot|The intervention is a brief, in-person motivational intervention followed by 4 weeks of text messaging to reduce heavy episodic drinking and sexual risk behavior (unprotected anal intercourse) among men-who-have-sex-with-men.
3133658|NCT03523715|Experimental|Prunes|The study group will be instructed to consume 4 oz of prunes as well as docusate sodium twice daily for 3 days after surgery.
3180577|NCT00685022|Experimental|A|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses).~The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study."
3188777|NCT00770666|Experimental|1|Nicotine patch, nicotine inhaler, bupropion
3188778|NCT00770666|Active Comparator|2|Nicotine patch
3188779|NCT00770705|Experimental|1|Group receiving phenoxybenzamine
3133659|NCT03523715|Placebo Comparator|Control|The placebo group will be instructed to take docusate sodium twice daily for 3 days after surgery.
3133660|NCT03523871|Experimental|Post Lung Transplant Patients|The lung transplantation will be performed per standard of care techniques,and all post-transplant management of the transplanted organ, including immunosuppression, will be carried out per standard of care.
3133661|NCT03523988|Active Comparator|Acetaminophen|Acetaminophen 650mg powder in gel capsule taken by mouth before entering appointment
3133662|NCT03523988|Active Comparator|Ibuprofen|Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
3133663|NCT03523988|Experimental|Acetaminophen and Ibuprofen|Acetaminophen 650mg and Ibuprofen 400mg powder in gel capsule taken by mouth before entering appointment
3188780|NCT00770705|Other|2|Historical control
3133664|NCT03524157|Experimental|PRO-087|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: chondroitin sulfate 0.18%, sodium hyaluronate 0.1% ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
3133665|NCT03524157|Active Comparator|Xyel Ofteno|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days, Active principles: Xanthan gum 0.9 mg, sodium chondroitin sulfate 1.0 ophthalmic solution made by Laboratorios Sophia, S.A. de C.V., transparent solution, free of visible particles in a sterile multi-dose bottle.
3133666|NCT03524157|Active Comparator|Systane ultra|Dosage: 1 drop in both eyes, 4 times a day during the waking period per 10 days Active principles: Polyethylene glycol 400 0.4%, propyleneglycol 0.3%, Ophthalmic solution, multi-dose dropper bottle, made by Alcon Laboratories, Inc.
3133667|NCT03524339|Placebo Comparator|Placebo|
3133668|NCT03524339|Experimental|Tamsulosin|
3133669|NCT03525119|Other|HAV Vaccine 1.0 ml + Placebo/ Placebo|HAV vaccine 1.0 ml, injection, IM, and placebo-matching injection, SC, once on Day 1 (first dose) followed by placebo-matching injection, SC on Day 90 (second dose).
3133670|NCT03525119|Experimental|TDV 0.5 ml + Placebo/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and placebo-matching injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
3133671|NCT03525119|Experimental|TDV 0.5 ml + HAV Vaccine 1.0 ml/ TDV 0.5 ml|TDV 0.5 ml, injection, SC, and HAV vaccine 1.0 ml, injection, IM, once on Day 1 (first dose) followed by TDV 0.5 ml, injection, SC on Day 90 (second dose).
3133672|NCT03525210|Other|HIV patients|All HIV patients will receive the study vaccines
3133673|NCT03525210|Other|SOT patients|All SOT patients will receive the study vaccines
3133674|NCT03525444|Placebo Comparator|Placebo|Participants who received placebo matched to VX-445/TEZ/IVA for 24 weeks in the TC treatment period.
3133675|NCT03525444|Experimental|VX-445/TEZ/IVA TC|Participants who received VX-445 200 mg/TEZ 100 mg/IVA150 mg as fixed-dose combination (FDC) tablets in the morning and IVA 150 mg as mono tablet in the evening for 24 weeks in the TC treatment period.
3133676|NCT03525548|Active Comparator|TEZ/IVA|Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
3133677|NCT03525548|Experimental|VX-445/TEZ/IVA TC|Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.
3133678|NCT03525678|Experimental|Participants receiving frozen 2.5 mg/kg belantamab mafodotin|Participants will receive 2.5 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
3133679|NCT03525678|Experimental|Participants receiving frozen 3.4 mg/kg belantamab mafodotin|Participants will receive 3.4 mg/kg frozen liquid belantamab mafodotin. Participants will be administered with frozen liquid belantamab mafodotin via infusion pump every 3 weeks.
3133680|NCT03525678|Experimental|Participants receiving lyophilized belantamab mafodotin|Participants in lyophilized arm will receive lyophilized belantamab mafodotin once lyophilized configuration becomes available and enrollment has been completed for frozen liquid arms.
3133681|NCT03525834|Experimental|Everolimus|Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
3133682|NCT03526055|Active Comparator|<500 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to <500 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
3133683|NCT03526055|Experimental|>1000 µS Pulse Width|Intervention includes spinal cord stimulation will be programmed to >1000 µS pulse width and patient will undergo an Algovita Spinal Cord Stimulation System trial procedures. Following the trial procedure, the subject's EPG will be set to the appropriate pulse width, based on the arm assigned, and then programmed to achieve optimal pain relief.
3133684|NCT03526458|Active Comparator|Holmium:YAG laser: 0.2J&15Hz|Patients are assigned to treat stones with 0.2J&15Hz of the holmium laser.
3133685|NCT03526458|Experimental|Holmium:YAG laser: 0.8J&15Hz|Patients are assigned to treat stones with 0.8J&15Hz of the holmium laser.
3133686|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen A."
3133687|NCT03526861|Experimental|Tralokinumab(Dose1) initial-> Tralokinumab(Dose1) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 1) maintenance SC injection regimen B."
3133688|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceA|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen A."
3133689|NCT03526861|Experimental|Tralokinumab(Dose2) initial-> Tralokinumab(Dose2) maintenanceB|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52 (maintenance period):~Tralokinumab (Dose 2) maintenance SC injection regimen B."
3133690|NCT03526861|Experimental|Placebo initial-> Placebo maintenance|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52 (maintenance period):~Placebo continuation SC injection regimen A."
3133691|NCT03526861|Experimental|Tralokinumab (Dose1) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 1) loading SC injection on Day 0 followed by tralokinumab (Dose 1) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
3133692|NCT03526861|Experimental|Tralokinumab (Dose2) initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Tralokinumab (Dose 2) loading SC injection on Day 0 followed by tralokinumab (Dose 2) injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
3133693|NCT03526861|Experimental|Placebo initial-> Open-label tralokinumab|"Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 52:~Tralokinumab (Dose 1) maintenance SC regimen A - open-label with allowed use of topical corticosteroids"
3133694|NCT03527173|Experimental|S. sonnei Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the S. sonnei study vaccine at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
3133695|NCT03527173|Placebo Comparator|Placebo Group|Male or female subjects between, and including, 18 and 50 years of age at the time of the first vaccination, received 2 doses of the placebo at Day 1 and Day 29 respectively, by intramuscular injection into the upper deltoid region of the non-dominant arm. At 28 days after the second dose (Day 57), subjects received the challenge dose of S. sonnei 53G strain, orally.
3133696|NCT03527550|Experimental|Cognitive Training plus Treatment as Usual|Participants in this arm will receive daily computerized cognitive training sessions during partial hospitalization, in addition to treatment as usual. Cognitive training sessions will alternate between response inhibition training and working memory training.
3133697|NCT03527550|No Intervention|Treatment as Usual (TAU)|Participants in the Treatment As Usual group will receive usual treatment in the partial hospitalization program.
3133698|NCT03527745|Experimental|200 mg albendazole|against T. trichiura in preschool-aged children or against hookworm infections in preschool-aged children, school-aged children and adults
3133699|NCT03527745|Experimental|400 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or against hookworm infections in preschool-aged children, school-aged children and adults
3133700|NCT03527745|Experimental|600 mg albendazole|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
3133701|NCT03527745|Experimental|800 mg albendazole|against T. trichiura in school-aged children and adults or against hookworm infections in school-aged children and adults
3133702|NCT03527745|Placebo Comparator|Placebo|against T. trichiura in preschool-aged children, school-aged children and adults or hookworm infections in preschool-aged children, school-aged children and adults
3133703|NCT03527966|Active Comparator|Intervention group - 5cc Vivigen and local autograft|
3133704|NCT03527966|Active Comparator|Control group - small kit rhBMP-2 with local autograft|
3133705|NCT03528174|Experimental|Single Hormone closed loop|Subjects will have glucose managed using the Artificial Pancreas Control system (APC) using insulin only. Insulin will be infused through the Pacific Diabetes Technologies CGM Insulin Infusion system.
3133706|NCT03528369|Experimental|CGS-200-1|CGS-200-1 (1% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
3133707|NCT03528369|Experimental|CGS-200-5|CGS-200-5 (5% Capsaicin content), a topical analgesic liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
3133708|NCT03528369|Sham Comparator|CGS-200 Vehicle|CGS-200 Vehicle (no Capsaicin), a topical liquid. A single dose will be topically applied to both knees for 60 minutes on Visit 2 on Day 1, Day 2, Day 3, and Day 4.
3133709|NCT03528512|Experimental|IN ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
3133710|NCT03528512|Active Comparator|IN midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
3133711|NCT03528551|Experimental|N8-GP, once weekly|All participants will receive turoctocog alfa pegol (N8-GP) once weekly.
3133712|NCT03528551|Experimental|N8-GP, twice weekly|All participants will receive N8-GP twice weekly.
3133713|NCT03528551|Experimental|N8-GP, three times weekly|All participants will receive N8-GP three times weekly.
3133714|NCT03528577|Experimental|Test|Albuterol Sulfate Inhalation Aerosol, eq 90 mcg
3133715|NCT03528577|Active Comparator|Reference|PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg
3133716|NCT03528577|Placebo Comparator|Test Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
3180578|NCT00685022|Active Comparator|B|Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses) The first treatment will be administered, followed by a 7 ±2 days washout period, after which the second of the two treatments will be administered. Cumulative dosing will occur according to the following schedule: 1 puff at 0 and 30 minutes, 2 puffs at 60 minutes, 4 puffs at 90 minutes and 8 puffs at 120 minutes. All study drug will be administered directly without using a spacer for the entire study.
3180579|NCT00685048|Experimental|1|psychoeducation
3133717|NCT03528577|Placebo Comparator|Reference Placebo|Placebo for Albuterol Sulfate Inhalation Aerosol
3133718|NCT03529162|Active Comparator|Suture Anchor Technique (SA)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached to the humerus using an FDA-approved suture anchor (SA) device for the suture anchor technique. The device to be used will be the Mitek Super Quick Anchor.
3180580|NCT00685048|Experimental|2|brief advice
3180581|NCT00685048|Experimental|3|Motivational Enhancement Therapy (MET)/Cognitive-Behavioral Therapy (CBT)
3180582|NCT00685061|Experimental|A|Thymoglobulin Induction
3133719|NCT03529162|Active Comparator|Pectoralis Major Technique (PMT)|If randomized to this group, the patient will receive an open subpectoral long head of biceps tenodesis technique whereby the long head of biceps is re-attached by suturing the biceps tendon into the pectoralis major tendon.
3180583|NCT00685061|Experimental|B|Campath-1H Induction
3180584|NCT00685061|Experimental|C|Daclizumab Induction
3180585|NCT00685074|Experimental|Brief computer-delivered intervention for drug use|A single interactive computer intervention based primarily on Motivational Interviewing principles.
3180586|NCT00685074|Placebo Comparator|Time control for drug use|An series of innocuous and therapeutically inactive computer segments.
3180587|NCT00685113|Experimental|1|
3180588|NCT00685113|Experimental|2|
3180589|NCT00685113|Placebo Comparator|3|
3133720|NCT03529409|Experimental|Project Khanya|Those assigned to Project Khanya (the behavioral intervention for substance use and adherence condition) will have approximately 6 sessions (including Life-Steps, behavioral activation, and relapse prevention) delivered by a peer interventionist plus standard of care, which is typically referral to a local outpatient substance use treatment clinic. They will also receive a Wisepill, a wireless, real-time adherence monitoring device.
3133721|NCT03529409|No Intervention|ESOC|Those assigned to the ESOC (enhanced standard of care) condition will receive the standard of care, which is referral to a local substance use treatment clinic. The substance use clinics in the location that this study occurs follow the Matrix, and evidence-based 16-week outpatient program to treat substance use. We will enhance patients' normal referral to Matrix for ESOC participants by promoting facilitating and following up on the referral. Additionally, those in the control group will also receive a Wisepill, a wireless adherence monitoring device.
3133722|NCT03529461|Other|Control|Intervention: nasal cannula (6L O2) + non invasive positive pressure nasal mask (not connected to machine)
3133723|NCT03529461|Experimental|Experimental|Intervention: Non invasive positive pressure nasal mask (connect to machine once patient is sedated)
3133724|NCT03529773|Experimental|Sentinel Arm 1|Low dose formulation A
3133725|NCT03529773|Experimental|Sentinel Arm 2|Mid dose formulation A
3133726|NCT03529773|Experimental|Sentinel Arm 3|High dose formulation A
3133727|NCT03529773|Experimental|Sentinel Arm 4|Low dose formulation B
3133728|NCT03529773|Experimental|Sentinel Arm 5|Mid dose formulation B
3133729|NCT03529773|Experimental|Sentinel Arm 6|High dose formulation B
3133730|NCT03529773|Placebo Comparator|Sentinel Arm 7|Placebo
3133731|NCT03529773|Experimental|Expanded Arm 8|Low dose formulation A and SIIV
3133732|NCT03529773|Experimental|Expanded Arm 9|Mid dose formulation A and SIIV
3133733|NCT03529773|Experimental|Expanded Arm 10|High dose formulation A and SIIV
3133734|NCT03529773|Experimental|Expanded Arm 11|Low dose formulation B and SIIV
3133735|NCT03529773|Experimental|Expanded Arm 12|Mid dose formulation B and SIIV
3133736|NCT03529773|Experimental|Expanded Arm 13|High dose formulation B and SIIV
3133737|NCT03529773|Experimental|Expanded Arm 14|Low dose formulation A and placebo
3133738|NCT03529773|Experimental|Expanded Arm 15|Mid dose formulation A and placebo
3133739|NCT03529773|Experimental|Expanded Arm 16|High dose formulation A and placebo
3133740|NCT03529773|Experimental|Expanded Arm 17|Low dose formulation B and placebo
3133741|NCT03529773|Experimental|Expanded Arm 18|Mid dose formulation B and placebo
3133742|NCT03529773|Experimental|Expanded Arm 19|High dose formulation B and placebo
3133743|NCT03529773|Placebo Comparator|Expanded Arm 20|placebo and placebo
3133744|NCT03529942|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
3133745|NCT03530098|No Intervention|Control (Without-AI)|This is the control arm where no intervention is provided; represents current standard of care.
3133746|NCT03530098|Experimental|Experiment (With-AI)|"This is the experiment arm where the intervention, BoneAgeModel, is provided. The participating radiologists in this arm will receive the output of the Artificial Intelligence algorithm. They will be asked to incorporate this new information with their normal workflows to make a diagnosis. The radiologists' diagnosis will be considered final."
3133747|NCT03530345|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
3133748|NCT03530345|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
3133749|NCT03530631|Experimental|Adderall/Truth|Participants will be told they are receiving Adderall and will actually be administered Adderall.
3133750|NCT03530631|Placebo Comparator|Placebo/Truth|Participants will be told they are receiving placebo and will actually be administered placebo.
3133751|NCT03530631|Experimental|Adderall/Deception|Participants will be told they are receiving Adderall and will actually be administered placebo.
3133752|NCT03530631|Experimental|Placebo/Deception|Participants will be told they are receiving placebo and will actually be administered Adderall.
3133753|NCT03530917|Experimental|Single Ascending Dose (SAD): Placebo|In SAD Cohorts 1-4, there will be eight participants in total receiving placebo, two in each cohort.
3133754|NCT03530917|Experimental|SAD: Cohort 1|Eight participants will be administered 40mg RO7020531 orally on Day 1.
3180590|NCT00685126|Experimental|A|"Low dose levalbuterol (0.15 mg, 0.31 mg or 0.63 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3180591|NCT00685126|Experimental|B|"High dose levalbuterol (0.31 mg, 0.63 mg or 1.25 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3133755|NCT03530917|Experimental|SAD: Cohort 2|Eight participants will be administered 100mg RO7020531 orally on Day 1.
3133756|NCT03530917|Experimental|SAD: Cohort 3|Eight participants will be administered 140mg RO7020531 orally on Day 1.
3133757|NCT03530917|Experimental|SAD: Cohort 4|Eight participants will be administered 170mg RO7020531 orally on Day 1.
3133758|NCT03530917|Experimental|Multiple Ascending Dose (MAD): Placebo|In MAD Cohorts 1-3, there will be six participants in total receiving placebo, two in each cohort.
3133759|NCT03530917|Experimental|MAD: Cohort 1|Eight participants will be administered 100mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
3133760|NCT03530917|Experimental|MAD: Cohorts 2 and 3|Sixteen participants will be administered 150mg RO7020531 orally on Day 1 and every other day (QOD) for 14 days.
3133761|NCT03530995|Experimental|Part 1, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg single dose on Day 1
3133762|NCT03530995|Experimental|Part 1, Period 2|"Drug: Itraconazole. Subjects will receive itraconazole 200 mg QD on Day 1 through Day 7.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + itraconazole 200 mg QD on Day 8 Subjects will receive itraconazole 200 mg QD on Day 9"
3133763|NCT03530995|Experimental|Part 1, Period 3|"Drug: Rabeprazole. Subjects will receive rabeprazole 20 mg BID on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg + rabeprazole 20 mg QD on Day 4."
3133764|NCT03530995|Experimental|Part 1, Period 4|"Drug: Rifampicin. Subjects will receive rifampicin 600 mg QD on Day 1 through Day 9.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg on Day 10."
3133765|NCT03530995|Experimental|Part 2, Period 1|Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID on Day 1.
3133766|NCT03530995|Experimental|Part 2, Period 2|"Drug: Omeprazole. Subjects will receive omeprazole 20 mg QD on Day 1 through Day 3.~Drug: Belumosudil. Subjects will receive belumosudil 200 mg BID + omeprazole 20 mg QD on Day 4."
3133767|NCT03531632|Experimental|MGD007 + MGA012|MGD007 is a gpA33 x CD3 bi-specific DART antibody; MGA012 is an anti-PD-1 monoclonal antibody.
3133768|NCT03531710|Experimental|3 boosters|Subjects will receive 3 doses of UB-311 and 2 doses of placebo.
3133769|NCT03531710|Experimental|3 priming doses followed by 2 boosters|Subjects will receive 5 doses of UB-311.
3133770|NCT03531840|Experimental|Arm 1/Olaparib|Twice daily oral olaparib
3133771|NCT03531905|Experimental|Bempedoic acid + Ezetimibe FDC|Bempedoic acid + Ezetimibe FDC Oral Tablet; Placebo oral capsule
3133772|NCT03531905|Active Comparator|Ezetimibe 10 mg|Ezetimibe 10Mg Oral Tablet; Placebo Oral Tablet
3133773|NCT03531905|Placebo Comparator|Placebo|Placebo Oral Tablet, Placebo oral capsule
3133774|NCT03532009|Experimental|Sodium Zirconium Cyclosilicate (ZS)|Powder for oral suspension
3133775|NCT03532009|Placebo Comparator|Placebo|Powder for oral suspension
3133776|NCT03532048|Experimental|Intervention Group|The Papás Saludables, Niños Saludables Program
3133777|NCT03532048|Other|Wait-list Control|The Papás Saludables, Niños Saludables Wait-list Control
3133778|NCT03532308|Experimental|Intervention|Daily Fermented Soy (two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
3133779|NCT03532308|Placebo Comparator|Placebo|Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
3133780|NCT03532451|Experimental|Cohort 1: Nivolumab|Nivolumab 480 mg IV on week 0 and week 4
3133781|NCT03532451|Experimental|Cohort 2: Nivolumab/Lirilumab|Nivolumab 480 mg IV and Lirilumab 240 mg on week 0 and week 4
3133782|NCT03532776|Experimental|Podofilox Gel 0.5 %|Podofilox Gel 0.5% twice a day, three days following by four days of discontinuation, up to four cycles
3133783|NCT03532776|Active Comparator|Condylox Topical Gel 0.5%|Condylox Topical Gel 0.5% twice daily, three days following by four days of discontinuation, up to four cycles
3133784|NCT03532776|Placebo Comparator|Placebo Gel|Subjects in this arm will receive a vehicle that matches the test product, except for the inclusion of the active ingredient
3133785|NCT03533036|Experimental|Virtual Reality Intervention|VR headsets consist of a Samsung phone dedicated to playing programs designed by the AppliedVR company. The phone is inserted in the front of the headset and can play videos that can be then viewed by the participant while wearing the headset. Participants in the experimental arm will be fitted with VR headsets prior to first trimester abortion and will wear the headset during the procedure. Participants will be able to choose a program of their preference (ex. guided meditation, beautiful scenery). The patient may remove the VR device at any time during the procedure. After the procedure, investigators will carry out a qualitative interview with the participant and ask about the experience of using the VR headset during first trimester abortion. Patients will also complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
3133786|NCT03533036|No Intervention|Control arm|In the control group, participants will not use virtual reality during the procedure. Patients in the control arm will complete surveys evaluating procedure-related anxiety. These will be administered before and after the procedure.
3133787|NCT03533114|Experimental|JZP-258|JZP-258 at the stable dose and regimen for 2 weeks.
3133788|NCT03533114|Placebo Comparator|Placebo|Placebo will be administered at a volume and regimen equivalent to the JZP-258 dose and regimen for 2 weeks.
3133789|NCT03533244|Placebo Comparator|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
3133790|NCT03533244|Experimental|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
3133791|NCT03533244|Experimental|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
3133792|NCT03533374||Patients with epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
3180592|NCT00685126|Active Comparator|C|"Racemic albuterol (0.63, 1.25 mg or 2.5 mg); the first three doses will be delivered every 20 minutes for the first hour. Up to three additional doses may be given every 40 minutes thereafter. Additional doses may be administered at the investigator's discretion.~Period II: Double blind, active-treatment period following discharge from the Emergency Department or Physician's Office. Subject will receive TID double-blind dosing. Period III: Double blind, active-treatment period following Visit 2. Subjects will receive double-blind dosing at the discretion of the investigator (PRN to TID)."
3180593|NCT00685152|Experimental|Active rTMS|Repetitive Transcranial Magnetic Stimulation
3180594|NCT00685152|Sham Comparator|2|Device: Sham (placebo)
3133793|NCT03533374||Patients with non-epileptic seizures|"Electroencephalogram (EEG) and visual evaluation~- Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians)."
3133794|NCT03533608|Experimental|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
3180595|NCT00685191|Experimental|1|HIV-1-infected subjects initiating raltegravir-including salvage therapy
3180596|NCT00685204|Experimental|A|This is a non-random, multicenter, open label, single agent study. Patients with mailgnanat mesothelioma that has reccured or progressed following chemotherapy, and who qualify for this study, will receive oral milataxel.
3133795|NCT03533829|Active Comparator|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
3133796|NCT03533829|Active Comparator|Music|Music will be selected and listened to as a distraction before and during vaccination.
3133797|NCT03533829|Active Comparator|Buzzy® and Music|Buzzy® will be applied to the arm prior to and during vaccination and music will be selected and listened to before and during vaccination.
3133798|NCT03534427|No Intervention|Control group|No exercise intervention
3180597|NCT00685217|Experimental|TVT Secur surgical device|Single incision tape device
3180598|NCT00685217|Active Comparator|TVT surgical device|Usual care retropubic tape device
3180599|NCT00685230|Experimental|1|Alacramyn and midazolam as needed
3180600|NCT00685230|Placebo Comparator|2|placebo and midazolam as needed
3180601|NCT00685243|Active Comparator|Fraxel|Fraxel laser treatment
3180602|NCT00685243|Active Comparator|PDL|Pulsed dye laser treatment
3180603|NCT00685269|Active Comparator|A|eszopiclone 3 mg QD
3180604|NCT00685269|Placebo Comparator|B|placebo tablet
3133799|NCT03534427|Experimental|Jump rope exercise intervention|The jump rope exercise program was performed for 50 minutes with 5 minutes of warm-up and cool-down per day, 5 times a week for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4 and to 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Every subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
3133800|NCT03534986|Experimental|AffloVest The Vest Arm|Devices placed on highest intensity / highest frequency
3133801|NCT03534986|Experimental|AffloVest inCourage Arm|Devices placed on highest intensity / highest frequency
3133802|NCT03534986|Experimental|AffloVest SmartVest Arm|Devices placed on highest intensity / highest frequency
3180605|NCT00685282|Other|COGNITIVE BEHAVIORAL INTERVENTIONS|PSYCHOLOGICAL INTERVENTIONS TO INCLUDE, RELAXATION, STRESS REDUCTION, GUIDED IMAGERY, BREATHING EXERCISES
3180606|NCT00685321|Experimental|1|deep TMS treatment
3180607|NCT00685321|Sham Comparator|2|inactive treatment
3133803|NCT03535194|Experimental|250mg Q4W/250mg Q8W Mirikizumab|Participants received 250 Milligrams (mg) Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
3133804|NCT03535194|Experimental|250mg Q4W/125mg Q8W Mirikizumab|Participants received 250mg Mirikizumab once every four weeks (Q4W) by subcutaneous injection during blinded induction period followed by 125mg Mirikizumab once every eight weeks (Q8W) in maintenance period. Participants received matching placebo to blind Secukinumab.
3133805|NCT03535194|Experimental|Placebo/250mg Mirikizumab|Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
3133806|NCT03535194|Active Comparator|300mg Secukinumab|Participants received 300mg Secukinumab at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during induction period followed by 300mg Secukinumab Q4W from week 16 to 52 in maintenance period.
3133807|NCT03535194|Experimental|Japan GPP/EP|Participants received 250mg Mirikizumab Q4W in induction period followed by 250mg Q8W in maintenance period by subcutaneous injection.
3133808|NCT03535571|Experimental|Salmon Protein Hydrolysate (CollaGo®)|Dose: 1 sachet of CollaGo® will be mixed with 100-300 mL of water and consumed daily at breakfast.
3133809|NCT03535649||Vedolizumab|Participants diagnosed with moderate to severe active UC and having failed tumor necrosis factor alpha (TNF alpha) antagonist therapy and who have initiated vedolizumab intravenous treatment between 17 August 2017 and the date when at least 100 cases are collected from approximately 15 participating sites will be observed from the date of UC diagnosis until the date when participant is enrolled into the study or until the end of treatment or death of participants or lost-to-follow up.
3180608|NCT00685347|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3180609|NCT00685347|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3180610|NCT00685386|Experimental|I|
3180611|NCT00685386|Placebo Comparator|II|Room air will be used for insufflation as the placebo comparator arm.
3180612|NCT00685412|Experimental|0.6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3180613|NCT00685412|Experimental|2mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3180614|NCT00685412|Experimental|6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-3100 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Month 1 and Month 3
3133810|NCT03535740|Experimental|Brigatinib 90 mg/180 mg with Optional Dose Escalation to 240 mg|Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months from start of enrollment until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
3133811|NCT03535844|Experimental|Wolfberry with healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet. Subjects will also be provided specific instructions to cook and consume 15 g/day wolfberry as part of a mixed-meal.
3133812|NCT03535844|Active Comparator|Healthy diet|Each subject will be provided one-to-one dietary counselling by a research dietitian and an instruction sheet to achieve the healthy eating pattern diet.
3133813|NCT03535974|Active Comparator|Preparation with Spirulina|6 weeks bid Preparation with Spirulina
3133814|NCT03535974|Placebo Comparator|Placebo|6 weeks bid Placebo
3133815|NCT03536663|Other|Optiflux/Endexo|Optiflux (Active Comparator); Hemodialysis treatments on the Optiflux dialyzer (Optiflux Period) for 4 weeks - Visit 1 to 12 Endexo (Experimental); Subjects continue on Dialyzer with Endexo (Endexo Period) for 13 weeks - Visit 13 to visit 50
3133816|NCT03536702|Experimental|Creative Writing Workshop|The intervention arm will receive a dedicated workshop for one and a half hours every 2 weeks for 3 months.
3133817|NCT03536702|Active Comparator|Independent Writing - Control Group|The control arm will receive a book (i.e., Writing Down Bones by Natalie Goldberg) on creative writing and asked to read and do writing activities for one and a half hours once every two weeks for 3 months.
3133818|NCT03536819|Experimental|Treatment|Participants receive Votiva treatment
3133819|NCT03536923|Experimental|Leva Arm|Subjects will use the leva device twice daily to perform pelvic floor muscle exercises
3133820|NCT03536949|Experimental|RVL-1201 Ophthalmic Solution, 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
3133821|NCT03536949|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
3133822|NCT03537014|Experimental|MDMA-assisted therapy|Administration of 80 or 120 mg MDMA (with a supplemental dose offered 1.5 to 2 hours later of 40 or 60 mg MDMA respectively) in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart.
3133823|NCT03537014|Placebo Comparator|Placebo with therapy|Administration of inactive placebo in combination with therapy during 3 experimental sessions scheduled 3-5 weeks apart
3133824|NCT03537092|Experimental|Vaginal Film|Each participant who inserted a single use placebo vaginal film (Day 0) is randomized to the timing of Visit 3 (Day 3, 7, 10, or 14)
3133825|NCT03537261|Experimental|CPI-Parent Training|Will receive one-day (6-hour) training in P-CPI including the use of nonverbal, paraverbal, verbal, and physical intervention techniques.
3133826|NCT03537261|No Intervention|Waitlist Control|"Will not receive active P-CPI training during the experimental treatment interval.~NOTE: The waitlist group will be offered the P-CPI training session after the treatment group completes their follow-up measures."
3133827|NCT03537274|Experimental|PEG-Intron, 0.5 mg/kg|PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
3133828|NCT03537274|Experimental|PEG-Intron, 1.0 mg/kg|PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
3133829|NCT03537274|Experimental|PEG-Intron, 1.5 mg/kg|PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
3133830|NCT03537274|Active Comparator|Interferon Alfa-2b|Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.
3133831|NCT03537404|Active Comparator|Treatment A (Part 1/ Part 2)|Narlaprevir 200 mg once daily with Ritonavir 100 mg once daily for 5 days
3133832|NCT03537404|Active Comparator|Treatment B (Part 1)|Tenofovir disoproxil fumarate 300 mg once daily for 5 days
3133833|NCT03537404|Active Comparator|Treatment B (Part 2)|Raltegravir 400 mg twice daily for 5 days
3133834|NCT03537404|Experimental|Treatment C (Part 1)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and Tenofovir disoproxil fumarate 300 mg once daily for 5 days
3133835|NCT03537404|Experimental|Treatment C (Part 2)|Narlaprevir 200 mg once daily coadministered with ritonavir 100 mg once daily and 400 mg raltegravir twice daily for 5 days
3133836|NCT03537651|Experimental|TEZ/IVA|TEZ 50 mg once daily (qd)/IVA 75 mg every 12 hours (q12h) or TEZ 100 mg qd/IVA 150 mg q12h based on body weight for participants aged 6 through 11 years at enrollment and TEZ 100 mg qd/IVA 150 mg q12h for participants aged >=12 years at enrollment. Doses were adjusted upward for changes in body weight and/or age.
3133837|NCT03537664|Experimental|Total bacteria analysis after 1rst- and 2nd-visit procedures|DNA levels and activity (RNA/DNA ratio) of total bacteria after the first-visit procedures (root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation) and the second-visit protocol (intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation). Additionally, the composition of the active microbiome will be assessed by Next Generation Sequencing (NGS) analysis of the root canal samples, and the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
3133838|NCT03537664|Other|Bacterial species analysis after root canal preparation|DNA levels and activity (RNA/DNA ratio) of Bacteroidaceae sp. 272 , Cutibacterium acnes, Selenomonas spp., and Enterococcus faecalis after root canal preparation.Additionally, the success rate (apical repair) of the endodontic treatment after 1 follow-up period will be assessed by an intraoral radiograph and cone beam computed tomography (CBCT) analyses.
3133839|NCT03538431|Experimental|Buspirone|These subjects will receive buspirone prior to engaging in the driving simulation.
3133840|NCT03538431|Experimental|Unmedicated|These subjects will take no medication prior to engaging in the driving simulation
3133841|NCT03538678|Experimental|Kwit app|Use of Kwit smartphone app
3133842|NCT03538678|No Intervention|Standard of care|Patient initiated follow-up post discharge
3133843|NCT03538743|Placebo Comparator|Placebo|
3133844|NCT03538743|Experimental|PF-06882961 30 mg|
3133845|NCT03538743|Experimental|PF-06882961 100 mg|
3133846|NCT03538743|Experimental|PF-06882961 300 mg|
3133847|NCT03538743|Experimental|PF-06882961 600 mg|
3133848|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 5|
3133849|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 6|
3133850|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 7|
3133851|NCT03538743|Experimental|PF-06882961 dose TBD Cohort 8|
3133852|NCT03538795|Experimental|iTBS&eCIMT|Participants will first receive baseline testing followed by a no-treatment control period. Participants will then be tested again, receive the combination therapy, i.e., iTBS&eCIMT, and then receive post-treatment testing.
3133853|NCT03538808|Active Comparator|Therapeutic Dose Truth|told therapeutic dose medication + received therapeutic dose medication
3133854|NCT03538808|Placebo Comparator|Therapeutic Dose Deception|told therapeutic dose medication + received placebo
3133855|NCT03538808|Active Comparator|Low Dose Vareniclince Deception|told low dose medication + received therapeutic dose medication
3133856|NCT03538808|Placebo Comparator|Low Dose Placebo Deception|told low dose medication + received placebo
3133857|NCT03539211|Experimental|Rotation Exercises|8 minute program of rotation based exercises
3180615|NCT00685425|Experimental|A|Subjects randomized to the levalbuterol arm will complete 1 of 6 possible randomization sequences containing (a) levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3133858|NCT03539211|Active Comparator|Control Exercises|8 minute program of traditional exercises
3133859|NCT03539432|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily
3133860|NCT03539432|Placebo Comparator|Placebo|Microcrystalline cellulose powder packaged in capsules identical to the experimental condition
3133861|NCT03539458|Experimental|Device Arm|All subjects will undergo procedure with the Tendyne Mitral Valve System.
3133862|NCT03539484|Experimental|Part I: Single Participant Cohorts IV/MAD-Escalation|Part I was a multiple-ascending dose-escalation in single participant cohorts. RO7172508 was administered intravenously once every 3 weeks (Q3W). The starting dose of RO7172508 was 65 microgram (mcg) and the maximum dose explored was 1.6 milligram (mg).
3133863|NCT03539484|Experimental|Part II: Multiple Participant Cohorts IV/MAD-Escalation|Multiple ascending dose-escalation of IV-administered RO7172508 in multiple participant cohorts: The starting-dose for the initiation of the IV dose-escalation was determined by Part I and RO7172508 was initially given Q3W. Dose-escalation was undertaken based on safety until determination of the MTD or the highest safe dose if MTD is not reached. If on-target toxicity was reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
3148746|NCT00157027|Active Comparator|1|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
3180616|NCT00685425|Active Comparator|B|Subjects randomized to racemic albuterol will complete 1 of 6 possible randomization sequences containing (a) racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg). Subjects will receive treatment, according to the randomization sequence, followed by a 5±2 day washout.
3180617|NCT00685464|Active Comparator|2|Intravenous bolus Abciximab.
3180618|NCT00685464|Active Comparator|Abciximab|Intracoronary bolus abciximab.
3133864|NCT03539484|Experimental|Part II: Multiple Participant Cohorts SC/MAD-Escalation (QW)|Multiple ascending dose-escalation of SC-administered RO7172508 in multiple participant cohorts. These will be initiated once the IV schedule has shown RO7172508 preliminary clinical activity or the MTD has been established and is equal to or above 2 mg. The starting-dose and regimen once a week or once every 3 weeks (QW or Q3W) for SC administration will be proposed based on the evaluation of the safety and PK data observed following IV administration but will not exceed the highest safe dose tested in the IV Q3W dose escalation; a minimum dose of 2 mg is defined for a single SC administration. In addition, the QW SC starting-dose will not exceed one third of the IV MTD or of the highest safe IV dose tested. Dose escalation will continue based on safety until determination of the MTD or the planned maximum dose of 400 mg. If on-target toxicity is reported in the first cycle of treatment, fractionated dosing may be implemented for the first cycle to improve tolerability.
3180619|NCT00685490||Surgical|Retrospective chart review of 70 eyes of 70 consecutive patients who underwent PPV, with and without ILM peeling, for persistent macular edema associated with BRVO
3180620|NCT00685529|Active Comparator|A|12 µg of racemic formoterol fumarate BID
3133865|NCT03539549|Experimental|Abicipar pegol 2 mg|Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1 and Weeks 4, 8, 16, and 24.
3133866|NCT03540030|No Intervention|Observational|The observational treatment group will not have any changes from your surgeon's normal pain management process. Anesthesia will be utilized in a routine fashion with all routine perioperative medications. You will be discharged on routine postoperative medications including opioids, NSAIDS, and any other modalities typically used by the treating surgeon.
3133867|NCT03540030|Active Comparator|Non-Opioid Intervention|Oral dose of both gabapentin and celecoxib (toradol if sulfa allergy) in the preop area. US-guided interscalene regional block without the aid of opioid co-medication. Intra-op management by anesthesia with non-opioid modalities but should include one dose of IV acetaminophen during the procedure. Anesthetic modalities will include, but not limited to, regional block, propofol, IV lidocaine, rocuronium/vecuronium, and sevoflurane/desflurane. If the attending anesthesiologist deems it necessary to dose with opioids during procedure, it will be recorded and reported. Liposomal bupivacaine will be injected into the peri-articular soft tissues as an adjunct to the block. Post Op, cryotherapy, gabapentin, toradol. Toradol will transition to celecoxib for the duration of the hospitalization (or meloxicam for patients with sulfa allergy). As needed medications will include both oral and IV acetaminophen, as well as up to an additional 15mg of toradol per 6hr, depending on Cr clearance.
3180621|NCT00685529|Experimental|B|15 µg of nebulized arformoterol tartrate inhalation solution BID
3180622|NCT00685529|Active Comparator|C|24 µg of racemic formoterol fumarate BID
3180623|NCT00685542|Experimental|1|Diacerein 50mg bid
3133868|NCT03540134|Experimental|Intracerebral Infusion of Autologous CSF|All subjects will receive the intracerebral infusion of autologous cerebral spinal fluid (CSF) during their deep brain stimulation (DBS) surgery. The DBS surgery will be performed on the targeted nucleus either bilaterally or unilaterally, as previously determined by a multidisciplinary team of neurology, neurosurgery, and neuropsychology. During unilateral DBS surgery, the targeted nucleus will be infused using convection enhanced delivery (CED). The nondominant side will be infused during a bilateral DBS procedure.
3133869|NCT03540147|Experimental|Exercise with Hokanson cuffs|Participants will walk on the treadmill with Hokanson cuffs inflated.
3133870|NCT03540147|Experimental|Exercise with BStrong Bands|Participants will walk on the treadmill with BStrong bands inflated.
3133871|NCT03540147|Sham Comparator|Exercise without inflated bands/cuffs|Participants will walk on the treadmill with non-inflated BStrong bands.
3133872|NCT03540147|Experimental|Yoga poses with BStrong bands inflated|Participants will perform 15-20 yoga poses with BStrong bands inflated.
3133873|NCT03540147|Sham Comparator|Yoga poses with BStrong bands uninflated|Participants will perform 15-20 yoga poses with uninflated BStrong bands.
3133874|NCT03540160|Experimental|Experimental: 5 mg Serlopitant Tablets|Serlopitant Tablets
3133875|NCT03541044|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (2mg) by oral/buccal route of administration.
3133876|NCT03541044|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (2 mg) by oral/buccal route of administration.
3180624|NCT00685542|Placebo Comparator|2|placebo 50mg bid
3180625|NCT00685568|Experimental|Arm I|Patients receive oral celecoxib twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3180626|NCT00685568|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3133879|NCT03541356|Placebo Comparator|Placebo|
3133880|NCT03541356|Active Comparator|L-dopa 35 mg|
3133881|NCT03541356|Active Comparator|L-dopa 70 mg|
3133882|NCT03541356|Active Comparator|L-dopa 140 mg|
3133883|NCT03541356|Active Comparator|L-dopa 70 mg/carbidopa 7 mg|
3180627|NCT00685581|Experimental|A|Arms A: the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
3180628|NCT00685581|Experimental|B|Arms B: the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed.
3180629|NCT00685581|Experimental|C|Arms C: the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed.
3180630|NCT00685594|Experimental|1|Cholecalciferol 20.000 IU per week for 5 years
3133884|NCT03541941|Experimental|Exparel|Solution of 266mg of Exparel + 150mg Bupivacaine HCL + 40cc normal saline= 120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
3133885|NCT03541941|Active Comparator|Bupivacaine Hcl 0.25% Inj|Solution of 150mg Bupivacaine HCL expanded with 60cc of normal saline=120cc administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
3133886|NCT03541941|Placebo Comparator|Placebo|120 cc of normal saline administered through a transversus abdominis plane block performed intraoperatively by the surgeon under direct visualization
3133887|NCT03541980|Active Comparator|Intervention|Patients allocated to receive IV acetaminophen
3133888|NCT03541980|Placebo Comparator|Placebo|Patients allocated to receive IV normal saline placebo
3133889|NCT03542019|Active Comparator|Lithium disilicate|Lithium disilicate: a type of ceramic material used to make a dental prosthesis that replaces missing tooth structure following root canal treatment. Other names might include: E-max crowns, computer-aided design and computer-aided manufacturing (CAD CAM) crowns
3133890|NCT03542019|Active Comparator|Monolithic zirconia|Monolithic zirconia: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Zolid crown, Bruxzir, Bretau, CAD CAM crowns
3133891|NCT03542019|Active Comparator|Hybrid ceramic|Hybrid ceramic: a type of ceramic material used to make a dental prosthesis that replaces the missing tooth structure following root canal treatment. Other names might include: Enamec, Lava Ultimate, CAD CAM crowns
3133892|NCT03542266|Experimental|CC486 +CHOP|CC486 +CHOP
3133893|NCT03542305|Experimental|Mild|Mild renal impairment
3133894|NCT03542305|Experimental|Moderate|Moderate renal impairment
3133895|NCT03542305|Experimental|Severe|Severe renal impairment
3133896|NCT03542305|Other|Normal|Normal renal function
3133897|NCT03542474|Experimental|Exercise|6 months of high intensity endurance exercise on a treadmill (3 times per week)
3133898|NCT03543085|Experimental|Ultrahigh Frequency (500 KHz) Stimulation|This study is a prospective, single-arm, open label, single center to confirm the effectiveness and safety of an ultrahigh frequency spinal cord stimulation in patients with chronic back pain or lower limb pain.
3133899|NCT03543137|Experimental|Test Product|Participants will receive a single Nicotine Prototype Mini lozenge (4mg) by oral/buccal route of administration.
3133900|NCT03543137|Active Comparator|Reference Product|Participants will receive a single Nicorette Mini lozenge (4 mg) by oral/buccal route of administration.
3133901|NCT03543176||UMEC/VI|The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
3133902|NCT03543176||FLUT/SAL|The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.
3133903|NCT03543878|Experimental|Flicker for 8 Weeks|Participants will receive the Flicker exposure during the entire 8-week treatment period
3133904|NCT03543878|Active Comparator|Flicker for 4 Weeks|Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period
3133905|NCT03544216|Experimental|Single Vision First|Subjects in this group will receive the single vision spherical (Bausch + Lomb ULTRA®) lens for the first two weeks and be crossed over to the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lens for the second two weeks.Therefore, this group will receive both study interventions.
3133906|NCT03544216|Experimental|Multifocal first|Subjects in this group will receive the multifocal (Bausch + Lomb ULTRA® for Presbyopia) lenses for the first two weeks and be crossed over to the single vision spherical (Bausch + Lomb ULTRA®) lens for the second two weeks. Therefore, this group will receive both study interventions.
3133907|NCT03544307|Experimental|Taekwondo Training|Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks.
3133908|NCT03544307|No Intervention|Control|Sedentary control asked not to exercise
3133909|NCT03544333|Experimental|real transcranial magnetic stimulation|In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
3180631|NCT00685594|Placebo Comparator|2|
3180632|NCT00685607|Experimental|1|loperamide-simethicone
3133910|NCT03544333|Placebo Comparator|sham transcranial magnetic stimulation|In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.
3133911|NCT03544879|Experimental|Yoga|The yoga intervention consisted of 2x weekly 60-minute sessions for 10 weeks. Yoga consists of postures, breathing exercises, movement, and meditation/concentration..
3133912|NCT03544879|Active Comparator|Health Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. Sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion.
3180633|NCT00685607|Placebo Comparator|2|matching placebo
3133913|NCT03545165|Experimental|All Subjects|"177Lu-PSMA-617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~177Lu-J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration~68Ga-PSMA-HBED-CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging"
3133914|NCT03545412|Experimental|Microfocused ultrasound with visualization|
3133915|NCT03545503|Active Comparator|Etomidate|Etomidate will be dosed once at a standard of 0.3 mg/kg via IV Push
3133916|NCT03545503|Active Comparator|Ketamine|Ketamine will be dosed once at a standard 2 mg/kg via IV Push
3133917|NCT03545893|Active Comparator|Ibuprofen|
3133918|NCT03545893|Active Comparator|Ibuprofen + Oxycodone|
3180634|NCT00685620|No Intervention|Group 1|Standard care following detoxification
3180635|NCT00685620|Active Comparator|Group 2|Recovery housing following detoxification
3180636|NCT00685620|Experimental|Group 3|Recovery housing plus counseling
3133919|NCT03545984|Experimental|simulation-based training|The simulation-based training during the first week of rotation involves step-by-step instructions on insertion of the CSF drainage catheter including aseptic technique, position of patient (lateral vs. sitting), site of insertion. The simulation training is done on a mannequin to simulate actual conditions. We plan to use a simulation model, which is basically a torso with the ability to palpate the back and spinous processes and use the epidural needle with loss of resistance technique with haptic feedback. The trainees would be able to actually perform the procedure on the manikin.
3133920|NCT03545984|Active Comparator|problem based learning|The residents allocated to the non-simulation group (problem based learning) receives standard educational teaching in the form of a problem based learning discussion during the first week of rotation.
3133921|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 18 to 60 Years|Participants aged 18 to 60 years received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
3133922|NCT03546192|Experimental|Fluzone Quadrivalent Influenza Vaccine: 61 Years or Older|Participants aged 61 years or older received one 0.5-mL dose of Fluzone Quadrivalent influenza vaccine, intramuscularly, at Day 0.
3133923|NCT03546270|Experimental|Swimming|Participants performed SWM training (combination of free style, breast stroke, and backstroke) for 20 weeks. For the first 5 weeks subjects swam 25-30 minutes/day, 3-4 days/week at ~60% of maximal heart rate. As their overall level of fitness and exercise skill improved, the intensity and duration of exercise increased to 40-45 minutes/day, 3-4 days/week at an intensity of 70-75% of the HRmax. Target HR was adjusted based on the observation that maximal heart rate during SWM is approximately 12 beats/min lower than that during running. Each subject was instructed to swim continuously except during the time needed for checking a target heart rate
3133924|NCT03546270|No Intervention|Control|Participants in the non-exercising control group did not participate in a supervised exercise program and visited the laboratory at the same frequency as participants in the swim intervention and underwent recreational activities such as board games
3133925|NCT03546491|Experimental|Preventive Gel|0.4% stannous fluoride
3133926|NCT03546491|Active Comparator|Marketed Control|0.243 % Sodium Fluoride
3180637|NCT00685633|Active Comparator|Arm A|Patients are observed without treatment in weeks 1-12. Patients with a prostate-specific antigen (PSA) rise of > 50% above baseline or nadir (whichever is lowest) and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a rise PSA ≥ 50% above baseline or nadir, and a PSA rise of at least 5 ng/mL confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue to receive bicalutamide up to 72 weeks.
3133927|NCT03546621|Experimental|Arm A|Myrcludex B, 2 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
3133928|NCT03546621|Experimental|Arm B|Myrcludex B, 5 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
3133929|NCT03546621|Experimental|Arm C|Myrcludex B, 10 mg/day subcutaneously (s.c.) for 24 weeks + tenofovir with a further follow-up period of 24 weeks of continued tenofovir therapy.
3133930|NCT03546621|Active Comparator|Arm D|tenofovir treatment for 48 weeks
3133931|NCT03546647|Experimental|Toric, Then Sphere|Participants who received Toric contact lenses first and spherical lenses after 10 days
3133932|NCT03546647|Experimental|Sphere, Then Toric|Participants who received Spherical contact lenses first and Toric lenses after 10 days
3133933|NCT03546816|Experimental|5 mg Serlopitant Tablets|
3133934|NCT03546816|Placebo Comparator|Matching Placebo Tablets|
3133935|NCT03546842|Experimental|9vHPV vaccine|Participants will receive a single 0.5-mL intramuscular injection of the 9vHPV vaccine at Day 1, Month 2, and Month 6
3180638|NCT00685633|Active Comparator|Arm B|In weeks 1-12, patients receive oral enzastaurin hydrochloride twice daily. Patients with a PSA rise of > 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, may be started on bicalutamide before the end of week 12 at the discretion of the treating physician. In weeks 13-44, patients with a PSA rise of ≥ 50% above baseline or nadir, and a rise of at least 5 ng/mL, confirmed by a repeat PSA at least 2 weeks later, are removed from study. Patients receive oral enzastaurin twice daily and oral bicalutamide once daily. Patients achieving a PSA decline ≥ 50% in the absence of toxicity may continue on this combination therapy up to 72 weeks.
3180639|NCT00685646|Experimental|Arm I|Patients receive maximum androgen-blockade therapy and zoledronic acid for up to 24 courses.
3133936|NCT03547154|Experimental|Pegylated interferon alfa-2b|Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
3180640|NCT00685646|Active Comparator|Arm II|Patients receive maximum androgen-blockade therapy for up to 24 courses.
3180641|NCT00685672|Experimental|1|adrenalin
3180642|NCT00685672|Placebo Comparator|2|placebo
3180643|NCT00685711|Placebo Comparator|1|Placebo intradermal n = 2 with each dose level of Cat-PAD.
3180644|NCT00685711|Experimental|2|Intradermal injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 12 nmol may be administered to an additional cohort of 6 subjects.
3180645|NCT00685711|Placebo Comparator|3|Placebo subcutaneous n = 2 with each dose level of Cat-PAD.
3180646|NCT00685711|Experimental|4|Subcutaneous injection of increasing single doses of Cat-PAD (0.03, 0.3, 3, 12, 20 nmol) n = 6 per dose level. Based on review of blinded LPSR, an additional dose of Cat-PAD between 0.03 and 20 nmol may be administered to an additional cohort of 6 subjects.
3180647|NCT00685724|Experimental|1|Following 2 sessions of MET intervention received by all patients, patients in Condition 1 receive no further intervention.
3180648|NCT00685724|Experimental|2|Patients in Condition 2 will receive 8 sessions of the CBT (Cognitive Behavioral Therapy) intervention.
3180649|NCT00685724|Experimental|3|Patients in Condition 3 will receive 8 sessions of CBT plus aftercare treatment.
3180650|NCT00685737|Active Comparator|1|1-MNA-Low Dose
3180651|NCT00685737|Active Comparator|2|1-MNA-High Dose
3180652|NCT00685737|Placebo Comparator|3|Placebo
3180653|NCT00685776|Experimental|Anacetrapib|Participants randomly assigned to anacetrapib in base study will continue same treatment if enrolled in study extension.
3180654|NCT00685776|Placebo Comparator|Placebo|Participants randomly assigned to placebo in base study will continue same treatment if enrolled in study extension.
3180655|NCT00685789|Experimental|Acupuncture with Deqi|Needles were inserted and manipulated manually using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation of soreness, numbness, fullness, aching, cool, warmth, heaviness and radiating sensation (Deqi) occurred. The needles were retained for 30 min.
3180656|NCT00685789|Active Comparator|Acupuncture without Deqi|Needles were simply inserted and retained for 30 min, without any other stimulation.
3180657|NCT00685815|Experimental|24 participants|Intravenous Iron (FCM)
3180658|NCT00685815|Placebo Comparator|12 participants|Placebo
3180659|NCT00685828|Active Comparator|Arm I|Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
3180660|NCT00685828|Experimental|Arm II|Patients receive high-dose oral imatinib mesylate twice daily in the absence of disease progression or unacceptable toxicity.
3180661|NCT00685841|Experimental|A|Arformoterol 50 mcg QD and placebo MDI
3180662|NCT00685841|Experimental|B|Arformoterol 25 mcg BID and placebo MDI
3133937|NCT03547154|Active Comparator|Interferon alfa-2b|Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
3133938|NCT03547167|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
3133939|NCT03547167|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Month 6 (Vaccination 2)
3133940|NCT03547531|Active Comparator|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
3180663|NCT00685841|Experimental|C|Arformoterol 15 mcg BID and placebo MDI
3180664|NCT00685841|Active Comparator|D|Salmeterol MDI 42 mcg BID and placebo inhalation solution
3133941|NCT03547531|Experimental|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
3133942|NCT03547583|Experimental|Vericiguat up to 10 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, with sham titration at week 6.
3133943|NCT03547583|Experimental|Vericiguat up to 15 mg|Subjects will receive vericiguat (BAY1021189) for 24 weeks, starting at 2.5 mg once daily at randomization and up-titrated to 5 mg at week 2, to 10 mg at week 4, and to 15 mg at week 6.
3180665|NCT00685841|Placebo Comparator|E|Placebo BID MDI and inhalation solution
3133944|NCT03547583|Placebo Comparator|Placebo|Subject will receive placebo for 24 weeks, once daily, starting sham up-titration at weeks 2, 4, and 6.
3133945|NCT03547635|Experimental|AMNIOEXCEL Plus Amniotic Membrane|
3133946|NCT03547635|Active Comparator|A Marketed Comparator|
3133947|NCT03547635|Other|Standard of Care|
3180666|NCT00685867|Experimental|1|Rapid detection
3180667|NCT00685867|Other|2|Enhanced infection control
3180668|NCT00685893|No Intervention|Control Arm|6 Community hospital ICUs receiving delayed intervention activities after the completion of the randomized trial
3180669|NCT00685893|Experimental|Intervention Arm|6 community hospital ICUs receiving 5-component intervention.
3133948|NCT03547687|Experimental|Electrical Stimulation Treatment|Patient will receive electrical stimulation to the quadriceps muscle groups on both lower extremities simultaneously for 45 minutes at a time, for a total of 5 treatments each week (Mon-Sun), for up to 14 days or until ICU discharge, whichever comes first.
3133949|NCT03548337|Active Comparator|13vPnC with 2-PE from a MDV|Multi Dose Vial with preservative
3133950|NCT03548337|Active Comparator|13vPnC without 2-PE in a PFS|Pre Filled Syringe without preservative
3180670|NCT00685906|Experimental|1|
3180671|NCT00685906|Active Comparator|2|
3180672|NCT00685971|Experimental|Vitamin D|vitamin
3180673|NCT00685971|Placebo Comparator|Placebo|
3180674|NCT00685984||1|
3180675|NCT00685984||2|
3180676|NCT00685984||3|
3180677|NCT00686010|Placebo Comparator|1|Placebo
3180678|NCT00686010|Experimental|2|JTT-705 300mg
3133951|NCT03548935|Experimental|Semaglutide s.c. 2.4 mg once weekly|Participants will receive semaglutide for 68 weeks.
3133952|NCT03548935|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide matching placebo for 68 weeks.
3133953|NCT03548987|Experimental|Semaglutide|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
3180679|NCT00686010|Experimental|3|JTT-705 600mg
3180680|NCT00686010|Experimental|4|JTT-705 900mg
3180681|NCT00686023|Active Comparator|1|DHS fixation
3180682|NCT00686023|Active Comparator|2|IMN fixation
3180683|NCT00686049||Study Group|Participants will complete two audio computer assisted self interviews on laptop computers. This study will also involve the abstraction of participants' viral load and CD4 counts from their medical charts.
3180684|NCT00686062|Experimental|1|Women in this arm view the interactive, computerized, prenatal testing decision tool (PT Tool) we created.
3180685|NCT00686062|Active Comparator|2|Women in this arm view the age-appropriate computerized version of the educational pamphlet on prenatal testing developed and distributed by the State of California
3133954|NCT03548987|Placebo Comparator|Placebo|"Run-in Period: Participants will receive semaglutide at an escalating doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) for 20 weeks (week 0 to week 20). The dose will be escalated to next level every 4 weeks.~Maintenance period: Participants will be randomized to receive semaglutide placebo injection for 48 weeks (from week 20 to week 68).~The trial product will be administered as an adjunct to a reduced-calorie diet and increased physical activity during the trial period."
3133955|NCT03549117|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
3133956|NCT03549117|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH nasal strips placebo nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
3133957|NCT03549130|Experimental|Active nasal strip group|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
3133958|NCT03549130|Placebo Comparator|Placebo nasal strip group|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips (small/medium size) outside of the nose, from alar crease to alar crease, as per dispensing instructions
3133959|NCT03549234|Experimental|Erector Spinae (single injection)|
3133960|NCT03549234|Active Comparator|Paravertebral (single injection)|
3133961|NCT03549338|Experimental|Arm A (Sym004)|"Sym004 will be given as a loading dose of 9 mg/kg on Cycle 1 Day 1 (C1D1), followed by weekly doses of 6 mg/kg beginning C1D8.~For patients that crossover from Arm B and Arm C, Sym004 will be given at the dose level that contains the corresponding dose level of the respective individual antibody (futuximab or modotuximab) prior to crossover."
3133962|NCT03549338|Experimental|Arm B (Futuximab)|Futuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the End of Cycle 2 (EOC2), ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of progressive disease (PD).
3133963|NCT03549338|Experimental|Arm C (Modotuximab)|Modotuximab will be given as a loading dose of 4.5 mg/kg on C1D1, followed by weekly doses of 3 mg/kg beginning C1D8. At the EOC2, ongoing patients will crossover to Sym004; crossover may occur prior to the EOC2 in the event of early radiographic documentation of PD.
3133964|NCT03549429|Experimental|TegadermTM on R eye, EyeGard® on L eye|Patients will get TegadermTM on Right eye, EyeGard® on Left eye
3133965|NCT03549429|Experimental|TegadermTM on L eye, EyeGard® on R eye|Patients will get TegadermTM on Left eye, EyeGard® on Right eye
3133966|NCT03549598|Experimental|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan, 18FDG PET/CT scan and 13NH3 PET/CT scan will be performed on each subject
3133967|NCT03550066|Experimental|Values affirmation|In the values affirmation condition, the health outreach message contained a prompt asking participants to reflect on important personal values.
3133968|NCT03550066|Active Comparator|No affirmation|"In the no affirmation condition, the health outreach message appeared alone, with no values affirmation."
3133969|NCT03550209|Experimental|LCPUFA Oil Supplement, Low Dose|25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
3133970|NCT03550209|Experimental|LCPUFA Oil Supplement, Medium Dose|50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
3133971|NCT03550209|Experimental|LCPUFA Oil Supplement, High Dose|75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
3133972|NCT03550209|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
3133973|NCT03550313|Experimental|Group 1 - Coadministration|Multivalent pneumococcal conjugate vaccine coadministered with Prevnar 13
3133974|NCT03550313|Experimental|Group 2 - Staggered Administration|Multivalent pneumococcal conjugate vaccine given 1 month after Prevnar 13
3133975|NCT03550313|Active Comparator|Group 3 - Control with Supplemental Dose|Prevnar 13 with a single dose of multivalent pneumococcal conjugate vaccine
3133976|NCT03550378|Experimental|MEDI0382|Participants will receive subcutaneous (SC) dose of MEDI0382 titrated from 50 μg upto 300 μg (50 μg once daily for 4 days, followed by 100 μg daily for 7 days, 200 μg daily for 7 days, and 300 μg daily for 14 days) for 32 days.
3133977|NCT03550378|Placebo Comparator|Placebo|Participants will receive SC dose of placebo matched to MEDI0382 once daily for 32 days.
3133978|NCT03550989||Non-Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Abstinent for at least 12 months from the use of any nicotine and/or tobacco-containing product based on self-reporting.~Must not be exposed to tobacco or nicotine-containing products use in any other substantial way (family, partner, workplace, etc.)."
3133979|NCT03550989||Cigarette Smokers|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 cigarettes~Smokes cigarettes daily > 1/day~Uses IQOS less than daily~Uses less than 30 HeatSticks/month~Cigarette is > 95% of tobacco/nicotine product (all product use)"
3133980|NCT03550989||IQOS Passive Users (not using IQOS)|"Each participant can participate in one Non-Exposure Event and one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
3180686|NCT00686101||1|Normal control subjects (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, who are not actively trying to quit smoking at the time of the interview, and who must be free from Axis I psychotic disorder.)
3133981|NCT03550989||IQOS Active Users (using IQOS)|"Each participant can participate in one Exposure Event only.~Used at least 100 HeatSticks~Uses IQOS daily > 1/day~Smokes a cigarette less than daily~Smokes less than 30 cigarettes/month~IQOS is > 95% of tobacco/nicotine product (all product use) - excluding other products (e-cig/Ploom/etc.)"
3133982|NCT03551730|Experimental|Module 3 (210 mg bolus) original|210 mg PRT064445 given as a single IV bolus
3133983|NCT03551730|Experimental|Module 3 (420 mg bolus) original|420 mg PRT064445 given as a single IV bolus
3133984|NCT03551730|Experimental|Module 3 (210 mg) lyophilized|210 mg PRT064445 (lyophilized formulation) given as a single IV bolus
3133985|NCT03551730|Placebo Comparator|Module 3 Placebo|Placebo administered intravenously (IV) as a bolus.
3133986|NCT03551743|Experimental|Module 4 (600 mg bolus)|600 mg PRT064445 given as a single IV bolus
3133987|NCT03551743|Experimental|Module 4 (800 mg bolus + 480 mg infusion) 8mg/min|1280 mg PRT064445: 800 mg IV at ~30 mg/min, followed by a continuous infusion of 480 mg (4 mg /min over 60 minutes)
3133988|NCT03551743|Experimental|Module 4 (800 mg bolus)|800 mg PRT064445 as a single IV bolus
3133989|NCT03551743|Placebo Comparator|Module 4 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous infusion.
3133990|NCT03551821|Experimental|ATI-50002 Topical Solution|ATI-50002 Topical Solution
3133991|NCT03552198|No Intervention|General public/usual health advice|Healthy participants with a self-reported existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
3133992|NCT03552198|Experimental|General public/alternative health advice|Generally healthy participants were randomised to receive targeted health advice about the adoption of protective behaviours in an alternative format.
3133993|NCT03552198|No Intervention|At risk group/usual health advice|Participants with a self-reported pre-existing health condition were randomised to receive the usual UK Air Quality Indices health advice.
3133994|NCT03552198|Experimental|At risk group/alternative health advice|Participants with a self-reported existing health conditions were randomised to receive targeted health advice (based on their health condition) about the adoption of protective behaviours in an alternative format.
3180687|NCT00686101||2|Subjects with a DSM-IV diagnosis of schizophrenia or schizoaffective disorder (Males and females between 18-65 years, who smoke cigarettes daily, have an expired CO measurement of > 8 ppm to confirm cigarette smoking, and who are not actively trying to quit smoking at the time of the interview.)
3180688|NCT00686114|Experimental|A|Enlarged field + Paclitaxel + Cisplatin + Tarceva
3133995|NCT03552289|Active Comparator|Cook Enforcer balloon catheter|The Enforcer balloon will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
3180689|NCT00686114|Experimental|B|Enlarged field + Paclitaxel + Cisplatin
3180690|NCT00686114|Active Comparator|C|Conventional field + Paclitaxel + Cisplatin + Tarceva
3180691|NCT00686114|Active Comparator|D|Conventional field + Paclitaxel + Cisplatin
3180692|NCT00686140|Experimental|Celecoxib, immune adjustor|Celecoxib
3180693|NCT00686140|Placebo Comparator|Placebo|Placebo looks like the active drug celecoxib, with the same dose
3133996|NCT03552289|Active Comparator|Conventional angioplasty balloon catheters|Commercially available angioplasty balloon devices will be used in the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula.
3180694|NCT00686179|Experimental|1|Escalating doses of AZD3480 during 6 days
3133997|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
3133998|NCT03552523|Experimental|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
3133999|NCT03552536|Experimental|A: MK-8583 100mg|After fasting, a single oral dose of 100 mg MK-8583 in capsule form.
3134000|NCT03552536|Experimental|B: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
3180695|NCT00686179|Experimental|2|Repeated doses of AZD3480 during 6 days
3134001|NCT03552536|Experimental|C: MK-8583 ≤ 150 mg|After fasting, a single oral dose of ≤ 150 mg MK-8583 in capsule form, with the dose based on the results from earlier treatments
3134002|NCT03552549|Experimental|PEG-Intron|Participants with stage III node positive cutaneous melanoma will receive subcutaneous PEG-Intron (6.0 ug/kg weekly) for 2 years post-surgery.
3134003|NCT03552549|Experimental|INTRON A|Participants with stage III node positive cutaneous melanoma will receive intravenous INTRON A (20 million international units [MIU]/m^2/day, 5 days a week) for 4 weeks followed by subcutaneous INTRON A (10 MIU/m^2 three times per week) for 48 weeks post-surgery.
3134004|NCT03552757|Experimental|Semaglutide 1.0 mg|Participants will receive semaglutide 1.0 mg and semaglutide placebo I during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
3134005|NCT03552757|Experimental|Semaglutide 2.4 mg|Participants will receive semaglutide 2.4 mg and semaglutide placebo II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
3134006|NCT03552757|Placebo Comparator|Semaglutide placebo I/II|Participants will receive semaglutide placebo I and II during 68-week treatment period in addition to a reduced-calorie diet and increased physical activity.
3134007|NCT03553758|Experimental|Ketamine|15 subjects undergoing ketamine general anesthesia.
3134008|NCT03553823|Experimental|secukinumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered 300 mg secukinumab as two 150-mg s.c. injections at Baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 12 inclusive
3180696|NCT00686179|Placebo Comparator|3|Placebo during 6 days
3134009|NCT03553823|Active Comparator|Guselkumab|20 subjects with plaque psoriasis with an inadequate response to ustekinumab self-administered guselkumab as 100 mg s.c. injections at Baseline, Weeks 4, and 12.
3134010|NCT03553940|Experimental|Arm 1|A single dose of monovalent live attenuated influenza H3N2 M2SR vaccine (M2SR) administered intranasally on Day 1, and a single dose of licensed quadrivalent influenza vaccine (QIV) administered intramuscularly on Day 92. N=25
3134011|NCT03553940|Placebo Comparator|Arm 2|A single dose of Placebo administered intranasally on Day 1, and a single dose of licensed QIV administered intramuscularly on Day 92. N=25
3134012|NCT03554005|Experimental|PEG Interferon Alfa-2b 0.75 mcg/kg Once Weekly (OW)|Participants receive PEG interferon alfa-2b 0.75 mcg/kg by subcutaneous (SC) injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3134013|NCT03554005|Experimental|PEG Interferon Alfa-2b 1.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 1.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3134014|NCT03554005|Experimental|PEG Interferon Alfa-2b 3 mcg/kg OW|Participants receive PEG interferon alfa-2b 3 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3134015|NCT03554005|Experimental|PEG Interferon Alfa-2b 4.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 4.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3180697|NCT00686179|Active Comparator|4|Placebo during 5 days, active day 6
3134016|NCT03554005|Experimental|PEG Interferon Alfa-2b 6 mcg/kg OW|Participants receive PEG interferon alfa-2b 6 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3134017|NCT03554005|Experimental|PEG Interferon Alfa-2b 7.5 mcg/kg OW|Participants receive PEG interferon alfa-2b 7.5 mcg/kg by SC injection OW for up to 40 weeks. They also receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and 500 to 1000 mg afterwards every 4 to 6 hours as needed. Total daily dose of acetaminophen should not exceed 3000 mg.
3134018|NCT03554018|Experimental|Acetaminophen|Acetaminophen 500-1000mg every 6 hours for 7 days Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
3180698|NCT00686218|Experimental|Treatment (panobinostat, imatinib mesylate)|Patients receive oral panobinostat once daily on days 1, 3 and 5; 8, 10, and 12; 15, 17, and 19; and 22, 24, and 26. Patients also receive oral imatinib mesylate once daily on days 1-28. Treatment repeats every 21 or 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3134019|NCT03554018|Active Comparator|Placebo|Placebo Participants in this arm will also receive ibuprofen 600mg every 6 hours for 7 days and an educational intervention.
3134020|NCT03554486|Experimental|Fiasp then Novolog|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Fiasp insulin for 2 weeks, followed by Novolog insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
3134021|NCT03554486|Experimental|Novolog then Fiasp|Following a 2-week run-in period for pump-setting adjustments and monitoring, participants 1 will use Novolog insulin for 2 weeks, followed by Fiasp insulin for 2 weeks. Both the subject and the investigator will be blinded to which group the subject is assigned.
3180699|NCT00686244|Experimental|Training Group|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
3134022|NCT03554629|Other|Capnography CO2 Sampling Filterline Performance|Adult volunteer exhaled gas was sampled by 8 different CO2 cannula sampling filterline (CCSF) designs connected to a Capnostream 35 for measurement of CO2 during patient simulated scripted activities in order to assess patient interface design performance to provide a quality gas sample for CO2 partial pressure measurement.
3134023|NCT03554746|Experimental|GC group|It mainly involve core stability exercise, stretching exercise and gluteal control training. All of above will be arranged 3 times a week for a total 6 weeks.
3134024|NCT03554746|Experimental|CG group|It involve core stability exercise and stretching exercise. All of above will be arranged 3 times a week for a total 6 weeks.
3134025|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 62.5 mg|Single dose containing 62.5 mg of celecoxib in 10 ml solution
3134026|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 125 mg|Single dose containing 125 mg of celecoxib in 10 ml solution
3134027|NCT03554772|Experimental|DFN-15 (Celecoxib Oral Solution) 250 mg|Single dose containing 250 mg of celecoxib in 10 ml solution
3134028|NCT03554772|Placebo Comparator|Placebo|Single dose containing 0 mg of celecoxib in 10 ml solution
3134029|NCT03555266|Experimental|NSS-2 Bridge and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
3134030|NCT03555266|Sham Comparator|Sham NSS-2 BRIDGE and ERAS Protocol|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal. This arm will contain an inactive sham NSS-2 BRIDGE device plus standard of care for abdominal oncological surgeries. Rescue analgesia will be permitted as per the approved ERAS multi-modal anesthetic protocol
3134031|NCT03555305|Experimental|Insulin Glargine|Participants received 0.5 units per kilogram (U/kg) of Insulin Glargine subcutaneously (SC).
3134032|NCT03555305|Active Comparator|Lantus|Participants received 0.5 U/Kg of Lantus subcutaneously.
3134033|NCT03555435|Experimental|On Your Own|Participants in this group will use the online program on their own for 6 weeks.
3134034|NCT03555435|Experimental|Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
3134035|NCT03555435|Placebo Comparator|Wait|Participants in this group will wait 6 weeks.
3134036|NCT03555565||Alogliptin and Metformin hydrochloride|Alogliptin 25 mg and metformin hydrochloride 500 mg, combination tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
3180700|NCT00686244|No Intervention|Control Group|No guided training. Exercise optional after detailed consulting and handing over an information dossier for adequate physical activity.
3134037|NCT03555890|Experimental|Subjects of Group A: Part 1|Subjects in Group A will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 2.
3134038|NCT03555890|Experimental|Subjects of Group B: Part 1|Subjects in Group B will be randomized to receive levocetirizine ODT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
3180701|NCT00686270|Experimental|1|apricitabine
3134039|NCT03555890|Experimental|Subjects of Group C: Part 2|Subjects in Group C will be randomized to receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine ODT 5 mg without water in fasted state in Period 2.
3134040|NCT03555890|Experimental|Subjects of Group D: Part 2|Subjects in Group D will be randomized to receive levocetirizine ODT 5 mg without water in fasted state in Period 1. After a washout period of at least 5 days, subjects will receive levocetirizine IRT 5 mg with 150 mL water in fasted state in Period 2.
3134041|NCT03556579|Experimental|Test/Control|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
3134042|NCT03556579|Experimental|Control/Test|For Visit 1, subjects will be randomly assigned to 1 of 2 contralateral lens sequences (Right: Test, Left: Control) OR (Right: Control, Left: Test). Then for visit 2, subjects will be randomly assigned to the same 1 of 2 contralateral lens sequences again.
3134043|NCT03556761|Experimental|Oral furosemide|Oral furosemide 20 mg/day for a total of 5 consecutive doses.
3134044|NCT03556761|Placebo Comparator|Placebo Oral Tablet|Placebo once per day for a total of 5 consecutive doses.
3134045|NCT03556891|Experimental|eCoin Tibial Nerve Stimulation|
3134046|NCT03557034|No Intervention|Standard of Care Monitoring|Standard of Care
3134047|NCT03557034|Experimental|Kardia Monitoring|Kardia Mobile/Kardia Pro
3148747|NCT00157131|Experimental|FS 4IU VH S/D|"FS 4IU VH S/D was administered intraoperatively to the wound bed by spray application using the TISSOMAT and Spray Set. Only the DUPLOJECTvii system and Spray Set (connection tube with sterile filter and spray head) device was used for simultaneous spray application of the study product. A thin layer of FS 4IU VH S/D was applied to the wound bed using a painting motion from side to side to achieve coverage. The recommended dosing volume was 2.0 to 4.0 mL/100 cm2. One 2-mL pack (4 mL total volume) of FS 4IU VH S/D applied using the TISSOMAT and Spray Set was sufficient to coat a wound bed of 100-200 cm2."
3148748|NCT00157131|Active Comparator|Staples|Staples are the current standard of care in burn surgery and are well accepted as the control in this type of study.
3148749|NCT00157300|Experimental|Epoetin beta|
3148750|NCT00157339|Experimental|1|
3148751|NCT00157339|Active Comparator|2|
3148752|NCT00157612|Other|Intervention|use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, re-hydration and close monitoring by a research nurse
3148753|NCT00157612|No Intervention|Comparator|usual care
3148754|NCT00157651|Active Comparator|1|Receiving warfarin
3148755|NCT00157651|Placebo Comparator|2|Receiving matching placebo
3134048|NCT03557086|Experimental|Advanced Care Planning Video Decision Support Tool|We designed a 3-minute advance care planning video to provide patients with advanced liver disease general understanding of the types of medical care patients may receive at the end of life (EOL) and a description of medical interventions such as hospitalizations, intensive care unit (ICU) admission, cardiopulmonary resuscitation (CPR), and intubation. The video begins by addressing the importance of the patient's personal goals and perspectives by asking the viewer to reflect on their concerns about getting sick and their overall goals for their EOL care. The physician narrator then introduces a framework for choices of medical care at the EOL including: 1) life-prolonging care; 2) limited medical care; and 3) comfort care followed by visual images illustrating each of these EOL care choices. All three sequences of video images accompanying the narration attempt to help the viewer imagine the experience and likely outcomes of receiving these medical interventions at the EOL.
3134049|NCT03557086|Active Comparator|Verbal Narrative Control|Immediately after completing baseline assessments and randomization, patients assigned to the verbal narrative control arm will listen to the same description of the 3 goals of care used in the video arm read out by a research assistant
3134050|NCT03557125|Active Comparator|Receives QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
3134051|NCT03557125|Placebo Comparator|Receives Saline Skin Wheel No Block|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
3134052|NCT03557333|Experimental|INP104|24-week treatment period for all participants followed by a 28-week treatment extension period for a subset of participants
3134053|NCT03557372|Experimental|Mathematical Model-Adapted Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule
3148756|NCT00157677|Experimental|1|Selective D-Dimer use
3148757|NCT00157677|Active Comparator|2|Uniform D-Dimer use
3148758|NCT00157690|Active Comparator|1|Alendronate
3148759|NCT00157690|Placebo Comparator|2|Placebo
3148760|NCT00157807|No Intervention|No Ablation|
3148761|NCT00157807|Other|bipolar radiofrequency ablation of persistent and permanent AF|intra operative bipolar RF ablation of persistent and permanent AF
3148762|NCT00157846|Experimental|BiV Pacing|Biventricular pacing for 3 months, subsequently right ventricular pacing for 3 months
3148763|NCT00157846|Active Comparator|RV Stimulation|Right ventricular pacing for 3 months, subsequently biventricular pacing for 3 months
3148764|NCT00157924|Experimental|1|1. simvastatin/ezetimibe 10/20mg
3148765|NCT00157924|Active Comparator|2|2. atorvastatin 10mg
3148766|NCT00158028|Experimental|Risperidone|starting dose 0.25mg/day, titrated upward to 2mg/day over 9 weeks
3148767|NCT00158028|Placebo Comparator|Placebo|placebo match in identical tablets
3148768|NCT00158132|Experimental|Propranolol|Propranolol 100mg/day in 3 divided doses
3148769|NCT00158132|Experimental|Amantadine|Amantadine 100mg three times daily
3148770|NCT00158132|Experimental|Propranolol and Amantadine|Propranolol 100mg/day in 3 divided doses and Amantadine 100mg 3X's daily
3148771|NCT00158132|Placebo Comparator|Placebo|Identical Placebo pills
3148772|NCT00158158|Placebo Comparator|1|Usual care
3148773|NCT00158158|Experimental|2|Reduction in smoking
3148774|NCT00158171|Experimental|1|Nicotine patch
3148775|NCT00158171|Experimental|2|Nicotine gum
3148776|NCT00158171|Placebo Comparator|3|Folic acid
3134054|NCT03557476|Experimental|Octacosanol|Two capsules (20-mg x 2) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed daily by the octacosanol group for six days, one capsule 30 minutes after morning and afternoon meals.
3134055|NCT03557476|Placebo Comparator|Placebo|A placebo pill was taken twice daily in replacement of the octacosanol supplement
3134056|NCT03557658|Experimental|Hepatic Impaired|Subjects with hepatic impairment conforming to the Child-Pugh class B (total score 7-9)
3134057|NCT03557658|Experimental|Healthy Volunteer|Subjects with normal hepatic function
3148777|NCT00158275|Experimental|Integrated Intervention|Participants will receive cognitive behavioral therapy for back pain and antidepressants and/or problem solving therapy for depression. Study visits will initially occur once a week and then taper to once every 2 weeks for the 6-month duration.
3148778|NCT00158275|No Intervention|Standard of Care|Participants will receive care as usual from their health care provider.
3148779|NCT00158301|Experimental|1|Continuation phase cognitive behavioral therapy and drug therapy for 6 more months following acute treatment response
3148780|NCT00158301|Active Comparator|2|Continuation phase drug therapy only for 6 more months following acute treatment response
3148781|NCT00158327|Experimental|1|Participants will receive telephone-based collaborative care
3134058|NCT03557775|Experimental|Inspiratory Muscle Strength Training|"The participants in the IMST arm will receive, in addition to standard of care voice therapy, inspiratory muscle strength training (IMST).~The IMST intervention will consist of 5 sets of 5 breaths in the inspiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal inspiratory pressure (MIP). MIP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
3134059|NCT03557775|Experimental|Expiratory Muscle Strength Training|"The participants in the EMST arm will receive, in addition to standard of care voice therapy, expiratory muscle strength training (EMST).~The EMST intervention will consist of 5 sets of 5 breaths in the expiratory threshold device every day during four weeks, with a loading dose set at 75% of the participants' maximal expiratory pressure (MEP). MEP will be measured once a week during the weekly supervised session to adjust the inspiratory trainer."
3134060|NCT03557775|Active Comparator|Voice Exercises|The participants in the voice exercises group will receive standard of care voice therapy with a speech language pathologist, once a week during four weeks, plus daily practices.
3134061|NCT03557801|Active Comparator|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard of care protocol.
3148782|NCT00158327|Active Comparator|2|Participants will receive usual care
3148783|NCT00158340|Experimental|1|Participants will receive guided self-help cognitive behavioral therapy
3148784|NCT00158340|Active Comparator|2|Participants will receive treatment as usual
3148785|NCT00158353|Experimental|1|GirlPOWER! mentoring program
3148786|NCT00158353|Active Comparator|2|Big Brothers Big Sisters community-based mentoring program
3148787|NCT00158366|Experimental|1|Phase 1 participants who will receive behavioral training for 14 weeks
3148788|NCT00158366|Active Comparator|2|Phase 1 participants who will receive social skills training for 14 weeks
3148789|NCT00158366|Experimental|3|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training alone for 24 months in Phase 2
3148790|NCT00158366|Experimental|4|Participants in the Phase 1 behavioral training group who have a 4% or more weight loss and will be enrolled in weekly behavioral training plus biweekly booster treatments for 24 months in Phase 2
3134062|NCT03557801|Experimental|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, women in the intervention arm 1 will participate in a 20-30 minute educational session alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
3148791|NCT00158431|Active Comparator|Arthroscopy plus Medical Management|Arthroscopic Surgery of the Knee plus the optimized medical management including physiotherapy, education, medication, etc
3148792|NCT00158431|No Intervention|Medical Management|Optimized Medical management including physiotherapy, education, medication, etc
3148793|NCT00158522|Experimental|1|
3148794|NCT00158574|Placebo Comparator|Placebo|IPTi placebo
3148795|NCT00158574|Experimental|Sulphadoxine-pyrimethamine|IPTi SP
3148796|NCT00158574|Experimental|Mefloquine|
3148797|NCT00158574|Experimental|Chlorproguanil dapsone|
3148798|NCT00158652|Active Comparator|1|
3148799|NCT00158652|Experimental|2|
3148800|NCT00158652|Experimental|3|
3148801|NCT00158665|Experimental|Subjects receiving vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine 4 weeks apart.
3148802|NCT00158678|Active Comparator|1|Conventional RT 70Gy + concomitant cisplatin
3148803|NCT00158678|Experimental|2|IMRT 75Gy + concomitant cisplatin
3148804|NCT00158769|Experimental|Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment as defined by a Child-Pugh score of 7-9 will be included. Subjects will be given GR270773 as a loading infusion of 25 milligram per kilogram per hour (mg/kg/hr) for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours.
3134063|NCT03557801|Experimental|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
3134064|NCT03557931|Experimental|ASP4345 50 milligram (mg)|Participants on stable doses of antipsychotic medication received ASP4345 50 mg, capsules, orally, once daily for 12 weeks.
3180702|NCT00686283|Other|Exercise prescription|Each adolescents with type 1 or type 2 diabetes received individual fitness testing and a personalized exercise program prescription developed by an exercise physiologist. Pretest and posttest measures of glucose control and cardiorespiratory fitness, heart rate variability, metabolic control, lipid profile, body composition, and inflammatory markers, as well as psychological outcomes (i.e., diabetes quality of life) were completed.
3180703|NCT00686296|Active Comparator|Group II|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing. Gauze dressing changes will continue per standard of care until the scheduled follow-up visits (first or second visit). At the scheduled follow-up visits, the subject will have a Taliderm™ dressing applied and left in place until the next scheduled dressing change (up to eight hours), then will continue standard of care wet to dry gauze dressing changes until next scheduled follow-up visit.
3180704|NCT00686296|Other|III|standard wet to dry dressing with gauze
3180705|NCT00686296|Active Comparator|group I|Taliderm™ dressing applied until the next scheduled dressing change (up to eight hours), then replaced by a gauze dressing
3180706|NCT00686322|Other|1|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
3180707|NCT00686374|Experimental|Any adalimumab|Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
3180708|NCT00686400||1: FE|FE = first episode schizophrenia
3180709|NCT00686400||2: CO|CO = age and gender-matched control subjects
3180710|NCT00686413|Experimental|1|
3180711|NCT00686413|Experimental|2|
3180712|NCT00686426|Active Comparator|1|Low Dairy
3180713|NCT00686426|Experimental|2|Adequate Dairy
3180714|NCT00686439|Experimental|adalimumab|
3180715|NCT00686452||1|Swimmers without AHR
3180716|NCT00686452||2|Swimmers with asymptomatic AHR
3180717|NCT00686452||3|Swimmers with symptomatic AHR and use only of beta-2 adrenargic
3180718|NCT00686452||4|Swimmers with asthma and inhaled corticosteroids
3180719|NCT00686452||5|Healthy Subjects
3180720|NCT00686452||6|Healthy subjects with AHR
3180721|NCT00686452||7|Healthy subjects with symptomatic AHR (asthma) but without treatment
3180722|NCT00686465|Other|PET/CT scan|PET/CT scan
3180723|NCT00686478|Experimental|interferon alpha 2b (Intron A)|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
3180724|NCT00686478|Placebo Comparator|Placebo|Placebo administered subcutaneously once a day for 7 days, then three times a week for 23 weeks.
3180725|NCT00686491||1|Triathletes
3180726|NCT00686491||2|Cold air athletes
3180727|NCT00686491||3|Swimmers
3180728|NCT00686491||4|Other sports elite athletes
3180729|NCT00686491||5|Control subjects
3180730|NCT00686530||1|
3180731|NCT00686556|Experimental|Cohort -1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 12 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3180732|NCT00686556|Experimental|Cohort 1|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 15 Gy on Days -5 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3180733|NCT00686556|Experimental|Cohort 2|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 18 Gy on Days -6 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3180734|NCT00686556|Experimental|Cohort 3|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 21 Gy on Days -7 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3134065|NCT03557931|Experimental|ASP4345 150 mg|Participants on stable doses of antipsychotic medication received ASP4345 150 mg, capsules, orally, once daily for 12 weeks.
3134066|NCT03557931|Placebo Comparator|Placebo|Participants on stable doses of antipsychotic medication received ASP4345 placebo matching capsules, orally, once daily for 12 weeks.
3134067|NCT03558061|Experimental|Active|ALK4290 800 mg daily
3134068|NCT03558074|Experimental|Active|ALK4290 800 mg daily
3134069|NCT03558230|Experimental|Vibration|The experimental group will receive the wrist stimulation during standardized Constraint-Induced Movement Therapy.
3134070|NCT03558230|Placebo Comparator|No Vibration|"The control group will wear the vibration device with no vibration during standardized Constraint-Induced Movement Therapy.~The vibration device is a generic, commercially-available, vibrator, not particularly used for this peripheral skin stimulation purpose."
3134071|NCT03558516|Experimental|Magnesium group|The patient will receive magnesium sulfate injection 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed
3134072|NCT03558516|Placebo Comparator|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed
3134073|NCT03558555|Active Comparator|Oral Acetaminophen|Patients who are randomized to have oral acetaminophen will take oral acetaminophen preoperatively and receive saline intraoperatively.
3134074|NCT03558555|Active Comparator|Acetaminophen IV Soln|Patients randomized to IV acetaminophen will receive IV acetaminophen after induction of general anesthesia and will take placebo pills preoperatively.
3134075|NCT03558997|Experimental|Placebo|Participants received placebo matched to Dupilumab and placebo matched to Timothy grass subcutaneous immunotherapy (SCIT) every 2 weeks (Q2W) for 16 weeks. Both placebo doses were administered with a gap of 1 or 7 days.
3180735|NCT00686556|Experimental|Cohort 4|Patient receives preparative therapy including Fludarabine, cyclophosphamide, and total marrow irradiation of 24 Gy on Days -8 through -1, and starts immunosuppressive therapy using cyclosporine, Mycophenolate Mofetil, followed by umbilical cord blood transplantation, or HLA-matched related donor bone marrow transplantation and granulocyte colony-stimulating factor administration.
3134076|NCT03558997|Experimental|Dupilumab|Participants received placebo matched to SCIT and subcutaneous (SC) injections of Dupilumab at a loading dose of 600 milligrams (mg) on Day 1, followed by a 300 mg for Q2W for 16 weeks. Both placebo matched to SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
3134077|NCT03558997|Experimental|SCIT|Participants received SCIT titrated up to a 4000 bioequivalent allergy unit (BAU) for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks and SC injections of placebo matched to Dupilumab Q2W for 16 weeks. Both SCIT and placebo matched to Dupilumab doses were administered with a gap of 1 or 7 days.
3134078|NCT03558997|Experimental|Dupilumab + SCIT|Participants received SC injections of Dupilumab at a loading dose of 600 mg on Day 1, followed by 300 mg Q2W for 16 weeks and SCIT titrated up to 4000 BAU for 8 weeks followed by maintenance dose of 4000 BAU for following 8 weeks. Both SCIT and Dupilumab doses were administered with a gap of 1 or 7 days.
3134079|NCT03559062|Other|Placebo|Participants with genotype F/F received placebo matched to TEZ/IVA fixed dose combination (FDC) in the morning and placebo matched to IVA in the evening for 8 weeks.
3134080|NCT03559062|Experimental|TEZ/IVA|Participants with genotype F/F received TEZ/IVA FDC in the morning and IVA in the evening for 8 weeks. Participants with genotype F/RF received TEZ/IVA FDC and placebo matched to IVA in the morning and IVA in the evening for 8 weeks.
3134081|NCT03559062|Experimental|Ivacaftor|Participants with genotype F/RF received placebo matched to TEZ/IVA FDC in the morning and IVA in morning and evening for 8 weeks.
3134082|NCT03559179|Experimental|Waivered Providers Receive the Opioid Wizard|All providers who have a buprenorphine waiver will receive the OUD clinical decision support tool (Opioid Wizard).
3134083|NCT03559179|No Intervention|Does not Receive the Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid Wizard. This arm of providers will continue to treat their patients as usual.
3134084|NCT03559179|Experimental|Non-Waivered Providers who receive Opioid Wizard|All non-buprenorphine waivered providers will be randomized to receive or not receive the Opioid. This arm of providers will receive the OUD clinical decision support tool (Opioid Wizard).
3134085|NCT03559205|No Intervention|MSK-Tracker (before)|Before - (Usual care in clinic consultations)
3134086|NCT03559205|Active Comparator|MSK-Tracker (after)|After - (MSK-Tracker in clinic consultations)
3134087|NCT03559218|Other|Standard of care|Patients undergoing radiation therapy for breast cancer will be provided instructions for radiation dermatitis per institutional standard of care
3134088|NCT03559218|Experimental|KeraStat Cream|Patients undergoing radiation therapy for breast cancer will be provided KeraStat Cream for twice daily application.
3134089|NCT03559257|Experimental|Galcanezumab|Galcanezumab administered subcutaneously (SC).
3134090|NCT03559257|Placebo Comparator|Placebo|Placebo administered SC.
3180736|NCT00686608|Experimental|Glucose|IV glucose
3180737|NCT00686608|Active Comparator|Fructose|
3180738|NCT00686608|Placebo Comparator|Saline|
3134091|NCT03559517|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3134092|NCT03559517|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3180739|NCT00686660|Experimental|1|C-W G: in training period, patients do cycling on cycle ergometry at hospital. in non-training period, patients walk at community.
3180740|NCT00686660|Other|2|C-nonW G: in training period, patients do cycling at cycle ergometry at hospital, in non-training period, patients don't walk at community.
3134093|NCT03559517|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3134094|NCT03559530||Patients|Patients with microbiologically proven A. baumannii-related osteomyelitis
3134095|NCT03559829|Experimental|Single Arm - Intervention arm|RAPAEL Smart Glove Arm The participant will be issued a Smart Glove and a tablet preloaded with the game software. The available games provide various kinds of motion tasks such as ADL-related tasks presented in an entertaining manner. The learning schedule algorithm automatically adjusts to the optimal level of difficulty to balance challenge and motivation. The participant will be expected to use the Smart Glove at home for 60 min per day for at least 5 days per week.
3134096|NCT03559933|Experimental|PEPNS System|The pdSTIM lead will be temporarily inserted near the right and left phrenic nerves and connected to the PEPNS system console in order to stimulate the phrenic nerves and activate the diaphragm on the patients until extubated/removed from mechanical ventilation or until 48 hours has elapsed, whichever comes first.
3134097|NCT03560102|Experimental|MR-HIFU treatment|Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat& resect model
3134098|NCT03560128|Experimental|Endocuff Vision Arm|Colonoscopy with Endocuff Vision device attached to the distal end of the scope.
3134099|NCT03560128|Experimental|AmplifEYE Arm|Colonoscopy with AmplifEYE device attached to the distal end of the scope.
3134100|NCT03560141|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
3180741|NCT00686660|Experimental|3|W-W G: in training period, patients do walking along 60 meters place at hospital, in non-training period, patients do walking in community
3180742|NCT00686660|Other|4|W-nonW G: in training period, patients do walking along 60 meter place, in non-training period,patients don't walk at community.
3134101|NCT03560141|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for one night of extended (overnight) wear.
3134102|NCT03560245|Experimental|Bryostatin 20µg|20µg Bryostatin administered IV over 45 minutes every other week after 2 initial loading doses of 24 micrograms administered weekly. A total of 7 doses administered over 12 weeks.
3134103|NCT03560245|Placebo Comparator|Placebo|"Placebo administered IV over 45 minutes every other weekafter 2 initial doses administered weekly. A total of 7 doses administered over 12 weeks.~The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution."
3134104|NCT03560518|Experimental|Rapastinel 450mg|Rapastinel 450 mg (prefilled syringe, weekly intravenous IV administration)
3134105|NCT03560518|Experimental|Rapastinel 900mg|Rapastinel 900 mg (prefilled syringe, weekly intravenous IV administration)
3134106|NCT03560518|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration)
3134107|NCT03560739|Other|OMB 20mg PFS abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on abdomen
3134108|NCT03560739|Other|OMB 20mg AI abdomen|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on abdomen
3134109|NCT03560739|Other|OMB 20mg PFS thigh|ofatumumab 20 mg subcutaneous (sc.) injection with pre-filled syringes (PFS) administrated on thigh
3134110|NCT03560739|Other|OMB 20mg AI thigh|ofatumumab 20 mg subcutaneous (sc.) injection with autoinjector (AI) administrated on thigh
3134111|NCT03560869|Experimental|Normal hydration then dehydration|Participants will consume water to maintain proper hydration for three days prior to testing (visit 1). Seven to 60 days later, participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 2).
3134112|NCT03560869|Experimental|Dehydration than normal hydration|Participants will reduce water intake over three days and abstain from any water for the final 16 hours prior to testing (visit 1). Seven to 60 days later, participants will consume water to maintain proper hydration for three days prior to testing (visit 2).
3134113|NCT03560986|Experimental|Neridronic acid|"Neridronic acid 100 mg - 4 intravenous (i.v.) infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The investigational medicinal product (IMP) was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.~The maximum neridronic acid dose was 800 mg: 400 mg in Treatment Period A and 400 mg in Treatment Period B."
3134114|NCT03560986|Placebo Comparator|Placebo|Matching placebo - 4 intravenous infusions within 10 days (i.e., on Days 1, 4, 7, and 10). The IMP was diluted in sterile normal saline to a volume of approximately 500 mL before slow administration.
3134115|NCT03561090|Experimental|1500 mg IW-3718 BID + PPI|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
3134116|NCT03561090|Placebo Comparator|Placebo + PPI|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
3180743|NCT00686673|Experimental|A|Providing Videotape-based material & tailored workbook to make informed choice of disclosing terminal illness to patients
3134117|NCT03561883|Experimental|1500 mg IW-3718 BID|Three 500 mg IW-3718 tablets administered twice daily (BID), immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
3134118|NCT03561883|Placebo Comparator|Placebo|Three placebo tablets administered BID immediately after the morning and evening meals. Standard-dose PPIs administered QD approximately 30-60 minutes before the morning meal each day.
3134119|NCT03562117|Experimental|Normal Hepatic function, Part 1 (Group D)|The eligible subjects, with normal hepatic function, in this arm will receive a single oral dose of gepotidacin as 1500 milligram (mg), administered as 2 × 750 mg tablets on Day 1.
3134120|NCT03562117|Experimental|Moderate hepatic impairment, Part 1 (Group B)|The subjects in this arm, will be the one's with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
3134121|NCT03562117|Experimental|Mild hepatic impairment, Part 2 (Group A)|The subjects in this arm, will be the one's with a Child-Pugh score of 5 to 6, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets on Day 1. This will be optional arm.
3180744|NCT00686673|Other|B|"Attention control arm:~Providing videotape-based material & non-tailored workbook about pain control"
3134122|NCT03562117|Experimental|Severe hepatic impairment, Part 2 (Group C)|The subjects in this arm, will be the one's, with a Child-Pugh score of 7 to 9, and will receive a single oral dose of gepotidacin, as 1500 mg, administered as 2 × 750 mg tablets, on Day 1.
3134123|NCT03562117|Experimental|Normal Hepatic function, Part 2 (Group E)|The eligible subjects, with normal hepatic function, will be matching with those enrolled in Part1, and will receive a single oral dose of gepotidacin as 1500 mg, administered as 2 × 750 mg tablets on Day 1.
3134124|NCT03562377|Experimental|Tralokinumab|"Week 0 to 16:> Tralokinumab will be given as subcutaneous injections. >~> Subjects will receive a tralokinumab loading dose at Day 0 followed by tralokinumab injection regimen A. The last administration will occur at Week 14."
3134125|NCT03562377|Placebo Comparator|Placebo|"Placebo (dummy treatment) will be given as subcutaneous injections. >~> Subjects will receive a placebo loading dose at Day 0 followed by placebo injection regimen A. The last administration will occur at Week 14."
3134126|NCT03562481|Experimental|Buffered Anesthetic, then Unbuffered Anesthetic|Subjects randomized to Buffered Anesthetic, then Unbuffered Anesthetic will first receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine.
3134127|NCT03562481|Experimental|Unbuffered Anesthetic, then Buffered Anesthetic|Subjects randomized to Unbuffered Anesthetic, then Buffered Anesthetic will first receive an injection with 2% Unbuffered Lidocaine 1:100,000 Epinephrine. After one week minimum washout period, subjects will then receive an injection with 1% Buffered Lidocaine 1:100,000 Epinephrine.
3134128|NCT03562559||TKA Patients|
3134129|NCT03562663|Experimental|Active tDCS|Participants in this group received 20 minutes of active 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic intervention.
3134130|NCT03562663|Sham Comparator|Sham tDCS|Participants in this group received 20 minutes of sham 2 mA transcranial direct current stimulation over the motor cortex of the affected arm prior to robotic training.
3134131|NCT03562988|Other|Vitamin C gummy, Then Vitamin C Caplet|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.
3134132|NCT03562988|Other|Vitamin C tablet, Then Vitamin C gummy|The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.
3134133|NCT03563027|No Intervention|Control|This arm serves as control and uses a wearable device to track daily step counts
3134134|NCT03563027|Experimental|Social Incentive Gamification|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, and selects a support sponsor
3134135|NCT03563027|Experimental|Social Incentive Gamification and Financial Incentive|This arm uses a wearable device to track daily step counts, is entered into social incentive gamification, selects a support sponsor, and receives a financial incentive
3134136|NCT03563183||Overall Group|Adults aged ≥50 years of age in the Zoster-064 TVC who received herpes zoster subunit (HZ/su) vaccine or Placebo in Zoster-006/022 study
3134137|NCT03563313|Experimental|Closed Loop Control (CLC)|Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months.
3134138|NCT03563313|Active Comparator|Sensor-Augmented Pump (SAP)|Participants randomized to sensor-augmented pump (SAP) will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months.
3134139|NCT03563716|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle and placebo administered by IV infusion Q3W on Day 1 of each 21-day cycle.
3134140|NCT03563716|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 mg administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle and tiragolumab at a dose of 600 mg administered by IV infusion Q3W on Day 1 of each 21-day cycle.
3134141|NCT03564353|Experimental|memory task with tDCS location 1|memory task paired with tDCS targeting C2 nerve (anode left c2; cathode right C2)
3134142|NCT03564353|Experimental|memory task with tDCS location 2|memory task paired with tDCS targeting C2 nerve (anode right c2; cathode left C2)
3134143|NCT03564353|Experimental|memory task with tDCS location 3|memory task paired with tDCS targeting C5/6 nerve
3134144|NCT03564353|Experimental|memory task with tDCS location 4|memory task paired with tDCS targeting trigeminal nerve dermatomes (left and right temple/jaw)
3134145|NCT03564444|Experimental|Bivalent influenza vaccine|A single dose of bivalent vaccine (10^7±5 fluorescent focus unit of 2 cold-adapted, attenuated, temperature-sensitive, 6:2 reassortant influenza strain) will be administered as intranasal spray on Day 1
3134146|NCT03564444|Placebo Comparator|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
3134147|NCT03564886|Experimental|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
3134148|NCT03564886|Placebo Comparator|Normal Saline|Lactate Ringer's (LR, 273mOsm/L) is commonly used at our facility as our isotonic standard irrigation solution and will serve as the control to be evaluated against a hyperosmolar (1.9%, 600mOsm) solution.
3134149|NCT03565068|Experimental|Panel A (Healthy Participants): MK-8189 Monotherapy 4-24 mg|Healthy participants will receive MK-8189 monotherapy orally once daily (QD) in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
3134150|NCT03565068|Placebo Comparator|Panel A (Healthy Participants): Placebo Monotherapy|Healthy participants will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
3134151|NCT03565068|Experimental|Panel B (Schizophrenia Participants): MK-8189 Monotherapy 4-24 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
3180745|NCT00686738||A|"Study group will be made up of patients hospitalized to National Cancer Center, Korea, aged between 5 and 40 years, and diagnosed with high grade osteosarcoma by histological exam.~In this group, TGF-b1 measurement, PET/CT and MRS examination at diagnosis, after 1st cycle chemotherapy, and 2nd or 3rd chemotherapy (just before surgery) will be made.~In addition, evaluation of NF-kB expression status in tumor specimens at diagnostic biopsy and tumor removing surgery will be done.~The results of above studies will be correlated with the necrosis fractions of the tumor tissues removed by surgery."
3134152|NCT03565068|Placebo Comparator|Panel B (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-18.
3134153|NCT03565068|Experimental|Panel C (Schizophrenia Participants): MK-8189 Add-on Therapy 4-24 mg|In addition to background atypical antipsychotic (AAP) treatment, participants with Schizophrenia will receive MK-8189 add-on therapy orally QD in escalating doses from 4 mg to 24 mg, as follows: Days 1-3: 4 mg, Days 4-6: 8 mg, Days 7-9: 12 mg, Days 10-12: 16 mg, Days 13-15: 20 mg, Days 16-18: 24 mg, depending on safety and tolerability.
3134154|NCT03565068|Placebo Comparator|Panel C (Schizophrenia Participants): Placebo Add-on Therapy|In addition to background AAP treatment, participants with Schizophrenia will receive MK-8189 add-on therapy matching placebo orally QD on Days 1-18.
3134155|NCT03565068|Experimental|Panel D (Schizophrenia Participants): MK-8189 Monotherapy 8-48 mg|Participants with Schizophrenia will receive MK-8189 monotherapy orally QD in escalating doses from 8 mg to 48 mg, as follows: Days 1-3: 8 mg, Days 4-6: 16 mg, Days 7-9: 24 mg, Days 10-12: 36 mg, Days 13-15: 48 mg, depending on safety and tolerability.
3134156|NCT03565068|Placebo Comparator|Panel D (Schizophrenia Participants): Placebo Monotherapy|Participants with Schizophrenia will receive MK-8189 monotherapy matching placebo orally QD on Days 1-15.
3134157|NCT03565211|Experimental|Progesterone vaginal ring (PVR)|Treatment started on the day following oocyte retrieval and could be continued through Week 12 of pregnancy (10 weeks post-oocyte retrieval), depending on the participants pregnancy assessment. A new PVR was inserted every 7 days with up to 10 PVRs used.
3134158|NCT03565315|Experimental|Group 1: 10E8VLS (5 mg/kg) SC Single Dose Group|10E8VLS (5 mg/kg) administered by the subcutaneous (SC) route (Day 0)
3134159|NCT03565315|Experimental|Group 2: 10E8VLS (5 mg/kg) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
3134160|NCT03565315|Experimental|Group 3: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Single Dose Group|10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0)
3134161|NCT03565315|Experimental|Group 4: 10E8VLS+VRC07-523LS (5 mg/kg each) SC Multiple Dose Group* (*Only One Dose Received)|"10E8VLS (5 mg/kg)+VRC07-523LS (5 mg/kg) administered by the SC route (Day 0, Week 12*, Week 24*)~*Participants received only one product administration on Day 0 because of the voluntary study pause and termination by the IND Sponsor/PI decision."
3134162|NCT03565666|Active Comparator|Adult RCT: Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with either multiple daily injections or continuous subcutaneous insulin infusion (pump therapy) for 7 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM) and half of all subjects also were a senseonics CGM. The usual care period was followed by the other 2 arms according to each subject's randomization schedule
3134163|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
3134164|NCT03565666|Experimental|Adult RCT: closed-loop control with iLet using Fiasp|Participants randomized to the iLet with Fiasp first started the insulin-only iLet arm using faster insulin aspart (Fiasp) in PumpCart, where the pharmacokinetic (PK) parameter for tmax used by the insulin-dosing algorithm was set to the same value as is used for Humalog and Novolog (65 minutes). All subjects wore a Dexcom G5 CGM and half of all subjects also wore a Senseonics Eversense CGM. The iLet period was followed by the other 2 arms according to each subject's randomization schedule
3134165|NCT03565679|Experimental|Masimo SpO2 Adhesive Sensors, Adtx (1859) & (2329)|Reference sensors from the reprocessed oximeter device will be placed on each subject to evaluate the SpO2 accuracy and performance.
3180746|NCT00686751|Experimental|A|"There is only one arm in this study. Each subject will be studied through 3 phases lasting a total of 4 weeks:~Phase 1: administration of study medication at the end of hemodialysis treatment.~Phase 2: no administration of study medication. Phase 3: administration of study medication at the beginning of hemodialysis."
3180747|NCT00686764||Group 1|Trans-femoral amputees that meet the eligibility criteria.
3180748|NCT00686816|Placebo Comparator|1|
3134166|NCT03565679|Sham Comparator|Covidien Nellcor SpO2 Sensor, MAX-A and MAX-N|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
3134167|NCT03565874|Experimental|Heart Rate Variability Biofeedback|HRVB program conducted over the course of 2 weeks of individual daily exercises for 20 minutes per day.
3134168|NCT03565887|Experimental|RVL-1201 ophthalmic solution 0.1%|RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
3134169|NCT03565887|Placebo Comparator|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
3180749|NCT00686816|Experimental|2|
3180750|NCT00686868|Experimental|30mg|active
3180751|NCT00686868|Experimental|3mg|active
3180752|NCT00686868|Experimental|0.3mg|active
3180753|NCT00686868|Placebo Comparator|placebo|placebo
3180754|NCT00686868|Experimental|60mg|60mg
3134170|NCT03566238|Experimental|A4250 low dose|Capsules for oral administration (40 ug/kg) once daily for 24 weeks
3134171|NCT03566238|Experimental|A4250 high dose|Capsules for oral administration (120 ug/kg) once daily for 24 weeks
3134172|NCT03566238|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 24 weeks
3180755|NCT00686868|Experimental|100mg|100mg
3180756|NCT00686933|Experimental|1|
3180757|NCT00686946||NRAMP|Participants take their antipsychotic medication as prescribed by their clinical treating teams.
3180758|NCT00686985|Experimental|A|
3134173|NCT03566485|Experimental|Phase 2 (atezolizumab, cobimetinib)|Participants with TP53 gene mutation receive atezolizumab IV over 60 minutes starting with day 15 of course 1 and then on days 1 and 15 of subsequent courses, and cobimetinib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3134174|NCT03566485|Experimental|Phase 1b - Atezolizumab 840mg IV + Idasanutlin 100mg PO|
3134175|NCT03566550||CF|people with cystic fibrosis
3134176|NCT03566550||Control|people without cystic fibrosis
3134177|NCT03566680|Experimental|Orthokeratology Group|All subjects will be fit in orthokeratology contact lenses.
3134178|NCT03566732||Bereaved relatives|Bereaved relatives after cancer deaths in hospitals
3134179|NCT03566810|Experimental|First Test GXR (Fasting), Then Reference GXR (Fasting)|Participants received a single oral dose of 500 milligrams (mg) of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
3134180|NCT03566810|Experimental|First Reference GXR (Fasting), Then Test GXR (Fasting)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fasting conditions. There was a wash-out period of 7 days between each treatment period.
3134181|NCT03566810|Experimental|First Test GXR (Fed), Then Reference GXR (Fed)|Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg reference GXR (Merck Darmstadt/Germany) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
3134182|NCT03566810|Experimental|First Reference GXR (Fed), Then Test GXR (Fed)|Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/Germany) on Day 1 in treatment period 1 followed by a single oral dose of 500 mg test GXR (Merck Nantong/China) on Day 8 in treatment period 2 under fed conditions. There was a wash-out period of 7 days between each treatment period.
3134183|NCT03566823|Experimental|Ontamalimab 25 mg|Participants will receive 25 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3134184|NCT03566823|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3134185|NCT03566823|Placebo Comparator|Placebo|Participants will receive placebo matching with ontamalimab subcutaneous injection using a prefilled syringe on Week 0/Day 1, Week 4, Week 8, and Week 12.
3134186|NCT03566979|Experimental|Test naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two Test Naproxen Sodium 220 mg tablets (Test NPX)
3134187|NCT03566979|Active Comparator|Commercial naproxen sodium tablet|Single dose of 440 mg of naproxen sodium administered as two commercial naproxen sodium 220 mg tablets
3134188|NCT03566979|Active Comparator|Commercial naproxen sodium liquid gels capsule|Single dose of 440 mg of naproxen sodium administered as two 220 mg commercial liquid gels capsules
3134189|NCT03566979|Placebo Comparator|Placebo tablet|Single dose of two Placebo tablets
3134190|NCT03567005|Other|DACP Digital then DACP|Nelfilcon A digital contact lenses worn first, followed by nelfilcon A contact lenses. Each product worn bilaterally (in both eyes) for 7 days in a daily disposable modality.
3134191|NCT03567005|Other|DACP then DACP Digital|Nelfilcon A contact lenses worn first, followed by nelfilcon A digital contact lenses. Each product worn bilaterally for 7 days in a daily disposable modality.
3134192|NCT03567252|Experimental|Walking Group|Participants in this group will join an established walking group and travel by foot 1 kilometer to a local Farmer's Market. They will also receive handouts about nutrition information and nutritional choices.
3180759|NCT00687011|Experimental|Palonosetron-dexamethasone|
3180760|NCT00687037|Experimental|I|Cetylpyridinium chloride during 21 days.
3134193|NCT03567252|No Intervention|Non-Walking Group|Participants in this group will have no walking requirement. They will receive handouts about nutrition information and nutritional choices.
3134194|NCT03567291|Experimental|TEV-50717- Part A|All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.
3134195|NCT03567291|Experimental|TEV-50717- Part B RW|TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.
3134196|NCT03567291|Placebo Comparator|Placebo- Part B RW|Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.
3134197|NCT03567382|Experimental|High-risk HBV dyads|Mothers with high-risk HBV (defined as viral load >10^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of vertical transmission of HBV. All HBV-exposed infants (regardless of mother's status of high- or low-risk HBV) will receive monovalent HBV vaccine within 24 hours of life.
3134198|NCT03567382|Experimental|Low-risk HBV dyads|Mothers with low risk HBV (defined as a viral load <10^6 and negative HBeAg) will not receive tenofovir disoproxil fumarate therapy during or after pregnancy. Their infants will still receive monovalent HBV vaccine within 24 hours of life.
3134199|NCT03567616|Experimental|Part 1: Dose Escalation|Venetoclax (400 mg oral [PO], once daily [QD]) administered with pomalidomide (4 mg PO, QD) and dexamethasone (40 mg once weekly [qw]) in 28-day cycles until documented disease progression, documented unacceptable toxicity, withdrawal of consent, or the participant met other criteria for discontinuation per study protocol
3134200|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) positive|Participants positive for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
3134201|NCT03567616|Experimental|Part 2: Dose Expansion, t(11;14) negative|Participants negative for t(11;14) translocation were to receive the venetoclax dose determined to be safe in Part 1 as well as pomalidomide (4 mg oral [PO], once daily [QD]) and dexamethasone (40 mg once weekly [qw])
3134202|NCT03567980|Experimental|topical crisaborole 2%|
3134203|NCT03568500|Experimental|Aripiprazole|Participants received 1 oral tablet of CoEncapsulated (CoE) aripiprazole, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
3134204|NCT03568500|Experimental|Olanzapine|Participants received 1 oral tablet of CoE olanzapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
3134205|NCT03568500|Experimental|Quetiapine|Participants received 1 oral tablet of CoE quetiapine, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks.
3134206|NCT03568500|Experimental|Risperidone|Participants were to receive 1 oral tablet of CoE risperidone, wearing the DMS patch, and using the associated smartphone app for a total of 8 weeks. No participant took risperidone in this trial.
3134207|NCT03568539|Experimental|IBI308|
3134208|NCT03568942|Experimental|Female subjects with acute cystitis|Adult female subjects with suspected acute cystitis based on clinical presentation and pyuria (>=10 WBC/mm^3 or presence of leukocyte esterase) and/or nitrite will be included. Subjects will be administered 1500 mg gepotidacin BID for 5 days via the oral route.
3134209|NCT03569020|Experimental|Dietitian-Directed Diet|Participants will be provided $105/week ($15/day) to purchase foods in servings that correspond to the DASH diet and thus include fruits, vegetables, lean meat, low fat dairy, and high fiber foods. Participants will also be asked to restrict red meat, sweets, and sugary beverages during this intervention period. A dietitian will help participants order foods from a digital supermarket. Foods will be delivered to the Johns Hopkins ProHealth Research Clinic for weekly pick-up. This study period will last 4 weeks.
3134210|NCT03569020|No Intervention|Self-Directed Diet|Participants will be asked to consume their typical diet for 4 weeks. There will be no subsidy during this period.
3134211|NCT03569033|Experimental|Gefapixant 45 mg BID|Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
3134212|NCT03569033|Placebo Comparator|Placebo BID|Participants will receive a matching placebo tablet BID for 7 days.
3134213|NCT03569098|Experimental|Dysport Dose 1|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
3134214|NCT03569098|Experimental|Dysport Dose 2|Intramuscular injection of Dysport on day 1 of double-blind period, followed by up to 2 open-label injections during open-label cycles, during approximately 36 weeks.
3134215|NCT03569098|Placebo Comparator|Placebo|Intramuscular injection of Placebo on day 1 of cycle 1 (double-blind period)
3134216|NCT03569202|Experimental|Emulsion Eye Drops|Daily treatment with Piiloset Trehalose Emulsion Eye Drops
3134217|NCT03569202|Active Comparator|Control Eye Drops|Daily treatment with Hyaluronic Acid Eye Drops (a CE-marked medical device)
3134218|NCT03569371|Experimental|INCB054707|
3134219|NCT03569397|Experimental|Music Therapy|Administer music therapy during the operation
3134220|NCT03569397|No Intervention|Non-Music Therapy|No headphones or music therapy during the operation
3134221|NCT03569618|Active Comparator|Game 1|Tablet-based Game 1.
3134222|NCT03569618|Placebo Comparator|Game 2|Tablet-based Game 2.
3134223|NCT03569748|Experimental|IQOS|HEAT NOT BURN REDUCED RISK PRODUCT
3134224|NCT03569748|Active Comparator|E-CIG|ELECTRONIC CIGARETTE REDUCED RISK PRODUCT
3134225|NCT03570255|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
3134226|NCT03570476|Experimental|Treatment (olaparib, radical prostatectomy)|Participants receive olaparib orally twice daily for 90 days in the absence of unacceptable toxicity. Beginning 1 day after last olaparib dose, participants undergo radical prostatectomy.
3134227|NCT03570554|Experimental|Treatment A-D-C-B|Participants received naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by placebo for 4 days; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
3134228|NCT03570554|Experimental|Treatment B-C-D-A|Participants received acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by placebo for 4 days; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days.
3134229|NCT03570554|Experimental|Treatment C-A-B-D|Participants received celecoxib 200 mg daily for 3 days and 100 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by placebo for 4 days. Treatment periods were separated by a washout period of 3 to 7 days.
3134230|NCT03570554|Experimental|Treatment D-B-A-C|Participants received placebo for 4 days; followed by acetaminophen 3900 mg daily for 3 days and 1300 mg on the fourth day; followed by naproxen 660 mg daily for 3 days and 440 mg on the fourth day; followed by celecoxib 200 mg daily for 3 days and 100 mg on the fourth day. Treatment periods were separated by a washout period of 3 to 7 days
3134231|NCT03570658|Experimental|Single-Ascending Dose (SAD)|Participants will receive a single dose of RO7049389.
3134232|NCT03570658|Experimental|Multiple-Ascending Dose (MAD)|Participants will receive multiple doses of RO7049389.
3134233|NCT03570658|Placebo Comparator|Placebo|Participants will receive either a single dose (SAD cohorts) or multiple doses (MAD cohorts) of placebo matched to RO7049389.
3134234|NCT03570697|Experimental|Evolocumab|Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
3134235|NCT03570697|Placebo Comparator|Placebo|Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.
3134236|NCT03571256|Experimental|TEV-50717 High-Dose|TEV-50717 tablets twice daily (BID) up to 48 milligrams (mg)/day orally for a total of 8 weeks
3134237|NCT03571256|Experimental|TEV-50717 Low-Dose|TEV-50717 tablets BID up to 36 mg/day orally for a total of 8 weeks
3134238|NCT03571256|Placebo Comparator|Placebo|Placebo matched to TEV-50717 for a total of 8 weeks
3134239|NCT03571516|Experimental|Teduglutide|Participants will receive 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection of teduglutide into abdomen or into either the thigh or arm once daily (QD) in addition to standard medical therapy for 24 weeks.
3180761|NCT00687050|Active Comparator|1|HIV-positive hemodialysis patients (as a high risk group for cachexia) will be given daily drinks of Renilon 7.5 (125 ml, 2 kcal/ml) as peroral supplemental nutrition on top to their recommended high-protein, high-caloric diet.
3180762|NCT00687050|No Intervention|2|Chronic hemodialysis patients randomized to no peroral supplemental nutrition
3134240|NCT03571516|Other|Standard of Care (SOC)|Participants will receive standard medical therapy for 24 weeks.
3134241|NCT03571555||Young people with perinatally acquired HIV|Residential interventions (camps) and community based support (clubs)
3134242|NCT03571555||Caregivers of young people with perinatally acquired HIV|Community based support (clubs)
3134243|NCT03571607|Experimental|13-valent pneumococcal conjugate vaccine|
3134244|NCT03571672|Experimental|DEFINITY|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY contrast-enhanced ultrasound
3134245|NCT03571724|Experimental|Usual Brand (UB) non-mentholated filtered cigarettes|Usual Brand (UB) mentholated filtered cigarettes Usual Brand (UB) non-mentholated filtered cigarettes or to very low nicotine non-mentholated cigarettes
3134246|NCT03571724|Experimental|Usual Brand (UB) mentholated filtered cigarettes|Subjects will be randomized to continue to smoke Usual Brand (UB) mentholated filtered cigarettes or to very low nicotine mentholated cigarettes
3134247|NCT03572062|Experimental|Arm 1|Low dose formulation A and SIIV
3134248|NCT03572062|Experimental|Arm 2|Low dose formulation B and SIIV
3134249|NCT03572062|Experimental|Arm 3|Mid dose formulation A and SIIV
3134250|NCT03572062|Experimental|Arm 4|Mid dose formulation B and SIIV
3134251|NCT03572062|Experimental|Arm 5|High dose formulation A and SIIV
3134252|NCT03572062|Experimental|Arm 6|High dose formulation B and SIIV
3134253|NCT03572062|Experimental|Arm 7|High dose formulation C and SIIV
3134254|NCT03572062|Placebo Comparator|Arm 8|Placebo and SIIV
3134255|NCT03572062|Experimental|M0M2 Arm 1|High dose formulation B
3134256|NCT03572062|Placebo Comparator|M0M2 Arm 2|Placebo
3134257|NCT03572218|Experimental|BWL + BIAS|The behavioral weight loss (BWL) + weight bias internalization and stigma (BIAS) group will include standard BWL treatment (described in more detail in Intervention section) combined with a weight stigma-reduction intervention. During the initial 12 weeks, the weekly 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically in the context of weight management.
3134258|NCT03572218|Active Comparator|Standard BWL|The Standard BWL group will receive weekly BWL sessions (described in more detail in Intervention section) for 12 weeks, followed by every-other-week and monthly weight loss maintenance sessions from weeks 13-26. BWL content will last for 60 minutes, with an additional 30 minutes in this group devoted to discussing recipes and food preparation.
3134259|NCT03572478|Experimental|Combination Therapy (Phase 1b Cohort)|Participants will receive rucaparib plus nivolumab in 4 week cycles.
3134260|NCT03572478|Experimental|Rucaparib (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib alone in 4 week cycles.
3134261|NCT03572478|Experimental|Nivolumab (Phase 2b Randomized Cohort)|Participants randomized to receive nivolumab alone in 4 week cycles.
3134262|NCT03572478|Experimental|Combination Therapy (Phase 2b Randomized Cohort)|Participants randomized to receive rucaparib plus nivolumab in 4 week cycles. Participants will receive rucaparib alone in cycle 1 and begin nivolumab on day 1 of Cycle 2.
3134263|NCT03572972||Patients prescribed apixaban|
3134264|NCT03572972||Patients prescribed dabigatran|
3134265|NCT03572972||Patients prescribed rivaroxaban|
3134266|NCT03572972||Patients prescribed warfarin|
3134267|NCT03572972||Patients prescribed antiplatelet|
3134268|NCT03573206|Experimental|Treatment Arm|Cardiva Medical Mid-Bore VVCS for venous femoral access site closure
3134269|NCT03573323|Experimental|Ixekizumab|"A starting dose of 160 milligram (mg) of ixekizumab was given as 2 subcutaneous (SC) injections at Week 0. During the Induction Period, ixekizumab 80 mg was given every 2 weeks (Q2W) at Weeks 2, 4, 6, 8, 10, and 12. During the Extension Period, ixekizumab 80 mg was given as 1 SC injection (Q4W) every 4 weeks at Weeks 16 and 20.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
3180763|NCT00687050|Active Comparator|3|Chronic hemodialysis patients randomized to peroral supplemental nutrition.
3180764|NCT00687063||A|
3180765|NCT00687089||Subutex group|People who used opiates and willing to start with subutex treatment
3180768|NCT00687128|Experimental|1|Low-intensity aerobic exercise
3180769|NCT00687128|Experimental|2|Moderate-intensity aerobic exercise
3180770|NCT00687128|Active Comparator|3|Non-aerobic stretching exercise
3180771|NCT00687141|Experimental|1|
3180772|NCT00687141|Placebo Comparator|2|
3180773|NCT00687154|Active Comparator|1 Sitting|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 1 sitting
3180774|NCT00687154|Active Comparator|4 Sittings|Subjects with (1) OCT central subfield thickness ≤ 299 microns and (2) early proliferative or severe nonproliferative diabetic retinopathy for which investigator intends to perform full scatter photocoagulation in 4 sittings.
3180775|NCT00687180|Active Comparator|I|MMF
3180776|NCT00687180|Active Comparator|II|
3180777|NCT00687206|Experimental|1|
3134270|NCT03573323|Experimental|Guselkumab|"During the Induction Period, guselkumab 100 mg was given as 1 SC injection at Weeks 0, 4 and 12. 1 placebo injection (to maintain the blind) was given at Weeks 0, 2, 6, 8, and 10. During the Extension Period, guselkumab 100 mg was given at Week 20. 1 placebo injection (to maintain the blind) was given at Week 16.~The Post Treatment Follow Up Period was for safety monitoring following the last treatment period."
3180778|NCT00687232|Experimental|1|AZD4818
3180779|NCT00687232|Placebo Comparator|2|
3180780|NCT00687245|Experimental|1|esomeprazole magnesium 5 mg, weight 8 kg to < 20kg
3180781|NCT00687245|Experimental|2|esomeprazole magnesium 10 mg, weight 8 kg to < 20kg
3180782|NCT00687245|Experimental|3|esomeprazole magnesium 10 mg, weight > 20 kg
3180783|NCT00687245|Experimental|4|esomeprazole magnesium 20 mg, weight > 20 kg
3180784|NCT00687258|Experimental|1|VitabranE ViE: Vitamin E-bonded polysulfone dialyzer
3180785|NCT00687258|No Intervention|2|APS-U (Asahi Polysulfone APS): Polysulfone dialyzer
3180786|NCT00687284||A|
3188781|NCT00770718|Experimental|Recombinant Activated Factor VII|The first five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given. If a maximum total of 80mcg/kg has been administered without successful correction of INR, then FFP infusions will be utilized to complete correction.
3134274|NCT03573505|Experimental|BG00011|Participants will receive BG00011 56 mg once weekly by subcutaneous (SC) injection for 52 weeks.
3134275|NCT03573505|Placebo Comparator|Placebo|Participants will receive placebo once weekly by (SC) injection for 52 weeks.
3134276|NCT03573804|Experimental|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
3134277|NCT03573817|Experimental|Period 1: Revefenacin + Formoterol (Sequential)|Days 1 to 21: Revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
3134278|NCT03573817|Experimental|Period 2: Revefenacin + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from the Revefenacin + Formoterol (Sequential) Arm will be dosed for 21 days with a combination of revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
3134279|NCT03573817|Placebo Comparator|Period 1: Placebo + Formoterol (Sequential)|Days 1 to 21: Placebo versions of revefenacin and formoterol will be sequentially administered in the morning. Formoterol will be administered again in the evening.
3134280|NCT03573817|Placebo Comparator|Period 2: Placebo + Formoterol (Combo Solution)|Days 22 to 42: After a 21 day period, the participants from Placebo + Formoterol (Sequential) Arm the will be dosed for 21 days with a combination of placebo revefenacin and formoterol administered as a combined solution. Formoterol will be administered again in the evening.
3134281|NCT03573830|Active Comparator|Current material|Participants in this arm will be shown the online Transport Canada Material that is currently available at: https://www.tc.gc.ca/en/services/road/child-car-seat-safety/installing-using-child-car-seat-booster-seat-seat-belt/stage-3-booster-seats.html
3134282|NCT03573830|Experimental|Enhanced material|Participants in this arm will be shown an enhanced version of the online Transport Canada Material, which includes an introduction explaining how booster seats prevent injuries caused by seat belts.
3134283|NCT03573908|Experimental|Linaclotide 290 µg|Participants receive linaclotide 290 µg orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are rerandomized to receive either linaclotide 290 µg or placebo for 4 weeks in the Randomized Withdrawal Period.
3134284|NCT03573908|Placebo Comparator|Placebo|Participants receive placebo to linaclotide orally once daily for 12 weeks during the Treatment Period. At Week 12 participants are switched to receive linaclotide 290 µg for 4 weeks during the Randomized Withdrawal Period.
3134285|NCT03574441|Active Comparator|TegadermTM only|
3134286|NCT03574441|Active Comparator|Dressing with TegadermTM plus Steri-StripTM bands|
3134287|NCT03574441|Experimental|Dressing with TegadermTM plus catheter support pad.|
3134288|NCT03574753|Experimental|ABBV-399|"C-MET overexpression is seen in 30% of patients with lung squamous cell carcinoma (SCCA). ABBV-399 (Process II) is a first-in-class antibody-drug conjugate (ADC) comprised of ABT-700, an anti-c-Met monoclonal antibody linked to monomethyl auristatin E (MMAE), which is a potent microtubule inhibitor. This delivers a direct anti-mitotic effect without relying on MET pathway inhibition.~ABBV-399 will be administered intravenously on day 1 of each 21-day cycle. Treatment will continue in consenting patients until disease progression or intolerable toxicity."
3134289|NCT03574818|Experimental|Arm 1|"Chemotherapy and Necitumumab Regimen Gemcitabine 1250mg/m2 IV over 30 minutes, days 1 and 8 following necitumumab, Cisplatin 75mg/m2 IV over 60 minutes, day 1, immediately following gemcitabine,each cycle is 3 weeks (21 days).~Necitumumab 800mg absolute dose IV over a minimum of 60 minutes, days 1 and 8 prior to chemotherapy regimen Each cycle is 3 weeks (21 days).~The regimen will be given for a total of 3 cycles.~The regimen will be given for a total of 3 cycles."
3134290|NCT03575702|Experimental|Uritos®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
3134291|NCT03575702|Active Comparator|Urotol®|one tablet orally twice a day (after breakfast and dinner) for 12 weeks
3134292|NCT03575754|Experimental|Interventional|This arm utilizes the investigational device, as specified in protocol.
3134293|NCT03575806|Experimental|TACE+Tcm group|Experimental arm: TACE plus autologous Tcm immunotherapy to treat HCC.
3134294|NCT03575806|Active Comparator|TACE group|Active comparator: TACE to treat HCC.
3134295|NCT03575871|Experimental|PF-04965842 100 mg|
3134296|NCT03575871|Experimental|PF-04965842 200 mg|
3134297|NCT03575871|Placebo Comparator|Placebo|
3134298|NCT03575897|Experimental|Intervention Group|Infants randomly assigned to the intervention group will undergo serial measurements of infant body composition during their hospitalization. This information about infant body composition will be known to the clinicians caring for them (including reference data).
3134299|NCT03575897|Active Comparator|Control Group|Infants randomly assigned to the control group will also undergo serial measurements of infant body composition during their hospitalization, but this information will not be available to the clinicians caring for them.
3134300|NCT03575962|Experimental|GSK3640254 Bis-hydrochloride followed by GSK3640254 mesylate|The subjects in this arm will receive an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsules(reference), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1, during Period 2 of the study. The drug will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
3134301|NCT03575962|Experimental|GSK3640254 Mesylate followed by GSK3640254 Bis-hydrochloride|The subjects in this arm will receive an oral administration of 200 mg as 2 GSK3640254 Mesylate salt capsule (test), as single oral dose, on the morning of Day 1 during Period 1 of the study. This will be followed by an oral administration of 200 mg, as 2 GSK3640254 bis-hydrochloride salt Capsule, 100 mg (reference), as single oral dose, on the morning of Day 1 during Period 2, of the study. The drug, will be administered following a moderate calorie and fat meal. There will be a minimum washout of 7 days between each dose of study treatment.
3134302|NCT03575975||Mobile-bearing ankle prosthesis user|Users of the Stryker Scandinavian Total Ankle Replacement (STAR) mobile-bearing prosthesis.
3134303|NCT03575975||Control|Healthy individual age- and gender-matched to a participant in the mobile-bearing prosthesis user group.
3134304|NCT03575975||Fixed-bearing ankle prosthesis user|Users of the INBONE II Total Ankle Replacement fixed-bearing prosthesis.
3134305|NCT03576066|Experimental|ABI-H0731 + SOC NUC|Virologically suppressed participants will receive ABI-H0731 along with SOC NUC (ETV, TDF or TAF) tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
3134306|NCT03576066|Active Comparator|Placebo + SOC NUC|Virologically suppressed participants will receive matching placebo tablets and continue their SOC NUC (ETV, TDF or TAF) for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
3134307|NCT03576118|Experimental|Deep neuromuscular block|Deep neuromuscular relaxation and low pressure pneumoperitoneum
3134308|NCT03576118|Active Comparator|Moderate neuromuscular block|Moderate neuromuscular relaxation and standard pressure pneumoperitoneum
3134309|NCT03576183|Active Comparator|VLA1701|"VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)~The vaccine is administered orally in 2 doses about 1 week apart."
3134310|NCT03576183|Placebo Comparator|Placebo|"The buffer component of VLA1701 will be used as Placebo.~The vaccine is administered orally in 2 doses about 1 week apart."
3134311|NCT03576716|Experimental|Study Population|D6-25-hydroxyvitamin D3 with vitamin D3
3134312|NCT03576768|Experimental|Real cTBS to the vmPFC|Ten sessions of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
3134313|NCT03576768|Sham Comparator|Sham cTBS to the vmPFC|Ten sessions of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
3134314|NCT03576768|Experimental|Real iTBS to the dlPFC|Ten sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
3134315|NCT03576768|Sham Comparator|Sham iTBS to the dlPFC|Ten sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
3134316|NCT03577171|Experimental|ABI-H0731 + SOC ETV|Participants with cHBV who are currently not being treated will receive ABI-H0731 along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to continue open-label ABI-H0731 for up to an additional year if necessary.
3134317|NCT03577171|Experimental|Placebo + SOC ETV|Participants with cHBV who are currently not being treated will receive matching placebo along with SOC ETV tablets orally for 24 weeks. Eligible participants may enter a separate extension study after Week 24 to start treatment on open-label ABI-H0731 for up to a year if necessary.
3134318|NCT03577275|Placebo Comparator|Placebo oral capsule|Single dose of placebo to match NST-4016
3134319|NCT03577275|Active Comparator|Moxifloxacin 400mg|Single 400mg dose of active comparator moxifloxacin (open label)
3134320|NCT03577275|Experimental|NST-4016 600mg|Likely therapeutic dose of NST-4016
3134321|NCT03577275|Experimental|NST-4016 2000mg|Supratherapeutic dose of NST-4016
3134322|NCT03577730|Experimental|Experimental|Prepared intravenous piggyback solution of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
3134323|NCT03577730|Placebo Comparator|Control|Prepared intravenous piggyback solution of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants who are randomized to this group.
3134324|NCT03578146|Experimental|Module 2 (210 mg)|210 mg andexanet IV bolus administered over 7 minutes (~30 mg/min)
3134325|NCT03578146|Experimental|Module 2 (420 mg)|420 mg andexanet IV bolus administered over 14 minutes (~30 mg/min)
3134326|NCT03578146|Experimental|Module 2 (600 mg)|600 mg andexanet IV bolus administered over 20 minutes (~30 mg/min)
3134327|NCT03578146|Experimental|Module 2 (720 mg bolus + 240 mg infusion)|720 mg IV bolus administered over 24 minutes [~30 mg/min] followed by 240 mg continuous IV infusion [4 mg/min over 60 min)
3134328|NCT03578146|Experimental|Module 2 (800 mg bolus + 960 mg infusion)|800 mg IV bolus administered over 26.7 minutes [~30 mg/min] followed by 960 mg continuous IV infusion [8 mg/min over 120 min]
3134329|NCT03578146|Experimental|Module 2 Placebo|Placebo administered intravenously (IV) as a bolus or a bolus followed by continuous fusion.
3134330|NCT03578549||Oximetry testing of healthy teeth and those requiring removal|"To assess the ability of pulse oximeter to assess the presence of pulse in teeth and to correlate pulse oximeter readings with conventional pulp testing measures including cold test, electrical pulp test, percussion and palpation testings, pulse oximeter will be used with a special holding frame, for 15-30 seconds.~Note: the reading will not affect clinical practice; it is simply to gather data to see if pulse oximetry can facilitate diagnostic practices in the future"
3134331|NCT03578926|Experimental|fanfilcon A toric lens|Randomized participants will wear fanfilcon A toric contact lenses bilaterally for two weeks then switch to senofilcon A toric contact lenses for another two weeks.
3134332|NCT03578926|Active Comparator|senofilcon A toric lens|Randomized participants will wear senofilcon A toric contact lenses bilaterally for two weeks then switch to fanfilcon A toric contact lenses for another two weeks.
3134333|NCT03579290|Experimental|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use, Coping with craving, Substance refusal skills, Seemingly irrelevant decisions, Planning for emergencies, and Problem-solving skills. Staying Safe"
3134334|NCT03579433|Experimental|ORA with VerifEye+|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
3134335|NCT03579433|Active Comparator|Barrett Toric Calculator|First surgical eye randomly assigned to Acrysof® IQ Toric IOL and ORA with VerifEye+ or Acrysof® IQ Toric IOL and Barrett Toric Calculator, with the second surgical eye (fellow eye) assigned to the alternative group.
3134336|NCT03579719|Experimental|Balovaptan + Itraconzole|Dosing in Period 1 was separated by at least a 7 day washout period before dosing starts in Period 2. Participants received the study drugs in 2 periods over a total of 37 days.
3134337|NCT03579940|Experimental|Lasmiditan - Japanese|Single (50 milligram (mg), 100 mg, 200 mg, 400 mg) and repeated (2 × 200 mg) doses of Lasmiditan administered orally in up to three of three study periods.
3134338|NCT03579940|Placebo Comparator|Placebo - Japanese|Single and repeated (2 X placebo) doses of Placebo administered orally in up to one of three study periods.
3134339|NCT03579940|Experimental|Lasmiditan - Caucasian|Single (50 mg, 100 mg, 200 mg) dose of Lasmiditan administered orally in up to three of three study periods.
3134340|NCT03579940|Placebo Comparator|Placebo - Caucasian|Single dose of Placebo administered orally in up to one of three study periods.
3134341|NCT03580343|Experimental|Tofacitinib Treatment|11mg extended-release tofacitinib, once daily, oral
3148805|NCT00158769|Experimental|Healthy subjects|Subjects will be matched as closely as possible to the group of moderate hepatic subjects for gender, age and body mass index (BMI). Subjects will be administered 25 mg/kg/hr GR270773 as a loading dose for 2 hours followed by a maintenance infusion of 5 mg/kg/hr for 70 hours. Following a washout period of 21 days, the subjects will then receive a loading dose of 75 mg/kg/hr for 2 hours followed by a maintenance dose of 12.5 mg/kg/hr of GR270773 for 70 hours.
3134342|NCT03581084|Experimental|N-acetylcysteine|"This study will look at the effects of a medication, called n-acetylcysteine or NAC, on lung function. NAC is already approved for use in people with chronic airway conditions, including asthma. However, it is not known who this medication works best in. We believe this medication will likely have the most benefit in people with asthma that have mucus in their airways or mucus plugging. Initial study procedures will include lung function measurements, a low dose CT scan, a blood draw, and a sputum induction. The CT lung imaging will identify asthmatics with mucus plugs."
3134343|NCT03581097|Experimental|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of intravenous regional anesthesia
3134344|NCT03581097|No Intervention|Control Group|Patients assigned to this control group were not shown the video and underwent an otherwise identical preoperative preparation procedure.
3134345|NCT03581474|Other|aScope 3 Large|Bronchoscopic procedure
3134346|NCT03581825|Experimental|Test/Control|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
3134347|NCT03581825|Experimental|Control/Test|Myopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
3134348|NCT03582215|Experimental|Part 1: Cream|"Part 1: Cream~Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule"
3134349|NCT03582215|Experimental|Part 1: Lotion|"Part 1: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
3134350|NCT03582215|Experimental|Part 1: Spray 1|"Part 1: Spray 1~Ingredients: 3% Avobenzone; 6% Oxybenzone; 2.35% Octocrylene; 15% Homosalate; 5% Octisalate"
3134351|NCT03582215|Experimental|Part 1: Spray 2|"Part 1: Spray 2~Ingredients: 3% Avobenzone; 5% Oxybenzone; 10% Octocrylene"
3134352|NCT03582215|Experimental|Part 2: Lotion|"Part 2: Lotion~Ingredients: 3% Avobenzone; 4% Oxybenzone; 6% Octocrylene"
3134353|NCT03582215|Experimental|Part 2: Aerosol Spray|"Part 2: Aerosol Spray~Ingredients: 3% Avobenzone; 6% Oxybenzone; 10% Octocrylene; 15% Homosalate; 5% Octisalate"
3134354|NCT03582215|Experimental|Part 2: Nonaerosol Spray|"Part 2: Nonaerosol Spray~Ingredients: 3% Avobenzone; 10% Octocrylene; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
3134355|NCT03582215|Experimental|Part 2: Pump Spray|"Part 2: Pump Spray~Ingredients: 3% Avobenzone; 10% Homosalate; 5% Octisalate; 7.5% Octinoxate"
3134356|NCT03582553|Experimental|150 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 150 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
3134357|NCT03582553|Experimental|300 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 300 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
3134358|NCT03582553|Experimental|600 mg dose|Blood will be drawn at at 0, 2, 3, 3.5, 4, 4.5, 6, 8,12, and 24 hours to measure serum naringenin concentrations in response to a single 600 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
3134359|NCT03582553|Experimental|900 mg dose|Blood will be drawn at at 0, and 4 hours to measure serum naringenin concentrations in response to a single 900 mg oral dose of an extract of Citrus sinensis (sweet orange) containing naringenin and its precursor naringin.
3134360|NCT03582553|Placebo Comparator|Placebo|Subjects in the first cohort will receive 150 mg and 300 mg ascending doses of naringenin and subjects in the second cohort will receive 600 mg and 900 mg ascending doses of naringenin. Each cohort will also have a placebo group.
3134361|NCT03582813|Experimental|Self-directed care|Subjects receive traditional behavioral health and non-traditional services via a self-directed care model in which they develop a person-directed plan and create a budget for the purchase of medically necessary goods and services. Program staff acting as service brokers help them secure needed goods and services from within or outside the public behavioral health provider system. A fiscal intermediary manages financial resources to pay providers and enable the purchase of approved goods..
3134362|NCT03582813|Active Comparator|Services as usual|Subjects receive traditional behavioral health services as usual via the traditional service delivery system and its network of providers.
3134363|NCT03582826|Experimental|MEBO/PATM cohort|"Nutrition counselling and stress-management counselling behavioral interventions will be given to minimize subjects symptoms and observe corresponding changes in their microbiomes.~The following subcohorts were formed for analyses of different outcomes: MEBO and PATM subcohorts, TMAU positive and negative subcohorts, Active MEBO, Active PATM, Regression and Remission; MEBO/PATM Cohort that Submitted Gut Samples, MEBO/PATM cohort that answered QoL survey, MEBO/PATM Subcohort that observed and documented both flareups and improvements."
3134364|NCT03582826|No Intervention|non-MEBO cohort|Data volunteers that never experienced episodes of uncontrollable socially debilitating metabolic body odor (MEBO) or PATM
3148806|NCT00158782|Experimental|Cohort 1|Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.
3148807|NCT00158782|Experimental|Cohort 2|Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.
3134365|NCT03582943|Experimental|Remote limb ischemic conditioning (RLIC)|RLIC is achieved via blood pressure cuff inflation to 20 mmHg above systolic blood pressure on the dominant arm. RLIC requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. RLIC is performed on visits 1-7.
3134366|NCT03582943|Sham Comparator|Sham conditioning|Sham conditioning is achieved via blood pressure cuff inflation to 10 mmHg under diastolic blood pressure on the dominant arm. Sham conditioning requires 45 minutes and involves 5 cycles of 5 minutes blood pressure cuff inflation followed by alternating 5 minutes of cuff deflation. Sham conditioning is performed on visits 1-7.
3134367|NCT03583372|Experimental|Vibegron + Placebo to match Tolterodine|
3134368|NCT03583372|Active Comparator|Tolterodine + Placebo to match vibegron|
3134369|NCT03583385|Experimental|First Glucophage XR (Test), Then Glucophage XR (Comparator)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
3134370|NCT03583385|Experimental|First Glucophage XR (Comparator), Then Glucophage XR (Test)|Participants received single oral dose of 750 milligram (mg) Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) in treatment period 1 followed by single oral dose of 750 mg Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) in treatment period 2 under fasting conditions. The two periods were separated by a 7-day wash-out period.
3134371|NCT03583450|Experimental|Perioperative virtual reality headset|Perioperative virtual reality headset with mobile app and routine anesthetic care
3134372|NCT03583450|No Intervention|Control|Routine anesthetic care
3134373|NCT03583606|Experimental|ChAd3-EBO-Z + ChAd3-EBO-Z|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and ChAd3-EBO-Z (2 x 10^11 vp) intramuscularly into the opposite arm on Day 8, n = 20
3134374|NCT03583606|Experimental|ChAd3-EBO-Z + Placebo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and placebo intramuscularly into the opposite arm on Day 8, n = 20
3134375|NCT03583606|Experimental|ChAd3-EBO-Z + MVA- BN-Filo|ChAd3-EBO-Z (2 x 10^11 virus particles (vp)) intramuscularly into the deltoid on Day 1 and MVA-BN-Filo (1 x 10^8 Infectious Units (IU)) intramuscularly into the opposite arm on Day 8, n = 20
3134376|NCT03584009|Experimental|Venetoclax + Fulvestrant|Participants were administered Venetoclax 800mg orally once daily (QD) and Fulvestrant 500mg intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
3134377|NCT03584009|Active Comparator|Fulvestrant|Participants were administered Fulvestrant 500mg only intramuscularly (IM) on Day 1 and 15 of Cycle 1 and Day 1 of subsequent cycles (Cycle length = 28 days).
3148808|NCT00158782|Experimental|Cohort 3|Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.
3148809|NCT00158782|Experimental|Cohort 4|Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.
3134378|NCT03584100|Experimental|Patients with prior axillary lymph node dissection|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
3134379|NCT03584100|Active Comparator|Healthy Volunteers|Participants raise their arm for 15 minutes, then wear a tourniquet 8000 inflated for 25 minutes. Hand volume is measured by aqueous volumeter at baseline, after use of the tourniquet and every 5 minutes for 30 minutes, while the arm is placed at a raised on head position, shoulder-level brace position, or at waist in a sling position.
3134380|NCT03585244||Individuals with Prader-Willi Syndrome|Individuals with Prader-Willi Syndrome aged 12 and over will be recruited to gather data on weekly weight over six months
3134381|NCT03585296|Experimental|ATI-502|ATI-502 topical solution applied daily for four weeks.
3134382|NCT03585504|Experimental|Intervention group|Patients will undergo etonogestrel contraceptive implant insertion prior to hospital discharge per package instructions.
3134383|NCT03585504|Active Comparator|Control Group|These patients will receive an appointment to undergo etonogestrel contraceptive implant insertion at the postpartum visit occuring approximately six weeks after delivery as is standard care in our institution.
3134384|NCT03585543|Experimental|Single group intervention arm|
3134385|NCT03585712|Other|Arm A: Delayed then Missed Pill|Treatment period 2, Day 42 +/- 3 days: 6 hour delayed intake of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: missed pill of Norgestrel 75 mcg
3134386|NCT03585712|Other|Arm B: Missed then Delayed Pill|Treatment period 2, Day 42 +/- 3 days: missed pill of Norgestrel 75 mcg Treatment period 3, Day 70 +/- 3 days: 6 hour delayed intake of the pill of Norgestrel 75 mcg
3134387|NCT03585790|Other|Multifocal Optics first, then Single Vision Optics|First Intervention (1 week) Second Intervention (1 week)
3134388|NCT03585790|Other|Single Vision Optics first, then Multifocal Optics|First Intervention (1 week) Second Intervention (1 week)
3134389|NCT03585959|Experimental|Fluoroscopic Navigation Arm|An Electromagnetic navigation bronchoscopy (ENB) system which provides enhanced three-dimensional fluoroscopy to improve lesion visibility and to compensate for CT-to-body divergence, with an integrated real-time local registration feature allowing the operator to update the catheter position relative to the target during the procedure.
3134391|NCT03586167|Experimental|LID014341|LID014341 contact lenses worn bilaterally (in both eyes) for 30 days on a daily wear basis
3134392|NCT03586167|Active Comparator|Biofinity|Comfilcon A contact lenses worn bilaterally for 30 days on a daily wear basis
3134393|NCT03586544|Experimental|Albuterol first|Order albuterol and then interval warm up (IWU)
3134394|NCT03586544|Experimental|Interval warm-up first|Order is interval warm up (IWU) and then albuterol
3134395|NCT03586583||FBP (old processing)|Filtered back projection; old processing.
3134396|NCT03586583||ISR (new processing)|Iterative super resolution; new processing.
3134397|NCT03586648|Experimental|Test/Control|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Test/Control. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
3134398|NCT03586648|Experimental|Control/Test|Hyperopic subjects who are habitual soft contact lens wearers between the ages of 40 and 70 years of age, will be randomized to sequence Control/Test. Alternative Spherical lenses will be used if optimization cannot be achieved with the Multifocal lenses.
3134399|NCT03586726|Experimental|Balovaptan + Rifampicin|Participants received the study drugs in 2 periods. There was a minimum of a 14-day to a maximum of a 21-day washout between the last dose in Period 1 and the first dose in Period 2.
3134400|NCT03586830|Experimental|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase.
3134401|NCT03586830|Experimental|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase.
3134402|NCT03586830|Experimental|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase.
3134403|NCT03586830|Placebo Comparator|Placebo|Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.
3134404|NCT03587207|Experimental|MenABCWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).
3134405|NCT03587207|Active Comparator|rMenBOMV+ACWY_S Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).
3134406|NCT03587207|Active Comparator|rMenBOMV+ACWY_D Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).
3134407|NCT03587207|Active Comparator|rMenBOMV Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).
3134408|NCT03587207|Active Comparator|MenACWY Group|Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.
3134409|NCT03587428|Experimental|Zinc-A toothpaste|In this arm, participants received Zinc-A toothpaste (test product 1) in the form of slurry.
3134410|NCT03587428|Experimental|Zinc-B toothpaste|In this arm, participants received Zinc-B toothpaste (test product 2) in the form of slurry.
3134411|NCT03587428|Other|Mineral Water|In this arm, participants received mineral water.
3134412|NCT03587974|Experimental|REACH-VN|In-home psychosocial intervention to enhance caregiver knowledge and skills and to reduce stress delivered in 4-6 sessions over the course of 2-3 months
3134413|NCT03587974|No Intervention|Enhanced control|Single session with education about nature of dementia
3134414|NCT03588572|Experimental|Venlafaxine Group|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation ( each containing venlafaxine 75mg), 1 capsule per day, until 4 weeks after randomization.
3134415|NCT03588572|No Intervention|Controlled group|the patients in controlled group do not use the drug during the experiment, and the other treatments are same as the venlafaxine group.
3134416|NCT03588741|Experimental|Turoctocog alfa|
3134417|NCT03588806|Experimental|Xtampza ER (oxycodone) Treatment|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study. A standard conversion table will be used to calculate the dose of Xtampza ER that is equivalent to the subject's current opioid medication dosage. Subjects will be converted to 75% of the calculated dose for the first 7-10 days and then to 100% of the calculated dose for the remaining 3 weeks of the study. The Xtampza ER dosage may be modified at the discretion of the PI to ensure the safety of the subject. As per manufacturer recommendations, subjects will be instructed to open the capsules, sprinkle the microspheres onto soft food such as pudding or applesauce, and then consume the food.
3134418|NCT03588910|Active Comparator|Number of oxycodone tablets typically prescribed|Participants will receive a prescription for 10 tablets of 5 mg oxycodone (1 tablet every 6 hours as needed) as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
3134419|NCT03588910|Experimental|Half the number of oxycodone tablets typically prescribed|Participants will receive 5 tablets of 5mg oxycodone as well as 50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed) and 25 tablets ibuprofen 600mg (1tablet every 6 hours as needed).
3148810|NCT00158782|Experimental|Cohort 5|Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.
3148811|NCT00158782|Experimental|Cohort 6|Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.
3134420|NCT03589469|Experimental|Loncastuximab tesirine|Participants will receive loncastuximab tesirine as an IV infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg Q3W for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurs first.
3134421|NCT03589807|Experimental|Heterologous Arm 1|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=30
3134422|NCT03589807|Experimental|Heterologous Arm 2|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + ASO3 adjuvant administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
3134423|NCT03589807|Experimental|Heterologous Arm 3|3.75 mcg per 0.5 ml dose of 2013 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
3134424|NCT03589807|Experimental|Homologous Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 22. PBS diluent may be used to achieve targeted dosages. N=30
3134425|NCT03589807|Experimental|Homologous Arm 2|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 adjuvant administered intramuscularly on Day 1 and Day 121. PBS diluent may be used to achieve targeted dosages. N=30
3134426|NCT03589807|Experimental|Homologous Arm 3|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 IIV + AS03 Adjuvant administered intramuscularly on Day 1 and 15 mcg per 0.5 ml dose of 2017 A/H7N9 IIV administered intramuscularly on Day 121. PBS diluent may be used to achieve targeted dosages. N=30
3134427|NCT03589885|Placebo Comparator|Placebo 2 mL auto-injector|Placebo to secukinumab s.c., provided in 2 mL auto-injector form
3134428|NCT03589885|Placebo Comparator|Placebo 1 mL prefilled syringe|Placebo to secukinumab s.c., provided in 2 * 1 ml prefilled syringe form
3134429|NCT03589885|Experimental|Secukinumab 2 mL auto-injector|Secukinumab 300 mg provided in 2 mL auto-injector form
3134430|NCT03589885|Active Comparator|Secukinumab 1 mL prefilled syringe|Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL
3134431|NCT03590613|Experimental|Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID|The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
3148812|NCT00158782|Experimental|Cohort 7|Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.
3148813|NCT00158782|Experimental|Cohort 8|Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.
3134432|NCT03590613|Experimental|Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
3134433|NCT03590613|Experimental|Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
3134434|NCT03590613|Experimental|Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID|The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.
3134435|NCT03591068|Experimental|OPN-375 186 mcg BID|
3134436|NCT03591146|Experimental|TLC590 190mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3134437|NCT03591146|Experimental|TLC590 380mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3134438|NCT03591146|Experimental|TLC590 570mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3134439|NCT03591146|Experimental|TLC590 475mg|TLC590 (Ropivacaine Liposome Injectable Suspension) is a sustained-release liposome formulation of ropivacaine, white aqueous suspension with ropivacaine concentration at approximately 19 mg/mL.
3134440|NCT03591146|Active Comparator|Naropin 150mg|Naropin injection contains ropivacaine hydrochloride (HCl). Strength: 150mg/ 30mL (5 mg/mL) Size: 30mL fill, in a 30mL single dose vial
3134441|NCT03591406|Experimental|Ferric carboxymaltose (FCM)|Subjects treated with FCM given by IV injection or drip infusion
3134442|NCT03591406|Active Comparator|Iron sucrose (IS)|Subjects treated with IS given by IV injection or drip infusion
3134443|NCT03592121|Experimental|AB-101|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
3134444|NCT03592121|Placebo Comparator|Placebo|Apply to both nipple/areola regions approximately 1 hour prior to sexual activity
3134445|NCT03592186|Experimental|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program (www.parentingwisely.com), paired with engagement strategies: up to four in-person coaching sessions, daily text messages, and access to an online networking forum.
3134446|NCT03592186|Active Comparator|Treatment as Usual|"The active comparator is defined as residential treatment services as usual.~At short-term facility, average length of stay was 6-10 days. At long-term facility, average length of stay was 30-45 days."
3134447|NCT03592745|Experimental|active tVNS + robotic arm therapy|Transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
3134448|NCT03592745|Sham Comparator|sham tVNS + robotic arm therapy|Sham (placebo) transcutaneous Vagus Nerve Stimulation (tVNS) will be delivered non-invasively via the ear (targeting the auricular branch of the vagus nerve) during robotic arm therapy sessions lasting ~60 minutes, 3x per week for 3 weeks.
3134449|NCT03593200|Experimental|Experimental: Cohort 1|270 mg/day (up to 360 mg/day from Day 29) from Day 1 to Day 364*
3134450|NCT03593538|Experimental|Low Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 500 mg and 1 Placebo capsule per day; Days 15-23: Metformin 500 mg and 2 Placebo capsules per day
3134451|NCT03593538|Experimental|High Dose Metformin|Days 1-7: Metformin 500 mg per day; Days 8-14: Metformin 1000 mg per day; Days 15-23: Metformin 1500 mg per day
3134452|NCT03593538|Placebo Comparator|Placebo|Days 1-7: 1 Placebo capsule per day; Days 8-14: 2 Placebo capsules per day; Days 15-23: 3 Placebo capsules per day
3134453|NCT03593876|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
3134454|NCT03593902|Experimental|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, fludarabine, cyclophosphamide, Mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
3148814|NCT00158782|Experimental|Cohort 9|Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.
3134455|NCT03594045|Experimental|Apixaban for HIT|Patients with Heparin Induced Thrombocytopenia (HIT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 30 days.
3134456|NCT03594045|Experimental|Apixaban for HITT|Patients with Heparin Induced Thrombocytopenia with Thrombosis (HITT) will receive Apixaban, at an initial dose of 10 mg orally twice a day for 7 days followed by 5 mg twice a day for a total of 3 months.
3134457|NCT03594227|Active Comparator|400mg BID (Low dose)|ATI-501 low dose - oral administration
3134458|NCT03594227|Active Comparator|600mg BID (Mid dose)|ATI-501 mid dose - oral administration
3134459|NCT03594227|Active Comparator|800mg BID (High dose)|ATI-501 high dose - oral administration
3134460|NCT03594227|Placebo Comparator|Placebo|Placebo - oral administration
3134461|NCT03594500|Experimental|Intervention: PockeTalker|Consenting participants will be randomly assigned to the intervention group while receiving care in the emergency department
3134462|NCT03594500|Other|Control: No PockeTalker|Consenting participants will be randomly assigned to the control group while receiving care in the emergency department
3134463|NCT03595176|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
3134464|NCT03595215|Experimental|TENS Treatment Arm|This study is an early feasibility study which will be treating all patients at least 3 times per week, for 8 weeks, using the device.
3134465|NCT03595280|No Intervention|Control|Participants in the control group receive no study messages
3134466|NCT03595280|Experimental|Untailored Messages|Participants in the untailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones.
3134467|NCT03595280|Experimental|Tailored Messages|Participants in the tailored message group receive mobile multimedia service messages conveying the risks of hookah tobacco on their mobile phones that are personalized to their hookah tobacco use behavior and beliefs.
3134468|NCT03595449|Active Comparator|Lidocaine jelly|This is the group that will have lidocaine jelly applied during Mohs surgery
3134469|NCT03595449|Sham Comparator|Surgilube|This is the group that will have surgilube (placebo) applied during Mohs surgery
3134470|NCT03595579|Experimental|AXS-05|
3134471|NCT03595579|Active Comparator|Bupropion|
3134472|NCT03595618|Experimental|GLPG1972 75 mg|Participants received 1 film-coated tablet of GLPG1972 75 mg and 3 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
3134473|NCT03595618|Experimental|GLPG1972 150 mg|Participants received 2 film-coated tablets of GLPG1972 75 mg (total dose 150 mg) and 2 GLPG1972 matching placebo tablets, orally once daily for 52 weeks.
3134474|NCT03595618|Experimental|GLPG1972 300 mg|Participants received 4 film-coated tablets of GLPG1972 75 mg (total dose 300 mg), orally once daily for 52 weeks.
3134475|NCT03595618|Placebo Comparator|Placebo|Participants received 4 film-coated tablets of GLPG1972 matching placebo, orally once daily for 52 weeks.
3134476|NCT03595904|Experimental|E-Motivate group|Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
3134477|NCT03595904|Active Comparator|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
3134478|NCT03596151|Experimental|Click Device|One self collected vaginal swab for Click Device testing. Three health care provider collected vaginal swabs for comparator testing.
3134479|NCT03596177|Experimental|MEDI0382|Participants will receive subcutaneous (SC) injection of placebo for 16 days in the single-blind treatment period, and then SC injection of MEDI0382 titrated up to 300 μg for 42 days (100 μg for 4 days, followed by 200 μg for 4 days, and finally 300 μg for 34 days) in double-blind treatment period.
3134480|NCT03596177|Placebo Comparator|Placebo|Participants will receive SC injection of placebo for 16 days in the single-blind treatment period, and then SC injection of placebo matched to MEDI0382 for 42 days in double-blind treatment period.
3134481|NCT03596723|Experimental|KPI-121 1% BID (twice daily)|
3134482|NCT03596723|Active Comparator|Prednisolone acetate QID (four times daily)|
3134483|NCT03597009|Experimental|Open-label, single-arm Phase I|Talimogene laherparepvec (TVEC) administered into the intrapleural space of subjects with malignant pleural effusion (MPE) via a pleurX catheter with or without nivolumab
3134484|NCT03597022|Experimental|BAY1093884 100mg|Subjects received BAY1093884 100 mg once a week until premature termination of the study
3134485|NCT03597022|Experimental|BAY1093884 225mg|Subjects received BAY1093884 225 mg once a week until premature termination of the study
3134486|NCT03597022|Experimental|BAY1093884 400mg|Subjects received BAY1093884 400mg once a week until premature termination of the study
3134487|NCT03597061|Experimental|Healthy Start to Feeding Intervention|Participants and their parents will participate in a 3 session intervention targeting healthy introduction of complementary foods. Intervention sessions will occur when the infant is 4, 6, and 9 months of age.
3134488|NCT03597061|No Intervention|Control|Participants and their parents will complete pre- and post-treatment period study visits to assess study outcomes. They will receive no intervention.
3134489|NCT03597139|Experimental|Voclosporin ophthalmic solution (VOS)|0.2% VOS, Twice Daily (BID), both eyes for 28 days
3134490|NCT03597139|Active Comparator|Comparator|0.05% cyclosporine ophthalmic emulsion (Restasis®) BID, both eyes for 28 days
3134491|NCT03597178|Experimental|senofilcon A|Subjects that are of at least 60 years of age and non-habitual contact lens wearers will receive instructions to insert and remove a contact lens from each eye.
3134492|NCT03597295|Experimental|INCMGA00012|
3134493|NCT03597347|Experimental|Group 1|Participants with chronic pulmonary MAC or MABSC infection who have not consistently achieved negative NTM sputum cultures while currently on a multidrug NTM guideline-based antimycobacterial regimen, which has been ongoing for at least 9 months prior to the Baseline visit.
3134494|NCT03597347|Experimental|Group 2|Participants with chronic pulmonary MAC or MABSC infection who remain sputum culture positive but have stopped a multidrug NTM guideline-based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance.
3134495|NCT03597347|Experimental|Group 3|Participants with chronic pulmonary MAC or MABSC infection not meeting recommendations for treatment with a multidrug NTM guideline-based antimycobacterial regimen based on failure to meet American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) criteria for NTM pulmonary disease (i.e. absence of radiologic findings and clinical symptoms beyond what is expected from underlying CF).
3134496|NCT03597529|Experimental|Low-Dose Melatonin (mg)|melatonin 2mg (equal to or over 40kg) melatonin 1mg (under 40kg) Melatonin: melatonin
3134497|NCT03597529|Experimental|High-Dose Melatonin (mg)|melatonin 8mg (equal to or over 40kg) melatonin 4mg (under 40kg) Melatonin: melatonin
3134498|NCT03597789|Other|Helping the NonCompliant Child Treatment|"Families will participate in an average of 8 to 12 weeks of Behavioral Parent Training (BPT), by way of the standard-of-care training program Helping the Noncompliant Child (HNC) via weekly sessions and mid-week calls."
3134499|NCT03598647|Active Comparator|Physical activity information - for non-exercisers only|Non-exercisers randomized to this condition will receive basic information about physical activity. This includes the national physical activity guidelines,clarification of 'moderate-intensity', exercise safety, and the progression of physical activity within the weight loss program.
3134500|NCT03598647|Experimental|Affect and physical activity - for non-exercisers only|Non-exercisers randomized to this condition will receive the same basic information about physical activity as described above, but they will also receive a brief intervention focused on affective responses to exercise.
3134501|NCT03598647|No Intervention|Exercisers|Engaging in >=150 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
3134502|NCT03598647|No Intervention|Non-exercisers|Engaging in <30 min/week of moderate-intensity exercise over the past 6 months and a most recent typical week
3134503|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 0.7 mg (0.05 mg/mL concentration)|Each patient will receive a single dose of 0.7 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
3134504|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 2.1 mg (0.15 mg/mL concentration)|Each patient will receive a single dose of 2.1 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
3134505|NCT03599089|Active Comparator|CA-008 (vocacapsaicin) 4.2 mg (0.3 mg/mL concentration)|Each patient will receive a single dose of 4.2 mg CA-008 injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
3134506|NCT03599089|Placebo Comparator|Placebo|Each patient will receive a single dose of CA-008 vehicle (identical to active treatment but without CA-008) injected during an elective Bunionectomy with a multimodal analgesia regimen including a Nonsteroidal anti-inflammatory drug (NSAID) and regional Mayo block with bupivacaine.
3134507|NCT03599193|Experimental|DFD-03 Lotion|DFD-03 Lotion will be applied to the affected areas twice daily for 1 minute and rinsed off. 29 subjects will be enrolled into this arm.
3134508|NCT03599193|Active Comparator|Tazorac Cream|Tazorac Cream will be applied to the affected areas once daily and left on for ~12 hours. 29 subjects will be enrolled into this arm.
3134509|NCT03599271|Experimental|Drug-Coated Device|Randomized cohort: Drug-Coated Device to dilate randomized frontal sinus ostium.
3134510|NCT03599271|Active Comparator|Control Sinus Dilation Device|Randomized cohort: Control Device to dilate randomized contralateral frontal sinus ostium.
3134511|NCT03599271|Experimental|PK cohort- Drug-Coated Device|PK cohort: One Drug-Coated Device to dilate both frontal sinus ostia.
3134512|NCT03599349|Experimental|Microfocused ultrasound w/ visualization|Each subject to receive a full face and neck area treatment using a standard 800 line treatment with set energy levels (0.90 joules for the 4-4.5mm transducer, 0.30 joules for the 7-3.0mm/7-3.0N transducers and 0.75 joules for the 7-4.5mm transducer)
3134513|NCT03599362|Experimental|Multi Agent Chemotherapy Cancer Patients|Subjects will be enrolled into this study following completion of 2-6 months of multi agent chemotherapy with documentation of stable or responsive disease.
3134514|NCT03600142|No Intervention|Standard of Care (SoC)|Participants randomized to the control condition will receive the standard HIV counseling protocol in the clinic, which is administered by clinic nurses. According to the Tanzania PMTCT guidelines, HIV pre-test counseling should provide education about HIV and prepare a woman (and her partner, if present) for HIV testing. For anyone who tests positive for HIV, counseling should help the woman/couple to accept an HIV test result and discuss implications for treatment.
3134515|NCT03600142|Experimental|SoC + stigma counseling (Maisha)|Participants randomized to the intervention condition will receive the SoC counseling plus Maisha, a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. Maisha involves a video delivered to all women prior to HIV testing, and, if a woman tests positive for HIV, two counseling sessions. If a male partner is present with the women, he may also be enrolled and participate in the first two counseling sessions together with the woman.
3134516|NCT03600194|Active Comparator|PowerSleep Stim|In this arm soft audio tones (below 65dB) will be administered by the PowerSleep Stim Device during deep sleep as determined by the functionality of the device.
3134517|NCT03600194|Placebo Comparator|PowerSleep Sham|This PowerSleep Sham device is the same as the PowerSleep Stim device, however, it can be configured in a mode that does not play audio tones
3134518|NCT03600194|Active Comparator|Northwestern Stim|The NorthWestern Stim device is set up will function similarly to the PowerSleep prototype. Acoustic stimulation provided by headphones with an audible soft volume that do not result in arousals will be used.
3134519|NCT03600194|Placebo Comparator|Northwestern Sham|The Northwestern Sham device will be the same as the Northwestern Stim set up, however no audio tones will be played.
3134520|NCT03600376|Experimental|Ryanodex and Standard of Care|In addition to Standard of Care measures, Ryanodex (dantrolene sodium) for injectable suspension; 250 mg/vial will be administered.
3134521|NCT03600376|Other|Standard of Care only (SOC)|Standard of Care treatment will consist of the immediate start of cooling measures.
3134522|NCT03600428|Experimental|Live Attenuated Influenza Vaccine (LAIV)|Participants will receive one dose of live attenuated influenza vaccine via intranasal spray (administer approximately one half of the contents of the single-dose intranasal sprayer into each nostril, each sprayer contains 0.2 mL of vaccine)).
3134523|NCT03600428|Active Comparator|Inactivated Influenza Vaccine (IIV)|Participants will receive one dose of inactivated influenza vaccine via intramuscular injection (0.5 mL).
3134524|NCT03601052|Experimental|Remlarsen - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
3134525|NCT03601052|Placebo Comparator|Placebo - Intradermal|Six doses remlarsen (5.3 mg) over a period of 2 weeks at the site of one excisional skin wound and six doses Placebo over the same period at the site of a second excisional skin wound. Each subject will serve as their own simultaneous control.
3134526|NCT03601117|Experimental|Dorsolateral Prefrontal Cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC), for 10 sessions per day for up to 5 days.
3134527|NCT03601117|Experimental|Anterior Cingulate Cortex|The accelerated theta burst stimulation protocol will be applied to the left anterior cingulate cortex (ACC), for 10 sessions per day for up to 5 days.
3134528|NCT03601715|Active Comparator|Coplanar|Electrode placed side by side on the same aspect of the right tight.
3134529|NCT03601715|Active Comparator|Contraplanar|Electrode placed over opposite aspects of the right tight.
3134530|NCT03601715|Active Comparator|Longitudinal|One electrode is placed at each end of the limb in opposite aspects of the tight.
3134531|NCT03602053|Experimental|ROTAVAC 5D|Bharat Biotech International Ltd's new Rotavirus vaccine, ROTAVAC 5D is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. 5D is in liquid form.
3134532|NCT03602053|Experimental|ROTAVAC®|Bharat Biotech International Ltd's licensed rotavirus vaccine, ROTAVAC® is a live, attenuated G9P[11] monovalent vaccine at a dose of 0.5mL containing NLT log 10^5.0 focus forming units (FFU) per dose. ROTAVAC® is in frozen form and is thawed till fully liquid prior to administration.
3134533|NCT03602053|Active Comparator|Rotarix®|GSK Biologicals' licensed rotavirus vaccine, Rotarix® is a live attenuated RIX4414 strain of human rotavirus of the G1P[8] type containing not less than 106.0 CCID50 (cell culture infectious dose 50%) of the RIX 4414 strain of human rotavirus.
3134534|NCT03602339|Experimental|Arm 1_Suspected CNS-lesion|Patients with suspected or confirmed CNS-lesions underwent unenhanced MRI, and contrast-enhanced MRI after gadoterate injection.
3134535|NCT03602339|Experimental|Arm 2_Confirmed CNS-lesion|Patients with gadoterate-confirmed CNS-lesions (subgroup of Arm 1) underwent a second unenhanced MRI, and contrast-enhanced MRI after gadobutrol injection.
3134536|NCT03602482|Experimental|Standing|Participants will complete cognitive testing while standing.
3134537|NCT03602482|Active Comparator|Supine|Participants will complete cognitive testing while supine.
3134538|NCT03603028|Experimental|Exergaming|
3134539|NCT03603106|Experimental|Part I (Phase I)|In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
3134540|NCT03603106|Experimental|Part II (Phase IIA)|In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
3134541|NCT03603652|Experimental|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon.
3134542|NCT03604263|Experimental|Treatment Arm|Subjects enrolled and treated with ArcticLine Cardiac Cryoablation Catheter
3134543|NCT03604341|Experimental|Gestational age up to 10w0d - Dronabinol|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
3134544|NCT03604341|Placebo Comparator|Gestational age up to 10w0d - Placebo|Women with gestational age up to 10 weeks 0 days will be randomized to Dronabinol 5mg Cap or placebo
3134545|NCT03604497|Experimental|beacon alerts|active intervention - participants are receiving alerts to warn them about distracted pedestrian behavior near intersections
3134546|NCT03604497|No Intervention|no alerts baseline|baseline - participants do not receive any alerts on their mobile smartphone when near intersections
3134547|NCT03604497|Other|no alerts retention|retention phase - alerts have stopped after active intervention and behavior is monitored to test retention of learned behavior
3134548|NCT03604523|Active Comparator|Dilation by Balloon|Esophageal dilation by balloon device.
3134549|NCT03604523|Active Comparator|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device.
3134550|NCT03604705|Experimental|APX001 Treatment|
3134551|NCT03605212|Experimental|Cohort 1|Febuxostat film-coated tablets 2x20 mg/QD for 7-9 days
3134552|NCT03605212|Experimental|Cohort 2|Febuxostat film-coated tablets 3x20 mg/QD for 7-9 days
3134553|NCT03605212|Experimental|Cohort 3|Febuxostat film-coated tablets 1x80 mg/QD for 7-9 days (Adenuric® 80 mg)
3134554|NCT03605212|Experimental|Cohort 4|Febuxostat film-coated tablets 1x120 mg/QD for 7-9 days (Adenuric® 120 mg)
3134555|NCT03605212|Active Comparator|Adults|Febuxostat film-coated tablets 120 mg/QD for 7-9 days (Adenuric® 120 mg)
3148815|NCT00158782|Experimental|Cohort 10|Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.
3134556|NCT03605680|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
3134557|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134558|NCT03605680|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134559|NCT03605680|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134560|NCT03605693|Active Comparator|Early Psychological Intervention|Those assigned to Early Psychological Intervention will receive Written Exposure Therapy, a 5 session treatment in which participants write about their trauma event in a specified manner.
3134561|NCT03605693|No Intervention|Usual care|Those assigned to usual care will complete study assessments but will not be referred to any psychological treatment
3134562|NCT03605745|Experimental|Treatment|Prostatic Vapor Ablation with Rezum
3134563|NCT03605836|Experimental|Single-blind Run-in Period: Placebo|Placebo-matching tablets BID (twice daily) on Day -7 through Baseline (Day -1).
3134564|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 200 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 200 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134565|NCT03605836|Experimental|Double-blind Treatment Period: Centanafadine SR 400 mg|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine 400 mg SR tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134566|NCT03605836|Placebo Comparator|Double-blind Treatment Period: Placebo|Following Single-blind Run-in Period, participants with <30% improvement on Adult ADHD Self Report Scale (ASRS) scale score were randomized to receive centanafadine SR matching placebo tablets BID orally on Day 1 through Day 42 in the Double-blind Treatment Period.
3134567|NCT03605914|Experimental|NSAID|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
3134568|NCT03605914|Active Comparator|opioid|The Opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
3134569|NCT03606187|Experimental|Test Arm|Subjects randomized to this arm will receive test treatment
3134570|NCT03606187|Active Comparator|Control Arm|Subjects randomized to this arm will receive control treatment
3134571|NCT03606343|Experimental|Open Trial|Group based treatment targeting academic executive functioning skills such as organization, planning, and study skills. Likely to be 7 90-minute sessions attended weekly by parents and teens
3134572|NCT03606460|Experimental|Cohort 1|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for Dose 2 or Dose 3. Participants who have already received one or two doses of ocrelizumab according to the approved infusion protocol and have reported no serious infusion-related reactions (IRRs) will be enrolled. They will then receive the next infusion of ocrelizumab (Dose 2 or Dose 3) at a dosage of 600 milligram (mg) over the course of approximately 2 hours. Dose 2 is administered at Week 24, Dose 3 is administered at Week 48 after initial infusion.
3134573|NCT03606460|Experimental|Cohort 2|This cohort will examine the effect of administering ocrelizumab per a shorter infusion protocol for the second infusion of Dose 1. Ocrelizumab-naïve participants will be enrolled who, after receiving Dose 1 of ocrelizumab at the approved rate have no reported serious IRRs, will then receive the second 300-mg shorter infusion over approximately 1.5 hours.
3134574|NCT03607487|Experimental|Cohort 1|INCB054707 at the Cohort 1 dose or placebo.
3134575|NCT03607487|Experimental|Cohort 2|INCB054707 at the Cohort 2 dose or placebo.
3134576|NCT03607487|Experimental|Cohort 3|INCB054707 at the Cohort 3 dose or placebo.
3134577|NCT03607539|Experimental|Sintilimab in combination with pemetrexed and platinum|Injection; dosage form: 10ml: 100mg; frequency: 200mgQ3W (qualer 3 weeks); duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria Sintilimab 200mg + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
3134578|NCT03607539|Placebo Comparator|Sitilimab Placebo Comparator|placebo 2 vials + pemetrexed/ platinum 4 cycles then Sintilimab 200mg + pemetrexed maintains
3134579|NCT03607682|Experimental|Prevention (TTF therapy, NovoTTF-200A device)|
3134580|NCT03607695|Experimental|Gait training|1 hour walking exercise on a treadmill
3134581|NCT03607994|Active Comparator|HIRREM-SOP (BCC|Acoustic stimulation linked to brainwave activity and continued current care.
3134582|NCT03607994|Other|nonspecific acoustic stimulation (NCC)|Continued current care and acoustic stimulation that is not linked to brainwave activity.
3134583|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement|Vitamin D replacement (50.000 IU/per week, for 8 weeks)
3134584|NCT03608488|Experimental|Vitamin D<10 ng/ml; Vitamin D replacement and exercise|Vitamin D replacement (50.000 IU/per week, for 8 weeks) and Core and balance exercises for 8 weeks.
3134585|NCT03608488|Experimental|Vitamin D<10 ng/ml; exercise|Core and balance exercises for 8 weeks.
3134586|NCT03608488|Active Comparator|Vitamin D>30ng/ml; exercise|Core and balance exercises for 8 weeks.
3134587|NCT03608774|Experimental|Arm 1|1 gram of Azithromycin (4 capsules of 250 mg) administered orally as a single dose on Day 1, and Doxycycline placebo (1 capsule) administered orally twice daily for 7 days starting on Day 1. N=123
3134588|NCT03608774|Experimental|Arm 2|100 mg of Doxycycline (1 capsule) administered orally twice daily for 7 days starting on Day 1, and Azithromycin placebo (4 capsules) administered orally as a single dose on Day 1. N=123
3134589|NCT03608839|Experimental|0,01ml dexamethasone solution|One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
3134590|NCT03608839|Experimental|0,03 ml dexamethasone solution|One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
3134591|NCT03608839|Experimental|0,05 ml dexamethasone solution|One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.
3134592|NCT03609619|Experimental|AEVI-001|
3134593|NCT03609619|Placebo Comparator|Placebo|
3134594|NCT03609658|Experimental|Nurse Navigator Pathway Group|Participants in this Nurse Navigator led ACP pathway group will participate in ACP discussions, surveys, and participant visit(s) for duration of the study (12 months)
3134595|NCT03609658|Sham Comparator|Usual Care Group|Participants in the Usual Care group will follow usual daily living activities for the duration of the study (12 months).
3134596|NCT03610048|Experimental|ALKS 5461|Sublingual tablets
3134597|NCT03610165|Placebo Comparator|Arterial line - Control|Arterial line waveform and pressure
3134598|NCT03610165|Experimental|Acumen HPI-enabled EV1000 screen|Arterial line waveform and pressure + HPI alert from EV1000 monitor
3134599|NCT03610269|Experimental|INVSENSOR00026|All enrolled subjects receive INVSENSOR00026 Pulse CO-Oximeter and sensor for the noninvasive measurement of hemoglobin (SpHb).
3134600|NCT03610399|Other|Primaquine Regular Dose Unsupervised|This is the regular primaquine dose Brazil without directly observed therapy.
3134601|NCT03610399|Active Comparator|Primaquine Regular Dose Supervised|This is the regular primaquine dose in Brazil but with directly observed therapy.
3134602|NCT03610399|Active Comparator|Primaquine Double Dose Unsupervised|This is the double total primaquine dose (14 days) in Brazil with directly observed therapy.
3134603|NCT03610464|Experimental|Study patients (AMPH EROS)|All patients treated with extended-release oral suspension (AMPH EROS) that contains 2.5 mg/mL amphetamine base
3134604|NCT03610581|Experimental|Regimen 1: Single Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a dose of adenovirus serotype 26 (Ad26)-human papillomavirus (HPV)16 or HPV18 (Ad26.HPV16 or Ad26.HPV18) as prime immunization and a dose of Modified Vaccinia Ankara (MVA)-HPV16/18 (MVA.HPV16/18) as boost immunization.
3134605|NCT03610581|Experimental|Regimen 2: Double Ad26.HPV16 or Ad26.HPV18 and MVA.HPV16/18|Participants will receive a double dose of Ad26.HPV16 or Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
3134606|NCT03610581|Experimental|Regimen 3: Ad26.HPV16/Ad26.HPV18 mix and MVA.HPV16/18|Participants will receive a mix of Ad26.HPV16/Ad26.HPV18 as prime immunization and a dose of MVA.HPV16/18 as boost immunization.
3134607|NCT03610581|Placebo Comparator|Control: Placebo|Participants will receive matched placebo as prime and boost immunizations.
3134608|NCT03610633|Experimental|Oxytocin/alcohol use disorder|Participants will receive 24 IU of oxytocin prior to completing fMRI scanning procedures.
3134609|NCT03610633|Placebo Comparator|Placebo/Alcohol use disorder|Participants will receive placebo (saline solution) prior to completing fMRI scanning procedures.
3134610|NCT03611062|Experimental|VR Executive Functions Training|Participants will receive training of executive functions in a virtual reality environment.
3134611|NCT03611062|Placebo Comparator|Control|Participants will play a virtual reality game using the same hardware and similar environments, but without the training of executive functions.
3134612|NCT03611075|Experimental|Low-Functioning Autism Spectrum Disorder (ASD) Children|Participants will be 5-12 years old, with Intelligence Quotient (IQ) scores between 50-70
3134613|NCT03611075|Experimental|High-Functioning ASD Children|Participants will be 5-12 years old, with IQ scores of 70 or above
3134614|NCT03611075|Experimental|Low-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores between 50-70
3134615|NCT03611075|Experimental|High-Functioning ASD Adolescents|Participants will be 13-17 years old, with IQ scores of 70 or above
3134616|NCT03611075|Experimental|Low-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores between 50-70
3134617|NCT03611075|Experimental|High-Functioning ASD Adults|Participants will be 18-45 years old, with IQ scores of 70 or above
3134618|NCT03611075|No Intervention|Typically Developing (TD) Healthy Participant Children|Participants will be 5-12 years old
3134619|NCT03611075|No Intervention|TD Healthy Participant Adolescents|Participants will be 13-17 years old
3134620|NCT03611075|No Intervention|TD Healthy Participant Adults|Participants will be 18-45 years old
3134621|NCT03611582|Experimental|Semaglutide|Participants will receive semaglutide 2.4 mg during 68-week treatment period in addition to intensive behavioural therapy.
3134622|NCT03611582|Placebo Comparator|Semaglutide placebo|Participants will receive semaglutide placebo during 68-week treatment period in addition to intensive behavioural therapy.
3134623|NCT03611777||subjects with Pulmonary Disease, Chronic Obstructive|
3134624|NCT03611829|Active Comparator|Standard Care|Participants in the standard care condition were provided with diet and exercise counselling and psychoeducation from their physicians over the course of 8 sessions, as was routinely done at the clinic. Standard care did not involve any targeted intervention to reduce emotional eating.
3134625|NCT03611829|Experimental|ACT Intervention|In addition to receiving standard care, participants in the ACT condition were taught techniques to reduce their emotional eating. Three overarching skills were taught over the course of the ACT intervention: (1) values clarification and commitment, (2) metacognitive awareness, and (3) distress tolerance. Throughout the sessions, physicians formed if-then plans with the patients to specify how to habitually use the ACT techniques to reduce emotional eating in their everyday lives. At the end of each session, participants were given a one-page homework sheet that asked them to monitor their behavior and their use of the ACT techniques during the week.
3134626|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 1|Participants will receive a single dose of 0.25 mg/kg xisomab 3G3.
3134627|NCT03612856|Experimental|AB023 (xisomab 3G3)- Dose 2|Participants will receive a single dose of 0.5 mg/kg xisomab 3G3.
3134628|NCT03612856|Placebo Comparator|placebo|Participants will receive a single dose of placebo.
3134629|NCT03613129|Active Comparator|D0.20|Subcutaneous infusion of CT38 at 0.20 μg/kg/hour, for 3 hours on each of 2 days
3134630|NCT03613129|Active Comparator|D0.03|Subcutaneous infusion of CT38 at 0.03 μg/kg/hour, for 3.5 hours on each of 3 days
3134631|NCT03613129|Active Comparator|D0.06|Subcutaneous infusion of CT38 at 0.06 μg/kg/hour, for 3.5 hours on each of 3 days
3134632|NCT03613129|Active Comparator|D0.01|Subcutaneous infusion of CT38 at 0.01 μg/kg/hour, for 3.5 hours on each of 3 days
3134633|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic coils|
3134634|NCT03613454|Active Comparator|Splenic artery embolization with vascular embolic plugs|
3134635|NCT03613493|Other|HPV self-sampling kit + Interview|Participants will receive an HPV self-sampling kit to screen for HPV and then are interviewed about their experience using the tool.
3134636|NCT03613493|Experimental|Culturally-targeted Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
3134637|NCT03613493|Experimental|Fear appeal message HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV, accompanied by a culturally-targeted fear appeal message
3134638|NCT03613493|Active Comparator|HPV self-sampling kit|Participants will receive an HPV self-sampling kit to screen for HPV
3134639|NCT03613649|Experimental|Treatment A|2 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
3134640|NCT03613649|Experimental|Treatment B|4 g of zoliflodacin administered orally on Day 1 of each dosing period, n=72
3134641|NCT03613649|Placebo Comparator|Treatment C|Placebo for zoliflodacin administered orally on Day 1 of each dosing period, n=72
3134642|NCT03613649|Active Comparator|Treatment D|400 mg of moxifloxacin administered orally on Day 1 of each dosing period, n=72
3134643|NCT03613818|Experimental|eCHECKUP TO GO|Brief, web-based alcohol intervention
3134644|NCT03613818|No Intervention|Control|Assessment only
3134645|NCT03614078|Experimental|PRCL-02 Dose 1|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
3134646|NCT03614078|Experimental|PRCL-02 Dose 2|Loading dose followed by a once daily maintenance dose commencing on Day 2 and continuing for 12 weeks
3134647|NCT03614078|Placebo Comparator|Placebo|Loading dose followed by a once daily maintenance dose at matching treatment levels, commencing on Day 2 and continuing for 12 weeks
3134648|NCT03614130|Other|LID011121 (OD) / Biofinity (OS)|LID011121 contact lens worn in the right eye, with comfilcon A contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
3134649|NCT03614130|Other|Biofinity (OD) / LID011121 (OS)|Comfilcon A contact lens worn in the right eye, with LID011121 contact lens worn in the left eye, as randomized, for approximately 6 nights of extended (overnight) wear
3134650|NCT03614156|Experimental|Rapastinel weekly|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration)
3134651|NCT03614156|Experimental|Rapastinel clinically driven schedule|Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
3134652|NCT03614156|Placebo Comparator|Placebo weekly|Placebo (prefilled syringe, weekly IV administration)
3134653|NCT03614416|Experimental|EOXY device and Gold standard oximter and SaO2 measures|Heart rate and SPO2 measures provided from EOXY device Heart rate measures provided from gold standard oximeter. SaO2 measures provided from blood sampling There is only one arm: all subjects have simultaneously three interventions (as required in the European standard ISO 80601-2-61), to qualify a pulse oximeter
3134654|NCT03614975|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
3134655|NCT03614975|Active Comparator|Fluzone inactivated influenza vaccine|Participants receiving inactivated Fluzone influenza vaccine will receive 0.5 mL given intramuscularly
3134656|NCT03615001|Experimental|Urodynamics Arm|
3134657|NCT03615066|Experimental|Selgantolimod 3 mg + TAF|Participants with hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks.
3134658|NCT03615066|Experimental|Selgantolimod 1.5 mg + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3134659|NCT03615066|Placebo Comparator|Placebo + TAF|Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks.
3134660|NCT03615079|Other|Cognitive Behavioral Therapy (CBT) program|
3134661|NCT03615183|Experimental|Panel A: 10 mg MK-8527|Single oral dose of 10 mg MK-8527 capsule after an 8-hour fast
3134662|NCT03615183|Experimental|Panel B: 3 mg MK-8527|Single oral dose of 3 mg MK-8527 capsule after an 8-hour fast
3134663|NCT03615183|Experimental|Panel C: 1 mg MK-8527|Single oral dose of 1 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
3134664|NCT03615183|Experimental|Panel D: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
3134665|NCT03615183|Experimental|Panel E: ≤50 mg MK-8527|Single oral dose of ≤50 mg MK-8527 capsule after an 8-hour fast. Dose level determined by results of previous panels.
3134666|NCT03615404|Experimental|CMV-DCs with GM-CSF and Td (tetanus toxoid)|CMV-DCs are autologous dendritic cells derived from peripheral blood mononuclear cells (PBMCs) loaded with ribonucleic acid (RNA) encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF and Td vaccine as adjuvants.
3134667|NCT03615482|Experimental|Concomitant Vaccination|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 and a single 0.5 mL IM injection of QIV on Day 1 and a single 0.5 mL injection of placebo on Day 30
3134668|NCT03615482|Experimental|Non-concomitant Vaccination|Participants will receive a single 0.5 mL IM injection of QIV and a single 0.5 mL IM injection of placebo on Day 1 and a single 0.5 mL injection of V114 on Day 30
3134669|NCT03615534|Placebo Comparator|Placebo|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch daily single placebo capsule for eight weeks.
3134670|NCT03615534|Active Comparator|Fenofibrate Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate (Lipanthyl® 200 mg micronized fenofibrate capsule, Abbott Laboratories Fournier) for eight weeks.
3134671|NCT03615534|Active Comparator|WMER Niacin Monotherapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive a night-time 500 mg daily single dose of Wax Matrix Extended Release Niacin (WMER Niacin, ENDUR-ACIN®500mg, Endurance Products Company, Oregon USA) for one week, titrated up to 1000 mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
3134672|NCT03615534|Active Comparator|Combination Therapy|Non-responders to four-week therapeutic lifestyle changes run-in period, will start to receive an after lunch 200mg daily single dose of fenofibrate for eight weeks, in combination with a night-time 500 mg daily single dose of WMER Niacin for one week, titrated up to 1000mg by adding a daily morning-time ENDUR-ACIN®500mg tablet for the next seven weeks.
3134673|NCT03615807|Experimental|Short antibiotic arm|10 days for soft tissue infections 3 weeks for osteomyelitis
3134674|NCT03615807|Active Comparator|Standard antibiotic arm|20 days for soft tissue infections 6 weeks for osteomyelitis
3134675|NCT03615911|Experimental|Vaccination with 10^7 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
3134676|NCT03615911|Experimental|Vaccination with 10^8 PFU MVA-MERS-S|"Vaccinations occur on days 0 and 28~A subgroup will additionally receive a late booster immunization with 10^8 PFU MVA-MERS-S 12 months (+/- 4 months) after prime immunization."
3134677|NCT03615924|Experimental|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
3134678|NCT03615924|Placebo Comparator|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
3134679|NCT03616106|Experimental|Intervention Group|Participants in the intervention group will receive health education using infographics (Infographic Intervention) during their regularly scheduled clinic visits.
3134680|NCT03616171|Experimental|Interventional Group|"Intervention Group (SLEEP-Extend intervention): The SLEEP-Extend intervention consists of two components:~One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep (an investigator-developed brochure and information based on recommendations from the American Academy of Sleep Medicine and the National Sleep Foundation will be given and reviewed with the subject)~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later (subject will decide what works best for them)."
3134681|NCT03616171|Other|Control Group|Control group: consists of One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
3134682|NCT03616600|Experimental|Treatment|Wearing the orthokeratology lenses for 3 months
3134683|NCT03616600|No Intervention|Control|Not wearing any contact lenses
3134684|NCT03616899|Active Comparator|KPI-121 0.25% Ophthalmic Suspension|
3134685|NCT03616899|Placebo Comparator|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
3134686|NCT03616977|Experimental|LY900014 U-200|Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
3134687|NCT03616977|Experimental|LY900014 U-100|Single SC dose of LY900014 U-100 in two of four study periods.
3134688|NCT03617419|Other|VScan Access R2 Ultrasound System|"Pre-market: Vscan Access R2 Ultrasound System~The following post-market products will be used on label:~GE Corometrics 170 Series Fetal Monitor - as a reference for value of fetal heart rate GE Voluson P8 Ultrasound System - for verification of fetal location during measurement"
3134689|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 1: 6 to <36 months|Participants (aged 6 to <36 months) received a 0.25-milliliter (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3134690|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 2: 3 to <9 years|Participants (aged 3 to <9 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3134691|NCT03617523|Experimental|Fluzone Quadrivalent vaccine Group 3: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0.
3134692|NCT03617523|Experimental|Flublok Quadrivalent vaccine Group 4: 18 to <65 years|Participants (aged 18 to <65 years) received a 0.5-mL dose of Flublok Quadrivalent vaccine, intramuscularly, at Day 0.
3134693|NCT03617523|Experimental|Fluzone High-Dose vaccine Group 5: >=65 years|Participants (aged >=65 years) received a 0.5-mL dose of Fluzone High-Dose vaccine, intramuscularly, at Day 0.
3134694|NCT03617588|Experimental|Gallium-68 THP-PSMA|Single intravenous administration of Gallium-68 THP-PSMA
3134695|NCT03617770|Experimental|Sleep-Opt-In|Sleep optimization intervention
3134696|NCT03617770|Active Comparator|Healthy Living|Health education
3134697|NCT03617861|Experimental|Healthy Controls: Secretin Then Placebo|Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
3134698|NCT03617861|Experimental|Healthy Controls: Placebo Then Secretin|Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
3134699|NCT03617861|Experimental|Functional Dyspepsia: Secretin Then Placebo|Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.
3134700|NCT03617861|Experimental|Functional Dyspepsia: Placebo Then Secretin|Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.
3134701|NCT03617913|Experimental|Treatment (avelumab, chemotherapy, radiation therapy)|Participants receive avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants receive either fluorouracil IV on days 1-5 and 16-20 during RT and mitomycin IV on day 1 of course 3, or cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
3134702|NCT03618017|Experimental|CCC Website|The intervention, ConnectedCancerCare (CCC) Website is a personalized, navigation tool that is tailored to patients' preferences for provider roles in follow-up care, their satisfaction with their current primary care provider, and their worry about cancer recurrence. It involves a personalized, patient-facing website which includes a baseline survey, tailored educational modules, and a guide for their survivorship care, as well as a text or email based reminder system. The intervention also includes a provider-facing summary document, which will be faxed to both the oncology and primary care teams.
3134703|NCT03618017|Other|Static care plan|"The control arm will receive is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
3134704|NCT03618030|Experimental|Active Treatment|PRC-063 25, 35, 45, 55, 70, 85, or 100 mg
3134705|NCT03618030|Placebo Comparator|Placebo Treatment|Matched placebo
3134706|NCT03618420|Other|Clinical Investigation|All participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes Dual X-Ray Absorptiometry (DXA), renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI.
3134707|NCT03618628|Experimental|People using a CFO|People who are currently wearing a carbon fiber off loading orthosis (CFO) will have a new CFO fabricated for them based on the results of our finite element (FE) model. We will then test both CFOs ability to reduce peak plantar compared to barefoot and the peak plantarflexor power of both braces.
3134708|NCT03618641|Experimental|Nivolumab and CMP-001 Combination|"Prime Phase -Nivolumab 240mg, IV Infusion, every two weeks starting with Cycle 2 ( Cycles 2, 4, 6) for 6 weeks in combination with CMP-001, 5mg, Injection, at Week 1 and the remaining injections, 10 mg will be administered Weeks 2 -7.~Boost Phase -Nivolumab 240mg, IV Infusion, every two weeks, over a 46 week period in combination with CMP-001, 5mg, administered every 4 weeks for 1 year."
3134709|NCT03618823|Experimental|Opioid pain control|Patients in this group will be receiving triple therapy for pain control with oxycodone, acetaminophen, and ibuprofen. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the pain diary.
3134710|NCT03618823|Active Comparator|Non-opioid pain control|Patients in this group will be receiving therapy for pain control with acetaminophen and ibuprofen only. They will be asked to complete a pain diary which will be used to determine the level of pain control achieved with this regimen. The diary will be completed by post-operative day 14. A post-operative appointment between 4-8 weeks will be scheduled and the patient and caregiver will return the diary.
3134711|NCT03619135|Experimental|Use of Buzzy Device|The Buzzy device was used for IV access for this arm.
3134712|NCT03619135|Placebo Comparator|Control|No Buzzy device was used - standard IV access for this arm.
3134713|NCT03619590||Exposure Group|Pregnant women who were exposed to Twinrix within 28 days prior to conception or at any time during pregnancy. Reporting of exposed pregnancies is voluntary and prospective.
3134714|NCT03619811|Experimental|Symptomatic|This study examines the efficacy of the upper esophageal sphincter assist device as an adjunct to Proton-pump inhibitors (PPI) therapy in symptomatic subjects. (Reflux Band® Upper Esophageal Sphincter (UES) Assist Device)
3134715|NCT03619837|Experimental|Treatment Arm|"Single Arm: Sofosbuvir/Velpatasvir~Dosage: 400mg/100mg. Once daily for 12 weeks."
3134716|NCT03619889|Sham Comparator|Sham simulation group|A simulation of the pressure release technique, applying a soft pressure or contact in the same muscles sites or trigger points than in the intervention group.
3134717|NCT03619889|Experimental|Pressure release technique group|The release pressure technique is applied in the trigger points of masticatory and neck muscles (upper trapezius, sternal and clavicular sternocleidomastoid, deep and superficial masseter, posterior, medium and anterior temporalis.
3134718|NCT03620162|Active Comparator|Group 1: Prevnar 13™-Prevnar 13™-Prevnar 13™-Prevnar 13™|Participants will receive a single 0.5 mL intramuscular (IM) injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
3134719|NCT03620162|Experimental|Group 2: Prevnar 13™-Prevnar 13™-Prevnar 13™-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and a single 0.5 mL IM injection of V114 on Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
3134720|NCT03620162|Experimental|Group 3: Prevnar 13™-Prevnar 13™-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1), Month 2 (Vaccination 2) and a single 0.5 mL IM injection of V114 on Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
3134721|NCT03620162|Experimental|Group 4: Prevnar 13™-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of V114 on Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
3134722|NCT03620162|Experimental|Group 5: V114-V114-V114-V114|Participants will receive a single 0.5 mL IM injection of V114 on Day 1 (Vaccination 1), Month 2 (Vaccination 2), Month 4 (Vaccination 3) and Months 10-13 (Vaccination 4). Participants will concomitantly receive other licensed background pediatric vaccines as follows: RotaTeq™, Pentacel™, RECOMBIVAX HB™ on Day 1, Month 2, and on Month 4; HIBERIX™, M-M-R™ II, VARIVAX™ on Months 10-13.
3134723|NCT03620383|Experimental|Heat|Distal topical heat application
3134724|NCT03620383|No Intervention|No Heat|Inactive heat pack to blind the investigator.
3134725|NCT03620708|Experimental|Motivational Interviewing|35 minute individual motivational interviewing intervention concluding with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line
3134726|NCT03620708|Active Comparator|Nicotine Replacement Therapy Sampling|Participants are provided with a 2-week supply of nicotine patches and a 2 week supply of nicotine lozenges with a recommendation to try them and are also given a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
3134727|NCT03620708|Other|Referral Only|Participants are provided with a written referral sheet for a local smoking cessation clinic and the New Jersey State Quit Line.
3134728|NCT03620890|Active Comparator|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
3134729|NCT03620890|Active Comparator|Detemir|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
3134730|NCT03621085|Experimental|Ketamine|Subjects will receive up to 20 mg Ketamine Hydrochloride while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
3134731|NCT03621085|Placebo Comparator|Placebo|Subjects will receive placebo while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
3134732|NCT03621189|Active Comparator|Active-Active|"Participants received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 8 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
3134733|NCT03621189|Sham Comparator|Sham-Active|"Participants received the sham intervention of TBS (coil tilted one-wing 90° off the head) over the posterior superior temporal sulcus for 4 weeks (2 days/week) and then received the real intervention of TBS (iTBS 1200) over the posterior superior temporal sulcus for 4 weeks (2 days/week).~*iTBS = intermittent theta burst stimulation"
3134734|NCT03621202|Experimental|Saranas Early Bird Bleed Monitoring System (EBBMS)|
3134735|NCT03621787|Experimental|Single arm study: implant insertion|Participants in trial will be within a single study arm. All participants will have a placebo subcutaneous implant inserted with the device being studied. The implant accuracy will be assess through palpation and ultrasound depth measurements. The implant will then be removed. Safety will be assessed by measuring bruising and bleeding. A follow-up questionnaire will assess bruising and infection risk. A final visit will assess bruising and infection risk by a physician.
3134736|NCT03621878|Active Comparator|Control group|Patients in this group had 6 sessions in 2 weeks of Transcutaneous Electric Nerve Stimulation (TENS).
3134737|NCT03621878|Experimental|Tensioner Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Tensioner technique).
3134738|NCT03621878|Experimental|Slider Group|Patients in this group had 6 sessions in 2 weeks of TENS combined with neural mobilization exercises (Slider technique).
3134739|NCT03622112|Experimental|AZD7594 Dose 1|The randomized subjects will receive AZD7594 55 μg/50 μg (nominal/delivered dose), oral inhalation via dry powder inhaler (DPI) once daily.
3134740|NCT03622112|Experimental|AZD7594 Dose 2|The randomized subjects will receive AZD7594 99 µg/90 µg, oral inhalation via DPI once daily.
3134741|NCT03622112|Experimental|AZD7594 Dose 3|The randomized subjects will receive treatment with AZD7594 198 µg/180 µg, oral inhalation via DPI once daily.
3134742|NCT03622112|Experimental|AZD7594 Dose 4|The randomized subjects will receive treatment with AZD7594 396 µg/360 µg, oral inhalation via DPI once daily.
3134743|NCT03622112|Experimental|AZD7594 Dose 5|The randomized subjects will receive treatment with AZD7594 792 µg/720 µg, oral inhalation via DPI once daily.
3134744|NCT03622112|Placebo Comparator|Placebo|The randomized subjects will receive AZD7594 matching placebo oral inhalation via DPI once daily.
3134745|NCT03622112|Active Comparator|Fluticasone Furoate|The randomized subjects will receive treatment with fluticasone furoate (FF) oral inhalation via DPI, 100 µg per nominal dose, once daily (open-label).
3134746|NCT03622619|Experimental|Manuka eye drops|
3134747|NCT03622619|Active Comparator|Systane Ultra|
3134748|NCT03623035||Lumbar Plexus block Group|This group includes participants that received Lumbar Plexus blocks (LPB) as the regional analgesic technique in a direct anterior approach (DAA) Total Hip Arthroplasty.
3134749|NCT03623334|Experimental|Dose Level A: IGRT 3.33Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.33Gy for 15 fractions (total dose = 50 Gy) which is given over the course of about 3 weeks
3134750|NCT03623334|Experimental|Dose Level B: IGRT 3.67Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 55 Gy) which is given over the course of about 3 weeks
3134751|NCT03623334|Experimental|Dose Level C: IGRT 4.00Gy x 15 Fractions|Image-guided radiation therapy (IGRT) dose of 3.67Gy for 15 fractions (total dose = 60 Gy) which is given over the course of about 3 weeks
3134752|NCT03623373|Experimental|Bendamustine/Rituximab/Acalabrutinib/Cytarabine|"Patients will receive (6) 28 day cycles~Cycles 1-3 will consist of bendamustine on Days 1 and 2, rituximab on Day 1, and acalabrutinib twice per day (BID) on Days 1 through 28.~Cycles 4-6 will consist of rituximab on Day 1, cytarabine every 12 hours on Days 1 and 2, acalabrutinib BID on Days 1 through 7 and 22 through 28 (one week on, two weeks off, one week on), and growth factors as per institutional standard~After Cycle 6, patients will undergo leukapheresis"
3134753|NCT03623698||Before treatment|Children and young people with neuromuscular disease during the 12 months before being prescribed treatment with nebulised saline (0.9% - 7%)
3134754|NCT03623698||After treatment|Children and young people with neuromuscular disease during the 12 months after being prescribed treatment with nebulised saline (0.9% - 7%)
3134755|NCT03624192|Experimental|RECELL® Autologous Cell Harvesting Device|RECELL + Telfa™ Clear and Xeroform™ dressings
3134756|NCT03624192|Active Comparator|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
3134757|NCT03624504|Experimental|Micra Implant Group|Subjects with implant attempt with the Micra Transcatheter Pacing System (TPS)
3134758|NCT03624920|Placebo Comparator|THN102 Dosage A|THN102 Dosage A is a Placebo
3134759|NCT03624920|Experimental|THN102 Dosage B|THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
3134760|NCT03624920|Experimental|THN102 Dosage C|THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
3134761|NCT03624946|Experimental|Zika Virus Immune Globulin (ZIKV-IG)|Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
3134762|NCT03624946|Placebo Comparator|Placebo (Saline Solution)|Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
3134763|NCT03624972|Active Comparator|Resources Only|Patients will receive a list of resources on sexual and menopausal health in breast cancer. They will be asked to review the resources before their next clinic visit.
3134764|NCT03624972|Experimental|Resources + Video|"Patients will receive a list of web resources on sexual and menopausal health in breast cancer. In addition to the resources, patients will be asked to view an online video called Starting the Conversation and to complete an accompanying workbook. Patients in this arm will be asked to review the resource list, watch the Starting the Conversation video, and complete the workbook before their next clinic visit."
3134765|NCT03624972|No Intervention|Clinician Arm|Clinicians were consented in order to have their clinic visits audio recorded. No outcomes data were collected from clinician participants.
3134766|NCT03626415|Experimental|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
3134767|NCT03626623|Placebo Comparator|Standard of Care (SOC)|The usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds.
3134768|NCT03626623|Active Comparator|Cytal Wound Matrix 1-Layer|The application of the Cytal Wound Matrix 1-Layer device according to the Cytal Wound Matrix 1-Layer instructions for use (IFU).
3134769|NCT03626714|Experimental|Sustained Release Tacrolimus|All subjects will be treated with a single dose injection of sustained-release Tacrolimus
3134770|NCT03627065|Experimental|Parsaclisib|
3134771|NCT03627195|Experimental|DSP-1349M|Lurasidone injection suspension (30 mg, 75 mg, 150 mg, 300 mg, and 450 mg)
3134772|NCT03627195|Placebo Comparator|Placbo|placebo injection
3134773|NCT03627299|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive 300 mg glecaprevir/pibrentasivir 120 mg once daily by mouth for 4 weeks
3134774|NCT03627416|Experimental|active rTMS|10 hertz (Hz) rTMS will be administered over bilateral primary motor areas for the muscles of lower extremities. Therapy will include five daily sessions (on consecutive week days). In every sessions 3000 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
3134775|NCT03627416|Sham Comparator|Sham rTMS|Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
3134776|NCT03627494|Experimental|Part A: P1,PBO/GSK3439171A Dose 2/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 milligram (mg) up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence placebo (PBO) followed by Dose 2 of GSK3439171A followed by Dose 3 of GSK3439171A in period 1 (P1). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134777|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ PBO/GSK3439171A Dose 3|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and PBO as per randomized sequence: Dose 1 of GSK3439171A followed by PBO followed by Dose 3 of GSK3439171A in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3188782|NCT00770718|Experimental|Prothrombin Complex Concentrate (PCC)|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered before FFP will be used to complete the correction.
3134778|NCT03627494|Experimental|Part A: P1, GSK3439171A Dose 1/ GSK3439171A Dose 2/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 1 of GSK3439171A followed by Dose 2 of GSK3439171A followed by PBO in P1. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134779|NCT03627494|Experimental|Part A: P2, PBO/GSK3439171A Dose 5/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 5 of GSK3439171A followed by Dose 6 of GSK3439171A in period 2 (P2). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3188783|NCT00770718|Active Comparator|Fresh Frozen Plasma (FFP)|The last five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
3134780|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ PBO/GSK3439171A Dose 6|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by PBO followed by Dose 6 of GSK3439171A in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134781|NCT03627494|Experimental|Part A: P2, GSK3439171A Dose 4/ GSK3439171A Dose 5/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 4 of GSK3439171A followed by Dose 5 of GSK3439171A followed by PBO in P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134782|NCT03627494|Experimental|Part A: P3, PBO/GSK3439171A Dose 8/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: PBO followed by Dose 8 of GSK3439171A followed by Dose 9 of GSK3439171A in Period 3 (P3). There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134783|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ PBO/GSK3439171A Dose 9|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by PBO followed by Dose 9 of GSK3439171A in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134784|NCT03627494|Experimental|Part A: P3, GSK3439171A Dose 7/ GSK3439171A Dose 8/ PBO|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A and placebo as per randomized sequence: Dose 7 of GSK3439171A followed by Dose 8 of GSK3439171A followed by PBO in P3. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134785|NCT03627494|Experimental|Part B: GSK3439171A|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of GSK3439171A in part B
3134786|NCT03627494|Placebo Comparator|Part B: Placebo|Subjects will administer oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards of Placebo in part B
3134787|NCT03627494|Experimental|Part C: GSK3439171A fed followed by GSK3439171A fasted|Subjects will administer GSK3439171A in Fed condition in Part C P1 followed by GSK3439171A in fasted condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134788|NCT03627494|Experimental|Part C: GSK3439171A fasted followed by GSK3439171A fed|Subjects will administer GSK3439171A in fasted condition in Part C P1 followed by GSK3439171A in fed condition in Part C P2. There will be a washout period of 7 days or 5 half-lives, whichever is longer in between the doses.
3134789|NCT03627767|Experimental|PF-04965842 100 mg QD|Double-blind randomized treatment following open label run-in period.
3134790|NCT03627767|Experimental|PF-04965842 200 mg QD|Double-blind randomized treatment following open label run-in period.
3134791|NCT03627767|Placebo Comparator|Placebo QD|Double-blind randomized treatment following open label run-in period.
3134792|NCT03627832|Experimental|CBT-I|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for 6 weeks
3134793|NCT03627832|Active Comparator|Sleep Hygiene|Sleep hygiene handout delivered once to all participants
3134794|NCT03628417|Experimental|Calcium Electroporation|"Calcium~Calcium chloride 220 mmol/L (9 mg/ml):~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)"
3134795|NCT03628417|Experimental|Bleomycin based electrochemotherapy|"Bleomycin~Bleomycin 1000 IU/ml:~Tumor < 0.5 cm³ - 1 ml/cm³ tumor volume~Tumor > 0.5 cm³ - 0,5 ml/cm³ tumor volume Tumor volume = ab²π/6 (a = longest diameter, b = longest diameter perpendicular to a)~Maximum of injected bleomycin per tumor will be 1500 IU and total dose per treatment 7500 IU. Normal maximum limit for bleomycin is 15.000 IU/m² body surface area."
3134796|NCT03628456|Experimental|AffloVest Monarch Arm|Devices placed on highest intensity / highest frequency
3134797|NCT03628508|Experimental|Exercise|Six-week exercise including stretching, strengthening, endurance and gait modification
3134798|NCT03628599|Experimental|TOTAL1|Delefilcon A contact lenses worn bilaterally (in both eyes) for 4 weeks in a daily disposable modality
3134799|NCT03628599|Active Comparator|1-DAY|Senofilcon A contact lenses worn bilaterally for 4 weeks in a daily disposable modality
3134800|NCT03628885|No Intervention|General Vaccine Information|Brief (47 second) animated informational video about vaccines recommended for all young adolescents.
3188784|NCT00770731|Experimental|Torisel + Hycamtin + Velcade|"Torisel starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle.~Hycamtin starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle.~Velcade starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle."
3188785|NCT00770731|Experimental|Expansion Group|"Torisel + Hycamtin + Velcade Expansion Group~Addition of 10 participants at highest tolerated dose level"
3188786|NCT00770744|Experimental|Zicronapine|
3188787|NCT00770744|Active Comparator|Olanzapine|
3188788|NCT00770783|Experimental|Magnetic Seizure Therapy (MST)|
3188789|NCT00770783|Active Comparator|Electroconvulsive Therapy (ECT)|
3148816|NCT00158886|Experimental|Subjects with rectal cancer|Subjects will be administered topotecan along with concomitant radiation for five days per week for five weeks. Topotecan doses will start at 0.25 milligrams per square meter (mg/m˄2) and will be escalated 0.15 mg/m˄2 for subsequent cohorts. To advance to the next dose level of topotecan, at least two subjects will have to complete therapy with oral topotecan without experiencing grade 3 or 4 toxicity for three weeks after the oral topotecan treatment.
3148817|NCT00159081|Experimental|1|Maintenance antipsychotic treatment with risperidone
3148818|NCT00159081|Active Comparator|2|Maintenance antipsychotic treatment with haloperidol in low-dose
3134801|NCT03628885|Experimental|Top Concern Tailored Intervention|"Intervention includes the General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above. For those indicating #6, they will receive the same video as those indicating #1 (need more information)."
3134802|NCT03628885|Experimental|All Concerns Tailored Intervention|"Intervention includes the General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns: 1. I need more information about the vaccine; 2. My child is too young; 3. I am concerned about the long-term health effects or safety of the vaccine; 4. My child's health care provider did not recommend it or said my child could wait; 5. The vaccine is not required for school; 6. Other / none of the above."
3134803|NCT03628898|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00025 sensor
3134804|NCT03628924|Experimental|Group 1: Guselkumab Regimen 1|Participants will receive guselkumab dose 1 administered Intravenously (IV) followed by guselkumab dose 2 administered subcutaneously.
3134805|NCT03628924|Experimental|Group 2: Guselkumab Regimen 2|Participants will receive guselkumab dose 2 subcutaneously.
3134806|NCT03628924|Experimental|Group 3: Placebo then Guselkumab|Participants will receive placebo IV and SC and an additional SC placebo dose at Week 12 then cross over at Week 16 to receive guselkumab dose 2 and dose 3 SC and placebo SC.
3134807|NCT03629028|Active Comparator|Single Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
3148819|NCT00159107|Experimental|2|Placebo +Integrative behavior therapy
3134808|NCT03629028|Active Comparator|Double Layer|Diagnostic Test: Niche Presence in 6 to 9 months Diagnostic Test: Niche Measurements (depth of niche, the length of niche, the width of the niche in the transverse plane) Diagnostic Test: Residual myometrium thickness Diagnostic Test: Adjacent myometrium thickness Symptoms: postmenstrual bleeding/dysmenorrhea
3134809|NCT03629041|Experimental|Treatment A - Microneedle patch|The application of a 5% topical lidocaine gel to one of the identified areas within the participants mouth using a microneedle patch. The microneedle patch will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
3134810|NCT03629041|Sham Comparator|Treatment B - Patch with no microneedles|The application of a 5% topical lidocaine gel to one of the identified sites within the participants mouth using a patch with no microneedles. The patch with no microneedles will be applied to the oral mucosa of the identified site for 3 minutes, followed by infiltration with local anaesthetic to one of the identified areas within the participants mouth.
3134811|NCT03629054|Experimental|Test treatment (T)|Low strength empagliflozin/linagliptin/metformin XR fixed dose combination tablet
3188790|NCT00770796|Placebo Comparator|Placebo|placebo
3188791|NCT00770796|Active Comparator|Atorvastatin|80 mg die of Atorvastatin given at least two days before elective angiography or angioplasty and continued for two days after.
3188792|NCT00770822|Experimental|Device, HIFU|High Intensity Focused Ultrasound
3188793|NCT00770822|Active Comparator|Device, brachytherapy|Brachytherapy
3188794|NCT00770835|Experimental|Pioglitazone and Metformin QD|(along with lifestyle modification)
3188795|NCT00770835|Active Comparator|Glibenclamide and Metformin QD|(along with lifestyle modification)
3134812|NCT03629054|Experimental|Reference treatment (R)|Single tablets of empagliflozin + linagliptin + metformin XR
3134813|NCT03629184|Experimental|Baloxavir Marboxil|Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
3134814|NCT03629184|Active Comparator|Oseltamivir|Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1
3134815|NCT03629249|Experimental|QAW039 150 mg|QAW039 150 mg once daily orally
3134816|NCT03629249|Experimental|QAW039 450 mg|QAW039 450 mg once daily orally
3134817|NCT03629249|Placebo Comparator|Placebo|Placebo to QAW039 once daily orally
3148820|NCT00159107|Experimental|3|Acamprosate + treatment as usual
3134818|NCT03629535|Experimental|Patients in SICU|Patients in the SICU with an intra-arterial blood pressure monitor already in place will be considered as subjects.
3134819|NCT03629886|No Intervention|Vacc-039 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received HPV vaccine in HPV-039 study (NCT00779766), underwent cervical sample collection and didn't receive any vaccine in the current study.
3134820|NCT03629886|Experimental|Vacc-092 Group|Healthy Chinese female subjects, above 26 years of age at study entry, who previously received placebo (control group) in HPV-039 study (NCT00779766), were intended to receive HPV vaccine in the current study and were to provide cervical samples before HPV vaccination.
3134821|NCT03629925|Experimental|Sintilimab+ gemcitabine plus platinum|Sintilimab combination arm: Sintilimab in combination with gemcitabine plus cisplatin or carboplatin
3134822|NCT03629925|Placebo Comparator|Placebo+gemcitabine plus platinum|Placebo combination arm: Placebo in combination with gemcitabine plus cisplatin or carboplatin
3134823|NCT03630016|Active Comparator|Reference CO-Oximetry|Reference Co-Oximetry
3134824|NCT03630016|Experimental|Owlet BabySat v1.0|Owlet BabySat v1.0
3134825|NCT03630016|Experimental|Owlet Smart Sock V2 v1.1|Owlet Smart SockTM 2 , OSS v1.1 Sensor and Custom Adult Thumb Sock
3134826|NCT03630185|Experimental|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
3134827|NCT03630185|Active Comparator|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
3134828|NCT03630198|Active Comparator|Corticosteroid with lidocaine|This arm will include an injection mixture of corticosteroid and lidocaine
3148821|NCT00159107|Experimental|1|Acamprosate + Integrative behavior therapy
3180787|NCT00687310|Other|1|Educational Intervention At the initial visit (Visit 1), patients in the educational intervention group will complete a short Needs Assessment Questionnaire to help the investigator/nurse determine which section(s) of the tailored patient education booklet to give to, educate, and provide instruction on to the patient. This may, at the discretion of the investigator, include providing their patient with a peak flow meter and instructions on its use.Visit 2 will be scheduled for 1-month after the Visit 1 for the education intervention group. All educational materials provided at Visit 1 will be reviewed with the patient at Visit 2. The investigator/nurse will reassess the patient's use of the Turbuhaler® and asthma treatment plan. Patients will also be asked about any adverse events that may have occurred since Visit 1 and/or are observed at Visit 2. Once Visit 2 is completed with the patient, the investigator/nurse will complete the Educator Satisfaction Questionnaire.
3180788|NCT00687336|Active Comparator|1|Empirical eradication treatment
3180789|NCT00687336|Active Comparator|2|Eradication treatment according to a diagnostic test (URT, histological test, breath test or serology).
3180790|NCT00687349|Experimental|Intervention Arm|The training program will assign resident or NP student to a rotation. They will be receiving the educational intervention during 8 half-day sessions.
3134829|NCT03630198|Experimental|Corticosteroid with normal saline|This arm will include a mixture of corticosteroid and normal saline. The purpose of normal saline is to keep the volume and concentration similar when compared to the injections containing lidocaine.
3134830|NCT03630679||Preterm|born at <37 weeks of gestation
3134831|NCT03630679||Full term Term|born at >/= 37 weeks of gestation
3134832|NCT03631355|Active Comparator|ACL Reconstruction w/ BTB Autograft + IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients received two individual doses of intravenous TXA intra-operatively.
3134833|NCT03631355|No Intervention|ACL Reconstruction w/ BTB Autograft, no IV TXA|Patients receive a standard arthroscopic ACL reconstruction with a BTB autograft. In addition, these selected patients did not receive two individual doses of intravenous TXA intra-operatively. Only the consented surgery was performed.
3134834|NCT03631433|Active Comparator|ibuprofen|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
3148822|NCT00159120|Active Comparator|1|further maintenance antipsychotic treatment and prodrome-based early intervention
3148823|NCT00159120|Experimental|2|stepwise drug discontinuation (after 1 year maintenance antipsychotic treatment) and prodrome-based early intervention
3134835|NCT03631433|Experimental|ibuprofen/acetaminophen combination|A registered pharmacist compounded identical appearing tablets of 200 mg ibuprofen and tablets of 200 mg ibuprofen/216.7 mg acetaminophen. The tablets were placed in identical-appearing bottles (60 tabs of 200 mg ibuprofen or 60 tabs of a combination of 200 mg ibuprofen/216.7 mg acetaminophen). At the end of the debridement appointment, the patient received either a bottle containing 60 tabs of 200 mg ibuprofen or 60 tabs of 200 mg ibuprofen/216.7 mg acetaminophen. The patients were instructed to take 3 tablets every 6 hours as needed for pain.
3134836|NCT03631732|Experimental|B/F/TAF|Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
3148824|NCT00159133|Experimental|1|Early intervention with benzodiazepines in case of prodromal symptoms of an impending relapse
3148825|NCT00159133|Active Comparator|2|Early intervention with antipsychotics in case of prodromal symptoms of an impending relapse
3148826|NCT00159146|Active Comparator|A|Venlafaxine and pindolol
3148827|NCT00159146|Placebo Comparator|B|Venlafaxin and placebo
3134837|NCT03631732|Active Comparator|Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF|Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.
3134838|NCT03631927||Patient|Patients admitted to participating ICUs on the specified dates
3134839|NCT03632083|Active Comparator|Hy-Care Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Hy-Care contact lens solution.
3134840|NCT03632083|Active Comparator|Lite Contact Lens Solution|Each subject will wear fanfilcon A soft contact lens in one eye and comfilcon A soft contact lens in the other eye with each lens having been soaked overnight in the Lite contact lens solution.
3134841|NCT03632109|Experimental|Single Arm|Men who have sex with men (MSM) with pharyngeal gonorrhea will be treated with 360mg intramuscular gentamicin x 1.
3134842|NCT03632954||ACell Arm|"Cytal® Wound Matrix and/or MicroMatrix®~Cytal® Wound Matrix 1-Layer is composed of porcine-derived extracellular matrix also known as urinary bladder matrix. It is intended for the management of a variety of wounds. The individual device is intended for one time use.~MicroMatrix® is composed of a porcine-derived extracellular matrix known as urinary bladder matrix and is intended for the management of a variety of wounds. The devices are supplied in particle form in masses up to 1000mg. It is intended for one-time use."
3134843|NCT03633084|Experimental|RBM-007 Injectable Solution - 0.2 mg|No additional information.
3134844|NCT03633084|Experimental|RBM-007 Injectable Solution - 1.0 mg|No additional information.
3134845|NCT03633084|Experimental|RBM-007 Injectable Solution - 2.0 mg|No additional information.
3134846|NCT03633331|Experimental|Treatment (palbociclib, letrozole or fulvestrant)|Patients receive palbociclib PO QD on days 1-21. Patients also receive letrozole PO QD on days 1-28 or fulvestrant IM on days 1 and 15 of course 1 and on day 1 of subsequent courses per MD discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3134847|NCT03633344|Active Comparator|Carbowhite|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
3134848|NCT03633344|Placebo Comparator|Carbowhite placebo|3 tablets as a single dose (210 mg х 3 = 630 mg) TID (630 mg х 3 = 1,890 mg)
3134849|NCT03633448|Experimental|Mucinex® 1 x 200 mg (10 mL)|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
3134850|NCT03633448|Experimental|Mucinex® 1 x 400 mg (20 mL)|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
3148828|NCT00159198||1|Patients with frontotemporal dementia and amyotrophic lateral sclerosis
3134851|NCT03633487|Experimental|Mucinex® 1200 mg|Mucinex® 1200 mg Extended-Release (ER) Bi-Layer tablet (single dose)
3134852|NCT03633526|Experimental|VX-659/TEZ/IVA|Participants who received VX-659 120 milligram (mg)/TEZ 50 mg/ IVA 75 mg as fixed-dose combination (FDC) in the morning and IVA 75 mg as a mono tablet in the evening in the triple combination (TC) treatment period.
3134853|NCT03633825|No Intervention|Control|
3134854|NCT03633825|Experimental|Intervention|
3134855|NCT03633903|Active Comparator|Mindfulness|Mindfulness: Eight sessions, twice per week over four weeks. Surveys administered prior to each session.
3180791|NCT00687349|No Intervention|Control Arm|Resident or NP student is assigned to usual education.
3180792|NCT00687375|Other|1|Laparoscopic Inguinal Hernia Repair- Transabdominal preperitoneal (TAPP) approach
3180793|NCT00687375|Other|2|Laparoscopic Inguinal Hernia Repair- Totally extra peritoneal (TEP) Approach
3180794|NCT00687388|Active Comparator|Alpha-blocker|Alpha-blocker only
3134856|NCT03633903|No Intervention|Control|Treatment as usual (i.e., pharmacotherapy, psychotherapy, etc.) for the four week duration with twice weekly surveys administered.
3134857|NCT03633929||KIOS OUD|
3180795|NCT00687388|Active Comparator|NSAID|NSAID only
3134858|NCT03634085|Experimental|Cohort A|"Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort A of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.~The last session for the subjects in Cohort A will be under fed conditions where the same treatment allocation as in the session of the selected dose (administered under fasted conditions) will be used."
3134859|NCT03634085|Experimental|Cohort B|Ascending doses of BDM-2 in Bottle (50 mg - 3600 mg); oral suspension or placebo will be orally administered and will be investigated, alternately dosed in Cohort B of 8 healthy male subjects under fasted conditions. For each dose, 6 subjects will receive active treatment and 2 subjects will receive placebo. Subjects will be randomized in such a way that for each dose different subjects receive placebo.
3134860|NCT03634306|Active Comparator|ARM 1|Laparoscopic hysterectomy with use of the Ultravision System
3134861|NCT03634306|Placebo Comparator|ARM 2|Laparoscopic Hysterectomy per Standard of Care/no Ultravision System
3134862|NCT03634306|Active Comparator|ARM 3|Laparoscopic myomectomy with use of the Ultravision System.
3134863|NCT03634579|Experimental|MRI-guided focal laser ablation|Subjects will undergo MRI Guided Focal Laser Interstitial Thermal Ablation of localized low and intermediate risk prostate cancer.
3148829|NCT00159198||2|Relatives (first and second degree) of patients presenting an association of frontotemporal dementia with amyotrophic lateral sclerosis
3148830|NCT00159211|Active Comparator|1|UMULINE NPH at bed time
3148831|NCT00159211|Experimental|2|pioglitazone 30 mg
3180796|NCT00687388|Experimental|alpha-blocker and NSAID|Combination treatment of alpha-blocker and NSAID
3134864|NCT03634800|Experimental|nivolumab/radiotherapy|"All eligible patients will receive immunotherapy (Nivolumab) plus radiotherapy (6 Gy x 5 fractions) to a targetable lesion.~Nivolumab 240 mg IV starts with the first radiotherapy fraction 240 mg IV every 2 weeks from first radiotherapy fraction until disease prograssion or dose limiting toxicity is reached~Radiotherapy Dose of 6 Gy x 5 days will be given (patients will receive 1 fraction over 5 days for a total of 5 fractions) during the first week of starting Nivolumab"
3134865|NCT03634813|Experimental|High Blood Pressure Monitoring and Counseling|"Enrolled patients will be fitted with a HBPM device and instructed in its use. Patients will be asked to return the HBPM device on the morning of surgery. At the same time they receive the HBPM device, they will also be provided with the National Institutes of Health (NIH) booklet called Your guide on lowering blood pressure, which has several guidelines regarding diet, exercise and lifestyle changes that can be implemented to improve blood pressure control."
3134866|NCT03634813|Active Comparator|Usual Care|The usual care group will receive brief counseling after the PAT visit which will review their blood pressure readings taken at the clinic and how they compare with the American Heart Association (AHA) blood pressure guidelines. They will be offered the suggestion that they should follow up with their primary care doctor 2-4 weeks after their surgical episode is completed, or at their earliest convenience.
3134867|NCT03635086|Experimental|Group A: Two MV-CHIK lyophilized low dose|Participants received two vaccinations with MV-CHIK lyophilized formulation, low dose, on day 0 and day 28.
3134868|NCT03635086|Experimental|Group B: Two MV-CHIK liquid frozen low dose|Participants received two vaccinations with MV-CHIK liquid frozen low dose formulation on day 0 and day 28.
3134869|NCT03635086|Experimental|Group C: Two MV-CHIK liquid low dose stabilizing and protecting solution (SPS®)|Participants received two vaccinations with MV-CHIK liquid low dose SPS® formulation on day 0 and day 28.
3134870|NCT03635086|Experimental|Group D: Two MV-CHIK liquid frozen high dose|Participants received two vaccinations with MV-CHIK liquid frozen high dose formulation on day 0 and day 28.
3134871|NCT03635086|Experimental|Group E: One MV-CHIK liquid frozen high dose/placebo|Participants received one vaccination with MV-CHIK liquid frozen high dose formulation on day 0 and placebo on day 28.
3134872|NCT03635320|Experimental|investigational group|using Trochanteric Fixation Nail Advanced to treat the fracture
3134873|NCT03635320|Active Comparator|the control group|Using Proximal Femoral Nail Antirotation to treat the fracture
3134874|NCT03635424|Experimental|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
3134875|NCT03635775|Experimental|Anodal ipsilesional Active tDCS|Anodal tDCS (excitatory) applied to the lesioned hemisphere. Participant must have lesioned hemisphere MEP.
3134876|NCT03635775|Experimental|Cathodal contralesional Active tDCS|Cathodal tDCS (inhibitory) applied to the non-lesioned hemisphere. Participant must have lesioned hemisphere MEP.
3134877|NCT03635775|Experimental|Anodal contralesional Active tDCS|Anodal tDCS (excitatory) applied to the non-lesioned hemisphere. Participant must not have lesioned hemisphere MEP.
3134878|NCT03635775|Sham Comparator|Sham tDCS|Sham tDCS applied in one of the above configurations
3134879|NCT03635957|Experimental|Pegloticase With Methotrexate (MTX)|"Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase.~Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion."
3134880|NCT03636061|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, Low Dose, 0.12 mg/mL
3134881|NCT03636061|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray Mid dose, 0.6 mg/mL
3134882|NCT03636061|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray High dose, 1.2 mg/mL
3134883|NCT03636061|Placebo Comparator|Placebo|Placebo (vehicle) nasal spray
3134884|NCT03636386|Experimental|Percutaneous microelectrolysis group (MEP)|Group exposed to direct current application using an acupuncture needle with intensities in microamps (μA) in MTrP of upper trapezius muscle. Acupuncture needle correspond to negative electrode or cathode. This group was also be treated with conventional ultrasound (US) before MEP application. US treatments parameters will include; 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
3134885|NCT03636386|Active Comparator|Ultrasound therapy|Group treated with conventional ultrasound (US) on MTrP with 1MHz, 1.5W/cm2, 5cm2 ERA, 100% duty cycle and 15 minutes treatment time.
3148832|NCT00159224|Experimental|Lopinavir/ritonavir monotherapy|Patients with undetectable viral load while on 1st line ARV therapy will be randomized to the expermental arm: Lopinavir/ritonavir monotherapy
3180797|NCT00687414||adults|male and female with MDS and MPD and AML
3180798|NCT00687414||Healthy|Healthy control group
3134886|NCT03636893|Experimental|FLOT Chemotherapy regimen|"A total of four preoperative and four postoperative cycles of FLOT chemotherapy administered~A cycle consists of Day 1 5-fluorouracil(5-FU) 2600mg/M2 administered via an intravenous peripherally inserted central venous catheter(PICC) for 24 hour Leucovorin 200mg/M2 intravenous Oxaliplatin 85mg/ M2 intravenous Docetaxel 50mg/M2 intravenous~Repeated every 15th day"
3134887|NCT03636893|Active Comparator|SOX Chemotherapy regimen|"Three preoperative cycles and three postoperative cycles of SOX chemotherapy administered~A cycle consist of Day 1: Oxaliplatin 130mg/M2 intravenous Day 1-14 Tegafur gimeracil oteracil potassium capsule 80mg/M2 oral (twice daily)~Repeated every 21st day"
3134888|NCT03637296|Experimental|Critical time intervention|Individuals who receive intensive care management during and following discharge from the inpatient medical unit.
3180799|NCT00687427||A|Group A - 25 individuals or more, that start occupational therapy and agree to participate in the research.
3180800|NCT00687427||B|Group B- 25 individuals or more, half a year after hand injury that were treated in occupational therapy at the same institute.
3134889|NCT03637296|No Intervention|Treatment as usual|Individuals who receive routine care management during and following discharge from the inpatient medical unit.
3134890|NCT03637348|Other|TrueTear|Use of TrueTear device to stimulate tear production
3134891|NCT03637517|Experimental|DSM265-TPGS 34% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
3134892|NCT03637517|Active Comparator|DSM265-TPGS 34% SDD, 400 mg fed|Spray dried dispersion (SDD) formulation, powder containing 34.25% DSM265-TPGS (tocopheryl polyethylene glycol succinate)
3134893|NCT03637517|Active Comparator|DSM265 25% SDD, 400 mg fasted|Spray dried dispersion (SDD) formulation, powder containing 25% DSM265 as free base
3134894|NCT03637699|Other|Intervention|Subjects randomized to the intervention group will be complete five weeks of positive psychology exercises, one exercise per week, during the intervention phase (weeks 1-5) of the study.
3148833|NCT00159224|Active Comparator|Lopinavir/Ritonavir plus 2 NRTIs|Patients randomized to this arm will continue with standard of care triple therapy, based on Lopinavir/Ritonavir plus 2 NRTIs
3134895|NCT03637699|Other|Waitlist Control|Subjects randomized to the waitlist control group will complete five weeks of positive psychology exercises, one exercise per week, during the extension phase (weeks 6-10) of the study.
3134896|NCT03637842|Active Comparator|Lorcaserin XR|Lorcaserin XR 20mg daily
3134897|NCT03637842|Placebo Comparator|Placebo|Placebo Oral Capsule
3148834|NCT00159289|Experimental|1|Inhalation of LPS
3148835|NCT00159289|Placebo Comparator|2|PLacebo
3134898|NCT03638011|No Intervention|Standard of Care|These participant will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They standard neuraxial anesthesia with neuraxial Duramorph for post-operative pain.
3148836|NCT00159380|Experimental|Healthy volunteers|8 non smokers non asthmatic
3148837|NCT00159380|Experimental|Asthma volunteers|8 asthmatic mild
3148838|NCT00159406||cohort|Registry and Database
3134899|NCT03638011|Active Comparator|Bilateral TAP Block|These participants will receive standard neuraxial anesthesia for their Cesarean Section and post-operative standard of care breakthrough medications for post-operative pain control. They will receive standard neuraxial anesthesia without neuraxial Duramorph and a transverse abdominal plane (TAP) blocks immediately after surgery, with a mixture of bupivacaine and Exparel, for post-operative analgesia.
3134900|NCT03638323||LOOP group|Speech therapy consultation for patients with Alzheimer's disease
3134901|NCT03638622|Experimental|Aminolevulinic acid (ALA) and Photodynamic Therapy (PDT)|Aminolevulinic Acid (ALA) administration, Photodynamic Therapy (PDT) treatment using LED (Light-emitting diode) light source and follow-up.
3134902|NCT03638635|Active Comparator|Standard Bupivacaine|Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
3148839|NCT00159484|Experimental|A|EPO906, celecoxib
3134903|NCT03638635|Experimental|Bupivacaine Liposome|Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
3134904|NCT03638908|Other|Fluoxetine|"Dosing will be~Week 1-4: 20 mg daily~Week 5-8: 40 mg daily~Week 9-12: 60 mg daily~Week 13-24: 80 mg daily"
3148840|NCT00159497|Active Comparator|1|Standard porouscoated Trilogy Cup
3148841|NCT00159497|Experimental|2|HA coated Trilogy cup
3148842|NCT00159510|No Intervention|Control|The control group with neither nitric oxide nor methylene blue used
3148843|NCT00159510|Active Comparator|MB alone|Single methylene blue used
3148844|NCT00159510|Active Comparator|NO alone|Nitric oxide alone used
3134905|NCT03639311|Experimental|Participants receiving Injection CAB LA plus RPV LA|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose CAB LA (600 mg) plus RPV LA (900 mg) injections within 2 hours of the final oral dose of LATTE given on the same day. The second loading injections will be administered 1 month after initial loading dose (CAB LA 600 mg plus RPV LA 900 mg), with subsequent injections (CAB LA 600 mg + RPV LA 900 mg) occurring Q2M thereafter. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available. HAART therapy will be initiated within 8 weeks after the last Q2M injection.
3134906|NCT03639311|Experimental|Participants receiving Oral DTG plus RPV|The eligible participants in the arm (participants from LATTE, who were administered oral CAB 30 mg plus RPV 25 mg, who successfully complete Week 300) will receive their first dose of the DTG 50 mg plus RPV 25 mg, once daily as oral regimen on Day 1 until Month 12. Participants will continue to receive the treatment until the study intervention is locally approved and commercially available.
3134907|NCT03639675|Experimental|NVG patients|Japanese patients with neovascular glaucoma
3134908|NCT03639766|Experimental|Abobotulinum toxin A|Injection of 300 units of abobotulinum toxin A in 10 ml of non-bacteriostatic normal saline to chosen hand.
3134909|NCT03639766|Placebo Comparator|Saline solution|Injection of 10 ml of non-bacteriostatic normal saline to chosen hand.
3134910|NCT03639779|Experimental|Sodium thiosulfate|50 ml vials of sodium thiosulfate (250mg/ml) will be used for treatment.
3134911|NCT03639779|Placebo Comparator|Saline solution|30 ml vials of sodium chloride 0.9% will be used for the control treatment.
3134912|NCT03639857|Experimental|532nm laser and topical corticosteroid|532nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
3134913|NCT03639857|Experimental|1064nm laser and topical corticosteroid|1064nm laser is applied to the patient's lesion in-clinic in addition to a topical corticosteroid.
3134914|NCT03639857|Active Comparator|Topical corticosteroid alone|Topical corticosteroid is applied to the patient's lesion.
3134915|NCT03639987|Experimental|Group 1|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
3134916|NCT03639987|Experimental|Group 2|Aducanumab, intravenous infusion, every 4 weeks for up to Week 52 during the randomized treatment period. The dose will be titrated to a desirable dose. Participants will be managed for drug continuation and suspension. Following a 4-week follow-up period, eligible participants will continue to receive aducanumab, intravenous infusion, every 4 weeks for an additional 104 weeks in the long-term extension period.
3134917|NCT03640052|Placebo Comparator|Placebo|Placebo capsule 1 time before bedtime
3134918|NCT03640052|Active Comparator|LTM1201L|LTM1201L capsule 1 time before bedtime
3134919|NCT03640052|Active Comparator|LTM1201LN|LTM1201LN capsule 1 time before bedtime
3134920|NCT03640052|Active Comparator|LTM1201LB|LTM1201LB capsule 1 time before bedtime
3134921|NCT03640052|Active Comparator|LTM1201LD|LTM1201LD capsule 1 time before bedtime
3134922|NCT03640507|Active Comparator|Chlorhexidine-alcohol|Subjects will receive vaginal preparation with chlorhexidine-alcohol.
3134923|NCT03640507|Active Comparator|Povidine-iodine|Subjects will receive vaginal preparation with povidine-iodine.
3134924|NCT03640507|Placebo Comparator|Saline|Subjects will receive vaginal preparation with sterile saline.
3134925|NCT03640559|Placebo Comparator|Placebo|the group were having the administration of Placebo (saline 2.4 mL/kg IP)
3134926|NCT03640559|Experimental|Seroguard|the group were having the administration of Seroguard 0.41 g/L solution, 2.4 mL/kg IP
3134927|NCT03640832|Experimental|Test product|All the participant in this arm will receive the test product (development serum). Test product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
3134928|NCT03640832|Active Comparator|Reference product|All the participant in this arm will receive the reference product (Physiogel Calming Relief Anti-Redness Serum). Reference product will be applied twice daily to the freshly cleansed skin in place of the participant's current serum and before applying moisturizer.
3134929|NCT03641508|Active Comparator|Triamcinolone|The study drug used will be triamcinolone mixed with 1% lidocaine without epinephrine
3134930|NCT03641508|Active Comparator|Dexamethasone|The study drug used will be dexamethasone mixed with 1% lidocaine without epinephrine
3134931|NCT03641716|Experimental|Mealtime PREP Intervention|Parents of young children will receive 6 weekly sessions, each lasting approximately one-hour, in the home environment. An occupational therapy clinician will deliver the Mealtime PREP intervention to the family.
3134932|NCT03642262|Experimental|Treatment A: Mucinex® ER 600 mg|Mucinex® ER 600 mg bi-layer single dose tablet by mouth under fasting condition.
3134933|NCT03642262|Active Comparator|Treatment B: Guaifenesin 200 mg|Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.
3134934|NCT03642457|Active Comparator|Serratus Plane Group|Patients randomized to the group will receive a total 20cc of solution consisting of 0.5% bupivacaine with 133mg of liposomal bupivacaine injected in the serratus plane with the help of an ultrasound.
3134935|NCT03642457|Placebo Comparator|Placebo Group|Patients randomized to the group will receive a total 20cc of 133mg liposomal bupivacaine injected prior to skin closure at the incision site as per surgeon's practice.
3134936|NCT03642717||Subjects diagnosed with type 2 diabetes mellitus|
3148845|NCT00159510|Active Comparator|MB+NO|Both nitric oxide and methylene blue used
3134937|NCT03642873|Experimental|Treatment A|Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.
3148846|NCT00159523|Experimental|probiotic|
3148847|NCT00159523|Placebo Comparator|placebo|
3134938|NCT03642873|Experimental|Treatment B|Hydrocodone Bitartrate of 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals administered with 240 mL of room temperature water in the fasted state.
3180801|NCT00687427||C|Group C - 25 individuals or more, a year after hand injury that were treated in occupational therapy at the same institute
3148848|NCT00159536|Experimental|Metformin|Metformin 1000mg x 2 daily
3134939|NCT03642873|Experimental|Treatment C|Hydrocodone Bitartrate 10 mg in 3 oral doses of a single 3.33 mg tablet in three intervals and guaifenesin (Humibid®) 1200 mg ER administered with 240 mL of room temperature water in the fasted state.
3148849|NCT00159536|Placebo Comparator|placebo|Placebo x 2 daily
3148850|NCT00159562|Experimental|group education|Bipolar 1 and 2 patients in a stable euthymic phase will receive group education in 10 weekly sessions and then a session every third month for two years. Symptoms, admittances to hospital and function will be followed for two years.
3148851|NCT00159562|Active Comparator|individual education|Bipolar 1 and 2 patients in a stable euthymic phase will receive three individual sessions of education.
3148852|NCT00159575|Experimental|M: Metformin P: Placebo|
3148853|NCT00159601||outpatients in Child and Adolescent Mental Health Service|
3148854|NCT00159601||youth from general population|
3148855|NCT00159744|Active Comparator|Arm 1|Asenapine
3148856|NCT00159744|Active Comparator|Arm 2|Olanzapine
3148857|NCT00159744|Placebo Comparator|Arm 3|Placebo
3148858|NCT00159796|Experimental|Arm 1|Asenapine
3148859|NCT00159796|Active Comparator|Arm 2|Olanzapine
3148860|NCT00159796|Placebo Comparator|Arm 3|Placebo
3148861|NCT00159926|Experimental|1|With cell saver
3148862|NCT00159926|Active Comparator|2|Without cell saver
3148863|NCT00159939|Active Comparator|prone position|prone positioning
3148864|NCT00159939|No Intervention|supine position|
3148865|NCT00159952|Active Comparator|1|
3134940|NCT03643432|Active Comparator|Usual care|The usual care arm will consist of routine physiotherapy treatment, without the intervention.
3134941|NCT03643432|Experimental|Exercise adherence intervention|The intervention arm will consist of a brief behavioural assessment and recommended adherence strategies based on the outcome of the assessment.
3134942|NCT03643575|Experimental|Treatment A: Vicks Cough Syrup for Chesty Coughs|Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
3134943|NCT03643575|Experimental|Treatment B: Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
3134944|NCT03643575|Experimental|Treatment C: Organ-I- NR tablet|Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
3134945|NCT03643692|Experimental|ARISES|Observational study using wearable technologies to collect data and evaluate blood glucose correlations against physiological and environmental case parameters. Useful associations will assist the development of the CBR/machine learning algorithm and identify wearable devices for the final ARISES platform.
3134946|NCT03643952|Experimental|Daptomycin|Participants aged 1 to 17 years old with cSSTI or bacteremia will receive daptomycin intravenously every 24 hours for either 5-14 days for cSSTI or for 5-42 days for bacteremia.
3134947|NCT03644017|Experimental|WRAPSODY Stent Graft|All subjects will receive treatment via WRAPSODY Stent Graft Placement.
3134948|NCT03644095|Experimental|Mucinex® SE 600 mg (extended-release)|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet taken with 240 mL of water after an overnight fast
3134949|NCT03644095|Active Comparator|Vicks Cough Syrup 200 mg|Vicks Cough Syrup for Chesty Coughs 200 mg every 4 hours taken with 240 mL of water after an overnight fast
3134950|NCT03644108|Experimental|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg Extended-Release (ER) Bi-Layer tablet taken with 240 mL of water after an overnight fast
3134951|NCT03644173|Experimental|Study arm - PREP Intervention|Participants receiving the coaching intervention
3134952|NCT03644212|Active Comparator|Vitamin D treatment|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
3134953|NCT03644212|No Intervention|Non treated|Sixteen vitamin D deficient women (6 with PCOS and 10 without PCOS) were not supplemented vitamin D3. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
3134954|NCT03645421|Placebo Comparator|placebo|Placebo per day,SC injection on 48 days.
3134955|NCT03645421|Experimental|MEDI0382 100μg|50 μg/day,SC injection on the first 5 days and 100 μg/day,SC injection on 43 days
3134956|NCT03645421|Experimental|MEDI0382 200μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days and 200 μg/day,SC injection on 36 days.
3134957|NCT03645421|Experimental|MEDI0382 300μg|50 μg/day,SC injection on the first 5 days, 100 μg/day,SC injection on 7 days, 200 μg/day,SC injection on 7 days and 300 μg/day,SC injection on 29 days
3134958|NCT03645434|Experimental|Treatment sequence A|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
3134959|NCT03645434|Experimental|Treatment sequence B|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
3134960|NCT03645434|Experimental|Treatment sequence C|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follows:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: Matching placebo of AZD8871 and Anoro® Ellipta®"
3134961|NCT03645434|Experimental|Treatment sequence D|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 2: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
3148866|NCT00159991|Experimental|A|Total arterial revascularization
3148867|NCT00159991|Active Comparator|B|Conventional revascularization
3180802|NCT00687466|Experimental|1|Insulin yes
3180803|NCT00687466|No Intervention|2|Insulin no
3134962|NCT03645434|Experimental|Treatment sequence E|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 600 µg and Anoro® Ellipta® matching placebo.~Treatment period 3: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg."
3134963|NCT03645434|Experimental|Treatment sequence F|"Randomized patients will receive multiple oral dose of inhalation powder via DPI as follow:~Treatment period 1: Matching placebo of AZD8871 and Anoro® Ellipta®~Treatment period 2: AZD8871 matching placebo and Anoro® Ellipta® 55 μg / 22 μg.~Treatment period 3: AZD8871 600 µg and Anoro® Ellipta® matching placebo."
3180804|NCT00687479||1-NGT|normal glucose tolerance
3180805|NCT00687479||2-GDM|Gestational Diabetes mellitus
3180806|NCT00687479||3.GIGT|Gestational Impaired glucose tolerance
3180808|NCT00687518|Experimental|1|erythropoietin
3180809|NCT00687518|Placebo Comparator|2|Saline serum
3134964|NCT03645785|Active Comparator|Normal Diet/Drinking|Baseline diet and drinking patterns for patients. This is the pre-intervention baseline for cross-over analysis
3134965|NCT03645785|Experimental|Increased fluid Intake and Citrate Supplementation|Patients will increase fluid (with goal to double their baseline) and further take a citrate supplement in the form of True Lemon (citric acid).
3134966|NCT03645811|Experimental|Implementation of music therapy|"For the music therapy, lecturers specializing in music therapy were consulted and accordingly a mahur maqam, an instrumental piece of traditional Turkish music played on the saz, was chosen. The mahur maqam has a descending scale, which has a relaxing impact as it moves along a 1-2 octave sound spectrum. It elicits feelings of joy and positivity, and immediately draws the attention of the listener, helping keep the mind clear. The mahur maqam belongs to the rast maqam family. Rast maqams are usually evocative of feelings of peacefulness, surrender, tranquility, trust, and mystical sentiments."
3148868|NCT00160017||Collaborative group|Participants (i.e. profesionals) participate in a Breakthrough Collaborative intervention to improve diabetes care so that patients are provided more often with diabetes care as described in guidelines
3148869|NCT00160017||usual care group|Participants are offered no intervention and care is provided as usual
3148870|NCT00160030|Experimental|1|
3148871|NCT00160030|Active Comparator|2|
3148872|NCT00160043|Experimental|Arm 1|
3134967|NCT03645811|Experimental|Implementation of EFT|"The EFT application protocol was explained to the students with the help of the image in the picture for 5 minutes. The method was applied through the investigator tapping on their bodies and the students repeating the steps for three sessions. Each of the treatment sessions was approximately three minutes, resulting in a nine-minute treatment for intervention. Each EFT session was performed by following the steps below.~The content of each EFT session was as follows:~Preparation~Tapping Series~The Nine Gamut Sequence and Eye Movements"
3134968|NCT03645811|No Intervention|Control|For the control group, 15 minutes of free time was given.
3134972|NCT03645954|Active Comparator|Femoral Nerve Block|The femoral nerve block will be performed under the ultrasound guidance by a single injection of local anesthetic around all the femoral nerve branches inside the proximal part of the femoral triangle.
3134973|NCT03645954|Active Comparator|Femoral Triangle & Adductor Canal Blocks|"These two blocks will be performed together.~Firstly, the femoral triangle block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle. Local anesthetic will be injected laterally to the femoral artery.~Secondly, the adductor canal block will be performed under the ultrasound guidance by a single injection of local anesthetic at the level where the femoral vessels (artery and vein) dive deeper from the sartorius muscle. Local anesthetic will be injected under the femoral artery."
3134977|NCT03646305|Experimental|Verbally repeat body-related thoughts|A cognitive defusion strategy in which participants repeat a target unwanted thought out loud and as quickly as possible for 60 seconds.
3134978|NCT03646305|Experimental|Sing negative body-related thoughts|A cognitive defusion strategy in which participants sing a target unwanted thought to the tune of 'twinkle, twinkle' for 60 seconds
3134979|NCT03646305|No Intervention|Verbally repeat body-unrelated thoughts|"A control condition in which participants repeat the phrase I am talking out loud and as quickly as possible for 60 seconds."
3134980|NCT03646305|No Intervention|Sing body-unrelated thoughts|"A control condition in which participants sing the phrase I am singing to the tune of 'twinkle, twinkle' for 60 seconds"
3148873|NCT00160043|Experimental|Arm 2|
3180810|NCT00687570|Other|B|Nutritional drinks 7 days before surgery instead of traditional Bowel preparation with Laxabon®
3180811|NCT00687570|Other|A|Traditional bowel preparation with Laxabon®
3134981|NCT03646656|Experimental|peer partner|Veterans with at least one CVD risk factor who are interesting in increasing heart healthy behaviors through peer support
3134982|NCT03646656|Other|peer coach|Veterans with at least one CVD risk factor who have made and sustained changes in diet or exercise in the past 3-6 months prior to enrollment. While the investigators will collect data on peer coach participants, their participation is primarily as part of intervention to examine the feasibility and benefit of adding peer coaching to a peer partner intervention.
3134983|NCT03647033|No Intervention|phacoemulsification alone|routine phacoemulsification cataract surgery with intraocular lens implantation
3180812|NCT00687596|Experimental|A|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
3134984|NCT03647033|Experimental|phacoemulsification and iStent|phacoemulsification cataract surgery with intraocular lens implantation combined with iStent implantation
3134985|NCT03647046|Experimental|Customized Scleral Lens|A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
3134986|NCT03647267|Active Comparator|Pneumatic Vitreolysis|Participants randomized to the Pneumatic Vitreolysis arm will receive 0.3-mL intraocular injection of C3F8 gas.
3134987|NCT03647267|Placebo Comparator|Observation|Participants randomized to the observation group will receive a sham injection.
3148874|NCT00160056|Other|Hypoglycemia|Intrerfvention is a hypoglycemic stimulus
3148875|NCT00160069|Experimental|Arm 1|
3148876|NCT00160069|Experimental|Arm 2|
3148877|NCT00160069|Experimental|Arm 3|
3148878|NCT00160147|Experimental|1|
3148879|NCT00160147|Placebo Comparator|2|
3148880|NCT00160186|Experimental|1|
3134988|NCT03647475|Experimental|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent|Subjects who fulfilled the inclusion criteria and none of the exclusion criteria were treated with a Resolute Onyx stent followed by one-month DAPT. The clinical safety of the Resolute Onyx stent as compared to a performance goal was evaluated using a composite safety endpoint of cardiac death and myocardial infarction at 1 year for a one-month clear population.
3148881|NCT00160186|Placebo Comparator|2|
3148882|NCT00160290|Experimental|A|Lactulose Group
3134989|NCT03647488|Experimental|Run-in part: capmatinib + spartalizumab|Participants (enrolled in the run-in part) were treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
3134990|NCT03647488|Experimental|Randomized part: capmatinib+spartalizumab|Participants (enrolled in the randomized part) treated with capmatinib 400 mg twice daily (BID) and spartalizumab 400 mg intravenously (i.v.) once every 28 days
3134991|NCT03647488|Active Comparator|Randomized part: docetaxel|Participants (enrolled in the randomized part) treated with docetaxel 75mg/m2 i.v. following local guidelines as per standard of care and product labels once every 21 days
3134992|NCT03648853|Experimental|intervention|all participants receive the same intervention
3134993|NCT03648879|Experimental|1/Arm 1 - Upper white-light endoscopy and confocal endoscopic microscopy|Upper white-light endoscopy and confocal endoscopic microscopy
3134994|NCT03649412|Experimental|Subjects in Part A|Subjects in Part A will receive GSK2982772 MR (Period 1, 3, 4, 5 and 6) and GSK2982772 IR (Period 2).
3134995|NCT03649412|Experimental|Subjects in Part B|Subjects in Part B will receive GSK2982772 MR.
3134996|NCT03649477|Placebo Comparator|Placebo|matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods
3188796|NCT00770848|Other|Phase 1b - AMG 102|Phase 1b is an open-label study with AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed, will be administered by IV Q3W in combination with MP.
3134997|NCT03649477|Experimental|3.2 mg of LV-101|3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
3134998|NCT03649477|Experimental|9.6 mg of LV-101|9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods
3134999|NCT03649646||Patients|Patients with hypertension uncontrolled by antihypertensive drug
3135000|NCT03649750|Experimental|Treatment A: Mucinex® 600 mg (fast)|Mucinex® 600 mg ER bi-layer tablet by mouth after 10 hours fasting and subject will fast at least 4 hours post-dose
3135001|NCT03649750|Experimental|Treatment B: Mucinex® 600 mg (fed)|Mucinex® 600 mg ER bi-layer tablet by mouth in fed condition. After an overnight fast of at least 10 hours, subjects will consume a high fat, high calorie breakfast starting 30 minutes prior to drug administration
3135002|NCT03649815|Experimental|Use of mHealth Technology|This single arm of the study involves the provision of the mobile health technology entitled App4Independence.
3135003|NCT03649867|Other|Semi-structured interview|Each female patient who attended the Survive & Thrive course designed for survivors of interpersonal trauma who meets the inclusion criteria will be invited to take part in a semi-structured interview. This interview will explore their experience of this psychoeducational course.
3135004|NCT03649932|Experimental|L-citrulline 100 mg/kg/day|50 mg/kg given two times a day (100 mg/kg/day) for total 7 days.
3135005|NCT03649932|Experimental|L-citrulline 200 mg/kg/day|100 mg/kg given two times a day (200 mg/kg/day) for total 7 days
3135006|NCT03649932|Experimental|L-citrulline 300 mg/kg/day|150 mg/kg given two times a day (300 mg/kg/day) for total 7 days.
3135007|NCT03650192|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
3135008|NCT03650387|Experimental|RADIESSE® (+) Lidocaine|
3135009|NCT03650400|Experimental|Cohort A Fevipiprant 75 mg|QAW039 75 mg Chewable tablet
3135010|NCT03650400|Experimental|Cohort B Feviprant 375 mg|QAW039 375 mg Chewable tablet
3135011|NCT03650452|Placebo Comparator|Placebo|TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
3135012|NCT03650452|Experimental|TAK-935|TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
3135013|NCT03650842|Experimental|Laparoscopic pyloromyotomy|Infants undergoing laparoscopic pyloromyotomy.
3135014|NCT03651479|Experimental|real boxing group|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
3135015|NCT03651479|Experimental|virtual boxing group|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.
3135016|NCT03651856|Experimental|Atomoxetine|Atomoxetine 40mg daily for 2 weeks uptitration Atomoxetine 40mg BID for 4 weeks Atomoxetine 40mg daily for 1 week weaning off
3135017|NCT03652610|Experimental|GSK3536820A ACWY_Liq Group|Healthy adults, 18 to 40 years of age, receiving at Day 1 a single dose of investigational MenACWY liquid vaccine (GSK3536820A) formulation with approximately 30% Men A FS.
3135018|NCT03652610|Active Comparator|ACWY Group|Healthy adults 18 to 40 years of age, receiving at Day 1 a single dose of licensed GSK's MenACWY vaccine formulation (Menveo).
3135019|NCT03652662|Experimental|RESP-FIT Intervention|"Intervention:~IMST/EMST Training (5 breaths, 5 times a day, 5 times a week) Fitbit activity monitoring Daily symptom and training log entered into mobile application (SAMS)"
3135020|NCT03652662|Active Comparator|RESP-FIT Comparator|"Active Comparator:~Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)"
3135021|NCT03652675|Experimental|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|
3148883|NCT00160290|Active Comparator|B|Plantago Group
3148884|NCT00160316|Experimental|1|
3148885|NCT00160342|Active Comparator|1|
3148886|NCT00160342|Experimental|2|
3148887|NCT00160342|Experimental|3|
3135022|NCT03652675|No Intervention|Educational control condition|Participant will spend 20 minutes at the clinic, observed by the counselor, reviewing an educational pamphlet on drinking, HIV, and HCV.
3135023|NCT03652818|Experimental|Group A|"Pre-op Placebo 1;~Post-op Placebo 1;~Post-op Placebo 2"
3135024|NCT03652818|Experimental|Group B|"Pre-op Placebo 1;~Post-op Placebo 2;~Post-op acetaminophen."
3135025|NCT03652818|Experimental|Group C|"Pre-op Placebo 1;~Post-op pregabalin;~Post-op Placebo 2."
3135026|NCT03652818|Experimental|Group D|"Pre-op Placebo 1;~Post-op pregabalin~Post-op acetaminophen."
3135027|NCT03652818|Experimental|Group E|"Pre-op pregabalin;~Post-op Placebo 1;~Post-op acetaminophen."
3135028|NCT03653026|Experimental|Upadacitinib 45 mg|Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period.
3135029|NCT03653026|Placebo Comparator|Placebo|Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period.
3135030|NCT03653208|Experimental|Group 1 (hzVSF-v13 10mg)|Group 1 received a single 10mg dose of hzVSF-v13 on Day 1.
3135031|NCT03653208|Experimental|Group 2 (hzVSF-v13 20mg)|Group 2 received a single 20mg dose of hzVSF-v13 on Day 1.
3135032|NCT03653208|Experimental|Group 3 (hzVSF-v13 50mg)|Group 3 received a single 50mg dose of hzVSF-v13 on Day 1.
3135033|NCT03653208|Experimental|Group 4 (hzVSF-v13 100mg)|Group 4 received a single 100mg dose of hzVSF-v13 on Day 1.
3148888|NCT00160342|Active Comparator|4|
3135034|NCT03653208|Experimental|Group 5 (hzVSF-v13 200mg)|Group 5 received a single 200mg dose of hzVSF-v13 on Day 1.
3135035|NCT03653208|Experimental|Group 6 (hzVSF-v13 400mg)|Group 6 received a single 400mg dose of hzVSF-v13 on Day 1.
3148889|NCT00160342|Experimental|5|
3135036|NCT03653208|Experimental|Group 7 (hzVSF-v13 800mg)|Group 7 received a single 800mg dose of hzVSF-v13 on Day 1.
3135037|NCT03653208|Experimental|Group 8 (hzVSF-v13 1200mg)|Group 8 received a single 1200mg dose of hzVSF-v13 on Day 1.
3135038|NCT03653208|Placebo Comparator|Placebo|Placebo group received a single placebo on Day 1.
3135039|NCT03653351|Sham Comparator|Sham tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + sham tDCS and daily at home MBSR + sham tDCS.
3135040|NCT03653351|Active Comparator|Active tDCS and MBSR|Includes a combination of 8 weeks of in-class group MBSR + active tDCS and daily at home MBSR + active tDCS.
3135041|NCT03653416|Experimental|Ipack group|20 cc of bupivacaine(o.25%) will be injected with the help of ultrasound guidance. Patients will receive adductor canal catheter and peri articular infiltration as well.
3180813|NCT00687596|Placebo Comparator|B|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
3188797|NCT00770848|Experimental|Phase 2 Arm A - AMG 102 + MP|AMG 102 safe dose level in phase 1b in combination with MP, will be administered by IV Q3W.
3188798|NCT00770848|Placebo Comparator|Phase 2 Arm C- PLACEBO|Placebo in combination with MP, will be administered by IV Q3W.
3135042|NCT03653416|Active Comparator|Pai (peri articular) group|Patients will receive adductor canal catheter and peri articular infiltration.
3135043|NCT03653429|Active Comparator|Tranexamic acid group|10mg/kg intravenous tranexamic
3135044|NCT03653429|Placebo Comparator|Normal Saline group|10mg/kg intravenous normal saline
3148890|NCT00160342|Experimental|6|
3148891|NCT00160342|Active Comparator|7|
3148892|NCT00160342|Active Comparator|8|
3135045|NCT03654326|Experimental|Gefapixant|Participants will receive a gefapixant 45 mg tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
3135046|NCT03654326|Placebo Comparator|Placebo|Participants will receive a placebo matching gefapixant tablet twice a day for approximately 8 weeks (2 menstrual cycles). Naproxen sodium 275 mg tablets will also be provided to participants for use as rescue medication for endometriosis-related pain.
3135047|NCT03654417|Active Comparator|EMLA|
3135048|NCT03654417|Active Comparator|Lidocaine|
3135049|NCT03654560|Active Comparator|HemoStyp|Subjects with an appropriate target bleeding site will have Hemostyp applied in accordance to instructions for use.
3135050|NCT03654560|Active Comparator|Surgicel|Subjects with an appropriate target bleeding site will have Surgicel applied in accordance to instructions for use.
3135051|NCT03655054|Experimental|eCoin Tibial Nerve Stimulation|
3135052|NCT03655080|Experimental|nab-Paclitaxel and Radiation Therapy|"10 fractions of 3Gy radiation therapy will be delivered.~A total of 4 chemoradiation blocks should be delivered ideally in consecutive days~On day 1 of the chemoradiation block, nab-paclitaxel is delivered in the morning followed by radiotherapy the latest possible and ideally at least 6 hours later (no earlier than 4 hours after the start of nab-paclitaxel)~On day 2, radiotherapy is delivered in the morning, ideally within 24 hours from the start of nab-Paclitaxel infusion the previous day~There will be 2 radiation fractions that won't be part of any chemoradiation block and can be placed anywhere before, after, or between blocks"
3135053|NCT03655106|Active Comparator|Standard Long IV 4.78 cm 20 g catheter|Placement of Standard Long IV 4.78 cm 20 g catheter
3135054|NCT03655106|Experimental|Ultra-Long IV 6.35 cm 20 g catheter|Placement of Ultra-Long length IV 6.35 cm 20 g catheter
3148893|NCT00160342|Placebo Comparator|9|
3148894|NCT00160355|Other|1|
3148895|NCT00160381|Experimental|1|
3148896|NCT00160381|Experimental|2|
3135055|NCT03655301|Experimental|Copanlisib (Aliqopa, BAY80-6946)|All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
3135056|NCT03655405|Experimental|Individual Deprescribing Intervention|Participants allocated to the intervention arm will receive the Individual Deprescribing Intervention (pharmacist-led medication review, followed by the creation of a deprescribing plan by the pharmacist, physician and responsible nurse).
3135057|NCT03655405|No Intervention|Control|Participants allocated to the control group will receive usual care.
3135058|NCT03655444|Experimental|Phase I: Abemaciclib + Nivolumab|"Abemaciclib (150 mg) will be administered orally twice per day (with or without food) on Days 1 through 28 of every 4-week cycle~Nivolumab 480 mg will be given intravenously (IV) over 30 minutes on Day 1 of every 4-week cycle."
3148897|NCT00160381|Placebo Comparator|3|
3148898|NCT00160420|Experimental|1|
3148899|NCT00160433|Experimental|1|
3148900|NCT00160433|Experimental|2|
3148901|NCT00160433|Experimental|3|
3148902|NCT00160433|Placebo Comparator|4|
3148903|NCT00160446|Experimental|1|
3148904|NCT00160446|Experimental|2|
3148905|NCT00160446|Experimental|3|
3148906|NCT00160446|Placebo Comparator|4|
3148907|NCT00160459|Experimental|1|
3148908|NCT00160459|Experimental|2|
3148909|NCT00160459|Experimental|3|
3148910|NCT00160459|Placebo Comparator|4|
3148911|NCT00160485|Experimental|1|Glyburide,gestational diabetes, maternal complications, neonatal complications
3135059|NCT03655444|Experimental|Phase II: Abemaciclib + Nivolumab|"Phase II Lead-in: Patients will be treated with abemaciclib monotherapy at the recommended phase II dose (150 mg) on Day -7 through Day -1 prior to starting Cycle 1 with the combination of abemaciclib and nivolumab. Patients will proceed directly from Day -1 to Cycle 1 Day 1 of combination abemaciclib + nivolumab, there is not a Day 0.~Patients will be treated with abemaciclib at the RP2D (150 mg) (Days 1 through 28) + nivolumab (480 mg, Day 1) of each 4-week cycle."
3135060|NCT03655951|Experimental|Resource 1|Web-based resource on adolescent sexual health
3135061|NCT03655951|Active Comparator|Resource 2|Alternate web-based resource on adolescent sexual health
3135062|NCT03656939||Prevenar 13 cohort|This is a non-interventional study. Children in the study receive Prevenar 13 per normal medical practice.
3135063|NCT03657095|Experimental|Esuberaprost|Participants who received esuberaprost during the BPS-314d-MR-PAH-302 double-blind study will receive 2 tablets of 15 μg esuberaprost sodium tablets for oral administration QID for up to 7 months (which will include the 4 weeks of blinded transition).
3135064|NCT03657095|Placebo Comparator|Placebo/Esuberaprost|Participants who received placebo during the BPS-314d-MR-PAH-302 double-blind study will receive 1 esuberaprost tablet and 1 placebo tablet QID during the first 2 weeks of the blinded transition and then receive 2 esuberaprost tablets QID for the rest of the study, for up to 7 months (which will include the other 2 weeks of the total 4-week blinded transition).
3135065|NCT03657134|Experimental|EP Procedure|Patient will continuously wear the CoVa-2 monitoring system until they are discharged. During this period, data from the sensor will be sent to the Gateway and Cloud-based System, and then analyzed retrospectively.
3135066|NCT03657264|Experimental|Sequence 1|"The sequence of administration is: P/ScD/PC/CD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
3148912|NCT00160485|Active Comparator|2|Insulin, gestational diabetes, maternal complications, neonatal outcomes
3148913|NCT00160732|Experimental|Transplant|
3135067|NCT03657264|Experimental|Sequence 2|"The sequence of administration is: CD/PC/ScD/P~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
3135068|NCT03657264|Experimental|Sequence 3|"The sequence of administration is: ScD/CD/P/PC~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
3135069|NCT03657264|Experimental|Sequence 4|"The sequence of administration is: PC/P/CD/ScD~Where:~P = Placebo (Nacl 0.9%)~CD = P03277 tested at 0.1 mmol/kg~ScD = P03277 tested at 0.3 mmol/kg~PC = Positive control (moxifloxacin 400 mg - per os)."
3135070|NCT03657277|Other|Micropatch Application|This is the only study arm, which all participants complete. Five sites each on each the upper arm, forearm, and abdomen will be identified. Baseline measurements of trans-epidermal water loss, electrical resistance, hydration, and skin color will be made. Micropatches will be applied at three sites (at each body location). This only occurs on the first study day. Trans-epidermal water loss and electrical resistance are re-measured immediately after micropatch application. The sites will be covered with a small patch secured with medical tape. One site at each location will just be covered with a patch. The last site will not have micropatch application or patches. Electrical resistance will be re-measured at all sites for 3 days. Measurements from the 4th and 5th sites allow each subject to serve as their own control in data analysis.
3135071|NCT03657407|Active Comparator|B&O|29 women randomized to Belladonna & Opium suppository
3135072|NCT03657407|Sham Comparator|Placebo|27 women randomized to Glycerin suppository
3135073|NCT03658811|Experimental|Upper eyelid meibomian gland dysfunction|Patients with symptoms of dry eye disease in spite of previous or current use of currently available over the counter or prescription medications for dry eye and evidence of upper eyelid meibomian gland dysfunction and no prior intense pulsed light treatments or meibomian gland expression treatments
3135074|NCT03658876|Active Comparator|EPO group|
3135075|NCT03658876|Active Comparator|Iron group|
3135076|NCT03658889||Patients under treatment(s) for GCA|Patients at least 50 years old with Giant Cell Arteritis (GCA) and under treatment(s) for GCA
3135077|NCT03660241|Experimental|PF-04965842|PF 04965842 is an oral selevtive janus kinase (JAK) 1 inhibitor
3135078|NCT03660787|Placebo Comparator|Placebo, 1.5 mL/kg|each subject received the placebo at the dose of 1.5 mL/kg of body weight;
3135079|NCT03660787|Placebo Comparator|Placebo, 2.4 mL/kg|each subject received the placebo at the dose of 2.4 mL/kg of body weight;
3148914|NCT00160771||Joint Motion Analysis|Joint motion will be recorded for analysis.
3148915|NCT00160784|Active Comparator|Arthroscopic Manipulation|Manipulation of Shoulder performed during arthroscopy
3148916|NCT00160784|Active Comparator|Home exercise program|Shoulder exercise program performed at home to increase shoulder function
3148917|NCT00160875|Experimental|Cisplatin, Irinotecan|
3148918|NCT00160966|Active Comparator|1|Immunosuppression with Ciclosporin and Mycophenolate-mofetil; Ciclosporin treatment being started at the latest at day 4 after transplantation with 7 mg/kg body weight daily administered every 8 hours until the target trough level of 300 µg/l was reached. Then it was administered twice daily with daily monitoring of trough levels. The target trough level was lowered to 200 µg/l 1 month after transplantation. Thereafter dosage and target trough levels were adjusted at the investigators discretion. Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once ciclosporin was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted at the investigators discretion.
3148919|NCT00160966|Active Comparator|2|Immunosuppression with Tacrolimus and Mycophenolate-mofetil Mycophenolate-mofetil was started previous to transplantation procedure with a starting dosage of 3 g/day administered twice daily. Once tacrolimus was entered into the therapy-scheme Mycophenolate-mofetil dosage was reduced to 2 g/daily. The therapy was controlled by measuring of trough levels with a target trough level exceeding 1 µg/ml. The dosage was adjusted to clinical signs of overimmunosuppression (infections) or intolerance (mainly gastrointestinal side effects) or rejections.
3148920|NCT00160966|Active Comparator|3|Immunosuppression with Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus after completion of posttransplant wound healing
3148921|NCT00160979|Experimental|hypoxia and RT in prostate cancer|
3148922|NCT00161187|Experimental|Treatment|Biological/Vaccine: therapeutic allogeneic lymphocytes The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
3148923|NCT00161265||1|women with breast cancer
3148924|NCT00161304|Active Comparator|Testosterone Enanthate|Testosterone
3148925|NCT00161304|Placebo Comparator|Placebo|Placebo
3135080|NCT03660787|Experimental|Seroguard, 1.5 mL/kg|each subject received the test drug at the dose of 1.5 mL/kg of body weight;
3135081|NCT03660787|Experimental|Seroguard, 2.4 mL/kg|each subject received the test drug at the dose of 2.4 mL/kg of body weight.
3135082|NCT03660839|Experimental|Ferroquine 400 milligram (mg)|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition.
3135083|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 300 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 300 mg oral suspension.
3135084|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 600 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 600 mg oral suspension.
3135085|NCT03660839|Experimental|Ferroquine 400 mg + Artefenomel 1000 mg|On Day 0, participants received orally a single dose of FQ 400 mg (4 capsules of 100 mg) in fasted condition followed by OZ439 1000 mg oral suspension.
3135088|NCT03661346|Experimental|Esmolol|Patients receiving esmolol when intra-operative MAP > 80 mmHg.
3135089|NCT03661346|Active Comparator|Labetalol|Patients receiving labetalol when intra-operative MAP > 80 mmHg
3135090|NCT03661541|Experimental|Group A, 6 or more outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group A: 12 subjects with 6 or more herpes labialis outbreaks in the past 12 months.~Subjects in group A will receive 2% Squaric Acid Dibutyl Ester (SADBE) dose on the arm after their initial blood samples are obtained. Group A subjects will have blood collected and tests repeated 2 and 8 weeks later.~Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges."
3135091|NCT03661541|No Intervention|Group B, 1 or 2 outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group B: 12 subjects with 1 to 2 outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
3148926|NCT00161343|Experimental|1|Small interactive groups on preventing HIV infections using an Information-Behavioral Skills-Motivational model
3135092|NCT03661541|No Intervention|Group C, zero outbreaks per 12 months|"Subjects will be recruited in three groups, all of whom are infected with HSV-1, as shown by having IgG against HSV-1:~Group C: 12 subjects with zero outbreaks in the past 12 months. Subjects in Groups B and C will be matched to the subjects in Group A so that demographic characteristics (i.e., gender distribution, age and weight) are within broadly similar ranges. Invite these back for a further blood draw on Day 0."
3135093|NCT03661697|Experimental|Lytera Arm|4 week washout period with skin care regimen including Lytera 2.0 followed by 2 laser treatments.
3135094|NCT03661697|Active Comparator|Laser only arm|4 week washout period with a basic skin care regimen, no Lytera 2.0, followed by 2 laser treatments.
3135095|NCT03661762||Healthy Volunteers|All trial participants are within this group. All trial participants will wear the CAVA device for up to 23 hours a day, for 30 days.
3135096|NCT03661814|Experimental|Prevena|This group will receive the negative pressure wound therapy device.
3135097|NCT03661814|No Intervention|Standard of Care|This group will not receive the device and their surgery and clinical course will proceed as if they were not part of the study. They will receive the standard of care wound dressings.
3148927|NCT00161343|Placebo Comparator|2|Small interactive groups on general health-promotion topics using an Information-Behavioral Skills-Motivational model
3148928|NCT00161395|Active Comparator|1|Preconception advice.
3135098|NCT03661983|Experimental|Open Label Stabilization Phase: Aripiprazole|Participants began treatment with aripiprazole at a 2.0 mg/day dose, with the dose titrated to 5.0 mg/day after 2 days. Subsequent dose adjustments were based on the participant's weight to achieve optimum control of tics up to the maximum recommended doses based on the United States Labeling, up to Week 8 and then continued on the most stabilized dose up to minimum Week 14 or maximum Week 20. Participants who met stabilization criteria were randomized to Double-blind Randomization Phase.
3135099|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Full Dose|Participants who met stabilization criteria and randomized to receive full dose of aripiprazole i.e. 5 mg or 10 mg for <50 kg participants,and 10 mg or 20 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
3135100|NCT03661983|Experimental|Double Blind Phase: Aripiprazole Half Dose|Participants who met stabilization criteria and randomized to receive half dose of aripiprazole i.e. 2 mg or 5 mg for <50 kg participants, and 5 mg or 10 mg for >50 kg participants (2 tablets a day), based on stabilized dose in open-label stabilization phase, up to 12 weeks in Double-Blind Phase.
3135101|NCT03661983|Placebo Comparator|Double Blind Phase: Placebo|Participants who met randomization criteria and randomized to receive aripiprazole matching-placebo tablets, 2 daily, orally, up to 12 weeks in Double-Blind Phase.
3188799|NCT00770848|Experimental|Phase 2 Arm B - AMG 102 + MP|Safe dose level in phase 1b of AMG 102 + MP will be administered by Q3W
3135102|NCT03662074|Experimental|Treatment (gemcitabine, nivolumab)|Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
3135103|NCT03662139||Cerebral Palsy Group|16 patients will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
3135104|NCT03662139||Healthy Control Group|16 healthy children will be included. Dynamic Gait Index and other assessments will be performed twice with a 7 - 10 day interval by two evaluators
3135105|NCT03662282|Experimental|Drug - Omegaven®|Therapy with Omegaven® will be initiated at the goal dose of 0.5-1/kg/day. The default is over 24 hours, but shorter intervals may be considered if a program of total parenteral nutrition cycling is recommended. Omegaven® will be infused intravenously through either a central or peripheral catheter.
3135106|NCT03662334|Experimental|Hylenex recombinant|Comparing the preadministration of Hylenex recombinant in the setting of continuous subcutaneous insulin infusion (CSII).
3135107|NCT03662334|Sham Comparator|Sham Injection|Comparing the preadministration of a sham injection in the setting of CSII.
3135108|NCT03662360|No Intervention|GROUP A - control group|16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
3135109|NCT03662360|Experimental|GROUP B - aromatherapy group|16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy
3135110|NCT03662750|Experimental|Acute stroke cohort|Acute stroke cohort
3135111|NCT03662789|Active Comparator|Iron isomaltoside 1000|"The active drug, iron isomaltoside 1000 will be administered as a single, intravenous infusion of 20 mg/kg body weight (rounded off to the nearest 100 mg) dissolved in 100 ml NaCl as recommended by the drug manufacturer (on-label treatment)."
3135112|NCT03662789|Placebo Comparator|Placebo|Patients allocated to placebo will receive an intravenous infusion of 100 ml NaCl 0.9%
3135113|NCT03662997|Active Comparator|Five-layer vs Hydropolymer|Bordered Five-layer Foam Dressing for 2 weeks, followed by Hydropolymer Foam Dressing for 2 weeks.
3135114|NCT03662997|Active Comparator|Hydropolymer vs Five-layer|Hydropolymer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
3135115|NCT03662997|Active Comparator|Five-layer vs Hydrocellular|Bordered Five-layer Foam Dressing for 2 weeks, followed by Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks.
3135116|NCT03662997|Active Comparator|Hydrocellular vs Five-layer|Foam Hydrocellular Multi-layer Foam Dressing for 2 weeks, followed by Bordered Five-layer Foam Dressing for 2 weeks
3135117|NCT03663101|Experimental|Pre-Randomization, Run-In period (part A)|Crossover run-in part A - Subjects will be injected (Test 1) with either saline or local anaesthetic (lidocaine). One week later, they will be crossed over, injected with the other agent (Test 2).
3135118|NCT03663101|Experimental|Dysport dose 1 (part B)|Dysport dose 1 as a single-dose, intradermal injection.
3135119|NCT03663101|Experimental|Dysport dose 2 (part B)|Dysport dose 2 as a single-dose, intradermal injection.
3135120|NCT03663101|Experimental|Dysport dose 3 (part B)|Dysport dose 3 as a single-dose, intradermal injection.
3135121|NCT03663101|Placebo Comparator|Placebo (saline solution) (part B)|Placebo single-dose, intradermal injection.
3135122|NCT03663179|Experimental|Active TMS|Participants will receive 20 sessions of active TMS targeting the left DLPFC.
3135123|NCT03663179|Sham Comparator|Sham TMS|Participants will receive 20 sessions of sham TMS over the left DLPFC.
3135124|NCT03663231|Experimental|Biotene|People who present with dry mouth and will receive a single dose of Biotene.
3135125|NCT03663231|Placebo Comparator|Placebo|People who present with dry mouth and will receive a single dose of an alternative agent.
3135126|NCT03663283|Experimental|Liposomal Bupivacaine|Administered utilizing ultrasound guidance by an anesthesiologist. Study patients will receive 10ml (133 mg) of liposomal bupivacaine mixed with 7.5ml of 0.5% plain bupivacaine and 7.5ml of 0.25% bupivacaine. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
3135127|NCT03663283|Active Comparator|Plain Bupivacaine|Peripheral nerve blocks will be performed with ultrasound guidance by an anesthesiologist. Standard bupivacaine hydrochloride will be utilized. 25 ml of 0.5% bupivacaine for peripheral nerve block will be utilized. Further, 8 mg (2 ml) IV dexamethasone will be administered concomitantly at the time of the block.
3135128|NCT03663569||subjects with COPD|
3135129|NCT03663582|Experimental|Teduglutide 0.05 mg|Participants will receive teduglutide 0.05 milligram per kilogram (mg/kg) subcutaneous (SC) injection once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm for 24 weeks.
3135130|NCT03663816|Experimental|Healthy men and women|Participants will serve as their own control. Balance and gait measures will be collected during an initial visit and after one week of using the experimental foot device
3135131|NCT03664193|Other|Single Arm|Patients will receive 35 Gy in 5 fractions. Also, patients will receive 0.5-2 Gy per fx for a total dose of 37.5, 40, 42.5, or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
3135132|NCT03664544|Experimental|Subjects with severe hepatic impairment|HP PK MCI-186
3135133|NCT03664544|Experimental|Subjects with normal hepatic function|NHV PK MCI-186
3148929|NCT00161395|Experimental|2|Instruction in the Creighton Model Fertility Care System.
3148930|NCT00161421|Experimental|1|Lupron injection at Day -14 with load of dutasteride (24.5 mg) followed by 13 days of Dutasteride. On day 0, 11, 0.5 mg Dutasteride taken daily for next 11 days. Day 1 Oral Testosterone (T) 200mg without food, Day 2 Oral T 400 mg without food, Day 3 Oral T 400 mg with food. During the 2nd week of the study, we will repeat the testosterone doses, with a 2nd formulation of testosterone (Day8, 9, & 10.
3148931|NCT00161434|Experimental|1|
3148932|NCT00161434|Placebo Comparator|2|
3148933|NCT00161447|Active Comparator|1|Testosterone (T) gel for 6 months + DMPA (injected into muscle once)on Day 0 and at Month 3
3148934|NCT00161447|Active Comparator|2|Testosterone (T) gel for 6 months + DMPA (injected into muscle on Day 0 & at month 3) + Acyline (SQ) every two weeks for the first 12 weeks
3148935|NCT00161460|Active Comparator|1|Study nurse contacts subjects who enroll in the intervention to provide detailed education about screening tests, to assess their risk for colorectal cancer, and to facilitate screening.
3148936|NCT00161460|No Intervention|2|Patients who do not enroll receive usual care from their primary care providers.
3148937|NCT00161486|Placebo Comparator|1|Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks
3148938|NCT00161486|Active Comparator|2|Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks
3148939|NCT00161486|Active Comparator|3|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks
3135134|NCT03665155|Experimental|89Zr-daratumumab|"Three patients will be administered 2 mCi of 89Zr-daratumumab in a total of 50 mg of daratumumab antibody. Administered activity (1 to 5 mCi) of radioactivity and total amount of administered antibody (3 to 50 mg) will be adjusted in subsequent patients in order to maximize image quality.~Patients in phase I will have up to 4 PET/CT scans, multiple blood draws, whole-body counts, and safety monitoring to determine pharmacokinetics, radiation dosimetry, and safety of 89Zr-DFO-daratumumab for PET/CT imaging. Phase II (total of 21-24 patients). After pharmacokinetics and radiation dosimetry are determined in phase I, additional patients will be enrolled in phase II."
3135135|NCT03666026|No Intervention|Standard of care control|Participants in this group will not receive any MyChart influenza vaccination reminders
3135136|NCT03666026|Experimental|1 MyChart R/R|Participants in this group will receive up to 1 influenza reminder recall notice via their MyChart account
3135137|NCT03666026|Experimental|2 MyChart R/R|Participants in this group will receive up to 2 influenza reminder recall notices via their MyChart account
3135138|NCT03666026|Experimental|3 MyChart R/R|Participants in this group will receive up to 3 influenza reminder recall notices via their MyChart account
3135139|NCT03666663|Experimental|Lidocaine|Participants will receive SPG blocks with lidocaine.
3135140|NCT03666663|Experimental|Bupivacaine|Participants will receive SPG blocks with bupivacaine
3135141|NCT03666663|Experimental|Ropivacaine|Participants will receive SPG blocks with ropivacaine
3135142|NCT03666663|Placebo Comparator|Placebo (saline)|Participants will receive SPG blocks with placebo (saline)
3148940|NCT00161577|Other|A|Group A = Ketorolac
3148941|NCT00161577|Placebo Comparator|B|
3148942|NCT00161720||All participants|Participants with severe congenital protein C deficiency who were treated under an emergency use IND.
3148943|NCT00162110|Active Comparator|1|
3148944|NCT00162149|No Intervention|A1|
3148945|NCT00162149|Experimental|A2|
3148946|NCT00162149|Experimental|A3|
3135143|NCT03666858||Neosaldina|Participants with episodic TTH and who have already been treated with Neosaldina will be included in the observation period of this study. During the observation period, participants will be administered with Neosaldina 2 tablets, orally in the beginning of the TTH episode, every 6 hours, and at maximum of 8 tablets per day, according to regular clinical practice of the physicians. The participants will be observed in this study from Day 1 until Day 45.
3135144|NCT03667053|Experimental|dasiglucagon|Single fixed dose (s.c.injection) of dasiglucagon
3135145|NCT03667053|Placebo Comparator|placebo|Single fixed dose (s.c.injection) of placebo
3135146|NCT03667053|Active Comparator|GlucaGen®|Single fixed dose (s.c.injection) of GlucaGen®
3135147|NCT03667547|Experimental|Raltegravir|Participants will receive a single oral dose of raltegravir 1200 mg (600 mg tablet X 2) in a fasted state on Day 0 and will be followed up to 2 weeks
3135148|NCT03668600|Experimental|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
3135149|NCT03668613|Experimental|secukinumab low dose|secukinumab low dose
3135150|NCT03668613|Experimental|secukinumab high dose|secukinumab high dose
3148947|NCT00162149|No Intervention|B1|
3148948|NCT00162201|Experimental|1|
3148949|NCT00162214|Active Comparator|1|
3148950|NCT00162305|Active Comparator|1|
3148951|NCT00162305|Active Comparator|2|
3148952|NCT00162305|Active Comparator|3|
3148953|NCT00162305|Placebo Comparator|4|
3148954|NCT00162318|Experimental|A|
3135151|NCT03669081|Experimental|Toradol and Lyrica|Over-Encapsulated Pregabalin 75 mg was administered PO 30 minutes prior to operation; Ketorolac 30 mg IV x 1 was administered in the OR, followed by ketorolac 15 mg IV every 6 hours for 7 doses (or until discharge).
3135152|NCT03669081|Placebo Comparator|Placebo and Standard of Care|Identical placebo oral capsule (same size and color) was administered PO 30 minutes prior to operation; Saline placebo IV x 1 was administered in the OR, followed by saline placebo IV every 6 hours for 7 doses. Standard of care practices maintained.
3135153|NCT03669354||Cohort SMT|Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT
3180814|NCT00687622|Experimental|GSK1120212|Part 1 will identify the maximum tolerated dose using a dose-escalation procedure. Part 2 will explore further the safety, tolerability, and clinical activity of GSK1120212 in subjects with pancreatic, melanoma, non-small cell lung, and KRAS or BRAF mutation-positive colorectal cancer. Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic markers in tumor tissue
3135154|NCT03669354||Cohort OAT|Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT
3135155|NCT03669354||Cohort SMTX|Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT
3135156|NCT03669354||Cohort OATX|Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT
3135157|NCT03669549|Experimental|Nevanimibe hydrochloride|Ascending dose level of oral nevanimibe hydrochloride beginning with 500 mg BID up to 2000 mg BID
3135158|NCT03669861|Experimental|Abatacept|To assess the effect of weekly subcutaneous (SC) administration of abatacept on complete remission of IgG4-RD
3135159|NCT03670017|Other|Time In Range during OptiScanner Connection|Participants will be connected to the OptiScanner 5000 for up to 72 hours.
3135160|NCT03670030|Experimental|ABI-009|In this study, you will receive ABI-009 given through a vein (intravenous) once weekly for 2 weeks (on days 1 and 8) followed by a week of rest in a 21-day cycle.
3135161|NCT03670160|Active Comparator|Phenobarbital|Phenobarbital loading dose 20mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital continued throughout the infants hospitalization.
3135162|NCT03670160|Active Comparator|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be continued to achieve control of NAS symptoms. Clonidine may be weaned after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
3135163|NCT03670264|Experimental|Quitline Incentive|The incentive structure emphasizes engaging with the Quitline Delivered Treatment, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the Quitline, for maintaining involvement in the Quitline program (per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the Way to Health (WTH) platform.
3135164|NCT03670264|Experimental|Tobacco Cessation Incentive|The incentive structure emphasizes quitting regardless of engagement with the Quitline Delivered Treatment (though the Quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, compensation for submitting the cotinine swab and for confirmed quitting (negative salivary cotinine). Study procedures, payments and reminders are managed through the WTH platform.
3135165|NCT03670264|Placebo Comparator|No Financial Incentive|No financial incentive to engage in Quitline Delivered Treatment or report abstinence. Study procedures and reminders are managed through the WTH platform.
3135166|NCT03670537||First trimester pregnant women|
3135167|NCT03670641|Experimental|Insulin and CGM Intervention|10 individuals with newly diagnosed type 2 diabetes will be started on basal (glargine) bolus (lispro) insulin therapy for up to 4 weeks with titrations guided by continuous glucose monitor (Dexcom G6) to achieve euglycemia and then insulin stopped after 4 weeks with hopes of diabetes remission.
3135168|NCT03670810|Experimental|100 milligram (mg) Lasmiditan|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
3135169|NCT03670810|Experimental|200 mg Lasmiditan|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
3135170|NCT03670810|Placebo Comparator|Control 1 Sequence|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
3135171|NCT03670810|Placebo Comparator|Control 2 Sequence|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
3135172|NCT03670810|Experimental|100 mg Lasmiditan Maximum Extended Enrollment (MEE)|Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
3135173|NCT03670810|Experimental|200 mg Lasmiditan MEE|Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.
3135174|NCT03670810|Placebo Comparator|Control 1 Sequence MEE|"Control 1:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
3135175|NCT03670810|Placebo Comparator|Control 2 Sequence MEE|"Control 2:~Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.~Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.~Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks."
3180815|NCT00687648|Experimental|Arm I|Patients receive aromatase inhibitor (anastrozole, letrozole, or exemestane) as previously prescribed. Patients also receive oral cyclophosphamide once daily on days 1-28 and oral methotrexate twice on days 15, 16, 22, and 23 of course 1. For all subsequent courses, patients receive oral cyclophosphamide once daily and oral prednisolone once daily on days 1-28 and oral methotrexate twice on days 1, 2, 8, 9, 15, 16, 22, and 23. Treatment with cyclophosphamide, methotrexate, and prednisolone repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3180816|NCT00687648|Active Comparator|Arm II|Patients receive cyclophosphamide, methotrexate, and prednisolone as in arm I.
3135176|NCT03672006|Experimental|alteplase|patients will receive 30 min-4 hours dwells of alteplase (recombinant t-PA) (2mg/2ml, up to 2mg per dose) to central venous catheter every 3 days (maximum 10 doses)
3180817|NCT00687661|Active Comparator|1|Arm #1 will include patients randomized to receive bisphosphonate therapy for 24 months.
3180818|NCT00687661|Placebo Comparator|2|Arm #2 will include patients randomized to receive placebo therapy for 24 months
3180819|NCT00687687|Experimental|Pacitaxel/Carboplatin/Iniparib|Participants will be administered pacitaxel, carboplatin and BSI-201 (Iniparib) in 21 day treatment cycles. Treatment will continue until disease progression or adverse effects prohibit further therapy.
3135177|NCT03672006|Active Comparator|Heparin|patients will receive 30 min-4 hours heparin (10U/ml, up to 2 ml per dose) dwells to central venous catheter every 3 days (maximum 10 doses)
3135178|NCT03672032|Active Comparator|Fork-tip Needle|
3135179|NCT03672032|Active Comparator|Franseen Needle|
3135180|NCT03672097|Experimental|Prasugrel|Participants with ACS who underwent PCI, and were previously taking clopidogrel, receive a maintenance dose (MD) of prasugrel for a total of 28 weeks (optionally up to a maximum 12 months of P2Y12 inhibitor treatment after ACS underwent PCI)
3135181|NCT03672370||Alloclassic® Variall® Cup|Subjects who received the Alloclassic® Variall® Cup Ceramic Bearing System
3135182|NCT03672396|Experimental|Home-based Exercise|The sole intervention group will complete a combination of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour.
3135183|NCT03673670|Experimental|1.5 mg RPL554 and tiotropium/olodaterol|1.5 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
3180820|NCT00687700|Experimental|All subjects|Eligible subjects will receive GSK961081 (400 micrograms or 1200 micrograms), GSK961081 matching placebo, propranolol (80 milligrams) and propranolol matching placebo in five treatment sessions through ten different crossover treatment sequences. There will be a washout period between treatment sessions of 7 to 14 days.
3180821|NCT00687726|Experimental|G1|Standing balance and mini squat training
3135184|NCT03673670|Experimental|6 mg RPL554 and tiotropium/olodaterol|6 mg RPL554 suspension administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
3135185|NCT03673670|Experimental|Placebo and tiotropium/olodaterol|Placebo administered using a nebulizer twice daily plus 5 mcg/5 mcg tiotropium/olodaterol (Respimat) administered once daily
3135186|NCT03674112|Experimental|A: P+H IV Followed by PH FDC SC|In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
3180822|NCT00687726|Active Comparator|G2|Isometric knee extension exercise
3180823|NCT00687752||1|hydramnios
3180824|NCT00687752||2|normal
3180825|NCT00687765|Experimental|1|
3148955|NCT00162370|Experimental|Definity|All patients will undergo a gray scale baseline unenhanced imaging session (apical 2- or 4 chamber view), as well as a DEFINITY (Perflutren Lipid Microsphere Injectable Suspension)-enhanced rest and a DEFINITY enhanced exercise or dobutamine stress echocardiography imaging session. The unenhanced and DEFINITY-enhanced rest and stress echocardiography imaging sessions will be performed on the same day. For the DEFINITY-enhanced imaging sessions all patients will receive diluted DEFINITY intravenously (IV). Diluted DEFINITY will be prepared by mixing 1 mL of activated DEFINITY® with 9 mL of normal saline in a 10 mL syringe.
3148956|NCT00162383|Experimental|Cocktail|
3148957|NCT00162435|Experimental|Genetic|
3135187|NCT03674112|Experimental|B: PH FDC SC Followed by P+H IV|In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.
3135188|NCT03674177|Experimental|RSV MAT formulation 1 Group|Subjects received a single dose (30 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
3148958|NCT00162435|Experimental|Control|
3148959|NCT00162448|Experimental|A1|
3148960|NCT00162448|Placebo Comparator|A2|
3148961|NCT00162461|Experimental|Phenytoin|
3135189|NCT03674177|Experimental|RSV MAT formulation 2 Group|Subjects received a single dose (60 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
3148962|NCT00162474|Experimental|Warfarin|
3148963|NCT00162552|Active Comparator|1|Patients with severe cirrhosis treated with Pentoxifylline
3135190|NCT03674177|Experimental|RSV MAT formulation 3 Group|Subjects received a single dose (120 µg) injection of the investigational RSV maternal vaccine (GSK3888550A) at Day 1, intramuscularly into the deltoid region of the non-dominant arm
3135191|NCT03674177|Placebo Comparator|Control Group|Subjects received a single placebo saline injection at Day 1, intramuscularly into the deltoid region of the non-dominant arm
3148964|NCT00162552|Placebo Comparator|2|Patients with severe cirrhosis treated with a placebo
3148965|NCT00162565|Experimental|1|bbloquant treatment
3148966|NCT00162656|Active Comparator|Standard LMB B|
3148967|NCT00162656|Experimental|LMB B without COPADM3|
3148968|NCT00162656|Experimental|LMB B with half cyclophosphamide|
3148969|NCT00162656|Experimental|LMB B without COPADM3 and with half cyclophosphamide|
3148970|NCT00162656|Active Comparator|LMB C standard|
3148971|NCT00162656|Experimental|LMB C with mini CYVE and without 3 maintenance courses|
3148972|NCT00162682|Active Comparator|1|* VL-S, the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
3148973|NCT00162682|Experimental|2|CD4-S, the alternative CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
3148974|NCT00162890||Patient with degenerative cervical disease|
3148975|NCT00162916|Placebo Comparator|1|
3148976|NCT00162916|Experimental|2|
3135192|NCT03674281|Experimental|Sensor Augmented Pump (SAP)-Closed-Loop Control (CLC)|"SAP: Subjects will be utilizing their own insulin pumps (without automated insulin delivery) plus Dexcom G6 CGM to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period.~CLC with Control-IQ plus CGM: Following SAP, subjects will be utilizing the Tandem t:slim X2 with Control-IQ along with a Dexcom G6 continuous glucose monitor to control their blood glucose for 4 weeks. Subjects will be evaluated by actigraphy watch and by Ecological Momentary Assessments in approximately the final 14 days of the 4 week period."
3135193|NCT03674970|Experimental|Random Nicotine Delivery|One 0 mg or 4 mg nicotine film every 3-4 hours for a total of four films per day (not to exceed three non-consecutive 4 mg films in one day) for 6 weeks.
3135194|NCT03674970|Active Comparator|Steady State Nicotine Delivery|One 2 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
3135195|NCT03674970|Placebo Comparator|Placebo Control|One 0 mg nicotine film every 3-4 hours for a total of four films per day for 6 weeks.
3135196|NCT03675451|Experimental|Interventional|"Injection of study drug followed by PET/CT imaging.~Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.~Followed by prostatectomy"
3135197|NCT03675581|Experimental|All subjects|
3135198|NCT03675685|Experimental|CCH (Collagenase clostridium histolyticum)|
3135199|NCT03675776|Experimental|Rapastinel 450mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
3135200|NCT03675776|Experimental|Rapastinel 225mg|Rapastinel (prefilled syringe, weekly intravenous IV administration).
3135201|NCT03675776|Placebo Comparator|Placebo|Placebo (prefilled syringe, weekly IV administration).
3135202|NCT03676634|Experimental|Vaccine|rBV A/B
3135203|NCT03676725|Experimental|All subjects|All subjects get the lidocaine taste test
3135204|NCT03676803|Experimental|Mixed spices intervention group|healthy participants consume a capsule containing 5 g of mixed spices at culinary dose
3135205|NCT03676803|Placebo Comparator|placebo group|healthy participants consume placebo capsule containing 5 g of maltodextrin
3148977|NCT00162955|Experimental|ARB administration|80mg/day from the day of the start of 1st CHOP until the completion of all the evaluations
3148978|NCT00162955|No Intervention|non-administration|ARB non-administration group
3148979|NCT00163046|Experimental|Gabapentin|
3148980|NCT00163046|Placebo Comparator|Placebo|
3148981|NCT00163137|Experimental|Lasofoxifene 0.25 mg|lasofoxifene 0.25 mg/day
3148982|NCT00163137|Active Comparator|raloxifene|raloxifene 60 mg/day
3148983|NCT00163137|Placebo Comparator|Placebo|Placebo
3148984|NCT00163267|Placebo Comparator|ASS + Placebo|control arm
3148985|NCT00163267|Active Comparator|ASS + Plavix|active drug
3148986|NCT00163280|Experimental|1|ATL-104 50mg
3135206|NCT03676972|Experimental|LithoVue ureteroscope system|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes. It can also be used in conjunction with endoscopic accessories to perform various diagnostic and therapeutic procedures in the urinary tract.
3148987|NCT00163280|Experimental|2|ATL-104 100mg
3148988|NCT00163280|Experimental|3|ATL-104 150mg
3135207|NCT03677089|Experimental|ECHO Cohort|Sites undergo 12 ECHO Autism telehealth clinics. Clusters of two sites each will initiate intervention with 3 months between the start of each cluster.
3135208|NCT03677245|Experimental|Balance Biking|Strider Balance Bike riding for 5 days following the Strider Learn to Ride Curriculum
3135209|NCT03677375|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00026.
3135210|NCT03677401|Experimental|5 mg Serlopitant Tablets|
3135211|NCT03677401|Placebo Comparator|Matching Placebo Tablets|
3135212|NCT03677869|Experimental|Pneumatic vitreolysis (PVL)|Pneumatic vitreolysis is an in-office intraocular injection of an expansile gas (C3F8) to induce release of vitreomacular traction.
3135213|NCT03678103|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00029 sensor
3135214|NCT03678285|Experimental|HIFRT Workout|Consecutive completion of; 1 mile run, 100 pull ups, 200 push-ups, 300 bodyweight squats, 1 mile run.
3135215|NCT03678311|Other|Sleep Apnea ahi > 5|If Sleep Apnea index is > 5 and diagnosed with Long QT Syndrome
3135216|NCT03678870|Experimental|Education|Opioid Education
3135217|NCT03678870|No Intervention|Control|standard discharge instructions, which lists medications prescribed at discharge
3135218|NCT03679494|Experimental|SDM intervention group|Using shared decision making support tool for intervention
3135219|NCT03679494|No Intervention|Usual care group|No intervention, just continue using usual care
3135220|NCT03679741|Experimental|TEST/CONTROL/CONTROL|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
3135221|NCT03679741|Experimental|CONTROL/TEST/TEST|Subjects that are 18 to 49 years of age and current spherical soft contact lens wears will be randomized into one of two lens wear sequences. Subjects will wear the Test and Control lenses for two weeks each with one of the study lenses being worn twice for a total of 6 weeks.
3148989|NCT00163280|Placebo Comparator|4|Placebo
3135222|NCT03679975|Experimental|Subjects with ALS|Subjects with a diagnosis of probable or definite ALS in accordance with the Revised El-Escorial Criteria were administered a single dose of the Riluzole Oral Soluble Film (ROSF) 50 mg.
3135223|NCT03680105|Experimental|Part 1; Cohort 1; RJX or Placebo|Participants in Part 1; Cohort 1 will receive a single 0.024 mL/kg dose of RJX or matching placebo on Day 1.
3135224|NCT03680105|Experimental|Part 1; Cohort 2; RJX or Placebo|Participants in Part 1; Cohort 2 will receive a single 0.076 mL/kg dose of RJX or matching placebo on Day 1.
3135225|NCT03680105|Experimental|Part 1; Cohort 3; RJX or Placebo|Participants in Part 1; Cohort 3 will receive a single 0.240 mL/kg dose of RJX or matching placebo on Day 1.
3135226|NCT03680105|Experimental|Part 1; Cohort 4; RJX or Placebo|Participants in Part 1; Cohort 4 will receive a single 0.5 mL/kg dose of RJX or matching placebo on Day 1.
3135227|NCT03680105|Experimental|Part 1; Cohort 5; RJX or Placebo|Participants in Part 1; Cohort 5 will receive a single 0.759 mL/kg dose of RJX or matching placebo on Day 1.
3135228|NCT03680105|Experimental|Part 1; Cohort 6; RJX or Placebo|Participants in Part 1; Cohort 6 will receive a single dose of RJX or matching placebo, to be determined following review of safety and PK data from Cohorts 1 to 5, on Day 1.
3135229|NCT03680105|Experimental|Part 2; Cohort 1; RJX or Placebo|"Participants in Part 2; Cohort 1 will receive a dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.~The Part 2; Cohort 1 dose will be 1 log down from the maximum tolerated dose determined in Part 1 or at a dose determined to be safe and well tolerated in Part 1 with an acceptable PK profile."
3135230|NCT03680105|Experimental|Part 2; Cohort 2; RJX or Placebo|Participants in Part 2; Cohort 2 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
3135231|NCT03680105|Experimental|Part 2; Cohort 3; RJX or Placebo|Participants in Part 2; Cohort 3 will receive an escalated dose of RJX or matching placebo, determined based on the findings of Part 1, every day for 7 days.
3135232|NCT03680521|Experimental|Sitravatinib and nivolumab|Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.
3148990|NCT00163449|Active Comparator|1|Ciclesonide 40 µg
3135233|NCT03680742|Experimental|Treated|All eligible patients who underwent an attempt with the Contour device.
3135234|NCT03681093|Experimental|Fevipiprant 150 mg|Fevipiprant (QAW039) 150 mg once daily orally
3135235|NCT03681093|Experimental|Fevipiprant 450 mg|Fevipiprant (QAW039) 450 mg once daily orally
3135236|NCT03681093|Placebo Comparator|Placebo|Placebo once daily orally
3135237|NCT03681119|Experimental|Advanced Demential Patients|
3135238|NCT03681119|Experimental|Hospice IDT Members|
3148991|NCT00163449|Active Comparator|2|Ciclesonide 80 µg
3135241|NCT03681353|Experimental|Reduced Use Condition|This arm includes six weeks of mobile contingency management treatment administered via a smart-phone based application (mobile CM), in which participants are provided monetary reinforcement for reducing cannabis use.
3135242|NCT03681405|Experimental|Group I (eMMB)|Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery.
3135243|NCT03681405|Active Comparator|Group II (AC)|Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery.
3135244|NCT03681808|Experimental|Test|Soft Contact Lens
3180826|NCT00687778||1|100 patients with newly diagnosed tumors, which are often non-FDG avid or show only low intensity uptake: Soft tissue sarcomas, well-differentiated thyroid cancer, well-differentiated and bronchoalveolar lung cancer, indolent lymphomas, neuroendocrine tumors, GIST, uterine malignancies, mucin-producing cancer, teratoma, hepatoma, HCC and lobular breast carcinoma.
3180827|NCT00687791|Experimental|1|20 enrolled patients will be chosen according to the enrollment acceptance criteria. The evidence for the determination of enrolled patients shall be recorded, reviewed and approved. 2> Phacotrabeculectomy is performed.3> After completing phacotrabeculectomy, implant/place ologen™ Collagen Matrix on top of the scleral flap under the conjunctiva. For every inspection and observation, the detailed description and/or inspection data shall be recorded. If any unwanted adverse event is observed during inspection and observation, it shall be recorded and be reported to the investigation conductor.
3135245|NCT03681808|Active Comparator|Control|Contact lens
3135246|NCT03681886|Experimental|Primary Implantation (Cohort 1)|Primary implantation with HMIOL through Month 1 visit, followed by study exit. 1 site followed up to Month 12.
3135247|NCT03681886|Experimental|Optic Exchange (Cohort 2)|Subset of Cohort 1 with optic exchange at Month 1 post primary implantation, followed up to Month 1 post optic exchange
3135248|NCT03681951|Experimental|Part 1: Dose Escalation - GSK3145095 monotherapy|In Part 1, advanced or metastatic PDAC will be enrolled. Part 1 will be using escalating doses of GSK3145095 (total daily dose of 100 mg, 200 mg, 400 mg, 800 mg, and 1600 mg) orally as monotherapy for up to 2 years. For each dose level, subjects will receive a single dose of half the total daily dose on Day 1; and as BID (total daily dose divided in two equal doses) starting from Day 2.
3148992|NCT00163449|Active Comparator|3|Ciclesonide 160 µg
3148993|NCT00163449|Placebo Comparator|4|Placebo
3148994|NCT00163553|Experimental|P|Epidural pethidine group
3148995|NCT00163553|Placebo Comparator|N|placebo group
3148996|NCT00163566|Placebo Comparator|Placebo gel|Placebo gel twice per day
3148997|NCT00163566|Active Comparator|0.7% DHT gel, Dose 1|0.7% DHT gel twice per day, 35 mg/day
3135249|NCT03681951|Experimental|Part 2: Dose Escalation - GSK3145095 + pembrolizumab|In Part 2, subjects with selected solid tumors, including but not limited to, PDAC, NSCLC, TNBC and/or melanoma will be enrolled. Part 2 will be using GSK3145095 combination escalation to start at least one dose level below the highest dose of GSK3145095 shown to be safe in Part 1, orally BID for up to 2 years along with pembrolizumab 200 mg intravenous (IV) every 3 weeks (Q3W) for up to 2 years.
3135250|NCT03681951|Experimental|Part 3: Dose Expansion - GSK3145095 + pembrolizumab|In Part 3, subjects with selected solid tumors will be enrolled. Part 3 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with pembrolizumab 200 mg IV Q3W for up to 2 years.
3135251|NCT03681951|Experimental|Part 4: Dose Expansion - GSK3145095 + anticancer agent|In Part 4, subjects with selected solid tumors will be enrolled. Part 4 will be using GSK3145095 at one or two dose levels shown to be tolerable in Part 2 orally BID for up to 2 years along with combination of additional anticancer agents.
3135252|NCT03682107|Experimental|Arm 1 (2 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
3135253|NCT03682107|Experimental|Arm 2 (2 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 2 mg (2 injections of 0.5 ml (1 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
3135254|NCT03682107|Experimental|Arm 3 (4 mg ANDV - 3-dose regimen)|"1 sentinel subject assigned to the 3-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine on Days 29, 169, and matching placebo on Day 57 in double-blind manner.~11 subjects assigned to the 3-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 169, and matching placebo on Day 57 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
3135255|NCT03682107|Experimental|Arm 4 (4 mg ANDV - 4-dose regimen)|"1 sentinel subject assigned to the 4-dose regimen will receive 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Day 1 in an open label manner, and Days 29, 57 and 169 in double-blind manner.~11 subjects assigned to the 4-dose regimen will receive either 4 mg (2 injections of 0.5 ml (2 mg/0.5 ml each)) of ANDV DNA vaccine intramuscularly into the left and right deltoid on Days 1, 29, 57 and 169 (n=9) or matching placebo on Days 1, 29, 57, and 169 (n=2)."
3148998|NCT00163566|Active Comparator|0.7% DHT gel, Dose 2|0.7% DHT gel twice per day, 70 mg/day
3148999|NCT00163579|Experimental|Bryophyllum|
3149000|NCT00163579|Placebo Comparator|Placebo|
3135256|NCT03682120|Experimental|Arm 1|3.75 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
3135257|NCT03682120|Experimental|Arm 2|7.5 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
3180828|NCT00687843|Active Comparator|1|The TS-1 group
3180829|NCT00687843|Experimental|2|The TS-1+PSK Group
3180830|NCT00687869|Experimental|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
3180831|NCT00687869|Active Comparator|usual care|Usual stroke aftercare plus patient-information-notes
3135258|NCT03682120|Experimental|Arm 3|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + MF59(R) adjuvant administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=106
3135259|NCT03682120|Experimental|Arm 4|15 mcg per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) unadjuvanted administered intramuscularly on Day 1 and Day 22. Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages. N=53
3180836|NCT00687895|Experimental|1|training in clinical algorithm plus microscopy
3180837|NCT00687895|Experimental|2|clinical algorithm
3135260|NCT03682302|Experimental|Group 1: 12 to less than 17 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
3135261|NCT03682302|Active Comparator|Group 1: 12 to less than 17 years, undergoing spine surgery, bupivacine|Single dose of bupivacaine hydrochloride (HCl) 2 mg/kg (not to exceed a maximum total dose of 175 mg) via local infiltration at the end of spine surgery.
3135262|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing spine surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of spine surgery.
3135263|NCT03682302|Experimental|Group 2: 6 to less than 12 years, undergoing cardiac surgery, EXPAREL|Single dose of EXPAREL 4 mg/kg (not to exceed a maximum total dose of 266 mg) via local infiltration at the end of cardiac surgery.
3135264|NCT03682705|Placebo Comparator|ELS placebo/UPA placebo|Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
3135265|NCT03682705|Experimental|UPA 15 mg/ELS 60 mg|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
3180838|NCT00687895|No Intervention|3|Control
3135266|NCT03682705|Experimental|ELS 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
3135267|NCT03682705|Experimental|ELS 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
3135268|NCT03682705|Experimental|ELS 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
3135269|NCT03682705|Experimental|UPA 15 mg/ELS placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
3149001|NCT00163644|Active Comparator|Aerobic exercise plus resistance|Aerobic exercise plus resistance exercise for 6 weeks
3180839|NCT00687921||A|patients over the age of 18 who had knee trauma, intent to or had MRI assessment and are scheduled for arthroscopy.
3180840|NCT00687934|Experimental|Ganetespib|Ganetespib once weekly infusion, dose escalation study, with treatment until progression
3135270|NCT03682809|Experimental|Systane Complete|Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
3135271|NCT03682809|No Intervention|No Treatment|Subjects randomized to this group will not receive a treatment.
3135272|NCT03682965|Experimental|Intra-lymphatic allergenic extract|A series of three injections of 0.1 mL (about 2 drops) of the allergenic extract of Mountain Cedar Pollen given every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
3180841|NCT00687947|Experimental|1|MA-patients
3180842|NCT00687947|Experimental|2|FHM-patients
3180843|NCT00687947|Active Comparator|3|Healthy controls
3180844|NCT00687960|Experimental|1|Resistant Starch Type 4-Raw
3135273|NCT03682965|Placebo Comparator|Intra-lymphatic placebo|Diluent as placebo control (sterile saline solution containing 0.4% phenol as a preservative and matched concentration of glycerin) given as a series of three injections of 0.1 mL (about 2 drops) every four weeks into a superficial inguinal lymph node through guidance via ultrasonography using a 1-mL hypodermic syringe with a 25-gauge or smaller needle.
3135274|NCT03683576|Placebo Comparator|Placebo|Placebo once per day (QD) for 24 weeks
3135275|NCT03683576|Experimental|GB001 20 mg|GB001 20 mg QD for 24 weeks
3135276|NCT03683576|Experimental|GB001 40 mg|GB001 40 mg QD for 24 weeks
3180845|NCT00687960|Experimental|2|Resistant Starch Type 4-cooked
3180846|NCT00687960|Active Comparator|3|Puffed wheat
3180847|NCT00687960|Placebo Comparator|4|Dextrose
3180848|NCT00687986|Active Comparator|primary surgery|primary surgical resection
3180849|NCT00687986|Experimental|stereotactic radiotherapy|primary stereotactic radiotherapy
3180850|NCT00687999|Other|1|
3180851|NCT00688025||1|Insomniacs: Individuals reporting difficulty falling asleep or staying asleep within the past month for more than 3 days per week. Individuals much also meet screening criteria based on an overnight polysomnograph of latency to persistent sleep >20 minutes and/or >60 minutes of wake after sleep onset.
3180852|NCT00688025||2|Controls: Individuals reporting no difficulty falling asleep or staying asleep and objective sleep measures based on an overnight polysomnograph of latency to persistent sleep <20 minutes and/or <60 minutes of wake after sleep onset.
3180853|NCT00688038|Experimental|Laser Ablation + MRTI|Magnetic resonance thermal imaging = MRTI
3180854|NCT00688051|Experimental|1|
3135277|NCT03683576|Experimental|GB001 60 mg|GB001 60 mg QD for 24 weeks
3135278|NCT03683719|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
3135279|NCT03683719|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
3135280|NCT03683719|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
3180855|NCT00688077|Experimental|1|
3180856|NCT00688077|Placebo Comparator|2|NaCl 0,9% 2 ml, single subcutaneous injection
3180857|NCT00688090|Experimental|Low-Dose Peptide Cohort|
3180858|NCT00688090|Experimental|High-Dose Peptide Cohort|
3180859|NCT00688116|Experimental|ganetespib|
3180860|NCT00688129|Experimental|KITS Program|The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
3180861|NCT00688129|No Intervention|Services as usual|
3180862|NCT00688142||1|Individuals with shift work sleep disorder
3180863|NCT00688142||2|Healthy night shift workers without shift work sleep disorder
3180864|NCT00688168||Symptom Assessments|Patients diagnosed with multiple myeloma (MM) complete questionnaires with Neurocognitive Testing and Neurosensory Testing
3180865|NCT00688194|Active Comparator|Arm I|Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3135281|NCT03683719|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 16 weeks.
3135282|NCT03683719|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 16 weeks.
3135283|NCT03683758|Experimental|FIFA11+ / Intervention Group|This group will complete the FIFA11+ warm-up three times per week for eight weeks.
3135284|NCT03683758|Active Comparator|Typical Warm-up / Control Group|This group will complete their usual warm-up three times per week for eight weeks
3149002|NCT00163644|Active Comparator|Aerobic exercise|Aerobic exercise for 6 weeks
3149003|NCT00163644|Other|Control|No formal exercise and weekly phone calls
3149004|NCT00163670||Motor vehicle accident|
3149005|NCT00163670||Control|
3149006|NCT00163722|Active Comparator|Standard diagnostic strategy of culture and histology|The standard-diagnostic strategy was designed to be consistent with the 2002 guidelines for antimicrobial use in neutropenic patients with cancer. When an invasive fungal infection was suspected (e.g. persistent fevers) cultures of blood, urine, sputum (if available) and faeces (if clinically indicated), and HRCT scans of chest were performed. Bronchoscopy and biopsies were performed according to institutional protocols. Empiric antifungal therapy was recommended whilst undergoing these investigations and was continued, de-escalated to prophylaxis, or changed to treatment of invasive aspergillosis or other IFD according to test results.
3135285|NCT03683901|Experimental|TENS/t-NMES/No stimulation|TENS stimulation parameters were of a symmetric waveform, a frequency of 100 Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #7) applied for 10 seconds. t-NMES parameters were a symmetric waveform with 2 second ramp-up and 2 second ramp-down, a frequency of 35Hz, and a pulse duration of 300 microseconds (EMPI 300PVTM program PPR #3). The t-NMES current intensity was set by adjusting the amplitude to yield the strongest contraction of the underlying muscles without initiating pain. Device and electrodes remained in place but no stimulation was delivered over the 10 second interval. Exposed to each stimulation 3 times for each shoulder ROM.
3135286|NCT03684044|Experimental|Baloxavir Marboxil|"Participants will receive at least two doses of baloxavir marboxil on Days 1 and 4. A third dose of Baloxavir will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
3135287|NCT03684044|Placebo Comparator|Placebo|"Participants will receive at least two doses of placebo on Day 1 and 4. A third dose of placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5.~Study treatment will be given in combination with SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) in accordance with local clinical practice."
3135288|NCT03684265|Experimental|Test to Reference|
3135289|NCT03684265|Experimental|Reference to Test|
3135290|NCT03684642|Experimental|Efpeglenatide 4 mg|Participants received Efpeglenatide subcutaneous (SC) injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 4 mg once weekly for the treatment duration.
3135291|NCT03684642|Experimental|Efpeglenatide 6 mg|Participants received Efpeglenatide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 2 mg once weekly and increased every 2 weeks to the maximum of 6 mg once weekly for the treatment duration.
3180866|NCT00688194|Active Comparator|Arm II|Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.
3180867|NCT00688194|Active Comparator|Arm III|Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3180868|NCT00688194|Active Comparator|Arm IV|Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.
3180869|NCT00688207|Experimental|Rosiglitazone|An open-label, single, oral dose of 4mg of rosiglitazone in the morning under fasted conditions
3135292|NCT03684642|Active Comparator|Dulaglutide 1.5 mg|Participants received Dulaglutide SC injection once weekly up to Week 56 on top of metformin. Participants initiated dosing at 0.75 mg once weekly and increased after 2 weeks to 1.5 mg once weekly for the treatment duration.
3135293|NCT03684928|Active Comparator|Comfilcon A (test)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
3180870|NCT00688220||1|Those wearing garments fabricated with Celliant
3180871|NCT00688220||2|Those not wearing garments fabricated using Celliant (placebo).
3180872|NCT00688233|Experimental|F-seifi|
3180873|NCT00688272|Experimental|Arm 1|Eltrombopag 75 mg QD x 6 days
3180874|NCT00688272|Active Comparator|Arm 2|Ciprofloxicin 500mg BID x 6 days
3180875|NCT00688272|Placebo Comparator|Arm 3|Placebo QD x 6 days
3135294|NCT03684928|Active Comparator|Senofilcon C (control)|Participants were randomized to wear either test or control contact lenses bilaterally for one month during the cross-over study.
3135295|NCT03685344|Experimental|ADCT-402|"Dose escalation phase: Ascending doses of Loncastuximab tesirine will be administered using a traditional 3+3 design. Dose level 1: 90 µg/kg, every 3 weeks (Q3W). Dose level 2: 120 µg/kg, Q3W. Dose level 3: 150 µg/kg, Q3W. Loncastuximab tesirine will be given for 2 doses, 3 weeks apart.~Dose expansion phase: Loncastuximab tesirine will be administered at the recommended dose determined in the dose escalation phase. Durvalumab will also be administered at a dose of 1500 mg once every 4 weeks (Q4W) throughout the dose escalation phase and dose expansion phase."
3135296|NCT03685396|Experimental|Test Group|In the Test Group venous blood sampling was done in order to prepare PRF membranes used to cover the donor site of the connective tissue graft.
3135297|NCT03685396|Active Comparator|Control Group|In Control Group hemostatic agents with oxidized and regenerated cellulosa were used to cover the donor site.
3135298|NCT03685643|Experimental|Intervention - Dating application topic|The intervention will consist of four short videos with points of discussion, a scenario game, and a risk assessment tool regarding dating application usage.
3135299|NCT03685643|Placebo Comparator|Control - Health and exercise topic|The control will consist of four short videos with discussion points and an interaction game regarding exercise and healthy living tips.
3135300|NCT03685968|Experimental|Glidescope AVL|
3135301|NCT03685968|Experimental|King Vision Channeled VL|
3135302|NCT03685968|Experimental|King Vision Non-Channeled (Standard) VL|
3135303|NCT03686033|Experimental|Placebo, E2082 2.5 mg, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between all the treatment periods.
3135304|NCT03686033|Experimental|E2082 2.5 mg, E2082 25 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
3135305|NCT03686033|Experimental|E2082 25 mg, Placebo, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
3149007|NCT00163722|Experimental|Aspergillus galactomannan and PCR directed|Results of once to twice weekly testing with Aspergillus galactomannan and PCR directed the timing of CT scan performance and whether antifungal therapy was given
3149008|NCT00163761|Active Comparator|Commence VGF treatment|Drug. Vinorelbine, gemcitabine and filgrastim 21 day cycle
3149009|NCT00163761|Active Comparator|Commence F-GIV treatment|Drug. Gemcitabine, ifosfamide, Vinorelbine and filgrastim 21 day cycle
3149010|NCT00163826||Trauma Patients|Major trauma patients
3149011|NCT00163865||Clinical Group|clinical adolescent group
3149012|NCT00163865||Community Group|community adolescent group
3135306|NCT03686033|Experimental|Placebo, E2082 25 mg, E2082 2.5 mg, E2082 40 mg|Participants will receive a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 1 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 2 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
3135307|NCT03686033|Experimental|E2082 2.5 mg, Placebo, E2082 25 mg, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 1 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 2 followed by a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
3135308|NCT03686033|Experimental|E2082 25 mg, E2082 2.5 mg, Placebo, E2082 40 mg|Participants will receive a single dose of E2082 tablets at 25 mg orally (Treatment C) in Treatment Period 1 followed by a single dose of E2082 tablets at 2.5 mg orally (Treatment B) in Treatment Period 2 followed by a single dose of E2082-matched placebo tablet orally (Treatment A) in Treatment Period 3 followed by a single dose of E2082 tablets at 40 mg orally in Treatment Period 4. A wash-out phase of at least 2 weeks will be maintained between the treatment periods.
3135309|NCT03686176|Experimental|Virtual Reality Group (Study Group)|In this arm, patients will receive support from child life specialists plus may use virtual reality simulation goggles during a qualifying medical procedure.
3135310|NCT03686176|No Intervention|Active Control Group|In this arm, patients will receive standard of care with child life specialists plus distraction of the child's choosing, during a qualifying medical procedure.
3180876|NCT00688285|Active Comparator|1|education and automated clinical alerts
3149013|NCT00164021||Cystic Fibrosis|Patients with cystic fibrosis
3135311|NCT03686176|No Intervention|External Control (Reference Group)|No virtual reality and no child life specialists; no standardized or formal form of support.
3135312|NCT03687125|Experimental|Tinostamustine 180 mg/m^2|Participants received single dose of tinostamustine 180 milligrams per meter square (mg/m^2) intravenous (IV) injection on Day -1 followed by autologous stem cell transplantation (ASCT) on Day 1.
3135313|NCT03687125|Experimental|Tinostamustine 220 mg/m^2|Participants received single dose of tinostamustine 220 mg/m^2 IV injection on Day -1 followed by ASCT on Day 1.
3135314|NCT03687372|Experimental|A-101|topical solution
3135315|NCT03687372|Other|Vehicle|topical solution
3135316|NCT03687450|Experimental|Intervention (Yoga) Arm|Received a weekly 60-minute yoga-based class over 6 weeks with direction for a 5-10 minute daily home practice.
3135317|NCT03687450|No Intervention|No-treatment Control Arm|Waitlist control-- group received one session of yoga-based class at the completion of the study.
3135318|NCT03687684|Experimental|Japanese Cohort 1-A; TAK-831 100 mg + TAK-831 300 mg|TAK-831 100 milligrams (mg), tablets, orally, once daily on Day 1, followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
3135319|NCT03687684|Experimental|Japanese Cohort 1-B; TAK-831 100 mg + Placebo|TAK-831 100 mg, tablets, orally, once daily on Day 1 followed by TAK-831 matching placebo, tablets, orally, once daily on Day 9 in healthy Japanese participants.
3149014|NCT00164021||Control|
3180877|NCT00688285|Active Comparator|2|education session alone
3135320|NCT03687684|Experimental|Japanese Cohort 1-C; Placebo + TAK-831 300 mg|TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg, tablets, orally, once daily on Day 9 in healthy Japanese participants.
3149015|NCT00164138|Experimental|Pelvic Floor Training Group|Pelvic floor training, biofeedback.
3135321|NCT03687684|Experimental|Japanese Cohort 2; TAK-831 300 mg|TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 300 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
3135322|NCT03687684|Experimental|Chinese Cohort 3; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Chinese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
3135323|NCT03687684|Experimental|Japanese Cohort 4; TAK-831 600 mg|TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 600 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants. This cohort is optional and will be decided to run based on the data of Cohorts 1 and 2. The dose will be defined based on the result of Cohort 1 or Cohort 2.
3135324|NCT03687684|Experimental|Japanese Cohort 5; TAK-831|TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily on Day 1 followed by TAK-831 50 mg or TAK-831 matching placebo, tablets, orally, once daily from Day 4 to Day 17 in healthy Japanese participants.
3135325|NCT03687736|Other|AbobotulinumtoxinA|Open-label
3135326|NCT03687827|Experimental|Insulin degludec|Participants will receive insulin degludec in period 1 and 2 in a cross-over manner.
3135327|NCT03687827|Active Comparator|Insulin glargine|Participants will receive insulin glargine in period 1 and 2 in a cross-over manner.
3135328|NCT03687970|Experimental|Group A: Painful CIPN Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
3135329|NCT03687970|Active Comparator|Group B: Control Group|-Performed at baseline: NPSI, BPI, HADS, Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS), QST, CPM, and DLss
3135330|NCT03688282|Sham Comparator|Sham Wearable belt|Device will be worn but not turned on for 30 minutes.
3135331|NCT03688282|Experimental|Wearable vibration belt (30)|Device will be worn and turned on for 30 minute treatment.
3135332|NCT03688542|Experimental|Intervention|Nursing Homes allocated to the Intervention arm will enact the Quality Circle Deprescribing Module and create a local deprescribing consensus and implementation strategy.
3135333|NCT03688542|No Intervention|Control|Nursing Homes allocated to the Control arm will not enact the intervention.
3135334|NCT03688620|Other|Vaccinated_AlphaRix Tetra Group|Volunteered male and female subjects, 18 years of age and above, who received in Belgium one dose of GlaxoSmithKline's (GSK's) quadrivalent seasonal influenza vaccine (AlphaRix Tetra) between 01 October and 31 December 2018.
3149016|NCT00164203|Experimental|Cognitive Behavioral Therapy|School-based, 12-session protocol, weekly
3135335|NCT03688620|Other|Vaccinated_Influsplit Tetra Group|Volunteered subjects male and female subjects, 18 years of age and above, who received in Germany one dose of GSK's quadrivalent seasonal influenza vaccine (Influsplit Tetra) between 01 October and 31 December 2018.
3149017|NCT00164203|Active Comparator|activity control condition|Structured games and activities, weekly for 12 weeks
3149018|NCT00164281|Experimental|Continuous vs limited isoniazid|The placebo arm will receive 6 months of open label isoniazid before beginning placebo (as a coded medication). The treatment (experimental arm) will receive 6 months of open label isoniazid before beginning coded medication (isoniazid).
3135336|NCT03688620|Other|Vaccinated_Fluarix Tetra Group|Volunteered male and female subjects, between 6 months and 65 years of age, who received in Spain one or two dose(s) of GSK's quadrivalent seasonal influenza vaccine (Fluarix Tetra) between 01 October and 31 December 2018.
3135337|NCT03688685|Experimental|Open-label study of CAD-1883|Open-label study designed to evaluate the safety, tolerability, and efficacy of CAD-1883 administered twice daily orally to adult subjects with ET
3135338|NCT03688711|Experimental|Dasiglucagon|single fixed dose (subcutaneous injection) of dasiglucagon
3135339|NCT03688711|Placebo Comparator|Placebo|single fixed dose (subcutaneous injection) of placebo
3135340|NCT03688880|Active Comparator|Dermabond Advanced|Dermabond Advanced (a topical skin adhesive) was applied on Day 0. Dermabond Advanced was applied in 1 continuous layer onto a dry wound through painting motions; the wound was held for 60 seconds to allow for complete polymerization.
3180878|NCT00688298|Experimental|Arm 1|Female patients Greater than or 18 years of age, diagnosed with Stress Urinary Incontinence (SUI).
3180879|NCT00688311|Experimental|Synbiotic|Ingestion of synbiotic dietary supplement
3180880|NCT00688311|Placebo Comparator|Placebo|Ingestion of the Placebo
3180881|NCT00688337||1|Patients with newly diagnosed breast cancer. Clinically nodal negative.
3135341|NCT03688880|Experimental|MAR-CUTIS|MAR-CUTIS (polyurethane-based skin adhesive) was applied on Day 0. MAR-CUTIS was applied in 1 to 2 millimeter (mm) thick layer ensuring that at least 1 cm of the glue is applied over the length of the wound on each side; the wound was held for approximately 30 seconds to allow for initial polymerization.
3135342|NCT03689452|Placebo Comparator|Control|15 participants will receive 3 mL of preservative free normal saline injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
3135343|NCT03689452|Experimental|Treatment|15 participants will receive 3-6 mL of platelet rich plasma injected in a standardized pattern with each injection 1-2 cm apart with 0.2 to 0.3 mL per injection. Participants will receive this treatment at weeks 0, 4, 8, and 24.
3135344|NCT03689504|Active Comparator|Standard of Care|The standard of care is an intensive individualized home-based nutrition education program, together with a home food ration and micronutrient supplement, delivered by frontline workers for 6 months.
3135345|NCT03689504|Experimental|Home Garden Intervention|This arm adds an 8 month individualized home-based family garden intervention to the existing standard of care (home-based nutrition education)
3135346|NCT03689920|Active Comparator|WaveWriter Settings|WaveWriter Programming
3180882|NCT00688350|Experimental|Behavioral feedback|Behavioral feedback intervention to improve adherence to antihypertensive medication
3180883|NCT00688350|No Intervention|Control|Control group
3135347|NCT03689920|Active Comparator|Conventional Settings|Conventional Programming
3135348|NCT03690375|Experimental|BBL Left|Left arm selected to be treated with BBL, right arm not treated
3135349|NCT03690375|Experimental|BBL Right|Right arm selected to be treated with BBL, left arm not treated
3149019|NCT00164463|Experimental|Moxifloxacin|Moxifloxacin 400 mg po qd given 5 of 7 days per week
3180884|NCT00688363|Experimental|1|No blood-glucose self-control, no HbA1c
3135350|NCT03691727|Experimental|tirofiban hydrochloride (AGGRASTAT®)|"tirofiban hydrochloride (AGGRASTAT®) administered continuously over the course of 7 days.~MRI Neurological Exam Vital Signs Questionnaires"
3135351|NCT03691727|Active Comparator|Standard of Care Control Arm|Standard of Care Treatment MRI Neurological Exam Vital Signs Questionnaires
3135352|NCT03691779|Experimental|Part A: ELX/TEZ/IVA|Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.
3149020|NCT00164463|Active Comparator|Isoniazid|Isoniazid 300 mg po qd given 5/7 days per week
3149021|NCT00164515|No Intervention|Arm 1: Physical activity awareness|The awareness group received a physician-recommendation to exercise an informational brochure, and pedometer.
3149022|NCT00164515|Experimental|Arm 2: Lower Support|The lower support group received arm 1 plus monthly newsletter, weekly personalized exercise support via telephone.
3135353|NCT03691779|Experimental|Part B: ELX/TEZ/IVA|Participants in Part B weighing less than (<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
3135354|NCT03691831|Active Comparator|Active|A-101 45% (Topical solution, hydrogen peroxide 45%)
3135355|NCT03691831|Placebo Comparator|Vehicle|Topical solution, isopropyl alcohol and water
3135356|NCT03691844|Experimental|AMZ001 + Placebo|on the target knee
3135357|NCT03691844|Experimental|AMZ001|on the target knee
3135358|NCT03691844|Placebo Comparator|Placebo|on the target knee
3135359|NCT03691844|Active Comparator|Comparator|Diclofenac gel on the target knee
3135360|NCT03691948|Experimental|ROPEs|
3135361|NCT03691948|Active Comparator|Control|
3135362|NCT03692052|Experimental|AG-348|Participants with alpha or beta thalassemia received AG-348 50 mg twice daily (BID), orally up to Week 6. Following Week 6, depending on the participants' safety and hemoglobin (Hb) concentrations, they could undergo one potential dose-level increase from 50 to 100 mg BID. After completion of the Core Period of 24 weeks, participants were eligible to continue to receive AG-348 in the Extension Period which is up to 10 years.
3149023|NCT00164515|Experimental|Arm 3: Higher support|The higher support group received arm 1 plus arm 2 plus a face-to-face monthly exercise support group.
3135363|NCT03692676||Subjects with Asthma|Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC
3135364|NCT03693625|Experimental|Parent Study: GDC-0853|Participants (who had received 50, 150 and 200mg GDC-0853 in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
3135365|NCT03693625|Placebo Comparator|Parent Study: Placebo|Participants (who had received Placebo in Cohort 2 of the Parent GS39684 Study) received open-label fenebrutinib/GDC-0853 at a dose of 200mg orally twice a day.
3135366|NCT03693742|Experimental|18F-DCFPyL PET/CT scan with MSG drink|Food grade MSG will be dissolved in low sodium tomato juice, and administered orally before 18F-DCFPyL administration.
3135367|NCT03693742|Placebo Comparator|18F-DCFPyL PET/CT scan with placebo drink|Regular tomato juice will be used, and administered orally before 18F-DCFPyL administration.
3135368|NCT03693950|Experimental|BCD-066 1 µg/kg|Healthy volunteers will receive BCD-066 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
3149024|NCT00164619|Experimental|1|Standard STD clinic services and the VOICES/VOCES intervention
3149025|NCT00164619|Active Comparator|2|Standard STD clinic services
3180885|NCT00688363|Experimental|2|Blood-glucose self-control, no HbA1c
3149026|NCT00164697|Experimental|1|Parenting group
3180886|NCT00688363|Experimental|3|No blood-glucose self-control, HbA1c
3180887|NCT00688363|Experimental|4|Blood-glucose self-control, HbA1c
3180888|NCT00688389||healthy|
3180889|NCT00688389||DF|
3180890|NCT00688389||DHF|
3180891|NCT00688402|Experimental|1|IR Formulation 65 mg
3180892|NCT00688402|Experimental|2|IR Formulation 150 mg
3180893|NCT00688402|Experimental|3|MR formulation, 1h 65 mg
3180894|NCT00688402|Experimental|4|MR Formulation, 1h 150 mg
3180895|NCT00688402|Experimental|5|MR Formulation, 2h 150 mg
3180896|NCT00688428|Experimental|1|combination capsule of Esomeprazole 40mg + ASA 325mg
3135369|NCT03693950|Active Comparator|Aranesp 1 µg/kg|Healthy volunteers will receive Aranesp 1 μg/kg as weekly IV injections on Day 1, Day 8, Day 15, and Day 22.
3135370|NCT03693989|Experimental|PRO-145.|Difluprednate 0.05%. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
3135371|NCT03693989|Active Comparator|Prednefrin|Prednefrin® SF. Prednisolone Acetate 1%. Prepared by Allergan, S.A. of C.V.
3180897|NCT00688428|Experimental|2|Esomeprazole 40 mg capsule and ASA 325 mg tablet
3180898|NCT00688441|Experimental|Active|CO2 Gas
3180899|NCT00688441|Placebo Comparator|Placebo|Inactive Placebo Gas
3180900|NCT00688454||Pt with hypercholesteremia|Patients treated with CRESTOR because of hypercholesteremia
3135372|NCT03694197|Experimental|Open label|
3135373|NCT03694210|Experimental|EndoRotor Therapy|Physicians will perform direct endoscopic necrosectomy using the EndoRotor in patients with walled off necrosis.
3135374|NCT03694275|Experimental|Soticlestat Dup 15q|Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
3180901|NCT00688480|Placebo Comparator|I|CKD Stage 3 (estimated GFR 30 - 60 ml/min/1.73m2), Echo LVH
3180902|NCT00688480|Active Comparator|2|
3135375|NCT03694275|Experimental|Soticlestat CDD|Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing <60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
3135376|NCT03694548|Other|Part A Survey: Group 1 Adolescent Patients with SCD|Adolescent patients with SCD and chronic pain completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
3135377|NCT03694548|Other|Part A Survey: Group 2 Parents of Adolescent Patients with SCD in Part A|Parents of adolescent patients with SCD and chronic pain from Group 1 completed a survey designed to capture pain characteristics, attitudes and practices related to yoga, and potential acceptability of a yoga program for chronic pain in SCD.
3135378|NCT03694548|Experimental|Part B Yoga Program|Participants from Part A Group 1 had the opportunity to enroll in Part B to receive eight in-person instructor-led group yoga sessions.
3180903|NCT00688493|Experimental|20 mg single dose of dapagliflozin|20 mg dapagliflozin
3135379|NCT03694613|Other|Placental/Umbilical Cord Blood sample|Placental/Umbilical Cord Blood sample will be collected after delivery from every participant.
3135380|NCT03694925||Primary total knee arthroplasty|Primary TKA patients included in the study, to provide a baseline level for calprotectin.
3135381|NCT03694925||Aseptic revision total knee arthroplasty|Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.
3135382|NCT03694925||Revision septic total knee arthroplasty|Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.
3135383|NCT03695094|Experimental|Cohort 1|Cohort 1 (Inducers): Study participants on stable therapy with oxcarbazepine (OXC) either as monotherapy or adjunctive to levetiracetam (LEV), lamotrigine (LTG), or brivaracetam (BRV). OXC may be used as monotherapy or in combination with 1 or more of LEV, LTG, or BRV. Padsevonil (PSL) will be dosed to steady state and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
3135384|NCT03695094|Experimental|Cohort 2|Cohort 2 (Neutral): Study participants on stable therapy with lamotrigine (LTG), levetiracetam (LEV), or brivaracetam (BRV). LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. LTG or LEV may be used as monotherapy or in combination with each other. BRV may only be used in combination with LTG. Padsevonil (PSL) will be dosed to steady state (4.5 days) and the effect of background therapy on PSL pharmacokinetics will be assessed at steady state.
3135385|NCT03695367|Experimental|Cohort 1: HTX-011 + MMA Regimen|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen.
3180904|NCT00688493|Experimental|150 mg single dose of dapagliflozin2|150 mg dapagliflozin
3135386|NCT03695367|Experimental|Cohort 2: HTX-011 + MMA Regimen + Ketorolac|HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac.
3135387|NCT03695393|Experimental|Intervention- ACT Therapy|Participants randomized to this group will receive three ACT sessions over 1 month
3135388|NCT03695393|No Intervention|Standard of Care|Participants in the control group will receive standard care as normally provided to patients by civil society organizations.
3149027|NCT00164697|No Intervention|2|"Families in this usual care comparison group were not prevented from utilizing any service that would otherwise be available to them, even if the service was similar to the services received in the intervention arm of the study."
3149028|NCT00164723|Other|NSAID|patients taking NSAID will undergo capsule endoscopy
3149029|NCT00164723|Other|Aspirin|patients taking Aspirin will undergo capsule endoscopy
3149030|NCT00164723|Other|Non-user|patients didn't take NSAID or ASA will undergo capsule endoscopy
3149031|NCT00164736|Active Comparator|Maternal ARVs & Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & daily nutritional supplement given to the mother
3149032|NCT00164736|Active Comparator|Infant NVP & Nutrition Supplement|Extended infant nevirapine for prophylaxis & daily nutritional supplment given to the mother
3149033|NCT00164736|Active Comparator|Maternal ARVs & No Nutrition Supplement|Extended maternal ARVs for prophylaxis (for the infant) & no nutritional supplement given to the mother
3149034|NCT00164736|Active Comparator|Infant NVP & No Nutrition Supplement|Extended infant nevirapine for prophylaxis & no nutritional supplment given to the mother
3180905|NCT00688493|Active Comparator|400 mg single dose of moxifloxacin|Moxifloxacin
3180906|NCT00688493|Placebo Comparator|Placebo|Placebo
3180907|NCT00688506|Experimental|1|Combined sono-electro-magnetic therapy
3135389|NCT03695913|Experimental|Normal Diet + CGM then low carb + CGM|"Phase I (part 1) - regular diet:~Patients will wear a CGM sensor (with no real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings.~Phase II (part 2) - low carb diet:~Patients will wear a CGM sensor (with real time feedback) for 11 days; document what they eat on a food log; and rate their postprandial fatigue and cravings; document their blood sugar before and two hours after eating (as well as before breakfast and before going to bed)."
3135390|NCT03696108|Experimental|Gefapixant 15 mg BID|Participants will receive gefapixant 15 mg tablet and placebo tablet to match gefapixant 45 mg twice daily (BID) during the study period (52 weeks).
3135391|NCT03696108|Experimental|Gefapixant 45 mg BID|Participants will receive gefapixant 45 mg tablet and placebo tablet to match gefapixant 15 mg BID during the study period (52 weeks).
3135392|NCT03696342|Experimental|PRO-157|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
3180908|NCT00688506|Placebo Comparator|2|placebo therapy
3180909|NCT00688532||1|Prostate cancer patients treated with bicalutamide or not
3180910|NCT00688532||2|General population cohort
3180911|NCT00688558|Experimental|1|JTT-705 600 mg and simvastatin 40 mg
3180912|NCT00688558|Placebo Comparator|2|Placebo and simvastatin 40 mg
3180913|NCT00688571|Experimental|Melody TPV Implant|Melody Transcatheter Pulmonary Valve implanted into a dysfunctional RV-PV conduit.
3180914|NCT00688584|Experimental|1|
3180915|NCT00688584|Placebo Comparator|2|
3180916|NCT00688584|No Intervention|No intervention control|
3180917|NCT00688649|Active Comparator|1|Standard ONS
3180918|NCT00688649|Active Comparator|2|High Energy ONS
3180919|NCT00688675||Treated GERD pts|Previously diagnosed GERD patients on treatment in Switzerland
3180920|NCT00688714|Experimental|1|
3180921|NCT00688714|Placebo Comparator|2|
3180922|NCT00688727|Experimental|1|Cognitive behavioural Therapy
3180923|NCT00688727|Active Comparator|2|Standard Care
3180924|NCT00688766|Experimental|IPI-504|retaspimycin hydrochloride (IPI-504) plus best supportive care
3180925|NCT00688766|Placebo Comparator|Placebo|Placebo plus best supportive care
3180926|NCT00688779|Experimental|1|
3180927|NCT00688779|Placebo Comparator|2|
3180928|NCT00688805|Experimental|Arm 1|
3180929|NCT00688805|Placebo Comparator|Arm 2|
3135393|NCT03696342|Active Comparator|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
3135394|NCT03696576|Active Comparator|PhoRTE|This group will undergo standard PhoRTE therapy.
3135395|NCT03696576|Experimental|PhoRTE + EMST|This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.
3135396|NCT03696758|Experimental|Sildenafil followed by Metoprolol|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given sildenafil in between imaging scans at one visit, and will receive intravenous metoprolol in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
3135397|NCT03696758|Experimental|Metoprolol followed by Sildenafil|Young adults born premature, recruited either from the National Lung Project Cohort or the general public, will undergo Cardiac Magnetic Resonance Imaging before and after medication administration. This will occur twice, on two separate visits. Subjects will be given metoprolol in between imaging scans at one visit, and will receive intravenous sildenafil in between scans at next visit. There will be a minimum period of 12 hours between drug interventions to ensure adequate drug wash-out. Subjects will also undergo pulmonary function testing and electrocardiogram.
3135398|NCT03697083|Experimental|Reminders Through Association Arm|participants will be prompted to think of a reminder cue that will help them remember to pick up the prescription.
3135399|NCT03697083|Active Comparator|Active Control Arm|Participants will be asked to think about where they will store their prescription.
3180930|NCT00688818|Experimental|Quetiapine and existing psychotropics|
3135400|NCT03697083|Active Comparator|Baseline Control Arm|Participants are thanked for enrolling in the reminder program.
3135401|NCT03697122|Experimental|HHBC and Forced Air Warming|Patients admitted to intensive care unit hypothermic (≤ 35 C) following surgical procedures involving cardiopulmonary bypass. Will be rewarmed with heated humidified breathing circuits (ANAPOD) and standard forced air warming blankets.
3135402|NCT03697252|Experimental|KarXT|
3135403|NCT03697252|Placebo Comparator|Placebo|
3135404|NCT03697460|Experimental|INCB018424|INCB018424 Cream
3135405|NCT03697993|Experimental|Strategy 1|Fosfomycin 3 g orally once daily for 5-7 days as initial or step-down oral therapy for complicated urinary tract infections (cUTI) without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therapy, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy. N=317
3135406|NCT03697993|Experimental|Strategy 2|Levofloxacin 750 mg orally once daily for 5-7 days as initial or step-down oral therapy for cUTI without bacteremia with a uropathogen after 0-48 hours of parenteral antibiotic therap, and if indicated a subsequent investigator-directed adjustment to another adequate oral therapy.y. N=317
3135407|NCT03698279|Experimental|Group 1: QIV-HD 30 μg (US: 6 months to 17 years)|Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3135408|NCT03698279|Experimental|Group 2: QIV-HD 45 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3135409|NCT03698279|Experimental|Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)|Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3180931|NCT00688818|Placebo Comparator|Placebo and existing psychotropics|
3180932|NCT00688831|Experimental|A|AZD1305 solution for iv infusion
3135410|NCT03698279|Active Comparator|Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)|Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3135411|NCT03698279|Experimental|Group 5: QIV-HD, 60 μg (Canada: 6 to <24 months)|Participants from Canada (aged 6 to less than [<] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3135412|NCT03698279|Active Comparator|Group 6: Adjuvanted TIV (Canada: 6 to <24 months)|Participants from Canada (aged 6 to <24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3135413|NCT03698331|Experimental|Valbenazine|Valbenazine or placebo oral capsules administered once daily for 7 weeks.
3135414|NCT03698331|Placebo Comparator|Placebo|Placebo oral capsules administered once daily for 7 weeks.
3135415|NCT03698591|Experimental|Transcranial magnetic stimulation (TMS), then Sham TMS.|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes after stimulation, experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
3135416|NCT03698591|Sham Comparator|Sham TMS, then Transcranial magnetic stimulation (TMS)|Experimenters will employ a sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject. Experimenters have defined the target coordinates for the stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task. Thirty minutes post sham stimulation, experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates.
3135417|NCT03699124|Active Comparator|GP 1: two doses of FD MVA-BN--Lot 1|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 1
3135418|NCT03699124|Active Comparator|GP 2: two doses of FD MVA-BN--Lot 2|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 2
3135419|NCT03699124|Active Comparator|GP 3: two doses of FD MVA-BN--Lot 3|Healthy, vaccinia-naïve subjects receiving two subcutaneous (SC) vaccinations, four weeks apart with freeze-dried (FD) MVA-BN® - Lot 3
3180933|NCT00688831|Placebo Comparator|B|NaCl solution for iv infusion
3135420|NCT03700320|Active Comparator|Oral SOC Migraine Preventive Medication|Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.
3135421|NCT03700320|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet taken orally, once daily for 52 weeks.
3135422|NCT03700372|Experimental|IOWA Approach Cardiac Ablation|Subjects who are treated with the IOWA Approach Cardiac Ablation System for paroxysmal atrial fibrillation.
3135423|NCT03700385|Experimental|IOWA Approach Endocardial Ablation|Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.
3135424|NCT03700671|Experimental|High intensity interval training|HIIT was set at > 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
3135425|NCT03700671|Active Comparator|Circuit training|The CT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80%. Participants initially performed 20 minutes of CT with duration gradually increased to the desired 40 minutes as tolerated. Each station was occupied for three to six minutes depending on session duration with minimal rest in-between.
3180934|NCT00688857|Experimental|A|Diazoxide choline controlled-release coated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 9 through 16).
3135426|NCT03700736|Active Comparator|Facebook|"Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via a private (secret) Facebook group. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. A study counselor will facilitate discussions about the topics posted in the Facebook group. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to download the MyFitnessPal app to track daily diet."
3149035|NCT00164736|Active Comparator|No Drugs & Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & daily nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
3180935|NCT00688857|Experimental|B|Diazoxide choline controlled-release uncoated tablets administered orally once daily (Days 1 through 8). Diazoxide choline controlled-release coated tablets administered orally once daily (Days 9 through 16)
3180936|NCT00688883|Experimental|Arm 1|
3180937|NCT00688896|Experimental|1|JTT-705 600 mg and pravastatin 40 mg
3180938|NCT00688896|Experimental|2|JTT-705 300 mg and pravastatin 40 mg
3180939|NCT00688896|Placebo Comparator|3|Placebo and pravastatin 40 mg
3135427|NCT03700736|Active Comparator|Traditional|Women will receive the Healthy Moms intervention, a 6-month behavioral weight loss intervention, via in-person 90-minute group sessions (weekly in months 1-4, every other week in months 5-6). The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based lifestyle intervention. Intervention components will be introduced in the format of handouts, group discussions, and lists of existing resources. Each participant will get an individualized calorie and physical activity goal to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
3135428|NCT03700892|Experimental|Cinnamaldehyde, then PG/VG|Participants will inhale cinnamaldehyde e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale Propylene Glycol/Vegetable Glycerin (PG/VG) e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour.
3135429|NCT03700892|Experimental|PG/VG, then Cinnamaldehyde|Participants will inhale PG/VG e-liquid in 6, 5-minute paced vaping segments (1 puff/minute) over 1 hour. A 2-3 week washout period will follow. Then participants will inhale cinnamaldehyde e-liquid in 6, 5-minute vaping segments (1 puff/minute) over 1 hour.
3135430|NCT03700892|No Intervention|Healthy Controls|Participants will only undergo the baseline testing and thus serve as a non-exposed/non-vaping control group.
3135431|NCT03701061|Experimental|Participants that received AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine with AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
3180940|NCT00688961|No Intervention|1|Baseline
3180941|NCT00688961|Experimental|2|Aspirin (1 day after a single, 625 mg dose)
3180942|NCT00688961|Experimental|3|Omacor
3180943|NCT00688961|Experimental|4|Omacor plus aspirin
3180944|NCT00688974||Roux-en-Y gastric bypass|Patients with class 3 obesity and type 2 diabetes submitted to Roux-en-Y gastric bypass
3180945|NCT00688974||Adjustable gastric banding|Patients with class 3 obesity and type 2 diabetes submitted to adjustable gastric banding
3135432|NCT03701061|Active Comparator|Participants that did not receive AS03 Adjuvant|Subjects that participated in HIPCVAX-010 Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine without AS03 Adjuvant study are included in the study. Subjects will receive a single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent).
3135433|NCT03701074|Experimental|ibuprofen and acetaminophen arm (intervention arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Acetaminophen will be administered as oral formulation. Acetaminophen is given at a dose of 15 mg/Kg/dose, q 6 hours, for 3 days (total of 12 doses).
3135434|NCT03701074|Active Comparator|ibuprofen and placebo arm (control arm)|ibuprofen and acetaminophen will be administered concomitantly. Ibuprofen will be administered through intravenous route. The dose of ibuprofen will be the standard dosing regimen used in our unit: dosing based on the postnatal age. For Infants > 108 h of postnatal age: 18 mg/kg/dose loading dose followed by 9 mg/kg/dose, two doses at q24 intervals, started 24 h after the loading dose. Placebo will be sterile water, with similar volume and color as acetaminophen, will be given through the oro-gastric tube, for three days at 6 h intervals.
3135435|NCT03702010|Active Comparator|CME branch|In this study, the conventional spinal cord stimulation method (control Branch-CME branch)
3135436|NCT03702010|Experimental|EME branch|In this study, the experimental spinal cord stimulation method are used in the same patient with the EVOLVE programming guide (EME branch)
3135437|NCT03702166|Other|Interventional CPT|This study will examine the effectiveness of Cognitive Processing Therapy (CPT) for the alleviation of PTSD and tinnitus-related distress among individuals with co-morbid PTSD and tinnitus.
3135438|NCT03702608|Other|EluNIR 38mm|
3135439|NCT03703336|Experimental|ROTAVIN Liquid Formulation|Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
3135440|NCT03703336|Active Comparator|ROTAVIN-M1 Frozen Formulation|Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
3135441|NCT03703466|Experimental|200 mg Abemaciclib With a Meal|200 mg abemaciclib given twice a day (BID) orally with a meal.
3135442|NCT03703466|Experimental|200 mg Abemaciclib Without a Meal|200 mg abemaciclib given twice a day (BID) orally without a meal, taken in the modified fasted condition.
3135443|NCT03703466|Experimental|200 mg Abemaciclib Without Regard to Food|200 mg abemaciclib given twice a day (BID) orally without regard for food.
3135444|NCT03703817||tofacitinib citrate users|patients who have been using tofacitinib citrate for 6 months or more and less than 2 year in RA patients
3135445|NCT03703817||adalimumab users|patients who have been using adalimumab for 6 months or more and less than 2 year in RA patients
3180946|NCT00688974||Healthy controls|Non-obese, non-diabetic adults
3180947|NCT00688987|Active Comparator|1|Subjects with AI will be randomized to each of three doses of hydrocortisone for 4 months on each dose.
3135446|NCT03704194|Experimental|Adapted LiFE|Participants in the Adapted LiFE group learns to imbed 19 exercise activities (7 balance and 12 lower extremity muscle strength activities) into daily routines. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
3135447|NCT03704194|Sham Comparator|Attention control|Participants in the attention control group will learn gentle stretch exercise. An Occupational Therapy practitioner conducts 7 in-home visits over 12 weeks and a follow phone call a month after the last in-home visit.
3180948|NCT00688987|Active Comparator|2|isocaloric diet
3180949|NCT00689000|Experimental|CHR-2797 (tosedostat)|oral, once daily administration of CHR-2797 to determine safety & anti-disease activity.
3135448|NCT03704376|Active Comparator|Femoral Nerve Blockade|Ultrasound guided FNB (30 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) below the inguinal ligament using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ) with stimulator confirmation.
3135449|NCT03704376|Active Comparator|Adductor Canal Blockade|Ultrasound guided ACB (15 ml of 0.2% ropivacaine with 100 mcg clonidine using a 22-gauge 40 mm ProBloc II insulated needle; Kimberly-Clark, Roswell, Georgia) at the mid-thigh using a high-frequency linear ultrasound transducer (4-12 Hz; Mindray M7; Mindray North America, Mahwah, NJ).
3135450|NCT03704467|Experimental|Part A: Carboplatin + M6620 + Avelumab|
3135451|NCT03705273|Experimental|Dexamethasone IV for PO|Dexamethasone IV for PO solution mixed with sugar syrup to be given orally
3135452|NCT03705273|Active Comparator|Dexamethasone crushed tablets|Dexamethasone tablet crushed and placed in apple sauce or pudding to be given orally
3135453|NCT03705481|Other|Remote treatment of PCI.|5 sequential subjects presenting for remote PCI who have signed informed consent.
3135454|NCT03705494|Active Comparator|Home-based peer counselling intervention|Women planning to breastfeed who meet the study's inclusion criteria
3135455|NCT03705494|No Intervention|Standard usual care|Women planning to breastfeed who meet the study's inclusion criteria
3180950|NCT00689013|No Intervention|1|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the first month of observation. These patients have not been exposed to pharmacist-driven interventions utilized in this study. This group serves as the control group.
3180951|NCT00689013|Experimental|2|Patients voluntarily presenting to community pharmacies who request receipt of the herpes zoster vaccine during the second month of observation. These patients may or may not have been exposed to pharmacist-driven interventions utilized in this study. This group serves as the study/intervention group.
3180952|NCT00689039|Experimental|A|AZD1305 ER tablet
3180953|NCT00689039|Placebo Comparator|B|Placebo tablet
3180954|NCT00689065|Experimental|CALAA-01|
3135456|NCT03705793|Experimental|Mometasone Furoate Nasal Irrigation|The study intervention will be mometasone furoate powder (1.2 mg/capsule) and placebo nasal spray. The placebo nasal spray will contain the same inert ingredients found in MF nasal spray: glycerin, microcrystalline cellulose and carboxymethylcellulose, sodium citrate, citric acid, benzalkonium chloride, and polysorbate 80. The placebo nasal spray will be packaged identically to the mometasone nasal spray. Participants will be required to dissolve the contents of two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
3149036|NCT00164736|No Intervention|No Drugs & No Nutrition Supplement|"No extended maternal ARV prophylaxis nor infant nevirapine prophylaxis & no nutritional supplement given to the mother.~Note: As of March 2008, the third arm of the antiretroviral intervention, in which neither mother nor infant received drugs beyond enhanced standard of care, was stopped based on recommendations of a Data and Safety Monitoring Board review of interim efficacy results and safety data after 77% participants had received treatment assignment."
3149037|NCT00164749|Placebo Comparator|Placebo|Color-matched placebo
3149038|NCT00164749|Experimental|1 gram|1 g/day curcumin
3149039|NCT00164749|Experimental|4 gram|4 g/day curcumin
3149040|NCT00164775|Active Comparator|Imipramine|Imipramine 25mg nocte for first 2 weeks then Imipramine 50 mg nocte for 10 weeks
3149041|NCT00164775|Placebo Comparator|Placebo|Placebo 1 tablet for first 2 weeks then Placebo 2 tablets for 10 weeks
3149042|NCT00164788|Active Comparator|IV Nexium|Intravenous bolus injection of esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
3135457|NCT03705793|Active Comparator|Mometasone Nasal Spray|The study intervention will be mometasone nasal spray (50 mcg/spray) and placebo nasal irrigation. The placebo will contain lactose monohydrate and will be supplied in capsules identical to the budesonide capsules. Participants will be required to dissolve the contents of the two capsules into an 8-ounce (240 mL) sinus rinse bottle along with the saline rinse. All participants will be instructed to perform the following once daily: irrigation of both right and left nasal cavity with one-half of the contents of the nasal rinse followed by 2 sprays per nostril of the nasal spray.
3135458|NCT03706040|Placebo Comparator|Placebo|Participants randomized to receive placebo for 16 weeks in Period A followed by either risankizumab 150 mg or risankizumab 300 mg for 36 weeks in Period B.
3135459|NCT03706040|Experimental|Risankizumab 150 mg|Participants randomized to receive risankizumab 150 mg for 16 weeks in Period A followed by risankizumab 150 mg for 36 weeks in Period B.
3135460|NCT03706040|Experimental|Risankizumab 300 mg|Participants randomized to receive risankizumab 300 mg for 16 weeks in Period A followed by risankizumab 300 mg for 36 weeks in Period B.
3135461|NCT03706313|Active Comparator|Genicular nerve block with bupivacaine|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
3135462|NCT03706313|Placebo Comparator|Genicular nerve block with saline|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
3135463|NCT03706456|Experimental|Darvadstrocel 24 mL|Darvadstrocel (Cx601) 24 mL suspension of 120 million cells of expanded allogeneic adipose-derived stem cells (eASC) as an intralesional injection, once on Day 1.
3135464|NCT03706469|Experimental|Fasted (T2 50 mg+T3 50 mg+T3 600 mg+T2 600 mg)+Fed (T3 600 mg)|TAK-831 T2 50 milligram (mg), tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
3135465|NCT03706469|Experimental|Fasted (T3 50 mg+T2 600 mg+T2 50 mg+T3 600 mg)+Fed (T3 600 mg)|TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
3149043|NCT00164788|Active Comparator|Oral Nexium|Oral esomeprazole (Astra Pharmaceutica AG, Dietikon, Switzerland) 40mg every 12 hours for 24 hours
3180955|NCT00689156|Active Comparator|Regimen 1|Epirubicin 90 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times three followed by docetaxel 100 mg/m2 intravenously day 1 every 3 weeks times three
3180956|NCT00689156|Experimental|Regimen 2|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
3180957|NCT00689169|Experimental|Experimental|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan) ASCT Rituximab
3180958|NCT00689182|Experimental|A|All patients will receive phlebotomy
3180959|NCT00689195|Experimental|C|Curcumin
3180960|NCT00689195|Experimental|A|Ashwagandha extract
3180961|NCT00689234|Placebo Comparator|A|"At time of inclusion randomised in the no intervention arm (the subjects will be re-evaluated 6 months later and will get intervention at that time (cross-over protocol)"
3180962|NCT00689234|Active Comparator|B|At time of inclusion the subject get the intervention
3180963|NCT00689247|Experimental|A|AZD1305 given as oral solution
3180964|NCT00689247|Experimental|B|AZD1305 given as iv infusion
3149044|NCT00164853|Active Comparator|Standard sphincterotomy (ES)|After deep cannulation, a pull-type sphincterotomy will be performed with a 25mm sphincterotome (eg clever cut, Olympus, Tokyo, Japan) with division of sphincter up to the duodenal wall. A complete sphincterotomy is defined by the free passage of a fully bowed sphincterotome with a 25m wire and spontaneous bile drainage.
3135466|NCT03706469|Experimental|Fasted (T2 600 mg+T3 600 mg+T3 50 mg+T2 50 mg)+Fed (T3 600 mg)|TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
3149045|NCT00164853|Active Comparator|Sphincterotomy plus balloon dilation (ESBD)|After complete sphincterotomy, a 3-cm long 15mm diameter CRE balloon is passed over a guidewire across the lower end of common bile duct. The contrast filled balloon is inflated to the size of the bile duct for around 30 seconds until waisting is abolished.
3149046|NCT00164905|Active Comparator|Doppler ultrasound|
3149047|NCT00164905|No Intervention|No Doppler ultrasound|
3149048|NCT00164944||FDR of CRC patient|First degree relatives of patients having CRC
3149049|NCT00164944||FDR of normal colonoscopy|First degree relatives of patients having normal colonoscopy
3149050|NCT00165009|No Intervention|DUAL THERAPY|DUAL THERAPY
3149051|NCT00165009|Experimental|'Resolution clip|'Resolution clip
3149052|NCT00165035|Experimental|1|CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
3149053|NCT00165035|Active Comparator|2|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
3149054|NCT00165152|Active Comparator|Genetic Counseling|
3149055|NCT00165152|Active Comparator|Informed Consent Counseling|
3149056|NCT00165178|Experimental|Individualized ASP dose|
3149057|NCT00165178|Active Comparator|Fixed dose ASP|
3149058|NCT00165178|Experimental|Dexamethasone|
3149059|NCT00165178|Active Comparator|Prednisone|
3149060|NCT00165256|Experimental|Observation (omission of RT)|Wide excision of DCIS; no radiotherapy (RT).
3149061|NCT00165282|No Intervention|Usual Care|Normal standard of care
3149062|NCT00165282|Active Comparator|Nurse education|Meets with oncology nurse
3149063|NCT00165282|Experimental|Mindfulness training|Taught Mindfulness meditation
3149064|NCT00165308|Experimental|Tamoxifen|Single arm: Tamoxifen 20mg daily
3149065|NCT00165425|Experimental|Cardiac screening|"Interventions:~Participants will~meet with study cardiologist~undergo cardiac risk factors screening~undergo resting and stress echocardiogram (echo and stress echo)"
3149066|NCT00165542||All patients|A PROTEIN levels in all patients and with all tumor types.
3149067|NCT00165633|Experimental|1|
3149068|NCT00165633|Experimental|2|
3149069|NCT00165633|Placebo Comparator|3|
3135467|NCT03706469|Experimental|Fasted (T3 600 mg+T2 50 mg+T2 600 mg+T3 50 mg)+Fed (T3 600 mg)|TAK-831 T3 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 1, followed by TAK-831 T2 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 2, followed by TAK-831 T2 600 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 3, followed by TAK-831 T3 50 mg, tablet, orally, once, under fasted condition on Day 1 of Treatment Period 4, further followed by TAK-831 T3 600 mg, tablet, orally, once, under fed condition on Day 1 of Treatment Period 5. There will be a washout period of at least 7 days between study drug in-take in subsequent treatment periods.
3135468|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 1|Two administrations of 1000 mg P218 (capsules p.o.), 48 hours apart
3149070|NCT00165750|Experimental|1|
3149071|NCT00165763|Experimental|1|
3149072|NCT00165802|Experimental|1|
3149073|NCT00165828|Experimental|1|
3149074|NCT00165828|Experimental|2|
3149075|NCT00165919||HCV+|No group or cohort; not a clinical trial
3149076|NCT00166010|Experimental|Nesiritide|
3135469|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 1|Two administrations of P218 placebo (capsules p.o.), 48 hours apart
3135470|NCT03707041|Experimental|P218 1000 mg (Oral Capsules) - Cohort 2|One administration of 1000 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 1000 mg P218 (capsules p.o.), 48 hours after first administration.
3135471|NCT03707041|Placebo Comparator|P218 Placebo Oral Capsules - Cohort 2|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.,) 48 hours after first administration.
3135472|NCT03707041|Experimental|P218 100 mg (Oral Capsules) - Cohort 3|One administration of 100 mg P218 (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of 100 mg P218 (capsules p.o.), 48 hours after first administration.
3135473|NCT03707041|Active Comparator|P218 Placebo Oral Capsule - Cohort 3|One administration of P218 placebo (capsules p.o.), 2 hours after PfSPZ Challenge and one administration of P218 placebo (capsules p.o.), 48 hours after first administration.
3135474|NCT03707522|Experimental|Growth mindset + MRF Information|Online growth mindset interactive article followed by equal length interactive article describing the relationship between modifiable risk factors (MRF) and mental health outcomes
3135475|NCT03707522|Experimental|Control + MRF information|Online daily activity scheduling interactive article (control) followed by equal length interactive article describing the relationship between modifiable risk factors and mental health outcomes
3135476|NCT03707522|Experimental|Control + Growth mindset|Online growth mindset interactive article followed by equal length online daily activity scheduling interactive article (control)
3135477|NCT03707522|Placebo Comparator|Control + Control|2 doses online daily activity scheduling interactive article (control)
3135478|NCT03707587|Experimental|1200 mg intravenous (IV) of M7824|Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
3135479|NCT03707821|Experimental|senofilcon A TEST Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.
3135480|NCT03707821|Active Comparator|senofilcon A CONTROL Lens|Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.
3135481|NCT03707912|Experimental|Anaferon|"1 tablet per administration. Day 1: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals through the rest of the day.~Days 2-5: 1 tablet 3 times a day. The drug is taken out of the meal (in the interval between meals or 15-30 minutes before eating), keep the tablet in the mouth, without swallowing, until completely dissolved."
3135482|NCT03707912|Placebo Comparator|Placebo|Placebo using Anaferon regimen until the end of the study.
3180965|NCT00689286|Experimental|"BION twitch stimulation"|"The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation."
3180966|NCT00689286|Experimental|BION tetanic-frequency stimulation|The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions.
3180967|NCT00689286|No Intervention|Standardized program|A third group of experimental subjects will have a standardized program of voluntary exercise.
3180968|NCT00689312|Active Comparator|1|
3180969|NCT00689312|Experimental|2|
3180970|NCT00689312|Experimental|3|
3180971|NCT00689364||CTTCT+CWMT|"CTTCM:taking TCM decoction based on syndrome differentiation daily and each dosage is decocted two times for intervention one year with a Chinese patent medicine at least.~CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline)."
3180972|NCT00689364||CWMT cohort|CWMT :with or without chemotherapy/or radiotherapy after the radical operation (R0) (according to the latest NCCN clinical guideline).
3180973|NCT00689377||1|Subjects of either sex, any race, with at least two CVD risk factors, with no overt cardiovascular diseases nor diabetes mellitus
3180974|NCT00689403|Experimental|Part A: 2x2 crossover|4 different AZD1305 ER formulations
3180975|NCT00689403|Experimental|Part B: 3x3 crossover|2 different AZD1305 ER formulations and a reference formulation
3180976|NCT00689416|Experimental|1|
3180977|NCT00689416|Placebo Comparator|2|
3180978|NCT00689442|Experimental|1|JTT-705 600 mg and atorvastatin 20 mg
3180979|NCT00689442|Placebo Comparator|2|Placebo and atorvastatin 20 mg
3180980|NCT00689455||1|Primary care population
3180981|NCT00689468|Placebo Comparator|1|"Osteopathic sham treatment plus placebo Echinacea drops"
3180982|NCT00689468|Active Comparator|2|Active Echinacea drops plus sham osteopathic treatment
3180983|NCT00689468|Active Comparator|3|"Active osteopathic manipulation plus placebo Echinacea drops"
3180984|NCT00689468|Active Comparator|4|Active osteopathic manipulation plus active Echinacea drops.
3180985|NCT00689507|Experimental|Dose Escalation Phase(Part A):|1,10, 30, 100 or 300 mg of LY2127399 IV on day 1 of specific 21 day cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each 21 day cycle
3135483|NCT03708211|Experimental|Part1: TAK-931 80 mg PIC + TAK-931 80 mg Tablet|TAK-931 80 milligram (mg), PIC, orally, once on Day 1 Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, tablet, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until progressive disease (PD), or unacceptable toxicity or any treatment discontinuation is determined.
3135484|NCT03708211|Experimental|Part1: TAK-931 80 mg Tablet + TAK-931 80 mg PIC|TAK-931 80 mg, tablet, orally, once on Day 1 of Cycle 0 (16-day treatment cycle), followed by TAK-931 80 mg, PIC, orally, once on Day 3 Cycle 0, further followed by TAK-931 50 mg, PIC, orally, once daily from Day 5 to Day 16 Cycle 0. Participants will receive TAK-931 50 mg PIC, orally, once daily for up to 14 days in 21-day treatment cycles until PD, or unacceptable toxicity or any treatment discontinuation is determined.
3149077|NCT00166049|Placebo Comparator|Usual Care Attention Control|Usual care with provision of supplemental printed educational material on HF self care
3180986|NCT00689507|Experimental|Dose Confirmation Phase (Part B1):|Dose determined by PK/PD modeling, LY2127399 IV on day 2 of Cycle 1 and on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of each cycle
3149078|NCT00166049|Experimental|Group 2 Patient Family Education PFE|Patient Family Education PFE Heart Failure Patients and family member dyads were provided with an educational and counseling session, and attended a 2 hour patient-family education session on heart failure self management with emphasis on dietary sodium and medication taking behaviors.
3180987|NCT00689507|Experimental|Dose Confirmation Phase (Part B2):|Dose determined by PK/PD modeling, LY2127399 IV on day 1 of specific cycles and 1.3 mg/m2 Bortezomib IV on days 1, 4, 8, and 11 of specific cycles
3180988|NCT00689520|Experimental|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months.
3180989|NCT00689520|Active Comparator|acenocoumarol|tinzaparin for 1 weeks followed by acenocoumarol for 6 months
3180990|NCT00689546||I/A|All cases of acute viral hepatitis irrespective of type (A, B, E) with underlying Type 2 diabetes mellitus
3135485|NCT03708211|Experimental|Part 2: TAK-931 Fed + TAK-931 Fasted + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fed state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fasted state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
3135486|NCT03708211|Experimental|Part 2: TAK-931 Fasted + TAK-931 Fed + Esomeprazole 40 mg|TAK-931 tablet, orally, once under fasted state on Day 1 Cycle 0 (22-day treatment cycle), followed by TAK-931 tablet, orally, once under fed state on Day 3 Cycle 0, further followed by esomeprazole 40 mg, tablet, orally, once daily from Day 5 to Day 13 Cycle 0 and TAK-931 tablet, orally, once on Day 12, Day 14 to Day 22. Participants will receive TAK-931 tablets, orally, once daily for up to 14 days in 21-day treatment cycles until PD, unacceptable toxicity or any treatment discontinuation is determined. Dose of TAK-931 in Part 2 will be determined based on relative bioavailability data available from Part 1 of the study.
3135487|NCT03708367|Experimental|Study Group: LipiFlow Treatment at PreOp|Study subjects that meet all inclusion and exclusion criteria will be randomized to receive LipiFlow Thermal Pulsation System treatment at preoperative visit before bilateral implantation with commercially-available Symfony Intraocular Lens
3135488|NCT03708367|Other|Control Group|Study subjects that meet all inclusion and exclusion criteria will be randomized to not receive the LipiFlow Thermal Pulsation System treatment at a preoperative visit before bilaterally implanted with the commercially available Symfony Intraocular Lens. Control Group will receive LipiFlow treatment as cross-over group at 3 months postoperative visit.
3180991|NCT00689546||I/B|Age and sex matched non- diabetic patients with acute viral hepatitis (irrespective of type) recruited from all the patients of acute viral hepatitis registered during the time period in which cases were recruited.
3180992|NCT00689546||II/A|All diabetic who have acute icteric viral hepatitis due to HEV infection
3180993|NCT00689546||II/B|Age and sex matched diabetic who have acute icteric viral hepatitis due to hepatiits virus other than HEV.
3180994|NCT00689559|Experimental|1|AZD3480 + Aripiprazole
3180995|NCT00689559|Experimental|2|Placebo + Aripiprazole
3180996|NCT00689585|Placebo Comparator|1|
3180997|NCT00689585|Experimental|2|
3180998|NCT00689598|Placebo Comparator|III|Placebo
3180999|NCT00689598|Experimental|Experimental|Drug intervention
3181000|NCT00689624|Experimental|1|FOLFOXIRI+Erbitux
3181001|NCT00689637|Experimental|1|AZD3480 + warfarin
3181002|NCT00689637|Experimental|2|Placebo+ warfarin
3135489|NCT03708393|Active Comparator|Imagio IUS|Read 1 - Mammo (as available) + Imagio Ultrasound
3135490|NCT03708393|Experimental|Imagio (IUS+OA)|Read 2 - Mammo (as available) + (Imagio Ultrasound + OA)
3135491|NCT03708562|Other|endoAVF|
3135492|NCT03708744|Experimental|Treatment A|Treatment A: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (upper arm application)
3135493|NCT03708744|Experimental|Treatment B|Treatment B: M207 3.8 mg administered as two 1.9 mg patches, 30 min wear time (thigh application)
3135494|NCT03708744|Experimental|Treatment C|Treatment C: M207 3.8 mg administered as two 1.9 mg patches, 1 hour wear time (upper arm application)
3181003|NCT00689650|Experimental|A|
3135495|NCT03708744|Active Comparator|Treatment D|Treatment D: Intranasal zolmitriptan 2.5 mg
3135496|NCT03708770|Other|endoAVF|
3135497|NCT03709602||Adolescents ages 11 to 14 years|Adolescents ages 11 to 14 years who have received 1 dose of the HPV vaccine series between January 2017 and December 2017
3135498|NCT03709602||Parent of adolescents|Parents as defined as the adolescent's biological mother or father, step-parents, or legal guardian, and who self-identified as the primary caregiver of the adolescent child and most likely to make medical decisions for the adolescent.
3181004|NCT00689650|No Intervention|B|
3181005|NCT00689663|Active Comparator|1|Dissection staring at the triangle of calots. Dissection with electrocautery.
3181006|NCT00689663|Active Comparator|2|Dissection as fundus first with electrocautery.
3181007|NCT00689663|Active Comparator|3|Dissection as fundus first with ultrasonic dissection.
3135499|NCT03709602||Cohort of Adolescents From Electronic Health Record (EHR)|A cohort of adolescents ages 11 to 14 who received 1 dose of the HPV vaccine from January 2017 to December 2017 within the university's health system network. The cohort was followed from January 2018 to February 2019 to assess vaccine completion within a 14-month period.
3135500|NCT03709654|Experimental|Treatment Arm|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of NB01 probiotic applied topically.
3135501|NCT03709654|Placebo Comparator|Vehicle Control|Subjects will undergo 1 week lead-in with BPO followed by 11 weeks of vehicle applied topically.
3135502|NCT03709810|Experimental|Test Denture Adhesive|Test denture adhesive will be applied directly from the tubes using a continuous strip pattern to the upper and lower denture which will then be placed in mouth of the participants.
3135503|NCT03709810|Other|Control|Participants will not apply any denture adhesive in this treatment arm.
3135504|NCT03709823|Experimental|1.5 mg Cytisine, Commercial Schedule|1.5 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
3135505|NCT03709823|Experimental|3.0 mg Cytisine, Commercial Schedule|3.0 mg cytisine dose using the commercial 25-day titration schedule + behavioral support
3181008|NCT00689676||Study Group|20 very low birth weight preterm toddlers
3181009|NCT00689676||Control Group|20 full-term toddlers
3181010|NCT00689689|Active Comparator|Fully Coated Prodigy Stem (AML)|Total hip arthroplasty with fully coated prodigy stem (AML)
3181011|NCT00689689|Active Comparator|Cemented Endurance Hip Stem|Total hip arthroplasty with cemented Endurance hip stem component
3181012|NCT00689715|Experimental|EP|Single treatment arm
3181013|NCT00689741|Experimental|A|
3181014|NCT00689741|Placebo Comparator|B|
3181015|NCT00689754|Active Comparator|NGA|Patients will receive the standard of care to proceed with nasogastric tube placement, aspiration and lavage up to 1L of normal saline
3181016|NCT00689754|No Intervention|NO NGA|Patient presenting with Upper GI hemorrhage going straight to endoscopy.
3181017|NCT00689767|Experimental|A|This arm will receive the coated stent
3181018|NCT00689767|Active Comparator|B|This arm will receive a bare metal stent
3181019|NCT00689780|Experimental|1|AZD1940 + Placebo
3181020|NCT00689780|Other|2|
3181021|NCT00689806|Placebo Comparator|Placebo|
3181022|NCT00689806|Active Comparator|Lovastin|
3181023|NCT00689832|Experimental|A|
3181024|NCT00689832|Active Comparator|B|
3181025|NCT00689845|Experimental|Cohort 1|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1. Patients also receive oral prednisolone on days 1-5. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3181026|NCT00689845|Experimental|Cohort 2|Patients receive rituximab IV, cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1, oral prednisolone on days 1-5, and filgrastim (G-CSF) subcutaneously (SC) on days 5-12. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3135506|NCT03709823|Placebo Comparator|Placebo, Commercial Schedule|Placebo tablets using the commercial 25-day titration schedule + behavioral support
3135507|NCT03709823|Experimental|1.5 mg Cytisine, TID Schedule|1.5 mg cytisine dose for 25 days using a simplified 3 times daily (TID) schedule + behavioral support
3135508|NCT03709823|Experimental|3.0 mg Cytisine, TID Schedule|3.0 mg cytisine dose for 25 days using a simplified TID schedule + behavioral support
3135509|NCT03709823|Placebo Comparator|Placebo, TID Schedule|Placebo tablets for 25 days using a simplified TID schedule + behavioral support
3135510|NCT03710083|Experimental|Study arm|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).
3135511|NCT03710161|Experimental|4000 IU Vitamin D|4000 IU Vitamin D taken daily for six months
3135512|NCT03710161|Active Comparator|800 IU Vitamin D|800 IU Vitamin D taken daily for six months
3135513|NCT03710187|Experimental|Combination|Hydrocortisone 50 mg IV Q6h plus Fludrocortisone 50 mcg PO/PFT Q24h
3135514|NCT03710187|Active Comparator|Hydrocortisone only|Hydrocortisone 50 mg IV Q6h
3135515|NCT03710577|Experimental|Yoga|40 minutes of Vinyasa yoga
3135516|NCT03710577|Placebo Comparator|Quiet Rest|40 minutes of quiet rest
3135517|NCT03710590|Active Comparator|Cigarette smokers|
3135518|NCT03710590|Active Comparator|Electronic cigarette users|
3135519|NCT03710889|Experimental|Abaloparatide|Participants self-administered a single daily dose of 80 micrograms (µg) of abaloparatide subcutaneously (SC) during the treatment period. Participants were instructed to use a new injection pen after each 30-day period.
3181027|NCT00689845|Experimental|Cohort 3|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV and doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; methotrexate IV on days 8, 36, and 64; vincristine IV on days 8, 22, 36, 50 ,64, and 78; bleomycin IV on days 22, 50, and 78; and oral prednisolone on days 1-84, followed by a taper.
3135520|NCT03711396|Experimental|Advance Care Planning Group Visits - amnestic Mild Cognitive Impairment|Participants with amnestic Mild Cognitive Impairment will attend group visits to discuss advance care planning with their study partners. Group visits will last up to two hours and be help up to twice.
3135521|NCT03711396|Experimental|Advance Care Planning Group Visits - Care Partners|Care partners of persons with amnestic Mild Cognitive Impairment will attend group visits, with the person with Mild Cognitive Impairment, to discuss advance care planning. Group visits will last up to two hours and be help up to twice.
3181028|NCT00689845|Experimental|Cohort 4|Patients receive rituximab IV on days 1, 22, 43, 64, 85, and 106; cyclophosphamide IV on days 1, 29, and 57; doxorubicin hydrochloride IV on days 1, 15, 29, 43, 57, and 71; etoposide phosphate IV on days 15, 16, 43, 44, 71, and 72; vincristine IV and bleomycin IV on days 8, 22, 36, 50, 64, and 78; and oral prednisolone on days 1-84, followed by a taper.
3181029|NCT00689845|Experimental|Cohort 5|Patients receive rituximab IV, doxorubicin hydrochloride IV, and cyclophosphamide IV on day 1; vindesine IV and bleomycin IV on days 1 and 5; oral prednisone on days 1-5; methotrexate intrathecally on day 2; and G-CSF SC on days 6-13 for 4 courses in the absence of disease progression or unacceptable toxicity. After completion of 4 courses of R-ACVBP, patients receive consolidation therapy comprising high-dose methotrexate IV, rituximab IV, ifosfamide IV, etoposide phosphate IV, and cytarabine SC according to protocol GELA LNH03-2B.
3135522|NCT03711578|Experimental|Tenalisib|Participants receive Tenalisib 800 mg BID in 28-Days Cycle for 8 Cycles
3135523|NCT03712189|No Intervention|Alaris Pump|Participants will receive IV fluids delivered by the Alaris IV Pump (standard of care) until their bladder is full.
3135524|NCT03712189|Experimental|LifeFlow|Participants will receive IV fluids delivered by the LifeFlow Fluid Device until their bladder is full.
3135525|NCT03712280|Experimental|Group A: MNK6106 2 grams (tid)|Participants receive 2 tablets of MNK6106 three times daily (tid) for 5 days
3135526|NCT03712280|Experimental|Group B: MNK6106 4 grams (bid)|Participants receive 4 tablets of MNK6106 twice daily (bid) for 5 days
3135527|NCT03712280|Experimental|Group C: MNK6106 4 grams (tid)|Participants receive 4 tablets of MNK6106 tid for 5 days
3135528|NCT03712280|Active Comparator|Group D: Rifaximin 550 mg (bid)|Participants receive 1 tablet of rifaximin bid for 5 days
3149079|NCT00166049|Experimental|Group 3 Family Partnership Intervention|Patient and family member received one individual dyadic education/counseling session, and two group sessions focused on developing family approaches to HF self management. the emphasis of the two group sessions was on developing autonomy supportive approaches to family support.
3181030|NCT00689858|Experimental|1|Period 1: Cilostazol, Ginkgo biloba Period 2:Cilostazol, placebo
3149080|NCT00166075||Female ED patients|All eligible African American female patients were approached in the ED waiting room during study periods. Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
3149081|NCT00166088|Experimental|Mediterranean Diet Arm|
3149082|NCT00166088|Active Comparator|Mediterranean Dietary Supplement Arm|
3149083|NCT00166088|No Intervention|Control Arm|
3135529|NCT03712449|Experimental|BELKYRA Treatment|"BELKYRA was injected into the subcutaneous fat for maximum of 6 treatments, 1 month apart from Month 0 to Month 5. Maximum dose did not exceed 100 milligrams (mg) [10 milliliters (mL)] in a single treatment.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 6 to Month 11.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 6 to Month 8. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 9 and Month 10."
3135530|NCT03712449|Experimental|Non-BELKYRA Treatment|"Participants who did not receive BELKYRA.~SkinMedica products: (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer, Optional: Total Defense + Repair Broad Spectrum Sunscreen SPF34), applied daily from Month 0 to Month 5.~Facial filler injectable treatment (JUVÉDERM VOLBELLA with Lidocaine and/or JUVÉDERM VOLIFT with Lidocaine and/or JUVÉDERM VOLUMA with Lidocaine and/or JUVÉDERM VOLITE with Lidocaine) from Month 0 to Month 2. The volume of filler injected at initial and touch-up treatments was determined by the investigator.~BOTOX Cosmetic 20 units (U) to glabellar lines and/or 2-6 U injected bilaterally to crow's feet lines and/or 24 U total injected to forehead lines at Month 3 and Month 4."
3135531|NCT03712852|Active Comparator|PRF+CAF treated patients|The clot collected from the blood samples is pressed through a calibrated compression system into the PRF box the folded membrane is transferred on a sterile gauze. A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the PRFs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
3135532|NCT03712852|Active Comparator|SCTG+ CAF treated patients|SCTG is taken from the opposite palate area of gingival defect. The graft is collected with a single incision technique and it is measured and adjusted to 1 mm by measuring with a standard caliper.A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the SCTGs are placed over the exposed root surface, ﬂap is coronally positioned and sutures over the enamel in a tension-free position.
3135533|NCT03712852|Active Comparator|CAF treated patients|A modified coronally advanced flap technique (MCAF) is used to treat the recession defect, the flap is sutured over the enamel in a tension free position.
3135534|NCT03712917|Active Comparator|Greater Occipital Nerve Block|"The GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg), and 1 ml 0,9% NaCl. The solution is administered using a 22G × 1¼ (0.7 × 40mm) injector with the patient lying prone on the table. Injection is applied to medial of the occipital artery localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. The scalp is cleaned with iodine before the procedure, and the injections are performed bilaterally at a volume of 2 mL after negative aspiration for blood."
3135535|NCT03712917|Active Comparator|Topiramate|Topiramate is administered twice a day at a dose of 25 mg/day, which is increased to 100 mg/day in the second week.
3135536|NCT03712917|Active Comparator|Flunarizine|Flunarizine is introduced with a single dose of 10 mg/day.
3135537|NCT03712930|Experimental|Pamiparib|Participants will receive pamiparib for a period up to 1 year
3135538|NCT03713398|Experimental|T4C-SMI Group|Participants will receive the T4C-SMI intervention, in addition to standard prison mental health services
3135539|NCT03713398|No Intervention|Control Group|The control group receives standard prison mental health services
3135540|NCT03714022|Experimental|Treatment A|Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
3135541|NCT03714022|Active Comparator|Treatment B|Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
3149084|NCT00166192|Active Comparator|Chemical Peel|Split face treatment paradigm
3181031|NCT00689858|Active Comparator|2|Period 1: Cilostazol, placebo Period 2: Cilostazol, Ginkgo biloba
3181032|NCT00689897|Experimental|1|In acupuncture treatment, immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation, the needles are retained for 30 minutes.
3135542|NCT03714256|Experimental|Children 6-17 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
3135543|NCT03714256|Experimental|Children 18 - 36 months|"Device, patient mobility, powered:~Usability of the pediatric mobility device by both parent/guardian and occupational/physiological therapist, performed according to instructions for use at a one time occasion."
3135544|NCT03714659|Experimental|Intervention|Group will receive a single injection of autologous, micro-fragmented adipose tissue into the torn meniscus and knee joint. The group will then be followed for one year, filling out pain and function questionnaires.
3135545|NCT03714672|Experimental|Tramadol/Diclofenac 50/50|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 50 mg/50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
3149085|NCT00166231||Chest pain patients|
3149086|NCT00166231||Murmur group|
3149087|NCT00166244|Active Comparator|Fixed Dose|1 g MMF twice-daily (bid) for adults or 600 mg/m2 bid for paediatric patients. Treatment to be given orally unless it is not possible, in which case it is administered via intravenous (iv) infusion.
3135546|NCT03714672|Experimental|Tramadol/Diclofenac 25/25|Participants received 3 doses of tramadol hydrochloride/diclofenac sodium 25 mg/25 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
3135547|NCT03714672|Active Comparator|Tramadol 50|Participants received 3 doses of tramadol hydrochloride 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction.
3135548|NCT03714672|Active Comparator|Diclofenac 50|Participants received 3 doses of diclofenac sodium 50 mg over a 24-hour period if they developed acute moderate to severe pain within 4 hours after third molar extraction
3135549|NCT03714919|Experimental|Non-opiod pain relief|Subjects will receive preoperative oral dextromethorphan & acetaminophen and intraoperative intravenous dexmedetomidine & ketamine.
3149088|NCT00166244|Active Comparator|Concentration Controlled|1 g MMF bid for adults or 600 mg/m2 bid for paediatric patients. Thereafter, MMF doses will be adjusted to MPA AUC0-12 between 30-60mg.h/L based on 3-point abbreviated AUCs (taken at timepoints: 0, 30 min and 120 min always in fasted patients, except for pediatric patients on concomitant tacrolimus) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine MPA levels in plasma.
3149089|NCT00166257|Active Comparator|Medical antitrhombotic treatment|
3149090|NCT00166257|Experimental|Device Implant|Percutaneous closure of patent foramen ovale
3135550|NCT03715426|Experimental|MKit WebApp Intervention|The intervention arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors. In addition, they will receive access the MKit WebApp, which will give them access to content, goal setting, and resources for 14 topic areas.
3135551|NCT03715426|No Intervention|Standard of Care|The control arm will receive the usual standard of care training package for incoming students at the University of Michigan which includes: 1) Haven, an online module about healthy relationships and sexual violence completed before coming to campus; 2) Relationship Remix, an interactive peer-delivered program on healthy relationships and sexual violence; and 3) Change it Up, a bystander intervention educational theater performance delivered by student actors.
3149091|NCT00166270|Experimental|1|
3135552|NCT03715452||DyeVert Plus Contrast Reduction System|DyeVert Plus Contrast Reduction System
3135553|NCT03715530|Experimental|Pregnant subjects|These are pregnant women that are admitted to Labor &Delivery (L&D) or an outpatient in the Women's Health Clinic that are being evaluated for rupture of membranes.
3135554|NCT03715530|Active Comparator|Pregnant controls|These women will be found primarily in the Women's Health Clinic, when being seen for their routine antepartum appointments. Most of them will be recruited at about 36 weeks, since they will be having a pelvic exam at this time, as part of their routine antepartum care.
3135555|NCT03715530|Sham Comparator|Non pregnant controls|These women will be found in the Women's Health Clinic, when being seen for gynecology appointments. Nursing staff and the dashboard will help to identify those patients who will be having a pelvic exam.
3135556|NCT03715803||Calistar A|Calistar A mesh to treat anterior and apical POP
3135557|NCT03715803||Calistar S|Calistar S mesh to treat anterior and apical POP
3135558|NCT03716024|Experimental|PTK 0796|
3135559|NCT03716024|Active Comparator|Linezolid|
3149092|NCT00166283|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for five weeks (10 training sessions).
3135560|NCT03716050|Other|Group 1|Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No treatment, including dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.
3135561|NCT03716050|Active Comparator|Group 2|Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.
3135562|NCT03716050|Active Comparator|Group 3|Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.
3135563|NCT03716050|Active Comparator|Group 4|Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.
3181033|NCT00689897|Active Comparator|2|In acupuncture treatment, immediately after insertion of a needle, it is NOT manually rotated backwards or forwards to induce the DeQi sensation, and retained for 30 minutes.
3135564|NCT03716050|Active Comparator|Group 5|Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.
3135565|NCT03716050|Active Comparator|Group 6|Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.
3181034|NCT00689949|Other|folic acid|
3181035|NCT00689962|Experimental|1|Patients with unstable Lisfranc foot fracture-dislocations that receive bioabsorbable screw fixation through surgery.
3181036|NCT00689962|Active Comparator|2|Patients with unstable Lisfranc fracture-dislocations of the foot that receive steel screw fixation through surgery.
3181037|NCT00689988|Experimental|SG|Study Group: five children with Down syndrome submitted to speech-language intervention with AAC intervention
3181038|NCT00690001||1|HIV-1 infected patients in Taiwan
3181039|NCT00690014|Experimental|A|
3181040|NCT00690027|Active Comparator|A|"Objective: See Brief Summary, page 2. Eligibility: Patients who require > 2 units blood transfusion for bleeding esophageal varices due to cirrhosis.~Randomization: By the blind card method to emergency portacaval shunt (EPCS) or emergency endoscopic sclerotherapy (EST) followed by long-term repetitive EST.~Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 8hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months, or rebleeding after varices were obliterated.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong. Data Collection on line, analysis by biostatistician Florin Vaida, PhD External Advisory, Data Monitoring and Safety Committee by 3 senior academicians."
3135566|NCT03716050|Active Comparator|Group 7|Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.
3135567|NCT03716050|Active Comparator|Group 8|Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.
3135568|NCT03716076|Experimental|Participant receives 50 mcg of carbetocin post-delivery.|Participant receives 50 mcg of carbetocin post-delivery.
3135569|NCT03716076|Experimental|Participant receives 100 mcg of carbetocin post-delivery.|Participant receives 100 mcg of carbetocin post-delivery.
3135570|NCT03717012|Active Comparator|Nintedanib treatment alone|
3135571|NCT03717012|Experimental|Nintedanib with a pulmonary rehabilitation program|
3149093|NCT00166283|Placebo Comparator|placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
3181041|NCT00690027|Active Comparator|B|Emergency endoscopic sclerotherapy
3181042|NCT00690053|Experimental|1|
3135572|NCT03717051|Experimental|Intervention|The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
3135573|NCT03717051|Active Comparator|Control|The control group subjects will receive medication counseling. They will be advised to obtain free NRT by enrolling in the smoking cessation services, but will not be given the sampling. The same one-page leaflet will be provided by the SC clinics.
3135574|NCT03717064|Experimental|Pitavastatin|"Period 1: Participants will receive a single dose of pitavastatin on Day 1, followed by a wash-out period of at least 7 and up to 21 days.~Period 2: Participants will receive RO7049389 on Days 1-6. Participants will also receive a single dose of pitavastatin on Day 4."
3181045|NCT00690079|Experimental|AZD1386|7 groups receiving a specified volume of the active component AZD1386 at different points of time.
3181046|NCT00690079|Placebo Comparator|Placebo|7 groups receiving a specified volume of placebo at different points of time
3181047|NCT00690092|Active Comparator|1|Volunteers with a history of pulmonary coccidioidomycosis verified by serology and/or histology or mycology.
3149094|NCT00166387||Phase I, II, III|Phase I consists of a brother pair with hemophilia, one or both of whom has a history of inhibitors, and their parents; Phase II consists of a person with hemophilia and an inhibitor, and both his parents; Phase III consists of an unrelated group of people with hemophilia.
3149095|NCT00166413|Experimental|CC5013|Assess the proportion of confirmed hematologic responses (HCR, HPR) resulting from treatment with CC5013 after 3 months in patients with primary systemic amyloidosis.
3149096|NCT00166530|Active Comparator|1|Arm 1: Active comparator
3149097|NCT00166530|Experimental|2|Arm 2: Drug
3149098|NCT00166543|Experimental|TAS-108 40 mg|
3149099|NCT00166543|Experimental|TAS-108 80 mg|
3149100|NCT00166543|Experimental|TAS-108 120 mg|
3181048|NCT00690092|Active Comparator|2|Volunteers without a history of pulmonary coccidioidomycosis confirmed by serology (naive).
3135575|NCT03717155|Experimental|Avelumab and Cetuximab|Participants received 800 milligrams Avelumab, 1250 milligrams per square meter (mg/m^2) gemcitabine on Day 1 and Day 8, cisplatin at a dose of 75 mg/m^2 on Day 1 along with 250 mg/m2 body surface area Cetuximab on Day 1 and 500 mg/m2 body surface area on Day 8 of each cycle as intravenous (IV) infusions up to maximum of 4 cycles (each cycle is of 3 weeks) until disease progression or unacceptable toxicities. In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles. Subsequently participants were administered with avelumab and cetuximab as IV infusion at the dose of 800 mg and 500 mg/m^2 respectively, every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
3135576|NCT03717506|Experimental|Test product|GDC 268 Lotion applied topically as directed.
3135577|NCT03717506|Active Comparator|Reference Product|Clindamycin Phosphate Lotion, 1% applied topically as directed.
3181049|NCT00690092|Active Comparator|3|Volunteers with a history of pulmonary histoplasmosis but no history of coccidioidomycosis confirmed by serology.
3181050|NCT00690105|Experimental|A|
3135578|NCT03717506|Placebo Comparator|Placebo|GDC Vehicle lotion applied topically as directed.
3135579|NCT03718000|No Intervention|Control|Participants in this group received no intervention during t he holiday season
3181051|NCT00690105|Active Comparator|B|
3181052|NCT00690118|Active Comparator|1|
3181053|NCT00690118|Placebo Comparator|2|
3181054|NCT00690131|Experimental|1|
3135580|NCT03718000|Experimental|Daily Self-Weighing (DSW)|Participants in this group performed daily self-weighing using digital WiFi scales during the holiday season
3135581|NCT03718871|Experimental|Healer HIV testing intervention|We will follow Ugandan National protocols to administer voluntary HIV testing at 9 TH practice locations throughout Mbarara District over a 9 month period.
3135582|NCT03718871|No Intervention|Healer control arm|Patients will undergo protcolized usual TH care at 8 practices, which include HIV education and a referral to receive VCT through existing resources. Study staff will contact the client at 3 months following enrollment to assess for self-report of VCT.
3135583|NCT03719300|Experimental|Single Arm BC-819|inodiftagene vixteplasmid
3135584|NCT03719378|No Intervention|Traditional Fluid|"NPO Clears and Food after midnight.~2 Liters of lactated ringers administered by anesthesia intraoperatively.~Postoperatively - 2 Liters of Crystalloid while in PACU and Inpatient Room for a Total of 4 Liters of Crystalloid within 24 hours. (Patient will receive 500 milliliters while in PACU and 1500 milliliters while in their Inpatient Room, for a total of 2 Liters).~Normal diet postoperatively."
3149101|NCT00166699|No Intervention|Palpation|Use of palpation to guide the the insertion site of combined spinal epidural needle in obese parturients
3135585|NCT03719378|Experimental|Oral Fluid|"Pre Operative Oral Fluids (Patients encouraged to drink a minimum of 60 ounces of clear liquid per day for the 3 days prior to procedure.)~NPO Food/Milk: none beginning 8 hours prior to procedure time.~Pre Operative Oral Fluids (Patients are asked to drink 10 ounces of clear liquid 4 hours prior to their scheduled procedure time.)~Preoperative holding area, IV is started in the patient with Lactated Ringers IV fluid at a rate of 75ml/hr. IV fluids will be stopped and hep-locked in the PACU when the patient is taking PO fluid; the total amount of IV fluids is not to exceed 500ml total.~PO fluid protocol: a minimum of 60 ounces of liquid per day for 3 days."
3135586|NCT03719586|Experimental|A|Remdesivir plus optimized Standard of Care (oSOC)
3135587|NCT03719586|Experimental|B|MAb114 plus optimized Standard of Care (oSOC)
3135588|NCT03719586|Experimental|C|REGN-EB3 plus optimized Standard of Care (oSOC)
3135589|NCT03719586|Experimental|Control|Zmapp plus optimized Standard of Care (oSOC)
3135590|NCT03719612|Experimental|DEFINITY®|Each patient will undergo an unenhanced ultrasound examination and a DEFINITY® contrast-enhanced ultrasound
3135591|NCT03719677|Experimental|Habit development intervention|Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.
3135592|NCT03719885|Experimental|Intervention|
3135593|NCT03720470|Experimental|PF-04965842 100 mg + Placebo Inj followed by PF-04965842 100mg|Once-daily oral PF-04965842 100 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 100 mg from Week 16 to Week 20
3135594|NCT03720470|Experimental|PF-04965842 200 mg + Placebo Inj followed by PF-04965842 200mg|Once-daily oral PF-04965842 200 mg + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral PF-04965842 200 mg from Week 16 to Week 20
3149102|NCT00166699|Experimental|ultrasound|The use of ultrasound to guide the insertion of a combined spinal epidural needle
3181055|NCT00690131|No Intervention|2|
3135595|NCT03720470|Active Comparator|Dupilumab Injection + Oral Placebo followed by Oral Placebo|Dupilumab injected subcutaneously once every 2 weeks + once-daily oral Placebo from Day 1 until Week 16 followed by once-daily oral Placebo from Week 16 to Week 20
3135596|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 100 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 100 mg PF-04965842 from Week 16 to Week 20
3149103|NCT00166868|Experimental|Neomycin prescribed|Interventions: 10 cases received Neomycin for 6 months
3135597|NCT03720470|Placebo Comparator|Oral Placebo + Placebo Inj followed by 200 mg PF-04965842|Once-daily oral Placebo + Placebo injected subcutaneously once every 2 weeks from Day 1 until Week 16 followed by once-daily oral 200 mg PF-04965842 from Week 16 to Week 20
3149104|NCT00166868|Experimental|Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed|Interventions: 10 cases received Probiotics for 6 months
3135598|NCT03720652|Experimental|8-Week Mindful Self-Compassion (MSC)|CNAs in Aim 1 will participate in the standardized, 8-week Mindful Self-Compassion course. Each 8-week session will last for 2.5 hours. Also included is a half day retreat, that CNAs may attend if they are able.
3135599|NCT03720652|Experimental|6-Week Mindful Self Compassion (MSC)|CNAs from both nursing homes in Aim 2 will participate in the 6-week Mindful Self-Compassion course, that was shortened and customized to fit the needs of health care staff. Each 6-week session will last for 1 hour.
3149105|NCT00166868|No Intervention|control|10 cases without intervention were historical control.
3149106|NCT00166881|Experimental|A, 2, III|Weekly Docetaxel-Irinotecan for Inoperable Gastric Cancers After P-HDFL
3149107|NCT00167141|Experimental|testosterone injections|injections of testosterone to normal men (arm 1) and two men with subnormal semen parameters (arm 2)
3149108|NCT00167154|Experimental|risperidone|risperidone
3149109|NCT00167154|Placebo Comparator|placebo|placebo comparator
3149110|NCT00167167|Experimental|BMT patients|All patients treated.
3149111|NCT00167219|Experimental|Intent-to-Treat|Patients receiving study regimen.
3149112|NCT00167232|Active Comparator|Naltrexone 150mg/day|
3149113|NCT00167232|Placebo Comparator|Placebo Sugar Pill|
3149114|NCT00167271|Experimental|Experimental|Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
3149115|NCT00167271|Active Comparator|Control|Subjects given pamphlets from the Arthritis Foundation
3149116|NCT00167297|Experimental|Atomoxetine|Atomoxetine (Strattera) 25mg peroral (PO) each day for seven days, then up to 40mb bid 40mg PO each day for three days, then 80mg PO bid.
3149117|NCT00167362|Experimental|1|Participants will receive cognitive enhancement therapy
3135600|NCT03720847|Experimental|Active condition, then Inactive condition|Beginning 7 days after ovulation, active treatment begins 7 days after ovulation with an estradiol transdermal patch (0.1 mg/24 hrs) applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days. A 1-month washout is observed. Then, beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days.
3149118|NCT00167362|Placebo Comparator|2|Participants will receive enriched supportive therapy
3181056|NCT00690144|Experimental|simulation group|the trainees in the simulation group receive simulation-based training
3149119|NCT00167466|Experimental|A|4 week brushing with experimental Soladey-3 toothbrush followed by 4 week washout period followed by 4 week brushing with placebo Soladey-3 toothbrush
3149120|NCT00167466|Placebo Comparator|B|subjects to brush with Placebo Soladey-3 toothbrush for 4 weeks followed by a 4 week washout followed by 4 week brushing with experimental Soladey-3 toothbrush
3149121|NCT00167505|Experimental|Risk Avoidance|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
3149122|NCT00167505|Experimental|Risk Reduction|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes both classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
3149123|NCT00167531|Experimental|Treadmill walking|30 minutes per day of treadmill walking with body weight support and assistance from one therapist
3149124|NCT00167531|Active Comparator|Overground walking|30 minutes per day of overground walking with assistance from one therapist
3149125|NCT00167557|Experimental|Single Arm Study|
3149126|NCT00167583|Active Comparator|A Cyclosporin A|Cyclosporin A
3149127|NCT00167583|Active Comparator|B Interferon alpha|Interferon-alpha2a
3149128|NCT00167596|Experimental|1|Early goal directed therapy based on StO2 evaluation
3149129|NCT00167596|Active Comparator|2|Early goal directed therapy
3149130|NCT00167622|Active Comparator|1|Physiotherapy, oxygen as needed
3135601|NCT03720847|Placebo Comparator|Inactive condition, then active condition|Beginning 7 days after ovulation, inactive placebo capsules will be taken twice daily by mouth along with the application of inactive clear patches applied to the skin weekly for 14 days. After completing a 1-month washout, active treatment begins 7 days after ovulation with an (active) estradiol transdermal patch applied to the skin weekly (spanning 14 days of treatment) along with (active) 100 mg oral micronized progesterone capsules taken twice daily by mouth for 14 days.
3135602|NCT03720938|No Intervention|Control Group|Physically inactive children who did not play AVGs.
3135603|NCT03720938|Experimental|Intervention Group|Physically inactive children who played alternately Nintendo Wii® active video games for 50-60 min, 3 days a week, 12 weeks, in laboratory environment.
3135604|NCT03721172|Experimental|Placebo-controlled Phase:|Participants received placebo as oral tablets twice daily (BID) for up to 16 weeks (Week 0 to Week 16).
3135605|NCT03721172|Experimental|Placebo-controlled Phase: Apremilast 30 mg|Participants received apremilast 30 mg as oral tablets BID for up to 16 weeks (Week 0 to Week 16).
3135606|NCT03721172|Experimental|Extension Phase: Apremilast 30 mg|Eligible participants who completed the placebocontrolled phase entered the extension phase and received apremilast 30 mg as oral tablets BID for up to an additional 16 weeks (Week 16 to Week 32).
3135607|NCT03721276|Experimental|Therapy|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
3135608|NCT03721276|Other|Waitlist|Individuals assigned to waitlist will be put on a waitlist for 3 months after baseline assessment, after which they will also receive the same treatment as the therapy group.
3135609|NCT03721549|Experimental|Moderate Dose Inoculum|Moderate dose of Norwalk GI.1 Virus, 3.6x10^5 genome copies
3135610|NCT03721549|Experimental|Higher Dose Inoculum|Higher dose of Norwalk GI.1 Virus, 1x10^6 genome copies
3149131|NCT00167622|Experimental|2|Mechanical ventilation
3135611|NCT03722030|Experimental|Strength-Training Intervention|Following baseline measures, participants will receive an initial in-person instructional session, instructional material and resistance training equipment, support and feedback via video coaching, mid-point assessment, and an in-person study visit to collect post study measures. Intervention will be 10 weeks, with a 5 week follow up period.
3135612|NCT03722030|Placebo Comparator|Waitlist Control|Following baseline measures, participants will provide mid-point measures, and in-person post-study measures with no 10-week strength training intervention.
3135613|NCT03722238|Experimental|Ibuprofen 600 mg Immediate Release/Extended Release Tablets|Ibuprofen 600 mg Immediate Release/Extended Release Tablets
3135614|NCT03722264|Experimental|OpalSeal|"OpalSeal will be applied~to the buccal surfaces of to-be-extracted teeth on one side of the mouth which will be determined randomly for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Since OpalSeal has fluoride releasing capability, this would be experimental arm"
3135615|NCT03722264|Placebo Comparator|Transbond XT|"TransbondXT will be applied~to the buccal surfaces of to-be-extracted teeth on the other side of the mouth which will be determined based on which side received OpalSeal for each participant during bonding of orthodontic brackets, or~to the proximal surfaces following IPR in accordance to manufacturer instructions. Transbond XT does not have fluoride and hence would be considered as a placebo."
3135616|NCT03722446|Other|Arrow Catheter Kit.|Arrow FlexTip Plus Epidural Catheterization Kit is a single orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
3135617|NCT03722446|Other|B.Braun Catheter Kit|Perifix FX Springwound Epidural Catheter Kit is a multi-orifice flex tip catheter used to place epidurals in pregnant women in labor who request an epidural for pain management in labor. This kit will be used in half of the randomized weeks.
3149132|NCT00167635|Experimental|1|Face-to-Face Individualized Comprehensive Self-Management (CSM-FF) Group. Participants in the individualized CSM-FF group will be scheduled for 9 weekly sessions with the nurse therapist followed by post-intervention follow-up assessment.
3181057|NCT00690170|Active Comparator|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotine IV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
3181058|NCT00690170|Placebo Comparator|Placebo Comparator|-Placebo administration: Normal saline (sodium chloride 0.9%)over 95 minutes
3135618|NCT03722524||Patients with arterial hypertension|"The patient is included in the program if prior to the study his/her doctor decided to adjust treatment, targeted at the BP control improvement, by prescription of a triple FDC of amlodipine / indapamide / perindopril arginine. The prescription of the triple FDC of amlodipine / indapamide / perindopril arginine during the program is made by the doctor's decision according to the instructions for medical use of this FDC.~Presumably, each doctor will include 4 patients in average. It is planned to include 1,300 patients."
3135619|NCT03722576|Experimental|Vidofludimus Calcium (VC)|Daily dosing of VC over 6 months
3135620|NCT03722784|Experimental|Invigor A (test)|Subjects will be randomized to wear Invigor A (test) for one month of daily wear during the study.
3135621|NCT03722784|Active Comparator|Invigor B (Control)|Subjects will be randomized to wear Invigor B (Control) for one month of daily wear during the study.
3181059|NCT00690170|Active Comparator|Ketamine and Placebo|"Ketamine administration: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes~Placebo administration: Normal saline (sodium chloride 0.9%)over 94 minutes"
3135622|NCT03723915|Experimental|Treatment (pembrolizumab, wild-type reovirus)|See Detailed Description
3135623|NCT03724812|Experimental|Portico valve and FlexNav™ Delivery System|Portico valve implantation with the second-generation FlexNav Delivery system
3135624|NCT03725982|Experimental|With exoskeleton, then without exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) with the exoskeleton, then without the exoskeleton.
3181060|NCT00690170|Active Comparator|Nicotine and Placebo|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg)IV (in the arm), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
3181061|NCT00690196|Experimental|1|Tai Chi Chih
3181062|NCT00690196|Active Comparator|2|Cognitive Behavioral Therapy
3181063|NCT00690222|No Intervention|TM|Topical mydriasis without pseudoexfoliation
3181064|NCT00690222|Experimental|ICM|Intracameral mydriasis without pseudoexfoliation
3181065|NCT00690222|No Intervention|TM - PXF|Topical mydriasis with pseudoexfoliation
3181066|NCT00690222|Experimental|ICM - PXF|Intracameral Mydriasis with pseudoexfoliation
3181067|NCT00690248||1|Bipolar patients admitted to a psychiatric Unit due to an acute mania episode.
3181068|NCT00690261||lung cancer|patients diagnosed of lung cancer with malignant pleural effusions
3181069|NCT00690287|Experimental|Part A, arm 1|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo together with food
3181070|NCT00690287|Experimental|Part A, arm 2|1) 8 pats: AZD6370 increasing oral single doses a+b+c+placebo without food
3135625|NCT03725982|Experimental|Without exoskeleton, then with exoskeleton|Subject will first perform the conditions (simulated, simplified, industrial standing work) without the exoskeleton, then with the exoskeleton.
3135626|NCT03727841|Experimental|1/Arm 1 Marizomib|Marizomib at days 1, 8, and 15 of each 28-day cycle
3135627|NCT03727841|No Intervention|P/Pregnancy Evaluation|Data collection on pregnancy, birth and Health of Child
3181071|NCT00690287|Experimental|Part B, arm1, 2, and 3|"AZD6370 dose x mg o.d.~dose x/2 mg b.i.d.~dose x/4 mg q.i.d."
3181072|NCT00690287|Experimental|Part B, arm 4|4) Placebo
3135628|NCT03736967|Experimental|REGN3500|
3135629|NCT03736967|Experimental|Dupilumab|
3135630|NCT03736967|Experimental|Combo|
3135631|NCT03736967|Experimental|Placebo|
3135632|NCT03739840|Experimental|Padsevonil dosing regimen 1|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
3135633|NCT03739840|Experimental|Padsevonil dosing regimen 2|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
3135634|NCT03739840|Experimental|Padsevonil dosing regimen 3|Subjects will be randomized to receive a combination of tablets of padsevonil and placebo (as appropriate) to maintain the blinding.
3135635|NCT03739840|Placebo Comparator|Placebo|Subjects randomized to the placebo group will receive a combination of several placebo tablets to maintain the blinding.
3135636|NCT03739983|Experimental|VRP Therapy|All subjects on this study will receive the Vaginal Renewal Program intervention. Enrolled subjects will receive inperson instruction on how to perform the VRP. Subjects will be encouraged to use the device for 3-4 days per week for 5 minutes at a time.
3181073|NCT00690313|Active Comparator|Arm 1|Arm 1: receives Vigamox eye drops 3Xday for 3 days prior to intravitreal injection
3135637|NCT03746002|Active Comparator|Metolazone Pre-dosing|Metolazone 5 mg by mouth administered 60 minutes prior to furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
3135638|NCT03746002|Active Comparator|Metolazone Concurrent Dosing|Metolazone 5 mg by mouth administered at the same time as furosemide background therapy (120 - 160 mg intravenous bolus, followed by furosemide 120 - 160 mg intravenous bolus 12 - 24 hours after)
3181074|NCT00690313|Active Comparator|Arm 2|Arm 2: receives Vigamox eye drops 3Xday for 1 day prior to intravitreal injection
3135639|NCT03748771|Experimental|ApneaLink Air|Half of the participants will undergo HST no greater than one week prior to their in-laboratory PSG, while the other half will undergo HST no greater than one week following their in laboratory PSG. All participants will also undergo their HST concurrent to their in-laboratory PSG. The rational for splitting participants in these two groups is to equally distribute the effects of the first night evenly, in which the sleep architecture including reduced total rapid eye movement (REM) sleep time can vary during the first ever sleep study. As the HST will be compared to the in-lab PSG, we would like to evenly distribute this effect by having two groups of ten participants.
3135640|NCT03752177|Experimental|LY3415244 Dose Escalation|Participants received 3 milligrams (mg) LY3415244 (Cohort A1), 10 mg LY3415244 (Cohort A2), 30 mg LY3415244 (Cohort A3) and 70 mg LY3415244 (Cohort A4) as an intravenous (IV) infusion on day (D)1 and D15 of each 28-day cycle every 2 weeks (Q2W).
3135641|NCT03752177|Experimental|LY3415244 Dose Expansion|Phase 1b dose expansion was planned but not initiated as dose escalation ended at cohort A4. Study did not achieve its primary objective of establishing a recommended phase 2 dose (RP2D) due to early termination of the study by Cohort A4.
3135642|NCT03753763|Experimental|Active|Safinamide methanesulfonate film-coated tablets once daily
3181075|NCT00690326|Experimental|A|"treatment type: behavioral(lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
3135643|NCT03753763|Placebo Comparator|Placebo|Safinamide Methanesulfonate matching placebo film-coated tablets once daily
3135644|NCT03756571|Experimental|Ankle Foot Orthoses-Footwear Combination|The intervention is a Ankle Foot Orthoses Footwear Combination (AFO-FC). This is some form of solid ankle AFO combined with modified footwear individually designed per algorithm.
3135645|NCT03756571|Active Comparator|Traditional Solid Ankle AFO (TSAFO)|"The intervention is a solid AFO (SAFO) aligned with the ankle at 90 degrees and worn with regular footwear. We'll refer to this as the traditional SAFO (TSAFO)..."
3135646|NCT03761537|Experimental|Tralokinumab + TCS|4 subcutaneous (SC) injections of tralokinumab 150 mg as a loading dose on Day 0, followed by 2 SC injections of tralokinumab 150 mg every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
3181076|NCT00690326|Placebo Comparator|B|Arm B given placebo comparator ie pamphlets
3135647|NCT03761537|Placebo Comparator|Placebo + TCS|4 subcutaneous (SC) injections of placebo as a loading dose on Day 0, followed by 2 SC injections of placebo every 2 weeks (Q2W) regimen for 26 weeks. The last administration of the Investigational Medicinal Product (IMP) occurred at Week 24. From Day 0 to Week 24, a Topical corticosteroid (TCS) cream was dispensed to the participants at each IMP dosing visit (e.g., Q2W). Participants were instructed to treat active lesions as needed and to discontinue the TCS treatment when control was achieved.
3135648|NCT03763877|Experimental|Group 1|PXL770 Dose 1
3181077|NCT00690391||Surgical observation|patients with cancer in a palliative setting and in need of surgical interventions
3181078|NCT00690404|Experimental|1|
3181079|NCT00690417|Placebo Comparator|1|
3135649|NCT03763877|Experimental|Group 2|PXL770 Dose 2
3135650|NCT03763877|Experimental|Group 3|PXL770 Dose 3
3135651|NCT03763877|Placebo Comparator|Group 4|Placebo oral capsule
3135652|NCT03764007|Experimental|18F-Fluorocholine PET|Patients will undergo a single fluorocholine PET imaging study prior to surgery.
3135653|NCT03772587|Placebo Comparator|Group 1|
3135654|NCT03772587|Experimental|Group 2|
3135655|NCT03772587|Experimental|Group 3|
3135656|NCT03772587|Experimental|Group 4|
3135657|NCT03772587|Experimental|Group 5|
3135658|NCT03789292|Experimental|CT-P17 Subcutaneous(SC) (adalimumab)|CT-P17 SC (adalimumab)
3135659|NCT03789292|Active Comparator|Humira SC (adalimumab)|Humira SC (adalimumab)
3135660|NCT03799289|Experimental|Iyengar Yoga|Participants randomized to the yoga intervention arm will receive 12 weeks of group-based yoga instruction, following a 12-week standard behavioral weight loss program. Group-based yoga instruction will occur twice per week and classes will be 60 minutes in duration. The yoga program will consist of breathing, postural, and meditation practices and home-based yoga practice will also be prescribed.
3181080|NCT00690417|Active Comparator|2. 2500 IU vitamin D in a food preparation|Daily ingestion of 2500 IU vitamin D in a food preparation.
3181081|NCT00690456|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
3149133|NCT00167635|Experimental|2|Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
3181082|NCT00690456|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily on top of metformin
3135661|NCT03799289|Active Comparator|Cooking/dietary education|Participants randomized to the cooking/dietary education intervention arm will receive 12 weeks of group-based, cooking/dietary education instruction, following a 12-week standard behavioral weight loss program. This group-based instruction will occur twice per week and classes will be 60 minutes in duration. Classes will focus on providing basic nutrition knowledge and culinary skills, and will include cooking demonstrations.
3135662|NCT03805438|Experimental|Chloroprocaine dose|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
3135663|NCT03808948|Experimental|All Patients|VFI dose: 47 mg / 3 mL Number of doses: 2 Route of administration: intravenous
3149134|NCT00167635|No Intervention|3|Usual Care Control Group (UC). Following randomization the participants in the control group will receive two short phone calls to maintain contact during the comparable 9-week intervention in the treatment groups.
3149135|NCT00167648|Active Comparator|A|Leuprolide 7.5 mg or Goserelin 3.6 mg
3149136|NCT00167648|Experimental|B|Transdermal estradiol 0.6 mg q 3 days
3149137|NCT00167674|Active Comparator|B|Combined short-course Zidovudine/Nevirapine
3149138|NCT00167674|Experimental|A|HAART during pregnancy and 6 months postpartum
3149139|NCT00167687|Placebo Comparator|2|
3149140|NCT00167700|Experimental|Probiotics|
3149141|NCT00167700|Experimental|Probiotics + Dietary counseling|
3149142|NCT00167700|Experimental|Dietary counseling + placebo|
3149143|NCT00167700|Experimental|Prebiotics|
3149144|NCT00167700|Placebo Comparator|Placebo|
3149145|NCT00167700|No Intervention|Control|
3149146|NCT00167804|Other|1|Present Centered Therapy focuses on the veterans problems in the here and now. It uses a problem solving approach and avoids discussion of war related traumatic events.
3149147|NCT00167830|Experimental|Lifestyle Intervention|Dietary modification and exercise.
3149148|NCT00167856|Experimental|1|Venlafaxine HCL (extended release)
3149149|NCT00167856|Active Comparator|2|Benztropine Mesylate
3149150|NCT00167947|Active Comparator|A|
3149151|NCT00167947|Experimental|B|
3149152|NCT00168025|Experimental|IgPro10|
3149153|NCT00168220||Drug hypersensitive group|HIV positive patients with a history of a Hypersensitivity Reaction to the antiretroviral medications Nevirapine, Abacavir or Efavirenz
3149154|NCT00168220||Drug tolerant group|HIV positive patients selected based on drug exposure greater than 2 weeks and tolerance to to Abacavir or Nevirapine.
3149155|NCT00168233||1|No antiretroviral therapy for 12 months
3149156|NCT00168233||2|Initiating ARV therapy with an NNRTI based regimen
3149157|NCT00168233||3|Initiating ARV therapy with a PI based regimen
3149158|NCT00168415|Experimental|1|Botulinum Toxin Type A
3149159|NCT00168480|Experimental|1|Botulinum Toxin Type A
3135664|NCT03810053|Experimental|Mobile App/Online Module|Subjects will watch a short video containing information about cancers and benefits of uptake cancer prevention and early detection measures. Information regarding gender, age, smoking status, BMI and positive cancer history in family will be captured. Subjects will be provided with a list of cancer prevention and early detection measures based on the responses provided.
3135665|NCT03812224|Experimental|Erenumab|Participants were to receive erenumab 70 mg once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
3135666|NCT03812224|Placebo Comparator|Placebo|Participants were to receive placebo to erenumab once a month for 24 weeks during the double-blind treatment period followed by erenumab 70 mg once a month for 28 weeks during the open-label treatment period.
3135667|NCT03817528|Experimental|ITI-007|Open-Label ITI-007 40-60 mg
3135668|NCT03817580|Experimental|Project X 26ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 26ml volume. Single use.
3135669|NCT03817580|Experimental|Project X 5.1ml|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use swabstick. 5.1ml volume. Single use.
3135670|NCT03817580|Active Comparator|Prevantics Maxi Swabstick|3.15 % w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. 5.1ml volume. Single use.
3149160|NCT00168493|Active Comparator|intervention|there is no sham or placebo control arm It is a single arm study
3149161|NCT00168519|Active Comparator|1|
3149162|NCT00168558|Active Comparator|1|Standard titre Edmonston-Zagreb measles vaccine at 4½ and 9 months of age
3135671|NCT03817853|Experimental|Obinutuzumab+Chemotherapy|Participants received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone [CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone [CVP - 21-day cycle]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator is free to choose the chemotherapy for each patient. Obinutuzumab and chemotherapy is administered during induction phase and obinutuzumab monotherapy is administered during maintenance phase.
3135676|NCT03828422||patients with essential thrombocythemia|"essential thrombocythemia with JAK2 V617F positive mutation~patients from the Department of Haematology at University Medical Centre Ljubljana, Slovenia, who were diagnosed with JAK2 V617F positive ET between 2011 and 2014~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~examined twice, the first time in the years 2014-2015 and for the second time in the years 2018-2019~blood for laboratory tests~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
3135677|NCT03828422||control group|"the control group is selected among healthy employees of the University Medical Centre Ljubljana and their relatives~they are matched with the patient group for age and sex distribution and classical risk factors for cardiovascular disease~no personal history of clinically manifest atherosclerotic vascular disease (myocardial infarction, angina pectoris, peripheral arterial disease, aortic disease, transient ischemic attack or ischemic stroke)~all signed the informed consent~blood for laboratory tests~examined twice, the first time in the years 2014-2015 and for the second time the in years 2018-2019~imaging and functional examination: ultrasound examination, EndoPat plethysmography, coronary artery calcium scanning"
3135678|NCT03829228|Experimental|Proglucamune treatment|Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.
3149163|NCT00168558|Active Comparator|2|Standard titre Schwarz measles vaccine at 9 months of age
3135679|NCT03829618|Active Comparator|Topical Lidocaine|16 ml of 1% lidocaine sprayed in 4 ml aliquots to vocal cords, midtrachea, left main stem bronchus and right main stem bronchus.
3135680|NCT03829618|Active Comparator|Nebuliser Solution|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via jet nebulizer in operating room over ten minutes.
3135681|NCT03829618|Active Comparator|Nebuliser Suspension|2% lidocaine dosed at 2mg/kg with max dose of 160mg nebulized via vibrating mesh nebulizer in operating room over ten minutes.
3135682|NCT03830333|Experimental|Ceftolozane/Tazobactam + Metronidazole|Participants receive ceftolozane/tazobactam 1500 mg (ceftolozane 1000 mg + tazobactam 500 mg) plus metronidazole 500 mg administered as an intravenous (IV) infusion every 8 hours for 4 to 14 days (per protocol, ceftolozane/tazobactam may be adjusted to 500 mg/250 mg if creatinine clearance [CrCL] is 30 to ≤50 mL/min)
3135683|NCT03830333|Active Comparator|Meropenem + Placebo|Participants receive meropenem 1000 mg plus saline administered as an IV infusion every 8 hours for 4 to 14 days (per protocol, meropenem may be adjusted to every 12 hours if CrCL was 30 to ≤50 mL/min).
3135684|NCT03831880|Other|Daily to Weekly|Genotropin to somatrogon
3135685|NCT03831880|Other|Weekly to Daily|somatrogon to Genotropin
3135686|NCT03831945|Active Comparator|Single infusion of VRC01 and 10-1074|Single infusion of 40 mg/kg VRC-HIVMAB060-00-AB (VRC01) in 100 mL of saline and 30 mg/kg of 10-1074 in 250 mL of saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
3135687|NCT03831945|Placebo Comparator|Single infusion of Normal Saline|Single infusion of 100 mL and 250 mL of normal saline when viral load is >/= 200 copies/mL in HIV-infected individuals undergoing antiretroviral treatment interruption.
3135688|NCT03835728|Active Comparator|Treatment Arm|Ocrelizumab will be administered 3 times over a 1 year study period. Subjects will receive a dose of 300 mg at week 0 (baseline) and again at week 2. The final dose of 600 mg will be administered at week 24.
3135689|NCT03835728|Placebo Comparator|Treatment Placebo Arm|Saline will be used as the matching placebo
3135690|NCT03840174|Experimental|V160|Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.
3135691|NCT03840174|Placebo Comparator|Placebo|Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.
3135692|NCT03848910|Experimental|Investigational device - Sound Processor|
3135693|NCT03852524|Experimental|Study Arm|The study arm will receive subcutaneous methylnaltrexone (0.15mg/kg rounded to 8 or 12 mg) before surgery and then daily, for the following three days after surgery (four doses).
3135694|NCT03852524|Placebo Comparator|Placebo Arm|The placebo arm will receive subcutaneous placebo before surgery and then daily, for the following three days after surgery (four doses).
3135695|NCT03857841|Experimental|20 pmol phospholipid/kg body weight|UNEX-42 administered at 20 pmol phospholipid/kg body weight
3135696|NCT03857841|Experimental|60 pmol phospholipid/kg body weight|UNEX-42 administered at 60 pmol phospholipid/kg body weight
3135697|NCT03857841|Experimental|200 pmol phospholipid/kg body weight|UNEX-42 administered at 200 pmol phospholipid/kg body weight
3135698|NCT03857841|Placebo Comparator|Placebo|Phosphate-buffered saline
3135699|NCT03861780|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
3135700|NCT03861780|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 5.1ml volume. Single use.
3135701|NCT03861780|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) / 70% v/v IPA (isopropyl alcohol). Swabstick. Single use.
3149164|NCT00168558|Active Comparator|3|Standard titre Edmonston-Zagreb measles vaccine at 9 months of age
3188800|NCT00770887||Study participants|This study will enroll 50 English-speaking/literate women at least 18 years of age of any race who have sought contraception with DMPA at the Planned Parenthood of Southwest and Central Florida clinics in Tampa and Fort Myers. Patients who choose to begin DMPA or who have already been using DMPA will be approached regarding voluntary participation in the study. Because DMPA is contraindicated in pregnancy, women with a positive urine pregnancy will not be eligible. Should a woman become pregnant during the study, she will receive no further DMPA injections
3188801|NCT00770900|Experimental|Montelukast|Asthmatic children and teenagers took montelukast daily.
3135702|NCT03862625|Experimental|a modular adaptive seating system|In the first group, there is home exercises program for scoliosis and a modular adaptive seating system.
3135703|NCT03862625|Active Comparator|home exercises for scoliosis|In the second group there is only home exercise program for scoliosis.
3135704|NCT03862755|Experimental|Thromboprophylaxis|All surgical patients classified into low risk and moderate/high risk groups based on Caprini score and received different thromboprophylaxis strategies Briefly, early ambulation alone was used in patients at low risk, early ambulation plus chemoprophylaxis with Low Molecular Weight Heparin was used in patients at moderate/high risk.
3188802|NCT00770900|Placebo Comparator|Placebo|Placebo to montelukast tablet daily.
3188803|NCT00770926|Experimental|Program immediately|Receives the lifestyle program as soon as possible after randomization
3188804|NCT00770926|No Intervention|Wait list control|Wait one year and at the end of the year, is offered the option of participating in the program
3188805|NCT00770952|Experimental|Pioglitazone 30 mg to 45 mg QD + Glimepiride 2 mg to 4 mg QD|
3188806|NCT00770952|Active Comparator|Glimepiride 4 mg to 6 mg QD|
3188807|NCT00770978|Experimental|Ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
3188808|NCT00770978|Experimental|Ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
3135705|NCT03869541||Intensive care patients|Adult intensive care patients receiving vasoactive drugs
3135706|NCT03869541||Intensive care unit clinicians|Clinicians for participation in a survey on the hypothetical randomization of patient participants in a future randomized controlled trial.
3135707|NCT03869541||ICU rehabilitation clinicians|Clinicians for participation in a survey on the feasibility of an ICU physical rehabilitation adverse event tool.
3135708|NCT03875092|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin Area Under the Curve (AUC) 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
3149165|NCT00168688|Active Comparator|FeFol|Iron (60 mg) and folic acid (400 ug), standard of care
3188809|NCT00771004|Experimental|Pioglitazone 30 mg to 45 mg QD|
3135709|NCT03875092|Active Comparator|Chemotherapy|Participants receive normal saline by IV infusion prior to chemotherapy on Day 1 of each 21-day cycle for up to 35 cycles PLUS Investigator's choice of paclitaxel (200 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles) or nab-paclitaxel (100 mg/m^2 by IV infusion on Days 1, 8, 15 of each 21-day cycle for 4 cycles) PLUS carboplatin AUC 6 by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
3135710|NCT03877224|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
3135711|NCT03877224|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
3135712|NCT03880565|Experimental|ECMO Facilitated Resuscitation|Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
3149166|NCT00168688|Experimental|MN1|"1 RDA of 15 micronutrients, including iron (30 mg) and folic acid (400 ug)~Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg"
3188810|NCT00771004|Placebo Comparator|Placebo QD|
3149167|NCT00168688|Experimental|MN2|"2 RDA of 14 micronutrients including iron (30 mg) and folic acid (800 ug)~Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg"
3149168|NCT00168714||Pregnant participants|Pregnant participants who were exposed to Avonex within approximately 1 week of conception or during the first trimester of pregnancy
3149169|NCT00168753|Experimental|1|
3149170|NCT00168766|Experimental|1|interferon-beta-1a in combination with methylprednisolone
3135713|NCT03880565|Other|Standard ACLS Resuscitation|Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.
3135714|NCT03883607|Experimental|Elafibranor 80 mg|Participants received Elafibranor 80 mg tablet orally once daily for 12 weeks.
3135715|NCT03883607|Experimental|Elafibranor 120 mg|Participants received Elafibranor 120 mg tablet orally once daily for 12 weeks.
3135716|NCT03885596|Experimental|CA-008 Cohort 1|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block followed by a sciatic (popliteal) nerve block."
3135717|NCT03885596|Experimental|CA-008 Cohort 2|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
3135718|NCT03885596|Experimental|CA-008 Cohort 3|"CA-008 4.2 mg reconstituted in saline~All subjects received monitored anesthesia care (MAC) and a Mayo block."
3135719|NCT03885596|Active Comparator|Exparel|"106 mg [8 mL of the 133 mg/10 mL suspension] only~All subjects received monitored anesthesia care (MAC) and a Mayo block."
3135720|NCT03885661|Experimental|Icosapent ethyl|Icosapent ethyl with a total daily dose of 4 grams, as 2 x 1 gram capsules by mouth twice daily, against a statin background
3135721|NCT03885661|No Intervention|Usual Care|Statin background
3135722|NCT03886493|Experimental|Dupixent Subcutaneous (SQ) Injection|Participants will be treated with dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43. They will then undergo surgery on day 57. 14 days after the last dose of Dupixent, prostate glands will be harvested at the time of radical prostatectomy, and prostate tissue will be examined for the secondary endpoints.
3149171|NCT00168766|Placebo Comparator|2|interferon-beta-1a in combination with placebo
3149172|NCT00168909|Experimental|1|alfacalcidol 1µg/d
3149173|NCT00168909|Placebo Comparator|2|placebo
3149174|NCT00169000|Experimental|Capecitabine and Docetaxel|Escalating doses of capecitabine days 1-14 with a fixed dose of docetaxel on Day 8 of a 21 day cycle
3149175|NCT00169065|Active Comparator|Clozapine|Clozapine or olanzapine in treatment resistant schizophrenia
3149176|NCT00169065|Active Comparator|olanzapine|clozapine or olanzapine in treatment resistant schizophrenia
3181083|NCT00690469||Observational (biomarker analysis)|"Participants undergo a structured telephone interview questionnaire. The parental questionnaires collect basic demographic data (including age, race, education, and income), occupational history, medical radiation exposure, diet and supplement use (for the year before pregnancy for father, during pregnancy for mother), tobacco use, and alcohol use. The mothers are also asked about residential pesticides and prior assisted reproductive technology.~Controls (parents) provide saliva samples. If a patient is also enrolled on COG-ARET0332, then the patient blood and tumor samples should be submitted. Parents of patients on this protocol should also submit a blood sample. Blood samples from the affected child, and blood and/or sputum samples from the parents may be submitted. Tumor specimens should be submitted if available.~For some patients, a RB1 mutation detection assay on DNA derived from peripheral blood is performed. If the mutation is found, the parents? DNA is also screened."
3181084|NCT00690521|Active Comparator|1|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
3181085|NCT00690521|Active Comparator|2|Patients will be randomized to receive either metolazone or HCTZ in a randomized, double-blind, placebo controlled crossover trial. The patients will receive the alternative medication if The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
3181086|NCT00690534|Active Comparator|CMAY|Insulin in young
3181087|NCT00690534|Experimental|IMAY|L-NMMA + insulin in young
3181088|NCT00690534|Experimental|SNPY|SNP in young
3181089|NCT00690534|Active Comparator|CSNP|Insulin in elderly
3135723|NCT03888235|Experimental|Immediate corrective exercises|"At this visit, participants will be examined as described in the protocol and given an exercise to correct their sacroiliac malrotation. They will use this exercise as needed for pain control. They will be reassessed one month later.~At that time they will be given the pelvic support belt and the concurrent use of both treatments will be assessed at their last visit one month after that."
3181090|NCT00690534|Experimental|ISNP|SNP in elderly
3181091|NCT00690534|Experimental|SNPE|SNP in elderly
3149177|NCT00169091|Experimental|Clozapine|Clozapine 12.5-300 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
3181092|NCT00690534|Active Comparator|CMealO|Meal in elderly
3135724|NCT03888235|Experimental|Immediate use of pelvic support belt|"Participants will be given a pelvic support belt to stabilize their pelvis. They will use this belt for activities likely to precipitate back pain. They will be reassessed one month later.~At that time they will be given the exercises and the concurrent use of both treatments will be assessed at their last visit one month after that."
3149178|NCT00169091|Active Comparator|Haloperidol|Haloperidol 2-12 mg taken orally per day for 12 weeks in the acute phase of the study and up to 130 weeks (total) in the Follow-up portion of the study.
3181093|NCT00690534|Experimental|SMealO|SNP+meal in elderly
3135725|NCT03888235|Active Comparator|Delayed treatment|"These participants will continue using their current therapies to deal with their low back pain for one month prior to being scheduled for a treatment visit. At the treatment visit, one month later they will be given both the exercise and the belt.~The concurrent use of both treatments will be assessed at their last visit one month after that."
3181094|NCT00690534|Active Comparator|MealY|meal in young
3181095|NCT00690534|Experimental|ExIns|insulin+exercise in elderly
3181096|NCT00690534|Experimental|ExMeal|meal+exercise in elderly
3181097|NCT00690547||Test Group|
3181098|NCT00690560|Experimental|R-CHOP14 chemotherapy|
3181099|NCT00690625|Experimental|A|MyoRx cream
3181100|NCT00690625|Placebo Comparator|B|Placebo cream, same composition as experimental cream, without Omega 3 fatty acid
3181101|NCT00690638|Placebo Comparator|1|Placebo
3181102|NCT00690638|Experimental|2|PHX1149T 200 mg
3181103|NCT00690638|Experimental|3|PHX1149T 400 mg
3181104|NCT00690651|Active Comparator|2|this group will rest in bed with operated leg well elevated for 48 hour and then mobilize with physiotherapist with aim for discharge home when safe.
3181105|NCT00690651|Experimental|1|mobilize with physiotherapist within 24 hours of surgical fixation of fractured ankle
3181106|NCT00690664||B|Caucasian women
3181107|NCT00690664||A|African American women
3181108|NCT00690690|Experimental|video|
3181109|NCT00690690|Active Comparator|HCT|Offer of HIV counseling and testing
3181110|NCT00690703|Experimental|1|Treatment
3135726|NCT03889158|Experimental|Acute Inflammation|All participants will receive the typhoid vaccination (intramuscular injection, 0.5 mL, 1 time).
3135727|NCT03889158|Experimental|Ascorbic Acid|All participants will receive ascorbic acid (Vit C) on two occasions [oral pill, 2g, 2x (baseline, during acute inflammation)].
3135728|NCT03890419|Active Comparator|Control Group|Control Group participants will be exposed to full spectrum light during the study.
3135729|NCT03890419|Experimental|Green light Group|Green light Group participants will be exposed to green light during the study.
3135730|NCT03890419|Experimental|Blue light Group|Blue light Group participants will be exposed to blue light during the study.
3135731|NCT03894540|Experimental|IPN60090|"Part 1: Dose escalation of IPN60090, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose administered up to Maximum Tolerated Dose (MTD) over a 21-day cycle"
3135732|NCT03894540|Experimental|IPN60090 in combination with pembrolizumab|"Part 1: Dose escalation of IPN60090 in combination with pembrolizumab, Part 2: Dose expansion~IPN60090 given as a Bis in Die (BID) oral dose, starting with pharmacologically active dose identified in 1dose escalation of IPN60090 as a single agent, over a 21-day cycle in combination with 200 mg pembrolizumab given every 21 days (Day 1 of every cycle) as IV infusion"
3135733|NCT03894540|Experimental|IPN60090 in combination with paclitaxel|"Part 1: Dose escalation of IPN60090 in combination with paclitaxel, Part 2: Dose expansion~IPN60090 given as a BID oral dose, starting with pharmacologically active dose identified in dose escalation of IPN60090 as a single agent over a 21-day cycle in combination with 175 mg/m2 or 135 mg/m2 paclitaxel given every 21 days (Day 1 of every cycle) as IV infusion"
3135734|NCT03894540|Experimental|IPN60090 food effect|"Part 1: Food Effect of IPN60090~IPN60090 given as a single oral dose as a single agent at the recommended dose (RD) under fasting and fed conditions followed by IPN60090 given as a BID oral dose administered at the RD over a 21-day cycle."
3135735|NCT03897348|Experimental|Crossover Sequence A: Placebo, then Lacosamide 200 mg, then Lacosamide 100 mg|Participants receive a single dose of Placebo in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
3135736|NCT03897348|Experimental|Crossover Sequence B: Lacosamide 200 mg, then Lacosamide 100 mg, then Placebo|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 100 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
3149179|NCT00169117|Experimental|1|Behavioural intervention: Songs/posters aimed at behaviour change to increase repair and maintenance of mosquito nets
3149180|NCT00169156|Experimental|Rituximab + CHOP|Rituximab + CHOP regimen Prednisone - Doxorubicine - Cyclophosphamide - Vincristine
3149181|NCT00169182|Experimental|TPF|Docetaxel, Cisplatine, 5-FU
3149182|NCT00169182|Active Comparator|PF|Cisplatine, 5-FU
3149183|NCT00169195|Experimental|R-GEMOX|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
3181111|NCT00690716|Experimental|1|Nasal CO2
3135737|NCT03897348|Experimental|Crossover Sequence C: Lacosamide 200 mg, then Placebo, then Lacosamide 100 mg|Participants receive a single dose of Lacosamide 200 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Placebo. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Lacosamide 100 mg.
3135738|NCT03897348|Experimental|Crossover Sequence D: Lacosamide 100 mg, then Lacosamide 200 mg, then Placebo|Participants receives a single dose of Lacosamide 100 mg in ADP Session 1. After a 1 week washout period, they undergo ADP Session 2 in which they receive a single dose of Lacosamide 200 mg. After another 1 week washout period, they undergo ADP Session 3 in which they receive a single dose of Placebo.
3135739|NCT03900416|Experimental|Mindfulness App|Guided mindfulness exercises will be delivered via mobile app for three weeks.
3135740|NCT03900416|No Intervention|Control condition|Participants will use app for assessment for three weeks, but no mindfulness exercises will be delivered.
3135742|NCT03905863|No Intervention|Standard of care arm|SOC was defined to include wound cleansing with sterile water or saline solution, and gentle irrigation of the study ulcer with warm tap water; sharp debridement using a standardised protocol based on TIME principles for wound bed preparation; offloading with a TCC twice in the first week and weekly thereafter (all exceptions had to be agreed by the lead investigator; a fixed ankle walker boot or similar device was acceptable as an alternative, but shoe inserts were not deemed to provide sufficient offloading); moisture balance was provided using a hydrofibre or alginate dressing. In addition, patients were instructed on adherence to the protocol and given instructions to call their clinic if they suspected any signs of an infection.
3149184|NCT00169208|Experimental|Experimental|4 cycles of rituximab + fludarabine + mitoxantrone
3149185|NCT00169221|Active Comparator|postop chemoradio with cisplatin|postoperative chemoradiotherapy with cisplatin
3149186|NCT00169221|Experimental|postop chemoradio (cisplatin)+gefitinib|postoperative chemoradiotherapy with cisplatin + gefitinib
3181112|NCT00690716|Placebo Comparator|2|Inactive Placebo
3135743|NCT03905863|Active Comparator|Intervention arm|Same protocol as SOC only but were also provided with a Natrox® Oxygen Wound Therapy System, consisting of two elements: the Natrox® OG and the Natrox® ODS. The OG is a multi-use battery powered device which generates oxygen though water electrolysis at a rate of 15mL/hr. The ODS is a sterile, single use device that allows wound exudate to pass through to the secondary dressing while allowing the diffusion of oxygen across the wound bed. It connects directly to the OG via a thin flexible fine-bore tube. While the ODS can remain in situ for 7 days, it should be changed at each dressing change, based on exudate level or clinical judgement. This is a battery-operated system with a 30-hour battery life; the kit includes two interchangeable, rechargeable batteries. Each participant was advised to charge one battery while the other was in use, as the battery required changing daily. The oxygen generator is worn in a holster so that patients can remain ambulatory.
3135744|NCT03907033|Active Comparator|Standard Bupivacaine|Patients in the control group will receive 0.25% bupivacaine hydrochloride (bupivacaine HCl). 10cc will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc of will be injected bilaterally into the deeper uterosacral ligaments.
3135745|NCT03907033|Experimental|Liposomal Bupivacaine|Patients in the study group will receive a mixture of 0.5% bupivacaine HCl and liposomal bupivacaine in 1:1 ratio. 10cc of the mixture will be injected bilaterally into each uterosacral ligament prior to the colpotomy incision. After entry into the posterior cul-de-sac, an additional 10cc will be injected bilaterally into the deeper uterosacral ligaments
3181113|NCT00690729|Experimental|1|Bibliotherapy - cognitive behavior therapy focusing on exposure and response prevention directed by the family
3135749|NCT03909178|Active Comparator|Hip Arthroscopy Surgery with Acetabular Labral Repair|Hip Arthroscopy Surgery with Acetabular Labral Repair
3135750|NCT03909178|Active Comparator|Physical Therapy Focused on the Hip and Hemi-pelvis|Physical Therapy focusing on the hemipelvis strengthening, including the lower back, lower abdominal core, quadriceps, hamstrings, and gluteal muscles.
3181114|NCT00690729|Active Comparator|2|Cognitive Behavioral Therapy - therapist-directed exposure response prevention over a 12-week period
3181115|NCT00690768|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
3181116|NCT00690768|Active Comparator|B|Pars plana vitrectomy only
3181117|NCT00690781|Experimental|Casein Pulse|"casein is the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
3181118|NCT00690781|Experimental|Casein Spread|"casein is the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
3181119|NCT00690781|Experimental|MSP Pulse|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a pulse protein feeding pattern : 8% for breakfast, 80% for lunch, 4% around 1600h, and 8% for dinner."
3181120|NCT00690781|Experimental|MSP Spread|"Milk soluble proteins (MSP) are the main protein consumed, it is given during 6 weeks with a spread protein feeding pattern : 25% for breakfast, 25% for lunch, 25% around 1600h, and 25% for dinner."
3181121|NCT00690807|Experimental|1|PH-10 treatment
3181122|NCT00690846|Experimental|1|40 mg weekly subcutaneous injection of adalimumab
3181123|NCT00690859||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
3181124|NCT00690885|Experimental|1|lozenges containing 150 IU of natural human interferon-alpha
3181125|NCT00690885|Placebo Comparator|2|matching placebo lozenges
3181126|NCT00690911|Experimental|1|open label adalimumab 40mg
3181127|NCT00690937|Experimental|1 ECS|Low dose treatment
3181128|NCT00690937|Experimental|2 ECS|High dose treatment
3181129|NCT00690937|Active Comparator|3 Colesevelam|Active control treatment
3181130|NCT00690937|Placebo Comparator|4 Placebo|Placebo matched to low dose treatment
3181131|NCT00690937|Placebo Comparator|5 Placebo|Placebo matched to high dose treatment
3135751|NCT03909971|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
3135752|NCT03920215|Active Comparator|OC-01 Low Dose, 0.12 mg/mL|OC-01 (varenicline) nasal spray, 0.12 mg/mL
3135753|NCT03920215|Active Comparator|OC-01 Mid Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.60 mg/mL
3135754|NCT03920215|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
3135755|NCT03920215|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
3135756|NCT03921151|Other|Cocaine-dependent|Participants who use and are dependent on cocaine
3135757|NCT03921151|Other|Non-drug using Healthy Controls|Participants who are not drug users
3135758|NCT03926039|Experimental|sharing decision-making program interventions|"Description of conventional traditional treatment options and add sharing decision-making program The intervention measures in this study sharing decision-making plan mainly includes sharing the decision-making talks and the decision-making assistance tools used in the process."
3135759|NCT03926039|No Intervention|Description of traditional treatment options|Description of conventional traditional treatment options
3135760|NCT03927911|Active Comparator|Open or mini-open surgical technique cohort|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
3135761|NCT03927911|Active Comparator|Tubular or Percutaneous cohort (Minimally Invasive Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
3135762|NCT03927911|Active Comparator|Lumbar decompression without fusion (Outpatient Cohort)|Local infiltration Analgesia administered (with EXPAREL and bupivacaine HCl) in EXPAREL arm within cohort. EXPAREL arm to be compared to SOC arm within cohort
3135763|NCT03937570|Experimental|EO GROUP|Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.
3135764|NCT03937570|No Intervention|CONTROL GROUP|Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.
3135765|NCT03938857|Placebo Comparator|Fen. SOC+saline placebo (bolus+infusion)|Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
3135766|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
3135767|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
3135768|NCT03938857|Active Comparator|Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)|Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
3135769|NCT03941912|Experimental|Erchonia EVRL|635 nanometers (nm) and 405 nm dual-diode laser application
3135770|NCT03945981|Experimental|Participants receiving Dolutegravir + Lamivudine FDC|Participants will receive DTG 50mg and 3TC 300 mg FDC tablet orally once daily (OD) with or without food
3135773|NCT03950167||Hyperemesis gravidarum|pregnant women before 14 weeks of pregnancy diagnosed with hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
3135774|NCT03950167||Healthy pregnant women|Healthy pregnant women before 14 weeks of pregnancy without hyperemesis gravidarum will be assessed in terms of gallbladder functions and serum cholecystokinin levels after a fatty meal.
3135775|NCT03950674|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin Area Under the Curve (AUC) 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by pembrolizumab 200 mg IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression (up to 35 treatment administrations; up to approximately 2 years).
3149187|NCT00169234|Experimental|0.1mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.1mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3181132|NCT00690976|Experimental|1.Group Intervention|A group-based intervention consisting of 4 sessions lasting approximately 90 minutes each. Using a variety of pedagogical and interactive approaches, facilitators will introduce new concepts and skills.
3135776|NCT03950674|Active Comparator|Control|Participants receive saline placebo IV PLUS pemetrexed 500 mg/m^2 IV (with vitamin supplementation) PLUS cisplatin 75 mg/m^2 IV OR carboplatin AUC 5 IV on Day 1 of every 3-week cycle (Q3W) for 4 cycles followed by saline placebo IV PLUS pemetrexed 500 mg/m^2 IV Q3W until progression. If documented progression occurs, participants may be able to receive pembrolizumab Q3W for the remainder of the study or until documented further progression (up to 35 treatment administrations; up to approximately 2 years).
3135777|NCT03954834|Experimental|5 mg Tirzepatide|Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
3135778|NCT03954834|Experimental|10 mg Tirzepatide|Participants received 10mg of tirzepatide as subcutaneous injection once a week.
3135779|NCT03954834|Experimental|15 mg Tirzepatide|Participants received 15mg of tirzepatide as subcutaneous injection once a week.
3135780|NCT03954834|Placebo Comparator|Placebo|Participants received placebo as subcutaneous injection once a week.
3135781|NCT03958071||Subjects with Idiopathic Pulmonary Fibrosis|
3135782|NCT03961529|Experimental|0.3% OPA-15406 ointment|Twice daily
3135783|NCT03961529|Experimental|1% OPA-15406 ointment|Twice daily
3135784|NCT03968159|Experimental|Drug - pimavanserin|Pimavanserin 34 mg tablets
3181133|NCT00690976|Active Comparator|2. HCT|Offer of HIV counseling and testing
3181134|NCT00691041|Experimental|1|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
3181135|NCT00691041|No Intervention|2|HIV/STI counseling and testing and a single 15 minute session of resources available in the community
3135785|NCT03968159|Placebo Comparator|Placebo|Placebo tablets
3135786|NCT03968965|Experimental|3D MvIGS|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 3D MvIGS intraoperative navigation guidance.
3135787|NCT03968965|Other|2D Fluoroscopy|One, two and three-level posterior spine fusion surgery using bilateral pedicle screw instrumentation under 2D fluoroscopy.
3135788|NCT03970824|Experimental|CT-P17|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
3135789|NCT03970824|Active Comparator|US-licensed Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
3135790|NCT03970824|Active Comparator|EU-approved Humira|a single subcutaneous (SC) injection via pre-filled syringe (PFS)
3135791|NCT03978403|Experimental|ABDC|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
3149188|NCT00169234|Experimental|0.5mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3181136|NCT00691067|Experimental|Mifepristone|600mg of Mifepristone
3181137|NCT00691067|Placebo Comparator|Placebos|Placebo
3135792|NCT03978403|Experimental|BCAD|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
3135793|NCT03978403|Experimental|CDBA|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
3149189|NCT00169234|Experimental|1.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 1.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3149190|NCT00169234|Experimental|2.0mL Pneumococcal Conjugate Vaccine|Participants in this group were randomized at enrollment to receive 2.0mL PCV7, Prevnar® at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3149191|NCT00169234|Experimental|0.5mL Pneumococcal Polysacc Vaccine|Participants in this group were randomized at enrollment to receive 0.5mL Pneumovax 23 at the enrollment visit and then 0.1mL Pneumococcal Polysaccharide Vaccine 12 months later.
3149192|NCT00169260|Experimental|1|Intervention
3149193|NCT00169260|Placebo Comparator|2|Control
3149194|NCT00169273|Active Comparator|Weight loss only intervention|Structured group weight loss intervention
3149195|NCT00169273|Experimental|Combined intervention|Structured group program for weight loss and depression
3149196|NCT00169338|Experimental|deep brain stimulation|Paladin deep brain stimulation
3149197|NCT00169338|Placebo Comparator|sham deep brain stimulation|no stimulation
3149198|NCT00169377|Active Comparator|Group A|Deep brain stimulation on followed by off
3149199|NCT00169377|Sham Comparator|Group B|No stimulation, deep brain stimulation off followed by on
3149200|NCT00169390||pregnant smokers|
3149201|NCT00169390||pregnant non smokers|
3149202|NCT00169533|Experimental|Arm 1|Lapatinib either 750, 1000, 1250 or 1500 mgs
3149203|NCT00169546|Experimental|Arm 1|
3149204|NCT00169559|Placebo Comparator|Arm 1|Placebo
3149205|NCT00169559|Active Comparator|Arm 2|Fenofibrate
3135794|NCT03978403|Experimental|DACB|"A: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a Sled coater packaged in foil pouches; B: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a MACAP coater packaged in foil cups; C: M207 3.8 mg administered as two 1.9 mg upper arm patches 30 min made on a miniMac coater packaged in foil cups; D: Zolmitriptan nasal 2.5 mg/0.1 mL single dose"
3135795|NCT03979807||Subjects with Chronic obstructive pulmonary disease|
3135796|NCT03980470|Other|Normal-dose versus Low-dose|"The standard intervention consists of the routinely performed cardiac CT datasets reconstructed with a standard iterative reconstruction algorithm (ASIR-V). Median radiation dose is about 0.5 mSv, range between about 0.2 and 1.2 mSv; median contrast agent administration about 45 mL, range between 35 and 55 mL.~The experimental intervention is an additional CT scan with a lower dose (about 20 to 50% decrease) and a similar contrast agent administration that is reconstructed with a deep-learning image reconstruction immediately after the clinical CT scan. The additional time required is about 5 minutes."
3135797|NCT03982069|Active Comparator|FluMist live attenuated influenza vaccine|Participants receiving live attenuated FluMist influenza vaccine will receive 0.2 mL given intranasally
3135798|NCT03982069|Active Comparator|Flucelvax inactivated influenza vaccine|Participants receiving inactivated Flucelvax influenza vaccine will receive 0.5 mL given intramuscularly
3181138|NCT00691080||ASD children|"ASD children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~Diagnosis of Autism Spectrum Disorder; supported by ADOS and the ADI or SCQ (subjects).~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness."
3181139|NCT00691080||"Healthy control children"|"Healthy control children as defined by:~Age greater than or equal to 4 or less than or equal to 9 years~A SCQ score of less than 10 without parental or physician concern for another neurodevelopmental disorder will be used to define normal children.~No current use of psychoactive medications (e.g. fluoxetine, methylphenidate, risperidone, lithium, etc.)~No current or use within the last 1 month of beta-blockers or melatonin~No current use of sleep aids;~No presence of untreated medical problems that could otherwise explain sleep problems (e.g. obstructive sleep apnea, gastroesophageal reflux disease - GERD)~(6) No blindness. (7) No current or past diagnosis of ADHD, depression, anxiety or with any other psychiatric conditions.~(8) No sibling with a diagnosis of Autism Spectrum Disorder."
3181140|NCT00691119|Experimental|A|Relaxation and Visualization Therapy group
3181141|NCT00691119|Active Comparator|B|Health education group
3181142|NCT00691119|No Intervention|C|Control group
3181143|NCT00691145|Experimental|1|
3181144|NCT00691158|Placebo Comparator|1- Normal Saline|4.7 mls normal saline IV bolus
3181145|NCT00691158|Active Comparator|2 Metreleptin|IV Leptin bolus
3181146|NCT00691158|Active Comparator|3 Pramlintide|IV Pramlintide bolus at Timpoint +0 and +30 minutes
3181147|NCT00691158|Active Comparator|4 Leptin plus Pramlintide|leptin and pramlintide IV bolus injection at timpoints 0 and +30 minutes
3181148|NCT00691171||1|GERD: Patients with established diagnoses of GERD based on ICD-9 codes
3181149|NCT00691171||2|Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma)
3181150|NCT00691171||3|Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin)
3181151|NCT00691184|Experimental|Group 1|0% Terbinafine HCl Nail Lacquer for 28 days.
3181152|NCT00691184|Experimental|Group 2|10% Terbinafine HCl Nail Lacquer.
3181153|NCT00691184|Active Comparator|Group 3|1% Lamisil® Cream
3181154|NCT00691184|Active Comparator|Group 4|Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.
3181155|NCT00691223||Experimental|Individuals with Goltz syndrome and their first degree relatives.
3181156|NCT00691236|Active Comparator|A|standard chemotherapy which is Adriamycin, Cisplatinum and Ifosfamide
3135799|NCT03984812|Experimental|Part 1,Cohort 1:Subjects receiving blinded GSK3732394 10mg/PBO|GSK3732394 10 milligram (mg) or PBO will be administered by subcutaneous (SC) injection to the subjects.
3135800|NCT03984812|Experimental|Part 1,Cohort 2:Subjects receiving blinded GSK3732394 40mg/PBO|GSK3732394 40 mg or PBO will be administered by SC injection to the subjects. This is projected dose, dose will be based on PK/PD results from preceding dosing cohorts.
3135801|NCT03984812|Experimental|Part1,Cohort 3:Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 3 will be based on PK/PD results from preceding dosing cohorts.
3135802|NCT03984812|Experimental|Part1,Cohort 4:Subjects receiving blinded GSK3732394 350mg/PBO|GSK3732394 350 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 4 will be based on PK/PD results from preceding dosing cohorts.
3181157|NCT00691236|Experimental|B|zoledronic acid prior to standard chemotherapy
3181158|NCT00691236|Experimental|C|zoledronic acid alone 4mg IV 3 weekly for 6 doses
3181159|NCT00691249|Experimental|1|Resistant starch type 4-Raw
3181160|NCT00691249|Experimental|2|Resistant starch type 4-Raw
3135803|NCT03984812|Experimental|Part1,Cohort5: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects. This is a projected dose. The dose administered in Part 1, Cohort 5 will be based on PK/PD results from preceding dosing cohorts.
3135804|NCT03984812|Experimental|Part1,Cohort6: Subjects receiving blinded GSK3732394 800mg/PBO|GSK3732394 800 mg or PBO will be administered by SC injection to the subjects. This is a projected dose and will be given if necessary. The dose administered in Part 1, Cohort 6 (if necessary) will be based on PK/PD results from preceding dosing cohorts.
3181161|NCT00691249|Experimental|3|Resistant starch type 4-Cooked
3181162|NCT00691249|Experimental|4|Resistant starch type 4-Cooked
3181163|NCT00691249|Placebo Comparator|5|Shredded wheat
3181164|NCT00691262|Experimental|1|
3181165|NCT00691275|Placebo Comparator|2|Saline
3181166|NCT00691275|Active Comparator|1|Zofran
3181167|NCT00691288|Experimental|1|
3181168|NCT00691288|Experimental|2|
3181169|NCT00691314|Experimental|1|
3181170|NCT00691314|Active Comparator|2|
3181171|NCT00691340||1|Control 1 (young subjects)
3135805|NCT03984812|Experimental|Part2,Cohort1: Subjects receiving blinded GSK3732394 130mg/PBO|GSK3732394 130 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The dose administered in Part 2, Cohort 1 will be based on PK/PD results from preceding dosing cohorts.
3135806|NCT03984812|Experimental|Part2,Cohort2: Subjects receiving blinded GSK3732394 400mg/PBO|GSK3732394 400 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 2 will be based on PK/PD results from preceding dosing cohorts.
3135807|NCT03984812|Experimental|Part2,Cohort3: Subjects receiving blinded GSK3732394 600mg/PBO|GSK3732394 600 mg or PBO will be administered by SC injection to the subjects on Days 1, 8, 15, and 22 of the study. This is a projected dose. The administered dose in Part 2, Cohort 3 will be based on PK/PD results from preceding dosing cohorts and will not exceed the maximum exposure observed in SAD (Part 1).
3135808|NCT03985813|Experimental|Screening Wizard|Youth and parents receiving Screening Wizard will be screened for depression and suicidal risk within their pediatric primary care provider's office. Screening will be analyzed in real-time to produce a decision support tool meant to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
3135809|NCT03989232|Experimental|Semaglutide 2.0 mg|All participants will receive one injection per week during a 12-week dose escalation period, until the target dose for semaglutide 2.0 mg is reached. From week 13 to week 40, semaglutide will be given in two weekly injections of 1.0 mg each.
3135810|NCT03989232|Active Comparator|Semaglutide 1.0 mg|All participants will receive one injection per week during a 12-week dose escalation period. From week 13 to week 40, the 1.0 mg group will receive an additional injection of semaglutide placebo in order to maintain the blinding.
3135811|NCT03998163|Experimental|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
3135812|NCT04000373|Other|gait training with exoskeleton device|uncontrolled pre-post intervention study of gait training using the Ekso GT™exoskeleton
3181172|NCT00691340||2|Control 2 (old subjects)
3181173|NCT00691340||3|Glaucoma patients
3135813|NCT04001517|Experimental|Neflamapimod|40 mg capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
3135814|NCT04001517|Placebo Comparator|Placebo|40 mg matching placebo capsules administered orally, BID or TID with food for 16 weeks; subjects will follow the BID regimen if weighing <80 kg or the TID regimen if weighing ≥80 kg
3135815|NCT04005859|Active Comparator|CONTROL: IV Lido|CONTROL: Intravenous lidocaine, pre- and post-surgery (IV Lido)
3135816|NCT04005859|Experimental|EXPERIMENTAL: Exparel|EXPERIMENTAL: TAP block with liposomal bupivacaine will be given as an injection (Exparel)
3135817|NCT04006171|Active Comparator|women with polycystic ovary syndrome|36 patients with PCOS
3181174|NCT00691340||4|Alzheimer patients
3181175|NCT00691379|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
3181176|NCT00691392|Experimental|1|Linezolid 600 mg po daily for 16 weeks (112 doses) given in addition to optimized background therapy for MDR TB
3181177|NCT00691392|Placebo Comparator|2|Over-encapsulated microcrystalline methylcellulose (Avicel) - an inert filler
3181178|NCT00691405|Experimental|A1|Arformoterol 5 mcg BID for 14 days
3181179|NCT00691405|Experimental|A2|Arformoterol 15 mcg BID for 14 days
3181180|NCT00691405|Experimental|A3|Arformoterol 25 mcg BID for 14 days
3135818|NCT04006171|Active Comparator|Healthy women of reproductive age|30 patients with regular normal menstrual cycle
3135819|NCT04011436|Experimental|Core, Hip and knee.|Physical Exercises to strengthen the core, hip and knee.
3135820|NCT04011436|Sham Comparator|Hip and Knee|Physical Exercises to strengthen the hip and knee.
3181181|NCT00691405|Placebo Comparator|A4|Placebo inhalation solution BID for 14 days
3181182|NCT00691405|Experimental|B1|Arformoterol 15 mcg QD for 14 days
3149206|NCT00169650||1|Registry and database of subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction
3149207|NCT00169676||cohort|Registry and Database
3149208|NCT00169689|Sham Comparator|rTMS|sham coil system versus verum rTMS stimulation
3149209|NCT00169702|Other|Standard|standard information
3149210|NCT00169702|Active Comparator|Intervention|weight management program, 12 sessions, 2 weekly, psychoeducational program, interactive topics like healthy food, diet behavior, physical activity, stress reduction.
3149211|NCT00169715|Other|A|
3149212|NCT00169741|Other|cohort|
3149213|NCT00169754|Other|cohort|mapping and data collection
3149214|NCT00169767||A|Comparison study between KTP and HoLAP procedures for BPH
3149215|NCT00169780||cohort|patients who require a CT scan prior to kidney stone surgery for diagnostic purposes
3149216|NCT00169793|Other|A|
3135821|NCT04011592|Experimental|Ketamine 0.5 mg/kg, then Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.2 mg/kg)
3135822|NCT04011592|Experimental|Ketamine 0.2 mg/kg, then Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg), washout period of seven days, and then single intravenous infusion of Ketamine (0.5 mg/kg)
3135823|NCT04013529|Placebo Comparator|Control|Participate in technology-enabled care without regret lottery
3135824|NCT04013529|Experimental|Experimental|Participate in technology-enabled care with regret lottery
3135825|NCT04016324|Other|Basic evaluation|Subjects with overactive bladder will go through InterStim basic evaluation with the commercially approved foramen needle and basic evaluation kit.
3135826|NCT04018066|Experimental|GP-SPI intervention|20 g of GP-SPI taken twice per day for 10 days
3135827|NCT04018794|Experimental|Behavioral/organizational skills intervention plus mobile app|Behavioral/organizational skills intervention plus mobile application (16, 20-30 minute sessions, twice/weekly for 8 weeks)
3135828|NCT04032327|Active Comparator|Plain Bupivacaine|20 mL of 0.25% plain bupivacaine
3135829|NCT04032327|Active Comparator|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed
3149217|NCT00169806|Other|cohort|Subjects who are scheduled to undergo a percutaneous kidney stone removal who do not have complicated comorbidities
3135830|NCT04033640|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as finger-stick capillary blood samples.~At the clinic site, study staff performed the SD Biosensor STANDARD G6PD test and the POC HemoCue hemoglobin test on finger stick blood samples.~At the reference laboratories, G6PD activity was measured from whole blood samples using the SD Biosensor STANDARD G6PD test and the Pointe Scientific G6PD reference assay and hemoglobin was measured using the HemoCue hemoglobin test and by a complete blood count (CBC) using an automated hematology analyzer (Manaus site only)."
3135831|NCT04033640|No Intervention|Health Workers|Participants were trained on use of the SD Biosensor STANDARD G6PD test by members of the study team with extensive experience with G6PD diagnostics and the STANDARD G6PD test. Health worker participants were surveyed to assess label and packing comprehension as well as results interpretation.
3149218|NCT00169832|Experimental|Rosiglitazone (Avandia)|
3135832|NCT04036292|Active Comparator|OC-01 Low Dose, 0.6 mg/mL|OC-01 (varenicline) nasal spray, 0.6 mg/ML
3135833|NCT04036292|Active Comparator|OC-01 High Dose, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/ML
3135834|NCT04036292|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
3135835|NCT04041440|Experimental|Auditory Training|Pre- and post assessments of auditory training intervention
3135836|NCT04041570|Experimental|Group 1: cAd3-EBO S vaccine (1x10^10 PU)|cAd3-EBO S vaccine (1x10^10 PU) administered intramuscularly (IM) with needle and syringe in a volume of 1 mL
3135837|NCT04041570|Experimental|Group 2: cAd3-EBO S vaccine (1x10^11 PU)|cAd3-EBO S vaccine (1x10^11 PU) administered IM with needle and syringe in a volume of 1 mL
3135838|NCT04042077|Experimental|Delafloxacin|Delafloxacin IV, with the option to switch to delafloxacin oral
3135839|NCT04042077|Active Comparator|Best Available Therapy|"Cardiothoracic / related leg SSI~Vancomycin IV~Linezolid IV, with the option to switch to linezolid oral.~In case of suspicion of Gram-negative, additional therapy shall be added as per investigator's choice~Abdominal SSI~Piperacillin/Tazobactam IV, OR~Tigecycline IV~In case of suspicion of MRSA, if the pre-selected treatment is Piperacillin/Tazobactam, additional therapy shall be added as per investigator's choice."
3135840|NCT04043143|Placebo Comparator|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
3149219|NCT00169832|Placebo Comparator|Placebo|
3149220|NCT00169845|Experimental|Alpha-Tocopherol and Beta-Carotene|Patients received a daily supplementation of alpha-tocopherol (one capsule of 400 IU dl-alpha-tocopherol) and beta-carotene (one capsule of 30 mg) for 3 years after the end of radiation therapy. Due to ethical concerns, the beta-carotene supplementation was stopped during the trial (after the randomization of 156 patients). See details in JNCI, 2005: 97 (7), 481-8.
3149221|NCT00169845|Placebo Comparator|Placebo|Patients received two capsules of placebos per day during 3 years. When the beta-carotene was stopped, they received only one capsule.
3149222|NCT00169897|Experimental|Hospital-based|This group has to go at the hospital 3 times per week to do the exercise program.
3149223|NCT00169897|Active Comparator|Home-Based|The group had to do the exercise program at home with indirect supervision (Polar watches and a phone call per week).
3149224|NCT00169910|Active Comparator|1|AUC monitored withdrawal of MMF
3149225|NCT00169910|Active Comparator|2|AUC monitored withdrawal of CNI
3149226|NCT00170001|Placebo Comparator|Sugar pill|
3149227|NCT00170001|Active Comparator|Active Comparator|
3149228|NCT00170079|Experimental|Step care vs. regular care|Participants were randomized either to (1) Step care intervention, where smokers who failed to quit or who relapsed received increasingly intensive smoking cessation interventions; vs. (2) Regular care, where smokers who failed to quit or who relapsed received repeated intervention.
3135841|NCT04043143|Experimental|Arm 2 Prescription Tool Intervention|At the time of writing the discharge prescription for a patient the provider will be informed by the best practice alert (BPA) Prescription Tool that a patient may be considered for a lower post-discharge opioid dose (no opioids for patients who did not take any opioids in the last 24 hours, and 10 oxycodone 5mg tablets, for patients having taken less than 22.5 MME, e.g. 1-3 oxycodone 5mg tablets in the last 24 hours). Final dosing decisions and drug choices will remain at the discretion of the treating provider and decisions will be tracked.
3135842|NCT04049123|Active Comparator|Insulin Lispro (Humalog)|15 units (U) Insulin Lispro (Humalog) administered once, subcutaneously (SC), in one of three study periods.
3135843|NCT04049123|Experimental|LY900014|7 U, and 15 U LY900014 administered once, SC, in two of three study periods.
3135844|NCT04051463|Active Comparator|Netarsudil|A drop of Netarsudil 0.02% ophthalmic solution will be instilled into both eyes once daily at night.
3135845|NCT04051463|Placebo Comparator|Placebo|A placebo eye drop, consisting of the vehicle for netarsudil ophthalmic solution without the active ingredient, will be instilled into both eyes once daily at night.
3135846|NCT04052204|Experimental|Combination A|Avelumab + Bempegaldesleukin (NKTR-214) for treatment of locally recurrent (not amendable for treatment with curative intent) or metastatic squamous cell carcinoma of the head and neck
3149229|NCT00170209|Active Comparator|Isoniazid|The standard therapy will be daily self-administered INH, 10-15 mg/kg/day (max=300mg/day) for 9 months (9INH).
3135847|NCT04052204|Experimental|Combination B|Avelumab + Bempegaldesleukin (NKTR-214) + Talazoparib for treatment of metastatic castration-resistant prostate cancer (mCRPC). Phase 2 will focus on enrolling participants with DDR defect positive mCRPC.
3135848|NCT04052204|Experimental|Combination C|Combination C: Avelumab + Bempegaldesleukin (NKTR-214) + Enzalutamide for Treatment of mCRPC
3149230|NCT00170209|Active Comparator|Rifampin|The experimental arm will be daily self-administered RIF 10-20 mg/kg/day for 4 months (4RIF).
3149231|NCT00170235|Experimental|1|Prehabilitation (exercises pre surgery)
3181183|NCT00691405|Experimental|B2|Arformoterol 25 mcg QD for 14 days
3135849|NCT04054661|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor STANDARD point-of-care G6PD test and the point-of-care HemoCue hemoglobin test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
3135850|NCT04067011|Experimental|Group 1:Ciprofloxacin + AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 1 will concomitantly receive ciprofloxacin."
3135851|NCT04067011|Experimental|Group 2: Doxycycline +AV7909|"Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.~Group 2 will concomitantly receive doxycycline."
3135852|NCT04067011|Experimental|Group 3: AV7909|Participants meeting entry criteria will be randomized 1:1:1 to one of three investigational study groups. Groups 1 to 3 will each receive a manufactured lot of AV7909 per the study visit schedule.
3149232|NCT00170235|Active Comparator|2|Usual care as provided by the institution
3149233|NCT00170248|No Intervention|1|Physicians in this arm will be using the standard MOXXI electronic health record.
3149234|NCT00170248|Experimental|2|In addition to the standard MOXXI electronic health record, physicians in this arm will be using the computer-based decision support for asthma management
3149235|NCT00170274|No Intervention|Control Arm|Algorithms for prevention and termination of AF not activated
3149236|NCT00170274|Active Comparator|Prevention and Therapy Algorithms on|Activation of preventive and therapeutic algorithms
3135853|NCT04072159|Experimental|Pharmacist-Administered HPV Vaccine Series Completion group|For the Pharmacist-Administered HPV Vaccine Series Completion group (intervention group), primary care providers will refer patients who have received the initial HPV vaccine to receive the additional doses at patients' community retail pharmacies. Patients between ages 9-14 will need to receive one additional HPV vaccine dose with their community pharmacist 6-12 months after receiving Dose 1. Patients aged 15 and older will need to receive the 2nd dose 1-2 months after receiving the first HPV vaccine dose and the 3rd dose 6-months after receiving the initial dose.
3149237|NCT00170287|Experimental|1|ICD Therapy plus VT-Ablation
3149238|NCT00170287|Active Comparator|2|ICD Therapy only
3149239|NCT00170313|Experimental|Conducted AF-Response Algorithm (CAFR) On|"CAFR: On~Level medium~Max. Rate: 110ppm VSR: Off"
3149240|NCT00170313|Active Comparator|Conducted AF-Response Algorithm (CAFR) Off|CAFR: Off VSR: Off
3181184|NCT00691405|Experimental|B3|Arformoterol 50 mcg QD for 14 days
3181185|NCT00691405|Placebo Comparator|B4|Placebo inhalation solution QD for 14 days
3181186|NCT00691418|Active Comparator|1|600 mg per day of docosahexaenoic acid (DHA)
3181187|NCT00691418|Placebo Comparator|2|Placebo
3181188|NCT00691457|Experimental|1|Opti-Free contact lens solution
3181189|NCT00691457|Active Comparator|2|ReNu Multiplus contact lens solution
3181190|NCT00691457|Active Comparator|3|Clear Care contact lens solution
3181191|NCT00691470|Experimental|1. ATI-5923|Dose adjusted ATI-5923
3135854|NCT04072159|No Intervention|Primary Care Provider HPV Vaccine Series Completion|Participant in the Primary Care Provider HPV Vaccine Series Completion (control group) will receive standard care and will be scheduled to return to the clinic for the remaining HPV vaccine doses.
3135855|NCT04085341|Experimental|GB-102 Dose 1 (1 mg)|Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline.
3135856|NCT04085341|Experimental|GB-102 Dose 2 (2 mg)|Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline.
3135857|NCT04094870|Active Comparator|Antidepressant medication|Daily self-administered selective serotonin reuptake inhibitor (SSRI) Sertraline 25 mg table
3135858|NCT04094870|Active Comparator|Interpersonal therapy|Up to 11 planned therapy sessions over a 24-week period beginning the day of randomization
3135859|NCT04096482|Experimental|Standard 30° 4mm Endoscope Followed by Peregrine Endoscope|Participants will receive an endoscopy with the standard 30° 4mm endoscope followed by an endoscopy with the Peregrine Drivable ENT Scope.
3135860|NCT04098172|Experimental|Pressure Guidewire test subject|Stable patients with suspected or known CAD, who are scheduled for diagnostic angiography and pressure wire assessment, and signed the informed consent, will be screened for enrollment in this study.
3135861|NCT04103515||Subjects implanted with PCR TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
3135862|NCT04103515||Subjects implanted with PS TKA|Subjects who have been implanted with a Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
3135863|NCT04111276|Experimental|Subjects diagnosed with osteoarthritis of the knee|Subjects must be diagnosed with marked unicompartimental degenerative joint space narrowing.
3135864|NCT04123405|Experimental|Group A: 600 mg acetylcysteine|one tablet test product plus three tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
3135865|NCT04123405|Experimental|Group B: 1200 mg acetylcysteine|two tablets test product plus two tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
3135866|NCT04123405|Experimental|Group C: 2400 mg acetylcysteine|four tablets test product per day (taken as two tablets dissolved in a glass of water, twice daily)
3135867|NCT04123405|Placebo Comparator|Group D: Placebo|four tablets placebo per day (taken as two tablets dissolved in a glass of water, twice daily)
3135868|NCT04132804|Experimental|Tai Chi Treatment|All patients in the trial will receive 1-hour Tai Chi lessons once per week for a total of 8 weeks.
3135869|NCT04132973|Experimental|Compassion guided self-help|Participants will engage in a six-week online compassion-based self-help programme with email guidance from the researcher.
3135870|NCT04133415|Experimental|Lattice stereotactic body radiation therapy|-Lattice SBRT prescribed to a dose of 20 Gy in 5 fractions with a simultaneous integrated boosts of 66.7 Gy in 5 fractions
3181192|NCT00691470|Active Comparator|2. Coumadin|Dose adjusted Coumadin (warfarin)
3135871|NCT04138758||Patients initiating Tiotropium+Olodaterol therapy|
3135872|NCT04138758||Patients initiating Long-acting beta agonist/inhaled corticosteroid therapy|
3135873|NCT04147715|Placebo Comparator|Part 1: Placebo|Participants received a single oral dose of matching placebo in a fasted state on Day 1.
3135874|NCT04147715|Experimental|Part 1: 10 mg S-648414|Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.
3181193|NCT00691496|Experimental|1|Receives HIV testing and counseling and 5 week intervention
3181194|NCT00691496|No Intervention|2|Receives only HIV Testing and Counseling
3181195|NCT00691548|Experimental|1|
3181196|NCT00691561|Experimental|1|Participants receive HIV counseling and testing and 8 intervention sessions to assist them with reducing unsafe sexual behaviors.
3135875|NCT04147715|Experimental|Part 1: 30 mg S-648414|Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.
3135876|NCT04147715|Experimental|Part 1: 100 mg S-648414|Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.
3135877|NCT04147715|Experimental|Part 1: 250 mg S-648414|Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.
3135878|NCT04147715|Experimental|Part 1: 500 mg S-648414|Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.
3135879|NCT04147715|Experimental|Part 1: 1000 mg S-648414|Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.
3135880|NCT04147715|Placebo Comparator|Part 2: Placebo + Midazolam|Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.
3149241|NCT00170326|Active Comparator|Dual Chamber pacing|conventional dual-chamber pacemaker/ICD implantation with the ventricular lead in the right ventricular apex
3135881|NCT04147715|Experimental|Part 2: 50 mg S-648414 + Midazolam|Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
3181197|NCT00691561|No Intervention|2|Participants receive HIV counseling and testing only.
3181198|NCT00691587|Experimental|1|Low-dose KB001, a monoclonal antibody
3149242|NCT00170326|Experimental|Biventricular pacing|Biventricular pacing: dual-chamber biventricular pacemaker/ICD implantation with leads at the right ventricular apex and the left ventricle
3149243|NCT00170456|Active Comparator|1|Low dose rPA vaccine regime 1
3135882|NCT04147715|Experimental|Part 2: 30 mg S-648414 + Midazolam|Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.
3135883|NCT04147715|Experimental|Part 3: 100 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.
3149244|NCT00170456|Active Comparator|2|Low dose rPA vaccine regime 2
3149245|NCT00170456|Active Comparator|3|High dose rPA vaccine regime 1
3135884|NCT04147715|Experimental|Part 3: 200 mg S-648414 + Dolutegravir|Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.
3149246|NCT00170456|Active Comparator|4|High dose rPA vaccine regime 2
3181199|NCT00691587|Experimental|2|High-dose KB001, a monoclonal antibody
3149247|NCT00170469|Experimental|1|Low dose rPA vaccine
3149248|NCT00170469|Experimental|2|High dose rPA vaccine
3149249|NCT00170469|Active Comparator|3|Active vaccine control
3149250|NCT00170495||observation|male and female adults age 65 and older with acute respiratory illness (common colds, flu, bronchitis, pneumonia)
3149251|NCT00170547|Experimental|Group 3|382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
3149252|NCT00170547|Experimental|Group 4|382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
3149253|NCT00170547|Experimental|Group 1|382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
3149254|NCT00170547|Experimental|Group 2|382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
3149255|NCT00170573|Experimental|Caelyx|
3135885|NCT04150068|Experimental|Cohort 1A: Lenacapavir|"Participants with human-immunodeficiency virus-1 ribonucleic acid (HIV-1 RNA) ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at Cohort Selection visit compared with screening visit will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive subcutaneous (SC) lenacapavir 927 mg and will initiate an OBR at Day 1 SC Visit (14 days after the first dose of oral lenacapavir). Participants will receive their subsequent SC lenacapavir injection at Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
3135886|NCT04150068|Placebo Comparator|Cohort 1B: Placebo|"Participants with HIV-1 RNA ≥ 400 copies/mL and with a <0.5 log10 HIV-1 RNA decline at the Cohort Selection visit compared with screening visit will receive oral lenacapavir placebo on Days 1, 2, and 8 while continuing their failing regimen in blinded Functional Monotherapy Period (Baseline to Day 14); followed by unblinded Maintenance Period where participants will receive oral lenacapavir 600 mg on Days 15 and 16 and 300 mg on Day 22, and will initiate an OBR on Day 15. At Day 1 SC (14 days after the first dose of oral lenacapavir), participants will receive SC lenacapavir 927 mg while continuing OBR. Participants will receive their next SC injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given an option to receive SC lenacapavir every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue study in the country."
3181200|NCT00691587|Placebo Comparator|3|Placebo
3181201|NCT00691613|Experimental|1|EPO
3181202|NCT00691613|Placebo Comparator|2|NaCl
3181203|NCT00691626|Experimental|Arm 1: CBT for Insomnia plus Imagery Rehearsal|CBT for Insomnia plus Imagery Rehearsal
3181204|NCT00691626|Active Comparator|Arm 2: CBT for Insomnia|CBT for Insomnia
3181205|NCT00691639||1|Patients who are or were participants in any Alcon AL-3789 study.
3135887|NCT04150068|Experimental|Cohort 2: Lenacapavir|"Participants with a ≥ 0.5 log10 copies/mL HIV-1 RNA decline at the Cohort Selection Visit compared with the screening visit or with HIV-1 RNA < 400 copies/mL or if Cohort 1 is fully enrolled will receive oral lenacapavir 600 mg tablet on Days 1 and 2 and 300 mg tablet on Day 8, and will initiate an OBR on Day 1 in Oral Lead-in Period (Baseline to Day 14); followed by Maintenance Period where participants will receive SC lenacapavir 927 mg at Day 1 SC Visit (14 days after the first dose of oral lenacapavir) while continuing their OBR. Participants will receive their subsequent SC lenacapavir injection at the Week 26 Visit (relative to Day 1 SC).~At Week 52 (relative to Day 1 SC), participants will be given the option to receive SC lenacapavir injections every 6 months (26 weeks), while continuing their OBR, until the product becomes accessible to participants through an access program or until Gilead elects to discontinue the study in the country."
3135888|NCT04154605|Active Comparator|ClariFix|Cryotherapy of the nasal passages with the ClariFix device.
3135889|NCT04154605|Sham Comparator|Sham|Sham cryotherapy of the nasal passages with the ClariFix device
3135890|NCT04160091|Experimental|FX006 32mg in Glenohumeral OA Population|Single intra-articular (IA) injection
3135891|NCT04160091|Placebo Comparator|Normal Saline in Glenohumeral OA Population|Single intra-articular (IA) injection
3135892|NCT04160091|Experimental|FX006 32mg in Adhesive Capsulitis Population|Single intra-articular (IA) injection
3135893|NCT04160091|Placebo Comparator|Normal Saline in Adhesive Capsulitis Population|Single intra-articular (IA) injection
3135894|NCT04160260|Experimental|Omadacycline: Omadacycline Tablets|
3181206|NCT00691678|Experimental|chondroitin and glucosamine|Postmenopausal breast cancer patients that have joint symptoms induced by aromatase inhibitors and are receiving chondroitin and glucosamine.
3181207|NCT00691691|Experimental|1|Eligible patient will be treated with 48 Gy in 4 fractions encompassing the entire target lesion in 2 weeks with a minimum of 48 hours between each dose.
3135895|NCT04164758|Experimental|Drug - pimavanserin|Pimavanserin 34 mg provided as 2 x 17 mg encapsulated tablets
3135896|NCT04164758|Placebo Comparator|Placebo|Placebo encapsulated tablet
3135897|NCT04164758|Active Comparator|Quetiapine|Immediate release Quetiapine encapsulated tablets
3135898|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A1 High Dose|Participants received high dose LY3499446 as oral monotherapy twice daily (BID) in 21-day cycles.
3135899|NCT04165031|Experimental|LY3499446 Phase 1 Cohort AO Mid Dose|Participant received mid dose LY3499446 as oral monotherapy once every other day (QOD) in 21-day cycles.
3135900|NCT04165031|Experimental|LY3499446 Phase 1 Cohort A-2 Low Dose|Participants received low dose LY3499446 as oral monotherapy once daily (QD) in 21-Day cycles.
3135901|NCT04165031|Experimental|LY3499446 + Combination Drugs Phase 1|"LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~This trial was terminated prior to initiation of combination therapy cohorts."
3135902|NCT04165031|Experimental|LY3499446 Monotherapy + Combination Drugs Phase 2|"LY3499446 as oral monotherapy and LY3499446 combined with either abemaciclib (orally), erlotinib (orally), or cetuximab (IV).~The trial was terminated prior to initiation of Phase 2 of this study."
3135903|NCT04165031|Active Comparator|Docetaxel Phase 2|"Docetaxel IV infusion.~The trial was terminated prior to initiation of Phase 2 of this study."
3135904|NCT04166032|Experimental|ANICGM|non-invasive continuous glucose monitoring device
3135905|NCT04171414|Experimental|"CT-P17 SC AI (adalimumab)"|CT-P17 Subcutaneous(SC) Autoinjector(AI) (adalimumab)
3135906|NCT04175808|Experimental|Part A|After an overnight fast of at least 10 hours participants received a single oral dose of 25 mg omecamtiv mecarbil on Day 1.
3135907|NCT04175808|Experimental|Part B|"Participants with a maximum observed plasma OM concentration ≤ 350 ng/mL in Part A were randomly assigned to receive a single dose of each the following 3 treatments in one of six treatment sequences:~Placebo~50 mg omecamtiv mecarbil~400 mg moxifloxacin Each treatment was separated by a washout of at least 7 days."
3149256|NCT00170612|Experimental|A|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 18 months
3135908|NCT04178720|Experimental|LID018869|Lehfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
3135909|NCT04178720|Active Comparator|Biofinity|Comfilcon A contact lenses worn in both eyes at least approximately 8 hours per day and approximately 5 days per week during waking hours only. The lenses will be removed nightly for cleaning and disinfection and replaced monthly over the 3-month wear period.
3135910|NCT04184297||Subjects initiated with Tiotropium and Olodaterol (Tio+Olo)|
3135911|NCT04184297||Subjets initiated with LABA/LAMA/ICS|Long-acting beta2/ Long-acting muscarinic antagonists/Inhaled corticosteriods
3135912|NCT04189848|Experimental|Semaglutide followed by dulaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3135913|NCT04189848|Experimental|Dulaglutide followed by semaglutide|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3135914|NCT04210232|Experimental|TECNIS® TORIC II Intraocular Lens (IOL)|Subjects will be implanted with the TECNIS Toric II IOL in one or both eyes qualified for study inclusion
3135915|NCT04211909|Experimental|SOF/VEL|Participants with chronic HCV infection (genotype 1 or 2), who are treatment-naive or treatment-experienced with interferon (IFN)-based treatments will receive SOF/VEL for 12 weeks.
3135916|NCT04211909|Experimental|SOF/VEL/VOX|Participants with chronic HCV infection (genotype 1), who are treatment-experienced with nonstructural protein 5A (NS5A) direct-acting antiviral (DAA)-based treatments of at least 4 weeks duration will receive SOF/VEL/VOX for 12 weeks.
3135917|NCT04218110|Experimental|Project X 26ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 26ml volume. Single use.
3135918|NCT04218110|Experimental|Project X 10.5ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
3181208|NCT00691717|Experimental|24 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye
3135919|NCT04218110|Experimental|Project X 5.1ml|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within a saturated at use applicator. 10.5ml volume. Single use.
3135920|NCT04218110|Active Comparator|Prevantics Maxi Swabstick|3.15% w/v CHG (chlorhexidine gluconate) /70% v/v IPA (isopropyl alcohol) contained within pre-saturated applicator. 5.1ml volume. Single use.
3135921|NCT04222725|Experimental|TRS01 low dose|
3135922|NCT04222725|Experimental|TRS01 medium dose|
3135923|NCT04222725|Experimental|TRS01 high dose|
3135924|NCT04222725|Placebo Comparator|Placebo|
3135925|NCT04223843|Experimental|Active Arm|Tiotropium + Olodaterol Fixed Dose Combination (FDC) via Respimat
3135926|NCT04223843|Placebo Comparator|Placebo Arm|Matching placebo via Respimat
3135927|NCT04229303|Experimental|Part 1 - ZP-059 5mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 1: 5mg (1 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
3135928|NCT04229303|Experimental|Part 1 - ZP-059 10mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 2: 10mg (2 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
3149257|NCT00170612|Experimental|B|PCV at 6 weeks, 10 weeks, and 14 weeks; PPS at 12 months and 18 months
3135929|NCT04229303|Experimental|Part 1 - ZP-059 20mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 3: 20mg (4 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
3135930|NCT04229303|Experimental|Part 1 - ZP-059 40mg|"Part 1: administration of single ascending doses (SAD) of ZP-059.~Cohort 4: 40mg (8 x 5 mg capsule) ZP-059 single dose administered via DPI (RS01 monodose device) on Day 1."
3149258|NCT00170612|Experimental|C|PCV at 6 weeks and 14 weeks; PPS at 18 months
3149259|NCT00170612|Experimental|D|PCV at 6 weeks and 14 weeks; PPS at 12 months and 18 months
3181209|NCT00691717|Experimental|48 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye
3135931|NCT04229303|Experimental|Part 2 - ZP-059 10mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Days 1 to 10.~Cohort 1: 10mg (2 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
3135932|NCT04229303|Experimental|Part 2 - ZP-059 20mg bid|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 2: 20mg (4 x 5 mg capsule) ZP-059 twice daily (bid) administered via DPI (RS01 monodose device) for 9 days and once in the morning of Day 10."
3149260|NCT00170612|Experimental|E|PCV at 14 weeks; PPS at 18 months
3181210|NCT00691717|Experimental|60 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye
3135933|NCT04229303|Experimental|Part 2 - ZP-059 40mg qd|"Part 2: administration of multiple ascending doses (MAD) of ZP-059 on Day 1 to 10.~Cohort 3: 40mg (8 x 5 mg capsule) ZP-059 once daily (qd) administered via DPI (RS01 monodose device) on Days 1 to 10."
3135934|NCT04229303|Experimental|Part 3 - ZP-059 / Oral Voriconazole|Crossover treatment period: Single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI, and a single dose of oral voriconazole (200 mg Vfend® tablet) on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
3149261|NCT00170612|Experimental|F|PCV at 14 weeks; PPS at 12 months and 18 months
3149262|NCT00170612|Experimental|G|No PCV; PPS at 12 months and 18 months
3149263|NCT00170612|Active Comparator|H|No PCV; PPS at 18 months
3149264|NCT00170664|Experimental|Paclitaxel, Carboplatin|
3149265|NCT00170677|Active Comparator|A|
3149266|NCT00170677|Experimental|B|
3149267|NCT00170690|Experimental|1|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
3149268|NCT00170690|Experimental|2|Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc
3149269|NCT00170716|Active Comparator|Control|
3149270|NCT00170716|Experimental|Investigational|
3149271|NCT00170755|Experimental|1|Darifenacin
3149272|NCT00170768|Experimental|1|Darifenacin
3149273|NCT00170768|Active Comparator|2|Oxybutynin
3149274|NCT00170768|Placebo Comparator|3|Placebo
3149275|NCT00171145|Experimental|1|Darifenacin
3149276|NCT00171145|Placebo Comparator|2|Placebo
3135935|NCT04229303|Experimental|Part 3 - Oral Voriconazole / ZP-059|Crossover treatment period: Single dose of oral voriconazole (200 mg Vfend® tablet), and a single inhaled dose (20 mg) of ZP-059 5mg capsules administered via DPI on the morning of Day 1 of the respective treatment period with a washout period of at least 96 hours.
3135936|NCT04231825|Experimental|Verum Stimulation|This group will receive 6-Hz tACS
3135937|NCT04231825|Active Comparator|Frequency Control|This group will receive 1-Hz tACS
3149277|NCT00171171|Experimental|Deferasirox|
3149278|NCT00171184|Experimental|1|Darifenacin
3149279|NCT00171184|Placebo Comparator|2|Placebo
3149280|NCT00171496|Experimental|Cyclosporine microemulsion|
3149281|NCT00171496|Active Comparator|Tacrolimus|
3149282|NCT00171509|Active Comparator|BID cyclosporine|control group continuing with a BID administration of cyclosporine and C2 monitoring.
3149283|NCT00171509|Experimental|OAD cyclosporine|conversion to OAD administration of cyclosporine with the same daily dose as received prior to conversion
3149284|NCT00171509|Experimental|OAD cyclosporine reduced|OAD administration of cyclosporine with a daily dose adjusted to a reduced C2
3149285|NCT00171808|Experimental|Letrozole|
3149286|NCT00171821|Experimental|ICL670 (Deferasirox)|
3149287|NCT00171847|Experimental|A - HER-2 +ve patients with Femara alone|
3149288|NCT00171847|Experimental|B - HER-2 +ve patients with Femara + Herceptin|
3149289|NCT00171847|Experimental|C - HER-2 -ve patients with Femara alone|
3149290|NCT00171860|Experimental|STI571|
3149291|NCT00171886|Experimental|octrotide|
3149292|NCT00171899|Experimental|STI571|
3149293|NCT00171912|Experimental|imatinib mesylate (STI571)|
3181211|NCT00691717|Placebo Comparator|Anecortave Acetate Vehicle|Single depot administration of 0.8 mL in the study eye
3181212|NCT00691743||1|Primary care
3181213|NCT00691756|Experimental|1|Cold blood renal perfusion
3181214|NCT00691756|Active Comparator|2|Cold crystalloid renal perfusion
3181215|NCT00691769||I|CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
3181216|NCT00691769||II|patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
3181217|NCT00691769||III|Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.
3181218|NCT00691782||1|African American females between the ages of 21 and 60
3181219|NCT00691795|Experimental|CLONIDINE|Participants randomized to this arm of the study receive 75 micrograms clonidine with the bupivacaine in their epidural when requesting pain relief in advanced labor
3181220|NCT00691795|Experimental|FENTANYL|Participants randomized to this arm of the study receive 75 micrograms fentanyl with the bupivacaine in their epidural when requesting pain relief in advanced labor
3181221|NCT00691821|Active Comparator|1|Standard Dressings
3181222|NCT00691821|Experimental|2|Negative Pressure Wound Therapy
3181223|NCT00691834|Experimental|1|Intracoronary delivery of unfractionated bone marrow mononuclear cells
3149294|NCT00171964|Experimental|zoledronic acid + radiotherapy|zoledronic acid every 4 weeks in combination with radiotherapy
3149295|NCT00171977|Experimental|Imatinib Mesylate|400 mg once per day
3149296|NCT00172003|Experimental|Zoledronic acid|Zoledronic acid, dosage according to calculated creatinine clearance, administered as a 15 minute infusion every 3 weeks for 12 months. Study infusion visits should occur not earlier than the scheduled visit and no later than 3 days after the scheduled visit. The dose of zoledronic acid in patients with baseline creatinine clearance > 60 mL/min was recommended to be 4 mg infused over no less than 15 minutes.
3149297|NCT00172016|Experimental|ZOL446 (zoledronic acid)|
3135938|NCT04243421|Experimental|Group with implants|"Flap will be elevated following the crestal and releasing incisions (if necessary).~After having completed the cleaning, the surgeon will perform the osteotomy. After the use of the final drill ᴓ3.2 the surgeon will take the measurement of the buccal and palatal/lingual walls height.~If wall discrepancy is 1.5-2mm the site will be included in the study. Clinical photographs of probe within the osteotomy have to be taken. The osteotomy will be prepared with the conical drill, therefore the implant will be inserted in a special manner - lower part of the sloped collar will be located at the buccal aspect of the osteotomy preparation. At the buccal aspect the implant will positioned at the crestal bone level, while at the palatal aspect it will be either at the level of the bone crest or 0.5 mm below."
3135939|NCT04244084|Experimental|MMH-407|Tablet for oral use. One tablet per intake. On day 1, five tablets are taken in the first 2 hours (one tablet every 30 min), followed by three more tablets regularly spaced during the rest of the day. From day 2 through 5, one tablet is administered three times daily. The drug is administered not during meals (i.e. between the meals or 15-30 minutes before meal). The tablet should be held in mouth until complete dissolution.
3181224|NCT00691834|Placebo Comparator|2|Intracoronary delivery of placebo
3181225|NCT00691847||1|Bilateral post refractive procedure
3181226|NCT00691860|Experimental|1|Patients receiving conventional sigmoid end colostomy plus a lightweight mesh Ultrapro®
3135940|NCT04244084|Placebo Comparator|Placebo|According to the scheme of receiving MMN-407 until the end of the study.
3135941|NCT04256603|Other|Gabapentin early|Gabapentin prior to admission
3135942|NCT04256603|Other|Gabapentin late|Gabapentin during admission
3135943|NCT04256603|Other|No gabapentin|No gabapentin
3135944|NCT04258995|Experimental|GBS6 no aluminum phosphate (GBS6 no AlPO4)|
3135945|NCT04258995|Experimental|GBS6 with aluminum phosphate (GBS6 with AlPO4)|
3135946|NCT04280445|Experimental|Psychological therapy|All participants will receive psychological therapy. There will be no placebos or waiting list controlled participants to compare findings to.
3149298|NCT00172029|Experimental|ZOL446 Standard radiotherapy dosage|
3149299|NCT00172029|Experimental|ZOL446 Low radiotherapy dosage|
3149300|NCT00172055|Experimental|ZOL446 (zoledronic acid)|
3149301|NCT00172068|Experimental|Treatment Group|
3149302|NCT00172068|Active Comparator|Control Group|
3149303|NCT00172081|Placebo Comparator|placebo|Daily subcutaneous injection into thigh or abdomen with 700 mg Calcium and 400 IU Vitamin D daily
3181227|NCT00691860|Other|2|Patients receiving conventional sigmoid end colostomy, without mesh
3181228|NCT00691873|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3149304|NCT00172081|Experimental|PTH(1-84) 100 mcg|Subcutaneous injection of PTH(1-84) with 700 mg Calcium and 400 IU Vitamin D daily
3149305|NCT00172094|Placebo Comparator|1|PLACEBO
3149306|NCT00172094|Experimental|2|400 mg 1776 powder
3149307|NCT00172094|Experimental|3|1776 (800 mg)
3149308|NCT00172107|Placebo Comparator|1|Placebo drug injectable subcutaneously
3149309|NCT00172107|Experimental|2|50 mcg PTH(1-84)
3149310|NCT00172107|Experimental|3|75mcg PTH(1-84)
3149311|NCT00172107|Experimental|4|100 mcg PTH(1-84)
3149312|NCT00172133|Experimental|1|All patients entering the study will receive 100mcg daily for up to 6 months, making their total exposure 24 months
3149313|NCT00172172|Experimental|1|PTH 100 mcg and 700 mg calcium
3149314|NCT00172172|Experimental|2|PTH 100 mcg and placebo
3149315|NCT00172172|Placebo Comparator|3|Placebo and 700 mg calcium
3149316|NCT00172224||osteoporosis|
3149317|NCT00172380|Experimental|docetaxel and cisplatin|docetaxel 36mg/m2 and cisplatin 75mg/m2
3149318|NCT00172419|Experimental|Atorvastatin|
3149319|NCT00172536|Other|Control|Received oral general education about proper diet, regular physcial activity and other medical care if necessary
3135947|NCT04290494||CNSR I (2007 to 2008)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
3135948|NCT04290494||CNSR II (2012 to 2013)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
3149320|NCT00172536|Experimental|Exercise training|Received a supervised structure treadmill training
3149321|NCT00172809|Active Comparator|1|Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks
3149322|NCT00172809|Active Comparator|2|Interferon alfa-2a (Roferon, Hoffmann-LaRoche) 3 MU tiw for 24 weeks
3149323|NCT00173108|No Intervention|Term group|
3149324|NCT00173108|No Intervention|Usual care program group|
3149325|NCT00173108|Experimental|Clinic-based interveniton program group|
3149326|NCT00173108|Experimental|Home-based interveniton program group|
3149327|NCT00173433||Culture-confirmed relapse of TB|Patients who have a recurrent episode of culture-confirmed TB after completion of treatment for the first episode of culture-confirmed TB
3149328|NCT00173537|Other|other|
3149329|NCT00173862|Experimental|A|
3149330|NCT00173875|Experimental|A|Iressa
3149331|NCT00173888|Experimental|A|
3149332|NCT00173888|Active Comparator|B|
3149333|NCT00174369|Experimental|PD0325901|15 mg BID
3149334|NCT00174434|Experimental|A|
3149335|NCT00174499|Experimental|1|2 mg nicotine gum
3149336|NCT00174499|Experimental|2|4 mg nicotine gum
3149337|NCT00174616|Experimental|Single arm|
3149338|NCT00174629|Experimental|1|
3149339|NCT00174629|Active Comparator|2|
3149340|NCT00174642|Experimental|1|Insulin Glargine + 3 bolus of Insulin Glulisine + Metformin
3149341|NCT00174642|Experimental|2|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin
3149342|NCT00174642|Experimental|3|Insulin Glargine + 1 to 3 bolus of Insulin Glulisine + Metformin + Insulin secretagogue
3149343|NCT00174655|Active Comparator|A1|
3149344|NCT00174655|Active Comparator|A2|
3135949|NCT04290494||CNSR III (2015 to 2017)|"For this group following patients will be analysed:~The overall AIS patients aged 18 to 80 years who arrived at hospital within 7 days of symptom onset (Patient group A)~Thereof: IVT eligible patients:~AIS patients who arrived at hospital within 2 hours (patient group B) and 3.5 hours (patient group B') of symptom onset and with no documented absolute contraindications to IVT treatment~Thereof: IV rtPA treated patients:~IVT eligible patients who arrived at hospital within 2 hours of symptom onset and received IV rtPA within 3 hours of symptom onset (patient group C) and those who arrived at hospital within 3.5 hours of symptom onset and received IV rtPA within 4.5 hours of symptom onset (patient group C')"
3135950|NCT04303156|Experimental|Severe Renal Impairment|Participants with severe renal impairment received a single oral dose of 60 mg MK-8591 (Islatravir) administered in capsule form.
3135951|NCT04303156|Experimental|Healthy|Healthy participants received a single oral dose of 60 mg Islatravir administered in capsule form.
3135952|NCT04317040|Experimental|CD24Fc|Participants receive single dose of 480 mg CD24Fc, diluted to 100 ml with normal saline, intravenous (IV) infusion in 60 minutes on Day 1.
3135953|NCT04317040|Placebo Comparator|Placebo|Participants receive single dose of placebo as normal saline solution 100 ml, IV infusion in 60 minutes, on Day 1.
3149345|NCT00174655|Experimental|B|
3149346|NCT00174655|Experimental|C|
3135954|NCT04319159|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single Photodynamic therapy (PDT)."
3181229|NCT00691873|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3181230|NCT00691886|No Intervention|1|Subjects randomized to arm 1 of the study will recieve standard of care conscious sedation for EBUS; midasolam and or fentanyl.
3181231|NCT00691886|Active Comparator|2|Subjects undergoing EBUS randomized to arm 2 of the study will recieve demedetomadine hydrochloride plus standard of care conscious sedation
3181232|NCT00691899|Experimental|1|
3181233|NCT00691899|Placebo Comparator|2|
3181234|NCT00691912|Experimental|Myocet/Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
3181235|NCT00691925||1|bilateral post refractive surgery subject
3181236|NCT00691964|Experimental|A|
3181237|NCT00691964|Active Comparator|B|
3181238|NCT00691964|Placebo Comparator|C|
3181239|NCT00691977|Experimental|A|Radiation Therapy followed by prostatectomy
3181240|NCT00691990|Active Comparator|A|Classic thyroidectomy with drains
3181241|NCT00691990|Active Comparator|B|Classic thyroidectomy without drains
3181242|NCT00692016|Other|Arm 1|
3135955|NCT04321239|Experimental|Intervention group|Participants will engage in a 7-week positive psychology-based chronic pain self-management program.
3135956|NCT04321239|No Intervention|Usual care control group|After completing the follow-up telephone survey, individuals in the control condition will be given access to the online program, a wearable physical activity tracker to use and keep, and will be invited to attend a one-time 2.5-hour in-person or telephone workshop that summarizes intervention content and that will be led jointly by study staff and a community health worker.
3181243|NCT00692016|Other|Arm 2|
3181244|NCT00692042|Experimental|1|
3181245|NCT00692055|Experimental|1|PN400
3181246|NCT00692055|Active Comparator|2|naproxen 375 mg
3181247|NCT00692068||A|with residual renal function
3135957|NCT04323852|Experimental|vitamin D|35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units
3181248|NCT00692068||B|without residual renal function
3135958|NCT04323852|Placebo Comparator|control group|35 patients that will receive placebo for 3 days and each day for 3 doses
3135959|NCT04327843|Experimental|CAE + LAI|Customized Adherence Enhancement (CAE) + Long-Acting Injectable Antipsychotic (LAI)
3135960|NCT04331899|Experimental|Study drug Peginterferon Lambda-1a|Study participants assigned to study drug will receive a single subcutaneous dose of Peginterferon Lambda-1a in addition to standard of care treatment.
3135961|NCT04331899|Placebo Comparator|Placebo injection|Study participants will receive a placebo along with the standard of care treatment.
3181249|NCT00692081|Experimental|A|8 group sessions social competence training (CBT)
3181250|NCT00692081|Active Comparator|B|special vocational training as usual
3181251|NCT00692107|Active Comparator|1|68 Gy
3135962|NCT04334148|Active Comparator|Hydroxychloroquine|Hydroxychloroquine tablet 600mg bid loading dose on day 1 followed by 400mg on days 2-30.
3135963|NCT04334148|Placebo Comparator|Placebo|Matching placebo tablets
3135964|NCT04343287|Active Comparator|BRM421 Ophthalmic Solution|A topical solution of BRIM421 ophthalmic drops
3135965|NCT04343287|Placebo Comparator|Placebo|A vehicle ophthalmic drops
3149347|NCT00174668|Experimental|1|Mealtime insulin glulisine 3x daily and insulin glargine 1 x daily subcutaneously
3149348|NCT00174668|Active Comparator|2|Two daily injection conventional insulin therapy
3149349|NCT00174707|Active Comparator|A|Sequential Epidoxorubicin followed by CMF: ciclophosphamide/Methotrexate/fluorouracile (±TAM: tamoxifen)
3149350|NCT00174707|Experimental|B|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
3149351|NCT00174707|Experimental|C|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
3149352|NCT00174772|Experimental|B|Concurrent chemoradiotherapy followed by consolidation chemotherapy
3149353|NCT00174772|Experimental|A|Induction chemotherapy followed by concurrent chemoradiotherapy
3149354|NCT00174798|Placebo Comparator|Placebo|
3149355|NCT00174798|Experimental|SSR240600C|
3149356|NCT00174798|Active Comparator|Tolterodine|
3149357|NCT00174837|Experimental|Tirapazamine + Cisplatin|
3149358|NCT00174837|Active Comparator|Cisplatin|
3149359|NCT00174928|Experimental|Lansoprazole 0.5 mg/kg QD|
3149360|NCT00174928|Experimental|Lansoprazole 1.0 mg/kg QD|
3149361|NCT00174993|Experimental|Pioglitazone QD|
3149362|NCT00174993|Placebo Comparator|Placebo QD|
3149363|NCT00175032|Experimental|Lansoprazole 30 mg QD + Naproxen 500 mg BID|(and added aspirin)
3149364|NCT00175032|Active Comparator|Celecoxib 200 mg QD|(and added aspirin)
3149365|NCT00175045|Experimental|Lansoprazole IV 30 mg QD|
3149366|NCT00175045|Active Comparator|Lansoprazole Capsule 30 mg QD|
3135966|NCT04347954|Experimental|Povidone-Iodine 2%|"Participants will administer PVP-I 2% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
3181252|NCT00692107|Experimental|2|78 Gy
3181253|NCT00692120|Experimental|1|
3181254|NCT00692120|Experimental|2|
3181255|NCT00692120|Experimental|3|
3181256|NCT00692120|Experimental|4|
3181257|NCT00692146|Experimental|1|36 subjects receiving a specified volume of the active component AZD1386 in a single dose.
3181258|NCT00692146|Placebo Comparator|2|36 subjects receiving a specified volume of placebo in a single dose.
3181259|NCT00692159|Experimental|1|Dose finding single arm
3181260|NCT00692172|Experimental|1|
3181261|NCT00692224|Active Comparator|1|study group received zinc gluconate in a dose of 10 mg/day
3135967|NCT04347954|Experimental|Povidone-Iodine 0.5%|"Participants will administer PVP-I 0.5% nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5"
3149367|NCT00175058|No Intervention|1|Control - Patients with acute anterior myocardial infarction revascularized by means of PCI with stenting within 6 hours of onset of symptoms, no experimental intervention
3135968|NCT04347954|Placebo Comparator|Isotonic saline 0.9%|"Participants will administer two sprays of isotonic saline nasal spray for 5 days. Nasopharyngeal swabs will be taken on Day 1 at baseline, Day 1 at four hours post-first dose, and Day 5.~Participants will complete a daily symptom journal from Day 1 through Day 5."
3135969|NCT04349098|Experimental|Selinexor 20 mg|Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
3135970|NCT04349098|Placebo Comparator|Placebo|Participants will receive 20 mg of placebo matched to selinexor oral tablet on Days 1, 3, and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).
3135971|NCT04353037|Experimental|Sub Study 1 Patients|Patients tested for COVID-19 who meet symptomology and age requirements for eligibility
3135972|NCT04353037|Experimental|Sub Study 2 Health Care Workers|Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months
3135973|NCT04355117|Experimental|Treatment: TEV-48125|
3135974|NCT04355767|Experimental|Convalescent Plasma|Participants receive 1 unit of convalescent plasma.
3135975|NCT04355767|Placebo Comparator|Placebo|Participants receive 1 unit of saline with multivitamin.
3135976|NCT04356573|Placebo Comparator|Gold Kiwifruit First, then Green Hayward Kiwifruit|Subjects first ate 2 gold kiwifruit with midday meal for 2 weeks before crossing over to the green Hayward kiwifruit intervention
3135977|NCT04356573|Active Comparator|Green Hayward Kiwifruit first, then Gold Kiwifruit|Subjects first ate 2 green Hayward kiwifruit with midday meal for 2 weeks before crossing over to the gold kiwifruit intervention
3135978|NCT04357379|Experimental|IQOS group|
3135979|NCT04358068|Experimental|Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro)|"Hydroxychloroquine 400 mg (administered as two 200 mg capsules) orally twice daily for 2 doses starting on Day 0, followed by 200 mg (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Azithromycin 500 mg (administered as two 250 mg capsules) orally as a single dose on Day 0, followed by 250 mg (administered as one 250 mg capsule) orally once daily for 4 doses (4 days)."
3135980|NCT04358068|Placebo Comparator|Arm B: Placebo for Hydroxychloroquine and Azithromycin|"Placebo for Hydroxychloroquine (administered as two matching placebo capsules) orally twice daily for 2 doses starting on Day 0, followed by Placebo for HCQ (administered as one 200 mg capsule) orally twice daily for 12 doses (6 days), PLUS:~Placebo for Azithromycin (administered as two matching placebo capsules) orally as a single dose on Day 0, followed by Placebo for Azithromycin (administered as one matching placebo capsule) orally once daily for 4 doses (4 days)."
3135981|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 70 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 70 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
3135982|NCT04366349|Experimental|Participants receiving melrilimab (GSK3772847) 140 milligram (mg)|Participants will receive a single dose of melrilimab (GSK3772847) 140 milligram (mg) subcutaneously (SC) injection by an health care professional (HCP).
3135983|NCT04366349|Placebo Comparator|Participants receiving Placebo|Participants will receive a single dose of placebo subcutaneously (SC) injection by an health care professional (HCP).
3135984|NCT04369885|Experimental|Home Telemedicine Device|This arm will receive the intervention of the home telemedicine device for three months.
3181262|NCT00692224|Placebo Comparator|2|placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
3181263|NCT00692263|Experimental|A|Escitalopram - tramadol
3149368|NCT00175058|Experimental|2|AO Therapy group - anterior acute myocardial infarction patients revascularized by means of PCI with stenting within 6 hours of symptom onset, receiving adjunctive infusion of hyperoxemic blood into target coronary artery for 90 minutes post-PCI.
3149369|NCT00175071|Experimental|Comparison of cooking oils|Postmenopausal women (50-85 y) with LDL cholesterol 120 mg/dL.
3149370|NCT00175097|Other|soybeans and products made thereof|Diet: soybeans and products made thereof (soynuts, soynut butter, soy flakes & grits)
3149371|NCT00175097|Other|soybean flour and products made thereof|Diet: soybean flour and products made thereof (textured soybean)
3149372|NCT00175097|Other|soybean milk|Diet: soybean milk (tofu, soybean yogurt, cheese, etc.)
3149373|NCT00175097|Other|animal protein based diet|Diet: animal protein based diet
3149374|NCT00175136|Active Comparator|I-beam|I-beam stem design of tibial component for Total Knee Arthroplasty.
3149375|NCT00175136|Active Comparator|wedge|Wedge stem design of tibial component for Total Knee Arthroplasty.
3149376|NCT00175149|Active Comparator|1|Given alfacalcidiol. Dose adjusted after PTH level
3149377|NCT00175149|No Intervention|2|The untreated arm
3149378|NCT00175162|Active Comparator|Osteopal G bone cement|
3149379|NCT00175162|Active Comparator|Refobacin-Palacos R bone cement|
3149380|NCT00175188|Active Comparator|Cemented PIP implant|Avanta PIP
3149381|NCT00175188|Active Comparator|Uncemented PIP implant|Avanta PIP
3149382|NCT00175227|Experimental|Intervention|Saline hydration + mannitol + furosemide
3149383|NCT00175227|Placebo Comparator|Controls|Saline hydration without mannitol or furosemide
3149384|NCT00175344|Experimental|A|Arm A: Self-administered massage of the postoperative scar after breast cancer surgery.
3149385|NCT00175357|Active Comparator|1|Oral methadone
3149386|NCT00175357|Experimental|2|Injected diacetylmorphine
3181264|NCT00692263|Experimental|B|Placebo - tramadol
3181265|NCT00692263|Experimental|C|placebo - placebo
3181266|NCT00692302|Experimental|SAFETY I|Phase I participants who will receive SAFETY
3181267|NCT00692302|Experimental|SAFETY II|Phase II participants who will receive SAFETY
3135985|NCT04373421|Active Comparator|chlorhexidine gluconate plus benzydamine hydrochloride|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects. The most common side effect of chlorhexidine is oral discoloration, taste changes and allergic responses. Furthermore, it has been reported that chlorhexidine has cytotoxic effect on gingival fibroblasts, epithelial cells, neutrophils and red blood cells; also shows incremental trend in genotoxicity as the duration of usage is increased. Benzydamine hydrochloride is a nonsteroidal anti-inflammatory drug that elicits anti-inflammatory, analgesic, anesthetic and antimicrobial effects. It is often used in addition to the topical application of chlorhexidine.. However, side effects such as urticaria, erythema, pruritus, photosensitivity, bronchospasm and renal problems can be observed associated with the use of benzydamine.
3181268|NCT00692302|Active Comparator|Control|Phase II participants who will receive enhanced usual care
3181269|NCT00692315|Experimental|Methyl B12|Subcutaneous injection of 75 micrograms/Kg
3181270|NCT00692315|Experimental|Folinic Acid|400 micrograms orally twice a day
3181271|NCT00692328|Active Comparator|1|The subjects will be told they receive levodopa or acupuncture.
3181272|NCT00692328|Placebo Comparator|2|The subjects will be told they receive placebo/sham levodopa or acupuncture.
3149387|NCT00175383|Experimental|Leuprolide preparations|One versus three-month Leuprolide preparations in patients otherwise suitable for our Brachytherapy Program
3149388|NCT00175396|Active Comparator|1|
3149389|NCT00175396|Experimental|2|
3181273|NCT00692328|Experimental|3|The subjects will be told they have 50% chance of receiving real or placebo/sham levodopa or acupuncture.
3181274|NCT00692367|Other|Exercise|Structured exercise program
3181275|NCT00692380|Experimental|A|Fractionated Radiation Therapy followed by Carboplatin and Taxol
3181276|NCT00692393|Active Comparator|1|Surgery : Hartmann intervention
3181277|NCT00692393|Experimental|2|Surgery : primary resection with anastomosis with protective stoma
3181278|NCT00692445|Active Comparator|citalopram + TC-5214|
3181279|NCT00692445|Placebo Comparator|citalopram + placebo|
3181280|NCT00692458|Experimental|1|odanacatib
3181281|NCT00692458|Placebo Comparator|2|placebo
3181282|NCT00692471||1|Patients meeting the diagnostic criteria for the Postural Tachycardia Syndrome, a form of Orthostatic Intolerance
3181283|NCT00692471||2|Healthy control subjects who do not meet the criteria for the Postural Tachycardia Syndrome
3181284|NCT00692484|Experimental|1|Chlorhexidine gluconate 2%
3181285|NCT00692484|Active Comparator|2|Povidone iodine scrub and paint
3181286|NCT00692497|Active Comparator|1|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
3181287|NCT00692497|No Intervention|2|Patients in the control group are randomised to use the regular patient pathway prior to day case outpatient surgery. All these patients are referred to the surgical outpatient clinic. At the outpatient clinic patients are examined by a surgeon and indications for surgery is decided by the surgeon. If indicated, patients are then referred to outpatient surgery and the surgical procedure is performed several weeks after the examination.
3181288|NCT00692510|Experimental|1|AZD3480 + cocktail
3181289|NCT00692510|Placebo Comparator|2|Placebo + cocktail
3181290|NCT00692523|Active Comparator|1|The control group will receive 8 recreational therapy sessions over a 2-week (14 day) period, to be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
3181291|NCT00692523|Experimental|2|Patients randomized to Wii technology will receive an intensive program consisting of 8 Wii gaming sessions, 60 minutes each, over a 2-week (14 day) period. These 8 sessions can be scheduled in a flexible manner as long as all 8 sessions are completed within the 2 week period, and no more than 2 sessions are completed on any one day.
3181292|NCT00692536|Active Comparator|1|NNR
3149390|NCT00175409|Active Comparator|1|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
3149391|NCT00175409|Active Comparator|2|Infants will be randomized to two interventions which will take place during two separate blood collections that are required for clinical management. For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
3181293|NCT00692536|Active Comparator|2|MPD
3149392|NCT00175435|Experimental|1|2 doses of HPV vaccine 0.5 mL. given IM with Topical Immune Modulator in 9-13 year-olds.
3149393|NCT00175435|Active Comparator|2|3 doses of HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 9-13 year-olds.
3181294|NCT00692549|Experimental|Ultrasound|use of ultrasound
3181295|NCT00692549|No Intervention|no ultrasound|no ultrasound
3181296|NCT00692562|Experimental|A|
3181297|NCT00692575|Experimental|1: Experimental|Problem-solving, education based telephone counseling.
3181298|NCT00692575|Sham Comparator|2: No intervention|Standard of care control group
3181299|NCT00692588||Placebo|Subjects who received placebo in DARAD Trial
3181300|NCT00692588||Doxycycline|Subjects who received doxycycline in DARAD Trial
3181301|NCT00692588||Rifampicin|Subjects who received rifampicin in DARAD Trial
3149394|NCT00175435|Active Comparator|3|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator in 16-26 year-olds.
3149395|NCT00175812|Experimental|ATRA plus valproic acid plus theophyllin|ATRA for 14 days, continuous treatment with valproic acid and theophyllin
3149396|NCT00175838|Active Comparator|Intermediate risk group|Intermediate risk patients are randomised to a either a group receiving Aspirin only, or a group receiving both Hydroxyurea and Aspirin.
3149397|NCT00175838|Active Comparator|Low risk group|Patients are given Aspirin only with observation.
3149398|NCT00175890|Placebo Comparator|Placebo|Matching oral solution to Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
3149399|NCT00175890|Experimental|Levetiractem|10 % oral solution Levetiracetam b.i.d. (twice a day) for a maximum treatment duration of 20 days.
3135986|NCT04373421|Active Comparator|St. John's wort oil|St. John's Wort (Hypericum perforatum) is a European medicinal plant with a history of more than 2000 years which possessing a variety of important constituents including phloroglucinols (hyperforin and adhyperforin), naphthodianthrones (hypericin and pseudohypericin), xanthones, essential oil, biflavones (biapigenin and amentoflavone), flavonol derivatives and phenolic compounds. The important components of St. John's Wort such as hypericin and hyperforin exert anti-inflammatory, antimicrobial, anticancer effects as well as stimulating tissue growth and differentiation. Hypericin exhibits anti-inflammatory effects by inhibiting the production of interleukin-12; whereas hyperforin reveals this effect by inhibiting the mechanisms of cyclooxygenase 1, 5-lipoxygenase and prostaglandin E2. St. John's Wort oil is extracted by maceration of the hypericum herb in carrier oil, such as virgin olive oil.
3135987|NCT04373421|Active Comparator|Virgin olive oil|The olive oil, a product extracted from the fruit of Olea europaea, exerts also antioxidant and anti-inflammatory effects due to its important contents including oleic acids, phenolic acids, secoiridoids and flavonoids. The oral application of olive oil has been shown to have protective anti-inflammatory effects and accelerated epithelial healing.
3181302|NCT00692588||Doxycycline and Rifampicin|Subjects who received doxycycline and rifampicin in DARAD Trial
3181303|NCT00692588||Control|Normal controls
3181304|NCT00692601|Experimental|1|acute oral ingestion of 3 mg capsiate
3135988|NCT04381728|Experimental|Womed Leaf|"At the end of the hysteroscopic myomectomy, Womed Leaf is delivered in the uterus thanks to a 5mm diameter, flexible inserter. Then an endovaginal ultrasound will be performed to assess the positioning of the uterine film.~Another ultrasound will be performed at 2 hours, prior to patient discharge in order to record images of the uterine film deployment.~A second look hysteroscopy will performed at 4-8 weeks to evaluate the presence of intrauterine adhesion."
3181305|NCT00692601|Experimental|2|acute oral ingestion of 10 mg capsiate
3181306|NCT00692601|Placebo Comparator|3|acute oral ingestion of 0 mg capsiate ( same number of capsules as two other trials and identical looking placebo capsules)
3181307|NCT00692614|Experimental|1|100 mcg triamcinolone acetonide
3181308|NCT00692614|Experimental|2|500 mcg triamcinolone acetonide
3181309|NCT00692614|Experimental|3|925 mcg triamcinolone acetonide
3135989|NCT04382053|Experimental|DFV890 + SoC|DFV890 was administered for 14 days in addition to SoC.
3135990|NCT04382053|Active Comparator|Standard of Care (SoC)|SoC was used as an active comparator arm.
3135991|NCT04388826|Experimental|Veru-111 18 mg|Veru-111 18mg capsules
3135992|NCT04388826|Placebo Comparator|Placebo|Placebo capsules
3135993|NCT04391036|Experimental|High Eudragit® Film, then Low Eudragit® Film|High (12.8%) Eudragit® content vaginal film, then low (6.4%) Eudragit® content vaginal film
3135994|NCT04391036|Experimental|Low Eudragit® Film, then High Eudragit® Film|Low (6.4%) Eudragit® content vaginal film, then high (12.8%) Eudragit® content vaginal film
3135995|NCT04394845|Experimental|[18F]GTP1|Participants will receive a single bolus injection of radioligand [18F]GTP1 intravenously (IV).
3135996|NCT04398732||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.
3149400|NCT00175903|Experimental|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
3181310|NCT00692614|No Intervention|4|sham control - not implanted, no medication
3135997|NCT04401293|Experimental|Full Dose LMWH anticoagulation therapy|Subjects in this study arm will be treated with therapeutic doses of subcutaneous low-molecular-weight heparin (enoxaparin). Enoxaparin 1mg/kg SQ BID for CrCl ≥ 30ml/min (or Enoxaparin 0.5mg/kg SQ BID for CrCl ≥ 15ml/min and < 30ml/min) during the course of their hospitalization.
3149401|NCT00175903|Active Comparator|Older Antepileptic Drugs|Older AEDs consist of CBZ-CR 200 mg and 400 mg and VPA-ER 300 mg and 500 mg.
3149402|NCT00175929|Placebo Comparator|Placebo|Matching placebo tablets administered twice a day
3149403|NCT00175929|Experimental|Brivaracetam 50 mg/day|Brivaracetam 50 mg/day, 25 mg administered twice a day
3181311|NCT00692640|Experimental|1|
3135998|NCT04401293|Active Comparator|Prophylactic/Intermediate Dose LMWH or UFH therapy|Subjects in this study arm will be treated with Local institutional standard-of-care for prophylactic-dose or intermediate-dose UFH or LMWH. Regimens allowed are UFH up to 22,500 IU daily in BID or TID doses (i.e. UFH 5000 IU SQ BID/TID or 7500 IU BID/TID), enoxaparin 30mg and 40mg SQ QD or BID (the use of weight-based enoxaparin i.e. 0.5mg/kg SQ BID for this arm is acceptable but strongly discouraged), dalteparin 2500IU or 5000IU QD.
3135999|NCT04411628|Experimental|LY3819253|Participants received single doses of 700 milligrams (mg), 2800 mg or 7000 mg LY3819253 administered as intravenous infusion.
3181312|NCT00692653|Experimental|P4|Participant uses P4 program before meeting with his clinician to discuss treatment options.
3136000|NCT04411628|Placebo Comparator|Placebo|Participants received single dose of Placebo as intravenous infusion.
3136001|NCT04418947|No Intervention|No intervention|
3136002|NCT04418947|Active Comparator|MPM control letter|
3136003|NCT04418947|Experimental|MPM intervention letter|
3136004|NCT04418947|Active Comparator|Mailed control letter|
3181313|NCT00692653|No Intervention|Usual care+|Usual care plus participant is directed to reputable websites highly rated in research literature to learn more about prostate cancer treatments.
3181314|NCT00692705|Other|1|Alzheimer's Disease (AD) patients
3181315|NCT00692705|Other|2|Healthy volunteers
3136005|NCT04418947|Experimental|Mailed intervention letter|
3136006|NCT04420273|Experimental|SSE educational intervention|Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.
3136007|NCT04420273|Active Comparator|Active control: Healthy Living|Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.
3136008|NCT04420572|Experimental|ozone injection group|ozone injection will be applied in three doses (1st, 4th, 7th and 10th days) for a total of 4 doses. In ozone injection applications, 1st dose 25 gamma, 2nd dose 20 gamma, 3rd and 4th dose 15 gamma 10 cc ozone will be injected.
3136009|NCT04420572|Experimental|steroid injection group|1ml betamethasone will be used for steroid injection.
3136010|NCT04425720|Active Comparator|Standard Of Care|Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
3181316|NCT00692731||Active|Tea catechin sport beverage
3181317|NCT00692731||Control|Control beverage
3181318|NCT00692744||Randomized microsurgical|After randomization, this group was constituted of patients treated by microsurgical clipping.
3181319|NCT00692744||Randomized endovascular|After randomization, this group was constituted of patients treated by endovascular coiling.
3136011|NCT04425720|Experimental|Monitored|Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary
3136012|NCT04428411||Patients with moderate to severe plaque psoriasis|Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease
3136013|NCT04435184|Experimental|Crizanlizumab|Crizanlizumab is a monoclonal antibody targeting P-selectin. Crizanlizumab 5.0 mg/kg in 100 ml IV once.
3136014|NCT04435184|Active Comparator|Placebo Saline|0.9% saline 100 ml IV once.
3136015|NCT04476784|Other|LID018869, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
3136016|NCT04476784|Other|Biofinity, then LID018869|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes during waking hours only for at least 5 days per week over a 30-day period. CLEAR CARE will be used for nightly cleaning and disinfection.
3136017|NCT04484207|Experimental|Video-based intervention|A brief video about coping with COVID-19 stress presented to the participants
3136018|NCT04484207|Experimental|vignette intervention|A brief vignette about coping with COVID-19 stress presented to the participants
3136019|NCT04484207|No Intervention|Control|Only assessment, no intervention arrm
3136020|NCT04485455|Experimental|iTBS Therapy|Teenage participants with depression will receive iTBS therapy using a Transcranial Magnetic Stimulation (TMS) protocol delivering electro-magnetic stimulation
3136021|NCT04492475|Experimental|Remdesivir plus Interferon Beta-1a|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 44 mcg of interferon beta-1a administered by a 0.5 mL subcutaneous injection on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
3136022|NCT04492475|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and a 0.5 mL placebo injection administered subcutaneously on Days 1, 3, 5, and 7 while hospitalized for a total of 4 doses.
3136023|NCT04495283|Experimental|PGB and APAP (Group A)|Group A receives PGB plus APAP prior to surgery and placebo 1 post-surgery.
3136024|NCT04495283|Experimental|APAP (Group B)|Group B receives placebo 2 prior to surgery and APAP post-surgery.
3181320|NCT00692744||Prospective observational microsurgical|The randomization was ethically unsuitable because of the aneurysm predisposed to the microsurgical clipping after discussion into the neurovascular interdisciplinary team.
3136025|NCT04495283|Experimental|Placebo (Group C).|Group C receives placebo 1 prior to surgery and placebo 2 post-surgery.
3136026|NCT04497948|Other|Single Arm|Single Arm
3136027|NCT04501640|Experimental|Mirabegron 25 mg fed/Mirabegron 25 mg fasted|Participants received single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 25 milligram (mg) mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
3136028|NCT04501640|Experimental|Mirabegron 25 mg fasted/Mirabegron 25 mg fed|Participants received single dose of 25 mg mirabegron tablet under fasted condition orally, on day 1 of period 1 followed by single dose of 25 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
3136029|NCT04501640|Experimental|Mirabegron 50 mg fed/Mirabegron 50 mg fasted|Participants received single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fasted condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
3136030|NCT04501640|Experimental|Mirabegron 50 mg fasted/Mirabegron 50 mg fed|Participants received single dose of 50 mg mirabegron under fasted condition orally, on day 1 of period 1 followed by single dose of 50 mg mirabegron tablet under fed condition orally, on day 1 of period 2. A washout period of 10 days was maintained between the mirabegron administrations in each period.
3136031|NCT04501952|Experimental|Remdesivir (RDV)|Participants will receive a single dose of intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg on Days 2 and 3.
3136032|NCT04501952|Placebo Comparator|Placebo|Participants will receive IV placebo to match (PTM) RDV on Days 1 to 3.
3136033|NCT04504032|Experimental|Rivaroxaban|
3136034|NCT04504032|Placebo Comparator|Placebo|
3136035|NCT04507763||Patients with ankylosing spondylitis|Iraqi patients diagnosed with ankylosing spondylitis that received Etanercept as treatment for disease
3136036|NCT04507867|Sham Comparator|control group|Patients who received the standard diet
3136037|NCT04507867|Experimental|Intervention group|Patients who received the nutritional support system (NSS) and the standard diet
3149404|NCT00175929|Experimental|Brivaracetam 150 mg/day|Brivaracetam 150 mg/day, 75 mg administered twice a day
3149405|NCT00176046|Experimental|viscum album pini|immediate start of treatment with Iscador P s.c.
3136040|NCT04525079|Experimental|Cohort 1|Cohort 1 will receive a dose of CT-P59 or matching placebo
3136041|NCT04525079|Experimental|Cohort 2|Cohort 2 will receive a dose of CT-P59 or matching placebo
3136042|NCT04525079|Experimental|Cohort 3|Cohort 3 will receive a dose of CT-P59 or matching placebo
3136043|NCT04525079|Experimental|Cohort 4|Cohort 4 will receive a dose of CT-P59 or matching placebo
3136044|NCT04527978|Other|PRECISION1, then Biotrue ONEday|Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
3136045|NCT04527978|Other|Biotrue ONEday, then PRECISION1|Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
3136046|NCT04528017|Other|PRECISION1, then Clariti 1-Day|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
3136047|NCT04528017|Other|Clariti 1-Day, then PRECISION1|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type will be worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
3136048|NCT04529109|Experimental|Test/Control|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Test/Control).
3136049|NCT04529109|Experimental|Control/Test|Eligible subjects that are habitual soft contact lens wearers and current wearers of circle/cosmetic contact lenses will be randomized into lens wear sequence (Control/Test).
3136050|NCT04536571|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for 30 minutes, and then cross-over to control lenses.
3136051|NCT04536571|Active Comparator|Control Contact lens|Subjects will be randomized to wear control lenses for 30 minutes, and then cross-over to test lenses.
3136052|NCT04537234|Experimental|Group 1: High-Dose Quadrivalent Influenza Vaccine (QIV-HD)|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
3136053|NCT04537234|Active Comparator|Group 2: Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD)|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
3149406|NCT00176046|Active Comparator|waiting group|identical treatment with Iscador P s.c. after waiting period of 3 months
3149407|NCT00176085||healthy|healthy volunteers
3149408|NCT00176124|No Intervention|1|storage and transfusion of autologous whole blood without leukocyte depletion : Control group
3149409|NCT00176124|Experimental|2|storage and transfusion of leukocyte depleted autologous whole blood : leukocyte depletion group
3149410|NCT00176241|Experimental|1|
3149411|NCT00176267|Experimental|1|
3149412|NCT00176293|Experimental|1|dexamethasone
3149413|NCT00176293|No Intervention|2|
3149414|NCT00176449|Active Comparator|Bupropion SR|
3149415|NCT00176449|Placebo Comparator|Placebo|
3149416|NCT00176475|Experimental|Therapeutic allogeneic lymphocytes with rituximab|
3149417|NCT00176683||All comers|capnography used for all consenting subjects
3149418|NCT00176722||surgical|males & females undergoing spine surgery in the prone position
3149419|NCT00176748|Experimental|1|
3149420|NCT00177086|Experimental|Alfuzosin|
3149421|NCT00177086|Placebo Comparator|Placebo|
3149422|NCT00177138|Active Comparator|Group 2|Tacrolimus/MMF/TMG
3149423|NCT00177138|Experimental|Group 1|Campath/MMF/TMG
3149424|NCT00177177|Experimental|1|L Carnosine
3149425|NCT00177177|Placebo Comparator|2|Placebo
3149426|NCT00177229|No Intervention|A|Enhanced usual care: 2 free, individual consultations with a nutritionist over first 6 months. Medical monitoring throughout study period.
3149427|NCT00177229|Experimental|B|
3149428|NCT00177346|Experimental|CAS with cerebral protection|
3149429|NCT00177346|Active Comparator|CAS without cerebral protection|
3149430|NCT00177372|Experimental|1|Mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
3149431|NCT00177411|Experimental|PTHrP group|Subjects receiving PTHrP in varying doses.
3136056|NCT04544787|Experimental|Group 1: One Dose of Novel OPV2 Candidate 1|Participants previously vaccinated with oral polio vaccine (OPV) received one dose of novel OPV2 candidate 1 on Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ 50% cell culture infectious dose units [CCID50]).
3136057|NCT04544787|Experimental|Group 2: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with OPV received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3136058|NCT04544787|Experimental|Group 3: One Dose of Novel OPV2 Candidate 2|Participants previously vaccinated with OPV received one dose of novel OPV2 candidate 2 on study Day 0, administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3149432|NCT00177424|Active Comparator|1|Sertraline
3149433|NCT00177424|Placebo Comparator|2|matching placebo
3149434|NCT00177463|Experimental|L- Carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
3149435|NCT00177463|Placebo Comparator|Placebo|Placebo
3149436|NCT00177489|Experimental|Treatment|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
3149437|NCT00177489|Other|Control|"Caregivers in the control group received 2 brief check-in telphone calls during the 6 month intervention."
3149438|NCT00177515|Experimental|1|Computerized counseling about Emergency Contraception
3149439|NCT00177515|Active Comparator|2|Computerized counseling about peri-conception folate
3149440|NCT00177541|Experimental|Biofeedback|Biofeedback assisted pelvic floor muscle therapy (3 visits)
3136059|NCT04544787|Experimental|Group 4: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated OPV received two doses novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3136060|NCT04544787|Experimental|Group 5: Two Doses of Novel OPV2 Candidate 1|Participants previously vaccinated with inactivated polio vaccine (IPV) received two doses of novel OPV2 candidate 1 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3136061|NCT04544787|Experimental|Group 6: Two Doses of Novel OPV2 Candidate 2|Participants previously vaccinated with IPV received two doses of novel OPV2 candidate 2 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).
3136062|NCT04544787|Placebo Comparator|Group 7: Two Doses of Placebo|Participants previously vaccinated with IPV received two doses of placebo 28 days apart (Day 0 and Day 28), administered orally as six drops (0.3 mL total).
3136063|NCT04555031|Experimental|kalifilcon A lenses|
3136064|NCT04555031|Active Comparator|Dailies Total 1|
3136065|NCT04555031|Active Comparator|Precision 1|
3136066|NCT04555031|Active Comparator|Biotrue ONEday|
3136067|NCT04559282|Experimental|New SP followed by Baha 5 SP followed by single blinded SP|Aided hearing with new Sound Processor followed by aided hearing with the Baha 5 sound processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
3136068|NCT04559282|Experimental|Baha 5 SP followed by the New SP followed by single blinded SP|Aided hearing with Baha 5 sound processor followed by aided hearing with the new Sound Processor followed by unaided hearing followed by aided hearing with the new Sound Processor and Baha 5 in a laboratory environment (subject blinded for hearing testing).
3136069|NCT04573972|Active Comparator|Regular incentive|During the two-week intervention period, the standard incentive group will earn $2 per day when they meet their step goal, and this reward is earned regardless of whether they walk alone or with others.
3136070|NCT04573972|Experimental|Social Incentive|During the two-week intervention period, he social incentive group will earn $1 per day when they meet their step goal and an additional $1 if they walk 2,000 steps together with another study participant.
3136071|NCT04580290||JewelACL + Autograft (Hybrid)|JewelACL + Autograft (Hybrid)
3136072|NCT04580290||JewelACL only|JewelACL only
3136073|NCT04601103|Experimental|Comparator: No SLS Toothpaste|3M Oral Rinse in combination with no SLS toothpaste (A)
3136074|NCT04601103|Experimental|Comparator: Medium SLS Toothpaste|3M Oral Rinse in combination with medium SLS toothpaste (B)
3136075|NCT04601103|Experimental|Comparator: High SLS Toothpaste|3M Oral Rinse in combination with high SLS toothpaste (C)
3136076|NCT04617574||AEON Endostapler|Stapling performed with AEON Endostapler
3136077|NCT04617574||Endo GIA Reloads with Tri-Staple Technology|Stapling performed with Endo GIA Reloads with Tri-Staple Technology
3136078|NCT04658797|Active Comparator|Single Vision Spectacle for Vision correction|Single Vision Spectacle
3136079|NCT04658797|Experimental|somofilcon A Daily disposable contact lenses|Daily disposable contact lenses
3181321|NCT00692744||Prospective observational endovascular|The randomization was ethically unsuitable because of the aneurysm morphology predisposed to the endovascular coiling after discussion into the neurovascular interdisciplinary team.
3181322|NCT00692744||Prospective observational conservative|This group was constituted of patients whom no curative treatment of the aneurysm sac could not be proposed.
3181323|NCT00692757|Experimental|A|Hypochlorous acid
3181324|NCT00692757|Active Comparator|B|Iodopovidone
3181325|NCT00692796|Experimental|1|
3181326|NCT00692809||1|HIV+ve+LTBI (n=100)
3181327|NCT00692809||2|HIV+ve+clinical TB (n=50)
3181328|NCT00692809||3|HIV-ve+clinical TB (n=15)
3136080|NCT04664855|Experimental|Experimental Yoga Group|35 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
3136081|NCT04664855|No Intervention|Control Group (No Yoga Intervention)|20 freshman students enrolled in a health and wellness/physical education class at a rural Montana high school
3136082|NCT04701658|Experimental|Bamlanivimab|Participants received 700 milligram single intravenous infusion of Bamlanivimab.
3136083|NCT04701658|No Intervention|Controls|"Matched controls who received standard of care.~[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]"
3136084|NCT04706416|Experimental|N-Acetyl Glucosamine|All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
3136085|NCT04706416|Placebo Comparator|Control|All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.
3136086|NCT04709484|Experimental|USG-guided steroid injection group|In the USG-guided group, steroid injection will be made to the area where the fascia is thickened under USG guidance. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
3136087|NCT04709484|Experimental|Palpation-guided steroid injection group|In the palpation-guided group, the most painful point will be found by palpation on the calcaneus bone and steroid injection will be made to that part. The content of the steroid solution will be 1 ml of 1% Lidocaine + 1 ml (40 mg) methylprednisolone.
3181329|NCT00692809||4|Normal control (n=15)
3181330|NCT00692835|Active Comparator|A|Patients with mini Video Assisted Thyroidectomy (miVAT)
3181331|NCT00692835|Active Comparator|B|Immediate postoperative course of patients with classic Thyroidectomy (cTT)
3181332|NCT00692848|Experimental|PCT+|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm procalcitonin result is revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him
3181333|NCT00692848|No Intervention|PCT-|Investigations include CBC, blood culture, urine analysis and culture and procalcitonin. In this arm, procalcitonin is not revealed to the attending physician. The decision to treat with antibiotics or to hospitalize was left to him.
3181334|NCT00692887||1|Subjects diagnosed as new CNV or treated CNV
3181335|NCT00692900|Experimental|1|intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin
3136088|NCT04717323|Experimental|Patients|Gait with and without pelvic assistance
3136089|NCT04717323|Experimental|Controls|Gait with no pelvic assistance
3136090|NCT04727749|Experimental|Therapy Dog Team Visit|Patient interacts with the therapy dog and handler.
3136091|NCT04727749|No Intervention|No Therapy Dog Team Visit|No patient interaction with the therapy dog or handler.
3136092|NCT04777214|Active Comparator|Active TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS are delivered to a previously determined optimal response site in right frontal lobe.
3181336|NCT00692900|Experimental|2|intravenous (IV) oxaliplatin and intraperitoneal(IP) docetaxel
3136093|NCT04777214|Sham Comparator|Sham TMS|There are 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz TMS are delivered, however, the coil will be rotated 90 degrees during stimulation.
3136094|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH|The ovarian stimulation (OS) protocols included monotherapy protocols with using follitropin alpha biosimilar only and antagonists/agonists of of gonadotropin-releasing hormone (GnRH): ganirelix, cetrorelix, triptorelin, buserelin.
3136095|NCT04854707||Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH|The OS protocols included: mixed protocols (recombinant with addition of urinary-derived gonadotropins) and antagonists/agonists of GnRH (ganirelix, cetrorelix, triptorelin, buserelin), where follitropin alpha biosimilar used for at least 5 days during OS.
3136096|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and antagonists of GnRH|The OS protocols included: monotherapy protocols with using only follitropin alpha biosimilar and antagonists of GnRH.
3136097|NCT04854707||Monoprotocols: follitropin alpha biosimilar only and agonist of GnRH|The OS protocol included: monotherapy protocols with using only follitropin alpha biosimilar and agonists of GnRH.
3136098|NCT04854707||The overall protocols|The OS protocols included: (1) Monoprotocols: follitropin alpha biosimilar only and antagonists/agonists of GnRH, (2) Mixed protocols: recombinant and urinary-derived gonadotropins and antagonists/agonists of GnRH
3136099|NCT04926233||COPD patients from US IBM Marketscan database|
3136100|NCT04926233||COPD patients from UK CPRD GOLD database|
3136101|NCT04943159|Experimental|Afamelanotide group A|
3136102|NCT04943159|Experimental|Afamelanotide group B|
3136103|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation|
3136104|NCT04947436|Active Comparator|Mechanical insufflation/ exsufflation|
3136105|NCT04947436|Active Comparator|High Frequency Chest Wall Oscillation and Mechanical insufflation/ exsufflation|
3136106|NCT05002972|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
3136107|NCT05002985|Experimental|Walking Group|Subjects will participate in a walking group led by a community organizer as a means to get to a local farmer's market.
3149441|NCT00177645|Experimental|sodium bicarbonate|inhaled sodium bicarbonate
3149442|NCT00177840|Experimental|1|True acupuncture using true needles
3149443|NCT00177840|Sham Comparator|2|sham acupuncture using sham needles
3149444|NCT00177853|Experimental|1|Celecoxib, Irinotecan and Concurrent Radiotherapy
3149445|NCT00177892|Experimental|1|non-OSAH/overweight individuals with the Metabolic Syndrome
3149446|NCT00177892|Experimental|2|non-OSAH/overweight individuals without Metabolic Syndrome
3149447|NCT00177892|Active Comparator|3|non-OSAH/normal weight without Metabolic Syndrome
3136108|NCT04512482|Experimental|Experimental: Bromelain, Then Placebo|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of bromelain that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the placebo rinse (powdered sugar), following the same protocol and series of intraoral photographs.
3136109|NCT04512482|Placebo Comparator|Experimental: Placebo, Then Bromelain|Subjects were asked to chew a disclosing tablet, swish, and expectorate. Intraoral photographs were obtained. They then received a vial containing 1 gram of powdered sugar that was reconstituted with 15ml of pineapple juice at 50 degrees F. Subjects swished the solution in their mouth for 2 minutes and then expectorated. Intraoral photographs were obtained. Subjects then received a toothbrush and were asked to brush their teeth for 2 minutes. Intraoral photographs were obtained. The subjects were then given a Waterpik and instructed to use the appliances to clean their teeth and brackets to the best of their ability, for 2 minutes. Intraoral photographs were obtained. After a 1 week washout period, they received the bromelain rinse, following the same protocol and series of intraoral photographs.
3136110|NCT04499599|Active Comparator|Fast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 19 hours.
3136111|NCT04499599|Placebo Comparator|Breakfast Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a breakfast bar on day 2.
3136112|NCT04499599|Experimental|Fast Bar Group|Subjects will be asked to consume a standardized ready-to-eat dinner meal before 5 pm on day 1. Subjects will fast overnight for approximately 15 hours and then consume a Fast Bar on day 2.
3136113|NCT04525157|Experimental|Afamelanotide and NB-UVB|Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
3136114|NCT04525157|Placebo Comparator|Placebo and NB-UVB|Participants received Placebo implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0).
3136115|NCT04525157|Experimental|Single-Arm, Open Label Group|"The study design was modified into a single-arm, open label study with only one treatment group receiving afamelanotide implants plus NB-UVB light.~Participants received Afamelanotide implants (Days 28, 56, 112, 140, and 168) and NB-UVB light (twice weekly for 7 months from Day 0)."
3136116|NCT04523831|Active Comparator|Ivermectin and Doxycycline|Ivermactin 6 mg 2 tab stat, cap Doxycycline 100 mg 1 cap BD 5 days
3136117|NCT04523831|Placebo Comparator|Placebo|Standard treatment
3136118|NCT04521777|Experimental|Supportive care (exercise intervention)|Patients complete a physical function test over 15 minutes at baseline, and at days 14, 28, and 56. Patients also participate in an 8-week home-based strengthening and walking program consisting of a strengthening/resistance program for 30 minutes, 3 times a week, and walking program for 20-30 minutes at least 3 times a week.
3136119|NCT04512703||Healthy Group|Healthy male and female volunteers. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 30 days.
3136120|NCT04512703||Arrhythmia Monitoring Group|Patients with a clinical indication for outpatient cardiac monitoring. Subjects older than 21 years of age. Subjects to wear the µCor device for up to 90 days.
3136121|NCT04512703||Front Position Devices|All devices placed in the front position
3136122|NCT04512703||Side Position Devices|All devices placed in the side position
3136123|NCT04511520|Experimental|Physical training|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of 6 months)
3136124|NCT04511520|Experimental|Trimetazidine|Treatment of trimetazidine in addition to standart therapy
3136125|NCT04511520|No Intervention|Control|Standard follow-up at the participating heart center
3136126|NCT04507776||Patients with spondyloarthropathies|Patients with spondyloarthrosis that received Etanercept as treatment for disease
3149448|NCT00177892|Experimental|4|OSAH patients with chronic positive airway pressure therapy
3149449|NCT00177892|Experimental|5|OSAH patients without chronic positive airway pressure therapy
3149450|NCT00177918||lung transplant patients|
3149451|NCT00177931||liver transplant patients in ICU|
3149452|NCT00177944||patients with funal infections|
3181337|NCT00692926|Other|20% primed UCB|20% of UCB is ALDHbr sorted and primed and give on transplant day after conventional graft
3181338|NCT00692926|Other|20% un-primed|20% of UCB is ALDHbr freshly sorted and give on transplant day 4-8 hrs after conventional graft
3136127|NCT04502979|Experimental|Responsive Feeding|Intervention families will receive approximately 4 hours of ASL and development specific content related to language and feeding during home visits and phone calls. The initial in-home session with families will focus on teaching ASL signs indicative of hunger, thirst, and satiety. A video and placemat of mealtime signs will be left with families at the completion of the first visit. The remaining sessions, in-home over the next 3 months and by phone monthly thereafter for 6 months total, will focus on reinforcing ASL signing in addition to focused education on particular aspects of language development (receptive language preceding expressive language and increasing intentional communication), feeding development (such as hunger and fullness cues, fear of new foods, the importance of repeated food exposures, variations in intake from meal-to-meal, and the propensity to reject bitter tastes [many vegetables]55], and appropriate portion sizes and variety for healthy growth.
3136128|NCT04502979|No Intervention|Routine Care|No intervention is provided to the families in this group; however, portions of the intervention lessons will be made available after completion of data collection.
3136129|NCT04502056|Experimental|AMA RI - B- B - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color.
3136130|NCT04502056|Experimental|AMA RI - B - B - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
3181339|NCT00692926|Other|Double- 1 unit primed|patient receives 1 conventional UCB unit and 1 unit that has been ALDHbr sorted and primed
3181340|NCT00692926|Other|Double- 1 unit unprimed|Patient receives 1 UCB unit and a second UCB unit that has been freshly ALDHbr sorted
3181341|NCT00692939|Experimental|1|High-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
3181342|NCT00692952|Experimental|1|120 subjects using BenZalkonium Chloride Contraceptive Gel
3136131|NCT04502056|Experimental|AMA RI - W - W - R|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
3136132|NCT04502056|Experimental|AMA RI - W - W - N|Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
3136133|NCT04502056|Experimental|AMA DP - B- B - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will include information on the disproportionate impact on communities of color .
3136134|NCT04502056|Experimental|AMA DP - B- B - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
3136135|NCT04502056|Experimental|AMA DP - W- W - R|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will include information on the disproportionate impact on communities of color.
3136136|NCT04502056|Experimental|AMA DP - W- W - N|Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will be white - the message on Covid-19 will not include information on the disproportionate impact on communities of color.
3136137|NCT04502056|Placebo Comparator|Control: AMA RI - B - B|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA"
3136138|NCT04502056|Placebo Comparator|Control: AMA RI - W - W|"Respondents will be randomized to an AMA statement acknowledging racial injustice read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~Acknowledgement Racial Injustice AMA: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants will receive a AMA statement on racial injustice.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA"
3149453|NCT00177996|Active Comparator|Sertaline high dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline high dose titration) are consistent with recommended FDA guidelines.
3136139|NCT04502056|Placebo Comparator|Control: AMA DP - B - B|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by an African American individual. The messenger / doctor in the follow-up AMA videos will also be African American - No message on Covid-19 will be shown.~African American Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a African American sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
3136140|NCT04502056|Placebo Comparator|Control: AMA DP - W - W|"Respondents will be randomized to an AMA statement acknowledging drug pricing read by a white individual. The messenger / doctor in the follow-up AMA videos will also be white - No message on Covid-19 will be shown.~White Sender Acknowledgement: Investigators will also vary the messenger of the acknowledgement sender. In this arm participants receive a white sender in acknowledgment of AMA~AMA Acknowledgement Drug Pricing: Investigators will examine whether acknowledgements of racial inequality are helpful towards improving knowledge retention and behaviors associated with the intervention among participants. In this arm, participants receive AMA information on drug pricing"
3136141|NCT04498403|Experimental|Crisaborole 2%|Crisaborole 2% ointment applied twice daily (BID)
3136142|NCT04495374|Placebo Comparator|Group P(0) - Placebo|Patients were randomly allocated to Group P(0) - Placebo by a double blind randomized study. Group P(0) received two placebo tablets as medication, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
3136143|NCT04495374|Experimental|Group P(1) - Pregabalin 300mg|Patients were randomly allocated to Group P(1) - Pregabalin 300mg by a double blind randomized study. Group P(1) received two tablets of pregabalin 150mg, 02h before the start of the anesthesic-surgical procedure in identical sealed envelops, only identified as medication A or B
3136144|NCT04495712|Active Comparator|Spironolactone|Patients randomized to active therapy with spironolactone
3136145|NCT04495712|Placebo Comparator|placebo|patients randomized to placebo
3136146|NCT04492397|Experimental|Test Contact lens|Subjects will be randomized to wear test lenses for one week and then switch to control lenses for one week.
3136147|NCT04492397|Active Comparator|Control Contact Lens|Subjects will be randomized to wear control lenses for one week and then switch to test lenses for one week.
3136148|NCT04491994|No Intervention|Standard of Care (SOC)|Patients selected in supportive arm will be given daily standard doses of oral Vit C (2g), Vit D (alfacalcidiol 1µg), Zinc (50mg) and paracetamol (as required).
3181343|NCT00692952|Active Comparator|2|120 subjects using Nonoxynol-9 contraceptive gel
3136149|NCT04491994|Experimental|HCQ arm|Patients selected in experimental arm will be given Tab HCQ (400mg BD on D0 followed by 200mg BD D1-D5) in addition to supportive treatment
3136150|NCT04491240|Experimental|EXO-1|Participants (n=10) in this group will receive standard therapy and exosomes of the first type.
3136151|NCT04491240|Experimental|EXO-2|Participants (n=10) in this group will receive standard therapy and exosomes of the second type.
3136152|NCT04491240|Placebo Comparator|Placebo|Participants (n=10) in this group will receive standard therapy and inhalation placebo solution.
3136153|NCT04490863|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
3136154|NCT04490499|Experimental|HBVAXPRO™|Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™).
3136155|NCT04490239|Experimental|Experimental Arm|"Subjects will be administered heparin sodium (porcine) bottled in a nasal sprayer with a volume per spray of 0.1 mL.~Acute phase:~On day 1, each subject will be administered 0.1 mL per nostril of 5000 U/mL heparin sodium (porcine), for a total dose of 1000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~On day 2, each subject will be administered 0.1 mL per nostril of 10000 U/mL heparin sodium (porcine), for a total dose of 2000 U. Vital signs, blood work, and follow-up clinical observation will be used to detect adverse effects.~Chronic phase:~The highest acute dose that has no impact on aPTT or INR will be used for the chronic phase of this study. Each subject will be administered a daily dose for fourteen days. The first and last dose will be administered in the clinic; all other doses will be self-administered by subjects at home at the same time of day using a dosing diary to keep records."
3136156|NCT04486235|Experimental|Intervention|Receive experiential pamphlet
3136157|NCT04486235|No Intervention|Control|No materials, usual care
3136158|NCT04483011|Experimental|RiaGev|RiaGev, 2000mg, BID
3136159|NCT04483011|Active Comparator|Comparator|Comparator matched to RiaGev, BID
3136160|NCT04475588|Experimental|Arm A - Itolizumab + BSC|
3136161|NCT04475588|Active Comparator|Arm B - Best supportive care (BSC)|
3136162|NCT04474496||Marshallese adults in the U.S.|Marshallese persons 18 years of age or older currently residing in the United States
3136163|NCT04448210|Experimental|Educational website intervention|The intervention is an educational website designed to teach youth (12-17 years) about pediatric clinical trials.
3136164|NCT04448210|No Intervention|Wait-list control|The wait-list control group did not receive the intervention between the pre-test and post-test assessments. After completing the post-test questionnaire, youth in the wait-list control group had the option to receive access to the intervention (DigiKnowIt News).
3136165|NCT04474405|Experimental|Brain flortaucipir PET scan|Subjects receiving a brain PET scan after flortaucipir administration
3136166|NCT04474405|Experimental|Whole body flortaucipir PET scan|Subjects receiving a whole body PET scan after flortaucipir administration
3136167|NCT04474405|Other|MRI and Amyloid Extension Cohort|Magnetic resonance imaging (MRI) scans and amyloid scans for subjects previously participating in Study T807000 (NCT01733355)
3136168|NCT04470375|Experimental|VR pain education|Students receiving the 45 minute pain education through Virtual Reality
3136169|NCT04468347|Experimental|Alzheimer's disease (AD)|Alzheimer's disease subjects receiving a flortaucipir PET scan at baseline and 12 months
3136170|NCT04468347|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment subjects receiving a flortaucipir PET scan at baseline and 12 months
3136171|NCT04468347|Experimental|Subjective memory complainers (SMC)|Subjective memory complainers receiving a flortaucipir PET scan at baseline and 12 months
3136172|NCT04468347|Experimental|Cognitively normal (CN)|Cognitively normal subjects receiving a flortaucipir PET scan at baseline and 12 months
3136173|NCT04467424|Experimental|Pediatric anesthesia with ketofol|ketamine, propofol
3136174|NCT04467424|Experimental|Pediatric anesthesia with ketofol plus lidocaine|ketamine, propofol, lidocaine
3181344|NCT00692991||1|People undergoing percutaneous coronary interventions.
3181345|NCT00693004|Placebo Comparator|Placebo|
3181346|NCT00693004|Experimental|PRX-03140|
3181347|NCT00693004|Active Comparator|donepezil|
3181348|NCT00693030|Active Comparator|1|Device, Sirolimus drug-eluting stents implanted in overlap
3136175|NCT04465422|Experimental|Intervention Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~The research at this stage is based on the theoretical framework of the MOHO model and the clinical practice of OTPF-3. Clinical experts are requested to assist in providing relevant suggestions as a reference for modifying intervention activities. Design OT@tcpc service model for occupational therapy intervention activities. The event design is based on the 4 systems of determinationl, habits, performance and environment, and 2 events are designed for each to be carried out in a group. Each activity includes 4 parts: warm-up, activity, feedback and homework. Each activity group will be explained separately so that the occupational therapist of the group can complete it under the guidance."
3136176|NCT04465422|Active Comparator|Control Group|"We will recruit 70 inpatients with schizophrenia and divided into intervention group and control group. The Intervention group provided Occupational therapy based on the MOHO theory, while the control group adopted the original Occupational therapy model.~This study was approved by the Institutional Review Board of Taipei City Hospital. After informed consent, the patients signed the consent form for this study and became the participant of this study.~Each activity group will be explained separately so that the participants of each group can complete it under the guidance. The group description includes: activity title, activity time (location), MOHO theory system, group purpose, activity content, equipment or materials, precautions, etc."
3136177|NCT04463004|Active Comparator|Intervention|Treatment infusion
3136178|NCT04463004|Placebo Comparator|Control|Placebo infusion
3136179|NCT04463069|Experimental|intervention group|Participants in the intervention group participated in the APA intervention consisting of simple and fun endurance and strength-building exercise at a frequency of two sessions per week.
3136180|NCT04463069|No Intervention|control group|Participants in the control group received no intervention in the study time period.
3181349|NCT00693030|Active Comparator|2|Device, paclitaxel polymer drug eluting stent
3181350|NCT00693030|Active Comparator|3|Device, zotarolimus drug eluting stent
3136181|NCT04448561|Experimental|ASP8062 in combination with morphine|Participants received ASP8062 tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 dose.
3136182|NCT04448561|Placebo Comparator|Placebo in combination with morphine|Participants received ASP8062 matching placebo tablet, orally once daily on days 1 through 10. On day 10, participants also received morphine tablet as single oral dose immediately after the ASP8062 matching placebo dose.
3136183|NCT04462731|Experimental|Obturation technique: WVT|Warm vertical compaction technique (WVT): Teeth filled with AH Plus Jet Root Canal Sealer were filled with .04 taper gutta-percha points by WVT. The sealer was introduced with the master cone. The depth of heated plugger was within 3-5 mm of WL in the WVT group, and the remaining canal space was backfilled with additional sealer and thermoplasticized gutta-percha.
3136184|NCT04462731|Active Comparator|Obturation technique: SBT|Sealer-based filling technique (SBT): Teeth filled with SBT were obturated with EndoSequence BC Sealer by injecting the sealer into the coronal third of each canal. Size 30 Lentulo spiral coated with additional sealer was introduced 3 mm short of WL depth at 300rpm. Bioceramic coated gutta-percha was dipped in BC sealer and introduced into the canal to WL. A heated plugger was used to sear the gutta-percha point at each orifice.
3136185|NCT04459585|Experimental|Dabigatran + Quizartinib|Participants who will receive a single oral dose of 150mg dabigatran etexilate on Day 1 of Period 1 and then will receive a single oral dose of 60mg quizartinib 2 hours prior to the administration of a single oral dose of 150mg dabigatran etexilate on the morning of Day 5 of Period 2.
3136186|NCT04458818|Experimental|Prolene Mesh Implant|The Group of Patients who were offered Prolene mesh Laryngeal implants for Vocal Cord Medialization.
3136187|NCT04456634|Experimental|AL&RUX|"Oral administration of:~• 20 mg/120 mg artemether-lumefantrine (AL) + 20 mg ruxolitinib phosphate (Rux)"
3136188|NCT04456634|Placebo Comparator|AL& Placebo|20 mg/120 mg artemether-lumefantrine (AL) + Placebo
3136189|NCT04454138||Targeted supratenon's placement of XEN 45|Placement of Xen-45 gelatin microstent in the supra-tenon's space to maximize aqueous outflow, while preventing obstruction, limiting fibrosis of the bleb, and promoting long-term patency.
3136190|NCT04454138||Non-targeted placement of XEN 45|Implantation of the XEN-45 gelatin microstent within the subconjunctival space, avoiding intra-tenon's placement.
3136191|NCT04452435|Experimental|C21 100 mg twice daily|Oral C21 treatment 100 mg twice daily for 7 days
3136192|NCT04452435|Placebo Comparator|Placebo|Oral placebo treatment 100 mg twice daily for 7 days
3136193|NCT04451707||non-cholera Vibrio infection|Patients diagnosed with non-cholera Vibrio infection in Western France from 2000 to 2019
3136194|NCT04449263|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (test) the control Lens B for 2 weeks in this randomized, cross-over bilateral dispensing study.
3136195|NCT04449263|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) and Lens A (Test) for 2 weeks in this randomized, cross-over bilateral dispensing study.
3136196|NCT04449263|Active Comparator|Habitual Lenses|All subjects will wear their habitual lenses for two weeks prior to randomization of Test lens A and control lens B.
3136197|NCT04450381|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter & DCI Mini sensor for measurement of hemoglobin.
3136198|NCT04449341|Experimental|Standard care venipuncture with additional of virtual reality|Patients undergoing blood draw while interacting with VR application Ocean Rift while wearing Oculus Go headset
3136199|NCT04449341|No Intervention|Standard care venipuncture without addition of virtual reality|Patients undergoing blood draw while wearing Oculus Go headset that is turned off
3136202|NCT04441255|Experimental|TAK-788 160 mg Fasted + TAK-788 160 mg Fed|TAK-788 160 milligram (mg), capsule, orally, once on Day 1 of Period 1 under fasted conditions (Treatment A), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fed conditions (Treatment B).
3136203|NCT04441255|Experimental|TAK-788 160 mg Fed + TAK-788 160 mg Fasted|TAK-788 160 mg, capsule, orally, once on Day 1 of Period 1 under fed conditions (Treatment B), followed by 10 days washout period, followed by TAK-788 160 mg, capsule, orally, once on Day 1 of Period 2 under fasted conditions (Treatment A).
3136204|NCT04440449|Experimental|Behavioral Lifestyle Intervention|The participants will receive behavioral lifestyle intervention with a smartphone-based self-monitoring for diet and physical activity. This group also includes a total of 10 Group sessions over 6 months.
3136205|NCT04440449|Other|Group B control arm|Participants use the smart-phone app to record their daily diet and physical activity, with no group sessions.
3136206|NCT04439344|Experimental|Treatment (binimetinib)|Patients receive binimetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136207|NCT04439123|Experimental|Treatment (capivasertib)|Patients receive capivasertib PO BID on days 1-4, 8-11, 15-18, and 22-25. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136208|NCT04439214|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30-60 minutes on days 1 and 15 of cycles 1-4 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136209|NCT04439279|Experimental|Treatment (trametinib)|Patients receive trametinib dimethyl sulfoxide PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3181351|NCT00693030|Active Comparator|4|bare metal coronary stents
3136210|NCT04439240|Experimental|Treatment (AZD4547)|Patients receive AZD4547 PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3136212|NCT04438785|Experimental|INTERVENTION (AirwayGym) GROUP|Patients newly diagnosed with severe OSAHS should perform muscle upper airway exercises using the AirwayGym app for 20 min a day for 90 days.
3136213|NCT04438785|No Intervention|CONTROL GROUP|Patients newly diagnosed with severe OSAHS do no therapy for 90 days.
3136214|NCT04435808|Experimental|Hydroxychloroquine Arm|Group A: up to 275 health care workers who choose to take hydroxychloroquine. Will receive a 600 mg loading dose, followed by 200 mg daily (tablets).
3136215|NCT04435808|No Intervention|No Intervention Arm|Group B: Up to 75 health care workers who choose not to take hydroxychloroquine.
3136216|NCT04431908||Outpatients (Drive Thru)|Patients receiving testing through a drive thru location.
3136217|NCT04431908||High Risk Asymptomatics|Asymptomatic patients (residents) in a high risk location.
3136218|NCT04413929||Ergoferon|Oral administration in the therapeutic dosage specified in the instructions for medical use.
3136219|NCT04430634|Experimental|ABDC|Subjects use MybluTM e-cigarette product variant A (2.4 % nicotine) ad libitum for 2 days, then switch to use variant B (3.6% nicotine) for 2 days, then D (4.0% nicotine) for 2 days and then C (2.5% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
3136220|NCT04430634|Experimental|BCAD|Same as previous arm, but in a different randomization order.
3136221|NCT04430634|Experimental|CDBA|Same as previous arm, but in a different randomization order.
3136222|NCT04430634|Experimental|DACB|Same as previous arm, but in a different randomization order.
3136223|NCT04430634|Experimental|EFHG|Subjects use MybluTM e-cigarette product variant E (3.6 % nicotine) ad libitum for 2 days, then switch to use variant F (2.4% nicotine) for 2 days, then H (3.6% nicotine) for 2 days and then G (4.0% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
3136224|NCT04430634|Experimental|FGEH|Same as previous arm, but in a different randomization order.
3136225|NCT04430634|Experimental|GHFE|Same as previous arm, but in a different randomization order.
3136226|NCT04430634|Experimental|HEGF|Same as previous arm, but in a different randomization order.
3136227|NCT04429932|Experimental|Product use sequence ABDC|Subjects use MybluTM e-cigarette product variant A (2.4% nicotine) ad libitum for 2 days, then switch to use variant B (2.4% nicotine) for 2 days, then D (2.4% nicotine) for 2 days and then C (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
3136228|NCT04429932|Experimental|Product use sequence BCAD|Same as previous arm, but in a different randomization order.
3136229|NCT04429932|Experimental|Product use sequence CDBA|Same as previous arm, but in a different randomization order.
3136230|NCT04429932|Experimental|Product use sequence DACB|Same as previous arm, but in a different randomization order.
3136231|NCT04429932|Experimental|Product use sequence EFHG|Subjects use MybluTM e-cigarette product variant E (1.2% nicotine) ad libitum for 2 days, then switch to use variant F (1.2% nicotine) for 2 days, then H (2.4% nicotine) for 2 days and then G (2.4% nicotine) for 2 days. A washout period of 12 hours product abstinence is observed between product variants. For each product variant, in the morning of the second product use day, a controlled product use session is performed (10 puffs taken at 30-second intervals, with puffs 3 seconds in duration).
3136232|NCT04429932|Experimental|Product use sequence FGEH|Same as previous arm, but in a different randomization order.
3136233|NCT04429932|Experimental|Product use sequence GHFE|Same as previous arm, but in a different randomization order.
3136234|NCT04429932|Experimental|Product use sequence HEGF|Same as previous arm, but in a different randomization order.
3136235|NCT04428502||Patients with psoriatic arthritis|Iraqi patients diagnosed with psoriatic arthritis that receive Enbrel as treatment for disease
3136236|NCT04428424||Patients with rheumatoid arthritis|Iraqi patients with rheumatoid arthritis that received Enbrel as treatment for disease
3136237|NCT04428359|Experimental|Measles, Mumps, Rubella vaccine|All Group A patients will receive intralesional MMR.
3136238|NCT04428359|Experimental|Vitamin D3|All Group B patients will receive intralesional Vitamin D3
3136239|NCT04410159|Experimental|Povidone-iodine|gargle with povidone-iodine 10mL, 30 seconds, 3 times per day, 7 days
3136240|NCT04410159|Experimental|Essential Oils|gargle with essential oils 20mL, 30 seconds, 3 times per day, 7 days
3136241|NCT04410159|Experimental|Tap water|gargle with tap water 100 mL, 30 seconds, 3 times per day, 7 days
3136242|NCT04410159|No Intervention|Control|This group will receive the standard treatment protocol without any additional intervention
3136243|NCT04425850||IVER+|Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
3136244|NCT04425850||IVER-|Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
3136245|NCT04425863||Mild cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting only mild symptoms such as: fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain.
3136246|NCT04425863||Moderate cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 3 severe symptoms (i.e. fever above 38.5 °C, diarrhea with more than 3 daily depositions, flictenular conjunctivitis, strong desaturation (92% or less), tachypnea (FR> 25 / minute) or 2 severe symptoms + 2 mild symptoms (fever not above 38.5 °C; isolated diarrheal episodes, hyposmia or hypogeusia, mild desaturation (93 - 96 %), dyspnea without matter, polymyoarthralgias, persistent headache, abdominal pain)
3136247|NCT04425863||Severe cases|This group includes patients diagnosed positive for COVID-19 via rtPCR and presenting either: 4 severe symptoms or 3 severe symptoms and not less than 2 mild symptoms or clinical signs of bilateral viral pneumonia
3136248|NCT04425746|Experimental|Afamelanotide|Subjects visited the clinic on Day 0 (administration of afamelanotide implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
3136249|NCT04425746|Placebo Comparator|Placebo|Subjects visited the clinic on Day 0 (administration of placebo implant and porfimer sodium), Day 2 (photodynamic therapy), and Days 20 and 90 for assessments of adverse events, concomitant medication and the results of evaluation of phototoxicity.
3136250|NCT04422561|Experimental|Ivermectin group|Contacts who will receive prophylactic ivermectin
3136251|NCT04422561|No Intervention|Control group|Contacts who will be only observed without prophylaxis
3136252|NCT04421404|Experimental|COVID-19 Convalescent Plasma|Subjects in the COVID-19 convalescent plasma group will receive a single infusion of 250 ml anti-SARS-CoV-2 convalescent fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
3136253|NCT04421404|Placebo Comparator|Placebo|Subjects in the placebo group will receive a single infusion of 250 ml of standard fresh frozen plasma, ABO compatible with the patient, within 24 hours of randomization.
3136254|NCT04419311|Experimental|Ultra-congruent insert group|Ultra-congruent inserts were used during total knee arthroplasty in patients randomized to this group.
3136255|NCT04419311|Experimental|Posterior cruciate ligament-stabilized insert|Posterior cruciate ligament-stabilized inserts were used during total knee arthroplasty in patients randomized to this group.
3136256|NCT04415489|Active Comparator|Office Hysteroscopy|Use of office hysteroscope with operative port to evaluate uterine cavity, and potentially treat minor abnormalities within the same procedure with hysteroscopic graspers. This involve inserting the hysteroscope through the cervix and instillation of saline for a direct look at the cavity.
3136257|NCT04415489|No Intervention|Saline Infusion Sonography (SIS)|This is our institution's current first line approach for screening evaluation of the uterine cavity. If not enrolled in the study, patients are required to do this to move forward with embryo transfer. It involves instillation of saline into the uterus via a small catheter with simultaneous imaging with pelvic ultrasound.
3136258|NCT04411667|Experimental|Group A (study drug+SOC)|Standard of care plus IVIG (Octagam) 0.5g/kg IVPB actual body weight daily x 3 days, with premedication methylprednisolone 40 mg IV push x 1 30-50 minutes before each IVIG infusion. Initial infusion rate of IVIG (Octagam) will be of 0.6 mL/kg/hour, increasing to a maximum rate of 100ml/hr, if tolerated.
3136259|NCT04411667|No Intervention|Group B (SOC)|Standard of Care
3136260|NCT04409886|Experimental|HBOT (Hyperbaric Oxygen Therapy)|Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients (HBOT)
3136261|NCT04407507|Experimental|Ivermectin|Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
3136262|NCT04407507|Placebo Comparator|Placebo|Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days
3136263|NCT04406194|Experimental|FAVICOVIR then AVIGAN|Participants first received Favicovir 200 mg FT manufactured by Atabay in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state.
3136264|NCT04406194|Experimental|AVIGAN then FAVICOVIR|Participants first received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favicovir 200 mg FT manufactured by Atabay in a fasting state.
3136265|NCT04404907||Males who never deliberately tan|Males responded to an anonymous online survey that they never deliberately tan
3136266|NCT04404907||Males who ever deliberately tan|Males responded to an anonymous online survey that they had ever deliberately tan
3136267|NCT04404010|Active Comparator|Immersive Virtual Reality|"Participants randomized to the immersive virtual reality (iVR) study arm, considered the intervention group will receive training on completion of a reverse shoulder arthroplasty using an iVR simulator (PrecisionOS Technology)."
3136268|NCT04404010|Other|Surgical Video|"Participants randomized to the standard video study arm, considered the control group will receive training on completion of reverse shoulder arthroplasty using a technical surgical instructional video."
3136269|NCT04403399|Experimental|Varenicline then Placebo|Varenicline 0.5 mg BID orally for 3 weeks, followed by a 3-week washout period, then placebo BID orally for 3 weeks
3136270|NCT04403399|Experimental|Placebo then Varenicline|Placebo BID orally for 3 weeks, followed by a 3-week washout period, then Varenicline 0.5 mg BID orally for 3 weeks
3136271|NCT04402970|Experimental|Inhaled/nebulized dornase alfa|Patient to receive inhaled/nebulized dornase alfa (Pulmozyme) 2.5 mg twice daily in the ventilator circuit for 3 days, along with standard of care for ARDS.
3136272|NCT04402970|No Intervention|Standard of care|Standard of care provided for ARDS.
3136273|NCT04403113|Experimental|Study Group (SG)|feeding and oral motor intervention strategies+structured neck and trunk stabilization exercises+caregiver training related to feeding (Study Group)
3136274|NCT04403113|Placebo Comparator|Control Group (CG).|feeding and oral motor intervention strategies+caregiver training related to feeding (Control Group)
3136275|NCT04401202|Experimental|NSO|Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
3136276|NCT04401202|No Intervention|Control|Standard of care
3136277|NCT04401579|Experimental|Remdesivir plus Baricitinib|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
3136278|NCT04401579|Placebo Comparator|Remdesivir plus Placebo|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
3136279|NCT04400682|Experimental|FAVIRA then AVIGAN|Participants first received Favira 200 mg FT manufactured by Novelfarma in a fasting state. After a washout period of 48 hours, they then received Avigan FT200 mg manufactured by Toyama Chemical Industry Co.Ltd./ Japan in a fasting state.
3136280|NCT04400682|Experimental|AVIGAN then FAVIRA|Participants first received Avigan FT 200 mg manufactured by Toyama Chemical Industry Co.Ltd./Japan in a fasting state. After a washout period of 48 hours, they then received Favira 200 mg FT manufactured by Novelfarma in a fasting state.
3136281|NCT04399161|Experimental|Child Participants|Residential school children aged 5-12 yrs at high risk for caries. A total of 36 children will be recruited for the study and randomly divided into 3 groups with 12 participants per group.The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
3136282|NCT04399161|Experimental|Elderly Participants|Elderly citizens (above 60 yrs) at high risk for caries. A total of 36 elderly will be chosen based on eligibility criteria and randomly divided into 3 groups with 12 participants per group. The subjects will be asked to rinse their mouth once daily (at night) for 2 minutes, using 15 ml of mouth rinse provided to them. The intervention will be carried out for a period of 14 days.
3136283|NCT04399980|Active Comparator|Intervention|Treatment infusion
3136284|NCT04399980|Placebo Comparator|Control|Placebo infusion
3136285|NCT04399122|Active Comparator|Acetaminophen with codeine|codeine 30mg/acetaminophen 325mg Take one to two tablets every 4 to 6 hours as needed for pain for up to 4 days following surgery.
3136286|NCT04399122|Active Comparator|Acetaminophen with oxycodone|oxycodone 5mg/acetaminophen 325mg Take one tablet every 4 to 6 hours as needed for pain for up to 4 days following surgery.
3136287|NCT04397445|Experimental|Ranitidine and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of ranitidine (300 mg) plus low nitrite/NDMA meals (noncured-meats diet)
3136288|NCT04397445|Placebo Comparator|Placebo and Low Nitrite/NDMA Meals (Noncured-Meats Diet)|Single dose of placebo plus low nitrite/NDMA meals (noncured-meats diet)
3136289|NCT04397445|Experimental|Ranitidine and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of ranitidine (300 mg) plus high nitrite/NDMA meals (cured-meats diet)
3136290|NCT04397445|Placebo Comparator|Placebo and High Nitrite/NDMA Meals (Cured-Meats Diet)|Single dose of placebo plus high nitrite/NDMA meals (cured-meats diet)
3136291|NCT04397094|Experimental|Theracal LC|Theracal LC was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
3136292|NCT04397094|Active Comparator|Formocresol|Formocresol was used as a medicament to cover root stumps of asymptomatic thirty primary molars with vital pulp exposures. Teeth were followed up clinically and radiographically for 12 months.
3136293|NCT04396639|Experimental|Treatment Arm|Fifty eligible male subjects will be enrolled in the treatment arm to receive Moroctocog alfa (AF-CC) until 24 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
3136294|NCT04396665|Experimental|Precam Group (Intervention Group)|150 Women without breast cancer, aged from 25 to 50 years old
3136295|NCT04396665|No Intervention|Control Group|150 Women without breast cancer, aged from 25 to 50 years old
3136296|NCT04393493|Experimental|GROUP A|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution~Day 2 Furosemide 200mg / day infused with 100cc of Hartmann solution~Day 3 Furosemide 300mg / day infused with 100cc of Hartmann solution~Day 4 Furosemide 400mg / day infused with 100cc of Hartmann solution"
3149454|NCT00177996|Active Comparator|Sertaline low dose titration|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of Sertraline hydrochloride. The doses and titration schedules used in this arm (Sertaline low dose titration) are consistent with recommended FDA guidelines.
3136297|NCT04393493|Experimental|GROUP B|"Furosemide 80 mg every 24 hrs (morning) intravenously every 24 hrs for 4 consecutive days, additionally:~Day 1 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 2 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs.~Day 3 furosemide 100mg / day infused with 100cc of Hartmann solution + Chlortalidone 50mg VO every 24 hours + Spironolactone 50mg VO every 24 hrs."
3136298|NCT04392362|Active Comparator|Intervention group|Method of giving adenosine at 6mg then 12mg repeated twice to abort svt Intervention is giving the drug in a simplified method mixing it with 20 ml saline as a whole flush
3136299|NCT04392362|Active Comparator|Control group|Giving adenosine Ising the recommended AHA two syringe method
3136300|NCT04392141|Experimental|Standard Treatment|Patients diagnosed with COVID-19 which receive the standard treatment national guideline
3136301|NCT04392141|Experimental|Colchicine and Herbal Phenolic Monoterpene Fractions|Patients diagnosed with COVID-19 which receive the standard treatment national guideline plus Colchicine and Herbal Phenolic Monoterpene Fractions
3136302|NCT04392219|Experimental|EIDD-2801|EIDD-2801: Part 1: Participants were randomized to receive 50 to 1600 mg EIDD-2801 powder-in bottle (fasted); Part 2: Participants were randomized to receive two single 200 mg doses (fed or fasted); Part 3: Participants were randomized to receive twice daily doses of EIDD-2801 in an open-label manner.
3136303|NCT04392219|Placebo Comparator|Placebo|Placebo: Part 1: Participants were randomized to receive placebo (fasted); Part 3: Participants were randomized to receive placebo (fasted).
3136304|NCT04391842|Experimental|Experimental: SAM ultrasound and diclofenac patch|Patients receive treatment from the SAM Ultrasonic Diathermy Device for 4 hours every day for 7 days combined with 1% diclofenac patch. The SAM device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
3136305|NCT04390022|Active Comparator|Ivermectin|Participants on this arm will receive a single, oral dose of ivermectin 400 mcg/kg at the enrolment visit.
3136306|NCT04390022|Placebo Comparator|Placebo|Participants on the arm will receive a single, oral dose of placebo tablets at the enrollment visit.
3136307|NCT04386902||Patients|Patients who are assessed by the clinical staff using Mini-Mental State Exam (MMSE)
3136308|NCT04385238||Pregnant Women|Pregnant women who are 18 years of age or older.
3136309|NCT04385238||Post-partum women|Women who gave birth within the last 6 months who are 18 years of age or older.
3136310|NCT04384523|Experimental|OsrHSA 20 mg/kg IV|
3136311|NCT04384523|Experimental|OsrHSA 40 mg/kg IV|
3136312|NCT04384523|Experimental|OsrHSA 80 mg/kg IV|
3136313|NCT04384523|Experimental|OsrHSA 140 mg/kg IV|
3136314|NCT04384523|Experimental|OsrHSA 200 mg/kg IV|
3136315|NCT04383665|Sham Comparator|STN DBS off|
3136316|NCT04383665|Experimental|STN DBS 10Hz|
3136317|NCT04383665|Active Comparator|STN DBS 130Hz|
3136318|NCT04383132|Experimental|Abdominal Binder Intervention Group|Patients randomized to Abdominal Binder Intervention Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy.
3136319|NCT04383132|Sham Comparator|Sham Group|Sham Group will have the abdominal binder secured firmly between Spina iliaca anterior superior and subcostal area to the abdomen just prior the colonoscopy but it will be loosened just prior the procedure
3136320|NCT04382066|Experimental|Experimental 1|Plitidepsin 1.5 mg / day x 3 consecutive days
3136321|NCT04382066|Experimental|Experimental 2|Plitidepsin 2.0 mg / day x 3 consecutive days
3136322|NCT04382066|Experimental|Experimental 3|Plitidepsin 2.5 mg / day x 3 consecutive days
3136323|NCT04381481|Experimental|Control beverage, text snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
3136324|NCT04381481|Experimental|Control beverage, control snack|The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a barcode label (control label) (task 2).
3136325|NCT04381481|Experimental|Control beverage, graphic snack|"The participant will see fruit drinks with no nutrition claims (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
3136326|NCT04381481|Experimental|Claim 1 beverage, text snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
3136327|NCT04381481|Experimental|Claim 1 beverage, control snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a barcode label (control label) (task 2)."
3136328|NCT04381481|Experimental|Claim 1 beverage, graphic snack|"The participant will see fruit drinks with the nutrition claim No Artificial Sweeteners (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
3136329|NCT04381481|Experimental|Claim 2 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
3136330|NCT04381481|Experimental|Claim 2 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a barcode label (control label) (task 2)."
3136331|NCT04381481|Experimental|Claim 2 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% Vitamin C daily value (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
3136332|NCT04381481|Experimental|Claim 3 beverage, text snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a text warning WARNING: High in added sugar (task 2)."
3136333|NCT04381481|Experimental|Claim 3 beverage, control snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a barcode label (control label) (task 2)."
3136334|NCT04381481|Experimental|Claim 3 beverage, graphic snack|"The participants will see fruit drinks with the nutrition claim 100% All Natural (task 1). They will see a snack with a graphic label (image of sugar cubes in a cup) along with the text WARNING: High in added sugar (task 2)."
3136335|NCT04380688|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
3136336|NCT04380688|No Intervention|Arm 2|Best Supportive Care
3136337|NCT04376060|Experimental|Study population|Fifteen patients (1 male, 14 females) aged between 27 and 64 years old
3136338|NCT04374500|Experimental|Leptin infusion|This applies to protocol 1 when 10 healthy men got leptin infused locally in the forearm and blood flow was measured. The other forearm was used as the control.
3136339|NCT04374500|Experimental|Leptin infusion plus vasodilator infusion|This applies to protocol 2 when 10 healthy men got either a background infusion of leptin or saline locally in the forearm when measuring vasoresponse to four vasodilatators. Each participant had two examinations with either leptin or saline and the order was randomised. The other forearm was used as the control.
3136340|NCT04374500|Experimental|Vasodilator infusion in CAD patients|This applies to protocol 3 when 83 men and women with known CAD (coronary artery disease) got three vasodilators locally infused in the forearm while measuring vasoresponse. The other forearm was used as the control.
3136341|NCT04372186|Placebo Comparator|Placebo|Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.
3136342|NCT04372186|Experimental|Tocilizumab|Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.
3136343|NCT04371419|Experimental|Control - CDC - Mask (Control) - Concordant|Control Intro, CDC Social Distancing, Mask Control version delivered by minority doctor of same background as the recipient - other definitions are similar
3136344|NCT04371419|Experimental|Control - CDC - Mask (Control) - Discordant|Control Intro, CDC Social Distancing, Mask Control version delivered by majority doctor of different background as the recipient - other definitions are similar
3136345|NCT04371419|Experimental|Control - MGH - Mask (Control) - Concordant|Control Intro, MGH Social Distancing, Mask Control version delivered by concordant doctor
3136346|NCT04371419|Experimental|Control - MGH - Mask (Control) - Discordant|Control Intro, MGH Social Distancing, Mask Control version delivered by discordant doctor
3136347|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Concordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by concordant MD
3136348|NCT04371419|Experimental|Ack. Discrimination- MGH - Mask (Control) - Discordant|Introduction Acknowledges past discrimination, MGH doctor talks about Social Distancing, Mask Control all by discordant MD
3136349|NCT04371419|Experimental|Ack. econ. circumstance- MGH - Mask (Control ) Concordant|Intro econ. circumstance -MGH - Mask (Control ) Concordant
3136350|NCT04371419|Experimental|Ack. econ. circumstance - MGH - Mask (Control ) Discordant|
3136351|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Concordant|Control Intro - CDC - Mask (antiStigma) Concordant messenger
3136352|NCT04371419|Experimental|Control Intro - CDC - Mask (antiStigma) Discordant|Control Intro - CDC - Mask (antiStigma) discordant messenger
3136353|NCT04371419|Experimental|Control - MGH - MaskS (antiStigma) Concordant messenger|Control - MGH - MaskS (antiStigma) Concordant sender
3136354|NCT04371419|Experimental|Control- MGH-MaskS (antiStigma) Discordant messenger|Control - MGH - MaskS (antiStigma) Discordant sender
3136355|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Concordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Concordant sender
3136356|NCT04371419|Experimental|Ack. Discrimination - MGH - MaskS (antiStigma) Discordant|Acknowledge Discrimination - MGH - MaskS (antiStigma) Discordant sender
3136357|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Concordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) Concordant sender
3136358|NCT04371419|Experimental|Ack. Econ Hardship- MGH - Mask (antiStigma) Discordant|Acknowledge Econ Hardship- MGH - Mask (antiStigma) discordant sender
3136359|NCT04371419|Placebo Comparator|Info later - Pure Control|This group will not receive the videos but will receive information later.
3136360|NCT04370834|Experimental|Other (tocilizumab)|Patients receive tocilizumab IV over 60 minutes. A second dose may be given if there is sustained or recurrent fever, no decrease or not more than a 1-category improvement on the 7-category ordinal scale (only stabilization or partial improvement following first dose), or a >= 1-category worsening on the 7-category ordinal scale from nadir.
3136361|NCT04370548|Experimental|Clindamycin phosphate vaginal gel, 2%|
3136362|NCT04370548|Placebo Comparator|Placebo vaginal gel (Universal HEC Placebo Gel)|
3136363|NCT04370028||Divaza|Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.
3136364|NCT04368429|Experimental|Group 1: MenACYW Conjugate Vaccine|Participants received a single intramuscular (IM) dose of MenACYW Conjugate vaccine on Day 0.
3136365|NCT04368429|Active Comparator|Group 2: Menactra® vaccine|Participants received a single IM dose of Menactra® vaccine on Day 0.
3136366|NCT04363736|Active Comparator|TCZ 8 mg/kg|Participants will receive intravenous (IV) tocilizumab (TCZ) at a dose of 8 mg/kg in addition to standard-of-care treatment.
3136367|NCT04363736|Experimental|TCZ 4 mg/kg|Participants will receive IV tocilizumab (TCZ) at a dose of 4 mg/kg in addition to standard-of-care treatment.
3136368|NCT04366583|Experimental|Argon plasma coagulation plus distilled water injection|The patients in this group received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
3136369|NCT04366583|Active Comparator|Hemoclipping plus distilled water injection|The patients in this group received hemoclipping (Olympus HX 110/610, Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of56-day study period.
3136370|NCT04365699|Experimental|Interventional Patients: AT-001|AT-001 1500 mg (3 capsules) were administered by mouth twice daily for up to 14 days
3136371|NCT04365699|No Intervention|Control Match Group 1|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The first matching approach selected all subjects with diabetes mellitus and hypertension, and available data to match participants who received AT-001 for gender, age group (in bins of 5 years), weight, and C-reactive protein (CRP) value at the time of hospital admission.
3136372|NCT04365699|No Intervention|Control Match Group 2|Matched control from a contemporaneous de-identified registry of hospitalized patients with clinical COVID-19 diagnosis at the same institution was selected. The second matching approach selected all subjects in the registry with diabetes mellitus and available data to match participants who received AT-001 for gender, age group (in bings of 5 years), and weight (+/- 0.5 kgs).
3136373|NCT04365153|Active Comparator|High Dose Intervention|600 mg of canakinumab (8 mg/kg for patients </= 40 kg)
3136374|NCT04365153|Active Comparator|Low Dose Intervention|300 mg of canakinumab (4 mg/kg for patients </= 40 kg)
3136375|NCT04365153|Placebo Comparator|Control|Placebo
3136376|NCT04363879|Active Comparator|Endometrial scratch with Pipelle curette|For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.
3136377|NCT04363879|Experimental|Endometrial scratch with Shepard catheter|For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
3136378|NCT04362813|Experimental|Canakinumab|Canakinumab 450 mg for body weight 40-<60 kg, 600 mg for 60-80 kg or 750 mg for >80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
3136379|NCT04362813|Placebo Comparator|Placebo|250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.
3136380|NCT04362137|Experimental|Ruxolitinib 5 mg|Ruxolitinib 5 mg tablets twice daily (b.i.d.) for 14 days with possible extension of treatment to 28 days
3136381|NCT04362137|Placebo Comparator|Placebo|Matching-image placebo for 14 days with possible extension of treatment to 28 days
3136382|NCT04359771|Active Comparator|Yellow MPL|
3136383|NCT04359771|Active Comparator|Diode MPL|
3136384|NCT04358991||invasive bacterial infections|patients who are receiving Ceftazidime-avibactam are asked to provide blood samples around a dosing of the medication for analysis of samples
3136385|NCT04358081|Experimental|Arm 1: hydroxychloroquine + aithromycin placebo|Hydroxychloroquine 600mg o.d. as loading dose (Day 1) +followed by 200mg t.i.d was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin (AZT) placebo o.d.
3136386|NCT04358081|Experimental|Arm 2: hydroxychloroquine + azithromycin|Hydroxychloroquine 600 mg o.d. as a loading dose (Day 1) followed by 200 mg t.i.d. was initiated within 8-12 hours of the loading dose (not to exceed 12 hours) Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5
3136387|NCT04358081|Placebo Comparator|Arm 3: hydroxychloroquine placebo + azithromycin placebo|Hydroxychloroquine placebo o.d. (day 1) followed by hydroxychloroquine placebo t.i.d Azythromycin placebo o.d.
3136388|NCT04356937|Experimental|Tocilizumab|"Review effect of Tocilizumab on multi-organ dysfunction in a phase 3 randomized controlled trial among hospitalized patients with COVID-19 infection.~Participants will receive an intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg) tocilizumab.Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures."
3136389|NCT04356937|Placebo Comparator|Standard of care plus placebo|Participants will receive an placebo intravenous (IV) injection of 8 mg/kg (not to exceed 800 mg).Specifically, as compared to placebo, we will test whether tocilizumab is associated with a reduction in multi-organ dysfunction among hospitalized COVID-19 adult patients with elevated inflammatory measures.
3136390|NCT04355663|Experimental|Motor program activating therapy|MPAT is method developed and verified by our team. In this therapy, patients are corrected into a postural position where the joints are functionally centered. Somatosensory (manual and verbal) stimuli are then applied to activate motor programs in the brain, which then lead to the co-contraction of the patient's whole body when laying, sitting, standing up or moving forward. Activated programs are repeated under various conditions and in different situations and environments to teach the patients to automatically use the acquired motor skills in daily life. Therapy was realized within the ambulatory area of the Department of Neurology at Kralovske Vinohrady University Hospital in Prague.
3136391|NCT04355663|Experimental|Vojta's reflex locomotion|VRL is a standard approach for patients with MS in the Czech Republic. In the therapy, global patterns of the reflex locomotion are activated by stimulation of specific zones, with the individual placed in a precisely determined initial position (supine, prone and side laying, low kneeling position). These movement patterns have the qualities of the forward movement (locomotion) and the movement responses are precisely defined. Reflex locomotion (reflex turning and reflex creeping) is used in therapy to activate involuntarily responses of muscle function, which are necessary for spontaneous movements. Therapy was realized at the Department of Rehabilitation and Sport Medicine at Motol University Hospital.
3136392|NCT04355663|Experimental|Functional electric stimulation|Functional electric stimulation in the postural corrected position was developed at our workplace. Participants first underwent individual two-hour session consisting of postural correction using MPAT and the device (The WalkAide® System, Innovative Neurotronics Inc., 4999 Aircenter Circle, Suite 103 Reno, NV 89502, USA) programming (28). Patients received the device to use as much as they felt they were able to during their normal daily living activities thereafter.
3136393|NCT04354870|Experimental|HCQ Group|Approximately 300 Health Care Workers (HCW) who choose to be provided HCQ
3136394|NCT04354870|No Intervention|Control Group|approximately 50 HCW who choose not to be provided HCQ
3136395|NCT04350307|Active Comparator|22-Gauge Arm|Patient undergoing epidural injection in this arm will get 22-gauge Quincke needle
3136396|NCT04350307|Active Comparator|25-Gauge Arm|Patient undergoing epidural injection in this arm will get 25-gauge Quincke needle
3136397|NCT04352660|Active Comparator|Injection group|MMC delivered by preoperative subconjunctival injection
3136398|NCT04352660|Active Comparator|Sponge group|MMC delivered by intraoperative direct scleral application with impregnated cellulose sponges
3136399|NCT04350788|Placebo Comparator|Survivorship Care Plan (SCP)|The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
3136400|NCT04350788|Experimental|Enhanced SCP (ESCP)|ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
3136401|NCT04349917|Placebo Comparator|Placebo, then Methylphenidate|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
3136402|NCT04349917|Experimental|Methylphenidate, then Placebo|All children with ADHD in this study will receive one dose of methylphenidate and one dose of placebo over the course of two sessions approximately one week apart (order randomized and double-blind).
3136403|NCT04348851|Experimental|4-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
3181352|NCT00693043|No Intervention|Standard anesthesia group|Patients randomized to arm 1 received standard of care anesthesia for pleuroscopy. Duration of the procedure will be recorded. Pain management will be monitored prior to, intraoperatively and at the end of the procedure.
3136404|NCT04348851|Experimental|8-Week Intervention|Registered nurses (RNs) will conduct the combined Internet and telephone intervention condition. The intervention is based on the relational/problem-solving model of stress originally developed by D-Zurilla and Nezu. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on our national RESCUE Stroke Caregiver website. (http://www.cidrr8.research.va.gov/rescue/).
3136405|NCT04348851|Active Comparator|8-Week Attention Control|The Registered Nurses (RNs) will only provide active listening and paraphrasing. The RNs will ask caregivers to talk about their caregiver experiences. The nurses will not provide advice, but rather direct caregivers to access information on the Caregiver Family Alliance website (www.caregiver.org) for managing problems or to contact their healthcare provider.
3136406|NCT04348851|No Intervention|Standard Care|Caregivers receiving standard of care
3136407|NCT04348357|Active Comparator|Traditional Visit|Patients come to the office for a traditional postoperative visit
3136408|NCT04348357|Experimental|Tele-medicine|Patients receive postoperative care via telemedicine
3136409|NCT04347408||Healthy Children|Healthy children of healthcare workers between 2 and 15 years of age
3136410|NCT04346199|Experimental|Arm 1|Acalabrutinib+ Best Supportive Care
3136411|NCT04346199|No Intervention|Arm 2|Best Supportive Care
3136412|NCT04345653|Experimental|Study arm - Hydroxychloroquine Sulfate (HCQ)|HCQ sulfate HCQ 400mg (2x 200mg tablets) by mouth 6-12 hours apart on day 1, followed by 3 weeks of weekly 400mg (2x 200mg tablets) by mouth
3136413|NCT04343261|Experimental|COVID-19 patients treated with convalescent plasma|Severely ill COVID-19 patients treated with convalescent plasma
3136414|NCT04343222|Experimental|Group A: Bromfenac then Artificial Tears|Participant receives 1 drop of topical Bromfenac 0.09% 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
3136415|NCT04343222|Experimental|Group B: Artificial Tears then Bromfenac|Participant receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of topical Bromfenac 0.09% immediately after the injection and wash.
3136416|NCT04343222|Placebo Comparator|Group C: Artificial Tears then Artificial Tears|Participants receives 1 drop of an artificial tear eye drop 30 minutes prior to the injection and then 1 drop of an artificial tear eye drop immediately after the injection and wash.
3136417|NCT04343092|Experimental|Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT)|Ivermectin 12 mg /weekly )+ Hydroxychloroquine 400mg/daily + azithromycin 500mg daily
3136418|NCT04342663|Experimental|Fluvoxamine|Start fluvoxamine 100mg capsules, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in the RCT for approximately 15 days.
3136419|NCT04342663|Placebo Comparator|Placebo|Start placebo one capsule, three times daily. May reduce dose (or start at reduced dose) for tolerability reasons. Will be followed in RCT for approximately 15 days.
3136420|NCT04342897|Experimental|LY3127804|Participants received 20 milligrams (mg) per kilogram (kg) of LY3127804 as an intravenous (IV) infusion on Days 1 and 15.
3136421|NCT04342897|Placebo Comparator|Placebo|Participants received 20 mg/kg of Placebo as an IV infusion on Days 1 and 15.
3136422|NCT04342130|Experimental|All Participants|People with low back pain who were given and oral dose of 30 mg morphine.
3136423|NCT04340557|Experimental|Group A (Study drug+SOC)|Standard of Care plus an ARB to be taken orally twice daily for up to 10 days or until discharged from the hospital, whichever occurs first. Investigator may increase dose on days 2 - 10 if confident the subject will tolerate.
3136424|NCT04340557|No Intervention|Group B (SOC)|Standard of Care
3136425|NCT04339972|Experimental|Active LIFUP then Sham LIFUP|Real LIFUP is delivered to the participant for visit 1, followed by sham lifup visit 2
3136426|NCT04339972|Sham Comparator|Sham LIFUP then Active LIFUP|Sham LIFUP is delivered to the participant for visit 1, followed by real lifup visit 2
3136427|NCT04339296|Experimental|Intervention group|Intervention group included medication management with Spencer.
3136428|NCT04339296|No Intervention|Control Group|The control group continued to use their current method of medication management, such as blister packs, strip packs, pill organizers and plastic prescription vials.
3136429|NCT04338009|Experimental|Discontinuation arm|The randomized intervention will be the discontinuation of ACEI/ARBs
3136430|NCT04338009|Experimental|Continuation arm|The randomized intervention will be the continuation of ACEI/ARBs
3136431|NCT04338074|Experimental|Tranexamic Acid Treatment|
3136432|NCT04338074|Placebo Comparator|Placebo Treatment|
3136433|NCT04336475|Experimental|Group 1|exercise regimen and oral hygiene care advices
3136434|NCT04336475|Active Comparator|Group 2|oral hygiene care advices
3136435|NCT04335929|Experimental|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
3136436|NCT04335812|Experimental|R-ICBT|The intervention offered is a guided relaxation-based CBT offered via the Internet. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules provided will focus on applied relaxation only.
3136437|NCT04335812|Active Comparator|F-ICBT|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned. The modules are a mixture of applied relaxation, Cognitive Behavioral Therapy and advice addressing common problems
3136438|NCT04335136|Active Comparator|Group A (active) APN01|Recombinant human angiotensin-converting enzyme 2 (rhACE2) - APN01
3136439|NCT04335136|Placebo Comparator|Group B (placebo control)|
3136440|NCT04335552|Active Comparator|Standard of care|
3136441|NCT04335552|Experimental|Standard of care plus hydroxychloroquine|Standard of care plus hydroxychloroquine for 5 days
3136442|NCT04335552|Experimental|Standard of care plus azithromycin|Standard of care plus azithromycin for 5 days
3136443|NCT04335552|Experimental|Standard of care plus hydroxychloroquine plus azithromycin|Standard of care plus hydroxychloroquine plus azithromycin for 5 days
3136444|NCT04334876|Other|High Risk Healthcare Workers|At home, finger prick, antibody test.
3136445|NCT04334681||UC Group|Patients operated on the un-roofing curettage method in the treatment of pilonidal disease will be analyzed in this group.
3136446|NCT04334681||LF Group|Patients who have been operated with the modified Limberg flap method after rhomboid excision in the treatment of pilonidal disease will be analyzed in this group.
3136447|NCT04333225|Experimental|Hydroxychloroquine|Subjects who chose to enter the HCQ arm received a loading dose of 800 mg HCQ on day 1 followed by two 200 mg tablets once a week for a total of 7 weeks
3136448|NCT04333225|No Intervention|Control|Subjects who declined taking HCQ were considered as controls
3136449|NCT04333199|No Intervention|Control|Patients do not receive an email
3136450|NCT04333199|Experimental|Timely nudge - view results|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a View My Lab Results button, which encourages them to click as a pre-commitment step that then brings them to the myGeisinger sign-up page."
3136451|NCT04333199|Experimental|Timely nudge - get started|"Patients are emailed about myGeisinger when they have a lab result ready to view. The email includes a Get Started With myGeisinger button that is transparent about the next step in the process, before the patient can view test results."
3136452|NCT04332991|Active Comparator|Hydroxychlorquine|Participants assigned to the hydroxychloroquine arm will receive hydroxychloroquine sulfate 400 mg twice daily on the day of enrollment, then 200 mg twice daily for the next 4 days for a 5 day total course.
3136453|NCT04332991|Placebo Comparator|Placebo|Participants randomized to the control group will receive a dose of placebo enterally twice daily for 5 days (a total of 10 doses). The placebo pills will be as similar as possible to the hydroxychloroquine pills to ensure blinding.
3136454|NCT04332614||Control|A standard marketing message encouraging activation and describing the benefits of myGeisinger
3136455|NCT04332614||Focused on provider communication|A simple message focused on one benefit of myGeisinger: communicating easily with providers
3136456|NCT04332614||Focused on scheduling|A simple message focused on one benefit of myGeisinger: scheduling and managing appointments online
3136457|NCT04332614||Focused on medical information access|A simple message focused on one benefit of myGeisinger: accessing medical information, like test results
3136458|NCT04332614||Social proof|A message similar to control, but including information about how many other patients are using myGeisinger
3136459|NCT04332614||Endowment / decision staging|"A message similar to control, but framing myGeisinger as something that patients already have, and just need to take one more step to activate.~Endowment: Give patients the impression they already have the account, so they value it more.~Decision staging: Break down the process into multiple stages - having an account and activating that account- and giving the impression that they are almost there because the first stage is complete"
3136460|NCT04322968|Experimental|Chronic pain with PTSD+IV ketamine infusion|
3136461|NCT04322968|Active Comparator|Chronic pain with PTSD+IV ketorolac infusion|
3136462|NCT04322968|Experimental|Chronic pain without PTSD+IV ketamine infusion|
3136463|NCT04322968|Active Comparator|Chronic pain without PTSD+IV ketorolac infusion|
3136464|NCT04332419|Experimental|PET/CT & PET/MR|One-time PET/MR imaging in addition to the standard PET/CT imaging, both performed on the same day of the treatment procedure (Selective Internal Radiation Therapy Y-90 RE). Participants will be randomized to receive either of the imaging modalities first, based on the availability of the imaging device, and less than 1 hour apart.
3136465|NCT04332081|Experimental|Hyperbaric oxygen therapy (HBOT)|
3136466|NCT04332081|No Intervention|Standard of Care|
3136467|NCT04332107|Experimental|Azithromycin|1.2g of oral azithromycin
3136468|NCT04332107|Placebo Comparator|Placebo|Matching placebo
3136469|NCT04323592||Exposed to Methylprednisolone|Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
3136470|NCT04323592||Non-exposed to Methylprednisolone|Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.
3136472|NCT04326842||Carotid artery stenosis|Patients with carotid artery stenosis. Procedure: Carotid artery revascularization procedure
3136473|NCT04326842||Control|Patients without carotid artery stenosis
3136474|NCT04325542|Other|HBSAG positive with rapid test|Newborns from woman who are positive with HBSAG rapid test got WHO recommended HBV vaccination at birth to avoid HBV transmission
3136475|NCT04329923|Active Comparator|Cohort 1 HCQ|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with hydroxychloroquine 400 mg twice a day for up to 14 days
3136476|NCT04329923|Placebo Comparator|Cohort 1 Placebo|COVID-19 PCR+ patients quarantined at home randomized to this arm will be treated with placebo twice a day for up to 14 days. Crossover is allowed if symptoms worsen after 7 days of treatment.
3136477|NCT04329923|Experimental|Cohort 2 HCQ high dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg twice a day for up to 14 days
3136478|NCT04329923|Active Comparator|Cohort 2 HCQ low dose|Hospitalized COVID-19 PCR+ patients randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for up to 7 days
3136479|NCT04329923|Experimental|Cohort 3 HCQ|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with hydroxychloroquine 600 mg once a day for 2 months
3136480|NCT04329923|Placebo Comparator|Cohort 3 Placebo|Health care workers at high risk of contracting COVID-19 randomized to this arm will be treated with placebo for 2 month. Crossover is allowed if subject becomes SARS-CoV2 positive.
3136481|NCT04328467|Experimental|Intervention Once Weekly|400 mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg weekly for the duration of follow up, up to 12 weeks
3136482|NCT04328467|Experimental|Intervention Twice Weekly|400mg orally once, followed by 400mg 6 to 8 hours later, thereafter 400mg twice weekly for the duration of follow up, up to 12 weeks
3136483|NCT04328467|Placebo Comparator|Control Group|Placebo 2 tabs once, followed by 2 tabs 6 to 8 hours later, thereafter two tabs weekly or twice weekly for the duration of follow up, up to 12 weeks
3136484|NCT04327388|Experimental|Sarilumab 200 mg|"Sarilumab 200 milligrams (mg), single dose of intravenous (IV) injection on Day 1. Participants could receive a second dose of sarilumab 200 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in fraction of inspired oxygen (FiO2) requirement or~Required vasopressors, extracorporeal membrane oxygenation (ECMO) or development of multi-organ dysfunction."
3181353|NCT00693043|Experimental|Lidocaine Group|Patients randomized to arm two will receive a reduced topical dose of lidocaine of 2mg/kg and additional lidocaine 3mg/kg infused into the pleura cavity. Duration of procedure will be monitored from the time initial dose of intradermal lidocaine until the start of surgical wound closing, pain scale will be administered prior to the procedure and at the end of the procedure. Lidocaine serum levels will be monitored at 30, 60, and 120 minutes after initial intradermal administration of lidocaine.
3136485|NCT04327388|Experimental|Sarilumab 400 mg|"Sarilumab 400 mg, single dose of IV injection on Day 1. Participants could receive a second dose of sarilumab 400 mg 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
3136486|NCT04327388|Placebo Comparator|Placebo|"Placebo (for sarilumab), single dose of IV injection on Day 1. Participants could receive a second dose of placebo (for sarilumab) 24 to 48 hours after the first dose if first and any one of last three criteria was met as compared to Day 1 (as per following protocol amendment 2 [dated 08-Apr-2020]):~Benefit risk assessment by the investigator favored the administration of another dose of study drug without compromising safety and~Increase/recurrence of fever or~Increase/no change in FiO2 requirement or~Required vasopressors, ECMO or development of multi-organ dysfunction."
3136487|NCT04322526|Experimental|Naltrexone, then placebo|Naltrexone is thought to strongly block μ-opioid receptors. Oral (pill) opioid antagonist which will be used to modulate neural responses during the Contextual Framing and the Antidepressant fMRI Task.
3136488|NCT04322526|Placebo Comparator|Placebo, then naltrexone|In the naltrexone condition, participants will receive one tablet of 50mg Naltrexone hydrochloride.
3136489|NCT04322500|Other|Group A: conservative|conservative treatment
3136490|NCT04322500|Experimental|Group B: probiotics|in addition to the conservative treatment they receive a probiotics mixture (Streptococcus thermophilus ST10, Lactococcus lactis LLCO2 and Lactobacillus delbrueckii subsp. bulgaricus LDB01)
3136491|NCT04322682|Active Comparator|Colchicine|Patients will receive study medication colchicine 0.5 mg per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
3136492|NCT04322682|Placebo Comparator|Placebo|Patients will receive a placebo per os (PO) twice daily for the first 3 days and then once daily for the last 27 days. If a dose is missed, it should not be replaced.
3136493|NCT04321980|Experimental|Cohort 1|Subjects in Cohort 1 will be administered 4 mg/kg OP-101 as a subcutaneous (SC) injection.
3136494|NCT04321980|Experimental|Cohort 2|Subjects in Cohort 2 will be administered 8 mg/kg OP-101 as a SC injection.
3136495|NCT04322396|Placebo Comparator|Control|"This arm will receive standard care and placebo in 15 days.~Azithromycin placebo:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine placebo:~Day 1-15: 200 mg x 2"
3136496|NCT04322396|Active Comparator|Intervention|"This arm will receive standard care and azithromycin and hydroxychloroquine in 15 days.~Azithromycin:~Day 1-3: 500 mg x 1 Day 4-15: 250 mg x 1~Hydroxychloroquine:~Day 1-15: 200 mg x 2"
3136497|NCT04320823|Experimental|Experimental Group|Plasma collection using a modified version (version 1.3.90) of NexSys PCS embedded software installed on current FDA-cleared NexSys PCS device hardware (PCS-300-US), with the new plasma collection feature enabled.
3136498|NCT04320823|Active Comparator|Control Group|Plasma collection using a modified version (version 1.3.90) of NexSys® PCS embedded software installed on current FDA-cleared NexSy PCS device hardware (PCS-300-US), with the new plasma collection feature disabled.
3136499|NCT04320615|Experimental|Tocilizumab (TCZ) Arm|Participants will receive 1 intravenous (IV) infusion of TCZ, dosed at 8 mg/kg, up to a maximum dose 800 mg. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
3136500|NCT04320615|Placebo Comparator|Placebo Arm|Participants will receive 1 IV infusion of placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen or show no improvement.
3136501|NCT04318535|Experimental|Participants receiving T1T2R|Participants will receive a single oral dose of Griseofulvin T1: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
3136502|NCT04318535|Experimental|Participants receiving T2RT1|Participants will receive a single oral dose of Griseofulvin T2: 1 x 250 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin R: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
3136503|NCT04318535|Experimental|Participants receiving RT1T2|Participants will receive a single oral dose of Griseofulvin R: 1 x 500 mg Tablet once in Period 1 on Day 1 followed by a washout period of at least 7 days. In Period 2 on Day 8, same participants will receive Griseofulvin T1: 1 x 500 mg Tablet once followed by a washout period of at least 7 days. In Period 3 on Day 15, same participants will receive Griseofulvin T2: 1 x 250 mg Tablet once. All the above-mentioned doses will be administered with 240 +- 2 milliliters (mL) of water at ambient temperature under fed condition.
3181354|NCT00693056|Placebo Comparator|1|
3181355|NCT00693056|Experimental|2|
3181356|NCT00693056|Experimental|3|
3136504|NCT04316260|Experimental|Smoking cessation electronic visit (e-visit)|This group will be sent 1) an invitation to complete an electronic visit (e-visit) focused on cigarette smoking and 2) an invitation to complete a follow-up e-visit one-month after the initial e-visit.
3136505|NCT04316260|Active Comparator|Treatment As Usual|This group will be provided information about the state quitline and about the importance of quitting smoking and it will be recommended that they contact their PCP to schedule a medical visit to discuss quitting smoking.
3136506|NCT04314037|Experimental|Sequence 1 (T1-R1-T2-R2)|Participants will receive first dose of Cesol on Day 1 in treatment period 1 followed by first dose of Biltricide on Day 8 in treatment period 2 followed by second dose of Cesol on Day 15 in treatment period 3 followed by second dose of Biltricide on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
3136507|NCT04314037|Experimental|Sequence 2 (R1-T1-R2-T2)|Participants will receive first dose of Biltricide on Day 1 in treatment period 1 followed by first dose of Cesol on Day 8 in treatment period 2 followed by second dose of Biltricide on Day 15 in treatment period 3 followed by second dose of Cesol on Day 22 in treatment period 4. A washout period of 7 days will be maintained between 4 treatment periods.
3136508|NCT04315298|Experimental|Sarilumab 200mg IV (P2)|Phase 2
3136509|NCT04315298|Experimental|Sarilumab 200mg IV (P3:C1)|Phase 3: Cohort 1
3136510|NCT04315298|Experimental|Sarilumab 400mg IV (P2)|Phase 2
3136511|NCT04315298|Experimental|Sarilumab 400mg IV (P3:C1)|Phase 3: Cohort 1
3136512|NCT04315298|Experimental|Sarilumab 800mg IV (P3:C2)|Phase 3: Cohort 2
3136513|NCT04315298|Experimental|Sarilumab 800mg IV (P3: C3)|Phase 3: Cohort 3
3136514|NCT04313647|Experimental|1X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (2.0*10^8 nano vesicles/3 ml)
3136515|NCT04313647|Experimental|2X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (4.0*10^8 nano vesicles/3 ml)
3136516|NCT04313647|Experimental|4X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (8.0*10^8 nano vesicles/3 ml)
3136517|NCT04313647|Experimental|6X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (12.0*10^8 nano vesicles/3 ml)
3136518|NCT04313647|Experimental|8X level|Aerosol inhalation of MSCs-derived exosomes treatment participants will receive once aerosol inhalation of MSCs-derived exosomes (16.0*10^8 nano vesicles/3 ml)
3136519|NCT04310085|Experimental|PfSPZ-DVI challenge and artemether lumefantrine|"16 healthy, malaria-naïve males and females, aged 18-55 years, were enrolled in 2 cohorts (8 participants/cohort; a participant may be enrolled in one cohort only). There were two target levels of parasitaemia previously achieved in healthy participants in malaria VIS at other study sites, i.e., 5000 parasites/mL blood in Cohort 1 and 10000 parasites/mL blood in Cohort 2. (Based on observed levels of parasitaemia in Cohort 1, the target threshold for treatment in Cohort 2 was maintained at 5,000 p/mL).~qPCR was performed, malaria clinical score assessed twice daily and participants were administered registered antimalarial therapy, i.e., Riamet®, when the following criteria were met:~Cohort 1: ≥5000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion.~Cohort 2: ≥10000 parasites/mL blood or earlier if a participant has a malaria clinical score >6 or at Investigator's discretion."
3136520|NCT04309617||patients with Renal Cell Carcinoma(RCC)|Patients diagnosed with RCC who received a nephrectomy between 01Apr2014 and 31Mar2019
3136521|NCT04308239|Experimental|Reactive balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~Reactive balance training involved both slip and trip training.~Slip training involved repeatedly stepping onto a low-friction interface (nylon fabric placed over a 0.9 × 0.9 meter polycarbonate sheet) while practicing controlling/decelerating the slipping foot and properly positioning the non-slipping foot under the pelvis.~Trip training involved repeatedly practicing recovery from simulated trips on a modified treadmill. While standing on a modified treadmill, the treadmill belt was quickly accelerated posteriorly to elicit a forward loss of balance that mimicked a trip while walking. Participants attempted to step to avert a fall, and to establish a stable gait on the treadmill, after which the treadmill speed was slowed to zero to complete the trial."
3136522|NCT04308239|Active Comparator|Control balance training|"Four training sessions, conducted twice a week for two weeks in groups of 1-2 participants. Each session was 0.5-1 hours, with an active training time of 30 minutes for each participant.~The control intervention involved general balance exercises adapted from the Otago Exercise program. Briefly, all four sessions involved balance exercises and strength exercises using ankle weights, and were progressively increased as performance improved by increasing ankle weights or the difficulty of the balance exercises (e.g., not holding onto a wall or support)."
3136523|NCT04308668|Experimental|Treatment|Participants in this arm will receive the study drug.
3136524|NCT04308668|Placebo Comparator|Placebo|Participants in this arm will receive a placebo treatment.
3136525|NCT04307940|Experimental|Naproxen sodium|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
3136526|NCT04307940|Active Comparator|Hydrocodone/Acetaminophen|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
3136527|NCT04307940|Placebo Comparator|Placebo|After completion of the surgical teeth extractions, qualified participants will be randomized into one of three treatments with a 2:2:1 ratio. (Naproxen sodium=2, Hydrocodone/Acetaminophen=2, Placebo=1)
3136528|NCT04302545|Experimental|Cystoinflation group|Bladder will be recognized by observing its gradual distension during bladder retro-fill with 300cc saline to perform adhesiolysis.
3136529|NCT04302545|No Intervention|Control group|Pelvic adhesiolysis will be performed without bladder retrofill.
3136530|NCT04297631|Experimental|Vancomycin Powder|All patients getting vancomycin to see concentration after 24hrs in knee drain and serum levels.
3136531|NCT04297631|Experimental|Tobramycin Powder|All patients getting Tobramycin to see conceration after 24hrs in knee drain and serum levels.
3136532|NCT04297241|Experimental|Isosorbide Dinitrate|Each enrolled participant will be on a titrated dosage of isosorbide dinitrate to determine effectiveness on both primary and secondary outcome measures.
3136533|NCT04296448|No Intervention|Traditional Otoscope|Pediatric trainees use a traditional otoscope to evaluate pediatric patient ears. Trainees' supervisors will also evaluate patients with the traditional otoscope. The study evaluates concordance of the exams.
3136534|NCT04296448|Experimental|Cellscope|Pediatric trainees use a cellphone otoscope (Cellscope) to evaluate pediatric patient ears. Trainees' supervisors will evaluate patients remotely with the video on the cellphone otoscope. The study evaluates concordance of the exams.
3136535|NCT04296227|Experimental|ISO 81060-2:2018.|The intended purpose of the test is to evaluate the Vital Detect blood pressure monitor to ISO 81060-2:2018. The intended use for these products are manual and automatic Non-Invasive Blood Pressure monitoring on adults age 18 and older.
3136536|NCT04295356|Active Comparator|Auto injector|a single dose (40 mg) of CT-P17 via AI
3136537|NCT04295356|Active Comparator|Pre-filled syringe|a single dose (40 mg) of CT-P17 via PFS
3136538|NCT04292639|Experimental|Respiratory Rate|The purpose of this study is to conduct a Respiratory Rate accuracy validation comparing the Vital USA Vital Detect to an FDA cleared End Tidal Carbon Dioxide monitor Reference Standard (GE Datex-Ohmeda). This report documents exclusively the results of the Respiratory Rate accuracy performance for the Vital USA Vital Detect.
3136539|NCT04292535|Active Comparator|Passive Control|20 minute sedentary control period during which participants watched an emotionally neutral video.
3136540|NCT04292535|Experimental|Acute Exercise|20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video.
3136541|NCT04292171|Active Comparator|Gabapentin Arm|Gabapentin 600 mg given 1-2 hours prior to surgical abortion
3136542|NCT04292171|Placebo Comparator|Placebo Arm|Placebo (vit C) given 1-2 hours prior to surgical abortion
3136543|NCT04292899|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
3136544|NCT04292899|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
3136545|NCT04292899|Experimental|Part B: Remdesivir, 10 Days (Extension)|Part B (Extension) will enroll participants after enrollment to Part A is complete. Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10.
3136546|NCT04292899|Experimental|Part B: Remdesivir 10 days (Mechanically Ventilated)|Participants on mechanical ventilation will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2-10
3136547|NCT04292730|Experimental|Part A: Remdesivir (RDV), 5 Days|Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
3136548|NCT04292730|Experimental|Part A: Remdesivir, 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
3136549|NCT04292730|Active Comparator|Part A: SOC Therapy|Participants will receive continued standard of care therapy.
3136550|NCT04292730|Experimental|Part B: Extension Treatment, Remdesivir 10 Days|Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
3136551|NCT04290676||DEXYCU (dexamethasone intraocular suspension) 9%.|DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).
3136552|NCT04290039|Active Comparator|Low Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
3149455|NCT00178217|Experimental|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
3136553|NCT04290039|Active Comparator|High Dose Sublingual|"Atropine sulfate ophthalmic solution, USP 1% is a sterile topical anti-muscarinic indicated for cyclopegia, mydriasis, and penalization of the healthy eye in the treatment of amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains active ingredient: atropine sulfate 10 mg equivalent to 8.3 mg of atropine. Inactive ingredients include benzalkonium chloride 0.1 mg (0.01%), dibasic sodium phosphate, edetate disodium, hypromellose (2910), monobasic sodium phosphate, hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0), and water for injection, USP. Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in dropper bottles containing 2 mL.~Each bottle will only be used to administer a single dose, to a single subject."
3136554|NCT04290039|Active Comparator|Intravenous (IV)|"Atropine sulfate injection is indicated for temporary blockade of severe or life-threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia.~Atropine sulfate injection, USP,8mg/20mL (0.4 mg per mL) is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; sodium chloride 9 mg; and may contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8).~Atropine sulfate injection will be supplied in multidose vials containing 20 mL.~Each vial will only be used to administer a single dose, to a single subject."
3136555|NCT04289623||Standard email|This email mentions the cost-saving benefits of enrollment by participants who met their 2018 goals. It also includes the message that registration can be completed quickly (in less than five minutes). Finally, it also includes reward incentive information, wherein registering by a March deadline provides qualified recipients with the potential to win prizes. This information is contained in all other emails.
3136556|NCT04289623||Loss frame email|"In addition to the content of the generic email, the subject line and content of the loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action. This email further frames the reward as something recipients will miss out on if they do not sign up.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
3136557|NCT04289623||Testimonial (medical expert) email|"In addition to the content of the generic email, the testimonial (medical expert) email includes a testimonial from a doctor, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a presumed authority figure. Recipients may be more likely to enroll for this program if they see a physician - who would be seen as an authority on health and wellness - talking about the medical benefits of the program. It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
3136558|NCT04289623||Testimonial (rank-and-file) email|"In addition to the content of the generic email, the testimonial (rank-and-file) email includes a testimonial from a customer care specialist, which notes the personal benefits of myHealth Rewards in terms of managing blood pressure, blood sugar, cholesterol, weight, and stress.~This intervention shows proof of other people successfully enrolling and benefitting from the program. Specifically, it is an endorsement from a peer (relative to most Geisinger employees). Recipients may be more likely to enroll for this program if they see a rank-and-file employee talking about the program as this person would be more relatable (relative to a doctor). It is unclear in the current context and population if a message from an expert or rank-and-file employee would be more effective."
3136559|NCT04289623||Social norms (percentage) email|"In addition to the content of the generic email, the social norms (percentage) email will include communication about the percentage of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a majority of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. The use of percentages makes it clear that this behavior is indeed being done by most people in the group. It is unclear in the current context and population if a message using percentages or numbers would be more effective."
3136560|NCT04289623||Social norms (number) email|"In addition to the content of the generic email, the social norms (number) email will include communication about the number of benefit-eligible employees who had already registered for myHealth Rewards.~This message sets up a descriptive norm, showing that a large number of people are doing a certain behavior. When people see a behavior as the norm, they are more likely to follow it. While the use of numbers does not indicate that this behavior is being done by a majority, using a large number can be more convincing just in showing sheer quantity."
3181357|NCT00693056|Experimental|4|
3136561|NCT04276207|Experimental|100 U/mL LY900014|100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
3136562|NCT04276207|Active Comparator|100 U/mL Insulin Lispro (Humalog)|100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.
3136563|NCT04289714|Experimental|R-DOT|Remote Directly Observed Therapy
3136564|NCT04289714|Experimental|Haillie|Smartinhaler Haillie
3136565|NCT04289714|Experimental|Rafi-tone/INCA|Rafi-tone with Flo-tone /INCA
3136566|NCT04288752|Experimental|VR101 Lubricating Intravaginal Ring|VR101 is a clear, flexible, torus-shaped lubricating intravaginal ring (IVR) manufactured from hollow tubing formed from Excipient Grade Thermoplastic Urethane Pathway® Polymer PY-PT42DE35 by hot-melt extrusion. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.
3136567|NCT04288752|Sham Comparator|Sham Ring|"Performance of VR101 will be compared to that of an inactive ring. Subjects randomized to this arm will be asked to use each ring for 7 days and replace with a new ring each week for 4 weeks. This will be followed by an optional 2-week open-label extension with active rings and a 1-week follow-up.~Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added."
3136568|NCT04280705|Placebo Comparator|Placebo|200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
3136569|NCT04280705|Experimental|Remdesivir|200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.
3136570|NCT04287517|Active Comparator|Capacitive-Resistive Therapy Group|This group was treated with capacitive resistive diathermy and exercise
3136571|NCT04287517|Sham Comparator|Sham Group|This group was treated with sham capacitive-resistive diathermy and exercise
3181358|NCT00693069|Active Comparator|1|Clopidogrel 300 mg the day before PCI
3181359|NCT00693069|Experimental|2|Clopidogrel 600 mg the day before PCI
3181360|NCT00693069|Experimental|3|300 mg followed by 75 mg daily started one week prior to angiography
3181361|NCT00693069|Experimental|4|300 mg followed by 150 mg daily started one week prior to angiography
3181362|NCT00693082|Experimental|1|
3181363|NCT00693095|Experimental|1|CMV-ALT + CMV-DCs
3181364|NCT00693095|Experimental|2|CMV-ALT + Saline
3181365|NCT00693108|Experimental|1|Transdermal testosterone treatment during the five days preceding gonadotropin therapy in IVF cycles
3181366|NCT00693108|No Intervention|2|
3181367|NCT00693121|Placebo Comparator|Placebo|Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
3181368|NCT00693121|Active Comparator|Amantadine|Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
3181369|NCT00693134||Myocarditis Patients|Patients initially diagnosed with myocarditis.
3181370|NCT00693134||Control Patients|Patients with no known cardiomyopathies
3181371|NCT00693147|Active Comparator|A|mini Video Assisted Thyroidectomy (miVAT)
3181372|NCT00693147|Active Comparator|B|Classic Total Thyroidectomy
3181373|NCT00693186|Experimental|1|
3181374|NCT00693186|Experimental|2|
3181375|NCT00693199|Experimental|1|
3181376|NCT00693199|Active Comparator|2|
3181377|NCT00693199|Experimental|3|
3181378|NCT00693212|Experimental|a|This arm was only open to subjects entering the second, open-label phase. All subjects were given open-label methylphenidate. Dosing was flexible.
3181379|NCT00693212|Experimental|MPH|This is the active treatment arm of the double-blind placebo controlled phase. Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
3181380|NCT00693212|Placebo Comparator|PBO|This 2 week arm is the placebo part of the crossover design. Subjects receive placebo in a manner similar to the MPH arm. It lasts 2 weeks.
3181381|NCT00693251|Experimental|bifurcation stent technique|crush technique
3181382|NCT00693251|Active Comparator|bifurcation stent techniqe|provisional T stenting
3136572|NCT04287036|Experimental|Test/Control|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Test/Control
3136573|NCT04287036|Experimental|Control/Test|Eligible Subjects aged 18 to 39 years (inclusive) who are habitual soft contact lens wearers will be randomized into sequence, Control/Test.
3136574|NCT04286412|Experimental|Treatment Arm|At least twenty five eligible male subjects will be enrolled in the treatment arm to receive Nonacog alfa until 16 exposure days (EDs) or a period of up to 8 weeks on treatment had occurred (whichever occurs first).
3181383|NCT00693264|Experimental|1|Participants will take 1- 750 mg capsule of Hoodia gordonii and have the primary and secondary outcomes measured over an 8 hour visit.
3136575|NCT04285411|Experimental|ARMS SpO2 70-100%|Comparison to Reference CO-Oximetry
3136576|NCT04284930|Experimental|Depobupivacaine|Group 1 will receive an injection of 166mg of Depobupivacaine diluted in 60 ml.
3181384|NCT00693264|Placebo Comparator|2|Participants will take a placebo capsule and have the primary and secondary outcome measures taken over an 8 hour study day.
3181385|NCT00693290|Active Comparator|1|Fleet plus low residue diet sheet.
3181386|NCT00693290|No Intervention|2|No intervention, usual care, Fleet plus liquid only diet
3181387|NCT00693316|Experimental|ORM-12741|
3181388|NCT00693316|Placebo Comparator|Placebo|
3181389|NCT00693342|Experimental|Arm I|Patients receive polyvalent antigen-KLH conjugate vaccine in combination with OPT-821 subcutaneously (SC) once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
3181390|NCT00693342|Experimental|Arm II|Patients receive OPT-821 SC once in weeks 1, 2, 3, 7, 15, 27, 39, 51, 63, 75, and 87.
3181391|NCT00693355|Experimental|1|sodium butyrate
3181392|NCT00693355|Placebo Comparator|2|NaCl
3136577|NCT04284930|Active Comparator|OnQ Pump|Group 2 : The OnQ group will receive an infiltration via an OnQ soaker catheter of 0.25% bupivacaine at 4 ml/hour.
3136578|NCT04284930|Active Comparator|bupivacaine|Group 3: The 0.25% bupivacaine patients will receive 2mg/kg of 0.25% bupivacaine.
3136579|NCT04283773||Malignant ovarian germ cell tumors ( MOGCTs).|22 cases of malignant ovarian germ cell tumors ; include Dysgerminoma , yolk sac tumor and immature teratomas will be treated by anti P16 antibody and Ki67 antibody.
3136580|NCT04283773||Mature cystic teratomas.|20 cases of mature teratomas will be treated by anti P16 antibody .
3136581|NCT04283773||Normally apparent ovaries.|20 cases of normally apparent ovaries will be treated by anti P16 antibody .
3136582|NCT04281901|Experimental|PVRP treated participants|Participants will receive PVRP in the chronically inflamed radical cavity at the baseline evaluation (day 0) and 1 month later (1. follow-up). There will be 2 additional follow-ups with a 1-month interval.
3136583|NCT04281901|Active Comparator|Standardly treated participants|Participants will receive standard conservative measures for the chronically inflamed radical cavity at the baseline evaluation (day 0), 1 month later (1. follow-up), 2 months later (2. follow-up) and 3 months later (3. follow-up).
3136584|NCT04280653|Experimental|NDE L68 StableFit® punctal plug|Each study subject that qualifies at the baseline visit will receive an NDE L68 StableFit® punctal plug in the lower punctum in one of their eyes. All study plugs will remain in the study subject's lower punctum for a period of 28 + 4 days after insertion
3181393|NCT00693381|Experimental|1|Tacrolimus/MMF/steroids throughout the study
3181394|NCT00693381|Experimental|2|Tacrolimus/MMF/steroids with MMF reduction from week 7 to 12 and MMF discontinuation at month 3
3136585|NCT04277936|Experimental|Levetiracetam (LEV) 500 mg|Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
3136586|NCT04275336|Experimental|EMLA group|The specialist nurse who is to perform IV cannulation determine the puncture site. A thick layer of cream (lidocaine and propiocaine 2.5%/2.5%) will be applied on a 1x1 cm2 area of skin on the cannulation site. The transparent dressing will be left in place for 30 minutes, then remove and clean with a sterile cotton swab. Then nurse performed IV cannulation for them.
3136587|NCT04275336|Experimental|Distraction group|The multiple distractions including toy whistles, cartoon books, a TV showing cartoons, and various electronic products with video games will be provided for the children to choose and play with. They are also taught breathing exercises (i.e. inhaling through the nose for 3 seconds and exhaling for 5 seconds, while they are counting) if they are willing. A play therapist play with the children for 5 min. prior to and throughout the venipuncture procedure.
3136588|NCT04275336|Experimental|Combined group|both EMLA cream and distraction techniques will be used. EMLA cream will be applied on the pre-puncture site for 30 minutes as the EMLA group, then 5 minutes before the venipuncture, the play therapist encourage them to choose their favorite toys to play with or to learn breathing exercises. During IV cannulation the play therapist will also continue distracting the child with toys.
3136589|NCT04272775|Experimental|Cohort 1: Ixazomib 4.0 mg|Ixazomib 4.0 milligram (mg), capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
3181395|NCT00693407|Experimental|1, FD patients|Eighty male and female FD patients according to Rome III criteria (Drossman, 2006), aged 18 to 70 years, will be recruited from primary and secondary care via advertisements and our referral networks
3136590|NCT04272775|Experimental|Cohort 2: Ixazomib 4.0 mg + Lenalidomide and Dexamethasone|Ixazomib 4.0 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 milligram per day (mg/day), capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 62.
3136591|NCT04272775|Experimental|Cohort 3: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle for up to Cycle 87.
3136592|NCT04272775|Experimental|Cohort 4: Ixazomib 5.5 mg + Lenalidomide and Dexamethasone|Ixazomib 5.5 mg, capsules, orally, once, on Days 1, 8, and 15 in 28-day treatment cycle along with lenalidomide 25 mg/day, capsules, orally, once, from Days 1 to 21 and dexamethasone 40 mg/day, tablets, orally, once, on Days 1, 8, 15, and 22 in 28-day treatment cycle for up to Cycle 87.
3136593|NCT04271020|Experimental|UroLift|
3136594|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, B, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, B, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3181396|NCT00693407|Experimental|2,Healthy controls|Forty male and female healthy volunteers, aged 18 to 70 years without any gastrointestinal pathology or history of significant abdominal pain, bowel disorders, bloating or discomfort during the last 3 months will be recruited.
3181397|NCT00693433|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive temsirolimus IV over 30 minutes once weekly on days 1, 8, 15, and 22 and oral dexamethasone once on days 1, 2, 8, 9, 15, 16, 22, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3181398|NCT00693446|Other|2|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time."
3136595|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, C, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, C, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3181399|NCT00693446|Other|1|Patients receive Tacrolimus from day 0 to the end of the study (Arm Tacrolimus).
3136596|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, A, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, A, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3136597|NCT04274075|Experimental|GDC-9545 Treatment Sequence A, C, and B|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence A, C, and B (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3136598|NCT04274075|Experimental|GDC-9545 Treatment Sequence B, A, and C|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence B, A, and C (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3136599|NCT04274075|Experimental|GDC-9545 Treatment Sequence C, B, and A|Participants randomized to this arm will receive one dose of GDC-9545 at the start of each of three periods according to the treatment sequence C, B, and A (refer to the intervention descriptions). The washout period between doses will be a minimum of 10 days.
3136600|NCT04271605|Experimental|behavior intervention and pharmacological therapy|"For participants with abnormal biochemical markers, pharmacological therapy and diet modification are applied.~Dietary education on phosphorus additives is applied specifically for retention of phosphorus or high serum phosphorus level.~Exercise for bone and cardiovascular health.~Osteoporosis medications are initiated according to the reimbursed criteria of National Health Insurance, otherwise medications are used with non-insurance payment."
3136601|NCT04271761||Current adult recipients of Cochlear Carina System|Adults who are current recipients of the Cochlear Carina System. Participants will attend one scheduled visit where several acoustic measurements will be taken that do not require active participation by the participant.
3136602|NCT04268316|Experimental|Virtual Reality Behavioral Activation|Participants randomized to this arm will perform all of their behavioral activation in virtual reality. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable activities to enjoy in virtual reality.
3181400|NCT00693511|Experimental|Circuit Training|Participants received CT exercise training two times per week for approximately 60-90 min per session for 16 wk
3181401|NCT00693511|Experimental|Circuit training + motivational interviewing|Participants in the CT + MI group received the same CT classes but also received four individual MI and four group MI sessions throughout the 16-wk program by two trained research staff
3181402|NCT00693511|No Intervention|Control|No intervention
3181403|NCT00693524|Experimental|1|Tacrolimus + Anti-IL2R AB + Mycophenolate mofetil
3181404|NCT00693524|Active Comparator|2|Tacrolimus + Steroid
3136603|NCT04268316|Active Comparator|Behavioral Activation in real-life|Participants randomized to this arm will perform all of their behavioral activation in real life. Participants will meet with the clinician once a week for three weeks (4 sessions). In between weekly therapy sessions, participants will pick four pleasurable or mastery activities to perform in real life.
3136604|NCT04268316|No Intervention|Waitlist Control|Participants randomized to this arm will not receive any type of intervention and will be asked to complete the PHQ-9 once a week for three weeks (4 sessions) to track symptoms. Participants will be offered to engage in behavioral activation in real life or with virtual reality when the four weeks are complete. Their data will only be used from the time they were on the waitlist.
3136605|NCT04269629||patients with a history of an anaphylactic sting reaction|At Visit 1, patients will be included after carefully reviewing all inclusion and exclusion criteria. All data concerning the index sting, laboratory parameters like immunoglobulin E (IgE) and tryptase levels and skin test results will be recorded as well as the concomitant diseases and medication. Visit 2 will be performed after VIT updosing is finished. At this Visit data concerning the immunotherapy - premedication, preparation, updosing protocol, the outcome of possible large, local reactions (LLR) and systemic reactions (SR) and changes in diseases and medication will be recorded. One year after reaching the maintenance dose, Visit 3 will be performed. At this Visit data concerning the maintenance phase like premedication and possible side effects will be recorded as well as the outcome of insect stings.
3136606|NCT04267575|Experimental|Primary Arm|After the gross solid tumor is removed, cold plasma is sprayed in the area of the resected tumor margins.
3181405|NCT00693537|Experimental|A|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
3181406|NCT00693537|No Intervention|B|Control
3136607|NCT04267770|Experimental|circadian insulin infusion rates|Initial variable basal rates aim to replicate circadian changes in insulin requirements and are derived from total basal insulin in adults over 24 years old, and from weight in adults aged 18 to 24 years.
3136608|NCT04267770|Active Comparator|flat rates|flat basal rate
3136609|NCT04266925|Experimental|3 referees|Three referees were present on the field during these youth soccer matches.
3136610|NCT04266925|Active Comparator|1 referee|One referee was present on the field during these youth soccer matches.
3181407|NCT00693563|No Intervention|Control Group|The Control Group will receive usual care following discharge from the inpatient rehabilitation unit.
3136611|NCT04263142|Experimental|Part 1: Treatment AB|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3136612|NCT04263142|Experimental|Part 1: Treatment BA|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3149456|NCT00178217|No Intervention|Standard Care Control|Subjects will receive standard care at control condition sessions, which includes the use of television, books, CD's, a child life specialist (when available) or other activities to help cope with the procedure.
3181408|NCT00693563|Experimental|Treatment Group|Scheduled Telephone Intervention
3136613|NCT04263142|Experimental|Part 2: Treatment CDE|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3149457|NCT00178360|Experimental|Music Therapy|Subject will participate in one, individual, half-hour long music therapy session every other week and one hour-long group music therapy session each month, for a period of three months.
3149458|NCT00178360|No Intervention|Standard Care|During the Standard Care time period, participants will continue to receive all of the medical care that they would normally receive for the treatment of Huntington's Disease, without the addition of music therapy services.
3136614|NCT04263142|Experimental|Part 2: Treatment DEC|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3136615|NCT04263142|Experimental|Part 2: Treatment ECD|Participants will receive a single dose of GSK3640254 200 mg (Treatment E- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3136616|NCT04256785|Experimental|VSL#3|probiotic VSL#3, 2 sachets b.i.d for 3 months
3136617|NCT04256785|Placebo Comparator|placebo|matched placebo, 2 sachets b.i.d for 3 months
3181409|NCT00693576|Experimental|A|patients who will take simvastatin 20 mg daily
3181410|NCT00693589|Active Comparator|R|Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks
3136618|NCT04252092|Experimental|Sensory Group|15 patients who will be applied 15 sessions of sensory training
3136619|NCT04252092|Experimental|Electrical Stimulation Group|15 patients who will be applied 15 sessions of electrical stimulation
3136620|NCT04251884|Experimental|Receiving the pudendal nerve block|
3136621|NCT04251884|Active Comparator|Not receiving the pudendal nerve block|
3136622|NCT04250987|Experimental|IC connected to a sensor|Single use of a IC connected to a sensor
3136623|NCT04249336|Experimental|BioMin F Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
3136624|NCT04249336|Active Comparator|Colgate Sensitive Pro relief Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
3136625|NCT04249336|Active Comparator|Sensodyne Rapid Action Trade Mark Dentifrices|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
3149459|NCT00178373|Experimental|Modafinil|Modafinil 200 mg taken by mouth once a day. Subjects will take 2 100 mg tablets each morning.
3181411|NCT00693589|Active Comparator|V|Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin
3181412|NCT00693602|Experimental|1|
3181413|NCT00693615|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
3136626|NCT04249336|Placebo Comparator|Colgate Total Trade Mark|Participants will be instructed to dose a dry toothbrush with a full strip of dentifrices and to brush teeth for 1 minute twice daily.
3136627|NCT04249310||Tiotropium/Olodaterol|Combination of Tiotropium and Olodaterol
3136628|NCT04249310||Tiotropium|
3136629|NCT04247581|Other|Cohort 1|This will include subjects with no known history of AF and are in normal sinus rhythm at time of screening
3136630|NCT04247581|Other|Cohort 2|This will include subjects with known persistent or permanent AF who are in AF at the time of screening
3136631|NCT04247061|Experimental|Smoking Cessation intervention|At a dental cleaning visit, participants will watch a brief educational video that provides guidance and advice on smoking cessation. Participants will then interact with a text program for a month to motivate them to use smoking cessation resources. Participants will also be required to make contact with the resources in order to demonstrate feasibility of study flow.
3136632|NCT04245202|Active Comparator|Active Comparator: HFNCOT|Set between 2 to 25 l/min, adjusted to obtain peripheral oxygen saturation >92%.
3136633|NCT04245202|Active Comparator|Active Comparator: St-FMOT|To obtain oxygen saturation >92%
3136634|NCT04243369|Other|Experimental - Collaboration Live software|
3149460|NCT00178373|Placebo Comparator|placebo|Inactive sugar pill, 2 are taken once a day in the morning
3149461|NCT00178412|Experimental|1|Treatment group
3149462|NCT00178412|Active Comparator|2|Comparison Group
3149463|NCT00178490|Experimental|1|Children with high blood pressure who will receive treatment for high blood pressure
3149464|NCT00178490|No Intervention|2|Children with normal blood pressure who will undergo no treatment
3149465|NCT00178620|Active Comparator|I|Retavase 10 U IV Bolus
3181414|NCT00693615|Experimental|Group B|Formulation 2 of the vaccine [with Al(OH)3]
3136635|NCT04241146|Active Comparator|Standard Blind Technique of Tube placement|FDA approved technique of enteral nutrition tube placement
3136636|NCT04241146|Active Comparator|CORTRAK enteral access system (CEAS) placement|An electromagnetic device used to enable enteral nutrition tube placement
3136637|NCT04240678|Experimental|HBV Alert Group|
3136638|NCT04240678|No Intervention|Control Group|
3136639|NCT04238650|Experimental|MB02 (Bevacizumab Biosimilar)|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3136640|NCT04238650|Active Comparator|EU approved Avastin®|Intervention Description: Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3136641|NCT04238663|Experimental|MB02 (Bevacizumab Biosimilar)|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3136642|NCT04238663|Active Comparator|EU approved Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3136643|NCT04238663|Active Comparator|US licenced Avastin®|Sterile vial 400mg/16ml, single-dose 3mg/kg administered as 90-minute infusion on day 1.
3136644|NCT04238429|Experimental|Toothpaste containing effective ingredients|Use the toothpaste containing 10% high cleaning silica base,0.5% sodium phytate and 0.5% sodium pyrophosphate to brush teeth twice daily for 8 weeks
3136645|NCT04238429|Placebo Comparator|Negative control toothpaste|Use the negative control dentifrice to brush teeth twice daily for 8 weeks
3149466|NCT00178620|Other|II|
3149467|NCT00178659||1 healthy volunteers|Healthy volunteers to act as controls - Recruitment is complete for this cohort
3149468|NCT00178659||2 head trauma|Head trauma patients meeting enrollment criteria - Recruitment is complete for this cohort
3181415|NCT00693615|Experimental|Group C|Formulation 3 of the vaccine (without adjuvant)
3136646|NCT04235582|Experimental|Outcomes Group|"During the intervention period, the Outcomes group will receive incentives for abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care and a similar mobile app and debit card as the Inputs group. However, the app will prompt patients in this group to submit saliva drug tests through their mobile phones on a random schedule (averaging three tests per week). Patients will receive immediate financial rewards in exchange for submitting drug-negative samples. Saliva tests typically have a window of detection between 24-48 hr after drug use."
3181416|NCT00693641|Active Comparator|1|"Safe Sea™ jellyfish sting inhibitor (barrier, or repellent) lotion"
3181417|NCT00693641|Placebo Comparator|2|Regular sun lotion
3181418|NCT00693667|Placebo Comparator|A|Placebo
3136647|NCT04235582|Experimental|Inputs Group|"Will receive incentives for behaviors that are inputs to abstaining from drug use. Patients in this group will receive the same services and urine drug-test schedule as standard of care. Additionally, patients will be registered for a mobile phone app provided by DynamiCare Health and provided with a linked debit card. The app will prompt patients to complete actions that are inputs to abstinence an average of three times per week. These actions will be tailored to the patient's individual needs, and may include:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions"
3136648|NCT04235582|Experimental|Combination Group|"Will receive interventions from both Inputs and Outputs groups, as well as standard of care therapy services and urine drug tests an average of three times per week, total. Interventions include incentives for:~Drug adherence to prescribed SUD pharmacotherapy~Attendance at individual and group psychotherapy sessions~Random saliva tests"
3136649|NCT04203225|Active Comparator|Single LET|One (single) application of LET topical gel [Lidocaine (4%), Epinephrine (0.1%), and Tetracaine (0.5%)] applied for 30 minutes
3181419|NCT00693667|Active Comparator|B|250 mg active ingredient
3181420|NCT00693667|Active Comparator|C|500 mg active ingredient
3181421|NCT00693667|Active Comparator|D|750 mg active ingredient
3136650|NCT04203225|Experimental|Triple LET|Three applications of LET topical gel, one applied every 10 minutes
3136651|NCT04234672|Experimental|TAK-831 500 mg + [14C]TAK-831 50 μg + [14C]TAK-831 500 mg|TAK-831 500 mg, tablet, orally, once on Day 1, followed by [14C]TAK-831 50 micrograms (μg) [approximately 1 microcurie (μCi)], infusion, intravenously (IV), once on Day 1 of Treatment Period 1, followed by a washout period of 8 days, further followed by [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, once under fasted state on Day 1 of Treatment Period 2.
3136652|NCT04223635|Experimental|Hepatic impaired|Participants with moderate hepatic impairment who will receive a single oral dose of pexidartinib.
3136653|NCT04223635|Experimental|Healthy controls|Sex-, age-, and weight-matched healthy participants who will receive a single oral dose of pexidartinib.
3181422|NCT00693680|Active Comparator|1|zinc + imipramine
3181423|NCT00693680|Placebo Comparator|2|placebo + imipramine
3181424|NCT00693732|Active Comparator|1, IBS patients|
3181425|NCT00693732|Experimental|2,Healthy controls|
3181426|NCT00693758|No Intervention|1|healthy volunteers without intervention
3181427|NCT00693758|No Intervention|2|patients with suspected coronary artery disease without intervention
3136654|NCT04214951||Recombinant human thrombopoietin (rh-TPO) group|Patients who fail previous steroids and eltrombopag and then switch to Rh-TPO will be enrolled. The reason for switch will be recorded. Patients will be given rh-TPO 300 U/kg once daily for 21 days. Rh-TPO will be terminated any time the platelet counts increased above 100 × 10^9/L. The efficacy, safety, and patient/physician preference will be assessed.
3136655|NCT04214951||Eltrombopag group|Patients who fail previous steroids and rh-TPO and then switch to eltrombopag will be enrolled. The reason for switch will be recorded. Patients will be given eltrombopag 50mg once daily for 6 weeks. Eltrombopag will be terminated any time the platelet counts increased above 300× 10^9/L.The efficacy, safety, and patient/physician preference will be assessed.
3136656|NCT04234425|Experimental|Experimental Group|18 high school students in a weight training class will be assigned to this experimental group and will receive the one-hour intervention twice weekly for 8 weeks.
3181428|NCT00693758|Experimental|3|Healthy volunteers during adenosine infusion
3181429|NCT00693758|Experimental|4|Healthy volunteers during changes of breathing gases (CO2, O2)
3136657|NCT04232137|Experimental|Coffee ceremony|Antenatal care patients will be told on their first antenatal care visit that a postpartum coffee ceremony will be organized for them and up to 4 relatives
3136658|NCT04232137|No Intervention|NO Coffee ceremony|Antenatal care patients will be told that they will NOT receive a postpartum coffee ceremony, as is the current status quo
3136659|NCT04222699|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
3136660|NCT04208698|Experimental|CIN-102 Tablets Dose 1|CIN-102 tablets by mouth twice daily for 14 days
3136661|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 1|Placebo tablets by mouth twice daily for 14 days
3181430|NCT00693758|Experimental|5|patients with suspected coronary artery disease during adenosine infusion
3181431|NCT00693758|Experimental|6|patients with suspected coronary artery disease during changes of breathing gases
3136662|NCT04208698|Experimental|CIN-102 Dose 2|CIN-102 tablets by mouth twice daily for 14 days
3136663|NCT04208698|Placebo Comparator|Placebo for CIN-102 Dose 2|Placebo tablets by mouth twice daily for 14 days
3181432|NCT00693758|Experimental|7|Assessment of reactive hyperemia in arms of healthy volunteers to improve sequences
3181433|NCT00693771|Experimental|1|
3181434|NCT00693797||I, observation|patients with aortic stenosis
3181435|NCT00693797||II, observation|patients with aortic stenosis
3181436|NCT00693823|Active Comparator|1|Femoral-popliteal surgical bypass with prosthetic graft
3181437|NCT00693823|Active Comparator|2|Interventional angioplasty and placement of an ePTFE covered stent graft within the femoral-popliteal artery as an endoluminal bypass percutaneously
3181438|NCT00693849|Active Comparator|A|Escitalopram
3181439|NCT00693849|Active Comparator|B|Sertraline
3136664|NCT04206293|Experimental|Juvéderm® VOLITE|Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
3136665|NCT04228302|Experimental|EC5026|Single Ascending Doses of oral EC5026
3136666|NCT04228302|Placebo Comparator|Placebo|Single doses of matching oral placebo
3181440|NCT00693849|Active Comparator|C|Venlafaxine-XR
3181441|NCT00693849|No Intervention|D|Healthy matched controls
3181442|NCT00693862|Experimental|Stalevo|
3181443|NCT00693862|Active Comparator|levodopa/carbidopa|
3136667|NCT04227119|Experimental|Irrigated ablation catheter and 5F balloon tipped PA catheter|Participants undergoing cardiac ablation will have cardiac pressures measured with an irrigated ablation catheter (standard protocol for this procedure) and a 5F balloon tipped pulmonary artery (PA) catheter (for study purposes only).
3136668|NCT04224753|Experimental|INVSENSOR00027 Test group|The subjects will be enrolled into the test group and will receive the INVSENSOR00027 investigational sensor.
3136669|NCT04218799|Experimental|Intranasal Mupirocin and Topical Chlorhexidine|
3181444|NCT00693888|Experimental|interventional group|individual comprehensive primary advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)
3136670|NCT04204057|Experimental|Tenalisib|Patients receive Tenalisib 800 mg BID, Orally in 28-Day cycle for 7 cycles
3181445|NCT00693888|No Intervention|Control group|only informative flyer, no further advice in any direction
3136671|NCT04195594|Experimental|Nic's Keto Diet|
3136672|NCT04223687|Experimental|Sugar-Sweetened Beverage Warning Label|
3136673|NCT04223687|Other|Neutral label|
3136674|NCT04223232|Experimental|MD1003|radiolabeled 14C MD1003 (High Dose Biotin) 100mg
3136675|NCT04189224|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Test/Control.
3136676|NCT04189224|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized to sequence, Control/Test.
3136677|NCT04214600|Experimental|Cognitive Behavioral Therapy|This group will receive four CBT sessions twice a month for two months
3136678|NCT04214600|No Intervention|Control|This group will be scheduled the same number of visits as a follow up for diabetes
3136679|NCT04202497|Experimental|TAK-418 1.5 mg|TAK-418 1.5 milligram (mg), orally, once on Day 1. Participants will also receive 10 millicurie (mCi) of [18F]MNI-1054 injection intravenously, prior to each PET scans on Day -1, Day 1, and either on Day 2 or 3. Dose levels for subsequent participants may vary based on available review of imaging and pharmacokinetics (PK) data.
3136680|NCT04214080|Experimental|Study Group (SG)|"In addition to feeding and oral motor intervention strategies, intensive neck and trunk stabilization exercises based on Neurodevelopmental treatment-Bobath (NDT-B) concept principles were applied to this group.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
3136681|NCT04214080|Placebo Comparator|Control Group (CG).|"(NDT-B) concept approaches and feeding and oral motor intervention strategies were applied to this group in routine treatment.~Treatments were continued 2 days a week for 6 weeks (12 sessions)."
3136682|NCT04209530|Experimental|Buttock & Posterolateral Thigh|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
3136683|NCT04209335|Other|healthy working age population|isometric core muscle endurance tests (McGill V-sit, Biering-Sorensen and sideplank)
3136684|NCT04207333|Experimental|Prolonged Sitting + Mental Stress, Then Brief Sitting + Mental Stress|Participants will sit for 120 min prior to being exposed to mental stress Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 120 minutes while watching a documentary. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (brief sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Following the 10 minutes quiet rest in the seated position, participants will be subjected to a 5 minute mental arithmetic test.
3181446|NCT00693901|Experimental|1|Parks will be assigned to the community-based participatory research condition.
3149469|NCT00178659||3 orthopedic injury|"The orthopedic injury cohort will include patients admitted to the ED able to provide informed consent with the following:~Fracture confirmed radiographically~No head trauma~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
3181447|NCT00693901|Active Comparator|2|Parks will be assigned to the director-only condition.
3181448|NCT00693901|No Intervention|3|Parks will be assigned to the control condition and will receive no intervention.
3181449|NCT00693914||1: Brain Tumor Survivors (n=50)|
3181450|NCT00693914||2: Healthy Sibling Controls (n=40)|
3181451|NCT00693914||Solid Tumor Survivors (n=40)|
3181452|NCT00693927|Active Comparator|1|Unmanipulated PBSC
3136685|NCT04207333|Experimental|Brief Sitting + Mental Stress, Then Prolonged Sitting + Mental Stress|Following 10 minutes of supine rest, participants will switch to an upright sitting position and remain seated for 10 minutes. Following the 10 minutes quiet rest the participants will be subjected to a 5 minute mental arithmetic test. Following a 2-5 day wash-out period, participants will be exposed to the other condition (prolonged sitting, followed by mental stress). For this condition participants will rest in the supine position for 10 minutes, then will be switched to an upright seated position. Participants will sit quietly for 120 min while watching a documentary, following which the participants will be subjected to a 5 minute mental arithmetic test.
3136686|NCT04207840|Experimental|Primatene Mist, E004|Participants who dosed with Primatene Mist.
3136687|NCT04207840|Active Comparator|Epinephrine Injection Auto-Injector (Generic of EpiPen)|Participants who were dosed with an Epinephrine Injection Auto-Injector.
3136688|NCT04207840|Active Comparator|Albuterol HFA|Participants who dosed with Albuterol HFA.
3181453|NCT00693927|Experimental|2|CD8-Depleted PBSC
3181454|NCT00693940|Experimental|1|Participants will receive treatment with group mediated cognitive behavioral sessions.
3181455|NCT00693940|Active Comparator|2|Participants will receive treatment with health education sessions.
3181456|NCT00693953||1|Year one
3181457|NCT00693953||2|Year two
3181458|NCT00693966|Experimental|Group A|Formulation 1 of the vaccine (MEDI-517 HPV-16/18 VLP AS04 vaccine)
3181459|NCT00693966|Experimental|Group B|Formulation 2 of the vaccine
3181460|NCT00693966|Experimental|Group C|Formulation 3 of the vaccine
3181461|NCT00693966|Experimental|Group D|Formulation 4 of the vaccine [with Al(OH)3]
3181462|NCT00694005|Active Comparator|bifurcation stent techniqe|"cross over stenting without kissing balloon angioplasty leave alone"
3181463|NCT00694005|Experimental|bifurcation stent technique|kissing balloon angioplasty
3181464|NCT00694031|Active Comparator|A|Hemodialysis
3181465|NCT00694031|Experimental|B|On-line hemodiafiltration
3181466|NCT00694044|Active Comparator|Weekly titration|
3181467|NCT00694044|Active Comparator|Two Week QD|
3181468|NCT00694044|Active Comparator|Two Week BID|
3181469|NCT00694044|Placebo Comparator|Placebo|
3181470|NCT00694057|Placebo Comparator|Placebo|Placebo capsules BID
3181471|NCT00694057|Experimental|Active|HE3286 10 mg (5 mg BID)
3181472|NCT00694083|Experimental|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles).
3136689|NCT04206800|No Intervention|Routine care|Routine care is normally having men abstain from ejaculation from 2 to 5 days prior to the scheduled oocyte retrieval date. Men in the routine care arm will abstain from ejaculation greater than 48 hours before providing a semen sample the day of the scheduled oocyte retrieval.
3136690|NCT04206800|Experimental|Ejaculatory abstinence less than 24 hours|Males will ejaculate within 24 hours of the scheduled oocyte retrieval date.
3136691|NCT04205669|Active Comparator|Individual Treatment|
3181473|NCT00694135|Active Comparator|EGP-437 1.6 mA-min at 0.4 mA|Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA
3136692|NCT04205669|Active Comparator|Household Treatment|
3181474|NCT00694135|Active Comparator|EGP-437 4.8 mA-min at 1.2 mA|Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA
3136693|NCT04198948|Experimental|Omeprazole, Then Placebo|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.
3136694|NCT04198948|Experimental|Placebo, Then Omeprazole|Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.
3181475|NCT00694135|Active Comparator|EGP-437 10.0 mA-min at 2.5 mA|Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA
3181476|NCT00694135|Active Comparator|EGP-437 14.0 mA-min at 3.5 mA|Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA
3181477|NCT00694174|Active Comparator|1|2 ml sucrose 25% oral solution one time only dose by mouth
3181478|NCT00694174|Placebo Comparator|2|sterile water 2 ml one time only dose given by mouth prior to heel lance
3181479|NCT00694200|Experimental|1|Vinorelbine metronomic + bevacizumab
3181480|NCT00694213|Experimental|1|
3181481|NCT00694213|Experimental|2|
3181482|NCT00694213|Experimental|3|
3181483|NCT00694213|Placebo Comparator|4|
3188811|NCT00771017|Active Comparator|Arm I|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment comprising leuprolide acetate or goserelin intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
3136695|NCT04206384|Experimental|Treatment group|Each patient shall receive a total of 3 treatments. Each treatment shall consist of applying the ultrasound device for 30 minutes to the skin surface, working the device methodically over the abdominal area. The device shall be set at the maximum emission level, have an intensity of approximately 1.0 watt/cm^2.
3136696|NCT04204200|Active Comparator|Allocated to conventional vitamin C (n= 22)|"Received allocated conventional vitamin C (n= 22)~Did not receive allocated conventional vitamin C (n= 0)"
3136697|NCT04204200|Active Comparator|Allocated to liposomal vitamin C (n= 22)|"Received allocated liposomal vitamin C (n= 22)~Did not receive allocated liposomal vitamin C (n= 0)"
3188812|NCT00771017|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive GVAX prostate cancer vaccine (CG1940 and CG8711) intradermally (ID) on day 1. Beginning on day 1 of week 3, patients receive booster doses of CG1940 and CG8711 ID every 2 weeks for 24 weeks.
3136698|NCT04204200|Placebo Comparator|Allocated to placebo (n= 22)|"Received allocated intervention (n= 22)~Did not receive allocated intervention (n= 0)"
3136699|NCT04196907|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse Oximeter and DCI Mini sensor for measurement of hemoglobin.
3136700|NCT04195893|Experimental|somofilcon A|Subjects will be randomized to wear somofilcon A daily disposable lenses for one week and then switch to etafilcon A daily disposable lenses for one week.
3136701|NCT04195893|Active Comparator|etafilcon A|Subjects will be randomized to wear etafilcon A daily disposable lenses for one week and then switch to somofilcon A daily disposable lenses for one week.
3136702|NCT04195880|Experimental|Experimental VA Community Living Centers|Eight VA CLCs selected to receive the INTERACT intervention
3136703|NCT04195880|No Intervention|Control VA Community Living Centers|Eight CLCs, matched to experiment CLCs, based on size, location to VAMC, and hospitalization rates, did not receive the intervention and continued care as usual
3136704|NCT04195581|Experimental|comfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
3136705|NCT04195581|Experimental|comfilcon A with All in One Light Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
3136706|NCT04195581|Experimental|comfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
3136707|NCT04195581|Active Comparator|fanfilcon A with Hy-Care Multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
3136708|NCT04195581|Active Comparator|fanfilcon A with All in One Light multi-purpose solution|Subjects were randomized to wear each lens and solution combination for a month.
3136709|NCT04195581|Active Comparator|fanfilcon A with Refine One Step Hydrogen Peroxide Solution|Subjects were randomized to wear each lens and solution combination for a month.
3136710|NCT04194151|Active Comparator|2 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 2 mg/kg of propofol
3136711|NCT04194151|Active Comparator|2 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1,5 mg/kg of propofol
3136712|NCT04194151|Active Comparator|2 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 2 minutes to inject 1 mg/kg of propofol
3136713|NCT04194151|Active Comparator|1 minute - 2 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 2 mg/kg of propofol
3136714|NCT04194151|Active Comparator|1 minute - 1,5 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1,5 mg/kg of propofol
3136715|NCT04194151|Active Comparator|1 minute - 1 mg/kg group|2 mcg/kg of fentanyl administrated intravenously. wait for 1 minute to inject 1 mg/kg of propofol
3136716|NCT04194008|Experimental|Nerivio device treatment|Treatment with active Nerivio device
3188813|NCT00771043|No Intervention|TYSABRI|
3188814|NCT00771043|No Intervention|AVONEX|
3136717|NCT04191668|Other|PSG and NightOwl|Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent. All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
3136718|NCT04189081|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
3136719|NCT04189081|Sham Comparator|Water Control|Water will be used as a mouth rinse and can be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using water, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
3136720|NCT04189081|Active Comparator|Positive Control|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds for a week. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 6-hours after first use (at-home) on Day 1 and Day 8. There are no eating or drinking restrictions Day 2-Day 7.
3136721|NCT04186780|Experimental|Intervention group|Intervention group: patients with borderline cholesterol consumed two cereal bars with Shiitake per day for 66 days.
3136722|NCT04186780|Placebo Comparator|Placebo group|Patients with borderline cholesterol consumed two placebo cereal bars for 66 days.
3136723|NCT04186806|Experimental|3M Dry Mouth Moisturizing Spray|Dry mouth agent
3136724|NCT04186806|Active Comparator|Biotene Moisturizing Mouth Spray|Dry mouth agent
3136725|NCT04186481||Minitac Ti 2.0 suture anchor|Subjects who have undergone extremities repair using the Minitac Ti 2.0 Suture anchor
3136726|NCT04184999|Experimental|Intracameral dexamethasone 9% + postoperative topical prednisolone acetate|dexamethasone intraocular suspension, 9% injected intracamerally at the time of cataract surgery + topical ophthalmic prednisolone acetate for 3 weeks post-operatively
3188815|NCT00771069||1|Type II Diabetes Mellitus patients with Complication and Hypertension
3181484|NCT00694226|Experimental|1|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
3181485|NCT00694226|Active Comparator|2|Treatment as usual (TTU): Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol. After completing the assessment individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis
3181486|NCT00694239|No Intervention|B|Standard Care
3181487|NCT00694239|Experimental|A|Risk Assessment plus standard care
3181488|NCT00694252|Experimental|1|Lapatinib
3181489|NCT00694265||1|Surgical treatment
3136727|NCT04184999|Active Comparator|postoperative topical prednisolone acetate|topical ophthalmic prednisolone acetate for 3 weeks post-operatively
3136728|NCT04184271|Experimental|38% silver diamine fluoride|38% silver diamine fluoride, topical, 1 drop, single application
3136729|NCT04183231|Experimental|Anti-caries varnish|topical dental varnish, 10% PVP-I, 2.5% NaF, topical application to teeth, 0.4 ml, single application
3136730|NCT04182958|Experimental|(14C)-OPC-61815|
3181490|NCT00694265||2|Conservative treatment
3181491|NCT00694291|Experimental|1|Sorafenib 400 mg orally twice daily
3136731|NCT04179838|Experimental|Sleep-Deprived first, then Non-Sleep Deprived|Participants will first be tested after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with normal sleep (non-sleep deprived, 8 h sleep).
3136732|NCT04179838|Experimental|Non-Sleep Deprived first, then Sleep-deprived|Participants will first be tested after 1 night with normal sleep (non-sleep deprived, 8 h sleep). After a washout period of 4 weeks, they will be tested again after 1 night with partial sleep deprivation (sleep-deprived, 4 h sleep).
3136733|NCT04179461|Experimental|Personalized Treatment|"Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention."
3181492|NCT00694291|Placebo Comparator|2|Placebo
3181493|NCT00694330|Experimental|GM-K562 Vaccination|
3136734|NCT04179474|Experimental|Part 1 (Intervention A then B then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention B: Single subcutaneous (SC) injection of erenumab 140 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
3136735|NCT04179474|Experimental|Part 2 (Intervention A then C then D)|Intervention A: Single oral dose of ubrogepant 100 mg tablet on Day 1 under fasted conditions; followed by Intervention C: Two SC injections of galcanezumab 120 mg on Day 8; followed by Intervention D: Ubrogepant 100 mg tablet orally once daily on Days 12, 13, 14 and 15 under fasted conditions.
3136736|NCT04178590|Experimental|SRP + Injectable Platelet-Rich Fibrin|Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin
3136737|NCT04178590|Placebo Comparator|SRP + placebo|Scaling and root planing in conjunction with saline
3136738|NCT04177862|Experimental|Sublingual Sufentanil|Single dose of sublingual sufentanil for acute pain.
3136739|NCT04177862|Active Comparator|IV Fentanyl|single dose of IV fentanyl for acute pain.
3181494|NCT00694343|Experimental|Group A|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
3181495|NCT00694343|Active Comparator|Group B|1000 mL Ringer's Lactate solution
3181496|NCT00694382|Experimental|Semuloparin|Semuloparin sodium 20 mg once daily until change in chemotherapy regimen
3136740|NCT04176406|Active Comparator|rTMS over a node within the fronto-parietal network|excitatory 5Hz rTMS will be applied over a node within the fronto-parietal network, defined via network analysis.
3136741|NCT04176406|Sham Comparator|Sham rTMS over a node within the fronto-parietal network|electrical sham coil applied over a node within the fronto-parietal network.
3136742|NCT04176406|Active Comparator|rTMS over the DLPFC|excitatory 5Hz rTMS will be applied over the dorso-lateral prefrontal cortex showing the strongest fMRI activation.
3136743|NCT04176406|Sham Comparator|Sham rTMS over the DLPFC|electrical sham coil applied over the DLPFC.
3136744|NCT04175262||Patients with mRCC|Patients diagnosed with metastatic RCC receiving first line (1L) combination of IOs therapies followed by Sunitinib as a second line (2L) treatment
3136745|NCT04171102|Active Comparator|Short term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-5 weeks post implantation
3136746|NCT04171102|Active Comparator|Mid term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 3-4 months post implantation
3136747|NCT04171102|Active Comparator|Long term post inguinal hernia repair wit ProFlor|Determining presence and level of maturation of nervous structures in the hernia implant named ProFlor at 6-8 months post implantation
3136748|NCT04175509|Active Comparator|Rectal acetaminophen|Patients will receive two 650mg suppositories rectally of acetaminophen for a total dose of 1300mg at the end of surgery.
3136749|NCT04175509|Active Comparator|Intravenous acetaminophen|Patients will receive one dose of 1000mg of acetaminophen, administered intravenously, at the end of surgery.
3181497|NCT00694382|Placebo Comparator|Placebo|Placebo (for semuloparin) once daily until change in chemotherapy regimen
3181498|NCT00694408|Active Comparator|Steroid immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid containing immunosuppression regimen post transplant. This group of patients will receive steroids in conjunction with other prescribed immunosuppressive agents. Intervention is use of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management
3136750|NCT04174638|Experimental|"Intervention Group"|The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring.
3181499|NCT00694408|Active Comparator|Steroid free immunosuppressive regimen|Freedom from rejection and safety in children undergoing paediatric liver transplant using steroid free immunosuppression regimen post transplant. The patients in this arm will receive immunosuppression but not steroids to compare with those treated with steroids to measure differences in rejection and safety of a steroid free immunosuppressive regimen. Intervention is omission of methyl prednisolone, hydrocortisone, prednisolone as routine post transplant management. No steroids will be used routinely in this arm
3188816|NCT00771095|Active Comparator|Control (available) podcast|
3136751|NCT04174638|No Intervention|"Control Group"|The control group received routine hemodialysis treatment and nursing care in the hemodialysis unit.
3136752|NCT04174313||VILI VORTEX and No VILI VORTEX|Measurement of pulmonary pressures and volumes in the same patient
3136753|NCT04173429|Experimental|nadroparin calcium-warfarin sequential therapy group|nadroparin calcium every 12 hours for 1 month followed by an oral administration of warfarin for 5 months
3136754|NCT04173429|No Intervention|Control group|No anticoagulation therapy.
3136755|NCT04173741||Leg Rise Position - 3 Minutes|Patients who stayed in passive leg rise position for 3 minutes
3136756|NCT04173741||Leg Rise Position - 1 Minute|Patients who stayed in passive leg rise position for 1 minute
3181500|NCT00694421||1|"adults who participate in study, Social and Psychological Risks for Infectious Disease here at Children's Hospital of Pittsburgh"
3188817|NCT00771095|Experimental|Enhanced podcast|
3136757|NCT04169061|Experimental|All participants|"Participants receive:~a shot of Acthar (80 units) under the skin twice a week for 12 weeks~a shot of Acthar (40 units) twice a week for 2 weeks~a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms."
3136758|NCT04157738|Experimental|Fixed Group|Children and adolescents with newly-diagnosed T1DM will receive a fixed mealtime carbohydrate with a fixed mealtime insulin dose, that is a simplified regimen that provides a set amount of insulin for a set amount of carbohydrates, and ensures that each dose and each meal is consistent.
3136759|NCT04157738|Active Comparator|Insulin to carbohydrate ratio (ICR) Group|Children and adolescents with newly-diagnosed T1DM will receive an Insulin to carbohydrate ratio (ICR) with variable carbohydrate intake mealtime regimen
3181501|NCT00694421||2|"children 2-6 years who participate in Role of Virus and Genetic Susceptibility study here at Children's Hospital of Pittsburgh"
3136760|NCT04156646|Experimental|Treatment sequence ABC|In Period 1 participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
3181502|NCT00694434||1|Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle.
3181503|NCT00694434||2|Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle.
3136761|NCT04156646|Experimental|Treatment sequence BAC|In Period 1 participants will receive 1 tablet of balovaptan after 10-hour fast. In Period 2, after 12 to 21 days wash-out, participants will receive 1 tablet of balovaptan after high-fat, high-calorie meal. In Period 3 participants will receive esomeprazole administered once daily for 6 days and with a single oral dose of balovaptan in the fasted state 1 hour after the fifth esomeprazole dose
3136762|NCT04170686|Experimental|Immediate Treatment|Participants will have immediate access to the self-help app. They will take 8 weeks to work through the content at their own pace.
3181504|NCT00694447|Experimental|Real acupuncture|Real acupuncture
3181505|NCT00694447|Sham Comparator|Sham acupuncture|Sham acupuncture
3181506|NCT00694460|Experimental|1|
3181507|NCT00694460|Experimental|2|
3181508|NCT00694460|Experimental|3|
3181509|NCT00694460|Experimental|4|
3181510|NCT00694460|Active Comparator|5|
3181511|NCT00694486||1|Healthy adult volunteers
3181512|NCT00694499||Observation|Patients with blunt liver injury
3181513|NCT00694512|Placebo Comparator|1|low fat diet for two weeks.
3181514|NCT00694512|Active Comparator|2|High fat diet for two weeks followed by blood sampling.
3181515|NCT00694512|Active Comparator|3|Medium Chain Triglyceride diet
3181516|NCT00694525||1|Women in this group will have 21-OHD CAH.
3181517|NCT00694525||2|Women in this group will be healthy controls and will not have 21-OHD CAH.
3136763|NCT04170686|No Intervention|Waitlist Control|"Participants in the waitlist will receive no intervention for 8 weeks, other than a few check in emails from study personnel. At the end of 8 weeks, they will be crossed over to the active treatment group and will be given access to the app."
3136764|NCT04169113|Active Comparator|Group 1 - Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
3136765|NCT04169113|Active Comparator|Group 2 - Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
3136766|NCT04160975|Experimental|Black R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
3136767|NCT04160975|Experimental|Black R/Race C/Layperson/Standard Script|Video which contains a racially concordant actor playing a layperson and reading a standard script. The receiver of the message will be Black.
3136768|NCT04160975|Experimental|Black R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be Black.
3136769|NCT04160975|Experimental|Black R/Race D/Doctor/Acknowledgement Script|Video which contains a racially discordant actor playing a doctor and reading an acknowledgement script. The receiver of the message will be Black.
3136770|NCT04160975|Experimental|White R/Race C/Doctor/Standard Script|Video which contains a racially concordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
3181518|NCT00694538|Active Comparator|1|100 patients are being treated with a single laser beam over pain area.
3136771|NCT04160975|Experimental|White R/Race D/Doctor/Standard Script|Video which contains a racially discordant actor playing a doctor and reading a standard script. The receiver of the message will be White.
3136772|NCT04153409|Experimental|Active|Subjects will be given two 30 mg capsules of the investigational medicinal product (LAT8881), and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
3136773|NCT04153409|Placebo Comparator|Placebo|Subjects will be given two capsules of placebo, and instructed to take both capsules within the first hour of the onset of a migraine of moderate to severe intensity.
3149470|NCT00178659||4 Mild TBI|"The mild TBI patients will be defined as those admitted to the ED experiencing, - Recruitment is complete for this cohort~Non-penetrating head trauma manifesting one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Altered mental status~Focal neurologic deficits, seizure~GCS> 12~No abnormalities on CT other than contusion~No operative Lesions~Length of hospital stay < 48 hrs~No other known inflammatory process or infection~No history of neurological or psychiatric disorders or alcohol or drug dependency"
3149471|NCT00178698|Other|1|Thermochemotherapy
3149472|NCT00178724||No Treatment Given|Any male or female 18 years or older admitted to a NACTN hospital, at the time of injury, with an initial (first time) spinal cord injury caused by trauma and has paralysis (muscle weakness) or loss of sensation (touch). The patient has not received medical or surgical care for this injury prior to admission to a NACTN hospital. Patient or family member must give consent to participate.
3136774|NCT04151628|Experimental|Coronary Lithotripsy System|All subjects will receive lithotripsy treatment from the Shockwave Medical Coronary IVL System
3136775|NCT04167189|Other|Observational study of prevalence in hard-to-treat ADHD|Subjects will be tested with lidocaine gel.
3181519|NCT00694538|Experimental|2|100 patients are being treated with interferential laser from two independent sources
3136776|NCT04162795|Experimental|Loratadine chewable tablet|Participants received one dose of loratadine chewable tablet to chew completely before swallowing.
3181520|NCT00694577|Experimental|Group 1|Study Participants 1-100 Partial Breast Irradiation using 32 Gy / 8 fractions BID in one week
3136777|NCT04161807|Experimental|Nerivio device treatment|participant will receive the Nerivio device for treating their migraine attacks. Treatment will be perform as soon as the participant feel that the migraine attack started
3136778|NCT04161144|Active Comparator|Rapamycin 15mg (sirolimus)|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
3136779|NCT04161144|Placebo Comparator|Placebo|Participants will receive three 5mg pills from a nurse in the Research Nexus, some participants will receive the study medication and others will be randomized to the placebo control group.
3136780|NCT04161131|Experimental|ONBOARD Intervention|ONBOARD consists of four 60-minute sessions over 3 months. Each session will target a key barrier to CGM use: physical, data, social, and trust. Sessions will be delivered individually to participants by a doctoral level psychologist with diabetes expertise. Each session will include relevant first-person digital stories told adults to with T1D, recounting how they managed relevant CGM barriers.
3136781|NCT04161079||MAR population|Subjects, who underwent MV repair operation with successful MAR implantation in clinical investigation 2010-040
3149473|NCT00178763|Experimental|1|All protocol subjects are treated with fever-range whole-body thermal therapy combined in an optimized schedule with cisplatin + gemcitabine + metronomic low-dose interferon-alpha
3149474|NCT00178776|Experimental|Transtheoretical Model Group|
3149475|NCT00178776|Active Comparator|Education / Advice|
3149476|NCT00178802|Other|1|thermochemotherapy using fever-range whole-body thermal therapy combined with continuous infusion 5-fluorouracil, Doxil, and low-dose interferon-alpha.
3149477|NCT00178880||Healthy volunteers|
3149478|NCT00178880||Depressed patients|
3149479|NCT00178971|Active Comparator|1|buspirone 15-30 mg qd
3149480|NCT00178971|Placebo Comparator|2|placebo
3149481|NCT00178984||poor blood flow|Group with partial ischemia to the small intestine
3136782|NCT04158466|Experimental|Kalifilcon A Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb kalifilcon A daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
3149482|NCT00178984||Good blood flow|Group with normal blood flow, given different conditions to effect electrical currents in normal smooth muscle
3136783|NCT04158466|Active Comparator|Biotrue ONEday Daily Disposable Contact Lenses|Participants will wear Bausch + Lomb Biotrue ONEday daily disposable contact lenses for at least 8 hours per day at least 5 days per week for approximately 3 months. Participants will be provided with Bausch + Lomb Sensitive Eyes Drops for use as needed during the study and lens cases for return of worn study lenses to the Investigator at the end of the study.
3136784|NCT04152083|Experimental|Eptinezumab|Participants will receive a single dose of eptinezumab 100 milligrams (mg) administered via intravenous (IV) infusion on Day 0.
3136785|NCT04152083|Placebo Comparator|Placebo|Participants will receive a single dose of placebo matching to eptinezumab administered via IV infusion on Day 0.
3149483|NCT00178997||Good blood flow|Group without ischemia to the small intestine
3149484|NCT00178997||Poor blood flow|Groups that have partial ischemia to their small intestine
3136786|NCT04155567|Experimental|TAK-123|TAK-123 as 3.75 gram per square meter (g/m^2) of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 90 minutes, followed by TAK-123 as 3.75 g/m^2 of sodium phenylacetate and 3.75 g/m^2 of sodium benzoate, intravenous administration over 24 hours.
3136787|NCT04155047|Active Comparator|Glycopyrrolate Inhalation Solution|Glycopyrrolate Inhalation Solution 25mcg administered by Magnair
3136788|NCT04155047|Placebo Comparator|Placebo|Placebo Inhalation Solution administered by Magair
3136789|NCT04152642|Active Comparator|Marketed Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
3136790|NCT04152642|Experimental|Experimental Mouth Rinse|dry mouth rinse to be taken up to 5x a day, at least twice a day, 15 ml for 30 seconds. Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after first use (on-site) on Day 1 and Day 4.
3136791|NCT04152642|Sham Comparator|Water/Negative Control|subjects will swallow 15 ml of water (on-site). Subjects will be restricted from using mouth rinse, acclimation products, eating or drinking for 4-hours after water intake (on-site) on Day 1 and Day 4.
3136792|NCT04150861|Experimental|Follitropin delta 12 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 12 μg on Day 1.
3136793|NCT04150861|Experimental|Follitropin delta 18 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 18 μg on Day 1.
3136794|NCT04150861|Experimental|Follitropin delta 24 μg|Participants received single subcutaneous abdominal injection of Follitropin delta 24 μg on Day 1.
3149485|NCT00179023|Other|Part 1|Estimation of resting energy expenditure and effect of autonomic blockade with trimethaphan infusion.
3149486|NCT00179023|Other|Part 2 (closed)|Estimation of autonomic function and effect of autonomic blockade with trimethaphan infusion.
3149487|NCT00179023|Other|Part 3|Estimation of energy metabolism and effect of sympathetic stimulation with pseudoephedrine.
3149488|NCT00179023|Other|Part 4a (closed)|Isoproterenol sensitivity in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
3136795|NCT04150250|Experimental|iOWH032|On Day 1, participants were challenged with 10^6 colony-forming units (CFU) of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral iOWH032 500 mg tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
3136796|NCT04150250|Placebo Comparator|Placebo|On Day 1, participants were challenged with 10^6 CFU of freshly-harvested wild-type V. cholerae. At the onset of diarrhea, or at 48 hours after challenge, whichever occurred first, participants received oral matching iOWH032 placebo tablets every 8 hours for 3 days. Participants received a 3-day course of antibiotics starting 4 days post-challenge, or sooner if the participant met the criterion for severe cholera diarrhea.
3136797|NCT04149925||AEON Endostapler|Stapling performed by AEON Endostapler
3136798|NCT04149925||Echelon Flex Powered Stapler|Stapling performed by Echelon Flex Powered Stapler
3136799|NCT04150224|Experimental|Cohort 1 (C1A), PBTZ169|Two doses of PBTZ169: 640 mg OD fasted and 640 mg OD after meal. Wash-out period ≥6 days.
3136800|NCT04150224|Experimental|Cohort 1 (C1B), PBTZ169|Two doses of PBTZ169: 640 mg OD after meal and 640 OD mg fasted. Wash-out period ≥6 days.
3136801|NCT04150224|Experimental|Cohort 2 (C2), PBTZ169|Single dose of PBTZ169: 960 mg fasted
3136802|NCT04150224|Experimental|Cohort 3 (C3), PBTZ169|Two doses of PBTZ169: 640 mg twice a day (fasted) with a 12-hour interval; total daily dose - 1280 mg
3181521|NCT00694577|Experimental|Group 2|Study Participants 101-200 Partial Breast Irradiation using 36 Gy / 9 fractions BID in one week
3181522|NCT00694577|Experimental|Group 3|Study Participants 201-330 Partial Breast Irradiation using 40 Gy / 10 fractions BID in one week
3181523|NCT00694590|Experimental|plerixafor|
3181524|NCT00694616|Other|1|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
3136803|NCT04150224|Experimental|Cohort 4 (C4), PBTZ169|Single dose of PBTZ169: 1280 mg fasted
3136804|NCT04150224|Experimental|Cohort 5 (C5), PBTZ169|Multiple administration of PBTZ169: 1280 mg once a day after meal for 14 days
3136805|NCT04149405|Active Comparator|Group A|"Subjects with chronic periodontitis and osteoporosis.~Phase 1 periodontal therapy and bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
3136806|NCT04149405|Active Comparator|Group B|"Subjects with chronic periodontitis and systemically healthy.~Phase 1 periodontal theraphy was administered to the subjects."
3181525|NCT00694616|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
3181526|NCT00694629|Active Comparator|1|rifampin, isoniazid, pyrazinamide, ethambutol
3181527|NCT00694629|Experimental|2|rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
3181528|NCT00694629|Experimental|3|rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
3181529|NCT00694629|Experimental|4|rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol
3181530|NCT00694642|Active Comparator|selected CD133+cells|Transendocardial injection of selected CD133+cells
3181531|NCT00694642|No Intervention|no injection|Boths groups were treated with G-CSF, underwent an apheresis and NOGA mapping
3136807|NCT04149405|Active Comparator|Group C|"Subjects with periodontally healthy and osteoporosis.~Bisphosphonate therapy ( Aclasta: intravenous infusion of 5 mg of zoledronic acid once a year) were administered to the subjects."
3136808|NCT04149405|No Intervention|Group D|"Systemically and periodontally healthy controls~No intervention has been made."
3136809|NCT04144088|Active Comparator|Wu Ling San|"Drug : Wu Ling San Extract Granules Sun-Ten"
3136810|NCT04144088|Active Comparator|Yin-Chen Wu Ling San|"Drug : Yin-Chen-Wu-Ling-San Extract Power SUN-TEN"
3136811|NCT04144088|Placebo Comparator|Placebo|Drug : 1/10 Wu Ling San
3136812|NCT04149353|Experimental|PET/MR|Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.
3181532|NCT00694655|Other|vaccine|There are no arms for this study. All participants will receive the YFV vaccine if they meet the screening criteria.
3181533|NCT00694668|Experimental|1|Cognitive Behavioural Treatment
3181534|NCT00694668|Experimental|2|Mindfulness Based Cognitive Therapy-training
3181535|NCT00694694|Experimental|1AZ+AQ|Azithromycin + artesunate
3181536|NCT00694694|Active Comparator|2AL|Artemether-lumefantrine
3181537|NCT00694720|Experimental|Dose Level 1|
3181538|NCT00694720|Experimental|Dose Level 2|
3181539|NCT00694720|Experimental|Dose Level 3|
3181540|NCT00694720|Experimental|Dose Level 4|
3181541|NCT00694720|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
3181542|NCT00694733|Placebo Comparator|1|Men on placebo injections for 4 months
3181543|NCT00694733|Active Comparator|2|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and aromatase inhibitor for 4 months.
3181544|NCT00694733|Active Comparator|3|Men who receive Depo Lupron for 4 months, then are replaced with testosterone and placebo for 4 months.
3181545|NCT00694733|Placebo Comparator|4|Women on placebo cream
3181546|NCT00694733|Active Comparator|5|Women on estrogen cream
3136813|NCT04148651|Experimental|CO2RE® Treatment|All eligible subjects will undergo up to 5 treatments at 4±1-week intervals to the vulva with a fractional CO2 laser.
3136814|NCT04137783||homozygous or compound heterozygous ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated homozgyous or compound heterozygous ABCA3 mutations.
3136815|NCT04137783||single ABCA3 mutation|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which indicated single mutations.
3136816|NCT04137783||no ABCA3 mutations|patients meet the criteria for fatal respiratory distress sydrome and undergone exome sequencing, which exclude all gene mutations involving in the respiratory disease.
3136817|NCT04136444|Experimental|Healthy participants|Participants will receive assigned single and multiple doses of padsevonil.
3136818|NCT04136444|Experimental|Hepatically impaired participants|Participants will receive assigned single and multiple doses of padsevonil.
3136819|NCT04124536|Experimental|Intervention|In addition to standard partner notification services, the intervention arm will receive HIV self-test kits and structured counseling about HIVST, regardless of HIV status.
3136820|NCT04124536|No Intervention|Control|Standard partner notification services, regardless of HIV status.
3136821|NCT04147611|Experimental|Remote Microphone (RM) Technology Group|"The RM technology group will limited to the pediatrics participants.~Participants will be tested separately on the three following conditions:~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
3149489|NCT00179023|Other|Part 4b (closed)|Metabolic and hemodynamic response to submaximal exercise in adipose and muscle tissue with and without systemic autonomic blockade with trimethaphan infusion.
3136822|NCT04147611|Active Comparator|Normal Hearing Controls|"The normal hearing controls will be limited to 15 adults.~Participants will be tested separately on the six following conditions:~Unaided~Unilateral hearing aid with contralateral plug.~Unilateral hearing aid + Digital Adaptive RM System (using Roger™, Sonova)~Bone Conduction Device (BAHA) only~BAHA + Wireless Audio-Streaming Accessory~BAHA + Digital Adaptive RM System"
3136823|NCT04147442|Experimental|Music program fine-tuned and standard|The fine-tuned program and the standard program will be compared within the same instrument as a hearing aid can have up to 4 different listening programs in it.
3136824|NCT04147455|Experimental|RealConsent|Participants randomized to this study arm will receive an adapted program of RealConsent.
3136825|NCT04147455|Active Comparator|Health Education Control Condition|Participants in the control arm will receive a web-based health promotion program.
3136826|NCT04146272|Active Comparator|Moderate Hearing loss current Mermaid first, then new|Participants were randomized to wear the current Mermaid hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new Mermaid Hearing aid for another 10 days.
3149490|NCT00179036||Good blood flow|Group without any ischemia to the small intestine
3149491|NCT00179036||Poor blood flow|Group with partial ischemia to the small intestine
3181547|NCT00694746|Experimental|Fish oil|Omega-3-acid ethyl esters in the form of fish oil capsules with ram up from 1g to 4 g/day (capsules 1g)
3149492|NCT00179062|Active Comparator|1|
3181548|NCT00694746|Placebo Comparator|Placebo|Placebo
3149493|NCT00179062|Active Comparator|2|
3149494|NCT00179140|No Intervention|1|control period
3149495|NCT00179140|Active Comparator|2|protein supplementation plus resistance exercise
3136827|NCT04146272|Active Comparator|Moderate Hearing loss new Mermaid first, then current|Participants were randomized to wear the new Mermaid hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current Mermaid Hearing aid for another 10 days.
3181549|NCT00694759|Active Comparator|A|Pioglitazone will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3181550|NCT00694759|Active Comparator|B|Metformin will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3181551|NCT00694759|Placebo Comparator|C|Placebo will be given to women with PCOS. After one month and six months of therapy, measure (a) 24-hour CPR, ACTH, free cortisol, and CBG, (b) adipocyte, liver, and whole body HSD 1 activity, and (c) insulin sensitivity, visceral fat, and androgen levels.
3181552|NCT00694772|Active Comparator|Electrocautery|
3181553|NCT00694772|Experimental|Coblation|
3181554|NCT00694785|Experimental|Group NT3|Patients will receive a total dose of approximately 1.7 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL
3181555|NCT00694785|Experimental|Group T3|Patients will receive a total dose of approximately 1.4 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 3 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
3181556|NCT00694785|Experimental|Group NT6|Patients will receive a total dose of approximately 3.9 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL.
3136828|NCT04146272|Active Comparator|Severe hearing loss current Power first, then new|Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
3149496|NCT00179140|Active Comparator|3|protein supplementation only
3149497|NCT00179153|Active Comparator|1|
3149498|NCT00179166|Active Comparator|1|supplement contains protein content of 1.4 g/kg/day
3149499|NCT00179166|Active Comparator|2|supplement contains protein content of 2.0 g/kg/day
3149500|NCT00179179|Active Comparator|1|nutritional supplement plus resistance exercise
3136829|NCT04146272|Active Comparator|Severe hearing loss new Power first, then current|Participants were randomized to wear the new power hearing aid that uses the new feedback cancellation first for 10 days. Then they wore the current power Hearing aid for another 10 days.
3136830|NCT04143945|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3136831|NCT04143945|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3136832|NCT04143373|Experimental|Warm saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 37 ± 1 ° C as for the experimental side.
3136833|NCT04143373|No Intervention|Room temperature saline|this site was irrigated during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C as for the control side.
3136834|NCT04142216|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum for three months.
3181557|NCT00694785|Experimental|Group T6|Patients will receive a total dose of approximately 3.1 mg/kg of ARC1779 over 72 hours to achieve a target plasma concentration of 6 mcg/mL. The infusion of ARC1779 will be tapered by 50% from 48 hours to 60 hours and again by 50% from 60 hours to 72 hours.
3181558|NCT00694798|Experimental|Mw|All enrolled patients to receive Mycobacterium w
3136835|NCT04142216|No Intervention|Control group|The patients will not chewing gum during three months.
3181559|NCT00694811|Experimental|A|1 week of re-feeding
3181560|NCT00694811|Experimental|B|6 weeks of re-feeding
3181561|NCT00694824||A|
3181562|NCT00694837|Experimental|B|
3181563|NCT00694850|Experimental|Arm 1|
3136836|NCT04141930|Other|Study Drug Eligible|Baloxavir given in 40 mg and 80 mg tablets for single-dose oral consumption during the first influenza infection for that participant
3136837|NCT04142450|Experimental|CoolSculpting® System|Participants underwent a single CoolSculpting® treatment session on Day 1 that was comprised of timed segments of cooling followed by 2 minutes of manual massage. Each treated arm had up to two timed segments (or cycles) in the treatment session, each treated thigh had one timed segment (or cycle) in the treatment session.
3136838|NCT04142242|Experimental|Group 1: MenACYW Conjugate Vaccine (MET 49 - Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MEQ00066).
3181564|NCT00694863|Experimental|1|In this open-label study all patients included are treated in the experimental group.
3181565|NCT00694876||1|Adequate Health Literacy (as determined by TOFHLA)
3181566|NCT00694876||2|Inadequate Health Literacy (as determined by TOFHLA)
3181567|NCT00694889|Active Comparator|1|Participants will use commercially available computer games.
3181568|NCT00694889|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3136839|NCT04142242|Experimental|Group 2: MenACYW Conjugate Vaccine (MET49 - MenACYW Conjugate Vaccine-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence (at enrollment [Day 0]) followed by a single IM dose of MenACYW Conjugate vaccine at Day 0 in the present study (MEQ00066).
3149501|NCT00179179|Active Comparator|2|nutritional supplement only (resistance exercise will not be performed)
3149502|NCT00179192|No Intervention|1|control group
3136840|NCT04142242|Experimental|Group 3: MenACYW Conjugate Vaccine (MET49: Menomune-primed Participants)|Participants who received a single dose of Menomune vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
3136841|NCT04142242|Experimental|Group 4: MenACYW Conjugate Vaccine (MET49: MenACYW-primed Participants)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET49, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066).
3149503|NCT00179192|Active Comparator|2|angioplasty intervention
3149504|NCT00179192|Active Comparator|3|surgery intervention
3149505|NCT00179205|Active Comparator|1|
3149506|NCT00179205|Placebo Comparator|2|
3149507|NCT00179218|Active Comparator|1|only protein supplementation
3149508|NCT00179218|Active Comparator|2|protein supplementation plus exercise
3149509|NCT00179348|Experimental|Group I (yoga-based rehabilitation program)|Participants undergo a yoga-based rehabilitation program up to 5 days a week for 1.5 hours and practice at home at least once daily for 12 weeks.
3149510|NCT00179348|Active Comparator|Group II (standard care/control)|After a 3 month wait period, participants undergo a yoga-based rehabilitation program as in Group I.
3149511|NCT00179374|Experimental|1|Tailored telephone intervention plus mailed print educational materials
3149512|NCT00179374|Active Comparator|2|print intervention with no telephone component
3149513|NCT00179387|Active Comparator|1|Psycho-educational / Stress Management group
3149514|NCT00179387|Active Comparator|2|Spiritual-Existential Support Group
3149515|NCT00179400|Active Comparator|Pioglitazone|
3149516|NCT00179400|Placebo Comparator|Placebo|
3149517|NCT00179452|Experimental|Intervention|Subjects invited to participate in yoga practice.
3181569|NCT00694889|Active Comparator|3|Healthy participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3181570|NCT00694902|Experimental|Sequence 1 of Cohort-I|Subjects in Sequence 1 will receive Placebo during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3181571|NCT00694902|Experimental|Sequence 2 of Cohort-I|Subjects in Sequence 2 will receive 10 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3181572|NCT00694902|Experimental|Sequence 3 of Cohort-I|Subjects in Sequence 3 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
3188818|NCT00771108|No Intervention|control|Subjects will serve as controls, continuing current diet and activity levels. Subjects will get monthly weights by the investigator at the research center.
3136842|NCT04142242|Other|Group 5: Menomune-primed Participants (MET44)|Participants who received a single dose of Menomune vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
3136843|NCT04142242|Other|Group 6: MenACYW Conjugate Vaccine-primed Participants (MET44)|Participants who received a single dose of MenACYW Conjugate vaccine in a previous study MET44, provided a blood sample for assessment of antibody persistence at enrollment (Day 0) in the present study (MEQ00066). These participants did not receive any vaccination in the present study (MEQ00066).
3136844|NCT04140890|Experimental|Treatment|Participants in the treatment group will be asked to meet with an occupational therapist in their home weekly over 12 weeks. Each session takes an hour. In the first session, the occupational therapist will introduce the program. In session 2, the therapist will discuss pain and pain management with the participant. In session 3-12, the therapist will help the participant to develop physical activity and healthy eating habits. In each session the participant will pick two healthy behaviors to turn them into a habit. The therapist will give the participant a workbook and teach the participant to track his/her progress. The focus of session 3-5 will be physical activity, and session 6-11 will be healthy eating. In the last session (session 12), the therapist will wrap up the program and help the participant to develop a maintenance plan.
3149518|NCT00179465|Active Comparator|Antipsychotic plus study drug|Half of the subjects will receive the study medications in addition to their ongoing antipsychotic regimen.
3149519|NCT00179465|Placebo Comparator|Antipsychotics plus placebo|Half of the subjects will receive placebo in addition to their antipsychotic regimen.
3149520|NCT00179491|Active Comparator|Group 1|604 patients received intercessory prayer after being informed they may or may not receive prayers (Group 1)
3149521|NCT00179491|No Intervention|2|597 patients did not receive prayer after being informed they may or may not receive prayer (Group 2)
3149522|NCT00179491|Experimental|Group 3|601 patients received intercessory prayer after being informed they would receive it (Group 3).
3149523|NCT00179634|No Intervention|1|Usual Care
3149524|NCT00179634|Experimental|2|Usual care and exposure to a visually enriched milieu (landscape photograph)
3149525|NCT00179634|Experimental|3|Usual care, exposure to a visually enriched milieu and audio taped guided visualization with healing suggestions.
3136845|NCT04140890|Placebo Comparator|Control|Participants in the control group will receive newsletters focused on general healthy aging topics over 12 weeks. With the exception of two, 1-page handouts covering PA and dietary recommendations, the weekly content will not overlap with the treatment content. Within 4 days of mailing the newsletter, a trained research assistant (RA) will call the participant, verify receipt of the newsletter, and ask them if they have any questions about the materials. The phone call will last ~15 minutes. Control condition participants receive no further intervention.
3136846|NCT04139018|Experimental|Timolol Gel Arm|Participants in the timolol gel arm (active medication arm) will receive timolol nasal gel 0.1% with 0.5 mL applied to each nostril twice daily via a syringe that will amount to a 2 mg total daily dose.
3136847|NCT04139018|Placebo Comparator|Placebo Gel Arm|Participants in the placebo gel arm will receive the gel itself with no active medication.
3136848|NCT04138810|Experimental|post-op VCE|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The VCE group will conduct their encounter via the videoconference section of the MyChart mobile applications. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
3136849|NCT04138810|Active Comparator|Office post-operative visits|As per standard of care, all subjects will be scheduled for a nursing clinical encounter 48-72 hours following discharge from the hospital from their surgery. The traditional follow up group will receive a telephone call from the office nurse as is current standard of care. At the end of this nursing encounter, the office nurse will schedule the patient for a 30 day postoperative visit within 4 to 6 weeks after their surgery.
3136850|NCT04131556|Experimental|Part 1: Sequence ABC|Participants will receive 200 milligram (mg) of maribavir tablet orally (Sequence A) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3149526|NCT00179764|Other|Reduced Intensity Conditioning Regimen|
3149527|NCT00179803|Experimental|high dose chemotherapy|
3149528|NCT00179894|Experimental|1 Physician training|Physician participants will receive training in guidelines and medication monitoring
3136851|NCT04131556|Experimental|Part 1: Sequence BCA|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3149529|NCT00179894|No Intervention|2|Physician participants will provide usual care and no special intervention
3149530|NCT00179985||Training|Behavioral: Newborn Individualized Care and Assessment Program (NIDCAP)
3149531|NCT00180011|Experimental|omaluzimab|
3136852|NCT04131556|Experimental|Part 1: Sequence CAB|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3149532|NCT00180167|Active Comparator|Daunorubicin + Ara-C|
3149533|NCT00180167|Experimental|Mitoxantrone + Ara-C|
3149534|NCT00180219||1|20 to 22 years
3149535|NCT00180219||2|30 to 32 years
3149536|NCT00180219||3|40 to 42 years
3136853|NCT04131556|Experimental|Part 1: Sequence CBA|Participants will receive maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 1 followed by 200 mg maribavir powder for oral suspension with 32.5 percent (%) drug loading (Sequence B) on Day 4 and followed by 200 mg of maribavir tablet orally (Sequence A) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3181573|NCT00694902|Experimental|Sequence 4 of Cohort-I|Subjects in Sequence 4 will receive 10 microgram GSK610677 during treatment period 1, 50 microgram GSK610677 during treatment period 2 and 250 microgram GSK610677 during treatment period 3.
3181574|NCT00694902|Experimental|Sequence 5 of Cohort-II|Subjects in Sequence 5 will receive Placebo during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3181575|NCT00694902|Experimental|Sequence 6 of Cohort-II|Subjects in Sequence 6 will receive 30 microgram GSK610677 during treatment period 1, Placebo during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3136854|NCT04131556|Experimental|Part 1: Sequence ACB|Participants will receive 200 mg of maribavir tablet orally (Sequence A) on Day 1 followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 4 and followed by 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 7 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3149537|NCT00180232||1|Patients starting an aminobisphosphonate therapy due to medical reasons Broca-index: between -20 and +25% who are willing and capable to confirm written consent to enrolment after ample information has been provided
3181576|NCT00694902|Experimental|Sequence 7 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and Placebo during treatment period 3.
3181577|NCT00694902|Experimental|Sequence 8 of Cohort-II|Subjects in Sequence 7 will receive 30 microgram GSK610677 during treatment period 1, 100 microgram GSK610677 during treatment period 2 and 500 microgram GSK610677 during treatment period 3.
3181578|NCT00694902|Experimental|Cohort III|Subjects in Cohort III after randomization will either receive 1000 microgram GSK610677 or placebo.
3181579|NCT00694915|Experimental|Mw|Mycobacterium w
3181580|NCT00694915|Active Comparator|BCG|bacillus Calmette-Guerin (BCG)
3181581|NCT00694928|Experimental|1|clindamycin phosphate/butoconazole nitrate
3181582|NCT00694928|Active Comparator|2|butoconazole nitrate
3181583|NCT00694941|Experimental|E|ONO-2506PO in the presence of Riluzole
3181584|NCT00694954|Experimental|1|Wireless capsule endoscopy
3181585|NCT00694954|Active Comparator|2|Standard Care
3181586|NCT00694967|Active Comparator|1|McDonald cerclage
3181587|NCT00694967|Active Comparator|2|17 hydroxyprogesterone caproate
3149538|NCT00180310|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
3181588|NCT00694980|Experimental|1|
3136855|NCT04131556|Experimental|Part 1: Sequence BAC|Participants will receive 200 mg maribavir powder for oral suspension with 32.5 % drug loading (Sequence B) on Day 1 followed by 200 mg of maribavir tablet orally (Sequence A) on Day 4 and followed by maribavir 200 mg powder for oral suspension with 36.1% drug loading (Sequence C) on Day 7 and with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4 and 7.
3149539|NCT00180310|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
3149540|NCT00180388|Experimental|Endoscopic vein harvesting|Harvesting of vein for coronary artery bypass grafting using endoscopy to visualize the vein
3149541|NCT00180388|Active Comparator|Open Vein harvesting|Harvesting of vein for coronary artery bypass grafting without endoscopy
3188819|NCT00771108|Experimental|Exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
3149542|NCT00180401||QRS 120-150 ms|Subjects with a QRS width between 120-150 ms
3149543|NCT00180401||QRS >150 ms|Subjects with a QRS width >150 ms
3149544|NCT00180453|Experimental|1|Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System
3149545|NCT00180453|Active Comparator|2|Abbott Vascular MULTI-LINK VISION® BMS
3149546|NCT00180505|Other|1|The purpose of the ASSESS Registry is to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries.
3181589|NCT00694993|Experimental|Subjects receiving GSK1004723 + placebo in cohort I and II|Eligible subjects will receive GSK1004723 nasal spray with single doses of 50 micrograms, 100 micrograms, 200 micrograms, 500 micrograms and 1000 micrograms. Subjects will also receive placebo nasal spray.
3181590|NCT00694993|Experimental|Subjects receiving GSK1004723 200 micrograms in cohort III|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 200 micrograms given once daily for 14 days.
3181591|NCT00694993|Experimental|Subjects receiving placebo in cohort III|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
3181592|NCT00694993|Experimental|Subjects receiving GSK1004723 1000 micrograms in cohort IV|Eligible subjects will receive nasal spray of GSK1004723 with escalated repeat doses of 1000 micrograms given once daily for 14 days.
3181593|NCT00694993|Experimental|Subjects receiving placebo in cohort IV|Eligible subjects will receive nasal spray of placebo given once daily for 14 days.
3136856|NCT04131556|Experimental|Part 2: Sequence DEGF|Participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 1 followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 4 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 7 and then followed by participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
3136857|NCT04131556|Experimental|Part 2: Sequence EFDG|Participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 1 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 4 followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 7 and then followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
3136858|NCT04131556|Experimental|Part 2: Sequence FGED|Participants under fast will receive 200 mg of maribavir powder for oral suspension (Sequence F) on Day 1 followed by participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 4 followed by participants under fast will receive 100 mg of maribavir powder for oral suspension (Sequence E) on Day 7 and then followed by 50 mg of maribavir powder for oral suspension (Sequence D) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
3136859|NCT04131556|Experimental|Part 2: Sequence GDFE|Participants feed with a high fat meal will receive 200 mg of maribavir powder for oral suspension (Sequence G) on Day 1 followed by participants under fast will receive 50 mg of maribavir powder for oral suspension (Sequence D) on Day 4 followed by 200 mg of maribavir powder for oral suspension (Sequence F) on Day 7 and then followed by 100 mg of maribavir powder for oral suspension (Sequence E) on Day 10 with a washout period of minimum 72 hours and maximum of 73 hours between Day 1, 4, 7 and 10. Doses to be evaluated in Part 2 may be adjusted based on relative bioavailability of the selected pediatric formulation (powder for oral suspension) to the Phase 3 tablet formulation observed in Part 1.
3136860|NCT04126174|Active Comparator|Femtosecond limbal relaxing incision (LRI)|Eyes will be treated with arcuate incisions from a femtosecond laser system.
3136861|NCT04126174|Active Comparator|Manual LRI|Eyes will be treated with arcuate incisions completed manually with a blade.
3136862|NCT04134429||Everion®|The Everion® will be given to the participants for the duration of 2 weeks (fourteen days) with the instruction to wear it all the time, with exception of the time needed for battery charging and the patients' hygiene.
3181594|NCT00695006|Sham Comparator|II|Sham Traction
3136863|NCT04130425|Experimental|Healthy Individuals|Subject will be measured for forearm rotation while wearing the custom orthoses Hely & Weber MTC Fracture Brace, thermoplastic orthosis, and delta cast orthosis.
3136864|NCT04138498|Experimental|Sequence 1 (ADBC)|Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
3136865|NCT04138498|Experimental|Sequence 2 (BACD)|Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
3136866|NCT04138498|Experimental|Sequence 3 (CBDA)|Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
3136867|NCT04138498|Experimental|Sequence 4 (DCAB)|Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
3136868|NCT04138043|Experimental|GSK2330811 450 mg|Participants will receive a single 450 mg SC dose of GSK2330811, administered as three separate SC injections of 150 milligrams per milliliter [mg/mL]).
3136869|NCT04138043|Placebo Comparator|Placebo|Participants will receive GSK2330811 matching placebo administered as three separate SC injections.
3136870|NCT04137627|Experimental|Melatonin|The group received standard treatment with the oral administration of Melatonin
3136871|NCT04137627|Placebo Comparator|Placebo|The group received standard treatment with the oral administration of Placebo
3136872|NCT04136145|Experimental|Belimumab SC|Subjects will be administered a single dose of belimumab 200 mg via the SC route. The dose will be administered in the front of the thigh via auto-injector device.
3181595|NCT00695006|Active Comparator|I|Traction
3136873|NCT04136145|Experimental|Belimumab IV|Subjects will be administered a single dose of belimumab 200 mg via the IV route administered over approximately 1 hour.
3136874|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 1|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/medium low dose) after extraction of third molars
3136875|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 2|Participants received a single dose of two tablets of naproxen sodium/caffeine (low dose/low dose) after extraction of third molars
3136876|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 3|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ medium low dose) plus one tablet of placebo after extraction of third molars
3136877|NCT04132336|Experimental|Naproxen sodium/caffeine - Dose 4|Participants received a single dose of one tablet of naproxen sodium/caffeine (low dose/ low dose) plus one tablet of placebo after extraction of third molars
3136878|NCT04132336|Active Comparator|Naproxen sodium|Participants received a single dose of one tablet of naproxen sodium (low dose) plus one tablet of placebo after extraction of third molars
3136879|NCT04132336|Active Comparator|Caffeine|Participants received a single dose of two tablets of caffeine (medium low dose) after extraction of third molars
3188820|NCT00771121|Active Comparator|new emulsion|
3136880|NCT04132336|Placebo Comparator|Placebo|Participants received a single dose of two tablets of matching placebo after extraction of third molars
3136881|NCT04131517|Experimental|Oral contraceptive|Participants will receive oral contraceptive in Period 2 of Sequence A and Period 1 of Sequence B of Part 1 and Part 2.
3136882|NCT04131517|Experimental|Oral contraceptive + padsevonil|Participants will receive padsevonil + oral contraceptive in Period 1 of Sequence A and Period 2 of Sequence B of Part 1 and Part 2.
3149547|NCT00180518|Experimental|1|"To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) To evaluate the efficacy of the OTW ACCUNET System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA).~To demonstrate equivalence in the safety and performance of the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection System and the corresponding OTW devices."
3149548|NCT00180544|Other|1|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
3136883|NCT04128293|Experimental|Sequence 1 - Treatment ABCD|Participants will receive a single dose of GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3149549|NCT00180557|Experimental|Active fixation lead|Active fixation lead was implanted
3149550|NCT00180557|Active Comparator|Passive fixation lead|Passive fixation lead was implanted
3149551|NCT00180583|Experimental|1|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
3149552|NCT00180635|Experimental|Healthy volunteers non smoker|Control group
3149553|NCT00180635|Experimental|Healthy volunteers smoker|More than 10 pack-years
3149554|NCT00180635|Experimental|Chronic Obstructive Pulmonary Disease COPD|COPD diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease guidelines
3136884|NCT04128293|Experimental|Sequence 2 - Treatment BADC|Participants will receive a single dose of GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in fourth intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3136885|NCT04128293|Experimental|Sequence 3 - Treatment CDAB|Participants will receive a single dose of GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3149555|NCT00180700|Experimental|Self-hypnosis|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 13 participants with diagnosed HIV
3149556|NCT00180700|Experimental|Johrei healing method|A course of four weekly 2-hour training sessions coupled with daily self-hypnosis practice was given to 9 participants with diagnosed HIV
3149557|NCT00180843|Placebo Comparator|saline control|nebulized saline
3149558|NCT00180843|Active Comparator|salbutamol and ipratropium bromide nebules|salbutamol 2.5 mg and ipratropium bromide 0.5 mg
3149559|NCT00181181|Active Comparator|Atorvastatin|Atorvastatin for 3 months
3149560|NCT00181181|Placebo Comparator|Placebo|
3149561|NCT00181298|Active Comparator|1|
3149562|NCT00181298|Placebo Comparator|2|
3149563|NCT00181571|Active Comparator|1|Concerta
3149564|NCT00181571|Placebo Comparator|2|Placebo
3149565|NCT00181584|Active Comparator|Group 1|
3149566|NCT00181584|Placebo Comparator|Group 2|
3149567|NCT00181649|Experimental|Recombinant human prolactin|
3149568|NCT00181753|Experimental|1|Burn Patients receiving at least 3 days of parenteral feeding on routine formula
3149569|NCT00181753|Experimental|2|Burn patients receiving at least 3 days on parenteral feeding on glutamine enriched formula.
3149570|NCT00181753|Experimental|3|Burn patients receiving at least 3 days of enteral feeding on routine formula.
3136886|NCT04128293|Experimental|Sequence 4 - Treatment DCBA|Participants will receive a single dose of GSK3640254 200 mg (Treatment D- Test), tablets, orally under high fat conditions on Day 1 in first intervention period; followed by GSK3640254 200 mg (Treatment C- Reference), tablets, orally under fasted conditions on Day 1 in second intervention period; followed by GSK3640254 200 mg (Treatment B- Test), tablets, orally under moderate fat conditions on Day 1 in third intervention period; further followed by GSK3640254 200 mg (Treatment A- Reference), capsules, orally under moderate fat conditions on Day 1 in first intervention period. There will be at least 7 days wash out period between each dose of study intervention.
3149571|NCT00181753|Experimental|4|Burn patients receiving at least 3 days of enteral feeding on glutamine-enriched formula.
3188821|NCT00771121|Placebo Comparator|new emulsion placebo|
3136887|NCT04126343|Experimental|Padsevonil|Study participants randomized to this arm will receive assigned doses of padsevonil twice daily. On Day 8 padsevonil will be administered in the morning, and placebo will administered in the evening.
3136888|NCT04126343|Placebo Comparator|Placebo|Study participants randomized to this arm will receive placebo twice daily to maintain the blinding.
3136889|NCT04126343|Active Comparator|Moxifloxacin|Study participants randomized to this arm will receive padsevonil-placebo twice daily. On Day 8 placebo will be administered in the morning, and moxifloxacin will administered in the evening.
3136890|NCT04126187||Panoptix|Bilateral implantation of the Panoptix trifocal IOL
3136891|NCT04124952||Panoptix|Patients bilaterally implanted with the Panoptix intraocular lens.
3136892|NCT04123665|Experimental|Experimental Test Dentifrice|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
3136893|NCT04123665|Placebo Comparator|Control Dentifrice|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as sodium monofluorophosphate [SMFP] to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
3136894|NCT04122534|Experimental|Treatment Group|Treatment groups receives the intervention training.
3181596|NCT00695045|Experimental|1|patients in this group got 100mcg of intrathecal morphine.
3188822|NCT00771134|Experimental|Lu AA39959|
3136895|NCT04121078|Experimental|Sequence AB: TAK-906 25 mg + TAK-906 25 mg and Rifampin 600 mg|TAK-906 25 milligram (mg) (Treatment A), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 7 days, further followed by rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 2.
3136896|NCT04121078|Experimental|Sequence BA: TAK-906 25 mg and Rifampin 600 mg + TAK-906 25 mg|Rifampin 600 mg, infusion, once, intravenously over 30 minutes along with TAK-906 25 mg (Treatment B), capsule, orally, once immediately after the end of infusion on Day 1 of Study Period 1 followed by a washout period of at least 7 days, further followed by TAK-906 25 mg (Treatment A), capsule, orally, once on Day 1 of Study Period 2.
3136897|NCT04117607|Experimental|BA1|100 mg (1 injection of 1.0 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered subcutaneously into the abdomen on Day 1, and 100 mg (250 ml) or MTD of Rezafungin administered via intravenous infusion on Day 22 in an open label manner. n=5.
3136898|NCT04117607|Experimental|BA2|100 mg (250 ml) or maximum tolerated dose (MTD) determined in SAD of Rezafungin administered via intravenous infusion on Day 1, and 100 mg (1 injection of 1.0 ml) or MTD of Rezafungin administered subcutaneously into the abdomen on Day 22 in an open label manner. n=5.
3136899|NCT04117607|Experimental|MAD1|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
3181597|NCT00695045|Experimental|2|patients in this group got 200 mcg intrathecal morphine
3188823|NCT00771134|Placebo Comparator|Placebo|
3136900|NCT04117607|Experimental|MAD2|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
3136901|NCT04117607|Experimental|MAD3|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
3136902|NCT04117607|Experimental|MAD4|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as three doses, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Days 1, 8, and 15 in a double-blind manner.
3136903|NCT04117607|Experimental|SAD1|1 mg (1 injection of 0.1 ml diluted 1:10 in 5% Dextrose Injection, USP) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=3 (no sentinel dosing), or matching placebo, n=1 (no sentinel dosing), on Day 1 in a double-blind manner.
3181598|NCT00695045|Experimental|3|patients in this group given 300 mcg intrathecal morphine.
3181599|NCT00695058|Experimental|1|Women with stress incontinence treated with active TMNS (vibration)
3181600|NCT00695058|Placebo Comparator|2|Women with stress incontinence treated with placebo TMNS (vibration)with an amplitude of 0
3188824|NCT00771134|Active Comparator|Quetiapine|
3188825|NCT00771147||Group 1|
3181601|NCT00695058|Experimental|3|Women with overactive bladder syndrome treated with active TMNS (vibration)
3181602|NCT00695058|Placebo Comparator|4|Women with overactive bladder syndrome treated with placebo TMNS (vibration)with an amplitude of 0
3181603|NCT00695058|Experimental|5|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with active TMNS (vibration)
3181604|NCT00695058|Placebo Comparator|6|males who are still incontinent at a minimum of one year after a radical prostatectomy treated with placebo TMNS (vibration)with an amplitude of 0
3181605|NCT00695071|Active Comparator|A|
3181606|NCT00695084|Experimental|1|Treatment with Constraint-Induced Movement Therapy
3181607|NCT00695123||Only 1 participant group (cohort)|The subject may have a blood disorder, may be a stem cell transplant donor, or may be a healthy volunteer.
3181608|NCT00695162|Other|1|hearing impaired inpatients
3181609|NCT00695162|Other|2|Non-hearing-impaired inpatients
3188826|NCT00771160|Experimental|1|MK0476 5mg
3188827|NCT00771160|Experimental|2|MK0476 10mg
3136904|NCT04117607|Experimental|SAD2|10 mg (1 injection of 0.1 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
3136905|NCT04117607|Experimental|SAD3|30 mg (1 injection of 0.3 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
3136906|NCT04117607|Experimental|SAD4|60 mg (1 injection of 0.6 ml) of Rezafungin administered subcutaneously into the abdomen as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
3136907|NCT04117607|Experimental|SAD5|100 mg (1 injection of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
3136908|NCT04117607|Experimental|SAD6|200 mg (2 injections of 1.0 ml) of Rezafungin administered subcutaneously into alternating abdominal quadrants as a single dose, n=6 (1 sentinel, 5 non-sentinel), or matching placebo, n=2 (1 sentinel, 1 non-sentinel), on Day 1 in a double-blind manner.
3136909|NCT04116684|Experimental|Intervention Group (digital BP monitoring)|This group will receive a Withings digital BP monitor to transmit recordings to the study team who will make medication adjustments.
3136910|NCT04116684|No Intervention|Standard of care BP monitoring|This group will use a standard BP cuff and record and transmit data to their medical team as instructed by their providers or if they are concerned.
3136911|NCT04096365|Experimental|Subcostal temporary extracardiac pacing lead|All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.
3136912|NCT04080297|Experimental|100 mg Q-122|10 patients treated with Q-122, 100 mg. Dosage was 100 mg Q-122 administered orally as two 50 mg capsules once daily for 28 days.
3136913|NCT04080297|Experimental|200 mg Q-122|11 patients treated with Q-122, 200 mg. Dosage was 200 mg Q-122 administered orally as four 50 mg capsules once daily for 28 days.
3136914|NCT04115358|Experimental|Hyaluronic acid|Gengigel teething (%0,54 hyaluronic acid), 0,1ml to the orifice of the root canals of the primary molar.
3136915|NCT04115358|Active Comparator|Formocresol|0,1 ml to the orifice of the root canals of the primary molar.
3136916|NCT04115358|Active Comparator|Ferric sulfate|0,1 ml to the orifice of the root canals of the primary molar.
3188828|NCT00771186||children with vocal fold immobility|
3136917|NCT04114058|Active Comparator|Liposomal Bupivicaine|Following hip arthroscopy, local field infiltration with liposomal bupivicaine will be performed for adjunct pain control
3136918|NCT04114058|Active Comparator|fascia iliaca blockade|Preoperatively before hip arthroscopy, a fascia iliaca blockade will be performed for adjunct pain control
3136919|NCT04113785||Klassic TKA|Subjects implanted with a Klassic TKA. Subjects will undergo flouoroscopic evaluation during a deep knee bend evaluation and the postoperative kinematics will be reported.
3136920|NCT04113694|Experimental|Extended Wear Infusion Set|Each subject is given 12 Extended Wear Infusion Sets to wear.
3136921|NCT04112160|Placebo Comparator|control|normal saline 0.9%
3136922|NCT04112160|Active Comparator|Ketorolac|30 mg of Ketorolac
3136923|NCT04112069|Active Comparator|Usual care|Participants randomized to usual care first started the usual care arm (UC) managing their diabetes with continuous subcutaneous insulin infusion (pump therapy) for approximately 5 days. All subjects wore a Dexcom G5 continuous glucose monitor (CGM). If randomized to the usual care arm first, subjects crossed over to the bionic pancreas arm following a 2-day washout period.
3149572|NCT00181805||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
3188829|NCT00771199|Experimental|Transdermal Therapeutic System (TTS)-Fentanyl|
3188830|NCT00771212||001|
3136924|NCT04112069|Experimental|iLet Bionic Pancreas with Humalog or Novolog|Participants randomized to the iLet with humalog/novolog first started the insulin-only iLet arm using the insulin analog that they use for their usual care (either Humalog or Novolog) for approximately 5 days. All subjects wore a Dexcom G5 CGM. If randomized to the bionic pancreas arm first, subjects crossed over to the usual care arm following a 2-day washout period.
3136925|NCT04109703|Active Comparator|High level pulsed heat|Subjects randomized to this arm received a generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered as waves peaking at 45° C.
3136926|NCT04109703|Placebo Comparator|Low level steady heat|Subjects randomized to this arm received an identical generation 5 device (Soovu Labs Inc.) that produced 30 minutes of heat. The heat was delivered in a steady manner at 37° C.
3136927|NCT04109443|Experimental|Young Men & Media Program group|Participants randomized to the Young Men and Media Program group will have access to the online sexual health media literacy materials. They will also complete three assessments at baseline, post-intervention, and a 3 month follow-up.
3136928|NCT04109443|Active Comparator|Control group|Participants randomized to the control group will have access to available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections including HIV. They will complete three assessments at baseline, post-intervention, and a 3 month follow-up.
3136929|NCT04109222|Experimental|Group 1: Fluzone Quadrivalent Influenza vaccine: 6 to < 36 Months|Participants aged 6 to <36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
3136930|NCT04109222|Experimental|Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to < 9 years|Participants aged 3 to 9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 0. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.
3136931|NCT04109222|Experimental|Group 3: Fluzone High-Dose Influenza Vaccine: >= 65 years|Participants aged >=65 years received a of 0.5-mL dose of Fluzone high-dose vaccine, intramuscularly, at Day 0.
3136932|NCT04107493|Active Comparator|Portable oxygen cylinder|Continuous flow oxygen cylinders will be used as a comparison.
3136933|NCT04107493|Experimental|Mobi™ Portable Oxygen Concentrator|Mobi™ is indicated for patients who require supplemental oxygen, including COPD patients. It provides supplemental, high oxygen concentration to these patients. It is available via prescription only and may be used in the home, institution, and hospital settings, as well as travel environments
3136934|NCT04106817|Experimental|Cohort 1|1:10 dilution of neat virus (0.25mL of 1:10 dilution per nostril of neat virus; approximate quantity 3.5 x 10^6TCID50/dose)
3136935|NCT04106817|Experimental|Cohort 2|1:5 dilution of neat virus (0.25mL of 1:5 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
3136936|NCT04106817|Experimental|Cohort 3|1:10 dilution of neat virus (0.5mL of 1:10 dilution per nostril of neat virus; approximate quantity 7 x 10^6TCID50/dose)
3188831|NCT00771225|Other|prolapse surgery with fascial repair|
3188832|NCT00771225|Other|prolapse surgery with mesh repair|
3136937|NCT04105972|Active Comparator|TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received TEZ 100 milligrams (mg) once daily (qd)/IVA 150 mg every 12 hours (q12h) in the treatment period for 24 weeks.
3136938|NCT04105972|Experimental|ELX/TEZ/IVA|Following TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
3136939|NCT04105218|Experimental|Evening Exercise|Participants will arrive in the Clinical and Translation Research Center (CTRC) and enter the whole room calorimeter approximately 1 hour after arrival. During the evening exercise condition, participants will perform 45-minutes of moderate intensity continuous exercise on a treadmill 12 hours after habitual wake time in the evening. Participants will begin with a warm-up for 5 minutes at 2.0-2.5 mph. Heart rate will be monitored continuously with a heart rate monitor. Participants will maintain heart rate at 65% of age-predicted maximum heart rate. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
3188833|NCT00771251|Experimental|CNTO 148 50 mg|
3136940|NCT04105218|Placebo Comparator|Control|Participants will arrive in the Clinical and Translation Research Center (CTRC) in the morning within 2 hours of their habitual wake time. Participants will enter the whole room calorimeter approximately 1 hour after arriving at the CTRC. Throughout the day, participants will be required to eat the standardized meals provided at breakfast lunch and dinner. At the time of bed, participants will be instructed to turn off the lights, lay down in bed and to refrain from using electronic devices. In the morning, a metabolic test will be performed and melatonin levels will be measured in the saliva
3181610|NCT00695201|Experimental|1|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
3181611|NCT00695201|Experimental|2|Patients will undergo pump placement and biopsy of diseased liver tissue. Chemotherapy will be initiated as soon as possible following verification of adequate pump placement and perfusion by radiographic pump study. Treatment will continue indefinitely unless a patient experiences a treatment endpoint.
3149573|NCT00181805||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
3181612|NCT00695214|Other|1|OSA Patients considering surgical treatment
3136941|NCT04102956|Experimental|Kallikrein+Standard treatment group|The Kallikrein+Standard treatment group was given kallikrein through intravenous injection to treatment for 0.15 PNA/day+standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
3136942|NCT04102956|No Intervention|Standard treatment group|The Standard treatment group was only given standard treatment medicine based on the guidelines for the treatment of acute ischemic stroke for 14 ± 5 days.
3136943|NCT04102540|Experimental|Infographic intervention group|Participants in the infographic intervention group will receive health education using infographics during a study visit scheduled immediately following their regularly scheduled clinic visits.
3136944|NCT04102345|Experimental|Lavender|1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.
3149574|NCT00181857||1|Children of Adults with ADHD NOS
3149575|NCT00182039|Experimental|A|metoprolol
3149576|NCT00182039|Placebo Comparator|B|placebo
3149577|NCT00182052|Active Comparator|Group 1|
3181613|NCT00695227|Experimental|Screening for Barrett's Esophagus|
3181614|NCT00695240|Experimental|Bupiv analgesia|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. The catheter was placed in the operating room with a peel-away trocar and attached to the pump. The trocar was inserted through a 5 mm stab incision made near the superior part of the pubic bone between the genitoinguinal fold and the midline of the symphysis. Once through the incision, the trocar is advanced subcutaneously and made to exit the posterior fourchette just beneath the posterior vaginal mucosa where it is advanced by tenting up the skin.
3181615|NCT00695266||1|
3181617|NCT00695305|Placebo Comparator|placebo|placebo to match
3181618|NCT00695305|Active Comparator|rilapladib|250 mg/day
3181619|NCT00695331|Experimental|1|Titrated Oral Misoprostol Solution
3181620|NCT00695331|Active Comparator|2|Intravenous Oxytocin
3181621|NCT00695344|Experimental|1|Everolimus 2 times per day + cyclosporin low dose +/- steroids
3188834|NCT00771251|Experimental|CNTO 148 100 mg|
3181622|NCT00695344|Active Comparator|2|Cyclosporin + azathioprine or mofetil mycophenolate +/- steroids (the same treatment that patient had before the study).
3181623|NCT00695383|Experimental|1|
3181624|NCT00695383|Active Comparator|2|
3181625|NCT00695422||Specimen Collection|Blood collection, anal cytology and biopsy of observed lesions. Additional cervical cytology and biopsy for females.
3181626|NCT00695448|Experimental|Cohorts|The starting dose is 6mg once daily (QD); dose is to be escalated using a standard 3 + 3 dose escalation scheme.
3181627|NCT00695461|Experimental|1|Receives Lactobacillus plantarum 299v in an oatmeal drink, at a concentration of 10(9) colony-forming-units/ml, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
3181628|NCT00695461|Placebo Comparator|2|Receives oatmeal drink, 100 ml per day, starting one week before surgery, finishing 5 days after surgery.
3181629|NCT00695474||A|The cohort consists of type 2 diabetics from the outpatient clinic at Silkeborg Hospital.
3181630|NCT00695487|Experimental|1|Receives 0.125mg/kg THC before emergence
3181631|NCT00695487|Placebo Comparator|2|Receives NaCl before emergence
3181632|NCT00695513|Experimental|I|BENEO synergy1
3136945|NCT04102345|Active Comparator|Zolpidem|Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.
3136946|NCT04092907|Experimental|HBM9036 0.25% Ophthalmic Solution|HBM9036, Ophthalmic Solution, twice a day, in the morning and evening
3149578|NCT00182052|Placebo Comparator|Group 2|
3149579|NCT00182143|Active Comparator|LMWH (Fragmin, dalteparin)|Placebo dose (normal saline) = AM dose LMWH (Fragmin, dalteparin) 5000IU daily = PM dose
3149580|NCT00182143|Active Comparator|2|Unfractionated Heparin 5000IU BID
3149581|NCT00182156||1|conventional HD
3149582|NCT00182156||2|short daily HD
3149583|NCT00182156||3|PD
3136947|NCT04092907|Placebo Comparator|Placebo Ophthalmic Solution|placebo, Ophthalmic Solution, twice a day, in the morning and evening
3136948|NCT04089982|Active Comparator|Varenicline|Varenicline BID
3136949|NCT04089982|Placebo Comparator|Placebo|
3181633|NCT00695526|Active Comparator|A|
3181634|NCT00695552|Experimental|1|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
3136952|NCT04086433||Arm A - Echelon Stapler|"Excised gastric tissue specimens will be resected with the Echelon Stapler (Ethicon, size: 60mm, Echelon) and evaluated for burst pressure and staple malformation"
3136953|NCT04086433||Arm B - Titan Stapler|"Excised gastric tissue specimens will be resected with the Titan SGS Stapler (Standard Bariatrics, Titan) and evaluated for burst pressure and staple malformation"
3181635|NCT00695552|Placebo Comparator|2|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises.
3149584|NCT00182260|Active Comparator|Proton Pump Inhibitor|Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.
3188835|NCT00771251|Experimental|Placebo|
3136954|NCT04086407|Experimental|Forehead sensor recording precision head pitch and roll angle|During an overnight polysomnography, participants were coached by sleep research technologists to sleep with their head in positions hypothesized to minimize apnea severity ≤20⁰ or ≥160⁰, and those hypothesized to maximize apnea severity between 30⁰ and 150⁰. Head roll angles were measured and recorded by the participant's forehead sensor attached with adhesive and tape. Extreme head positions were attempted with the torso in both supine and non-supine positions so show insensitivity to torso position. A custom interface was developed to maintain compatibility with specific bedside polysomnography recorder auxiliary inputs. Sleep epochs were considered those where the subject slept for at least 10 minutes. Each head position epoch was analyzed for apnea hypopnea index and oxygen desaturation.
3136955|NCT04099277|Experimental|Part A: 10 milligrams (mg) LY3435151|Participants received intravenous (IV) push or IV bolus infusion of 10 mg LY3435151.
3149585|NCT00182260|Active Comparator|Laparoscopic Nissen Fundoplication|Surgical patients underwent LNF using previously published technique.
3136956|NCT04099277|Experimental|Part B: LY3435151 + Pembrolizumab Dose Escalation|Pembrolizumab was not administered as study was terminated before completion of Part A of the dose escalation period.
3136957|NCT04099277|Experimental|Part C: LY3435151 Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
3136958|NCT04099277|Experimental|Part D: LY3435151 + Pembrolizumab Dose Expansion|Participants were not enrolled in to this arm, as trial was terminated in dose escalation phase.
3136959|NCT04098809|Active Comparator|Catheter 16 French|16 French urinary catheter
3136960|NCT04098809|Active Comparator|Catheter 20 French|20 French urinary catheter
3136961|NCT04098575||Patients receiving Empagliflozin until mid Sep 2015|Patients receiving Empagliflozin before the EMPA-REG-OUTCOME study was published time until mid-Sept. 2015; Cohort 1
3136962|NCT04098575||Patients receiving Empagliflozin until CV Label Change time|Patients receiving Empagliflozin starting from the EMPA-REG-OUTCOME study being published until CV Label Change time from mid-Sept. 2015-mid-Jan. 2017; Cohort 2
3136963|NCT04098575||Patients receiving Empagliflozin until last available data cut|Patients receiving Empagliflozin starting from mid-Jan. 2017 until last; Cohort 3
3136964|NCT04098458|Experimental|NDURE|NDURE is a navigation-based, multilevel intervention targeting barriers to timely, guideline-adherent PORT at the patient-, healthcare team-, and organization-levels.
3149586|NCT00182338||Peritoneal Dialysis Patients|
3149587|NCT00182455|Experimental|1|Topiramate 25 - 400 mg/day x 12 weeks
3149588|NCT00182455|Placebo Comparator|2|Placebo
3136967|NCT04095286|Experimental|AMB dispersed in water/AMB oral tablet/reference AMB|Eligible participants will receive a single oral dose of 5 milligram (mg) AMB tablet dispersed in water during treatment period 1 followed by a single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive a single oral dose of reference 5 mg AMB tablet. There will be a washout period of 7 days between doses in each treatment period.
3136968|NCT04095286|Experimental|AMB oral tablet/reference AMB/AMB dispersed in water|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3, participants will receive single dose of 5 mg AMB tablet dispersed in water. There will be a washout period of 7 days between doses in each treatment period.
3136969|NCT04095286|Experimental|Reference AMB/AMB dispersed in water/AMB oral tablet|Eligible participants will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
3136970|NCT04095286|Experimental|AMB dispersed in water/reference AMB/AMB oral tablet|Eligible participants will receive single dose of 5 mg AMB tablet dispersed in water during treatment period 1 followed by single dose of reference 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
3149589|NCT00182468|Experimental|1|Women are screened for intimate partner violence prior to seeing a health care provider.
3149590|NCT00182468|No Intervention|2|Women see their health care provider without being asked about intimate partner violence.
3149591|NCT00182520|Experimental|1|Topiramate
3149592|NCT00182520|Placebo Comparator|2|placebo
3149593|NCT00182533|Experimental|1|Sertraline
3149594|NCT00182533|Placebo Comparator|2|Placebo
3149595|NCT00182559|Active Comparator|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
3149596|NCT00182559|Active Comparator|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
3149597|NCT00182663|Experimental|Treatment (immunomodulator, antiangiogenesis, steroid therapy)|Patients receive thalidomide PO QD dexamethasone PO once weekly, and clarithromycin PO BID. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Treatment with thalidomide continues in the absence of disease progression or unacceptable toxicity.
3136971|NCT04095286|Experimental|AMB oral tablet/AMB dispersed in water/reference AMB|Eligible participants will receive single dose of 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB tablet dispersed in water in treatment period 2. In treatment period 3 participants will receive single dose of reference 5 mg AMB oral tablet. There will be a washout period of 7 days between doses in each treatment period.
3136972|NCT04095286|Experimental|Reference AMB/AMB oral/AMB dispersed in water|Eligible participants in this arm will receive single dose of reference 5 mg AMB oral tablet during treatment period 1 followed by single dose of 5 mg AMB oral tablet in treatment period 2. In treatment period 3 participants will receive single dose of 5 mg AMB tablet dispersed in water There will be a washout period of 7 days between doses in each treatment period.
3136973|NCT04094883|Experimental|4CMenB Vaccine|Participants will receive the 4CMenB (Bexsero) vaccine by an injection in the deltoid region of the upper arm or the higher front area on one side of the thigh at the enrollment visit (Day 0) and at week 5.
3136974|NCT04091659|Active Comparator|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
3136975|NCT04091659|Experimental|Virtual Reality|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
3136976|NCT04091061|Experimental|PF-06865571 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
3181636|NCT00695591||1SevereRLD,NMD|Patients with FEV1<40%
3181637|NCT00695591||2VerySevereRLD,NMD|FEV1<30%
3181638|NCT00695591||3NINV|FEV1<25%,on non invasive ventilation
3181639|NCT00695591||ModerateRLD,NMD|Patients with FEV1 40-50% of predicted
3136977|NCT04091061|Experimental|PF-06865571 Severe Hepatic Impairment|This arm includes participants with severe hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
3136978|NCT04091061|Experimental|PF-06865571 Mild Hepatic Impairment|This arm includes participants with mild hepatic impairment who will receive an oral dose of PF-06865571 100 mg on Day 1
3136979|NCT04091061|Experimental|PF-06865571 Healthy Participants|This arm includes healthy participants who will receive an oral dose of PF-06865571 100 mg on Day 1
3136980|NCT04090242|Active Comparator|App plus Nano|Use of BD Diabetes Care Application for Mobile devices PLUS the use of BD Nano 2nd Gen Pen Needle for delivery of insulin
3136981|NCT04090242|No Intervention|Standard Care|Standard of Care/Subject is to continue on their current diabetes management regime
3136982|NCT04089761|Experimental|Active Device|Treatment of acute migraine with an active form of Nerivio device
3136983|NCT04079803|Placebo Comparator|Placebo Cohort|Subjects administered placebo oral tablets twice daily (BID)
3136984|NCT04079803|Experimental|Simufilam (PTI-125) 100 mg tablets Cohort|Subjects administered simufilam (PTI-125) 100 mg oral tablets twice daily (BID)
3136985|NCT04079803|Experimental|Simufilam (PTI-125) 50 mg tablets Cohort|Subjects administered simufilam (PTI-125) 50 mg oral tablets twice daily (BID)
3136986|NCT04087343|Experimental|Meals plus exercise|
3136987|NCT04087343|Active Comparator|Meals only|
3136988|NCT04087122|Experimental|Esophageal warming|Patients receive the Attune Medical Esophageal Heat Transfer Device
3149598|NCT00182702|Experimental|Treatment|Patients receive ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3181640|NCT00695604|Placebo Comparator|1|"Placebo Comparator~All patients assigned to this group will receive:~Placebo via Metered Dose Inhaler (MDI).~Albuterol via MDI."
3181641|NCT00695604|Active Comparator|2|"Active Comparator~All patients assigned to this group will receive:~Fluticasone via MDI.~Albuterol via MDI."
3181642|NCT00695617|Experimental|A|citrate first
3181643|NCT00695617|Experimental|B|no anticoagulation first
3181644|NCT00695630|Experimental|1|Flumazenil 2mL
3181645|NCT00695630|Placebo Comparator|2|Saline, 2mL SM
3136989|NCT04084769|Experimental|Group 1: MenACYW Conjugate vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 (NCT02199691) or MET43 (NCT02842853), received a single intramuscular (IM) dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
3136990|NCT04084769|Experimental|Group 2: MenACYW Conjugate vaccine (Menveo Vaccine-primed)|Participants who received a single dose of Menveo vaccine in previous study MET50 or outside of Sanofi Pasteur trials, received a single IM dose of MenACYW Conjugate vaccine, at Day 0 in the present study (MET59).
3181646|NCT00695643|Experimental|A|
3181647|NCT00695643|Placebo Comparator|B|
3181648|NCT00695656||1|
3181649|NCT00695708|Experimental|BFT|20 schizophrenic patients
3181650|NCT00695708|Active Comparator|CP|19 schizophrenic patients
3136991|NCT04084769|Experimental|Group 3: MenACYW Conjugate vaccine + Trumenba vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Trumenba vaccine at Day 0 in the present study (MET59).
3136992|NCT04084769|Experimental|Group 4: MenACYW Conjugate vaccine + Bexsero vaccine|Participants who received a single dose of MenACYW Conjugate vaccine in previous studies MET50 or MET43, received a single IM dose of MenACYW Conjugate vaccine, concomitantly with 1 dose of Bexsero vaccine at Day 0 in the present study (MET59).
3181651|NCT00695708|No Intervention|HCG|20 healthy age and sex matched subjects
3181652|NCT00695734||Hemodialysis|Patients under chronic hemodialysis for chronic end stage renal failure
3181653|NCT00695747|No Intervention|1|Standard 1 site Procedure using a fornix based incision, performed superiorly
3181654|NCT00695747|Experimental|2|2 Site Combined Procedure
3181655|NCT00695799||1|Anesthesia Providers at UMDNJ
3181656|NCT00695812||1|Siblings of children with Autism
3181657|NCT00695812||2|Siblings of children with typical development
3181658|NCT00695825|Experimental|A1|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
3181659|NCT00695825|Experimental|A2|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
3181660|NCT00695838||1|
3181661|NCT00695851|Experimental|1|15 mg/m2 weekly of PCK3145
3181662|NCT00695851|Experimental|2|7.5 mg/m2 twice per week of PCK3145
3181663|NCT00695877|Experimental|1|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
3181664|NCT00695877|Experimental|2|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^10 virus particles (VP) given at Days 0, 28, and 168
3136993|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 1|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
3136994|NCT04086576|Experimental|Commercial Smartphone-paired breathalyzers-Set 2|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: BACtrack Vio, Drinkmate, and Floome which will be tested in a randomized order and recorded. Participants blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
3136995|NCT04086641|Experimental|Foot 1: Crossover Foot, Foot 2: Energy Storing Foot|Participant randomized to crossover foot as first condition, energy storing foot as second condition
3136996|NCT04086641|Experimental|Foot 1: Energy Storing Foot, Foot 2: Crossover Foot|Participant randomized to energy storing foot as first condition, crossover foot as second condition
3136997|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 1|AbobotulinumtoxinA dose 1 injected into platysma bands
3136998|NCT04080882|Placebo Comparator|placebo|placebo injected into platysma bands
3136999|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 2|AbobotulinumtoxinA dose 2 injected into platysma bands
3137000|NCT04080882|Active Comparator|AbobotulinumtoxinA dose 3|AbobotulinumtoxinA dose 3 injected into platysma bands
3137001|NCT04086472|Experimental|MK-1654 100 mg|Participants receive a single IV infusion of MK-1654 100 mg on Day 1.
3137002|NCT04086472|Experimental|MK-1654 200 mg|Participants receive a single IV infusion of MK-1654 200 mg on Day 1.
3137003|NCT04086472|Experimental|MK-1654 300 mg|Participants receive a single IV infusion of MK-1654 300 mg on Day 1.
3137004|NCT04086472|Experimental|MK-1654 900 mg|Participants receive a single IV infusion of MK-1654 900 mg on Day 1.
3137005|NCT04086472|Placebo Comparator|Placebo|Participants receive a single IV infusion of placebo on Day 1.
3137006|NCT04085289|Experimental|Galcanezumab|Participants received single subcutaneous (SC) doses of 120 milligram (mg) or 240 mg Galcanezumab.
3137007|NCT04085289|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
3137008|NCT04084015|Experimental|Early axillary Impella®|Early placement of axillary Impella® for LV unloading and LV recovery in patients with VA ECMO
3137009|NCT04082663|Experimental|Dental Mouthpiece|Each participant will be fitted with a maxillary orthotic (mouthpiece). The mouthpiece is fabricated with polyvinyl ethylene acetate which is non-toxic to humans.
3137010|NCT04084028|Experimental|Active Cooking +meal kits and recipes|"Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal.~Following 6 weeks of cooking classes, participants will receive 6 weeks of home-delivered meal kits. Following 6 weeks of meal kits, participants will received 6 weeks of recipes. Both the meal kits and recipes will accommodate major dietary needs (vegan, gluten-free, etc.)"
3137011|NCT04084028|Active Comparator|Active cooking only|Participants will attend a weekly 2-hour cooking class to learn how to prepare meals. Participants cook and sample the meal at the end of class and the chef will walk them through a sensory exercise. At the end of each class, participants will be provided with the recipe for the next class and asked to create a timeline for the various steps of preparation. Participants will bring this timeline to class and discuss as a group before preparing the meal. Unlike the previous arm, no further instruction will be given once cooking classes end.
3137012|NCT04084028|Active Comparator|Meal Kits only|Participants will receive weekly meal kit deliveries for 6 weeks. Following 6 weeks of meal kit deliveries, students will receive emails at the beginning of each week providing them with 5 healthy recipes.
3137013|NCT04084028|No Intervention|Control|Participants will receive no interventions.
3137014|NCT04082819|Other|Low Blood Pressure|Low blood pressure (systolic: 0-129, diastolic: 0-79)
3137015|NCT04082819|Other|Medium Blood Pressure|Medium blood pressure (systolic: 130-160, diastolic: 80-100)
3137016|NCT04082819|Other|High Blood Pressure|High blood pressure (systolic: 161 or higher, diastolic: 101 or higher)
3137017|NCT04081961||Asymptomatic current smokers|No respiratory symptoms and preserved pulmonary function based on spirometry (FEV1/FVC of at least 0.70 after bronchodilation treatment and FVC ≥80% of the expected value)
3137018|NCT04081961||"Grey zone current smokers"|Initially preserved pulmonary function based on spirometry, but with clinical symptoms based on COPD Assessment Test (CAT≥10) and results of the 6-min walk test (6 MWT) less than 450 meters.
3137019|NCT04081961||Current smokers with COPD|Current smokers with a confirmed diagnosis of COPD (GOLD stage I-III)
3137020|NCT04081610|Experimental|Lagricel® Ofteno Multidose|Lagricel® Ofteno Multidose 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
3137021|NCT04081610|Active Comparator|Lagricel® Ofteno Single dose|Lagricel® Ofteno single dose. 0.4% hyaluronate. Ophthalmic solution. Laboratorios Sophia
3137022|NCT04081324|Placebo Comparator|Placebo|Participants received placebo administered orally on Day 1 and repeated doses on Days 4 to 10 (7 days of dosing).
3181665|NCT00695877|Experimental|3|3 injections of rAd5.ENVA.48 HIV-1 vaccine or placebo at 1 x 10^11 virus particles (VP) given at Days 0, 28, and 168
3137023|NCT04081324|Experimental|50 milligram (mg) Lasmiditan|Participants received 50 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 50 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
3137024|NCT04081324|Experimental|100 mg Lasmiditan|Participants received 100 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 100 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
3137025|NCT04081324|Experimental|200 mg Lasmiditan|Participants received 200 mg lasmiditan administered orally once on the morning of Day 1 after an overnight fast of at least 8 hours. Following a period of at least 72 hours without dosing, participants received multiple once-daily oral doses of 200 mg lasmiditan on Days 4 to 10 (7 days of dosing) after overnight fasts of at least 8 hours prior to each dose.
3181666|NCT00695877|Experimental|4|1 injection of rAd5.ENVA.48 HIV-1 vaccine or placebo at a dose determined by the safety data from Arms 1, 2 and 3 given at Day 0.
3181667|NCT00695890||1|Healthy volunteers
3181668|NCT00695942||1|pregnancy women
3181669|NCT00695981|Active Comparator|Rotator cuff repair|Surgery following a 3 months period of active non-operative treatment
3181670|NCT00695981|Active Comparator|Conservative treatment|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3181671|NCT00695994|Experimental|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle.
3181672|NCT00695994|Experimental|Gemcitabine and carboplatin|Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion.
3181673|NCT00696007|Experimental|1|A neoadjuvant chemotherapy (gemcitabine and cisplatin) regimen administered before surgery-nephroureterectomy for upper tract TCC
3181674|NCT00696007|Other|2|A retrospective cohort group (approximately 60 subjects) identified from an institutional cancer registry who have undergone a nephroureterectomy alone over the past five years
3181675|NCT00696033|Experimental|1|Oral Lorazepam
3181676|NCT00696033|Experimental|2|Oral Diazepam
3181677|NCT00696033|Placebo Comparator|3|Oral placebo
3181678|NCT00696059|Other|1|Open-label, one arm only. All patients receiving active drug according to recommendations (adalimumab (Humira) 40 mg subcutaneously every other week).
3181679|NCT00696085|Other|I|Pregnant women are recruited and screened for alcohol use using a validated alcoholism screening questionnaire. Those who screen positive are then entered into the next phase of the study.
3181680|NCT00696098|Experimental|1|sodium butyrate
3181681|NCT00696098|Placebo Comparator|2|
3137026|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 1|Healthy adult subjects will receive a single oral dose of gepotidacin 1500 mg (2 X 750 mg, treatment A), tablets, on Day 1 of Period 1; two oral doses of gepotidacin 3000 mg (4 x 750 mg, Treatment C), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment E), tablets, at 0 and 6 hours on Day 9 of Period 3.
3137027|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 1|Healthy adult subjects will receive a single oral dose of matching placebo (treatment B), tablets, on Day 1 of Period 1; two oral doses of matching placebo (treatment D), tablets, at 0 and 12 hours on Day 5 of Period 2; and two oral doses of matching placebo (treatment F), tablets, at 0 and 6 hours on Day 9 of Period 3.
3137028|NCT04079790|Experimental|Subjects receiving Gepotidacin in Part 2|Healthy adolescent subjects will receive a single oral dose of gepotidacin 1500 mg (2 x 750 mg, treatment A), tablets, on Day 1 of Period 1; and two oral doses of gepotidacin 3000 mg (4 x 750 mg, treatment G), tablets, at 0 and 6 hours on Day 1 of Period 2.
3137029|NCT04079790|Placebo Comparator|Subjects receiving Placebo in Part 2|Healthy adolescent subjects will receive a single oral dose of matching placebo (treatment B), tablets on Day 1 of Period 1; and two oral doses of matching placebo (treatment H), tablets at 0 and 6 hours on Day 1 of Period 2.
3137030|NCT04079127||Patients suffering from severe hip pain and disability|Patients in need of a total hip arthroplasty.
3181682|NCT00696111|Experimental|1A|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive estrogen plus placebo for another 6 weeks.
3137031|NCT04076787||Favorable IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as favorable IMDC risk group for having 0 individual risk factor
3137032|NCT04076787||Intermediate IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as intermediate IMDC risk group for having 1 or 2 individual risk factors
3137033|NCT04076787||Poor IMDC risk group|The cohort of mRCC patients receiving sunitinib as first-line treatment and classified as poor IMDC risk group for having 3 or more individual risk factors
3137034|NCT04075812|Experimental|Neuromuscular Stimulator|Neuromuscular Stimulator is setup and calibrated, various spatial and temporal stimulation patterns will be tested to evoke wrist/hand movements in various sequences of individual and combined movements.
3137035|NCT04075409|Experimental|Extensive metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
3137036|NCT04075409|Experimental|Intermediate metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
3137037|NCT04075409|Experimental|Poor metabolizers|Participants will receive assigned single and multiple doses of padsevonil.
3137038|NCT04074941|Experimental|Low sodium diet|This group will get a low sodium diet (<0.9 mg per kcal of energy intake).
3137039|NCT04074941|Active Comparator|Usual sodium diet|This group will get a usual sodium diet (~2 mg per kcal of energy intake).
3137040|NCT04073823|Active Comparator|Flexitouch Plus|
3137041|NCT04073823|Experimental|Flexitouch Plus with SW|
3137042|NCT04073407|Active Comparator|AXA1957|AXA1957 20.4g
3137043|NCT04073407|Placebo Comparator|Placebo|Placebo 24g
3137044|NCT04073368|Active Comparator|AXA1957 high dose|AXA1957 20.3g
3137045|NCT04073368|Active Comparator|AXA1957 low dose|AXA1957 13.5g
3137046|NCT04073368|Active Comparator|AXA1125|AXA1125 24g
3137047|NCT04073368|Placebo Comparator|Placebo|Placebo 24g
3181683|NCT00696111|Experimental|1B|Randomized to receive depot Lupron for 6 weeks. Then randomized again to receive progesterone plus placebo for another 6 weeks.
3181684|NCT00696111|Experimental|3|Randomized to receive CPAP (continuous positive airway pressure) treatment for 6 weeks.
3181685|NCT00696124|Experimental|Cohort 1|2mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3181686|NCT00696124|Experimental|Cohort 2|4mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3181687|NCT00696124|Experimental|Cohort 3|8mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3181688|NCT00696124|Experimental|Cohort 4|16mg dose VM202. The first half of the total dose given on Day 1 and the second half on Day 15.
3181689|NCT00696150|Placebo Comparator|loss of resistance|Anterior psoas compartment nerve block inserted using loss of resistance
3181690|NCT00696150|Active Comparator|nerve stimulator|Anterior psoas compartment nerve block inserted using nerve stimulator
3181691|NCT00696150|Active Comparator|ultrasound|Anterior psoas compartment nerve block inserted using ultrasound
3181692|NCT00696163||A|
3181693|NCT00696176|Experimental|A|STAT 3 decoy administration
3181694|NCT00696202|Experimental|Arm 1|
3181695|NCT00696215|Placebo Comparator|1|
3137048|NCT04073186|Experimental|ACUVUE® OASYS with Transitions™|Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.
3137049|NCT04072432|Experimental|120 mg FeS IV infusion|A single dose of 120 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
3181696|NCT00696215|Active Comparator|2|Rasagiline
3137050|NCT04072432|Experimental|240 mg FeS infusion|A single dose of 240 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
3137051|NCT04072432|Experimental|360 mg FeS Infusion|A single dose of 360 mg FeS by IV infusion consisting of 3 healthy volunteers and 3 subjects with stage 3-4 CKD.
3181697|NCT00696228|Placebo Comparator|AFN A|High Fat Diet Placebo
3181698|NCT00696228|Experimental|AFN B|MUFA
3181699|NCT00696228|Experimental|AFN C|PUFA
3181700|NCT00696228|Experimental|AFN D|SFA
3137052|NCT04072237|Experimental|Study Population|MarzAA (Coagulation Factor VIIa variant) 18 µg/kg intravenously (Stage 1) followed by MarzAA 30 µg/kg subcutaneously (SC) (Stage 2), MarzAA 45 µg/kg SC (Stage 3), MarzAA 60 µg/kg SC (Stage 4), MarzAA 2x30 µg/kg SC (Stage 5), MarzAA 90 µg/kg SC (Stage 6), MarzAA 120 µg/kg SC (Stage 7), MarzAA 2×60 µg/kg SC (Stage 8), MarzAA 3x60 µg/kg SC (Stage 9)
3137053|NCT04063371||Control Group 1|At least one location will serve as the control office and will continue to conduct their visits including screening for cognitive impairment as they normally do using their usual method based on the primary care provider's normal practice.
3188836|NCT00771303||Ct scan|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer measurement, lower limb compression ultrasonography and multi-slice computed tomography.
3188837|NCT00771329|Experimental|1|BIIB023
3188838|NCT00771329|Placebo Comparator|2|
3181701|NCT00696280||Group 1|"All patients will be given the Functional Living Index - Emesis (FLIE) standardized questionnaire during their scheduled clinic visit prior to receiving chemotherapy.~This is a self-administered questionnaire. Patients will complete the questionnaire during the 5 days following carboplatin administration (at 24 hours, 48 hours, 72 hours, and 96 hours) of their first and third cycles of chemotherapy.~Patients will also be interviewed by a trained CRA or research nurse over the telephone 24-48 hours following carboplatin administration in order to assess the severity of the delayed nausea and vomiting."
3137054|NCT04063371||Intervention Group|At least one different location will serve as the intervention office where all the providers, as their standard of care, use a standardized method for screening for cognitive impairment consisting of using the SAGE or eSAGE test and having a conversation with an individual who knows the patient well (if possible) to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
3137055|NCT04063371||Control Group 2|Control group 2 consists of patients handled by the intervention office who did not complete the SAGE or eSAGE.
3137056|NCT04042324|Experimental|Triferic post-dialyzer; UFH via continuous infusion|Patients will receive Triferic 6.75 mg IV over 3 hours into the post-dialyzer blood line (or drip chamber) administered by an infusion pump. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin using the on-machine infusion pump. The infusion of heparin to be stopped at hour 3 of hemodialysis.
3137057|NCT04042324|Experimental|UFH and Triferic admixture|"Patients will receive Triferic 6.75 mg IV plus the appropriate volume of unfractionated heparin for continuous infusion over 3 hours into the pre-dialyzer heparin line. This mixture will be administered by the on-machine syringe infusion pump for continuous infusion. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of Triferic + heparin. The infusion of Triferic + heparin will be stopped at hour 3 of hemodialysis."
3137058|NCT04042324|Experimental|UFH via continuous infusion pre-dialyzer|Patients will receive no Triferic. Anti-coagulation will be provided by a bolus of heparin administered into the venous return line immediately prior to the initiation of hemodialysis followed by a continuous infusion of heparin via the on-machine syringe pump. The infusion of heparin to be stopped at hour 3 of hemodialysis
3137059|NCT04071392||Post-Essure Group|"Healthy women with history of Essure hysteroscopic permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
3137060|NCT04071392||Control Group|"Healthy women with no history of permanent contraception.~Eligible participants will then undergo the HSG imaging study - a standard radiological imaging study to determine that the fallopian tubes are open and free of disease. It also checks the uterine cavity for any abnormalities."
3137061|NCT04071301|Experimental|Investigational Device|TENA SmartCare Change Indicator
3181702|NCT00696319|Experimental|1|Arm 1 will go through a rehabilitation protocol with perturbation training exercises.
3181703|NCT00696319|Experimental|2|Arm 2 will go through a rehabilitation protocol with traditional exercises for balance and stability training.
3181704|NCT00696332|Experimental|Talampanel 50mg|50mg Talampanel 3 times per day
3137062|NCT04071158|Experimental|Lower RSV vaccine dose and Tdap|Lower RSV vaccine dose and Tdap
3137063|NCT04071158|Experimental|Lower RSV vaccine dose and Placebo|Lower RSV vaccine dose and Placebo
3137064|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap|Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
3137065|NCT04071158|Experimental|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo|Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
3137066|NCT04071158|Placebo Comparator|Placebo and Tdap|Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
3137067|NCT04070287|Active Comparator|SMART Pack|"This involves using SMART Pack a HIV self-testing kit to promote uptake of HIV self-testing among young people at community centers."
3137068|NCT04070287|Active Comparator|Luv Box|"The intervention involves using Luv Box a box that include personal hygiene products and HIV self-testing kit as strategy to promote uptake of HIV testing among young people."
3181705|NCT00696332|Experimental|Talampanel 25mg|25mg Talampanel 3 times per day
3137069|NCT04070287|Active Comparator|Bili Vibes|"The intervention involves using a program program called Bili that leverages community youth events such as football matches as a strategy to promote the uptake of HIV self-testing among young people."
3181706|NCT00696332|Placebo Comparator|Placebo|placebo 3 times per day
3181707|NCT00696345||1|Colorectal cancer patients, Stages I-IV
3137070|NCT04070287|Active Comparator|BeterDoc|"This intervention involve using BeterDoc Safety kits that includes HIV self-testing kit, location and phone number to the health centers in the community as a strategy to promote update of HIV self-testing among young people."
3181708|NCT00696345||2|Non colorectal cancer patients, verified by colonoscopy
3181709|NCT00696358|Active Comparator|A|308 nm excimer lamp
3181710|NCT00696358|Active Comparator|B|308 nm excimer laser
3181711|NCT00696397||A|adult men and women between 18 and 50 years of age with atopic dermatitis
3181712|NCT00696462|No Intervention|A|Patients in Group A will undergo passive warming with a warmed cotton blanket placed over their upper extremities
3188839|NCT00771342|Experimental|1|1% gasoue nitric oxide, delivered topically for 40 minutes daily for three consecutive days
3137071|NCT04070287|Active Comparator|IUNGO|This intervention involves using a program utilizes community vocational skills training centers to promote uptake of HIV self-testing among young people.
3137074|NCT04069715|Experimental|Farlong NotoGinseng™ (Farlong Ginseng Plus® Panax Notoginseng)|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
3181713|NCT00696462|Active Comparator|B|Patients in Group B will have a forced-air warming device applied to the upper body above the waist at the 43 degree Celsius setting.
3181714|NCT00696475|Experimental|1|Diazoxide equivalent dose
3181715|NCT00696475|Experimental|2|Diazoxide equivalent dose
3137075|NCT04069715|Placebo Comparator|Placebo|Participants will be instructed to take two capsules once per day in the morning, thirty minutes before a meal. Clinic staff will instruct participants to save all unused and open packages and return them to clinic at each subsequent visit (visit 3, visit 4 and visit 5) for a determination of compliance. If a dose is missed, participants are instructed to take one as soon as they remember that day. Participants will be advised not to exceed two capsules daily.
3137076|NCT04050722|Experimental|Test Product|Participants with no visible plaque will be instructed to apply full ribbon of the test product (containing 0.454 percent [%] of stannous fluoride] on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
3137077|NCT04050722|Other|Negative Control Dentifrice|Participants with no visible plaque will be instructed to apply full ribbon of the negative control dentifrice (containing sodium fluoride) on head of toothbrush provided and brush their teeth for 1 timed minute twice a day (morning and evening), for 3 weeks.
3181716|NCT00696475|Experimental|3|Diazoxide equivalent dose
3181717|NCT00696475|Placebo Comparator|4|
3181718|NCT00696514|Placebo Comparator|2|placebo capsule, once per day
3181719|NCT00696514|Experimental|1|Vitamin B12 and folic acid capsule, once a day
3181720|NCT00696527||1|
3181721|NCT00696540|Experimental|1|Salbutamol is diluted in hypertonic (3%) saline.
3181722|NCT00696540|Active Comparator|2|Salbutamol is diluted in normal (0.9%) saline.
3181723|NCT00696553|Active Comparator|B1|Nutrition
3181724|NCT00696553|Experimental|B2|Nutrition plus Exercise
3181725|NCT00696566|Experimental|A|All subjects will receive Clopidogrel and Rifampicin.
3137078|NCT04069221|Experimental|Part 1, single arm|"This was an open-label study in 8 healthy subjects to determine the absolute bioavailability of OZ439 following a single oral dose of OZ439 and co-administration of a single iv infusion of a [14C]-OZ439 radiolabeled microdose at the anticipated Tmax of the oral dose. Subjects received the following treatment:~Treatment A: A single oral dose of 800 mg OZ439 simple granules administered as a 100-mL dispersion followed by a 15-minute 10-mL iv infusion of 100 μg [14C]-OZ439 (47 kBq [1.27 μCi]) beginning 3 hours after the oral dose administration."
3137079|NCT04069221|Experimental|Part 2, Treatment B: single oral dose of 800 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
3181726|NCT00696579|Active Comparator|A|Group A received BCG instillation 14 days after II look-TURB:6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
3181727|NCT00696579|Experimental|2|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
3181728|NCT00696631|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3181729|NCT00696631|Placebo Comparator|Placebo|matching placebo tablets
3181730|NCT00696644||Patients with severe osteoporosis|Postmenopausal women and men aged > 21 years old affected by severe osteoporosis
3181731|NCT00696683||A|Patients from the identified scorpion envenomation cases, who met inclusion/exclusion criteria.
3181732|NCT00696722|Experimental|1|Placebo treatment first, atazanavir treatment second
3181733|NCT00696722|Experimental|2|Atazanavir treatment first, placebo treatment second
3181734|NCT00696735|Active Comparator|1|standard chemotherapy arm, the CHVP (cyclophosphamide, low-dose doxorubicin, teniposide, and prednisone) regimen consisted of cyclophosphamide (600 mg/m2), doxorubicin (25 mg/m2), and teniposide (60 mg/m2), all administered intravenously on day 1, and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
3181735|NCT00696735|Experimental|2|VCAP (cyclophosphamide, high-dose doxorubicin, prednisone, and vincristine) regimen as a first-line therapy combining vindesine (3 mg/m2) on day 1, cyclophosphamide (1500 mg/m2) on day 2, doxorubicin (80 mg/m2) on day 2, and prednisolone (50 mg/m2) on days 1 to 5, every 3 weeks.19,31,32 Patients in CR, VGPR, or PR after the second or third VCAP cycle continued on to stem-cell harvesting and received, before transplantation, one course of IMVP16 (ifosfamide, methotrexate, and VP-16), which combined ifosfamide (1.5 g/m2) and VP16 (100 mg/m2) on days 1 through 3, and methotrexate (30 mg/m2) on days 1 and 10. Patients with less than PR after the VCAP cycles received, as salvage therapy, 2 to 3 courses of DHAP (dexamethasone, high-dose cytarabine, and cisplatin) combining cisplatine (100 mg/m2) on day 1, cytarabine (4 g/m2) on day 2, and dexamethasone (40 mg/m2) on days 1 through 4. If at least a PR was obtained after DHAP, stem cells were harvested or patients were considered as failures
3181736|NCT00696748|Active Comparator|1|Men receiving Nebido
3181737|NCT00696748|Placebo Comparator|2|Men receiving Placebo
3181738|NCT00696813||paliperidone ER|Newly switched to or started on Paliperidone ER, not longer than 2 weeks ago
3181739|NCT00696813||Any other oral antipsychotic|Newly switched to or started on any other oral antipsychotic treatment (either atypical or conventional), not longer than 2 weeks ago
3181740|NCT00696839|No Intervention|1|Usual care (adherence education)
3181741|NCT00696839|Experimental|2|Usual care and Cognitive Behavioral Therapy sessions
3181742|NCT00696852|Active Comparator|Mindfulness Meditation|
3181743|NCT00696852|Active Comparator|Yoga|
3181744|NCT00696852|Active Comparator|Conventional Stress Reduction|
3181745|NCT00696865|Experimental|1|
3181746|NCT00696865|Placebo Comparator|2|
3181747|NCT00696891|Experimental|Group A|
3181748|NCT00696891|Active Comparator|Group B|
3181749|NCT00696904|Other|1|Healthy volunteers, receiving 10-1200 mg ABT-333 or placebo, single dose
3181750|NCT00696904|Other|2|HCV+ treatment-naive subjects receiving 100-300 mg ABT-333 or placebo, multi-dose, QD or BID
3181751|NCT00696904|Other|3|Healthy volunteers, receiving 100 mg ABT-333, multi-dose, food effect
3181752|NCT00696917|Active Comparator|Group A|Three doses according to 0, 1, 6-month schedule
3181753|NCT00696917|Experimental|Group B|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3181754|NCT00696917|Experimental|Group C|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3181755|NCT00696917|Experimental|Group D|Two doses according to 0, 6-month schedule, with a placebo injection at Month 1
3181756|NCT00696943|Experimental|18F-ML-10,|Pre-treatment baseline and post treatment follow-up 18F ML-10 PET/CT sessions.
3181757|NCT00696956|Placebo Comparator|A|Normal balloon for balloon angioplasty (Submarine, Ampherion Deep by Invatec)
3181758|NCT00696956|Active Comparator|2|Paclitaxel coated balloon (same balloon like in the control group, but coated with 3 µg/mm2 Paclitaxel)
3181759|NCT00696969|Active Comparator|1|
3181760|NCT00696969|Experimental|2|
3181761|NCT00696969|Experimental|3|
3181762|NCT00696969|Experimental|4|
3181763|NCT00696982|Experimental|A|diabetic patients who are treated with metformin wiyh HBA1C>7% will get sitagliptin
3181764|NCT00696982|Experimental|B|diabetic patients who are treated with metformin with HBA1C>7% will get glibenclamide
3181765|NCT00696995||A|
3181766|NCT00697008||GERD patients|Patients with typical GERD symptoms
3181767|NCT00697021|Active Comparator|1|Patients who suffered acute STEMI and were treated by PPCI and by Aspirin 100mg and Plavix 75mg and showed on treatment platelet over-reactivity observed by TEG system on the 5th day after admission to ICCU
3181768|NCT00697021|Other|2|Patients who suffered acute STEMI and were treated by PPCI and recieved by Aspirin 100mg and Plavix 75mg and showed platelet inhibition observed by TEG system on the 5th day after admission to ICCU
3181769|NCT00697034|Experimental|1|Study subjects will be patients with chronic plaque-type psoriasis
3181770|NCT00697047|No Intervention|1- Usual Care|Usual Care (UC) includes an annual birthday letter with information on overdue screening tests including CRC screening.
3181771|NCT00697047|Experimental|2 - Automated Mailing|Usual care plus automated mailing. Mailing 1 is a pamphlet about screening choices and number to call for colonoscopy. Mailing 2 is a FIT kit if not requesting colonoscopy. Mailing 3 is a Reminder letter.
3188840|NCT00771342|Placebo Comparator|2|Nitrogen gas delivered topically for 40 minutes, daily, for 3 consecutive days
3188841|NCT00771355||1|Subjects with vitiligo.
3181772|NCT00697047|Experimental|3 - Automated Mailing Plus Assisted|Usual care, automated mailing plus, if screening is still not completed, phone assistance by a medical assistant (MA) who asks about patients screening intent, and provides brief assistance to complete this (e.g. sends another fecal test, assists with provider order for a colonoscopy).
3188842|NCT00771355||2|Subjects with melasma.
3188843|NCT00771355||3|Subjects with post-inflammatory hyper-pigmentation.
3137080|NCT04069221|Experimental|Part 2, Treatment C: single oral dose of 400 mg OZ439|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
3137081|NCT04069221|Experimental|Part 2, Treatment D:single oral dose 400 mg OZ439+cobicistat|This was an open-label, randomized, single-dose, 3-way cross-over study in 18 healthy subjects. Each subject participated in 3 treatment periods and each subject received a single dose of each of the following 3 treatments in a randomized order with a 14-day wash-out period between each treatment: Treatment B: A single oral dose of 800 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment C: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion Treatment D: A single oral dose of 400 mg OZ439 simple granules administered as a 64.5-mL dispersion and co-administered with a 150 mg cobicistat tablet (CYP3A4 inhibitor)
3137082|NCT04067141|Experimental|somofilcon A, then nelfilcon A|Subjects will bilaterally wear the somofilcon A lenses, then crossover to nelfilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
3137083|NCT04067141|Experimental|nelfilcon A, then somofilcon A|Subjects will bilaterally wear the nelfilcon A lenses, then crossover to somofilcon A lenses after one week of wear. Both lenses will be worn on a daily wear basis for one week.
3137084|NCT04065074|Experimental|FX006 32 mg|Single intra-articular (IA) injection of FX006 32 mg
3137085|NCT04049578|Experimental|Balovaptan|
3137086|NCT04067401|Experimental|Wingman Connect|Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
3188844|NCT00771355||4|Subjects with post-inflammatory hypo-pigmentation.
3137087|NCT04067401|Active Comparator|Stress Management|The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.
3137088|NCT04067050|Experimental|comfilcon A asphere|Subjects will wear their comfilcon A asphere contact lenses for two months. Lenses will be worn on a daily wear, reusable basis for at least 8 hours per day, 5 days per week.
3137089|NCT04067050|Active Comparator|Habitual Spectacles|Subjects will wear their single vision habitual spectacles for two months for at least 8 hours per day, 5 days per week.
3137090|NCT04066647|Experimental|Dexamthesone|Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.
3149599|NCT00182780|Experimental|Arm I - American ginseng (low dose)|"Patients receive oral American ginseng twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study.~Quality of life is assessed at baseline, every 2 weeks during treatment, and at the end of treatment.~PROJECTED ACCRUAL: A total of 280 patients (70 per treatment arm) will be accrued for this study within 35 months."
3149600|NCT00182780|Experimental|Arm II - American ginseng (mid-dose)|"Patients receive oral American ginseng at the mid-dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3181773|NCT00697047|Experimental|4 - Auto Plus Assisted Plus Navigation|Usual care, automated mailing, phone assistance by a medical assistant, plus navigation by a registered nurse (RN) if still not screened. Navigators are trained to use motivational interviewing techniques. They assess CRC and procedure risk, facilitate screening choice, address barriers, and provide follow-up until screening is completed.
3181774|NCT00697060|Experimental|Stage 1/2|Imexon plus docetaxel
3181775|NCT00697086|Experimental|1|
3137091|NCT04066426|Experimental|naproxen sodium+codeine phosphate|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Codeine phosphate is an opioid analgesic which has similar applications to those of morphine. However, it is significantly less potent as an analgesic and has only mild sedative effects. The drug's principal site of action is at the µ-opioid receptors (MOR) which are distributed in the central nervous system. Peak effect is reached within 2 hours and analgesic action continues for approximately 4 hours. Naproxen sodium (550 mg)+codeine phosphate (30 mg) was used twice daily in this study.
3137092|NCT04066426|Experimental|naproxen sodium+dexamethasone|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily + dexamethasone (8 mg) was used once daily in this study.
3137093|NCT04066426|Experimental|naproxen sodium|Naproxen sodium is a propionic acid derivative with analgesic, antipyretic, and antiinflammatory properties. Its mechanism of action relies on the inhibition of prostaglandin synthesis, and significant pain relief and plasma levels can be obtained within 20 minutes following intake. The elimination half-life of naproxen sodium is reportedly around 14 hours, and naproxen sodium is used in doses ranging from 275 to 550 mg in surgical procedures. Naproxen sodium (550 mg) was used twice daily in this study.
3137094|NCT04066426|Active Comparator|paracetamol|Paracetamol is a mild analgesic and antipyretic, and is recommended for the treatment of most painful and febrile conditions, for example, headache including migraine, toothache, neuralgia, colds and influenza, sore throat, backache, rheumatic pain and dysmenorrhoea.
3137095|NCT04061694|Experimental|Digital Immediate loading|Single dental implant installed with the assistance of fully guided-surgery, submitted to immediate loading with restorations fabricated with the help of intraoral scanning and 3D printing
3137096|NCT04061694|Other|Immediate loading|Historic cohort subjected to immediate loading
3137097|NCT04060654|Experimental|SUBLOCADE|All subjects will receive SUBLOCADE 300mg on Day 1, followed by injections every 4 weeks at a dose determined by the Investigator (either 100 mg or 300 mg) for up to 5 total injections
3137098|NCT04059250|Experimental|Nobio flange|On the Nobio flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it the Nobio composite.
3137099|NCT04059250|Placebo Comparator|Traditional composite flange|On the traditional composite flange side of the lower partial denture the gap model will include a double sterilized piece of human enamel, a small gap, and next to it a traditional composite.
3137100|NCT04058353|Active Comparator|Control: IVA or TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants either received IVA 150 milligrams (mg) every 12 hours (q12h) or TEZ 100 mg once daily (qd)/IVA 150 mg q12h in the treatment period for 8 weeks.
3137101|NCT04058353|Experimental|TC: ELX/TEZ/IVA|Following an IVA or TEZ/IVA run-in period of 4 weeks, participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 8 weeks.
3137102|NCT04057248|Experimental|Digital platform and CDE coaching intervention for patients with type 2 Diabetes|"Patients provided with digital platform and connected devices. They undergo digital and human (CDE) intervention based on patient captured clinical data.~Clinical parameters (HbA1C, weight, lipids profile, etc.) before and after intervention is assessed."
3137103|NCT04055519|Other|LID017569, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
3181776|NCT00697086|Placebo Comparator|2|
3188845|NCT00771368|Experimental|Nitric Oxide|gaseous nitric oxide delivered topically for 30 minutes
3137104|NCT04055519|Other|Biofinity, then LID017569|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn in both eyes on a daily wear basis at least 8 hours a day, 5 days a week, for 30 days. Lenses will be removed nightly for cleaning and disinfection.
3137105|NCT04055675||Asymptomatic Male Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are male.
3137106|NCT04055675||Asymptomatic Female Volunteers|These are subjects over the age of 18 who have no acute symptoms, volunteered to provide a urine sample, and are female.
3137107|NCT04054765|Experimental|Teens in the Invite Only VR videogame|155 adolescents playing the Invite Only VR intervention
3137108|NCT04054765|Other|Teens receive treatment as usual|132 adolescents receive treatment as usual, which includes regular instruction in health class regarding the dangers of e-cigarettes
3188846|NCT00771381|Experimental|1|18F-FAZA + FluGlucoScan Injection
3188847|NCT00771394|Placebo Comparator|1. Tamsulosin alone|
3137109|NCT04054011|Experimental|deoxycholic acid|Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)
3188848|NCT00771394|Experimental|2. Tamsulosin + solifenacin (low dose)|
3188849|NCT00771394|Active Comparator|3. Tamsulosin + solifenacin (high dose)|
3188850|NCT00771420|Active Comparator|1|0.01mg/kg and 0.03mg/kg CAM-3001
3137110|NCT04059094|Placebo Comparator|Placebo|2 puffs ofmatching placebowere inhaledorally via theRespimat®inhaler twice dailyfor a treatmentperiod of 4 weeksin patients withcystic fibrosis.
3137111|NCT04059094|Experimental|BI 1265162 50 μg b.i.d.|2 puffs of 25micrograms (μg)BI 1265162(Total: 50μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:100μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
3188851|NCT00771420|Active Comparator|2|0.1mg/kg CAM-3001
3188852|NCT00771420|Active Comparator|3|0.3mg/kg CAM-3001
3137112|NCT04059094|Experimental|BI 1265162 100 μg b.i.d.|2 puffs of 50micrograms (μg)BI 1265162(Total: 100μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:200μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
3137113|NCT04059094|Experimental|BI 1265162 200 μg b.i.d.|2 puffs of 100micrograms (μg)BI 1265162(Total: 200μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:400μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
3137114|NCT04059094|Experimental|BI 1265162 20 μg b.i.d.|2 puffs of 10micrograms (μg)BI 1265162(Total: 20μg)were inhaledorally via theRespimat®inhaler twice daily(b.i.d., daily dose:40μg) for atreatment periodof 4 weeks inpatients withcystic fibrosis.
3137115|NCT04051684|Experimental|TAP, Bupivacaine|This group will receive general anesthesia and at the end of the operation, but still in the operating room, a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
3137116|NCT04051684|No Intervention|No intervention|General anesthesia
3137117|NCT04046341|Experimental|Behavioral Sleep Intervention|Parents attend 1-3 one-hour sessions at their primary care office or via telemedicine, where they receive sleep education and work with interventionists to develop strategies to help their child at bedtime.
3137118|NCT04045964|Experimental|Motivational advice and free NRT|
3137119|NCT04045964|Active Comparator|Quitline referral|
3137120|NCT04043416|Experimental|System + Fall Prevention First, then Fall Prevention|"Participants in this arm will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the first 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program. Following the 6 week washout period, the participants in this arm will just participate in the Fall Prevention program alone.~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
3149601|NCT00182780|Experimental|Arm III - American ginseng (high-dose)|"Patients receive oral American ginseng at the high dose twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3149602|NCT00182780|Other|Arm IV - Placebo|"Patients receive oral placebo twice daily for 8 weeks in the absence of unacceptable toxicity.~After 8 weeks of treatment, patients in arms I-III may continue to receive American ginseng on the optional continuation portion of the study for an additional 8 weeks. Patients in arm IV may begin oral American ginseng twice daily for 8 weeks on the optional continuation portion of the study."
3149603|NCT00182819|Other|radiotherapy|Radiotherapy (control arm), 50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
3149604|NCT00182819|Experimental|Temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles (experimental arm)
3181777|NCT00697099|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
3149605|NCT00182832|Experimental|1|
3149606|NCT00182832|Active Comparator|2|
3181778|NCT00697099|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
3181779|NCT00697125|Active Comparator|Group A|
3181780|NCT00697125|Experimental|Group B|
3181781|NCT00697125|Experimental|Group C|
3181782|NCT00697138|Experimental|A|
3181783|NCT00697151|Active Comparator|Warfarin|Warfarin (target International Normalized Ratio: 1.4 to 2.8) plus placebo aspirin
3181784|NCT00697151|Active Comparator|Aspirin|Aspirin 325 mg plus placebo warfarin
3181785|NCT00697164|Placebo Comparator|1|Patients in group I received intravenous quinine followed by oral ACT for a total period of 6 days.
3181786|NCT00697164|Experimental|2|Patients in group II received antimalarial drug as in group I and in addition 1500U/kg/day of rHUEPO for the initial 3 days.
3181787|NCT00697216|Experimental|Group A|
3181788|NCT00697216|Active Comparator|Group B|
3181789|NCT00697229|Experimental|Group A|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3188853|NCT00771420|Active Comparator|4|1.0mg/kg CAM-3001
3137121|NCT04043416|Experimental|Fall Prevention first, then System +Fall Prevention|"Participants in this arm will participate in the Fall Prevention program alone during the first 6 week campaign. Following the 6 week washout period the participants will be invited to use the jDome BikeAround system for up to 30 minute sessions up to 3 times a week during the second 6 week campaign. During this campaign the participants will also participant in the standard fall prevention program~Fall Prevention Program focuses on reducing the incidence of residents' falls and mitigating risks of falls through a resident focused, team approach which ensures that a resident's environment and social, physical, cognitive and emotional strengths are supported. This is an interdisciplinary program involving nursing and program staff, physician/pharmacist, dietician, physiotherapist, housekeeping staff and the resident/POA. They communicate regarding their planned interventions and evaluation of resident progress and outcomes in falls prevention through documentation."
3137122|NCT04057768|Other|Intervention|Device: Venus Viva
3137123|NCT04054375|Experimental|Weekly Steroid|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
3137124|NCT04052542|Active Comparator|Traditional online continuing education|
3137125|NCT04052542|Active Comparator|Interprofessional education|
3137126|NCT04052542|Active Comparator|Just-in-time education|
3181790|NCT00697229|Experimental|Group B|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3181791|NCT00697229|Experimental|Group C|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3181792|NCT00697229|Experimental|Group D|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 2 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3181793|NCT00697229|Experimental|Group E|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3181794|NCT00697229|Experimental|Group F|Subjects will receive HBV-MPL vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3181795|NCT00697229|Experimental|Group G|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of HBV-MPL vaccine at 70 months
3181796|NCT00697229|Experimental|Group H|Subjects will receive Engerix™-B vaccine in the primary schedule 0, 6 months and will receive a booster dose of Engerix™-B vaccine at 70 months
3181797|NCT00697242|Experimental|Group A|
3181798|NCT00697242|Experimental|Group B|
3181799|NCT00697242|Experimental|Group C|
3181800|NCT00697242|Active Comparator|Group D|
3181801|NCT00697242|Experimental|Group E|
3181802|NCT00697281|Experimental|1|Dose level 1
3181803|NCT00697281|Experimental|2|Dose level 2
3181804|NCT00697281|Experimental|3|Dose level 3
3181805|NCT00697281|Experimental|4|Dose level 4
3181806|NCT00697281|Experimental|5|Dose level 5
3188854|NCT00771420|Active Comparator|5|3.0mg/kgCAM-3001
3188855|NCT00771420|Active Comparator|6|10.0mg/kg CAM-3001
3137127|NCT04054193|Experimental|Fosaprepitant Treatment|Participants received fosaprepitant dimeglumine once daily (QD) for 3 days and were followed for 14 days during the 17-day Cycle 1. Participants also optionally received dexamethasone as background therapy, and a serotonin (5-hydroxytryptamine [5-HT3]) receptor antagonist on Day 1 and optionally on Days 2-3 as background therapy. After completing Cycle 1, participants had the option to continue for up to 2 additional 17-day cycles of the same treatment regimen.
3137128|NCT04050618|Experimental|ocufilcon D control lens, then fanfilcon A test lens|Participants will wear the ocufilcon D control lens for 4 weeks, then crossover to fanfilcon A test lens for 4 weeks of daily wear.
3137129|NCT04050618|Experimental|etafilcon A controls, then fanfilcon A test lens|Participants will wear the etafilcon D control lens for 2 weeks, then crossover to fanfilcon A test lens for 2 weeks of daily wear.
3137130|NCT04053465|Experimental|Exercise in heat group|Exercise in a hot environment
3137131|NCT04053465|Placebo Comparator|Exercise in cool group|Exercise in a cool environment
3137132|NCT04053270|Experimental|Group A|Group A was administered active implants on Days 0, 120, 240 and placebo implants on Days 60, 180, 300
3137133|NCT04053270|Placebo Comparator|Group B|Group B was administered placebo implants on Days 0, 120, 240 and active implants on Days 60, 180, 300
3137134|NCT04049552|Experimental|RAPA intervention|Rapamycin ointment will be applied to one keloid on the subject
3137135|NCT04049552|Placebo Comparator|Placebo|Placebo will be applied as a control on one keloid on the subject
3137136|NCT04053023|Experimental|Participants receiving obeticholic acid and linerixibat|In Part A, participants will be administered one tablet of 10 milligrams (mg) obeticholic acid once daily continuously for 37 days (study Day 1 to study Day 37). Two tablets of 45 mg linerixibat will be administered twice daily from study Day 20 to study Day 37. 1 tablet of 45 mg linerixibat will be administered on Day 38. After evaluation of Part A, if optional part B is conducted, participants will be administered linerixibat and obeticholic acid at an alternative dosing regimen.
3137137|NCT04051710|Experimental|Group-I (Test)|One inhalation of Beclomethasone dipropionate HFA, 0.04 mg/ INH (Test) twice daily.
3137138|NCT04051710|Active Comparator|Group-II (Reference)|One inhalation of QVAR® 40 mcg (Beclomethasone dipropionate HFA), Inhalation Aerosol twice daily.
3181807|NCT00697294|Experimental|Supplement|Subjects will serve as their own control in this single-arm protocol. All subjects will receive 400 IU/day of vitamin D as the intervention. Comparisons will be made between Caucasian and Hispanic infants.
3181808|NCT00697320||A|
3188856|NCT00771420|Placebo Comparator|7|Placebo
3137139|NCT04051710|Placebo Comparator|Group-III (Placebo)|One inhalation of Placebo Inhalation Aerosol twice daily.
3137140|NCT04050865|Experimental|OTX-DP|
3137141|NCT04050865|Placebo Comparator|Placebo|
3137142|NCT04050605|Experimental|somofilcon A toric (habitual), then fanfilcon toric (test)|Participants are habitual wearers of somofilcon A toric lens and refitted with fanfilcon A toric lens.
3137143|NCT04050371|Experimental|TRUVADA DOT|one tablet containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate as single dose with daily observed therapy performed either via video calling, or at study visit, for a total of 28 to 30 days
3149608|NCT00183014|Experimental|1|discussion session and exercise class
3137144|NCT04048460|Experimental|eAudiology|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
3137145|NCT04048681|Experimental|Diet Soda|12oz can of Diet Coke
3137146|NCT04048681|Active Comparator|Soda|12oz can of Coke
3137147|NCT04048681|Placebo Comparator|Carbonated Water|12oz can of carbonated (unflavored) water
3137148|NCT04046250|Experimental|TK112690|TK112690 treatment
3137149|NCT04046250|Placebo Comparator|Placebo|TK112690 formulation
3137150|NCT04047342||Standard welcome email|The standard welcome email mentions the benefits of enrollment (maintaining good health and saving money on insurance premiums), the average premium savings, the ease of the registration process, and the deadline for registering and having health measures on file, plus it provides registration steps and hyperlinks for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
3137151|NCT04047342||Loss frame email|"The loss frame email recommends that GHP members not throw away a precise dollar amount in savings (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action.~This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction."
3137152|NCT04044352|Experimental|Group 1|2 mL (approximately 5x10^6/mL tissue culture infective dose (TCID50)) of influenza A/Bethesda/MM2/H1N1challenge virus administered intranasally via a sprayer on Day 1. N=80.
3149609|NCT00183014|Active Comparator|2|exercise class only
3149610|NCT00183079|Active Comparator|1|Brief, motivationally-focused alcohol intervention
3149611|NCT00183157|Active Comparator|1|Patients will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call.
3149612|NCT00183157|Active Comparator|2|Patients will receive an assessment and a list of community resources
3149613|NCT00183157|Active Comparator|3|Patients will receive only the list of resources.
3137153|NCT04043728|Experimental|Mindfulness|This module introduces mindfulness training skills, with the goal of cultivating nonjudgmental, present-focused experience of emotions, thoughts, and physical sensations related to cigarette smoking. By progressing though a series of experiential exercises (e.g., awareness of the breath, anchoring in the present), this module seeks to reduce maladaptive attempts to control negative emotions and facilitate tolerance of the physical and emotional symptoms of nicotine withdrawal.
3137154|NCT04043728|Experimental|Interoceptive Exposure (Practice Quitting)|This module introduces interoceptive exposure, a technique in which participants purposefully and systematically complete exercises to evoke physical sensations typically associated with anxiety and distress, in order to reduce fear and avoidance of these sensations. Interoceptive exercises will focus on a gradual exposure to nicotine withdrawal symptoms, through a series of 'practice quit attempts' (i.e., brief periods of smoking abstinence without intention to permanently quit).
3137155|NCT04043728|Experimental|Behavioral Activation (Countering Emotional Behaviors)|This module introduces behavioral activation, which seeks to increase positive emotions by systematically introducing greater engagement with natural rewards. Treatment sessions focus on the identification of avoidance strategies, including cigarette smoking as a coping strategy for negative emotions. The goal of this treatment module is to replace smoking with adaptive coping strategies to facilitate contact with and enjoyment of reinforcing activities that are incompatible with smoking.
3137156|NCT04041453|Active Comparator|Albendazole 400mg|Albendazole 400mg in single dose
3137157|NCT04041453|Experimental|Albendazole/Ivermectin|Combination of albendazole 400mg + ivermectin 600mcg/kg in single dose.
3137158|NCT04041453|Experimental|Albendazole 400mg x 3|Albendazole 400mg/day for 3 consecutive days
3137159|NCT04041453|Experimental|Albendazole/Ivermectin x 3|Combination of albendazole 400mg/day + ivermectin 600mcg/kg/day for 3 consecutive days
3137160|NCT04041414|Experimental|Intervention schools|Schools will be assigned to either intervention or control schools. Students in intervention schools will receive the intervention in semester 1.
3137161|NCT04041414|Active Comparator|Control schools|Students in control schools will receive no intervention
3137162|NCT04041219|Experimental|Allogeneic blood or marrow transplantation|Subjects undergoing allogeneic blood or marrow transplantation (BMT) at Mayo Clinic in Rochester Minnesota
3137163|NCT04041700|Experimental|Osia 2 system|
3137164|NCT04040933|Active Comparator|Marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3137165|NCT04040933|Active Comparator|Marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed only on Days 3, 5, 7, 9, 11, 13, 15, and 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3181809|NCT00697333|No Intervention|A|Irradiation of all tumor manifestations detectable by CT and/or positron emission tomography using fluoro-deoxy-glucose including a part of eventual atelectasis and the whole affected lymph node stations by 60 - 74 Gy/2Gy) irradiation of elective lymph node stations up to 50 Gy/2 Gy
3181810|NCT00697333|Experimental|B|Irradiation of all tumor manifestations detectable by positron emission tomography using fluoro-deoxy-glucose including the whole affected lymph node stations by 60 - 74 Gy/2Gy
3137166|NCT04040933|Active Comparator|Non-marketed Adhesive Bandage #1|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3181811|NCT00697359|Experimental|1|There is only one group in this cohort study.
3137167|NCT04040933|Experimental|Non-marketed Adhesive Bandage #2|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3137168|NCT04040933|Experimental|Non-marketed Adhesive Bandage #3|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3137169|NCT04040933|Experimental|Non-marketed Adhesive Bandage #4|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3137170|NCT04040933|Experimental|Non-marketed Adhesive Bandage #5|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, bandage will be applied. This adhesive bandage will be changed daily from Day 1 through Day 16 and all wound sites will be uncovered from Day 16 to Day 28 for assessments.
3137171|NCT04040933|No Intervention|No Treatment (Uncovered, Negative Control)|Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, no treatment will be applied as the wound will be kept uncovered as negative control.
3137172|NCT04039867|Experimental|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
3137173|NCT04039412|Active Comparator|(1) Hybrid regimen|omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
3181812|NCT00697372|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
3137174|NCT04039412|Active Comparator|(2) Reverse hybrid regimen|clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
3137175|NCT04039412|Active Comparator|(3) Levofloxacin quadruple regimen|levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
3137176|NCT04035161|Experimental|Investigational Product|Skin will be prepared with investigational product
3137177|NCT04035161|Other|Reference Standard|Skin will be prepared with reference standard
3137178|NCT04035161|Active Comparator|Active Control|Skin will be prepared with active comparator
3137179|NCT04035161|Other|Negative Control|Skin will be prepared with negative control
3181813|NCT00697372|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
3181814|NCT00697385|Experimental|TA|on treatment
3181815|NCT00697398|Placebo Comparator|1|Sound placebo
3181816|NCT00697398|Experimental|2|Sound
3181817|NCT00697411||Experimental|Individuals with Aicardi syndrome and their first-degree relatives
3181818|NCT00697424|Experimental|1|All subjects will be placed on continuous positive airway pressure (CPAP) therapy during a full night sleep study or polysomnography (PSG). The subjects will spend 2 hours on sub-therapeutic CPAP 4 cmH2O of pressure and the remainder on there therapeutic pressure. Values reported on the device will be compared to scored values from manual scoring of the sleep study.
3137180|NCT04029519|Experimental|PN40082|All subjects in this study will receive one open-label treatment with PN40082.
3181819|NCT00697437|Experimental|docetaxel only|
3137181|NCT04024228|Experimental|Group 1: QIV-HD|Participants received a single injection of 0.7 milliliters (mL) QIV-HD, intramuscularly (IM) at Day 0.
3137182|NCT04024228|Active Comparator|Group 2: QIV-SD|Participants received a single injection of 0.5 mL QIV-SD, IM at Day 0.
3137183|NCT04039919|Experimental|Part A: Padsevonil and Ethanol|Subjects will be randomized to receive Padsevonil and Ethanol.
3137184|NCT04039919|Placebo Comparator|Part A: Padsevonil and Ethanol-Placebo|Subjects will be randomized to receive Padsevonil and Ethanol-Placebo.
3137185|NCT04039919|No Intervention|Part A: Ethanol and Ethanol-Placebo|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
3137186|NCT04039919|No Intervention|Part A: Ethanol-Placebo and Ethanol|Subjects will be randomized to receive Ethanol and Ethanol-Placebo.
3137187|NCT04039919|Experimental|Part B: Padsevonil and Cannabidiol|Subjects will be randomized to receive Padsevonil and Cannabidiol.
3137188|NCT04039919|Placebo Comparator|Part B: Padsevonil-Placebo and Cannabidiol|Subjects will be randomized to receive Padsevonil-Placebo and Cannabidiol.
3137189|NCT04037969|Experimental|Nesofilcon A/Delefilcon A|Nesofilcon A was worn in right eye and delefilcon A worn in the left eye.
3137190|NCT04037969|Experimental|Delefilcon A/Nesofilcon A|Delefilcon A was worn in right eye and Nesofilcon A worn in the left eye.
3137191|NCT04037865|Experimental|PF-06651600 Severe Renal Impairment|This arm includes participants with severe renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
3137192|NCT04037865|Experimental|PF-06651600 Normal Renal Function|This arm includes participants with normal renal function who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
3137193|NCT04037865|Experimental|PF-06651600 Moderate Renal Impairment|This arm is in Part 2 which will be conducted if decision criterion to proceed to Part 2 is met. This arm includes participants with moderate renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10
3181820|NCT00697437|Experimental|docetaxel with ketoconazole|
3181821|NCT00697450||All participants|
3181822|NCT00697476|Experimental|Vorinostat/Topotecan|"Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.~Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2"
3181823|NCT00697489|Active Comparator|1|unique surgery
3181824|NCT00697489|Active Comparator|2|Double surgery
3137194|NCT04037865|Experimental|PF-06651600 Mild Renal Impairment|This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met. The arm includes participants with mild renal impairment who will receive oral doses of PF-06651600 50 mg on Day 1 through Day 10.
3149614|NCT00183209|Experimental|14 session behavioral intervention|7 sessions addressing problem alcohol and drug use and 7 session addressing parenting challenges (monitoring, negotiation, etc) based on based on Social Action Theory (Ewart, 1991) and Motivational Interviewing
3181825|NCT00697502|Experimental|Group 2: TSER 3R/3R|Cohorts of 3-6 patients in each genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
3181826|NCT00697502|Experimental|Group 1: TSER 2R/2R or 2R/3R|Cohorts of 3-6 patients in this genotype group will receive escalating doses of capecitabine until MTD is reached. Once MTD is determined, an additional 6-9 patients (for a total of 12 patients) will receive treatment at that dose.
3181827|NCT00697528||Group control with healthy subjects|Healthy subjects without thyroid disease, ocular disease and previous surgery in the orbit or eye used in the study.
3181828|NCT00697528||Graves' Ophthalmopathy - fibrotic phase|Patients that are clinically inactive (CAS equal or lower than 2). This group will be subdivided in the miogenic and lipogenic groups.
3137195|NCT04037748|Experimental|First Puran T4®, then Eutirox®|Participants received single oral dose of Puran T4® 600 micrograms (mcg) (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
3137196|NCT04037748|Experimental|First Eutirox®, then Puran T4®|Participants received single oral dose of Eutirox® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 1 followed by single oral dose of Puran T4® 600 mcg (3 tablets of 200 mcg Levothyroxine sodium) in Treatment Period 2 under fasting conditions. A wash-out period of 70 days was maintained between the Treatment Periods 1 and 2.
3149615|NCT00183209|Active Comparator|Brief Video Intervention|Single session brief video intervention to build motivation to reduce or eliminate problem drinking/drug use
3137197|NCT04036838|Experimental|Indication for H.pylori testing|Walk in basis: Symptomatic patients of H.pylori infection will be enrolled for this study if all acceptance criteria are met. Patients will undergo C13 Urea Breath Test in addition to at least 2 other diagnostic tools from one obtained biopsy as comparison.
3137198|NCT04034121|Other|DESolve Cx|DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System
3137199|NCT04027686|Experimental|SRP + Adjunctive Laser Therapy|Laser therapy used as an adjunct to scaling and root planing
3137200|NCT04027686|Active Comparator|SRP alone|Scaling and root planing used as conventional non-surgical periodontal therapy
3149616|NCT00183261|Experimental|1|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine at study entry and on Weeks 4 and 26
3181829|NCT00697528||Graves' Ophthalmopathy - active phase|Patients that are clinically active, presenting a CAS of 4 or more points, with or without disthyroid optic neuropathy.
3137201|NCT04022694|Active Comparator|Calorie/Control Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. It will simply state that those beverages are sold in the school store.
3137202|NCT04022694|Experimental|SSB Warning and Non-SSB Promotion Poster|This poster will display images of both SSBs and low or no sugar beverages with calories listed below the beverages. In addition, the message will state that SSBs are high in sugar and should be avoided, while low or no sugar beverages are healthier options and should be chosen.
3137203|NCT04022694|No Intervention|Baseline for Calorie/Control Poster|We will collect baseline data from a group of students before posting the Calorie/Control Poster in the control school.
3137204|NCT04022694|No Intervention|Baseline for SSB Warning and Non-SSB Promotion Poster|We will collect baseline data from a group of students before posting the SSB Warning and Non-SSB Promotion Poster in the intervention school.
3137205|NCT04036110|Experimental|Intervention 1|Vitamin C 500 mg taken daily for 3 months
3181830|NCT00697554|Experimental|Group A|
3181831|NCT00697554|Active Comparator|Group B|
3181832|NCT00697567|Experimental|Group A|HSV seropositive subjects
3181833|NCT00697567|Experimental|Group B|HSV seronegative subjects
3181834|NCT00697567|Experimental|Group C|HSV seropositive subjects
3181835|NCT00697567|Experimental|Group D|HSV seronegative subjects
3181836|NCT00697580|No Intervention|1|Control (C)
3137206|NCT04036110|Experimental|Intervention 2|Vitamin C 1000 mg taken daily for 3 months
3137207|NCT04036110|Placebo Comparator|Control|Placebo tablets taken daily for 3 months
3137208|NCT04035694|Experimental|Intervention|Participants will receive access to Media Aware.
3181837|NCT00697580|Experimental|2|Nutrition (N)
3181838|NCT00697580|Experimental|3|Strength Training & Nutrition (ST + N)
3137209|NCT04035694|No Intervention|Delayed-Intervention Control|Participants will receive their regular health education programming not related to sexual health education or media literacy education.
3137210|NCT04035577|Experimental|Extended usability of a mobile self-help intervention|Participants will have open access to the Intellicare Hub app for 8-weeks and be surveyed at Baseline, 4-weeks, and 8-weeks
3137211|NCT04035564|Active Comparator|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life one
3137212|NCT04035564|Experimental|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life one
3181839|NCT00697580|Experimental|4|Circuit Training & Nutrition (CT + N)
3149617|NCT00183261|Placebo Comparator|2|Participants will receive the MRKAd5 HIV-1 gag/pol/nef vaccine placebo at study entry and on Weeks 4 and 26
3181840|NCT00697606|Experimental|A|Seprafilm®
3181841|NCT00697606|Sham Comparator|B|Control
3181842|NCT00697632|Experimental|1|
3181843|NCT00697645|Sham Comparator|1|Patients with stroke will be treated with usual stroke care and sham TMS will be applied
3181844|NCT00697645|Experimental|2|Deep TMS applied over the motor strip in patients with stroke in addition to usual stroke care.
3181845|NCT00697658||001|
3181846|NCT00697671|Other|Strata A|Patients with ALL, CML, JMML, MDS, or NHL with bone marrow relapse after stem cell transplant.
3181847|NCT00697671|Other|Strata B|Patients with ALL, CML, JMML , MDS, or NHL with primary induction failure and persistent disease; or participants with relapsed ALL, CML, JMML, MDS, or NHL with persistent disease after re-induction
3137213|NCT04032977|Experimental|PN40082|Test device: PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w
3137214|NCT04032977|Active Comparator|Restylane Silk|Restylane Silk (manufactured by Q-Med AB for Medicis - A Division of Valeant Pharmaceuticals Corporation North America, LLC ) is a clear, colorless gel in 1.0 mL pre-filled syringes formulated to a concentration of 20 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
3137215|NCT04032652|Active Comparator|1200 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 1200 mg asacol
3137216|NCT04032652|Active Comparator|2400 mg Asacol once daily for 1 week|Rectal dialysis will be done after 1 week on 2400 mg asacol
3137217|NCT04024501|Experimental|Treatment 1|During this treatment period, healthy participants will receive 1 x 12 mg verinurad ER8 capsule formulation in fasted state.
3181848|NCT00697684|No Intervention|Cohort 1|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3188857|NCT00771433|Experimental|Group 1|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses.
3137218|NCT04024501|Experimental|Treatment 2|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fasted state.
3137219|NCT04024501|Experimental|Treatment 3|During this treatment period, healthy participants will receive 2 x 6 mg verinurad A-capsule formulation in fed state.
3137220|NCT04024501|Experimental|Treatment 4|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fasted state.
3137221|NCT04024501|Experimental|Treatment 5|During this treatment period, healthy participants will receive 2 x 6 mg verinurad B-capsule formulation in fed state.
3137222|NCT04032613|Experimental|Vascular access quality improvement program participants|All participants enrolled in the study who are involved in the Vascular Access Navigation and Education Quality Improvement Program.
3137223|NCT04032171|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
3137224|NCT04032171|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
3188858|NCT00771433|Experimental|Group 2|Patients receive G-CSF SC once daily on days 6-11 of each course of chemotherapy as primary prophylaxis. Chemotherapy courses repeat every three weeks for 3-6 courses. Patients may also receive secondary prophylaxis with G-CSF if they experience an episode of neutropenia.
3137225|NCT04032158|Experimental|Evobrutinib + Avonex® matched Placebo|Participants received active evobrutinib twice daily (BID) along with concomitant intramuscular (IM) injection of placebo matched to Avonex® once a week. Treatment period was planned to be of 96 weeks.
3149618|NCT00183313|Experimental|1|Participants will receive nurse case management intervention
3149619|NCT00183313|Active Comparator|2|Participants will receive usual care
3149620|NCT00183326|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy
3149621|NCT00183326|Active Comparator|2|Participants will receive child-centered supportive therapy
3149622|NCT00183352||1|Women with bipolar disorder
3149623|NCT00183352||2|Women who are healthy controls
3137226|NCT04032158|Active Comparator|Avonex® + Evobrutinib matched Placebo|Participants received IM injection of active Avonex® once a week along with concomitant placebo matched to evobrutinib BID. Treatment period was planned to be of 96 weeks.
3149624|NCT00183365|Experimental|1|Participants will receive the Protecting Families Program with individual parent training
3181849|NCT00697684|Experimental|Cohort 2|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3181850|NCT00697684|Experimental|Cohort 3|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3137227|NCT04031404|Experimental|Glucose drink followed by placebo|Participants will consume the glucose drink at session 1, then they will consume the placebo (water) at session 2.
3137228|NCT04031404|Experimental|Placebo followed by glucose drink|Participants will consume the placebo (water) at session 1, then they will consume the glucose drink at session 2.
3137229|NCT04031885|Experimental|Abemaciclib + Fulvestrant|150 milligram (mg) Abemaciclib given orally twice a day (BID) with 500 mg fulvestrant given by intramuscular (IM) injection on Cycle 1 Day 1 (C1D1) and Cycle 1 Day 15 (C1D15), then Day 1 of each subsequent cycle.
3137230|NCT04031885|Active Comparator|Standard Chemotherapy|Standard chemotherapy of physician's choice (capecitabine, docetaxel, nab paclitaxel, or paclitaxel), administered according to product label.
3137231|NCT04018924|Experimental|T - Treated|After standard cleansing or debridement of all wounds, on wound or portion of wound selected for treatment is treated with EmoLED device. Then covered with hydro fibre medication and dressing or compressive dressing when needed on the whole wound (SOC). Treatment is repeated once a week.
3137232|NCT04015440|Experimental|HBMT|
3137233|NCT04015440|Placebo Comparator|Placebo|
3137234|NCT04030104|Active Comparator|Imagio IUS|Read 1 (Control): History + Mammogram (if available) + IUS (Imagio Ultrasound) stills and videos provided), IUS Probability of Malignancy (POM) and Breast Imaging Reporting and Data System (BI-RADS) scored and the data form then locked.
3149625|NCT00183365|Active Comparator|2|Participants will receive parent training alone
3137235|NCT04030104|Experimental|Imagio (IUS+OA)|Read 2 (Test): History + Mammogram (if available) + IUS (stills and videos provided), and Imagio (IUS+OA) (stills and videos provided). Imagio (IUS+OA) POM and Breast Imaging Reporting and Data System (BI-RADS) assigned after viewing the SenoGram® output. The dataform is locked.
3137236|NCT04029961|Active Comparator|Video Education|Participants will receive video education on radiation therapy.
3137237|NCT04029961|Experimental|VR-based Education|Participants will receive VR-based education on radiation therapy.
3137238|NCT04025684|Other|Test toothbrush 1|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 1 after applying a strip of standard fluoride (1450 parts per million [ppm] fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
3149626|NCT00183378|Active Comparator|1|Routine medical care with education: therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support.
3188859|NCT00771446|Experimental|ELAD (plus Standard of Care)|Treatment with ELAD in addition to standard of care therapy Standard of care therapy defines uniform treatment for ascites, esophageal varices, dietary recommendations, etc.
3137239|NCT04025684|Other|Test toothbrush 2|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 2 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
3181851|NCT00697684|Experimental|Cohort 4|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
3181852|NCT00697710|Experimental|Cohort A|50 mg S-777469 or Placebo, BID
3137240|NCT04025684|Other|Test toothbrush 3|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 3 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
3137241|NCT04025684|Other|Test toothbrush 4|Participants will brush their entire dentition twice daily (morning and evening) for 1-timed minute with test toothbrush 4 after applying a strip of standard fluoride (1450 ppm fluoride) toothpaste (full brush head) and will then rinse with 10 mL of water post brushing for 5 seconds (on site). Offsite participants will be permitted to rinse with tap water according to their normal habitat.
3149627|NCT00183378|Active Comparator|2|Walking: the therapist introduces a walking program and assists the caregiver in establishing a daily walking routine of 30 minutes for the study participant.
3149628|NCT00183378|Active Comparator|3|Light exposure: the therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
3181853|NCT00697710|Experimental|Cohort B|200 mg S-777469 or Placebo, BID
3181854|NCT00697710|Experimental|Cohort C|800 mg S-777469 or Placebo, BID
3137242|NCT04019054|Experimental|Active iTBS, Ventromedial Prefrontal Cortex (vmPFC)|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vmPFC, as determined by position Fpz of the international 10-20 EEG electrode system."
3181855|NCT00697749|Experimental|Group A|
3181856|NCT00697749|Active Comparator|Group B|
3181857|NCT00697762|Placebo Comparator|003|Placebo tablet twice daily for 12 weeks
3181858|NCT00697762|Experimental|002|RWJ-333369 200 mg tablet twice daily for 12 weeks
3181859|NCT00697762|Experimental|001|RWJ-333369 100 mg tablet twice daily for 12 weeks
3181860|NCT00697775|Experimental|Group A|HBV-MPL Formulation A at months 0 and 6
3181861|NCT00697775|Experimental|Group B|HBV-MPL Formulation B at months 0 and 6
3181862|NCT00697775|Experimental|Group C|HBV-MPL Formulation A at month 0 and Engerix™-B at month 6
3181863|NCT00697775|Active Comparator|Group D|Engerix™-B at months 0, 1, 6
3181864|NCT00697814|Experimental|Clomiphene|Clomiphene 50 mg/day for 12 weeks
3181865|NCT00697840|Experimental|Group A|
3149629|NCT00183378|Active Comparator|4|Combination: the therapist provides education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
3149630|NCT00183404|Experimental|Olanzapine|Participants will take open olanzapine for up to 20 additional weeks after phase 1.
3149631|NCT00183417|Experimental|1|Participants will receive cognitive behavioral therapy
3137243|NCT04019054|Placebo Comparator|Control iTBS, vertex|"Stimulation intensity of 100% of the individual resting motor threshold in bursts of three pulses at a frequency of 50 Hz every 200 ms on top of a 5Hz carrier wave. Pulse delivery is over 2 s and repeated every 10 s, 20 times in succession, for a total of 600 pulses delivered in 3.33 minutes.~Delivered over vertex, as determined by position Cz of the international 10-20 EEG electrode system."
3137244|NCT04029545|Experimental|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w. The study device will be provided by the Sponsor.
3181866|NCT00697840|Active Comparator|Group B|
3181867|NCT00697840|Experimental|Group C|
3181868|NCT00697853|Active Comparator|Group A|
3181869|NCT00697853|Experimental|Group B|
3181870|NCT00697853|Experimental|Group C|
3181871|NCT00697853|Experimental|Group D|
3181872|NCT00697853|Experimental|Group E|
3181873|NCT00697866|Experimental|Group A|HBV-MPL Lot A
3181874|NCT00697866|Experimental|Group B|HBV-MPL Lot B
3149632|NCT00183417|Active Comparator|2|Participants will receive supportive/expressive therapy
3181875|NCT00697866|Experimental|Group C|HBV-MPL Lot C
3181876|NCT00697866|Active Comparator|Group D|Engerix™-B
3137245|NCT04029545|Active Comparator|RV001 with lidocaine cream|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used with LMX4, a topical lidocaine. The study device will be provided by the Sponsor. LMX4 will be provided in commercial stock packaging by the Sponsor
3137246|NCT04029545|Experimental|RV001|RV001 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid to be used alone. The study device will be provided by the Sponsor.
3137247|NCT04029584|Experimental|Fluvastatin Alone First, Then Fluvastatin +IV Rifampin 600 mg|"The effect of rifampin on the pharmacokinetics of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to receive one oral dose of fluvastatin (Lescol®) 20mg capsule first. Separated by one day of washout, they then receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.~Before starting hepatic induced period, subjects will have a washout for greater than one week.~To induce hepatic enzyme and transporter, Subjects will be pretreated with 5 days with 600mg oral rifampin. Subjects will be then randomized first to receive a single dose of fluvastatin 20mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg."
3149633|NCT00183417|Active Comparator|3|Participants will receive bibliotherapy
3149634|NCT00183417|No Intervention|4|Participants in the control condition will receive no treatment
3181877|NCT00697879|Experimental|1|Oral, once daily administration of CHR-3996 to determine safety and tolerability
3137248|NCT04029584|Experimental|Fluvastatin +IV Rifampin 600 mg First, Then Fluvastatin Alone|"The effect of rifampin on the disposition of fluvastatin will be studied in healthy volunteers with or without hepatic induction in a randomized, unblinded, crossover clinical trial.~For uninduced periods, subjects will be randomized to first receive one oral dose of fluvastatin (Lescol®) 20mg capsule immediately following a 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline.Separated by one day of washout, subjects will be then receive a single dose of fluvastatin (Lescol®) 20mg capsule.~Before starting induction periods, subjects will have a washout greater than one week.~To induce hepatic enzyme and transporter, subjects will be pretreated with 5 days with 600mg oral rifampin. subjects will be randomized to receive first one oral dose of fluvastatin 20mg immediately after a 30-min IV infusion of rifampin 600mg. Separated by one day of washout, subject will then receive one oral dose of fluvastatin 20mg."
3137249|NCT04029311|Experimental|Combination Therapy with Preferred Mask|Preferred Mask refers to a type of existing medical mask used for PAP therapy.
3137250|NCT04029311|Experimental|Combination Therapy with Custom Mask|Custom Mask refers to a mask which is supported by an interface which attaches directly to the patient's oral appliance.
3137251|NCT04028960|Placebo Comparator|Placebo|No active drug
3137252|NCT04028960|Experimental|Humulin-R|Insulin
3137253|NCT04026399|Experimental|stimulation + therapy|The participant receives stimulation and home therapy.
3137254|NCT04026399|Sham Comparator|no stimulation + therapy|The participant receives no stimulation and receives home therapy.
3137255|NCT04023578|Experimental|Rheo Knee XC|Amputee subjects currently using either magneto-rehologic or hydraulic MPKs are fitted with the Rheo Knee XC, a magneto-rheologic MPK.
3137256|NCT04023695|Active Comparator|Corticosteroid with lidocaine with epinephrine|This arm includes an injection mixture of corticosteroid and lidocaine with epinephrine
3137257|NCT04023695|Experimental|Corticosteroid with normal saline|This arm includes a mixture of corticosteroid and normal saline. The purpose of normal saline is the keep the volume and concentration similar when compared to the injections containing lidocaine.
3137258|NCT04018664|Placebo Comparator|Placebo|"Placebo~150 mL flavored beverage"
3137259|NCT04018664|Experimental|90 mg nalbuphine HCl solution|"90 mg nalbuphine HCl solution~9 mL × 10 mg/mL hydromorphone HCl + 141 mL flavored beverage"
3137260|NCT04018664|Experimental|120 mg nalbuphine HCl solution|"120 mg nalbuphine HCl solution~12 mL × 10 mg/mL hydromorphone HCl + 138 mL flavored beverage"
3137261|NCT04018664|Experimental|150 mg nalbuphine HCl solution|"150 mg nalbuphine HCl solution~15 mL × 10 mg/mL hydromorphone HCl + 135 mL flavored beverage"
3137262|NCT04018664|Experimental|180 mg nalbuphine HCl solution|"180 mg nalbuphine HCl solution~18 mL × 10 mg/mL hydromorphone HCl + 132 mL flavored beverage"
3137263|NCT04018664|Experimental|270 mg nalbuphine HCl solution|"270 mg nalbuphine HCl solution~27 mL × 10 mg/mL hydromorphone HCl + 123 mL flavored beverage"
3137264|NCT04018664|Experimental|Up to 405 mg nalbuphine HCl solution|"Up to 405 mg nalbuphine HCl solution~Up to 40.5 mL × 10 mg/mL hydromorphone HCl + at least 109.5 mL flavored beverage"
3137265|NCT04018664|Experimental|Up to 540 mg nalbuphine HCl solution|"Up to 540 mg nalbuphine HCl solution~Up to 54 mL × 10 mg/mL hydromorphone HCl + at least 96 mL flavored beverage"
3137266|NCT04016259|Experimental|Self-CES|
3137267|NCT04016259|Placebo Comparator|Sham-CES|
3137268|NCT04016077|Experimental|PF-06651600 Moderate Hepatic Impairment|This arm includes participants with moderate hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
3137269|NCT04016077|Experimental|PF-06651600 Healthy participants|This arm includes healthy adult participants who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10.
3181878|NCT00697892|Experimental|Group A4|healthy volunteers assigned to the efavirenz with artemether/lumefantrine intervention
3137270|NCT04016077|Experimental|PF-06651600 Mild Hepatic Impairment|"This arm is in Part 2 which will be conducted if the decision criterion to proceed to Part 2 is met.~The arm includes participants with mild hepatic impairment who will receive oral doses of PF-06651600 30 mg on Day 1 through Day 10."
3137271|NCT04027803|Experimental|BCD-148|39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min
3137272|NCT04027803|Active Comparator|Soliris|39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min
3137273|NCT04016311|Experimental|Mindful Drinking/Eating Group|Behavioral: Mindful Drinking/Eating Intervention Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
3137274|NCT04016311|No Intervention|Wait list control|Usual care. Offered intervention after post-test data collected.
3181879|NCT00697892|Experimental|Group A3|healthy volunteers assigned to the lopinavir/ritonavir with artemether/lumefantrine intervention
3137275|NCT04027439|Active Comparator|Part A: RPL554|Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
3137276|NCT04027439|Active Comparator|Part B: RPL554|Double-blind, placebo-controlled, complete block cross-over
3181880|NCT00697905|Experimental|A|
3181881|NCT00697905|Active Comparator|B|
3181882|NCT00697918|Experimental|001|RWJ-333369100 mg to 400 mg twice daily
3181883|NCT00697931|Experimental|Group A|
3181884|NCT00697931|Active Comparator|Group B|
3181885|NCT00697957|No Intervention|2|Control group
3181886|NCT00697957|Experimental|1|Exercise
3181887|NCT00697970|Experimental|Group A|
3181888|NCT00697970|Experimental|Group B|
3137277|NCT04027218|Active Comparator|Current clinical practice-Dry heat|"The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice)."
3137278|NCT04027218|Active Comparator|Current clinical practice- Hihg pressure|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice)."
3137279|NCT04027218|Active Comparator|Current clinical practice-Combination|"The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice)."
3137280|NCT04026750|Experimental|Pitolisant|
3137281|NCT04026750|Placebo Comparator|Matching placebo|
3137282|NCT04026308|No Intervention|Written Safety Plan|Participants will complete a traditional written suicide safety plan.
3137283|NCT04026308|Experimental|Electronic Safety Plan|Participants will complete a suicide safety plan in the Safety Net app using a tablet.
3137284|NCT04023682|Other|Anesthesia Provider hands|"Each provider will serve as their own control.~Control phase is at baseline using standard hygiene practices.~Intervention phase will include the addition of Provodine hand sanitizer"
3181889|NCT00697970|Experimental|Group C|
3181890|NCT00697970|Experimental|Group D|
3137285|NCT04021771|Other|Group A (Intervention Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. Participants in Group A will be given access to the online interactive module and will have the opportunity to have video-based DP sessions with the SPs. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP. Group A will return for a third visit (T3) to provide information about the decay of learned skills and if performance on the task is maintained by a single intervention.
3149635|NCT00183482|Experimental|Family Group Cognitive Behavioral|The intervention is a family group cognitive behavioral program for families of parents with a history of depression to teach parenting skills to parents and coping skills to children.
3181891|NCT00697970|Experimental|Group E|
3181892|NCT00697970|Active Comparator|Group F|
3137286|NCT04021771|Other|Group B (Control Group)|Participants will have at least three study visits. The first visit (T1) will consist of a baseline test, during which participants will complete a simulated encounter with a standardized patient (SP) to establish a baseline score. The second visit (T2) will be scheduled 4-8 weeks after T1 and will consist of another simulated encounter with the SP; following this session, participants in Group B will be introduced to the intervention. Group B will return for a third visit (T3) to provide information on how the curriculum impacts their score.
3137287|NCT04019626|Active Comparator|Continue-smoking|The subject's usual brand of combustible cigarette
3181893|NCT00697983||Fracture cohort|Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).
3181894|NCT00698048||1|Controls
3181895|NCT00698048||2|Sepsis
3181896|NCT00698048||3|Septic Shock
3181897|NCT00698061|Experimental|Group A|
3181898|NCT00698061|Active Comparator|Group B|
3181899|NCT00698074|Experimental|1|Cardiac Resynchronisation Therapy
3181900|NCT00698087|Experimental|Group A|
3181901|NCT00698087|Active Comparator|Group B|
3181902|NCT00698087|Experimental|Group C|
3181903|NCT00698100|Experimental|1|Patients will get human tyrosinase vaccination.
3181904|NCT00698100|Experimental|2|Patient will get mouse tyrosinase DNA vaccination.
3181905|NCT00698113|Active Comparator|1|This group receives the massage intervention for a period of six weeks. Children and parents are asked to journal weekly for the six week period.
3137288|NCT04019626|Experimental|myblu Tobacco 2.5%|myblu e-cigarette system with Tobacco flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
3181906|NCT00698113|No Intervention|2|The control group does not receive any massage intervention during the initial six weeks of the study. The children are asked to journal during this six week period.
3181907|NCT00698126||A|
3137289|NCT04019626|Experimental|myblu Tobacco 4.0%|myblu e-cigarette system with Tobacco flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
3137290|NCT04019626|Experimental|myblu Honeymoon 2.5%|myblu e-cigarette system with Honeymoon flavor, 2.5% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
3181908|NCT00698126||B|
3181909|NCT00698152||ArComXL® polyethylene|ArComXL® polyethylene
3181910|NCT00698165||Patients|1200 adults with mild to severe Alzheimer's disease
3181911|NCT00698165||Caregivers|1200 informal caregivers
3181912|NCT00698178||NERD|patients with typical gastro-reflux symptoms but no erosions were discernible on upper gastrointestinal endoscopy
3181913|NCT00698178||EE|Patients with both typical gastroesophageal reflux symptoms and characteristic flam-like erosions as demonstrated on upper gastrointestinal endoscopy
3137291|NCT04019626|Experimental|myblu Honeymoon 4.0%|myblu e-cigarette system with Honeymoon flavor, 4.0% nicotine. At Day 28 of the study, subjects may be allowed to switch to another myblu variant.
3137292|NCT04019626|Active Comparator|JUUL 5%|JUUL® system with Virginia Tobacco Flavor JUULpod, 5.0% nicotine. This arm is only included in the PK sub-study.
3137293|NCT04023994|Placebo Comparator|Placebo|In Cohorts 1-5, there were ten participants in total who received placebo, two in each cohort.
3137294|NCT04023994|Experimental|RO7126209 (0.1 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.1 mg/kg).
3137295|NCT04023994|Experimental|RO7126209 (0.4 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (0.4 mg/kg).
3137296|NCT04023994|Experimental|RO7126209 (1.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (1.2 mg/kg).
3137297|NCT04023994|Experimental|RO7126209 (3.6 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (3.6 mg/kg).
3137298|NCT04023994|Experimental|RO7126209 (7.2 mg/kg)|Healthy volunteers will be administered a single intravenous dose of RO7126209 (7.2 mg/kg).
3137299|NCT04022668||STEMI|Current international ECG criteria (New ST-segment elevation at the J-point in two contiguous leads with the cut-points: ≥0.1 mV millivolts (mV) in all leads other than leads V2-V3; for leads V2-V3: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age) with troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia.
3137300|NCT04022668||NSTEMI|Troponin rise above 99th percentile in a clinical situation suggestive of myocardial ischemia without abovementioned criteria.
3137301|NCT04022668||Normal|Emergency department admission with a clinical picture compatible with acute coronary syndrome, but no change in serial ECGs and no rise in cardiac biomarkers
3137302|NCT04020822|Experimental|Subjects Wearing Guardian Sensor (3)s|Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear.
3137303|NCT04019990|Other|Wheelchair basketball and ambulant basketball players|13 players from the North Cyprus wheelchair Basketball Team and 15 players from the Koop Bank Basketball Men's Team voluntarily will participate in the study. Subjects will include to study if they fulfil criteria. Athletes will involve in 8 weeks Thrower's Ten exercise program. After 8. Weeks and 12. Weeks assessments will be repeated.
3137304|NCT04017611|Experimental|INVSENSOR00038|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00038 sensor.
3137305|NCT04015232|Experimental|INTP5 biosimilar product|INTP5 subcutaneously at a dose of 6 mg/0.6 mL.
3137306|NCT04015232|Active Comparator|US Neulasta reference product|US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.
3137307|NCT04016623|Experimental|1-day toric test contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
3137308|NCT04016623|Active Comparator|1-day toric control contact lens|Each subject will wear the 1-day toric test (Test) lens in one eye and 1-day toric control (Control) contact lens in the other eye. Patient will wear as an unmatched pair, per predetermined randomization schedule (to determine which eye receives the Test or Control contact lens).
3137309|NCT04013737||Patients and Public|Exploration of patient and public engagement with antibiotic decision making in secondary care. Prospective evaluation of a co-designed intervention to support enhanced knowledge and understanding of infections and their management.
3137310|NCT04013737||Prescribers|Quantitative evaluation of the impact of using a clinical decision support system to support antibiotic decision making.
3137311|NCT04014062|Experimental|INTP5 Period I Crossover|"Period I: Subjects received a single dose of INTP5 subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of US Neulasta."
3137312|NCT04014062|Active Comparator|US Neulasta Period I Crossover|"Period I: Subjects received a single dose US Neulasta subcutaneously at a dose of 6 mg/0.6 mL.~Period II: After the first treatment cycle and a six week wash out period, patients received a single dose of INTP5."
3137313|NCT04013789|Other|DACP FreshTech, then DACP|DACP FreshTech contact lenses worn first, followed by DACP contact lenses, as randomized. Each product was worn in both eyes for approximately 8 hours per day for 1 week with a new pair of lenses worn each day.
3137314|NCT04013789|Other|DACP, then DACP FreshTech|DACP contact lenses worn first, followed by DACP FreshTech contact lenses, as randomized.. Each product was worn in both eyes for approximately 8 hours per day, for 1 week with a new pair of lenses worn each day.
3137315|NCT04012970|Experimental|A - Intervention then control|Intervention (30 minutes spinal mobilisations) received in first session, then control (30 minutes lying still) received in second session.
3137316|NCT04012970|Experimental|B - Control then intervention|Control (30 minutes lying still) received in first session, then intervention (30 minutes spinal mobilisations) received in second session.
3137317|NCT04013191|Experimental|Adult study participants|Participants will receive assigned single and multiple doses of padsevonil.
3137318|NCT04013191|Experimental|Elderly study participants|Participants will receive assigned single and multiple doses of padsevonil.
3137319|NCT04011631|Experimental|Patients with cardiac surgery|All patients undergoing cardiac surgery at the Ziekenhuis Oost-Limburg, meeting all inclusion and no exclusion criteria, are asked to participate in the investigation.
3137320|NCT04011735||Respimat SMI-experienced: Switching to re-usable Respimat|patients who had been on maintenance treatment with a disposable Respimat and who switched to a re-usable Respimat SMI at study entry.
3137321|NCT04011735||Respimat SMI-naïve|patients who have not previously used a Respimat SMI product and receive their first prescription at study entry
3137322|NCT04011735||Respimat SMI-experienced: Maintenance treatment|patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry.
3149636|NCT00183482|Active Comparator|Written Information|The comparison arm involves providing written information about depression and stress to parents with a history of depression and their children.
3149637|NCT00183508|Experimental|1 Cognitive behavioral therapy|
3149638|NCT00183508|Experimental|2 Psychoeducation|
3149639|NCT00183521|Experimental|1|Participants will receive raise-CO2 breathing regulation training
3149640|NCT00183521|Experimental|2|Participants will receive lower-CO2 breathing regulation training
3149641|NCT00183521|Active Comparator|3|Participants will receive no breathing regulation training
3149642|NCT00183547|Experimental|1|"Living in Harmony depression prevention program"
3149643|NCT00183547|Active Comparator|2|Depression-prevention education and support
3149644|NCT00183560|Experimental|1|Participants will receive mindfulness based cognitive therapy
3149645|NCT00183560|Active Comparator|2|Participants will receive maintenance antidepressant pharmacotherapy
3149646|NCT00183560|Placebo Comparator|3|Participants will receive placebo plus clinical management
3149647|NCT00183573|Experimental|1|Brief Motivational Intervention only
3181914|NCT00698178||FD|Patients report no typical reflux symptoms but fulfill diagnostic criteria of functional dyspepsia, whose upper gastrointestinal endoscopy are negative.
3181915|NCT00698191|Experimental|1|
3181916|NCT00698230|Experimental|Treatment A - INCB013739 & Metformin|INCB013739 5 mg QD and Metformin
3181917|NCT00698230|Experimental|Treatment B - INCB013739 & Metformin|INCB013739 15 mg QD and Metformin
3149648|NCT00183573|Experimental|2|Brief Informational Intervention only
3181918|NCT00698230|Experimental|Treatment C - INCB013739 & Metformin|INCB013739 50 mg QD and Metformin
3137323|NCT04010695|Other|G6PD Diagnostic Testing|"Participants provided whole blood samples as well as fingerstick capillary blood samples.~At the clinic site lab, study staff conducted the SD Biosensor point-of-care G6PD test and the point-of-care HemoCue Hb test on both finger stick blood and whole blood samples.~At the reference laboratory, G6PD activity was measured from whole blood samples using the Pointe Scientific G6PD reference assay and hemoglobin was measured using a hematology analyzer."
3137324|NCT04009577|Experimental|Cohort 1 (LEM 5 mg)|"Participants who were taking zolpidem tartrate (ZOL) at least 3 but fewer than 5 nights per week, for each of at least 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.~Participants who meet both criteria for intermittent (Cohort 1) and frequent ZOL use (Cohort 2A and 2B) for 1 week each of the last 2 weeks of the 3-week Screening Period will be assigned to Cohort 1 and also will receive LEM 5mg."
3137325|NCT04009577|Experimental|Cohort 2A (LEM 5 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 5 mg administered as a tablet, orally for up to 2 weeks.
3137326|NCT04009577|Experimental|Cohort 2B (LEM 10 mg)|Participants who were taking ZOL at least 5 nights per week, during, at minimum, the last 2 weeks of the 3-week Screening Period, will initially receive LEM 10 mg administered as a tablet, orally for up to 2 weeks.
3181919|NCT00698230|Experimental|Treatment D - INCB013739 & Metformin|INCB013739 100 mg QD and Metformin
3181920|NCT00698230|Experimental|Treatment E - INCB013739 & Metformin|INCB013739 200 mg QD and Metformin
3137327|NCT04007159|Experimental|Developmental Serum|The participants will be applied a semi-occlusive adhesive patch containing the developmental serum (0.02 milliliters per centimeters square [mL/cm^2] in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
3181921|NCT00698230|Placebo Comparator|Treatment F - Placebo|Matching placebo
3137328|NCT04007159|Experimental|Developmental Lotion|The participants will be applied a semi-occlusive adhesive patch containing the developmental lotion (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
3149649|NCT00183573|Experimental|3|Brief Motivational Intervention + Intensive Informational Intervention
3149650|NCT00183573|Experimental|4|Brief Motivational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
3149651|NCT00183573|Experimental|5|Brief Informational Intervention + Intensive Informational Intervention
3149652|NCT00183573|Experimental|6|Brief Informational Intervention + Intensive Information-Motivation-Behavioral Skills Intervention
3149653|NCT00183586|Experimental|1|Participants will receive family-based treatment
3137329|NCT04007159|Experimental|Developmental Cream|The participants will be applied a semi-occlusive adhesive patch containing the developmental cream (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
3149654|NCT00183586|Active Comparator|2|Participants will receive individual adolescent focused therapy
3149655|NCT00183599|Experimental|1|
3149656|NCT00183599|Experimental|2|
3149657|NCT00183599|Experimental|3|
3181922|NCT00698243|Experimental|Schedule 1|Once daily for 3 days every 7 days
3181923|NCT00698243|Experimental|Schedule 2|Once weekly
3137330|NCT04007159|Placebo Comparator|Negative Control|The participants will be applied a semi-occlusive adhesive patch containing the 0.9 percent (%) normal saline (0.02 mL/cm^2 in an individual cell of the patch) topically to the dorsum, repeatedly for 3 weeks (9 times) in induction phase (48 hours in weekdays and 72 hours in weekends) and for 48 hours (single application) in the challenge phase.
3181924|NCT00698243|Experimental|Schedule 3|Once daily
3181925|NCT00698256|Experimental|1|
3181926|NCT00698256|Placebo Comparator|2|
3181927|NCT00698269||A|
3137331|NCT04007107|Experimental|DV3396 followed by PDS290|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3137332|NCT04007107|Experimental|PDS290 followed by DV3396|The 2 treatments will be administered at least 30 minutes apart, one in each side of the stomach
3149658|NCT00183638|Experimental|1|Participants will receive Internet-based tailored prevention messages
3149659|NCT00183638|Active Comparator|2|Participants will receive non-tailored messages containing information on reproductive health
3149660|NCT00183651|Experimental|S-DBT|Participants receive standard dialectical behavior therapy
3149661|NCT00183651|Active Comparator|DBT-I|Participants receive individual dialectical behavior therapy plus activities group
3137333|NCT04006795|Experimental|Developmental Serum|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental serum (0.02milliliters per centimeter square[mL/cm^2] in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental serum will be re-applied and 1 of the 2 sites will be irradiated with 2.5 Joules per centimeters square(J/cm^2) ultraviolet(UV) A radiation,then with 0.3 minimal erythemal doses(MEDs) of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
3137334|NCT04006795|Experimental|Developmental Lotion|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental lotion (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental lotion will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
3137335|NCT04006795|Experimental|Developmental Cream|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing developmental cream (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, developmental cream will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
3149662|NCT00183651|Active Comparator|DBT-S|Participants receive dialectical behavior therapy group skills plus case management
3149663|NCT00183690|Experimental|1|Participants receiving prolonged exposure therapy
3149664|NCT00183690|Active Comparator|2|Participants receiving active psychotherapy
3149665|NCT00183703||Qualitative Interview|Participants with rapid cycling bipolar disorder (RCBPD)
3149666|NCT00183716|Experimental|1|Participants will receive Trauma Recovery and Empowerment Model and usual care
3149667|NCT00183716|Active Comparator|2|Participants will receive usual care
3149668|NCT00183755||1|Control participants
3149669|NCT00183755||2|Participants with MDD
3149670|NCT00183820|Experimental|1|
3149671|NCT00183833|Experimental|A|Xeloda plus gleevec
3137336|NCT04006795|Placebo Comparator|Negative Control|All participants in induction phase will be topically applied 2 semi-occlusive patch (Monday) containing 0.9 percent normal saline (0.02mL/cm^2 in an individual cell of patch) at 2 sites on the dorsum for 24 hours, post patch removal(Tuesday), sites will be cleaned, normal saline will be re-applied and 1 of the 2 sites will be irradiated with 2.5J/cm^2 UVA radiation, then with 0.3 MEDs of UVA+UVB radiation. 24 hours post irradiation (Wednesday), sites will be assessed and duplicate patches applied as on Monday for 24 hours. Irradiation on Thursday similar to Tuesday and assessment post 24 hour irradiation on Friday. Same process repeated for 3 weeks. In challenge phase all participants will be applied 2 semi-occlusive patches at 2 naive sites for 24 hours, post which 1 site will be irradiated (same as induction phase). Assessment will be after 24, 48 and 72 hours of irradiation
3137337|NCT04005885|Experimental|somofilcon A then stenfilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear somofilcon A daily disposable test lens for 1 week of daily wear and stenfilcon A daily disposable test lens for 1 week of daily wear.
3137338|NCT04005885|Experimental|stenfilcon A then somofilcon A contact lens|Participants were fitted with comfilcon A lens on a daily wear, reusable basis for 1 month, then randomized to wear stenfilcon A daily disposable test lens for 1 week of daily wear and somofilcon A daily disposable test lens for 1 week of daily wear.
3137339|NCT04000815|Active Comparator|Reproductive age women|The healthy women between 18-40 years old.
3137340|NCT04000815|Active Comparator|Perimenopausal women|The healthy women between 40-49 years old.
3137341|NCT04000815|Active Comparator|Postmenopausal women|The healthy women that has been in to menopause more than a year
3149672|NCT00183859|Experimental|A|Intraperitoneal Irinotecan
3181928|NCT00698269||B|
3137342|NCT03999944|Other|Sequence 1|"FRESCA Airbox Flow Generator set to fixed pressure first, then FRESCA Airbox Generator set to auto-adjusting pressure.~Second intervention within 1 - 10 days of first intervention."
3137343|NCT03999944|Other|Sequence 2|"FRESCA Airbox Flow Generator set to auto-adjusting pressure first, then FRESCA Airbox Generator set to fixed pressure.~Second intervention within 1 - 10 days of first intervention."
3137344|NCT03995680|Experimental|Chewable tablet of mebendazole|"3-5 year olds allocated to the swallowable tablet arm will be given the crushed tablet on a spoon mixed with a small amount of clean water;~6-12 year olds allocated to the swallowable tablet arm will be given the whole tablet to swallow with a glass of clean water;"
3137345|NCT03995680|Active Comparator|Swallowable tablet of mebendazole|"3-5 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and swallow it without water; if they cannot chew it then a small amount of water will be added to the tablet in a spoon;~6-12 year olds allocated to the chewable tablet arm will be encouraged to chew the tablet and then swallow it without water."
3137346|NCT04006366|Other|Intervention|To test the effects of a 10-hour time restricted eating intervention before and after the 12 weeks of treatment on weight (primary), caloric and macronutrient intake, and a variety of psychosocial measures, including sleep, physical activity, blood pressure and eating behaviors (all secondary).
3137347|NCT04006145|Experimental|Elobixibat|Elobixibat 5 mg once daily
3137348|NCT04006145|Placebo Comparator|Placebo|Placebo
3137349|NCT04005755|Experimental|Maxigesic® IV|Acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion. The study drug will be administered by injection into a dedicated indwelling venous cannula, infused over 15 minutes. The study drug will be administered every 6 hours (q6h) for a minimum of 48 hours up to at least 5 days, with a maximum of 4 doses within a 24 hour period.
3137350|NCT04005586|Experimental|Light Delivery Device (LDD)|Patient's study eye will undergo light delivery treatments to the commercially available light adjustable lens.
3137351|NCT04005404|Experimental|intertrochanteric femoral fractures|geriatric patients with intertrochanteric femoral fracture who have consented to the study intervention
3181929|NCT00698269||C|
3181930|NCT00698282|Experimental|1|
3137352|NCT04005404|Experimental|neck femur fractures|geriatric patients with neck of femur fracture who have consented to the study intervention
3137353|NCT04005404|Experimental|subtrochanteric femoral fractures|geriatric patients with subtrochanteric femoral fracture who have consented to the study intervention
3137354|NCT03993288|Experimental|Ferrum Lek|Participants received Ferrum Lek® 2 tablets daily (200 mg) for 12 weeks
3137355|NCT03993288|Active Comparator|MALTOFER|Participants received MALTOFER® 2 tablets daily (200 mg) for 12 weeks
3137356|NCT03990298|Other|All subjects|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages.
3181931|NCT00698282|Experimental|2|
3181932|NCT00698282|Placebo Comparator|3|
3149673|NCT00183885|Experimental|Cisplatin + Mitomycin-C|CDDP 60mg/m2 + Mitomycin-C 12mg/m2
3149674|NCT00183898|Experimental|Oxaliplatin and Capecitabine|Oxaliplatin given every 21 days Capecitabine given daily x 14 days every 21 days
3149675|NCT00183937|Experimental|Bortezomib and Docetaxel|Bortezomib 1.6 mg/m2 Docetaxel 75 mg/m2
3149676|NCT00184015|Experimental|Schedule A|
3149677|NCT00184015|Experimental|Schedule B|
3181933|NCT00698321|Experimental|1|Participating schools will deliver HIV/STD prevention modules.
3181934|NCT00698321|Active Comparator|2|Participating schools will deliver general health promotion modules.
3137357|NCT03988647|Experimental|Pembrolizumab + Palliative Radiation Therapy|Pembrolizumab will be administered at 200 mg IV every 3 weeks as standard of care. Palliative radiation therapy will be given between the first and second cycles of immunotherapy
3137358|NCT03979872|Active Comparator|Arm 1: Skin Cancer Education Only|Participants will be randomized to receive education only.
3181935|NCT00698334|Experimental|HIV infected|HIV infected patients with active TB
3181936|NCT00698334|Active Comparator|HIV negative|HIV negative patients with active TB
3137359|NCT03979872|Experimental|Arm 2: Skin Cancer Education + UV Photo|Participants randomized to receive education + UV photo will have a UV light photo taken of their face to show UV damage in the skin that is invisible to the naked eye in addition to receiving skin cancer education.
3137360|NCT03979872|Experimental|Arm 3: Skin Cancer Education + MC1R Testing|Participants randomized to receive education + genetic testing will be asked to provide a saliva sample for MC1R testing in addition to receiving skin cancer education.
3181937|NCT00698347||M2a-Magnum™ Hip System|Patients who received the M2a-Magnum™ Hip System
3181938|NCT00698360||A|MDRD 10-30
3181939|NCT00698360||B|MDRD 30-60
3181940|NCT00698360||C|MDRD 60-80
3181941|NCT00698360||D|MDRD > 80
3181942|NCT00698373||1|PET study
3181943|NCT00698399||1|Live Donor
3181944|NCT00698399||2|Cadaveric Donor
3181945|NCT00698412|Experimental|1|Cane group
3181946|NCT00698412|No Intervention|2|Control Group
3181947|NCT00698425|Experimental|1: 0 mA-min (0 mA for 4 min)|Ocular iontophoresis 0 mA-min (0 mA for 4 minutes)
3181948|NCT00698425|Experimental|2: 4 mA-min (2 mA for 2 min), + polarity|Ocular iontophoresis 4 mA-min (2 mA for 2 minutes), positive polarity
3137361|NCT03979872|Experimental|Arm 4: Skin Cancer Education + UV Photo + MC1R Testing|Participants randomized to receive education + UV photo + genetic testing will have a UV light photo taken of their face, Submit a saliva sample for MC1R testing, and receive skin cancer education.
3137362|NCT03978832|Experimental|Oral Risperidone followed by PERSERIS|All subjects will receive 2 SC injections of PERSERIS at each study visit every 28 days for a total of 4 visits of 2 injections each. The first 3 visit injections will be administered in the abdomen and the final visit injections will be administered in the back of the upper arm.
3137363|NCT04005391|Experimental|Postpartum Contraceptives offered to Intervention Clusters|"Women will have postpartum contraceptive options (condoms vive amor, birth control pills segura plus, injectable cyclofem, contraceptive implant jadelle) offered to them at their routine forty day postpartum visit after routine care is provided, first."
3137364|NCT04005391|No Intervention|Routine Care offered to Control Clusters|Women will receive routine postpartum care
3137365|NCT04004481||Adult patients undergoing major open abdominal surgery|Observational study. In the patients undergoing major open abdominal surgery for cancer tramadol will be used for postoperative analgesia. In the postoperative period parent compound and metabolites of tramadol will be measured. Postoperative analgesia and adverse effects will be registered and compared between CYP2D6 phenotypes observed.
3137366|NCT04004260|Experimental|Experimental group|The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.
3181949|NCT00698425|Experimental|3: 5 mA-min (2.5 mA for 2 min), +|Ocular iontophoresis 5 mA-min (2.5 mA for 2 minutes), positive polarity
3181950|NCT00698425|Experimental|4: 6 mA-min (3 mA for 2 min), + polarity|Ocular iontophoresis 6 mA-min (3 mA for 2 minutes), positive polarity
3181951|NCT00698425|Experimental|5: 7 mA-min (3.5 mA for 2 min), +|Ocular iontophoresis 7 mA-min (3.5 mA for 2 minutes), positive polarity
3181952|NCT00698425|Experimental|6: 8 mA-min (4 mA for 2 min), + polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), positive polarity
3181953|NCT00698425|Experimental|7: 7 mA-min (3.5 mA for 2 min), -|7 mA-min (3.5 mA for 2 minutes), negative polarity
3181954|NCT00698425|Experimental|8: 8 mA-min (4 mA for 2 min), - polarity|Ocular iontophoresis 8 mA-min (4 mA for 2 minutes), negative polarity
3181955|NCT00698425|Experimental|9: 20 mA-min (4 mA for 5 min), +|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), positive polarity
3181956|NCT00698425|Experimental|10: 20 mA-min (2 mA for 10 min), +|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), positive polarity
3137367|NCT04004260|Other|Weekly check-in control group|The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.
3137368|NCT03997851|Experimental|Topical 5% acetaminophen gel|Topical 5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
3181957|NCT00698425|Experimental|11: 20 mA-min (4 mA for 5 min), -|Ocular iontophoresis 20 mA-min (4 mA for 5 minutes), negative polarity
3137369|NCT03997851|Experimental|Topical 2.5% acetaminophen gel|Topical 2.5% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
3137370|NCT03997851|Experimental|Topical 1% acetaminophen gel|Topical 1% acetaminophen gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
3137371|NCT03997851|Placebo Comparator|Topical vehicle gel|Topical vehile gel will be applied to one 4x4 cm predefined skin area on the ventral forearm during 2 study visits. The gel will be applied to the test area and will be allowed 30 minutes to adsorb. Following this pre-treatment, residual gel will be removed and itch induction/sensory testing will commence, strictly within the pre-treated area.
3137372|NCT03991715|Experimental|Activity Tracker|Participants provided an activity tracker to wear and weekly reports
3137373|NCT03990415|Experimental|Stay Strong, Stay Healthy Group|The Stay Strong, Stay Healthy strength training group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured program to learn and progress through strength training exercises designed to increase overall fitness, flexibility, and balance.
3137374|NCT03990415|Active Comparator|Walking Group|The walking group will meet two times per week for an hour, for eight consecutive weeks. This class provides participants a structured walking program to help delineate the effects of the strength training program and exercise in general.
3137375|NCT03990415|No Intervention|Delayed Start Group|The delayed start group will not make any changes to their sedentary lifestyle and will be encouraged to not begin any exercise programs throughout the duration of the study.
3137376|NCT04002960|Experimental|INVSENSOR00036|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00036 sensor
3181958|NCT00698425|Experimental|12: 20 mA-min (2 mA for 10 min), -|Ocular iontophoresis 20 mA-min (2 mA for 10 minutes), negative polarity
3181959|NCT00698425|Experimental|13: 0 mA-min (0 mA for 10.5 min)|Ocular iontophoresis 0 mA-min (0 mA for 10.5 minutes)
3181960|NCT00698425|Experimental|14: 13.5 mA-min (4.5 mA for 3 min), +|Ocular iontophoresis 13.5 mA-min (4.5 mA for 3 minutes), positive polarity
3181961|NCT00698425|Experimental|15: 15 mA-min (5 mA for 3 min), +|Ocular iontophoresis 15 mA-min (5 mA for 3 minutes), positive polarity
3137377|NCT04002973|Experimental|INVSENSOR00037|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00037.
3137378|NCT04002648||MT-Right|
3137379|NCT04002648||Sternotomy|
3137380|NCT03993210|Experimental|GYN Cancer Cases|"Confirmed diagnosis of primary or recurrent gynecological (GYN) malignancies.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
3137381|NCT03993210|Active Comparator|GYN Benign Controls|"Benign gynecological (GYN) fibroids.~Routine clinical standard of care pelvic magnetic resonance imaging (MRI) along with advanced techniques Magnetic Resonance Fingerprinting (MRF) and Q-space Trajectory Imaging (QTI) will be performed using a clinical 3T MRI scanner lasting 30-45 minutes with an additional 10-15 minutes for the advanced scans. Per protocol, patient undergoes one scan on visit day 1 and is followed for up to 4 years."
3137382|NCT03992014|Experimental|Linerixibat + [14C]-linerixibat|Subjects will receive a single oral dose of linerixibat 90 milligram (mg) (2*45 mg) tablets concomitantly with [14C]-linerixibat 100 microgram (approximately 9.25 kilobecquerel; 250 nano curie) IV infusion for 3 hours, after an overnight fast that continues for 2 hours after the oral dose/start of IV infusion, small standard high-fat meal will be given on Day 1 in treatment Period 1; followed by a single oral dose of [14C]-linerixibat 90 mg (approximately 4.96 megabecquerel; 134.1 micro curie) solution on Day 1 in treatment Period 2. A wash out period of at least 13 days will be maintained between oral doses of treatment periods.
3137383|NCT03990649|Placebo Comparator|Double-Blind Treatment Period - Part A: Placebo|Soticlestat matching placebo tablets, orally, twice daily (BID) for Weeks 1, 2 and 3 in Double blind Titration Period. Soticlestat matching placebo tablets, orally BID for 12 weeks in Double blind Maintenance Period. Taper period (if participant did not continue to Part B): Dose of soticlestat matching placebo tablets was reduced to next lower dose every 3 days (maximum 6 days) until discontinuation.
3181962|NCT00698425|Experimental|16: 16.5 mA-min (5.5 mA for 3 min), +|Ocular iontophoresis 16.5 mA-min (5.5 mA for 3 minutes), positive polarity
3149678|NCT00184041|Experimental|Intensified Post-Remission: MTX/LV/PEG-Asparaginase|Daunorubicin 60 mg/m2 iv on days 1, 2, 3 Vincristine 1.4 mg/m2 iv on days 1, 8, 15, 22 Peg-Asparaginase 2000 U/m2 iv on day 15 Prednisone 60 mg/m2 mg po on days 1-28 MTX 12 mg IT on days 8 & 15
3149679|NCT00184067|Experimental|Peptide vaccine with Montanide ISA 51 + GM-CSF|Peptide vaccine with Montanide ISA 51 GM-CSF
3149680|NCT00184067|Active Comparator|Peptide vaccine with Montanide ISA 51|Peptide vaccine with Montanide ISA 51
3149681|NCT00184106|Active Comparator|Cognitive Therapy|Cognitive Therapy
3149682|NCT00184106|Active Comparator|Seroxat and SE|SSRI with Self exposure
3137384|NCT03990649|Experimental|Double-Blind Treatment Period - Part A: Soticlestat|Soticlestat, tablet, orally, 100 mg BID for Week 1, followed by 2×100 mg tablets, soticlestat, orally BID for Week 2, further followed by 3×100 mg tablets, soticlestat, orally BID for Week 3. Dose was uptitrated every week based on safety and tolerability. Part A (Double blind Maintenance Period): 3×100 mg tablets, soticlestat, orally BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period (if participant did not continue to Part B): Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
3137385|NCT03990649|Experimental|Open-Label Extension Period - Part B: Soticlestat|Soticlestat, 2×100 mg tablets, orally, BID for Week 1, followed by 3×100 mg tablets, soticlestat, orally, BID for Week 2. Dose was uptitrated every week based on safety and tolerability. Part B (Open label extension: Maintenance Period): 3×100 mg tablets, soticlestat, orally, BID for 12 weeks. Dose was adjusted during Maintenance Period due to safety and tolerability. Taper Period: Dose of soticlestat was reduced to next lower dose every 3 days (maximum 6 days) until soticlestat was discontinued.
3137386|NCT04002791|Placebo Comparator|Group 1: TR Band Arm|"Patients will receive hemostatic compression using the current standard of care TR band (Terumo Corporation, Japan). The band will be applied according to the instructions for use, with optimal pressure applied using Patent hemostasis protocol to achieve full hemostasis."
3137387|NCT04002791|Active Comparator|Group 2: Vaso-band Arm|Patients will receive Vaso-band (VasoInnovations, Inc, USA), applied with ulnar balloon inflated with 15 ml of air, and the radial balloon inflated after the sheath is removed, to apply optimal pressure for obtaining full hemostasis. Ulnar balloon will be deflated after 60 minutes of radial artery hemostatic compression.
3137388|NCT04000581|Active Comparator|Arm I (usual care)|Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
3137389|NCT04000581|Experimental|Arm II (additional mobility)|Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
3137390|NCT03996694|Experimental|Treatment A: Belbuca 300 µg and oral placebo|Subjects treated with Belbuca 300 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137391|NCT03996694|Experimental|Treatment B: Belbuca 600 µg and oral placebo|Subjects treated with Belbuca 600 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137392|NCT03996694|Experimental|Treatment C: Belbuca 900 µg and oral placebo|Subjects treated with Belbuca 900 µg and oral placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137393|NCT03996694|Active Comparator|Treatment D: Oxycodone 30 mg and buccal placebo|Subjects treated with Oxycodone 30 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137394|NCT03996694|Active Comparator|Treatment E: Oxycodone 60 mg and buccal placebo|Subjects treated with Oxycodone 60 mg and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137395|NCT03996694|Placebo Comparator|Treatment F: Oral Placebo and buccal placebo|Subjects treated with oral placebo and buccal placebo will be randomized to 1 of 6 treatment sequences in a 1:1:1:1:1:1 ratio.
3137396|NCT03988907|Experimental|Part 1|Participants will receive a dose of 5 milligram (mg) risdiplam once daily (QD) for 14 consecutive days
3137397|NCT03988907|Experimental|Part 2|All study participants will receive a single oral dose of 2 mg midazolam on Day 1. On Day 3, the 14-day QD treatment period with risdiplam will begin. The precise dose will be based on the results of Part 1, with single dose administration of 2 mg midazolam again on Day 15 (1 hour after the thirteenth dose of risdiplam)
3149683|NCT00184106|Active Comparator|Seroxat and Cognitive Therapy|Combination of Seroxat and Cognitive Therapy
3137398|NCT03988088|Experimental|Lasmiditan|Participants with lower body weight (15 to ≤40 kilograms (kg)) received single oral dose of 100 milligrams (mg) Lasmiditan in Cohort 1 and higher body weight (>40 to ≤55 kg) participants received single oral dose of 200 mg Lasmiditan in Cohort 2.
3137399|NCT03980522|Experimental|KPL-914: Part 1 Participants|Part 1 enrolls symptomatic participants with recurrent idiopathic pericarditis (RIP) with an elevated marker of systemic inflammation (C-reactive protein [CRP] > 1mg/dL).
3137400|NCT03980522|Experimental|KPL-914: Part 2 Participants|Part 2 enrolls symptomatic participants with RIP with CRP ≤1 mg/dL which, in the opinion of the Investigator, can be attributed to concomitant medications (e.g., corticosteroids) and with pericardial inflammation present on cardiac magnetic resonance imaging (MRI) confirmed by the imaging core lab.
3137401|NCT03980522|Experimental|KPL-914: Part 3 Participants|Part 3 enrolls participants with corticosteroid-dependent RIP not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
3137402|NCT03980522|Experimental|KPL-914: Part 4 Participants|Part 4 enrolls symptomatic participants with recurrent post pericardiotomy syndrome (PPS) with an elevated marker of systemic inflammation (CRP > 1mg/dL).
3137403|NCT03980522|Experimental|KPL-914: Part 5 Participants|Part 5 enrolls participants with corticosteroid-dependent recurrent PPS not experiencing symptoms which would meet the diagnostic criteria for a flare of pericarditis.
3137404|NCT03999684|Experimental|Tretinoin|-Participants will receive Tretinoin orally divided over two daily doses for days 1 through 14 of a 28-day cycle
3137405|NCT03995784|Experimental|Intravenous Dose|Coagulation Factor IX variant, 50 IU/kg by intravenous route
3137406|NCT03995784|Experimental|Subcutaneous Dosing|Coagulation Factor IX variant, 100 IU/kg by subcutaneous route
3137407|NCT03993392|Experimental|TM buprenorphine followed by SUBLOCADE 300 mg|Participants with a diagnosis of OUD stopped use of their current opioid prior to coming to the clinic to be assessed for withdrawal symptoms. If confirmed to be in withdrawal, participants were administered 4 mg transmucosal (TM) buprenorphine. If tolerated without sensitivity, clinical signs of sedation, or precipitated withdrawal, 300 mg SUBLOCADE was administered. Following SUBLOCADE administration, participants remained in the clinic for approximately 48 hours and were assessed for safety and tolerability, as well as for any signs of precipitated withdrawal. Participants returned to the clinic weekly, until the end-of-treatment (EOT) visit (28 days after SUBLOCADE administration).
3137408|NCT03989427|Experimental|Brushing First and Flossing Later (BF)|The participants in BF group were asked to use modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) and then floss with Colgate® dental floss using Spool method for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to FB wherein they will floss first and brush later.
3137409|NCT03989427|Experimental|Flossing First and Brushing Later (FB)|The participants in FB group were asked to floss first with Colgate® dental floss using Spool method and then modified bass method of tooth brushing first using Colgate® tooth brush (the amount of Colgate® tooth paste used is half-length of the toothbrush's head) for a 2-week period. This is followed by a one week wash out period wherein they will practice oral hygiene according to their habitual method. After this cross over is done in which participants will change the sequence to BF wherein they will brush first and floss later.
3137410|NCT03981822|Active Comparator|Part A: VP-102 2 hour-Active|For part A, VP-102 will be applied for 2 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 2 hours and removed.In both parts, VP-102 is applied every 21 days for 4 treatments.
3137411|NCT03981822|Active Comparator|Part A: VP-102 6-hour Active|For part A, VP-102 will be applied for 6 hours and removed. If selected as a dose regimen for Part B VP-102 will be applied for 6 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
3137412|NCT03981822|Active Comparator|Part A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. In both parts, VP-102 is applied every 21 days for 4 treatments.
3137413|NCT03981822|Placebo Comparator|Part A: Placebo|For part A, VP-102 will be applied for 2-,6- or 24- hours and removed. Placebo is applied every 21 days for 4 treatments.
3137414|NCT03981822|Active Comparator|Part B & A: VP-102 6 hour-Active|Part B, VP-102 will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
3137415|NCT03981822|Placebo Comparator|Part B & A: 6-hour-Placebo|Part B, Placebo will be applied for 6 hours and removed. VP-102 is applied every 21 days for 4 treatments.
3137416|NCT03981822|Active Comparator|Part B & A: VP-102 24-hour Active|For part A, VP-102 will be applied for 24 hours and removed. If 24 hours is selected as a dose regimen for Part B, VP-102 will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
3137417|NCT03981822|Placebo Comparator|Part B & A: 24-hour-Placebo|Part B, VP-Placebo will be applied for 24 hours and removed. VP-102 is applied every 21 days for 4 treatments.
3137418|NCT03992482|Experimental|IVIG-Eye Drop|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
3137419|NCT03992482|Placebo Comparator|Placebo-Eye Drop|Normal Saline Eye Drops (0.9% NaCl)
3137420|NCT03993119||patients with NVAF|
3137421|NCT03991494|Experimental|Pamiparib|
3137422|NCT03989570|Experimental|Group I (A group)|31 patients Will undergo ESP block with 40 ml bupivacine 0.25% (20 ml on each side), and TAP block with 40 ml saline 0.9% (20 ml on each side).
3137423|NCT03989570|Active Comparator|Group II (B group)|31patients Will undergo TAP block with 40 ml bupivacine 0.25% (20 ml on each side), and ESP block with 40 ml saline 0.9% (20 ml on each side).
3137424|NCT03989570|Placebo Comparator|Group III (C group)|31 patients anesthetized with the protocol followed by Minia University Hospital
3137425|NCT03988803|Experimental|All subjects|
3137426|NCT03987932|Experimental|NEAT!2|Participants will be asked to use the NEAT!2 app for 3 months after randomization. App use between 4-6 months is optional.
3137427|NCT03987932|Experimental|NEAT!2+Calls|Participants will be asked to use the NEAT!2 app for 3 months after randomization. In addition, participants will receive bi-weekly coaching calls over 3 months. App use between 4-6 months is optional.
3137428|NCT03987932|Other|Delayed NEAT!2|Participants will receive the NEAT!2 app to use between 3 and 6 months.
3149684|NCT00184106|Placebo Comparator|Pill-Placebo|Pill Placebo
3149685|NCT00184119|Experimental|Psychiatric Intensive Care Unit|
3137429|NCT03987191|Active Comparator|Standard of Care Transition|Stopping of insulin pump on the day of randomization and starting insulin degludec in 1:1 ratio (same units as total basal insulin on pump) and insulin Aspart for meals and corrections
3137430|NCT03987191|Experimental|Inverstigational Transition|Administration of insulin degludec in 1:1 ratio (same units as total basal insulin on pump) on the day of randomization AND concomitant use of the insulin pump for 48 hours from transition, where insulin pump basal rate will be reduced by 50% during the first 24 hours from transition and by 75% during 24 to 48 hours from transition. Insulin pump will be disconnected after 48 hours from transition
3137431|NCT03988842|Experimental|Alteplase & Unfractionated Heparin & Apixaban|Alteplase 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
3137432|NCT03988842|Active Comparator|Placebo & Unfractionated Heparin & Apixaban|Alteplase placebo solution 24mg intravenous infusion for 20 minutes followed by unfractionated heparin intravenous infusion over 24 hours followed by apixaban 10mg tablet twice-daily for one week followed by apixaban 5mg tablet twice-daily for at least 6 months.
3137433|NCT03981861|Experimental|Overall Study|Treatment with Metformin and Spironolactone
3137434|NCT03974334|Experimental|OWL-Hypertension 8 Wk Trial|Two groups of thirteen participants will use the Our Whole Lives - Hypertension eHealth online tool for 8 weeks each, with baseline, midline, and follow-up data collected to determine any change due to the intervention.
3149686|NCT00184119|Active Comparator|Whole acute unit|
3181963|NCT00698425|Experimental|17: 18 mA-min (6 mA for 3 min), +|Ocular iontophoresis 18 mA-min (6 mA for 3 minutes), positive polarity
3181964|NCT00698425|Experimental|18: 19.5 mA-min (6.5 mA for 3 min), +|Ocular iontophoresis 19.5 mA-min (6.5 mA for 3 minutes), positive polarity
3181965|NCT00698425|Experimental|19: 20 mA-min (7 mA for 3.84 min), +|Ocular iontophoresis 20 mA-min (7 mA for 3.84 minutes), positive polarity
3181966|NCT00698438|Active Comparator|a|Implantation of Ex-PRESS mini glaucoma shunt under a scleral flap
3181967|NCT00698438|Active Comparator|b|Trabecolectomy
3181968|NCT00698464|Experimental|Pasireotide|
3181969|NCT00698490|Experimental|Group A|HSV-seronegative subjects
3181970|NCT00698490|Experimental|Group B|HSV-seropositive subjects
3181971|NCT00698490|Experimental|Group C|HSV-seronegative subjects
3181972|NCT00698490|Experimental|Group D|HSV-seronegative subjects
3181973|NCT00698490|Experimental|Group E|HSV-seronegative subjects
3181974|NCT00698503||M2a- 38™ Hip System|
3181975|NCT00698529|No Intervention|No POL Training|Participating NGOs and their staff will receive no specialized training.
3149687|NCT00184132|Experimental|Norwegian home style ward|The walls received wainscots, colourful wallpaper and paintings; the ceilings were lowered and had multiple lighting spots, the windows tasteful curtains; we put wardrobes, chairs, flowers and personal items in the patient rooms; and Italian ceramic tile covered the entire bathroom
3181976|NCT00698529|Experimental|Face-to-Face|Participating NGOs and their staff will receive training through face-to-face seminars held at the NGOs and through post-seminar consultation telephone calls.
3181977|NCT00698529|Experimental|Distance Learning|Participating NGOs and their staff will receive training through Web-based seminars and through post-seminar consultation telephone calls.
3181978|NCT00698542||1|Patients in the NCU at VUH
3181979|NCT00698555|Experimental|Group A|
3149688|NCT00184132|Active Comparator|sparsely furnished ward|traditional interior design and furnishings. The rooms had sparse furniture, walls in grey colours lacking pictures, no window curtains, single lamps in the ceiling 4 m high, bathroom with grey, laminated paint all over, and patient rooms with a single bed and a chair of metal tubes
3181980|NCT00698555|Experimental|Group B|
3181981|NCT00698555|Experimental|Group C|
3137435|NCT03988426|Experimental|Octanorm|Human Normal Immunoglobulin for Subcutaneous Administration (Octanorm) is a liquid formulation of normal human IgG at a concentration of 16.5% administered as a SC infusion at weekly intervals (either done at the study center [during first training sessions and then for every 4th administration] or at home by the patient or caregiver). The initial weekly dose was determined based on subjects' previous IVIG treatment.
3137436|NCT03988374|Active Comparator|0% Baking Soda Dentifrice|
3137437|NCT03988374|Active Comparator|20% Baking Soda Dentifrice|
3137438|NCT03988374|Active Comparator|35% Baking Soda Dentifrice|
3137439|NCT03987074|Experimental|Semaglutide|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) for 24 weeks
3137440|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg for 24 weeks
3137441|NCT03987074|Experimental|Semaglutide + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 30 mg for 24 weeks
3137442|NCT03987074|Experimental|Semaglutide + Cilofexor 100 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + cilofexor 100 mg for 24 weeks
3137443|NCT03987074|Experimental|Semaglutide + Firsocostat 20 mg + Cilofexor 30 mg|Semaglutide 0.24 mg - 2.4 mg (dose escalated over 16 weeks) + firsocostat 20 mg + cilofexor 30 mg for 24 weeks
3149689|NCT00184145|Experimental|EMDR|The experimental group was treated for animal phobia by EMDR, control group received an attention placebo (relaxation plus breathing exercises). Afterwards, both groups were treated by exposure therapy (therapy of choice for animal phobia).
3149690|NCT00184171|Experimental|Budesonide|Budesonide 9mg
3149691|NCT00184171|Experimental|bismuth|Bismuth mixture
3149692|NCT00184171|Sham Comparator|Fiber|Fiber preparation
3149693|NCT00184197|Experimental|Botox|
3149694|NCT00184197|Placebo Comparator|placebo|
3181982|NCT00698555|Experimental|Group D|
3181983|NCT00698555|Experimental|Group E|
3137444|NCT03977935|No Intervention|The first-generation MCCG group|"The patients swallowed the first-generation MCCG with a small amount of water in the left lateral decubitus position. Once the capsule reached the stomach after investigating the esophagus, it was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After finishing the stomach examination twice, the endoscopist controlled the capsule to face the pylorus and drag it close to the pylorus. The capsule would enter the duodenal bulb and was held stationary to investigate the duodenal bulb using the 360-degree automatic scanning mode. In the descending part of duodenum, the endoscopist tried to control the capsule to view the major papilla. After passing through the duodenum, the capsule started to complete the small-bowel examination with the small-bowel mode. The magnetic steering time for passing through the pylorus was not allowed more than 15 min."
3137445|NCT03977935|Experimental|The second-generation MCCG group|All process in this study were the same except that the second-generation capsule (Ankon Navicam-2) was used in the experimental group.
3137446|NCT03988049|Active Comparator|1,550 laser|This arm is the side of the face treated with the 1550-nanometer Fracionated Photothermolysis laser.
3137447|NCT03988049|Active Comparator|755 laser|This arm is the side of the face treated with the 755-nanometer alexandrite picosecond laser.
3137448|NCT03979820|Experimental|10 mg BI 1467335/10 mg BI 1467335 + Tyramine|
3137449|NCT03979820|Experimental|15 mg BI 1467335/15 mg BI 1467335 + Tyramine|
3137450|NCT03979820|Active Comparator|Phenelzine/Phenelzine + Tyramine|
3137451|NCT03979820|Placebo Comparator|Placebo/Placebo + Tyramine|
3149695|NCT00184223|Experimental|motivational interviewing|Manual guided motivational interviewing in addition to treatment as usual
3149696|NCT00184223|Other|control group|treatment as usual
3149697|NCT00184236|Active Comparator|Aerobic interval training|Aerobic interval training (AIT)
3149698|NCT00184236|Active Comparator|Multitreatment approach|multitreatment approach (MTG)
3149699|NCT00184249|Experimental|Bipolar radiofrequency ablation|
3137452|NCT03972137|Experimental|Heart Rate Variability Biofeedback-Smoking Cessation Therapy|All participants in this open trial received individualized cognitive-behavioral smoking cessation treatment (SCT), up to 8 weeks of the transdermal nicotine patch (NRT) and individualized heart rate variability biofeedback (HRVB).
3137453|NCT03970395|Experimental|Osteopathic manipulative therapy|"Repositioning Therapy plus Osteopathic Manipulative Therapy (OMTh).~Osteopathic Manipulative Therapy. Participant OMT group receive 6 OMTh in 3 months, as follows: first at baseline, the second after 1 week, the third after 3 weeks, and then once every 3 weeks for three more visits."
3137454|NCT03970395|Sham Comparator|Light Touch Therapy|"Repositioning Therapy plus Light Touch Therapy (LTT)~Participants to the LTT group receive the LTT protocol at the same date of the OMTh group."
3137455|NCT03987620|Experimental|Ibrexafungerp (SCY-078)|300 mg BID for one day
3137456|NCT03987620|Placebo Comparator|Placebo|Matching Placebo
3137457|NCT03983317|No Intervention|Baseline|For the first week of the study, participants will not administer treatment with the Empower device. Participants will complete surveys to establish baseline values for each participant.
3137458|NCT03983317|Experimental|Active treatment|Participants will self-administer treatment with the Empower device two times daily for two weeks. Participants will complete surveys over the two-week period to evaluate the effects of the Empower treatment.
3137459|NCT03985657|Active Comparator|Baseline Sleep Study|Baseline sleep polysomnography will involve the collection of electroencephalogram, electromyogram, electrocardiogram, airflow, heart rate, blood pressure, and pleural pressure during sleep with no CPAP. Participants in this arm would switch to CPAP within one week of the study.
3137460|NCT03985657|Experimental|CPAP Sleep Study|Participants will be treated with continuous positive airway pressure to relieve sleep-disordered breathing. Participants in this arm would switch to Baseline study within one week of the study.
3149700|NCT00184262|Active Comparator|ERP cognitive therapy|
3149701|NCT00184262|Experimental|ERP behavioral therapy|
3149702|NCT00184301|Experimental|inpatient treatment|inpatient treatment during 1 year
3149703|NCT00184301|Active Comparator|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
3149704|NCT00184353||brain metastases|6 patients
3149705|NCT00184353||healthy|13 volunteers
3149706|NCT00184379|Experimental|1 S+E|Relatives of patients with schizophrenia, who receive education
3149707|NCT00184379|No Intervention|2 S-E|Relatives of patients with schizophrenia, who do not receive education
3149708|NCT00184379|Experimental|3 B+E|Relatives of patients with bipolar disorder, who receive education
3149709|NCT00184379|No Intervention|4 B-E|Relatives of patients with bipolar disorder, who do not receive education
3149710|NCT00184392|Experimental|debridement or saline irrigation|1 arm undergo debridement of the nose 1 week and 2 weeks after surgery the other arm rinse their nose with saline irrigation
3149711|NCT00184418||All patients admitted to a psychiatric acute ward|
3137461|NCT03981939||CD Participants with CPAF - The Ottawa Hospital (TOH)|Participants diagnosed with Complex Perianal Fistula (CPAF) from the Ottawa Hospital (TOH) were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
3137462|NCT03981939||CD Participants without CPAF (ICES database)|Participants diagnosed with CD and without CPAF from Institute for Clinical Evaluative Sciences (ICES) database who did not meet the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
3137463|NCT03981939||CD Participants with CPAF (ICES database)|Participants with CD and CPAF from ICES database who met the case definition were observed retrospectively in this arm group for the index period (April 1, 2007 to March 31, 2013).
3149712|NCT00184431|Experimental|A|Intensive task specific balance training
3149713|NCT00184431|Active Comparator|B|Traditional physical therapy
3149714|NCT00184444|Experimental|Hypoxic Interval training|4 x 4 minutes interval training with 100% oxygenated air
3149715|NCT00184444|Experimental|Normoxic interval training|4 x 4 minutes interval training in normoxic air
3149716|NCT00184483|Experimental|Lichtenstein's operation|Patients with a primary unilateral inguinal hernia are randomized to Lichtenstein's operation to repair their groin hernia
3149717|NCT00184483|Active Comparator|Prolene Hernia System|Patients with a primary unilateral inguinal hernia are randomized to Prolene Hernia System to repair their groin hernia
3149718|NCT00184496|Active Comparator|methadon|Morphine methadone stop and go switch
3149719|NCT00184496|Active Comparator|Methadone|Methadon morphine overlap switch
3149720|NCT00184522|Experimental|Aflurax|pectin-containing natural product
3149721|NCT00184522|Active Comparator|esomeprazole (Nexium)|esomeprazole (Nexium)
3149722|NCT00184587|Experimental|candesartan|candesartan cilexetil 16 mg (one tablet/day) in week 1 and 32 mg (2 tablets/day) in week 3, provided for the study by AstraZeneca
3181984|NCT00698555|Active Comparator|Group F|
3149723|NCT00184587|Placebo Comparator|placebo|placebo one tablet/day in week 1 and 2 tablets/day in week 3, provided for the study by AstraZeneca. Same size, weight, taste and appearance as experimental drug
3149724|NCT00184795|Experimental|ALD 0.1|
3149725|NCT00184795|Experimental|ALD 0.25|
3181985|NCT00698568|Experimental|Group A|
3149726|NCT00184795|Placebo Comparator|Placebo|
3149727|NCT00184873|Active Comparator|Lifestyle counseling|Patients receiving lifestyle counseling
3149728|NCT00184873|No Intervention|Regular care|Patients receiving regular care
3149729|NCT00184925|Active Comparator|subglottic drainage|suctioning of subglottis with cannula
3149730|NCT00185159|Experimental|1|olmesartan medoxomil
3149731|NCT00185159|Placebo Comparator|2|placebo
3149732|NCT00185172|Placebo Comparator|1|2 week placebo run-in
3149733|NCT00185172|Experimental|2|Olmesartan medoxomil tablets for 8 weeks
3149734|NCT00185172|Experimental|3|Olmesartan medoxomil tablets, or olmesartan medoxomil tablets + hydrochlorothiazide tablets for 4 weeks
3149735|NCT00185185|Experimental|1|olmesartan medoxomil
3149736|NCT00185185|Active Comparator|2|atenolol
3137464|NCT03973905||Pertussis Case Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
3149737|NCT00185198|Active Comparator|Arm 1|
3149738|NCT00185198|Placebo Comparator|Arm 2|
3149739|NCT00185224|Experimental|Arm 1|
3149740|NCT00185224|Active Comparator|Arm 2|
3149741|NCT00185237|Experimental|Arm 1|
3149742|NCT00185237|Placebo Comparator|Arm 2|
3149743|NCT00185250|Experimental|Arm 1|
3149744|NCT00185250|Experimental|Arm 2|
3149745|NCT00185250|Placebo Comparator|Arm 3|
3149746|NCT00185250|Placebo Comparator|Arm 4|
3149747|NCT00185263|Experimental|1|Ad5FGF-4
3149748|NCT00185263|Experimental|2|Ad5FGF-4
3149749|NCT00185263|Placebo Comparator|3|Placebo
3149750|NCT00185276|Experimental|Arm 1|
3149751|NCT00185276|Experimental|Arm 2|
3149752|NCT00185289|Experimental|Arm 1|
3149753|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 3 mg|Subjects received 3 mg MS-275 orally biweekly (Days 1 and 15 of a 4 week cycle) or until disease progression or unacceptable toxicity
3181986|NCT00698568|Placebo Comparator|Group B|
3137465|NCT03973905||Control Group|"Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).~This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa."
3137466|NCT03984838|Experimental|Subjects receiving Dolutegravir and Rilpivirine FDC|Subjects will receive Dolutegravir/Rilpivirine 50mg/25mg fixed dose combination (FDC) tablet as a single oral dose in a fed state.
3181987|NCT00698594|Active Comparator|1|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
3137467|NCT03983941|Active Comparator|FNB-AC + Sciatic nerve block|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for sciatic nerve block under ultrasound guidance.
3137468|NCT03983941|Experimental|FNB-AC + IPACK|Patients will receive up to 20 mL of 0.2% ropivacaine for FNB-AC and up to 20 mL of 0.2% ropivacaine for posterior knee capsular infiltration under ultrasound guidance (IPACK)
3137469|NCT03976752|No Intervention|Pre-drug|Participants enrolled in the pre-drug arm will not receive any drug. At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
3137470|NCT03976752|Experimental|Genvoya - 2 and 48 hours specimen collection|Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
3137471|NCT03976752|Experimental|Genvoya - 4 and 72 hours specimen collection|Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
3181988|NCT00698594|Active Comparator|2|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
3181989|NCT00698594|Placebo Comparator|3|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
3137472|NCT03976752|Experimental|Genvoya - 24 and 96 hours specimen collection|Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
3137473|NCT03976752|Experimental|Genvoya - Single time point specimen collection|Specimen collection 8 hours after taking the medication in the clinic (visit 4).
3149754|NCT00185302|Experimental|Histone Deacetylase Inhibitor, 7 mg|Subjects received 7 mg MS-275 orally weekly (Days 1, 8, and 15 of a 4 week cycle) until disease progression or unacceptable toxicity
3149755|NCT00185315|Experimental|Arm 1|
3149756|NCT00185328|Experimental|Arm 1|
3149757|NCT00185341|Experimental|CCR-1 Receptor Antagonist|Subjects received 600 mg (2 x 300 mg tablets) of CCR-1 Receptor Antagonist 3 times daily
3149758|NCT00185341|Placebo Comparator|Placebo|Subjects received placebo corresponding to verum
3149759|NCT00185354|Experimental|Arm 1|
3149760|NCT00185354|Active Comparator|Arm 2|
3137474|NCT03984825|Experimental|Portia followed by Portia co-administered with GSK3640254|Subjects will be administered Portia (0.03 mg EE/0.15 mg LNG) once daily on Days -3 to -1 during run-in period and on Days 1 to 10 in treatment period A. Subjects will then receive Portia (0.03 mg EE/0.15 mg LNG) co-administered with GSK3640254 200 mg once daily on Days 11 to 21 in treatment period B.
3149761|NCT00185367|Experimental|Arm 1|
3149762|NCT00185367|Active Comparator|Arm 2|
3149763|NCT00185393|Experimental|Arm 1|
3149764|NCT00185393|Other|Arm 2|
3149765|NCT00185419|Active Comparator|Arm 1|
3149766|NCT00185419|Active Comparator|Arm 2|
3149767|NCT00185445|Experimental|Arm 1|
3149768|NCT00185484|Experimental|Arm 1|
3149769|NCT00185510|Experimental|Arm 1|
3137475|NCT03971721|Experimental|Wave Mattress Support|The mattress support will be delivered at the subject's home by professional staff of the sponsor (Hill-Rom) in the presence of the research coordinator or investigator. The subject will sleep on mattress support for the duration of study participation.
3137476|NCT03982433|Experimental|Intervention|participants all receive the intervention
3137477|NCT03979677|Experimental|Intervention Group|All participants will be provided written and verbal instructions regarding the lifestyle modification intervention.
3137478|NCT03976466|Experimental|Calcium sulfate Group|Group of members that will be submitted to prophylaxis with medicated calcium sulfate beads for hip or knee joint replacement
3137479|NCT03976466|Active Comparator|Control Group|Group of members that will be submitted to classic prophylaxis for hip or knee joint replacement
3137480|NCT03979638|Experimental|BLU-5937 oral tablet BID|Randomized crossover design of 4 different doses (25, 50, 100, 200 mg BID) of BLU-5937 tablets to be administered orally BID
3137481|NCT03979638|Placebo Comparator|Placebo oral tablet BID|Randomized crossover design of matching placebo tablets to be administered orally BID
3137482|NCT03979274|Experimental|Reference Eutirox®, then Test Eutirox®|Participants received single oral dose of Reference Eutirox® 600 microgram (mcg) (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
3137483|NCT03979274|Experimental|Test Eutirox®, then Reference Eutirox®|Participants received single oral dose of Test Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 1 followed by single oral dosing of Reference Eutirox® 600 mcg (3 tablets of 200 mcg) in Treatment Period 2. A wash-out period of 35 days was maintained between the Treatment Periods 1 and 2.
3137484|NCT03979066|Active Comparator|Atezolizumab|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
3137485|NCT03979066|Experimental|Atezolizumab in combination with PEGPH20|Atezolizumab 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery in combination with PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
3137486|NCT03977727|Experimental|Fiasp/Novolog|7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
3137487|NCT03977727|Experimental|Novolog/Fiasp|7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion
3137488|NCT03977155|Experimental|High dose of BOS-589|Participants will receive a high dose of BOS-589 orally twice a day (BID).
3137489|NCT03977155|Experimental|Low dose of BOS-589|Participants will receive a low dose of BOS-589 orally BID.
3137490|NCT03977155|Placebo Comparator|Placebo|Participants will receive matching placebo orally BID.
3137491|NCT03972813|Experimental|cervical cancer - sexually transmitted (STD) - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
3137492|NCT03972813|Experimental|cervical cancer - STD - 12 years old (y.o.)|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
3149770|NCT00185510|Placebo Comparator|Arm 2|
3137493|NCT03972813|Experimental|cervical cancer - STD - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
3137494|NCT03972813|Experimental|cervical cancer - infectious - standard|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
3137495|NCT03972813|Experimental|cervical cancer - infectious - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
3137496|NCT03972813|Experimental|cervical cancer - infectious - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
3181990|NCT00698607|Experimental|E6|Everolimus-eluting stent 6-month clopidogrel therapy
3181991|NCT00698607|Active Comparator|S6|Sirolimus-eluting stent 6-month clopidogrel therapy
3181992|NCT00698607|Experimental|E12|Everolimus-eluting stent 12-month clopidogrel therapy
3181993|NCT00698607|Active Comparator|S12|Sirolimus-eluting stent 12-month clopidogrel therapy
3181994|NCT00698633||M2a- Taper™ Hip System|M2a- Taper™ Hip System
3188860|NCT00771446|Other|Standard of Care (Control)|Standard of care treatment Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
3188861|NCT00771459|Active Comparator|Ropivacaine|
3188862|NCT00771459|Placebo Comparator|Placebo|
3188863|NCT00771485|Experimental|1|
3188864|NCT00771485|Other|2|
3188865|NCT00771498|Other|lopinavir|Patients with HIV/TB co-infection will receive treatment for both infection, and PK of lopinavir 800mg + ritonavir 200mg (PO BID) during 5 months will be performed
3188866|NCT00771511|Experimental|1|Capsaicin cream applied to cervix after lidocaine gel
3188867|NCT00771511|Placebo Comparator|2|only lidocaine applied to the cervix
3137497|NCT03972813|Experimental|cervical cancer - blank - standard|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China.
3137498|NCT03972813|Experimental|cervical cancer - blank - 12 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine.
3137499|NCT03972813|Experimental|cervical cancer - blank - 18 y.o.|The Human Papilloma Virus (HPV) causes cervical cancer. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine.
3137500|NCT03972813|Experimental|many cancers - STD - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
3137501|NCT03972813|Experimental|many cancers - STD - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
3137502|NCT03972813|Experimental|many cancers - STD - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is a sexually transmitted disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
3188868|NCT00771524|Experimental|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
3137503|NCT03972813|Experimental|many cancers - infectious - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
3188869|NCT00771524|No Intervention|Control|Standard of care antibiotics prior to hip replacement surgery
3188870|NCT00771563|Active Comparator|Arm A|Chemotherapy without LMWH
3188871|NCT00771563|Experimental|Arm B|Chemotherapy with LMWH
3137504|NCT03972813|Experimental|many cancers - infectious - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
3137505|NCT03972813|Experimental|many cancers - infectious - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~HPV is an infectious disease. Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
3137506|NCT03972813|Experimental|many cancers - blank - standard|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China."
3137507|NCT03972813|Experimental|many cancers - blank - 12 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between grade school and middle school is a particularly good time to think about the HPV vaccine."
3137508|NCT03972813|Experimental|many cancers - blank - 18 y.o.|"The Human Papilloma Virus (HPV) causes cancers all over the body, from the head to the reproductive system.~Currently, safe and effective HPV vaccines are available for women 9-45 years of age in China. The transition between high school and college or work is a particularly good time to think about the HPV vaccine."
3181995|NCT00698659||patients on anti-VEGF therapy|"This study aims to assess the pharmacodynamic effects of anti-VEGF therapy. The following groups of patients will be approached:~Those who are starting on anti-VEGF therapy (such as but not limited to bevacizumab, sunitinib, and sorafenib) as part of routine clinical management or on clinical studies~All patients must be aged aged ≥ 21 years All patients must have a signed written informed consent prior to study enrollment. A separate consent will be obtained from patients already involved in a clinical study using anti-VEGF treatment.~Patients with a known allergy to intravenous contrast used in fluorescein and indocyanine green angiography will be exempt from these investigations but will undergo other study assessments."
3181996|NCT00698672|Active Comparator|2|articulation Spectron EF CoCr/ Reflection All-Poly Eto-sterilized
3181997|NCT00698672|Active Comparator|3|articulation Spectron Ef CoCr/ Reflection All-Poly XLPE
3181998|NCT00698672|Active Comparator|4|articulation Spectron EF Oxinium/ Reflection All-Poly Eto-sterilized
3181999|NCT00698672|Active Comparator|5|articulation Spectron EF Oxinium/ Reflection XLPE
3182000|NCT00698672|Active Comparator|1|articulation Charnley/ Ogee
3182001|NCT00698698||Non diabetic|Normal age and sex matched population
3182002|NCT00698698||Grade 1|Diabetic population with no retinopathy or Mild non proliferative diabetic retinopathy
3137509|NCT03974802|Experimental|somofilcon A (habitual) lens, then fanfilcon A (test) lens|Participants are habitual wearers of somofilcon A lens and refitted with fanfilcon A lens.
3182003|NCT00698698||Grade 2|Moderate non proliferative diabetic retinopathy
3182004|NCT00698698||Grade 3|Severe non proliferative diabetic retinopathy
3182005|NCT00698698||Grade 4|Proliferative diabetic retinopathy and advanced diabetic eye disease
3182006|NCT00698711|Experimental|1|"Three groups of 5 patients enrolled sequentially comprised from will receive MUC-2-KLH vaccines at the following g amounts of MUC-2-KLH per vaccination.~10 + 100 μg QS21 30 + 100 μg QS21 3 + 100 μg QS21"
3182007|NCT00698724|Active Comparator|1|Group 1: Xibrom, Optive
3182008|NCT00698724|Active Comparator|2|Group 2: Xibrom, Pred Forte
3182009|NCT00698750||Copeland™ Humeral Resurfacing Head|Copeland™ Humeral Resurfacing Head
3182010|NCT00698763|Experimental|A|Levosimendan
3182011|NCT00698763|Placebo Comparator|B|Placebo
3182012|NCT00698776|Experimental|Active|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
3137510|NCT03970733|Experimental|VLA15 with Alum lower dose|Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued
3137511|NCT03970733|Experimental|VLA15 with Alum higher dose|Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo
3137512|NCT03970733|Placebo Comparator|Placebo|Main Study Phase: placebo - Booster Phase: arm discontinued
3137513|NCT03968978|Experimental|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
3137514|NCT03968978|Experimental|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
3137515|NCT03968848|Experimental|Subjects with Severe Hepatic Impairment|Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.
3137516|NCT03968848|Experimental|Matched-Control Subjects|Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.
3137517|NCT03967444|Other|Restylane Kysse|Hyaluronic acid
3137518|NCT03967444|Other|Restylane Kysse with other HA|Hyaluronic acid
3137519|NCT03966924|Experimental|Rotational fractional resection (1.5mm Diameter Device)|Single treatment of skin resection and with and without focal lipectomy (removal of loose skin and fat)
3137520|NCT03966911|Other|Subjects with diabetes wearing Guardian™ Sensor (3)|Subjects wear Guardian™ Sensor (3) and Guardian™ Connect Transmitter over 7 days and participate in FSTs. Zero calibration sensor algorithm applied to raw sensor data.
3182013|NCT00698789|Experimental|Treatment A|5 mg of INCB019602 in AM with placebo administration in PM
3182014|NCT00698789|Experimental|Treatment B|20 mg of INCB019602 in AM with placebo administration in PM
3137521|NCT03966365|Experimental|PRO-122|- Dosage: 1 drop every 12 hours, in both eyes
3137522|NCT03966365|Active Comparator|Krytantek Ofteno®|- Dosage: 1 drop every 12 hours, in both eyes
3182015|NCT00698789|Experimental|Treatment C|5 mg of INCB019602 in PM with placebo administration in AM
3137523|NCT03965403|Experimental|Arm motor function retraining with BURT|All participants will receive 1 hour sessions, 2-3x/week for 6 weeks (total 18 sessions). Sessions will be organized with 30 minutes of robotic-assisted training and 30 minutes of hands-on training with a research therapist to work on the baseline goals of the subject. Hands-on training will be done with routinely employed techniques in therapy to transfer the skills gained with the robotic device in everyday life activities.
3137524|NCT03965754||No email|No email will be sent out to this subset of GHP members during the week that the other emails are sent.
3137525|NCT03965754||Standard email reminder|The standard email reminder mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding free health screenings where health measures can be collected and registered at one convenient time and location.
3182016|NCT00698789|Experimental|Treatment D|20 mg of INCB019602 in PM with placebo administration in AM
3137526|NCT03965754||Social norms email|The social norms email notes that a majority (78%) of GHP members' colleagues had enrolled in 2018, it provides a testimonial from a medical director at Geisinger's Commonwealth School of Medicine, stating the ways in which myHealth Rewards helped that doctor personally, and it emphasizes the simplicity and ease of taking the first step toward enrollment.
3137527|NCT03965754||Loss framing|"The loss framing email suggests that GHP members are currently throwing away a precise dollar amount (over $2,000) by not participating and that they can therefore avoid missing out on substantial gains (i.e., savings) by taking action."
3182017|NCT00698789|Experimental|Treatment E|7.5 mg of INCB019602 in PM QoD with placebo administration in AM as well as PM on non active dose days
3137528|NCT03965533|Placebo Comparator|Part A: Placebo IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of 0.9% weight by volume (w/v) saline placebo.
3137529|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Caucasian Participants|Caucasian male participants were administered a single IV infusion of GSK2831781 at a dose of 450 milligram (mg), diluted in 0.9% w/v saline.
3137530|NCT03965533|Placebo Comparator|Part A: Placebo IV- Japanese Participants|Japanese male participants were administered a single IV infusion of 0.9% w/v saline placebo.
3137531|NCT03965533|Experimental|Part A: GSK2831781 450 mg IV- Japanese Participants|Japanese male participants were administered a single IV infusion of GSK2831781 at a dose of 450 mg, diluted in 0.9% w/v saline.
3137532|NCT03965533|Placebo Comparator|Part B: Placebo SC|Caucasian male participants were administered three SC injections of 0.9% w/v saline placebo.
3137533|NCT03965533|Experimental|Part B: GSK2831781 150 mg SC|Caucasian male participants were administered a single SC injection of a unit dose strength of 150 mg per milliliter (mL) of GSK2831781, diluted in 0.9% w/v saline. Participants also received 2 dummy injections of 0.9% w/v saline placebo SC to maintain the blinding.
3137534|NCT03965533|Experimental|Part B: GSK2831781 450 mg SC|Caucasian male participants were administered three SC injections of a unit dose strength of 150 mg per mL of GSK2831781 to achieve a dose of 450 mg.
3137535|NCT03965351|Experimental|Probenecid|the study medication (probenecid) as well as a placebo.
3137536|NCT03965351|Placebo Comparator|Placebo|placebo compared to probenecid
3137537|NCT03964220||Patients with Asthma|
3137538|NCT03958955|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 6 weeks
3137539|NCT03958955|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 6 weeks
3182018|NCT00698789|Placebo Comparator|Treatment F|Placebo BID
3182019|NCT00698802|Experimental|A|
3137540|NCT03965052|Experimental|PRO-179|Dosage: 1 drop every 24 hours, at night, in both eyes.
3137541|NCT03965052|Active Comparator|Travatan®|Dosage: 1 drop every 24 hours, at night, in both eyes.
3137542|NCT03965039|Active Comparator|Marketed stannous fluoride toothpaste|Brush twice daily
3137543|NCT03965039|Active Comparator|Marketed potassium nitrate toothpaste|Brush Twice Daily
3137544|NCT03965039|Placebo Comparator|Marketed sodium monofluorophosphate toothpaste|Brush Twice Daily
3137545|NCT03965039|Experimental|Experimental dipotassium oxalate toothpaste|Brush Twice Daily
3137546|NCT03963401|Experimental|PF-06700841 60 mg once daily|PF-06700841 60 mg once daily for 52 weeks
3137547|NCT03963401|Experimental|PF-06700841 30 mg once daily|PF-06700841 30 mg once daily for 52 weeks
3137548|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 60 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 60 mg once daily until Week 52
3182020|NCT00698802|Active Comparator|B|
3182021|NCT00698828|Experimental|Group 1|SUN11031 for injection, low dose, twice daily for 12 weeks
3137549|NCT03963401|Experimental|PF-06700841 10 mg once daily followed by 30 mg once daily|PF-06700841 10 mg once daily for 16 weeks, followed by 30 mg once daily until Week 52
3137550|NCT03963401|Placebo Comparator|Placebo once daily followed by 60 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 60 mg once daily until Week 52
3137551|NCT03963401|Placebo Comparator|Placebo once daily followed by 30 mg once daily|Placebo once daily for 16 weeks, followed by PF-06700841 30 mg once daily until Week 52
3137552|NCT03962634|Experimental|Kovanaze Nasal Spray (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
3137553|NCT03962634|Active Comparator|Articaine Injections (Pediatrics)|Children >20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth
3137554|NCT03962790|Experimental|Test/Control|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
3182022|NCT00698828|Experimental|Group 2|SUN11031 for injection, higher dose, twice daily for 12 weeks
3182023|NCT00698828|Placebo Comparator|Group 3|Placebo injection, twice daily for 12 weeks
3137555|NCT03962790|Experimental|Control/Test|Eligible subjects that are habitual wearers of hydrogel daily disposable contact lenses in both eyes will be randomly assigned to one of two sequences, (Test/Control) or (Control/Test).
3137556|NCT03956225|Experimental|iLux|Single treatment with the Systane iLux Dry Eye System and 12-month follow-up. Both eyes will be treated.
3137557|NCT03956225|Active Comparator|LipiFlow|Single treatment with the LipiFlow Thermal Pulsation System and 12-month follow-up. Both eyes will be treated.
3137558|NCT03951610|Experimental|Test lens|Subjects wearing the test lens for one week, either randomized as the first or second pair.
3137559|NCT03951610|Active Comparator|Control lens|Subjects wearing the control lens for one week, either randomized as the first or second pair.
3182024|NCT00698854||Vanguard™ Complete Knee System|Vanguard Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
3137560|NCT03958149|Other|Spinal collar|Participants will undergo MRI scans in and out a spinal collar to assess whether the measurements of angulation of the C-spine change whilst wearing a spinal collar.
3137561|NCT03953183|Other|P3P-1mg|Subjects randomized to exclusive use of P3P-1mg
3137562|NCT03953183|Other|P3P-2mg|Subjects randomized to exclusive use of P3P-2mg
3137563|NCT03949335|Experimental|Investigational|Bilateral implantation with investigational IOL Model ZFR00V
3137564|NCT03949335|Active Comparator|Control|Bilateral implantation with control IOL Model ZCB00
3137565|NCT03962738|Experimental|50 milligram (mg) Lasmiditan|50 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
3137566|NCT03962738|Experimental|100 mg Lasmiditan|100 mg Lasmiditan tablet plus two placebo tablets (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
3137567|NCT03962738|Experimental|200 mg Lasmiditan|200 mg Lasmiditan (two 100 mg tablets) plus one placebo tablet (to match Lasmiditan dose) administered once orally to treat a single migraine attack.
3137568|NCT03962738|Placebo Comparator|Placebo|Placebo tablets (to match 50 mg, 100 mg, 200 mg Lasmiditan dose tablets) administered once orally to treat a single migraine attack.
3137569|NCT03962101|Experimental|OPC-61815 injection|Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.
3137570|NCT03959137||Primary study group|Stage IV untreated NSCLC
3137571|NCT03946124|Other|Fesoterodine|Subjects (irrespective of preference) will receive a 90-day supply of open label fesoterodine 4 mg per day. Medication will start 1 week after the baseline visit. After 2 weeks of treatment, dose may be increased to 8 mg over the telephone based on symptom report. This dosing regimen is direct alignment with clinical care. Change of prescription to another anti-cholinergic may occur during the study period, if determined necessary by the physician.
3137572|NCT03961308|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
3137573|NCT03961308|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
3137574|NCT03961295|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
3137575|NCT03961295|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
3137576|NCT03960957|Experimental|Experimental|AbobotulinumtoxinA
3137577|NCT03960957|Placebo Comparator|Placebo|
3137578|NCT03956862|Experimental|GB001|GB001 40 mg once per day (QD) for 16 weeks
3137579|NCT03956862|Placebo Comparator|Placebo|Placebo QD for 16 weeks
3137580|NCT03954444|Active Comparator|Oxymetazoline hydrochloride Cream, 1%|Oxymetazoline hydrochloride cream, 1%
3137581|NCT03954444|Active Comparator|RHOFADE Cream, 1%|RHOFADE Cream, 1%
3137582|NCT03954444|Placebo Comparator|Vehicle Cream|Vehicle cream
3137583|NCT03953820|Experimental|Diazepam Buccal Film, Then Diastat Rectal Gel|Participants received a single dose of Diazepam Buccal Film following a moderate-fat meal and then received a single dose of Diastat Rectal Gel following a moderate-fat meal with a 28-day washout between doses.
3137584|NCT03953820|Experimental|Diastat Rectal Gel, Then Diazepam Buccal Film|Participants received a single dose of Diastat Rectal Gel following a moderate-fat meal and then received a single dose of Diazepam Buccal Film following a moderate-fat meal with a 28-day washout between doses.
3137585|NCT03953820|Experimental|Diazepam Buccal Film following a High-Fat Meal|Participants who volunteered to participate in the second period received a second dose of Diazepam Buccal Film at the same dose and exactly the same manner as the earlier dose with the exception that the dose was administered following ingestion of a high-fat meal.
3182025|NCT00698854||Vanguard™ Patient-Specific Femur|Vanguard Total Knee System used in combination with Signature technique to provide a patient-specific femur
3182026|NCT00698880|Active Comparator|HVE|Hepatic vein embolization after portal vein embolization
3182027|NCT00698880|No Intervention|PVE|Only portal vein embolization, historical control group
3182028|NCT00698893|Experimental|Group A|
3137586|NCT03951766|Other|Smiling Instead of Smoking App|This is a pilot study; all participants will use the app in the same manner/time period.
3182029|NCT00698893|Experimental|Group B|
3182030|NCT00698906|Experimental|Group A|
3182031|NCT00698906|Experimental|Group B|
3137587|NCT03961100|Experimental|Part 1|Participants will be randomly assigned to one of the three treatment sequences (T1T2R, T2RT1, RT1T2). In each treatment sequences, participants will cross-over to three periods taking different formulations of entrectinib. Entrectinib will be administered as a single 600 milligram (mg) oral dose under fed condition in three different formulations. Test formulation 1 (T1): film-coated mini-tablet; Test formulation 2 (T2): film-coated mini-tablet; Reference formulation (R): hard capsule.
3182032|NCT00698906|Experimental|Group C|
3182033|NCT00698906|Experimental|Group D|
3182034|NCT00698906|Experimental|Group E|
3182035|NCT00698906|Active Comparator|Group F|
3182036|NCT00698919||Development cohort|A first group of one hundred patients with SIRS will be included to evaluate the accuracy of this new test.
3182037|NCT00698919||Validation Cohort|Depending on the result of the previous (development) cohort we will more accurately evaluate the need of number of patients with SIRS to include in the second cohort of patients.
3182038|NCT00698945|Active Comparator|2|Alphagan
3182039|NCT00698945|Active Comparator|1|Istalol and Optive
3182040|NCT00698958|Active Comparator|1|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
3137588|NCT03961100|Experimental|Part 2|Participants will be randomly assigned to one of the two treatment sequences (TR, RT). In each treatment sequences, participants will cross-over to two periods taking different formulations of entrectinib. Entrectinib will be administered as a single 200 mg oral dose under fasted condition in two different formulations. Test formulation (T): hydroxypropyl methylcellulose (HPMC) capsule; Reference formulation (R): hard capsule.
3137589|NCT03950856|Experimental|V114 Lot 1|Single intramuscular (IM) dose at 0.5 mL of V114 Lot 1 pneumococcal conjugate vaccine at Visit 1 (Day 1)
3137590|NCT03950856|Experimental|V114 Lot 2|Single IM dose at 0.5 mL of V114 Lot 2 pneumococcal conjugate vaccine at Visit 1 (Day 1)
3137591|NCT03950856|Experimental|V114 Lot 3|Single IM dose at 0.5 mL of V114 Lot 3 pneumococcal conjugate vaccine at Visit 1 (Day 1)
3137592|NCT03950856|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
3137593|NCT03947983|Experimental|Intervention Group|The intervention group will receive a sensor-controlled digital game (SCDG) app and weight monitoring and physical activity sensors
3137594|NCT03947983|Active Comparator|Control group|The control group will receive only the weight monitoring and physical activity sensors
3137595|NCT03960658|Experimental|Ketamine and PE|ketamine treatment followed by a standardized prolonged exposure session for the first 3 weeks; then, weekly prolonged exposure as usual.
3137596|NCT03959332|Experimental|Baloxavir Marboxil 40 mg|
3137597|NCT03959332|Experimental|Baloxavir Marboxil 80 mg|
3137598|NCT03959189|Experimental|ERX-963 then placebo|Participants in this arm will receive ERX-963 followed by a washout period. After the washout period, participants will receive placebo.
3137599|NCT03959189|Experimental|Placebo then ERX-963|Participants in this arm will receive placebo followed by a washout period. After the washout period, participants will receive ERX-963.
3137600|NCT03956550|Experimental|REGN5069 Low Dose|Randomized in a 1:1:1 ratio
3137601|NCT03956550|Experimental|REGN5069 High Dose|Randomized in a 1:1:1 ratio
3137602|NCT03956550|Experimental|Matching Placebo|Randomized in a 1:1:1 ratio
3137603|NCT03954158|Experimental|Crisaborole ointment 2% once daily (QD) vs vehicle QD|intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
3137604|NCT03954158|Experimental|Crisaborole ointment 2% twice daily (BID) vs vehicle BID|Intra-participant comparison, treatment will be randomly assigned to target lesion 1 and lesion 2.
3137605|NCT03958656|Experimental|1/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Dose Escalation|Patients will receive escalating doses (up to 4 planned) of Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)-CAR+ T cells infused on day 0 + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30 mg/m^22 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
3137606|NCT03958656|Experimental|2/Conditioning Chemotherapy Plus Chimeric Antigen Receptor (CAR) T-cells Expansion Phase|Maximum tolerated dose (MTD) dose of Anti-Anti-Signaling lymphocytic activation molecule F7 (SLAMF7)- CAR T Cells + Cyclophosphamide: 300 mg/m^2 intravenous (IV) infusion over 30 minutes on days -5, -4 and -3 + Fludarabine: 30mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4, and -3
3137607|NCT03955133|Experimental|intervention|This is a single arm before and after study with data collection at 4 time points.
3137608|NCT03954626|Experimental|RTH258|Intravitreal injection
3149771|NCT00185523||CML in first Chronic Phase or Accelerated Phase|Busulfan/cyclophosphamide Day -7: Busulfan 1.0 mg/kg IV q6 hrs** Day -6: Busulfan 1.0 mg/kg IV q6 hrs Day -5: Busulfan 1.0 mg/kg IV q6 hrs Day -4: Busulfan 1.0 mg/kg IV q6 hrs Day -3: Cyclophosphamide 60 mg/kg Day -2: Cyclophosphamide 60 mg/kg Day -1: rest Day 0: Allogeneic PBSC infusion
3137609|NCT03954743|Experimental|HRV PCV-free Liq Group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) porcine circovirus (PCV)-free vaccine in liquid formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries. PCV-free implies no detection of PCV-1 and PCV-2 according to the limit of detection of the tests used.
3137610|NCT03954743|Active Comparator|HRV Lyo group|Subjects aged 6 to 12 weeks at the time of first vaccination, who received two doses of oral live-attenuated human rotavirus (HRV) vaccine in lyophilized formulation, one at Day 1 and one at Month 1 or Month 2, according to the immunization schedule for rotavirus (RV) vaccine administration in participating countries.
3182041|NCT00698958|Experimental|2|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
3182042|NCT00698984|Active Comparator|1|30 mg BONISTEIN(R) 150 ug Vitamin K1 800 IU Vitamin D3 1000 mg PUFA 500 mg Calcium
3182043|NCT00698984|Placebo Comparator|2|500 mg Calcium
3182044|NCT00699023|Experimental|1|ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
3137611|NCT03951805|Experimental|Insulin 287 algorithm A|Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
3137612|NCT03951805|Experimental|Insulin 287 algorithm B|Controlled on metformin with or without DPP4i and with or without SGLT2i.
3182045|NCT00699023|Placebo Comparator|2|placebo + simvastatin tablets 20 mg/die six weeks
3182046|NCT00699036|Experimental|1|avandia
3182047|NCT00699036|Experimental|2|avandia plus metformin
3137613|NCT03951805|Experimental|Insulin 287 algorithm C|Controlled on metformin with or without DPP4i and with or without SGLT2i.
3182048|NCT00699036|Experimental|3|avandia plus losartan
3182049|NCT00699049|Placebo Comparator|Alpha blocker and placebo|
3182050|NCT00699049|Experimental|Alpha blocker and solifenacin|
3182051|NCT00699062|Placebo Comparator|Placebo pill|The patients allocated into this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator plus placebo for 6 months.
3137614|NCT03951805|Active Comparator|Insulin Glargine algorithm D|Controlled on metformin with or without DPP4i and with or without SGLT2i.
3137615|NCT03944785||Parkinson's Disease Patients|PD patients who have been newly prescribed safinamide (XADAGO) for the treatment of OFF episodes as described in the XADAGO Package Insert
3137616|NCT03950622|Experimental|V114|Single intramuscular (IM) dose at 0.5 mL of V114 pneumococcal conjugate vaccine at Visit 1 (Day 1)
3137617|NCT03950622|Active Comparator|Prevnar 13™|Single IM dose at 0.5 mL of Prevnar 13™ at Visit 1 (Day 1)
3137618|NCT03949621|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
3137619|NCT03949621|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
3137620|NCT03949244|Active Comparator|Latanoprost 0.005%|Latanoprost 0.005% drops to the nailfold.
3137621|NCT03949244|Experimental|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% drops to the nailfold.
3137622|NCT03949244|Placebo Comparator|Normal saline 0.9%|Normal saline 0.9% to the nailfold.
3137623|NCT03948581|Active Comparator|Group A: Vedolizumab SC PFS|Vedolizumab SC 108 mg, injection, subcutaneously using a PFS, once on Day 1.
3182052|NCT00699062|Experimental|Singular pill|The patients in this placebo comparator arm will receive inhale corticosteroid plus long-acting bronchodilator and montelukast for 6 months
3182053|NCT00699088||Balance® Microplasty™ Hip System|
3137624|NCT03948581|Experimental|Group B: Vedolizumab SC Investigational Device|Vedolizumab SC 108 mg, injection, subcutaneously using an investigational device, once on Day 1.
3137625|NCT03948386|Active Comparator|isobaric bupivacaine|"Isobaric bupivacaine 12.5 mg (2.5 cc of 0.5%) for ≤ 74 height and 15 mg (3 cc) for > 74 height"
3137626|NCT03948386|Active Comparator|hyperbaric bupivacaine|"hyperbaric bupivacaine 10.25 mg (1.5 cc 0.75%) for ≤ 74 height and 13.125 mg (1.75 cc) for > 74 height"
3137627|NCT03948386|Active Comparator|isobaric mepivacaine|"isobaric mepivacaine 52.5 mg (3.5 cc of 1.5%) for ≤ 74 height and 60 mg (4 cc) for > 74 height"
3137628|NCT03948334|Experimental|ZPL389 30mg|30mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
3182054|NCT00699101|Experimental|A|Conture Multi-Lumen Balloon
3182055|NCT00699114|Placebo Comparator|Placebo|Single dose placebo capsule
3182056|NCT00699114|Active Comparator|Ibuprofen 400 mg|Single dose ibuprofen 400 mg capsule
3182057|NCT00699114|Active Comparator|Ibuprofen 600 mg|Single dose ibuprofen 600 mg capsule
3182058|NCT00699114|Active Comparator|Ibuprofen 800 mg|Single dose ibuprofen 800 mg capsule
3137629|NCT03948334|Experimental|ZPL389 50mg|50mg of ZPL389 + TCS and/or TCI for patients re-randomized from the core study (received placebo/ZPL389 3mg/ 10mg in the core study) and for patients continuing in the same arm from the core study
3149772|NCT00185523||AML and ALL in first or second remission|FTBI/VP-16 Day -7: FTBI 120 cGy x 3 fractions Day -6: FTBI 120 cGy x 2 fractions Day -5: FTBI 120 cGy x 3 fractions Day -4: FTBI 120 cGy x 3 fractions* Day -3: VP-16 at 60 mg/kg Day -2: rest Day -1: rest Day 0: Allogeneic PBSC infusion
3149773|NCT00185601|Other|on-line self management intervention|
3149774|NCT00185601|No Intervention|usual care control group|
3149775|NCT00185601|Experimental|on-line self management intervention with email reinforcement|
3149776|NCT00185744|Experimental|Accelerated Partial Breast Irradiation|lumpectomy with accelerated partial breast irradiation
3149777|NCT00185744|Active Comparator|Standard Therapy|lumpectomy and whole breast irradiation
3149778|NCT00185757|Experimental|Cytokine-induced Killer Cells|The first cohort =1X10 7 cf expanded cells/kg. The second cohort = 5x10 7 expanded cells/kg. The second cohort = 1X10 8 expanded cells/kg.
3149779|NCT00185796|Experimental|TLI/ATG conditioning|Lymphoid irradiation and anti-thymocyte globulin (TLI/ATG).
3149780|NCT00185848|Experimental|[18F]FHBG arm|
3149781|NCT00185887|Active Comparator|Terbutaline|
3149782|NCT00185887|Active Comparator|Nitroglycerine|
3149783|NCT00185952|Active Comparator|Nifedipine|Maintenance tocolysis with nifedipine.
3149784|NCT00185952|Placebo Comparator|Placebo|Maintenance tocolysis with placebo tablets.
3149785|NCT00185991|Active Comparator|Once daily Gentamicin|
3149786|NCT00185991|Active Comparator|Every eight hour Gentamicin|
3149787|NCT00186082|Active Comparator|Cefotetan, Cefoxitin or Clindamycin|
3149788|NCT00186082|Placebo Comparator|Normal Saline|
3149789|NCT00186147||Graft recipients and donors|
3149790|NCT00186173|Experimental|After school sports|After school team sports intervention designed specifically for overweight and obese children
3149791|NCT00186173|Active Comparator|After school health education|After school heath and nutrition education program
3182059|NCT00699114|Active Comparator|Paracetamol 500 mg|Paracetamol 500 mg (acetaminophen) capsule
3137630|NCT03946059|Experimental|iTBS then cTBS|"Participants in this arm first receive the iTBS brain stimulation in week 1, then have a one-week washout period and then receive cTBS brain stimulation in week 2.~intermittent Theta-Burst-Stimulation (iTBS) entails a 2 second train of stimuli (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). Each 2 second train is followed by an 8 second pause, followed by another 2 second train. In total, 20 trains will be delivered, for a total of 200 bursts and 600 total pulses.~continuous Theta-Burst-Stimulation (cTBS) consists of a continuous stimulus train (stimuli occurring as a 50 Hz burst of three pulses separated by 200ms). In total, 200 bursts and 600 total pulses will be delivered."
3137631|NCT03946059|Experimental|cTBS then iTBS|Participants in this arm first receive the cTBS brain stimulation in week 1, then have a one-week washout period and then receive iTBS brain stimulation in week 2.
3137632|NCT03944707|Experimental|LOU064|LOU064 100 mg once daily orally
3137633|NCT03944707|Placebo Comparator|Placebo|Placebo once daily orally
3137634|NCT03944668|Experimental|Intervention|Exercise intervention
3137635|NCT03943095|Experimental|Test Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 5 % weight by weight (w/w) potassium nitrate and 0.454% w/w stannous fluoride (1100 parts per million [ppm] fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
3137636|NCT03943095|Active Comparator|Control Dentifrice|Participants will be instructed to apply a strip of dentifrice (a full brush head) containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush their two selected 'test teeth' first, followed by the whole mouth for at least one timed minute, twice daily (morning and evening), and will be permitted to rinse with water post-brushing.
3137637|NCT03943290|Experimental|Part 1 Cohort 1a|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for FSHD patients
3182060|NCT00699114|Active Comparator|Paracetamol 1000 mg|Single dose paracetamol 1000 mg (acetaminophen) capsule
3182061|NCT00699114|Active Comparator|Paracetamol 1000 mg + codeine 60 mg|Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
3137638|NCT03943290|Experimental|Part 1 Cohort 1b|ACE-083 240 mg/muscle administered bilaterally by injection into the BB muscle every 4 weeks for up to 6 doses for FSHD patients
3137639|NCT03943290|Experimental|Part 1 Cohort 1c|ACE-083 240 mg/muscle administered bilaterally by injection into the TA muscle every 4 weeks for up to 6 doses for CMT patients
3137640|NCT03943290|Experimental|Part 2 Cohort 2a|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for FSHD patients
3137641|NCT03943290|Experimental|Part 2 Cohort 2b|ACE-083 Administered into the BB muscle q4w for up to 24 months (24 doses) for FSHD patients
3137642|NCT03943290|Experimental|Part 2 Cohort 2c|ACE-083 Administered into the TA muscle q4w for up to 24 months (24 doses) for CMT patients
3137643|NCT03943290|Experimental|Part 2 Cohort 3a|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for FSHD patients
3137644|NCT03943290|Experimental|Part 2 Cohort 3b|ACE-083 Administered into the BB muscle q8w for up to 24 months (12 doses) for FSHD patients
3137645|NCT03943290|Experimental|Part 2 Cohort 3c|ACE-083 Administered into the TA muscle q8w for up to 24 months (12 doses) for CMT patients
3137646|NCT03942042|Experimental|Ixekizumab|"Induction Dosing Period:~Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10.~Maintenance Dosing Period:~Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study.~Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1."
3137647|NCT03938337|Experimental|Cohort 1 Not Previously Treated|Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
3137648|NCT03938337|Experimental|Cohort 2 Treated Previously|Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
3137649|NCT03923530|Experimental|Eplerenone|Eplerenone 50 mg daily, administered orally for 8 weeks.
3137650|NCT03914417|Experimental|Imiquimod 3.75% cream|applied topically
3137651|NCT03913377|Experimental|Observational|Eligible subjects that are habitual spectacle wearers will use their habitual optical correction and undergo ocular evaluations and questionnaires at the baseline and 1-week visit.
3137652|NCT03913377|Experimental|Interventional|Eligible subjects that are habitual contact lens wearers who own spectacles will be randomized into 1 of 2 sequences (Spectacle/ACUVUE OASYS 1-Day or ACUVUE OASYS 1-Day/Spectacle)
3137653|NCT03937791|Experimental|Arm 1/1x10^11 E7 T Cell Receptor (TCR) T cells|1x10^11 E7 TCR T cells will be administered intravenously over 20 to 30 minutes on day 0.
3149792|NCT00186342|Experimental|CIK cell|The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
3137654|NCT03937778|Experimental|Tourniquet block to left upper arm|Participants underwent ~10 minutes of baseline testing followed by a tourniquet placement to left upper arm and inflated to 80-100 mmHG above systolic blood pressure. Participants repeatedly rated a variety of sensory stimuli after tourniquet was placed. Participants rated intensity and pleasantness of slow brushing and deep pressure on both hands/forearms at baseline and after loss of A-beta sensation.
3137655|NCT03937479|Experimental|RPL554 0.375 mg twice daily|RPL554 0.375 mg twice daily
3137656|NCT03937479|Experimental|RPL554 0.75 mg twice daily|RPL554 0.75 mg twice daily
3137657|NCT03937479|Experimental|RPL554 1.5 mg twice daily|RPL554 1.5 mg twice daily
3137658|NCT03937479|Experimental|RPL554 3.0 mg twice daily|RPL554 3.0 mg twice daily
3137659|NCT03937479|Placebo Comparator|Placebo twice daily|Placebo twice daily
3137660|NCT03936387|Experimental|Bilateral erector spinae blocks|Bilateral erector spinae block catheters are placed at end of the sternotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. Patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH.
3137661|NCT03935399|Other|Oxytocin first, then saline placebo|Intramuscular injection of oxytocin (Pitocin®), 10 IU on the first study day and of 1 ml saline placebo on the second study day
3137662|NCT03935399|Placebo Comparator|Saline placebo first, then oxytocin|Intramuscular injection of 1 ml saline placebo on the second study day and of oxytocin (Pitocin®), 10 IU on the second study day
3137663|NCT03936608|Experimental|Individualized RV-LV Pacing Offset|
3137664|NCT03936608|Active Comparator|No RV-LV Pacing Offset|
3182062|NCT00699127|Experimental|1|The group that will have lecture of information regarding infants in NICU.
3137665|NCT03936244|Active Comparator|M-TURP|The M-TURP procedure requires the use of a resectoscope (Olympus or Storz, 26Ch), camera system and irrigation fluid (Glycine 1.5%, Baxter). The system consists of a generator unit (ForceTriadTM, Medtronic) and a stainless steel loop with an electrical current running through the loop used to cut (120W) prostate tissue and cauterize (80W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
3182063|NCT00699127|No Intervention|2|The group that will not have lecture of information regarding NICU hospitalization
3182064|NCT00699166|Experimental|1|
3182065|NCT00699166|Experimental|2|
3182066|NCT00699166|Placebo Comparator|3|
3182067|NCT00699179||A|
3137666|NCT03936244|Experimental|PK-TURP|The PK-TURP procedure requires the use of a resectoscope (Storz, 26Ch), camera system and irrigation fluid (NaCl 0.9%, Baxter). The system consists of a generator unit (PlasmaKineticTM Superpulse de Gyrus, ACMI) and a platinum-iridium superloop with an electrical current running through the loop used to cut (180W) prostate tissue and cauterize (100W). Prostate tissue is cut away in small pieces and removed at the end of the procedure using an Ellik evacuator
3137667|NCT03935126||All patients|
3182068|NCT00699231|Active Comparator|Group A1|Non-responders to vaccination after at least 7 previous injections
3182069|NCT00699231|Experimental|Group A2|Non-responders to vaccination after at least 7 previous injections
3137670|NCT03928327|Experimental|Part 1, Treatment Sequence AB|TAK-788 20 mg, capsule, at Hour 0 on Day 1 followed by an overnight fast (Treatment A). Following Treatment A, participants received itraconazole 200 mg solution, orally, once daily (QD) on Days 1 to Day 14 and a single oral dose of TAK-788 20 mg capsule was coadministered on Day 5 (Treatment B). There was a washout period of 7 days between the two treatments.
3137671|NCT03928327|Experimental|Part 2, Treatment Sequence CD|TAK-788 160 mg, orally, at Hour 0 on Day 1 following an overnight fast (Treatment C). Following Treatment C, participants received rifampin 600 mg as capsules, orally, once daily (QD) on Days 1 to 13 and TAK-788 160 mg as capsules, orally was coadministered on Day 7 (Treatment D). There was a washout period of 7 days between the two treatments.
3182070|NCT00699231|Active Comparator|Group B1|Vaccine-responders requiring a booster dose
3182071|NCT00699231|Experimental|Group B2|Vaccine-responders requiring a booster dose
3182072|NCT00699231|Active Comparator|Group C1|Volunteers participating in the hospital's vaccination program
3137672|NCT03933462|Experimental|InnoSpire Go|The InnoSpire Go is a handheld, single patient use, vibrating mesh nebulizer system designed to aerosolize liquid medications for respiratory disease. The device operates continuously once initiated and automatically switches off once the medication has been delivered. The device may be used in pediatric and adult populations, as permitted by the prescribed medication, and is suitable for use in home environments or hospital/clinic settings.
3137673|NCT03933462|Active Comparator|Jet Nebulizer|Jet Nebulizers are the standard delivery system for aerosolized medications. A nebulizer breaks up medical solutions into small droplets suspended in air (aerosol) so that they may be delivered to the patient's airways for respiratory therapy.
3137674|NCT03933774|Experimental|Tretinoin 0.05% cream group|Tretinoin 0.05% cream 25g for 1 month, applied on the half side of the face after randomization, once a day every night
3137675|NCT03933774|Placebo Comparator|Placebo|PHYSIOGEL Daily Moisture Therapy Creme 150ml for 1 month, applied on the other half side of the face once a day every night
3137676|NCT03931330|Experimental|Percutaneous neurostimulation|Subjects will have 4 weeks of active therapy.
3137677|NCT03918811|Experimental|Positive Pressure Extubation Technique|ETT is removed in PSV 15/10 mode and without endotracheal suction.
3137678|NCT03918811|Active Comparator|Traditional Extubation Technique|ETT is removed with continuous endotracheal suction
3137679|NCT03912259|Experimental|Placebo Q2W|Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.
3137680|NCT03912259|Placebo Comparator|Dupilumab 300 mg Q2W|Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.
3137681|NCT03933618|Other|anastrazole-clomiphene-placebo|anastrozole for eight weeks then clomiphene for eight weeks then placebo for eight weeks
3137682|NCT03933618|Other|anastrazole-placebo-clomiphene|anastrozole for eight weeks then placebo for eight weeks then clomiphene for eight weeks
3137683|NCT03933618|Other|clomiphene-anastrazole-placebo|clomiphene for eight weeks then anastrozole for eight weeks then placebo for eight weeks
3137684|NCT03933618|Other|clomiphene-placebo-anastrazole|clomiphene for eight weeks then placebo for eight weeks then anastrozole for eight weeks
3137685|NCT03933618|Other|placebo-clomiphene-anastrazole|placebo for eight weeks then clomiphene for eight weeks then anastrozole for eight weeks
3137686|NCT03933618|Other|placebo-anastrazole-clomiphene|placebo for eight weeks then anastrozole for eight weeks then clomiphene for eight weeks
3137687|NCT03931785|Experimental|MD-7246 300 μg|1 MD-7246 300-μg oral tablet and 3 matching placebo oral tablets
3137688|NCT03931785|Experimental|MD-7246 600 μg|2 MD-7246 300-μg oral tablets and 2 matching placebo oral tablets
3137689|NCT03931785|Experimental|MD-7246 1200 μg|4 MD-7246 300-μg oral tablets
3137690|NCT03931785|Placebo Comparator|Placebo|4 matching placebo oral tablets
3137691|NCT03930641|Experimental|RTH258|brolucizumab 6 mg in a prefilled syringe
3137692|NCT03927846|Active Comparator|Telephone Contact (Nurse)|6 regular telephone contacts by nurses who will use a motivational interviewing technique
3137693|NCT03927846|Active Comparator|E-mail contact|6 computer generated email reminders (control arm) over an 8-week period.
3137694|NCT03927105|Experimental|Nivolumab + Cabiralizumab|Nivolumab 240mg IV + Cabiralizumab 4mg/kg on day 1 of every 14 day cycle.
3137695|NCT03923933|Placebo Comparator|Placebo|This group will receive 3 milligrams of bumetanide per day for a week plus placebo (starch) that will simulate the chlorthalidone dose of the treatment group. In case the dose is well tolerated, the dose of bumetanide will be increased to 4 milligrams per day.
3137696|NCT03923933|Experimental|Treatment grup|This group will receive 3 milligrams of bumetanide plus 50 milligrams of chlorthalidone per day, for a week. If the dose is well tolerated, it will be increased to 4 milligrams of bumetanide and 100 milligrams of chlorthalidone per day.
3182073|NCT00699231|Experimental|Group C2|Volunteers participating in the hospital's vaccination program
3137697|NCT03909295|Experimental|LCZ696|Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
3137698|NCT03908970|Experimental|1% OPA-15406|Twice daily
3137699|NCT03908970|Placebo Comparator|Placebo|Twice daily
3137700|NCT03897179|Experimental|INVSENSOR00032 and INVSENSOR00033 test group|All subjects will be enrolled into the test group and will receive the INVSENSOR00032 and/or INVSENSOR00033 device.
3137701|NCT03930264|Active Comparator|Imurek®,|Generic name : Azathioprine Trade name : Imurek® 50mg tablet Dosage form : Tablet containing 50 mg azathioprine Dose : 1 x Imurek 50mg Tablet per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Aspen Pharma Trading Limited, Dublin, Ireland Country of origin : Ireland
3182074|NCT00699231|Active Comparator|Group D1|Unvaccinated haemodialysis patients
3182075|NCT00699231|Experimental|Group D2|Unvaccinated haemodialysis patients
3137702|NCT03930264|Experimental|Jayempi™|"Generic name : Azathioprine~Trade name : (Jayempi™) 10 mg/ mL Oral solution Dosage form : Oral suspension containing 10 mg/mL Azathioprine Dose : 1 x 5mL (50 mg) of Jayempi™ Oral Suspension 10mg/mL per treatment period under fasting conditions Mode of administration : Orally Manufacturer : Nova Laboratories Ltd. Country of origin : Leicester, UK"
3182076|NCT00699244|Experimental|Peripheral placement of local anesthesia|to receive ultrasound guided peripheral placement of local anesthetic
3137703|NCT03929367|Other|Oxytocin (Pitocin®), 10 IU|Oxytocin 10 IU administered once per intravenous injection
3137704|NCT03928522|Active Comparator|Pre-mixed tobramycin|patients will receive pre-mixed tobramycin cement
3137705|NCT03928522|Active Comparator|hand mixed tobramycin|patients will receive hand mixed tobramycin cement
3137706|NCT03928522|Active Comparator|hand mixed vancomycin|patients will receive hand mixed vancomycin cement
3137707|NCT03928522|Experimental|hand-mixed vancomycin and tobramycin|patients will receive hand mixed vancomycin and tobramycin
3137708|NCT03910439|Experimental|1/Avelumab 800 mg intravenous (IV) every two weeks in combination with radiation therapy|Avelumab 800 mg IV every two weeks in combination with radiation therapy
3137709|NCT03907241|Experimental|Octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
3137710|NCT03927950|Experimental|Escitalopram bupropion open-label|No comparator
3137711|NCT03927781|Experimental|Pregabalin 300mg|300mg pregabalin, PO, once, 1 hr before surgery
3137712|NCT03927209|Experimental|BI 1467335 (low dose)|
3137713|NCT03927209|Experimental|BI 1467335 (high dose)|
3137714|NCT03920670|Experimental|Tetragraph (TG)|TetraGraph placed on dominant hand, ToFscan placed on non-dominant hand
3137715|NCT03920670|Active Comparator|ToFscan (TS)|ToFscan placed on dominant hand, TetraGraph (TG) placed on non-dominant hand
3137716|NCT03919422|Active Comparator|IC group|Interscalene brachial plexus-Cervical plexus
3137717|NCT03919422|Experimental|ICTP group|Interscalene brachial plexus-Cervical plexus combined with T2 Paravertebral blockade
3182077|NCT00699244|Active Comparator|Central placement of local anesthesia|to receive central placement of local anesthetic
3182078|NCT00699257||Oxford® Partial Knee System|
3137718|NCT03907579|Experimental|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.
3137719|NCT03905811|Experimental|Active|Terazosin administered 5 mg once daily p.o. for 12 weeks
3137720|NCT03905811|Placebo Comparator|Placebo|Placebo administered once daily p.o. for 12 weeks
3137721|NCT03898063|Active Comparator|Control|participants will receive a standard-of-care brochure detailing HIV status disclosure.
3137722|NCT03898063|Experimental|intervention: 90 DAYS film|participants will watch the film, 90 DAYS
3137723|NCT03895307|Experimental|kinesio taping|two 15 cm I type kinesio tape applied longitudinally
3137724|NCT03895307|Placebo Comparator|sham kinesio taping|two 15 cm I type kinesio tape applied longitudinally but without stretching
3137725|NCT03895307|Experimental|local anesthetic|18-20 cc %0.5 lidocaine subcutaneous injection
3137726|NCT03895307|Placebo Comparator|local serum physiologic|18-20 cc % 0.09 NaCl subcutaneous injection
3137727|NCT03926208|Active Comparator|Control|Subjects in this group will receive the standard chlorhexadine prep of the foot (standard of care) prior to surgery, and a cotton swab will be collected from the hallux nail fold.
3137728|NCT03926208|Experimental|Soak and Scrub|In addition to the standard chlorhexadine prep of the foot prior to surgery, subjects in this group will also receive a betadine soak and scrub of the foot, and a cotton swab will be collected from the hallux nail fold.
3137729|NCT03926065|Experimental|Standard Palatability and Standard Portion Size|Vegetables with Standard Palatability and Standard Portion Size
3137730|NCT03926065|Experimental|Standard Palatability and Larger Portion Size|Vegetables with Standard Palatability and Larger Portion Size
3137731|NCT03926065|Experimental|Enhanced Palatability and Standard Portion Size|Vegetables with Enhanced Palatability and Standard Portion Size
3137732|NCT03926065|Experimental|Enhanced Palatability and Larger Portion Size|Vegetables with Enhanced Palatability and Larger Portion Size
3137733|NCT03922750|Experimental|Insulin 287 (with 100% loading dose)|Participants will receive insulin 287 injections once weekly (OW). A unit to unit switch approach with an additional 100% loading dose of insulin 287 will be used.
3137734|NCT03922750|Experimental|Insulin 287 (without loading dose)|Participants will receive insulin 287 injections OW. A unit to unit switch approach without loading dose of insulin 287 will be used.
3137735|NCT03922750|Active Comparator|Insulin glargine U100|Participants will receive insulin glargine U100 once daily (OD).
3137736|NCT03909100|Experimental|CoolSculpting® System|Participants received up to two CoolSculpting® treatment sessions for the abdomen, flanks or both 8 weeks apart. A treatment session was comprised of timed segments of cooling (treatment cycles) followed by 2 minutes of manual massage. Up to 12 cycles per treatment session were performed at the investigator's discretion.
3137737|NCT03905642|Experimental|560 mg Arikayce™|Subjects in this cohort will receive 560 mg of Arikayce™
3149793|NCT00186745|Experimental|1|All patients in this cohort receive treatment with weight-adjusted, standard-dose tinzaparin for treatment of venous thromboembolism. Trough anti-Xa level measurements done on any 2 of days 3, 5 or 7 of treatment. Patients with a trough anti-Xa level > 0.5 IU/mL receive dose adjustment of the tinzaparin.
3149794|NCT00186758|Sham Comparator|1, Phase l, True or Sham|this treatment will be True or Sham (placebo) on one side of the head, phase I
3149795|NCT00186758|Active Comparator|2, phase ll, Sham or True|This treatment will be Sham(placebo)or True on the other side of the head phase II.
3149796|NCT00186771|Active Comparator|True Transcranial Magnetic Stimulation|True treatment with TMS over the temporoparietal cortex.
3149797|NCT00186771|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham treatment with rTMS over the temporoparietal cortex.
3149798|NCT00186810|Other|1|
3149799|NCT00186823|Other|1|
3137738|NCT03892889|Experimental|Abilify MyCite®|Participants received Abilify MyCite® a combination product of aripiprazole tablet embedded with sensor and wearable patch for 3 months (Months 1 to 3) and continued for an additional 3 months (Months 4 to 6) as per investigators assessment or switch to a standard-of-care treatment of oral atypical antipsychotics or a long acting injectable.
3137739|NCT03921723|Experimental|Subject receiving Dolutegravir 10 mg|Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of >= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
3137740|NCT03921190|Active Comparator|Open-mouth|Patients receiving maxillary buccal infiltration anesthesia (MBIA) with their mouth wide open
3137741|NCT03921190|Experimental|Closed-mouth|Patients receiving MBIA using a closed-mouth technique
3137742|NCT03920865|Experimental|Part 1|Participants with mild hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
3137743|NCT03920865|Experimental|Part 2|Participants with moderate hepatic impairment and demographically matched healthy participants with normal hepatic function will be enrolled. Participants will receive a single oral dose of 5 mg risdiplam.
3137744|NCT03918239|Experimental|SHP643 Prefilled Syringe (PFS)|Participants will receive 300 milligram (mg) of SHP643 PFS Subcutaneous (SC) injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
3149800|NCT00186849|Other|1|
3149801|NCT00186862|Other|1|
3149802|NCT00186914|Other|1|
3137745|NCT03918239|Experimental|SHP643 Autoinjector (AI)|Participants will receive 300 mg of SHP643 AI SC injection into the abdomen on Day 1 during the in-house period (Day 1 to Day 5).
3182079|NCT00699270||Biomet Humeral Stems|Biomet Humeral Stems: Comprehensive®, BioModular®, and Bi-Angular® Shoulder Systems
3137746|NCT03917823|Experimental|Cryoneurolysis (active)|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation (active or sham) separated by 1-minute defrost periods.
3137747|NCT03917823|Sham Comparator|Sham|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
3137748|NCT03911752||People with Acquired Brain Injury|People with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=8).
3137749|NCT03911752||Partners of people with Acquired Brain Injury|Partners of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
3137750|NCT03911752||Relatives of people with Acquired Brain Injury|Relatives of people with Acquired Brain Injury in a subacute stage who go to occupational therapy (N=2).
3137751|NCT03902613|Experimental|Lurasidone|Open-label treatment with lurasidone within the dose range of 20-60 mg daily
3137752|NCT03902574|Experimental|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
3137753|NCT03902574|Experimental|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
3137754|NCT03902574|Experimental|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
3137755|NCT03914950|Other|PET/CT results with TOF/without TOF|"Diagnostic CT of the abdomen or upper abdomen (in case of already performed diagnostic CT of the abdomen < 2 weeks ago) with 2 phases, 1 - 4 mSv, ca. 20 sec., 1 x~Contrast medium (Iodixanol 550 mg/ml) 1 x 1.4 ml/kg body weight i.v. for 40 sec, 1 x if creatinine, GFR, and TSH levels are within the normal range~1 x 500 ml water oral, 1 x~Biopsy or FNA (fine-needle aspiration) or operation of the pancreas"
3137756|NCT03911843|Experimental|CASES|Of eligible subjects, 26/64 started an intervention program with Ω-3 (CASES). The intervention consisted in supplementation with highly purified Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months
3137757|NCT03911843|Active Comparator|CONTROLS|Others 38/64 subjects joined to the study as data contributors, and were entered as controls (CONTR).
3137758|NCT03896633|Active Comparator|Azopt 1% ophthalmic suspension|Ophthalmic suspension
3137759|NCT03896633|Experimental|Brinzolamide 1% ophthalmic suspension|ophthalmic suspension
3137760|NCT03894813|Experimental|Probiotics and Metronidazole|Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
3137761|NCT03894813|Active Comparator|Metronidazole vaginal|Metronidazole vaginal suppositories(1 suppositories,qd,7 days )
3137762|NCT03911960|Experimental|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of Acceptance and Commitment Therapy for tobacco cessation plus up to 8 weeks of nicotine patch.
3137763|NCT03911960|Active Comparator|Enhanced Usual Care|2 in-person sessions of tobacco cessation counseling, electronic referral to state quitline, up to 8 weeks of nicotine patch
3137764|NCT03907072|Experimental|WVE-210201 (3 mg/kg)|Weekly IV administrations of WVE-210210 at 3 mg/kg
3137765|NCT03907072|Experimental|WVE-210201 (4.5 mg/kg)|Weekly IV administrations of WVE-210210 at 4.5 mg/kg
3137766|NCT03907072|Placebo Comparator|Placebo|Weekly IV administrations of phosphate buffered saline solution visually identical in appearance to WVE-21021
3137767|NCT03906448|Experimental|Astrocytoma Patients|Patients newly diagnosed with Grade II and III astrocytoma.
3137768|NCT03906448|No Intervention|Control Arm|Data collection from medical record only
3137769|NCT03911401|Experimental|0.3% OPA-15406|Twice daily
3137770|NCT03911401|Experimental|1% OPA-15406|Twice daily
3137771|NCT03911401|Placebo Comparator|Placebo|Twice daily
3137772|NCT03909763|Experimental|Berberine plus danazol|Berberine plus danazol group
3137773|NCT03909009|Active Comparator|Active rTMS|Group 1 will receive high frequency repetitive transcranial magnetic stimulation (10hz-HF-rTMS) A total 14 sessions of HF-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
3182080|NCT00699296|Experimental|1|
3137774|NCT03909009|Sham Comparator|Sham rTMS|Group 2 will receive sham stimulation. A total 14 sessions of sham-rTMS, 10 sessions daily (5 days/week, 2 weeks) and 4 sessions weekly (1 day/week, 4 weeks).
3137775|NCT03906968|Experimental|SinuSonic Device|SinuSonic Device used twice a day for four to six weeks.
3137776|NCT03904420|Experimental|Group A - New Model|Standardized programming and testing method
3137777|NCT03904420|Active Comparator|Group B - Traditional Model|Traditional clinical model which is not standardized across clinical sites
3137778|NCT03903822|Experimental|PF-06700841 0.1% cream QD|PF-06700841 0.1% cream applied once daily (QD)
3137779|NCT03903822|Experimental|PF-06700841 0.3% cream QD|PF-06700841 0.3% cream applied once daily (QD)
3137780|NCT03903822|Experimental|PF-06700841 1% cream QD|PF-06700841 1% cream applied once daily (QD)
3137781|NCT03903822|Experimental|PF-06700841 3% cream QD|PF-06700841 3% cream applied once daily (QD)
3137782|NCT03903822|Experimental|PF-06700841 0.3% cream BID|PF-06700841 0.3% cream applied twice daily (BID)
3137783|NCT03903822|Experimental|PF-06700841 1% cream BID|PF-06700841 1% cream applied twice daily (BID)
3137784|NCT03903822|Placebo Comparator|Vehicle cream QD|Vehicle cream applied once daily (QD)
3137785|NCT03903822|Placebo Comparator|Vehicle cream BID|Vehicle cream applied twice daily (BID)
3137786|NCT03905096|Experimental|Part 1|
3137787|NCT03905096|Experimental|Part 2|
3137788|NCT03899064|Experimental|Induction:MC2-01 Cream, irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
3137789|NCT03899064|Experimental|Induction: MC2-01 Cream, no irradiation|Applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
3137790|NCT03899064|Experimental|Induction: MC2-01 vehicle, irradiation|Applications with MC2-01 vehicle, followed by irradiation
3137791|NCT03899064|Experimental|Induction: MC2-01 vehicle, no irradiation|Applications with MC2-01 vehicle, no irradiation
3137792|NCT03899064|Experimental|Challenge: MC2-01 Cream, irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), followed by irradiation
3137793|NCT03899064|Experimental|Challenge: MC2-01 Cream, No irradiation|Application with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%), no irradiation
3137794|NCT03899064|Experimental|Challenge: MC2-01 vehicle, irradiation|Application with MC2-01 vehicle, followed by irradiation
3137795|NCT03899064|Experimental|Challenge: MC2-01 vehicle, no irradiation|Application with MC2-01 vehicle, no irradiation
3137796|NCT03899064|Experimental|Challenge: Control, irradiation|No application, but irradiation
3137797|NCT03894969|Experimental|Sh_NTHi-Mcat_1 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61, and following a 1-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 91, and Day 151.
3137798|NCT03894969|Experimental|Sh_NTHi-Mcat_3 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 3-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 151 and Day 211.
3137799|NCT03894969|Experimental|Sh_NTHi-Mcat_6 Group|Subjects enrolled in this group received 2 doses of GSK Biologicals' Shingrix vaccine at Day 1 and Day 61 and, following a 6-month gap, subjects received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart at Day 241 and Day 301.
3137800|NCT03894969|Active Comparator|NTHi-Mcat Group|Subjects enrolled in this group received 2 doses of GSK Biological's NTHi-Mcat investigational vaccine 2 months apart, at Day 1 and Day 61.
3137801|NCT03894969|Experimental|Shingrix-Only Group|Subjects belonging to this group were originally randomized to either Sh_NTHi-Mcat_1 Group, Sh_NTHi-Mcat_3 Group or Sh_NTHi-Mcat_6 Group, they received at least 1, maximum 2 doses of GSK Biologicals Shingrix vaccine at Day 1 and Day 61, but didnt receive any dose of NTHI Mcat investigational vaccine. Only safety data were collected for these subjects.
3137802|NCT03903159|Other|Treatment Group|Positive Peer Journaling (PPJ)
3137803|NCT03902392|Active Comparator|NATUR-OX Group (A)|Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
3137804|NCT03902392|Placebo Comparator|Placebo Group (B)|Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
3137805|NCT03901105|Experimental|Flortaucipir PET Scan|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) will be read by independent, blinded readers.
3137806|NCT03895853|Active Comparator|Group I (standard of care)|Patients receive standard of care for septic shock.
3137807|NCT03895853|Experimental|Group II (early metabolic resuscitation)|Patients receive standard of care treatment for septic shock and early metabolic resuscitation (IV) over continuous infusion for up to 7 days.
3137808|NCT03901313|Experimental|Sequence ABC|Healthy volunteers will receive Treatments A, then B, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137809|NCT03901313|Experimental|Sequence ACB|Healthy volunteers will receive Treatments A, then C, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137810|NCT03901313|Experimental|Sequence BAC|Healthy volunteers will receive Treatments B, then A, and then C, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137811|NCT03901313|Experimental|Sequence BCA|Healthy volunteers will receive Treatments B, then C, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137812|NCT03901313|Experimental|Sequence CAB|Healthy volunteers will receive Treatments C, then A, and then B, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137813|NCT03901313|Experimental|Sequence CBA|Healthy volunteers will receive Treatments C, then B, and then A, with a 6-day washout between treatments, during a stay at the clinic of 20 days
3137814|NCT03901092|Experimental|Flortaucipir PET Scan|Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
3137815|NCT03895034|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
3137816|NCT03900728|Active Comparator|Auriculotherapy with needles (acupuncture) + usual care|A designated trained therapist will perform auriculotherapy with 1mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place until removal at the 1-week follow-up visit
3137817|NCT03900728|Active Comparator|Auriculotherapy with gold beads (acupressure) + usual care|A designated trained therapist will perform auriculotherapy with beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place until removal at the 1-week follow-up visit.
3137818|NCT03900728|Sham Comparator|Placebo group + usual care|A designated trained therapist will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place until removal at the 1-week follow-up visit.
3137819|NCT03900299|Other|oncoplastic breast surgery|
3137820|NCT03898349|No Intervention|Non-Texters|"Patients did not receive the automated text messaging system Annie"
3137821|NCT03898349|Active Comparator|Texters|Patients received the Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
3137822|NCT03897634|Experimental|Experiences Hearing Aid user|Single arm study, all participants in this arm. Participants will be experienced hearing aid users.
3137823|NCT03895372|Experimental|PF-06826647 Drug Dose Level 1|Delivered orally for 16 weeks during the Investigational Treatment Period
3137824|NCT03895372|Experimental|PF-06826647 Placebo|Delivered orally for 16 weeks during the Investigational Treatment Period
3137825|NCT03895372|Experimental|PF-06826647 Drug Dose Level 2|Delivered orally for 16 weeks during the Investigational Treatment Period
3182081|NCT00699309||Taperloc® Microplasty™ Hip System|
3137826|NCT03895372|Experimental|PF-06826647 Drug Dose Level 3|Delivered orally for 16 weeks during the Investigational Treatment Period then 24 weeks in Extension Period.
3182082|NCT00699322|Experimental|1|Sitagliptin
3182083|NCT00699322|Active Comparator|2|Glimepiride
3182084|NCT00699361|Experimental|1|Measurement before Pantoprazole application
3182085|NCT00699361|Experimental|2|Measurements after Pantoprazole application
3137827|NCT03895372|Experimental|PF-06826647 Drug Dose Level 4|Delivered orally for 16 weeks then for 24 weeks in Extension Period.
3137828|NCT03896022|Active Comparator|Auriculotherapy - Acupressure with Gold Beads|A designated trained auriculotherapy provider will place gold beads at five acupoints on each ear (10 points total). The beads are affixed with a small round adhesive disk. The beads will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
3137829|NCT03896022|Active Comparator|Auriculotherapy - Acupuncture with Pyonex Needles|A designated trained auriculotherapy provider will place 1.2mm (Pyonex) needles at five acupoints on each ear (10 points total). The needles are affixed with a small round adhesive disk. The needles will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
3182086|NCT00699387|Experimental|Benznidazole|Treatment of pediatric Chagas disease with benznidazole
3137830|NCT03896022|Sham Comparator|Placebo Group|A designated trained auriculotherapy provider will place adhesive disks at five acupoints on each ear (10 points total). The disks resemble those used with the active treatments. The disks will stay in place during the aspiration abortion and will be removed before the participant is discharged home.
3137831|NCT03891862|Experimental|Open-label Valbenazine|Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
3137832|NCT03891862|Placebo Comparator|Placebo-controlled Placebo|Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
3137833|NCT03891862|Experimental|Placebo-controlled Valbenazine|Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
3137834|NCT03894449|Placebo Comparator|Placebo only|
3137835|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt FeSO4|
3137836|NCT03894449|Experimental|Prebiotic GOS & Iron Salt FeSO4|
3137837|NCT03894449|Experimental|Prebiotic Inulin & Iron Salt NaFeEDTA|
3137838|NCT03894449|Experimental|Prebiotic GOS & Iron Salt NaFeEDTA|
3137839|NCT03892564|Experimental|MC2-01 Cream, irradiation|One applications with MC2-01 Cream (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream, followed by irradiation
3137840|NCT03892564|Experimental|MC2-01 Cream, no irradiation|One application of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
3137841|NCT03892564|Experimental|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
3137842|NCT03892564|Experimental|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
3137843|NCT03892564|Experimental|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
3137844|NCT03892707||NSAIDs group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors)
3137845|NCT03892707||NSAIDs+Milgamma+Milgamma compositum group|Patients with acute non-specific low back pain prescribed with modern NSAIDs (preferential/selective COX-2 inhibitors) + Milgamma® / Milgamma® compositum
3137846|NCT03892460|Experimental|Treatment|Neuromuscular electrical stimulation
3137847|NCT03892460|No Intervention|Control|No treatment control
3137848|NCT03891641|Experimental|Treadling Group|Treadling subjects will do so 3x per week (15 min sessions) for 6 weeks.
3137849|NCT03891641|No Intervention|Control Group|Control Subjects continue their normal daily activities.
3137850|NCT03890367|Experimental|Group 1: MenACYW Conjugate Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of MenACYW Conjugate vaccine on Day 0.
3137851|NCT03890367|Active Comparator|Group 2: Nimenrix® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of Nimenrix® vaccine on Day 0.
3137852|NCT03890367|Active Comparator|Group 3: NeisVac-C® Vaccine|Healthy, toddlers aged 12 to 23 months received a single dose of NeisVac-C® vaccine on Day 0.
3182087|NCT00699426|Active Comparator|Nexium + Yoghurt|
3182088|NCT00699426|Placebo Comparator|Nexium + Placebo|
3182089|NCT00699426|Placebo Comparator|Placebo+ Yoghurt|
3182090|NCT00699426|Placebo Comparator|placebo+placebo|
3137853|NCT03889704|Experimental|Neuromuscular electrical stimulation|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. It will be applied for 20 minutes per session. For each patient, there will be 2 sessions per week, spaced 3 to 4 days apart. Each patient will participate in 16 sessions over the 8 weeks of the study. There will be 6 patients total.
3137854|NCT03889444||OZURDEX®|Participants with diabetic macular edema prescribed dexamethasone intravitreal implant, 0.7 mg (OZURDEX®) as per routine clinical practice.
3137855|NCT03888755|Experimental|Icatibant|Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.
3137856|NCT03888391|Experimental|Active TNS|Participants will receive trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for up to 12 months of this open-extension trial.
3182091|NCT00699439|Active Comparator|A|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the paper-based flow-chart will be printed out to place on the chart.
3137857|NCT03888482|Other|DDT2, then Clariti|Verofilcon A contact lenses worn first, with somofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
3137858|NCT03888482|Other|Clariti, then DDT2|Somofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
3137859|NCT03888274|Experimental|Active|
3137860|NCT03888365||Cohort A: Treprostinil|Participants who are currently prescribed and using inhaled treprostinil for the treatment of PAH.
3137861|NCT03888365||Cohort B: Non-Treprostinil PAH Medications|Participants who are taking other PAH medications (instead of inhaled treprostinil).
3137862|NCT03888469|Other|DDT2, then 1DAVM|Verofilcon A contact lenses worn first, with etafilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
3137863|NCT03888469|Other|1DAVM, then DDT2|Etafilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each product was worn bilaterally (in both eyes) for 8 -1/+2 days in a daily disposable modality.
3137864|NCT03887442|Active Comparator|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
3137865|NCT03887442|Experimental|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
3137866|NCT03887286|Experimental|treatment group|All participants to receive standard transthoracic echocardiogram and hand held echocardiogram
3137867|NCT03881007|Experimental|LCM, then placebo|Mouthwash with LCM for 3 months followed by mouthwash with placebo for 3 months.
3137868|NCT03881007|Experimental|Placebo, then LCM|Mouthwash with placebo for 3 months followed by mouthwash with LCM for 3 months
3137869|NCT03878602|Active Comparator|Control Group|Newborns will be subjected to umbilical cord immediate clamping
3137870|NCT03878602|Experimental|Study Group|Newborns will be subjected to umbilical cord delayed clamping
3149803|NCT00186927|Experimental|Participants|"Participants will be studied in three cohorts:~Healthy seropositive children 3 years up to 6 years~Healthy seropositive toddlers 12 months up to 24 months~Healthy seronegative toddlers 12 months up to 24 months.~Each cohort will receive Sendai virus vaccine."
3149804|NCT00186940||1|
3149805|NCT00186953|Other|1|
3137871|NCT03875118|Experimental|The intervention group|Subjects in the intervention group received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
3137872|NCT03875118|Active Comparator|The control group|Subjects in the control group also received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
3149806|NCT00186966|Other|FLAG|
3149807|NCT00186966|Other|FLAG and LP Dox|
3149808|NCT00186979|Other|1|
3182092|NCT00699439|No Intervention|B|If a patient is identified as having an asthma exacerbation by the Bayesian Network, and assigned to the control group, no flow-chart will be printed out.
3182093|NCT00699452|Active Comparator|1|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
3182094|NCT00699452|Placebo Comparator|2|Placebo
3137873|NCT03873987|Active Comparator|Current Formulation of Oritavancin|Three single-use vials, each containing 400 mg (1200 mg total) of oritavancin diphosphate (as the free base) and the inactive component mannitol. Oritavancin vials will be reconstituted with SWFI and further diluted in D5W for a total volume of 1000 mL and infused intravenously over 3 hours.
3182095|NCT00699465|Active Comparator|1|Early enoxaparin
3137874|NCT03873987|Experimental|Kimyrsa|A single vial containing 1200 mg of oritavancin, HPβCD, and mannitol. Kimyrsa vials will be reconstituted with SWFI and further diluted with 0.9% sodium chloride for a total volume of 250 mL and infused intravenously over 1 hour.
3137875|NCT03870893|Experimental|Intervention group|Intervention is administered to patients in this Arm.
3137876|NCT03870893|No Intervention|control group|No intervention
3137877|NCT03887299|Placebo Comparator|Standard Wound Care|Wound dressing and care as per our current practice. Compression dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively. Dressing will be removed after 24 hours from surgery completion and subjects will have an absorption pad with overlying garments for the remaining postoperative days until standard postoperative visit for wound check.
3137878|NCT03887299|Active Comparator|CHG Wound Care|ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's instructions intraoperatively. The dressing will be in place until the postoperative clinic visit on postoperative day 7.
3137879|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 33G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2
3137880|NCT03878758|Experimental|BD Nano™ PRO pen needle vs 34G Artsana Insupen Extr3me|Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2
3137881|NCT03878758|Experimental|BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™|Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2
3137882|NCT03849300|No Intervention|Control Group|No exercise intervention
3149809|NCT00186992|Other|Treatment|Eligible patients will be accessioned at the time of irradiation and undergo a pre-radiotherapy evaluation, treatment planning, image-guided radiotherapy delivery and intra-and post-irradiation evaluations.
3149810|NCT00187005|Other|1|
3149811|NCT00187031|Other|1|
3149812|NCT00187044|Other|1|
3149813|NCT00187057|Other|1|Acute Lymphoblastic Leukemia (ALL) Low Risk
3137883|NCT03849300|Experimental|Aquatic walking exercise group 1|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
3137884|NCT03849300|Experimental|Aquatic walking exercise group 2|"The aquatic walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of hip flexion-extension, hip abduction-adduction, and knee flexion-extension. The last 30 minutes included water walking (forward, backward).~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
3149814|NCT00187057|Other|2|Acute Lymphoblastic Leukemia (ALL) - High Risk
3149815|NCT00187057|Other|3A|B-Cell Non-Hodgkins Lymphoma (Group A)
3149816|NCT00187057|Other|3B|B-Cell Non-Hodgkins Lymphoma (Group B)
3149817|NCT00187057|Other|4|Hodgkins Disease
3149818|NCT00187070|Other|1|
3149819|NCT00187083|Experimental|1|Native asparaginase
3149820|NCT00187083|Experimental|2|PEG-asparaginase
3149821|NCT00187122|Other|1|See Detailed Description section for description of treatment plan.
3149822|NCT00187148|Other|1|
3149823|NCT00187161|Experimental|A|"Group A: Resected Stage I and resected abdominal Stage II~Subjects will receive two courses (3 weeks apart) of COPAD."
3149824|NCT00187161|Experimental|B|"Group B: Other Stage II, Stage III, Stage IV or B-ALL M blast <70%; no CNS involvement.~Subjects in Group B will receive one week of treatment of COP."
3137885|NCT03849300|Active Comparator|Land-based walking exercise group|"The land-based walking exercise program was performed for 60 minutes per day, 4 times per week for 12 weeks.~The program consisted of a warm-up (10 min) and cool-down (10 min) which included stretching and gait training. The 40-minute main exercise session included 10 minutes of low-intensity forward, backward, and lateral side-stepping movements on flat group. The remaining 30 minutes included treadmill walking exercise.~The program intensity was established using heart rate reserve (HRR). Weeks 1-4 were at 50-60% HRR, weeks 5-8 were at 60-70% HRR, and weeks 9-12 were at 70-85% HRR. Subjects wore a heart rate monitor during the whole exercise training session in order to maintain the designated training intensity."
3137886|NCT03887429|Experimental|SXC-2023 200 mg followed by placebo|SXC-2023 200mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
3182096|NCT00699465|Placebo Comparator|2|Late enoxaparin
3137887|NCT03887429|Experimental|Placebo followed by SXC-2023 200 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 200mg dosed once daily for 5 days.
3137888|NCT03887429|Experimental|SXC-2023 800 mg followed by placebo|SXC-2023 800mg dosed once daily for 5 days, followed by 9 day washout, then Placebo dosed once daily for 5 days.
3137889|NCT03887429|Experimental|Placebo followed by SXC-2023 800 mg|Placebo dosed once daily for 5 days, followed by 9 day washout, then SXC-2023 800mg dosed once daily for 5 days.
3137890|NCT03886701|Experimental|Experimental|Period 1: DOR twice-daily alone (Study days 1-4) and Period 2: DOR twice-daily with RPT and INH once-weekly (Study days 7-21)
3137891|NCT03883113|Experimental|MVA-NP+M1 & H3N2 Challenge Virus|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
3182097|NCT00699478|Experimental|1|post total gastrectomized patients due to gastric cancer who has vitamin B12 deficiency - given oral vitamin B 12 supplementation
3137892|NCT03883113|Placebo Comparator|Saline Placebo & H3N2 Challenge Virus|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)
3137893|NCT03880227|Experimental|Anodal followed by sham stimulation tDCS to rTPJ|cross-over design - active stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the rTPJ followed by behavioral testing.
3137894|NCT03880227|Active Comparator|Anodal followed by sham stimulation tDCS to dmPFC|cross-over design - active stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week washout, sham stimulation tDCS to the dmPFC followed by behavioral testing.
3137895|NCT03880227|Experimental|Sham followed by anodal stimulation tDCS to rTPJ|cross-over design - sham stimulation tDCS to the rTPJ followed by behavioral testing. After 1 week delay, active stimulation tDCS to the rTPJ followed by behavioral testing.
3137896|NCT03880227|Active Comparator|Sham followed by anodal stimulation tDCS to dmPFC|cross-over design - sham stimulation tDCS to the dmPFC followed by behavioral testing. After 1 week delay, active stimulation tDCS to the dmPFC followed by behavioral testing.
3182098|NCT00699504|Experimental|Lead in Phase|Supratherapeutic dose of cangrelor
3137897|NCT03876743|Experimental|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
3137898|NCT03876743|Experimental|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
3137899|NCT03876743|Experimental|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
3182099|NCT00699504|Experimental|A|therapeutic dose cangrelor treatment
3182100|NCT00699504|Experimental|B|supratherapeutic dose cangrelor treatment
3137900|NCT03876743|Experimental|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
3137901|NCT03885934|Experimental|V114, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL intramuscular (IM) injection for 7 to 11 months of age (Pneumococcal conjugate vaccine [PCV]-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
3137902|NCT03885934|Active Comparator|Prevnar 13®, Schedule A: Participants 7-11 months|Each participant received a 0.5 mL IM injection for 7 to 11 months of age (PCV-naïve)(3 doses). Dose 1: at randomization, Dose 2: 4 to 8 weeks after Dose 1, and Dose 3: 8 to 12 weeks after Dose 2 and ≥12 months of age.
3137903|NCT03885934|Experimental|V114, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
3137904|NCT03885934|Active Comparator|Prevnar 13®, Schedule B: Participants 12-23 months|Each participant received a 0.5 mL IM injection for 12 to 23 months of age (PCV-naïve)(2 doses). Dose 1: at randomization, and Dose 2: 8 to 12 weeks after Dose 1.
3137905|NCT03885934|Experimental|V114, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced) (1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
3137906|NCT03885934|Active Comparator|Prevnar 13®, Schedule C: Participants 2-17 years|Each participant received a 0.5 mL IM injection for 2 to 17 years of age (PCV-naïve or PCV-experienced)(1 dose). Single dose administered at randomization and at least 8 weeks after previous PCV for participants who were PCV-experienced.
3137907|NCT03885726|Active Comparator|Treatment as Usual|
3137908|NCT03885726|Experimental|High Velocity Nasal Insufflation|
3137909|NCT03885154|Active Comparator|Valproic Acid|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
3137910|NCT03885154|Active Comparator|Dihydroergotamine|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
3149825|NCT00187161|Experimental|C|"Group C: B-ALL with >70% BM blasts; CNS involvement, Group B COP failures i.e., <20% reduction Treatment Pre-Induction~Subjects will receive one week of treatment of COP."
3137911|NCT03885154|Active Comparator|Cross-Over to Dihydroergotamine|An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels. Patients who do not respond to VPA after 24 hours will be given Dihydroergotamine (DHE) for the next 24 hours. Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours.
3149826|NCT00187174|Experimental|Phase 1|
3149827|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) VVI-40|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
3137912|NCT03885154|Active Comparator|Cross-Over to Valproic Acid|Dihydroergotamine (DHE) will be given as weight-based dosing, with no single dose >1mg and not exceeding 3mg over 24 hours. Patients who do not respond to DHE after 24 hours will be given Valproic Acid (VPA) for the next 24 hours. An initial dose of Valproic Acid (VPA) will be given IV at 20mg/kg, followed by continuous infusion of 1mg/kg/hour for 24 hours. Serum levels of VPA will be checked at 4 and 24 hours, with additional timepoints possible at 8 and 12 hours based on drug levels.
3137913|NCT03883386|Experimental|Loratadine first|Take treatment daily for 7 days.
3137914|NCT03883386|Placebo Comparator|Placebo first|Take placebo daily for 7 days.
3182101|NCT00699504|Active Comparator|C|active comparator treatment
3182102|NCT00699504|Placebo Comparator|D|placebo treatment
3182103|NCT00699517|Experimental|1|
3137915|NCT03882528|Experimental|Infective controls|Controlled Human Malaria Infection (CHMI) will consist of exposure to Plasmodium falciparum sporozoites through the bites of infected mosquitoes. Beginning 5 days after the challenge, subjects will be evaluated daily for the development of malaria infection using a blood smear.
3137916|NCT03882801|Experimental|Sequence 1: Placebo -> Gefapixant|In Period 1, participants receive a single oral dose of placebo matching gefapixant (MK-7264) every night at bedtime (QHS), for 7 days. In Period 2, participants receive a single oral dose of gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
3137917|NCT03882801|Experimental|Sequence 2: Gefapixant -> Placebo|In Period 1, participants receive a single oral dose of gefapixant (MK-7264) QHS for 7 days. In Period 2, participants receive a single oral dose of placebo matching gefapixant (MK-7264) QHS, for 7 days. The two 7-day dosing periods are separated by a 7-day washout period.
3137918|NCT03882424|Experimental|TRS003|Proposed biosimilar of bevacizumab，Intravenous administration
3137919|NCT03882424|Active Comparator|China-approved Bevacizumab|Intravenous administration
3137920|NCT03882424|Active Comparator|US-licensed Avastin|Intravenous administration
3137921|NCT03882047|Experimental|Mometasone furoate nasal spray|Participants receive 200 mcg of mometasone furoate nasal spray and fluticasone propionate placebo matching nasal spray once daily.
3137922|NCT03882047|Active Comparator|Fluticasone propionate nasal spray|Participants receive 200 mcg of fluticasone propionate nasal spray and mometasone furoate placebo matching nasal spray once daily.
3137923|NCT03882047|Placebo Comparator|Placebo nasal spray|Participants receive mometasone furoate placebo matching nasal spray and fluticasone propionate placebo matching nasal spray once daily.
3137924|NCT03881163|Experimental|Single dose regime of N-acetylcysteine (NAC)|On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.
3137925|NCT03881163|Experimental|Multiple dose regime of N-acetylcysteine (NAC)|On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.
3137926|NCT03881059|Placebo Comparator|Part A: Placebo|
3137927|NCT03881059|Experimental|Part A: BMS-986165 Dose A|
3137928|NCT03881059|Experimental|Part A: BMS-986165 Dose B|
3137929|NCT03881059|Experimental|Part B: Ustekinumab + BMS-986165 Placebo|
3182104|NCT00699517|Placebo Comparator|2|
3137930|NCT03881059|Experimental|Part B: BMS-986165 Dose A + Ustekinumab Placebo|
3137931|NCT03881059|Experimental|Part B: BMS-986165 Dose B + Ustekinumab Placebo|
3137932|NCT03881670|Placebo Comparator|Lotrafilcon B|
3137933|NCT03881670|Active Comparator|Lotrafilcon B Hydraluxe|
3137934|NCT03880266|Active Comparator|Group 1 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
3137935|NCT03880266|Placebo Comparator|Group 1 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes with occlusion (non-latex glove)
3137936|NCT03880266|Active Comparator|Group 2 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
3182105|NCT00699530||Hyperprolactinemia|Patients recently diagnosed with hyperprolactinemia
3182106|NCT00699543|Experimental|C|Coroflex Please stent implantation
3137937|NCT03880266|Placebo Comparator|Group 2 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes with occlusion (non-latex glove)
3137938|NCT03880266|Active Comparator|Group 3 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 15 minutes
3137939|NCT03880266|Placebo Comparator|Group 3 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 15 minutes
3137940|NCT03880266|Active Comparator|Group 4 Active|Glycopyrronium cloth, 2.4% applied to the hands once daily for 14 days: 30 minutes
3137941|NCT03880266|Placebo Comparator|Group 4 Vehicle|Vehicle cloth applied to the hands once daily for 14 days: 30 minutes
3137942|NCT03875664|Active Comparator|Intervention|Receives 20 mL liposomal bupivacaine expanded with 10 mL of injectable sterile normal saline solution (0.9%) for a total of 30 mL injected in the posterior vaginal compartment in a standardized technique
3137943|NCT03875664|Placebo Comparator|Placebo|Receives 30 mL of injectable sterile normal 0.9% saline solution injected in the posterior vaginal compartment in a standardized technique
3137944|NCT03856320|No Intervention|Usual Care|Patient attends a MOVE! visit (weight management visit).
3137945|NCT03856320|Experimental|Intervention|Patient attends a MOVE! visit (weight management visit) and watches an educational video describing obesity treatment options available in the VA.
3137946|NCT03848871|Experimental|Enstilar foam|Subjects will receive calcipotriene hydrate/betamethasone dipropionate (Enstilar) foam and apply to affected areas once daily. A target lesion located on elbow or knee will be identified by the Investigator for daily treatment with the medicated foam from Baseline through week 4.
3137947|NCT03880474|Experimental|MVA-NP+M1|Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.)
3137948|NCT03880474|Placebo Comparator|Saline Placebo|Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%)
3137949|NCT03878160|Other|Women and Men, <2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS within the past 2 years and have elevated depression symptoms.
3137950|NCT03878160|Other|Women and Men, >2 years, Individual Interview|Individual interviews for women and men who have experienced an ACS greater than 2 years ago and have elevated depression symptoms.
3137951|NCT03878160|Other|Women and Men, Lifetime History of ACS, Individual Interview|Individual interviews for women and men who have experienced an ACS at some point in their life and do not have elevated depression symptoms.
3137952|NCT03864627|Placebo Comparator|Placebo|Participants will receive MOR106 matching placebo via s.c. injection every other week on Day 1, 15, 29 and 43 given concomitantly with a medium potency TCS once daily until Day 57.
3137953|NCT03864627|Experimental|MOR106 320 mg|Participants will receive MOR106 320 milligrams (mg) via s.c. injection every other week on Day 15, 29 and 43 given concomitantly with a medium potency topical TCS once daily until Day 57. A loading dose of MOR106 2 x 320 mg via s.c. injection will be administered on Day 1.
3182107|NCT00699543|Active Comparator|T|Taxus stent implantation
3182108|NCT00699569|Experimental|1|Patients receiving active investigational product
3137954|NCT03861000|Experimental|Whole body PET Scan with intravenous 11C-T-1650|10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.
3182109|NCT00699569|Placebo Comparator|2|Patients receiving Placebo
3182110|NCT00699595||Term pregnant women|Healthy women scheduled for elective Cesarean section.
3182111|NCT00699621|Active Comparator|1|Platelet transfusion
3182112|NCT00699621|No Intervention|2|No platelet transfusion
3182113|NCT00699686|Active Comparator|Glargine|During this arm/phase patients take subcutaneous glargine daily for 3 months.
3182114|NCT00699686|Experimental|Detemir|During this arm/phase, patients take insulin Detemir subcutaneously for 3 months.
3182115|NCT00699712|Experimental|A|Open-label regimen of doses 1 and 2 of CDNP
3137955|NCT03861000|Experimental|Brain PET scan with 11C-T-1650 and blocking with BPN14770|Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.
3137956|NCT03848403|Experimental|Ixekizumab (Reference)|Reference formulation 80 milligram (mg) ixekizumab administered as a subcutaneous (SC) injection in a prefilled syringe in one of three study periods.
3137957|NCT03848403|Experimental|Ixekizumab (Test 1)|Test 1 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
3137958|NCT03848403|Experimental|Ixekizumab (Test 2)|Test 2 formulation 80 mg ixekizumab administered as an SC injection in a prefilled syringe in one of three study periods.
3137959|NCT03847233|Experimental|Jetstream Atherectomy System|
3137960|NCT03879603|Experimental|Group 1: 6 mcg WEVEE vaccine|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
3137961|NCT03879603|Experimental|Group 2: 6 mcg WEVEE vaccine + alum|6 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
3137962|NCT03879603|Experimental|Group 3: 30 mcg WEVEE vaccine|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
3137963|NCT03879603|Experimental|Group 4: 30 mcg WEVEE vaccine + alum|30 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
3137964|NCT03879603|Experimental|Group 5: 60 mcg WEVEE vaccine|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) administered IM on Day 0 and Week 8
3137965|NCT03879603|Experimental|Group 6: 60 mcg WEVEE vaccine + alum|60 mcg of WEVEE vaccine (VRC-WEVVLP073-00-VP) and 500 mcg of Alum (VRC-GENMIX083-AL-VP) administered IM on Day 0 and Week 8
3137966|NCT03879772|Experimental|MFNS 25 mcg QD|Mometasone furoate nasal spray 12.5 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
3137967|NCT03879772|Experimental|MFNS 100 mcg QD|Mometasone furoate nasal spray 50 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
3182116|NCT00699712|Experimental|B|Open-label regimen of doses 2 and 3 of CDNP
3182117|NCT00699712|Experimental|C|Open-label regimen of doses 3 and 4 of CDNP
3182118|NCT00699725||1|NSAID patients with risk factors treated with gastroprotective drugs
3137968|NCT03879772|Experimental|MFNS 200 mcg QD|Mometasone furoate nasal spray 100 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening), daily for 4 weeks. A matching placebo nasal spray was administered intranasally (1 spray per nostril) in the evening. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
3182119|NCT00699738|Experimental|1|Healthy women during pregnancy and in the postpartum period, breastfeeding
3182120|NCT00699738|Active Comparator|2|Healthy women during pregnancy and in the postpartum period,bottlefeeding
3137969|NCT03879772|Active Comparator|BDP 84 mcg BID|Beclomethasone dipropionate nasal spray 42 mcg/spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
3137970|NCT03879772|Placebo Comparator|Placebo|Matching placebo nasal spray was administered intranasally, one spray per nostril in the morning (upon awakening) and in the evening, daily for 4 weeks. Chlorpheniramine maleate syrup 2 mg/5 mL was to be used for relief of intolerable SAR symptoms.
3137971|NCT03878277|Experimental|Cold Brew Coffee|6 days of drinking 1 bottle of Starbucks® Cold brew 325ml [205 mg caffeine] every morning between 6am-9am.
3137972|NCT03878745|Experimental|BD Nano™ PRO 32G pen needle|Participants are to perform 6 pairs of injections.
3137973|NCT03878745|Active Comparator|Terumo Nanopass® 34G pen needle|Participants are to perform 6 pairs of injections.
3137974|NCT03848221|Experimental|Systane Complete|Subjects in this group will use Systane Complete before, during, and after contact lens use.
3137975|NCT03848221|Active Comparator|Sensitive Eyes Rewetting Drops|Subjects in this group will use Sensitive Eyes Rewetting Drops before, during, and after contact lens use.
3137976|NCT03848221|No Intervention|No Treatment|Subjects in this group will not be allowed to use artificial tears or rewetting drops during the study.
3137977|NCT03878108|Active Comparator|LCHF diet then LFHC diet|Low carbohydrate, high fat (LCHF) diet then low fat, high carbohydrate diet (LFHC) diet
3137978|NCT03878108|Active Comparator|LFHC diet then LCHF diet|Low fat, high carbohydrate diet (LFHC) diet then low carbohydrate, high fat (LCHF) diet
3137979|NCT03877432|Experimental|Dermatome stimulation|Check the effect of improving the function of bladder storage and bladder capacity before and after dermatome stimulation.
3137980|NCT03877237|Experimental|Dapagliflozin|Green, diamond shaped, film coated tablets 10 mg administered orally, once daily
3137981|NCT03877237|Placebo Comparator|Placebo|Green, diamond shaped, film coated tablets placebo administered orally, once daily
3137982|NCT03866434|Experimental|SPD422 + Omeprazole|Participants will receive 1 milligram (mg) of SPD422 (Anagrelide hydrochloride) (2*0.5 mg) capsule orally on Day 1 in fasted state (10 hours prior to and until 4 hours following administration of anagrelide), followed by 40 mg of Omeprazole capsule orally once daily (prior to breakfast) on Days 2 to Day 7, followed by 1 mg of Anagrelide in fasted state in combination with Omeprazole 40 mg on Day 8.
3137983|NCT03863210|Experimental|Participants who received informations about lifestyle change|
2380741|NCT03704441|Other|bupivacaine 7mg|bupivacaine 7mg
3137984|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.2 mg/kg|Participants will receive single subcutaneous (SC) injection of 0.2 mg/kg SHP681 in the abdomen.
3137985|NCT03859323|Experimental|Single Ascending Dose (SAD): 0.5 mg/kg|Participants will receive single SC injection of 0.5 mg/kg SHP681 in the abdomen.
3137986|NCT03859323|Experimental|Single Ascending Dose (SAD): 1 mg/kg|Participants will receive single SC injection of 1 mg/kg SHP681 in the abdomen.
3137987|NCT03859323|Experimental|Single Ascending Dose (SAD): 2 mg/kg|Participants will receive single SC injection of 2 mg/kg SHP681 in the abdomen.
3137988|NCT03859323|Experimental|Single Ascending Dose (SAD): 4 mg/kg|Participants will receive single SC injection of 4 mg/kg SHP681 in the abdomen.
3137989|NCT03859323|Placebo Comparator|Single Ascending Dose (SAD): Placebo|Participants will receive single SC injection of placebo matched to SHP681 in the abdomen.
2380742|NCT03704441|Other|bupivacaine 8mg|bupivacaine 8mg
3137990|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.2 mg/kg|Participants will receive SC injection of 0.2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
3137991|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 0.5 mg/kg|Participants will receive SC injection of 0.5 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
3182121|NCT00699738|No Intervention|3|Healthy non-pregnant women
3137992|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 1 mg/kg|Participants will receive SC injection of 1 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
3137993|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 2 mg/kg|Participants will receive SC injection of 2 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
3137994|NCT03859323|Experimental|Multiple Ascending Dose (MAD): 4 mg/kg|Participants will receive SC injection of 4 mg/kg SHP681 once weekly for 5 weeks in the abdomen.
3182122|NCT00699764|Experimental|Group A|
3137995|NCT03859323|Placebo Comparator|Multiple Ascending Dose (MAD): Placebo|Participants will receive SC injection of placebo matched to SHP681 once weekly for 5 weeks in the abdomen.
3137996|NCT03867838|Experimental|Stroke survivors|Stroke survivors with upper extremity motor impairments
3137997|NCT03855059|Placebo Comparator|Placebos|Depending on the randomization, this group will receive a saline solution either in the IV catheter or the saline solution will be given perineural with the Mepivicaine nerve block solution.
3137998|NCT03855059|Active Comparator|Dexamethasone Sodium Phosphate|Depending on the randomization, this group will receive dexamethasone 0.1 - 0.15 mg/kg, either in the IV catheter or the dexamethasone, 0.1 - 0.15 mg/kg will be given perineural with the Mepivicaine nerve block solution.
3137999|NCT03852537|Active Comparator|Usual Care|Usual care as determined by the patient's primary team.
3138000|NCT03852537|Experimental|Biomarker-adjusted Steroid Dosing|Individualized, biomarker concordant steroid use: dosing, titration and duration according to CRP level. This is a predetermined dosing table that adjusts dose of steroid by CRP level. Specifically: if CRP < 50 mmol/L: discontinue steroid; if CRP is between 51-100 mmol/L: 0.5 mg methylprednisolone (or dose equivalent of oral prednisone); if CRP is between 101-150 mmol/L: 0.75 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level is between 151-200 mmol/L: 1 mg/kg methylprednisolone (or dose equivalent of oral prednisone); if CRP level > 200 mmol/L: 1.5 mg/kg methylprednisolone (or dose equivalent of oral prednisone).
3138001|NCT03875859|Experimental|Remetinostat|Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.
3138002|NCT03875508|Experimental|Risankizumab|Risankizumab solution (150 mg/mL) for injection; self-administered subcutaneously via a pre-filled autoinjector at Weeks 0, 4, 16, and 28
3138003|NCT03869333|Experimental|Invaplex[AR-Detox] 2.5 μg|Participants received an intramuscular injection of 2.5 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
3138004|NCT03869333|Experimental|Invaplex[AR-Detox] 10 μg|Participants received an intramuscular injection of 10 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
3138005|NCT03869333|Experimental|Invaplex[AR-Detox] 25 μg|Participants received an intramuscular injection of 25 μg Invaplex[AR-DETOX] vaccine on Days 1, 22, and 43.
3138006|NCT03869333|Placebo Comparator|Placebo|Participants received an intramuscular injection of placebo solution on Days 1, 22, and 43.
3138007|NCT03864900|Experimental|The intervention group|The medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
3138008|NCT03864900|No Intervention|The control group|Participants in the control group received regular medication education, 10-minute individual instruction for health knowledge and six follow-up telephone calls for concerning health.
3138009|NCT03863795||Observational (survey)|Participants are recruited and pre-screened via an online crowdsourcing program MTurk, and then respond to a one-time research survey over 20 minutes on SurveyGizmo, an on-line survey software platform
3138010|NCT03875482|Experimental|Risankizumab|Subcutaneous (SC), self-administered 150 mg doses of risankizumab at Weeks 0, 4, and 16
3138011|NCT03875482|Placebo Comparator|Placebo|Subcutaneous (SC), self-administered doses of placebo solution at Weeks 0, 4, and 16
3182123|NCT00699764|Placebo Comparator|Group B|
3182124|NCT00699777|Experimental|1|One risedronate 150 mg tablet administered orally after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
3138012|NCT03874377|Experimental|Mindfulness|The mindfulness intervention consists of 6 weekly sessions, blending material from the evidence-based Learning to BREATHE and Mindfulness-Based Eating Awareness Training manualized interventions. Sessions will focus on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.Participants in this arm will also receive the usual care provided by the weight management clinic.
3138013|NCT03863496|Other|Neuromuscular scoliosis|Efficacy of Surgical Treatment by Different Pedicle Screw Systems in Pediatric Neuromuscular Spinal Deformity
3182125|NCT00699777|Active Comparator|2|Two risedronate 75 mg tablets administered as a single oral dose after an overnight (10 hour) fast, followed by a 4 hour post-dose fast
3182126|NCT00699790|Experimental|A1|
3182127|NCT00699790|Placebo Comparator|A2|
3138014|NCT03874013|Experimental|MOD-4023 Treatment Arm|MOD-4023 (investigational treatment): weekly MOD-4023 SC injections for 12 months; initially over the first 6 weeks, MOD-4023 will be administered in 3 stepwise escalating doses (0.25 mg/kg/week, 0.48 mg/kg/week and 0.66 mg/kg/week), each for two weeks sequentially. For the remaining 46 weeks, patients will continue to receive MOD-4023 at a dose of 0.66 mg/kg/week.
3138015|NCT03874013|Active Comparator|Genotropin Treatment Arm|Genotropin® (reference treatment): daily Genotropin® (0.025 mg/kg/day).
3138016|NCT03873116|Experimental|BCX7353 110mg once daily|BCX7353 capsules administered orally once daily
3138017|NCT03873116|Experimental|BCX7353 150mg once daily|BCX7353 capsules administered orally once daily
3138018|NCT03873116|Placebo Comparator|Placebo|Matching placebo oral capsules administered orally once daily
3138019|NCT03872843|Active Comparator|Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Norco 5milligram-325milligram Tablet for postoperative pain after ureteroscopy with stent placement.
2380743|NCT03704441|Other|bupivacaine 9mg|bupivacaine 9mg
3138020|NCT03872843|Active Comparator|Non-Opioid Group|This group includes subjects with renal stones who are consented for a ureteroscopy. They will be randomized to Ibuprofen 400 milligram for postoperative pain after ureteroscopy with stent placement.
3138021|NCT03870997|Experimental|Diabetes Digital Intervention|
3138022|NCT03870997|Experimental|Generic Digital Intervention|
3138023|NCT03870997|No Intervention|No Influenza Vaccination Intervention|
3138024|NCT03869684|Experimental|MT-0814 High dose|
3138025|NCT03869684|Experimental|MT-0814 Low dose|MT-0814 plus placebo
3138026|NCT03869684|Placebo Comparator|Placebo|
3138027|NCT03861338|Experimental|sublocade|Sublocade buprenorphine extended-release (BXR) injection, 300 mg and 100 mg
3138028|NCT03858335|Experimental|Constraint-induced movement therapy|Children in constraint-induced movement therapy (CIMT) group will wear forearm splint on the unaffected arm 24 hours for 3 weeks, and receive 15 mCIMT sessions(30-hour dosage)
3138029|NCT03858335|No Intervention|Control|Children in control group will receive only traditional rehab therapies without wearing splint
3138030|NCT03857243|Experimental|dTDCS plus physical therapy|active dual transcranial direct current stimulation (TDCS) arm (M1-M1)
3138031|NCT03857243|Placebo Comparator|Sham dTDCS plus physical therapy|Non-effective dose dual TDCS stimulation arm, identical with intervention arm except for the stimulation intensity/duration used.
3138032|NCT03851744|Active Comparator|Sea Level|Carbohydrate metabolism measured at SL
3138033|NCT03851744|Experimental|High Altitude|Carbohydrate metabolism measured at HA
2380744|NCT03704441|Other|bupivacaine 10mg|bupivacaine 10mg
3138034|NCT03849937|Experimental|Intervention|Three nursing homes will receive the training and three control nursing homes will complete assessments, but not receive the training.
3138035|NCT03849937|Active Comparator|Waitlist Control|After the intervention group takes the training, the waitlist control group will crossover and take the training.
3182128|NCT00699829||1|Mohs' micrographic surgery (MMS)
2380745|NCT03704441|Other|bupivacaine 11mg|bupivacaine 11mg
3138036|NCT03848416|Experimental|Ixekizumab (Reference)|Reference formulation ixekizumab 80 milligram (mg) administered as a subcutaneous (SC) injection in a prefilled syringe.
3138037|NCT03848416|Experimental|Ixekizumab (Test 1)|Test 1 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
3138038|NCT03848416|Experimental|Ixekizumab (Test 2)|Test 2 formulation ixekizumab 80 mg administered as an SC injection in a prefilled syringe.
3182129|NCT00699829||2|Conventional surgery
3182130|NCT00699868|Experimental|1|Infection to CMV
3138039|NCT03847987|Experimental|Part 1|Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses.
3138040|NCT03847987|Experimental|Part 2|Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses.
3138041|NCT03854253|Experimental|Long introducer 6Fr-25cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using long introducer sheath 6Fr-25cm
3138042|NCT03854253|Active Comparator|Short introducer 6Fr-10cm|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using short introducer sheath 6Fr-10cm
3138043|NCT03870737|Experimental|Active TNS|Participants who previously underwent screening and determination of eligibility in a double-blind sham-controlled trial of TNS for ADHD, and randomized to sham, will be offered upon unblinding at the end of the 5-week controlled trial to receive 4-weeks open treatment with the active TNS condition.
3138044|NCT03860181|Active Comparator|Traditional Dermabond + subcuticular sutures - Surgeon 1|Subcuticular sutures with traditional Dermabond applied to incision.
3138045|NCT03860181|Active Comparator|Metal staples - Surgeon 2|Metal staples
3138046|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 1|Dermabond PRINEO System
3182131|NCT00699868|Other|2|"Group control CMV"
3138047|NCT03860181|Experimental|Dermabond PRINEO - Surgeon 2|Dermabond PRINEO System
3138048|NCT03856944|Experimental|ReSTOR Toric|Patients will be bilaterally implanted, with the Toric ReSTOR +2.5D model implanted in the dominant eye and the Toric ReSTOR +3.0D model implanted in the non-dominant eye. Patients will self-select for multifocal implantation.
2380746|NCT03704441|Other|bupivacaine 12mg|bupivacaine 12mg
3138049|NCT03853551|Experimental|Single|Single arm
3149828|NCT00187187|Active Comparator|Implantable Defibrillator (ICD) AAI-70|The DAVID II Clinical Study evaluates the hypothesis that, in patients needing an ICD but without overt indications for pacing, AAI pacing with maximal concomitant drug therapy (AAI-70)will not increase the rate of the combined endpoint of mortality or hospitalization for new or worsened heart failure, compared to patients with ventricular backup pacing (VVI-40).
3149829|NCT00187239|Active Comparator|AICS On|Patients in this arm have Autointrinsic conduction search programmed ON.
3149830|NCT00187239|No Intervention|AICS Off|Patients assigned to this arm do not have Autointrinsic Conduction Search programmed on.
3149831|NCT00187252|Experimental|1|CRT + AF Suppression turned ON
3149832|NCT00187252|Active Comparator|2|CRT + AF Suppression turned OFF
3138050|NCT03870555|Experimental|Sequence 1|"Period 1: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 2: TAK-954 0.1 milligram (mg), infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
3149833|NCT00187317|Experimental|PERT|Perturbation-based balance training.
3149834|NCT00187317|Placebo Comparator|CON|Flexibility and relaxation training.
3138051|NCT03870555|Experimental|Sequence 2|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2.~Period 3: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 2 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~A washout period of at least 16 days will be maintained between each Treatment Period."
3138052|NCT03870555|Experimental|Sequence 3|"Period 1: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 0.5 mg, infusion, administered intravenously over 60-minutes once on Day 2.~Period 2: TAK-954 0.1 mg, infusion, administered intravenously over 60-minutes, once on Day 1, TAK-954 1 mg, infusion, administered intravenously over 60-minutes, once on Day 2.~Period 3: TAK-954 placebo-matching infusion, administered intravenously over 60-minutes, once on Day 1 and Day 2. A washout period of at least 16 days will be maintained between each Treatment Period."
3138053|NCT03861845|Active Comparator|Standard off-the-shelf pillbox|Participants will engage in reflection on medication routines. Then they will receive a standard off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
3138054|NCT03861845|Experimental|Custom off-the-shelf|Participants will engage in reflection on medication routines. Then they will receive a custom off-the-shelf pillbox. Finally, the participants will receive education & training on how to use the pillbox.
3138055|NCT03861845|Experimental|Custom designed and manufactured|Participants will engage in reflection on medication routines. Then they will receive a custom designed and manufactured pillbox. Finally, the participants will receive education & training on how to use the pillbox.
3138056|NCT03851094|No Intervention|Standard of Care (Group A)|Standard of care is dictated by the HME normal practices for new CPAP patients.
3138057|NCT03851094|Experimental|Wellth App (Group B)|Intervention is use of the Wellth app during the initial compliance period.
3138058|NCT03869450|Experimental|Restylane Volyme|According to the treatment algorithm, treated with Restylane Volyme
3138059|NCT03869450|Experimental|Restylane Defyne|According to the treatment algorithm, treated with Restylane Defyne
3138060|NCT03869450|Experimental|Restylane Lyft Lidocaine|According to the treatment algorithm, treated with Restylane Lyft Lidocaine
3138061|NCT03868631|Active Comparator|Soy protein group|
3138062|NCT03868631|Active Comparator|Whey protein group|
3138063|NCT03865953|Active Comparator|LAT8881|1 x 30 mg capsule of LAT8881 taken by mouth, twice daily (morning and evening) during the four-week treatment period.
3138064|NCT03865953|Placebo Comparator|Placebo|1 x 30 mg capsule of placebo, taken by mouth, twice daily (morning and evening) during the four-week treatment period.
3138065|NCT03865381|Other|Virtual Diabetes Clinic|The Onduo Virtual Diabetes Clinic (VDC) is the suite of diabetes management services including remote monitoring, diet/lifestyle coaching, medication management accessed via Onduo App and partner apps. Subjects will engage with a Care Lead through the App and will have a medical consultation via telemedicine with an Onduo VDC Physician.
3138066|NCT03865446|Experimental|Cohort 1 (Dacomitinib)|severe hepatic impairment group
3138067|NCT03865446|Experimental|Cohort 2 (Dacomitinib)|normal hepatic function
3149835|NCT00187356|Experimental|Surgical Conduit|The surgical arm will be composed of the experimental arm (the use of the radial artery) versus an active comparator (the use of the saphenous vein graft).
3149836|NCT00187421|No Intervention|1|Graft patency assessment by routine clinical assessment with/without intraluminal coronary probe
3149837|NCT00187421|Experimental|2|Graft patency assessment by indocyanine green angiography and transit-time flowmetry
3138068|NCT03862027|Experimental|Esophageal Balloon catheter|All patients will have an esophageal balloon catheter inserted into their nare while upright (head of bed > 30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20 cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
3138069|NCT03868059|Experimental|LPCN 1021|LPCN 1021 at a 225 mg dose taken twice daily (total daily dose of 450 mg taken as 225 mg in the morning and 225 mg in the evening),
3138070|NCT03850444|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
3138071|NCT03850444|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
3149838|NCT00187460|Active Comparator|Early Feedback Arm|Hospital corporations randomized to receive early feedback in the form of a report card
3138072|NCT03868254||Implant|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent as a standalone procedure from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
3138073|NCT03868254||Implant + Phaco|Chart review was conducted in participants with open angle glaucoma who underwent placement of the implant XEN 45 Gel Stent in combination with phacoemulsification (Phaco) from 1 January 2014 to 1 October 2015. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until the last visit was extracted from existing medical records.
3138074|NCT03865407|Active Comparator|Allopurinol|Allopurinol will be administered to this treatment arm group for 6 months. Participants will receive the lowest FDA recommended dose for weight, and will be titrated upwards to achieve the goal uric acid level of 3-5 mg/dL throughout the trial.
3138075|NCT03865407|No Intervention|Standard of Care Control|The treatment arm will be compared to a standard of care arm.
3182132|NCT00699881|Experimental|A|administer cetuximab in combination with modified FOLFIRI
3138076|NCT03857230|Experimental|Sequence A: Primapur - Gonal-F|Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.
3138077|NCT03857230|Active Comparator|Sequence B: Gonal-F - Primapur|Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.
2381843|NCT03696953|No Intervention|Placebo|Microcrystalline Cellulose
3138078|NCT03855189|Experimental|Mometasone Furoate (MF)|Participants receive 200 mcg nasal MF in the morning upon awakening and placebo approximately 12 hours later in the evening (200 mcg total daily dose) for 29 days.
3138079|NCT03855189|Active Comparator|Beclomethasone Dipropionate (BDP)|Participants receive 168 mcg nasal BDP in the morning upon awakening and an additional 168 mcg approximately 12 hours later in the evening (336 mcg total daily dose) for 29 days.
3138080|NCT03855189|Placebo Comparator|Placebo|Participants receive nasal placebo in the morning upon awakening and again approximately 12 hours later in the evening for 29 days.
3138081|NCT03865329|Experimental|Intervention- Home Pulmonary Rehabilitation|Participants will be offered a Home-based pulmonary rehabilitation program with health coaching.
3149839|NCT00187460|Active Comparator|Delayed Feedback Arm|Hospitals randomized to receive delayed feedback in the form of a hospital report cared, 21 months after the early feedback arm.
3149840|NCT00187538|Active Comparator|1|
3149841|NCT00187538|Active Comparator|2|
3149842|NCT00187538|Active Comparator|3|
3149843|NCT00187538|Active Comparator|4|
3149844|NCT00187551|Experimental|interruption of enfuvirtide|enfuvirtide interruption
3149845|NCT00187577|Active Comparator|application to eyelid of latanoprost solution|Subject will apply latanoprost solution with applicator daily to affected eye lid(s)
3149846|NCT00187577|Active Comparator|Application of bimatoprost to eyelid|Subject will apply bimatoprost solution with applicator daily to affected eye lid(s)
3149847|NCT00187590|Experimental|Intervention|Phone call after an ER visit.
3138082|NCT03864653|Other|MoodGym|"Non-randomized single-arm intervention; eligible persons are newly enrolled methamphetamine use treatment service program (i.e., Getting Off) participants who will be invited to participate in the study during their enrollment, and can enroll in the study at any time during their first two weeks of program participation. Participants who enroll will take the preexisting, low-intensity MoodGym intervention."
3138083|NCT03862482|Active Comparator|Brånemark® 2, Swede-Vent® 2, Screw-Vent® 1 (Configuration 1)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at one site
3138084|NCT03862482|Experimental|Brånemark® 1, Swede-Vent® 2, Screw-Vent® 2 (Configuration 2)|Device placement: B (Brånemark® dental implant) placed at one site, SW (Swede-Vent® dental implant) placed at two sites, SC (Screw-Vent® dental implant) placed at two sites
3149848|NCT00187590|No Intervention|Control|No phone call after an ER visit.
3149849|NCT00187629|Experimental|1|dietary phosphorus
3149850|NCT00187629|Active Comparator|2|other
3138085|NCT03862482|Experimental|Brånemark® 2, Swede-Vent® 1, Screw-Vent® 2 (Configuration 3)|Device placement: B (Brånemark® dental implant) placed at two sites, SW (Swede-Vent® dental implant) placed at one site, SC (Screw-Vent® dental implant) placed at two sites
3149851|NCT00187668||African American|Must self identify as African American with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3182133|NCT00699894|Experimental|1|aprepitant 40 mg + normal saline IV
3138086|NCT03853213|Experimental|Cognitive Bias Modification Training|"Participants in this intervention group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is Cognitive Bias Modification Training for Attention. It is designed to reinforce attention away from ACS threat-related stimuli (e.g., death, chest pain) and toward neutral stimuli (e.g., curve, barn doors). The second task is Cognitive Bias Modification Training for Interpretation. It is designed to train participants to appraise ambiguous information that is potentially related to ACS threat as benign."
3138087|NCT03853213|Sham Comparator|Attention Control Training|Participants in this placebo control group complete two tasks, each repeated 8 times over the course of 4 weeks (twice per week). The first task is the placebo version of Cognitive Bias Modification Training for Attention. It is designed NOT to train attention toward or away from threatening or neutral information. The second task is the placebo version of Cognitive Bias Modification Training for Interpretation. It is designed NOT to train the interpretation of information as either threatening or benign.
3138088|NCT03847610|Experimental|Healthy volunteer|
3182134|NCT00699894|Active Comparator|2|placebo PO + ondansetron 4 mg IV
3138089|NCT03850093|Active Comparator|gabapentin|gabapentin 1200 mg was given to patients of gabapentin group 2 hours preoperative
3138090|NCT03850093|Active Comparator|bisoprolol|bisoprolol 2.5 mg was given to patients of bisoprolol group 2 hours preoperative
3138091|NCT03850093|Placebo Comparator|control|placebo was given to patients of control group 2 hours preoperative
3138092|NCT03848208|Experimental|Cohort 1: Cytisine 6.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138093|NCT03848208|Placebo Comparator|Cohort 1: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138094|NCT03848208|Experimental|Cohort 2: Cytisine 9.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138095|NCT03848208|Placebo Comparator|Cohort 2: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138096|NCT03848208|Experimental|Cohort 3: Cytisine 12.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138097|NCT03848208|Placebo Comparator|Cohort 3: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3182135|NCT00699920|Experimental|1|Coarsucam double-layer artesunate/amiodaquine tablets
3182136|NCT00699920|Active Comparator|2|Coartem (artemether/lumefantrine) fixed-dose combination tablets
3182137|NCT00699933||1|Evaluation of one study cohort
3138098|NCT03848208|Experimental|Cohort 4: Cytisine 15.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138099|NCT03848208|Placebo Comparator|Cohort 4: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138100|NCT03848208|Experimental|Cohort 5: Cytisine 18.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138101|NCT03848208|Placebo Comparator|Cohort 5: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138102|NCT03848208|Experimental|Cohort 6: Cytisine 21.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138103|NCT03848208|Placebo Comparator|Cohort 6: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138104|NCT03848208|Experimental|Cohort 7: Cytisine 24.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3182138|NCT00699946|Active Comparator|1|
3182139|NCT00699946|Placebo Comparator|2|
3138105|NCT03848208|Placebo Comparator|Cohort 7: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138106|NCT03848208|Experimental|Cohort 8: Cytisine 27.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138107|NCT03848208|Placebo Comparator|Cohort 8: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138108|NCT03848208|Experimental|Cohort 9: Cytisine 30.0 mg|Cytisine will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3138109|NCT03848208|Placebo Comparator|Cohort 9: Placebo|Placebo will be administered in the morning, orally, with 240 mL of water, after fasting overnight for at least 10 hours.
3182140|NCT00699959||1|patients with heart failure
3138110|NCT03847389|Other|clobetasol propionate topical oil|clobetasol propionate 0.05% topical oil applied as thin film twice daily for 2 weeks
3149852|NCT00187668||Cuacasian|Must self identify as Caucasian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3149853|NCT00187668||Hispanic|Must self identify as Hispanic with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3138111|NCT03862040|Experimental|Cefiderocol|All participants were receiving standard of care (SOC) antibiotic treatment for pneumonia. Forty hours after the start of SOC treatment, participants will be administered 2 g doses of cefiderocol (or renally adjusted doses) infused intravenously over 3 hours, every 8 hours (or every 6 hours for participants with augmented renal function), for an expected minimum of 3 doses and up to a total of 6 doses in participants with normal renal function and participants with mild or moderate renal impairment, and for an expected minimum of 6 doses and up to a total of 9 doses in participants with severe renal impairment.
3138112|NCT03855228|Experimental|MFNS 200 µg + Loratadine 10 mg|Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet.
3138113|NCT03855228|Active Comparator|MFNS 200 µg|Daily administration of 200 µg of MFNS plus oral placebo tablet.
3138114|NCT03855228|Active Comparator|Loratadine 10 mg|Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray.
3138115|NCT03855228|Placebo Comparator|Placebo|Daily administration of placebo nasal spray plus oral placebo tablet.
3138116|NCT03861936|Experimental|BOTOX® 72U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 72 units (U) total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
3138117|NCT03861936|Experimental|BOTOX® 48U|OnabotulinumtoxinA (botulinum toxin Type A; BOTOX®) 48U total dose administered intramuscularly to the bilateral masseter muscles on Day 1.
3138118|NCT03861936|Placebo Comparator|Placebo|Placebo (Normal saline) administered intramuscularly to the bilateral masseter muscles on Day 1.
3138119|NCT03859739|Experimental|Panel A. MK-8558 400 mg|Single oral dose of MK-8558 administered at 400 mg following a 10-hour fast.
3138120|NCT03859739|Experimental|Panel B. MK-8558 at dose level 2|Single oral dose of MK-8558 administered at dose level 2 following a 10-hour fast. Dose level 2 shall not exceed 900 mg. Per protocol, dose will be selected following review of data from panel A.
3138121|NCT03859739|Experimental|Panel C. MK-8558 at dose level 3|Single oral dose of MK-8558 administered at dose level 3 following a 10-hour fast. Dose level 3 shall not exceed 1600 mg. Per protocol, dose will be selected following review of data from panel B.
3182141|NCT00699959||2|patients without heart failure
3138122|NCT03859739|Experimental|Panel D. MK-8558 at dose level 4|Single oral dose of MK-8558 administered at dose level 4 following a low-fat breakfast. Dose level 4 shall not exceed 1600 mg. Per protocol, Panel D is optional pending results of Panels A-C, and dose will be selected following review of data from panel C.
3138123|NCT03857750||Elderly (>80 years)|Patients planned for elective surgery above 80 years
3138124|NCT03857750||Younger (18-40 years)|Patients planned for elective surgery between 18-40 years
3138125|NCT03856255|Experimental|Micro-Tech Endoscopic Gauge|Use of the device during screening or surveillance colonoscopy
3138126|NCT03850509|Experimental|OPS-2071 150 mg BID|Participants were to receive OPS-2071 150 mg, tablets, orally, twice daily (BID) in the morning and evening (8 to 12 hours apart) with 240 milliliters (mL) of water for up to 12 weeks.
3138127|NCT03850509|Experimental|OPS-2071 300 mg BID|Participants received OPS-2071 300 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 6 weeks.
3138128|NCT03850509|Experimental|OPS-2071 600 mg BID|Participants were to receive OPS-2071 600 mg, tablets, orally, BID in the morning and evening (8 to 12 hours apart) with 240 mL of water for up to 12 weeks.
3138129|NCT03850509|Placebo Comparator|Placebo|Participants received OPS-2071-matched placebo, tablets, orally, BID in morning and evening (8 to 12 hours apart) with 240 mL of water for up to 4 weeks.
3138130|NCT03861559|Experimental|mometasone furoate nasal spray|Participants administered mometasone furoate nasal spray 200 mcg once daily (QD), as two 50 mcg sprays per nostril, for 14 consecutive days.
3138131|NCT03861559|Placebo Comparator|placebo nasal spray|Participants administered placebo nasal spray QD, as two placebo sprays per nostril, for 14 consecutive days.
3138132|NCT03860753|Experimental|Pioglitazone|
3138133|NCT03860753|Placebo Comparator|Placebo|
3138134|NCT03848455||Parkinson's disease group|"Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria;~Newly diagnosed primary PD patients, diagnosed within 3-6 months;~informed consent to the study;~age > 18 older."
3138135|NCT03848455||Non-parkinson group|Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age > 18 older.
3138136|NCT03858894|Experimental|Drug Arm: DE-117 QD|DE-117 Ophthalmic Solution QD (20:00) and Vehicle (8:00; no active DE-117 ingredient) QD
3138137|NCT03858894|Experimental|Test Arm: DE-117 BID|DE-117 Ophthalmic Solution BID Twice daily (20:00 and 8:00)
3138138|NCT03856164|Active Comparator|Tranexamic acid|Tranexamic Acid for intravenous administration.
3138139|NCT03856164|Placebo Comparator|Placebo|Normal saline for intravenous administration.
3138140|NCT03850275|Experimental|Experimental: Placebo, then caffeinated placebo, then e+shots|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
3138141|NCT03850275|Experimental|Experimental: Caffeinated placebo, then placebo, then e+shots|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the e+shot and were tested for 108 minutes
3138142|NCT03850275|Experimental|Experimental: placebo, then e+shots, then caffeinated placebo|Participants received placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received e+shots and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
3138143|NCT03850275|Experimental|Experimental: caffeinated placebo, then e+shots, then placebo|Participants received caffeinated placebo and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the e+shots and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
3138144|NCT03850275|Experimental|Experimental: e+shots, then caffeinated placebo, then placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the caffeinated placebo and tested for 108 minutes. After another 48 hour washout period they received the placebo and were tested for 108 minutes.
3149854|NCT00187668||Asian|Must self identify as Asian with parents and grandparents of the same ethnicity. Must be healthy taking no over the counter medications or prescription medications.
3149855|NCT00187707|Other|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
3149856|NCT00187733||Fasting|Other: Fasting blood and urine collection
3149857|NCT00187746|Experimental|Age 18-25 years|African American subjects between the ages 18 to 25 years given Adefovir dipivoxil.
3149858|NCT00187746|Experimental|Age 48-55 years|African American subject between the ages 48 to 55 years given Adefovir dipivoxil.
3149859|NCT00187798|Other|Metformin|Metformin HCl
3149860|NCT00187837|Experimental|SW intervention|Stepwise Excavation
3149861|NCT00187837|Other|DCE intervention|Control intervention Direct complete excavation. The updated terminology for completed excavation is non-selective excavation to hard dentin
3149862|NCT00187850|Experimental|PP|Partial pulpotomy
3149863|NCT00187850|Other|DPC|Direct pulp capping
3149864|NCT00187863||Exercise induced pain perception|
3149865|NCT00187863||Surgical pain perception|
3149866|NCT00187915|Other|CellCept + Prograf|Standard of Care Regime
3149867|NCT00187915|Other|CellCept + Neoral|Standard of Care Regime
3138145|NCT03850275|Experimental|Experimental: e+shots, then placebo, then caffeinated placebo|Participants received e+shots and were tested for 108 minutes after consumption. After a 48 hour washout period, they received the placebo and tested for 108 minutes. After another 48 hour washout period they received the caffeinated placebo and were tested for 108 minutes.
3138146|NCT03851016|Experimental|Life Story Book Intervention First, Then Usual Care|Participants first received the Life Story Book Intervention once a week for 3 weeks. After a washout period of 1 week, they then received the Usual Care Intervention for 3 weeks. Posttests were then conducted for 1 week.
3138147|NCT03851016|Experimental|Usual Care First, Then Life Story Book Intervention|Participants first received the Usual Care Intervention for 3 weeks. After a washout period of 1 week, they then received the Life Story Book Intervention once a week for 3 weeks. Posttests were then conducted for 1 week.
3138148|NCT03850496|No Intervention|Group A|No device utilised for 6 weeks.
3138149|NCT03850496|Experimental|Group B|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 30 mins / day for 6 weeks.
3138150|NCT03850496|Experimental|Group C|Revitive IX Neuromuscular Stimulation Device - Neuromuscular stimulation device used for 60 mins / day for 6 weeks.
3138151|NCT03848949|Experimental|Orthotic Group|Subjects enrolled in the orthotic group receive the orthotic (Evenup) meant to increase the effective leg length of the uninjured limb.
3138152|NCT03848949|No Intervention|Control|Subjects enrolled in the control group receive the standard treatment associated with their injury (no orthotic)
3138153|NCT03849690|Experimental|TAK-906 25 mg; Esomeprazole 40 mg + TAK-906 25 mg|TAK-906 25 milligram (mg), capsule, orally, once on Day 1 of Study Period 1, followed by a washout period of at least 4 days, further followed by esomeprazole 40 mg, capsule, orally, once daily on Days 1 to 5 along with TAK-906 25 mg, capsule, orally, once on Day 4 of Study Period 2.
3138154|NCT03846219|Experimental|IMU-838 (30 mg/day)|"Tablet containing 15 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 30 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
3138155|NCT03846219|Experimental|IMU-838 (45 mg/day)|"Tablet containing 22.5 mg Vidofludimus calcium (IM90838). Once-daily oral dose of 45 mg consists of 2 tablets.~Duration: until the end of the main treatment period (24 weeks) and, optionally, during the extended treatment period (up to 9.5 years)."
3149868|NCT00187941|Other|CellCept|CellCept + Prograf or Neoral + Steroids
3149869|NCT00188058|Active Comparator|Minimal alveolar distension|PEEP is set for a total PEEP (PEEP + intrinsic PEEP) between 5 and 9 cm H2O
3138156|NCT03846219|Placebo Comparator|Placebo|"Tablet containing no active ingredient. The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Once-daily oral dose consists of 2 active compound-free tablets.~Duration: until the end of the main treatment period (24 weeks). For the optional extended treatment period, patients receiving placebo during the main treatment period will be randomized to 30 or 45 mg/day IMU-838."
3149870|NCT00188058|Experimental|Maximal alveolar distension|PEEP is set for a plateau pressure between 28 and 30 cm H20
3149871|NCT00188175|Experimental|IMRT for lower limb soft tissue sarcoma|
3149872|NCT00188214|Other|CT perfusion scan|
3138157|NCT03845933|Active Comparator|Water exchange (WE) colonoscopy|Water exchange will be used during colonoscopy insertion. Upon arriving at the cecum, CO2 will be opened. The scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). The scope will be reinserted into the cecum by the first endoscopist. A tandem inspection of right colon will be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
3138158|NCT03845933|Active Comparator|CO2 insufflation colonoscopy|The colonoscopy is performed in the usual fashion, with minimal insufflation required to aid insertion. Cleaning will be performed entirely during withdrawal. Upon arriving at the cecum, CO2 insufflation will be used and the scope will be withdrawn to the hepatic flexure. All polyps identified will be resected (colon polypectomy). Then the scope will be reinserted into the cecum by the first endoscopist using CO2. A tandem inspection of the right colon will then be performed by a second endoscopist. All polyps found herein will be counted as the missed polyps. After the second withdrawal to the mark of distal hepatic flexure, the remainder of the colon will be examined in a standard manner by the first endoscopist.
3138159|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.01%|1 drop daily into each eye in the evening for 28 days
3138160|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.02%|1 drop daily into each eye in the evening for 28 days
3138161|NCT03844945|Experimental|Netarsudil Ophthalmic Solution 0.04%|1 drop daily into each eye in the evening for 28 days
3138162|NCT03844945|Placebo Comparator|Netarsudil Ophthalmic Solution Placebo|1 drop daily into each eye in the evening for 28 days
3138163|NCT03844321|Experimental|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
3138164|NCT03844321|Experimental|Brief Mindfulness|3 sessions of online mindfulness therapy
3138165|NCT03843632|Experimental|VARIVAX™|All participants will receive one dose subcutaneous (SC) VARIVAX™ on Day 1. Adult participants and adolescent participants 13 years and older will also receive a second SC dose VARIVAX™ on Day 43.
3138166|NCT03840811|Experimental|Group 1|Subjects (n = up to 8) will receive a bacterial inoculum containing only the isogenic mutant N. gonorrhoeae strain
3138167|NCT03840811|Experimental|Group 2|Subjects (n = up to 8) will receive a bacterial inoculum containing only the wild-type (WT) N. gonorrhoeae strain.
3138168|NCT03840811|Experimental|Group 3|Subjects (n= up to 16) will receive a bacterial inoculum containing a mixture of equivalent numbers the isogenic mutant and WT strain
3138169|NCT03837028||HPV 16/18 (+), cytology normal|"Women who have HPV 16/18 positivity and normal cytology results in their cervical cancer screening test (co-test) results.~The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later."
3138170|NCT03837028||HPV 16/18 (+), cytology abnormal|Women who have HPV 16/18 positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
3138171|NCT03837028||non-16/18 HPV (+), cytology abnormal|Women who have non- 16/18 high-risk HPV positivity and abnormal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
3138172|NCT03837028||non-16/18 HPV (+), cytology normal|Women who have non- 16/18 high-risk HPV positivity and normal cytology results in their cervical cancer screening test (co-test) results. The FSFI and BAI questionnaires were performed to the women in this group at the time of admission and two months later.
3138173|NCT03825939|Experimental|Intravenous Tranexamic Acid|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery"
3138174|NCT03825939|Placebo Comparator|Intravenous Placebo|- IV 0.9% sterile saline
3138175|NCT03825939|Active Comparator|Intravenous Tranexamic Acid followed by Intravenous Placebo|"1g TXA administered intravenous piggyback at start of surgery OR~1g TXA administered intravenous piggyback at start and at time of closure of surgery~IV 0.9% sterile saline"
3138176|NCT03817775|No Intervention|Control|The control group will undergo coronary angiography without music intervention.
3138177|NCT03817775|Experimental|Music therapy|The intervention group will also undergo coronary angiography and will administer music therapy between 10 minutes prior to the beginning of the procedure until its end.
3138178|NCT03843372|Experimental|First night HFNC group|The first night will receive high flow nasal cannula (HFNC) therapy and the second night accept continuous positive airway pressure (CPAP) therapy.
3138179|NCT03843372|Active Comparator|First night CPAP group|In contrast, the first night will receive continuous positive airway pressure and the second accept high flow nasal cannula therapy.
3138180|NCT03841331|Experimental|5 mg Serlopitant Tablets|Serlopitant Tablets
3138181|NCT03841331|Placebo Comparator|5 mg Placebo Tablets|Placebo Tablets
3138182|NCT03840278|Experimental|Bihormonal iLet first, then Insulin-Only iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the bihormonal iLet bionic pancreas for 1 week. They then used the insulin-only iLet bionic pancreas for 1 week."
3138183|NCT03840278|Experimental|Insulin-Only iLet first, then Bihormonal iLet|"Each sequence of the study will use the iLet Bionic Pancreas. The iLet is an autonomous infusion pump controlled by the bionic pancreas control algorithm that calculates and doses insulin and/or dasiglucagon based on glucose values received by the Dexcom G5 Continuous Glucose Monitor (CGM).~For this sequence, participants first used the insulin-only iLet bionic pancreas for 1 week. They then used the bihormonal iLet bionic pancreas for 1 week."
3138184|NCT03840135|Experimental|Polyoxidonium 6 mg/ml|Polyoxidonium 6 mg/ml nasal and sublingual spray - 0,15 mg/kg daily - 7 days.
3138185|NCT03840135|Placebo Comparator|Placebo|Placebo, nasal and sublingual spray - 7 days.
3138186|NCT03839641|Experimental|High Fat Meal First|Arm 1 participants randomized to receive high fat meal first, and low fat meal second
3138187|NCT03839641|Experimental|High Fat Meal Second|Arm 2 participants randomized to receive low fat meal first, and high fat meal second
3138188|NCT03839212|Experimental|Happy Older Latinos are Active (HOLA)|A 16-week multi-component, health promotion intervention
3138189|NCT03839355|Active Comparator|Eliquis|
3138190|NCT03839355|Active Comparator|Warfarin|
3138191|NCT03838874|Active Comparator|Low-Dose Bupivacaine|Subjects in this group will be given 10mg of Low-Dose Bupivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
3138192|NCT03838874|Active Comparator|Mepivacaine|Subjects in this group will be given 70mg of Mepivacaine, which is within standard of care for spinal anesthesia during TKA or THA.
3138193|NCT03838731|Experimental|REGN1908-1909|
3138194|NCT03838731|Placebo Comparator|Placebo|
3138195|NCT03838198|Other|Safety plan + booster text messages + booster call (Group A)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group A: Participants will receive the in-person MI-enhanced safety plan (individual meeting with the adolescent and a family meeting) during hospitalization -- focused on developing a personalized list of coping strategies and enhancing adolescents' motivation and self-efficacy to utilize these strategies-- which will be followed by 4 weeks of daily post-discharge booster text messages and a phone booster call.
3138196|NCT03838198|Other|Safety plan + booster text messages (Group B)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group B: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by 4 weeks of daily booster text messages post discharge.
3138197|NCT03838198|Other|Safety plan + booster call (Group C)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group C: Participants will receive the in-person MI-enhanced safety plan during hospitalization followed by a post-discharge booster call.
3138198|NCT03838198|Other|Safety plan (Group D)|Sequencing of MI-SafeCope intervention components (Phase 1 and Phase 2) resulting in Group D: Participants will receive the in-person MI-enhanced safety plan during hospitalization.
3138199|NCT03831451|Experimental|Stroke Preparedness Intervention|The stroke preparedness educational intervention was designed with input from the community where it is being tested. It will be delivered in-person by a research team member. The intervention focuses on recognizing stroke symptoms and the importance of calling 911.
3138200|NCT03831451|Active Comparator|Healthy lifestyle intervention|The Healthy lifestyle stroke risk reduction educational intervention is based on patient materials from the American Heart Association. It will be delivered in-person by a research team member. The intervention focuses on stroke risk reduction.
3182142|NCT00699985||1|Behcet's Disease patients that their diagnosis was based on the new International Criteria for Behcet's Disease (ICBD).
3182143|NCT00699985||2|Non-Behcet's Disease patients were patients mimicking BD.
3138201|NCT03822078|Placebo Comparator|Placebo|Participants received a single subcutaneous injection of placebo to denosumab on day 1.
3138202|NCT03822078|Experimental|Denosumab|Participants received a single subcutaneous dose of denosumab on day 1. Doses included 0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg.
3138203|NCT03815240|Other|no dressing (A)|No dressing will be applied at sacrum before 3.5 hours loading period in supine position
3138204|NCT03815240|Active Comparator|Mepilex (B)|'Mepilex® Border Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
3138205|NCT03815240|Active Comparator|Allevyn (C)|'ALLEVYN Life Sacrum' dressing will be applied at sacrum before 3.5 hours loading period in supine position
3138206|NCT03815240|Active Comparator|Optifaom (D)|'Optifoam® Gentle Sacrum' Dressing will be applied at sacrum before 3.5 hours loading period in supine position
3138207|NCT03836859|Experimental|rhNGF 20μg/mL|rhNGF 20μg/mL eye drop solution, formulation containing L-methionine as excipient.
3138208|NCT03836859|Placebo Comparator|Placebo|Vehicle: formulation containing L-methionine as excipient.
3138209|NCT03835078|Experimental|methalfilcon A contact lenses / fanfilcon A contact lenses|All subjects will first wear methafilcon A contact lenses for four (4) weeks of daily wear, then be refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
3138210|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 1.
3138211|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 2.
3138212|NCT03834025|Experimental|Phase 1 Condition 1, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of financial support available for participation. If they enroll, in Phase 2 of the study these participants will be in condition 3.
3138213|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 1.
3138214|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 2.
3182144|NCT00700024|Active Comparator|1|testim
3182145|NCT00700024|Experimental|2|placebo
3138215|NCT03834025|Experimental|Phase 1 Condition 2, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include additional mention of financial support available for participation, but will not include prosocial messaging (Phase 1 Condition 2). If they enroll, in Phase 2 of the study these participants will be in condition 3.
3138216|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 1.
3138217|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 2.
3138218|NCT03834025|Experimental|Phase 1 Condition 3, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of financial support available for participation (Phase 1 Condition 3). If they enroll, in Phase 2 of the study these participants will be in condition 3.
3138219|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 1|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 1.
3138220|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 2|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 2.
3138221|NCT03834025|Experimental|Phase 1 Condition 4, Phase 2 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of financial support available for participation (Phase 1 Condition 4). If they enroll, in Phase 2 of the study these participants will be in condition 3.
3138222|NCT03836677|Experimental|BGF-GFF|Subject first treated with Budesonide/Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Glycopyrronium/Formoterol Fumarate
3138223|NCT03836677|Experimental|GFF-BGF|Subject first treated with Glycopyrronium/Formoterol Fumarate followed by a washout period then treated with Budesonide/Glycopyrronium/Formoterol Fumarate
3149873|NCT00188266|Experimental|5-Fluorouracil (5FU) and Cisplatin with Radiation|
3149874|NCT00188279|Experimental|MnDCT|
3149875|NCT00188292||High-grade disease|Those who had histologic anal high-grade disease.
3149876|NCT00188292||Control|Those who had less than highgrade histologic anal disease
3149877|NCT00188305|Experimental|1 In person|In person general health, colorectal cancer risk information and screening recommendations.
3149878|NCT00188305|Active Comparator|2 Telephone|Telephone general health counselling, colorectal cancer risk information and screening recommendations.
3182146|NCT00700024|Experimental|3|training
3138224|NCT03836989|Experimental|High-volt electrical stimulation|"Plan to use a monophasic waveform having 100µmsec pulse duration, at 35 Hz using tolerated voltage to generate a contraction a total of 20 minutes.~The stimulation will have 10 seconds on time, 30 seconds off time and 2 second ramp up and down. Electrical stimulation will be produced with the Orthostim 3 device (VQ Ortho Care). The cathode will be placed on the ipsilateral muscle to stimulate and the anode over the ipsilateral mastoid region.~Four facial muscles will be stimulated: 1)frontalis, 2) orbicularis oculi, 3) zygomaticus major, and 4) orbicularis oris.~The voltage is turned up by the participant until he or she can see twitches or as high as tolerated. Ten contractions in each muscle group will be performed or 5 minutes per muscle if no contraction is achieved."
3138225|NCT03836989|Placebo Comparator|Subsensory electrical stimulation|"Plan to use the same device and settings to provide placebo treatment by delivering minimal electricity. The settings will be the same as the intervention except the voltage will be subsensory. ie. below the minimum at which patients feels any effect of the current.~The voltage is turned down two clicks from the voltage at which the participant can first notice any electricity or at the minimal setting."
3138226|NCT03827564|Experimental|ITN [TrueTear®] - Intranasal Application|Intranasal application of the ITN. Single application at application visit.
3138227|NCT03827564|Experimental|ITN [TrueTear®] - Extranasal Application|Extranasal application of the ITN. Single application at application visit.
3138228|NCT03824236|Experimental|P-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
3138229|NCT03824236|Experimental|NP-Fx group|Healthy subjects, between and including 18 and 55 years of age, vaccinated with RTS,S/AS01 vaccine (different doses/formulations) and not protected following the first challenge at the time of the MALARIA-092 study (NCT03162614), who received, in the current study, a fractional (Fx) booster dose of RTS,S/AS01E 12 months after completion of the vaccination course in the Malaria-092 study, and underwent sporozoite challenge.
3182147|NCT00700037|Experimental|1|Atorvastatin 20mg
3182148|NCT00700037|Active Comparator|2|atorvastatin 5mg
3138230|NCT03824236|No Intervention|InfectivityCtrl group|Healthy subjects, between and including 18 and 55 years of age, who did not receive, in the current study, any immunization but underwent sporozoite challenge.
3138231|NCT03811951|Experimental|Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl (Sodium Chloride) solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
3138232|NCT03811951|Experimental|Non-Smokers|All participants receive both Novolin R (experimental drug) and 14% NaCl solution (placebo), to be administered in randomly assigned order on two separate testing sessions. During administration of either Novolin R or 14% NaCl, participants will receive 1 spray in each nostril every 3 minutes for a total of 6 sprays. The nasal spray bottle delivers 0.1 ml of liquid per spray. Since the concentration of insulin in Novolin R is 100 IU/mL, six sprays will deliver a 60 IU dose.
3138233|NCT03810235|Active Comparator|Transdermal Lidocaine Patch|Drug: Including placebo The intervention is the post-operative application of a 5% lidocaine transdermal patch for women who have undergone Cesarean delivery.
3138234|NCT03810235|Placebo Comparator|Transdermal Hydrocolloid Placebo Patch|Drug: Including placebo The intervention is the post-operative application of a hydrocolloid transdermal patch for women who have undergone Cesarean delivery.
3138235|NCT03806556|Experimental|Tranexamic Acid|Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).
3138236|NCT03806556|Placebo Comparator|Placebo|Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.
3138237|NCT03836664|Experimental|Group 1: Timolol|Participants will be given 0.5% timolol ophthalmic solution to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
3138238|NCT03836664|Placebo Comparator|Group 2: Placebo|Participants will be given matching placebo (0.9% normal saline solution) to use after migraine onset. Participants will put 2 drops of solution in each eye after migraine and then again 2 hours later.
3138239|NCT03832738|Experimental|JTE-451 Dose 1|JTE-451 Tablets Dose 1 daily for 16 weeks.
3138240|NCT03832738|Experimental|JTE-451 Dose 2|JTE-451 Tablets Dose 2 daily for 16 weeks.
3138241|NCT03832738|Placebo Comparator|Placebo|Placebo Tablets daily for 16 weeks.
3138242|NCT03823391|Experimental|ABBV-3373 Followed by Placebo|Participants will be administered with 100 mg ABBV-3373 by intravenous infusion and placebo to adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive placebo to adalimumab every other week until Week 22.
3138243|NCT03823391|Experimental|Adalimumab|Participants will be administered with placebo to ABBV-3373 by intravenous infusion and 80 mg adalimumab by subcutaneous injection every other week for 12 weeks. After 12 weeks, participants will receive 80 mg adalimumab subcutaneously every other week until Week 22.
3138244|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 8 Weeks|Direct-acting antiviral (DAA)-naive participants without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 8 weeks.
3138245|NCT03820258|Experimental|Experimental: Cohort 1 (12 to < 18 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 1 (12 to < 18 years old) will receive SOF/VEL/VOX FDC 400/100/100 mg for 12 weeks.
3138246|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
3138247|NCT03820258|Experimental|Experimental: Cohort 2 (6 to < 12 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 2 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
3138248|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 8 Weeks|DAA-naive participants without cirrhosis in Cohort 3 (6 to < 12 years old) will receive SOF/VEL/VOX FDC for 8 weeks.
3138249|NCT03820258|Experimental|Experimental: Cohort 3 (3 to < 6 years old), 12 Weeks|DAA-naive participants with cirrhosis or DAA-experienced participants with or without cirrhosis in Cohort 3 (3 to < 6 years old) will receive SOF/VEL/VOX FDC for 12 weeks.
3138250|NCT03819491|Experimental|Group A|100 mg OD
3138251|NCT03819491|Experimental|Group B|100 mg BID
3138252|NCT03808298|Experimental|Treatment Sequence 1: A, B, C|
3138253|NCT03808298|Experimental|Treatment Sequence 2: A, C, B|
3138254|NCT03808298|Experimental|Treatment Sequence 3: B, A, C|
3138255|NCT03808298|Experimental|Treatment Sequence 4: B, C, A|
3138256|NCT03808298|Experimental|Treatment Sequence 5: C, A, B|
3138257|NCT03808298|Experimental|Treatment Sequence 6: C, B, A|
3138258|NCT03808298|Experimental|Treatment Sequence 7: A, B, D|
3138259|NCT03808298|Experimental|Treatment Sequence 8: A, D, B|
3138260|NCT03808298|Experimental|Treatment Sequence 9: B, A, D|
3138261|NCT03808298|Experimental|Treatment Sequence 10: B, D, A|
3138262|NCT03808298|Experimental|Treatment Sequence 11: D, A, B|
3138263|NCT03808298|Experimental|Treatment Sequence 12: D, B, A|
3138264|NCT03836729|Experimental|TAF/FTC followed by TAF/FTC + GSK3640254|Subjects will receive TAF/FTC 25/200 mg QD on Days 1 through 14 in Treatment Period 1. Subjects will be co-administered TAF/FTC 25/200 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Treatment Period 2.
3138265|NCT03835975|Active Comparator|13vPnC|Pneumococcal conjugate vaccine
3138266|NCT03835975|Active Comparator|PPSV23|Pneumococcal polysaccharide vaccine
3138267|NCT03835975|Experimental|20vPnC|Pneumococcal conjugate vaccine
3138268|NCT03821259||Older adults with mental health history|Eligible participants, aged 65 and over, will be established in treatment for PTSD, anxiety or depression in the Older Adult Psychological Therapies service.
3138269|NCT03803085|Experimental|Control Condition|Participants only saw their own daily walking steps using the WeRun function in WeChat. They did not use WeChat to see other group members' daily steps and did not engage in social contact with their group members.
3138270|NCT03803085|Experimental|Treatment condition|Participants saw their own and other group member's daily walking steps using the WeRun function in WeChat and they were able to contact the other members of their group using We Chat.
3138271|NCT03801473|Experimental|robot assisted training (RAT)|RoboGait which is an automated locomotor therapy system was used for treating RAT group. The system composed of a robotic lower extremity orthosis, adjustable dynamic gait support, synchronized treadmill and biofeedback utilities
3138272|NCT03801473|Active Comparator|conventional training (CT)|Participants in CT group had physiotherapist assisted walking exercises on the parallel bars and on the ground with aids/cane, tripod or walker.
3138273|NCT03834168|Other|Study Individuals|Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).
3138274|NCT03828149|Active Comparator|Drug: OP0201|20 mg dose one time, followed by a washout and then a 0 mg dose one time, cross over design
3138275|NCT03828149|Placebo Comparator|Drug: Placebo|0 mg dose one time, followed by a washout and then a 20 mg dose one time, cross over design
3138276|NCT03835221|Experimental|methafilcon A toric / fanfilcon A toric contact lenses|All subjects will first wear methafilcon A toric contact lenses for four (4) weeks of daily wear, then refitted with fanfilcon A toric contact lenses for four (4) weeks of daily wear.
3138277|NCT03819634|Experimental|Lantern infusion set|Multi-slitted lantern infusion set
3138278|NCT03812679|Experimental|AMIA APD Solution Generation System|A simulated treatment will take place before the patient receives study treatment, during week 1 and after 4, 8 and 12 weeks of study treatment period. The dialysis solution generated by the simulated treatment will be collected from the system in the heater bag and used to evaluate the chemical composition of the final dialysis solution produced by patients using the AMIA APD Solution Generation System. Also, product water from the Water Device (pre-sterilizing filters) will be collected and tested at each visit.
3138279|NCT03809052|Experimental|A1 - 5 mg GB1211 single dose and Placebo|6 healthy subjects are administered 5 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
3138280|NCT03809052|Experimental|A2 - 20 mg GB1211 single dose and Placebo|6 healthy subjects are administered 20 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
3138281|NCT03809052|Experimental|A3 - 50 mg GB1211 single dose (food effect cohort) and Placebo|6 healthy subjects are administered 50 mg of GB1211 capsules orally as a single dose. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion. Each subject will participate in 2 treatment periods separated by a minimum of 7 days. In Treatment Period 1 doses will be administered in the fasted state, in Treatment Period 2 doses will be administered 30 minutes after the start of a high fat breakfast. Subjects will receive the same treatment in both periods.
3138282|NCT03809052|Experimental|A4 - 100 mg GB1211 single dose and Placebo|6 healthy subjects are administered 100 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
3138283|NCT03809052|Experimental|A5 - 200 mg GB1211 single dose and Placebo|6 healthy subjects are administered 200 mg of GB1211 capsules orally as a single dose in the fasted state. 2 subjects receive placebo. 2 subjects (1 active and 1 placebo) will be dosed at least 24 hours before the remaining subjects, where continuation to dose the remaining subjects will be at the Investigator's discretion.
3138284|NCT03809052|Experimental|B1 - GB1211 multiple ascending doses, 50mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule.
3138285|NCT03809052|Experimental|B2 - GB1211 multiple ascending doses, 100mg BID and Placebo|GB1211 administered orally twice daily over 10 days. 8 healthy subjects received GB1211 and 3 subjects will receive placebo. Following review of data in Part A (Cohorts A1 to A6), subjects received twice daily (BID) doses under fasted conditions on Days 1 to 9, inclusive, and a final single dose administration on the morning of Day 10 in accordance with the randomisation schedule..
3138286|NCT03809052|Experimental|A6 - 50mg GB1211 single dose and Placebo|8 healthy subjects are administered 50 mg (10 x 5mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
3138287|NCT03809052|Experimental|A7 - 400 mg GB1211 single dose and Placebo|8 healthy subjects are administered 400 mg (8 x 50mg capsules) or placebo without sentinel dosing. Optional cohort, as was added following dose-escalation analysis.
3138288|NCT03809052|Experimental|Part A - Placebo for GB1211|In Part A - 2 subjects from each arm (A1-A5) will receive placebo.
3138289|NCT03809052|Experimental|Part B - Placebo for GB1211 (BID)|Part B - 3 subjects from each arm B1 and B2 will receive placebo.
3138290|NCT03802565|Experimental|Tolperisone 50 mg|TID (150 mg/day)
3138291|NCT03802565|Experimental|Tolperisone 100 mg|TID (300 mg/day)
3138292|NCT03802565|Experimental|Tolperisone 150 mg|TID (450 mg/day)
3138293|NCT03802565|Experimental|Tolperisone 200 mg|TID (600 mg/day)
3138294|NCT03802565|Placebo Comparator|Placebo|TID
3138295|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TOB) + Dexlansoprazole 30mg (TPC)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
3138296|NCT03801148|Experimental|Part 1:Dexlansoprazole 30mg (TPC) + Dexlansoprazole 30mg (TOB)|Dexlansoprazole 30 mg, delayed-release capsule manufactured by TPC (Regimen B [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 30 mg, delayed-release capsule manufactured by TOB (Regimen A [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
3138297|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TOB) + Dexlansoprazole 60mg (TPC)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
3138298|NCT03801148|Experimental|Part 2:Dexlansoprazole 60mg (TPC) + Dexlansoprazole 60mg (TOB)|Dexlansoprazole 60 mg, delayed-release capsule manufactured by TPC (Regimen D [reference]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 1, followed by minimum of 5 day washout period, followed by dexlansoprazole 60 mg, delayed-release capsule manufactured by TOB (Regimen C [test]), orally, once, after a high fat/calorie breakfast on Day 1 of Period 2.
3138299|NCT03832907|Experimental|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|"The Dexcom G6 CGM is a commercially available factory-calibrated sensor system. The system measures interstitial glucose every 5-15 minutes, providing real-time and more complete glycemic profile during 24-hours compared to standard POC glucose testing, and replaces the need for finger sticking. Potential limitations include the need for removing the sensor before MRI or diathermy treatment, and the potential interference in patients with severe dehydration.~In parallel, same participants will be monitored by the standard of care point-of-care (POC) capillary glucose tests. Diabetes guidelines recommend bedside capillary POC testing before meals and at bedtime to assess glycemic control and to adjust insulin therapy in the hospital."
3149879|NCT00188305|Placebo Comparator|3 Control|Standard care for 2 months followed by summary letter with general health information, colorectal cancer risk information and screening recommendations.
3149880|NCT00188318|Experimental|Hyperfractionated Accelerated Radiotherapy|Hypofractionated Accelerated Radiotherapy with integrated neck surgery
3138300|NCT03832322||Water exchange colonoscopy|During the insertion phase of the first-pass colonoscopy, water exchange (WE) method was used. WE entailed the infusion of water to open the lumen and sequentially suction of water. When the cecum was reached and after most of the water was suctioned to collapse the cecal lumen, CO2 was opened during the withdrawal phase of the first-pass colonoscopy. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
3138301|NCT03832322||CO2 insufflation colonoscopy|During the first-pass colonoscopy, the procedure was performed in the usual fashion, with minimal CO2 insufflation to aid insertion. Cleaning of colon was predominantly performed during withdrawal. After the first complete withdrawal of the colonoscope, a second colonoscopic examination aided by CO2 insufflation during insertion and withdrawal was performed by the same endoscopist. The colonoscope was reinserted into the cecum as quickly as possible, and the entire colon was re-examined. Polyp resection was carried out during insertion and withdrawal of the first- and second-pass examinations.
3138302|NCT03832387|Experimental|Non-invasive mechanical ventilation|"Non-invasive ventilation (NIV) was initiated with progressive levels of inspiratory positive airway pressure and expiratory positive airway pressure until a minimum inspiratory positive airway pressure of 10-15 cmH2O and an expiratory positive airway pressure of 5-6 cmH2O were achieved in the first hour. Continuous positive airway pressure (CPAP) was initiated with a initial positive end-expiratory pressure level was 5 cmH2O, with progressive increases up to 10-15 cmH2O.~The objective pressures were set to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. NIV/CPAP were maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
3138303|NCT03832387|Active Comparator|Venturi mask|"For oxygen therapy were used both a Venturi mask with an fraction of inspired oxygen up to 0.5 (15 L/min) and a reservoir mask connected to a high-flow flowmeter with 30 L/min of O2.~The objective oxygen therapy was to reduce dyspnoea and respiratory mechanics, with an respiratory rate between 25 and 28 bpm. Oxygen therapy was maintained continuously (except for hygiene or oral intake) until the patient exhibited improvement from the clinical and/or gasometric perspective."
3138304|NCT03831971|Experimental|ANS-6637 & Midazolam|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
3138305|NCT03831854|Active Comparator|lamotrigine|Patient will receive 300 mg of oral lamotrigine with small sips of water to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
3138306|NCT03831854|Placebo Comparator|Placebo|Patient will receive oral Placebo with small sips of water, to reduce the psychologic side effects (measured by four key items of Brief Psychiatric Rating Scale: conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) of intraoperative ketamine use.
3138307|NCT03807739|Experimental|Part I: GDC-0134 F16 vs F09 Capsule Formulation|In Part 1 participants will receive single doses of either GDC-0134 F16 capsules (prototype) or GDC-0134 F09 capsules (reference) after having consumed a standard meal.
3138308|NCT03807739|Experimental|Part II: GDC-0134 F15 vs F09 Capsule Formulation|In Part 2, participants will receive a single dose of either GDC-0134 F15 capsules (prototype) or GDC-0134 F09 capsules (reference) after an overnight fast.
3138309|NCT03831282|Experimental|RD SET Neo SpO2|All subjects enrolled in the study will receive the investigational sensor (RD SET Neo SpO2) for evaluation of SpO2.
3138310|NCT03824912|Experimental|Test: Ketoconazole Cream 2%|Test: Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd)
3138311|NCT03824912|Active Comparator|Reference: Ketoconazole Cream 2%|Ketoconazole Cream 2% (G&W Laboratories Inc.; Registrant: Teva Pharmaceuticals USA Inc.)
3138312|NCT03824912|Placebo Comparator|Placebo: Cream (Test vehicle)|Placebo Cream (Test vehicle) (Encube Ethicals Pvt Ltd)
3138313|NCT03822884|Experimental|Hemax® PFS 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
3138314|NCT03822884|Experimental|Hemax® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
3138315|NCT03822884|Active Comparator|Erypo ® 40,000 UI|Epoetin Alfa 40000 UNT/ML subcutaneous single dose
3138316|NCT03816709|Other|Therapeutic ultrasound treatment|All subjects received a therapeutic ultrasound treatment with the Chattanooga Intelect Legend XT machine with the following parameters: 3 MHz, 1.0 W/cm2, 15 minute treatment time.
3138317|NCT03810014|Experimental|Arm 1|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
3138318|NCT03810014|Experimental|Arm 2|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
3138319|NCT03810014|Experimental|Arm 3|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
3138320|NCT03810014|Experimental|Arm 4|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
3138321|NCT03806270||Midazolam|"Demizolam, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with cherry juice of maximum 5 ml. in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication and doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
3138322|NCT03806270||Midazolam&Hydroxyzine dihydrochloride1/2|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with hydroxyzine dihydrochloride (dose of 0.5 mg/kg) in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
3138323|NCT03806270||Midazolam&Hydroxyzine dihydrochloride|"Midazolam and Hydroxyzine dihydrochloride, once on the operation day, usually ordered 15 minutes before strabismus operation by another anesthesiologist who is charged to perform anesthesia who is not related with the trial.The maximum dose of 0.5 mg/kg midazolam is given orally with the maximum dose of 1mg/kg hydroxyzine dihydrochloride in Yeditepe University Hospital to the pediatric patients by the anesthesiologists.~In all groups patients are not selected to the groups and premedication doses are not given by the investigator, they grouped according to the premedication given by the anesthesiologists, after the operation retrospectively."
3149881|NCT00188331||1|adjuvant/neoadjuvant chemotherapy
3149882|NCT00188331||2|non-chemotherapy group
3149883|NCT00188331||3|limited metastatic disease or localised recurrence to receive first line metastatic chemotherapy
3138324|NCT03830892|Active Comparator|E-cigarette User (Exclusive)|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette
3138325|NCT03830892|Active Comparator|Dual User|Other: E-cigarette Lab Session 15 watts, 10 mg nicotine Other: E-cigarette Lab Session 15 watts, 30 mg nicotine Other: E-cigarette Lab Session 30 watts, 10 mg nicotine Other: E-cigarette Lab Session 30 watts, 30 mg nicotine Other: Own Brand Session - E-cigarette/Cigarette
3138326|NCT03830307|Experimental|Intervention Group|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
3138327|NCT03825042|Experimental|Food supplement|A mix of bacopa, lycopene, astaxanthin and vitamin B12 Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
3138328|NCT03825042|Placebo Comparator|Placebo|Inactive compound Dosage form: tablets Dosage: 1 tablet/die Duration: 8 weeks
3138329|NCT03823378|Experimental|ABBV-599 in M16-063/ABBV-599 in M16-763|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks
3138330|NCT03823378|Experimental|ABBV-105 60 mg/UPA placebo|60 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
3138331|NCT03823378|Experimental|ABBV-105 20 mg/UPA placebo|20 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
3138332|NCT03823378|Experimental|ABBV-105 5 mg/UPA placebo|5 mg elsubrutinib capsule once a day by mouth for 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 48 weeks
3138333|NCT03823378|Experimental|UPA 15 mg/ABBV-105 placebo|15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks; placebo capsule for elsubrutinib once a day by mouth for 48 weeks
3138334|NCT03823378|Experimental|Placebo in M16-063/ABBV-599 in M16-763|Placebo in M16-063; 60 mg elsubrutinib capsule once a day by mouth for 48 weeks and 15 mg film-coated upadacitinib tablet once a day by mouth for 48 weeks in M16-763
3138335|NCT03831191|Experimental|50 mg LY3375880|"Induction Period:~Participants received 50 mg LY3375880 administered SC Q4W."
3138336|NCT03831191|Experimental|150 mg LY3375880|"Induction Period:~Participants received 150 mg LY3375880 administered SC Q4W."
3138337|NCT03831191|Experimental|600 mg LY3375880|"Induction Period:~Participants received 600 mg LY3375880 administered SC Q4W."
3138338|NCT03831191|Placebo Comparator|Placebo|"Induction Period:~Participants received placebo administered subcutaneously (SC) every 4 weeks (Q4W)."
3138339|NCT03830281|Active Comparator|Insulin Lispro (Humalog)|Participants received individual dose of 100 U/mL insulin lispro (Humalog) by CSII; where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
3138340|NCT03830281|Experimental|Ultra-Rapid Lispro|Participants received individual dose of 100 units per milliliter (U/mL) ultra rapid lispro by continuous subcutaneous insulin infusion (CSII); where mealtime boluses were delivered 0 to 2 minutes prior to the start of each meal, with basal infusion rates 24 hours/day, and correction boluses as necessary.
3138341|NCT03828734|Experimental|TMS to frontal cortex followed by TMS to parietal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the frontal cortex on the scalp. In their second session, the TMS coil will be placed over the parietal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
3138342|NCT03828734|Experimental|TMS to parietal cortex followed by TMS to frontal cortex|Participants will receive TMS while performing a cognitive control task. In their first stimulation session, the TMS coil will be placed over the parietal cortex on the scalp. In their second session, the TMS coil will be placed over the frontal cortex on the scalp. During every session, subjects receive Theta TMS, Alpha TMS, and Arrhythmic TMS.
3138343|NCT03827395|Experimental|HEV-239|0.5 mL of HEV-239 administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=20
3138344|NCT03827395|Placebo Comparator|Placebo|0.5 mL of HEV-239 placebo administered intramuscularly into the deltoid muscle as a single injection on Days 1, 29, and 180. N=5
3138345|NCT03819218|Experimental|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
3138346|NCT03818815|Active Comparator|Drug: OP0201 + Antibiotics|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
3138347|NCT03818815|Placebo Comparator|Placebo Comparator: Placebo +Antibiotics|Placebo 0 mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
3138348|NCT03828487|Experimental|Neonatal Test group|Subjects will receive a Masimo O3 Neonatal sensors as well as a 510(k) cleared sensor.
3138349|NCT03828617|Experimental|20vPnC Lot 1|20vPnC Lot 1
3138350|NCT03828617|Experimental|20vPnC Lot 2|20vPnC Lot 2
3138351|NCT03828617|Experimental|20vPnC Lot 3|20vPnC Lot 3
3138352|NCT03828617|Active Comparator|13vPnC|13vPnC
3138353|NCT03828539|Experimental|Erenumab|70 mg and 140 mg Erenumab
3149884|NCT00188344|Active Comparator|1|pneumatic dilatation
3138354|NCT03828539|Active Comparator|Topiramate|Topiramate in the highest tolerated dose (50 - 100 mg/day)
3138355|NCT03824704|Experimental|Cohort A: Ovarian Cancer Cohort|"Oral rucaparib and Intravenous (IV) nivolumab (combination therapy)~Cohort A1~Cohort A2"
3138356|NCT03823937||Fibromyalgia|Diagnosed with ACR 2016 criteria
3138357|NCT03823937||Control|18-70 years healthy subjects
3138358|NCT03817879|Experimental|VivaSight double-lumen tube|
3138359|NCT03817879|Active Comparator|Conventional double-lumen tube|
3138360|NCT03811834|Experimental|Mobocertinib 160 mg and [14C]-Mobocertinib 50 mcg + [14C]-Mobocertinib 160 mg|Mobocertinib 160 mg, capsule, orally, once under fasted state, followed by [14C]-mobocertinib 50 mcg (approximately 2 microcurie [mcCi]), infusion, intravenously, once on Day 1 of Period 1, further followed by a washout period of 9 days, followed by [14C]-mobocertinib 160 mg (approximately 100 mcCi), solution, orally, once under fasted state on Day 1 of Period 2.
3138361|NCT03806127|Experimental|Vibegron 75 mg|Participants will receive vibegron 75 milligrams (mg) orally once daily for 12 weeks.
3138362|NCT03806127|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily for 12 weeks.
3138363|NCT03827473|Experimental|Arm A (ADT, docetaxel)|Participants receive androgen deprivation therapy (ADT) per standard of care and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3138364|NCT03827473|Experimental|Arm B (ADT, abiraterone acetate, prednisone)|Participants receive androgen deprivation therapy (ADT) per standard of care, abiraterone acetate PO daily, and prednisone PO twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3138365|NCT03826914|Experimental|Experimental group|Participants in the experimental group will be given 1 serving (10g) of Cardioflex each day.
3138366|NCT03826914|Placebo Comparator|Control Group|Participants in the control group will be given a flavoured 10g placebo that looks and tastes exactly like Cardioflex.
3138367|NCT03812328|Experimental|SelK2 and Enoxaparin|I.V., single-dose (SelK2) and SC, QD for up to 10 ± 2 days (Enoxaparin)
3138368|NCT03812328|Active Comparator|Enoxaparin|SC, QD for up to 10 ± 2 days
3138369|NCT03812328|Experimental|SelK2|I.V., single-dose
3138370|NCT03808688|Other|Netarsudil Ophthalmic Solution 0.02%|
3138371|NCT03811093|Experimental|Care as Usual Group|A randomly selected group of 20 participants who received treatment per the prescribed trial protocol using a fully functional invisa-RED Technology Elite device. Treatment protocol was as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular LLLT protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
3138372|NCT03811093|Placebo Comparator|Sham Group|A randomly selected group of 20 participants who will receive treatment per the prescribed trial protocol using a non functional invisa-RED Technology Elite device. (The sham device will be disabled and will deliver no low laser light energy during therapy.) Treatment protocol is as follows: Participants will undergo nine (9) therapy sessions of 20 minutes each over a three week period; using a singular protocol setting for pulse (3.5s) and delay (0.2s), however power settings will be based on the participants Fitzpatrick Scale skin type. For skin types i and ii a power setting of 7 will be used, for skin types iii and iv a power setting of 6, for skin types v and vi a power setting of 4 will be employed.
3138373|NCT03822182|Other|Control/Bupivicaine +DMSO|Group 1 will serve as the control and receive the standard injection consisting 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone.
3149885|NCT00188344|Active Comparator|2|Laparoscopic myotomy
3138374|NCT03822182|Active Comparator|Liposomal bupivicaine|Group 2 will receive a block with 15ml 0.5% bupivacaine and 10ml (133mg) of liposomal bupivicaine (Exparel) and 5.4ml of Normal Saline
3138375|NCT03822182|Active Comparator|Liposomal Bupivicaine +DMSO|Group 3 will receive 15ml of 0.5% bupivicaine and 10ml (133mg) of Liposomal Bupivicaine (Exparel) and 0.4ml (4mg) dexamethasone and 5ml normal saline
3138376|NCT03822416|Experimental|Intervention|Intervention group will receive counseling and nicotine replacement therapy including the nicotine patch and/or nicotine lozenges.
3138377|NCT03822416|Other|Control|Control group will receive information about mental illness and smoking cessation and a listing of community resources available for assistance with smoking cessation.
3138378|NCT03809104|Experimental|elderly with sarcopenia|Virtual reality-based rehabilitation programs
3138379|NCT03807089|Experimental|Short-Turn Radius Colonoscope|Colonoscopy performed with Short-Turn Radius Colonoscope. The colonoscope will provide a forward-facing view of the colon during advancement to the cecum (standard of care). The scope will then be withdrawn all the way to the rectum and the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and be withdrawn using the retrograde view.
3138380|NCT03807089|Active Comparator|Conventional Pediatric Colonoscope|Colonoscopy will be performed with a conventional pediatric colonoscope. During withdrawal, the colon will be inspected using the forward-facing view (standard of care). The colonoscope will then be re-advanced to the cecum and again withdrawn using the forward-facing view.
3138381|NCT03806231|Experimental|Outpatient Cervical Ripening|Patients randomized to the outpatient cervical ripening arm will come in for a scheduled visit in Labor and Delivery prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be monitored for 2 hours and sent home after a the following are present: (1) reactive non-stress test (NST) (2) category 1 tracing x 2 hours (3) no vaginal bleeding (4) normal maternal vital signes (5) intact bag of water (BOW) and (6) less than 1 contraction every 10 minutes at the time of discharge. The patient will remove the insert the following morning prior to her scheduled induction.
3138382|NCT03806231|Active Comparator|Inpatient Cervical Ripening|The patient will be admitted into the Labor and Delivery unit prior to her scheduled induction. A research nurse will examine her and place the Cervidil insert into the posterior vaginal fornix. The patient will be watched with continuous fetal monitoring for 2 hours. The patient remains hospitalized and the following morning the induction will be started per Intermountain Healthcare protocol.
3138383|NCT03804710|Experimental|Test Product 1|Participants will apply 2 pumps of the test product (approximately 0.3ml x 2= 0.6ml) to the randomly assigned side of the face, including forehead and chin, and 6 pumps of test product (approximately 0.3 ml x 6 = 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) topically twice-daily (in the morning and evening) after cleansing.
3138384|NCT03804710|Experimental|Test Product 2|Participants will apply pea-sized amount of the test product (approximately 0.6ml) to the randomly assigned side of the face, including forehead and chin, and walnut-sized amount of the test product (approximately 1.8 ml) to the randomly assigned lower leg (below the knee; above the ankle) twice-daily (in the morning and evening) after cleansing.
3138385|NCT03804710|Placebo Comparator|Standard soap cleanser|Participants will use wet soap with warm water and form lather. Participants will cleanse their entire face and both lower legs (between the knees and ankles) twice daily (morning and evening).
3138386|NCT03822377|Experimental|Ticagrelor orodispersible tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as orodispersible tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as orodispersible tablets."
3138387|NCT03822377|Active Comparator|Ticagrelor standard tablets|"STEMI or very high-risk NSTEMI patients undergoing primary PCI and receiving Ticagrelor 180 mg loading dose as standard coated tablets.~Intervention: administration of Ticagrelor 180 mg loading dose as standard coated pills."
3138388|NCT03820388|Experimental|Propofol Group|Propofol 2 mg/kg
3138389|NCT03820388|Experimental|Etomidate Group|Etomidate 0.3 mg/kg
3138390|NCT03820388|Experimental|Propofol plus Etomidate Group|Propofol 1 mg/kg plus Etomidate 0.15 mg/kg
3138391|NCT03816696|Experimental|DTG followed by GSK3640254 followed by DTG+GSK3640254|Subjects will receive DTG 50 mg QD on Days 1 through 5 in Period 1 followed by a wash-out period of 4 days. Subjects will then receive GSK3640254 200 mg QD on Days 1 through 7 in Period 2 followed by co-administration of DTG 50 mg QD with GSK3640254 200 mg QD on Days 1 through 7 in Period 3.
3149886|NCT00188513|Experimental|Conformal intensity modulated radiotherapy (IMRT)|All patients shall receive a continuous course of intensity modulated conformal radiotherapy consisting of 66 Gy in 22 (3 Gy) fractions over 4.5 weeks.
3138392|NCT03821064|Experimental|Patient Navigation|45 patients (15 African American, 30 white) will interact with a patient navigator three times over three months to identify and address barriers before they cause breakdowns in care delivery, employing resources, education, and care coordination from the day of surgery until post-operative radiation treatment begins.
3138393|NCT03820544|Experimental|SEMS|Patients undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) with Self Expanding Metal Stents (SEMS) placement before standard of care surgical resection.
3138394|NCT03820544|Active Comparator|Standard of care surgical resection|Patients undergo standard of care surgical resection.
3138395|NCT03820024|Experimental|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
3138396|NCT03820024|No Intervention|No Messages|No feedback messages
3138397|NCT03807544|Experimental|TENS treatment arm|This study is a usability study, where all subjects will receive the same experimental treatment for their single visit.
3138398|NCT03809182|Experimental|Dexmedetomidine|After anesthesia induction, patients who were randomized to the Dexmedetomidine group received a bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
3138399|NCT03809182|Placebo Comparator|0.9% Sodium-chloride|After anesthesia induction, patients who were randomized to the Placebo group received a bolus and infusion of 0.9% normal saline at the same rate as the Dexmedetomidine group until the end of surgery. In the case of intraoperative increment of the blood pressure and/or heart rate more than 25% from its baseline, fentanyl 1ug/kg was administered.
3138400|NCT03816761|Experimental|Fast-acting insulin aspart, default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with default tmax setting (t65 = 65 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
3138401|NCT03816761|Experimental|Fast-acting insulin aspart, non-default tmax setting|Participants will receive fast-acting insulin aspart using the iLet™ with non-default tmax setting (t50 = 50 minutes, t40 = 40 minutes or t30 = 30 minutes) in two different treatment periods in a cross-over manner. There will be 3 different cohorts with 2 treatment periods in each cohort.
3138402|NCT03801044||PD patients|All PD patients treated in out unit were enrolled.
3138403|NCT03805672|Active Comparator|Low Dose Enoxaparin|Subjects are randomized to receive or begin prophylactic dosing (30 mg BID) of enoxaparin for 6 weeks or until DVT resolution.
3138404|NCT03805672|Active Comparator|High Dose Enoxaparin|Subjects are randomized to begin therapeutic dosing (1 mg/kg body weight BID) of enoxaparin for 6 weeks or until DVT resolution.
3138405|NCT03808493|Experimental|Study 1, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
3138406|NCT03808493|Experimental|Study 1, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 1 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally without water under fasted condition, on Period 2 Day 1 in Study 1 (Day 9).
3138407|NCT03808493|Experimental|Study 2, TAK-438 OD + TAK-438|One TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
3138408|NCT03808493|Experimental|Study 2, TAK-438 + TAK-438 OD|One TAK-438 20 mg tablet, orally with water under fasted condition, on Period 1 Day 1 in Study 2 (Day 1), followed by a wash-out period (Days 2 to 8), followed by one TAK-438 OD 20 mg tablet, orally with water under fasted condition, on Period 2 Day 1 in Study 2 (Day 9).
3138409|NCT03815292|Experimental|MMH-MAP|Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
3138410|NCT03815292|Placebo Comparator|Placebo|Placebo for 24 weeks, according to the MMH-MAP dosing regimen.
3138411|NCT03812510|Experimental|A-101|Topical Solution
3138412|NCT03802994|Experimental|1.Aging RT|Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
3138413|NCT03802994|Active Comparator|2.Young RT|Renal transplant recipients between 35-45 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.
3138414|NCT03802994|Active Comparator|3.Healthy elderly|Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
3138415|NCT03802994|Active Comparator|4.Elderly DMII or HTN and normal renal function|Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)
3149887|NCT00188539|Experimental|Pre-treatment tumour oxygen measurements (under anesthesia)|
3149888|NCT00188578|Experimental|IMRT Gynecological Cancers|
3138416|NCT03802994|Experimental|5.Healthy young|Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.
3138417|NCT03810183|Experimental|QAW039 450 mg|QAW039 (fevipiprant) 450 mg once daily for 6 weeks administered orally as a tablet.
3138418|NCT03810183|Placebo Comparator|Placebo|Placebo once daily for 6 weeks administered orally as a tablet.
3138419|NCT03809910|Experimental|Prototype PTB (Gum line mode)|Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste
3138420|NCT03809910|Experimental|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype power toothbrush in Gum line mode with a fluoride toothpaste. Following this, participants will brush their teeth with prototype power toothbrush in 'Interdental' mode with a fluoride toothpaste."
3138421|NCT03809910|Sham Comparator|Reference MTB|Participants will brush their teeth with manual toothbrush and fluoride toothpaste.
3138422|NCT03809910|Active Comparator|Reference PTB|Participants will brush their teeth with reference power toothbrush and fluoride toothpaste.
3138423|NCT03806790|Experimental|LEO 90100 foam|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
3138424|NCT03806790|Active Comparator|Dovobet® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g
3138425|NCT03809611|Experimental|UNR844-Cl Ophthalmic Solution|1.5% UNR844-Cl ophthalmic solution for twice-daily dosing
3138426|NCT03809611|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution for twice-daily dosing
3138427|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® 25 mcg intramuscular 2 times with 4 weeks apart
3138428|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 25|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
3138429|NCT03807245|Experimental|GBS-NN/NN2 with Alhydrogel® 50|Intramuscular GBS-NN/NN2 with Alhydrogel® injection 50 mcg 2 times with 4 weeks apart
3138430|NCT03807245|Placebo Comparator|Placebo GBS-NN/NN2 with Alhydrogel® 50|Intramuscular injection with Alhydrogel® 2 times with 4 weeks apart
3138431|NCT03805971||patient aged more than 18 years admitted for thoracoscopy|Probe based confocal laser endomicroscopy (Mauna kea technologies) will be used, after intravenous fluorescein injection, for every patients admitted for medical thoracoscopy, to study the pleural cavity. Images will be compared with biopsies
3138432|NCT03802916|Experimental|Low dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 75 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
3138433|NCT03802916|Experimental|High dosage|Patients in this group will receive a total daily dosage of deferiprone DR tablets that is closer to 100 mg/kg/day. The total dosage will be divided into two equal parts, taken about 12 hours apart.
3138434|NCT03809039|Experimental|Single Ascending Dose: MT-6345 & Placebo|
3138435|NCT03809039|Experimental|Multiple Ascending Dose: MT-6345 & Placebo|
3138436|NCT03807700|Experimental|Experimental denture adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
3138437|NCT03807700|No Intervention|No adhesive|In this arm, participants will not use any denture adhesive.
3138438|NCT03804918|Experimental|Interventional group: All participants|Given access to a selected breaking bad news mobile learning resource (VitalTips application).
3138439|NCT03805386|Active Comparator|Standard of Care|Subjects will be prescribed the standard amount of opioids that are typically prescribed by our practice after surgery. Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
3138440|NCT03805386|Experimental|Patient Directed Care|Subject directed arm will be prescribed the number of opioids that the patient decides to be appropriate after discussion with the surgeon. This can be as low as 0 pills and as much as 30 pills as described in the standard care.
3138441|NCT03803475|Experimental|Ga-68 labeled PSMA-11 PET PSMA|The imaging agent (Ga-68 PSMA-11 or PSMA-HBED-CC) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET imaging. The injected dose will be 3 to 7 millicurie (mCi) +/- 10% of 68Ga-PSMA-11.
3138442|NCT03802227|Experimental|Group 1|NKTR-181 400 mg and oxycodone IR placebo
3138443|NCT03802227|Experimental|Group 2|Oxycodone IR 40 mg and NKTR-181 placebo
3138444|NCT03802864|Experimental|Liposomal Bupivacaine|Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
3138445|NCT03802864|Active Comparator|Standard Bupivacaine|Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.
3138446|NCT03801265|Active Comparator|Lumbar Plexus block|0.5% ropivacaine 100 mg (20 ml) will be injected
3138447|NCT03801265|Experimental|Quadratus Lumborum type 3 block|0.5% ropivacaine 100 mg (20 ml) will be injected
3138448|NCT03802344|Experimental|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
3138449|NCT03802344|Active Comparator|Cal/BDP combination|Calcipotriene/betamethasone (Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream. One application daily for 8 weeks
3138450|NCT03802344|Placebo Comparator|Vehicle|One application daily for 8 weeks
3138451|NCT03801928||Ulcerative Colitis|Group treated with Inflectra for Ulcerative Colitis
3138452|NCT03801928||Crohn's Disease|Group treated with Inflectra for Crohn's Disease
3138453|NCT03800173|Experimental|Galidesivir|Galidesivir IV infusion
3138454|NCT03800173|Placebo Comparator|placebo|Placebo IV infusion
3138455|NCT03799783|Experimental|Dexmedetomidine|2 mcg/Kg iv dexmedetomidine (this dose may be repeated up to 2 times) followed by 1-2 mcg/Kg/hour iv continuous infusion
3138456|NCT03800030|Experimental|Theta-gamma, Delta-beta, Sham|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Delta-beta tACS, then Sham tACS"
3138457|NCT03800030|Experimental|Theta-gamma, Sham, Delta-beta|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Theta-gamma tACS, then Sham tACS, then Delta-beta tACS"
3138458|NCT03800030|Experimental|Delta-beta, Theta-gamma, Sham tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Theta-gamma tACS, then Sham tACS"
3138459|NCT03800030|Experimental|Delta-beta, Sham, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Delta-beta tACS, then Sham tACS, then Theta-gamma tACS"
3138460|NCT03800030|Experimental|Sham, Delta-beta, Theta-gamma tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Delta-beta tACS, then Theta-gamma tACS"
3138461|NCT03800030|Experimental|Sham, Theta-gamma, Delta-beta tACS|"Every participant will receive Theta-gamma tACS, Delta-beta tACS, and Sham tACS on separate sessions during performance of a computerized task.~Sequence: Sham tACS, then Theta-gamma tACS, then Delta-beta tACS"
3138462|NCT03799211|Experimental|Motivational Interviewing|
3138463|NCT03799211|Active Comparator|Usual Care|
3138464|NCT03798717|No Intervention|Control|Participants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
3138465|NCT03798717|Experimental|Pre OGTT|Condition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
3138466|NCT03798717|Experimental|Post OGTT|Condition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
3138467|NCT03798483|Experimental|Individualized exercise|Participants after a lateral kneecap dislocation will be enrolled into an individualized exercise intervention supervised by a physiotherapist
3138468|NCT03798366|Experimental|GLPG1690 600 mg|Participants received GLPG1690 600 milligrams (mg), orally once daily for 24 weeks.
3138469|NCT03798366|Placebo Comparator|Placebo|Participants received GLPG1690 matching placebo, orally once daily for 24 weeks.
3138470|NCT03799952|Experimental|Intervention|Participants are offered to attend a 12-week exercise program, classes offered twice a week, each class 60 minutes in length.
3138471|NCT03799952|No Intervention|Control|"Participants are instructed to continue with their daily activities and their normal physical activity levels for 12-weeks."
3138472|NCT03797872|Active Comparator|Standard care|Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard NHS practice. Commonly Initial therapy will be with methotrexate alone unless this is contraindicated. In cases of non-response or intolerance to methotrexate, participants will have an alternative DMARD (sulfasalazine or leflunomide). In cases of failure of two DMARDs, treatment can be escalated to biologic therapy as per National Institute for Health and Clinical Excellence (NICE) recommendations. If the requisite disease activity is not met or if there are contraindications to biologics, alternative DMARD combinations will be used.
3188872|NCT00771576||A. Healthy Controls|subjects w/ predicted normal BCM (healthy, normalweight, nondiabetic individuals who have stimulated insulin and cpeptide levels within the normal range);
3138473|NCT03797872|Experimental|Local/IM steroid injections|Symptomatic therapy arm. The intervention will delay standard treatment with disease-modifying anti-rheumatic drugs (DMARDs) and use local injections of methylprednisolone or triamcinolone to affected joints instead. Oral non-steroidal anti-inflammatory drugs (NSAIDs) will also be allowed as concomitant medication. All active joints will be treated with injections. Injections can be either be given as an intra-articular injection or as an intra-muscular injection. If any joint requires more than 2 local injections of glucocorticoid within a 6 month period, then the patient is deemed to have failed symptomatic therapy and will be withdrawn from the treatment protocol and be treated as per usual care (in most cases with DMARD therapy).
3138474|NCT03799614|Experimental|Lower dose vibration|RMBand lower dose vibration
3138475|NCT03799614|Experimental|Higher dose vibration|RMBand higher dose vibration
3138476|NCT03799484|Other|Topical Anesthesia|2.5% Lidocaine/2.5% Prilocaine Cream will be applied to one side of the forehead and Petrolatum Ointment to the other prior to administration of Botulinum Toxin Type A Injection
3138477|NCT03799484|Other|Petrolatum|Petrolatum Ointment will be applied to one side of the forehead and 2.5% Lidocaine/2.5% Prilocaine Cream to the other side prior to administration of Botulinum Toxin Type A Injection
3138478|NCT03796728|Experimental|Juvéderm® VOLIFT™ with Lidocaine|Initial treatment with Juvéderm® VOLIFT™ with Lidocaine injectable gel to augment the lips on Day 1, with an optional touch-up treatment 14 days later, if applicable. Volume was determined by the Investigator not to exceed 3.0 milliliters (mL).
3138479|NCT03797144|Experimental|Fenestrated Screw System|
3138480|NCT03782571|Experimental|Test1/Test2/Control/Test3|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
3138481|NCT03782571|Experimental|Test2/Test3/Test1/Control|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
3138482|NCT03782571|Experimental|Test3/Control/Test2/Test1|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
3138483|NCT03782571|Experimental|Control/Test1/Test3/Test2|Subjects that are adapted soft contact lens wearers between the ages of 18-40 years of age will be randomly assigned to one of four sequences. Upon completion, each subject will have worn all three lens types and been assigned the bare eye condition in both eyes.
3138484|NCT03796260|Experimental|F1 to F06 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F1 (test formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F06 (reference formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
3138485|NCT03796260|Experimental|F06 to F1 Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib F06 (reference formulation) on Day 1 of Period 1 after a standardized meal. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib F1 (test formulation) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
3138486|NCT03796039|Experimental|Standing and Social Intervention|Participants be exposed to an additional 100 minutes of standing per week. Participants will do this by standing for 20 minutes Monday through Friday.
3138487|NCT03796039|No Intervention|Control Group|Control group will receive social visits, but no exposure to standing
3138488|NCT03783780|Experimental|INVSENSOR00031|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00031 sensor during motion and non-motion.
3138489|NCT03780959|Placebo Comparator|Etanercept/Placebo|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to receive placebo subcutaneous injection twice weekly for up to 4 months.
3138490|NCT03780959|Experimental|Etanercept/Etanercept|Participants received 0.4 mg/kg etanercept twice weekly for 90 days during Part 1. In Part 2 participants were randomized to continue receiving etanercept twice weekly for up to 4 additional months.
3138491|NCT03796182|Experimental|Sequence 1|Patients in sequence 1 will received treatment A (metformin) in Period 1 then complete at least 4 days of washout and continue to period 2 where treatment B (PF-04965842 + metformin) will be administered.
3138492|NCT03796182|Experimental|Sequence 2|Patients in Sequence 2 will start treatment B (PF-04965842 + metformin) then go through a washout period of at least 4 days and continue to Period 2 where treatment A (metformin) will be administered.
3138493|NCT03796013|Experimental|Form A to Form C Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
3138494|NCT03796013|Experimental|Form C to Form A Crossover|Participants first randomized to this arm will receive a single oral dose of entrectinib form C (test form) under fasted conditions on Day 1 of each Period. This dose will be followed by a minimum 14-day washout period, after which participants will receive a single oral dose of entrectinib form A (reference form) under fasted conditions on Day 1 of Period 2 (Periods 1 and 2 = 6 days).
3138495|NCT03796676|Placebo Comparator|Placebo|Placebo
3138496|NCT03796676|Experimental|PF-04965842 100 mg QD|active
3138497|NCT03796676|Experimental|PF-04965842 200 mg QD|active
3149889|NCT00188630|Active Comparator|N-Acetylcysteine|IV NAC as a 100mg/kg bolus at the start of the surgical procedure (prior to the initiation of CPB), followed by a 10 mg/kg/hr infusion until 4 hours after completion of surgery
3138498|NCT03795753|Experimental|F2S Communicator|The F2S Communication System is a communication aid for use with a noninvasive ventilation (NIV) mask covering at least the mouth. It is a two-component system consisting of (1) a disposable, single patient use patch and signal cable and (2) a reusable communicator with power cable.The non-invasive aid for patients receiving BPAP/CPAP therapy delivers communication between the patient and medical personnel.
3138499|NCT03795753|Sham Comparator|Non-functioning Communicator|Non-functioning study communication device is used.
3138500|NCT03792477|Experimental|Part 1: Treatment A|Single 200mg IM testosterone cypionate solution (Test formulation)
3138501|NCT03792477|Active Comparator|Part 1: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
3138502|NCT03792477|Experimental|Part 2: Treatment A|Single 200 mg IM testosterone cypionate solution (Test formulation)
3138503|NCT03792477|Active Comparator|Part 2: Treatment B|Single 200 mg IM testosterone cypionate solution (Reference formulation)
3138504|NCT03783962|Experimental|Active Intervention - Cooking|Twelve cooking classes will be run every other week after the in-person weight loss meetings. These lessons will be patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for individuals specifically interested in weight loss. Classes will begin with a brief lecture on the day's topic, followed by a laboratory session. Participants work in teams of two in the Nutrition and Food Sciences (NFS) foods lab to actively practice skills and cook a meal. Subjects will receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. Classes will be taught by a chef trained in the pedagogy by Dr. Trubek and participants will have the opportunity to sample the food they prepared at the end of class.
3138505|NCT03783962|Active Comparator|Demonstrations - Cooking|"The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All participants will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group."
3138506|NCT03782272|Experimental|AA-ORS|Those receiving enterade oral re-hydration solution with amino acids
3138507|NCT03782272|Placebo Comparator|Placebo|Those receiving placebo solution without amino acids or rehydration salts
3138508|NCT03779724|Experimental|isokinetic exercise|The isokinetic dynamometer (Biodex Multijoint Pro 3) was used for isokinetic exercises. The isokinetic exercise program was implemented over eight weeks, twice a week on non-consecutive days under the supervision of a doctor. The number of repetitions undertaken by the patients over the program were as follows: first week 5 at 60°/s and 10 at 180°/s, second week 10 at 60°/s and 15 at 180°/s, third week 15 at 60°/s and 20 at 180°/s, fourth week 20 at 60°/s and 30 at 180°/s, and in the last four weeks 20 at 60°/s and 40 at 180°/s angular velocities. Each block of 10 repetitions were performed as a set.
3138509|NCT03779724|Active Comparator|home exercise|The patients undertook lower extremity strengthening and balance exercises three times a week for eight weeks without supervision. They started with three repetitions, which was gradually increased to 10-15. The patients were called two times a week to inquire about exercise continuity and encouraged to undertake the recommended exercises.
3138510|NCT03775915|Experimental|Real Neurofeedback|3 sessions of Real Neurofeedback over 1 week
3138511|NCT03775915|Sham Comparator|Sham Neurofeedback|3 sessions of Sham Neurofeedback over 1 week
3138512|NCT03794752|Other|Vision Aided by a Head Mounted Device|A Head-Mounted Visual Enhancement Device developed by Evergaze Technology LLC has designed an electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation.
3138513|NCT03794024||Dorsal Column Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Nuvectra Algovita Dorsal Column Spinal Cord Stimulator
3138514|NCT03794024||Dorsal Root Ganglion Stimulation|Subjects with Complex Regional Pain Syndrome receiving implant with the Axium Neurostimulator System
3138515|NCT03793751|Experimental|DEX Group|Receiving Dexmedetomidine injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
3138516|NCT03793751|Placebo Comparator|CONTROL Group|The Control Group will receive an equal volume placebo infusion of normal saline.
3138517|NCT03793556|Experimental|GERDOFF® + omeprazole|"GERDOFF® (tablets) was orally administered 3 times per day after meals; omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).~Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days)."
3138518|NCT03793556|Active Comparator|Omeprazole|Omeprazole was orally administered once a day before breakfast (2 capsules). The treatment lasted 6 weeks (+/- 2 days).
3138519|NCT03785548||Mirror group|This group of patients agree to have the mirror pelvic exam, and they will undergo routine pelvic examination by a physician with the usage of a mirror in the room.
3138520|NCT03785548||No mirror group|This group of patients decline a mirror, and they will undergo the standard pelvic examination.
3138521|NCT03793010|Experimental|FX006|FX006 32mg
3138522|NCT03793010|Placebo Comparator|Normal Saline|Normal Saline
3138523|NCT03782701|Active Comparator|Lumify Eye Drop|Participants will be randomized to receive a single drop of Lumify to either the left or right eye.
3138524|NCT03782701|Active Comparator|Saline Solution Eye Drop|Participants will be randomized to receive a single drop of sterile balanced saline solution to either the left or right eye.
3138525|NCT03773133|Experimental|Treatment|i.v. administrations of up to three radioactivity levels of Satoreotide tetraxetan.
3138526|NCT03792737|Experimental|Investigational group 1|Investigational group 1: Use the study device Spiral PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and MONOCRYL Plus for continuous subcuticular suture.
3138527|NCT03792737|Experimental|Investigational group 2|Investigational group 2: Use PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the study device Spiral MONOCRYL Plus for continuous subcuticular suture.
3138528|NCT03792737|Active Comparator|Control group|Control group: Use the control device PDS Plus for continuous suture of the ribbon muscles, VICRYL Plus for interrupted suture of the platysma, and the control device MONOCRYL Plus continuous subcuticular suture.
3149890|NCT00188630|Placebo Comparator|Placebo|The control arm will instead receive placebo (5% dextrose solution), both as a bolus and infusion.
3149891|NCT00188708|Experimental|hypoxia measurement|Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
3138529|NCT03792672|Experimental|TAK-653 6 mg + TAK-653 0.5 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 6 milligram (mg) high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 milligram per kilogram (mg/kg), intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3138530|NCT03792672|Experimental|TAK-653 6 mg + Placebo + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3138531|NCT03792672|Experimental|TAK-653 0.5 mg + TAK-653 6 mg + Placebo + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3149892|NCT00188721||1|Women with confirmed unilateral breast carcinoma or ductal carcinoma in situ (DCIS)
3149893|NCT00188721||2|Women without radiological suspicious lesions, matched to cases by age (± 2.5 years), date of screening mammogram, and screening center.
3138532|NCT03792672|Experimental|TAK-653 0.5 mg + Placebo + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3149894|NCT00188825|Experimental|basiliximab|
3149895|NCT00188825|Placebo Comparator|placebo|
3138533|NCT03792672|Experimental|Placebo + TAK-653 0.5 mg + TAK-653 6 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3138534|NCT03792672|Experimental|Placebo + TAK-653 6 mg + TAK-653 0.5 mg + Ketamine 0.5 mg/kg|TAK-653 placebo-matching tablets, orally, once on Day 1 of Treatment Period 1, followed by TAK-653 6 mg high dose tablets, orally, once on Day 1 of Treatment Period 2, further followed by TAK-653 0.5 mg low dose tablets, orally, once on Day 1 of Treatment Period 3, followed by Ketamine 0.5 mg/kg, intravenous infusion, once on Day 1 of Treatment Period 4. A washout of 10 to 15 days will be maintained between each treatment period.
3138535|NCT03786744|Experimental|ASD CB-MNC injection.|ASD CB-MNC injection from different donors and standard therapy.
3138536|NCT03786744|Other|Standard therapy.|Patients with standard therapy as control group.
3138537|NCT03782181|Active Comparator|Whole body vibration plat|An arm type in which a group of patients with fibromyalgia receives an intervention based on the use of a whole body vibration platform, considered to be effective by clinical evidence.
3138538|NCT03782181|No Intervention|Control group|No intervention arm
3138539|NCT03792191|Experimental|Ultrasonography|Preprocedural lumbar spinal ultrasonography and skin marking. Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
3138540|NCT03792191|Active Comparator|Palpation|Sham ultrasound procedure. Conventional landmark palpation and skin marking.Spinal anesthesia will be administered with injection of intrathecal bupivacaine and intrathecal fentanyl.
3138541|NCT03791489|Experimental|Active Treatment|Cryotherapy of the posterior nasal nerve using the ClariFix device
3138542|NCT03790865|Experimental|Low-Dose Livoletide|Daily subcutaneous injection of ~ 60 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
3138543|NCT03790865|Experimental|High-Dose Livoletide|Daily subcutaneous injection of ~120 mcg/kg for 3 month double-blind core period and 9 month open label extension period.
3138544|NCT03790865|Placebo Comparator|Placebo|Daily subcutaneous injection of 0.9% NaCl for the 3 month double-blind core period and then low-dose or high-dose livoletide for 9 month open label extension period.
3138545|NCT03784300|Active Comparator|50 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.
3138546|NCT03784300|Placebo Comparator|50 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.
3138547|NCT03784300|Active Comparator|100 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.
3138548|NCT03784300|Placebo Comparator|100 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.
3138549|NCT03784300|Active Comparator|200 mg PTI-125|Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.
3138550|NCT03784300|Placebo Comparator|200 mg PTI-125 Placebo|Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.
3138551|NCT03790878|Experimental|Mindful Breathing|Participants receive training in a mindful breathing skill to regulate their emotional distress during a stressor task. They will then receive one week of reminders to use this skill, delivered through their mobile phones.
3138552|NCT03790878|Active Comparator|Habituation|Participants receive an exposure/habituation intervention to regulate their emotional distress during a stressor task. They will then receive one week of reminders, delivered through their mobile phones.
3138553|NCT03790878|Placebo Comparator|Control|Participants complete the stressor task with no emotion regulation training. Similar to the other conditions, they will then receive one week of reminders, delivered through their mobile phones to test for placebo effects.
3138554|NCT03789474|No Intervention|Group A|No intervention was done ,served as a control group.
3138555|NCT03789474|Experimental|Group B|Intervention:peristaltic pneumatic compression device was placed on the legs of the patient and was active. HUNTLEIGH FLOWTRON ACS900 calf length device was used.
3149896|NCT00188890||1|prior occupational exposure at least 20 years ago to ASBESTOS and / or documented pleural plaques on a chest x-ray Must be 30 years of age or older. NO prior cancers, except non-melanic skin cancers
3149897|NCT00188942|Active Comparator|Fluoxetine + Olanzapine|
3149898|NCT00189007|Experimental|Allopurinol|500 mg allopurinol/ 50 mL water for injection intravenously
3149899|NCT00189007|Placebo Comparator|Placebo|500 mg mannitol/50 mL water for injection intravenously
3149900|NCT00189020|Experimental|2-dose|PCV7 at age 2 and 4 months
3149901|NCT00189020|Experimental|2+1-dose|PCV7 at age 2, 4 and 11 months
3149902|NCT00189020|No Intervention|Control|Control group
3149903|NCT00189163|Active Comparator|Pioglitazone|30 mg, taken orally, once per day
3149904|NCT00189163|Placebo Comparator|Placebo|Sugar pill, taken orally, once a day
3149905|NCT00189176|Experimental|Tetrathiomolybdate|
3149906|NCT00189254||Imiquimod 5% cream|No investigational treatments were given during this study.
3149907|NCT00189280|Experimental|imiqimod 5% cream|
3149908|NCT00189293|Experimental|1|Imiquimod 5% cream
3149909|NCT00189293|Other|2|vehicle cream
3149910|NCT00189514|Experimental|1|
3149911|NCT00189514|Experimental|2|
3149912|NCT00189514|Experimental|3|
3149913|NCT00189514|Placebo Comparator|4|
3149914|NCT00189527|Experimental|respiratory support|a mode of ventilation in comparison
3149915|NCT00189527|Active Comparator|Assist Control|an other mode of ventilation in comparison
3149916|NCT00189553|Active Comparator|Standard|Paclitaxel-Carboplatin
3149917|NCT00189553|Experimental|Experimental|Caelyx-Carboplatin
3149918|NCT00189592|Experimental|A|Percutaneous Fasciotomy
3149919|NCT00189592|Active Comparator|2|Standard Fasciotomy
3149920|NCT00189605|Active Comparator|1|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)
3149921|NCT00189605|Experimental|2|Percutaneous Disc Decompression of the lumbar level which is secondary to radicular pain
3149922|NCT00189618|Placebo Comparator|1|
3138556|NCT03789175|Other|Nicotinamide riboside (NR) in Li-Fraumeni syndrome|Nicotinamide riboside (NR) to be initiated at week 0 at dose of 250 mg twice a day. At Week 1, NR will be titrated to 500 mg twice a day. At Week 6, NR will be titrated to 750 mg twice a day. At Week 7, NR will be titrated to 1000 mg twice a day or as tolerated until end of week 12. At week 12, if participant responds to primary endpoint, participant will washout of NR at week 18 then restart NR at week 24 until week 30. If there is not response to NR treatment at week 12, the participant may continue taking NR at a tolerated dose until week 24 and the primary endpoint will be re-measured. If participant has a positive response to NR treatment at week 24, then the participant will washout of NR until week 30, at which time the primary endpoint will be re-measured to ensure return to baseline. If there is no response to continued NR treatment at week 24, the study will be ended.
3149923|NCT00189618|Active Comparator|2|
3149924|NCT00189709|Experimental|1|
3182149|NCT00700050||CF Females|CF females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
3182150|NCT00700050||Non-CF Females|Non-CF control females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
3182151|NCT00700050||CF Males|CF males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
3182152|NCT00700050||Non-CF males|Non-CF control males, 14 - 28 years old. No intervention is being tested. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
3138557|NCT03787615|Other|The sipIT tools|The wrist-worn sensors used to detect a drinking event (FitBit Versa with custom algorithm), an H2OPal connected water bottle and fluid consumption monitoring mobile applications.
3138558|NCT03786718|Experimental|Intervention|Patients have access to a patient web portal with the Patient-facing Diabetes Dashboard activated.
3138559|NCT03784963|Experimental|Primary Prevention Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
3138560|NCT03784963|Placebo Comparator|Primary Prevention Non-Intervention|In patients with CF-LVAD who have not had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
3138561|NCT03784963|Experimental|Secondary Prevention Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to intervention will receive 4 grams of Nature Made Ultra Omega-3 Fish Oil once daily for 1 year along with standard of care.
3138562|NCT03784963|Placebo Comparator|Secondary Prevention Non-Intervention|In patients with CF-LVAD who have had a gastrointestinal bleed, patients randomized to placebo will receive no fish oil and only standard of care.
3149925|NCT00189709|Active Comparator|2|
3149926|NCT00189826|Active Comparator|1|
3138563|NCT03771274|Experimental|Tecnis ZLB00 & Symfony IOL|The Tecnis multifocal ZLB00 and the Symfony IOLs are presbyopia correcting lenses designed to improve the vision at distance, intermediate and near reducing the need for glasses in patients undergoing cataract surgery.
3138564|NCT03787472|Experimental|Test/Control|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into one the sequence (Test/Control).
3149927|NCT00189826|Experimental|2|
3149928|NCT00189839|Active Comparator|1|
3149929|NCT00189839|Experimental|2|
3138565|NCT03787472|Experimental|Control/Test|Hyperopic subjects that are habitual soft contact lens wearers and have presbyopia will be randomized into the sequence (Control/Test).
3138566|NCT03787212|Experimental|MiBo ThermoFlo / Bruder mask|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
3138567|NCT03787212|Experimental|Bruder Mask / MiBo ThermoFlo|Subjects between the ages of 18 to 80 years will be randomly assigned to 1 of 2 treatment sequences in a contralateral fashion.
3138568|NCT03784001|Active Comparator|Gratitude + No Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks.
3138569|NCT03784001|Experimental|Gratitude + Expectations|Participants will type online lists of up to five items they are grateful for, every two days for two weeks. They will also be told a benefit of gratitude each time they write an online gratitude list.
3138570|NCT03784001|Active Comparator|Events Control|Participants will type online lists of up to five events from their day, every two day for two weeks.
3138571|NCT03784898|Other|Participants Diagnosed With ITP|Participants with RMS who developed ITP after Lemtrada treatment were included in this study and provided blood samples for future genetic testing and biomarker analysis.
3149930|NCT00189852|Experimental|Docobo|telemonitoring at home system for heart failure
3182153|NCT00700076|Active Comparator|1|
3138572|NCT03783702|Experimental|Experimental group|Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.
3138573|NCT03783702|Active Comparator|Control group|Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).
3138574|NCT03781479|Experimental|Amifampridine Phosphate - Placebo|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
3182154|NCT00700076|Placebo Comparator|2|
3182155|NCT00700089|Experimental|A|The concept is to support and guide the person shortly after the in-hospital treatment for self-injury through a recommended follow-up or after treatment based on assertive principles. The intervention is an indicated prevention strategy targeting people with suicide attempts and deliberate self-harm as a high-risk group. They will be offered 8-20 assertive outreach contacts. The outreach contacts will be home visits focusing on providing support and motivating patients to comply with follow-up treatment.
3182156|NCT00700089|Placebo Comparator|B|Standard treatment consists of referral to a range of different treatment modalities depending on the diagnosis and clinical and social condition of the patient. In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
3182157|NCT00700128|Experimental|Group 2|Frovatriptan or placebo given in a certain sequence depending on what group that the woman are randomized to.
3182158|NCT00700128|Experimental|Group1|Group I will receive in a different sequence either frovatriptan 2.5 mg or placebo bid starting the last day of taking OC and continuing during the hormone free interval (HFI) of 4 days.
3182159|NCT00700154|Experimental|Insulin infusion (aspart)|
3182160|NCT00700154|No Intervention|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
3182161|NCT00700167|Experimental|1|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months.~The vaccines will be given during an outpatient visit. If for some reason, you happen to be in the hospital, you can still receive the vaccines. These visits should take no longer than 15-30 minutes."
3182162|NCT00700193|Other|Group A|Equal to or greater 6 months to less than 3 years old
3182163|NCT00700193|Other|Group B|Equal to or greater 3 years to less than 9 years old
3138575|NCT03781479|Experimental|Placebo - Amifampridine Phosphate|Oral tablets, 30 to 80 mg per day in divided doses 3 to 4 times a day for 4 weeks
3138576|NCT03781037|Experimental|GIVE module|The GIVE module consists of one 50-minute treatment session and a second partial session (15-20 minutes) embedded within a larger cognitive behavioral treatment (CBT) protocol for anxiety or depression. The GIVE module uses cognitive behavioral principles to target youth's beliefs that they are a burden or drain on others.
3138577|NCT03784079|Experimental|Part 1: GSK3640254 10 mg|Participants will receive GSK3640254 10 milligram (mg), capsules, orally for 10 days.
3138578|NCT03784079|Experimental|Part 1: GSK3640254 200 mg|Participants will receive GSK3640254 200 mg, capsules, orally for 10 days.
3138579|NCT03784079|Placebo Comparator|Part 1: Placebo|Participants will receive placebo capsules, orally for 10 days.
3138580|NCT03784079|Experimental|Part 2: GSK3640254 40 mg|Participants will receive GSK3640254 40 mg, capsules, orally for 7 days.
3138581|NCT03784079|Experimental|Part 2: GSK3640254 80 mg|Participants will receive GSK3640254 80 mg, capsules, orally for 7 days.
3138582|NCT03784079|Experimental|Part 2: GSK3640254 140 mg|Participants will receive GSK3640254 140 mg, capsules, orally for 7 days.
3138583|NCT03784079|Placebo Comparator|Part 2: Placebo|Participants will receive placebo capsules, orally for 7 days.
3138584|NCT03783039|Experimental|SURGICEL Powder|SURGICEL Powder is an absorbable hemostat that is oxidized regenerated cellulose in a powder form
3138585|NCT03783039|Active Comparator|SURGICEL Original|SURGICEL Original is an bsorbable hemostat that is oxidized regenerated cellulose in a fabric form
3138586|NCT03783130|Experimental|Group 1: Trimer 4571 (100 mcg) IM with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
3138587|NCT03783130|Experimental|Group 2: Trimer 4571 (100 mcg) SC with alum|Trimer 4571 injections (100 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
3138588|NCT03783130|Experimental|Group 3: Trimer 4571 (500 mcg) IM with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered intramuscularly (IM) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
3138589|NCT03783130|Experimental|Group 4: Trimer 4571 (500 mcg) SC with alum|Trimer 4571 injections (500 mcg), with 500 mcg of alum field mixed, administered subcutaneously (SC) in a 1 mL volume by Needle/Syringe on Day 0, Week 8, and Week 20
3138590|NCT03776175|Placebo Comparator|Placebo|Placebo (PF 05221304) BID Placebo (PF 06865571) BID
3138591|NCT03776175|Experimental|PF-05221304 Monotherapy|15 mg PF-05221304 BID Placebo (PF-06865571) BID
3138592|NCT03776175|Experimental|PF-06865571 Monotherapy|Placebo (PF-05221304) BID 300 mg PF-06865571 BID
3138593|NCT03776175|Experimental|PF-05221304 and PF-06865571 Combination|15 mg PF-05221304 BID 300 mg PF-06865571 BID
3138594|NCT03771963|Experimental|Tetravalent Dengue Vaccine (TDV)|TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose).
3138595|NCT03771352|Other|RxSight RxLAL IOL|Eligible patients will be implanted with the RxSight RxLAL intraocular lens (IOL)
3138596|NCT03773796|Other|Treatment Group|Assessment of long-term efficacy and safety of nabilone 0.25 mg - 2 mg
3138597|NCT03782233|Experimental|deep neuromuscular blockade group (Group D)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive deep neuromuscular blockade (post-tetanic count = 1-2) using high dose rocuronium.
3138598|NCT03782233|Other|moderate neuromuscular blockade group (Group M)|Patients undergoing elective laparoscopic surgery for gastrectomy will be randomized to receive moderate neuromuscular blockade (train-of-four count = 1-2) using moderate dose rocuronium.
3138599|NCT03781726|Experimental|Treatment with glecaprevir/pibrentasvir Fixed Dose Combination|8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir
3138600|NCT03781375|Placebo Comparator|Methotrexate + Placebo|Participants received placebo subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
3138601|NCT03781375|Experimental|Methotrexate + Etanercept|Participants received 0.4 mg/kg etanercept subcutaneous injections twice weekly and methotrexate once a week at the same dose as prior to study entry for 6 months. After month 6 participants received open-label 0.4 mg/kg etanercept twice weekly plus methotrexate for an additional 6 months.
3138602|NCT03781336|Experimental|Mindfulness-based self-care|Mindfulness-based self-care (5 weeks)
3138603|NCT03781336|No Intervention|Life as usual control|Life as usual control (5 weeks)
3138604|NCT03780400|Experimental|Osteoarthritis Physical Activity Care Pathway|4 month physical activity (PA) counseling intervention
3138605|NCT03779997|Experimental|Video-based DOT Application|
3138606|NCT03779997|No Intervention|Treatment as Usual (TAU)|
3138607|NCT03779503|Active Comparator|midafilcon A|Subjects will be randomized to wear midafilcon A 1 day for one week of daily wear during the study.
3138608|NCT03779503|Active Comparator|somofilcon A|Subjects will be randomized to wear somofilcon A 1 day for one week of daily wear during the study.
3138609|NCT03780010|Experimental|TRC105 + B + P + C|TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
3149931|NCT00189852|No Intervention|Control|No telemonitoring system in place
3138610|NCT03778190|Experimental|Magnet|The physician will attempt to remove the corneal foreign body using an eye magnet for these patients.
3138611|NCT03777059|Placebo Comparator|Placebo|Placebo-matching atogepant tablets orally once daily for 12 weeks.
3138612|NCT03777059|Experimental|Atogepant 10 mg|Atogepant 10 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
3138613|NCT03777059|Experimental|Atogepant 30 mg|Atogepant 30 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
3138614|NCT03777059|Experimental|Atogepant 60 mg|Atogepant 60 mg tablet orally once daily and placebo-matching atogepant tablets orally once daily for 12 weeks.
3138615|NCT03772522|Experimental|Immediate dk Leadership Intervention|"Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm."
3138616|NCT03772522|Placebo Comparator|Delayed dk Leadership Intervention|"Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses."
3138617|NCT03772327|Experimental|Routine counseling + AdhereTech bottle|"Participants will receive routine medication adherence counseling and be given the AdhereTech smart bottle with reminders."
3138618|NCT03772327|Active Comparator|Routine counseling|Participants will receive routine medication adherence counseling.
3138619|NCT03777865|Experimental|13vPnC provided as a 0.5-mL dose in a prefilled syringe|All subjects receive a single dose (0.5mL) of 13vPnC
3138620|NCT03774576|Experimental|RO7017773|Single dose of RO7017773
3138621|NCT03774576|Experimental|RO7017773 and Itraconazole|Single dose of RO7017773 and multiple doses of itraconazole
3138622|NCT03776539|Experimental|ELX-02|Drug: ELX-02
3138623|NCT03772041|Experimental|OPC-61815 injection 16 mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
3149932|NCT00189878|Active Comparator|1 methotrexate|patient to receive methotrexate
3149933|NCT00189878|Placebo Comparator|2 Placebo|given placebo capsules
3138624|NCT03772041|Active Comparator|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
3138625|NCT03775681|Experimental|Device feasibility (Laryngeal Mask Airway, ERCP)|Patients wear Laryngeal Mask Airway after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.
3138626|NCT03774823|Experimental|Freeze Plus|Subjects in this arm will receive treatment using RF and PEMF
3138627|NCT03774823|Experimental|Ultrasound|Subjects in this arm will receive treatment using ultrasound
3138628|NCT03774745|Experimental|Progesterone|"Micronized progesterone 200mg oral capsules starting 24 hours after mifepristone 200mg ingestion (day 1).~Progesterone treatment days 2-4: two capsules twice daily orally. Progesterone treatment days 5-15, 16 or 17: two capsules once daily orally."
3138629|NCT03774745|Placebo Comparator|Placebo oral capsule|Placebo capsules starting 24 hours after mifepristone 200mg ingestion (day 1). Placebo treatment days 2-4: two capsules twice daily orally. Placebo treatment days 5-15, 16 or 17: two capsules once daily orally.
3138630|NCT03774433|Experimental|Laddr|All participants in the study will be invited to use Laddr, described in the intervention section.
3138631|NCT03771560|Experimental|Open-label|In this open-label trial, all subjects will receive the twice daily dose of folinic acid. Folinic acid will be delivered in pill form at a weight-based dose.
3138632|NCT03770091|Experimental|Foam and Compression Wrap|Patients will use Theraworx foam and a compression wrap
3138633|NCT03770091|Placebo Comparator|Placebo Foam and Compression Wrap|Patients will use placebo foam and a compression wrap
3138634|NCT03770091|Experimental|Foam alone|Patients will use Theraworx foam without compression wrap
3138635|NCT03769896|Active Comparator|Treatment Group|Nabilone 0.25 mg
3138636|NCT03769896|Placebo Comparator|Placebo Group|Placebo (corn starch)
3138637|NCT03769649|Experimental|Treatment arm|Subjects receive CelluTite treatment followed by Morpheus8 treatment
3138638|NCT03769207|Other|Ambulatory ECG|
3138639|NCT03769194|Active Comparator|VLA15 low dose|VLA15 low dose with Alum.
3138640|NCT03769194|Active Comparator|VLA15 medium dose|VLA15 medium dose with Alum.
3138641|NCT03769194|Active Comparator|VLA15 high dose|VLA15 high dose with Alum.
3138642|NCT03769194|Placebo Comparator|Placebo|
3138643|NCT03768856|Experimental|Temporally Feathered Radiation Therapy (TFRT)|"Temporally feathered radiation therapy is designed for targets within close proximity to multiple organs at risk. The foundation of this planning technique is the rotation of radiation dose to the nearby organs at risk on a daily basis, and hence the term feathering."
3149934|NCT00189917|Experimental|GP 1: healthy, no AD|Healthy subjects without any history of, or current signs and symptoms of atopic disease, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
3149935|NCT00189917|Experimental|GP2: prev. allerg. rhinitis|Subjects having documentation of at least one allergic rhinitis event during the previous year, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
3149936|NCT00189917|Experimental|GP3: history of AD|Subjects having documentation of a history of Atopic Dermatitis, receiving two doses IMVAMUNE (MVA-BN), subcutaneous..
3149937|NCT00189917|Experimental|GP4: active AD|Subjects presenting active Atopic Dermatitis and having an individual SCORAD value between 1 and 15, receiving two doses IMVAMUNE (MVA-BN), subcutaneous.
3149938|NCT00189930|Active Comparator|1|High dose
3138644|NCT03768726|Experimental|Ziprasidone|All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period. During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules. During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication.
3138645|NCT03768206|Experimental|PATH|PATH participants will receive Standard Outpatient Physical Therapy. In addition, physical therapist discuss physical activity & assist with goal setting during therapy sessions.
3138646|NCT03768206|Active Comparator|PATH-12|PATH-12 participants will receive Standard Outpatient Physical Therapy. In addition, PATH-12 participants will receive a Physical activity session (1-hour) focusing on physical activity and goal setting at 12 weeks after surgery.
3138647|NCT03767894|Experimental|MyHand orthosis|Subjects are trained to control and use the MyHand orthosis either with a shoulder harness or an electromyography (EMG) band. The MyHand orthosis aims to aid in fine motor skills such as picking up and holding items of varying shape, size and weight.
3138648|NCT03767738|Experimental|Intravitreal Aflibercept Injection (IAI)|Cohort 1 - Initial patients Cohort 2 - Additional patients
3138649|NCT03767153|Experimental|80 pin applicator|
3138650|NCT03767153|Active Comparator|160 pin applicator|
3138651|NCT03767062|Active Comparator|Topiramate|Topiramate will be introduced 25 mg/day b.i.d. for the first week and increased to 100 mg/day b.i.d. for the second week.
3149939|NCT00189930|Active Comparator|2|Low dose
3149940|NCT00189930|Placebo Comparator|3|
3149941|NCT00189956|Active Comparator|Group 1|healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
3138652|NCT03767062|Active Comparator|Greater Occipital +Supratrochlear Nerve Block|"Greater occipital nerve block (GONB) will be applied to medial of the occipital artery which localized at the medial one-third of the superior nuchal line between the occipital tubercle and mastoid process. GONB solution is prepared with 1 ml triamcinolone (40mg), 2 ml bupivacaine (10 mg) and 1 ml 0,9% sodium chloride (NaCl). The injection is performed using a 22 gauge (G) × 1¼ (0.7 × 40mm) injector when the patient is lying prone on the table. The scalp is cleaned with iodine before procedure and injections are performed bilaterally with a volume of 2 mL after negative aspiration for blood. Supratrochlear nerve block (STNB) is applied 1 cm medial to superior orbital fissure using a mixture of 8 mg bupivacaine and 1.4 ml 0,9% NaCl. STNB is performed bilaterally with a volume of 1.5 mL after negative aspiration for blood."
3138653|NCT03766646|Experimental|Speech|Participants were asked to read a standardised script aloud for 3 minutes whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
3149942|NCT00189956|Active Comparator|Group 2|healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous
2382843|NCT03689803|Active Comparator|Lipidemia|
3138654|NCT03766646|Active Comparator|Non-speech|Participants were asked to breathe in and out of their nose for 3 minutes, with a closed mouth, whilst receiving oxygen from the Optiflow device. At the end of 3 minutes End Tidal Oxygen was measured and recorded.
3138655|NCT03766373|Active Comparator|Drug: OP0201|
3138656|NCT03766373|Placebo Comparator|Drug: Placebo|
3138657|NCT03766165|Experimental|Intervention|Job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
3138658|NCT03766165|Other|Control|Job announcements only
3138659|NCT03765996|Active Comparator|Decongestive Physiotherapy|This group received Complex Decongestive Physiotherapy.
3138660|NCT03765996|Experimental|Decongestive Physiotherapy plus taping|This group received Complex Decongestive Physiotherapy, and also applying taping to anastomosis regions.
3138661|NCT03765762|Experimental|GRF6019|Subjects will receive intravenously 250 mL of GRF6019 each day for 5 consecutive days.
3138662|NCT03765762|Placebo Comparator|Placebo|Subjects will receive intravenously 250 mL of placebo each day for 5 consecutive days.
3138663|NCT03765502|Experimental|Nasal Glucagon Device (NG)|Empty NG device administered to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
3138664|NCT03765502|Active Comparator|Glucagon Emergency Kit (GEK)|Commercially available GEK delivered intramuscularly to a manikin during simulations of severe hypoglycaemia emergencies. No drug will be administered to humans.
3138665|NCT03765164|Active Comparator|Control|Control participants will care for the same set of CPV patients as the intervention arm, but will not have knowledge of or access to GlycoMark 1,5-AG test results. Investigators will compare control participants' clinical recommendations to those in the intervention arm.
3138666|NCT03765164|Experimental|Intervention|Intervention participants will care for the same set of CPV patients as the control arm, but will be educated on and given access to GlycoMark 1,5-AG test results. Investigators will compare intervention participants' clinical recommendations to those in the control arm.
3182164|NCT00700206|Experimental|1|Dose Schedule 1: Two weeks treatment with Telintra 3000 mg per day in two divided doses followed by one week with no treatment per three week cycle.
3182165|NCT00700206|Experimental|2|Dose Schedule 2: Three weeks treatment with Telintra 2000 mg per day in two divided doses followed by one week with no treatment per four week cycle.
3182166|NCT00700219||1|Women presenting in preterm labor with intact amniotic membranes
3182167|NCT00700232||1|Normal multiparous pregnant women without intrahepatic cholestasis of pregnancy (control group)
3138667|NCT03765138|Experimental|PE/Pramipexole|Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
3138668|NCT03764449|Experimental|Cohort 1|Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
3138669|NCT03764449|Experimental|Cohort 2|Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
3138670|NCT03763929|Experimental|Trans Sodium Crocetinate|Trans sodium crocetinate (TSC) will be administered intravenously as a bolus to subjects randomized to experimental drug. The bolus dose will consist of 0.25 mg/kg of TSC based on the estimated subject weight.
3138671|NCT03763929|Placebo Comparator|Placebo|The placebo consists of commercially available sterile saline. Placebo will be administered intravenously as a bolus to subjects randomized to placebo. The volume of sterile saline will be based on the estimated subject weight.
3138672|NCT03763747|Experimental|Scoreflex NC Scoring PTCA Catheter|Single arm with investigational Scoreflex NC Scoring PTCA catheters
3138673|NCT03763175|Active Comparator|SYN-010 21 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (21 mg PO QD). Study activities will be the same across all three arms.
3149943|NCT00189956|Active Comparator|Group 3|"healthy, vaccinia naïve subjects~1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous"
3149944|NCT00190060|Active Comparator|1|Transdermal testosterone gel (Testogel 1% )
3149945|NCT00190060|Placebo Comparator|2|Matched transdermal placebo gel
3149946|NCT00190164|Experimental|1|Macular hole surgery with alleviated positioning
3149947|NCT00190164|No Intervention|2|Macular hole surgery with no alleviated positioning
3149948|NCT00190190|Experimental|1|With Peeling of Limiting the Intern of the Retina
3138674|NCT03763175|Active Comparator|SYN-010 42 mg|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of lovastatin (42 mg PO QD). Study activities will be the same across all three arms.
3138675|NCT03763175|Placebo Comparator|Placebo|Enrolled subjects will be screened and randomized into the three study arms in a 1:1:1 ratio. 50 subjects with constipation-predominant irritable bowel syndrome (IBS-C) will be administered a 12-week course of placebo. Study activities will be the same across all three arms.
3138676|NCT03763058|Other|Music intervention|The music intervention is administered via a smartphone- (and computer-) based application called Music Care.
3138677|NCT03762993|Experimental|Healthy Adults|Participants will complete vocal rest and controlled phonation
2382844|NCT03689790|Active Comparator|liver function|liver function
3138678|NCT03762993|Experimental|Healthy Adults reporting Vocal Fatigue|Participants will complete vocal rest and controlled phonation
3138679|NCT03762681|Experimental|Part 1: Single Ascending Dose, HV|Healthy volunteers will be administered a single dose of RO7239958 or placebo subcutaneously (SC).
3138680|NCT03762681|Experimental|Part 2a: Multi-dose, CHB|Participants with chronic hepatitis B will be administered different dose levels of RO7239958 or placebo SC. Dosages will be determined from data collected from Part 1.
3138681|NCT03762681|Experimental|Part 2b: Multi-dose, CHB (Optional)|Additional study arm to open based on data collected from Part 2a. Participants with chronic hepatitis B will be administered different doses and frequencies of RO7239958 or placebo SC.
3138682|NCT03762668|Other|MDACL, then DACL|Modified delefilcon A contact lenses (MDACL) worn first, followed by delefilcon A contact lenses (DACL), as randomized. Each product worn bilaterally (in both eyes) for approximately 1 week in a daily disposable modality.
3138683|NCT03762668|Other|DACL, then MDACL|DACL worn first, followed by MDACL, as randomized. Each product worn bilaterally for approximately 1 week in a daily disposable modality.
3138684|NCT03762616|Experimental|Micro-Ultrasound Biopsy|
3138685|NCT03762616|Experimental|MRI Targeted Biopsy|
3149949|NCT00190190|Active Comparator|2|Traditional Procedure Without Peeling of Limiting
3149950|NCT00190203|Experimental|A|HEMICRANIECTOMY
3149951|NCT00190216|Experimental|A|
3149952|NCT00190229|Experimental|1|Cyclophosphamide
3138686|NCT03762213|Experimental|Oculus GO VR HMD, application Happy Place (© Mimerse)|"Oculus GO is a stand-alone, consumer-grade, virtual reality head-mounted display (HMD). The HMD is placed on the head of the user blocking off the surrounding environment. The visuals and audio are relayed through the HMD in a virtual space.Happy Place (© Mimerse) is a publicly available application with an explicit intent to be used for chronic pain patients. It has the critical elements of VR, namely immersion and interactivity.~Immersion: The scene is a serene lakeside campground with guided relaxation and soothing music. The application intends to promote positive effects such as calmness and feeling of wonder.~Interactivity: Happy Place uses an innovative 'gaze-based interaction' with the virtual world. Around 50 'gaze objects' are placed around the scene and gazing at them would trigger an event.~The entire duration of the experience will be kept at 10 minutes."
3138687|NCT03762213|Placebo Comparator|iPad, application Happy Place (© Mimerse)|An iPad with earphones (Apple Inc. Cupertino CA) will be used for controls. The participants in control group will watch the same content for the same duration on an iPad screen (flat version of Happy Place). This experience will be different from the intervention group in two ways: first, lack of an immersive environment, and second, lack of interactivity with the environment.
3138688|NCT03762200|Other|SURGICEL Powder - Single arm|Single arm clinical trial where all qualified subjects will be treated SURGICEL Powder
3138689|NCT03761368|Experimental|RIPC group|The RIPC group underwent Remote Ischemic Preconditioning.
3138690|NCT03761368|Sham Comparator|Control group|Patients from control group had sham Remote Ischemic Preconditioning.
3138691|NCT03761147|Experimental|Paula Method|
3138692|NCT03761147|No Intervention|Standard of Care|
3182168|NCT00700245|Active Comparator|EXO|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction),
3182169|NCT00700245|Active Comparator|DIO|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet)
3138693|NCT03760913|Experimental|OLP-1002: Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 μg, 3 μg, 6 μg, 12 μg, 20 μg, 40 μg, 80 μg, 160 μg
3182170|NCT00700245|Active Comparator|DEX|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
3182171|NCT00700284|Placebo Comparator|A|
3138694|NCT03760913|Experimental|OLP-1002: Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
3138695|NCT03760913|Placebo Comparator|Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
3138696|NCT03760913|Placebo Comparator|Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
3182172|NCT00700284|Experimental|B|
3138697|NCT03760796|Experimental|Corrie Health Digital Platform group|Receives the Corrie Health intervention plus the standard of care
3138698|NCT03760640|Experimental|LY900014|Participants received 100 units per milliliter (U/mL) of LY900014 administered via continuous subcutaneous insulin infusion (CSII) by the Medtronic MiniMed 670G insulin pump.
3138699|NCT03760640|Active Comparator|Insulin Lispro (Humalog)|Participants received 100 U/mL of Insulin lispro (Humalog) administered via CSII by the Medtronic MiniMed 670G insulin pump.
3138700|NCT03760510|Experimental|Adhesive Tape|Patients in adhesive tape arm had endotracheal tube secured with adhesive tape
3138701|NCT03760510|Experimental|Tube Fastener|Patients in the tube fastener arm had endotrachel tube secured with tube fastener
3138702|NCT03760250|Experimental|Imiquimod|5% Imiquimod cream once daily to keloid area 5-times a week for 6 weeks, starting 1-week prior to keloid excision
3138703|NCT03760068|Active Comparator|MYL-1601D Product (100 U/mL)|
3138704|NCT03760068|Active Comparator|FlexPen NovoLog® (100 U/mL)|
3138705|NCT03759600|Experimental|Niraparib 300 mg|Niraparib 300 milligrams (mg), capsules, orally, once daily on Days 1 - 28 of each 28-day treatment cycle up to 6 cycles till data cut-off: 01 July 2019.
3138706|NCT03759587|Experimental|Niraparib 300 mg|Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment Cycle (Up to 3 Cycles till data cut-off 17 March 2019).
3138707|NCT03759340|Experimental|ATI 502 0.46% Topical Solution|Subjects will apply ATI-502 Topical Solution, 0.46% twice-daily for 24 weeks followed by a 4-week post-treatment follow up period.
3138708|NCT03758716|Experimental|FB825|Only one arm in the study. The subjects are planned to be dosed by IV injection with experimental drug FB825. The other name of FB825 is FB825-15D11, or Anti-CemX.
3138709|NCT03758365|Experimental|MC2-01 Cream|Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
3138710|NCT03758365|Active Comparator|Clobetasol propionate 0.05% lotion|Single application of Clobetasol propionate 0.05%,
3138711|NCT03758365|Active Comparator|Betamethasone dipropionate 0.05% cream|Single application of Betamethasone dipropionate 0.05%,
3138712|NCT03758365|Active Comparator|Triamcinolone acetonide 0.1% cream|Single application of Triamcinolone acetonide 0.1%,
3138713|NCT03758365|Active Comparator|Hydrocortisone Butyrate 0.1% cream|Single application of Hydrocortisone Butyrate 0.1% Cream
3138714|NCT03758365|Active Comparator|Desonide 0.05% cream|Single application of Desonide 0.05%
3138715|NCT03758365|Placebo Comparator|Vehicle cream|Single application of Vehicle
3138716|NCT03758157||Temperature Measurement|Each subject will have his or her temperature measured by both the welloStationX Automated Non-Contact Thermometer and the Welch Allyn SureTemp Oral Thermometer.
3138717|NCT03757988|Experimental|Single Arm Experimental Walking Group|This is a pilot project with one single group that will be evaluated on the adherence to a walking protocol (Exercise Intervention- PACE-Life). Subjects will be walking two times a week under the supervision of the psychiatric clinic. In addition, subjects will be encouraged to add walking on their own on the days when subjects are not exercising under the supervision of the clinic. This pilot will be used to inform the final design of the subsequent randomized clinical trial that will be implemented following this pilot.
2382845|NCT03689777|Active Comparator|Glomerular Filtration Rate|
3138718|NCT03757312|Experimental|Fontan|Patients undergoing Fontan procedure to redirect blood flow from the lower body to the lungs.
3138719|NCT03757312|Active Comparator|Non-Fontan|Patients undergoing other cardiac surgeries requiring cardiopulmonary bypass.
3138720|NCT03757234|Experimental|Omadacycline 200 iv/200 iv|On Day 1, participants received omadacycline 200 milligrams intravenously (iv). On Days 2 through 7, participants continued to receive omadacycline 200 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
3138721|NCT03757234|Experimental|Omadacycline 200 iv/100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes.
3138722|NCT03757234|Experimental|Omadacycline 200 iv/300 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 300 milligrams per oral (po). All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
3138723|NCT03757234|Experimental|Omadacycline 200 iv/450 po or 100 iv|On Day 1, participants received omadacycline 200 milligrams iv. On Days 2 through 7, participants received omadacycline 100 milligrams iv or omadacycline 450 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
3149953|NCT00190242|Experimental|group1:3 administrations of Havrix|group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24
3138724|NCT03757234|Active Comparator|Levofloxacin 750 iv/750 po or iv|On Day 1, participants received levofloxacin 750 milligrams iv. On Days 2 through 7, participants received levofloxacin 750 milligrams iv or levofloxacin 750 milligrams po. All doses were administered once-per-day and iv doses were administered in 150 milliliters of normal saline as continuous infusions over 90 minutes. All oral doses were taken in a fasted state.
3138725|NCT03757039|Experimental|Multifocal Contact Lenses|Multifocal soft contact lenses according to the subject's prescription and fitted using the Alcon multifocal fitting guide. Lenses were worn bilaterally (in both eyes) for up to 3 hours, 1 day only.
3138726|NCT03757039|Active Comparator|PAL Spectacles|Progressive addition lens spectacles according to the subject's habitual prescription, with testing up to 3 hours, 1 day only.
3138727|NCT03756883|Experimental|Test|Fluticasone Propionate and Salmeterol Inhalation Powder, 100 mcg/50 mcg
3138728|NCT03756883|Active Comparator|Reference|ADVAIR DISKUS® 100/50 (fluticasone propionate and salmeterol) Inhalation Powder
3138729|NCT03756883|Placebo Comparator|Placebo|Placebo
3149954|NCT00190242|Active Comparator|group2: 2 administrations of Havrix|group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24
3149955|NCT00190268|Experimental|3,4-diaminopyridine|3,4-diaminopyridine
3149956|NCT00190294|Experimental|1|MIFEPRISTONE 200 mg and misoprostol 400 µg
3149957|NCT00190307|Experimental|1|Aspirin:KARDEGIC
3149958|NCT00190333|Active Comparator|A|
3149959|NCT00190372|Other|A|
3138730|NCT03756506|Active Comparator|Novel Microbicidal Liquid Polymer|"All pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge,tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris. Step 3: Apply product with Q-tip on clean dry wound around (extending approximately one inch around pin site) and on the pin. The Polymer will be applied daily while in the hospital and then at a minimum of at least three times a week until pin removal."
3149960|NCT00190385|Active Comparator|A|
3149961|NCT00190398|Experimental|1|Carotid angioplasty and stenting with cerebral protection
3149962|NCT00190411|Experimental|Treatment|Celiprolol
3149963|NCT00190424|No Intervention|control|
3149964|NCT00190424|Experimental|CpG-ODN|
3149965|NCT00190437|Experimental|1|Amoxicillin-clavulanic
3149966|NCT00190450|Experimental|1|Early Graft (Early G)
3149967|NCT00190450|Experimental|2|Late Graft (Late G)
3149968|NCT00190515|Active Comparator|1|5-FU/l-LV
3149969|NCT00190515|Experimental|2|UFT/LV
3149970|NCT00190528|Active Comparator|Surgery|
3149971|NCT00190528|Experimental|Chemotherapy + Surgery|
3149972|NCT00190541|Active Comparator|1|Procedure/Surgery: Mesorectal excision with lateral lymph node dissection
3149973|NCT00190541|Experimental|2|Procedure/Surgery: Mesorectal excision without lateral lymph node excision
3149974|NCT00190580|Experimental|1|
3149975|NCT00190580|Experimental|2|
3149976|NCT00191126|Other|A|
3149977|NCT00191126|Experimental|B|
3149978|NCT00191243|Experimental|A|
3149979|NCT00191243|Experimental|B|
3182173|NCT00700297|Active Comparator|Colchicine|Patients who received Colchicine and went on placebo after 4 months
3182174|NCT00700297|Placebo Comparator|Placebo|Patients who received placebo and went on Colchicine after 4 months
3182175|NCT00700323|Active Comparator|1|Patients receiving active product
3182176|NCT00700323|Placebo Comparator|2|Patients receiving placebo
3182177|NCT00700349|No Intervention|1|Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to continue receiving no loan.
3149980|NCT00191698|Experimental|A|Atomoxetine is administered at 1.2 mg/kg/day, PO for 8 weeks, followed by 1.2 or 2.4 mg/kg/day, PO for 4 weeks, open label administration can continue for up to one year
3149981|NCT00191698|Placebo Comparator|B|Placebo is administered by mouth, daily for 8 weeks. After 8 weeks, those randomized to placebo may be titrated to 1.2 mg/kg/day atomoxetine for the remainder of the study up to one year
3149982|NCT00192127|Active Comparator|1|FluMist
3149983|NCT00192127|Placebo Comparator|2|Placebo
3149984|NCT00192140|Active Comparator|1|FluMist
3149985|NCT00192179|Experimental|CAIV-T|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3149986|NCT00192179|Placebo Comparator|Placebo|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3149987|NCT00192218|Experimental|1|FluMist
3149988|NCT00192270|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|All subjects were scheduled to receive 2 doses of CAIV-T.The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3149989|NCT00192283|Experimental|1|CAIV-T
3149990|NCT00192283|Placebo Comparator|2|Placebo
3149991|NCT00192309|Experimental|Cold-adapted influenza vaccine (CAIVT)|A single intranasal dose of 10^7 fluorescent focus units.
3149992|NCT00192309|Active Comparator|Trivalent inactivated vaccine (TIV)|A single dose of commercially available Flushield was administered intramuscularly.
3149993|NCT00192309|Placebo Comparator|Placebo|The 0.2 mL administered intranasally.
3149994|NCT00192322|Experimental|CAIV-T 10^5|a single intranasal 0.2 mL dose of liquid CAIV-T 10^5 (approximately 0.1 mL into each nostril)
3149995|NCT00192322|Experimental|CAIVT 10^7|A single intranasal 0.2 mL dose of liquid CAIV-T 10^7 (approximately 0.1 mL into each nostril)
3149996|NCT00192322|Placebo Comparator|Placebo|A single intranasal 0.2 mL dose of placebo
3149997|NCT00192322|Active Comparator|Trivalent inactivated vaccine (TIV)|A single intramuscular injection of commercially available vaccine
3149998|NCT00192335|Active Comparator|1|CAIVT-The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
3149999|NCT00192335|Active Comparator|2|FluMist- The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
3150000|NCT00192413|Experimental|Cold-adapted influenza vaccine trivalent (CAIV-T)|A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
3150001|NCT00192413|Active Comparator|Trivalent Inactivated Vaccine (TIV)|A single dose was administered by intramuscular injection.
3150002|NCT00192465|Experimental|1|MEDI-524 (Numax-TM)
3150003|NCT00192465|Experimental|2|MEDI-524 (Numax-TM)
3150004|NCT00192465|Experimental|3|MEDI-524 (Numax-TM)
3150005|NCT00192465|Experimental|4|MEDI-524 (Numax-TM)
3150006|NCT00192465|Experimental|5|MEDI-524 (Numax-TM)
3150007|NCT00192478|Active Comparator|1|MEDI-524
3150008|NCT00192491|Active Comparator|2|FluMist
3150009|NCT00192491|Placebo Comparator|3|Placebo
3150010|NCT00192491|Active Comparator|1|FluMist with other solution
3150011|NCT00192517|Active Comparator|1|MEDI-522
3150012|NCT00192517|Placebo Comparator|2|Placebo
3150013|NCT00192543|Active Comparator|case|diet of fish and fruit addition compared to regular diet
3150014|NCT00192543|Placebo Comparator|control|regular diet
3150015|NCT00192569|Experimental|Treated|Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)
3150016|NCT00192569|No Intervention|Untreated|Subjects will be followed for natural history of newly acquired HCV
3150017|NCT00192595|Active Comparator|Arm 1:|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
3150018|NCT00192595|Experimental|Arm 2|Zidovudine (AZT), tenofovir (TDF), efavirenz (EFV)
3150019|NCT00192595|Experimental|Amr 3|Lamivudine (LAM), tenofovir (TDF), efavirenz (EFV)
3150020|NCT00192608|Experimental|saquinavir at baseline|patients receiving NRTIs + saquinavir + ritonavir 1000/100 mg BID at entry switch from 200 mg SQV capsules to 500 mg SQV tablets following PK at day 0. After PK at day 8 NRTIs ceased and regimen changed to ATV/SQV/RTV 300/1500/100 QD using 500 mg SQV formulation and continued to week 48
3150021|NCT00192608|Experimental|other boosted PI at baseline|Patients receiving NRTIs + PI/RTV randomised at baseline to receive ATV/SQVRTV 300/1500/100 QD using 500 mg SQV formulation or ATV/SQV/RTV 300/1600/100 QD using 200 mg formulation. Following PK at day 7, SQV formulation switched with second PK assessment at day 15. Patients then receive ATV/SQV/RTV 300/1500/100 QD to week 48.
3150022|NCT00192634|Active Comparator|1|Abacavir 600mg/Lamivudine 300mg
3150023|NCT00192634|Active Comparator|2|Tenofovir 300mg/emtricitabine 200mg
3150024|NCT00192699||Group 1: Cemented Bi-Metric femoral stem|Cemented Bi-Metric femoral stem
3138731|NCT03756506|No Intervention|Control group: no Novel Microbicidal Liquid Polymer|"The usual care of pin track sites will be followed as outlined belowAll pins and wire sites will be cleaned daily while hospitalized. Basic pin care will be performed once daily by hospital nursing staff prior to discharge. Following discharge from the hospital, the pin care protocol will be continued by research participant's caregiver.~Research participants will be instructed to notify the Principal Investigator if they observe any signs or symptoms of infection. These include redness around pin site, discharge, tenderness in the soft tissue, loosening of the pin, nausea, vomiting, fever or chills.~Research participants will be instructed that the approach to pin care should occur in a step-wise fashion. Step 1: Brush the pin sites with saline using an ordinary soft toothbrush or gauze with sterile gloves Step 2: If following Step 1, debris remains, use forceps (tweezers) to gently remove debris."
3138732|NCT03756285|Experimental|AZD4831|AZD4831 tablets taken orally for for 90 days.
3138733|NCT03756285|Placebo Comparator|Placebo|Placebo tablets taken orally for 90 days.
3138734|NCT03756129|Experimental|MIJ821 low dose weekly|Infusion. MIJ821 low dose weekly - 0.16 mg/kg
3138735|NCT03756129|Experimental|MIJ821 low dose bi-weekly|Infusion. MIJ821 low dose bi-weekly - 0.16 mg/kg
3138736|NCT03756129|Experimental|MIJ821 high dose weekly|Infusion. MIJ821 high dose weekly - 0.32 mg/kg
3138737|NCT03756129|Experimental|MIJ821 high dose bi-weekly|Infusion. MIJ821 high dose bi-weekly - 0.32 mg/kg
3138738|NCT03756129|Placebo Comparator|Placebo weekly|Infusion. Placebo weekly
3138739|NCT03756129|Active Comparator|Ketamine 0.5 mg/kg weekly|Infusion. Ketamine 0.5 mg/kg weekly
3138740|NCT03756038|Experimental|Drug: Oral Lorazepam (1mg)|Lorazepam (Ativan) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
3138741|NCT03756038|Placebo Comparator|Drug: Oral Placebo|
3138742|NCT03756012|Active Comparator|Low Pulse Width (<500 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths <500 μsec.
3138743|NCT03756012|Active Comparator|High Pulse Width (>1000 μsec)|Spinal Cord Stimulation System will be programmed to pulse widths >1000 μsec
3138744|NCT03755882|Experimental|TEST/CONTROL|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
3150025|NCT00193011|Experimental|1|Docetaxel
3150026|NCT00193011|Experimental|2|Cyclophosphamide + Methotrexate + 5-fluorouracil
3138745|NCT03755882|Experimental|CONTROL/TEST|Female subjects between the ages of 18 to 29 years who are habitual reusable soft cosmetic contact lens wearers will be randomized into one of two lens sequences.
3138746|NCT03755661|Experimental|Intervention|This intervention arm is a combined in-person text messaging intervention
3138747|NCT03755661|No Intervention|Assessment Only Control|The is the assessment only comparison condition
3138748|NCT03754582|Experimental|Perampanel|Participants with POS with or without secondarily generalized seizures or PGTC seizures will receive perampanel 8 to 12 milligram (mg), tablets, orally, once daily for 28 days (Day -28 to Day -1) in Pretreatment Phase and followed by 8 to 12 mg dose of perampanel as intravenous infusion for 30 minutes, once daily from Day 1 to Day 4 in Treatment Phase, and then again 8 to 12 mg, tablets, orally, once daily from Day 5 to Day 11 in Follow-up Phase as an adjunctive therapy, along with 1 to a maximum of 3 marketed concomitant antiepileptic drugs (AEDs).
3138749|NCT03754556||Women with IUD|Women with an intrauterine device (IUD) and electronic health records in the Kaiser Permanente Northern California (KPNC), Kaiser Permanente Southern California (KPSC), Kaiser Permanente Washington (KPWA) and the Regenstrief Institute (RI) databases.
3138750|NCT03753113|Experimental|Treatment group|The patients will be applied 1 mL of solutions(Herbal and Minoxidil) at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
3138751|NCT03753113|Active Comparator|Control group|The patients will be applied 1 mL of Minoxidil 5% solutions at morning and evening intervals to the thinning hair areas of the scalp for 36 weeks.
3138752|NCT03752567||Group study|Follow up of the patients for 12 months by the community pharmacist in the role of case manager and execution of the activities foreseen by the PAI (individual assistance plan) through telemedicine (ecg, fundus oculi, ankle arm index) and self analysis (glycated hemoglobin, lipid profile, uric acid microalbuminuria).
3138753|NCT03752528||Part A Cohort|Representative data set of participants from study RB-US-13-0003 or both studies RB-US-13-0003 and INDV-6000-301 who received at least 2 doses of SUBLOCADE 12-36 months prior. Part A consists of a single visit (Visit 1) for both screening and collection of blood and urine samples.
3138754|NCT03752528||Part B Cohort|Part A participants with a quantifiable (i.e. positive) result for buprenorphine and/or norbuprenorphine and a non-quantifiable (i.e. negative) result for naloxone continue in the study for two additional visits (Visits 2 and 3) which are conducted approximately 30 days apart during which blood and urine samples are collected.
3138755|NCT03752151|Experimental|MARVEL 2 Algorithm Monitor Mode, Then MARVEL 2 Adaptive Mode|Participants first received MARVEL 2 algorithm monitor mode which provides standard VVI pacing for approximately 20 minutes followed by MARVEL 2 algorithm adaptive mode for approximately 2 hours which provides VDD pacing.
3138756|NCT03751657|Experimental|Insulin 287|Participants will receive once weekly insulin 287 and once daily placebo in combination with metformin with or without dipeptidyl peptidase-4 inhibitors (DPP4i) during 26 weeks of treatment period.
3138757|NCT03751657|Active Comparator|Insulin glargine|Participants will receive once daily insulin glargine and once weekly placebo in combination with metformin with or without DPP4i during 26 weeks of treatment period.
3138758|NCT03751280|Experimental|PEAR-004|Eligible participants were able to access PEAR-004 (an investigational digital therapeutic) on a mobile device (iOS and Android based) as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
3138759|NCT03751280|Sham Comparator|Sham|Eligible participants were able to access a sham control downloaded on a mobile device (iOS and Android based) as needed to receive notifications prompting the participant to open the sham app, which displayed a prescription timer for the remaining duration of app availability.
3182178|NCT00700349|Experimental|2|"Individuals who were rejected from receiving a loan from a micro-lending organization were randomized to receive a second look, to be reconsidered for a loan by loan officers."
3182179|NCT00700388|Experimental|1|TPEP added to conventional manually assisted breathing techniques (MABT)
3182180|NCT00700388|Active Comparator|2|Manually assisted breathing techniques (MABT) alone
3182181|NCT00700414||Participants|Any participant who meets eligibility criteria and consents to participate in the trial.
3182182|NCT00700453|Active Comparator|Control 1 Group|Subjects randomized to the Control 1 group will abstain from playing any video games for the entire study participation.
3182183|NCT00700453|Active Comparator|VG1- Control 2 Group|Subjects randomized to the Control 2 group will play a selected violent video game for 60-120 minutes/day during week 2 of the study and will abstain from any video game play during week 3 of the study.
3182184|NCT00700453|Active Comparator|VG1- VG2 group|Subjects randomized for VG1-VG2 group will play 60-120 minutes/day of a violent video game during weeks 2 & 3 of study participation.
3138760|NCT03751020|Experimental|Expressive Writing (EW)|Expressive Writing (EW) prompts individuals to write about personally stressful events, potentially enabling cognitive processing of unresolved, psychological and physiological stressors.
3138761|NCT03751020|Experimental|Self-Affirmation (SA)|Self-Affirmation (SA) interventions prompt individuals to write advice to a (hypothetical) similarly stigmatized person regarding how best to cope with stigma-related stress. By affirming one's own stigmatized identity through the process of helping another similarly stigmatized person.
3138762|NCT03751020|Placebo Comparator|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days.
3138763|NCT03750955|Experimental|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where plaque induced gingivitis results from a cessation of oral hygiene in a sextant using a stent-induced biofilm overgrowth model.
3138764|NCT03750955|Active Comparator|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene (tooth brushing with fluoride toothpaste and flossing twice daily) is maintained.
3138765|NCT03750695|Experimental|Acute Resistance Exercise|One acute exercise session of 40 minutes of resistance exercise
3138766|NCT03750695|Experimental|Acute Aerobic Exercise|One acute session of 40 minutes of aerobic exercise
3138767|NCT03750695|Placebo Comparator|Acute Resting Session|One session of 40 minutes of quiet rest
3138768|NCT03748992|Experimental|gNO|Subjects will be receiving nitric oxide every week day for 3 weeks.
3138769|NCT03748979|Experimental|Cohort A1; TAK-925 (Dose Level A1)|TAK-925, Dose Level A, once daily for up to 7 days in healthy participants.
3138770|NCT03748979|Experimental|Cohort A2; TAK-925 (Dose Level A2)|TAK-925, Dose Level A2, once daily for up to 7 days in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138771|NCT03748979|Experimental|Cohort A3; TAK-925 (Dose Level A3)|TAK-925, Dose Level A3, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
2386368|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody naïve NSCLC|
3138772|NCT03748979|Experimental|Cohort A4; TAK-925 (Dose Level A4)|TAK-925, Dose Level A4, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138773|NCT03748979|Experimental|Cohort A5; TAK-925 (Dose Level A5)|TAK-925, Dose Level A5, once daily for up to 7 days in healthy participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138774|NCT03748979|Experimental|Cohort A6; TAK-925 (Dose Level A6)|TAK-925, Dose Level A6, once daily for up to 7 days in healthy elderly participants. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3182185|NCT00700453|Active Comparator|VG1-CT group|Subjects randomized to the VG1-CT group will play 60-120 minutes of a selected violent video game during week 2 of the study and play a selected computerized cognitive training program for 60-120 minutes/day during week 3 of the study.
3182186|NCT00700466||1|Patients with hypertension and/or tachycardia prior to induction of anesthesia requiring i.v. beta-blockade for treatment of raised hemodynamic
3182187|NCT00700466||2|Patients with normal hemodynamic values prior to induction of anesthesia not requiring treatment
3138775|NCT03748979|Placebo Comparator|Part A (Cohorts A1-A6); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in healthy participants.
3138776|NCT03748979|Experimental|Cohort B1; TAK-925 (Dose Level B1)|TAK-925, Dose Level B1, once daily for up to 7 days in participants with narcolepsy.
3182188|NCT00700479|Experimental|A|Aldosterone plus low salt diet
3182189|NCT00700479|Experimental|B|Aldosterone plus high sodium diet
3182190|NCT00700479|Placebo Comparator|C|Placebo plus low sodium diet
3182191|NCT00700479|Placebo Comparator|D|placebo plus high sodium diet
3182192|NCT00700492|No Intervention|control|
3182193|NCT00700492|Experimental|utrogestan|daily use of vaginal progesterone capsules
3182194|NCT00700505|Experimental|Heating Garment|FlowPants(R) Garment with Heating
3182195|NCT00700518|Placebo Comparator|1.|placebo cream applied to 2 adjacent fingers on non-dominant hand one time
3182196|NCT00700518|Active Comparator|2|0.6mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand
3182197|NCT00700518|Active Comparator|3|1.2mg of Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
3182198|NCT00700518|Active Comparator|4|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers on non-dominant hand one time
3182199|NCT00700518|Active Comparator|5|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
3182200|NCT00700531|Experimental|1|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on the Gambro HCO 1100 dialysers
3182201|NCT00700531|Active Comparator|2|Patients receive standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
3182202|NCT00700544|Active Comparator|B|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~-idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5 ), subcutaneously~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
3182203|NCT00700544|Experimental|A|"Induction therapy Idarubicin, 8mg/m2 d1-5; Cytarabine, 100mg/m2 d1-7 and Lomustine, 200mg/m d1) If CR ou PR~maintenance therapy every 3 months = 6 courses of reinduction with :~idarubicin (8mg/m2 d1),cytarabine (100mg/m2d1-5, subcutaneously)~10 to 20 mg (according to body weigh) of norethandrolone daily~between the courses, a continuous regimen of methotrexate and 6-mercaptopurine."
3182204|NCT00700557|Active Comparator|Probiotics - Lactobacillus casei and Bifidobacterium breve|"Yakult LB®~1 sachet (1g) of Lactobacillus casei and Bifidobacterium breve - 6 x 108 UFC/g on a juice three times a day"
3182205|NCT00700557|Placebo Comparator|maize starch|725mg on juice three times a day
3182206|NCT00700583|Experimental|1|
3182207|NCT00700596|Active Comparator|1|Salvinorin A (SA)
3182208|NCT00700596|Placebo Comparator|2|Control or Placebo SA
3182209|NCT00700609|Experimental|1|"Attachment Based Family Therapy (ABFT)~ABFT developed by Dr. Guy Diamond and colleagues is a brief, 12 week, manualized family-based intervention."
3182210|NCT00700609|Active Comparator|2|"Treatment as usual (TAU)~No attempt is made to standardize TAU. Regular clinical staff will provide mental health services."
3138777|NCT03748979|Experimental|Cohort B2; TAK-925 (Dose Level B2)|TAK-925, Dose Level B2, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138778|NCT03748979|Experimental|Cohort B3; TAK-925 (Dose Level B3)|TAK-925, Dose Level B3, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138779|NCT03748979|Experimental|Cohort B4; TAK-925 (Dose Level B4)|TAK-925, Dose Level B4, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138780|NCT03748979|Placebo Comparator|Part B (Cohorts B1-B4); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
3138781|NCT03748979|Experimental|Cohort C1; TAK-925 (Dose Level C1)|TAK-925, Dose Level C1, once daily for up to 7 days in participants with narcolepsy. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3182211|NCT00700648||A|
3182212|NCT00700661|Experimental|1|Drug
3138782|NCT03748979|Experimental|Cohort C2; TAK-925 (Dose Level C2)|TAK-925, Dose Level C2, once daily for up to 7 days in participants with narcolepsy. This group is an additional optional cohort and dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138783|NCT03748979|Placebo Comparator|Part C (Cohorts C1-C2); TAK-925 Placebo|TAK-925 Placebo, once daily for up to 7 days in participants with narcolepsy.
3138784|NCT03748979|Experimental|Cohort A'1; TAK-925 (Dose Level A'1)|TAK-925, Dose Level A'1, single dose in healthy participants.
3182213|NCT00700661|Placebo Comparator|2|Pbo
3182214|NCT00700674||1|Entropy group
3138785|NCT03748979|Experimental|Cohort A'2; TAK-925 (Dose Level A'2)|TAK-925, Dose Level A'2, single dose in healthy participants. Dose level will be determined based on the data of safety, tolerability and PK data from previous cohorts.
3138786|NCT03748758|Active Comparator|Drug: OP0201 (30 mg)|Cohort A- 30 mg per day X 14 days
3182215|NCT00700674||2|Control
3182216|NCT00700687|Experimental|1|PA32540
3182217|NCT00700687|Experimental|2|PA32540 and celecoxib
3182218|NCT00700687|Active Comparator|3|aspirin and celecoxib
3182219|NCT00700700|Active Comparator|CRT-ON/CRT-OFF|Group initially randomized to CRT-ON, then cross-over to CRT-OFF
3182220|NCT00700700|Active Comparator|CRT-OFF/CRT-ON|Group initially randomized to CRT-OFF, then cross-over to CRT-ON
3182221|NCT00700726||A.|participants with atopic and non-atopic asthma
3182222|NCT00700765||A|
3182223|NCT00700830||A|
3182224|NCT00700856|Experimental|1|metformin 2000 mg + pioglitazone 15-45 mg
3138787|NCT03748758|Placebo Comparator|Drug: Placebo|Cohort A- 0 mg per day X 14 days Cohort B- 0 mg per day X 14 days
3138788|NCT03748758|Active Comparator|Drug: OP0201 (60 mg)|Cohort B-60 mg per day X 14 days
3138789|NCT03748706|Experimental|Simufilam (PTI-125)|Simufilam (PTI-125) 100 mg oral tablets administered twice daily (BID)
3138790|NCT03748264|Active Comparator|Standard of Care|In the standard of care or the control condition, participants will receive the sites therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. This group will use a wireless modem that is attached to the PAP device and uploads adherence and other therapy information daily to a secured database (Encore Anywhere). With this method, therapy information is not directly available to the participant. Therapy information is available continuously to site staff personnel in the standard care arm.
3150027|NCT00193154|Experimental|OSI-774 & bevacizumab|OSI-774 (Tarceva) 150mb PO, days 1-28; bevacizumab (Avastin) 10mg/kg, IV infusion, days 1 and 15; Regimen will be repeated every 28 days.
3138791|NCT03748264|Experimental|DreamMapper Application|The DreamMapper Application group will receive the site's therapy initiation standard of care for setting up and educating the participants on their Obstructive Sleep Apnea, mask, and device information. Participants in this group will also download the DreamMapper application on their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper through the application. Study personnel will have access to adherence and therapy information continuously as well
3150028|NCT00193635|Active Comparator|1|oral MMF
3150029|NCT00193648|Active Comparator|1|Avandia (rosiglitazone)
3150030|NCT00193648|Active Comparator|2|Humira (adalimumab)
3150031|NCT00193674|Experimental|1|
3150032|NCT00193674|Placebo Comparator|2|
3150033|NCT00193726|Experimental|Arm B- Experimental|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
3150034|NCT00193726|Placebo Comparator|Arm A - Placebo|Tab Placebo once a day for 5 days prior to each cycle of chemotherapy
3150035|NCT00193739|Active Comparator|NACT followed by surgery|3 cycles of neoadjuvant chemotherapy (NACT) (Inj.Paclitaxel +Inj.Carboplatin) followed by surgery (radical abdominal hysterectomy Class III , bilateral pelvic lymphadenectomy & lower para aortic lymph node sampling)
3150036|NCT00193739|Active Comparator|Concurrent chemoradiotherapy|Radiation therapy will be administered to whole pelvis followed by intracavitary brachytherapy. Patients will be given chemotherapy (Inj.Cisplatin) concurrently with external beam radiotherapy.
3150037|NCT00193765|Active Comparator|Wait and Watch|Therapeutic neck dissection on developing nodal relapse
3150038|NCT00193765|Experimental|Elective Neck dissection|Elective neck dissection in early oral cancer at the time of primary surgery
3150039|NCT00193778|Experimental|Loco Regional Treatment Arm (LRT)|Surgery for breast cancer. (MRM/BCT)
3150040|NCT00193778|Active Comparator|No Loco-regional Treatment Arm|No surgery for Breast cancer
3150041|NCT00193791|No Intervention|Radiation (RT) Alone|Standard radical radiation therapy alone
3138792|NCT03748264|Experimental|DreamMapper Application with Therapist Assist|The DreamMapper Application wit Therapist Assist group will not receive the site's therapy initiation standard of care but will review the Therapist Assist automated educational material on Obstructive Sleep Apnea, and their Philips Respironics mask. and DreamMapper. These participants will download the DreamMapper application onto their iPhone or Android smart phone. Therapy information and educational material will be available continuously to the participant with DreamMapper. Study personnel will have access to adherence and therapy information continuously as well
3138793|NCT03747497|Experimental|contezolid acefosamil|contezolid acefosamil 1500 mg IV x 1 dose, followed by 1000 mg IV q12h for at least 3 total IV doses, followed by 1300 mg PO q12h for 10 to 14 days
3138794|NCT03747497|Active Comparator|linezolid|linezolid 600 mg IV q12h for at least 3 total IV doses, followed by 600 mg PO q12h for 10 to 14 days
3138795|NCT03746405|Active Comparator|Repetitive TMS (rTMS)|excitatory rTMS applied over the medial prefrontal cortex (fMRI-guided)
3138796|NCT03746405|Sham Comparator|Sham repetitive TMS (rTMS)|electrical sham coil applied over the medial prefrontal cortex (fMRI-guided)
2386562|NCT03664895|No Intervention|control arm(TMX, MDR<5%)|keep go on TMX
3138797|NCT03745937|Experimental|MEDI0382 Cohort 1|Participants will receive subcutaneous (SC) dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week treatment extension period (TEP).
3138798|NCT03745937|Placebo Comparator|Placebo Cohort 1|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the uptitration period and thereafter once daily through 3 week TEP.
3138799|NCT03745937|Experimental|MEDI0382 Cohort 2|Participants will receive SC dose of MEDI0382 uptitrated weekly once daily up to 8 weeks during the up-titration period and thereafter once daily in 3-week TEP.
3138800|NCT03745937|Placebo Comparator|Placebo Cohort 2|Participants will receive SC dose of placebo matched to MEDI0382 once daily up to 8 weeks during the up-titration period and thereafter once daily through 3 week TEP.
3138801|NCT03745222|Experimental|Arm 1:Tislelizumab + cCRT followed by tislelizumab monotherapy|Tislelizumab 200 mg is administered by intravenous (IV) administration and given together upfront with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV adminstration monotherapy. The standard platinum-based chemotherapy options include carboplatin/ paclitaxel and cisplatin/etoposide
3138802|NCT03745222|Experimental|Arm 2: Placebo + cCRT followed by tislelizumab monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by tislelizumab 200 mg by IV administration monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
3138803|NCT03745222|Placebo Comparator|Arm 3: Placebo + cCRT followed by placebo monotherapy|Placebo is given with concurrent platinum-based chemoradiotherapy (cCRT) for the first 6 weeks, followed by placebo monotherapy. The standard platinum-based chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide.
3138804|NCT03745092|Experimental|NBO group|Between the two time 30min-EEG recordings, the patients in the NBO group would receive NBO (8L/min, via face mask) for 45min.
3138805|NCT03745092|Placebo Comparator|Control group|Between the two time 30min-EEG recordings, the patients in the control group would have a rest (lying, sitting or walking) for 45min.
3138806|NCT03744780|Experimental|ACT Workshop for Emotional Eating|All participants will be assigned to a one-day intervention using Acceptance and Commitment Therapy (ACT) techniques to help reduce emotional eating.
3138807|NCT03743311||Surgical treatment of Hemmorhoid|Patients after surgical treatment (Instrumental Invasive Surgical Procedures or Thrombectomy, Hemorrhoidectomy etc.)
3138808|NCT03743311||Conservative treatment of Hemmorhoid|Patients taken conservative treatment (Detralex)
3138809|NCT03743311||Combined treatment of Hemmorhoid|Combined treatment patients (surgery and conservative treatment)
3138810|NCT03743038|Experimental|FMX101 vehicle|FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)
3138811|NCT03743038|Experimental|Hydro-alcohol solution base|Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)
3138812|NCT03742973|Experimental|Baricitinib Cohort A|Participants received 2 milligram (mg) of Baricitinib tablet orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
3138813|NCT03742973|Placebo Comparator|Placebo Cohort A|Participants received placebo orally once a day for 12 weeks. Cohort A is not reported due to protection of personal identifiable information based on enrollment futility.
3138814|NCT03742973|Experimental|Baricitinib Cohort B|Participants received 4 mg of Baricitinib orally once a day for 12 weeks. Cohort B was planned, but due to enrollment futility, the strategic decision was made to terminate the study.
3138815|NCT03742973|Placebo Comparator|Placebo Cohort B|Placebo administered orally. Cohort B was planned, but due enrollment futility, the strategic decision was made to terminate the study.
3138816|NCT03742440|Other|GrafixPL PRIME|Open-label case series to evaluate GrafixPL PRIME. All subjects receive the product.
3138817|NCT03742427|Experimental|effect of c-collar in optic nerve sheath diameter|Comparing the effect of c-collar in minor head trauma patients by using optic nerve sheath diameter ultrasonography
3150042|NCT00193791|Experimental|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
3138818|NCT03742271|Experimental|senofilcon A|Subjects that are habitual spectacle wearers that have never worn contact lenses and have had an eye exam and an updated spectacle prescription in the last 6 months will be enrolled and fitted into the senofilcon A TEST Lens for a total period of 4 weeks.
3138819|NCT03742154|Experimental|Varenicline Group|50 participants will be enrolled in this group. They will receive a sample of varenicline to use for up to 4-weeks. They are receiving 40 - 0.5mg pills of varenicline, with instructions for titration.
3138820|NCT03742154|No Intervention|Control Group|49 participants will be enrolled in this group.
3138821|NCT03741725|Experimental|Pay-it-forward|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
3138822|NCT03741725|Experimental|Pay-what-you-want|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
3138823|NCT03741725|No Intervention|Standard of care|First, participants will be provided a brief introduction to gonorrhea and chlamydia testing. Then, participants will be offered gonorrhoea and chlamydia testing at the standard patient price.
3138824|NCT03741088|Experimental|VORTX Rx treatment|Focused ultrasound ablation of liver tumors.
3138825|NCT03741062|Experimental|J. Morita AdvErl Evo Er:YAG laser|Immediately following completion of the surgical procedure, this group will receive photobiomodulation treatment of the palatal tissue donor site with Er:YAG laser according to the parameters recommended by experts in this field and which have shown to induce maximal proliferation of human gingival fibroblasts (Energy Setting: 80 mJ, Pulse Rate: 25 Hz, Duration: 30 s).
3138826|NCT03741062|Sham Comparator|Control|This group will receive sham treatment of the palatal tissue donor site. The laser unit will be turned off. The clinician will simulate usage of the Er:YAG laser in a manner that is indistinguishable to the patient from the experimental group.
3138827|NCT03740659|Experimental|Levofloxacin + Dexamethasone|"Levofloxacin 5 mg/ml + Dexamethasone 1 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
3138828|NCT03740659|Active Comparator|Levofloxacin|"Levofloxacin 5 mg/ml (30 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
3138829|NCT03740659|Active Comparator|Dexamethasone|"Dexamethasone 1.14 mg/ml (26 μl administered twice before Limbal paracentesis).~Limbal paracentesis will be performed prior to cataract surgery."
3138830|NCT03740152|Experimental|Transcranial Light Therapy|All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.
3182225|NCT00700856|Active Comparator|2|metformin 2000 mg + glibenclamide 5-15 mg or metformin 2000 mg + gliclazide 30-120 mg or metformin 2000 mg + glimepiride 2-6 mg
3138831|NCT03739866|Experimental|Part A: Lenacapavir 20 mg|Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
3138832|NCT03739866|Experimental|Part A: Lenacapavir 50 mg|Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138833|NCT03739866|Experimental|Part A: Lenacapavir 150 mg|Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138834|NCT03739866|Experimental|Part A: Lenacapavir 450 mg|Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138835|NCT03739866|Experimental|Part A: Lenacapavir 750 mg|Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138836|NCT03739866|Placebo Comparator|Part A: Placebo|Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138837|NCT03739866|Experimental|Part B: TAF 200 mg|Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138838|NCT03739866|Experimental|Part B: TAF 600 mg|Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
3138839|NCT03739684|Experimental|18F-DCFPyL Injection|9 mCi (333 MBq) IV injection of 18F-DCFPyL
3182226|NCT00700869|Experimental|1|Tracheal tube withdrawal governs by respiratory behaviour status
3138840|NCT03739593|Experimental|AR-1105-CF1|Single dose of AR-1105-CF1 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
3138841|NCT03739593|Experimental|AR-1105-CF2|Single dose of AR-1105-CF2 (dexamethasone, targeted dose of 340 mcg) administered as an intravitreal implant into a single eye of up to 20 subjects who will be followed for 6 months
3138842|NCT03739528|Experimental|Levofloxacin + Dexamethasone followed by dexamethasone|Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
3138843|NCT03739528|Active Comparator|Tobramycin + dexamethasone|Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
3138844|NCT03739242|Experimental|Nutraceutical combination|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Each tablet contains phytosterols 800 mg, Monascus purpureus (167 mg) titrated at 3% in monacolin K (5 mg), niacin 27 mg, linear aliphatic alcohols titrated to 60% octacosanol.
3138845|NCT03739242|Placebo Comparator|Placebo|One film-coated tablet (1300 mg) per os per day to be taken in the evening. Placebo tablets identical in appearance, size, shape, weight and taste to the active product.
3138846|NCT03738865|Experimental|G-Pen followed by Novo Glucagon|1 mg G-Pen at the first treatment visit followed by 1 mg Novo Glucagon at the second treatment visit
3138847|NCT03738865|Active Comparator|Novo Glucagon followed by G-Pen|1 mg Novo Glucagon at the first treatment visit followed by 1 mg G-Pen at the second treatment visit
3138848|NCT03738826|Experimental|Intervention arm|Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers. We will assess the feasibility and acceptability of the intervention.
3138849|NCT03738475|Experimental|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8.
3138850|NCT03738475|Placebo Comparator|Placebo|Normal saline administered intravenously on days 1 and 8.
3138851|NCT03738241|Experimental|Arm 1|Participants will have prior administration of 2013 A/H7N9 IIV with MF59. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
3150043|NCT00193804||2|Patients with histologically proven, cervical cancer FIGO Stage IIB eligible will be invited for the study. The patients will recieve either 3D conformal radiation or IMRT external radiation with concomitant cisplatin chemotherapy followed by brachytherapy.
3150044|NCT00193856|Active Comparator|A|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 mths)
3188873|NCT00771576||B. Longstanding T1D|subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or not measurable stimulated insulin and c peptide levels);
3150045|NCT00193856|Active Comparator|B|LH-RH analogue for 5 months prior to and during first month of radiation treatment (total 6 months) + bisphosphonate therapy.
3188874|NCT00771576||C. Obese Subjects|subjects with predicted increased beta cell mass (euglycemic obese subjects with fasting hyperinsulinemia).
3188875|NCT00771589|Experimental|Prosthesis|Motorized External Knee prosthesis for above knee amputees. Comprised of agonist and antagonist actuators to mimic behavior of knee joint during locomotion.
3150046|NCT00193856|Experimental|C|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months)
3150047|NCT00193856|Experimental|D|LH-RH analogue as for arm A, but continued for further 12 months (total 18 months) + bisphosphonate therapy.
3150048|NCT00193882|Active Comparator|A: Radiotherapy|Radiotherapy alone
3138852|NCT03738241|Experimental|Arm 2|Participants will have prior administration of 2013 A/H7N9 IIV with AS03. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
3138853|NCT03738241|Experimental|Arm 3|Participants will have prior administration of 2013 A/H7N9 IIV 15 mcg or 45 mcg unadjuvanted. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=50) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=50). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
3138854|NCT03738241|Experimental|Arm 4|Participants will have prior administration of 2013 A/H7N9 IIV + MF59 or AS03 (1st) then 2013 A/H7N9 IIV 15 mcg (2nd). Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
3138855|NCT03738241|Experimental|Arm 5|Participants who are A/H7 IIV-Naïve. Then, 3.75 mcg Hemagglutinin (HA) per 0.5 ml dose of 2017 A/H7N9 Inactivated Influenza Virus Vaccine (IIV) + AS03 adjuvant administered intramuscularly on Day 1 (n=30) or 3.75 mcg HA per 0.5 ml dose of 2017 A/H7N9 IIV unadjuvanted administered intramuscularly on Day 1 (n=30). Phosphate buffered saline (PBS) diluent may be used to achieve targeted dosages.
3138856|NCT03738163|Other|Epaderm Cream|This is an open, non randomised single arm study.
3138857|NCT03738020|Experimental|HA IDF|
3138858|NCT03738020|Active Comparator|Restylane|
3138859|NCT03736928|Placebo Comparator|Placebo|Intramuscular single treatment
3138860|NCT03736928|Experimental|AbobotulinumtoxinA dose level 1 or 2|Intramuscular single treatment
3138861|NCT03736928|Experimental|AbobotulinumtoxinA dose level 3|Intramuscular single treatment
3138862|NCT03736928|Experimental|AbobotulinumtoxinA dose level 4|Intramuscular single treatment
3138863|NCT03736785|Experimental|LY3209590 Algorithm 1|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of <140 milligram per deciliter (mg/dL).
3138864|NCT03736785|Experimental|LY3209590 Algorithm 2|Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of <120 mg/dL.
3138865|NCT03736785|Active Comparator|Insulin Degludec|Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C <7%.
3150049|NCT00193882|Experimental|B: Chemo-radiotherapy|Chemotherapy (Cisplatin + 5-Fluorouracil ) and Radiotherapy
3150050|NCT00193895|Active Comparator|Radiotherapy alone|Radiotherapy alone (60Gy or 66Gy in 30-33 fractions 5-5/week)
3138866|NCT03736031|Experimental|Intervention (Promotora)|The intervention group will have three face-to-face meetings with the promotora. Participant will continue to receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
3138867|NCT03736031|No Intervention|Self-Education (Control)|Participant will receive the standard of care for his or her oncologic diagnosis as determined by his or her treating oncologist over the course of the study. During the study period, all participants will complete baseline, interim and exit surveys covering demographics, quality of life and pain management. Information pertaining to hospitalizations and emergency room visits will be obtained from their medical records and public health records.
3138868|NCT03735862||Observations Group|Patients who have undergone a hiatal hernia repair with MIROMESH.
3138869|NCT03734991|Experimental|Ibrexafungerp (SCY-078)|300 mg orally every 12 hrs for 1 day (2 doses in 1 day)
3138870|NCT03734991|Placebo Comparator|Placebo|Matching Placebo
3138871|NCT03734822|Other|CF|Cystic fibrosis patients undergoing general anesthesia.
3138872|NCT03734601|Experimental|TBI+TLI|TBI, single exposure on Day -1, 80 centigray (cGy) in addition to total lymphoid irradiation (TLI, 120 cGy/day for 9 days, weekends excluded) and anti-thymocyte globulin (ATG) 1.5 mg/kg (conditioning regimen)
3182227|NCT00700895|Experimental|Pharmacogenetics-guided dosing group|For patients randomized to the pharmacogenetics-guided dosing group, this 10mls of blood will be immediately sent for genotyping studies. Genotyping results will be available for pharmacogenetics-guided dosing within 3 working days, (ranging 3 to 5 days). During this period, if patients need to be initiated on anticoagulation, a low molecular weight heparin, Fraxiparine, will be given. Fraxiparine will be overlapped with warfarin for 2 to 3 days until target INR is achieved. Elective cases should have the pharmacogenetics-based warfarin dose available at the time of warfarin therapy.
3188876|NCT00771628|Experimental|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
3188877|NCT00771628|Active Comparator|2 Malleable|
3138873|NCT03733899|Experimental|Upper lid margin/Lower lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences of an ocular surface region. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3138874|NCT03733899|Experimental|Lower lid margin/Cornea/ Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3138875|NCT03733899|Experimental|Cornea/Upper lid margin/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3138876|NCT03733899|Experimental|Cornea/Lower lid margin/Upper lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3150051|NCT00193895|Experimental|Radiotherapy plus chemotherapy|Radiotherapy plus chemotherapy (Radiotherapy 60Gy or 66Gy in 30-33 fractions 5/week + Carboplatin (AUC 2) intravenously weekly)
3150052|NCT00193908|Experimental|1|
3150053|NCT00193908|Experimental|2|
3150054|NCT00193921|Experimental|A|Vinorelbine + cisplatin + high-dose palliative radiotherapy
3150055|NCT00193921|Active Comparator|B|Gemcitabine + high-dose palliative radiotherapy
3150056|NCT00193934||1|Cervical Cancer Patients
3188878|NCT00771641|Active Comparator|Standard Fractionation|Standard Fractionation: 2 Gy/Fx, Q.D. 5 Days/wk, Total Dose: 70 Gy/35 Fx x 7 wks
3138877|NCT03733899|Experimental|Upper lid margin/Cornea/Lower lid margin|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3138878|NCT03733899|Experimental|Lower lid margin/Upper lid margin/Cornea|Subjects that are at least 18 years of age wearing their habitual lenses will be randomized into one of six unique sequences. For each region within a sequence, the two treatments will be randomly assigned to the left and right eye (anesthesia left eye/placebo right eye OR placebo left eye/anesthesia left eye).
3138879|NCT03733483|Experimental|Sleep Deprivation|
3138880|NCT03733470|Experimental|Nonsusceptible Smokers (NS)|8 subjects recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
3138881|NCT03733470|Experimental|Susceptible Smokers (SS)|11 subjects recruited to study non-contrast imaging at TLC and 20% VC and with contrast using DECT to assess pefused blood volume. For the intervention the subject will be administered 20 mg of Sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
3138882|NCT03733301|Experimental|4 Milligram (mg) Baricitinib|4 mg Baricitinib administered orally once daily in combination with topical corticosteroids (TCS). Placebo administered orally once daily to match 2 mg Baricitinib.
3138883|NCT03733301|Experimental|2 mg Baricitinib|2 mg Baricitinib administered orally once daily in combination with TCS. Placebo administered orally once daily to match 4 mg Baricitinib.
3138884|NCT03733301|Placebo Comparator|Placebo|Placebo administered orally once daily in combination with TCS.
3138885|NCT03732638|Experimental|Rimegepant|Rimegepant - Randomization Phase: Participants received a single oral dose of rimegepant 75 mg tablet every other day (EOD) for 12 weeks.
3138886|NCT03732638|Placebo Comparator|Placebo|Placebo - Randomization Phase: Participants received a single oral dose of matching placebo tablet every other day (EOD) for 12 weeks.
3138887|NCT03732248|Active Comparator|Rapamycin (sirolimus) 15mg|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
3138888|NCT03732248|Placebo Comparator|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
3138889|NCT03731182|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1.
3138890|NCT03731182|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1.
3150057|NCT00193947||women initiating ARV therapy during pregnancy with neveripine|
3150058|NCT00193973|Active Comparator|1|
3182228|NCT00700895|Experimental|Traditional dosing group|For patients randomized to the traditional dosing regime, the blood will be stored and genotyped retrospectively at the end of the study. Overlapping of warfarin with Fraxiparine or heparin till target INR is achieved is allowed for this group as per normal clinical practice. All warfarin dosage adjustments based on INR results will be according to the current protocol used by the NUH Anticoagulant Clinic.
3182229|NCT00700908|Experimental|1|Automated telephone intervention
3182230|NCT00700908|Active Comparator|2|Usual care
3182231|NCT00700921|Experimental|Active Drug (Lovastatin)|
3182232|NCT00700921|Placebo Comparator|Placebo (inactive comparator)|
3188879|NCT00771641|Experimental|Hyperfractionation|Hyperfractionation: 1.2 Gy/Fx, b.i.d. (> 6 hours apart, 5 days/wk) Total Dose: 81.6 Gy/68 Fx/7 weeks
3138891|NCT03730961|Experimental|Placebo+Diuretic to BMS-986231+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
3138892|NCT03730961|Experimental|BMS-986231+Diuretic to Placebo+Diuretic|Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods
3138893|NCT03730116||the patients with HT and concomitant stable CAD|
3150059|NCT00194038|Experimental|1|
3150060|NCT00194064|Experimental|Olanzapine|Subjects were be started on a standardized minimum first-day dose of 15 mg olanzapine. After the first day of therapy, the daily dose was either increased or decreased, as clinically indicated, by 5 mg, within an allowed range of 5 to 40 mg
3150061|NCT00194103|No Intervention|TAU|
3150062|NCT00194103|Active Comparator|Telephone Monitoring|
3138894|NCT03730103|No Intervention|Historical control group|The investigators will use data from a historical control group discharged on POD 1 after minimally invasive sacrocolpopexy to examine Aim 1 and Aim 2. This is a cohort of 60 women matching our eligibility criteria from a prospective randomized trial of two different types of lightweight polypropylene mesh (IRB #14-354). This study completed recruitment 2017. It consists of a group of women who underwent minimally invasive sacrocolpopexy using the same surgical approaches, at the same institutions
3150063|NCT00194103|Experimental|Telephone Monitoring and Counseling|
2387670|NCT03657498|No Intervention|Control Group I|No intervention
3138895|NCT03730103|Experimental|Same day discharge group|47 women will be recruited for same day discharge after laparoscopic sacrocolpopexy. We will compare aim 1 and 2 (serious adverse events and procedure-related costs) between the two groups
3138896|NCT03729960|Other|LENA|Lena device with Fitbit and Cocooncam being optional
3138897|NCT03729024|Experimental|Light adjustable lens (LAL) and Light Delivery Device (LDD)|
3150064|NCT00194194|Active Comparator|moderate|moderate behavioral management
3150065|NCT00194194|Experimental|intensive|intensive behavioral management
3138898|NCT03728790|No Intervention|Usual Care|Usual care group patients will be assigned to the usual care given to patients with hypertensive disorders of pregnancy at Columbia University Irving Medical Center (CUIMC). This involves a prescription for a blood pressure cuff if they do not already have one, with which they will be asked to measure their blood pressure twice per day. They will be asked to keep a log of their blood pressure measurements and to bring that log to their next provider visit.
3138899|NCT03728790|Experimental|Remote Patient Monitoring|Remote Patient Monitoring patients will use a Bluetooth-enabled blood pressure cuff, which will transmit blood pressure measurements via Bluetooth from the monitor to a tablet, which is able to be accessed by nurses staffing a remote clinical care center. Patients will also be prompted to answer surveys assessing symptoms of preeclampsia. The nurses will review measurements and survey results, which will be flagged in order of urgency. The measurements uploaded into the remote monitoring system will also be reviewed at the patient's next provider visit.
3138900|NCT03728348||Subject aged 45-49 with Average CRC Risk|Subject aged 45-49 with average risk for development of CRC.
3138901|NCT03728140|Experimental|Self-spent Culture Medium|Changing embryo transfer solution with self-spent culture medium
3138902|NCT03728140|No Intervention|New Culture Medium|embryo transfer with new culture medium in IVF-ET
3138903|NCT03727854|Experimental|Premeal protein group|Premeal protein enriched bar with dietary modification
3138904|NCT03727854|Other|Dietary modofication only group|Dietary modification only
3138905|NCT03727425|Experimental|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy procedures will be performed using the Monarch platform.
3138906|NCT03727347|Experimental|InSeca Stylus Treatment Group|Subjects treated with low power radiofrequency energy applied to the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus)
3138907|NCT03726996|Experimental|Children with INAD|Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality.
3138908|NCT03726164|Active Comparator|Remote Conditioning group|Patients will receive a standard remote ischaemia preconditioning protocol comprising a blood pressure cuff placed on arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle repeated three times, prior to the PCI procedure.
3138909|NCT03726164|Placebo Comparator|Control Group|Patients will receive a standard sham remote ischaemia preconditioning protocol with an un-inflated cuff be placed on the arm in this group of patients for 30 minutes. This is the sham intervention for this group.
3138910|NCT03725852|Experimental|GLPG1205 100 mg|Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
3138911|NCT03725852|Placebo Comparator|Placebo|Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone.
3138912|NCT03725722|Experimental|Delgocitinib cream 1 mg/g|Delgocitinib cream applied twice daily for 8 weeks
3138913|NCT03725722|Experimental|Delgocitinib cream 3 mg/g|Delgocitinib cream applied twice daily for 8 weeks
3138914|NCT03725722|Experimental|Delgocitinib cream 8 mg/g|Delgocitinib cream applied twice daily for 8 weeks
3138915|NCT03725722|Experimental|Delgocitinib cream 20 mg/g|Delgocitinib cream applied twice daily for 8 weeks
3138916|NCT03725722|Placebo Comparator|Delgocitinib cream vehicle|Delgocitinib cream vehicle applied twice daily for 8 weeks
3138917|NCT03725098|Experimental|HEMOBLAST Bellows (Hemostatic Device)|Bleeding sites will be treated with HEMOBLAST Bellows per its approved Indications for Use
3138918|NCT03725098|Active Comparator|FLOSEAL (Hemostatic Device)|Bleeding sites will be treated with FLOSEAL per its approved Indications for Use
3138919|NCT03725085|Experimental|Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)|"2 tablets of Mucinex™ (GGE, 600 mg ER bi-layer tablets, taken as 1200 mg BID dose) every 12 hours (twice daily, in the morning and the evening) orally with a full glass of water for 7 days.~GGE = Guaifenesin~BID = Twice in a day"
3138920|NCT03725033|Experimental|Subetta|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
3138921|NCT03725033|Placebo Comparator|Placebo|Tablet for oral use. 2 tablets twice daily. The tablets should be held in mouth until completely dissolved 15 min prior to meal.
3138922|NCT03724981|Experimental|Dulaglutide Pen|Injection of commercial dulaglutide pen on a practice pad.
3138923|NCT03724981|Experimental|Semaglutide Pen|Injection of commercial semaglutide pen on a practice pad.
3138924|NCT03724968|Experimental|Arm A|Nivolumab and Relatlimab
3138925|NCT03724968|Experimental|Arm B|Nivolumab and Ipilimumab
3138926|NCT03724877||Subjects with Chronic obstructive pulmonary disease (COPD)|
3138927|NCT03724253|Experimental|Phase II dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
3138928|NCT03724253|Experimental|Phase II non-dosimetry group|All eligible participants were to receive recommended dose of [68Ga]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) [but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)].
3138929|NCT03723980|Active Comparator|Control Group or Group I or Calcium hydroxide Group|
3138930|NCT03723980|Experimental|Experimental Group or Group II or Propolis Group|
3138931|NCT03723603|Experimental|Fibrillar Collagen Powder Dressing|
3182233|NCT00700947|Experimental|1|Patients who are asymptomatic with normal left ventricular systolic function and who agree to be treated medically for severe primary mitral regurgitation with Beta-blocker therapy. Patients may entered into the Arm 2 (surgical treatment) later on when they develop symptoms or enlarged left ventricle or left ventricular dysfunction or wishes to have surgical treatment of severe primary mitral regurgitation.
3182234|NCT00700947|No Intervention|2|Patients will be surgically treated for severe primary mitral regurgitation as a routine clinical care if they want to be treated surgically or develop symptoms or significant adverse left ventricular remodeling or left ventricular dysfunction.
3138932|NCT03723447|Active Comparator|Bupivacaine/epinephrine/dexamethasone TAP block|For the bupivacaine/epinephrine/dexamethasone treatment arm, a standard weight-based dose of bupivacaine and epinephrine combined with 8mg dexamethasone will be administered.
3138933|NCT03723447|Active Comparator|Liposomal bupivacaine TAP block|For the liposomal bupivacaine treatment arm, 266mg liposomal bupivacaine (Exparel) will be administered.
3138934|NCT03723070|Experimental|PV Cryoablation|Ablation of the ostium of the pulmonary veins (PV) as a means to electrically isolate the veins in the treatment of atrial fibrillation. A cryoablation balloon will be inserted into the left atrium and cryo applications will be administered to create an endocardial thermal injury by using the Cryterion Cardiac Cryoablation System
3138935|NCT03720210|Experimental|RFA group|RFA
3138936|NCT03718455|Experimental|Axillary Magseed|Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.
3138937|NCT03718143|Experimental|Arm A: Elderly Newly diagnosed AML|"Combination AZD1775 with AraC~Elderly, newly diagnosed AML"
3138938|NCT03718143|Experimental|Arm B:Relapsed AML and MDS|"Combination AZD1775 with AraC~Relapsed/Refractory AML & HMA failure AML/ MDS"
3138939|NCT03718143|Active Comparator|Arm C: Relapsed AML, MDS and MF|"AZD1775 only~Relapsed/Refractory AML & HMA failure AML/ MDS and Relapsed/Refractory Primary & Secondary MF"
3138940|NCT03709576|Experimental|Pevonedistat and Azacitidine|The study period is from the start of study treatment, cycle 1 day 1 until 28 days after the last treatment dose. (Cycle 5 day 9). Treatment will be continued until cycle 5 is completed or the study is terminated for the patient. The cycles will be repeated every 28 days. Cycle 1 Day 1 of study treatment will be between day +30 and day +45 post-transplant. Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3, 4, 5, 8 and 9. The drugs can be administered either through a central catheter or a peripheral line.
3138941|NCT03704636|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor.
3138942|NCT03703791|Active Comparator|Group 1 (AR101 Treatment + standard of care)|Subjects receiving AR101 treatment will have 3 consecutive AR101 dosing periods before exiting (completing) the study: initial dose escalation, up dosing, and maintenance.
3138943|NCT03703791|No Intervention|Group 2 (Standard of Care Treatment)|Subjects receiving standard of care alone will have approximately 18 months of observation before study exit, with an OLFC (open label food challenge) approximately 12 months after randomization.
3138944|NCT03701295|Experimental|Treatment (pinometostat, azacitidine)|Patients receive pinometostat IV continuously on days 1-28 and azacitidine IV over 10-40 minutes or SC for 7 of the first 10 days of the cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
3138945|NCT03697551|Experimental|68Ga-OPS202|A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.
3138946|NCT03694821|Experimental|Ketorolac|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
3138947|NCT03694821|Active Comparator|Corticosteroid|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
3138948|NCT03694821|Active Comparator|Hyaluronic Acid|One knee injection of Hylan G-F 20 (Synvisc-One)
3138949|NCT03686969|Experimental|Octanorm|0.5g/kg/week octanorm 16.5%
3138950|NCT03686969|Placebo Comparator|Placebo|Placebo
3138951|NCT03682367|Placebo Comparator|Control|Standard of care use of perioperative analgesia with acetaminophen and opioids that is supplemented with placebo solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and placebo.
3138952|NCT03682367|Experimental|Intervention|Interventional use of perioperative analgesia with acetaminophen and opioids that is supplemented with gabapentin solution. Participants will then be discharged after surgery with postoperative acetaminophen, opioids, and gabapentin.
3138953|NCT03680911|Experimental|NAC Group|NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
3138954|NCT03680911|Placebo Comparator|Placebo Group|Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
3138955|NCT03656692|Other|Acthar Gel|Participants received Acthar 1 mL (80 units [U]) subcutaneously (SC) 2 times per week for 36 weeks followed by a taper to Acthar 1 mL (80 U) SC once a week for 2 weeks, then 0.5 mL (40 U) SC once a week for 2 weeks.
3138956|NCT03648983|Active Comparator|Standard LE detection|Arm measurements taken. Patients undergo arm circumference measurement at 4, 10, 16, 22, 28, and 34 months.
3138957|NCT03648983|Experimental|Enhanced LE detection|Bioimpedance spectroscopy used along with arm measurements. Patients undergo arm circumference measurement and bioimpedance spectroscopy at 4, 10, 16, 22, 28, and 34 months.
3138958|NCT03643159|Experimental|Abilify MyCite|Participants received Abilify MyCite during Months 1-3. During Months 4-6 use of Abilify MyCite was to be prohibited. Thereafter, at Day 180, a second, optional interventional period (up to 6 months of Abilify MyCite) could have been initiated per the joint decision of the participants with their study physician.
3138959|NCT03643159|Active Comparator|Virtual Matched Controls|Virtual matched controls were to receive treatment as usual (that is, any product other than Abilify MyCite, which could have been oral aripiprazole or any other product) throughout the duration of the trial. Virtual matched controls were not to be enrolled into the study, but identified from health insurance claims data and matched to the enrolled Abilify MyCite participants at the end of the study for analysis.
3138960|NCT03632655|Active Comparator|Transrectal Ultrasound Guided Biopsy (TRUS)|Patients will receive a transrectal guided prostate biopsy
3138961|NCT03632655|Active Comparator|Transperineal Prostate Biopsy|Patients will receive a transperineal prostate biopsy
3138962|NCT03630120|Active Comparator|Standard of Care: DTC|Standard of Care (SOC) TKI Therapy for Differentiated Thyroid Cancer (DTC): Lenvatinib + Sorafenib.
3138963|NCT03630120|Experimental|Adaptive Care: DTC|SOC followed by Adaptive Care TKI Therapy for DTC Participants with >=50% drop: Lenvatinib + Sorafenib.
3138964|NCT03630120|Active Comparator|Standard of Care: MTC|Standard of Care (SOC) TKI Therapy for Medullary Thyroid Cancer: Cabozantinib + Vandetanib.
3138965|NCT03630120|Experimental|Adaptive Care: MTC|SOC followed by Adaptive Care TKI Therapy for MTC Participants with >=50% drop: Cabozantinib + Vandetanib.
3138966|NCT03621657|Experimental|Low dose FMT Capsule DE|FMT Capsule double-encapsulated (DE) by mouth, 5 capsules once daily with antibiotic, followed by 5 capsules daily for 7 days post-antibiotic
3138967|NCT03621657|Active Comparator|Single dose FMT Capsule DE|FMT Capsule DE by mouth, 30 capsules in a single one-time dose 48-72 post-antibiotic course.
3138968|NCT03621657|Placebo Comparator|Placebo Oral Capsule|Oral placebo capsules manufactured to mimic study capsule, 5 capsules daily with antibiotic course, followed by 5 capsules for 7 days post-antibiotic
3138969|NCT03615508|Other|10% phenylephrine|All patients will receive 10% phenylephrine at their eye examination as the drug to dilate the pupil. After pupil dilation, pupil size will be measured.
3138970|NCT03615144|Active Comparator|Melphalan/Thiotepa/Clofarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
3188880|NCT00771641|Experimental|Accelerated Hyperfractionation with split|Accelerated Hyperfractionation with split: 1.6 Gy/Fx b.i.d. (> 6 hours apart), 5 days/wk, Total Dose: 67.2 Gy/42 Fx/6 wks with a 2 week rest after 38.4 Gy
3138971|NCT03615144|Active Comparator|Melphalan/Thiotepa/ Fludarabine|Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
3138972|NCT03605303|Active Comparator|CONTROL- etafilcon A current molding|1-Day ACUVUE® MOIST
3138973|NCT03605303|Experimental|TEST- etafilcon A novel molding|Investigational Contact Lens
3138974|NCT03600740|Experimental|GPi DBS|Patients selected to undergo GPi DBS placement will be eligible for enrollment in the study. In addition to standard-of-care tests, subjects will undergo an MRI consisting of the proposed novel imaging protocol prior to placement of DBS. The patient will subsequently undergo standard-of-care therapy for DBS placement. Once the stimulator has been programmed post-operatively, the stimulation parameters and corresponding clinical changes will be collected and used to model the volume of activated tissue. The patient will additionally undergo a follow-up MRI used to localize the electrode within the brain to further localize the volume of activated tissue.
3138975|NCT03598140|Placebo Comparator|Placebo oral capsule|If randomized to placebo, the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
2387990|NCT03655496|No Intervention|Control group|Subject to standard care.
3188881|NCT00771641|Experimental|Accelerated fractionation with concomitant boost|Accelerated fractionation with concomitant boost
3138976|NCT03598140|Active Comparator|Sildenafil Citrate|If randomized to sildenafil (60mg), the participant will receive single (Group 1) or multiple (once-a-day for 14 days; Group 2) treatments.
3138977|NCT03598036|Experimental|Voclosporin|"Cohort 1:~Maximum dose of 3 capsules (7.9mg) BID~Cohort 2~Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1."
3138978|NCT03591458|Experimental|Amitriptyline|Participants will be initiated on 25 mg Amitriptyline daily for two weeks during the Titration Period. Amitriptyline dose will be increased to 50 mg daily for 8 weeks during the Intervention Period. Finally, the dose of Amitriptyline will be reduced to 25 mg daily during the two week Taper Period.
3138979|NCT03591458|Placebo Comparator|Placebo|Participants will be initiated on a daily Placebo capsule matching the 25 mg Amitriptyline during the Titration Period. The daily dose will be changed to the Placebo capsule matching the 50 mg Amitriptyline for 8 weeks during the Intervention Period. Finally, the daily dose will be changed back to the Placebo capsule matching the 25 mg Amitriptyline during the two week Taper period.
3138980|NCT03590743|Active Comparator|Apixaban|Apixaban 5mg (10 mg twice daily for 7 days followed by 5 mg twice daily for 3 months).
3138981|NCT03590743|Placebo Comparator|Placebo|Patients will receive matching placebo.
3138982|NCT03580382|Experimental|NRAS mutant melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
3138983|NCT03580382|Experimental|WT melanoma|C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)
3138984|NCT03572634|Experimental|Group 1-TP 0903 monotherapy|"Adult patients with CLL/SLL who:~are intolerant to, or have had progressive disease on B-cell receptor antagonists, BCL-2 antagonists or other investigational treatments for CLL/SLL"
3138985|NCT03572634|Experimental|Group 2-TP-0903 and ibrutinib combination therapy|"Adult patients with CLL/SLL who:~have progression of disease on ibrutinib, yet the treating provider considers continuation of ibrutinib therapy to be in the best interest of the patient"
3138986|NCT03571646|Other|Capnostream 20|Continuous monitoring of CO2
3138987|NCT03571646|Other|PM1000N-RR|Continuous monitoring of SpO2
3138988|NCT03565328|Experimental|Nicotinamide Riboside in patients with stable heart failure|Nicotinamide Riboside (NR) will be started at 500 mg daily (250 mg BID) then increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000 mg PO BID (2000 mg/day) in patients with stable, systolic heart failure.
3138989|NCT03544242|Active Comparator|Control group|
3138990|NCT03544242|Experimental|Pre-Isolation Infusion|
3138991|NCT03544242|Experimental|Post-Isolation Infusion|
3138992|NCT03543358|Experimental|Arm A: Post-Treatment Follow-Up/Optional Retreatment|Arm A includes participants who enter the extension study while in post-treatment follow-up. This arm includes optional rovalpituzumab tesirine retreatment plus dexamethasone per participant per retreatment period.
3138993|NCT03543358|Experimental|Arm B: Continued Treatment|Arm B includes participants who enter the extension study while receiving ongoing rovalpituzumab tesirine treatment plus dexamethasone in the parent study.
3138994|NCT03538015|Experimental|Carvedilol 3.125 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
3138995|NCT03538015|Experimental|Carvedilol 2.5 mg|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of low-dose carvedilol treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
3150066|NCT00194311||pregnancy complications|prospective cohort study is to determine if maternal infection with Human papillomavirus (HPV) is associated with pregnancy complications including spontaneous preterm delivery (sPTD), severe preeclampsia (PE) (as per current ACOG: American College of Obstetrics and Gynecology criteria), and intrauterine growth restriction (IUGR).
3138996|NCT03538015|Placebo Comparator|Placebo capsule|After enrollment, participants will be placed on continuous glucose monitoring (CGM). One week after CGM placement, participants will undergo the first hypoglycemic clamp study to obtain baseline measures of hypoglycemia frequency, hypoglycemia awareness scores and hormone responses. Following the initial clamp procedure, participants will receive 4 weeks of placebo treatment. After 4 weeks of treatment, the participants will undergo a second hypoglycemic clamp session.
3138997|NCT03534362|Active Comparator|Nasopore Group|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent intervention applied to the post-operative outflow tract.
3138998|NCT03534362|Active Comparator|Propel Stent Group|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement intervention applied to the post-operative outflow tract.
3138999|NCT03509207|Experimental|Vorinostat, Zolinza Oral Capsules|Vorinostat Oral Capsules 400mg daily
3139000|NCT03505372|Experimental|Contrast enhanced mammography|"The CESM images will be performed according to clinical protocol~Images will be acquired within approximately 2-12 minutes of contrast injection~A total of four images per breast will be acquired with low and high energy~Two radiologists will prospectively review the CESM, and will use a third as tie-breaker~The CESM will be evaluated for the biopsy site and up to two additional findings in either breast~The biopsy site will be evaluated for abnormal findings that would suggest malignant involvement"
3139001|NCT03500406|Sham Comparator|Group 1 - Control|No treatment will be administered and men will not have to delay their IPP procedure
3139002|NCT03500406|Experimental|Group 2 - PTT 3x daily x 3 months|Men will utilize penile traction therapy for 30 minutes three times daily for the 3 months prior to placement of their IPP
3139003|NCT03500341|Experimental|Test Subject|All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor
3139004|NCT03500159|Experimental|AQX-1125|AQX-1125 200 mg
3139005|NCT03500159|Placebo Comparator|Placebo|Matching placebo
3139006|NCT03490916|Experimental|Acetazolamide normal dose|One (1) dose of 250mg of Acetazolamide
3139007|NCT03490916|Placebo Comparator|Placebo|One (1) dose of placebo
3139008|NCT03483051|Experimental|Potassium Nitrate (KNO3)|Capsules containing 18 mmoles of KNO3 per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
3139009|NCT03483051|Sham Comparator|Potassium Chloride|Capsules containing 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day for 4 weeks.
3139010|NCT03477903|Experimental|Group A: TAK-954 0.1 mg|TAK-954 0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
3139011|NCT03477903|Experimental|Group B: TAK-954 0.3 mg|TAK-954 0.3 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
3139012|NCT03477903|Experimental|Group C: TAK-954 1.0 mg|TAK-954 1.0 mg, intravenously, administered as 60 minute-infusion, once daily along with 2 mL normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.
3139013|NCT03477903|Active Comparator|Group D: Metoclopramide 10 mg|Metoclopramide 10 mg, injection, intravenously, three times a day along with 100 mL normal saline 60-minute infusion, intravenously, once daily for a minimum of 5 days up to a maximum of 14 days.
3139014|NCT03469258|Experimental|Zenpep|"Pancrelipase (Zenpep) will be administered with every meal (breakfast, lunch, dinner) and snack(s), continuously.~Participants will begin pancrelipase on the day of enrollment and continue therapy until 1 year after surgery per calendar date"
3139015|NCT03466658|Experimental|JumpStart group|This group will have the JumpStart dressing pre-operatively. Intervention: JumpStart dressing
3139016|NCT03466658|No Intervention|Control group|This group will have no intervention pre-operatively. Intervention: none
3139017|NCT03465891|Experimental|atezolizumab|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
2391048|NCT03634787||Healthy|No major systemic illness
3139018|NCT03465891|Experimental|atezolizumab plus low-dose, local radiotherapy|All patients will receive open-label atezolizumab 1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year). 4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
3139019|NCT03465735|Other|Standard of Care|Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
3139020|NCT03465735|Other|Vascular Boot Group|"For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day"
3139021|NCT03461705|Experimental|Primary|All patients who are referred for coronary angiography and require physiological assessment of intermediate lesions will have both RFR and iFR measured during their standard of care procedure. Both the RFR wire (St. Jude Medical (SJM) Aeris Pressure Wire System) and iFR (Volcano Verrata Pressure Wire) wire will be advanced across the lesion with the sensor located at least 3 cm distal from the lesion.
3139022|NCT03457818|Experimental|Treatment Group|Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.
3139023|NCT03457818|Placebo Comparator|Control Group|Placebo SC at Baseline and 6 months.
3139024|NCT03455556|Experimental|Treatment (anetumab ravtansine, atezolizumab)|Participants receive anetumab ravtansine IV over 60 minutes and atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2393674|NCT03616379|Placebo Comparator|Psychoeducational Control|
3139025|NCT03447639|Experimental|Povidone-Iodine Irrigation|Bladder irrigation with 2% povidine-iodine irrigation immediately prior to catheter removal
3139026|NCT03447639|No Intervention|Standard of Care|Catheter removal with no bladder irrigation
3139027|NCT03429712|Experimental|Dose Split CT|
3139028|NCT03426137|Active Comparator|Full Dose (FD)|Participants in the FD arm will receive NSAIDs and Oxycodone (5mg).dosed in accordance with the Guidelines for Use from University of Maryland Shock Trauma Center.
3139029|NCT03426137|Placebo Comparator|PR (Partial Reinforcement)|Participants in this group will receive NSAIDs, Oxycodone (5mg), and placebo pills to reach a 50% reduction of the total intake of opioids.
3139030|NCT03426137|Placebo Comparator|C (Control)|Participants in this group will receive NSAIDs and placebo pills
3139031|NCT03425799|Placebo Comparator|Sodium Chloride 0.9%|Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
3139032|NCT03425799|Experimental|Tranexamic Acid 10 mg/mL|Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg
3139033|NCT03423654|Experimental|Training Group|Spatial training
3139034|NCT03423654|Other|Control Group|Letter number matching
3139035|NCT03387059|Experimental|Forielle Endometrial Washing|
3139036|NCT03387059|No Intervention|No Endometrial Washing|
3139037|NCT03382925|Active Comparator|cervical interlaminar with lidocaine|Group #1: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL 1% lidocaine (total volume 4 mL).
3139038|NCT03382925|Active Comparator|cervical interlaminar with normal saline|Group #2: Interlaminar cervical ESI at the C7-T1 level with triamcinolone acetonide 80 mg (40 mg/mL) + 2 mL preservative saline (total volume 4 mL).
3139039|NCT03379233|Active Comparator|Usual Care|Concept2 inhaler
3139040|NCT03379233|Experimental|Telehealth|Concept2 inhaler with patient application
3139041|NCT03370536|Experimental|Patients with AF|Patients with AF and planned to undergo first catheter procedure
3139042|NCT03363633|No Intervention|Observation|
2393675|NCT03616379|Experimental|Affect Regulation Condition|
3139043|NCT03363633|Experimental|Injection + Compression|
3139044|NCT03363633|Active Comparator|Compression|
3139045|NCT03361228|Experimental|INCB001158 + Epacadostat + Pembrolizumab|
3139046|NCT03361228|Experimental|INCB001158 + Epacadostat|
3139047|NCT03360903|Experimental|Placebo then Caffeine|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control) followed by a washout period and then anesthetized again and allowed to wake after injection of caffeine (15 mg/ kg).
3139048|NCT03360903|Experimental|Caffeine then Placebo|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg) followed by a washout period and then anesthetized again and allowed to wake after injection of saline (placebo control).
2393676|NCT03616379|Experimental|Affect Labelling Condition|
3139049|NCT03359174|Experimental|All-trans retinoic acid (ATRA) therapy|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
3139050|NCT03352882|Other|Open Label|All enrolled participants will undergo hepatic ultrasound with acoustic radiation force impulse (ARFI) before and 30 days after creation of TIPS.
3139051|NCT03348904|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum doublet
3139052|NCT03348904|Active Comparator|Arm B|Platinum doublet chemotherapy
3139053|NCT03348904|Experimental|Arm C|Nivolumab plus placebo in combination with platinum doublet chemotherapy.
3139054|NCT03345901|Experimental|Pemafibrate|.2 mg pemafibrate orally BID
3139055|NCT03345901|Placebo Comparator|Placebo|Placebo pill orally BID
3139056|NCT03344562|Experimental|CES Active|Active cranial electrical stimulation device
3139057|NCT03344562|Sham Comparator|CES Sham|Inactive device identical to the active device.
3139058|NCT03342638|Experimental|Control Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) will be administered post-transplant.
3139059|NCT03342638|Experimental|IVIg Arm|Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. IVIg and G-CSF will be administered post-transplant.
3139060|NCT03342157|Experimental|High-dose|8.6/50 mg of senna/docusate, oral, twice daily
3139061|NCT03342157|Experimental|Low-dose|8.6/50 mg of senna/docusate, oral, once daily
3150067|NCT00194402|Active Comparator|1|Atorvastatin 10 mg for 12 weeks followed by Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) taken with atorvastatin 10 mg for an additional 12 weeks
3150068|NCT00194402|Active Comparator|2|Slo-Niacin (titrated from 500 to 1500 mg over 8 weeks) for 12 weeks followed by atorvastatin 10 mg taken with Slo-Niacin 1500 mg for an additional 12 weeks
3139062|NCT03339401|Experimental|Brincidofovir|"Brincidofovir (BCV) for the treatment of adenovirs (AdV) infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Brincidofovir (BCV) treatment began no later than 100 days post-transplant and was to continue for a maximum of 16 weeks. Brincidofovir (BCV) was discontinued once AdV viremia was confirmed undetectable.~Subjects who did NOT receive concurrent cyclosporine on Day 1:~If ≥48kg body weight, one 100mg oral tablet BIW (or 10mL of 10mg/mL oral suspension if unable to take tablets).~If <48kg body weight, 2mg/kg oral volume of 10mg/mL oral suspension BIW.~Subjects who received cyclosporine on Day 1 (or initiated cyclosporine at any time):~1.4mg/kg (maximum of 70mg) oral volume of 10mg/mL oral suspension BIW.~2mg/kg (maximum of 100mg) oral volume of 10mg/mL oral suspension BIW if discontinued cyclosporine."
3150069|NCT00194415|Other|1|HSV-2 antepartum testing
3150070|NCT00194415|Other|2|Subjects will receive safer-sex counseling during pregnancy
3150071|NCT00194428|Experimental|1|Almond enriched diet
3150072|NCT00194428|Active Comparator|2|Low-fat diet
3150073|NCT00194441|Experimental|1|Highly visible continually updating color coded bar computer display of cerebral perfusion pressure.
3150074|NCT00194441|Placebo Comparator|2|Bedside computer display with a blank screen except for a message indicating that the program is running.
2394243|NCT03612544|Active Comparator|Control group|
3150075|NCT00194454|Experimental|1|Nine session psychosocial/behavioral counseling with homework
3150076|NCT00194454|Active Comparator|2|Usual clinic care with booklet describing depression following stroke
3150077|NCT00194467|Experimental|1|
3150078|NCT00194467|Placebo Comparator|2|
3150079|NCT00194480|Experimental|PegInterferon|Arm 1: 24 weeks of weekly injections of peginterferon Arm 2: control (no treatment)
3150080|NCT00194493|Experimental|1|Patient's clinician receives graphical report of patient-reported symptoms and quality of life issues.
3150081|NCT00194493|No Intervention|2|
3150082|NCT00194519|Active Comparator|Acyclovir|
3150083|NCT00194519|Placebo Comparator|Placebo|
3150084|NCT00194545|Experimental|1|Medication diary
3139063|NCT03339401|Other|Standard of Care|"Local institutional standard of care (SoC) (i.e., investigator-assigned therapy) for the treatment of adenovirus infection in high-risk pediatric allogeneic hematopoietic cell transplant (HCT) recipients.~Management of these subjects was prescribed by the investigator as being in the best interests of the subject and may have included a watch-and-wait approach, with or without decreased immunosuppression (ergo, no treatment), or treatment administration with other available antivirals, most commonly cidofovir intravenously.~Decisions regarding SoC, including administration of therapy, dose and regimen of therapy, modification of immunosuppression, and monitoring was the responsibility of the clinical team caring for the subject, according to institutional guidelines, local practices, and applicable guidelines for the management of AdV infection."
3139064|NCT03339245|Experimental|Glucose, Then Fructose|Participants first receive Glucose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Fructose Solution (75 Grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
3139065|NCT03339245|Experimental|Fructose, Then Glucose|Participants first receive Fructose Solution (75 grams) from Day 3 through Day 16 of an inpatient stay with usual diet. After a 2-3 week washout period, they will then receive Glucose Solution (75 grams) from Day 3 through Day 16 on a second inpatient stay with usual diet.
3139066|NCT03333746|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139067|NCT03329404|Experimental|Mirasol Red Blood Cells (MIR RBCs)|MIR RBCs: RBCs will be derived from WB collected in CPD solution, treated with the Mirasol System for WB, LR, and stored in AS-3 for ≤ 21 days at 1-6°C
3139068|NCT03329404|Active Comparator|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs); LR apheresis RBCs or WB-derived RBCs will be per site standard inventory
3139069|NCT03326869|Experimental|Delayed|"Intervention: Raindrop Near Vision Inlay~In the delayed approach, the corneal pocket is created and dissected but the corneal inlay is not implanted. After one to three months, the corneal inlay is implanted on a second surgical day."
3139070|NCT03326869|Active Comparator|Non-Delayed|"Intervention: Raindrop Near Vision Inlay~In the non-delayed approach, the corneal pocket is created and inlay implanted on the same surgical day."
3139071|NCT03325114|Other|Chlorthalidone|Chlorthalidone 12.5-50 mg by mouth daily for 4 weeks
3139072|NCT03319407|Other|Observation|All participants will be monitored with EPAD system
3150085|NCT00194545|No Intervention|2|Caregivers only receive counseling which is the standard of care
3150086|NCT00194584|Experimental|1|
3150087|NCT00194584|No Intervention|0|
3150088|NCT00194649|Experimental|1|100 mg Miglustat BID (twice daily) for six weeks
3150089|NCT00194714|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once per month for 6 months in the absence of disease progression or unacceptable toxicity.
3150090|NCT00194727|Experimental|1|Vinorelbine (20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle) and capecitabine (825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle). Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
3150091|NCT00194740|Experimental|1|
3150092|NCT00194753|Experimental|1|Weekly doxorubicin (24 mg/m2 IV) with daily oral cyclophosphamide (60 mg/m2 PO) for 12 weeks with G-CSF support days 2 - 7 of each week followed by weekly paclitaxel (80 mg/m2 IV) for 12 weeks.
3150093|NCT00194766|Experimental|1|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
3150094|NCT00194805|Experimental|1|Subjects randomized into the treatment group received the computer treatment
3150095|NCT00194818|Active Comparator|1|Asacol 6 tablets BID (4.8 grams/day)
3150096|NCT00194818|Active Comparator|2|Asacol 4 tablets TID (4.8 grams/day)
3150097|NCT00194844|Experimental|1|Nurse Caring
3150098|NCT00194844|Experimental|2|Self Caring
3139073|NCT03316105|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) stimulation|During this TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will take pressure readings after being placed. After four hours, subjects will again be given a second meal. Fifteen minutes of electrical stimulation will be given to subjects fifteen minutes before ingestion of lunch. After ingestion of lunch, 60 minutes of the electrical stimulation will be applied. When the test is done, the tube will be removed.
3150099|NCT00194844|Experimental|3|Combined Caring
3150100|NCT00194844|No Intervention|4|This group is not treated and serves as control.
3150101|NCT00194870|Other|Digital EEG|Digital EEG
3150102|NCT00194922|Placebo Comparator|A|
3150103|NCT00195052||Epilepsy Patients|
3182235|NCT00700947|No Intervention|3|Health Control includes the subjects with no remarkable past medical history and not currently taking any medications. Normal subjects will be used for comparison with patients with severe primary mitral regurgitation in term of clinical, echocardiographic and neuro-hormonal findings.
3182236|NCT00700960||A|
3182237|NCT00700986|Experimental|1|
3182238|NCT00700986|Placebo Comparator|2|
3182239|NCT00701012|Experimental|1|low ligation, which the IMA is ligated below the origin of the left colic artery
3182240|NCT00701012|Active Comparator|2|high ligation, which the IMA is ligated at its origin from the aorta
3182241|NCT00701025||1|35 asthmatic participants with EIB
3182242|NCT00701025||2|35 without EIB
3182243|NCT00701077|Experimental|1|3,4-Di-amino-Pyridine : a single 20 mg dosing
3182244|NCT00701077|Placebo Comparator|2|
3182245|NCT00701142|Active Comparator|Haemocomplettan® P|Intravenous infusion during aortic surgery
3182246|NCT00701142|Placebo Comparator|Saline solution|
3182247|NCT00701155||A|
3182248|NCT00701181|Active Comparator|Laser|This is a procedure - not a drug intervention.
3139074|NCT03316105|Sham Comparator|No TENS stimulation|During this no TENS unit stimulation arm, subjects will have a narrow tube (about the diameter of a telephone cord) placed into the subjects small intestine by the study physician and trained technician. The technician will use a small amount of fluoroscopy (radiation) to make sure the tube is placed in the proper position. About one hour after the tube has been placed subjects will be given a breakfast meal. The narrow tube (GDM) will record stomach pressure readings after being placed. After four hours, subjects will again be given a second meal. The TENS unit stimulation will be placed but no electrical stimulation will be given. When the test is done, the tube will be removed.
3182249|NCT00701181|Experimental|PF-04523655 (High)|
3182250|NCT00701181|Experimental|PF-04523655 middle|
3182251|NCT00701181|Experimental|PF-04523655 low|
3139075|NCT03305055|Experimental|Fentanyl Plus Ketamine|"Study drug group~Ketamine Loading Dose (Low Dose, Slow Infusion) =~• 0.3 mg/kg; Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, … Then,~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg. This is given to participants in both Group 1 and Group 2 initiated < 1 minute prior to wound care.~Ketamine (Study Drug, Infusion) = • 2.5 mcg/kg/min, Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~Fentanyl PRN dose* = 1 mcg / kg. Provided when participant requires additional pain medication."
3182252|NCT00701194|Experimental|1|EIFC/MTFC-P
3182253|NCT00701194|No Intervention|2|Services as usual
3182254|NCT00701194|No Intervention|Community Comparison|Non-maltreated community pre-schoolers from low-income biological families.
3182255|NCT00701220|Active Comparator|1|Patients with Ischemic Cardiomyopathy receiving Lipitor.
2397525|NCT03589339|Experimental|NBTXR3 activated by SABR|
3182256|NCT00701220|Active Comparator|2|NonIschemic Cardiomyopathy receiving Lipitor treatment
3182257|NCT00701220|No Intervention|3|Healthy subjects with no history of high cholesterol, heart disease, or heart attacks
3139076|NCT03305055|Active Comparator|Fentanyl Plus Saline|"Usual care group~Saline Loading Dose (Low Dose, Slow Infusion) =~• An identical volume of saline as that in 0.3 mg/kg of ketamine. Initiated approximately 10 minutes before wound care start, pump set to deliver slowly over approximately 5 minutes, (i.e., same time/rate as STUDY DRUG GROUP receives ketamine loading dose), … Then, ...~Fentanyl Loading Dose (UC, injection) =~• 1 mcg / kg: This is given to participants in both Group 1 and Group 2 initiated <1 minute prior to wound care.~Saline (Placebo, Infusion) = • Identical volume of fluid as that in 2.5 mcg/kg/min of ketamine; Pump initiates infusion immediately after the fentanyl Loading Dose and continued for session duration. The nurse determines session end, then turns off infusion.~FENTANYL PRN DOSE = 1 mcg / kg. Provided when participant requires additional pain medication."
3139077|NCT03303469|Experimental|FMISO PET imaging post TACE and Stereotactic body radiation therapy (SBRT)|FMISO imaging at baseline, post-TACE and post-SBRT
3139078|NCT03302247|Experimental|Nivolumab+Gemcitabine|Nivolumab infusion on day 1 and 15 with the addition of gencitabine on day 1, 8 and 15 of 28 day cycle
3182258|NCT00701233|Active Comparator|2|Corticosteroid injection into Carpal Tunnel
3182259|NCT00701233|Active Comparator|1|Botulinum toxin injection into Carpal Tunnel
3182260|NCT00701246|Experimental|I|I Treatment: a daily dose (5 times a week) of either 4,2 mg/kg/day of ferrous sulfate + folic acid (50 mcg)
3182261|NCT00701246|Placebo Comparator|II|II Treatment of anemic children with 4,2 mg/kg/day of ferrous sulfate and folic acid placebo.
3182262|NCT00701246|Experimental|III|Prevention of anemia in non-anemic children ( 5 times a week)- 1,4 mg/kg/day of ferrous sulfate and folic acid
3150104|NCT00195091|Experimental|Tetrathiomolybdate (TM)|"Induction period - TM 40 mg is administered three x per day with meals and TM 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Maintenance Period - Total TM dose per day will be in 20 mg increments to tailor the therapy to individualized patient needs to maintain the Cp level at 5-17mg/dL. Thus all dose modifications will be dependent on individual patient Cp levels. TM 40 mg p.o. BID with meals and TM 20 mg at bedtime. Subjects who have no evidence of disease (NED) and are receiving a benefit of TM can continue taking the drug for up to 120 months."
3150105|NCT00195104|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours
3182263|NCT00701246|Placebo Comparator|IV|1,4 mg/kg/day of ferrous sulfate plus folic acid placebo, five days a week.
3182264|NCT00701259|Experimental|1|15 mg lansoprazole
3150106|NCT00195117|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal.
3150107|NCT00195117|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their asthma and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their participation in this study.
3150108|NCT00195182||1. No intervention|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
3182265|NCT00701259|Experimental|2|30 mg lansoprazole
3182266|NCT00701259|Placebo Comparator|3|placebo
3182267|NCT00701272||1|Patients undergoing liver transplant for end-stage liver disease due to Hepatitis C
3139079|NCT03300024|Active Comparator|Expanded polytetrafluoroethylene (ePTFE)|The ePTFE grafts used are the Flixene (Maquet-Atrium Medical, Hudson, NH), Advanta VXT (Maquet-Atrium), GORE-TEXStretch Vascular Graft For Vascular Access (W. L. Gore and Associates, Flagstaff, Ariz), or Venaflo (Bard Peripheral Vascular, Tempe, Ariz). The choice of graft used is at the surgeons' discretion. The graft it is offered in both large and small diameters, as well as thin-wall and rapidly-tapering designs for cases where arterial steal syndrome is a potential complication. A 6 mm graft featuring external supporting rings in 5 cm centered or 7 cm offset sections enables tight loop configurations and crossing the cubitus. A 4-7 mm tapered graft with 10 or 15 cm of removable rings allows for tailoring or exact placement of the ringed section.
3182268|NCT00701272||2|"Control population:~Patients undergoing liver transplantation for end-stage liver disease due to alcoholic cirrhosis"
3182269|NCT00701285|Active Comparator|1|strong statin
3182270|NCT00701285|Active Comparator|2|mild statin
3182271|NCT00701298|Active Comparator|Group 1 (chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients whose disease is not responding after the first course may crossover to group 2.
3182272|NCT00701298|Experimental|Group 2 (chemotherapy and antineoplastic agent)|Patients receive decitabine as in group 1 and pegylated interferon alfa-2b subcutaneously on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3182273|NCT00701324|Experimental|Arm A|BI 811283, 24h infusion d1 and d15 every 4 weeks
3139080|NCT03300024|Experimental|Bovine carotid Artery Graft|The bovine carotid artery biological grafts (Artegraft®; Artegraft, Inc., North Brunswick, NJ) consist of a biological fibrous matrix processed to enhance long-term patency and provide a tightly woven, cross-linked conduit that is flexible and compliant.
3139081|NCT03283709|Experimental|Full-contour monolithic Zirconia crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from multi-layered monolithic zirconia
3139082|NCT03283709|Other|Conventional abutment crowns|If participants assigned to this arm are in need of surveyed crowns on RPD abutment teeth they will be fabricated from type III gold or high-noble metal veneered with feldspathic porcelain
3139083|NCT03277183|Placebo Comparator|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
3139084|NCT03277183|Experimental|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
3139085|NCT03269968|Experimental|Negative pressure wound therapy (NPWT)|Women receiving NPWT will have a PREVENA Incision Management Therapy System applied directly onto their skin over the closed incision after delivery.
3139086|NCT03269968|Placebo Comparator|Standard dressing|Standard dressing
3139087|NCT03248141||Hemophilia B|real world administration patterns and resource utilization implications
3139088|NCT03248141||Hemophilia A|real world administration patterns and resource utilization implications
3139089|NCT03263806|Active Comparator|SOC Group Management|Attending physicians will dictate SOC management according to their own clinical judgment for medical management, stress test plus imaging or coronary artery catheterization with invasive fractional flow reserve.
3139090|NCT03263806|Experimental|CTFFR-Guided Group Management|Patients in this group will be triaged using CTFFR. CTFFR values will be provided to physicians with recommendations for medical management or coronary artery catheterization with invasive fractional flow reserve.
3139091|NCT03261531|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Healthy volunteers who are overweight or have class I obesity will receive T6 dermatomal electrical stimulation via Transcutaneous electrical nerve stimulation (TENS)
3139092|NCT03251326|Experimental|Nabilone|Nabilone capsules (4 mg)
3139093|NCT03251326|Active Comparator|Propranolol|Propranolol capsules (40mg)
3139094|NCT03251326|Experimental|Smoked cannabis|(0.0 and 5.6% THC)
3182274|NCT00701324|Experimental|Arm B|BI 811283, 24h infusion d1 every 3 weeks
3139095|NCT03251326|Placebo Comparator|Placebo|Placebo capsules
3139096|NCT03219372|Experimental|Pravastatin Pill|Daily pravastatin (40mg)
3139097|NCT03219372|Placebo Comparator|Placebo Oral Tablet|Placebo
3139098|NCT03217175|Active Comparator|Bihormonal Bionic Pancreas|Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the bihormonal bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with glucagon.
3139099|NCT03217175|Placebo Comparator|Insulin Only Bionic Pancreas|Insulin-only bionic pancreas exercise visit - Bihormonal bionic pancreas exercise visit - subjects will participate in the outpatient bihormonal bionic pancreas run in period, and will use the insulin-only bionic pancreas for their exercise visit at the end of the run in. The glucagon pump of the bionic pancreas will be filled with placebo (normal saline).
3139100|NCT03231397|Other|Control Group|"Six control subjects (three males and three females) with known atherosclerosis by standard clinical criteria without aneurysmal disease.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
3139101|NCT03231397|Other|Small AAA's|"Six subjects (three males and three females) with small AAAs (diameter 3.0-4.5cm).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
3139102|NCT03231397|Other|Rapidly expanding AAA's|"Six subjects (three males and three females) with rapidly expanding AAAs (>0.5cm over 6 months and/or >1.0cm over 12 months).~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
3139103|NCT03231397|Other|AAA's undergoing treatment|"Six subjects (three males, AAA >5.5cm and three females, AAA >5.0cm) with AAAs that are indicated for treatment.~To assess AAA rupture risk by PET-CTA scans, participants will undergo PET-CT scan using 11C-PBR28 and 18F-fludeoxyglucose (FDG) tracer. Participants will have a blood draw for genetic testing, pregnancy testing if female and creatinine testing."
3182275|NCT00701337|Experimental|1 Oral|oestradiol by oral administration - Estrofem 2 mg
3139104|NCT03232892|Experimental|Trametinib 2.0mg PO daily|Trametinib 2.0mg PO daily in 28-day cycles. A maximum of two trametinib dose level reductions are allowed (1.5mg and 1mg) in the case of adverse reactions.
3139105|NCT03223662|Other|Neoadjuvant Chemoradiotherapy and esophagectomy|Standard of care neoadjuvant chemoradiotherapy (nCRT) and esophagectomy
3139106|NCT03212144|Experimental|High Intensity Interval Training then Peanut Consumption|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
3150109|NCT00195182||2. Experimental|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
3182276|NCT00701337|Experimental|2 patch|oestradiol par patch - Estrapatch 60microg/24h
2397968|NCT03586271||bifocal lens 3|bifocal lens implantation(ReSTOR +2.5D)
3150110|NCT00195195||1|Sirolimus
3150111|NCT00195728|Experimental|hydrocodone/acetaminophen extended release|
3150112|NCT00195845|Experimental|Double-Blind Galantamine vs Placebo|Double-Blinded, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction
3150113|NCT00195845|Placebo Comparator|Placebo Control Group|Placebo-Controlled Group
3150114|NCT00195858|Active Comparator|Diet and Aerobic Exercise|
3150115|NCT00195858|Active Comparator|Diet and Resistane Exercise|
3150116|NCT00195858|Active Comparator|Diet and Combined Aerobic and Resistance Exercise|
3150117|NCT00195858|Other|Diet-only control group|
3150118|NCT00195884|Experimental|Aerobic Group|Aerobic training is divided into three stages: the Starter phase (during the run-in period), the Progression phase, and the Maintenance phase. All aerobic activities are performed on a cycle ergometer, treadmill, elliptical exercise machine or stairclimber. Subjects are free to vary the machine(s) used from one visit to the next. Exercise intensity is standardized using Polar Heartminder heart rate monitors that display the subject's heart rate and emits a warming signal when heart rate is outside the prescribed training zone, thus guiding the subject in adjustment of the work load up or down to achieve the desired intensity.
3150119|NCT00195884|Experimental|Resistance Group|"Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row (back), seated biceps curls, supine bench press (chest), leg press, shoulder press (shoulders and neck); leg extension (quadriceps)~Group B: abdominal crunches, lat pulldown (back), sitting chest press (chest), leg press, upright row (shoulders and neck), triceps pushdown, leg curls (hamstrings).~Subjects are instructed to exhale while lifting a weight and inhale while lowering it, in order to minimize blood pressure excursions. Warm-up and cooldown are the same as for aerobic training."
3150120|NCT00195884|Experimental|Combined Aerobic and Resistance Training|Combined aerobic and resistance training. This group will perform both aerobic and resistance training programs, as described above. The aerobic and resistance components are performed on the same days, in varying orders.
3150121|NCT00195884|No Intervention|Control Group|Members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program.
3150122|NCT00195910|Active Comparator|Morphine|"single dose of intravenous (IV) morphine, 0.1 mg/kg~intervention: 0.1 mg/kg IV morphine"
3150123|NCT00195910|Experimental|Hydromorphone|"single dose of intravenous (IV) hydromorphone, 0.015 mg/kg~intervention: 0.015 mg/kg IV hydromorphone"
3150124|NCT00195936|Experimental|Overall Study|Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
3150125|NCT00195975||1|Children with FD
3150126|NCT00195975||4|Healthy controls
3150127|NCT00196092|Other|1|Roll-in
3150128|NCT00196092|Other|2|Surgical
3150129|NCT00196092|Other|3|Standard Risk
3150130|NCT00196092|Other|4|High Risk
3150131|NCT00196092|Other|5|Compassionate Use
3150132|NCT00196092|Other|6|Treatment for females.
3150133|NCT00196092|Other|7|Standard Risk Continued Access
3150134|NCT00196092|Other|8|High Risk Continued Access
3150135|NCT00196131|No Intervention|0|
3139107|NCT03212144|Experimental|Peanut Consumption then High Intensity Interval Training|Exercise group: 4 training sessions/week, 24 hour rest-periods between each training day. 3-min low intensity warm-up, and then exercise as rapidly as possible for 20 seconds, aiming to reach 85% of their maximum heart rate established during the submaximal cardiopulmonary exercise testing. Then followed by 40 seconds of low intensity exercise. Peanut group: Regular daily caloric intake estimated using data from 24hr recalls, the Miflin-St. Jeor equation, and stress/activity factors. Participants consume dry roasted, unsalted peanuts equivalent to approximately 10% of daily energy intake twice a day, range from approximately 2.4-3.6 ounces. Daily caloric intake will not differ from participants' typical diet. Participants are asked to bring back the empty, numbered peanut packets by the end of every week and will be given new packets weekly. Additionally, subjects will be informed that they will be randomly assessed weekly for compliance.
3150136|NCT00196144|Experimental|1|Optimization of the postventricular atrial blanking period to avoid far-field R-wave sensing.
3150137|NCT00196144|Experimental|2|Programming of the nominal setting for the post-ventricular atrial blanking period (100 ms)
3150138|NCT00196157|Experimental|1|linear lesions to ablate persistent atrial fibrillation
3150139|NCT00196157|Experimental|2|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
3182277|NCT00701350||1|Women presenting with preterm gestation and ruptured membranes
3182278|NCT00701428|Active Comparator|1|Hypertensive Men and Women Without OSA on Losartan (n=30)
3182279|NCT00701428|Active Comparator|2|Hypertensive Men and Women With OSA on Losartan (n=30)
3182280|NCT00701428|Experimental|3|Hypertensive Men and Women with OSA on Losartan and CPAP (n=30)
3182281|NCT00701454||1|Healthy participants (physically and mentally).
3182282|NCT00701467||Observation|
3139108|NCT03218163|Experimental|MEDI-551 Treatment Arm|Medi-551 maintenance therapy will be initiated on Day 60, Day 90, or Day 120 of NM-AlloSCT based on the eligibility criteria for the initiation of maintenance therapy as described in Section 3.1. MEDI-551 will be administered on 28-day cycles at a dose of 4mg/kg, as an IV infusion over 60 ±15 minutes. Infusion sets must contain a 0.2 micron in-line filter. MEDI-551 will be administered on days 1, 8, 15, and 22 of cycle 1, then 4mg/kg IV on day1 of cycles 2 through 12. Treatment may be stopped earlier if there is unacceptable toxicity, development of Grade 3 or 4 graft-versus-host disease (GVHD), documentation of disease progression, or patient withdrawal for other reasons.
3150140|NCT00196170|Experimental|1|8mm tip ablation catheter for ablation of cavotricuspid isthmus
3150141|NCT00196170|Experimental|2|irrigated tip ablation catheter for ablation of cavotricuspid isthmus
3139109|NCT03172520|Experimental|Facial Nerve Monitoring with APS electrode|The investigators will use the Facial Nerve Monitor along with the automatic periodic stimulating(APS) electrode during parotidectomy surgery.
3139110|NCT03204539|Experimental|Alternative Treatment|Half of the participants will be randomized to blinded individualized lot selection for ITI.
3139111|NCT03204539|Other|Standard Treatment|The other half of the participants will receive random lot selection for ITI.
3139112|NCT03206216|Experimental|Group A - Painful CIPN|Participants with painful chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
3139113|NCT03206216|Active Comparator|Group B - Painless CIPN|Participants with painless chemotherapy-induced peripheral neuropathy (CIPN) undergo Diode Laser fiber type Selective Stimulator (DLss) test over 30 minutes at 9 and 21 weeks after the first day of standard of care chemotherapy. A questionnaire is used to assess the level of pain after stimulation.
3139114|NCT03195660|Experimental|ASV Therapy|ASV Therapy
3139115|NCT03195465|Experimental|Cacao group|1 group of subjects will all receive the high antioxidant cacao bars. 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m.
3139116|NCT03166618|Experimental|VOLUMA® XC Treatment|Participants will be treated with JUVÉDERM® VOLUMA® XC injectable gel in both temples (area above the eye). Participants are eligible for touch-up treatment 30 days later.
3139117|NCT03166618|No Intervention|Control_No Treatment|No treatment is administered.
3139118|NCT03169530|Active Comparator|Alcohol|One standard serving of alcohol (~15 gm) daily
3139119|NCT03169530|No Intervention|Abstention|Abstention from alcohol
3139120|NCT03189433|Active Comparator|Ryanodex + Standard of Care|Ryanodex (dantrolene sodium) 50 mg/mL suspension to be administered as a rapid IV push of 2.5 mg/kg, added to Standard of Care (SOC). SOC is defined as efficient body cooling by physical methods and supportive measures [ice packs, evaporative cooling(application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities]. Administer a single dose of Ryanodex. If a subject does not show an adequate clinical response within 10 - 30 minutes post-dose, a second IV bolus dose of 2.5 mg/kg may be administered.
3150142|NCT00196170|Experimental|3|cryo 10mm tip ablation catheter for ablation of cavotricuspid isthmus
3150143|NCT00196170|Experimental|4|Cryo 6.5mm tip ablation catheter for ablation of cavotricuspid isthmus
3150144|NCT00196183|Experimental|1|trigger-guided ablation of paroxysmal atrial fibrillation
3150145|NCT00196183|Experimental|2|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
3150146|NCT00196209|Experimental|1|catheter ablation to treat persistent atrial fibrillation
3150147|NCT00196209|Experimental|2|cardioversion and drug prophylaxis to treat persistent atrial fibrillation
3150148|NCT00196222|Experimental|1|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
3150149|NCT00196222|Experimental|2|cryo energy ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
3150150|NCT00196339|Experimental|Cyproterone acetate 5 mg ( DR-2031)|1 tablet daily
3150151|NCT00196339|Experimental|Cyproterone acetate 15 mg ( DR-2031)|1 tablet daily
3139121|NCT03189433|No Intervention|Standard of Care only (SOC)|Standard of Care is defined as efficient body cooling by physical methods and supportive methods and supportive measures[ice packs, evaporative cooling (application of room temperature water via mist with use of a fan], benzodiazepines to ameliorate shivering, IV fluids, respiratory support, and other treatments deemed necessary to treat complications or comorbidities].
3139122|NCT03151226|Other|capnography monitoring|single arm, all subjects receiving duramorph will receive capnography monitoring
3139123|NCT03165747|Experimental|VSL#3|VSL#3 two active sachets [containing 450x109 colony-forming units (CFU)/sachet], taken daily in a single administration.
3139124|NCT03165747|Placebo Comparator|Control|Placebo, no supplemental probiotics.
3139125|NCT03168906|Experimental|NEOD001|Study Drug given IV every 28 days at 24mg/kg
3139126|NCT03168906|Placebo Comparator|Placebo|Placebo
3139127|NCT03178201|Experimental|TGR-1202|Patients with relapsed or refractory grade 1, 2, or 3A follicular lymphoma will receive TGR-1202.
3139128|NCT03172026|Experimental|Maraviroc + Augmented Rehabilitation|Participants will take Maraviroc 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
3139129|NCT03172026|Placebo Comparator|Placebo + Augmented Rehabilitation|Participants will take placebo 300 mg daily for 60 days, plus receive rehabilitation therapy as prescribed by the doctors and via telerehabilitation.
3139130|NCT03152526|Other|Single-arm trial|Multi-center, open-label, single-arm, phase I/II clinical trial
3139131|NCT03161964|Experimental|Propranolol|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Propranolol Arm will be treated with Propranolol 80 Mg Oral Capsule, Extended Release daily for four weeks.
3139132|NCT03161964|Experimental|Placebo|After enrollment and the initial two-week continuous glucose monitoring assessment, study subjects randomized to the Placebo Arm will be treated with matching placebo oral capsule daily for four weeks.
3139133|NCT03150160|Experimental|Simbrinza + Travatan|Brinzolamide 1%/brimonidine 0.2% fixed combination + travoprost 0.004% ophthalmic solution
3139134|NCT03150160|Placebo Comparator|Placebo + Travatan|Placebo + travoprost 0.004% ophthalmic solution
3150152|NCT00196339|Experimental|Cyproterone acetate 25 mg ( DR-2031)|1 tablet daily
3150153|NCT00196339|Placebo Comparator|Placebo|1 tablet daily
3150154|NCT00196352|Experimental|1|
3150155|NCT00196365|Experimental|1|
3150156|NCT00196365|Active Comparator|2|
3150157|NCT00196378|Experimental|1|
3150158|NCT00196378|Placebo Comparator|2|
3150159|NCT00196391|Experimental|1|
3150160|NCT00196391|Experimental|2|
3150161|NCT00196391|Experimental|3|
3150162|NCT00196391|Experimental|4|
3150163|NCT00196391|Experimental|5|
3182283|NCT00701480|Experimental|1|skin cleanser contained Hibiscus sabdariffa
3182284|NCT00701480|Active Comparator|2|marketed skin cleanser
3182285|NCT00701506|Experimental|1|"15 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings."
3139135|NCT03137225|Experimental|Nasal Intermittent Positive Pressure Ventilation (NIPPV) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NIPPV to NAVA), at the same PEEP (positive end-expiratory pressure) and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NAVA)"
3182286|NCT00701506|Placebo Comparator|2|"5 Patients (may be expanded) will receive stimulation with the following parameters:~20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
3182287|NCT00701532|Experimental|1|active
3139136|NCT03137225|Experimental|Neurally Adjusted Ventilatory Assist (NAVA) Mode|"After a one hour stabilization period, during which small adjustments to the noninvasive settings can be made to clinically optimize the settings, the study will begin. A Nellcor pulse oximeter probe will be placed on an extremity to provide a continuous non-invasive downloadable measure of saturation (blood oxygen level) and heart rate. Data from the ventilator will be downloaded in real-time to a laptop.~These data will be recorded for 4 hours continuously. After that, the ventilator will be switched to the other mode (NAVA to NIPPV), at the same PEEP and respiratory rate. One hour will be allowed to adjust the ventilator settings. Data will then be collected for 4 hours on the second ventilation mode (NIPPV)"
3139137|NCT03123393|Experimental|Cohort A: TAK-659 100 mg|TAK-659 100 mg tablet, orally, once daily (QD), during each 28-days cycle (median exposure was 41 days).
3139138|NCT03123393|Experimental|Cohort B: TAK-659 Ramp-up Dosing|TAK-659 60-100 mg tablet, orally, QD, dose based on safety and tolerability during each 28-days cycle (median exposure was 28 days).
3150164|NCT00196391|Placebo Comparator|6|
3150165|NCT00196404|Experimental|1|
3139139|NCT03123328|Experimental|Test Subjects|Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU.
3139140|NCT03119662|Experimental|Visipaque™: Contrast-Enhanced Computed Tomography (CECT)|Participants received 1 intravenous injection of Visipaque™ 320 mg I/ml injection (100 mL iodixanol) and underwent computed tomography (CT) examination.
3150166|NCT00196404|Experimental|2|
3150167|NCT00196404|Placebo Comparator|3|
3139141|NCT03119662|Placebo Comparator|Saline: Non-Enhanced Computed Tomography (NECT)|Participants received 1 intravenous injection of saline placebo (matched to Visipaque™ 320 mg I/ml injection) and underwent computed tomography (CT) examination and supplemental non-contrast duplex ultrasonography imaging examination.
3139142|NCT03109418|Placebo Comparator|Control Group|OSA patients will receive standard inhaled anesthesia with normal saline infusion
3139143|NCT03109418|Active Comparator|Ketamine Group|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion.
3139144|NCT03120676|Experimental|Atezolizumab|Treatment will be Atezolizumab administered at 1200 mg IV every 3 weeks. A cycle is defined as 3 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death for a maximum duration of treatment of 36 cycles.
3150168|NCT00196560|Experimental|exernal rotation|external rotation at 90 degrees
3150169|NCT00196573|Active Comparator|Shoulder bursectomy and acromioplasty|
3139155|NCT03109873|Experimental|Arm I (EBRT, metformin hydrochloride)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive metformin hydrochloride PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
3139156|NCT03109873|Placebo Comparator|Arm II (EBRT, placebo)|Patients undergo External Beam Radiation Therapy (EBRT). Beginning 1 week prior to start of EBRT, patients receive placebo PO QD for 3 days and BID thereafter until 2 weeks after completion of EBRT.
3139157|NCT03100617|Experimental|REACH-VA family caregiver intervention|Behavioral intervention with several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
3139158|NCT03115853|Experimental|HCTZ plus Aliskiren then HCTZ and Placebo|"HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated.~Then HCTZ 25 mg po plus Placebo"
3139159|NCT03115853|Experimental|HCTZ and Placebo, then HCTZ and Aliskiren|"HCTZ 25 mg po plus Placebo.~Then HCTZ 25 mg plus Aliskiren 150mg for 2weeks. Aliskiren is increased to 300mg for 4 week if 150mg was tolerated."
3182288|NCT00701532|Placebo Comparator|2|Placebo
3182289|NCT00701545||1|Patients with von Willebrand disease treated with Humate P® ivr in Canada
3182290|NCT00701571|Experimental|1|3 cohorts: 18-21 years, 40-60 years, and older than 60 years
3139160|NCT03113071|Experimental|Newly diagnosed AML/MDS|For Group#1 a total of 37 patients with newly diagnosed MDL or MDS will be enrolled, including the eligible patients originally enrolled in the phase Ib portion (safe dose group) of the study, with the goal of determining the clinical activity of our experimental regimen. In the phase II segment, all new patients who are enrolled will initially be randomized in a 1 to 1 fashion to receive decitabine alone or decitabine plus digoxin for one cycle before receiving decitabine plus digoxin for all subsequent cycles for a total of 6 cycles.
3139161|NCT03113071|Experimental|Refractory or relapsed AML/MDS|or Group#2 the target will be to enroll a total of 60 patients with relapsed or refractory AML/MDS, including the eligible patients enrolled in the phase Ib group. This group will have randomization and treatments similar to Group#1.
3139162|NCT03110900|Active Comparator|haloperidol + lorazepam|IM haloperidol 5mg + IM lorazepam 2mg + placebo inhaler
3139163|NCT03110900|Experimental|loxapine|Inhaled loxapine 10mg + IM normal saline
3139164|NCT03078868|Experimental|Single-point intervention|magnetic resonance scanner
3139165|NCT03078270|Other|Open-label|10 participants will be recruited for an open-label study. All will receive the active medication and complete depression and anxiety surveys at baseline, 4-weeks, and 8-weeks post injection. All participants will receive botulinum toxin A.
3139166|NCT03078270|Placebo Comparator|Double-Blind|30 participants will be recruited for a double-blind, comparison study. Participants will be randomized to the active or control groups. Each will receive an injection (active medication or placebo) and will complete a depression and anxiety survey at baseline, 4-weeks and 8-weeks post injection. Participants in the active group will receive botulinum toxin A; participants in the control group will receive a placebo.
3139167|NCT03065933|Experimental|clonidine as an antimanic agent|Subjects with Bipolar Disorder, Mania receive an extended-release form of clonidine on the second day of this 3-day study. Rating scales, record of sleep, and a questionnaire of adverse effects is recorded on each of the three days.
3139168|NCT03070002|Experimental|Treatment (denosumab)|Patients receive denosumab SC on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression, unexpected toxicity, or patient withdrawal or death.
3139169|NCT03058705|Experimental|Hexaminolevinulate HCL with Near Infrared Fluorescence (NIRF)|During the transurethral resection of the bladder procedure, the bladder will initially be examined in a systematic meridian fashion. Suspicious tumors identified by white light only, NIRF only, and both will be identified. If intense fluorescence is observed in the initial patient(s) at 10 min, dwell duration will be reduced to 5 min for the next patient(s); if abundant fluorescence is detected there as well, dwell duration will be shortened again to 2.5 min. At least three patients will be studied at each duration to document intense fluorescence before proceeding to shorter instillation durations in subsequent patients.
3139170|NCT03061279|Experimental|Fixation by Acutrak headless screw|
3182291|NCT00701610||1|All infants born in our hospital between August 2007 and August 2009 will participate.
3182292|NCT00701623|Experimental|1|patients treated with heparin
3182293|NCT00701623|Experimental|2|Patients treated with heparin
3182294|NCT00701623|Active Comparator|3|patients treated with folder water directly on the injured area
3182295|NCT00701649|Experimental|1|
3182296|NCT00701649|Placebo Comparator|2|
3182297|NCT00701688|Experimental|Dose Level 1|Palifermin 40 mcg/kg/day intravenous
3139171|NCT03061279|Active Comparator|Fixation by headed screws, plates and or wire|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes LC-DCP Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire.
3139172|NCT03040323|Experimental|biopsy with Lumason|liver biopsy performed with prior contrast enhancement with Lumason 60.7Mg Powder for Injection (experimental method)
3139173|NCT03040323|Placebo Comparator|biopsy with placebos|liver biopsy performed without prior contrast enhancement (standard method)
3139174|NCT03053518|Active Comparator|Life Style|
3139175|NCT03053518|Experimental|Life Style + Metformin|
3139176|NCT03050398|Experimental|ribociclib + letrozole|ribociclib with letrozole per the core study
3139177|NCT03042780|Experimental|FOLFIRINOX Treatment|Participants will receive modified FOLFIRINOX which consists of 85 mg/m^2 of oxaliplatin, 400 mg/m^2 of leucovorin over the first 2 hours, 165 mg/m^2 of irinotecan in a 90-minute infusion on day 1, followed by a continuous, 46-hour infusion of 5-FU at a dosage of 2,400 mg/m^2. A cycle will be repeated every 14 days. Granulocyte colony-stimulating factor (G-CSF) prophylaxis will be allowed after each cycle. Participants will undergo re-staging studies every 8 weeks. Participants will receive up to 12 cycles during the study. Additional cycles will be determined per investigators' discretion.
3139178|NCT03053960||Diagnostic (helical CT, PET/CT, MRI, CBCT)|Patients undergo helical (Computed Tomography) CT,(Positron Emission Tomography and Computed Tomography) PET/CT, (Magnetic Resonance Imaging) MRI, and (Cone-Beam Computed Tomography) CBCT scans. Patients also undergo therapeutic conventional surgical resection of tumor.
3139179|NCT03036735|Experimental|Steroid Eluting Spacer|"Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side.~The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer."
3139180|NCT03029832|Experimental|MOXR0916 plus Atezolizumab|
3139181|NCT03029832|Active Comparator|Atezolizumab|
3139182|NCT03020446|Experimental|Sorbion dressing to venous leg ulcer|any venous leg ulcer will receive sorbion dressing weekly for 4 weeks than wound will be assessed
3182298|NCT00701688|Experimental|Dose Level 2|Palifermin 60 mcg/kg/day intravenous
3139183|NCT03031340|Placebo Comparator|Placebo|
3139184|NCT03031340|Experimental|Pregabalin|
3139185|NCT03017040|Experimental|Scapholunate tear|Subjects with a full scapholunate tear will have a CT scan and fluoroscopy images taken
3139186|NCT03017040|Active Comparator|Control Wrist|Subjects will have a CT scan and fluoroscopy image taken of the contralateral wrist serve as the control.
3139187|NCT03007719|Experimental|Cohort 1: Neoadjuvant|Patients with localized bladder cancer who are eligible for the UCSF phase 2 clinical trial of neoadjuvant atezolizumab before definitive surgery (NCT02451423) (Cohort 1). For the neoadjuvant cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating atezolizumab and within 7 days before surgery. Approximately 12 patients will be enrolled.
3182299|NCT00701688|Experimental|Dose Level 3|Palifermin 90 mcg/kg/day intravenous
3139188|NCT03007719|Experimental|Cohort 2: Standard of Care (SOC)|Patients with any cancer type who are planned to initiate standard of care (SOC) anti-PD-1 or anti-PD-L1 treatment (Cohort 2). For the SOC cohort, study participants will undergo whole body PET/MR imaging with [18F]F-AraG within 7 days of initiating Cycle 1 anti-PD-1 or anti-PD-L1, and between Cycle 1 Day 15 (C1D15) and Cycle 2 Day 7 (C2D7) anti-PD-1 or anti-PD-L1. Approximately 19 patients will be enrolled.
3139189|NCT03010423|Experimental|Nicorandil|
3139190|NCT02985801|Experimental|Placebo First, then Pancrelipase|Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in first intervention period, and Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in second intervention period (after 2 week washout period).
3139191|NCT02985801|Experimental|Pancrelipase First, then Placebo|Pancrelipase 3 capsules are taken with or after meals (4800 lipase units) and 2 capsules with or after snacks (3200 lipase units) during 4 weeks in first intervention period, and Placebo oral capsule: 3 capsules taken with or after meals, and 2 capsules taken with or after snacks during 4 weeks in second intervention period (after 2 week washout period).
3139192|NCT02991430|Active Comparator|active|active neuromodulation
3139193|NCT02991430|Placebo Comparator|placebo|placebo neuromodulation
3139194|NCT02995967|Active Comparator|Botulinum toxin A alone group|Just the intradetrusor injection of 100 units of botulinum toxin A alone
3139195|NCT02995967|Experimental|Hydrodistention group|Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A
3182300|NCT00701740|Active Comparator|A|A - 21 subjects were treated 20mg isotretinoin 3/week plus moisturizer and sunscreen,for three months; 10 randomly selected were submitted to skin biopsies before and after the end of treatment
3182301|NCT00701740|Active Comparator|B|11 subjects received only the same moisturizer/sunscreen
3182302|NCT00701753||Olanzapine|Subjects treated with olanzapine as part of their routine clinical care
3182303|NCT00701753||Risperidone|Subjects treated with risperidone as part of their routine clinical care
3182304|NCT00701753||Quetiapine|Subjects treated with quetiapine as part of their routine clinical care
3182305|NCT00701792|Active Comparator|1|surgery : liver transplantation
3182306|NCT00701792|Active Comparator|2|standard care for liver disease
3182307|NCT00701831|Experimental|1|Insulin glargine
3182308|NCT00701844|Experimental|Experimental Writing Type 1|
3182309|NCT00701844|Experimental|Experimental Writing type 2|
3182310|NCT00701844|Active Comparator|Control writing type 1|
3139196|NCT02994251|Experimental|All subjects|Patients must have advanced, unresectable intrahepatic cholangiocarcinoma (ICC) defined as biopsy-confirmed adenocarcinoma in the liver, with an immunohistochemical profile consistent with a pancreatico-biliary primary, not involving the common bile duct or bifurcation, and not amenable to surgical resection.
3139197|NCT02978885|Other|Normal preoperative lung function|Patients with normal lung function undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
3139198|NCT02978885|Other|Preoperative COPD|Patients with moderate COPD undergoing Whipple procedures or other major surgeries will receive an injection of AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
3139199|NCT02978833|Experimental|PRP|
3139200|NCT02978833|Active Comparator|Whole Blood|
3139201|NCT02971839|Experimental|VX-561 20 mg|
3139202|NCT02971839|Experimental|VX-561 100 mg|
3139203|NCT02971839|Experimental|VX-561 150 mg|
3139204|NCT02971839|Active Comparator|Ivacaftor|
3139205|NCT02971839|Placebo Comparator|Placebo|
3139206|NCT02985840|Active Comparator|Ondansetron|Ondansetron (4 mg) followed by two 5 ml normal saline flush
3139207|NCT02985840|Experimental|Ondansetron plus dexamethasone|Ondansetron (4 mg), followed by dexamethasone (4 mg), followed by a single 5 ml normal saline flush
3139208|NCT02982720|Experimental|Pembrolizumab and Sylatron|Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
3139209|NCT02966223|Experimental|MRI and HIDA scan|
3139210|NCT02965846|Experimental|AGN-195263|
3139211|NCT02965846|Placebo Comparator|Vehicle|
3139212|NCT02974803|Experimental|Dabrafenib and Trametinib|Dabrafenib, PO, 150mg BID Continuously Trameteinib, PO 2mg OD Continuously
3139213|NCT02974686|Active Comparator|Interventional (EVR)|Patients experiencing gastrointestinal adverse effects in the first year post transplant will be converted from mycophenolate to everolimus
3139214|NCT02974686|Active Comparator|Prior Agent (MPA)|Patient will have baseline data collected while on MPA for comparison with EVR
3139215|NCT02956005|Other|Envarsus|Open Label; Envarsus XR started at the time of transplant. Initial dosing of 0.17mg/kg. Target trough level of 8-10 ng/mL
3139216|NCT02966184|No Intervention|Benzalkonium chloride (BAC) Albuterol|This arm includes the current standard of care which patients receive at the institution. No interventions will be made within this group of patients.
3139217|NCT02966184|Experimental|Preservative Free Albuterol|This arm includes the preservative free albuterol which is being investigated. Treatment for this arm will follow current standards of care, with the only difference being the albuterol formulation.
3139218|NCT02940223|Experimental|Group I (ethyl icosapentate, physical activity)|Patients receive ethyl icosapentate PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally continue to receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks.
3182311|NCT00701844|Placebo Comparator|Control writing type 2|
3182312|NCT00701857|Experimental|Pemetrexed, Cisplatin, Radiation Therapy|Concomitant Pemetrexed and CDDP Plus Radiation Therapy
3139219|NCT02940223|Experimental|Group II (placebo, physical activity)|Patients receive placebo PO BID for 8 weeks. Patients complete resistance exercises 3 days per week and undergo walking program at least 5 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
3139220|NCT02940223|Experimental|Group III (placebo, stretching exercises)|Patients receive placebo PO BID for 8 weeks. Patients meet with an exercise specialist during the first week to learn different stretching exercises and complete the stretching exercises 3 days per week for 8 weeks. After 8 weeks, patients may optionally receive ethyl icosapentate, complete resistance exercises, and undergo walking program for 4 weeks as in Group I.
3139221|NCT02954159|Active Comparator|Treatment arm|vedolizumab at standard regimen with concomitant induction treatment of tacrolimus (starting 0.05 mg per Kg twice daily)
3139222|NCT02954159|Placebo Comparator|Placebo Arm|vedolizumab at standard regimen with placebo.
3139223|NCT02954952|Other|Standard of care (baseline)|Subjects will receive the Sedline sensor. The anesthesiologist will be blinded to the PSI Rev 1.X score and the raw EEG data from the Masimo device. Anesthesia management will be in accordance with standard of care protocols and procedures.
3139224|NCT02954952|Experimental|PSI Rev 1.X|The anesthesiologist will be monitoring subjects using an old version of PSI (Rev 1.X).
3139225|NCT02954952|Experimental|PSI Rev 2.X|The anesthesiologist will be monitoring subjects using a new version of PSI (Rev 2.X).
3139226|NCT02950896||intraoperative FHR monitoring|Intraoperative fetal heart rate (FHR) monitoring
3139227|NCT02947022|Experimental|Calcium DTPA followed by Zinc DTPA|Subjects will receive IV administration of Ca-DTPA on Day 1 and Zn-DTPA on Day 2 at each of treatment time-points. Three identical treatment time-points are scheduled on Month 1, Month 2 and Month 3.
3150172|NCT00196755|Experimental|Sevelamer Hydrochloride (Renagel®)|
3150173|NCT00196755|Active Comparator|Calcium acetate (PhosLo® )|
3139228|NCT02936999|Experimental|Vitamin D3|Patients will be dispensed cholecalciferol, 32 capsules/bottle of 1cap/4000 IU PO QD on Day 1 visit to take home. Bottle must be labeled with instructions on how to take the drug and the assigned patient ID number. Patients will be instructed to take 1 capsule per day, with water, for 29 days using the dispensed study bottle. They will be instructed to stop taking their daily vitamin D3 dose after 30 days of treatment. A study drug diary will be provided at Day 1 visit and patients will be instructed to complete the study drug diary daily from Day 2 to Day 30. Patient's report of vitamin-D3 intake from the diary must be reconciled against the number of capsules returned at Day 30 visit.
3139229|NCT02950480|Experimental|Zafirlukast|Zafirlukast
3139230|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
3139231|NCT02949947|Experimental|Group A - Ferric Carboxymaltose|"Participants receive a Ferric Carboxymaltose injection by vein. Dose repeated 1 week later.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
3139232|NCT02949947|Active Comparator|Group B - Iron Supplement|"Participants take iron supplements by mouth every day for up to 3 months.~Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24."
3139233|NCT02947100|Experimental|SCD-Omegatex™|single arm
3139234|NCT02936206|Experimental|Fulvestrant|750 mg injection in 3 divided doses
3139235|NCT02936206|Active Comparator|Tamoxifen|20mg orally
3139236|NCT02934932|Experimental|Brexpiprazole 2mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
3139237|NCT02934932|Experimental|Brexpiprazole 4mg|Subjects will be titrated to this dose of brexpiprazole for 6 weeks.
3139238|NCT02934932|Placebo Comparator|Placebo|Subjects will be titrated to this dose of placebo for 6 weeks.
3139239|NCT02908516|Experimental|Tranexamic acid|Study subjects randomized to receive the TXA group will receive 3 oral capsules of 650 mg each of TXA for a total of 1.95 g. One dose will be given upon diagnosis of a hip fracture in the emergency department (ED) and a second dose will be given two hours prior to surgical incision.
3139240|NCT02908516|Placebo Comparator|Placebo|Study subjects randomized to the placebo group will receive an equivalent dose of cellulose in 3 oral capsules. One dose will be given upon diagnosis of a hip fracture in the ED and a second dose will be given two hours prior to surgical incision.
3139241|NCT02923830|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
3139242|NCT02923830|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
3139243|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 1[110 mg])|
3139244|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 2[150 mg])|
3139245|NCT02920450|Experimental|Treatment Arm (Phase 1b; Gedatolisib Dose Level 3[180 mg])|
3139246|NCT02920450|Experimental|Treatment Arm (Phase 2; MTD of Gedatolisib from Phase Ib)|
3139247|NCT02920177|Experimental|platelet-rich plasma|platelet-rich plasma injection into the head-neck junction of the hip joint
3139248|NCT02920177|Active Comparator|Kenalog 10 mg/mL Injectable Suspension|corticosteroid injection into the head-neck junction of the hip joint
3139249|NCT02926638|Experimental|Arm I (rilotumumab, erlotinib)|Patients receive rilotumumab IV over 60-120 minutes on day 1 and erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
3139250|NCT02926638|Active Comparator|Arm II (erlotinib)|Patients receive erlotinib hydrochloride PO daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL AND INTERVENTION 11/25/2014)
3139251|NCT02920242|Experimental|Rifaximin|Patients received Rifaximin 200 mg tablet 3 times per day for 3 days.
3139252|NCT02920242|Active Comparator|Xifaxan|Patients received Xifaxan 200 mg tablet 3 times per day for 3 days.
3150174|NCT00196781|Experimental|the Information + Decision Aid group|
3139253|NCT02920242|Placebo Comparator|Placebo|Patients received placebo tablet 3 times per day for 3 days.
3139254|NCT02900781|Active Comparator|Active Comparator Steprite™ Device'|steprite™ device active Comparator- The steprite™ System is a monitoring and biofeedback system for the Monitoring of rehabilitation patients Measuring pressure distribution, gait and range of motion of the lower extremities while a patient performs specified rehabilitation exercises
3139255|NCT02900781|Placebo Comparator|Control|Control outcomes with no device. Standard of care physical therapy and outcomes.
3139256|NCT02892500|Experimental|bupivacaine hydrochloride and betamethasone sodium phosphate|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed the area will be injected with a mixture of 5 ml of 0.25 % bupivacaine hydrochloride and 2 ml of 3 mg/ml betamethasone sodium phosphate (Celestone® Soluspan®) (BTM)
3139257|NCT02892500|Active Comparator|bupivacaine hydrochloride|When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
3139258|NCT02904356|Experimental|Brainsway H-coil for rTMS|Brainsway H-coil for repetitive transcranial magnetic stimulation: High-frequency rTMS will be administered to the medial prefrontal cortex for 3 weeks.
3150175|NCT00196781|Active Comparator|Information Only group|
3150176|NCT00196807|Experimental|Information plus DA at home|
3150177|NCT00196807|Active Comparator|UC Information at home|
3150178|NCT00196807|Experimental|Information plus decision aid at clinic|
3150179|NCT00196807|Active Comparator|UC Information at clinic|
3182313|NCT00701870|Experimental|ezatiostat hydrochloride (Telintra®)|Chemotherapy with docetaxel and carboplatin followed by Telintra until ANC recovery
3182314|NCT00701870|No Intervention|No Intervention|Chemotherapy with docetaxel and carboplatin alone
3182315|NCT00701883|Placebo Comparator|Placebo/Placebo|
3182316|NCT00701883|Experimental|MBX-8025 50 mg/Placebo|
3139259|NCT02899728|Experimental|Arm I (chemotherapy, cediranib maleate, olaparib)|"Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.~NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion."
3139260|NCT02899728|Experimental|Arm II (chemotherapy, cediranib maleate, olaparib)|"Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28."
3182317|NCT00701883|Experimental|MBX-8025 100 mg/Placebo|
3182318|NCT00701883|Active Comparator|Placebo/Atorvastatin 20 mg|
3139261|NCT02875067|Experimental|Pembrolizumab and Lenalidomide|"An intravenous infusion of 200 mg of pembrolizumab (MK3475) once every 3 weeks for a total of 4 infusions~Lenalidomide at either 15 mg, 10 mg or 20 mg (depending on which cohort patients are enrolled in) days 1-14 every 21 days"
3139262|NCT02877732|Experimental|Concussed Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
3139263|NCT02877732|Active Comparator|Control Subject|EYE-SYNC eye-tracking device, Level of Alertness, SCAT-3 subtests (Symptom, Immediate memory, Balance and Orientation), Simple Reaction Time subtest of ANAM-SRT and DEM. Investigators will be collecting medical history and demographics from each subject.
3139264|NCT02860169|Experimental|Participants with cold and flu|Eligible participants with cold and flu were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
3139265|NCT02860169|Placebo Comparator|Healthy participants|Eligible healthy participants were instructed to answer the self administered questionnaire and participate in the assessment that included Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP
3139266|NCT02865395|Experimental|Pre-operative Suppository|A B&O Suppository will be placed in the patient's rectum after the induction of anesthesia, but before the surgery.
3139267|NCT02865395|Active Comparator|Post-operative Suppository|A B&O Suppository will be placed in the patient's rectum while still under anesthesia, but after the surgery.
3139268|NCT02865395|Placebo Comparator|Rectal Exam|Patient's will be given a rectal exam after the procedure but while still under anesthesia to serve as a placebo.
3139269|NCT02868892|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 will be administered on an outpatient basis on an every three week schedule. Pemetrexed will be administered as a 10 minutes intravenous (IV) infusion in (for 500-mg vial) 100 ml of saline via peripheral vein or central line on Day 1 of each 21 day cycle.
3139270|NCT02865083|Active Comparator|Treatment|Subjects will receive use of the Traxi pannus retractor when undergoing cesarean section
3139271|NCT02865083|No Intervention|Standard|Patients will receive use of the standard of care option which is the montgomery straps
3139272|NCT02865122|Experimental|NTRA-9620-A|NTRA-9620 Dose 1 To be dosed orally for 24 weeks, 4 times/day
3139273|NCT02865122|Experimental|NTRA-9620-B|NTRA-9620 Dose 2 To be dosed orally for 24 weeks, 4 times/day
3139274|NCT02865122|Placebo Comparator|Placebo|Placebo To be dosed orally for 24 weeks, 4 times/day
3139275|NCT02865915|Placebo Comparator|Placebo|Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
3139276|NCT02865915|Experimental|MLE4901|Plain, round, biconvex, white film-coated tablets administered twice per day
3139277|NCT02855411|Experimental|0.15 mg PF-04958242|Participants received 0.15 mg oral capsule, twice daily (BID) for 12 weeks
3139278|NCT02855411|Experimental|0.5 mg PF-04958242|Participants received 0.5 mg oral capsule, twice daily (BID) for 12 weeks
3139279|NCT02855411|Placebo Comparator|Placebo|Participants received matching placebo oral capsule, twice daily (BID) for 12 weeks
3139280|NCT02826161|Experimental|Napabucasin plus Weekly Paclitaxel|Patients randomized to this arm will receive napabucasin administered orally, twice daily in combination with paclitaxel administered intravenously, once weekly, on 3 of every 4 weeks.
3139281|NCT02826161|Active Comparator|Weekly Paclitaxel|Patients randomized to this arm will receive weekly paclitaxel alone administered intravenously, once weekly, on 3 of every 4 weeks.
3139282|NCT02828124|Experimental|Dose Escalation Monotherapy|
3139283|NCT02828124|Experimental|Dose Expansion Monotherapy|
3139284|NCT02828124|Experimental|Dose Escalation Combination Therapy|
3139285|NCT02828124|Experimental|Dose Expansion Combination Therapy|
3139286|NCT02826551|Placebo Comparator|No Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study."
3139287|NCT02826551|Experimental|Injection|"These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study."
3139288|NCT02825043|Experimental|High Flow Nasal Cannula Participants|High Flow Nasal Cannula Participants will be their own control, they will be in study for 3 months prior to receiving equipment and then will be studied for 3 additional months on study.
3139289|NCT02819804|Experimental|Treatment (dasatinib, nivolumab)|Patients receive dasatinib PO QD on days 1-28 and nivolumab IV over 30 minutes on days 8 and 22 of course 1 and on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139290|NCT02809118|Placebo Comparator|Placebo|Placebo gel for intratympanic use
3139291|NCT02809118|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
3182319|NCT00701883|Experimental|MBX-8025 50 mg/Atorvastatin 20 mg|
3182320|NCT00701883|Experimental|MBX-8025 100 mg/Atorvastatin 20 mg|
3182321|NCT00701909|Experimental|1|During the first wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK) before the WCP according to randomization. During the second wound care procedure, they will receive the drugs and doses that they had not received the first time.
3182322|NCT00701909|Active Comparator|2|During the second wound care procedure, patients will receive either morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS) or morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg (MK), whichever drugs and doses that they had not received the first time.
3182323|NCT00701948||A-1|Proven nosocomial bacterial infection (NBI)
3182324|NCT00701948||A-2|Possible NBI
3182325|NCT00701948||B-1|Absence of NBI
3182326|NCT00701948||B-2|Probable absence of NBI
3139292|NCT02809118|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
3139293|NCT02818946|Other|MRI|Patients who have undergone mammography, breast sonography, and planning to have a contrast-enhanced breast MRI for evaluation of nipple discharge.
3139294|NCT02819908|Active Comparator|Imprimis Dropless|TriMoxiVanc 0.2cc intravitreal one time
3139295|NCT02819908|Active Comparator|Imprimis Less Drops|Pred Moxi, 1 drop tid for 1 week then, PredKeterolac bid for 2-4 weeks.
3139296|NCT02808390|Experimental|80 mg BID|GED-0507-34-Levo 80 mg BID for 8 Weeks
3139297|NCT02808390|Experimental|160 mg BID|GED-0507-34-Levo 160 mg BID for 8 Weeks
3139298|NCT02808390|Experimental|Placebo|Placebo BID for 8 Weeks
3139299|NCT02806960|Experimental|Treatment 1|Treatment 1, single nasal glucagon (NG) dose of 3 milligram (mg).
3139300|NCT02806960|Experimental|Treatment 2|Treatment 2, NG dose of 3 mg plus 3 mg NG dose in same nostril 15 minutes later.
3139301|NCT02806960|Experimental|Treatment 3|Treatment 3, NG dose of 3 mg plus 3 mg NG dose in the opposite nostril 15 minutes later.
3139302|NCT02806960|Experimental|Treatment 4|Treatment 4, NG dose of 3 mg then immediately 3 mg NG dose in the opposite nostril.
3139303|NCT02815397|Experimental|Single arm, open label|Metformin added to standard of care treatment for all patients
3139304|NCT02802592|Active Comparator|Epogen|1000 IU/kg Epogen in 250 ml of normal saline infused over 1 hr
3139305|NCT02802592|Placebo Comparator|Normal Saline|250 ml normal saline infused over 1 hr
3139306|NCT02774148|Active Comparator|PO Acetaminophen|1,000mg Acetaminophen po every 8 hours until discharge.
3139307|NCT02774148|Experimental|IV Acetaminophen|1,000mg Acetaminophen IV every 8 hours until the patient has received 3 doses post-operatively. Then 1,000mg Acetaminophen po every 8 hours until discharge.
3139308|NCT02773576|Experimental|2x360 mg risperidone implant|2, 360 mg risperidone implants
3139309|NCT02773576|Experimental|3x300 mg risperidone implant|3, 300 mg risperidone implants
3139310|NCT02730793|Active Comparator|Standard Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Nasal Placebo-Normal Saline twice per day
3139311|NCT02730793|Experimental|Study Therapy|Oral Inhalation via PARI Altera Device: Standard Therapy Comparator (Oral Aztreonam 75mg three times a day) AND Nasal Inhalation via PARI PAS Device: Experimental- Nasal Aztreonam 75 mg twice per day
3139312|NCT02744352|Active Comparator|continuous IBP block|Subjects will receive 60 hour continuous infraclavicular brachial plexus block (0.2% of ropivacaine at 8 milliliter/hour) with initial four intermittent 5ml bolus (20ml) of 0.5% Ropivicaine given preoperatively to help with operative and postoperative pain
3139313|NCT02744352|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
3139314|NCT02760602|Experimental|Solanezumab|Solanezumab given intravenously (IV) once every 4 weeks for up to 2 years.
3139315|NCT02760602|Experimental|Placebo|Placebo given IV once every 4 weeks for up to 2 years.
3139316|NCT02757521|Placebo Comparator|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
3139317|NCT02757521|Experimental|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
3139318|NCT02758132|Active Comparator|Alliance A031201|Denosumab plus enzalutamide, abiraterone and prednisone
3139319|NCT02758132|Active Comparator|Standard of Care|Denosumab plus enzalutamide alone
3139320|NCT02757547|Placebo Comparator|Transcranial magnetic stimulation - Placebo Arm|A placebo TMS coil is used.
3139321|NCT02757547|Active Comparator|Transcranial magnetic stimulation - Active Arm|An active TMS coil is used.
3182327|NCT00701961|Experimental|1|Pregnat women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
3182328|NCT00701961|Active Comparator|2|Non-pregnant women receiving MQ-AS fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, dosed once daily such that mefloquine dose is approximately 8mg/kg/day for 3 days.
3182329|NCT00701974|Experimental|1|patients treated with collagenase (IRUXOL)
3182330|NCT00701974|Experimental|2|patients treated with collagenase (Kollagenase)
3182331|NCT00701987|Experimental|1|ALS-357 applied topically twice weekly for four weeks.
3139322|NCT02757053|Experimental|Guardian Cap|The set of high school football players wearing the Guardian Cap on their helmets
3139323|NCT02757053|No Intervention|No Guardian Cap|The set of high school football players not wearing the Guardian Cap on their helmets
3150180|NCT00196820|Experimental|A|Capecitabine 2000 mg/m2 orally day 1-14 q day 22 until progression, unacceptable toxicity, patient's request or withdrawal from study
3150181|NCT00196859|Active Comparator|A|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
3150182|NCT00196859|Experimental|B|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
3182332|NCT00701987|Experimental|2|ALS-357 applied topically every other day for four weeks.
3182333|NCT00701987|Experimental|3|ALS-357 applied topically once daily for four weeks.
3139324|NCT02734940|Active Comparator|Unrestricted Fentanyl|"Will receive injection of sterile saline (2cc) in lower back area (to minimize participant bias) and unrestricted amount of intraoperative opioids (fentanyl) at the discretion of the Anesthesiologist.~Both groups will receive General Anesthesia with volatile agents and single dose of iv Tylenol intraoperatively. Both groups of patients will be transported to Intensive Care Unit (ICU) on Dexmedetomidine (dose range 0.25 - 0.7 mcg/kg/hr). Dose titration is based on sedation level and hemodynamic goals set by Cardiac Anesthesiologist."
3150183|NCT00196872|Experimental|ETC-with Ibandronat|ETC follwoed by Ibandronat
3150184|NCT00196872|Experimental|ETC without Ibandronat|ETC not followed by Ibandronat
3150185|NCT00196872|Experimental|EC-TX with Ibandronat|EC-TX followed by Ibandronat
3150186|NCT00196872|Experimental|EC-TX without Ibandronat|EC-TX not followed by Ibandronat
3150187|NCT00197444|Experimental|1|Chemoradiotherapy
3150188|NCT00197548|Active Comparator|Multivitamins|Multivitamins-vitamins B-complex, C, and E
3150189|NCT00197548|Placebo Comparator|Placebo|Placebo pill
3150190|NCT00197561|Active Comparator|Selenium|Selenium (200 ug as selenomethionine)
3150191|NCT00197561|Placebo Comparator|Placebo|Placebo
3150192|NCT00197587|Active Comparator|maternal nevirapine|
3150193|NCT00197587|Placebo Comparator|maternal placebo|
3139325|NCT02734940|Experimental|Lidocaine, Dexmedetomidine and Ketamine|Will receive pre-operative spinal duramorph (4mcg/kg up to max dose of 300mcg), intra-operative intravenous (iv) infusion of Ketamine (0.4 mg/kg/hr), Lidocaine (20 mcg/kg/min) and Dexmedetomidine (0.25 mcg/kg/hr) started after induction of General Anesthesia and maintained through the Cardiopulmonary Bypass (CPB) towards the end of surgery. At this point all infusions will be turned off except Dexmedetomidine. The total intraoperative fentanyl dose will be limited to <250mcg (or 3mcg/kg) and total midazolam to ≤ 2mg in the study group.
3139326|NCT02749617|Experimental|apixaban|apixaban 2.5 mg PO BID
3139327|NCT02749227|Experimental|Pasireotide LAR Therapy|Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.
3139328|NCT02745210|Experimental|Experimental|13C Magnetic resonance (MR) spectroscopy.
3139329|NCT02725671|Other|Cardiogoniometry and ECG Assessment|The same patient will undergo both advanced ECG assessment using cardiogoniometry and standard ECG
3139330|NCT02746263|Experimental|IV acetaminophen/Morphine|IV acetaminophen 1000 mg every 6 hours over 18 hours
3139331|NCT02746263|Active Comparator|Oral acetaminophen/Morphine|Oral acetaminophen two 500 mg tablets every 6 hours over 18 hours
3182334|NCT00701987|Experimental|4|ALS-357 applied topically twice daily for four weeks.
3182335|NCT00702000||1.|Those with ICU-acquired weakness
3182336|NCT00702013||1|
3182337|NCT00702013||2|
3182338|NCT00702013||3|
3182339|NCT00702013||4|
3182340|NCT00702013||5|
3182341|NCT00702013||6|
3182342|NCT00702013||7|
3182343|NCT00702013||8|
3182344|NCT00702026|Experimental|1|
3182345|NCT00702026|Placebo Comparator|2|
3182346|NCT00702039||1|Those patients receiving intravitreal injections who will be listening to classical music during injection.
3182347|NCT00702039||2|Those patients receiving intravitreal injections who will not be listening to any music during injection.
3182348|NCT00702065||1|
3182349|NCT00702065||2|
3182350|NCT00702078|Other|usual care|follow-up according to todays best practice.
3182351|NCT00702078|Experimental|cooperation|Follow-up from the hospital and the primary healthcare in cooperation
3182352|NCT00702117|Active Comparator|A|IV flecainide in atrial fibrillation
3182353|NCT00702117|Experimental|B|IV ajmaline in atrial fibrillation
3182354|NCT00702117|Active Comparator|c|iv procainamide in ventricular tachycardia
3182355|NCT00702117|Experimental|d|iv ajmaline in ventricular tachycardia
3182356|NCT00702117|Active Comparator|e|iv flecainide in diagnosis of Brugada Sd
3182357|NCT00702117|Experimental|f|iv ajmaline in diagnosis of Brugada Sd
3182358|NCT00702130|Experimental|A|this arm will receive Pravastatin 40 mg per os daily
3182359|NCT00702130|No Intervention|1|
3182360|NCT00702156|Experimental|1|Bisoprolol
3182361|NCT00702156|Placebo Comparator|2|Identical appearance matching placebo
3182362|NCT00702169||1|Premature and term newborn infants (male/female)
3182363|NCT00702182|Experimental|Conventional Vinorelbine, Erlotinib|Escalating doses of vinorelbine on Day 1 and Day 8 of 21 Day cycle; Erlotinib 100 mg OD
3139332|NCT02721277|Experimental|SMOFlipid|Subjects with cholestasis will receive 3 G/kg/day of intravenous SMOFlipid daily until parenteral nutrition (PN) is discontinued. In addition, the following monitoring for effects of SMOFlipid will be performed: total days of parenteral nutrition, maximum conjugated bilirubin, time to resolution of bilirubin, time to liver transplant, time to death, positive blood cultures, rates of increase in weight, length, and head circumference, time dependent changes in liver function tests, including triglycerides, and length of hospital stay.
3139333|NCT02732327|Experimental|CAZ-AVI + Vancomycin or Linezolid|Ceftazidime-Avibactam (CAZ-AVI) 2.5 mg intravenous (IV) infusion every 8 hours for 5 to 14 days, duration determined by the investigator, plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local standard of care [SOC]) may be allowed after at least 72 hours (ie, minimum of 9 doses for CAZ-AVI) of inpatient IV study drug.
3139334|NCT02732327|Active Comparator|Standard of Care+Vancomycin or Linezolid|Standard of Care (cefepime 2 g IV infusion every 8 hours or meropenem 1 g IV infusion every 8 hours or piperacillin/tazobactam 4.5 g IV infusion every 6 hours for 5 to 14 days, duration determined by the investigator) plus vancomycin 15 mg/kg IV or linezolid 600 mg IV every 12 hours. A switch to open-label oral or IV therapy (IV therapy for outpatient or home administration per local SOC) may be allowed after at least 72 hours (ie, minimum of 9 doses for SOC therapies, except piperacillin/tazobactam, which is a minimum of 12 doses) of inpatient IV study drug.
3182364|NCT00702182|Experimental|Metronomic Vinorelbine, Erlotinib|Escalating doses of vinorelbine TIW; erlotinib 100 mg OD
3182365|NCT00702195||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) from trial 38805 (7.5 μg, 15 μg, 30 μg and 60 μg)
3139335|NCT02726399|Experimental|Ramucirumab With Trastuzumab and Capecitabine/Cisplatin|This will be a single arm study of ramucirumab 8mg/kg administered intravenously on days 1 and 8 + trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days. On subsequent cycles for all patients capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period, in addition to cisplatin 80mg/m2 administered as an IV infusion every 21 days. Each cycle consists of 21 days.
3139336|NCT02720510|Active Comparator|Arm 1 - RVD + Pan|Revlimid, Velcade, dexamethasone and Farydak
3139337|NCT02720510|Active Comparator|Arm 2 - RVD|Revlimid, Velcade and Dexamethasone
3182366|NCT00702195||Experimental Group 2|Placebo
3139338|NCT02715765|Sham Comparator|Sham|The sham procedure involves only 40 sec direct current stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec.
3139339|NCT02715765|Experimental|Active tDCS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). The current is held constant for 20 min. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
3139340|NCT02715765|Experimental|Active tRNS|Current (2mA) is initiated in a ramp-like fashion over 10s from 0mA to 2mA using (SPONSTIM-25 25cm2 electrodes). Once at 2mA, an alternating current of 2mA with a 0mA offset is applied at random frequencies over a range of 0.1 to 100 Hz. This is performed for 20 minutes. Then the current is decreased in a ramp-like fashion over 10s from 2mA to 0mA.
3139341|NCT02717949|Experimental|sofosbuvir/ledipasvir|sofosbuvir and ledipasvir fixed dose combination given orally once a day for genotype 1 and 4.
3139342|NCT02717949|Experimental|sofosbuvir and ribavirin|Sofosbuvir 400 mg given orally once a day with weight-base ribavirin of 1200 mg for those >75 kg and 1000 mg for those <75kg given in divided dose twice a day. This intervention is for genotype 2 and 3
3139343|NCT02717130|Experimental|Aripiprazole (Abilify Maintena)|Aripiprazole once monthly (300-400 mg for entire study duration) plus 14 days oral antipsychotic medication (first injection only) (dosage according to package inserts). After the 14 day oral lead-in, after the first injection of aripiprazole once monthly, only oral aripiprazole will be allowed as a rescue medication.
3139344|NCT02685202|Experimental|Mandibular advancement splint|An oral appliance which is standard of care in treating mild or moderate obstructive sleep apnea by repositioning the mandible in a forward position
3139345|NCT02709083|Experimental|Treatment-dasatinib, nilotinib, imatinib|Patients receive dasatinib orally (PO) once a day (QD) or nilotinib PO twice a day (BID) at the discretion of the treating hematologist. Patients achieving either a 1 log reduction at 3 months or a 2 log reduction at 6 months in their breakpoint cluster region-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) transcript levels may switch to imatinib mesylate PO QD.
3182367|NCT00702195||Experimental Group 3|all doses of Org 36286 (corifollitropin alfa) from trial 38807 (120 μg, 180 μg and 240 μg)
3139346|NCT02693171||Dinutuximab administered for 5 cycles|High-risk neuroblastoma patient treated with Unituxin as standard of care
3139347|NCT02696226|Experimental|SAVR Warfarin Arm|Warfarin arm-(target INR of 2-3)
3139348|NCT02696226|Experimental|TAVR Warfarin and Clopidogrel Arm|Warfarin (target INR of 2-3) and Clopidogrel (75mg/day) arm
3139349|NCT02696226|Experimental|SAVR Aspirin Arm|Aspirin arm (81mg/day)
3139350|NCT02696226|Experimental|TAVR Aspirin and Clopidogrel Arm|Aspirin (81mg/day) and Clopidogrel (75mg/day) arm
3139351|NCT02693743|Active Comparator|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) will be delivered to the left PFC, deﬁned as a location 6 cm (cm) anterior to the right hand motor thumb area. A research nurse will deliver the treatments. rTMS will be delivered with a ﬁgure-eight coil at 120% motor threshold, 10 Hertz (Hz), 5 s (s) train duration, 20 s intertrain interval for 50 min (6000 pulses) 3 times daily for 3 days (total 9 sessions, 54,000 stimuli).
3139352|NCT02693743|Sham Comparator|Sham rTMS|Parameters for sham Repetitive Transcranial Magnetic Stimulation (rTMS) are identical to those for active stimulation except that aluminum plate blocks the propagation of a magnetic field. The sound and physical sensation is the same as with the active coil while been biologically inactive.
3139353|NCT02706691|Experimental|BGJ398 (infigratinib) Dosing|Patients receive BGJ398 (125 mg) by mouth once daily on a three weeks on, one week off schedule. Courses repeat every 28 days until disease progression or unacceptable toxicity.
3139354|NCT02708849|Experimental|Ketamine plus lamotrigine|
3139355|NCT02708849|Placebo Comparator|ketamine plus placebo|
3139356|NCT02693717|Experimental|Treatment (pemetrexed disodium)|Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3139357|NCT02694757|Experimental|Ostom-i device|Subjects will receive an Ostom-i device which will be worn over the ostomy bag underneath the subject's clothing. Output will be monitored daily by the Ostom-i application.
3139358|NCT02693002|Active Comparator|Hormone replacement therapy|Estradiol/norethindrone acetate 1mg/0.5 mg by mouth oral daily for 12 weeks
3182368|NCT00702195||Experimental Group 4|150 IU Puregon®
3182369|NCT00702247|Experimental|1|
3139359|NCT02693002|Placebo Comparator|Placebo|Inert ingredients by mouth oral daily for 12 weeks
3139360|NCT02689518|Other|Treatment - On-Label|On-label intravitreal aflibercept (Eylea) injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks (2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months
3139361|NCT02687165|Active Comparator|Milnacipran augmented by D-cycloserine|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving D-cycloserine in addition to Milnacipran
3139362|NCT02687165|Placebo Comparator|Milnacipran augmented by Placebo|participants will be receiving Milnacipran for 12 weeks. During weeks 6-12 participants will be receiving placebo in addition to Milnacipran
3139363|NCT02679560|Active Comparator|Liposomal Bupivacaine|In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered
3139364|NCT02679560|Placebo Comparator|Ropivacaine HCL|In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered
3139365|NCT02679066|Active Comparator|Sugar-tong splint|Patients are placed in a sugar-tong splint for immobilization of the distal radius fracture.
3139366|NCT02679066|Active Comparator|Short Forearm Cast|Patients are placed in a short forearm cast, with bivalve, for immobilization of the distal radius fracture.
3139367|NCT02673684|Sham Comparator|Sham Neurostim System (Sham NSS)|In this arm, the subject will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive a sham Neuro-Stim System device that will only be active for five minutes. Identical to the active device in placement, labeling, and packaging. It will remain on the subject's ear for 5 days at which point the subject may discard the device.
3182370|NCT00702286||1|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
3182371|NCT00702286||2|Two arm, double blinded, comparative, randomized, placebo controlled (active:sham - 2:1) study
3139368|NCT02673684|Experimental|Working Neurostim System (Working NSS)|In this arm, the patient will receive the standard-of-care with regard to his pain management (which may or may not include opioids such as morphine). Additionally, the subject will receive an active Neuro-Stim System that generates electrical impulses that stimulate the neurovascular bundles in the ear. It will remain on subject's ear for 5 days at which point the subject may discard the device.
3139369|NCT02674204|Experimental|Study Agent|One atorvastatin 20 mg oral capsule per day
3139370|NCT02674204|Placebo Comparator|Control|One matching placebo daily
3139371|NCT02665221|Placebo Comparator|Control group|
3139372|NCT02665221|Experimental|Treatment group|
3139373|NCT02672033|Experimental|Treatment (hypofractionated IMRT, pleurectomy/decortication)|Patients undergo 5 fractions of accelerated hypofractionated IMRT over 1 week with simultaneous integrated boost to gross disease. Patients then undergo pleurectomy/decortication within 14 days after completion of IMRT.
3139374|NCT02671461|Experimental|BMS-986141 0.8mg|BMS-986141 0.8mg orally (tablets) and Aspirin (ASA) 75 to 162 mg orally (tablets)
3139375|NCT02671461|Experimental|BMS-986141 4.8mg|BMS-986141 4.8mg orally (tablets) and ASA 75 to 162 mg orally (tablets)
3139376|NCT02671461|Placebo Comparator|Placebo|Placebo orally (tablets) and ASA 75 to 162 mg orally (tablets)
3139377|NCT02671136|Other|CWC with HBO|Conventional Wound Therapies (CWC) with adjunctive Hyperbaric Oxygen Therapy
3139378|NCT02671136|Other|CWC without HBO|Conventional Wound Therapies (CWC) without adjunctive Hyperbaric Oxygen Therapy
3139379|NCT02663752|Other|Deferasirox|All patients are already on commercial deferasirox before entering the study.
3139380|NCT02658357|Experimental|600 mg|Two, 300 mg Risperidone Implants
3139381|NCT02658357|Experimental|900 mg|Three, 300 mg Risperidone Implants
3139382|NCT02665988|Experimental|Real tDCS|Those receiving experimental treatment will receive real tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
3139383|NCT02665988|Placebo Comparator|Sham tDCS|Those receiving sham tDCS will receive active tDCS during 20-minute periods over the course of 10 sessions. The treatment will be delivered by trained clinical personnel.
3139384|NCT02660528|Experimental|Tocilizumab|Tocilizumab 162 mg sc q2weeks x 4 doses
3139385|NCT02658877|Experimental|Omalizumab|
3139386|NCT02658877|Placebo Comparator|Placebo|
3139387|NCT02654782|Active Comparator|Lactated Ringer's|Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
3139388|NCT02654782|Active Comparator|5% Human Albumin|Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.
3139389|NCT02656199||Main Cohort|all patients enrolled will have an ultrasound of their diaphragm performed once they are on a pressure support trial. Intervention: Diaphragm Ultrasound
3139390|NCT02654639|Experimental|TAS-102 and Bevacizumab|Oral TAS-102 and intravenous Bevacizumab.
3139391|NCT02653495|Experimental|Influenza vaccine in metabolic syndrome|Influenza vaccine
3139392|NCT02653495|Experimental|Influenza vaccine in healthy controls|Influenza vaccine
3139393|NCT02640573|Experimental|Hydroxurea|Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria.
3139394|NCT02639390|Experimental|Robotic|The experimental group will receive 1-hour robotic training sessions, 3 times per week for a total of 12 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive the same dosage and schedule (1-hour sessions, 3 times/week, 12 total sessions) of conventional one-on-one therapy from an occupational therapist.
3182372|NCT00702312|Experimental|Study group|Study group that will attend low-salt educational community programme
3182373|NCT00702312|No Intervention|Control group|Subjects in this arm will have routine medical and dietetic treatment for low-salt reduction.
3182374|NCT00702351|Experimental|Arm 1|150 µg Org 36286 (corifollitropin alfa)
3182375|NCT00702351|Experimental|Arm 2|100 µg Org 36286 (corifollitropin alfa)
3182376|NCT00702416|Experimental|US Group|In this group, the continuous block will be performed under real-time ultrasound (US) guidance.
3182377|NCT00702416|Active Comparator|ENS Group|In this group, the continuous block will be performed with an electrical nerve stimulation (ENS) technique.
3182378|NCT00702429|Experimental|1|Patients achieve of parodontopathies
3182379|NCT00702429|Placebo Comparator|2|Patients without parodontales diseases
3182380|NCT00702442|Placebo Comparator|A|Placebo Administrated 30min prior to operation
3182381|NCT00702442|Experimental|B|0.625 mg Droperidol administrated i.v 30 min prior surgery
3182382|NCT00702455|Active Comparator|Self-Directed|
3182383|NCT00702455|Active Comparator|Guided|
3182384|NCT00702481|Experimental|Nimotuzumab/CDDP/RT|Open label treatment arm of Nimotuzumab and cisplatin and radiation
3182385|NCT00702494|Experimental|1|Multiple IV doses of TB-403, an antibody directed against PlGF
3139395|NCT02639390|Active Comparator|Conventional|Subjects will receive 24 hours of one-on-one treatment from an occupational therapist. The treatment schedule will parallel that given to the experimental group (1-hour sessions, 3 times/week).
3139396|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - Low Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
3150194|NCT00197652||Diarrheal specimens from infants born to HIV infected mothers|400 diarrheal specimens will suffice to determine the prevalence of specific pathogens in the region. Of these, 300 specimens will be collected from infants born to HIV infected mothers, and 100 specimens will be collected from infants born to HIV uninfected mothers.
3182388|NCT00702572|Experimental|1|Phase I dose escalating scheme
3182389|NCT00702572|Experimental|2|Phase 2 will evaluate the toxicities and safety profile of the 4-drug regimen.
3139397|NCT02634606|Active Comparator|Gamma Delta Tocotrienols - High Dose|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
3182390|NCT00702585|Experimental|Org 36286 7.5 µg|Org 36286 7.5 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3139398|NCT02634606|Placebo Comparator|Sugar Pill|33 subjects with cholesterol level (>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
3139399|NCT02634827|Experimental|Treatment (decitabine, midostaurin)|Patients receive decitabine intravenously (IV) over 1 hour on days 1-5 and midostaurin orally (PO) twice daily (BID) on days 8-21 of courses 1 and 2, and on days 1-28 of each subsequent course. Patients failing to achieve complete response (CR)/complete response with incomplete recovery (CRi)/partial response (PR)/morphologic leukemia-free state by end of course 2 receive midostaurin PO BID on days 1-28. Patients achieving CR/CRi/PR/morphologic leukemia-free state by end of course 8 may continue on current regimen. Patients failing to achieve a CR/CRi/PR/ morphologic leukemia-free state in bone marrow blasts by end of course 8 go to event monitoring. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3139400|NCT02636283|Active Comparator|Entresto|oral route
3139401|NCT02636283|Placebo Comparator|Placebo group|Oral placebo
3139402|NCT02638129|Other|Lead-In: Naltrexone/Bupropion + Placebo|Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
3139403|NCT02638129|Other|Lead-In: Placebo + Naltrexone/Bupropion|Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
3139404|NCT02638129|Active Comparator|Naltrexone/Bupropion|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
3182391|NCT00702585|Experimental|Org 36286 15 µg|Org 36286 15 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3139405|NCT02638129|Placebo Comparator|Placebo|Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
3139406|NCT02615990|Experimental|Erigo Pro plus standard Physical Therapy|The Erigo device therapy is a combination of tilt table with robotic stepper device allowing for cyclic leg loading. It also includes Functional Electrical Stimulation to optimize active neuromuscular stimulation. It will be used once a day to replace one of the standard PT therapies. The exercise mimics walking beyond what regular range of motion provides. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
3139407|NCT02615990|Active Comparator|Standard Physical Therapy|Patients will have 3 standard Physcial Therapy session. Patients will have 2 additional PT therapies 20 minutes of standard range of motion movements.
3139408|NCT02640677||Pregnant women exposed to 4CMenB|Pregnant women within the United States (U.S) who received at least 1 dose of 4CMenB vaccine within 30 days prior to Last Menstrual Period (LMP) or at any time during pregnancy
3139409|NCT02633540|Experimental|IMRT Radiation|All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.
3139410|NCT02623959|Experimental|Indwelling Pleural Catheter (IPC) + Saline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Saline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status."
3139411|NCT02623959|Active Comparator|Indwelling Pleural Catheter (IPC) + Doxycycline|"Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Doxycycline. Participant given a Fentanyl patch which should be worn at follow up visit 5 days after IPC placement. Fentanyl patch then be removed and Fentanyl by vein given prior to catheter draining. Study staff drains the IPC and places Doxycycline in the catheter.~After the IPC is removed, participant is called one time each month by study staff to check on their status"
3139412|NCT02631148|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 6 weeks
3139413|NCT02631148|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 6 weeks
3139414|NCT02630472|Experimental|Quinine Sulfate|"Each study participant randomized into the experimental arm will receive 28 tubes with 1mg/ml (6 mls total) of quinine sulfate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes. Patients will apply 3 mls of quinine sulfate to each nostril twice per day. Thus the patients will be exposed to a maximum of 12mls or 12.0 mg of quinine per day.~The Investigational Drug Service (IDS) will prepare and record the distribution of the irrigant. The Clinical Research Coordinator or Clinical Research Nurse will pick up the solutions and will demonstrate the application to the subject. The application of the solution is exactly the same as if the study subject were to irrigate with regular saline as part of their daily regimen for chronic rhinosinusitis."
3139415|NCT02630472|Placebo Comparator|Placebo|"The placebo arm will be spiked with Sucrose Octaacetate which has a bitter taste, but does not stimulate sinonasal nitric oxide production.~Each study participant will receive 28 tubes with 0.5mg/ml sucrose octaacetate, as well as 28 3cc syringes with the mucosal atomizing devices. The solutions will be supplied in light-protected tubes.~The placebo arm will mirror the experimental arm exactly, except for the treatment solution contained in the vials."
3139416|NCT02626520|Experimental|Resectable, Low Risk|Systemic chemotherapy followed by definitive surgery without pre-operative or post-operative radiotherapy.
3139417|NCT02626520|Experimental|Locally Advanced|Systemic chemotherapy followed by chemoradiation, followed by definitive surgery
3139418|NCT02614898||Eculizumab|The targeted population consists of pediatric and adult participants with aHUS who received eculizumab at the discretion of the treating physician.
3139419|NCT02622828|Other|Behavioural|Participant-identified community based activity
3139420|NCT02624739|Experimental|Intervention|Reassure Non-Contact Respiration Monitor: Respiration parameters transmitted by the Reassure device will be evaluated daily by the study team and participants will be contacted for further evaluation if a change in respiration patterns is noted. Participants will continue with standard of care heart failure treatment.
3139421|NCT02624739|Active Comparator|Control|Reassure Non-Contact Respiration Monitor: Respiration parameters will be transmitted and stored, but there will be no active evaluation of respiration patterns. Participants will continue with standard of care heart failure treatment.
3139422|NCT02608905|Experimental|Dapagliflozin|Dapagliflozin 5 mg daily by mouth for 2 weeks followed by 10 mg by mouth daily for 10 weeks
3139423|NCT02608905|Placebo Comparator|Placebo|Placebo tablets by mouth daily for 12 weeks
3139424|NCT02619812|Active Comparator|Group A: SBI + Placebo|Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams + placebo twice per day
3139425|NCT02619812|Active Comparator|Group B: Colesevelam + Placebo|Colesevelam 1.875 g + Placebo twice per day
3139426|NCT02619812|Active Comparator|Group C: Colesevelam + SBI|Colesevelam 1.875 g + Serum-derived bovine immunoglobulin/protein isolate (SBI) 10 grams twice per day
3139427|NCT02619812|Placebo Comparator|Group D: Double Placebo|Double placebo twice per day
3139428|NCT02612285|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules to total 100 mg/m2 every other day for 21 days (total = 11 doses), followed by a 7-day drug-free period. Each treatment cycle will be 28 days. Subjects will repeat this 28-day schedule until the cancer progresses or the subject is unable to tolerate SNX-5422.
3139429|NCT02614586|Experimental|Placebo + TAK-058 + Ondansetron|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 milligram (mg), solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
3150195|NCT00197652||Breast milk from HIV infected and HIV uninfected women|Breast milk from HIV infected and HIV uninfected women who are breastfeeding is collected at 2 days, 2 weeks, 2 months, and 5 months post-partum. This breast milk will be compared for in vitro functional quality of immunoglobulins to selected diarrheal and respiratory pathogens.
3139430|NCT02614586|Experimental|TAK-058 + Placebo + Ondansetron|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of third intervention period (2 days).
3139431|NCT02614586|Experimental|Ondansetron + Placebo + TAK-058|Ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
3150196|NCT00197678|Experimental|Multivitamins-Single RDA|Multivitamins at doses resembling a single daily Recommended Dietary Allowance (RDA)
3150197|NCT00197678|Active Comparator|Multivitamins-Multiples of RDA|Multivitamin supplements at multiples of the Recommended Dietary Allowance (RDA)
3150198|NCT00197704|Placebo Comparator|Placebo|Placebo
3150199|NCT00197704|Experimental|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium
3150200|NCT00197730|Experimental|Multivitamins|Vitamin E, Vitamin C, and Vitamin B complex
3150201|NCT00197730|Placebo Comparator|Placebo|Placebo
3150202|NCT00197743|Active Comparator|Vitamin A|Vitamin A + Beta Carotene
3182392|NCT00702585|Experimental|Org 36286 30 µg|Org 36286 30 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3182393|NCT00702585|Experimental|Org 36286 60 µg|Org 36286 60 µg administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3182394|NCT00702585|Placebo Comparator|Placebo|Placebo to Org 36286 administered as a single subcutaneous injection on the day of the onset of a spontaneous or progestagen induced withdrawal bleeding or one to two days later.
3182395|NCT00702598|Experimental|1|Telephone-based Cognitive Behaviour Therapy
3182396|NCT00702598|Placebo Comparator|2|Telephone reminder calls
3150203|NCT00197743|Active Comparator|Multivitamins|Vitamins B, C, and E
3150204|NCT00197743|Active Comparator|Vitamin A + Multivitamins|Vitamin A + Beta Carotene, Vitamins B, C, and E
3150205|NCT00197743|Placebo Comparator|Placebo|Placebo
3150206|NCT00197756||Vitamin A|Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
3150207|NCT00197756||No Vitamin A|Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
3150208|NCT00197756||Multivitamins|Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
3139432|NCT02614586|Experimental|Placebo + Ondansetron + TAK-058|TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
3150209|NCT00197756||No Multivitamins|Participants from the parent study who had been randomized to vitamin A alone or placebo
3150210|NCT00197808|Experimental|Vaccine schedule 1|Menjugate vaccine at 2 and 3 months
3150211|NCT00197808|Experimental|Vaccine schedule 2|Menjugate vaccine at 2 and 4 months
3150212|NCT00197808|Experimental|vaccine schedule3|Neissvacc at 2 and 3 months
3150213|NCT00197808|Experimental|vaccine schedule 4|Neissvacc at 2 and 4 months
3150214|NCT00197808|Experimental|Vaccine schedule 5|Meningitec at 2 and 3 months
3150215|NCT00197808|Experimental|Vaccine schedule 6|Meningitec at 2 and 4 months
3139433|NCT02614586|Experimental|TAK-058 + Ondansetron + Placebo|TAK-058 150 mg, solution, orally along with ondansetron placebo-matching capsule orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by ondansetron 16 mg, capsule, orally, along with TAK-058 placebo-matching solution, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
3139434|NCT02614586|Experimental|Ondansetron + TAK-058 + Placebo|Ondansetron 16 mg, capsule, orally along with TAK-058 placebo-matching solution, orally, on Day 1 of first intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 150 mg, solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of second intervention period (2 days), followed by 1 week washout period, further followed by TAK-058 placebo-matching solution, orally, along with ondansetron placebo-matching capsule, orally, on Day 1 of third intervention period (2 days).
3139435|NCT02606279|Placebo Comparator|Placebo control|20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
3139436|NCT02606279|Experimental|Valsartan|20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.
3139437|NCT02605824|Experimental|20% n-acetylcystine (NAC)|NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.
3139438|NCT02605824|Placebo Comparator|0.9% saline|Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.
3139439|NCT02598622|Experimental|Acetyl-L-Carnitine only|The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
3139440|NCT02598622|Experimental|Acetyl-L-Carnitine or Placebo|Subjects 16-30 will be randomized to receive drug or placebo.
3139441|NCT02589145|Experimental|Lenalidomide + Vorinostat/Gem/Bu/Mel + AutoSCT|"Vorinostat and lenalidomide administered orally at the same time within 1 hour before the daily dose of chemotherapy.~Gemcitabine administered as a loading dose of 75 mg/m2 followed by infusion on days -8 and -3.~Busulfan test dose administered as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1.~Melphalan administered at 60 mg/m2 on days -3 and -2.~Patients with CD20+ tumors receive rituximab 375 mg/m2 on day -9 in the AM as an inpatient.~Dexamethasone 8 mg by vein twice a day from day -8 to day -2. Caphosol oral rinses 30 mL four times a day used from day -8. Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on day -8.~Pyridoxine 100 mg by vein or mouth three times a day from day -1. Enoxaparin 40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3."
3139442|NCT02582749|Active Comparator|Control Arm A|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days.
3139443|NCT02582749|Experimental|Experimental Arm B|All subjects will receive LHRH agonist/antagonist per dosage and route of administration specified by the treating physician. Bicalutamide, 50mg, PO will be administered daily. Cycles will be 28 days. Radium-223 dichloride, 50 kBq/kg body weight, will be administered as a bolus intravenous (IV) injection at intervals of every 28 days for up to 6 cycles.
3139444|NCT02590068|Experimental|Hepatitis C infected volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to Hepatitis C infected volunteers
3139445|NCT02590068|Active Comparator|Healthy volunteers|Zoster vaccine live (Zostavax), 0.65 ml dose, administered subcutaneously to healthy volunteers
3139446|NCT02593682|Experimental|Suvorexant Group|In this arm, subjects will receive 10 mg suvorexant 2 hours before a one-minute 35% CO2 challenge.
3139447|NCT02593682|Placebo Comparator|Placebo Group|In this arm, subjects will receive a placebo, compounded to look identical to the study drug, 2 hours before a one-minute 35% CO2 challenge.
3139448|NCT02587650|Experimental|Arm A (capmatinib)|Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
3139449|NCT02587650|Experimental|Arm B (ceritinib)|Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
3139450|NCT02587650|Experimental|Arm C (regorafenib)|Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
3139451|NCT02587650|Experimental|Arm D (entrectinib)|Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.
3139452|NCT02569957|Active Comparator|Arm I (topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 (+/- 1 day window for each treatment day). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139453|NCT02569957|Experimental|Arm II (topotecan hydrochloride, acetylcysteine)|Patients receive topotecan hydrochloride as in Arm I. Patients also receive acetylcysteine IV over 60 minutes on days 1, 8, 15, and 22 (+/- 1 day window for each treatment day) and acetylcysteine PO BID on days 2-7, 9-14, 16-21, and 23-28, unless administration window was utilized. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139454|NCT02568007|No Intervention|No Cyproheptadine treatment|Patients will receive standard of care behavior and nutritional interventions. They will not receive cyproheptadine.
3139455|NCT02568007|Experimental|Continuous Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
3150216|NCT00198055|Experimental|Aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
3139456|NCT02568007|Experimental|Cycled Cyproheptadine|Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for two weeks cycled with no cyproheptadine given for two weeks for a total of two months. Patients on cycled dosing will be given cyproheptadine for two weeks, then no medication for two weeks; repeating this cycle for the two month duration of study
3139457|NCT02575365|Experimental|Fingolimod arm|0.5 mg p.o fingolimod daily
3139458|NCT02549755|Other|Radiotherapy treatment monitoring of hepatocellular carcinoma|All patients enrolled in the trial will undergo 3 PET/CT studies using 11C-acetate at the injected radiotracer. The patients will be imaged prior to their radiation therapy and at 1 and 3 months following the completion of their radiation therapy. They will also undergo an MRI scan of the liver at each of those time points.
3139459|NCT02547129|Active Comparator|Static Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Static Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
3139460|NCT02547129|Active Comparator|Articulating Antibiotic Spacer|Patient with prosthetic joint infection of their knee will have a two stage joint replacement surgery with the Articulating Antibiotic Spacer Surgical Implant being used to treat the joint infection until the second stage of surgery which will replace the joint after the infection is treated.
3139461|NCT02528097|Placebo Comparator|Active Comparator Standard Care|albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
3150217|NCT00198068||Group 1: aPL+/SLE-|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units; no SLE
3139462|NCT02528097|Experimental|Experimental|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline). If albumin not administered at 48 hours, BUN and Cr will be monitored daily for 72 hours and will be administered if Cr > 1.0 or BUN or Cr are above baseline.
3139463|NCT02549716|Experimental|IV acetaminophen + oral placebo|Patients in this group will receive IV acetaminophen and an oral placebo. The IV formulation will be given using the FDA approved OFIRMEV which comes in a single glass bottle at a concentration of 1000mg/100ml (10mg/ml) containing a total of 1 gram of acetaminophen.
3139464|NCT02549716|Experimental|Oral acetaminophen + IV placebo|Patients in this group will receive oral acetaminophen and a saline solution placebo through their IV. The enteral formulation will be in the standard tablet form of 500mg per pill. Patients will receive two pills, or 1 gram of acetaminophen.
3139465|NCT02540434|Active Comparator|RiaSTAP Arm|Subjects will be infused with RiaSTAP if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
3188882|NCT00771654|Placebo Comparator|Placebo|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
3139466|NCT02540434|Active Comparator|Cryopreciptiate Arm|Subjects will be infused with cryoprecipitate if the ROTEM FIBTEM A10 value is less than or equal to 10 mm and microvascular bleeding is present.
3150218|NCT00198068||Group 2: aPL+/SLE+|Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM >= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM >= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.
3150219|NCT00198068||Group 3: aPL-/SLE+|No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.
3150220|NCT00198068||Group 4: aPL-/SLE-|Healthy controls: no antiphospholipid antibodies; no SLE
3150221|NCT00198120|Experimental|1|Participants will receive D-Cycloserine for 8 weeks.
3150222|NCT00198120|Placebo Comparator|2|Participants will receive placebo for 8 weeks.
3150223|NCT00198263|Experimental|Bleomycin|Bleomycin 4 USP Units/mL; intratumorally at dose of 0.25mL/cm^3
3139467|NCT02531308|Experimental|R-CHOP with Metformin|"Rituximab 375 mg/m2 IV infusion Day 1 Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Vincristine 1.4 mg/m2 (2 mg cap) IV Day 1 Prednisone 100 mg PO Days 1-5 Pegfilgrastim 6 mg subcutaneous within 72 hours of cyclophosphomide Metformin 500 mg PO daily D 1-7, 500 mg twice daily D8-21, 850 mg twice daily D22 - 30days post study.~Cycles are 21 days. Above treatment given for 4 cycles, then restaging done. If complete response (CR) or partial response (PR), 2 more cycle given; stable disease (SD) or progressive disease (PD)- salvage therapy off study."
3139468|NCT02533531|Experimental|1-Lead Outpatient Telemetry|1-Lead Outpatient Patch study participants. Patients assigned to outpatient telemetry monitoring will receive the 1-Lead patch upon discharge from hospital inpatient status. ECG data will be submitted by the 1-lead patch to a central database.
3139469|NCT02534038|Placebo Comparator|Placebo|Placebo drug to be taken twice a day for 6 weeks
3139470|NCT02534038|Active Comparator|AVP-786|Participants randomized to AVP-786 will take one dose of AVP-786 once a day and one dose of placebo once a day for the first 7 days; from day 8, participants will receive AVP-786 twice a day for 5 weeks.
3139471|NCT02520726|Experimental|Sertraline|Patients age 18-65: sertraline 50mg PO qday for one week, then 100mg PO qday for one week, then 150mg PO qday for one week, then 200mg PO qday for one week, with flexible titration. Patient age >65: sertraline 25mg PO qday for one week, then 50mg PO qday for one week, then 75mg PO qday for one week, then 100mg PO qday for one week, with flexible titration
3182397|NCT00702611|Experimental|1|Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
3182398|NCT00702611|Active Comparator|2|Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks
3182399|NCT00702676|Experimental|1|Quetiapine Fumarate Immediate Release
3182400|NCT00702676|Experimental|2|Quetiapine Fumarate Extended Release
3182401|NCT00702728|Experimental|1|Furosemide and matched saline hydration by RenalGuard system
3182402|NCT00702728|Active Comparator|2|Standard IV saline infusion
3182403|NCT00702741|Experimental|A|Chondrogen (low dose)
3182404|NCT00702741|Experimental|B|Chondrogen (high dose)
3182405|NCT00702741|Placebo Comparator|C|Hyaluronan
3139472|NCT02520726|Placebo Comparator|Placebo|Placebo 1 capsule PO qday for one week, then 2 capsules PO qday for one week, then 3 capsules PO qday for one week, then 4 capsules PO qday for one week.
3139473|NCT02520297|Experimental|TRV130|Drug: TRV130
3139474|NCT02519712|Experimental|Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells|This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.
3139475|NCT02518750|Experimental|Study Participants|"Participants with ALL will receive the following interventions in three treatment blocks:~Block A: Dexamethasone, panobinostat, liposomal vincristine, mitoxantrone, peg-asparaginase, bortezomib, intrathecal triples.~Block B: High-dose methotrexate, 6-mercaptopurine, intrathecal triples, high-dose cytarabine.~Block C: Nelarabine or clofarabine, cyclophosphamide, etoposide."
3139476|NCT02516228|Experimental|GTEN 100|All patients will receive treatment according to the protocol with the GTEN 100 device, pulsed only.
3139477|NCT02515851|Active Comparator|Active Group|Group that receives actual liposomal bupivacaine injections
3139478|NCT02515851|Placebo Comparator|Placebo Group|Group that receives placebo injections
3182406|NCT00702793|Experimental|1|Smoking cessation drug - varenicline
3139479|NCT02506985|Experimental|rivaroxaban|For the first 3 weeks, patients will receive rivaroxaban 15mg twice-daily; thereafter they will take rivaroxaban 20mg once-daily as per the drug label. Rivaroxaban will be initiated immediately following completion of alterplase infusion, and heparin will be discontinued at the time of rivaroxaban administration.
3150224|NCT00198276|Experimental|Bleomycin|Bleomycin 4.0 U/mL at dose of 1 U/cm^3 of treatment area; Medpulser EP
3150225|NCT00198315|Active Comparator|Surgery Control|Patients will receive standard of care surgical removal of their tumor.
3150226|NCT00198315|Experimental|MedPulser EPT with Bleomycin|Patients who are eligible for surgical excision will receive MedPulser electroporation with injection of bleomycin sulfate into the tumor treatment area.
3150227|NCT00198328|Active Comparator|Surgery Control|Patients receive surgical excision of their tumor.
3150228|NCT00198328|Experimental|MedPulser EPT|Patients receive electroporation with injection of Bleomycin Sulfate.
3150229|NCT00198341|Experimental|1|Radiological arm (Clinical Visit + X-Ray Chest)
3150230|NCT00198341|Experimental|2|Scan ARM : Clinical Visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous type)
3150231|NCT00198354|Experimental|A: pre-operative chemotherapy|pre-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
3150232|NCT00198354|Experimental|B: pre-operative chemotherapy|pre-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
3150233|NCT00198354|Experimental|C: peri-operative chemotherapy|peri-operative chemotherapy (gemcitabine+cisplatine, 4 cycles)
3139480|NCT02506985|Experimental|heparin-warfarin|Unfractioned heparin (UFH), following hospital protocol to achieve a target PTT or enoxaparin, 1.0mg/kg twice-daily, for a minimal duration of treatment of 5 days. Warfarin may be started on the night after CDT. UFH or enoxaparin should continue until the INR is >= 2.0 on two consecutive measurements at least 24 hours apart with an advised overlap with VKA for 4 to 5 days. VKA dosages will be adjusted to maintain the INR within the therapeutic range (target 2.5, range 2.0 - 3.0).
3139481|NCT02514252|Experimental|Fentanyl Sublingual Spray (FSS)|Hospitalized participants asked to complete a number of surveys at baseline. Participants then receive one single dose of intravenous opioid rescue for their first episode of breakthrough pain, and then receive up to 4 doses of FSS for subsequent episodes of breakthrough pain. Initial FSS starting dose is proportional to the patient's morphine equivalent daily dose (MEDD). Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose. At the time of discharge, if FSS was helpful in controlling participant's pain, they are then able to continue with FSS use for 1 month. Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
3139482|NCT02501759|Experimental|Diagnostic (MRI, MRI-guided biopsy, TRUS-guided biopsy)|Patients receive gadodiamide IV and undergo a diagnostic multiparametric endorectal MRI. Patients with lesions visible on the diagnostic multiparametric endorectal MRI undergo transrectal MRI-guided biopsy within 2 weeks of diagnostic multiparametric endorectal MRI. Patients then undergo TRUS-guided biopsy per standard clinical care approximately 2 weeks after transrectal MRI-guided biopsy.
3139483|NCT02487277|Experimental|Combination therapy with 1 week Run-In|"PEGPH20: 3ug/kg on Days 1 and 4~1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
3139484|NCT02487277|Experimental|Combination therapy alone|"1 cycle = 28 days~PEGPH20: 3ug/kg on Days 1, 8, 15~Gemcitabine: 1000mg/m^2 on Days 1, 8, 15~Nab-paclitaxel: 125mg/m^2 on Days 1, 8, 15"
3139485|NCT02506101|Experimental|narrow-band ultraviolet B phototherapy|We will use the 3 Series PC & SP Phototherapy Cabinet for treatment of vitiligo.
3139486|NCT02506101|No Intervention|no intervention|untreated
3150234|NCT00198354|Experimental|D: peri-operative chemotherapy|peri-operative chemotherapy (paclitaxel+carboplatin, 4 cycles)
3150235|NCT00198367|Experimental|Cisplatin-Gemzar|Cisplatin-Gemzar
3139487|NCT02507973||Airway Pressure Release Ventilation:APRV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and Low Tidal Volume Ventilation on patient intracranial pressure and hemodynamic values.
3139488|NCT02507973||Low Tidal Volume Ventilation:LOTV|Each participant will serve as his/her own control using our observational crossover study comparing the effects of Airway Pressure Release Ventilation and LOTV on patient intracranial pressure and hemodynamic values.
3139489|NCT02499887|Active Comparator|Standard of Care|"Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
3139490|NCT02499887|Experimental|Treatment|"Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications."
3139491|NCT02504099|Experimental|OBV/PTV/r ± DSV ± RBV for 12 or 24 weeks|OBV/PTV/r (ombitasvir/paritaprevir/ritonavir [25 mg/150 mg/100 mg once daily]) with or without dasabuvir (250 mg twice daily) with or without weight-based ribavirin (± RBV; dosed 1,000 or 1,200 mg daily divided twice a day) for 12 or 24 weeks, dosed as per label based on HCV genotype/subtype and presence of cirrhosis.
3150236|NCT00198367|Experimental|Cisplatin-Navelbine-Radiotherapy|Cisplatin-Navelbine-Radiotherapy
3150237|NCT00198367|Experimental|Carboplatin-Taxol-Radiotherapy|Carboplatin-Taxol-Radiotherapy
3150238|NCT00198380|Experimental|1|
3150239|NCT00198393|Experimental|A|Gefitinib
3150240|NCT00198393|Experimental|B|Gemcitabine
3150241|NCT00198393|Experimental|C|Docetaxel
3150242|NCT00198419|Experimental|Vitrase|a single intradermal dose of 3 USP Units of Vitrase (ovine hyaluronidase) at one site and the same volume of saline at a distant site for comparative control
3150243|NCT00198445|Experimental|Bromfenac|Topical bromfenac ophthalmic solution 0.1%
3150244|NCT00198445|Placebo Comparator|Placebo|Vehicle of bromfenac
3139492|NCT02500901|Experimental|Experimental Treatment|Subjects will receive enzalutamide 160 mg/day PO in a 28-day lead-in cycle to assess tolerability. If well-tolerated, cycle 1 of combined enzalutamide and niraparib will commence. Enzalutamide will continue at 160 mg PO daily. Niraparib will be administered in three dose-escalation cohorts of 100mg PO, 200mg PO or 300 mg PO daily. Six subjects will be enrolled at each dose level. Each cycle will be 28 days. Combination treatment will continue until documented progression, unmanageable toxicity, or subject or treating investigator decision to discontinue for any reason.
3139493|NCT02483533|Experimental|Experimental: LIPO-202|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
3139494|NCT02483533|Placebo Comparator|Placebo Comparator: Placebo|Subjects received either LIPO-202 or Placebo for LIPO-202 in the parent study (LIPO-202-CL-18 or LIPO-202-CL-19). Subjects will not receive any additional treatment in this follow-on study.
3139495|NCT02496039|Other|NUEDEXTA®|NUEDEXTA capsules (20 mg dextromethorphan hydrobromide and 10 mg quinidine sulfate) administered orally, once a day from Days 1 to 7 and twice a day from Days 8 to 180
3139496|NCT02492295|Experimental|Propofol|"Propofol is administered intravenously as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes."
3139497|NCT02494206|Experimental|QBX258 (VAK694 3mg/kg and QAX576 6mg/kg)|This will be a single arm, open label design pilot study, aiming to test the efficacy of QBX258, a combination of two fully human monoclonal antibodies that neutralize the biologic activity of interleukin 4 and interleukin 13 (IL4/IL13), for the treatment of stage I or II breast cancer related upper extremity lymphedema (BCRL).
3139498|NCT02473445|Experimental|Cysteamine Bitartrate Delayed-release|Participants received cysteamine bitartrate delayed-release capsules (RP103) twice daily for up to 2 years. The starting dose was the same as the last dose received in study RP103-MITO-001, the maximum dose was 1.3 g/m²/day.
3139499|NCT02491411|Experimental|Treatment (dexamethasone and enzalutamide)|Patients receive dexamethasone PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity until there is evidence of PSA progression, clinical disease progression, or radiographic disease progression. At time of progression, dexamethasone will be stopped via a rapid taper over one week if patients were treated for over 30 days. Patients then receive enzalutamide PO once daily on days 1-28. Treatment repeats every 28 days for up to 3 courses in the absence of clinical disease progression or unacceptable toxicity.
3139500|NCT02476994|Experimental|Clinolipid (lipid injectable emulsion, USP) 20%|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
3139501|NCT02476994|Active Comparator|Intralipid 20% (lipid injectable emulsion, USP)|Dosing schedule based on subject's age, weight, and medical condition and as per ESPEN-ESPHAN guidelines.
3139502|NCT02473523|Experimental|Participants|"Leukemia, Hodgkin Lymphoma and non-Hodgkin's Lymphoma patients who meet eligibility requirements and consent to participate in the study.~Interventions: Yoga Therapy, PedsQL Multidimensional Fatigue Scale, PedsQL Cancer Module, Verbal Numeric Pain Scale. Biodex System 3 Dynamometer, Jamar Hydraulic Hand Dynamometer, Sit and Reach Test, and Test of Motor Proficiency."
3139503|NCT02468583|Experimental|FX006 32mg|Single 5 mL intra-articular (IA) injection Extended-release formulation
3139504|NCT02468583|Active Comparator|TCA IR 40 mg|Single 1 mL intra-articular (IA) injection Immediate-release formulation
3139505|NCT02450591|Experimental|Oligometastatic Non-Small Cell Lung Cancer|Patients will be placed on EGFR-TKI for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will undergo induction TKI for 12 weeks. At the conclusion of 12 weeks on erlotinib, patients without disease progression [partial response (PR) or stable disease (SD)] will undergo definitive local treatment to all remaining sites of disease. After local therapy, erlotinib will be resumed until progression of disease (POD) by RECIST criteria. All assessments completed during the 12 week TKI induction phase are to be performed per protocol with a ± 7 day window.
3139506|NCT02472639|Experimental|Ostom-i Alert Sensor|Patients will wear Ostom-i sensor
3139507|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not wear Ostom-i sensor
3182407|NCT00702806|Experimental|Org 36286 120 μg + Puregon® 150 IU|On Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 120 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3182408|NCT00702806|Experimental|Org 36286 180 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 180 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3188883|NCT00771654|Experimental|Phentermine|Subjects will be randomized to the daily dosing of either oral Phentermine 37.5mg or placebo to commence at their 2 week follow-up appointment following their gastric band procedure
3139508|NCT02469415|Experimental|Pacritinib + Azacitidine or Decitabine|"Part 1: Pacritinib 200 mg taken by mouth twice daily. Study cycles administered every 28 days.~Part 2: After 4 cycles of treatment, Pacritinib combined with 5-azacitidine or Decitabine. Pacritinib decreased to 200 mg in morning and 100 mg in evening for first cycle of combined therapy with Pacritinib increased to 200 mg twice a day on subsequent cycles of combined therapy. Those with disease progression prior to 4 cycles of Pacritinib may initiate Pacritinib + HMA study portion prior to completion of 4 cycles. Starting dose of either 5-azacitidine 75 mg/m2 by vein (IV) or Decitabine 20 mg/m2 IVon Days 1 - 5 of Cycles 5 and beyond."
3139509|NCT02461550|Experimental|IRE procedure|The IRE procedure will be performed in the operating room at the time of scheduled clinical resection of colorectal lung metastases by the surgeon with guidance from the Interventional Radiologist.
3139510|NCT02461355|Experimental|Anodal tDCS|Anodal tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
3139511|NCT02461355|Sham Comparator|Sham tDCS|Sham tDCS over the left posterior language areas during aphasia therapy for 8 one-hour sessions
3139512|NCT02452359|Experimental|Treatment Group|Group receiving treatment with Venus Versa IPL energy
3139513|NCT02434146|Experimental|Supportive care (topical phenylephrine solution)|Patients undergoing a cyclophosphamide and total body irradiation regimen receive topical phenylephrine solution via spray to the oral mucosa 15-20 minutes prior to each cyclophosphamide infusion, 25-30 minutes after the beginning of each cyclophosphamide infusion, and 15-20 minutes prior to each radiation treatment.
3139514|NCT02452398|Experimental|Treatment Group|Hair removal treatment using Venus Versa IPL energy
3139515|NCT02452398|Placebo Comparator|No intervention|Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
3139516|NCT02447887|Experimental|Ixazomib and pegylated IFN alfa - 2b|Ixazomib capsules and pegylated IFN alfa 2b injections weekly. Ixazomib will be taken for the last 3 weeks of 28 day cycle. Pegylated IFN alfa 2b injection will be administered weekly, each week of the 28 day cycle.
3139517|NCT02431494|Active Comparator|BLP arm (Blue Light Phototherapy)|In this arm participants will receive 5 BLP sessions at 1 week intervals. The duration of each session will be approximately 20 minutes. At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes.
3139518|NCT02431494|Active Comparator|MCT arm (Microcurrent Therapy)|In this arm participants will receive 5 MCT sessions 1 week intervals using MCT machine. The duration of each session will be approximately 45 minutes. The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated.
3139519|NCT02431494|Active Comparator|Combination of BLP and Microcurrent|In this arm participants will receive 5 BLP and 5 MCT sessions at 1 week intervals. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
3139520|NCT02439970|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; 1 tablet) administered orally twice weekly, plus valganciclovir (vGCV) placebo (2 tablets) administered orally once daily.
3139521|NCT02439970|Active Comparator|Treatment 2|900 mg valganciclovir (vGCV; two 450 mg tablets) administered orally once daily, plus brincidofovir (BCV) placebo (1 tablet) administered orally twice weekly.
3188884|NCT00771680||A|
3139522|NCT02439957|Active Comparator|Treatment 1|100 mg brincidofovir (BCV; one 100 mg tablet) twice weekly plus valganciclovir (vGCV) placebo (2 tablets) once daily.
3139523|NCT02439957|Active Comparator|Treatment 2|900 mg valanciclovir (vGCV; two 450 tablets) once daily plus brincidofovir (BCV) placebo (1 tablet) twice weekly.
3139524|NCT02441036|Active Comparator|Group 1 - 1-3 hours prior|Subjects will receive Ultherapy treatment 1-3 hours prior to tissue resection.
3139525|NCT02441036|Active Comparator|Group 2 - 1 day prior|Subjects will receive Ultherapy treatment 1 day prior to tissue resection.
3139526|NCT02441036|Active Comparator|Group 3 - 3 days prior|Subjects will receive Ultherapy treatment 3 days prior to tissue resection.
3139527|NCT02441036|Active Comparator|Group 4 - 7 days prior|Subjects will receive Ultherapy treatment 7 days prior to tissue resection.
3139528|NCT02441036|Active Comparator|Group 5 - 45 days prior|Subjects will receive Ultherapy treatment 45 days prior to tissue resection.
3139529|NCT02436265|Sham Comparator|Group 1 Ropivacaine|Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
3150245|NCT00198458|Experimental|Vitrase|A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control.
3139530|NCT02436265|Active Comparator|Group 2 Ropivacaine and Dexamethasone|Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement
3139531|NCT02429583|Active Comparator|Recombivax in HCV infected individuals|Recombivax vaccine administered IM to HCV-infected individuals
3139532|NCT02429583|Active Comparator|Recombivax in healthy volunteers|Recombivax vaccine administered IM to healthy individuals
3139533|NCT02417870|Experimental|aldesleukin|
3139534|NCT02430532|Experimental|Dimethyl fumarate|BG00012 120 mg (1 BG00012 120 mg capsule + 1 matching placebo capsule) orally twice daily (BID) for 1 week, followed by BG00012 240 mg orally BID thereafter.
3150246|NCT00198471|Experimental|Vitrase|A single intravitreous injection of Vitrase 93 USP Units (75 IU) on Study Day 1.
3139535|NCT02430532|Experimental|Placebo|BG00012 120 mg capsule orally once a day supplemented with matching placebo capsules for the first 4 weeks of treatment, as an additional blinding measure. Matched placebo capsules only thereafter.
3139536|NCT02428231|Active Comparator|Standard Treatment (One-Week Titration)|120 mg DMF twice daily for 1 week, then 240 mg (as 2 120-mg capsules) DMF twice daily for 11 weeks
3139537|NCT02428231|Experimental|Slow Up-Titration (Six-Week Titration)|120 mg DMF once daily (morning dose) and placebo once daily (evening dose) for 2 weeks, then 120 mg DMF twice daily for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF in the morning and 120 mg in the evening for 2 weeks, then 240 mg (as 2 120-mg capsules) DMF twice daily for 6 weeks
3139538|NCT02424565|Experimental|Test|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
3139539|NCT02424565|Placebo Comparator|Placebo|2 ± 0.2 g of product will be gently rubbed for 15 seconds on the affected knee joint.
3139540|NCT02413047|Experimental|Immunomodulator|Azathioprine, 6 mercaptopurine or methotrexate.
3139541|NCT02414698|Active Comparator|Percutaneous Hydrodiscectomy|Percutaneous Hydrodiscectomy with the SpineJet Hydrodiscectomy System
3139542|NCT02414698|Active Comparator|TESI|Transforaminal Epidural Steroid Injections
3139543|NCT02422303|Active Comparator|Ketamine Group|This group will receive ketamine 0.5mg/kg IV at induction of general anesthesia.
3139544|NCT02422303|No Intervention|No ketamine group|This group will not receive ketamine at induction of general anesthesia.
3139545|NCT02415166|Experimental|VACCINE MDD|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
3139546|NCT02415166|Placebo Comparator|PLACEBO MDD|SALINE (0.5ML) DELIVERED I.M.
3139547|NCT02415166|Experimental|VACCINE HC|SEASONAL INFLUENZA VACCINE (0.5ML) DELIVERED I.M.
3139548|NCT02415166|Placebo Comparator|PLACEBO HC|SALINE (0.5ML) DELIVERED I.M.
3139549|NCT02414152|Experimental|anakinra|100mg of Anakinra administered as a daily subcutaneous injection
3139550|NCT02410551|Experimental|Pacritinib + Allogeneic Stem Cell Transplantation|Participants start Pacritinib 200 mg by mouth twice a day. Participants proceed to transplant after 60 days of Pacritinib but not more than 180 days. Pacritinib stopped 21 days prior to starting preparative regimen for standard of care stem cell transplantation (SOC Allo TP). SOC transplant conditioning with Fludarabine and Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days. Questionnaires about symptoms and quality of life completed at baseline, 1, 3, 6, and 12 months after transplant. Phone calls made by study staff to participant on second and third week of each month.
3139551|NCT02411643|Other|topical calcipotriene 0.005% ointment|Calcipotriene 0.005% applied to affected areas twice daily to all enrolled subjects
3150247|NCT00198484|Experimental|Vitrase|ovine hyaluronidase injection 150 USP Units in 1 mL solution. Single dose of Vitrase will be administered as an adjuvant prior to ophthalmologic surgery
3150248|NCT00198497|Experimental|Vitrase|Single Hyaluronidase ophthalmic intravitreal injection
3150249|NCT00198497|Placebo Comparator|Placebo|Single Saline solution intravitreal injection
3150250|NCT00198510|Experimental|Vitrase|A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber.
3150251|NCT00198510|No Intervention|Observation|Observation only, no medication or intravitreal injection
3150252|NCT00198523|Experimental|Prednisolone and Tobramycin|Prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
3150253|NCT00198523|Active Comparator|Prednisolone|Prednisolone acetate 1.0% ophthalmic suspension. One drop of test agent will be instilled in the inferior cul de sac of the operative eye prior to cataract extraction.
3150254|NCT00198536|Experimental|Ecabet 2.83%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
3150255|NCT00198536|Experimental|Ecabet 3.70%|Ecabet ophthalmic solution One drop in study eye 4 times daily for 90 days.
3150256|NCT00198536|Placebo Comparator|Vehicle|One drop of vehicle in study eye 4 times daily for 90 days.
3150257|NCT00198562|Active Comparator|1|target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
3150258|NCT00198562|Active Comparator|2|antihypertensive drug (amlodipine vs losartan)
3150259|NCT00198666|Experimental|Treatment|Children with severe pneumonia were randomly assigned to receive supplementation with elemental zinc.
3150260|NCT00198666|No Intervention|Control|Children with severe pneumonia were randomly assigned to receive supplementation with placebo tablets.
3150261|NCT00198718|Experimental|Infant vitamin A Mother vitamin A|Infant received 50,000 IU vitamin A, mother received 400,000 IU vitamin A
3150262|NCT00198718|Experimental|Infant vitamin A Mother placebo|Infant received 50,000 IU vitamin A, mother received placebo
3139552|NCT02410954|Experimental|tDCS electrode configuration|Three rounds of tDCS using NeuroConn Direct Current stimulator Multiple Channel -4, Rogue Resolutions treatment optimization where each round includes identifying a promising electrode configuration based on electric field modeling using a realistic head model and capitalizing on the experience with the prior round (for rounds 2 and 3) and testing that electrode placement by administering a series of electrical doses of tDCS with that tDCS electrode configuration (carrying out a dose titration) in a cohort of 10 healthy control subjects to see if we can find an electrical dose which is well-tolerated, safe, suppresses the AOT pupil response and is below recommended current density safety limits (the safety limit in terms of Amperage varies depending on the electrode configuration)
3139553|NCT02410954|Placebo Comparator|Using tDCS to reduce acute fear|Administration of 7.5% CO2 to see if this elicits symptoms of Acute Fear and activates LC and whether tDCS safely inhibits the LC response to 7.5% CO2 compared with sham in a pilot cross-over trial (N=10). A 3-year double-blind, randomized, controlled trial where clinical symptoms of Acute Fear, the primary outcome are elicited with 7.5% CO2 in healthy volunteers is the final study component.
3150263|NCT00198718|Experimental|Infant placebo, mother vitamin A|Infant received placebo, mother received 400,000 IU vitamin A
3139554|NCT02410577|Experimental|89Zr-J591|Patients will not be required to fast prior to imaging with 89Zr-J591 injection or imaging. The total dose of humanized mAb J591 will be 20mg. Patients will first receive an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody (IND11407) followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg). Administration of the cold antibody will be followed by the labeled compound.
3139555|NCT02409355|Experimental|Atezolizumab|Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
3139556|NCT02409355|Active Comparator|Gemcitabine + Cisplatin/Carboplatin|Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
3150264|NCT00198718|Experimental|Infant received placebo, mother received placebo|Infant and mother received placebo
3139557|NCT02403154|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be internal fixator.
3139558|NCT02403154|Experimental|Randomized to External Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention will be external fixator.
3188885|NCT00771706|Experimental|Proton Pump Inhibitor|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
3188886|NCT00771706|Placebo Comparator|Sugar Pill|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough
3139559|NCT02403154|Other|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the internal fixator intervention based on their preference for the specific case or the patient chose the internal fixator.
3139560|NCT02403154|Other|Observational - External Fixator|Patient signed consent but did not want to randomize their procedure and either the treating physician selected the external fixator intervention based on their preference for the specific case or the patient chose the external fixator.
3139561|NCT02404545|No Intervention|Group 1 - Ideal Conduit No Mesh|No mesh will be placed at the time of radical cystectomy and ileal conduit.
3139562|NCT02404545|Active Comparator|Group 2 - Ileal Conduit with Mesh|Ethicon Physiomesh will be placed at the time of radical cystectomy and ileal conduit.
3150265|NCT00198770|Experimental|Crossover design - 1 arm|Meat week followed by mushroom week, counterbalanced order
3150266|NCT00198796|Experimental|H10407|H10407
3188887|NCT00771719|Experimental|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
3188888|NCT00771732|Experimental|1|Light therapy
3139563|NCT02392377|Experimental|Arm I (paclitaxel, carboplatin, radiation therapy, surgery)|"INDUCTION: Patients receive chemotherapy with carboplatin and paclitaxel. Patients receive carboplatin (AUC=2) and paclitaxel (90 mg/m2) intravenously on days 1 and 8 of a 21 day treatment cycle for two cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive carboplatin (AUC=2) and paclitaxel (50 mg/m2) intravenously once weekly for five weeks throughout the duration of their radiation which is daily (Monday through Friday).~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
3150267|NCT00198861||Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors
3150268|NCT00198874|Active Comparator|Psychoeducation|
3188889|NCT00771732|Sham Comparator|2|"6 minute session given with machine off"
3150269|NCT00198874|Experimental|Conitive Behavorial Therapy|
3150270|NCT00198874|Experimental|Family Therapy|
3150271|NCT00198874|Experimental|Intergrated Family|
3150272|NCT00198939|Active Comparator|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
3150273|NCT00198939|Experimental|Conitive Behavorial Therapy|The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
3150274|NCT00198939|Experimental|Family Therapy|Participants assigned to the Family Therapy arm received a family-centered intervention to support targeted adolescent behavior change. The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases.
3139564|NCT02392377|Experimental|Arm II (combination chemotherapy, radiation therapy, surgery)|"INDUCTION: Patients receive mFOLFOX6 where they get oxaliplatin 85 mg/m2 intravenously on day 1, leucovorin 400 mg/m2 IV on day 1, 5-FU 400 mg/m2 IV on day 1 and then 5FU at 2400 mg/m2 IV to be administered over a 46 hour period. This is repeated every 2 weeks for 3 cycles (total of 6 weeks).~CHEMORADIATION THERAPY: Patients receive oxaliplatin 85 mg/m2 IV on day 1 every 2 weeks for a total of 3 cycles (6 weeks) as well as 5FU 300 mg/m2/day over 96 hours via continuous infusion each week of radiation for a total of 6 weeks.~SURGERY: Approximately 4-10 weeks after completion of chemoradiation therapy, patients undergo esophagectomy at the discretion of the treating team."
3139565|NCT02399111|No Intervention|Not obese:BMI<30; Standard Care|Standard Wound Care
3139566|NCT02399111|No Intervention|Obese:BMI≥30; Standard Care|Standard Wound Care
3139567|NCT02399111|Other|Not Obese:BMI<30; Wound Vac|Using Prevena Incision Management System
3139568|NCT02399111|Other|Obese:BMI≥30; Wound Vac|Using Prevena Incision Management System
3139569|NCT02402036|Experimental|Regorafenib|Regorafenib 120 mg orally daily for 21 days out of a 28 day cycle
3150275|NCT00198939|Experimental|Intergrated Family and Cognitve Behavioral Therapy|Participants assigned to the IFCBT arm received the Cognitive Behavioral Therapy and Family Therapy intervention components.
3150276|NCT00199134|Other|Letrozole|Letrozole 2.5 mg per day
3150277|NCT00199290|Placebo Comparator|P|
3150278|NCT00199290|Experimental|L|low dose (0.2 %)
3139570|NCT02394665|Experimental|Group 1: SIB + IMRT|"Simultaneous Integrated Boost (SIB) plus Fractionated Intensity Modulated Radiation therapy (IMRT), with concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
3139571|NCT02394665|Experimental|Group 2: SRS Boost + IMRT|"For patients with High-Risk Tumor Volumes (HTV) <= 4cm; or multiple HTVs <= 3 cm:~Stereotactic Radiosurgery Boost (SRS Boost) followed one week later by Fractionated Intensity Modulated Radiation therapy (IMRT), and concurrent Temozolomide therapy for 6 weeks;~3D MRSI during week 3, end of RT and other protocol-defined time points during adjuvant Temozolomide therapy;~Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire administered at protocol-defined time points;~Adjuvant Temozolomide Therapy for up to 12 cycles."
3139572|NCT02389712|Active Comparator|Lamotrigine|Subjects on this arm will be randomized to Lamotrigine.
3139573|NCT02389712|Active Comparator|Fluoxetine|Subjects on this arm will be randomized to Fluoxetine.
3139574|NCT02390362|Experimental|Rituximab|Rituximab 375 mg/m2 will be administered intravenously on Study weeks 1 & 3.
3150279|NCT00199290|Experimental|M|medium dose (0.3 %)
3139575|NCT02390362|Active Comparator|Mycophenolate Mofetil (MMF)|Mycophenolate Mofetil will be continued in the patients in the MMF arm at a standard oral dose of 600 mg/m2 PO, BID starting on Study week 1 and continuing for 12 months
3139576|NCT02388776|Experimental|ROTEM|Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.
3139577|NCT02383433|Experimental|Treatment (regorafenib, gemcitabine hydrochloride)|Patients receive regorafenib PO QD on days 1-21 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139578|NCT02382588|Experimental|Gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
3139579|NCT02382588|Placebo Comparator|hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
3139580|NCT02381626|Experimental|Intervention Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. At the end of the initial two weeks, portable HEPA air purifiers (136) will be placed in the Intervention Group drivers' cars and the air monitoring and biological parameters will be repeated for another 2-week period, to determine changes in PM levels and physiological measurements as a result of this targeted intervention.
3139581|NCT02381626|Experimental|Wait-list Control Group|During the first 2 weeks, measurements (e.g. biological markers and air monitoring) will be taken under usual conditions. The Wait-list Control Group drivers will not receive a HEPA air purifier at this time, but will also have the air monitoring and biological parameters repeated for another 2 weeks. At the end of the 1 month period of measurements for both groups of drivers, the Wait-list drivers will then receive a HEPA air purifier, so that they may also potentially benefit from the intervention being tested in this study, but no further measurements will be taken.
3139582|NCT02379390|Experimental|Cabazitaxel|Participants received Cabazitaxel 25 mg/m^2, intravenously for 1 hour along with prednisone 10 mg orally on Day 1 of every treatment cycle (each cycle was of 3 weeks) until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
3150280|NCT00199290|Experimental|H|high dose (0.4 %)
3150281|NCT00199485|Experimental|1|Angelica Sinensis
3150282|NCT00199485|Placebo Comparator|2|placebo
3150283|NCT00199498|Experimental|Septal RV lead placement|patient randomized to Septal RV lead placement
3150284|NCT00199498|Active Comparator|Apical RV lead placement|patient randomized to Apical RV lead placement (current standard placement)
3150285|NCT00199524|Active Comparator|1|ureteroscopy with ureteral access sheath
3150286|NCT00199524|No Intervention|2|ureteroscopy without ureteral access sheath
3150287|NCT00199550|Active Comparator|2|Bipolar Electrosurgical Unit
3150288|NCT00199550|Active Comparator|1|Monopolar Electrosurgical Unit
3150289|NCT00199563|Active Comparator|active drug|Viagra 100 mg / daily for 12 weeks.
3150290|NCT00199563|Placebo Comparator|Placebo|placebo/daily for 12 weeks
3150291|NCT00199602|No Intervention|lack of drug prophylaxis|
3150292|NCT00199602|Experimental|HBPM 2500 UI anti Xa in one subcutaneous injection per day|
3150293|NCT00199602|Experimental|warfarine 1mg daily|
3139583|NCT02379390|Active Comparator|Abiraterone acetate or Enzalutamide|Participants received abiraterone acetate 1000 mg (4 tablets of 250 mg), orally once daily along with prednisone 5 mg, orally twice daily from Day 1 to 21 in each treatment cycle (each cycle was of 3 weeks) or enzalutamide 160 mg, orally, until disease progression, unacceptable toxicity, or participant's refusal of further study treatment.
3139584|NCT02373865|Experimental|Arm A|Patients receiving Sitagliptin 100 mg+ Glimepiride-placebo (adapted dosage)
3139585|NCT02373865|Active Comparator|Arm B|Glimepiride (adapted dosage) + Sitagliptin 100 mg Placebo
3139586|NCT02365688|Other|Initial bolus pre-incision|Initial pre-incision bolus of 500 cc of fluids with hemodynamic response recorded
3139587|NCT02361580|Experimental|Diary|Subjects that are randomized to the diary group will be told to keep a diary of their recovery. The study is focusing on the effect of keeping a diary on disability, rather than the content of the diary.
3139588|NCT02361580|No Intervention|No Diary|Control Group
3139589|NCT02369744|Active Comparator|Silodosin|Subjects in the Silodosin Group will be given silodosin 8 mg tablets, one tablet to be taken PO each day for two weeks.
3139590|NCT02369744|Active Comparator|Tamsulosin|Subjects in the Tamsulosin Group will be given tamsulosin 0.4 mg tablets, one tablet to be taken PO each day for two weeks.
3139591|NCT02379585|Active Comparator|HER2 negative breast cancer|Doxorubicin and cyclophosphamide every two weeks for four cycles (one cycle is defined as 14 days). After completing fourth cycle, paclitaxel every two weeks for an additional four cycles. The appropriate surgery will be done three to six weeks after completing the last cycle of paclitaxel.
3139592|NCT02379585|Active Comparator|HER2 positive breast cancer|Docetaxel, trastuzumab, and pertuzumab every three weeks for four cycles. Pegfilgrastim after docetaxel. Surgery three to six weeks after completing the last docatexel. If additional chemotherapy is needed patients will receive both doxorubicin and cyclophosphamide every three weeks for four cycles and after the fourth cycle then trastuzumab for one year
3182409|NCT00702806|Experimental|Org 36286 240 μg + Puregon® 150 IU|Cycle Day 2 or Day 3, a single intra-abdominal injection of Org 36286 240 μg was administered to participants. On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3182410|NCT00702806|Active Comparator|Puregon® 150 IU|On stimulation Day 8, a daily subcutaneous dose of Puregon® 150 IU was administered up to and including the time of Pregnyl® administration as a single dose of 10,000 IU subcutaneously. The maximum treatment duration of Puregon® 150 IU was 19 days. Orgalutran® 0.25 mg was administered subcutaneously once daily up to and including the day of Pregnyl®, when the leading follicle reached a size of >= 14 mm.
3139593|NCT02370888|Experimental|Lenalidomide|"Lenalidomide will be administered for a total of 42 days.~The dose levels of lenalidomide will be as follows:~Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles~Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles"
3139594|NCT02367170|Experimental|IMST Intervention group|IMST will be conducted 5 days per week by study staff using a threshold inspiratory muscle training device (Respironics model 735). Prior to training, the tracheal cuff pressure is assessed to ensure no air leakage and appropriate inflation. The IMST training takes approximately 15 minutes to complete. To perform IMST, FiO2 is increased for 2 minutes prior to each training bout to maintain oxygen saturation more than 92%.
3139595|NCT02367170|Sham Comparator|SHAM group|SHAM training will also be conducted five days per week with an identical training device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout.
3139596|NCT02376933|Experimental|Vertebroplasty with Radiotherapy|Vertebroplasty with Radiotherapy is given in either order. Radiotherapy dosage is at the discretion of the treating physician. Vertebroplasty is applied to fractured vertebrae.
3139597|NCT02365233|Active Comparator|Thiazolidinedione|(Pioglitazone, 15 mg/day)
3139598|NCT02365233|Active Comparator|Lantus Insulin|0.35 U per kg body weight once daily
3139599|NCT02365233|Active Comparator|DPP4 inhibitor|Sitagliptin, 100 mg/day or Saxagliptin, 5 mg/day
3139600|NCT02365207|Experimental|BCG treatment of invasive bladder cancer|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
3139601|NCT02360111|Experimental|Post Transplant Cyclophosphamide|Melphalan 70 mg/m 2/d will be administered intravenously on d-6 and -5 Fludarabine 25 mg/m 2/d will be administered intravenously on d-6 thru -2 Day -1 will be a day or rest Cyclophosphamide and mesna will be given on d+3 and +4 Siro +/- MMF will be started in those patients who are to receive it on d+5. Neupogen will begin d+7.
3139602|NCT02353468|Experimental|Enzyme inhibitor, biological therapy, chemotherapy|"CONSOLIDATION: Patients receive VLD therapy comprising bortezomib IV on days 1, 4, 8, and 11, lenalidomide PO QD on days 1-14, and dexamethasone PO or IV on days 1, 2, 4, 5, 8, 9, 11, and 12. Courses continue for 28 days and repeat every 3 months in the absence of disease progression or unacceptable toxicity.~In between courses of VLD, patients receive LD therapy comprising lenalidomide PO QD on days 1-21 and dexamethasone PO QD or IV every Monday (x3). Courses continue for 28 days.~MAINTENANCE: Starting in the third year of therapy, patients receive lenalidomide PO QD on days 1-14 and dexamethasone PO QD or IV every Monday (x2). Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity."
3139603|NCT02360059|Experimental|Metformin Group|"Participants take 1,000 mg Metformin by mouth twice daily for 12 weeks during Paclitaxel treatment.~Adaptation phase begins 12 days prior to the start of the Paclitaxel therapy. During this phase, study medication dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by the desired dose of 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
3139604|NCT02360059|Placebo Comparator|Placebo Group|"Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.~Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.~Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit."
3139605|NCT02350777|Experimental|active infection and/or organ compromise or GVHD.|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
3139606|NCT02350777|Experimental|active infection, active or controlled GVHD &/or organ compro|This protocol includes two single-arm phase II trials to assess the efficacy and confirm the safety of administration of TCD stem cell boost or bone marrow (BM) HPC (M) boost from the original donor for patients with poor graft function after allogeneic hematopoietic stem cell transplantation.
3139607|NCT02345460|Experimental|Treatment (FOLFIRINOX)|Patients receive FOLFIRINOX regimen comprising irinotecan hydrochloride IV over 90 minutes, oxaliplatin IV over 120 minutes, leucovorin calcium IV over 120 minutes, and fluorouracil IV over 1-2 minutes and then continuously over 46 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3182411|NCT00702832|Experimental|Vestibular rehabilitation|early supported vestibular rehabilitation
3182412|NCT00702832|Active Comparator|standard|standard treatment
3139608|NCT02346877|No Intervention|Standard of Care Cohort|The first 100 participants will be enrolled in the standard of care (control) cohort. These participants will receive treatment with Enbrel® (etanercept) in routine clinical practice and will complete a 52 week study period as per the investigator's standard of care.
3139609|NCT02346877|Other|Personalized Patient Counselling Cohort|Initiation of the personalized patient counselling cohort will begin after 75% of participants in the control cohort have been analyzed and shown not to have high persistence. Participants will receive Enbrel® (etanercept) therapy in routine clinical practice and personalized patient counselling based on the Information-Motivation-Strategy (IMS) model based on Beliefs about Medicines Questionnaire (BMQ) baseline results through a patient assistance program for patients on Enbrel (etanercept) therapy.
3139610|NCT02351063|Experimental|Daily BNP|Subjects will be asked to test their BNP at home every day for a period of 180 days using the AlereTM HeartCheck System (the Test System). In addition to BNP, weights and signs and symptoms of HF will be collected each day of testing. The HeartCheck data is transmitted via a secure wireless protocol to the HealthCOM health monitoring portal where it is available to the medical staff. The subject's's physician and medical staff will be required to evaluate the data and determine if a change in HF treatment is advisable. All changes of heart failure medications are at the discretion of the treating physician and medical staff of the institution.
3182413|NCT00702858|Active Comparator|1|Blue Citrus either months 1-3 or 4-6
3182414|NCT00702858|Placebo Comparator|2|Placebo
3182415|NCT00702871|Active Comparator|1|Arm 1 was given Injection Ranitidine 50mg i.v. 8 hourly for stress ulcer prophylaxis.
3182416|NCT00702871|Active Comparator|2|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
3139611|NCT02345772|Experimental|Treatment Protocol|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery. Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
3139612|NCT02340728|Experimental|ERCP with SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period. Sequential applications of RFA are applied along the entire length of the stricture with an overlap of 1cm.
3182417|NCT00702910|Experimental|GW642444M/lactose|GW642444M/lactose 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3182418|NCT00702910|Experimental|GW642444M/MgSt|GW642444M/MgSt 6.25, 25 and 100 microgram, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3182419|NCT00702910|Placebo Comparator|Placebo|Placebo containing lactose, single inhaled dose for two days treatment in each treatment sequence (crossover design)
3139613|NCT02340728|Active Comparator|ERCP with SEMS alone (standard of care)|Endoscopic retrograde cholangiopancreatogram (ERCP) is performed under standard conditions with cannulation of the bile duct, and demonstration on a cholangiogram the location, diameter and length of the biliary stricture. The HabibTM EndoHBP probe (EMcision, London, United Kingdom) is advanced through the working channel of a side viewing endoscope over a 0.035in guidewire, and positioned across the occluded SEMS under fluoroscopy. 7-10W are usually delivered for 90 seconds with a standard high frequency generator, followed by a 1 minute resting period.
3139614|NCT02353572|Experimental|Melphalan, Bortezomib, Autologous transplant|Patients receive melphalan IV continuously on days -5 to -2 and bortezomib IV over 3-5 seconds on days -4 and -1. Patients also receive dexamethasone IV on day -1 prior to the second dose of bortezomib. Beginning two days after completion of melphalan infusion, patients undergo autologous hematopoietic stem cell transplant. Eligible patients may undergo a second transplant 2-4 months after completion of the first transplant.
3139615|NCT02345369|Active Comparator|Locked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
3182420|NCT00702936|Active Comparator|R|Twenty-five patients assigned to ramipril 5 mg daily
3182421|NCT00702936|Active Comparator|T|Twenty-five patients assigned to Telmisartan 80 mg daily
3182422|NCT00702988||Experimental Group 1|all doses of Org 36286 (corifollitropin alfa) (60 μg, 120 μg and 180 μg)
3182423|NCT00702988||Experimental Group 2|150 IU recFSH
3182424|NCT00703001|Active Comparator|1--Educational Intervention|Students in this arm will receive several in-class educational modules on basic oral health topics.
3182425|NCT00703001|Active Comparator|2--Referral intervention|Parents of student subjects will receive assistance in accessing oral health care for their child
3182426|NCT00703040||Component 1|Existing linkage to care protocols will be obtained from the 15 sites. This component does not involve study subjects.
3182427|NCT00703040||Component 2|Person-to-person or telephone interviews with ATN clinical site staff and staff from their community partners will be audio-taped.
3182428|NCT00703040||Component 3|Notes from direct observation of the linkage to medical care process within sites will be taken.
3182429|NCT00703066|Experimental|1|three doses of 30µg GMZ2,
3182430|NCT00703066|Experimental|2|3 doses of 100 µg of GMZ2
3182431|NCT00703066|Active Comparator|3|Rabies vaccine
3139616|NCT02345369|Active Comparator|Unlocked Set Screw|In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.
3139617|NCT02343263|No Intervention|Control|44 patients will be randomized to receive no topical treatment to their tonsillectomy (or adenotonsillectomy) wound bed as is the current standard of care at our institution. The wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis alone.
3182432|NCT00703079||Group A|>15 patients treated only with SSA (octreotide-LAR or lanreotide depot)
3182433|NCT00703079||Group B|>15 patients treated with surgery after a period of SSA treatment of 6-24 months
3182434|NCT00703079||Group C|>15 patients cured after surgery only
3139618|NCT02343263|Active Comparator|Fibrin Sealant Alone|44 patients will be randomized to receive application of topical fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
3182435|NCT00703079||Group D|>15 patients treated with surgery first and then with SSA after 6-12 months
3182436|NCT00703105|Experimental|Autologous Dendritic Cell Vaccination|DC vaccination with 1 x 10(6th) tumor lysate or WT1 and MUC1 peptide and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals(6 weeks)
3182437|NCT00703131||1|Anal Fistula Plug
3182438|NCT00703144|Experimental|Pharmacokinetic|
3139619|NCT02343263|Experimental|Bupivacaine-infused Fibrin Sealant|44 patients will be randomized to receive application of topical bupivacaine-infused fibrin sealant to their tonsillectomy (or adenotonsillectomy) wound bed to assess the pain reduction benefits of fibrin sealant alone. Prior to application of fibrin sealant, the wound bed will be treated with instrumentation in the operating room to ensure adequate hemostasis.
3139620|NCT02343159|Experimental|Arm 1: Standard MEMS Cap|A standard MEMS cap that records the time and date when the bottle is opened without a visual LCD reader. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3139621|NCT02343159|Experimental|Arm 2: Smart MEMS Cap|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings). Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3182439|NCT00703170|Experimental|Dose Level 1 (original)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 30 mg/m2 once every 4 weeks"
3182440|NCT00703170|Experimental|Dose Level 1 (revised)|"Temsirolimus IV 20 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
3139622|NCT02343159|Experimental|Arm 3: Smart MEMS Cap + Counseling|A smart MEMS cap with feedback (an LCD reader that allows the participant to monitor DMF bottle openings) and an adherence counseling intervention. Standard-of-care commercial supply of DMF (BID oral capsule) will be used in this study.
3139623|NCT02341495|Experimental|Drug Treatment|Deferasirox (20mg/kg/day)on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Cholecalciferol(4,000 units/day), on days 1-7 of protocol, repeated every four weeks for 8 cycles given PO Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol, repeated every four weeks for 8 cycles given either subcutaneously or IV
3139624|NCT02336425|Experimental|QGE031 240 mg|QGE031 240 mg subcutaneous injection every 4 weeks
3139625|NCT02336425|Experimental|QGE031 72 mg|QGE031 72 mg subcutaneous injection every 4 weeks
3139626|NCT02336425|Experimental|QGE031 24 mg|QGE031 24 mg subcutaneous injection every 4 weeks
3139627|NCT02336425|Placebo Comparator|Placebo to QGE031|Placebo subcutaneous injection every 4 weeks
3139628|NCT02336763|Experimental|Treatment (external beam radiation therapy)|Patients undergo external beam radiation therapy daily over 20 minutes on Monday-Friday for up to 10 fractions over approximately 2 weeks.
3139629|NCT02320825|Experimental|single-fraction SRS (24 Gy)|single-fraction (24Gy) SRS within eight weeks of having undergone spinal decompression surgery.
3139630|NCT02320825|Experimental|high-dose hypofractionated SRS (27 Gy in 3 fractions)|hypofractionated (3 fractions of 9Gy, total dose of 27Gy) SRS within eight weeks of having undergone spinal decompression surgery.
3139631|NCT02319005|Active Comparator|Revusiran (ALN-TTRSC)|administered by subcutaneous (SC) injection
3139632|NCT02319005|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|administered by subcutaneous (SC) injection
3139633|NCT02318901|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. Intravenous (i.v.) trastuzumab 6 mg/kg on day 1 every 21 days.
3139634|NCT02318901|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. ado-trastuzumab emtansine 3.6 mg/kg on day 1 every 21 days.
3182441|NCT00703170|Experimental|Dose Level 2|"Temsirolimus IV 25 mg weekly~Pegylated liposomal doxorubicin IV 25 mg/m2 once every 4 weeks"
3182442|NCT00703183|Experimental|1|ACU-4429
3182443|NCT00703183|Placebo Comparator|2|matching placebo
3139635|NCT02318901|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks. i.v. cetuximab 400 mg/m2 on cycle 1 day 1, then i.v. cetuximab 250 mg/m2 on day 8. Each subsequent cycle will be i.v. cetuximab 250 mg/m2 on days 1 and 8 every 21 days.
3139636|NCT02317276|Experimental|Treatment|Topical Triamcinolone 0.1% ointment will be provided for twice daily application, during treatment periods.
3139637|NCT02307188|Experimental|Basket Catheter|The Constellation Full Contact Mapping Catheter (multipolar catheter) to be utilized for collection of atrial electrograms.
3182444|NCT00703196|Experimental|Arm I|Patients receive oral folic acid pill once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
3139638|NCT02308475|Experimental|Myocardial Stress CT Perfusion|"Dynamic volume CT myocardial perfusion using the experimental scanner (Force, Siemens), applying the dynamic shuttle mode will be used to rapidly cover the entire cardiac anatomy during infusion of a contrast medium bolus for monitoring bolus passage through the left ventricular myocardium."
3139639|NCT02308735||Control|Pregnant women without either gestational or pre-gestational diabetes mellitus (and their offspring).
3139640|NCT02308735||A1 IDM|Pregnant women with abnormal glucose tolerance test but normal fasting serum glucose levels (and their offspring).
3139641|NCT02308735||A2 IDM|Pregnant women with abnormal glucose tolerance test and fasting hyperglycemia (and their offspring).
3139642|NCT02308735||PGDM - IDM|Pregnant women with diabetes mellitus diagnosed prior to current pregnancy (and their offspring).
3139643|NCT02299206|Experimental|CeraVe Baby Diaper Rash Cream|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
3139644|NCT02299206|Experimental|Desitin Maximum Strength Original Paste|Healthy 3-18 months old infants with mild to moderate diaper dermatitis.
3182445|NCT00703196|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 12 months in the absence of unacceptable toxicity or any other adverse effects.
3139645|NCT02302859|Experimental|Standard Treatment (ST)|"Participants supplied with a 8-week supply of nicotine patches, a smart phone and brief advice to quit smoking. Participants also receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months after intervention.~Participants complete saliva cotinine test 3 months after intervention."
3182446|NCT00703209|Active Comparator|1|Patients who are randomized to receive surgical care, will receive the nerve decompression, along with similar incisions on the opposite leg, but no decompression on that leg. This will serve as the patient's control leg, and also blind them to the treatment leg.
3182447|NCT00703209|No Intervention|2|Subjects who are not randomized to receive the surgical procedure will be followed up with the same clinic visits as the patients who are receiving the surgical procedure.
3182448|NCT00703222|Experimental|Dose Level 1|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 1 SKNLP
3139646|NCT02302859|Experimental|Automated Treatment (AT)|"Participants supplied with a 8-week supply of nicotine patches and a smart phone. Participants also receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone.~Participants receive weekly assessments to complete for the 8-week treatment period via smartphone, and again at 3 months.~Participants complete saliva cotinine test 3 months after intervention."
3139647|NCT02299934|Other|Subjects who fulfill the criteria for living liver donation|Subjects who fulfill the criteria for living liver donation and are evaluated for the procedure with Computerized Tomography (CT) and Magnetic Resonance Imaging (MRI).
3139648|NCT02297230|Experimental|Arm 1 Capecitabine and RT|Her-2/neu negative patients will be given Capecitabine (xeloda, 750mg/m2 twice daily orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
3139649|NCT02297230|Experimental|Arm 2 Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) will begin on day 1 of radiation therapy and be administered weekly to Her-2/neu Positive patients. The first dose will be 4mg/kg given IV over 90 minutes. Weekly doses will be 2 mg/kg/week IV over 30 minutes.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour.
3182449|NCT00703222|Experimental|Dose Level 2|SNJB-JF-IL2 and SJNB-JF-Lptn + Dose Level 2 SKNLP
3182450|NCT00703248|Experimental|1|
3182451|NCT00703248|No Intervention|2|
3139650|NCT02297230|Experimental|Arm 3: Paclitaxel and RT|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour to Her-2/neu negative patients. Treatment will be initiated during the first week of radiation therapy and should be administered on a Monday/Thursday or Tuesday/Friday schedule.
3182452|NCT00703274|Experimental|Navigation Group|Participants enrolled in this group will receive education concerning primary and secondary PROTECT DC goals. Primary PROTECT DC goals adhere to the following medication directives: 1) Anti-hypertensive, 2) Lipid Lowering, 3) Anti-Coagulant, and 4) Anti-Diabetic. PROTECT DC secondary goals include the following behaviors 1) Smoking Cessation, 2) Consuming an AHA Diet, 3) Regular Exercise, and 4) Knowledge of Stroke Risk and Warning Signs. Participants will also receive assistance with overcoming resource-related barriers to the PROTECT DC goals.
3139651|NCT02297230|Experimental|Arm 4: Paclitaxel/Trastuzumab and RT|Trastuzumab (Herceptin®) tx will be administered weekly, together with one of the 2 weekly doses of Paclitaxel to Her-2/neu Positive patients. The 1st dose will be 4mg/kg given IV over 90 minutes. Weekly doses will b given at a dose of 2 17mg/kg/week IV over 30 minutes. The Tx with Trastuzumab will continue weekly after the completion of the radiation tx until surgery & thereafter as per std of care up to 1 yr post surgery.Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Tx will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab.
3139652|NCT02294981|Active Comparator|Conventional Dosing|Patients psoriasis to be treated with Excimer laser phototherapy based on conventional dosing guidelines. These guidelines determine the starting dose based on plaque thickness and the skin type of the patient. Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
3139653|NCT02294981|Experimental|Plaque based dosing|Patients will also be evaluated for psoriasis plaque response to test doses. The best dose will be selected from a test matrix of doses.
3139654|NCT02284906|Experimental|Pioglitazone 0.8 mg|Pioglitazone 0.8 mg, tablets, orally, once, daily, for minimum of 2 years.
3139655|NCT02284906|Placebo Comparator|Placebo|Pioglitazone placebo-matching tablets, orally, once, daily, for minimum of 2 years.
3139656|NCT02287025|Experimental|SMART|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
3139657|NCT02287025|Active Comparator|Standard of Care|Investigators were supported with standard prescribing information.
3139658|NCT02282332|Experimental|Patiens Discharged on Ticagrelor|Patients to be discharged on ticagrlore regiment of 90mg twice a day for 6 months.
3139659|NCT02287636|Experimental|Diagnostic (fludeoxyglucose F 18 PET/CT and PET/MRI)|Patients undergo fludeoxyglucose F 18 PET/CT followed by PET/MRI.
3139660|NCT02276560|Experimental|Neoadjuvant Cisplatin,nab-paclitaxel|Neoadjuvant cisplatin (75 mg/m2) D1 and nab-paclitaxel (125 mg/m2) D1, 8, 15, repeat each 28D cycle x 3 and then surgery per standard of care
3139661|NCT02276560|Experimental|Adjuvant Cisplatin,nab-paclitaxel|Adjuvant cisplatin (75mg/m2) D1, nab-paclitaxel (125 mg/m2)for D1, 8, 15 repeat each 28D x 2
3139662|NCT02276560|Other|Cisplatin+pemetrexed or gemcitabine|Adjuvant cisplatin (75mg/m2) D1, pemetrexed (500mgm2) D1 or; cisplatin (75 mg/m2),Gemcitabine (1000mg/m2) D1, 8 repeat each 21D cycle x 4
3139663|NCT02280252|Experimental|Concurrent Paclitaxel and RT|"Patients will be administered pre-operatively over 12 weeks either:~Paclitaxel, 30mg/m^2 twice per week, intravenously over 1 hour on a Monday/Thursday or Tuesday/Friday schedule~Abraxane, 30mg/m^2 twice per week, intravenously administered over 30 minutes, on a Monday/Thursday or Tuesday/Friday schedule~Patients will concurrently receive 6 weeks of radiation therapy, weeks 2-7:~Patients will receive a total dose to the breast, axilla and supraclavicular area of 45 Gy at 1.8 Gy/fraction, +14 Gy to the area of the original palpable tumor at 2 Gy/fraction (32 fractions)"
3182453|NCT00703274|No Intervention|Control Group|Participants enrolled in this group will receive periodic follow up through mailings, phone calls etc to ensure availability for 1 year assessment.
3182454|NCT00703287|Sham Comparator|A2|Generic physiotherapy
3139664|NCT02284373|Other|Randomization Arm 1:|70 subjects with venous ulcers will receive pneumatic compression with the Flexitouch® for the duration of one month in addition to routine care of venous ulcers and lymphedema. A pre- and post-PCD treatment CIVIQ-2 quality of life questionnaire will be administered to the subjects. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded
3182455|NCT00703287|Experimental|A1|Specialized Physiotherapy
3182456|NCT00703300|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.
3182457|NCT00703313|Active Comparator|2|described in intervention
3182458|NCT00703313|Active Comparator|3|described in intervention
3139665|NCT02284373|Other|Randomization Arm 2:|70 subjects with venous ulcers will receive routine care of venous ulcers and lymphedema. A quality of life questionnaire will be administered at enrollment and again after one month. For subjects with venous ulcers, wound area pre- and post-treatment will be recorded.
3139666|NCT02284373|Other|Observational Arm 3|50 subjects with lymphedema will ALL receive PCD treatment. A pre-and post- PCD treatment CIVIQ-2 QOL questionnaire will be administered to all subjects at enrollment and again after one month of treatment.
3139667|NCT02285270|Other|Single group assignment|Diagnostic test/procedure - FDG PET/CT
3139668|NCT02275481|Experimental|BROVANA|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
3139669|NCT02275481|Active Comparator|SPIRIVA|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
3182459|NCT00703313|Active Comparator|1|described in intervention
3182460|NCT00703352|Active Comparator|1|Eplerenone
3139670|NCT02266914|Experimental|Arm 1|Patients who have received a cardiac transplant at The Ohio State University Ross Heart Hospital will undergo Magnetic Resonance Elastography (MRE) (using a Magnetic Resonance Elastography driver) within 24-48 hours of standard of care biopsy. Results of both will be compared to determine if MRE can successfully predict cardiac transplant rejection.
3139671|NCT02273752|Experimental|Supportive care (real-time pharmacokinetic TDM of everolimus)|Patients receive everolimus PO daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also undergo real-time pharmacokinetic TDM on days 4, 8, and 15 of course 1. Dosing adjustments of everolimus will be performed on day 8, if necessary. If the everolimus dose is adjusted, patients will continue to undergo real-time pharmacokinetic TDM weekly until goal concentrations are achieved on 2 consecutive measures. Patients whose everolimus dose is not adjusted undergo real-time pharmacokinetic TDM on day 1 of courses 2-6.
3139672|NCT02270684|Experimental|Device|Participants in this arm will receive the StepRite device. They will have a remote visit with their Physical Therapist in place of one in-person visit per week during the outpatient phase of their treatment
3139673|NCT02270684|No Intervention|Usual and customary care|Participants in this arm will undergo usual care and will not be issued with the StepRite device
3139674|NCT02262000|Experimental|A - 7.5 Gy x 10 daily fractions|Radiotherapy: 7.5 Gy x 10 daily fractions delivered with VMAT or regular IMRT at West Virginia University.
3139675|NCT02262000|Experimental|B - 12 Gy x 5 daily fractions|Radiotherapy: Optional schedule of 12 Gy x 5 daily fractions can may also be used ONLY in situations where dose constraints for organs at risk can be EASILY met while optimal PTV coverage is achieved
3139676|NCT02271594|Active Comparator|Intervention|Intensive education on injection technique
3139677|NCT02271594|Placebo Comparator|Control|Standard education on injection technique
3139678|NCT02263365|No Intervention|Control|
3139679|NCT02263365|Experimental|Therapeutic|Patients randomized to this arm will be administered 4mg tid (three times daily) of loperamide from the day of discharge onwards. A total of duration of 14 days of medication will be administered
3182461|NCT00703352|Placebo Comparator|2|Placebo
3182462|NCT00703365|Experimental|1|Sorafenib
3182463|NCT00703378|Experimental|Group 1|Group 1: normal liver function
3182464|NCT00703378|Experimental|Group 2|Group 2: AST and/or ALT up to 1-5 x upper limit of normal; SAP 1- 5x upper limit of normal, total bilirubin within normal limits
3182465|NCT00703378|Experimental|Group 3|Group 3: Any SAP and AST/ALT >5-10 x upper limit of normal and/or total bilirubin 1-1.5 x upper limit of normal
3182466|NCT00703417||1|Healthy post-menopausal women
3182467|NCT00703417||2|Diabetic without fracture
3182468|NCT00703417||3|Diabetic with fracture
3182469|NCT00703430|Experimental|1|Memantine
3182470|NCT00703456|Experimental|1|Balance Training, 3 times a week for 4 weeks
3182471|NCT00703456|No Intervention|2|Education/No intervention
3182472|NCT00703469|Experimental|1|
3182473|NCT00703469|Placebo Comparator|2|
3182474|NCT00703482|Placebo Comparator|1|
3182475|NCT00703482|Active Comparator|2|
3182476|NCT00703482|Active Comparator|3|
3182477|NCT00703482|Experimental|4|
3182478|NCT00703482|Experimental|5|
3182479|NCT00703482|Experimental|6|
3182480|NCT00703482|Experimental|7|
3139680|NCT02266797|Active Comparator|Dexamethasone|Subject will receive doses of intravenous dexamethasone, a corticosteroid. The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
3182481|NCT00703521|Placebo Comparator|1,2,3,4,5|"Rabies vaccine 1.0 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.5 mL IM on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 7, 28,and 1 year~Rabies vaccine 0.1 mL Intradermal on day 0, 28,and 1 year~Japanese encephalitis vaccine 0.25 mL subcutaneous"
3139681|NCT02266797|Placebo Comparator|Saline|Subject will receive doses of intravenous physiological saline solution.
3139682|NCT02249377|Experimental|Platelets-Rich-Plasma Group|Patients will be asked to stop taking any type of anti-inflammatory medication from 7 days before the procedure to 2 weeks after and fasting for 3 hours before the procedure. At the moment of the procedure, the radiology team will draw 60ml of venous blood from the patient, the blood will be processed with different components of the PRP kit and centrifuged in the SmartPrep PRP machine, to obtain the PRP. The patient is then scanned prone using a linear 14 or 9 megahertz (MHz) transducer. A 20 Gauge spinal needle is usually employed for purposes of aspiration. Sterile saline will be used to confirm needle placement in the cyst in lieu of lidocaine and then inject the PRP by the radiologist.
3182482|NCT00703547|Experimental|Subjects receiving treatment in cohort 1|Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).
3182483|NCT00703547|Experimental|Subjects receiving treatment in cohort 2|Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)
3182484|NCT00703560||1|HIV and HCV genotype 1 coinfected (any race)
3182485|NCT00703560||2|HCV genotype 1 (any race)
3139683|NCT02249377|Active Comparator|Corticosteroid group:|Patients will be asked to stop taking any kind of anti-inflammatory medication from 7 days before the procedure to 2 weeks after but fasting in this group won't be required. An ultrasound guided aspiration and triamcinolone (40 mg) diluted with lidocaine without epinephrine and ropivacaine will be used to anesthetize the tissues down to the cyst (including within the cyst for steroid injections). A compression bandage will be placed locally for 7 days. Investigators will monitor any side effect from the injection and treat the patients per standard care - this can include prescription of analgesics.
3139684|NCT02253394|Active Comparator|AMB + Spiro, Cardiopulmonary fitness|Ambrisentan 5 or 10 mg every day (QD) Spironolactone 50 mg QD
3139685|NCT02253394|Placebo Comparator|Placebo Cardiopulmonary fitness|Placebo mimics spironolactone 50 mg and will be taken QD
3139686|NCT02241551|Experimental|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
3139687|NCT02241551|Experimental|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
3182486|NCT00703573|Experimental|Group A|S-777469 400 mg BID (two 200 mg tablets of S-777469 and two tablets of placebo BID)
3182487|NCT00703573|Experimental|Group B|S-777469 800 mg BID (four 200 mg tablets of S-777469 BID)
3182488|NCT00703573|Placebo Comparator|Group C|Placebo BID (four tablets of placebo BID)
3139688|NCT02246114|Experimental|no CO monitor|Not given a piCO+ Smokerlyzer® monitor, will receive daily text messages.
3139689|NCT02246114|Experimental|CO monitor|Given a piCO+ Smokerlyzer® monitor, will receive daily text messages, will receive feedback about the relative level of carbon monoxide.
3139690|NCT02232880|Active Comparator|abatacept|"Subjects randomized to abatacept weighing 60 to 100 kg will receive 750 mg, and those >100 kg will receive 1000 mg abatacept by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
3139691|NCT02232880|Placebo Comparator|placebo|"Subjects randomized to placebo will receive 100 ml normal saline by intravenous infusion at 0 [randomization], 2, and 4 weeks and then every 4 weeks thereafter for a total of 24 weeks.~All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase."
3139692|NCT02248740|Active Comparator|Radiofrequency Ablation|"Device: ClosureFast radiofrequency catheter (VNUS Medical Technologies Inc, San Jose, CA).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
3139693|NCT02248740|Active Comparator|Laser Ablation|"Device: EVLT 980nm diode laser system (Angiodynamics, Queensbury, NY).~Patients will have the intervention, ablation of the incompetent small saphenous vein, using this device."
3139694|NCT02239627|Active Comparator|Steroid|Epidural steroid injection
3139695|NCT02239627|Experimental|Clonidine|Epidural clonidine injection
3139696|NCT02244944|Experimental|EZ-URSO Combination Therapy|Ursodiol (URSO Forte) 13-15 mg per kg (250-500 mg b.i.d. or t.i.d depending on body weight) combined with Ezetimibe (Zetia) 10 mg o.p.d.
3150294|NCT00199862|Experimental|Radio-labeled huA33 Antibody|"Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .~Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.~Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure."
3139697|NCT02241187|Experimental|PEGPH20 And Cetuximab|5 participants will undergo DW- & DCE-MRI for sequence parameter optimization. The 1st stage of the study, patients (n = 5) will have the option to undergo (DW-) & (DCE)-MRI for repeatability investigation & T1 mapping. Optional DW- & DCE-MRI will be repeated 2 to 5 days later, followed shortly by administration of 1 intravenous dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.Blood samples will be drawn at various time points. The resected tumor specimen will be studied. If deemed safe, we will proceed to the second stage of the study. Patients (n = 5) will have the option to undergo DW- & DCE-MRI. 1 to 3 days later, patients will receive 1 IV dose of PEGPH20 at 3 μg/kg/10 min. Optional DW- & DCE-MRI will be repeated 1 to 2 days after PEGPH20 administration, followed on that day by administration of 1 IV dose of cetuximab at 250 mg/m2/60 min. Pancreatic tumor resection will be performed 1 to 2 days later.
3139698|NCT02239926|Active Comparator|Ranolazine|tablet, 1000 mg twice daily for four weeks
3139699|NCT02239926|Placebo Comparator|Placebo|Placebo
3139700|NCT02231892|Experimental|Real TMS|rTMS (frequency and intensity)
3139701|NCT02231892|Sham Comparator|Sham TMS|Sham setting on coil
3139702|NCT02241343|Other|Trial cohort|Measurements taken before and after venous occlusion applied
3139703|NCT02242578|Experimental|Active|Active rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
3139704|NCT02242578|Experimental|Placebo|Sham rTMS stimulation (1 Hz rTMS, 10 Hz rTMS)
3139705|NCT02234011|Experimental|Ketamine/Placebo|Participants in this group will receive 5 sprays (10 mg each) of intranasal ketamine for the first treatment visit, then receive 5 sprays of placebo (saline solution) at the second treatment visit two weeks later.
3139706|NCT02234011|Experimental|Placebo/Ketamine|Participants in this group will receive 5 sprays of placebo (saline solution) for the first treatment visit, then receive 5 sprays (10 mg each) of intranasal ketamine at the second treatment visit two weeks later.
3139707|NCT02236546|Experimental|FDG-PET/CT|Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). Molecular assays on biopsied tissue obtained from a subset of patients will also undergo molecular assays, the results from which will be correlated with FDG-PET/CT data.
3139708|NCT02234687|Placebo Comparator|Placebo|Placebo, one dose
3139709|NCT02234687|Experimental|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
3139710|NCT02234687|Experimental|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
3139711|NCT02224599|Experimental|CYP, TAPA-pulsed DC vaccine, Imiquimod|TAPA-Pulsed DC Vaccine Cyclophosphamide Pill Imiquimod Topical Cream
3139712|NCT02201472|Experimental|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
3139713|NCT02202044|Experimental|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks of Intravesical Intravesical BCG and EMDA/MMC
3139714|NCT02192775|Experimental|MV-NIS + Cyclophosphamide|
3139715|NCT02200328|Experimental|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
3139716|NCT02200328|Placebo Comparator|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
3139717|NCT02200042|Experimental|Radiation therapy|Liver-directed radiation therapy
3139718|NCT02200042|No Intervention|Observation|No radiation therapy
3139719|NCT02181790|Experimental|First Group|excimer laser treatment to one palm and/or one sole
3139720|NCT02181790|Experimental|Second Group|excimer laser treatment to both palms and/or soles
3139721|NCT02198833|Experimental|Micro-Patterned Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
3139722|NCT02198833|Active Comparator|Standard-of-Care Foley Catheter|Procedures: Foley Catheter Insertion, Device Specific Adverse Event Assessment, Urine Cultures, Foley Catheter Tip Culture, Scanning Electron Microscopy
3139723|NCT02175628|Experimental|Acoustic Angiography|All breast patients will be included in the experimental group.
3139724|NCT02175628|Experimental|Healthy Volunteers|A volunteer group was added to the study to perfect the image acquisition techniques.
3139725|NCT02177266|Placebo Comparator|Placebo|A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
3139726|NCT02177266|Experimental|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
3139727|NCT02184520|Active Comparator|TRANSITION|Stabilization System
3139728|NCT02184520|Active Comparator|REVERE|Stabilization System
3139729|NCT02170298|Placebo Comparator|Placebo|"Participants may be randomized into the placebo comparator arm. Participants in this group will be given a sugar pill titrated up to 70 mg daily over the course of 9 weeks.~Drug: Placebo"
3150295|NCT00199927|Active Comparator|standard therapy|Standard therapy
3139730|NCT02170298|Experimental|Lisdexamfetamine|"Participants may be randomized into the experimental arm. Participants in this arm will be given lisdexamfetamine titrated up to 70 mg daily over the course of 9 weeks.~Drug: Lisdexamfetamine"
3139731|NCT02177773|Experimental|Ga-68 DOTA-TOC PET/CT|Patients receive Gallium Ga 68-DOTA-TOC IV over 1-2 minutes. Within 55-70 minutes, patients then undergo either a PET/CT scan lasting 30-40 minutes or a PET/MRI scan lasting 50 minutes.
3139732|NCT02162979|Experimental|Viagra|subjects will be randomized to active treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
3139733|NCT02162979|Placebo Comparator|Placebo comparator|subjects will be randomized to placebo treatment for 2 weeks, washout for 1 week, then enter the other study arm for two weeks.
3139734|NCT02169830|Active Comparator|nortriptyline|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to nortriptyline for eight (8) weeks. If still experiencing symptoms, they will receive topiramate for eight (8) weeks.
3150296|NCT00199927|Active Comparator|fluvastatin|40-80 mg/day
3182489|NCT00703586|Experimental|1|"ARM A:~Intensification with maraviroc for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine"
3182490|NCT00703586|Active Comparator|2|"ARM B~Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc."
3182491|NCT00703599|Experimental|1|This is the only arm and that is the treatment group.
3139735|NCT02169830|Active Comparator|topiramate|If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
3139736|NCT02169830|Other|diet modification|Participants will begin with diet modification for four (4) weeks.
3139737|NCT02163187|Experimental|InterStimTM the device on|The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
3150297|NCT00200005|Experimental|InterStim therapy|Patients being treated with sacral neuromodulation with InterStim therapy.
3182492|NCT00703612|Experimental|Treatment Group|This is the only arm and that is the treatment group.
3182493|NCT00703625|Experimental|Cohort 1|"Temsirolimus IV 15 mg weekly~Docetaxel 60 mg/m2 IV once every three weeks."
3139738|NCT02163187|Experimental|InterStimTM the device off|The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.
3139739|NCT02161016|Other|map3 allogeneic bone graft|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
3139740|NCT02159040|Active Comparator|Azacitidine|75mg/m2 7days/28 day cycle
3139741|NCT02159040|Experimental|Azacitidine and Deferasirox|azacitidine 75mg/m2 7 days/28 day cycle deferasirox 10 mg/kg/day
3139742|NCT02168270|Experimental|Treatment (ascorbic acid, temozolomide)|Patients receive ascorbic acid IV over 90-120 minutes three times per week and temozolomide orally days 1-28. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3139743|NCT02157116|Experimental|Induction Chemotherapy|Cisplatin 75mg/m2 IV days 1, 15, 29; Docetaxel 75mg/m2 IV days 1, 15, 29; and Pegfilgrastim 6mg SC day 2, 16, 30
3139744|NCT02154087|Experimental|HP802-247|
3139745|NCT02152670|Experimental|Baseline|Subjects will receive 2 baseline PET scans with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
3139746|NCT02152670|Experimental|Dopamine Release|Subjects will receive 1 PET scan following a PO dose of 60mg of methylphenidate to facilitate dopamine release with the radioligand (11C)(+)PHNO
3139747|NCT02152670|Experimental|Endogenous Dopamine|Subjects will receive 2 PET scans following 48 hours of dopamine depletion via AMPT with the radioligands (11C)(+)PHNO and (11C)(+)raclopride
3139748|NCT02152566|Experimental|Diagnostic PSG/PG, PSG w. nasal high flow therapy|All patients recruited will undergo a diagnostic sleep study, either a full in laboratory attended polysomnography (PSG), or an in-home polygraphy (PG). If respiratory insufficiencies with Cheyne-Stokes respiration (CSR) are detected, these patients will undergo an overnight in laboratory attended PSG on a nasal high flow therapy device to test the primary endpoint of this study. Patients without respiratory insufficiencies after the first PSG/PG will take no further part in the trial.
3139749|NCT02137096|Experimental|High Dose Conditioning|Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation
3139750|NCT02147834|Active Comparator|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3139751|NCT02147834|Placebo Comparator|Sugar pill|"Sugar pill that looks like the drug ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
3139752|NCT02145390|Experimental|TURBT, NAC and Chemoradiation|"Transurethral Resection of the Bladder Tumor & Cystoscopy (TURBT);~Neoadjuvant Chemotherapy (NAC), per standard of care: Cisplatin and Gemcitabine therapy, within 8 weeks following the TURBT and cystoscopic evaluation;~For subjects with complete response (CR): Chemoradiation within 6 weeks after post-neoadjuvant evaluation. Intensity Modulated Radiation Therapy (IMRT/VMAT); Cisplatin therapy per standard of care;~For subjects who have pT1 or worse tumor response: Radical Cystectomy, per standard of care, within 12 weeks post-neoadjuvant chemotherapy evaluation;~Expanded Prostate Cancer Index Composite Short Form 12 (EPIC SF-12);~International Prostate Symptom Score (IPSS)."
3139753|NCT02132884|Active Comparator|Arm A (standard of care treatment)|Patients receive standard of care treatment based on the discretion of the treating physician.
3139754|NCT02132884|Experimental|Arm B (genetic sequencing and targeted therapy)|Patients undergo collection of tissue and blood samples for analysis via sequencing. Upon disease progression following front-line treatment, patients receive specific targeted therapy based on the mutational status obtained during sequencing.
3139755|NCT02144155|Experimental|Oxytocin: 24 IU - 168 IU|Oxytocin twice daily for 3 weeks
3139756|NCT02144155|Sham Comparator|Vehicle placebo|Placebo for 3 weeks
3139757|NCT02140788|Active Comparator|Metformin|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added metformin will receive metformin 250 mg BID days 1-3, 500 mg BID days 4-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate a dose escalation will have the metformin dose reduced to the previously tolerated lower dose.
3139758|NCT02140788|Active Comparator|Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.
3139759|NCT02140788|Active Comparator|Metformin and Fish Oil|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will receive Metformin and Fish Oil as part of the study.
3139760|NCT02140788|No Intervention|No medication added|Subjects will continue to take the clozapine prescribed as standard of care. Subjects will not receive Metformin or Fish Oil.
3139761|NCT02150863|Active Comparator|Ultrapulse laser alone|
3139762|NCT02150863|Active Comparator|Ultrapulse laser plus Cellutome Harvesting system|
3139763|NCT02150863|No Intervention|Control|
3139764|NCT02145169|Experimental|Nitrous Oxide arm|Patients will receive a 50/50 mixture of Oxygen and Nitrous oxide via non breather mask
3139765|NCT02130622|Experimental|Promethazine|Promethazine 12.5 mg P.O. t.i.d. for 4 weeks
3139766|NCT02130622|Placebo Comparator|Sugar Pill|Placebo P.O. t.i.d. for 4 weeks
3150298|NCT00200044|Sham Comparator|Sham|This arm of the study has the procedure but does not get the Gatekeeper prostheses. The Sham arm has the option to cross-over to the Treatment arm at the 6-month visit.
3150299|NCT00200044|Active Comparator|Treatment|The treatment arm has the Gatekeeper devices implanted.
3139767|NCT02133534|Experimental|Atorvastatin|Subjects will be treated with atorvastatin 10 mg/day for 30 days. The study team will obtain one blood and urine sample at baseline prior to starting atorvastatin therapy, and again after 30 days of drug therapy. The study team will do ultrasound imaging of the arm in which a probe will be placed over the blood vessels to measure the diameter of the artery and how this changes after a blood pressure cuff is inflated and then deflated. Subjects will take one nitroglycerine tablet during the ultrasound imaging.
3139768|NCT02134912|Experimental|Arm I (crizotinib, pemetrexed disodium)|Patients receive crizotinib PO BID on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.
3139769|NCT02134912|Experimental|Arm II (pemetrexed disodium)|ARM II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Upon disease progression or symptomatic deterioration, patients may crossover to Arm I.
3139770|NCT02131155|Experimental|Afatinib (BIBW2992)|Once daily
3139771|NCT02131155|Placebo Comparator|Placebo|Once daily
3139772|NCT02117050|Experimental|Rebif® via Rebidose® auto-injector|
3150300|NCT00200083|Active Comparator|A|"All subjects enrolled will be implanted with an IGS system. The active group are those randomized to on and will receive active stimulation for 12 months."
3139773|NCT02110069|Active Comparator|Vincristine|"Induction phase: participants assigned to vincristine will receive vincristine weekly at a dose of 0.05mg/kg/dose IV (for participants less than 10kg) or a dose of 1.5 mg/m2/dose (for participants greater than 10kg) for 2 months.~Maintenance: if participants continue to receive vincristine weekly for 2 months, every 2 weeks for 5 months and every 3 weeks for 5 months."
3139774|NCT02110069|Experimental|Sirolimus|"Sirolimus will be administered at a dose of 0.8mg/m2/dose twice a day on a continuous dosing schedule throughout the trial for participants randomized to Sirolimus or for participants who fail vincristine may cross-over to the sirolimus arm.~Sirolimus trough levels will be maintained between 10-15 ng/ml."
3139775|NCT02110277|Experimental|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
3139776|NCT02109809|Experimental|Supportive Care (TLI)|Patients undergo LD-TLI daily for 1-2 days.
3150301|NCT00200083|Placebo Comparator|B|"All subjects enrolled will be implanted with an IGS system. The placebo group are those randomized to off and will receive no stimulation for 12 months."
3150302|NCT00200096|Active Comparator|1|Acupuncture and questionnaires
3150303|NCT00200096|Sham Comparator|2|placebo acupuncture and questionnaires
3150304|NCT00200109|Other|Group 1|See protocol
3150305|NCT00200109|Other|Group 2|See protocol
3150306|NCT00200109|Other|Group 3|See protocol
3150307|NCT00200109|Other|Group 4|See protocol
3150308|NCT00200135||1|Treated and released from ED (minor injuries)
3150309|NCT00200135||2|Trauma, admitted to the hospital (injured)
3150310|NCT00200135||3|Fatalities reported by the coroner (deaths)
3150311|NCT00200135||4|Reported by the police (No medical treatment)
3150312|NCT00200148|Experimental|1|For patients randomized to ANH
3150313|NCT00200148|Active Comparator|2|standard intraoperative management
3150314|NCT00200174|Active Comparator|A|Raloxifene followed by combination therapy
3139777|NCT02105116|Experimental|Standard chemotherapy followed by allogenic therapy|INDUCTION CHEMOTHERAPY: Patients receive standard induction chemotherapy with fludarabine phosphate IV over 1 hour QD for 5 days and cytarabine IV over 4 hours for 5 days. G-CSF 5 mcg/kg will be started at day14 if day14 bone marrow does not have >5% leukemic blasts. Treatment may continue for 1 or 2 courses at the discretion of the treating physician. If the patient enters a complete remission they are eligible for ALLOGENEIC CELLULAR THERAPY: Patients eligible for the experimental therapy undergo irradiated Donor Lymphocyte Infusion (DLI) of 3 x 10^8 CD3+ cells/kg at 8 weeks. Patients with stable disease may repeat irradiated DLI every 8-12 weeks in the absence of disease progression or unacceptable toxicity.
3139778|NCT02099318|Active Comparator|Active SRP cases|SRP cases: After patients have provided written informed consent, the CT and/or MRI images obtained as part of routine preoperative care will be used to construct the model that the neurosurgeons will use in the SRP. No new or additional images will be obtained as part of this study, and the SRP modeling will rely on neuroimaging conducted as part of standard preoperative assessment. For SRP cases, prior to performing surgery, surgeons will plan and rehearse patient-specific cerebral aneurysm surgery. Similarly to the CT/MRI studies, the SRP will be available for the surgeons during the surgery for evaluation of optional surgery approaches.
3139779|NCT02099318|Placebo Comparator|Control cases|Control cases: The control group will be randomly selected according to a predetermined alternating sequence of consecutive prospectively video recorded aneurysm cases. Informed consent from all patients in both the control and SRP groups will be obtained.
3139780|NCT02099344|Active Comparator|Artegraft|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
3139781|NCT02099344|Active Comparator|Propaten|Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
2400839|NCT03566706|Experimental|Sedentary Behavior|
3139782|NCT02094352|Experimental|Ketamine Infusion + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of KETAMINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three ketamine booster infusions over the course of three months."
3150315|NCT00200174|Active Comparator|B|Exemestane followed by combination therapy
3150316|NCT00200200|Active Comparator|1|Bevacizumab in addition to HAI plus systemic chemotherapy
3139783|NCT02094352|Placebo Comparator|Control Group + Epidural Infusion + Booster Infusion|"Inpatient: Patients will receive a subanesthetic continuous intravenous infusion of SALINE 500mg/500ml in 0.9% Sodium Chloride with an epidural infusion.~Outpatient: Patients will receive three saline booster infusions over the course of three months."
3139784|NCT02096042|Experimental|Brentuximab Vedotin|Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle (+/- 3 days).
3139785|NCT02096042|Experimental|Brentuximab Vedotin + 5-Azacytidine|"Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle. All patients receive 5-azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle. Patients receive 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days. Patients can receive up to a total of 12 cycles of treatment (weekly + monthly combined)."
3139786|NCT02088957|Experimental|Brivaracetam|"Subjects will receive an acute intravenous (iv) dose of Brivaracetam (BRV) 200 mg as a bolus on Day 1. If seizures recur, a second iv bolus of BRV 100 mg can be given no sooner than 15 minutes after the first bolus. If the second acute bolus is not needed within12 hours after first iv bolus, BRV will be continued as 100 mg iv dose every 12 hours (bid). The total dose for the first 24 hours of treatment should not exceed a maximum dose of 400 mg. The rate of bolus administration is 50 mg (5 mL) undiluted BRV/min. On study Day 5 (or earlier), subjects will transition from iv to oral formulation, at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
3139787|NCT02088957|Active Comparator|Phenytoin|"Subjects will receive an acute intravenous (iv) dose of Phenytoin (PHT) 20 mg/kg at a rate of 50 mg/min on Day 1. If seizures recur, a second acute dose of PHT iv will be given no sooner than 15 minutes after the first dose. Treatment with PHT iv will be continued with at least 2 daily divided doses according to site practice. Daily PHT dose can be adapted according to investigator's clinical judgment. On study Day 5 (or earlier), subjects will transition from iv to oral formulation at comparable dosing for a maximum of 6 months.~Subjects should transition to oral medication as soon as they are able to swallow tablets."
3139788|NCT02093689|Experimental|Part 1 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3139789|NCT02093689|Experimental|Part 2 OMS302|OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
3139790|NCT02093689|Placebo Comparator|Part 2 Placebo|Placebo contains 20mM sodium citrate diluted in BSS and administered as irrigation solution.
3139791|NCT02091752|Experimental|Ruxolitinib|All participants received ruxolitinib.
3139792|NCT02068547|Active Comparator|Group 1 - Surigical Best Practice|Group 1 will receive current best practice for posterior instrumented fusion (locally harvested autograft, demineralized bone matrix, and cadaveric allograft)
3139793|NCT02068547|Experimental|Group 2 - autograft/BMAC|Group II, will receive locally harvested autograft and 20 cc of bone marrow aspirate concentration.
3150317|NCT00200200|Experimental|2|HAI plus systemic chemotherapy alone
3150318|NCT00200226|Placebo Comparator|1|Vitamin B6
3150319|NCT00200226|Active Comparator|2|misoprostol
3150320|NCT00200239|Experimental|1|Behavioral: eating breakfast from portioned and unportioned foods
3182494|NCT00703625|Experimental|Cohort 2|"Temsirolimus IV 25 mg weekly~Docetaxel IV 60 mg/m2 once every 3 weeks"
3182495|NCT00703625|Experimental|Cohort 1A|"Temsirolimus IV 15 mg weekly~Docetaxel IV 50 mg/m2 every 3 weeks."
3182496|NCT00703638|Experimental|Sorafenib/Pemetrexed/Cisplatin|Patients receiving a dose escalation scheme of daily oral sorafenib (200 mg or 400 mg bid) when given in combination with fixed dose intravenous pemetrexed and cisplatin for the treatment of solid tumors.
3150321|NCT00200239|Experimental|2|Behavioral: eating breakfast with portioned and unportioned foods
3150322|NCT00200252|Active Comparator|group B|women in group B will receive 10 uts oxytocin IM
3150323|NCT00200252|Active Comparator|group C|women in group C will receive oxytocin 5 uts IV
3139794|NCT02075411|Active Comparator|Males Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
3150324|NCT00200252|Active Comparator|group A|women in group A will receive oxytocin 5 uts IM
3150325|NCT00200265|Experimental|1|Behavioral: diet
3150326|NCT00200265|Experimental|2|Behavioral: diet
3150327|NCT00200265|Placebo Comparator|3|Behavioral: diet
3150328|NCT00200291|Experimental|1|Behavioral: hypocaloric low-fat diet
3150329|NCT00200291|Placebo Comparator|2|Behavioral: hypocaloric, low-fat diet
3150330|NCT00200395|Experimental|OSI-774 (Tarceva)|Oral treatment with OSI-774 (Tarceva) will be given as a 150 mg tablets daily for 14 days. On day 15 and if there are no adverse effects the dose will be increased to 200 mg.
3150331|NCT00200408||smokers|college students who smoke
3150332|NCT00200408||non smokers|college students who don't smoke
3150333|NCT00200577|Experimental|TIL+IL2|TIL + IL2
3150334|NCT00200577|No Intervention|control|Patients are not treated
3150335|NCT00200707|Experimental|The treatment group|Intracoronary Injection of Autologous Bone Marrow Mononuclear C
3150336|NCT00200707|No Intervention|the control group|
3150337|NCT00200720|Experimental|Atkins Diet|Participants randomized to this arm will consume a low carbohydrate diet as described by Dr. Robert Atkins in his book: Dr. Atkins' New Diet Revolution New York: Avon Books, 2002.
3139795|NCT02075411|Active Comparator|Females Single shot peripheral nerve block|a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
3139796|NCT02075411|Active Comparator|Males Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
3139797|NCT02075411|Active Comparator|Females Continuous peripheral neural infusion|The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
3182497|NCT00703651|Experimental|1|
3139798|NCT02074904|Experimental|Topiramate|up to 200mg/day orally (over 8 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
3139799|NCT02074904|Placebo Comparator|Placebo|placebo
3139800|NCT02084147|Experimental|PET-CT and PET-MRI|Patients undergo PET-CT over approximately 30 minutes and PET-MRI over approximately 45-90 minutes.
3139801|NCT02081183|Experimental|MMF, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 to (-) 1 grams per square meter (g/m^2), intravenously (IV) pulse once per month. Participants also received prednisone, 1 milligram per kilogram per day (mg/kg/day), orally (PO); the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received mycophenolate mofetil (MMF), 1 g/day, PO, twice daily (BID) for 2 weeks; 1.5 g/day, PO, three times daily (TID) for the next 2 weeks; 2 g/day, PO, BID for the remainder of the Maintenance Phase. Participants also received prednisone, as in the Induction Phase."
3182498|NCT00703651|Experimental|2|
3182499|NCT00703651|Active Comparator|3|
3182500|NCT00703690|Experimental|1|MK0767; 2.5 mg/day
3139802|NCT02081183|Active Comparator|Maintenance Cyclophosphamide, Prednisone|"Induction Phase (Months 1 through 6): Participants received cyclophosphamide, 0.5 - 1 g/m^2, IV, pulse once per month. Participants also received prednisone, 1 mg/kg/day), PO; the dose was reduced by 5 mg/day to a final dose of 10 mg/day.~Maintenance Phase (Months 7 through 12): Participants received cyclophosphamide, 0.5-1 g/m^2, IV, pulse once every 3 months. Participants also received prednisone, as in the Induction Phase."
3139803|NCT02067611|Experimental|X0002|low dose, BID;middle dose, BID, or high dose, BID.
3139804|NCT02067611|Placebo Comparator|Placebo|low dose, BID; middle dose, BID, or high dose, BID.
3139805|NCT02067104|Placebo Comparator|Placebo|receive 150 mg of oral placebo daily for a period of 2 months
3139806|NCT02067104|Experimental|Vismodegib|receive 150 mg of vismodegib daily for a period of 2 months
3139807|NCT02075021|Experimental|lenalidomide and nab-paclitaxel|100 mg/m^2 of Abraxane weekly for 3 weeks and 10 mg Revlimid daily for 21 days, with a dose escalation for Revlimid to 15 mg and to 25 mg. One cycle is 4 weeks. Dose de-escalations will also be performed for both drugs as necessary. Patients will be treated until disease progression.
3139808|NCT02057874|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI at baseline (=< 2 weeks before TACE) and at 2-4 weeks, 4-8 weeks, and 12 weeks after TACE. Each 3T MRI session will utilize a sequence of the following modalities: CEST-MRI, MT-MRI, DW-MRI, and DCE-MRI.
3139809|NCT02057237|Experimental|single arm|Mitotane will be administered on an outpatient or inpatient basis.
3139810|NCT02047747|Experimental|dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
3139811|NCT02058537|Experimental|Bethanechol|Oral administration of 25 milligrams of bethanechol taken twice daily for a minimum of 7 days. Total dose taken daily for a minimum of 7 days is 50 mg.
3139812|NCT02057276|Active Comparator|Active rTMS|Participants will receive daily active rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
3139813|NCT02057276|Sham Comparator|Sham rTMS|Participants will receive daily sham rTMS with occupational therapy immediately following rTMS for 10 consecutive weekdays.
3139814|NCT02038153|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
3139815|NCT02054910|Experimental|Celiac Plexus Block|Celiac Plexus Block will be administered following EUS
3139816|NCT02054910|Sham Comparator|Sham|A celiac plexus block will not be administered for pain management
3139817|NCT02044302|Active Comparator|standard analgesics|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Placebo application during surgery will be made to establish perfection in the study design in terms of randomization and blinding. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3139818|NCT02044302|Experimental|standard analgesics and bupivacaine|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into the chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine during surgery. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3139819|NCT02044302|Experimental|standard analgesics and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during your operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3139820|NCT02044302|Experimental|standard analgesics, bupivacaine and botulinum toxins|Current standard post-operative care for expander-implant breast reconstruction surgery consists of conventional pain medications including narcotics (like morphine, etc.) and sedatives (like valium). Patients will receive through an injection into your chest 10 ml (about 2 teaspoons) of 0.5% bupivacaine and 50 U of Botox diluted in 4ml (about 1 teaspoon) of normal saline per breast during the operation. Injections will be done intramuscularly to the main chest muscle (pectoralis major) by the surgeon.
3139821|NCT02046226|Experimental|OxyGenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
3139822|NCT02046226|No Intervention|Standard Wound Care|Standard wound care using gauze dressings per institutional standard of care.
3139823|NCT02044848|Experimental|Secukinumab|Secukinumab will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
3139824|NCT02044848|Placebo Comparator|Placebo|Placebo will be delivered as part of an induction regimen followed by a maintenance regimen for up to 1 year
3182501|NCT00703690|Experimental|2|MK0767; 5mg/day
2400840|NCT03566693|Experimental|Continous Glucose Monitor|
3139825|NCT02042950|Experimental|Carfilzomib|Carfilzomib given at a dose of 20*/56 mg/m^2 (* CFZ 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
3139826|NCT02048904|Active Comparator|Sitagliptin|100 mg/day for 3 months
2400841|NCT03566693|Active Comparator|Self Monitoring Blood Glucose|
3139827|NCT02048904|Placebo Comparator|Placebo|1 pill/day for 3 months
3139828|NCT02044822|Experimental|Idelalisib + rituximab|Participants will receive rituximab for 8 weeks and Idelalisib continuously throughout the study (up to 10 years).
3139829|NCT02042924|Experimental|Imaging studies|Subjects will have a FLT PET/CT and a MRI prior to starting the preparative regimen for transplant and another of each scan 100 days after transplant.
3139830|NCT02043860|Experimental|Total Marrow Irradiation|Escalating doses of total marrow irradiation (3Gy, 6Gy, 9Gy, or 12Gy) with standard high dose melphalan prior to autologous stem cell rescue.
3139831|NCT02017522|Experimental|11C-PBR PET|"Subjects will have a blood sample drawn to evaluate the presence of a specific genetic variation which would prevent the new type of imaging test we are evaluating from working and we will test the inflammatory cells in the blood for the same purpose.~All participants who proceed will have to return on at least one additional day to undergo a positron emission tomography (PET) scan similar to the scan your doctor ordered. we will use 11C-PBR28 as the radiotracer. This study will evaluate whether 11C-PBR28 can show areas of inflammation due to cardiac sarcoidosis. On either the same day or a different day, you will also undergo a cardiac MRI."
3139832|NCT02030015|Experimental|Syner-G Therapy Regimen|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet, and daily treatment with orally-administered miglustat, for the duration of the 60-month study.
3139833|NCT02015663|Experimental|Arm 1|Tobramycin Inhalation Powder (112 mg) once daily during 168 days
3139834|NCT02015663|Active Comparator|Arm 2|Tobramycin Inhalation Powder (112 mg) twice daily on days 1-28, days 57-84 and days 113-140
3139835|NCT02029846|Active Comparator|Standard Treatment|A regimen with traditional drugs only
3139836|NCT02029846|Experimental|Incretin-based Treatment|A regimen including incretin-based drugs
3139837|NCT02027272|Active Comparator|Dexamethasone|Dexamethasone 12 mg, 2 doses, 12 hours apart.
3139838|NCT02027272|Placebo Comparator|Placebo|Placebo, 2 doses, 12 hours apart
3139839|NCT02012608|Active Comparator|Glutamine|Powdered Glutamine, 10.0 grams by mouth three times a day (TID) for 30 days, so that daily dose is 30 grams per day
3139840|NCT02012608|Placebo Comparator|Placebo|Powdered Dextrose, 8.33 grams by mouth TID for 30 days, so that daily dose is 25 grams per day
3139841|NCT02017379|Experimental|Erythromycin|Intravenous erythromycin infusion (dose: 250 mg) 30 min-60 min before procedure
3139842|NCT02017379|Experimental|Metoclopromide|Intravenous metoclopromide infusion (dose: 10 mg) 30-60 minutes prior to endoscopy
3139843|NCT02017379|No Intervention|Control|no medications will be given prior to endoscopy
3139844|NCT02011542|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
3139845|NCT02011542|Active Comparator|VSL #3|VSL #3 (probiotic mixture) is given to this group
3139846|NCT02008370|Experimental|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
3139847|NCT02009982|Experimental|Cardioneuroablation|Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
3139848|NCT02009982|No Intervention|Standard Medical Thearpy|Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy
3139849|NCT02013414|Experimental|3D ultrasound-guided biopsy|Participants will have a 3D ultrasound-guided biopsy of the prostate rather than the standard of care 2D ultrasound-guided biopsy.
3139850|NCT02005445|Experimental|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure
3139851|NCT02005445|Sham Comparator|Healthy Lifestyle and Sleep Education (HLSE)|Healthy living and sleep education
3139852|NCT02020837|Experimental|Lymphaticovenous Micro-Anastomosis|
3139853|NCT02015910|Experimental|Januvia (Sitagliptin)|Sitagliptin 100 mg a day for 12 weeks
3139854|NCT02015910|Placebo Comparator|Placebo|Placebo
3139855|NCT02006927|Experimental|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
3139856|NCT01996982|Experimental|Device|CCS Device application
3139857|NCT02006407|Other|Primary Brain Tumor|Patients receiving standard cranial radiotherapy will undergo (1) Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) and (2) Neuro-cognitive testing (CogState-a computerized software testing system that offers various cognitive assessments based on traditional expansive neurocognitive tests) at four timepoints (Baseline, 3 weeks, 6 weeks and 6 months).
3139858|NCT01986751|Experimental|Clonidine and Ropivacaine|A bolus of 20 mL of 0.5% ropivacaine mixed with clonidine 1mcg/kg will be injected through the stimulating needle with gentle aspiration between divided doses (5 mL per dose).
3139859|NCT01986751|Active Comparator|Ropivacaine|Standard saphenous nerve block (adductor canal approach) will be performed using 15ml of 0.5% ropivacaine
3139860|NCT01996410|Active Comparator|Chemotherapy 1 Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
3139861|NCT01996410|Active Comparator|Chemotherapy 2 Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
3139862|NCT01996410|Active Comparator|Chemotherapy 3 Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
3182502|NCT00703690|Experimental|3|MK0767; 10 mg/day
3182503|NCT00703690|Active Comparator|4|fenofibrate 200 mg
3182504|NCT00703690|Placebo Comparator|5|Matching Placebo
3182505|NCT00703703|Experimental|1|Darifenacin
3182506|NCT00703703|Active Comparator|2|Tolterodine
3182507|NCT00703703|Placebo Comparator|3|Placebo
3182508|NCT00703742|Experimental|A,1|A: Escitalopram, 20 mg/day,8weeks
3150338|NCT00200720|Active Comparator|DASH Diet|Participants randomized to this arm will consume the Dietary Approaches to Stop Hypertension (DASH) diet as described here: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf
3150339|NCT00200746|Experimental|2|Moderate Arginine
3150340|NCT00200746|Sham Comparator|3|Polycose control arm
3150341|NCT00200746|Experimental|1|High Arginine
3150342|NCT00200863|Experimental|1|420 nm light
3150343|NCT00200863|Experimental|2|480 nm
3150344|NCT00200863|Experimental|3|507 nm
3182509|NCT00703755|Experimental|1|
3139863|NCT01996410|Active Comparator|Chemotherapy 4 Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
3139864|NCT01996410|No Intervention|Chemotherapy 1 No Acupuncture|"Chemotherapy 1: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) concurrently on day 1 every 2 weeks for 4 cycles followed by Taxol (175mg/m2) on day 1 every 2 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every treatment for a total of 8 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 8 MDASI forms."
3150345|NCT00200863|Experimental|4|555 nm
3150346|NCT00200863|Experimental|5|620 nm
3150347|NCT00200863|Experimental|6|460 nm
3150348|NCT00200876|Active Comparator|pain challenge|
3150349|NCT00200876|Sham Comparator|non-painful control|
3150350|NCT00200889|Experimental|auricular tVNS|active and inactive auricular transcutaneous vagus nerve stimulation (tVNS)
3150351|NCT00200954|Placebo Comparator|placebo|placebo group
3139865|NCT01996410|No Intervention|Chemotherapy 2 No Acupuncture|"Chemotherapy 2: This group will receive Adriamycin (60mg/m2) and Cytoxan (600mg/m2) on day 1 every 2 weeks for 4 cycles followed by Taxol (80mg/m2) on day 1 weekly for 12 cycles. Patients who randomize to the experimental (acupuncture) group will undergo acupuncture the morning of every treatment day of the adriamycin/cytoxan cycles; they will receive acupuncture for every third Taxol treatment, beginning with the first treatment. They will receive a total of 8 acupuncture sessions: 4 with the adriamycin/cytoxan cycles and 4 with the Taxol cycles. Both groups will fill out MDASI on day 3 (+/- 1 days) of each Adriamycin/Cytoxan cycle; they will also fill out the MDASI on day 3 (+/- 1 days) of every third Taxol treatment for a total of 8 MDASI forms."
3139866|NCT01996410|No Intervention|Chemotherapy 3 No Acupuncture|"Chemotherapy 3: In the adjuvant setting- This group will receive Taxotere (75mg/m2) and Cytoxan (600 mg/m2) on day 1 every 3 weeks for 4 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Cytoxan for a total of 4 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 4 MDASI forms."
3150352|NCT00200954|Active Comparator|2|Probiotic bacteria group
3150353|NCT00201019|Experimental|1|Active intervention participants receive a physician-pharmacist collaborative intervention.
3150354|NCT00201019|No Intervention|2|Control participants do not receive recommendations from a clinical pharmacist.
3182510|NCT00703755|Experimental|2|
3182511|NCT00703755|Experimental|3|
3182512|NCT00703755|Experimental|4|
3182513|NCT00703755|Experimental|5|
3182514|NCT00703755|Experimental|6|
3182515|NCT00703755|Placebo Comparator|7|
3139867|NCT01996410|No Intervention|Chemotherapy 4 No Acupuncture|"Chemotherapy 4: In the neoadjuvant setting- This group will receive Taxotere (75 mg/m2), Carboplatin (AUC 6), Perjeta (840 mg loading fixed dose, followed by 420 mg maintenance fixed dose) day 1 every 3 weeks for 6 cycles. Patients on this regimen who randomize to the experimental (acupuncture) group will undergo acupuncture on the morning of every Taxotere/Carboplatin/Perjeta treatment for a total of 6 acupuncture sessions. Both groups will complete a MDASI on day 3 (+/- 1 days) of each cycle of chemotherapy for a total of 6 MDASI forms."
3139868|NCT01996852|Active Comparator|Standard ED Care|Standard medical treatment of erectile dysfunction (ED) including administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)
3139869|NCT01996852|Experimental|Standard ED Care + Cognitive-Behavioral Intervention|standard medical treatment of ED (administration of sildenafil citrate (Viagra) and/or vacuum constriction devices (pump)) in addition to cognitive-behavioral meetings
3139870|NCT01996852|No Intervention|Usual Care (UC)|Study participants will not receive any study intervention, but will continue with standard care.
3139871|NCT01997567|Active Comparator|Grp 1 Ropivacaine Block|Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
3139872|NCT01997567|Placebo Comparator|Grp 2 Placebo Block|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
3139873|NCT01977729|Experimental|CBT with SRT|CBT (Cognitive Behavioral Therapy)+SRT (Sertraline) will be scheduled at weeks 9-12, 14, 16, 18, 20 with telephone visits at weeks 15, 17, and 19. The same therapist as in Phase I will deliver CBT in Phase II, which will occur in conjunction with the psychiatrist visits. Phase II CBT will emphasize continued therapist prescribed in-session and out-of-session exposure tasks (developed with patient) and continued patient cognitive-affective processing of exposure sessions with therapist, with no instruction on new skills or therapeutic strategies. Therapists will be encouraged to discuss clinical status with patients, psychiatrists, and PIs to allow for treatment integration (e.g., psychiatrist could increase the dose of SRT, or not, depending on whether the patient Is making sufficient progress in CBT).
3150355|NCT00201019|No Intervention|3|Passive intervention participants receive care by the same physicians caring for participants in the active intervention arm but are not seen by a clinical pharmacist. They are not actively enrolled in the study and do not have study visits for measuring blood pressure.
3150356|NCT00201045|Experimental|Intervention|Intervention patients receive care from a clinical pharmacist to improve blood pressure.
3150357|NCT00201045|No Intervention|Control|Control patients receive usual care and do not have a clinical pharmacist included in their care.
3150358|NCT00201058|Experimental|1|Receives tailored web-based program
3150359|NCT00201058|Active Comparator|2|Control students receive existing web-based, generic asthma education
3150360|NCT00201071||South Bronx, Harlem, Lower East Side|
3150361|NCT00201084|Active Comparator|1|Uncertainty reduction tools, at physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
3150362|NCT00201084|No Intervention|2|Usual primary care
3150363|NCT00201110|Experimental|1|Intensive Intervention: CVD Risk Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
3150364|NCT00201110|Active Comparator|2|Brief Intervention: CVD Risk Education (1 session) + Brief Health Problem-Solving Training (1 session)
3150365|NCT00201136|No Intervention|MD-C/PT-C|Physician and patient control group.
3150366|NCT00201136|Experimental|MD-I/PT-C|MD CQI-type intervention; Patient control
3150367|NCT00201136|Experimental|MD-C/Pt-I|MD control; patient behavioral intervention
3150368|NCT00201136|Experimental|MD-I/Pt-I|MD CQI-type intervention; Patient behavioral intervention
3150369|NCT00201149|Experimental|1|In one team of clinicians we will implement only the patient-centered counseling program.
3150370|NCT00201149|No Intervention|3|The control group will provide usual care
3139874|NCT01977729|Experimental|Switch to SRT alone|Sertraline is a selective serotonin reuptake inhibitor. Sertraline is FDA approved for the treatment of major depressive disorder, obsessive compulsive disorder, posttraumatic stress disorder, panic disorder, social anxiety disorder, and premenstrual dysphoric disorder in adults. Sertraline is also approved for the treatment of obsessive compulsive disorder in children and adolescents. Pharmacotherapy visits will be scheduled at weeks 9-12, 14, 16, 18, 20 with phone visits at weeks 15, 17, and 19. The psychiatrist will meet for ~30 min. with the youth and parents. Efforts will be made to use the most effective and tolerated SRT dose.
3139875|NCT01973062|Experimental|rituximab and yttrium Y 90 ibritumomab tiuxetan|Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity.
3139876|NCT01982253|Placebo Comparator|Placebo|Fasiglifam placebo-matching tablets, orally, twice daily for up to 12 weeks.
3139877|NCT01982253|Experimental|Fasiglifam 25 mg BID|Fasiglifam 25 mg tablets, orally, twice daily (BID) for up to 12 weeks.
3139878|NCT01982253|Experimental|Fasiglifam 50 mg QD +Placebo QD|Fasiglifam 50 mg tablets, orally once daily (QD) and fasiglifam placebo-matching tablets, orally, once daily for up to 12 weeks.
3139879|NCT01984268|Experimental|Four week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of four weeks.
3139880|NCT01984268|Experimental|Twelve week ACTHAR treatment|Rheumatoid arthritis subjects with inadequate response to methotrexate will be randomized to receive twice a week dosing of ACTHAR for a period of twelve weeks.
3139881|NCT01974284|Experimental|percutaneous ethanol ablation|The experimental group of the study is comprised of patients that will undergo percutaneous ethanol ablation for the management of papillary thyroid microcarcinoma.
3139882|NCT01971853|Placebo Comparator|oral placebo|an Ibuprofen and Acetaminophen Placebo will be added to a Demerol-Vistaril regimen
3139883|NCT01971853|Active Comparator|Oral Analgesics|5 mg/kg ibuprofen + 15 mg/kg acetaminophen will be added to a Demerol-Vistaril regimen
3139884|NCT01980875|Experimental|Safety Run-In: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks. Following 4 weeks of treatment, safety data will be reviewed by an independent data monitoring committee (DMC). If acceptable tolerability is observed, the randomized portion of the study will begin.
3139885|NCT01980875|Experimental|Randomized: Idelalisib+obinutuzumab|Participants will receive idelalisib for 96 weeks and obinutuzumab over 21 weeks.
3139886|NCT01980875|Active Comparator|Randomized: Obinutuzumab+chlorambucil|Participants will receive obinutuzumab over 21 weeks and chlorambucil over 23 weeks.
3139887|NCT01982383|Experimental|Micropulse Laser Treatment|Patient's randomized to ML treatment would be treated with the following settings: 200 micron spot size, 0.2 second duration, 15% duty cycle, and 300 milliWatt power. Their eyes would be dilated prior to treatment with standard mydriatic medications, including Tropicamide and Phenylephrine
2401199|NCT03564327||Patients with sinus rhythm|
3139888|NCT01982383|Placebo Comparator|No Treatment|Patients randomized to this treatment arm, will not receive treatment for CSC. They will continue to be observed at month 1 and month 3. If any worsening of pathology is found during the follow up visits, the patient will be removed from the study and given appropriate standard of care by the attending
3139889|NCT01980342|Experimental|Efavirenz|Healthy, reproductive-age women using the etonogestrel contraceptive implant who will take a two-week course of efavirenz 400 mg orally each night.
3139890|NCT01978535|Experimental|Iron infusion|Iron Sucrose (Venofer (R))
3139891|NCT01978535|Placebo Comparator|Normal saline infusion|Equal volume to intervention of normal saline
3139892|NCT01974635|Experimental|AMES Therapy and Diagnostic|During treatment, the AMES device rotates the hand, into flexion and extension, while the patient assists with this motion,and while the lengthening muscle(s) are vibrated mechanically. At the end of the treatment, several diagnostic tests are performed to measure the participant's level of proprioceptive perception. This study provides for 25 AMES treatments and diagnostic tests over 8-13 weeks, at a rate of 2-3 sessions per week.
3139893|NCT01975467||Control Group - Nonoperative|Subjects that were treated with a sling for their displaced midshaft clavicle fracture.
3139894|NCT01975467||Test Group - Intramedullary Nail|Subjects that were treated with an intramedullary nail for their displaced midshaft clavicle fracture.
3139895|NCT01970462|Experimental|Sitagliptin|Patients will receive Sitagliptin (renally dosed) prior to hospital discharge and 6 weeks following discharge
3182516|NCT00703768||A|Patients who have been identified as having a doubling in PSA from nadir of greater than one year
3182517|NCT00703768||B|Patients who have been identified as having a doubling in PSA from nadir of less than one year.
3182518|NCT00703794||AXIUM Coils|
3182519|NCT00703807|Experimental|1|Daily oral RAD001 for 21 days in combination with oral topotecan on days 1-5 of a 21 day cycle
3182520|NCT00703833|Experimental|1|Drug
3182521|NCT00703833|Placebo Comparator|2|Placebo
3182522|NCT00703872|Experimental|1|Oral HDV-Interferon
3182523|NCT00703872|Experimental|2|Injectable HDV-Interferon + ribavarin
3182524|NCT00703950|Experimental|A,1|Cup feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
3182525|NCT00703950|Active Comparator|A,2|bottle feeding - conventional method Bottle feeding is the conventional method to feed preterm infant before breastfeeding or to substitute breastfeeding. We are using this method in the control group.
3182526|NCT00703989|Experimental|I|Patients with Type 1 diabetes
3182527|NCT00703989|No Intervention|II|Age-matched male subjects without Type 1 diabetes
3182528|NCT00704002|Experimental|A|antegrade intramedullary splinting
3182529|NCT00704002|Active Comparator|B|conservative treatment
3182530|NCT00704015|Experimental|A|Smoking cessation
3182531|NCT00704015|No Intervention|B|
3139896|NCT01970462|Placebo Comparator|Placebo|Patients will receive placebo prior to discharge and 6 weeks after discharge.
2401200|NCT03564327||patients with atrial fibrillation|
3139897|NCT01969565|Experimental|Carfilzomib in combination with dexamethasone|Carfilzomib will be administered at a dose of 20 mg/m², with a dose escalation to 36 mg/m² after Days 1 and 2 of Cycle 1 in level 1; and at a dose of 20 mg/m², with a dose escalation to 45 mg/m² after Days 1 and 2 of Cycle 1 in level 2 in subjects with multiple myeloma who are newly diagnosed and treatment naïve. Dexamethasone will be given as a fixed dose of 20 mg PO/IV (1, 2, 8, 9, 15, 16, 22, and 23) for cycles 1 to 4 and for subsequent cycles.
3139898|NCT01968226|Experimental|PET imaging with [F-18] RDG-K5|This is an observational study of a group of individuals who all have carotid artery stenosis. The observation will be the measurement of [F-18]RGD-K5 uptake by the carotid artery plaque after intravenous administration of this radiolabeled tracer using PET imaging.
3139899|NCT01965782|Experimental|[^14C]-LY3023703|Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
3139900|NCT01962675|Experimental|tDCS and skilled training|tDCS and skilled leg training. Transcranial direct current stimulation + step training TDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
3139901|NCT01962675|Sham Comparator|Sham tDCS and skilled leg training|Sham (Non active) tDCS and skilled leg training. 'Sham transcranial direct current stimulation + step training Sham tDCS will be delivered to the motor cortical area in conjunction with skilled locomotor training
3139902|NCT01962974|Experimental|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
3139903|NCT01954160|Other|Early Symplicity Renal Denervation|Subjects undergo Symplicity Renal Denervation within 2 weeks of baseline visit will follow usual care after week 13 visit
3139904|NCT01954160|Other|Late Symplicity Renal Denervation|Subjects following usual care until week 13 visit will then undergo Symplicity Renal Denervation within 2 weeks of Week 13 visit
3139905|NCT01951378|Active Comparator|Hudson RCI® nebulizer|"Patients randomized to the standard arm will receive treatments as dictated by our standard ED asthma pathway (Fig. 1). All treatments will be administered with our standard ED nebulizer, the Hudson RCI® Up-Draft® Neb-U-Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ), and a simple mask (Hudson RCI®, Teleflex Medical®, Research Triangle Park, NJ)."
3139906|NCT01951378|Active Comparator|NebuTech® HDN® nebulizer|"Patients randomized to the NebuTech® arm will receive treatments as dictated by our trial pathway, referred to as the rapid Albuterol/Proventil delivery pathway (Fig. 2). All nebulizations in this arm will be administered via the Breath-Enhanced High Density Jet Nebulizer, NebuTech® HighDensityNebulizer®,(Salter Labs®, Arvin, CA). Respiratory Therapists (RT) will attempt to deliver all treatments with a mouthpiece, as that has been shown to be the most efficient and reliable mode of aerosol delivery for most children 31, 32. If the Respiratory Therapist feels that the child will not or cannot effectively use a mouthpiece, a mask will be used."
3139907|NCT01941615|Experimental|BI 207127 + faldaprevir + Microgynon|Period A: Microgynon®; Period B: Microgynon® + FDV + BI 207127
3139908|NCT01946542|Placebo Comparator|placebo|placebo drink, single dose, taste and color-matched to experimental drink
3139909|NCT01946542|Experimental|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
3139910|NCT01937507|Experimental|HAI with FOLFOX|Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid
3139911|NCT01944059|Active Comparator|Theramine|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
3139912|NCT01944059|Placebo Comparator|placebo (l-alanine)|"2 capsules before breakfast and dinner (BID) for 16 weeks.~Migraine preventative medications will be permitted, but no changes in dosage will be allowed during the four month study. Migraine abortive meds will be permitted and will be administered per their standard routine."
3150371|NCT00201149|Experimental|2|In a subset of those clinicians receiving the patient-centered counseling program intervention, we will augment it with cultural competency training.
3150372|NCT00201162|Experimental|Intervention|dietary supplement soy protein containing isoflavones
3150373|NCT00201162|Placebo Comparator|Placebo|dietary supplement casein placebo
3150374|NCT00201188|Experimental|1|Participants will receive feedback and peak flow monitoring reports from their doctors.
2404562|NCT03540784|Experimental|Nutrition|high-protein nutrition therapy
3150375|NCT00201188|No Intervention|2|Participants will receive usual care.
3150376|NCT00201227|Experimental|Practice Change|Enhancement of primary care practice performance and practice guideline adherence
3150377|NCT00201227|No Intervention|Control|Usual care
3150378|NCT00201266||Exacerbation resistant asthma|Control group
3150379|NCT00201266||Exacerbation prone asthma|Cases
3150380|NCT00201396|Active Comparator|A arm|CCRT
3150381|NCT00201396|Experimental|B arm|Induction/CCRT
3150382|NCT00201422|Experimental|Omeprazole, Amoxicillin, Clarithromycin|Anti-H. pylori Therapy (Triple therapy)
3150383|NCT00201461|Active Comparator|1|Best medical therapy
3150384|NCT00201461|Experimental|2|STARFlex arm
3150385|NCT00201474||brief depressive periods|brief depressive periods together with other fluctuating psychiatric symptoms
3150386|NCT00201474||major depressive disorder|
3150387|NCT00201500||preeclampsia|women with preeclampsia
3150388|NCT00201500||controls|healthy pregnant women
3150389|NCT00201513|Experimental|TrA exercise|Isolated Transversus abdominis (TrA) exercises (low load)
3150390|NCT00201513|Experimental|sling exercise|Sling exercises (high load)
3150391|NCT00201513|Active Comparator|group exercise|Non-specific group exercises
3150392|NCT00201539|Active Comparator|double dose once|double dose immediate-release oral morphine at bedtime in cancer patients, placebo after 4 hours
3150393|NCT00201539|Experimental|single dose twice|single dose immediate-release oral morphine at bedtime in cancer patients, second single dose after 4 hrs
3150394|NCT00201617||1|normal hearing sensitivity
3139913|NCT01935947|Experimental|Arm I (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice comprising irinotecan hydrochloride IV on day 1, docetaxel IV on day 1, pemetrexed disodium IV on day 1, or gemcitabine hydrochloride IV on days 1 and 8. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3150395|NCT00201617||2|Unilateral deafness who are implanted with a Bone Anchored Hearing Aid
3150396|NCT00201656|Active Comparator|1 Retention of Cerclage|Group one = Subject whose Cerclage is retained after randomization.
3150397|NCT00201656|Active Comparator|2 - Removal of Cerclage|Group 2 = Subjects who will have cerclage removed after randomization
3150398|NCT00201669|Experimental|Arm I|
3150399|NCT00201682|Experimental|Arm I|Etanercept 25 mg administered sub-cutaneously twice weekly (Monday and Thursday) weeks 1-5 of therapy (total of 10 doses). The third dose of etanercept will be administered 1 hour prior to receiving rituximab. Rituximab: Patients will receive 375 mg/M2 of rituximab three times weekly for four weeks (a total of 12 doses of rituximab).
3150400|NCT00201708|Active Comparator|Arm A (Docetaxel before doxorubicin/cyclophosphamide)|"Docetaxel 75 mg/m2 every 2 weeks for 4 cycles followed by A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles."
3150401|NCT00201708|Active Comparator|Arm B (Docetaxel after doxorubicin/cyclophosphamide)|"A (doxorubicin) 60 mg/m2 & C (cyclophosphamide) 600 mg/m2 every 2 weeks for 4 cycles followed by Docetaxel 75 mg/m2 every 2 weeks for 4 cycles."
3139914|NCT01935947|Experimental|Arm II (azacitidine, entinostat, chemotherapy)|Patients receive azacitidine PO on days 1-21 and entinostat PO on days 3 and 10. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or progressive disease receive chemotherapy of the treating oncologist's choice as in Arm A.
3139915|NCT01935947|Active Comparator|Arm III (chemotherapy)|Patients receive chemotherapy of the treating oncologist's choice as in Arm A.
3139916|NCT01939223|Experimental|Regorafenib|4 regorafenib tablets taken orally in the morning daily, followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
3139917|NCT01939223|Placebo Comparator|Placebo|4 placebo tablets taken orally in the morning daily,followed by a low fat meal for 3 weeks on off treatment followed by 1 week off without treatment,Treatment 21 days.
3139918|NCT01938716|Experimental|Gemcitabine Infusion|Gemcitabine administered intravenously as a dose of 500 mg/m2 at a fixed dose rate of 10 mg/m2/min for the first 5 patients (to validate hematologic safety). Next 15 subsequent patients receive 750 mg/m2 at a fixed dose rate of 10 mg/m2/min. The drug infusion started 50-75 minutes prior to complete gross tumor removal (timing dependent on dose) in order to have drug administration complete at tumor removal.
3139919|NCT01936974|Experimental|Platinum, Gemcitabine and Bevacizumab|"Platinum:~Carboplatin* on day 1~*If a patient is allergic to carboplatin, then give~Cisplatin** on day 1~**If a patient is allergic to cisplatin and carboplatin, then give~Oxaliplatin on day 1~Gemcitabine on day 1 only~Bevacizumab on day 1"
3139920|NCT01936974|Active Comparator|Gemcitabine and Bevacizumab|"Gemcitabine on days 1 and 8~Bevacizumab on day 1"
3139921|NCT01938833|Experimental|Treatment (Romidepsin and Abraxane)|Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3139922|NCT01934647|Experimental|1 mg MK-8892|Participants will receive a single oral dose of 1 mg MK-8892.
3139923|NCT01934647|Experimental|4 mg MK-8892|Participants will receive a single oral dose of 4 mg MK-8892.
3139924|NCT01934647|Experimental|8 mg MK-8892|Participants will receive a single oral dose of 8 mg MK-8892.
3139925|NCT01934504||Tolerant AAV|Tolerant participants with AAV
3139926|NCT01934504||Non-Tolerant AAV|Non-Tolerant participants with ANCA-associated vasculitis (AAV)
3139927|NCT01934504||Healthy Controls|Healthy participants that fulfill eligibility criteria -similar in age to Tolerant and Non-Tolerant AAV participants.
3139928|NCT01934504||AAV Discontinuing Immunosuppression|Participants have been in clinical remission and on minimal maintenance therapy for at least 2 years prior to screening. Their primary physicians have planned to discontinue immunosuppression medication in the next year after screening.
3139929|NCT01928082|Experimental|Transdermal estradiol|Transdermal estradiol 0.05 mg/day for 4 weeks, followed by 0.10 mg/day for 4 weeks
3139930|NCT01928615|Experimental|Trastuzumab - Thigh first, then upper arm|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the thigh for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the upper arm for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
3150402|NCT00201786|Experimental|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS.
3150403|NCT00201799|Experimental|Infliximab|Patients will be treated with infliximab day 1 prior to starting myeloblative chemotherapy or radiotherapy. A total of 6 doses will be administered.
3150404|NCT00201890|Experimental|1|Standard of Care plus Lymphatic massage (Decongestive Lymphatic Therapy)
3150405|NCT00201890|No Intervention|2|Standard of Care
3150406|NCT00201916|Experimental|1|5250 cGy in 20 fractions over 28 days
3150407|NCT00201916|Active Comparator|2|6600 cGy in 33 fractions over 45 days
3150408|NCT00201968|Other|FES training|Arm 1 receives functional electrical stimulation while walking on body weight suspension training.
3150409|NCT00201968|Other|Control Group training|Aerobic and resistance training program
3150410|NCT00201981|Active Comparator|1|rebamipide 1%
3139931|NCT01928615|Experimental|Trastuzumab - Upper arm first, then thigh|In the run-in phase, participants received trastuzumab intravenously every 3 weeks for 18 weeks (Cycles 1-6). They first received trastuzumab 8 mg/kg once (Cycle 1) followed by trastuzumab 6 mg/kg 5 times for 15 weeks (Cycles 2-6). Participants could also receive a maximum of 6 cycles of standard chemotherapy for early breast cancer (neo-adjuvant or adjuvant) in the run-in phase. Following the run-in phase, participants received trastuzumab 600 mg subcutaneously (SC) every 3 weeks into the upper arm for 12 weeks (Cycles 7-10) followed by trastuzumab 600 mg SC every 3 weeks into the thigh for 12 weeks (Cycles 11-14). In Cycles 15-18, participants received trastuzumab 600 mg SC every 3 weeks into either the thigh or the upper arm (participant's choice) for 12 weeks (Cycles 15-18).
3139932|NCT01911793|Experimental|Stoma tube|Stoma tube (18 French) red robinson catheter inserted into stoma at the time of surgery
3139933|NCT01911793|No Intervention|Standard Stoma|Patients will have standard stoma created without insertion of stoma tube. Stoma tube will only be inserted postoperative if the patient is felt to have postoperative ileus, nausea, vomiting, and decreased stoma output as per standard protocol.
3139934|NCT01912404|Experimental|IDN-6556|IDN-6556 capsules, 25 mg BID
3139935|NCT01912404|Placebo Comparator|Placebo|Placebo capsules BID
3139936|NCT01910389|Active Comparator|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
3139937|NCT01910389|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
3139938|NCT01921114|Active Comparator|BioFlo™ PICC|BioFlo™ Peripherally Inserted Central Catheter (PICC)
3139939|NCT01921114|Active Comparator|Bard® PowerPICC SOLO2®|Bard® Dual-Lumen PowerPICC SOLO2®
3150411|NCT00201981|Active Comparator|2|Rebamipide 2%
3150412|NCT00201981|No Intervention|3|placebo
3150413|NCT00202033|Experimental|1|self monitor blood glucose 3 times a day per usual diabetes class curriculum
3139940|NCT01916590|Active Comparator|Bupivacaine|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine)through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
3139941|NCT01916590|Placebo Comparator|Placebo|All patients who give consent will undergo ultrasound guided placement of a femoral catheter with injection of 30 cc of 0.5% bupivacaine (without epinephrine) through the catheter. After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with saline solution, and the infusion will be started at 6 ml/hr. gh the catheter.
3139942|NCT01913327|Experimental|aripiprazole|aripiprazole with flexible, blind dosing between 7.5 mg and 30 mg, once daily.
3139943|NCT01913327|Active Comparator|risperidone|risperidone with flexible, blind dosing between 1 mg and 8 mg, once daily.
3139944|NCT01902888||Popliteal aneurysm|GORE® VIABAHN® Endoprosthesis used to treat popliteal aneurysm
3139945|NCT01901224|Experimental|Metformin 1000 mg|metformin 1000 mg twice daily: In order to avoid gastrointestinal side effects, the starting dose of metformin will be 500 mg twice daily. After one week, the dose will be increased to 1000 mg twice daily (as two 500 mg tablets twice daily). Subjects will be instructed to take medications with breakfast and with dinner.
3139946|NCT01901224|Placebo Comparator|Control|placebo twice daily: In order to maintain blinding during the titration period, individuals randomized to placebo will receive one placebo tablet twice daily for one week, followed by an increase to 2 placebo tablets twice daily. Subjects will be instructed to take medications with breakfast and with dinner.
3139947|NCT01910441|Experimental|Group A: Vildagliptin plus metformin|Participants received Vildagliptin 50 mg twice daily as an add-on to metformin (1000-1500mg daily).
3139948|NCT01910441|Active Comparator|Group B: Glimepiride plus metformin|Participants received Glimepiride 1-6 mg once daily as an add-on to metformin (1000-1500mg daily).
3139949|NCT01902966|Experimental|Propranolol + Relaxation/Guided Imagery|A starting dose of propranolol 20 mg is taken by mouth twice a day (40 mg/day). If patient tolerates the initial dose (no hypotension or bradycardia), dose increased to 40 mg by mouth twice a day at start of second month of therapy. Patients record study medication taken each day in a pill diary. Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes. Relaxation diary completed stating whether patient was able to complete the sessions and whether they had any difficulties with it. Questionnaires completed at baseline, 2 months, and 4 months.
3139950|NCT01901679|Experimental|Celebrex|10 days treatment with Celebrex to evaluate reduction of PGE-M in urine
3139951|NCT01900730|Placebo Comparator|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks. Patient contacted by phone to assess tolerance and instruction to increase dose. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
3139952|NCT01900730|Experimental|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks. Questionnaires completed at baseline, weeks 2, 6, and 10. Patient given a pill diary to record the time each dose taken. Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
3139953|NCT01877564|Experimental|Group 1 - Metformin|oral metformin at 500 mg twice a day for 14-21 days followed by surgery
3139954|NCT01877564|No Intervention|Group 2 - No treatment|
3139955|NCT01890694|Placebo Comparator|Placebo|"Subjects will receive placebo once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
3150414|NCT00202033|Experimental|2|only self monitor blood glucose when fasting
3150415|NCT00202033|Experimental|3|no self monitoring of blood glucose
3150416|NCT00202046||Patients with lymphedema|Identification of risk factors for lymphedema in women who have had axillary surgery for breast cancer.
3150417|NCT00202046||Control patients without lymphedema|Controls matched on type of axillary surgery and surgery date for comparison in quality of life (QOL) ratings from women who have lymphedema.
3150418|NCT00202098|Experimental|1|ALI/ARDS patients
3150419|NCT00202137|Active Comparator|1|home blood pressure monitoring with automatic blood pressure device
3150420|NCT00202137|Active Comparator|2|physician monitoring of blood pressure by 3 monthly office visits
3150421|NCT00202176|Experimental|1|Ipratropium Bromide
3150422|NCT00202176|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3150423|NCT00202189|Experimental|1|Budesonide
3150424|NCT00202189|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3150425|NCT00202228|Experimental|1|Individuals living with HIV who are naive to antiretroviral treatment, or who have been on a treatment interruption for at least six months
3150426|NCT00202228|Experimental|2|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT
3182532|NCT00704054|Experimental|1|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
3182533|NCT00704067|Experimental|1|Supported employment for 12 months plus cognitive training for the first 12 weeks
3182534|NCT00704067|Active Comparator|2|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks
3182535|NCT00704080|Experimental|1|
3139956|NCT01890694|Experimental|Tolvaptan|"Subjects will receive Tolvaptan once daily.~They will undergo the following procedures in every visit: Vitals (blood pressure, heart rate, respiration, temperature, weight, height), Laboratory Tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin), ascites assessment, evaluation for edema. Quality of life assessments (SF-36, and LDQOL 1.0) will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge. Hepatic encephalopathy assessment (Number Connection Test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status) will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge."
3139957|NCT01900626|Active Comparator|single epidural catheter|
3139958|NCT01900626|Active Comparator|double epidural catheter|
3139959|NCT01890577||Study population|Single cohort of dialysis patients
3139960|NCT01895959|Other|Euflexxa|EUFLEXXA® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.
3139961|NCT01889420|Experimental|Combination therapy|Pomalidomide: 1 tablet orally, daily for 21 days of a 28 day cycle (dose per cohort) Everolimus: 1 tablet orally for 21 days of a 28 day cycle (dose as per cohort) Dexamethasone 40 mg (20 mg >75yrs) orally, days 1, 8,15, 22 of a 28 day cycle
3139962|NCT01884077|Active Comparator|Reverse Shoulder Arthroplasty|Shoulder Joint Replacement Reverse Arthroplasty Implant to surgically replace arthritic shoulder
3139963|NCT01884077|Active Comparator|Total Shoulder Arthroplasty|Shoulder Joint Replacement Total Arthroplasty Implant used to surgically replace osteoarthritic shoulder joint
3139964|NCT01881984|Experimental|Ravicti|Open Label Study
3139965|NCT01893359|Experimental|LASIK followed by Cross-linking (Continuous Wave)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 2 minutes continuous UVA.
3182536|NCT00704106||Group 1|Persistent viremia after 48 weeks or longer.
3139966|NCT01893359|Experimental|LASIK followed by Cross-linking (Pulsed)|Following LASIK, the corneal bed will be thoroughly coated with five drops of riboflavin ophthalmic solution, rinsed with saline solution, and the corneal flap repositioned. The eye will then be irradiated at 30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off.
3139967|NCT01893359|Placebo Comparator|LASIK Only|Eyes assigned to this arm will receive standard LASIK with no cross-linking.
3139968|NCT01883908|Experimental|Acupuncture with Seirin® needles|Participants will be randomized to receive acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
3139969|NCT01883908|Active Comparator|Usual medical care|Participants will be randomized to receive usual medical care for 8 weeks coinciding with their chemoradiation treatments. Patients will receive usual medical care such as viscous Lidocaine for relief of pain.
3139970|NCT01887288|Experimental|Capecitabine with Digoxin|"Capecitabine PO daily b.i.d., no breaks, starts at day 1 of the first cycle; Digoxin: once daily, starts at day -7 of the first cycle~(1 cycle - 4 weeks)"
3139971|NCT01868139|Experimental|Cryotherapy|Liquid nitrogen spray cryotherapy with the truFreeze device
3139972|NCT01881932|No Intervention|Standard Care|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). In standard care arm, patients will not receive additional therapy for CIPN. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed.
3150427|NCT00202228|Experimental|3|Individuals living with HIV who are on an antiretroviral regimen including one of D4T/ddI/ddC/AZT and have liver disease.
3150428|NCT00202228|Experimental|4|HIV negative control group
3182537|NCT00704106||Group 2|<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
3182538|NCT00704106||Group 3|Patients who responded to adefovir and were switched to entecavir.
3182539|NCT00704106||Group 4|Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.
3182540|NCT00704145|Experimental|A|Device, paclitaxel drug-eluting stent
3182541|NCT00704210|Sham Comparator|B|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
3182542|NCT00704210|Experimental|A|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
3150429|NCT00202267|Active Comparator|1|Clients randomized to short-stretch bandaging application
3150430|NCT00202267|Active Comparator|2|Clients randomized to four-layer bandaging application
3150431|NCT00202280|Placebo Comparator|Placebo pill|Placebo pill daily for 3 months
3150432|NCT00202280|Experimental|5mg folic acid, 0.4mg B12, 50mg B6|5mg folic acid, 0.4mg B12, 50mg B6 in one pill, daily for 3 months
3150433|NCT00202293|Experimental|Lithium and olanzapine|
3150434|NCT00202293|Active Comparator|Lithium and chlorpormazine|
3150435|NCT00202358|Placebo Comparator|placebo|
3150436|NCT00202358|Experimental|atenolol|
3150437|NCT00202397|Placebo Comparator|2|placebo bid for 8 weeks
3182543|NCT00704223||A|
3182544|NCT00704236|Experimental|A|
3182545|NCT00704236|Placebo Comparator|B|
3182546|NCT00704249|Experimental|1|Full-dose nevirapine from baseline (200 mg bid).
3182547|NCT00704249|Active Comparator|2|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
3182548|NCT00704275|Experimental|A|0.05% cyclosporin
3182549|NCT00704275|Active Comparator|B|Refresh
3182550|NCT00704288|Experimental|1|
3182551|NCT00704301|Experimental|1|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Rivastigmine: two times 1,5 mg a day; The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
3182552|NCT00704301|Placebo Comparator|2|Haloperidol: aged 70 years or less: 1 mg haloperidol three times a day i.v. older than 70 years: 0,5 mg haloperidol three times a day i.v. Placebo: 2 times a day
3182553|NCT00704314|Active Comparator|1|Simvastatin therapy, 80 mg/d for 8 weeks
3139973|NCT01881932|Experimental|Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive acupuncture until the end of their chemotherapy. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels. All patients will follow the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. In standard care arm, patients will not receive additional therapy for CIPN.
3150438|NCT00202397|Experimental|1|Riluzole, capsule-shaped 50 mg tablets bid for 8 weeks
3150439|NCT00202410|Placebo Comparator|physiologic solution|subcutaneous administration of physiologic solution
3150440|NCT00202410|Experimental|Bacille Calmette-Guèrin (BCG) Vaccine|Anti-Tubercular Vaccination
3150441|NCT00202436|Active Comparator|1|Phlebotomy
3150442|NCT00202436|Active Comparator|2|Erythrocytapheresis
3150443|NCT00202475|Active Comparator|1|
3150444|NCT00202475|Active Comparator|2|
3150445|NCT00202670||1|SPECT
3150446|NCT00202670||2|dobutamine echocardiography
3150447|NCT00202696|Experimental|1|Nalmefene 40 mg
3150448|NCT00202696|Experimental|2|Nalmefene 80 mg
3150449|NCT00202696|Other|3|Placebo
3150450|NCT00202709|Experimental|Thought Field Therapy (TFT)|Treatment with TFT, first one hour, then 1/2 hour.
3150451|NCT00202709|No Intervention|Wait list control|
3139974|NCT01881932|Active Comparator|Sham Acupuncture|Patients will be stratified based on cancer type (breast cancer vs colorectal cancer). The patients will be randomly assigned to receive sham acupuncture until the end of their chemotherapy while following the same chemotherapy dose reduction algorithm. No concomitant anti-neuropathy medication is allowed. Patient will complete a weekly questionnaire during the study to determine severity of nerve pain symptoms. Each week record the total amount of chemotherapy received in the past week. Record how much chemotherapy received all together. Each week patient will have blood drawn (about 1 teaspoon) to check nerve growth factors levels.
3139975|NCT01878786|Experimental|ERL & TAC|Concentration controlled everolimus(ERL) & Low dose tacrolimus(TAC) + corticosteroid withdraw
3139976|NCT01878786|Experimental|ERL & TAC --> MMF/MPA|Concentration controlled everolimus & low dose tacrolimus --> mycophenolate mofetil (MMF) at Month 3 + corticosteroid
3139977|NCT01878786|Experimental|Standard dose TAC + MMF/MPA|Standard dose of tacrolimus + mycophenolate mofetil + corticosteroid withdraw
3139978|NCT01877343|Experimental|CVInsight (TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical)and blood pressure will be measured at different table positions (different angles). A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
3139979|NCT01861717|Experimental|Somatuline Depot Subcutaneous (SC)|Somatuline Depot SC 90mg deep subcutaneous injection every 4 weeks for 3 doses before surgery. The dose will be 60 mg for patients with mild liver or kidney dysfunction.
3139980|NCT01866709|Active Comparator|Sodium Polystyrene Sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
3139981|NCT01866709|Placebo Comparator|Silicified microcrystalline cellulose|Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS.
3139982|NCT01860040|Experimental|Cisplatin and pemetrexed|Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
3139983|NCT01860040|Experimental|Cisplatin and gemcitabine|Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
3139984|NCT01869478|Active Comparator|Intravenous Thrombolysis|0.9mg/kg intravenous rt-PA (max dose 90mg) - 10% administered as a bolus over 1 minute and the remainder infused over 60 minutes.
3139985|NCT01869478|Active Comparator|Endovascular Arterial Reperfusion|Therapeutic options will include mechanical thrombectomy/clot disruption (Penumbra aspiration system, Solitaire device, and/or Reflex catheter) and/or intracranial stent deployment.
3139986|NCT01851174|Experimental|Gemcitabine and nab-Paclitaxel|"Gemcitabine (1,000 mg/m^2) administered intravenously on days 1 and 15, every 28 days~nab-Paclitaxel (125 mg/m^2) administered intravenously on days 1 and 15, every 28 days"
3139987|NCT01846182|Active Comparator|Group 1|60 mg of duloxetine in the AM for 20 weeks and placebo in PM
3139988|NCT01846182|Active Comparator|Group 2|300 mg of pregabalin in the PM for 20 weeks and placebo in AM
3139989|NCT01846182|Placebo Comparator|Group 3|placebo in the AM & PM for 20 weeks
3139990|NCT01844206|Active Comparator|Epidural Morphine|Group receiving 3mg epidural morphine, 24 hours after the initial dose
3182554|NCT00704314|Placebo Comparator|2|Placebo, one pill daily for 8 weeks
3139991|NCT01844206|Placebo Comparator|Epidural Saline|Group receiving epidural saline 6ml, 24 hours after receiving epidural morphine 3mg.
3139992|NCT01856322|Active Comparator|Sulindac|one tablet twice daily
3182555|NCT00704366|Experimental|1|AZD0530
3182556|NCT00704392|Experimental|1|
3139993|NCT01856322|Placebo Comparator|Placebo|one tablet twice daily
3139994|NCT01856322|Other|Normal Volunteers (or control group)|Normal volunteers (or control group) enrolled with the only purpose to validate assays and the shipping method.
3182557|NCT00704431|Experimental|darapladib|darapladib
3182558|NCT00704444||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
3182559|NCT00704444||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
3182560|NCT00704457||A|One arm study. Urine collection.
3182561|NCT00704470|Active Comparator|1|Classic one-day simulator training for intensivists.
3182562|NCT00704470|Experimental|2|Crew resource management training
3182563|NCT00704483|Experimental|1|1g tid
3182564|NCT00704483|Active Comparator|2|Sevelamer HCl
3139995|NCT01853176|Experimental|Liposomal injection bupivicaine (Exparel)|Patients will have the maximum approved dose of Exparel, 266 mg, diluted in 20 mL normal saline, infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
3182565|NCT00704483|Experimental|3|SBR759 1.5 g tid
3182566|NCT00704483|Active Comparator|4|Sevelamer HCl
3182567|NCT00704509|Experimental|Bifeprunox|
3182568|NCT00704509|Placebo Comparator|Placebo|
3182569|NCT00704509|Active Comparator|Quetiapine|
3182570|NCT00704548|Active Comparator|1|Simvastatin 40 mg
3182571|NCT00704548|Placebo Comparator|2|
3182572|NCT00704561|Active Comparator|DES|Zotarolimus drug-eluting stent
3182573|NCT00704561|Active Comparator|BMS|bare metal stent
3182574|NCT00704574||A|
3182575|NCT00704600|Experimental|nelfinavir|see intervention
3182576|NCT00704626||Cohort 1|Subjects with multiple sclerosis and other autoimmune and inflammatory disease of the nervous system
3182577|NCT00704639|Experimental|Single arm|Chemoradiation (Cetuximab, Carboplatin and Radiotherapy)
3182578|NCT00704652||A|Diabetic patients suffering from renal insufficiency with stable haemoglobin levels (receiving no EPO supplementation)
3182579|NCT00704652||B|Diabetic patients with renal insufficiency and in need of recombinant human EPO (darbepoetin alfa) substitution because of inadequate erythropoiesis. In both groups the target haemoglobin level is 10-12 gHb/ml, all treatment is performed according to label.
3182580|NCT00704665|Placebo Comparator|2|Placebo
3139996|NCT01853176|Active Comparator|Standard bupivicaine|Patients will receive the maximum safe allowance of 0.25% bupivacaine, or 1.5 mg/kg (eg. 150 mg or 60 mL for a 100 kg patient) infiltrated into the rectus fascia and subcutaneous tissues at the time of abdominoplasty.
3139997|NCT01857271|Experimental|Treatment (erlotinib hydrochloride and thoracotomy)|Patients receive erlotinib hydrochloride PO QD for 2 months and then undergo thoracotomy.
3182581|NCT00704665|Experimental|A|10ug/kg/day or 25/ug/kg/day
3139998|NCT01856361|Experimental|Ramipril|The initial dose of ramipril will be 2.5 mg that will be started at visit 2, week zero of the study. The dose will be increased to 5 mg during visit 3, 4 weeks into the study, for a total of 32 weeks.
3139999|NCT01856361|Sham Comparator|Placebo|The placebo group will get a similar pill that will be started at visit 2, week zero of the study. Subjects will be asked to double the dose by taking two pills during visit 3, four weeks into the study, for a total of 32 weeks.
3140000|NCT01853982|Experimental|Ceftolozane/Tazobactam|3000 milligrams (mg) ceftolozane/tazobactam (comprised of 2000 mg ceftolozane and 1000 mg tazobactam), administered intravenously (IV), every 8 hours for 8 days
3140001|NCT01853982|Active Comparator|Piperacillin/Tazobactam|4500 mg piperacillin/tazobactam (comprised of 4000 mg piperacillin and 500 mg tazobactam), administered IV, every 6 hours for 8 days
3140002|NCT01836809|Experimental|Total Artificial Heart|Nesiritide
3140003|NCT01836809|Placebo Comparator|Total Artificial Heart: Placebo|Control arm for subjects receiving the Total Artificial Heart and randomized to receive placebo
3140004|NCT01836809|Active Comparator|LVAD: Nesiritide|Active arm of the LVAD group
3140005|NCT01836809|Placebo Comparator|LVAD: Placebo|Control arm for subjects receiving LVAD and randomized to placebo
3140006|NCT01831596|Experimental|ciSNaP|
3140007|NCT01834144|Active Comparator|Moderate intensity exercise|150-200 minutes of weekly moderate intensity exercise (45-55% of peak fitness)
3140008|NCT01834144|Active Comparator|Moderate + Vigorous Intensity Exercise|150-200 minutes of weekly moderate intensity exercise, with short bouts of vigorous intensity exercise (80-90% of peak fitness)
3182582|NCT00704678|Experimental|1|1g bid
3140009|NCT01821963|Experimental|Pegylated Interferon Alfa 2a + Ribavirin + Telaprevir|Triple combination with Telaprevir, PegIFN alfa-2a and Ribavirin administered for 12 weeks, followed by dual therapy with PegIFN alfa-2a and Ribavirin. Dual therapy continued for 48 weeks of total duration of therapy, as standard of care treatment for cirrhotic patients, or until day of transplantation, whichever comes first. Starting doses for standard of care pegylated interferon (PegIFN) alfa-2a 180 mcg subcutaneously once weekly, for ribavirin (RBV) 1,000 mg orally daily (< 75 kg) and 1,200 mg orally daily (≥ 75 kg), and for telaprevir 750 mg taken orally 3 times a day.
3140010|NCT01821898|Active Comparator|Positive for food allergy: Group A|Oral Budesonide
3140011|NCT01821898|Active Comparator|Positive for food allergy: Group B|Elimination diet
3140012|NCT01814722||Raltegravir + 2 NRTIs|Raltegravir is an integrase inhibitor. Two Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
3140013|NCT01814722||NNRTI + 2 NRTIs|Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) could include: delavirdine, efavirenz, etravirine, rilpivirine, nevirapine; and two NRTIs.
3140014|NCT01814722||PI + 2 NRTIs|Protease inhibitors (PI) could include: nelfinavir, lopinavir, saquinavir, tipranavir, atazanavir and darunavir; and two NRTIs.
3140015|NCT01830790|Active Comparator|Healthy Controls|Healthy individuals >65 years old without ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
3140016|NCT01830790|Experimental|AMD patients|Age-related macular degeneration (AMD) patients >65 years old without other ocular disease, who will be given a single dose of 100mg sildenafil citrate, then imaged with EDI-OCT to determine a change in choroidal thickness
3140017|NCT01829477|Experimental|TAK-875 50 mg|TAK-875 50 mg tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
3140018|NCT01829477|Placebo Comparator|Placebo|TAK-875 placebo-matching tablet, orally, once daily and glimepiride 6 mg (or Maximum Tolerated Dose), tablets, orally, once daily for up to 24 weeks.
3182583|NCT00704678|Active Comparator|2|0.8 g tid
3182584|NCT00704678|Experimental|3|1.5 g tid
3140019|NCT01803711|Experimental|Desvenlafaxine + Omega 3 FA supplement|Desvenlafaxine 50mg/day & Omega 3 FA supplement (range 2.4 gm/day - 4.8 gm day) over a 12 week period
3140020|NCT01803711|Active Comparator|Desvenlafaxine + Placebo (for Omega 3 FA supplement)|Desvenlafaxine 50mg/day & Placebo (for Omega 3 FA supplement) over a 12 week period
3182585|NCT00704678|Active Comparator|4|1.6 g tid
3182586|NCT00704691|Experimental|Lenalidomide|
3182587|NCT00704743|Active Comparator|1|Cylindrical cast
3182588|NCT00704743|Active Comparator|2|Modified sugar tong cast
3182589|NCT00704743|Active Comparator|3|Volar dorsal splint
3182590|NCT00704756||Arm 1|Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium.
3182591|NCT00704782|Experimental|Dimebon|20 mg by mouth 3 times a day
3182592|NCT00704795||1|Patients with type 1 diabetes mellitus
3182593|NCT00704795||2|Healthy control subjects matched for body mass index (BMI), age and gender.
3182594|NCT00704821|Experimental|Stage 1|In Stage 1, PTC299 will be given orally twice a day (BID) each day at about the same time each day for the first 28 days of each cycle. Each cycle will constitute a 4-week (28 days) period followed by a ≥2-week (14-day) washout period. Participants will be assigned to 0.3 milligrams (mg)/kilograms (kg)/dose BID, 0.6 mg/kg/dose BID, or 1.2 mg/kg/dose BID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
3182595|NCT00704821|Experimental|Stage 2|In Stage 2, PTC299 will be given BID or 3 times a day (TID) orally each day at about the same time each day; therefore, 84 (for BID) or 126 (for TID) doses of PTC299 will be delivered during the 6-week (42-day) period in each cycle. Each participant will be assigned to 100 mg/dose BID, 100 mg/dose TID, 120 mg/dose TID, 160 mg/dose TID, or 200 mg/dose TID sequentially based on safety evaluations by the Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
3140021|NCT01821859|Experimental|Abraxane/Bevacizumab|"Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.~Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion."
3140022|NCT01808950|Experimental|0.06% Resiquimod Gel - A|"60 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
3140023|NCT01808950|Experimental|0.06% Resiquimod Gel - B|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation"
3140024|NCT01808950|Experimental|0.06% Resiquimod Gel - C|"100 mg gel~Once daily prior to normal sleeping hours~5x within 1 week (Monday to Friday) for 4 weeks (at maximum) or until clinical manifestation of skin erosion/crust formation~The BCC will be pretreated. A shave biopsy (curettage or scraping off the tissue in a broad, superficial, tangential way) will be performed"
3140025|NCT01806051|Experimental|PKU Participants (Arm 1)|"Subjects will be administered Kuvan once daily.~They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6)."
3140026|NCT01806051|No Intervention|Control Group (Arm 2)|"Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2)."
3140027|NCT01808794|Active Comparator|Mucograft|Placement of randomized membrane on half of subjects Mucograft
3140028|NCT01808794|Active Comparator|Dynamatrix|Placement of randomized membrane on half of subjects Dynamatrix Membrane Placement
3140029|NCT01809899|Experimental|Enhanced Consent Procedure|Participants in this group will receive an enhanced consent that will be an hour longer than usual.
3140030|NCT01809899|Active Comparator|Consent as Usual Procedure|Participants in this group will receive a normal consent procedure to the study
3140031|NCT01810302|Experimental|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
3140032|NCT01810302|Placebo Comparator|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
3140033|NCT01806961||clearance at end of trial SP848-AK-1101|no trial medication during this follow-up trial
3140034|NCT01804166|Other|IBD patients with HSTCL|Subjects with Inflammatory Bowel Disease with a diagnosis of Hepatosplenic T-cell lymphoma
3140035|NCT01783015|Experimental|Group A|Subjects who are mAb ADA positive
3140036|NCT01783015|Experimental|Group B|Subjects who are mAb ADA negative
3140037|NCT01783015|Placebo Comparator|Group C|Subjects who are mAb ADA positive
3140038|NCT01783015|Placebo Comparator|Group D|Subjects who are mAb ADA negative
3140039|NCT01800162|Active Comparator|Uterine evacuation, then MTX for some|Subjects will undergo a uterine evacuation. If hCG levels do not sufficiently decrease after the uterine evacuation, the subject will be treated with methotrexate. If hCG levels do sufficiently decrease after the uterine evacuation, no further treatment is required.
3140040|NCT01800162|Active Comparator|Empiric treatment with MTX for all|Subjects will be treated with methotrexate, receiving one dose on day 0 and a subsequent dose on day 4. Additional doses will be administered as needed based on hCG levels.
3140041|NCT01800162|Active Comparator|Expectant Management|Subjects will have their PPUL expectantly managed using serum hCG monitoring.
3140042|NCT01794936|Experimental|VTI Probe|During robotic-assisted laparoscopic prostatectomy, the VTI Doppler probe (test) will utilized to measure blood blow within the neurovascular bundles. This is to be completed after the bladder neck and seminal vesicles are identified and dissected. To use the probe, the assistant surgeon will place the Doppler probe within the abdomen and systematically move it cephalad along the lateral prostate pedicles to identify NVB vessels. The Doppler flow in these regions will be quantified as arterial (strong) flow, venous (minimal) flow or no flow. The procedures will proceed by dissecting the lateral margin of prostate step by step up to the gland's apex. Blood loss and the time required to identify and dissect the NVB will be recorded.
3140043|NCT01794936|No Intervention|Non-Probe|Patients randomized to not receive probe evaluation.
3140044|NCT01797380|Placebo Comparator|Sugar Pill|Placebo
3140045|NCT01797380|Active Comparator|Active Drug|Escitalopram tablet, 10mg, daily, 9 weeks.
3140046|NCT01781026|Experimental|Vemurafenib Administration|Vemurafenib 960 mg orally, twice per day
3150452|NCT00202735|Active Comparator|Immobilization in internal rotation|"Immobilization in internal rotation:All patients in this group are immobilized with the arm in internal rotation.~The arm is immobilized with a normal collar and cuff device."
2404730|NCT03539770||Control|Children without scoliosis
3140047|NCT01788475|Active Comparator|Dexamethasone implant up to every 3 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time > 3 months following last injection in group 1 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3140048|NCT01788475|Active Comparator|Dexamethasone implant up to every 6 Mo.|"Ozurdex (dexamethasone) 0.7 mg implant will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit.~Re-implantation of Ozurdex (dexamethasone) may occur at any time >6 months following last injection in group 2 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3140049|NCT01788475|Sham Comparator|Sham Implant|"Sham Procedure will be performed on Day 0. All patients will be evaluated monthly thereafter.~Intervention: One month following initial implantation/sham, patients will be evaluated for focal or grid laser treatment if the investigator feels the patient will benefit. Also, at 13 months, patients in the sham group will be eligible for Ozurdex (dexamethasone) 0.7 mg implantation if initial inclusion/exclusion criteria are met. These patients would follow re-implantation guidelines of group 2.~Sham implantation may occur at any time > 6 months following last sham injection in group 3 if any of the following conditions are met:~Increase of > 50 microns from the best previous CRT measurement~Recurrence of intraretinal cystic edema~Persistent intraretinal cystic edema"
3140050|NCT01784991|Active Comparator|1mg + 1mg Hydromorphone|Patient will receive 1 mg of hydromorphone for pain at timepoint 0. After 15 minutes, patients will be asked if the still need pain medication. If yes, patients will immediately receive 1mg hydromorphone. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion.
3140051|NCT01784991|Active Comparator|Usual Care Group|"Patient will receive pain medicine per doctor's discretion at timepoint 0. After 15 minutes, patients will be asked if they still need pain medication. If yes, physicians will not be notified and patient will continue to have pain managed as deemed necessary by physician per usual care. Patients will be under continuous monitoring for respiratory depression via capnometer. At 60 minutes, pain will be re-assessed for a second time. If needed, physician will give additional pain meds per their discretion."
3140052|NCT01777854|Active Comparator|Omeprazole|"Yes. Omeprazole (generic) will be used. Children >20 kg will be given 20 mg PO daily for 4 weeks prior to tonsillectomy. This is the normal standard pediatric dosing for reflux.~Omeprazole is authorized to treat reflux in children. The study focuses on laryngopharyngeal reflux that possibly contributes to post tonsillectomy pain."
3140053|NCT01777854|Placebo Comparator|Sugar pill|The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look.
3140054|NCT01760993|Experimental|SPD489|
3140055|NCT01772719|Experimental|Study Arm|Study Arm
3140056|NCT01764997|Experimental|Adalimumab Open Label run-in|Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.
3140057|NCT01764997|Active Comparator|Etanercept + MTX (Randomized)|Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.
3140058|NCT01764997|Experimental|Sarilumab 150 mg + MTX (Randomized)|Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
3140059|NCT01764997|Experimental|Sarilumab 200 mg + MTX (Randomized)|Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.
3140060|NCT01764997|Experimental|Sarilumab 150 mg + MTX Open Label Sub-study|Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.
2404786|NCT03539289|Other|MUFA Diet|Monounsaturated Fatty Acids Diet
3188890|NCT00771771|Active Comparator|Day unit rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation in a day unit, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
3140061|NCT01760941|Experimental|Treatment (radiation therapy)|"This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize standard of care techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment."
3140062|NCT01769443|No Intervention|No Desensitization Therapy|Subject(s) randomized to no desensitization therapy pre-transplant.
2404787|NCT03539289|Other|SFA Diet|Saturated Fatty Acids Diet
3140063|NCT01769443|Experimental|Desensitization Therapy|"Subject(s) randomized to desensitization therapy pre-transplant.~Desensitization therapy regimen pre-transplant: Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib."
3140064|NCT01760889|Experimental|SPD489 Low Dose Range|
3140065|NCT01760889|Experimental|SPD489 High Dose Range|
3140066|NCT01760889|Placebo Comparator|Placebo|
3140067|NCT01749826|Experimental|Chronic Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
3140068|NCT01749826|Experimental|Acute Opioid Exposure|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
3140069|NCT01756586|Active Comparator|Control|Plain bupivacaine
3140070|NCT01756586|Experimental|Experimental|Bupivacaine with Dexamethasone
3140071|NCT01754987|Experimental|Ascorbic Acid + Sorafenib|"Drug: Vitamin C Other Names: Ascorbic Acid, Ascorbate~Dosage:~Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral)"
3140072|NCT01754987|Other|Sorafenib alone|Sorafenib: taken daily (oral)
3140073|NCT01756560|Active Comparator|control|in this group, plain bupivacaine will be used to block femoral and sciatic nerve
2404788|NCT03539276|No Intervention|Pre-intervention|Usual care
3140074|NCT01756560|Experimental|Dexamethasone|Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve
3140075|NCT01756573|Active Comparator|Bupivacaine|Control
3140076|NCT01756573|Experimental|Bupivacaine with Dexamethasone|Dexamethasone will be mixed with bupivacaine
3140077|NCT01756573|Active Comparator|Intravenous Dexamethasone|Dexamethasone will be given intravenously
3150453|NCT00202735|Experimental|Immobilization in external rotation.|Immobilization in external rotation (ER. All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling ER, 15˚ version.To control the position, a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed
3140078|NCT01745913|Experimental|Haplo-Cord SCT|The UCB unit must supply a minimum of 1.0 x107/kg pre-cryopreserved nucleated cell dose. The unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
3150454|NCT00202761|Experimental|PIH|Intensified training of children with CP. Functional training (motor, speech, executive function). Coaching of parents by psychologist, individually and in groups.
3140079|NCT01745913|Active Comparator|UCB SCT|For the standard arm, UCB units will be selected using the Minnesota strategy and the strategy followed in a recent CTN study.17;19Each unit must supply a minimum of 1.5 x107/kg pre-cryopreserved nucleated cell dose. Subjects must have two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient. This may include 0-2 antigen mismatches at each A or B (at the antigen level) or DRB1 (at the allele level) loci. All typing will be done using molecular typing. Though molecular level typing will be available, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1
3140080|NCT01752023|Experimental|Cisplatin + Gemcitabine with SUBATM-itraconazole|SUBATM-itraconazole 200 mg BID, Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then SUBATM-itraconazole 200 mg BID alone.
3140081|NCT01752023|Active Comparator|Cisplatin + Gemcitabine|Arm B = Cisplatin 75 mg/m2 day 1, Gemcitabine 1000 mg/m2 days 1 + 8 for 6 cycles. Then Best supportive care.
3150455|NCT00202787|Experimental|1|FOLFOX-4+cetuximab
3150456|NCT00202787|Active Comparator|2|FOLFOX-4
3150457|NCT00202852|Placebo Comparator|1|
3140082|NCT01740154|Experimental|Supportive care (sunitinib malate, neuromuscular testing)|Patients receive sunitinib malate PO daily for 4 weeks. Patients undergo neuromuscular testing at baseline and on day 28 and complete fatigue assessment at baseline and on days 14 and 28.
3140083|NCT01748890|Experimental|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
3140084|NCT01748162|Experimental|Inhaled steroids|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
3140085|NCT01748162|Active Comparator|Oral control|Patient and clinician observation with short term oral prednisolone as needed. Offered at 1mg/kg (body weight) daily dosing for symptomatic treatment on as needed basis for three days, but may be modified per managing physician's discretion.
3140086|NCT01738698|Experimental|SPD489 40mg|
3140087|NCT01738698|Experimental|SPD489 100mg|
3140088|NCT01738698|Experimental|SPD489 160mg|
3140089|NCT01738698|Placebo Comparator|Placebo|
3140090|NCT01732926|Experimental|Rituximab + Bendamustine + Idelalisib|Participants will receive rituximab + bendamustine + idelalisib.
3150458|NCT00202852|Experimental|2|
3150459|NCT00202865|Experimental|1|
3140091|NCT01732926|Experimental|Rituximab + Bendamustine + Placebo|Participants will receive rituximab + bendamustine + placebo.
3140092|NCT01727167|Placebo Comparator|Control Group|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
3140093|NCT01727167|Experimental|CO group|This group will breath 200 ppm of CO for one hour per day over the course of the three days immediately prior to surgery.
3140094|NCT01732913|Experimental|Rituximab + idelalisib|Participants will receive rituximab + idelalisib.
3140095|NCT01732913|Placebo Comparator|Rituximab + Placebo|Participants will receive rituximab + placebo. Following confirmation of iNHL disease progression by the independent review committee and unblinding, participants may be eligible to receive open-label idelalisib 150 mg twice daily.
3140096|NCT01732211|Experimental|PD 0360324|
3140097|NCT01732211|Placebo Comparator|Placebo|
3140098|NCT01716052|Active Comparator|Ibuprofen|Pfizer 200 mg caplets (Advil)
3140099|NCT01716052|Placebo Comparator|Placebo|Lactulose
3150460|NCT00202865|Placebo Comparator|2|
3150461|NCT00202904|Experimental|Arm 1|
3150462|NCT00202904|Active Comparator|Arm 2|
3150463|NCT00202969|Experimental|1|S-1
3150464|NCT00202969|Active Comparator|2|S-1 plus CDDP
3150465|NCT00202969|Active Comparator|3|5-FU plus CDDP
3150466|NCT00202982|Active Comparator|glatiramer acetate 20 mg|glatiramer acetate 20 mg
3150467|NCT00202982|Active Comparator|glatiramer acetate 40 mg|glatiramer acetate 40 mg
3140100|NCT01718444|Experimental|Group A (No PIES)|"Subjects randomized to this group will receive clomiphene citrate (CC) without using progestin throughout their treatment course.~CC 50 mg oral for 5 days (Days 3-7)~If no ovulation, CC 100 mg for 5 days (Days 12-16)~If no ovulation, CC 150 mg for 5 days (Day 21-25)~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
3150468|NCT00202995|Experimental|1|Glatiramer Acetate 20 mg s.c. daily
3150469|NCT00202995|Active Comparator|2|Betaseron 250 ug every other day or Rebif 44 ug 3 times a week
3150470|NCT00203008||Observational procedure|Patients will be examined and any suspicious skin abnormalities will be biopsied
3150471|NCT00203034|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
3150472|NCT00203034|Experimental|Experimental 2|1.0 mg rasagiline mesylate oral once daily
3150473|NCT00203034|Placebo Comparator|Placebo|Placebo Comparator
3150474|NCT00203060|Experimental|A|Rasagiline treatment
3150475|NCT00203060|Placebo Comparator|B|placebo arm
3150476|NCT00203073|Active Comparator|Copaxone 20 mg|Copaxone 20 mg
3150477|NCT00203073|Active Comparator|Copaxone 20mg with Novantrone induction|Copaxone 20mg with Novantrone induction
3150478|NCT00203099|Active Comparator|Glatiramer Acetate, N-Acetylcysteine|
3150479|NCT00203112|Active Comparator|Glatiramer Acetate injection with oral minocycline|Glatiramer Acetate 20mg with oral minocycline 100mg
3150480|NCT00203112|Experimental|Glatiramer Acetate with placebo|Glatiramer acetate injection 20mg with oral placebo
3150481|NCT00203151|Experimental|1|
3150482|NCT00203151|Placebo Comparator|2|
3150483|NCT00203164|Experimental|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
3150484|NCT00203177|Experimental|Experimental 1|0.5 mg rasagiline mesylate oral once daily
3150485|NCT00203177|Experimental|Expermental 2|1.0 mg rasagiline mesylate oral once daily
3150486|NCT00203372|Experimental|Bevacizumab 7.5 and TAC|one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.
3150487|NCT00203372|Placebo Comparator|Placebo 7.5 and TAC|Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.
3150488|NCT00203372|Experimental|Bevacizumab 15 and TAC|one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.
3150489|NCT00203372|Placebo Comparator|Placebo 15 and TAC|Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.
3150490|NCT00203385|Experimental|Divalproex|Divalproex; oral up to 2000mg/d; open label
3150491|NCT00203450|Experimental|Zonegran|Zonegran
3150492|NCT00203450|Placebo Comparator|Placebo|Placebo pill
3150493|NCT00203567|Active Comparator|Equetro|Equetro
3150494|NCT00203606|Experimental|Active Treatment|Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin
3140101|NCT01718444|Active Comparator|Group B (PIES Group)|"Women randomized to this group will receive progestin to induce endometrial shedding before starting any doses of clomiphene citrate (CC)~Progestin 10 mg oral for 10 days to induce endometrial shedding (PIES)~CC 50 mg oral for 5 days (Day 3-7)~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding (starting on CD28) and CC 100 mg x 5 days, starting on day 3 of induced menses~If no ovulation, progestin 10 mg for 10 days to induce endometrial shedding, and CC 150 mg for 5 days~Exit study if no response to 150 mg CC, or if no pregnancy after 5 ovulatory cycles"
3140102|NCT01712854|Experimental|Symbicort|A combination of budesonide + long acting beta agonist (Symbicort): Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
3140103|NCT01712854|Placebo Comparator|Budesonide only|Budesonide 80 mcg (Entocort EC) only
3140104|NCT01717482|Active Comparator|Metformin|Metformin 850mg twice a day
3140105|NCT01717482|Placebo Comparator|Observation|Standard of Care Observation
3140106|NCT01702896|Experimental|Interleukin-2|Interleukin-2 will be used in this group
3140107|NCT01709136|Experimental|Sirolimus|
3140108|NCT01708057|Experimental|1|Single dose of AZD8683 50 µg
3140109|NCT01708057|Experimental|2|Single dose of AZD8683 150 µg
3140110|NCT01708057|Experimental|3|Single dose of AZD8683 300 µg
3140111|NCT01708057|Experimental|4|Single dose of AZD8683 900 µg
3140112|NCT01708057|Placebo Comparator|5|Single dose of placebo
3140113|NCT01708057|Active Comparator|6|Single dose of tiotropium 18 µg
3140114|NCT01697332|Experimental|Subjects with and without COPD|All subjects will inhale hyperpolarized 129Xe gas and then have a MRI scan performed to measure lung function.
3140115|NCT01693367|Active Comparator|DLS 5.0 (Dynamic Locking Screws)|ORIF with DLS 5.0 (Dynamic Locking Screws)
3140116|NCT01693367|Active Comparator|SLS (Standard locking screw)|ORIF with SLS (Standard locking screw)
3140117|NCT01705106|Experimental|Treatment (capecitabine, celecoxib)|Patients receive celecoxib PO BID for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3140118|NCT01702909|Experimental|Interleukin-2|Interleukin-2
3140119|NCT01701622|Experimental|Allopurinol, febuxostat|Patients currently treated with allopurinol will be switched to febuxostat, and the blood pressure differences between the two arms will be compared.
3140120|NCT01697800|Placebo Comparator|Placebo|Patients received placebo capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
3140121|NCT01697800|Active Comparator|Tadalafil|Patients received 20 mg tadalafil capsules for 2 weeks prior to standard of care treatment and continued for 3 months post standard of care treatment
3140122|NCT01700348|Experimental|Airflosser|Use of Airflosser
3140123|NCT01700348|Active Comparator|Manual Floss|Normal Routine
3140124|NCT01693484|Experimental|ICG administered|The ICG dose (10 mg/4cc per image capture) will be administered in its entirety via push injection through IV access established for standard surgical procedure, followed by 10 cc Normal Saline bolus. This ICG dose will be administered twice, 1X prior to anesthesia, and 1X after the tourniquet on operative extremity has been removed for at least 15 minutes.
3140125|NCT01693653|Active Comparator|Tocilizumab|tocilizumab infusion every 4 weeks over 3 months
3140126|NCT01693653|Placebo Comparator|Placebo|placebo infusion 0.9% sodium chloride every 4 weeks over 3 months
3140127|NCT01692691|Experimental|Dacarbazine, carmustine, neulasta|Dacarbazine IV - Day 1; Carmustine IV - Day 2; Neulasta SC - Day 3
3140128|NCT01691079|Placebo Comparator|placebo|placebo 2 puffs prior to exercise challenge
3140129|NCT01691079|Active Comparator|ipratropium bromide|ipratropium bromide HFA 2 puffs prior to exercise challenge
3140130|NCT01690910|Active Comparator|Front Wheeled Walker|The Front Wheeled Walker is a standard walker that is used to assist patients while walking.
3140131|NCT01690910|Active Comparator|Rifton Gait Trainer|The Rifton Gait Trainer is used to assist patients while walking. It includes a harness to support the patient and prevent falls.
3140132|NCT01689974|Other|Arm A: Ipilimumab|Ipilimumab administered alone Day 4, 25, 46, and 67
3140133|NCT01689974|Other|Arm B: Ipilimumab and Radiation|Radiation Therapy and Ipilimumab. Radiation treatment is administered for 5 fractions (sessions) over 1 week. On Day 4 treatment with Ipilimumab begins and continues on Days 25, 46, and 67.
3140134|NCT01676961|Experimental|Supportive care (romiplostim)|Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count > 50 x 10^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen..
3140135|NCT01681589|Sham Comparator|Control Group|The control group will receive sham-tDCS and computerized cognitive training also twice a week for 20 minutes for 6 weeks (12 training sessions).
3140136|NCT01681589|Experimental|Transcranial Direct Current Stimulator (TDCS)|The experimental group will receive active tDCS for 20 minutes and computerized cognitive training twice a week for 30 minutes for 6 weeks.
3140137|NCT01681589|Other|Healthy Control Group|Fifteen (15) healthy control subjects will participate.
3140138|NCT01681745|Experimental|Cryo-Touch Treatment|Initial treatment with Cryo-Touch III and three optional re-treatments (up to 4 treatments) performed 68 days to 1 day prior to abdominoplasty.
3140139|NCT01682928|Active Comparator|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
3140140|NCT01682928|Active Comparator|Hydrotherapy Group|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
3140141|NCT01668940|Experimental|Lillipops Iced Soothies (4 flavours)|"Initially, women will be given 1 multiflavour box of Lillipop samples minus the ginger flavour (4 flavours). Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3140142|NCT01668940|Experimental|Lillipop Iced Soothies (Ginger flavour)|Initially, women will be given 1 Ginger flavor box of Lillipop samples. Each box contains 24 freezies (20 mL each). Each 20ml contains 80mg of dried ginger root. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 a day and to not have any other popsicles, freezies or other ginger products throughout the duration of the study (7 days). Due ginger's antiemetic property, a maximum daily dose is up to 1000mg/day of dried ginger root powder in pregnancy.They can request an additional box of freezies at each follow-up, as needed.All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol.
3140143|NCT01668940|Active Comparator|Mr. Freeze Freezies (4 flavours)|"Initially, women will be given 1 multiflavour box of Mr. Freeze samples. Each box contains 24 freezies (20 mL each), 6 of each flavor. They will be told to eat the freezies as needed to alleviate symptoms, up to a maximum of 12 per day, and to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days). They can request an additional multiflavour box of freezies at each follow-up, as needed.~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3150495|NCT00203606|No Intervention|Observation|Observation with no active treatment for Hepatitis C. Observation period is based on standard treatment duration based on genotype of Hepatitis C. Active treatment offered to participants at conclusion of observation. (Protocol Amendment #1, October 30, 2001. Ethics approval Jan 19, 2004).
3188891|NCT00771771|Active Comparator|Home rehabilitation|Discharge from the hospital to the patients' homes as soon as possible, supported by an out-patient ambulatory coordinating multidisciplinary team. The patients will be offered rehabilitation treatment in their homes, and multidisciplinary policlinical follow-ups will be performed 3 and 6 months after inclusion.
3188892|NCT00771771|No Intervention|Treatment as usual|Patients will receive rehabilitation treatment after today's principles and routines.
3188893|NCT00771784||1|Short term endotracheal intubation.
3140144|NCT01668940|No Intervention|Natural Course Group|"Women will not receive any freezies and will be asked to not have any other popsicles, freezies or any ginger products throughout the duration of the study (7 days).~All participants will initially receive counselling and advice by the Motherisk NVP Counsellor about symptom management. This includes advice about dietary, non-medicinal and medical treatments as per the Motherisk NVP protocol"
3140145|NCT01663285|Experimental|Neoadjuvant Gemcitabine and Cisplatin|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
3140146|NCT01683864|Experimental|positive cytology with HIPEC|gastric cancer cytology positive with HIPEC Mytomycin and cisplatin intraoperative
3140147|NCT01683864|No Intervention|positive cytology without HIPEC|gastric cancer cytology positive without HIPEC
3140148|NCT01683864|No Intervention|negative cytology without HIPEC|gastric cancer with negative cytology
3140149|NCT01675011|Experimental|Embozene® Microspheres|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
3140150|NCT01675011|Active Comparator|Embosphere®|Uterine Fibroid Embolization (UFE)will be used to treat the fibroids. The procedure involves injecting embolizing particles into the uterine artery which causes the fibroid to shrink.
3140151|NCT01673425|Experimental|Live Attenuated Influenza Vaccine|Single intervention study- all participants will receive LAIV instead of injectable flu vaccine.
3140152|NCT01673061|Active Comparator|Lidocaine|Lidocaine injection will be used for anesthesia prior to incision and drainage. 2% Lidocaine with epinephrine will be injected into the abscess site. Amount injected will be per physician discretion.
3140153|NCT01673061|Active Comparator|Vapocoolant|Vapocoolant spray will be used for anesthesia prior to incision and drainage. The spray will be administered to the abscess site for a duration of 2 seconds, from a distance of 12 cm.
3140154|NCT01675960|Experimental|Gabapentin, then placebo|Participants first receive gabapentin 3 times per day, with varying dosing based on the protocol. After 34-38 days, a washout period of 3 days occurs, before then receiving the placebo dose for 32 days.
3150496|NCT00203619|Experimental|1|Wireless capsule endoscopy
3140155|NCT01675960|Experimental|Placebo, then Gabapentin|Participants first receive placebo 3 times per day. After 34-38 days, a washout period of 3 days occurs, before then receiving Gabapentin, with varying dosing based on the protocol, for 32 days.
3140156|NCT01668147|Experimental|Control|Session 1: Control (no pretreatment) - IV 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
3140157|NCT01668147|Active Comparator|Oral ritonavir|Session 2: Pretreatment with oral ritonavir for 3 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
3140158|NCT01668147|Active Comparator|Oral efavirenz|Session 3: Pretreatment with oral efavirenz for 14 days followed by IV 10-14 mCi of [11C]dLop with PET/CT imaging
3140159|NCT01676701|Experimental|Tabalumab Auto-Injector|Tabalumab 180 milligram (mg) loading dose administered using auto-injectors at Week 0 as 2 subcutaneous (SC) injections (90 mg each), followed by a 90 mg SC injection every 2 weeks (Q2W) up to Week 12.
3150497|NCT00203619|Active Comparator|2|Standard care
3140160|NCT01676701|Experimental|Tabalumab Prefilled Syringe|Tabalumab 180 mg loading dose administered using prefilled syringes at Week 0 as 2 SC injections (90 mg each), followed by a 90 mg SC injection Q2W up to Week 12.
3140161|NCT01669148|Active Comparator|Conventional + Tomosynthesis|conventional (2D) imaging plus tomosynthesis (3D) imaging first then tomosynthesis alone 1 month later.
3140162|NCT01669148|Active Comparator|Tomosynthesis alone|tomosynthesis (3D) imaging alone first then conventional (2D) imaging plus tomosyntheis 1 month later.
3150498|NCT00203645|Experimental|Brief self-directed treatment|self-help workbook plus motivational telephone intervention
3150499|NCT00203645|Experimental|Self-directed plus telephone support|Self-help workbook, motivational telephone intervention plus telephone booster calls
3150500|NCT00203645|Active Comparator|Workbook only|Workbook only
3150501|NCT00203645|No Intervention|Waitlist|Six week waitlist
3150502|NCT00203749|Experimental|1|Intervention communities will receive the community-based VCT intervention community mobilization, mobile VCT, and post-test support services), as well as standard clinic-based VCT
3150503|NCT00203749|Active Comparator|2|Comparison communities will receive standard clinic-based VCT
3150504|NCT00203788|Experimental|1|Individual Placement and Support Plus Workplace Fundamentals Module
3150505|NCT00203788|Active Comparator|2|Brokered Vocational Rehabilitation
3150506|NCT00203879|Experimental|1|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
3140163|NCT01662102|Experimental|Zevalin Regimen Consolidation (Group A)|"90Y-Ibritumomab tiuxetan administered 8 to 12 weeks after the last chemotherapy infusion. Each participant randomized to this treatment group was to receive a therapeutic dose of 14.8 MBq/kg (0.4 mCi/kg of total body weight) of 90Y ibritumomab tiuxetan (maximum 1,184 MBq or 32 mCi). Participants with a pre-treatment platelet count between 100 and 149 x10^9/L were to receive 0.3 mCi/Kg 90Y-ibritumomab tiuxetan. (Body weight ≤80 kg: 14.8 MBq [0.4 mCi] yttrium-90/kg and Body weight >80 kg: 1,184 MBq [32 mCi] maximum dose).~The 90Y ibritumomab tiuxetan regimen is as follows: Day 1 rituximab (250 mg/m^2); Day 7,8, or 9 rituximab (250 mg/m^2) followed by 90Y ibritumomab tiuxetan within 4 hours of the end of the rituximab infusion. (Maximum duration of study was up to approximately 2.7 months)."
3188894|NCT00771784||2|Long term endotracheal intubation.
3188895|NCT00771797|Experimental|1|Treatement with low dose flavanoids over 60 days
3188896|NCT00771797|Experimental|2|Treatment with high dose flavanoids over 60 days
3188897|NCT00771823|Active Comparator|2|
3188898|NCT00771823|Active Comparator|1|"Maraviroc 300 mg twice daily for the first 14 days of the study.~Placebo twice daily for the last 14 days of the study"
3188899|NCT00771862|Placebo Comparator|1. standard care|1 day of perineural ropivacaine 0.2% infusion followed by 4-5 days of normal saline infusion.
3188900|NCT00771862|Active Comparator|2: experimental care|4-5 days of perineural ropivacaine 0.4% infusion.
3188901|NCT00771888|Other|1|lanreotide
3140164|NCT01662102|Active Comparator|Rituximab Maintenance (Group B)|Participants were to receive 375 mg/m^2 of rituximab, administered by intravenous (I.V.) infusion every 8 weeks, starting 8 to 12 weeks after the last R-chemotherapy cycle. (Maximum duration of study was up to approximately 2.7 months).
3188902|NCT00771940|Active Comparator|Ghrelin|
3140165|NCT01659554|Experimental|Out-Patient Intraperitoneal Chemotherapy|Intraoperative (hyperthermic) cisplatin followed by 4 courses of intraperitoneal cisplatin and doxorubicin given on days 1 & 8 during a 3 week cycle.
3140166|NCT01658813|Experimental|5-Fluorouracil and Interferon|"5-Fluorouracil~Interferon-alfa-2b"
3140167|NCT01648296|Experimental|Dosimetry Group|A total of 12 subjects will receive a single intravenous injection of[18F]FluorbetaOx followed by PET-CT imaging. Four normal healthy volunteer subjects and 8 subjects with or without Type 2 Diabetes Mellitus with Chronic Dilated Cardiomyopathy.
2405489|NCT03534648|Experimental|Effect of PF-06865571 on PF-05221304 PK|
3140168|NCT01648296|Experimental|Kinetic Dynamic Group|A total of 38 subjects will receive a single intravenous injection of [18F]FluorbetaOx, [11C]Palmitate, and [15O]Water followed by PET-CT imaging. Ten normal healthy volunteer subjects and 28 subjects with or without Type 2 Diabetes Mellitus of which 18 subjects will have Chronic Dilated Cardiomyopathy and 10 obese subjects with a Body Mass Index of ≥ 30kg/m2.
3140169|NCT01649505|Experimental|Arm I (fibrin sealant)|Patients undergo sharp dissection technique with fibrin sealant closure.
3140170|NCT01649505|Active Comparator|Arm II (standard electrocoagulation)|Patients undergo standard electrocoagulation dissection technique.
3150507|NCT00203879|Experimental|2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 without IL-2
3150508|NCT00203905|Active Comparator|A|Hydroxyurea at 500 mg PO q 12 hours x 6 days (11 total doses); Infusion of 5-FU (600 mg/m2/day x 5 days [120 hours]
3150509|NCT00203905|Experimental|B|Bevacizumab: 10 mg/kg will be given as a 90-minute infusion
3150510|NCT00203918||Prostate biopsies|Males undergoing prostate biopsies
3188903|NCT00771966|Placebo Comparator|Standard treatment|
3150511|NCT00203944||international adopted infants|international adoptees making their first visit to international adoption clinic
3150512|NCT00203944||Control infants|
3150513|NCT00203957|Experimental|Group A|Patients who completed double-blind treatment studies 6002-US-013, 6002-US-013, 6002-US-018 immediately prior to entering this open-label trial and may have had an interuption of study drug of 14 days or less.
3150514|NCT00203957|Experimental|Group B|Patients who previously completed double-blind treatment studies 6002-US-013, 6002-US-018 or 6002-EU-007 or discontinued from open label study 6002-US-007 and have had an interuption of study drug greater than 14 days.
3150515|NCT00204022|Experimental|1|Mycophenolate mofetil (target dose 2g/day)
3150516|NCT00204022|Active Comparator|2|Azathioprine (target dose 2mg/kg/day)
3150517|NCT00204061|Placebo Comparator|supportive management|needs-focused, unspecific supportive management
3150518|NCT00204061|Experimental|amisulpride|24 months amisulpride 50 to 800 mg, needs-focused, unspecific supportive management.
3150519|NCT00204243|Experimental|Naltrexone implant|Naltrexone implant (GoMedical Inc. 6 months implant)
3140171|NCT01642732|Experimental|Everolimus with combined hormonal and radiation therapy|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 10 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
3140172|NCT01645709|Experimental|Verapamil|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
3140173|NCT01645709|Placebo Comparator|Placebo|Subjects will be randomized to receive a single injection of IA Verapamil or IA Placebo at a ratio of 1:1.
3140174|NCT01648270|Experimental|Study Arm|"Subjects will be studied on four occasions. Sessions and drugs are:~Intravenous buprenorphine~Sublingual buprenorphine~Cyclosporine plus intravenous buprenorphine~Cyclosporine plus sublingual buprenorphine"
3140175|NCT01643525|Other|Nautilus NeuroWave Recording Arm|Nautilus NeuroWaveTM System
3140176|NCT01641601|No Intervention|Usual Management|Patients in the usual management arm will have no pre-hospital cervical ripening and will undergo labor induction according to standard labor induction protocols on an inpatient basis.
3188904|NCT00771966|Active Comparator|SV maximization|
3188905|NCT00771979|Experimental|1|
3150520|NCT00204243|Active Comparator|Methadone|Methadone Maintenance Treatment
3150521|NCT00204308|Experimental|combination tenofovir-emtricitabine|
3150522|NCT00204308|No Intervention|control arm|
3150523|NCT00204412|Experimental|1|flax lignan
3150524|NCT00204412|Placebo Comparator|2|placebo
3150525|NCT00204425|Experimental|1|exercise/soy isoflavone
3150526|NCT00204425|Experimental|2|exercise/isoflavone placebo
3150527|NCT00204425|Experimental|3|exercise placebo/soy isoflavone
3150528|NCT00204425|Placebo Comparator|4|exercise placebo/isoflavone placebo
3150529|NCT00204516|Experimental|mRNA Vacc|
3150530|NCT00204529|Experimental|PegIFN|pegylated interferon-alpha-2a
3150531|NCT00204529|Active Comparator|IFN|interferon-alpha-2a
3150532|NCT00204542|Active Comparator|A|Solaraze(R) 2x/day for 3 months
3150533|NCT00204542|Active Comparator|B|Solaraze(R) 2x/day for 6 months
3150534|NCT00204568|Active Comparator|1|Adriamycin mono
3150535|NCT00204568|Experimental|2|Trofosfamide
3150536|NCT00204594|Experimental|Antibody|
3150537|NCT00204698|Active Comparator|1|All subjects will be given active drug.
3188906|NCT00772044|Active Comparator|Provent|Those receiving the active device
3188907|NCT00772044|Sham Comparator|Sham|Those receiving sham device
3188908|NCT00772057|Active Comparator|Propranolol group|
3188909|NCT00772057|Placebo Comparator|Placebo group|
3140177|NCT01641601|Experimental|Outpatient transcervical Foley balloon|Patients in the experimental group will have a 30 cc transcervical Foley balloon placed in the outpatient setting approximately 12-18 hours prior to their labor induction. Once admitted, they will undergo inpatient labor induction as per usual protocols.
3140178|NCT01633814|Experimental|Transdermal estradiol|Transdermal estradiol, delivery rate 100 µg day-1
3140179|NCT01633814|Placebo Comparator|Placebo|placebo patch.
2406477|NCT03527875|Experimental|EBS group|Endoscopic Biliary Stenting
3140180|NCT01636466|Experimental|Everolimus conversion|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to take everolimus 0.75 mg twice daily after discontinuing current calcineurin inhibitor. Subjects will be weaned off of all other immunosuppression medicines when dialysis starts.
3140181|NCT01636466|No Intervention|Control|Subjects who have previously undergone a kidney transplant and are in late stage renal allograft failure will be randomized to continue on current immunosuppressive regimen. Subjects will be weaned off of all immunosuppression medicines when dialysis starts.
3182596|NCT00704821|Experimental|Stage 3|In Stage 3, PTC299 will be given BID or TID (for total of 42 [for BID] or 63 [for TID] doses) orally about same time per day starting on Day 1 in each 3-week (21-day) cycle. Starting dose will be 1 dose level below maximum tolerated dose (MTD) from Stage 2 or 80 mg/dose BID if 100 mg/dose TID in Stage 2 exceeds MTD. Dose escalation will be based on safety evaluations by Sponsor's medical monitor in Cycle 1. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant. Participants will also receive docetaxel as a 1-hour IV infusion on Day 1 per cycle at starting dose of 75 mg/m^2 with body surface area calculation based on body weight. Dose will be sequentially reduced to 60 and 50 mg/m^2 in participants with a docetaxel-related dose-limiting toxicity (DLT). Participants will be medicated with oral corticosteroids with docetaxel administration. Recommended dose is 8 mg BID dexamethasone for 3 days starting 1 day prior to docetaxel administration.
3182597|NCT00704821|Experimental|Stage 4|In Stage 4, PTC299 will be given orally each day continuously starting on first day of each cycle at about same time per day; so, 42 doses of PTC299 will be delivered for 3 weeks (21-day) in Cycle 1 (BID dosing), and 84 doses will be delivered for 3-weeks (21-day) in Cycle 2 and beyond (TID dosing). For Cycle 1, participants will be assigned to 600, 800, or 1000 mg/dose BID sequentially based on safety evaluations by Sponsor's medical monitor at enrollment. For Cycle 2 and beyond, participants will receive PTC299 160 mg/dose TID. During Cycle 1, Cohort 1 participants will eat a meal containing of ≤15 grams (g) of dietary fat and Cohort 2 participants will eat a meal containing of ≤25 g of dietary fat prior to each dose of PTC299. If ≤2 of 6 participants had experienced DLT during Cycle 1 in either diet plan, then the dose will be escalated to 800 mg BID in Cohort 3 at the optimal diet. Treatment cycles can continue if therapy appears to be safely offering tumor control to participant.
3182598|NCT00704834||1|Normal Controls
3182599|NCT00704834||2|Patients with a clinically isolated syndrome (CIS)
3182600|NCT00704834||3|Patients with relapsing, remitting Multiple Sclerosis (RRMS) who are not on treatment
3182601|NCT00704834||4|Patients with Chronic Progressive Multiple Sclerosis who are not on treatment
3182602|NCT00704860|Experimental|TR|TR- Subjects defined as having treatment resistant depression, who have failed at least 2 adequate trials of an antidepressant. Subjects will be treated in an open label trial for their depression, with the goal of sustained remission.
3182603|NCT00704886|No Intervention|1|verbal
3182604|NCT00704886|Experimental|2|video
3182605|NCT00704899|Experimental|2|anti-depressants
3182606|NCT00704899|Experimental|1|physiotherapy
3182607|NCT00704951||Patients|Immunosuppressed/Immunocompromised patients at high risk for invasive fungal infections
3182608|NCT00704977|Active Comparator|1|Pterygium surgery using alcohol 20% + wound closure by bare sclera technique
3188910|NCT00772083|Experimental|1|
3188911|NCT00772083|Active Comparator|2|standard approach currently being used
3140182|NCT01629329|Active Comparator|Aspirin, Acetaminophen, Caffeine pills|Patients receiving AAC(acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet)will receive 2 pills with active compound and placebo syringe with 2 ml of saline.
3140183|NCT01629329|Active Comparator|Prochlorperazine 10mg|Patients will receive active compound of Prochlorperazine 10mg via IV syringe and 2 unmarked placebo pills
3140184|NCT01627899|Other|VerioIQ|Subjects replaced own Blood Glucose Monitoring system with VerioIQ.
3140185|NCT01632020|Placebo Comparator|Placebo|Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
3140186|NCT01632020|Active Comparator|Metformin|Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
3140187|NCT01602471|Experimental|[F-18]RDG-K5|[F-18]RDG-K5 was administred and PET scan performed
3140188|NCT01619800|Experimental|Blended Sensor Optimization (BSO)|Patients in this arm will undergo pacemaker placement and will have blended sensor optimization. Minute Ventilation will be optimized/activated
3140189|NCT01619800|Sham Comparator|Accelerometer Alone (AA)|Patients in this arm will undergo pacemaker implantation but will not have Minute Ventilation Sensor activated. Only accelerometer will remain active
3140190|NCT01608906|Experimental|continuous low dose intravenous heparin infusion|titrated to a PTT of 40-45
3140191|NCT01608906|Active Comparator|subcutanous heparin 5000 units 3 times/day|standard of care
3140192|NCT01621737|Experimental|Oxytocin: Low Dose|42 IU BID for the six weeks
3140193|NCT01621737|Experimental|Oxytocin: High Dose|84 IU BID for six weeks
3140194|NCT01621737|Placebo Comparator|Placebo|
3188912|NCT00772096|Experimental|Verum|
3188913|NCT00772096|No Intervention|No treatment|
3140195|NCT01614067|Experimental|Delayed Start|Study subjects will receive 7 days of pre-treatment with a GnRH antagonist (Delayed Start) before standard ovarian stimulation with FSH/LH.
3140196|NCT01614067|Active Comparator|Conventional Start|Ovarian stimulation with standard antagonist protocols (no delay).
3140197|NCT01607320|Experimental|Raloxifene|3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
3140198|NCT01607320|Active Comparator|Clomiphene|3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7
3140199|NCT01605019|Experimental|CoSeal Arm|patient randomized to received Coseal during LVAD implantation
3140200|NCT01605019|Placebo Comparator|BioGlue® Surgical Adhesive|BioGlue® Surgical Adhesive or use of no sealant application
3140201|NCT01609231|Experimental|Arm A: Dalotuzumab + Irinotecan|Participants receive irinotecan intravenously (IV), 180 mg/m^2 once every two weeks + dalotuzumab IV, 10 mg/kg once weekly, during ≥1 42-day treatment cycle(s).
3182609|NCT00704977|Active Comparator|2|"Alcohol 20% for pterygium separation + wound closure by sliding flap technique.~The main steps of surgery are described below.Wound closure technique is as follows.~Disection of conjunctiva adjascent to the wound, bringing the dissected conjunctiva to the wound area and suturing by vicril 6/0 sutures"
3182610|NCT00704977|Active Comparator|3|"Alcohol 20 % for pterygium separation + using amniotic membrane and biological glue for wound closure.~The steps of surgery are as described below, wound closure technique is as follows.~Amniotic membrane is applied with its mesenchimal side to conjunctiva and glued by biological glue (main ingradients: calcium and thrombin)"
3182611|NCT00704990|Experimental|A|All study participants take part in the experimental arm
3182612|NCT00705042|Experimental|A|25 mg
3140202|NCT01609231|Active Comparator|Arm B: Cetuximab + Irinotecan|Participants receive cetuximab IV, initial dose of 400 mg/m^2 and then 250 mg/m^2 IV weekly + irinotecan IV, 180 mg/m^2 once every two weeks, during ≥1 42-day treatment cycle(s).
3140203|NCT01602198|Active Comparator|Exelon transdermal patch|Exelon [rivastigmine] transdermal patch
3140204|NCT01602198|Placebo Comparator|Placebo transdermal patch|Placebo transdermal patch
3140205|NCT01606150|Active Comparator|Subcutaneous Lidocaine|0.1 ml/kg of 1% Lidocaine
3140206|NCT01606150|Active Comparator|Topical Lidocaine|LMX-4, 1 gram placed over lumbar puncture needle insertion site 30 minutes prior to the procedure
3140207|NCT01603043|Experimental|AL-78898A|1 intravitreal injection per month for up to 12 months
3140208|NCT01603043|Sham Comparator|Sham Injection|1 mock injection per month for 12 months
3140209|NCT01605370|Experimental|Nebivolol|Subjects randomized to this arm will receive Nebivolol 2.5 mg once daily.
3140210|NCT01605370|Other|Metoprolol succinate|Subjects randomized to this arm will receive metoprolol succinate 50 mg once daily.
3182613|NCT00705042|Experimental|B|50 mg
3182614|NCT00705055||1|Normal Males
3182615|NCT00705055||2|Normal Females
3182616|NCT00705055||3|Abnormal Males
3182617|NCT00705055||4|Abnormal Females
3140211|NCT01605617|Active Comparator|PTNS + fesoterodine fumarate first, then PTNS + placebo|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + 4mg of fesoterodine fumarate first for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + placebo.
3140212|NCT01605617|Placebo Comparator|PTNS + placebo first, then PTNS + fesoterodine fumarate|Participants were to be given Percutaneous Tibial Nerve Stimulation (PTNS) + placebo for 12 weeks followed by 4 weeks of washout followed by 12 weeks of PTNS + 4mg of fesoterodine fumarate
3140213|NCT01606709|Experimental|GnRH agonist trigger|Induction of oocyte maturation with GnRH agonist
3140214|NCT01606709|Active Comparator|hCG trigger|Induction of oocyte maturation with hCG
3140215|NCT01603121|Experimental|Lisofylline subcutaneous|Lisofylline 12mg/kg as a continuous subcutaneous infusion over a 10 hours period
3140216|NCT01603121|Experimental|Lisofylline intravenous|Lisofylline 9 mg/kg as a continuous intravenous infusion over a 10 hours period
3182618|NCT00705094||1|Testicular cancer patients who have received surgery and are scheduled for surveillance
3140217|NCT01602016|No Intervention|Phase I|Baseline Visit Phase 1: The screening portion of the CELF will be administered to the child to screen for language impairment. If a child is determined to be pre-verbal they will automatically qualify,If there is no language impairment, the subject will not be eligible. If language impairment is confirmed, the participant will immediately go on to the baseline visit of Phase 2.
3182619|NCT00705094||2|Testicular cancer patients who have received surgery and are scheduled for chemotherapy
3182620|NCT00705120|Other|1|
3182621|NCT00705120|Other|2|
3182622|NCT00705172||A|
3182623|NCT00705185||1|Adults with Major Depressive Disorder- as defined by the criteria in the DSM-IV
3182624|NCT00705185||2|Healthy Controls- research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)
3182625|NCT00705198||Newly diagnosed patients|Patients treated with temozolomide for newly diagnosed malignant glioma
3182626|NCT00705198||Relapsed patients|Patients treated with temozolomide for relapsed malignant glioma
3140218|NCT01602016|Other|Phase II: 12 week Folinic Acid or Placebo intervention|The child will be consented for Phase 2 (the RCT) and undergo a blood draw (up to 20mL) for metabolic and autoantibody testing. the child will undergo language and behavioral assessment while the parent will be interviewed for the Vineland and other questionnaires (ASQ, RBS-R, SRS, and ABC). Demographic information including; age, race, gender, and ethnicity will be collected. The research pharmacist will randomize the participant to either Intervention A or B (only the research pharmacist will know which intervention has the folinic acid). The research pharmacist will distribute the drug or placebo to the parent and instruct the parent of the proper administration of the intervention. This will be considered the 12 week randomly controlled clinical trial that is investigating the safety and efficacy of folinic acis interventions in ASD and will last for approximately 12 weeks. At the end of 12 weeks, the same assessments that were conducted at baseline will be readministered
3182627|NCT00705198||Newly diagnosed anaplastic astrocytoma patients|Patients treated with temozolomide for newly diagnosed anaplastic astrocytoma
3182628|NCT00705211||Zetia monotherapy|Patients to be treated with Zetia alone (10-mg tablets,) for hypercholesterolemia
3182629|NCT00705211||Zetia combination therapy|Patients to be treated with Zetia (10-mg tablets,) in combination with other lipid-lowering drugs for hypercholesterolemia
3182630|NCT00705276|Experimental|I|
3182631|NCT00705302|Experimental|patient education including self-help|Patients in the arm will participate in a three months patient education and exercise program including a self-help group in 3 months of time.
3182632|NCT00705302|Active Comparator|patient education|Patients in arm 2 will participate in the same patient education and exercise program as arm 1, but without an additional self-help group.
3182633|NCT00705315|Experimental|1|Bevacizumab->Epirubicin->Docetaxel
3182634|NCT00705328|Experimental|1|
3182635|NCT00705328|Experimental|2|
3182636|NCT00705328|Experimental|3|
3182637|NCT00705354|Active Comparator|1|Control group undergoing standard ESS will have a saline soaked Nasopore sponge placed during surgery and will receive routine oral antibiotics post-operatively
3182638|NCT00705354|Experimental|2|Treatment group undergoing ESS will have Nasopore sponge soaked with Bacitracin, but will not receive oral antibiotics post-operatively
3182639|NCT00705380|Experimental|1|Participants will receive cognitive behavioral therapy with panic control treatment.
3140219|NCT01602016|Experimental|Phase III: Open Label Extension of Folinic Acid|If consent for Phase 3 is signed by parents with children who qualify for Phase 3, the research pharmacist will provide a 12 week supply of folinic acid to the parent. This arm will be offered to all clients that completed phase 2 of the trial. After consenting and 12 weeks of folinic acid dosing, the client will come back and complete the same protocol and be tested on the same measures used in phase II of the study. This will be a rolling stopping point so that new therapies can be started, if the parent/caregiver is so inclined
3140220|NCT01603394|Experimental|Pregabalin (300-600 mg/day; 150 mg/day starting dose)|
3182640|NCT00705380|Active Comparator|2|Participants will receive cognitive behavioral therapy with panic control treatment after a 12-week waitlist period.
3182641|NCT00705419||Previous vicriviroc 30 mg QD|Subjects who previously received vicriviroc 30 mg daily in a Phase 2 or 3 clinical trial.
3182642|NCT00705419||Previous vicriviroc 20 mg QD|Subjects who previously received vicriviroc 20 mg daily in a Phase 2 or 3 clinical trial.
3182643|NCT00705419||Control Group|Subjects who previously received active control or placebo in a Phase 2 or 3 clinical trial involving vicriviroc.
3140221|NCT01592383|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3140222|NCT01598025|Experimental|REGIMEN 1|"REGIMEN 1: Patients undergo hyperfractionated TBI TID for a total of 11-12 doses on days -10 to -7 and receive thiotepa IV over 4 hours QD on days -6 and -5, fludarabine phosphate IV over 30 minutes QD on days -6 to -2, and anti-thymocyte globulin IV on days -4 to -2.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
3182644|NCT00705445|Active Comparator|A|This group will not receive any of the intervention supplements. The group will only receive nutritional counselling and education, and treatment provided for any encountered illness according to IMCI guidelines.
3140223|NCT01598025|Experimental|Regimen 2|"To be given to patients non-malignant, life-threatening diseases and patients with hematologic malignancies, with extensive prior therapy and comorbidities who are unable to receive TBI, consists of Melphalan 70mg/m2 IV x 2 days, thiotepa 5mg/kg IV x 2 days (or 10mg/kg x 1 day), and fludarabine 25 mg/m2 IV x 5 days.~TRANSPLANTATION: Patients undergo CD34-selected allogeneic PBSCT on day 0."
3140224|NCT01587963|Active Comparator|Ascorbic Acid|Ascorbic Acid
3140225|NCT01587963|Placebo Comparator|Ringers Lactate or Normal Saline|Ringers Lactate or Normal Saline
3140226|NCT01591096|Experimental|Tissue plasminogen activator|All patients will receive study drug.
3140227|NCT01591954|Experimental|Video Augmentation|Qualitative assessment of the value of video-based navigation system
3140228|NCT01589926|Experimental|Bi-level Positive Airway Pressure Device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
3140229|NCT01589926|Sham Comparator|Sham CPAP|Physiologic continuous positive airway pressure (CPAP) initiated for at least 16 hours per day for a minimum of 48hrs.
3150538|NCT00204711||Outpatient Surgery with Sedation|SNAP II EEG data will be recorded continuously during the sedation and intermittently compared to routinely monitored parameters of sedation adequacy including vital signs, patient movement, grimacing, verbal complaints, and patient responsiveness to verbal and tactile stimuli. Following surgery, patients will be questioned to determine recall or memory of discomfort.
3150539|NCT00204737|Active Comparator|Prednisone|Prednisone 20mg daily x 2 weeks
3150540|NCT00204737|Placebo Comparator|placebo|placebo
3150541|NCT00204750|Active Comparator|1|Bougie dilation
3150542|NCT00204750|Experimental|2|Needle-knife incision
3150543|NCT00204763|Active Comparator|2|Solid state catheter
3150544|NCT00204763|Experimental|A|
3150545|NCT00204828||1.|Children with asthma
3150546|NCT00204828||2.|Children without asthma
3150547|NCT00204867||A|In vivo surveillance of 6-9 mm polyps detected at CTC
3150548|NCT00204893|Experimental|Open label|Each participant will be treated with three 3900 mg doses of calcium formate on each study day (i.e., days 1-14).
3150549|NCT00204919|Placebo Comparator|1|
3150550|NCT00204919|Active Comparator|2|
3150551|NCT00204971|Experimental|1|Nutritional supplement
3150552|NCT00204971|Placebo Comparator|2|placebo
3150553|NCT00204997|Experimental|1|Laparoscopic Ovarian Transposition
3150554|NCT00205023|Experimental|A|
3150555|NCT00205075||Case|
3150556|NCT00205075||Control|
3150557|NCT00205101||1|Triad allograft
3150558|NCT00205101||2|other anterior lumbar interbody fusion (ALIF)
3150559|NCT00205101||3|transforaminal lumbar interbody fusion (TLIF)
3150560|NCT00205101||4|posterior lumbar interbody fusion (PLIF)
3150561|NCT00205153|Experimental|TEAM Care|Intervention pharmacies implement 6-month TEAM program.
3150562|NCT00205153|No Intervention|Usual Care|"Control pharmacies provide usual care only."
3150563|NCT00205166|Active Comparator|1|Caffeine 400 mg PO 1 hour before adenosine infusion
3140230|NCT01576575|Experimental|Healthy males and non-pregnant females|"Subjects will be studied during a maximum of seven occasions.~Study drugs are intravenous buprenorphine (0.025-0.2 mg infused over 1 hr) and sublingual buprenorphine (2-4 mg), with 1-3 week washout between sessions.~Sessions 1&2: Control (no pretreatment) - intravenous and sublingual buprenorphine. Some subjects will only undergo session 1 (IV)~Sessions 3&4: Liver and gut CYP3A induction (rifampin 600 mg daily), intravenous and sublingual buprenorphine~Session 5: Gut only CYP3A inhibition (grapefruit juice the night before), sublingual buprenorphine~Sessions 6&7: Liver and gut CYP3A inhibition (ketoconazole 400 mg daily), intravenous and sublingual buprenorphine"
3140231|NCT01590394|Experimental|Pancreatic Cancer Patients|A large plastic biliary stent was placed in the bile duct.
3140232|NCT01577628|Other|Group 1: Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
3140233|NCT01577628|No Intervention|Group 2: No intervention control group|Subjects may use a moisturizer if they wish to but no instruction or product is provided
3140234|NCT01582100|Experimental|GERD subjects with nausea|subjects with GERD and nausea will receive treatment with Reletex
3140235|NCT01583647|Experimental|MK-0524A 1 g/20 mg (Panel A)|Single oral dose of 1 tablet of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
3140236|NCT01583647|Experimental|MK-0524A 2 g/40 mg (Panel B)|Single oral dose of 2 tablets of MK-0524A. Each tablet contained Extended Release (ER) Niacin 1g and laropiprant 20 mg
3140237|NCT01575028|Active Comparator|Local anesthetic infiltration injection|Patients will receive local anesthetic infiltration injected at the surgical site by the surgeon at the end of surgery.
3140238|NCT01575028|Experimental|Transversus abdominis plane (TAP) block|Patients will receive a transversus abdominis plane (TAP) block.
3140239|NCT01578785|Experimental|Glatiramer Acetate|Glatiramer acetate (GA) 20 mg/0.5 ml solution in prefilled syringe for subcutaneous injection once daily.
3140240|NCT01578785|Placebo Comparator|Placebo|Placebo solution in prefilled syringe for subcutaneous injection once daily.
3140241|NCT01576549|Experimental|LY2127399|LY2127399 given subcutaneously (SC) at 240 milligrams (mg) as a loading dose in the first week followed by 120 mg SC every 4 weeks for up to 52 weeks.
3140242|NCT01570634|Experimental|Open Label CASAD|Treatment with CASAD for 14 days
3140243|NCT01566370|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
3140244|NCT01566370|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
3140245|NCT01561989|Experimental|Arm I (400 IU cholecalciferol and vaccine therapy)|Patients receive low-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
3140246|NCT01561989|Experimental|Arm II (4,000 IU cholecalciferol and vaccine therapy)|Patients receive high-dose cholecalciferol PO QD for 12 weeks, followed by the seasonal (2012-2013) trivalent influenza vaccine IM.
3140247|NCT01564732|Active Comparator|Standard-LAGB|Subjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
3140248|NCT01564732|Experimental|Plicated-LAGB|"Subjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to anchor the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months."
3140249|NCT01560507|Active Comparator|varenicline (Chantix)|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation Nicotine Replacement Therapy (NRT) assessed the day before the scheduled quit day. They will receive varenicline.
3140250|NCT01560507|Active Comparator|nicotine patches|This group will consist of smokers who, based on smoking behavior, respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will continue to using only nicotine patches.
3182645|NCT00705445|Experimental|B|"This group will receive micronutrient supplements containing microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid.~This group will also receive Nutritional Counselling and Education and treatment according to IMCI Guidelines for any serious illness."
3182646|NCT00705445|Experimental|C|"This group will receive Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, Folic Acid, and Zinc.~This group will also receive nutritional counselling, education and treatment according to IMCI Guidelines in case of any untoward illness."
3182647|NCT00705458|Experimental|CTA|Initial EKG-gated computed tomography angiography of the coronary arteries
3182648|NCT00705458|Active Comparator|MPI|Initial nuclear stress myocardial perfusion imaging
3140251|NCT01560507|Active Comparator|bupropion (Zyban) and nicotine patches|This group will consist of smokers who, based on smoking behavior, DO NOT respond favorably to pre-cessation NRT (assessed the day before the scheduled quit day). They will receive bupropion with nicotine patches.
3140252|NCT01557881|Experimental|Diagnostic (PET/MRI)|After undergoing standard PET/CT, patients undergo PET/MRI.
3140253|NCT01555489|Experimental|Ascorbic Acid, Gemcitabine & Erlotinib|Ascorbic Acid (50-100g, 3x weekly) Standard Chemotherapy of Gemcitabine and Erlotinib for Pancreatic Cancer
3140254|NCT01549977|Experimental|Febuxostat 80 mg|Febuxostat 80 mg, tablets, orally, once daily for up to 12 weeks.
3140255|NCT01549977|Placebo Comparator|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 12 weeks.
3140256|NCT01558492|Experimental|All subjects|Carboplatin and Paclitaxel
3140257|NCT01550562|Placebo Comparator|Sham Stimulation|Sham subthreshold spinal cord stimulation therapy
3140258|NCT01550562|Active Comparator|Treatment 1|subthreshold spinal cord stimulation therapy
2408337|NCT03515629|Active Comparator|Pembrolizumab|Pembrolizumab
3140259|NCT01550562|Experimental|Treatment 2|subthreshold spinal cord stimulation therapy
3140260|NCT01561495|Experimental|All Participants|Proton Radiotherapy
3140261|NCT01555073|Active Comparator|Pregabalin/celecoxib group|pregabalin/celecoxib twice a day for 13 days.
3140262|NCT01555073|Active Comparator|Pregabalin/placebo group|pregabalin/placebo twice a day for 13 days.
3140263|NCT01555073|Active Comparator|Celecoxib/placebo group|celecoxib/placebo twice a day for 13 days.
3140264|NCT01555073|Placebo Comparator|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
3140265|NCT01551082||Outpatient chest tubes|All patients, mixed gender, race, and age, who underwent thoracic resection by one surgeon over the past seven years and discharged home with air leak present and chest tube to portable drainage device.
3150564|NCT00205166|Active Comparator|2|Caffeine 200 mg po one hour before adenosine infusion
3140266|NCT01556009|Active Comparator|Drug (Vismodegib)|Vismodegib taken orally 150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
3182649|NCT00705471||Infliximab|Because of the difficulty of finding subjects with exactly the same disease severity, information will be recorded for the time period for up to three years before and for one year after their initial infliximab infusion for comparison of health care costs and utilization prior to infliximab and post infliximab use.
3182650|NCT00705497|Experimental|1|
3182651|NCT00705510|Active Comparator|A|
3182652|NCT00705510|Placebo Comparator|B|
3182653|NCT00705549|Experimental|1|Gemzar/Cisplatin
3182654|NCT00705549|Experimental|2|Taxotere/Cisplatin
3182655|NCT00705549|Experimental|3|Cisplatin/Navelbine metronomic
3182656|NCT00705549|Experimental|4|Taxotere/Gemzar
3182657|NCT00705549|Experimental|5|Gemzar
3182658|NCT00705549|Experimental|6|Taxotere
3182659|NCT00705549|Experimental|7|Navelbine metronomic
3182660|NCT00705549|Experimental|8|Alimta/Cisplatin
3182661|NCT00705549|Experimental|9|Alimta/Gemzar
3140267|NCT01556009|Active Comparator|Aminolevulinic acid %20 topical solution|Aminolevulinic acid HCL 20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
3140268|NCT01550510|Experimental|Ascorbic Acid + Irinotecan|Ascorbic Acid (50-100g, 3x weekly) with 350mg/m2 irinotecan once a week every 3 weeks
3140269|NCT01550510|Active Comparator|Standard of Care (irinotecan alone)|350mg/m2 irinotecan once a week every 3 weeks
3140270|NCT01541397|No Intervention|Non-Kuvan treated|Adults with hyperphenylalaninemia who have are not receiving Kuvan therapy.
3140271|NCT01541397|Experimental|Kuvan treated|Adults with hyperphenylalaninemia who are treated with Kuvan (sapropterin).
3140272|NCT01546207|Other|catheter-based ablation|catheter ablation - a medical procedure used to treat some types of arrhythmia
2408338|NCT03515629|Experimental|REGN2810/ipi|REGN2810/ipi
3140273|NCT01553240|Experimental|TMS and fMRI|"functional MRI~single and paired pulse TMS (to identify the difference of motor excitability between patients and healthy controls)"
3140274|NCT01547728|Experimental|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
3140275|NCT01548651|Placebo Comparator|Placebo|Placebo 5 mg orally daily for 6 months
3140276|NCT01548651|Experimental|Saxagliptin|Saxagliptin 5 mg orally daily for 6 months
3140277|NCT01545648|Experimental|denosumab|"Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
2408339|NCT03515629|Experimental|REGN2810/chemo/ipi|REGN2810/chemo/ipi
3140278|NCT01546883|Experimental|Dabigatran|Patients with Atrial fibrillation taking Dabigatran etexilate as the anti-coagulant
3140279|NCT01545518|Experimental|all subjects|IVIG
3182662|NCT00705549|Experimental|10|Taxotere
3140280|NCT01536015|Experimental|Rotigotine|Rotigotine patch titrated from 4 mg/24 h - 8 mg/24 h or until effective or maximum dose is reached.
3140281|NCT01536015|Placebo Comparator|Placebo|Placebo patch.
3140282|NCT01539590|Experimental|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
3140283|NCT01539590|Placebo Comparator|Normal Saline|Daily intravenous administration for four (4) days
3140284|NCT01539811|Active Comparator|Short course antibiotics|Surgical intervention followed by short course of antibiotics (<2 weeks)
3140285|NCT01539811|Active Comparator|Long course antibiotics|Surgical intervention followed by a long course of antibiotics (>2 weeks)
3140286|NCT01534676|Active Comparator|Transfusion of Fresh blood|The recipient will receive one or two units of fresh blood <14 days old, as per their chronic transfusion schedule - on or off chelation therapy.
3140287|NCT01534676|Experimental|Transfusion of Stored blood|The recipient will receive one or two units of old blood >28 days old, as per their chronic transfusion schedule - on or off chelation therapy.
3140288|NCT01534676|Active Comparator|Transfusion of Cryopreserved Blood|The recipient will receive one or two units of cryopreserved (fresh/old) blood, as per their chronic transfusion schedule - off chelation therapy.
3182663|NCT00705549|Experimental|11|Alimta
3182664|NCT00705562|Experimental|1|Experimental milk protein based infant formula with varying carbohydrate and protein source
3182665|NCT00705562|Experimental|2|Experimental milk protein based infant formula with varying carbohydrate and protein source
3182666|NCT00705562|Experimental|3|Experimental milk protein based infant formula with varying carbohydrate and protein source
3182667|NCT00705562|Experimental|4|Experimental milk protein based infant formula with varying carbohydrate and protein source
3182668|NCT00705562|Experimental|5|Experimental milk protein based infant formula with varying carbohydrate and protein source
3182669|NCT00705588|Experimental|1|Patients treated with epoprostenol (Flolan) will be given tadalafil (Cialis).
3182670|NCT00705588|Experimental|2|Patients receiving iloprost (Ventavis) will receive vardenafil (Levitra)
3182671|NCT00705601||1|
3182672|NCT00705627|Experimental|B|Drug: cisplatin. Patients in the control arm received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
3182673|NCT00705640|Experimental|Arm 1A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
3140289|NCT01534676|Active Comparator|Transfusion of Washed Blood|The recipient will receive one or two units of washed (fresh/old) stored blood >28 days old, as per their chronic transfusion schedule - off chelation therapy.
3140290|NCT01533753|Experimental|Arm A: Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
3182674|NCT00705640|Experimental|Arm 1B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
3182675|NCT00705640|Experimental|Arm 1C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
3182676|NCT00705640|Experimental|Arm 1D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3140291|NCT01533753|Experimental|Arm B: Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
3140292|NCT01534143|Experimental|Treatment (chemotherapy, enzyme inhibitor)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -7 to -3, busulfan IV on days -6 to -3, and bortezomib IV on day -2.~GVHD PROPHYLAXIS: Patients receive thymoglobulin IV on days -3 to -1, sirolimus PO on day -3, and tacrolimus IV on day -3. Patients undergo allogeneic HSCT on day 0."
3140293|NCT01530880|Experimental|Intravenous Ibuprofen|Patients assigned to the ibuprofen treatment group will receive a 400 mg IV ibuprofen bolus over 30 minutes followed by an infusion of ibuprofen at 85 mg/hr.
3140294|NCT01530880|Other|Standard of Care|Patients assigned to the standard of care group will be given 650 mg of oral acetaminophen and continue to receive 650 mg of oral acetaminophen every 6 hours as needed to maintain temperature < 38.3 C (100.9 F).
3140295|NCT01530087|Experimental|Treatment|CASTLE Barrier
3140296|NCT01527942|Experimental|Arm 1 - Active Drug|Preoperative administration of 1,000 mg IV Acetaminophen will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
3140297|NCT01527942|Placebo Comparator|Arm 2 - Placebo|Preoperative IV Placebo (0.9 Sodium Chloride 100 ml) will be administered after induction of general anesthesia and prior to incision and every 6 hours thereafter for 24 hours.
3140298|NCT01521143|Experimental|Part A - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
3140299|NCT01521143|Placebo Comparator|Part A - Placebo|Participants received intradermal injections of placebo given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks.
3150565|NCT00205270||Pre-transplant Vaccine|Cohort consists of individuals waiting for lung transplantation. Inactivated influenza vaccine will be administered intramuscularly annually.
3140300|NCT01521143|Experimental|Part B - Cvac|Participants received intradermal injections of Cvac given at 4-week intervals for the first 3 doses, and then every 12 weeks for 3 additional doses, for a total of 6 doses over 44 weeks. Each injection had an approximate concentration of 60 × 10^6 viable dendritic cells/mL.
3140301|NCT01521143|No Intervention|Part B - Observational standard of care|Participants in this group did not receive any treatment during the study.
3140302|NCT01532635|Experimental|Allogeneic HSCT Using Two Related Donors|"CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28."
3140303|NCT01531387|No Intervention|Standard Therapy: Observation|Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
3140304|NCT01531387|Experimental|Hydroxyurea|Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
3140305|NCT01532362|Experimental|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
3140306|NCT01532362|Other|No drug intervention|
3140307|NCT01527292|Active Comparator|Control Group|Baseline Assessments and followup assessments are the same for both arms. Control group Intervention: Stereotactic Radiation Therapy only
3140308|NCT01527292|Experimental|Treatment Group|SRT with Vertebral Augmentation Procedure Baseline Assessments and followup assessments are the same for both arms. Treatment group Intervention: Stereotactic Radiation Therapy with Vertebral Augmentation Procedure
3140309|NCT01525745|Active Comparator|Radiosurgery/SBRT|Radiosurgery/SBRT
3140310|NCT01525745|Active Comparator|External Beam Radiation Therapy|External Beam Radiation Therapy
3140311|NCT01528696|Placebo Comparator|Standard Dressing|Obese patients undergoing cesarean section in this arm will receive a standard island-type dressing
3140312|NCT01528696|Experimental|Silverlon|Obese patients undergoing cesarean section in this arm will receive Silverlon, a silver impregnated dressing
3140313|NCT01526408|Placebo Comparator|Placebo Arm|Treatment with 3 months of placebo
3140314|NCT01526408|Active Comparator|Active Arm|Treatment with 3 months of active drug
3140315|NCT01528293|Active Comparator|ActiVAC System+ Compression therapy|ActiVAC System + Compression therapy group consisting of the application of this device along with compression therapy.
3140316|NCT01528293|Other|Compression therapy only|Standard of Care compression therapy only
3140317|NCT01525927|Active Comparator|Chemotherapy non-responders|Patients treated with three cycles neoadjuvant chemotherapy who do not exhibit response to chemotherapy are then allocated to recieve standard dose and schedule radiotherapy.
3140318|NCT01525927|Experimental|Chemotherapy responders|Patients who respond to chemotherapy are treated with reduced dose radiotherapy.
3140319|NCT01520714|Experimental|Medtronic passive fixation LV lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
3140320|NCT01520714|Experimental|Medtronic 4195 Active Fixation LV Lead|Medtronic 4195 Active Fixation LV lead and Medtronic passive fixation LV lead arms will both have same follow-up testing and schedule
3140321|NCT01507233|Active Comparator|IV morphine sulfate|morphine sulfate (or Sponsor-approved equivalent)
3140322|NCT01507233|Experimental|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3140323|NCT01516034|Experimental|Treatment|Cupola Tattoo Removal Device
3140324|NCT01500772|Experimental|Alisporivir|ALV 400 mg twice daily (BID), plus PEG and RBV for 48 weeks
3140325|NCT01517763|Placebo Comparator|Conventional CPAP|Fisher & Paykel HC244™
3140326|NCT01517763|Active Comparator|CPAP without Humidification|Fixed pressure ICON™ without ThermoSmart™
3140327|NCT01517763|Experimental|APAP with all technologies|Auto ICON™ with SensAwake™ and ThermoSmart™
3140328|NCT01507584|Active Comparator|Prostaglandin Analogue|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (PGA + BB)
3140329|NCT01507584|Active Comparator|Carbonic Anhydrase Inhibitor|WDT protocol Visit 1 - (WDT after washout) 20 Visit 2 - (WDT with treatment) 20 Visit 3 - (WDT with PGA or BB add-on) 20 (CAI+ BB)
3140330|NCT01510756|Experimental|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days).
3140331|NCT01511081|Experimental|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
3140332|NCT01511081|Experimental|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
3140333|NCT01500109|Experimental|Ofirmev®|Oral inert cherry syrup will be administered preoperatively as placebo for oral acetaminophen. Ofirmev® will be administered in the operating room once intravenous access is established. Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon before surgical incision as well as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patients will receive Ofirmev® every 6 hours as well as placebo oral cherry elixir every 6 hours and morphine as needed for 24 hours.
3140334|NCT01500109|Active Comparator|Oral acetaminophen|Patients will receive oral acetaminophen cherry elixir preoperatively. After intravenous access is obtained intraoperatively patients will receive placebo for Ofirmev® (saline). Patients will receive standardized dose of local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to surgical incision as wel as at the completion of surgery with Bupivacaine 0.25% with Epinephrine. Postoperatively patient will receive oral acetaminophen every six hours and intravenous placebo (normal saline) for intravenous acetaminophen. Intravenous morphine will be administered as needed for 24 hours.
3150566|NCT00205270||0-6 Months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 0-6 months post transplant.
3150567|NCT00205270||13-60 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine 13-60 months post transplant.
3150568|NCT00205270||Greater than 110 months Post-transplant Vaccine|Cohort consist of individuals who have received lung transplants and received inactivated influenza vaccine greater than 110 months post transplant.
3150569|NCT00205270||Healthy Controls|Healthy controls to measure normal immune response to the influenza vaccine
3150570|NCT00205335|Other|glucose monitoring|Each participant received a Bayer Breeze Monitor and glucose test strips for monitoring blood sugar.
3150571|NCT00205361||1|well-nourished
3150572|NCT00205361||2|malnourished
3150573|NCT00205426|Experimental|Natrecor infusion|Nesiritide
3150574|NCT00205439||Fluorescence bronchosopy with sputum cytology|Patients undergo surgery with Fluorescence bronchosopy and sputum cytology.
3182677|NCT00705640|Experimental|Arm 1E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine comprising incomplete Freund's adjuvant only SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (6 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3182678|NCT00705640|Experimental|Arm 2A|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive no replicate vaccine. Patients undergo surgical biopsy at replicate vaccine site on day 1.
3140335|NCT01500109|Placebo Comparator|Opioid only|This group will receive placebo oral cherry elixir prior to going to the operating room and placebo Ofirmev® after securing intravenous access in the operating room with redosing every six hours. They will receive local anesthetic (Lidocaine 0.5% with Epinephrine) infiltration by the surgeon prior to incision as well as at the completion of surgery with Bupivicaine 0.25% with Epinephrine. Postoperatively they will receive only Morphine prn for pain control.
3140336|NCT01509053|Experimental|Aripiprazole IM depot injection|Patients who had no history of tolerability to oral aripiprazole received 10-15 mg/day (up to 30 mg/day) oral aripiprazole for 1 to 4 weeks to determine tolerability in the Tolerability Assessment Phase prior to receiving treatment with aripiprazole IM Depot. In the Open-label Aripiprazole IM Depot Phase, participants received aripiprazole intramuscular (IM) Depot 400 mg injection (dosage could be adjusted to 300 mg at the investigator's discretion) monthly in the clinic for a total of 6 injections + concomitant oral aripiprazole 10-15 mg/day for the first 14 days. Participants at the investigator's discretion were eligible to continue to receive aripiprazole IM depot (400 or 300 mg) injection monthly in the Open-label Aripiprazole IM Depot Extension phase. Oral aripiprazole was available as rescue medication if necessary.
3150575|NCT00205543|Experimental|1|suture palate after resection
3150576|NCT00205543|Experimental|2|suture one side of palate afer resection
3150577|NCT00205543|Experimental|3|no sutures in palate after resection
3150578|NCT00205556|Other|1: low flux hemodialysis|standard treatment
3150579|NCT00205556|Active Comparator|2 on-line hemodiafiltration|
3150580|NCT00205569||1|Individuals with traumatic brain injury requiring inpatient rehabilitation.
3150581|NCT00205829|Experimental|Active Therapy|Occipital nerve stimulation (ONS) therapy delivered to a subject implanted with a bion ONS device
3150582|NCT00205907|Experimental|single|BLVR treatment
3150583|NCT00205920|Experimental|single|BLVR Treatment
3150584|NCT00205946|Placebo Comparator|Placebo|
3150585|NCT00205946|Active Comparator|Bupropion|
3150586|NCT00206011|Experimental|1|
3150587|NCT00206011|Other|2|
3150588|NCT00206232|Active Comparator|Spironolactone|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
3150589|NCT00206232|Placebo Comparator|Placebo|Randomized, double-blind, placebo controlled trial evaluating the safety and efficacy of spironolactone 25mg daily for 6 months.
3150590|NCT00206388|Experimental|Zolendric acid with Cyclophosphamide|Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
3150591|NCT00206414|Experimental|Iressa Day 1 with Arimidex and Faslodex|Subjects randomized to Iressa on Day 1 in combination with Arimidex and Faslodex.
3140337|NCT01495988|Active Comparator|Vemurafenib/Cobimetinib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3140338|NCT01495988|Experimental|Vemurafenib/Cobimetinib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Bevacizumab will be administered at the MTD (determined by phase Ib safety lead-in), intravenously, every 2 weeks. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3140339|NCT01495988|Active Comparator|Vemurafenib|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3150592|NCT00206414|Active Comparator|Iressa Day 21 with Arimidex and Faslodex|Subjects randomized to Iressa Day 21 in combination with Arimidex and Faslodex
3150593|NCT00206466|Active Comparator|One|Taxotere
3150594|NCT00206492|Experimental|Iressa and Tamoxifen|Iressa and Tamoxifen
3150595|NCT00206544|Active Comparator|1|Tamoxifen 40 mg daily
3150596|NCT00206544|Active Comparator|2|Progesterone 20 mg daily
3150597|NCT00206544|Placebo Comparator|3|Placebo daily
3140340|NCT01495988|Experimental|Vemurafenib + Bevacizumab|Vemurafenib will be given at a dose of 960 mg p.o. BID to all patients. Patients assigned to the combination arm will also receive bevacizumab 15 mg/kg every IV every 3 weeks. Patients will be assessed for toxicity every 3 or 6 weeks (depending on the specific toxicity) and be restaged for tumor response/progression every 6 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
3140341|NCT01498991|Experimental|AMES Treatment|The subject will receive 30 treatment sessions, conducted 3-4 times per week on the AMES device. Each session will consist of testing followed by 40 minutes of treatment time (20 minutes per each leg) using the AMES device.
3140342|NCT01497171|Active Comparator|Elevate Mesh|Elevate transvaginal mesh - surgical repair of prolapse
3140343|NCT01497171|Active Comparator|Anterior Colporrhaphy|Anterior colporrhaphy - surgical repair of prolapse
3140344|NCT01483872|Experimental|NAC/Tigecycline/Heparin combination lock solution|A combination of the above three drugs will form the catheter lock solution that will be instilled into the catheter
3140345|NCT01483872|Placebo Comparator|Standard anticoagulant (heparin or citrate)|Standard anticoagulant (heparin or citrate)
3140346|NCT01487499|Experimental|patients with limited stage SCLC|Subjects with limited stage SCLC treated sequentially with cisplatin.
3140347|NCT01487499|No Intervention|Historical Controls|No intervention
3140348|NCT01478113|Active Comparator|WBT + amphetamine/dextroamphetamine|In the active group, participants will receive treatment with Well-being therapy and amphetamine-dextroamphetamine.
3140349|NCT01478113|Placebo Comparator|WBT + placebo|In the placebo group, participants will receive treatment with Well-being therapy and pill placebo.
3140350|NCT01483209|Experimental|Botox injection|Use of botulinum toxin A to determine efficacy in treating vasopressor-induced digital ischemia
3140351|NCT01484314|Experimental|Migration Arm|Administration of eltrombopag to support platelets during chemotherapy
3140352|NCT01482598|Active Comparator|Optimal Remote Care|Patient follow up is performed through remote care, remote alerts on CRT-D device data are transmitted daily to the hospital, remote follow up is scheduled every 6 months, hospital in clinic follow up is scheduled at 12 months after implant.
3140353|NCT01482598|No Intervention|Optimal Standard Care|Patient standard in clinic visits are performed every 6 months.
3140354|NCT01479010|Experimental|Anakinra|
3140355|NCT01482325|Experimental|Subjects requiring blood pressure monitoring|Any subject (neonate-adult) requiring hospital or clinic blood pressure monitoring
3140356|NCT01477177|Experimental|Polar Wand Treatment|Cryotherapy device utilizing carbon dioxide (room temperature gas) for treatment of GI neoplasia
3140357|NCT01473732|Experimental|Everolimus (Zortress)|
3140358|NCT01473732|Active Comparator|Reduced dose Tacrolimus (Prograf)|
3140359|NCT01472692|Active Comparator|Febuxostat|
3140360|NCT01472692|Placebo Comparator|Placebo|
3140361|NCT01465230|Experimental|lenalidomide|Maintenance treatment with lenalidomide following induction treatment with bendamustine and rituximab.
3140362|NCT01464723|Experimental|Lucentis|Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
3140363|NCT01446250|Experimental|Alisporivir|At the time of partial clinical hold, participants randomized to original treatment arms A and B (Alisporivir triple therapy arms with Peginterferon alfa-2a and Ribavirin) discontinued alisporivir treatment immediately while continuing their treatments with the other two therapies. These participants were combined into the same arm because they received the same dose of alisporivir 400 mg twice per day (BID) for the same duration. Amendment 1 offered them the opportunity to continue in the study receiving boceprevir triple therapy.
3140364|NCT01446250|Active Comparator|Boceprevir|Participants randomized to boceprevir triple therapy with Peginterferon alfa-2a and Ribavirin (the original treatment arm C).
3140365|NCT01463293|Experimental|High-dose probiotic|Capsule containing 10 billion cfu B. lactis HN019
3140366|NCT01463293|Experimental|Low dose probiotic|Capsule containing 1 billion cfu B. lactis HN019
3140367|NCT01463293|Placebo Comparator|Placebo|Placebo capsule
3140368|NCT01457053|Active Comparator|Ultrafiltration|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretics (loop diuretics: furosemide, bumetanide, and/or torsemide). Patients in this arm are randomized to ultrafiltration.
3140369|NCT01457053|Active Comparator|Diuretic Therapy|Patients with acute decompensated heart failure will be randomized to either ultrafiltration or diuretic therapy ((loop diuretics: furosemide, bumetanide, and/or torsemide). The myocardial blood flow of patients treated with ultrafiltration will be actively compared to diuretic therapy with either furosemide, bumetanide, and/or torsemide.
3140370|NCT01451723|Experimental|Polyphenon E 400mg twice a day|Two capsules of Polyphenon E containing 200mg of EGCG each taken twice a day with food.
3140371|NCT01451723|Placebo Comparator|Placebo|Matching placebo capsules.
3140372|NCT01452854||Cancer|The study cohort will include adult women of childbearing potential with a diagnosis of low grade glioma (WHO grade II) who are being treated with low doses of Temozolomide (Temodar).
3140373|NCT01440517|Experimental|Tc99m-Maraciclatide|
3140374|NCT01440595|Experimental|Grazoprevir 200 mg + Peg-IFN + RBV|Grazoprevir 200 mg in combination with Peg-IFN and RBV for 12 weeks.
3140375|NCT01440595|Experimental|Grazoprevir 400 mg + Peg-IFN + RBV|Grazoprevir 400 mg in combination with Peg-IFN and RBV for 12 weeks.
3140376|NCT01440595|Placebo Comparator|Placebo + Peg-IFN + RBV|Placebo to grazoprevir in combination with Peg-IFN and RBV for 12 weeks, followed by open-label Peg-IFN and RBV for an additional 12 weeks.
3140377|NCT01440595|Experimental|Grazoprevir 800 mg + Peg-IFN + RBV|Grazoprevir 800 mg in combination with Peg-IFN and RBV for 12 weeks.
3140378|NCT01446796|Placebo Comparator|Native Conduction|Devices will be programmed to continuous atrial pacing at an AAI (atrial inhibited pacing) setting with base rate 90 bpm. Patients will not receive ventricular pacing.
3140379|NCT01446796|Experimental|Continuous RV Pacing|Devices will be programmed to continuous dual chamber pacing at a DDD (dual chamber dual pacing) setting with base rate ≥ 90 bpm (not to exceed 100 bpm) to achieve a majority (>80%) of paced right ventricular beats
3140380|NCT01443923|Active Comparator|1-HCV|Hepatitis C Mono-infected
3140381|NCT01443923|Active Comparator|2 HCV/HIV|Hepatitis C and HIV co-Infected
3140382|NCT01439347|Experimental|Vincristine Sulfate Injection (VSI)|VSI dosed at 1.4 mg/m^2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes.
3140383|NCT01439347|Experimental|Marqibo|Marqibo dosed at 2.25 mg/m^2 (without any dose cap) as an IV infusion over 60 minutes.
3140384|NCT01440452|Experimental|Group A|For 3 weeks, you will need to come to the International Center for Spinal Cord Injury at Kennedy Krieger Institute (ICSCI) one (1) time per week during which you will perform FES cycling for 1 hour each.
3140385|NCT01440452|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
3140386|NCT01440452|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
3140387|NCT01440452|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
3140388|NCT01433471|Experimental|Trichuris suis ova followed by placebo|Subjects in this arm will receive Trichuris suis ova for 12 weeks, followed by placebo for 12 weeks after crossover
3140389|NCT01433471|Active Comparator|Placebo followed by Trichuris Suis Ova|Subjects in this arm will receive placebo for 12 weeks, followed by Trichuris suis ova for 12 weeks after crossover
3140390|NCT01436084|Experimental|SB1518|400 mg orally a day for 28 day cycle.
3140391|NCT01434511|Experimental|OBI-1|
3140392|NCT01426555|Active Comparator|FES Rowing|Group 1 - FES-Rowing Exercise for entire study period
3140393|NCT01426555|Experimental|FES Rowing + Zoledronic acid|Group 2 - FES-Rowing Exercise for entire study period plus Zoledronic Acid 5mg administered by i.v. infusion one-time at the end of observation period
3140394|NCT01434745|Placebo Comparator|Placebo|placebo
3140395|NCT01434745|Experimental|Simvastatin|0.5 mg/kg body weight/day
3140396|NCT01415986|Experimental|Subjects receiving Temoporfin|
3140397|NCT01410799|Experimental|Growth Hormone Releasing Hormone (GHRH)|Drug: GHRH
3140398|NCT01426113|Experimental|bimatoprost ophthalmic solution formulation A and vehicle|1 drop bimatoprost vehicle in the affected eye(s) in the morning and 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning and 1 drop bimatoprost vehicle in the affected eye(s) in the evening for 6 additional weeks.
3140399|NCT01426113|Active Comparator|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
3140400|NCT01426516|No Intervention|Treatment as usual (TAU)|Subjects will give DNA sample for genetic testing but will not receive genetic results and will therefore receive treatment as usual.
3140401|NCT01426516|Experimental|Genecept Assay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account.
3140402|NCT01420965|Active Comparator|Arm A|Sipuleucel-T autologous active cellular immunotherapy only for 3 cycles (cycle = 14 days)
3140403|NCT01420965|Experimental|Arm B|Sipuleucel-T for 3 cycles (cycle = 14 days) + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
3140404|NCT01420965|Experimental|Arm C|Sipuleucel-T for 3 cycles (cycle = 14 days)+ cyclophosphamide (125 or 250mg/m2) IV [first cycle only] + CT-011 (3mg/kg) IV infusion delivered over approximately 2 hours, 2 days after each Sipuleucel-T infusion
3140405|NCT01417377||Cohort|Mircera
3140406|NCT01416272|Experimental|KeraSoft IC Soft Contact Lenses|KeraSoft IC Soft Contact Lenses, with CIBA Clear Care solution provided for lens care
3140407|NCT01414166|Experimental|ERN/LRPT group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive ERN/LRPT for 16 weeks.
3140408|NCT01414166|Placebo Comparator|Placebo group|All participants will begin with a screening period of 1 week, followed by a placebo run-in period of 2 weeks before being randomized to receive placebo for 16 weeks.
3140409|NCT01406860|Experimental|Droperidol|
3140410|NCT01406860|Active Comparator|Metoclopramide + Diphenhydramine|
3140411|NCT01401049|Experimental|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
3140412|NCT01401049|Active Comparator|Propofol/Lidocaine|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (a lipid based medication); Lusedra (a water based medication); and the drug combination of propofol with lidocaine (a local anesthetic commonly used with propofol injection).
3140413|NCT01408641|Experimental|Topiramate|Topiramate arm will be titrated (dose will increase slowly) over 6 weeks to 400mg or highest tolerated dose.
3140414|NCT01408641|Placebo Comparator|Placebo (Sugar Pill)|Placebo arm will receive matching capsules without topiramate.
3140415|NCT01409031|Experimental|Intravenous Sildenafil|
3140416|NCT01409031|Placebo Comparator|Placebo|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
3140417|NCT01402531|Experimental|Submucosal Bevacizumab|200mg Bevacizumab, submucosal injection
3140418|NCT01394926|Experimental|Arm Number 1|
3140419|NCT01383681||All Participants|This was a retrospective chart review in patients with spasticity in the Spanish population. There was no treatment in this study.
3140420|NCT01403194|Experimental|CPAP/Bi-PAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
3140422|NCT01397552|Active Comparator|Dexamethasone|Subjects randomized to receive dexamethasone, will undergo epidural using this medication, however the physician and subject will be blinded
3140423|NCT01397552|Active Comparator|methylprednisolone acetate|Subjects randomized to receive methylprednisolone acetate, will undergo epidural using this medication, however the physician and subject will be blinded
3140424|NCT01392170|Experimental|PEG-IFNá-2a|PEG-IFNá-2a (Pegasys) 45 mcg subcutaneously as single weekly dose.
3140425|NCT01389817|Experimental|Symptomatic LHON patients.|Study Arm 1) symptomatic LHON patients. Male and female LHON patients with treatable bilateral optic atrophy. Treat the worse of the 2 eyes if there is a measurable difference in subjective visual functions (visual acuity, peripheral vision).
3140426|NCT01389817|No Intervention|Asymptomatic LHON mutation carriers|Study Arm 2) asymptomatic LHON mutation carriers. Can be male or female; have some dysfunction, with changes occurring over months. Patients in study arm 2 will not be exposed to NIR-LED, but only undergo diagnostic studies.
3140427|NCT01397695|Experimental|bevacizumab|
3140430|NCT01390181|Experimental|Losartan|
3140431|NCT01385033|Experimental|Part I, Healthy Elderly (HE) and AD Participants|HE and AD participants will receive a single intravenous (IV) dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part I of the study
3140432|NCT01385033|Experimental|Part II, Healthy Young, HE and AD Participants|Healthy Young, HE and AD participants will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part II of the study
3140433|NCT01385033|Experimental|Part III, Participants with aMCI|Participants with aMCI will receive a single IV dose of ~150 megabecquerel (MBq) [18F]MK-3328 in Part III of the study
3140434|NCT01394211|Experimental|Neoadjuvant enzyme inhibitor therapy|"Patients receive pazopanib hydrochloride* PO QD and anastrozole PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients then undergo therapeutic conventional surgery.~NOTE: *Pazopanib hydrochloride is stopped 7-14 days before definitive surgery."
3140435|NCT01388920|Experimental|Tesamorelin 2 mg|Tesamorelin 2 mg/day
3140436|NCT01388920|Experimental|Tesamorelin 3 mg|Tesamorelin 3 mg/day
3140437|NCT01388920|Placebo Comparator|Placebo|
3140438|NCT01377441|Experimental|Ibuprofen|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo.
3140439|NCT01377441|Placebo Comparator|Placebo/Saline solution|Eligible subjects will be randomized to one of the two treatment group in a 1:1 ratio to receive either IV ibuprofen or matching placebo
3140440|NCT01383447|Experimental|Treatment (entinostat and imatinib mesylate)|Patients receive entinostat PO daily on days 1, 8, 15, and 22 and imatinib mesylate PO twice daily on days 1-28 (days 4-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3140441|NCT01372618|Experimental|SOM 230/Pasireotide|Treatment with SOM230 600mcg twice daily for 20 days.
3140442|NCT01385280|Experimental|Arm I|Patients receive oral therapeutic estradiol once daily on days 1-3, twice daily on days 4-7, and thrice daily on days 8-90. Beginning on day 98, patients receive oral exemestane once daily in the absence of disease progression or unacceptable toxicity. Also laboratory biomarker analysis and enzyme-linked immunosorbent assay will be taken for correlative studies.
3140443|NCT01379274|Experimental|lenalidomide and azacitidine combination|Lenalidomide and azacitidine combination to be utilized in patients who did not respond to 3 months of lenalidomide monotherapy.
3140444|NCT01379469|Active Comparator|Drug-Carbamazepine (Tegretol XR)|One arm receives Drug-Carbamazepine (Tegretol XR).All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
3140445|NCT01379469|Placebo Comparator|Drug-Carbamazepine (Tegretol XR) Placebo|One arm receives Carbamazepine (Tegretol-XR) placebo.All subjects have severe liver disease due to alpha-1-antitrypsin deficiency.
3140446|NCT01369641|Experimental|Experimental Ear - Sodium Thiosulfate (STS)|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
3140447|NCT01369641|Placebo Comparator|Comparator Ear - Placebo|Subjects enrolled to study will have their ears randomized for treatment with STS. The experimental ear will receive STS treatments, while the comparator ear will receive a placebo.
3140448|NCT01365156|Experimental|EPLND + Chemoradiation|Group 1: Extraperitoneal laparoscopic lymphadenectomy followed by chemoradiation therapy
3140449|NCT01365156|Active Comparator|Chemoradiation|Group 2: standard-of-care chemoradiation therapy only
3140450|NCT01359254|Experimental|Conditioning Regimen I|Arm I contains fludarabine, melphalan, and antithymocyte globulin (ATG)
3140451|NCT01359254|Experimental|Conditioning Regimen II|Arm II contains fludarabine, busulfan, antithymocyte globulin (ATG), and total body irradiation (TBI).
3140452|NCT01347632|Other|BV pre treatment|Open Label Study. All participants had BV and took metronidazole 500 mg po BID for 7 days.
3140453|NCT01356667|Active Comparator|Treatment-As-Usual|Substance Abuse treatment typically received
3140454|NCT01356667|Experimental|DARTNA|12-week DARTNA program
3140455|NCT01354951|Experimental|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|This is a non-randomized, Phase II study examining the tolerance profile (primary endpoint) as well as the secondary endpoints of QOL changes, efficacy and the correlation of post-treatment MRI findings with post-treatment biopsy outcomes in men with early stage low volume prostate cancer treated with focal brachytherapy.
3140456|NCT01350232|Experimental|HSCT|"Subjects receive the preparative regimen in 2 steps. The first step will be with fludarabine and cytarabine and a low dose of total body irradiation. This will be followed by the first step of the transplant graft - the donor lymphocytes. The second step of the chemotherapy will be two doses of cyclophosphamide. This will then be followed by the second step of the transplant graft - the stem cells.~Only subjects with prior alloimmunization against donor will receive desensitization. Subjects who demonstrate alloimmunization against the HLA of the donor will receive bortezomib and rituximab in combination with plasmapheresis prior to the admission for transplant."
3140457|NCT01350583|Experimental|Sodium Bicarbonate Therapy|Dose Escalation
3140458|NCT01352416|Active Comparator|CABG surgery with Ranolazine|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Ranolazine 1000 mg (2-500mg tablets) twice daily. If intolerant to the study drug due to adverse effects,or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice daily.
3140459|NCT01352416|Placebo Comparator|CABG surgery with placebo|Patient will undergo Coronary Artery Bypass Graft (open heart surgery) and will receive, Placebo 1000mg mg (2-500mg tablets)twice daily. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily.
3140460|NCT01352416|Active Comparator|Heart Valve surgery with Ranolazine|Patient will undergo heart Valve surgery and will receive, Ranolazine1000mg (2-500 mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500 mg (1-500mg tablet) twice a day.
3140461|NCT01352416|Placebo Comparator|Heart Valve surgery with placebo|Patient will undergo heart Valve surgery and will receive, Placebo 1000mg (2-500mg tablets) twice a day. If intolerant to the study drug due to adverse effects, or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice a day.
3140462|NCT01350258|Experimental|Transplant Treatment Group|All patients treated on this research study.
3140463|NCT01349595|Experimental|Bortezomib|Bortezomib is a type of targeted chemotherapy
3140464|NCT01349595|No Intervention|Standard Post-transplant Treatment|Mayo Clinic standard post kidney transplant follow-up.
3140465|NCT01337609|Experimental|GanedenBC30|Arm 1 will take GanedenBC30 (Bacillus coagulans GBI-30, 6086, 1 capsule/day) for 60 days.
3140466|NCT01337609|Placebo Comparator|Sugar pill|Arm 2 will take placebo (sugar pill) for 60 days.
3140467|NCT01337609|Other|Ganeden BC30, Sugar pill|Arm 3 will take placebo (sugar pill) for 30 days, followed by Ganeden BC30 for 30 days.
3140468|NCT01347840||All Subjects|This is a one arm study where all the subjects will receive the same treatment and will not be blinded. No subjects will be assigned to different treatment groups.
3140469|NCT01340573||Genotype 1 CHC Participants|
3140470|NCT01340573||Non-genotype 1 CHC participants|
3140471|NCT01335997|Experimental|ERN/LRPT/SIM → ERN/LRPT+SIM|Weeks 0-4 (Period 1): Participants will take ERN/LRPT/SIM 1 g/10 mg and SIM-matching placebo tablets daily; Weeks 5-12 (Period 2): Participants will be advanced to ERN/LRPT/SIM 2 g/20 mg and SIM-matching placebo tablets daily; Weeks 13-20 (Period III): Participants will crossover to ERN/LRPT 2 g + SIM 20 mg coadministration treatment.
3140472|NCT01335997|Active Comparator|ERN/LRPT+SIM → ERN/LRPT/SIM|Weeks 0-4 (Period I): Participants will take ERN/LRPT co-administered with SIM (ERN/LRPT 1g + SIM 10 mg tablets) daily; Weeks 5-12 (Period II): Participants will be advanced to ERN/LRPT 2 g + SIM 20 mg daily; Weeks 13-20 (Period III): Participants will crossover to the ERN/LRPT/SIM 2 g/20 mg combination treatment and SIM-matching placebo tablets.
3140473|NCT01340885|Active Comparator|atomoxetine|Strattera 10-30 mg b.i.d.
3140474|NCT01340885|Active Comparator|rivastigimine|Exelon 1.5-4.5 mg b.i.d.
3140475|NCT01340885|Placebo Comparator|Placebo|sugar pill
3140476|NCT01341587|No Intervention|Control|Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
3140477|NCT01341587|Active Comparator|Intervention|"Home diabetes monitoring by patient using cellular enabled glucometer to communicate information and receive feedback.~Care provider can access raw and analyzed patient data; Physician receives report summary."
3140478|NCT01334606|Experimental|Nano: 4mm x 32G Pen Needle|Subjects will use the 4mm x 32G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
3140479|NCT01334606|Experimental|Short: 8mm x 31G Pen Needle|Subjects will use the 8 mm x 31G pen needle for all self-administered pen injections of diabetes medications during the assigned three week study period.
3150598|NCT00206583|Experimental|EV/DNG (Qlaira, BAY86-5027)|Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral)
3150599|NCT00206596|Experimental|Arm 1|
3140480|NCT01326923|Other|Single arm|Single arm Phase II Study Induction Chemo then Concurrent Chemoradiotherapy with Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer
3140481|NCT01332799|Active Comparator|Allopurinol|
3140482|NCT01332799|Placebo Comparator|Placebo (sugar pill)|
3140483|NCT01329549|Experimental|BIBF 1120 (low) + Carboplatin + PLD|BIBF 1120 (low dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3140484|NCT01329549|Experimental|BIBF 1120 (medium) + Carboplatin + PLD|BIBF 1120 (medium dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3140485|NCT01329549|Experimental|BIBF 1120 (high) + Carboplatin + PLD|BIBF 1120 (high dose) + carboplatin (AUC5 mg/mL*min) + PLD (30 mg/m2)
3140486|NCT01326845|Experimental|Deferasirox am|Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
3140487|NCT01326845|Experimental|Deferasirox pm|Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal
3140488|NCT01329341|Experimental|Arm 1|Service Dogs
3140491|NCT01319760|Sham Comparator|Standard of care|Patients in the control arm will be treated with standard of care for post-PCI STEMI patients in accordance with the the 2004 ACC/AHA Guidelines for the Management of Patients with ST-elevation Myocardial Infarction.
3140492|NCT01319760|Experimental|Impella 2.5|24 hours of support with the Impella 2.5 post-PCI for acute myocardial infarction.
3140493|NCT01320683|Experimental|Treatment (combination chemotherapy and radioimmunotherapy)|FOLFOX* + BEVACIZUMAB CHEMOTHERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 12 courses in the absence of disease progression or unacceptable toxicity. RIT: Within 4-12 weeks after completion of post-hepatic resection therapy chemotherapy, patients receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes. Treatment repeats every 6-10 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. NOTE:*Patients previously failing oxaliplatin regimen receive FOLIFIRI chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, leucovorin calcium over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes. Treatment repeats for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3140494|NCT01313273|Other|Arm A|
3140495|NCT01313273|Experimental|Arm B|
3140496|NCT01321008|Experimental|Radiation + Chemotherapy|Radiation therapy total dose of 50.4 to 54 Gy over 28 to 30 treatments; CHOP Chemotherapy of Cyclophosphamide 750 mg/m2 intravenous piggyback (IVPB), Doxorubicin 50 mg/m2 IVPB, Vincristine 1.4 mg/m2 (max dose 2 mg) IVPB on Day 1, and Oral Prednisone 100 mg daily days 1-5 for four 21-day cycles.
3140497|NCT01310803|Experimental|Maintenance therapy|Chemotherapeutic: EN3329-301 (VALSTAR)
3140498|NCT01310803|Other|No Maintenance (Standard of care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
3140499|NCT01309581|Experimental|Ketamine|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
3140500|NCT01309581|Active Comparator|Methohexital|Participants receiving ECT for depression will be randomized 1:1 to either ketamine (experimental condition) or methohexital (standard anesthetic).
3140501|NCT01315873|Experimental|Bortezomib and Bendamustine|
3140502|NCT01313923|Experimental|Sirolimus (formerly known as Rapamycin)|Subjects with stable pemphigus vulgaris already on treatment with prednisone will be enrolled. Subjects will start taking oral sirolimus and have it up-titrated while decreasing the prednisone dosage. Their disease state will be monitored during this time.
3140503|NCT01321697||Vulvar Cancer|
3140504|NCT01312428|Other|Pelvic Alignment Level (PAL)|Pelvic Alignment Level Instrument Used
3140505|NCT01312428|Other|No Pelvic Alignment Level (PAL)|No Pelvic Alignment Level Instrument Used
3140506|NCT01313416|Experimental|Single arm|Combination CT-011 and Gemcitabine
3140507|NCT01303003|Experimental|Treatment Arm 1|Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
3140508|NCT01303003|Active Comparator|Treatment Arm 2|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
3140509|NCT01302444|Active Comparator|Tadalafil|first 4 weeks are for adjusting treprostinil dose, then Tadalafil 40mg daily for 12 weeks, Group is randomly chosen from entire cohort
3140510|NCT01302444|Placebo Comparator|Placebo|first 4 weeks for adjusting treprostinil dose, then Placebo for 12 weeks
3140511|NCT01301963|Active Comparator|Arm I|Patients receive G-CSF SC QD on days 1-4.
3140512|NCT01301963|Experimental|Arm II|Patients receive G-CSF SC QD on days 1-4 and plerixafor SC QD on days 4-8.
3140513|NCT01298921|Active Comparator|Continous Flow Oxygen|
3140514|NCT01298921|Experimental|Oxygen Demand Valve|
3140515|NCT01292070|Experimental|Control-Experimental arm|Each subject will serve as their own control with the left arm receiving the control protein (Histamine prick, intradermal diluent and intradermal CAT) and right arm receiving the experimental protein (GFD).
3140516|NCT01292265|Experimental|CZP 200 mg|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
3140517|NCT01290822|Experimental|BiVP Pacing|BIVP optimize AVD, VVD, and LVPS parameters and assess the effect on cardiac output.
3182679|NCT00705640|Experimental|Arm 2B|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on day 1 and undergo surgical biopsy at replicate vaccine site on day 8 (1 week after replicate vaccine 1).
3140518|NCT01290822|Active Comparator|AAI Pacing|Traditional atrial (AAI) pacing
3140519|NCT01290718|Experimental|Single Arm|
3140520|NCT01293123|Experimental|Raltegravir|
3140521|NCT01293123|Active Comparator|Efavirenz|
3140522|NCT01294046|Experimental|Deep brain stimulation of SPG for migraine|Electrical SPG for Treatment of Migraine
3140523|NCT01280643|Experimental|Arm A|Patients receive FOLFIRI (FOLolinic acid (leucovorin) Fluorouracil (5-FU) IRInotecan (irinotecan)) chemotherapy comprising fluorouracil intravenously (IV) over 46 hours continuously, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3140524|NCT01280643|Experimental|Arm B|Patients receive FOLFOX (FOL- Folinic acid (leucovorin) F - Fluorouracil (5-FU) OX - Oxaliplatin (Eloxatin)) chemotherapy comprising fluorouracil IV over 46 hours continuously on day 1 and leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on days 1 and 15. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3140525|NCT01280643|Experimental|Arm C|Patients receive FOLFIRI chemotherapy as in Arm A and bevacizumab IV over 30-90 minutes on days 1 and 15.
3140526|NCT01280643|Experimental|Arm D|Patients receive FOLFOX chemotherapy as in Arm B and bevacizumab IV over 30-90 minutes on days 1 and 15.
3140527|NCT01280643|Experimental|Arm E|Patients receive CapeIRI (Capecitabine and Irinotecan) chemotherapy comprising capecitabine orally (PO) twice daily (BID) on days 1-14 and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3140528|NCT01280643|Experimental|Arm F|Patients receive CapeOX (capecitabine (Xeloda) and oxaliplatin (Eloxatin)) chemotherapy comprising capecitabine PO BID on days 1-14 and oxaliplatin IV over 2 hours on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 1 and 8.
3140529|NCT01280643|Experimental|ARM G|Patients receive CapeIRI chemotherapy as in Arm E and bevacizumab IV over 30-90 minutes on day 1.
3140530|NCT01280643|Experimental|Arm H|Patients receive CapeOX chemotherapy as in Arm F and bevacizumab IV over 30-90 minutes on day 1.
3140531|NCT01280643|Experimental|Arm I|Patients receive treatment as in Arm D.
3140532|NCT01281124|Experimental|Treatment (azacitidine)|Patients receive azacitidine subcutaneously on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3140533|NCT01272141|Experimental|Arm A: Lapatinib plus Everolimus|
3140534|NCT01282216|Active Comparator|Donor PCV13|Donors receive PCV13 prior to bone marrow donation.
3140535|NCT01282216|Active Comparator|Donor Havrix|Donors receive Havrix prior to bone marrow donation.
3140536|NCT01282216|Active Comparator|Recipient vaccine|Recipients receive Havrix and PCV13 post bone marrow transplant.
3140537|NCT01284491|Active Comparator|Standard of Care (SOC)|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3140538|NCT01284491|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
3140539|NCT01284504|Experimental|Celecoxib|Celecoxib, 200 mg tab
3140540|NCT01284504|Placebo Comparator|Placebo|placebo, tab
3140541|NCT01269034|Experimental|Part A|Exenatide and long acting insulin before the boost.
3140542|NCT01269034|Active Comparator|Part B|Rapid and long acting insulin before the boost
3140543|NCT01269034|Active Comparator|Part C|long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost
3140544|NCT01269034|No Intervention|Healthy controls|healthy controls without any medication before the boost.
3140545|NCT01274533|Experimental|Lenalidomide|Oral lenalidomide is initiated on Day 1 of Cycle 1 and continues once daily days 1-21 of a 28 day cycle. Subjects may continue participation in the Treatment Phase of the study for 24 months unless disease progression or drug is discontinued for safety reasons.
3140546|NCT01279616|Experimental|Hematopoietic Stem Cell Transplant|Stem cell infusion on Day 0.
3140547|NCT01276054|Experimental|SNB plus ARM or ALND (+/- SNB) plus ARM|Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping.
3140548|NCT01276054|Active Comparator|SNB or ALND (+/- SNB)|Patients undergo SNB and/or ALND using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node.
3140549|NCT01264965|Active Comparator|Acetaminophen|
3140550|NCT01264965|Active Comparator|Long Acting Oxycodone|
3140551|NCT01266824|Experimental|Proparacaine|Infants in this group will receive 1 drop of Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) into each eye prior to receiving mydriatic eye drops
3140552|NCT01266824|No Intervention|Standard of Care|Infants in this arm will not receive Proparacaine Hydrochloride Ophthalmic Solution (anesthetic eye drop) prior to mydriatic eye drops.
3140553|NCT01274429|Experimental|Open label peanut flour|Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
3140554|NCT01273064|Experimental|CTS-1027 60 mg + ribavirin + peglyated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg.
3150600|NCT00206596|Placebo Comparator|Arm 2|
3150601|NCT00206622|Active Comparator|Arm 1|
3150602|NCT00206622|Active Comparator|Arm 2|
3140555|NCT01273064|Experimental|CTS-1027 30 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 30 mg, supplied in a blinded kit containing one bottle of 30 mg tablets, and one bottle of placebo tablets (in order to maintain blind). One tablet from each of the bottles is taken twice daily, for a total daily dose of 60 mg of CTS-1027.
3140556|NCT01273064|Experimental|CTS-1027 15 mg + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027 15 mg (supplied in a blinded kit containing one bottle each of of 5 mg and 10 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 30 mg.
3140557|NCT01273064|Active Comparator|placebo + ribavirin + pegylated interferon|Standard of Care (ribavirin plus pegylated interferon) plus placebo (supplied in a blinded kit containing two bottles of placebo tablets). One tablet is taken from each of the placebo bottles twice daily, for a total daily dose of 4 tablets.
3140558|NCT01274559|Experimental|Extended-release niacin/laropiprant|ERN/LRPT 1 g (1 tablet for 4 wks) followed by ERN/LRPT 2 g (2 tablets for 8 wks); Each 1-g tablet contains 1 g of ER niacin and 20 mg of laropiprant.
3140559|NCT01274559|Placebo Comparator|Placebo|Matching 1 g Placebo (1 tablet for 4 wks) followed by 2 g placebo (2 tablets for 8 weeks)
3150603|NCT00206622|Placebo Comparator|Arm 3|
3140560|NCT01270581|Experimental|High Flow Nasal Cannula|Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7. Newborns randomized to HFNC will be started on a flow rate of 4L/min and supplemental oxygen will be provided to maintain oxygen saturations between 88-93% (experimental group). Once initiated, the gas flow rate will be titrated as needed by the attending neonatologist to ameliorate signs of respiratory distress to a maximum flow rate of 6L/min. The nasal cannula size (0.2 cm or 0.3 mm outer diameter) will determined by the caliber of the subject's nares).
3140561|NCT01270581|Active Comparator|Control Group- Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
3140562|NCT01269749|Other|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
3140563|NCT01269749|Other|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
3140564|NCT01270919|Other|BioDuct Meniscal Repair Device|BioDuct Meniscal Repair Device
3140565|NCT01262339|Active Comparator|Comparator of Hand A intervention vs Hand B|Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
3140566|NCT01267825|Experimental|CT-guided intervention|CT guided perineural injection of corticosteroid+ bupivicaine Also get typical medical care
3140567|NCT01267825|Active Comparator|Standard medical care|
3140568|NCT01264679|Experimental|Ferumoxytol|When a participant has persistent or recurrent IDA (defined as hemoglobin <12.0 grams [g]/deciliter [dL] and with either transferrin saturation <40% or ferritin <100 nanograms/milliliter), the participant will begin a 7-week treatment period. Participants will receive 2 IV injections of ferumoxytol 7.0 milligrams (mg) iron/kilogram (maximum of 510 mg/dose), the first dose administered on Day 1 and the second on Days 3 through 9 of the Treatment Period.
3140569|NCT01259284|Experimental|Atorvastatin|1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
3140570|NCT01259284|Experimental|Fish Oil Supplement|3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
3140571|NCT01259284|Placebo Comparator|Placebo|4 capsules orally every morning and 3 every evening for 5 days pre-surgery.
3150604|NCT00206635||Group 1|
3150605|NCT00206648|Experimental|Arm 1|
3150606|NCT00206648|Active Comparator|Arm 2|
3150607|NCT00206661|Experimental|Arm 1|
3140572|NCT01249157|Experimental|MRI and PEM scans|All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.
3140573|NCT01263028|Experimental|Ergocalciferol supplementation|
3140574|NCT01256281|Experimental|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
3140575|NCT01253668|Experimental|Arm 1|Patients receive oral brivanib alaninate daily in the absence of disease progression or unacceptable toxicity.
3140576|NCT01259024|Experimental|doxorubicin-eluting LC Bead|transarterial chemoembolization using doxorubicin-eluting LC Beads
3140577|NCT01251952|Experimental|Denileukin Diftitox (Ontak)|Denileukin Diftitox (Ontak) administered Post Autologous Transplantation.
3140578|NCT01251120|Experimental|1|
3140579|NCT01251120|Active Comparator|2|
3140580|NCT01248130|Active Comparator|Omega-3 Fatty Acid Treatment|
3140581|NCT01248130|Placebo Comparator|Placebo (Sugar Pill)|
3140582|NCT01243892||Cohort 1: IGHD participants|Isolated growth hormone deficient (IGHD) participants who initiated somatropin (Deoxyribonucleic acid [DNA] origin) (recombinant human growth hormone [rhGH]) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
3140583|NCT01243892||Cohort 2: ISS participants|Idiopathic short stature (ISS) participants who initiated somatropin (DNA origin) (rhGH) using the NuSpin device, will be observed for at least 2 years. The choice of initiation of NuSpin treatment and the treatment regimen will be as per treating physician's discretion, the study protocol does not enforce or specify any treatment regimen.
3140584|NCT01246011|Experimental|Heparin PF4 antibody positive -Drug (argatroban and warfarin)|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive argatroban and warfarin
3140585|NCT01246011|No Intervention|Heparin PF4 antibody positive no drug|Post-CABG heparin PF4 antibody positive with no signs or symptoms of HIT randomized to receive no medication
3140586|NCT01246011|No Intervention|Heparin PF4 antibody negative|Post-CABG heparin PF4 antibody negative with no signs or symptoms of HIT randomized to receive no medication
3140587|NCT01242020|Other|Lean Healthy Subjects|"Lean defined as (BMI ≥18 and ≤25)"
3140588|NCT01242020|Other|Obese Healthy Subjects|Obese grade I-II defined as (BMI>30 and ≤35)
3140589|NCT01244620|Experimental|Treatment A|sitaxsentan 100 mg QD for 6 days (Treatment A)
3140590|NCT01244620|Experimental|Treatment B|tadalafil 40 mg QD for 6 days
3140591|NCT01244620|Experimental|Treatment C|sitaxsentan 100 mg QD co-administered with tadalafil 40 mg QD for 6 days
3140592|NCT01244620|Experimental|Treatment D|sitaxsentan 100 mg QD co-administered with sildenafil 20 mg TID for 6 days
3140593|NCT01240304|Experimental|Gemcitabine, radiation therapy, surgery|
3140594|NCT01241279|Experimental|Crystalens AO|A silicone multi-piece accommodating intraocular lens
3140595|NCT01241279|Active Comparator|SoftPort LI61AO|A silicone multi-piece foldable aspheric intraocular lens
3140596|NCT01230788|Experimental|rituximab|study drug given
3140597|NCT01239680|Placebo Comparator|Ringer's Lactate and Placebo for Glutamine|Ringer's Lactate 1 liter once over 6 hours
3140598|NCT01239680|Experimental|Ringer's Lactate with 25 grams Glutamine|Ringer's Lactate with 25 grams Glutamine (1 liter) once over 6 hours
3140599|NCT01237613|Experimental|Artelon|This is an open, prospective study with an anticipated enrollment of 10 patients with chronic or repeat Achilles tendon rupture undergoing surgical repair augmented with Artelon® Tissue Reinforcement.
3140600|NCT01234103|Experimental|Preventing sexual health risks|The over goal is to prevent STIs, unintended pregnancies, and related behaviors including sexual risk, alcohol and other substance misuse
3140601|NCT01234103|Other|Improving nutrition, fitness and injury prevention|The goals are: (1) maintain and improve nutrition and physical fitness through healthier lifestyle and food choices; (2) reduce the risk of sports or physical training injuries and learning how to treat injuries; and (3) Learn to recognize stress and the steps you can take to reduce stress
3140602|NCT01231750|Active Comparator|0.1% Capsaicin Cream|0.1% capsaicin cream spread 8cm x 15cm on abdomen, once, 45 minutes prior to exercise
3140603|NCT01231750|Placebo Comparator|Placebo Cream|Inactive cream, 4cm spread 8cm x 15cm on the abdomen, once, 45 minutes prior to exercise
3140604|NCT01230307|Active Comparator|Vitamin D|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
3140605|NCT01230307|Placebo Comparator|Placebo|A placebo loading dose will be given followed by two placebo tablets daily for 6 months.
3140606|NCT01230489|No Intervention|Standard Care|This group will undergo the current standard of care for post operative exit sites at the involved institutions. This group will act as the control or the group to which the interventional group will be compared too.
3140607|NCT01230489|Experimental|MediHoney|This study group will have the dry 2 x 2 dressing replaced with a honey 2 x 2 dressing. Additionally all indentations in the exit site wound will be filled with honey ointment prior to the application of the dressing.
3140608|NCT01222871|Experimental|Triamcinolone|Triamcinolone soaked nasopore dressing
3140609|NCT01222871|Placebo Comparator|Control Group|Saline soaked sponge
3140610|NCT01219673|Placebo Comparator|Placebo|Placebo by mouth 2 times every day.
3140611|NCT01219673|Experimental|Armodafinil|Armodafinil 150 mg by mouth once a day.
3140612|NCT01219673|Experimental|Minocycline|Minocycline 100 mg by muth two times a day.
3140613|NCT01219673|Experimental|Bupropion|Bupropion 100 mg by mouth two times a day.
3150608|NCT00206661|Experimental|Arm 2|
3150609|NCT00206674|Experimental|Arm 1|
3140614|NCT01219673|Experimental|Armodafinil + Minocycline|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by mouth two times a day."
3140615|NCT01219673|Experimental|Armodafinil + Bupropion|"Armodafinil 150 mg by mouth once a day.~Bupropion 100 mg by mouth two times a day."
3140616|NCT01219673|Experimental|Minocycline + Bupropion|"Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
3140617|NCT01219673|Experimental|Armodafinil + Minocycline + Bupropion|"Armodafinil 150 mg by mouth once a day.~Minocycline 100 mg by muth two times a day.~Bupropion 100 mg by mouth two times a day."
3140618|NCT01223001|Active Comparator|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
3140619|NCT01223001|Placebo Comparator|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
3140620|NCT01217060|Experimental|Docetaxel + 5-FU + Radiation + Surgery|Docetaxel 20 mg/m2 given by vein (IV) once a week up to 5 1/2 weeks. Dexamethasone 10 mg IV 30 minutes prior to weekly Docetaxel. 5-FU 300 mg/m2 IV, continuously for 96 hours 5 days a week for about 5 1/2 weeks. Radiation 50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks. Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
3140621|NCT01217047|Experimental|Group A|For 3 weeks, you will need to come to the ICSCI one (1) time per week during which you will perform FES cycling for 1 hour each.
3140622|NCT01217047|Experimental|Group B|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform FES cycling for 1 hour each.
3140623|NCT01217047|Experimental|Group C|For 3 weeks, you will need to come to the ICSCI five (5) times per week during which you will perform FES cycling for 1 hour each.
3140624|NCT01217047|Experimental|Group D|For 3 weeks, you will need to come to the ICSCI three (3) times per week during which you will perform cycling without FES for 1 hour each.
3140625|NCT01206101|Experimental|Liraglutide|
3140626|NCT01206101|Placebo Comparator|Liraglutide placebo|
3140627|NCT01216631|Active Comparator|IA steroid|Intra-articular injection of steroid (80mg depomedrone)
3140628|NCT01216631|Experimental|IA infliximab|intra-articular injection of 100mg infliximab
3140629|NCT01216631|Experimental|IV infliximab|intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)
3140630|NCT01211756|Experimental|Oxytocin|20 IU of intranasal oxytocin twice per day for the first week, 40 IU of intranasal oxytocin twice per day for the following 3 weeks, one week wash out, 4 week placebo trial.
3140631|NCT01211756|Placebo Comparator|Placebo|Four week placebo trial, one week wash out, 20 IU of intranasal oxytocin twice per day for one week, 40 IU of intranasal oxytocin twice per day for 3 weeks.
3140632|NCT01209520|Experimental|Adjuvant Chemotherapy + Vidaza|
3150610|NCT00206674|Placebo Comparator|Arm 2|
3150611|NCT00206687|Experimental|Arm 1|
3150612|NCT00206687|Sham Comparator|Arm 2|
3140633|NCT01207726|Experimental|Arm I (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-5 and 8-10 and entinostat PO QD on days 3 and 10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3140634|NCT01207726|No Intervention|Arm II (standard of care)|Patients receive standard of care.
3140635|NCT01206296|Experimental|Intraperitoneal Gemcitabine|Intraperitoneal Gemcitabine
3140636|NCT01207102|Experimental|Abraxane, Carboplatin|Abraxane 100mg/m2 IV days 1, 8 and 15 of a 28 day cycle Carboplatin area under the concentration curve, (AUC)2 IV days 1,8, and 15 of a 28 day Cycle
3140637|NCT01213329|Experimental|Phase I: Alemtuzumab|During Phase I Portion: Each kidney transplant recipient received one 30mg dose (IV push)of Alemtuzmab in the operating room per Standard of Care.
3140638|NCT01202110|Experimental|Propranolol|Propranolol 1mg iv
3140639|NCT01202110|No Intervention|Control|Routine care
3140640|NCT01206439|Experimental|Nebivolol 5 or 10 mg, oral, daily|Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
3140641|NCT01204788|Experimental|Arm 1 (Prophylactic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Prophylactic White Cell Transfusion
3140642|NCT01204788|Experimental|Arm 2 (Therapeutic Arm)|Prophylactic Treatment (standard of care prophylactic antibiotics) + Therapeutic White Cell Transfusion
3140643|NCT01200602|Experimental|Arm A|Patients receive oral megestrol acetate 1-2 times daily for 4 weeks.
3140644|NCT01200602|Active Comparator|Arm B|Patients have clinical observation for weight loss and gain for 4 weeks.
3140645|NCT01198548|Experimental|Treatment (FOLXFOX, bevacizumab, cholecalciferol)|Patients receive high-dose cholecalciferol once daily. Patients also receive bevacizumab IV over 10 minutes, leucovorin calcium IV over 2 hours, oxaliplatin* IV over 2 hours, and fluorouracil IV continuously over 46 hours once a week. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *Treatment with oxaliplatin is discontinued after course 8
3140646|NCT01194908|Experimental|Arm A|Patients treated with decitabine and LBH589
3140647|NCT01194856|Active Comparator|Efavirenz 600 mg|Serving as the Control Arm - patients will maintain EFV-containing antiretroviral regimen
3140648|NCT01194856|Experimental|Arm B - Atazanavir/Ritonavir|Atazanavir 300 mg orally with Ritonavir 100 mg orally once daily for 96 wks
3140649|NCT01194427|Experimental|Vorinostat and Tamoxifen|Vorinostat and tamoxifen are taken for about 14 days prior to definitive surgery.
3140650|NCT01193556|Active Comparator|Standard of Care|Traditional electrosurgery will be used for the tonsillectomy.
3140651|NCT01193556|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the tonsillectomy.
3140652|NCT01189435|Experimental|erlotinib|This will be a single institution, single-arm, two-stage, open-label study of erlotinib in the treatment of patients with recurrent EGFR-mutant lung cancer following completion of adjuvant erlotinib or gefitinib therapy.
3140653|NCT01193530|Experimental|Bright Light Therapy|Daily Bright Light Therapy using Bright Light Litebook device for two 14 day periods.
3140654|NCT01193530|Placebo Comparator|Dim Red Light Therapy|Daily Dim Red Light Therapy (placebo) using control Red Light Litebook device for 14 days then proceed to the open label phase and receive daily bright light for 14 days.
3140655|NCT01182610|Experimental|Treatment group|"Panitumumab 9mg/kg on Days 1, 22, and 43~Paclitaxel 200mg/m2 on Days 1 and 22~Carboplatin AUC=6 on Days 1 and 22~5FU 225mg/m2/day on Days 1-15 and 22-36"
3140656|NCT01189071|Active Comparator|Darifenacin|3 days of preoperative darifenacin anticholinergic medication
3140657|NCT01189071|No Intervention|no pill|The control group will have the standard of care which is no preoperative anticholinegic medication.
3150613|NCT00206700|Experimental|Arm 1|
3150614|NCT00206713|Experimental|Arm 1|
3150615|NCT00206713|Placebo Comparator|Arm 2|
3150616|NCT00206752|Experimental|unilateral radiation therapy|definitive external beam radiation in the ipsilateral neck.
3140658|NCT01183416|Experimental|3F8 monoclonal antibody and 13-cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. The patients are post-transplant and in 1st complete/very good partial remission (CR/VGPR),89 with no evidence of NB by standard studies, but are at high risk for relapse.
3140659|NCT01184456|Experimental|GanedenBC30, GBI-30, PTA-6086|
3140660|NCT01184456|Placebo Comparator|Placebo|
3140661|NCT01183221|Experimental|Syntocinon then Placebo|24IU intranasal oxytocin, minimum of 3 weeks off, then placebo
3140662|NCT01183221|Placebo Comparator|Placebo then Syntocinon|Placebo, minimum of 3 weeks off, then 24IU intranasal oxytocin or placebo
3140663|NCT01189227|Experimental|Arm 1: Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
3140664|NCT01189227|Experimental|Arm 2: Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
3140665|NCT01190306|Experimental|CXL Treatment|Eyes randomized to the CXL treatment group with be treated with riboflavin and UV light.
3140666|NCT01190306|Active Comparator|Sham Control|Eyes in the control group will be treated with riboflavin only.
3140667|NCT01179737|Experimental|Nilotinib|Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
3140668|NCT01179737|Placebo Comparator|Placebo|Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
3140669|NCT01183468|Experimental|Part 1a(Aralast NP)-Subjects Aged 16-35 Yrs|Subjects aged 16-35 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by intravenous (IV) infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
3140670|NCT01183468|Experimental|Part 1a (Aralast NP)-Subjects 8-15 Yrs|Subjects aged 8-15 years at enrollment with new-onset type 1 diabetes mellitus (T1DM) received Aralast NP 45 mg/kg by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants underwent a minimum 3-week washout period. After the washout period, each participant proceeded to a high dose of Aralast NP 90 mg/kg by IV infusion for the next 6 weeks, for a total of 12 infusions.
3140671|NCT01183468|Experimental|Part 1b (Aralast NP)--Subjects Aged 18-35 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
3140672|NCT01183468|Experimental|Part 1b (Aralast NP)-Subjects 8-17 Yrs|Aralast NP 90 mg/kg/wk by IV infusion once a week for 6 weeks. Following the Week 6 infusion, participants undergo a minimum 3-wk washout period than then, each participant proceeds to high dose Aralast NP 180 mg/kg/wk by IV infusion for the next 6 weeks, for a total of 12 infusions.
3140673|NCT01181921|Experimental|Galantamine|
3140674|NCT01188798|Experimental|Transplant recipients receiving Methotrexate|Participants will be biologically stratified according to disease, donor, and KIR match. In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
3140675|NCT01188798|Experimental|Transplant recipients receiving Pentostatin|Participants will be biologically stratified according to disease, donor, and KIR match.between donor and host.In addition to a standard backbone of 2 GVHD prophylactics, a computer generated randomization procedure will assign participants to a third GVHD prophylactic medication (MTX or pentostatin)
3140676|NCT01174368|Experimental|Cancer macrobeads|Cancer Macrobead placement in abdominal cavity
3140677|NCT01183897|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|This phase II study of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response in of primary refractory neuroblastoma in bone marrow (i.e., incomplete response to standard treatment).
3150617|NCT00206830|No Intervention|Control-Blinded from Results|
3150618|NCT00206830|Experimental|Access to Results|
3150619|NCT00206843|Experimental|Results available|
3150620|NCT00206843|No Intervention|Results blinded|
3140678|NCT01183884|Experimental|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles.
3140679|NCT01183429|Experimental|3F8 and 13-cis-retinoic acid|This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles. Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(8), patients no longer receive high dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles.
3140680|NCT01166178|Experimental|Zoledronic Acid|Participants received zoledronic acid infusion in addition to calcium and vitamin D
3140681|NCT01166178|Placebo Comparator|Placebo|Participants received placebo to zoledronic acid infusion in addition to calcium and vitamin D
3140682|NCT01176513|Experimental|GE 148-002|
3140683|NCT01165450|Active Comparator|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
3140684|NCT01165450|Placebo Comparator|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
3140685|NCT01179399|Experimental|TAK-960|
3140686|NCT01169753|Placebo Comparator|Placebo|Patients randomized to nonintervention will take a placebo every morning for 2 weeks.
3140687|NCT01169753|Experimental|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
3140688|NCT01171534|Active Comparator|Vessel Loop fasciotomy closure|Fasciotomy closure using vessel loops and staples.
3140689|NCT01171534|Experimental|DermaClose fasciotomy closure|Fasciotomy closure via DermaClose device
3140690|NCT01169610|Experimental|Varenicline|
3140691|NCT01155388|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
3140692|NCT01155388|Active Comparator|Oral Iron|Participants will receive oral iron: 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
3140693|NCT01163084|Experimental|Arm I (leuprolide acetate, goserelin acetate, vismodegib)|Patients receive LHRH analogue comprising leuprolide acetate IM or goserelin acetate SC on day 1 and vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
3140694|NCT01163084|Active Comparator|Arm II (leuprolide acetate, goserelin acetate)|Patients receive LHRH analogue comprising leuprolide acetate or goserelin acetate as in Arm I. Treatment repeats every 28 days for up to 16 weeks in the absence of disease progression or unacceptable toxicity.
3140695|NCT01166724|Active Comparator|Sirolimus|patients will be switched from Tacrolimus to Sirolimus
3140696|NCT01166724|No Intervention|Tacrolimus|Patient will stay on Tacrolimus
3140697|NCT01155375|Experimental|Ferumoxytol|"Participants will receive 1 of the following 2 ferumoxytol dose regimens:~Four IV injections of ferumoxytol 3.5 mg Fe/kg (maximum of 255 mg/dose) administered on nonconsecutive days within a 14-day period as follows: Day 1 (dose 1), Days 3* through 10 (dose 2), Days 5 through 12 (dose 3), and Days 7 through 14 (dose 4). *Participants participating in PK sampling received the second dose on Day 4 after the 72-hour PK sample was collected.~Two IV injections of ferumoxytol 7.0 mg Fe/kg (maximum of 510 mg/dose), the first administered on Day 1 and the second on Days 3 through 9."
3140698|NCT01155375|Active Comparator|Oral Iron|Participants will receive oral iron 2.5 mg Fe/kg twice daily (maximum of 100 mg/dose) on Days 1 through 35.
3140699|NCT01162382|Experimental|Transcranial Magnetic Stimulation|Open-label transcranial magnetic stimulation
3140700|NCT01157533|Experimental|Vancomycin Loading|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
3140701|NCT01162304|Active Comparator|ER Oxycodone vs IR Oxycodone|"Extended release Oxycodone to assess pain relief adverse effects, treatment satisfaction and impact of treatment on health related quality of life.~IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every four hours"
3140702|NCT01151904|Experimental|COMBIGAN® with Latanoprost|Patients on current latanoprost monotherapy that qualify for study entry will have COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) added to the latanoprost for 12 additional weeks.
3140703|NCT01155518|Experimental|testosterone|intramuscular injections every 2 weeks
3140704|NCT01155518|Experimental|clomiphene|oral drug thrice a week
3140705|NCT01155518|Placebo Comparator|placebo for testosterone|placebo for testosterone arm
3140706|NCT01155518|Placebo Comparator|placebo for clomiphene|oral placebo for clomiphene arm
3140707|NCT01155518|No Intervention|eugonadal obese|obese men with normal testosterone level
3140708|NCT01155518|No Intervention|lean|healthy lean men (control)
3140709|NCT01150409|Experimental|hydrocortisone|Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
3140710|NCT01150409|Placebo Comparator|Normal Saline (placebo)|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
3140711|NCT01151553|Other|Patients with CHF with CRT Therapy|Patients with CHF with CRT Therapy
3140712|NCT01148056|Experimental|Short course IMRT|Patients will receive short course IMRT (Intensity Modulated Radiation Therapy) prior to surgery. Dose will be 5 Gy x 5, followed by surgery the week after
3140713|NCT01147393|Experimental|All subjects|two weekly infusions of 90Y-epratuzumab tetraxetan in combination with four weekly infusions of 200 mg/m2 veltuzumab.
3140714|NCT01147042|Active Comparator|gp91 CGD with relatively high baseline superoxide|"Patients with X-linked Chronic Granulomatous Disease (CGD) with a missense gp91phox mutation and relatively high baseline superoxide production.~IFN-gamma was the administered intervention."
3140715|NCT01147042|Active Comparator|Autosomal Recessive CGD with p47|Patients with Autosomal Recessive Chronic Granulomatous Disease (CGD) with p47 phox mutation. IFN-gamma was the administered intervention.
3140716|NCT01147536|Experimental|HSPPC-96 Vaccine|Participants will receive up to 8 administrations of HSPPC-96 25 µg intradermally over 3 months (4 weekly doses, followed by 4 bi-weekly doses [at Weeks 14, 15, 16, 17 19, 21, 23, and 25 in Part 1a and at Weeks 1-4, 6, 8, 10, 12 in Part 1b). Participants will remain untreated with HSPPC-96 for the initial 3-month period in Part 1a for immune monitoring blood draw.
3140717|NCT01139996|Experimental|Transdermal Clonidine/Oral Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of a Clonidine Transdermal system at a dose of 0.3 mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3 mg after 12 hours
3140718|NCT01139996|Placebo Comparator|Comparator|Placebo group will receive a placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final placebo tablet
3140719|NCT01142128|Active Comparator|Nexium alone|Nexium alone is given for one month to be compared to a placebo to Nexium, Viokase 16 plus Nexium and Viokase 16 plus a placebo to Nexium
3140720|NCT01142128|Placebo Comparator|Placebo to Nexium, alone|Placebo to Nexium is given instead of Nexium for one month. This will be compared to the Nexium alone, Viokase 16 plus Nexium and Viokase 16 plus placebo to Nexium
3140721|NCT01142128|Active Comparator|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month.
3140722|NCT01142128|Placebo Comparator|Viokase 16 + placebo to Nexium|Viokase 16 is given with a placebo to Nexium for one month to be compared against Viokase 16 plus Nexium, Nexium alone and Placebo to Nexium alone
3140723|NCT01131884|Active Comparator|Fosamax|Fosamax at 70 mgs q weekly by mouth for the duration of the study.
3140724|NCT01131884|Placebo Comparator|Placebo Sugar Pill|Double blind study using Fosamax versus placebo. Placebo is an inactive drug.
3140725|NCT01128114|Experimental|Quetiapine XR|Quetiapine fumarate (Seroquel XR)
3140726|NCT01126879|Experimental|Arm I|Patients receive oral genistein once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
3140727|NCT01126879|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 3 months beginning at least 1 month prior to radical prostatectomy.
3140728|NCT01136811|Experimental|Computer assisted surgery|
3140729|NCT01139294|No Intervention|standard IV therapy|control arm of the study
3140730|NCT01139294|Experimental|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hours with a maximum dose of 3 injections in 72 hours
3140731|NCT01139125|Experimental|Cystagon, Cysteamine Bitartrate|We are examining the safety and efficacy of this medication on the treatment of schizophrenia patients.
3140732|NCT01136668|Experimental|Treatment group|Bupivacine-TAP block
3140733|NCT01136668|Active Comparator|Control Group|Bupivacaine- wound infiltration
3140734|NCT01133639|Placebo Comparator|Placebo|Placebo plus standard of care
3140735|NCT01133639|Experimental|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
3140736|NCT01131455|Active Comparator|Fusion+ACP+Autograft|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus, external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with dissection through the capsule and penetration to the joint. Standard debridement of the gutters, tibia osteophyte, tibia-talor joint resection and autograft preparation will be performed in the joint. Depending on randomization of the subject, (Autologous concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and reduced.
3150621|NCT00206934|Placebo Comparator|1|
3150622|NCT00206934|Placebo Comparator|2|
3140737|NCT01131455|Active Comparator|Fusion + ACP +DBM|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). Depending on the randomization of the subject, (Autologous Concentrated Plasma)ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
3140738|NCT01131455|No Intervention|Standard-Fusion +Autograft only|Standard anatomic reduction will be adhered to- neutral alignment will be employed (5° valgus and external rotation and neutral foot dorsiflexion). The arthrodesis undertaken for all groups will be the standard arthroscopic ankle arthrodesis with portals to the ankle (anterior medial / anterior lateral), skin incision only technique with blunt dissection through the capsule and penetration to the joint. Depending on the randomization of the subject, ACP-A or ACP-DBM mixture will be added to the arthrodesis site with the joint taken through range of direct motion and then reduced.
3140739|NCT01126801|Experimental|Estradiol|
3140740|NCT01126801|Placebo Comparator|Placebo control|
3140741|NCT01123850|Active Comparator|Single ARM - Copios Bone Filler|All subjects will undergo an instrumented, pedicle screw PLF procedure. Autograft or other interbody devices identified by the surgeon to be in the best interest of the patient may be used. Enrolled patients will receive CopiOs BVF sponge soaked with bone marrow aspirate on one side and autologous bone on the other side. All patients will receive both CopiOs BVF and autologous bone. Patients will serve as self-controls in this counter-balanced study.
3140742|NCT01126957|Experimental|Ketamine|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed 0.5 mg/kg Ketamine infusion, followed by propofol to maintain sedation.
3140743|NCT01126957|Placebo Comparator|Placebo|Participants received 0.5-1.5 micrograms/kg Fentanyl, followed by placebo infusion, followed by propofol to maintain sedation.
3140744|NCT01127503|Experimental|Metyrosine|
3140745|NCT01127503|Placebo Comparator|Placebo|
3140746|NCT01122511|Experimental|700 ug dexamethasone and ranibizumab|Intravitreal injection of 700 ug dexamethasone and ranibizumab into study eye
3140747|NCT01122511|Active Comparator|ranibizumab and sham|Intravitreal injection of ranibizumab and Sham into study eye
3140748|NCT01118013|Experimental|Treatment|"Matched-unrelated donor: Patients receive antithymocyte globulin, tacrolimus, and methotrexate as in HLA-identical donor regimen. Patients also receive oral mycophenolate mofetil twice daily on days 0 to 60.~Allogeneic Stem Cell Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation on days 0 and 1. Patients then receive filgrastim subcutaneously daily beginning on day 7 and continuing until blood counts recover.~Donor Lymphocyte Infusion (DLI): After day 180 (or day 210 for patients without an HLA-identical donor), patients with stable or progressive disease and no active GVHD may receive up to 3 DLIs every 8 weeks.~Blood samples are collected at baseline and then periodically during study therapy for pharmacokinetic studies.~After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for up to 5½ years."
3140749|NCT01122381|Experimental|Arm 1-ethosuximide|"ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
3140750|NCT01122381|Placebo Comparator|Arm 2-placebo comparator|"placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed 30mg/kg/d) vs maximum tolerability"
3140751|NCT01116232|Experimental|anti-thymocyte globulin, rituximab, sirolimus, tacrolimus,|"anti-thymocyte globulin: Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter~Rituximab: The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour;~For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).~Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose."
3140752|NCT01110174|Experimental|HD PET/CT|utilization of PET/CT for diagnostic of breast cancer progression.
3150623|NCT00206947|Active Comparator|1|
3150624|NCT00206947|Placebo Comparator|2|
3150625|NCT00206960|Active Comparator|1|
3150626|NCT00206960|Active Comparator|2|
3140753|NCT01115699|Experimental|Repetitive Transcranial Magnetic Stimulation|All subjects will receive 10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for a fixed-flexible period of 5 treatments per week for up to 6 weeks.
3140754|NCT01108666|Experimental|Proton RT and Nelfinavir|
3140755|NCT01115244|Experimental|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
3140756|NCT01115244|No Intervention|Not treated|One arm of the patient will be left untreated.
3140757|NCT01108523|Experimental|HP828-101|HP828-101 Experimental Formulation
3140758|NCT01106534|Placebo Comparator|12 month DAPT arm|placebo + aspirin
3140759|NCT01106534|Active Comparator|30 month DAPT arm|clopidogrel + aspirin OR prasugrel + aspirin
3140760|NCT01104116|Experimental|PET/CT imaging|Surgical patients will undergo [18F]-FDG PET/CT imaging
3140761|NCT01100658|Active Comparator|Methylphenidate|Administered 1 capsule each day for 1 week, .3 mg/kg dose.
3140762|NCT01100658|Placebo Comparator|Placebo|Administered 1 capsule each day for 1 week.
3140763|NCT01103180|Experimental|Escitalopram|10-20 mg of escitalopram for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
3140764|NCT01103180|Placebo Comparator|Placebo|Inert placebo (sugar pill) taken daily for eight weeks
3140765|NCT01090141|Active Comparator|Subjects recieving 100 mg of Micafungin|
3140766|NCT01090141|Active Comparator|Subjects recieving 300 mg of Micafungin|
3140767|NCT01102140|Active Comparator|POMx|15 subjects will received 1000 mg of oral POMx for 12 weeks.
3140768|NCT01102140|Placebo Comparator|Control- sugar Pill|15 subjects will receive a matching sugar pill for 12 weeks.
3140769|NCT01095250|Experimental|AIN457 300mg s.c every 2 weeks|AIN457 300 mg s.c. at baseline, Week 1 and Week 2, then every 2 weeks.
3140770|NCT01095250|Experimental|AIN457 300mg s.c. every 4 weeks|AIN457 300 mg s.c. at baseline and Week 2, then every 4 weeks.
3140771|NCT01095250|Experimental|AIN457 150mg s.c every 4 weeks|AIN457 150 mg s.c. at baseline and Week 2, then every 4 weeks
3140772|NCT01095250|Placebo Comparator|Placebo s.c every 2 weeks|Placebo s.c at baseline, Week 1 and Week 2, then every 2 weeks
3140773|NCT01094561|Experimental|Synthetic Human Secretin|Single arm (open label).
3140774|NCT01093846|Experimental|AIN457 300 mg every 2 weeks|
3140775|NCT01093846|Experimental|AIN457 300 mg monthly|
3140776|NCT01093846|Placebo Comparator|Placebo|
3140777|NCT01078844|Placebo Comparator|Placebo|Treatment as usual plus placebo
3140778|NCT01078844|Active Comparator|memantine|Treatment as usual plus memantine
3140779|NCT01081886|Experimental|PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
3140780|NCT01081886|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3140781|NCT01085643|Active Comparator|Lubiprostone|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
3150627|NCT00206986|Experimental|1|
3150628|NCT00206986|Experimental|2|
3150629|NCT00206999|Experimental|1|
3150630|NCT00207051|Experimental|1|
3150631|NCT00207064|Experimental|1|
3140782|NCT01085643|Placebo Comparator|Placebo|Same patients are included in both the Lubiprostone arm and the Placebo arm. The reason why the same patients are assigned to two arms is because an effect comparison is done after taking the placebo and later after taking the lubiprostone.
3140783|NCT01083472|Active Comparator|Strattice(TM) TM repair|Strattice(TM) TM will be placed in the intraperitoneal or retrorectus position to support the repair of abdominal wall defect
3140784|NCT01083472|Active Comparator|Standard of Care repair|Abdominal wall defect will be repaired using current standard of care techniques of either suture alone or suture with absorbable surgical mesh
3140785|NCT01080768|Experimental|Aliskiren/amlodipine + Placebo to amlodipine|"During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
3140786|NCT01080768|Active Comparator|Amlodipine + Placebo to aliskiren/amlodipine|"During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day."
3140787|NCT01079598|Other|Treatment|RF ablation with ClosureRFS Stylet
3140788|NCT01074502|Experimental|apremilast|apremilast 20 mgs twice a day for 12 weeks
3140789|NCT01074437|Other|Group A: Corticosteroid with Placebo|Group A will receive oral, liquid Prednisolone, which is the standard corticosteroid that we use here at Seattle Children's, and oral liquid placebo. The dose of prednisolone that Group A will receive will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. This is a standard dose for IH treatment. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone. This treatment will be given for two months, as is our standard practice.
3140790|NCT01074437|Other|Group B: Corticosteroid with Propranolol|Group B will receive oral liquid prednisolone, and oral propranolol. As in Group A, the dose of prednisolone will be 1-2mg/kg/day for 7 days and then the dose will be slowly reduced and then stopped after 3 weeks. Oral liquid propranolol will be dosed at 2 mg/kg/day, following initiation in the Cardiology Clinic. Gastric prophylaxis (Zantac) will be given to help prevent any stomach problems associated with prednisolone.
3140791|NCT01069861|Experimental|one|
3140792|NCT01072526|Active Comparator|Intervention|Subjects will receive Euphrasia-based homeopathic therapy (Artificial Tears) in combination with cyclosporin solution (Restasis) .
3140793|NCT01072526|Placebo Comparator|Control|Subjects will receive placebo in combination with cyclosporin solution (Restasis) .
3140794|NCT01071993|Active Comparator|atorvastatin|
3140795|NCT01071993|Placebo Comparator|placebo|
3140796|NCT01065051|Experimental|Riociguat (Adempas, BAY63-2521)|Participants received a single oral dose of 1 mg riociguat.
3140797|NCT01065051|Placebo Comparator|Placebo|Participants received a single oral dose of 1 mg placebo.
3140798|NCT01069120|Active Comparator|50 mg Proellex®|2, 25 mg capsules
3140799|NCT01069120|Active Comparator|25 mg Proellex®|1, 25 mg capsule
3140800|NCT01066637|Experimental|Dosimetry Group|To determine its potential for use in humans, we measured 18F-NOS myocardial activity in patients after orthotopic heart transplantation (OHT) (3 women and 9 men) and normal healthy volunteers (2 women and 2 men), and correlated it with pathologic allograft rejection, tissue iNOS levels, and calculated human radiation dosimetry.
3140801|NCT01066637|Experimental|Kinetic Analysis Group|Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
3150632|NCT00207077|Experimental|A|
3140802|NCT01058642|Experimental|ADL5747|ADL5747 150 milligrams (mg) administered orally as 1 ADL5747 150-mg capsule and 1 placebo capsule twice daily (BID) for 14 days during 1 of 2 Treatment Periods.
3140803|NCT01058642|Placebo Comparator|Placebo|"Placebo: two placebo capsules administered orally BID for 14 days during 1 of 2 Treatment Periods.~Participants were also administered placebo orally BID during a 14-day washout period that took place between Treatment Period 1 and Treatment Period 2."
3140804|NCT01058642|Active Comparator|Pregabalin|Pregabalin administered orally as a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for the first 3 days, increased to a dose of 1 pregabalin 150-mg capsule and 1 placebo capsule BID for the last 11 days of 1 of 2 fourteen-day Treatment Periods, followed by a dose of 1 pregabalin 75-mg capsule and 1 placebo capsule BID for 3 days as a taper period.
3140805|NCT01065818|Experimental|Fluoro-L-Thymidine|Injection pre-Neoadjuvant Therapy (CRT, CT, or RT) and post-3 weeks Neoadjuvant Therapy (CRT, CT, RT)(3 weeks from the start of Neoadjuvant Therapy) prior to surgery.
3140806|NCT01051921|Experimental|CTS-1027, Peg IFN, Ribavirin|"Study drug (CTS-1027) plus Standard of Care treatment (pegylated interferon and ribavirin).~CTS-1027, 15 mg taken twice daily. Pegylated interferon, 180 μg injected once a week. Ribavirin, 1000 mg or 1200 mg daily (depending on patient weight), taken in two divided doses."
3140807|NCT01048125|Experimental|Study group|Subjects with documented stress cardiomyopathy who would serve as the study group. Sympathetic Nerve Activity; Mental StrCold Pressor Testess Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
3140808|NCT01048125|Active Comparator|Control|Control subjects will be age and sex matched otherwise healthy people with no prior cardiac disease or other severe medical conditions. Sympathetic Nerve Activity; Mental Stress Test (Color Word Test); The Modified Oxford Technique for Baroreflex Sensitivity; Cold Pressor Test; Echocardiographic evaluation
3140809|NCT01056315|Experimental|A GRT3983Y|Participants randomly assigned to receive GRT3983Y.
3140810|NCT01056315|Placebo Comparator|B Placebo|Participants randomly assigned to placebo.
3140811|NCT01058369|Experimental|Deferasirox|
3140812|NCT01048723|Experimental|RAD001 Administration|RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.
3140813|NCT01053221|Experimental|MPA monotherapy|Subjects will discontinue calcineurin inhibitor (cyclosporine or tacrolimus) and remain on MPA (mycophenolate mofetil or mycophenolate sodium) monotherapy
3140814|NCT01053221|Active Comparator|Control: MPA and CNI|Subjects will continue with their current immunosuppressive regimen of MPA (mycophenolate mofetil or mycophenolate sodium) and calcineurin inhibitor (cyclosporine or tacrolimus)
3140815|NCT01038752|Experimental|Suramin|This group will receive the combination of non-cytotoxic suramin with docetaxel and carboplatin.
3140816|NCT01038752|Placebo Comparator|Standard of care|This group will receive placebo with docetaxel and carboplatin.
3140817|NCT01050218|Other|DVS SR Open Label|Daily dose of 100mg or 200mg at the investigators discretion. Subjects already randomized at a dose of 400mg may continue at that dose level.
3140818|NCT01045694|Experimental|Botulinum Toxin Type A|Arm investigates the efficacy of Botulinum Toxin A injection for the treatment of basal thumb joint arthritis
3140819|NCT01045694|Active Comparator|Steroid - Triamcinolone Acetonide|Arm uses the standard of care - Steroid injection - as an active comparator to the experimental injection of Botulinum Toxin A for the treatment of basal thumb joint arthritis
3140820|NCT01045694|Placebo Comparator|Lidocaine|Arm uses plain lidocaine injection to serve as a baseline for evaluating the efficacy of Botulinum toxin as compared to steroid injection for the treatment of basal thumb joint arthritis.
3140821|NCT01035944|Experimental|HemCon Operating Room|The HemCon dressing is the intervention for the HemCon Operating Room arm. The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3150633|NCT00207103|Experimental|1|
3140822|NCT01035944|Active Comparator|Control Operating Room|The first sub-study will evaluate the use of HemCon dressings in the operating room setting. 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3140823|NCT01035944|Experimental|HemCon Bedside|The intervention for the HemCon Beside arm is the HemCon Dressing. The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3140824|NCT01035944|Active Comparator|Control Bedside.|The other sub-study will evaluate the use of HemCon dressings compared to control dressings in bedside debridement. In this sub-study, 20 patients will be treated with HemCon dressings following a debridement, and 20 patients will be treated with gauze dressings following a debridement.
3140825|NCT01031628|Active Comparator|Arm A|Patients with blood level less than 1100 will continue imatinib 400 mg daily
3140826|NCT01031628|Active Comparator|Arm B|Patients with blood level less than 1100 dose adjust imatinib mesylate to goal blood level ≥1100 ng/mL
3140827|NCT01031628|Active Comparator|Arm C|Patients with blood level ≥1100 will continue imatinib 400 mg daily
3140828|NCT01031628|Active Comparator|Arm D|Patients with tumors that harbor exon 9 mutations will continue imatinib mesylate at 400 mg or dose escalate up to 800 mg daily
3140829|NCT01030757|Experimental|Tomotherapy|Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.
3140830|NCT01035073|Experimental|Duloxetine|
3140831|NCT01031550|Active Comparator|standard anesthetic management|standard anesthetic management with propofol 100-150mcg/kg/min
3150634|NCT00207103|Experimental|2|
3150635|NCT00207103|Experimental|3|
3150636|NCT00207103|Experimental|4|
3150637|NCT00207103|Experimental|5|
3150638|NCT00207103|Experimental|6|
3150639|NCT00207116|Experimental|A|
3150640|NCT00207129|Experimental|A|
3150641|NCT00207129|Experimental|B|
3150642|NCT00207155|Experimental|A|
3150643|NCT00207194|Active Comparator|Automated Telephone Program|The intervention was a totally automated, computer-based, interactive telephone counseling system called Telephone- Linked-Care, designed to monitor, educate, and counsel African-American adults with hypertension and to provide summary data regularly to the patient's primary care provider.
3140832|NCT01031550|Experimental|preconditioning with 2 MAC isoflurane group|After induction, anesthesia will be maintained with 1MAC (minimum alveolar concentration) of Isoflurane according to age and end-expiratory concentration. Thirty minutes before the anticipated inflow occlusion and commencement of liver transaction, Isoflurane concentration will be gradually increased to 2 MAC over a period of 5 minutes (induction) and maintained at 2 MAC for 10 minutes (preconditioning). Then the concentration of Isoflurane will be decreased to 1 MAC during next 15 minutes (washout).
3140833|NCT01030198|Experimental|Fresh surgical scars|Treatment of scars
3140834|NCT01030198|Experimental|Mature scars|Treatment of scars
3140835|NCT01028300|Other|ProDisc L|
3140836|NCT01025271|Other|open label|patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin
3140837|NCT01022398|Experimental|Vitamin D|Subjects will receive Vitamin D supplementation 10,000 international units of cholecalciferol (vitamin D3) by mouth weekly
3140838|NCT01022398|Placebo Comparator|Placebo|Subjects will receive placebo (an exact replica of the vitamin D capsule that does not contain any medically active substance) by mouth weekly
3140839|NCT01019980|Experimental|Diclofenac potassium|
3140840|NCT01019980|Active Comparator|Acetaminophen|
3140841|NCT01025492|Active Comparator|Trilipix|Trilipix (fenofibric acid) 135 mg tablet orally, once daily for 12 weeks
3140842|NCT01025492|Placebo Comparator|Placebo|Matching placebo tablet orally, once daily for 12 weeks
3140843|NCT01017263|Active Comparator|Open label Vyvanse|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
3140844|NCT01020903|Active Comparator|Aprepitant|
3140845|NCT01020903|Placebo Comparator|Placebo|
3140846|NCT01023620|Experimental|Pioglitazone|10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
3140847|NCT01023620|Sham Comparator|Observation/Comparison|10 male patients with lipodystrophy not taking daily Pioglitazone
3140848|NCT01018810|Experimental|180 mg LY2525623|
3140849|NCT01018810|Placebo Comparator|Intravenous Placebo|
3140850|NCT01018810|Placebo Comparator|Subcutaneous Placebo|
3140851|NCT01018810|Experimental|3 mg LY2525623|
3140852|NCT01018810|Experimental|10 mg LY2525623|
3140853|NCT01018810|Experimental|30 mg LY2525623|
3140854|NCT01018810|Experimental|90 mg LY2525623|
3140855|NCT01016561|Experimental|Arm I|Patients undergo external beam radiotherapy (3-dimensional conformal OR intensity-modulated) and 4-6 insertions of MRI-guided intracavitary brachytherapy over 8 weeks. Patients also receive cisplatin IV over 30-60 minutes for 5-6 weeks during radiotherapy.
3140856|NCT01016847|Active Comparator|leukotriene receptor antagonist (LTRA) montelukast|Montelukast (LTRA) administered with moderate dose of inhaled steroid
3140857|NCT01016847|Placebo Comparator|Sugar Pill|High dose of inhaled steroid administered with sugar pill
3140858|NCT01014767|Experimental|Standard Arm (1)|Alternating chemotherapy cycles with etoposide 100 mg/m2 over 1 hour on days 1-5, carboplatin 350 mg/m2 over 2 hours on day 2 and 3, vincristine 1.5 mg/m2 on day 5 alternating with: etoposide 100 mg/m2 over 1 hour on days 1-5, cyclophosphamide 1 g/m2 over 1 hour on day 2 and 3, vincristine 1.5 mg/m2 on day 5. Six blocks are given in 4 week intervals (day1 to day1). Radiation is given between the second and the third cycle only to a small subgroup of patients defined by age histology staging and response to the first to cycles of chemotherapy.
3140859|NCT01014767|Experimental|Doxorubicin/cisplatin arm (2)|Doxorubicin 25 mg/m²/day over 12 hrs on days 1-3, Dactinomycin 45 µg/kg/day (max. 2 mg), i.v. on day 1, and Cisplatin 70 mg/m²/d over 6 hrs on day 4, and Vincristine 1.5 mg/m²/day (max. 2 mg), i.v. on days 8, 15. An identical second cycle is started on day 28 if the side effects allow it. The further treatment is identical to the standard arm with four more cycles of chemotherapy following radiation in some of the patients in all treatment arms.
3140860|NCT01014767|Experimental|Methotrexate Arm (3)|Methotrexate 5g/m^2 over 24 hours with leucovorin rescue at hour 42 given three times on days 1 15 and 29. The further treatment is identical in all four treatment arms.
3150644|NCT00207194|Placebo Comparator|Health Behavior Education|The comparator group received health education relating to the management of hypertension. Members of this group also received standard primary medical care.
3140861|NCT01014767|Experimental|Temozolomide Irinotecan arm (4)|Temozolomide is given at 150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day x 5 days as one hour infusions. Two of these cycles are followed by the common radiation - four cycle chemotherapy protocol.
3140862|NCT01013701|Active Comparator|Fluticasone Furoate|nasal steroid
3140863|NCT01013701|Placebo Comparator|Placebo|nasal spray vehicle without drug
3140864|NCT01012414|Experimental|oral paricalcitol 2 mcg daily|oral paricalcitol 2 mcg daily
2408340|NCT03515603|Active Comparator|microsurgical technique|
3140865|NCT01012414|Placebo Comparator|Placebo|one oral placebo drug daily
3140866|NCT01011634|Active Comparator|Moderate sedation|
3140867|NCT01011634|Active Comparator|Oral medication|
3140868|NCT01009931|Experimental|TPA + Dexamethasone and CMT|12-O-tetradecanoylphorbol-13-acetate (TPA) plus Dexamethasone & Choline magnesium trisalicylate (Trilisate)
3140869|NCT01001390|Other|Group One|Group one will take a six minute walk test with AFO device, and after a rest of fifteen minutes, they will take another six minute walk test without AFO, with similar speed to the previous test.
3150645|NCT00207220||3|subjects with heart failure and normal ejection fraction non-diabetic hypertensive controls hypertensive diabetic controls normotensive controls
3140870|NCT01001390|Other|Group Two|Group two will take a six minute walk test without AFO device, and after a rest of fifteen minutes, they will take another six minute walk test with AFO, with similar speed to the previous test.
3140871|NCT01006018|Experimental|Sitagliptin + Pioglitazone PLACEBO|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone PLACEBO daily by mouth"
3140872|NCT01006018|Experimental|Sitagliptin + Pioglitazone|"Sitagliptin (DPP-IV inhibitor) 100 mg daily by mouth~+ pioglitazone (TZD) 15 mg daily by mouth"
3140873|NCT01006018|Placebo Comparator|PLACEBO|"Sitagliptin (DPP-IV inhibitor) PLACEBO daily by mouth~+ pioglitazone (TZD) PLACEBO daily by mouth"
3140874|NCT01004510|Experimental|Zoledronic Acid|Zometa administered as a 15 minute IV infusion of either 4 mg, 3.5mg, 3.3 mg or 3.0 mg every 4 weeks based on the patient's baseline calculated creatinine clearance(CrCl)using the Cockcroft-Gault formula.
3140875|NCT01005914|Experimental|Group 1|"Drug:cyclophosphamide Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3~Drug:cytarabine Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4~Drug:dexamethasone Day 1-4; 11-14: 40 mg daily~Drug:doxorubicin hydrochloride Day 4: 50 mg/m2 IV over 2 hours~Drug:imatinib mesylate 600 mg/day~Drug:methotrexate Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion~Drug: methylprednisolone Day 1-3: 50mg IV BID~Drug: pegaspargase Day 3/Day4: 2,500 IU/ m2 IV~Drug: vincristine sulfate Day 4 & 11: 2 mg IV"
3140876|NCT00996333|Experimental|Gemzar, Taxotere, Xeloda|"Gemcitabine, Docetaxel, Capecitabine:~Gemzar intravenously on Day 4 and 11 Taxotere intravenously on Day 4 and 11 Xeloda tablet taken orally every day for 14 days"
3140877|NCT00998738|Experimental|Arm I (calcium gluconate, magnesium sulfate)|Patients receive calcium gluconate and magnesium sulfate IV over 30 minutes immediately before and after each ixabepilone administration.
3140878|NCT00998738|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV over 30 minutes immediately before and after each ixabepilone administration.
3140879|NCT00996502|Experimental|Combination regimen|"Bevacizumab, Erlotinib, Docetaxel, Prednisone (dose escalation)~Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle, 15mg/kg of Bevacizumab every 3 weeks, 200 mg of Erlotinib PO daily days 2-16, 5 mg of Prednisone PO bid"
3140880|NCT00997386|Experimental|busulfan, and melphalan, and alemtuzumab|Three drug regimen using busulfan, and melphalan, and alemtuzumab.
3140881|NCT00985738|Experimental|Dutasteride|The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
3140882|NCT00985738|Placebo Comparator|Placebo|The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
3140883|NCT00986999|Experimental|rosuvastatin|rosuvastatin 10 mg qd increased to 20 mg qd as tolerated
3140884|NCT00989937|Experimental|Group 1|20 IU BID for the first week, 40 IU BID for the following two weeks, one week washout, 3 week placebo trial
3140885|NCT00989937|Placebo Comparator|Group 2|Three week placebo trial, one week washout, 20 IU BID for the fifth week, 40 IU BID for the following two weeks
3140886|NCT00986947|Experimental|IvIg with Rituximab|
3140887|NCT00982995|Experimental|Palonosetron|Palonosetron 0.25 mg I.V. bolus
3140888|NCT00984490|Experimental|Metformin|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
3140889|NCT00986310|Active Comparator|fluoxetine|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization bringing the total dose of fluoxetine to 40 mg/day in patients randomized to receive this medication. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
3140890|NCT00986310|Placebo Comparator|Placebo|Patients will be randomized to receive either 20 mg/day of fluoxetine (one pill) or placebo (one pill), to be started one week prior to the scheduled hospital admission date. The dose will be increased to two pills per day on day 1 of hospitalization. On the day of discharge from the hospital, the study medication will be reduced to 1 pill per day and the patient will be instructed to stop the medication one week following discharge.
3140891|NCT00978874|Experimental|All subjects|
3140892|NCT00983645|Active Comparator|Neoral|Neoral is a pill indicated for the prophylaxis of organ rejection in kidney transplants
3140893|NCT00983645|Active Comparator|Prograf|Prograf is a medication used for the prophylaxis of rejection in allogeneic kidney transplants and may be used concomitantly with adrenal corticosteroids.
3140894|NCT00979147|Experimental|Modular Metal Tibial Baseplate|Patients who were randomized to receive the modular polished tibial baseplate/XLK TKA
3140895|NCT00979147|Active Comparator|All Polyethylene Tibial Baseplate|Patients who were randomized to receive the nonmodular APT/GVF TKA design.
3140896|NCT00970606|Placebo Comparator|Placebo tablet|Placebo
3140897|NCT00970606|Experimental|Rosuvastatin (crestor)|Experimental arm
3140898|NCT00979550|Experimental|Aldara cream|Imiquimod (Aldara cream) will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
3140899|NCT00979550|Placebo Comparator|non-medicated petroleum cream|Non-medicated petroleum cream will be applied nightly for four weeks after standard of care laser treatment for port wine stain.
3140900|NCT00966992|No Intervention|Arm 1 (No Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. All interventions on this arm are standard of care.
3140901|NCT00966992|Experimental|Arm 2 (Zometa)|Women will complete their standard chemoradiation treatment protocol and end of treatment PET scan at about 3 months from completion of radiation. Women randomized to zoledronic acid will receive 4 mg intravenously (IV) with their first dose chemotherapy and 3, 6 and 9 months after completion of radiation (total of 4 doses) along with scheduled follow-up dual-energy X-ray absorptiometry (DEXA) and biomarker studies.
3140902|NCT00981370|Other|Single Arm study|Single Arm study, all subjects to receive study medication, deferasirox (Exjade).
3140903|NCT00975611|Active Comparator|Amantadine 100mg BID|Subjects take amantadine 100mg tablets twice per day (BID)
3140904|NCT00975611|Active Comparator|Amantadine, 200mg BID|Subjects take amantadine 200mg tablets twice per day (BID)
3140905|NCT00975611|Placebo Comparator|Amantadine, placebo BID|Subjects take placebo tablets twice per day (BID)
3140906|NCT00978419|Active Comparator|Rosuvastatin|Rosuvastatin
3140907|NCT00978419|Placebo Comparator|Placebo|Placebo
3140908|NCT00973856|Experimental|PURELL Left Hand/ Placebo Right Hand|"One product will be assigned to each hand to minimize treatment confusion for the participants.~PURELL VF481 Left Hand/ Placebo Right Hand"
3150646|NCT00207233|Active Comparator|1|Will receive MCT study oil to supplement into liquid meal replacements.
3150647|NCT00207233|Placebo Comparator|2|Will receive LCT oil to supplement into their liquid meal replacements.
3140909|NCT00973856|Placebo Comparator|Placebo Solution Left Hand/ PURELL Right hand|"One (1) product will be assigned to each hand to minimize treatment confusion for the participants PURELL VF481 Right Hand/ Placebo Left Hand~One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed"
3140910|NCT00979810|Experimental|18F-FLT PET scan|This is a pilot study intended to collect preliminary data on 15 patients diagnosed with untreated high-grade glioma who are scheduled to undergo surgical resection.
3140911|NCT00974922|Active Comparator|Phase I: Aliskiren|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Aliskiren 150 mg to 300 mg once daily for 6 weeks
3140912|NCT00974922|Active Comparator|Phase I: Cholecalciferol|Two weeks of single-blind placebo, followed by randomization in a double-blind fashion to Cholecalciferol (3000 I.U.) once daily for 6 weeks
3140913|NCT00974922|Active Comparator|Phase II: Aliskiren and Vitamin D3|Aliskiren 150-300 mg orally once daily and Cholecalciferol 3000 I.U. in combination once daily for 6 weeks
3140914|NCT00976339|Experimental|Cholecalciferol 20,000 IU|Participants will receive Cholecalciferol 20,000 IU (2 capsules) weekly for one year.
3140915|NCT00976339|Experimental|Cholecalciferol 30,000 IU|Participants will receive Cholecalciferol 30,000 IU (3 capsules) weekly for one year.
3140916|NCT00965146|Experimental|Scorpio® CR Total Knee System|Scorpio® CR Total Knee System Study Device
3140917|NCT00972023|Experimental|DHEA, surgical resection|Day-14 (approx. 2 wks prior to surgery): begin a 2 week course of DHEA; Day-7 (approx. 1 wk after starting treatment): answer question about pill diary; Day 0 (approx. 2 wks after starting treatment, within 48 hours prior to surgery;
3140918|NCT00970736||1|20 healthy participants between 60 and 80 years of age. Ten men and 10 women.
3140919|NCT00957827|Experimental|keflex|keflex 500mg twice a day for five days
3140920|NCT00957827|Placebo Comparator|placebo|placebo 500mg twice a day for five days
3140921|NCT00953329|Experimental|Alefacept 15 mg IM qweek|Alefacept will be given to subjects with plaque psoriasis who have failed treatment with Fnbrel.
3140922|NCT00965055|Placebo Comparator|Atorvastatin|
3140923|NCT00965055|Experimental|Atorvastatin/Ezetimibe|
3140924|NCT00962429|Active Comparator|Lipoic acid|alpha lipoic acid
3140925|NCT00962429|Placebo Comparator|Placebo|sugar pill
3140926|NCT00958893|Experimental|25 mg Proellex|25 mg Proellex daily
3140927|NCT00966654|Placebo Comparator|Saline|Saline
3140928|NCT00966654|Active Comparator|GLP-1|GLP-1 (7-36) amide
3140929|NCT00960154|Experimental|PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
3140930|NCT00960154|Active Comparator|SOC|The SOC consists of scalpel for the skin incision and traditional electrosurgery for the entirety of the subcutaneous dissection.
3140931|NCT00960752|Active Comparator|Group 1: gp100 and MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3140932|NCT00960752|Active Comparator|Group 2: gp100 and MAGE-3|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3140933|NCT00960752|Active Comparator|Group 3-Metastatic Melanoma: gp100 + MAGE-3 + R848|"1 ml of gp100 peptide vaccine and 1 ml of MAGE-3 peptide vaccine daily for 8 weeks with R848 Gel applied to gp100 injection site immediately. Injections given intradermally and subcutaneously at 2 separate sites in separate extremities. Half of each dose given one way, and half given the other way. Vaccines given on the same day. Participant receives a total of 4 injections each week.~After 8 weeks, if participant has melanoma lesions, R848 applied to half of the lesions on body for 16 weeks."
3140934|NCT00958347|Other|Omnifit HA Hip Stem|Participants underwent total hip replacement surgery using the Omnifit HA Hip Stem.
3140936|NCT00954187|Experimental|Gabapentin|Neurontin
3140937|NCT00954187|Experimental|Pregabalin|Lyrica
3140938|NCT00953615|Experimental|Thalidomide|Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.
3140939|NCT00947284|Experimental|Women|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm.
3140940|NCT00947284|Experimental|Men|Both arms of this study will receive identical interventions. The only difference will be the sex of the participants in each study arm
3140941|NCT00957034|Placebo Comparator|placebo|placebo patch
3140942|NCT00957034|Experimental|300 µg/day testosterone|300 micrograms/day transdermal testosterone patch
3140943|NCT00957034|Experimental|450 µg/day testosterone|450 micrograms/day transdermal testosterone patch
3140944|NCT00949988|Active Comparator|Dasatinib - 100 mg (Phase I)|Dasatinib - 100 mg (Phase I)
3140945|NCT00949988|Active Comparator|Dasatinib - 70 mg (Phase I)|Dasatinib - 70 mg (Phase I)
3140946|NCT00948194|No Intervention|No nitric oxide|This arm will not receive nitric oxide, but will receive other standard inhaled anesthetics
3140947|NCT00948194|Experimental|Nitric Oxide|Will receive Nitric oxide and other standard inhaled anesthetics
3140948|NCT00946985|Experimental|001|paliperidone palmitate 50 75 100 or 150 mg eq. monthly injection for 2 years
3140949|NCT00946985|Active Comparator|002|oral risperidone 2 4 6 or 8 mg tabs once daily for two years
2408341|NCT03515603|Active Comparator|endoscopic technique|
3140950|NCT00950183|Other|Foot and Ankle Surgery|Please note that the study was terminated prior to randomization of patients.
3140951|NCT00950690||Study Drug - Xalatan 0.005% eye drops|
3140952|NCT00944229|Active Comparator|1 Drug Treatment - LOVAZA|Drug Treatment - LOVAZA 4 gm q24 for 8 weeks
3140953|NCT00944229|Placebo Comparator|2 placebo|Placebo 4 capsules q24 for 8 weeks
3140954|NCT00941928|Experimental|Haploidentical NK cells + Epratuzumab|Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
3140955|NCT00949403|Experimental|Obese Females (pre-bariatric surgery)|Twenty obese females (18-45 years of age, BMI > or equal to 45) who are scheduled to undergo bariatric surgery at Barnes-Jewish Hospital will be screened for enrollment over 2 years. They will be imaged with PET/CT and radiopharmaceuticals C-11 Acetate and C-11 Palmitate will be injected.
3140956|NCT00947791|Experimental|Ketamine/Midazolam|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to ketamine-midazolam. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
3140957|NCT00947791|Experimental|Midazolam/Ketamine|Patients receive both treatment conditions (ketamine and midazolam) in a single arm, crossover design. Patients are randomized to midazolam-ketamine. Each treatment occurs as a single intravenous infusion on one treatment day. The two treatment conditions occur 2 weeks apart.
3140958|NCT00947011|Placebo Comparator|Placebo|
3140959|NCT00947011|Active Comparator|Januvia|
3140960|NCT00943605|Active Comparator|Standard of Care|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
3140961|NCT00943605|Experimental|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
3140962|NCT00942409|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
3140963|NCT00936585|Other|Immunologic Monitoring|Blood draws and colonoscopy performed on patients enrolled in both intervention arms of the main study
3150648|NCT00207259|No Intervention|Control|Standard weekly treatments with radiation oncologist and nurse. All control patients offered intervention at end of 8-week course of radiotherapy.
3140964|NCT00936598|Experimental|zolpidem|Participants randomized to the zolpidem (intervention) group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
3140965|NCT00936598|Placebo Comparator|sugar pill|Participants randomized to the sugar pill (control) group will receive placebo. For the purposes of this double-blind trial, placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute. During their presurgery visit (visit 1), participants will be provided with their capsule and instructed to take it by mouth immediately before bedtime the night before surgery.
3140966|NCT00920309|Experimental|Rapamycin|"Drug: Rapamycin~Other Names:~sirolimus The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml."
3140967|NCT00920309|Placebo Comparator|Standard of Care-Placebo|Standard of Care
3140968|NCT00935649|Experimental|Randomized great toe|Subjects with both great toes infected. Right/left randomized to treatment / no treatment
3140969|NCT00935649|No Intervention|Untreated Toe|
3140970|NCT00934791|Active Comparator|Control Group|Tacrolimus, mycophenolate mofetil, and prednisone
3140971|NCT00934791|Active Comparator|Sirolimus Group|Sirolimus, mycophenolate mofetil, and prednisone
3140972|NCT00932152|Active Comparator|Arm B, Group 1|Best supportive care only: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support PRN
3140973|NCT00932152|Active Comparator|Arm B, Group 2|Best supportive care and Bevacizumab 15mg/kg every 21 days
3140974|NCT00932152|Experimental|Arm A, Group 1|Fulvestrant and anastrozole only
3140975|NCT00932152|Experimental|Arm A, Group 2|Fulvestrant, anastrozole and Bevacizumab
3140976|NCT00928499|Other|Interstim - continuous|Continuous stimulation
3140977|NCT00928499|Other|Interstim - cyclic|Cyclic stimulation
3140978|NCT00924807|Experimental|Androgen Depr, Radiotherapy, Sorafenib|Everyone will receive Leuprolide acetate, Bicalutamide,Sorafenib and radiotherapy.
3140979|NCT00930787|Experimental|Strattice Reconstructive Tissue Matrix|Use of Strattice Reconstructive Tissue Matrix to support hernia repair
3140980|NCT00930787|Active Comparator|Proceed Surgical Mesh|Use of Proceed Surgical Mesh to support hernia repair
3140981|NCT00929474|Experimental|QuickOpt|
3140982|NCT00929474|Active Comparator|Control|
3140983|NCT00925548|Experimental|Investigational Arm|"Investigational Arm:~Pretreatment (Single Dose): 300 milligrams per square meter (mg/m^2) up to a maximum dose of 600 mg of intravenous cyclophosphamide~tecemotide (L-BLP25) plus Hormonal Therapy (Standard Dose)"
3140984|NCT00925548|Active Comparator|Control Arm|"Control Arm:~Pretreatment (Single Dose): sodium chloride (NaCl) 9 grams per liter (g/L) infusion~Placebo plus Hormonal Therapy (Standard Dose)"
3140985|NCT00926575|Experimental|orBec®|Investigational drug
3140986|NCT00926575|Placebo Comparator|Placebo|Control
3140987|NCT00911053|No Intervention|Baseline|
3140988|NCT00911053|Experimental|Melatonin|Subjects will be administered melatonin.
3140989|NCT00911053|Experimental|Light|
3140990|NCT00911053|Experimental|Regular Sleep Schedule|
3140991|NCT00911053|No Intervention|Longitudinal Monitoring|Optional longitudinal study, an extension of the first study stage, for subjects whose rhythms are not clearly free-running.
3140992|NCT00918463|Experimental|all patients|
3140993|NCT00918645|Experimental|41 Ca|
3140994|NCT00907218|Experimental|1|Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.
3140995|NCT00895284|Experimental|Robot|Robotic hysterectomy
3140996|NCT00895284|Active Comparator|Standard|Standard hysterectomy
3140997|NCT00901303|Other|Early Stage Disease|Group A
3140998|NCT00901303|Other|Advance Stage Disease|Group B
3140999|NCT00906035|Active Comparator|Dipyridamole 200mg and Aspirin 25mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
3150649|NCT00207259|Experimental|Relaxation Therapy|Weekly relaxation therapy with PhD psychologist and home cognitive restructering practice
3141000|NCT00906035|Active Comparator|Dipyridamole 200 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy. (NIRS) of the legs.
3141001|NCT00906035|Active Comparator|Aspirin 25 mg bid|All subjects in this arm will take their assigned medication for 180 days and complete study visits on Day 1(Baseline), 30, 90 and 180. All subjects will bring a 24 hour urine collection and arrive in a fasting state on all visit days for a blood draw after which they will receive breakfast. After assessing vitals, Adverse Event status and medication compliance, they will be escorted to the vascular labs for Doppler Ultrasound and Near Infrared Spectroscopy (NIRS) of the legs.
3141002|NCT00904423|Experimental|Vitamin D|
3141003|NCT00903396|Experimental|Arm I|Patients receive palonosetron hydrochloride IV on day 1.
3141004|NCT00903396|Experimental|Arm II|Patients receive palonosetron hydrochloride IV on days 1 and 4.
3141005|NCT00903396|Placebo Comparator|Arm III|Patients receive placebo IV on day 1.
3141006|NCT00903396|Placebo Comparator|Arm IV|Patients receive placebo IV on days 1 and 4.
3141007|NCT00894790|Experimental|1|
3141008|NCT00894790|Active Comparator|2|
3141009|NCT00902668|Experimental|Supportive care (lovastatin)|Patients undergo 25-28 fractions of standard whole-breast irradiation followed by a boost to the tumor bed or 10 fractions of accelerated partial-breast irradiation with balloon brachytherapy BID over 5-10 days. Patients also receive lovastatin PO QD for 12 months beginning on day 1 of radiation therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3141010|NCT00881205|Experimental|Rivastigmine|Rivastigmine patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
3141011|NCT00881205|Placebo Comparator|Placebo|Placebo patch arm with the application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size.
3141012|NCT00896025|Active Comparator|N-acetycylcysteine|Each eligible Acute Liver Failure patient will be given N-acetylcysteine (NAC), beginning at a dose of 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour, followed by 50 mg/kg in 500 ml 5% dextrose over four hours, and 125 mg/kg in 1000 ml 5% dextrose over 19 hours, then 150 mg/kg in 1000 ml 5% dextrose per 24 hours for an additional 48 hours. The patient will be on continuous N-acetylcysteine infusion for a total of 72 hours.
3141013|NCT00896025|No Intervention|Standard of care|Each eligible Acute Liver Failure patient for whom the investigator chooses not to utilize N-acetylcysteine may serve as a control and receives standard of care.
3141014|NCT00903006|Active Comparator|Group 1: Fulvestrant|Group 1 will receive Fulvestrant only.
3141015|NCT00903006|Active Comparator|Group 2: Fulvestrant + Dasatinib|Group 2 will receive Fulvestrant and Dasatinib.
3141016|NCT00903006|Active Comparator|Group 3: Fulvestrant + MK-0646|Group 3 will receive Fulvestrant and MK-0646.
3141017|NCT00903006|Active Comparator|Group 4: Fulvestrant, MK-0646 + Dasatinib|Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.
3141018|NCT00904189|No Intervention|Standard of care radiation therapy|Standard of care given for treatment of cancer. Subjects receiving incidental radiation dose to fingernails.
3141019|NCT00887315|Active Comparator|Group 1|Chemotherapy only
3141020|NCT00887315|Active Comparator|2|Chemotherapy and hypofractionated image guided radiotherapy
3141021|NCT00891904|Experimental|Cetuximab|Patients receive cetuximab IV over 60-120 minutes once weekly in weeks 1-5
3141022|NCT00881608|Placebo Comparator|Placebo|Initiation-Placebo Cycle-Five (5) placebo capsules will be dispensed to subjects to self-administer for five days starting on cycle day 18.
3141023|NCT00881608|Experimental|3 mg Proellex|First Cycle (3 mg)- Five (5) 3 mg capsules of Proellex will be dispensed to subjects to self-administer for five days starting on cycle day 18.
3141024|NCT00881608|Experimental|6 mg Proellex|Second Cycle (6 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed ten (10) 3 mg capsules of Proellex to self-administer 2, 3 mg capsules each day for five days starting on cycle day 18.
3141025|NCT00881608|Experimental|12 mg Proellex|Third Cycle (12 mg)-Subjects, who have not experienced menses, will have their dose of Proellex escalated, and be dispensed twenty (20) 3 mg capsules of Proellex to self-administer 4, 3 mg capsules for five days starting on cycle day 18.
3141026|NCT00881608|Experimental|25 mg Proellex|Fourth Cycle (25 mg)-Subjects, who have not experienced menses, will be dispensed five (5) 25 mg capsules of Proellex to self-administer for five days starting on cycle day 18.
3141027|NCT00889421|Experimental|Treatment|Patients receiving apremilast.
3141028|NCT00875394|Experimental|1|sitagliptin + metformin
3141029|NCT00875394|Active Comparator|2|metformin + any other oral antidiabetic drug
3141030|NCT00875394|Active Comparator|3|metformin
3141031|NCT00882310|Experimental|Gemcitabine, Docetaxel, Capecitabine GTX|GTX - A two week regimen of Gemcitabine at 600 mg/m2 on days 4 and 1, infused over 60 minutes, Docetaxel at 30 mg/m2 on days 4 and 11, infused over 60 minutes and Capecitabine at 1000 mg/m2 (capped at 1000 mg BID days 1-14) followed by one week off for a total of a 21 day cycle. This is repeated for a total of 6 months.
3141032|NCT00880542|Experimental|Sorafenib + Ifosfamide|"* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.~NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.~Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.~Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy."
3141033|NCT00879619|Experimental|Chemotherapy and enzyme inhibitor|Patients receive docetaxel IV over 60 minutes on day 1, prednisone PO BID on days 1-21, and sunitinib malate PO QD on days 2-15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sunitinib malate PO QD on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3141034|NCT00874939|Experimental|PBO→MK-7.5→DON→MK-25|Treatment by single oral dose with Placebo (PBO) in the first crossover period; MK-0249 7.5 mg (MK-7.5) in the second crossover period; Donepezil 5 mg (DON) in the third crossover period; and MK-0249 25 mg (MK-25) in the fourth crossover period.
3141035|NCT00874939|Experimental|MK-7.5→PBO→MK-25→DON|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 25 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3141036|NCT00874939|Experimental|DON→MK-25→PBO→MK-7.5|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3141037|NCT00874939|Experimental|MK-25→DON→MK-7.5→PBO|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Placebo in the fourth crossover period.
3141038|NCT00874939|Experimental|PBO→MK-25→MK-7.5→DON|Treatment by single oral dose with Placebo in the first crossover period; MK-0249 25 mg in the second crossover period; MK-0249 7.5 mg in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3141039|NCT00874939|Experimental|MK-7.5→DON→PBO→MK-25|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; Donepezil 5 mg in the second crossover period; Placebo in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
3141040|NCT00874939|Experimental|DON→MK-7.5→MK-25→PBO|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and Placebo in the fourth crossover period.
3141041|NCT00874939|Experimental|MK-25→PBO→DON→MK-7.5|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; Placebo in the second crossover period; Donepezil 5 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3141042|NCT00874939|Experimental|PBO→DON→MK-25→MK-7.5|Treatment by single oral dose with Placebo in the first crossover period; Donepezil 5 mg in the second crossover period; MK-0249 25 mg in the third crossover period; and MK-0249 7.5 mg in the fourth crossover period.
3141043|NCT00874939|Experimental|MK-7.5→MK-25→DON→PBO|Treatment by single oral dose with MK-0249 7.5 mg in the first crossover period; MK-0249 25 mg in the second crossover period; Donepezil 5 mg in the third crossover period; and Placebo in the fourth crossover period.
3141044|NCT00874939|Experimental|DON→PBO→MK-7.5→MK-25|Treatment by single oral dose with Donepezil 5 mg in the first crossover period; Placebo in the second crossover period; MK-0249 7.5 mg in the third crossover period; and MK-0249 25 mg in the fourth crossover period.
3141045|NCT00874939|Experimental|MK-25→MK-7.5→PBO→DON|Treatment by single oral dose with MK-0249 25 mg in the first crossover period; MK-0249 7.5 mg in the second crossover period; Placebo in the third crossover period; and Donepezil 5 mg in the fourth crossover period.
3141046|NCT00878605|Experimental|Cyclo-Z (minimally effective)|3mg CHP plus 20mg zinc containing gel capsule;
3141047|NCT00878605|Experimental|Cyclo-Z (maximally effective)|9mg CHP plus 20mg zinc containing gel capsule;
3141048|NCT00878605|Experimental|Cyclo-Z (not additionally effective)|15mg CHP plus 20mg zinc containing gel capsule
3141049|NCT00878605|Placebo Comparator|Placebo (for CHP)|Placebo capsules containing no zinc or CHP
3141050|NCT00877071|Experimental|LC Drug Eluting Bead, Regional Chemoembolization|Use of LC Drug-Eluting Beads for chemoembolization will provide a method for downstaging patients with hepatocellular carcinoma which is not amenable to surgical resection or local ablative therapy to liver transplant eligibility
3141051|NCT00878969|Active Comparator|Valsartan|80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
3141052|NCT00878969|Active Comparator|Ramipril|2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
3141053|NCT00878969|Placebo Comparator|Placebo|matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months
3141054|NCT00865514|Experimental|Haplotypes and DCA metabolism|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
3141055|NCT00869414|Active Comparator|insulin glargine only in morning|Morning only administration of insulin glargine
3141056|NCT00869414|Active Comparator|insulin glargine only at evening|Evening only administration of insulin glargine
3141057|NCT00869414|Active Comparator|split dose insulin glargine|Split dose administration of insulin glargine, half dose in morning, half dose in evening
3141058|NCT00863512|Experimental|Arm I|Patients receive cisplatin IV on day 1 and vinorelbine ditartrate IV on days 1 and 8 OR docetaxel IV and cytarabine IV on day 1 OR gemcitabine hydrochloride IV on days 1 and 8 and cytarabine IV on day 1 OR pemetrexed disodium IV and cisplatin IV on day 1.. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3141059|NCT00863512|Experimental|Arm II|Patients receive standard care (observation).
3141060|NCT00868998|Experimental|Treatment|Gemcitabine, docetaxel, and capecitabine
3141061|NCT00869258|Experimental|GTX and Radiation Therapy with Gemzar|"Chemotherapy Treatment with Gemcitabine, Docetaxel, and Capecitabine:~A cycle of chemotherapy is made up of 21 days. During each cycle patients will take Xeloda® twice a day for 14 days followed by a rest period of 7 days. On day 4 and 11 (+/- 2 days) of each 21-day cycle patients will also receive Gemzar and Taxotere.~Weekly Radiation Therapy with Low-Dose Gemzar Chemotherapy:~After completing a total of 3 cycles of GTX chemotherapy each patient will receive 5 weeks of standard radiation therapy in combination with low-dose Gemzar chemotherapy."
3141062|NCT00863330|Experimental|Determine toxicity of treatment regimen.|
3141063|NCT00853229|Experimental|pregabalin/placebo|pregabalin and placebo given using a cross-over design
3141064|NCT00853229|Experimental|placebo/pregabalin|placebo and pregabalin given using a cross-over design
3141065|NCT00860249|No Intervention|Usual Care|Usual Care. Participants in this arm will receive Usual care until outcome assessment is performed at 6 months following randomization. At that time, they will be sent a letter reminding them to obtain the ordered preventative service test, however no further outcomes will be assessed. Thus, during the course of the study, all participants in this arm will have solely received usual care.
3141066|NCT00860249|Experimental|Behavioral: Letter Only|Behavioral: Letter Only Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
3141067|NCT00860249|Experimental|Behavioral: Letter and Educational DVD|Behavioral: Letter and Educational DVD Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
3141068|NCT00860158|Experimental|Single Arm Assignment|Neoadjuvant dasatinib plus leuprolide acetate followed by radical prostatectomy
3141069|NCT00853567|Active Comparator|25 g Proellex|25 mg oral daily dose of Proellex
3141070|NCT00853567|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
3141071|NCT00853567|Placebo Comparator|Placebo|Placebo treatment
3141072|NCT00849524|Experimental|Ad-ISF35|Ad-ISF35, intranodal injection, 3.3 x 10^10 ISF35 viral particles, every 2-4 weeks up to six total injections.
3141073|NCT00843986|Placebo Comparator|Placebo|Matching loading dose and continuous intravenous infusion for 48 hours
3141074|NCT00843986|Experimental|Conivaptan|20mg loading dose followed by a 20mg/ day continuous intravenous infusion for 48 hours
3141075|NCT00851682|Other|Radical prostatectomy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo radical prostatectomy and have not received any preoperative treatment for prostate cancer.
3141076|NCT00851682|Other|Brachytherapy patients|Patients who have been diagnosed with prostate cancer and are scheduled to undergo brachytherapy and have not received any preoperative treatment for prostate cancer.
3141077|NCT00852124|Placebo Comparator|Placebo|Packets similar to VSL#3 will be taken 2 X daily but not containing active bacteria
3141078|NCT00852124|Active Comparator|VSL#3|Packets of VSL#3 (powder containing 8 bacteria believed to be beneficial) will be taken 2 x daily in food or a cool beverage.
3141079|NCT00850421|Other|Botulinum Toxin Type A|
3141080|NCT00851747|Experimental|C Phosphatidylcholine Deoxycholate|Phosphatidylcholine Deoxycholate Injections. Group C will receive only study drug injections
3141081|NCT00851747|Placebo Comparator|A Saline|Group A will serve as a control and will receive only injections of saline as a placebo.
3141082|NCT00851747|Active Comparator|B PhosphatidylcholineDeoxycholate/Saline|Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side.
3141083|NCT00852241|Experimental|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
3141084|NCT00850720||Cardiac Surgery|Infants with congenital defects.
3141085|NCT00845845|Active Comparator|Omega-3-acid ethyl esters (Lovaza)|Participants receive 4 milligrams (mg) daily of omega-3-acid ethyl esters (Lovaza) and dietary counseling for 24 weeks
3141086|NCT00845845|Placebo Comparator|Placebo|Participants receive daily placebo and dietary counseling for 24 weeks
3141087|NCT00851591|Experimental|Fenugreek category 1|receive fenugreek
3141088|NCT00851591|Placebo Comparator|Placebo Category 2|receive placebo
3141089|NCT00847509|Experimental|FLT PET scan|Open label, nonrandomized, uncontrolled, single group assignment, multi-center clinical trial to evaluate [F-18] FLT as a PET imaging tool in cancer patients clinically scheduled for treatment with radiation or radiation - chemotherapy. Standard [F-18] FDG PET will be the active comparator.
3141090|NCT00843310|Experimental|ReMeDex|"Treatment phase (28 days/cycle x 6 cycles):~Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.~Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):~lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles."
3141091|NCT00847002|Active Comparator|Standard Wound Care|Gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
3150650|NCT00207259|Experimental|Reiki|Weekly Reiki therapy with a Reiki therapist, involves laying of the therapist's hands on the patient to rechannel energy, considered pleasant and calming
3141092|NCT00847002|Active Comparator|Flexitouch system with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis (FarrowWrap will be removed during the time they are using Flexitouch). The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
3141093|NCT00845702|Experimental|Dotarem|Each subject will receive one injection of Dotarem 0.2 ml/kg.
3141094|NCT00845702|Other|Time Of Flight Magnetic Resonance Angiography|Each subject undergo a TOF MRA
3141095|NCT00843830|Experimental|Treatment Arm|Participants will receive tumoral irradiation and dendritic cell vaccination.
3141096|NCT00835679|Experimental|Cohort A (no systemic neoadjuvant therapy)|Patients receive no systemic neoadjuvant therapy between enrollment and the time of definitive surgical resection of liver metastases. Liver biopsies were performed at surgery since this cohort received no systemic therapy.
3141097|NCT00835679|Experimental|Cohort B (cetuximab)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8. Definitive surgical resection of liver metastases will take place on day 15.
3141098|NCT00835679|Experimental|Cohort C (dasatinib)|Patients receive dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
3141099|NCT00835679|Experimental|Cohort D (cetuximab, dasatinib)|Patients receive 400 mg/m^2 cetuximab IV over 120 minutes on day 1 and 250 mg/m^2 cetuximab IV over 60-120 minutes on day 8 AND dasatinib 100 mg orally once daily on days 1-14. Definitive surgical resection of liver metastases will take place on day 15.
3141100|NCT00841035|Experimental|Eroltinib added to standard of care|150 mg of erlotinib for 7 days prior to surgery,then in the adjuvant stage the subject will receive 100mg of erlotinib and gemcitabine 1000mg/2 for 6 cycles
3141101|NCT00832520|Experimental|Remeron (Mirtazapine)|Mirtazapine 15 mg orally at bed time for 8 weeks
3141102|NCT00833859|Experimental|Chemotherapy followed by Radiation Treatment|GTX-SRS: Gemcitabine, Taxotere, Xeloda (GTX)-Stereotactic Radiosurgery (SRS)
3141103|NCT00843050|Experimental|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
3141104|NCT00840827|Experimental|all patients|Lenalidomide 10mg po daily/ CSA 250mg orally twice daily
3141105|NCT00835328|Experimental|Exendin (9-39) 0.02 mg/kg/hr|Cohort 1: Participants will be administered 0.02 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
3141106|NCT00835328|Experimental|Exendin (9-39) 0.04 mg/kg/hr|Cohort 2: Participants will be administered 0.04 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
3141107|NCT00835328|Experimental|Exendin (9-39) 0.10 mg/kg/hr|Cohort 3: Participants will be administered 0.10 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 6 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
3141108|NCT00835328|Experimental|Exendin (9-39) 0.20 mg/kg/hr|Cohort 4: Participants will be administered 0.20 mg/kg/hr of Exendin (9-39) and vehicle (normal saline), via continuous intravenous infusion, over 9 hours on two separate days in random order, with 3 hours of follow-up after the last dose is administered or until blood glucose is < 70 mg/dL (whichever comes first). Glucose infusion rates (GIR) will be titrated three hours prior to infusions to keep blood glucose in the range of 70-90 mg/dL. During both infusions, blood glucose will be measured every 30 minutes.
3141109|NCT00832572|Experimental|Placebo-Ranolazine|Participants were randomized to receive placebo to match ranolazine during Weeks 1 to 6, then ranolazine during Weeks 7 to 12.
3141110|NCT00832572|Experimental|Ranolazine-Placebo|Participants were randomized to receive ranolazine during Weeks 1 to 6, then placebo to match ranolazine during Weeks 7 to 12.
3141111|NCT00832624|Experimental|1|sitagliptin
3141112|NCT00832299|Experimental|6 cycles of FOLFOX pre and post TME|
3141113|NCT00836355|Experimental|Enoxaparin|
3141114|NCT00836355|Experimental|Minocycline|Minocycline 200 mg orally once daily for 5 days
3141115|NCT00836355|Experimental|Enoxaparin and minocycline|
3141116|NCT00836355|No Intervention|Control|
3141117|NCT00832598|Experimental|PET imaging|We will perform [18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc.
3141118|NCT00816777|Experimental|Chemoembolization|Chemoembolization with Irinotecan Bead in combination with Intravenous Chemotherapy Group (test arm)
3141119|NCT00816777|Active Comparator|Chemotherapy|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
3141120|NCT00823095|Experimental|Topically applied Nitric Oxide|Topically applied Nitric Oxide for 8 hours daily for 2 weeks.
3141121|NCT00827567|Experimental|RAD 001|RAD001-10 mg by mouth once everyday
3141122|NCT00815633|Experimental|Alefacept|Treatment Group (only one group)
3141123|NCT00814983|Experimental|Naive T-cell Depleted Stem Cell Transplant|Experimental: Cohort 2 will receive a T-cell depleted peripheral blood stem cell graft. All other aspects of this stem cell transplantation are in line with the standard of care.
3141124|NCT00814983|Active Comparator|Stem Cell Transplant No Manipulation|Control: Cohort 1 Stem Cell Transplant No Manipulation will receive the currently accepted standard approach to myeloablative allogeneic stem cell transplantation
3141125|NCT00825227|Active Comparator|Patient responses to 150 mg/day armodafinil|"150 mg/day armodafinil~taxane chemotherapy treatment alone or in combination with other agents"
3141126|NCT00825227|Placebo Comparator|Patient responses to placebo|"placebo~taxane chemotherapy treatment alone or in combination with other agents"
3141127|NCT00819832|Experimental|Phase 1 Group 1 Vertebroplasty|Vertebroplasty
3141128|NCT00819832|Experimental|Phase 1 Group 2 Kyphoplasty|Kyphoplasty
3141129|NCT00819832|Active Comparator|Phase 2 Group 1 Vertebroplasty|Vertebroplasty
3141130|NCT00819832|Active Comparator|Phase 2 Group 2 Vertebroplasty + Cavity SpineWand|Vertebroplasty with Cavity SpineWand
3141131|NCT00819832|Active Comparator|Phase 2 Group 3 Kyphoplasty|Kyphoplasty
3141132|NCT00819832|Active Comparator|Phase 2 Group 4 Kyphoplasty + Cavity SpineWand|Kyphoplasty with Cavity SpineWand
3141133|NCT00822679|Experimental|1: Eszopiclone|Subjects receive Eszopiclone for three consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
3141134|NCT00822679|Placebo Comparator|2: Placebo|Subjects given placebo for 3 consecutive nights to observe changes in sleep measures, and inflammatory and coagulation factors
3141135|NCT00814892|Experimental|DC-APCC|Patients undergo standard leukapheresis to harvest peripheral blood mononuclear cells for dendritic cell vaccine preparation. Patients receive the APCC vaccine and autologous dendritic cells derived from CD14-positive myeloid peripheral blood cells ID on days 0, 14, and 28 and then every 28 days for up to 14 courses in the absence of disease progression or unacceptable toxicity.
3141136|NCT00809458|Experimental|Arm 1 (Vitamin E)|Vitamin E
3141137|NCT00809458|Placebo Comparator|Arm 2|Placebo (same vehicle as used for vitamin E)
3141138|NCT00802659|Experimental|Group -1|1000 cGY radiation
3141139|NCT00802659|Experimental|Group 1|1200 cGY radiation
3141140|NCT00802659|Experimental|Group 2|1400 cGY radiation
3141141|NCT00802659|Experimental|Group 3|1600 cGY radiation
3141142|NCT00807365|Experimental|GHRH|Growth Hormone-Releasing Hormone
3141143|NCT00814333|Experimental|1|Thrombin-JMI
3141144|NCT00814333|Active Comparator|2|Merocel pack
3141145|NCT00808080|Experimental|Biologic|AML_CTL cells
3141146|NCT00802893|Experimental|Experimental Drug|
3141147|NCT00802893|Placebo Comparator|Placebo Comparator|
3141148|NCT00809341|Active Comparator|PET Negative|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a negative PET scan will complete their chemotherapy regimen as prescribed by their oncologist.
3141149|NCT00809341|Active Comparator|PET Positive|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or an equivalent anthracycline-containing regimen for 3 cycles, followed by PET scan. Participants with a positive PET scan will receive two cycles of R-ICE (rituximab, ifosfamide, carboplatin, etoposide) followed by HiCy (high-dose cyclophosphamide).
3141150|NCT00804349|No Intervention|Control|Patients will receive standard medical therapy for heart failure only and will not receive Autotitrating Positive Airway Pressure therapy.
3141151|NCT00804349|Active Comparator|Autotitrating Positive Airway Pressure|Patients will receive Autotitrating Positive Airway Pressure therapy in addition to standard medical care for heart failure.
3141152|NCT00803283|Experimental|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
3150651|NCT00207285|Other|In Person Training|These firefighters received the sleep education and sleep disorders screening in person by one of our research staff.
3141153|NCT00803283|Active Comparator|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every 24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
3141154|NCT00811590|Experimental|All patients|All participants enrolled.
3141155|NCT00808899|Experimental|1|Fixed doses of IV temsirolimus concomitantly with two courses of fixed dosages of irinotecan, 2 days off, repeated daily 5 times.If initial dosages are not tolerable, subsequent patients will be given a reduced dosage of temsirolimus with irinotecan.If this dosage combination is not tolerable,irinotecan dosage will be decreased.If this dosage combination is not tolerable.Further enrollment to initial six week treatment will be terminated.Second course of irinotecan will begin on day 22, response will be determined after six weeks. Resection of primary tumor will be attempted after initial therapy.Following initial treatment children will undergo alternating courses of induction chemotherapy with cyclophosphamide,doxorubicin,etoposide,topotecan, and cisplatin.First cohort of 17 patients will receive Block 2 with temsirolimus for all three courses, weekly 2 times.If this is not tolerated subsequent patients will receive Block 2 chemotherapy with reduced dosages of temsirolimus.
3141156|NCT00808769|Active Comparator|1|Zegerid®
3141157|NCT00808769|Experimental|2|Prilosec OTC®
3141158|NCT00803179|Experimental|Growth Hormone Therapy|"Nutropin Aqueous (AQ):~Initiation treatment for adult males is 0.2mg/d and for women 0.4mg/d"
3141159|NCT00801931|Experimental|A: Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated total body irradiation (TBI) will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1.The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/mycophenolate mofetil (MMF).
3141160|NCT00801931|Experimental|B: Full intensity without TBI|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. Granulocyte-macrophage colony-stimulating factor (GM-CSF) hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
3141161|NCT00801931|Experimental|C: Moderate Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
3141162|NCT00801931|Experimental|D: Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
3141163|NCT00801931|Experimental|E: Fanconi's Anemia|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and horse antithymocyte globulin on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
3141164|NCT00801931|Experimental|F: Regimen for non-malignant diseases|Patients will begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
3141165|NCT00793520|Experimental|1|Twice daily oral administration of milnacipran for 5 weeks, placebo for 2 weeks, and crossover to placebo for 5 weeks.
3141166|NCT00793520|Experimental|2|Twice daily oral administration of placebo for 5 weeks, placebo for 2 weeks, and crossover to milnacipran for 5 weeks.
3141167|NCT00806390|Active Comparator|Metoprolol|Receiving metoprolol
3141168|NCT00806390|No Intervention|Control|Not receiving metoprolol
3141169|NCT00795236|No Intervention|Observational|Observe to determine free-running versus entrained status.
3141170|NCT00795236|Experimental|Melatonin|Subjects with free-running rhythms will take melatonin.
3141171|NCT00799773|Experimental|1|Participants will receive rituximab in addition to plasma exchange and corticosteroids.
3141172|NCT00799773|Active Comparator|2|Participants will receive plasma exchange and corticosteroids.
3141173|NCT00790452|Active Comparator|Group 1 (Aspirin)|Aspirin 325 mg/day orally
3141174|NCT00790452|Placebo Comparator|Group 2 (Placebo)|Tablet/day orally
3141175|NCT00795665|Experimental|Bevacizumab and Carmustine|
3141176|NCT00787917|Experimental|Omalizumab|"Eligible participants received a maximum dose of 600 mg omalizumab via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. A maximum 600 mg dose required 4 injections. All participants who entered the study received itraconazole twice daily, while receiving oral corticosteroids, with a maximum daily dose of 400 mg.~Participants who completed double-blinded phase, entered open-label treatment period of 6 months and continued the same regimen of omalizumab of double-blinded phase."
3141177|NCT00787917|Placebo Comparator|Placebo|Eligible participants received placebo comparator via subcutaneous injection for 6 months in the double-blind phase of the study. The study medication was to be administered at the same time of day. Study medication was injected subcutaneously into the upper arm in the area of the deltoid or to the thigh. All participants who entered the study received itraconazole twice daily, while on oral corticosteroids, with a maximum daily dose of 400 mg.
3141178|NCT00798590|Experimental|GLP-1|
3141179|NCT00798590|Placebo Comparator|Saline|
3141180|NCT00796510|Experimental|Sitaxsentan|Monotherapy arm
3141181|NCT00796510|Experimental|Sitaxsentan and Sildenafil|Combination treatment
3141182|NCT00796861|Experimental|Single Arm|Sunitinib (50mg PO daily x 4 wks + 2 wks rest x 3 cycles if able to tolerate tx
3141183|NCT00791076|Placebo Comparator|Saline Placebo|Saline
3141184|NCT00791076|Active Comparator|Pancreatic Polypeptide|Pancreatic Polypeptide
3141185|NCT00790478|Placebo Comparator|Placebo|Placebo -- lactose pill.
3141186|NCT00790478|Active Comparator|Melatonin|Melatonin
3141187|NCT00796107|Experimental|R1507 in Combination With Letrozole|Participants received a full daily dose of 2.5 mg of orally administered Letrozole along with 16 mg/kg of intravenous R1507 administered q3w, and observed for dose limiting toxicity for the first 2 cycles of treatment.
3141188|NCT00791336|Experimental|Nelfinavir|
3141189|NCT00786682|Experimental|Docetaxel and Hydroxychloroquine|"Drug: Docetaxel 75 mg/m2 intravenously every 21 days on Day 1 of the treatment cycle~Drug: hydroxychloroquine 200 mg twice daily~A cycle is defined as an interval of 21 days."
3141190|NCT00787124||1|< 28 weeks gestation, < 30 days of age, < 3 previous transfusions
3141191|NCT00787124||2|< 28 weeks gestation, >=30 days of age, >= 3 previous transfusions
3141192|NCT00785356|Experimental|25 mg Proellex|Proellex 25 mg
3141193|NCT00785356|Experimental|Proellex 50 mg|Proellex 50 mg
3141194|NCT00785356|Placebo Comparator|Placebo|Placebo
3141195|NCT00791843|Experimental|GHRH and placebo|Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
3141196|NCT00784043|Experimental|Bilateral|Bilaterally implanted simultaneously
3141197|NCT00784043|Experimental|Unilateral|Unilaterally implanted
3141198|NCT00787618|Active Comparator|50 mg Proellex Mild impairment|50 mg Proellex single dose Female subjects with mild renal impairment function.
3141199|NCT00787618|Active Comparator|50 mg Proellex Moderate|50 mg Proellex, Female subjects with moderate renal impairment function.
3141200|NCT00787618|Active Comparator|50 mg Proellex, Normal|50 mg Proellex, Female subjects with normal renal function.
3141201|NCT00774306|Active Comparator|1|Participants randomized to Group 1 will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
3141202|NCT00774306|Active Comparator|2|Participants randomized to Group 2 will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses or in a once-daily extended release formulation.
3141203|NCT00774306|Active Comparator|3|Participants randomized to Group 3 will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
3141204|NCT00774306|No Intervention|4|Participants randomized to Group 4 will receive no drug intervention.
3141205|NCT00771602|Experimental|Rituximab|Group 1: 375 mg/m^2 IV Rituximab Alone
3141206|NCT00771602|Experimental|Alemtuzumab|Group 2: 30 mg SQ Alemtuzumab Alone
3141207|NCT00771602|Experimental|Rituximab + Alemtuzumab|Group 3: 375 mg/m^2 Rituximab + 30 mg SQ Alemtuzumab
3141208|NCT00779038|Experimental|Fentanyl ITS|40 microgram (mcg) per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an Iontophoretic Transdermal System (ITS). Total duration of treatment will be 72 hours.
3150652|NCT00207285|Other|Train the Trainer|These firefighters received the education and sleep disorder screening in person with someone taught by our research staff.
3141209|NCT00780455|Experimental|Interferon beta-1b, FRP within 15 days after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) within 15 days after randomization
3141210|NCT00780455|Experimental|Interferon beta-1b, FRP about 6 weeks after randomization|Interferon beta-1b (Betaseron, BAY86-5046) 250 microgram (8 MUI), sub-cutaneous, administration every other day, Participants starting the 6 weeks functional rehabilitation protocol (FRP) about 6 weeks after randomization
3141211|NCT00776100|Other|Arm I|Patients undergo observation for 6 weeks.
3141212|NCT00776100|Experimental|Arm II|Patients undergo radiotherapy 5 days a week for 6 weeks to all sites of gross disease.
3141213|NCT00771316|Experimental|Group 1|MK0826 (ertapenem)
3141214|NCT00771316|Active Comparator|Group 2|meropenem
3141215|NCT00780481|Experimental|Bradykinin|Patients will have flow mediated vasodilation and radial artery tonometry performed. They will then receive 0, 10, 20, 40 ng/100cc/min of intrabrachial bradykinin. Strain gauge plethysmography and blood sampling at each dose will be done to evaluate t-PA release. Blood will also be drawn for other biomarkers.
3141216|NCT00769652|Experimental|Medical nutrition therapy|Medical nutrition therapy
3141217|NCT00769652|Active Comparator|Standard care|Standard care
3141218|NCT00768040|Experimental|Aliskiren 300 mg|Aliskiren 300 mg once daily for 12 weeks
3141219|NCT00768040|Placebo Comparator|Placebo|Matching placebo once daily for 12 weeks
3141220|NCT00776555|Experimental|Vyvanse™|50mg capsule that has been emptied and made into solution
3141221|NCT00776555|Experimental|ADDERALL XR®|20mg capsule that has been emptied, crushed, and made into solution
3141222|NCT00775190|Active Comparator|Ortho tricyclen™|Participant Randomized to Ortho tricyclen 1 tablet by mouth Daily
3141223|NCT00775190|Active Comparator|Trinessa™|Participant Randomized to Trinessa 1 tablet by mouth Daily
3141224|NCT00755261|Experimental|Avastin and Doxorubicin|Patients will be treated with Avastin 15 mg/kg IV infusion plus doxorubicin 60 mg/M2 (body surface area) IV 6-hour infusion on Day 1 of each 21-day treatment cycle. Dose reductions/modifications will be applied as indicated by toxicities and/or patient tolerance.
3141225|NCT00762723|Experimental|Group 1|Trinica Anterior Lumbar Plate System with fixed screws only
3141226|NCT00762723|Experimental|Group 2|Trinica Anterior Lumbar Plate System with variable screws only
3141227|NCT00762723|Experimental|Group 3|Trinica Anterior Lumbar Plate with hybrid screw configuration (2 fixed-angle screws with 2 variable-angle screws).
3141228|NCT00770965|Experimental|AIN457 0.3 mg/kg|Participants received AIN457 0.3 mg/kg IV on Day 1.
3141229|NCT00770965|Experimental|AIN457 1.0 mg/kg|Participants received AIN457 1.0 mg/kg IV on Day 1.
3141230|NCT00770965|Experimental|AIN457 3.0 mg/kg|Participants received AIN457 3.0 mg/kg IV on Day 1.
3141231|NCT00770965|Placebo Comparator|Placebo|Participants received placebo to AIN457A IV on day 1.
3141232|NCT00769002|Active Comparator|Natural Infection|previously naturally infected
3141233|NCT00769002|Active Comparator|FluShield - influenza positivity|prior FluShield ipsilateral vaccinated
3141234|NCT00769002|Active Comparator|FluShield - influenza positivity2|prior FluShield contralateral vaccinated
3141235|NCT00769002|Active Comparator|FluMist|prior FluMist vaccinated.
3141236|NCT00766636|Experimental|Gemcitabine + Erlotinib Without Radiation|"Gemcitabine + Erlotinib without radiation - Arm A: Gemcitabine 1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42.~Surgical removal of the pancreas and duodenum."
3141237|NCT00766636|Experimental|Gemcitabine + Erlotinib With Radiation|Gemcitabine + Erlotinib with radiation - Arm B: Gemcitabine 400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day. Erlotinib 100 mg daily by mouth on days 1-42. Radiation therapy 1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy. Surgical removal of the pancreas and duodenum.
3141238|NCT00768248|Active Comparator|Active|3-7 days of perineural local anesthetic infusion
3141239|NCT00768248|Placebo Comparator|Placebo|3-7 days of perineural normal saline infusion
3141240|NCT00765765|Experimental|Ixabepilone and hydroxychloroquine|
3141241|NCT00764699|Experimental|rhIGF|Treatment with rhIGF (Increlex)
3141242|NCT00759577|Other|Home titration|Patients were given drug to self titrate
3141243|NCT00763009|Other|All subjects receive dipyridamole|Compare to baseline
3141244|NCT00761176|No Intervention|Standard of Care|Standard of Care will be utilized without the device.
3141245|NCT00761176|Other|The Provant Therapy System|Thirty minutes, twice daily treatment
3141246|NCT00749476|Experimental|1|
3141247|NCT00760461|Other|Domperidone|
3141248|NCT00749658|Active Comparator|Bupropion + Placebo Varenicline|Bupropion + Placebo Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Placebo Varenicline
3141249|NCT00749658|Active Comparator|upropion + Varenicline|Bupropion + Varenicline \Varenicline + Placebo Bupropion; Varenicline + Placebo Bupropion \Bupropion + Varenicline
3141250|NCT00754793|Active Comparator|1|escitalopram 10mg - 30mg daily
3141251|NCT00754793|Placebo Comparator|2|
3141252|NCT00754052|Active Comparator|1|
3141253|NCT00754052|Active Comparator|2|
3141254|NCT00754052|Placebo Comparator|3|
3141255|NCT00750555|Other|1|
3141256|NCT00754767|Experimental|Arm I|Patients receive oral L-carnitine L-tartrate twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
3141257|NCT00754767|Placebo Comparator|Arm II|Patients receive oral placebo twice daily beginning on day 2 of the first course of chemotherapy and continuing until after completion of 4 courses of chemotherapy.
3141258|NCT00750204|Experimental|APRV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
3141259|NCT00750204|Active Comparator|Conventional MV|Patients will be randomized to either arm. After 24 hours they will crossover to the alternative arm of the study for an additional 24 hours. After a total of 48 hours (24 hours in each study arm) the study will conclude.
3141260|NCT00748579|Experimental|Cohort 1|0.5 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
3141261|NCT00748579|Experimental|Cohort 2|≤ 1.0 hour loading dose followed by 1.0 hour maintenance dose of CK-1827452
3141262|NCT00748085|Experimental|Cryospray Ablation|Cryospray Ablation 4, 5-second spray cycles
3141263|NCT00752986|Experimental|Vandetanib at the dose of 100 mg|vandetanib at the dose of 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
3141264|NCT00752986|Experimental|Vandetanib at the dose of 300 mg|vandetanib at the dose of 300 mg orally once-daily plus placebo to match vandetanib 100 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3)
3141265|NCT00752986|Placebo Comparator|Placebo to match vandetanib 100 mg and 300 mg|placebo to match vandetanib 100 mg orally once-daily plus placebo to match vandetanib 300 mg orally once-daily plus fulvestrant LD (500 mg im. at day 1 and 250 mg at day 14, 28 and thereafter every 28th day +/- 3).
3141266|NCT00751335|Experimental|CPAP with ThermoSmart, then CPAP without ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
3141267|NCT00751335|Experimental|CPAP without ThermoSmart, then CPAP with ThermoSmart|"CPAP with ThermoSmart is the application of CPAP with heated humidification and a heated breathing tube.~CPAP without ThermSmart is the application of CPAP with heated humidification without a heated breathing tube."
3141268|NCT00746239|Active Comparator|1|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
3141269|NCT00746239|Placebo Comparator|2|Subjects will be randomly assigned to receive either Ramelteon and Escitalopram OR Placebo and Escitalopram.
3141270|NCT00754013|Active Comparator|Donepezil|
3141271|NCT00754013|Placebo Comparator|Placebo|
3141272|NCT00735553|Active Comparator|25 mg Proellex|25 mg oral daily dose of Proellex
3141273|NCT00735553|Active Comparator|50 mg Proellex|50 mg oral daily dose of Proellex
3141274|NCT00735553|Placebo Comparator|placebo|oral daily dose of placebo
3141275|NCT00751933|Experimental|2|Vaccination with Vivotif and Dukoral
3141276|NCT00751933|Experimental|3|Dietary supplement with oats
3141277|NCT00751933|Placebo Comparator|4|Placebo instead of vaccines No dietary supplement
3141278|NCT00751933|Experimental|1|Vaccination with Vivotif and Dukoral + dietary supplement with oats.
3141279|NCT00747916|Experimental|CryoSpray Ablation (TM) System|subjects will receive cryotherapy using the CryoSpray Ablation (TM) System DOSE: up to 3 cycles of 10-40 second sprays
3141280|NCT00745030|Experimental|1|Ramelteon (TAK-375) 8mg tablets
3141281|NCT00745030|Placebo Comparator|2|Placebo 8 mg tablets
3141282|NCT00747461|Experimental|Cryospray Ablation|Experimental CSA (Cryospray Ablation)
3141283|NCT00746018|Experimental|1|The patients will already be undergoing a total hysterectomy with removal of the tubes and ovaries for a specific indication diagnosed or defined by their surgeon. If the patient is suitable to proceed by the surgeon, then he/she will perform a right salpingooophorectomy with the LigaSure devices.
3141284|NCT00746603|Experimental|A Intervention Arm|Escalating dose of simvastatin in subjects who are survivors of Hodgkin Lymphoma
3141285|NCT00739050|Experimental|1|Arm 1: Drug
3141286|NCT00739050|Placebo Comparator|2|Arm 2: Placebo
3141287|NCT00736385|Active Comparator|Metformin|Metformin XR (extended-release) 2000 mg daily
3141288|NCT00736385|Placebo Comparator|Placebo|Placebo capsule
3141289|NCT00738972|Active Comparator|Valsartan 80 mg + Paravastin 40 mg|Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)
3141290|NCT00738972|Active Comparator|Valsartan 80 mg + Simvastatin 40 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)
3141291|NCT00738972|Experimental|Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg|Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)
3141292|NCT00738972|Active Comparator|Valsartan 80 mg|Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)
3141293|NCT00743197|No Intervention|Usual Care Group|USUAL CARE GROUP-therapy in this group will be no dictated medical therapy, but usual care, as dictated by their referring physician.
3141294|NCT00743197|Active Comparator|Medical Treatment Group|TREATMENT GROUP-therapy in this group will be conventional treatment for CAD but targeting endothelial function, which will include aspirin, ACE-inhibitor and statin therapy, and therapeutic lifestyle changes.
3141295|NCT00739063|Experimental|Tarceva daily|Tarceva oral 150 mg daily.
3141296|NCT00740597|Experimental|Arm 1|pre-operative radiation + surgery PTV will receive a total dose of 50 Gy in 25 fractions, 2 Gy per fraction, 5 fractions per week, over approximately 5 weeks. Concurrently, the GTV2, if present, will receive 54 Gy in 25 fraction. Dose will be prescribed to the isodose volume that encompasses the PTV. All patients will be treated by 6 MV photon beam.
3141297|NCT00737594|Placebo Comparator|Placebo TID|Participants receive matching placebo capsules three times daily (TID)
3141298|NCT00737594|Experimental|12 mcg TID|Participants receive 12 mcg Cobiprostone TID
3141299|NCT00737594|Experimental|18 mcg TID|Participants receive 18 mcg Cobiprostone TID
3141300|NCT00737282|Active Comparator|25 mg Proellex|Proellex 25 mg once daily
3141301|NCT00737282|Active Comparator|Proellex 50 mg|Proellex 50 mg once daily
3141302|NCT00739882|Active Comparator|Efalizumab|
3141303|NCT00739882|Placebo Comparator|Placebo|
3141304|NCT00739024|Active Comparator|Active Treatment|Ramelteon once daily (double-blind assignment)
3141305|NCT00739024|Placebo Comparator|Placebo|Placebo tablet, once daily (double-blind assignment)
3141306|NCT00731770|Placebo Comparator|Placebo, then Advair 250- matched|1 puff bid Placebo for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Advair 250- matched 1 puff bid for two weeks.
3141307|NCT00731770|Active Comparator|Advair 250, then Placebo- matched|1 puff bid Advair 250 for two weeks followed by a 4 week washout period with placebo. After the washout period, they then received Placebo- matched 1 puff bid for two weeks.
3141308|NCT00735254|Active Comparator|Pulsed dye laser|PDL Patient will be have scar treated with pulsed dye laser.
3141309|NCT00735254|Active Comparator|Affirm laser|Patient will be have scar treated with Affirm Laser
3141310|NCT00735254|Active Comparator|combined PDL and Affirm Lasers|Patient will be have scar treated with combined Affirm + PDL
3141311|NCT00735254|Placebo Comparator|Placebo|Patient will be have scar treated with Placebo
3141312|NCT00729365|Placebo Comparator|Dippers - Placebo Treated|Subjects with normal nighttime blood pressure profile that decreases at night (Dippers). This group are all given placebo.
3141313|NCT00729365|Placebo Comparator|NonDippers - Placebo Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given placebo.
3141314|NCT00729365|Active Comparator|NonDippers - Ramipril Treated|Subjects with nighttime blood pressure that does not drop during the night (non-dippers). This group will be given ACE inhibitor (study medication).
3141315|NCT00732680|Experimental|Botulinum Toxin Type A|Treatment will be in the form of 10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
3141316|NCT00726180|Experimental|Treatment arm|
3141317|NCT00724282|Other|Eszopiclone or Placebo|Subjects receive either eszopiclone or placebo for 9 days, followed by 3 week washout, then crossover to opposite treatment. Treatment is double-blinded.
3141318|NCT00730886|Experimental|1|Non-invasive procedure for fertility enhancement (i.e., ExAblate treatment)
3141319|NCT00730886|Active Comparator|2|Invasive surgical procedure for fertility enhancement (i.e., myomectomy)
3141320|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel, Bevacizumab|Cohort 1: Bevacizumab Eligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min Bevacizumab 15 mg/kg IV over 90 min for PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
3141321|NCT00728845|Experimental|Hydroxychloroquine, Carboplatin, Paclitaxel|Cohort 2: Bevacizumab Ineligible Patients All on Day 1 Paclitaxel 200mg/m2 IV over 3 hours Carboplatin AUC= 6 IV over 15-30 min PLUS Hydroxychloroquine 200 mg PO BID Cycles every 3 weeks for 4-6 Cycles
3141322|NCT00726830|Experimental|Arm I: Opioid rotation to oral methadone|Participants are switched from their current opioid medication (oxycodone or morphine) to methadone. Participants receive oral methadone 2-3 times daily for 4 weeks.
3141323|NCT00726830|Experimental|Arm II: Opioid rotation to another long-acting strong opioid|Participants currently receiving oxycodone are switched to sustained-release (SR) morphine. Participants currently receiving morphine are switched to SR oxycodone. Participants receive either oral SR morphine or oxycodone 2-3 times daily for 4 weeks.
3141324|NCT00726037|Experimental|1|Three doses of Ontak 9 mcg/Kg IV over 30 minutes every other day for 1 week
3141325|NCT00729560|Experimental|1|Flutamide
3141326|NCT00729560|Placebo Comparator|2|control to arm 1
3141327|NCT00716807|Experimental|TMD 1|
3141328|NCT00716807|Placebo Comparator|TMD 2|
3141329|NCT00716807|Experimental|BMS 1|
3141330|NCT00716807|Placebo Comparator|BMS 2|
3141331|NCT00714948|Experimental|1|This is a phase II trial of gemcitabine and Split-dose cisplatin plus sorafenib.
3141332|NCT00720343|Experimental|Choline|Oral choline
3141333|NCT00720343|Placebo Comparator|Placebo|Gelatin Capsule
3141334|NCT00719914|Active Comparator|1|Intracoronary injection of eptifibatide
3141335|NCT00719914|Placebo Comparator|2|Intra-coronary injection of normal saline.
3141336|NCT00718640|Experimental|Bortezomib and Dexamethasone|Bortezomib 1.3 milligram (mg) per meter^2 (m^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
3141337|NCT00720083|Active Comparator|RT + Cisplatin|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3141338|NCT00720083|Experimental|RT + Cisplatin + Vandetanib|Patients undergo radiotherapy as in arm I and receive cisplatin IV over 1 hour once a week beginning on day 1 of radiotherapy. Patients also receive oral vandetanib once daily beginning 14 days prior to the start of radiotherapy. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3141339|NCT00717275|Experimental|Temozolomide|
3141340|NCT00708734|Experimental|Arm 1|functional exercise training
3141341|NCT00711087|Placebo Comparator|ARM 2|Subjects randomized to receive placebo (saline) sham saline injections on Days 0 and 90.
3141342|NCT00711087|Active Comparator|ARM 1|Subjects randomized to receive 100 units BOTOX-A injections on Days 0 and 90.
3141343|NCT00706797|Active Comparator|Usual care|Utilized Disease-Modifying Antirheumatic Drugs (DMARDs) from a list of the 6 most commonly prescribed in the participating countries (Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, cyclosporine A and gold).
3141344|NCT00706797|Active Comparator|ETN + MTX|Etanercept (ETN) 50 milligrams (mg) sub-cutaneous (SC) injection once weekly (pre-filled syringe) plus continuation of current dose of Methotrexate (MTX) either oral (PO), SC, or intramuscular (IM).
3141345|NCT00713596|Sham Comparator|Control group|Septorhinoplasty with postoperative application of nasal taping and an external nasal cast. The tape and cast will be left in place for one week. No tissue glue will be used during the operation, although the nurse and surgical assistant will simulate the preparation and insertion of tissue glue using a syringe containing saline.
3141346|NCT00713596|Experimental|Fibrinogen, tape, and cast|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, fibrin sealant will be applied by the surgical assistant to the surgical site. Approximately 0.5 cc to 2 cc of tissue sealant will be applied. After closure, tape and cast will be applied and left in place for one week.
3141347|NCT00713596|Experimental|Fibrinogen and tape|Septorhinoplasty will be performed. At the termination of the procedure, prior to closure, 0.5 cc to 2 cc of tissue sealant will be applied. Nasal tape will be applied after closure.
3150653|NCT00207285|Other|Online Group|These firefighters took the sleep disorder screening and education online.
3141348|NCT00703885|Active Comparator|1|"0.25 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan.~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3141349|NCT00703885|Active Comparator|2|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~One-time, single dose.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3141350|NCT00703885|Placebo Comparator|Placebo|"Inactive ingredient in liquid matching appearance and volume of the two active alprazolam dose comparators.~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
3141351|NCT00703092|Experimental|Fiber-Stat|2 tablespoons daily
3141352|NCT00713258|Active Comparator|PTH (1-84)|PTH (1-84) + placebo alendronate
3141353|NCT00713258|Active Comparator|Alendronate|PTH (1-84) placebo + alendronate
3141354|NCT00706329|Experimental|Deflux|Treatment with Deflux.
3141355|NCT00707434|Experimental|Glucose Monitoring Device|Continuous glucose monitoring in critically ill patients.
3141356|NCT00707161|Experimental|All participants|
3141357|NCT00704496|Placebo Comparator|Placebo|Placebo
3141358|NCT00704496|Active Comparator|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
3141359|NCT00708916|Experimental|Apremilast|CC-10004 20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
3141360|NCT00700778|Experimental|Recombinant human chorionic gonadotropin|Patients receive recombinant human chorionic gonadotropin subcutaneously three times weekly. Treatment continues weekly for 90 days in the absence of unacceptable toxicity.
3141361|NCT00699842|Experimental|Lenalidomide|Lenalidomide will be given orally on day 1-21, followed by a 7day rest (28 day cycle). Cycles will be repeated every 28 days.
3141362|NCT00702962|Experimental|Phase I: Vorinostat 200 mg|"Vorinostat 200 mg PO QD D1-14; Administer with Carbo 6 (AUC) D3; Etoposide 100 mg/m2 D1,2,3 Vorinostat, Carboplatin, Etoposide"
3141363|NCT00703534|Experimental|AZD3355|
3141364|NCT00703534|Placebo Comparator|Placebo|
3141365|NCT00698009|Experimental|Fludarabine + Cyclophosphamide + NK Cell Infusion|Fludarabine 25 mg/m^2 intravenous (IV) Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2. Cyclophosphamide 60 mg/kg IV Daily Over 2 Hours On Days -5 and -4. Natural Killer Cell Infusion on Day 0. Mesna 12 mg/kg By Vein, Over about 15 minutes, 5 Times Per Day on Days -5 and -4. Interleukin-2 subcutaneously three times weekly for 9 total doses following NK Cell Infusion.
3141366|NCT00691444|Experimental|1|Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3141367|NCT00691444|Experimental|2|Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3141368|NCT00691444|Experimental|3|Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
3141369|NCT00702702|Experimental|A 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
3141370|NCT00702702|Experimental|B 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
3141371|NCT00702702|Placebo Comparator|C Placebo|Placebo, 2 capsules daily for 3 months
3141372|NCT00693628|Active Comparator|Shrinker|Patients receive 20-30 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
3141373|NCT00693628|No Intervention|No Shrinker|Control group - participants will not receive an intervention (compression shrinker).
3141374|NCT00693628|Active Comparator|Shrinker 2|Patients receive 30-40 mmHg compression shrinker, an elastic compression garment that is worn on the residual limb and is used to reduce edema and promote healing.
3141375|NCT00699413|Active Comparator|1 - nutrition education plus active supplement|nutrition education plus active supplement
3141376|NCT00699413|Placebo Comparator|2 - nutrition education plus inactive supplement|nutrition education plus inactive supplement
3141377|NCT00691652|Experimental|Oral Clofarabine + Rituximab in Relapsed B Cell NHL|"Phase I: Oral Clofarabine x 14 days for up to 8 cycles at assigned dose level below (1 cycle equals 14 days on drug, 14 days off).~Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV~Dose Level 1: 2 mg Dose Level 2: 4 mg Dose Level 3: 6 mg~Phase II:~Oral Clofarabine x 14 days for up to 8 cycles (Dose determined from phase I) AND Rituximab weekly for 4 weeks than monthly for up to 8 cycles on day 1 of cycle 375 mg/m2 IV"
3141378|NCT00686972|Experimental|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
3141379|NCT00693017|Active Comparator|Zonisamide|
3141380|NCT00693017|Placebo Comparator|Placebo|
3141381|NCT00691574|Active Comparator|2|Subjects will sit in front of a fluorescent bright light box while completing plasma samples to test for melatonin suppression in blood. This will be completed by both the SMS patient group and the control group of elderly individuals.
3141382|NCT00691574|Experimental|1|Subjects will take up to 3 mg of melatonin daily and will complete frequent (every 2-4 weeks) of saliva and/or plasma sampling to test for a change in the timing of the body clock in response to the melatonin.
3141383|NCT00692094|Experimental|1|Subjects will be given 0.5 mg at a time when melatonin should delay the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3141384|NCT00692094|Experimental|2|Subjects will be given 0.5 mg at a time when melatonin should advance the timing of their body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3141385|NCT00692094|Experimental|3|Subjects will be given a larger dose (up to 10 mg) at a time when the melatonin should advance the timing of the body clock. If the subject's body clock responds successfully to the dose, the dose will be reduced gradually until the lowest effective dose is found. If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3141386|NCT00692094|Experimental|4|Subjects will be given a larger dose (up to 20 mg) at a time when the melatonin should advance the timing of the body clock. If the subject successfully responds to the treatment, the dose will be reduced gradually until the lowest effective dose is determined (down to 0.025 mg). If the treatment does not work, the subject will be taken off treatment and later entered into a new treatment regimen.
3141387|NCT00689884|Experimental|Group A|All eligible patients will receive chemotherapy and one dose of Pegfilgrastim
3141388|NCT00692003|Active Comparator|Zonisamide|
3141389|NCT00692003|Placebo Comparator|Placebo|
3141390|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously.
3141391|NCT00678288|Experimental|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) twice daily (bid) per os (po), continuously plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
3141392|NCT00676026|Experimental|Zolpidem 1|Zolpidem will be administered twice to each participant; once in the follicular and luteal phases of the menstrual cycle.
3141393|NCT00676026|Experimental|Progesterone 2|Progesterone will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
3141394|NCT00676026|Experimental|Fluoxetine 3|Fluoxetine will be administered twice to each participant; once in both the follicular and luteal phases of the menstrual cycle.
3141395|NCT00689052|Experimental|Pramipexole ER|0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
3141396|NCT00689052|Placebo Comparator|Placebo|Placebo tablets, once daily in the evening
3141397|NCT00678574|Experimental|Premenstrual Dysphoric Disorder (PMDD) group|PMDD group received fluoxetine 20 mg daily by mouth for 2-3 months
3141398|NCT00678574|No Intervention|Healthy controls|
3141399|NCT00683917|Experimental|Proellex 25 mg|Proellex 25 mg
3141400|NCT00683917|Experimental|Proellex 50 mg|Proellex 50 mg
3141401|NCT00683917|Active Comparator|Lupron|Lupron Depot
3141402|NCT00688935|Experimental|Melatonin|Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.
3141403|NCT00685880|Experimental|Prolotherapy group|Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.
3141404|NCT00685880|Active Comparator|Corticosteroid Group|Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.
3141405|NCT00686036|Experimental|vandetanib|300 mg orally, once daily for up to 18 months
3141406|NCT00686036|Placebo Comparator|Placebo|orally, once daily for up to 18 months
3141407|NCT00681044|Experimental|SCT with melphalan conditioning|Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion
3141408|NCT00684255|Experimental|Reduced Intensity Regimen for Refractory SLE|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
3141409|NCT00684255|Experimental|Reduced Intensity Regimen for SSc|RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).
3141410|NCT00683787|Active Comparator|Arm I|Patients receive docetaxel IV once every 3 weeks.
3141411|NCT00683787|Experimental|Arm II|Patients receive docetaxel IV as in arm I and oral vandetanib (100 mg) once daily.
3141412|NCT00683787|Experimental|Arm III|Patients receive docetaxel IV as in arm I and oral vandetanib (300 mg) once daily.
3141413|NCT00679926|Experimental|Once daily|Patients taking 4 (four) lopinavir/ritonavir (200mg/50mg tablets) and 1 (one) tenofovir (300mg tablet) every 24 (twenty four) hours.
3141414|NCT00678041|Experimental|Arm 1: Nitrofurantoin Group|extended release nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
3141415|NCT00678041|Placebo Comparator|Arm 2: Placebo Group|identical appearing placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
3141416|NCT00680316|Experimental|Dornase alfa|
3141417|NCT00680316|Placebo Comparator|Placebo|
3141418|NCT00681629|Experimental|Quetiapine XR Alone|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
3141419|NCT00681629|Experimental|Quetiapine XR With Integrated Care Program (ICP)|Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
3141420|NCT00669461|Experimental|Patients|
3141421|NCT00671606|Experimental|Intraoperative Lymphatic Mapping|Intraoperative sentinel lymph node identification (lymphatic mapping)
3141422|NCT00673309|Experimental|Growth Hormone|Growth Hormone administered daily until 95% wound healing. Stable Isotope Infusion Study with collection of blood and tissue
3141423|NCT00673309|Experimental|Insulin High Dose|Insulin IV administered continuously to 95% healing. Stable Isotope Infusion Study with collection of blood and tissue
3141424|NCT00673309|Experimental|Oxandrolone|Oxandrolone administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
3141425|NCT00673309|Experimental|Propranolol|Propranolol administered daily until 95% wound healing Stable Isotope Infusion Study with collection of blood and tissue
3141426|NCT00673309|Experimental|IGF-1/IGFBP-3|IGF-1/IGFBP-3 will be administered until 95% wound healing
3141427|NCT00673309|Experimental|Insulin Low Dose|Insulin Low Dose will be administered until 95% wound healing.
3141428|NCT00673309|Experimental|Itraconazole|Itraconazole will be administered until 95% wound healing.
3141429|NCT00673309|Experimental|Growth Hormone and Propranolol|Growth Hormone and Propranolol will be administered until 95% wound healing.
3141430|NCT00673309|Experimental|Oxandrolone and Propranolol|Oxandrolone and Propranolol will be administered until 95% wound healing
3141431|NCT00673309|Placebo Comparator|Control/Placebo|Placebo or Control will be administered until 95% wound healing
3141432|NCT00673595|Active Comparator|Varenicline|Participants on this arm will receive varenicline tablets for 15 days.
3141433|NCT00673595|Placebo Comparator|Placebo|Participants on this arm will receive placebo tablets for 15 days.
3141434|NCT00673361|Experimental|"Chemo-Switch Regimen"|
3141435|NCT00670631|Experimental|Tandem autologous stem cell transplant|"Induction: DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant 1: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide) Transplant 2: 8 weeks to 6 months after the first transplant, participants will have the second transplant Maintenance: Year 1- VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3141436|NCT00668785|Experimental|Ranibizumab|Ranibizumab is being used off-label to test the safety and efficacy of its use in Diabetic Macular Edema post panretinal photocoagulation. Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
3182680|NCT00705640|Experimental|Arm 2C|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, and 15 and undergo surgical biopsy at replicate vaccine site on day 22 (1 week after replicate vaccine 3).
2409618|NCT03507296||Chronic low back pain patients|
2409619|NCT03507296||Asymptomatic subjects|
3141437|NCT00673179|Experimental|Outpatient Chemotherapy|Pre-Surgery, Regimen 1: Doxorubicin intravenous (IV) 90 mg daily, Cisplatin 60 mg/m^2/day for 2 days, Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Surgery; Post-Surgery, Regimen 1: Methotrexate 12 gm/m^2, Doxorubicin IV 90 mg, Cisplatin 60 mg/ m^2 twice daily, Leucovorin Rescue.
3141438|NCT00673179|Experimental|Additional Risk-Adapted Outpatient Chemotherapy|Pre-Surgery, Regimen 2: Dexrazoxane 900 mg/m^2 intravenous (IV) then Doxorubicin IV 90 mg daily, Cisplatin 120 mg/m^2 (intra-arterial); Surgery; Post-Surgery, Regimen 2: Methotrexate 12 gm/m^2, Leucovorin Rescue 10 mg IV, with 10 mg orally every 6 hours; Ifosfamide 2.8 grams m^2/day and Mesna 2.8 gm/m^2/day continuous IV over 6 days; Lung-Directed Chemotherapy, Regimen 2: Gemcitabine, Sargramostim Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg).
3141439|NCT00668265|Experimental|Seroquel|
3141440|NCT00660348|Active Comparator|morphine|morphine given traditionally (IV, pill, patch). This is standard of care dosing.
3141441|NCT00660348|Active Comparator|Intrathecal pump|Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20
3141442|NCT00667017|Experimental|IMTOX25 at 2mg/m²/dose|Patients will receive IMTOX25 at 2mg/m²/dose, by IV administration, every other day for a total of 3 doses. A total of 6 cycles of treatment will be allowed. A cycle is equal to 6 weeks, with IMTOX25 infusion on Day 1, 3 and 5, followed by a 5 week rest period.
3141443|NCT00665444|Experimental|A|Aripiprazole
3141444|NCT00656916|Experimental|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
3141445|NCT00656916|No Intervention|Observational Group|Comparator group, no intervention.
3141446|NCT00660595|Experimental|1|Oral
3141447|NCT00660595|Active Comparator|2|Oral
3141448|NCT00661466|Experimental|1|Either three or four 5x5-cm bupivacaine sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
3141449|NCT00661466|Placebo Comparator|2|Either three or four 5x5-cm placebo sponges implanted at 2 sites within the surgical field (1) over the abdominal viscera and under the fascia prior to closing the fascia and (2) in the subcutaneous tissue just under the skin incision.
3141450|NCT00646282|Experimental|Doxercalciferol|Stable kidney transplant recipients will receive Doxercalciferol
3141451|NCT00646282|No Intervention|Control|Stable kidney transplant recipients will not receive any drug
3141452|NCT00657553|Active Comparator|Bortezomib/Treatment Arm|Bortezomib Maintenance Year 1 - bortezomib days 1, 4, 8, 11 every 28 days Year 2 - bortezomib days 1, 4, 8, 11 every 2 months Year 3 - bortezomib days 1, 4, 8, 11 every 3 months
3141453|NCT00657553|No Intervention|Observation Arm (watchful waiting)|monitor myeloma parameters every 3-6 months
3141454|NCT00655057|Active Comparator|1|Healthy participants will undergo TRODAT-1 SPECT imaging.
3141455|NCT00655057|Experimental|2|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with s-citalopram.
3141456|NCT00655057|Active Comparator|3|Participants with depression will undergo TRODAT-1 SPECT imaging and treatment with cognitive behavioral therapy.
3141457|NCT00648895|Active Comparator|1|Nebivolol
3141458|NCT00648895|Active Comparator|2|Metoprolol ER (TM)
3141459|NCT00647426|Experimental|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
3141460|NCT00645567||Unassisted manual transfer|this group will use no additional aid in transfer.
3141461|NCT00645567||Standard sliding board transfer|The standard transfer board is a flat surface board designed to bridge the gap that exists with transfers from wheelchair to vehicle and/or other horizontally displaced seating surfaces.
3141462|NCT00645567||Glide n' Go Lift|The Glide n' Go lift is a flip down power list seat that enables the person to enter and exit the vehicle by lifting them from their wheelchair up tot eh vehicle seat that they can make an easy transfer into the vehicle. Trunk stability may be required to successfully use the device.
3141463|NCT00645567||Easy Reach lift|The Easy Reach lift seat allows the vehicles original seat to swivel out of the vehicle and lower to wheelchair height. the chair extends far from the vehicle to provide access for a safe, easy transfer.
3141464|NCT00645567||Ryno lift|The Ryno lift is an under-vehicle list (UVL) system. Using this lift, the wheelchair user is raised into the vehicle cab using independent controls and can then maneuver into a convenient position in the cab. The wheelchair is locked down and the lift stored beneath the vehicle chassis. This technology eliminated the need to store and retrieve a wheelchair during transit.
3141465|NCT00637806|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
3141466|NCT00637806|Active Comparator|2|Megestrol acetate concentrated suspension 60 mg/mL
3141467|NCT00637806|Placebo Comparator|3|
3141468|NCT00652457|Experimental|Memantine|Memantine 10 mg BID for three months
3141469|NCT00652457|Placebo Comparator|Placebo|Placebo 10 mg BID for three months
3141470|NCT00642603|Experimental|XELOX + bevacizumab (Q2W)|
3141471|NCT00642603|Experimental|XELIRI + bevacizumab (Q2W)|
3141472|NCT00629798|Experimental|1|This is a single arm phase II trial to assess the efficacy (decrease the transplant related mortality) and safety of peri-transplant Palifermin in combination with a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor in patients with advanced MDS and AML evolved from MDS. The addition of Palifermin is to decrease the toxicity and the infection rate associated with this regimen and transplant type and to foster earlier immune reconstitution.
3141473|NCT00645359||Diffusion MRI|Patients will undergo a Diffusion MRI (dMRI) at baseline and 7 days.
3141474|NCT00637728|Active Comparator|1|Megestrol acetate concentrated suspension 110 mg/mL
3141475|NCT00637728|Placebo Comparator|2|Placebo suspension
3141476|NCT00639626|Experimental|Levemir|
3141477|NCT00641108|Experimental|ADAM SPECT|Participants with depression will undergo ADAM SPECT scans and cognitive behavioral therapy.
3141478|NCT00641108|Active Comparator|Control|Healthy subjects without depression will undergo ADAM SPECT scans.
3141479|NCT00642382|Active Comparator|Active|Agilus (Hyaluronic Acid)
3141480|NCT00642382|Placebo Comparator|Control|Normal Saline
3141481|NCT00637416|Active Comparator|Lansoprazole and dietary control|Lansoprazole and dietary control
3141482|NCT00637416|Placebo Comparator|Placebo and dietary control|Dietary control and placebo
3141483|NCT00635167|Experimental|Contrast Enhanced Transrectal Ultrasound (TRUS)|
3141484|NCT00637312|Experimental|Advent™ Cervical Disc|Cervical artificial disc replacement: Advent™ Cervical Disc
3141485|NCT00637312|Active Comparator|Standard care - Control|Anterior cervical discectomy and fusion (ACDF) with Hallmark™ Anterior Cervical Plate System
3141486|NCT00638222|Active Comparator|All Study Participants|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
3141487|NCT00634322|Experimental|A|HDMTX-LV with glucarpidase
3141488|NCT00634322|Active Comparator|B|HDMTX-LV with placebo
3141489|NCT00634322|Experimental|C|compassionate use group to treat or prevent life threatening toxicity in the event of delayed elimination of MTX and/or renal impairment
3141490|NCT00633087|Experimental|2-deoxyglucose|
3141491|NCT00631137|Placebo Comparator|Arm 1: Control Group|whey protein powder
3141492|NCT00631137|Active Comparator|ARM 2 : Treatment Group|Testosterone Gel (10g pouch/day) applied to skin
3141493|NCT00634972|Experimental|1|
3141494|NCT00634972|Placebo Comparator|2|
3141495|NCT00633061|Experimental|A-randomized to treatment|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to treatment with enoxaparin for 6 weeks
3141496|NCT00633061|No Intervention|B-randomized to close|Patients diagnosed with asymptomatic catheter-related DVT who are randomized to close observation for 6 weeks
3141497|NCT00626444|Experimental|1|Intravenous vitamin C
3141498|NCT00630292|Experimental|1|
3141499|NCT00634010|Active Comparator|Morphine Capsule|Morphine 15 mg slow release orally every 12 hours + additional doses as needed
3141500|NCT00634010|Active Comparator|Methadone Capsule|Methadone 5 mg orally every 12 hours + additional as needed doses up to 40-50 mg/day
3141501|NCT00630487|Placebo Comparator|Placebo|
3141502|NCT00630487|Active Comparator|Verum|
3141503|NCT00629850|Experimental|Powerlung Performer|The arm will receive the lung trainer device to use for 10 weeks
3141504|NCT00629850|No Intervention|Control|Control. This arm will not receive any device
3141505|NCT00623974|Experimental|Calcium + Calcitriol|1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3141506|NCT00623974|Experimental|Teriparatide 20 mcg|Teriparatide at 20 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3141507|NCT00623974|Experimental|Teriparatide 40 mcg|Teriparatide at 40 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3141508|NCT00623974|Experimental|Teriparatide 60 mcg|Teriparatide at 60 mcg; and 1000 milligrams Calcium + 0.25 micrograms Calcitriol orally every 12 hours
3141509|NCT00624650|Active Comparator|Modified FACTT (control)|The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
3182681|NCT00705640|Experimental|Arm 2D|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 50 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3182682|NCT00705640|Experimental|Arm 2E|Patients receive primary vaccine, half of the volume subcutaneously (SC) and the other half intradermally (ID), 6 times over 7 weeks on days 1, 8, 15, 29, 36, and 43. Patients receive replicate vaccine (the same as primary vaccine) SC and ID on days 1, 8, 15, 29, 36, and 43 and undergo surgical biopsy at replicate vaccine site on day 85 (1 week after replicate vaccine 6). Patients are evaluated 1-3 weeks after biopsy.
3150654|NCT00207311|Placebo Comparator|Xenical placebo|Xenical placebo PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
3182683|NCT00705692|Experimental|Levamisole|Two 50 mg levamisole tablets daily, six days before and six days after Td vaccination.
2410101|NCT03503812|Experimental|Intervention 1 - Atrial Fibrillation|
3182684|NCT00705692|Placebo Comparator|Placebo|Two placebo tablets daily, six days before and six days after Td vaccination.
3182685|NCT00705705|Experimental|1|Participating social networks will receive standard HIV risk-reduction counseling and network leadership training on HIV prevention.
3182686|NCT00705705|Active Comparator|2|Participating social networks will receive standard HIV risk-reduction counseling.
3182687|NCT00705744|Experimental|I|
3182688|NCT00705770|Placebo Comparator|1|Placebo treatment with vehicle
3182689|NCT00705770|Experimental|2|Low dose of study medication
3141510|NCT00624650|Experimental|EVLW|"When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement.~Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome."
3141511|NCT00626561|Experimental|Bevacizumab + Paclitaxel|Bevacizumab 10 mg/kg intravenous (IV) twice weekly and Paclitaxel 60 mg/m^2 IV weekly.
3141512|NCT00613730|Experimental|Gemcitabine + panitumumab|Panitumumab 6 mg/kg was administered intravenously (IV) before gemcitabine on Day 1 of Weeks 1, 3, 5, and 7, and then every 2 weeks (day 1 and 15) of each subsequent 4-week chemotherapy cycle. Gemcitabine 1000 mg/m^2 was administered IV once weekly (on Day 1) for 7 weeks, followed by a 1-week rest period. In subsequent cycles, gemcitabine was given once weekly (on Day 1) for 3 consecutive weeks followed by 1 week of rest. Panitumumab and gemcitabine treatment continued until disease progression, unacceptable adverse events, death, or study withdrawal occurred.
3141513|NCT00625586|Experimental|RAV12 plus gemcitabine|
3182690|NCT00705770|Experimental|3|Middle dose of study medication
3182691|NCT00705770|Experimental|4|High dose of study medication
3141514|NCT00625703|Experimental|A|
3141515|NCT00625742|Experimental|Multimodal Treatment Strategy|Exercise Program + Pharmacologic Intervention (Melatonin + Atenolol + Ibuprofen) + Nutritional Supplementation (Juven) - Resistance training sessions twice weekly using Thera-bands. Walking or running for 3-4 minutes at 70-80% of maximum predicted heart rate. Melatonin 20 mg by mouth (PO) Daily. 90 calories of Juven, twice a day.
3141516|NCT00619242|Experimental|sorafenib|sorafenib 2 tablets by mouth
3141517|NCT00619151|Active Comparator|1|CarboMedics Supra-annular Top Hat Valve
3141518|NCT00619151|Active Comparator|2|St. Jude Medical Regent Valve
3141519|NCT00622167|Other|1|All patients will receive integrated backscatter IVUS and dual source CT.
3141520|NCT00616577|Experimental|Group CB|Subjects in this arm will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after induction of general anesthesia prior to surgical incision.
3141521|NCT00616577|Active Comparator|Group CA|Group CA (Caudal After-control group) will receive caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine after completion of surgery but before emergence from anesthesia.
3141522|NCT00616577|Active Comparator|Group LIA|Group LIA (Local Infiltration After-control group) will receive local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site at the conclusion of surgery but before emergence from anesthesia.
3141523|NCT00616759|Active Comparator|1|ECT as usual
2410102|NCT03503812|Experimental|Intervention 2 - Atrial Fibrillation|
3141524|NCT00616759|Experimental|2|ECT-induced seizures terminated with propofol
3141525|NCT00616642|Experimental|Group 1 (ACTH-secreting adenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 6 months in the absence of disease progression or unacceptable toxicity.
3141526|NCT00616642|Experimental|Group 2 (non-secreting macroadenomas)|Patients receive 4 mg oral rosiglitazone maleate once daily in week 1 and then 8 mg once daily beginning in week 2 and continuing for up to 12 months in the absence of disease progression or unacceptable toxicity.
3141527|NCT00619515|Experimental|CyberKnife® stereotactic radiosurgery|
3141528|NCT00616343|Active Comparator|Zonisamide|
3141529|NCT00612677|Experimental|Premetrexed and Oxaliplatin|Patients will be treated with oxaliplatin 120 mg/m^2 i.v. over 2 hours and pemetrexed 500 mg/m^2 i.v. over 10 minutes on Day 1 of a 21day cycle. Cycles of treatment will be repeated every 3 weeks. Folic acid and B12 supplementation is obligatory.
3141530|NCT00616603|Other|Group A|This is the control arm and subjects in Group A will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV of normal saline.
3141531|NCT00616603|Experimental|Group B|Subjects in Group B will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 8mg Dexamethasone + 2ml IV of normal saline.
3141532|NCT00616603|Active Comparator|Group C|Subjects in Group C will have sciatic nerve block with 20ml of 0.2% Ropivacaine + 2ml IV (8mg)of Dexamethasone.
3141533|NCT00613886|Experimental|Comparison for patients of lumbar drain and shunt surgery|"Subjective comparisons made for patients - before and after external lumbar drain, before and after shunt surgery.~Device: Programmable Shunt Insertion (Codman Medtronic)~Behavioral: Assessments in physical therapy, occupational therapy, and speech therapy~Follow-up testing to be administered by trained physician assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, mini-mental status exam, 9-hole grooved pegboard, motor visual perception test (MVPT), modified rankin score (MRS)"
3141534|NCT00610467|Experimental|Disease Group|Patients with suspicious breast diseases
3141535|NCT00610467|Experimental|Control Group|Healthy volunteers for system testing
3141536|NCT00610558|Experimental|Arm 1: Juvenile Myoclonic Epilepsy|Juvenile Myoclonic Epilepsy group of subjects will participate for imaging assessment
3141537|NCT00610558|Experimental|Arm 2: Frontal Lobe Epilepsy|Frontal Lobe Epilepsy group of subjects will participate for imaging assessment
3141538|NCT00610558|Experimental|Arm 3: Normal Controls|Normal Controls, eligible subjects don't have Juvenile Myoclonic Epilepsy or Frontal Lobe Epilepsy will be placed in this group
3141539|NCT00610532|Experimental|A|intravenous phenytoin alone
3141540|NCT00610532|Experimental|B|intravenous phenytoin plus probenecid
3141541|NCT00609765|Experimental|Protocol Specified Chemotherapy|"Protocol Specified Chemotherapy Every 28 Days: Avastin, Fluorouracil, Doxorubicin, Streptozocin.~Premedications: Dexamethasone, Ondansetron"
3141542|NCT00608465|Active Comparator|Treatment A|Eplerenone (study drug)
3141543|NCT00608465|Active Comparator|Treatment B|Ramipril
3141544|NCT00601848|Experimental|Photodynamic Therapy|PDT
3141545|NCT00607477|Active Comparator|1|Minoxidil
3141546|NCT00607477|Active Comparator|2|Hydralazine
3141547|NCT00595920|Experimental|Tovaxin, open-label|Tovaxin; 30-45 million autologous myelin reactive T cells
3150655|NCT00207311|Active Comparator|Xenical (orlistat)|Xenical (orlistat) 120mg PO three times daily with meals plus enrollment into the Xenicare program for 36 weeks followed by 48 weeks of therapy with Pegasys (180mcg/ml) plus weight based ribavirin for HCV genotype 1 or 4 and 24 weeks of therapy with Pegasys (180mcg/ml) plus 800mg ribavirin for HCV genotypes 2 and 3.
3150656|NCT00207350|Other|Brain tumor|Neurosurgical use of Interstitial Laser therapy
3150657|NCT00207363|Experimental|Initial induction therapy|Receive Peg Intron 3.0mcg/kg/wk for 12 weeks followed by Peg Intron 1.5 mcg/kg/wk for 36 weeks
3150658|NCT00207363|Active Comparator|Standard of Care|Peg Inter 1.5mcg/kg/wk for 48 weeks
3150659|NCT00207389||Laparoscopic gastric bypass|Patients undergoing Laparoscopic gastric bypass
3150660|NCT00207389||Open gastric bypass|Patients undergoing Open gastric bypass
3141548|NCT00596947|Experimental|Prednisone Withdrawal|Participants randomized to the prednisone withdrawal group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was given intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered to participants an inpatient or outpatient for a total of 3 to 5 doses. Participants also began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued indefinitely. The steroids were initially given in the operating room intravenously at time of transplant as Solu-medrol (methylprednisolone)and were then switched to daily oral prednisone doses. The participant's dose of prednisone was rapidly decreased until it was completely eliminated by day 6 post-transplant.
3150661|NCT00207402|Active Comparator|rosiglitazone|Treatment with rosiglitazone 4 mg twice a day for 3 months prior to and during the course of 48 weeks of treatment with interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin.
3141549|NCT00596947|Active Comparator|Prednisone Maintenance|Participants randomized to the prednisone maintenance group, received 4 medications to prevent rejection. Thymoglobulin (rabbit antithymocyte globulin) was initiated intravenously in the operating room at the time of transplant. Subsequent intravenous doses were administered an inpatient or outpatient for a total of 3 to 5 doses. Participants began taking Prograf (tacrolimus) and CellCept (mycophenolate mofetil)orally within 24 hours of transplant and continued on them indefinitely. The steroids were initially given intravenously in the operating room at time of transplant as Solu-medrol (methylprednisolone) and were then switched to daily oral prednisone tablets. Participants remained on all drugs according to their doctor's standard of care, and the prednisone was not be eliminated.
3141550|NCT00584012|Experimental|Dose Esclation|Determine the maximum tolerated dose (MTD) of escalating doses of lovastatin in combination with docetaxel in patients with any type of solid tumor.
3141551|NCT00599131|Experimental|Chemotherapy/Radiation/Surgery|"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.~On day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.~Depending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy."
3141552|NCT00597909|Experimental|Arm 1|
3141553|NCT00597909|Experimental|Arm 2|
3141554|NCT00597909|Placebo Comparator|Arm 3|
3141555|NCT00593320|Active Comparator|1|Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
3141556|NCT00593320|Active Comparator|2|High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy
3141557|NCT00589550|Experimental|Peginterferon alfa-2b|Peginterferon alfa-2b will be administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
3150662|NCT00207402|No Intervention|No Avandia|Monitoring period without rosiglitazone for 3 months prior to 48 weeks of interferon alfacon-1 15mcg/0.5ml SQ daily and weight-based ribavirin
3150663|NCT00207441|Experimental|Arthritis self management program|
3150664|NCT00207441|Experimental|Chronic Disease Self Management Program|
3150665|NCT00207688||Infliximab 5 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3150666|NCT00207688||Infliximab 10 mg/kg|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3150667|NCT00207688||Placebo|This is an observational study which includes patients from primary studies C0168T37, C0168T46, C0168T72.
3150668|NCT00207831|Experimental|Tegafur uracile + radiotherapy|
3150669|NCT00207831|Active Comparator|radiotherapy|
3150670|NCT00207857||With and Without PFTs|
3141558|NCT00577772|Active Comparator|Healthy Participants|Healthy Participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.
3150671|NCT00207948||Therapeutic Dose Adjustment|To adjust the doses of medications to meet target therapeutic concentrations
3150672|NCT00208078|No Intervention|Usual medical therapy|Usual CF care
3182692|NCT00705796|Experimental|Group 1|Group 1 will be treated with MPP10, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
3182693|NCT00705796|Active Comparator|Group 2|Group 2 will be treated with AndroGel® 50 mg, once daily in the morning after washing/showering.
3182694|NCT00705822|Experimental|1|Docetaxel + Estramustine + Hydrocortisone
3182695|NCT00705822|Active Comparator|2|Docetaxel + Prednisone
3150673|NCT00208078|Experimental|Non-invasive ventilation|Pressure support ventilator (SAIME,AIROX)
3150674|NCT00208104|Experimental|Motivational Interview Condition|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
3150675|NCT00208104|No Intervention|Non-supportive Counseling|A non-supportive counseling session will consist of regular nurse-patient interaction.
3182696|NCT00705835|Experimental|1|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Six patients will start on 50μg rsPSMA +0.5 mg Alhydrogel® Weeks 1,2,3 and 7.
3141559|NCT00577772|Active Comparator|Symptomatic Participants|"Subjects with symptoms suggestive of small bowel bacterial overgrowth (SBBO) (e.g., diarrhea, bloating, abdominal discomfort) for at least 3 months will be divided into 2 groups based on the results of their previous testing for SBBO (5 SBBO positive patients, 5 SBBO negative patients).~The symptomatic participants will report for simultaneous lactulose hydrogen breath test (H_2BT) and SmartPill study after an overnight fast. They will swallow the SmartPill Capsule at the study site. After 4 hours, they will be allowed to leave the study site and consume their usual diet. They will return for removal of the data recorder 5 days later.~After the capsule has been demonstrated to be passed from the subject, the subjects with SBBO present will then enter into an open-label treatment using Rifaximin (400 mg PO TID) for 7 days."
3141560|NCT00592007|Experimental|A|Single-arm study
3141561|NCT00595582|Other|single arm|Curcumin + Bioperine
3141562|NCT00588146|Experimental|Pegylated Interferon Alpha2b, then Standard Care|Weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months, then standard care for 6 months.
3141563|NCT00588146|Experimental|Standard Care, then Pegylated Interferon Alpha2b|Standard care for 6 months, then weekly subcutaneous injection of pegylated interferon alpha2b 1 microgram/kg/week for 6 months.
3141564|NCT00586209|Experimental|L-glutamine|"L-glutamine group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
3141565|NCT00586209|Placebo Comparator|Placebo|"Maltodextrin group will be given at the following dosage:~17-33.3 kg at 5 g 2x daily 33.4-66.6 kg at 10 g 2X daily >66.7 at 15 g 2X daily"
3141566|NCT00590538|Active Comparator|Phenylbutyrate|"The standard oral adult dose is 20 g/day for 4 days.~Every participant will receive Genistein during the NPD."
3141567|NCT00590538|Placebo Comparator|Placebo|The placebo is given to match the active comparator for 4 days. Every participant will receive Genistein.
3141568|NCT00583115|Experimental|Gleevec|Drug taken orally 260mg/M2/day once per day
3141569|NCT00582712|Experimental|Lithium Capsules|Lithium carbonate
3141570|NCT00586716|Other|Group 1 intravenous immune globulin|Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
3141571|NCT00586716|Other|Group 2 intravenous immune globulin|Intravenous immune globulin for patients who have living donors with positive crossmatch results.
3141572|NCT00583466|Active Comparator|1 Normal saline arm|Polypectomy with normal saline injected for submucosal cushion creation
3141573|NCT00583466|Active Comparator|2 HPMC arm|Polypectomy after injection of hydroxypropyl methylcellulose (HPMC) to create submucosal cushion
3141574|NCT00583466|Experimental|3 Blood arm|Polypectomy after injection of autologous blood
3141575|NCT00588471|Active Comparator|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
3141576|NCT00588471|Placebo Comparator|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
3141577|NCT00587795|Active Comparator|StabilAir Wrist Brace|One study group will consist of patients treated with the StabilAir Wrist Brace.
3141578|NCT00587795|Placebo Comparator|Control|Study arm will consist of patients that are treated with placement of sugar tong splint or plaster cast.
3141579|NCT00590135|Experimental|AORTIC STENOSIS PATIENTS|Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis
3141580|NCT00582036|Active Comparator|Arm 1|Regular Sliding Scale Insulin administration for hyperglycemia
3141581|NCT00582036|Experimental|Arm 2|MiniMed Paradigm monitoring device for hyperglycemia
3141582|NCT00585585|Experimental|Arm 1: Betahistine dihydrochloride|Oral betahistine dihydrochloride; daily dose 50-300 mg
3141583|NCT00585221|Experimental|All patients|All participants enrolled in the study.
3141584|NCT00581113|Active Comparator|1|Standard Whole Brain Radiotherapy
3141585|NCT00581113|Experimental|2|Neural Stem Cell-Preserving Whole Brain Radiotherapy
3141586|NCT00587223|Experimental|1|Apligraf (a living bilayered cell therapy product)
3141587|NCT00587223|Active Comparator|2|Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.
3141588|NCT00585611|Experimental|Atorvastatin|Heart failure patients assigned to atorvastatin
3141589|NCT00585611|Placebo Comparator|2|
3141590|NCT00572260|Experimental|A|Daptomycin as a single preoperative dose within 30 minutes prior to surgery Dosage: if creatinine clearance ≥ 30 ml/min: 6 mg/kg IV
3141591|NCT00571194|Other|peritoneal dialysis (CCPD)|PK profile of pravastatin
3141592|NCT00584935|Experimental|Rituximab|The Rituximab dose is 1000 mg (1gm) given as an IV infusion every two weeks for 2 doses (Days 1 and 15).
3141593|NCT00577395|Experimental|2|one 150 mg risedronate once a month, orally
3141594|NCT00577395|Placebo Comparator|1|Placebo tablet once a month, orally
3141595|NCT00573391|Experimental|VTD = Velcade, Thal, and Dex|VTD = Velcade, Thalidomide, and Dexamethasone
3141596|NCT00573391|Experimental|VMD = velcade, melphalan, and dex|VMD = velcade, melphalan, and dexamethasone
3141597|NCT00570258|Placebo Comparator|2|"Fulvestrant: 250 mg IM Q 4 weeks~Placebo: 150 mg PO QD"
3141598|NCT00570258|Active Comparator|1|"Fulvestrant: 250 mg IM Q 4 weeks~Erlotinib: 150 mg PO QD"
3141599|NCT00568802|Experimental|Hydroxyurea|
3141600|NCT00568802|Placebo Comparator|Placebo|
3141601|NCT00576524|Experimental|Sham Device first, ITD next|Subjects will be randomized to recieve sham device first, ITD next after washout of 7 days.
3141602|NCT00576524|Experimental|ITD first, sham device next|Subjects will be randomized to receive ITD first, sham device next, after washout of 7 days.
3141603|NCT00568698|Experimental|Hydroxyurea|
3141604|NCT00568698|Placebo Comparator|Placebo|
3141605|NCT00574080|Experimental|Arm A|DPACE Induction, Melphalan/DPACE Transplant 1, BEAM Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
3141606|NCT00574080|Experimental|Arm B|DPACE Induction, Melphalan/DPACE + VTD Transplant 1, BEAM + VTD Transplant 2, DPACE Consolidation, Dexamethasone Maintenance with Interim dexamethasone between treatment phases
3141607|NCT00558558|Other|Fermented Soy Supplement|4 oz Haelan orally twice daily for 8 weeks
3141608|NCT00573937|Active Comparator|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
3141609|NCT00573937|Active Comparator|Morphine|Oral slow-release morphine (15 mg) every 8 hours, and immediate-release morphine (10 mg) every 4 hours as needed for breakthrough pain.
3141610|NCT00577317|Experimental|Arm 1|Patients receive standard home maintenance therapy and perform self-manual lymphatic drainage once daily for 60 minutes for 24 weeks.
3141611|NCT00577317|Experimental|Arm II|Patients receive Flexitouch® home maintenance therapy once daily for 60 minutes for 24 weeks
3141612|NCT00571922|Active Comparator|Acamprosate|
3141613|NCT00571922|Placebo Comparator|Placebo|
3141614|NCT00569868|Experimental|Velcade|"Treatment on this study will last 2 cycles. Each cycle consists of 3 weeks, or 21 days. After you have gone off study, you will be followed every three months for approximately 2 years.~Each cycle will consist of 3 weeks (21 days) according to the schedule below.~DRUG ROUTE DOSE DAYS Velcade IV 1.3 mg/m2 1,4,8, and 11 This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a two cycles."
3141615|NCT00573157|Experimental|Atacicept Plus Mycophenolate mofetil Plus Corticosteroids|
3141616|NCT00573157|Placebo Comparator|Placebo Plus Mycophenolate mofetil Plus Corticosteroids|
3141617|NCT00570531|Experimental|Bevacizumab|
3141618|NCT00566462|Experimental|perampanel|
3141619|NCT00566462|Placebo Comparator|1|
3141620|NCT00561912|Experimental|Decitabine + Interferon Alfa-2b|Decitabine 15 mg/m^2 intravenous (IV) daily over one hour for 5 days + Interferon Alfa-2b 0.5 million Units Subcutaneously Twice Daily Continuously, as of Cycle 3, Day 1.
3141621|NCT00561795|Experimental|Arm A|Oral Pazopanib 800 mg once a day+ carboplatin area under the concentration-time curve (AUC) 5 intravenous (IV) over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
3141622|NCT00561795|Experimental|Arm B|Oral Pazopanib 800 mg once a day+ carboplatin AUC 6 IV over 1 hour every 3 weeks + paclitaxel 175 mg/m^2 IV over three hours day one q 3 weeks for six cycles
3141623|NCT00564876|Experimental|Treatment|Neoadjuvant dasatinib is to be administered as an oral dose of 70 mg PO twice daily on a continuous basis for 3 weeks prior to surgery. Patients will begin adjuvant dasatinib (70 mg PO twice daily) between 4-6 weeks after standard adjuvant therapy is complete or 4-8 weeks after surgery for those patients that do not receive adjuvant chemotherapy. Adjuvant dasatinib will be given on a continuous basis for up to 3 months after adjuvant chemotherapy or after surgery if no adjuvant chemotherapy is given.
3141624|NCT00558870|Active Comparator|Morphine Only|"Morphine - Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
3182697|NCT00705835|Experimental|2|This is an ascending, multiple dose study in up to 18 patients. As many as eight patients are planned at each of two dose levels, intrapatient dose escalation is not allowed. Eight patients will start on 250μg rsPSMA + 1.0 mg Alhydrogel Weeks 1,2,3 and 7
3182698|NCT00705848||1|10 patients with tracheobronchomalacia
3141625|NCT00558870|Active Comparator|Morphine + Methadone|"Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain.~1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)"
3182699|NCT00705848||2|10 patients with tracheal stenosis
3182700|NCT00705848||3|10 patients with normal airways (no known airway diseases)
3182701|NCT00705861|Placebo Comparator|1|
3182702|NCT00705861|Experimental|2|
2413948|NCT03477214||Overactive bladder|Overactive bladder conditions
3182703|NCT00705887|No Intervention|Control|Brochure from the American Academy of Dermatology on protecting your skin from UV rays.
3141626|NCT00559897|Experimental|3'-deoxy-3'-[18F]FLT PET & zoledronic acid|"Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid~Single photon emission computed tomography. Patient should receive the dose of zoledronic acid within 48 hrs of the first '3'-deoxy-3'-[18F]FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid."
3141627|NCT00556400|Active Comparator|Lo-ovral|1 tablet of lo-ovral is administered twice a day
3141628|NCT00556400|Placebo Comparator|sugar pill|Sugar pill was provided as a placebo
3141629|NCT00556075|Placebo Comparator|Placebo|Placebo once daily
3141630|NCT00556075|Experimental|25 mg|Proellex 25 mg once daily
3141631|NCT00556075|Experimental|50 mg|Proellex 50 mg once daily
3141632|NCT00556166|Experimental|Enterra Therapy|The Enterra Therapy Gastric Stimulator will be used on subjects who have failed all other medical options to treat gastroparesis and all have a gastric stimulator implanted.
3141633|NCT00521924|Experimental|Infliximab + basic treatment|3 mg/kg infliximab plus basic treatment
3141634|NCT00521924|Active Comparator|Basic treatment (DMARDs)|Rheumatoid Arthritis basic therapy (disease modifying anti-rheumatic drugs [DMARDs])
3141635|NCT00548886|Experimental|Epinephrine|Healthy pediatric subjects will receive epinephrine. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes.The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes. The epinephrine infusion is then discontinued.
3141636|NCT00547456|Other|Decrease in oxygen level when sleeping|Patients are their own controls and tested pre and post the addition of night time supplemental oxygen
3141637|NCT00539838|Experimental|Ocrelizumab 1000 mg|Ocrelizumab was administered i.v. at a dose on Days 1 and 15, followed by 1000 mg i.v. at Week 16 and then every 16 weeks
3141638|NCT00539838|Experimental|Ocrelizumab 400 mg|Ocrelizumab was administered at a dose 400 mg i.v. on Days 1 and 15, followed by 400 mg i.v. at Week 16 and then every 16 weeks
3141639|NCT00539838|Placebo Comparator|Placebo|Placebo infusions were administered on Days 1 and 15, followed by placebo infusion at Week 16 and then every 16 weeks
3141640|NCT00549328|Experimental|Pazopanib Open-label|Single-arm, non-randomised, single-stage pazopanib monotherapy.
3141641|NCT00548327|Active Comparator|Atomoxetine|"Atomoxetine 80 mg final dose. Arm lasts 14 days.~Schedule 25 mg Day 1 (or Day 22), 40 mg Day 2-3 (or Days 23-24), 60 mg Days 4-5 (or Days 25-26), 80 mg Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging (MRI) and neuropsychological testing in addition to psychopathology ratings"
3141642|NCT00548327|Placebo Comparator|Placebo|"Placebo administered for 14 days. Schedule Atomoxetine 25 mg Placebo Day 1 (or Day 22), Atomoxetine 40 mg Placebo Day 2-3 (or Days 23-24), Atomoxetine 60 mg Placebo Days 4-5 (or Days 25-26), Atomoxetine 80 mg Placebo Days 6-14 (or Days 27-35).~After 14 days, subjects undergo functional magnetic resonance imaging and neuropsychological testing in addition to psychopathology ratings"
3141643|NCT00542542|Active Comparator|Paravertebral Block + General Anesthesia|Group 1: Paravertebral Block + General Anesthesia (Ropivacaine)
3141644|NCT00542542|Active Comparator|General Anesthesia Alone|Group 2: General Anesthesia Alone (Propofol, Midazolam, Fentanyl)
3141645|NCT00545506|Active Comparator|conventional bandage|conventional bandage on sternal wound after skin closure after cardiac surgery. conventional gauze covered with elastic adhesive (Medipore™ Dress-it) The designated bandage will be positioned in the operating room by the surgeons after the skin will be closed. The conventional elastic bandage consists of several layers of gauze covered with a special adhesive bandage
3141646|NCT00545506|Active Comparator|warming bandage|The Warm-Up bandage consists of an adhesive shell and a foam frame that supports a clear window about one cm above the surface of the wound. A battery-powered heating card can then be inserted into the window to provide gentle warming of the wound. The surface temperature of heating card is fixed at 38°C, and heat is usually provided for two hours at a time. That is, the experimental bandage will be continuously applied to the wound and heated to 38°C using a two-hour on/off cycle.
3141647|NCT00547300|Experimental|Nebivolol|Nebivolol 5 mg, 10 mg or 20 mg
3141648|NCT00547300|Active Comparator|Metoprolol ER|Metoprolol ER 50 mg, 100 mg or 200 mg
2415340|NCT03467828|Experimental|Study Group|Infants diagnosed with BPD.
2415834|NCT03464500|Active Comparator|AMAZ-02 Low dose|
3182704|NCT00705887|Experimental|Intervention|Participation in a brief motivational enhancement session. These participants also received the same American Academy of Dermatology brochure on protecting your skin from UV rays.
3182705|NCT00705900|Experimental|1|LCD Solution: 2 applications / day
3182706|NCT00705900|Active Comparator|2|Calcipotriol cream: 2 applications / day
3141649|NCT00539617|Experimental|Tarceva and FOLFOX|"COMBINATION THERAPY PHASE: Patients receive erlotinib hydrochloride orally (PO) once daily (QD) on days 1-56. Patients also receive FOLFOX6 therapy comprising oxaliplatin intravenously (IV) over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1, 15, 29, and 43. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or no evidence of disease after course 2 or subsequent courses continue on to maintenance phase.~MAINTENANCE PHASE: Patients receive erlotinib hydrochloride PO QD on days 1-42. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity."
3141650|NCT00546455|Experimental|A|Subjects in this cohort will be given Fenretinide
3141651|NCT00546455|Placebo Comparator|B|Subjects in this cohort will be given placebo.
3141652|NCT00538980|Experimental|All patients|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
3141653|NCT00540969|Experimental|Arm I (percutaneous cryoablation)|Cryoprobes are inserted percutaneously under CT scan or ultrasound guidance, to the malignant soft tissue-bone interface. Patients undergo ablations using a freeze-thaw-freeze cycle lasting approximately 10-5-10 minutes, respectively.
3141654|NCT00540969|Active Comparator|Arm II (external-beam radiotherapy)|Patients undergo external-beam radiotherapy comprising either a single 8 Gy dose or 20 Gy/5 fractions administered over 1 week.
3141655|NCT00535262|Experimental|EmSam|EmSam will be administered in open-label fashion for 8-weeks during phase I of the study during which symptoms of depression will be assessed weekly. Those whose depression responds after 8-weeks will be entered into an 8-month open-label continuation phase during which they will be maintained on EmSam and be assessed on a monthly basis.
3141656|NCT00529464|Experimental|Colposcopy|Colposcopy - a direct magnified inspection of cervix
3141657|NCT00529464|Experimental|Colposcopy + Fluorescence Spectroscopy|Colposcopy - a direct magnified inspection of cervix + Fluorescence Spectroscopy - electromagnetic spectroscopy which analyzes fluorescence from a sample.
3141658|NCT00529464|Experimental|Colposcopy + LEEP Procedure|Colposcopy - a direct magnified inspection of cervix + loop electrosurgical excision procedure (LEEP) - thin, low-voltage electrified wire loop to cuts out cervix abnormal tissue.
3141659|NCT00537199|Other|OraTest + Visual Exam|OraTest dye
3141660|NCT00537446|Active Comparator|High-level ventilation|Each subject will spend 2 hours receiving high-level noninvasive ventilation.
3141661|NCT00537446|Active Comparator|Low-level ventilation|Each subject will receive 2 hours of low-level noninvasive positive pressure ventilation.
3182707|NCT00705913|Active Comparator|1|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
3182708|NCT00705913|Active Comparator|2|
3182709|NCT00705926|Experimental|A1|Antiretroviral therapy followed by discontinuation at Week 12.
3182710|NCT00705926|Experimental|A2|Antiretroviral therapy followed by discontinuation at Week 32.
3182711|NCT00705926|Placebo Comparator|B|No treatment.
3182712|NCT00705952|Experimental|1|
3141662|NCT00536978|Experimental|NK Cell/T-Cell Infusion|Possible Cell Adback - infusion NK cells or T-cells from donor given after blood stem cell transplantation for either Reduced intensity chemotherapy of campath, modified BEAM regimen of Campath-IH 15 mg intravenous (IV) Daily for 3 Days + BEAM Daily for 4 days (BCNU 300 mg/m^2 IV, Etoposide 100 mg/m^2 IV, Ara-C 100 mg/m^2 IV Daily for 4 days and Melphalan 100 mg/m^2 IV Over 30 Minutes for 1 Day) + Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks]; or Non-myeloablative Preparative Regimen [Fludarabine 30 mg/m^2 IV Daily Over 1 Hour for 3 Days; Cyclophosphamide 1000 mg/m^2 IV Daily Over 1 Hour for 3 Days; Rituximab 375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks; Campath-IH 15 mg IV Daily Over 30 Minutes for 3 Days; plus Total Body radiation (TBI)].
3141663|NCT00524485|Experimental|Arm 1 - ALA|Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.
3141664|NCT00524485|Experimental|Arm 2|Patients receive topical ALA topical (aminolevulinic acid) 4 hours before PDT
3141665|NCT00524485|Experimental|Arm 3|Patients receive topical ALA (aminolevulinic acid) 24 hours before PDT. Each anatomic area is divided into subunits (e.g., right and left arm, right and left side of the face). The subunits are randomized to receive 1 or 2 pulses of the laser treatment
3141666|NCT00524485|Experimental|Arm 4|Vbeam laser pulse (photodynamic therapy) is applied to the subunit
3182713|NCT00705965|Experimental|1|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
3182714|NCT00705965|Active Comparator|2|Usual cardiological care including one information session.
3182715|NCT00705978|Experimental|1|
3182716|NCT00705978|Placebo Comparator|2|
3182717|NCT00706017||A|
3182718|NCT00706069|Experimental|1|Vinorelbine oral plus Capecitabine
3182719|NCT00706108||1|Simulation of anesthesia induction with critical incidents: Analysis of technical and non-technical performance (15 Teams)
3182720|NCT00706108||2|Analysis of technical and non-technical performance in live anesthesia inductions (40 teams)
3182721|NCT00706108||3|Simulation of anesthesia inductions with advanced simulated critical incidents or events and analysis of technical and non-technical performance (max. 50 teams)
3182722|NCT00706147|Placebo Comparator|1|
3182723|NCT00706147|Active Comparator|2|
3141667|NCT00524485|Experimental|Arm 5|Vbeam laser pulses (photodynamic therapy) are applied to the subunit. Patients may receive up to 3 treatments (including pretreatment, ALA, and PDT) at least 1 month apart
3141668|NCT00533351|Experimental|AGN201781|AGN201781 50 mg capsules three-time daily for 2 weeks
3141669|NCT00533351|Placebo Comparator|Placebo|placebo 50 mg capsules three-times daily for 2 weeks
3182724|NCT00706173|Experimental|Hydrocortisone|
3182725|NCT00706173|Placebo Comparator|Placebo|
3182726|NCT00706199||Group A|donors
3182727|NCT00706225|Experimental|1|Bazedoxifene and Conjugated Estrogens (BZA & CE)
3182728|NCT00706251||Primary|All the patients in our medical center who underwent nasolacrimal intubation, due to mild epiphora, during the years 2000-2007.
3182729|NCT00706277|Active Comparator|TIVA|patients receiving total intravenous anesthesia (TIVA)
3182730|NCT00706277|Active Comparator|balanced|patients receiving balanced anesthesia
3182731|NCT00706290|Experimental|Intervention - CBT|Participants randomized to the intervention group received cognitive behavioral therapy (CBT) for anxiety after completing a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. After completing the CBT intervention, consisting of 6-7 sessions over the course of 2-3 months, participants completed a post-intervention assessment identical to the baseline.
3182732|NCT00706290|No Intervention|Routine Care Control|Participants randomized to the control condition completed a baseline assessment consisting of clinician administered psychiatric evaluations and a psychosocial self-report battery. They then received routine medical care. After 2 months and after completing the post clinical assessment identical to the baseline, they were offered the opportunity to receive the CBT intervention for free. This ensured that all participants ultimately received cognitive-behavioral therapy if desired, while permitting an examination of the effect size for the intervention compared to routine care.
3182733|NCT00706303|Active Comparator|1 Intervention group|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
3182734|NCT00706303|No Intervention|2|Usual care. The control group will receive usual care, as decided by their GP and or hospital consultant, and the patient themselves (e.g., NHS 24 helpline). They will be asked to complete diary cards and receive telephone follow up calls as an attention control, similar to the intervention group.
3141670|NCT00529282|Experimental|001|Ceftobiprole Medocaril 500 mg every 8 hours 120-minute infusion [250 mL]
3141671|NCT00529282|Active Comparator|002|Cefepime with or without vancomycin 2 g every 8 hrs-30 min infusion vancomycin 1 000mg every 12 hrs-60 min infusion
3141672|NCT00524134|Experimental|1|Carvedilol-CR up to 80mg daily, used as a P-glycoprotein inhibitor to increase drug concentrations in specific regions of the brain.
3141673|NCT00527748|No Intervention|Standard of care|Patient ankle range of motion will be assessed at clinic visit. No stretching exercises with the device, but will be provided standard care through physiotherapist in acute cases, and no stretching exercises for chronic patients. Reassessment will be done at six weeks and 10 weeks.
3141674|NCT00527748|Experimental|Non-Measuring Ankle Exerciser|Subjects will train using only one combination of movement, dorsiflexion with inversion. This is done by manipulating the ring so that the medial and anterior ropes are taut. Subject will start with 3 minute warm-up. Subject will then manipulate the ring so that the foot moves into dorsiflexion with inversion until a point of tolerable discomfort is felt; subject will hold this position for 30 seconds. Stretch will be repeated 10 times, each day, for six weeks. Reassessment will be done at six weeks and 10 weeks.
3141675|NCT00517699|Experimental|1|
3141676|NCT00528775|Experimental|HPPH|Patients will receive 4 mg/m2 HPPH (given light exposure precautions) and approximately 2 days later be treated endoscopically with 150J/cm of 665 +-5nm light.
3141677|NCT00528437|Other|Myeloablative Chemo-Temozolomide, Thiotepa, and Carboplatin.|
3141678|NCT00524511|Experimental|1|Women receiving Dermabond for skin closure
3141679|NCT00524511|Active Comparator|2|Women receiving standard surgical skin staples
3141680|NCT00517075|Experimental|A|high frequency rTMS to the left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
3141681|NCT00517075|Active Comparator|B|Active high frequency rTMS to the left dorsolateral prefrontal cortex
3141682|NCT00517075|Sham Comparator|C|Sham (placebo) high frequency rTMS to the left dorsolateral prefrontal cortex or left infero-parietal lobe, active/sham condition randomized (2:1), double-blind
3141683|NCT00517075|Experimental|Open cross over high frequency rTMS|Following the randomization phase with three arms, subjects who did not respond, have the possibility of receiving open active treatment to the target that they did not receive treatment to in the randomization phase. (i.e. randomized to IPL --> open phase DLPFC and vice versa)
3141684|NCT00527982|Experimental|Celecoxib treatment|600 mg orally (PO) daily
3141685|NCT00527982|No Intervention|No treatment|
3141686|NCT00517361|Experimental|Carboplatin + Avastin|
3141687|NCT00523939|Experimental|Lymphomatous|Subjects with Lymphomatous Meningitis
3141688|NCT00523939|Experimental|Leukemic|Subjects with Leukemic Meningitis
3141689|NCT00526331|Experimental|Study Group|FloTrac Sensor + Vigileo Monitor used to decide how much fluid to give during surgery.
3141690|NCT00526331|Experimental|Control Group|FloTrac Sensor + Vigileo Monitor only used for data collection during surgery; Standard of Care to decide fluid amount.
3141691|NCT00519090|Experimental|Nilotinib (AMN107)|
3141692|NCT00519090|Active Comparator|Imatinib|
3141693|NCT00523809|Experimental|Bevacizumab + Fludarabine + Melphalan|Bevacizumab 10 mg/kg intravenous (IV) on Day 1; Fludarabine 25 mg/m^2 IV Daily over 5 Days; Melphalan 70 mg/m^2 IV Daily over 2 Days; Thymoglobulin 0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1; plus Allogeneic Hematopoietic Stem Cell Transplantation on Day 8.
3141694|NCT00522301|Experimental|Oral Sorafenib (BAY43-9006)|Sorafenib is supplied as 200-mg tablets. Sorafenib will be administered as 400 mg orally daily x 28 days (continuous). One cycle = 28 days. There is no planned treatment interruption between cycles. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating). In the absence of intolerable toxicity, a patient may continue to receive treatment with sorafenib until disease progression, or until 24 months have elapsed.
3141695|NCT00504985||Fatigue in Emergency Center Patients|
3141696|NCT00503581|Experimental|Regimen 1 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily every day for 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after completing the megestrol treatment.
3141697|NCT00503581|Experimental|Regimen 2 (megestrol acetate, surgery)|Patients receive oral megestrol twice daily for two weeks continuously followed by no treatment for two weeks. This course is repeated for a total of 24 weeks. Approximately twelve weeks after treatment starts, clinical blood tests are obtained and research serum and plasma collected. Twenty-four weeks constitutes one course of treatment and a pill count is performed during the 12-week f/u visit and at the completion of the treatment course to determine compliance. After progestin therapy the patient has an induced-withdrawal bleed. Patients in this arm undergo a re-evaluation biopsy and hysterectomy a minimum of two weeks and a maximum of eight weeks after the megestrol treatment.
3182735|NCT00706316|Experimental|EBV-Specific CTLs and CD45 Mab|A dose escalation schema will be employed. Three to six patients will be treated at each of the following dose levels with EBV-Specific CTLs and CD45 Mab: Dose Level I: 2 x 10^7 cells/m2. Dose Level II: 5 x 10^7 cells/m2. Dose Level III: 1 x 10^8 cells/m2. Dose escalation decisions will be made after review of the data from the current dose level. There will be no intra-patient escalation. An additional 6-10 patients with measurable disease will be treated at the recommended phase II dose to expand the experience at this dose level.
3182736|NCT00706368|Experimental|1|Participants in this group will perform self-tests for the first half of the study and will have clinical examinations for the second half of the study
3182737|NCT00706368|Experimental|2|Participants in this group will have clinical examinations for the first half of the study and will perform self-tests for the second half of the study
3182738|NCT00706420|Experimental|1|Islet cell transplantation alone
3182739|NCT00706459||1|Patients with lumbar back pain scheduled for back surgery.
2415835|NCT03464500|Active Comparator|AMAZ-02 High Dose|
3182740|NCT00706459||2|Patients with degenerative disease without classic discogenic back pain
3182741|NCT00706459||3|Normal control without back pain.
3182742|NCT00706459||4|Post Surgical discectomy patients
3182743|NCT00706459||5|disc specimens
3182744|NCT00706537|Experimental|CP-945598 20 mg|
3182745|NCT00706537|Placebo Comparator|Placebo|
3141698|NCT00503581|Active Comparator|Regimen 3 (surgery/biopsy)|(Closed as of 6/3/2010) Patients do not receive megestrol. At the discretion of the managing physician, patients undergo the re-evaluation biopsy and hysterectomy anytime between 2-20 weeks after enrollment and randomization.
3141699|NCT00509600|Experimental|Etanercept|0.8 mg/kg subcutaneously weekly for 90 days
3141700|NCT00515112|Experimental|A|Twenty subjects will receive testosterone gel
3141701|NCT00515112|Placebo Comparator|B|Twenty subjects will receive the placebo
2415836|NCT03464500|Active Comparator|Placebo|
3141702|NCT00508872|Experimental|FOLFOX-B|FOLFOX-B: 5-Fluorouracil 400 mg/m^2 IV + Bevacizumab 5 mg/kg IV + Leucovorin 400 mg/m^2 IV + Oxaliplatin 85 mg/m^2 IV
3141703|NCT00514813|Experimental|Dynepo (Epoetin delta)|Subjects received Dynepo (Epoetin delta) either twice weekly (BIW), once weekly (QW), once every 2 weeks (Q2W) or once every 4 weeks (Q4W) based on what is appropriate for the subject
3141704|NCT00506064|Experimental|Melatonin|0.15 mg/kg capsules by mouth daily
3141705|NCT00506064|Placebo Comparator|Placebo|Starch capsules by mouth daily
3141706|NCT00503880|Experimental|Treatment|G-CSF 300 μg subcutaneously to begin one day prior to treatment and continued until ANC greater than 1.0 or recovers back to the patients baseline ANC for 3 days in a row subsequent to completion of chemotherapy (SOC) Low-dose Cytarabine 10 mg/m2 subcutaneously daily starting on day 1 for the first 5 consecutive days of the treatment course 2-4 hours following the end of the clofarabine infusion. (SOC) Clofarabine starting at dose level 0. Dose-10 mg/m2 IV over 1 hour daily starting on day 1 for the first 5 consecutive days of the treatment course The G-CSF and cytarabine doses are fixed. The dose of clofarabine is initially fixed. For the subsequent cohort, the dose of clofarabine will be advanced to the next dose level.
3141707|NCT00511329|Experimental|Somatropin|
3141708|NCT00501228|Experimental|Filgrastim Injections|
3141709|NCT00496782|Other|Single|
3141710|NCT00506909|Experimental|Group 1|Group 1: 20 IU BID for the first week, 40IU BID for the following two weeks, 1 week washout, 3 week placebo trial.
3141711|NCT00506909|Experimental|Group 2|Group 2: 3 week placebo trial, 1 week washout, 20 IU BID for the first week, 40IU BID for the following two weeks.
3141712|NCT00487578|Active Comparator|A|Naratriptan 2.5 mg tablet bid x 30 days
3141713|NCT00487578|Placebo Comparator|B|placebo matching naratriptan 2.5 mg tablet
3141714|NCT00503009|Active Comparator|Arm 1|
3141715|NCT00503009|Active Comparator|Arm 2|
3141716|NCT00503009|Placebo Comparator|Arm 3|
3141717|NCT00500045|Experimental|Treatment|Oral niacin
3141718|NCT00499590|Active Comparator|A|Lucentis® (0.5mg) every 4 weeks.
3141719|NCT00499590|Experimental|B|Bevasiranib (2.5mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3141720|NCT00499590|Experimental|C|Bevasiranib (2.5mg) every 12 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3141721|NCT00501345|Experimental|Aspirin|
3182746|NCT00706576|Experimental|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
3182747|NCT00706602||1|Swiss COPD cohort
3182748|NCT00706602||2|Dutch COPD cohort
3182749|NCT00706667|Placebo Comparator|1|Placebo for EPO and for Ferinject ®
3182750|NCT00706667|Active Comparator|2|Only Ferinject ® , Placebo for EPO
3182751|NCT00706667|Active Comparator|3|Ferinject ® + EPO
3141722|NCT00496756|Other|Sorafenib|"The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the table below, providing no dose limiting toxicity (Grade 3 or 4) is observed. If grade 3 or 4 toxicity is observed, delay and dose modification will occur as defined in protocol. Once dose level 3 is reached, the patient will remain at that dose as defined in following section.~Dose Level 1 Day 1-28 400 mg b.i.d. Dose Level 2 Day 29-56 600 mg b.i.d. Dose Level 3 Day 57- 800 mg b.i.d.~A treatment cycle will be 4 weeks.~Two 4-week cycles will be administered. At the completion of two cycles (week 8), restaging will occur. Patients will continue on therapy per study protocol."
3141723|NCT00495716|Active Comparator|Episodic Treatment Arm|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
3141724|NCT00495716|Active Comparator|Suppressive Therapy Arm|400 mg acyclovir orally twice daily for 1 year
3182752|NCT00706680|Experimental|1|All subjects meeting the entry criteria will be treated with the study immunosuppressive protocol.
3141725|NCT00500890|Experimental|Carboplatin + Etoposide + Vincristine|Carboplatin 350 mg/m^2 by vein, Over 2 Hours x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
3141726|NCT00500890|Experimental|Cyclophosphamide + Etoposide + Vincristine|Cyclophosphamide 1 g/m^2 by vein, Over 1 Hour x 2 Days. Etoposide 100 mg/m^2 by vein, Over 1 Hour x 5 Days. Vincristine 1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5. Radiation treatment over a period of about 6 weeks.
3141727|NCT00503841|Experimental|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
3141728|NCT00493025|Experimental|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy|Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
3141729|NCT00491400|Active Comparator|Fenofibrate First|Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second
3141730|NCT00491400|Active Comparator|Atorvastatin First|Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second
3141731|NCT00490776|Experimental|Panobinostat 20 mg|Participants received panobinostat, 20 milligrams (mg), capsules, orally, thrice weekly on alternate Days 1, 3, and 5 per week of a 28-day treatment cycle until unacceptable toxicity, disease progression, and/or physician's discretion to discontinue the treatment.
3141732|NCT00487162|Experimental|intensive glycemic control|In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.
3182753|NCT00706693|Active Comparator|Glucose|BD glucose tablets (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
3182754|NCT00706693|Active Comparator|Fructose|Fruit to Go (TM) is taken PO in response to a hypoglycemic event by participants randomized to this arm
3182755|NCT00706693|Active Comparator|Sucrose|Skittles (TM) are taken PO in response to a hypoglycemic event by participants randomized to this arm
3182756|NCT00706732|Active Comparator|T1|
3182757|NCT00706732|Active Comparator|T2|
3182758|NCT00706732|Placebo Comparator|C1|
3182759|NCT00706732|Placebo Comparator|C2|
3141733|NCT00487162|Active Comparator|conventional glycemic control|In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL
3141734|NCT00487981|Other|Spinal Cord Stimulation Group|Spinal Cord Stimulation (SCS) Treatment Group
3141735|NCT00491387|Experimental|metoprolol succinate|Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.
3141736|NCT00483119|Active Comparator|Group A|IVIg alone (intravenous immunoglobulin)
3141737|NCT00483119|Experimental|Group B|IVIg with cyclophosphamide
3141738|NCT00487461|Placebo Comparator|Control Group|Placebo tablet
3141739|NCT00487461|Experimental|Study Group #1|Simvastatin 40 mg
3141740|NCT00487461|Experimental|Study Group #2|Simvastatin 80 mg
3141741|NCT00484718|Active Comparator|A|
3141742|NCT00484718|Active Comparator|B|
3141743|NCT00484718|Placebo Comparator|C|
3141744|NCT00474188|Experimental|Single Arm|
3141745|NCT00477230|Experimental|1|Single ablation procedure with Endoscopic Ablation System
3141746|NCT00477230|Active Comparator|2|Medication
3141747|NCT00479258|Experimental|Inhaled insulin (Exubera)|
3141748|NCT00479258|Active Comparator|Subcutaneous Insulin (subject's prescribed)|
3141749|NCT00470067|Experimental|Doxorubicin and carboplatin|Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1
3141750|NCT00476827|Active Comparator|Bevacizumab / Capecitabine|Bevacizumab 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle.
3141751|NCT00476827|Active Comparator|Bevacizumab / Docetaxel|Docetaxel (taxotere) 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3141752|NCT00476827|Active Comparator|Bevacizumab /Irinotecan (Camptosar®, CPT-11)|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3141753|NCT00476827|Active Comparator|Bevacizumab / Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.
3182760|NCT00706745|Placebo Comparator|placebo|The control oil is based on the general fat consumption in a Western population and consists of an equal amount (4 gr) of fat. It is a blend of palm (80%) and soybean oil (20%). Two capsules will be taken in the morning and two in the evening.
3141754|NCT00476827|Active Comparator|Bevacizumab /Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle.
3141755|NCT00476827|Active Comparator|Bevacizumab / Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.
3141756|NCT00475657|Experimental|A|
3141757|NCT00472082|Experimental|1|The study drug Efalizumab will be given as part of a triple drug regimen including mycophenolate mofetil and prednisone. A test dose of Efalizumab 0.7mg/kg will be given at the enrollment visit. Beginning with study visit 2, Efalizumab 1mg/kg will be administered subcutaneously by injection on a weekly basis for 1 year. Mycophenolate mofetil will be given at a dose of 2gm/day which is the same as the standard of care dose. If patient experiences drug toxicity with mycophenolate mofetil they may be reduced and resume a minimum of at least 1gram daily to continue in the study. Patients will be maintained at 10mg of prednisone daily, same as standard of care.
3141758|NCT00478062|Experimental|Cell vaccine after initial therapy for Hodgkin lymphoma|Hodgkin's antigens-GM-CSF-expressing cell vaccine after initial therapy.
3141759|NCT00470574|Experimental|Vaccine Therapy and QS21|"Patients receive sialyl Lewisª -keyhole limpet hemocyanin conjugate vaccine subcutaneously (SC) and QS21 immunoadjuvant SC once in weeks 1, 2, 3, 7, and 19 in the absence of disease progression or unacceptable disease.~Blood samples are collected periodically and evaluated for circulating tumor cells and reactivity against sialyl Lewisª antigen in ELISA and/or immunoprecipitation-western blot assays.~After completion of study treatment, patients are followed every 3 months"
3141760|NCT00467753|Experimental|Oxcarbazepine|Oxcarbazepine is the active drug to be given to subjects in the experimental arm
3141761|NCT00467753|Placebo Comparator|Sugar Pill|Patients are given either active or inactive intervention.
3141762|NCT00456612|Other|Cyberknife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
3141763|NCT00469612|Experimental|A|NeuroVision's NVC treatment for low myopia
3141764|NCT00469612|No Intervention|B|The subjects in this group will serve as controls and will be the no intervention group.
3141765|NCT00461812|Experimental|Mometasone|
3141766|NCT00461812|Experimental|Advair|
3141767|NCT00459121|Experimental|Zactima, Paclitaxel, Carboplatin|"Zactima- 100 mg orally daily, starting on day 1 of cycle 1. Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1. Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1 Duration of each cycle: 21 days. The last dose of zactima will be on the first day of the last cycle.~Neoadjuvant Surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment."
3141768|NCT00462904|Experimental|BPI infusion group|BPI will be infused by bolus for 30 minutes followed by continuous infusion for 47.5 hours
3141769|NCT00450333|Active Comparator|1|Erythropoietin(EPO)-naive BIW
3141770|NCT00450333|Active Comparator|2|EPO-naive QW
3141771|NCT00450333|Active Comparator|3|EPO QW
3141772|NCT00450333|Active Comparator|4|EPO Q2W
3182761|NCT00706745|Active Comparator|oil rich in cis9, trans11 CLA|Subjects will receive daily 4 g of CLA oil (2.6 g cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
3141773|NCT00455143|Experimental|Dexmedetomidine|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
3141774|NCT00455143|Placebo Comparator|Placebo|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively or until discharge from the PACU.
3141775|NCT00456989|Experimental|Taxotere and Doxil|Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively. Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
3141776|NCT00448682|Experimental|FUdR + Leucovorin + Oxaliplatin + Docetaxel (Taxotere)|"Treatment will be administered on an outpatient basis. Chemotherapy will be administered weekly, 3 out of 4 weeks, on days 1, 8 and 15:~Day 1 and Day 15 Chemotherapy Administration: Patients will be administered oxaliplatin (85 mg/m2) and docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110 mg/kg//500 mg/m2) on Day 1 and Day 15 of each cycle.~Day 8 Chemotherapy Administration On Day 8, treatment will consist of docetaxel (25 mg/m2) followed by FUdR/Leucovorin (110mg/kg//500mg/m2).~There will be no treatment delivered week 4 (Day 22). For the purpose of this study, one cycle equals four weeks. There will be a maximum of 6 cycles."
3141777|NCT00454571|Experimental|Pazopanib|Patients receive pazopanib hydrochloride PO QD on days 1-28 after treatment with leuprolide acetate and goserelin acetate. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3141778|NCT00454571|Active Comparator|Observation|Patients undergo observation after treatment with leuprolide acetate and goserelin acetate.
3141779|NCT00452361|Experimental|1|Sirolimus therapy
3141780|NCT00452361|Active Comparator|2|Calcineurin Inhibitor therapy (either cyclosporine or tacrolimus)
3141781|NCT00443040|Placebo Comparator|Placebo|
3182762|NCT00706758|Active Comparator|1|Structured patients group intervention - IBS school
3182763|NCT00706758|Active Comparator|2|Written information - IBS-guidebook
3182764|NCT00706771|Active Comparator|Sodium bicarbonate|sodium bicarbonate: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
3182765|NCT00706771|Active Comparator|Sodium chloride|sodium chloride: loading of 0.5 mmol/kg and the continuous infusion o f0.2 mmol/kg/hr
3182766|NCT00706862|Experimental|1|Talactoferrin, Carboplatin, Paclitaxel
3141782|NCT00443040|Active Comparator|Asimadoline 1.0 mg|Asimadoline 1.0 mg b.i.d.
3141783|NCT00443040|Active Comparator|Asimadoline 3.0 mg|Asimadoline 3.0 mg b.i.d.
3141784|NCT00447603|Active Comparator|Losartan 50 mg|Losartan 50 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
3141785|NCT00447603|Active Comparator|Losartan 100 mg|Losartan 100 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg once daily for 4 weeks
3141786|NCT00447603|Experimental|Losartan 50 mg/HCTZ 12.5 mg|Losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 50 mg once daily for 4 weeks
3182767|NCT00706862|Placebo Comparator|2|Placebo, Carboplatin, Paclitaxel
3182768|NCT00706875||1|30 patients survived GTD post treatment for 0 - 5 years.
3182769|NCT00706875||2|30 patients survived GTD post treatment 6 - 10+ years.
3141787|NCT00447603|Experimental|Losartan 100 mg/HCTZ 12.5 mg|Losartan 100 mg/hydrochlorothiazide (HCTZ) 12.5 mg tablet, oral, once daily for 4 weeks. Participant also will be co-administered placebo for losartan 100 mg once daily for 4 weeks
3141788|NCT00447421|Experimental|A|
3141789|NCT00437398|Experimental|Islet Transplant|Subjects will receive standard intraportal transplantation or portal venous system infusion via laparotomy of purified pancreatic islets.
3141790|NCT00440271|Other|Standard of Care (SoC)|Standard of Care (SOC) Arm = Tipranavir/ritonavir (TPV/r) capsules taken orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR). No TPV/r dose changes were permitted.
3141791|NCT00440271|Other|Therapeutic Drug Monitoring (TDM)|Therapeutic Drug Monitoring (TDM) Arm = Patients began by receiving standard of care (SOC) tipranavir/ritonavir (TPV/r) capsules orally at a dose of 500 mg/200 mg twice a day (BID) plus optimized background regimen (OBR) followed, if needed, by TPV or ritonavir (RTV) dose adjustments at Week 4, 6, 10, 14, 18, 22, 26 and 30 based on viral response, phenotypic inhibitory quotient (IQ), and TPV trough concentrations.
3141792|NCT00442260|Experimental|Abraxane dose escalation + fixed dose DOXIL|Limited dose-escalation study of Abraxane and fixed dose of DOXIL in order to identify correct dose and side effect profile of the combination.
3141793|NCT00442351|Experimental|Asmanex Twisthaler|
3141794|NCT00442351|Placebo Comparator|Placebo inhaler|
3141795|NCT00429026|Experimental|Fludarabine + Cyclophosphamide with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
3141796|NCT00429026|Experimental|Fludarabine + Melphalan with ASCT|ASCT=Allogeneic Hematopoietic Stem Cell Transplantation
3182770|NCT00706888|Active Comparator|1|Female with active product
3182771|NCT00706888|Active Comparator|2|Male with active product
3182772|NCT00706888|Placebo Comparator|3|Female with placebo
3182773|NCT00706888|Placebo Comparator|4|Male with placebo
3182774|NCT00706953|Active Comparator|001|
3141797|NCT00428207|Active Comparator|Insulin Aspart Versus Insulin Lispro|Insulin aspart will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Insulin aspart doses will be adjusted by the principal investigator as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Lispro).
3182775|NCT00707018|Experimental|External rotation shoulder sling|External rotation shoulder sling
3141798|NCT00428207|Active Comparator|Insulin Lispro Versus Insulin Aspart|Insulin lispro will be used for diabetes management, and will be delivered continuously, subcutaneously using a pump for a four week period. Dose will be adjusted as needed to maintain glycemic control. Insulin dose adjustments will vary from patient to patient based on the carbohydrate consumption, level of physical activity, and fingerstick monitoring results SMBG (7 times per day). SMBG results collected during this four week period will be compared to the SMBG results collected while participant uses alternative treatment (insulin Aspart).
3141799|NCT00439569|Experimental|Single Arm|Cohorts of 3 subjects were to be enrolled sequentially in escalating dosage levels. The first three subjects enrolled at 500 mg/kg/day for the duration of the study drug period. The dosage of the next cohort was determined by the Modified Continual Re-assessment Method (MCRM) calculation and approval of the Study Monitoring Committee (SMC). The MCRM calculation could indicate that additional subjects should be enrolled at the same dosage or a higher dosage.
3182776|NCT00707018|Active Comparator|Internal rotation shoulder sling|Internal rotation shoulder sling
3141800|NCT00422669|Active Comparator|RV Mid-Septal Pacing|Pacing lead is placed in the right ventricle at the middle of the muscle separating the right and left sides of the heart
3141801|NCT00422669|Active Comparator|RV Apical Pacing|Pacing lead is placed at the bottom of the right ventricle of the heart, in the right ventricular apex
3141802|NCT00432445|Experimental|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks. Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
3182777|NCT00707044|Experimental|A|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
3182778|NCT00707044|Active Comparator|B|control group, care as usual, 24 hours intensive care stay
3182779|NCT00707070|Experimental|1|efalizumab 1 mg/kg/week subcutaneous plus acitretin 0.4 mg/kg/day oral
3182780|NCT00707070|Placebo Comparator|2|efalizumab 1 mg/Kg/week subcutaneous plus oral placebo
3182781|NCT00707083|Active Comparator|Standard- or Intermediate-Risk Maintenance Arm I|Patients receive oral mercaptopurine and oral methotrexate on days 1-56, dexamethasone IV on days 1-5 and 29-33, vincristine IV on days 1 and 29, and methotrexate IT on day 50. Treatment repeats every 8 weeks for up to 8 (girls)-11 (boys) courses.
3182782|NCT00707083|Experimental|Standard- or Intermediate-Risk Maintenance Arm II|Patients receive oral mercaptopurine once daily on days 8-28 and 36-56; oral methotrexate once on days 8,15, 22, 36, 43, and 50; dexamethasone IV on days 1-5 and 29-33; and vincristine IV on days 1 and 29. Patients also receive methotrexate IT on day 1, every 8 weeks, for 8 courses.
3182783|NCT00707122|Other|1, Albumin and Crystalloids|Treatment
3182784|NCT00707122|Other|2, Crystalloids|Control
3182785|NCT00707135|Experimental|1|
3182786|NCT00707148|Active Comparator|Group 2: Control|16 pregnant women to receive: antepartum: saline; postpartum; Tdap vaccine.
3182787|NCT00707148|Experimental|Group 1: Intervention|32 pregnant women to receive: antepartum: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) vaccine; postpartum: saline.
3182788|NCT00707148|Active Comparator|Group 3: Control|32 non-pregnant women to receive a single dose of Tdap vaccine.
3182789|NCT00707187|Experimental|1|35 doses of study medication, IC 351 (20 mg) -- crossover to placebo
3182790|NCT00707187|Experimental|2|35 placebo pills followed with 35 study medication (20 mg)
3182791|NCT00707200||1|Cases: Severe inpatient malaria, survivors or decedents. Severe malaria consists of any one or combination of severe malarial anemia (SMA), cerebral malaria (CM), lactic acidosis (LA), or a respiratory distress syndrome with hypoxia.
3182792|NCT00707200||2|Controls: Controls consist of mildly-affected children with P falciparum malaria who are either managed as inpatients or outpatients.
3182793|NCT00707213|Other|1|
3182794|NCT00707226||1|15 patients with primary open angle glaucoma
3182795|NCT00707226||2|15 age matched healthy subjects
3182796|NCT00707252|Experimental|Phase I/II|Phase I: Polyphenon E + Erlotinib - Polyphenon E 200, 400 and 800 mg/day dose levels evaluated in a step-wise manner with Erlotinib 150 mg/day to establish Maximum Tolerated Dose (MTD) of Polyphenon E. Phase II consists of MTD of Polyphenon E established in Phase I, administered alone for two weeks and thereafter together with Erlotinib 150 mg/day.
3141803|NCT00434590|Experimental|Full Dose Myfortic® and Reduced Dose Neoral®|The administration of gradual dose increased to reach 1440 mg/day (V4) of enteric-coated mycophenolate sodium (Myfortic®, EC-MPS) with simultaneous dose reduction of micro emulsion cyclosporine (Neoral®, CsA-ME) given to maintenance kidney transplant patients previously treated with reduced-dose mycophenolate mofetil (MMF) and standard dose CsA-ME
3182797|NCT00707265|Experimental|Investigational|Open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System.
3182798|NCT00707265|Active Comparator|Control|The bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.
3182799|NCT00707278|Experimental|All patients|All participants enrolled.
3182800|NCT00707304|Experimental|1|Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
3182801|NCT00707304|Placebo Comparator|2|Placebo contains the same phosphate-based buffer used as the diluent for the talactoferrin solution. In addition, the placebo will contain FD&C/EU grade dyes suitable for oral use to mimic the color of the vialed drug product.
3182802|NCT00707317||1|HIV infected individuals
3182803|NCT00707317||2|patients with chronic renal failure
3141804|NCT00434590|Active Comparator|Standard Dose of Myfortic® and Standard Dose of CsA-ME|Patients received unchanged dose of Myfortic® (equimolar to the prior established dose MMF) and unchanged standard dose of CsA-ME.
3141805|NCT00424645|Experimental|Voraxaze|Voraxaze administered 50 units/kg intravenously (IV) repeated a maximum of 2 times in a given cycle of chemotherapy.
3141806|NCT00424645|Placebo Comparator|Placebo|Placebo administered IV following Voraxaze arm.
3182804|NCT00707317||3|patients after solid organ transplantation (lung, liver, kidney, kidney-pancreas)
3182805|NCT00707317||4|patients with rheumatoid arthritis
3182806|NCT00707317||5|stem cell transplant recipients
3182807|NCT00707317||6|immunocompromised patients with confirmed tuberculosis
3141807|NCT00430027|Experimental|Capecitabine, oxaliplatin, cetuximab, and radiation therapy|Patients enrolled on the trial will receive neoadjuvant combined capecitabine, oxaliplatin, cetuximab, and radiation therapy. This will be followed by surgical resection and adjuvant capecitabine, oxaliplatin, and cetuximab
3141808|NCT00429858|Experimental|Targeted therapy group|Gemcitabine monotherapy until disease progression, followed by gemcitabine + S-1
3141809|NCT00425438|Experimental|Mycophenolate Mofetil|Participants received mycophenolate mofetil (MMF) 0.5 grams (g), orally (PO), twice daily (BID) from Day 0 to the end of Week 1, followed by 1.0 g, PO, BID from Weeks 2 through 24, and 0.75 g, PO, BID from Weeks 32 to 48. Participants also received prednisolone 0.75 to 1.0 milligrams per kilogram (mg/kg), PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
3182808|NCT00707317||7|immunocompetent controls with no known risk of exposure or tuberculosis
3182809|NCT00707330|Experimental|1|Subjects randomised to this arm will first be treated with Clarithromycin for a week, then have a 2-week washout, and finally one week of no treatment
3182810|NCT00707330|Active Comparator|2|Subjects randomised to this arm will first receive one week of no treatment, then have a 2-week washout, and finally be treated with Clarithromycin for a week
3182811|NCT00707356|Experimental|WST11(TOOKAD® Soluble)|Treatment with WST11-mediated VTP
3182812|NCT00707369|Experimental|test|Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
3182813|NCT00707369|Placebo Comparator|control|Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
3182814|NCT00707382|Other|Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1) the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment in accordance with the current guidelines from Sct. Hans hospital. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described in the clinical guidelines."
3182815|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
3182816|NCT00707382|No Intervention|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
3182817|NCT00707421|Placebo Comparator|1|placebo, artificial tears
3182818|NCT00707421|Active Comparator|3|corticosteroid , CS
3182819|NCT00707421|Active Comparator|2|non-steroidal anti-inflammatory drug, NSAID
3182820|NCT00707460|Active Comparator|1|Please, see design section for details.
3182821|NCT00707460|Experimental|2|"Traditional Diet~Please, see design section for details."
3141810|NCT00425438|Active Comparator|Cyclophosphamide/Azathioprine|Participants received cyclophosphamide 0.75 grams per square meter (g/m^2), intravenously (IV), every 4 weeks from Weeks 1 through 4, and 0.5 to (-) 1.0 g/m^2, IV, to maintain a minimum white blood cell (WBC) count of greater than or equal to (≥) 2500 per cubic millimeter (mm^3) every 4 weeks from Weeks 5 through 24. Participants also received azathioprine 100 mg, PO, daily for participants with a body weight of 50 to 70 kg and 150 mg, PO, daily for subjects with a body weight of more than 70 kg from Weeks 25 through 48. Participants also received prednisolone 0.75 to 1.0 mg/kg, PO, once per day, up to a maximum of 60 mg per day from Weeks 1 through 4, reduced by 10 mg per day every 2 weeks until dose reaches 40 mg per day, followed by a reduction of 5 mg per day every 2 weeks until dose reaches 10 mg per day up to Week 48.
3141811|NCT00421954|Experimental|Ziprasidone|
3141812|NCT00422942|Experimental|1|
3141813|NCT00409344|Placebo Comparator|1|Normal Saline
3141814|NCT00409344|Active Comparator|Dexmedetomidine|Dexmedetomidine is a highly specific a2 agonist with prominent central nervous system and cardiovascular effects. A postoperative sedative-hypnotic agent for intensive care patients for use up to 24 hours.
3141815|NCT00414453|Active Comparator|Lidocaine 5% + placebo patch, ER and placebo pills|5% lidocaine patch used as intervention placebo patch used with extended release oxycodone or with placebo pills and placebo patches a randomized subjects given extended release oxycodone and placebo patches during this treatment placebo pills used with lidocaine 5% patch group and with placebo patch/placebo pill group period
3141816|NCT00417248|Experimental|Investigational Treatment|Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
3141817|NCT00418145|Experimental|megadose oral methylprednisolone|1400 mg qd/5 days
3141818|NCT00418145|Experimental|IV methylprednisolone|1000 mg/qd/5 days
3141819|NCT00418301|Experimental|Precision Spinal Cord Stimulation and PET Scan|Positron emission tomography (PET) scan imaging procedures to assess Spinal Cord Stimulation.
3141820|NCT00409331|Experimental|IMRT + Amifostine|Intensity-Modulated Radiation Therapy (IMRT) 2.0 to 2.2 Gy delivered in 30 fractions + Amifostine 500 mg, 2 divided doses subcutaneously 30-60 minutes prior to IMRT.
3141821|NCT00392860|Experimental|PalmRim Experimental|Participants will have PalmRim installed on their wheelchair.
3141822|NCT00392860|Experimental|Natural-Fix Experiment|Participants will have a Natural-Fit installed on their wheelchair.
3141823|NCT00392860|Placebo Comparator|Handrim Control|Participants in this arm had a new standard handrim installed on their wheelchair as a control.
3141824|NCT00391430|No Intervention|Control|Participants assigned to the control condition will receive no treatment
3141825|NCT00391430|Active Comparator|Sertraline|Participants will receive treatment with sertraline
3141826|NCT00391430|Active Comparator|CBT|Participants will receive cognitive behavioral therapy
3141827|NCT00399841|Active Comparator|1|Stimulation will occur at the T7 followed by T8 during the trial implant period
3141828|NCT00399841|Active Comparator|2|Stimulation will occur at the T8 followed by T7 during the trial implant period
3141829|NCT00387673|Experimental|Arm 1|6 weeks of upper extremity training for 3 sessions/week, as follows: a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session);
3141830|NCT00387673|Active Comparator|Arm 2|a 6-week period of 2 hours somatosensory stimulation of the hand, without training
3141831|NCT00387673|Placebo Comparator|Arm 3|a 6-week period of 2 hours sham somatosensory stimulation of the hand, followed by 1 hour of activity-based training
3141832|NCT00386724|Experimental|Precision Spinal Cord Stimulation|Single arm Precision Spinal Cord Stimulation System with Artisan Surgical Lead
3141833|NCT00387244|Experimental|Precision for Spinal Cord Stimulation|Single arm Precision for Spinal Cord Stimulation
3141834|NCT00384293|Experimental|1|MK0524A
3141835|NCT00384293|Placebo Comparator|2|placebo
3141836|NCT00383630|Experimental|Group 1|Intramyocardial injection of bone marrow mononuclear cells + LVAD
3141837|NCT00383630|Experimental|Group 2|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
3141838|NCT00383630|Other|Group 3|LVAD alone
3141839|NCT00374543|Experimental|Ziprasidone|Ziprasidone will be dosed on a twice daily (BID) basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day, for 8 weeks. This time period reflects the rapid onset of effect seen in studies of atypical antipsychotics, but allows time for a potentially longer response for some anxiety symptoms.
3141840|NCT00374543|Placebo Comparator|Placebo Capsules|Identical placebo capsules will be dosed on a BID basis, with flexible dosing based on tolerability, with a total daily dose in the range of 40 to 160 mg/day.
3141841|NCT00377455|Experimental|Bosentan|
3141842|NCT00377455|Placebo Comparator|Placebo|
3141843|NCT00371462|Active Comparator|Arm 1|MOVE! level 2 group weight loss counseling, the VA standard of care alone (Standard Care);
3141844|NCT00371462|Experimental|Arm 2|MOVE! level 2 + Personal Digital Assistant decision support tool (PDA) (Treatment)
3141845|NCT00369265|Experimental|Lansoprazole|Lansoprazole 30 mg Twice Daily
3141846|NCT00369265|Placebo Comparator|Sugar pill|placebo
3141847|NCT00370695|Experimental|Precision Spinal Cord Stimulation System|Single arm Precision Spinal Cord Stimulation System.
3141848|NCT00364689|Experimental|lactulose given with a placebo (sugar pill)|
3141849|NCT00364689|Experimental|lactulose given with rifaximin|
3141850|NCT00364689|Active Comparator|rifaximin given alone|
3141851|NCT00352118|Experimental|Chemotherapy + Low Dose Radiation|Patients receiving chemotherapy and Low Dose (60 Gy) Radiation per protocol.
3141852|NCT00368654|Active Comparator|A|Monotherapy with Raptiva alone
3141853|NCT00368654|Experimental|B|Combination therapy with both Raptiva and Methotrexate
3141854|NCT00368654|Experimental|C|Continue Raptiva, discontinue methotrexate
3141855|NCT00368654|Experimental|D|Continue combination therapy with both Raptiva and Methotrexate
3141856|NCT00356421|Active Comparator|Control|
3141857|NCT00356421|Experimental|Experimental|
3141858|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3141859|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3141860|NCT00350623|Experimental|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
3141861|NCT00356187|Experimental|Propranol Treatment|
3141862|NCT00356187|No Intervention|Standard of Care|
3141863|NCT00353275|Other|1|Strict glycemic control with a blood glucose target range of 80-110 mg/dL
3141864|NCT00353275|Other|2|Conventional glycemic control with blood glucose target range of 110-140 mg/dL
3141865|NCT00350844|Experimental|Hydroxyurea|
3141866|NCT00348556|Experimental|Nesiritide|Subjects received an intrarenal infusion of nesiritide at 0.005 microgram/kg/min for 6 hours, 0.01 microgram/kg/min for 6 hours, 0.02 microgram/kg/min for 6 hours, and 0.03 microgram/kg/min for 6 hours.
3141867|NCT00319839|Experimental|Abraxane plus Cetuximab|Drug: Abraxane-260 mg/m2 IV over 30 minutes every 3 weeks. Drug: Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles.
3141868|NCT00344019|Active Comparator|atorvastatin 80 mg|80 mg atorvastatin on average of 2-4 hours pre angio/PCI for ACS
3141869|NCT00344019|Placebo Comparator|placebo oral tablet|placebo on average of 2-4 hours pre angio/PCI for ACS
3141870|NCT00344019|No Intervention|Screening|Patients signed consent if willing to participate. Patients will continue onto randomization if appropriate per inc/exc (i.e. stent placement) otherwise screen fail
3141871|NCT00338455|Experimental|001|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
3141872|NCT00338455|Placebo Comparator|002|Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
3141873|NCT00329108|Experimental|A|
3141874|NCT00329108|Active Comparator|B|
3141875|NCT00325572|Active Comparator|Oral zinc and vitamin C supplementation|Participant will receive oral zinc and vitamin C supplementation based on the child's weight. Blood levels of zinc, copper, liver and renal function as well as blood counts will be measured. Copper to zinc ratio will be calculated at 6 and 16 weeks
3182822|NCT00707460|Experimental|3|"Healthy Store-bought Diet~Please, see design section for details."
3141876|NCT00325572|Placebo Comparator|Oral Placebo|Participant will receive placebo liquid with volume based on child's weight to match the amount given to participants in the experimental group.
3141877|NCT00333762|Experimental|SPAM and SWCS|Smart Power Assistance Module (SPAM) Smart Wheelchair Component System (SWCS)
3141878|NCT00333229|Experimental|Zoledronic Acid|Patients randomized into the Zometa arm received a total of 8 study drug infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
3141879|NCT00333229|Placebo Comparator|Placebo|Patients randomized into the Placebo Arm received a total of 8 placebo infusions which were applied every 3 months. Patients received treatment for 24 months every 3 months.
3141880|NCT00322855||Chart Review|patients diagnosed with soft tissue sarcoma
3141881|NCT00323635|Experimental|Tolterodine|Tolterodine 4 mg q.d. X 8 weeks
3141882|NCT00323635|Placebo Comparator|Placebo|A capsule of identical to tolterodine in taste, smell and appearance that contains no tolterodine
3141883|NCT00329732|Active Comparator|Lidocaine/Bupivicaine|
3141884|NCT00329732|Placebo Comparator|saline|matching volume of saline injected
3141885|NCT00320931|Experimental|Hybrid PET/CT|
3141886|NCT00314353|Experimental|1|
3141887|NCT00314353|Experimental|2|
3141888|NCT00314327|Experimental|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
3141889|NCT00308113|Active Comparator|1|CoenzymeQ10 taken once a day each morning by mouth.
3141890|NCT00308113|Active Comparator|2|Prednisone taken once a day each morning by mouth
3141891|NCT00308113|Active Comparator|3|CoenzymeQ10 and prednisone each taken once a day in the morning by mouth.
3141892|NCT00308113|No Intervention|4|Enhanced standard of care.
3141893|NCT00305643|Experimental|Arm I: Celecoxib + Capecitabine|Celecoxib 200 mg given orally twice/day along with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day).
3141894|NCT00305643|Placebo Comparator|Arm II: Placebo + Capecitabine|Placebo with standard capecitabine treatment (Initial dose of 750-1500 mg/m^2 orally twice/day)
3141895|NCT00298740|Experimental|Aventis U-400 Insulin|
3141896|NCT00301080|Placebo Comparator|Placebo (original version)|Placebo administered orally twice per day for 4 weeks.
3141897|NCT00301080|Active Comparator|D-cycloserine 200mg|D-cycloserine administered orally at a dose of 200 mg twice per day for 12 weeks.
3141898|NCT00301080|Active Comparator|D-cycloserine 50 mg|D-cycloserine administered orally at a dose of 50 mg twice per day for 12 weeks.
3141899|NCT00301080|Active Comparator|D-cycloserine 250mg|This was the original active comparator arm (before the design was changed): D-cycloserine administered orally at a dose of 250 mg twice per day for 4 weeks.
3141900|NCT00301080|Placebo Comparator|Placebo (revised version)|Placebo administered orally twice per day for 12 weeks.
3141901|NCT00299195|Experimental|1|sulindac
3141902|NCT00299195|Placebo Comparator|2|placebo
3141903|NCT00295490|Experimental|240mg Devil claw|Sub clinical dose if the 3 doses employed
3141904|NCT00295490|Experimental|960mg Devil Claw|Active dose
3141905|NCT00295490|Experimental|1920 mg Devil claw|Active dose
3141906|NCT00295490|Placebo Comparator|Placebo|Comparator for all active intervention arms
3141907|NCT00268463|Active Comparator|Arm 1: Capecitabine + Oxaliplatin|Within 4-6 weeks after surgery and/or ablation, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity.
3141908|NCT00268463|Experimental|Arm 2: Floxuridine + Oxaliplatin + Capecitabine|Within 4-6 weeks after surgery and/or ablation, patients receive a continuous hepatic arterial infusion of floxuridine on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 42 days for 4 cycles in the absence of unacceptable toxicity. Beginning with cycle 5, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment with oxaliplatin and capecitabine repeats every 21 days for 4 cycles.
3141909|NCT00271102|Active Comparator|Anterior colporrhaphy|Anterior vaginal wall colporrhaphy (repair) for cystocele (dropped bladder)
3141910|NCT00271102|Active Comparator|Paravaginal defect repair|Abdominal paravaginal defect repair cystocele (dropped bladder)
3141911|NCT00276419|Experimental|Placebo First, then Diclofenac (Arm A)|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks, then compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks.
3141912|NCT00276419|Experimental|Diclofenac First, then Placebo (Arm B)|Compounded topical Diclofenac cream applied to the skin three times daily for 10 weeks, then placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks.
3141913|NCT00279409|Active Comparator|aripiprazole|"This treatment arm (also called the combination arm) consists of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus augmentation with aripiprazole. Aripiprazole pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis. Dosing will start at 2.5 mg and will be titrated up to 5 mg by week 1, and up to 10 mg by week 2 and for the remainder of the trial."
3141914|NCT00279409|Placebo Comparator|Sugar pill|"This treatment arm (also called the simple treatment arm) will consist of parent training plus continued treatment on a stimulant (that is tolerated but has not yet decreased ADHD symptoms enough to meet our criterion of response), plus a placebo matching aripiprazole. Placebo pills are taken once daily over a period of 8 weeks, with patients evaluated on a weekly basis."
3141915|NCT00281879|Active Comparator|Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)|
3141916|NCT00281879|Active Comparator|Busulfan and Cyclophosphamide (Cytoxan)|
3141917|NCT00281879|Active Comparator|BEAM Regimen|On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
3182823|NCT00707473|Experimental|Treatment (docetaxel, cisplatin, and fluorouracil)|"INDUCTION CHEMOTHERAPY: Patients receive docetaxel IV over 1 hour on day 1, cisplatin IV over 30-180 minutes or carboplatin IV on day 1, and fluorouracil IV continuously on days 1-4. Cycles repeat every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~Patients who achieve CR or PR receive 1 additional course of treatment and undergo chemoradiotherapy over 6-7 weeks. Patients who have SD or PD to induction therapy, or less than a complete response to chemoradiotherapy undergo surgery and radiation therapy."
3182824|NCT00707499|Experimental|1|
3182825|NCT00707525|No Intervention|1|Natural cycle oocyte donation
3182826|NCT00707525|Active Comparator|2|"Stimulated cycle oocyte donation.~Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).~Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.~COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations."
3182827|NCT00707538|Experimental|1|
3141918|NCT00281879|Active Comparator|Low-Dose Fludarabine and TBI(for second stem cell donation)|A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
3182828|NCT00707551|Experimental|1|Ketoconazole tablet + AZD1305 Extended Release tablet
3182829|NCT00707551|Experimental|2|Verapamil Extended Release tablet + AZD1305 Extended Release tablet
3182830|NCT00707551|Experimental|3|AZD1305 Extended Release tablet
3182831|NCT00707564|Experimental|1|HemCon Dental Dressing
3182832|NCT00707564|Active Comparator|2|Gauze with pressure
3188914|NCT00772122|Experimental|Granulocyte colony stimulating factor|The G-CSF group of 35 women, underwent a daily sub-cutaneous administration of the filgrastim (Neupogen, Dompe', Italy), the recombinant G-CSF, at a dosage of 1 micro gram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
3188915|NCT00772122|Placebo Comparator|placebo (saline solution)|The placebo group consisting of 33 subjects, was given a treatment with saline solution at the 0.2ml/day subcutaneously/, from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
2416627|NCT03459326||control group|men in relation
3141919|NCT00281879|Active Comparator|Busulfan, Cyclophosphamide, and Fludarabine (Pediatric only)|On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
3141920|NCT00281879|Active Comparator|ATG For Cord Blood Transplants|If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
3182833|NCT00707590|Experimental|Part A|"A: BMS-767778, Oral Solution, Oral, 1 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~B: BMS-767778, Oral Solution, Oral, 3 mg, once daily, 1 day OR Placebo Comparator, Oral Solution, Oral, 0 mg, once daily, 1 day~C: BMS-767778, Capsules, Oral, 10 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~D: BMS-767778, Capsules, Oral, 30 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~E: BMS-767778, Capsules, Oral, 100 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day~F: BMS-767778, Capsules, Oral, 300 mg, once daily, 2 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 2 days~G: BMS-767778, Capsules, Oral, 600 mg, once daily, 1 day OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 1 day"
3188916|NCT00772161|Experimental|Sequence 1|First treatment week (day 1 to day 7) 20mg Ritalin LA; second treatment week (day 8 to day 14) 20mg Medikinet retard.
3188917|NCT00772161|Experimental|Sequence 2|First treatment week (day 1 to day 7) 20mg Medikinet retard; second treatment week (day 8 to day 14) 20mg Ritalin LA.
2417846|NCT03450733||Control (Group 2)|Control, non-implanted subjects
3141921|NCT00281879|Active Comparator|DLI (Donor Leukocyte Infusion)|Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
3182834|NCT00707590|Experimental|Part B|"A: BMS-767778, Capsules, Oral, 10 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~B: BMS-767778, Capsules, Oral, 30 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~C: BMS-767778, Capsules, Oral, 100 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~D: BMS-767778, Capsules, Oral, 300 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days~E: BMS-767778, Capsules, Oral, 600 mg, once daily, 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, once daily, 14 days"
3188918|NCT00772174|Experimental|Pioglitazone + Metformin|
3188919|NCT00772174|Active Comparator|Metformin|
3182835|NCT00707590|Experimental|Part C|"A: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days~B: BMS-767778, Capsules, Oral, Adaptive design (between 10 to 600 mg), 14 days OR Placebo Comparator, Capsules, Oral, 0 mg, 14 days"
3182836|NCT00707603||Hepatitis C subjects|Due to start therapy for Hepatitis C
3182837|NCT00707603||Controls|Healthy males
3182838|NCT00707616||A|Subjects without type 2 diabetes living in Olmsted County, MN
3182839|NCT00707629||Insulin Pump Therapy|Children on insulin pumps for at least three years. Subjects must have type 1 diabetes for at least five years and diagnosed under the age of 5.
3182840|NCT00707642|Experimental|1|Low Dose WN-80E API (5 µg) + Alhydrogel (3.5 mg)
3182841|NCT00707642|Experimental|2|Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)
3182842|NCT00707642|Experimental|3|High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)
3182843|NCT00707642|Experimental|4|High Dose WN-80E API (50 µg), no adjuvant
3182844|NCT00707668||Control|Chung-ju cohort populations aged over 30 year-old
3182845|NCT00707681|Active Comparator|I|MS-20
3141922|NCT00281879|Active Comparator|Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric only)|On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
3141923|NCT00271947|Experimental|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after the conditioning regimen
3141924|NCT00271011|Experimental|Mitomycin C, Irinotecan and Cetuximab|"Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.~Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.~Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2."
3182846|NCT00707681|Placebo Comparator|2|Placebo
3182847|NCT00707694||Probands|Ashkenazi Jews ages 95 and older
3182848|NCT00707694||Offspring|Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95
3182849|NCT00707694||Controls|Ashkenazi Jewish people with no family history of longevity
3182850|NCT00707707|Experimental|1|paclitaxel + AZD2281
3182851|NCT00707720|Experimental|TERIS procedure|TERIS procedure for the treatment of obesity
3182852|NCT00707772|Active Comparator|1|Genotype 2 or 3 in Hemophilic Patients with HCV
3182853|NCT00707772|Active Comparator|2|Other Genotypes (except 2 or 3) in Hemophilic Patients with HCV
3182854|NCT00707785|Experimental|1|Sepsis - vitamin A
3182855|NCT00707785|Placebo Comparator|2|Sepsis - placebo
3182856|NCT00707785|Experimental|3|NEC - vitamin A
3182857|NCT00707785|Placebo Comparator|4|NEC - Placebo
3182858|NCT00707798|Experimental|Formulation 1|
3182859|NCT00707798|Experimental|Formulation 2|
3182860|NCT00707798|Experimental|Formulation 3|
3141925|NCT00253981|Experimental|Infrared Light Therapy|Intervention: The use of infrared light therapy for the treatment of tibial fracture. The treatment was assigned three times a week for four weeks.
3141926|NCT00253981|Placebo Comparator|Standard of Care|Standard of care was characterized by the use of standard medical treatment to include medication.
3141927|NCT00252174|Experimental|Stage 1 Active methylenedioxymethamphetamine & psychotherapy|8 subjects will receive full or nearly full doses of MDMA in Stage 1 and do not continue to participate into Stage 2.
3141928|NCT00252174|Active Comparator|Stage 1 low dose methylenedioxymethamphetamine & Psychotherapy|4 individuals will receive sub-threshold to threshold minimal doses of MDMA in Stage I
3141929|NCT00252174|Experimental|Stage 2 Active methylenedioxymethamphetamine & Psychotherapy|The 4 subjects assigned in Stage I to the control arm will have the option to continue into Stage 2 to repeat the experimental procedures of Stage I but with open-label MDMA at the near-full to full dosage strength.
3141930|NCT00256295|Experimental|Gemcitabine plus Oxaliplatin|Gemcitabine given 1000 mg/m2 IV over 100 minutes Every 21 days. Oxaliplatin given 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days.
2418383|NCT03446989|Experimental|Case management|
3141931|NCT00268450|Experimental|study intervention|Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
3141932|NCT00239720|Experimental|hOKT3gamma1 (Ala-Ala)|Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
3141933|NCT00239720|Placebo Comparator|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
3141934|NCT00250718|Experimental|Arm 1 Combination Treatment|"Treatment with combination therapy as follows:~VP-16 at 50 mg/day, orally for 14 days every 28 days; Chlorambucil at 0.1 mg/kg/day orally for 14 days every 28 days; Vincristine at 2 mg intravenously every 14 days; Dexamethasone at 200 mg intravenously every 24 days; Rituxan (rituximab) at 375 mg/m2 intravenously every 14 day; Levofloxacin at 500 mg orally daily; Diflucan at 200 mg orally daily~At least 2 courses, but no more than 8 courses total, will be administered to each patient"
3141935|NCT00244010|Other|1|
3141936|NCT00218036|Experimental|1|Modafinil 200mg / Methadone Maintenance (1.2mg/kg)
3141937|NCT00218036|Experimental|2|Modafinil 400mg/ Methadone Maintenance (1.2mg/kg)
3141938|NCT00218036|Experimental|3|Citalopram 20/ Methadone Maintenance 1.2mg/kg
3141939|NCT00218036|Experimental|4|Citalopram 40/ Methadone Maintenance 1.2 mg/kg
3141940|NCT00218036|Placebo Comparator|5|Placebo given to methadone-maintained subjects (1.2mg/kg) for the duration of the 12-week study
3141941|NCT00240227|Other|Placebo|Placebo no active medication
3141942|NCT00240227|Active Comparator|prazosin|Prazosin flexible dose titration up to 12 mg per day.
3141943|NCT00206375|No Intervention|1|Group 1 will be treated only with Synthroid.
3141944|NCT00206375|Experimental|2|Group 2 will be treated with Growth hormone, synthroid, and lupron.
3141945|NCT00206375|No Intervention|3|Group 3 will have acute hypothyroidism and will serve as controls.
3141946|NCT00229931|Active Comparator|Laser therapy|If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
3141947|NCT00229931|Active Comparator|Triamcinolone therapy|"At time of cataract surgery, will have IVTA injection. If macular edema does not show improvement at 1 month, then can have repeat IVTA injection. If the macular edema is stil not improved after 2nd injection, participant will be considered treatment failure and will be given the option to have laser therapy."
3141948|NCT00209131|Experimental|Flomax|Patients on this arm will be given 0.4mg of Flomax to be taken for one month following their shock wave lithotripsy procedure.
3141949|NCT00209131|Placebo Comparator|Sugar pill|Patients on this arm will be given a sugar pill to be taken for one month following their shock wave lithotripsy procedure.
3141950|NCT00233090|Experimental|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
3141951|NCT00233090|Placebo Comparator|Placebo|
3141952|NCT00214149|Experimental|1|breast brachytherapy to a dose of 34 Gy
3141953|NCT00205049|Experimental|Pentoxifylline/Placebo|All subjects will be randomized to receive either pentoxifylline 400mg orally or placebo 3 times daily for 28 days (20-40 treated, 1-20 placebo) with monthly follow up for 90 days.
3141954|NCT00209027|Experimental|schizophrenia subjects|Patients to be switched from baseline medication to aripiprazole, and fMRI measured at baseline and after med switch.
3141955|NCT00182637|Experimental|bortezomib|
3141956|NCT00176488|Experimental|Sequential epirubicin/vinorelbine|For patients with stage IIB (T3N0), IIIA, or IIIB breast cancer, epirubicin and vinorelbine will be administered for up to 5 cycles. For patients with stage IV breast cancer, epirubicin and vinorelbine will be administered as long as there is evidence of continued response or stable disease and no evidence of cardiac or other serious toxicities.
3141957|NCT00179127|Experimental|Glargine|0.3u/kg of glargine, subcutaneously, once
3141958|NCT00179127|Placebo Comparator|Placebo|0.3u/kg of saline, subcutaneously, once
3141959|NCT00183963|No Intervention|1|
3141960|NCT00183963|Active Comparator|2|Tamoxifen 20 mg
3141961|NCT00183963|Active Comparator|3|Fulvestrant 250mg
3141962|NCT00183963|Active Comparator|4|Fulvestrant 500mg IM
3141963|NCT00178477|Experimental|Breath-holding|MRI with breath-holding
3182861|NCT00707798|Experimental|Formulation 4|
3141964|NCT00162773|Placebo Comparator|Placebo|water injection
3182862|NCT00707798|Experimental|Formulation 5|
3182863|NCT00707798|Experimental|Formulation 6|
3182864|NCT00707798|Active Comparator|23 valent pneumococcal vaccine|
3141965|NCT00162773|Experimental|Omalizumab|"Other Names:~Xolair 150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE."
3141966|NCT00176631|Experimental|licorice root extract and docetaxel|
3141967|NCT00176501|Experimental|Irradiated allogeneic lymphocytes|
3141968|NCT00177970|Active Comparator|IVIG|
3141969|NCT00177970|Placebo Comparator|Placebo|
3141970|NCT00177866|Active Comparator|A Placebo or Celebrex|either placebo PO BID for the first eight weeks or Celebrex 200 mg PO BID for the first eight weeks
3141971|NCT00177866|Placebo Comparator|B Placebo or Celebrex|either placebo PO BID for the last eight weeks or Celebrex 200 mg PO BID for the last eight weeks
3141972|NCT00147238|Experimental|Ferumoxtran-10 MRI|MR lymphangiography using Ferumoxtran-10 contrast agent.
3141973|NCT00147238|Active Comparator|MRI|MR lymphangiography before injecting Ferumoxtran-10 contrast agent.
3182865|NCT00707824|Placebo Comparator|1|1= placebo
3182866|NCT00707824|Active Comparator|2|2=nalbuphine 5 mg
3182867|NCT00707824|Active Comparator|3|3=nalbuphine 10 mg
3182868|NCT00707837|Experimental|Infant Formula|Preterm infant formulas containing lipid soluble compounds
3182869|NCT00707837|Active Comparator|Preterm formulas|Standard preterm infant formula and discharge formulas
3182870|NCT00707850|Experimental|1|Thalassemic Patients with HCV
3182871|NCT00707876|Experimental|1|Dose 1 versus non-contrast MRA
3182872|NCT00707876|Experimental|2|Dose 2 versus non-contrast MRA
3141974|NCT00165503|Experimental|Surgery+Heated Cisplatin+Sodium Thiosulfate+Adjuvant CT|Participants undergo surgery, Pleurectomy/Decortication, followed by heated cisplatin given as a one-hour lavage of the chest and abdominal cavity then sodium thiosulfate given intravenously over 6 hours. The adjuvant chemotherapy regimen beginning 6-10 weeks after surgery is a combination of cisplatin and Alimta each given day 1 of a 21-day cycle for 3 cycles.
3141975|NCT00160563|Experimental|LCTZ-LCTZ|Levocetirizine after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ-LCTZ)
3141976|NCT00160563|Placebo Comparator|LCTZ-PLC|Placebo after having been randomized to Levocetirizine in the preceding A00309 trial - NCT00152464 (LCTZ - PLC)
3141977|NCT00160563|Placebo Comparator|PLC-PLC|Placebo after having been randomized to Placebo in the preceding A00309 trial - NCT00152464 (PLC-PLC)
3141978|NCT00142519|Active Comparator|1|methadone
3141979|NCT00142519|Experimental|2|methadone and morphine
3141980|NCT00145704|Active Comparator|Growth Hormone only|No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
3141981|NCT00145704|Experimental|Growth Hormone & Bisphosphonate Therapy|Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
3141982|NCT00138073|Experimental|Web-based waveform interpretation guide|The arm has access to the Web-based waveform interpretation guide.
3182873|NCT00707876|Experimental|3|Dose 3 versus non-contrast MRA
3182874|NCT00707889|Active Comparator|A|Open-label to Bevacizumab plus mFOLFOX6
3182875|NCT00707889|Active Comparator|B|Open-label to High-dose ABT-869 arm plus mFOLFOX6
3141983|NCT00113386|Other|Induction chemotherapy, surgery, consolidation chemotherapy|Induction/surgery/consolidation
3141984|NCT00113386|Other|Chemotherapy and radiation, surgery, consolidation ch|Induction/radiation/surgery/cosolidation
3141985|NCT00138151|Experimental|Paclitaxel, 13-cis Retinoic Acid, and Interferon Alpha-2b|"Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle~Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle~Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days"
3141986|NCT00126659|Experimental|Group I (cytoreductive nephrectomy and sorafenib tosylate)|"Patients undergo cytoreductive nephrectomy on day 1. Patients then receive oral sorafenib twice daily on days 15-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3182876|NCT00707889|Active Comparator|C|Open-label to low-dose ABT-869 arm plus mFOLFOX6
3188920|NCT00772187|Experimental|1|General anesthesia + I.V pca
3141987|NCT00126659|Experimental|Group II (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-7. Patients undergo cytoreductive nephrectomy on day 8. Patients then receive oral sorafenib twice daily on days 22-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3188921|NCT00772187|Experimental|2|General anesthesia + spinal analgesia + I.V pca
3182877|NCT00707902|Active Comparator|2|"Drug: Echinacea/sage~patients received additionally a placebo-spray for the synthetical comparator (chlorhexidine/lidocaine) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days.~Arms: 1"
3182878|NCT00707902|Active Comparator|1|"Drug: Chlorhexidine/lidocaine~patients received additionally a placebo-spray for the synthetical comparator (echinacea/sage) as the study was double dummy blinded.~Patients had to apply spray every 2 hours with two puffs to the pharyngeal area up to a maximum of 10 times daily. Treatment duration was until illness was resolved or for a maximum of 5 consecutive days."
3182879|NCT00707928|Active Comparator|1|1=nitroglycerine 100 microgram intravenous100-200 microgram of IV.
3182880|NCT00707928|Placebo Comparator|2|2=placebo with the same volume as NTG 100-200 microgram of IV.
3182881|NCT00707941|Experimental|1|Oseltamivir for 5 days for patients with illness duration < 48 hours
3182882|NCT00707941|Placebo Comparator|2|Placebo for 5 days for patients with illness duration < 48 hours
3182883|NCT00707941|Experimental|3|Oseltamivir for 5 days for patients with illness duration ≥ 48 hours
3141988|NCT00126659|Experimental|Group III (sorafenib tosylate and cytoreductive nephrectomy)|"Patients receive oral sorafenib twice daily on days 1-28. Patients undergo cytoreductive nephrectomy on day 29. Patients then receive oral sorafenib twice daily on days 43-84.~In all groups, patients with stable or regressing disease continue to receive oral sorafenib twice daily for up to 1 year in the absence of disease progression or unacceptable toxicity. Some patients may continue treatment for longer than 1 year at the discretion of the investigator."
3141989|NCT00133679|Experimental|1|Sildenafil x 45 days
3141990|NCT00133679|Placebo Comparator|2|Placebo x 45 d
3141991|NCT00125268|Active Comparator|MIRE|Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
3141992|NCT00125268|Sham Comparator|Sham|Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.
3141993|NCT00113399|Other|Radiotherapy and chemotherapy|Radiotherapy/paclitaxel/cisplatin/filgrastim
3141994|NCT00113399|Other|Chemotherapy|Cisplatin/fluorouracil/paclitaxel/docetaxel
3141995|NCT00118053|Experimental|Docetaxel, Carboplatin and Trastuzumab|"A total of six cycles of TCH [(Taxotere® (75 mg/m2) + Carboplatin (AUC = 6) + Herceptin® (2 mg/kg weekly after a 4 mg/kg load on Day 1)] will be administered every 3 weeks.Three weeks after receiving the sixth cycle of TCH, all patients will be restaged.~Those determined to have localized and operable disease (as determined by surgical consultation) will undergo a modified radical mastectomy or lumpectomy and axillary node dissection. After recovery from surgery, the patients will receive whole breast or chest wall irradiation (as determined by radiologist) with concurrent Herceptin® (6 mg/kg). Following radiation, patients will continue Herceptin® (6 mg/kg) every 3 weeks until they have been on study for a total of 52 weeks.~If patients are staged and are negative they will continue Herceptin® (6 mg/kg)every 3 weeks until they have been on study for a total of 52 weeks."
3141996|NCT00107614|Experimental|DT PACE/auto transplant/maint therapy|
3141997|NCT00107315|Experimental|Arm 1|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine twice daily on days 1-7
3141998|NCT00113919|Experimental|Busulfan|study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days
3141999|NCT00108342|Active Comparator|Nicotine Replacement Treatment (NRT) Sampling|"Sampling = 3 minute testing of each of 6 NRTs (3 forms x 2 dosages)~2 mg and 4 mg nicotine gum; 2 mg and 4 mg nicotine lozenges; frequent and infrequent puffing on a nicotine inhaler (can yield 4 mg from 10 mg device)."
3142000|NCT00108342|Sham Comparator|NRT Computer Learning|Computer learning: learning about 6 NRTs (3 forms x 2 dosages) by computer only
3142001|NCT00100828|Experimental|Irinotecan|
3142002|NCT00104728|Experimental|Neoadjuvant ZD1839 Preoperative Therapy|"The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food.~At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth."
3142003|NCT00089414|Experimental|1|Treatment arm # 1 consists of the continuous administration of Yasmin oral contraceptive (a combination of 30 µg of ethinyl estradiol and 3 mg of drospirenone) for 15 weeks starting on day 2 to 5 of the first menstrual cycle.
3142004|NCT00089414|Active Comparator|2|Treatment arm # 2 (interrupted Yasmin administration) will be identical to arm # 1 with the exception that the continuous administration of Yasmin will be interrupted by the substitution of placebo for Yasmin for one week during weeks 3, 8, and 14 of the study. The women participating in this treatment arm will experience episodes of menstruation after Yasmin withdrawal (when they are on placebo).
3142005|NCT00089414|Active Comparator|3|Yasmin oral contraceptive; CDB 2914 progesterone antagonist. Treatment arm # 3 is identical to treatment arm # 1 with the exception that the continuous administration of Yasmin will also include the administration of progesterone antagonist CDB-2914 during weeks 3, 8, and 14. Menses is anticipated to occur within 2-3 days of CDB-2914 administration. Women in treatment arms # 3 and # 1 will be exposed to continuous levels of Yasmin, but due to the local effects of the progesterone antagonist on the endometrium, women in arm # 3 will experience menses.
3142006|NCT00083915|Active Comparator|Auto Transplant w/ High Dose Melphalan|Autologous transplant with High Dose Melphalan alone
3142007|NCT00083915|Active Comparator|Auto Transplant w/ Melphalan + DT Pace|Melphalan plus Dexamethasone, Thalidomide, CisPlatinum, Adriamycin, Cyclophosphamide, and Etoposide
3142008|NCT00090870|Experimental|PEG-Intron, BM-CSF and thalidomide|
3142009|NCT00088972|Experimental|Arm I - Celecoxib|Patients receive oral celecoxib twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
3142010|NCT00088972|Placebo Comparator|Arm II - Placebo|Patients receive oral placebo twice daily for 12 months in the absence of unacceptable toxicity or diagnosis of cancer.
3142011|NCT00088829|Experimental|Paclitaxel|Paclitaxel given before surgery
3142012|NCT00089128|Experimental|Gemcitabine and Irnotecan|
3142013|NCT00075608|Experimental|2nd Stem Cell Transplant|Mobilization with filgrastim autologous stem cell transplantation with melphalan conditioning stem cell infusion
3142014|NCT00074724|Active Comparator|Medical Therapy|All medical interventions know to improve outcomes in patients with ischemic left ventricular dysfunction.
3142015|NCT00074724|Active Comparator|CABG|Surgical revascularization in conjunction with optimal medical therapy.
3142016|NCT00085631|Experimental|Arm I|Patients received cisplatin IV and concurrently underwent hyperthermia treatment over 60-90 minutes on day 1. Patients also underwent external beam radiation therapy once daily on days 1-5. Treatment repeated weekly for 5-6 weeks in the absence of disease progression or unacceptable toxicity. After completion of chemoradiotherapy and hyperthermia, patients underwent brachytherapy to the cervix for 2-3 days.
3142017|NCT00085631|Active Comparator|Arm II|Patients received cisplatin and undergo external beam radiation therapy (and brachytherapy) as in arm I.
3142018|NCT00062751|Experimental|A|
3142019|NCT00062751|Experimental|B|
3142020|NCT00062751|Active Comparator|C|
3142021|NCT00066807|Experimental|OFS plus T or E|Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
3142022|NCT00066807|Experimental|Chemotherapy plus OFS plus T or E|Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
3142023|NCT00058188|Experimental|Arm I|Patients receive zoledronate IV over 15 minutes on day 1 and oral calcium gluconate and oral cholecalciferol daily. Courses repeat every 3 months for 12 months in the absence of toxicity.
3142024|NCT00058188|Active Comparator|Arm II|Patients receive oral calcium gluconate and oral cholecalciferol as in arm I.
3142025|NCT00014560|Experimental|Single arm|Antibody
3142026|NCT00038142|Experimental|Arm A: VACdxr With ImmTher|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) intravenous (IV), Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days. Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin). ImmTher 900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
3142027|NCT00038142|Active Comparator|Arm B: VACdxr|Chemotherapy repeated every 3 weeks for 6 cycles: Vincristine 2.0 mg/m^2 (max 2.0 mg) IV. Doxorubicin 90 mg/m^2 IV over 30 minutes, Cyclophosphamide 2.0 g/m^2 IV daily for 2 days, Dexrazoxane 900 mg/m^2 IV (30 minutes prior to doxorubicin).
3142028|NCT00020722|Experimental|therapeutic autologous lymphocytes|
3142029|NCT00002975|Experimental|PDT|4-6h and 18-24h, 20%, ALA application of superficial and nodular epidermally-derived lesions using ca 633 nm laser irradiation
3142030|NCT00019747|Experimental|Arm 1 - Thalidomide once daily|Patients receive oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
3142031|NCT00019747|Placebo Comparator|Arm 2 - Placebo once daily|Patients receive oral placebo once daily.
3182884|NCT00707941|Placebo Comparator|4|Placebo for 5 days for patients with illness duration ≥ 48 hours
3182885|NCT00708006|Experimental|1|HGS1029
3182886|NCT00708045|Experimental|All patients|All participants enrolled.
3182887|NCT00708084|Experimental|A|CL184 combined with rabies vaccination
3182888|NCT00708084|Active Comparator|B|HRIG combined with rabies vaccination
3142032|NCT00006916|Experimental|Radiation therapy followed by bleomycin via Ommaya reservoir|60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.
3142033|NCT00003726|Experimental|Lepirudin|Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
3142034|NCT04051996|Experimental|DAC5|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
3142035|NCT04051996|Experimental|DAC10|Glasdegib will be administered at the starting dose of 100 mg orally once daily and continuously in combination with either DAC5 (decitabine 20 mg/m2 IV on a 5-day schedule) or DAC10 (decitabine 20 mg/m2 IV on a 10-day schedule) as per randomization. Treatment will be administered in 28-day cycles.
3142036|NCT02970799|Experimental|Intranasal then Extranasal Application|Intranasal Neurostimulator applied intranasally (active) followed by extranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence for Days 15 and 29.
3142037|NCT02970799|Experimental|Extranasal then Intranasal Application|Intranasal Neurostimulator applied extranasally (control) followed by intranasal application on Day 1. Participants were randomized to determine the intranasal and extranasal sequence at Days 15 and 29.
2420436|NCT03433092||G Pappalardo et. al,1997|
3142038|NCT02385292|Experimental|Intranasal then Extranasal Application|Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
3182889|NCT00708149|Active Comparator|1|lansprazole 30 mg qd from NG route or orally
3182890|NCT00708149|Placebo Comparator|2|control group without any PPI, H2 blockers or other medications for treating peptic ulcers.
3182891|NCT00708188|Experimental|Multidetector raw CT|
3182892|NCT00708240|Experimental|Escitalopram|
3182893|NCT00708253|Active Comparator|SBE|
3182894|NCT00708253|Active Comparator|DBE|
3182895|NCT00708266|Placebo Comparator|V2|28 hours continuous saline venous infusion.
3182896|NCT00708266|Experimental|V3|28 hours continuous lipid-heparin venous infusion.
3182897|NCT00708279|Experimental|A|After establishing a baseline for the first 4 weeks of trial involvement, thereby providing their own control group, all participants begin the intervention phase of osteopathic manipulation.
3182898|NCT00708292|Experimental|Single Agent AUY922|
3182899|NCT00708292|Experimental|AUY922 + Bortezomib|
3182900|NCT00708292|Experimental|AUY922 + Bortezomib + Dexamethasone|
3182901|NCT00708318|Experimental|A, B, C|
3182902|NCT00708331|Experimental|1|
3182903|NCT00708344|Active Comparator|Group 1|Usual elective titration regimen
3142039|NCT02385292|Active Comparator|Extranasal then Intranasal Application|Extranasal application of the Oculeve Intranasal Lacrimal Neurostimulator followed by Intranasal application of the Oculeve Intranasal Lacrimal Neurostimulator.
3142040|NCT02126878|Active Comparator|Kenalog 20mg|20mg/ 2ml and local anesthetic
3142041|NCT02126878|Active Comparator|Kenalog 40mg|40mg/ 2ml with local anesthetic
3142042|NCT02126878|Active Comparator|Kenalog 80mg|80mg/ 2ml and local anesthetic
3142043|NCT02221817|Active Comparator|Blind|Trochanter injection
3142044|NCT02221817|Experimental|Ultrasound|Trochanter injection
3142045|NCT02595996|Experimental|Treatment|Patients will be given propranolol in escalating doses
3142046|NCT03879044|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes before their scheduled work hours at least 3x/week for two consecutive weeks.
3142047|NCT03198156|Experimental|Transcranial Direct Current Stimulation|Active tDCS for 30 minutes daily for 4 sessions
3142048|NCT03198156|Sham Comparator|Sham stimulation|Sham stimulation sessions will be for 30 minutes daily for each of the 4 sessions; however, active stimulation for this arm of the study is only for 30 seconds; yet, will be applied at the same intensity as the Active arm of the study, albeit for only 30 seconds.
3142049|NCT02009384|Experimental|Ipilimumab|IV ipilimumab
3142050|NCT04558125|Experimental|Low-dose TNKase and Standard of Care Anticoagulation|"TNKase (0.25 mg/kg) bolus Other names: Tenecteplase, TNK~Standard of care anticoagulation (heparin or enoxaparin)"
3182904|NCT00708344|Active Comparator|Group 2|Active elective titration regimen
3182905|NCT00708357|Other|1|homozygous mutant: CC allele of the eNOS T-786C gene
3182906|NCT00708357|Other|2|homozygous mutant: TT allele of the eNOS T-786C gene
3182907|NCT00708370|Active Comparator|COACH|
3182908|NCT00708370|Placebo Comparator|Standard Care|
3182909|NCT00708383|Experimental|1|Embryo culture medium supplemented with 0.5% HSA and 10% SSS
3182910|NCT00708383|Active Comparator|2|Embryo culture medium supplemented with 0.5% HSA only
3182911|NCT00708396|Experimental|Patients|Patients which diagnosed as OCD and schizophrenia
3182912|NCT00708409||1|Autograft operations with the subcoronary technique
3182913|NCT00708409||2|Autograft operations with the root replacement technique
3182915|NCT00708474|Experimental|OsseoFit™|Treatment of bone graft site with OsseoFit™ Porous Tissue Matrix™.
3142051|NCT04558125|Active Comparator|Placebo and and Standard of Care Anticoagulation|"Placebo bolus (intravenous syringe identical to that of TNK )~Standard of care anticoagulation (heparin or enoxaparin)"
3142052|NCT02401308|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Parkinson's patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intra-operative stimulation"
3142053|NCT02401308|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery:Parkinson's patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrodes placement at the time of surgery.
3142054|NCT04381988|Experimental|Hydroxychloroquine|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of hydroxychloroquine 400mg daily.
3142055|NCT04381988|Placebo Comparator|Placebo|Every patient on trial must be scheduled to receive at least 10 radiation treatments prior to initiation of placebo 400mg daily.
3142056|NCT00521885|Active Comparator|Arixtra (Fondaparinox) 2.5 mg SC Daily|Arixtra (Fondaparinox) 2.5 mg SC Daily
3142057|NCT00521885|Active Comparator|Lovenox 40mg SC Daily|Lovenox 40mg SC Daily
3142058|NCT02376946|Active Comparator|Actipatch|The study group will be comprised of subjects that will receive PEMF ActiPatchTM treatment for postoperative management of pain and edema.
3142059|NCT02376946|Placebo Comparator|Placebo|The control group will be comprised of the subjects that will receive a placebo patch as treatment for postoperative management of pain and edema.
3142060|NCT00344487|Experimental|lopinavir/ritonavir (Kaletra)|lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.
3142061|NCT01780636|Experimental|Botulinum toxin (Botox) injection|All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.
3142062|NCT00479167|Experimental|Bortezomib and Tositumomab I-131|
3142063|NCT03998189|Experimental|Female Participants|45 female patients will be screened to participate.
3142064|NCT03998189|Experimental|Male Participants|45 male patients will be screened to participate
3142065|NCT02212574|Other|Chemotherapy|"Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1. Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15. Cisplatin is given directly into a vein over 8 hours on Day 1. This cycle lasts 42 days.~Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2. MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours. Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.This cycle lasts 28 days"
3182916|NCT00708474|No Intervention|Open|Treatment of bone graft site without OsseoFit™ Porous Tissue Matrix™.
3182917|NCT00708487|Experimental|1|5% oxygen embryo culture condition
3182918|NCT00708487|Active Comparator|2|21% oxygen embryo culture condition
2420542|NCT03432312|Experimental|Nicotine 4 mg mint lozenges|
3142066|NCT04422210|Experimental|Dose Escalation (Arm A1) (Maintenance only)|Cohort A1: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were administered continuous maintenance therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
3142067|NCT04422210|Experimental|Dose Escalation (Arm A2) (Maintenance only)|Cohort A2: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
3182919|NCT00708539|Active Comparator|1|Crinone vaginal gel 8% 90 mg once daily
3182920|NCT00708539|Active Comparator|2|Progesterone mic 400 mg three times daily
3182921|NCT00708578|Active Comparator|1|Administration of 4 mg of Glimepiride with Insulin Glargine
3182922|NCT00708578|Active Comparator|2|Administration of 1500 mg of Metformin with Insulin Glargine
3142068|NCT04422210|Experimental|Dose Escalation (Arm A3) (Maintenance only)|Cohort A3: Participants with ES-SCLC who completed 4-6 cycles of carboplatin and etoposide first-line induction chemotherapy, with or without atezolizumab, were to be administered continuous maintenance therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 21 and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. This cohort maybe explored if Dose-Limiting Toxicities (DLTs) are experienced and adverse events are thought to be potentially mitigated with a lower dose of venetoclax.
3182923|NCT00708578|Experimental|3|Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine
3182924|NCT00708591|Experimental|1|
3182925|NCT00708604|Experimental|1|Islet transplantation
3182926|NCT00708630|Experimental|1|Provision of extended symptom side effects information
3182927|NCT00708630|No Intervention|2|Standard information on side effects
3182928|NCT00708656|Experimental|1: once daily|Three 800mg tablets of mesalazine (Asacol®) in the morning
3182929|NCT00708656|Active Comparator|2: tds|Mesalazine (Asacol®) 800mg given three times daily
3182930|NCT00708669|Active Comparator|TAXUS group|
3182931|NCT00708669|Active Comparator|Cypher group|
3182932|NCT00708695||Free Transportation|The 166 families in this treatment condition received free transportation for scheduled prenatal care appointments. This group did not receive any postpartum services or assessments.
3182933|NCT00708695||Transportation, Child Screening/Referral|The 514 families received: 1) free transportation for prenatal care; and 2) child developmental screening and referral services.
3142069|NCT04422210|Experimental|Dose Escalation (Arm B1) (Induction + Maintenance)|Cohort B1: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (200mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
3142070|NCT04422210|Experimental|Dose Escalation (Arm B2) (Induction + Maintenance)|Cohort B2: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (400mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
3142071|NCT04422210|Experimental|Dose Escalation (Arm B3) (Induction + Maintenance)|Cohort B3: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 7, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
3182934|NCT00708695||Prenatal Nurse Home-Visiting|The 230 families received: 1) free transportation for prenatal care; and 2) nurse home-visiting during pregnancy and postpartum (one visit).
3142072|NCT04422210|Experimental|Dose Escalation (Arm B4) (Induction + Maintenance)|Cohort B4: Participants with ES-SCLC were to be administered non-continuous induction therapy with Venetoclax (800mg) once daily (QD) from Day 1 to 14, Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3. Participants who tolerated study treatment without excessive toxicity, and had not undergone disease progression were to be then proceeded to maintenance treatment with venetoclax plus atezolizumab. The venetoclax dose for the maintenance setting in Arm B will be the dose that has been cleared in the maintenance only arm (Arm A) of the study (maintenance RP2D, RP2D-M).
3150676|NCT00208117|Active Comparator|1|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If AEs occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained. The psychiatry fellow will be responsible for drug administration and will see all patients weekly. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess medical tolerance to the study medications, and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
3182935|NCT00708695||Nurse Home Visiting through Age 2|The 228 families: 1) free transportation for prenatal care; 2) nurse home-visiting during pregnancy and through child's second birthday; and 3) child developmental screening and referral.
3182936|NCT00708747|Experimental|B|Patients were randomised to receive a commercially available standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) containing all important transport and inhibitor proteins as well as immunoglobulins
3182937|NCT00708747|Active Comparator|A|Patients were randomised to receive a 5% albumin solution
3182938|NCT00708760||2|web based learning group
3182939|NCT00708760||1|paper based learning group
3182940|NCT00708773|Experimental|Single Arm|
3182941|NCT00708799|Experimental|Arm 1|Standard antibiotic therapy +Azithromycin 500 mg intravenously daily for 5 days
3182942|NCT00708799|No Intervention|Arm 2|Standard antibiotic therapy
3182943|NCT00708812|Active Comparator|The control group|paclitaxel-carboplatin
3182944|NCT00708812|Experimental|The treatment group|paclitaxel-carboplatin plus Endostar
3182945|NCT00708825||1|surgical outcome, observation
3182946|NCT00708838||1|
3182947|NCT00708838||2|
3182948|NCT00708838||3|
3182949|NCT00708838||4|
3182950|NCT00708838||5|
3182951|NCT00708890|Experimental|Intervention group|
3182952|NCT00708890|No Intervention|Control group|Will only get a standard information about TSG group (information about meeting etc.)
3182953|NCT00708903|Experimental|1|HKI-272
3182954|NCT00708903|Placebo Comparator|2|Placebo
3182955|NCT00708903|Active Comparator|3|Moxifloxacin
3182956|NCT00708929|Other|1|14 subjects homozygous HH for the Tyr402His single nucleotide polymorphism
3182957|NCT00708929|Other|2|14 subjects homozygous TT for the Tyr402His single nucleotide polymorphism
3182958|NCT00708968|Experimental|FOCUS Intervention|Dyads randomized to this arm received the FOCUS Program, 3 home visits and 2 phone calls by trained nurses.
3182959|NCT00708968|No Intervention|Standard Care|
3182960|NCT00708981|Active Comparator|Study Group|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
3182961|NCT00708981|No Intervention|Control Group|Control Group will keep on receiving the usual treatment that they used to receive from their respective clinics and the Diabetes-Renal team would not alter their therapy or interfere in their management.
3182962|NCT00708994|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
3182963|NCT00708994|Placebo Comparator|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
3182964|NCT00709007|Experimental|DAART|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
3142073|NCT04422210|Experimental|Dose Expansion|If the Recommended Phase II Dose (RP2D) for Venetoclax during induction is established, then the dose-expansion cohort would continue to test venetoclax in both induction and maintenance. Participants would be administered non-continuous induction therapy with Venetoclax (RP2D-I/induction RP2D), Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1, Carboplatin (5mg/mL/min) on Day 1 and Etoposide (100mg/m^2) on Days 1-3 followed by continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1. If significant toxicity and DLTs in induction precluded identification of an RP2D for venetoclax in induction treatment, then the safety and efficacy of venetoclax would only be investigated in dose-expansion in the maintenance setting. Participants would be administered continuous maintenance therapy with Venetoclax (RP2D-M) and Atezolizumab (1200mg) every 3 weeks (Q3W) on Day 1.
3142074|NCT04298918|Experimental|Dose Escalation Phase|Participants received venetoclax in combination with a fixed dose of trastuzumab emtansine.
3142075|NCT04298918|Experimental|Dose Expansion Phase|Participants were to receive venetoclax at the Phase II Recommended Dose (RP2D) in combination with trastuzumab emtansine.
3182965|NCT00709007|Active Comparator|SAT|Participants take their HIV medications on their own but visit the clinic for opioid agonist substitution therapy.
3182966|NCT00709020|Experimental|White Button Mushroom Extract|
3182967|NCT00709033|Experimental|autologous or syngeneic PBTLs and EBV-CTLs|The subject will be assigned a dose of CD19-CD28 chimeric receptor T cells at study entry.
3182968|NCT00709046|Experimental|1|High dose pantoprazole infusion
3182969|NCT00709046|Active Comparator|2|standard dose pantoprazole infusion
3182970|NCT00709072|Experimental|1|SMS reminders
3182971|NCT00709072|No Intervention|2|control group
3182972|NCT00709085||1|HCC patients without liver cirrhosis
3142076|NCT04298918|Experimental|Randomized Phase II Arm 1|Participants were to receive trastuzumab emtansine + placebo.
3142077|NCT04298918|Experimental|Randomized Phase II Arm 2|Participants were to receive trastuzumab emtansine + venetoclax.
3142078|NCT01996371|Other|Group 1|Unilateral pedicle screws
3142079|NCT01996371|Other|Group 2|Ipsilateral pedicle screws, contralateral facet screw
3142080|NCT01996371|Other|Group 3|Bilateral pedicle screws
3182973|NCT00709085||2|HCC patients with liver cirrhosis
3142081|NCT01561378|Experimental|Insulin|Aspart Insulin 40 IU intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
3142082|NCT01561378|Placebo Comparator|Normal saline|Normal saline (0.9% sodium chloride solution) intranasal spray via intranasal mucosal atomizer device, four times a day for 7 days or until hospital discharge, whichever occurs first
3142083|NCT00955929|Experimental|PRN Sildenafil|Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
3142084|NCT00955929|Experimental|Nightly Sildenafil Arm|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
3142085|NCT00955929|Experimental|Combination Therapy Arm|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).
3182974|NCT00709137|Active Comparator|1|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
3142086|NCT00402883|Experimental|Intervention|Induction treatment included: carboplatin AUC=5, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously weeks 1 and 4. Radiation was administered concurrently at a dose of 1.8 Gy/d weeks 1 to 7 to a total of 61.2 Gy per institutional guidelines. Consolidative therapy, following an 8-week break from chemoradiotherapy, included carboplatin AUC=6, pemetrexed 500 mg/m2, and bevacizumab 15 mg/kg each administered intravenously on week 16, repeated weeks 19 and 22. Folic acid (350 to 1,000 ug or equivalent) supplementation was administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinued study therapy. Vitamin B12(1,000ug) was administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinued therapy.
3142087|NCT03482505|Experimental|INVSENSOR00004|All enrolled subjects will receive the INVSENSOR00004 sensor. The INVSENSOR00004 rainbow acoustic monitoring (RAM) acoustic respiration sensor is designed to noninvasively convert acoustical airflow patterns into respiratory rate (RRa).
3150677|NCT00208117|Placebo Comparator|2|To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills. All randomized patients will also be seen at the mid-treatment, post-treatment, and follow-up visits by the study psychiatrist to determine depression symptom severity (HAM-D), assess the medical tolerance to the study medications (including placebo), and ensure patient psychiatric safety. The study psychiatrist will be blinded to treatment allocation.
3150678|NCT00208156|Experimental|mifepristone|
3150679|NCT00208169|Experimental|1|Aripiprazole start dose at 5 mg/day by day 4-6 increase to 10 mg/da and day 7 and subsequent visits flexible dosing from 10 up to 30 mg/day.
3150680|NCT00208234|Placebo Comparator|Control|Placebo
3150681|NCT00208234|Experimental|2|Omalizumab
3150682|NCT00208247|Experimental|CBT|The cognitive behavioural treatment developed by Salkovskis, Warwick and co-workers was used, with adaptations for the specific setting.
3150683|NCT00208247|Experimental|STPP|The short-term psychodynamic psychotherapy (STPP).
3182975|NCT00709137|Active Comparator|2|this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
3182976|NCT00709150|Experimental|1|Patients will receive collaborative depression care management.
3182977|NCT00709150|Active Comparator|2|Patients will receive enhanced usual care.
3182978|NCT00709163|Active Comparator|1|
3182979|NCT00709163|Placebo Comparator|2|
3150684|NCT00208247|Experimental|Waiting List|Patients in the waiting-list group were asked to keep in touch with their GP, who had been informed of the trial in writing. The patients and their GPs were instructed not to begin any other treatment during the study period. After 6 months, the patients on the waiting list were re-evaluated for inclusion and exclusion criteria and, if they still met the criteria, re-randomized to CBT or STPP.
3150685|NCT00208260|Active Comparator|A|FOLFIRI
3150686|NCT00208260|Active Comparator|B|FOLFOX-4
3150687|NCT00208260|Experimental|C|FOLFIRI-HD
3150688|NCT00208260|Experimental|D|FOLFOX-7
3150689|NCT00208260|Experimental|E|FOLFIRINOX
3150690|NCT00208273|Experimental|A|Letrozole 2.5 mg daily for 5 years started three weeks before the first day of adjuvant radiotherapy.
3150691|NCT00208273|Experimental|B|Letrozole 2.5 mg daily for 5 years started three weeks after the last day of adjuvant radiotherapy.
3142088|NCT02934503|Experimental|Cisplatin or carboplatin, Etoposide, Pembrolizumab & Radiation|"Cohort A: cisplatin (75 mg/m^2) + carboplatin (AUC 6) + etoposide (100mg/m^2) for four to six, 3-week cycles + pembrolizumab (200 mg) followed by radiation. Pembrolizumab will be started with first cycle of chemotherapy and continued for up to 2 years.~Cohort B: Pembrolizumab (200 mg) will be added to standard therapy with cisplatin (75 mg/m2) or carboplatin (AUC 6) and etoposide (100 mg/m2) (and radiation, if appropriate), after one 3- week cycle of standard therapy and continued for up to 2 years.~Cohort C: 200 mg IV infusion of Pembrolizumab every 3 weeks over about 30 minutes after completion of standard chemotherapy with cisplatin (75 mg/ m2) and etoposide (100 mg/m2). Treatment with pembrolizumab will continue for up to 2 years.~Cohort D: Pembrolizumab 200 mg IV infusion every 3 weeks in vein after completion of standard chemotherapy and radiation. Pembrolizumab will start within 6 weeks of completing radiation therapy and continue for up to 2 years."
3142089|NCT02137252|Experimental|Naltrexone|The treatment schedule includes a daily dose of naltrexone for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
3142090|NCT02137252|Placebo Comparator|Sugar Pill|The treatment schedule includes a daily dose of equivalent placebo for 5 weeks. Treatment will be initiated at 25 mg/day during the first week to improve tolerability. The dose will be escalated to 50 mg/day after one week barring significant early improvement in fatigue or adverse events precluding dose escalation, and participants will continue to take 50 mg/day (or 25 mg/day if dose is not escalated) for 4 weeks to complete a 5-week treatment period.
3142091|NCT03863522|Other|Fine Needle Aspiration|Participants will receive fine needle aspiration (FNA) later read by the cytopathologist and the cartridge. All patients will receive standard of care (Ultrasound-guided core needle biopsy and diagnosis).
3142092|NCT01294670|Experimental|Vorinostat and Etoposide|This is a multi-center, open label, phase I/II trial of escalating doses of vorinostat in combination with etoposide.
3150692|NCT00208286|Other|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
3182980|NCT00709176|Experimental|Brief|Dyads randomized to BRIEF arm received the Brief FOCUS Program (two home visits and one phone call by a trained nurse) in addition to standard clinical care.
3182981|NCT00709176|Experimental|Extensive|Dyads randomized to EXTENSIVE arm received the Extensive FOCUS Program (4 home visits and two phone calls by a trained nurse) in addition to standard clinical care.
3182982|NCT00709176|No Intervention|Control|Dyads randomized to CONTROL arm continued with standard clinical care.
3182983|NCT00709254|Active Comparator|Treatment Group A|Subjects received an i.v. dose of fentanyl (200 µg)
3182984|NCT00709254|Experimental|Treatment Group B|Subjects received a single dose of 3 mL AeroLEF (500 µg/1 mL)
3182985|NCT00709254|Experimental|Treatment Group C|Subjects received multiple doses of 3 mL AeroLEF (500 µg/1 mL) every 12 hours for a total of five doses over a 3 days
3182986|NCT00709280|Experimental|Active treatment group|7% Hypertonic Saline administered via inhalation twice daily for 48 ± 4 weeks
3150693|NCT00208286|Active Comparator|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
3150694|NCT00208299|Experimental|1|Regadenoson
3150695|NCT00208299|Active Comparator|2|Adenoscan
3150696|NCT00208312|Experimental|1|Regadenoson
3150697|NCT00208312|Active Comparator|2|Adenoscan
3182987|NCT00709280|Active Comparator|Control group|0.9% Isotonic Saline administered via inhalation twice daily for 48 ± 4 weeks
3150698|NCT00208338|Experimental|1|Rotator cuff repair with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
3150699|NCT00208338|Active Comparator|2|Standard rotator cuff repair
3182988|NCT00709293|Placebo Comparator|1|
3182989|NCT00709293|Active Comparator|2|
2420543|NCT03432312|Active Comparator|NiQuitin 4 mg mint lozenges|
3182990|NCT00709345|Experimental|Group Home|Participants will receive cognitive behavioral sessions.
3150700|NCT00208351|Active Comparator|1) Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished blasted finished cementless femoral component for use in total hip replacement.
3182991|NCT00709345|Active Comparator|Control|Participants will receive time-matched attention control sessions.
3182992|NCT00709358|Active Comparator|2|Detection by blood culture
3150701|NCT00208351|Active Comparator|2) Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
3142093|NCT03095287|Experimental|Alphanate|Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.
3142094|NCT03236662|Experimental|Treatment|(-)-epicatechin 50mg twice per day (100mg per day total dose)
3142095|NCT02930122|Experimental|Anakinra|Intervention: anakinra (150mg) Participants will receive an intraarticular injection of anakinra (150mg) at 0-28 days post injury
3142096|NCT02930122|Placebo Comparator|Placebo Control|Intervention: Saline (0.9%) Participants will receive a saline placebo injection within 28 days of injury
3142097|NCT01444209|Experimental|Radiation Therapy|Interstitial Radioactive Iodine Implants
3142098|NCT00893516|Experimental|1|CHOP chemo therapy + CD4 therapy
3142099|NCT00893516|Active Comparator|2|CHOP chemotherapy
3182993|NCT00709358|Experimental|1|Test LightCycler SeptiFast® (Roche)
3182994|NCT00709371|Placebo Comparator|Placebo|Combination tablet containing Zonisamide SR placebo plus bupropion SR placebo SR = Sustained Release
3182995|NCT00709371|Active Comparator|Bupropion 360|Combination tablet containing Zonisamide SR placebo plus bupropion SR 360 mg/day; SR = Sustained Release
3142100|NCT04267380||Corrona US RA Registry 11 mg|patients with RA who have been exposed to tofacitinib 11 mg QD tablet
3182996|NCT00709371|Active Comparator|Zonisamide 120|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR placebo; SR = Sustained Release
3182997|NCT00709371|Active Comparator|Zonisamide 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR placebo; SR = Sustained Release
3142101|NCT04267380||Corrona US RA Registry 5 mg|patients with RA who have been exposed to tofacitinib 5 mg BID tablet
3142102|NCT04090164||Study group|The data of breast cancer patients treated at OCMU in the last 10 years will be retrieved from the hospital data filing system. All consecutive patients with biopsy-proven invasive breast cancer will be included.
3182998|NCT00709371|Experimental|Zonisamide 120/Bupropion 360|Combination tablet containing Zonisamide SR 120 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
3142103|NCT04090164||Control group|A group of age-matched women from the same geographical distribution who are healthy volunteers or hospital patients without cancer diagnosis will serve as a control group for the HCV prevalence. We aim at a sample size with a study-to-control ratio of 1:3.
3142104|NCT04047121||Truven Health MarketScan|The Truven Health MarketScan Research Databases reflects the combined healthcare service use of individuals covered by Truven Health clients (including employers, health plans, and hospitals) nationwide.
3142105|NCT04036799||Hypertrophic Cardiomyopathy|
3142106|NCT04018001||Truven Health MarketScan Research Database|individuals who are privately insured and with Medicare Supplemental insurance
3142107|NCT04017754||Study sample|"In total, 267 women with unexplained recurrent pregnancy loss was included.~Only patients with a history of 3 or more consecutive spontaneous pregnancy losses are included. Both biochemical and clinical losses documented in hospital records are accepted. Verified extrauterine pregnancy losses, complete molar pregnancies, and induced abortions of social reasons are not included in the total number of pregnancy losses. Women are excluded from this study, if they have significant uterine malformations, significant parental chromosomal abnormalities, irregular and/or abnormal length of their menstrual cycle length (<22 and >35 days interval), and/or no MBL measurement."
3142108|NCT04017754||Reference Group|The MBL reference group comprised 185 Danish female blood donors of reproductive age (range 21 to 45 years), about whom we have no other information. After informed approval, all controls had an extra blood sample taken, which was analysed for p-MBL.
3142109|NCT04010370||Healthy individuals|Cross-Sectional. No intervention. Patients of both sexes who are not sedentary or who participate in heavy physical activities and residents of the metropolitan area of Guadalajara
3142110|NCT03975790||Truven Health MarketScan Research Database|Compare treatment patterns including dosing, concomitant medication use, adherence, persistence, and switching among tofacitinb+MTX patients who withdraw MTX vs. persist with MTX or experience interrupted MTX
3150702|NCT00208351|Active Comparator|3) Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
3150703|NCT00208351|Active Comparator|4) Ultima LX Collarless Stem - Polished Finished|A collarless polished finished cementless femoral component for use in total hip replacement.
3150704|NCT00208364|Other|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
3150705|NCT00208377|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
3142111|NCT00000105||Arm A: Intracel KLH|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly (this arm closed 1/2/02).
3142112|NCT00000105||Arm B: Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly (this arm closed 3/18/03).
3142113|NCT00000105||Arm C: Biosyn KLH with Montanide ISA51|Biosyn KLH 1000 mcg (1 mg) with Montanide ISA51 (replaced with vegetable (VG) source after 8/31/06) and subcutaneous Tetanus toxoid 0.5 ml intramuscularly.
3142114|NCT00000113|Experimental|Progressive Addition Lenses (PALs)|
3142115|NCT00000113|Active Comparator|Single Vision Lenses|
3142116|NCT00000145|Experimental|1|Antioxidants
3182999|NCT00709371|Experimental|Zonisamide 360/Bupropion 360|Combination tablet containing Zonisamide SR 360 mg/day plus bupropion SR 360 mg/day; SR = Sustained Release
2424184|NCT03407105|Experimental|Arm 2|Specified dose on specified days
3142117|NCT00000145|Experimental|2|Zinc
3142118|NCT00000145|Experimental|3|Antioxidants and zinc
3142119|NCT00000145|No Intervention|4|
3142120|NCT00000167|Experimental|1|Laser treatment
3142121|NCT00000170|Active Comparator|Patching|
3142122|NCT00000170|Active Comparator|Atropine|Atropine
3142123|NCT00000249|No Intervention|Control|Subject inhaled 0% N2O for 40 minutes with cold immersion at 10 and 30 minutes
3142124|NCT00000249|Active Comparator|20% N2O|Subject inhaled 20% N2O for 40 minutes with cold immersion at 10 & 30 minutes
3142125|NCT00000249|Active Comparator|30% N2O|Subject inhaled 30% N2O for 40 minutes with cold immersion at 10 and 30 minutes
3142126|NCT00000249|Active Comparator|40% N2O|Subject inhaled 40% N2O for 40 minutes with cold immersion at 10 and 30 minutes
3142127|NCT00000250|Active Comparator|Lukewarm water|Subjects will immerse forearm in lukewarm water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
3142128|NCT00000250|Active Comparator|Ice cold water|Subjects will immerse forearm in ice cold water while inhaling 0% and 40% N2O in 2 sampling trials, then choose between intervntions for one choice trial
3142129|NCT00000251|Placebo Comparator|Placebo|Subjects inhale 100% oxygen
3142130|NCT00000251|Active Comparator|30% N2O|Subjects inhale 30% N2O
3142131|NCT00000251|Active Comparator|0.2% isoflurane|Subjects inhale 0.2% isoflurane
3142132|NCT00000251|Active Comparator|0.4% isoflurane|Subjects inhale 0.4% isoflurane
3142133|NCT00000251|Active Comparator|0.2% isoflurane + 30% N2O|Subjects will inhale a combination of 0.2% isoflurane and 30% N2O
3142134|NCT00000251|Active Comparator|0.4% isoflurane + 30% N2O|Subjects will inhale a combination of 0.4% isoflurane and 30% N2O
3142135|NCT00000252|Sham Comparator|0% N2O|Subjects will inhale 0% N2O
3142136|NCT00000252|Active Comparator|10% N2O|Subjects will inhale 10% N2O
3142137|NCT00000252|Active Comparator|20% N2O|Subjects will inhale 20% N2O
3142138|NCT00000252|Active Comparator|30% N2O|Subjects will inhale 30% N2O
3142139|NCT00000252|Active Comparator|40% N2O|Subjects will inhale 40% N2O
3142140|NCT00000253|Active Comparator|Placebo + 10% N2O|0% N2O inhaled during psychomotor testing, 10% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3142141|NCT00000253|Active Comparator|Placebo + 20% N2O|Placebo inhaled during psychomotor testing, 20% N2O inhaled during psychomotor testing, then subject's choice of the 2.
3142142|NCT00000253|Active Comparator|Placebo + 30% N2O|Placebo inhaled during psychomotor testing, 30% N2O inhaled during psychomotor testing, then subject's choice of the 2.
3142143|NCT00000253|Active Comparator|Placebo + 40% N2O|Placebo inhaled during psychomotor testing, 40% N2O inhaled during psychomotor testing, then subject's choice of the 2.
2424185|NCT03407092||Stentriever Cohort|
3142144|NCT00000254|Sham Comparator|0% isoflurane|
3142145|NCT00000254|Active Comparator|0.2% isoflurane|
3142146|NCT00000254|Active Comparator|0.4% isoflurane|
3142147|NCT00000254|Active Comparator|0.6% isoflurane|
3142148|NCT00000255|Placebo Comparator|0% Nitrous oxide|
3142149|NCT00000255|Active Comparator|10% nitrous oxide|
3142150|NCT00000255|Active Comparator|20% nitrous oxide|
3142151|NCT00000255|Active Comparator|30% nitrous oxide|
3142152|NCT00000255|Active Comparator|40% nitrous oxide|
3142153|NCT00000256|Active Comparator|Placebo + 20% N2O|0% N2O inhaled during psychomotor testing, 20% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3142154|NCT00000256|Active Comparator|Placebo + 40% N2O|0% N2O inhaled during psychomotor testing, 40% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3142155|NCT00000256|Active Comparator|Placebo + 60% N2O|0% N2O inhaled during psychomotor testing, 60% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3142156|NCT00000256|Active Comparator|Placebo + 80% N2O|0% N2O inhaled during psychomotor testing, 80% N2O inhaled during psycho motor testing, then subject's choice of the 2.
3142157|NCT00000257|Active Comparator|Light drinkers|
3142158|NCT00000257|Active Comparator|Moderate drinkers|
3142159|NCT00000258|Active Comparator|Informed group|Group inhaled placebo and varying doses of nitrous oxide in pairs then chose which they wanted for a third inhalation.
3142160|NCT00000258|Active Comparator|Non-informed Group|Group and technician were blinded as to which gas they were inhaling in pairs with third inhalation subject's choice.
3142161|NCT00000259|Placebo Comparator|Placebo|Subject inhales no drug (100% oxygen)
3142162|NCT00000259|Active Comparator|0.3% sevoflurane|
3142163|NCT00000259|Active Comparator|0.6% sevoflurane|
3142164|NCT00000259|Active Comparator|15% Nitrous oxide|
3142165|NCT00000259|Active Comparator|30% Nitrous oxide|
3142166|NCT00000261|Experimental|Moderate drinking adults|
3142167|NCT00000262|Placebo Comparator|Placebo +/- 30% Nitrous oxide|
3142168|NCT00000262|Active Comparator|Sevoflurane 0.2% +/- 30% Nitrous oxide|
3142169|NCT00000262|Active Comparator|Sevoflurane 0.4% +/- 30% Nitrous oxide|
3142170|NCT00000263|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
3142171|NCT00000263|Active Comparator|0.25 g/Kg ethanol +/- 30% nitrous oxide|
3142172|NCT00000263|Active Comparator|0.5 g/Kg ethanol +/- 30% nitrous oxide|
3142173|NCT00000264|Placebo Comparator|0 g/Kg ethanol +/- 30% nitrous oxide|
3142174|NCT00000264|Active Comparator|0.35 g/Kg ethanol +/- 30% nitrous oxide|
3142175|NCT00000264|Active Comparator|0.7 g/Kg ethanol +/- 30% nitrous oxide|
3142176|NCT00000265||Low anxiety|
3142177|NCT00000265||Moderate anxiety|
3142178|NCT00000265||High anxiety|
3150706|NCT00208390|Other|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
3142179|NCT00000271|Experimental|Desipramine|Participants were treated with desipramine, up to 300 mg per day. All patients received weekly individual manual-guided relapse prevention therapy.
3142180|NCT00000271|Placebo Comparator|Placebo|Participants were treated with matching placebo. All patients received weekly individual manual-guided relapse prevention therapy.
3142181|NCT00000273|Experimental|Opiates|Opiate-dependent individuals who were currently not seeking treatment for their drug use, completed the 6-week protocol.
3142182|NCT00000299|Active Comparator|buprenorphine|depot buprenorphine
3142183|NCT00000299|Experimental|buprenorphine and ultra-low dose naloxone|depot buprenorphine and naloxone
3142184|NCT00000304|Experimental|1|15/30 mg d-amphetamine
2424186|NCT03407092||ADAPT cohort|
3142185|NCT00000304|Experimental|2|30/60 mg d-amphetamine
3142186|NCT00000304|Experimental|3|placebo
3142187|NCT00000308|Experimental|1|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
3142188|NCT00000308|Experimental|2|30 mg of d-amphetamine for first 8 weeks of study and 60 mg for the second 8 weeks
3142189|NCT00000308|Experimental|3|placebo
3142190|NCT00000311|Experimental|1|Methadone + CM (contingency management)
3142191|NCT00000311|Experimental|2|methadone + VC (voucher control)
3142192|NCT00000311|Experimental|3|Buprenorphine + CM
3142193|NCT00000311|Experimental|4|Buprenorphine + VC
3142194|NCT00000317|Placebo Comparator|PLacebo|Placebo plus relapse prevention counseling
3142195|NCT00000317|Experimental|Risperidone|Risperidone (4mg/day) plus relapse prevention counseling
3142196|NCT00000318|Experimental|1|Maintenance treatment with daily medication
3142197|NCT00000318|Experimental|2|Maintenance treatment with thrice-weekly medication
3142198|NCT00000320|Active Comparator|1; liquid formulation|liquid formulation
3142199|NCT00000320|Active Comparator|2; tablet formulation|tablet formulation
3142200|NCT00000331|Experimental|Test Drug|Test drug to prevent heroine withdrawal
3142201|NCT00000331|Placebo Comparator|Placebo Pill|Placebo drug
3142202|NCT00000359|Experimental|Canalith repositioning maneuver|Repositioning treatment for posterior canal BPPV
3142203|NCT00000359|Experimental|Modified Epley maneuver|
3142204|NCT00000359|Sham Comparator|Sham|The subject sat in a chair; the head was passively tilted downward, turned away from the involved side, turned back to center, upward, away from the involved side, twice, slowly.
3150707|NCT00208403|Active Comparator|1|Acryloc™ GHV
3142205|NCT00000359|Active Comparator|Liberatory maneuver|The standard liberatory maneuver (also known as the Semont maneuver) was used.
3188922|NCT00772200||Observational (neuropsychological and behavioral tests)|Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery at approximately 9, 30, and 60 months post-diagnosis in a 1-2 hour testing session conducted by a neuropsychologist or psychologist. The Battery consists of measures of intelligence, processing speed, attention, memory, language preference, behavioral/social/emotional function, executive function, adaptive function, and quality of life.
3142206|NCT00000359|Active Comparator|Brandt Daroff exercise|Modified Brandt Daroff exercise performed as a self-liberatory exercise.
3142207|NCT00000372|Experimental|Glycine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of glycine in 7 ounces of lemonade twice a day in addition to clozapine treatment.
3150708|NCT00208403|Active Comparator|2|Palacos R
3150709|NCT00208416|Active Comparator|1|DePuy MI System
3150710|NCT00208416|Active Comparator|2|Conventional surgical technique
3142208|NCT00000372|Placebo Comparator|Placebo|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with 30 grams of placebo powder in 7 ounces of lemonade twice a day in addition to clozapine treatment.
3142209|NCT00000372|Experimental|D-Cycloserine|The patients will undergo a 2 week single blind placebo lead in followed by an 8 week randomly assigned double blind treatment phase with D-cycloserine in addition to clozapine treatment.
3142210|NCT00000373|Active Comparator|olanzapine + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
3142211|NCT00000373|Placebo Comparator|placebo + fluoxetine|The specific aim was to determine whether combined treatment with fluoxetine plus olanzapine would be more effective than fluoxetine plus placebo in treating OCD subjects who were partial or nonresponders to a prospective, 8-week, open-label trial of fluoxetine.
3142212|NCT00000380|Experimental|GHRH|Growth-hormone-releasing hormone (GHRH), also known as growth-hormone-releasing factor (GRF, GHRF), somatoliberin or somatocrinin, is a releasing hormone for growth hormone.
3142213|NCT00000380|Placebo Comparator|Placebo|Placebo
3142214|NCT00000383|Experimental|Trauma-Focused CBT|Trauma -Focused CBT provides 12 sessions (45 minutes child, 45 minutes parent) of CBT treatment. This includes therapist-directed trauma-focused skills training, exposure, parenting, conjoint parent-child sessions, and safety component provided to child and parent.
3142215|NCT00000383|Active Comparator|Child Centered Therapy|Child Centered Therapy provides 12 sessions (45 minutes child, 45 minutes parent) of supportive interventions. This includes client-directed activities focused on the needs and interests of the child or parent, respectively.
3142216|NCT00000385|Experimental|1|Lithium 600 mg to 2700 mg per day
3142217|NCT00000385|Placebo Comparator|2|Matching placebo
3142218|NCT00000387|Experimental|A,1,III|Behavioral intervention - Self management therapy
3142219|NCT00000387|Active Comparator|A,2,III|Regular treatment
3142220|NCT00000395|Experimental|Group 1 - Folinic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folinic acid daily for 1 week.
3142221|NCT00000395|Experimental|Group 2: Folic acid|Subjects receiving Methotrexate for 6 weeks and 5 mg of Folic acid daily for 1 week.
3142222|NCT00000396|Experimental|1|Education in Arthritis Self-Help Course
3142223|NCT00000400|Experimental|PTH|Human parathyroid hormone [hPTH-(1-34)]
3142224|NCT00000400|Active Comparator|ALN|Alendronate
3142225|NCT00000400|Experimental|PTH+ALN|Human parathyroid hormone [hPTH-(1-34)] plus alendronate
3142226|NCT00000401|Experimental|1|The low dose group will receive CII 30 mcg daily for 10 weeks, then 50 mcg daily for 10 weeks, followed by 70 mcg daily for 10 more weeks.
3142227|NCT00000401|Experimental|2|The high dose group will receive CII 90 mcg daily for 10 weeks, then 100 mcg daily for 10 weeks, followed by 130 mcg daily for 10 more weeks.
3142228|NCT00000407|Active Comparator|Enrollment Intervention|The intervention consists of training sessions to help prospective VR clients with ARMD successfully enter and complete the vocational rehabilitation (VR) program, and training sessions for a randomly selected group of VR professionals to help them serve VR clients with ARMD more effectively.
3142229|NCT00000407|Placebo Comparator|Usual Care|
3142230|NCT00000408|Experimental|email discussion group|
3142231|NCT00000408|No Intervention|rancomized control group|usual care
3142232|NCT00000409|Active Comparator|Surgery|Decompressive Laminectomy Fusion-Instrumented Fusion-Non-instrumented
3142233|NCT00000409|Active Comparator|Non-surgical intervention|Other. Non-surgical treatments
3142234|NCT00000410|Active Comparator|Surgery|Diskectomy
3142235|NCT00000410|Active Comparator|Non-surgical intervention|Non-surgical treatments
3142236|NCT00000411|Active Comparator|Surgery|Decompressive laminectomy
3142237|NCT00000411|Active Comparator|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
3142238|NCT00000412|Active Comparator|Group A|Group A active alendronate (10 mg/day) and placebo calcitriol.
3142239|NCT00000412|Placebo Comparator|Group B|We will give Group B placebo alendronate and active calcitriol (0.25 micrograms BID).
3142240|NCT00000414|Experimental|Arthritis Self-Management Program|small group self-management program
3142241|NCT00000414|Experimental|SMART Program|Self-Managed Arthritis Relief Therapy: mailed self management material
3150711|NCT00208429|Other|Pinnacle Acetabular System|
3150712|NCT00208442|Active Comparator|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
3142242|NCT00000416|Experimental|Rehabilitation counseling|"Rehabilitation counseling~Experimental~Rehabilitation counseling was provided by rehabilitation counselors. They administered the Work Experience Survey; provided and discussed disability rights and responsibilities and provided career counseling they as needed."
3142243|NCT00000416|Active Comparator|printed information|"Active comparator~Control group participants received relevant printed information in the mail only; no rehabilitation counseling"
3142244|NCT00000421|Active Comparator|Prednisone arm|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
3142245|NCT00000421|Placebo Comparator|Placebo|Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
3142246|NCT00000428|Experimental|1|Patients received each intervention multiple times in random-order crossover design.
3142247|NCT00000431|Experimental|1|Upon evaluation, participant will be treated with a single intra-ulcer injection of PDGF-B/Ad5 in the wound. Patients will receive only one dose, which will be administered during a 72-hour inpatient stay in a research unit at the Hospital of the University of Pennsylvania. This study will use a standard three-six dose-escalation scheme.
3142248|NCT00000434|Experimental|1|Fit and Strong! is a multi-component exercise and health education program that incorporates flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
3142249|NCT00000435|Placebo Comparator|A|Subjects randomized to arm A received 25mg/day po of placebo
3142250|NCT00000435|Active Comparator|B|Subjects randomized to Arm B received 25mg/day po of peptide dnaJP1
3142251|NCT00000437|Experimental|Naltrexone Tablet and Nicotine Patch|
3142252|NCT00000437|Active Comparator|Naltrexone Tablet and Placebo Patch|
3142253|NCT00000437|Active Comparator|Placebo Tablet and Nicotine Patch|
3142254|NCT00000437|Placebo Comparator|Placebo Tablet and Placebo Patch|
3142255|NCT00000439|Active Comparator|sodium valproate|sodium valproate was added on treatment as usual and dose monitored by blood level measurements
3142256|NCT00000439|Placebo Comparator|placebo|Placebo comparator was added on treatment as usual and dose monitored by blood level measurements
3142257|NCT00000448|Placebo Comparator|Placebo|Subjects were given an inert placebo for 2 days, followed by daily doses of matching placebo for a total of 12 weeks.
3142258|NCT00000448|Experimental|Naltrexone|Subjects were prescribed 25 mg naltrexone for 2 days, followed by daily doses of 50 mg of naltrexone for a total of 12 weeks.
3142259|NCT00000450|Active Comparator|Naltrexone Tablet|
3142260|NCT00000450|Placebo Comparator|Matched Placebo Tablet|
3142261|NCT00000451|Experimental|1|Naltrexone plus Sertraline
3142262|NCT00000451|Experimental|2|Naltrexone alone
3142263|NCT00000457|Placebo Comparator|Placebo|Subjects who achieved smoking abstinence and give a bupropion-placebo (sugar) pill for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
3142264|NCT00000457|Active Comparator|Bupropion|Subjects who achieved smoking abstinence and give bupropion (300 mg/day) for 44 weeks in order to prevent relapse to smoking. Brief Behavioral Counseling is also given during this time.
3142265|NCT00000460||Low intensity exercise|
3142266|NCT00000460||High intensity exercise|
3142267|NCT00000511|Placebo Comparator|Potassium, Magnesium, Calcium, The 3 together, Placebo|Parallel study design, 4 treatment groups
3142268|NCT00000512|Experimental|Niacin-Colestipol Group|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation. Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
3142269|NCT00000512|Experimental|Lovastatin-Colestipol Group|Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
3142270|NCT00000512|Placebo Comparator|Conventional-Therapy Group|Patients assigned to conventional therapy (the control regimen) received placebos for colestipol and for lovastatin, given as described above, unless their base-line LDL cholesterol level exceeded the 90th percentile for age. We felt obliged to provide such patients (43 percent of the group) with colestipol instead of its placebo. For purposes of blinding, the lovastatin placebo dose for a patient assigned to conventional therapy was doubled each time the lovastatin dose was doubled for a patient assigned to receive lovastatin and colestipol.
3142271|NCT00000569|Active Comparator|Triamcinolone|1200 micrograms of triamcinolone in daily divided doses
3142272|NCT00000569|Placebo Comparator|Placebo|Placebo
3142273|NCT00000572|Experimental|Extracorporeal membrane oxygenation (CO2 removal)|Detailed Electronic Protocol Controlled Extracorporeal CO2 Removal with reduced positive-pressure ventilation
3142274|NCT00000572|Active Comparator|Protocol Controlled positive-pressure vent|Detailed Electronic Protocol Controlled positive-pressure ventilation
3142275|NCT00000607|Experimental|Left ventricular assist device|Subjects received Thermo Cardiosystems, Inc. (TCI) vented electric (VE) left ventricular assist device (LVAD) and were followed for at least two years
3183000|NCT00709384|Experimental|Prophylactic intervention|"We performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone). Conduction times between electrodes placed on both sides of the lesions are measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line and to try to induce atrial flutter are performed three month after the operation.~There is only an intervention arm, no control arm"
3183001|NCT00709397||Observation|antiretroviral-experienced patients requiring raltegravir to construct an adequately potent antiretroviral regimen.
3183002|NCT00709410|Experimental|1|This is a single arm study. All consenting, eligible participants will receive the oral cholera vaccine.
3183003|NCT00709423|Active Comparator|1|
3183004|NCT00709423|Placebo Comparator|2|
3142276|NCT00000607|Active Comparator|Optimal medical therapy|Subjects received optimal medical therapy (OMM) and were followed for at least two years
3142277|NCT00000774|Experimental|1|Patients who will receive rgp120/HIV-1MN
3142278|NCT00000774|Experimental|2|Patients who will receive rgp120/HIV-1SF2
3142279|NCT00000774|Placebo Comparator|3|Patients who will receive the placebo counterpart of 120/HIV-1MN
3142280|NCT00000774|Placebo Comparator|4|Patients who will receive the placebo counterpart of rgp120/HIV-1SF2
3142281|NCT00000783||1|Sexually active HIV-infected concordant couples
3142282|NCT00000783||2|Sexually active HIV-infected discordant couples
3142283|NCT00000784||A|Consenting patients newly enrolled in either CPCRA 007 or CPCRA 006
3142284|NCT00000785||A|All eligible CPCRA subjects
3142285|NCT00000815|Experimental|1|Participants who receive vaccination at 6 and 12 months of age
3142286|NCT00000815|Experimental|2|Participants who receive vaccination only at 12 months of age
3142287|NCT00000817|Experimental|1|Participants will receive standardized or alternate point acupuncture treatment twice weekly for the first 6 weeks, then once weekly for the next 8 weeks, plus either oral amitriptyline or placebo daily for the entire 14 weeks.
3142288|NCT00000829|Experimental|1|Patients receiving intramuscular heptavalent pneumococcal conjugate vaccine
3142289|NCT00000829|Placebo Comparator|2|Patients receiving placebo vaccine
3142290|NCT00000874||1|Participants who are failing a regimen of ZDV, 3TC, and IDV
3183005|NCT00709436|Experimental|1|PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.
3183006|NCT00709436|Placebo Comparator|2|Placebo at time 0 and specified time points thereafter.
3142291|NCT00000874||2|Participants who are failing a regimen of ZDV, 3TC, and SRQ
3142292|NCT00000874||3|Participants who are failing a regimen of ZDV, 3TC, and RTV
3142293|NCT00000874||4|Participants who are failing a regimen of d4T, 3TC, and IDV
3183007|NCT00709449|Experimental|1|20 patients with age related macular degeneration
3183008|NCT00709449|Experimental|2|20 patients with primary open angle glaucoma
3183009|NCT00709449|Experimental|3|20 age and sex matched control subjects
3183010|NCT00709475||A|
3183011|NCT00709488|Experimental|Litx™ BPH Therapy|
3188923|NCT00772213|Experimental|MIGTS treatment|controlled trial (quasi-randomized) versus controls (=conventional treatment not in the MIGTS)
3188924|NCT00772213|No Intervention|controls (=conventional treatment not in the MIGTS)|
3142294|NCT00000884|Experimental|1|Participants will undergo treatment intramuscularly
3142295|NCT00000884|Experimental|2|Participants will undergo treatment orally
3142296|NCT00000884|Experimental|3|Participants will undergo treatment intranasally
3142297|NCT00000884|Experimental|4|Participants will undergo treatment intrarectally
3142298|NCT00000884|Experimental|5|Participants will undergo treatment intravaginally
3142299|NCT00000884|Experimental|6|Participants will undergo treatment intranasally and intramuscularly
3142300|NCT00000884|Experimental|7|Participants will undergo treatment intrarectally and intramuscularly
3142301|NCT00000928|Experimental|A|All study participants
3142302|NCT00000930||A|HIV-infected individuals enrolled in HIVNET D01
3142303|NCT00000930||B|Individuals with newly acquired HIV infection
3142304|NCT00000932||A|Participants currently enrolled in or currently being followed in an ongoing qualifying study. Qualifying studies can be found in the protocol.
3188925|NCT00772226|Active Comparator|music|
3142305|NCT00000932||B|Participants previously enrolled in but not currently being followed in a qualifying study. Qualifying studies can be found in the protocol.
3142306|NCT00000932||C|Antiretroviral-naive participants not enrolling in a qualifying study (i.e., patients starting treatment outside the first study or patients deferring treatment)
3142307|NCT00000935|Experimental|Intravenous Immune Globulin (Human)|
3142308|NCT00000935|Placebo Comparator|Intravenous Immune Globulin (Human) Placebo|
3142309|NCT00000936|Experimental|Induction|subjects receiving hOKT3 induction therapy
3142310|NCT00000936|Active Comparator|Induction Free Therapy|Patients not receiving induction therapy
3142311|NCT00000948|Experimental|1|Participants will be broken into 3 groups. Each group will receive ART and escalating doses of aldesleukin. All participants will then receive that maximum tolerated dose of aldesleukin.
3142312|NCT00000948|Active Comparator|2|All participants will receive ART
3142313|NCT00000955|Other|A|All eligible study participants
3142314|NCT00001077||1|Participants will receive peptamen drinks and multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3142315|NCT00001077||2|Participants will receive NuBasics drinks or equivalent amounts of NuBasics soups or bars and daily multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3142316|NCT00001077||3|Participants will receive multivitamin and mineral supplements, taken in addition to a regular diet for 4 months
3142317|NCT00001082|Experimental|1|Participants will receive adefovir dipivoxil and L-carnitine
3183012|NCT00709501|Experimental|1|"Participants in the intervention condition are encouraged to access the Achieve Together website at least once each week. During each login, the following activities will occur:~Users will enter their weight and height, how well their plan for a healthy weight has been going, and clarify their goal weight.~Users will answer questions about each habit they are using to lose weight~Users will receive automated feedback about each habit and will be encouraged to change or delete habits that are being used but not helpful, more consistently use habits that are helpful but not used being used and to continue to use habits that are helpful and being used consistently.~Users are encouraged to search for habits that have helped people of similar age and gender to themselves."
3183013|NCT00709501|No Intervention|2|Participants in the control condition will have to wait 12 weeks before accessing the Achieve Together website. These participants will be a given a log where they can document weekly weight measurements (this part did not happen).
3188926|NCT00772226|Placebo Comparator|Pillow without music|
3142318|NCT00001082|Experimental|2|Participants will receive adefovir dipivoxil placebo and L-carnitine.
2425246|NCT03399825||Healthy controls|Children without eye disease
3142319|NCT00001131|Experimental|A|Patients will recieve a daily, self-administered subcutaneous injection of IL-2 while continuing treatment with their current oral anti-HIV medications
3142320|NCT00001131|Active Comparator|B|Patients will only follow their current oral anti-HIV medication regimen. No additional IL-2 injection will be given.
3142329|NCT00001183||Group 1|Pulmonary Patients
3183014|NCT00709514|Experimental|DCB-WH1 ointment|DCB-WH1 ointment 1.25%, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
3183015|NCT00709514|Placebo Comparator|Placebo|Placebo, topical use, two times daily for 12 weeks or until ulcer closes completely or discontinuation due to treatment failure, whichever comes first.
3183016|NCT00709527|Experimental|1|
3183017|NCT00709540|Experimental|single|10 subjects (8 active and 2 placebo)
3183018|NCT00709553|Experimental|1|midazolam, one single dose of 705mg
3142333|NCT00001214||Group 1|Patients with pancytopenia
3142334|NCT00001219||Patients undergoing MRI in the Clinical Center|All patients who, by virtue of the NIH protocol in which they are enrolled, who qualify for MRI will be eligible for participation in this protocol.
3183019|NCT00709553|Experimental|2|ZD4054(Zibotentan)- 10mg od, 7 days + midazolam (one single dose of 7.5 mg on day 6 )
3183020|NCT00709566|No Intervention|Control|Waiting List control.
3183021|NCT00709566|Active Comparator|Exercise therapy|
3183022|NCT00709566|Experimental|Combined therapy|Combined Exercise therapy and Manual Therapy
3183023|NCT00709579|Placebo Comparator|placebo|
3183024|NCT00709579|Active Comparator|RV3391A|
3183025|NCT00709657|Experimental|1|patients with age-related macular degeneration, which are already scheduled for intravitreal anti-VEGF therapy in one eye are measured before and after treatment.
3188927|NCT00772239|Experimental|Rotem|ROTEM: Rotation thromboelastometry
3150713|NCT00208442|Active Comparator|Enduron™|Standard UHMWPE polyethylene liner in a modular acetabular component
3150714|NCT00208455|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
3150715|NCT00208468|Other|European Hip|A cementless femoral component for use in total hip replacement
3150716|NCT00208468|Active Comparator|Zweymüller|A cementless femoral component for use in total hip replacement
3150717|NCT00208468|Active Comparator|CLS Spotorno|A cementless femoral component for use in total hip replacement
3150718|NCT00208533|Other|1 Open Label|Open Label Aripiprazole
3150719|NCT00208546|Experimental|1Capecitabine + bevacizumab + oxaliplatin + cetuximab|
3150720|NCT00208546|Active Comparator|21Capecitabine + bevacizumab + oxaliplatin|
3150721|NCT00208559|Other|1 Open Label|Open Label
3150722|NCT00208611|Experimental|Open-Label Treatment|Levodopa-treated Parkinson's Disease subjects with vitamin B12 < 200 pg/ml given oral vitamin B12 supplement
3150723|NCT00208702|Experimental|sertraline + triiodothyronine|
3150724|NCT00208702|Placebo Comparator|sertraline + placebo|
3150725|NCT00208780|Experimental|Dose-response of oral BH4|Eight subjects received 100 mg of oral BH4 twice a day and 8 received 200 mg twice daily.
3183026|NCT00709670|Experimental|whole population who receive both tests|this arm includes the whole study population who will receive both tests: MSCT and stress echocardiography
3183027|NCT00709683||A|
3183028|NCT00709709|Experimental|1|Scan
3183029|NCT00709748|Active Comparator|1|Subjects in this study arm will receive treatment (fully active) Empi Select TENS devices.
3183030|NCT00709748|Placebo Comparator|2|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
3183031|NCT00709787||Hypertensive Subjects undergoing primary prevention|
3183032|NCT00709800|Experimental|2|
3183033|NCT00709800|Experimental|3|
3183034|NCT00709800|Experimental|4|
3183035|NCT00709800|Placebo Comparator|5|
3183036|NCT00709800|Experimental|1|
3183037|NCT00709813|No Intervention|1|
3183038|NCT00709813|Experimental|2|
3183039|NCT00709865|Experimental|1|.03 mg/kg
3183040|NCT00709865|Experimental|2|.15 mg/kg
3142342|NCT00001247||1|Individuals with schizophrenia-spectrum illness from the community.
3142351|NCT00001259|Experimental|Group 1|Group I will receive 0.1 mg/day of estradiol via skin patch (Estraderm) for a period of five weeks. During the fifth week, progesterone suppositories (200 mgs twice daily) will be added
3142352|NCT00001259|Experimental|Group II|progesterone suppositories (200 mg BID) will be administered for the first five weeks, followed by a two week washout, and then estradiol 0.1 mg /day for five weeks, with the addition of progesterone during the fifth week of estrogen treatment.
3142353|NCT00001259|Experimental|Leuprolide|3.75 mg of Leuprolide via intramuscular injection on a monthly basis in our clinic for a maximum of twenty-four weeks
3142357|NCT00001277||Patients with hyperparathyroidism|Patients with confirmed or suspected primary hyperparathyroidism or complications.
3142362|NCT00001322|Experimental|Lupron|Lupron administration for 2 months
3183041|NCT00709865|Experimental|3|.3 mg/kg
3183042|NCT00709865|Placebo Comparator|4|Placebo
3188928|NCT00772239|Active Comparator|S|Standard coagulation managment procedure
3142375|NCT00001397||1|treated according to the guidelines of standard medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
3142378|NCT00001458||Cardiovascular|subjects with cardiovascular symptoms or known disease.
3183043|NCT00709904|Experimental|Semuloparin extension treatment|Extension treatment with Semuloparin sodium 20 mg (10 mg if SRI) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days.
3188929|NCT00772252||1|patient with hepatic failure undergoing liver support treatment in surgical intensive care unit
3183044|NCT00709904|Placebo Comparator|Placebo extension treatment|Extension treatment with placebo (for Semuloparin sodium) for 19-23 days following initial treatment with open-label Semuloparin 20 mg (10 mg if SRI) for 7-10 days
3142379|NCT00001464||Group 1|Smokers exposed to oxygen
3142380|NCT00001469||Specimens|Specimens
3183045|NCT00709917||A|
3142387|NCT00001621||1|Pulmonary Patients
3142388|NCT00001626|Experimental|A|D1-4 cyclophosphamide 50 mg/kg IV, then cyclosporine starting on d14 at 12 mg/kg/d for 6 months
3142389|NCT00001626|Experimental|B|ATG at 40 mg/kg/d for 4 days then cyclosporine at 12 mg /kg/d for 6 months
3142390|NCT00001627||Group 1|Normal Volunteers and patients.
3142396|NCT00001651|Experimental|HIV-infected subjects|HIV-infected adults
3142397|NCT00001651|Experimental|HIV-negative subjects|HIV-negative adults
3142398|NCT00001686||Cohort A|Children and adults with cancer (or a pre-cancer syndrome or rare disease), between the age(s) of 2 years - 40 years, who present with disease manifestations of special interest to POB investigators.
3183046|NCT00709930|Active Comparator|1,Exposed to ELF-EMF|Device: Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF
3183047|NCT00709930|Placebo Comparator|2,Placebo|Device: Placebo device with no magnetic fields
3183048|NCT00709969|Experimental|1|Artemether-lumefantrine
3183049|NCT00710047|Experimental|1|Fasting state
3183050|NCT00710047|Experimental|2|after high-fat breakfast
3183051|NCT00710060|Experimental|1|Participating communities will receive the Community Popular Opinion Leader intervention and HIV/STD educational materials.
3183052|NCT00710060|Active Comparator|2|Participating communities will receive HIV/STD educational materials only.
3183053|NCT00710073|Experimental|A|Combined sono-electro-magnetic therapy
3183054|NCT00710086|Active Comparator|1|Intravenous administration of hydromorphone intermittently
3183055|NCT00710086|Experimental|2|Remifentanil intravenous patient-controlled analgesia
3183056|NCT00710099|Experimental|1|
3183057|NCT00710099|Active Comparator|2|SNP iontophoresis
3183058|NCT00710112||VLBW|infants less than 1500 grams at birth
3183059|NCT00710125|Experimental|GPX-150 for Injection|GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
3183060|NCT00710138|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
3183061|NCT00710138|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
3183062|NCT00710151||1|Subjects with PCNSL who have survived disease-free for 2 years or more. Treatments will vary depending upon site of enrollment and will include chemotherapy, blood brain barrier disruption (BBBD) with chemotherapy, radiation, and stem cell transplantation.
3183063|NCT00710164|Experimental|A|
3183064|NCT00710164|Placebo Comparator|B|
3183065|NCT00710177||PPHN|Infants born at >= 34 weeks who are diagnosed with clinical and/or echocardiographic evidence of PPHN
3142402|NCT00001788||1|patients with primary immunodeficiency disorders
3142403|NCT00001806|Experimental|Group|Group education and counseling
3142404|NCT00001806|Active Comparator|Individual|Individual education and counseling
3183066|NCT00710177||Control|Randomly selected, normal healthy infants born at >= 34 weeks gestational age and do not have PPHN
3183067|NCT00710190|Experimental|Rheos Implant|
3183068|NCT00710216|Active Comparator|A|
3183069|NCT00710216|Experimental|B|
3183070|NCT00710229|Active Comparator|A|Intravitreal injectin of Ranibizumab (3 monthly injection followed by monthly injectins as long as required
3183071|NCT00710229|Active Comparator|B|Intravitreal injectin of Bevacizumab (3 monthly injection followed by monthly injectins as long as required
3183072|NCT00710242|Experimental|1|DF01
3183073|NCT00710242|Placebo Comparator|2|
3183074|NCT00710255||Asthmatics|Asthmatics with exercise induced bronchospasm
3142408|NCT00001823||A/Surgery Branch Protocol Candidates|Patients suspected of having, or with biopsy proven, malignant disease being evaluated for or treated on NCI Surgery Branch protocols
3142418|NCT00001964|Experimental|single arm|ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months
3142419|NCT00001964|Experimental|single arm 2|ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF
3142420|NCT00001978||Study Cohort|Selected patients with proteinuria
3142421|NCT00001981||Patients with acromegaly|Patients with acromegaly
3183075|NCT00710268|Experimental|1|Dose Escalation Study 50, 100, 200, 400 mg
3183076|NCT00710281|Other|2D/3D Phase contrast MR|
2427696|NCT03383042|Experimental|Cohort 7|Multiple-ascending cohort 2
3183077|NCT00710320||Cover and Uncover|Procedure/Surgery
3183078|NCT00710333|Placebo Comparator|1|500ng dose
3183079|NCT00710333|Experimental|2|
3142424|NCT00002463|Experimental|Combination Chemotherapy|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine
3142425|NCT00002484|Experimental|external beam radiotherapy|Patients undergo 3-dimensional conformal external beam radiotherapy 5 days a week for 8-10 weeks.
3142426|NCT00002485||Stratum 1|Not Enrolled / No IRB Applied
3142427|NCT00002485||Stratum 2|Not Enrolled / IRB Approved
3150726|NCT00208780|Experimental|Onset & duration of action of oral BH4|Eight hypertensive subjects were assigned to either 5 mg kg-1 day-1 (n=4) or 10 mg kg-1 day-1 (n=4) of BH4, given in two divided doses orally for 8 weeks.
3150727|NCT00208793|Experimental|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with food
3142428|NCT00002494|Experimental|Combination therapy|Patients receive combination therapy as described in the study description. All patients must complete at least the first 3 courses of chemotherapy. Courses 2 and 3 each repeat 3 times in the absence of disease progression or unacceptable toxicity. On days 134-139, patients who have had prior bone marrow involvement receive cranial radiation therapy. Patients who achieve less than a complete response and who have an HLA-matched sibling should undergo allogeneic bone marrow transplant on protocol CLB-9113. Patients are followed monthly for 6 months, every 2 months for 18 months, every 6 months for 2 years, and thereafter for survival.
3142429|NCT00002495|Experimental|Nodal RT|subtotal nodal irradiation will consist of mantle and periaortic/spleen fields treated sequentially. Total dose 3600-4000 cGy over 20 fractions.
3142430|NCT00002495|Experimental|Chemotherapy + Nodal RT|3 cycles (28 days each) of chemotherapy (doxorubicin 25 mg/m^2 on days 1 and 15, vinblastine 6 mg/m^2 on days 1 and 15). Four weeks after last cycle, subtotal nodal irradiation (total dose 3600-4000 cGy over 20 fractions) will be given as described for the Nodal RT arm.
3142431|NCT00002501|Experimental|cyclophosphamide + filgrastim|Patients receive cyclophosphamide IV over 90 minutes on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 3 and continuing until blood counts recover. Treatment continues every 2 weeks for 4 courses in the absence of disease progression or stable disease. Patients who achieve complete remission (CR) after completion of course 4 receive 2 additional courses. Patients who achieve partial remission (PR) after completion of course 4 receive 2 additional courses, and those who achieve CR after completion of course 6 receive 2 additional courses. Patients are followed every 2 months for 6 months, every 6 months for 2 years, and then annually thereafter.
3142432|NCT00002514|Experimental|Transplant|Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
3142433|NCT00002514|Active Comparator|Conventional Consolidation/Maintenance|Consolidation/Maintenance Therapy
3142434|NCT00002520|Experimental|Quit Smoking Intervention|Patients received advice and help to quit smoking. The intervention employed physician and patient resources that had already been developed and evaluated or pre-tested, including written materials, prescriptions for nicotine replacement, counseling, and follow-up contact.
3142435|NCT00002520|Active Comparator|Usual Care|"No special intervention after randomization. Usual care may or may not include advice or assistance to stop smoking. Physicians were reassured that usual care did not preclude quit smoking counseling."
3142436|NCT00002524|Experimental|Regimen A|Regimen A: 5-Drug Combination Chemotherapy followed by Radiotherapy.
3142437|NCT00002524|Experimental|Regimen B|Regimen B: 4-Drug Combination Chemotherapy alternating with 3-Drug Combination Chemotherapy followed, as indicated, by Radiotherapy
3142438|NCT00002524|Experimental|Regimen C|Regimen C: 2-Drug Combination Chemotherapy with Drug Modulation followed, as indicated, by Radiotherapy.
3142439|NCT00002527|Experimental|Aspirin|325 mg/day PO
3183080|NCT00710359|Active Comparator|1|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma) given as a single intramuscular injection. The syringe is covered so it is impossible to see whether or not it contains any substance.
3183081|NCT00710359|Sham Comparator|2|"The controls receive an intramuscular injection, however, it is only an introduction of the needle into the muscle, but no injections are given. The syringe is covered so it is impossible to see whether or not it contains any substance."
3183082|NCT00710372|Experimental|1|CYT006-AngQb
3183083|NCT00710372|Placebo Comparator|2|
3142440|NCT00002527|Placebo Comparator|Placebo|
3142441|NCT00002528|Experimental|Surgery w/ axillary clearance, tamox|Either a total mastectomy with axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) with axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
3142442|NCT00002528|Experimental|Surgery w/o axillary clearance, tamox|Either a total mastectomy without axillary clearance, or a lesser procedure (quadrantectomy or lumpectomy with radiotherapy to the conserved breast) without axillary lymph node dissection, and tamoxifen (20 mg) given after surgery for the duration of 5 years or until relapse.
3142443|NCT00002529|Experimental|AC with concurrent tamoxifen|AC for 4 cycles with concurrent tamoxifen for 5 years
3142444|NCT00002529|Experimental|AC followed by tamoxifen|AC for 4 cycles followed by tamoxifen to 5 years from randomization.
3142445|NCT00002529|Experimental|Tamoxifen alone|Tamoxifen alone for 5 years.
3142446|NCT00002529|Experimental|AC with concurrent toremifene|AC for 4 cycles with concurrent toremifene for 5 years.
3142447|NCT00002529|Experimental|AC followed by toremifene|AC for 4 cycles followed by toremifene to 5 years from randomization.
3142448|NCT00002529|Experimental|Toremifene alone|Toremifene alone for 5 years.
3142449|NCT00002537|Experimental|Arm I|Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.
3142450|NCT00002548|Active Comparator|HDCTX and PBSC|"High dose chemotherapy with peripheral blood stem cells~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7"
3142451|NCT00002548|Experimental|HDCTX with PBSC and Autologous BMT|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Auto Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0"
3150728|NCT00208793|Experimental|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
3142452|NCT00002548|Experimental|HDCTX with PBSC and interferon|"High dose chemotherapy with peripheral blood stem cells and interferon~Experimental: HDCTX with PBSC and interferon High dose chemotherapy with peripheral blood stem cells and interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Chemo: vincristine 1.2 mg/m2 IV D1, BCNU 20 mg/m2 IV D1, melphalan 8 mg/m2 PO D1-4, cyclophosphamide 400 mg/m2 IV D1, prednisone 40 mg/m2 PO D1-7~IFN: IFN 3 million units/m2 MWF SQ"
3142453|NCT00002548|Experimental|HDCTX with PBSC and transplant plus IFN|"High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~Experimental: HDCTX with PBSC and transplant plus IFN High dose chemotherapy with peripheral blood stem cells and autologous bone marrow transplant plus alpha interferon~High dose chemotherapy with peripheral blood stem cells IND (q 5 weeks): vincristine 0.5 mg/d cont IV D1-4; adriamycin 10mg/m2/d cont IV D1-4; dex 40 mg/d PO or IVPB D1-4, 9-12, 17-20~2nd Reg: cyclophosphamide 1.5g/m2 IV over 1 hr every 3 hrs x 3 (4.5g/m2 total); MESNA 4.5 g/m2 24 hr IV start with cyclo; GCSF 0.25 mg/m2/d SQ; PBSC collection~Trans: Mel 140mg/m2 IV D-5; TBI 150cGy D-4, -3, -2, -1; infusion D0~IFN: 3 million units/m2 MWF SQ"
3142454|NCT00002550|Experimental|RT + chemotherapy followed by surgery + chemotherapy|Induction radiation therapy (RT) + concurrent induction chemotherapy followed by surgery and additional chemotherapy
2427697|NCT03383042|Experimental|Cohort 8|Multiple-ascending cohort 3
3142455|NCT00002550|Active Comparator|RT + chemotherapy followed by chemotherapy + RT|Induction RT + concurrent induction chemotherapy followed by additional chemotherapy + RT
3142456|NCT00002551|Experimental|Bolus 5-FU, Pelvic XRT + PVI 5-FU, Bolus 5-FU|Bolus 5-FU (fluorouracil) (500mg/m2/day on days 1-5, 29-33), Pelvic XRT + PVI 5-FU, Bolus 5-FU (450mg/m2/day for 5 days beginning 28 days after RT, for 2 cycles on days 1-5 of a 28 days cycle).
3142457|NCT00002551|Experimental|PVI 5-FU+Pelvic XRT+PVI 5-FU+PVI 5-FU|5-FU (fluorouracil) 300mg/m2/day for 42 days followed by 2 week interruption, Day 57 through XRT will receive 225mg/m2/day of 5-FU followed by 1 month interruption, 4 weeks after completion of XRT 1 8wk cycle of 5-FU 300mg/m2/day.
3142458|NCT00002551|Experimental|Bol 5-FU+LV+LEV+Pel XRT+Bol 5-FU+LV Bol 5-FU + LV + LEV|5-FU (fluorouracil) 425/mg/m2/day Days 1-5,29-33; LV (leucovorin calcium) 20mg/m2/day Days 1-5,29-33; LEV (levamisole hydrochloride) 150mg/day (50mg TID) for 3 days every 14 days starting after each course of 5-FU. During RT: 5-FU and LV 4 days on wk 1 and wk 5 of RT. LV 20 mg/m2/day IV bolus within 2hrs after completion of that day's radiation therapy, for four days in each cycle. Followed immediately by 5- FU 400 mg/m2/day IV bolus. Treatment will be given on days 57 - 60 and 85 - 88.Treatment post-RT-chemotherapy 28 days after completion of RT consist of 5 days of chemotherapy in 28 day cycles. 5-FU, 380 mg/m2/day on days 1 - 5 and LV given at a dose of 20 mg/m2/day on days 1 - 5 with the 5-FU given immediately after the LV. For 2 post-radiation cycles on days 1 - 5 of a 28 day cycle. Levamisole will be given orally at a dose of 150 mg/day (50 mg tid) for 3 days every 14 days during the 1st 3 days of each cycle of 5-FU, and again 14 days after starting each course of 5-FU.
3142459|NCT00002556|Active Comparator|ARM A (VBMCP)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive VBMCP as in the induction phase. Courses repeat every 35 days in the absence of disease progression or unacceptable toxicity."
2380747|NCT03704428|Experimental|Cohort 1|Multiple subcutaneous injections of SHR-1314 dose 1
3150729|NCT00208793|Experimental|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with meals over 6 months
3150730|NCT00208793|Placebo Comparator|Placebo|
3150731|NCT00208806||congenital heart patients with congestive heart failure|20 effected patients with congestive heart failure patients total 50 patients
3150732|NCT00208845||adult ED patients|
3150733|NCT00208923|Active Comparator|1|Chemotherapy-only conditioning regimen comprising busulfan (Bu), cyclophosphamide (Cy) and fludarabine (FLUDARA) followed by an allogeneic stem cell transplant.
3150734|NCT00208962|Active Comparator|1|
3150735|NCT00209001|Sham Comparator|Sham acupuncture therapy|Sham acupuncture therapy
3150736|NCT00209001|Active Comparator|Acupuncture|Acupuncture
3150737|NCT00209001|No Intervention|Observation|Observation
3150738|NCT00209040|Experimental|1|Subjects with posttraumatic stress disorder
3150739|NCT00209040|Active Comparator|2|Healthy controls
3142460|NCT00002556|Experimental|Arm B (VBMCP, high dose cyclophosphamide, r alpha 2b IFN)|"INDUCTION PHASE: Patients receive VBMCP comprising vincristine sulfate IV on day 1, carmustine IV on day 1, melphalan PO on days 1-4, cyclophosphamide IV on day 1, and prednisone PO on days 1-7. Treatment repeats every 35 days for 2 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients receive vincristine sulfate, carmustine, and melphalan as in the induction phase, high-dose cyclophosphamide IV on days 1-4 and prednisone PO on days 1-4 during courses 3 and 5. Patients receive VBMCP as in the induction phase during even numbered courses. Patients receive recombinant interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, and 22 during odd courses beginning course 7. Treatment repeats every 35 days for courses 3-5, every 21 days for even courses beginning course 6, and every 22 days for odd courses beginning course 7 in the absence of disease progression or unacceptable toxicity."
3142461|NCT00002561|Active Comparator|Radiotherapy or ABVD + Radiotherapy|Radiotherapy
3142462|NCT00002561|Active Comparator|ABVD Alone|ABVD Alone
3142463|NCT00002565|Experimental|Arm I|"Sequential 4-, 5-, and 3-Drug Combination Chemotherapy. IdSHAP: IDA/CDDP/ARA-C/MePRDL; followed by BIdCOS: BLEO/IDA/CTX/VCR/MePRDL; followed by MINE: Mesna/IFF/DHAD/VP-16.~Alternating triple therapy (ATT) of IdSHAP (idarubicin, cisplatin, cytarabine, methylprednisolone), BIdCOS (idarubicin, vincristine, bleomycin, cyclophosphamide, methylprednisolone), and MINE (mesna, ifosfamide, mitoxantrone, etoposide)."
3142464|NCT00002565|Experimental|Arm II|4-Drug Combination Chemotherapy. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone): CTX/DOX/VCR/PRED.
3142465|NCT00002569|Active Comparator|Radiation therapy (RT) alone|Radiation therapy (RT) alone - External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume.
3142466|NCT00002569|Experimental|Intensive pre-treatment chemotherapy and radiation therapy|Intensive pre-treatment chemotherapy (Day 1 CCNU 130 mg/m2 p.o., Day 8 - Vincristine 1.4 mg/m2 i.v., Days 8-21 - Procarbazine 75 mg/m2 p.o., Day 29 - Vincristine 1.4 mg/m2 i.v.) followed by radiation therapy (External Beam RT 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week) to MR defined tumor volume).
3142467|NCT00002570|Active Comparator|Fluorouracil and folinic acid|
3142468|NCT00002570|No Intervention|Observation|
3142469|NCT00002571|Experimental|ProMACE-CytaBOM + G-CSF|6 cycles of 21 days each of ProMACE-CytaBOM (cyclophosphamide 490 mg/m^2 on day 1, doxorubicin 19 mg/m^2 on day 1, etoposide 90 mg/m^2 on day 1, cytarabine 225 mg/m^2 on day 8, bleomycin 5 u/m^2 on day 8, methotrexate 90 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, vincristine 1.4 mg/m^2 on day 8, prednisone 60 mg/m^2 on days 1-14, allopurinol 300 mg on days 1-21 of cycle 1 and days 1-8 of cycle 2 only) plus 1 double strength tablet TMP/SMX 3 days a week plus G-CSF 5 ug/kg on days 9-20. Patients also receive intrathecal cytarabine 30 mg/m^2 (BM positive: 5 doses spaced evenly during 1st 2 cycles, then on day 1 of cycles 3-6; CSF cytology positive: 5 doses spaced evenly during 1st cycle, then on day 1 of cycles 2-6; BM and CSF negative: 5 doses spaced evenly within 1 month of completion of cycle 6). All patients with CR or PR after systemic therapy and IT cytarabine receive 2400 cGy RT to the whole brain in 12 fractions.
3150740|NCT00209040|Active Comparator|3|Combat controls
3150741|NCT00209053|Experimental|Off Pump CABG|CABG without cardiopulmonary bypass.
3142470|NCT00002574|Experimental|Arm I|Single-Agent Chemotherapy plus Biological Response Modifier Therapy. Homoharringtonine, HH, NSC-141633; plus Interferon alfa (Schering), IFN-A, NSC-377523.
3142471|NCT00002575|Experimental|Conventional surgery|"Patients undergo open laparotomy and colectomy. A standard incision is made through the abdominal wall and the abdominal cavity is explored. A right or left colectomy or a sigmoid resection is performed.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
3142472|NCT00002575|Experimental|Laparoscopic-assisted colectomy|"Patients undergo a laparoscopic-assisted colectomy. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with CO2 to allow access and visualization. The abdominal cavity is explored. If advanced local disease is identified, a celiotomy and colectomy are performed. Otherwise, a right or left colectomy or sigmoid resection is performed using laparoscopic-assisted techniques.~Patients may be entered on adjuvant chemotherapy trials after surgery provided the subsequent trial does not include radiotherapy and allows entry of patients from both arms.~Quality of life is assessed at baseline and on days 2 and 14 after surgery, at 2 months, and then at 18 months. (closed as of 4/30/99)~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 3 years."
3142473|NCT00002583|No Intervention|Observation|Observation only
3142474|NCT00002583|Active Comparator|Chemotherapy|Cisplatin and Vinorelbine
3142475|NCT00002586|Experimental|13-cis retinoic acid|13-cis retinoic acid 50 mg/d
3142476|NCT00002586|Experimental|13-Cis Retinoic Acid and Tocopherol|13-Cis Retinoic Acid (50 mg/day) Tocopherol (800 mg/day)
3142477|NCT00002586|No Intervention|Observation|Observation
3150742|NCT00209053|Active Comparator|On-Pump CABG|CABG with cardiopulmonary bypass.
2427698|NCT03383042|Experimental|Cohort 9|Multiple-ascending cohort 4
3150743|NCT00209079|Active Comparator|1|
3150744|NCT00209105||1|Participants who have experienced early-life trauma will undergo a series of diagnostic tests.
3142478|NCT00002587|Experimental|Arm I|"Patients receive paclitaxel IV over 3 hours on day 1 followed 2-6 hours later by topotecan IV continuously on days 1-14. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan and paclitaxel until the maximum tolerated dose (MTD) of each drug is determined. The MTD is defined as the highest dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3142479|NCT00002590|Experimental|Regimen A|See detailed description.
3142480|NCT00002593|Active Comparator|5-FU/Leucovorin/Levamisole|levamisole hydrochloride: 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; leucovorin calcium: 20 mg/m^2/day, IV, Days 1-5 of each cycle; 5-fluorouracil: 425 mg/m^2/day, IV, Days 1-5 of each cycle;
3142481|NCT00002593|Active Comparator|Infusional 5-FU + Levamisole|levamisole hydrochloride : 50 mg every 8 hours x 3 days, PO, repeat every 14 days for 6 months; 5-fluorouracil: 250 mg/m^2/day, continuous infusion, daily for 56 days x 3 cycles of 8 weeks.
3150745|NCT00209144|Experimental|Angioplasty with Insulin|Coming in with acute infarct and received angioplasty with intensive insulin therapy
3150746|NCT00209144|No Intervention|Angioplasty w/o Insulin|Coming in with acute infarct and received angioplasty
3142482|NCT00002594|Experimental|Ablative chemo followed by autologous bone marrow (ABM) rescue|Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.
3142483|NCT00002602|Experimental|Group 1|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6] x 10) is ≤ 15. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
2428331|NCT03378453|Other|NarCo|Narcolepsy type 1 over 65 years old
3142484|NCT00002602|Experimental|Group 2|Clinical stages T1b-c or T2a-b with PSA + ([Gleason -6]x10)>15. Any clinical T2c with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
3188930|NCT00772265|Experimental|Wosulin N|Wosulin N, Isophane insulin for injection (Recombinant Human Insulin)(100 IU/mL), cartridges 3.0 mL
3142485|NCT00002602|Experimental|Group 3|Clinical stage T3 with PSA < 70. Must be lymph node negative. Escalating doses of three dimensional conformal radiation therapy (3D-CRT) until the maximum tolerated dose (MTD) is established.
3142486|NCT00002610|Experimental|STRATUM A|Treatment of children in Stratum A will be determined by the site of relapse and the presence of microscopic or gross residual disease after attempted surgical excision of the relapse.
3142487|NCT00002610|Experimental|Stratum B|All children who received combination chemotherapy with Regimen EE - 4A as their initial therapy for Wilms tumor will receive Regimen I and radiation therapy to the site of recurrence. All patients will receive prophylactic trimethoprim /sulfamethoxazole
3142488|NCT00002610|Experimental|STRATUM C|All children who received combination chemotherapy with Regimen DD - 4A as their initial therapy for Wilms tumor will be treated with the following chemotherapy. All patients will receive prophylactic trimethoprim/sulfamethoxazole
3142489|NCT00002610|Experimental|STRATUM D|Six week cycles of chemotherapy will be given to all patients who do not have progressive disease at the time of each week 0 re-evaluation.
3142490|NCT00002611|Active Comparator|Stratum 1|Stage I favorable histology (FH) Wilms' tumor, under 24 months of age, and tumor weight less than 550 g: After conventional surgery (nephrectomy), patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
3142491|NCT00002611|Active Comparator|Stratum 2|Stage I FH Wilms' tumor and age 24 months and over or tumor weight at least 550 g; stage I focal anaplastic (FA) or diffuse anaplastic (DA) Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
2380748|NCT03704428|Experimental|Cohort 2|Multiple subcutaneous injections of SHR-1314 dose 2
3142492|NCT00002611|Active Comparator|Stratum 3|Stage II FH Wilms' tumor: Patients receive regimen EE-4A comprising dactinomycin (DACT) IV weekly on weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate (VCR) IV weekly on weeks 1-10, 12, 15, and 18.
3142493|NCT00002611|Active Comparator|Stratum 4|Stage III FH Wilms' tumor; stage II or III FA Wilms' tumor: After conventional surgery (nephrectomy), patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy.
3142494|NCT00002611|Active Comparator|Stratum 5|Stage IV FH or FA Wilms' tumor: patients receive regimen DD-4A comprising dactinomycin DACT IV weekly on weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weekly on weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weekly on weeks 1-10, 12, 15, 18, 21, and 24. Patients also undergo abdominal radiation therapy, and whole lung radiation therapy (at the discretion of the investigator).
3188931|NCT00772265|Active Comparator|Novolin N|Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.
2428332|NCT03378453|Other|CoS|Cognitevement healthy controls
3183084|NCT00710398|Experimental|Control|A group consuming twice daily (post-exercise and in morning/afternoon) drinks containing no dairy protein or calcium. Daily protein intake (15% total kcals) should be from non-dairy sources (i.e. meat, egg, fish, chicken, wheat gluten).
3183085|NCT00710398|Experimental|Dairy Protein|A group consuming twice daily drinks (post-exercise and morning) containing 1% chocolate milk (in 1.5 cup servings = 3 cups/d). Daily protein intake is set at 15% total kcals with ~8% coming from dairy sources.
2380749|NCT03704428|Experimental|Cohort 3|Multiple subcutaneous injections of SHR-1314 dose 3
3183086|NCT00710398|Experimental|High Dairy Protein|A group consuming twice daily drinks of 1% artificially sweetened chocolate milk (in 1.5 cup servings = 3 cups/d). Their diet contains 30% protein (as opposed to only 15% in the Con and DairyPro groups) with at least 50% of that coming from dairy sources.
3183087|NCT00710411||A, 2|Polytraumatized patients with ISS > 18 and healthy controls
3183088|NCT00710437||1|Dexmedetomidine - used
3183089|NCT00710437||2|Dexmedetomidine - not used
3183090|NCT00710450||1|Allergic Asthma
3183091|NCT00710450||2|Allergic Rhinitis
3183092|NCT00710463||Control group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated.
3188932|NCT00772278|Active Comparator|CAS|carotid artery stenting
3188933|NCT00772278|Active Comparator|CEA|carotid endarterectomy
3183093|NCT00710463||NIV treatment group|patients receive a hospital based comprehensive pulmonary rehabilitation programme, including endurance training, physiotherapy, medical therapy, and long term oxygen treatment when indicated, plus newly introduced nocturnal non invasive ventilation.
3183094|NCT00710476|Experimental|1|Insemination of the oocytes with a lower concentration of spermatozoa.
3183095|NCT00710476|No Intervention|2|Insemination with a normal concentration of spermatozoa.
3183096|NCT00710502|Experimental|1|Transvaginal NOTES Cholecystectomy (Phase 1)
3183097|NCT00710502|Active Comparator|2|Laparoscopic Cholecystectomy (Phase 2)
3183098|NCT00710502|Experimental|3|Transvaginal NOTES cholecystectomy (Phase 2)
3183099|NCT00710515|Experimental|1|with food
3183100|NCT00710515|Experimental|2|without food
3183101|NCT00710528|Experimental|one arm|
3183102|NCT00710541|Experimental|NPPV group|Subjects in this arm receive standard COPD treatment, LTOT if indicated, and NPPV with ventilators designed for 'non invasive ventilation'(Resmed VPAP III ST-A, Weinmann Ventimotion, Tyco Healthcare Knight Star 330)
3183103|NCT00710541|No Intervention|control gorup|Subjects in this arm receive standard COPD treatment and LTOT if indicated.
3188934|NCT00772291|Placebo Comparator|placebo|
3188935|NCT00772291|Active Comparator|pregabalin|
3183104|NCT00710567|Other|Historical Data|"DuraHeart Patients will be implanted with a DuraHeart Left Ventricular Assist System (LVAS) as a bridge to transplant until a suitable heart can be found as a replacement. Parameters collected will be compared to a performance goal based on historical data for congestive heart failure patients"
3183105|NCT00710580|Experimental|A|
3183106|NCT00710580|Active Comparator|B|
3183107|NCT00710580|Placebo Comparator|C|
3183108|NCT00710619||A|
3183109|NCT00710645||Arm I|50 subjects with multiple sclerosis will be tested one time on the Lido Workset. The test will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
3183110|NCT00710645||Arm II|25 normal subjects will be tested on the Lido workset. The testing will be performed one time for each patient and will take approximately 25 minutes. The servo-controlled torque motor system will analyze resistance to passive movement of the knee. This testing may be repeated for a group of randomly selected control subjects. Each subject will be given the option to participate in the extended testing or to decline. The testing for this subset of subjects will be done as follows: first session, second session one week after the first session, third session three weeks after the first session. The total length of time for participation in this study may be up to three weeks.
3188936|NCT00772317|Experimental|HIFU|High Intensity Focused Ultrasound
3188937|NCT00772343|Placebo Comparator|Placebo Vaccine|0.9% Normal saline
3188938|NCT00772343|Experimental|Low dose|Low dose vaccine with adjuvant
2380750|NCT03704428|Experimental|Cohort 4|Multiple subcutaneous injections of SHR-1314 dose 4
3188939|NCT00772343|Experimental|High dose 1|High-dose vaccine with adjuvant
2429061|NCT03373643|Experimental|Patient suspected for NAFLD|
3142495|NCT00002611|Active Comparator|Stratum 6|Stage V FH, FA, or DA Wilms' tumor: After bilateral conventional surgery (biopsy), patients with FH receive chemotherapy as in stratum 1 (dactinomycin IV weeks 0, 3, 6, 9, 12, 15, and 18 and vincristine sulfate IV weeks 1-10, 12, 15, and 18) or 4 (dactinomycin IV weeks 0, 6, 12, 18, and 24; doxorubicin hydrochloride IV weeks 3, 9, 15, and 21; and vincristine sulfate VCR IV weeks 1-10, 12, 15, 18, 21, and 24). Patients with FA or DA receive chemotherapy as in stratum 7 (vincristine sulfate VCR IV weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy.
3183111|NCT00710658|Experimental|1|Patients had access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as to a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
3183112|NCT00710658|No Intervention|2|The control group receiving usual care
3183113|NCT00710671||Phase 1|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from four participating AMTU sites.
3188940|NCT00772343|Experimental|High dose 2|High-dose vaccine without adjuvant
3188941|NCT00772356|Experimental|A|
3142496|NCT00002611|Active Comparator|Stratum 7|Stages I-IV clear cell sarcoma): After conventional surgery (nephrectomy), patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
3183114|NCT00710671||Phase 2|Male, HIV+ participants from ages 16-24 who have had sex with another male in the past year and acquired HIV behaviorally. Participants will be drawn from all fifteen AMTU sites.
3183115|NCT00710697|Experimental|Single Arm|Picoplatin
3183116|NCT00710723|Experimental|1|vitrification
3183117|NCT00710723|No Intervention|2|Slow freezing
3183118|NCT00710736|Experimental|ARRY-334543 + capecitabine|
3183119|NCT00710775|Other|1|Patients undergoing surgical aortic valve replacement on cardiopulmonary bypass.
3183120|NCT00710788|Experimental|1|sevelamer as Phosphate-binder treatment
3183121|NCT00710788|Active Comparator|2|Calcium carbonate
3183122|NCT00710827|Experimental|Arm 1|
3183123|NCT00710827|Placebo Comparator|Arm 2|
3183124|NCT00710853|Experimental|1|YiRen Qi gong weekly class for 8 weeks
3183125|NCT00710853|Experimental|2|Tai Chi weekly class for 8 weeks
3183126|NCT00710853|Active Comparator|3|Hatha yoga weekly class for 8 weeks
3183127|NCT00710892|Experimental|Dose Level 1-3|Administration of suicide gene-modified allodepleted T cells.
3188942|NCT00772356|Active Comparator|B|
3188943|NCT00772395|Active Comparator|Risedronate|
3188944|NCT00772395|Placebo Comparator|Placebo|
3142497|NCT00002611|Active Comparator|Stratum 8|Stages II-IV DA Wilms' tumor: After conventional surgery (nephrectomy), Patients receive treatment as in stratum 7 (patients receive vincristine sulfate VCR IV weekly on weeks 1, 2, 4-8, 10-13, 18, and 24; cyclophosphamide sulfate (CTX) IV over 1 hour on days 1-3 of weeks 6, 12, 18, and 24 and on days 1-5 of weeks 3, 9, 15, and 21; doxorubicin hydrochloride IV (beginning after CTX infusion) weekly on weeks 0, 6, 12, 18, and 24; and etoposide (VP-16) IV over 1 hour (beginning after CTX infusion) on days 1-5 of weeks 3, 9, 15, and 21. Filgrastim (G-CSF) is administered subcutaneously (SC) beginning 24 hours after completion of chemotherapy and continuing until blood counts recover. Patients also undergo abdominal radiotherapy and whole lung radiotherapy (if pulmonary metastases are present).
3183128|NCT00710957||CHS All Stars|CHS All Stars is an ancillary study of the Cardiovascular Health Study (CHS), a longitudinal, observational, population-based study of the onset, progression, and course of heart disease and stroke in the elderly which began in 1988. The All Stars study reexamined the survivors of CHS to determine the likelihood of maintaining function later in life. A focus was to determine whether age-related biological factors are long-term predicators of functional aging which was assessed through a follow-up exam (Yr 18 visit conducted in 2005-06, n=1674 older adults, mean age =84 years) and 3 yrs of subsequent 6 month interval phone contacts. Vitamin D status (serum 25(OH)D and PTH) is being assessed in all CHS All Stars participants who provided a blood sample at the Yr 18 visit (n~1100).
3183129|NCT00710983|Active Comparator|A|Oral polio vaccine
3183130|NCT00710983|No Intervention|B|No oral polio vaccine
3183131|NCT00711035|Experimental|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line.
3183132|NCT00711048|Experimental|1|30 mg, oral, single dose
3183133|NCT00711048|Experimental|2|95 mg, oral, single dose
2429062|NCT03373630|Experimental|Midline catheter|
3183134|NCT00711048|Placebo Comparator|3|Oral solution, single dose
3183135|NCT00711061||1|18-25 year old males, growth hormone deficient, who completed growth hormone treatment 3-5 years prior to enrollment in study
3183136|NCT00711061||2|18-25 year old males, healthy, never treated with growth hormones.
3183137|NCT00711074|Experimental|1|
3183138|NCT00711126|Experimental|Arm 1|HVTs
3183139|NCT00711126|Experimental|Arm 2|HVTs
3183140|NCT00711126|Experimental|Arm 3|HVTs
3183141|NCT00711126|Experimental|Arm 4|HVTs
3183142|NCT00711126|Experimental|Arm 5|HVTs
3183143|NCT00711126|Experimental|Arm 6|HVTs
3183144|NCT00711139||1|AFFITOPE AD01
3183145|NCT00711139||2|AFFITOPE AD01 + Adjuvant
3183146|NCT00711152|Experimental|JADE with CHW|Patients will be enrolled into JADE program and will undergo annual comprehensive assessment (CA) with personalized JADE report with additional support by the CHW.
3183147|NCT00711152|Active Comparator|JADE only|Patients will be enrolled into JADE program and undergo annual comprehensive assessment (CA) with personalized JADE report without additional support by the CHW.
3183148|NCT00711165|Placebo Comparator|Placebo|Placebo, 2 puffs, bid
3183149|NCT00711165|Experimental|Memetasone|Mometasone
3183150|NCT00711178|Active Comparator|A|2 hours sunlight
3183151|NCT00711178|Active Comparator|B|3 hours of sunlight
3183152|NCT00711204|Placebo Comparator|1|
3183153|NCT00711204|Active Comparator|2|
3183154|NCT00711217|Experimental|#1 Medical food|
3183155|NCT00711217|Placebo Comparator|#2 Control|
3183156|NCT00711230|Experimental|1: Low dose DermaVir|"Dosage: 0.2 mg DNA~Dosage form: 1.6 mL DNA/PEIm nanomedicine~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3188945|NCT00772408||TB|patients with pulmonary TB
3183157|NCT00711230|Experimental|2: Low dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 2 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3183158|NCT00711230|Experimental|3: Medium dose DermaVir|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3150747|NCT00209196||pediatric solid organ transplants|Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.More recently, researchers have started to look at adherence with children who have undergone solid organ transplantation. This is because about 50% of these children are to some degree non-adherent with their medical regimen. This comes at a costly price as ongoing non-adherence in pediatric transplant can lead to the child's body rejecting the new organ and even death. This study has been designed to look at the reasons that pediatric patients may choose to be non-adherent.
3183159|NCT00711230|Experimental|4: Medium dose Placebo|"Dosage form: 1.6 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3183160|NCT00711230|Experimental|5: High dose DermaVir|"Dosage: 0.8 mg DNA~Dosage form: 6.4 mL DNA/PEIm nanomedicine~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 DermaVir treatments)"
3183161|NCT00711230|Experimental|6: High dose Placebo|"Dosage form: 6.4 mL Placebo~Administration with 8 DermaPrep patches~Frequency: every six weeks~Duration: 18 weeks (4 Placebo treatments)"
3183162|NCT00711256|Active Comparator|1|No sunscreen applied
2429334|NCT03371771|Active Comparator|MSW-delivered Behavioral Activation|
3183163|NCT00711256|Active Comparator|2|Sunscreen applied 0.5 mg/cm2
3183164|NCT00711256|Active Comparator|3|Sunscreen applied 1mg/cm2
3183165|NCT00711256|Active Comparator|4|Sunscreen applied 2mg/cm2
3183166|NCT00711282|Experimental|A|
3183167|NCT00711282|Experimental|B|
3183168|NCT00711295|Experimental|Cohort 1, Treatment Arm 1|"Stratum A (18-59 ys)/B(>=60 ys): 120 healthy volunteers per stratum will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Among Stratum A volunteers, 60 will participate in antibody kinetics evaluation and 30 in cellular immunity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio. Subjects in Treatment Arm 1 will be included in the immunologic determination of lot-to-lot consistency."
3183169|NCT00711295|Experimental|Cohort 1, Treatment Arm 2|"Stratum A (18-59 ys)/B(>=60 ys): 60 healthy volunteers per stratum will receive 2 vaccinations with 3.75 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.~Randomization to Treatment Arms 1 and 2 at 2:1 ratio."
2380738|NCT03704454|Experimental|Group C - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 50 mg PYC for the following 4 weeks
3188946|NCT00772408||control|healthy controls
3188947|NCT00772421||Responder|A subject having at least a 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase
3142498|NCT00002611|Active Comparator|Stratum 9|Stages I-IV rhabdoid tumor: After conventional surgery (nephrectomy), patients receive carboplatin IV on days 1-2 and VP-16 IV over 1 hour (beginning after carboplatin infusion) on days 1-3 of weeks 0, 3, 9, 12, 18, and 21 and CTX IV over 1 hour on days 1-5 of weeks 6, 15, and 24. Filgrastim G-CSF is administered as on stratum 7. Patients also undergo radiation therapy. After completion of chemotherapy, patients undergo second-look conventional surgery (laparotomy) and conventional surgery (partial nephrectomy or wedge excision if feasible). After conventional surgery (second-look surgery), patients without persistent or residual disease resume chemotherapy.
3142499|NCT00002618|Active Comparator|Regimen A|Patients begin radiotherapy (5 days a week for 4.5 weeks) to residual tumor on day 1 of maintenance.
3142500|NCT00002618|Active Comparator|Regimen B|Patients receive whole brain irradiation (5 days a week for 3.1 weeks) beginning on day 1 of maintenance. Patients are followed monthly for 6 months, every 3 months for 18 months, every 6 months for 3 years, and annually thereafter.
3142501|NCT00002621|Experimental|Alpha interferon (aIFN) treatment|See detailed description.
3142502|NCT00002622|Active Comparator|Talc slurry via chest tube|talc slurry via chest tube
3142503|NCT00002622|Active Comparator|Talc via insufflation|4 to 5 grams talc via insufflation through direct or videoscopic thoracoscopy, one time
2429335|NCT03371758|Experimental|vitiligo patients|
3142504|NCT00002624|Experimental|Radiotherapy + surgery|"Patients begin radiotherapy 2-8 weeks postoperatively. Patients with complete resection undergo radiotherapy 5 days a week for 5.6 weeks. Patients with incomplete resection undergo radiotherapy 5 days a week for 6.6 weeks.~Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
3150748|NCT00209209|Active Comparator|1|"randomisation: R-CHOP~randomisation: IFN maintenance"
3150749|NCT00209209|Experimental|2|"randomisation: R-FC~randomisation: Rituximab maintnenance"
3142505|NCT00002625|Experimental|Arm I|Radiosensitization plus Radiotherapy. Topotecan hydrochloride, TOPO, NSC-609699; plus external-beam irradiation using linear accelerators with photon energies between 4 and 10 MV (electrons acceptable for the boost field).
3142506|NCT00002633|Active Comparator|Total Androgen Blockade|
3142507|NCT00002633|Active Comparator|Total Androgen Blockade Vs TA Blockade Plus Pelvic Irradiation|
3142508|NCT00002642|Experimental|chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery and post-surgery boost chemotherapy
3142509|NCT00002643|Experimental|Arm I|See detailed description.
3142510|NCT00002644|Experimental|Tamoxifen citrate|Tamoxifen citrate 20 mg/day for 5 years
3142511|NCT00002644|Placebo Comparator|Placebo|Placebo 20 mg/day for 5 years
3142512|NCT00002649|Experimental|Arm I (autologous PBSCT, TBI, etoposide, cyclophosphamide)|"Part I: Autologous PBSC are harvested before study entry. Patients undergo total body irradiation twice a day on days -8 to -5, high-dose etoposide IV over 4 hours on day -4, and cyclophosphamide IV over 1 hour on day -2. PBSC are reinfused on day 0 and then G-CSF may be administered subcutaneously or IV on days 0-21.~Part II: Within 28-80 days after PBSC transplantation and after recovery from any toxic effects, patients with no active recurrent or progressive disease are randomized to 1 of 2 treatment arms.~Patients receive interleukin-2 IV continuously on days 1-4 and 9-18."
3142513|NCT00002649|No Intervention|Arm II (observation only)|Patients undergo observation only.
3142514|NCT00002656|Experimental|Pyrazoloacridine|Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
3142515|NCT00002657|Experimental|Immumosuppression, IFN-a, ProMACE-CytaBOM|Doses and schedules of immunosuppressive drugs (cyclosporin (or FK506), prednisone, and acyclovir) will depend on whether patients are judged to have clinically urgent disease or not. Patients who do not have a CR after initial immunosuppression will receive 3 cycles (28 days each) Interferon alpha 2b at 3.0 x 10^6 IU/m^2 on days 1-28. Patients who have a CR will then receive 6 additional cycles with 3 doses per week, then go onto observation. Patients who do not have a CR will then receive a maximum of 6 21-day cycles of chemotherapy, consisting of: cyclophosphamide 650 mg/m^2 on day 1, adriamycin 25 mg/m^2 on day 1, etoposide 120 mg/m^2 on day 1, prednisone 60 mg/m^2 on days 1-14, cytosine arabinoside 300 mg/m^2 on day 8, bleomycin 5 mg/m^2 on day 8, vincristine 1.4 mg/m^2 on day 8, methotrexate 120 mg/m^2 on day 8, leucovorin 25 mg/m^2 q 6 hours on days 8-9, G-CSF 5 ug/kg/day on days 2-14, and one double strength tablet trimethoprim-sulfamethoxazole 3 times per week.
3142516|NCT00002663|Experimental|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Patients receive adoptive immunotherapy with allogeneic Epstein Barr virus (EBV)-specific cytotoxic T lymphocytes IV on days 1, 8, and 15. After the third dose, patients will be observed for 3 weeks. After the 3 week observation period, additional courses of treatment may be given in the absence of disease progression or unacceptable toxicity.
3142517|NCT00002664|Experimental|Treatment|
3142518|NCT00002668|Active Comparator|Observation|Standard pain management interventions usually given by hospital staff
3142519|NCT00002668|Experimental|Educational Intervention and Behavioral Skills Training|Patients participated in a program including video presentations, written materials, and coaching in behavioral skills to improve pain control (not to reduce analgesic use).
3142520|NCT00002670|Active Comparator|Radiation therapy|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
3142521|NCT00002670|Experimental|Radiation therapy plus cisplatin|Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
3142522|NCT00002676|Experimental|CHOD + BVAM + WBRT|Patients 70 years old and younger with newly diagnosed, biopsy-proven PCNSL received one cycle of CHOD followed by two cycles of BVAM. Patients then received WBRT, 30.6 Gy, if a complete response was evoked, or 50.4 Gy if the response was less than complete; both doses were given in 1.8-Gy daily fractions.
3142523|NCT00002677|Experimental|Arm I|Patients receive oral tributyrin every 8 hours for 3 weeks. Treatment continues every 4 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease may receive additional courses at the discretion of the protocol chairperson. Cohorts of 3-6 patients receive escalating doses of tributyrin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
3142524|NCT00002678|Active Comparator|Melphan plus prednisone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.
3142525|NCT00002678|Active Comparator|Melphan, prednisone pluse dexamethasone|melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression
3142526|NCT00002682|Experimental|Antibiotic Treatment|
2380751|NCT03704428|Experimental|Cohort 5|Multiple subcutaneous injections of SHR-1314 dose 5
3142527|NCT00002704|Experimental|Arm I|Single Agent Chemotherapy. TSPA or DTC101. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 2-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. ARA-C/ASP; plus TIT. 4-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. CTX/MP/MTX/VP-16; with CF; plus TIT. 3-Drug Combination Chemotherapy plus Triple Intrathecal Therapy. DM/DNR/VCR; plus TIT. 6-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy. ARA-C/ASP/CTX/MP/MTX/VP-16; with CF; plus TIT. Radiotherapy plus 3-Drug Combination Chemotherapy. Craniospinal irradiation using x-rays with energies of 4-6 MV (electrons acceptable for spinal cord irradiation); plus ASP/DM/VCR. 2-Drug Combination Chemotherapy Alternating with 2-Drug Combination Chemotherapy. MP/MTX; alternating with CTX/VCR.
3142528|NCT00002705|Experimental|Arm I|Single-Agent Chemotherapy. Topotecan, TOPO, NSC-609699.
3142529|NCT00002706|Experimental|Arm I|Patients undergo vaginal hysterectomy and BSO via laparoscopy.
3150750|NCT00209222|Active Comparator|1|induction: R-CHOP consoldiation : TBI/Cyclo
3150751|NCT00209222|Experimental|2|induction: R-CHOP/DHAP consolditaion: TBI/TAM
3150752|NCT00209235|Experimental|AHO:neurocognitive and pyschosocial|Neurocognitive and psychosocial testing
3150753|NCT00209261|Active Comparator|1|
3150754|NCT00209261|Active Comparator|2|
3150755|NCT00209313|Other|1|Acyclovir 800 mg twice daily for 8 weeks, two week washout, 8 weeks placebo
3150756|NCT00209313|Other|2|8 weeks placebo, 2 week washout, 8 weeks 800 mg acyclovir twice daily
3150757|NCT00209378|Active Comparator|heparin|Citrate regional anticoagulation is compared with standard systemic heparinization.
3142530|NCT00002706|Active Comparator|Arm II|Patients undergo total abdominal hysterectomy and BSO via conventional laparotomy.
3142531|NCT00002707|Experimental|Group 2|doxorubicin and cyclophosphamide plus Taxotere prior to surgery plus tamoxifen
3142532|NCT00002707|Experimental|Group 3|doxorubicin and cyclophosphamide followed by surgery followed by taxotere plus tamoxifen
3142533|NCT00002707|Active Comparator|Group 1|doxorubicin and cyclophosphamide plus tamoxifen
3150758|NCT00209378|Active Comparator|Citrate|regional anticoagulation with citrate containing replacement solution
3183170|NCT00711295|Experimental|Cohort 1, Treatment Arm 3|"Stratum A (18-59 ys): 2060 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in safety evaluation only.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine."
3183171|NCT00711295|Experimental|Cohort 2, Treatment Arm 1|"300 immune compromised individuals 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21.~100 will participate in immunogenicity evaluation and 30 in cellular immunity evaluation."
2380752|NCT03704415|Active Comparator|Extended|Extended sinus surgery including all sinuses
3183172|NCT00711295|Experimental|Cohort 3, Treatment Arm 1|300 chronically ill patients 18 years or older will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity evaluation.
3183173|NCT00711295|Experimental|Cohort 1, Treatment Arm 4|"Stratum A (18-59): 540 healthy volunteers will receive 2 vaccinations with 7.5 µg A/Vietnam/1203/2004 on Days 0 and 21 and participate in immunogenicity assessment.~Randomization within Treatment Arms 3 and 4 at 1:1:1 ratio per study site to receive one of three different lots of the H5N1 influenza vaccine.~Subjects in Treatment Arm 4 will be included in the immunologic determination of lot-to-lot consistency."
3183174|NCT00711308|Experimental|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
2380739|NCT03704454|Experimental|Group D - Placebo & PYC|Placebo for the first 4 weeks and then switch over to 100mg PYC for the following 4 weeks
3183175|NCT00711308|Active Comparator|acenocoumarol|tinzaparin followed by acenocoumarol for 6 months
3183176|NCT00711321||2|AFFITOPE AD02 with adjuvant
3183177|NCT00711321||1|AFFITOPE AD02 without adjuvant
2380573|NCT03705468||Ketamine sedation|Ketamine sedation
2380574|NCT03705468||Propofol sedation|Propofol sedation
2380575|NCT03705455|Active Comparator|ISAP SMS|ISAP SMS will be sent to enrolled caregivers
2380576|NCT03705455|No Intervention|No ISAP SMS|No ISAP SMS will be sent to enrolled caregivers
2380577|NCT03705442|Placebo Comparator|Placebo|Placebo
2380578|NCT03705442|Experimental|Probiotics|Omni-Biotic 10
2380579|NCT03705429|Active Comparator|TC-H Chemotherapy|Docetaxel 75 mg/m2, Cyclophosphamide 600 mg/m2 and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy.
2380580|NCT03705429|Placebo Comparator|Paclitaxel(P) + Trastuzumab(T)|Paclitaxel 80 mg/m2 weekly for 12 weeks and Trastuzumab 8 mg/kg followed by 6 mg/kg Day 1 every 21 days for 4 cycles. Trastuzumab 6 mg/kg Day 1 every 21 days to complete 1 year of Trastuzumab therapy. Alternatively Trastuzumab 4 mg/kg followed by 2 mg/kg weekly to complete 1 year of treatment can be used.
2380581|NCT03705416||Endoscopic sleeve gastroplasty|All obese patients who will be undergoing an endoscopic sleeve gastroplasty (ESG). As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the endoscopic sleeve gastroplasty patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
2380582|NCT03705416||Surgery (VSG or RYGBP)|All obese patients who will be undergoing either a vertical sleeve gastrectomy or a Roux-en-Y gastric bypass. As part of the standard of care this patients will have a preoperative gastroscopy with wireless pH monitoring. Then after the surgical procedure patients will be followed up regarding GERD symptoms for 5 years. As part of the standard of care a follow up endoscopy will be done at year 1 and wireless pH monitoring will be performed
2380583|NCT03705403|Active Comparator|Control|Standard of Care (SOC) according to the local and national guidelines: (wait and see or surgery and/or chemotherapy and/or standard (symptomatic) radiation therapy and/or SABR (oligometastatic disease)
2380584|NCT03705403|Experimental|Experimental treatment|Standard of Care (SOC SABR (oligometastatic disease) or radiation therapy (diffuse disease) + L19-IL2 up to 6 cycles (Darleukin)
2380585|NCT03705390|Experimental|ILB|ILB subcutaneous injection
2380586|NCT03705377||Head Start children and families|children (2,400), parents (2,400), classrooms/teachers (720), program directors (180), center directors (360), family service staff (168)
2380587|NCT03705364|No Intervention|Wait List Control Group|Wait list control group
2380588|NCT03705364|Experimental|Fall Management program|Intervention arm
2380589|NCT03705351|Experimental|Treatment|Patients will receive trimodal therapy consisting of tumor treating fields therapy with the Optune device concurrent with temozolomide and radiation therapy.
2380590|NCT03705338||Electroencephalography|Electroencephalography (EEG) for induction and emergence in pediatric patients under general anesthesia with propofol.
2380591|NCT03705325|Experimental|Spirobank smart spirometer with VitalFlo mobile app|In this single arm study, all participants will be receive the spirometer and an iPhone 5S (without SIM card) loaded with the VitalFlo app.
2380592|NCT03705312|Placebo Comparator|Guideline-directed medical therapy|Standard guideline-directed medical treatment for heart failure
2380593|NCT03705312|Experimental|Transcatheter Mitral valve repair|MitraClip treatment
2380594|NCT03705299|Experimental|NeuMeDex NICVP (Non-Invasive CVP) vs Standard CVP|Three pressure readings recorded for both NeuMeDex NICVP and central line pressure catheter over a 10 minute period.
2380595|NCT03705286|Active Comparator|PVC-ETT|Polyvinylchloride endotracheal tube
2380596|NCT03705286|Experimental|EVAC-PU-ETT|Continuous aspiration of subglottic secretions with polyurethane cuff endotracheal tube
3183178|NCT00711373|Experimental|Unilateral and Bilateral Amputees|
3183179|NCT00711386|Experimental|Cohort A|50mg dose once daily for 7 days.
3183180|NCT00711386|Experimental|Cohort B|100mg dose once daily for 8 days.
2380599|NCT03705260|Active Comparator|Comparator- High Risk|A high risk sub group of those assigned to the comparator arm will be identified by their most recent A1C > 8. Patients in this group will receive usual care from their Primary Care Physician and dietitian.
2380600|NCT03705260|Active Comparator|Comparator- Well Controlled|The low risk sub group from the comparator arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their Primary Care Physician and their dietitian.
2380601|NCT03705260|Experimental|Enhanced Care- High Risk|A high risk sub group of those assigned to the enhanced care arm will be identified by their most recent A1C > 8. Patients in this group will receive the intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
2380602|NCT03705260|Experimental|Enhanced Care- Well Controlled.|The low risk sub group from the enhanced care arm (A1C < 8) and those who are unlikely to benefit from an intensive behavioral intervention will get usual care by their PCP and their dietitian. If they are found to be poorly controlled through monthly screening for risk, they may have the opportunity to move into the Enhanced Care High Risk group.
2380603|NCT03705234|Experimental|Inclisiran|Inclisiran sodium 300 milligrams (mg) will be administered as a SC injection at randomization, 3 months and then every 6 months.
2380604|NCT03705234|Placebo Comparator|Placebo|Placebo will be administered as SC injections of saline solution at randomization, 3 months and then every 6 months.
2380605|NCT03705221|Experimental|Group programme|Healthy Parent Carers group programme: A group-based peer led manualised programme called Healthy Parent Carers. The programme content is organised into 12 modules, which can be delivered over six longer (4-hour) sessions or 12 shorter (2-hour) sessions.
2380606|NCT03705221|Active Comparator|Online resources|Healthy Parent Carers online resources: Online resources from the Healthy Parent Carers programme, including materials for 12 modules and related videos and audio files to illustrate the content.
2380607|NCT03705208|Experimental|Youth First Curriculum|"The full Youth First curriculum provides holistic training of both emotional resilience and adolescent health concepts. The curriculum is comprised of a 15-session emotional resilience curriculum and a 10-session adolescent health program. The resilience curriculum aims to increase both internal assets (such as self-esteem, coping skills, health knowledge, and conflict-resolution skills) and external assets (such as positive bonds with peers and family).~The adolescent health curriculum provides in-depth training in physical health and wellness topics such as sexual and reproductive health, common diseases, nutrition, gender equality, and substance use.~The curriculum is imparted by school teachers are trained and certified by CorStone."
2380608|NCT03705208|No Intervention|School as usual|This arm is comprised of students attending school as usual and receiving the established government-designed curriculum.
2380609|NCT03705195|No Intervention|No Intervention|All participants in study will complete two matched clamp studies (OGTT + IGII). The first matched clamp without any intervention the second matched clamp with low dose gliclazide
2380610|NCT03705195|Experimental|Low Dose Gliclazide|"The first 8 participants will complete the dose-ranging phase of LOGIC study. Low dose gliclazide is being used a physiological stimulus. In the dose-ranging phase, 4 participants will receive 10mg gliclazide, the remaining 4 will receive 20mg gliclazide. The allocation to 10mg or 20mg will be randomised and unblinded. The study will analyse after the first 8 participants to assess which dose produces the greatest augmentation of insulin secretion when acting synergistically with the incretin effect.~The further 12 participants will complete the study with the identified best dose."
2380611|NCT03705182|Experimental|Interventiongroup|The intervention group will be shown the fluorescent areas on their skin (fluorescence visualization feedback)
2380612|NCT03705182|No Intervention|Control group|The control group will not be shown the fluorescent areas on their skin (no feedback)
3142534|NCT00002708|Experimental|Arm 1|Whole brain radiation therapy (WBRT) to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week followed by radiosurgery to all metastases
3142535|NCT00002708|Active Comparator|Arm 2|WBRT to 37.5 Gy/15 fractions/2.5 Gy once daily, 5 days/week
3142536|NCT00002715|Experimental|Combination Chemotherapy (Stanford V)|A combination chemotherapy regimen consisting of mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide and prednisone, administered on a compressed schedule
3142537|NCT00002716|Experimental|Arm I - laparotomy + conventional surgery + chemotherapy|"Patients undergo laparotomy for placement of a hepatic artery catheter and then subcutaneous placement of a hepatic artery infusion pump. Patients with unresected primary disease also undergo resection at the time of catheter and pump placement. Beginning within 1-2 weeks after surgery, patients receive floxuridine, dexamethasone, and leucovorin calcium (CF) via continuous hepatic artery infusion on days 1-14. Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
3142538|NCT00002716|Experimental|Arm II - conventional surgery + chemotherapy|"Patients receive CF IV and fluorouracil IV on days 1-5. Patients with unresected primary disease undergo resection within 3-4 weeks before initiation of chemotherapy.~Treatment for patients continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life and medical resource utilization are assessed at baseline, every 3 months for 1 year, and then at 18 months.~Patients are followed every 3 months."
3142539|NCT00002718|Experimental|Candidates for transplant|Pts stratified by number of HLA-incompatible alleles(1 vs 2 or 3). Harvest:Begin 6-10 d before transplant,allogeneic BM is harvest & tx in vitro. Begin 5-6 d before transplant,G-CSF-stimulated,PBSC harvest,selected for CD34+ cells,& treatment in vitro. If doable,ABM harvest in event of allogeneic graft failure. Myeloablation:Pts u/g TBI 3x d days -9 to -6, thiotepa IV over 4hrs days -5 & -4, & cyclophosphamide IV days -3 & -2. Transplant:CD34+, E-rosette & T-cell-depleted PBSC infuse over 15mins & T-cell-depleted bone marrow infused over 1-5mins day 0. Pts get G-CSF IV over 30 min begin day 1 & continue til blood counts recover & tapering. Pts get anti-thymocyte globulin IV over 4-6hrs days 8,10,12,&14 & oral methylprednisolone days 8-14 followed by tapered doses days 15-17. See detailed description for more details.
3142540|NCT00002721|Experimental|Prostate cancer patients|Prostate cancer patients that have not responded to hormon therapy
3142541|NCT00002723|Experimental|Low dose suramin|Low dose suramin
3142542|NCT00002723|Experimental|Intermediate dose suramin|Intermediate dose suramin
3142543|NCT00002723|Experimental|High dose suramin|High dose suramin
3142544|NCT00002725|Experimental|Arm I|Single-Agent Chemotherapy/Differentiation Therapy. Bryostatin 1, BRYO, NSC-339555.
3142545|NCT00002727|Active Comparator|Radiation therapy - conventional fractionation|Radiation therapy - conventional fractionation (70 Gy/2 Gy once per day/7 Weeks) 35 fractions
3142546|NCT00002727|Experimental|Radiation therapy - hyperfractionation|Radiation therapy - hyperfractionation (79.2 Gy/1.2 b.i.d/6.5 weeks) 66 fractions
3150759|NCT00209391|Experimental|Gadodiamide Injection|All subjects will receive a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide injection) at a dose of 0.1 mmol/kg.
3150760|NCT00209443|Experimental|Gadodiamide Injection|All subjects received a single intravenous bolus injection via a power injector of Omniscan (Gadodiamide Injection) at a dose of 0.1 mmol/kg
2380632|NCT03705143|Placebo Comparator|Treatment as Usual|Participants will receive no additional intervention besides the services they are currently receiving at the MMT clinic.
2380633|NCT03705143|Experimental|Chinese translated LETS ACT|In addition to services participants are currently receiving at the MMT clinic, individuals will attend six group-based one-hour behavioral activation treatment sessions.
2380634|NCT03705130||Group 1|All subjects will wear the 3 contact lenses: Single Vision, Multifocal 1 and Multifocal 2.
2380635|NCT03705117|Experimental|V565|V565 orally three times daily for up to 7 days
2380636|NCT03705104|Experimental|EPIO (e-health intervention)|Participants will get access to one module every third day (total 9 modules). The app consists of cognitive behavioral pain self-management material, including educational material and relaxation training exercises.
2380637|NCT03705104|No Intervention|treatment as usual|Participants will get treatment as usual during the study. All participants will get access to the app after ended study if interested.
2380638|NCT03705091||Transplant|Incident patients receiving a kidney transplant for end stage kidney disease. Patients will undergo functional magnetic resonance imaging at 2 months, 6 months and 12 months following transplantation.
2380639|NCT03705078|Other|early TIPS|Transjugular portosytemic shunt within 72h
2380640|NCT03705078|Other|Glue obliteration|glue obliteration repeated sessions
2380641|NCT03705065|Experimental|Treatment Group 1|Bupivacaine HCI by instillation into each pectoral pocket.
2380642|NCT03705065|Experimental|Treatment Group 2|Bupivacaine HCI by injection into each pectoral pocket.
2380643|NCT03705052|Other|Intervention|Patients and caregivers were asked to complete a questionnaire
2380644|NCT03705039|Active Comparator|Treatment Group|pulsed ultrasound treatment
2380645|NCT03705039|Placebo Comparator|Control Group|sham ultrasound treatment
2380646|NCT03705013||Baseline Cologuard positive and negative colonoscopy|Those whose Cologuard T0 result was positive and colonoscopy result was negative.
2380647|NCT03705013||Baseline Cologuard positive and no colonoscopy|Those whose Cologuard T0 result was positive and subject declined to complete a colonoscopy per protocol.
2380648|NCT03705013||3-year follow-up Cologuard positive and negative colonoscopy|Those whose Cologuard result at T3 was positive and colonoscopy result at T3 was negative.
2380649|NCT03705013||3-year follow-up Cologuard positive and no colonoscopy|Those whose Cologuard result at T3 was positive and subject declined to complete a colonoscopy per protocol.
2380650|NCT03705000|Experimental|Slit Stent II|The Slit Stent II (investigational) device is created by modifying an existing FDA cleared lacrimal stent (BIKA, manufactured by FCI Opthalmics) by adding additional 3 mm and 35 mm long slits of equal depth.
2380651|NCT03705000|Active Comparator|BIKA for DCR|The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device.
2380652|NCT03704987|Active Comparator|Klinefelter|Male patients followed with the diagnosis of klinefelter
2380653|NCT03704987|Active Comparator|Control|healthy male subjects
2380654|NCT03704974||Children of Parents Receiving IY|Children ages 3 to 6 years at start of group with behavior concerns whose parents are referred by their pediatricians for participation in a video-based parent training program from 2014 through 2018.
2380655|NCT03704961|Experimental|classical music|
2380656|NCT03704961|Experimental|Turkish music|
2380657|NCT03704961|Experimental|audiobook|
2380658|NCT03704948|Experimental|Listening Visits|Listening Visits delivered by a nurse.
2380659|NCT03704948|Active Comparator|Standard of Care (Social Work)|Standard mental health services provided by social workers.
2380660|NCT03704922|Experimental|≤10 day Blood|Subjects in this group will receive only blood stored ≤10 days for 3 consecutive transfusion events.
2380661|NCT03704922|Experimental|≥30 day Blood|Subjects in this group will receive only blood stored ≥30 days for 3 consecutive transfusion events.
2380662|NCT03704909|Active Comparator|Group Adrenaline: Group A|All parturients received a prophylactic i.v bolus of Epinephrine 0.15µg/Kg at time of SA. In this group, rescue boluses of Epinephrine 0.15µg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.
2380663|NCT03704909|Active Comparator|Group Ephedrine: Group E|All parturients received a prophylactic i.v bolus of Ephedrine 0.1mg/Kg at time of SA. In this group, rescue boluses of Ephedrine 0.1mg/Kg, will be given if maternal BP decreased more than 20% from the baseline value.E
2380664|NCT03704870|Active Comparator|Daily Chest Xray (standard)|
2380665|NCT03704870|Experimental|Chest Xray post chest tube removal only|
2380666|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380740|NCT03704441|Other|bupivacaine 6mg|bupivacaine 6mg
3150761|NCT00209495|Placebo Comparator|A|
3150762|NCT00209495|Experimental|B|Pregabalin
3150763|NCT00209495|Experimental|C|Pregabalin + dexamethasone
3150764|NCT00209521|Experimental|fospropofol|
2380667|NCT03704857|Experimental|Foraminal enlargement with sodium hypochlorite and PDT|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, PDT, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380668|NCT03704857|Experimental|Foraminal enlargement with chlorhexidine as irrigant|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, chlorhexidine as irrigant, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380669|NCT03704857|Active Comparator|Foraminal enlargement with sodium hypochlorite and AH Plus|Unirradicular teeth will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, sodium hypochlorite as irrigant, lateral condensation filling with AH Plus.The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380670|NCT03704857|Active Comparator|Foraminal enlargement with conventional irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, conventional irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380671|NCT03704857|Experimental|Foraminal enlargement with passive ultrasonic irrigation|Molars will be submitted to endodontic treatment with foraminal enlargement, instrumentation with reciprocating rotation, passive ultrasonic irrigation with sodium hypochlorite, lateral condensation filling with MTA Fillapex. The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours. The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months. In addition, patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
2380672|NCT03704844||Patients with renal congestion|
2380673|NCT03704844||Patients without renal congestion|
2380674|NCT03704831||IPACK group|IPACK group
2380675|NCT03704831||Surgical infiltration group|Surgical infiltration group
2380676|NCT03704818|Experimental|Dapagliflozin 5mg|
2380677|NCT03704818|Experimental|Placebo|
2380678|NCT03704805|Experimental|Problem-Solving Therapy|Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.
2380679|NCT03704805|Active Comparator|Enhanced Standard of Care|Participants in the control group receive enhanced standard of care.
2380680|NCT03704792|Experimental|Adult CLD Group|Only one group of patients in the study: adult patients with chronic liver disease (CLD), all etiologies combined, who will have a FibroScan 530 Compact examination to calculate the CAP value.
2380681|NCT03704779|Experimental|Multimodal Mindfulness Activity Program|Students assigned to the intervention will receive 8 weeks of the mindfulness activity intervention.
2380682|NCT03704779|No Intervention|Control Group|Students assigned to the control group will not receive any intervention.
2380683|NCT03704766|Experimental|Inflamed/Infected Joint|Patients undergoing joint aspiration/debridement due to suspicion of septic joint or rheumatologic/inflammatory condition
2380684|NCT03704766|Active Comparator|Normative Control|Patient undergoing procedure unrelated to infection/inflammation
2380685|NCT03704753|Active Comparator|SAPB group A|SAPB single injection. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
2380686|NCT03704753|Placebo Comparator|SAPB group B|SAPB single injection (placebo). 30ml of SodiumChloride 0.9 is injected above m. serratus anterior after thoracoscopic lung surgery. Infection is done under ultrasound guidance.
2380687|NCT03704753|Active Comparator|SAPB group C|SAPB single injection and catheter. 30ml of Ropivacaine 7,5mg/ml is injected above m. serratus anterior after thoracoscopic lung surgery and a multi-holed catheter is left in place. 20ml of Ropivacaine 2mg/ml is injected every 12h through catheter postoperatively.
2380688|NCT03704753|Active Comparator|SAPB group D|Continious intercostal catheter. 20ml of Ropivacaine 7,5mg/ml is injected through intercostal catheter, which i placed under thoracoscopic visualization. After single injection a continuous infusion of Ropivacaine 2mg/ml is started (weight dependent daily dosage).
2380689|NCT03704753|Active Comparator|SIP group A|SIP single injection 20ml of Ropivacaine 7,5mg/ml is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
2380690|NCT03704753|Placebo Comparator|SIP group B|SIP single injection (placebo) 20ml of SodiumChloride 0.9 is injected under pectoralis major muscle on both sides of sternum. Injection is done under ultrasound guidance.
2380691|NCT03704740|Experimental|NBP607-QIV|One or two doses of 0.5mL of NBP607-QIV by intramuscular injection
2380692|NCT03704740|Active Comparator|Agrippal|One or two doses of 0.25mL of Agrippal by intramuscular injection
2380737|NCT03704454|Experimental|Group B - PYC & Placebo|100 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
2380693|NCT03704727|Experimental|probiotic treatment|Probiotic: VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus. Administred orally
2380694|NCT03704714|Experimental|Treatment (nivolumab and R-CHOP)|Participants receive nivolumab IV over 30 minutes on day 1. Participants also rituximab IV on day 2, cyclophosphamide IV on day 2, doxorubicin hydrochloride IV over 3-5 hours on day 2, vincristine sulfate IV over 30 minutes on day 2, and prednisone PO on days 2-6 of course 1 and rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV over 3-5 hours on day 1, vincristine sulfate IV over 30 minutes on day 1, and prednisone PO on days 1-5 of courses 2-6. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2380695|NCT03704688|Experimental|Phase I: Dose Level -3|Trametinib 0.5mg PO q daily Ponatinib 15mg PO q daily
2380696|NCT03704688|Experimental|Phase I: Dose Level -2|Trametinib 1.0 mg PO q daily Ponatinib 15mg PO q daily
2380697|NCT03704688|Experimental|Phase I: Dose Level -1|Trametinib 1.5 mg PO q daily 15mg PO q daily
2380698|NCT03704688|Experimental|Phase I: Dose Level 1|Trametinib 2 mg PO q daily Ponatinib 15mg PO q daily
2380699|NCT03704688|Experimental|Phase I: Dose Level 2|Trametinib 2 mg PO q daily Ponatinib 30mg PO q daily
2380700|NCT03704688|Experimental|Phase II|Maximum tolerated dose as established in Phase I portion
2380701|NCT03704675|Experimental|Group I (Fasted->Fed)|Group 1 received a single oral dose in a fasting condition in Period 1, followed by a single oral dose after a high-fat diet in Period 2
2380702|NCT03704675|Experimental|Group II(Fed->Fasted)|Group 2 received a single oral dose after a high-fat diet in Period 1, followed by a single oral in a fasting condition in Period 2
2380703|NCT03704662|Other|Stereotactic Body Radiation Therapy|Patients undergo Stereotactic Body Radiation Therapy (25 to 35 Gy over five fractions)
2380704|NCT03704662|Other|Preoperative Fractionated Radiation Therapy and Chemotherapy|Concurrent chemotherapy with radiation treatment (50.4 Gy over 28 fractions).
2380705|NCT03704649|No Intervention|Standard nutrition education|The comparison group for the participatory video intervention.
2380706|NCT03704649|Experimental|Participatory nutrition education|Intervention arm integrates participatory video model to standard girls' club sessions to promote nutrition education.
3183181|NCT00711386|Experimental|Cohort C|200mg dose once daily for 8 days.
2380708|NCT03704623|Active Comparator|Paracetamol|Patients will receive IV 1 g of Paracetamol
2380709|NCT03704623|Active Comparator|Parecoxib|Patients will receive 40 mg of Parecoxib IV
3150765|NCT00209521|Active Comparator|propofol|
3150766|NCT00209612|Experimental|1|Paclitaxel+Irinotecan
2380712|NCT03704597|Active Comparator|7-hour cryotherapy|Standard of care
2380713|NCT03704597|Experimental|2-hour cryotherapy|Experimental treatment
3150767|NCT00209651|Experimental|1|Irinotecan and S-1
3150768|NCT00209690|Experimental|1|
2380716|NCT03704571|Experimental|Tailored Group|In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.
2380717|NCT03704571|Active Comparator|Control Group|In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.
2380718|NCT03704545|No Intervention|Control group|
2380719|NCT03704545|Experimental|Experimental group from the hospital|
2380720|NCT03704545|Experimental|Experimental group from the city|
2380721|NCT03704532||Operative treatment|Patients having undergone an operative treatment of achilles tendon rupture
2380722|NCT03704532||Nonoperative treatment|Patients having undergone a nonoperative treatment with functional rehabilitation of achilles tendon rupture
2380723|NCT03704519|Experimental|Men_EPD|Healthy male participants receive drugs in order Enzalutamide, Placebo and Darolutamide.
2380724|NCT03704519|Experimental|Men_DEP|Healthy male participants receive drugs in order Darolutamide, Enzalutamide and Placebo.
2380725|NCT03704519|Experimental|Men_PDE|Healthy male participants receive drugs in order Placebo, Darolutamide and Enzalutamide.
2380726|NCT03704519|Experimental|Men_DPE|Healthy male participants receive drugs in order Darolutamide, Placebo and Enzalutamide.
2380727|NCT03704519|Experimental|Men_EDP|Healthy male participants receive drugs in order Enzalutamide, Darolutamide and Placebo.
2380728|NCT03704519|Experimental|Men_PED|Healthy male participants receive drugs in order Placebo, Enzalutamide and Darolutamide.
2380729|NCT03704506|Experimental|treatment group 1|Reyanning mixture+amoxil capsule simulator
2380730|NCT03704506|Experimental|treatment group 2|Reyanning mixture +amoxil capsule
2380731|NCT03704506|Active Comparator|control group|Reyanning mixture simulator +amoxil capsule
2380732|NCT03704493|No Intervention|Image Group|The patients were looking at a static image of a lavender flower while exercising on the treadmill.
2380733|NCT03704493|Experimental|Video Group|The patients were watching a video of a group of amateur runners while exercising on the treadmill.
2380734|NCT03704480|Experimental|Amended ARM A|"One cycle equals 4 weeks (D1=D28);~Durvalumab: 1,500 mg by IV infusion on D1, until progression or unacceptable toxicity or withdrawal of consent.~Tremelimumab: 300 mg by IV infusion on D1 at cycle 1 only."
2380736|NCT03704454|Experimental|Group A - PYC & Placebo|50 mg of PYC for the first 4 weeks and then switch over to receive placebo for the following 4 weeks
3150769|NCT00209716|Experimental|1|
3150770|NCT00209729|Experimental|1|Docetaxel plus S-1
3150771|NCT00209742|Experimental|2|
3150772|NCT00209742|Experimental|3|
3150773|NCT00209742|Active Comparator|1|
3150774|NCT00209807|Experimental|1|subjects with MDD randomized to Escitalopram
3150775|NCT00209807|Active Comparator|2|MDD patients receiving reboxetine
3150776|NCT00209807|Other|3|Healthy volonteers
3150777|NCT00209898|Active Comparator|Rapid standard of care|Rapid standard of care treatment after screening
2380753|NCT03704415|Active Comparator|Limited|Limited sinus surgery with partial ethmoidectomy
2380754|NCT03704402||alcohol policy group|High schools that introduced the policy
2380755|NCT03704402||control group|High schools that did not introduce the policy
2380756|NCT03704389|Experimental|Clinical decision support intervention|Participating clinicians will receive any of three clinical decision support nudges within the electronic health record when all eligibility criteria are met within a patient's chart.
3142547|NCT00002734|Experimental|Arm I|Patients receive interferon alfa subcutaneously on days 1, 3, 5, and 7; paclitaxel intraperitoneally (IP) on day 4 or topotecan IP on day 6; and 177Lu-CC49 IP on day 6. Treatment continues every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-5 patients receive escalating doses of paclitaxel and decreasing doses of 177Lu-CC49 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 5 patients experience dose limiting toxicity. Once the MTD of paclitaxel is determined, the dose of 177Lu-CC49 is escalated. Once the MTD of 177Lu-CC49 is determined, 90Y-CC49 is substituted. The MTD of 90Y-CC49 is then determined when administered with paclitaxel. Topotecan is then substituted for paclitaxel (administered with the MTD of 177Lu-CC49 and interferon alfa only) and escalated until the MTD is determined.
3142548|NCT00002735|Experimental|Treatment arm|induction chemotherapy followed by chemoradiation
2380759|NCT03704363|Experimental|Infliximab|Intravenous infusion(biosimilar infliximab). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
2380760|NCT03704363|Placebo Comparator|Placebo|Intravenous infusion (NaCl intravenous infusion). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98.
3142549|NCT00002740|Experimental|Treatment - Carboplatin Chemotherapy|See detailed description.
3142550|NCT00002744|Experimental|Arm I|Therapy defined in description.
3142551|NCT00002744|Experimental|Arm 2|Therapy defined in description.
3142552|NCT00002744|Experimental|Arm 3|Therapy defined in description.
3142553|NCT00002744|Experimental|Arm 4|Therapy defined in description.
3142554|NCT00002745|Experimental|aminocamptothecin|aminocamptothecin
2380767|NCT03704337|Experimental|Commercially Available Food Bar|62 g. Food Bar
2380768|NCT03704337|Placebo Comparator|Placebo|25 g. Dextrose
2380769|NCT03704311|Experimental|Single|Evaluation of mitochondrial function after muscle biopsy and follow-up for surgical complications.
3142555|NCT00002756|Experimental|Chemo (Reduced Induction) No BMT (Open February 2004)|
2380771|NCT03704285||Propofol|Severe burn adult under general anesthesia with propofol + remifentanil evaluation of propofol effect using BIS
2380772|NCT03704272|No Intervention|Control|Families in the control group will receive treatment as usual, which includes reporting to child welfare agencies when appropriate.
2380773|NCT03704272|Experimental|Treatment|SunBrite
2380774|NCT03704246|Other|Anti-PD-1|Anti-PD-1 monoclonal antibody HX008 injection with a dose of 200mg (intravenous infusion, every 3 weeks)
2380775|NCT03704233||Cryobiopsy|Transbronchial cryobiopsy is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
2380776|NCT03704220|Other|Single anti-thrombotic treatment|Single anti-thrombotic treatment
3142556|NCT00002757|Active Comparator|Group A|All resected stage I and Abdominal stage II only. All Group A patients will be treated with two cycles of COPAD and will be followed in a confirmatory study of the current result of nearly 100% cure rate.
3183182|NCT00711386|Experimental|Cohort D|400mg dose once daily for 7 days.
3183183|NCT00711399||group A|Study group
2380780|NCT03704181|Experimental|colchicine|colchicine 0,5 milligram tablet by mouth every 12 hours, for 1 year
2380781|NCT03704181|Active Comparator|placebo|"placebo tablet by mouth every 12 hours, for 1 year~pill manufactured to mimic coclchicine 0,5 mg tablet"
3142557|NCT00002757|Active Comparator|Group B|Non resected stage I & II, stage III & st IV (CNS - ve, BM < 25%). Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimise the risk of this. Prior to any chemotherapy being administered intravenous hydration fluids should be given run at a rate of 3000 mls/m2/day. Alkalinisation may be necessary Pay close attention to fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumour lysis persists.
2380783|NCT03704155|Experimental|Experimental group (EG)|The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
2380784|NCT03704155|Active Comparator|Control group (CG)|GC was treated with physiotherapy (stretching, balancing training, functional walking training).
2380785|NCT03704142|Experimental|Tweak Focus|Speech understanding and listening effort will be assessed using the Tweak Focus personal sound amplifiers.
2380786|NCT03704142|Experimental|IQ Earbuds|Speech understanding and listening effort will be assessed using the IQEarbuds personal sound amplifiers.
2380787|NCT03704142|Experimental|Sound World Solutions CS50+|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
2380788|NCT03704142|Experimental|Bose Hearphones|Speech understanding and listening effort will be assessed using the Sound World Solutions CS50+ personal sound amplifiers.
2380858|NCT03703726|Active Comparator|Test meal B|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
2380954|NCT03703102|Placebo Comparator|Arm A|Subcutaneous administration of placebo
3142558|NCT00002757|Active Comparator|Group C|Bone marrow > 25% but CNS negative Patients with bulky disease are at risk from metabolic complications secondary to tumor lysis syndrome. Vigorous measures should be taken to minimize the risk of this. Intravenous hydration fluids should be given prior to chemotherapy. Alkalinisation may be necessary. Monitor fluid balance and continue hydration fluids after the administration of COP for as long as the risk of tumor lysis persists
3142559|NCT00002759|Experimental|Arm I|See detailed description.
3142560|NCT00002760|Other|Antiandrogen withdrawal|"antiandrogen therapy withdrawn; patient who progress will be crossed over to Arm 1A: 400 mg ketoconazole PO tid and hydrocortisone 30 mgs PO q am and 10 mgs PO qhs until treatment is no longer effective"
3142561|NCT00002760|Active Comparator|Antiandrogen withdrawal + therapy|Ketoconazole and hydrocortisone
2380789|NCT03704129|Experimental|"Tutor group"|"After a theoretical part through the administration of a video-tutorial, a 10-point questionnaire will be administered to evaluate the level of learning for each participant. Every single participant will pass the test if he/she correctly answer to >70% of the questions. Those passing the test, will be randomized to two groups.~The interventional group will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself."
2380790|NCT03704129|No Intervention|"No tutor group"|This control group will directly perform the ultrasound examination of the diaphragm. The expert tutor will only show the learners how to use the various functions of the ultrasound, the linear and convex probes both in two-dimensional and in M-mode.
2380791|NCT03704116|Active Comparator|Expedition: Strategic Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes escalating challenge levels.
2380792|NCT03704116|Placebo Comparator|Expedition: Informational Advantage|Software-based intervention simulating daily life cognitive challenges. Delivered 1 hour per day, 5 days per week for 4 weeks. Includes 8 check-in phone calls with an experimenter. Includes capped challenge levels.
2380793|NCT03704103|Experimental|iSage for adjustment of insulin|The provider will prescribe the iSage app to the subject and choose a treatment algorithm within the app to make insulin dose adjustments.
2380794|NCT03704103|No Intervention|Conventional management|Our clinic uses a modified treat-to-target algorithm which is summarized on a 3 x 5 refrigerator magnet.
2380795|NCT03704090|Active Comparator|Control|Standard non-pharmacological intervention during 5 days after surgery.
2380796|NCT03704090|Experimental|Treatment|Occupational therapy intervention twice a day plus standard non-pharmacological prevention intervention during 5 days after surgery.
2380797|NCT03704077|Experimental|Cohort A: relatlimab + nivolumab + paclitaxel|
2380798|NCT03704077|Experimental|Cohort A: nivolumab + paclitaxel|
2380799|NCT03704077|Active Comparator|Cohort A: ramucirumab + paclitaxel|Standard-of-care
2380800|NCT03704077|Experimental|Cohort B: relatlimab + nivolumab|
2380801|NCT03704077|Active Comparator|Cohort B: nivolumab|Standard-of-care
2380802|NCT03704077|Experimental|Cohort C: relatlimab + nivolumab|
2380803|NCT03704064|Experimental|Stigma + BWL Intervention|Participants in this group will receive the standard behavioral weight loss (BWL) program, which will be combined with a stigma-reduction intervention (more details provided in the Intervention section). All group meetings will be 90 minutes. Beginning at week 5, the 60-minute BWL sessions will be followed by 30 minutes devoted to stigma-related content. In the monthly and every-other-month weight loss maintenance sessions from weeks 21-72, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies specifically with physical activity.
2380804|NCT03704064|Active Comparator|Standard BWL Intervention|Participants in this group will be provided with 20 weekly behavioral weight loss (BWL) session (described in more detail in the Intervention section), followed by 6 monthly weight loss maintenance sessions and 3 every-other-month sessions (for a total of 29 visits over 72 weeks). All group meetings will be 90 minutes. Beginning at week 5, BWL content in these sessions will last 60 minutes, with an additional 30 minutes devoted to discussing recipes and food preparation.
2380805|NCT03704051|Experimental|Breast- versus Bottle-feeding|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
2380806|NCT03704038|Active Comparator|PEEP 5|
2380807|NCT03704038|Active Comparator|PEEP 0|
2380808|NCT03704038|Experimental|PEEP 10|
2380809|NCT03704025|Active Comparator|Current guidelines rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by diary.
2380810|NCT03704025|Experimental|Mobile device guided rehabilitation|Exercise rehabilitation at home according to current guidelines. Training is guided and controlled by virtual augmented reality glasses or by mobile device.
2380811|NCT03704012|No Intervention|Routine Care|Control Group receives routine care.
2380812|NCT03704012|Experimental|Massage and kinesiotherapy|Intervention Group, receives massage and kinesiotherapy. Behavioral: Protocol of massage therapy and kinesiotherapy. Infants received massage and kinesiotherapy twice a day; 15 minutes each.
2380813|NCT03703999||type 1 diabetic patients freestyle Libre|group of type 1 diabetic patients that will be selected to use Freestyle libre on the basis of clinicians decisions and reimbursement criteria
2380814|NCT03703986||END group|The patients in this group had an elevation of ≥ 2 points in the National Institute of Health Stroke Scale (NIHSS) within 7 days of stroke onset.
2380815|NCT03703986||non-END group|The patients in this group had a slight increase of < 2 points or a decrease in NIHSS within 7 days of stroke onset.
2380816|NCT03703973||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.We also measure their preoperative leukocyte telomere length.
2380817|NCT03703973||control group|We enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
2380818|NCT03703960|Experimental|"Group 1 Hypnosis"|
2380819|NCT03703960|Active Comparator|"Group 2 music"|
2380820|NCT03703960|No Intervention|Control group|
2380821|NCT03703947||Watchful-waiting group|The prospective, longitudinal part of the study will include an arm with 120 AAA watchful waiting patients, with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, and at 6, 12, 18 and 24 months for all patients. CT will be conducted at baseline and 12 and 24 months. Quality of life and depression questionnaires will be performed at baseline, at 12 and 24 months of follow-up in all patients.
2380859|NCT03703726|Experimental|Test meal C|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
2380822|NCT03703947||EVAR group|The prospective, longitudinal part of the study will include an arm with 120 AAA patients undergoing endovascular aneurysm repair (EVAR), with a 24-month follow-up period. Clinical data collection, and blood sampling will be conducted at baseline, at 1 month after EVAR and at 6, 12, 18 and 24 months after EVAR. CT will be conducted at baseline, at 1 month after EVAR and at 12 and 24 months after EVAR patients. Quality of life and depression questionnaires will be performed at baseline, at 1 month, at 12 and 24 months of follow-up after EVAR.
2380823|NCT03703947||Cross-sectional group (after EVAR)|A cross-sectional study will be performed in 200 patients treated for AAA with EVAR in the past years. In these patients, clinical data collection, blood sampling, ultrasound and CT will be performed at their next regular outpatient clinic visit.
2380824|NCT03703934||Psoriatic Arthritis|Patients with painful psoriatic arthritis
2380825|NCT03703934||Hand Osteoarthritis|Patients with painful nodal non-erosive hand osteoarthritis
2380826|NCT03703934||Healthy Controls|Patients without a painful condition
2380827|NCT03703908|Experimental|Sequential|All enrolled subjects will initially be treated with the active study medication CCX140-B at a dose of 5 mg twice daily. Dose will increase in a step-wise fashion up to 15 mg twice daily.
2380828|NCT03703895|Active Comparator|Active Comparator|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule. Subjects will complete up to 4 study visits where Topical AFX5931 will be applied twice daily for 28 days.
2380829|NCT03703895|Placebo Comparator|Placebo Comparator|Placebo Comparator, Topical Placebo. Subjects will complete up to 4 study visits where Topical Placebo will be applied twice daily for 28 days.
2380830|NCT03703882|Experimental|Dose 1|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day.
2380831|NCT03703882|Placebo Comparator|Placebo|Matching placebo
2380832|NCT03703869||Insulin glargine (U300)|Insulin glargine (U300) dosage and dosing time as per local product labeling
2380833|NCT03703856|Active Comparator|Memantine|
2380834|NCT03703856|Placebo Comparator|Placebo|
2380835|NCT03703843|Experimental|Active|ARTUS MONO
2380836|NCT03703830|Experimental|Experimental|Cerebellar transcranial current stimulation associated with locomotor training
2380837|NCT03703830|Sham Comparator|Sham comparator|Cerebellar transcranial current stimulation sham associated with locomotor training
3183184|NCT00711438|Experimental|FT|Breathlessness Intervention Service (BIS)
3183185|NCT00711438|Active Comparator|WL|Best supportive care
3183186|NCT00711451|Active Comparator|manual|Manual removal of placenta
3183187|NCT00711451|Active Comparator|expressed|expressed placental removal
2380846|NCT03703765|Experimental|Lower limb volume estimation|"Patients referred for a preoperative venous assessment as part of an indication for interventional management, whether by conventional or endovascular surgery, of a chronic venous pathology.~Intervention is measurement of lower limb volume with scanner 3D system before and after surgery or vascular intervention."
2380847|NCT03703752||Adhesive IH|Adhesive IH can further be divided into primary or secondary groups according to the history of abdominal and(or) pelvic surgery
2380848|NCT03703752||non-adhesive IH|Non-adhesive IH means the IH resulting from the abnormality of peritoneal structure.
2380849|NCT03703739|Active Comparator|Reference meal 1|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
2380850|NCT03703739|Active Comparator|Reference 2|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulfate was added Prior to give to participants. Rice meal consumed with bean sauce.
2380851|NCT03703739|Experimental|Test meal A|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice cofortified with zinc oxide and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
2380852|NCT03703739|Experimental|Test meal B|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate and ethylenediaminetetraacetic acid (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
2380853|NCT03703739|Experimental|Test meal C|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
2380854|NCT03703739|Experimental|Test meal D|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfafe and sodium pyrophosphate (mixing ratio 100:1), Rice meal consumed with mixed vegetable Sauce.
2380855|NCT03703739|Experimental|Test meal E|Commercial Rice (Jasmin Rice) was mixed with iron fortified extuded rice co-fortified with zinc sulfate, citric acid and trisodium citrate (mixing ratio 100:1), Rice meal consumed with bean Sauce.
2380856|NCT03703726|Active Comparator|Reference meal|50 g of Commercial Rice was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
2380857|NCT03703726|Experimental|Test meal A|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
3183188|NCT00711503|Placebo Comparator|2|The patients are instructed to administer placebo by subcutaneous injection
3183189|NCT00711503|Experimental|1|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
2380860|NCT03703726|Experimental|Test meal D|Commercial Rice was mixed with cold-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
2380861|NCT03703726|Active Comparator|Test meal E|Commercial Rice was mixed with warm-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
2380862|NCT03703726|Active Comparator|Test meal F|Commercial Rice was mixed with hot-extruded fortified Rice (mixing Ratio: 100:1) Rice meal consumed with mixed vegetable Sauce.
2380863|NCT03703713||Hyponatremia|Patients treated for hyponatremia (<125 mmol/L Sodium) in the intensive care department.
2380864|NCT03703700|Experimental|Zishen Yutai pill group|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
2380865|NCT03703700|Placebo Comparator|Placebo group|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
2380866|NCT03703687|Experimental|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
2380867|NCT03703674|Active Comparator|Standard Medical Therapy|Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
2380868|NCT03703674|Experimental|G-CSF + Standard Medical Therapy|"Drug: standard medical therapy Standard medical therapy involves primary treatment and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.~Drug: G-CSF G-CSF- 5 μg/Kg s.c every 12 hours for 5 consecutive days"
2380869|NCT03703661|Other|Control|primary closure with gauze and adhesive/occlusive dressing
2380870|NCT03703661|Experimental|Negative Pressure|primary closure with gauze and adhesive/occlusive dressing under negative pressure
2380871|NCT03703635|Experimental|Intracranial Angioplasty|Intracranial balloon angioplasty and aggressive medical care.
2380872|NCT03703635|No Intervention|Aggressive Medical Care|Aggressive medical care alone.
2380873|NCT03703622|Experimental|Video-debriefing with standard HBB training|Health workers are given standard HBB training according to American Association of Pediatrics (AAP) plus video-debriefing. Filming of the simulated case scenarios will be done and after which the films will be used for debriefing or feedback. Participants will be encouraged to give feedback with the guidance of master trainer and the PI. Teams of three participants(birth attendant, mother and helper) will perform the HBB simulation or scenarios. After each scenario, debriefing is done until all participants have had the opportunity to participate in the simulation exercise. All the participants in this arm will undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick newborn baby who needs resuscitation care. Pre and post-tests will be done to assess performance of all participants.
2380874|NCT03703622|Active Comparator|Standard HBB training only|Health workers are given standard HBB training according to AAP without video-debriefing. All the participants in this arm, like in intervention arm, will also undergo HBB practical sessions such as bag mask ventilation skills sessions, care of the health new-born and sick new-born baby who needs resuscitation care only. Pre-and post-tests will be done to assess performance of all participants.
2380875|NCT03703609|Experimental|Tele-yoga|Intervention of doing medical yoga at home (tele-yoga) using (1) an online videoconference system (zoom) for particpating in group-yogaled by a live yoga instructor for 60 minutes twice a week and (2) daily individual yoga for a minimum of 10 minutes using a yoga-app. Participants are provided with a tablet with conference system zoom and yoga app for 12 weeks
2380876|NCT03703609|No Intervention|Individual physical activty advice|The active control group will receive advice to be physically active that corresponds to the intervention group in time and effort, equivalent to 60 minutes for 2 days a week and a minimum of 10 minutes for 5 days a week. To compensate for the extra attention received by the intervention group by the instructor via tele-yoga group, the participants in the activecontrol group's patients will be dialed or have SMS contact (the participant chooses a type of contact) with a physiotherapist or nurse after 2, 4, 8 and 12 weeks.
2380877|NCT03703596|Experimental|Anlotinib hydrochloric|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
2380878|NCT03703596|Experimental|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
2380879|NCT03703583||Exclusively/predominantly Breastfeeding group|
2380880|NCT03703583||Exclusively/predominantly Formula feeding group|
2380881|NCT03703570|Experimental|KW-6356 Low Dose|Oral administration
2380882|NCT03703570|Experimental|KW-6356 High Dose|Oral administration
2380883|NCT03703570|Placebo Comparator|placebo|Oral administration
2380884|NCT03703557|Experimental|Sorbstar®|Odour sampling: Rub hands with Sorbstar® before and post-surgery
2380885|NCT03703557|Experimental|Dog detection|Odour sampling: Sleep over a night with a compress on the affected breast before and after surgery
2380886|NCT03703544|Experimental|High glycemic index|Subjects will consume locally consumed meals which are high glycemic index for breakfast, lunch snack and dinner will be provided.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
2380887|NCT03703544|Experimental|Low glycemic index|Subjects will consume locally consumed meals which are low glycemic index for breakfast, lunch snack and dinner will be provided. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
2380888|NCT03703531||Patients resuscitated in Istria county|Cardiopulmonary resuscitation performed for OHCA
2380889|NCT03703518|Experimental|Mixed reality|"Mixed reality exercise program using the Microsoft Hololens Roboraid game. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
2380890|NCT03703518|Active Comparator|Conventional exercise group|Conventional exercise program in cervical region based in deep neck flexors and deep neck extensors, isometric contraction during 6-8 seconds. This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions.
2380891|NCT03703505|Experimental|AG-348|On Day 1, participants fasting for at least 10 hours the night before will receive oral AG-348 followed by intravenous (IV) [13C6]AG-348, 1 hour post-oral dose.
3142562|NCT00002762||Patient interviewing + blood sampling|"Patients were interviewed at the time of the primary cancer surgery to determine the menstrual history. Blood sampling occurred within 1 day of surgery, and serum samples were shipped frozen to a central laboratory (Mayo Medical Laboratory, Rochester, MN) for E2, Pg, and LH determinations. Serum hormone levels, menstrual cycle length, and day of last menses were used to determine the menstrual phase at which surgery occurred.~Patients were observed every 6 months for the first year postregistration and annually for the next 2 to 10 years postregistration for adjuvant therapy information, disease recurrence, and death."
2380893|NCT03703479|Experimental|A-PRF group|Socket site that will receive A-PRF clot
2380894|NCT03703479|No Intervention|control|socket site that will not receive any intervention
2380898|NCT03703453|Experimental|REBOA|Patients undergoing REBOA for medical cardiac arrest
3142563|NCT00002768|Experimental|Autologous stem cell transplantation|Patients receive consolidation chemotherapy followed by autologous stem cell transplantation
3142564|NCT00002772|Experimental|High dose chemo|sequential high dose chemotherapy with doxorubicin, paclitaxel and cyclophosphamide with filgrastim support
2380901|NCT03703427|Experimental|Capecitabine|
2380902|NCT03703427|Experimental|Vinorelbine|
2380903|NCT03703414||Control|Healthy controls
2380904|NCT03703414||ECT|MDD patients receiving ECT treatment
2380905|NCT03703414||SSRI|MDD patients receiving SSRI treatment
2380906|NCT03703401||Women with recurrent miscarriage and no hydrosalpinx|
2380907|NCT03703401||Women with recurrent miscarriage and concurrent hydrosalpinx|
2380908|NCT03703401||Women with recurrent miscarriage and treated hydrosalpinx|
2380909|NCT03703388|Experimental|Arctigenin 250mg|Arctigenin 250mg will be administered for 28 days.
2380910|NCT03703388|Experimental|Arctigenin 400mg|Arctigenin 400mg will be administered for 28 days.
2380911|NCT03703388|Experimental|Arctigenin 500mg|Arctigenin 500mg will be administered for 28 days.
2380912|NCT03703375|Experimental|Administration of Oral Azacitidine (CC-486)|Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
2380913|NCT03703375|Active Comparator|Investigator's choice therapy - Romidepsin|Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
2380914|NCT03703375|Active Comparator|Investigator's choice therapy - Gemcitabine|Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
2380915|NCT03703362|Experimental|Progressive resistance training|Progressive resistance training tested in patients with external snapping hip
2380916|NCT03703349|Experimental|Preoperative oral Magnesium|Magnesium sulfate 8 tablets (8 x 0.4 g) per day, PO, for the 3 days preceding the surgical intervention
2380917|NCT03703349|Placebo Comparator|Control|Placebo oral tablet, for Magnesium Sulfate tablets, PO, for the 3 days preceding the surgical intervention
3142565|NCT00002772|Experimental|chemo with autologous stem cell support|conventional chemotherapy with doxorubicin and cyclophosphamide followed by autologous stem cell support
2380921|NCT03703310|Experimental|Patidegib Topical Gel, 2%,|Participants will be randomized to receive Patidegib Topical Gel, 2%. The Patidegib Topical Gel, 2% will be dispensed to participants at each study visit and applied topically twice daily to the face.
2380922|NCT03703310|Placebo Comparator|Patidegib Topical Gel, Vehicle|Participants will be randomized to receive Vehicle. The Patidegib Topical Gel, Vehicle will be dispensed to participants at each study visit and applied topically twice daily to the face.
3142566|NCT00002774|Experimental|Tirapazamine + cisplatin + 5-FU|2 cycles of induction chemotherapy (tirapazamine, cisplatin, and 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (tirapazamine, cisplatin, and 5-FU)
3142567|NCT00002774|Active Comparator|Cisplatin + 5-FU|2 cycles of induction chemotherapy (cisplatin + 5-fluorouracil [5-FU]) followed by simultaneous chemoradiotherapy (cisplatin + 5-FU)
3150778|NCT00209898|Active Comparator|Ordinary standard of care|Subject put on ordinary waiting list for hcv treatment in Our outpatient clinic
3150779|NCT00210132|Experimental|Ropivacaine|
3150780|NCT00210275|No Intervention|Control|Usual practice; no additional information provided.
2380926|NCT03703284||LHI Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients who developed cerebral hernia in 5 days post-stroke
2380927|NCT03703284||LHI Non-Hernia|Acute (<=48h) large hemispheric infarction (LHI) patients without cerebral hernia in 5 days post-stroke
2380928|NCT03703284||Healthy control|Healthy individuals
2380929|NCT03703271|Active Comparator|chemotherapy|Methotrexate 0.4mg/kg·d, im ,*5d started at the first day of cycle, two weeks a cycle
2380930|NCT03703271|Experimental|study group|hysteroscopic repeat curettage
2380931|NCT03703258|Experimental|Intervention|"The THRIVE app involves 3 weeks of daily activities. Day 1 involves identification of activities to add to a self-care activity list with guidance around selecting activities that increase social contact, reduce alcohol use, and reduce avoidance. They will also complete an active-learning exercise about cognitive distortions and create a stuck point to-do list consisting of their cognitive distortions. In subsequent days, participants will be prompted to complete activities from both lists. They will also have access optional activities on topics such as asking for help, preventing isolation, deciding whether to disclose an assault, coping with negative reactions to disclosure, and thinking in helpful ways about social support. They will be prompted to complete brief daily surveys in the app, which will populate a symptom tracker. Participants in will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use."
2380932|NCT03703258|No Intervention|Assessment-only control|The assessment-only control condition will involve access to a version of the app that includes daily surveys and a symptom tracker populated by these surveys, but without any of the other exercises included in the experimental version of the app. Participants in the control condition will have brief weekly phone contact with a coach to monitor safety and troubleshoot issues with app use.
2380933|NCT03703245||Experimental Dentifrice|Participants were advised to brush their teeth twice daily with a full strip of experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies covering the entire head of the toothbrush for 1 minute.
2380934|NCT03703245||Control Dentifrice|Participants were advised to brush their teeth with control dentifrice containing 0% w/w sodium bicarbonate covering the entire head of the toothbrush for 1 minute.
2380935|NCT03703232|Other|Lower extremity amputees|Community walking trial comparing usual prosthetic foot with investigational prosthetic foot.
2380936|NCT03703219||Mother Touch Program|Forty days of rest period of the mother after delivery, Full body massage, diet and belly binding methods were administered by trained carer.
2380937|NCT03703219||Usual care Program|comparison cohort were followed in usual care under the supervision of health professionals.
2380938|NCT03703206|Experimental|ACB + iPACK|Patients scheduled for TKA will be randomized to receive an adductor canal block with an additional ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK).
2380939|NCT03703206|No Intervention|ACB w/o iPACK|Patients enrolled in this arm will receive the standard of care adductor canal block (ACB) prior to their total knee arthoplasty.
2380940|NCT03703193|Experimental|Dry needling|The experimental group will receive a single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
2380941|NCT03703193|Active Comparator|Physical Therapy|This group will receive a single session of modulatory interventions targeting modulation of central nervous system.
2380942|NCT03703180||MS|representative cohort of relapsing-remitting MS (n=50) and progressive MS patients (n=50) over the typical age range of 18-65. During two years of follow-up the integrity and function of the visual system will be observed annually with optical coherence tomography, high and low contrast visual acuity and a vision related quality of life questionnaire.
2380943|NCT03703180||Controls|Age and Gender matched healthy controls (n=100) will undergo the same assessments as the MS cohort to build up a representative normative dataset.
2380944|NCT03703167|Experimental|ibrutinib in combination with rituximab and lenalidomide|Ibrutinib will be given day 1-28; Lenalidomide will be given day 1-21; Rituximab will be given on day 1. Rituximab is given for 6 cycles; Lenalidomide is given for 12 cycles; Ibrutinib is continued until disease progression, intolerable toxicity or death.
2380945|NCT03703154||Study Arm|The patients in the study arm will be converted from immediate release Tacrolimus to Envarsus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
2380946|NCT03703154||Control Arm|Patients in the control arm will remain on the immediate release Tacrolimus. After obtaining informed consent, participants will undergo baseline tests for cognitive function and cerebral blood flow. After 12 weeks, cognition and brain blood flow will be assesses again in all enrolled patients.
2380947|NCT03703141|Experimental|Sucralose 48 mg|Sucralose 48 mg in 60 ml of water O.D. for ten weeks
2380948|NCT03703141|Experimental|Sucralose 96 mg|sucralose 96 mg in 60 ml of water O.D. for ten weeks
2380949|NCT03703141|Placebo Comparator|Placebo|60 ml of water as placebo O.D. for ten weeks
2380952|NCT03703115|Active Comparator|Fasting|"Patients will have periodic fasting for 4 weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet with 2-3 litres of water and non calorie fluids allover the day."
2380953|NCT03703115|No Intervention|Nonfasting|Patients will have usual balanced diet as 3 meals and 2 snacks all over the day. Both groups should take adequate water and non calorie beverages intake daily ( 2-3 liters daily)
2380955|NCT03703102|Experimental|Arm B|Subcutaneous administration of KHK4083 (dose level 1, dosing regimen 2)
2380956|NCT03703102|Experimental|Arm C|Subcutaneous administration of KHK4083 (dose level 2, dosing regimen 1)
2380957|NCT03703102|Experimental|Arm D|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 1)
2380958|NCT03703102|Experimental|Arm E|Subcutaneous administration of KHK4083 (dose level 3, dosing regimen 2)
2380959|NCT03703089|Experimental|Gemcitabine and Nab-Paclitaxel|Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle.
2380960|NCT03703063|Experimental|Resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
2380961|NCT03703063|Experimental|Borderline resectable patients|Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucovorin 400 mg/m^2 followed by 5FU 2400 mg/m^2 on days 1, 15 of the 28 day cycle.
2380962|NCT03703050|Experimental|Cohort 1|Population: relapsed/refractory ALK+ ALCL with progressive disease after treatment (including chemotherapy and ALK inhibitor and/or brentuximab vedotin).
2380963|NCT03703050|Experimental|Cohort 2|Population: patients with a relapsed/refractory ALCL, having achieved CR with a treatment including ALK-inhibitor or Brentuximab vedotin of at least 2 months and for whom HSCT is considered for their consolidation therapy. In this case, nivolumab would be considered as consolidative immunotherapy instead as HSCT.
2380964|NCT03703037||Cohort|"This will be a nested case-control study. Women with low risk pregnancies at or beyond 41 weeks, who will be referred to our Maternal-fetal unit and admitted 1 to 2 days prior to induction of labour according institutional protocol will constitute the cohort.~Then women with intrapartum abnormal fetal heart rate tracings (cases) will be identified and match with controls. The primary outcome will be to obtain odds ratios for the Doppler ultrasound parameters (middle cerebral artery pulsatility index, mean uterine artery pulsatility index and Middle cerebral artery pulsatility index to mean uterine artery pulsatility index ratio) and Ultrasound assessment of amniotic fluid index that would be associated with intrapartum category III fetal heart rate tracing."
2380965|NCT03703037||Cases|"Cases will be patients with abnormal intrapartum cardiotocogram (category III fetal heart rate tracing).~Intervention: Ultrasound and Doppler ultrasound"
2380966|NCT03703037||Controls|"Those will be patients with normal intrapartum cardiotocogram (category I fetal heart rate tracing) or category II that converted into category I after intrauterine resuscitation methods.~Intervention: Ultrasound and Doppler ultrasound"
2380967|NCT03703024|Placebo Comparator|Placebo|Maltodextrin
2380968|NCT03703024|Active Comparator|Low dose|200mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
2380969|NCT03703024|Active Comparator|High dose|400mg raspberry leaf extract. One capsule to be taken every morning over a 12-13 week period. Subjects will be instructed to take 1 capsule every morning with their breakfast.
2380970|NCT03703011|Experimental|Interventional|Subjects aged >70 years, hospitalized in the rehabilitation geriatric ward in the Paul Brousse hospital, France, able to walk 10 meters, ready to be discharged, and a Mini mental state examination ≥ 20/30
2380971|NCT03702998||HIV-infected individuals +/- HBV/ HCV|"1 All HIV-infected individuals followed up in all public HIV clinics with and without HBV and/or HCV co-infection will be included in the analysis.~1.1 Inclusion criteria for HIV-infected individuals with and without HBV or HCV co-infection: 1.1.1 Positive HIV antibody 1.1.2 At least one visit in one of the HIV clinics 1.1.3 Subjects with positive HBsAg and/or anti-HBc will be regarded as having HBV co-infection 1.1.4 Subjects with positive HCV antibody will be regarded as having HCV co-infection"
2380972|NCT03702998||HBV/HCV mono-infected individuals|"2 All HBV and/or HCV-infected individuals followed up in public hospitals will be identified from the Hospital Authority electronic database.~2.1 Inclusion criteria for HBV/HCV mono-infected individuals 2.1.1 Documented diagnosis of hepatitis B or hepatitis C infection, or 2.1.2 Positive HBsAg and/or anti-HBc, or 2.1.3 Positive HCV antibody, and 2.1.4 Negative HIV antibody result, or no record of HIV diagnosis or anti-retroviral therapy prescription"
2380973|NCT03702985|Active Comparator|Capecitabine and Irinotecan without Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
2380974|NCT03702985|Experimental|Capecitabine and Irinotecan with Amifostine|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7) Amifostine: 400mg/m2 per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT Adjuvant Chemotherapy: depends on patients pathological review."
2380975|NCT03702959||Betamethasone group 1|Betamethasone Group 1 (5am-11am)
2380976|NCT03702959||Betamethasone Group 2|Betamethasone Group 2 (11am-5pm)
2380977|NCT03702959||Betamethasone Group 3|Betamethasone Group 3 (5pm-11pm)
2380978|NCT03702959||Betamethasone Group 4|Betamethasone Group 4 (11pm-5am).
2380979|NCT03702946|Experimental|study group|
2380980|NCT03702946|No Intervention|control group|
2380981|NCT03702933||Placebo|starch
2380982|NCT03702933||High Dose|3.5 g/d D-serine adjuvant treatment
2380983|NCT03702933||Low Dose|2.1 g/d D-serine adjuvant treatment
2380984|NCT03702920|Experimental|SMT+ PE-A 5%|PE-A 5% will be performed using 5% albumin (Albutein 5%) as the main replacement fluid administered intravenously.
2380985|NCT03702920|Active Comparator|Standard Medical Treatment (SMT)|Standard medical treatment (SMT) will be administered according to institution standards.
2380986|NCT03702907||Normal Cognition|No diagnosis of a cognitive disorder
2381126|NCT03701867|Experimental|Metabolic Flexibility Tests Group|
2429336|NCT03371758|Experimental|healthy controls|
2380987|NCT03702907||Cognitive Disorder|Diagnosed with a cognitive disorder such as :Mild Cognitive Impairment, Alzheimer's disease, Frontotemporal Dementia, Lewy Body Dementia, Vascular Dementia, or other neurodegenerative condition.
2380988|NCT03702894|Experimental|Clavamox,Coated Tablets, 875 mg + 125 mg|Clavamox, Film-coated Tablets, 875 mg + 125 mg, is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2380989|NCT03702894|Active Comparator|Augmentin®, Coated Tablets, 875 mg + 125 mg|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) were given a single tablet (containing 875 mg mg of amoxicillin and 125 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2380990|NCT03702881|Experimental|Bonded Spurs associated with posterior build-ups Group|The experimental group will consist of 25 patients treated with bonded spurs associated with build-ups.
2380991|NCT03702881|Active Comparator|Conventional bonded spurs Group|Active comparator group will consist of 25 patients treated with conventional bonded spurs
2380992|NCT03702855|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
2380993|NCT03702855|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
3142568|NCT00002779|Experimental|fludarabine + octreotide|Patients receive fludarabine IV over 10-30 minutes on days 1-5. Patients not currently receiving octreotide, receive a test dose of octreotide subcutaneously on day 1 during course 1 only and then receive octreotide intramuscularly monthly on day 1. Treatment repeats every 28 days for 4-6 courses. Patients then receive octreotide alone for 6-8 courses. Some patients may then receive another 12 courses of octreotide alone, for a total of 2 years of treatment. Patients are followed every 3 months for 5 years or until disease progression.
3142569|NCT00002784|Active Comparator|Standard chemotherapy|EC/AC x 4 followed by CMF x 3 and tamoxifen to 5 years after randomization.
3142570|NCT00002784|Experimental|Dose-intensive EC|High-dose EC x 3 supported by peripheral blood progenitor cells and tamoxifen to 5 years after randomization.
2380997|NCT03702829|Experimental|Experimental Drug|Inotersen, a transthyretin (TTR) antisense oligonucleotide. Administered subcutaneously weekly. Each dose shall contain 300 mg of active drug. Subsequent visits will occur at 3, 6, 12, 18 and 24 months. Every 2 weeks, blood will be monitored for renal function and platelet count and urine will be tested by dipstick for proteinuria.
2380998|NCT03702816|Experimental|Alzheimer's Disease|"Alzheimer's Disease (N=20)~GE180 PET Scan"
2380999|NCT03702816|Experimental|Parkinson's Disease|"Parkinson's Disease (N=20; 10 with PD-MCI, 10 PD with no cognitive impairment)~GE180 PET Scan"
2381000|NCT03702816|Experimental|Control|"Control Group (N=10)~GE180 PET Scan"
2381001|NCT03702816|Experimental|Mild Cognitive Impairment|"Mild Cognitive Impairment (N=20; 10 florbetapir positive, 10 florbetapir negative)~GE180 PET Scan"
2381002|NCT03702803|Experimental|Galphimia glauca standardized extract|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the experimental group and will be assigned the treatment consisting of hard gelatin capsules with a pharmaceutical formulation prepared with a standardized extract from G. glauca, which will be administered once a day.
2381003|NCT03702803|Active Comparator|alprazolam 1mg|Patients with a clinical diagnosis of GAD (with a score of 18 points or more on the Hamilton anxiety scale) that will be included in the control group and will be assigned the treatment consisting of hard gelatin capsules with the drug Alprazolam (1 mg ), which will be administered once a day.
2381004|NCT03702790||Back pain SPECT evaluation|Patients with poorly localized back pain being imaged for clinical decision making
2381005|NCT03702777|Experimental|ASP8302 100mg|Participants will receive ASP8302 100mg capsules orally once daily for up to 4 weeks.
2381006|NCT03702777|Placebo Comparator|Placebo|Participants will receive ASP8302 matching placebo orally once daily for up to 4 weeks.
2381007|NCT03702764||VP-SG 01|Study subjects that present concentric coronary plaques
2381008|NCT03702764||VP-SG 02|Study subjects that present eccentric coronary plaques
2381011|NCT03702738|Experimental|NAC|Patients will be randomized to receive standard TB treatment with N-acetylcysteine 1200 mg BID x 4 months, followed by 2 months of standard TB treatment alone
2381012|NCT03702738|No Intervention|No NAC|Patients will be randomized to receive 6 months standard TB treatment alone
2381013|NCT03702725|Experimental|Dose Escalation|"Dose escalation will consist of three different drug levels of Ibrutinib, Lenalidomide, and Dexamethasone.~Dose Escalation (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
2381014|NCT03702725|Experimental|Dose Expansion|"Dosage of the combination will depend on the determine of maximum tolerated dose learned from the Dose Escalation phase.~Dose Expansion (Ibrutinib, Lenalidomide, Dexamethasone Combination)"
2381015|NCT03702712|Active Comparator|Aerobic Exercise Only|Participants in the Aerobic Exercise Only arm will engage in three separate 20-minute sessions comprised of a 5-minute, resistance-free warm-up, and 15 minutes of moderate stationary aerobic cycling on a Cybex bike #525C (50-70% age-predicted heart rate max). Each session will be followed by 20 minutes of uninterrupted quiet rest. The bike will provide feedback including speed, rotations per minute, and time.
2381473|NCT03699449|Experimental|durvalumab + olaparib|durvalumab + olaparib combination therapy
3142571|NCT00002787|Experimental|Treatment (vaccine therapy)|Patients receive autologous immunoglobulin idiotype-KLH conjugate vaccine combined with sargramostim SC in weeks 0, 2, 6, and 10 and sargramostim SC QD for three days following each vaccine injection. Some patients also receive aldesleukin SC daily from weeks 2-14.
3150781|NCT00210275|Experimental|Printed Educational Message #1|Information about Angiotensin-converting enzyme inhibitors, hypertension treatment, and cholesterol lowering agents for diabetes
3150782|NCT00210275|Experimental|Printed Educational Message #2|Retinal screening for diabetes
3150783|NCT00210275|Experimental|Printed Educational Message #3|Diuretics for hypertension
2381016|NCT03702712|Active Comparator|Relaxation Only|Participants in the Relaxation Only arm will complete three separate 20-minute sessions of relaxation using a commercial wearable neurofeedback (headband) device. The device's accompanying software (connected to the headband through Bluetooth) encourages breathing strategies in response to recorded brain wave activity. Real time auditory feedback includes sounds of calm (soft) or loud winds in response to detected brain activity. A visual report of affective states and the user's brain activity is given (alpha and beta waves). Participants will also be asked to take part in 20 minutes of uninterrupted quiet rest in order to match the time of the aerobic only condition.
2381017|NCT03702712|Experimental|Aerobic Exercise and Relaxation|Participants in the Aerobic Exercise and Relaxation arm will complete the three separate 20-minute aerobic exercise sessions (identical to the aerobic exercise only condition) followed by the same 20-minute neurofeedback-guided mindfulness training (identical to the relaxation only condition).
2381018|NCT03702699||KOA group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
2381019|NCT03702699||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
2381020|NCT03702686|Experimental|FEEDBACK system|Mother / infant dyad will use the FEEDBACK system during a breastfeeding session.
2381021|NCT03702673|Experimental|Treatment A|K-877 CR Tablet A
2381022|NCT03702673|Experimental|Treatment B|K-877 CR Tablet B
2381023|NCT03702673|Experimental|Treatment C|K-877 CR Tablet E
2381024|NCT03702673|Experimental|Treatment D|K-877 IR Tablet
2381025|NCT03702660|Experimental|GIP(3-30)NH2|GIP receptor antagonist
2381026|NCT03702660|Placebo Comparator|Placebo|Placebo (saline infusions)
2381027|NCT03702660|Active Comparator|GLP-1|
2381028|NCT03702660|Experimental|GLP-1 + GIP(3-30)NH2|
2381029|NCT03702647|Experimental|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
2381030|NCT03702647|Placebo Comparator|Normal Saline|30mL of normal saline placed in the POEM tunnel
2381031|NCT03702634|No Intervention|Control (Usual Care)|Surrogate will receive usual care in the hospital, which could include visits from the unit chaplain or other staff from the spiritual care department.
2381032|NCT03702634|Experimental|Intervention|Spiritual Care Assessment and Intervention (SCAI) framework
2381033|NCT03702621|Active Comparator|Liposomal Bupivacaine|"LB (Liposomal Bupivacaine) group - This group will be receiving 20ml EXPAREL (266mg) and 40ml of 0.125% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
2381034|NCT03702621|Active Comparator|Standard Bupivacaine|"SB (Standard Bupivacaine) group - This group will be receiving 60ml of 0.25% bupivacaine in total, 30ml on each side.~For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane."
2381036|NCT03702595|Experimental|Interventional group|Hip flexors stretching protocol
2381037|NCT03702582|Experimental|Rivaroxaban|"Rivaroxaban: Direct inhibitor of Factor Xa, an enzyme that stimulates the formation of thrombin from prothrombin (A critical step in both the intrinsic and extrinsic aspects of the coagulation cascade)~Dosage form: Per Os (Oral)~Dosage and Frequency: 20 mg every evening with the evening meal (No titration requirements). For patients with decreased glomerular filtration rate (GFR between 15 ml/min and 50 ml/min), dosing will be decreased to 15 mg every evening with the evening meal.~Duration: 30 days (Possibility of continuation after post-operative cardiology clinic visit)"
2381038|NCT03702582|Active Comparator|Warfarin|"Warfarin: Competitive inhibitor of vitamin K epoxide reductase complex 1, an important enzyme in the activation pathway for vitamin K dependent coagulation factors~Dosage form: Per Os (Oral)~Dosage and Frequency: Initial dose of 2 - 5 mg nightly after the evening meal (QHS) with appropriate titration to goal INR 2.0 - 3.0 (Initial dose based on weight, age, gender, co-morbidities and concurrent medications). INR will be checked daily to weekly depending on stability of dosing and medication regimen.~Duration: 30 days (Possibility of continuation after post-operative Cardiology clinic visit)"
3150784|NCT00210314|Active Comparator|High-dose methotrexate alone|
2381040|NCT03702556|Active Comparator|Mastectomy without breast reconstruction|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2381041|NCT03702556|Active Comparator|Breast reconstruction with nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2381042|NCT03702556|Active Comparator|Breast reconstruction without nerve|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2381043|NCT03702530|Experimental|Intervention|3x 50 L3 larvae immunisation with albendazole treatment and 2x 50 L3 larvae infection
2381044|NCT03702530|Placebo Comparator|Placebo|3x placebo immunisation with albendazole treatment and 2x 50 L3 larvae infection
2381045|NCT03702517|Experimental|lateral stair walking exercise|The experimental group received 15 minutes of lateral stair walking exercise
2381046|NCT03702517|Active Comparator|traditional physiotherapy|strengthening exercise, balance training and gait training
2381047|NCT03702491|Experimental|Apatinib with SOX(Tegafur,Oxaliplatin)|Patients 3-4 weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
2381048|NCT03702491|Active Comparator|SOX( Tegafur,Oxaliplatin)|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
2381049|NCT03702478||No intervention, cross-sectional study|Questionnaire, cross-sectional study
2381181|NCT03701516|Experimental|CONTROL/TEST|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Control/Test sequence.
3142572|NCT00002796|Experimental|Treatment (fluorouracil, phenylbutyrate, indomethacin, IFN-G|"Phase I: Patients receive 5-FU IV over 24 hours on day 1; phenylbutyrate IV over 120 hours and oral indomethacin daily on days 2-6; and interferon gamma subcutaneously on days 2, 4, and 6. Courses repeat weekly in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which less than 2 of 6 patients experience dose-limiting toxicity (DLT).~Phase II: Patients receive 5-FU, phenylbutyrate, indomethacin, and interferon gamma as in phase I at the MTD."
3142573|NCT00002798|Experimental|Arm I (combination chemotherapy)|"Patients receive treatment as in induction therapy, plus G-CSF SC beginning on day 16 and continuing until blood counts recover. If CSF is clear by day 10 of induction, patients receive cytarabine IT on days 0, 10, and 35. If CSF is not clear, patients receive triple intrathecal therapy (TIT; cytarabine, hydrocortisone, methotrexate) on days 0 and 10.~See Detailed Description"
3142574|NCT00002798|Experimental|Arm II (combination chemotherapy)|"Patients receive fludarabine IV over 24 hours on days 0 and 1, cytarabine IV over 72 hours on days 2-4, and idarubicin IV over 15 minutes on days 0-2. G-CSF begins on day 6 and continues until blood counts recover. Patients also receive TIT on days -1 and 7, if CSF is not clear on day 10 of induction. Patients on both arms are reassessed on day 35. Those patients with M1 marrow proceed to intensification; all others are removed from the study.~Intensification: See Detailed Description"
2381053|NCT03702452|Experimental|Experimental group|Patients in experimental group were graded with modified Barthel index score, and according to the functional score of patients, the corresponding rehabilitation method was selected for functional rehabilitation from functional rehabilitation nursing program,twice a day with 30 min each time, last 1 week.
2381054|NCT03702452|Experimental|control group|Patients in control group were given conventional bedside rehabilitation ,twice a day with 30 min each time, last 1 week.
2381055|NCT03702426|Experimental|Norfloxacin with GM-CSF|Oral Norfloxacin 400mg daily and GM-CSF (Granulocyte-Macrophage colony-stimulating factor) in a dose of 1.5mcg/kg over 4 hour infusion every 15 days will be given in Group B
2381056|NCT03702426|Active Comparator|Norfloxacin|Patients who fulfil the inclusion criteria will receive oral norfloxacin 400 mg daily as secondary prophylaxis for SBP in Group A.
2381059|NCT03702400|Active Comparator|Phenylephrine 100 mcg|Phenylephrine will be used at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug to be used whenever systolic blood pressure falls below 10% of baseline.
2381060|NCT03702400|Experimental|Norepinephrine 5 mcg|Norepinephrine will be used at a dose of 5 mcg at a dilution containing 1 mcg / mL to be used whenever systolic blood pressure falls below 10% of baseline.
2381061|NCT03702387|No Intervention|Control Group|Patients in this group will have standard intravenous regional anesthesia (IVRA) performed before the start of their surgery.
2381062|NCT03702387|Experimental|Esmarch Reapplication Group|Patients in this group will have all the standard intravenous regional anesthesia (IVRA) procedures performed before the start of their surgery with one exception: After standard intravenous regional anesthesia (IVRA) is performed, The elastic Esmarch bandage will be reapplied again on the same arm then will be released. then the surgery will be initiated. the only difference between groups is that the Esmarch reapplied group will be applied the esmach two times. First time, at the standard standard intravenous regional anesthesia (IVRA) before the lidocaine injection and second time, after the injection is completed.
2381063|NCT03702374|Experimental|Combined Antioxidant Therapy group|This arm will be administered with the combined antioxidant therapy, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
2381064|NCT03702374|Placebo Comparator|Placebo group|This arm will be administered with placebo, and will consist of 30 patients with moderate non-proliferative diabetic retinopathy (NPDR), 30 subjects with severe NPDR and 30 patients with Proliferative diabetic retinopathy.
2381065|NCT03702361|Experimental|Rapid infusion of Vpriv|Rapid intravenous infusion of velaglucerase alfa (VPRIV) in treatment-naive patients with type 1 Gaucher disease
2381066|NCT03702348|Experimental|Resistance exercise group|Progressive resistance exercise protocol with elastic resistance to strengthen the muscle groups that stabilize the main joints affected by Chikungunya Fever. The sessions will be 2 times a week for 12 weeks.
2381067|NCT03702348|No Intervention|Control group|No intervention during the 12 weeks, being contacted through telephone calls. After the reevaluation at the end of the 12 weeks, this group will perform the same protocol as the experimental group
2381068|NCT03702335|Experimental|Dietary Counselling|Each subject will receive a comprehensive dietary counselling for the first 12-weeks of the study, which will be followed by another 12-weeks without dietary counselling.
2381069|NCT03702335|No Intervention|No Dietary Counselling|Subjects in the control group will be followed for 24-weeks without any dietary counselling.
2381070|NCT03702322|Other|Participants|All participants will undergo each treatment.
2381071|NCT03702309||LIBERATE|Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).
2381072|NCT03702296|Other|Intervention|Patients will be provided with ear plugs and eye masks, to be used from 10pm to 6am, for 3 days post-operatively.
2381073|NCT03702296|No Intervention|Control|No ear plugs or eye masks provided.
2381077|NCT03702257|Other|Bronchial fibroscopy|Bronchial fibroscopy with trans-bronchial biopsies
2381078|NCT03702244|No Intervention|Usual Care|For participants randomized to usual care, the participant's care team will select the specific noninvasive stress test (exercise electrocardiogram, stress nuclear imaging [including PET], stress MR, or stress echocardiogram); OR invasive test: (direct to diagnostic catheterization).
2381288|NCT03700749|Active Comparator|10%povidone-iodine + coated suture|10%povidone-iodine/triclosan-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with triclosan-coated suture for abdominal fascial closure.
2381079|NCT03702244|Other|Precision evaluation|Participants randomized to a precision strategy will be assigned to either guideline-recommended care without immediately planned testing (low risk) or cCTA with selective FFRct (elevated risk) using a risk tool based on pretest clinical characteristics derived from the PROMISE trial and validated in SCOT-HEART trial. Participants assigned to guideline-recommended care without planned testing will be treated with preventive and antianginal medical treatment per guideline recommendations and clinical judgment and followed without testing.
2381083|NCT03702218|Experimental|Hep C Ab + NAT - Donor to Naïve Recipient|"HCV Ab and HCV NAT testing at 3 days, week 1, week 2 and monthly for 3 months, at 6 months and 1 year. In approximately 16% of the patients, active hepatis C infection will ensue. For these patients, treatment is as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
2381084|NCT03702218|Experimental|Hep C Ab+ NAT+ Donor to Naïve Recipient|"HCV RNA levels, liver biochemistries, and renal function will be measured 3 days after transplant. HCV Genotype will be determined after HCV RNA is >1,000 IU/mL. HCV RNA levels will be measured weekly after transplant until HCV treatment is initiated.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
2381085|NCT03702218|Active Comparator|Hep C Ab- NAT - Donor to Naïve Recipient|Current standard of care for donor recipient infectious disease matching. No treatment necessary
2381086|NCT03702205|Experimental|Betaine supplementation|The experimental procedure for each athlete includes a 3-week betaine supplementation either 2.5 g or 5 g daily. Betaine will be administered in the form of capsules containing either 0.5 or 1 g betaine. The capsules will be ingested with at least 250 mL of water. Each athlete will ingest 5 betaine capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
2381087|NCT03702205|Experimental|Placebo treatment|The experimental procedure for each athlete included a 3-week placebo administration. Placebo will be capsules with starch. Placebo will be ingested with at least 250 mL of water. Each athlete will ingest 5 placebo capsules a day. On training days the supplements will be taken in the morning (2 capsules), in the evening (2 capsules) and 1.5 hours before training session (1 capsule). On rest days the supplements will be taken in the morning (2 capsules), in the afternoon (1 capsule) and in the evening (2 capsules).
2381088|NCT03702192|Experimental|single-arm novel anticoagulation|Single-arm clinical study to assess the safety, and effectiveness of a novel anticoagulation protocol to be used in conjunction with the Berlin Heart EXCOR Pediatric Ventricular Assist Device as a bridge to heart transplantation in children with severe heart failure who have failed optimal medical therapy.
2381089|NCT03702179|Experimental|Durvalumab + Tremelimumab|"The treatment consisted of initial TUR of the tumor, with multiple random biopsies of normal-appearing bladder urothelium, followed by durvalumab 1500 mg i.v. plus tremelimumab 75 mg i.v., every 4 weeks for a total of 3 doses.~Two weeks after the initiation of immunotherapy, normofractionated external-beam radiotherapy with high-energy photons will be started. Radiotherapy will be administered concurrently with immunotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder."
3183190|NCT00711542|Active Comparator|1|Intracoronary infusion of autologous bone marrow-derived progenitor cells after NSTEMI
2381091|NCT03702153|Experimental|Infected abdominal wall group|A cohort of 40 patients carrying an active chronic mesh infection (mesh sinus, exposed mesh or mesh related enteric fistulas) resulting from a previous hernia repair, with or without an associated recurrent ventral hernia, and submitted to abdominal wall reconstruction with synthetic mesh.
2381092|NCT03702153|Active Comparator|Clean control group|A cohort of 40 patients with ventral hernias, and submitted to clean ventral hernia repair with synthetic mesh.
2381093|NCT03702140|Active Comparator|TPTD 6M|
2381094|NCT03702140|Active Comparator|TPTD 6-12M|
2381095|NCT03702140|Active Comparator|TPTD 12-24M|
2381096|NCT03702127|Experimental|TMS in patients with intracranial electrodes|We will administer TMS to neurosurgical patients with intracranial electroencephalography in order to better understand the effects TMS has on the human brain. Participants will receive both active and sham stimulation at varying points during the study.
2381097|NCT03702114||MMG group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
2381098|NCT03702114||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
2381099|NCT03702101||Orofacial pain group|Patients in this group will receive auricular point detection which is accomplished by the novel auricular point detector device. There is no addition to the patient's routine care.
2381100|NCT03702101||Control group|This group includes healthy subject, for whom no treatment will be performed. Only auricular point detection by the auricular point detector will be conducted.
2381474|NCT03699449|Experimental|durvalumab + chemotherapy|durvalumab +chemotherapy
3183191|NCT00711542|Placebo Comparator|2|Intracoronary infusion of Placebo after NSTEMI
2381101|NCT03702075|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-administered program combining self-myofascial release using foam rollers and roller balls and active upper limb neurodynamic exercises. It consisted of three sessions of 50-60 minutes per week for 4 consecutive weeks.
2381102|NCT03702075|No Intervention|Control group|Those patients allocated to the control group received a booklet with information regarding neck pain and explaining basic exercises for active mobilization and stretching with pictures and a short text.
2381103|NCT03702062|Experimental|Observational Arm|Participants will be asked to measure self-assessed 6 minute walk test via the smart phone application twice a week for 2 months after discharge from a heart failure hospitalization, and weekly thereafter for 6 months.
2381104|NCT03702049|Experimental|RN/CHW TBI|Nurse-led Community Health Worker TBI (RN/CHW TBI) program
2381105|NCT03702023|Active Comparator|Intervention Group|Patients in the intervention group with receive the study medication 1000mg acetaminophen orally one time prior to their scheduled electrophysiology procedure.
2381106|NCT03702023|Placebo Comparator|Placebo Oral Tablet|Patients in the control group will receive a placebo orally one time prior to their scheduled electrophysiology procedure.
3183192|NCT00711568|Experimental|Arm 1|Left dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
3183193|NCT00711568|Experimental|Arm 2|Right dorsolateral frontal 20 Hz TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
2381109|NCT03701997||EXCOR Pediatric|Pediatric (age 0 - 21) patients who are transplant eligible in need of mechanical circulatory support and are supported with the EXCOR® Pediatric
2381110|NCT03701984|Experimental|lidocaine infusion arm|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
2381111|NCT03701984|Active Comparator|tramadol arm|will be administered with an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
2381112|NCT03701984|Placebo Comparator|placebo group|will be administered with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
2381113|NCT03701971|Experimental|Music Therapy|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale Itchy Quality of Life Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC~• Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale Questionnaire State-Trait Anxiety Inventory (STAI Y-A) PGIC"
2381114|NCT03701971|Active Comparator|Emollient cream|"a medical examination~Before and after music therapy, patients will have to answer questionnaires :~Before :~Questionnaire 5D itch scale~Itchy Quality of Life~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC~Patients will then benefit from a balneotherapy session the next morning. Patients will have to answer questionnaires before and after balneotherapy :~Before :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~After :~Pruritus assessment on the digital scale~Questionnaire State-Trait Anxiety Inventory (STAI Y-A)~PGIC"
2381115|NCT03701958|Other|Exalt DScope 01|Subjects will have a clinically indicated per standard of care ERCP procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
2381116|NCT03701945|Experimental|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to every patient that accepts the intervention and presents an acute exacerbation
2381117|NCT03701932|Experimental|TMS and Lumosity® cognitive retraining|Group will receive TMS and will concurrently engage in cognitive retraining exercises comprised of the Lumosity® battery.
2381118|NCT03701932|Active Comparator|TMS and non cognitive computer games|Group will receive TMS while concurrently engaging in selected computer games from several gaming software that includes Play 101 Games and Hoyle Puzzle and Board Games®. They will also be allowed to spend time on gaming activities of their choice in order to keep them engaged
2381119|NCT03701919|Experimental|Botulinum toxin pyloroplasty|Intraoperative laparoscopic intramuscular injection of 100units (10cc) of Botulinum toxin into the pylorus
2381120|NCT03701919|Placebo Comparator|Normal saline pyloric injection|Intraoperative laparoscopic intramuscular injection of 10cc normal saline into the pylorus
2381121|NCT03701906|Active Comparator|Lactobacillus PS11603 & Bifidobacterium PS10402|A mixture of 1*10E9 colony forming unit (CFU) of Lactobacillus PS11603 and 1*10E8 CFU of Bifidobacterium PS10402 in 1 vial will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
2381122|NCT03701906|Active Comparator|Placebo|1 vial of Placebo will be dissolved and enterally administered daily until discharge from the Neonatal Unit or until the 36th post-gestational week of age.
2381123|NCT03701893|Experimental|Lactobacillus PS11610|Lactobacillus PS11610 for couples with genital dysbiosis and infertility. Each dose contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610.Two daily doses for her and one daily dose for him until pregnancy or end of study period (6 months).
2381124|NCT03701880|Experimental|Ivabradine group|an initial dose of 5 mg/12 hours of Ivabradine will be added to beta-blockers (bisoprolol 2.5 mg/day) and ivabradine will be increased until a dose of 7.5 mg/12 hours according to HR. The heart rate target will be at least <70 bpm and not lower than 60 bpm. If HR decreases below 60 bpm, ivabradine and/or beta-blockers doses will be decreased to the previous dose. After discharge, beta-blockers up-titration will be continued during follow-up visit.
2381125|NCT03701880|Active Comparator|Control group|beta-blocker (bisoprolol 2.5 mg/day) and it will be doubled every 2 weeks during the admission according to the stability of HR, blood pressure and tolerability of patients. Ivabradine will be only added after reaching bisoprolol optimal dose (10mg) or maximum tolerated dose and the HR is still above 70 bpm. If HR decreases below 60 bpm, ivabradine dose will be decreased.
2381127|NCT03701854||Heart failure patients with pacemakers|Functional (6-Minute Walking test (6-MWT)) and maximal exercise capacity (Incremental Shuttle Walking test (ISWT)), respiratory (MIP, MEP; Mouth pressure device) and peripheral muscle strength (Dynamometer), pulmonary function (Spirometry) dyspnea (Modified Medical Research Council Dyspnea scale) (MMRC)), and fatigue (Fatigue Severity scale (FSS)) were evaluated in 50 patients.
2381128|NCT03701854||Healthy controls|Healthy individuals (n=40) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
2381129|NCT03701841||PEG-rhG-CSF primary prophylaxis|Patients receiving chemotherapy who have a overall FN risk >=20% receive PEG-rhG-CSF for primary prophylaxis
2381130|NCT03701841||PEG-rhG-CSF secondary prophylaxis|Patients receiving chemotherapy who had FN or dose-limited neutropenia receive PEG-rhG-CSF for secondary prophylaxis
3142575|NCT00002798|Experimental|Arm III (combination chemotherapy, aldesleukin)|Patients receive interleukin-2 IV continuously on days 1-4 and 9-18.
2381132|NCT03701815|Experimental|Post-stroke|Patients will receive a 12-week lifestyle medicine program.
2381133|NCT03701802||HIV-1 serodiscordant couples|Heterosexual couples in which one partner is infected with HIV-1 and the other partner is HIV-1 uninfected
2381134|NCT03701802||Concordant HIV-1 negative couples|Heterosexual couples in which both partners are HIV-1 uninfected
2381135|NCT03701789|Other|Patients with Rheumatoid Arthritis|In-label treatment with Baricitinib
3142576|NCT00002798|Active Comparator|Arm IV (combination chemotherapy)|No further treatment
3142577|NCT00002798|Experimental|Arm V (combination chemotherapy, radiotherapy)|Patients undergo radiotherapy to the chloroma 5 days a week for 2 weeks.
3142578|NCT00002804|Experimental|Chemotherapy Regimen|Induction (Weeks 1-6) Vincristine sulfate (1.5 mg/m2) day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Weeks 2 and 3 - Vincristine sulfate (1.5 mg/m2) IV day 1, week 5 no chemotherapy. Evaluate for response. Local Control (Weeks 7-13) Conventional surgery and radiation therapy. Vincristine sulfate (1.5 mg/m2) IV day 1, Ifosfamide (3 grams/m2) days 1-3, Doxorubicin (30 mg/m2) days 1-2, filgrastim day 4. Treatment continues per protocol.
3142579|NCT00002805|Experimental|Treatment|Induction will consist of one course of cytarabine and mitoxantrone. Patients achieving a complete or partial response by the end of induction will start intensification. Intensification will consist of one course of chemotherapy (Cytarabine (Ara-C), Etoposide (VP-16), Filgrastim (G-CSF)). Patients who do not attain a CNS remission following the completion of intensification therapy, or who develop recurrence of CNS disease and have not previously received radiation therapy involving the central nervous system should receive craniospinal radiotherapy. Continuation Therapy: cladribine (2CdA), Etoposide.
3142580|NCT00002806|Experimental|procarbazine + lomustine + vincristine + radiation|PCV followed by external-beam cranial irradiation using at least 6 MV photons.
2381141|NCT03701750|Experimental|Experimental Arm|Low Molecular Weight Heparin (enoxaparin sodium) + routine luteal phase support
2381142|NCT03701750|No Intervention|Control Arm|routine luteal phase support
3142581|NCT00002807|No Intervention|Observation|
2381147|NCT03701698|Experimental|combination therapy|"There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.~Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.~Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days."
2381148|NCT03701685|Other|nerve grafting|The stumps of digital nerve are connected with nerve graft
2381149|NCT03701672||Opioid Analgesic Treatment|Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs
2381150|NCT03701659|Experimental|TUPKRP+MAB Group|These patient will be treated by TUPKRP and MAB.
2381151|NCT03701659|Active Comparator|MAB Group|These patient will be treated by MAB only.
2381152|NCT03701646||arterial line|Pediatric patients admitted tot he ICU with a medically indicated arterial line.
2381153|NCT03701646||cardiac output|Pediatric patients requiring cardiac output measurement by thermodilution through cardiac catheterization.
2381154|NCT03701633||Prior to breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
2381155|NCT03701633||After breastfeeding - cross section|Measurements of the UtA doppler postpartum ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
2381156|NCT03701607||PD-L1|
2381182|NCT03701503|Experimental|Obese|"Women age 20-40, with BMI ≥ 25-35 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
2381477|NCT03699449|Experimental|durvalumab +chemotherapy|durvalumab +chemotherapy
3142582|NCT00002807|Experimental|Radiation|Post-operative pelvic radiation therapy (45 Gy in 25 fractions over 5 weeks)
3150785|NCT00210314|Experimental|High-dose methotrexate associated with high dose cytarabine|
3183194|NCT00711568|Sham Comparator|Arm 3|Left or right dorsolateral frontal 20 Hz sham TMS delivered for 2 seconds every 30 seconds for a total of 2000 stimuli
2381157|NCT03701594|Experimental|Yoga-based physical therapy group|The yoga-based physical therapy session will take place in an enclosed, quiet space to minimize outside noise or distraction. The lights will be dimmed, and light, instrumental, calming music will be played throughout. The group will consist of approximately 2-5 individuals depending on the physical capabilities and assistance levels required. The session will consist of an introduction to pranayama (foundational breath-based exercises) followed by asanas, or physical postures, that will be modified according to each individual's physical abilities. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
2381158|NCT03701594|Active Comparator|Seated rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
2381159|NCT03701594|Active Comparator|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
2381160|NCT03701581|Experimental|Group A: Investigational Treatment|"4-Aminopyridine (FDA-approved drug)~Subjects will not take more than 2 tablets in a 24-hour period~Subjects will take the tablets whole. They will not break, crush, chew, or dissolve tablets before swallowing.~The subjects will be told that the medication is released slowly over time and if the tablet is broken, the medicine may be released too fast which can raise the chance of having a seizure.~Study drug can be taken with or without food.~If a dose is missed they should not make up the missed dose. They will be told not to take two doses at the same time but to take the next dose at the regular scheduled time.~Subjects will be reminded not to take study drug together with other aminopyridine medications, including compounded 4-AP (sometimes called 4-aminopyridine or fampridine)."
2381161|NCT03701581|Placebo Comparator|Group B: Placebo|"Subjects will receive an oral dose of placebo treatment the day after surgery, continuing daily for 3 months (90 days) following the same administration instructions as the investigational treatment. The placebo tablets will be manufactured by The University of Iowa Pharmaceuticals, 115 South Grand Avenue G-20, Iowa City, IA 52242. The Investigational Drug Service at the University of Rochester will manage the placebos.~Placebo composition will include:~97% Microcrystalline Cellulose, NF (Avicel Ph 102) 2% Sodium Starch Glycolate, NF~1% Magnesium Stearate, NF~The placebo will be covered in White Opadry, formulation OY-S-9603 and tooled to look similar to the investigational treatment."
2381162|NCT03701555|Experimental|Part 1, Cohort 1A-1 to 1D-1 Healthy Participants|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to healthy participants in Cohorts 1A-1, 1B-1, 1C-1, and 1D-1.
2381163|NCT03701555|Experimental|Part 1, Cohort 1E-1 Healthy Participants|A single dose of the maximum feasible dose (MFD) of PvP002 will then be administered to healthy participants in Cohort 1E-1.
2381164|NCT03701555|Experimental|Part 1, Cohort 1A-2 - 1D-2 Celiac Disease (CeD)|A single dose of PvP001 placebo, PvP001 100 mg, PvP001 300 mg, or PvP001 900 mg will be administered in ascending order to participants with CeD in Cohorts 1A-2, 1B-2, 1C-2, and 1D-2.
2381165|NCT03701555|Experimental|Part 1, Cohort 1E-2 CeD|A single dose of the MFD of PvP002 will then be administered to participants with CeD in Cohort 1E-2.
2381166|NCT03701555|Experimental|Part 2, Cohort 2A - Cohort 2C Healthy Participants|Participants will be blinded to the PvP001 dose (placebo or MTD of PvP001) and will also receive MTD of PvP001 following 7 days of PPI treatment.
2381167|NCT03701555|Experimental|Part 2, Cohort 2D Healthy Participants|Participants will receive PvP001 placebo or MFD of PvP001.
2381168|NCT03701555|Experimental|Part 2, Cohort 2E Healthy Participants|Participants will receive PvP002 placebo or MFD of PvP002.
2381169|NCT03701555|Experimental|Part 2, Cohort 2F- Cohort 2H Healthy Participants|Participants will receive the PvP001 placebo and either 300 mg or 600 mg of PvP001.
2381170|NCT03701555|Experimental|Part 2, Cohort 2I and Cohort 2J Healthy Participants|Participants will receive the PvP001 placebo and 900 mg of PvP001.
2381171|NCT03701555|Experimental|Part 3, Cohorts 3A and 3B Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 with pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
2381172|NCT03701555|Experimental|Part 3, Cohorts 3C and 3D Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
2381173|NCT03701555|Experimental|Part 3, Cohorts 3E and 3F Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution after an approximately 50 milliliter (mL) portion of a standardized 1 gm gluten-containing study meal.
2381174|NCT03701555|Experimental|Part 3, Cohorts 3G and 3H Healthy Participants|Participants will receive single dose of PvP003 placebo and 600 mg of PvP003 without pretreatment buffer solution before a standardized gluten-free study meal followed approximately 30 minutes later by a standardized 1 gm gluten-containing study meal.
2381175|NCT03701555|Experimental|Part 4, Cohorts 4A and 4B Healthy Participants|Participants will receive multiple dose of PvP003 placebo and 600 mg of PvP003.
2381176|NCT03701555|Experimental|Part 3, Cohorts 3I and 3J Healthy Participants|Participants will receive single dose of PvP003 placebo and 150 mg of PvP003 without pretreatment buffer solution before a standardized 1 gm gluten-containing study meal.
2381177|NCT03701542||Group of 22 patients|Group of 22 patients who underwent vitrectomy due to macular hole
2381178|NCT03701529|Experimental|Sevoflurane|1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.
2381179|NCT03701529|Active Comparator|Propofol|2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.
2381180|NCT03701516|Experimental|TEST/CONTROL|Subjects between the ages of 18 and 70 years of age and are habitual wearers of daily disposable contact lens wearers will be randomly assigned to the Test/Control sequence.
2381183|NCT03701503|Active Comparator|Non Obese|"Women age 20-40, with BMI 18,5-23 kg/m2 Given a balanced breakfast (Protein 12,4%, carbohydrate 68,2%, fat 22,6%) with calories according to their energy requirement,which is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity.~Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure every outcome. After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
2381184|NCT03701490|Experimental|Prolutex|
2381185|NCT03701490|Experimental|Progeffik|
2381186|NCT03701477|Experimental|Trans-diagnostic approach|Trans-diagnostic cognitive-behavioral therapy In this arm, patients will participate in 10 sessions of therapy. During each session, specific topics will be discussed and participants will need to complete their homework for the next session. Each session lasts for 120 minutes. Sessions will be held in groups of 5-10 subjects weekly, except the last session that will be held after a two-week interval.
2381187|NCT03701477|Sham Comparator|Control|General relaxation/stress management therapeutic session In this arm, patients will attend a 3-hour meeting in which basic techniques of relaxation and overcoming stress and anxiety will be discussed.
2381188|NCT03701464|Experimental|Endoscopic naso-gallbladder drainage|After selective bile duct cannulation, a 0.025- or 0.035-inch guidewire is advanced into the cystic duct and subsequently into the gallbladder. A 5F naso- Pancreas catheter was inserted into the gallbladder for ENGBD.
2381189|NCT03701464|Active Comparator|Percutaneous gallbladder drainage|Ultrasound guided，an 18-gauge needle is inserted into the gallbladder，0.035 inch guidewire is coiled into the gallbladder and 9Fr dilator expands the skin,then 8Fr-20cm catheter is placed.
2381190|NCT03701451|Experimental|decitabin and cisplatin induced chemotherapy followed by CC|Treated by demethylated drug decitabine injection combined with cisplatin induced chemotherapy followed by concurrent chemoradiotherapy
2381191|NCT03701438||Idelalisib|Participants currently enrolled in a Gilead-sponsored study, who are currently being treated with 100 or 150 mg of idelalisib twice daily for at least 7 consecutive days prior to receiving an influenza vaccine.
2381192|NCT03701425|Experimental|Mediterranean diet and exercise plan|"Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the distribution of macronutrients: Protein contribution 0.8-1.2 gram, Carbon Hydrates 45-50% Lipids 30% An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
2381193|NCT03701425|Experimental|Mediterranean diet|Random assignment, through software, to 4 groups of treatment: consume the Mediterranean diet: according to the definition, with the following distribution of macro nutrients: Protein contribution 0.8-1.2 gram Carbon Hydrates 45-50% Lipids 30%
2381194|NCT03701425|Active Comparator|Only exercise|"An exercise plan: The classic exercise program who they will carry out a 5-minute warm-up program with active mobilizations. After that, they will perform intervals of 5 min with resistance to maintain the heart rate prescribed, with active breaks of 1 - 2 min, 4 repetitions. At the end, there will be a return to calm The program of high-intensity anaerobic exercise will consist of a 5-minute warm-up , followed by 5 sets of isokinetic exercise with protocol November 20, rest of 90 s between series. The program will be done 3 times per week for 12 weeks."
2381195|NCT03701425|Active Comparator|Low standard low fat diet|Random assignment, through software, to 4 groups of treatment: consume the low standard low fat diet: according to the definition, with the following distribution of macro nutrients:Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 20%
3150786|NCT00210405|Active Comparator|Food aid only|Children in this arm received fortified food aid commodities supplied through the maternal and child health and nutrition program implemented by World Vision. They received fortified corn-soy blend, which contained iron.
3183195|NCT00711581|Experimental|A|Subjects will undergo a laparoscopic cholecystectomy. The gallbladder will be retracted using the Endograb retractor.
2381198|NCT03701386|Active Comparator|cesarean hysterectomy|Elective Cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. The operation will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
2381199|NCT03701386|Experimental|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade was performed
2381200|NCT03701373|Experimental|S-1 maintenance group|S-1 maintenance
2381201|NCT03701373|Other|Observation group|Observation without anti-tumor treatment
2381202|NCT03701360||Aspirin alone group|- Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed
2381203|NCT03701360||Aspirin + Clopidogrel resinate group|"Aspirin: 75~100mg once per day, initial loading dose of 300~500mg/d is allowed~Clopidogrel resinate: 75mg once per day, initial loading dose of 300mg/d is allowed"
2381204|NCT03701347|Active Comparator|Reeve's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Reeve's simulators
2381205|NCT03701347|Active Comparator|Hefler's model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Hefler's simulators
2381206|NCT03701347|Experimental|Ida's Model|After introduction of Loop excision electrosurgical procedure through video, participants will undergo Ida's simulators
2381209|NCT03701321|Experimental|Phase I (DVd, venetoclax)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, dexamethasone PO on days 1, 8, and 15 of cycles 1-8, and venetoclax PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2381286|NCT03700749|Active Comparator|2%chlorhexidine + coated suture|2%alcoholic chlorhexidine + triclosan-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with triclosan-coated suture for abdominal fascia closure.
2381210|NCT03701321|Experimental|Phase II Arm D (DVd, venetoclax)|Patients receive venetoclax PO QD on days 1-21, daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2381211|NCT03701321|Active Comparator|Phase II Arm E (DVd)|Patients receive daratumumab IV on days 1, 8, and 15 of cycles 1-3 and on day 1 of subsequent cycles, bortezomib SC on days 1, 8, and 15 of cycles 1-8, and dexamethasone PO on days 1, 8, and 15 of cycles 1-8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3142583|NCT00002812|Experimental|Arm A - Standard BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow. Consolidation (Phase II) (5 weeks) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3142584|NCT00002812|Experimental|Arm B - Standard BFM with Double Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (5 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3183196|NCT00711607|Experimental|1|Group 1: NOMAC-E2 (days 1-24 and day 35)
2381217|NCT03701256|Experimental|TAP Group|Bilateral ultrasound TAP bloc performed via 20 ml of 2.5% bupivacaine without neuromuscular blocking agents
2381218|NCT03701256|Active Comparator|TRAC Group|Neuromuscular blocking agent: Atracurium 0.1 mg/kg per bolus
2381219|NCT03701243|Experimental|mNT-BBAVF|These patients will receive a modified non-transposed brachiobasilic arteriovenous fistula (mNT-BBAVF) at elbow for hemodialysis acess.
2381220|NCT03701243|Active Comparator|RCAVF|These patients will receive a radiocephalic arteriovenous fistula (RCAVF) at wrist for hemodialysis acess.
2381221|NCT03701230|Experimental|low temperature rota-flush solution|A total of 55 patients are assigned to low temperature rota-flush solution group after randomization schedule.
2381222|NCT03701230|No Intervention|room temperature rota-flush solution|A total of 55 patients are assigned to room temperature rota-flush solution group after randomization schedule.
2381223|NCT03701217|Experimental|Eltrombopag treatment|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10'9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10'9/L, after consolidation therapy in AML patents. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
2381224|NCT03701217|Active Comparator|Eltrombopag free|Eltrombopag treatment is not performed in this group. Platelet transfusion application is routinely done when platelet count is lower than 20×10'9/L or active hemorrage happens to patients.
2381225|NCT03701204|Experimental|DynamiCare Rewards|The study will test the feasibility/acceptability and efficacy of DynamiCare Rewards™. DynamiCare Rewards is an iOS/Android app which automates Contingency Management (CM) to help the patient self-monitor and focus attention on his/her behavioral goals (i.e., abstinence) for alcohol or other substance use disorders.
2381226|NCT03701204|No Intervention|Control|Treatment as usual
2381227|NCT03701191|Experimental|Grpup A (Test group)|Inverted periosteal pedicle flap will be carried out
2381228|NCT03701191|Active Comparator|Group B (Control group)|Coronally advanced flap with subepithelial connective tissue graft
2381229|NCT03701178|Active Comparator|zirconia veneered crowns|we will use zirconia veneered single crowns as a control to evaluate the marginal integrity and fracture and patient satisfaction
2381230|NCT03701178|Experimental|milled BioHpp PEEK|we will use milled BioHPP PEEK single crowns as a intervention to evaluate the marginal integrity and fracture and patient satisfaction
2381231|NCT03701165|Other|Snoring cohort.|Subjects will undergo two nights of polysomnography. The first night will be a baseline recording. The next night subjects will use the DryMouth Shield during the polysomnography.
2381232|NCT03701152|Experimental|Negative pressure therapy|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Continuous course
2381233|NCT03701152|Experimental|Investigator|Negative pressure therapy topical application using negative pressure therapy sub atmospheric pressure Splitted course
2381234|NCT03701139|Experimental|posterior capsulotomy|Primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing during phacoemulsification.
2381235|NCT03701139|Active Comparator|Nd:YAG laser capsulotomy|Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
2381236|NCT03701126|Active Comparator|group A|Transversus Abdominis Plane block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
2381237|NCT03701126|Active Comparator|group B|Caudal block using 1ml/kg of bupivacaine 0.25% under ultrasound guidance
2381287|NCT03700749|Active Comparator|10% povidone-iodine + non-coated suture|10% povidone-iodine and non-coated suture. Intervention: skin preparation with 10% povidone-iodine in combination with non-coated suture for abdominal fascial closure.
3183197|NCT00711607|Placebo Comparator|2|Group 2: NOMAC-E2 (days 1-24) followed by Placebo (day 35)
3183198|NCT00711620|Experimental|Thymosin alpha 1+Standard Therapy|Patients receive treatment based on SSC guideline with additional thymosin alpha1
2381238|NCT03701113|Active Comparator|Milk-based protein matrix (MBPM)|Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.
2381239|NCT03701113|Other|CONTROL|Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover
2381240|NCT03701100|Active Comparator|Active tDCS|Direct current (DC) generated by a Eldith DC stimulator was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). One anode was placed with the middle of the electrode over a point midway between International 10-20 electrode positions F3 and Fp1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The other was located over a point midway between F4 and Fp2 (right dorsolateral prefrontal cortex and left prefrontal cortex). The reference electrodes were placed on bilateral forearms. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
2381241|NCT03701100|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
2381242|NCT03701087|No Intervention|normal serum vitamin D|normal serum vitamin D
2381243|NCT03701087|Experimental|low serum level of vitamin D|this arm will intake vitamin D 2800 IU daily
2381244|NCT03701087|Placebo Comparator|low serum vitamin D|this arm will intake placebo omega 3
3183199|NCT00711620|Placebo Comparator|normal saline+standard therapy|Patients receive treatment based on SSC guideline with additional normal saline.
3183200|NCT00711633|Experimental|1|the fermented preterm formula (FPF)
3183201|NCT00711633|Placebo Comparator|2|formula adapted for preterm infants (PF)
3183202|NCT00711659||1|all third year medical students starting their pediatric clerkship rotation
2381249|NCT03701048|Active Comparator|reappoximation of rectus muscle|During Cesarean Section rectus muscle will be reapproximated with interrupted sutures.
2381250|NCT03701048|Active Comparator|no reappoximation of rectus muscle|During Cesarean Section rectus muscle will not be closed.
2381251|NCT03701035|Experimental|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
2381252|NCT03701035|Active Comparator|Non-aerobic Training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2® 3 * weekly, 12 weeks
2381253|NCT03701022|Experimental|SHR1210 +Apatinib|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
2381254|NCT03701009|Other|Stone removal (Saline 50ml each time)|After CBD stone removal via lithotripsy, and the cholangiogram showed normal, residual CBD stones were detected by SpyGlass in the first round, if CBD not clean, sterile saline 50ml were intermittently irrigated into the CBD. After that, if bile duct clearance was not achieved, another 50ml saline will be irrigated into CBD again until the clear bile duct determined by SpyGlass.
2381255|NCT03700983|Experimental|Nutri-PEITC jelly|a single serving of 200 g Nutri-PEITC jelly
2381256|NCT03700970|Experimental|TAP block with liposomal bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
2381257|NCT03700970|Active Comparator|TAP block with regular bupivacaine|Local analgesia (TAP blocks) will be administered under ultrasound guidance in the operating room after the patient is intubated and under general anesthesia. Under sterile conditions and ultrasound guidance, the fascial plane between the internal oblique and transversus abdominis muscles (muscles of the abdominal wall) will be identified at the anterior axillary line, midway between the costal margin and iliac crest. The epidural needle will be inserted through the skin to the appropriate fascial plane, and the local anesthetic will be injected in that plane. 20mL of 0.25% bupivacaine injected on each side.
2381258|NCT03700957|Experimental|Docosahexaenoic Acid Group|participants will recieve 100 milligrams of Docosahexaenoic Acid per day for 14 days
2381259|NCT03700957|Placebo Comparator|Control Group|participants will recieve placebo
2381260|NCT03700944|Experimental|YOG|The yoga group (YOG) was required to complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week
2381261|NCT03700944|No Intervention|CON|The control group (CON) had normal life.
3183203|NCT00711672||1|Medical Oncologists treating patients with metastatic colorectal cancer
3183204|NCT00711672||2|Patients with metastatic colorectal cancer receiving re-staging CT scans
3183205|NCT00711698|Active Comparator|1|In this arm patients will be randomized to receive a bolus of narcotic followed by PCA.
3183206|NCT00711698|Active Comparator|2|In this arm patients will be randomized to the current standard of care of bolus narcotic treatment.
3183207|NCT00711724||MGH 1|Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
3183208|NCT00711776|Experimental|Subjects receiving new formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3183209|NCT00711776|Active Comparator|Subjects receiving current formulation in blank test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3183210|NCT00711776|Experimental|Subjects receiving new formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3183211|NCT00711776|Active Comparator|Subjects receiving current formulation in pre-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
2381262|NCT03700931|Experimental|Eating recall condition|Participants receive a questionnaire asking them to write down what they ate the day before at breakfast, between breakfasts and lunch, at lunch, between lunch and dinner, at dinner, and after dinner, reporting for each episode the foods and drinks consumed, place, time of the day and people present (10).
2381263|NCT03700931|Active Comparator|Non-eating recall condition|Participants receive a questionnaire asking them to write down their school, homework (assignment), study, or work-related activities, two at morning, two at afternoon and two at night, of the day before reporting the name of each activity, place, time of the day and people present.
3183212|NCT00711776|Experimental|Subjects receiving new formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
2381265|NCT03700905|Experimental|Neoadjuvant/adjuvant Nivolumab and Ipilimumab|"Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery~Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only), start within 6 weeks post-surgery~Arm Ia:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months~Arm Ib:~• Adjuvant administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months"
2381266|NCT03700905|Active Comparator|Surgical resection + adjuvant radio(-chemo)therapy|"Surgical resection of primary tumor including neck dissection according to standard of care~6-7 weeks risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (40mg/m2) in high risk patients), start within 6 weeks post-surgery~Standard follow-up"
3183213|NCT00711776|Active Comparator|Subjects receiving current formulation in main-test group|Eligible subjects will receive acyclovir cream 5 % following single topical application.
3183214|NCT00711789|Active Comparator|Angiotensin II|
3183215|NCT00711789|Placebo Comparator|Placebo|
2381270|NCT03700866|Experimental|(Functional splinting time)|"Teeth with crown root fracture will be surgically extruded and splinted then the Periotest values will determine when the splint should be removed which will indicate the functional periodontal healing and as well the functional splinting time.~The Periotest readings will be repeated with one week time interval between each series When the Periotest values of the traumatized tooth reach or even approximate the values of the corresponding normal tooth the splint will be removed."
2381271|NCT03700866|Active Comparator|(IADT splinting time)|Teeth with crown root fracture in this group will be surgically extruded and splinted for two weeks according to the international association of dental traumatology (IADT) splinting time two ,weeks splinting, regardless the Periotest score.
2381272|NCT03700840|Other|Clinical examination and sample|"Cross-sectional observational study~Measure of 6 indices:~Bleeding on Intergental Brush Index (BOIB)~Gingivitis Score (GI)~Plaque index score (PI)~ICDAS~Salivary test~Individual caries risk assessment~Determination of interdental brushes adapted to each interdental site~Recovery of the interdental brush passed through the 4 sites (between 15-16, 25-26, 35-36, 45-46) on which the interdental biofilm was fixed during the passage in the interdental space.~The interdental brush is immediately put in a sterile tube and then sent in dry ice to maintain the integrity of the genetic material.~Quantitative PCR experiments will be performed and a qualitative and quantitative analysis of the interdental flora will be made."
2381273|NCT03700827|Experimental|Resistance Training Group|Resistance training will consist of 3 whole body circuits per week for 3 weeks lasting approximately 1 hour per session. All major muscle groups will be involved (leg press, bent-over-row, bench press, back squat, dumbbell jump squats, dead-lifts, and weighted abdominal crunches). Each participant will go through each circuit three times with 30 seconds between each exercise and 2 minutes between each set.
2381274|NCT03700827|Experimental|Aerobic Training Group|Aerobic interval training will consist of 3 sessions/week for 3 weeks for approximately 45-50 minutes per session depending on exercise energy expenditure. There will be two periods of intervals. The first period will be 3 minutes of high-intensity activity and the second period will be reduced to moderate-intensity for 2 minutes. The speed/incline will change depending on the participants perception or Borg's rating of perceived exertion. Intensity will be measured using Lactate levels after each session.
2381275|NCT03700827|No Intervention|Control Group|The control group must attend sessions but will not exercise.
2381276|NCT03700814|Experimental|Antibiotics group|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which will be injected 30 minutes prior to the incision during surgery.
2381277|NCT03700814|No Intervention|No antibiotics group|Patients belonging to this group will not receive any systemic antibiotic during intraoperative or post-operative period.
2381278|NCT03700801|Experimental|Triple combination therapy group|triple combination therapy group: Triple oral hypoglycemic therapy based on metformin 0.5mg twice a day, dapagliflozin 10mg per day plus saxagliptin 5mg per day.
2381279|NCT03700801|Active Comparator|Premixed insulin therapy group|premixed insulin therapy group: The initial total dose is 0.3U-0.5U/Kg, twice a day, subcutaneous injection before breakfast and dinner, adjusted according to the blood glucose level detected by the blood glucose meter
2381280|NCT03700788|Experimental|Clorhexidine|2% Chlorhexidine
2381281|NCT03700788|Active Comparator|Calcium Hydroxide|Calcium Hydroxide
2381282|NCT03700775|Experimental|Telemonitoring intervention|
2381283|NCT03700762||pathologically results|finally proved by pathologically results
2381284|NCT03700762||evaluate by ultrasound gray-scale ratio|the results confirmed by the cut-off value of ultrasound gray-scale ratio
2381285|NCT03700749|Active Comparator|2%chlorhexidine + non-coated suture|2%alcoholic chlorhexidine + non-coated suture. Intervention: skin preparation with 2%alcoholic chlorhexidine in combination with non-coated suture for abdominal fascial closure.
2381475|NCT03699449|Experimental|durvalumab + tremelimumab + chemotherapy|durvalumab + tremelimumab + chemotherapy
3183216|NCT00711815||UA|HPV positive
3183217|NCT00711841|Placebo Comparator|saline solution|Placebo (saline solution), 2 mL, intravenous, every 12 hours, for 48 hours
3183218|NCT00711841|Active Comparator|Dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
3183219|NCT00711854|Experimental|1|trimethoprim-sulfamethoxazole (TMP-SMX) plus rifampicin
3142585|NCT00002812|Experimental|Arm C - Augumented BFM of Standard Duration (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
3142586|NCT00002812|Experimental|Arm D - Augmented BFM with Dbl Delayed Intensification (RER)|Induction chemotherapy Days 0 - 7. Prednisone 60 mg/m² PO 4 x day. Vincristine sulfate 1.5 mg/m² IV push weekly x 2 Days 0 and 7. Daunomycin (daunorubicin hydrochloride) 25 mg/m² IV push (over 15 min.) weekly x 2 Days 0 and 7. IT Cytosine Arabinoside (cytarabine, Ara-C) Day 0. Asparaginase 6000 IU/m² IM x 3 Days 3, 5, and 7. Day 7 Bone Marrow Consolidation (9 weeks) (Phase II) Prednisone Taper, cyclophosphamide, cytosine arabinoside (Ara-C), mercaptopurine, vincristine sulfate, pegaspargase, IT Methotrexate and radiation therapy.
2381291|NCT03700723|Experimental|Resusix|The experimental drug (Resusix) will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
2381292|NCT03700723|Active Comparator|FP24 (Frozen Plasma)|The active comparator FP24 will be administered intravenously to subjects enrolled in this arm of the study. Subjects may receive doses of 1-4 units during the blinded intervention period.
2381293|NCT03700710|Active Comparator|Self-Guided Approach|"In the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry."
2381294|NCT03700710|Experimental|Dietitian-led Approach|"In the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants.~The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.~The web platform will be used to share participant dietary and weight data with dietitians."
2381295|NCT03700697|Experimental|Family Stress Module Intervention|Primary care clinicians will use the CHADIS Family Stress Module including the reviewing ACE, Positive Childhood Experiences, and FASS Plus questionnaires at designated child ages; address family stressors revealed using the motivational interviewing teleprompter and refer parents with stressors as indicated using the care coordination functionality.
2381296|NCT03700697|No Intervention|Controls|Control primary care providers will provide care as usual.
2381297|NCT03700684|Experimental|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.
2381298|NCT03700684|Experimental|SpeechVive|Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.
2381299|NCT03700684|Active Comparator|Control|Persons with Parkinsons disease do not receive voice intervention
3183220|NCT00711854|Active Comparator|2|Linezolid
3183221|NCT00711893||ICD and CRT-D|Patients indicated for an implantable defibrillator or cardiac resynchronization defibrillator
2381302|NCT03700658|Experimental|TV-46046 - 1|One of 24 sequences
2381303|NCT03700658|Experimental|TV-46046 - 2|One of 24 sequences
2381304|NCT03700658|Active Comparator|medroxyprogesterone acetate injectable suspension|One of 24 sequences
2381305|NCT03700658|Placebo Comparator|TV-46046 Placebo|One of 24 sequences
2381306|NCT03700645|No Intervention|PCI and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and receive standard medical treatment according to practice guidelines.
2381307|NCT03700645|Active Comparator|PCI, standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by PCI and in addition to standard medical treatment, receive treatment with allopurinol.
2381308|NCT03700645|No Intervention|CABG and standard medical treatment|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and receive standard medical treatment according to practice guidelines.
2381309|NCT03700645|Active Comparator|CABG standard treatment and Allopurinol|Patients diagnosed with multi vessel disease that after Heart team discussion underwent intervention by CABG and in addition to standard medical treatment, receive treatment with allopurinol.
2381310|NCT03700632|Experimental|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week.
2381311|NCT03700632|No Intervention|Control|no intervention will be done
2381345|NCT03700359|Experimental|Anlotinib/Lobaplatin/Etoposide|EL regimen for 4 cycles followed by Anlotinib Hydrochloride maintenance therapy
2381346|NCT03700359|Active Comparator|Lobaplatin/Etoposide|EL regimen for 4 cycles
2381347|NCT03700346|Other|survivors|survivor at ICU discharge muscle microdialysis
2381348|NCT03700346|Other|Non survivors|death before ICU discharge muscle microdialysis
2381476|NCT03699449|Experimental|durvalumab + tremelimumab + paclitaxel|durvalumab + tremelimumab + paclitaxel
3142587|NCT00002816|Experimental|EARLY # CNS RELAPSE with BM DONOR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, PEG, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, pegaspargase, Ifosfamide with Mesna) and Idarubicin and CXRT.
3150787|NCT00210405|Experimental|Micronutrient sprinkles + food aid|Children in this arm were enrolled in the food assisted program, and therefore received fortified food aid, as well as 60 sachets of a multiple micronutrient powder (Sprinkles) containing iron, zinc, vitamin A, vitamin C and folic acid
2381315|NCT03700593||Single Port Robotic Colorectal Surgery Patients|All patients who undergo a single port robot colorectal surgery.
2381316|NCT03700580|Active Comparator|Hydrogel treatment|It refers to the standard treatment currently applied for foot ulcers at the Health Center where the study was conducted. The intervention was applied to the cohort, three times a week during 16 weeks or when the wound attained full epithelization. The wound bed was cleaned with physiological serum before application of Hydrogel.
2381317|NCT03700580|Experimental|P1G10 treatment|It refers to the experimental parallel intervention consisting of three weekly applications of 0.1% P1G10 dispersed in the hydrosoluble vehicle during a 16-week period, or until full epithelization of the wound. The wound bed was cleaned with physiological serum before application of the drug.
2381318|NCT03700567|Experimental|low temperature contrast|A total of 150 patients are assigned to low temperature contrast group after randomization schedule.
2381319|NCT03700567|No Intervention|room temperature contrast|A total of 150 patients are assigned to room temperature contrast group after randomization schedule.
2381320|NCT03700554|Experimental|Pleuralvent™|Patients treated with Pleuralvent™ device
2381321|NCT03700554|Active Comparator|Chest tube|Patients treated with Chest tube
2381324|NCT03700528|Experimental|Intervention|This is a single-cohort ACT based intervention.
2381325|NCT03700515|Placebo Comparator|Placebo|Saline infusion
2381326|NCT03700515|Experimental|EPO|Erythropoetin infusion (9 IU/kg)
2381327|NCT03700515|Experimental|EPO II|Erythropoetin infusion (20 IU/kg)
2381328|NCT03700502||patients with painful diabetic neuropathy|
2381329|NCT03700502||diabetics with non-pain neuropathy|
2381330|NCT03700502||gender and age matched healthy controls|
2381331|NCT03700489|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
2381332|NCT03700489|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
2381333|NCT03700476|Experimental|Sintilimab arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 12 cycles, started on day 1 of induction chemotherapy.
2381334|NCT03700476|Active Comparator|Chemoradiation arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 6996cGy in 33 fractions will be given. Concurrent cisplatin of 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT.
2381335|NCT03700450|Experimental|Cyclophosphamid post Tranplant|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
2381336|NCT03700437|Experimental|Fasting-Mimicking Diet (FMD)|"Participants randomized to the intervention arm (FMD) will be provided with Chemolieve®, a plant-based FMD that provides ~300 calories/fasting day and includes all the food to be consumed during the dietary intervention including supplements~Subjects will start the diet 3 days prior to chemo-immunotherapy and continue on the first day of chemo-immunotherapy for the first 4 cycles of therapy."
2381337|NCT03700424|Experimental|Trehalose|Participants will be received intravenous trehalose infusion weekly (15 g/week) for a period of 12 weeks
2381338|NCT03700424|Placebo Comparator|Placebo|Participants will be received equal volume of normal saline weekly for a period of 12 weeks
2381342|NCT03700398|Experimental|first OE|
2381343|NCT03700398|Other|First WLI|
3183222|NCT00711906|Experimental|1|HIV-negative women taking CTX as chemoprophylaxis
3183223|NCT00711906|Active Comparator|2|HIV-negative women taking SP as IPT
2381349|NCT03700333|Experimental|S-1 Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Tegafur,Gimeracil and Oteracil Potassium Capsules (S-1)
2381350|NCT03700333|Active Comparator|Pemetrexed Group|Stage IIIB or IV non-small-cell lung cancer (NSCLC) population treated by Pemetrexed
3183224|NCT00711906|Experimental|3|HIV-positive women (CD4> 200) taking CTX as chemoprophylaxis
3183225|NCT00711906|Active Comparator|4|HIV-positive women (CD4 > 200) taking SP as IPT
2381353|NCT03700307|Experimental|pulmonary vein isolation|patients will receive circumferential pulmonary vein isolation using cryoballoon ablation
2381354|NCT03700307|Experimental|pulmonary vein and left atrial roof linear isol|patients will receive circumferential pulmonary vein and left atrial roof linear isolation using cryoballoon ablation
2381355|NCT03700294|Experimental|ADCT-601|
2381356|NCT03700281|No Intervention|Control|No intervention
2381357|NCT03700281|Experimental|Messaging|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail
2381358|NCT03700281|Experimental|Messaging plus incentive|Group will be sent flu vaccine promotion messages via text, email and U.S. Mail, and will be eligible to receive a gift card as incentive for receiving flu vaccine
2381359|NCT03700268|Experimental|Manual fitting|The patient is receiving the classical treatment : 10 sessions of 1 hour during one year where the clinician programs manually the Cochlear implant.
2381360|NCT03700268|Experimental|Artificial Intelligence|The patient is receiving the new treatment : 4 sessions of 1 hour during one year where the clinician programs the Cochlear implant with the FOX (Fitting to Outcome eXpert) software using artificial intelligence.
2381361|NCT03700255|Experimental|Group A|Group A will undergo the PickUpSimTM simulation training program
2381362|NCT03700255|No Intervention|Group B|Group B will only have the classic training with no simulation.
2381363|NCT03700242|Experimental|Group 1|1 IM dose of human diploid cell vaccine (HDCV) on D0 and D7 (short HDCV IM PrEP regimen), followed by 1 IM dose of HDCV on Year (Y)1 and Y1 + 3 days
2381364|NCT03700242|Active Comparator|Group 2|1 IM dose of HDCV on D0, D7, and D21 (reference), followed by 1 IM dose of HDCV on Y1 and Y1 + 3 days
2381365|NCT03700242|Experimental|Group 3|2 intradermal (ID) doses of HDCV on D0 and D7 (short HDCV ID PrEP regimen), followed by 1 ID dose of HDCV on Y1 and Y1 + 3 days
2381366|NCT03700242|Experimental|Group 4|1 IM dose of purified Vero cell rabies vaccine (PVRV) on D0 and D7 (short PVRV IM PrEP regimen), followed by 1 IM dose of PVRV on Y1 and Y1 + 3 days
2381367|NCT03700242|Experimental|Group 5|2 ID doses of PVRV on D0 and D7 (short PVRV ID PrEP regimen), followed by 1 ID dose of PVRV on Y1 and Y1 + 3 days
2381368|NCT03700229|Experimental|Bortezomib +Rituximab|Bortezomib +Rituximab
2381369|NCT03700203||Early cardiac arrest patients|Cases will be consecutive adult patients with EMS-treated OHCA and transport to the 14 emergency departments of participating hospitals. A prospective OHCA patient cohort will be developed and all survived OHCA cases will be followed at 1-month and 6-month after ED discharge by telephone. During the study period, the investigators aim to recruit a total 1,780 cases (200 cases between September 2017 and August 2018, 600 cases between September 2018 and August 2020, 80 cases between September 2020 and December 2020, and 900 cases between January 2021 and December 2023).
2381370|NCT03700203||Matched community-based controls|Matched community-based controls (2:1 matching) will be selected from two health screening centers. Controls are those who visit the participating health screening centers for their annual routine physical examinations. During the study period, the investigators aim to recruit a total 3,560 controls (400 controls between September 2017 and August 2018, 1200 controls between September 2018 and August 2020, 160 controls between September 2020 and December 2020, and 1800 controls between January 2021 and December 2023).
2381371|NCT03700190||Control|Healthy child
2381372|NCT03700190||Experimental|Patients with Autism Spectrum Disorder
2381373|NCT03700177|Active Comparator|ropivacaine + dexamethasone|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml dexamethasone (8mg).
2381374|NCT03700177|Placebo Comparator|ropivacaine + placebo|Every participant receives general anesthesia and a modified pectoral nerve block for breast surgery. Participants of this arm receive single-shot ropivacaine (0,2%, 30ml) plus 2ml placebo (NaCl 0,9%).
2381375|NCT03700164|Experimental|Cold exposure|Participants will be wrapped in a water-perfused suit. The temperature of the suit will be lowered to 10°C. From the onset of shivering, the participants will remain in the suit for 1 hour.
2381376|NCT03700164|Other|Thermoneutral (Control)|"Participants will be wrapped in a water-perfused suit. The temperature of the suit will remain at a thermoneutral temperature (32°C) to avoid shivering and excessive sweating.~The duration will be matched to that during the cold exposure."
2381377|NCT03700151|Experimental|Children with SSD|Participants will receive a piloted treatment programme for children with severe speech sound disorders, especially childhood apraxia of speech.
2381378|NCT03700138|Experimental|Privigen|TThe treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 6 weeks, with a total of 3 perfusions administered (W0, W4, W8).
2381379|NCT03700138|Placebo Comparator|Placebo|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
2381380|NCT03700125|Experimental|ECMO resuscitation|6 patients who meet the eligibility criteria will be treated by pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable and can establish ECMO flow within 30 minutes of collapse
2381381|NCT03700112|Experimental|JUUL Virginia Tobacco flavored 5.0% ENDS|"Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed using 10 puffs delivery method~Administration of JUUL Virginia Tobacco flavored 5.0% ENDS product consumed Ad-libitum delivery method"
2381382|NCT03700112|Experimental|PMI iQOS Heat sticks|"Administration of PMI iQOS Heat sticks - Regular consumed using 10 puffs delivery method~Administration of PMI iQOS Heat sticks - Regular consumed ad-libitum delivery method"
2381383|NCT03700112|Experimental|Reynolds VUSE Solo ENDS - Original|"Administration of Reynolds VUSE Solo ENDS - Original consumed using 10 puffs delivery method~Administration of Reynolds VUSE Solo ENDS - Original consumed using ad-libitum delivery method"
3188948|NCT00772421||Non-responder|A subject with a less than 50% reduction in total seizure frequency compared to the SANTE study 3-month Baseline Phase.
2381384|NCT03700112|Experimental|Imperial MyBlu ENDS - Original|"Administration of Imperial MyBlu ENDS - Original consumed using 10 puffs delivery method~Administration of Imperial MyBlu ENDS - Original consumed using ad-libitum delivery method"
2381385|NCT03700112|Experimental|Altria MarkTen ENDS - Bold Classic|"Administration of Altria MarkTen ENDS - Bold Classic consuming using 10 puffs delivery method~Administration of Altria MarkTen ENDS - Bold Classic consuming using ad-libitum delivery method"
2381386|NCT03700112|Experimental|MLV PHIX ENDS - Original Tobacco|"Administration of MLV PHIX ENDS - Original Tobacco consumed using 10 puffs delivery method~Administration of with MLV PHIX ENDS - Original Tobacco consumed using ad-libitum delivery method"
2381387|NCT03700112|Experimental|NJOY Daily EXTRA ENDS - Rich Tobacco|"Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using 10 puffs delivery method~Administration of NJOY Daily EXTRA ENDS - Rich Tobacco consumed using delivery method and ad-libitum"
2381388|NCT03700112|Experimental|Altria Marlboro combustible cigarette - Red|Administration of Altria Marlboro combustible cigarette - Red consumed using 10 puffs delivery method Administration of Altria Marlboro combustible cigarette - Red consumed using ad-libitum delivery method
2381389|NCT03700099|Other|Study cohort|Docetaxel 75 mg/m2 i.v. every 3 weeks for 6-10 cycles. Upon disease progression after docetaxel, participants will receive enzalutamide 160 mg p.o. daily until limiting toxicity or disease progression.
2381390|NCT03700086|Experimental|Negative wound pressure device (PICO)|The disposable negative wound pressure device (PICO) will be used to cover the midline incision. The dressing is changed on POD3 and removed on POD7. Data are collected on POD3, POD7 and POD30.
2381391|NCT03700086|Active Comparator|Standard sterile dressing|The OPsite post-op visible standard sterile dressing will be used to cover the midline incision. Dressing is changed q48h. Data are collected on POD3, POD7 and POD30.
2381392|NCT03700073|Experimental|Walk training plus virtual reality|Experimental group (GTVR): The intervention consisted of treatment with the robotic CL1Walker gait training system in combination with virtual reality
2381393|NCT03700073|Active Comparator|Walk training|Control group (GT): The intervention consisted of treatment with the robotic CL1Walker gait training system
2381394|NCT03700060||General Practice|Volunteering General Practices who registers contacts from nursing homes on residents with suspected UTI
2381395|NCT03700034|Experimental|mHealth Integrated Antenatal Care|The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.
2381396|NCT03700034|No Intervention|Routine Antenatal Care|In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs).
2381397|NCT03700008|Other|Participants with mental illness|"Participant with pre known or actually diagnosed mental disorder, especially affective or neurodevelopmental disorder.~Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements."
2381398|NCT03700008|Other|Participants without any mental illness|Participant with never diagnosed mental disorder, in a healthy mental state. Using the speech analysis tool with 120 seconds of free speech, measure the mental state with SCL-90, PRIME-MD, B5T, ADHD-VAS as conventional psychological measurements.
2381399|NCT03699995|Experimental|Screening (imaging, biopsy)|Participants undergo imaging of suspicious moles via smartphone app MoleMapper/Sklip app/native smartphone camera app, digital dermoscopy, and confocal microscopy. Participants then receive lidocaine SC and undergo shave or punch biopsy of suspected melanomas.
2381400|NCT03699982|Experimental|Cystic fibrosis patients|Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.
2381401|NCT03699969|Experimental|Hypofractionated dose escalated VMAT|Hypofractionated dose escalated VMAT radiotherapy
2381402|NCT03699969|No Intervention|Conventional concurrent chemoradiation|Conventional concurrent chemoradiation
2381403|NCT03699956|Experimental|Arm 1|"RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
2381404|NCT03699956|Active Comparator|Arm 2|"Cisplatin/carboplatin plus etoposide (up to 4 cycles):~Cisplatin or Carboplatin:~Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks~Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks"
2381405|NCT03699943|Active Comparator|CaverStem 1.0 - Low|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. low dose 30 cc
2381406|NCT03699943|Active Comparator|CaverStem 1.0 - High|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. high dose 60 cc
2381407|NCT03699943|Active Comparator|Caverstem 2.0 - Clinical Registry|Intra-cavernosal injection of autologous bone marrow concentrate for the treatment of Erectile Dysfunction. 20 cc
2381408|NCT03699930|Active Comparator|tDCS + speech therapy|Participants will receive 20 minutes of anodal tDCS paired with speech and language therapy over five consecutive days.
2381409|NCT03699930|Sham Comparator|sham + speech therapy|Participants will receive 20 minutes of sham tDCS paired with speech and language therapy over five consecutive days.
2381410|NCT03699917||Patients with SVV < 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of less than 12.
2381411|NCT03699917||Patients with SVV > or = 12|Patients undergoing pancreaticoduodenectomy with an intraoperative stroke volume variation of greater than or equal to 12.
2381412|NCT03699904|Experimental|Active arm|Valaciclovir 1 gram orally three times daily for 8 weeks.
2381413|NCT03699904|Placebo Comparator|Placebo arm|Matching placebo capsules (containing Avicel blend). Two capsules three times daily for 8 weeks.
2381414|NCT03699878||patients undergoing robotic esophagectomy|Patients 20 years or older who undergo robotic esophagectomy
2381415|NCT03699865|Experimental|Purple|Participants will receive cigarettes with intermediate or very low nicotine content in purple packaging
2381416|NCT03699865|Experimental|White|Participants will receive cigarettes with intermediate or very low nicotine content in white packaging
2381417|NCT03699865|Experimental|Black|Participants will receive cigarettes with intermediate or very low nicotine content in black packaging
2381418|NCT03699852|Experimental|LED group|The study had two groups of participants: the LED group (GL) and the control group (GC), both with Membracel®, a porous membrane that regenerates crystalline cellulose, as the primary cover in the donor area of the skin graft (no secondary cover was used) ). In one of the groups (GL), a light-emitting diode (LED) plate was applied, which was covered with sterile waterproof and transparent film to prevent contamination. The participant was positioned so that the skin graft donor area was accessible. The LED plate covered the entire skin donor area and was irradiated with a radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED plate was applied in contact with the skin graft donor area in the immediate postoperative period and on Membracel® on the 1st, 3rd, 5th and 7th postoperative days. The primary coverage remained until spontaneous removal.
2381419|NCT03699852|Other|Control group|The participants remained and were evaluated under the same conditions. The only difference between the groups is that no LED photobiomodulation session was applied to the control group.
2381420|NCT03699839|Experimental|High dose influenza vaccine|Administration of high-dose influenza vaccine
2381421|NCT03699839|Experimental|MF59-adjuvanted influenza vaccine|Administration of MF59-adjuvanted vaccine
2381422|NCT03699839|Active Comparator|Standard influenza vaccine|Administration of standard intramuscular influenza vaccine
2381423|NCT03699826|Experimental|TMS|
2381424|NCT03699813||scoliosis bleeding management based on aPTT/PT|"Bleeding and coagulopathy during surgery managed by clinical approach and aPTT/PT tests.~Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed."
2381425|NCT03699813||scoliosis bleeding management based on ROTEM|Bleeding and coagulopathy during surgery managed by ROTEM. Blood loss, consumption of fresh frozen plasma (FFP), red blood cell units consumption and time to aPTT/PT tests result will be analysed.
2381426|NCT03699800|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
2381427|NCT03699800|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
2381428|NCT03699787|Experimental|Graphomotor intervention program|The experimental group (EG) intervention comprises a graphomotor intervention program according to a psychomotor approach. The program integrates two group sessions (6-8 children)/week of 30 minutes for 8 weeks (16 sessions).
2381429|NCT03699787|No Intervention|Control Group|The control group (CG) participants will maintain their normal classroom activities. After the study, control group participants will be offered the opportunity to integrate a similar graphomotor intervention program.
2381430|NCT03699774|Experimental|All Participants|"In treatment Period 1 (Day 1 through Day 4), on Day 1, participants receive a single dose of rosuvastatin 10 mg orally with food, and in Period 2 (Day 1 through Day 16), starting on Day 1, participants receive DS-8500a 75 mg orally qd with food for 16 days with concomitant administration of a single dose of rosuvastatin 10 mg qd on Day 14.~In both the periods, rosuvastatin and DS-8500a are administered after an overnight fast of 8 hours and within 10 minutes after consuming a standardized breakfast of 500 calories."
2381431|NCT03699761|Experimental|Pelvic Peritonization|
2381432|NCT03699761|No Intervention|Without Pelvic Peritonization|
2381433|NCT03699748|Experimental|Intervention Group Arm|"Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice).~The intervention arm will also receive usual care as provided by Unite Here Health and their local oncologists."
2381434|NCT03699748|Active Comparator|Control Group Arm|The control group arm will receive usual care as provided by Unite Here Health and their local oncologists.
2381435|NCT03699735|Active Comparator|Hearing Aid with beam form principle_A|Device: Hearing Aid beam former principle_A (simulation of real ear condition). Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
2381436|NCT03699735|Experimental|Hearing Aid with beam form principle_B|Device: Hearing Aid beam former principle_B. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
2381437|NCT03699735|Experimental|Hearing Aid with beam form principle_C|Device: Hearing Aid beam former principle_C. Each participant will be fitted with the 3 different beam former (directionality change) principles on the same hearing aid, saved to 3 manual programs. Beam former principle is a sound processing algorithm to focus to a target source in a noisy situation to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of beam forming and good speech quality.
2381438|NCT03699722|Experimental|Education + Activities|12 modules which include the following topics: introduction to the CN and intervention, video about PrEP, PrEP use in combination with other HIV, STI, and pregnancy prevention, identification and strategizing about beliefs regarding PrEP initiation, addressing perceived risk, strategizing about vulnerability factors that may interfere with PrEP uptake, skills building for PrEP uptake, and enhanced referral to a PrEP provider. Up to 4 follow-up phone calls to reinforce strategies. Text messaging for support PrEP adherence.
2381439|NCT03699722|Active Comparator|Information|PrEP information brochures, frequently asked questions and questions to ask provider. Listing of local PrEP providers.
2381442|NCT03699696||65-75 years of age|Patients who are between the ages of 65 and 75, including 65 but not including 75, and receive propofol for induction of anesthesia.
2381443|NCT03699696||75-85 years of age|Patients who are between the ages of 75 and 85, including 75 but not including 85, and receive propofol for induction of anesthesia.
2381444|NCT03699696||85+ years of age|Patients who are 85 years of age or older, and receive propofol for induction of anesthesia.
2381445|NCT03699683|Experimental|Physical Combined Activity Program|Before and after a 6-months supervised and individualized program that combined aerobic and resistance training were performed in post bariatric patients. Body composition, physical fitness and cardiovascular risk factors were measured before, after the physical activity program and 6 months later (13 months sinde the program started)
2381446|NCT03699657|Active Comparator|RFA with DSM mode|RFA is performed in dual switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
2381447|NCT03699657|Active Comparator|RFA with SSM mode|RFA is performed in single switching mode using a separable clustered electrode (Octopus®) and a three-channel dual-generator unit.
2381448|NCT03699644|Active Comparator|Healthy Control|Healthy controls will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all healthy controls will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
2381449|NCT03699644|Active Comparator|Alzheimer's Dementia|Subjects with Alzheimer's Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, all subjects with Alzheimer's Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
2381450|NCT03699644|Active Comparator|Frontotemporal Dementia|Subjects with Frontotemporal Dementia will undergo a single magnetic resonance imaging (MRI) and PET (positron emission tomography) scan of the brain. In addition, subjects with Frontotemporal Dementia will receive a comprehensive ophthalmic examination as well as undergo photography and imaging of the eye.
2381451|NCT03699631|Experimental|Tacrolimus/Methotrexate/Tocilizumab|"Patients enrolled on the clinical trial will receive tacrolimus initiating at Day -1 at doses to maintain therapeutic levels per institutional preference and continued until at least Day +90 post-transplant.~Methotrexate will be administered intravenously and dosed at 15 mg/m2 Day +1 and 10 mg/m2 Days +3, +6 and +11.~Tocilizumab will be administered intravenously at a dose of 8 mg/kg on Day -1 and at day +100 (+/- 14 days)."
2381452|NCT03699618||Anti-VEGF injection only|Patients who will receive monthly intravitreal anti-VEGF injection for 12 months, followed by anti-VEGF at standard of care treatment interval during months 12-24
2381453|NCT03699618||Hemorrhage displacement + Anti-VEGF|Hemorrhage displacement (at investigators' discretion) followed by monthly intravitreal anti-VEGF injections for 12 months, and standard of care treatment interval during months 12-24
2381454|NCT03699605|Experimental|VESMP|"Participants used VESMP at least half hour session thrice a week over an average of 4 months. The instruction before every domain included using it independently on the participant's own smart phone, or with a trained person either in the clinic or on their phone brought to the participant's home.~Total 25 patients with diagnosis of severe non-fluent aphasia included, ages 40+, at least 3 months post-onset of single unilateral CVA affecting the language dominant hemisphere at the time of baseline testing also including, Participant demographics, aphasia classification and severity. All subjects participated in an intensive 2-week VESMP treatment program prior to beginning the individualized programs."
2381455|NCT03699605|Active Comparator|Traditional Therapy|Control group received traditional therapy total 25 patients with diagnosis of severe non-fluent aphasia included, All subjects participated in an traditional therapy group in routine and received language therapy for 4 months of periods with three sessions per week.
2381456|NCT03699592|No Intervention|Control|
2381457|NCT03699592|Experimental|Reach Home and Read|This arm will receive the Reach Home and Read early literacy intervention
2381458|NCT03699566||Healthy volunteers|"Individuals aged 18-65 without chronic disease.~Interventions: Assessment of Respiratory Muscle Strength, Spirometer, Trunk Muscles Endurance Tests"
2381465|NCT03699514||Subject who completed or will complete a BNA test|
2381466|NCT03699501||Patients|
2381467|NCT03699501||Voluntary patients|
2381468|NCT03699475|Experimental|A: haplo-HSCT plus rivogenlecleucel|"αβ T-cell and CD19+ B-cell-depleted haploidentical stem cell transplantation plus rivogenlecleucel~Rimiducid will be administered to inactivate rivogenlecleucel in the event of GVHD not responsive to standard of care treatment"
2381469|NCT03699475|Active Comparator|B: haplo-HSCT followed by cyclophosphamide|haploidentical stem cell transplantation followed by cyclophosphamide post-transplant
2381470|NCT03699462|Active Comparator|Plasma A group|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
2381471|NCT03699462|Experimental|Albumin group|The group receiving receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
2381472|NCT03699449|Experimental|olaparib + cediranib|olaparib+cediranib combination therapy
2381478|NCT03699436|Experimental|Electric Stimulation Therapy Group|The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
2381479|NCT03699436|Active Comparator|Control Group|The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
2381480|NCT03699423|Active Comparator|0.01% atropine eye drops|Participants will receive one drop per eye every night for two weeks
2381481|NCT03699423|Active Comparator|0.02% atropine eye drops|Participants will receive one drop per eye every night for two weeks
2381482|NCT03699423|Active Comparator|0.03% atropine eye drops|Participants will receive one drop per eye every night for two weeks
2381483|NCT03699397|Experimental|Dry electrode cap EEG|In this diagnostic accuracy study, all patients that are included in the study will undergo a dry electrode electroencephalography (EEG).
2381484|NCT03699384|Experimental|Azacitidine and Avelumab|All enrolled patients will receive 1 cycle of AZA followed by cycles of combination AZA+Avelumab.
2381485|NCT03699371|Experimental|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of continuous renal replacement therapy (CRRT) 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU for the purpose of the study.
2381486|NCT03699371|No Intervention|Late Supplemental Parenteral Nutrition|Control group: would receive EN reaching up to 20 % of daily nutritional requirements and late (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day ) in SPN on 7th day of stay in ICU if it is not already met via enteral route.
2381487|NCT03699358||Group 1: Myeloid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
2381488|NCT03699358||Group 2: Lymphoid recipients|Patients diagnosed with hematologic malignancy were recipients who undergone allogeneic-HSCT. Recipients were included in the current study and grouped as myeloid and lymphoid according to origin of their diagnosis. Recipients who had myeloid type disorders were included in myeloid group as well as recipients who had lymphoid type disorders were included in lymphoid group.
2381489|NCT03699345||Edwards CENTERA THV|
2381490|NCT03699332|Experimental|Intraoperative multi-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Labetuzumab-IRDye800CW. At day 4 or 5 after antibody injection a SPECT/CT scan will be acquired. At day 6 or 7 standard of care cytoreductive surgery will be performed. This will be extended with the use of dual-modality imaging.
2381491|NCT03699319|Experimental|Standard Dose Cohort: CPI-613 + mFOLFIRINOX|"Novel drug and mitochondrial inhibitor, CPI-613 in conjunction with standard-of-care FOLFRINOX.~Consists of a Standard Dose Cohort and Dose escalation cohort using a standard 3 + 3 design starting at 750 mg/m^2 given at a rate of 4 ml/min (dose level (DL) 2). Participants receiving a dose of 1000mg/m^2 will be treated over 2 hours. In the absence of any DLT, the next DL will begin enrollment. If 1 DLT occurs, the DL will be expanded by 3 participants. If <33% of participants experience a DLT, the next DL will be opened and will proceed in similarly. Only 2 DLs are expected to be studied: 750 mg/m^2 and 1000 mg/m^2.~Participants may be enrolled in this cohort after the accrual goal of the standard cohort is met but prior to the completion of treatment of all patients in the standard dose cohort~Participants experiencing a DLT will be allowed to continue on the study at the standard DL of 500 mg or lower."
2381492|NCT03699306|Active Comparator|Conventional r blinded|the participants were allocated to have NG tube inserted in a conventional or blind method.
2381493|NCT03699306|Active Comparator|Brake cable|the participants were assigned to have NG tube inserted by use of a bike brake cable as a guide wire.
2381494|NCT03699306|Active Comparator|High way man's hitch|they were selected to have NG tube inserted by use of silk thread knot.
2381495|NCT03699293|Active Comparator|ASA and Celecoxib|Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
2381496|NCT03699293|Active Comparator|ASA and Naproxen|Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)
2381497|NCT03699280|Experimental|Virtual Reality|VR video to be played during the procedure
2381498|NCT03699280|No Intervention|Standard Procedure|Routine protocol outpatient hysteroscopy
2381499|NCT03699267||UBR TRAM / GBA|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
2381500|NCT03699267||UBR TRAM / GBA + TAP|Patients scheduled for unilateral breast reconstruction surgery with TRAM flap whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
2381501|NCT03699267||M + UBR TRAM / GBA|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia
2381502|NCT03699267||M + UBR TRAM / GBA + TAP|Patients scheduled for partial/total or totalization mastectomy followed by TRAM reconstruction whose anesthetic plan adopted by the anesthetist was general balanced anesthesia combined with US-guided bilateral TAP block
2381503|NCT03699254|Active Comparator|Control|"Control Group (universal prophylaxis + pre-emptive therapy; 6+6): The recommendation of the Spanish Consensus Document will be followed according to the strategy described below:~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +6. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend on each center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of patients will depend oneach center's clinical practice.~Pre-emptive therapy guided by viral load from month +6 to month +12. For a viral load above> 38 copies/mL (> 35 IU/mL) and depending on each center's clinical practice, treatment with valganciclovir may be initiated (900 mg/12h, corrected for renal function)."
2381539|NCT03698994|Experimental|Treatment (ulixertinib)|Patients receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2430141|NCT03365960|Active Comparator|Active2|watermelon flesh
2381504|NCT03699254|Experimental|Experimental|"Experimental Group (reduced prophylaxis + immuno-guided prophylaxis; 3+9):~Universal prophylaxis with valganciclovir (900 mg/24h, corrected for renal function) up to month +3. The use of associated immunotherapy (e.g., anti-CMV hyperimmune immunoglobulin) will depend oneach center's clinical practice. During this period, the treatment of blips of viral replication detected during the usual clinical follow-up of the patients will depend on the each center's clinical practice.~Immuno-guided prophylaxis. This will consist of a monthly determination of cellular immunity by QF-CMV from month +3 to month +12."
2381505|NCT03699241|Placebo Comparator|Group 1|HIV-Uninfected participants
2381506|NCT03699241|Placebo Comparator|Group 2|HIV-Uninfected participants
2381507|NCT03699241|Placebo Comparator|Group 3|HIV-Uninfected participants
2381508|NCT03699241|Placebo Comparator|Group 4|HIV-Uninfected participants
2381509|NCT03699241|Placebo Comparator|Group 5|HIV-Uninfected participants
2381510|NCT03699215|Placebo Comparator|placebo|solution for intravenous infusion, with similar organoleptic characteristics than active treatment.
2381511|NCT03699215|Experimental|levosimendan|Concentrate for solution for perfusion. Pack with a 5 ml vial
2381512|NCT03699202|Experimental|100mg AK0529 Arm|Patients randomised into this arm will be orally administered with 100mg AK0529 q.d. for five days.
2381513|NCT03699202|Experimental|200mg AK0529 Arm|Patients randomised into this arm will be orally administered with 200mg AK0529 q.d. for five days.
2381514|NCT03699202|Experimental|300mg AK0529 Arm|Patients randomised into this arm will be orally administered with 300mg AK0529 q.d. for five days.
2381515|NCT03699202|Placebo Comparator|Placebo Arm|Patients randomised into this arm will be orally administered with placebo q.d. for five days.
2381516|NCT03699189|Experimental|Immediate ANAIS|Participants that attend the training course immediately.
2381517|NCT03699189|No Intervention|Delayed ANAIS|Participants that attend the training course a year later.
2381518|NCT03699176|Experimental|Vilaprisan|2 treatment periods of 12 weeks without a break
2381519|NCT03699176|Placebo Comparator|Placebo|2 treatment periods of 12 weeks without a break
2381520|NCT03699163||Endoscopy patients|Patients who are attending hospital for a colonoscopy as part of their routine clinical care, or as part of the Bowel Cancer Screening Programme, will be asked to give a sample of their breath prior to the procedure.
2381521|NCT03699163||Colorectal cancer patients|Patients who have known pre-diagnosed colorectal cancer (adenocarcinoma) attending hospital as part of their clinical care will be asked to give a breath sample prior to their cancer operation.
2381522|NCT03699150||Postmenopausal women|Outpatients referred to the Gynecologic Endocrinology, FTGM
2381523|NCT03699137||Cases with confirmed ACS|Cases with confirmed diagnosis of acute coronary syndrome in the MINAP database (national registry of ACS patients). No interventions apply to this group as this is an observational study.
2381524|NCT03699137||EMS personnel|Emergency Medical Service (EMS) personnel will take part in the focus group. No intervention applies to this group in this qualitative component of the study.
3183226|NCT00711919|Active Comparator|1|Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months. After administration, serum LDL-cholesterol should be kept between 100 and 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
3183227|NCT00711919|Active Comparator|2|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months. After administration, serum LDL-cholesterol should be kept under 80 mg/dL by controlling the dose of Pitavastatin or adding other anti-hyperlipidemia agents other than statins.
3183228|NCT00711984|Active Comparator|1|Renal artery stenting and Best medical treatment
2381528|NCT03699085|Experimental|ED-LINC Intervention Condition|Patients in this arm will receive the ED-LINC intervention. Elements of ED-LINC are based on evidence-based treatments and are central components of collaborative care. ED-LINC will be supported by a novel Emergency Department Information Exchange (EDIE) technology platform that allows for the creation of ED care plans and electronic alerts and will assist in care coordination of this complex population.
2381529|NCT03699085|No Intervention|Usual Care Condition|Patients in this arm may receive a spectrum of consulting services visits including social work services, psychiatric consultation, inpatient psychiatry consult, rehabilitation psychology consultation, addiction intervention services, pain team consultation services that include MD psychiatric and PhD psychologist providers, spiritual care or other consulting services which shall count as usual care.
2381530|NCT03699059|Other|Health Care Professionals|A purposeful sample of 5 HCP's from the transplant team will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
2381531|NCT03699059|Other|Kidney Transplant Patients|A purposeful sample of 10 kidney transplant patients will test the online intervention and be interviewed using qualitative methods. This data will be analysed and used to plan a second study (feasibility RCT).
2381532|NCT03699046|Active Comparator|Subchondroplasty and Knee Arthroscopy|Patients randomized to the Subchondroplasty and Knee Arthroscopy group will receive the subchondroplasty procedure before or after knee arthroscopy that will be completed based on current standard of care guidelines.
2381533|NCT03699046|Sham Comparator|Knee Arthroscopy Alone|Patients randomized to the Knee Arthroscopy Alone group will receive the knee arthroscopy that will be completed based on current standard of care guidelines.
2381534|NCT03699033|Experimental|Radiation|2.5 Gy/Fraction
2381537|NCT03699007|Experimental|Graded Exposure Therapy (GET Living)|GET Living is jointly delivered by a pain psychologist and a physical therapist. The GET Living treatment was based on a published graded in-vivo exposure treatment manual for adults with adaptations to target a pediatric audience.
2381538|NCT03699007|Active Comparator|Typical Pain Management (TPM)|TPM is a treatment intervention that is representative of current standards of care in a multidisciplinary pain clinic setting. It consists of Cognitive Behavioral Therapy (CBT) and Physical Therapy (PT) sessions, delivered separately by a pain psychologist and a physical therapist.
2381540|NCT03698981|Experimental|Mothers Moving towards Empowerment (MME)|The MME intervention arm will complete our 8-session intervention, weekly for 60-70 minutes per session. Homework will be assigned each week and reviewed the next session. Certificates will be issued to participants who complete the intervention. Fidelity assessments for each session will be evaluated by local research personnel.
2381541|NCT03698981|No Intervention|Treatment As Usual (TAU)|Control condition participants will receive Treatment as usual (TAU), including using free ART and antenatal services as they wish. Control condition participants are assessed on all 'Primary outcomes' at the same time points as the MME intervention group.
2381542|NCT03698968|Other|Single prospective intervention|
2381543|NCT03698955|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
2381544|NCT03698955|Active Comparator|Mediterranean diet|The diet group will be asked to follow a Mediterranean diet for 16 weeks.
2381545|NCT03698929|Active Comparator|Dietary Effect of Cholesterol - Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the egg phase participants will consume two egg yolks a day for four weeks. Each week, participants will be given a week's worth of baked goods containing two egg yolks each.
2381546|NCT03698929|Placebo Comparator|Dietary Effect of Cholesterol - No-Egg Phase|In a randomized, 9-week crossover trial, we will test the effects of dietary cholesterol in individuals without baseline cholesterol intake through two 4-week dietary intervention periods, using baked goods containing egg yolks or egg-free baked goods. During the no-egg phase participants will consume an egg-free product for four weeks. Each week participants will be given a week's worth of egg-free baked goods.
2381547|NCT03698903|Experimental|Take a STAND 4 Health: Immediate|Receives the coaching calls + mHealth intervention first, then receives only the mHealth intervention after the 4 week assessment.
2381548|NCT03698903|Active Comparator|Take a STAND 4 Health: Delayed|Will receive no intervention for the first 4 weeks but then after assessment will be provided the opportunity to receive the full coaching calls + mHealth intervention.
2381549|NCT03698890|No Intervention|Control|Usual care of 3 to 6-monthly clinic visit
2381550|NCT03698890|Experimental|Intervention|Network-based home blood pressure monitor (Fora P20b Blood Pressure Monitor) and telephone consult with care team
2381551|NCT03698864|Experimental|PCS499 900mg twice a day|
2381552|NCT03698851|Experimental|Test Group|Guidor® and Guidor easy-graft® CRYSTAL Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CRYSTAL (Test).
2381553|NCT03698851|Active Comparator|Control Group (C)|Guidor® and Guidor easy-graft® CLASSIC Regeneration of the lesion will be performed with a synthetic membrane (Guidor®) with either Guidor easy-graft® CLASSIC (Test).
2381554|NCT03698838||McDESPOT Study Group|Patients aged 0-19 who have an MRI ordered clinically and have one of the following conditions: epilepsy, hydrocephalus, craniosynostosis or mild traumatic brain injury. Epilepsy, hydrocephalus and craniosynostosis patients will be both newly diagnosed and chronic. MTBI patients will be acute and chronic and defined as a glascow coma score (GCS) of 13-15.These patients will have a 10 minute MRI sequence (McDESPOT) added to their standard of care T1 and T2 scans.
2381555|NCT03698838||Control Model|Control model derived from a linear mixed-effects model (Spader et al 2013)
2381556|NCT03698825|Experimental|Dose Escalation of TEW-7197|TEW-7191 will be given twice daily (BID) for 5 days followed by 2 days off with a cycle of 4 weeks
2381557|NCT03698812||CTL group|control group
2381558|NCT03698812||EXP group|Colonoscope
2381559|NCT03698799||LPV|Patients receive LPV strategy at the initiation of MV support. The LPV strategy is defined as ventilation with tidal volume of <8 mL/kg of PBW plus applying PEEP of at least 5 cm H2O.
2381560|NCT03698799||Non-LPV|Patients do not receive LPV strategy at the initiation of MV support.
2381561|NCT03698786||European males|"This study will involve a cohort of 15 White European men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
2381562|NCT03698786||South Asian males|"This study will involve a cohort of 15 South Asian (India, Pakistan, Sri Lanka, Nepal, Bangladesh, Maldives and Bhutan), men, between the ages of 18-50 years. Participants will be non-smokers, not dieting, and physically well to participate.~Participants will be required to exercise on one occasion."
2381563|NCT03698773|Active Comparator|Baseline Group|Access to existing educational materials about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
2381564|NCT03698773|Experimental|Website Group|Access to a tablet computer set to display an educational website (thepainlesspush.com) with information about labor/delivery pain relief options, as well as an opportunity to ask physicians, nurses, and other relevant personnel for more information.
2381565|NCT03698760|Experimental|Mild stage Alzheimer group|Participants with mild stage Alzheimer's disease
2381566|NCT03698760|Experimental|Control Group|Participants without cognitive disorders
2381567|NCT03698747||mTBI Study Group with McDESPOT sequence|Study group (30 subjects) of football players diagnosed with mTBI (scan at diagnosis, 3-month follow-up scan, genetic screening, concussion assessment at both interaction)
2381568|NCT03698747||Control Group|Control group (30 subjects) of age match non-contact sport players (scan, genetic testing, concussion assessment)
2381569|NCT03698734|Active Comparator|Evening primrose oil|
2381570|NCT03698734|Placebo Comparator|placebo|
2381571|NCT03698708|Experimental|CARES Intervention|Participants in the intervention will participate in 12 weekly group-based telemedicine intervention sessions (up to 60 minutes each) with other parents/caregivers of children with T1D. Intervention sessions focus on cognitive-behavioral therapy to treat depression, including identifying cognitive distortions, cognitive restructuring, behavioral activation, coping strategies, and learning diabetes management skills.
2381572|NCT03698695|Experimental|THN201|THN201: Donepezil 5mg capsule and Mefloquine 10mg capsule once daily for 15 days
2381573|NCT03698695|Active Comparator|Donepezil|Donepezil 5mg capsule and Mefloquine placebo capsule once daily for 15 days
2381574|NCT03698695|Placebo Comparator|Placebo|Donepezil placebo capsule and Mefloquine placebo capsule once daily for 15 days
2381575|NCT03698682|Experimental|Short treatment group|1 tablet Levofloxacin 500mg / day for two days completed by 1 tablet Placebo Levofloxacin 500mg / day for 5 days.
2381576|NCT03698682|Experimental|Standard treatment group|1 tablet of Levofloxacin 500mg prescribed for 7days
2381577|NCT03698669|Experimental|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS, consists of three main components: (1) psychoeducation about pain, depression, opioid use, their interactions, and the maintaining role of avoidance; (2) coaching in being an informed, activated patient (based in part on the chronic care model and on approaches to self-management of chronic illness); and (3) behavioral activation to increase engagement in meaningful activities.
2381578|NCT03698669|Active Comparator|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity.
2381579|NCT03698630|Experimental|Dexamethasone|Single dose of 0.3 mg/kg dexamethasone (rounded off to the nearest 2 mg, max. 12 mg) prescribed on day 1
2381580|NCT03698630|Active Comparator|Prednisolone|1 mg/kg prednisolone (rounded off to the nearest 5 mg, max. 40 mg) prescribed daily for three days from day 1
2381581|NCT03698617|Experimental|HSK3486|"Dose Escalation Cohort:~0.1 mg/kg, 0.2 mg/kg, 0.3mg/kg 0.4 mg/kg 0.5 mg/kg, 0.6 mg/kg, 0.7mg/kg, 0.8 mg/kg Dose Expansion Cohort: 0.3 mg/kg and 0.5 mg/kg."
2381582|NCT03698617|Active Comparator|Propofol|Dose Escalation Cohorts:2.0mg/kg and 2.5mg/kg; Dose Expansion Cohorts: 2.0mg/kg
2381583|NCT03698604|Active Comparator|Total Laparoscopic Hysterectomy|The group that will undergo total laparoscopy hysterectomy with bilateral salpingoophrectomy.
2381584|NCT03698604|Active Comparator|Total Abdominal hysterectomy|The group that will undergo total abdominal hysterectomy with bilateral salpingoophrectomy.
3183229|NCT00711984|Active Comparator|2|Best medical treatment alone
3183230|NCT00712023|Active Comparator|1|warming by circulating-water mattress
2381587|NCT03698578|Experimental|group 1 combat fight|Consisting of professional, high-performance paratletas. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
2381588|NCT03698578|Experimental|group 2 combat fight|Constituted by amateur paratroopers. Intervention: Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
2381589|NCT03698565|Experimental|PPI and ANI measurements|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
2381590|NCT03698552|Experimental|ADCT-602|Patients receive ADCT-602 by vein over 30 minutes on day 1. Courses repeat every 21 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR/CRi receive ADCT-602 every 28 days.
3142588|NCT00002816|Experimental|LATE CNS RELAPSE with/without BM DONOR, TESTICULAR or OCULAR|Induction (Etoposide, Ifosfamide with Mesna Uroprotection,Ifosfamide, Dexamethasone, Vincristine sulfate, pegaspargase, ITT (methotrexate, cytosine arabinoside and therapeutic hydrocortisone), and leucovorin calcium then Intensification (4 courses of 6 weeks, ITT, dexamethasone, vincristine, methotrexate, leucovorin, 6-Thioguanine, cytarabine (Ara-C), Etoposide, PEG, Ifosfamide with Mesna) and Idarubicin), and Maintenance (4 x 12 courses) of ITT, Vincristine, Methotrexate, T-thioguanine.
3142589|NCT00002825|Experimental|Arm I|All patients receive docetaxel with G-CSF every 21 days for up to 12 courses.
3142590|NCT00002827|Experimental|Treatment #1 (Without Zinecard)|"All patients undergoing a splenectomy must receive penicillin or erythromycin prophylaxis twice a day. Pneumocystis prophylaxis:TMP/SMZ 150mg/m2(maximum 300 mg) of TMP in 2 divided doses on 3 consecutive days each week. Aerosolized Pentamidine (200mg/m2/dose - maximum dose 300 mg) should be substituted monthly for patients who cannot tolerate TMP/SMZ therapy. Continue pneumocystis prophylaxis for 6 months after stopping therapy.~Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Bleomycin sulfate 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Vincristine sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15 Etoposide 10mg/m2/day 1-5. IV drip ( < 0.4mg/ml) over 1 hour. Monitor blood pressure every 15 minutes during infusion. G-CSF (filgrastim) 5 mcg/Kg/day start on day 6 (24-36 hrs after 5th dose of VP16) and continued through day 13 (total 8 days)."
3142591|NCT00002827|Experimental|Treatment #2 (with Zinecard)|Zinecard (DZR) 250 mg/m2 IV push on days 1 and 15 before administration of doxorubicin and bleomycin sulfate. Give bleomycin sulfate and doxorubicin within 30 minutes of Zinecard (dexrazoxane hydrochloride). Bleomycin 10 IU/m2/day IV push over 10 minutes on days 1 and 15 Doxorubicin hydrochloride 25mg/m2/day IV push over 15 minutes days 1 and 15 Vincristine Sulfate 1.5mg/m2/day IV push (maximum 2mg) days 1 and 15
2381595|NCT03698526|Active Comparator|Palliative care I|Palliative care
2381596|NCT03698526|Active Comparator|Control II|Patients with mamma carcinoma and (neo-) adjuvant radiotherapy
2381597|NCT03698526|Active Comparator|Control III|Patients before colonoscopy
2381598|NCT03698513|Experimental|BMS-986177 + Aspirin + Clopidogrel (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
2381599|NCT03698513|Experimental|BMS-986177 (Part 1)|BMS-986177 200 mg capsule twice daily (days 1-5)
3142592|NCT00002829|Experimental|Bone Marrow Transplantation|
3142593|NCT00002831|Experimental|Deoxyazacytidine + Busulfan + Cyclophosphamide|Deoxyazacytidine + Busulfan + Cyclophosphamide With Allogeneic Stem Cell Transplantation
3142594|NCT00002832|Experimental|Decitabine + Stem Cell Transplantation|
3150788|NCT00210418|Experimental|Preventive targeting|This arm targeted pregnant and lactating women as well as children 6-23.9 months of age to receive BCC and food assistance. A total of 27 months of enrollment in this program arm was possible.
2381600|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin + Clopidogrel (Part 1)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5) + Clopidogrel 300 mg once daily (day 1) then 75 mg tablet once daily (days 2-5)
2381601|NCT03698513|Experimental|BMS-986177 (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5)
2381602|NCT03698513|Placebo Comparator|BMS-986177 placebo + Clopidogrel (Part 2)|BMS-986177 placebo match capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
2381603|NCT03698513|Experimental|BMS-986177 + Clopidogrel (Part 2)|BMS-986177 200 mg capsule twice daily (days 1-5) + Clopidogrel 300 mg tablet once daily (day 1) then 75 mg tablet once daily (days 2-5)
2381604|NCT03698513|Experimental|BMS-986177 (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5)
2381605|NCT03698513|Placebo Comparator|BMS-986177 placebo + Aspirin (Part 3)|BMS-986177 placebo match capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
2381606|NCT03698513|Experimental|BMS-986177 + Aspirin (Part 3)|BMS-986177 200 mg capsule twice daily (days 1-5) + Aspirin 325 mg tablet once daily (days 1-5)
2381607|NCT03698500|Other|Patients with intestinal colitis and control patients|Device: qPCR diagnostic of specific microRNAs in peripheral blood (10 ml)
2381608|NCT03698487|No Intervention|Retrospective Chart Review|"Specifically, it consists of:~A retrospective study (NB: ethics for this part of the overall study has been sought separately and already approved, file number 1023666).~A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
2381609|NCT03698487|Active Comparator|Intervention|"A before/after intervention~A multiple case study (a sub-study of the before/after intervention)"
2381610|NCT03698474|Active Comparator|SPMC-S|Natrium picosulfate /Magnesium citrate ( Picoprep™, oral solution) 2L in the evening before colonoscopy
2381611|NCT03698474|Active Comparator|SPMC-D|Natrium picosulfate/ Magnesium citrate ( Picoprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
2381612|NCT03698474|Active Comparator|PEGA-S|Polyethylene glycol / Ascorbic acid ( Moviprep™, oral solution) 2L in the evening before colonoscopy
2381613|NCT03698474|Active Comparator|PEGA-D|Polyethylene glycol / Ascorbic acid (Moviprep™, oral solution) 1L in the evening and 1L in the morning before colonoscopy
2381614|NCT03698474|Active Comparator|SULF-S|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 1 L in the evening before colonoscopy
2381615|NCT03698474|Active Comparator|SULF-D|Natrium/ Kalium/ Magnesium sulfate ( Eziclen™, oral solution) 0,5 L in the evening and 0,5L in the morning before colonoscopy
2381616|NCT03698461|Experimental|Atezolizumab, Bevacizumab, FOLFOX|Atezolizumab 1200mg IV Once, Atezolizumab (840mg IV D1 of C1-12) + Bevacizumab (5mg/kg IV D1 of C1-12) + FOLFOX(Oxaliplatin 85mg/m2 IV D1 of C1-12, Levoleucovorin 200mg/m2 IV D1 of C1-12, 5-FU - bolus 400mg/m2 IV D1 of C1-12, - infusional 2400mg/m2 IV continuous(46 hours) D1-3 of C1-12)
2381617|NCT03698448|Placebo Comparator|Placebo DPI|Matching placebo dry powder for inhalation. OligoG is replaced by lactose. 10 capsules, BID
2381618|NCT03698448|Active Comparator|Low dose OligoG DPI|17.5 mg OligoG dry powder for inhalation. 10 capsules, BID
2381619|NCT03698448|Active Comparator|medium dose OligoG DPI|27.5 mg OligoG dry powder for inhalation. 10 capsules, BID
2381620|NCT03698448|Active Comparator|High dose OligoG DPI|37.5 mg OligoG dry powder for inhalation. 10 capsules, BID
2381621|NCT03698435||Prophylaxis|Patients who receive (val)ganciclovir for prophylaxis of cytomegalovirus
2381622|NCT03698435||Treatment|Patients who receive (val)ganciclovir for treatment of cytomegalovirus
2381623|NCT03698422||Healthy controls|"Estimated glomerular filtration rate (eGFR) > 60 mL/min for > 3 months and no known current or chronic medical or surgical conditions.~Blood and urine samples are collected for every 3rd hour during 24 hours"
2381624|NCT03698422||Predialysis CKD subjects|"Estimated glomerular filtration rate (eGFR) between 30 and 15 mL/min for > 3 months (i.e. CKD stage 4).~Blood and urine samples are collected for every 3rd hour during 24 hours"
2381625|NCT03698422||ESKD subjects|"Maintenance haemodialysis treatment for > 3 months for ESKD and with anuria (urine excretion < 100 mL/day).~Blood and urine samples are collected for every 3rd hour during 24 hours"
2381626|NCT03698409|No Intervention|Botox in preservative-free saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative-free saline, as recommended by the manufacturer. 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites)
2381627|NCT03698409|Active Comparator|Botox in preserved saline|OnabotulinumtoxinA (Botox) 200u will be reconstituited using 4 ml of preservative saline (i.e. bacteriostatic saline). 155-195 u of Onabotulinumtoxin A (Botox) will be injected in subjects with chronic migraine, consistent with FDA-approval indications, following the standard injection protocol (31 sites).
2381628|NCT03698396|Experimental|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cell will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
2381629|NCT03698383|Experimental|Herzuma plus Gedatolisib|
2381630|NCT03698370|Experimental|Arm I (Ga68-NeoBOMB1 and Ga68 PSMA-R2|Participants receive gallium Ga 68 DOTA-NeoBOMB1 IV and 45 minutes later, undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 PSMA-R2 IV then undergo PET/MRI 45-60 minutes later.
2381631|NCT03698370|Experimental|Arm II (Ga68 PSMA-R2 and Ga 68-NeoBOMB1)|Participants receive gallium Ga 68 PSMA-R2 IV and 45-60 minutes later undergo PET/MRI. Within 2 weeks, participants receive gallium Ga 68 DOTA-NeoBOMB1 IV then undergo PET/MRI 45 minutes later.
2381632|NCT03698357|Experimental|Interactive video balance-based exercise|Fifteen participants in group A will undergo 30 minutes a day and 3 days a week interactive video balance-based exercise intervention for four weeks.
2381633|NCT03698357|Active Comparator|Conventional physiotherapy|Another 15 participants allocated to the group B will receive 30 minutes a day and 3 days a week conventional rehabilitation for four weeks.
2381634|NCT03698344|Experimental|Biodiesel exhaust exposure|A single arm study in which first a filtered air baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute biodiesel exhaust will start.
3183231|NCT00712023|No Intervention|2|Forced-air warming mattress
2381637|NCT03698318|Experimental|Subject sequence 1|Subject allocation sequence 1. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381638|NCT03698318|Experimental|Subject sequence 2|Subject allocation sequence 2. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381639|NCT03698318|Experimental|Subject sequence 3|Subject allocation sequence 3. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381640|NCT03698318|Experimental|Subject sequence 4|Subject allocation sequence 4. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381641|NCT03698318|Experimental|Subject sequence 5|Subject allocation sequence 5. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381642|NCT03698318|Experimental|Subject sequence 6|Subject allocation sequence 6. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381643|NCT03698318|Experimental|Subject sequence 7|Subject allocation sequence 7. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381644|NCT03698318|Experimental|Subject sequence 8|Subject allocation sequence 8. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381645|NCT03698318|Experimental|Subject sequence 9|Subject allocation sequence 9. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381646|NCT03698318|Experimental|Subject sequence 10|Subject allocation sequence 10. Intervention : the subject will receive the five products (tested product n°1, tested product n°2, tested product n°3, tested product n°4 and tested product n°5) in a certain order of assignment of each study product (which will be randomly attributed to him via the randomization sequence).
2381647|NCT03698305|Experimental|ASP5354 Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, 4 subjects will be randomized to receive escalated doses of ASP5354. Each subject will receive a single intravenous bolus injection under fasting conditions.
2381648|NCT03698305|Placebo Comparator|Placebo Dose Escalation (5 Dose Levels)|Healthy male and female subjects will be assigned to Cohorts 1-5. In each cohort, two subjects will be randomized to receive placebo.
2381649|NCT03698292|Active Comparator|First group|Metoclopramide 10 mg tablets will be taken by the patients of this group three times daily for 7 days
2381650|NCT03698292|Active Comparator|Second Group|Itopride 50 mg tablets will be taken by the patients of this group three times daily for 7 days
3183232|NCT00712036|Active Comparator|Interim|Methadone maintenance for up to 4 months with emergency counseling only for individuals on program waiting lists.
3183233|NCT00712036|Active Comparator|Comprehensive|Methadone Treatment provided with counseling as usual.
3183234|NCT00712036|Active Comparator|Restored|Methadone Treatment with counseling provided by a clinician with a lower caseload than counseling as usual.
3183235|NCT00712049|Active Comparator|1|Nicotinic acid + Simvastatin
3183236|NCT00712049|Active Comparator|2|Simvastatin
3183237|NCT00712062|Experimental|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
2381657|NCT03698266|Other|All Enrolled Patients|Receive needle knife fistulotomy as a starting technique to gain access to the biliary system
3183238|NCT00712088|Experimental|1: Group Intervention|Group level intervention
3183239|NCT00712088|Active Comparator|2: HCT|Offer of HIV counseling and testing
3183240|NCT00712101|Experimental|1|Abciximab bolus administration intracoronary
3183241|NCT00712101|Active Comparator|2|Abciximab bolus intravenously
3183242|NCT00712114|Experimental|Cohort 1|10 mg HE3286 (1 x 5 mg HE3286, BID)
3183243|NCT00712114|Experimental|Cohort 2|20 mg HE3286 (2 x 5 mg HE3286 BID)
3183244|NCT00712114|Experimental|Cohort 3|40 mg HE3286 (4 x 5 mg HE3286 BID)
3183245|NCT00712127|Experimental|Diet and Exercise|Diet and Exercise for Class II and Class III Obesity
3183246|NCT00712127|Experimental|Diet and Exercise-Delayed|Diet and Exercise-Delayed for 6 months for Class II and Class III Obesity
3183247|NCT00712127|No Intervention|Control|Normal weight, overweight and Class I obesity
3183248|NCT00712140|Active Comparator|Arm I|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
3183249|NCT00712140|Experimental|Arm II|Patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. All patients also receive standard chemotherapy regimens as per local institutional protocols either concurrently with or sequentially to trastuzumab.
2381658|NCT03698253|Experimental|Regorafenib plus FOLFIRI|"Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followedby Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).~Regorafenib is administered at adjusted doseage of 120 mg daily for 3 weeks in a 4-week cycle."
2381659|NCT03698240|Experimental|Mindfulness-based program|Children and parents receive the program
2381660|NCT03698240|No Intervention|Waiting-list|Children and parents receive no-interventions.
2381661|NCT03698227|Experimental|Study treatment|"Olaratumab 20 mg/kg IV on day 1 and day 8 of cycle 1 and 15 mg/kg olaratumab IV on day 1 and day 8 of cycles 2-8.~Plus dexrazoxane at a dose equal to 10 times the doxorubicin dose (mg/m2) IV on day 1 of each 21 day cycle for 8 cycles~Plus doxorubicin 75 mg/m2 IV on day 1 of each 21 day cycle for 8 cycles~Beginning with cycle 9, olaratumab maintenance monotherapy at 15 mg/kg IV on day 1 and day 8 of each subsequent 21 day cycle"
2381662|NCT03698214||isolated traumatic brain injury|Adult patients having isolated traumatic brain injury with a head abbreviated injury scale (AIS) ≥ 3 and without severe injury to other regions (other AIS ≤ 1) were included. The patients were grouped and analyzed according to reversed shock index < 1 or reversed shock index ≥ 1.
2381663|NCT03698201||Cohort 1 / High grade Glioma|"Cohort 1:~Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV)~Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)"
2381664|NCT03698201||Cohort 2 / Low grade Glioma|"Cohort 2:~Histologically confirmed low grade (grade II) glioma~Planned treatment either~expectant monitoring or~RT alone or~Chemotherapy alone or~a combination of RT/Chemotherapy"
2381665|NCT03698188|Experimental|Injectable platelet-rich fibrin|A platelet concentrate will be prepared from the patient's own blood in plain plastic tubes, without the use of anticoagulants, and applied immediately within the root canal before coagulation.
2381666|NCT03698188|Active Comparator|Platelet-rich plasma|A platelet concentrate will be prepared from the patient's own blood in tubes containing anticoagulants to maintain the fluid consistency and applied within the root canal.
2381667|NCT03698175|Experimental|Three good things exercise|
2381668|NCT03698175|Placebo Comparator|Unspecific childhood memory recall exercise|
3142595|NCT00002833|Experimental|Group 1A|"Group 1A - With or Without Remission + Failing Fludarabine therapy:~Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3 with Cladribine continuous infusion for 5 days, beginning 4 hours before Ara-C first dose. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
3142596|NCT00002833|Experimental|Group 1B|"Group 1B: With or Without Remission, No previous Fludara Therapy~Fludarabine IV over 30 minutes daily on days -6, -5, -4 and -3. Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours. Idarubicin IV Days -6, -5 and -4. Cells infused on day 0. Cyclosporine via continuous IV infusion, oral cyclosporine administered for 6 months postinfusion (tapered 10% weekly until discontinued). Methylprednisolone begins 5 days after infusion then gradually tapered."
2381671|NCT03698149|Experimental|Electrocorticography-based brain computer interface|
2381672|NCT03698136|Experimental|Stimulation of denervated muscle|direct muscle stimulation 5 times a week for 33 minutes 3 minutes warm up 30 minutes treatment
2381673|NCT03698123|Experimental|Dietary Modification|On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
2381674|NCT03698110|Experimental|Intervention Group|Participated in one introductory session, in the four sessions of PUEDES program during four weeks and in a closing session.
2381675|NCT03698110|No Intervention|Control Group|Participated in one introductory session and in a closing session.
2381676|NCT03698084||Active|200 infants enrolled; family demographics collected and samples at day 5 (venepuncture, nasopharyngeal swab, urine and stool), actively followed up through their first RSV season for signs of respiratory symptoms. If respiratory symptoms are due to RSV infection (by point of care testing) samples as taken at day 5 are repeated at time of infection and again 7 weeks later. Annual questionnaire enquiring into respiratory illness, hospitalisations and family health and health quality of life, for up to 3 years.
2381677|NCT03698084||Passive|1800 infants enrolled; family demographics collected. Questionnaire follow up at 1 year of age enquiring into respiratory illness, hospitalisations and family health and health quality of life. If infant was hospitalised in first year of life, follow up will continue for up to 3 years.
3183250|NCT00712205|Placebo Comparator|A|20 Patients with asthma in a crossover design
2381679|NCT03698058|Experimental|A2 Growing Up Milk|
2381680|NCT03698058|No Intervention|Traditional non-A2 milk|
2381681|NCT03698058|Active Comparator|Other Growing Up Milk|
2381682|NCT03698045|Experimental|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (c/6 hours) during 10 days.
2381683|NCT03698032|Active Comparator|Water Arm|Participants will consume water only as the intervention
2381684|NCT03698032|Active Comparator|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
2381685|NCT03698032|Active Comparator|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
3183251|NCT00712205|Active Comparator|B|20 Patients with asthma in a crossover design
3183252|NCT00712218|Active Comparator|A|
2381688|NCT03698006|Experimental|Tibial nerve block|Adductor canal and tibial nerve blocks performed by the anesthetist under ultrasound guidance before spinal block.
2381689|NCT03698006|Active Comparator|Local infiltration analgesia|Adductor canal block by the anesthetist under ultrasound guidance before spinal block. Infiltration of the knee by the surgeon with local anesthetic at the end of the surgery.
2381693|NCT03697967|Experimental|Supine|Infant placed supine for 120 seconds before cord clamping
2381694|NCT03697967|Experimental|Prone|Infant placed prone for 120 seconds before cord clamping
2381695|NCT03697954||overactive bladder patients|Female patients with refractory overactive bladder and urge urinary incontinence undergoing direct full stage implantation
2381696|NCT03697941||Surgical cut-down and arterial puncture under direct vision|
2381697|NCT03697941||Percutaneous arteriotomy closed with closure device|
2381698|NCT03697928||CrAT subjects|"13 healthy adult men, with a wide range of maximal aerobic capacity will be included.~Subjects will be classified as trained, physical active and untrained according to their VO2max.~Subject will perform one-legged knee extension and flexion exercise inside the MRS scanner and cycling outside the scanner"
2381699|NCT03697915|Experimental|Experimental group|Experimental group, in which a physical therapy programme supplemented by the James lift system was applied
2381700|NCT03697915|Placebo Comparator|Control|Control group, in which a conventional physical therapy programme was applied.
2381701|NCT03697889|Experimental|Treatment Sequence AB|Participants will receive Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 1 followed by Treatment B (reference product Nalgesin, 1 x 275 mg) dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
2381702|NCT03697889|Experimental|Treatment Sequence BA|Participants will receive Treatment B (reference product Nalgesin, 1 x 275 mg) at dosing period 1 followed by Treatment A (test product Naproxen sodium tablet, 1 x 275 mg) at dosing period 2. There is a wash-out period of 7 days between the two dosing periods.
2381705|NCT03697863||Noninvasive Adjusted Ventilatory Assist|
2381706|NCT03697863||Noninvasive Pressure Support|
2381707|NCT03697850|Experimental|atezolizumab|Anti-PD-L1 immunotherapy: atezolizumab (1200 mg) administered IV over 1 h every 3 weeks for 12 months (18 injections). Beginning 30 days (±5 days) after chemo-radiotherapy.
2381708|NCT03697837|Experimental|Parent Management Training|Parents will receive a web-based parenting intervention for tantrums and disruptive behavior in young children
2381709|NCT03697824|Experimental|GSK3377794+pembrolizumab|After screening, eligible subjects will enter a leukapheresis phase, followed by lymphodepletion phase where they will be administered fludarabine and cyclophosphamide. On Day 1, subjects will receive a single dose of GSK3377794 administered as an intravenous infusion of 1 to 6 x10^9 total transduced cells. On Day 22, subjects will be administered pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks for adults and 2 mg/kilogram (kg) (up to 200 mg) once every 3 weeks for children for up to 35 cycles (2 years) or until subsequent disease progression.
2381710|NCT03697811|Experimental|DE-117 Ophthalmic Solution 0.002%|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
2381711|NCT03697798|Active Comparator|Children aged between 7-10 years of age|Healthy children from 7 up to 10 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country. They will receive Boostrix®-IPV combination vaccine.
2381712|NCT03697798|Active Comparator|Children aged between 11-15 years of age|Healthy children from 11 up to 15 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 36 in each country aiming for comparable numbers of participants with aP vs wP vaccination background. They will receive Boostrix®-IPV combination vaccine.
2381713|NCT03697798|Active Comparator|Adults aged between 20-34 years of age|Healthy young adults from 20 up to 34 years of age, determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
2381714|NCT03697798|Active Comparator|Adults aged between 60-70 years of age|Older adults from 60 up to 70 years of age determined by date of birth (dd/mm/yyyy), at the time of the first visit. Male + female, approximately equally distributed, n = 25 in each country. They will receive Boostrix®-IPV combination vaccine.
2381715|NCT03697785|Experimental|Beacon Caresystem with weaning advice|Beacon care system set up to give weaning advice and options to accept or reject advice.
2381716|NCT03697785|Other|Beacon Caresystem for monitoring only|Beacon care system attached but only for data collection purposes. No advice will be given.
2381717|NCT03697772||multmorbid patients|patients with 2 chronic diseases (medical conditions requiring management for more than 6 months)
2381718|NCT03697759|Experimental|Usual care + selfBACK|Participants will use the selfBACK system and app
2381719|NCT03697746|Active Comparator|Paracetamol|1000 mg Paracetamol vial intravenously
2381720|NCT03697746|Active Comparator|Dexketoprofen Trometamol|50 mg Dexketoprofen Trometamol vial intravenously
2381721|NCT03697746|Active Comparator|Ibuprofen|400 mg Ibuprofen vial intravenously
2381722|NCT03697733|Experimental|Oral Etoricoxib group|Subjects will receive oral Etoricoxib120 mg 30 minutes before fractional curettage then added intravenous Propofol 2 mg/kg when start the procedure
2381723|NCT03697733|Placebo Comparator|Intravenous Fentanyl group|Subjects will receive oral placebo [folic acid] 1 tab 30 minutes before the procedure then added intravenous Propofol 2 mg/kg and Intravenous Fentanyl 1 microgram/kg when start the procedure
2381724|NCT03697720|Experimental|Primary Dysmenorrhea|We will look at the effects of naproxen 500mg use on pain starting just before and during menses.
2381725|NCT03697707|Experimental|Cohort 1: Low dose|patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
2381726|NCT03697707|Experimental|Cohort 2: High dose|patients receiving 4 bi-weekly vaccinations with 50E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
2381727|NCT03697694|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
2381728|NCT03697694|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
2381729|NCT03697681|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
2381730|NCT03697681|Placebo Comparator|Placebo|placebo
2381731|NCT03697668|Experimental|imatinib-Dihydroartemisinin-piperaquine|triple combination
2381732|NCT03697668|Active Comparator|Dihydroartemisinin-piperaquine|standard of care
2381733|NCT03697655|Experimental|PREDATOR-BR Cohort A|n=46, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
2381734|NCT03697655|No Intervention|PREDATOR-BR Cohort B|n=46, Control Group, Observation (no treatment)
2381735|NCT03697655|Experimental|PREDATOR-MRD Cohort A|n=59, Daratumumab 20 MG/ML [Darzalex], 16 mg/kg body weight administered as an intravenous infusion
2381736|NCT03697655|No Intervention|PREDATOR-MRD Cohort B|n=59, Control Group, Observation (no treatment)
2381737|NCT03697642|Experimental|NG tube placement with nasopharyngeal tube|
2381738|NCT03697642|Active Comparator|NG tube placement without nasopharyngeal tube|
2381739|NCT03697629|Experimental|Daratumumab|Increased infusion rate daratumumab monotherapy
2381740|NCT03697616|Experimental|Ridge augmentation with sticky bone and GBR|Ridge augmentation using Autologous concentrated Growth factors (CGF) enriched bone graft matrix (sticky bone) and guided bone regeneration using native collagen membrane in horizontally deficient maxilla
2381741|NCT03697603|Experimental|Brexpiprazole 1mg|Tablets, Oral, 1mg once daily, 14 weeks Other Name: REXULTI
2381742|NCT03697603|Experimental|Brexpiprazole 2mg|Tablets, Oral, 2 mg once daily, 14 weeks Other Name: REXULTI
2381743|NCT03697603|Placebo Comparator|Placebo|Tablets, Oral, once daily, 14 weeks
2381744|NCT03697590|Experimental|PDT with no curettage|
2381745|NCT03697590|Active Comparator|Standard PDT|
2381747|NCT03697564|Experimental|gemcitabine +nivolumab + cabiralizumab|
2381749|NCT03697538|Experimental|Adductor Canal Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
2381750|NCT03697538|Active Comparator|Femoral Nerve Block|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
2381751|NCT03697525|Experimental|Vibration Group (VG)|VG participants undergo rMV treatment, carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
2381752|NCT03697525|Sham Comparator|Control Group (CG)|CG participants undergo the sham rMV by positioning the vibrator close to the tendon but without touching the skin. In this condition, patients were only subject to the faint buzzing sound of the vibrator. Sham rMV treatment is carried out for three consecutive days by 2 trained physiatrists; each daily session consists of three 10-minute treatment (for each treated limb), interspersed with a 5-minute break. During the rMV, subjects are required to make a voluntary isometric contraction of the treated muscle
3150789|NCT00210418|Active Comparator|Recuperative targeting|This arm targeted pregnant and lactating women as well as mothers of malnourished children (WAZ <-2 zscores) between 6 and 59 months of age. A total of 18 months of enrollment was possible in this program arm.
2381754|NCT03697499|Experimental|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
2381755|NCT03697499|Sham Comparator|fish oil and shame exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
2381756|NCT03697499|Placebo Comparator|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
2381757|NCT03697499|Other|soy oil and shame exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
2381758|NCT03697486|Experimental|High Protein|(40,6% protein)
2381759|NCT03697486|Experimental|Moderate Protein|(23.5% protein)
2381760|NCT03697486|Experimental|Low Protein|(12.4% protein)
2381844|NCT03696940|Experimental|Experimental Group|2 tablets of: L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
3150790|NCT00210522|Experimental|001|RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
3150791|NCT00210652|Experimental|001|RWJ 333369: Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
2381761|NCT03697473|Active Comparator|Nordic Hamstring Exercise Group|Participants were required to kneel on a gym mat keeping their hips in a slightly flexed position and to slowly lower themselves in a controlled manner as far as they could towards the ground. When they could no longer lower themselves as such, they were instructed to utilise their arms to buffer the fall and touch their chest off the ground, while maintaining tension in their hamstrings. Once their chest touched the ground they were instructed to immediately return to the starting position by pushing up with their hands.
2381762|NCT03697473|Experimental|Hip Extension Exercise Group|The participant lay on an exercise bench at a 45° angle with their hips held just over the top of the bench, their trunk erect and hips extended and their heel supported. Participants slowly flexed their hip until they reached 90° from the starting position and were then required to return to the starting position by extending through the hip while maintaining a neutral pelvic and trunk posture throughout. This exercise was then repeated on the opposite leg
3183253|NCT00712218|Experimental|B|
2381764|NCT03697447|Experimental|Endermotherapy treated scar|Endermotherapy massage treatment
2381765|NCT03697447|No Intervention|Control scar|No intervention, standard of care
2381766|NCT03697434|Experimental|Palliative Care referral|Participants with specific uncontrolled symptoms or critical events in course of their Parkinson disease will be referred to a palliative care specialist for supportive care.
2381768|NCT03697408|Experimental|Itacitinib and everolimus|
2381769|NCT03697382|Experimental|Very Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 2,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
2381770|NCT03697382|Experimental|Low Steps|Subjects will be asked to undergo reduced daily stepping to a level of 5,000 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
2381771|NCT03697382|Experimental|Moderate Steps|Subjects will be asked to undergo reduced daily stepping to a level of 7,500 steps/d for 2 days. On the evening of day 2, they will be asked to run at 65% of VO2max for 1-hour.
2381772|NCT03697369||Observation group|Individuals with T1D ages 0-20 years who switched management modality from MDI to pump as part of their clinical care and were followed up prospectively in the next 12 months.
2381773|NCT03697356|Experimental|Rituximab&Bortezomib&Lenalidomide&Dexamethasone|
2381774|NCT03697343|Other|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm) and no margin as defined by the RTOG 9005
2381775|NCT03697343|Other|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm margin
2381776|NCT03697330|Active Comparator|Ringer's lactate 18-20 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group L:will receive 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
2381777|NCT03697330|Active Comparator|Ringer's lactate 4-6 ml/kg|"Patients will be randomly allocated into two groups of 40 patients each:~Group R: will receive 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia."
2381778|NCT03697317|Experimental|Televideo Lifestyle Coaching|
2381779|NCT03697317|Active Comparator|Enhanced Usual Care|
3150792|NCT00210678||Group: 1|Men with premature ejaculation (PE)
3150793|NCT00210678||Group: 2|Men without PE
3150794|NCT00210899|Active Comparator|Vancomycin plus Ceftazidime|Vancomycin 1g q12h as 1h infusions plus Ceftazidime 1g q8h in 2h-infusions, 7-14d
3150795|NCT00210899|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
3183254|NCT00712231||phakic eyes|the cases did not accept any intraocular surgery
3183255|NCT00712231||pseudophakic eyes|tht cases did not accept any intraocular surgery expect for cataract surgery
3188949|NCT00772460|Active Comparator|Forced Air|Warming with forced air (BairHugger)
2381788|NCT03697291|Experimental|PS wire|self-invented iECG wire
2381789|NCT03697291|Active Comparator|Certodyn|Commercially available iECG system - Certodyn
2381790|NCT03697278|No Intervention|Control group|Using clinical routinely regime device to use and monitor postoperative controlled pain (PCA) after surgery.
2381791|NCT03697278|Experimental|Smith medical CADDsolis|This study group use a new device to use and monitor postoperative controlled pain (PCA) after surgery.
2381792|NCT03697265|Experimental|Sepranolone (UC1010) low dose|Sepranolone (UC1010) low dose administered subcutaneously (SC) during the luteal phase
2381793|NCT03697265|Experimental|Sepranolone (UC1010) high dose|Sepranolone (UC1010) high dose administered subcutaneously (SC) during the luteal phase
2381794|NCT03697265|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) during the luteal phase
2381797|NCT03697239|Experimental|AA NABPLAGEM|ascorbic acid paclitaxel protein-bound cisplatin gemcitabine
2381798|NCT03697226|Experimental|Dose 1|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
2381799|NCT03697226|Experimental|Dose 2|Topical ABI-1968 Cream applied at Day 1, Day 8, Day 15 and Day 22
2381800|NCT03697226|Experimental|Dose 3|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
2381801|NCT03697226|Experimental|Dose 4|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
2381802|NCT03697226|Experimental|Dose 5|New Topical ABI-1968 Formulation applied at Day 1, Day 8, Day 15 and Day 22
2381803|NCT03697213||General Practitioners|Registered General Practitioners in one of the six participating countries.
2381804|NCT03697200|Active Comparator|Auricular Point Acupressure (APA)|Patients with active points related to Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS). The points for AIMSS include (1) points corresponding to body pain location and (2) three points known for alleviating stress and pain (i.e., shenmen, sympathetic, and nervous subcortex)
2381841|NCT03696966|Experimental|Intermittent Very-Low Calorie Diet|Intermittent Restriction: follow very-low calorie diet (500-800) with portion-controlled meals three days per week and structured healthy eating on other days
2381842|NCT03696953|Experimental|Probiotic|"Florajen3 Combination Probiotic Product 15 billion CFU per capsule~1 capsule daily from 28 weeks until the time of birth."
2381805|NCT03697200|Sham Comparator|Sham APA control|The same procedure of APA will be applied but the tapes/seeds will be placed on different points (points not related to AIMSS). Participants in the Sham APA Control will receive APA on the five ear points comprising mouth, stomach, duodenum, internal ear, and tonsils. These points are chosen for the Sham APA Control for two reasons: First, they are distinct from the zones of the ear (and the points therein) associated with AIMSS and correspond to body regions in which BCS (Breast Cancer Survivors) are usually pain-free; second, they are equivalent in number to those points used in the APA treatment group and no negative impacts have been observed among these points in our pilot study.
2381806|NCT03697200|Other|Education Control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Educational sessions are intended to reflect usual standard medical care per guidelines from the American Society of Clinical Oncology (ASCO), while also meeting the needs of trial participation, including (1) the knowledge of hormonal therapy and side effects; (2) assessment and management of physical long-term and late effects; (3) assessment and management of psychological long-term and late effects; and (4) dietary (developed by Co-I, van Londen) and physical activity in Breast Cancer Survivors (BCS) (developed by Co-I, Stearns). These materials have been used by the research team, and clinical practice. Materials will be tailored so that they can be delivered within 15 minutes for each session.
2381807|NCT03697187||Hereditary Angioedema|Patients with Hereditary Angioedema who are receiving treatment with Ruconest (rhC1INH).
2381808|NCT03697174|Experimental|Exposure group|Subjects in exposure group will be exposed to 200 ppb ozone for 2 hours in a chamber.
2381809|NCT03697174|Sham Comparator|Control group|Subjects in control group will be exposed to 0 ppb ozone (clean air) for 2 hours in a chamber.
2381810|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 1|Once Daily
2381811|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 2|Twice Daily
2381812|NCT03697161|Experimental|OV101 (gaboxadol) Regimen 3|Three Times Daily
2381814|NCT03697135||Seed Contacts|Initial participants who will invite previous injecting contacts to take a hepatitis C test using a respondent driven sampling method
2381815|NCT03697135||Initial Nominations for Testing|Contacts of initial participants who consent to be tested and enrol in the study using a respondent driven sampling method
2381816|NCT03697135||Second Level Nominations for testing|Contacts of wave one participants who consent to be tested and enrol in the study using a respondent driven sampling method
3188950|NCT00772460|Experimental|Conductive Warming|Warming with the conductive device (HotDog)
3150796|NCT00210951||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
3150797|NCT00210964|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
3150798|NCT00210964|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
2381821|NCT03697096|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
2381822|NCT03697096|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for UTI in non-ICU patients in the first 3 days of hospitalization.
2381826|NCT03697070|Active Comparator|Routine Care|Continued routine antibiotic stewardship strategies.
2381827|NCT03697070|Active Comparator|INSPIRE CPOE Smart Prompt|Use of a computerized physician order entry (CPOE) smart prompt alert to guide empiric choice of antibiotics for PNA in non-ICU patients in the first 3 days of hospitalization.
2381828|NCT03697057||patients|Patients scheduled for elective ambulatory gynaecological surgery, which was performed under standardised general anaesthesia
2381829|NCT03697057||healthy volunteers|Female healthy volunteers matched to the patient group regarding the age
3150799|NCT00210977||Erythropoietin receptor agonist|Participants with borderline serum anti erythropoietin (EPO) antibody (Ab) titers and who are treated with any erythropoietin receptor agonist (ERA) for any indication, having anti-EPO Ab identified by radioimmunoprecipitation (RIP), who are responding to ERA therapy, will be included in the study.
2381831|NCT03697018|Experimental|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material, enriched with zirconia (10% by weight), the material offers natural esthetics with successful outcome.
2381832|NCT03697018|Active Comparator|monolithic zirconia|Zirconia or zirconium dioxide (ZrO2) is a highly attractive ceramic material in prosthodontics due to its excellent mechanical properties. It is widely used to build prosthetic devices.
2381833|NCT03697005|Experimental|BioHPP PEEK single posterior crowns|BioHPP PEEK copings veneered with composite resin
2381834|NCT03697005|Active Comparator|zirconia-based single posterior crowns|yttria stabilized tetragonal zirconia used as copings to be veneered with porcelain
2381835|NCT03696992|Experimental|NBI|Tandem colonoscopy with NBI follow by WL
2381836|NCT03696992|Active Comparator|BLI|Tandem colonoscopy with BLI follow by WLI
2381837|NCT03696992|Experimental|WLI|Tandem colonoscopy with WLI follow by WL
2381838|NCT03696979|Active Comparator|myofascial induction|Twice a week for 8 weeks. Lumbar interfacial field stroke application, Lumbar interfacial field to deep application, Lumbar region cross-hands induction technique, Hip flexor region induction.
2381839|NCT03696979|Active Comparator|Therapeutic Pain education|Pain education,twice a week for 8 weeks. The mechanism of pain,Pain processing in the center, How sensitive the central nervous system is in chronic pain, Pain becomes chronic with the contribution of factors, Problems related to fear of pain will be explained in detail.
2381840|NCT03696966|Active Comparator|Continuous Calorie Restriction|Daily calorie restriction: follow low-calorie diet (1,200-1,500 calories) daily using portion-controlled meals
2381845|NCT03696940|Active Comparator|Control Group|2 tablets of: Atorvastatin 10 mg
2381846|NCT03696927|Experimental|User Focus Group Participants|Target user population will be human subjects with spinal cord injury at levels C3 to C5, and ASIA Impairment Scale (AIS) A, B, or C.
2381847|NCT03696914||Eosinophilic|Asthmatic patients showing 3% or more sputum eosinophils
2381848|NCT03696914||Non-eosinophilic|Asthmatic patients showing less than 3% sputum eosinophils
2381849|NCT03696901||use of Xydalba, >18 years|Male and female patients, ≥18 years of age at the time of receipt of Xydalba. Patients who received at least one Xydalba administration in Germany
2381850|NCT03696888|Experimental|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
2381851|NCT03696888|Active Comparator|TeleCoach control|A web-app giving information on health-related consequences of alcohol consumption.
2381852|NCT03696875|Experimental|Multilevel Guided Discharge Planning|
2381853|NCT03696875|Active Comparator|Standard of care|
2381854|NCT03696862|Experimental|collagen plug|collagen plug used to seal the socket after atraumatic extraction of the badly deacayed teeth with immediate implant placement and bone graft
2381855|NCT03696849|Active Comparator|glazed emax Press|
2381856|NCT03696849|Experimental|Polished emax Press|
2381857|NCT03696836|Experimental|Trammpolin® meniscus prosthesis|The patients will be implanted with the Trammpolin® meniscus prosthesis
2381858|NCT03696810|Other|• Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
3142597|NCT00002835|Experimental|Arm I|"3 courses of early intensification:~First course: Ifosfamide (IFF) IV continuously and Etoposide (VP-16) IV over 2 hours every 12 hours on days 1-3. Filgrastim (G-CSF) administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover then autologous peripheral blood stem cells (PBSC) are harvested, selected for CD34 positive cells, and purged in vitro. If more than 5% of the WBC contains lymphoma cells after induction, then 2 courses of IFF and VP-16 are administered before PBSC harvest.~Second course: IFF IV continuously on days 1-3, mitoxantrone (DHAD) IV on day 1, and G-CSF SC as in first course.~Third course: Carmustine IV over 1 hour on day -6, ARA-C and VP-16 IV every 12 hours on days -5 to -2, and melphalan IV on day -1. PBSC are reinfused on day 0. G-CSF is administered SC beginning on day 0 and continuing until blood counts recover. Each course lasts 3 weeks in the absence of disease progression or unacceptable toxicity."
3142598|NCT00002835|Experimental|Arm II|IDSHAP during 4 week courses 2 and 5, MBIDCOS during courses 3 and 6, and IFF and VP-16 IV over 1 hour on days 1-3 and DHAD IV over 15 minutes on day 1 during courses 1, 4, and 7.
3142599|NCT00002836|Experimental|Filgrastim + Chemotherapy|
3142600|NCT00002836|Experimental|Filgrastim|
2381863|NCT03696771|Experimental|NJH395|Includes non-breast HER2-positive advanced malignancies
3183256|NCT00712257|Other|Spectranetics Laser plus Gore Viabahn Endoprosthesis|Spectranetics Laser for optimal debulking followed by adjunctive PTA plus GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface placement
3183257|NCT00712283|Placebo Comparator|D|healthy volunteers
2381866|NCT03696745|Placebo Comparator|Placebo|preterm infants with severe hypoxic ischemic encephalopathy receive only 0.9% Sodium-chloride
2381867|NCT03696745|Experimental|infusion|preterm infants with severe hypoxic ischemic encephalopathy will receive up to 4 infusions of their own volume reduced cord blood stem cells. The number of doses will be determined by the amount of available cord blood stem cells. The dose for each infusion is 5x107 cells/kg
2381868|NCT03696732||Women undergoing cesarean section|Women undergoing cesarean section under spinal anesthesia with prophylactic phenylephrine drip.
2381869|NCT03696719|Active Comparator|Undergoing surgery under general anesthesia|Patients will undergo the surgery under general anesthesia, anesthetic regime will be according to standard clinical practice.
2381870|NCT03696719|Active Comparator|Undergoing surgery under regional anesthesia|Patients will undergo the surgery under neuroaxial anesthesia.
2381871|NCT03696706|Active Comparator|LED group|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
2381872|NCT03696706|Placebo Comparator|Placebo group|For the placebo group, all measures described for the LED group will be adopted, however, the equipment will be switched off.
2381873|NCT03696706|No Intervention|Control group|In this group, the participants will only be evaluated. No intervention will take place.
2381874|NCT03696693||children with chronic rhinosinusitis|Children aged 6-18 years presented with symptoms of chronic rhinosinusitis will be recruited from the otorhinolaryngology out-patient clinic and department at Assiut University Hospital from October, 2018 to October, 2019.
2430142|NCT03365960|Active Comparator|Active3|watermelon seeds
3142601|NCT00002837|Experimental|Doxorubicin, Paclitaxel + Cyclophosphamide with PBPC|
3142602|NCT00002838|Experimental|Combination Chemotherapy + PSCT|PSCT = Peripheral Stem Cell Transplantation
3142603|NCT00002844|Experimental|Cyclophosphamide + TBI + BMT|TBI = Total Body Irradiation and BMT = Bone Marrow Transplantation (allogeneic or autologous bone marrow)
3142604|NCT00002849|Experimental|induction and maintenance|dexamethasone induction followed by alpha interferon maintenance
3142605|NCT00002852|Active Comparator|Arm I (surgery, observation)|Patients receive no further therapy.
3142606|NCT00002852|Experimental|Arm II (surgery, chemotherapy)|Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
3142607|NCT00002854|Experimental|Sequential high dose chemotherapy|
3142608|NCT00002855|Experimental|Arm I|Arm I: Medical or surgical castration followed by an anti-androgen therapy with either flutamide, bicalutamide, or nilutamide.
3142609|NCT00002855|Experimental|Arm II|Arm II: Chemo/hormonal therapy for 3 x 8-week courses, followed by total androgen blockade. Each course consists of 6 weeks of cytotoxic therapy with doxorubicin, ketoconazole, vinblastine, and estramustine followed by 2 weeks rest. Maintained on hydrocortisone both during treatment and during rest.
3142610|NCT00002860|Other|surgery|
2381875|NCT03696693||children without chronic rhinosinusitis|Children have the same age and number in the study group which are presented with vocal symptoms and have not chronic rhinosinusitis will be recruited for the same duration.
2381876|NCT03696680|Experimental|FSRT Stereotactic radiation therapy|Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
2381877|NCT03696667|Active Comparator|Affective BCI training|15 participants in the intervention group will undergo 24 sessions of BCI-based emotion regulation training over an 8-week period. Each session will take about 30-minute to complete where participants will listen to music with audio feedback to regulate emotions toward positive affect.
2381878|NCT03696667|No Intervention|Control group|15 participants in the control group will take part in 24 music sessions (with no audio feedback) over an 8-week period. Each session will take about 30-minute to complete.
2381879|NCT03696654|No Intervention|Before treatment|
2381880|NCT03696654|Active Comparator|After treatment|
2381881|NCT03696641|Active Comparator|glazed IPS e.max|lithium disilicate glazed crowns that proved to have a good color stability
2381882|NCT03696641|Experimental|polished IPS e.max|polished lithium disilicate crowns with the polishing kit
2381883|NCT03696628|Other|Healthy children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
2381884|NCT03696628|Other|Cardiomyopathic children|Blood test with generated hiPSC-cardiomyocytes Physical Examination. Electrocardiogram. Echocardiography.
2381885|NCT03696615|Experimental|Tabata Kettlebell Swings|"Participants in this group performed:~A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)~Receive instruction on the kettlebell swing~Performed a high-intensity workout in a Tabata Kettlebell Swings format, which involves 20 seconds of all out effort followed by 10 seconds of rest, repeated for a total of 8 times."
2381886|NCT03696615|Active Comparator|Control Group|"Participants in this group performed:~1. A brief dynamic warm-up (10 clockwise and counterclockwise arm circles, 10 horizontal arm swings, and 15 air squats)"
2381887|NCT03696602||test with methacholine|
2381888|NCT03696602||test with exercise|
3183258|NCT00712283|Active Comparator|C|healthy volunteers
3183259|NCT00712283|Active Comparator|B|healthy volunteers
2381891|NCT03696563|Active Comparator|Control group|In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
2381892|NCT03696563|Experimental|FreeO2 group|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration to reach the SpO2 target set by paramedic.
2381895|NCT03696537|Experimental|Fludarabine + Total Marrow Irradiation|
2381896|NCT03696524|Experimental|Intervention Group|This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
2381897|NCT03696524|No Intervention|Usual Care|The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
2381898|NCT03696511|Active Comparator|group 1:maxillary insertion|Orthodontic miniscrew insertion; maxillary insertion. buccal
2381899|NCT03696511|Active Comparator|group 2: mandible insertion|Orthodontic miniscrew insertion; mandible insertion.
2381900|NCT03696511|Active Comparator|group 3: palatal insertion|Orthodontic miniscrew insertion; palatal insertion
2381901|NCT03696498|Experimental|Partial caries excavation (1 step)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Local anaesthesia shall be used. as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: A permanent resin restoration is placed on top of the remained caries."
2381902|NCT03696498|Active Comparator|Partial caries excavation (2 steps)|"Patients with radiographical caries within the pulpal ¼ of the dentine with the presence of a radiodense zone separating the pulp from the demineralised dentine is candidates for the treatment. Before randomisation, the participants receive the first excavation procedure as this procedure is identical for the two interventions tested in this trial. A partial removal of carious dentine is performed with superficial removal of the outermost infected and necrotic part of the demineralised dentine.~Intervention: After randomisation, a calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months, the temporary restoration is removed, final excavation is carried out with hand excavators until firm but stained dentine remains, and a permanent resin restoration is placed."
2381903|NCT03696485|Experimental|group 1: low dose|One intrathecal (IT) administration of SCM-010 at baseline visit
2381904|NCT03696485|Experimental|group 2: high dose|One intrathecal (IT) administration of SCM-010 at baseline visit
2381905|NCT03696472|Experimental|robotic-assisted left colonic resection|Standard left colonic resection assisted by Davinci Robotic
2381906|NCT03696472|Active Comparator|laparoscopic left colonic resection|Standard laparoscopic left colonic resection
2381907|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 1|Participants will receive single oral dose of JNJ-53718678, 2000 milligram (mg) suspension or matching placebo on Day 1, under fasted conditions.
2381908|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 2|Participants will receive single oral dose of JNJ-53718678, of maximum 3000 mg suspension or matching placebo on Day 1, under fasted conditions.
2381909|NCT03696459|Experimental|Part 1 (Dose escalation): Panel 3|Participants will receive single oral dose of JNJ-53718678 4500 mg suspension (this dose may be used in Part 2, Treatment F) or matching placebo on Day 1, under fasted condition.
2382458|NCT03692429|Experimental|CYAD-101 with FOLFOX|Infusion after standard FOLFOX chemotherapy
3183260|NCT00712283|Active Comparator|A|healthy volunteers
2381910|NCT03696459|Experimental|Part 1 (Dose Escalation): Panel 4 (Optional)|Participants will receive single oral dose of JNJ-53718678 (dose to be decided [this dose may be used in Part 2, Treatment F]) suspension or matching placebo on Day 1, under fasted condition, if 4500 mg dose in Panel 3 is considered safe and tolerable and if pharmacokinetic data require further dose escalation to reach the target exposure.
2381911|NCT03696459|Experimental|Part 2 Group 1: Treatment Sequence EHFG|Participants will receive single oral dose of JNJ-53718678, 500 mg suspension with single oral dose of moxifloxacin placebo and JNJ 53718678 placebo (Treatment E) in Period 1, then participants will receive single oral dose of moxifloxacin 400 mg with single oral dose of JNJ-53718678 placebo (Treatment H) in Period 2 then will receive single oral dose of JNJ-53718678, 4500 mg (dose will be based on review of safety, tolerability, and PK data obtained in Part 1 [either from Panel 3 or 4], this dose may be lower/higher) suspension with single oral dose of moxifloxacin placebo (Treatment F) in Period 3 followed by single oral dose of JNJ-53718678 placebo with single oral dose of moxifloxacin placebo (Treatment G) in Period 4, on Day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
2381912|NCT03696459|Experimental|Part 2 Group 2: Treatment Sequence FEGH|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment G in Period 3 followed by Treatment H in Period 4 on Day 1 of each treatment period.
2381913|NCT03696459|Experimental|Part 2 Group 3: Treatment Sequence GFHE|Participants will receive Treatment G in Period 1, then Treatment F in Period 2, then Treatment H in Period 3 followed by Treatment E in Period 4 on Day 1 of each treatment period.
2381914|NCT03696459|Experimental|Part 2 Group 4: Treatment Sequence HGEF|Participants will receive Treatment H in Period 1, then Treatment G in Period 2, then Treatment E in Period 3 followed by Treatment F in Period 4 on Day 1 of each treatment period.
2381915|NCT03696446|Experimental|Virtual Cardiac Rehabilitation Program|This group will receive access to the NWC (NexJ Connected Wellness TM (NCW) and will be provided with a fitness tracker (Garmin Vivofit 3) to monitor their exercise, sedentary behaviours, and sleep patterns. The NWC platform includes components for education (health library, workbooks etc), collaboration (personal care plan, appointment scheduler, secure messaging system etc), and motivation (motivational messages on their homepage etc). With the Health Coach, participants will engage in: reviews of their risk factor profile and health priorities; goal setting and action planning; problem solving and skill building; and discussions of relapse prevention. Participants will receive a total of seven hours of health coaching delivered across nine sessions over a 26-week period
2381916|NCT03696446|Other|Case Managed Home Program|The Case Managed Home Program (CMHP) is delivered primarily via telephone. Following their CR intake, patients are linked with their CMHP Health Coach and attends their visit (in person or over the phone) which includes a comprehensive review of their health history, current symptoms, medications, activity, and individual concerns. Following this visit, participants will receive a total of 10 individualized telephone calls over a 26 week period. The program action plan is individually formulated based on the participant's goals and learning needs. Participants are provided with educational kits (exercise, nutrition, stress management or prevention) that are based on the principle of single point learning and incorporate behavioural change techniques.
2381917|NCT03696433|Experimental|Low- then high-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
2381918|NCT03696433|Experimental|High- then low-salt diet|10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.
2381919|NCT03696420||DBS surgery targeting the VIM|Patient who underwent a DBS surgery targeting the VIM at Bordeaux University Hospital
2381920|NCT03696394|No Intervention|Group I|Group I consists of 5 patients receiving a microfracture as per standard of care.
2381921|NCT03696394|Active Comparator|Group II|Group II consists of 10 patients receiving a microfracture with BioCartilage®.
2381922|NCT03696381|Experimental|Real tRNS|Real tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
2381923|NCT03696381|Sham Comparator|Sham tRNS|Sham tRNS + Guttmann NeuroPersonalTrainer (GNPT) 3 days per week over 8 weeks.
2381924|NCT03696355|Experimental|Stratum A1|"Dose Escalation Phase:~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive single-agent oral GDC-0084 at one of the 4 dose levels once daily in cycles of 28 days. During cycle 1 only, a single dose of GDC-0084 will be withheld on day 2, for a total of 27 doses. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.~Dose Expansion Phase~Four to 12 weeks after the completion of standard RT, subjects who are able to swallow capsules will receive the MTD dose established in the Stratum A dose escalation phase. Subjects who completed the first course of therapy may take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity."
2381925|NCT03696355|Experimental|Stratum A2|Four to 12 weeks after the completion of standard RT, subjects will received the MTD dose established in the Stratum A1 dose escalation phase. Subjects who are unable to swallow capsules will initially be enrolled until the Stratum A1 expansion cohort is filled. Once the Stratum A1 expansion cohort has been filled, both subjects who are able to swallow capsules and those unable to swallow capsules may be enrolled. Subjects who are unable to swallow capsules will take GDC-0084 as an open capsule sprinkled in purée such as applesauce. Subjects who have completed the first course of therapy and are able to swallow capsules may take GDC-0084 as capsules. Treatment may be continued for up to 24 months (26 cycles) in the absence of disease progression or unacceptable toxicity.
3183261|NCT00712309|Active Comparator|1|Percutaneous transluminal angioplasty (PTA)
2382459|NCT03692429|Experimental|CYAD-101 with FOLFIRI|Infusion after standard FOLFIRI chemotherapy
3183262|NCT00712309|Active Comparator|2|Primary stenting
3183263|NCT00712322|Experimental|Cohort 1|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.030 mg/kg/day).
2381928|NCT03696329|Experimental|Tetrabenazine Tablets|Tetrabenazine Tablets 25 mg of Dr. Reddy's Laboratories Limited
2381929|NCT03696329|Active Comparator|Xenazine|Xenazine Tablets 25 mg of Lundbeck Inc.
2381930|NCT03696303||Cases|Suspected community-acquired bacterial pneumonia
2381931|NCT03696303||Controls|Healthy children, age-matched to enrolled cases
2381932|NCT03696303||Controls with URI|Children 5 years of age or younger with upper respiratory infection (URI) (controls with URI)
2381933|NCT03696290|Active Comparator|Aztreonam lysine, 3 doses per day|3 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
2381934|NCT03696290|Placebo Comparator|Placebo, 3 doses per day|3 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
2381935|NCT03696290|Active Comparator|Aztreonam lysine, 2 doses per day|2 doses per day of nebulised Aztreonam lysine (75 mg) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
2381936|NCT03696290|Placebo Comparator|Placebo, 2 doses per day|2 doses per day of nebulised placebo (5 mg lactose monohydrate) for 1 month, followed by 1 month off treatment. The month on, month off regimen will be repeated for a total peroid of 12 months.
2381937|NCT03696277|Experimental|Stereotactic ablative body radiation (SABR)|SAbR will be used to treat all sites of measurable metastases. New sites of metastasis will be treated if deemed appropriate by both medical and radiation oncologists with SAbR.
2381938|NCT03696264|Experimental|Resistance-trained, adult males|Subjects receive varying levels of amino acid intakes ranging from 0.2-3.0g/kg/d
2381939|NCT03696251||master's nursing program|the graduates of master's nursing program in recent three years in Taiwan
2381940|NCT03696238|Experimental|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
2381941|NCT03696238|Placebo Comparator|500mg of placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
2381942|NCT03696225|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
2381943|NCT03696225|Active Comparator|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
2381944|NCT03696212|Experimental|grapiprant and pembrolizumab combination|Participants will be treated with grapiprant in combination with pembrolizumab.
2381945|NCT03696199|No Intervention|Traditional Pain Control Care|Standard of care post-operative pain control with oral narcotics
2381946|NCT03696199|Experimental|Regional Anesthesia|Single injection perioperative peripheral nerve block + followed by administration of oral narcotics on a need-based system
2381947|NCT03696199|Experimental|Long-Acting Local Anesthesia|Subcutaneous local cocktail injection + followed by administration of oral narcotics on a need-based system
2381948|NCT03696186|Active Comparator|Luminal type-1|Standard treatment
2381949|NCT03696186|Experimental|Luminal type-2|Experimental treatment
2381950|NCT03696186|Active Comparator|Neuroendocrine type-1|Standard treatment
2381951|NCT03696186|Experimental|Neuroendocrine type-2|Experimental treatment
2381952|NCT03696186|Active Comparator|Atypical type-1|Standard treatment
2381953|NCT03696186|Experimental|Atypical type-2|Experimental treatment
2381954|NCT03696173||Participants taking abatacept|
2381955|NCT03696173||Participants taking abatacept with methotrexate|
2381956|NCT03696160|Experimental|Biktarvy|"Bictegravir is an inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection.~Biktarvy® received marketing authorisation valid throughout the European Union (EU) in June 2018.~Biktarvy is a combination of bictegravir, emtricitabine, and tenofovir (B/F/TAF).~Method of administration: One combined B 50mg/F 200mg/TAF 25mg tablet taken orally once daily for up to 48 weeks without regard to food."
2381957|NCT03696160|Experimental|Symtuza|"Symtuza® is a boosted PI indicated for the treatment of HIV-1 infection.~Symtuza® received marketing authorisation valid throughout the EU in September 2017.~Symtuza is a combination of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF)~Method of administration: One combined D 800mg/C 150mg/F 200mg/TAF 10mg tablet taken orally once daily for up to 48 weeks with the addition of food."
2381958|NCT03696121|Experimental|Intervention|Desmopressin injection
2381959|NCT03696121|Placebo Comparator|Control|Normal Saline
3183264|NCT00712322|Experimental|Cohort 2|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.0625 mg/kg/day).
3183265|NCT00712322|Experimental|Cohort 3|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.125 mg/kg/day).
2381962|NCT03696095|Active Comparator|Continous infusion ropivacaine|Continuous infusion via peri-neural femoral nerve catheter of Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode) at rate of 6ml/h + patient controlled bolus of 3ml ...
3183266|NCT00712322|Experimental|Cohort 4|Estimated pediatric study doses of darifenacin liquid oral suspension: (0.250 mg/kg/day).
2381963|NCT03696095|Experimental|PIB ropivacaine|Programmed intermittent bolus of Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode) : 6ml each 60min + patient controlled bolus 3ml ...
2381964|NCT03696082|Experimental|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
2381965|NCT03696082|Experimental|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
2381966|NCT03696082|Experimental|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
2381967|NCT03696082|Experimental|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
2381968|NCT03696069||Patients treated with immunotherapy and BRAF/MEK inhibitors|
2381969|NCT03696056|Experimental|Kirtan Kriya meditation|Participants will mediate for 12 minutes a day for 8 consecutive weeks.
2381970|NCT03696056|Active Comparator|Relaxing instrumental music|Participants will relax listening to music for 12 minutes a day for 8 consecutive weeks.
2381971|NCT03696043|Active Comparator|EVD placement|Catheter placement is most commonly performed via a freehand approach using external anatomical landmarks to help identify the location of the lateral ventricle within the brain without the aid of imaging. Proper identification of the ventricles on pre-procedure imaging, surgeon skill, and estimation of pathologic perturbations to the normal location of the ventricles all factor into the success of catheter placement. Multiple passes are often required. The accuracy rate from the freehand technique has been reported to range from 40 to 98 percent.
2381972|NCT03696043|Experimental|Axium Stealth Image Guidance|The novelty of this study is to investigate whether using image guidance technology can improve EVD catheter placement. Image guidance is used very commonly for EVD and shunt placement in the operating room with excellent accuracy and precision. We hypothesize that using this same workflow at the bedside will improve accuracy; decrease the number of passes needed for a successful placement, decrease the number of post-placement hemorrhagic events, and help improve the effectiveness of the catheter as well as patient outcomes.
2381973|NCT03696030|Experimental|Treatment (HER2-CAR T cells)|Patients receive HER2-CAR T cells via intraventricular administration over 5 minutes once weekly for 3 doses in the absence of disease progression or unacceptable toxicity. If patients continue to meet all eligibility criteria, they may receive additional cycles of HER2-CAR T cells at principal investigator's discretion.
2381974|NCT03696017||Group 1|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse opioids (40 patients per group).
2381975|NCT03696017||Group 2|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse benzodiazepines (BZD) (40 patients per group).
2381976|NCT03696017||Group 3|Patients newly admitted to Substance Use Disorder treatment in Wayne County who abuse BZD/opioid (40 patients per group).
2381977|NCT03696004|Active Comparator|Retros FEC-100 +BRS|Contains record of already treated patients with six cycles of FEC-100 Fluorouracil ,Epirubicin and Cyclophosphamide and later had Breast conservative Surgery(BRS)
2381978|NCT03696004|Active Comparator|PROS 30 FEC-100 +BRS|These are new patients who will be treated with six cycles of FEC-100 (Flourouracil,Epirubicin and Cyclophosphamide) and will undergo Breast Conservative Surgery (BRS)after 6 weeks
2381979|NCT03695991||Study group|Patients will be recruited from out-patient clinics and in-patient sectors of Assiut Urology and Nephrology hospital
2381983|NCT03695965||study group|patients with history of ankle trauma or chronic lateral ankle pain
2381984|NCT03695952||Hepatocellular carcinoma|Hepatocellular carcinoma patients treated with nivolumab
2381985|NCT03695952||Biliary Tract Cancer|Biliary tract cancer patients treated with pembrolizumab
3183267|NCT00712361|Experimental|Group A|The group A incorporates three subgroups of individuals at various ages. A.1 Age: 16 - 30 A.2 Age: 31 - 60 A.3 Age > 60 All subgroups will be randomly distributed according to the following factors: BMI, gender, race and hematocrit.
2381987|NCT03695926|Experimental|[18F]MNI-1054|To measure blood metabolites, dynamic uptake, and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.
3183268|NCT00712374|Experimental|Intervention|Children 3 months to 10 years old will receive a treatment dose of SP+AQ on three occasions during the malaria transmission season, delivered by the local health post
2381989|NCT03695900|Other|Targeting SpO2 at 93-95% followed by targeting at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
2381990|NCT03695900|Other|Targeting SpO2 at 90-92% followed by targeting at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours, followed by FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours.
2381991|NCT03695887|Experimental|Nitrous Oxide Inhalant Product|Nitrous oxide
2381992|NCT03695887|Placebo Comparator|Placebo|placebo comparator
3188951|NCT00772473||1 group, usual acute triptan treatment|
2381993|NCT03695874||Phase 1: statistical purification|"400 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
2381994|NCT03695874||Phase 2: statistical validation|"200 Hereditary Haemorrhagic Telangiectasia patients:~over 18 years~able to read French~with clinically confirmed Hereditary Haemorrhagic Telangiectasia disease (presence of at least 3 Curaçao criteria) and / or molecular biology~who received the information and did not object to participate in the study"
2381995|NCT03695861|Experimental|Whole-body 18F-FDG PET-CT scan|
2381996|NCT03695835||Adenocarcinoma treated with MyVaccx|MyVaccx combines tumor ablation and immunotherapeutic agents for treatment of late stage cancer disease..
2381997|NCT03695822|Experimental|Mirabegron|OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
2381998|NCT03695796|Other|Single arm|Only one arm because diagnostic study evaluating non-invasive tests using liver biopsy as reference
3142611|NCT00002862|Experimental|Arm I|Groups of 3-6 patients receive escalating doses of oral perillyl alcohol three times per day until the maximum tolerated dose or recommended phase II dose is determined. Treatment at the assigned dose continues until disease progression or unacceptable toxicity intervenes. Patients with stable disease after 8 weeks of treatment are removed from study.
3142612|NCT00002864|Active Comparator|Octreotide|
2382001|NCT03695770|Experimental|target population|All the target population should be included in the experimental arm
2382002|NCT03695757|Experimental|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
2382003|NCT03695757|Experimental|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
2382004|NCT03695744|Experimental|Daratumumab Bortezomib Dexamethasone|IV daratumumab 16mg/kg body weight weekly for weeks 1-9 followed by daratumumab 16mg/kg body weight once every 3 weeks from weeks 10 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; S.C bortezomib and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 9 months from start of study. After 9 months, patient only continues on daratumumab until progression.
2382005|NCT03695731|Experimental|Patients without Neuropathy|activation of cold induced brown adipose tissue
2382006|NCT03695731|Experimental|Patients with Neuropathy|activation of cold induced brown adipose tissue
2382007|NCT03695705|Other|Primary prophylaxis arm|28 Patients with decompensated cirrhosis without past history of SBP were randomised to receive Rifaximin at dose 550 mg twice daily.29 Patients with decompensated cirrhosis without past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
2382008|NCT03695705|Other|Secondary prophylaxis arm|26 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Rifaximin at dose 550 mg twice daily.33 Patients with decompensated cirrhosis with past history of SBP were randomized to receive Norfloxacin at dose 400 mg once daily
2382009|NCT03695692|Experimental|Connective tissue massage group|Pelvic floor exercises and connective tissue massage have been applied
2382010|NCT03695692|Experimental|Control group|Pelvic floor exercises alone have been applied
2382011|NCT03695679|Experimental|Intervention group|Interactive computer-based intervention
2382012|NCT03695679|No Intervention|Control group|An one-page online information about procedures and tips of condom use with minimal intervention
2382013|NCT03695666||Cycle 1|Counted number of patients booked into clinic. No individual patient data collected.
2382014|NCT03695666||Cycle 2|Counted number of patients booked into clinic. No individual patient data collected.
2382015|NCT03695653|Active Comparator|Drink Tracking (MA) Condition|Ps will receive weekly mobile assessment trick tracking described above for six months in addition to the guidelines on safe drinking.
2382016|NCT03695653|Experimental|TA Intervention|The TA intervention is tailored but will adapt over time too
2382017|NCT03695653|Experimental|Tailored Content Only (TO)|The TO treatment arm includes tailored text messages sent at 6pm daily based on the baseline assessment.
2382018|NCT03695640|Active Comparator|Group L|continuous femoral nerve block with levobupivacaine
2382019|NCT03695640|Experimental|Group LM|continuous femoral nerve block with levobupivacaine and magnesium sulfate
2382020|NCT03695627|Experimental|Meditation Group|Participants in the meditation group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks
2382021|NCT03695627|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
2382022|NCT03695614|Experimental|Cognitive Remediation|CR is a form of group therapy that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. CR is administered in groups consisting of 2-8 participants and one or two therapists. The CR groups meet twice per week for two hours per session over twelve weeks, for a total of 24 sessions.
2382023|NCT03695601||HeartCare|Diagnostic Test: Heart Care 2300 patients managed with HeartCare (AlloMap® and AlloSure-Heart® )
2382024|NCT03695601||Control|A historical control group will be matched to the estimated 1150 HeartCare group patients who complete at least two years of HeartCare surveillance use and inclusive of year 3 post-transplant clinical follow-up for outcome. The criteria for the matched controls will be based on allograft donor type, age, gender, ethnicity/race, and other clinical factors. Propensity scores will be used to perform the matching.
2382025|NCT03695588|Active Comparator|Quadratus lumborum block|Bilateral posterior QLB with 20ml 0.25% L-Bupivacaine.
2382026|NCT03695588|Sham Comparator|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle. Patient blinded due to residual spinal anaesthetic block.
2382598|NCT03691597|Experimental|Bioactive cement|recent cement improve the marginal integrity
3142613|NCT00002864|Active Comparator|Tamoxifen|
3188952|NCT00772486|Experimental|Experimental: ISF35 and FCR|ISF35 and FCR
2382027|NCT03695575|Other|Study sample|A repeated-measures model will be used. This means that participants in a single arm will be tested in all conditions. Speech recognition and listening effort outcomes will be measured in two conditions: with and without a bone-conduction headset.
2382028|NCT03695562|Experimental|implant placement using sequential drilling|patient with vitamin D deficiency using sequential drilling technique
2382029|NCT03695562|Active Comparator|implant placement using single drilling|Patient with vitamin D deficiency using single drilling technique
2382030|NCT03695549|Active Comparator|intervention|CAF+ APRF
2382031|NCT03695549|Active Comparator|control|CAF+SCTG
2382032|NCT03695536||ultrasound use during resuscitation|The group with ultrasound integrated into the resuscitation efforts.
2382033|NCT03695536||no ultrasound use during resuscitation|The group without ultrasound integrated into the resuscitation efforts.
2382034|NCT03695523|Experimental|PLAY (PhysicaL ActivitY) Policy Intervention|The childcare physical activity policy will be adopted for 8 weeks within participating toddler and preschool classrooms of facilities allocated to the experimental group.
2382035|NCT03695523|No Intervention|Control group|Childcare centres will maintain their typical daily programming and standard of care for the duration of the 8-week intervention period.
2382036|NCT03695510|Experimental|Study arm|afatinib + pembrolizumab
2382037|NCT03695497|Experimental|Direct anterior approach|total hip arthroplasty with direct anterior approach
2382038|NCT03695497|Experimental|Direct Lateral Approach|total hip arthroplasty with direct lateral approach
2382039|NCT03695484||Manual guided RF ablation|Patients with paroxysmal atrial fibrillation treated with Manual guided RF ablation using Contact Force catheters
2382040|NCT03695484||Cryoballoon ablation|Patients with paroxysmal atrial fibrillation treated with Cryoballoon ablation. Cryoballoon: Arctic Front Advance, Medtronic - 28 mm
2382041|NCT03695484||RMN guided RF ablation - High power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and high power settings.~High power ablation settings: a minimum of 40 Watt, 43grC, flow 17ml/min. Higher voltages (e.g. anterior wall) are allowed with respect to the operators' preference."
2382042|NCT03695484||RMN guided RF ablation - Low power|"Patients with paroxysmal atrial fibrillation treated with Remote Magnetic Navigation guided RF ablation with e-Contact and low power settings.~Low power ablation settings: a maximum of 39 Watt, 43grC, flow 17ml/min. Lower voltages are allowed with respect to the operators' preference."
2382043|NCT03695471|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity. Patients receiving complete response during courses 2-9 are held for the remaining courses. If patients relapse while treatment is being held, the patient will then complete remaining courses.
2382044|NCT03695458|Placebo Comparator|Placebo-Control|Photobiomodulation Therapy with the placebo program will be applied in both legs.
2382045|NCT03695458|Active Comparator|irradiation effect Local|Photobiomodulation Therapy with the active irradiation will be applied on the exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the non-exercised leg.
2382046|NCT03695458|Active Comparator|irradiation effect Systemic|Photobiomodulation Therapy with the active program will be applied on non-exercised leg and Photobiomodulation Therapy with the placebo program will be applied on the exercised leg.
2382047|NCT03695445||Peripheral Norepinephrine|Patients who will undergo surgery with need for vasopressor support.
2382048|NCT03695432|Experimental|Vaccine|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
2382049|NCT03695432|Experimental|Probiotic|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic
2382050|NCT03695432|Placebo Comparator|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
2382051|NCT03695432|Placebo Comparator|Placebo probiotic|capsul
2382052|NCT03695406|Experimental|Mind-Body Group Intervention|
3188953|NCT00772499|Experimental|1|olmesartan medoxomil tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
3142614|NCT00002875|Experimental|Regimen A|Following surgery, craniospinal irradiation followed by a boost to the primary tumor. Beginning within 1 week after initiation of radiotherapy, patients receive vincristine sulfate weekly for 8 doses. Beginning 6 weeks after the completion of radiotherapy, patients receive adjuvant lomustine/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
3142615|NCT00002875|Experimental|Regimen B|Following surgery, craniospinal irradiation plus vincristine sulfate, followed by adjuvant cyclophosphamide/vincristine sulfate/cisplatin every 6 weeks for a total of 8 courses.
3142616|NCT00002879|Experimental|cladribine|Patients receive cladribine (2-chlorodeoxyadenosine; 2-CdA) daily for 5 days every 4 weeks for a maximum of 6 courses; response is assessed after every 2 courses. Patients in complete remission or with stable disease discontinue treatment and are followed; those with disease progression at any time are removed from study. Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and annually for 2 years.
3142617|NCT00002880|Experimental|Etoposide|Oral etoposide for relapsed or refractory non-Hodgkin's lymphoma
3142618|NCT00002882|Experimental|IFN-A Therapy Schedule A|Schedule A: IV Interferon alfa-2b (IFN-A) induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
3142619|NCT00002882|Experimental|IFN-A Therapy Schedule B|Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks.
2382061|NCT03695354|Experimental|Whole body vibration plus conventional therapy group|conventional therapy + whole body vibration training for 40 minutes per day, five days per week for two-week period.
3142620|NCT00002882|Experimental|Adjuvant Biochemotherapy|Cisplatin IV Days 1-4; Vinblastine IVPB Days 1-4; Dacarbazine (DTIC) IVPB on Day 1; IFN-A is given subcutaneously on days 1-5; IL-2 continuous infusion for 96 hours on Days 1-4. Each course repeated every 21 days for 4 courses.
3142621|NCT00002909|Experimental|Arm I|All patients receive oral phenylbutyrate three times daily. Groups of 4 or more patients receive escalating doses of phenylbutyrate until the maximum tolerated dose (MTD) is determined. Treatment continues until disease progression or unacceptable toxicity intervenes.
2382062|NCT03695354|Active Comparator|conventional training group|conventional therapy (passive range of motion exercise and walking exercise) for 40 minutes per day, five days per week for two-week period.
2382063|NCT03695341||Fulvestrant|Fulvestrant 500mg per month (D1, D28, q28d), with a loading dose 500mg of first dose at D15
2382064|NCT03695341||Everolimus plus Exemestane|Everolimys 10 mg or 5 mg daily; Exemestane 25mg per day
2382065|NCT03695328||physical activity level|Children categorized either in the group with moderate to vigorous physical activity or in the group with low physical activity according the accelerometer's measures
2382066|NCT03695328||dietary intake|Childrens' 24th dietary recalls for 7 days analyzed for protein, calcium, vitamin D and phosphorus intake and they categorized according the RDAs above or below them.
2382067|NCT03695315||OSA with hypoxia|People with obstructive sleep apnea and hypoxia before and after treatment with continuous positive airway pressure
2382068|NCT03695315||OSA without hypoxia|People with obstructive sleep apnea and without hypoxia before and after treatment with continuous positive airway pressure
2382069|NCT03695289|Experimental|iOTA-SMI|Participants randomized to iOTA-SMI arm will participate in a 16 week interactive obesity treatment approach (iOTA) program approach.
2382070|NCT03695289|Active Comparator|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly in-person health coaching visits for 16 weeks.
2382071|NCT03695276|Experimental|PuSHCon model|A health coach will contact patients with poorly controlled asthma or COPD. The health coach will gather information from the patient and medical record and review the case with a pulmonary specialist. The specialist will provide recommendations to the primary care clinician based on the case review; the specialist may request an in-person patient visit if needed. The health coach will follow up with the primary care clinician and will support implementation of recommendations that the the primary care clinician accepts,
2382072|NCT03695276|Active Comparator|Usual care|Patients with poorly controlled asthma or COPD will receive the standard of care, which usually means management within primary care. The study team will provide in-service sessions on COPD and asthma guidelines to primary care clinicians in both arms. As in standard practice, a primary care clinician may refer a patient for specialty consultation or diagnostic testing at any time.
2382073|NCT03695263|Experimental|N-of-1 Trial|Multiple crossovers between one of the available intervention options (mindfulness meditation, gratitude journaling, physical activity, laughter therapy, or random acts of kindness) and usual activities
2382075|NCT03695237|Experimental|Participants receiving Leuprolide Acetate (LA)|Participants with Central Precocious Puberty receiving LA
2382076|NCT03695224||Group A|Subjects with normal topological perception
2382077|NCT03695224||Group B|Subjects with abnormal topological perception
2382078|NCT03695211|Active Comparator|LM group|LM group use conventional landmark technique, which selects the midpoint of the posterior border of the sternocleidomastoid muscle as the puncture point of superficial cervical plexus block
2382079|NCT03695211|Experimental|GAN Group|This group firstly locate the superficial cervical plexus by ultrasound scanning of the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle (GAN Point). GAN Group apply the precise block technique, selects the GAN Point as the puncture point of superficial cervical plexus block
2382080|NCT03695198|Experimental|LY3361237 - Subcutaneous (SC)|LY3361237 administered SC
2382081|NCT03695198|Placebo Comparator|Placebo - SC|Placebo administered SC
2382082|NCT03695198|Experimental|LY3361237 - Intravenous (IV)|LY3361237 administered IV
2382083|NCT03695198|Placebo Comparator|Placebo - IV|Placebo administered IV
2382084|NCT03695185|Experimental|ABBV-323|Participants administered with ABBV-323 dose A IV at Week 0 and ABBV-323 dose B for 12 Weeks. Participants who achieve clinical response may enter the maintenance period in which participants are administered with ABBV-323 dose B
2382085|NCT03695172|Active Comparator|TAP block|Patients will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
2382086|NCT03695172|Active Comparator|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
2382087|NCT03695172|Active Comparator|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
3142622|NCT00002912|Experimental|Arm I|Patients undergo induction therapy consisting of etoposide IV and mitoxantrone IV on days 1-5. Patients then receive PSC-833 IV over 124 hours beginning on day 2. A second course is administered no sooner than 21 days from the start of the first course if the marrow is hypocellular after the first course. Patients with persistent disease after 2 induction courses are removed from the study. Patients receive a total of 3 courses of etoposide/mitoxantrone. Patients who achieve complete remission after 1 induction course receive 2 courses of etoposide/mitoxantrone with PSC-833 as consolidation, beginning within 4 weeks of attainment of complete remission. Patients who achieve complete remission after 2 induction courses receive 1 course of etoposide/mitoxantrone with PSC-833 as consolidation. Cohorts of 3-6 patients receive escalating doses of PSC-833 until the maximum tolerated dose is determined. Patients are followed every 6 months.
3188954|NCT00772499|Active Comparator|2|Atenolol tablets with added doses of hydrochlorothiazide, amlodipine, or hydralazine, if required to maintain target blood pressure
3188955|NCT00772512|Experimental|A|
2382091|NCT03695133|Experimental|intervention group|"Group-based interventions Group-based interventions include physical activity, sightseeing, picnics, theater, cinema, group educations.~Individual interventions Individual interventions include interventions in the Omaha System Nursing Interventions Scheme that is specific to health problems of elderly women."
2382092|NCT03695133|No Intervention|control group|The control group will not take any intervention, the post-tests will be collected at the end of 12 weeks.
2382093|NCT03695120|No Intervention|Full Dose ACEI/ARB or Home Dose Group|This group will receive the full dose of ACEI/ARBs.
2382160|NCT03694639|No Intervention|Pregabaline group|where patients received pregabaline 150 mg twice daily.
2382094|NCT03695120|Active Comparator|No ACEI/ARB Group|This group will not receive the full dose of ACEI/ARBs for the first 72 hours of hospitalization.
2382095|NCT03695107||XBDP1-|
2382096|NCT03695107||XBDP2-|
3183269|NCT00712387|No Intervention|A|General surgical trainees who will receive the 'traditional' training programme; i.e. will receive whatever clinical training on a patient their supervising consultant deems appropriate. This is the way junior surgeons are currently trained. They will also receive the standard didactic teaching on the School for Surgeons e-learning resource.
2382099|NCT03695081|Experimental|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
2382100|NCT03695081|No Intervention|No intervention|Business as usual. The Patient Pathway Pharmacist is not involved and the nurses and physicians are responsible for medicine reconciliation, -review and section in the discharge summary.
3142623|NCT00002913|Experimental|Treatment (paclitaxel, cisplatin, topotecan hydrochloride)|"Patients receive paclitaxel IV over 3 hours and cisplatin IV on day 1, followed by topotecan IV over 30 minutes on days 1-3. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 4 and continuing until blood counts recover. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 4-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities."
3142624|NCT00002920|Active Comparator|Tamoxifen alone|Tamoxifen alone x 5 years
2382103|NCT03695055|Experimental|Arm 1|Rituximab maintenance
2382104|NCT03695055|Active Comparator|Arm 2|DPP/DCEP-G alternation regimen
2382105|NCT03695055|No Intervention|Arm 3|
2382106|NCT03695042|Experimental|BFR THEN without BFR|Will perform exercises with BFR at the first visit and without BFR at the second visit
2382107|NCT03695042|Experimental|Without BFR THEN with BFR|Will perform exercises without BFR at the first visit and with BFR at the second visit
2382108|NCT03695029|Experimental|treatment group|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
2382109|NCT03695029|No Intervention|control group|control group receive no drug, only follow-up
2382110|NCT03695016|Experimental|Immediate Intervention|Participants will receive the ActiveGOALS 13 week, online self-directed intervention for increasing aerobic physical activity and decreasing time spent sitting. The intervention is based on social-cognitive theory models of behavior changes and utilizes barrier recognition, problem solving, and monitoring of behavior to initiate behavior change. They will also receive weekly feedback from a coach and be provided with online, paper, and wearable tracking devices. They will also be provided with links to tools that support physical activity.
2382111|NCT03695016|Other|Wait-listed Control|This group will receive a monthly newsletter with general health advice during the wait period (3 months). After the three month follow-up visit/ collection of outcomes they will be offered the ActiveGOALS intervention in its entirety.
2382112|NCT03695003|Active Comparator|600 mg sage/polyphenol combination|600 mg of this sage/polyphenol combination will be consumed, via capsule, per day for 29 days.
2382113|NCT03695003|Placebo Comparator|Placebo|The same number of aesthetically similar capsules will be consumed per day for 29 days.
2382114|NCT03694990||Short-term|Patients will be scheduled for PO follow-up visits 2 weeks, and 8 weeks after surgery.
2382115|NCT03694990||Intermediate|Patients will be scheduled for PO follow-up visits 4 weeks, and 8 weeks after surgery.
2382116|NCT03694990||Long-term|Patients will be scheduled for PO follow-up visits 8 weeks after surgery.
2382117|NCT03694977|Experimental|MCS110/PDR001 combination|
2382118|NCT03694964|Experimental|Supplementation with Citrulline|Patients will receive citrulline (ProteoCIT®) 10 mg by day during 45 days
2382119|NCT03694964|Placebo Comparator|Placebo|Patients will receive placebo (one tablet by day) during 45 days
2382120|NCT03694951|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of reducing their daily sedentary behaviour to <7 hours per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for reducing their daily sedentary behaviour. Strategies may include: setting an alarm while studying to break up sedentary behaviour, to stand rather than sit on transit, and/or to achieve an active step profile (i.e., ≥10,000 steps a day) through pedometer self-monitoring.
2382121|NCT03694951|No Intervention|Control Group|The control group will not receive any behavioural intervention.
3142625|NCT00002920|Experimental|Tamoxifen plus MPA|Tamoxifen Plus Medroxyprogesterone Acetate (MPA) x 5 years
2382126|NCT03694912||Aggressive RCC Group|RCC with synchronous metastasis, recurrence, or cancer-specific death
2382127|NCT03694912||Non-aggressive RCC Group|RCC without synchronous metastasis, recurrence, or cancer-specific death
3142626|NCT00002921|Experimental|Suramin|
3142627|NCT00002923|Experimental|KRN5500|
3142628|NCT00002924||Source of patient samples|The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
3142629|NCT00002925|Active Comparator|ADE|
3142630|NCT00002925|Experimental|ADEP|
3142631|NCT00002934|No Intervention|Pathology Review, Observation and Follow-up|Pathology review, observation and follow-up
3142632|NCT00002938|Other|Surgery|Salvage prostatectomy
3142633|NCT00002939|Experimental|Paclitaxel in combination with Irinotecan|The first study cohort will receive 60 mg/m2 of paclitaxel on cycle days 1, 8, and 15 as a 1 hr infusion. Immediately following paclitaxel, 30 mg/m2 irinotecan will be administered as a 90 minute intravenous infusion. Irinotecan doses will be administered in an identical infusion schedule on days 8 and 15 of each treatment cycle.
2382128|NCT03694899|Experimental|one|acetaminophen 650 mg three times/day ibuprofen 600 mg three times/day opioid dose based on use in hospital day prior to discharge
2382129|NCT03694886|Active Comparator|Caffeine with small sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
2382130|NCT03694886|Active Comparator|Caffeine with large sucrose pill|Participants will be given one dose of 90 milligrams caffeine anhydrous dissolved in 8 ounces of water and a 5 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
2382131|NCT03694886|Placebo Comparator|No caffeine with small sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
2382132|NCT03694886|Placebo Comparator|No caffeine with large sucrose pill|Participants will be given 8 ounces of water and a 1 mm sucrose pill to consume in 10 minutes. After 30 minutes post-administration, the cognitive tests will be administered.
2382133|NCT03694873|Experimental|tramadol|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
2382134|NCT03694873|Active Comparator|celecoxib|one tablet of Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
2382135|NCT03694847||Asthma with CRSwNP|Asthmatic patients with a diagnosis of CRSwNP
2382136|NCT03694847||Asthma without CRSwNP|Asthmatic patients without a diagnosis of CRSwNP
3183270|NCT00712387|Active Comparator|B|Surgical trainees who are assigned to the 'proficiency-based progression' training programme. These trainees will be required to train on the virtual reality simulator (Lap Sim™) for a laparoscopic cholecystectomy. Trainees will have objectively set goals to reach on the simulator and will have to demonstrate proficiency before they are permitted to progress to the next, more challenging level. Group B will also receive the standard School for Surgeons instruction but, unlike Group A, they will have to demonstrate proficiency on the didactic module before they progress to the operating theatre
2382141|NCT03694808|Active Comparator|Fluad Vaccine|A single adjuvanted dose (AD) intramuscular injection
2382142|NCT03694808|Active Comparator|Fluzone Vaccine|A single high dose (HD) intramuscular injection
2382143|NCT03694782||Experimental group|Gardeners starting gardening in a community garden in Montpellier (France)
2382144|NCT03694782||Control Group|Volunteers living in the same neighborhoods but with no experience in community gardening.
2382145|NCT03694769||All participants|Semi-structured interview and drop attack diary
2382148|NCT03694743|Experimental|2Shape rotary system|root canal preparation using 2Shape rotary system in mandibular molars with symptomatic pulpitis
2382149|NCT03694743|Active Comparator|Protaper Next rotary system|root canal preparation using Protaper Next rotary system comparing to 2Shape rotary system in mandibular molars with symptomatic pulpitis
2382150|NCT03694730|Experimental|Pain-guided Activity Modification|Participants in the Pain guided Activity Modification group will receive an exercise program consisting of progressive patellar tendon loading exercises Outside of physical therapy treatment, these participants will modify activity based on the Pain-Monitoring Model.
2382151|NCT03694730|Active Comparator|Pain-free Activity Modification|Participants in the Pain-free Activity Modification group will receive an identical exercise program to the Pain-guided Activity Modification group. However, participants will not be allowed to participate in activities that cause patellar tendon pain or excessively load the patellar tendon (e.g. jumping) outside of physical therapy treatment.
2382152|NCT03694717||Patients|The patients will receive a 500 ml fluid expansion over a standardized 10 minutes period
2382153|NCT03694704|Experimental|CI with FineHearing Strategy|cochlear implant with FineHearing strategy
2382154|NCT03694691|Experimental|Biopsy|Biopsies taken at protocol specified time points
2382155|NCT03694678|Experimental|Recovering Together|Dyads who are randomly assigned to the Recovering Together program will receive any usual clinic care as determined by their clinicians. Additionally, dyads will be invited to participate in 6 30-minute skills sessions. All sessions will include both pt and cg. A clinical psychologist will deliver the majority of sessions while the PI will deliver at least 10% of the sessions. The main intervention goal is to provide dyads with resiliency and interpersonal communication skills necessary to optimize their recovery and reduce emotional distress and PTS.
2382156|NCT03694678|No Intervention|Health Education|Patients randomly assigned to the control condition will receive an educational program that mimics the dose and duration of the Recovering Together Program but without teaching any of the resiliency or interpersonal communication skills that are hypothesized to be responsible for improvement in emotional distress. The control will entail 2 in-person dyadic visits in the NICU and 4 dyadic virtual visits after discharge.
2382157|NCT03694665|Other|Morbidly anesthetized obese|Morbidly obese patients undergoing bariatric surgery (single-arm study) will receive a Lung recruitment maneuver to treat atelectasis..
2382158|NCT03694652|Experimental|PACE+DApp|Participants in this group will receive combined intervention and a mobile phone app.
2382159|NCT03694652|Active Comparator|PACE+Dface-to-face|Participants in this group will receive combined intervention and in person/phone communication.
2430143|NCT03365960|Placebo Comparator|Control Comparator|placebo
2382161|NCT03694639|Active Comparator|Pregabaline plus ganglion impar block group|where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.
2382162|NCT03694626|Active Comparator|Healthy Control subjects|
2382163|NCT03694626|Active Comparator|TBI Patients without photosensitivity|
2382164|NCT03694626|Active Comparator|Migraine patients without photosensitivity|
2382165|NCT03694626|Active Comparator|Migraine patients with photosensitivity|
2382166|NCT03694626|Active Comparator|TBI patients with photosensitivity|
2382168|NCT03694600||men or women between 21-84|Multi-analyte blood test screening alone and as combination with multi-analyte Test and Ultrasound in subjects diagnosed with liver cirrhosis
2382169|NCT03694587|Active Comparator|Test IMP|
2382170|NCT03694587|Active Comparator|Reference IMP|
2382171|NCT03694574|Other|Low schizotypy|Schizotypy score < 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
2382172|NCT03694574|Other|High schizotypy|Schizotypy score ≥ 14 measured by the German Version of Schizotypal Personality Questionnaire (Klein, Andresen, & Jahn, 1997)
2382173|NCT03694561||Late-Onset Pompe disease|Individuals with a confirmed diagnosis of Late-Onset Pompe disease via NBS
2382177|NCT03694535|Experimental|Bladder wall thermochemotherapy|Mitomycin-C application with bladder wall thermochemotherapy system after TUR bladder tumor in intermediate and high risk non muscle invasive bladder cancer
2382178|NCT03694522|Active Comparator|bemarituzumab (FPA144)+mFOLFOX6|"15mg/kg of bemarituzumab (FPA144) given intravenously and mFOLFOX6 administered after the end of the bemarituzumab (FPA144) infusion~*Cycle 1 will consist of a one-time dose of 7.5 mg/kg of bemarituzumab (FPA144) given intravenously on Day 8~Treatment is repeated every 2 weeks."
2382179|NCT03694522|Placebo Comparator|Placebo+mFOLFOX6|"Placebo given intravenously and mFOLFOX6 administered after the end of the placebo infusion~* Cycle 1 will consist of a one-time dose of placebo given intravenously on Day 8~Treatment is repeated every 2 weeks."
2382180|NCT03694509|Experimental|Breakfast tea with full fat milk|Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
2382181|NCT03694509|Active Comparator|Water|Water 250ml
2382182|NCT03694496|Experimental|peer-led theory-based intervention group|2-6 students (depending on the headcount of the grade 2 students of the school) will be selected as peer leaders and they will receive oral health training first. After being trained and qualified, they will deliver oral health talks and workshops to their peers. The peer leaders will be requested to conduct six activities during 6 months, including health talks, workshops, information leaflets, etc.
2382183|NCT03694496|No Intervention|Control group|Participants in the control group will continue their present practice, and no additional interventions will be given except oral health pamphlets delivery. We will record their present practice in detail. As the control group is in different schools, so they will have very low opportunity to get access to the peer-led activities conducted in the intervention group. Contamination will be quite minimum.
3142634|NCT00002941|Experimental|Reinduction Therapy|Two courses of reinduction chemotherapy followed by bone marrow biopsy and aspirate prior to peripheral blood stem cell (PBSC) harvest. If marrow involvement is still present at harvest, then 2 additional courses of induction chemotherapy are given. The PBSC transplantation preparative regimen should begin within 2 weeks of completing reinduction therapy course, consisting of the following: Carmustine IV over 3 hours on days -8, -7, and -6, Etoposide continuous IV over days -8, -7, and -6, Cyclophosphamide IV over 1 hour daily on days -5, -4, -3, and -2, Mesna as a 15 min infusion before each dose of cyclophosphamide then at 3, 6, 9, and 12 hours after initiation of each cyclophosphamide dose Methylprednisolone IV is given to protect lungs from the toxic effects of carmustine.
3142635|NCT00002942|Active Comparator|Peripheral Blood Progenitor Cells|
2382186|NCT03694457|Active Comparator|deltopectoral approach|the patients are treated with deltopectoral approach surgery
2382187|NCT03694457|Other|lateral approach|the patients are treated with a lateral approach surgery
2382188|NCT03694444|Active Comparator|AMY-101 treatment|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the AMY-101 treatment arm after clinical assessments and sample collection at baseline, test treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
2382189|NCT03694444|Placebo Comparator|Placebo|Subjects who meet inclusion criteria will be enrolled in the study and sites will be randomized to treatment groups (AMY-101 or placebo) in split mouth design. In the placebo arm, after clinical assessments and sample collection at baseline, placebo treatments will be administered to each of the interproximal papilla and will be repeated on Day 7 and 14.
2382190|NCT03694431|Active Comparator|Standard HBPC|Patients and caregivers in standard HBPC will continue to receive usual care from the palliative care team which includes home visits
2382191|NCT03694431|Experimental|Tech-supported HBPC|Patients and caregivers in tech-supported HBPC will receive synchronous video visits with a provider (physician or nurse practitioner) while the nurse is in the patient's home. Home visits by the palliative care team will be determined based on patients/caregivers' needs.
3142636|NCT00002942|Experimental|Autologous Bone Marrow Collection|
2383211|NCT03687112||Alzheimer desease and related disorders|Alzheimer desease and related disorders
3142637|NCT00002944|Experimental|Regimen A (CV Chemotherapy)|Induction will consist of 10 weeks of therapy (carboplatin, vincristine sulfate),followed by 2 weeks without chemotherapy. Induction should only be interrupted in the event of grade 3 neurotoxicity, grade 2 renal toxicity, grade 4 hematologic toxicity, or tumor progression. Maintenance-Four Courses (2 cycles/course) commences on Day 84 (week 12) of Induction or when peripheral counts recover with ANC >1,000/$L and platelet count >100,000/$L. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine sulfate (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.
3142638|NCT00002944|Experimental|Regimen B (TPCV Chemotherapy)|Each cycle of chemotherapy consists of 4 days of oral chemotherapy (Thioguanine, procarbazine hydrochloride, Lomustine and Vincristine sulfate beginning Day 0, followed by vincristine sulfate IV on Days 14 and 28. The cycle is repeated every 6 weeks (42 days). A total of 8 cycles will be given.
3142639|NCT00002946|Experimental|Arm I|atients enrolled on the bioavailability portion of this study receive one dose of IV penclomedine over 1 hour followed by 2 weeks of rest. At the end of two weeks, they receive oral penclomedine for 5 days every 28 days. The starting dose is determined by a single primary patient who has been administered oral penclomedine and observed for dose limiting toxicity (DLT). [Bioavailability portion completed as of 3/98.] Those not on the bioavailability portion of study start on a standard design dose escalating schedule in which patients enroll in cohorts of 3. Patients are administered oral penclomedine daily for 5 days. This treatment repeats every 4 weeks. The MTD is defined as the dose immediately below that at which 2 patients experience DLT. Treatment repeats for 6 courses or until severe toxicity or tumor progression is observed.
3142640|NCT00002949|Experimental|Arm A|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2), Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy) Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
2382195|NCT03694405|Experimental|Group 1A|3 doses prior MenC , randomized to receive MenACWY-CRM (Menveo)
2382196|NCT03694405|Experimental|Group 1B|3 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
2382197|NCT03694405|Experimental|Group 1C|3 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
2382198|NCT03694405|Experimental|Group 2A|2 doses prior MenC, randomized to receive MenACWY-CRM (Menveo)
2382199|NCT03694405|Experimental|Group 2B|2 doses prior MenC, randomized to receive MenACWY-DT (Menactra)
2382200|NCT03694405|Experimental|Group 2C|2 doses prior MenC, randomized to receive MenACWY-TT (Nimenrix)
2382201|NCT03694405|Experimental|Group 3A|1 dose prior MenC, randomized to receive MenACWY-CRM (Menveo)
2382202|NCT03694405|Experimental|Group 3B|1 dose prior MenC, randomized to receive MenACWY-DT (Menactra)
2382203|NCT03694405|Experimental|Group 3C|1 dose prior MenC, randomized to receive MenACWY-TT (Nimenrix)
2382204|NCT03694392||Flublok Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.
2382205|NCT03694392||SD-IIV Recipients|Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).
2382206|NCT03694379|Experimental|Apneic Oxygenation|Participants receiving apneic oxygenation
2382207|NCT03694379|No Intervention|No Apneic Oxygenation|Participants not receiving apneic oxygenation
2382208|NCT03694366||Five facilities in Bassar District|Estimated population of 34,676 served by five public sector facilities in Bassar District.
2382209|NCT03694366||Seven facilities in Binah District|Estimated population of 31,027 served by seven public sector facilities in Binah District.
2382210|NCT03694366||Four facilities in Dankpen District|Estimated total population of 40,165 served by four public sector facilities in Dankpen District.
2382211|NCT03694366||Five facilities in Kéran District|Estimated total population of 31,866 served by five public sector facilities in Kéran District.
2382212|NCT03694353|Experimental|Pegvaliase|
2382213|NCT03694340|Other|Re-programming of cochlear implant|The cochlear implant is programmed with a new MAP based on behavioral measurements of T- and C-levels and used by the participant for 4 months before follow up.
2382214|NCT03694327|Experimental|Treatment A Mobile Application|Treatment A Digital Intervention: Smartphone application designed to assist with smoking cessation.
2382215|NCT03694327|Active Comparator|Treatment B Mobile Application|Treatment B Digital Intervention: Smartphone application designed to assist with smoking cessation.
2382216|NCT03694314|Experimental|Omega-3 fatty acids|Both the mother and child will receive omega-3 supplements in the form of a 200 mL drink to be taken once daily. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
2382217|NCT03694314|Placebo Comparator|Placebo|The mother and child will both receive a placebo drink to take daily, with no known effect on the brain. The intervention will last 45 days. Assessments will take place at 0 months (baseline), 45 days (end of treatment), and 3 months (1 and a half months post-treatment).
2382218|NCT03694288|Active Comparator|Removal Group|The implant removal group will have surgery scheduled 6 months after their initial surgical fixation.
2382219|NCT03694288|No Intervention|Retention Group|The implant retention group will retain their implant for a minimum of 2 years from the time of their initial surgery.
2382222|NCT03694262|Experimental|Treatment|Cycle length = 21 days Atezolizumab 1,200mg IV on day 1 Bevacizumab 15mg/kg IV on day 1 Rucaparib 600mg orally twice daily by continuous dosing
2382223|NCT03694249|Experimental|Group 1 (ifetroban)|ifetroban capsule (250mg) will be taken by mouth daily.
2382224|NCT03694249|Placebo Comparator|Group 2 (placebo)|Placebo capsule (250mg) will be taken by mouth daily.
2382225|NCT03694236|Experimental|durvalumab|This study is single arm phase II study to evaluate efficacy and safety of durvalumab and chemoradiotherapy (paclitaxel and carboplatin) in treatment-naïve clinical stage II/IIIa NSCLC.
2382226|NCT03694223|Experimental|Booklets|Health education delivery method: Booklet. Patients will be given 2 leaflets on the low FOMDAP diet produced by the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London. These booklets have been produced by dietitians and are commonly used in clinical practice across the UK.
3142641|NCT00002951|Experimental|Arm A (Hyper-FHX)|Concomitant chemoradiotherapy consisting of hydroxyurea (PO, BID, x 6days), continuous infusion 5-fluorouracil (IV, x 5days), hyperfractionated radiotherapy (150 cGy twice daily for 5 days every 14 days, 5 cycles)
3142642|NCT00002952|Experimental|Arm A|Melan-A peptide loaded PBMCs (sc, q3wk x 3), rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
3142643|NCT00002956|Experimental|infusions of EBV specific cytotoxic T lymphocytes|Donors undergo leukapheresis, and Epstein-Barr virus (EBV) specific cytoxic T lymphocytes are cultivated in vitro. Patients receive infusions of EBV specific cytotoxic T lymphocytes over 5 to 10 minutes on weeks 0, 2, and 4. Patients with stable disease and those achieving partial remission are followed weekly for signs of disease progression
3142644|NCT00002961|Active Comparator|Total body irradiation|Total body irradiation 1200 centigray
3142645|NCT00002961|Active Comparator|Busulfan|Busulfan 16 doses
3142646|NCT00002965|Experimental|Arm 1: Benign Meningiomas|INF alpha as a subcutaneous injection Monday to Friday for 8 weeks.
2382227|NCT03694223|Experimental|Mobile application|Health education delivery method: Mobile application. Patients will be asked to download an application on their mobile phones or tablets. This application has been produced by dietitians from the Department of Nutrition and Dietetic in Guy's & St Thomas' NHS Foundation Trust, and the Diabetes and Nutritional Sciences Division at King's College London.
2382228|NCT03694223|Active Comparator|One to one consultation with dietitian|Health education delivery method:One-to-one consultation with dietitian. Patients will attend a clinic visit for a one-to-one consultation with a dietitian. As per current clinical practice, the initial visit will last for 1 hour. During the visit, tailored information on the low FOMDAP diet will be given to match patients' individual needs. During the visit, either the leaflets (used in group 1) or the application (used in group 2) will be used to facilitate the visit. The choice of using the leaflets or the app during the visit will be based on the dietitian's judgment based on the patients' needs.
3142647|NCT00002965|Experimental|Arm 2: Other Pathologies|INF alpha as subcutaneous injection Monday to Friday for 8 weeks.
3142648|NCT00002968|Experimental|Arm I (edrecolomab)|Patients receive adjuvant edrecolomab IV over 2 hours on day 1. Treatment repeats every 28 days for 5 courses. Patients must begin therapy no earlier than 7 days and no later than 42 days postsurgical resection. Patients also undergo observation at 3 and 6 months postrandomization.
3142649|NCT00002968|No Intervention|Arm II (no treatment)|Patients undergo observation at 3 and 6 months postrandomization. .
2382233|NCT03694145||Diabetic patients w. risk of retinopathy|The 300-500 patients to be enrolled for the study are diabetic patients normally seen by the Los Angeles County Department of Health Services (LACDHS) Teleretinal Diabetic Retinopathy Screening Program and Reading Center. In addition to receiving their recommended LACDHS annual teleretinal screening, for the study, participants will receive an additional in-person eye examination.
2382234|NCT03694132|Experimental|functional MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical and mechanical stimuli of ADM proprioceptors
2382235|NCT03694132|Experimental|structural MRI|a group of patients with ALS and a group of gender and age matched healthy subjects will have diffusion MRI acquisition to evaluate their brain structures
2382236|NCT03694132|Experimental|EEG/MEG|a group of patients with ALS and a group of gender and age matched healthy subjects will have functional MRI acquisition conditioned by electrical stimuli of ADM proprioceptors
2382237|NCT03694119|Active Comparator|Phenelzine|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Phenelzine arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 31, then receiving Phenelzine 15mg BID plus ozanimod placebo QD from Days 32 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
2382238|NCT03694119|Placebo Comparator|Placebo|Following tyramine challenging in Period 1, eligible subjects randomly assigned to Placebo arm are receiving Phenelzine placebo BID plus ozanimod placebo QD from Days 11 to 38. Subjects receive second tyramine challenge from Day 39 to up to Day 49
2382239|NCT03694119|Experimental|ozanimod|Following tyramine challenging in Period 1, eligible subjects randomly assigned to ozanimod arm are receiving Phenelzine placebo BID plus ozanimod 1.84mg QD from Days 11 to 38, including dose escalation days. Subjects receive second tyramine challenge from Day 39 to up to Day 49
2382240|NCT03694093||Patients with Hyperhidrosis|Subjects with Primary Hyperhidrosis will be followed in this study. Because this study is observational, there will be no intervention.
2382241|NCT03694080|Experimental|Calcium Electroporation treatment|Calcium electroporation for colorectal cancer as a preoperative treatment before elective surgery.
2382242|NCT03694067||Androgenetic alopecia patients|Two 1 mm scalp punch skin biopsy will be taken per patient
2382243|NCT03694054|Experimental|Care coordination patients, caregivers|Patients and caregivers enroll in using care coordination tool during oncology care and treatment.
2382244|NCT03694054|No Intervention|Standard of care patients, caregivers|Patients and caregivers receive oncology care and treatment.
2382245|NCT03694054|Experimental|Oncology Care Providers|Oncology care providers with patients enrolled in care coordination tool.
2382246|NCT03694041|Experimental|SAD: APX-115|Experimental: APX-115 SAD group
2382247|NCT03694041|Placebo Comparator|SAD: Placebo|Experimental: Placebo group
2382248|NCT03694041|Experimental|MAD: APX-115|Experimental: APX-115 MAD group
2382249|NCT03694041|Placebo Comparator|MAD: Placebo|Experimental: Placebo group
2382250|NCT03694041|Active Comparator|Food effect - Fasting condition|Experimental: APX-115 under fasting condition
2382251|NCT03694041|Active Comparator|Food effect - fed condition|Experimental: APX-115 under fed condition
2382252|NCT03694041|Placebo Comparator|Drug Interaction - metabolic probe|Experimental: metabolic probe
2382253|NCT03694028|Experimental|Limb Loading|This group will be exposed to a sudden unilateral lowering of the supporting surface to induce lateral weight transfer of the paretic limb.
2382254|NCT03694028|Active Comparator|Conventional Training|This group will practice weight shifting and step training that focuses on the paretic limb.
3142650|NCT00002970|Experimental|Arm I|"GROUP 1: Patients receive a 1 hour infusion of compound 506U78 daily for 5 days in the absence of neurologic toxicity. The course repeats every 21 days. If a first relapse T-cell ALL study of higher priority is not open, then the patient may continue to receive the drug every 21 days for a maximum of 2 years provided that the patient has achieved a second complete response.~GROUPS 2 and 4: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. After 3 courses a patient may be given CNS prophylaxis with triple intrathecal therapy (TIT), consisting of methotrexate, cytarabine and hydrocortisone after consultation with study coordinator. TIT should be given every 12 weeks.~GROUP 3: Patients receive compound 506U78 every 21 days for a maximum of 2 years, in the absence of disease progression. TIT will be given on day 1 of weeks 1-4, 6, 9 and every 6 weeks for 12 weeks, and then every 9 weeks thereafter. This stratum is open."
3142651|NCT00002981|Experimental|PET Scan|Each patient receives C11-methionine intravenously. PET imaging begins immediately after injection for approximately 60 minutes total using standard imaging procedures. Immediately following the completion of imaging after C11-methionine administration, each patient receives FDG intravenously. PET imaging begins approximately 45 minutes thereafter for approximately 60 minutes using standard imaging procedures.
2382455|NCT03692455|Experimental|Sleeve Group|Patients will be submitted to Vertical Sleeve Gastrectomy Surgery.
2382257|NCT03694002|Experimental|Arm A (ramucirumab, carboplatin, paclitaxel)|Patients receive ramucirumab IV over 60 minutes, carboplatin IV, and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have not progressed may continue to receive ramucirumab for up to 1 year.
2382258|NCT03694002|Active Comparator|Arm B (carboplatin, paclitaxel)|Patients receive carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3188956|NCT00772512|Experimental|B|
2382261|NCT03693976||Ectoin Rhinosinusitis Nasal Spray|application of 1-2 sprays of SNS01 into each nostril several times a day
2382262|NCT03693976||Xylometazoline nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
2382263|NCT03693976||Xylometazoline + Ectoin Nasal Spray|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Spray (SNS01): 1-2 sprays per nostril several times a day
2382264|NCT03693963|Other|Single Arm, treated with Serranator|Subjects treated with Serrantor
2382267|NCT03693911|Experimental|Prevention group|AcceptME- digital gamified Acceptance and Commitment Therapy prevention program
2382268|NCT03693911|No Intervention|Waitlist control|Waitlist control group
2382269|NCT03693898|Other|Persons with collagen VI defect|Observational
2382270|NCT03693885|Experimental|OCT-group|Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.
2382271|NCT03693885|No Intervention|Control|standard procedure before planned caesarean section
2382272|NCT03693872|Other|Apomorphine|Withdrawal of dopaminergic agonists at pump initiation
2382273|NCT03693872|Other|Dopaminergic Agonist + Apomorphine|Continuation of dopaminergic agonists at pump initiation
2382274|NCT03693859|Experimental|Behavioral Weight Loss + Gaming|Treatment will consist of 12-weekly, one-hour group sessions of approximately 15 participants per group. Participants will provide logs of serious gaming (intervention).
2382275|NCT03693859|Active Comparator|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks. Participants will provide logs of video segment watching (control).
2382277|NCT03693833|Experimental|Intervention|10mg Cannabidiol (CBD) tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
2382278|NCT03693833|Placebo Comparator|Placebo|10mg Placebo Oral tablets once daily for the first two weeks increasing to twice daily for week 3 and 4 if adequate analgesic effect is not attained at week 5 then the dose can be increased to 10mg thrice daily from week 5 and onward.
2382279|NCT03693820|Active Comparator|the infiltration group|a cocktail of 5 mg/Kg lidocaine normal saline in a volume of 3 ml/Kg 5 mcg/ml adrenaline. We will administrate 5 ml lidocaine at each port site before incision, then immediately after the creation of the pneumoperitoneum, the surgeon will spray 50-75 ml of the total solution on the upper surface of the liver under the right sub-diaphragmatic space and another 50-75ml over the parietal peritoneum. The Trendelenburg position will be maintained for 2 minutes. Then 50 ml will be infiltrated in the bladder bed and pedicle after clamping of the cystic duct and artery. Infiltration will be through a laparoscopic suction needle, diameter 0.9 /330 mm (Zhejiang, China).
2382280|NCT03693820|Placebo Comparator|the control group|the same technique but the 50 ml for gallbladder infiltration will be replaced by saline.
3142652|NCT00002994|Experimental|Monoclonal antibody + interleukin 2|"Cycle 1: low dose IL2 days 1-7; MoAb day 7; intermediate dose IL-2 days 8-10; Low dose IL2 days 11-20.~Cycle 2 & all subsequent cycles: MoAb day 1; intermediate dose IL2 days 1-3; low dose IL2 days 4-14"
2382282|NCT03693781|Active Comparator|Colchicine 0.01mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
2382283|NCT03693781|Active Comparator|Colchicine 0.005 mg/kg/day + Riluzole 100 mg|Oral colchicine will be administered at fast, at specified dose pro kilograms for 30 weeks, while taking Riluzole 100 mg/day
2382284|NCT03693781|Placebo Comparator|Placebo + Riluzole 100 mg|Placebo pills will be administered at fast, while taking Riluzole 100 mg/day
2382285|NCT03693768|Experimental|Health coaching ARM|Participants in this ARM will undergo health coaching for 4 months.
2382286|NCT03693755|Active Comparator|In-plane Group|In this Group the femoral nerve catheter will be placed with the in-plane technique.
2382287|NCT03693755|Active Comparator|Out-of-plane Group|In this Group the femoral nerve catheter will be placed with the out-of-plane technique.
3142653|NCT00002998|Experimental|gemcitabine + cisplatin|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.
3142654|NCT00003005|Experimental|deoxycoformycin and cordycepin|Dose escalation for deoxycoformycin and cordycepin
2382290|NCT03693729|Experimental|Active DLPFC during task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
2382291|NCT03693729|Active Comparator|Active DLPFC after task|HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min after the memory and metamemory task and during a filler task.
2382292|NCT03693729|Sham Comparator|Sham DLPFC during task|Sham HD-tDCS will be applied over the DLPFC at 2mA in a single session for up to 30 min during the memory and metamemory task
2382293|NCT03693716|Experimental|Dynamic Anterior Stabilization|Arthroscopic Dynamic Anterior Capsular Stabilization with Trans subscapular Long Head of the Biceps Tenodesis
3142655|NCT00003006||Group 1|At the time of thoracotomy and pulmonary resection, patients have samples of bone marrow, primary tumor, and intrathoracic lymph nodes harvested. The presence of occult metastases in bone marrow and lymph nodes is assessed using immunohistochemistry or reverse transcriptase-polymerase chain reaction.
2382294|NCT03693703|Experimental|bi-parametric MRI|Patients will undergo axial T2-weighted and diffusion-weighted imaging (no contrast agent injection)
2382295|NCT03693703|Active Comparator|multi-parametric MRI|Patients will undergo multiparametric MRI including morphological study (T2- and T1-weighted imaging) and functional acquisitions (diffusion-weighted and dynamic contrast-enhanced imaging)
2382296|NCT03693677|Experimental|Nal-IRI/5-FU/LV + Nab-paclitaxel/Gemcitabine alternatively|"Nal-IRI plus 5-FU/LV and Nab-Paclitaxel plus Gemcitabine alternately every two months~Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.~Nab-Paclitaxel + Gemcitabine (6 injections, one injection three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel plus Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
2382297|NCT03693677|Experimental|Nal-IRI/5-FU/LV|Nal-IRI plus 5-FU/LV Nal-IRI at 80 mg/m2 IV over 90 minutes followed by folinic acid (leucovorin 400 mg/m2 IV, or Elvorin 200 mg/m2 IV over 30 minutes) then by 5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
2382298|NCT03693677|Active Comparator|Nab-paclitaxel/Gemcitabine|"Nab-Paclitaxel plus Gemcitabine Nab-Paclitaxel + Gemcitabine (6 courses, one course three weeks out of four; so ≈ 2 months per cycle)~Day 1 (D1): Nab-Paclitaxel + Gemcitabine at the dose of :~Gemcitabine: 1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min).~Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43."
2382299|NCT03693651||Parent of a Premature infant / PP|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
2382300|NCT03693651||Parent of a baby born on time / PT|self-report questionnaire that assesses sleep quality (The Pittsburgh Sleep Quality Index (PSQI)) filled at 1 month, 3 months and 6 months from child birth.
2382301|NCT03693638|Active Comparator|Single dose (SD)|2,5 ml total anesthetic drug dose (Bupivacaine-fentanyl) were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
2382302|NCT03693638|Active Comparator|Fractionated dose (FD)|1,5 ml of total anesthetic drug dose (Bupivacaine-fentanyl) followed by 1 ml remaining dose after 90 s interval were given
3183271|NCT00712400|Active Comparator|1|Latanoprost 0.005%, Xalatan®
3183272|NCT00712400|Placebo Comparator|2|Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug)
2382305|NCT03693612|Experimental|Part 1: feladilimab +tremelimumab|In Part 1, subjects with advanced selected solid tumors will be enrolled. Subjects will be administered escalating doses of feladilimab and tremelimumab in combination. feladilimab will be administered every 3 weeks and tremelimumab will be administered every 3 weeks for 6 doses and every 12 weeks thereafter.
2382306|NCT03693612|Experimental|Part 2: feladilimab +tremelimumab|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered feladilimab in combination with tremelimumab at recommended Phase 2 dose as determined from Part 1.
2382307|NCT03693612|Active Comparator|Part 2: SOC|In Part 2, subjects with R/R HNSCC who have disease progression after receiving at least one platinum-based chemotherapy and at least one anti-PD-1/PD-L1 will be enrolled. Subjects will be administered a single agent SOC therapy of either paclitaxel, docetaxel or cetuximab as per the investigators choice.
2382308|NCT03693599|Experimental|carbetocin|600 women received single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
2382309|NCT03693599|Active Comparator|Syntometrine|600 women received one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 micrograms of ergometrine diluted in 10 ml of Ringer's lactate solution and was administered intravenously over 2 minutes
2382310|NCT03693573|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab in combination with bevacizumab.
2382311|NCT03693560|Experimental|vildagliptin / metformin|Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
2382312|NCT03693560|Experimental|glimepiride / metformin.|Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
2382313|NCT03693547|Experimental|utidelone|Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC
2382314|NCT03693534||Long Antagonist Protocol|Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.
2382315|NCT03693534||Long Agonist Protocol|Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.
2382316|NCT03693521|Experimental|Intervention group|Standard care at yearly check-up by diabetes-nurse in primary care. Handgrip strength measurement bilaterally. Measurement of physical activity level.
2382317|NCT03693521|Active Comparator|Control group|Standard care at yearly check-up by diabetes-nurse in primary care. Measurement of physical activity level.
2382318|NCT03693508|Experimental|Arm 1|Naive HIV patients with severe immunosuppression.
2382319|NCT03693495|Experimental|ellume·lab Group A Streptococcus Test|"ellume·lab Group A Streptococcus Test~Pharyngeal samples from participants will be tested with:~ellume.lab Group A Streptococcus Test; Polymerase Chain Reaction (PCR) and bacterial culture."
2382320|NCT03693469|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during immunization.
2382321|NCT03693469|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
2382322|NCT03693456|Experimental|Responders Without Epinephrine|Subjects experienced a positive response during previous oral food challenge without a severe adverse event and did not require epinephrine. Will be subjected to a conjunctival allergen challenge.
3183273|NCT00712426|Active Comparator|A|Randomized to receive creatine monohydrate (up to 40 grams daily)
3183274|NCT00712426|Placebo Comparator|B|Randomized to receive placebo (up to 40 grams daily)
3183275|NCT00712439|Experimental|1|
2382323|NCT03693456|Experimental|Responders With Epinephrine|Subjects experienced a positive response during previous oral food challenge and required epinephrine. Will be subjected to a conjunctival allergen challenge.
2382324|NCT03693456|Experimental|Non-Responders|Subjects did not experience a positive response during previous oral food challenge. Will be subjected to a conjunctival allergen challenge.
3142656|NCT00003011|Active Comparator|Marmistat|10 mg PO BID
3142657|NCT00003011|Placebo Comparator|Placebo|10 mg PO BID
2382327|NCT03693417|Active Comparator|Control|
2382328|NCT03693417|Experimental|Heat|
2382329|NCT03693404|Experimental|Spinal Anesthesia|Injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
2382330|NCT03693404|Active Comparator|General Anesthesia|The control group will receive no injection into area surrounding the fracture site
2382331|NCT03693391|Experimental|Cohort 1: JNJ-64140284|Participants in cohort 1 will receive single oral dose of JNJ-64140284 at a starting dose of 0.5 milligram (mg) under fasted conditions. The dose levels of JNJ-64140284 will be escalated sequentially based on the decisions of an independent Data Review Committee (iDRC), the clinical team and the investigator. First 3 participants will also receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq). Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent positron emission tomography-computed tomography (PET-CT) scan.
2382332|NCT03693391|Experimental|Cohort 2: JNJ-64140284|Participants in cohort 2 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
2382333|NCT03693391|Experimental|Cohort 3: JNJ-64140284|Participants in cohort 3 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
2382334|NCT03693391|Experimental|Cohort 4: JNJ-64140284|Participants in cohort 4 will receive next dose level of JNJ-64140284 based upon the data-review from the previous cohort and on the decisions of an iDRC, the clinical team and the investigator. At least 3 participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq. Participants with no measurable brain receptor occupancy will receive second (escalated) dosing with JNJ-64140284 and subsequent PET-CT scan.
2382336|NCT03693352||Patients undergoing surgeries|Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning.
2382337|NCT03693339|Experimental|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
2382338|NCT03693326|Experimental|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
2382339|NCT03693313|Experimental|CrossFit KAMP Group 1|14 weeks of CrossFit Kids exercise program
2382340|NCT03693313|Active Comparator|CrossFit KAMP Wait-list Group|Waitlist group that waits 14 weeks while group 1 does exercise program. After first 14 weeks will then participate in 14 weeks of CrossFit Kids exercise program
3142658|NCT00003018|Experimental|Chemotherapy|dipyridamole: 75mg/dose, PO, Days 1-28 of 5 week cycle; fluorouracil: 200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle; leucovorin calcium: 30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle; mitomycin C: 10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
3142659|NCT00003019|Experimental|Chemotherapy Treatment|Patients receive vinblastine sulfate (5 mg/m2) IV and methotrexate (30 mg/m2) IV weekly for 26 weeks, then every 2 weeks for an additional 26 weeks. Treatment continues for a maximum of 1 year in the absence of unacceptable toxicity or disease progression. Patients with a complete response receive an additional 8 doses of chemotherapy. Patients are followed every 6 months for 4 years and then annually thereafter.
2382343|NCT03693287|Active Comparator|Personalized-Parenteral Nutrition (P-PN)|"These patients will receive personalized parenteral nutrition (PN) as it is customary in the participating centers.~Dosing range: glucose from 9 to 13 g/kg/d, AA from 2.0 to 3.0 g/kg/d, and FAT from 1.5 to 2.5 g/kg/d.~Intravenous macronutrient intakes:~PN day 1: 2.0 g/kg of AA, 1.6 g/kg of FAT and 9 g/kg of glucides.~PN day 2: 2.5 g/kg of AA, 2.0 g/kg of FAT and 11 g/kg of glucides.~PN day 3 and the days after: 3.0 g/kg of AA, 2.5 g/kg of FAT and 13 g/kg of glucides.~Intravenous vitamins will be supplied according to local clinical practice. Variations in macronutrient intakes will be tolerated within ±20%.~Nutritional goal: to ensure at least 2.5 g/kg/d of AA and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
2382344|NCT03693287|Experimental|Standardized-Parenteral Nutrition (S-PN)|"These patients will receive standardized parenteral nutrition (PN) by using a triple chamber bag (Numeta G13%E®).~Dosing range: 80-300 ml/d. Intravenous macronutrient intakes: 65 ml/kg at PN day 1, 80 ml/kg at PN day 2 and then 100 ml/kg from PN day 3.~Nutritional goal: to ensure at least 2.5 g/kg/d of amino acids (AA) and 70 kcal/kg/d of no protein energy (NPE) from PN day 2."
2382345|NCT03693274|Experimental|Mindfulness Course|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center and will also be given access to BreatheAware for Pain Management, a 16- week web-based mindfulness course.
2382346|NCT03693274|No Intervention|Usual Care|Patient will be provided usual care for chronic pain at the Interventional Pain Clinic at Vanderbilt University Medical Center.
2382456|NCT03692442||immunotherapy effective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
3142660|NCT00003034|Experimental|Arm I|Patients receive ranpirnase IV over 30 minutes weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression. Patients demonstrating evidence of clinical response or stable disease may continue on maintenance therapy with ranpirnase as a single agent until disease progression.
3183276|NCT00712439|Placebo Comparator|2|
2382347|NCT03693261||Coronary Artery Disease (CAD)|Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.
2382348|NCT03693261||controls|Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).
2382349|NCT03693248|Experimental|Two cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Two cycles of neoadjuvant chemotherapy and four cycles of adjuvant chemotherapy."
2382350|NCT03693248|No Intervention|Three cycles of neoadjuvant chemotherapy|"Paclitaxel (175mg/m2) and carboplatin (AUC 5.0 or 6.0) IV, D1, every three weeks.~Three cycles of neoadjuvant chemotherapy and three cycles of adjuvant chemotherapy."
2382351|NCT03693235|Experimental|70 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 70 degrees.
2382352|NCT03693235|Experimental|80 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 80 degrees.
2382353|NCT03693235|Experimental|90 degrees|During tracheal intubation using a lightwand, the tracheal tube combined with a lightwand will be bent by 90 degrees.
2382354|NCT03693222|Experimental|tramadol use|Cases were assessed as intravenous opioid with 1 mg/kg tramadol hydrochloride
2382355|NCT03693222|Experimental|quadratus lumborum block|Cases were assessed asquadratus lumborum block for postoperative analgesia
2382356|NCT03693209|Experimental|General trigger|"VHS with one general trigger: If I am getting angry... and 10 strategies (e.g. Then I will take deep breaths). Participants are instructed to link trigger with strategies."
2382357|NCT03693209|Experimental|Specific triggers|"VHS with a list of 10 specific situations that can act as anger triggers (e.g. If I am getting angry when people act like they know it all) and 10 strategies. Participants are instructed to link triggers with strategies."
2382358|NCT03693209|No Intervention|Control|List of 10 specific situations that can act as anger triggers and 10 strategies. Participants are instructed to select most encountered triggers and most useful strategies.
2382359|NCT03693196|Other|Straumann®|Titanium implants the surfaces of which were roughened with SLA (sandblasted and acid-etched titanium surface) (Straumann®, Basel, Sweden). Immunological parameters (PICF, Perio-paper®) , microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
2382360|NCT03693196|Other|Astra Tech, OsseoSpeed™|Implants the surfaces of which were roughened by modifying with fluorine (Astra Tech, OsseoSpeed™, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis (subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
2382361|NCT03693196|Other|Nobel Biocare, Replace®|Implants the surfaces of which were roughened by anodization (TiUnite Nobel Biocare, Replace® Conical Connection, Sweden). Immunological parameters (PICF, Perio-paper®), microbiological parameters of peri-implantitis(subgingival plaque, Hu-Friedy®), demographic and clinical periodontal measurements (Williams probe, PCPNU-15 Hu-Friedy®) were compared between groups.
2382362|NCT03693183|Experimental|Ketorolac/HPMC|"Drug: Ketorolac/HPMC Ophthalmic Solution~1 drop administered in each eye 4 times per day for 2 days"
2382363|NCT03693183|Active Comparator|HPMC|"Drug: 0.80% Hydroxypropyl Methylcellulose(HMPC) Ophthalmic Solution~1 Drop administered in each eye 4 times per day for 2 days"
2382364|NCT03693183|Placebo Comparator|Vehicle|"Drug: Vehicle Ophthalmic Solution~1 drop administered in each eye 4 times a day for 2 days"
2382365|NCT03693170|Experimental|1 Arm|encorafenib plus binimetinib plus cetuximab
2382366|NCT03693144|Experimental|Intervention Group 1 Full LIITA3H App|Participants will be given the LIITA3H app, which is a combination product consisting of 3 main features that will track their visits to fast food restaurants (using the ELI feature), send tailored text messages to prompt healthy choices when they are in a fast food restaurant (using the POP feature), and allow them to submit pictures of their food (using the SNAP feature).
2382367|NCT03693144|Active Comparator|Control Group 2 Partial LIITA3H App|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) and they will submit pictures of their food (using the SNAP feature). However, they will not receive tailored text messages.
2382368|NCT03693144|Other|Control Group 3 LIITA3H Location only|Participants will be given the LIITA3H app that will track their visits to fast food restaurants (using the ELI feature) but they will not receive tailored messages or submit pictures of their food.
2382369|NCT03693131|Experimental|MND-2119 2 g|MND-2119 2 g, orally, once daily after breakfast for 12 weeks.
2382370|NCT03693131|Experimental|MND-2119 4 g|MND-2119 4 g, orally, once daily after breakfast for 12 weeks.
2382371|NCT03693131|Active Comparator|EPADEL CAPSULES 300 1.8 g|EPADEL CAPSULES 300 0.9 g, orally, twice daily after breakfast and dinner for 12 weeks.
2382372|NCT03693131|Active Comparator|EPADEL CAPSULES 300 2.7 g|EPADEL CAPSULES 300 0.9 g, orally, three-times daily after each meal for 12 weeks.
2382373|NCT03693118|Experimental|Grup1, Grup2|
2382374|NCT03693118|Experimental|Grup1,Grup2|
2382375|NCT03693105|Active Comparator|Dorsolateral prefrontal cortex|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (DLPFC)
2382376|NCT03693105|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
2382377|NCT03693079|Experimental|Wet Cupping|wet cupping therapy will be applied to all participants
2382378|NCT03693066|Experimental|ozone|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with ozone. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The cavity was exposed to gaseous ozone for 60 seconds, with an ozone delivery system. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement to reopen 4 months later.
2382451|NCT03692481|Experimental|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
2382457|NCT03692442||immunotherapy ineffective group|PD1, TMB and serum cytokines was detected before nivolumab treatment
2382379|NCT03693066|Active Comparator|chlorhexidine digluconate|Thirty five molar teeth with deep caries lesion were selected to apply two-visit indirect pulp therapy with chlorhexidine digluconate. The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. Following the excavation, 2% chlorhexidine digluconate was applied to the cavity for 60 seconds using a brush. According to the manufacturer instructions, puddled solution was removed with a new brush without dry to leave site moist. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
2382380|NCT03693066|Active Comparator|Control|Thirty five molar teeth with deep caries lesion were selected to apply conventional two-visit indirect pulp therapy (control). The peripheral demineralized dentin and the superficial necrotic dentin were completely removed, and left some caries at the central part. The remaining caries dentin was covered with calcium hydroxide base material and cavity sealed with glass ionomer cement.
2382381|NCT03693040|Experimental|DHFS with IS-Truvada|Digital Health Feedback System (DHFS) with IS-Truvada 1 capsule daily for 12 weeks
2382382|NCT03693027|Experimental|PTx800|Qualified subjects will dissolve one oral lozenge (PTx800 lozenges) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
2382383|NCT03693027|Placebo Comparator|Placebo|Qualified subjects will dissolve one oral lozenge (placebo control) by mouth 3 times a day (after breakfast, lunch and dinner) throughout the 6 week study.
3142661|NCT00003034|Experimental|Arm II|Patients receive doxorubicin as in arm I for up to 6 courses.
2382385|NCT03693001|Experimental|IC/FM Patients|All patients had been diagnosed with fibromyalgia and were suffering from IC by standard criteria.
2382386|NCT03692988|Experimental|Interventiongroup|Dignity Therapy. Patients receive dignity-therapy-Intervention after randomization
2382387|NCT03692988|No Intervention|Waitinggroup|Patients receive dignity-therapy-Intervention after a waiting time of 3 months post randomization
2382388|NCT03692975|Experimental|CIS patients|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially suggestive of multiple sclerosis (MS) whatever the mode of presentation
2382389|NCT03692975|Active Comparator|Control|50 Healthy controls
2382390|NCT03692962|Sham Comparator|Sleep restriction without acoustic stimulation|
2382391|NCT03692962|Experimental|Sleep restriction with acoustic stimulation|
2382392|NCT03692949|Experimental|LY3451838 Part A|Single ascending doses, administered intravenously (IV)
2382393|NCT03692949|Experimental|LY3451838 Part B|Single doses administered subcutaneously (SC)
2382394|NCT03692949|Placebo Comparator|Placebo Part A|Matching single doses administered intravenously (IV)
2382395|NCT03692949|Placebo Comparator|Placebo Part B|Matching single doses administered subcutaneously (SC)
2382396|NCT03692923|No Intervention|control group|participants received ordinary prenatal care.
2382397|NCT03692923|Experimental|virtual community group|participants were invited to join a virtual community to interact with peers in addition to their ordinary prenatal care.
2382398|NCT03692910|Experimental|SAGE-217|
3142662|NCT00003039|Experimental|Arm I|Patients receive treatment on an outpatient basis. Flavopiridol is administered as a continuous infusion over 72 hours every 2 weeks. Patients receive a minimum of 4 cycles of therapy unless unacceptable toxicity or disease progression occurs.
2382400|NCT03692871|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of double-blind V114 at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
2382401|NCT03692871|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of double-blind Prevnar 13™ at approximately 2, 4, 6, and 12-15 months of age (Study Day 1, Month 2, Month 4, and Month 10-13). Nonstudy pediatric vaccines are permitted and should be administered according to the local recommended schedule.
2382402|NCT03692858|Active Comparator|Group A|
2382403|NCT03692858|Active Comparator|Group B|
2382404|NCT03692845|Other|O-TLIF group|Spinal fusion ,Transforaminal lumbar interbody fusion procedure will be performed through open surgery.
2382405|NCT03692845|Other|MI-TLIF group|Spinal fusion,Transforaminal lumbar interbody fusion procedure will be performed through minimally invasive surgery using a tubular retractor.
2382406|NCT03692832|Experimental|Group L|
2382407|NCT03692832|Active Comparator|Group V|
2382408|NCT03692819|Active Comparator|placebo|Periodontal debridement treatment will be performed in a single session after the therapy will be administered the Placebo Oral Tablet twice a day for 21 days.
2382409|NCT03692819|Experimental|Metronidazole and Amoxicillin|Periodontal debridement treatment in a single session Metronidazole 400mg + Amoxicillin 500mg every 8 hours for 7 days.
2382410|NCT03692819|Experimental|Lactobacillus reuteri|Periodontal debridement treatment in a single session Lactobacillus reuteri Oral Drops twice a day for 21 days.
2382411|NCT03692806|Experimental|Stablor|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
2382412|NCT03692806|Placebo Comparator|placebo|2 sachets to be taken twice a day at breakfast and in the afternoon as a snack during 12 weeks
2382413|NCT03692793|Experimental|Pulmonary rehabilitation|The PRP (24-session, three times for week) will be delivered according to ATS/ERS (Spruit et al, 2013),
2382414|NCT03692780|Experimental|Careseng 1370|
2382415|NCT03692780|Placebo Comparator|Matched Placebo|
2382416|NCT03692767|Experimental|Anti-CD22 CAR NK cells|Total dose of 50-600 thousand /kg Anti-CD22 CAR NK cells will be administered at day0
2382417|NCT03692754|Active Comparator|AT with 10 mg/d|The patients will be given receive atorvastatin in 10 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
2382418|NCT03692754|Active Comparator|AT with 20 mg/d|The patients will be given atorvastatin in 20 mg/d for 1 month plus dexamethasone 40mg/d for 4 days.
2382419|NCT03692754|Experimental|Dexamethasone|The patients will be given dexamethasone 40mg/d for 4 days.
2382452|NCT03692468|Experimental|Intervention Group|Participants will engage in a 5 session psychotherapy intervention focused on improving pain and mood.
2382453|NCT03692468|No Intervention|Control Group|Patients will receive treatment as usual from their care providers.
3188957|NCT00772512|Placebo Comparator|C|
2382420|NCT03692728||CC children|CC children were registered members of the Childhood Cataract Program of the Chinese Ministry of Health (CCPMOH). All of them were diagnosed with CC by two experienced pediatric ophthalmologists based on a comprehensive evaluation of the onset age (within one year after birth), morphological features of lens opacity, family history, and detailed medical records.
2382421|NCT03692728||NV children|NV children were recruited from the Optometry Department of the ZOC as the control group. NV was defined as BCVA ≥0.3 (log MAR) in children between 3-5 years old or BCVA ≥0.15 (log MAR) in children older than 5 years. Children with strabismus and high refractive error (myopia or hyperopia: >6.0 Diopters; astigmatism: >3.0 Diopters) were excluded from NV group.
3142663|NCT00003040|Experimental|Transoral CO2 laser laryngectomy and RT|Transoral CO2 laser supraglottic laryngectomy and irradiation
3142664|NCT00003045|Experimental|Hyperthermia|XRT and Hyperthermia Post-therapy evaluation PSA, Clinical Exam, and Prostate Biopsy ( @ 12 Months)
2382424|NCT03692702|Experimental|WE PLAY|Teachers in this condition received the WE PLAY training.
2382425|NCT03692702|No Intervention|Control|Preschools in this condition received the same physical activity equipment that preschools in the WE PLAY condition received. Teachers were not provided with any specific instructions or information about physical activity.
2382426|NCT03692689|Experimental|SCT200|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3142665|NCT00003046|Experimental|Interleukin-12|
2382428|NCT03692663|Experimental|anti-PSMA CAR NK cells treatment group|
2382429|NCT03692637|Experimental|anti-Mesothelin Car NK Cells|Total dose of 0.5-3 million /kg cells will be administered at day0
2382430|NCT03692624|Experimental|Intervention Group|Biofeedback. Participants receiving the HRV-B intervention will complete a baseline assessment, a minimum of 4 weeks and up to 6 weekly training sessions (until the criterion of HRV coherence is met), and a final appointment (3-7 days later) where post-training HRV and symptom inventories will be recorded.
2382431|NCT03692624|No Intervention|Control Group|To control for the laboratory environment or other potential placebo effects, a control group will receive their usual follow-up care for their cancer diagnosis and will complete baseline and post-baseline outcome assessments without any HRV-B training.
2382432|NCT03692611|Experimental|Skills to Manage Pain (STOMP)|The intervention group will receive treatment as usual plus the STOMP behavioral intervention. The STOMP behavioral intervention consists of 12 intervention sessions (6 group and 6 individual sessions). The sessions will be completed over a period of 12-16 weeks from enrollment. The first intervention session will be a group session for all participants followed by individual and then alternating group and individual sessions for the rest of the intervention. The intervention group will utilize a study manual on pain management in which they will use with each session.
2382433|NCT03692611|Active Comparator|comparison group|The comparison group will receive treatment as usual.The comparison group will also be provided with the intervention manual, however, no additional treatment will be provided to participants allocated to the control group. The group will not receive the PSM intervention.
2382434|NCT03692598|Experimental|MIA Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach
2382435|NCT03692598|Experimental|MIA Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach
2382436|NCT03692572|Active Comparator|Nitrate supplementation|Nitrate rich (6.8 mmol) beet root juice (70ml) twice a day
2382437|NCT03692572|Placebo Comparator|Placebo|Nitrate depleted (0.04 mmol) placebo juice (70ml) twice a day
2382438|NCT03692559|Experimental|full sterile dressing|Patients receive full sterile dressing
2382439|NCT03692559|No Intervention|usual standard care|Patients receive usual standard care
2382440|NCT03692546|Experimental|Liposomal Bupivacaine (LB)|Administration of 20 ml of LB diluted with an additional 40 ml of saline was injected into a triangular soft tissue surgical field block, along with standard bupivacaine interscalene block
2382441|NCT03692546|No Intervention|Interscalene Block Alone (ISB)|Administration of 20mL of 0.5% standard bupivacaine interscalene block with no additional soft tissue surgical field block
2382442|NCT03692533|Active Comparator|Group A|Group (A) [study cases] Adult patients who will undergo radical or partial nephrectomy.for primary renal cell carcinoma.
2382443|NCT03692533|Active Comparator|Group B|Group (B) [control cases] Adult patients who will undergo simple nephrectomy for benign causes
2382444|NCT03692520|Experimental|SCT200|Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression
2382445|NCT03692507|Experimental|HMB only|Taking HMB supplements three times a day
2382446|NCT03692507|Experimental|Protein and HMB|Drinking Ensure Enlive shakes
2382447|NCT03692507|Experimental|Current ERAS (High Protein)|Drinking Ensure surgery shakes + Ensure pre-surgery
2382448|NCT03692494|Experimental|Unilateral vocal fold paralysis standard of care voice therapy|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques.
2382449|NCT03692494|Experimental|Unilateral paralysis standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
2382450|NCT03692494|Experimental|Parkinson's disease standard of care voice therapy plus EMST|The participants will receive the standard of voice therapy including improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relations techniques. EMST consists of blowing into respiratory device at a measure threshold pressure. As strength improves threshold resistance will be increased.
2382454|NCT03692455|Experimental|BPG Group|Patients will be submitted to Roux-en-Y Bypass Gastric Surgery.
3142666|NCT00003048|Experimental|Amifostine|Amifostine IV 2 weeks, followed by 2 weeks rest (4 week cycle)
3183277|NCT00712452|Other|1|systemic lupus erythematosus
3183278|NCT00712452|Other|2|breast cancer
2382460|NCT03692416|Active Comparator|Ibuprofen|"Patients in this group will receive:~Ibuprofen~Oral~At a dosage of 30 to 40 mg/kg/day, divided into 3 or 4 doses/day, max 2400 mg/day, given with food, in the form of suspension or tablets.~Duration of therapy: 4 - 6 weeks."
2382461|NCT03692416|Active Comparator|Prednisone Oral or Methylprednisolone IV|"Steroids:~Pednisone (for mild/moderate cases):~Oral~Single daily morning dosage of 0.05-2.0 mg/kg/day, or in 2 - 4 divided doses, max 80 mg/d.~Duration: 4 - 6 weeks, with gradual tapering to the lowest effective dose.~Methylprednisolone (for severe/acute cases):~IV~10-30 mg/kg/dose (max 1 g), over 1 hr daily for 1-5 days, followed by oral prednisone, with gradual tapering to the lowest effective dose.~The duration is variable according to the condition of the patient."
2382462|NCT03692416|Active Comparator|Methotrexate|"Patients in this group will receive:~Methotrexate~Oral~At a dosage of 10 to 20 mg/m2/wk (0.35 to 0.65 mg/kg/wk), max dose 25 mg/wk.~Duration of therapy: 6 - 12 weeks."
3142667|NCT00003056|Active Comparator|Unselected peripheral blood haemopoietic stem cells (PBSC)|Unselected PBSC together with control graft versus host disease (GVHD) prophylaxis - Control
3142668|NCT00003056|Experimental|CD34+ cells isolated from PBSC|CD34+ cells isolated from PBSC using the Isolex 300i system together with cyclosporine
3142669|NCT00003058|Experimental|Troglitazone|Patients received troglitazone 800 mg oral once-daily. Treatment continued as long as patient was responding or in stable disease clinically and ended if patient experienced progression or unacceptable toxicity.
3142670|NCT00003070|Experimental|Stratum 1 < 350/mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
2382467|NCT03692390|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app while undergoing procedural sedation
2382468|NCT03692390|No Intervention|Standard-of-Care|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
2382469|NCT03692377||Children Aged 2-6|Children 2 to 6 years of age who are arriving with a guardian to the Emergency Department with a low acuity condition (Canadian Triage scale (CTAS) 4 or 5) and are waiting to be seen by the doctor, or are waiting for test results.
2382470|NCT03692364|Active Comparator|Metal-on-conventional polyethylene|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a CoCr prosthetic femoral head and an acetabular liner made of intermedially cross-linked polyethylene polyethylene (Duration, Stryker, Mahwah, NJ, US).
2382471|NCT03692364|Experimental|Ceramic-on-ceramic|Uncemented hip arthroplasty (ABG-2, Stryker, Mahwah NJ, US) with a prosthetic femoral head and an acetabular liner made of alumina ceramic (Biolox Forte, Ceramtec, Plochingen, Germany).
2382472|NCT03692351|Active Comparator|Cup with screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US), screw fixation (2 or 3 screws)
2382473|NCT03692351|Experimental|Cup without screw holes|Uncemented Trilogy cup (Zimmer, Warzaw, IN, US) without screw holes, press-fit fixation
2382474|NCT03692338|Experimental|12 week supervised exercise program|"Patients will be asked to complete 3 30-minute supervised exercise sessions/week under the guidance of the study exercise physiologist. The preferred mode will be treadmill walking, however, alternatives such as cycling or stair climbing machines will be used. For these sessions, patients will be asked to wear a heart rate monitor. Following a 5 minute warm-up, the exercise physiologist will increase speed to correspond with an intensity of approximately 80% VO2peak for 1-minute before returning to a lower speed for 1-minute (50% VO2peak). Patients will complete up to 20 of each 1-minute interval, then cool-down for 5 minutes. At the end of each higher intensity interval patients will be asked to rate their perceived exertion (RPE).~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
2382475|NCT03692338|Experimental|12 week semi-supervised exercise program|"This cohort will complete 12 weeks of a semi-supervised exercise program independently. Patients will be scheduled for an exercise session with a study exercise physiologist during clinical appointments to complete a sample intensity and time specific exercise session. The preferred mode will be walking, however cycling is also permitted. For each session the patient will wear a heart rate monitor. Following a 5 minute warm-up, patients will increase the intensity of exercise to reach a heart rate corresponding to approximately 60% VO2peak, and will continuously maintain this intensity for their individualized duration to elicit the desired energy expenditure. Each week, the exercise physiologist will call the patient and discuss how to approach the next set of exercise sessions.~Additionally, patients will receive standard of care nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks."
2382476|NCT03692338|No Intervention|Control cohort|Participants will have routine care for 12 weeks. This will consist of nivolumab (3 mg/kg i.v.) and ipilimumab (1 mg/kg i.v.) q3 weeks x 4 doses followed by nivolumab at 3 mg/kg q2 weeks.
3142671|NCT00003070|Experimental|Stratum 2 < 350mg/m2 anthracycline dose|< 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
2382480|NCT03692299|Active Comparator|Saccaromyces boulardii oral tablet|Saccharomyces boulardii Oral Tablet 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
2382481|NCT03692299|Active Comparator|Metronidazole plus S. boulardii|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months.
2382482|NCT03692299|Active Comparator|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, plus Saccharomyces boulardii 200 mg b.i.d. during 1 week, follow for only Saccharomyces 200 mg b.i.d. for one another week, 2-week rest period and then this regimen is repeated for two consecutive months.
2382483|NCT03692286|Active Comparator|AgNP/Ca(OH)|Patients receiving combined Silver nanoparticle/Calcium hydroxide administered as intracanal medication at the first visit after cleaning and shaping
2382484|NCT03692286|Active Comparator|AgNP|Patients receiving silver nanoparticles in gel form administered as intracanal medication at the first visit after cleaning and shaping
2382485|NCT03692286|Active Comparator|Ca(OH)|Patients receiving calcium hydroxide intracanal medication at the first visit after cleaning and shaping
2382486|NCT03692273|Experimental|Laser|Laser treatment to 3x3cm2 area. It will receive the Luminous ultra pulse fractional ablative carbon dioxide laser at 150mJ, 3% density and 250Hz.
2382487|NCT03692273|Experimental|0.5mm punch biopsy|0.5mm punch biopsy area. This area will receive 0.5mm punch biopsies 75 per cm2 at a depth of 5mm.
2382488|NCT03692273|No Intervention|No treatment|3x3cm2 area designated as no treatment that will serve as a control
2382489|NCT03692260|Active Comparator|intervention group|3D stent in Herbert screw insertion vs titanium plate
2382490|NCT03692260|No Intervention|control group|titanium plate
2382491|NCT03692247|Other|Quantitative Sensory Testing|After answering brief questionnaires assessing psychosocial factors related to anxiety, catastrophizing, and pain, participants will undergo quantitative sensory tests where they will use a simple numeric rating scale (0-10) to rate pain and anxiety at several points during two QST sessions. During the second QST session, participants will use Unwind, a smartphone-based music intervention.
2382492|NCT03692234|Placebo Comparator|placebo|placebo capsules containing lactose - oral once weekly administration for six month
2382493|NCT03692234|Active Comparator|homoarginine|125 mg L-homoarginine supplement - oral once weekly administration for six month
2382494|NCT03692221|Experimental|MSC treatment group 1|Low dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 2 x 106/ml concentrated solution
2382495|NCT03692221|Active Comparator|MSC treatment group 2|High dose of Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) -A one time injection of 1-2 ml of 4 x 106/ml concentrated solution
2382496|NCT03692221|Active Comparator|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
2382497|NCT03692208|Experimental|Intervention|Patients that are enrolled in the intervention arm will receive an email message via MyChart (University of Chicago patient portal) to complete an initial questionnaire. Completion of the questionnaire will be required prior to initiating risk factor tracking and opening the portal to requests for care management support. A study team member (diabetes nurse educator) will contact the patient, if requested via the survey, to initiate telephonic care management or links to additional support services. Upon completion the study, all patients will receive a post-survey via MyChart.
2382498|NCT03692208|Active Comparator|Delayed Intervention/Control|Patients enrolled in the delayed intervention arm will receive usual care for the first 6 months, and then will receive the survey and intervention as stated above.
2382499|NCT03692195|Experimental|Week WHOOP is worn|Participants will wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
2382500|NCT03692195|Placebo Comparator|Week WHOOP is not worn|Participants will not wear the WHOOP strap 2.0 either 7 days prior to or 7 days after their sleep study.
2382501|NCT03692182||Study group|Participants enrolled in PACE who received an antipsychotic medication.
2382502|NCT03692169||CSC patients|Half-dose photodynamic therapy was performed when a serous retinal detachment involving the macular fovea was present; The treatment field size was set as 3000 microns. This was achieved by administering 3mg/m² of Verteporfin intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the GLD was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². OCTA (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
2382503|NCT03692143||teriparatide group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide
2382504|NCT03692143||PVP group plus alendronate|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with vertebroplasty. Then alendronate was prescribed.
2382505|NCT03692143||teriparatide and PVP group|The group of postmenopausal women who diagnosis with osteoporotic fractures treated with teriparatide after vertebroplasty
2382506|NCT03692130|Active Comparator|New Treatment|"The patients will be treated with psychological group treatment for 8 Sessions with focus on mindfulness, acceptance and commitment in a special adapted treatment process.This will be called Mindfulness, Acceptance and Commitment-Therapy for depressive Patients."
2382507|NCT03692130|Sham Comparator|Known Treatment|"The participants will be treated with a relaxation-treatment, long time established as jacobson muscle relaxing technique."
2382508|NCT03692091|Active Comparator|Anterior portal|Injection in to subacromial space from anterior portal
2382509|NCT03692091|Active Comparator|Lateral portal|Injection in to subacromial space from lateral portal
2382510|NCT03692078|No Intervention|GROUP 1: Continue Smoking|Subjects will be asked to continue smoking their OB cigarettes ad libitum for 7 days.
2382511|NCT03692078|Experimental|GROUP 2: OTDN product 1|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
2382512|NCT03692078|Experimental|GROUP 3: OTDN product 2|Subjects will reduce their normal daily cigarette consumption by at least 50% of their baseline CPD and use at least 3 product units per day for 7 days.
2382513|NCT03692078|Experimental|GROUP 4: OTDN product 1|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
2382514|NCT03692078|Experimental|GROUP 5: OTDN product 2|Subjects will completely switch to exclusive use of an oral tobacco-derived nicotine product, using at least 3 product units per day for 7 days.
2382515|NCT03692078|Experimental|GROUP 6: Tobacco Cessation|Subjects will completely stop all tobacco product usage for 7 days.
2382516|NCT03692065|Active Comparator|Apixaban film coated tablets 2.5 mg|Patients randomized in the apixaban reduced dose group will receive an apixaban 2.5 mg tablet and a placebo of apixaban 5 mg tablet, twice daily for 12 months.
2382517|NCT03692065|Active Comparator|Apixaban film coated tablets 5 mg|Patients randomized in the apixaban full dose group will receive a placebo of apixaban 2.5 mg tablet and an apixaban 5 mg tablet, twice daily for 12 months.
3142672|NCT00003070|Experimental|Stratum 3 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
2382519|NCT03692039|Experimental|M-pro files|Instrumentation using M-pro files in rotating motion
2382520|NCT03692039|Active Comparator|ProTaper Next files|Instrumentation using ProTaper Next files in rotating motion
2382521|NCT03692026|Experimental|Study group|Immediate implant placement in fresh extraction sockets with addition of Hyaluronic acid and Melatonin mixture to the implant surface, into the extraction socket and to the peri-implant area.
3142673|NCT00003070|Experimental|Stratum 4 < 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
3183279|NCT00712452|Other|3|Hodgkin disease
2382522|NCT03692026|Active Comparator|Control group|Immediate implant placement in fresh extraction sockets without adding any material.
2382523|NCT03692013|Experimental|nighttime group|patients with nocturnal hypertension taking losartan at nighttime
2382524|NCT03692013|Active Comparator|daytime group|patients with nocturnal hypertension taking losartan at daytime
2382525|NCT03692000||Men with a history of prostate cancer|Men with a history of prostate cancer invited to participate in design-workshops , interviews or usabilitytesting.
2382526|NCT03691987|Experimental|Preprocessed thawed donor FMT|"The active transplants are processed in a 2-3 weeks period before treatment of the first participant. Fifty to eighty grams of freshly delivered feces from donors is mixed with 100 mL isotonic saline and 25 mL 85% glycerol, homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60 ml luerlock syringes and stored at -40°C.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the FMT-syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in an enema bag prior to installation."
2382527|NCT03691987|Placebo Comparator|Preprocessed thawed autologous FMT|"The placebo transplant from each participant is prepared during the inclusion process four to six weeks before intervention and stored at -40°C. Fifty to eighty grams of freshly delivered feces from participants is mixed with 100 mL isotonic saline and 25 mL 85% glycerol is homogenized and poured through a 0.5 mm mesh steel strainer, and transferred to 60ml Luerlock syringes.~Frozen transplants are slowly thawed 2 hours prior to administration by transferring the Luerlock syringes to a waterbath (+30°C). The transplant is then mixed with 125 mL 12°C isotonic saline in the enema bag prior to installation."
3183280|NCT00712465|Experimental|1|AZD1305 tablet
3183281|NCT00712465|Experimental|2|AZD1305 tablet + digoxin
2382530|NCT03691961|Experimental|Medium dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥400 to 800 µg budesonide of budesonide/formoterol Symbicort Turbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
2382531|NCT03691961|Experimental|High dose of Symbicort Turbuhaler®|"The population is asthmatic patients meeting the inclusion and exclusion criteria for whom the optimized total daily dose to treat the disease is ≥800 µg budesonide of budesonide/formoterol Symbicort TurbuhalerTurbuhaler®.~Hair sampling after 4 months treatment.~Analysis of hair's drug concentrations."
3183282|NCT00712465|Active Comparator|3|Digoxin
3183283|NCT00712478||A|
2382534|NCT03691935|Experimental|Ropivicaine|Erector Spinae Block of 20ml 0.5% ropivicaine bolus, connected to a pump containing 0.2% ropivicaine receiving 15ml every 3 hrs.
2382535|NCT03691935|Sham Comparator|Normal Saline|Erector Spinae Block of 20ml normal saline placebo bolus, then connected to pump of normal saline receiving 15ml every 3 hrs.
2382536|NCT03691922|Active Comparator|ESP Block|Preoperative US guided active Erector Spinae Plane (ESP) block and a saline PAI
2382537|NCT03691922|Other|PAI with LA|Preoperative US guided ESP blockade with saline and an active Periarticular Infiltration (PAI)
2382538|NCT03691909|Experimental|Treatment Arm|Single IV administration of autologous adipose-derived mesenchymal stem cells Baseline laboratory data will be collected prior to infusion; follow up data will be compared against baseline at 1, 3, 6 and 12 months. Joint Assessment 68 will be administered at 1, 3, 6 and 12 months.
2382539|NCT03691896|Experimental|Lower dose|cholecalciferol 400UNT, oral solution
2382540|NCT03691896|Active Comparator|Middle dose|cholecalciferol 800UNT, oral solution
2382541|NCT03691896|Experimental|Higher dose|cholecalciferol 1200UNT, oral solution,
2382542|NCT03691883||TB patients|TB patients diagnosed and followed-up in Barcelona, at the following Hospitals/Clinics: Servicios Clínicos, Hospital Universitari Germans Trias i Pujol, Hospital Universitari Vall d'Hebron-Drassanes, Hospital del Mar.
2382543|NCT03691870|Active Comparator|standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment.~The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
2382544|NCT03691870|Experimental|Trans-Venous Embolization (TVE) (+/- Arterial) strategy|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.~It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion)."
3183284|NCT00712491|Experimental|1|
3183285|NCT00712491|Experimental|2|
3183286|NCT00712504|Experimental|1|SU011248 in combination with docetaxel
3183287|NCT00712517|Active Comparator|1|Patients will receive propofol anesthesia during varicose vein stripping surgery.
3183288|NCT00712517|Active Comparator|2|Patients will receive sevoflurane anesthesia during varicose vein stripping surgery.
2382552|NCT03691818|Experimental|Low-dose test drug group|X0002 Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
2430144|NCT03365947|Active Comparator|ARO-HBV Injection|
2382553|NCT03691818|Active Comparator|Low-dose active drug control group|Ibuprofen Tablet 400 mg/time, 3 times /day; X0002 Placebo Spray 1 Spray/time/Knee, 2 times/day.
2382554|NCT03691818|Placebo Comparator|Low-dose placebo control group|Placebo Spray 1 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times/day.
2382555|NCT03691818|Experimental|Medium-dose test drug group|X0002 Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
2382556|NCT03691818|Active Comparator|Medium-dose active drug control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
2382557|NCT03691818|Placebo Comparator|Medium-dose placebo control group|X0002 Placebo Spray 2 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
2382558|NCT03691818|Experimental|High-dose test drug group|X0002 Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Placebo Tab 400 mg/time, 3 times /day.
2382559|NCT03691818|Active Comparator|High-dose active drug control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Ibuprofen Tablet 400 mg/time, 3 times /day.
2382560|NCT03691818|Placebo Comparator|High-dose placebo control group|X0002 Placebo Spray 4 Spray/time/Knee, 2 times/day; Placebo Tablet 400 mg/time, 3 times /day.
2382561|NCT03691805|Active Comparator|anodal tDCS over rDLPFC|Participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal Cortex (DLPFC).
2382562|NCT03691805|Sham Comparator|sham tDCS|Participants will receive sham tDCS (transcranial direct current stimulation) of the DLPFC.
2382563|NCT03691792|Experimental|Cognitive-Behavioral Therapy (CBT-SAD)|12 1.5-hour group sessions at a rate of 2 sessions per week over 8 weeks.
2382564|NCT03691792|Active Comparator|Light Therapy|6 weeks of daily light therapy at home, using a 10,000-lux light box beginning at 30 minutes upon waking, with dose subsequently adjusted per treatment algorithm.
3142674|NCT00003070|Experimental|Stratum 5 >= 350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
3142675|NCT00003070|Experimental|Stratum 6 >=350mg/m2 anthracycline dose|< 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
2382567|NCT03691766|Experimental|Photobiomodulation Therapy|Experimental: Photobiomodulation Therapy comprising 640 nm, 875 nm, and 905 nm light (red lights)
2382568|NCT03691766|Placebo Comparator|Control|Placebo device with different wavelengths of light without known physiologic effect.
2382569|NCT03691753|Experimental|Experimental arm|Patients will be treated with Fitaya Vena Cava Filter System.
2382570|NCT03691753|Active Comparator|Control arm|Patients will be treated with Aegisy Vena Cava Filter.
2382571|NCT03691740|Experimental|Experimental|Ocular light will be applied via a mask. The participants allocated to the experimental group will receive blue light
2382572|NCT03691740|Placebo Comparator|Control|Ocular light will be applied via a mask. The participants allocated to the control group will receive red light
3142676|NCT00003070|Experimental|Stratum 7 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis < 4 years since cessation of anthracycline treatment
2382576|NCT03691701|Experimental|Strict SBP Target|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
2382577|NCT03691701|No Intervention|Usual SBP Target|Usual care, no home SBP target
2382578|NCT03691688||Aspirin|Aspirin 100mg
2382579|NCT03691688||Clopidogrel|Clopidogrel 75mg
2382580|NCT03691675|Experimental|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
2382581|NCT03691662|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
2382582|NCT03691662|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
2382583|NCT03691649|Experimental|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
2382584|NCT03691649|Active Comparator|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
2382585|NCT03691636|Experimental|Eyelash Prostheses|Each subject in this arm will receive eyelash prostheses according to a specified algorithm by a certified eyelash extensions.
2382586|NCT03691636|Active Comparator|5.0% Lifitegrast Ophthalmic Solution|Each subject in this arm will receive 5.0% Lifitegrast eye drops BID
2382587|NCT03691623|Experimental|EDP-938 Arm A|Subjects will take EDP-938 Dose 1 oral suspension for 5 days
2382588|NCT03691623|Experimental|EDP-938 Arm B|Subjects will take EDP-938 Dose 2 oral suspension for 5 days
2382589|NCT03691623|Placebo Comparator|Placebo Arm C|Subjects will take matching placebo oral suspension for 5 days
2382590|NCT03691623|Experimental|EDP-938 Arm D|Subjects will take EDP-938 Dose 3 oral suspension for 5 days
2382591|NCT03691623|Experimental|EDP-938 Arm E|Subjects will take EDP-938 Dose 4 oral suspension for 5 days
2382592|NCT03691623|Placebo Comparator|Placebo Arm F|Subjects will take matching placebo oral suspension for 5 days
3142677|NCT00003070|Experimental|Stratum 8 >= 350mg/m2 anthracycline dose|>= 4 years of age at diagnosis >= 4 years since cessation of anthracycline treatment
3142678|NCT00003075|Experimental|Fenretinide|
3142679|NCT00003075|Placebo Comparator|Placebo|
3142680|NCT00003077|Experimental|Omega-3 fatty acid|"Patients receive omega-3 fatty acids orally in two equal doses with/after breakfast and lunch for 4 months or until weight loss is observed.~Dose is escalated in cohorts of two patients, although dose escalation is allowed in individual patients. Patients are evaluated for cachexia response every 2 weeks, and tumor response every 4 weeks for a maximum of 4 months. If no response of cachexia or tumor after a 2 month period, patients will be discontinued from study. Patients will be followed for survival post-treatment."
2382597|NCT03691597|Active Comparator|Adhesive resin cement|type of cement used for cementation of crowns have a good adhesion bond
3142681|NCT00003084|Experimental|Arm I (Estramustine + Etoposide)|Arm I: Oral Estramustine 3 x day + oral Etoposide 2 x day on days 1-14 + Paclitaxel IV over 1 hour Day 2, repeats every 21 days.
2382602|NCT03691558|Experimental|Ketogenic diet|Subjects followed 5 weeks of ketogenic diet
2382603|NCT03691558|Active Comparator|Western Diet|Subjects followed 5 weeks of a western diet
2382604|NCT03691545|Experimental|Intervention Group|(1) 12 weekly interactive sessions with a health coach to help them set goals and make changes toward becoming physically active and consuming the recommended number of fruits and vegetables.
2382605|NCT03691532|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~60 min (duration of exercise performed in other arm). Following the intervention they are fed a liquid meal.
2382606|NCT03691532|Experimental|Arm cycle exercise (ACE)|Participants complete continuous arm cycle exercise (ACE) for ~60 min. Following the intervention they are fed a liquid meal.
3142682|NCT00003084|Experimental|Arm II (Chemotherapy + Ketoconazole)|Arm II: Doxorubicin IV Days 1, 15, and 29, Vinblastine IV Days 8, 22, and 36, Oral Ketoconazole 3 x day on Days 1-7, 15-21, + 29-35, and Oral Estramustine 3 x day on Days 8-14, 22-28, and 36-42; 6 weeks of alternating chemotherapy and 2 weeks rest, for 8 week course.
3142683|NCT00003088|Experimental|Sequential chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles followed by cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles.
2382609|NCT03691506|Active Comparator|Classic CIMT group|Total session of 6 hours a day, 5 days per week for 3 weeks to Classic CIMT groups will be given.
2382610|NCT03691506|Experimental|mCIMT group|Session of 6 hours a day, 5 session per week for first 2 weeks (CIMT), session of 2 hours a day, 5 days per week for last 1 week (BIT) to modified CIMT group will be given.
2382611|NCT03691493|Experimental|Radiation, palbociclib, hormone therapy|Patients undergo radiation therapy over 5-10 days and receive palbociclib PO QD on days 1-21. At the discretion of treating physician, patients also receive letrozole, anastrozole, exemestane, or tamoxifen PO QD on days 1-28, or fulvestrant IM on days 1 and 15 of cycle 1 and on day 1 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2382612|NCT03691480|Experimental|simple exsufflation|
2382613|NCT03691480|Experimental|Fuhrman catheter and ambulatory care|
2382614|NCT03691467|Experimental|immediate implant with hyaluronic acid.|immediate dental implant with topical application of hyaluronic acid.
2382615|NCT03691467|Active Comparator|immediate implant.|immediate dental implant placement with placebo gel
2382616|NCT03691454|Experimental|DOS|Docetaxel+Oxaliplatin+S-1
2382617|NCT03691454|Active Comparator|SOX|Oxaliplatin+S-1
2382618|NCT03691441|Experimental|Resection/adjuvant radio(-chemo)therapy|"Transoral surgical resection within 4 weeks after randomization~Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization~6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery"
2382619|NCT03691441|Active Comparator|Adjuvant radio(-chemo)therapy/salvage neck dissection|"6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization~70-72 Gy, SIB possible~Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33~+/- Salvage neck dissection 12±2 weeks after treatment"
2382620|NCT03691428|Experimental|Intervention|
2382621|NCT03691428|Other|Wait-list|Participants will get the WOOP training after the last outcome assessment.
2382622|NCT03691415||BELKYRA Inj.|Each patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart and follow-up within 3 months of the last treatment session.
3142684|NCT00003088|Experimental|Concurrent chemotherapy 14 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 2 weeks for four cycles with filgrastim days 3 to 10 of each cycle at 5 µg/kg rounded to either 300 or 480 µg total dose.
3142685|NCT00003088|Experimental|Sequential chemotherapy 14 days|Patients received doxorubicin 60 mg/m2 every 2 weeks for four cycles followed by paclitaxel 175 mg/m2 every 2 weeks for four cycles followed by cyclophosphamide 600 mg/m2 every 2 weeks for four cycles, with filgrastim days 3 to 10 of each cycle (a total of seven doses) at 5 µg/kg, which could be rounded to either 300 or 480 µg total dose.
2382625|NCT03691376|Experimental|Treatment (autologous NY-ESO-1 engineered T and HSC)|Patients receive melphalan IV over 30 minutes on day -1. Patients then receive autologous NY-ESO-1 CD4-TCR CD34+ HSC IV on day 0 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV between days 7 and 21. Patients also receive aldesleukin SC BID for 14 days on the following day after the T cell infusion (between days 8 and 22).
2382626|NCT03691363|Experimental|M-STEP|Mobile exercise intervention
2382627|NCT03691350|Active Comparator|Group I (usual cigarette brand)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Participants continue to smoke their usual brand of cigarettes. Participants undergo a second bronchoscopy on day 71.
2382628|NCT03691350|Experimental|Group II (SREC with nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC with nicotine for 2 weeks and switch completely to the SREC with nicotine starting day 15 for 8 weeks. Participants undergo a second bronchoscopy on day 71.
3142686|NCT00003088|Experimental|Concurrent chemotherapy 21 days|Patients received doxorubicin 60 mg/m^2 plus cyclophosphamide 600 mg/m^2 every 3 weeks for four cycles followed by paclitaxel 175 mg/m^2 every 3 weeks for four cycles.
3142687|NCT00003092|Experimental|Paclitaxel|"Patients receive a single dose of IV paclitaxel over 3 hours. Additional cycles of paclitaxel will be given at the discretion of the physician.~Patients are followed for second malignancies, disease progression, and survival."
3142688|NCT00003093|Experimental|Treatment|See detailed description.
3142689|NCT00003095||bone marrow transplant|bone marrow transplant
3142690|NCT00003095||standard chemotherapy|standard chemotherapy
2382629|NCT03691350|Experimental|Group III (SREC without nicotine)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
2382630|NCT03691350|Experimental|Group IV (usual cigarette brand, nicotine-containing SREC)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the nicotine-containing SREC for 2 weeks and use both their usual brand of cigarettes and the nicotine-containing SREC starting day 15 for 8 weeks with the intention of smoking reduction to 5 cigarettes or less per day. Participants undergo a second bronchoscopy on day 71.
2382631|NCT03691350|Experimental|Group V (NRT)|Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 2 days before the day 15 quit date, participants stop smoking using NRT comprising either patch, gum, or lozenge for 8 weeks. Participants undergo a second bronchoscopy on day 71.
2382632|NCT03691337|Active Comparator|Low dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.11 mL x subject height)
2382633|NCT03691337|Active Comparator|High dosis bupivacaine|Preoperative fascia iliaca block with Marcaine 0.25% (0.22 mL x subject height)
2382634|NCT03691337|Placebo Comparator|Placebo|Preoperative fascia iliaca block with Sodium Chloride 0.9% (0.11 mL x subject height)
2382635|NCT03691324|Experimental|Intervention|Patients receive an inhalation technique education based on standardized procedure developed by The Norwegian Pharmacy Association. In addition they are offered a discharge service day before or the day of discharge; a second inhalation training and dispensing of their prescribed COPD- medicines.
2382636|NCT03691324|No Intervention|Standard care|Patients receive standard care and follow up of their COPD-treatment
3183289|NCT00712556||Flourine 18-fluorodeoxyglucose PET|PET using fluorine 18-fluorodeoxyglucose to image cancer tumors
2382639|NCT03691298||Arthroscopic hip repair|
2382640|NCT03691285|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
2382641|NCT03691285|Active Comparator|Two-implant mandibular overdenture|Participants allocated to this group will have two implants placed in the inter-foraminal region after 3 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
2382642|NCT03691272|Experimental|rTMS- Real Air Film Coil|Patient MR brain scans will be loaded and processed using the Brainsight TMS neuronavigation software and stereotaxic data for localization of the TMS stimulation site will be determined through a co-registration method between the TMS coil position and the projected site on the MR brain scan. The DLPFC will be located through MNI coordinates (-48, 20, 34). Electromyography (EMG) electrodes will be attached to the right abductor digiti minimi (ADM) muscle. The resting motor threshold (RMT) is determined as the minimal stimulation intensity required to elicit motor-evoked response of 50 microvolts peak-to-peak amplitude in at least 5 out of 10 consecutive trials of the ADM (contralateral to stimulation).
2382643|NCT03691272|Sham Comparator|rTMS- Sham coil|The same procedure for determining RMT as described above will be employed for the Sham Arm. However, a sham coil will be used when the treatment over the left DLPFC is applied.
2382644|NCT03691259|Experimental|Dance Group|Dance group will participate in one-hour ballet classes twice per week for 10 weeks
2382645|NCT03691259|No Intervention|Control Group|The control group will not participate in the ballet classes
2382646|NCT03691220|Experimental|Telemetric Intervention Arm|Adolescent with MLVI>2 to receive the telemetric intervention.
2382647|NCT03691220|No Intervention|Standard of Care Arm|Adolescent with MLVI>2 to receive standard of care.
2382649|NCT03691194|Experimental|fresh orange juice|Subject will take 8 ounces of fresh orange every day for 28 days.
2382650|NCT03691194|Active Comparator|concentrated orange juice|Subject will take 8 ounces of concentrated orange juice every day for 28 days.
2382651|NCT03691181|Experimental|Open Ambulatory Ventilation|"monitoring with the use of the Life2000 Open Ventilation System for a period of six months with measures of nutrition, feeling of breathlessness, exercise tolerance, and quality of life.~BODE Index B - BMI - BMI stands for body mass index, a calculation made by comparing height vs weight.~O - Airway obstruction - Airway obstruction is measured by evaluating FEV1 - the amount of air that can be forcefully exhaled in 1 second after a deep breath.~D - Dyspnea - Dyspnea refers to the degree of breathlessness someone experiences while living with COPD.~E - Exercise tolerance - Exercise testing refers to how well some does on a 6-minute walk test.~Modified Medical Research Council Dyspnea Scale"
2382652|NCT03691142||Women with Hereditary Haemorrhagic Telangiectasia|Women with Hereditary Haemorrhagic Telangiectasia with at least one full term pregnancy
2382653|NCT03691129|Experimental|Yoga participant groups|Yoga participant groups will practice elderly yoga for four months. We will collect their blood before and after their participation in the elderly yoga program. There will be two subgroups which are Advanced group and Beginner group.
2382654|NCT03691129|No Intervention|Non-Yoga participant groups|Non-Yoga participant groups will not practice yoga for four months and will be used as the control. We will collect their blood before and after the elderly yoga program. There will be two subgroups which are Elderly group and Young group.
2382655|NCT03691116|Experimental|Digital Health Profile|A digital health check-up, with questions, brief feedback and information about alcohol, tobacco, diet and exercise, as a complement to treatment as usual. (Psychological assessment and treatment)
2382656|NCT03691116|Active Comparator|Treatment as usual|Psychological assessment and treatment as usual.
2382657|NCT03691090|Experimental|SHR-1210 + paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，SHR-1210 200mg，Day 2，every 3 weeks, maximum 6 cycles, then SHR-1210 maintenance
2382658|NCT03691090|Active Comparator|placebo+paclitaxel + cisplatin|Paclitaxel 175mg/m2, Day 1，cisplatin 75mg/m2，Day 1，placebo，Day 2，every 3 weeks, maximum 6 cycles, then placebo maintenance
2382659|NCT03691077|Experimental|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
2382660|NCT03691064||LUTATHERA|Treated per labeled LUTATHERA dosing regimen.
2382662|NCT03691038|Active Comparator|Pregabalin 75mg bid|The patients who were prescribed according to the conventional flexible dose regimen
2382663|NCT03691038|Experimental|pregabalin 25mg,50mg|The patients who were prescribed according to the new flexible dose regimen.
2382664|NCT03691025||RALPD|
2382665|NCT03690999|Placebo Comparator|Placebo group|Placebo product
2382666|NCT03690999|Experimental|Prebiotic Supplement, low dose|
2382667|NCT03690999|Experimental|Prebiotic Supplement, high dose|
2382668|NCT03690986|Experimental|Group A (VX15/2503)|Patients receive VX15/2503 IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
2382669|NCT03690986|Experimental|Group B (VX15/2503, ipilimumab)|Patients receive VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
2382670|NCT03690986|Experimental|Group C (VX15/2503, nivolumab)|Patients receive VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
2382671|NCT03690986|Experimental|Group D (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
2382672|NCT03690986|Experimental|Group E (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Beginning days 17-36, patients undergo standard of care surgery.
2382673|NCT03690986|No Intervention|Group F (no treatment)|Patients undergo standard of care surgery.
2382674|NCT03690973|Active Comparator|Alveolar socket preservation with graft and flap surgery|
2382675|NCT03690973|Experimental|Immediate implant placement with bone using flapless surgery|
2382676|NCT03690973|Experimental|Immediate implant placement with bone and flap surgery|
2382677|NCT03690973|Experimental|Alveolar socket preservation with graft and flapless surgery|
2382678|NCT03690960|Experimental|electrospun TAP nanofibers|Revascularization procedure with Electrospun TAP nanofibers as as an intracanal medicament for immature necrotic teeth
2382679|NCT03690960|Active Comparator|modified TAP paste|Revascularization procedure with modified TAP paste as an intracanal medicament for immature necrotic teeth
2382680|NCT03690947|Experimental|Combination Therapy Group|
2382681|NCT03690947|Active Comparator|Intravitreal Ranibizumab Group|
2382682|NCT03690934|Experimental|Fistula-tract laser closure (FiLAC™)|The treatment technique consists of laser coagulation of fistulous tract walls with a diode laser with a wavelength of 1470 nm, which leads to thermo-obliteration of the fistulous tract.
2382683|NCT03690934|Active Comparator|Fistula monopolar cogulation|The treatment technicque consists of monopolar coagulation of fistulous tract walls with suturing the internal fistulas opening.
2382684|NCT03690921|Experimental|Treatment (LET-IMPT, chemotherapy)|Patients undergo linear energy transfer-optimized intensity modulated proton therapy 5 times per week for 5-6 weeks. Patients also receive standard cisplatin and fluorouracil IV weekly for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
2382685|NCT03690908||IgG4-related orbital inflammation|patients with orbital inflammation and positive IgG4 immunostaining in orbital biopsy
2382686|NCT03690908||non IgG4-related orbital inflammation|patients with orbital inflammation and negative IgG4 immunostaining in orbital biopsy
2382687|NCT03690895||Cases|
2382688|NCT03690882||Cases of unclassified acute cervical pain|
2382689|NCT03690869|Experimental|Phase 1|Patients in both the Solid Tumor Cohort and the CNS Cohort will receive REGN2810 monotherapy. Each Cohort will have 2 subgroups by age (0 to <12 years, 12 to <18 years).
2382690|NCT03690869|Experimental|Efficacy with Newly Diagnosed DIPG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
2382691|NCT03690869|Experimental|Efficacy with Newly Diagnosed HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
2382692|NCT03690869|Experimental|Efficacy with Recurrent HGG|≥ 3 to < 12 years cohort and 12 to ≤ 25 years cohort with combination of REGN2810 and radiation therapy
2382693|NCT03690856|Experimental|depressiv people|
2382696|NCT03690830|Experimental|Case group RIF|blood samples, analyzing endometrial cells
2382697|NCT03690830|Experimental|Case group IRPL|blood samples, analyzing endometrial cells
2382698|NCT03690830|Active Comparator|Control group|blood samples, analyzing endometrial cells
2382699|NCT03690817||Bilateral vestibulopathy|Patients with bilateral vestibulopathy, according to the Barany Criteria (2017, Strupp).
2382700|NCT03690817||Healthy controls|Subjects without vestibular or neurological diseases (DHI<5), and with normal hearing thresholds according to their age.
2382701|NCT03690804|Experimental|newborn is above 28 weeks of gestational age|40 parent-newborn duos in which the newborn is above 28 weeks of gestational age and less than 3 months of life and hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France)
2382702|NCT03690791|Active Comparator|MediCabilis CBD Oil|
2382703|NCT03690791|Placebo Comparator|Placebo Oil|
2382704|NCT03690778|Experimental|Group I|"Period I: administration of Metformin and Rosuvastatin seperately Period II: JLP-1310"
2382705|NCT03690778|Experimental|Group II|"Period I: JLP-1301 Period II: administration of Metformin' and Rosuvastatin seperately"
2382707|NCT03690752|Sham Comparator|weighted|"The weighted group uses the same Alter-G Treadmill as the unweighted group but were not allowed to use the unweighting function of the treadmill.~Intervention: unweighting using Alter-G Anti-Gravity Treadmill"
2382708|NCT03690752|Experimental|unweighted|"The unweighted group uses the same Alter-G Anti-Gravity Treadmill as the weight group but is allowed to adjust their weight using the weight control feature.~Intervention: normal weight using Alter-G Anti-Gravity Treadmill"
2382709|NCT03690739|Active Comparator|platinum-based chemotherapy|According to the investigator's discretion
2382710|NCT03690739|Active Comparator|PLD + Trabectedin|PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21
2382711|NCT03690726|Experimental|Active rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to active treatment arm receive consecutive treatment sessions with rTMS directed at cranium and cortex regions as described in protocol.
2382712|NCT03690726|Sham Comparator|Sham rTMS|SCI patients fulfilling criteria for participation giving informed written and verbal consent, who are enrolled and randomised to sham/control arm receive consecutive treatment sessions with coil from rTMS that fires at other spot (pillow/mattress) as described in protocol.
2382713|NCT03690713||Patient and Vessels underwent physiologic evaluation|The total 1397 patients (1694 vessels) which evaluated using pressure-temperature sensor wire and measured FFR, CFR, and IMR.
2382714|NCT03690700|Active Comparator|active BFRE|14 consecutive paraplegic SCI patients are block-randomized to active arm
2382715|NCT03690700|Sham Comparator|sham BFRE|14 consecutive paraplegic SCI patients are block-randomized to sham arm
2382716|NCT03690687||Group I. Primary anastomosis|Resection of the small bowel to place primary anastomosis into small intestine or transverse colon during relaparotomy.
2382717|NCT03690687||Group II. Delayed anastomosis|Resection of the small intestine to place delayed anastomosis. After the closure of the afferent and efferent loops of the small intestine, anastomosis was not applied. A decompression probe was introduced into the upper small intestine. In 24-36 hours, delayed anastomosis was placed into the small intestine or transverse colon during the planned relaparotomy with arrested postoperative peritonitis.
2382718|NCT03690687||Group III. Enterostomy|Resection of the small intestine with enterostomy. In case there was no postoperative peritonitis relief and was organ dysfunction progression, anastomosis was not placed. The surgery was completed with enterostomy to perform open abdomen.
2382719|NCT03690674|Experimental|Lifestyle Enhancement for ADHD Program|There is no comparison/control arm.
2382720|NCT03690661|Experimental|Intervention Video Game|Participants will play the Intervention Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
2382721|NCT03690661|Placebo Comparator|Control Video Game|Participants will play the Control Video Game for 3 months, 3 times a week for a minimum of 30 minutes each session
2382722|NCT03690648||Saliva collection|"Clinical examination;~Quality of life survey;~Saliva collection for genetical analysis"
2382723|NCT03690648||Saliva and Blood collection|"Clinical examination;~Quality of life survey;~Saliva and blood collection for genetical analysis"
2382724|NCT03690635|Experimental|VISTA technique|evolution of a newer approach known as Vestibular Incision Subperiosteal Tunnel Access (VISTA) was proposed to avoid some of the potential complications occurring with other intrasulcular tunneling techniques
2382725|NCT03690635|Active Comparator|tunneling technique|Several modifications of tunnel technique have been described in order to preserve esthetics, avoid relapse of gingival recession and maintain papillary integrity. These modifications also attend to avoid scar formation and delayed healing related to vertical releasing incision
2382726|NCT03690622|Sham Comparator|BSS|Balanced salt solution
2382727|NCT03690622|Active Comparator|Dexmedetomidine|dexmedetomidine (0.0055%)
2382728|NCT03690609|Active Comparator|Nutraceutical intervention, 3 capsules daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 3 capsules daily in the morning.
2382729|NCT03690609|Active Comparator|Nutraceutical intervention, 2 capsules twice daily.|Participants will consume the nutraceutical blend CytoQuel at a dose of 1850 mg, by consuming 4 capsules daily: Two in the morning and two later in the day.
2382733|NCT03690583|Experimental|Zinc group|Zinc sulfate 10 mg in children younger than 1 year old, 20 mg in children older than 1 year old
2382734|NCT03690583|Placebo Comparator|Placebo group|Glucose
2382735|NCT03690557|Experimental|IncentaHealth|All patients who decide to join the weight loss program will be enrolled in the commercially-available IncentaHealth program - a comprehensive, evidence-based, behavioral weight management program designed to help patients initiate and maintain weight loss. The program is delivered completely online, via website, emails, mobile app, and (if requested by the participant) text messaging over 12 months. Each participant will be given a digital scale that wirelessly syncs with a smartphone app. Participants' weights are automatically uploaded to the Incentahealth online portal. In the informed consent process, participants will need to agree to release their weight data to researchers at the University of Nebraska Medical Center in order to participate in this program.
2382736|NCT03690544|Experimental|Single Arm|Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)
2382737|NCT03690531||Take Pause Virtual Reality Head Set|The mbVR intervention arm will be a Take-Pause virtual reality simulation will be for 5 minutes shown through a virtual reality goggle, headset and iPhone.
2382738|NCT03690531||Passive Distraction Group_IPAD|The Passive Distraction group will utilize the standard or passive distraction technique of using an IPAD lasting 5 minutes.
2382741|NCT03690505|Other|Assessment|Assessment of the Knowledge and Needs of Patients With AMD Before a Therapeutic Patient Education Program is Put in Place
2382742|NCT03690492|Experimental|The Box 2.0|Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.
2382743|NCT03690492|No Intervention|Controls|Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.
2382744|NCT03690479|Active Comparator|Ball Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the new trial tip (ball-end probe, 0.6mm diameter).
2382745|NCT03690479|Active Comparator|Florida Probe Straight Tip Probe|One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip (straight-end probe, 0.45mm diameter).
2382746|NCT03690466|Experimental|Study device treatment|Transcutaneous non-invasive ultrasound will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
2382747|NCT03690466|Sham Comparator|Sham device treatment|Sham treatment will be administered to the spleen for 30 minutes every day for 2 weeks (14 days total) via a portable device.
3183290|NCT00712569||1|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information.
3188958|NCT00772525|Experimental|Sequence 1|"placebo,1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
2382753|NCT03690414|Active Comparator|Experimental BHVI2 eye drops|20 participants will receive one drop per eye every night for four weeks.
2382754|NCT03690414|Active Comparator|0.02% Atropine eye drops|20 participants will receive one drop per eye every night for four weeks.
2382755|NCT03690414|Active Comparator|Experimental BHVI2 plus 0.02% atropine|20 participants will receive one drop per eye every night for four weeks.
2382756|NCT03690401||Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed before treatment and after completion of treatment. Moving On assessments will be performed at first and last study visits.
2382757|NCT03690401||Non-Moving On Group|Participants' body composition will be estimated using a SOZO device at 5 different time points over 12 weeks. Participant will also complete questionnaires and physical assessments during each study visit. These include waist & hip measurements, weight/BMI, brief fatigue inventory, timed up and go test, 6 minute walk test, cancer distress assessment, ECOG performance status, hand grip strength test, and 3-day food diary. DEXA scans will be performed at first and last study visits.
2382758|NCT03690388|Experimental|Cabozantinib|cabozantinib (60 mg) once daily orally (qd)
2382759|NCT03690388|Placebo Comparator|Placebo|placebo once daily orally (qd)
2382762|NCT03690362|Experimental|Group 1 - Control|Healthy control subjects will be matched by gender, weight, and age to subjects with renal impairment
2382763|NCT03690362|Experimental|Group 2 - Mild Renal Impairment|Mild renal impairment
2382764|NCT03690362|Experimental|Group 3 - Moderate Renal Impairment|Moderate Renal Impairment
2382765|NCT03690362|Experimental|Group 4 - Severe Renal Impairment|Severe Renal Impairment
2382766|NCT03690362|Experimental|Group 5 - ESRD|End Stage Renal Disease undergoing chronic intermittent hemodialysis
2382767|NCT03690349||Skin test in severe asthma exacerbation|Skin test in asthmatic children hospitalized due to severe asthma exacerbation in a preceding year
2382768|NCT03690349||skin test in outpatient|Skin test in asthmatic children without severe asthma exacerbation in a preceding year
2382769|NCT03690336||Patients with haemophilia B|Patients with haemophilia B treated with nonacog beta pegol who report adverse events to the PedNet and EUHASS, and possibly other national or international registries.
2382770|NCT03690323|Experimental|RFA|"RFA: laparotomy is performed followed by radiofrequency ablation of the tumor.~After recovery of the RFA patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel + gemcitabine or gemcitabine monotherapy"
2382771|NCT03690323|Active Comparator|Chemotherapy|"Patients will continue chemotherapy:~FOLFIRINOX or nab-paclitaxel plus gemcitabine or gemcitabine monotherapy"
2382772|NCT03690310|Experimental|Anti-CD19 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19 CAR NK cells will be administered at day0
2382773|NCT03690297|Experimental|LCI|Linked Color Imaging
2382774|NCT03690297|Active Comparator|WL|White Light
2382777|NCT03690271||Groupe 5-5|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 5 ml~dose to be administered every hour by the patient : 5 ml"
2382778|NCT03690271||groupe 6-6|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way : 6 ml~dose to be administered every hour by the patient : 6 ml"
2382779|NCT03690271||groupe 7-7|"Patients for whom the clinician has prescribed local anesthetics in the epidural:~fixed dose administered every hour in a systematic way :7 ml~dose to be administered every hour by the patient :7 ml"
2382780|NCT03690258|Experimental|Variable load exercise|"Variable load intervention (The nHANCE-squat ultimate - iso-inertial load, with power output in watts performed 3 x per week) will being performed to determine whether this training approach is an effective countermeasure to attenuate for rapid declines in muscle power, function, contractile capacity that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in seniors.~Data available at: http://nhance.se/"
2382781|NCT03690258|Experimental|Variable load intervention|"This study is being conducted to determine whether this variable load (The nHANC dead lift - eccentric overload performed 3 x per week for 4-6 weeks) intervention is an effective countermeasure to modulate blood pressure in seniors. Since age-related incline in resting blood pressure (hypertension) is accelerated already after short bouts of physical inactivity, any attempt to counteract age-related and disuse-related decline have high clinical significance. In addition, we aim to examine endothelial function via non-invasive flow mediated dilatation (FMD) technique.~Based on the findings, we could develop safety guidelines and protocols aimed at reducing health risks in this specific population. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system, especially for reducing economic burden."
2382782|NCT03690245|Active Comparator|Control|Infants will have immediate cord clamping and respiratory support afterwards
2382783|NCT03690245|Experimental|Initiation of Resuscitation While Attached to the Cord|Infants will receive respiratory support for 120 seconds while attached to the cord.
2382784|NCT03690232|Experimental|Glucose group|The glucose group underwent 3 sessions of 6cc 25% glucose injection with a 2-week interval between each treatment
2382785|NCT03690232|Active Comparator|hyaluronic acid group|The HA group was administered intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment.
3183291|NCT00712569||2|Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information.
2382789|NCT03690193|Experimental|Ketogenic Diet Arm|All participants will be assigned to the 3-month ketogenic diet intervention. Study partners will be instructed to assist participants in adherence to a 1:1 ketogenic diet (approximately 70% fat, <10% carbohydrate, and 20% protein). Participants will be provided medium chain triglyceride oil with a target intake of 1-2 tablespoons per day and micronutrient supplements consisting of multivitamin, vitamin D, calcium, and phosphorus. After the 3-month ketogenic diet, participants will complete a 1-month washout period in which they halt adherence to the ketogenic diet and resume their normal diet.
2382790|NCT03690180||Diabetics with microalbuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
2382791|NCT03690180||Diabetics with normal albuminuria|"Diabetics with micro albuminuria will be subjected to full clinical examination.~Measurement of weight, height, waist, hip and calculation of BMI and waist hip ratio,laboratory assessment of serum creatinine,HbA1C,magnesium and urinary albumin creatinine ratio"
2382792|NCT03690167|Active Comparator|Concentrated Growth Factor (CGF)|Participants with impacted lower third molar
2382793|NCT03690167|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|Participants with impacted lower third molar
2382794|NCT03690167|Sham Comparator|Control|Participants with impacted lower third molar
2382795|NCT03690154|Experimental|FN-1501|
2382796|NCT03690141|Experimental|tomivosertib (eFT508)|Tomivosertib (eFT508) is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics, Inc. as an anticancer therapy. Tomivosertib (eFT508) down regulates AR and acts by inhibiting mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK1) and MNK2.
2382797|NCT03690128|Active Comparator|Control Arm - standard EWS procedure|Standard use of the current implement Early Warning System, based on the principles of the National Early Warning Score and with a standard escalation protocol.
2382798|NCT03690128|Active Comparator|Intervention Arm - I-EWS|"Implementation of Individual Early Warning Score (I-EWS) with a systematic clinical assessment with a standard escalation protocol as intervention 7 parameters (Respiration rate, pulse, saturation, systolic blood pressure, consciousness, temperature, Oxygen) are registered , an aggregated score is generated. In the electronic patient journal (Sundhedsplatformen), the nursing staff is asked to reevaluate the aggregated score based on their clinical assessment of the patient. The aggregated score can be upgraded with up to 6 points and downgraded with up to 4.~This new I-EWS score interacts with the standard escalation protocol which defines the observation frequency and relevant clinical actions."
2382799|NCT03690115|Experimental|Experimental|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
2382800|NCT03690102|Experimental|No BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario before attending the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
2382801|NCT03690102|Experimental|With BLS course. No T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will not receive T-CPR."
2382802|NCT03690102|Experimental|With BLS course. With T-CPR.|"The participant is presented for a cardiac arrest scenario after completion of the ERC standardized BLS course.~During the scenario test, the participant will receive T-CPR."
2382803|NCT03690089|Experimental|Intervention Group (Atropine 0.01%)|The intervention group will receive 0.01% atropine sulfate eye drops, administered once daily for two years.
2382804|NCT03690089|Placebo Comparator|Placebo Group|The control group will receive placebo eye drops, administered once daily for two years.
2382805|NCT03690076||Control|patients with normal weight (23 < BMI < 27) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
2382806|NCT03690076||Endocarditis|patients with normal weight (23 < BMI < 27) carriers of endocarditis with surgery indication
2382841|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 3|Corresponding Placebo will be administered by s.c. injection.
2382807|NCT03690076||Obese|obese patients (BMI > 30 with waist to hip ratio > or = 1 in men and 0.85 in women) operated for myocardial revascularization by bypass surgery, without infarction, or for valve pathologies without endocarditis
2382808|NCT03690050|Experimental|Diode Subthreshold Micropulse Laser|"DSML is a relatively new laser technology aimed at minimising damage (tissue-sparing) to choroid and retina but maintaining treatment efficacy by its selective effect on the retinal pigment epithelium (RPE). It is performed using laser that, instead of delivering a continuous-wave laser beam, as the standard laser, it provides very small, repetitive, low energy pulses of laser separated by a brief rest period. This rest period allows the tissue to cool down between laser pulses avoiding the increased tissue heat that would be produced by continuous laser and allowing the use of lower laser energy power to achieve an effect. The reduced heat produced in the tissue and the reduced energy power required for the treatment may reduce side effects."
2382809|NCT03690050|Active Comparator|Standard threshold laser (532 nm laser)|Green-yellow argon laser photocoagulation at threshold levels has been used for many years as the standard laser for the treatment of many retinal disorders including DMO. The ETDRS demonstrated the efficacy of laser in preventing visual loss in patients with DMO.
2382810|NCT03690037|Experimental|Intervention Group 1|Intervention Group 1: 1g intravenous Tranexamic Acid 100 milligrams (MG)/ML peri-operatively plus 1g oral Tranexamic Acid 500mg Tablets every 8hrs for up to 24hrs
2382811|NCT03690037|Experimental|Intervention Group 2|Intervention Group 2: 1g intravenous Tranexamic Acid 100 MG/ML peri-operatively
2382812|NCT03690037|No Intervention|Control Group 3|Standard care - no TXA
2382814|NCT03689998|Experimental|implant placement with melatonine|immediate implant placement with melatonine
2382815|NCT03689998|Active Comparator|immediate implant placement alone|immediate implant placement alone
2382816|NCT03689985|Experimental|General|One arm study: smART Feeding Tube System.
2382817|NCT03689972|Experimental|Part 1: Standard Interval Dosing (SID) IV|Participants will receive natalizumab 300 milligram (mg) intravenous (IV) infusion every 4 weeks (-2/+5 days) up to Week 72.
2382818|NCT03689972|Experimental|Part 1: Extended Interval Dosing (EID) IV|Participants will receive natalizumab 300 mg IV infusion every 6 weeks (-2/+5 days) up to Week 72.
2382819|NCT03689972|Experimental|Part 2: EID SC, then EID IV|Participants will receive natalizumab 300 mg SC injection every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg IV infusion every 6 weeks from Week 132 through Week 150.
2382820|NCT03689972|Experimental|Part 2: EID IV, then EID SC|Participants will receive natalizumab 300 mg IV infusion every 6 weeks from Week 108 through Week 126 followed by natalizumab 300 mg SC injection every 6 weeks from Week 132 through Week 150.
2382821|NCT03689959|Experimental|Patients|13 child with fixed knee flexion deformity more than 10° on one or both sides with 12 months or more predicted growth remaining subjected to eight plate hemiepiphysiodesis of the distal femur
2382822|NCT03689946|Experimental|Evolocumab, F18-NaF PET, CCTA|Evolocumab self-administration for 18 months. Baseline (pre-treatment) and follow-up 18F-NaF PET and CCTA (possible beta-blocker and nitroglycerin, if medically safe).
2382823|NCT03689933|Experimental|root analog implant|The tooth indicated for extraction will be extracted atraumatically using periotome, socket preservation using Iodoform packing strips, and then optical scanning of the remaining tooth structure with optical scanner will be made to obtain a 3D virtual model, this model will be modified by addition of macro-retentions strictly to the interdental area to avoid any fracture in thin cortical bone, the cervical portion of implant circumference will be decreased by 0.1 to 0.2 mm to avoid pressure resorption of alveolar crest of bone and addition of prepared crown stump for the future crown to be placed.
2382824|NCT03689933|Active Comparator|conventional stock root-form titanium implant|Using a conventional implant as a comparator as it's the gold stander in restoring the non-restorable teeth.
3183292|NCT00712569||3|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it.
2382827|NCT03689907||Allogeneic Stem-Cell Transplant Recipients|"At day +14/15-post transplant - lineage-specific chimerism analysis will be performed on a peripheral blood sample drawn from the patient.~At day +30-post transplant, most participants will be in the outpatient setting and would undergo chimerism evaluation as part of the standard of care for transplant patients."
2382828|NCT03689894|Experimental|Ibrutinib plus Rituximab|"Rituximab~*375 milligrams (mg) per meter squared intravenous infusion weekly for 4 (may repeat 8 weeks after initial therapy, if suboptimal response)~Ibrutinib~420 mg (140 mg capsule x3) by mouth daily~May be given beyond 3-6 months (for maintenance)."
2382829|NCT03689881|Experimental|Tomosynthesis|Tomosynthesis of SI joints
2382830|NCT03689868|Experimental|Virtual Reality|
2382831|NCT03689868|No Intervention|Control|
2382832|NCT03689855|Experimental|Ramucirumab + Atezolizumab|"Ramucirumab will be given intravenously over the course of an hour on an outpatient basis on Day 1 of each 21-day cycle at a dose of 10 mg/kg.~Atezolizumab will be given intravenously on an outpatient basis on Day 1 of each 21-day cycle at a dose of 1200 mg."
2382833|NCT03689842|Experimental|Couple donor - recipient|
2382834|NCT03689829|Experimental|MOR106 Single Dose A, i.v. infusion, Part 1|A single dose of MOR106 will be administered by i.v. infusion.
2382835|NCT03689829|Experimental|MOR106 Single Dose B, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
2382836|NCT03689829|Experimental|MOR106 Single Dose C, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
2382837|NCT03689829|Experimental|MOR106 Single Dose D, s.c. injection, Part 1|A single dose of MOR106 will be administered by s.c. injection.
2382838|NCT03689829|Experimental|MOR106 Repeated Doses E, s.c. injection, Part 2|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
2382839|NCT03689829|Placebo Comparator|Placebo s.c.injection, Part 2|Corresponding Placebo will be administered by s.c. injection.
2382840|NCT03689829|Experimental|MOR106 Repeated Doses F, s.c. injection, Part 3|Repeated doses of MOR106 will be administered by s.c. injection with a loading dose on the first day of administration.
2382842|NCT03689816|Experimental|bone density|bone density
2382846|NCT03689764|Experimental|Group A|Group A underwent interactive video game-based exercise for the initial 6 weeks, with no treatment in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
2382847|NCT03689764|Experimental|Group B|Group B had no intervention in the first 6 weeks and then received interactive video game-based exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
2382848|NCT03689751|No Intervention|LSCS Control Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
2382849|NCT03689751|Experimental|LSCS Intervention ArmIntervention Arm|Patients undergoing elective LSCS allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (LSCS Video) as an additional educational resource.
2382850|NCT03689751|No Intervention|TVT/TOT Control Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway. This typically included face-to-face consultation and written information leaflets.
2382851|NCT03689751|Experimental|TVT/TOT Interventional Arm|Patients undergoing elective TVT/TOT allocated to this arm underwent the normal preoperative educational pathway, but prior to the operation were shown the educational RSAV (TVT/TOT Video) as an additional educational resource.
2382852|NCT03689738|Experimental|Potato condition|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g RS per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
2382853|NCT03689738|Active Comparator|Control condition|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
2382854|NCT03689725|Experimental|Preterm music group|Music exposure with headphones
2382855|NCT03689725|No Intervention|Preterm control group|headphones without music
2382856|NCT03689725|No Intervention|Full-term control group|
2382857|NCT03689712|Experimental|GC4419|
2382858|NCT03689712|Placebo Comparator|Placebo|
2382859|NCT03689699|Experimental|Arm A: Nivolumab alone|Men with hormone-sensitive prostate cancer will receive Nivolumab alone every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + Degarelix every 4 weeks for 16 weeks (4 doses).
2382860|NCT03689699|Experimental|Arm B: Nivolumab plus BMS-986253|Men with hormone-sensitive prostate cancer will receive Nivolumab plus BMS-986253 every 4 weeks for 8 weeks (2 doses), followed by Nivolumab + BMS-986253 + Degarelix every 4 weeks for 16 weeks (4 doses).
2382861|NCT03689686|Experimental|Patients|Fifteeen children with Acute Respiratory Failure admitted to a PICU, needing noninvasive respiratory support
2382862|NCT03689660|Experimental|Virtual Reality Training|Virtual reality treatment will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
2382863|NCT03689660|Experimental|Biofeedback Training|Biofeedback training will be applied during the 12 weeks. The training will consist of three sessions per week and 30 minutes per session.
2382864|NCT03689660|Other|Conventional Rehabilitation|Participants will continue this rehabilitation program if they are already getting rehabilitation in a rehabilitation center. If they do not participate in any rehabilitation program, they will be included in the conventional rehabilitation program by us.
2382865|NCT03689647|Experimental|Single Group Experimental|Each participant will act as their own control with variables of interest measured while walking without the assistive device and while walking with the assistive device.
2382866|NCT03689634|Experimental|Move For Surgery Preconditioning Program Intervention Group|
2382867|NCT03689634|No Intervention|Standard Preoperative Care Group|
2382868|NCT03689621|Active Comparator|Transcutaneous vagal nerve stimulation (tVNS)|tVNS administered for 4 hours each day and behaviour is recorded.
2382869|NCT03689621|Placebo Comparator|Baseline|tVNS worn but not switched on whilst collecting behavioural data.
2382870|NCT03689608|Experimental|Intermittent Fasting (IF)|3 days fasting per week
2382871|NCT03689608|Experimental|Daily Restriction (DR)|daily energy restriction
2382872|NCT03689608|Other|standard care (SC)|usual care
2382873|NCT03689595||Specimen Collection|"Samples of blood (2-4 tablespoons) from 3 tubes will be collected~Analysis will be performed on the blood to test for multiple myeloma precursor conditions once sent to outside labs at Mayo Clinic and the Broad Institute"
2382874|NCT03689582|Experimental|68Ga-PSMA|PET/CT imaging
2382875|NCT03689569|Experimental|Exercise|Exercise only: Patients randomized to this group will receive a placebo (corn starch) and be given 16 weeks of personal training.
2382876|NCT03689569|Experimental|Resistant Starch|Resistant starch only: Patients randomized to this group will receive 30 g of resistant starch daily for 16 weeks. They will not be given an exercise training
2382877|NCT03689569|Experimental|Exercise & Resistant Starch|Exercise & resistant starch: Patients assigned to this group will do 16 weeks of personal training and they will be supplemented with 30 g of resistant starch daily for the 16 week period
2382878|NCT03689569|Placebo Comparator|Starch|Corn starch only: Patients assigned to this group will not be given and exercise program and they will receive the placebo for 16 weeks
2382879|NCT03689556||FLT PET/CT|Patients with locoregionally recurrent nasopharyngeal carcinoma (LR-NPC) will receive FLT PET/CT scans before CIRT and after completion of CIRT.
3188959|NCT00772525|Experimental|Sequence 2|"placebo,1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
2382885|NCT03689517|Experimental|placebo arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. Participants took placebos (pills made by starch) that were told to be an effective analgesic
2382886|NCT03689517|Sham Comparator|sham arm|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar. But participants do not take placebos
3142691|NCT00003098|Experimental|fat reduction increased fiber|Patients are randomized to dietary fat reduction with increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
3150800|NCT00211029||Participants Receiving Epoetin Alfa or Another Erythropoietin|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
2382889|NCT03689491|Experimental|rTMS+visual feedback|10-minute rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
2382890|NCT03689491|Active Comparator|sham rTMS+visual feedback|10-minute sham rTMS and then a 30-minute visual feedback training ,3 times a week, for 4 weeks
2382891|NCT03689491|Active Comparator|sham rTMS+traditional training|10-minute sham rTMS and then a 30-minute traditional rehabilitation training,3 times a week, for 4 weeks
2382893|NCT03689465|Active Comparator|PTCy-ATG group|PTCy-ATG group refers to treatment with PTCy-ATG protocol as GVHD prophylaxis at a total dose of 4.5mg/kg ATG, a dose of 50mg/kg/d cyclophosphamide (CTX), a dose of 2.5mg/kg/d Ciclosporin A （CsA）, and a dose of 1.0g/d Mycophenolate Mofetil(MMF).
2382894|NCT03689465|Active Comparator|ATG group|ATG group refers to treatment with ATG protocol as GVHD prophylaxis at a total dose of 7.5mg/kg ATG, a dose of 2.5mg/kg/d Ciclosporin A （CsA）, a dose of 1.0g/d Mycophenolate Mofetil(MMF) and methotrexate (MTX, on days +1, +3 and +6).
3188960|NCT00772525|Experimental|Sequence 3|"50 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~400 mg Nerispirdine, 1 day treatment period 3"
2382897|NCT03689413|Experimental|1 mg/kg|"For '1 mg/kg' group, sugammadex of 1 mg/kg (ex. 60 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
2382898|NCT03689413|Active Comparator|2 mg/kg|"For '2 mg/kg' group, sugammadex of 2 mg/kg (ex. 120 mg for 60 kg patient) will be administered to the assigned patient for this group after tracheal intubation.~We will use Sugammadex 200 MG in 2 ML Injection for this."
3150801|NCT00211042||Pure Red Cell Aplasia (PRCA)|This study will examine the relationship of the presence of anti-erythropoietin antibodies to the clinical course and outcome of participants currently or previously treated with recombinant human erythropoietin and who have PRCA identified from all notified reports (spontaneous postmarketing reports or from clinical trials reports).
2382901|NCT03689361|Other|with migraine aura.|patient with migraine aura detected by MRI, then MRI control 3 month after
2382902|NCT03689361|Other|without migraine aura|patient without migraine aura detected by MRI, then telephone consultation 3 month after
2382903|NCT03689348|Placebo Comparator|Placebo|Maltodextrin powder is the placebo ingredient and this is encased in the same pale green capsules as the active ingredient. Participants, if in the placebo group, will consume x3 capsules of placebo per day for 28 days.
2382904|NCT03689348|Experimental|300mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x2 placebo capsules (described above) and x1 300mg capsule of Avena sativa per day for 28 days.
2382905|NCT03689348|Experimental|600mg Avena sativa|If in the 600mg of Avena sativa group, participants will consume x1 placebo capsule (described above) and x2 300mg capsule of Avena sativa per day for 28 days.
2382906|NCT03689348|Experimental|900mg Avena sativa|If in the 300mg of Avena sativa group, participants will consume x3 300mg capsule of Avena sativa per day for 28 days.
2382907|NCT03689335|Active Comparator|Operative|Surgical fixation of the humeral shaft fracture
2382908|NCT03689335|Active Comparator|Non-operative|Conservative treatment of the humeral shaft fracture, using a humeral brace
2382909|NCT03689322|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
2382910|NCT03689322|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
2382911|NCT03689322|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
2382912|NCT03689309|No Intervention|1. Classic SBT (C-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but oxygen delivered through a heat humidifier filter that is usually connected on tracheotomy.
2382913|NCT03689309|Experimental|2. High Flow Oxygen SBT (HFO-SBT)|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
2382914|NCT03689296||Users|Person with a long-term mental disorder
2382915|NCT03689296||Caregivers|Adult helping a person with a long-term psychological disorder
2382916|NCT03689296||Primary care professionals|Primary care professional in practice following at least one person with a long-term mental disorder
2382917|NCT03689296||Psychiatric professionals|Psychiatric specialist working in a hospital or in private practice
2382918|NCT03689283|Experimental|Dry Needling Group|Individuals in the DN arm will receive two treatment sessions of DN to latent trigger points of the gastrocnemius muscle.
2382919|NCT03689283|Sham Comparator|Control Group|Individuals in the control group will receive two treatment sessions of sham dry needling.
2382920|NCT03689270||Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
2382921|NCT03689270||Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
3142692|NCT00003098|Experimental|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber). All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
3142693|NCT00003099|Active Comparator|Arm 1 Tamoxifen + Fenretinide|Tamoxifen + Fenretinide daily for 14-28 days
3142694|NCT00003099|Placebo Comparator|Arm 2 Placebo|Placebo daily for 14-28 days
2382925|NCT03689218|No Intervention|Control|The control arm will receive routine public and private health services available in the area.
2382926|NCT03689218|Experimental|Intervention|Pregnant women in intervention arm will receive 30 sachets of Maamta (Nutritious Food Supplement) during pregnancy and first six months of lactation. Children 6-24 months of age will receive 30 sachets of Wawamum (Lipid-Based Nutrient Supplement) every month during the study.
2382927|NCT03689205||Patients that BMI> 30kg / m2 (Group A)|Venous puncture pain on patients that Body mass index > 30kg / m2
2382928|NCT03689205||Patients that BMI< 30kg / m2 (Group B)|Venous puncture pain on patients that Body mass index < 30kg / m2
2382929|NCT03689192|Experimental|ARG1-18,19,20 peptide vaccine|One ARG1-vaccine every third week for 45 weeks.
2382930|NCT03689179|Experimental|Treatment with Follow-up (Group A)|"After an initial orientation/control period (4 weeks), group A will receive access to the Time for Living & Caring (TLC) intervention for 8 weeks, followed by an optional 8-week control period where they can continue to use the TLC intervention if they choose."
2382931|NCT03689179|Experimental|Wait-List Control w/Treatment (Group B)|"After the initial 4-week orientation period, Group B will receive 8 weeks of waitlist (no treatment) control, followed by access to the Time for Living & Caring (TLC) intervention for 8 weeks."
2382932|NCT03689166|Active Comparator|Probiotics group|Probiotic drug
2382933|NCT03689166|Placebo Comparator|Control group|This group will receive placebo
2382934|NCT03689153|Experimental|Cohort 1: JNJ-63733657 or Placebo|Participants will receive a single intravenous (IV) low dose of JNJ-63733657 or matching placebo.
2382935|NCT03689153|Experimental|Cohort 2: JNJ-63733657 or Placebo|Participants will receive a single IV middle dose of JNJ-63733657 or matching placebo.
2382936|NCT03689153|Experimental|Cohort 3: JNJ-63733657 or Placebo|Participants will receive a single IV high dose of JNJ-63733657 or matching placebo.
2382937|NCT03689140|Experimental|App-only|The intervention will consist of participants will only use a smoking cessation app
2382938|NCT03689140|Experimental|Telemedicine counseling only|The intervention will consist of participants will only use telemedicine counseling
2382939|NCT03689140|Experimental|App + telemedicine counseling|The intervention will consist of participants will only use a smoking cessation app + telemedicine counseling
2382940|NCT03689140|No Intervention|Usual Care|The participants will continue with usual care
2382941|NCT03689127|Active Comparator|Control|Heated breathing circuit will be turned off.
2382942|NCT03689127|Experimental|Heat|Heated breathing circuit will be turned on.
2382943|NCT03689114|Experimental|Low dose|Dosage is in mg: low dose carbamazepine, 300 ; low dose levetiracetam, 500; low dose valproate, 300; low dose zonisamide, 150; low dose oxcarbazepine, 600; low dose topiramate, 100; low dose lamotrigine, 100; low dose gabapentin, 450. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
2382944|NCT03689114|Active Comparator|Standard dose|Dosage is in mg: standard dose carbamazepine 600; standard dose levetiracetam 1000; standard dose valproate, 600; standard dose zonisamide 300; standard dose oxcarbazepine 1200; standard dose topiramate, 200; standard dose lamotrigine, 200; standard dose gabapentin 900. Study drugs are in form of tablets for daily administration. Study drug administration duration is 12 months. The choice of the drug is left to the caring physician's discretion but it must be limited to the AEDs marketed for monotherapy use. All the study drugs will be used according to the respective SPCs, which will be sent by the promoter to all the study investigators.
2382945|NCT03689101|Experimental|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7) to count endometrial CD138.
2382946|NCT03689088|Experimental|Investigational device (Goldfish)|IOP will be monitored for 24 h in the Goldfish eye
2382947|NCT03689088|Active Comparator|Tonometry|IOP will be acquired by standard tonometry at specific times in the the fellow eye
2382948|NCT03689075|No Intervention|Immediate release tacrolimus|Patients will continue on immediate release tacrolimus
2382949|NCT03689075|Active Comparator|Extended release tacrolimus|
2382950|NCT03689062|Active Comparator|conservative group|patient assigned to the observation group will be assessed in the labor and delivery suite for 2 to 4 hours with continuous external fetal heart rate monitoring and tocodynamometry. In the absence of non reassuring fetal status , initiation of labor , or infection , these women will be transferred to antepartum room where maternal vital signs. Patients will be restricted to bed rest with bathroom privileges and remained hospitalized until delivary .
2382951|NCT03689062|Experimental|active group|Patients assigned to active management will receive induction of labour with intravenous oxytocin with use of controlled infusion pump Oxytocin will be administered by continuous intravenous infusion beginning at 0.5 mU/min , doubling the dose every 30 minutes to 2mU/min , and then increasing by 2 mU/min every 30 minutes there after until a satisfactory labor pattern is achieved.
2382952|NCT03689049|Experimental|SPIDER|QI Learning Collaboratives.
2382953|NCT03689049|Placebo Comparator|Usual Care|Standard primary care.
2382986|NCT03688854|Experimental|SCFA mixture high dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 20 grams of fiber.
3188961|NCT00772525|Experimental|Sequence 4|"50 mg Nerispirdine, 1 day treatment period 1~400 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
2382954|NCT03689023|Experimental|A controlled multimodal intervention|A uniform and systematic patient education about cardiovascular risk factors, physical activity and a healthy diet lifestyle starting early in the primary rehabilitation process with 6 months of follow up.
2382955|NCT03689010|Active Comparator|Azelaic acid foam 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
2382956|NCT03689010|Active Comparator|Finacea® (azelaic acid) Foam, 15%|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
2382957|NCT03689010|Placebo Comparator|Vehicle of the test product|Topical, twice daily (Apply the foam (morning and evening) to the entire facial area (cheeks, chin, forehead, and nose).
2382958|NCT03688997|Experimental|Experts|"For the novice group, the investigators recruited 30 residents within their first year of surgical residency (Post-Graduate Year [PGY]-1) in general surgery, vascular surgery, plastic surgery, orthopedic surgery, cardio-thoracic surgery, gynecology and urology.~The intervention administered was the use of a simulator by the participants."
2382959|NCT03688997|Experimental|Novice|"The expert's group included 15 attending surgical faculty members in the general surgery, vascular surgery, cardio-thoracic surgery and gynecology services.~The intervention administered was the use of a simulator by the participants."
2382960|NCT03688984|Experimental|Cognitive Behavioural Therapy for Insomnia|Six sessions of in person Cognitive Behavioural Therapy for Insomnia (CBT-I)
2382961|NCT03688984|No Intervention|Treatment As Usual|Participants will receive regular care in the Treatment As Usual (TAU) condition. Participants will be offered CBT-I at the completion of the trial.
2382962|NCT03688971|Experimental|Omiganan Topical Gel|Omiganan 1.75%
2382963|NCT03688971|Active Comparator|Ketoconazole Topical Cream|Ketoconazole 2.0%
2382964|NCT03688971|Placebo Comparator|Vehicle|
2382965|NCT03688958|Placebo Comparator|Early Cancer placebo|"The daily supplement of a vegetable colored water solution (drops) for 7 to 35 days in early breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the activity of placebo on tumor size, and molecular tumor response, as well as side effects attenuation"
2382966|NCT03688958|Experimental|Early Cancer Iodine|The daily supplement of an iodine solution (drops, 5 mg/day) for 7 to 35 days in early breast cancer diagnosticated woman
2382967|NCT03688958|Placebo Comparator|Advanced Cancer FEC/TE placebo|"The daily supplement of an vegetable colored water solution (drops) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman.~Placebo: vegetable colored water solution (drops). Evaluate the adjuvancy of placebo in FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation."
2382968|NCT03688958|Experimental|Advanced Cancer FEC/TE + Iodine|"The daily supplement of an iodine solution (drops, 5 mg/day) within 4 to 6 cycles of chemotherapy with FEC/TE in advanced breast cancer diagnosticated woman Drug: Iodine solution (5 mg/day). Evaluate the adjuvancy of I2 on FEC/TE treatment on tumor size and molecular tumor response, as well as side effects attenuation.~Other Name: evaluating the adjuvancy of iodine supplement in FEC/TE treatment"
2382969|NCT03688945|Experimental|Arm I (art sessions)|Participants attend at least 1 session of viewing art pieces over 15 minutes every day for 2 years.
2382970|NCT03688945|Active Comparator|Arm II (standard of care)|Participants receive standard of care for 2 years.
2382971|NCT03688932|Experimental|WBV + IMT|Whole body vibration training associated with respiratory muscle training (WBV + IMT)
2382972|NCT03688932|Active Comparator|WBV + IMTsham|Whole body vibration training associated with respiratory muscle training sham (WBV + IMTsham)
2382973|NCT03688932|Sham Comparator|WBVsham + IMTsham|Whole body vibration training sham associated with respiratory muscle training sham (WBVsham + IMTsham)
2382974|NCT03688919|No Intervention|Comparison|Adolescents and their families in this group will not receive any of the interventions.
2382975|NCT03688919|Experimental|Self-Regulation Intervention|This arm will use a computer-based working memory training game (NBack) targeting Executive Functioning and in-person relaxation and biofeedback training targeting Emotion Regulation. As well, adolescents will receive Future Orientation training by being asked to envision and describe future events they are looking forward to, using concrete, vivid descriptive language.
2382976|NCT03688906||Cohort A|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
2382977|NCT03688906||Cohort B|"Blood and stool specimen collection.~Samples must be collected prior to performing bowel preparation for the colonoscopy."
2382978|NCT03688906||Cohort C|"Blood and stool specimen collection.~Study samples must be collected prior to any treatment."
2382979|NCT03688893|Experimental|Laser Application|35% Hydrogen Peroxide (Whitening HP, FGM SC Brazil) 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes Laser Application and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. Experimental
2382980|NCT03688893|No Intervention|No Laser Application|35% Hydrogen Peroxide (Whitening HP FGM SC Brazil), 40 minutes divided in two phases of 20 minutes each one (5 minutes colocation, 10 minutes waiting and 5 minutes moving the product) from premolar to premolar in superior and inferior teeth. No Laser Application No Intervention
3150802|NCT00211068||Epoetin alfa|Four control patients will be matched to each index patients enrolled in protocol EPO-IMU-301 identified as having chronic kidney disease and an immune-mediated cause of pure red cell aplasia (PRCA) indicated by the presence of anti-erythropoietin (EPO) antibodies in their serum at the time of loss of efficacy.
2382984|NCT03688854|Placebo Comparator|Placebo|Placebo are capsules containing cellulose.
2382985|NCT03688854|Experimental|SCFA mixture low dose|Encapsulated SCFA mixture in the ratio of 67:6:27 (acetate, propionate, butyrate) equivalent of 10 grams of fiber.
2383070|NCT03688152|Experimental|INCB053914 + INCB050465|INCB053914 in combination with INCB050465.
3150803|NCT00211263|Experimental|Enhanced Clinical Intervention|
3150804|NCT00211263|Active Comparator|Clinical Intervention|
3150805|NCT00211354|Experimental|anecortave acetate|anecortave acetate 15 mg. juxtascleral injection every 6 months for 24 months
3150806|NCT00211393|Experimental|Drug: ketoconazole|"Drug: ketoconazole~Other Names:~ketoconazole~600mg. /day for 6 weeks~--------------------------------------------------------------------------------"
3150807|NCT00211432|Experimental|Title: Treatment of Pseudovitellium Detachment|Open-Label Anecortave Acetate Sterile Suspension(15mg)
2382987|NCT03688841|Experimental|Bridged V.A.C.® with compression therapy|A vacuum assisted closure device will be placed on the ulcer. A compression dressing will be placed over the V.A.C.® device
2382988|NCT03688841|Active Comparator|Conventional compression therapy|A Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings will be applied and changed once to three times per week (dependant on exudate).
3142695|NCT00003117|Experimental|Paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of each course. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
3142696|NCT00003117|Experimental|Paclitaxel + Carboplatin|Patients receives paclitaxel as in Arm I, followed by carboplatin IV over 1 hour. Treatment is repeated every 21 days for 6 courses in the absence of tumor progression or unacceptable toxicity. Quality of life assessments are conducted before treatment and at 2, 6, 9, and 12 months. Patients are followed every 3 months for 2 years, then every 6 months until disease progression or death.
2382991|NCT03688815||Patients with ischemic heart disease|Patients with ischemic heart disease scheduled for myocardial perfusion scintigraphy were enrolled. Biomarkers were analysed form periferal blood. Patients outcome data were followed up to 5 years.
2382994|NCT03688789|Experimental|Hydrocortisone supplementation|
2382995|NCT03688776|Experimental|1805AA, 1805AB Use Group|Use of product 1805AA exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AB exclusively for approximately 3 days prior to a PK assessment.
2382996|NCT03688776|Experimental|1805AB, 1805AA Use Group|Use of product 1805AB exclusively for approximately 3 days prior to a PK assessment, followed by use of product 1805AA exclusively for approximately 3 days prior to a PK assessment.
3142697|NCT00003118|Experimental|Chemotherapy + Radiation + Surgery|
2382998|NCT03688737|Placebo Comparator|control group|"A) Control group:~Has Surgical procedures von Langenbeck technique  to repair cleft palate and will come for follow up visit at day of surgery, 1st day and 3rd day for placebo device like LLL and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
2382999|NCT03688737|Active Comparator|study group|"B) Study group:~This group will be subjected to the same surgical procedure von Langenbeck technique to repair cleft palate but low level laser Therapy will be at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative"
2383002|NCT03688698||PAH|
2383003|NCT03688698||Controls|
2383005|NCT03688672|Other|Apioc Lens|All subjects will wear the same, Apioc Contact Lens design.
2383006|NCT03688659|Other|vancomycin,gentamycin in endocarditis|patients with infective endocarditis will recieve intravenous infusion Vancomycin 30 mg/kg/day for 4:6 weeks and intravenous Gentamycin 3mg/kg/day for 2 weeks
2383007|NCT03688646|Experimental|Intervention group|Intensive nutrition intervention group receiving standardised oral nutrition supplement provided once daily throughout cancer treatment with 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement
2383008|NCT03688646|No Intervention|Control group|Routine care were given to this group inclusive of 4 session of dietary consultation by designated dietitian for monitoring of diet intake and diet modification to meet patient's requirement and also prescription of oral nutrition supplement where needed. Oral nutrition supplement was not provided
3142698|NCT00003118|Active Comparator|Surgery|
3142699|NCT00003119|Experimental|Treatment 1 - Asymptomatic - no immediate chemotherapy|
2383014|NCT03688607||POKE|All babies in NICU at Intermountain Healthcare hospitals
2383015|NCT03688594|Experimental|couple : man and pregnant women|
2383016|NCT03688568|Experimental|Imatinib Mesylate Arm|Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.
2383017|NCT03688555|Experimental|ACT-774312|Subjects will receive ACT-774312 400 mg b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
2383018|NCT03688555|Placebo Comparator|Placebo|Subjects will receive placebo b.i.d. for 12 weeks together with mometasone furoate nasal spray (200 μg) either b.i.d. or o.d.
2383021|NCT03688516|Experimental|Atypical development|30 children with Williams-Beuren syndrome will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
3142700|NCT00003119|Experimental|Symptomatic - immediate chemotherapy|
3142701|NCT00003120|Active Comparator|paclitaxel 3 cycles|paclitaxel given for 3 cycles
3142702|NCT00003120|Experimental|paclitaxel for 12 cycles|paclitaxel given for 12 cycles
3142703|NCT00003126|Experimental|Interleukin-2 (IL-2)|Patients randomized to this arm will receive one course of IL-2 [600,000 U/kg every 8 hours on post-operative days 1 to 5 and days 15 to 19 (maximum 28 doses)].
3142704|NCT00003126|No Intervention|Observation|Patients randomized to this arm will receive their normal medical care
3142705|NCT00003127|Experimental|carbo, taxol, amifostine|carbo, taxol, amifostine
3142706|NCT00003130|Experimental|paclitaxel|Patients receive single fixed dose intravenous paclitaxel over 3 hours on day 1. Blood samples must be drawn prior to the first paclitaxel infusion and then at 1, 6, and 24 hours after the start of the infusion during course 1 only. Treatment courses of intravenous paclitaxel are repeated every 3 weeks at the discretion of the treating physician. Patients are evaluated for response after the second course. Patients are followed at the discretion of the physician.
3150808|NCT00211562|Active Comparator|Olanzapine|
3150809|NCT00211562|Active Comparator|Omega 3|
2383022|NCT03688516|Sham Comparator|Typical development|30 control children matched for mental age will be presented with two tasks of episodic memory, one with visual stimuli and another one with audio-verbal stimuli. Manipulation of valence and modality (negative, positive, neutral) in order to measure influence of emotion on episodic memory:Spatial and recognition memory ans source and content memory. The tasks will be presented one after another with a break of 15 minutes. In both tasks the participants will have to encode the stimuli and then first recall them and second to recognize the encoded stimuli amongst new stimuli. The stimuli will be presented on the computer. The responses will be collected by the experimenter for recall task and by the computer for recognition task. During the recognition task the EEG recording will be done.
2383023|NCT03688503|Active Comparator|magnesium|magnesium glycinate supplement, 480 mg/day
2383024|NCT03688503|Placebo Comparator|placebo|placebo supplement
2383025|NCT03688477|Experimental|iovera°|Patients will receive iovera° prior to stand of care ACL
2383026|NCT03688477|No Intervention|Standard of Care|Patients will receive standard of care ACL procedure without iovera° treatment.
2383027|NCT03688464|Active Comparator|Melatonin Treatment|Subjects to receive melatonin 0.1 mg/kg (minimum dose of 1 mg, maximum dose of 5 mg) 30 minutes prior to bedtime (1 mg/ml oral compound suspension) for 4 weeks.
2383028|NCT03688464|Active Comparator|Diphenhydramine Treatment|Subject to receive diphenhydramine 2.5 mg/ml oral liquid, dosed at 1 mg/kg at bedtime for 4 weeks.
2383029|NCT03688464|Placebo Comparator|Placebo|Subjects will receive cherry flavored placebo at bedtime for 4 weeks.
2383030|NCT03688451|Experimental|Intrathecal rituximab|Cohort 1: 10 mg dose, day 1 chemotherapy cycles 2-5 Cohort 2: 20 mg dose, day 1 chemotherapy cycles 2-5
2383031|NCT03688438|No Intervention|Standard of Care|Standard of care wound closure and dressing No active interventions
2383032|NCT03688438|Experimental|WoundVAC (CINPT)|Closed-Incision Negative-Pressure Therapy
2383033|NCT03688425|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
2383034|NCT03688425|Active Comparator|IOL implantation active comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
2383035|NCT03688412||Cook lead extraction devices|The Cook lead extraction devices are indicated for use in patients requiring percutaneous removal of CIED leads, indwelling catheters and foreign objects.
2383036|NCT03688399|Experimental|IOL Implantation experimental|hydrophobic, trifocal intraocular lens POD L GF with light distribution far > intermediate > near
2383037|NCT03688399|Active Comparator|IOL Implantation Comparator|hydrophobic, trifocal intraocular lens POD F GF with light distribution far > near > intermediate
2383038|NCT03688386|Experimental|Language Intervention|"1. Review language and infant bonding curriculum 2. 1st LENA recording and heart rate variability of mother reading to infant 3. Provide LENA linguistic feedback and review curriculum 4. 2nd LENA recording and heart rate variability of mother reading to infant 5. Provide LENA linguistic feedback and review curriculum 6. 3rd LENA recording and heart rate variability of mother reading to infant 7. Provide LENA linguistic feedback~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
2383039|NCT03688386|Active Comparator|Infant bonding|"1. Review infant bonding curriculum with mother 2. 1st LENA recording and heart rate variability of mother holding infant 3. Review infant bonding curriculum 4. 2nd LENA recording and heart rate variability of mother holding infant 5. Review infant bonding curriculum 6. 3rd LENA recording and heart rate variability of mother holding infant 7. Provide linguistic feedback of all 3 LENA recordings~Assessments: 1. NICU Network Neurobehavioral Scale (NNNS) profile at 36 weeks 2. Fragile Infant Parent Readiness Evaluation at 36 weeks 3. Parent perception survey of reading and curriculum at 36 weeks and 12 months 4. Bayley Scales of Infant and Toddler Development at 12 and 24 months 5. DNA methylation of genes pre and post intervention"
2383040|NCT03688373|Experimental|Exposure-in-big-steps|In the big steps exposure sessions the adolescent moves in three a set pace of big steps from bottom to top (1-5-10) in their fear hierarchy. From 0-5 in the first session and from 5-10 in the second session.
2383041|NCT03688373|Experimental|Exposure-in-small-steps|In the small steps exposure sessions the adolescent moves in a step-by-step pace of their own choice from bottom to top in their fear hierarchy, for example from 1 to 2 to 3 to in the first session and from 4 to 5 to 6 etc. in the second session.
2383042|NCT03688360|Experimental|Therapist-guided in-session|The participants will engage in 2 x 45 minutes of exposure exercises conducted together with the therapist in the mental health care centre. In addition, they will conduct 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
2383043|NCT03688360|Experimental|Self-guided out-session|The participants will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises by themselves out of session as a homework assignment.
2383044|NCT03688360|Experimental|Parent-guided out-session|The participants and one of their parents will prepare and discuss the exposure exercises together with the therapist in the mental health care centre, and conduct 2 x 2 x 45 minutes of exposure exercises together with their parent out of session as a homework assignment.
2383045|NCT03688334|Active Comparator|IPF patients|Supplementation of oxygen treatment (40% FiO2) during steady state cardiopulmonary exercise testing
2383046|NCT03688334|Sham Comparator|IPF patients (crossover)|Supplementation of medical air (sham Oxygen) during steady state cardiopulmonary exercise testing
2383047|NCT03688321|Active Comparator|Probiotic capsule GR-1 and RC-14|The intervention for study group is taking 2 capsules containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
2383048|NCT03688321|Placebo Comparator|Placebo capsule|The intervention for placebo group is taking 2 capsules not containing probiotic strains GR-1 and RC-14 before sleep for 18 weeks after being confirmed as GBS positive on 28th week gestation
2383049|NCT03688308|Experimental|Shoulder arthroscopy with BMAC|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair along with 3-4cc of BMAC produced from the Harvest/Terumo BCT system
2383071|NCT03688139|Experimental|Engage Therapy|Participants receive Engage therapy for 9 weeks.
2383050|NCT03688308|Active Comparator|Shoulder arthroscopy alone|This arm will have patients who receive surgical intervention with arthroscopic rotator cuff repair without administration of BMAC.
2383051|NCT03688295|Other|experimental group|no antibiotherapy post surgery for complicated acute appendicitis (CAA)
2383052|NCT03688295|Active Comparator|control group|antibiotherapy post surgery for complicated acute appendicitis (CAA)
3188962|NCT00772525|Experimental|Sequence 5|"400 mg Nerispirdine, 1 day treatment period 1~placebo, 1 day treatment period 2~50 mg Nerispirdine, 1 day treatment period 3"
2383055|NCT03688269|Experimental|Intravenous dexamethasone|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 8mg/2ml Dexamethasone during the regional anesthesia"
2383056|NCT03688269|Placebo Comparator|Intravenous saline|"Axillary Brachial Plexus Block with perineural Ropivacaine. Concentration determined by sequential up and down method.~Intravenous injection of 2ml Saline 0.9% during the regional anesthesia"
2383057|NCT03688243||Cohort 1 'IMPACT Cohort'|Subjects with intermediate AMD in both eyes, and at least one eye with a drusen volume in the central 3 mm circle centered on the fovea of at least 0.02mm3 in the absence of GA or nGA as diagnosed with OCT en face imaging OR subjects with AMD (early or intermediate) diagnosed in one eye and exudative AMD diagnosed in the fellow eye will undergo SS-OCT imaging every 3 months for 2 years
2383058|NCT03688243||Cohort 2 'SWAGGER Cohort'|Subjects with GA or nGA secondary to AMD that is at least the size of a large druse (125 microns in diameter; 0.05 mm2) and no greater than 7 disc areas (17 mm2) in at least one eye will undergo SS-OCT imaging every 3 months for 2 years
2383059|NCT03688243||Cohort 3|Subjects with GA enrolled in another trial
2383060|NCT03688230|Experimental|Abituzumab + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Abituzumab 1000 mg: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the abituzumab infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
2383061|NCT03688230|Placebo Comparator|Placebo + Cetuximab + FOLFIRI|"Cetuximab:~400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min~(60 min [± 5 min] after completion of the cetuximab infusion) Placebo: every 2 weeks for 60 min~(60 min [± 5 min] after completion of the placebo infusion) FOLFIRI: every 2 weeks Irinotecan 180 mg/m² IV, 30 - 90 min day 1 Folinic acid (racemic) 400 mg/m² IV, 120 min day 1 5-FU 400 mg/m² bolus day 1 5-FU 2400 mg/m² IV over a period of 46 h day 1-2"
2383062|NCT03688217|Experimental|Philani Intervention Model+MOVIE (PIM+M)|Participants will receive the standard PIM perinatal home visiting program together with the MOVIE intervention (13 entertainment-education videos about infant feeding). The PIM is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others. The MOVIE videos will be integrated into the regular home visiting program.
2383063|NCT03688217|Active Comparator|Philani Intervention Model (PIM)|Participants will receive the standard PIM perinatal home visiting program, which is a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
2383064|NCT03688191|Experimental|Study Group|participants who received sirolimus treatment
2383065|NCT03688178|Experimental|Gr1: DC vaccine (DC pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 1 patients will receive autologous unpulsed DC vaccines administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine as pre-conditioning.
2383066|NCT03688178|Experimental|Gr2: DC Vaccine (Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
2383067|NCT03688178|Experimental|Gr3:DC Vaccine+varlilumab(Td pre-conditioning)|Patients will receive TMZ at a target dose of 150-200 mg/m^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 3 patients will receive the first 3 DC vaccines every 2 weeks, same as Groups 1 and 2, but they will also receive varlilumab intraveneously (IV) 7 days before vaccine #1 and again at the same visit as vaccine #1, as well as 7 days before every DC vaccine except vaccine #2. Prior to the 4th vaccine, patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side.
2383068|NCT03688165||Treadmill-based Robotic Gait Training|The Treadmill-based Robotic Gait Training (TRGT) period will last 20 sessions, 3-5 days/week for at least 400' of exercise totally. The parameters to be respected for the robotic training will be the following for all patients: 0.9 km / h starting speed up to a maximum of 2.5 km / h; weight support not exceeding 40-45% of the body weight at the beginning and gradual progressive reduction depending on the case; for Lokomat: maximum assistance required at the start of treatment and gradual decrease during the treatment. The TRGT will always be associated with the traditional gait rehabilitation, and will be part of the Individual Rehabilitation Project which normally includes 3 hours of rehabilitation treatments for patients in the subacute phase, 60' of treatment for those in chronic phase.
2383069|NCT03688165||Traditional Over-ground Gait Training|"The Traditional Over-ground Gait Training (TOGT) period will last 20 sessions, 3-5 days / week for a total time that corresponds to the same total time of traditional overground gait training, or at least 400' totally at the end of the period.~By Traditional Therapy we mean any technical approach aimed at achieving control of the postural passages from sitting upright, of load transfer in laterality and antero-posterior in orthostatism and reorganization of the step up to the assisted path to the parallels and then with various aids."
2383072|NCT03688139|Active Comparator|Supportive Therapy|Participants receive supportive therapy for 9 weeks.
2383073|NCT03688126|Experimental|Self-Guided Lifestyle Intervention|Lifestyle modification program that is developed by the participant to meet his/her specific needs.
2383074|NCT03688126|Experimental|Structured Lifestyle Intervention|Lifestyle modification program that involves participants completing structured activities that target diet, physical exercise, and intellectual and social stimulation.
2383075|NCT03688113|Experimental|Treatment|
2383076|NCT03688113|Other|Wait list|
3142707|NCT00003134|Experimental|Arm I: irinotecan|"Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. This is followed by a 2 week rest and continues for a maximum of 6 courses. Patients who received prior nitrosoureas, also receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
3142708|NCT00003134|Experimental|Arm II: irinotecan|"Patients receive irinotecan on day 1 every 3 weeks for up to 12 courses. Patients who received prior nitrosoureas receive reduced starting doses of irinotecan. The dosages may be increased once per patient after the first course if toxic effects are acceptable.~Patients are followed every 3 months for the first year, every 6 months for the next 4 years, then annually until death."
2383079|NCT03688087|Placebo Comparator|placebo|"Smartphone application placebo"
2383080|NCT03688087|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
2383081|NCT03688074|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
2383082|NCT03688074|Placebo Comparator|Placebo|Placebo subcutaneous injection
2383083|NCT03688061|Experimental|Group 1 (low dose/healthy volunteers)|5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10*7 pfu) IM at week 8
2383084|NCT03688061|Experimental|Group 2 (higher dose/healthy volunteers)|10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10*8 pfu) IM at week 8
2383085|NCT03688061|Experimental|Group 3 (higher dose/HCV cured volunteers)|10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10*8 pfu) IM at week 8
2383086|NCT03688048|Experimental|Bright light treatment|Single-dose bright light treatment (1 hour, 10 000 lux)
2383087|NCT03688048|Placebo Comparator|Sham placebo|Deactivated negative ion generator in conjunction with a plausible cover story
2383088|NCT03688022|Experimental|MT-7117 BA and DDI (fasted)|MT-7117 lower content tablets, higher content tablets, higher content tablets with PPI (fasted), higher content tablets with PPI and acidic beverage (fasted)
2383089|NCT03688022|Experimental|MT-7117 food effect and DDI (fed)|MT-7117 higher content tablets (fasted and fed), higher content tablets with PPI (fed), higher content tablets with PPI and acidic beverage (fed)
2383090|NCT03688009|Experimental|Mindfulness-Based Family Psycho-Education (MBFBE)|A programme focuses on non-judgmental attitudes, collaborative inquiry and self-care, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
2383091|NCT03688009|Active Comparator|Family Psycho-Education (FPE)|A programme focuses on information giving, problem-solving and mutual support, including components of understanding early psychosis, medication, treatment management, mental health service collaboration, attention to caregiver's experiences and distress, strategies for improving communication and problem-solving, and crisis planning.
2383092|NCT03687983|Experimental|Intervention arm|Participants will be treated with GoldenFlow Peripheral Stent System.
3142709|NCT00003136|Experimental|Arm A|Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)
3142710|NCT00003137|Experimental|irinotecan|"Patients receive irinotecan (CPT-11) by IV over 90 minutes every 3 weeks. Dosage modifications are made based on toxicity. Retreatment may be delayed another 3 weeks (for a total of 6 weeks) to allow for recovery from toxic effects. Patient is taken off study if they do not recover from toxic effects, unless cause is documented to be unrelated to CPT-11. Patients with stable disease or partial response continue on treatment until disease progression or intolerable toxicity. Patients with complete response continue on treatment for another 2 courses and then are observed.~Patients are followed every 3 months for 3 years or until disease progression."
2383164|NCT03687424|Active Comparator|Obese 30<BMI<40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
2383243|NCT03686904|Placebo Comparator|SOC GROUP [Cohort A]|Debridement, SOC irrigation & SOC topical gel
3142711|NCT00003139|Experimental|Pilocarpine hydrocloride|5mg pilocarpine hydrochloride tablets commencing 3 days prior to irradiation
3142712|NCT00003139|Placebo Comparator|Placebo|Placebo tablets commencing 3 days prior to irradiation
3142713|NCT00003140|Experimental|Arm I|Patients receive oral letrozole once daily.
3142714|NCT00003140|Placebo Comparator|Arm II|Patients receive oral placebo once daily.
3142715|NCT00003141|Experimental|Treatment (combination chemotherapy, PBSC transplant)|Pts undergo conventional surgery for diagnosis & max tumor resection. In 6 wks of surgery or when stable pts begin induction chemotherapy(cisplatin IV over 6 hrs on day 0; vincristine sulfate IV on days 0,7,14; cyclophosphamide IV over 1 hr on days 1-2; and etoposide IV over 1 hr on days 0-2. 24 hrs after the last cyclophosphamide dose, pts receive filgrastim (G-CSF) & undergo peripheral blood stem cell harvest 2 days later. Treatment repeats every 21 days for up to 3 crs. Within 6 wks after induction, pts receive consolidation (carboplatin IV over 2 hrs on days 0-1 next esc. doses of thiotepa IV over 2 hrs. Pts undergo peripheral blood stem cell transplantation 48 hrs after last thiotepa dose. Pts receive G-CSF SC daily on days 3-21. Treatment repeats every 21 days for up to 3 crs. Pts with dose-limiting toxicity due to thiotepa are removed from study. Pts are followed at 4 wks, 3 mths for 1 yr, 6 mths for 3 yrs, annually for 3 yrs or until relapse.
3150810|NCT00211562|Active Comparator|Vitamin E +C|
3150811|NCT00211783||Autism|
3150812|NCT00211783||Control|
3150813|NCT00211822||Pathologic Gamblers|
3150814|NCT00211822||Obsessive Compulsive Disorder|
3150815|NCT00211822||Healthy Controls|
3142716|NCT00003143|Experimental|DHAP + amifostine|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
2383098|NCT03687931|Experimental|Arm 1|Dexamethasone suspension dose level 1
2383099|NCT03687931|Experimental|Arm 2|Dexamethasone suspension dose level 2
2383100|NCT03687905||Lupus nephritis III or IV/chloroquine|receiving chloroquine with daily dose 5 mg/kg
2383101|NCT03687905||Lupus nephritis III or IV/hydroxychloroquine|receiving hydroxycholorquine with daily dose 5 mg/kg
2383102|NCT03687905||Systemic lupus erythematosus|not received hydroxychloroquine nor chloroquine .
2383103|NCT03687892|Experimental|continuous Theta Burst Stimulation|The investigators will perform two applications of 40s of continuous Theta Burst Stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
2383104|NCT03687892|Experimental|intermittent Theta Burst Stimulation|The investigators will perform two applications of 40s of intermittent Theta Burst Stimulation (iTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left motor cortex will be determined by Localite Neuronavigation. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
2383105|NCT03687853|Experimental|Intrahepatic Arterial Infusion chemotherapy|chemotherapy through intrahepatic arterial Infusion is one of the most widely used liver tumor treatments.
2383106|NCT03687853|No Intervention|control|chemotherapy through Peripheral venous is one of the regularly used method.
2383107|NCT03687840|Other|Study Group|Spatio-Temporal gait analysis of subjects with unilateral lower extremity burn injuries due to diabetic polyneuropathy.
2383108|NCT03687840|Other|Control Group|Spatio-Temporal gait analysis of subjects with only diabetic polyneuropathy.
3183293|NCT00712582|Experimental|Consolidation A|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is < 80% will receive 3 cycles of standard dose ICE Chemotherapy."
3188963|NCT00772525|Experimental|Sequence 6|"400 mg Nerispirdine, 1 day treatment period 1~50 mg Nerispirdine, 1 day treatment period 2~placebo, 1 day treatment period 3"
2383111|NCT03687814|Experimental|Low FODMAP diet plus PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax).
2383112|NCT03687814|Sham Comparator|Sham diet plus PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax).
2383113|NCT03687801|Experimental|Online hearing support|The intervention group will have access to online hearing support for five weeks. The online hearing support will include a program that consists of three elements: 1) reading material; 2) reading instructions and weekly assignments related to the reading material; and 3) online and telephone interaction with a professional.
2383114|NCT03687801|Active Comparator|Standard care|"The control group will have access to traditional support that the Hearing Organization provides (standard care)."
2383115|NCT03687788|Experimental|Intervention Group|Intervention group received laughter therapy twice a week for six weeks.
2383116|NCT03687788|No Intervention|Control Group|The control group did not take part in the laughter therapy program. This group received the routine care given by the nurses in the center.
2383117|NCT03687775||DSG-Stabi|The group consists of patients with primary trapeziometacarpal osteoarthritis and an indication for trapeziectomy alone or in combination with the resection-suspension-interposition arthroplasty.
2383118|NCT03687762|Active Comparator|Cognitive Therapy (CT) Condition|"Participants randomized to this arm will be taught to recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
2383119|NCT03687762|Active Comparator|Mindfulness Meditation (MM) Condition|Participants randomized to this arm will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.
2383120|NCT03687762|Active Comparator|Activation Skills (AS) Condition|Participants randomized to this arm will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
2383121|NCT03687749||Women with breast cancer-related lymphedema|Individuals with upper limb lymphedema developed after breast cancer treatment
2383122|NCT03687749||Healthy control subjects|Healthy individuals without breast cancer-related lymphoedema.
3188964|NCT00772551|Active Comparator|1|
2383124|NCT03687697|Experimental|Global vs. G-TL Media|Global medium will be compared with G-TL (Time-Lapse) medium.
2383125|NCT03687697|Experimental|Global vs. Cornell's C3 Media|Global medium will be compared with Cornell's C3 single step medium.
2383126|NCT03687697|Experimental|Global vs. Cornell's sequential Media|Global medium will be compared with Cornell's C1/C2 sequential medium.
2383134|NCT03687671|Experimental|Animal-assisted therapy|The intervention is animal-assisted occupational therapy, animal-assisted physiotherapy or animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
2383135|NCT03687671|Active Comparator|Treatment as usual (activation program)|As control intervention patients receive treatment as usual (TAU) in speech therapy, occupational therapy or physiotherapy. The control intervention is named activation program.
2383136|NCT03687658|Experimental|Binge Eating Group|All participants in the study will be invited to use Laddr, described in the intervention section.
2383137|NCT03687658|Experimental|Smoking Group|All participants in the study will be invited to use Laddr, described in the intervention section.
2383138|NCT03687645|Experimental|Prostate Cancer|Patients with biopsy-proven prostate cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
2383139|NCT03687645|Experimental|Renal Cancer|Patients with biopsy-proven renal cell carcinoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
2383140|NCT03687645|Experimental|Breast Cancer|Patients with biopsy-proven breast cancer will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
2383141|NCT03687645|Experimental|Lymphoma|Patients with biopsy-proven lymphoma will be recruited for an additional Hyperpolarised MRI scan prior to any treatment
2383142|NCT03687632|Experimental|Single arm - active|ST266 eye drops given to the study eye for 28 days (112 doses total will be administered).
2383143|NCT03687619|Experimental|CO-OP|Cognitive Orientation to daily Occupational Performance (CO-OP) is a top-down approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
2383144|NCT03687619|Experimental|Conductive Education|Conductive Education is a down-top approach. This programme will be conducted as a small group. Each group will averagely have 5 children. The primary investigator will conduct the programmes. It will be one hour session, twice a week, 12 weeks.
2383145|NCT03687606|Active Comparator|Human Chorionic Gonadotropin alone|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for 3 years.
2383146|NCT03687606|Experimental|hCG alone for 6 months then hMG added|Human Chorionic Gonadotropin 2000U~6000U, intramuscular injection, two times per week for six months, then 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week, was added and last for the next 30 months.
2383147|NCT03687606|Experimental|hCG and hMG|Human Chorionic Gonadotropin 2000U~6000U and 75~150IU human menopausal gonadotropin, intramuscular injection, two times per week for 3 years.
3150816|NCT00211835|Experimental|Treatment Arm 1|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
3150817|NCT00211835|Experimental|Treatment Arm 2|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
2383150|NCT03687567||HBA|alpha-Thalassemia
2383151|NCT03687567||HBB|beta-Thalassemia
2383152|NCT03687554|Experimental|Venglustat|Single dose of Venglustat is given, orally under fasting conditions
3150818|NCT00211874|Experimental|Nurse-management|nurse-led intervention focused on specific management problems
2383154|NCT03687515|Experimental|budesonide inhalation suspension|
2383155|NCT03687515|Active Comparator|budesonide aqueous nasal spray|
2383156|NCT03687515|Active Comparator|oral steroids|
2383157|NCT03687502|Experimental|Experimental|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, up to 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
2383158|NCT03687489|Experimental|Intervention arm|Participants will be treated with Abdominal Aortic Aneurysm Stent Graft System
2383159|NCT03687476|Experimental|VTS-270 (Part A)|VTS-270 200 milligram per milliliter (mg/mL) will be administered intrathecally by lumbar puncture every 2 weeks followed by dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. The highest tolerable dose is considered as clinically relevant dose which will be administered throughout the remaining duration of the 20-week treatment period of Part A.
2383160|NCT03687476|Experimental|VTS-270 (Part B)|VTS-270 200 mg/mL will be administered intrathecally by lumbar puncture every 2 weeks in Part B followed by a re-challenge to dose escalation of 100 mg/mL increments up to a maximum tolerable dose of 900 mg/mL. In case of intolerance, the dose should be returned to previously tolerable dose and should be continued throughout the duration of Part B (end of study).
2383163|NCT03687424|Active Comparator|Normal weight 18<BMI<30 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
3150819|NCT00211874|No Intervention|Usual Care|Usual care as control group
3150820|NCT00211900|Experimental|vaccine|single dose of StaphVAX in hemodialysis patients
3150821|NCT00211913|Experimental|vaccine|single dose of StaphVAX®
3150822|NCT00211913|Placebo Comparator|placebo|single dose
3150823|NCT00211926|Experimental|StaphVAX|
3150824|NCT00211926|Placebo Comparator|Placebo|
3150825|NCT00211939|Experimental|1|PhosLo + atorvastatin
3150826|NCT00211939|Active Comparator|2|Sevelamer + atorvastatin
3150827|NCT00211965|Experimental|vaccine|single dose
3150828|NCT00211965|Placebo Comparator|placebo|single dose
3150829|NCT00211978|Experimental|PhosLo|
3150830|NCT00211978|Placebo Comparator|placebo|
3150831|NCT00212004|Active Comparator|Pioglitazone|Participants in the pioglitazone group were administered a pioglitazone tablet (15 mg) once a day. In the event of the side effects such as oedema, the dosage of pioglitazone was reduced to half or a quarter of the original dosage. Otherwise, we tried to increase the dose of pioglitazone to 30mg/day.
2383165|NCT03687424|Active Comparator|Morbidly obese BMI ≥40 kg/m2 LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
2383166|NCT03687424|Experimental|Normal weight 18<BMI<30 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
2383167|NCT03687424|Experimental|Obese 30<BMI<40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
2383168|NCT03687424|Experimental|Morbidly obese BMI ≥40 kg/m2 HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
3142717|NCT00003143|Other|DHAP|Patients are randomized to receive salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP) with or without amifostine. Patients receive cisplatin IV over 3 hours followed by cytarabine IV for 2 doses. Patients also receive dexamethasone orally or IV. Treatment repeats every 3-4 weeks for 2-6 courses. Arm I: Patients receive amifostine IV over 15 minutes prior to all courses of DHAP, as a 15 minute infusion, beginning 30 minutes prior to cisplatin administration. Arm II: Patients do not receive amifostine. On day 3 of the last DHAP course, patients receive filgrastim (G-CSF) until the last day of progenitor stem cell (PSC) mobilization. PSC transplant continues daily for 4-10 days.
2383170|NCT03687398||control|does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
2383171|NCT03687398||patient|has laparoscopically proven endometriosis
2383172|NCT03687385|Active Comparator|ASA I / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
2383173|NCT03687385|Active Comparator|ASA II / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
2383174|NCT03687385|Active Comparator|ASA III / LFNO|Low-flow nasal oxygenation (LFNO) O2 flow 5L/min, FiO2 40%
2383175|NCT03687385|Experimental|ASA I / HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
2383176|NCT03687385|Experimental|ASA II/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
2383177|NCT03687385|Experimental|ASA III/ HFNO|High-flow nasal oxygenation (HFNO) O2 flow 40L/min, FiO2 40%
2383180|NCT03687359||Participants with atopic dermatitis (AD)|Participants receive AD therapy as part of their usual care as determined by their physician independent of decision to enroll in the study.
3142718|NCT00003145|Experimental|Treatment (chemotherapy, TBI, PBSCT, DLI)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV BID or TID on days -3 to 56 with taper to day 77 or 180, and mycophenolate mofetil PO or IV BID on days 0-27.~DLI: At least 2 weeks after completion of immunosuppression, patients with > 5% donor CD3+ T cells and no evidence of GVHD receive donor lymphocytes IV over 30 minutes. Patients may receive up to 3 DLIs at increasing cell doses in the absence of GVHD."
3150832|NCT00212004|Active Comparator|Control|Participants assigned to Control group were treated with diet and exercise therapy or sulfonylurea (SU) or other additional drugs than pioglitazone.
2383183|NCT03687333|Experimental|Alglucosidase Alfa therapy|Alglucosidase Alfa dose is calculated per kg body weight and administered once every 2 weeks for up to 52 weeks.
2383186|NCT03687294||Group I|patients suffering from malignant salivary gland tumors.
2383187|NCT03687294||Group II|patients suffering from benign salivary gland tumors.
2383188|NCT03687281||Male patients living with HIV and having sex with men|Male patients living with HIV and having sex with men followed at Universitary Hospital Center of Reunion Island
2383189|NCT03687268|Placebo Comparator|Placebo|
2383190|NCT03687268|Experimental|Naloxone 24 mg|
2383191|NCT03687268|Experimental|Naloxone 48 mg|
2383192|NCT03687255|Experimental|cefepime/AAI101 combination|Cefepime 2 g in combination with AAI101 500 mg q8h (2 hour infusion)
2383193|NCT03687255|Active Comparator|piperacillin/tazobactam|Piperacillin 4 g in combination with Tazobactan 500 mg q8h (2 hour infusion)
2383194|NCT03687242|Experimental|SPR001|SPR001 at Dose A
2383195|NCT03687229||Patient|"Chronic HCV patients before treatment & 3 months after starting of treatment. not known to be:~Cirrhosis~Diabetes Mellitus.~Hemochromatosis~HBV~HIV.~Hepatocellular carcinoma (HCC)~Chemotherapy~Organ transplantation"
2383196|NCT03687229||Control|Apparently healthy individuals
2383197|NCT03687216|Experimental|HVPG group|HVPG-guided therapy (TIPS or EVL plus NSBB according to HVPG)
2383198|NCT03687216|Active Comparator|Routing group|Routing therapy (EVL plus NSBB)
2383199|NCT03687190|Experimental|Tai chi|participants in this group accepted Tai chi exercise and conventional medicine.
2383200|NCT03687190|Active Comparator|controlled group|participants were not received Tai chi exercise, but only routine conventional medicine
2383201|NCT03687177|Other|Control group|Nurses from intensive care informed on the prevention of VAP and without visual cue to estimate the angle of elevation of the head of intubated patients
2383202|NCT03687177|Other|Experimental group|Nurses from intensive care informed on the prevention of VAP with visual cue to estimate the angle of elevation of the head of intubated patients.
2383203|NCT03687164|Experimental|Group Medical Visits|Group visits which will provide aspects of support, empowerment, education and medical care.
2383204|NCT03687164|No Intervention|Usual Care|Usual clinical office visits
2383205|NCT03687151||patients with a diagnosis of invasive or in situ cancer|patients with a diagnosis of invasive or in situ cancer living in the French Region Sud-Provence-Alpes-Côte d'Azur since 2005
2383206|NCT03687138||Control 1|This is the control population. The analysis will be done with a 24h urin sample. We will compare this population with the other two.
2383207|NCT03687138||Control 2|This is the control LES population. The analysis will be done with a 24h urin sample. We will compare this population with the other control population and the study population.
2383208|NCT03687138||Study population|This is the study population. The analysis will be done with a 24h urin sample. We will compare this population with the other two controls populations.
3150833|NCT00212017|Active Comparator|the voglibose group|Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.
2383212|NCT03687086|Experimental|Program A|cognitive behavioral therapy type A plus medications in packaging type A
2383213|NCT03687086|Active Comparator|Program B|cognitive behavioral therapy type B plus medications in packaging type B
2383214|NCT03687073|Experimental|Single-dose PK study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil once at the study center. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will also be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
2383215|NCT03687073|Experimental|Multi-dose PK Study|Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Ten mL of blood will be collected at the time points described in Section 9.14. Concurrently, urine will be collected for 24 hours after the first dose of I3C, Sil or I3C + Sil, divided into the time intervals.
2383216|NCT03687073|Experimental|Safety Study|Safety data will be generated during the multi-dose PK and PD study, as DLT is not anticipated in the single-dose PK study. Enrollment into dose cohorts 1 and 2 can occur on a continuous basis. Enrollment for dose cohorts 3 and 4 will be done sequentially using a modified 3+3 design (see Section 8.2). The first three subjects enrolled into a dose cohort must complete at least 21 days of the multi-dose PK/PD study without a DLT before the remaining 4 subjects in the cohort can be enrolled.
2383217|NCT03687073|Experimental|Cohort 4 PD Study|The effect of I3C, Sil, or I3C + Sil on the pharmacodynamic endpoints listed under the Secondary Objectives in Section 1.2 will be characterized. This PD study will be done concurrently with the multi-dose PK study. Subjects will take the assigned dose of I3C, Sil, or I3C + Sil for 8 weeks. Nasal epithelium, oral cavity cells, buccal cells, blood, and urine will be collected at the time points described in the study calendar in Section 4.0.
2383218|NCT03687060|Other|Organization Level|
2383219|NCT03687060|Other|Provider Level|
2383220|NCT03687060|Other|Patient Level|
2383221|NCT03687047|Experimental|New complete dentures|"Steps: 1) Preliminary impressions will be done using stock trays and impression compound; 2) primary casts will be fabricated to make custom trays for definitive impressions; 3) definitive impressions will be made using zinc oxide eugenol impression paste;4) definitive impressions will be poured with type III dental stone to obtain mastercasts; 5)jaw relations will be recorded, and the casts will be mounted on the articulator; 6) the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up. After denture insertion, post-denture insertion instructions such as oral hygiene will be explained to the patients.~The Oral Health Related to Quality of Life assessment will be conducted before treatment (Baseline) and at 3, 6, 9, 12 and 18 months after treatment."
2383222|NCT03687034|Experimental|BRCX014|Subjects will receive escalating doses of BRCX014 in conjunction with standard-of-care (SOC) treatment. For patients with GBM, following standard chemo-radiation treatment (radiation: 2 Gy per day for a total of 60 Gy; and temozolomide: 75 mg per square meter of body-surface area per day, seven days per week from the first to the last day of radiotherapy), SOC treatment comprises six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle), with or without use of alternating electric field therapy (Optune device).
2383223|NCT03687021|No Intervention|endometriosis|tissue biopsy from patients (n=10) with endometriosis
2383224|NCT03687021|No Intervention|without endometriosis|tissue biopsy from patients (n=10) without endometriosis
2383225|NCT03687021|Experimental|Intramuscular progesterone|Intramuscular progestin(20mg)
2383226|NCT03687021|Experimental|vaginal progesterone|vaginal progestin (90mg)
2383227|NCT03687021|Experimental|oral progesterone|oral progestin(40mg)
2383228|NCT03687008|Experimental|Adolescents with SVHD|All adolescents will receive the intervention Cogmed. This is an in home, computer based, cognitive intervention to improve working memory, supervised by trained coaches, [25 sessions, each 30-45 minutes, 5 days a week / 5 week duration].
2383229|NCT03686982|Experimental|Active Nitrate Bar|include dietary nitrate; L-citrulline; epicatechin; vitamin C and glutathione
2383230|NCT03686982|Placebo Comparator|Placebo Bar|Containing no active ingredients
3188965|NCT00772551|Active Comparator|2|
3188966|NCT00772564|Experimental|Atorvastatin 80 mg|
2383233|NCT03686956|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
2383234|NCT03686956|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
2383235|NCT03686943||Elderly|Patient over 75 years seen with the mobile extra hospital geriatric team
2383236|NCT03686930|Active Comparator|Cohort 1 - FP-045 oral solution|FP-045 powder for oral solution, will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
2383237|NCT03686930|Placebo Comparator|Cohort 1 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
2383238|NCT03686930|Active Comparator|Cohort 2 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
2383239|NCT03686930|Placebo Comparator|Cohort 2 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
2383240|NCT03686930|Active Comparator|Cohort 3 - FP-045 oral solution|FP-045 powder for oral solution (escalated dose), will be reconstituted once daily (QD) dose, administered for 7 consecutive days.
2383241|NCT03686930|Placebo Comparator|Cohort 3 - Placebo for FP-045 oral solution|Placebo oral solution that is identical to the test product, but without FP-045.
2383242|NCT03686917||CHAT-P|Survey
2430145|NCT03365947|Placebo Comparator|Placebo|
3188967|NCT00772564|Experimental|Atorvastatin 10 mg|
2383244|NCT03686904|Active Comparator|SOC TOPICAL GEL & TORRENT X GROUP [Cohort B]|Debridement, benzalkonium irrigation & SOC topical gel
2383245|NCT03686904|Active Comparator|BLASTX and SALINE (SOC) GROUP [Cohort C]|Debridement, SOC saline irrigation & benzalkonium gel
2383246|NCT03686904|Active Comparator|BLASTX and TORRENTX GROUP [Cohort D]|Debridement, benzalkonium irrigation & benzalkonium gel
2383247|NCT03686878|Experimental|Intervention Group|Lifitegrast 5% ophthalmic solution group
2383248|NCT03686865||dental implants|
2383249|NCT03686852|Active Comparator|group A|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A).
2383250|NCT03686852|Active Comparator|groppo B|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 150IU (Group B)
2383251|NCT03686852|Active Comparator|Group C|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 250IU (Group C) of recFSH (Puregon®, MSD).
2383252|NCT03686839|Experimental|SMR neurofeedback training to MCI|"Sensorimotor rhythm neurofeedback protocol consisted of 20 individual sessions, twice a week, during 11 weeks maximum. For each subject MCI, NF was planned and conducted by a neuropsychologist experienced in neurophysiology and neurofeedback. Each session lasted 1h10-15min and was conducted as follows:~Preparation and installation of the electrodes, verification of the impedance, adjustment of the calibration and thresholds (15 minutes).~NF training (tasks and video described below) (45 minutes).~Feedback and debriefing about the session (15 minutes)."
2383253|NCT03686826||multiple sclerosis patients|
2383254|NCT03686826||healthy volunteers|
2383257|NCT03686800|Experimental|Rivelin® plain patches|This is an open label study with the objectives to establish information on adhesion time, tolerability and usability of Rivelin® plain patches when applied to VLS lesions. Furthermore, the design of the Rivelin® plain patch will also be evaluated.
2383258|NCT03686774|Experimental|Memantine group|Memantine will be given orally for four weeks starting two weeks before surgery. Memantine will be given in increasing doses: 5 mg/day for 3 days; 10 mg/day for 3 days; 15 mg/day for 3 days and 20 mg/day for 5 days.
2383259|NCT03686774|Other|Usual care group|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment."
2383260|NCT03686761|Experimental|Study|A Involvement with the osteotomy site of the surgery, osteotomy was performed then GCF were collected from teeth neighboring the
2383261|NCT03686761|Active Comparator|Control|Involvement with the osteotomy site of the surgery, surgical osteotomy was performed then GCF were collected from teeth away from the osteotomy site
2383262|NCT03686748|Experimental|Two-point intervention|Two point discrimination training.
2383263|NCT03686748|Active Comparator|One-point intervention|One point discrimination of size of probe
2383264|NCT03686748|No Intervention|Healthy Controls|Observational component of differences in discrimination between chronic pain patients and healthy controls.
2383265|NCT03686735||Satisfaction measure 1|25% of the cohort
2383266|NCT03686735||Satisfaction measure 2|25% of the cohort
2383267|NCT03686735||Satisfaction measure 3|25% of the cohort
2383268|NCT03686735||Satisfaction measure 4|25% of the cohort
2383269|NCT03686722|Active Comparator|Metformin|Subjects administered Metformin 500mg(Glucophage tablets) twice daily till day(4) then Metformin 1000mg twice daily till day(7)
2383270|NCT03686722|Experimental|Metformin and Daclatasvir|Subjects Coadministered Metformin 500mg(Glucophage tablets) twice daily and Daclatasvir 60mg tablets once daily till day (4) then Metformin 1000mg twice daily and Daclatasvir 60mg tablets once daily till Day(7)
2383271|NCT03686709|Experimental|SIR-Spheres Therapy Selection|Patient selected for SIR-spheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
2383272|NCT03686709|Experimental|TheraSpheres Therapy Selection|Patient selected for TheraSpheres radioembolization therapy using standard of care selection. Infusion of the therapy dose will be monitored using external detectors placed on the delivery system as well as the points on the patient. Blood draws will be collected before, during, and after the therapy infusion to monitor radiation levels in the blood. Following therapy, the patient will undergo standard of care bremsstrahlung SPECT imaging as well post-infusion PET/CT. A final blood draw will take place in conjunction with PET/CT imaging.
2383273|NCT03686696|No Intervention|No Beta blocker and no ACEI/ARB|No Beta blocker and no ACEI/ARB
2383274|NCT03686696|Experimental|Beta blocker and ACEI/ARB|Beta blocker and either ACE inhibitor or Angiotensin receptor blocker
2383275|NCT03686696|Experimental|Beta blocker alone|Beta blocker alone
2383276|NCT03686696|Experimental|ACEI/ARB alone|Either ACE inhibitor or Angiotensin receptor blocker alone
2383277|NCT03686683|Experimental|Treatment Group: Sipuleucel-T|Sipuleucel-T is an autologous cellular immunotherapy available as a suspension for intravenous infusion. Subjects randomized to sipuleucel-T arm will receive 3 infusions of sipuleucel-T at approximately 2-week intervals.
2383348|NCT03686150|Active Comparator|Part 1, Cohort 4 Vitamin D3 oral regimen|Vitamin D: 600 IU daily dose
2383278|NCT03686683|No Intervention|Control Arm: Active Surveillance|Subjects randomized to the control arm will be followed on Active Surveillance described in the schedule of events.
2383279|NCT03686657|No Intervention|Healthy adults with NGT|Healthy adults with normal glucose tolerance (NGT) and beta cell function will be administered placebo.
2383280|NCT03686657|Active Comparator|Metformin-Drug naive patients & Patients with inadequate glycemic control with Metformin|Patients receive metformin once daily
2383281|NCT03686657|Experimental|RK-01 Low|Patients receive valsartan, celecoxib and metformin (low dose) once daily
2383282|NCT03686657|Experimental|RK-01 High|Patients receive valsartan, celecoxib and metformin (high dose) once daily
2383283|NCT03686644|Experimental|Children with Cerebral Palsy|Children with Cerebral Palsy (CP) will be included. They will have to wearing of night splint ankle foot orthoses (phase A) and then no wearing of night splint ankle foot orthoses (phase B). The phases A and B will be repeated twice. In more, they will have an ultrasound, isokinetic dynamometer and measure of quality of night sleeping.
2383284|NCT03686631|No Intervention|Passive Arm|This arm uses a passive tracking device to assess the number of times a patient uses their prescribed incentive spirometer.
2383285|NCT03686631|Experimental|Smartphone Arm|This arm uses a smartphone connected device and smartphone application to remind and encourage patients to use the spirometer as well as track the number of times they utilize the spirometer.
2383286|NCT03686618|No Intervention|Cohort X|no secretin administered. All observations
2383287|NCT03686618|Active Comparator|Cohort 1|32 mcg (<50kg) or 40 mcg (≥50kg) secretin two times a day (40 mcg; q 12 hrs)
2383288|NCT03686618|Active Comparator|Cohort 2|32 mcg (<50kg) or 40 mcg (≥50kg) secretin four times a day (40 mcg; q 6 hrs)
2383289|NCT03686618|Active Comparator|Cohort 3|32 mcg (<50kg) or 40 mcg (≥50kg) secretin six times a day (40 mcg; q 4 hrs)
2383290|NCT03686605||Cancer pain patients|
2383291|NCT03686592|Experimental|pancreatectomized patients|Patients with pancreatic cancer who underwent a pancreatectomy at Institut Paoli Calmettes
2383292|NCT03686592|Active Comparator|Volunteers|
2383293|NCT03686579||chest trauma|"Early detection and diagnosis of associated thoracic injuries .~decrease of costs required for investigations . 3- sensitivity and specificity of the investigations"
2383294|NCT03686566||13C-glucose infusion|Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
2383295|NCT03686566||No 13C-glucose infusion|Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
2383296|NCT03686553||infected, with SSI|patients with SSI
2383297|NCT03686553||non-infected|patients without SSI
2383298|NCT03686527||Echocardiography|
2383299|NCT03686527||MRI Fibrosis|
2383300|NCT03686514|Experimental|H3N2 birth cohort|The H3N2 cohort consists of participants born between 1968-1977.
2383301|NCT03686514|Experimental|H1N1 birth cohort|The H1N1 cohort consist of participants born between 1948-1957.
2383302|NCT03686501|Experimental|PF-06412562|To assess the D1 receptor occupancy (D1 RO) in striatum after a single oral administration of PF-06412562.
3150834|NCT00212017|Active Comparator|the control group|Participants assigned to the control group were treated only with diet and exercise therapy.
2383304|NCT03686475|Experimental|Biodentine pulpotomy|Biodentine (Septodont, France) Pulpotomy for primary molars Clinical and radiographic evaluation Follow up at 1,3,6 and 12 months
2383305|NCT03686475|Active Comparator|MTA pulpotomy|"MTA (Angelus- Londrina, Brazil) Pulpotomy for primary molars . it is fine hydrophilic powder consisting of tricalcium silicate, tricalicum aluminate, tricalcium oxide, silicate oxide and bismuth oxide11.~It is currently being used in pulpotomy of primary molars with a high rate of success.~Clinical and radiographic evaluation. Follow up at 1,3,6 and 12 months"
2383306|NCT03686462|Experimental|Virtual reality-based interactive treadmill training|In this group, the subjects will receive virtual reality (VR)-based interactive treadmill training. During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
2383307|NCT03686462|Sham Comparator|Treadmill training without VR-based interaction|The subjects in this group will receive the treadmill gait training. Virtual reality environment will be provided during the gait training but no feedback and interaction will be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of treadmill-based training.
2383308|NCT03686449|Experimental|study group 1|Non-cultured Autologous Keratinocyte Suspension
2383309|NCT03686449|Experimental|study group 2|Adipose-Derived Stem cell-Keratinocyte Suspension
2383310|NCT03686449|Active Comparator|Control group|Split skin graft
2383311|NCT03686410|Experimental|1. Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
2383312|NCT03686410|Active Comparator|2. Convetional Tretament|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
2383313|NCT03686397|Experimental|SVT-15652|1 vial twice daily
2383314|NCT03686397|Placebo Comparator|Placebo|1 vial twice daily
2383315|NCT03686384|Experimental|SVT-15652|1 vial twice daily
2383316|NCT03686384|Placebo Comparator|Placebo|1 vial twice daily
2383346|NCT03686150|Experimental|Part 1, Cohort 2 Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 10,000 IU daily dose
2383347|NCT03686150|Experimental|Part 1, Cohort 3 Vitamin D3 oral regimen|Vitamin D: 6000 IU daily dose
2430154|NCT03365921|Experimental|Hepatitis E vaccine lot 3|
2383317|NCT03686345|Experimental|Core binding factor acute myeloid leukemia (CBF-AML)|Patients must have an unequivocal diagnosis of de novo-CBFL, prior to start midostaurin, documented by rearrangement of Core Binding Factor (CBF) genes, namely AML1-ETO and CBFB-MYH11. The experimental arm involves the administration of Midostaurin orally 50 mg (two 25 mg tablets) twice a day, from the end of induction chemotherapy, for 14 days. Patients should take Midostaurin at approximately 12 hours intervals. During all consolidation cycles, Midostaurin 50 mg (two 25 mg tablets) is administered orally twice a day, on days 8-21. Patients in complete remission after 3 cycles of remission consolidation therapy, will receive Midostaurin continuation therapy for 12 months. Midostaurin 50 mg (two 25 mg tablets) will be given orally twice a day for 12 months.
2383318|NCT03686332|Other|Arm A: Atezolizumab and Radiotherapy|"Patients in this group will concurrently be treated with locoregional radiotherapy and atezolizumab.~Drug: Arm A: Atezolizumab and Radiotherapy~Atezolizumab, 1200 mg, every 3 weeks, by IV infusion and receive 33 fractions of 1.5 or 1.8 Gy irradiation."
2383319|NCT03686332|Other|Arm B: Atezolizumab|Atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
2383320|NCT03686319|No Intervention|control groups|"Primiparas appropriate for the criteria, admitted to the clinic due to CS and accepting to participate in the study were randomly placed into groups. Reflexology was performed in the intervention group mothers, and the questionnaires and scales were self-reportingly filled in by the lead researcher (SC).~Different rooms were allocated for the participants in the intervention and control groups not to affect each other."
2383321|NCT03686319|Experimental|"intervention (foot reflexology)"|Reflexology was performed in those in the intervention group after CS on right foot for 10 min and left foot for 20 min as continuing 30-min seances three times per day every eight hours for three days. The procedure was started at mean 3rd hour after mothers became stable. Reflexology was performed for none of those in the control group.
2383324|NCT03686293|Experimental|Paracetamol and breakfast|One tablet of paracetamol (500 mg) and a standardized breakfast will be consumed within 15 minutes one morning upon 10 hours of fasting
2383325|NCT03686280|Experimental|Robot in combination with traditional reeducation|
2383326|NCT03686280|Active Comparator|Standard rehabilitation|
2383327|NCT03686267|Experimental|intervention (I1)|Lithium disilicate crowns over titanium abutments covered by a layer of opaque porcelain
2383328|NCT03686267|Experimental|Intervention (I2)|Lithium disilicate crowns over titanium abutments covered by lithium disilicate (high opacity) coping
2383329|NCT03686267|Active Comparator|Lithium disilicate crowns over uncovered titanium abutments|Lithium disilicate crowns over uncovered titanium abutments directly without masking
2383330|NCT03686254|Active Comparator|The control Arm|bevacizumab and second-line chemotherapy
2383331|NCT03686254|Experimental|The experimental Arm|RFA, bevacizumab and second-line chemotherapy
3142719|NCT00003147|Experimental|Arm I|Patients receive adenovirus p53 construct by percutaneous injection to a maximum of two lesions on day 1. Treatment is repeated every 28 days for up to 6 courses. In the absence of dose-limiting toxicity (DLT) in the first cohort of 6 patients treated, subsequent cohorts of 6 patients each receive escalating doses of the drug on the same schedule. If DLT occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and that dose is declared the maximum tolerated dose. Study treatment may continue in the absence of disease progression and unacceptable adverse events.
3142720|NCT00003157|Experimental|radiation + gemcitabine + cisplatin|Patients undergo radiotherapy to the tumor and lymph nodes, followed by a decrease in radiotherapy to the tumor alone. Radiation therapy is administered for a total of 5.5 weeks. Patients receive intravenous gemcitabine twice weekly over the first 3 weeks of radiotherapy. Cisplatin is administered intravenously twice weekly following gemcitabine therapy. Three patients are treated at each dose level. Dose escalation does not occur until all patients at a given dose level have completed radiotherapy and returned for a 4 week follow up. Patients exhibiting stable disease remain on therapy until disease progression or intolerable toxic effects. Patients experiencing toxic effects and no disease progression are retreated at a lower dose. Patients are followed every 3 months for the first 2 years then every 6 months for the next year.
2383336|NCT03686202|Experimental|Group A: Safety Cohort|Subjects with advanced solid tumors already on ICI will receive treatment with MET-4 in addition to SOC ICI. MET-4 is administered orally as an initial daily loading dose (5g) of MET-4 over 2 days followed by a daily maintenance dose (1.5g) of MET-4 and will be continued until unacceptable toxicity, progression of disease
2383337|NCT03686202|Experimental|Group B|Eligible subjects with advanced solid tumors starting ICI will be randomised in a 3:1 ratio stratifying for prior IO exposure, to receive MET-4 together with any approved PD-1/PD-L1 inhibitor as per SOC or control group. There will be a run-in period for subjects in the MET-4 treatment group. Following the run-in period of ICI therapy, subjects will be administered the same MET-4 dose as subjects in group A.
2383338|NCT03686202|Experimental|Group C|In group C, eligible subjects with advanced solid tumors whom are already on ICI with first unconfirmed PD on evaluation scans per investigator's assessment, will be randomised in a 1:1 ratio to receive MET-4 in addition to the PD-1/PD-L1 inhibitor as per SOC or control group. These subjects must be clinically stable and are to be continued on ICI at the discretion of the investigator. There will be no run-in period for this cohort. Subjects will be administered the same MET-4 dose as subjects in groups A and B.
2383339|NCT03686189|Experimental|Intervention arm|Participants will be treated with Iliac Bifurcation Stent Graft System
2383343|NCT03686163|Experimental|IN-NGF group|Patients who underwent acute ischemic stroke will be chosen to receive NGF randomly
2383344|NCT03686163|Placebo Comparator|Control group|Patients who underwent acute ischemic stroke will be chosen to receive normal saline randomly
2383345|NCT03686150|Experimental|Part 1, Cohort 1 Vitamin D3 oral regimen|Intervention: Vitamin D: Single 50,000 IU loading dose + 6000 IU daily dose
2383349|NCT03686150|Experimental|Part 2, Cohort A Vitamin D3 oral regimen|Vitamin D: Single 50,000 IU loading dose + 8,000 IU daily doseD
2383350|NCT03686150|Active Comparator|Part 2, Cohort B Vitamin D oral regimen|Vitamin D: 600 IU daily dose
2383351|NCT03686137||Institut Paoli-Calmettes patients undergoing liver surgery|
2383352|NCT03686124|Experimental|Dose Escalation|Dose escalation of IMA203
2383353|NCT03686124|Experimental|Extension Cohort A|IMA203 at MTD
2383354|NCT03686124|Experimental|Extension Cohort B|IMA203 at MTD + atezolizumab
2383355|NCT03686111||infertile patientes with medical assistance to procreation|
2383356|NCT03686111||Infertile patientes with induction of ovulation to give their|
2383357|NCT03686098|Experimental|Dietary Soy Arm|Participants will be asked to increase soy in their diet by an equivalent of 50mg/day for 12 months
2383358|NCT03686098|Active Comparator|Soy Supplement Arm|Participants will consume 2 tablets of 50mg each per day for 12 months
2383359|NCT03686098|No Intervention|Control Arm|No diet or supplement changes
2383360|NCT03686085|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
2383361|NCT03686085|Placebo Comparator|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
2383362|NCT03686072|Other|Cataract surgery with goniosynechialysis|
2383363|NCT03686059|Experimental|punctal plug|SOFT PLUG® Preloaded Silicone Plugs by OASIS®
2383364|NCT03686059|Experimental|Combined|SOFT PLUG® Preloaded Silicone Plugs by OASIS® plus Daily intake of DHA (docosahexaenoic acid)
2383365|NCT03686059|No Intervention|control|no medication was given
2383366|NCT03686046||Exploratory use|Brief (2 hour) exploratory use of prototype self-adjusted wearable Master Hearing Aid
3183294|NCT00712582|Experimental|Consolidation B|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Patients whose disease is FDG-PET negative or patients whose FDG-PET scan is positive but repeat biopsy is negative and whose initial Ki-67 expression is ≥80% will receive 2 cycles of augmented RICE Chemotherapy (as per MSKCC protocol 03-075)."
3183295|NCT00712582|Experimental|Consolidation C|"Induction: RR-CHOP-14 Chemotherapy for Three Cycles Each cycle lasts approximately 14 days. A total of 3 cycles of RR-CHOP-14 will be given. One cycle of CHOP will follow.~Consolidation C: Patients with biopsy proven disease after induction therapy. Patients whose bone marrow remain positive at interim restaging will have the option of getting an allogeneic[m3] stem cell transplant, in lieu of an ASCT, if they have an acceptable HLA match donor. The allogeneic[m4] stem cell transplant regimen will be decided by the MSK Bone Marrow Transplant Service."
3183296|NCT00712595|Experimental|1|Mifepristone 10 mg daily for three months
3183297|NCT00712595|Experimental|2|Mifepristone 5 mg daily for three months
3183298|NCT00712608|Active Comparator|1|Marketed cow's milk-based formula
3183299|NCT00712608|Experimental|2|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
2383373|NCT03686020||Group I|participants suffering from oral potentially malignant lesions
2383374|NCT03686020||Group II|participants suffering from diagnosed oral malignant lesions
2383375|NCT03686020||Group III|healthy participants who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.
2383376|NCT03686007|Experimental|Group I (MSM intervention)|Patients and FCGs receive the MSM intervention consisting of videos, a handbook, and research nurse coaching over 40-60 minutes, approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive research nurse support via telephone(separate sessions for FCGs and patients) over 20-30 minutes at 2 and 7 days, and 2 months post-discharge.
2383377|NCT03686007|Active Comparator|Group II (Attention Control)|"Patients and FCGs receive attention control intervention consisting of videos (American Cancer Society video on Clinical Trials), American Cancer Society print materials, and assistance from a CRA approximately 3-7 days before surgery and within 24 hours of planned discharge. Patients and FCGs also receive assistance from CRAs via telephone at 2 and 7 days, and 2 months post-discharge."
2383378|NCT03685994||the patients who will undergo TIPS|
2383379|NCT03685981|Experimental|Incentives information provided|
2383380|NCT03685981|No Intervention|No incentives information provided|
3183300|NCT00712608|Experimental|3|Cow's milk based formula with prebiotic, different level of fatty acids and fat and a different calcium source
3183301|NCT00712621|Other|I|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm I: Quality of life is assessed at baseline and at 3 and 6 months."
3183302|NCT00712621|Other|II|"OUTLINE: This is a randomized, multicenter study. Patients are selected according to age ( 25 to 49 vs 50 to 85), time since initial completion of therapy (3 to 18 months), and are separated in two groups.~Arm II: Quality of life is assessed at baseline and at 3 and 6 months."
2383384|NCT03685955||Genitourinary Reconstruction with Amniotic Membranes|Patients who undergo genitourinary reconstruction with amniotic membranes
2383570|NCT03684824|Other|obese group|100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility
3183303|NCT00712634|Experimental|CMV-seropositive participants|Participants are randomized to receive 1 of 4 escalating doses of CMVpp65-A*0201 peptide vaccine containing either helper T-lymphocyte (HTL) PADRE peptide or HTL tetanus toxoid peptide. Within each vaccine dose group, two participants are randomized to receive a placebo. Participants receive the vaccine or a placebo subcutaneously (SC) on days 0 and 28 in the absence of unacceptable toxicity.
3183304|NCT00712634|Experimental|CMV-seronegative participants|Participants are randomized to receive 1 of 4 established doses (established in CMV-seropositive participants) of CMVpp65-A*0201 peptide vaccine containing either HTL PADRE peptide or HTL tetanus toxoid peptide. Participants receive the vaccine on days 0, 28, and 56 in the absence of unacceptable toxicity. Participants with a partial or low-level immune response receive one additional booster vaccine on day 90.
3183305|NCT00712647|Active Comparator|1|Asbestos-exposed participants and heavy smokers
3183306|NCT00712647|Placebo Comparator|2|Asbestos-exposed participants and heavy smokers
3142721|NCT00003162|Active Comparator|3.0 Gy x 10 fractions in two weeks|3.0 Gy x 10 fractions for a total dose of 30.0 Gy in two weeks
3142722|NCT00003162|Experimental|8.0 Gy x 1 fraction|8.0 Gy x 1 fraction for a total dose of 8.0 Gy in a single dose
3142723|NCT00003166|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.~Cohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
2383390|NCT03685916|Other|Control|50 grams carbohydrate in the form of rice, 200 milliliters of plain water and 20 grams of garden peas.
2383391|NCT03685916|Experimental|Cumin Rice|50 grams carbohydrate in the form of rice with cumin, 200 milliliters of plain water and 20 grams of garden peas.
2383392|NCT03685916|Experimental|Cumin Drink|50 grams carbohydrate in the form of rice, 200 milliliters of cumin extract in solution and 20 grams of garden peas.
2383393|NCT03685916|Experimental|Cornsilk Rice (Low dose)|50 grams carbohydrate in the form of rice with cornsilk extract (low dose), 200 milliliters of plain water and 20 grams of garden peas.
2383394|NCT03685916|Experimental|Cornsilk Rice (High dose)|50 grams carbohydrate in the form of rice with cornsilk extract (high dose), 200 milliliters of plain water and 20 grams of garden peas.
2383395|NCT03685916|Experimental|Cornsilk Drink (Low dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (low dose) in solution and 20 grams of garden peas.
2383396|NCT03685916|Experimental|Cornsilk Drink (High dose)|50 grams carbohydrate in the form of rice, 200 milliliters of cornsilk extract (high dose) in solution and 20 grams of garden peas.
2383397|NCT03685916|Experimental|Tamarind Rice|50 grams carbohydrate in the form of rice with Tamarind, 200 milliliters of plain water and 20 grams of garden peas.
2383398|NCT03685916|Experimental|Tamarind Drink|50 grams carbohydrate in the form of rice, 200 milliliters of Tamarind extract in solution and 20 grams of garden peas.
2383399|NCT03685903|Experimental|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
2383400|NCT03685890|Experimental|ILP + Nivolumab|The day before planned ILP, the patient will receive one infusion of nivolumab 480mg
2383401|NCT03685890|Placebo Comparator|ILP + Placebo|The day before planned ILP, the patient will receive one infusion of placebo
2383402|NCT03685864|Experimental|Suture Embedding Acupuncture|Suture Embedding Acupuncture 1 time for two weeks, total 3 times.
2383403|NCT03685864|Sham Comparator|Sham acupuncture|Sham Acupuncture 1 time for two weeks, total 3 times.
2383404|NCT03685851||UT-DSAEK|With graft 6 months thick less than 100 µm
2383405|NCT03685851||DSAEK|With graft thicker than 100 µm
2383406|NCT03685838|Active Comparator|Compression|Patient will receive Class II above knee compression stockings, and will be asked to wear it for 1 week. This would involve wearing the stocking during daytime but patients will be allowed to take it off at night whilst in bed.
2383407|NCT03685838|No Intervention|No Compression|Patient will not receive any compression stockings.
2383408|NCT03685812||patients with patellofemoral pain syndrome , Auto Cad software|Patients referred with a confirmed diagnosis of patellofemoral pain syndrome, with a visual analogue scale of more than 3. Anterior or retropatellar knee pain from at least 2 of the following Activities : (1) prolonged sitting; (2) stair climbing; (3) squatting; (4) running; (5) kneeling; and (6) hopping/jumping.
2383409|NCT03685799||DHG on Barrett's esophagus|patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
2383410|NCT03685786|Experimental|Experimental: CART19 cell and auto-HSCT|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
3142724|NCT00003167|Experimental|Treatment (adenovirus p53)|"Group 1 patients receive adenovirus p53 (Ad-p53) intravesically on days 1 and 4. Treatment continues every 4 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3 patients in group 1 receive escalating doses of Ad-p53. In the absence of grade 3 or worse toxicity in the first 3 patients treated, subsequent cohorts of 3 patients each receive escalating doses of Ad-p53 on the same schedule. If 1 of 3 patients experiences grade 3 toxicity, an additional 3 patients are treated at that dose level and dose escalation continues. If 1 of 3 patients experience grade 4 toxicity or 2 of 3 patients experience grade 3 toxicity, dose escalation ceases and the MTD is defined as the previous dose level. Group 2 patients receive Ad-p53 at the MTD on days 1-4, and group 3 patients receive Ad-p53 at the MTD on days 1-4 and 8-11."
3150835|NCT00212030|Active Comparator|1|
3150836|NCT00212030|Placebo Comparator|2|
3150837|NCT00212056|Active Comparator|ANP|
3150838|NCT00212056|Placebo Comparator|Control|
2383423|NCT03685760|Experimental|Reiki|Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
2383424|NCT03685760|Sham Comparator|Sham Reiki|Sham Reiki will be administered for 5 consecutive days even if the subject is transferred to the floor from the ICU. Thirty minutes before and after the daily sham Reiki, session, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data.
2383425|NCT03685760|No Intervention|Usual Care|Twice per day, 30 minutes apart, the bedside nurse will obtain a set of baseline vital signs (heart rate, respiratory rate, blood pressure; non-invasively) for safety monitoring data. Usual care will also involve a 5-day period.
2430321|NCT03364790|No Intervention|group4|participant without operation
2383426|NCT03685747|Experimental|Vancomycin|A single 20 mg/kg intraperitoneal dose in 1-liter of 7.5% icodextrin solution of vancomycin will be administered. Sparse blood sampling will be obtained during an overnight 12-hour dwell and during the exchange period.
3142725|NCT00003170|Experimental|glutamine|Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
3142726|NCT00003170|Placebo Comparator|placebo|Beginning the first or second day of radiotherapy, patients receive placebo twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
3142727|NCT00003178|Experimental|1st Untreated Relapse for AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
2383431|NCT03685695|Experimental|Supportive care (physical activity)|Participants wear Fitbit Charge 2 to monitor physical activity for 3 courses (9-12 weeks). Participants then increase their activity minutes to 30 minutes, 5 times a week or by 30% for 6 additional months.
2383432|NCT03685682|Experimental|VZV seronegative Transplant Patients|recombinant subunit Herpes zoster vaccine
2383433|NCT03685669||Lung nodule group|
2383434|NCT03685669||Healthy Control group|
2383435|NCT03685656|Experimental|ANACA3|ANACA3 slimming gel
2383436|NCT03685656|Placebo Comparator|Placebo|Slimming gel contening no active ingredient
3188968|NCT00772616|Experimental|1|Patients will receive propofol and remifentanil automatically administered (closed-loop administration using bispectral index as the single input for the controller).
3188969|NCT00772616|Active Comparator|2|Patients will receive propofol automatically administered (closed-loop administration using bispectral index as the single input for the controller) and sufentanil according to usual criteria
2383439|NCT03685630|Experimental|Brivaracetam|Subjects in this arm will receive open-label Brivaracetam.
2383440|NCT03685617|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
2383441|NCT03685617|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
2383442|NCT03685604|Active Comparator|Cardiothoracic surgery - PI disinfection|
2383443|NCT03685604|Active Comparator|Cardiothoracic surgery - CHX disinfection|
2383444|NCT03685604|Active Comparator|Abdominal surgery - PI disinfection|
2383445|NCT03685604|Active Comparator|Abdominal surgery - CHX disinfection|
3142728|NCT00003178|Experimental|Primary Refractory AML|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
2383462|NCT03685565|Experimental|Dermabond with underlying steristrips|
2383463|NCT03685565|Active Comparator|Dermabond|
2383464|NCT03685552|Experimental|Prog: Purify-2|All subjects will be participating in a diet life style modification program (High Phytopro dietary program) ( a modified Mediterranean style low glycemic load food plan) and will be receiving a supportive nutritional supplements over a 4 week period.
2383465|NCT03685539|Experimental|Diagnostic (DECT)|Within 7 days before the standard Gamma Knife MRI, patients undergo DECT scan over 6 seconds at 1.5, 5, 10, and 20 minutes after receiving the contrast agent.
2383466|NCT03685526|Experimental|Interventional arm|Patients will be treated with Cinenses Lung Volume Reduction Reverser System.
2383467|NCT03685513|Active Comparator|Metal ceramic single posterior crowns|Metal copings veneered with feldspathic porcelain
2383468|NCT03685513|Experimental|BioHPP PEEK-based single posterior crowns|BioHPP PEEK copings veneered with composite resin
2383469|NCT03685500|Active Comparator|Arm 1|Patients who postpone switching from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) four weeks
2383470|NCT03685500|Experimental|Arm 2|Patients who switch from ABC/3TC/DTG to Symtuza® (TAF/FTC/DRV/c) during the baseline visit
2383471|NCT03685487||patients with failures of decolonization S. aureus|patients with failures of decolonization S. aureus in their nose
2383472|NCT03685474|Experimental|Facing Your Fears-School Based (FYF-SB)|This group will receive the Facing Your Fears - School Based intervention during the fall semester
2383473|NCT03685474|Active Comparator|Usual Care (UC)|This group will receive usual care of anxiety treatment during the fall semester, but will be in the FYF-SB arm the following spring semester.
2431297|NCT03357718|Active Comparator|Midazolam|0.5 mg/kg dormicum
2383474|NCT03685461|Other|Arm 1: Audible ECochG Response Off|Arm 1: Audible ECochG Response Off This condition is identical to the current standard-of-care for conventional CI surgery used worldwide. The surgeon will perform his or her electrode insertion without ECochG monitoring. Minute manipulations of the electrode are a normal part of conventional electrode insertion; manipulations such as redirecting the insertion vector or slowing down insertion speed will be made, as deemed necessary by the surgeon. A full electrode insertion will be performed, as appropriate. The ECochG responses will be recorded, but the surgeon will be blinded to this information during surgery.
2383475|NCT03685461|Experimental|Arm 2: Audible ECochG Response On|This condition will have the audible ECochG response on and available to the surgeon. In this condition, the surgeon perform a conventional electrode insertion while listening to the running ECochG signal for drop in amplitude (suggesting impending trauma). If no drop is detected, insertion will proceed to the full electrode length according to the standard-of-care. If an ECochG amplitude drop is observed, the surgeon will place this observation in its clinical context and evaluate insertion parameters, (i.e., insertion vector, insertion speed, etc.), customary practice with conventional CI surgery, but here supplemented by the ECochG response. In the case of an ECochG amplitude drop that does not recover, the standard-of-care practice of achieving a full electrode insertion will be followed.
2383476|NCT03685448|Experimental|Experimental: Cabozantonib|Cabozantinib 60 mg/day for up to 12 cycles (one cycle is 28 days), taken orally
2383477|NCT03685435||Non-fasting patients|We will examine non-fasting patients using bedside ultrasound. First we examine the gaster in a supine position. Then we repeat the procedure in a right lateral position.
2383478|NCT03685422|Experimental|Virtual Reality|Patient will be given a Samsung Gear VR3 headset fitted with a smartphone. She will choose the desired playlist on calming scenario and experience the Virtual Reality (VR) for about 10 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Patient will be asked on their satisfaction on the VR experience after the intervention. Questionnaires will be conducted during this period. During and after the gynecologic surgery, baseline demographic data and analgesia usage will be recorded. Patient will be sent to the recovery room after the surgery, and the study team members will collect their questionnaire scorings. All the headsets will be disinfected following the hospital's infection control guideline.
2383479|NCT03685409|Active Comparator|Metformin-Group|Metformin hydrochloride tablets 500 mg taken orally once daily for 3 months
2383480|NCT03685409|Placebo Comparator|Placebo-Group|Starch placebo tablets taken orally once daily for 3 months
2383483|NCT03685383|Experimental|intervention group: eCPR + CytoSorb|In addition to standard treatment in patients undergoing eCPR in the intervention group the CytoSorb removal column will be added to the ECLS-system (intervention: CytoSorb removal column in eCPR).
2383484|NCT03685383|Active Comparator|control group: eCPR - CytoSorb|Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
2383485|NCT03685370|Active Comparator|LOS group|Patients randomized to recieve epidural catheter placement with LOS technique, without any Rx control
2383486|NCT03685370|Experimental|X-ray group|Patients randomized for X-ray placement of epidural catheter
2383487|NCT03685357||Idiopathic Parkinson's|"Oral glucose tolerance test~The Unified Parkinson's Disease Rating Scale (UDPRS)."
2383488|NCT03685357||Diabetics receive sulphonylurea group|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
2383489|NCT03685357||Diabetics on sulphonylurea and metformin|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score"
2383490|NCT03685357||Healthy|"Record RBDSQ (Rapid eye movement Sleep Behavior Disorder Screening Questionnaire) total score~Oral glucose tolerance test"
3150839|NCT00212095|Experimental|docetaxel and ketoconazole|
2383492|NCT03685331|Experimental|Phase I Level 0|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1"
2383493|NCT03685331|Experimental|Phase I Level 1|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
2383494|NCT03685331|Experimental|Phase I Level 2|"(28-day cycle)~Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
2383495|NCT03685331|Experimental|Phase II|"(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21~Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal."
2383496|NCT03685318|Active Comparator|Conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo for two weeks. The conventional mouthguard is designed with the palatal margin at 6 mm from the cervical line.
2383571|NCT03684811|Experimental|Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)|
2383572|NCT03684811|Experimental|Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)|
3150840|NCT00212108|Experimental|Celecoxib and ZD1839|Celecoxib and ZD1839 will be given twice a day and daily respectively for two consecutive weeks prior to further anti-cancer treatment.
3150841|NCT00212121|Active Comparator|1|low dose boost (16 Gy)
3150842|NCT00212121|Experimental|2|high boost (26 Gy)
3150843|NCT00212147|Active Comparator|I|General anesthesia that includes nitrous oxide
3150844|NCT00212147|Active Comparator|II|General anesthesia not including nitrous oxide
3150845|NCT00212160|Experimental|RYGB with omentectomy|Subjects undergoing RYGB will be randomized to also have the greater omentum removed at the time of surgery.
2383497|NCT03685318|Active Comparator|Shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo for two weeks. The shortened mouthguard is designed with the palatal margin at 2 mm from the cervical line.
2383498|NCT03685305|Experimental|Hypocaloric diet with hunger reduction strategy|Participants will be prescribed a hypocaloric diet with additional instructions to promote hunger reduction. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
2383499|NCT03685305|Active Comparator|Hypocaloric diet without hunger reduction strategy|Participants will only be prescribed a hypocaloric diet. The hypocaloric diet will range 1200-1500 kcal/d, and will be based upon the 2015 US Dietary Guidelines for Americans. Dietary instructions will be provided by a Registered Dietitian.
2383500|NCT03685292||Group A|Subject(s): A Subgroup
2383501|NCT03685292||Group B|Subject(s): B Subgroup
2383502|NCT03685292||Group C|Subject(s): C Sub Group
2383503|NCT03685279|Experimental|NHA Group|"Six-week, online intervention with weekly, sequential, content knowledge and skills practice. Each week included recorded, slide presentations (narrated by the developer of the NHA, Howard Glasser); readings from The Transforming the Intense Child Workbook by Howard Glasser with Melissa Lowenstein; participants' skills practice, web postings, and live sessions with Howard Glasser and Advanced NHA Trainers."
2383504|NCT03685279|Other|Control Group|The Control Group received the same intervention after the collection of NHA Group post-intervention surveys.
2383505|NCT03685266||Pediatric Residents|Participating pediatric residents from first postgraduate year (PGY-1) through third postgraduate year (PGY-3) will be observed over a 12 month timeframe.
2383506|NCT03685253|Placebo Comparator|Placebo|Participants randomized to placebo will take 2 capsules by mouth twice a day for 6 months. The placebo capsules are matched to the NR capsules.
2383507|NCT03685253|Experimental|Niagen®|Participants randomized to Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will take 250 mg capsules. Participants will take 2 capsules by mouth twice a day (1000 mg) for 6 months
2383508|NCT03685240|Experimental|Intervention|AI-enabled camera fall detection with Human-in-the-Loop (HIP) review
2383509|NCT03685240|No Intervention|Control|No camera detection
2383510|NCT03685227|No Intervention|Control|Participant will lie quietly for 90 minutes. They will be allowed to sleep.
2383511|NCT03685227|Experimental|Yoga Nidra|Participant will practice yoga nidra (using a recording) during the first 30 minutes of the 90 minute measurement period. Then they will be allowed to sleep.
2383512|NCT03685214|Experimental|0.9% saline|We use 0.9% saline for resuscitation fluid in ICU septic patients
2383513|NCT03685214|Experimental|Balanced Crystalloids|We use acetated Ringer's solution for resuscitation fluid in ICU septic patients
2383514|NCT03685201|Active Comparator|Orange Juice1|100% orange juice
2383515|NCT03685201|Experimental|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
2383516|NCT03685201|Placebo Comparator|Raw Orange|raw orange
2383517|NCT03685188|Experimental|Oxycodone group|PCIA is formulated at 0.4 mg/ml of oxycodone.
2383518|NCT03685188|Active Comparator|Sufentanil group|PCIA is formulated at 2 μg/ml of sufentanil.
3150846|NCT00212160|No Intervention|RYGB without omentectomy|Subjects undergoing RYGB will be randomized to NOT have the greater omentum removed at the time of surgery.
3150847|NCT00212160|No Intervention|Normal body weight|Healthy normal weight subjects studied via hyperinsulinemic-euglycemic clamp to obtain reference values for insulin sensitivity and other metabolic parameters.
2383521|NCT03685149|Active Comparator|Flecainide|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
2383522|NCT03685149|Placebo Comparator|Placebo|The same subjects will be treated in a random order with flecainide or placebo for 4 weeks each with 1 week washout between crossover periods.
2383523|NCT03685123|Experimental|PA-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the minimum physical activity recommendations
2383524|NCT03685123|Experimental|WM-REC|This group will participate in an OPTIFAST weight loss program. After achieving clinically significant weight loss, participants will exercise at the weight maintenance recommendations
2383525|NCT03685110||CoreHip|Clinical and Radiological Data of 300 patients of a Standard Patient Population, who are treated with CoreHip Total Hip Arthroplasty for Indications according to the Instructions for Use (IfU) with a five year follow Up
2383526|NCT03685097||Cardiac surgery patients|Patients undergoing elective cardiac surgery requiring cardiopulmonary bypass.
2383527|NCT03685084|Placebo Comparator|0.9% saline infusion|Saline 0.9% infusion
2383528|NCT03685084|Experimental|AAI101 i.v.|"600 mg, 1g, 2g, 4g, 1g q6h, 2g q6h.~Drug-Drug Interaction:~Sequence 1 = piperacillin 4 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v. - cefepime 2 g i.v. - AAI101 2 g + cefepime 2 g i.v.~Sequence 2 = cefepime 2 g i.v. - piperacillin 4 g i.v. - AAI101 2 g + cefepime 2 g i.v. - AAI101 2 g i.v. - AAI101 2 g + piperacillin 4 g i.v."
2383529|NCT03685084|Experimental|Piperacillin i.v.|Piperacillin 3 g
2383530|NCT03685084|Experimental|Cefepime i.v.|Cefepime 1 g
2383531|NCT03685058|Active Comparator|The control group|A total of 88 non-cavitated proximal carious lesions treated with standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish (Vanish 5% Sodium Fluoride White Varnish with Tri-Calcium Phosphate, 3M ESPE, St. Paul, MN, U.S.A.), oral hygiene instruction, and dietary counseling applied at initial, six-months follow-up, and 12-months follow-up visits.
2383532|NCT03685058|Experimental|The test group|Intervention: A total of 88 non-cavitated proximal carious lesions treated with light curable resin modified glass ionomer varnish (Vanish™ XT Extended Contact Varnish, 3M ESPE, St. Paul, MN, U.S.A.) at initial and six-months follow-up visits. In addition to, standard-of-care preventive measures, applied at initial, six-months follow-up, and 12-months follow-up visits.
2383533|NCT03685045|Experimental|Campaign Days|All participants have the intervention of the campaign days which include hepatitis C screening, fibroscans and clinical assessments.
2383573|NCT03684811|Experimental|Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)|
2383574|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 2b)|
2383534|NCT03685032|Experimental|The study group (Gr. D)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. D was administered 4 mg of dexamethasone in 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. D received ondansetron 4 mg in 2 ml iv."
2383535|NCT03685032|Placebo Comparator|the control group (Gr. N)|"After patients received general anesthesia, a sequentially numbered opaque sealed envelope was opened. Gr. N received normal saline 1 ml iv.~At the end of the operation when suturing the dura mater, Gr. N received normal saline 2 ml iv."
2383536|NCT03685019|Experimental|Valgus stress - lateral compartment|Valgus stress radiograph. Joint space width measured in lateral compartment.
2383537|NCT03685019|Experimental|Varus stress - medial compartment|Varus stress radiograph. Joint space width measured in medial compartment.
2383538|NCT03685019|Experimental|0 degree flexion - medial compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
2383539|NCT03685019|Experimental|0 degree flexion - lateral compartment|0 degree flexion radiograph. Joint space width measured in medial compartment.
2383540|NCT03685019|Experimental|20 degree flexion - medial compartment|20 degree flexion radiograph. Joint space width measured in medial compartment.
2383541|NCT03685019|Experimental|20 degree flexion - lateral compartment|20 degree flexion radiograph. Joint space width measured in lateral compartment.
2383542|NCT03685019|Experimental|45 degree flexion - medial compartment|45 degree flexion radiograph. Joint space width measured in medial compartment.
2383543|NCT03685019|Experimental|45 degree flexion - lateral compartment|45 degree flexion radiograph. Joint space width measured in lateral compartment.
2383544|NCT03684993|Experimental|Arabic gum extract|natural product Arabic gum (acacia gum) prepared as a mouthwash
2383545|NCT03684993|Experimental|Licorice root extract|natural product Licorice (Glycyrrhiza Glabra) root extract prepared as a mouthwash
2383546|NCT03684993|Active Comparator|Chlorhexidine|chemical agent Chlorhexidine as a mouthwash
2383547|NCT03684980|Experimental|Arm A - Rituximab + MTX|Patients will receive rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort A) will receive MTX 3 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
2383548|NCT03684980|Experimental|Arm B - Rituximab + MTX|Patients will receive up to 8 cycles of treatment consisting of rituximab Day 1 (+/- 7 days) and MTX Day 2 (+/- 7 days) as per standard of care. Voraxaze will be administered each cycle 24 hours (+/- 2 h) after start of MTX infusion. Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8. Patients will be treated with rituximab 500 mg/m^2. (Cohort B) will receive MTX 8 g/m2. Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
2383549|NCT03684980|Experimental|Arm C - HD-MTX|In Arm COVID-19, the primary endpoint is HD-MTX levels <100 nmol/L 48 hours post-MTX administration. This will be determined via mass spectrometry/HPLC drawn 48 hours after start of MTX infusion +/- 2 hours.
2383550|NCT03684980|Experimental|Arm D - MTX + Voraxaze|Participants will receive MTX 3.5 g/m2 followed by reduced-dose Voraxaze (2000u, determined in Arm A). MTX will be administered in both the inpatient and outpatient settings.
2383551|NCT03684967|Experimental|fruquintinib|Fruquintinib treatment: administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.
2383552|NCT03684954|Other|Used of PRF in clsed sinus lifting|Used of PRF in closed sinus lifting with implant placement
2383553|NCT03684954|No Intervention|Closed sinus with xenograft|used of xenograft in closed sinus lift with implant placement.
2383554|NCT03684941|Experimental|Treatment Period One|LoFric, hydrophilic urinary catheter for single use. The study device is based on commercially available hydrophilic urinary catheters for intermittent catheterization, but with a different coating process than the comparator. Treatment Period One will last 1 week.
2383555|NCT03684941|Active Comparator|Treatment Period Two|CE-marked LoFric®, hydrophilic urinary catheter for single use. The comparator product is today commercially available and produced by WHC. Treatment Period Two will last 1 week.
2383558|NCT03684915|Experimental|rotary files|"Pre-operative radiograph showing all roots and their apices.~Local anaesthetic (to enable use of rubber dam clamp).~Rubber dam isolation.~Removal of caries.~Removal of roof of pulp chamber.~Removal of any remains of coronal pulp tissue with sharp sterile excavator or large bur in slow hand piece.~Identify root canals.~Irrigate with normal saline (0.9%)~Estimate working lengths of root canals keeping 2 mm short of the radiographic apex.~Insert rotary files into canals and debride the canals lightly and gently.~Irrigate the root canals.~Dry canals with pre-measured paper points, keeping 2 mm from root apices.~Canals will be dried with paper points, obturated by injecting Metapex. (Meta Biomed - Metapex Root Canal Filling Material)~Stainless steel crown will be performed"
2383559|NCT03684915|Active Comparator|manual files|All steps as that of intervention group are to be followed except step (j) instead of it; a manual files will be inserted into the canals for debridement lightly and gently
2383560|NCT03684902|Experimental|xpolration|women who underwent emergency midline laprotomy
2383561|NCT03684889|Experimental|SCRI-huCAR19v2|Patients will receive SCRI-huCAR19v2 in either Phase 1 or Phase II
2383562|NCT03684889|Experimental|SCRI-huCAR19v1 - [CLOSED]|Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
2383563|NCT03684863|No Intervention|Standard therapy|
2383564|NCT03684863|Experimental|capecitabine|
2383565|NCT03684850|Active Comparator|Exercise therapy group|(n = 40)
2383566|NCT03684850|Experimental|Knee brace and exercise group|(n = 40)
2383567|NCT03684850|Experimental|Footwear device group|(n = 40)
2383568|NCT03684837|Active Comparator|D vitamine|a dose for week
2383569|NCT03684837|Placebo Comparator|D vitamine placebo|a dose for week
2383575|NCT03684811|Experimental|Phase 1b and 2 Cohort Combination (Cohort 4b)|
2383576|NCT03684798|Experimental|Mental Contrasting with Implementation Intentions (MCII)|"Mental Contrasting with Implementation Intentions (MCII) combines two methods: Mental Contrasting and Implementation Intentions.~Mental Contrasting (MC) consists of imaging a desired future and comparing it with obstacles of the present reality (Oettingen, 2000, 2014; Oettingen, Pak, & Schnetter, 2001) in order to increase goal commitment when expectations of success are high (Gollwitzer, 2014). Implementation Intentions on the other hand specify when, where, and how to strive for a goal in form of an if-then-plan, e.g. If situation Y is encountered, then I will perform the goal-directed response Z (Gollwitzer, 2014; Wieber, Thürmer, & Gollwitzer, 2015)."
2383577|NCT03684798|Active Comparator|Treatment as usual|The control group receive a control training, which consists of an exercise from treatment as usual. Thus, patients in the control group are supported in their intention for abstinence and in the reappraisal of risk situations and relapse, while no individual motivational strategies are planned or provided
3142729|NCT00003178|Experimental|MDS|Patients receive idarubicin IV over 15 minutes on days 1-3, cladribine IV over 2 hours on days 1-5, and filgrastim (G-CSF) subcutaneously beginning on day 6 and continuing until blood counts have recovered for 2 days. Treatment repeats every 3 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response after completion of course 1 may proceed to other chemotherapy or bone marrow transplantation at the discretion of the protocol investigator. Patients with extramedullary disease may receive intrathecal chemotherapy or radiotherapy to symptomatic sites.
3142730|NCT00003190|Experimental|Arm I (cytarabine, daunorubicin, etoposide)|Patients receive cytarabine IV continuously over 7 days and daunorubicin IV bolus followed by etoposide IV over 2 hours on days 1-3.
3142731|NCT00003190|Experimental|Arm II (valspodar, daunorubicin, etoposide, cytarabine)|"Patients receive treatment as in arm I with the addition of PSC 833 induction. A loading dose of PSC 833 IV is given over 2 hours, followed by a 74-hour continuous infusion of PSC 833 beginning 2 hours before daunorubicin and etoposide. Patients may receive a second induction course if residual leukemia is present in the bone marrow. Patients who experience a CR and meet certain other criteria receive postremission chemotherapy consisting of cytarabine IV continuously over 5 days plus daunorubicin IV followed by etoposide IV over 2 hours on days 1 and 2. Patients who are randomized to receive PSC 833 during induction chemotherapy receive a loading dose of PSC 833 before beginning a 48-hour continuous infusion of PSC 833 concurrently with cytarabine/daunorubicin/etoposide postremission chemotherapy.~After completing postremission chemotherapy, patients are randomized to a no further treatment group or IL-2 immunotherapy."
3142732|NCT00003191|Experimental|Arm I|Patients receive oral fenretinide 3 times a day on days 1-7. Treatment repeats every 3 weeks for up to 8 courses. Patients may receive an additional 22 courses of therapy in the presence of stable or responding residual tumor. Patients with recurrent neuroblastoma, after prior myeloablative therapy with no measurable disease, will stop treatment after 8 courses. Cohorts of 3-6 patients receive escalating doses of fenretinide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
3142733|NCT00003192|Experimental|Arm A|9-aminocamptothecin (25 mcg/m2/hr x 120hrs, days 1-5 and 8-12 of each 3 week cycle)
3142734|NCT00003193|Experimental|Paclitaxel, amifostine, RT|Dose-escalation arm for paclitaxel with amifostine and RT.
3142735|NCT00003196|Experimental|Treatment (irradiation, transplant, immunosuppression, DLI)|"CYTOREDUCTION: If necessary, patients with advanced malignancies undergo cytoreductive chemotherapy to reduce tumor size at discretion of primary physician and study investigators.~CONDITIONING REGIMEN: Patients undergo low-dose total-body irradiation followed by allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 to 0 and then PO BID on days 1-35 with taper to day 56. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST-TRANSPLANT DLI: Patients with mixed chimerism on day 56 and no evidence of GVHD undergo DLI over 30 minutes on day 65 and may receive up to 3 additional infusions in the absence of GVHD and disease progression or persistence. Patients who have not achieved mixed chimerism at day 56 undergo DLI if complete response is not obtained after a 2 month monitoring period."
2383585|NCT03684772|Experimental|ICVT|Digoxin and Furosemide (0.125%)
2383586|NCT03684772|Experimental|Furosemide|Furosemide (0.125%)
2383587|NCT03684772|Experimental|Digoxin|Digoxin (0.125%)
2383588|NCT03684772|Placebo Comparator|Placebo|Vehicle Gel
2383589|NCT03684746||Medial Experts|Including doctors- surgeons - consultants
2383590|NCT03684746||Care specialist|including nurses - before/after care staff
2383591|NCT03684733||Arm 1: Cohort 1 - Retrospective Analysis|Participants attending MRI & XRM for a clinical indication with at least one normal breast
2383592|NCT03684733||Arm 2: Cohort 2 - Retrospective Analysis|"BRCA1 or BRCA2 mutation carriers attending MRI & XRM for breast screening:~Genetic risk of breast cancer"
2383593|NCT03684733||Arm 2: Cohort 3 - Retrospective Analysis|"Participants attending MRI & XRM for breast screening post mantle radiotherapy:~Environmental risk of breast cancer"
2383594|NCT03684733||Arm 2: Cohort 4 - Prospective|"General population attending XRM for breast investigation:~Population risk of breast cancer MRI"
2383595|NCT03684720|Experimental|Discover followed by direct instruction [DD]|The intervention group which will be taught suturing using guided-discovery-learning
2383596|NCT03684720|No Intervention|Instruction followed by practice [IP]|The control group which will be taught suturing using traditional instructional teaching.
2383597|NCT03684707|Active Comparator|Metformin Hcl 500Mg 24Hr Sa Tab|Metformin Hcl 500Mg 24Hr Sa Tab drug is given to the patient
2383598|NCT03684707|Placebo Comparator|control|starch tablets
3142736|NCT00003200|Experimental|Taxotere|"After the screening procedures confirm participation in the research study:~Taxotere-Administered weekly for 1 hour (6 doses)~Radiation Therapy (XRT) -5 days a week for 6 weeks~Exam under anesthesia~Neck Dissection (if indicated)"
2383603|NCT03684681|Other|Peer Navigator|Current standard of care
2383604|NCT03684681|Other|Social Worker|Current standard of care
2383605|NCT03684668|Experimental|Psychoeducational intervention|The psychoeducational intervention, with the use of meta-universes,consists of three sessions in which techniques based on three of the four sources of self-efficacy described are applied.
2384050|NCT03681795|Experimental|patient|patients with Gilles de la Tourette syndrome
2383606|NCT03684668|No Intervention|Control|The control arm will not receive the psychoeducational intervention. Students in this group will complete the questionnaires before the beginning of the intervention and after its end.
2383607|NCT03684655|Experimental|[18F]F-AraG|"radiofluorinated imaging agent, [18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)~Trade name: VisAcT"
3150848|NCT00212160|No Intervention|Tissue samples|Tissue samples (omental fat, subcutaneous fat, muscle,and blood)are obtained from subjects of varying weights during abdominal surgery in order to compare various parameters, including inflammation, oxidative stress, and gene expression, among tissues across weight classes.
3150849|NCT00212212|Experimental|1|200 µg selenium as selenate
2383611|NCT03684629|Experimental|the response of KPI and corresponding suggestion|The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month. The multifaceted quality improvement interventions include: 1) implementation of standardized templates of medical record, evidence-based clinical pathway, and written care protocols; 2) feedback system of performance measures; 3) expert online consultation.
2383612|NCT03684629|No Intervention|a control arm|The control group indicated that the hospitals will not be provided with the multifaceted quality improvement interventions. They just provide patients with routine care.
2383613|NCT03684616||Statin treatment prior to cardiac arrest|
2383614|NCT03684616||No Statin treatment prior to cardiac arrest|
2383615|NCT03684603|Active Comparator|Acoustic cueing|The melody will be played during training and during slow wave sleep.
2383616|NCT03684603|Sham Comparator|Control|The melody will be played during training.
2383617|NCT03684590|Active Comparator|Standard opioid administration|Intraoperative opioid will be administered by guiding standard practice
2383618|NCT03684590|Experimental|ANI-guided opioid administration|Intraoperative opioid will be administered based on the analgesia nociceptive index (ANI)
2383619|NCT03684577|Experimental|Hypnotherapy for Agoraphobia|A total of 8-12 individual sessions of hypnotherapy over 12 weeks will be delivered. Hypnotherapy consists of hypnotic activation and reinforcement of the patient's own resources, the use of relevant positive and negative experiences from the biography, and the development of positive solution imagery. The central technique is the work with a symptom regression and the resolution of old and actual experiences. Furthermore, formal trance induction, utilisation techniques, indirect techniques such as the use of metaphors or the representative technique, or work with time progression will be used.
2383620|NCT03684577|No Intervention|Wait-list control group|Patients in the wait-list control group will receive 8-12 sessions of individual hypnotherapy after a waiting period for 12 weeks.
2383621|NCT03684564|Experimental|Rivaroxaban (Treatment Arm)|
2383622|NCT03684564|Active Comparator|Warfarin (Control Arm)|
2383623|NCT03684551|Active Comparator|No dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. The supervisory feedback session for CHWs in the control arm was not facilitated by a visual Dashboard tool or any personalised quantitative feedback on quantity, speed, or quality of care. CHW supervisors were instructed to continue providing CHWs in the control arm with feedback informed by patient perspectives and direct observation during the individual supervision visit.
2383624|NCT03684551|Experimental|Dashboard supervision tool|CHWs received monthly individual supervision from a dedicated CHW supervisor. For CHWs randomised to the intervention arm, a visual feedback tool, the CHW Performance Dashboard, was employed during individual supervision, starting in January 2016. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month. The feedback provided to CHWs in the intervention arm, therefore, was both quantitative, informed by the Dashboard, and qualitative, informed by patient perspectives and direct observation of CHW service provision during the individual supervision visit.
2383625|NCT03684538|Experimental|Group Probiotics|Patients in this group will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive probiotics (Saccharomyces boulardii) one dose per day.
2383626|NCT03684538|Experimental|Group Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
2383627|NCT03684538|Active Comparator|Group Probiotics & Zinc|Patients will be given the standard of care (initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified). In addition to that, the patients in this group will receive a combination of probiotics (Saccharomyces boulardii) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day.
2383628|NCT03684525|Experimental|Extraction of primary canines only|"A total of 43 patients with unilateral mesioangular displaced maxillary canines Interceptive treatment: Extraction of both maxillary primary canines will be held at baseline visit At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
2383629|NCT03684525|No Intervention|Control group- no extraction|"A total of 43 patients with unilateral mesioangular displaced maxillary canines At Baseline (T0): Clinical examinatiion + CBCT scan , no extraction At 6 month follow-up (T1): Clinical examination At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
2384051|NCT03681795|Experimental|Control|healthy control
2383630|NCT03684512|Experimental|Adolescent Only|Remote based physical activity intervention delivered to adolescents only. Adolescents will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity.
2383631|NCT03684512|Active Comparator|Adolescent and Parent|Remote based physical activity intervention delivered to adolescents and their parent. Adolescents and a parent will be asked to attend weekly group exercise sessions, individual support sessions, and monitor their daily physical activity. Parents will have access to a Parent Facebook group.
2383632|NCT03684499|Other|study group (1)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
2383633|NCT03684499|No Intervention|control group( 2)|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
2383634|NCT03684486|Experimental|rehabilitation by effort|8 sessions of rehabilitation by effort in sports medicine
2383635|NCT03684473|Experimental|Yoga Intervention|Participants in the intervention condition will be assigned to an 8-week online delivered trauma-informed yoga protocol focused on home-based daily practice of yoga and mindfulness meditation.
2383636|NCT03684473|No Intervention|Waitlist Control|Participants in the wait list control condition will be invited to attend a 60-minute online mental health education session to learn how to recognize signs and symptoms of PTSD and outline potential strategies to alleviate stress to reduce the risk of heightened severity of mental health challenges. The materials used will be based on the Canadian Mental Health Association resource hub on understanding symptoms of mental illness. All participants in the wait list control condition will be offered the opportunity to participate in the intervention free of charge after completion of the study.
2383637|NCT03684460|Experimental|Bright Light|"Intervention: Daytime Bright Light~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 09:00 to 13:00 starting on study day 2 and continuing through study day 5 or MICU discharge whichever is longer up to 30 days. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor, if the patient is transferred (prior to study day 5). Feasibility metrics will also be collected."
2383638|NCT03684460|Active Comparator|Usual Light|"Intervention: Usual Care~Patients will be eligible if they were admitted within 30 hours of noon on enrollment day (e.g. at or after 06:00 on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise, have usual care."
2383639|NCT03684447|Experimental|Propofol High Dose|high propofol injectable, individually dosed, three times per week
2383640|NCT03684447|Experimental|Propofol Low Dose|low propofol injectable, individually dosed, three times per week
2383641|NCT03684434|Experimental|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
2383642|NCT03684434|Active Comparator|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
2383643|NCT03684421||Long Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Long Antagonist Protocol for COS
2383644|NCT03684421||Classical Antagonist Protocol|Clinical pregnancy rate and live birth rates of patients who followed Classical Antagonist Protocol for COS
2383645|NCT03684408|Other|RFID and Wire Localization|Part A of this project is for physician training to master the technique of RFID placement and retrieval. On the day of surgery prior to going to the operating room, all participants will have the RFID placed first to allow radiologists to become familiar with placement of the RFID localizer. Participants will then immediately undergo wire localization. Either ultrasound or mammogram guidance will be used for the localization at the discretion of the performing radiologist. Surgeons will use a reader to locate the RFID chip during surgery. The wire will be present in the event the area of concern cannot be adequately located with the reader.
2383646|NCT03684408|Experimental|RFID Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
2383647|NCT03684408|Active Comparator|Wire Localization|Participants will be stratified based on technique of localization (either US guidance or mammographic guidance). They will then be randomized to receive either the wire or RFID localization. There will be four visits: one pre-op breast surgery visit in which enrollment will occur, one radiology procedure visit for localization, one surgical visit, and one post-operative visit. This is the same number of visits as standard of care.
2383648|NCT03684395||DOACs (Direct Oral Anticoagulants)|
2383649|NCT03684395||Standard of care|
2383650|NCT03684382|Experimental|NeW-I group|Participants engage in a weekly structured writing task of 15-30 minutes which provides them an opportunity to reflect on the emotional, practical and financial demands of caregiving, and the means to cope with these challenges (week 1), explore avenues where they can seek information and resources for caregiving (week 2), explore the sources of support which they have within their network of family and friends (week 3) and examine how they (and their children) can rise above illness-related challenges and live their lives as fully as possible (week 4). After participants complete their weekly writing task, the written narrative will be reviewed and edited by the therapist within the next 3-4 days. The revised draft will be shared with the participant along with constructive feedback, empathic support and psychoeducation. In week 5, participants will receive a 'legacy' document and engage in a voice call with the therapist to receive psychosocial support and for closure of therapy.
2383651|NCT03684382|No Intervention|Control group|Participants engage in a weekly unstructured writing task of 15-30 minutes with a single open-ended question for each week which allows them to respond in any manner they find acceptable. Simple empathic weekly feedbacks are provided by the therapist to encourage continuous participation. In week 5, a consolidated document that includes all unedited journal writings together with a brief summary statement of appreciation by the therapist will be given to participants to indicate conclusion of participation.
2383652|NCT03684369|Experimental|Augmented TENS|Transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions.
2383653|NCT03684369|Sham Comparator|Sham|Transient (10 s) application of transcutaneous electrical nerve stimulation applied to each leg separately while participants perform steady submaximal contractions .
2383654|NCT03684356|Experimental|experimental|immediate implant with socket shield technique
2383655|NCT03684356|Active Comparator|control|immediate implant placement with filling the buccal gap with xenograft
2383656|NCT03684343|Other|Atopic Dermatitis patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
2383657|NCT03684343|Other|Healthy patients|Filmed consultation with a dermatologist. Laterality and tactile sensitivity test.
2383658|NCT03684330|Active Comparator|Vitamin D supplementation|
2383659|NCT03684330|Placebo Comparator|Vitamin D placebo|
3150850|NCT00212212|Experimental|2|400 µg selenium as selenate
3150851|NCT00212212|Experimental|3|200 µg selenium as selenomethionine
2383662|NCT03684291||Group V|The patients in this group are ventilated using VCV (Volume Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute, I/E ratio: 1/2, PEEP not applied)
2383663|NCT03684291||Group P|The patients in this group are ventilated using PCV-VG (Volume Guaranteed Pressure Control Ventilation) mode (FiO2 50%, Tidal volume: 6-8 ml/kg (ideal body weight), frequency: 12/minute (EtCO2 kept between 35-40 mmHg), Pressure limit: 30 cm H2O, I/E:1/2, PEEP not applied)
2383664|NCT03684278|Active Comparator|Infusion of 5 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 5 mg of Infliximab, per kg of patient body weight.
2383665|NCT03684278|Active Comparator|Infusion of 10 mg/kg Infliximab|Infliximab (Remicade) to be administered as a one time intravenous infusion in 250 ml (500 ml if patient weighs over 100 kg) 0.9% sodium chloride solution over a period of 2 hours. Dosage calculated at 10 mg of Infliximab, per kg of patient body weight.
2383666|NCT03684278|Placebo Comparator|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) 0.9% Sodium Chloride to be administered as a one time intravenous infusion over a period of 2 hours.
2383669|NCT03684252|Other|Control|Treatment as usual
2383670|NCT03684252|Experimental|Intervention|CBT-based intervention
2383671|NCT03684239|Experimental|G-CBT group|G-CBT group has 40 patients, maybe will be divided them into 4 groups. Every group has 8-10 patients. Every group receive 10 times CBT group therapy and 1 times a week for 120 minutes each time.
2383672|NCT03684239|Active Comparator|Conventional treatment group|Conventional treatment group has 40 patients, received routine outpatient treatment. Once every two weeks for 45 minutes each time, including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
2383673|NCT03684213|Active Comparator|Control (Norepinephrine)|Subjects will be administered norepinephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
2383674|NCT03684213|Experimental|Norepinephrine + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
2383675|NCT03684213|Experimental|Norepinephrine + L-NAME|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) at the same rate and for the same time as the control arm.
2383676|NCT03684213|Experimental|Norepinephrine + L-NAME + Ascorbic Acid|Subjects will be coinfused with the same norepinephrine concentrations as the control arm and combined L-NAME (Nω-Nitro-L-arginine methyl ester hydrochloride; 20 mM) and ascorbic acid (Vitamin C; 10 mM) at the same rate and for the same time as the control arm.
3150852|NCT00212212|Placebo Comparator|4|placebo tablet
3150853|NCT00212251|Experimental|Lifestyle counseling|10 ActiveMoms classes, 8 Moms Time Out nutrition classes, 6 coaching calls, supportive materials
3150854|NCT00212303|Experimental|Exercise training|Exercise training, 3 times per week, for 6 months.
3150855|NCT00212303|No Intervention|Control|Usual care no active exercise intervention
3150856|NCT00212342|Experimental|Norethisterone,Ethinylestradiol|
3150857|NCT00212342|Placebo Comparator|Sugar pill|
2383677|NCT03684200|Experimental|Copenhagen adductor exercise|20 players allocated to the Copenhagen adductor exercise group complete a progressive strengthening programme comprising of the Copenhagen adductor exercise over a period of 6 weeks. They will complete two exercise sessions a week consisting of one set of the Copenhagen adductor exercise. The exercise will be performed on each side. The training load will increase from 5 repetitions in week 1, to 15 repetitions in week 6. The exercise programme is performed at the end of the warm-up of a regular football training session.
2383678|NCT03684200|No Intervention|Control|19 players allocated to the control group will be asked not to perform the Copenhagen adductor exercise or any other specific strength training for the adductor muscles and to continue to play football as usual.
2383679|NCT03684187|Experimental|Stress in Control for Healthy Liver (SynC-HL) Intervention:|This mindfulness based intervention to target healthy liver focuses on teaching skills of mindfulness, yoga and self-control to improve lifestyle choices and decision making.
2383680|NCT03684161||Surgically closed VSDs|Patients born with a ventricular septal defect, which have been closed in early childhood.
2383681|NCT03684161||Small, persistent VSDs|Patients born with a small, hemodynamically insignificant ventricular septal defect.
2383682|NCT03684161||Healthy controls|Healthy control subjects.
2383683|NCT03684148|Experimental|Motor imagery practice|In addition to routine physical therapy patients that will be included in the motor imagery practice (MIp) group will receive an additional intervention based on motor imagery beginning immediately after the TKA procedure.
2383684|NCT03684148|No Intervention|Control group|Patients from the control group will underwent the same post-surgery rehabilitation program, but will not be engaged in MI practice.
2383685|NCT03684135|Experimental|Use of cosmetics during chemotherapy and thermal cure|Use of cosmetics during chemotherapy and post-treatment thermal cure
2383686|NCT03684122|Experimental|Injection of Umbilical cord derived MSCs|Allogenic Umbilical Cord derived stem cells injected intravenously to enrolled PD patients
2383687|NCT03684122|Experimental|Injection of MSCs differentiated into neural stem cells NSCs|Allogenic Umbilical Cord derived stem cells (MSCs) differentiated into neural stem cells (NSCs) injected intrathecaly and intravenously to enrolled PD patients.
2383689|NCT03684096|Active Comparator|non-estrogenic pollen extract PCC-100|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
2383690|NCT03684096|Placebo Comparator|placebo|After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
2383691|NCT03684083||Case|patients having received heterologous stem cell transplantation (HSCT)
2383692|NCT03684083||Control|patients without HSCT
2383693|NCT03684070|Experimental|Enhanced Walking|FitBit + Lifestyle counseling/education session(8 weeks) + WeChat motivational messages and peer interaction
2383694|NCT03684070|Active Comparator|Walking Only|FitBit + Lifestyle counseling/education session(8 weeks)
2383695|NCT03684057|Experimental|App-based mindfulness training|The Unwinding Anxiety program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.
2383696|NCT03684057|Other|Wait list control|Individuals in the wait list group will complete the assessments without an intervention. (Note: participants will be transitioned to the Unwinding Anxiety program following the 2-month wait list control)
3183307|NCT00712660|Experimental|A|In the active-ITAREPS group, the e-mail ALERT message feedback to the investigator will be activated. The core study intervention was 20% antipsychotic dose increase within 24 hours in response to a Pharmacological Intervention Requiring Event (PIRE) defined as either: A) the receipt of any INITIAL ALERT (IA) e-mail. A dose increase was obligatory in such cases regardless of the current clinical status of the patient; or B) the receipt of an ALERT EMERGENCY (AE) e-mail after which the investigator confirmed clinical worsening via phone contact with the patient. AE is defined as further worsening in EWSQ scores during 3 week period after announcement of IA.
2383699|NCT03684031|Experimental|Cognitive Control Training|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
2383700|NCT03684031|Sham Comparator|Sham Cognitive Control Training Program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
2383701|NCT03684018|Experimental|IgPro10 (single dose)|
2383702|NCT03684018|Experimental|IgPro10 (multiple dose)|
2383703|NCT03684005|Other|Single-Arm Smartphone App Use|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
2383704|NCT03683992||cemented and cementless Triathlon group|cemented group are patients who get randomized to receive cemented knee implant and Patient randomized to receiving cement less knee implant.
2383705|NCT03683979|Experimental|Interpretation bias modification program|Participants in this arm will complete a computer-based training program two times in the lab. Participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
2383706|NCT03683979|Sham Comparator|Control training program|Participants in this arm will complete a sham training program two times in the lab. The program will look similar in length and design to the experimental training program, but the content of the program will remain affectively neutral. As in the experimental condition, participants will complete the first training session in the lab during their initial visit and they will return to the lab one week later to complete the second session.
2383707|NCT03683953|Placebo Comparator|Placebo|0.9% sodium chloride intratracheal instillate on 14 days after birth
2383708|NCT03683953|Experimental|mesenchymal stem cells|mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg
2383709|NCT03683940|Other|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
2383710|NCT03683927|Experimental|Probiotics|Probiotics consist on Bacillus clausii in a plastic vial that will be administered to the infant 4 times a week
2383711|NCT03683927|Placebo Comparator|Placebo group|Sterile water contained in a plastic vial will be administered to the infant 4 times a week
2383712|NCT03683914|Experimental|dinoprostone arm|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
2383713|NCT03683914|Placebo Comparator|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
3183308|NCT00712660|Placebo Comparator|TAU|In the treatment-as-usual study arm (control, non-active ITAREPS), the e-mail ALERT message feedback will not be activated. In this group, even in the presence of early warning sings, the investigators will be kept blinded to the EWSQ scores, will receive no ALERT message and thus no early pharmacologic intervention based on the ITAREPS program will be prompted. Treatment in the control group will consist of routine clinical and medication management with the frequency of visits common in the outpatient clinical settings. There will be no intevention based on ITAREPS.
2383715|NCT03683888|Experimental|Healthsnap|50 patients will receive HealthSnap assessment in addition to their current treatment regardless of their participation into the study
2383716|NCT03683888|Active Comparator|Diet|50 patients will receive standard of care dietary counselling in addition to their current treatment regardless of their participation into the study
2383717|NCT03683862|Experimental|Thermoplastic Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
2383718|NCT03683862|Active Comparator|Hawley Retainer|Impressions of the upper arch will be taken at the day of bracket debonding and the retainer will be delivered in 24 hours. TheraMon microchip will be embedded within the appliance and patients will be instructed to wear the appliance 24 hours/ day.
2383719|NCT03683849|Experimental|Dancing group|Dance intervention group, inspired by the rhythm of Salsa. Training will be administered for an hour twice a week, for six months.
2383720|NCT03683849|Active Comparator|Strength training group|Strength training group. Training will be administered for an hour twice a week, for six months.
2383721|NCT03683849|No Intervention|Control|Control group
2383722|NCT03683836||Study Group|
2383723|NCT03683823|Experimental|Attention guidance|In addition to the components included in the control intervention the experimental attention guidance condition consists of three unique components: (1) the rationale will include information about the importance of visually attending to the faces of the audience; (2) in addition to being given a speech topic, participants will be given target audience members to focus their gaze on during the speech. They will be told that they should look at and focus on the target audience member for the whole speech; (3) between speeches, the researcher will tell participants the percentage of time they were focused on the target face.
2383724|NCT03683823|Active Comparator|Control intervention|"Participants will complete two intervention sessions within one week. The intervention will use a manualized protocol.~On the first session, participants will receive a brief standardized psychoeducation module, presented via a 15-minute video recording. This video will explain the intervention, its rationale, and the procedure.~Participants will then have 5 minutes to plan and outline a speech based on a topic given to them. All participants will receive the same topic. Participants will not be allowed to use the outline during the public speaking exposure trials.~Participants will then give six speeches that are each 3 minutes long on the same topic. Participants will give all the speeches in the immersive 360º-video environment.~Between speeches participants will have a 1-minute break."
2383725|NCT03683810|Experimental|Lactoferrin|Participants will receive 4gr lactoferrin per day for a duration of 3 months + standard treatment for anemia
2383726|NCT03683810|Active Comparator|Standard treatment|Participants will receive only the standard treatment for anemia
2383727|NCT03683797|Experimental|Post-discharge call|Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
2383728|NCT03683797|No Intervention|No post-discharge call|Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health.
2383729|NCT03683784||Males|Male diabetics or male subjects proved to be diabetics
2383730|NCT03683784||Female|Female diabetics or male subjects proved to be diabetics
3183309|NCT00712686|Active Comparator|A1|
3183310|NCT00712686|Active Comparator|B1|
2383733|NCT03683745||Maryland|Maryland is a county in southeast Liberia. Survey clusters based on catchment populations served by community health volunteers (CHVs) around 24 district health facilities (primary sampling unit). Clusters will constitute ~600 people (~100 households) with population-weighted cluster selection applied. In total, 80 clusters will be required. CHVs would conduct house-to-house visits to develop a full census and listing of all possible cases using broad case definitions. Full details of all potential cases will then be passed to an expert verification team based at the closest health facility. Suspected cases will arrive at the health facility over a 10-day verification period to receive a diagnosis using clinical examination and/or laboratory confirmation.
2383734|NCT03683732||Frenchteenagers|
2431396|NCT03356938|Experimental|Sleep deprivation|
2383740|NCT03683706|Active Comparator|Intervention|Participants in this arm will receive 12 sessions of LTP in My Own Way Plus interventions.
2383741|NCT03683706|No Intervention|Treatment as Usual|Participants in this arm will be getting their usual treatment
2383742|NCT03683693|No Intervention|Standard of Care group|Historical Group = Standard of Care group. Decision for stopping antibiotics taken by ICU physician: assessment on the basis of the clinical picture and traditional inflammatory biomarkers such as crp and leucocytosis
2383743|NCT03683693|Experimental|Procalcitonin group|ICU physician gets on regular base PCT value, what can be used as additive tool in the decision-making for stopping antibiotics.
2383744|NCT03683680|Experimental|MRiS|"The specimens to be collected will include at least five pleural biopsy samples~MPT test and the CLDN15/VIM test will be performed"
2383745|NCT03683667|Placebo Comparator|Placebo & Control|Placebo / Nutrition education
2383746|NCT03683667|Experimental|Placebo & Protein Supplement|Placebo / Protein-rich blended food / Nutrition education
2383747|NCT03683667|Placebo Comparator|Placebo & Isocaloric Supplement|Placebo / Isocaloric blended food / Nutrition education
2383748|NCT03683667|Experimental|Placebo & Egg|Placebo / Egg / Nutrition education
2383749|NCT03683667|Experimental|Azithromycin & Control|Azithromycin / Nutrition education
2383750|NCT03683667|Experimental|Azithromycin & Protein Supplement|Azithromycin / Protein-rich blended food / Nutrition education
2383751|NCT03683667|Experimental|Azithromycin & Isocaloric Supplement|Azithromycin Isocaloric blended food Nutrition education
2383752|NCT03683667|Experimental|Azithromycin and Egg|Azithromycin Egg Nutrition education
2383753|NCT03683641|Active Comparator|Shock Wave group|Applying shock wave to patient's Achilles tendon insertion
2383754|NCT03683641|Sham Comparator|Sham Control group|Applying sham shock wave to patient's Achilles tendon insertion
2383757|NCT03683615|Other|patients with traumatic recent orbital blow out fractures|
2383758|NCT03683602|Experimental|PNF group|PNF techniques, patterns, re-education of postural control, once a day 10 days,
2383759|NCT03683602|Active Comparator|Manual therapy group|traction, joints mobilization, pos-isometric relaxation, once a day 10 days
2383760|NCT03683589||Study group|"Participants will receive deuterated water for 10 days before undergoing bariatric surgery.~Liver biopsy collected, lipids extracted and DNL measured via GC/MS."
2383765|NCT03683563|Active Comparator|4% citrate|dialysis catheter locked with 4% sodium citrate
2383766|NCT03683563|Experimental|30% citrate|dialysis catheter locked with 30% sodium citrate
2383767|NCT03683550|Experimental|SPEC/CT|SLNE with preoperative hybrid SPECT/CT
2383768|NCT03683550|Active Comparator|Standard|Standard SLNE (with planar preoperative lymphoscintigraphy)
2383769|NCT03683537||Delayed Neurocognitive decline|Patients in whom there is Delayed Neurocognitive Recovery (DNR) after surgery, based on neuropsychological tests or clinically. DNR is defined as follow: 1)decrease of scores of neuropsychological test scores for more than 1 standard deviation (SD) of these tests; 2)clinically - inability of patient to perform test after surgery because of neurocognitive impairment.
2383770|NCT03683537||Normal postop neurocognitive function|Patients in whom there is no clinical signs of DNR, defined as in previous group.
2383771|NCT03683524|Experimental|Experimental group|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
2383772|NCT03683524|Active Comparator|Control group|continuation of their current stable ART
2383773|NCT03683498|Experimental|Regulatory T-cell enriched infusion|"Dose escalation sequential cohorts Regulatory T-cell enriched infusion (Cells/kg) will be administered. The cohorts will be dose escalated per the schema below:~Dose-level A: 0.5 x 10ˆ6 Cells/kg Dose-level B: 1 x 10ˆ6 cell/kg Dose-level C: 2 x 10ˆ6 cell/kg"
2383774|NCT03683485|Experimental|long duration EPBD group|Balloon dilation was performed using wire-guided hydrostatic balloon catheters. An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy. Stones were removed by standard techniques, including balloon or basket catheters.
2383775|NCT03683485|Active Comparator|endoscopic sphincterotomy (EST) group|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage. A complete sphincterotomy was defined by the free passage of a fully bowed sphincterotome and the presence of spontaneous bile drainage.
2383776|NCT03683472|No Intervention|Treatment as usual (TAU)|Individuals will receive treatment as usual
2383777|NCT03683472|Active Comparator|TAU and Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety. Together, these help individuals unlearn/extinguish worry at a core mechanistic level."
2383778|NCT03683459|Experimental|interventional arm|Participants will be treated with FemFlow Drug-Eluting Peripheral Balloon Catheter.
2383819|NCT03683147|Experimental|Intervention (online sessions, content manual, relaxation CD)|Participants receive online group sessions over 60 minutes for 6 weeks, including 15 minutes of practice on that session's topic and daily meditation or yoga for 45 minutes. At the conclusion of the study period participants participate in mindfulness meditation over 3 hours. Participants also receive a content manual and relaxation CD.
2383779|NCT03683446||Laparoscopic Rectal Surgery|A minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon. For abdominal entry, at the beginning of the procedure, the abdomen is inflated with carbon dioxide gas to provide a working and viewing space for the surgeon. For both, the laparoscope transmits images from the abdominal cavity or anus to high-resolution video monitors to allow the surgeon detailed images of the abdomen on the monitor.
2383780|NCT03683446||Open Rectal Surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
2383781|NCT03683433|Experimental|Treatment (azacitidine, enasidenib mesylate)|Patients receive azacitidine SC or IV over 30 minutes on days 1-7 and enasidenib mesylate PO QD beginning on day 1. Cycles repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
2383782|NCT03683420|Experimental|Group I (music)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. The study consists of a presurvey, active listening period, and a post-survey.
2383783|NCT03683420|No Intervention|Group II (control)|The intervention is a behavioral intervention, which consists of giving patients and caregivers iPods to listen to music for up to 60 minutes while the patient is receiving a chemo infusion. Participants and caregivers in the control condition complete a presurvey and post survey but do not listen to music during infusion session .
2383784|NCT03683407||Chemotherapy Group|All participants are advanced NSCLC without druggable gene mutation (EGFR, ALK, ROS-1, Met, Ret. BRAF, etc), who would receive platinum-based chemotherapy.
2383785|NCT03683394|Active Comparator|SMARRT Intervention|The SMARRT intervention team will use a standardized procedure to develop an individualized Alzheimer's risk profile for each participant randomized to the SMARRT intervention arm. Participants will then meet in-person with an interventionist to review their risk profile and develop an initial personalized risk reduction action plan. For the few participants enrolled during COVID, initial interventionist visits were conducted by phone. Targeted areas will include: increasing physical, mental and social activities; quitting smoking; healthy diet; controlling cardiovascular risk factors (diabetes, hypertension), including avoiding hypoglycemia in people with diabetes; reducing depressive symptoms; improving sleep; and decreasing use of potentially harmful medications.
2383786|NCT03683394|Active Comparator|Health Education Intervention|Participants in the Health Education arm will be mailed general information that will address factors that will be targeted in the SMARRT intervention, including physical, mental and social engagement; management of cardiovascular risk factors; quitting smoking, healthy diet; depression; sleep; and contraindicated medications. HE participants will not be provided with personalized information about their risk of Alzheimer's and dementia.
2383787|NCT03683381|Experimental|intervention|Patients in the intervention group will receive a 6-week app-based intervention to treat insomnia
2383788|NCT03683381|Experimental|patient education|Participants in the patient education group will receive weekly information on insomnia symptoms
2383789|NCT03683368|Experimental|Soft cannula first|Subjects will be randomized (50%) to the soft cannula infusion set for two weeks and then will be switched to the steel needle infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the soft cannula infusion set.
2383790|NCT03683368|Experimental|Steel cannula first|Subjects will be randomized (50%) to the steel cannula infusion set for two weeks and then will be switched to the soft cannula infusion set for two additional weeks. Participants will aim for 7 day use of each infusion set type twice, starting with the steel cannula infusion set.
2383791|NCT03683355||Edwards Sapien 3|Patients who underwent transcatheter aortic valve replacement with the Edwards Sapien 3 valve
2383792|NCT03683355||Core Valve Evolut R|Patients who underwent transcatheter aortic valve replacement with the Core Valve Evolut R valve
2383793|NCT03683342|Active Comparator|Ankle Block|Ankle block will be performed under ultrasound guidance.
2383794|NCT03683342|Active Comparator|Popliteal sciatic nerve block (PSNB)|PSNB will be performed under ultrasound guidance, along with a saphenous nerve block at the ankle
2383795|NCT03683329|Experimental|Antibiotic de-escalation|"According to the results of the antibiogram of the suspected causative bacteria, the ''pivotal'' antibiotic (antipseudomonal betalactam) used for empirical treatment is switched to an antibiotic with a spectrum as narrow as possible according to the targeted pathogens,~Stop the companion antibiotic (aminoglycoside, fluoroquinolone, macrolide) between day 2 and day 3 of antibiotic treatment as much as possible,~Stop the empirical antibiotic directed against methicillin-resistant staphylococcus aureus (MRSA) or an enterococcus in the absence of these bacteria in the culture."
2383796|NCT03683329|Active Comparator|Standard treatment without de-escalation|"The companion antibiotic is stopped between day 3 and day 5 of antibiotic treatment as much as possible and according to the local prescription,~Empirical antibiotics directed against MRSA or enterococcus were used according to local prescription and/or international guidelines,~The pivotal antibiotic of the empirical treatment is continued for the entire duration of the treatment, independently of microbiological results. For prolonged treatment, the physician has the choice of de-escalating after 8-15 days of treatment."
2383797|NCT03683316||all infants|"There will be one arm for this study. All infants will receive a similar intervention during their routine kangaroo mother care (KMC). KMC is a national and international standard of care. This is an observational study of how infants breath while participating in KMC compared to how they breath while in a crib or incubator. Work of breathing will be measured at baseline and then during KMC. Mothers will participate in KMC regardless of participation in the study. Work of breathing will be measured by using Respiratory Inductance Plethysmography (RIP). This scientifically measures work of breathing (specifically phase angles) by placing soft bands around the abdomen and chest. The actual intervention is a standard of care and something that the mother infant dyad will do regardless of the study. Each mother / infants pair is expected to be actively enrolled for approximately 2 hours."
2383820|NCT03683134|Experimental|Mediterranean diet group|Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.
2383821|NCT03683134|Active Comparator|American Heart Association group|Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.
2383798|NCT03683303|Experimental|mobile applications (APP)|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
2383799|NCT03683303|Active Comparator|oral education|"A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
2383800|NCT03683277|Experimental|Ixazomib/Pomalidomide/Dexamethasone|"Single arm treatment organized in 2 separate phases~Induction phase : association of Ixazomib, Pomalidomide & Dexamethasone (IPD) 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Maintenance phase : association of Ixazomib and Pomalidomide (IP) 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
2383801|NCT03683264|Other|Vacuum delivery|Deliveries completed using vacuum instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The vacuum was a metal vacuum (Bird's cup 50 mm, 80 kPa) was used to perform fetal extraction. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in vacuum delivery following Valme's University Hospital clinical practice guideline for instrumental deliveries.
2383802|NCT03683264|Other|Forceps delivery|Deliveries completed using forceps instrumentation were performed by obstetricians with a minimum of five years' experience in obstetric practice. In terms of analgesia, epidural analgesia was used for intrapartum analgesia. The forceps used for the instrumentation was the forceps of Kielland. Traction was carried out during contraction, along with maternal push, at a rate of 2-3 tractions per contraction, and without associating Kristeller maneuver. The procedure was abandoned if, after three cup slides or 15 min, fetal extraction had not been successful. Selective episiotomy was carried out in VD following Valme's University Hospital clinical practice guideline for instrumental deliveries.
2383810|NCT03683225|Experimental|CTC-413|Pramipexole with/with out aprepitant orally once daily
2383811|NCT03683212|Experimental|Intervention period : early and comprehensive care bundle|
2383812|NCT03683212|No Intervention|acute heart failure standard therapy|
2383813|NCT03683199|Experimental|Cleft lip nasal deformity|"•Anthropometric evaluation of the nose (will be measured pre and post-operative) This represents the objective evaluation. It will be done by measuring the angles and ratios of the nose and its relation to the face. Common parameters will be measured from the photos (frontal, oblique, lateral and basal views) for all the patients to compare the pre-operative measures with the post-operative ones.~MSCT flesh mode will be used to measure nose related angels and ratios. It also gives idea about nasal skeleton pre-operative for proper design of the operative strategy, and it will be done post-operative for assessment and comparizon."
3150858|NCT00212381|Experimental|oral DIM (Active agent)|2mg/kg/day po of DIM
2383815|NCT03683173|Experimental|Multilevel Intervention|Participants will receive the multilevel intervention consisting of community events, walking group formation, and short messaging service.
2383816|NCT03683173|No Intervention|Control|Does not receive the multilevel intervention.
2383817|NCT03683160|Experimental|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
2383818|NCT03683147|Experimental|Control (online sessions, content manual, CD after 6 weeks)|Participants randomized to the wait-list control condition complete the online intervention as in the intervention arm after the initial 6-week period has ended.
2383906|NCT03682575||Infants WITHOUT diagnosis of bronchopulmonary dysplasia (BPD|Preterm infants who were not on oxygen at 28 days of life.
2383822|NCT03683121||the traditional follow-up group|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding
2383823|NCT03683121||Non-traditional follow-up|The dose and notes for the use of the Non-selective beta blockers were informed during telephone or WeChat follow-ups for the patients with a history of esophageal variceal bleeding
2383824|NCT03683121||Combine of Group1 and Group2|The dose and notes for the use of the Non-selective beta blockers were informed during outpatient follow-ups for the patients with a history of esophageal variceal bleeding,and the patients were followed up by telephone or WeChat again on the same day.
2383825|NCT03683108|Experimental|Resveratrol and Carbossimetyl Beta Glucan|
2383826|NCT03683108|Placebo Comparator|Saline solution|
2383827|NCT03683095||Lymphovenous bypass|Patients with extremity lymphedema treated with lymphovenous bypass.
2383828|NCT03683082|Active Comparator|PAH patients|Supplementation of oxygen therapy (40% FiO2) during steady state cardiopulmonary exercise testing, via Venturi mask
2383829|NCT03683082|Sham Comparator|PAH patients (crossover)|Supplementation of medical air (sham oxygen) during steady state cardiopulmonary exercise testing, via Venturi mask
3150859|NCT00212381|Active Comparator|Red rice bran (Placebo)|this agent is not generally thought to be active but may be
3150860|NCT00212407|Experimental|Umbilical cord blood unit(s) transplant|Transplantation of cryopreserved umbilical cord blood unit(s)
2383832|NCT03683056|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
2383833|NCT03683056|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
2383834|NCT03683043|Active Comparator|Transabdominal guided transfer|In the trans-abdominal guided embryo transfer group, the patients' bladder were filled by 500-700 ml saline; in order to enhance the visualization. The trans-abdominal probe is applied on pelvis by an assistant nurse or the attending gynecologist intern
2383835|NCT03683043|Active Comparator|Transvaginal guided transfer|the trans-vaginal guided embryo transfer group had their bladder emptied by the gynecologist via catheter prior to transfer or else the patient was asked to void. The speculum is applied followed by insertion of the outer sheath of the transfer catheter. The speculum is removed with caution; to maintain the outer sheath in place. The TVUS probe is applied vaginally and endometrium is visualized before transfer. The transfer is done through an inner catheter applied to the already inserted outer sheath
3150861|NCT00212459|Experimental|1|Patients are contacted every two weeks after initial counseling to discuss completion of bleeding records.
2383837|NCT03683017|Experimental|I-OP2.0|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
2383838|NCT03683017|Experimental|I-OP2.1|Patients receive Invisalign orthodontic treatment, with 3.5 day Aligner changes, by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.1 device.
2383839|NCT03683017|Experimental|F-OP2.0|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Patients receive OrthoPulse 2.0 device.
2383840|NCT03683004||CRC patients (Ctx+ group)|Postoperative CRC patients scheduled to begin CTX
2383841|NCT03683004||CRC patients (CT- group)|Postoperative CRC patients who do not receive CTX
2383842|NCT03683004||Healthy control group|Study participants that are demographically matched to CRC study patients and meet all inclusion criteria
2383843|NCT03682991|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
2383844|NCT03682991|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
2383845|NCT03682978|Experimental|Arbaclofen|"Arbaclofen is provided as orally disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg.~A flexible dose titration schedule will be utilized during the first 5 weeks of the Treatment Period. Dosing regimens will be stratified by age. The total up-titration to 15 mg TID or 20 mg TID, and dose adjustment period to the optimal dose will be 35 days. If a participant does not tolerate a dose increase, he or she should return to the previous dose level and must remain at the dose level for the remainder of the Treatment Period. No changes should be made to dosing after 5 weeks, unless for safety.~5-11 years: Week 0 (BID) 5mg; Week 1 (BID) 5mg; Week 2 (TID) 10mg; Week 3 (TID) 10mg; Week 4-16 (TID) 15mg.~12-17 years: Week 0 (QD) 5mg; Week 1 (BID) 10mg; Week 2 (BID) 10mg; Week 3 (TID) 15mg; Week 4-16 (TID) 20mg."
2383846|NCT03682978|Placebo Comparator|Placebo|"Placebo tablets will have similar form, colour, smell and taste compared to the Arbaclofen tablets, and will be provided in non-distinguishable packaging.~Dosage level is n/a."
2383849|NCT03682952|Experimental|Experimental group|Alprostadil and Beraprost sodium tablets are used to improve the microcirculation of CKD patients.
2383850|NCT03682952|No Intervention|Anemia control group|Anemia patients
2383851|NCT03682952|No Intervention|Control group|Healthy person
2383907|NCT03682562||Oral Cancer|Patients diagnosed clinically and histopathologically as having oral cancer.
3150862|NCT00212459|Active Comparator|2|After the initial counseling with regards to bleeding records, there are no more contacts made with the control patients.
3150863|NCT00212472|Active Comparator|1|Low-dose treatment (50 FVIII u/kg three times a week).
3150864|NCT00212472|Active Comparator|2|High-dose treatment (200 FVIII u/kg per day).
3150865|NCT00212498||TB diagnosis|
3150866|NCT00212550||TB diagnosis|
2383852|NCT03682939|Experimental|Single arm|Single arm, open-label, all participants will receive both Bexsero® (meningitis B vaccine) and Menveo® (meningitis ACWY vaccine) vaccines.
2383853|NCT03682926|Experimental|electrostimulation individualized|Selective electrostimulation for tonic fiber, phasic fiber FIa and FIIb and different stimulus times. Muscle fibers (Tonic) with a frequency of 20Hz, pulse width (t) of 700μs to 1ms, time of rise and fall of the wave of 1.0 seconds, duration of contraction and repetition was based on the perineal evaluation But the resting time was twice as long as sustained. For the IIa (phasic) fibers the frequency was 50 Hz with a pulse width of 400μs to 500μs, for 3 seconds of sustentation and 6 seconds of relaxation, time of rise of 0,5 seconds and 0,5 seconds of descent. E for type IIb (phasic) fibers, 80 Hz frequency, pulse width 250μs to 400μs, 1 second contraction for 3 seconds rest and 0.2 seconds rise and fall time.
2383854|NCT03682926|Active Comparator|electrostimulation with fixed protocol|Intervention -Electro-stimulate all fibers with a single electrical parameter. Pulse width 700μs, rise and fall time of 2 seconds each, sustain time of 4 seconds and rest 8 seconds for 20 minutes, the intensity will be modulated, as in the previous group by patient tolerance in milliamperes.
2383855|NCT03682913|Experimental|P-CIT protocol|OCD patients who receive the P-CIT intervention.
2383856|NCT03682913|Placebo Comparator|Placebo|OCD patients who don't receive the P-CIT intervention.
2383857|NCT03682900|Experimental|Click City Tobacco Prevention Program|Click City program used as part of school curriculum
2383858|NCT03682900|No Intervention|Usual Tobacco Prevention Curriculum|Will vary by school district.
2383859|NCT03682887|Active Comparator|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm cryoballoon catheter will be used.~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and ablation times will be evaluated.~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
2383860|NCT03682887|Experimental|Cryoballoon PV isolation w/ RA linear ablation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter as the same as cryoballoon PV isolation group.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional SVC-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local RF ablation will be followed.~The procedure and ablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
2383861|NCT03682861|Placebo Comparator|Placebo|Placebo flavored drink similar to treatments but with no energy will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
2383862|NCT03682861|Experimental|Carbohydrate drinks|Sweet corn derived starch mixed in water at three different concentrations (6%, 12% and 18%) will be ingested post glycogen lowering exercise, followed by a 20 km time trial intervention
2383863|NCT03682848|Experimental|Participants receiving DTG + 3TC FDC|Eligible participants will receive FDC of DTG + 3TC 50/300 milligrams, tablets, given orally once daily.
2383864|NCT03682835|Placebo Comparator|Placebo treatment arm|Placebo: 2 capsules per dose, 2 doses per study day.
2383865|NCT03682835|Experimental|POCO treatment arm|FDGard Capsule containing a combination of peppermint oil (41,5mg) and caraway oil (50mg); 2 capsules per dose, 2 doses per study day.
2383866|NCT03682822|Experimental|Early artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
2383867|NCT03682822|Active Comparator|Delayed artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
2383870|NCT03682796|Experimental|Escalation|Estimated to be <31 subjects across multiple centers
2383871|NCT03682796|Experimental|Expansion|Estimated to be <121 subjects across multiple centers
2383872|NCT03682783||Fundus Image|Glaucomatous and Non-glaucomatous fundus images that have been taken from the last 5 years in Shanghai General hospital.
3150867|NCT00212576|Experimental|Building Blocks (0-3)|"Randomized at birth to receive Building Blocks Project from birth through 3 years of age.~Note: This arm not followed past 3 years of age; NOT re-randomized to any group at age 3."
2383875|NCT03682757||Severe Injury/Shock|Severely injured trauma patients presenting with shock, as defined by an Injury Severity Score (ISS)>=25, and base deficit (BD)>=6.
2383876|NCT03682757||Without Severe Injury/Shock|Not severely injured trauma patients presenting without shock, as defined by an Injury Severity Score (ISS)<25, and base deficit (BD) <6.
2383877|NCT03682757||Healthy Controls|Uninjured healthy volunteers
2383878|NCT03682744|Experimental|anti-CEA CAR-T cells|One intraperitoneal infusion of gene-modified anti-CEA T cells are administered to patients with CEA-expressing peritoneal metastases or malignant ascites
2383879|NCT03682718|Experimental|vaginal misoprostol and intracervical Foley catheter|participants will receive misoprostol by the same dose and method. Transcervical Foley catheter (size 16F, with 30ml balloon capacity) will be passed. The catheter will deﬂated, removed and cervix re-assessed if no spontaneous expulsion occurred at 12 hours post- insertion. A new catheter will be passed for another 12 hours, if the Bishop score is less than 8 this will be considered as failure of induction.
2383903|NCT03682588|Experimental|Functional exercise group|Functional exercise program with 14 exercises, two times/week, during 14 weeks. Two sets of 10 repetitions each, with 30 seconds interval.
2383904|NCT03682588|Active Comparator|Stretching exercise group|Stretching exercise program with 17 exercises, two times/week, during 14 weeks and each movement was repeated by three times and held for 20 seconds each
2383880|NCT03682718|Active Comparator|vaginal misoprostol|"Misoprostol group; participants will receive 50 μg intravaginal in the posterior vaginal fornix, 25 μg will be given every 4 hours for another two doses, if a satisfactory Bishop score of 8 not reached, patient will take an overnight rest and she will continue induction by the same doses on the next day-provided that there is no ROMs- (this is according to Ain Shams University Protocol) The maximum dose of Misoprostol is 200 μg.~Oxytocin infusion will not started until 6 hours after the last dose or if there is no adequate contractions obtained."
3183311|NCT00712699|Experimental|Sequence 1: XR-MAS then placebo|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
2383887|NCT03682692|Experimental|ACEI/CCB|
2383888|NCT03682692|Experimental|ACEI/DIU|
2383889|NCT03682666|Active Comparator|KT group|the patients will perform Kinesiotaping for 5 days per week for 3 weeks
2383890|NCT03682666|Sham Comparator|mCIMT group|"the unaffected limb will be constraint for 2 hours a day, 5 days a week for three weeks.~And they will receive sham taping on the affected limb."
2383891|NCT03682666|Experimental|KT+mCIMT group|the patients will perform Kinesiology taping for 5 days per week for 3 weeks, and while being taped, the modified Constraint Induced Movement Training would be also executed.
2383892|NCT03682653|Active Comparator|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
2383893|NCT03682653|Placebo Comparator|Placebo|a single dose of placebo will be administered to infants between their 8-27th days of life
2383894|NCT03682640|Experimental|AIDIT protocol|"Treatment as usual with the addition of:~i) Azithromycin Monohydrate, three times a week (≥ 48 h between doses) during 52 weeks. 500 mg if body weight ≥ 30 kg, 250 mg if body weight < 30 kg.~ii) Extra intensive insulin treatment periods for maximum beta-cell rest with Insulin lispro (Sanofi). This treatment will be given i.v. for one episode of 72 hours in the first week after inclusion and s.c. on seven 6-8 h occasions during the study year. The dose will be individually titrated to reach target blood glucose 4.0±0.5 mmol/L.~ii) Dietician support; Extra advice and support from the study dietician within the first week after randomization and after 1.5 and 4 months."
2383895|NCT03682640|No Intervention|Control|Patients will receive treatment as usual (TAU). All patients will receive standard therapeutic treatment consisting of insulin replacement with insulin analogues aiming for normoglycemia from diagnosis. Rapid acting insulin analogue will be administered via insulin pump (continuous subcutaneous infusion) with access to insulin injections in case of malfunction in the pump system.
2383896|NCT03682627|Active Comparator|preventive fenestration|Fenestration is performed at the time of kidney transplantation
2383897|NCT03682627|Experimental|preventive fenestration and clipping|Fenestration and clipping of the edges are performed at the time of kidney transplantation
2383898|NCT03682614|Experimental|HCG group|All patients will accept HCG 500IU intrauterine injection 2 days before blastocyte transfer
2383899|NCT03682614|Placebo Comparator|control group|All patients will accept same dose of culture medium intrauterine injection 2 days before blastocyte transfer
2383900|NCT03682601|Placebo Comparator|Placebo|"15 postmenopausal women will apply a 1/2 inch strand of Placebo ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
2383901|NCT03682601|Active Comparator|5% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 5% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
2383902|NCT03682601|Active Comparator|10% Topical sinecatechins ointment|"15 postmenopausal women will apply a 1/2 inch strand of 10% sinecatechins topical ointment once daily to their vulvar vestibule for a total of 4 weeks.~They will come for three office visits with the gynecologist, who will exam their vulvar vestibule and perform a Qtip test. The Qtip test consists of applying pressure with a cotton tipped swab to the vulvar vestibule and asking the participant to rate the degree of pain that they experience on a scale from 0-10 ( 0=no pain; 1-3=mild pain; 4-6=moderate pain; 7-9=significant pain; 10=severe pain).~A swab will be taken of the lateral vaginal wall for to assess the degree of vaginal atrophy.~The participant will fill out questionnaire during office visits with the gynecologist. In addition, questionnaire will be filled out online on a HIPAA compliant web based survey at the end of weeks 1 and 3 and one week after stopping study ointment."
2383905|NCT03682575||Infants WITH diagnosis of bronchopulmonary dysplasia (BPD)|Preterm infants who were on oxygen at 28 days of life.
2383908|NCT03682562||Premalignant Oral Lesions|Patients diagnosed clinically and histopathologically with either leukoplakia or oral lichen planus as stated by modified WHO criteria
2383909|NCT03682562||Normal Subjects|"Patients who give a history of:~No smoking~No alcohol~No systemic disease; and who on conventional oral examination have:~No visible oral lesions on conventional oral examination .~Good oral hygiene."
2383910|NCT03682549||HCV positive Patients|"patients will be recruited from the outpatient's viral hepatitis clinic~The patients will be diagnosed as HCV positive through (antiHCV-Ab) and (HCV-PCR) tests"
2383911|NCT03682549||Successfully treated former HCV patients|Patients formerly diagnosed as HCV positive who received DAA treatment successfully.
2383912|NCT03682549||Normal Individuals|healthy volunteers recruited from the outpatient clinic of the Faculty of Dentistry- Cairo University
3150868|NCT00212576|Experimental|VIP (0-3), VIP (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
2383915|NCT03682523|No Intervention|Control Group|Fitted with an accelerometer to measure time spent out of bed while in hospital. Otherwise, participants in the control group will receive usual care from the hospital medical team during their hospital stay. Daily activities of participants will not be restricted if patients are assigned to the control group.
2383916|NCT03682523|Experimental|Intervention Group|Fitted with accelerometer to measure time spent out of bed while in hospital; daily goals set for time spent out of bed; real-time feedback on goal attainment provided on bedside tablet; mobilization feedback real-time feedback on goal attainment; hands on mobilization by physiotherapist for participants in late afternoon for participants who do not meet daily goal.
2383917|NCT03682510|Active Comparator|stepwise devascularization|routine stepwise devascularization
2383918|NCT03682510|Active Comparator|B-Lynch Transverse Compression Suture|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side."
2383919|NCT03682510|Experimental|N&H technique|"In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade. As follow:~(i) 100-cm Vicryl no. 1 was thrown to form two nearly equal parts (each 50 cm) on a blunt semicircular 70-mm needle, the curve of the needle was straightened.~(ii) The needle transfixed the right side of the uterine wall from anterior to posterior, about 2 cm below the hysterotomy incises posterior, then the needle transfixed the left side of the uterine wall from posterior to anterior, about 2 cm below the hysterotomy incision."
2383920|NCT03682497|Active Comparator|Spironolactone|Spironolactone treatment for 28 days
2383921|NCT03682497|Experimental|AZD9977|AZD9977 treatment for 28 days
2383922|NCT03682484|Experimental|MA-0211 Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
2383923|NCT03682484|Placebo Comparator|Placebo Single Ascending Dose (fasting conditions)|Successive cohorts of 8 participants (1-7 cohorts) will be started on a fixed single dose of MA-0211 or matching Placebo under fasting conditions. The first two participants will receive either MA-0211 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed.
2383924|NCT03682484|Experimental|MA-0211 Single Ascending Dose (food effect)|A single cohort of 8 participants will be started on a fixed single dose of MA-0211, within 30 minutes after the start and 5 minutes after the completion of an US Food and Drug Administration (FDA) high fat breakfast.
2383925|NCT03682484|Experimental|MA-0211 Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
2383926|NCT03682484|Placebo Comparator|Placebo Multiple Ascending Dose|Successive cohorts of 12 participants (1-3 cohorts) will receive oral doses of MA-0211 or matching Placebo for 14 days.
2383927|NCT03682471||Deoxycholic Acid Injection, 5 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 5 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
2383928|NCT03682471||Deoxycholic Acid Injection, 10 mg/mL|Non-treatment observational follow-up study: Participants were previously treated with deoxycholic acid injection, 10 mg/mL in studies ATX-101-10-16 or ATX-101-10-17.
2383929|NCT03682471||Placebo|Non-treatment observational follow-up study: Participants were previously treated with placebo in studies ATX-101-10-16 or ATX-101-10-17.
2383930|NCT03682445|Active Comparator|High intensity interval exercise|Participants with type 2 Diabetes mellitus in High intensity interval exercise (HIIE) group will make aerobic exercise using bicycle at high intensity followed by low intensity periods under observation in the hospital.
2383931|NCT03682445|Active Comparator|Moderate intensity continuous exercise|Participants with type 2 Diabetes mellitus in Moderate intensity continuous exercise (MIC) group will make aerobic exercise using bicycle at moderate intensity during the session under observation in the hospital.
2383932|NCT03682445|No Intervention|Control group|The participants in the control group will make stretching exercise at home
2383933|NCT03682419|Experimental|VKA Patients|Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy
2383934|NCT03682419|Experimental|non-Vka Patients|Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy
2383960|NCT03682263|Experimental|Basic Service Treatment|The Basic Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services.
2384119|NCT03681249|Placebo Comparator|ShenqiDihuang Decoction placebo|ShenqiDihuang Decoction placebo 150ml by mouth, twice a day for 24 weeks
2383935|NCT03682406|Experimental|CAMS-G|CAMS-G is an group-based adaptation of the Collaborative Assessment and Management of Suicidality (CAMS) that has been developed to address perceived burdensomeness and thwarted belongingness, two drivers of suicide risk. Ongoing assessment and treatment planning are completed using the CAMS Suicide Status Form in the group modality, with involvement from group members and group facilitators. Driver-focused intervention strategies and group process also occur in the group based upon the unique needs of the group members. Groups are 90-minutes in length and occur on a weekly basis.
2383936|NCT03682406|Other|Care as Usual|Care as usual includes access to all existing forms of treatment that currently exist at the Robley Rex VAMC and affiliated CBOCs, such as individual and group psychotherapy, suicide prevention programming and case management, psychiatric care, social work services, and substance use disorder counseling. We will essentially track the control condition over time as they engage in the typical services provided to suicidal Veterans through the Robley Rex VAMC. The CAMS-G study participants will have access to the same services delivered as part of care as usual, with the only difference being their participation in the CAMS-G treatment for suicidality.
2383937|NCT03682393|Experimental|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
2383938|NCT03682393|Placebo Comparator|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
2383939|NCT03682380|Experimental|Part 1: Seltorexant High Dose|In Part 1, participants will receive the following treatments: Treatment A: Two low doses of seltorexant tablets (reference formulation), Treatment B: High dose of seltorexant tablet (Test formulation 1), Treatment C: High dose of seltorexant tablet (Test formulation 2), Treatment D: Two low doses of seltorexant tablets (Test formulation 3), Treatment E: Two low doses of seltorexant tablets (Test formulation 4), Treatment F: Two low doses of seltorexant tablets (Test formulation 5), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-6). There will be a washout Period of 7 to 14 days from dosing on Day 1 of each treatment period.
2383940|NCT03682380|Experimental|Part 2: Seltorexant High Dose|Participants will receive the following treatments: Treatment G: Two low doses of seltorexant tablets (Reference formulation), Treatment H: High dose or two low doses of seltorexant tablet (Test formulation 1), Treatment I: High dose of seltorexant tablet (Test formulation 2), as one of 6 possible treatment sequences on Day 1 in each treatment Periods (Period 1-3). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
2383941|NCT03682380|Experimental|Part 3: Seltorexant Low Dose or High Dose|Part 3 will have 3 subparts (Part 3A, Part 3B, and Part 3C). In Part 3A and 3B, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7) respectively in a different food conditions on Day 1 in each treatment Periods (Periods 1-5). In Part 3C, participants will receive high dose of seltorexant (selected formulation 6) and two low doses of seltorexant (selected formulation 7 ) on Day 1 in each period (Period 1 and 2). There will be a washout period of 7 to 14 days from dosing on Day 1 of each treatment period.
3183312|NCT00712699|Experimental|Sequence 2 Placebo then XR-MAS|Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 2 will first receive treatment with PBO for 3 weeks and then XR-MAS for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period (stimulants are not clinically suspected to have lingering effects beyond initial dosing/day of administration)otherwise occurs, including the crossover week to XR-MAS.
3183313|NCT00712751||1|usual care (UC) which is the standard care that patients receive
2383944|NCT03682354|Active Comparator|Intercostal Nerve Block with PCIA|Intercostal Nerve Block with patient-controlled intravenous analgesia
2383945|NCT03682354|Experimental|Erector Spinae Plane Block (ESPB)|Continuous Erector Spinae Plane Block
2383946|NCT03682341||Group A|Patients with ovarian endometriosis cyst
2383947|NCT03682341||Group B|Patients with ovarian teratoma cyst
2383948|NCT03682328|Active Comparator|vertebroplasty|Patients will be managed by equipment of vertebroplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
2383949|NCT03682328|Active Comparator|kyphoplasty|Patients will be managed by equipment of kyphoplasty (Osteofix from Tsunami Medical Made in Italy which is composed of a packet of PMMA and ampule of MMA).
2383950|NCT03682315|Active Comparator|Biphasic phycogenic biomaterial|Biphasic phycogenic biomaterial and Autogenous cortical bone
2383951|NCT03682315|Experimental|Xenograft bovine hydroxyapatite|Xenograft bovine hydroxyapatite and Autogenous cortical bone
3183314|NCT00712751||2|Cancer Survivorship Intervention-Sexual Health (CSI-SH)plus Usual Care (US)
3183315|NCT00712764|Active Comparator|1|
3183316|NCT00712764|Placebo Comparator|2|
3183317|NCT00712777|Active Comparator|1|homozygote mutant: Insertion/Insertion (40 patients)
2383956|NCT03682289|Experimental|Arm I (ATR kinase inhibitor AZD6738)|Participants who are BAF250a negative or ATM-Mutant receive ATR kinase inhibitor AZD6738 PO twice a day on days 1-14. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
2383957|NCT03682289|Experimental|Arm II (ATR kinase inhibitor AZD6738, olaparib)|Participants who are BAF250a positive receive ATR kinase inhibitor AZD6738 PO every day on days 1-7 and olaparib PO twice a day on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
2383958|NCT03682276|Experimental|Treatment Group|Ipilimumab, solution for infusion, 1 milligram per kilogram body weight, once every 3 weeks, for 3 weeks; Nivolumab, solution for infusion, 3 milligrams per kilogram body weight, once every 3 weeks, for 6 weeks
2383959|NCT03682263|Experimental|Full Service Treatment|The Full Service Arm receives the Individual Placement and Support (IPS) model of employment services integrated with behavioral health services and care management services, as well as Medication Management Support (MMS) from a Nurse Care Coordinator (NCC).
3183318|NCT00712777|Active Comparator|2|homozygote mutant: Deletion/Deletion (40 patients)
3183319|NCT00712790|Experimental|Sequential Radioembolization-Sorafenib|Sorafenib (400 mg twice-daily) was initiated 14 days post-radioembolization with yttrium-90 (Y) resin microspheres given as a single procedure.
2383961|NCT03682263|No Intervention|Usual Services|Members of the Usual Service group seek services as they normally would (or would not) in their community. At the time of randomization, each Usual Services group member receives a comprehensive manual describing mental health and employment services in their local community, as well as state and national resources.
2383962|NCT03682250||Patients with type 1 diabetes with a high cardiovascular risk|
2383963|NCT03682237|No Intervention|A) Standard diabetes training (control)|"More specifically, group training in general diabetes health issues, how to do experienced based dosing, how to handle sick days, exercise etc. in general terms. The group will not be taught in carbohydrate counting or bolus calculation. They will be encouraged to measure SMBG at least 4 times daily with patients own preferred glucose meter.~Patients will be offered 6 months treatment with FGM after study end."
2383964|NCT03682237|Active Comparator|B) Carbohydrate counting, automated bolus calculation|
2383965|NCT03682237|Active Comparator|C) Flash glucose monitoring (FGM)|Group training with same content as for group A.
2383966|NCT03682237|Active Comparator|D) Carbohydrate counting, automated bolus calculation, FGM|Group training as group B. A more sophisticated education concept will be developed for how FGM should be used to adjust settings and suggestions from the automated bolus calculator (MySugr app).
3142737|NCT00003203|Experimental|Newly diagnosed cerebral PNET with histologic verification|Begin therapy within 31 days of surgery. Radiation therapy will be given in standard fractions along with filgrastim. The craniospinal axis will be treated first. Patients will receive carboplatin at 35 mg/m2/day IV over 15-20 minutes Monday through Friday, 1-4 hours prior to radiation for 6 weeks (total of 30 doses). Vincristine sulfate 1.5 mg/m2 IV will be given weekly x 6. Following radiation, patients will receive Maintenance chemotherapy. Patients enrolled prior to Amendment #5 will receive six cycles of cyclophosphamide and vincristine (Regimen A). Patients enrolled after Amendment #5 will receive six cycles of cyclophosphamide, vincristine sulfate and cisplatin (Regimen B).
3142738|NCT00003204|Experimental|Arm I (cyclophosphamide, fludarabine)|Patients receive cyclophosphamide IV over 30-45 minutes on day 1 and fludarabine IV over 10-20 minutes on days 1-5. Treatment repeats every 28 days in the absence of disease progression for a minimum of 4 courses and a maximum of 6 courses.
2383969|NCT03682211|Experimental|Active Intranasal Fentanyl|Subjects will receive 50 μg/ml intranasal fentanyl citrate and a placebo matched to intravenous morphine (1 ml water for injection) at time 0
2383970|NCT03682211|Active Comparator|Active IV Morphine|Subjects will receive 10 mg/ml intravenous morphine sulphate and a placebo matched to intranasal fentanyl (2 ml water)
2383971|NCT03682198|Other|One strategy for all enrolled patients:|All patients will participate in three substudies, in which they also act as controls, with exposure to the same three interventions: 1) NIRS-measurement on skin, skull and dura, 2) Phenylephrine 0.1 mg iv., and 3) inspired oxygen fraction of 0.3 vs. 0.8
2383972|NCT03682185|Experimental|Timed Activity Intervention Protocol|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem solving approaches, and provide education.
2383973|NCT03682185|Active Comparator|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
2383974|NCT03682172|Experimental|GLP-2 (10pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10pmol/kg/min
2383975|NCT03682172|Experimental|GLP-2 (1pmol/kg/min)|A single four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
2383976|NCT03682172|Experimental|Placebo|A single four hour intravenous infusion with saline water (placebo)
2383977|NCT03682159|No Intervention|control|
2383978|NCT03682159|Experimental|intervention|
2383979|NCT03682146|Experimental|R-LRPE|robot-assisted laparoscopic prostatectomy
2383980|NCT03682146|Experimental|LRPE|conventional radical laparoscopic prostatectomy
2383981|NCT03682133||Prehabilitation|The care as given in a participating hospital is according to the local guideline and will not be changed for this study. Whether prehabilitation is applied in a participating hospital is based on a predefined definition of oncological surgical prehabilitation.
2383982|NCT03682133||Usual care|Guideline based colon cancer surgery, without prehabilitation.
3142739|NCT00003204|Experimental|Arm II (cyclophosphamide, vincristine, prednisone)|Patients receive cyclophosphamide IV over 30-45 minutes and vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 21 days in the absence of disease progression for a minimum of 6 courses and a maximum of 8 courses.
3142740|NCT00003204|Experimental|Arm III (rituximab)|Patients receive maintenance therapy with rituximab (IDEC-C2B8 monoclonal antibody) IV weekly for 4 weeks. Courses repeat every 6 months for 2 years. Maintenance therapy begins 4 weeks after the last chemotherapy.
2384044|NCT03681847|Active Comparator|Hydroxyethyl starch|Patients will receive hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
2384045|NCT03681847|Active Comparator|Hypertonic saline|Patients will receive hypertonic saline 3% (7ml/kg) over 15-20 minutes.
3142741|NCT00003204|No Intervention|Arm IV (no intervention)|Patients undergo no maintenance therapy and are observed. Patients are followed every 3 months for 2 years, every 6 months for the next 3 years, and then annually thereafter.
3150869|NCT00212576|Experimental|VIP (0-3), Control (3-5)|"Randomized at birth to receive Video Interaction Project from birth through 3 years of age.~Re-randomized at 3 years to receive care as usual (control) from 3-5 years of age."
3150870|NCT00212576|Experimental|Control (0-3), VIP (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive Video Interaction Project from 3-5 years of age."
3142742|NCT00003207|Experimental|Phase 1 (Doxil & PSC 833)|Patients will receive Doxil at the standard dose of 20 mg/m2 IV for the 1st cycle. On the 2nd cycle of Doxil, the first patient will receive Doxil at 40% of standard dose or 8 mg/m2 (dose level 1) IV over one hr. 15 mn after the 2nd and subsequent cycles of Doxil, PSC 833 will be given at 2 mg/kg for 2 hrs. Simultaneously, a 72 hour CIVI of PSC 833 will be started with the loading dose. If no DLT occurs, then a double dose escalation of Doxil (dose levels 3, 5, 7 ) will be given to the same patient in the subsequent cycles until DLT occurs. On the 2nd cycle, Doxil will be given at the next dose level above the starting dose tolerated by the first patient. If no DLT occurs, a double dose escalation will also be done for the subsequent cycles (dose levels 5, 7, 9). The single-patient-cohort will terminate when a patient experiences DLT or when two episodes of grade 2 toxicity occur. At that point patients will be enrolled into cohorts of 3 patients to determine the MTD.
3142743|NCT00003210|Experimental|Treatment (interleukin-12)|Patients receive interleukin-12 subcutaneously twice a week. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
2383991|NCT03682094|Experimental|Probiotic|The treatment will consist of VSL#3, 3 grams (g), taken orally once a day for 4 weeks. The VSL#3 will be delivered in the form of a sachet of freeze-dried powder. Participants will be instructed to mix the sachets with water to consume. Those participants taking thickened liquids will mix the sachet with liquids thickened to the level (nectar versus honey) prescribed by their clinician. In order to facilitate delivery of the probiotic solution throughout the oral cavity, participants will be instructed to swish the solution in the mouth for up to 10 seconds (as tolerated) prior to each swallow.
2383992|NCT03682081|No Intervention|Usual care|Usual care groups will receive standard swallowing interventions identified by the Speech-Language Pathologist as appropriate to treat the patient's dysphagia and common in clinical practice. Such treatment would likely consist of dietary (e.g., thickened liquids or pureed foods) or postural compensatory strategies (e.g., chin down posture while swallowing). No progressive lingual strengthening approaches or regimented salivary substitute protocols are utilized.
2383993|NCT03682081|Experimental|Saliva Substitute Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied to the oral cavity regularly for 8 weeks.
2383994|NCT03682081|Experimental|Lingual Strengthening Intervention|Patient-caregiver dyads will be trained in the lingual strengthening protocol and patients will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
2383995|NCT03682081|Experimental|Saliva Substitute and Lingual Strengthening Intervention|Each patient-caregiver dyad will be provided with a commercially available gel-based saliva substitute, Biotene® Oral Balance Gel that will be applied regularly to the oral cavity for 8 weeks. Each dyad will also be trained in the lingual strengthening protocol and will undergo this intervention for 8 weeks. Isometric tongue strengthening will be facilitated by the Iowa Oral Performance Instrument (IOPI) device.
3142744|NCT00003211|Experimental|Average-risk|"Participants meeting the eligibility requirements for assignment to the average-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
3142745|NCT00003211|Experimental|High-risk|"Participants meeting the eligibility requirements for assignment to the high-risk arm.~Interventions: filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy."
3142746|NCT00003213|Experimental|Oral Granisetron + Dexamethasone|"1 mg Granisetron in the morning~1 Metoclopramide placebo in the afternoon~1 mg Granisetron in the evening 4 mg Dexamethasone in the morning"
2383999|NCT03682055|Experimental|Phase 1 Dose Escalation (Accelerated Titration)|VK-2019 QD in Accelerated Titration dose escalation cohorts enrolling EBV+ NPC
2384000|NCT03682055|Experimental|Phase 1 Dose Escalation (Rolling Six)|VK-2019 QD in Rolling Six dose escalation cohorts enrolling EBV+ NPC.
2384001|NCT03682055|Experimental|Phase 1 Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified criteria for clinical and/or biological activity.
2384002|NCT03682055|Experimental|Phase 2a Dose Expansion(s)|VK-2019 QD in expansion cohorts that may be opened at doses that meet pre-specified efficacy criteria in Phase 1 Dose Escalation cohorts.
2384003|NCT03682042|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
2384004|NCT03682042|No Intervention|Early Cord Clamping|The umbilical cord is clamped immediately after the delivery (within 60 seconds).
2384005|NCT03682029|Experimental|Vitamin C|Vitamin C (ascorbic acid) 500 mg/capsule. Ingestion of 2 capsules (1000 mg) daily for 12 months.
2384006|NCT03682029|Placebo Comparator|Placebo|Placebo capsule. Ingestion of 2 capsules daily for 12 months. Placebo will be prepared as capsules that look and taste identical to the vitamin C supplement capsules. The content of the placebo is lactose, potato starch, gelatin, magnesium stearate, and talc.
2384007|NCT03681990|Experimental|3M CHG/IPA Prep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
2384008|NCT03681977|Experimental|Zimmer MP Persona|Zimmer MP Persona is total knee prosthesis intended to resurface the articulating surface of the femoral, tibial and patellar bones. It employs modular components between the tibial plates and articular surfaces and a medial congruent bearing manufactured from Vivacit-E Highly Crosslinked Polyethylene (HXPE). Persona® Medial Congruent Bearing is available in several sizes and offers up to a 13mm anterior lip height to provide greater anterior constraint and subluxation resistance. Can be used with a with both cruciate retaining and posterior stabilized femoral provisionals
2384046|NCT03681821|Experimental|The intervention group|Patients in the intervention group receiving the follow-up TTM-based intervention sessions.
2384047|NCT03681821|No Intervention|The control group|No interventions except conventional care were performed for the control group.
3183320|NCT00712803|Experimental|1|One subcutaneous vaccination (10^3 dose of vaccine) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
3142747|NCT00003213|Experimental|Metoclopramide + Dexamethasone|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening) 4 mg Dexamethasone in the morning
3142748|NCT00003217|Experimental|Treatment|See detailed description.
3142749|NCT00003223|Experimental|treatment|Fenretinide 200 mg PO days 1-25, q 28 days x 6 cycles.
2384009|NCT03681977|Active Comparator|Zimmer Persona Knee-PS|Zimmer Biomet Persona® Knee-PS is a semiconstrained knee prosthesis that employs modular components between the tibial plates and articular surfaces. The device is intended to resurface the articulating surface of the femoral, tibial and patellar bones. The posterior stabilized (PS) femoral provisionals and components can be used with the PS or constrained posterior stabilized (CPS) bearings provisionals and components when the PCL is deficient and removed.The Persona Femur offers 21 distinct profiles, in 2 mm increments.
2384010|NCT03681977|No Intervention|Healthy Participants|The control group for the kinematic assessment
3183321|NCT00712803|Experimental|2|One subcutaneous vaccination (10^5 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm OR one subcutaneous vaccination (10^1 dose of vaccine or placebo) of rDEN3-3'D4delta30 vaccine into the deltoid region of either arm.
3183322|NCT00712816|Experimental|A|
3183323|NCT00712816|Active Comparator|B|
3183324|NCT00712829|Experimental|1|123-I-MIP-1072 administration followed by 123-I-MIP-1095 administration two weeks later.
2384015|NCT03681938||Intensification treatment: Autograft|
2384016|NCT03681938||Standard chemotherapy (without autograft)|
2384017|NCT03681925|Experimental|Intervention|Dietitians randomized to the intervention arm will have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and base their intervention on these results.
2384018|NCT03681925|No Intervention|Control|Dietitians randomized to the control arm will not have access to their participating patients' Nutrition Literacy Assessment Instrument (NLit) scores, and will provide the standard-of-care intervention for their patients.
2384019|NCT03681912||Implementation Block 1|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 3 months.
2384020|NCT03681912||Implementation Block 2|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 6 months.
2384021|NCT03681912||Implementation Block 3|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 9 months.
2384022|NCT03681912||Implementation Block 4|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 12 months.
2384023|NCT03681912||Implementation Block 5|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) performed monthly but reported quarterly, starting at 15 months.
2384024|NCT03681912||Sustainment Block 1 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
2384025|NCT03681912||Sustainment Block 2 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
2384026|NCT03681912||Sustainment Block 3 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
2384027|NCT03681912||Sustainment Block 4 Facilitated CoP|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.
2384028|NCT03681912||Sustainment Block 5 Facilitated CoP|Randomized Guided Development of CoPs with an internal facilitator after one year of implementation.
2384029|NCT03681912||Sustainment Block 1 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
2384030|NCT03681912||Sustainment Block 2 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
2384031|NCT03681912||Sustainment Block 3 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
2384032|NCT03681912||Sustainment Block 4 CoP Alone|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
2384033|NCT03681912||Sustainment Block 5 CoP Along|After one year of implementation, site is randomized to receive CoP development without internal facilitation.
2384034|NCT03681899||Subjects aged of 65 years or older|Subjects aged of 65 years or older, taking at least one oral medication for two weeks or more.
3183325|NCT00712829|Experimental|2|123-I-MIP-1095 administration followed by 123-I-MIP-1072 administration two weeks later.
3183326|NCT00712842||1|Patients with non or mild non-proliferative diabetic retinopathy
2384037|NCT03681873|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose exams
2384038|NCT03681860|Other|Group 1 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
2384039|NCT03681860|Other|Group 2 Dose Escalation Adults|3 adults who are parents of EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
2384040|NCT03681860|Other|Group 3 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 5 x10^9 vp
2384041|NCT03681860|Other|Group 4 Age De-escalation Adolescents|3 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp
2384042|NCT03681860|Experimental|Group 5/6 Randomised Comparison|30 adolescents who are EMaBS participants, to receive ChAdOx1 85A at 2.5 x10^10 vp followed by MVA85A boost versus 30 adolescents who are EMaBS participants, to receive BCG revaccination
2384043|NCT03681847|Active Comparator|normal saline|Patients will receive normal saline 0.9% 15 ml/kg over 15-20 minutes.
2431624|NCT03355352||Patients treated with conventional i.v. PCA|
3183327|NCT00712842||2|Healthy control subjects
3183328|NCT00712855|Experimental|A|mapatumumab and sorafenib
3183329|NCT00712868|Experimental|1|Lactic Acid once a day during 21 days
3183330|NCT00712894|Experimental|D|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of diltiazem via an infusion microcatheter distal to the angioplasty site was performed.
3183331|NCT00712894|Active Comparator|V|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of verapamil via an infusion microcatheter distal to the angioplasty site was performed.
3183332|NCT00712894|Active Comparator|N|If no-reflow/slow-flow phenomenon was observed post-PCI, intracoronary infusion of nitroglycerin via an infusion microcatheter distal to the angioplasty site was performed.
3183333|NCT00712907|Active Comparator|1|vitamin C (Mayrhofer)
3183334|NCT00712907|Placebo Comparator|2|Placebo
3183335|NCT00712933|Experimental|1|1 mg/kg dose of belimumab given IV every 28 days.
3142750|NCT00003225|Experimental|Ethyol plus Irinotecan|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. 10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
3142751|NCT00003234|Experimental|Stratum 1 - Soft Tissue Sarcoma|See detailed description.
3142752|NCT00003234|Experimental|Stratum 2 - CNS Tumors|See detailed description.
3142753|NCT00003234|Experimental|Stratum 3 - Neuroblastoma|See detailed description.
2384056|NCT03681756|No Intervention|Group 1|Participants will receive an in-person session and an activity monitor
2384057|NCT03681756|Experimental|Group 2|Participants will receive an in-person session, an activity monitor, and social support through BAND
2384058|NCT03681743|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
2384059|NCT03681743|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors and/or parents.
2384060|NCT03681730|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during an IV start.
2384061|NCT03681730|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
2384062|NCT03681717|Experimental|Virtual Reality|Participants are distracted by wearing the virtual reality headset and watching a roller coaster app during laceration repair with sutures.
2384063|NCT03681717|No Intervention|Control (Standard-of-Care)|Participants are distracted with Standard-of-Care by doctors, nurses, nurse practitioners, child life specialists and/or parents.
2384064|NCT03681704|Experimental|HuangQi Decoction|HuangQi Decoction 150ml by mouth ,twice a day for 24 weeks
2384065|NCT03681704|Placebo Comparator|HuangQi Decoction placebo|HuangQi Decoction placebo 150ml by mouth, twice a day for 24 weeks
2384066|NCT03681691|Experimental|Post menopausal women with diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women with type 2 diabetes
2384067|NCT03681691|Experimental|Post menopausal women without diabetes|8-week administration of transdermal 17β-estradiol (Climara) patch in postmenopausal women without type 2 diabetes.
2384068|NCT03681678||fCO2 Laser Therapy Group|Women treated with the fCO2 laser
2384069|NCT03681665||Abscess|Patients group with abdominal abscess
2384070|NCT03681652||Azathioprine or 6MP|Patients treated with thiopurines for post-operative prophylaxis.
2384071|NCT03681652||Anti-TNF drug|Patients treated with anti-TNF alpha monotherapy for post-operative prophylaxis.
2384072|NCT03681639|Experimental|Patients who received Metasul Monoblock in hip resurfacing|Patients who received the Zimmer Hip Resurfacing System utilising the Metasul Monoblock Component™ Cup in a Hip Resurfacing Application with the Durom® Hip Resurfacing Femoral Component and whose Serum metal ion levels is being measured.
2384073|NCT03681626|Active Comparator|tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed with a standardized tracheal suction.
2384074|NCT03681626|Experimental|no tracheal suction|After a standardized protocol during the thirty minutes before extubation, extubation was performed without tracheal suction.
2384075|NCT03681613|Experimental|Exercise Therapy With CNS Treatment|NEMEX program combined with a CNS-focused protocol
2384076|NCT03681613|Experimental|Exercise Therapy alone|NEMEX program alone
2384077|NCT03681574|Experimental|Placebo Group|The placebo group will receive placebo concentrate orally (0.3 mL/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
2384078|NCT03681574|Experimental|GABA 15mg/kg Group|The GABA 15mg/kg group will receive gabapentin syrup orally (15 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
2384079|NCT03681574|Experimental|GABA 30mg/kg Group|The GABA 30mg/kg group will receive gabapentin syrup orally (30 mg/kg) only once, 1 to 2 hours before the oncologic procedure. All patients will undergo the same anesthetic protocol. Afterward, the patients will be submitted to oncologic procedures: Myelogram or Lumbar Puncture.
2384080|NCT03681561|Experimental|Ruxolitinib and Nivolumab|
2384332|NCT03679884|Experimental|ACT-541468 50 mg|Tablets administered orally, once daily in the evening
3142754|NCT00003239|Experimental|Chemotherapy with Cytarabine + Homoharringtonine|Interferon alfa and cytarabine daily by subcutaneous injection. Homoharringtonine is administered by continuous infusion on days 1-5.
3142755|NCT00003248|Experimental|Arm I|"Patients receive fludarabine and chimeric anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab) induction. Rituximab is administered IV over 4 hours on day 1, on day 3, and over 1 hour on day 5 of week 1. Subsequent doses are given over 1 hour on day 1 every 4 weeks for a total of 6 courses. Fludarabine IV is administered over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Following the sixth course of fludarabine, patients undergo clinical staging and are then observed for an additional 2 months, after which they undergo repeat clinical staging, including bone marrow aspiration. Patients achieving a complete or partial response or stable disease then proceed to consolidation therapy consisting of weekly intravenous infusions of rituximab once weekly for 4 weeks.~Patients are followed every 3 months for 1 year, and then every 6 months thereafter."
3142756|NCT00003248|Experimental|Arm II|Patients receive fludarabine induction. Patients receive fludarabine IV over 10-30 minutes daily for 5 days during weeks 1, 5, 9, 13, 17, and 21 for a total of 6 courses. Patients then proceed as in arm I. Patients are followed every 3 months for 1 year, and then every 6 months thereafter.
3142757|NCT00003249|Experimental|Arm I|Patients receive oral carboxyamidotriazole (CAI) as a test dose on day 1. Patients receive oral ketoconazole on day 7, followed by CAI plus ketoconazole on day 8. CAI and ketoconazole are administered in combination on day 1 and days 3-28 of the first course. Ketoconazole is administered alone on day 2 of the first course. Subsequent courses begin at 28 day intervals in the absence of disease progression or unacceptable toxic effects. Cohorts of 3 patients are evaluated at each dose level prior to dose escalation. If one of three patients within a cohort experiences dose limiting toxicity (DLT), that dose level is expanded to incorporate six patients. If two or more patients experience DLT, the next lower dose is declared to be the maximum tolerated dose.
2384081|NCT03681548|Active Comparator|Reference Product - R|Doxorubicin Hydrochloride Liposome Injection (Sun Pharma); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma), will receive in Cycle 2 the Test Product (doxorubicin hydrochloride liposome injection (Ayana); after at least 4 weeks (RT).
2384082|NCT03681548|Experimental|Test Product - T|Doxorubicin Hydrochloride Liposome Injection (Ayana Pharma Ltd); 20 mg/10 mL i.e. 2 mg/mL (50mg/m2 dose). As this is a cross over study, subjects receiving in Cycle 1 the Test Product (doxorubicin hydrochloride liposome injection (Ayana)will receive in Cycle 2 the Reference Product (doxorubicin hydrochloride liposome injection SunPharma); after at least 4 weeks (RT).
2384083|NCT03681535|Experimental|Single arm interventional study|RT to 19.5-20Gy is given after 3 cycles of rituximab containing chemotherapy. RT is administered daily, 5 days per week in 1.5-2Gy fractions (treatments).
2384084|NCT03681522|Experimental|Pelvic plexus block|The injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
2384085|NCT03681522|Active Comparator|Periprostatic nerve block|The injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle.
2384086|NCT03681509|Experimental|Pramipexole|Maximum daily dose: 1.0 mg of pramipexole salt
2384087|NCT03681509|Placebo Comparator|Placebo|Lactose
3142758|NCT00003254|Experimental|776C85 + 5-FU|776C85, 10mg/m2/dose, PO, Days 1-28 (BID), q 5 wk; 5-FU, 1.0mg/m2/dose, PO, Days 1-28 (BID), q 5 wk.
2384089|NCT03681470|Experimental|Patients with Acne Vulgaris|Acne Vulgaris in Patients With Skin of Color
2384090|NCT03681457|Other|Group 1 - Normal Hepatic Function|Normal hepatic function - Control - control group
2384091|NCT03681457|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment - Child-Pugh A (Score 5-6)
2384092|NCT03681457|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment - Child-Pugh B (Score 7-9)
2384093|NCT03681457|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment - Child-Pugh C (score 10-15)
2384094|NCT03681444|Experimental|Regular diet|no dietary restriction
2384095|NCT03681444|Placebo Comparator|Clear fluid diet|no solid material
2384096|NCT03681444|Experimental|Low residue diet|easy digestible food
2384097|NCT03681431|Experimental|Ceftriaxone 4g/ 24h|Single intravenous dose of Ceftriaxone 4g/ 24h
2384098|NCT03681431|Active Comparator|Ceftriaxone 2g/ 12h|Two intravenous doses of Ceftriaxone 2g/ 12h
2384099|NCT03681418|Other|Patients with operable breast cancer|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.
3142759|NCT00003255|Experimental|topotecan + carboplatin|Patients receive continuous intravenous infusions of topotecan and carboplatin for 5 days. Treatment repeats every 3-4 weeks during induction (two courses) and every 6-10 weeks during consolidation. No more than four courses of treatment are given. Patients are followed every 6 months for 5 years.
3142760|NCT00003256|Experimental|Arm I|Patients receive intravenous flavopiridol over 72 hours every 2 weeks for at least 4 courses. After 2 courses of treatment, patients not experiencing unacceptable toxic effects may receive a dose escalation.
2384104|NCT03681366|No Intervention|Single vision soft contact lens|single vision, spherical soft contact lens
2384105|NCT03681366|Experimental|DISC3.5 Plus lens|A soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
3183336|NCT00712933|Experimental|2.|10 mg/kg dose of belimumab given IV every 28 days.
2384107|NCT03681340|Experimental|Hydroxyapatite toothpaste|4 weeks toothbrushing with a hydroxyapatite toothpaste
2384108|NCT03681340|Active Comparator|Fluoridated toothpaste|4 weeks toothbrushing with a fluoridated toothpaste
2384109|NCT03681314|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
2384110|NCT03681314|No Intervention|Immediate Cord Clamping|The umbilical cord is clamped immediately after the delivery.
2384111|NCT03681301|Experimental|Interventional|Additional self-directed learning and practice using virtual reality simulator, after conventional training session
2384112|NCT03681301|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
2384113|NCT03681288|Experimental|MSC|Mindful Self-Compassion Intervention
2384114|NCT03681275|Experimental|Tofacitinib|Patient will receive two days treatment with tofacitinib prior to the surgery.
2384115|NCT03681275|Placebo Comparator|Placebo|Patient will receive two days treatment with placebo prior to the surgery.
2384116|NCT03681262|Experimental|High frequency spinal cord stimulation|Implant of the device that can deliver high frequency waveform to spinal cord
2384117|NCT03681262|Experimental|Burst spinal cord stimulation|Implant of the device that can deliver burst waveform to spinal cord
2384118|NCT03681249|Experimental|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml by mouth, twice a day for 24 weeks
2431625|NCT03355352||Patients treated with Zalviso|
3142761|NCT00003276|Experimental|irinotecan|Patients receive a 90 minute continuous infusion of irinotecan on days 1, 8, 15, and 22 for 4 weeks, followed by a 2 week rest period. Courses of treatment are repeated every 42 days. Patients continue treatment in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for the next 4 years.
3142762|NCT00003278|Experimental|radiation + dexamethasone|"Patients undergo whole-brain radiotherapy (WBRT) daily 5 days a week for 4.5 weeks. Beginning 30 days after WBRT is completed, patients receive high-dose dexamethasone IV on days 1-5 during course 1 and on day 1 only during all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed at 1 month after radiotherapy, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."
2384120|NCT03681236|No Intervention|No alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O
2384121|NCT03681236|Active Comparator|Alveolar recruitment maneuver|Applying ventilation with tidal volume 6-8mL/kg (ideal body weight) and PEEP 5cmH₂O. In addition to this, performing alveolar recruitment maneuver at 2 moments: before surgical incision, end of pneumoperitoneum
2384122|NCT03681223|Active Comparator|Restorelle® Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
2384123|NCT03681223|Experimental|Vertessa® Lite Y mesh|All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
2384125|NCT03681197|Active Comparator|Metformin Group|Will receive metformin plus clomiphene citrate
2384126|NCT03681197|Placebo Comparator|Placebo|Will receive placebo plus clomiphene citrate.
3142763|NCT00003281|Experimental|topotecan + paclitaxel + radiotherapy|"Patients receive topotecan IV over 30 minutes on days 1-3 and paclitaxel IV over 3 hours on day 3. Courses repeat every 4 weeks.~Patients who achieve partial response or stable disease continue treatment in the absence of complete response or disease progression. Patients who develop disease progression in the CNS only should receive whole brain radiotherapy and then continue treatment. Patients who achieve complete remission receive a maximum of 6 courses of treatment. Patients may then undergo prophylactic cranial irradiation and/or thoracic radiotherapy at the discretion at the attending physician.~Patients are followed every 3 months for 2 years and then at 3 years after study."
3142764|NCT00003282|Experimental|Diagnostic (EF5)|Patients receive etanidazole derivative EF5 IV over 1-2 hours beginning approximately 24 hours prior to surgery. Tumors are then resected or biopsied after Eppendorf needle electrode measurements.
2384129|NCT03681171|Experimental|Children with CP|Children with CP (9-15 years old) participated in a therapeutic dance program to improve physical, physiological and cognitive outcomes.
2384130|NCT03681158|Experimental|sodium valproate|Single oral dose of sodium valproate containing [14C]-sodium VPA
2384131|NCT03681145|Experimental|Group A-Intervention|Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
2384132|NCT03681145|Experimental|Group B-Wait-list|Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.
2384133|NCT03681132|Other|Low-threshold re-start|Re-start antiviral therapy if HBV DNA viral load >2000 IU/ml and ALT >80 U/L.
2384134|NCT03681132|Other|High-threshold re-start|"Re-start antiviral therapy if:~ALT >100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR~ALT >400 U/L persisting for more than 2 months in consecutive assays."
2384137|NCT03681106|Experimental|Kinesiotape|Kinesio Tex taping treatment for 10 days + usual care
2384138|NCT03681106|No Intervention|Control|usual care
2384142|NCT03681080|No Intervention|lying|cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)
2384143|NCT03681080|No Intervention|standing|cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)
2384144|NCT03681080|Experimental|crossed legs|cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)
2384145|NCT03681067|Experimental|GSK10708060|Humanised antibody GSK1070806
2384146|NCT03681067|Placebo Comparator|Placebo - sodium chloride|Placebo
2384147|NCT03681054|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
2384148|NCT03681054|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
2384149|NCT03681041||Pancreatic injury|Patient diagnosed with pancreatic trauma by surgery, computed tomography, Endoscopic retrograde cholangiopancreatography (ERCP) and Magnetic resonance cholangiopancreatography (MRCP) were included
3142765|NCT00003288|Experimental|Arm I|See arm description.
2384153|NCT03681002|Other|structured lifestyle program|individual counseling focusing on Lifestyle habits
2384154|NCT03680989|Placebo Comparator|Natural Light|"Participants will use a therapy light that provides ~500 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
2384333|NCT03679884|Placebo Comparator|Placebo|Tablets administered orally, once daily in the evening
3142766|NCT00003292|Experimental|ifosfamide|ifosfamide
3142767|NCT00003299|Active Comparator|Cisplatin + Etoposide|
3142768|NCT00003299|Experimental|Cisplatin + Etoposide + Paclitaxel|
3142769|NCT00003311|Experimental|Regimen A|Methotrexate IV over 24 hours on day 1. Cytarabine is administered IV over 2 hours every 12 hours on days 2 and 3. Filgrastim (G-CSF) is administered subcutaneously (SC) daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for up to 8 courses.
3150871|NCT00212576|No Intervention|Control (0-3), Control (3-5)|"Randomized at birth to receive care as usual (control) from birth through 3 years of age.~Re-randomized at 3 years to receive receive care as usual (control) from 3-5 years of age."
2384155|NCT03680989|Active Comparator|Bright Light|"Participants will receive Bright Light Exposure using a therapy light that provides ~10,000 lux at 22 for 30 minutes each morning beginning 30 minutes after waking."
2384156|NCT03680976|Experimental|10-nitro-octadeca-9-enoic acid (CXA-10)|CXA-10 150 mg tablet taken orally once a day for 12 weeks
2384157|NCT03680976|Placebo Comparator|Placebo|Placebo 150 mg tablet taken orally once a day for 12 weeks
2384158|NCT03680963|Experimental|Non-invasive strategy|Non-invasive strategy consisting of blood pressure monitoring by non-invasive automated cuff measurements
2384159|NCT03680963|Other|Control strategy|Usual strategy of systematic indwelling arterial catheter insertion in the early hours of acute circulatory failure
2384160|NCT03680950|Experimental|Upper Gastrointestinal Monitoring System|Participants who meet criteria of enrollment and is willing to join in this study will wear a real-time upper gastrointestinal monitoring system for checking whether upper gastrointestinal rebleeding occurs continuously for 3 days.
2384161|NCT03680937||Immature oocytes vitrified before in vitro maturation|Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
2384162|NCT03680937||Immature oocytes vitrified after in vitro maturation|A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
2384163|NCT03680937||Fresh oocytes|The culture of immature oocytes will be performed during 36 hours
2384166|NCT03680898|Experimental|revogene Testing|The swab will be used for the testing on the revogene using the GenePOC Carba assay.
2384167|NCT03680898|Active Comparator|Reference Method|The other swab will be used in the Reference Method.
2384168|NCT03680885|Active Comparator|Reports getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
2384169|NCT03680885|Active Comparator|Reports trouble getting numb at dentist|Subjects will be tested twice with lidocaine gel, twice with a Placebo and once with Injected Lidocaine to assess effectiveness of lidocaine. Each assessment will be on a different day.
3142770|NCT00003311|Experimental|Regimen B|Cyclophosphamide IV over 3 hours every 12 hours on days 1-3. Doxorubicin is administered IV over 24 hours on days 4 and 5. Vincristine is administered IV over 30 minutes on days 4 and 11. Dexamethasone is administered orally or IV on days 1-4 and 11-14. G-CSF is administered SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for up to 7 courses.
2384171|NCT03680859||Diabetic|Participants with a primary etiology of diabetic gastroparesis
2384172|NCT03680859||Idiopathic|Participants with a primary etiology of idiopathic gastroparesis
2384173|NCT03680859||Post-fundoplication|Participants with a primary etiology of post-Nissen fundoplication gastroparesis
2384174|NCT03680859||Diabetic with Normal Emptying|Diabetic participants with symptomatic nausea and vomiting with normal gastric emptying
2384175|NCT03680859||Idiopathic with Normal Emptying|Idiopathic participants with symptomatic nausea and vomiting with normal gastric emptying
2384176|NCT03680859||Post-fundoplication with Normal Emptying|Post-fundoplication participants with symptomatic nausea and vomiting with normal gastric emptying
3142771|NCT00003313|Experimental|Arm 1|Radiation therapy and chemotherapy + Amifostine
3142772|NCT00003313|Active Comparator|Arm 2|Radiation therapy and chemotherapy alone
2384179|NCT03680833|Other|prospective cohort study|"Prospective cohort study with detection of sentinel lymph nodes followed by a full pelvic lymphadenectomy. Patients will act as their own controls.~The intervention is the detection and removal of sentinel lymph nodes"
2384180|NCT03680820||Ages 5-9, gastroparesis|Participants 5-9 years of age at screening with documented gastroparesis (delayed gastric emptying)
2384181|NCT03680820||Ages 5-9, gastroparesis-like syndrome|Participants 5-9 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
2384182|NCT03680820||Ages 10-17, gastroparesis|Participants 10-17 years of age at screening with documented gastroparesis (delayed gastric emptying)
2384183|NCT03680820||Ages 10-17, gastroparesis-like syndrome|Participants 10-17 years of age at screening with cardinal symptoms of gastroparesis, but who have normal gastric emptying
2384184|NCT03680807||Older adults with knee osteoarthritis (>50 years)|
2384185|NCT03680807||Healthy older adults (> 50 years)|
2384186|NCT03680794|Experimental|Patients with ophthalmic surgery|
2384187|NCT03680781|Experimental|Accelerated theta burst treatment|All participants will receive theta-burst TMS.
2384188|NCT03680755|Experimental|Tr1 group|Participants assigned to Tr1 will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
2384189|NCT03680755|Experimental|Tr2 group|Participants assigned to Tr2 will complete the experimental dental anxiety management program, which will be facilitated by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
2384190|NCT03680755|No Intervention|Active control|Participants assigned to the control group, will not complete the experimental dental anxiety management program at this time. They will complete study paperwork and watch a non-dental video for 45 minutes before their scheduled dental appointment. Immediately after the dental appointment, they will complete a brief interview with the research staff person.
2384216|NCT03680573|Experimental|Apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone)|This site will receive 100 µM apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone) at an infusion rate of 2 µl/min.
2384334|NCT03679871|Other|Questionnaire validation|"22-items questionnaire Spiritual Resources and Distress"
3150872|NCT00212615|Active Comparator|A|Standard XELOX
3150873|NCT00212615|Active Comparator|B|Chronomodulated XELOX
3150874|NCT00212745|No Intervention|2|Receives only EEG and questionnaire testing, no behavioral intervention or meditative relaxation
2384192|NCT03680729|Experimental|aBSB|aBSB is the adaptation of BSB. BSB a two part intervention to improve rates of community-based HIV testing and prevention education in black young MSM (YMSM). BSB was developed on Information Motivation Behavioral Skills (IMB) theory. The first part of BSB uses Motivational Interviewing in a culturally appropriate way to encourage participants to accept testing and return for test results. The second part is conducted after the participant has received his result, assuming it was not reactive and offers prevention education.
2384193|NCT03680729|Active Comparator|Street Outreach|Standard street outreach was used as the control in the original BSB trial.
2384194|NCT03680716|Experimental|IPACK block|Saphenous nerve block and IPACK block by anesthetist under ultrasound guidance.
2384195|NCT03680716|Active Comparator|Local infiltration analgesia|Periarticular infiltration by surgeon
2384196|NCT03680703|Experimental|Internet|Guided self-help behavioral weight loss treatment delivered via the internet
2384197|NCT03680703|Experimental|Internet Plus Phone|Guided self-help behavioral weight loss treatment delivered via the internet with weekly phone consultations
2384198|NCT03680690||Group A|women with normal uterus,detected by hysteroscopy.
2384199|NCT03680690||Group B|Women with detected or corrected uterine cavitary lesions by hysteroscopy.
2384200|NCT03680677||Cancer Directed Therapy or Best Supportive Care|Cancer-directed therapy with intensive regimens, clinical trial, hypomethylating agent, hypomethylating agent combinations, targeted agents alone, or best supportive care
2384201|NCT03680677||Transplant|Bone marrow or peripheral blood graft (BMT) or CAR T-cell therapy
2384202|NCT03680664|Experimental|Active tDCS + MBSR|"Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice."
2384203|NCT03680664|Sham Comparator|sham tDCS + MBSR|"The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.~After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice."
2384204|NCT03680638|Sham Comparator|Control (Lactated Ringer's)|This site will only be infused with Lactated Ringer's during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
2384205|NCT03680638|Experimental|Tempol|This site will only be infused with tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
2384206|NCT03680638|Experimental|Apocynin|This site will only be infused with apocynin (1-(4-Hydroxy-3-methoxyphenyl)ethanone; 100µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
2384207|NCT03680638|Experimental|Allopurinol|This site will only be infused with tempol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 10µM) during the local heating stimulus. After the local heating stimulus, this site will be infused with L-NAME (Nω-nitro-L-arginine methylester; 20mM) to inhibit nitric oxide synthase and with SNP (sodium nitroprusside; 28mM) to elicit vasodilation. This will help establish nitric oxide contribution to vasodilation and establish maximal vasodilation for data normalization, respectively.
3142773|NCT00003317|Active Comparator|Surgery + paclitaxel + carboplatin|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
3142774|NCT00003317|Experimental|Surgery + paclitaxel + carboplatin + radiotherapy|Four to eight weeks after surgery, all patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on days 1, 22, 43, and 64. Following completion of four courses of chemotherapy, patients receive radiotherapy 5 days a week for 5 weeks to the mediastinum, beginning 2.5 to 4 weeks after completion of chemotherapy. Patients are followed at least every 4 months for 2 years, then every 6 months thereafter.
2384210|NCT03680612|Experimental|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|cefepime 1 g or cefepime 2 g in combination with AAI101 500 mg or 750 mg
2384211|NCT03680612|Active Comparator|cefepime monotherapy|cefepime 1 g or cefepime 2 g
2384212|NCT03680599|Experimental|Connection to Health for Smokers|Participants in this arm will participate in the Connection to Health for Smokers Arm of the study, wherein an electronic survey will be administered and participants will be guided through an evidence-based action planning sequence, taking into account each patient's unique social environment, health related behaviors, and behavioral health status, with multimodal follow up.
2384213|NCT03680599|Active Comparator|Enhanced Standard of Care|Participants in this arm will participate in Enhanced Standard Care, wherein participants will receive a brief electronic survey and receive standard smoking cessation program that does not include formal action planning and multimodal follow up.
2384215|NCT03680573|Active Comparator|Control- Lactated Ringers|This site will serve as the control site and will receive lactated Ringer's (saline solution) at an infusion rate of 2 µl/min.
2384330|NCT03679884|Experimental|ACT-541468 10 mg|Tablets administered orally, once daily in the evening
2384217|NCT03680573|Experimental|Allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)|This site will receive 10 µM allopurinol (1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one)at an infusion rate of 2 µl/min.
2384218|NCT03680573|Experimental|BH4 ((6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride)|This site will receive 10 mM (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (BH4) at an infusion rate of 2 µl/min.
2384219|NCT03680560|Experimental|ACTR T cell product in combination with trastuzumab|
2384220|NCT03680534|Experimental|Reciproc Blue|Patients in which root canal from a lower premolar was prepared with the Reciproc Blue technique.
2384221|NCT03680534|Experimental|WaveOne Gold|Patients in which root canal from a lower premolar was prepared with the WaveOne Gold technique.
2384222|NCT03680534|Experimental|XP EndoShaper|Patients in which root canal from a lower premolar was prepared with the XP EndoShaper technique.
3183337|NCT00712946||1|Arteriosclerosis obliterans patients undergoing elective vascular surgery
2384224|NCT03680508|Experimental|TSR-022 (Cobolimab) and TSR-042 (Dostarlimab)|Patients receive TSR-022 (cobolimab, TIM-3 binding antibody) and TSR-042 (dostarlimab, PD-1 binding antibody) via IV day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2384225|NCT03680495||AECOPD with Respiratory Failure|The AECOPD cohort will be hospitalized for an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure requiring invasive or non-invasive mechanical ventilation. We will be following patients from admission through to discharge, and during a follow-up visit (~2 months from discharge). During the follow-up visit we will be administering 60mg of methylprednisolone once to study possible steroid resistance.
2384226|NCT03680495||Stable COPD|The Stable COPD cohort will not have had an AECOPD within the past 6 months and will be frequency matched to the AECOPD cohort. The Stable COPD cohort will have one research visit where we will administer 60mg of methylprednisolone once to study possible steroid resistance.
2384227|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose.
2384228|NCT03680482|No Intervention|Intervention ingest a water (control group)|Subjects with type 2 diabetes who ingest a water (control group)
2384229|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet."
2384230|NCT03680469|Active Comparator|standard early rehabilitation|The standard early rehabilitation program after acute stroke is an intervention regularly utilized in the stroke center of National Taiwan University Hospital.
2384231|NCT03680469|Experimental|adding early out-of-bed mobilization|The adding early out-of-bed mobilization treatment will be defined as the patients with acute ischemic stroke who receive out-of-bed mobilization treatment in addition to standard early rehabilitation care.
2384232|NCT03680456|Active Comparator|Intervention|due to postoperative Hemoglobin Level intravenous iron Ferriccarboxymaltose is Infuses, dosage is based on the Ganzoni-Algorithm
2384233|NCT03680456|Placebo Comparator|Placebo|Natriumchlorid is the placebo
2384234|NCT03680430|Experimental|limb soft tissue sarcoma|
2384235|NCT03680417|Active Comparator|Safety Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, only assess the safety outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. This study group only assessed for safety profile of the Measles-Rubella vaccine.
2384236|NCT03680417|Active Comparator|Sub Study (Measles-Rubella vaccine)|open labeled, prospective intervention study, assess the safety and immunogenicity outcome. The Measles-Rubella vaccine is administered in infants age 9-12 months or 18 - 47 months. For Sub study, pre- and post immunization sera will be obtained from 200 infants and/or children. Safety assessment also evaluated for 28 days after immunization.
2384237|NCT03680404|Active Comparator|Control (Phenylephrine)|Subjects will be administered phenylephrine at varying concentrations (10^-2 to 10^-8 M phenylephrine) at a rate of 2 microliters/minute for 10 minutes at each dose to construct a dose-response curve.
2384238|NCT03680404|Experimental|Phenylephrine + Apocynin|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and apocynin (10^-4 M) at the same rate and for the same time as the control arm.
2384239|NCT03680404|Experimental|Phenylephrine + Allopurinol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and allopurinol (10^-5 M) at the same rate and for the same time as the control arm.
2384240|NCT03680404|Experimental|Phenylephrine + Tempol|Subjects will be coinfused with the same phenylephrine concentrations as the control arm and Tempol (10^-5 M) at the same rate and for the same time as the control arm.
2384241|NCT03680391||early postoperative feeding|103 patients will have early postoperative oral fluids and semisolid food after 6 hours of cesarean section irrespective to intestinal sounds ,flatus or stool passage
2384242|NCT03680391||Late postoperative feeding|97 patient will start oral fluids 6 hours with no solid or semi solid until after passage of flatus or stool
2384243|NCT03680378|Experimental|Cefepime 2 gram + AAI101 1 gram|cefepime 2 grams in combination with AAI101 1 gram intravenous infusion
2384244|NCT03680352|Experimental|cefepime/AAI101 combination|Investigational drug
2384245|NCT03680339|Active Comparator|Routine ecbolic group|100 patients will receive routine ecbolics ( oxytocin) after delivery of baby
2384246|NCT03680339|Active Comparator|Misoprostol group|The 100 patients will receive routine ecbolics (oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
2384247|NCT03680326||OCT|only optical coherence tomography and visual acuity testing at each visit, patients were recruited retrospectively, only data analysis
2384248|NCT03680313||Hypertension group|"All adult patients (above 18 year of age) were recruited between May, 2016 and June 2017, at Duc Giang General Hospital. The inclusion criteria are as followed:~Patients have never been diagnosed with hypertension.~Has been diagnosed with primary hypertension, but not take any treatment."
2384249|NCT03680313||Control group|A group of normal people with the similar age to hypertension group was recruited as control group at the same time
3183338|NCT00712946||2|Healthy age-matched volunteers
2384250|NCT03680300|Experimental|Post Facilitating Stretch|Each patient in group A will be given with hot pack along with Tens for 20 mins then the patient will receive post facilitation stretch only, for about one month on daily basis.
2384251|NCT03680300|Experimental|Post Isometric Relaxation|Each patient in group B will receive hot pack along with Tens for 20 mins then the patients will receive post isometric relaxation alone for about one months on daily basis.
2384252|NCT03680300|Experimental|Frictional Massage|Frictional massage will be given to 3rd group
2384253|NCT03680287|Active Comparator|Uninterrupted Sleep|Participants will be permitted to sleep without interruption for 8 hours.
2384254|NCT03680287|Experimental|Sleep Disruption|Participants will be repeatedly awakened throughout the night according to a standardized protocol.
2384255|NCT03680274|Experimental|Vitamin C|Vitamin C: 50 mg/kg every 6 hours for 96 hours.
2384256|NCT03680274|Placebo Comparator|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
2384257|NCT03680261|Experimental|Adjuvant chemoradiotherapy group|Adjuvant chemoradiotherapy (1 cycle CT: Oxaliplatin plus capecitabine (Xelox) or S-1 plus oxaliplatin (SOX), Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
2384258|NCT03680261|Active Comparator|Adjuvant chemotherapy group|Adjuvant chemotherapy (6 cycles CT: Xelox or SOX, Q21d×3) for patients enrolled in this group.
2384259|NCT03680248|Experimental|Healthy subjects, Fat|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load intervention
2384260|NCT03680248|Experimental|Steatosis, Fat|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load intervention
2384261|NCT03680248|Other|Healthy subjects, Fasting|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fasting
2384262|NCT03680248|Other|Steatosis, Fasting|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fasting
2384263|NCT03680248|Experimental|Healthy subjects, Fat+Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + glucose administration
2384264|NCT03680248|Experimental|Steatosis, Fat+Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + glucose administration
2384265|NCT03680248|Experimental|Healthy subjects, Glucose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - glucose administration
2384266|NCT03680248|Experimental|Steatosis, Glucose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - glucose administration
2384267|NCT03680248|Experimental|Healthy subjects, Fat+Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - high-fat load + fructose administration
2384268|NCT03680248|Experimental|Steatosis, Fat+Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - high-fat load + fructose administration
2384269|NCT03680248|Experimental|Healthy subjects, Fructose|non-obese insulin-sensitive male volunteers with normal hepatic fat content (less than 5% of liver fat) - fructose administration
2384270|NCT03680248|Experimental|Steatosis, Fructose|non-obese non-diabetic male volunteers with hepatosteatosis (more than 5% of liver fat) - fructose administration
2384271|NCT03680235|Active Comparator|Group I: (standard information about pregnancy, breastfeeding)|Participants receive standard information about pregnancy and breastfeeding. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
2384272|NCT03680235|Experimental|Group II (information about breastfeeding and cancer)|Participants receive standard information about pregnancy and breastfeeding as well as information about breastfeeding and breast cancer. Participants may also participate in a focus group with their partner/spouse or family members after the baby's birth.
2384273|NCT03680222|No Intervention|Standard method|Standard method recommended by the guide
2384274|NCT03680222|Experimental|Reversed Tracking Method|Reversed Tracking Method
3142775|NCT00003323|Experimental|Hormone Therapy|Treatment of prostate cancer pts post radiation or surgery with potency sparing hormones
2384276|NCT03680183||Pre-exposure|Entecavir 1Mg Oral Tablet
2384277|NCT03680183||Post-exposure|Entecavir 1Mg Oral Tablet
2384278|NCT03680170|Experimental|Working memory updating training|"Training with web-based program on the internet for 30 sessions (4-5 times a week). The result of the training is registered.~Intervention Device: web-based cognitive training"
2384279|NCT03680170|Placebo Comparator|Placebo training|"Low dose, short term memory training. Intervention: Training with computer based program on the internet for 30 sessions (4-5 times a week).~Intervention Device: Web-based cognitive training"
2384280|NCT03680144|Experimental|Diagnostic (MRI, DSC-MRI)|Participants undergo diagnostic magnetic resonance imaging (MRI) with and without contrast and treatment planning dynamic susceptibility contrast-MRI (DSC-MRI) series before receiving SRS at 4-6 weeks after SRS, and then every 3 months unless clinically indicated sooner.
3142776|NCT00003325|Other|Sentinenal lymph node mapping|Sentinenal lymph node mapping
3142777|NCT00003330|Experimental|Arm I|See detailed description.
3142778|NCT00003350|Experimental|Arm I (paclitaxel)|"Patients receive paclitaxel over 3 hours by intravenous infusion. Treatment course repeats every 2 weeks. Patients are evaluated every third course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
3150875|NCT00212745|Experimental|1|Andrews/Reiter behavioral treatment for epilepsy and EEG and questionnaire testing
2384285|NCT03680118|Experimental|autogenous rings with GBR and autogenous graft with ti-mesh|Augmentation with autogenous onlay ring blocks covered by guided bone regeneration (GBR) using collagen membrane and autogenous bone graft using titanium mesh (ti-mesh) only
2384331|NCT03679884|Experimental|ACT-541468 25 mg|Tablets administered orally, once daily in the evening
3150876|NCT00212771|Experimental|Arm 1|
3150877|NCT00212771|Active Comparator|Arm 2|
3150878|NCT00212784|Experimental|Arm 1|
3150879|NCT00212784|Active Comparator|Arm 2|
3183339|NCT00712972||1|"Patients enrolled in this study are those whom present to our institution for elective knee arthroscopy. All patients scheduled to receive a knee arthroscopy scheduled through the office of Dr. Harold Battenfield will be asked to participate in the study on the day of their procedure as long as they do not fall into one of the exclusion criteria categories.~Patients will not be allowed to participate in this study if they have an allergy to iodine or shell fish, if they have a knee effusion diagnosed clinically on the day of surgery, if the knee or surrounding tissues display cellulitis or other signs of infection, or if the patient has had a traumatic accident to their knee which significantly changes its anatomical relationships"
3183340|NCT00712998||1|Twenty subjects receiving health check program without X-ray computed tomography examination will be included as the control group.
3183341|NCT00712998||2|Twenty subjects receiving health check program including X-ray computed tomography examination of lung will be included as the treatment group-1.
3183342|NCT00712998||3|Twenty subjects receiving health check program including X-ray computed tomography examination of heart will be included as the treatment group-2.
3183343|NCT00713011|Experimental|Arm 1|
3183344|NCT00713011|Active Comparator|Arm 2|
2384295|NCT03680092|Experimental|Cyclophosphamide and abatacept|The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
2384296|NCT03680092|Active Comparator|methotrexate and tacrolimus|The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus
2384297|NCT03680079|Other|Youth with type 1 diabetes|A group of 16 teens (ages 13-18) with poorly -controlled type 1 diabetes will be recruited to participate in this study.
2384298|NCT03680066|Experimental|Foods with traces|Oral food challenge with foods with traces
2384299|NCT03680053|Experimental|PPOS group|Ovarian stimulation will use the progestin-primed ovarian stimulation (PPOS) protocol.Women will receive progesterone (oral duphaston 20mg) daily from Day 3 till the day of ovulation trigger.
2384300|NCT03680053|Active Comparator|Antagonist group|Ovarian stimulation will use the antagonist protocol. Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
2384301|NCT03680027|No Intervention|Control Group|In 'Control group' participants had 6 week follow-up without any intervention.
2384302|NCT03680027|Experimental|Interventional Group|In 'Interventional group' participants had 6 week follow-up and during that period of time, they were asked to consume 40g/day walnut. Participants in intervention group was ensured to consume all 40g of walnut every day, during their snack times for 6 weeks.
2384303|NCT03680014||1|Capable of independent of daily activities and able to mobilise unaided. No previous of falls.
2384304|NCT03680014||2|Capable of independent of daily activities and able to mobilise unaided. With a previous of atleast one fall.
2384305|NCT03680014||3|Requires help with most daily activities, mobilises with a single walking stick. No previous falls.
2384306|NCT03680014||4|Requires help with most daily activities, mobilises with a single walking stick. With a previous of atleast one fall.
2384307|NCT03680014||5|Requires help with most daily activities. Mobilise with frame or roller frame. No previous falls.
2384308|NCT03680014||6|Requires help with most daily activities. Mobilise with frame or roller frame. Previous history of at least one fall.
3183345|NCT00713024||1|Healthy control subjects
2384310|NCT03679962|Experimental|Triple Chronotherapy|Four-day intervention, with 24-hour total sleep deprivation, 3-days of sleep phase advancement and daily bright light therapy.
2384311|NCT03679962|Active Comparator|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
2384312|NCT03679949|Placebo Comparator|Placebo|Participants will receive 0 mg oxycodone (oral) and placebo cannabis (vaporized)
2384313|NCT03679949|Experimental|Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and placebo cannabis (vaporized)
2384314|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0)|Participants will receive 0 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
2384315|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
2384316|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1)|Participants will receive 0 mg oxycodone (oral) and cannabis with equal CBD and THC concentrations (vaporized)
2384317|NCT03679949|Experimental|Cannabis (THC:CBD = ~1:0) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high THC concentrations (vaporized)
2384318|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 0:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with high CBD concentrations (vaporized)
2384319|NCT03679949|Experimental|Cannabis (THC:CBD = ~ 1:1) + Oxycodone|Participants will receive 2.5 mg oxycodone (oral) and cannabis with equal concentrations of THC and CBD (vaporized)
2384320|NCT03679936||Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
2384321|NCT03679936||Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
2384322|NCT03679936||Multiple primary lung cancer group|PET/CT dynamic scan,needle biopsy and gene detection
2384323|NCT03679936||Intrapulmonary metastases group|PET/CT dynamic scan,needle biopsy and gene detection
2384324|NCT03679923|Experimental|NEM® brand eggshell membrane|NEM, 500 mg, #0 capsule, once daily orally for 2 weeks
2384325|NCT03679923|Placebo Comparator|Placebo|Placebo, 500 mg, #0 capsule, once daily orally for 2 weeks
2384326|NCT03679910||Group 1|pancreatic cancer patients (50 patients)
2384327|NCT03679910||Group2|A- Non-pancreatic cancer subjects with benign diseases will be 20 subjects. B- Healthy individuals (control): 20 apparently healthy volunteers after informed consent.
2384328|NCT03679897|Experimental|Ropivacaine group|BPB with 0.375% ropivacaine solution
2384329|NCT03679897|Active Comparator|Levobupivacaine group|BPB with 0.25% levobupivacaine solution
2431631|NCT03355313|Experimental|Low level light therapy 2|
3183346|NCT00713024||2|Patients having neuropathic pain
2384335|NCT03679858||Platelet function test in patients|Platelet function test in patients on antiplatelet therapy
2384336|NCT03679858||Platelet function test in healthy|Platelet function test in healthy subjects
2384337|NCT03679845|Experimental|Sarilumab Arm|200 mg of sarilumab every two weeks
2384338|NCT03679832||Historical Group 1|Patients admitted at UMC between September 2015 and October 2016
2384339|NCT03679832||Historical Group 2|Patients admitted at UMC between November 2016 and up to the beginning of the QIP
2384340|NCT03679832||Nutrition-Focused QIP|Patients admitted at UMC that meet eligibility criteria and prospectively enrolled into QIP including malnutrition screening, nutrition consultation, expedited provision of oral nutritional supplementation (ONS) and encouragement of ONS consumption 30-days post discharge
2384341|NCT03679819||HR-TRUS|HR-TRUS for the detection of prostate cancer in men scheduled for radical prostatectomy for localized prostate cancer
2384342|NCT03679806|Experimental|Halliwick|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
2384343|NCT03679806|Experimental|Aquatic Plyometric Exercise|Exercises were performed in a private pool owned by the local MS society twice in a week for 8 weeks. Pool depth was 120 cm 30-31°C. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase included.
2384344|NCT03679793|Active Comparator|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger.
2384345|NCT03679793|Experimental|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
2384346|NCT03679780|Active Comparator|Control|This site will serve as the control site and will receive lactated Ringer's (saline solution) (2 µl/min) throughout the entire duration of the protocol. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
2384347|NCT03679780|Experimental|Inhibitor of Endothelin Type B Receptor|This site will receive 300 nM BQ-788, an inhibitor of the endothelin type B receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
2384348|NCT03679780|Experimental|Inhibition of Endothelin Type A Receptor|This site will receive 500 nM aBQ-123, an inhibitor of endothelin type A receptors. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
2384349|NCT03679780|Experimental|L-Arginine|This site will receive 10 mM L-Arginine to supplement the substrate for endothelial nitric oxide synthase. This site will additionally receive 20mM L-NAME and 28mM SNP to inhibit nitric oxide (NO) production and elicit vasodilation, respectively, to assess NO contribution and maximal vasodilation.
3142779|NCT00003350|Experimental|Arm II (pegylated liposomal doxorubicin hydrochloride)|"Patients receive doxorubicin HCL liposome over 30-60 minutes by intravenous infusion. Treatment course is repeated every 3 weeks. Patients are evaluated before every odd course.~Patients in both arms continue treatment if there is no disease progression or unacceptable toxicity. Patients with complete response continue on study treatment for 2 courses beyond documented complete response.~Quality of life is assessed before, during, and after treatment."
2384351|NCT03679754|Experimental|Ad-RTS-hIL-12 + veledimex|Intratumoral Ad-RTS-hIL-12 and oral veledimex
2384354|NCT03679728||First trimester|Group of children from mother affected by Zika virus in the first trimester of pregnancy.
2384355|NCT03679728||Second trimester|Group of Children from mother affected by Zika virus in the second trimester of pregnancy.
2384356|NCT03679715|Experimental|Intervention group|The participants in the Intervention group will be participants of the museum participatory art-based activity.
2384357|NCT03679715|No Intervention|Control Group|The Control arm will be composed of older community dwellers matched on age and sex compared to the Intervention group but who will not be participants at the museum participatory art-based activity.
2384358|NCT03679702|Other|Active treatment|
2384359|NCT03679689|No Intervention|Control group|no changes in their alimentary habits
2384360|NCT03679689|Experimental|intervention group|no intake of artificially sweetened beverages
2384361|NCT03679676|Other|Cohort A: Omalizumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with placebo
2384362|NCT03679676|Other|Cohort B: Omalizumab/Dupilumab|Participants will be treated with omalizumab for 8 weeks, followed by 24 weeks of treatment with dupilumab.
2384363|NCT03679676|Other|Cohort C: Dupilumab|Participants will be treated with placebo for 8 weeks, followed by 24 weeks of treatment with dupilumab.
2384364|NCT03679663|No Intervention|Palpation|Anesthesia performed without ultrasound
2384365|NCT03679663|Experimental|Ultrasound|Anesthesia performed after ultrasound
3142780|NCT00003351|Experimental|Arm I: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every week for 4 weeks followed by a 2 week rest period. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
3142781|NCT00003351|Experimental|Arm II: irinotecan|"Patients receive irinotecan intravenously over 90 minutes every 3 weeks for 6 weeks. Treatment is repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before and during treatment. Patients are followed every 3 months for 2 years, then annually for 1 year."
2384368|NCT03679637|Experimental|Intervention group|Each participant will receive a tablet-based aphasia therapy
2384402|NCT03679442|Experimental|Healthy individuals|Healthy individuals received intravenous N-acetylcysteine (NAC) treatment to investigate its actions on macrophage activation assessed by the markers soluble CD163 and CD206
3142782|NCT00003369|Experimental|tirapazamine/cisplatin|tirapazamine and cisplatin given Day 1 of each 21-day treatment cycle
3150880|NCT00212797|Experimental|Org 34517_1|low dose Org 34517
3150881|NCT00212797|Experimental|Org 34517_2|high dose Org 34517
2384373|NCT03679598|Active Comparator|Alvelestat (MPH966)|Alvelestat (MPH966) 120mg (4 30mg tablets) twice daily by mouth for 12 weeks
2384374|NCT03679598|Placebo Comparator|Placebo|4 Placebo tablets twice daily by mouth for 12 weeks
2384375|NCT03679585|Experimental|Supportive Care (social media intervention)|Participants undergo Talking Pictures social media intervention for 10 weeks, receiving weekly assignments via email with requirements to use the Pixstori app to take and upload photographs with verbal narratives attached to a website. Participants can then share their pixstories to a group page and view and respond to others' pixstories.
2384376|NCT03679572|Experimental|Robot assisted partial nephrectomy super-selective clamping|The Da Vinci robot (device) allows to use near-infrared fluorescence in order to clamp precisely the branches of the vascularization for the partial nephrectomy. The healthy parenchyma ischemia is avoided.
2384377|NCT03679572|Active Comparator|Robot assisted partial nephrectomy with renal artery clamping|The partial nephrectomy with robotic assistance is performed using a renal artery. It's the conventional method.
2384378|NCT03679559|Experimental|Arm I (home-based walking program, resistance training)|Participants wear Fitbit, receive home-based DVD containing instructions to warm-up and cool-down, and brisk walk 30 minutes per day 5 days a week in order to achieve the 150 minutes per week of moderate intensity exercise. Participants also receive resistance training by watching the illustration video and completing 6 total blocks of 2-week per block exercise using the Thera-BandR exercise bands.
2384379|NCT03679559|Experimental|Arm II (home-based Zumba program, resistance training)|Participants wear Fitbit and receive a XBOX system and the video game to strive for at least 3 50-minute medium or high intensity classes per week over 12 weeks. Participants may also take 20-minute classes or a mixture of 50- and 20-minute classes to meet the target. Participants receive resistance training as in Arm I.
2384380|NCT03679559|Experimental|Arm III (HIIT, resistance training)|Participants wear Fitbit and attend supervised HIIT exercise sessions 3 days per week over 12 weeks. Participants receive resistance training as in Arm I.
2384381|NCT03679559|Active Comparator|Arm IV (supervised moderate intensity walking program)|Participants wear Fitbit and attend supervised moderate intensity walking sessions weekly for 50-60 each over 12 weeks. Participants undergo resistance training as in Arm I.
2384382|NCT03679559|Active Comparator|Arm V (usual physical activity)|Participants wear Fitbit and continue their usual physical activity over 12 weeks.
2384383|NCT03679546|Experimental|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
2384384|NCT03679546|Experimental|Vedolizumab|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
2384385|NCT03679533|Active Comparator|Active Cranberry Study Food|
2384386|NCT03679533|Placebo Comparator|Placebo Study Food|
2384387|NCT03679520|Experimental|New programme|A new programme of antenatal parental preparation provided by midwives to groups with 8-16 individuals. It will include 5 sessions á 2 hours and start in gestational week 25.
2384388|NCT03679520|Active Comparator|Regular programme|A regular programme of antenatal parental preparation provided by midwives to groups of 8-16 individuals and encompassing between 5 and 7 hours of antenatal parental preparation.
2384389|NCT03679507|Active Comparator|Group A|The first patient group will receive Low Intensity Ultrasound Therapy on the affected knee joint, using the CPI-LIPUS Device
2384390|NCT03679507|Placebo Comparator|Group B|"Will be treated with an identical device whose ultrasound emitting capabilities has been nullified. This device appears to operate, including illumination of the operating light."
2384391|NCT03679507|Active Comparator|Group B1|The first patient group will receive high CBD oil applied topically to the affected knee joint.
2384392|NCT03679507|No Intervention|Group B2|This group of patients will not receive high CBD oil to the affected joint.
2384395|NCT03679481|Experimental|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
2384396|NCT03679481|Placebo Comparator|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
2384397|NCT03679468|Sham Comparator|Cognitive Rehab & Sham Exercise|Cognitive Rehabilitation by computer based brain tasks, and Sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
2384398|NCT03679468|Sham Comparator|Sham Cognitive Rehab & Sham Exercise|Sham cognitive Rehabilitation will consist of basic internet searches and learning to use a computer, and sham exercises focusing primary on balance and stretching. Sessions will take place twice a week for 12 weeks.
2384399|NCT03679468|Sham Comparator|Sham Cognitive rehab & Aerobic Exercise|Sham cognitive rehabilitation will consist of basic internet searches and learning to use a computer, and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
2384400|NCT03679468|Active Comparator|Cognitive Rehab & Aerobic Exercise|Cognitive Rehabilitation by computer based brain tasks and aerobic exercises will focus primarily on improving cardio-respiratory fitness using a recumbent bike. Sessions will take place twice a week for 12 weeks.
2384401|NCT03679455|Experimental|Treatment arm|Obinutuzumab (RO5072759) 25 MG/ML; Obinutuzumab will be administered by iv. infusion as an absolute (flat) dose of 1000 mg.
2384519|NCT03678688|Active Comparator|Stage 1 and Stage 2: RHEZ|
2384520|NCT03678688|Experimental|Stage 1 Cohort 1|
3150882|NCT00212797|Placebo Comparator|Placebo|
3150883|NCT00212836|Experimental|Asenapine|
3150884|NCT00212836|Active Comparator|Olanzapine|
3150885|NCT00212862||Patients with chemotherapy induced anemia|
3150886|NCT00212979||non intervention study|
3150887|NCT00213252|Experimental|1|
3150888|NCT00213252|Active Comparator|2|
3150889|NCT00213265|Active Comparator|1|
2384403|NCT03679429||Control group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
2384404|NCT03679429||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined by using the NBI function of the scope.
2384405|NCT03679403||ADHD Probands|Subjects with DSM-IV ADHD who received the same MRI and CANTAB+CPT assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at the estimated age of 15-25.
2384406|NCT03679403||Unaffected siblings of ADHD|The unaffected siblings received the MRI and CANTAB+CPT assessments during 2013.8-2015.7 (NCT01682915) will be recruited and assessed.
2384407|NCT03679403||Neurotypicals Follow-up|Subjects without any lifetime diagnosis of DSM-IV ADHD or other psychiatric disorders as the control group of the ADHDFU group around 4-8 years ago when they received the same MRI and neuropsychological assessments during 2010.8-2015.7(NCT00916851, NCT01682915) at their age of 8-17 will be reassessed at their estimated age of 15-25.
2384408|NCT03679390|Experimental|10-20 y/o|We will include the teenagers who need intravenous general anesthesia(IVGA), and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
2384409|NCT03679390|Experimental|20-40y/o group|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
2384410|NCT03679390|Experimental|>70 y/o|We will include patients who need IVGA, and inject propofol with/without ketamine 0.5mg/kg with full monitor. We will record the EEG during the who operation.
2384411|NCT03679377|Experimental|Mandibular slotplate|Mandibular slotplates are placed during BSSO surgery and their clinical usefullness is tested. Afterwards the plates are removed and the osteotomy is fixated by three bicortical screws.
2384412|NCT03679364||LUOTAI group|LUOTAI group treated with LUOTAI with dosage, dosing schedule and duration follows local clinical practice in accordance with the terms of the local marketing authorization: 400mg of LUOTAI injectable lyophilized powder diluted in 250ml of 5% Glucose Solution or 0.9% Normal Saline for included diabetic patients, via slow intravenous infusion, once daily for consecutive 14 days, and followed by 200mg of LUOTAI soft capsules, three times a day for 65 days.
2384413|NCT03679364||Control group|Control group comprises of patients who are not treated with LUOTAI, and follows local clinical practice for ischemic stroke.
2384414|NCT03679338|Other|Ablation Therapy With Bipolar Radio Frequency|
2384415|NCT03679325|Active Comparator|vitamine D|a dose once a week
2384416|NCT03679325|Placebo Comparator|vitamine D placebo|a dose once a week
2384417|NCT03679312|Experimental|COPD Group|COPD to receive either placebo or inhaled nitric oxide (40ppm)
2384418|NCT03679312|Experimental|Control Group|Control group to receive either placebo or inhaled nitric oxide (40ppm)
3142783|NCT00003370|Experimental|Arm I|"If the dose limiting toxicity is myelosuppression in stratum 1, then stratum 1 is closed and stratum 2 opens.~Stratum 2 consists of the following: patients receiving no more than 2 prior chemotherapy regimens; patients who have not received prior central axis radiation or bone marrow transplantation; and patients with no known bone marrow involvement. Patients receive intravenous 6-hydroxymethylacylfulvene over 10 minutes daily for 5 days. The course is repeated every 28 days unless disease progression or unacceptable toxic effects are observed. Patients with stable or responding disease may receive up to 1 year of therapy. If dose limiting toxicity occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the maximum tolerated dose. Dose escalation will not occur until all patients within a cohort have been observed for 28 days from day 1 of therapy. Patients are followed until death."
3142784|NCT00003375|No Intervention|Observation|Observation only.
2384421|NCT03679286||All subjects|No intervention
2384422|NCT03679273|Experimental|Abound supplement|The participant will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
2384423|NCT03679273|No Intervention|Traditional supplement|The participant will take traditional diabetes-specific formula as provided by dietitians.
2384424|NCT03679260|Experimental|Arm A|Carbohydrate restricted diet and phone counseling with dietitian. After 6 months, patients will crossover to a non-restricted diet.
2384425|NCT03679260|Experimental|Arm B|Non-restricted diet and after 6 months, patients will crossover to a carbohydrate restricted diet and phone counseling with dietitian
3142785|NCT00003375|Experimental|Radiation therapy|Radiation therapy only.
3142786|NCT00003375|Experimental|Radiation plus PCV chemotherapy|Radiation and Procarbazine/CCNU/Vincristine (PCV) chemotherapy
2384428|NCT03679234|Experimental|Intervention|Routine infant formula
2384429|NCT03679221||Group 45-54 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
2384430|NCT03679221||Group 54-64 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
2384431|NCT03679221||Group 65-74 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
2384432|NCT03679221||Group 75-85 years old|divided in two subgroups: individuals with and without cardio-vascular risk factors and diseases
2384433|NCT03679208|Experimental|Stage 1 Safety cohort|Two injections of the investigational device (KIO014) at 3-month interval in 10 patients and 12-month follow-up to establish long-term safety as primary endpoint.
2384434|NCT03679208|Experimental|Stage 2 Performance (test group)|One injection of the investigational device (KIO014) in 60 patients to evaluate the reduction in pain at 3 months as primary endpoint. Additional follow-up at 6 months.
2384435|NCT03679208|Active Comparator|Stage 2 Performance (control group)|One injection of the control device (Durolane(r)) in 30 patients to evaluate the reduction in pain at 3 months as control endpoint. Additional follow-up at 6 months.
2384521|NCT03678688|Experimental|Stage 1 Cohort 2|
2384522|NCT03678688|Experimental|Stage 1 Cohort 3|
2384523|NCT03678688|Experimental|Stage 1 Cohort 4|
3150890|NCT00213265|Experimental|2|
3150891|NCT00213278|Experimental|1|
2384436|NCT03679195|Experimental|NO Ultra (Nitric Oxid Ultra Capsules)|764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline. Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
2384437|NCT03679195|Placebo Comparator|Placebo (Cellulose Capsules)|Participants will consume cellulose capsules that are similar in shape and size to the NO ultra product, i.e. 2 capsules between breakfast and lunch and 2 other capsules between lunch and dinner.
2384438|NCT03679182|Experimental|Olanzapine|Olanzapine 5 mg at 0, 12, 24 and 36 hours
2384439|NCT03679169|Experimental|Group RAMPS|Radical antegrade modular pancreatosplenectomy
2384440|NCT03679169|Active Comparator|Group SPS|standard pancreatosplenectomy
2384441|NCT03679143|Experimental|ZSP1273(single dose)-100 mg(Cohort 1)|ZSP1273 100 mg /Placebo
2384442|NCT03679143|Experimental|ZSP1273(single dose)-200 mg(Cohort 2)|"ZSP1273 200mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1."
2384443|NCT03679143|Experimental|ZSP1273(single dose)-400 mg(Cohort 3)|"ZSP1273 400mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2."
2384444|NCT03679143|Experimental|ZSP1273(single dose)-600 mg(Cohort 4)|"ZSP1273 600 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3."
2384445|NCT03679143|Experimental|ZSP1273(single dose)-900 mg(Cohort 5)|"Drug:ZSP1273 900 mg/Placebo 900mg；~Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4."
2384446|NCT03679143|Experimental|ZSP1273(single dose)-1200 mg(Cohort 6)|"ZSP1273 1200 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5."
2384447|NCT03679143|Experimental|ZSP1273(Food Effect)-Cohort 7|"Drug:ZSP1273 /Placebo； Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8."
2384448|NCT03679143|Experimental|ZSP1273(multiple doses)-Low Dose(Cohort 8)|"while fasted or fed according to the results of Cohort FE~ZSP1273 /Placebo for 5 Days."
2384449|NCT03679143|Experimental|ZSP1273(multiple doses)-Median Dose(Cohort 9)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
2384450|NCT03679143|Experimental|ZSP1273(multiple doses)-High Dose(Cohort 10)|"while fasted or fed according to the results of Cohort FE~ZSP1273/Placebo for 5 Days."
2384451|NCT03679130|Experimental|Structured exercise training (EXE)|Structured supervised exercise training (EXE) contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
2384452|NCT03679130|Experimental|Motivational counseling (MOT)|Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
2384453|NCT03679130|No Intervention|Control group (CON)|Control group receiving standard treatment.
2384454|NCT03679117|Experimental|Mindfulness Training|Phone-delivered mindfulness training
2384455|NCT03679117|No Intervention|Treatment as Usual|Prenatal care
2384456|NCT03679104|Active Comparator|Endoscopic clips|Closure of mucosotomy using endoscopic clips
2384457|NCT03679104|Active Comparator|OverStitch™ suturing device|Closure of mucosotomy using OverStitch™ suturing device
2384460|NCT03679078|Experimental|IDDSI nutritional supplement drink|Single arm designed, 28day on IDDSI nutritional supplement drink
2384461|NCT03679065|Active Comparator|P (Paracetamol) group:(n=100)|
2384462|NCT03679065|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
2384463|NCT03679065|Placebo Comparator|Placebo|
2384464|NCT03679052|Active Comparator|Group I (Mirtazapine group): (n=100)|
2384465|NCT03679052|Active Comparator|Group II (Clonidine group): (n=100)|
2384466|NCT03679052|Placebo Comparator|Group III (Control group): (n=100)|
2384467|NCT03679026||CVRF|individuals with cardio-vascular risk factors and diseases
2384468|NCT03679026||WCVRF|individuals without cardio-vascular risk factors and diseases
2384469|NCT03679013|Other|Opoid based standard of care regimen.|Inova Heart and Vascular Institute (IHVI) opioid based standard of care regimen given for post operative cardiac surgery pain.
2384470|NCT03679013|Experimental|Opioid sparing pain regimen.|Multimodal pain regimen consisting of PO Gabapentin paired with intravenous Acetaminophen given for post operative cardiac surgery pain.
2384471|NCT03679000||The reproductive health of couples|The study is a prospective cohort study, and its participants are childbearing couples who are seeking assisted reproductive technologies for having a baby in the reproductive center in Tongji Hospital.The study is a observational study.
2384472|NCT03678987||SSc on MMF|"Patients with systemic sclerosis using mycophenolate mofetil (mycophenolic acid, MMF) since >3 months.~During a 6 hour time period, P-MPA concentration will be measured 4 times."
2384473|NCT03678974|Experimental|Exercise|Subjects will receive metabolic testing, exercise prescription, YMCA memberships, and physician based on Intensive Behavioral Therapy for Obesity utilizing CardioCoach app.
2384474|NCT03678961||Group N|Neutral position
2384475|NCT03678961||Group E|External rotation of leg by 45 degrees
2384476|NCT03678961||Group EF45|External rotation of leg by 45 degrees, hip flexion by 45 degrees, and knee flexion by 45 degrees
2384477|NCT03678961||Group EF15|External rotation of leg by 45 degrees, hip flexion by 15 degrees, and knee flexion by 15 degrees
2384524|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid|
2384525|NCT03678688|Experimental|Stage 2: OPC-167832/Bedaquiline|
2384526|NCT03678688|Experimental|Stage 2: OPC-167832/Delamanid/Bedaquiline|
2384478|NCT03678948|Active Comparator|Radiofrequency-Based Debridement|The Smith and Nephew WEREWOLF COBLATION System is indicated for all soft tissue types in the knee. The WEREWOLF COBLATION System is a FDA cleared bipolar, radiofrequency electrosurgical system designed for use in orthopaedic/arthroscopic surgical procedures.
2384479|NCT03678948|Active Comparator|Mechanical Debridement|
2384480|NCT03678935|Active Comparator|Low FODMAP diet (LFD)|The LFD wil receive advice on how to follow a low FODMAP diet. They wil follow this diet for 4 weeks. Thereafter they receive advice on how to reintroduce high FODMAPs again.
2384481|NCT03678935|No Intervention|Control|Control group. Participants follow their regular gluten-free diet (GFD), with no changes to their diet. They wil receive the same dietary advice as the LFD-group after the 4-week study.
2384482|NCT03678909||Hypoplastic Left Heart Disease|Patients with congenital hypoplastic left heart disease who will undergo surgical palliation with Norwood procedure or DKS or Damus-Kaye-Stansel procedure
2384483|NCT03678896|Experimental|CrewD Program approach|"The aim was to increase education about the disease by using narrative skills through the CrewD Program. The sessions were conducted by two group leaders: a health professional and a literature professor manager of creative writing groups.~Each session had a title, which parallels the classical structured educational approach (active comparator condition), which was known in advance by the subjects: a) Who I am in Diabetes?; b) Nutrition; c) The body where I live; d) Fears; e) Can attention change things?; and f) Roots.~Team leaders directed a discussion of different texts used in the sessions with the participants focusing on their feelings and on how the texts relate to themselves and to their diabetes. Patients were encouraged to participate and freely express their opinion."
2384484|NCT03678896|Active Comparator|Classical structured education|"Each session was 90 minutes long, with a similar internal structure in all of them. Each session included the following topics: a) Chronic Disease; b) Nutrition; c) Exercise; d) Complications; e) Self-management; and f) Diabetic foot. The sessions were held in a large room, in which the seats were arranged in circle. Every session was chaired by two healthcare providers, who worked as group leaders.~There was a different visual presentation in each session, with relevant theoretical information. A board with sheets of paper was available for use in the discussion along with brochures about the disease.~Patients were encouraged to actively participate and take part in group-problem solving. Group leaders guided the discussion by asking questions and encouraging the discussion."
2384485|NCT03678883|Experimental|9-ING-41|Drug: 9-ING-41
2384486|NCT03678883|Experimental|9-ING-41 plus Gemcitabine|Drugs: Gemcitabine - 21 day cycle. 9-ING-41
2384487|NCT03678883|Experimental|9-ING-41 plus Doxorubicin|Drugs: Doxorubicin. 9-ING-41
2384488|NCT03678883|Experimental|9-ING-41 plus Lomustine|Drugs: Lomustine. 9-ING-41.
2384489|NCT03678883|Experimental|9-ING-41 plus Carboplatin|Drugs: Carboplatin. 9-ING-41.
2384490|NCT03678883|Experimental|9-ING-41 plus nab paclitaxel Gemcitabine|Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.
2384491|NCT03678883|Experimental|9-ING-41 plus Paclitaxel/Carboplatin|Drugs: Paclitaxel. Carboplatin. 9-ING-41.
2384492|NCT03678883|Experimental|9-ING-41 plus Irinotecan|Drugs: Irinotecan. 9-ING-41.
2384495|NCT03678857|Experimental|Creatine Before|Receives Creatine before and placebo after training.
2384496|NCT03678857|Experimental|Creatine After|Receives creatine after and placebo before training.
2384497|NCT03678844|Experimental|Taekwondo practice|
2384498|NCT03678844|Placebo Comparator|CONTROL|
2384499|NCT03678831||Arthritic patients with knee prosthetic replace|Arthritic post-menopausal patients with knee prosthetic replacement Each patient is her own control since the two cell types are compared within the same patient The main criteria is based on a comparison of two cell types from the same patient. The secondary criteria are based on a comparison of cell types according to a grouping of patients according to different metabolic parameters.
2384500|NCT03678818|Experimental|Handling Medium Supplemented with Latrunculin A|
2384501|NCT03678818|No Intervention|Handling Medium as it is.|
2384502|NCT03678805|Experimental|Acceleration|The impacted canines will undergo acceleration by corticotomy accompanied with traditional traction techniques.
2384503|NCT03678805|Active Comparator|Traditional Traction|"Traditional traction will be employed in this group of patients with impacted canines.~Traditional withdrawal techniques will be used."
2384504|NCT03678792|Other|Buprenorphine-Naloxone|Standard of Care
2384505|NCT03678792|Experimental|Morphine|
2384506|NCT03678792|Experimental|Tramadol|
2384507|NCT03678779|Experimental|Incentive|Each week parents received one $5 grocery store gift card per child in the household, intended for the purchase of healthy snacks, donated to the study by a partnering grocery store
2384508|NCT03678779|Experimental|Education|Parents received brief weekly nutrition education videos (approximately one minute in length, uploaded on YouTube and viewable on most operating systems and on mobile devices
2384509|NCT03678779|Experimental|Combined|Parents received both the Incentive and Education arm interventions
2384510|NCT03678766|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experimental learning.
2384511|NCT03678766|Experimental|Cognitive Behavior Therapy (CBT)|CBT provides coping skills, self-monitoring, and goal setting.
2384514|NCT03678714|Experimental|Exercise Intervention|Structured exercise intervention will be undertaken for 12 weeks
2384515|NCT03678714|Experimental|Lifestyle Physical Activity|Increased lifestyle physical activity undertaken for 12 weeks
2384516|NCT03678714|No Intervention|Control|Resting control
2384517|NCT03678701|Experimental|Protein group|The protein group will consume 30g of 100% whey protein shake 1 hour before lunch and before dinner, for 12 weeks
2384518|NCT03678701|No Intervention|Control group|Control group will not consume any protein supplements. They will continue the usual feeding habits
2384527|NCT03678675|No Intervention|Standard Protocol|Subjects randomized to the standard group will receive the standard postoperative pain protocol that is currently used at Tufts Medical Center. It includes two doses of IV Ketorolac every 6 hours as needed for postoperative pain.
2384528|NCT03678675|Experimental|Ketorolac Protocol|Subjects randomized to the Ketorolac protocol will receive the study postoperative pain protocol. This includes 5 doses of IV Ketorolac, scheduled every 6 hours. The first dose is administered in the operating room.
2384529|NCT03678662|Experimental|hyperalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-enhancing effects.
2384530|NCT03678662|Experimental|hypoalgesia expectation|In this group the subjects will be told that the 3 minutes wall squat will have pain-diminishing effects.
2384531|NCT03678662|Active Comparator|Neutral|In this group the subjects expectations are not manipulated
2384532|NCT03678649|Experimental|the treatment arm|"1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .~it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent"
2384533|NCT03678649|No Intervention|the control arm|clinical observation
2384534|NCT03678636|Experimental|Intervention|The wound will be treated with a silver antimicrobial dressing appropriate for the exudate level as per manufacturer instructions for use for 2 weeks +/- 3 days, in addition to any necessary standard care (e.g. compression for a venous leg wound).
2384535|NCT03678636|Active Comparator|Control|The wound will be treated as per usual care.
2384536|NCT03678623||Office-based workers|Individuals working in an office environment with their main tasks involving use of a computer, reading, phoning, making presentations and participating in meetings, who perform more than 30 hours per week mostly sitting at a computer.
2384537|NCT03678610|Experimental|ICSI medium supplemented with Ionomycin and Latrunculin A|
2384538|NCT03678610|No Intervention|ICSI medium as it is|
2384539|NCT03678597|Experimental|Handling Medium Supplemented with Latrunculin B|
2384540|NCT03678597|No Intervention|handling Medium as it is.|
2384541|NCT03678584|Experimental|Handling Medium Supplemented with Chaetoglobosin A|
2384542|NCT03678584|No Intervention|handling Medium as it is.|
2384543|NCT03678571|Experimental|Latrunculin A supplemented vitrification medium|
2384544|NCT03678571|No Intervention|Vitrification medium with no supplementation|
2384545|NCT03678558|Experimental|Cytochalasin B supplemented vitrification medium|
2384546|NCT03678558|No Intervention|Vitrification medium with no supplementation|
3150892|NCT00213291|Experimental|1|
3150893|NCT00213304|Experimental|varicella vaccine (VARIVAX)|varicella vaccine (VARIVAX)
2384549|NCT03678532|Experimental|Daily interruption of sedation (control group)|Control group received daily interruption of sedation. After intubation, patients received IV infusion of midazolam. 1-2 mg / hour with increments 1-2 mg/hr gradually increasing dose till RASS reached -4 or -5. Infusion stopped at 7:00 AM. If the patient is awake no need for resuming infusion. If signs of discomfort occurred, infusion resumed at half of the prior dose, targeting conscious sedation (RASS 0: -3)
2384550|NCT03678532|Experimental|No sedation|Intervention group were managed by no-sedation strategy. Patients received bolus doses of midazolam (1-5 mg) only when needed, after atrial to control agitation by correcting the underlying cause. If the patient needed more than 3 bolus doses , IV infusion of midazolam was given by the daily interruption protocol as in the control group. No crossover was allowed between groups. Analysis was done by intension-to-treat principle.
2384551|NCT03678519||Exposed workers|Flour mills workers exposed to health hazards
2384552|NCT03678506|Experimental|Positive D-Dimer|At the first positive D-dimer results (during anticoagulation or after its temporary withdrawal) the patients are invited to assume Eliquis (apixaban) 2.5 mg twice daily, and continue this therapy for the following 18 months.
2384553|NCT03678506|No Intervention|Negative D-Dimer|Patients with persistently negative results at the four serial D-dimer measurements, stay definitively without anticoagulation and discouraged to resume any antithrombotic drug for secondary VTE prevention.
2384554|NCT03678493|Experimental|AML Patients undergoing Intensive Chemothera|
2384555|NCT03678493|Placebo Comparator|AML Patients undergoing Intensive Chemotherapy Control|
2384556|NCT03678493|Experimental|AML Patients undergoing Allo-HCT Patients|
2384557|NCT03678493|Placebo Comparator|AML Patients undergoing Allo-HCT Patients Control|
2384558|NCT03678480|Experimental|HTD1801 500 mg BID (twice daily), or 1000 mg/day|HTD1801 tablets in double-blind capsules, 250 mg
2384559|NCT03678480|Active Comparator|Ursodeoxycholic Acid (UDCA) 250 mg BID, or 500 mg/day|UDCA tablets in double-blind capsules, 250 mg
2384560|NCT03678467|Experimental|EB-CMF Implant|Subject receiving EB-CMF implant
2384561|NCT03678441|Experimental|Group I (BrainCheck and paper and pen cognitive assessment)|Patients receive the BrainCheck cognitive assessment over 15 minutes followed by the paper and pen assessment 2 months prior to surgery and within 2 months after surgery.
2384562|NCT03678441|Active Comparator|Group II (pen and paper and BrainCheck cognitive assessment)|Patients receive the paper and pen assessment followed by the BrainCheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.
2384563|NCT03678428|Experimental|FUDR/Oxaliplatin HAI plus irinotecan|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
2384564|NCT03678428|Active Comparator|FOLFOXIRI|"Patients will receive Systemic FOLFOXIRI every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and Day 15; Oxaliplatin 85 mg/m2 IV in 3-6 hours on Day 1 and Day 15; Leucovorin 200mg/m2 and 5-FU 2400mg/m2 CIV in 46 hours on Day 1 and Day 15."
2384600|NCT03678129|Experimental|AZD7325_10, AZD7325_20, Placebo|Dose order: AZD7325 10mg, AZD7325 20mg, Placebo
2384601|NCT03678129|Experimental|AZD7325_20, AZD7325_10, Placebo|Dose order: AZD7325 20mg, AZD7325 10mg, Placebo
2385189|NCT03674060|Experimental|SYO-1644 100mg|SYO-1644 tablet, PO, 1 100mg tablet
2384565|NCT03678415|Experimental|Control|In the control arm, the community healthcare providers serve usual health education like counseling as they provided in perinatal period of enrolled mothers regular follow up basis. This health education is different from developed intervention. But service provider does not know. The investigators select community clinic before provide training regarding training manual. For this, the investigators selected 11 cluster randomly among the 23 community clinics' in the primary health care in study area and provide common health education instructions to the enrolled mothers. But service providers does not know the intervention package services that will provide in intervention arm's service providers.
2384568|NCT03678376|Other|complaint, cognitive and functional assessments|All patients will be included in a single arm. They will complete an evaluation with their General Practitioner, followed by an evaluation at the Memory Clinic with a specialist (neurologist, geriatrician or psychiatrist).
2384569|NCT03678363|Experimental|interventional group A|2 tai chi session per week during 4 month (M0 to M4)
2384570|NCT03678363|Placebo Comparator|Control group B|2 tai chi session per week during 2 month (M2 to M4)
3150894|NCT00213421||1|
2384572|NCT03678337||Observational cohort with plasma samples|
2384573|NCT03678324|Other|Fabry|Must be 18 or older and able to have an MRI.
2384576|NCT03678272|Active Comparator|HERNIOPLASTY WITH PANAVALE MESH|Preformed polypropylene mesh.
2384577|NCT03678272|Active Comparator|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|Mesh consisting of mono lament polyester with a resorbable polylactic acid (PLA) microgrip technology.
2384578|NCT03678272|Active Comparator|HERNIOPLASTY WITH ADHESIX MESH|Self-adhesive mesh.
2384579|NCT03678272|Active Comparator|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh.
2384580|NCT03678259|Experimental|124I-p5+14 Injection|A single-injection dose of 124I-p5+14 adequate for imaging amyloid deposits by using PET/CT imaging in subjects with confirmed systemic amyloidosis of several sub-types.
2384581|NCT03678246|Experimental|LSFOI (Ramped)|LSFOI (Ramped)
2384582|NCT03678246|Active Comparator|LSFOI (Supine)|LSFOI (Supine)
2384583|NCT03678233|Active Comparator|Intervention|AndroGel® AndroGel 16.2 mg/L will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women
2384584|NCT03678233|No Intervention|Control|In the control group, AndroGel will not be administered.
2384585|NCT03678220|Experimental|Patients using LapAR system|
2384586|NCT03678207||Potential Undiagnosed HTN|
2384587|NCT03678194|Experimental|Smartphone application|This group of subjects receives mobile support system and conventional treatment (clinical evaluation and follow-up). The smartphone application will be downloaded on patients' smartphone to daily evaluate symptomatology, medication adherence…
2384588|NCT03678194|No Intervention|Standard services|This group of patients receives conventional treatment only. Clinical evaluations are provided at the same endpoint. Patients still receive standard services for depression.
2384589|NCT03678181|Active Comparator|Information-Only Arm|The HMP 2.0 Information-Only Control Arm will feature a streamlined version of the website that provides tailored information and content for YBLMT. This follows the design of HMP 1.0 where control arm participants had access to HIV-related Knowledge Center articles of the main intervention without access to the engagement features, interactive forums, or doctor Q&A. HIV-negative and sero-unknown participants also will be able to request HIV home test kits. The choice of control arm balances equipoise with research study design; in HMP 1.0, control arm participants also experienced a statistically significant intervention benefit.
2384590|NCT03678181|Experimental|HMP 2.0 Arm|Participants in this experimental arm will receive access to HMP 2.0, an interactive site that includes a Knowledge Center focused on HIV prevention content, interactive forums, and a provider question & answer platform.
2384591|NCT03678181|Experimental|Peer-referred HMP network arm|Participants randomized to Intervention Arm 2 (peer-created network) will be enrolled into a parallel (but separate) version of HMP 2.0. The only difference between the two intervention arms is that the peer-referred HMP network arm will allow participants to refer and enroll 2 peers of their choosing into the study.
2384592|NCT03678168|Other|Control|Standard care (Throat pack) which will be used as a control.
2384593|NCT03678168|Experimental|Intervention|Pharyngeal tampons which will be used as a comparator against throat pack.
2384594|NCT03678155|Active Comparator|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
2384595|NCT03678155|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2384596|NCT03678129|Experimental|Placebo, AZD7325_10, AZD7325_20|Dose order: Placebo, AZD7325 10mg, AZD7325 20mg
2384597|NCT03678129|Experimental|Placebo, AZD7325_20, AZD7325_10|Dose order: Placebo, AZD7325 20mg, AZD7325 10 mg
2384598|NCT03678129|Experimental|AZD7325_20, Placebo, AZD7325_10|Dose order: AZD7325 20mg, Placebo, AZD7325 10mg
2384599|NCT03678129|Experimental|AZD7325_10, Placebo, AZD7325_20|Dose order: AZD7325 10mg, Placebo, AZD7325 20mg
3150895|NCT00213421||2|
3150896|NCT00213525||Patients With Scleroderma|Assessments of questionnary for environmental factors research
3150897|NCT00213525||Healthy Controls|Assessments of questionnary for environmental factors research
3150898|NCT00213590|No Intervention|1|the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L
2384602|NCT03678116|Placebo Comparator|Sugar Pill (Placebo)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
2384603|NCT03678116|Experimental|Caffeine (plus Teacrine and Cayenne)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
2384604|NCT03678116|Experimental|Caffeine (plus Teacrine)|Taken with 8oz of water after baseline REE and hemodynamic measurements have been taken. One of three interventions to be consumed by the subjects. One week washout period required between treatments.
2384606|NCT03678090|Active Comparator|tPA standard dosage|Tissue Plasminogen Activator (tPA) dose of 10 to 25 mg.
2384607|NCT03678090|Experimental|tPA low dosage|tPA dose of 2.5mg
2384608|NCT03678077||Mild traumatic brain injury|"Patients between 18-60 years, who were hospital admitted, emergency or outpatient treated with mild traumatic brain injury (ICD-10 S06.0). Data were extracted from the Danish national patient register from January 2003 - December 2007.~Patients who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
2384609|NCT03678077||Matching controls|"Matching controls without concussion of the same age, from the same municipality and of same gender as the included cases. Controls were included during 2003 - 2007. Data were extracted from the population register.~Controls who were not resident in Denmark 5 years before and during the inclusion period were excluded (1998-2007)."
2384610|NCT03678064|Experimental|Lokomat|16 sessions total. Provided by study PT twice weekly for 8 weeks.
2384611|NCT03678051|Active Comparator|Treatment as Usual (TAU)|Standard of care
2384612|NCT03678051|Experimental|TAU+CBT4CBT|TAU with access to the CBT4CBT program
2384613|NCT03678038|Experimental|rotator interval injection|patient received ultrasound-guided steroid injection via rotator interval
2384614|NCT03678038|Active Comparator|posterior recess injection|patient received ultrasound-guided steroid injection via posterior recess
3142787|NCT00003384|Experimental|Diagnostic|"Patients undergo a Pap smear followed by a ThinPrep cervical cell specimen collection at the time of direct colposcopic examination. Patients then undergo a cone biopsy of the cervix using loop electrosurgical excision procedure with an endocervical curettage, an excisional cone biopsy of the cervix with or without endocervical curettage, or a hysterectomy. Patients who are perimenopausal or postmenopausal or have a negative cervical cone biopsy also undergo endometrial biopsy or curettage. The Pap smear specimen is analyzed to determine MN antigen expression and the ThinPrep specimen is analyzed for the presence of high-risk human papilloma virus and to determine MN antigen and other marker (e.g., P16) expression.~Patients who do not undergo hysterectomy are followed every 6 months for 2 years. All other patients are followed at 4, 26, and 30 weeks."
3142788|NCT00003387|Experimental|Chemo + radiation|
3142789|NCT00003387|Experimental|Induction chemo + chemo & radiation|
2384618|NCT03678012|Active Comparator|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
2384619|NCT03678012|Placebo Comparator|Hydrogen peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio
2384620|NCT03678012|Sham Comparator|Water|Sham solution (water; negative control)
2384621|NCT03677999||Brain tumor patients with Glioma|"Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.~Passed the safety screen for MRI~Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI."
2384622|NCT03677986|No Intervention|Usual Care|Participants in this group will be referred to receive office-based buprenorphine treatment
2384623|NCT03677986|Experimental|Video DOT+|Participants in this group will be referred to receive office-based buprenorphine treatment and will receive financial incentives for taking their daily buprenorphine dose.
2384624|NCT03677973|Active Comparator|Active: Dose Escalation|Healthy volunteers will receive AB680 as a single intravenous (IV) infusion at 7 dose levels and as multiple IV infusions at 1 dose level. Assignment to receive AB680 or matching placebo will be random.
2384625|NCT03677973|Placebo Comparator|Placebo: Dose Escalation|Healthy volunteers will receive matching placebo as a single IV infusion and as multiple IV infusions. Assignment to receive AB680 or matching placebo will be random.
2384626|NCT03677960|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
2384627|NCT03677960|Experimental|Dose 2 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
2384628|NCT03677960|Experimental|Dose 3 - Multiple Ascending Dose(MAD)|Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic
3142790|NCT00003416|Experimental|treatment|"Ind:~dexamethasone 40 mg/d PO D1-4,9-12,17-20 q35 days x 3 cycles~SC Collection:~cyclophosphamide 1.5gm/m2 IV q3 hrs x 2 mesna 3 gm/m2 conIV start with cyclo GCSF 5mcg/kg/d SQ start 1 day after cyclo until WBC > 50,000/mcg~Trans (x2):~melphalan 100 mg/m2/d IV D-1,-2 PBSC infusion D0~Maint:~interferon 3 million units/m2 SQ 3x/wk"
3142791|NCT00003425|Experimental|Amifostine trihydrate|
3142792|NCT00003432|Experimental|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed DC cancer vaccine
3150899|NCT00213590|Experimental|2|the low-exposure group the cyclosporine AUC0-12h target was 50% usual target or 2.2 (2.0 to 2.6, range) mg•h/L
2384633|NCT03677921|Experimental|Investigational Group- Bio-Germanium|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Duration of use: 8 weeks"
2384634|NCT03677921|Placebo Comparator|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Duration of use: 8 weeks"
2384635|NCT03677908||13 high|High-Density ElectroEncephaloGraphy analysis of 13 healthy premature infants
2384636|NCT03677908||15 low|Low-Density ElectroEncephaloGraphy analysis of other 15 healthy premature infants
2431632|NCT03355313|Experimental|Low level light therapy 3|
3150900|NCT00213629|Other|no arm|no arm
3150901|NCT00213655||Daily instillation of BCG for 3 weeks then every 6 months|Effect of daily instillation of BCG (27 mg) for 3 weeks then one instillation of BCG (27 mg) every 6 months for 36 months on bladder tumor recurrence
2384637|NCT03677895|Experimental|patients with rotator cuff disorders|patients with rotator cuff disorders, including impingment, rotator cuff disorders and rotator cuff tear receiving hyaluronic acid injection over subacromial bursa
2384638|NCT03677882|No Intervention|Treatment as Usual (TAU)|Participants assigned to Treatment As Usual (TAU) will receive the normal standard of care treatment from the Suicide Prevention Team and the Mental Health Service which may include individual therapy, group therapy, and/or medication therapy, all as decided by the individual and his/her doctor. Treatment as usual also includes monitoring by the Suicide Prevention Team.
2384639|NCT03677882|Experimental|Treatment As Usual with Mind-Body Bridging (TAU + MBB)|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator.
2384641|NCT03677856|Experimental|Paravertebral Blockade|Anaesthesia to single side of the patient's chest
2384642|NCT03677856|Active Comparator|Thoracic epidural block|Anaesthesia to both sides of the patient's chest
2384643|NCT03677843||cerebral palsy|They are included in GMFCS level 3, 4, 5. and they have diplegia or quadriplegia
2384644|NCT03677830|Active Comparator|Intravenous Acetaminophen|Infants randomized to the intervention arm will receive scheduled IV acetaminophen per LexiComp dosing guideline (28 0/7-32 6/7 weeks 10 mg/kg/dose every 12 hours; 33 0/7-38 6/7 weeks 10 mg/kg/dose every 8 hours; >39 0/7 weeks 10 mg/kg/dose every 6 hours). N-PASS scores will guide administration of IV morphine. Continuous infusion of morphine will be started if an infant requires 3 doses of morphine within a 6-hour period and titrated as needed per N-PASS scores.
2384645|NCT03677830|Placebo Comparator|Intravenous Placebo|Infants randomized to the control arm will receive normal saline placebo IV at the appropriate volume and times for the gestational age. IV acetaminophen is concentrated at 10 mg/ml; corresponding saline volumes will be 1 ml to 5 ml, approximately, based on subject weight. Control infants will also have N-PASS scores assessed using the same protocol following the surgical procedure for 72 hours. Dosing of IV morphine will be the same as the dosing for the intervention arm.
2384646|NCT03677817|Active Comparator|Lidocaine|perioperative IV administration regimen of lidocaine will be as follows: 1.5 mg/kg IV induction bolus dose (before intubation and at least 30 minutes before incision) followed by continuous infusion of 3.mg/kg/h, until 2 hours after skin closure
2384647|NCT03677817|Placebo Comparator|Placebo|perioperative IV administration regimen of placebo solution (NaCl 0,9%) will be as follows: induction bolus (before intubation and at least 30 minutes before incision) followed by continuous infusion of placebo solution (NaCl 0,9%) until 2 hours after skin closure
2384648|NCT03677791|Experimental|Virtual 360° intervention|counselling in the virtual 360° environment and also counselling in accordance with current practice
2384649|NCT03677791|Active Comparator|Control group|counselling in accordance with current practice
2384650|NCT03677778|Placebo Comparator|Placebo group|This control group will have no normal saline injected into their nerve catheter (no intervention). This group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
2384651|NCT03677778|Active Comparator|Treatment group|This group will have 30ml normal saline injected into their nerve catheter. The treatment group will have the following measured/ assessed after 10 minutes: incentive spirometry volume, bilateral diaphragmatic excursion via ultrasonography, pain scores (using the Numeric Rating Scale), and brachial plexus motor and sensory exams. Investigators will be blinded to whether the patient is in the intervention or treatment group.
2384652|NCT03677765|Active Comparator|Infraclavicular group|In the infraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle.
2384653|NCT03677765|Active Comparator|Supraclavicular group|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
2384654|NCT03677752|Experimental|GP_Posit|Participants allocated to this arm will receive the GP_Posit intervention.
2384655|NCT03677752|No Intervention|Control|Participants in the control arm will receive usual care.
3150902|NCT00213655||Daily instillation of BCG for 2 weeks then every 3 months|Effect of daily instillation of BCG (27 mg) for 2 weeks then one instillation of BCG (27 mg) every 3 months for 36 months on bladder tumor recurrence
3150903|NCT00213759|Active Comparator|groupe filigrastin|
2384658|NCT03677726|Experimental|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
2384659|NCT03677726|Active Comparator|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise of eight weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
2384660|NCT03677713|Active Comparator|Nasal Packing|Nasal packing will be placed at the end of surgery.
2384661|NCT03677713|Experimental|No Nasal Packing|No nasal packing will be placed during or after the surgery.
2384662|NCT03677687|Experimental|Mindfulness for Physical Activity|A 6-week mindfulness programme (2 hours per week) aimed at increasing physical activity in underactive participants.
2384663|NCT03677674|Experimental|dehydrated|The participants will be dehydrated (at least 2% of their body weight) before performing the Sterkowicz test.
3150904|NCT00213759|Placebo Comparator|groupe placebo|
3150905|NCT00213928|No Intervention|Control|
3150906|NCT00213928|Active Comparator|Horse Chestnut Seed Extract|Horse chestnut seed extract (escins, aesins)
3150907|NCT00213954|Other|interscalene block|Locoregional anesthesia selection
2384664|NCT03677674|No Intervention|euhydrated|The participants will be normally hydrated (= euhydration) before performing the Sterkowicz test (i.e. no specific intervention will be implemented).
2384665|NCT03677661|Active Comparator|Conventional approach|Graded aerobic exercise and advice for graded cognitive stimulation approach based on the 2016 Berlin consensus
2384666|NCT03677661|Experimental|Personalized rehabilitation program|Cervico-vestibular rehabilitation personalized patient-centered clinical program combined with the exercise and advice of the conventional approach
3142793|NCT00003439|Experimental|Arm I|Cohorts of 3-6 patients each receive escalating doses of intraperitoneal recombinant human interleukin-12 (rhIL-12) administered weekly for 9 weeks. If a patient tolerates rhIL-12 and shows evidence of objective response or stable disease, patient may receive up to 9 additional weeks of treatment. Treatment continues in the absence of unacceptable toxicity or disease progression. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which no more than 1 of 6 patients experiences dose limiting toxicity.
3142794|NCT00003440|Experimental|Arm A (paclitaxel)|Patients receive paclitaxel intravenously (IV) over 3 hours every 3 weeks.
3142795|NCT00003440|Active Comparator|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour weekly.
3142796|NCT00003440|Experimental|Arm C (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm I. Patients also receive trastuzumab IV weekly.
2384671|NCT03677635|Experimental|Intervention|Guided autobiographical memory recall to enhance specificity and links to the future.
2384672|NCT03677635|No Intervention|Control|Recall without prompts or psychoeducation video.
2384673|NCT03677622|Experimental|Stroke volume (SV) group|"As bellow but with the addition of HES (Voluven (R)) to near maximal stroke volume of the heart:~A bolus injection of 200 ml Voluven® is given repeatedly with measurement of the SV until the increase in SV in response to the bolus is <10%.~The Case Report File give detailed instructions for the interpretation of the SV during changes in position of the patient during laparoscopic surgery."
2384674|NCT03677622|Active Comparator|Restricted group|"Preoperatively: Clear oral fluids until 2 h before surgery. During surgery: If preoperative fluid intake <500 ml, NaCl 0.9% is given until 500 ml.~Lost blood is replaced volume by volume with HES (Voluven®) with allowance of 500 ml extra.~Postoperative fluid: The rest of the day of surgery, fluid is given to meet the basic needs, i.e. 1000 ml K-Na-glucose, K-glucose or glucose 5%. The patient is encouraged to drink and eat as soon possible.~In the surgical department, fluid charts and weight changes monitor fluid balance. A body weight increase of two kilograms is allowed.~Fluid losses is replaced with a fluid having a similar electrolyte composition as the loss and in an equal volume. If the weight increases more than two kilogram, furosemide is given to increase the diuresis."
2384675|NCT03677609|Experimental|Intervention|Physicians will receive a training or trainings to improve their communication and interaction with patients. The primary trainings will involve teaching physicians how to understand and leverage patient psychology as part of clinical care. Impact on patient health will then be assessed.
2384676|NCT03677609|No Intervention|Control|
3142797|NCT00003440|Active Comparator|Arm D (paclitaxel, trastuzumab)|Patients receive paclitaxel as in Arm II and trastuzumab as in Arm III.
2384679|NCT03677583|Experimental|Duckweed|daily lunch with 150-180g wet weight duck weed
2384680|NCT03677583|Active Comparator|Spinach|daily lunch with 150-180g wet weight spinach
2384681|NCT03677570||Female athletes|A total of 45 female athletes (15 volleyball, 15 handball, and 15 football players) (average age: 22,26 ± 6,43 / BMI: 21,45 ± 2,39) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
2384682|NCT03677570||Healthy Control|15 sedentary females (average age: 24,86 ± 3,02 / BMI: 21,42 ± 1,90) participated in the study.Trunk muscle endurance of the participants was measured with the McGill core endurance tests and the prone bridge test. Postural stability of the participants was evaluated using Biodex Biosway Portable Balance System (950- 460 USA) device. Sportive performance was tested with the vertical jump test and the hexagonal obstacle test.
2384683|NCT03677557|Other|Cutaquig Intervention|Participants with primary or secondary immunodeficiency disease who are currently on subcutaneous immunoglobulin treatment but have developed adverse events including allergic reaction and are willing to change the treatment product to 16.5% Cutaquig.
2384684|NCT03677544||exploratory cohort (A)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation. procedures were performed between 1980 and 2013
2384685|NCT03677544||exploratory cohort (B)|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation procedures were performed between 2001 and 2013
2384686|NCT03677531|Experimental|Other (radiation therapy, videos)|Participants undergo daily radiation therapy and watch videos/movies of their choice during treatments.
2384687|NCT03677505|Experimental|KoMAC group|Orotracheal intubation with KoMAC videolaryngoscope
2384688|NCT03677505|Active Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscope
2384689|NCT03677492|Experimental|Handling Medium Supplemented with Cytochalasin D|
2384690|NCT03677492|No Intervention|Handling Medium as it is.|
2384691|NCT03677479|Experimental|socket preservation with camelline bone|natural hydroxyapatite derived from camels prepared by investigator
2384692|NCT03677479|Active Comparator|socket preservation with bovine bone|natural hydroxyapatite derived from cows (Bio-Oss)
2384693|NCT03677466|Experimental|Pharmaco-invasive strategy|Fibrinolytic therapy (Streptokinase, Alteplasa, Tenecteplasa in standard dose) is conducted within 12 h of symptom onset in the pre-hospital setting if primary PCI cannot be performed within 120 min from STEMI diagnosis. Then PCI is performed to all of patients.
2384694|NCT03677466|Active Comparator|Primary PCI|Primary percutaneous coronary intervention (PCI) in patients with primary STEMI
2384695|NCT03677453|Active Comparator|IPTP|Patients will have access to the web-based interactive teaching tool.
2384696|NCT03677453|No Intervention|Non-IPTP|Patients will not have access to the web-based interactive teaching tool.
2385190|NCT03674060|Experimental|SYO-1644 150mg|SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet
2384697|NCT03677440|Experimental|Treadmill Walking Exercise Training|"This condition will include 3-months of supervised, progressive light, moderate, and vigorous intensity treadmill walking exercise training based on ACSM guidelines for maximizing adaptations with exercise training. Exercise intensities will be prescribed based on percent oxygen consumption reserve (% VO2R) using values derived from the baseline graded exercise test.~The exercise training itself will be led by trained exercise leaders who are not involved in the collection of outcome assessments. At the outset of each session, participants will be fitted with a Polar HR Monitor (Oy, Finland), and HR will be monitored continuously throughout each session. Each session will begin with a 5-10 min warm-up, followed by the exercise; the target heart rate reserve (HRR) range associated with the VO2R range will be maintained for as long as possible during each exercise period. This will be followed by a 5-10 min cool-down."
2384698|NCT03677440|Active Comparator|Stretching-and-Toning Exercise Training|The active, non-aerobic exercise condition will involve stretching-and-toning activities using the same frequency and duration of the treadmill walking exercise condition. These activities will be based on a manual provided by the National Multiple Sclerosis Society and sessions will be led by trained exercise leaders who are not involved in the collection of outcome assessments. Activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, ankle/foot. The progression of activities over the 3-month period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands that provide minimal resistance. Each session is designed to last up to 60 minutes in total. Each session will begin with a warm-up of up to 10 minutes, followed by stretching-and-toning (following the same duration as the treadmill walking exercise training condition) activities, and a cool-down of up to 10 minutes.
2384699|NCT03677427|Experimental|5 fractions|
2384700|NCT03677427|Experimental|15 fractions|
3183347|NCT00713037|Experimental|(18F)-FMISO/CT|The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).
3183348|NCT00713050|Experimental|Experimental|Computer-based Aphasia therapy
3183349|NCT00713050|Active Comparator|Control|Control Arm - Healthy subjects.
2384704|NCT03677362|Experimental|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
2384705|NCT03677349|Experimental|Resensitized group|Patients with resensitized free flap by neurorrhaphy
2384706|NCT03677349|Experimental|Non Resensitized group|Patients without resensitized free flap by neurorrhaphy.
2384707|NCT03677336|Other|Group l: 1st cycle MVP/placebo OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=d1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized vaginal progesterone 200 mg capsules 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): 'Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo 'Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days."
2384708|NCT03677336|Other|Group ll: 1st cycle placebo MVP/OD|"2 cycles of controlled ovarian stimulation, dual triggering, oocyte retrieval (OR) and LPS, with an interval period of 2 to 12 months. The only difference of the second cycle being the other LPS study medication as compared to the first cycle.~1st cycle: Start on day of oocyte retrieval (OR) (=day 1): Micronized Progesterone 200 mg intravaginal capsules 3 times daily + placebo Dydrogesterone Oral Tablet 10 mg 3 times daily, for 8 days.~2nd cycle: Start on day of oocyte retrieval (OR) (=day 1): Dydrogesterone Oral Tablet 10 mg 3 times daily + Placebo micronized progesterone 200 mg intravaginal capsules 3 times daily, for 8 days."
2384709|NCT03677323|Experimental|Virtual reality|The virtual reality device will consist of the virtual reality headset and headphones for full immersion.
2384710|NCT03677323|Active Comparator|Drug sedation|The sedation group will benefit from drug sedation used in current practice, that is to say an association of Sufentanil, Droleptan and Propofol.
2384711|NCT03677310|Experimental|3% sodium chloride|Subjects in this group will receive 3% sodium chloride over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
2384712|NCT03677310|Sham Comparator|Normal Saline|This group will receive normal saline over a period of 24 hours at a rate of 10 cc/hour beginning immediately prior to incision.
2384713|NCT03677297|Experimental|ROSUVASTATIN|1.2% Rosuvastatin Gel. Insertion in infrabony defects once
2384714|NCT03677297|Placebo Comparator|placebo|No intervention used on control site
2384715|NCT03677284|Experimental|Intervention group|"Information brochure about daily time management, frequent problems, and suggested strategies to manage them.~Time assistive product. Time assistive products for time perception are products making the passage of time visible and understandable, to know for how long to perform an activity or how long to wait until the next activity starts e.g a time log.~Time assistive products for time orientation includes the use of schedules, calendars and other visual aids to promote orientation to the time of the day, week, or year.~Time assistive products for time management would compensate for deficits in time management and focus on self-scheduling skills."
2384716|NCT03677284|Active Comparator|Control group|Information brochure about daily time management, frequent problems, and suggested strategies to manage them.
2384717|NCT03677271|Other|Physical Activity|
2384718|NCT03677258|Experimental|Collagen injections|30 females with aging facial problems from 35 to 65 years old prescribed collagen ingection once every 3 weeks, cours of therapy - 3 procedures
2384719|NCT03677258|Active Comparator|Hyaluronic acid injections|30 females with aging facial problems from 35 to 65 years old prescribed hyaluronic acid ingection once every 3 weeks, cours of therapy - 3 procedures
2384721|NCT03677232||Hong Kong Chinese adolescents with CHD|Hong Kong Chinese adolescents with CHD aged 12-18 who are able to read and write chinese
2384722|NCT03677219|No Intervention|Control|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, and do not view an educational video.
2384723|NCT03677219|Experimental|Video|Parents in this arm receive the standard lumbar puncture consent discussion and answer a survey about their concerns, then view a 2 minute educational video and respond to a second survey.
2384724|NCT03677206|Sham Comparator|Exposure to white LED light.|Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks
2384725|NCT03677206|Experimental|Exposure to green LED light|Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks.
2384726|NCT03677206|Other|Cross over|Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks.
2384727|NCT03677193|Experimental|Experimental arm|
2384728|NCT03677167|Experimental|walking on a treadmill barefoot group|26 Patients in this group will walk barefoot on the treadmill and will be asked to walk barefoot at home and report the time of barefoot walking at home
2384729|NCT03677167|Active Comparator|Walking on a treadmill with shoes group|26 Patients in this group will walk with shoes on the treadmill
3142798|NCT00003440|Experimental|Am E (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm C.
3142799|NCT00003440|Active Comparator|Arm F (paclitaxel, trastuzumab)|Patients receive paclitaxel and trastuzumab as in Arm D.
3142800|NCT00003441|Experimental|Irofulven|6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days every 28 day cycle.
2384739|NCT03677128|Experimental|mNavigator|Allied health providers will use mNavigator to guide diagnosis and treatment for pediatric cancer patients at Bugando Medical Centre (BMC).
2384740|NCT03677128|No Intervention|Historical controls|BL (DLBCL)/Rb retrospective patients (treated between 2015-2019) when standardized treatment protocols for BL (DLBCL) and Rb were introduced at BMC.
3150908|NCT00213954|Other|axillary block|Locoregional anesthesia selection
3150909|NCT00213954|Other|lumbar block|Locoregional anesthesia selection
2384746|NCT03677063|No Intervention|Dressing|"It is the historical cohort which is composed of patients over 18 years of age treated by peritoneal dialysis in the nephrology department of Universty Hospital of Caen Normandie. Patients with the same non-inclusion criteria as the experimental group will not be included. The data will be extracted from the Registry of Peritoneal Dialysis of French Language. The number of patients included from the register can not be fixed in advance; this number will correspond to the 4-year follow-up at the start date of the study to ensure at least two years of patient follow-up~Usually care~First dressing 5 or 10 days after the pose of the catheter :~Cleaning emergence with antiseptic soap~Rinsing with saline~Drying~Application of a hazelnut mupirocin on the exit-site~Application of an occlusive dressing on the exit-site Then, care is the same. Exit-site care is performed daily if the patient takes a shower or twice a week."
2384747|NCT03677063|Experimental|No dressing|No application of sterile dressing at the exit-site of periotoneal dialysis catheter for all patients (30 days after the placement of the peritoneal dialysis catheter)
2384748|NCT03677050|No Intervention|Control|patients receiving standard care (verbal and written instructions) before colonoscopy
2384749|NCT03677050|Experimental|Intervention|Patients instructed to use a smart phone patient education app in addition standard care
2384750|NCT03677037|Experimental|Short-term MBT|The experimental group is short-term mentalization-based therapy. The treatment program includes 20 weeks of mentalization-based group therapy with conjoined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
2384751|NCT03677037|Active Comparator|Long-term MBT|The control group is long-term mentalization-based therapy. The treatment program includes 14 months of weekly mentalization-based group therapy with combined individual therapy every second week. The program also includes psychoeducation and individual caseformulations.
2384752|NCT03677024|Experimental|SLN arm|"Experimental:~Intra-operative sentinel lymph node (SLN) mapping with indocyanin green injected into the stroma of the cervix.~Full bilateral laparoscopic lymphadenectomy and hysterectomy:~If bilateral SLN are detected, all positive SLN will be removed. Then the surgeons proceeds to a total hysterectomy.~If only unilateral SLN are detected, surgeons will proceed to pelvic lymphadenectomy on the opposite side.~If non SLN are detected, surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy."
2384753|NCT03677024|No Intervention|Lymphadenectomy arm|Surgeons will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic lymphadenectomy.
2384754|NCT03677011|Other|category 1|Low responder
2384755|NCT03677011|Other|category 2|Medium Responder and High Responder
3150910|NCT00213954|Other|parasacral plexus block|Locoregional anesthesia selection
3150911|NCT00213993|Experimental|A|antiperspirant topically to one foot once daily
3150912|NCT00214032|Experimental|1|pycnogenol daily
3150913|NCT00214032|Placebo Comparator|2|placebo daily
3150914|NCT00214123|Experimental|Bin 1|bin assignment based on tumor volume
3150915|NCT00214123|Experimental|Bin 2|Bin assignment based on tumor volume
2384756|NCT03676998|Other|Measurement of diaphragm function|Patients will be followed up from admission to weaning with twice a week a diaphragm function multimodal evaluation (ultrasound, phrenic nerves stimulation technique)
2384757|NCT03676985|Experimental|ZKAB001 5 mg/kg/time|Three or six patients will treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
2384758|NCT03676985|Experimental|ZKAB001 10 mg/kg/time|Three or six patients will treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
2384759|NCT03676985|Experimental|ZKAB001 15 mg/kg/time|Three or six patients will treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT was observed within 28 days after administration.
3150916|NCT00214123|Experimental|Bin 3|Bin assignment based on tumor volume
2384761|NCT03676959|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384762|NCT03676959|Experimental|ZKAB001 10 mg/kg|Three or six patients will be treated with the dose of 10 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384763|NCT03676959|Experimental|ZKAB001 15 mg/kg|Three or six patients will be treated with the dose of 15 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384764|NCT03676946|Experimental|ZKAB001 5mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384765|NCT03676946|Experimental|ZKAB001 10mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384766|NCT03676946|Experimental|ZKAB001 15mg/kg|Three or six patients will be treated with the dose of 5 mg/kg/time of ZKAB001 IV bi-weekly. DLT will be observed within 28 days after administration.
2384767|NCT03676933|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
2384768|NCT03676933|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 56 days: DS107E taken topically twice a day
2384769|NCT03676920|Experimental|Intervention Arm|This feasibility study includes only one arm. All enrolled patients will be asked to use the intervention.
2384770|NCT03676907|No Intervention|single layer suturation technique|in this arm we use single layer suturation technique to suture uterine incision
2384771|NCT03676907|Experimental|double layer suturation technique|in this arm we use double layer suturation technique to suture uterine incision
2384772|NCT03676894|Sham Comparator|Sham Treatment|Sham Fotona SP Dynamis Treatment - minimum energy delivered through sham handpiece.
2384773|NCT03676894|Active Comparator|Intravaginal Treatment|Intravaginal Fotona SP Dynamis Treatment - energy delivered intravaginally.
2384774|NCT03676894|Experimental|Intravaginal and intraurethral Treatment|Intravaginal and intraurethral Fotona SP Dynamis Treatment Intravaginal Treatment - energy delivered intravaginally and intraurethrally.
2384775|NCT03676881||Mild Cognitive Impairment (MCI)|30 MCI patients their study partners will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 MCI with their study partners will be part of The NeuroCatch™ Platform (NCP) project.
2384776|NCT03676881||Cognitively normal subjects (CN)|30 CN participants who are cognitively normal that will be part of the 'Computerized cognitive battery- Cognigram (CG) project and 30 CN will be part of The NeuroCatch™ Platform (NCP) project.
2384777|NCT03676855|Active Comparator|bladder dissection before uterine incision|
2384778|NCT03676855|Experimental|bladder dissection after uterine incision|
2384779|NCT03676842|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter followed by an IN.PACT Admiral Drug-Coated Balloon (Medtronic Vascular; Galway, Ireland).
2384780|NCT03676829|Experimental|Arterial Embolization of the Shoulder (AES)|Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
2384781|NCT03676816|Experimental|Vaginal self-sampling and provider performed endocervical sampling|Patients will take part in both provider-performed endocervical sampling (standard care) and vaginal self-sampling.
2384784|NCT03676790|Experimental|Group I|(in the first month, continuous ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
2384785|NCT03676790|Experimental|Group II|(in the first month, pulsed ultrasound was applied three times a week and in the second month patients performed only exercise sessions three times a week)
2384786|NCT03676790|Experimental|Group III|(in the first month, the continuous ultrasound was applied three times a week and in the second month, three times a week, the continuous ultrasound associated with exercises was applied)
2384787|NCT03676790|Experimental|Group IV|(in the first month, the pulsed ultrasound was applied three times a week and in the second month, three times a week, the pulsed ultrasound associated with exercises was applied)
2384788|NCT03676790|Experimental|Group V|(patients received only exercise sessions three times a week for eight weeks)
2384789|NCT03676777||Infection|Patients admitted or developed bacterial/fungal infection while hospitalization
2384790|NCT03676777||Non-infection|Patients without bacterial/fungal infection
2384791|NCT03676764|Active Comparator|Biannual mass oral azithromycin|Bi-annual Mass Azithromycin distribution to all children 1-60 months old in participating communities
2384792|NCT03676764|Placebo Comparator|Biannual mass oral placebo|Bi-annual Mass Placebo distribution to all children 1-60 months old in participating communities
3150917|NCT00214123|Experimental|Bin 4|Bin assignment based on tumor volume
3150918|NCT00214123|Experimental|Bin 5|Bin assignment based on tumor volume
3150919|NCT00214162|Other|1|internet access and computer for 1 year
3150920|NCT00214162|Experimental|2|computer and Full CHESS
3150921|NCT00214175||patients|patients who will receive XRT
3150922|NCT00214175||matched volunteers|Spouse or sibling
3150923|NCT00214240|Experimental|1|Cytogam in addition to standard of care (IV ganciclovir therapy)
2384793|NCT03676764|Placebo Comparator|Targeted oral placebo|Targeted placebo to children 5 to 12 weeks old at vaccine visit or other healthy child visit
2384794|NCT03676764|Active Comparator|Targeted oral azithromycin|Targeted azithromycin to children 5 to 12 weeks old at vaccine visit or other healthy child visit
2384795|NCT03676751|Active Comparator|Azithromycin|A single dose of azithromycin will be administered to children between the ages of 8 days and 59 months old.
2384796|NCT03676751|Placebo Comparator|Placebo|A single dose of placebo will be administered to children between the ages of 8 days and 59 months old.
2384797|NCT03676738||In-patient spine surgery|Scheduled for an in-patient, elective spine surgery where subject will receive general anesthesia
2384798|NCT03676738||Non-surgical spine care|Presenting to spine clinic and undergoing conservative, non-surgical management of spine disorder
2384800|NCT03676712|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 20 degree wear scoliosis brace for six months
2384801|NCT03676686|Experimental|Nåva Foot Cream|Topical Nåva foot cream administered twice daily.
2384802|NCT03676673||ASD group|120 patients with clinical diagnosis of ASD according to the DSM-5 diagnostic criteria
2384803|NCT03676673||Unaffected siblings of ASD|40 unaffected siblings of ASD probands
2384804|NCT03676673||TD group|40 healthy age/gender-matched TD controls according to age and neighborhood distribution of the ASD group after interviewed by the Chinese K-SADS-E-DSM-5
3150924|NCT00214240|No Intervention|2|Receive standard of care therapy (IV ganciclovir)
3150925|NCT00214253|Experimental|1|Thiazolidinedione therapy
2384807|NCT03676621|Experimental|study group|patients will receive buccal misoprostol
2384808|NCT03676621|Active Comparator|control group|patients will receive intravenous oxytocin
2384809|NCT03676608|Experimental|Bee wax mammary areolae|"Usual educational care plus the product.~The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams."
2384810|NCT03676608|Active Comparator|Control|Usual educational care.
2384811|NCT03676595|Experimental|Group A|Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
2384812|NCT03676595|Experimental|Group B|Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
2384813|NCT03676569|Experimental|Experimental group|Autologous ADRC transplantation in autoimmune refractory epilepsy
2384814|NCT03676556|Active Comparator|Topical lidocaine|23 patients will recieve lidocaine solution before wound treatment
2384815|NCT03676556|Placebo Comparator|Saline serum|23 patients will recieve saline solution before wound treatment
2384816|NCT03676543|Experimental|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
2384817|NCT03676530|No Intervention|Relative Rest (Control)|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. No compression. Standard of care therapy includes relative extremity rest, stretches and graduated run program.
2384818|NCT03676530|Experimental|Compression Garments|Male/Female Military Trainees with symptoms consistent with Tibial Stress Syndrome. Standard of care therapy includes compression garments worn, stretches and graduated run program.
2384819|NCT03676517|Experimental|Preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
2384820|NCT03676504|Experimental|Stratum I|Adult patients with relapsed or refractory ALL
2384821|NCT03676504|Experimental|Stratum II|Adult patients with relapsed or refractory CLL, DLBCL, FL or MCL
2384822|NCT03676504|Experimental|Stratum III|Pediatric patients with relapsed or refractory ALL
2384823|NCT03676491|Experimental|Experimental Group|"Music Intervention: Participants listen to music minimum 30 minutes at bedtime for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer"
2384824|NCT03676491|No Intervention|Waitlist Control Group|"No intervention: Participants are monitored for a period of 4 weeks wearing accelerometer.~Participants are monitored for a 4 week follow up period wearing accelerometer."
2384825|NCT03676478|No Intervention|start enteral support @ POD1|The standard of care (SoC) in our department consists of enteral nutritional support of maximum 1000 kilocalories (kCal) through a peroperatively placed jejunostomy feeding tube started at POD 1. Oral caloric intake is resumed at POD 4.
2384826|NCT03676478|Active Comparator|delayed start enteral support @ POD5|As study intervention (INT), a period of caloric restriction is set by starting the enteral nutritional support later, at POD 5. Oral caloric intake is resumed at POD 4, similarly as in the control group. This intervention results in a relative caloric defect of 4.000 kCal in the immediate postoperative course.
2384866|NCT03676192|Experimental|CT-P16|Drug: Bevacizumab 15mg/kg IV of CT-16 will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
3150926|NCT00214253|No Intervention|2|
3150927|NCT00214266|Experimental|Campath-1H Induction Therapy Combined With CellCept® Therapy|Campath-1H Induction Therapy Combined With CellCept® Therapy
2384829|NCT03676452|Experimental|Intervention group|Participants of the intervention group train for 16 weeks (three times per week) with a multicomponent virtual reality-based exergame at their home. The Active@Home exergame contains strength training with Tai Chi-based exercises, balance training with dancing and a cognitive training with specific cognitive-motor games. Each training session lasts about 30 to 40 minutes.
2384830|NCT03676452|No Intervention|Control group|Participants of the control group go on with their usual daily life. After post-measurements, they get the Active@Home exergame to use the training system at home. They don't have to follow a specific training plan.
2384831|NCT03676439|Active Comparator|Treated Arm: Magnetic Spinal Stimulation plus PKT|Three months of kinesthetic and phoniatric treatment, and Magnetic Spinal Stimulation, 80% of the cervical muscles's motor threshold, 100 pulses at 10Hz, lasting 10 seconds, repeated during 30 minutes, twice a week for 3 months on cervical lateral location, focalized on the Lateral Spinal Cord.
2384832|NCT03676439|Placebo Comparator|Sham comparator|They will receive kinesthetic and phoniatric treatment, and during 3 months,with equal periodicity, they will receive a sensible false magnetic stimulation, of equal localization that other arm, with insufficient intensity, to blind clinical experience.
2384833|NCT03676426|Experimental|Web-based AD|Patients will be encouraged to use the web platform for advance care planning/advance directive to document their care preferences..
2384834|NCT03676426|Active Comparator|Paper AD|Patients will be given the standard advance directive and encouraged to complete on their own.
2384835|NCT03676413|Experimental|Test (T)|Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals
2384836|NCT03676413|Active Comparator|Reference (R)|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK
2384837|NCT03676413|Placebo Comparator|Placebo|
2384838|NCT03676400|Experimental|NGF-574H|"NGF-574H is hair serum with 5% conditioned media of umbilical cord blood-derived stem cells containing various trophic factors that help alleviate hair loss.~NGF-574H will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks."
2384839|NCT03676400|Placebo Comparator|placebo|Hair serum without conditioned media of umbilical cord blood-derived stem cells will be directed to use on hair and scalp by subject her/himself at home twice a day (in the morning and evening) for 24 weeks.
2384840|NCT03676387|No Intervention|Aged based group (group AB) (n = 27)|ETT size was determined according to age
2384841|NCT03676387|Active Comparator|Ultrasound based group (group UB) (n = 27): ETT was determined|ETT was determined according to the subglottic transverse diameter that was estimated with ultrasonography.
2384842|NCT03676374|Experimental|Prucalopride|Prucalopride 2mg once a day as add-on for PPI 2x/d
2384843|NCT03676374|Placebo Comparator|Placebo|Placebo once a day as add-on for PPI 2x/d
2384844|NCT03676361|Experimental|Desmopressin|All ten subjects will be evaluated pre and post nephrectomy at 6 months.
2384845|NCT03676335|Experimental|0.3 g: 0.15 mg（1)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
2384846|NCT03676335|Experimental|0.3 g: 0.15mg（2)&Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.15 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
2384847|NCT03676335|Experimental|0.3 g: 0.3 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA eye gel: 0.3 g: 0.3 mg, 1 times daily, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
2384848|NCT03676335|Active Comparator|0.4 ml: 0.2 mg &Hypromellose Eye Drops|Sixty subjects will be treated with CsA for eye emulsion: 0.4 ml: 0.2 mg, 2 times daily, interval of about 12 hours, The treatment period is 12 weeks. The basic medicine is Hypromellose Eye Drops, 3 times daily for 12 weeks.
2384849|NCT03676322|Experimental|Part A: M5049|
2384850|NCT03676322|Placebo Comparator|Part A: Placebo|
2384851|NCT03676322|Experimental|Part B: M5049|
2384852|NCT03676322|Placebo Comparator|Part B: Placebo|
2384853|NCT03676322|Experimental|Part C: M5049|
2384854|NCT03676309|Placebo Comparator|placebo|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
2384855|NCT03676309|Active Comparator|nutraceutical oral capsule|nutraceutical oral capsule 920 mg twice a day for 12 weeks
2384856|NCT03676296|Experimental|Puerarin|Puerarin (90.2 mg daily) in granules
2384857|NCT03676296|Placebo Comparator|Placebo|Placebo in granules
2384858|NCT03676283|Experimental|Web-based psycho-educational support for family caregivers|Gaining access to the website (närstående.se) with supportive films and texts
2384859|NCT03676244|Experimental|immediate implant placement in anterior esthetic zone|extraction of badly broken anterior maxillary teeth with immediate implant placement
2384860|NCT03676231|Experimental|High-dose SGM-1019|
2384861|NCT03676231|Experimental|Low-dose SGM-1019|
2384862|NCT03676231|Placebo Comparator|Placebo|
2384863|NCT03676218||Elderly cancer patients|
2384864|NCT03676205|Experimental|Platelet-Rich Plasma|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 6-7 ml of PRP .~After 4-5 days from the injury the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will recived the second infiltration of 6-7 ml of PRP."
2384865|NCT03676205|Other|Traumel ®|"24-72 hours after having a muscular lesion, the doctor injects an intramuscular ecoguided infiltration of 4 ml of a homeopathic product (Traumeel ®) After 4-5 days from the date of injury, the patient starts physiotherapy adapted by stages, according to the muscular group affected.~After 7 days from the first infiltration, the patient will receive the second infiltration of 4 ml of a homeopathic product."
2384867|NCT03676192|Active Comparator|Avastin|Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or intolerable toxicity during the Maintenance Period.
2384868|NCT03676179|Active Comparator|unicompartment knee arthroplasty and patella denervation|UKA and patella denervation
2384869|NCT03676179|Experimental|unicompartment knee arthroplasty and patella non-denervation|UKA and patella non-denervation
2384870|NCT03676166|Experimental|0mg THC smoked cannabis|placebo smoked cannabis
2384871|NCT03676166|Experimental|10mg THC smoked cannabis|smoked cannabis containing 10mg THC
2384872|NCT03676166|Experimental|25mg THC smoked cannabis|smoked cannabis containing 25mg THC
2384873|NCT03676166|Experimental|0mg THC vaporized cannabis|placebo vaporized cannabis
2384874|NCT03676166|Experimental|10mg THC vaporized cannabis|vaporized cannabis containing 10mg THC
2384875|NCT03676166|Experimental|25mg THC vaporized cannabis|vaporized cannabis containing 25mg THC
2384876|NCT03676153|Experimental|Nurse-guided arm|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
2384877|NCT03676153|Active Comparator|Non nurse-guided arm|Integrative medicine treatment program, with no nurse-provided guidance on patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
2384878|NCT03676140|Active Comparator|Separate Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 8'
2384879|NCT03676140|Experimental|Co-Administration|'Albendazole on day 1' 'Ivermectin on day 1' 'Diethylcarbamazine on day 1' 'Azithromycin on day 1'
2384880|NCT03676127||Study Group|ultrasonographic dermal thickness measurements in patients with unilateral breast cancer related lymphedema
2384881|NCT03676114|Experimental|ketamine group|
2384882|NCT03676114|Placebo Comparator|normal saline group|
2384883|NCT03676101|Experimental|9-valent HPV Recombinant Vaccine|
2384884|NCT03676101|Placebo Comparator|Placebo|
2384885|NCT03676088|Experimental|Test group - rhPDGF-BB+MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The test group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB
2384886|NCT03676088|Active Comparator|Control group - MCAT+CTG|Root coverage surgical procedure.The patients were assigned into two treatment groups (test and control). Intervention - The control group recession coverage is treated with modified coronally advanced tunnel with connective tissue graft alone
2384887|NCT03676062|Active Comparator|stabilization exercise group|Spinal stabilization exercise were applied all patients additional with hotpack, TENS application in this group accompanied by physiotherapist.
2384888|NCT03676062|Active Comparator|yoga group|Yoga program were applied all patients in this group accompanied by physiotherapist. Sessions included selected breathing exercises, warm up, asana and relaxation.
2384889|NCT03676062|Active Comparator|home exercise group|Home exercise were applied all patients in this group supervised, controlled by physiotherapist every week.To make compliance easier for patients; a booklet including suggestions to prevent low back pain and description of exercises, were given. Prescribed exercises were selected in this booklet and checked&progressed in each control sessions.
2384890|NCT03676036|Experimental|DS107E and Steroid|First 7 days: Steroid taken topically once a day and DS107E taken once a day Next 28 days: DS107E taken topically twice a day
2384891|NCT03676036|Placebo Comparator|Vehicle and Steroid|First 7 days: Steroid taken topically once a day and Vehicle taken once a day Next 28 days: Vehicle taken topically twice a day
2384892|NCT03676023||Pulmonary Hemorrhage|Patients treated for pulmonary hemorrhage with inhaled Transexamic Acid
2384893|NCT03676010||Sarcoma and GIST|
2384894|NCT03676010||Breast cancer|
2384895|NCT03676010||Pancreatic cancer|
2384896|NCT03676010||Renal cell carcinoma|
2384897|NCT03676010||Colon Cancer (adjuvant setting)|
2384898|NCT03676010||Solid tumours undergoing image-guided tumor ablation|
2384899|NCT03675997||Autografted patients|Patients hospitalized in the hematological department of the Institute will complete the first day of conditioning and then weekly HAD (Hospital Anxiety and Depression) scale.
2384900|NCT03675984|Experimental|asymmetrical stabilization exercise group|'asymmetrical stabilization exercise' patient learn asymmetrical stabilization exercise according to the asymmetrical paraspinal muscles weakness and curve type
2384901|NCT03675971|Experimental|Medical Cannabis|Drug: Cannabidiol
2384902|NCT03675971|Placebo Comparator|Placebo|Placebo comparator
2384903|NCT03675958|Experimental|GJPS + S|Experimental group: (GJPS + S) : Application Johnstone´s Pressure Splint plus Stretching in in 4 different treatment postures.
2384904|NCT03675958|Active Comparator|GS|Control group (GS): Just Stretching in 4 different treatment postures.
2384905|NCT03675932|Experimental|Cycling Intervention|Single-arm trial. All participants will receive the same intervention of Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
3150928|NCT00214279|No Intervention|1|Remain on 3-drug standard of care immunosuppression including prednisone
3150929|NCT00214279|Experimental|2|Corticosteroid withdrawal / prednisone taper over 14 weeks
2384908|NCT03675906||preoperative albumin levels <3.8|
2384909|NCT03675906||preoperative albumin level >3.8|
2384910|NCT03675906||postoperative Day 2 albumin level <2.9|
2384911|NCT03675906||postoperative Day 2 albumin level >2.9|
2384912|NCT03675893|Experimental|Cohort 1A|"Abemaciclib is administered by mouth twice daily~Letrozole is administered by mouth once daily"
2384913|NCT03675880|Experimental|1.25mg(0.05ml) single-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose
2384914|NCT03675880|Experimental|2.00mg(0.08ml) single-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose
2384915|NCT03675880|Experimental|2.50mg(0.10ml) single-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose
3183350|NCT00713063|Experimental|1|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
2384916|NCT03675880|Experimental|1.25mg(0.05ml) multiple-dose|Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose
2384917|NCT03675880|Experimental|2.00mg(0.08ml) multiple-dose|Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose
2384918|NCT03675880|Experimental|2.50mg(0.10ml) multiple-dose|Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose
2384919|NCT03675867||Obese teenagers|
2384920|NCT03675854|Experimental|Extended Group|3 weeks of antibiotics
2384921|NCT03675854|Active Comparator|Conventional Group|2 weeks of antibiotics
2384922|NCT03675841|Experimental|0.1% single-dose pre|Three subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
2384923|NCT03675841|Experimental|0.1% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.1% single dose
2384924|NCT03675841|Experimental|0.3% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.3% single dose
2384925|NCT03675841|Experimental|0.5% single-dose|Ten subjects will be treated with Pazufloxacin Mesilate ear drops 0.5% single dose
2384926|NCT03675828|Experimental|Virtual Visit|In this arm, the 7-day post discharge visit will be completed by a scheduled virtual visit with a member of the study team using the Cleveland Clinic Online Express Care application on a computer or a tablet/phone.
2384927|NCT03675828|No Intervention|Outpatient Clinic|In this arm, the 7-day post discharge visit will be completed by a standard-of-care, in-person outpatient visit with a member of the study team in the heart failure clinic.
2384928|NCT03675815|Active Comparator|Standard of care|darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet + (N(t)RTIs) po qd
2384929|NCT03675815|Experimental|Dolutegravir + tenofovir (TDF) + either lamivudine (3TC) or emtricitabine (FTC)|dolutegravir 50 mg oral tablet + TDF 300 mg oral tablet + either 3TC 300 mg oral tablet or FTC 200 mg oral capsule po qd
2384930|NCT03675815|Experimental|Dolutegravir + darunavir|dolutegravir 50 mg oral tablet + darunavir 800 mg oral tablet + ritonavir 100 mg oral tablet po qd
2384931|NCT03675802|Active Comparator|Arm number one ,misoprostol|
2384932|NCT03675802|Active Comparator|Arm number 2 dinoprostone|
2384933|NCT03675789||STEMI|50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
2384934|NCT03675789||Stable angina|50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
2384935|NCT03675789||Controls|50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
3183351|NCT00713063|Active Comparator|2|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
3183352|NCT00713076|Experimental|1|Polyquaternium-preserved Multi-purpose solution
3183353|NCT00713089||1|75 subjects randomised into the placebo arm of an ongoing randomised double-blind placebo controlled clinical trial at National University Hospital, Singapore
2384939|NCT03675763|Experimental|Craniosacral therapy|Craniosacral therapy and parent information on how to manage colic.
2384940|NCT03675763|No Intervention|Parent information|Parent information on how to manage colic.
2384943|NCT03675724|Experimental|Treatment|Fisetin 20mg/kg/day, orally for 2 consecutive days
2384944|NCT03675724|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
2384945|NCT03675711|Active Comparator|Midline Catheter|Pt. will receive midline catheters.
2384946|NCT03675711|Active Comparator|Standard Peripheral venous Catheter|Pt. will receive a standard Peripheral venous catheter
2384948|NCT03675672|Active Comparator|Group 1|Misoprostol Oral tablet, 200mcg, QID
2384949|NCT03675672|Placebo Comparator|Group 2|Placebo Oral Tablet, 1 tab, QID
2384950|NCT03675659|Active Comparator|intra-articular injection|intra-articular injection with magnesium sulfate at weekly interval for four weeks
2384951|NCT03675659|Placebo Comparator|control|intra-articular injection with saline
2384952|NCT03675646|Experimental|Morphine group M|Experimental group M were administered preservative-free morphine 250 mcg in 2.5 ml NS intrathecal using 25 G needle in L1/2 - L5/S1 interspaces.
2384953|NCT03675646|No Intervention|Control group C|No intervention
2384954|NCT03675633||FEUrea in decompensated liver cirrhosis|FEUrea for the differential diagnosis of AKI in patients with cirrhosis and ascites Specifically, the ability of FEUrea to distinguish between ATN versus Pre renal azotemia and HRS
2384955|NCT03675620|Active Comparator|Standard Rehabilitation (Control Group)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to this group will begin with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for for the first 6 weeks of post-operative care. Standard rehabilitation will continue until discharge.
2385021|NCT03675165|No Intervention|Waiting List Control|Participants are informed that they are on a waiting list and will receive the intervention at the end of the study.
2384956|NCT03675620|Experimental|Blood Flow Restriction (BFR)|All participants will perform traditional post-operative shoulder rehabilitation exercises. Participants randomized to the BFR group will begin combining BFR with lower extremity strengthening exercises (prior to shoulder strengthening) 2-3 times per week for the first 6 weeks post-operative care. Standard rehabilitation will continue until discharge.
2384957|NCT03675607||Caregivers infants <2years old|Caregivers of infants under 2 years of age (parents or other), of any gender, who prepare complementary feeding regularly (more than once a week).
2384958|NCT03675594|Experimental|intervention arm|the group of participants will take the CAD/CAM titanium denture bases and assessment during and after the first 3 months after delivery of the first type.
2384959|NCT03675594|Experimental|intervention arm 2|the same group of participants will take the CAD/CAM cobalt/chromium denture bases and assessment during and after the second 3 months after delivery of the second type.
3183354|NCT00713089||2|The expecting mothers visiting at the well mother clinics at Gadjah Mada University Hospital were invited to participate in the study
2384961|NCT03675568|Experimental|study group|Non-Cultured autologous keratinocyte suspension
2384962|NCT03675568|Active Comparator|Control group|Split skin Graft
2384963|NCT03675555|Active Comparator|M (Mirtazapine) (Merta) group:(n=100)|
2384964|NCT03675555|Active Comparator|D (Dexamethasone) (Dex) group: (n=100)|
2384965|NCT03675555|Placebo Comparator|C (Control) group: (n=100)|
2384966|NCT03675542|Experimental|Study medication|HSP90 inhibitor (CUDC-305)
2384967|NCT03675529|Experimental|High Intensity Interval Training bout|Patients randomized to this group will perform a wattmax test immediately followed by 4 intervals of high and low intensity based on percentage of wattmax. Immediately after the exercise bout is finished patients will receive one dose of pimonidazole hydrochloride (500 mg per m2 body surface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
2384968|NCT03675529|No Intervention|Controls (usual care)|Patients randomized to the control group will not be doing any exercise, but will after approximately 35 min from baseline blood sampling receive one dose of pimonidazole hydrochloride (500 mg per m2 bodysurface) in order to quantify tumor hypoxia by pathological analyses after removal of the prostate by radical prostatectomy the following day.
2384969|NCT03675516||Rheumatoid arthritis cases|New onset cases of rheumatoid arthritis
2384970|NCT03675516||Controls|Age, gender and primary care practice-matched controls
2384971|NCT03675503|No Intervention|Control|No change in the standard of care.
2384972|NCT03675503|Experimental|Fall Prevention Decision Support|"Nursing assesses patient using the Assistive Device Checklist and provides assistive devices to patients, if appropriate.~Decision support aimed at preventing hospital falls and empowering nurses."
2384973|NCT03675490|Experimental|Exercise|Participants will engage in a physiotherapist-prescribed home exercise program with ABLE, the interactive technology. The exercises that will be prescribed are designed to improve functional mobility via challenging lower extremity strength and balance in a multicomponent exercise program. The difficulty of each exercise will be chosen at the discretion of the physiotherapist based on the participants' performance on the baseline assessments. The exercises will be prescribed at a moderate intensity (moderate balance challenge, 8-12 repetitions for strength exercises with the last few repetitions being challenging) and will be progressed over the study duration to ensure they remain a moderate challenge.
2384974|NCT03675477|Active Comparator|SHR0302 dose A|Participants randomized in this arm will receive dose A of SHR0302 until end of study at week 16.
2384975|NCT03675477|Active Comparator|SHR0302 dose B|Participants randomized in this arm will receive dose B of SHR0302 until end of study at week 16.
2384976|NCT03675477|Active Comparator|SHR0302 dose C|Participants randomized in this arm will receive dose D of SHR0302 until end of study at week 16.
2384977|NCT03675477|Placebo Comparator|palcebo|Participants randomized in this arm will receive placebo until week 8, and then will be re-randomized into one of the 3 active arms (dose A, dose B, and dose C of SHR0302) in a 1:1:1 allocation ratio until the end of study at week 16.
3183355|NCT00713102||1|The group includes 10189 patients with on board medical or surgical emergencies.
2384979|NCT03675438|Experimental|Sub-epitheilal TCA Inlay|Implantation of a sub-epithelial presbyopia corrective inlay using TCA technology
2384980|NCT03675425|Experimental|Group 1: non chest shielding|non chest shielding generic name: non dosage: non frequency and duration: in first 48 h eco with pad diameter will be measured in before and after phototherapy,
2384981|NCT03675425|Placebo Comparator|Group 2: chest shielding|chest shielding generic name: Phototrephy dosage: non frequency and duration: in first 48 h echo with pad diameter will be measured in before and after phototherapy,
2384982|NCT03675412|Active Comparator|Glaucoma Patients|Eligible participants include patients with mild, moderate or advanced primary open angle glaucoma (POAG) or primary angle closure glaucoma (PACG). Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
2384983|NCT03675412|Active Comparator|Healthy controls|Eligible participants include healthy subjects with no eye diseases. Each participant will complete baseline study tasks. Each participant will then receive one 200 mg caffeine tablet to ingest. Study tasks will be performed 1 hour and 2 hours after caffeine ingestion.
2384984|NCT03675399|Experimental|Supra-threshold isometric exercise|Participants will perform 10 isometric external rotation supra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
2384985|NCT03675399|Experimental|Infra-threshold isometric exercise|Participants will perform 10 isometric external rotation infra-threshold contractions of the affected shoulder, each held for 15 seconds, with resting intervals of 15 seconds between contractions.
2384986|NCT03675399|No Intervention|Control|Participants will remain resting.
2385022|NCT03675152|Experimental|Soft spinal brace|Soft spinal brace used 23 hours a day for 4 months.
2385023|NCT03675152|Active Comparator|thoracolumbar orthosis|Thoracolumbar orthosis used 23 hours a day for 4 months.
2385191|NCT03674060|Experimental|SYO-1644 200mg|SYO-1644 tablet, PO, 2 100mg tablet
2385192|NCT03674060|Active Comparator|Nexavar|Nexavar 200mg/tablet, PO, 1 tablet
3183356|NCT00713141||1|Early breast cancer
2384987|NCT03675386|Active Comparator|Control Group|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
2384988|NCT03675386|Experimental|Interventional Group|Patients in the interventional group will be given a Transitional Pain Service follow-up appointment at the following postoperative time points (2 to 6 visits for the first two months, and then 1 to 2 visits on a monthly basis until one year). At each visit, patients will meet with the clinical psychologist and chronic pain specialist. Patients in the intervention group will have access to the Manage My Pain (MMP) App. which allows people living with pain to quickly and easily track their pain and function on a daily basis on their smartphones or a browser on their desktop or mobile device. One-page clinical reports will capture the changes in patients' outcome data between clinical visits over the course in time.Clinic visits can be offered in person at the hospital or over telehealth (video conference) based on the patient's preference and clinician's judgment for telehealth suitability.
2384989|NCT03675373|Experimental|Intervention group|Alcohol brief intervention+mobile chat-based instant messages
2384990|NCT03675373|Active Comparator|control group|Alcohol brief intervention
2384991|NCT03675360|Experimental|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
2384992|NCT03675360|No Intervention|Usual Diet|"No dietary intervention.~At baseline, participants will receive written information with standard dietary advice and standard physical activity recommendations."
2384993|NCT03675334|Active Comparator|Test Group|"Active comparator: gingival recession~the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions"
2384994|NCT03675334|Placebo Comparator|Control Group|the aim of this study is to compare if the collagen matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions. The control group was treated with the same technique as the collagen matrix graft.
2384995|NCT03675321|Experimental|Auricular Neurostimulation|Intervention: Active Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks
2384996|NCT03675321|Sham Comparator|Sham Auricular Neurostimulation|Intervention: Sham (Inactive) Percutaneous Electrical Nerve Field Stimulation (PENFS) 5 days/week x 4 weeks.
2384997|NCT03675308|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
2384998|NCT03675308|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
2384999|NCT03675295|Active Comparator|Comparator: Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
2385000|NCT03675295|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
2385001|NCT03675282|Experimental|Parkinson Disease - Stage 1|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385002|NCT03675282|Experimental|Parkinson Disease - Stage 2|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385003|NCT03675282|Experimental|Parkinson Disease - Stage 3|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385004|NCT03675282|Experimental|Parkinson Disease - Stage 4|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385005|NCT03675282|Experimental|REM Sleep Behavior Disorder|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385006|NCT03675282|Experimental|Healthy Controls|MRI Brain at Baseline and 24 Months PE2i PET Scan at Baseline and 24 Months Office Visit at Baseline and 24 Months
2385007|NCT03675269|Experimental|Treatment|HBOT
2385008|NCT03675269|Active Comparator|Control|Standard wound care
3183357|NCT00713154|Placebo Comparator|1|Placebo group
3183358|NCT00713154|Active Comparator|2|Control Group
3183359|NCT00713167|Experimental|Grape Seed Extract|Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
2385012|NCT03675230|Active Comparator|3DCRT|This arm will be planned by 3DCRT to the treatment of the Medulloblastoma
2385013|NCT03675230|Experimental|Tomotherapy HD，TOMO|This arm will be planned by TOMO to the treatment of the Medulloblastoma
2385014|NCT03675217|Experimental|PE and PCFPC|Physical Exercise and primary care family caregivers program
2385015|NCT03675217|Active Comparator|Usual Care|Usual Care: PCFPC (primary care family caregivers program)
2385016|NCT03675191|Experimental|orlistat|Orlistat 120Mg Cap (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
2385017|NCT03675191|Placebo Comparator|placebo|placebo (120mg, three times a day, within 1hour after meal) combined with phentermine pill (37.5mg, once a day, within 1hour after meal)
2385018|NCT03675178|Experimental|treatment group|Anerning particle +ceftriaxone sodium
2385019|NCT03675178|Placebo Comparator|control group|Anerning particle placebo+ceftriaxone sodium
2385020|NCT03675165|Experimental|Intervention|Participants receive a tailored version of Laura King's 'Best Possible Self' intervention: a brief, self-administered, psychological intervention. It is fundamentally a writing exercise, whereby recipients are asked to spend 10 minutes writing about their best possible future self and the steps they need to take to become that person. This helps the individual set goals while facilitating positive affect. Our version of the task has people focus on their health-related goals in particular.
2385186|NCT03674086||Existing hearing aid user|Using hearing aids for 6 months or more.
2385024|NCT03675139|Experimental|Medroxyprogesterone Acetate|EH patients will take MPA (Medroxyprogesterone Acetate) 10mg daily from tenth day of menstruation for 15 days for 3months. Endometrial Biopsy (Pipelle) will be performed every 3 months to examine the endometrium. All of the findings will be recorded.
2385025|NCT03675139|Experimental|dydrogesterone|EH patients will take dydrogesterone 10 mg, 2 tablets twice daily from tenth day of menstruation for 15 days for 3-6 months. Endometrial Biopsy (Pipelle) will be performed every 3-month to examine the endometrium. All of the findings will be recorded.
3183360|NCT00713167|Placebo Comparator|Placebo|Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
2385027|NCT03675113|Experimental|upper extremity aerobic group|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be 3 day per a week through 6-weeks.
2385028|NCT03675113|Sham Comparator|control group|Deep breathing exercises combination with arm movements will be given as a home program in the control group. Training duration will be 3 day per a week through 6-weeks.
2385029|NCT03675100|Sham Comparator|IBS group|Patients who were diagnosed with IBS according to the ROME III criteria. Colonoscopic mucosal biopsy was undertaken for every subject.
2385030|NCT03675100|Active Comparator|Control group|Healthy participants who have no gastrointestinal symptoms and no colonoscopic abnormality. Colonoscopic mucosal biopsy was undertaken for every subject.
2385031|NCT03675074|Experimental|Treatment|A dual path jejunoileal side-to-side anastomosis is endoscopically created using the Neujia device.
2385032|NCT03675061|Other|Control group|Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
2385033|NCT03675061|Other|PartoSure group|"Each women have a biochemical test = PartoSure Test.~PartoSure test negative : For a negative test, the patient will be able to benefit from a nifedipine tocolysis, if the uterine contractions require it, then she will return home with a control by a midwife at home twice a week up to 34 weeks of amenorrhea.~PartoSure test positive : For a positive test, the patient will be hospitalized 7 days with a care identical to the control group."
2385034|NCT03675048|Experimental|Intervention group|The intervention group will receive 5 drops (10^8 cfu Lactobacillus reuteri DSM 17938) twice daily during feeding for 4 weeks.
2385035|NCT03675048|Placebo Comparator|Placebo group|The placebo group will receive 5 drops twice daily during feeding for 4 weeks. Placebo composition will be identical to that of the study drug but will not contain L. reuteri.
2385036|NCT03675048|No Intervention|Control group|The infants from the control group will comply with the same requirements and will undergo the same procedures as participants from the main group except for randomization and treatment.
2385037|NCT03675035|Experimental|Endomina|Reduction trough sutures of the gastro-jejunal anastomosis
2385038|NCT03675022|Experimental|Dupilumab|Dupilumab injections every 2 weeks.
2385039|NCT03675009|Other|Early Intervention|Educational curriculum will be delivered earlier in the timeframe after IAQ monitoring has initiated.
2385040|NCT03675009|Other|Late Intervention|Educational curriculum will be delivered later in the timeframe after IAQ monitoring has initiated.
2385041|NCT03674996|Experimental|Same day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 12 hours after the surgery.
2385042|NCT03674996|Experimental|Next-day discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 24 hours after the surgery.
2385043|NCT03674996|Other|2-days discharge|Patients submitted to minimally invasive radical prostatectomy, and discharged 48 hours after the surgery.
2385044|NCT03674983|Experimental|CEI Group|CEI Group will receive the standard of care (information, prescription, free PrEP) and economic incentives contingent on sufficiently-high adherence to PrEP.
2385045|NCT03674983|No Intervention|SOC Group|SOC Group will receive the standard of care only (information, prescription, free PrEP.)
3183361|NCT00713180|No Intervention|1|Pterygium free participants
3183362|NCT00713180|Experimental|2|Pterygium participants
3183363|NCT00713193|Experimental|1|Patients in this arm will receive cyclosporine (Neoral) at a dose of 2-3 mg/kg orally as an adjunct to plasma exchange.
2385049|NCT03674944|Experimental|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|This program includes: 1) Dialectical Behavior Therapy (DBT) skills 2) Behavioral coaching 3) Emotional Focused Parent Training (EFPT) 4) Behavioral Weight Loss (BWL) skills.
2385050|NCT03674944|Active Comparator|Behavioral Weight Loss (BWL)|This program includes information about diet and physical activity education, in addition to parent management skills, and behavioral modification principles including: modeling, reinforcement, and operant conditioning.
2385051|NCT03674931|Experimental|musical practice|Intensive weekly musical keyboard training over 12 months
2385052|NCT03674931|Active Comparator|music education|Recreative weekly musical courses without practice over 12 months
2385053|NCT03674918||persons with arterial hypertension|patients referred to consultation cardiology for hypertension. They get a 24 h blood pressure monitoring to define the exact mean arterial blood pressure
2385054|NCT03674905|Other|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
2385055|NCT03674905|Other|Peripheral nerve block|Pre-operative peripheral nerve block.
2385056|NCT03674879|No Intervention|Phone Call|Follow up contact is attempted via phone call.
2385057|NCT03674879|Experimental|Text Message|Follow up contact is attempted via text message.
2385058|NCT03674866||Patients with diabetes|Patients with type 1 diabetes and type 2 diabetes who received at least one prescription of insulin degludec (Tresiba®).
2385059|NCT03674853|Experimental|Wuling Capsule group|Patients who were treated with Wuling Caspule
2385060|NCT03674853|Active Comparator|Oryzanol group|Patients who were treated with oryzanol
2385193|NCT03674047|Experimental|newly-diagnosed BOS|-Participants will take ruxolitinib twice every day
3183364|NCT00713193|Active Comparator|2|Patients in this arm will receive prednisone at a dose of 1 mg/kg as an adjunct to plasma exchange.
3183365|NCT00713232||test construction|university student living in Taiwan for more than 5 years No known neurological, psychiatric or speech language disorders
2385061|NCT03674840|Other|control group|Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
2385062|NCT03674840|Experimental|design group|Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
3142801|NCT00003451|Experimental|Arm I|Cohorts of 3 patients receive interleukin-12 IV push on day 1, followed by escalating doses of interferon alfa by subcutaneous injection at 24, 48, 72, 96 and 120 hours. Courses repeat every 2 weeks for 6 months (12 courses total) in the absence of unacceptable toxicity and disease progression. Patients achieving partial response or stable disease at the completion of 6 months of therapy may receive additional courses of therapy for up to 24 months. Dose escalation of interferon alfa continues in subsequent cohorts in the absence of dose limiting toxicity (DLT). If 1 of 3 patients experiences DLT at a dose level, then 3 additional patients are entered at that dose level. If 2 of 6 patients experience DLT, then dose escalation stops. The maximum tolerated dose is defined as 1 level below that dose at which 2 or more of 6 patients experience DLT. Patients are followed every 3 months for 1 year and then every 6 months thereafter.
3142802|NCT00003452|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385065|NCT03674814|Experimental|Dose Level|Relacorilant will be given at a dose once daily. Enzalutamide will be given at a dose once daily.
2385066|NCT03674788||TAVI|Transcatheter Aortic Valve Implantation
2385067|NCT03674788||TMVI|Transcatheter Mitral Valve Intervention
2385068|NCT03674788||TTVI|Transcatheter Tricuspid Valve Intervention
2385069|NCT03674775|Active Comparator|Intervention Group Providers|DART QI Program Participation
2385070|NCT03674775|No Intervention|Control Group Providers|Usual Care
2385071|NCT03674762|Experimental|dental implants|microgrooved dental implants submerged
2385072|NCT03674762|Experimental|dentale implants|microgrooved dental implants nonsubmerged
2385073|NCT03674749|Active Comparator|Hyperbaric Oxygen|Hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks
2385074|NCT03674749|Experimental|Meditation with Hyperbaric Oxygen|Meditation session combined with each hyperbaric oxygen treatment with 100% oxygen at 2.0 ATA for 90 min, once daily, five times a week for 8 consecutive weeks,
3142803|NCT00003454|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142804|NCT00003485|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142805|NCT00003489|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142806|NCT00003491|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385079|NCT03674723|Experimental|Arms|Methionine bioavailability in Mung beans Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods). You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or a Mung bean stew with or without rice or wheat, which will be provided by the investigators
2385080|NCT03674710|Experimental|Group A|"Patients assigned to group A will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385081|NCT03674710|Experimental|Group B|"Patients assigned to group B will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385082|NCT03674710|Experimental|Group C|"Patients assigned to group C will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385083|NCT03674710|Experimental|Group D|"Patients assigned to group D will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385084|NCT03674710|Experimental|Group E|"Patients assigned to group E will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385085|NCT03674710|Experimental|Group F|"Patients assigned to group F will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
2385086|NCT03674697|Experimental|Active Treatment Group (Green LED)|Subjects will be exposed to a Green LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 8W; Voltage: 120V; Wavelength: 525 nm; Intensity: 4-100 Lux
3142807|NCT00003494|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385087|NCT03674697|Placebo Comparator|Control Group (White LED)|Subjects will be exposed to a White LED light for 3 weeks prior to surgery, during their hospital stay and for an additional 10 weeks after hospital discharge. Wattage: 9.6W; Voltage: 120V. Intensity: 4-100 Lux
2385088|NCT03674684||hydroxyethyl starch|Patients who received hydroxyethyl starch
2385089|NCT03674684||gelatin|Patients who received gelatin
2385090|NCT03674684||crystalloids|Patients who received crystalloids
2385091|NCT03674671|Experimental|Intravenous Ketamine|
2385092|NCT03674671|Active Comparator|Electroconvulsive Therapy|
2385093|NCT03674658|Experimental|A drug|Rhynorm(A drug)
2385094|NCT03674658|Active Comparator|B drug|Rytmonorm (B drug)
2385095|NCT03674645|Experimental|MRI|MRI exam performed on 200 healthy volunteers
2385096|NCT03674632|Experimental|relaxation meditation tape|Participants in this arm will be asked to use the relaxation therapy during the feed at least once a day. Participants will be given a diary to record when it is used. Participants will be encouraged to use the tape as often as they find it helpful.
2385097|NCT03674632|No Intervention|Normal care|Participants in this arm will receive normal care from the Beijing Children Hospital
2385098|NCT03674619|Active Comparator|Surgical treatment|Anterior discectomy
2385099|NCT03674619|Active Comparator|Conservative treatment|Patients will attend an experienced specialist in physical medicine and rehabilitation and a physiotherapist.
2385100|NCT03674606|Experimental|Routine low-dose aspirin|Subjects shall receive standard antenatal care as well as taking oral low-dose aspirin from the eligibility visit until 36-week gestation once daily, as prescribed by the research clinician. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
2385101|NCT03674606|No Intervention|No aspirin|No low-dose aspirin will be prescribed. Fetal Medicine Foundation screening test results from the recruitment visit shall not be disclosed to the participants in this arm.
2385102|NCT03674606|Active Comparator|Test-indicated low-dose aspirin|The Fetal Medicine Foundation screening test will be used to determine whether a subject is at high risk of developing any pre-eclampsia until 42-week gestation. Participants with risk > 1:8 must start low-dose aspirin treatment immediately. Participants with a risk < 1:8 will be excluded.
2385103|NCT03674593|Experimental|Mitral valve chordae prosthesis|"Patients of this group receive mitral valve chordae replacement performed in five stages:~Measure the required length of the chordae.~Forming loops.~Fixation of the loop group to the papillary muscles.~Fixation of chordal loops to the free edge of the valve.~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse."
2385104|NCT03674593|Active Comparator|Mitral valve chordae translocation|"The technique of translocation of secondary chordae:~The method consists essentially of three stages:~Selection of the secondary chordae.~Fixation of secondary chordae to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
2385105|NCT03674580||Suicidal patients|No intervention. Follow-up of the suicidal patients
3142808|NCT00003495|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142809|NCT00003496|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142810|NCT00003497|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
3142811|NCT00003500|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385110|NCT03674554|Experimental|titanium bases group|full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
2385111|NCT03674554|Experimental|transmucosal abutment group|a full-arch screw-retained implant prosthesis with transmucosal abutment
2385112|NCT03674541|Active Comparator|Study Drug - Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
2385113|NCT03674541|Placebo Comparator|Placebo|Placebo by mouth as a one time dose
3142812|NCT00003501|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142813|NCT00003512|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385116|NCT03674515|Placebo Comparator|placebo|"Smartphone application placebo"
2385117|NCT03674515|Active Comparator|"Bouge"|"Smartphone equipped with the application Bouge"
2385118|NCT03674502|Experimental|ADU-1604|ADU-1604 administered as an IV infusion
2385119|NCT03674489|Active Comparator|Neurodynamic Slider Mobilization|
2385120|NCT03674489|Active Comparator|Neurodynamic Tensioner Mobilization|
2385121|NCT03674489|Sham Comparator|Sham Neurodynamic Mobilization|
2385122|NCT03674476|Experimental|Mild Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
2385123|NCT03674476|Experimental|Moderate Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
2385124|NCT03674476|Experimental|Severe Renal Impairment|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
2385125|NCT03674476|Other|Normal|The renal function will be defined by estimated glomerular filtration rate (eGFR) at Screening.
2385126|NCT03674463|Experimental|LCAR-B4822M treatment group|r/r multiple myeloma patients will be treated with LCAR-B4822M CAR-T cells with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
2385127|NCT03674450|Experimental|Interventional|
2385187|NCT03674073|Experimental|Microwave Ablation + Neoantigen Vaccines|The HCC patients will be treated firstly by Microwave Ablation, and then treated by courses of Neoantigen Vaccines.
3142814|NCT00003513|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142815|NCT00003515|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385131|NCT03674424|Experimental|DD-MVAC + avelumab|"Methotrexate, vinblastine, doxorubicin and cisplatin (DD-MVAC) given in combination with Avelumab.~DD-MVAC consists of Methotrexate 30 mg/m2 iv day 1, Vinblastine 3 mg/m2 iv day 2, Cisplatin 70 mg/m2 iv day 2 and Doxorubicin 30 mg/m2 iv day 2. Each cycle is given every 2 weeks for a maximum of 4 administrations Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 2 every 2 weeks.~Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
2385132|NCT03674424|Experimental|CG+ avelumab|"Cisplatin, gemcitabine (CG) consists of Gemcitabine 1000 mg/m2 iv in day 1 and day 8 and Cisplatin 70 mg/m2 iv in day 1. Each cycle is given every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
2385133|NCT03674424|Experimental|PG+ avelumab|"Paclitaxel, gemcitabine (PG) consists of Paclitaxel 80 mg/m2 iv in day 1 and day 15 and Gemcitabine 1000 mg/m2 iv in day 1 and day 15. Each cycle is repeated every 3 weeks for a maximum of 4 administrations.~Chemotherapy is associated with Avelumab 10 mg/kg, 1-hour intravenous (iv) infusion, given on day 1 every 2 weeks Cystectomy will be performed 3 to 6 weeks after last administration of chemotherapy"
2385134|NCT03674424|Experimental|Avelumab|"Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (iv) infusion once every 2 weeks. Dose reductions are not allowed.~Avelumab will be given alone for 4 administrations. Cystectomy will be performed 2 weeks after the last administration of avelumab"
2385135|NCT03674411|Experimental|FLU, CY, TBI + MGTA-456 infusion|
2385136|NCT03674411|Experimental|BU/ FLU/ MEL + MGTA-456 infusion Suspended: No|
2385137|NCT03674398|Experimental|Exercise+CT|Aerobic exercise for 30 minutes and smart-phone delivered cognitive training application for 20 minutes, 3 times per week for 4 weeks
2385138|NCT03674398|Active Comparator|Exercise only|Aerobic exercise for 30 minutes and smart-phone delivered videos for 20 minutes, 3 times per week for 4 weeks
2385139|NCT03674385|Experimental|vitamin E group|30 patient
2385140|NCT03674385|Active Comparator|control group|clomiphene
2385141|NCT03674372|Experimental|Fetuses with Left CDH (O/E LHR < 25%)|Fetuses with Left CDH (O/E LHR < 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
2385142|NCT03674372|Experimental|Fetuses with L- sided CDH with O/E LHR <30%.|Fetuses with Left CDH (O/E LHR < 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
2385143|NCT03674372|Experimental|Fetuses with R- sided CDH with O/E LHR < 45%|Fetuses with Right CDH (O/E LHR < 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)
2385144|NCT03674359||Cohort|Patients hospitalized in intensive care, meeting the inclusion criteria. BDG analysis
2385145|NCT03674346|Experimental|Hypnoanalgesia group|It is performed by a radiologist technologist who has been trained in Ericksonian hypnoanalgesia in the Hospices Civils de Lyon and has been practicing it regularly for 1 year.
2385146|NCT03674346|Other|MEOPA Group|The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA)
2385147|NCT03674333|Experimental|Group A|Folic acid 1mg daily will be given to the participants of Group A.
2385148|NCT03674333|Placebo Comparator|Group B|A Placebo (a sugar pill) will be given to the participants of the Group B.
2385149|NCT03674320|Placebo Comparator|Placebo|Placebo (saline) injections will be given via intramuscular injection at study weeks 2,3, 6, 7, 10, and 11.
2385150|NCT03674320|Active Comparator|Testosterone Enanthate|Testosterone Enanthate (100mg men, 25mg women) will be given via intramuscular injection at study weeks 2, 3, 6, 7, 10 and 11.
2385151|NCT03674307|Experimental|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
2385152|NCT03674307|Active Comparator|Regular screening|Regular (yearly or 2nd yearly) screening for asymptomatic coronary artery disease after wait-list entry
2385153|NCT03674294|Experimental|Palonosetron/Dexamethasone/Aprepitant|
2385154|NCT03674294|Placebo Comparator|Palonosetron/Dexamethasone/Placebo|
2385156|NCT03674255||1|Participants in group 1 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained, in addition to venous blood samples obtained from the cannula inserted as part of the standard clinical procedure. These blood samples will be collected before and after the stress echocardiogram. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
2385157|NCT03674255||2|Participants in group 2 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
2385188|NCT03674073|Active Comparator|Microwave Ablation|The HCC patients will be treated only by Microwave Ablation.No vaccine will be used.
3142816|NCT00003516|Experimental|Antineoplastons|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
3142817|NCT00003520|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142818|NCT00003521|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385158|NCT03674255||3|Participants in group 3 will be recruited at their stress echocardiogram appointment. Anonymised versions of the stress echocardiograms will be obtained. These participants will be followed up by telephone call after one year to determine whether they had any additional cardiac tests or events outside of their hospital trust. Medical records relating to the participant will be reviewed annually for up to 10 years to identify if the patient has been admitted and obtain health outcome data.
2385159|NCT03674255||4|Participants in group 4 will be recruited at their stress echocardiogram appointment, regardless of the type of investigation. A simplified data set and an anonymised version of the stress echocardiography report will be collected as a part of this registry phase. Participants will be followed up over a 10-year period.
2385160|NCT03674242|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed at Day 1 and Day 8 of each 3-week cycle in combination with~Gemcitabine IV infusion 1000 mg/m2, Day 1 and Day 8.~Carboplatin IV infusion at a calculated area under the curve (AUC) of 2.0 (AUC2), Day 1 and Day 8."
2385161|NCT03674242|Active Comparator|Chemotherapy alone|Gemcitabine plus carboplatin dosed at Day 1 and Day 8 of each 3-week cycle
2385162|NCT03674229|Active Comparator|Group I (information about weight management programs)|Participants receive information about commercially-available weight management programs and encouragement to participate in one of the programs for 6 months.
2385163|NCT03674229|Experimental|Group II (information, call from patient navigator)|Participants receive information about commercially-available weight management programs encouragement to participate in one of the programs for 6 months. Participants also receive 6 phone calls over 20-30 minutes each from an assigned patient navigator for 6 months.
2385164|NCT03674203|Experimental|Application of platelet-rich plasma|The patients received three sessions of PRP application, at intervals of 15 days between each of them. It was applied by means of a 32G needle to introduce the PRP by means of superficial micro-injections via the mesotherapy technique (approximately 1.5-2.0 mm deep) and it was deposited in the papillary dermis of the rosotro.
2385165|NCT03674190|Experimental|Anterior Lumbar Interbody Fusion|Surgical treatment Anterior Lumbar Interbody Fusion
2385166|NCT03674190|Active Comparator|Total disc replacement|Surgical treatment total disc replacement in the lumbar spine
3183366|NCT00713232||normative data|normal subjects 20-80 y/o Living in Taiwan for at least 5 years No know neurological, psychiatric and speech-language disorders
3183367|NCT00713271|Experimental|1|Low dose
3183368|NCT00713271|Experimental|2|intermediate dose
3183369|NCT00713271|Experimental|3|high dose
2385171|NCT03674151|Active Comparator|Device: Silver Nylon dressing|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
2385172|NCT03674151|Active Comparator|Device: Manuka-Honey|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
2385173|NCT03674151|Active Comparator|Device: Povidone-Iod (PVP-Iod)|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
2385174|NCT03674151|Active Comparator|Device: Hydrogel|1/4 of a split-skin grafted third-degree burn wound in a Group (n=20): Consent-capable male and female patients ≥18 years of age who have a split-skin grafted third-degree burn on ≥3% and ≤30% of the surface of the body.
3183370|NCT00713271|Placebo Comparator|4|
3183371|NCT00713297||Observation|Those who will use the new CPOE system
2385177|NCT03674125|Experimental|Group 1|GLS-6150 at 2.0 mg DNA/dose (3 dose prime plus boost)
2385178|NCT03674125|Experimental|Group 2|GLS-6150 at 1.0 mg DNA/dose (3 dose prime plus boost)
2385179|NCT03674125|Experimental|Group 3|GLS-6150 at 2.0 mg DNA/dose(3 dose prime plus boost)
2385180|NCT03674125|Experimental|Group 4|GLS-6150 at 2.0 mg DNA/dose(2 dose prime plus boost)
3183372|NCT00713336|Experimental|1|ZD4054 + Moxifloxacin placebo
3183373|NCT00713336|Active Comparator|2|ZD4054 placebo + Moxifloxacin
2385183|NCT03674099|Experimental|Imatinib|Imatinib will be administered orally one tablet (400mg) twice daily, 800mg per day for 14 consecutive days.
2385184|NCT03674099|Active Comparator|Methylprednisolone|Methylprednisolone will be administered once a day either in tablets; Medrol 1g per day or iv; Solumedrol 1000 mg per day, both for three consecutive days.
2385185|NCT03674086||First-time hearing aid user|Using hearing aids less than or equal to three months.
3183374|NCT00713336|Experimental|3|ZD4054 + ZD4054 placebo + Moxifloxacin placebo
3183375|NCT00713336|Placebo Comparator|4|ZD4054 Placebo + Moxifloxacin placebo
3183376|NCT00713362|Active Comparator|1|Surgery: Video-assisted thoracoscopic surgery
3183377|NCT00713362|Active Comparator|2|Chest tube drainage
3183378|NCT00713401|Experimental|Cohort A|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol low dose infusion
3183379|NCT00713401|Experimental|Cohort B|Period 1: 150 mcg, i.v. bolus. Period 2: 150 mcg, i.v. bolus + esmolol low dose infusion
3183380|NCT00713401|Experimental|Cohort C|Period 1: 300 mcg, i.v. bolus. Period 2: 300 mcg, i.v. bolus + esmolol low dose infusion
3183381|NCT00713401|Experimental|Cohort D|Period 1: 75 mcg, i.v. bolus. Period 2: 75 mcg, i.v. bolus + esmolol high dose infusion
3183382|NCT00713401|Experimental|Cohort E|Period 1: 150 or 300 mcg, i.v. bolus. Period 2: 150 or 300 mcg, i.v. bolus + esmolol high dose infusion
3183383|NCT00713440|Experimental|1|10 healthy Caucasian subjects without family history of diabetes
3183384|NCT00713466||1|all third year medical students entering their pediatric clerkship at the Medical College of Wisconsin
3183385|NCT00713492|Experimental|1|Alcohol
3183386|NCT00713505|Experimental|Arm I (parent intervention program and usual care)|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care). Parents also receive 8 weekly face-to-face training sessions (75-90 minutes each) with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
2385194|NCT03674047|Experimental|Established BOS|-Participants will take ruxolitinib twice every day
2385195|NCT03674034||term|50 CTscan and MRI images of children aged at term
2385196|NCT03674034||one month|50 CTscan and MRI images of children aged one month
2385197|NCT03674034||two months|50 CTscan and MRI images of children aged two months
2385198|NCT03674021|Experimental|Intervention Arm|Patients in the intervention arm will receive the Chest Pain Choice visual aid prior to discussion with their primary physician regarding disposition.
2385199|NCT03674021|No Intervention|Control Arm|Patients in the control arm will not receive the Chest Pain Choice visual aid and will receive standard care.
2385200|NCT03674008|Experimental|HSK3486|0.4mg/kg/0.2 mg/kg
2385201|NCT03674008|Active Comparator|Propofol|1.5mg/kg/0.75mg/kg
2385202|NCT03673995|Experimental|Myo-inositol+L-tyrosine|One sachet per day containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid for improving PCOS symptoms.
2385203|NCT03673982|Experimental|iCASK Group|Materials and support to aid transitions.
2385204|NCT03673969|Active Comparator|MGB|Mini gastric bypass
2385205|NCT03673969|Active Comparator|Roux enY gastric bypass|Roux enY gastric bypass
2385206|NCT03673956|Experimental|Topical Antibiotic Nasal Saline Rinse|The topical antibiotics will prescribed to the patient in capsule form as compounded by the Mayo Clinic pharmacy, or suitable licensed 3rd party compounding pharmacy. One capsule will subsequently be added to a nasal saline irrigation bottle, and the patient will administer this irrigation to him or herself in the usual fashion twice per day.
2385207|NCT03673943|Experimental|PET/CT imaging with 64Cu-DOTATATE|64Cu-DOTATATE is an investigational radioactive drug that binds to somatostatin receptors on NETs cancer cells.
2385208|NCT03673930|Active Comparator|Zanthozylum armatum|fruit extract
2385209|NCT03673930|Placebo Comparator|Placebo|placebo
2385210|NCT03673917|Experimental|Educational video|The educational video on skin cancer for cosmetologists
2385211|NCT03673917|Active Comparator|Control video|A publicly accessible healthy lifestyle video on YouTube, which did not contain any information on skin cancer
2385212|NCT03673904||Prediabetics|Ages ranging from 18 to 60 years old,males and females were included . A fasting blood glucose level (100 to 125 mg/dL). or A 2-hour blood glucose level (140 to 199 mg/dL) .or Hb A1C 5.7% to 6.4%.
2385213|NCT03673904||Newly diagnosed type 2 diabetes|Ages ranging from 18 to 60 years old,males and females were included Newly diagnosed type 2 diabetes: (maximum within one month from diagnosis) A fasting blood glucose level >126 mg/dl A 2-hour blood glucose level > 200 mg/d Hb A1C > 6.5%
2385214|NCT03673891|No Intervention|Control|After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
2385215|NCT03673891|Experimental|LifeFlow group|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
3142819|NCT00003522|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385218|NCT03673852|Other|Peer Wellness Enhancement (WE Harambee)|This project employs a pragmatic, stepped wedge experimental design in which 60 BHH participants are randomly assigned to one of 3 waves of WE Harambee implementation (20 in each wave) during the 2 year study. Participants in this arm receive the WE Harambee Wellness Enhancement and are enrolled in a Behavioral Health Home. WE Harambee is a 6-month peer-delivered whole health intervention intended to address the 8 dimensions of wellness and the social determinants of health.
2385219|NCT03673852|Other|Behavioral Health Home enrollment|"In the stepped wedge experimental design, 40 participants at any time during the 2 year study are receiving only the Behavioral Health Home (BHH) intervention. The 2010 Patient Protection and Affordable Care Act (ACA) established a health home option under Medicaid that serves enrollees with chronic conditions including serious mental illness and chronic physical illness."
2385220|NCT03673839|Active Comparator|Animal proteins (crossover)|
2385221|NCT03673839|Experimental|Plant-based protein blends type 1 (crossover)|
2385222|NCT03673839|Experimental|Plant-based protein blends type 2 (crossover)|
2385223|NCT03673839|Experimental|Plant-based protein blends type 3 (crossover)|
2385224|NCT03673826|Experimental|Arm A|Rd combination (Cycles 1-9 lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
2385225|NCT03673826|Experimental|Arm B|KRd combination (Cycles 1-9 carfilzomib 20/36 mg/m2, lenalidomide 25 mg, dexamethasone 20 mg cycles 1-4 and 10 mg cycles 5-9); followed by extended lenalidomide dosing (10 mg days 1-21 of a 28 day cycle for 24 cycles).
2385228|NCT03673787|Experimental|Phase I|Increasing doses of ipatasertib in combination with a fixed dose of atezolizumab to establish the recommended phase II dose.
2385229|NCT03673787|Experimental|Phase II|The Phase II part of the study will evaluate the recommended phase II dose of ipatasertib identified in Phase I, in combination with atezolizumab, in six patient cohorts: patients with solid tumours who have hyperactivation of the PI3K pathway; patients with castrate-resistant prostate cancer with PTEN loss; patients with glioblastoma; patients with melanoma; patients solid tumour types refractory to immune-checkpoint inhibitors; patients with gynaecological cancers.
3142820|NCT00003524|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385231|NCT03673761||Cushing's syndrome|"a) Patients with Sd Cushing (SC): 40 women (25-60 years) with SC, with controlled hypercortisolism after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
2385232|NCT03673761||acromegaly|"b) Patients with acromegaly: 40 patients of both sexes (25-60 years) with GH / Insulin-like-Growth Factor (IGF-I) controlled after treatment and without clinical / biochemical signs of relapse for more than 5 years.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
2385233|NCT03673761||Healthy controls|"Controls: n = 40; normal healthy control paired by age, sex and BMI will be included.~This group will under go the following procedures:~muscle MRI~dual-energy x-ray absorptiometry~muscle ultrasounds~blood testing"
2385234|NCT03673748|Experimental|Mesenchymal stromal cells (MSC)|Participants will receive a single Intravenous infusion of Mesenchymal Stem Cells (MSV) 1.5 million cells per kg wt suspended in isotonic medium (Physiological saline solution + 1% Human Albumin + 5 mM Glucose). All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial. GMP-compliant MSV will be prepared by IBGM-University of Valladolid
2385235|NCT03673748|Placebo Comparator|Placebo|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells. The placebo infusion will consist of physiological saline solution + 1% Human Albumin + 5 mM Glucose, which is the same vehicle used to deliver the MSCs in the experimental groups.
2385236|NCT03673735|Experimental|Experimental Arm|Patients will receive 1 infusion of 1500 mg Durvalumab within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with Durvalumab will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
2385237|NCT03673735|Placebo Comparator|Control arm|Patients will receive 1 infusion of placebo within 1 week prior to concurrent chemoradiotherapy. Chemoradiation should start within 6 weeks after surgery and within 1 week maximum of the induction phase. Radiation will consist of 33 fractions over 6 weeks for a total of 66 Gy. Chemotherapy will consist of cisplatin 100 mg/m2 given on days 1, 22 and 43 of radiotherapy. Maintenance phase with placebo will begin within 1 to 28 days maximum after the end of radiotherapy and will consist of 6 doses administered every 4 weeks.
2385238|NCT03673722|Experimental|MDP only|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern through interaction with the online LEAP2 platform
2385239|NCT03673722|Experimental|MDP plus PA|Participants will be asked to increase their consumption of foods that are consistent with a Mediterranean Dietary Pattern AND to increase Physical Activity using a mixture of structured and non-structured activities through interaction with the online LEAP2 platform
2385240|NCT03673722|Placebo Comparator|Control|Participants will be given generic healthy eating advice based on the NHS 'Eatwell' plate and British Heart Foundation (BHF) guidelines
2385241|NCT03673709|No Intervention|Individual Antenatal Care (usual care)|Women are provided antenatal care services on a first come, first serve basis and listen to a health lecture. They meet individually with a midwife for a physical assessment. Women complete laboratory tests (including HIV testing) at their first visit. Congruent with the new WHO recommendations, individual antenatal care consists of 8 antenatal care visits and 2 postnatal visits at 1 week and 6 weeks.
2385242|NCT03673709|Experimental|Group Antenatal Care (intervention)|Women have the same number of visits as those in individual care. Their first antenatal care (intake) and first postnatal visit is done individually (identical to individual care). Women in group care bypass the waiting area and have a 2-hour visit with the same provider in a group of 8-12 women at a similar stage of pregnancy. Women assess their blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
2385243|NCT03673696|Experimental|50 mg single dose|It includes two group, one group is pilot study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=2) . Another group is formal study, healthy subjects receive a single dose of 50 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
2385244|NCT03673696|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
2385245|NCT03673696|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg HEC74647PA capsule (N=16) or matching placebo (N=2) under fed or fasted conditions, this group is a two-sequence, two-period crossover study.
2385246|NCT03673696|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
2385247|NCT03673696|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
2385248|NCT03673696|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg HEC74647PA capsule (N=8) or matching placebo (N=2).
2385249|NCT03673696|Experimental|100 mg multiple doses|Healthy subjects, receiving 100 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
2385250|NCT03673696|Experimental|200 mg multiple doses|Healthy subjects, receiving 200 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
3142821|NCT00003525|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385251|NCT03673696|Experimental|400 mg multiple doses|Healthy subjects, receiving 400 mg HEC74647PA capsule (N=10) or placebo(N=2) once daily (q.d.) for 7 days.
2385252|NCT03673683|Active Comparator|Usual Care|Sedation and ventilation weaning that is non-protocol-based and primarily medically-driven.
2385253|NCT03673683|Experimental|SANDWICH protocol|A protocol-based intervention for managing sedation and ventilation weaning.
3183387|NCT00713505|Active Comparator|Arm II (wait-list/usual care control [UCC])|Child participants and their families undergo usual care as in arm I and are placed on a wait-list.
3183388|NCT00713518|Active Comparator|Arm 1 ranibizumab|0.5 mg ranibizumab intravitreal injection given every 4 weeks from baseline to Week 12
3183389|NCT00713518|Experimental|Arm 2 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg PF-04523655 given by intravitreal injection every 2 weeks from Week 4 to Week 12
2385257|NCT03673657|Experimental|A|"ONS from the start of radiotherapy; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
2385258|NCT03673657|Experimental|B|"ONS from the time of grade 2 radiation esophagitis; Energy goal-based ONS: daily total nutritional intake of 30-35kcal/kg.~Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy."
2385259|NCT03673657|Experimental|C|ONS from the start of radiotherapy; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
2385260|NCT03673657|Experimental|D|ONS from the time of grade 2 radiation esophagitis; Prealbumin goal-based ONS. Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy; Weekly DP chemotherapy concurrent with thoracic radiotherapy.
2385261|NCT03673644||Primary Open-Angle Glaucoma|"Two following two questionnaires will be administered:~Life Space Questionnaire: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.~Low Luminance Questionnaire: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions."
2385262|NCT03673631||NFHC-O2 Group|NFHC-O2 therapy alone with gas flow at least 40L/min,
2385263|NCT03673631||NIV/Standard-O2 Group|NIV sessions with at least 30% FiO2 and standard oxygen therapy
2385264|NCT03673631||NFHC-O2/NIV Group|combination of NIV sessions and NFHC-O2 therapy,
2385265|NCT03673618|Experimental|PROMOTIR soluble corn fiber|Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
2385266|NCT03673618|Placebo Comparator|Malodextrin|Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.
2385267|NCT03673605|Experimental|Rivaroxaban|
2385268|NCT03673605|Active Comparator|Warfarin|
2385269|NCT03673592||Euploid embryos analyzed by PGT-A|Embryos with a normal chromosome copy number. This embryos will be transferred to the uterus.
2385270|NCT03673592||Low-grade mosaic embryos (PGT-A)|Embryos with a lower aneuploidy percentage (<50%). This embryos will be considered for transfer to the uterus.
2385271|NCT03673592||High-grade mosaic embryos (PGT-A)|Embryos with a high aneuploidy percentage (50-70%). This embryos will be discarded for transfer.
2385272|NCT03673592||Aneuploid embryos analyzed by PGT-A|Embryos with an abnormal number of chromosomes. This embryos will be discarded for transfer.
2385273|NCT03673579|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
2385274|NCT03673579|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
2385275|NCT03673579|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
2385276|NCT03673566|Experimental|NICU Dashboard: Parent|"The parental intervention group will have access to the parent application on the NICU Dashboard. Parents will be able to view basic information about their baby's condition, educational material, and track core measures and developmental milestones.~Parents of NICU babies will be asked to complete questionnaires at baseline and within 48 hours of NICU discharge."
2385277|NCT03673566|No Intervention|Standard Care: Parent|The Parental Control group will receive standard of care without any study devices.
2385278|NCT03673566|Experimental|NICU Dashboard: Clinician|"The Clinician group will have access to the NICU Dashboard, which presents information from the EHR, bedside monitoring, and other systems of record through a pre-released FDA Class 2 clinical decision support rule-based system, to assist the appropriate evidence-based guidelines be integrated with team workflows. Caregivers educate and coach parents to facilitate integrating them into their infant's care.~NICU clinicians will be asked to complete questionnaires 1) prior to clinical go-live of the intervention (baseline), 2) at the study mid-way point, and 3) upon completion of parent recruitment."
2385279|NCT03673553||Association of people with fibromyalgia|Control group included people affiliated to the FM Patient Association of Terres de l'Ebre, Spain.
2385280|NCT03673553||Multimodal treatment of patients with FM|The intervention group was made up of patients from the specialist FM Unit in the Hospital of Lleida, Spain.
2385281|NCT03673540|Experimental|CBT with smartphone application (EMI on)|CBT with CBT+ smartphone application (EMI on)
2385282|NCT03673527|Experimental|topical formulation of tacrolimus|
2385283|NCT03673514|Active Comparator|THA Posterior Approach|The posterior approach to the hip has been described by many authors and yields good results. Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
2385284|NCT03673514|Active Comparator|THA Direct anterior approach|The modified Hueter approach, based on the Smith-Peterson approach, was performed for the direct anterior minimally invasive surgery. This approach could have some advantages as it is a muscle sparing approach, hence yielding a faster recovery. A traction table was used for DAA as surgeons were trained to use this method. No intra-operative fluoroscopy was used for implant confirmation.Implants used were Quadra®-H stem and Versacup® hip system, Medacta, Switzerland, with metal on polyethylene bearing. All implants were non-cemented.
2385285|NCT03673501|Experimental|DCC-2618|150 mg QD DCC-2618
2385286|NCT03673501|Active Comparator|sunitinib|50 mg QD sunitinib
2385287|NCT03673488||TephaFlex™ mid-urethral sling for SUI|P4HB material ( TephaFlex ™) will be implanted in 25 women with confirmed Stress Urinary Incontinence (SUI).
2385288|NCT03673475||fluid responsiveness|Assessment of fluid responsiveness using pleth variebility index and jugular vein distensibility in patients undergoing major abdominal surgery
3142822|NCT00003528|Experimental|Arm I|Patients receive raltitrexed intravenously over 15 minutes once weekly for 3 weeks followed by 1 week of rest. Treatment continues in the absence of disease progression and unacceptable toxicity.
2385291|NCT03673449|Experimental|SilkBridge treatment|Surgery for digital nerve reconstruction with SilkBridge
2385292|NCT03673436||Patients with low back pain|Cohort of 200 low back pain patients, 18 years+, who have been undergoing a lumbar spinal fusion
2385293|NCT03673410|Active Comparator|Laparoscopic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with a standard of care laparoscopic procedure.
2385294|NCT03673410|Experimental|Robotic revisional bariatric surgery|Patients requiring revisional bariatric surgery will be treated with the same procedure but performed robotically.
2385295|NCT03673397|Experimental|Aerobic exercise|Patients allocated to the intervention group will perform a single bout of supervised aerobic exercise. The starting time will be approximately 1630 hrs. The exercise mode will be a bicycle ergometer. After a warm-up period, during which the intensity is gradually increased, an intensity of 80% of the individual anaerobic threshold will be maintained for 30 minutes. The intensity level was chosen based on clinical experience that this corresponds to an approximate rate of perceived exertion of 13 (on a scale from 6-20) in this population.
2385296|NCT03673397|No Intervention|Control|Individuals allocated to the control group will be placed in a room with analogous conditions to the exercise group concerning light, temperature and absence of music at the same time as individuals performing the exercise intervention. The control group will be asked to remain seated and read magazines.
2385297|NCT03673384|Experimental|experimental group|"Received infrared-C ray irradiation by hot compress with a powered heating compress and an eye mask for 40 minutes/time/day Treated regions: eyes and nose region, back region of head, shoulder neck and low back.~Received medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate."
2385298|NCT03673384|Placebo Comparator|Control group|received only medical treatment, e.g., Xyzal Oral Product and Fluticasone Furoate.
2385299|NCT03673371||Women Veterans with Lower Limb Amputations|Questionnaire
2385300|NCT03673358|Experimental|Intervention - CBT|Participants in this arm will receive cognitive behavioural therapy. Participants will have the choice of completing six real-time telephone or video-delivered CBT sessions with a therapist OR complete online modules with asynchronous feedback with a dedicated therapist in addition to standard of care for their fracture injury.
2385301|NCT03673358|No Intervention|No intervention- - control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
2385302|NCT03673345|Experimental|Cohort 1A|0.25 mL dose of IIV-4 administered intramuscularly on days 0 and 28 of study year 1 and on day 0 of study year 2 in children 6-12 months of age who have not previously had an influenza infection or vaccination, n=20
2385303|NCT03673345|Experimental|Cohort 1B|0.25 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 after primary influenza infection in study year 1 in children 3-12 months of age, who have not previously had an influenza vaccination, n=20
2385304|NCT03673345|Experimental|Cohort 2A|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=60
2385305|NCT03673345|Experimental|Cohort 2B|0.25 mL (less than 36 months of age) or 0.5 mL (36 months of age or older) dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children greater than 12 months of age and born after 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
2385306|NCT03673345|Experimental|Cohort 3A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2006 and 2009, who have previously received 2 doses of influenza vaccine prior to the study, n=30
2385307|NCT03673345|Experimental|Cohort 3B|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2006 and 2009, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
2385308|NCT03673345|Experimental|Cohort 4A|0.5 mL dose of IIV-4 administered intramuscularly on day 0 of study year 1 and day 0 of study year 2 in children born between 2003 and 2006, who have previously received 2 doses of influenza vaccine prior to the study, n=30
2385309|NCT03673345|Experimental|Cohort 4B|0.5 mL does of IIV-4 administered intramuscularly on day 0 of study year 2 in children born between 2003 and 2006, who have previously had an influenza infection in study year 1 and have received 2 doses of influenza vaccine prior to the study, n=20
2385310|NCT03673332|Experimental|treatment including immune checkpoint inhibitors|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
2385359|NCT03673085|Experimental|Group 3-1|The dose of CN128 is 10 mg/kg bw.
2385360|NCT03673085|Placebo Comparator|Group 3-2|The dose of placebo is 10 mg/kg bw.
2385311|NCT03673319|Experimental|Positive expectative|"Participants in the positive expectation group will be told that DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
2385312|NCT03673319|Experimental|Neutral expectatives|"Participants in the neutral expectation group will be told that DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
2385313|NCT03673306||Pregnant cohort|Women with one or more pregnancies any time after breast cancer diagnosis
2385314|NCT03673306||Non-pregnant cohort|Women with no subsequent pregnancies after breast cancer diagnosis
2385315|NCT03673280|Placebo Comparator|Classical spinal anesthesia|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + placebo quadratus lumborum block.
2385316|NCT03673280|Experimental|Spinal anaesthesia with block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg + quadratus lumborum block.
2385317|NCT03673280|Experimental|Classical anaesthesia plus block|Patients allocated to this group will receive spinal anesthesia with bupivacaine 12.5mg, Fentanyl 20mcg and Morphine 80mcg + quadratus lumborum block.
2385318|NCT03673267|Experimental|Nutricity|
2385319|NCT03673241|No Intervention|Control Group|The Control Group will receive the standard support surface mattresses/bed surfaces and recovery chairs without the non-invasive perfusion enhancement system (The Guardian System)
2385320|NCT03673241|Experimental|Study Arm|The Study Arm will have the non-invasive perfusion enhancement system placed on their beds and recovery chairs. Patients will be utilizing the systems while lying in bed or sitting in the chair.
3142823|NCT00003530|Experimental|Antineoplaston Therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385323|NCT03673215|Experimental|A|
2385324|NCT03673215|Experimental|B1|
2385325|NCT03673215|Placebo Comparator|B2|
2385326|NCT03673215|Experimental|C1-1|
2385327|NCT03673215|Placebo Comparator|C1-2|
2385328|NCT03673215|Experimental|C2-1|
2385329|NCT03673215|Placebo Comparator|C2-2|
2385330|NCT03673215|Experimental|C3-1|
2385331|NCT03673215|Placebo Comparator|C3-2|
2385332|NCT03673202||UC monitoring patients|Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations. All patients will have urine samples taken and analyzed for urine cytology and Cxbladder. No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes.
2385333|NCT03673189|Experimental|Healthy volunteers|Sensors assigned for 3 weeks
2385334|NCT03673189|Experimental|Patients with arythmic disease or peripheral vascular disease|Sensors assigned for 3 weeks
2385335|NCT03673176|Experimental|Stereotactic Ablative Radiotherapy|Experimental stereotactic ablative radiation treatment
2385336|NCT03673163|Experimental|Lidocaine|Lidocaine treatment
2385337|NCT03673163|Placebo Comparator|Control|Placebo treatment
2385338|NCT03673150||women with breast cancer|women who gave birth in 2002/2005 with cord blood collection and developed invasive or non-invasive breast cancer in the following years (2005- O6/2018) to the exclusion of another cancer.
2385339|NCT03673150||women without breast cancer|Controls will be obtained by matching by date of delivery, location, age (woman's date of birth), parity at the time of cord collection and not having had breast cancer
2385340|NCT03673137|Experimental|Synchronous treatment group|Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
2385341|NCT03673137|Active Comparator|Traditional treatment group|The initial gemcitabine administration was on day 7 following IRE treatment. Once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
2385342|NCT03673124|Other|Ribociclib and letrozole|Ribociclib 600mg oral daily for 3 weeks then 1 week off plus Letrozole 2.5 mg oral daily
2385343|NCT03673111|Experimental|1.0 mg|Y14 single dose, subcutaneous
2385344|NCT03673111|Experimental|2.0 mg|Y14 single dose, subcutaneous
2385345|NCT03673111|Experimental|6.0 mg|Y14 single dose, subcutaneous
2385346|NCT03673111|Experimental|9.0 mg|Y14 single dose, subcutaneous
2385347|NCT03673111|Experimental|18.0 mg|Y14 single dose, subcutaneous
2385348|NCT03673111|Experimental|36.0 mg|Y14 single dose, subcutaneous
2385349|NCT03673111|Placebo Comparator|Placebo|0.9% saline
2385350|NCT03673111|Experimental|26.0 mg (B1)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 12mg on day 8, 16mg on day 15, 20mg on day 22 and 26mg on day 29.
2385351|NCT03673111|Experimental|36mg (B2)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 9mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
2385352|NCT03673111|Experimental|36mg (B3)|Y14 multiple dose, subcutaneous 5 doses over a 4 week treatment period: 12mg on day 1, 24mg on day 8, 36mg on day 15, no dose on day 22 and 36mg on day 29.
2385353|NCT03673098|Experimental|Intervention Group: Adapted 3RP|The intervention condition will consist of the 10-week adapted 3RP intervention.
2385354|NCT03673098|No Intervention|Control Group: Supportive Psychotherapy|The control condition will be a 10-week supportive therapy program. Visits include supportive psychotherapy to address stressful or difficult topics related to aging as a woman living with HIV. The program was developed to approximate the most frequent mental health counseling provided to adults with HIV at the community level.
2385355|NCT03673085|Experimental|Group 1-1|The dose of CN128 is 2.5 mg/kg bw.
2385356|NCT03673085|Placebo Comparator|Group 1-2|The dose of placebo is 2.5 mg/kg bw.
2385357|NCT03673085|Experimental|Group 2-1|The dose of CN128 is 5 mg/kg bw.
2385358|NCT03673085|Placebo Comparator|Group 2-2|The dose of placebo is 5 mg/kg bw.
2385361|NCT03673085|Experimental|Group 4-1|The dose of CN128 is 15 mg/kg bw.
2385362|NCT03673085|Placebo Comparator|Group 4-2|The dose of placebo is 15 mg/kg bw.
2385363|NCT03673085|Experimental|Group 5-1|The dose of CN128 is 20 mg/kg bw.
2385364|NCT03673085|Placebo Comparator|Group 5-2|The dose of placebo is 20 mg/kg bw.
2385365|NCT03673085|Experimental|Group 6-1|The dose of CN128 is 30 mg/kg bw.
2385366|NCT03673085|Placebo Comparator|Group 6-2|The dose of placebo is 30 mg/kg bw.
2385367|NCT03673085|Experimental|Group 7-1|The dose of CN128 is 45 mg/kg bw.
2385368|NCT03673085|Placebo Comparator|Group 7-2|The dose of placebo is 45 mg/kg bw.
2385369|NCT03673085|Experimental|Group 8-1|The dose of CN128 is 60 mg/kg bw.
2385370|NCT03673085|Placebo Comparator|Group 8-2|The dose of placebo is 60 mg/kg bw.
2385371|NCT03673072|Experimental|Arm A (gemcitabine plus cisplatin)|Patients assigned to arm A will receive treatment with gemcitabine plus cisplatin. Chemotherapy will be administered for 3 cycles preoperatively (neoadjuvant part) and for 3 cycles postoperatively (adjuvant part).
2385372|NCT03673072|Active Comparator|Arm B (standard postoperative management)|Patients assigned to arm B will receive surgery directly, without receiving perioperative chemotherapy (Standard of Care / SOC). After surgery, adjuvant chemotherapy can be administered by investigator's choice.
2385373|NCT03673059|Experimental|OTC Eczema Moisturizer Regimen|Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
2385374|NCT03673059|Experimental|Cosmetic Moisturizer Regimen|Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).
2385375|NCT03673046|Experimental|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD.
2385376|NCT03673046|Other|12 Week Waitlist Control|12 week waitlist control. (Note: participants will be crossed over to 12-week Smartphone-delivered CBT for BDD following the 12-week waitlist control).
2385378|NCT03673007|Experimental|Treatment Group|Women in this arm of the study receive a voucher which can be used to buy contraception and related services at Planned Parenthood
2385379|NCT03673007|No Intervention|Control Group|Women in this arm of the study DO NOT receive a voucher for contraceptives. Women in this arm receive the Planned Parenthood standard of care priced according to the Planned Parenthood sliding scale.
2385380|NCT03672994||Asthma|Patients with prior confirmed diagnosis of bronchial asthma
2385381|NCT03672994||Chronic Obstructive Pulmonary Disease|Patients with prior confirmed COPD
2385382|NCT03672994||Pneumonia|Patients with X-ray confirmed community acquired pneumonia
2385383|NCT03672994||Heart failure|Patients with confirmed heart failure
2385384|NCT03672994||Healthy volunteers|Healthy participants with no otherwise known cardiorespiratory condition
2385385|NCT03672981|Experimental|Supportive Care (aerobic exercise and resistance training)|Patients undergo moderately intense aerobic/cardiovascular exercise over 30-60 minutes and complete 1-2 sets of 8 to 10 resistance/strength training exercises, 8 to 12 repetitions of each exercise, 3 days per week for 12 weeks. Patients also participate in weekly phone calls with an exercise physiologist to ensure adherence to the program and to provide support.
2385386|NCT03672942|Experimental|Communication Skills|Male and female participants will listen to a description of John Gottman's Gentle Start-up communication skills training exercise and practice the technique in the lab for approximately 8 minutes.
2385387|NCT03672942|Experimental|Mindfulness|Male and female participants will listen to a script about Acceptance/Willingness of unwanted emotions written by Amie Zarling and practice this technique in the lab for approximately 8 minutes.
2385388|NCT03672942|Placebo Comparator|Placebo|Male and female participants will listen to music in lieu for 8 minutes.
2385389|NCT03672929|No Intervention|Full cohort|Prospective non Controlled to Document long term performance of Allofit IT Shell in combination with the Longevity® Liner when used in primary total hip arthroplasty.
2385390|NCT03672929|Other|Subgroup RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years and will only be conducted on 40 patients.
2385391|NCT03672916||Patients who received the Allofit IT with BIOLOX delta|Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the BIOLOX delta Taper Liners
2385392|NCT03672903|Experimental|Intervention|Subjects in this arm will carry heavy weight vests for three weeks.
2385393|NCT03672903|Placebo Comparator|Control|Subjects in this arm will carry light weight vests for three weeks.
2385394|NCT03672890||Pre-Telestroke|Retrospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH 2 years prior to implementation of an inpatient telestroke service.
2385395|NCT03672890||Post-Telestroke|Prospective collection of defined metrics for all ischemic stroke patients admitted to the participating ASRH after implementation of an inpatient telestroke service.
2385396|NCT03672877|Experimental|Immediate training group|Children will participate in intensive exercise intervention for 3 months and will be followed for 9 months following the intervention
2385397|NCT03672877|No Intervention|Delay training group|Children will be assessed for 6 months with no intervention. After the 6 month period children will be given the same intervention as the immediate group and followed for 3 months after the intervention.
2385398|NCT03672864|Experimental|Immediate Group|The intervention is intensive exercise, delivered over 12 weeks beginning on admission to the study. The group will then be followed for 9 months post intervention.
2385399|NCT03672864|No Intervention|Delay Group|The group will be followed for 6 months with no intervention. After 6 months the group will be given the opportunity to receive the same intensive exercise intervention as the Immediate group. The group will be followed for 3 months following the intervention.
2385400|NCT03672851|Experimental|anti-CD123 CAR-T treatment|
2385401|NCT03672838|Active Comparator|Cohort 1|Patients with NF1
2385402|NCT03672838|Active Comparator|Cohort 2|Patients with NF2
2385404|NCT03672812|No Intervention|placebo|0,5ml
2385405|NCT03672812|Experimental|liraglutide|0,5ml
2385406|NCT03672799|Experimental|Rehabilitation Planning Consult (RPC)|"The RPC is a trans-disciplinary, consultative intervention. In the RPC, individualized rehabilitation needs are established, goals are set, strategies to achieve the goals are developed, and follow-through with strategies and goal attainment is facilitated by a rehabilitation professional who consults and collaborates with the survivor. The Rehabilitation Consultant does not provide hands-on treatment, but rather determines the survivors' priority individualized rehabilitation goals, and then helps devise a plan for the survivor to meet those goals independently.~Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consultant and second consultation 2 to 12 weeks later."
2385407|NCT03672799|Active Comparator|Wait list control (WLC)|"There is no standard rehabilitation care for survivors of head and neck cancer at the Princess Margaret Cancer Centre.~Participants allocated to WLC will enter a 12 week waiting period after which they will crossover to the RPC group."
2385408|NCT03672786|Active Comparator|Control Group|Sedentary: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
2385409|NCT03672786|Experimental|Experimental Group|Athletes: Multicentrum® 2 months. Subjects maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 2 months
3142824|NCT00003532|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385411|NCT03672760|Active Comparator|IMT PowerBreath|"Participants will have PowerBreath device for IMT adjusted for 30% of maximal inspiratory pressure and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will provide re-adjustment of load through maximal inspiratory pressure performance"
2385412|NCT03672760|Placebo Comparator|IMT PowerBreath Placebo|"Participants will have PowerBreath device for IMT with no load and will perform the exercise at home for five days/week during 10 minutes for five weeks.~An once a week meeting will not re-adjustment the load though maximal inspiratory pressure performance will be performed"
2385413|NCT03672760|Active Comparator|CardioBreathApp|CardioBreathApp group will have the app settings of profile and spontaneous respiratory rate to determine the exercise rate of exercises, which will be performed at home for five days/week during 10 minutes for five weeks An once a week meeting will provide re-adjustment of respiratory rate to perform exercises
2385414|NCT03672747|Active Comparator|Anodal|Participants will receive occipital anodal stimulation using high-definition tDCS
2385415|NCT03672747|Active Comparator|Cathodal|Participants will receive occipital cathodal stimulation using high-definition tDCS
2385416|NCT03672747|Placebo Comparator|Sham|Participants will receive occipital sham stimulation (placebo) using high-definition tDCS
2385417|NCT03672721|Experimental|IA Carbo + radiation|Intraarterial carboplatin + radiation
2385418|NCT03672708|Other|Cresyl violet|
2385419|NCT03672695|Experimental|S64315 and venetoclax administered in combination|
2385420|NCT03672682||DLBCL with chemoresistance|15 patients with DLBCL with chemoresistance or relapsed less than 2 years after completion of first-line therapy
2385421|NCT03672682||DLBCL with chemosensitivity|15 patients with DLBCL with chemosensitivity without relapse within 2 years following the end of first-line therapy.
2385422|NCT03672682||Healthy patients|15 healthy patients
2385423|NCT03672669|Active Comparator|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF was applied into the tooth socket after mandibular third molar surgery.
2385424|NCT03672669|Active Comparator|Leukocyte- and platelet-rich fibrin (L-PRF)|L-PRF was applied into the tooth socket after mandibular third molar surgery.
2385425|NCT03672656|Experimental|pattern scanning laser system Pascal|
2385426|NCT03672656|Active Comparator|conventional laser|
3142825|NCT00003533|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
3142826|NCT00003534|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2385430|NCT03672617||Children and adolescents|Children and adolescents, who administer growth hormone (GH) themselves (self-injections) will be asked to complete the questionnaire.
2385431|NCT03672617||Parents/legal guardians|Parents/legal guardians who administer the GH to their child will be asked to complete the questionnaire.
2385432|NCT03672604|Placebo Comparator|Part A: Single Dose|"Cohort 1 = 0.25 mg NLY01 Cohort 2 = 0.8 mg NLY01 Cohort 3 = 2.5 mg NLY01 Cohort 4 = 5 mg NLY01 Cohort 5 = 10 mg NLY01~All cohorts include 8 subjects randomized to receive a single dose of NLY01 or placebo (6 active, 2 placebo)."
2385433|NCT03672604|Placebo Comparator|Part B: Multiple Dose|"In Part B, NLY01 or placebo will be administered once-weekly for 4 doses. There will be 3 sequentially-enrolled, ascending-dose cohorts of 8 subjects (6 active, 2 placebo). Doses in Part B will be a fraction of the maximum tolerated dose (MTD) established in Part A.~Cohort 6 = 15% of the single-dose MTD Cohort 7 = 35% of the single-dose MTD Cohort 8 = 70% of the single-dose MTD"
2385434|NCT03672604|Placebo Comparator|Part C:Multiple Dose|"In Part C, NLY01 or placebo will be administered once-weekly for 6 doses.~Cohort 10 = 2.5 mg NLY01 Cohort 11 = 5 mg NLY01"
2385435|NCT03672591||HFpEF patients|Patients suffering from heart failure with preserved ejection fraction
2385436|NCT03672591||Control group|Subjects without HFpEF who participated in different studies during which renal clearance examination has been performed with the constant infusion input clearance technique in our Clinical Research Center (clin. gov. numbers: NCT00627952, NCT01835678, NCT00136188, NCT00905528, NCT00160745)
3183390|NCT00713518|Experimental|Arm 3 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg PF-04523655 given by intravitreal injection evey 4 weeks to Week 12
2385437|NCT03672578|Experimental|Loss-frame, text-only, no attribution|Label participants will see is loss-frame, text-only, and with no attribution
2385438|NCT03672578|Experimental|Gain-frame, text-only, no attribution|Label participants will see is gain-frame, text-only, and with no attribution
2385439|NCT03672578|Experimental|Loss-frame, icon, no attribution|Label participants will see is loss-frame, icon, and with no attribution
2385440|NCT03672578|Experimental|Grain-frame, icon, no attribution|Label participants will see is gain-frame, with an icon, and with no attribution
2385441|NCT03672578|Experimental|Loss-frame, icon, attribution|Label participants will see is loss-frame, icon, and with attribution
2385442|NCT03672578|Experimental|Gain-frame, icon, attribution|Label participants will see is grain-frame, icon, and with attribution
2385443|NCT03672578|Experimental|Loss-frame, text-only, attribution|Label participants will see is loss-frame, text-only, and with attribution
2385444|NCT03672578|Experimental|Gain-frame, text-only, attribution|Label participants will see is gain-frame, text-only, and with attribution
2385445|NCT03672578|Placebo Comparator|No label|Participant will not see a label
2385446|NCT03672565|Active Comparator|Hospital setting|ERPs may be conducted in various settings on hospital grounds (e.g., cafeteria, hallways) but will not be conducted off property.
2385447|NCT03672565|Active Comparator|Community setting|Community ERP sessions will be conducted locations deemed most relevant to the child's symptom presentation such as in the home or at other community locations (e.g., church, downtown).
2385448|NCT03672552|Experimental|FFWP and Improved Oral Care|Receiving dental hygienist cleaning with supervised tooth brushing and FFWP (plain, unmodified water).
2385449|NCT03672552|No Intervention|Standard Care|This group has assessments and standard oral care with no dental hygienist cleaning, no FFWP or supervised tooth brushing and continuing with agreed upon diet texture and fluid modification.
2385450|NCT03672539|Experimental|Treatment (CPX-351, gemtuzumab ozogamicin)|"INDUCTION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3, and 5 of cycle 1 and days 1 and 3 of cycle 2 and gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~CONSOLIDATION CYCLE: Patients receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3 and gemtuzumab ozogamicin over 120 minutes on day 1. Treatment repeats every 28 days for up to 2 cycles in the absence of unacceptable toxicity.~MAINTENANCE CYCLE: Patients receive gemtuzumab ozogamicin IV over 120 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
2385451|NCT03672526|Experimental|device compuflo|
2385452|NCT03672513|Placebo Comparator|Placebo Supplemented Group|Placebo control
2385453|NCT03672513|Experimental|Magnesium Supplemented Group|Magnesium Group
2385454|NCT03672513|Experimental|Zinc Supplemented Group|Zinc Group
2385455|NCT03672500|Active Comparator|Bupivacaine arm|The edges of the 2PT/Epi will be infiltrated with 10ml of Bupivacaine 0.5%+Epinephrine 50mcg prior to suture placement.
2385456|NCT03672500|Sham Comparator|Control arm|Sham injection will be done using a syringe filled with 10ml of NaCl 0.9%, but the fluid will not be injected to the edges of the laceration but discarded. The sham injection will last no less than 10 seconds.
3142827|NCT00003545|Experimental|Arm I|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. If residual leukemia/lymphoma is present on day 22, then patients receive a second course of 506U78. If day 22 marrow is hypocellular, then a repeat bone marrow biopsy should be obtained on day 29 to assess response. For day 22 or 29 marrow that is in complete response, patients receive 506U78 for two more courses on days 1, 3, and 5, administered every 21 days. Patients are followed every 3 month for 1 year, then every 6 months for a maximum of 10 years.
3142828|NCT00003546|Experimental|gemcitabine + radiation|Patients receive radiation therapy 5 days per week for 5 1/2 weeks and gemcitabine IV over 30 minutes not greater than 2 hours prior to radiation therapy twice weekly. This combination radiation therapy and chemotherapy is followed by 2 weeks of rest. Patients with stable or responding disease receive a higher dose of gemcitabine IV over 30 minutes weekly for 3 weeks followed by 1 week of rest. This 4 week course is repeated 3 more times for a total of 16 weeks of gemcitabine therapy alone. Patients are followed every 2 months for the first year and then every 3 months for the next 2 years or until disease progression. Upon documentation of disease progression, patients are followed every 3 months for survival and secondary malignancy.
2385459|NCT03672474|Experimental|Photobiomodulation REGEnLIFE RGn530 device group|
2385460|NCT03672474|Sham Comparator|Sham REGEnLIFE RGn530 device group|
2385461|NCT03672461|Experimental|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population. The study will feature a therapeutic program based primarily on Iyengar yoga, a form of Hatha yoga that is known for its potential therapeutic applications.
2385462|NCT03672461|Active Comparator|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants. Similar to postures in the yoga intervention program, the exercises in the stretching/strengthening program have been selected for their potential to be performed safely by women across a range of ages and flexibility levels."
2385463|NCT03672448||Neurocognitive disorder|Dementias
2385464|NCT03672448||Normal Aging|Normal Aging with normal cognitive function
2385465|NCT03672435||proparacaine|Received topical proparacaine 0.5% with routine antibiotic-steroid ointment in operative eye(s) following strabismus surgery
2385466|NCT03672435||No proparacaine|Received no topical proparacaine 0.5% but did receive routine antibiotic-steroid ointment in the operative eye(s) following strabismus surgery
2385467|NCT03672422||Acute Recurrent Pancreatitis|At least 2 episodes of acute pancreatitis with complete resolution of pain and a >1 month pain-free interval between episodes.
2385523|NCT03672045|Active Comparator|Carbetocin 100mcg|Patient is given 100 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
3142829|NCT00003553|Experimental|1|The target for progenitor cell is >=5 x 106 CD 34/kg.
2385468|NCT03672422||Chronic Pancreatitis|"Children with at least:~1) One irreversible structural change* in the pancreas with or without abdominal pain +/- exocrine pancreatic insufficiency +/- diabetes.~*irreversible structural changes:~Ductal calculi, dilated side branches, parenchymal calcifications found in any imaging (abdominal ultrasound (abd US), magnetic resonance imaging/magnetic resonance cholangiopancreatography (MRI/MRCP), computerized tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), endoscopic US (EUS).~Ductal obstruction or stricture/dilatation/irregularities that are persistent (for >2 months) on any imaging.~Parenchymal atrophy, irregular contour, accentuated lobular architecture, cavities alone are not diagnostic findings for CP.~Surgical or pancreatic biopsy specimen demonstrating histopathologic features compatible with CP (acinar atrophy, fibrosis, protein plugs, infiltration with lymphocytes, plasma cells, macrophages)."
2385469|NCT03672409|Other|Intervention in knowledge|All participants will be offered learning sessions to improve knowledge in diabetes
3183391|NCT00713518|Experimental|Arm 4 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 3 mg of PF-04523655 given by intravitreal injection every 4 weeks from Week 4 to Week 12
2385471|NCT03672383|Experimental|BAY987534 (Treated Arm)|Subjects with quiescent atopic dermatitis. Right or left volar forearm with test product applied.
2385472|NCT03672383|No Intervention|Untreated Arm|Subjects with quiescent atopic dermatitis. Right or left volar forearm without test product applied.
3183392|NCT00713518|Experimental|Arm 5 ranibizumab and PF-04523655|0.5 mg ranibizumab given by intravitreal injection at baseline followed by 1 mg of PF-04523655 (30 minutes later) given in combination every 4 weeks from baseline to Week 12
2385474|NCT03672357|Experimental|Laparoscopic liver resection|Laparoscopic hepatectomy
2385475|NCT03672357|Other|Open liver resection|Open hepatectomy
2385476|NCT03672344|Active Comparator|BioStream Training|
2385477|NCT03672344|Placebo Comparator|Alternative Game|
2385478|NCT03672331|Other|Standard arm|Participants will be screened for breast cancer according to current national/regional guidelines and procedures: with a mammogram and/or tomosynthesis (TS) every 1-3 years starting at age 40-50 years, up to age 69-74 years, with or without ultrasound and MRI depending on breast mammographic density and current recommendations. The national/regional guidelines in use in the including center may be subjected to changes during the study. Guidelines and procedures in the standard arm will be updated accordingly.
2385479|NCT03672331|Experimental|Risk-based arm|Participants will be screened according to a personalised timetable based on their estimated 5-year risk of developing breast cancer: with a mammography and/or tomosynthesis every 1-4 years with or without ultrasound depending on breast density. Risk estimation will be performed using the following variables: age, family history, previous history of benign breast biopsy, personal hormone and reproductive history, breast mammographic density and genotyping (polygenic risk score). Risk assessment will be conducted using Mammorisk™ for women with at most one first-degree relative with breast or ovarian cancer and using Tyrer-Cuzick™ risk score for those women with more than one first-line first degree relative with breast or ovarian cancer.
2385481|NCT03672305|Other|c-Met/PD-L1 CAR-T cells treating group|Intervention Name:c-Met/PD-L1 CAR-T cell injection dosage form: injection dosage:The backtransfusion dose (recommended dose: 2 * 10^6/kg) was determined by the investigator based on the subject's own/disease condition and in vitro preparation.
2385482|NCT03672292|Experimental|SCY-078 plus Voriconazole|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral SCY-078 tablets (loading dose of 500 mg BID on Days 1 and 2 followed by maintenance dose of 500 mg QD from Day 3 onwards). Treatment duration = minimum 6 weeks/Max 13 weeks"
2385483|NCT03672292|Placebo Comparator|Voriconazole mono-therapy|"Either IV voriconazole (loading dose of 6 mg/kg BID on Day 1 followed by maintenance dose of 4 mg/kg BID from Day 2 onwards) OR oral voriconazole (loading dose of 400 mg BID on Day 1 followed by maintenance dose of 200 mg BID from Day 2 onwards).~PLUS Oral Placebo Tablets matching SCY-078 tablets (loading dose of 2 tablets given BID on Days 1 and 2 followed by maintenance dose of 2 tablets given QD from Day 3 onwards).~Treatment duration = minimum 6 weeks/Max 13 weeks"
2385486|NCT03672266||Neurological Disorder|Individuals with neurological disorders such as Autism Spectrum Disorder(s), including those who may also have an ADHD diagnosis, Asperger's Syndrome, Alzheimer's Disease, Fragile X syndrome, Parkinson's disease, Lewy Body Dementia, and/or Frontoparietal Dementia
2385487|NCT03672266||Neurotypical|Healthy individuals with no known neurological disorders
2385488|NCT03672253|Experimental|CAR-T Re-treatment group|Patients will be treated with CAR-T cells targeting BCMA (Different epitope with the previous CAR-T cell treatment they had been used) with a escalation approach, 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
2385489|NCT03672240|Experimental|APL-1202|"APL-1202 will be administered orally at daily 750 mg (250 mg, TID) for 5-7 days prior to the first intravesical BCG treatment and continue for additional 11 weeks (a total 12 weeks of dosing with APL-1202).~Standard intravesical BCG induction course (once weekly for 6 weeks) 50 mg TICE BCG in 50 mL sterile saline (or a full dose standard vial of BCG) will be initiated on Week 2."
2385490|NCT03672227|Experimental|Mealtime Matters Training|This group of teachers will get a 3 hour nutrition training, followed by 2 one hour booster sessions.
2385491|NCT03672227|No Intervention|Family Style Dining in Head Start|This group of teachers will not get the 3 hour nutrition training until the study has concluded.
2385492|NCT03672214|Experimental|Without placement of a catheter|No placement of indwelling catheter prior to Caesarean section
2385493|NCT03672214|Active Comparator|With placement of a catheter|Placement of indwelling catheter prior to Caesarean section
2385966|NCT03668899|Experimental|Chitosan NPs group|irrigation with Chitosan nanoparticles (final flush)
2385494|NCT03672201|Active Comparator|The Integrated Care Pathway (ICP) Arm|The ICP consists of 1) a cleanup phase during which a thorough assessment of pharmacotherapy to discontinue unnecessary medications, is performed; 2) Structured non-pharmacological interventions, which would have started as soon as randomization occurred and would continue before any pharmacological intervention for 2 weeks as stand-alone interventions; and 3) a pharmacological intervention phase: in this phase the medications algorithm for AD-AA is initiated.
2385495|NCT03672201|No Intervention|Treatment-As-Usual (TAU) Arm|Following eligibility and baseline assessments, half of the participants will be randomized to TAU. TAU will consist of the typical care that the interdisciplinary team provides at each site for AD-AA. No predetermined cleanup phase, non-pharmacological interventions, algorithmic pharmacological interventions will be systematically part of TAU.
2385498|NCT03672175|Experimental|SAGE-217 (low dose)|
2385499|NCT03672175|Experimental|SAGE-217 (high dose)|
2385500|NCT03672175|Placebo Comparator|Placebo|
2385501|NCT03672162|Active Comparator|Gabapentin Group|Subjects will receive Gabapentin 600 mg (two capsules of Gabapentin 300 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
2385502|NCT03672162|Active Comparator|Celecoxib Group|Subjects will receive Celecoxib 400 mg (two capsules of Celecoxib 200 mg) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
2385503|NCT03672162|Placebo Comparator|Placebo group|Subjects will receive Placebo (two capsules of placebo) at two hours prior to surgery with clear water 30 ml and undergo elective total abdominal hysterectomy
2385504|NCT03672149|Other|Infection needing cefazolin|a) If a patient requires antimicrobial therapy for a proven or suspected infection at the time of CRRT initiation or at any time receiving CRRT, they are eligible for inclusion. If cefazolin is part of the empiric or definitive treatment regimen, it will be mixed in the CRRT solution(s) and administered via a continuous infusion to obtain pharmacokinetic and safety data of administering cefazolin via the CRRT solution and infection treatment related data. For this indication, pharmacokinetic and safety data will be obtained for the duration the patient receives cefazolin via the CRRT solution(s) for the proven or suspected infection as dictated by the primary team caring for the patient.
2385505|NCT03672149|Other|Infection not needing cefazolin|b) If a patient is deemed a candidate for CRRT and requires therapy with any anti-microbial for a proven or suspected infection not requiring cefazolin as part of the anti-microbial drug regimen, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
2385506|NCT03672149|Other|No infection|c) If a patient is deemed a candidate for CRRT and does not require any anti-microbial therapy, administration of cefazolin via the CRRT solution(s) will occur to solely obtain pharmacokinetic and safety data. For this indication, pharmacokinetic and safety data will be obtained for a 72-96-hour duration.
2385507|NCT03672136|Experimental|Concurrent Chemoradiotherapy+Anlotinib|"Radiotherapy: Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy. If radiotherapy and chemotherapy are conducted in the same day, chemotherapy should be priority to radiotherapy.~Chemotherapy: Platinum based dual drug regime determined by researcher.After finishing concurrent chemoradiotherapy, there is no need of maintenance chemotherapy.~Anlotinib: Combined with 12mg/d QD Anlotinib on the first, second weeks and fourth, fifth weeks of radiotherapy, that is on the day1~14, day22~36.~Maintenance therapy: One month after finishing concurrent chemoradiotherapy, 12mg/d QD Anlotinib can be administrated, each cycle is defined as 2 weeks on-treatment followed by 1 week off-treatment. The treatment can continue until disease progression or treatment intolerance, but should not exceed 24 months.~During the course of study, it's not allowed to receive other anti-tumor therapy."
2385508|NCT03672123||APE with RVD|RVD (right ventricle disfunction) defined according to ESC (European Society of Cardiology) criteria
2385509|NCT03672123||APE without RVD|RVD defined according to ESC criteria
2385510|NCT03672110|Active Comparator|Standard tacrolimus group|Control group: Advagraf will be administered as usual (0.2mg/kg bodyweight), trough levels will be measured every day in the first week after kidney transplantation (TX) and Advagraf dose will be adjusted accordingly.
2385511|NCT03672110|Experimental|Fixed dose tacrolimus group|Study group: Advagraf will be administered per fix dose 5mg/day, trough levels will be blinded during the first week, there will be no adjustments in the first week after TX.
3183393|NCT00713557||1|patients with acute ST-elevation myocardial infarction and receiving primary percutaneous coronary intervention Subgroup: Patient Transferring vs. Physician Transferring strategy
2385513|NCT03672071|Other|Group E|If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Ephedrine i.v. will be administered to patient will be performed. In the case of hypotension,
2385514|NCT03672071|Other|Group NE|.If a 20% decrease in any parameter compared to their baseline levels is sustained, necessary interventions 5 mg Noradrenaline, i.v. will be administered to patient will be performed. In the case of hypotension,
2385515|NCT03672071|Other|Group N|. If a 20% decrease in parameter compared to their baseline levels is sustained, necessary interventions mg Ephedrine + 2.5 mg Noradrenaline i.v. will be administered to patient will be performed. In the case of hypotension,
2385516|NCT03672058|Experimental|Fitbit plus personalised text messaging & Goal Setting|
2385517|NCT03672058|Active Comparator|Fitbit Only|
2385518|NCT03672045|Active Comparator|Carbetocin 10mcg|Patient is given 10 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
2385519|NCT03672045|Active Comparator|Carbetocin 20mcg|Patient is given 20 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
2385520|NCT03672045|Active Comparator|Carbetocin 40mcg|Patient is given 40 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
2385521|NCT03672045|Active Comparator|Carbetocin 60mcg|Patient is given 60 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
2385522|NCT03672045|Active Comparator|Carbetocin 80mcg|Patient is given 80 mcg of carbetocin intravenously over 1 minute, immediately upon delivery of the fetal head.
2385526|NCT03672019||Patients Undergoing Percutaneous Biliary Drainage|Following Percutaneous Biliary Drainage (PBD), participants will complete Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
3183394|NCT00713557||2|patients with acute ST-elevation myocardial infarction treated by thrombolysis or facilitated PCI Subgroup: upstream use of Tirofiban + primary PCI vs. downstream use of tirofiban + primary PCI
3183395|NCT00713557||3|patients with non-ST-elevation ACS treated by immediate PCI
2385529|NCT03671993|Experimental|EPNS group|Electrical pudendal nerve stimulation (EPNS) is a type of conservative treatment which can directly modulate the pudendal nerve and produce a regulation effects on both the sensory fibers and the motor fibers of pudendal nerve.
2385530|NCT03671993|Active Comparator|II group|Intravesical instillation (II) are mixture solution administered due to poor oral bio-availability establishing high drug concentrations within the bladder, with few systemic side-effects.
2385531|NCT03671980|Experimental|Web-intervention|30 participants using a self-management website and home faecal calprotectin smartphone monitoring instead of usual outpatient follow up as a means of managing their inflammatory bowel disease for 6 months after stopping an IBD medication.
3183396|NCT00713557||4|patients with non ST-elevation ACS treated by elective PCI
3183397|NCT00713557||5|STEMI patient with multivessel disease, complete revascularization is planned to achieve during the index hospitalization.i.e.P-PCI for culprit lesion,combined with staged PCI for remaining diseased vessel.
2385534|NCT03671954|Experimental|TKA Intervention Group|The TKA intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy.
2385535|NCT03671954|Active Comparator|TKA Control Group|The TKA control group will receive standard physical therapy alone.
2385536|NCT03671954|Active Comparator|Healthy Control Group|The Healthy Control Group, aged 49-85 years without any signs of degenerative joint, disease will undergo the preoperative assessments only.
2385537|NCT03671941|Active Comparator|Group A|D578 Tab. 1T
2385538|NCT03671941|Experimental|Group B|CKD-357 Tab. 1T
2385539|NCT03671928|Other|bowel ischemia|
2385540|NCT03671928|Other|non-digestive abdominal pain|
2385541|NCT03671915|Active Comparator|Usual System (Open-loop)|In open loop: sensor-augmented pump (SAP) therapy using standard insulin pump setting combined with the six-generation glucose sensor (Dexcom G6).
2385542|NCT03671915|Experimental|DIABELOOP System (Closed-loop)|"In the closed loop: Diabeloop software (an MPC-based glucose control algorithm) running on handset associated with the six-generation glucose sensor (Dexcom G6) and Kaleïdo insulin pump.~A remote monitoring system managed by specialized nurse on behalf diabetologist, is provided in closed-loop session."
2385543|NCT03671902|Other|Lower Body Negative/Positive Pressure|
2385545|NCT03671876|Active Comparator|Intervention plus therapy|"Case group:~A population that suffered a stroke and treated to improve mobility with the Selfit system (25 patients) for twice a week, at least 30 minutes per session, for a period of 3 weeks.~Intervention with the Selfit system include a set of mobility task exercises."
2385546|NCT03671876|No Intervention|Therapy and no intervention|"Control group:~A population that suffered a stroke and is being treated in the hospital without any interventions with the Selfit system."
2385547|NCT03671863||Infants who are treated for clubfoot|Infants who are treated for clubfoot in the reference reeducation center
2385548|NCT03671850|Experimental|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
2385549|NCT03671850|Placebo Comparator|Placebo|Peripheral blood mononuclear cell, PBMC
2385550|NCT03671837|Experimental|Oyxgen|Nasal Insufflation with 15 L/min O2 and a nasopharyngeal airway
2385551|NCT03671837|Active Comparator|Air|Nasal Insufflation with 15 L/min air and a nasopharyngeal airway
2385552|NCT03671824||Lean|BMI ≤ 30 kg/m2
2385553|NCT03671824||Obese|BMI ≥30 kg/m2
2385554|NCT03671811|Experimental|Arm I (pterostilbene, megestrol acetate)|Patients receive pterostilbene PO BID and megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
2385555|NCT03671811|Experimental|Arm II (megestrol acetate)|Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
2385556|NCT03671798||REM sleep behavior disorder (RBD)|Diagnosis of RBD according to ICSD-3: 1) Sleep talking or complex movement during sleep. 2) Such movement was recorded by video PSG (AV-PSG) during REM sleep or according to history the movements were occurred during REM. 3) REM sleep without atonia (RWA) during PSG monitoring. 4) This abnormal phenomenon cannot be explained by other sleep disorder, psychiatric disease, drug or substance abuse.
2385557|NCT03671798||Controls|Subjects with 1) No RBD symptoms and PSG characteristics. 2) No neurological symptoms or diseases, MRI scan will be employed to exclude brain pathology. 3) No narcolepsy or hypersomnia, ruled out by multiple sleep latency test. 4) No history of mental illnesses or use of antidepressants
2385560|NCT03671772||FDRs of idiopathic RBD patients|First-degree relatives of idiopathic RBD patients
2385561|NCT03671772||FDRs of controls|First-degree relatives of controls
2385562|NCT03671759|Experimental|Experimental: N-of-1|"Participants will be randomized in two-day blocks to consume then avoid caffeine (Start: On Caffeine) or avoid then consume caffeine (Start: Off Caffeine). Using an N-of-1 strategy delivered by the NIH-funded, UCSF-run Eureka platform utilizing a mobile smartphone-based application, participants will receive instructions and answer questions to help us understand the relationship between caffeine and heart rhythm."
2385563|NCT03671746|Placebo Comparator|Standard of Care without NSAID|Polytrauma participants will receive standard of care in addition to saline solution according to standard ATLS and standard ICU routine medical care.
2385564|NCT03671746|Experimental|Standard of Care with NSAID|Participants in the group will receive Ketorolac in addition to standard of care for the standard ATLS or ICU routine medical care.
2385565|NCT03671733|Experimental|Liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 12 weeks.
2385566|NCT03671733|Experimental|Exenatide|Administered subcutaneously (s.c., under the skin) twice daily for 12 weeks.
2434406|NCT03335956|Placebo Comparator|MAD Placebo Cohort 1|
2385567|NCT03671733|Experimental|Exenatide Microspheres for Injection|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
2385568|NCT03671720|Experimental|personalized vaccine|
2385569|NCT03671707|Experimental|Intervention group|Brief AWARD advice + Nicotine replacement therapy sampling + Active referral
2385570|NCT03671707|Active Comparator|Control group|Very brief advice (VBA) + Leaflet
2385571|NCT03671694|Active Comparator|laser treatment|Erbium-YAG laser treatment to the vagina
2385572|NCT03671694|Placebo Comparator|sham treatment|sham treatment with laser placebo
2385573|NCT03671681|Experimental|MT group|Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and six group sessions of 45 minutes of mindfulness-based treatment.
2385574|NCT03671681|Other|MED group|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (i.e. clinical features, previous failures and contraindications)
2385575|NCT03671668|Active Comparator|Screw retained prosthesis on transmucosal abutments|
2385576|NCT03671668|Experimental|Screw retained prosthesis on titanium bases|
2385577|NCT03671655|Experimental|Drug-eluting stent|Drug-eluting stent is nitinol stent coated with Paclitaxel drug Other Names: Zilver PTX stent Zilver Paclitaxel stent
2385578|NCT03671655|Active Comparator|Bare metal stent|Bare metal stentis Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
2385579|NCT03671642|Experimental|Perfusion assessment|Q-ICG: quantitative perfusion assessment with FA White light perfusion assessment FA: fluorescence angiography without quantification
2385580|NCT03671629|Experimental|Intervention group|In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital.
2385581|NCT03671629|No Intervention|Control group|This group receives standard care, which might include a medication review at the hospital.
2385582|NCT03671616|Experimental|IPV-Al SSI|Single arm trial. All subjects will receive the IPV-Al SSI as booster vaccination
2385583|NCT03671603||Iodixanol|Participants will receive Iodixanol 270 mg I/ml or Iodixanol 320 mg I/ml injection as a part of routine clinical practice at the medical discretion of the physician.
3142830|NCT00003556|Experimental|Arm I|Patients receive ALVAC-hB7.1 alone or combined with ALVAC-hIL-12 intratumorally on days 1, 4, 8, and 11. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at each dose level of ALVAC-hB7.1. The maximum tolerated dose is defined as the dose of ALVAC-hB7.1 at which no more than 1 of 5 patients experiences dose limiting toxicity.
3142831|NCT00003557|Experimental|Arm A|Dolastatin-10 (400 mcg/m2 IV every 3 weeks)
2385586|NCT03671577|Experimental|Active Treatment|four week computerized intervention designed to reduce fear of intimacy
2385587|NCT03671577|No Intervention|Wait List Control|Participants will continue as usual and will be given the option to receive the active treatment after completion of the study
2385588|NCT03671564|Experimental|Dose Escalation - Milademetan|All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
2385589|NCT03671551||Psychomotor/psychological evaluation|Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.
2385590|NCT03671538|Experimental|Anlotinib Plus Pemetrexed and Cisplatin|pemetrexed 500mg/m2 and Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
3142832|NCT00003563|Experimental|WBRT|3 Gy of WBRT daily for a total of 10 days
3142833|NCT00003563|Experimental|MGd|IV does of 5.0 mg/kg MGd plus WBRT
2385593|NCT03671512|Experimental|Periodontal Structure Repair (PSR)|Periodontal pockets treated with PSR
2385594|NCT03671512|Active Comparator|Standard Root Planing (SRP)|Periodontal pockets treated with SRP
2385595|NCT03671499|Experimental|Social Cognitive Theory based text messages|The study only contains 1 arm. All participants will receive the same experimental protocol. Participants will receive daily text messages and bi-weekly newsletters for reducing sedentary behavior based on Social Cognitive Theory.
2385596|NCT03671486||GBS-negative pregnant women|One Hundred Healthy GBS-negative pregnant women will be follow-up since the first trimester of pregnancy until one month post-delivery
3142834|NCT00003564|Experimental|Arm I (Procarbazine + Isotretinoin)|Arm I: Oral procarbazine once daily on days 1-14 every 28 days, and Oral isotretinoin every 12 hours on days 15-28 every 28 days; 6 courses of combined therapy, then continue oral isotretinoin alone on days 15-28 of each 28 day course.
3142835|NCT00003564|Experimental|Arm II (Procarbazine Alone)|Arm II: Oral Procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses of treatment.
2385599|NCT03671460|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
2385600|NCT03671447|Active Comparator|ICU usual care|control condition
2385601|NCT03671447|Experimental|"Intervention ERIC"|intervention condition
3142836|NCT00003565|Experimental|docetaxel|OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
2385609|NCT03671408||periodontitis|periodontitis patients which were diagnosed based on clinical parameters
2385610|NCT03671408||gingivitis/healthy|gingivitis healthy patients which were diagnosed based on clinical parameters
2385611|NCT03671382|Experimental|Intervention Arm|Communication Training Program and Patient Prompt Sheet
2385612|NCT03671382|No Intervention|Control Arm|Oncologists will not receive the communication skills training program and their patients will not receive the Patient Prompt Sheet
2385628|NCT03671239|Other|Product Sequence C|Participants will use rectal suppositories during the first 4-week product use period, rectal inserts during the second 4-week product use period, and rectal douches during the third and final 4-week product use period.
2385967|NCT03668899|Experimental|Chlorhexidine group|irrigation with CHX (final flush)
2434407|NCT03335956|Experimental|MAD Active Cohort 1|
2385613|NCT03671369||Cervarix Group|The study group comprises of 9-25 year-old male and female subjects who will be administered 3 doses of Cervarix vaccine, according to a 0, 1, and 6 months schedule, as per locally approved prescribing information (PI) in Korea. The 9-14 years old subjects can be vaccinated with 2 doses, according to a 0 and 6-12 months schedule. In the 2-dose schedule, if the second dose is administered before 5 months after the first dose, the third dose vaccination is required. In the 3 doses schedule, if the vaccination schedule requires flexibility, the second dose can be administered between 1 and 2.5 months and the third dose can be administered between 5 and 12 months after the first dose.
2385614|NCT03671343|Experimental|Intervention : Physical rehabilitation|"The Arm Physical rehabilitation will benefit from the implementation of the Loss of Mobility Prevention program set up in the Department of Aging Medicine of the Center Hospitalier Lyon Sud (CHLS) of Pr BONNEFOY."
2385615|NCT03671343|No Intervention|Control : optimized medical treatment|"The Arm Optimized medical treatment will not benefit from the implementation of the Loss of Mobility Prevention program."
2385616|NCT03671330|Experimental|Ribociclib|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal experimental arm: NSAI + Goserelin + Ribociclib; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal experimental arm:~Letrozole + Ribociclib~PK Cohort: Open-label ribociclib + Letrozole treatment combination.~For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
2385617|NCT03671330|Placebo Comparator|Ribociclib Placebo|"Patients in pre- and postmenopausal cohorts will be randomized in the 1:1 ratio to the experimental arm or the control arm.~Premenopausal control arm: NSAI + Goserelin + Placebo; For pre-menopausal only, patient is an adult, female ≥ 18 years old and < 60 years old at the time of informed consent.~It is the investigators choice for NSAI based on patient's past medical history.~Postmenopausal control arm:~Letrozole + Placebo For postmenopausal only, patient is an adult, female ≥ 18 years old at the time of informed consent"
2385618|NCT03671317|Experimental|Intervention group|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
2385619|NCT03671317|No Intervention|Non-intervention group|This arm will continue usual care with no intervention from medical clowns. They will be asked to complete pre and post surveys about the blood draw process.
2385620|NCT03671304|Experimental|Just-in-time Adaptive Intervention|Participants will receive a Fitbit Versa and instructions on its use. The study design is not a traditional randomized controlled trial in which participants are randomized to either the intervention or control group. Instead the study utilizes a microrandomized design. This is a within-subjects design in which participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days.
2385621|NCT03671291|Experimental|Recently infected with HIV|Men and women recently infected with HIV and have been eligible for PrEP based on the recommendation of french national regulatory agency regarding the prescription of Truvada® in prophylaxis to HIV exposure. The potential reasons behind these missed opportunity of Pre-exposure prophylaxis will be studied through a self-administrated questionnaire.
2385622|NCT03671278|Other|STarT Back Screening Tool Approach|After baseline consultation, all patients will receive usual care from their medical doctors as well as an educational booklet and weekly videos containing information on the prognosis of back pain and how patients could deal with their problems. Six weeks after baseline consultation all patients will be screened by the STarT Back Screening Tool (SBST) and will receive a stratified care according to their SBST classification.
2385623|NCT03671265|Experimental|SHR-1210 + Chemotherapy + Radiotherapy|"Radiotherapy(IMRT or VMAT): 95%PTV 54Gy/30 fraction,95%PTV 60Gy/30 fraction ,5 fractions per week, for 6 weeks. Radiation begun the day on which first dose of SHR-1210.~SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.~Chemotherapy: Docetaxel 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22, total 4 cycles; Cisplatin 25mg/m2/w, intravenous infusion on days 1, 8, 15, 22;, total 4 cycles.~Apatinib: 250mg/d，PO Qd(4 weeks after Radiotherapy, until the end of 8th ycle )"
2385624|NCT03671252|Experimental|Experimental: Group 1|Patient will receive FOLFOXIRI regimen every two weeks for 4-6 cycles within 2-3 months.Two weeks after completing 3 and 6 cycles of FOLFOXIRI regimen,patients will have two efficacy evaluations according to RECIST criteria and toxicity evaluation .If the tumor is defined as no progression without severe toxicity at the first efficacy evaluation, the rest of 3 cycles of FOLFOXIRI regimen will be performed.If it is defined as progression of primary tumor or it is defined as progression of primary tumor and MRF(+)at the second efficacy evaluation,patients are assigned into active comparator group. If distant metastasis occurred during chemotherapy, patients are treated according to the guidelines for metastatic colorectal cancer.Chemotherapy is initiated at 3-4 weeks after R0 resection. XELOX regimen is performed post-operatively (about 4-6 cycles). If postoperative pathology confirmed as positive margin, postoperative chemoradiotherapy was given.
2385625|NCT03671252|Active Comparator|Active Comparator:Group 2|The patients are scheduled to receive chemoradiotherapy. After 5 weeks from the end of chemoradiotherapy, patients will have a efficacy evaluation according to RECIST criteria. If the tumor is defined as CR、PR or SD, and the TME operation is conducted within 5-10 weeks after chemoradiotherapy completion. If tumor is defined as progressive disease with the possibility of R0 resection, the operation was also conducted within 5-10 weeks after chemoradiotherapy . If tumor is defined as progressive disease without possibility of R0 resection, the palliative chemotherapy was performed . If distant metastasis occurred during chemoradiotherapy, patients are treated according to the guidelines for metastatic colorectal cancer. Adjuvant chemotherapy of XELOX is performed post-operatively (about 4-6 cycles).
2385626|NCT03671239|Other|Product Sequence A|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
2385627|NCT03671239|Other|Product Sequence B|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
2385968|NCT03668899|Experimental|Combination group|irrigation with CHX/ nano Chitosan combination (final flush)
2434408|NCT03335956|Placebo Comparator|MAD Placebo Cohort 2|
2385629|NCT03671239|Other|Product Sequence D|Participants will use placebo rectal inserts during the first 4-week product use period, placebo rectal suppositories during the second 4-week product use period, and placebo rectal douches during the third and final 4-week product use period.
2385630|NCT03671239|Other|Product Sequence E|Participants will use placebo rectal douches during the first 4-week product use period, placebo rectal inserts during the second 4-week product use period, and placebo rectal suppositories during the third and final 4-week product use period.
2385631|NCT03671239|Other|Product Sequence F|Participants will use placebo rectal suppositories during the first 4-week product use period, placebo rectal douches during the second 4-week product use period, and placebo rectal inserts during the third and final 4-week product use period.
2385632|NCT03671226|Experimental|Supportive Care (questionnaire)|Patients and their caregivers complete a questionnaire over 15 minutes either in person or over the phone within 3 days after their supportive care center visit.
2385633|NCT03671213|Experimental|Calypso|Calypso Knee System
2385634|NCT03671187|Experimental|Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
2385635|NCT03671187|Experimental|Ex- Smoking|8 week exercise program consists of breathing exercises, strength training and endurance training
2385636|NCT03671174|Experimental|Prednisone + hydroxychloroquine + anticoagulation|Oral low-dose prednisone PLUS Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
2385637|NCT03671174|Experimental|Hydroxychloroquine + anticoagulation|Oral hydroxychloroquine PLUS Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
2385638|NCT03671174|Active Comparator|Anticoagulation|Oral low-dose aspirin PLUS subcutaneous low-molecular-weight heparin
2385639|NCT03671161|Experimental|Patients with poorly controlled diabetes type 1|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day swithced to Insulin Pump and flash glucose monitoring
2385640|NCT03671148|Experimental|Risankizumab|Participants randomized to receive double-blind risankizumab for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
2385641|NCT03671148|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo for 24 weeks (Period 1) followed by open-label risankizumab for 184 weeks (Period 2).
2385642|NCT03671135|Experimental|TCA Intrastromal Inlay|A monocular intrastromal corneal inlay will be implanted.
2385643|NCT03671122||PREFERS main study|500 patients with new onset heart failure will be characterized into those with HFpEFand HFrEF at baseline and undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis
2385644|NCT03671122||CABG PREFERS|500 Patients undergoing elective by pass surgery with or without diastolic or systolic dysfunction as Proxy for HFpEF and HFrEF will undergo Cardiac imaging by Doppler echocardiography and cMRI, blood tests for biomarker analysis and cardiac biopsies
2385645|NCT03671109|Experimental|IPTp-DHA-PPQ|Monthly IPTp-DHA-PPQ over three days plus daily ARVs and cotrimoxazole prophylaxis
2385646|NCT03671109|Placebo Comparator|IPTp-Placebo|Monthly IPTp-placebo over three days plus daily ARVs and cotrimoxazole prophylaxis
2385647|NCT03671096|Experimental|Intrastromal TCA Inlay|Implant Intrastromal TCA using femto-second laser surgery It is expected to be carried out once only during the study duration
2385648|NCT03671083||Injured and Matched Control Subject Pool|Injured subjects consist of subjects who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
2385649|NCT03671083||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) subjects and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
2385650|NCT03671070|Active Comparator|Low dose Epinephrine boluses|Patients suffering from acute hypo-tension will receive low dose IV epinephrine boluses ≤ 5 μg/kg/dose, 3 doses, within 3 hours
2385651|NCT03671070|Placebo Comparator|Traditional management of shock|Patients suffering from acute hypo-tension will be managed according to Traditional algorithm of Hypotension
2385652|NCT03671057|Experimental|HospiAvontuur|Intervention group - Non-pharmacological (HospiAvontuur) preparation HospiAvontuur is a simple point and click adventure game on a I-pad. The game describes the pathway which a child and his parents will take before, during and just after a hospital admission for an elective otorhinolaryngeal procedure under general anaesthesia.
2385653|NCT03671057|Active Comparator|Midazolam|control group: The children of the control group will not play the game HospiAvontuur as an at home preparation for surgery. These children will be prepared for surgery according to the current practice at the Jessa hospital. Children receive only the basic information during the consultation with the surgeon. There is no specific at home preparation required. When admitted at the hospital, children receive a pharmacological preparation, 45 - 60 minutes prior to the induction of the anaesthesia. The medication is administered orally by a small syringe in the mouth and contains Dormicum 0.3mg/kg body weight and atropine 0.02mg/kg body weight supplemented with raspberry syrup.
2385654|NCT03671044|Experimental|Nanosomal Docetaxel Lipid Suspension - 75 mg/m2|Experimental: NDLS for Injection, 75 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 75 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
2385655|NCT03671044|Experimental|T2, Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Experimental: NDLS for Injection, 100 mg/ m2 Nanosomal Docetaxel Lipid Suspension for Injection; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
2385656|NCT03671044|Active Comparator|R, Taxotere® (100 mg/m2)|Active Comparator: Taxotere® Injection Concentrate Docetaxel Injection Concentrate; Dose: 100 mg/m2; Frequency: Every 3-weeks; Duration of treatment: Patient will be dosed with drug until disease progression and/or unacceptable toxicity
2385657|NCT03671031||isolated roux loop|isolated roux loop reconstruction following pancreaticoduodenectomy as the first group.
2385658|NCT03671031||single loop|single loop reconstruction following pancreaticoduodenectomy as the second group.
3142837|NCT00003566|Experimental|video-thorascopy + surgery|Patients will undergo ipsilateral video-thorascopic evaluation. Patients may undergo surgery at the discretion of the surgeon and treating physicians.
3142838|NCT00003571||Samples of tumor and normal tissue|Samples of tumor and normal tissue are obtained from CALGB 8896 patients. The samples are tested for somatic mutations and tumor replication error (RER) tumor status. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
3142839|NCT00003573|Experimental|Treatment 1, Etoposide, 50mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
3183398|NCT00713557||6|STEMI patient with multivessel disease, complete revascularization is planned to achieve at 6 weeks after STEMI onset.i.e.P-PCI for culprit lesion during index hospitalization,combined with staged PCI for remaining diseased vessel at 6-week's follow-up(secondary hospitalization).
2385663|NCT03671005|Experimental|Mindfulness-based group therapy (MBGT)|The mindfulness-based group therapy (MBGT) involves a four-week manual with three group therapy sessions per week in addition to TAU. The therapy represents the first German group-based mindfulness manual for psychosis. One sixty-minute session was held by a certified psychotherapist who is experienced in mindfulness-based therapy. A trained co-therapist implements two 30-minute sessions. On a weekly basis, a new theme is discussed in the three sessions to ensure the internalization of different mindfulness concepts. Namely, the topics Mindfulness of the Breath (1), Mindfulness of the Senses in the Context of Nature (2), Mindfulness of Detachment (3), and Mindfulness in the Context of Bodily Awareness (4) are addressed during the group-sessions.
2385664|NCT03671005|Active Comparator|treatment as usual (TAU)|Treatment as usual (TAU) at the ward consists of a variety of daily activity groups the patients can choose from. Every patient at the ward receives a daily schedule depending on individual needs for therapy. The therapies offered at the ward include occupational therapy, physiotherapy, psychoeducative groups, and concentration practice of two levels, all not related to mindfulness interventions. In addition to the group activities at the ward, every patient receives individual psychotherapy sessions at least once a week, held by a certified psychiatrist or psychologist. Psychopharmacological treatment is provided by the physicians, and social workers are available in order to support patients in managing their everyday lives after the stationary treatment. Weekly group meetings at the ward, together with the treating physicians, psychotherapists, social workers and the respective patient, foster the exchange success and possible improvements of the treatment.
2385665|NCT03670992||Pancreatic Metastases|Patients with only pancreatic metastases from RCC
2385666|NCT03670992||extra-pancreatic metastases|patients with extra pancreatic metastases from RCC
2385667|NCT03670979|Experimental|bone swaging alone|xenograft alone
2385668|NCT03670979|Experimental|bone swaging plus EDTA|bone swaging with EDTA
2385670|NCT03670953|Experimental|IPX203 ER CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to investigational product IPX203 ER CD-LD and IR CD-LD placebo.~IR CD-LD active and placebo are tablets and IPX203 ER CD-LD active is capsules. Dosage and frequency is patient specific."
2385671|NCT03670953|Active Comparator|IR CD-LD|"Following IR CD-LD dose adjustment and conversion to IPX203 ER CD-LD, subjects will be randomized to IPX203 placebo and IR CD-LD active comparator.~IR CD-LD active is tablets and IPX203 active and placebo are capsules. Dosage and frequency is patient specific."
2385672|NCT03670940||COPD patients|COPD patients without bronchiectasis
2385673|NCT03670940||COPD and bronchiectasis patients|COPD patients with bronchiectasis
2385674|NCT03670927||Cases|Cases (incident patients with a diagnosis of primary sarcoma and histologically confirmed by an expert pathologist of the RRePS or ResOs networks in the 15 districts of France participating to this study) Environmental, occupational and lifestyle-related exposures
2385675|NCT03670927||Controls|"Subjects never diagnosed with a primary sarcoma and individually-matched by sex, age (5-years group), and districts of residence and randomly selected from electoral list.~Environmental, occupational and lifestyle-related exposures"
2385676|NCT03670914|Experimental|WatchPAT 200 and In-Lab Study|Patients who are referred to the sleep center for an overnight study that are narcotic users will be offered to the opportunity to participate in the study. Patients who fulfill the inclusion exclusion criteria and have given informed consent will undergo a standard in-lab polysomnography while simultaneously wearing the WatchPAT200 device.
2385677|NCT03670901|Experimental|JHL1101|375 mg/m2 of JHL1101 is given intravenously on D1 of each cycle
2385678|NCT03670901|Active Comparator|MabThera|375 mg/m2 of Rituximab is given intravenously on D1 of each cycle
2385679|NCT03670888|Experimental|JHL1101|Single dose IV infusion of 375 mg/m2 of JHL1101
2385680|NCT03670888|Active Comparator|Rituxan|Single dose IV infusion of 375 mg/m2 of Rituximab
2385681|NCT03670875|Experimental|Agave inulin|Agave inulin 2.3 g, by mouth, every 12 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
2385682|NCT03670875|Experimental|Curcumin|Curcumin 600 mg (turmeric 600 + black pepper 5 mg) by mouth, daily for 3 months. Plus recommendations to decrease calories intake an do exercise.
2385683|NCT03670875|Experimental|Omega 3 Fatty Acids|O3FA 600 mg (eicosapentaenoic acid 360; docosahexaenoic acid 240) Three times a day by mouth, every 8 hours for 3 months. Plus recommendations to decrease calories intake an do exercise.
2385684|NCT03670875|Other|Control|Recommendations to decrease calories intake an do exercise.
2385685|NCT03670862||stroke|Ischemic stroke patients with sympton onset in 24 hours
2385686|NCT03670849|Experimental|Patients using LapAR system|
2385714|NCT03670693|Experimental|Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) suffering from fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 >14, and a score of >4 in the Fatigue questionnaire.)
2434409|NCT03335956|Experimental|MAD Active Cohort 2|
2385687|NCT03670836|Experimental|Dilapan group|"Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations. The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded. Dilapan will be left in cervix for 12 hours. Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring. Nothing per vagina including douching and no bathing is allowed."
2385688|NCT03670836|Experimental|Misoprostol group|Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses. All subjects will have continuous fetal monitoring. A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor). Administration of Misoprostol will be done by the nurse assigned to the patient.
2385689|NCT03670823||Healthy subjects|50 healthy subjects for a control group
2385690|NCT03670823||Patients with Major Depression|50 patients with major depression for a research group
3183399|NCT00713570||A,1,II|
3183400|NCT00713622|Active Comparator|1|
3183401|NCT00713622|Active Comparator|2|
3183402|NCT00713635||1|Fetuses and neonates with congenital heart disease consisting of hypoplastic left heart syndrome (HLHS)
3183403|NCT00713635||2|Fetuses and neonates with congenital heart disease consisting of transposition of the great arteries (TGA)
3183404|NCT00713635||3|Fetuses and neonates with congenital heart disease consisting of tetralogy of fallot
3183405|NCT00713635||4|Fetuses and neonates with lung masses but without congenital heart disease will serve as a control group
3183406|NCT00713674|No Intervention|1|No Treatment
2385699|NCT03670797||controlled diabetic patients|
2385700|NCT03670797||uncontrolled diabetic patients|
2385701|NCT03670784||Women_KPNC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Northern California (KPNC).
2385702|NCT03670784||Women_KPSC|Women of reproductive age who are enrolled in the US-health plan Kaiser Permanente Southern California (KPSC).
2385703|NCT03670758||Group 1|Will include 30 women with unexplained primary infertility; will be recruited from the outpatient infertility clinic
2385704|NCT03670758||Group 2|another 30 fertile women who got pregnant and delivered at least once in the previous year with no history of recurrent abortions; will recruited from outpatient gynecology clinic as control
3150930|NCT00214305|Experimental|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
3183407|NCT00713674|Experimental|2|Theraworx intranasal
2385707|NCT03670732|Active Comparator|CPAP first|The intervention is application of continuous positive airway pressure (CPAP). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
2385708|NCT03670732|Active Comparator|NIPPV first|The intervention is application of nasal intermittent positive pressure ventilation (NIPPV). The order of the two interventions of this crossover study is randomized but each subject will be exposed to both interventions. The period of CPAP will be compared to the period of NIPPV.
2385709|NCT03670719|Experimental|Manual Therapy and Exercise Group|Combination of manual therapy and exercises for chronic cervical pain
2385710|NCT03670719|Active Comparator|Exercise Group|Only exercises for chronic cervical pain
2385711|NCT03670706|Active Comparator|Group A|Exercise training, then crossover to analgesic optimisation
2385712|NCT03670706|Active Comparator|Group B|Analgesic optimisation, then crossover to exercise training
2385713|NCT03670706|No Intervention|Group C|Control group
2385861|NCT03669614|Experimental|AR-501 inhaled|Three doses (low, medium, high) of inhaled AR-501 will be used.
2434410|NCT03335956|Placebo Comparator|MAD Placebo Cohort 3|
3183408|NCT00713674|Active Comparator|3|mupirocin antibiotic ointment intranasal
3183409|NCT00713687|Experimental|1|Treatment by combination of photodynamic therapy and chemotherapy
3183410|NCT00713713|Experimental|1|Two different tidal volumes (6 and 12 ml.kg-1 of ideal weight) are alternatively delivered to patients 30 minutes each one. The order of the two tidal volumes is randomized. Between the two study tidal volumes, patient returns for 30 minutes to the tidal volume used before the study recruitment.
3183411|NCT00713726|Active Comparator|F|Patients that received continued infusion of fentanyl at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
3183412|NCT00713726|Experimental|T|Patients that received continued infusion of tramadol at a steady dose for the first 48 hours and, then, doses were gradually decreases until stop
3183413|NCT00713739|Experimental|1|Alfuzosin 10mg daily
3183414|NCT00713739|Active Comparator|2|Nifedipine XL 30mg daily
3183415|NCT00713739|Active Comparator|3|Doxazosin 4 mg daily
3183416|NCT00713739|Active Comparator|4|Prazosin 1 mg BID
3183417|NCT00713765|Experimental|A|AZD3480 + Donepezil
3183418|NCT00713778|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
3183419|NCT00713778|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel
3183420|NCT00713778|Active Comparator|3|Laparotomic ovarian cystectomy using suture
3183421|NCT00713791|Experimental|1|There are 5 variations of the ZD4054 (Zibotentan) 10mg tablet - A, B, C, D, and E. A minimum washout period of 1 week will occur between each treatment period.
3183422|NCT00713804|Experimental|GC|Genetic counseling (GC): One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
2385715|NCT03670693|Experimental|Non-Fatigued Crohn's Disease|Crohns disease patients in remission(Harvey Bradshaw index <4 and CRP<5mg/dl and faecal calprotectin <50ug/g) without fatigue (General fatigue and physical fatigue score on the Multiple Fatigue Inventory-20 <14, and a score of <4 in the Fatigue questionnaire.)
2385716|NCT03670693|Experimental|Healthy Volunteers|Age,gender,muscle mass, and physical activity-matched healthy controls.
2385717|NCT03670680|Experimental|Lina LibrataTM|Use of the Lina LibrataTM
2385718|NCT03670667||RA patients treated with abatacept|
2385719|NCT03670667||RA patients treated with anti-TNFi's|
2385720|NCT03670667||RA patients treated with other biologics|
2385721|NCT03670654|Active Comparator|Pilates Method|The intervention of active comparator will be Pilates Method exercises.
2385722|NCT03670654|Sham Comparator|Muscle stretching exercises|The intervention of sham comparator will be muscle stretching exercises.
3150931|NCT00214305|Placebo Comparator|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
2385726|NCT03670615|Experimental|Exercise and tDCS|Patients randomized to this group will attend Toronto Rehabilitation Institute - University Health Network (TRI-UHN) for an individualized exercise program and active tDCS intervention.
2385727|NCT03670615|Other|Exercise Education and tDCS|Patients randomized to this group will undergo treatment as usual, receiving routine advice about physical activity and active tDCS intervention.
2385728|NCT03670615|Other|Exercise and Sham tDCS|Patients randomized to this group will attend TRI-UHN for an individualized exercise program and sham tDCS intervention.
2385729|NCT03670602|Experimental|Episodic Future Thinking (EFT)|Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
2385730|NCT03670602|Other|Control Thinking|Participants will generate or be provided with non-future cues.
2385731|NCT03670589||radiosurgery gammaknife group|Patient treated by radiosurgery gammaknife for a one side vestibular schwannoma
2385732|NCT03670589||microsurgery resection group|Patient treated by microsurgery resection for a one side vestibular schwannoma
2385733|NCT03670576||Case|A diagnosis of Fibrotic Lung disease classified in 4 categories, RA-UIP, Asbestosis, Chronic HP and Unclassifiable as agreed by an ILD MDT consensus panel.
2385734|NCT03670576||Control|Positive control will be frequency matched to cases of ILD and will be people in secondary care who have an MDT diagnosis of Definite IPF.
2385735|NCT03670563|Experimental|Exercise 1|Short foot exercise protocol instructed utilizing verbal instruction, passive modeling, active-assisted modeling, and active modeling.
2385736|NCT03670563|Active Comparator|Exercise 2|Short foot exercises plus NMES. Short foot exercise protocol instructed utilizing verbal instruction, passive modeling assisted by neuromuscular electric stimulation (NMES), active-assisted modeling assisted by neuromuscular electric stimulation, and active modeling.
2385737|NCT03670563|No Intervention|Control|No exercise intervention; continue normal physical activity, but do not start any new exercise programs
2385738|NCT03670550|Experimental|Knee Brace|"ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy.~Dynamic X-ray imaging of the knee will take place prior to surgery, and again upon clearance from physical therapy 7-9 months after surgery. The injured knee will be imaged with and without the brace, and the contralateral limb will be imaged for use as a control."
2385740|NCT03670524|Experimental|Targeted neighborhoods for Greenness|Using greenness as a therapeutic intervention, we will plant shrubs, grasses, young and mature trees (40-50 ft in height), so that we can evaluate changes in health and pollution, 2 years after planting.
2385741|NCT03670524|No Intervention|Control Group|No intervention
2385742|NCT03670511|Experimental|sit-to-stand|
2385743|NCT03670511|Active Comparator|six minute walking test|
2385744|NCT03670498|Experimental|4 channel Electrical Stimulation(revised sequential)|apply 4 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it sequentially Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.
2385745|NCT03670498|Active Comparator|2 channel Electrical Stimulation(classical)|apply 2 channel electrical stimulation device with protocol Is a revised sequential activation protocol, it simultaneously suprahyoid m (ch 1), thyrohyoid m (ch 2) with 2 channel electrical stimulation device.
2385746|NCT03670485|Experimental|Revised sequential activation protocol|"Apply 4 channel electrical stimulation device with a revised sequential activation protocol.~It sequentially activates Rt. suprahyoid m (ch 1), Lt. suprahyoid m (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device."
2385747|NCT03670485|No Intervention|control subject|Apply 4 channel electrical stimulation device without any stimulation
2385748|NCT03670459|Experimental|Group 1|Patients in G1 will receive traditional physical therapy program (balance exercises) for twelve sessions; day after day
2385749|NCT03670459|Experimental|Group 2|Patients in G2 will receive Cawthorne Cooksey Exercises in addition to traditional physical therapy program for twelve sessions; day after day .
2385750|NCT03670459|Experimental|Group 3|Patients in G3 will receive vestibular habituation exercises in addition to traditional physical therapy program for twelve sessions; day after day.
2385751|NCT03670446|Experimental|Pharmacists' intervention|A group of participants assigned to a pharmaceutical intervention
2385752|NCT03670446|No Intervention|Routine therapy|A group of participants assigned to a control (routine therapy)
3150932|NCT00214331||1|ciprofloxacin
3150933|NCT00214331||2|azithromycin
2385753|NCT03670433||Patients admitted in the Polyvalent Internal Medical Unit|"Patients over 65 years old admitted in the Polyvalent Internal Medical Unit (UMIP) of Rennes University Hospital between 09/04/2017 and 10/31/2017 or going back home or to a rehabilitation service during the same period.~Cost analysis of medication reconciliation."
2385754|NCT03670420|Experimental|Medical honey in addition to standard care|In addition to the usual care provided by the maternity unit, women allocated to this group apply honey on first and second degree perineal tears, episiotomies and anterior vulvar tears twice a day for four days from randomization.
2385755|NCT03670420|No Intervention|Standard care|This group benefits from the standard care offered by the maternity: hygiene advice, analgesics, ice packs, buoys and positioning.
2385756|NCT03670407|No Intervention|Control group|Participants who opt not to go ahead with ovarian fragmentation.
2385757|NCT03670407|Experimental|Study group|Participants who opt for ovarian fragmentation.
2385758|NCT03670381||ASD group|ASD patients with HDAC4 CNVs
2385759|NCT03670381||TD group|Typically developing controls without lifetime ASD or a family history of ASD
2385760|NCT03670368|Experimental|Intervention (Mentor/Mentee)|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on social relationships, coping behaviors, and healthy lifestyles.
2385761|NCT03670368|Active Comparator|Comparison group - written materials|Youth in the comparator group will receive written versions of all materials covered in the mentoring sessions.
3150934|NCT00214331||3|gentamicin
3150935|NCT00214474|Active Comparator|ATSM Intervention|ATSM Intervention: Automated Telephone Self-Management Support
2385764|NCT03670329|Experimental|URGO2875|Dressing
2385765|NCT03670316|Experimental|Algorithm Treatment plus referral to quitline (AT)|will be assigned a pharmacotherapy treatment regimen recommended to their provider.
2385766|NCT03670316|Active Comparator|Quitline (eTAU)|will be referred to quitlines, telephone-based tobacco cessation services.
2385767|NCT03670303|Experimental|Intervention group|This group will include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance will be assessed at 6 months follow-up after baseline assessment than educational intervention will be given. Six months after intervention compliance will be assessed again.
2385768|NCT03670303|No Intervention|Control group|This group will also include randomly selected two boys and two girls schools. Vision screening and refraction will be carried out at base line.Compliance towards spectacle use will be assessed at 6 months after baseline assessment. No intervention will be given in this group. Compliance will be assessed again at the same time when assessed in intervention group 6 months after the intervention.
2385769|NCT03670290||Group 1|Group I will receive 30 ml of Bupivacaine 0.25% solution through the fascia iliaca compartment catheter. Catheter will be inserted with US.
2385770|NCT03670290||Group 2|Group II will receive, morphine 0.1 mg/ml via patient controlled analgesia pump. every pump will be set 1 mg dose morphine per use and 15 min lockout time.
2385771|NCT03670290||Group 3|Group III will receive 10 ml of Bupivacaine 0.25% solution through the epidural catheter.
2385775|NCT03670251|Other|Blood sampling|blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots
2385776|NCT03670238|Experimental|Orogastric intubation|Orogastric intubation using a polyurethane enteral tube followed by fixation of the tube tip to a superior molar.
2385777|NCT03670238|Active Comparator|Nasogastric intubation|Nasogastric intubation using a polyurethane enteral tube followed by fixation of the tube to the patient face.
2385778|NCT03670225|Other|Invia Motion Endure|
2385779|NCT03670212|Placebo Comparator|Placebo|The placebo compound, Lactose Monohydrate Powder, was encapsulated in generic opaque capsules identical to the capsules used in the acute stress session. During the placebo session, two capsules were self-administered (swallowed) by each subject. At 11:45am, subjects self-administered a capsule containing 54mg of lactose. At 12:15pm, subjects self-administered a capsule containing 10mg of lactose.
2385780|NCT03670212|Experimental|Acute Stress|During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
2385781|NCT03670199|Experimental|Experimental group|nutritional and functional management coordinated by dieticians and physiotherapists, with adapted nutritional and physical advice and support, realized with the use of Nutrimus booklet in order to facilitate coordination and delivration of cares proposed to the patients
2385782|NCT03670199|Active Comparator|Control group|usual preoperative advice for patients who undergoing surgical procedure concerning nutritional cares and physical activity
2385783|NCT03670186|Experimental|V66V-HIIT|Val/Val carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
2385784|NCT03670186|Experimental|V66M-HIIT|Val/Met carriers who undergo high-intensity interval training (HIIT) for 6 weeks, 3 times per week
2385969|NCT03668899|Active Comparator|Hypochlorite group|irrigation with NaOCL (final flush)
3150936|NCT00214474|Active Comparator|GMV Intervention|GMV Intervention: Group Medical Visits
3150937|NCT00214474|No Intervention|Usual Care|Usual Care: Standard care for diabetic patients
3150938|NCT00214500|Experimental|Migalastat|"Migalastat was administered orally during the 12-week treatment period and then during the optional 2 treatment extension periods.~Treatment Period:~Migalastat 25 mg BID for Weeks 1 and 2 (Day 1 through the morning dose on Day 14).~Migalastat 100 mg BID for Weeks 3 and 4 (Day 15 through the morning dose on Day 28).~Migalastat 250 mg BID for Weeks 5 and 6 (Day 29 through the morning dose on Day 42).~Migalastat 25 mg BID for Weeks 6 to 12 (Days 43 to 84).~Extension Period:~Migalastat 25 mg BID for Weeks 12 through 48.~Migalastat 50 mg QD for Weeks 48 through 96."
3150939|NCT00214669|Experimental|1|"Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.~Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Lorig's chronic disease self-management programme.~Improved follow-up in primary care through appointment-booking by the specialist nurse."
3150940|NCT00214669|No Intervention|2|Usual Care
2385785|NCT03670173|Experimental|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year. One course of osalmid treatment lasts four weeks. Response will be assessed at the end of each treatment course, and patients who have achieved MR (minor remission) or more than MR at the end of the fourth course will continue to take 1.0g tid osalmid daily for consolidation / maintenance therapy. Otherwise, patients who have not achieved MR at the end of the fourth course and patients who are assessed for PD (progression of disease) at the end of each course will receive salvage treatment, such as a combined treatment of osalmid and dexamethasone or the VCD (bortezomib, cyclophosphamide and dexamethasone) regimen.
3142840|NCT00003573|Experimental|Treatment 2, Etoposide, 35mg/m2/day|"Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7).~Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51)."
3183423|NCT00713804|Active Comparator|EB|Educational Booklet (EB): One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
2385788|NCT03670147|Experimental|Pain Returns|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain returns after switching to the LAP will be considered Group 1.
2385789|NCT03670147|Experimental|No Pain|PF-SCS programming: in a blinded fashion, subjects will be asked to switch to the lowest amplitude program (LAP). Subjects whose pain does not return after switching to the LAP will be considered Group 2.
2385790|NCT03670134|Experimental|Volumetric laser Endomicroscopy (VLE)|Volumetric laser Endomicroscopy (VLE) is a second-generation optical coherence tomography platform that can image the human esophagus in cross-section at microscopic resolution this will performed by using the Nvision VLE Imaging System.
2385792|NCT03670108||patients receiving an individualized SMS|
2385793|NCT03670108||patients receiving a standard SMS|
2385794|NCT03670095|Experimental|Lactose-free memantine tablet|(treatment A - test) - 10 mg; orally as a single dose in fed and fasted state
2385795|NCT03670095|Experimental|Lactose-containing memantine tablet (Ebixa®)|(treatment B - reference) - 10 mg, orally as a single dose in fed and fasted state
2385796|NCT03670082|Experimental|Group 1: Fasting condition in Period I|Subjects will be in fasting condition in Period I and in a fed condition in Period II.
2385797|NCT03670082|Experimental|Group 2: Fed condition in Period I|Subjects will be in fed condition in Period I and in fasting condition in Period II.
2385799|NCT03670056|Experimental|Nivolumab and Ipilimumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
2385800|NCT03670043|Active Comparator|Metformin ER|The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
2385801|NCT03670043|Experimental|Psyllium|The subjects developing GI-related symptoms with metformin will be randomized to Psyllium
2385804|NCT03670004||Unilateral Below Knee Amputation|Individuals who walk with a below knee prosthesis
2385805|NCT03670004||Non-Impaired|Able-bodied controls
2385806|NCT03669978||Patients with chronic occlusive arthritis of the Lower Limbs|"Patients with chronic occlusive arthritis of the Lower Limbs with lesions on the femoro-popliteal stage and candidates for endovascular treatment of these lesions.~Creation of a bone and arterial panorama using EndoNaut® software."
2385807|NCT03669965|Experimental|Part A Arm 1|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
2385808|NCT03669965|Experimental|Part A Arm 2|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
2385809|NCT03669965|Experimental|Part A Arm 3|KRT-232 120mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
2385810|NCT03669965|Experimental|Part B KRT-232 Arm|Recommended KRT-232 dose and schedule from Part A
2385811|NCT03669965|Active Comparator|Part B Ruxolitinib Arm|Ruxolitinib per approved prescribing label
2385812|NCT03669965|Experimental|Part A Arm 4b|KRT-232 240mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
2385813|NCT03669965|Experimental|Part A Arm 2b|KRT-232 240mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
2385814|NCT03669952||Invasive ductal carcinoma|Patients with Invasive ductal carcinoma
2385815|NCT03669939||Communication strategy|Primary Care providers who see HIV patients and follow them on opiates for chronic pain to receive communication strategies developed by the study team wit the guidance from the HV community and providers
2385816|NCT03669939||Standard of Care|Primary Care Providers - who see HIV patients and follow them on opiates for chronic pain will receive education on the the standard information about the CDC Guidelines
2385817|NCT03669926|Other|DBT+SM|Digital Breast Tomosynthesis+synthetic mammography (DBT+SM) All women are screened with DBT+SM. All examinations are independently double read. Consensus used to decide whether or not to recall.
2385818|NCT03669913|Experimental|Intervention|Intervention arm will receive a pre evaluation survey, 11 lessons on CSE sequentially in a period of one year and a post evaluation survey
2385819|NCT03669913|No Intervention|Control arm|This is a control arm that receives no intervention but will have and pre and post evaluation in one year
2385862|NCT03669614|Placebo Comparator|inhaled AR-501 Placebo|Three doses (low, medium, high) of inhaled placebo will be used
2386014|NCT03668561|Experimental|Treatment (CALIGALOC)|Wearing of the Caligaloc orthosis
2385820|NCT03669900|Other|a minimally invasive surgery (SERI)|The surgery consisted of varus traction, skin incision, metatarsal osteotomy and K- wire insertion. All the cases were done by the senior consultant orthopedic surgeon, including preoperative planning, the osteotomy itself and the follow up in the clinic. Another orthopedic surgeon was involved in collecting the data, doing all the measurements preoperative and postoperative and assisting the primary surgeon during the surgery.
2385821|NCT03669887|Experimental|Lifestyle Modification Program|
2385822|NCT03669887|No Intervention|Control|
3183424|NCT00713804|No Intervention|WT|Waitlist (WT)
2385824|NCT03669848||Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO) Measurements are taken with a noninvasive method by placing a sensor on a patient, usually on the fingertip.
2385825|NCT03669835|Experimental|Dietary supplement and standard therapy.|Participants will take a supplement of 1 sachet (20 mg) 3 times/day accompanied with the standard therapy for 1 month.
2385826|NCT03669835|Other|Standard therapy only.|Patients would be given standard treatment for 1 month.
2385828|NCT03669809||male, non-obese|male with BMI<28
2385829|NCT03669809||male, obese|male with BMI≥28
2385830|NCT03669809||female, non-obese|female with BMI<28
2385831|NCT03669809||female, obese|female with BMI≥28
2385832|NCT03669796|Experimental|supplementary Marine protein hydrolysate|20 mg powder per kg body weight of Marine protein hydrolysate (MPH)
2385833|NCT03669796|Placebo Comparator|control|20 mg powder per kg body weight of casein/maltodextrin
2385834|NCT03669783|Active Comparator|treatment VAD|Vincristin, Actinomycin-D and Doxorubicin
2385835|NCT03669783|Experimental|treatment VCE|Vincristin, Carboplatin and Etoposide
2385836|NCT03669757|Experimental|LEO 134310 Dose A|Once daily application
2385837|NCT03669757|Experimental|LEO 134310 Dose B|Once daily application
2385838|NCT03669757|Experimental|LEO 134310 Dose C|Once daily application
2385839|NCT03669757|Experimental|LEO 134310 Dose D|Once daily application
2385840|NCT03669757|Placebo Comparator|LEO 134310 vehicle|Once daily application
2385841|NCT03669757|Active Comparator|0.1% betamethasone valerate ointment (class III steroid)|Once daily application
2385842|NCT03669744||Patients with trigeminal neuralgia resistant|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018
2385843|NCT03669731|Experimental|Group 1|Urinary urea 24 hours and food diary
2385844|NCT03669731|Experimental|Group 2|Urinary urea 24 hours and food diary
2385845|NCT03669731|Experimental|Group 3|Urinary urea 24 hours and food diary
2385848|NCT03669692|Active Comparator|Control|Patients in the control group will be assigned to a free diet (ad libitum), according to the Spanish Association of Urology lifestyle recommendations for patients with LUTS
2385849|NCT03669692|Experimental|Caloric Restriction|"Patients in the experimental group will be assigned to intermittent caloric restriction, based on an early time restricted eating, with a 16/8 fasting/feeding scheme.~The patients in this group will have a RC progressive scheme until achieve a maximum of 5 days a week of fasting."
2385850|NCT03669679|Active Comparator|Group A|"participants undergoing superomedial pedicle breast reduction Hall-Findlay technique"
2385851|NCT03669679|Active Comparator|Group B|"participants undergoing inferior pedicle breast reduction Robbins technique"
2385852|NCT03669666||control group|10 normal healthy subjects are conducted for cardiac magnetic resonance imaging examination
2385853|NCT03669666||case group|25 patients with valvular heart disease diagnosed clinically and by echocardiography are conducted for cardiac magnetic resonance imaging examination
2385854|NCT03669653|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
2385855|NCT03669653|Placebo Comparator|Sham RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to Guidelines for diagnosis and treatment of acute ischemic stroke in China 2014
2385858|NCT03669627|Active Comparator|Group 1: aTIV primer, QIV booster|Two doses (0.25 mL) aTIV (FLUAD )received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2.
2385859|NCT03669627|Other|Group 2: QIV primer, QIV booster|"Standard of care control group:~Two doses (0.5 mL) QIV (Fluzone) received one month apart in year 1. One dose (0.5 mL) QIV (Fluzone) received as booster in year 2."
2385860|NCT03669627|Experimental|Group 3: aTIV primer, aTIV booster|"This arm is experimental in that some participants will be receiving the MF59-adjuvanted TIV (FLUAD) in year two of the study, after the age of two years, which is off label.~Two doses (0.25 mL) TIV (FLUAD) received one month apart in year 1. One dose (0.25 mL) TIV (FLUAD) received as booster in year 2."
2385863|NCT03669601|Experimental|Continuous AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily for 21 days of a 28 day cycle. Dose range from 40mg to 120mg."
2385864|NCT03669601|Experimental|Intermittent AZD6738 & gemcitabine|"Intravenous gemcitabine on days 3, 10 and 17 of a 28 day cycle. Dose range from 500mg/m2 to 1000mg/m2.~Oral tablet AZD6738 once daily and intermittently for up to 12 days of a 28 day cycle. Dose range from 40mg to 120mg."
2385865|NCT03669588|Experimental|ARGX-113|
2385866|NCT03669588|Placebo Comparator|Placebo|
2385867|NCT03669575|Experimental|omega 7 - placebo|Receiving the active first then switch to the placebo after three weeks
2385868|NCT03669575|Active Comparator|placebo - omega 7|Receiving the placebo first then switch to the active after three weeks
2385869|NCT03669562|Experimental|Alprostadil liposome|
2385870|NCT03669562|Placebo Comparator|Placebo|
3183425|NCT00713843|Experimental|1 Manual Therapy Utrecht|"Manual Therapy Utrecht (MTU) During the first consultation the manual therapist enquires about the complaints of the patient. The manual therapist conducts a number of measurements according to protocol. During treatment preferred movements are executed by the manual therapist in the patient's joints. The treatment techniques used by the manual therapist are very gentle mobilizations, without high velocity thrust techniques and are in general painless. In Manual Therapy Utrecht (MTU) it is common to give advices and recommend exercises.~A treatment session lasts between 30 and 60 minutes (repeated after one or two weeks). The maximum number of sessions is six.~The manual therapist has a minimum of five years of working experience."
2385873|NCT03669510|Active Comparator|computer gaiuded IAN|Computer guided surgical technique
2385874|NCT03669510|Experimental|Classical technique|Non computer guided surgical technique
2385876|NCT03669484|Experimental|Remimazolam|"The induction of anesthesia: intravenous infusion of 6 mg/kg/h until registration of loss of consciousness.~Maintenance of anesthesia: Remimazolam intravenous infusion initiated at a dose of 1 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation to 2 mg/kg/h maximum; In case of loss of consciousness was not registered in 2.5 minutes of continuous intravenous infusion: drug administration was terminated. If loss of consciousness was not registered during 30 seconds, other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed: intravenous bolus infusion (maximum level of 12 mg/kg/h for 1 minute). If signs of awakening remained remimazolam administration was discontinued and other sedatives were used."
2385877|NCT03669484|Active Comparator|Propofol|"The induction of anesthesia: intravenous infusion of 1.5-2.5 mg/kg for about 1 minute.~Maintenance of anesthesia: intravenous infusion for a total dose of 4-12 mg/kg/h; the dose level was adjusted accordingly based on a systemic patient monitoring until the end of operation.~In case of loss of consciousness was not registered other sedative drugs were used for induction and maintenance of anesthesia.~In case of signs of awakening (fluctuation of blood pressure/heart rate, lacrimation, sweating, etc.) were observed and propofol dose adjustment had not resulted in the desired effect and signs of awakening were saved: the use of propofol was discontinued and other sedatives were used."
2385878|NCT03669471||FAIS group|Subjects who have had a hip arthroscopy for femoroacetabular impingement during the preceding 6-30 months
2385879|NCT03669458|Experimental|Arm 1: BTK intervention with SPUR/DCB|Below the knee peripheral intervention using SPUR/DCB.
2385880|NCT03669458|Experimental|Arm 2: BTK intervention using SPUR Only|Below the knee peripheral intervention using SPUR only.
2385881|NCT03669458|Experimental|ARM 3: BTK intervention using DCB Only|Below the knee peripheral intervention using DCB only.
2385882|NCT03669445|Experimental|four drugs combination|21-day cycles induction, then 28-day cycles consolidation and maintenance with Lenalidomide, Ixazomib, and Dexamethasone Plus Daratumumab
2385883|NCT03669432|Experimental|Intensity Modulated radiotherapy|"In this Arm, after surgery, patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the PTV of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
2385884|NCT03669432|Other|Surgery alone|In this Arm, after surgery patient will receive radio-iodine treatment as per guidelines, 6-8 weeks after surgery. Patient under surgery arm will receive no further treatment after surgery and radio-iodine therapy and will be kept on a routine follow up
2385885|NCT03669406|Experimental|Autograft fat|Paraplegic patients with healed pelvic eschar
2385886|NCT03669393|Experimental|THR-317|
2385887|NCT03669380||conservative treatment|Conservative treatment consisted of bowel rest, intravenous fluid therapy, nutritional support, strict blood pressure control, anticoagulation (with or without antiplatelet) and close observation
2385888|NCT03669380||Interventional and surgical treatment|Interventional and surgical treatment
2385889|NCT03669367|Experimental|abatacept|abatacept monotherapy (subcutaneous route).: 125 mg solution for injection in pre-filled syringe. In the first year (0-12 months) at a a dose of 125 mg per week (full dose) and in the second year (12-24 months) at a dose of 125 mg every other week (q2w) (optimized dose) injection) - 125 mg x week - subcutaneous use.
2385890|NCT03669367|Active Comparator|hydroxycloroquina|Hydroxyclorquina (Coated tablet)- (5 mg/Kg/day) monotherapy for 2 years (0-48 months)
2385895|NCT03669341|Experimental|Deep Inspiration Breath Hold (DIBH)|DIBH extended by prior hyperventilation while breathing 100% O2
2385896|NCT03669341|Active Comparator|High Frequency Percussive Ventilation (HFPV)|passive Ventilation by a jet ventilator
2385897|NCT03669328||Group 1|patients of 2016, June with locoregional anesthesia
2385898|NCT03669328||Group 2|patients of 2018, June with locoregional anesthesia
2434411|NCT03335956|Experimental|MAD Active Cohort 3|
2385899|NCT03669315|Active Comparator|Active cTBS treatment|Active cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly coil. TBS consists of bursts of 3 pulses separated by 20ms (i.e. 50 Hz), with each triplet being repeated every 200 ms (i.e. 5 Hz). Stimulus intensities will be set at 80% of AMT. The investigators will use 2 trains of 600 pulses each separated by 1 minute (a total of 1200 pulses).
2385900|NCT03669315|Sham Comparator|Sham cTBS treatment|Sham cTBS will be administered with a Magventure MagPro Stimulator R30 using a butterfly sham coil. The same active cTBS configuration will be used.
2385901|NCT03669302|Sham Comparator|Robotic gait training|Robotic gait training only
2385902|NCT03669302|Experimental|Robotic gait training & low-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at low frequency (0.3 Hz).
2385903|NCT03669302|Experimental|Robotic gait training & high-frequeny transspinal stimulation.|Robotic gait training will be administered along with non-invasive transspinal stimulation over the thoracolumbar region during assisted stepping at high frequency (30 Hz).
2385904|NCT03669289|Experimental|Enhanced model of primary care|
2385905|NCT03669263|Experimental|Fentanyl buccal soluble film (FBSF)|Single arm
2385906|NCT03669250|Active Comparator|CVN058, low dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 15mg or 75mg substitution of 15mg.
2385907|NCT03669250|Active Comparator|CVN058, high dose|CVN058 prepared in concentrations of 10mg/mL, and are compounded by the clinical site. Subjects will receive one dose of CVN058 at 150mg.
2385908|NCT03669250|Placebo Comparator|Placebo|Matching placebo.
2385909|NCT03669237|Experimental|end-to-side anastomosis|
2385910|NCT03669237|No Intervention|end-to-end anastomosis|
2385911|NCT03669224|Experimental|Nano Care Gold|Silver and Gold nano particles suspended in 70 % isopropyl alcohol. It will be used for cavity pre-treatment. This arm will be compared with no intervention (negative control).
2385912|NCT03669224|Active Comparator|Chlorhexidine|2% chlorhexidine gluconate solution will be applied to prepared cavity followed by adhesive system then resin composite. This arm will be compared with no intervention (negative control).
2385913|NCT03669211|Experimental|Cardiac stress test|
2385914|NCT03669198|Active Comparator|NT-pro BNP group|Subjects who be included in NT-pro BNP group examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group can be discharged if the NT-pro BNP level decreased ≥ 30% from baseline. If the target percent decline is not met, we will do intensification of therapy according to the algorithm
2385915|NCT03669198|No Intervention|Control group|Patients in the control group were managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not was determined by cardiologist in charge of the patient based on clinical assessment.
2385916|NCT03669185|Placebo Comparator|Placebos|Placebos, 2 times daily 1 tablet, intake max. 133 days
2385917|NCT03669185|Active Comparator|Pentalong|Pentalong, 2 times daily 1 tablet, intake max. 133 days
2385918|NCT03669172|Experimental|NK cells infusion|NK cells incubated infusion (CD56 +, CD3) ex vivo with IL-15 in patients with acute myeloid leukemia undergoing high-risk allogeneic haploidentical Pt-C donor
3142841|NCT00003575|Experimental|Arm I|All patients receive ifosfamide IV by continuous infusion for 2 days, etoposide IV over 2 hours daily on days 1 and 2, and filgrastim (G-CSF) subcutaneously (SC) daily on days 4-13. Courses are repeated every 21 days. Patients who have complete or partial remission after a minimum of 4 courses of chemotherapy receive maintenance therapy consisting of interleukin-12 SC twice weekly beginning on day 28 of the final chemotherapy course and continuing for 6 months or until disease progression. All patients also receive combination antiretroviral therapy during study.
3142842|NCT00003587|Experimental|carboplatin/gemcitabine/paclitaxel|IV carboplatin AUC=5.5 day 1 every 21 days X 3 IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3 IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
3142843|NCT00003587|Experimental|cisplatin/vinorelbine/docetaxel|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3 IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3 IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
2385922|NCT03669133|Active Comparator|Group A|Vitamin E 800 IU/daily for 24 weeks
2385923|NCT03669133|Placebo Comparator|Group B|Matching placebo for 24 weeks
2385924|NCT03669120|Active Comparator|Arm I (mainstream instructional care)|Participants receive mainstream instructional care including brief advice on how to quit smoking, 10-week supply of NRT in the form of nicotine patches, and intensive print materials to promote smoking cessation.
2385925|NCT03669120|Experimental|Arm II (tailored intensive care)|Participants receive tailored intensive care including brief advice on how to quit smoking, NRT, and intensive print materials to promote smoking cessation as in Arm I. Participants also receive individualized text based messages to promote smoking cessation for 6 months.
2385926|NCT03669107|Experimental|Gum chewing|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at 30 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
2385927|NCT03669107|No Intervention|Control group|no gum
2385928|NCT03669094|Active Comparator|L. salivarius V4II-90|Lactobacillus salivarius V4II-90; approximately 1*10E9 colony forming unit (CFU) of L. salivarius V4II-90 in 1 oral capsule per day for 12 weeks.
2385929|NCT03669094|Placebo Comparator|Control group|Placebo supplement in 1 oral capsule per day for 12 weeks.
2385932|NCT03669068||Elective endoscopy|Patients undergoing gastrointestinal endoscopy unrelated to anticoagulant-induced gastrointestinal bleeding.
2385933|NCT03669068||Gastrointestinal bleeding|Patients with anticoagulant-induced gastrointestinal bleeding will be analyzed separately
2434412|NCT03335956|Placebo Comparator|MAD Placebo Cohort 4|
2385934|NCT03669055|Experimental|Pre-operative and post operative Magnetic Resonance Imaging|Realization of an angio-MRI with 4D phase contrast sequence before and after the endovascular treatment of the aortic dissection
2385935|NCT03669042|Experimental|Treatment|All patients will undergo a vascular repair or reconstruction surgery, which requires the use of PhotoFix. The surgical procedures will vary by patient and by underlying etiology. Therefore, PhotoFix implant sites will also vary. In all cases, PhotoFix will be implanted per the Instructions for Use (IFU).
2385936|NCT03669029|Experimental|Week 6 Responders|In patients with clinical response at week 6, serum golimumab levels and anti-golimumab antibody levels will be correlated with clinical response.
2385937|NCT03669029|Experimental|Week 6 Non Responders|In patients without clinical response at week 6, golimumab treatment will be optimized.
2385938|NCT03669016|Experimental|Face-to-face group-based mindfulness|8 weeks training.
2385939|NCT03669016|Experimental|Internet-based mindfulness|8 weeks training.
2385940|NCT03669016|No Intervention|Waiting-list control group|No training during the study.
2385941|NCT03669003|Experimental|Gelfoam|Gelfoam slurry will be injected at the end of the biopsy procedure.
2385942|NCT03669003|Active Comparator|Standard procedure|Standard procedure of lung biopsy
2385943|NCT03668990|Other|persons with Multiple Sclerosis (MS)|"25 persons with MS Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
2385944|NCT03668990|Other|stroke patients|"25 stroke patients Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
2385945|NCT03668990|Other|Healthy controls|"50 healthy controls Persons perform funtional-oriented upper limb movments while wearing IMUs (Xsens, MVN Studio). This is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.~Funcitonal-oriented upper limb movements are performed at two different test days."
2385946|NCT03668977|No Intervention|Routine care|"In all four groups, the following antenatal and post-natal interventions will be offered:~Women encouraged to enroll in routine antenatal care at their local health post/center.~A clean birthing kit consisting of a clean blade, string, and plastic disc for cutting the cord, a plastic sheet, a bar of soap, and a tube of chlorhexidine ointment for application to the umbilical stump.~Women encouraged to deliver at a certified birthing facility and participate in the government's incentive scheme.~Nutritional, hygiene, and infant care counseling.~Tetanus toxoid (if needed) and iron-folic acid supplements."
2385947|NCT03668977|Experimental|Supplementation-pregnancy|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing throughout pregnancy. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
2385948|NCT03668977|Experimental|Supplementation-lactation|A daily fortified balanced protein-energy nutritional supplement beginning after delivery and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
2385949|NCT03668977|Experimental|Supplementation-pregnancy & lactation|A daily fortified balanced protein-energy nutritional supplement beginning in the 2nd trimester and continuing through 6 months post-partum. The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approximately 400 Kcal/day with approximately 14 g of protein.
2385950|NCT03668964|Experimental|Vitamin B2|Daily dose of 75 mg Vitamin B2
2385951|NCT03668964|Experimental|Vitamin C|Daily dose of 500 mg Vitamin C
2385952|NCT03668964|Experimental|Vitamin B2 + C|Daily dose of 75 mg Vitamin B2 and 500 mg Vitamin C
2385953|NCT03668964|Experimental|Vitamin A|Daily dose of 250 µg Vitamin A
2385954|NCT03668964|Experimental|Vitamin D3|Daily dose of 60 µg Vitamin D3
2385955|NCT03668964|Experimental|Vitamin E|Daily dose of 100 mg Vitamin E
2385956|NCT03668964|Placebo Comparator|Placebo|Daily dose of 575 mg microcrystalline cellulose
2385957|NCT03668951|Experimental|Buccal DEX 2 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
2385958|NCT03668951|Experimental|Intranasal DEX 3 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
2385959|NCT03668951|Experimental|Intranasal DEX 4 mcg/kg|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia, placement of an endotracheal tube and an arterial line. Once these are accomplished, Dexmedetomidine is administered according to group assignment.
2385960|NCT03668938|Experimental|intervention|The occupational therapy intervention provides a treatment aimed at improving autonomy in the activities chosen by the patient
2385961|NCT03668938|Active Comparator|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
2385962|NCT03668925|Experimental|"Group Case"|patient diagnosed with hidrosadenitis suppurativa
2385963|NCT03668925|Active Comparator|"Group control"|patient without hidrosadenitis suppurativa
2385964|NCT03668912|Experimental|Guided participation group|
2385965|NCT03668912|No Intervention|Usual care group|
2434413|NCT03335956|Experimental|MAD Active Cohort 4|
2385970|NCT03668886|Experimental|multimodal exercise program|Elderly in this group will receive multimodal exercise program. The duration of exercise is 60 minutes and frequency is 2 times/week.
2385971|NCT03668886|No Intervention|Control group|Elderly in this group will continue to attend community activity as usual. The activity includes active activity is 60 minutes and frequency is 2 times/week.
2385972|NCT03668873|Experimental|Sleep Parent Training|The five SPT sessions (each 60-90 minutes in duration) are individually delivered over 10-weeks. In addition to the five sessions, there are three home visits conducted via Express Care Online (HIPAA compliant video-chat). After Session A, session order may be adjusted to address child-specific problems. One-on-one delivery of SPT permits flexibility for child-specific problems within the program.
2385973|NCT03668873|Active Comparator|Sleep Parent Education|SPE consists of five 60-90 minute sessions, delivered individually over 10 weeks. SPE provides useful information to families of young children with ASD and sleep problems. Session A is designed to develop rapport. The sleep hygiene session (Session B) has been modeled from the RUBI manual. The other sessions include a systematic presentation on several relevant topics. An example of a SPE session is provided in the Intervention section. This condition is intended to parallel what would be offered in typical care, but by telehealth, where a parent might be educated about ASD as well as attend an outpatient appointment at a sleep clinic.
2385974|NCT03668860|Active Comparator|Treatments A & B (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
2385975|NCT03668860|Active Comparator|Treatments B & A (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))~(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))"
2385976|NCT03668860|Active Comparator|Treatments C & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
2385977|NCT03668860|Active Comparator|Treatments D & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))"
2385978|NCT03668860|Active Comparator|Treatments E & D (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
2385979|NCT03668860|Active Comparator|Treatments D & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))~(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))"
2385980|NCT03668860|Active Comparator|Treatments C & E (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)"
2385981|NCT03668860|Active Comparator|Treatments E & C (6 subjects)|"After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.~Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.~E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)~C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)"
2386015|NCT03668548|Experimental|Leucine group|To receive leucine on a daily basis for 10 weeks
2386016|NCT03668548|Placebo Comparator|Control group|To receive a placebo supplement on a daily basis for 10 weeks
2385983|NCT03668834|Active Comparator|Dermabrasion with NCES|Intervention-Dermabrasion with autologous non cultured epidermal cell suspension Recipient site preparation using dermabrasion followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
2385984|NCT03668834|Active Comparator|Dermaroller with NCES|Intervention-Dermaroller with autologous non cultured epidermal cell suspension Recipient site preparation using dermaroller system followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
2385985|NCT03668834|Active Comparator|Liquid nitrogen induced blister with NCES|Liquid nitrogen induced blister with autologous non cultured epidermal cell suspension Recipient site preparation using liquid nitrogen induced blister followed by autologous non cultured epidermal cell suspension technique of 1 stable vitiligo patch of each of the 36 patients.
2385986|NCT03668821||Carotid Artery Disease|Patients with Carotid Artery Disease. Quality of life and frailty questionnaires
2385987|NCT03668821||Aneurysmal Disease|Patients with Aneurysmal Disease. Quality of life and frailty questionnaires
2385988|NCT03668821||Peripheral Artery Disease|Patients with Peripheral Artery Disease. Quality of life and frailty questionnaires
2385989|NCT03668808|Experimental|Insulin Degludec|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Degludec and the TRESIBA® FLEXTOUCH® pens during a long-haul flight and randomized to this arm first or second.
2385990|NCT03668808|Active Comparator|Insulin Glargine U100|Subjects with type 1 diabetes and on multiple daily injections will use basal insulin Glargine U100 and the LANTUS® SOLOSTAR® INSULIN PEN during a long-haul flight and randomized to this arm first or second.
2385991|NCT03668782||immediate cord clamping|Tthe umbilical cord of neonates was cut and clamped.
2385992|NCT03668782||umbilical cord milking.|Tthe umbilical cord of neonates was milked.
2385993|NCT03668769|Experimental|Prevention (smoking reduction, Quitting Schedule mobile app)|"AIM I: Participants follow an individually tailored gradual reduction of smoking schedule for 5 weeks while MDACC eHealth adapts WebCASSI into a smartphone app: Quitting Schedule.~AIM II: Participants pre-test the Quitting Schedule mobile smartphone app for 5 weeks."
2385994|NCT03668756||Computer-Assisted Navigation TKA|the patients who were received CAS TKA in one limb
2385995|NCT03668756||Conventional TKA|the patients who were received conventional TKA in one limb
2385996|NCT03668730|Experimental|Reduced dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome, Cisplatin and 5-Fluorouracil, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (30 fractions). Patients also receive cisplatin once per three week for 3 cycles.
2385997|NCT03668730|Experimental|Standard dose group|After 2 cycles of induction chemotherapy with Paclitaxel Liposome,Cisplatin and 5-Fluorouracil, patients undergo standard-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cisplatin once per three week for 3 cycles.
2385998|NCT03668704||Medial Bicompartmental Knee Arthroplasty|Patient who have received a robotic-arm assisted medial and patellofemoral knee arthroplasty.
2385999|NCT03668678|Experimental|iGrow Readers Curriculum|The iGrow Readers nutrition and physical activity curriculum was implemented in early-childhood classrooms assigned to the IGrow Readers intervention group.
2386000|NCT03668678|No Intervention|Standard Curriculum|The standard curriculum was provided within early-childhood classrooms assigned to the control group.
2386001|NCT03668665|Active Comparator|Conventionell Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~1st half: conventional treatment with moist dressings (mepilex and fixomull)"
2386002|NCT03668665|Experimental|Treatment with Ready Medical Post Treatment|"After split skin removal, the wound is divided into 2 parts (=2 arms):~2nd half: conventional treatment with moist dressings (mepilex and fixomull) and additional treatment with ready medical post treatment"
2386003|NCT03668652|Experimental|Focal prostate cancer treatment by HIFU|Patients with target lesion distance < 30 mm from the rectum will be treated with High Intensity Focused Ultrasound (HIFU) applied by FocalOne HIFU device and patients with lesion > 30 mm from the rectum will be treated with TULSA applied by TULSA-PRO.
2386004|NCT03668652|Active Comparator|Radical Prostatectomy|Robot assisted laparoscopic radical prostatectomy or open retro-pubic radical prostatectomy will be performed using validated radical prostatectomy technique. Nerve sparing surgery on side of cancer free prostate lobe will be performed and type of nerve sparing procedure will be specified.
2386006|NCT03668626|No Intervention|Term infants|Healthy term infants
2386007|NCT03668626|No Intervention|Usual care program (UCP)|In-hospital and after-discharge intervention (telephone calls)
2386008|NCT03668626|Experimental|Family-centered intervention program (FCIP)|In-hospital and after-discharge intervention (clinic and home visits)
2386012|NCT03668574|Experimental|Aerobic exercise group|Patients will firstly warm up for 5 minutes and begin training on the treadmill. There will be two weekly sessions, lasting 40 minutes, for 6 weeks, reaching a total of 12 sessions. The exercise intensity will vary from 60 to 90% of the maximum heart rate (HRmax) predicted by the percentage formula HR = HR rep + percentage (HRmax - HR rep), where HRmax = 220-age (years) and HR rep = HR obtained for five minutes of rest. Heart rate and level of subjective perception of the effort will be monitored during all sessions. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
2386013|NCT03668574|Placebo Comparator|Placebo Group|Patients will received a detuned pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes, twice weekly for 6 weeks. The devices will be used with disconnected internal cables to obtain the placebo effect; however, it will be possible to manipulate the devices and adjust the doses and alarms as if they were connected, in order to simulate the pragmatism of clinical practice as well as to increase the credibility of the use of these devices in patients. Patients from this group will also be educated about their back pain by receiving a copy of The back Book.
2386017|NCT03668535|Active Comparator|Bladder Filling arm|Group A have triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
2386018|NCT03668535|Active Comparator|Bladder deflation arm|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
2386019|NCT03668522||children|age<=17
2386020|NCT03668522||adult|age>17
2386021|NCT03668509|Experimental|Cohort 1|oral adminstration of SHR1459, dose 1
2386022|NCT03668509|Experimental|Cohort 2|oral adminstration of SHR1459, dose 2
2386023|NCT03668509|Experimental|Cohort 3|oral adminstration of SHR1459, dose 3
2386024|NCT03668496|Experimental|SHR-1210 +chemotherapy|subject will receive SHR-1210 200mg every 3 weeks, carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
2386025|NCT03668496|Active Comparator|chemotherapy|carboplatin AUC 5 on Day 1 of each 21 day, 4-6 cycles Paclitaxel 175mg/m2, Day 1 of each 21 day, 4-6 cycles
2386026|NCT03668483|Experimental|Pulmonary Rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
2386027|NCT03668470|Experimental|Dulaglutide|Experimental group receiving 1.5 mg Dulaglutide subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
2386028|NCT03668470|Placebo Comparator|placebo|Control group receiving placebo subcutaneously weekly in addition to their usual insulin regimen during 24 weeks
2386029|NCT03668457|Experimental|Intervention to Patients|Only patients receive intervention
2386030|NCT03668457|Experimental|Intervention to Psychiatrists|Psychiatrists receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
2386031|NCT03668457|Experimental|Mixed Intervention|Patients and Psychiatrists associated with these patients receive intervention
2386032|NCT03668457|Other|Control|Psychiatrists provide the usual care Patients receive usual care
2386033|NCT03668444|Experimental|TXS- Supportive Text Group|Participants randomized to this arm (TXS) of the study will receive care as usual within the Drug Treatment Court (DTC) system plus supportive daily text messages which will be delivered at specific times each day for 30 days and will be signed by the judge for their specific DTC. (TXS) Group receives text messages for drug treatment compliance.
2386034|NCT03668444|Placebo Comparator|TAU- Treatment As Usual Group|Participants randomized to the (TAU) arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive motivational text messages for 30-days.
2386035|NCT03668431|Experimental|PDR001, Dabrafenib, Trametinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive PDR001, Dabrafenib, Trametinib. Treatment will be administered on an outpatient basis.~After the screening procedures confirm participation in the research study:~Dabrafenib will be taken twice a day for 28 consecutive days~Trametinib will be taken once a day for 28 consecutive days~PDR001 will be administered IV every 28 days."
2386036|NCT03668418||Colorectal cancer|Patients operated for colorectal cancer with or without liver metastasis undergoing a chemotherapy treatment after surgery
2386037|NCT03668418||Esophagus/gastric cancer|Patients operated for esophagus/gastric cancer undergoing a chemotherapy treatment after surgery
2386038|NCT03668418||Biliary duct cancer|Patients operated for biliary duct cancer undergoing a chemotherapy treatment after surgery
2386039|NCT03668418||Pancreatic cancer|Patients operated for pancreatic cancer undergoing a chemotherapy treatment after surgery
2386040|NCT03668405|Experimental|Lu AF20513 high dose|
2386042|NCT03668379|Active Comparator|Behavioral Activation Therapy|"During the initial stage treatment, the active comparator arm is the behavioral activation (BAT) program intervention. BAT is informed by behavioral theory and has been shown to be a highly efficacious treatment for depression. A total of five, 1-hour sessions will be delivered every two weeks. During Session 1, the focus will be on providing an introduction to BAT, as well as building confianza (mutual trust) between the patient and provider. Sessions 2 & 3 will review the initial session, introduce high value activities and barriers to BAT protocols. Sessions 4 & 5 will review progress, challenges & maintenance strategies."
2386043|NCT03668379|Experimental|Behavioral Activation Therapy & mHealth|"During the initial stage treatment, the experimental arm will deliver a BAT program identical to the active comparator arm, as well as a mobile health (mHealth) component in the form of one-way and two-way SMS text-messages. Direct personalized text-messages will be delivered twice a week to facilitate engagement with the BAT intervention activities. One-way messages will be sent as appointment and BAT adherence reminders. Two-way messages will be sent once a week during a set block of protected hours, creating a mobile drop-in clinic where messages can be sent and received."
2386044|NCT03668366|Experimental|S-1 arm|The patients in the S-1 arm will receive IMRT (66-70.4Gy to GTV, 57-60.8Gy to CTV1, 54-56Gy to CTV2, given in 30-32 fractions). During the IMRT course, S-1 will be administered orally according to body surface area (BSA<1.25m2, 30mg; BSA: 1.25-1.5m2, 40mg; BSA>1.5m2, 50mg) twice per day for 30-32 days. The dose modifications of S-1 will not be permitted during concurrent chemotherapy unless progression of the disease, toxicities of grade 4 or patient's refusal.
2386045|NCT03668353|Experimental|treatment 1|Recombinant SeV-hFGF2/dF Injection 2×10 8CIU
2386046|NCT03668353|Experimental|treatment 2|Recombinant SeV-hFGF2/dF Injection 1×10 9CIU
2386047|NCT03668353|Experimental|treatment 3|Recombinant SeV-hFGF2/dF Injection 5×10 9CIU
2386048|NCT03668353|Experimental|treatment 4|Recombinant SeV-hFGF2/dF Injection 1×10 10CIU
2386049|NCT03668340|Experimental|Part A: AZD1775|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
2386050|NCT03668340|Experimental|Part B: AZD1775 in Carcinosarcoma|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
2386366|NCT03666156||Whole Sample|Female, caucasians, aged 18-65 years
2386051|NCT03668340|Experimental|Part C: AZD1775 in Uterine Serous with biopsiable disease|-AZD1775 will be taken by mouth daily on days 1 through 5 and days 8 through 12 of each 21-day cycle
2386052|NCT03668314|Experimental|Cohort 1:1 - 1:6 RDN-929|RDN-929 single dose capsule
2386053|NCT03668314|Placebo Comparator|Cohort 1:1 - 1:6 placebo|Placebo single dose capsule
2386054|NCT03668314|Experimental|Cohort 2:1|Fed/Fast RDN-929
2386055|NCT03668314|Experimental|Cohort 3:1- 3:4 RDN-929|RDN-929 multiple dose capsules once daily for 12 days
2386056|NCT03668314|Placebo Comparator|Cohort 3:1- 3:4 placebo|placebo multiple dose capsules once daily for 10 days
2386057|NCT03668301||Group CPB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery with cardiopulmonary bypass
2386058|NCT03668301||Group OPCAB-T2DM|Patients with diabetes mellitus undergoing cardiac surgery without cardiopulmonary bypass
2386059|NCT03668301||Group CPB-C|Control patients undergoing cardiac surgery with cardiopulmonary bypass
2386060|NCT03668301||Group OPCAB-C|Control patients undergoing cardiac surgery without cardiopulmonary bypass
2386061|NCT03668288||PID patients|Adults with primary or secondary immunodeficiency for whom human immunoglobulin-assisted recombinant human hyaluronidase treatment is initiated
2386062|NCT03668275|Experimental|Intervention|(partial) oncological home-hospitalization
2386063|NCT03668275|No Intervention|Control|standard oncological ambulatory hospital care
2386064|NCT03668262||0.15mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.
2386065|NCT03668262||0.1mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.15/1.5=0.1 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
2386066|NCT03668262||0.07mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.1/1.5=0.0667 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
2386067|NCT03668262||0.05mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.07/1.5=0.0466( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
2386068|NCT03668262||0.03mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.05/1.5=0.0333 ( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
2386069|NCT03668262||0.02mg/ kg group|Administration method of cis-atracurium: the dose of the first patient is 0.15 mg / kg, and the ratio between adjacent doses is 1.5. 0.03/1.5=0.02( If the laryngeal mask insertion condition of this patient is satisfactory, the next patient will use the lower dose. If the laryngeal mask insertion condition of this patient is not satisfactory, the next patient will use a higher dose. Starting from the first case of dissatisfaction, the number of observation units is counted. Dissatisfaction - satisfaction occurs at 7 exchange points and then the test ends.)
2386070|NCT03668249||All Participants|Participants diagnosed with CD from approximately 12 to 15 investigational sites will be observed retrospectively for previous 5 years.
2386071|NCT03668236|Experimental|Fluid restriction group|"No IV fluids unless one of the extenuating circumstances occur; then, IV fluid may be given in measured amounts:~In case of severe hypoperfusion or severe circulatory impairment defined by either:~Lactate≥4 mmol/L~MAP<50 mmHg (with or without vasopressor/inotrope)~Mottling beyond the kneecap (mottling score >2) OR~Urinary output<0.1 mL/kg bodyweight/h, but only in the first 2hrs after randomisation~A bolus of 250-500 ml of IV crystalloid solution may be given followed by re-evaluation~In case of overt fluid losses (e.g. vomiting, large aspirates,…) IV fluid may be given to correct for the loss, but not above the volume lost.~In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to:~Correct dehydration or electrolyte deficiencies~Ensure a total fluid input of 1L per 24hrs~IV fluids may be given as carrier for medication, but the volume should be reduced to the lowest possible"
2386072|NCT03668236|Active Comparator|Standard-care|"There will be no upper limit for the use of either IV or oral/enteral fluids. In particular:~IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline.~IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid~IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte derangements"
2386073|NCT03668223|Experimental|Promoting Resilience in Stress Management (PRISM)|Resilience Skills Training
2386074|NCT03668223|No Intervention|Usual Care|Standard psychosocial care
2386075|NCT03668210||Patients with contralateral ACL after Ligamentoplasty|"Athletic patients who have consulted in Sports Medicine Department at the Rennes University Hospital, victims of an ACL rupture during sports activity and who declared a contralateral ACL after the ligamentoplasty.~Isokinetic evaluation."
2386076|NCT03668210||Patients without contralateral ACL rupture|"Athletic patients who have consulted in Sports Medicine Department at Rennes University Hospital, without ACL rupture.~Isokinetic evaluation."
2386077|NCT03668171|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2 weeks
2386078|NCT03668171|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 1, 2
2386079|NCT03668158||recurrent HCC|recurrent HCC after LT
2386080|NCT03668158||non-recurrent HCC|non- recurrent HCC after LT
2386081|NCT03668145|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 0.1-1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8 plus UDCA.
2386082|NCT03668145|Placebo Comparator|control|placebo infusions (placebo infusion differs from the experimental infusion in only that placebo has no mesenchymal stem cells) will be administered via peripheral vein at week 0, 4, 8 plus UDCA.
2386083|NCT03668132||Left damage|Have the ischemic brain damage and the location of the damage ,and in the left brain
2386084|NCT03668132||Right damage|Have the ischemic brain damage and the location of the damage ,and in the right brain
2386085|NCT03668132||Normal control|Not have the ischemic brain damage
2386086|NCT03668119|Experimental|Nivolumab + Ipilimumab Combination|
2386087|NCT03668119|Experimental|Nivolumab Monotherapy|
2386088|NCT03668106|Active Comparator|swim up method|Measure volume using a sterile 2 mL pipet.Transfer specimen from a plastic cup to a sterile 15 mL- conical centrifuge tube. Gently mix the specimen with equal volume of Sperm Washing Media. Centrifuge the tubes at 1500 rpm for 10 minutes.Carefully aspirate the supernatant without disturbing the pellet and resuspend the pellet in 50mcm of fresh washing medium, then place layer of 0.5 ml of washing medium gently on the surface. Incubate the tubes at a 45° angle for 1 hour for swim-up in vertical rack in a 37°C incubator. After the incubation period, aspirate the entire supernatant from the round bottom tube. Aliquots of the detached sperm were analyzed by halosperm assay for DNA fragmentation another aliquots of same supernatant were used for ICSI then fertilization, division, blastulation, pregnancy and implantation rates were tabulated and statistically tested.
2386089|NCT03668106|Active Comparator|sperm gradient centrifugation|"PureSperm gradients 40 % and 80 % were used for the experiment. All procedures were conducted under sterile conditions. Using a sterile pipette, 2.0 mL of the lower layer (80% PureSperm gradient) was transferred into a conical centrifuge tube.~Using a new sterile pipette, 2.0 mL of the upper layer (40% PureSperm gradient) was gently dispensed on top of the lower layer. A liquefied semen sample was then placed on top of the upper layer and the tube was centrifuged for 20 minutes at 300g. The upper and lower layers were carefully aspirated without disturbing the pellet. Using a transfer pipette, 2-3 mL of Ham's F10 +10% HAS was added to the pellet and the resuspended pellet was centrifuged for 7 minutes at 300g. The supernatant was then removed and the pellet was suspended in a volume of 0.5 mL of Ham's F10 + FCS 10%. Aliquots of the detached sperm were dealt with like previous arm"
2386090|NCT03668106|Active Comparator|zeta method|"sperm samples were diluted 5 million in 1 ml. To induce a positive charge, the tube was placed inside a latex glove up to the cap and grasping the cap, the tube was rotated two or three turns and rapidly pulled out. Each tube was kept at room temperature for 1 minute to allow adherence of the charged sperm to the wall of the centrifuge tube.~Tubes were hold by the cap to avoid grounding of the tube. After 1 minute the tubes were centrifuged at 200g for 5 minutes. Then, the medium and pellet were discarded in order to discard non adhering sperm and other cells. The surface of tube was washed by 0.2ml of Ham's F10+ FCS 10% in order to neutralize the charge on the wall of the tube and detach the adhering sperm.~The collected medium at the bottom of each tube was repipetted and used to rinse the wall of the same tube several times to increase the number of recovered sperm . Aliquots of the detached sperm were dealt with like previous arm"
2386091|NCT03668093|Experimental|ICCMS|Intervention
2386092|NCT03668093|Active Comparator|CAMBRA|Comparator
2386093|NCT03668080||surgical residents|Surgical specialties included general surgery, plastic surgery, urology, vascular surgery, obstetrics and gynecology, orthopedic surgery, pediatric surgery, cardiothoracic surgery and otolaryngology.
2386094|NCT03668080||non-surgical residents|Non-surgical specialties included cardiology, rheumatology, neurology, pulmonary disease, endocrinology, nuclear medicine, pediatrics, psychiatry, internal medicine, oncology, nephrology, hygiene and preventive medicine, anesthesiology, child and adolescent psychiatry, radiology, radiation oncology, infectious disease, dermatology, pathology, microbiology, hematology, gastroenterology, geriatric medicine, medical genetics, sports medicine, occupational and environmental medicine.
2386095|NCT03668067||2WIN|Accommodation, refraction and ocular alignment are estimated by infrared photoscreener using the 2WIN photoscreener device. Photoscreener screening makes use of light crescent quantification from off-axis flash-to-lens in a camera.
2386096|NCT03668067||school bus skiascopy|Refractive error estimated by child-friendly skiascopy rack holding lenses from +1.00 D to +10.00 D and -5.00 D. Skiascopy is a common, old-fashioned form of retinoscopy.
2386097|NCT03668054|Experimental|Bevacizumab (Lumiere®)|Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
2386098|NCT03668041|Active Comparator|Trazodone|Participants who are assigned to take trazodone, an active study medication.
2386099|NCT03668041|Active Comparator|Eszopiclone|Participants who are assigned to take eszopiclone, an active study medication.
2386100|NCT03668041|Active Comparator|Gabapentin|Participants who are assigned to take gabapentin, an active study medication.
2386101|NCT03668041|Placebo Comparator|Placebo|Participants who are assigned to take a placebo, a non-active study medication.
2386102|NCT03668028|Experimental|TPX-114|Subjects undergo arthroscopic rotator cuff repair with TPX-114.
2386103|NCT03668028|Placebo Comparator|Placebo|Subjects undergo arthroscopic surgery for rotator cuff repair without TPX-114.
2386104|NCT03668015|Experimental|Group A (Xylitol then sorbitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group A used Xylitol gum.(2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group A used Gum Sorbitol"
2386105|NCT03668015|Experimental|Group B (Sorbitol then xylitol gum)|"Subjects were randomly allocated to a group and entered a 4-week washout period during which no gum was chewed, followed by a 3-week treatment period (treatment period 1) during which Group B used sorbitol gum. Group B used Gum Sorbitol (2 gum pieces, 3 times daily after meals for 6 minutes).Then underwent another 4-week washout period before entering treatment period 2 during which Group B used Gum xylitol"
2386106|NCT03668002|Placebo Comparator|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
2386107|NCT03668002|Active Comparator|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
2386108|NCT03667989|Other|123I-MIBG CZT SPECT|Patients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
2386109|NCT03667976|No Intervention|Control Group|All participants in the control group will receive a study pedometer and a physical activity logbook. Participants will also receive the Canadian Society of Exercise Physiology/ParticipACTION physical activity guidelines for adults ages 18 to 64.
2386110|NCT03667976|Experimental|Intervention Group|All participants in the intervention group will receive a study pedometer and a physical activity logbook. Participants will also receive the South Asian women Together in a Health Initiative (SATHI) intervention which consists of a gender and culturally specific South Asian physical activity education booklet and video and 2) a matched peer. Peers will encourage physical activity and provide motivation and suggestions for incorporating physical activity into daily life of a South Asian woman based on Bandura's Self-Efficacy construct. Peer contact will occur via telephone, text/email messaging or in person at least once weekly and more often as determined by participants.
2386111|NCT03667963|Other|Low Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
2386112|NCT03667963|Other|High Salivary Amylase Activity|Glucose Glucose plus lactulose Hot Rice Cold Rice
2386113|NCT03667950|Experimental|hyperspectral imaging|diagnostic hyperspectral Imaging of the gastrointestinal anastomosis and calculating the anastomotic Perfusion measures
2386114|NCT03667937|Experimental|CUTIMED|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply the CUTIMED dressing. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~If the wound exudate decreases, or the removal of the dressing is difficult, it will be changed to CUTIMED gel; in case of abundant exudate, the use of alginate without silver will be allowed for the treatment, because it is neutral with the bacterial load, placed on the CUTIMED dressing.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
2386115|NCT03667937|Active Comparator|AQUACEL silver|"After an initial culture to determine the bacterial load by smear, we will proceed to the cure of the ulcer by washing the area with physiological saline solution and to mechanical debridement, if necessary, to apply Aquacel-Ag. It will be covered with a secondary gauze dressing and a double compression bandage with a normal crepe bandage.~Primary and secondary end-points will be measured at baseline and at 4, 8 and 12 weeks, except quality of life (only baseline and at 12 weeks)."
2386116|NCT03667924|Experimental|PorchLight Project Intervention Group|Participants in the intervention group will receive home-based support and respite services from PorchLight Project trained Senior Companion volunteers of the Lutheran Social Services of Minnesota.
2386117|NCT03667911|No Intervention|Control Group|Only routine patient education on bowel preparation of colonoscopy. Give oral instructions on bowel preparation(including definition, significance, correct steps as well as dietary limitations) by a well-trained nurses or doctors. Written instructions are offered, which have the some contents.
2386118|NCT03667911|Experimental|Virtual-reality Group|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
2386119|NCT03667898|Experimental|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
2386120|NCT03667898|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided lumbar plexus block.
2386121|NCT03667885||Small renal Masses|patients with a renal mass of 4 cm or less. Typically incidentally found. Blood and urine samples will be collected from each patient at baseline before a biopsy of the tumor is collected and 14 days later. In addition, all patients will be offered a Multi planar MRI before the biopsy. Patients elected for curative treatment for malignant tumors will have another set of blood and urine samples collected at 1 month and 6 months after the intervention.
2386122|NCT03667872|Experimental|Device|MRI compatible and LFP recordable implantable stimulator
2386123|NCT03667859||Women undergoing Brachytherapy|Women with either uterine or cervical malignancy treated primarily by brachytherapy.
2386124|NCT03667859||Women undergoing Pelvic Radiation|Women with either uterine or cervical malignancy treated primarily by pelvic radiation.
2386127|NCT03667833|Experimental|shoulder brace with comfortable tension|"Self-comfortable tension of strap will be adjusted by subject's feedback with comfortable feeling as please feel postural correction by shoulder brace without tight pressure."
2386128|NCT03667833|Experimental|shoulder brace with forced tension|Forced tension, the self-comfortable tension of strap will be increased till forced tension of strap using buckles.
2386129|NCT03667820|Experimental|Osimertinib|Osimertinib in combination with Stereotactic Ablative Radiation (SABR)
2386130|NCT03667807|Experimental|rTMS condition 1|
2386131|NCT03667807|Experimental|rTMS condition 2|
2386132|NCT03667807|Experimental|rTMS condition 3|
2386133|NCT03667794||PH patients|Patients with known or first diagnosis of PH
2386134|NCT03667794||healthy controls|Healthy controls had normal lung function testing including whole-body plethysmography and transfer factor, no previously diagnosed pulmonary disease as well as no respiratory symptoms.
2386135|NCT03667794||non-healthy controls|Non-healthy controls were allowed to have stable pulmonary comorbidities including chronic obstructive pulmonary disease (COPD), sarcoidosis, asthma, or fibrosis as well as non-pulmonary comorbidities.
2386136|NCT03667781||Patients Interviewed|Patients in cardiology clinic with uncontrolled hypertension despite being on 2 medications
2386137|NCT03667781||Providers Interviewed|Providers in cardiology clinic
2386138|NCT03667781||Patients Blood Draw|Patients seen in interventional clinic for post PCI followup will have a venous blood draw which will be sent for therapeutic drug monitoring
2386139|NCT03667768|Experimental|Glass ionomer sealant|Two hand-mixed glass ionomer cements (GICs) available in the dental market were used, and they were mixed according to the manufacturer's instructions (powder/liquid ratio 1:1). The molars were cleaned with a toothbrush and wet cotton wool pellets. Isolation was performed with cotton wool rolls and the occlusal surface was conditioned with GIC liquid (20s), rinsed with wet cotton wool pellets and dried with dry cotton wool pellets. GIC was placed on the occlusal surface and pressed into the pits and fissures using the press-finger technique. The excess of material was removed and the occlusion checked and adjusted. Sealant was protected with a new layer of petroleum jelly and the children were instructed not to eat for at least one hour. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
2386140|NCT03667768|Other|Non-sealant (toothbrushing)|No sealant was performed. Children received instructions on how to brush their teeth (1,000-ppm fluoridated dentifrice), as well as advices regarding diet and information about dental caries was given by a dental assistant and those instructions were repeated every 6 months.
2386141|NCT03667755|Experimental|fast track recovery|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Subjects are given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3 hours prior to operation drink) of a lactose-free clear tea-colour fruit flavoured fluid contains 14% whey protein, 86% carbohydrates and 0% lipids. Participants fast for solids for 6 hours from the operation. Participants will be given clear fluid (2 packs Resource peach) within 24 hours post-surgery (without present of bowel sound) and reviewed by dietitian. Staff nurse in-charged will monitor anesthetic risk of drinking whey protein and ensure subject to finish specific drinks prior surgery. When they tolerated at least 500ml of clear fluids, they were given a regular solid diet.
2386142|NCT03667755|No Intervention|conventional|Participants will attend dietitian clinic to have anthropometry & dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
2386143|NCT03667729|Experimental|progressive muscle relaxation|The experimental group received PMR once a week for a total of 12 weeks. Subjects completed measures at baseline, 3-month, and 3-month follow-up.
2386144|NCT03667729|No Intervention|Control group|treatment-as-usual(TAU)
2386145|NCT03667716|Experimental|P1a Arm A (Monotherapy Dose Escalation).|COM701 monotherapy sequential dose escalation administered IV every 3 weeks and a Cohort IV every 4 weeks. Up to 8 dose escalation cohorts may be evaluated until a maximum tolerated dose or recommended phase 2 dose is identified.
2386146|NCT03667716|Experimental|P1a Arm B (Combination Dose Escalation).|COM701 sequential dose escalation administered IV every 3 weeks in combination with Opdivo (Nivolumab) 360mg administered IV every 3 weeks and COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480mg administered IV every 4 weeks.
2386147|NCT03667716|Experimental|P1a Arm A (Monotherapy Expansion).|COM701 monotherapy administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (NSCLC, Breast, Ovarian, Endometrial and Colorectal cancer).
2386148|NCT03667716|Experimental|P1b (Combination Cohort Dose Expansion).|COM701 administered IV every 4 weeks in combination with Opdivo (Nivolumab) 480 mg administered IV every 4 weeks. Cohort expansion in subjects with the following select tumor types (Breast, Ovarian, Endometrial and Colorectal cancer).
2386149|NCT03667703|Placebo Comparator|Placebo|Subjects randomized to placebo will receive an equivalent volume (mL) of normal saline intravenously or Ora-plus orally based on weight and age.
2386150|NCT03667703|Active Comparator|Study Drug|Subjects randomized to study drug will receive famotidine, a histamine-2 receptor antagonist. Dosing will be weight based and age-dependent. Infants < 90 days old will receive either 0.5mg/kg intravenously daily or 0.5mg/kg orally twice a day of famotidine. Infants ≥ 90 days or older will receive 0.25mg/kg intravenously every 12 hours or 0.5mg/kg orally twice a day.
2386151|NCT03667690|Experimental|Group 1: Rezafungin for Injection|"Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses.~Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day."
2386152|NCT03667690|Active Comparator|Group 2: Caspofungin|"Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met.~If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind."
2386153|NCT03667677|Experimental|Group 1|Tandospirone + Amlodipine
2386154|NCT03667677|Experimental|Group 2|Tandospirone placebo + Amlodipine
2386155|NCT03667677|Experimental|Group 3|Tandospirone + Amlodipine placebo
2386156|NCT03667677|Placebo Comparator|Group 4|Tandospirone placebo + Amlodipine placebo
2435045|NCT03332381|Active Comparator|Attention training technique|
2386157|NCT03667664|Other|Prevention of loss of autonomy|Lifestyle counseling for elderly people about physical exercises and nutrition in a preventive way
2386158|NCT03667651|Active Comparator|Twice daily use treatment with EpiCeram|They will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for 6 months. The prophylactic use of EpiCeram™ is the intervention that is being tested for its effect on infant skin barrier function. We will instruct parents to apply approximately 6 grams of EpiCeram™ per application at two regular times each day, including after bathing the infant, or at the time they would normally bathe their child.
2386159|NCT03667651|No Intervention|Standard skin care|Parents are to follow standard skin care practices
2386160|NCT03667638|Experimental|PRP Intervention|PRP injection into wound border
2386161|NCT03667625|Experimental|Aquatic group|Aquatic multidimensional mobility exercises were given in the treatment pool at Balcova Thermal Centre, Izmir, Turkey. Group of 6-7 patients was instructed by a specialized physiotherapist twice in a week for eight weeks. The water temperature was 33-340C and the depth was between 110-140 cm, patients were asked to keep T11 level submersion during vertical exercises. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
2386162|NCT03667625|Experimental|Land group|Multidimensional mobility exercises were given at exercise unit of Dokuz Eylul University School of Physical Therapy, Izmir, Turkey. Group of 6-7 patients were instructed by a specialized physiotherapist twice in a week for eight weeks. The room temperature was 23-240C. Exercise span was kept 30-40 min in first 4 weeks then increased to 45-50 min with additional exercises.
2386163|NCT03667625|Active Comparator|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks.
2386164|NCT03667612||Patients with breast cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres~Realization of tumor samples series of cuts and paraffin shavings for:~Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
2386165|NCT03667612||Patients with colorectal cancer|"Patients clinical data collection~Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments~Realization of series of cuts and paraffin shavings of the tumor samples for:~Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin~Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)~Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)~Characterization of lymphocyte populations~Measurement of the endothelial cell density, the lymphatic endothelium and the High Endothelial Venules"
2386166|NCT03667599|Experimental|Home care|This is the arm for patients who receive their transplant care in their homes.
2386167|NCT03667599|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
2386168|NCT03667599|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
2386169|NCT03667586|Experimental|Group Cognitive Behavioral Therapy|Cognitive behavioral psychotherapy sessions will be conducted at an appropriately accommodated office of the Psychiatry Department in groups of 6-10 patients and will be coordinated by a qualified psychologist of the research team. Each session will be of 90 minutes duration. The initial two sessions will be psycho-educational and the remaining sessions will be based on the principles of Cognitive Behavioral Therapy (CBT). In total, the psychotherapeutic intervention will last for 6 months with participants attending weekly sessions for the first 3 months and monthly follow-up sessions for the next 3 months.
2386170|NCT03667586|Placebo Comparator|Standard care|Regular brief follow-ups by the gastroenterologists and the nurse of the research team
2386171|NCT03667573|Experimental|tsDCS Dosage A and textured insoles|"tsDCS dosage A and textured shoe insoles"
2386172|NCT03667573|Experimental|tsDCS Dosage B and textured insoles|"tsDCS dosage B and textured shoe insoles"
2386173|NCT03667573|Experimental|tsDCS Dosage A and smooth insoles|"tsDCS dosage A and smooth shoe insoles"
2386174|NCT03667573|Experimental|tsDCS Dosage B and smooth insoles|"tsDCS dosage B and smooth shoe insoles"
2386175|NCT03667560|Experimental|Dermacell ADM without basement membrane|Dermacell ADM without a basement membrane
2386176|NCT03667560|Active Comparator|FlexHD|FDA-approved FlexHD Pliable
2386178|NCT03667521||non-nerve-sparing laparaoscopic sacrocolpopexy.|
2386179|NCT03667521||nerve-sparing laparaoscopic sacrocolpopexy.|
2386180|NCT03667508|Experimental|Rapid Maxillary Expansion|Patients will undergo Rapid Maxillary Expansion using a rapid maxillary expanding device, i.e. a Hyrax expander (modified by McNamra).
2386181|NCT03667508|Active Comparator|Slow Maxillary Expansion|Patients will undergo Slow Maxillary Expansion using a slow maxillary expanding device, i.e. a removable appliance with a central screw.
2386182|NCT03667495||Relapse|Patients who suffered colorectal cancer or adenoma relapse after curative surgery
2386183|NCT03667495||Remission|Patients who get remission after curative surgery
2386185|NCT03667469|Experimental|Stapleless one anastomosis gastric bypass|Laparoscopic stapleless-separated one anastomosis (mini-) gastric bypass procedures
2435046|NCT03332381|Active Comparator|Mindful self-compassion|
2386186|NCT03667469|Active Comparator|Staple use mini-gastric bypass|Laparoscopic stapler-separated one anastomosis (mini-) gastric bypass procedures
2386187|NCT03667469|Active Comparator|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
2386188|NCT03667456|Experimental|Self-rehabilitation by digital support|"Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.~Monitoring and regulation of remote self-reeducation by tele-reeducation. Evaluation of the acceptance of the tool and the quality of life of the patients by questionnaire at day 0, and two and twelve months after."
2386189|NCT03667443|Active Comparator|Myo-inositol plus folic|
2386190|NCT03667443|Active Comparator|Myo-inositol + folic a. + α-lactalbumin|
2386191|NCT03667430|Experimental|Normal weight subjects|Healthy normal weight (BMI 20-25) men 18-35 year. Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 Total study time 21 days
2386192|NCT03667430|Experimental|Subjects with obesity|Obese otherwise healthy men (BMI 30-45) 18-35 year Intervention: The participants will take placebo or silica powder with specified doses administrated in vials and with instructions to mix with water as; Placebo (microcrystalline cellulose) day 1-5 Porous silica 1gx3 daily for day 6-9 Porous silica 2gx3 daily for day 10-14 Porous silica 3gx3 daily for day 15-21 The dose of Silica 3gx3 for additional 10 weeks Total study time 84 days
2386193|NCT03667417||subjects carrying a BRCA gene mutation|subjects carrying a BRCA gene mutation
2386196|NCT03667378||supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinician
2386197|NCT03667378||without supportive care visits|A concurrent supportive care intervention (intervention arm) Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).intervention arm will have at least monthly visits with a supportive care clinicianTo receive the investigational cancer treatment alone (control arm) no monthly visit with a supportive care clinician.
2386198|NCT03667365|Experimental|aortic valve replacement|
2386199|NCT03667365|Active Comparator|strict clinical surveillance|
2386200|NCT03667352|Experimental|Scalp & TAP Block (Group T)|Group T received 0.2% Ropivacaine + clonidine 1µg/kg mixture, for ipsilateral scalp block (10ml),TAP block under USG guidance (20ml) and intravenous saline 0.1ml/kg/hr (sham infusion) for continuous infusion.
2386201|NCT03667352|Active Comparator|Intravenous Fentanyl (Group C)|Group C received saline, for ipsilateral scalp block (10ml) and TAP block under USG guidance (20ml) and I.V fentanyl 1 µg/kg/hr as analgesic.
2386202|NCT03667339||outpatients group|Patient schedulded to undergo outpatient Direct Anterior Total Hip Arthroplasty
2386203|NCT03667339||inpatients group|Patient schedulded to undergo inpatient Direct Anterior Total Hip Arthroplasty
2386204|NCT03667326|Active Comparator|Low-Dose Aspirin (LDA) Intervention Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take 81mg of aspirin daily for up to 3 weeks postpartum, starting within 4 days after delivery.
2386205|NCT03667326|Placebo Comparator|Placebo Control Group|Subjects diagnosed with severe preeclampsia prior to delivery (antepartum or intrapartum) will take placebo oral capsule daily for up to 3 weeks postpartum, starting within 4 days after delivery.
2386206|NCT03667313|Experimental|sirolimus-eluting balloon (SEB)|treatment of bare-metal (BMS) or drug-eluting in-stent restenosis (DES-ISR) with SEB
2386207|NCT03667313|Active Comparator|paclitaxel-eluting balloon (PEB)|treatment of BMS- or DES-ISR with PEB
2386208|NCT03667300|Active Comparator|Evogliptin Group|Intervention group will take daily evogliptin 5mg per oral, not linagliptin 5mg per oral
2386209|NCT03667300|Active Comparator|Linagliptin Group|Control group will take daily linagliptin 5mg per oral, not evogliptin 5mg per oral
2386210|NCT03667287|Experimental|Full-thickness skin graft|Repair of parastomal hernia with full-thickness skin graft, placed intraperitoneally, as reinforcement.
2386211|NCT03667287|Active Comparator|Synthethic mesh|Repair of parastomal hernia with best available conventional method, using synthetic mesh material as reinforcement
2386212|NCT03667261|Active Comparator|cover screw|extraction of hopeless mandibular molars followed by immediate implants that will be covered using cover screw
2386213|NCT03667261|Experimental|sealing socket abutment|extraction of hopeless mandibular molars followed by immediate implants that will be covered using sealing socket abutment
2386214|NCT03667222|Experimental|BPX-04 Active|BPX-04 1% minocycline topical gel
2386215|NCT03667222|Placebo Comparator|BPX-04 Vehicle|BPX-04 topical gel vehicle
2386216|NCT03667209|Experimental|Traditional exercise and pain neuroscience education|Will include exercises of the neck and scapular regions using traditional methods and pain neuroscience education
2386217|NCT03667209|Active Comparator|Suspension exercise and pain neuroscience education|Will include suspension exercises of the neck and scapular regions using traditional methods and pain education.
2386218|NCT03667196||Observational|
2386219|NCT03667183|Experimental|Pilates Group|Female adolescents with eating disorders who receive Pilates for 10 weeks.
2386220|NCT03667170|Experimental|Cohort1: MSI-H Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
2386221|NCT03667170|Experimental|Cohort2: dMMR Non-Colorectal Cancer|Cohort 1 patients receive KN035 150 mg Subcutaneously on Day 1, 8, 15, 22 of every 4-week cycle (Q4W)
2386222|NCT03667157|Active Comparator|moderate-to-severe Graves Orbitopathy|active, moderate-to-severe Graves Orbitopathy according to EUGOGO.
2386223|NCT03667157|Active Comparator|Dysthyroid Orbit Neuropathy|Dysthyroid Orbit Neuropathy according to EUGOGO
2386224|NCT03667131|Experimental|Enalapril Maleate|Enalapril Maleate 5 mg every 12 hrs for 90 days.
2386225|NCT03667131|Experimental|Placebo|Substance that lacks in itself therapeutic action.
2386226|NCT03667118|Experimental|Food Supplement|Infants who received the active food supplement powder
2386227|NCT03667118|Placebo Comparator|Placebo|Infants who received the placebo powder
2386228|NCT03667105|Experimental|CAF+XDM|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous dermal collagen matrix graft (AXDM - Mucoderm®, Botiss,) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
2386229|NCT03667105|Experimental|CAF+MC|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Mucograft®, Geistlich Pharma) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
2386230|NCT03667105|Active Comparator|CAF|CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Then, the flap will be coronally positioned and sutured to completely cover the graft. This group will be the control group.
2386231|NCT03667092|Experimental|Non-drug intervention type|"Exploration of gene transcript variation on seriate blood samples before treatment, before and after the 2nd and the 4th Lu-Dotatate injection and before and after the 6 month post treatment follow-up.~Measures of stability and reproducibility of selected gene transcripts and miRNA as radio sensitivity genes or progressive metastatic midgut neuroendocrine tumors genetic signatures before and during Lu-177 Dotatate internal vectorized therapy, as well as on the 6-month follow-up."
2386232|NCT03667079|Experimental|Integrated|Intervention 'integrated delivery of deworming and vaccination' will be delivered to this arm of the study
2386233|NCT03667079|Active Comparator|Deworming only|Intervention 'Mass deworming only' will be delivered to villages in this arm of the study
2386234|NCT03667079|Active Comparator|Rabies vaccination only|Villages assigned to this arm received mass vaccination of dogs against rabies only
2386238|NCT03667040|No Intervention|Control Group|75 participants will take part in three visits (baseline, 30days and 60days)
2386239|NCT03667040|Active Comparator|Intervention|75 participants will take complete a baseline visit and then participate in the intervention. They will use the application, the JOOL app for 30 days. Then complete surveys at 30days and 60days after the interventions
3142844|NCT00003588|Experimental|Arm I|Patients undergo laparoscopy for p53 assessment and catheter placement. Patients receive daily intraperitoneal injections of adenovirus p53 (Ad-p53) for 5 days every 3 weeks. Treatment is repeated every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each are treated at each dose level of Ad-p53. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity.
3142845|NCT00003591|Experimental|Pacilitaxel + External Beam Radiation Therapy (PXRT)|Paclitaxel 50 mg/m2 given on Days 1, 8, 15, 22, 29 and 36. Radiation therapy: 50.4 Gy/28 fractions (1.8 Gy per fraction) once a day in 5.5 weeks.
2386243|NCT03667014|Experimental|Dupilumab treatment|30 subjects will receive dupilumab for a treatment period of 52 weeks. All patients quality of life measures will be assessed with Psychological General Well-Being scale (PGWB), Work Productivity and Activity Impairment scale (WPAI), and Dermatology Life Quality Index (DLQI). Symptom and satisfaction will be assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), Itch Numerical Rating Scale, Pain Numerical Rating Scale, and Pittsburgh Sleep Quality Assessment (PSQI).
2386244|NCT03667001|Experimental|Lidocaine Hydrochloride|"1.5 mg/kg lean body mass lidocaine (lidocaine 1%) bolus I.V. as general anesthesia steady state concentration is accomplished~1.5 mg/kg lean body mass/h lidocaine I.V. with beginning of surgical procedures~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: lidocaine infusion up to four hours from completion of surgery, or till transfer to surgical ward"
2386245|NCT03667001|Placebo Comparator|Saline Solution|"0.15 ml/kg lean body mass saline 0.9% bolus I.V. as general anesthesia steady state concentration is accomplished~0.15 ml/kg lean body mass/h saline 0.9% I.V. with beginning of surgical procedure~after completion of surgery: transfer to PACU, pain evaluation for 48 hours~duration of intervention: saline infusion up to four hours from completion of surgery, or till transfer to surgical ward"
2386246|NCT03666988|Experimental|Part 1: GSK3368715 dose escalation|Eligible participants with solid relapsed/refractory tumors will receive escalating doses of GSK3368715 at a starting dose of 50 mg, administered orally once daily.
2386247|NCT03666988|Experimental|Part 1: GSK3368715 PK/PD/Metabolite/Biomarker|Additional participants in Part 1, treated at or close to the expected the maximum tolerated dose (MTD)/RP2D, will be evaluated for metabolic and biomarker profiling. Participants may be enrolled into this cohort(s) even after MTD/RP2D has been identified and Part 2 has been initiated.
2386248|NCT03666988|Experimental|Part 1: GSK3368715 Food effect|Eligible participants will receive single dose of GSK3368715 at starting dose of 50 mg tablet orally in fasted state followed by fed state in Period 1 and Fed followed by fasted state in Period 2.
2386249|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion - DLBCL participants|Eligible participants with relapsed/refractory DLBCL will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
2386250|NCT03666988|Experimental|Part 2:GSK3368715 dose expansion-solid tumor participants|Eligible participants with relapsed/refractory solid tumors (pancreas cancer, NSCLC, and bladder cancer) will receive RP2D of GSK3368715 established during Part 1, administered orally once daily.
2386251|NCT03666975|Experimental|LIV 30 Hz, 0.4 g|LIV 30 Hz, 0.4 g Low intensity vibration to short leg 3x / week x 10 wks
2386252|NCT03666975|Experimental|LIV 30 Hz, 1.0 g|LIV 30 Hz, 1.0 g Low intensity vibration to short leg 3x/week x 10 wks
2386253|NCT03666962||case group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
2386254|NCT03666962||control group|According to the scores of MGLS, compliance was divided into three groups: A score of 0 indicated high compliance; a score of 1 or 2 illustrated intermediate compliance; and a score of 3 or 4 indicated low compliance.
2386255|NCT03666949|Other|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
2386256|NCT03666949|Other|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
2386257|NCT03666936|Experimental|Intervention|Social-health care intervention
2386258|NCT03666923|Experimental|THR-687 dose level 1|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1
2386259|NCT03666923|Experimental|THR-687 dose level 2|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2
2386260|NCT03666923|Experimental|THR-687 dose level 3|Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3
2386261|NCT03666910||children of rheumatic diseased mothers not on treatment|
2386262|NCT03666910||children of rheumatic diseased mothers on antimalarial drugs|
2386263|NCT03666910||children of normal mothers|
2386264|NCT03666897|Other|DTI Outcomes and Biomarkers|Imaging and Lab Collection
2386265|NCT03666884|Active Comparator|dry eye patients 1|dry eye patients treated for 1 month and patient symptoms after 1 month
2386266|NCT03666884|Active Comparator|dry eye patients 2|dry eye patients treated for 1 month and patient symptoms after 1 month
2386270|NCT03666845||Sciatic nerve block|Patients scheduled for foot and ankle surgery under sciatic nerve block and who had chronic kidney disease
2386271|NCT03666832|Experimental|Arm1|TEW-7197 100mg will be administered orally once a day 5days and rest 2days. Study treatment will be continued until objective disease progression.
2386272|NCT03666819|Experimental|Treatment (carbon dioxide fractional laser)|Participants undergo carbon dioxide fractional laser therapy over 10-15 minutes on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2386273|NCT03666806|Experimental|Influenza vaccine|Influenza vaccine: An inactivated influenza vaccine (split virion) shall be used during the study. The product information is attached as an appendix to the proposal. Brief description of the type of influenza vaccine to be used for the study, mechanism of action, dose justification, efficacy, safety and its use in the population.
2386274|NCT03666806|Placebo Comparator|Normal saline|Placebo: Placebo will be normal saline which shall be prepared by the pharmacist for injection by the immunization nurse in a similar syringe as the investigational product.
2386275|NCT03666793|No Intervention|Control|Standard healthcare procedures
2386276|NCT03666793|Experimental|experimental: Reconciliation group|medical reconciliation at admission, multidisciplinary medication review, medical reconciliation at discharge of the hospital
3142846|NCT00003593|Experimental|Arm A: TMD patients only|Patients are observed if their transient myeloproliferative disorder (TMD) does not require intervention. Patients who require therapy for TMD undergo leukapheresis or exchange transfusion for up to 3 consecutive days. If the TMD does not resolve or there is significant organ involvement, patients receive low-dose cytarabine IV continuously on days 0-4. Treatment repeats at least every 2 weeks for up to 4 courses. Patients who experience a recurrence of TMD at least 8 weeks after resolution or have refractory disease may proceed to group II for further treatment. patients will continue to be followed for remission induction, EFS, DFS and OS regardless of the type of leukemia that develops.
2386278|NCT03666767||Oesophageal atresia (OA) +/- tracheo-oesophageal fistula (TOF)|
2386279|NCT03666767||Congenital diaphragmatic hernia (CDH)|
2386280|NCT03666767||Intestinal atresia (IA)|
2386281|NCT03666767||Gastroschisis|
2386282|NCT03666767||Exomphalos|
2386283|NCT03666767||Anorectal malformation (ARM)|
2386284|NCT03666767||Hirschsprung's disease|
2386287|NCT03666728|Experimental|SHR-1210+BP102|Subjects receive SHR-1210 200 mg and BP102 15 mg/kg in day 1 intravenously every 3 weeks, until disease progression or unacceptable toxicity.
2386288|NCT03666715||Participants with Schizophrenia|Participants diagnosed with schizophrenia who switched from oral antipsychotics (OAPs) to Paliperidone Palmitate 1-month formulation (PP1M), with available information concerning the annual schizophrenia-related hospitalizations before and after initiation of PP1M treatment, and who switched to PP1M at least 6-months after it was available for reimbursement in Portugal will be observed. The primary data source for this study will be the medical records of each participant.
2386367|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant NSCLC|
2386289|NCT03666702|Experimental|Upper limb physiotherapy programme|A progressive, individualised four week upper limb physiotherapy intervention programme delivered via web-based physiotherapy lasting up to 30 minutes/session, five times per week + usual care.
2386290|NCT03666702|Active Comparator|Usual care|An average of 4 to 5 physiotherapy sessions per week, lasting approximately 45 minutes each.
2386291|NCT03666689||MHV reconstruction|Both ends of middle hepatic vein tributaries V8 and/or V5 of modified right lobe graft will be anastomosed to side of a single synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice.
2386292|NCT03666689||Separate tributaries reconstruction|End of V8 middle hepatic vein tributary of modified right lobe graft; if present, will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's middle/left hepatic vein orifice, and end of V5; if present; will be anastomosed to end of a synthetic graft which will be anastomosed to recipient's Inferior Vena Cava directly.
3183426|NCT00713843|Active Comparator|2 Physical Therapy - Exercise Therapy|"The physical therapist conducts a complaint related function examination. Treatment consist of active exercises, manual traction or stretching and massage. The aims of active exercises are improvement of strength, mobility and movement coordination. Specific mobilization techniques are not a part of physiotherapeutic treatment. Treatment sessions take place no more than twice a week with a maximum of nine sessions (approximately 30 minutes) with a minimum of twenty minutes on active exercise therapy combined with instruction.~To prevent overlap with MTU (experimental arm), physical therapists are selected who are not (also) trained as manual therapists or have started this education.~The physical therapist has at least five years of working experience."
2386300|NCT03666650|Other|Rotem|
2386301|NCT03666624|Experimental|Personalized care network|9 60-minute virtual sessions for 6 weeks plus personalized exercise coaching once a week for 6 weeks
2386302|NCT03666624|No Intervention|Routine medical care|No intervention
2386303|NCT03666598|No Intervention|No tourniquet|No use of tourniquet during surgery
2386304|NCT03666598|Experimental|Tourniquet|Use of tourniquet during surgery. The cuff will be inflated to 300mmHg
2386305|NCT03666585|Active Comparator|mobile application actuated rehabilitation exercise guidance|
2386306|NCT03666585|Active Comparator|routine rehabilitation exercise guidance|
2386307|NCT03666572|Active Comparator|B. infantis alone (Bif) in SAM infants|B. infantis alone (Bif) in Severe Acute Malnourished infants
2386308|NCT03666572|Active Comparator|B. infantis + prebiotic Lacto-N-neotetraose [LNnT]|B. infantis + prebiotic Lacto-N-neotetraose [LNnT] (Bif+prebiotic) in Severe Acute Malnourished infants
2386309|NCT03666572|Placebo Comparator|Placebo (Lactose)|Placebo (Lactose) in Severe Acute Malnourished infants
2386310|NCT03666572|Active Comparator|B. infantis alone (Bif) in Not SAM Infants|B. infantis alone (Bif) in not Severe Acute Malnourished infants
2386311|NCT03666559|Experimental|Azacitidine|Azacitidine is administered by sub-cutaneous injection at 75 mg/m2 per day for seven consecutive days every 4 weeks until progression, intolerance or end of the study.
2386312|NCT03666546|Experimental|Laevolac crystals 20 g|Lactulose crystals, oral intake, 20 g single dose
2386313|NCT03666546|Experimental|Laevolac crystals 30 g|Lactulose crystals, oral intake, 30 g single dose
2386314|NCT03666546|Experimental|Laevolac liquid 20 g|Lactulose liquid, oral intake, 20 g single dose
2386315|NCT03666546|Experimental|Laevolac liquid 30 g|Lactulose liquid, oral intake, 30 g single dose
2386316|NCT03666546|Active Comparator|Glucose 30 g|Glucose Monohydrate, oral intake, 33 g single dose
2386317|NCT03666546|Placebo Comparator|Water|Still water, oral intake, 250 mL single dose
2386318|NCT03666533|Active Comparator|Active tDCS|active tDCS plus gait training
2386319|NCT03666533|Sham Comparator|Sham tDCS|sham tDCS plus gait training
2386320|NCT03666520||Control Group|Clinician not prompted to change the drug from intravenous to oral equivalent.
2386321|NCT03666520||Cohort with clinician being prompted to convert drug|This arm would include the provider being prompted to change the intravenous drug to the oral equivalent.
2386322|NCT03666507||Brain stem associated tumors|Brain stem associated tumors
2386323|NCT03666507||Tumors without brain stem assocation|Tumors without brain stem assocation
2386324|NCT03666494|Active Comparator|Control Arm|As part of the patient's anesthetic induction, they will receive propofol and fentanyl.
2386325|NCT03666494|Active Comparator|Ketamine Arm|As part of the patient's anesthetic induction, they will receive propofol, fentanyl, as well as ketamine hydrochloride.
2386326|NCT03666481|Experimental|MPAI group|Patients in this group participated in a 6-months Motivational Physical Activity Intervention (MPAI) to explore its effects on different variables related to PA levels and psychosocial aspects of life of bariatric patients. Concretely, the fundamental goals of the MPAI group were three: to increase the self-determined forms of motivation of the patients towards exercise or reduce those related to non-self-determined motivation; to improve post-operative levels of PA with respect to pre-operative levels, and; transfer the benefits of the intervention on different variables related to the perceived health-related quality of life.
2386327|NCT03666481|No Intervention|Control group|Patients in this group did not participate in any intervention, but the same measurements were made in them as in the MPAI group in the same temporal spaces.
2386328|NCT03666468|Experimental|PlayMed|"PlayMed, a highly immersive role-playing computer game~- Focus on Paediatric Asthma and Seizure management"
2386329|NCT03666468|Active Comparator|Online Package (OP)|"Online package (OP) of NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
2386330|NCT03666468|Placebo Comparator|Paper Guidelines|"Paper NSW Health Guidelines~- Focus on Paediatric Asthma and Seizure management"
2386331|NCT03666455|Experimental|Acceptance and Commitment Therapy|The intervention consists of eight individual (one-on-one) acceptance and commitment therapy sessions approximately one week apart over a 12-week period.
2386332|NCT03666442|Experimental|chemotherapy group|patients receive 4 cycles of Xelox
2386333|NCT03666429|Active Comparator|Bulb suction|Patients in this arm will be given bulb suction to treat nasal congestion. This group will contain participants who have used bulb suction in the past.
2386334|NCT03666429|Experimental|NoseFrida|Patients in this arm will be given the NoseFrida to treat nasal congestion. This group will contain participants who will trial the NoseFrida in the emergency department.
2386335|NCT03666416|Experimental|Sprint Interval Training|Participants will be scheduled for two in-lab experimental appointments: sprint interval training (SIT) and Non-SIT. During the SIT appointment, the researcher will lead the participant through a set of stretches and three minutes of low-intensity cycling on a Schwinn AD2 Airdyne leg-cycling and arm-cranking ergometer to warm up and increase blood flow to active muscles. Participants will then complete 16 minutes of SIT, consisting of eight bouts of 20 seconds of cycling followed by 100 seconds of rest. Participants will complete computer-based tests of sustained attention and working memory during both the SIT (15 minutes following the exercise) and Non-SIT appointments.
2386336|NCT03666403|Experimental|Patients|This prospective one-year study enrolled consecutive 30 children of ≤3 years-old with suspected major airway diseases and therefore scheduled for diagnostic FB. During FB, PIP measurements and associated lumen images were obtained at six airway locations using three studied NIV modes, including 1) NIV rate: 0/min, 2) NIV rate: 10-20/min, 3) NIV rate: 5-10/min.
2386337|NCT03666390|Experimental|0.5mg/kg Ketamine|Anesthesia
2386338|NCT03666390|Active Comparator|0.045mg/kg Midazolam|Benzodiazepine
2386339|NCT03666377|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
2386340|NCT03666377|Experimental|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
2386341|NCT03666364|Experimental|Magnetic nanoparticle selection for teratozoospermia|
2386342|NCT03666364|No Intervention|Density gradient centrifugation for teratozoospermia|
2386343|NCT03666351|Experimental|The intensive care group|"The intensive care group is targeted at ≤ 130 mmHg of systolic blood pressure, and treatment is done by changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
2386344|NCT03666351|Experimental|The usual care group|"The usual care group is targeted at ≤ 140 mmHg of systolic blood pressure, and treatment is done by maintaining the current treatment, adding the investigational product, or changing the current treatment to the investigational product.~In case of treatment with the investigational product (IP), the IP titration period is total six months. According to an IP titration scheme(Amlodipine 5 mg or Losartan 50 mg -> Losartan and Amlodipine 5/50 mg -> Losartan and Amlodipine 5/100 mg -> Amlodipine/Losartan/Chlorthalidone 5/100/12.5 mg), IP is successively modified until the target blood pressure is reached, and IP will remain the same after the target blood pressure scope for each group is reached. An IP titration interval is decided by the investigator depending on the subject's condition."
2386345|NCT03666338|Active Comparator|Early, goal-directed mobilization|Early goal-directed mobilization with (1) SOMS algorithm and (2) facilitator
2386346|NCT03666338|No Intervention|Standard of Care|Standard of Care regarding mobilization
2386347|NCT03666325|Experimental|Pembrolizumab|Pembrolizumab 200 mg, IV infusion on Day 1 of each 3 week cycle. After 3 cycles patient will be evaluated. In case of disease control (SD, PR, CR) the patient will continue to receive pembrolizumab. In case of progression the patient will receive also Cetuximab (250 mg/m2 after loading dose of 400mg/m2 IV infusion every week.
2386348|NCT03666312||Cohort A|The study will include patients from the two main Italian liver transplantation centers (Ospedale Le Molinette, Torino and Azienda Ospedaliera Pisana, Pisa), allowing to enroll 220 patients in the first 18 months of the proposed study. More in details, all >18-years-old patients listed for and undergoing liver transplantation will be included in the study after signing an informed consent. Each patient will then be prospectively followed one year.
2386349|NCT03666312||Cohort B|A second cohort of 55 patients will then be enrolled in the following 6 months as internal validation sample, and will be analogously monitored until the end of the 3-years-long study.
2386350|NCT03666299|Experimental|Lidocaine|Lidocaine treatment
2386351|NCT03666299|Placebo Comparator|Control|Placebo treatment
2386352|NCT03666286||Intensive Care Patients|Patients >24h on intensive care
3183427|NCT00713856|Active Comparator|1|
3183428|NCT00713856|Active Comparator|2|
3183429|NCT00713869||1|Patients between the ages of 21 and 35 undergoing in-vitro fertilization will be included in this study.
2386356|NCT03666260|Experimental|Quadratus Lumborum Block arm|
2386357|NCT03666260|Active Comparator|Femoral block arm|
2386358|NCT03666247|Experimental|HealthMindr Application|Participants in this study arm will have access to the mobile messaging platform (HealthMindr) for 3 months.
2386359|NCT03666247|Other|Waitlist|Participants in this study arm will not have access to the mobile messaging application during the course of the study. After the Month 9 follow up assessment participants in this study arm will be offered access to HealthMindr.
2386360|NCT03666221|Experimental|Nimotuzumab plus IMRT|Patients with recurrent nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent intensity modulated radiation therapy(IMRT) , folowing weekly nimotuzumab (200 mg/week) for totally 8 weeks concurrent with IMRT.
2386361|NCT03666208|Experimental|Thrombosed Arteriovenous Graft|Single arm pilot study to investigate effect of sirolimus coated balloon in thrombosed arteriovenous graft
2386362|NCT03666195|Active Comparator|Group A|complete dentures will be fabricated using poly methyl methacrylate resin denture base material modified with 5%wt titanium dioxide nanoparticles.
2386363|NCT03666195|No Intervention|Group B|complete dentures will be fabricated with poly methyl methacrylate resin denture base material.
2386364|NCT03666182||Whole Sample|Female, Caucasian participants aged 18-65 years.
2386365|NCT03666169||Whole Cohort|UK Citizens, aged 18-65 years
3183430|NCT00713869||2|Recipients using only frozen donor eggs
3183431|NCT00713882||Observational|
2386369|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody refractory/resistant RCC|
2386370|NCT03666143|Experimental|Metastatic or advanced RCC without prior systemic therapy|
2386371|NCT03666143|Experimental|Anti-PD-1/PD-L1 naïve recurrent / platinum resistant OC|
2386372|NCT03666143|Experimental|Anti-PD-1/PD-L1 treated metastatic, squamous NSCLC|
2386373|NCT03666143|Experimental|Anti-PD-1/PD-L1 antibody R/R melanoma|
2386374|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, non-sq NSCLC|
2386375|NCT03666143|Experimental|PD-L1 positive, naïve, advanced or metastatic, sq NSCLC|
2386376|NCT03666130|Active Comparator|endoscopic septoplasty|in this arm the participants will undergo endoscopic septoplasty for correction of the deviated nasal septum
2386377|NCT03666130|Active Comparator|conventional septoplasty|in this arm the participants will undergo conventional septoplasty operation for correction of the deviated nasal septum that will done by surgical traditional septoplasty technique using head lamb and anterior rhinoscopy
2386378|NCT03666117||Study group|children and adolescents with type 1 diabetes
2386379|NCT03666078||normal vaginal delivery|
2386380|NCT03666078||assisted vaginal delivery|
2386381|NCT03666078||elective cesarean delivery|
2386382|NCT03666078||emergency cesarean delivery|
2386383|NCT03666065|Active Comparator|Aspart-U100 Insulin|Standard Concentration Rapid Acting Insulin
2386384|NCT03666065|Experimental|Aspart-U25 Insulin|Diluted Concentration of Rapid Acting Insulin
2386385|NCT03666039|Experimental|Sensorimotor training|The participants will receive a tablet-based app for at home training that contains sensorimotor components.
2386386|NCT03666039|Active Comparator|Control training|The participants will receive a tablet-based app for at home training that contains relaxing components.
3150941|NCT00214682|Experimental|Folic acid (400mcg) + Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
2386391|NCT03666013||Young healthy subjects|20-30 years old, max 1h of exercise per week
2386392|NCT03666013||Elderly with a normal physical function|65-80 years old, max 1h of exercise per week
2386393|NCT03666013||Elderly with a decreased physical function|65-80 years old, max 1h of exercise per week, SPPB under 9 or frailty score lower then 10
2386394|NCT03666013||Active elderly|65-80 years old, minimal 3h of exercise per week
2386395|NCT03666000|Experimental|Dose Level 1|"PBCAR0191, 3 x 10^5 CAR T cells per kg body weight.~In this study, PBCAR0191, allogeneic anti-CD19 CAR T Cells, is used to treat patients with relapsed or refractory (r/r) Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia.~Route of Administration: Intravenous infusion.~Lymphodepletion Conditioning: Lymphodepletion will be conducted several days prior to PBCAR0191 infusion. A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
2386396|NCT03666000|Experimental|Dose Level 2|PBCAR0191, 1 x 10^6 CAR T cells per kg body weight.
2386397|NCT03666000|Experimental|Dose Level 3a|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight.
2386398|NCT03666000|Experimental|Dose Level 3b|PBCAR0191, 3 x 10^6 CAR T cells per kg body weight as 3 administrations of 1 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
2386399|NCT03666000|Experimental|Dose Level 4|PBCAR0191, 6 x 10^6 CAR T cells per kg body weight as 2 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
2386400|NCT03666000|Experimental|Dose Level 5|PBCAR0191, 9 x 10^6 CAR T cells per kg body weight as 3 administrations of 3 x 10^6 CAR T cells per kg body weight administered after a single lymphodepletion.
2386401|NCT03665987||properative assessment clinic group|The treatment group will be seen in the preoperative clinic before hospitalization.
2386402|NCT03665987||Control group|The control group will get anesthetic consultation after hospitalization without clinic service.
2386403|NCT03665974||Women with gestational diabetes mellitus|GDM screening at this hospital involves a two-step procedure. The diagnosis of GDM was confirmed if at least 2 of 4 glucose levels exceed based on Carpenter-Coustan criteria: fasting ≥ 95 mg/dL (5.3 mmol/L), 1 hour ≥ 180 mg/dL ( 10.0 mmol/L), 2 hour ≥ 155 mg/dL (8.6 mmol/L), and 3 hour ≥ 140 mg/dL (7.8 mmol/L).
2386404|NCT03665974||Women non gestational diabetes mellitus|Women with normal serum glucose levels ≤129 mg/dL (7.2 mmol/L) after GCT.
2386405|NCT03665961||Central obesity|Cases with central obesity as defined by waist circumference cut-offs ≥ 90 cm in men and ≥ 80 cm in women for Asians
2386406|NCT03665961||No central obesity|Controls with no central obesity
2386407|NCT03665948|Experimental|Ketogenic Diet (KD)|Group consuming very low carbohydrate ketogenic diet. The ketogenic diet model was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement up to 5% of energy from carbohydrates. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with fats (fats covered more than 75% of the daily energy requirement). Each of the subjects in this group received 10-day menus.
2386408|NCT03665948|Active Comparator|Low-Glycemic Index Diet (CHO-LGI)|Group consuming carbohydrate, low-glycemic index diet. The carbohydrate diet model with a low glycemic index was energetically normalized (covered the estimated energy expenditure) and assumed coverage of the daily energy requirement of 25% of fat. Proteins were administered in the amount of 1.7 g per kilogram of body mass. The remaining energy needs were covered with carbohydrates (carbohydrates covered about ~55% of the daily energy requirement). The glycemic index of individual meals as well as the daily diet was calculated in accordance with the appropriate recommendations. Each of the subjects in this group received 10-day menus.
2386409|NCT03665922|Experimental|BroccoMax®|Following randomization, subjects will begin to take four BroccoMax® tablets in the morning with breakfast and four tablets in the evening with dinner. The eight BroccoMax® tablets will provide a daily internal dose of 64 mg of SFN.
2386410|NCT03665922|Placebo Comparator|Placebo|Following randomization, subjects will begin to take four placebo tablets in the morning with breakfast and four tablets in the evening with dinner.
2386411|NCT03665909|Experimental|Remote activity monitoring|"Receive the remote activity monitoring system (i.e., eNeighbor; see intervention description) over an 18-month period."
2386412|NCT03665909|No Intervention|Control|Control participants do not receive the remote activity monitoring intervention.
2386413|NCT03665896|Active Comparator|VivaSight DLT group|Thoracic surgery patient is intubated with VivaSight double-lumen tube (intubation with VivaSight double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by the embedded camera, is recorded. The tube position is reconfirmed by fiberoptic bronchoscopy.
2386414|NCT03665896|Placebo Comparator|Standard DLT group|Thoracic surgery patient is intubated with standard double-lumen tube (intubation with standard double-lumen tube). The intubation time, duration between the passage of the tube through the vocal cords and the confirmation of proper tube positioning by fiberoptic bronchoscopy, is recorded.
2386415|NCT03665883|Active Comparator|Diathermy preferred|Monopolar energy is the preferred dissection approach in this group of patients undergo TEP. Total time of activation of monopolar machine will recorded by specially designed device
2386416|NCT03665883|Active Comparator|Blunt dissection preferred|Blunt dissection is the preferred dissection approach in this group of patients undergo TEP. Use of monopolar energy for haemostasis is still allowed upon surgeons' decision. Total time of activation of monopolar machine will recorded by specially designed device
2386417|NCT03665870|Experimental|Intervention Arm|Hypoglycemia Education: Participants will receive educational support to prevent repeat episodes of hypoglycemia.
2386418|NCT03665857|Experimental|multicomponent intervention|"Schools in the intervention arm will receive a multicomponent intervention at the school-, parent- and student-level, with a mobile application to promote the collaboration between investigators, school teachers, parents and students.~The school-level intervention elements will include school policies and health education for teachers.~The parent-level intervention elements will include health education for parents and promoting students' physical activity at home.~The student-level intervention elements will include health education for students, promoting students' physical activity in school and monthly monitoring of weight and height."
2386419|NCT03665857|No Intervention|usual-care control|Schools assigned to the control group will have usual education provision throughout their participation in the trial, and after finishing the study they will be offered the health education package, policy suggestion and materials as the schools in the multicomponent intervention group.
2386420|NCT03665844|Placebo Comparator|SmartSleep Boost Off|Participants wear the device for baseline data collection in boost off mode. There is no intervention. This is known as SmartSleep Boost Off mode.
2386421|NCT03665844|Active Comparator|SmartSleep Boost On|Participants wear the device for 3 weeks in boost on mode. This is known as SmartSleep Boost On mode.
2386422|NCT03665831|Experimental|Active H1 Coil deep rTMS active treatment|
2386423|NCT03665818|Experimental|Oral appliance intervention|
2386424|NCT03665818|No Intervention|Without oral appliance intervention|
2386425|NCT03665779|Experimental|isosorbide mono-nitrate group|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
2386426|NCT03665779|Placebo Comparator|placebo group|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.
2386427|NCT03665766||IFN group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Cyclosporine A as primary immunosuppression ,this was routinely taken not as intervention according to local practice
2386428|NCT03665766||IFN group received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received Peg IFN-α 2a and RBV as antiviral therapy and Tacrolimus as primary immunosuppression ,this was routinely taken not as interventing according to local practice
2386429|NCT03665766||Sof plus Rbv group received Cyclosporine|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
2386430|NCT03665766||Sof plus Rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
2386431|NCT03665766||Sof,dac pus ribavirin received cyclosporine|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Cyclosporine as primary immunosuppression,this was routinely taken not as intervention according to local practice
2386432|NCT03665766||sof,dac plus rbv received tacrolimus|Living donor liver transplantation recipients with recurrent HCV received daclatasvir, sofosbuvir and RBV as antiviral therapy and Tacrolimus as primary immunosuppression,this was routinely taken not as intervention according to local practice
2386433|NCT03665753|Experimental|Ketorolac 10mg|Subjects will be administered 10 mg of Ketorolac.
2386434|NCT03665753|Experimental|Ketorolac 20mg|Subjects will be administered 20 mg of Ketorolac
2386435|NCT03665753|Experimental|Ketorolac 30mg|As a part of standard care, subjects will be administered 30 mg of Ketorolac.
2386436|NCT03665740|Experimental|Resveratrol|Doses of resveratrol at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the resveratrol, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment.
2386437|NCT03665740|Placebo Comparator|Placebo|Doses of placebo at 500 mg will begin with a dose titration period. In order to reach a maximum dose of 2000 mg for the placebo, titration will begin at 500 mg for 6 weeks, then increased to 1000 mg for 6 weeks and increased to 1500 mg for 6 weeks and increased to 2000 mg for the remaining 6 weeks on treatment
2386438|NCT03665727|Experimental|Mindfulness|15 minute mindfulness session
2386439|NCT03665727|Experimental|Suggestion|15 minute therapeutic suggestion session
2386440|NCT03665727|Active Comparator|Psychoeducation|15 minute psychoeducation session
2386441|NCT03665727|No Intervention|Usual Care|The usual care comparison group was comprised of patients who underwent total joint arthroplasty of the hip or knee at the same academic medical center during the study period but who did not attend Joint Academy.
2386563|NCT03664895|Active Comparator|OFS add arm(TMX + OFS, MDR<5%)|OFS add on to TMX
2386442|NCT03665714|Experimental|Impact Oral|"Preoperatively:~1 bottle each time (250ml/bottle), 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~1 bottle (250 ml each) per day of test product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~2 bottles (250 ml each) per day of test product on D 3 and D 4 post surgery, corresponding to 707Kcal.~3 bottles (250 ml each) per day of test product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
2386443|NCT03665714|Active Comparator|Enteral nutrition Emulsion(TPF-T)|"Preoperatively:~272ml each time, 3 times per day, equivalent to approximately 1060.5kcal per day.~Postoperatively:~Patient should receive:~272ml of control product on D 1 and D 2 post surgery, corresponding to 353.5Kcal.~544ml of control product on D 3 and D 4 post surgery, corresponding to 707Kcal.~816ml of control product on D 5, D 6 and D 7 post surgery, corresponding to 1060.5 kcal.~At the discretion of the authorized investigator/nutritionist, the amount of study products, can be increased to meet the daily caloric goal: 1500Kcal."
2386444|NCT03665701|Experimental|Inhibitory effects of Fevipiprant|in vitro experiments: The reaction of the innate lymphoid cells by cytokine secretion in response to the stimulation by Prostagalandin D2 metabolites and the measurement of a potential suppressive effect of Fevipiprant will be assessed.
3142847|NCT00003593|Experimental|Arm B: AML/MDS patients only|(closed to accrual as of 6/24/04 except for patients first enrolled in group I): Patients receive induction therapy comprising cytarabine IV continuously, daunorubicin hydrochloride IV continuously, and oral thioguanine twice daily on days 0-3. Treatment repeats every 28 days for 4 courses. Patients with no CNS disease at diagnosis receive cytarabine intrathecally (IT) on day 0. Patients with CNS disease at diagnosis receive cytarabine IT on days 0, 5, and 7. If CNS disease persists on day 7, patients receive up to 6 courses of cytarabine IT, therapeutic hydrocortisone IT, and methotrexate IT, twice weekly beginning on day 10. Asparaginase during Intensification 1 day 1 hour 18.
3183432|NCT00713895|Active Comparator|Standard Self-Help|receive a standard self-help manual in Chinese and English of the participants' choice at baseline
2386447|NCT03665675|Experimental|Treatment (CMV-specific CTLs)|Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with partial response, may receive up to 2 additional doses at monthly intervals.
2386448|NCT03665662|Experimental|Intervention|Patients in this arm will receive patient-selected music through headphones throughout their procedure.
2386449|NCT03665662|No Intervention|Control|Patients will be wearing headphones during their procedure (for the purpose of blinding the care team), but will not receive any music, sounds or sound-cancelling effects through the headphones.
2386450|NCT03665649|Other|CD133+ human donors|CD133+ cells isolation
2386452|NCT03665610||Mandatory Safety Population|All subjects who enrolled in studies RPC01-1912, RPC01-1913, or RPC01-1914 and received at least one dose of ozanimod or IP (per parent studies), excluding subjects who discontinued during Period 1 of study RPC01-1913.
2386453|NCT03665610||Optional pharmacokinetic(s) and pharmacodynamics(s) population|Subjects in study RPC01-1913 have completed the study at least through Period 2 and completed the 7 ± 2 days postdose follow-up assessments; or subjects in study RPC01-1914 have completed the study through the 7 ± 2 days postdose follow-up and had no major protocol violations in the parent studies that are deemed to impact PK or PD assessments.
2386454|NCT03665597|Experimental|Pembrolizumab Sequence 1|Participants receive a single dose of pembrolizumab (pembro) in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A subcutaneously (SC); Cycle 2 Day 1: pembro Dose B intravenously (IV); Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386455|NCT03665597|Experimental|Pembrolizumab Sequence 2|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose A SC; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386456|NCT03665597|Experimental|Pembrolizumab Sequence 3|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose B IV; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386457|NCT03665597|Experimental|Pembrolizumab Sequence 4|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose C SC; Cycle 2 Day 1: pembro Dose B IV; Cycle 3 Day 1: pembro Dose A SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386458|NCT03665597|Experimental|Pembrolizumab Sequence 5|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose C SC; Cycle 3 Day 1: pembro Dose A SC: Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386459|NCT03665597|Experimental|Pembrolizumab Sequence 6|Participants receive a single dose of pembro in each 21-day cycle in the following sequence: Cycle 1 Day 1: pembro Dose B IV; Cycle 2 Day 1: pembro Dose A SC; Cycle 3 Day 1: pembro Dose C SC; Cycle 4 Day 1 and every cycle thereafter (up to a total of 35 cycles) Day 1: pembro Dose B IV.
2386460|NCT03665597|Experimental|Pembrolizumab Dose D|Participants receive a single dose of pembro Dose D IV on Day 1 of each 42-day cycle (every 6 weeks; Q6W) for up to 18 cycles (up to approximately 2 years).
2386461|NCT03665584|Active Comparator|FxCO2 Laser|FxCO2 laser treatment will be performed by scanning across the entire affected anogenital region. The FxCO2 treatment will be performed at baseline and then repeated at 4 week intervals for a total of 5 treatments. The laser parameters change with each treatment: power (18, 20, 22, 24, 26W), dwell time (800, 900, 1000, 1000, 1000us) and spacing (1200, 1100, 1000, 1000, 1000um) in respective order.
2386462|NCT03665584|Sham Comparator|Sham Laser|Sham laser treatment will be performed by scanning across the entire affected anogenital region. The sham treatment will be performed using 4W (power), 400us (dwell time), and 1500um (spacing). The laser has no effect on the vulvar tissue using these parameters.
2386463|NCT03665571||Conventional Activation method|NK cell was incubated with either K562 cells
2386464|NCT03665571||Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
2435753|NCT03327870||5|Excluded by 2016 ACR/EULAR Classificastion Criteria
2386465|NCT03665558|No Intervention|Aortic dP/dt in sinus rhythm|Left ventricular and aortic dP/dt values were recorded at baseline condition while patients are on sinus rhythm.
2386466|NCT03665558|Active Comparator|Aortic dP/dt during DDD pacing|Patients will be their own control. Aortic and ventricular pressures will be recorded under temporary DDD pacing again and these data collected at every pacing steps will be compared to the pressures recorded at baseline condition.
2386467|NCT03665545|Active Comparator|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
2386468|NCT03665545|Experimental|IMA950/Poly-ICLC and pembrolizumab|Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly- ICLC administered subcutaneously
2386469|NCT03665532|Experimental|Interactive 2-way texting|Biweekly text message communications with counselors for problem solving
2386470|NCT03665532|Active Comparator|Passive text reminders|Automated weekly text message health care reminders
2386471|NCT03665519|Experimental|Dietary supplement and ursodeoxycholic acid therapy.|Participants will take a supplement (sublimated mare milk) of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) twice/day accompanied with standard therapy of ursodeoxycholic acid therapy (dosage of 15/kg/day) for 3 months.
2386472|NCT03665519|Other|Ursodeoxycholic acid therapy only.|Patients would be given the standard treatment of ursodeoxycholic acid only for 3 months.
2386473|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications ON|Idiopathic Parkinson's patient's with Hoehn and Yahr score of 1.5- 2 i.e. in an early stage of the disease, under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
2386474|NCT03665493|Experimental|PD patients H&Y=3 Medications ON|Parkinson's patient's with Hoehn and Yahr score of 3, i.e. in moderate-to-advanced stages of the disease under stable treatment with the administration of L-dopa and dopamine agonists. Patients will not present severe sensory deficits or any other neurological disease besides PD, as will be assessed by a standard neurological examination, and they will be all right-handed as will be assessed by the Edinburgh handedness inventory. Age range: 40-70
2386475|NCT03665493|Experimental|PD patients H&Y=1.5-2 Medications OFF|Same as above described
2386476|NCT03665493|Experimental|PD patients H&Y=3 Medications OFF|Same as above described
2386477|NCT03665493|Experimental|Healthy age-matched controls|Healthy controls. Right-handed healthy subjects (it will be assessed by the Edinburgh handedness inventory) with normal or corrected-to-normal vision, without a history of neurological diseases. Age range: 40-70.
2386478|NCT03665480|Experimental|G-CSF treatment|In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.
2386479|NCT03665480|No Intervention|G-CSF-free|In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.
2386480|NCT03665454|Experimental|PF-06412562|Subjects will receive 25 mg of PF-06412562 twice daily on study Days 2 and 3, along with placebo carbidopa/levodopa dosed at these times. Additional carbidopa/levodopa placebo capsules also will be administered according to the subject's home regimen.
2386481|NCT03665454|Active Comparator|Standard of Care carbidopa/levodopa|Subjects will take placebo tablets for the PF-06412562 twice daily on study Days 2 and 3, along with active carbidopa/levodopa (25/100 mg) administered at these times. Additional active carbidopa/levodopa capsules also will be administered according to the subject's home regimen.
2386482|NCT03665441|Experimental|Eryaspase plus Chemotherapy|"eryaspase 100 U/kg dosed every 2 weeks in combination with~Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle as follows:~Abraxane (125 mg/m2) IV~Gemcitabine (1000 mg/m2) IV~Or~Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle as follows:~Onivyde 70 mg/m2 (irinotecan freebase) IV (recommended dose in patients homozygous for UGT1A1*28 is 50 mg/m2)~Leucovorin 400 mg/m2 IV~5 FU 2400 mg/m2~Or~FOLFIRI: Irinotecan 180 mg/m2 IV~Leucovorin 400 mg/m² IV~5 FU 400 mg/m² IV bolus~5 FU 2400 mg/m² IV continuous infusion over 46 hours immediately following bolus 5 FU"
2386483|NCT03665441|Other|Chemotherapy alone|Standard treatment: Gemcitabine plus abraxane (albumin-bound paclitaxel) administered on Days 1, 8, and 15 of each 4 week cycle Or Irinotecan plus 5-FU plus leucovorin administered on Days 1 and 15 of each 4 week cycle
2386484|NCT03665428|Experimental|PAMB group|PAMB treatment (modified quadruple therapy) for 14 days
2386485|NCT03665428|Active Comparator|PMBT group|PBMT treatment (bismuth-containing quadruple therapy) for 14 days
2386486|NCT03665415|Other|Formative|This stage represents an initial formative phase to implement the NDGame Squad intervention with small samples of youth in order to make any modifications necessary before embarking on the full pilot in both sites in the next phase. Three (n=3) participants from the school site only will participate in an initial 4-week Game Squad intervention in the first formative phase. Participant feedback including barriers to engagement and suggestions for improvements will be obtained via parent/caregiver and child interviews post-intervention.
2386487|NCT03665415|Experimental|Pilot Intervention|Participants in the pilot intervention arm will receive either 10 or 14 weeks of the NDGameSquad intervention. School site participants will receive 10 weeks during the school year, followed by another 4 weeks during summer vacation. Clinic site participants will receive 10 weeks only.
2386488|NCT03665415|Other|Pilot Waitlist Control|Participants at both sites randomized to the waitlist control arm will be asked to maintain current physical activity levels during the first 10-week period. They will then be provided the intervention equipment and training. School site control arm participants will then participate in a 4-week, unsupported summer NDGame Squad intervention. Clinic site control arm participants will not be required to participate in the NDGameSquad intervention.
2386489|NCT03665402|Active Comparator|Rapid metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
2386490|NCT03665402|Active Comparator|Slow metabolizer (Standard treatment)|Standard isoniazid dose regimen (300 mg qd)
2386491|NCT03665402|Experimental|Slow metabolizer (PGx treatment)|Decreased isoniazid dose regimen (200 mg qd)
2386523|NCT03665181||without modification of dose and without bismuth mask|The cranial CT imaging presrcibed in usual care will be performed without modification of dose and without bismuth mask
2386492|NCT03665389|Other|Single Arm|Among patients who undergo TAVR at the kobe university hospital, those who are found to have moderate or severe stenosis on cCTA performed before surgery and judged to clinically require ischemia evaluation will be included in this study.
2386493|NCT03665376|Experimental|ERAS arm|Preoperative: Counseling and education about the ERAS program; Oral intake until 6 hours before the surgery; Carbohydrate drinks load; No mechanical bowel preparation; Antithrombotic prophylaxis (Tinzaparin 3500 IU) Intraoperative: Spinal anaesthesia (15 mg hyperbaric Bupivacaine + 200mcg intrathecal Morphine); Intravenous Ceftriaxone 2g, Metronidazole 500mg / Gentamycin 160mg, Ondansetron 8mg and Dexamethasone 8mg; Crystalloid fluid 10 to 20ml/Kg; Adrenaline 200mcg in each 500 ml of intravenous fluid; Avoidance of abdominal drains; Postoperative: Early oral intake; Nasogastric tube and urinary catheter removed immediately after the surgery; Early enteral nutrition; Chewing gum for 2 to 4 hours after surgery; Oral sips 8 hours postoperatively; Intravenous fluids discontinued at four hours after transfer to the ward.
2386494|NCT03665376|No Intervention|Control arm|Preoperative: No carbohydrate drink loads, no antithrombotic prophylaxis; Mechanical bowel preparation as needed; Spinal anaesthesia, fluid therapy and antibiotherapy done according to standard hospital practice. The urinary catheter and drains were removed at the discretion of the surgeon. Postoperative: Enteral feeding delayed by the auscultation of bowel sounds. The standard hospital practices involve keeping active the nasogastric tube, fasting patients postoperative, strict bed rest… Pain control was managed with medication of choice by surgeon and anesthesiologist.
2386498|NCT03665350|No Intervention|non insulin|standard care + antidiabetic therapy non insulin
2386499|NCT03665350|Experimental|Insulin|standard care including insulin
2386500|NCT03665337|Experimental|mTranS-C|Access to a mobile and computer accessible adaptation of Transdiagnostic Sleep and Circadian Intervention
2386501|NCT03665337|Active Comparator|Control|Access to a mobile and computer accessible control intervention that targets coping skills and sleep education.
2386502|NCT03665324||Veteran athletes with Supraventricular arrhythmias|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) with documented paroxysmal supraventricular arrhythmias.
2386503|NCT03665324||Veteran athletes without supraventricular arrhythmia|Subjects who consulted in the Sports Medicine Department between January 1, 2010 and January 1, 2017 Veteran athletes (age> 35 years) without documented supraventricular arrhythmia.
2386504|NCT03665311|Placebo Comparator|Normal Saline|100 mL 0.9% Normal Saline at the initiation of SLED and another 100 mL 0.9% Normal Saline after 4 hours of treatment
2386505|NCT03665311|Active Comparator|25% Albumin fluid|100 mL 25% Albumin fluid at the initiation of SLED and another 100 mL 25% Albumin fluid after 4 hours of treatment
2386506|NCT03665298|Experimental|Needle X|Smartphone application application to enhance access to sterile needles, naloxone overdose kits, and addiction treatment programs in New York City.
2386507|NCT03665285|Experimental|NC318|NC318 for IV infusion of various dose strengths administered in 14 day dosing cycles. Alternative dosing schedules may be explored once RP2D has been determined.
2386508|NCT03665272|Experimental|fixation by tissue adhesive|In this group, deepithelialized gingival grafts were fixed by tissue adhesive without any suture.
2386509|NCT03665272|Experimental|fixation by sutures|In this groups, deepithelialized gingival grafts were fixed by 4.0 round vicryl sutures.
2386510|NCT03665259|Active Comparator|Pure oxygen group|The patients receive 100% oxygen therapy during the induction phase of induction
2386511|NCT03665259|Experimental|Lower oxygen group|The patients received 60% oxygen therapy during the induction phase of induction
2386512|NCT03665246|Experimental|Intervention (iMBC/ECD + C-PrES)|The intervention group of women/children dyads who consent will receive 14 sessions of the Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) curriculum in addition to the C-PrES curriculum. Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages and group-based iMBC booster sessions every 3 months.
2386513|NCT03665246|No Intervention|Control (C-PrES)|The control group of women/children dyads who consent will have exposure to 14 sessions of the C-PrES curriculum which promotes the adoption of key MNCHN behaviors (e.g. newborn care, exclusive breastfeeding, etc.). Upon completion of 14 sessions, women will continue to receive MNCHN and ECD messages.
2386514|NCT03665233|Sham Comparator|Sh-group|The patients in this arm get standard treatment, together with a sham version of a VR session.
2386515|NCT03665233|Active Comparator|VR-group|These patients get a VR session with the standard treatment
2386516|NCT03665220|Experimental|Ergonomic adjustment group|Ergonomic intervention program at home for post-stroke patients. The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form.
2386517|NCT03665220|Experimental|Kinesiotherapy + ergonomics group|A Kinesiotherapy plus ergonomic adjustments program for post-stroke patients. This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
2386518|NCT03665220|Active Comparator|Healthcare education|A conservative intervention program for post-stroke patients
2386519|NCT03665207|Experimental|Tight glucose control|Target normal fasting blood glucose concentrations (80-110 mg/dl) with insulin therapy, administered through continuous intravenous infusion.
2386520|NCT03665207|Active Comparator|Liberal glucose control|Tolerate hyperglycemia up to 215 mg/dl. In patients requiring insulin therapy, insulin will be titrated to target blood glucose concentrations between 180 and 215 mg/dl.
2386521|NCT03665194|Experimental|Cortexolone 17α-propionate 7.5% solution|
2386522|NCT03665194|Placebo Comparator|Vehicle solution|
2386561|NCT03664895|No Intervention|observation arm(TMX, MDR≥5%)|keep go on TMX
2386524|NCT03665181||with modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and with bismuth mask
2386525|NCT03665181||without modification of dose and with bismuth mask|e cranial CT imaging presrcibed in usual care will be performed without modification of dose and with bismuth mask
2386526|NCT03665181||with modification of dose and without bismuth mask|e cranial CT imaging presrcibed in usual care will be performed with modification of dose and without bismuth mask
2386527|NCT03665168||Patients in the palliative stage|Adult patients in various settings will be included (General Practioners practices, home care facilities, general and academic hospitals, hospices) and with any underlying life-limiting disease.
3183433|NCT00713895|Experimental|Expert System|receive an expert system intervention that included the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
2386529|NCT03665142|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 36 participants were taped for the TTH.50-mm wide and 0.5-mm thick KT was applied to the upper trapezius muscle with one I-shaped tape. The tape was measured from the acromion to the hairline at the back, and the upper trapezius fibers were extended in the extended position, ie the cervical vertebrae were flexed to the opposite side and applied to the same side in the flexion and rotation position.
2386530|NCT03665142|Placebo Comparator|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
2386531|NCT03665129|Experimental|Dose escalation|IPH5401 at different doses and schedule + Durvalumab
2386532|NCT03665129|Experimental|Cohort expansion NSCLC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in NSCLC anti-PD-(L)1 pretreated patients
2386533|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 naive|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 naive patients
2386534|NCT03665129|Experimental|Cohort expansion HCC anti-PD-(L)1 pretreated|IPH5401 at recommended dose and schedule + Durvalumab in HCC anti-PD-(L)1 pretreated patients
2386535|NCT03665116|Experimental|Arginine|L-arginine 1.5 g capsule by mouth, once daily for 6 months
2386536|NCT03665116|No Intervention|No Intervention|no supplement for 6 months
2386537|NCT03665103|Experimental|Laser-assisted ICSI|
2386538|NCT03665103|No Intervention|conventional ICSI|
2386539|NCT03665077|Experimental|Participants|Patients with breast cancer who have completed all their primary treatments (surgery±radiation therapy) and are scheduled to start their adjuvant hormonal therapy.
2386540|NCT03665051|Other|Young adults|Obtain muscle biopsy specimens from young adults (ages 20-40) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
2386541|NCT03665051|Other|Older adults|Obtain muscle biopsy specimens from older adults (ages 60-80) to develop a millifluidic chip for electrical stimulation of human primary muscle cell hydrogel cultures.
2386542|NCT03665038|Experimental|Brexanolone|
2386543|NCT03665025|Experimental|immediate implant placement with xenograft|Immediate implant placement with the use of xenograft as grafting material
2386544|NCT03665025|Experimental|immediate implant using mixed allograft and xenograft|Immediate implant placement with using mixture of allograft and xenograft material
2386545|NCT03664999||Parturients physiologic pregnancy|Parturients undergoing caesarean delivery with physiologic pregnancy
2386546|NCT03664999||Parturients with risk pregnancy|Parturients undergoing caesarean with risk of complications (pre-eclampsia, HELLP syndrom, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
2386547|NCT03664986|Experimental|Exparel pudendal block|This group will have intra-operative pudendal block performed with Liposomal Bupivacaine (EXPAREL) solution.
2386548|NCT03664986|No Intervention|Comparison group|This group will be those to receive current standard treatment with no pudendal block performed.
2386549|NCT03664973|Experimental|continuous|continuous local anesthetic infusion (ropivacaine 0.2%)on the serratus plane for at least 72h adds to a Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml.
2386550|NCT03664973|Active Comparator|single-shot|Single-shot serratus plane block with ropivacaine 0.37% solution 20 ml
2386551|NCT03664960|Experimental|1 to 3.0 mg/kg of AK002|Subjects in this arm will receive 26 monthly doses of AK002: a first dose of 1 mg/kg, followed by monthly doses of 3 mg/kg
2386552|NCT03664947|Experimental|exercise|The exergaming training programs have included recent daily living activities in games. In our study we have planned the Nintendo Wii Fit Plus Game Console in the therapy training.
2386553|NCT03664947|No Intervention|control|No exercise training applied for the control group.
2386554|NCT03664934|Experimental|Patients, Neck-specific exercises|Patients before and after neck-specific exercises, subgroup to NCT01528579 with additional measures
2386555|NCT03664934|No Intervention|Healthy controls|Healthy controls, no treatment
2386556|NCT03664921|Experimental|Omnitram|Oral Omnitram (10 mg tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet (10 mg) and 4 tablets (40 mg) to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
2386557|NCT03664921|Placebo Comparator|Placebo|Oral placebo (tablets) dosed three times daily. During the first two weeks each dose will be titrated between 1 tablet and 4 tablets to provide pain relief. The doses administered at the end of two weeks will be maintained during the final two weeks of treatment.
2386558|NCT03664908|Experimental|serum samples of SLE patients without LN|100 serum samples coming from systemic lupus erythematosus (SLE) patients without lupus nephritis (LN).
2386559|NCT03664908|Experimental|serum samples of Lupus nephritis (LN) patients|100 serum samples coming from systemic lupus erythematosus(SLE) patients with lupus nephritis (LN)
2386560|NCT03664908|Experimental|healthy voluntary blood donors (control group)|100 serum sample coming from 100 healthy voluntary blood donors (provided by Regional blood center of Reims). This arm will be our control group.
3183434|NCT00713934|Experimental|1|
3183435|NCT00713934|Experimental|2|
3183436|NCT00713947|Active Comparator|A|Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
3183437|NCT00713947|Experimental|B|Pantoprazole
3183438|NCT00713947|Placebo Comparator|C|Placebo
3183439|NCT00713960||1|Patients in secondary prevention of cardiovascular disease in primary care
2386564|NCT03664882|Experimental|Fexofenadine|Fexofenadine, single administration
2386565|NCT03664882|Placebo Comparator|Placebo|Placebo, single administration
2386566|NCT03664869|Active Comparator|Group A|"BCG instillation therapy with induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used."
2386567|NCT03664869|Experimental|Group B|"Sequential BCG and EMDA mitomycin C treatment with nine weekly instillations of BCG, BCG, EMDA-MMC x3 followed by nine monthly instillations of EMDA-MMC, EMDA-MMC, BCG x3~Dosage of Bacillus of Calmette-Guerin (BCG) is dependent on the preferred brand of BCG by the participating institution. Either 2 x 10^8 - 3 x 10^9 for BCG-MEDAC, 2-8 x 10^8 colony forming unit for OncoTICE or, 81mg for ImmuCYST and TheraCys. The investigators will nominate which BCG brand is used.~Mitomycin C dosage is 40 mg of MMC with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water"
2386568|NCT03664856|Experimental|experimental group|Subject suffering from a locally advanced or metastatic cancer therefore falling under palliative care as defined by the definition of the French Society of Support and Palliative Care An interview will be performed
2386569|NCT03664843||The chemotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before chemotherapy and at a series of scheduled time-points after chemotherapy , with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
2386570|NCT03664843||The radiotherapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before radiotherapy and at a series of scheduled time-points after radiotherapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
2386571|NCT03664843||The targeted therapy cohort|Blood samples for ctDNA and biomarkers analysis are collected at before targeted therapy and at a series of scheduled time-points after targeted therapy, with serial two-weekly blood samples collected from a subset of patients. Meanwhile, imaging technology such as CT scan detection would be performed.
2386572|NCT03664830|Experimental|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
2386573|NCT03664817|Experimental|social capital intervention|This group will receive intervention developed from Phase 1 study and based on photovoice project
2386574|NCT03664817|Active Comparator|group-based health promotion intervention|"The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)"
3183440|NCT00713973||1|Submitted to the American protocol for prophylaxis of deep vein thrombosis
2386576|NCT03664791||Vanguard Rocc knee implant|Patient in need for a total knee arthroplasty and who met the inclusion/ exclusion criteria and received the Vanguard Rocc implant
3183441|NCT00713973||2|Submitted to the Brazilian protocol for prophylaxis of deep vein thrombosis
3183442|NCT00713973||3|Submitted to the SBCP modified protocol for prophylaxis of deep vein thrombosis
2386579|NCT03664752|Experimental|IDP-120 Gel|Component A
2386580|NCT03664752|Placebo Comparator|IDP-120 vehicle gel|Vehicle
2386581|NCT03664739|Experimental|IDP-120 Gel|Component A
2386582|NCT03664739|Placebo Comparator|IDP-120 Vehicle Gel|Gel
2386583|NCT03664726|Experimental|Episodic Future Thinking (EFT)|Participants will complete an episodic thinking task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties, and so forth). EFT participants will list positive future events they are looking forward to and list events that could happen at different general future time points (e.g., 1 month, 2-6 months, 7-12 months)
2386584|NCT03664726|Active Comparator|Episodic Recent Thinking (ERT)|Participants will complete an episodic task to generate episodic cues where they will list and describe events for different time periods.The episodic component of the thinking task will occur while the participants are asked to describe what they are imagining about each event (e.g., vacations, weddings, parties). ERT participants will list positive recent events that have already happened and that they have enjoyed, at different general recent time points (e.g., a few hours ago, 1 day ago, 2-6 days ago, 7-12 days ago)
2386585|NCT03664713|Experimental|EMDR plus TAU|Individual Eye Movement Desensitization and Reprocessing (EMDR) Therapy: This consists of 25 individual sessions of 60 minutes each, applying the standard protocol with the existing validated modifications for specific pathologies. The standard EMDR protocol consists of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation.
2386586|NCT03664713|No Intervention|TAU only|Treatment As Usual (TAU): The patients in this condition will participate in the psychosocial activities proposed by the inpatient unit (with a focus on autonomy, psychoeducation, treatment adherence, insight, functioning and family interventions). Patients who receive EMDR therapy will also participate in these activities.
2386587|NCT03664700||LMA Protector|The LMA Protector will be used
2386588|NCT03664687|Active Comparator|Zoledronate one dose (4 mg)|One 4 mg dose of Zoledronate
2386589|NCT03664687|Active Comparator|Zoledronate 4 mg every 6 months x 3 years|One 4 mg dose of Zoledronate given every 6 months for 3 years
2386590|NCT03664674|Experimental|OTO-104|
2386591|NCT03664674|Placebo Comparator|placebo|
2386592|NCT03664661|Experimental|experimental group|BCMA nanobody CAR-T cells
2386593|NCT03664648||Adult Pregnant Women Exposed to HEPLISAV-B|Adult women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy.
2386594|NCT03664635|Experimental|Phase I - Safety Dose Level|In phase I three (3) + 3 patients will be treated with 1x10^5 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the preceding safety dose level
2386595|NCT03664635|Experimental|Phase I - Dose Level 1|In phase I six (6) + 3 patients will be treated with 1x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 1
2435964|NCT03326466||Patients with SAP|
2386596|NCT03664635|Experimental|Phase I - Dose Level 2|In phase I six (6) + 3 patients will be treated with 3x10^6 MB-CART20.1 cells per kg body weight administered intravenously as single dose in the dose level 2
2386597|NCT03664635|Experimental|Phase II|The number of additional patients who will be treated with MB-CART20.1 cells in Phase II is depending on the number of evaluable patients treated with the maximum tolerated dose (MTD) level and the results in Part I
2386598|NCT03664622|Experimental|group K|patients with a ketamine infusion intraoperative
2386599|NCT03664622|Experimental|group M|patients with a Morphine infusion intraoperative
3183443|NCT00713986|Sham Comparator|Noanalgesia|Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
2386603|NCT03664596|Experimental|Dietary supplement only|Participants will take a sublimated mare milk of 1 sachet 3 times a day during 2 months.
2386604|NCT03664596|Other|Dietary supplement and ursodeoxycholic acid therapy|Patients with non-alcoholic steatohepatitis will take ursodeoxycholic acid (2-3 times/day) combined with the mare's milk supplement (1 sachet, 3 times/day) for two months.
2386605|NCT03664596|Active Comparator|Ursodeoxycholic acid therapy only|Patients with verified diagnosis of non-alcoholic steatohepatitis would be given treatment of ursodeoxycholic acid (2-3 times/day) for a two-month period.
2386606|NCT03664583|Experimental|Intervention Group|Patients randomly assigned to the intervention group will be offered the ACHRU-Community Partnership Program (CPP) intervention in addition to usual primary care services offered by their local diabetes education centre or primary care setting. The CPP is a 6-month self-management intervention consisting of six core components: 1) home or virtual visits (up to 3) supported by phone calls by either a Registered Nurse (RN) or Registered Dietician (RD); 2) wellness sessions (up to 6, one per month) provided to patients and their caregivers at the location of the community partner or virtually; 3) monthly team case conferences with the provider team; 4) caregiver support; 5) collaboration with the primary care interprofessional team and other specialists; 6) nurse-led care coordination/system navigation.
2386607|NCT03664583|No Intervention|Control Group|Those who are randomly assigned to the control group will continue to be offered usual primary care services through their local diabetes education centre or primary care setting. The services that comprise usual diabetes care vary across the provinces e.g., length and focus of educational sessions, whether classes are strongly recommended versus optional (e.g., foot care, cardiac health, eating and exercise interventions), home visits, access to on-site professionals (e.g., endocrinologist, dietitian, physiotherapist, exercise specialist, pharmacist), connections with support services and community resources, and type of follow-up services available. Details of usual care provided at each site will be recorded.
2386608|NCT03664570|Experimental|Condition A|"Infusion rate = 25 ml/h~Radiography: confirmation balloon position~VIPUN Balloon Catheter~13C-Octanoate Breath Test o"
2386609|NCT03664570|Experimental|Condition B|"Infusion rate = 75 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Test"
2386610|NCT03664570|Experimental|Condition C|"Infusion rate = 250 ml/h~Magnetic resonance imaging~VIPUN Balloon Catheter~13C-Octanoate Breath Testt"
2386611|NCT03664557|Experimental|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
2386614|NCT03664531|Experimental|Gluten, ATIs, nocebo|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
2386615|NCT03664531|Experimental|Gluten, nocebo, ATIs|Participants will start on 1 week of muesli bars with purified gluten followed by 14 days washout. They will then take 1 week of nocebo muesli bars (with nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
2386616|NCT03664531|Experimental|ATIs, gluten, nocebo|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of nocebo muesli bars (with nothing).
2386617|NCT03664531|Experimental|ATIs, nocebo, gluten|Participants will start on 1 week of muesli bars with non-purified gluten (containing ATIs) followed by 14 days washout. They will then take 1 week of nocebo muesli bars (containing nothing) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
2386618|NCT03664531|Experimental|Nocebo, ATIs, gluten|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars containing non-purified gluten (containing ATIs) followed by 14 days of washout. Finally, they will have 1 week of muesli bars with purified gluten.
2386619|NCT03664531|Experimental|Nocebo, gluten, ATIs|Participants will start on 1 week of nocebo muesli bars (with nothing) followed by 14 days washout. They will then take 1 week of muesli bars with purified gluten followed by 14 days of washout. Finally, they will have 1 week of muesli bars with non-purified gluten (containing ATIs).
2386620|NCT03664518|Experimental|Eltrombopag|58 enrolled patients are picked up to take eltrombopag at the indicated dose.
2386621|NCT03664505|Active Comparator|Garment based on manual measurement|Garment based on manual measurement is used on burn scar
2386622|NCT03664505|Experimental|Garment based on scan measurement|Garment based on scan measurement is used on burn scar
2386623|NCT03664492|Other|Educational Whiteboard video|All the interested participants contacting us will be provided an info email and an internet link via email to access the study through REDCap. Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
2386681|NCT03664063|Experimental|Combination Therapy of Azithromycin for Yaws and IDA for LF|Patients will receive combination therapy for both yaws and IDA for Lymphatic Filariasis at the same time.
2386624|NCT03664479|Experimental|classical electrical stimulation protocol|"apply 4 channel electrical stimulation device with protocol 1.~It will simultaneously stimulate suprahyoid, thyrohyoid and sternothyroid m with 4 channel electrical stimulation device.~during apply the device, we evaluate the manometry and videofluoroscopic swallowing study for evaluation of deglutition function."
2386625|NCT03664479|Experimental|revised sequential activation protocol|"apply 4 channel electrical stimulation device with protocol 2~Is a revised sequential activation protocol, it sequentially stimulate bilateral suprahyoid m (channel 1), pharyngeal constrictors (ch 2), thyrohyoid m (ch 3), sternothyroid m (ch 4) with 4 channel electrical stimulation device.~during apply the synchronized electrical stimulation device, we will evaluate the parameters same as group 1."
2386626|NCT03664466|Experimental|Astaxanthin|Astaxanthin 12mg twice daily by mouth
2386627|NCT03664466|Placebo Comparator|Placebo|Placebo twice daily by mouth
2386628|NCT03664453|Experimental|Food Effect (Fasted)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fasted state (Period 1) with a crossover and then in the fed state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
2386629|NCT03664453|Experimental|Effect (Fed)|"Subjects will be randomly assigned to one of the two treatment sequences. Two single doses of omaveloxolone 150 mg (taken in multiple 50 mg capsules) will be administered to the subjects beginning in the fed state (Period 1) with a crossover and then in the fasted state (Period 2).~Subjects will be confined beginning on Study Day -1 through the last PK blood draw on Study Day 6 during Period 1, and from Study Day 14 through the last PK blood draw on Study Day 20 during Period 2."
2386630|NCT03664453|Experimental|Dose Proportionality|"Subjects will be randomly assigned to one of two omaveloxolone dosages. A single dose of omaveloxolone (in either 50 mg or 100 mg) will be administered to the subjects in 50 mg capsules in a fasted state.~Subjects will be confined beginning on Study Day -1 through the last blood sample collection on Study Day 6."
2386631|NCT03664440|Placebo Comparator|continuation arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers, to continue their current regimen of NVP 200 mg twice daily plus TDF/3TC (group A1) and plus TDF/FTC (groupB1)
2386632|NCT03664440|Active Comparator|switch arm|patients who currently received TDF/3TC/NVP (group A) or TDF/FTC/NVP (group B) were block 4 randomly assigned (1:1) by computer-generated random numbers to switch from NVP to RPV 25 mg once-daily plus TDF/3TC (group A2) and plus TDF/FTC (groupB2)
2386633|NCT03664427||Group 1: Patients with VOD|paediatric patients with Veno-Occlusive Disease (VOD) complicating haematological stem cell transplantation
2386634|NCT03664427||Group 2: matched controls|Paediatric patients defined as matched controls without veno-occlusive disease complicating haematological stem cell transplantation
2386635|NCT03664414|Placebo Comparator|Placebo group|Placebo group will receive 1 tablet of cellulose pill to mimic pentoxifylline tablets three times a day with meals, during the following two years.
2386636|NCT03664414|Active Comparator|Pentoxifylline group|Pentoxifillyne or experimental group will receive 400 mg of pentoxifylline three times a day with meals, during the following two years.
2386637|NCT03664401|Experimental|Kerecis Oral™|The Fish Skin Graft will be is cut to shape of wound bed and placed directly on the appropriate prepared recipient wound bed. The Fish skin graft has the smooth side down and the scaly side facing out. The graft will be sutured in place at either coronal end with resorbable sutures and may be secured apically if needed. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed.
2386638|NCT03664401|Active Comparator|Autogenous Free Gingival Graft|"The recipient bed will be prepared at the appropriate sequential time as described. The graft will be harvested from the same side that the Free Gingival Graft is to be placed. A measurement will be made to determine the size of the donor tissue needed to be placed at the recipient site. Local anesthetic will be administered. The donor tissue will be harvested using the usual techniques. The width will be 5 mm and the length will match the predetermined measurement. The graft will be thinned as is usual practice.~The harvested palatal graft will be centered on the study tooth and placed on the appropriately prepared recipient wound bed. The graft will be sutured with resorbable sutures on the mesial and distal aspects of the tooth. A surgical dressing (Coe-Pak® ) will be placed over the graft if needed."
2386639|NCT03664375|Experimental|Experimental Group|The experimental group received botulinum toxin type A. After one week of Botox administration, a specially made task specific training program was started for these patients. It was provided for a duration of one hour and for three times per week for a total of 12 weeks by a trained physiotherapist.
2386640|NCT03664375|Placebo Comparator|Control Group|The control group received only task specific training program with the same protocol as for the experimental group; for a duration of one hour and for three times per week up to a total of 12 weeks by a trained physiotherapist
2386641|NCT03664362|Experimental|The BSHAPE Intervention|Participants in the BSHAPE intervention attend a 9 sessions program post-assessments which is a combination of individualized and group-based sessions.
2386642|NCT03664362|No Intervention|Usual care or no treatment control|Participants in the control arm either are receiving no services or are engaged in usual care provided by community-based/health care organizations
2386643|NCT03664349||Older Adult Participants and Informal/Formal Caregiver Pairs|A sub-cohort of approximately 10 participant-caregiver pairs will utilize SE9000 and communication strategies over a 4-6-week period between LVR visits.
2386644|NCT03664349||Older Adult Participants|The pilot cohort of approximately 100 adults over age 60, with vision impairment, will complete the Hearing Handicap Inventory for the Elderly (HHIE), an assessment of perceived impact of hearing impairment, and an objective hearing evaluation.
2386645|NCT03664349||Formal/Informal Caregivers|Identified persons who assist willing and eligible older adult pilot participants with two or more ADLs/IADLs.
2386646|NCT03664323||Group 1 Sequential strategy|Patients for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (19 patients, 63%).
2386647|NCT03664323||Group 2 Concomitant strategy|Patients for whom a combination of CT with anti-PD-1 therapy was initiated (11 patients, 37 %).
2386682|NCT03664050|Experimental|Group A Letrozole group|2.5 mg letrozole oral tablets will be administered on the 2nd -3rd day of menses and then every day for 5 days.
2386648|NCT03664310|Experimental|FSET Anxiety and Sleep Treatment|The FSET Anxiety and Sleep Treatment (FAST) is a brief, 45-minute computerized intervention that can be accessed by any device connected to the Internet. The majority of the information is delivered via text. The program contains some interactive features such as quizzes, which direct participants to content, personalized to the individual user (for example screenshots, see Figure 2). FAST contains four modules: motivation, psychoeducation, behavioral tools, and behavior change.
2386649|NCT03664310|Active Comparator|Control|The control condition is the Physical Health Education Treatment (PHET) used in several of our laboratory's prior studies (Schmidt, Capron, Raines, & Allan, 2014). PHET is also a 45-minute computerized intervention, including audio and visual features as well as comprehension quizzes.
2386650|NCT03664297|Experimental|SHR1459|Oral administration, once a day, 28 days for a cycle, until the disease progression or the intolerable toxicity occurs.
2386651|NCT03664284|Active Comparator|intervention group|
2386652|NCT03664284|No Intervention|control group|
2386653|NCT03664271|Experimental|in-clinic video intervention|Intervention: Caregivers will watch an educational video in clinic, and also be given information about how to access the video from home (ideal condition). The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
2386654|NCT03664271|Active Comparator|at home video intervention|Intervention: Caregivers will be given information about how to watch the video at home, but will not watch it in clinic (real-world condition).The intervention video will contain educational information about eczema, as well as routine skincare and common treatments.
2386655|NCT03664271|No Intervention|usual care|Control: Caregivers will not watch the educational video, but will be given access to it at the conclusion of the study.
2386656|NCT03664245||experimental group|Critically ill patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
3183444|NCT00713986|Experimental|Skin-to-skin|Patients in this group wil receive 2mL of water 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
2386659|NCT03664219|Active Comparator|isolation of IAN nerve with collagen membrane|
2386660|NCT03664219|Experimental|without isolation of the IAN with collagen|
2386661|NCT03664206||Patients|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
2386662|NCT03664206||Healthy subjects|"MRS, conventional TMS and treshold tracking TMS~The participants will be told not to consume coffee or alcohol or do exhausting exercise 12, 24 and 48 hours, respectively, prior to the examinations"
2386664|NCT03664180|Experimental|anticoagulation|
2386665|NCT03664180|Placebo Comparator|No anticoagulation|
2386666|NCT03664167|Experimental|intervention|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
2386667|NCT03664167|No Intervention|control|usual care
2386668|NCT03664154|Experimental|Stress and Feeding (SAFE)|The SAFE intervention is grounded in a general theory of guided participation (GP) that posits learning will be facilitated by an emotionally regulated state of the mother. Efforts to help mothers manage stress will better position them to learn and attend to feeding their infants. GP links the two components: stress management (SM) and guided feeding (GF). SM provides skills to manage perceived stress and regulate emotion. GF provides education with skill building to help mothers become more sensitive and responsive to their infant. SAFE is delivered through a secure, password-protected responsive website with practice opportunities.
2386669|NCT03664141|Placebo Comparator|Placebo group|1 drop of regular oil for food labeled as 3% cannabis oil once a day during 3 months
2386670|NCT03664141|Experimental|Cannabis oil group|1 drop of 3% cannabis oil once a day during 3 months
2386671|NCT03664128||pregnant women positive for anxiety|"100 pregnant women who screen positive for anxiety symptoms (>21 on the Perinatal Anxiety Screening Scale). Participants are matched for age, parity, and gestational age at enrollment.~Coping with Anxiety through Living Mindfully (CALM) Pregnancy: Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants)"
2386672|NCT03664128||healthy pregnant controls|100 matched healthy pregnant women. Participants are matched for age, parity, and gestational age at enrollment.
2386673|NCT03664115|Experimental|Itraconazole Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles + itraconazole 200 mg oral tablet daily, on a 21-day cycle.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
2386674|NCT03664115|Active Comparator|Control Arm|"Patients will receive intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
2386675|NCT03664102||Sutures with hand-tied knots|Minimally-invasive isolated aortic valve replacement with Sutures were secured with hand-tied knots
2386676|NCT03664102||Sutures with automated fastener device (Cor-Knot)|Minimally-invasive isolated aortic valve replacement with Sutures were secured with automated fastener device (Cor-Knot)
2386677|NCT03664089|Experimental|Intervention|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), instructions on ankle weight usage (wear during normal activity for 2 hours/day, 7 days/week). The weight type and weight amount were chosen based on previously published literature and used in our preliminary work.
2386678|NCT03664089|Placebo Comparator|Control|All women in the control group will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
2386679|NCT03664063|Active Comparator|Azithromycin for Yaws|Patients will receive standard treatment for yaws alone
2386680|NCT03664063|Active Comparator|IDA for Lymphatic Filariasis|Patients will receive standard IDA (Ivermectin & Diethylcarbamazine & Albendazole) treatment for Lymphatic Filariasis alone
2386683|NCT03664050|Active Comparator|Group B laparoscopic ovarian drilling group|bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
2386684|NCT03664037|Active Comparator|D group, (n=55)|
2386685|NCT03664037|Placebo Comparator|C group, (n=55)|
3142848|NCT00003594|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
2386687|NCT03664011|Experimental|All Subjects|
2386688|NCT03663998|Active Comparator|A|CN54ENV IM EP 400 g
2386689|NCT03663998|Active Comparator|B|CN54ENV IM EP 1000 g
2386690|NCT03663998|Active Comparator|C|CN54ENV IM EP 4000 g
2386691|NCT03663998|Active Comparator|D|CN54ENV ID EP 600 g
2386692|NCT03663998|Active Comparator|E|CN54ENV ID EP 1200 g
2386693|NCT03663998|Active Comparator|F|CN54ENV ID EP 1800 g
2386694|NCT03663998|Active Comparator|G|"CN54ENV IM1 EP~+ pIL-12 (500 g)"
2386695|NCT03663998|Active Comparator|H|"CN54ENV IM1 EP~+ pIL-12 (1500 g)"
2386696|NCT03663998|Active Comparator|I|"CN54ENV IM1 EP~+ ID2 EP"
2386697|NCT03663972|Active Comparator|Motoric Arm|Children will participate in an intervention based on traditional articulation approaches to speech therapy.
2386698|NCT03663972|Active Comparator|Phonologic Arm|Children will receive intervention that targets the conceptual representation of sounds.
2386699|NCT03663959||Vaginal Sacrospinous Fixation group|Women who had vaginal sacrospinous fixation procedure with Dr.Aksakal's Desta suture carrier in our clinic between January 2014 and June 2018.
2386700|NCT03663959||Laparoscopic Pectopexy Group|Women who had Laparoscopic Pectopexy procedure in our clinic between January 2014 and June 2018
2386701|NCT03663946||Patients taking combination therapy with Yervoy and Opdivo|Medical records will be reviewed for safety and treatments for specific ADR
3183445|NCT00713986|Experimental|Glucose|Patients in this group wil receive 2mL of glucose 25% 2 minutes prior vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
2386704|NCT03663907|Experimental|Telemonitoring|Structured follow-up in the basis of using telemedicine. Telemedicine will include daily signs and symptoms telemonitoring and structured follow-up by the means of video or audio-conference.
2386705|NCT03663907|No Intervention|Usual Care|Patients with usual care follow-up in a heart failure program.
2386706|NCT03663881|Experimental|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
2386707|NCT03663868|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
2386708|NCT03663868|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 3 of embryo growth (cleavage stage embryo)
2386709|NCT03663868|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as described by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on morphology on day 5 of embryo growth (blastocyst stage embryo)
2386711|NCT03663842|Experimental|Neural tissue management|Myofascial release technique; Hip joint mobilization technique; Cross-fiber friction over the sacroiliac joints; Neural mobilization to improve sciatic nerve excursion.
2386712|NCT03663829||Participants RA who have received a TNFi|
2386713|NCT03663829||Participants with RA who have received abatacept|
2386715|NCT03663803|Experimental|Intervention|Participants in the intervention group received the offer of four 2h group sessions during five weeks, and two further sessions after one and six months. The attendance rates of the sessions were 95%, 88%, 87%, 73%, 67% and 51%, respectively. The course was delivered by health care staff in the Holstebro Health Care Centre, including a dietitian and an occupational therapist, both with health pedagogic competences. It was delivered to seven intervention groups, which varied in size from 5 to 15 participants.
2386716|NCT03663803|No Intervention|Control|Usual practice
2386717|NCT03663790|No Intervention|Control|No intervention
2386718|NCT03663790|Experimental|Foot Progression|Participants will visualize a desired foot progression angle bandwidth in real-time that they should target with their foot angle
2386719|NCT03663790|Experimental|Trunk Lean|Participants will visualize a desired trunk lean angle bandwidth in real-time that they should target with their trunk lean angle
2386720|NCT03663777|Experimental|Isometric Handgrip Training|Experimental group will perform home-based bilaterall handgrip exercise and will be recommended to increase daily physical activity levels.
2386721|NCT03663777|Other|Control group|Control gorup will be recommended to increase daily physical activity level
2386723|NCT03663751|Experimental|Treatment|The peripheral and bone marrow T cell and mono nucleated cell chimerism will be closely followed-up. In case of decreasing donor chimerism, patients will receive low-dose decitabine with 5mg/m2 daily for 5 days every 6-8 weeks until the chimerism recovered to full donor type (>98%).
2386797|NCT03663244|Experimental|MindfulnessBasedStressReduction(MBSR)|Standardised, curriculum-based MBSR-programme: 2.5-hour weekly group sessions over 8 weeks; one 6-hour silence retreat day; and 45 minutes daily homework 6 days a week.
2386724|NCT03663738|Active Comparator|health mobile app for T2DM patients|It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
2386725|NCT03663738|No Intervention|Control|Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)
2386726|NCT03663725|Experimental|Intensified protocol|Early Temozolomide (TMZ) Concomitant TMZ Adjuvant TMZ Prolonged TMZ
2386727|NCT03663725|Active Comparator|Stupp protocol|Concomitant Temozolomide (TMZ) Adjuvant TMZ
3142849|NCT00003594|Experimental|oxaliplatin + leucovorin + fluorouracil|"Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
2386729|NCT03663699|Experimental|Exergaming|24 week access to the exergaming platform PlayPulse
2386730|NCT03663699|No Intervention|Control|Asked to continue with their normal daily routine
2386731|NCT03663686|Placebo Comparator|25mg single doses|Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386732|NCT03663686|Placebo Comparator|50mg single doses|Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386733|NCT03663686|Placebo Comparator|100mg single doses|Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386734|NCT03663686|Placebo Comparator|200mg single doses|Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386735|NCT03663686|Placebo Comparator|400mg single doses|Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386736|NCT03663686|Placebo Comparator|600mg single doses|Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386737|NCT03663686|Placebo Comparator|800mg single doses|Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily
2386738|NCT03663673|Other|Clinical pilot study|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
2386739|NCT03663660||before the OIPP|Period 1 : Children hospitalized before the OIPP implementation
2386740|NCT03663660||after the OIPP implementation|Period 2 :Children hospitalized after the OIPP implementation
2386741|NCT03663634|Experimental|Handling Medium Supplemented with Cytochalasin B|
2386742|NCT03663634|No Intervention|Handling Medium as it is.|
2386743|NCT03663621||Initial survey and interview (Aim 2)|Participants in Aim 2 will be asked to complete an initial 15-minute survey and 20-30 minute semi-structured interview. The purpose of this study is to learn the best ways to support healthful behaviors and weight loss prior to pregnancy. Researchers are also interested in what motivates or prevents women of reproductive age from engaging in a structured weight loss program.
2386744|NCT03663621||Formal weight loss program (Aim 3)|Participants in Aim 3 have expressed interest in referral to the Mass General Weight Center. The purpose of this study is to learn what motivates or prevents women of reproductive age from engaging in a structured weight loss program. Researchers will ask for no more than a half hour of participant's time to complete a 5- minute interview following Orientation at the Weight Center and another 10-minute interview after a participant has participated in a program offered at the Weight Center.
2386745|NCT03663595|No Intervention|Control Group|Females asymptomatic for patellofemoral pain syndrome
2386746|NCT03663595|Experimental|PFPS: Proximal factors - Model 1 (Hip and Knee)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
2386747|NCT03663595|Experimental|PFPS: Proximal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in proximal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in distal (foot and ankle) and local (knee) factors.
2386748|NCT03663595|Experimental|PFPS: Distal factors - Model 1(Hip and Knee)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in proximal (hip) and local (knee) factors.
2386749|NCT03663595|Experimental|AKP: Distal factors - Model 2 (knee, foot and ankle)|Females symptomatic for PFPS with modification in distal factors related to patellofemoral pain. This group will be submitted to the rehabilitation program with exercises focusing in local (knee) and distal (foot and ankle) factors.
2386752|NCT03663556||Very Preterm Infants|Newborn infants with less than 32 weeks admitted in the NICU.
2386798|NCT03663244|Experimental|Local Stress Reduction (LSR)|Local stress reduction programme ; developed and delivered by two local psychologists. This programme is delivered in groups of 12 participants, in 2.5-hour weekly sessions over 8 weeks and includes approximately 10 minutes daily homework between the sessions.
2386799|NCT03663244|No Intervention|Wait-list|Usual practice
2435965|NCT03326466||Healthy Controls|
2386753|NCT03663543|Active Comparator|Active Arm|Participants randomized to the active arm will receive a single infusion of conjugated estrogens at the time of admission if within 8 hours of the expected surgery time or at approximately 8 hours to the expected surgery time if admission is earlier than that. Participants will then receive two daily infusions of conjugated estrogens after transplant given at 8 hours after reperfusion of the transplanted kidney and 24 hours after the first post transplant dose (32 hours after reperfusion of the transplanted kidney).
2386754|NCT03663543|Placebo Comparator|Placebo Arm|Participants randomized to the placebo arm will receive normal saline (0.9% sodium chloride) at the same rate as the active arm.
2386755|NCT03663530|Experimental|Circadian misalignment|Meals in this condition will be delayed by 4 hours relative to the circadian alignment condition. Food intake during this period will be from 1 PM to 11 PM.
2386756|NCT03663530|Active Comparator|Circadian alignment|Meals in this condition will be aligned to the sleep episode. Food intake during this period will be from 9 AM to 7 PM.
2386757|NCT03663517||pregnant women|pregnant women in Hong Kong
2386758|NCT03663504|Active Comparator|No Preparation|No preparation before surgery
2386759|NCT03663504|Active Comparator|Oral Antibiotics|Oral antibiotics (neomycin and flagyl), to be taken the day before the surgery
2386760|NCT03663491|Experimental|Unsedated Nasal Gastroscopy|Transnasal Endoscopy. No sedation used. Use of local anesthesia.
2386761|NCT03663491|Active Comparator|Oral Gastroscopy, unsedated|Transoral Endoscopy. No sedation used. Use of local anesthesia.
2386762|NCT03663491|Active Comparator|Oral Gastroscopy, sedated|Transoral Endoscopy. Intravenous sedation used.
2386763|NCT03663478|Active Comparator|Intervention|Ropivacaine
2386764|NCT03663478|Placebo Comparator|Control|Isotonic saline
2386765|NCT03663465|Experimental|Hawthorn and SGAs|SGAs has a dose of 3-20 gm/day, Hawthorn at a dose of 3 gm/day for six months.
2386766|NCT03663465|Active Comparator|Hawthorn|Hawthorn at a dose of 3 gm/day for six months.
2386767|NCT03663452|Active Comparator|Prolonged exposure training|
2386768|NCT03663452|Experimental|TACTICS|
2386769|NCT03663439|Experimental|modified shell technique|block of bone from the mandibular ramus divided into two shells ,grafting one shell in the anterior maxilla to increase width
2386770|NCT03663439|Active Comparator|onlay bone graft|grafting block of bone from the mandibular ramus in the atrophic anterior maxilla
2386771|NCT03663426|Active Comparator|control group opioid anesthesia|standard anesthesia using opioids
2386772|NCT03663426|Experimental|study group opioid free anesthesia|opioid free anesthesia and high dose glucocorticoids
2386773|NCT03663413||BIS|Monitored with BIS (bispectral index) monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
2386774|NCT03663413||Narcotrend|Monitored with Narcotrend monitor in addition to other conventional monitors of blood pressure, ECG, oxygen saturation and anesthetic agent concentration.
3183446|NCT00713986|Experimental|Skin&Glucose|Patients in this group wil receive 2mL of glucose 25% PO 2 minutes prior vaccination and will be put on skin-to-skin contact with their mothers at the same time. After this time cleansing of the right tigh will be done followed by intra-muscular injection for hepatitis B vaccination. Patients will stay on skin-to-skin contact with their mothers for the following 2 minutes after injection. Infants will not receive any additional sensorial stimulation during the whole procedure outside the prespecified above.
2386776|NCT03663387||Normal subjects|70
2386777|NCT03663374|Experimental|Odelepan|One tablet once daily
2386778|NCT03663374|Placebo Comparator|Placebo|One tablet once daily
2386779|NCT03663361|Experimental|SMART Intervention|"The SMART intervention will utilize the elements of the Standard of Care intervention, and will also include Sensorimotor Improvements and other specific additions that will focus on sensory inputs, motor outputs, and integration of the sensory and motor pathways."
2386780|NCT03663361|Active Comparator|Standard of Care Intervention|The Standard of Care intervention will include restoration of ankle joint range of motion, strength and functional movement.
2386781|NCT03663335|Experimental|Arm 1/Cohort 1|CFZ533 dose A+ MMF + Corticosteroids
2386782|NCT03663335|Experimental|Arm 2/Cohort 1|CFZ533 dose B + MMF + Corticosteroids
2386783|NCT03663335|Active Comparator|Arm 3/Cohort 1|Control/Standard of Care: TAC + MMF + Corticosteroids
2386784|NCT03663335|Experimental|Arm 1/Cohort 2|CFZ533 dose C + MMF ± Corticosteroids
2386785|NCT03663335|Active Comparator|Arm 2/Cohort 2|Tac + MMF ± Corticosteroids
2386786|NCT03663322|Experimental|OMT Protocol|Subjects assigned to this arm will have selected osteopathic manipulative treatment techniques administered during the treatment sessions
2386787|NCT03663322|Sham Comparator|OMT-Sham Protocol|Subjects assigned to this arm will have sham-osteopathic manipulative treatment techniques administered during the treatment sessions
2386788|NCT03663309||study group|"Children and adolescents aged 2-17 years, reported to be on gluten free diet for at least a year, diagnosed with celiac disease~Children and adolescents aged 2-17 years that are reported to be noncompliant with gluten free diet, diagnosed with celiac disease for at least 1 year."
2386789|NCT03663309||control group|Healthy controls aged 2-17 years old matched for age and sex.
2386790|NCT03663296|Experimental|Interventional|Additional 30 minutes of self-directed learning and practice using the mobile application, after conventional training session
2386791|NCT03663296|No Intervention|Control|Conventional training session which includes didactic teaching and low-fidelity simulation session involving trainer's demonstration, followed by hands-on practice
3183447|NCT00713999|Experimental|STI/PZQ 1|Baseline and post-treatment follow-up (anti-STI and praziquantel Rx)
3183448|NCT00714012||1 Visualization users|End users of the domain specific visualizations.
2386794|NCT03663270|Active Comparator|Intervention arm|HPI monitoring to predict hypotension
2386795|NCT03663270|No Intervention|Control arm|blinded HPI monitoring
2386796|NCT03663257||AneurysmFlow Observational Cohort|Subjects with unruptured, >5mm saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent enrolled at the centers participating in this CARO study.
3183449|NCT00714025|Experimental|I|40 patients with metastatic or locally advanced transitional bladder cancer with failed platinum-based chemotherapy receiving RAD001 10mg daily PO.
3183450|NCT00714038||1|Patients with asthma in primary care
2386802|NCT03663218|Other|Single Arm|This is a modified dose escalation and de-escalation study with an expansion of 3 or 6 pts to allow the recommended phase II dose (RP2D) be examined in a total of 9 pts. The dose limiting toxicity (DLT) is defined as Grade 3 or higher toxicity related to preoperative radiotherapy according to the Clavien-Dindo Classification. 3 radiation dose levels, 5 Gy, 6 Gy and 6.5Gy are considered. At the start of each dose level, 3 pts will be enrolled and treated for five days. If none of the 3 pts develop the DLT, the testing dose will escalate to the next level. If 1 of the 3 pts develops the DLT, the current dose will be tested in an additional 3 pts. If no additional pts develop the DLT, the dose will escalate.
3142850|NCT00003594|Experimental|oxaliplatin + irinotecan|"Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.~Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3142851|NCT00003595|Experimental|Arm I|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 3 and oral prednisone on days 3-7. Patients receive rituximab on day 1. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response in the absence of disease progression or unacceptable toxicity. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy with rituximab followed by radiotherapy beginning 3 weeks after completion of the third course. Patients who achieve partial response for a minimum of 28 days or complete response receive maintenance rituximab IV beginning on day 28 of the final course of chemotherapy. Maintenance rituximab treatment repeats every 4 weeks for 3 courses.
3183451|NCT00714064|Active Comparator|23vPPV in Pregnancy|
3183452|NCT00714064|Active Comparator|23vPPV at Birth|
3183453|NCT00714064|Other|Control|Control
3183454|NCT00714077||adjuvant capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
2386809|NCT03663153||SEMA4C high value follow-up group|Postoperative SEMA4C value is higher than 5.00 ng/ml.
2386810|NCT03663153||SEMA4C low value follow-up group|Postoperative SEMA4C value is lower than 5.00 ng/ml.
2386811|NCT03663140||Group 1-Health periodontal|This group created by individuals with healthy periodontal tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386812|NCT03663140||Group 2- Healthy peri-implant|This group created by individuals with healthy peri-implant tissues. Periodontal status/peri-implant was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386813|NCT03663140||group 3- Gingivitis|This group created by individuals with gingivitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386814|NCT03663140||Group 4-Peri-implant Mucositis|This group created by individuals with peri-implant mucositis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386815|NCT03663140||Group 5-Periodontitis|This group created by individuals with periodontitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386816|NCT03663140||Group 6-Periimplantitis|This group created by individuals with peri-implantitis. Periodontal/peri-implant status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions.
2386817|NCT03663127|Experimental|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage."
2386818|NCT03663127|Placebo Comparator|Placebo|Subjects receive two bottles placebo per day for 8 weeks of a stage.
2386819|NCT03663114||Lenvatinib|Participants receiving lenvatinib capsules 12 milligrams (mg) based on participant's body weight greater than or equal to (>=) 60 kilograms (kg) or 8 mg based on participant's body weight less than (<) 60 kg, orally, once daily dose will be centrally registered and observed prospectively for up to 1 year after the administration of dose.
3183455|NCT00714077||adjuvant oxaliplatin and capecitabine|To compare different adjuvant concurrent chemoradiotherapy regimen (Oxaliplatin with capecitabine vs capecitabine) for patients with II/III rectal cancer
3183456|NCT00714090|Active Comparator|A|Double active comparator : venlafaxine (150 mg/day) and rTMS (5 times/week)
3183457|NCT00714090|Experimental|B|active rTMS (5 times/week) and sham venlafaxine (150 mg/day)
3183458|NCT00714090|Sham Comparator|C|sham rTMS (5 times/week) and active venlafaxine (150 mg/day)
3183459|NCT00714103|Experimental|8-Chloro-Adenosine|Starting dose for first cohort of patients 45 mg/m2 intravenous over 1 hr daily for 5 days every 4 weeks (± 3 days).
3183460|NCT00714116|Experimental|SBI-087|
3183461|NCT00714129|Experimental|1|Weight loss diet - normal diet
2386827|NCT03663075|Experimental|Group 1|This group will receive the intervention Group information (GI).
2386828|NCT03663075|Experimental|Group 2|This group will receive the intervention Group information (GI) followed by Structured person-centered support (PCS)
2386829|NCT03663075|Experimental|Group 3|This group will receive the intervention Structured person-centered support (PCS)
2386830|NCT03663075|No Intervention|Group 4|This is a control group.
2386831|NCT03663049|No Intervention|Usual care|These patients will continue as statins as usual.
2386832|NCT03663049|Experimental|Discontinue statin|Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.
2386833|NCT03663036|Experimental|FL-ASCR|Magnetic Resonance Imaging of the shoulder Radiograph of the shoulder
3183462|NCT00714129|Experimental|2|Weight loss diet - low in simple sugars (specifically fructose)
3183463|NCT00714142|Active Comparator|1|Normal volunteers
3183464|NCT00714142|Active Comparator|2|Renal failure patients on dialysis
3183465|NCT00714142|Active Comparator|3|Renal artery stenosis patients
3183466|NCT00714155||1|Physical examination, questionnaires, retrospective chart review
3183467|NCT00714155||2|Questionnaires, retrospective chart review
2386838|NCT03662984|Active Comparator|Ciprofibrate|1dd100mg at breakfast
2386839|NCT03662984|Placebo Comparator|Placebo|1dd0mg at breakfast
2386840|NCT03662971|Experimental|0.0005% single-dose|Two subjects will be treated with Germinal peptide eye drops 0.0005% single dose.
2386841|NCT03662971|Experimental|0.001% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.001% single dose (eight treatment and two placebo).
2386842|NCT03662971|Experimental|0.002% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% single dose (eight treatment and two placebo).
2386843|NCT03662971|Experimental|0.004% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% single dose (eight treatment and two placebo).
2386844|NCT03662971|Experimental|0.008% single-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% single dose (eight treatment and two placebo).
2386845|NCT03662971|Experimental|0.002% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.002% multiple dose (eight treatment and two placebo).
2386846|NCT03662971|Experimental|0.004% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.004% multiple dose (eight treatment and two placebo).
2386847|NCT03662971|Experimental|0.008% multiple-dose|Ten subjects will be treated with Germinal peptide eye drops 0.008% multiple dose (eight treatment and two placebo).
2386848|NCT03662958|Experimental|Lutrate|a novel leuprolide acetate 3.75mg depot
2386849|NCT03662958|Active Comparator|Enantone|market reference leuprolide acetate 3.75 mg depot
2386850|NCT03662945|Experimental|Intervention group|Mobile Geriatric Team intervention including physicians and nurses with the aim of developing person-centered, safe, sustainable and coordinated care plans. These care plans are developed in collaboration with the patient, his/her relatives and staff from the municipality. Among the main ambitions of this concept are improved communication flows between patients, their relatives and healthcare providers in combination with the delivery of medical as well as care measures. Other ambitions are to avoid unnecessary traditional healthcare utilization in the form of inpatient care and EMR visits, for example.
2386851|NCT03662945|No Intervention|Control group|Standard care including primary care units, home care and home help.
2386852|NCT03662932|Experimental|Early intensive mobilization|Progressed mobilization from postoperative day 0.
2386853|NCT03662919||Flixabi|Infliximab naive participants or participants who were previously treated with other infliximab biologics will receive Flixabi (infliximab) as prescribed by physician according to the local prescribing procedures.
2386854|NCT03662919||Imraldi|Adalimumab naive participants or participants who were previously treated with other adalimumab biosimilars will receive Imraldi (adalimumab) as prescribed by physician according to the local prescribing procedures.
3142852|NCT00003595|Active Comparator|Arm II|Patients receive cyclophosphamide IV, doxorubicin IV, and vincristine IV on day 1 and oral prednisone on days 1-5. Treatment repeats every 3 weeks for a minimum of 4 courses or 2 courses beyond complete response. Patients with stage I, stage IE (including bulky), or nonbulky stage II or IIE disease receive 3 courses of chemotherapy. Patients receive radiotherapy beginning 3 weeks after completion of the third course of chemotherapy.
3142853|NCT00003597|Experimental|Cohort 1|Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). rhTPO began on the last day of ICE (Ifosfamide, Carboplatin and Etoposide) chemotherapy (Day 4) and subsequent doses will be administered on Days 6, 8, 10 and 12 (5 doses total). The initial dose of rhTPO was 1.2 μg/kg/dose and was subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one only).
2386857|NCT03662893|Sham Comparator|Behavioural therapy with written guideline|Patients were instructed to apply only written guideline forms of behavioural therapy which were the same as those in the checklist over six-month period.
2386858|NCT03662893|Active Comparator|Behavioural therapy with checklist|Patients were instructed to apply behavioural therapy with a written checklist for patients to fully complete over six-month period.
2386859|NCT03662893|Active Comparator|antimuscarinic drug plus verbal behavioural therapy|Patients received medical treatment (once or twice per day) plus behavioural therapy without checklist over six-month period.
2386860|NCT03662893|Active Comparator|antimuscarinics plus checklist|Patients received medical treatment (once or twice per day) with a written checklist to fully complete over six-month period.
2386861|NCT03662880|Other|Cardiac Magnetic Resonance &Trans-esophageal echo|patients undergo Percutaneous Mitral Commissurotomy will do cardiac magnetic resonance and trans esophageal echo for detection of left atrial thrombus
2386862|NCT03662867|Experimental|Family-based mindfulness intervention|Family-based mindfulness intervention is a parallel-group intervention containing one parent program and one child program. The parent mindfulness program lasts for 6 weeks, one session per week, and each session lasts for 1.5 hours. The child mindfulness program lasts for 8 weeks, one session per week, and each session lasts for 1 hour. In the fourth and sixth sessions of the parent program, 30-minute joint practice of parents and children is incorporated. All sessions are implemented by qualified instructors.
2386863|NCT03662867|Other|Wait-list control|Intervention group participants were assessed at baseline (T1) and after the intervention (T2). Control group participants were assessed at the same time with the intervention group, and would receive the same program after posttest of intervention groups.
2386864|NCT03662854|Experimental|Hair Stimulating Complex|Hair Stimulating Complex (HSC) is derivative of hypoxia-induced multipotent cell conditioned media enriched for certain key growth factors
2386865|NCT03662854|Placebo Comparator|Phosphate Buffered Saline|Phosphate Buffered Saline
2386866|NCT03662841|Other|ACE for HCC of size >10cm|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
3183468|NCT00714155||3|Retrospective chart review
2386868|NCT03662802||ECG Data|Coded data including; wavelengths, amplitude, intervals, timing, frequence
2436579|NCT03321981|Experimental|Cohort 1 triplet|
3142854|NCT00003597|Experimental|Cohort 2|"Chemotherapy days 0-4, G-CSF (5 μg/kg/d) as a daily subcutaneous injection beginning on Day 5. All patients receive recombinant human thrombopoietin (rhTPO). The dose of rhTPO 1.2 μg/kg/dose and subsequently escalated to 2.4 and 3.6 μg/kg/dose as tolerated. Patients assigned to Cohort II will receive pre-chemotherapy rhTPO at 3.6 μg/kg/dose on Days -5, -3, -1, and post-chemotherapy rhTPO on Days +4, +6, and +8 (6 doses total. Subsequent courses of chemotherapy will begin as soon as the ANC recovers to~≥ 1,000/μL and the platelet count to ≥ 100,000/μL between days 21 and 35. Therapy will continue for maximum six courses. Pharmacokinetic data will be obtained (during course one nly). For the second cohort, full data collection will occur for cycles one and two and limited data collection for cycles 3, 4, 5, and 6."
3142855|NCT00003599|Experimental|Arm I|Alpha-tocopherol (AT) orally and isotretinoin orally daily (arm I)
2386873|NCT03662763|Placebo Comparator|Placebo|
2386874|NCT03662763|Experimental|Extended-release Guanfacine Hydrochloride (SPD503)|
2386876|NCT03662737||Group 1 -Chronic cannabis use|Individuals between 18 and 50 years old who have been using at least 2 joints per day for at least 3 years. They should have used cannabis during the last 24h but not during the 3h prior to participation to the study and they should test positive for cannabis in their urine. Individuals with another substance use or severe mental disorder will be excluded (except tobacco use)
2386877|NCT03662737||Group 2 - Alcohol dependence|Individuals between 18 and 50 years old diagnosed with alcohol use disorder according to DSM-V criteria and have been consuming alcohol for at least 3 years. Individuals who are diagnosed with another substance use or severe mental disorder will be excluded (except tobacco use).
2386878|NCT03662737||Control Group|Individuals matched in gender and age with the experimental groups and with no diagnosis of substance use or severe mental disorder (except tobacco use)
2386879|NCT03662711|Active Comparator|Long-acting beta-agonist (LABA) or LABA/LAMA|long-acting bronchodilator agents (LABD, LAMA or LABA/LAMA) but no inhaled steroids plus usual care for comorbidities
2386880|NCT03662711|Experimental|Long-acting muscarinic antagonist (LAMA) and/or LABA plus ICS|Bronchodilator agents LAMA and/or LABA with inhaled steroids plus usual care for comorbidities
2386881|NCT03662698|Experimental|Guided Imagery|The GI intervention will include direct, written, and audio delivery of one of three GI vignettes (depiction).The patient will be able to choose one of the three vignettes.
2386882|NCT03662698|Active Comparator|Treatment as Usual|The control, or treatment as usual condition, will include an orientation to RT from the clinic nurse coordinator.
2386883|NCT03662685|Active Comparator|Goeckerman Therapy|Patients with psoriasis who will receive Goeckerman therapy 5 days per week for 6 weeks.
2386884|NCT03662685|Active Comparator|Phototherapy Only|Patients with psoriasis who will receive narrowband ultraviolet B (NB-UVB) phototherapy 3 days per week for 12 weeks.
2386885|NCT03662685|Active Comparator|Crude Coal Tar Only|Patients with psoriasis who will receive skin treatment with crude coal tar only 5 days per week for 6 weeks.
2386886|NCT03662672|Experimental|Rib-raising Intervention|We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
2386887|NCT03662672|Sham Comparator|Sham Intervention|We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
3142856|NCT00003599|Experimental|Arm II|Isotretinoin orally plus AT placebo orally daily (arm II).
3142857|NCT00003600|Experimental|epoetin alfa|Patients receiving chemotherapy are randomized to receive epoetin alfa subcutaneously once a week for a maximum of 16 weeks Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
2386890|NCT03662646||IBD patients|
2386891|NCT03662646||Healthy controls|
2386892|NCT03662633||Breast cancer group|Patients who have histologically confirmed new diagnosis of breast cancer are recruited.
2386893|NCT03662633||Benign breast tumor group|Patients who have histologically confirmed new diagnosis of benign breast tumors are recruited.
2386894|NCT03662620|Experimental|ARM1|"In ARM1, 32 subjects will be assigned and the subjects will be administered comparator drug at Day1/Day43 and study drug at Day22/64."
2386895|NCT03662620|Experimental|ARM2|"In ARM2, 32 subjects will be assigned and the subjects will be administered study drug at Day1/Day43 and comparator drug at Day22/64."
2386896|NCT03662607|No Intervention|Control|Standard pre-procedural education for cardiac catheterization.
2386897|NCT03662607|Experimental|Treatment|Standard pre-procedural education plus virtual reality experience for cardiac catheterization.
2386898|NCT03662594|Other|ECMO tube|
2386899|NCT03662581|Experimental|Mindfulness Group Program|A primary care mindfulness-based rolling admissions program where subjects must attend 4 of 8 consecutive group sessions, to be considered to have completed the program.
2386900|NCT03662568|Experimental|Part A:Group A|Subjects will receive GLS4+RTV on Day 1,followed by ETV on Day11-21 and co-administration with GLS4+RTV on Day 21.
2386901|NCT03662568|Experimental|Part A:Group B|Subjects will receive ETV on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with ETV on Day 21.
2386902|NCT03662568|Experimental|Part B:Group C|Subjects will receive GLS4+RTV on Day 1,followed by TDF on Day11-21 and co-administration with GLS4+RTV on Day 21.
2386903|NCT03662568|Experimental|Part B:Group D|Subjects will receive TDF on Day 1,followed by GLS4+RTV on Day11-21 and co-administration with TDF on Day 21.
2386904|NCT03662555|Experimental|NMES and BFR (80%)|Group 1, participants will undergo NMES and BFR (80% pressure) applied to the quadriceps for 25 min.
2386905|NCT03662555|Experimental|NMES and BFR (40%)|Group 2, participants will undergo NMES and BFR (40% pressure) applied to the quadriceps for 25 min.
2386906|NCT03662555|Active Comparator|NMES alone|Group 3, participants will undergo NMES applied to the quadriceps for 25 min.
2387022|NCT03661918|Other|Group 3|In-person first session, second caregiver, no wifi-enabled scale
2436580|NCT03321981|Experimental|Cohort 2|
3142858|NCT00003600|Placebo Comparator|placebo|Patients receiving chemotherapy are randomized to receive placebo subcutaneously once a week for a maximum of 16 weeks. Quality of life is assessed at randomization and monthly throughout study. Patients are followed every 6 months for 1 year.
3142859|NCT00003610|Experimental|capsaicin + radiation therapy|Patients receive one lozenge orally of capsaicin four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
3142860|NCT00003610|Placebo Comparator|placebo + radiation therapy|Patients receive one lozenge orally of placebo four times daily. Treatment begins within the first 3 days of radiation therapy and continues during and for two weeks after radiation therapy is completed.
2386910|NCT03662529|Experimental|Mind Freedom Plan therapy sessions|The Four-Session Mind Freedom Plan (MFP) is cognitive behavioral therapy (CBT)-based, client-centered, manualized individual therapy that functions as part of intensive outpatient substance abuse treatment. The MFP model is based on efficacious brief interventions, with content and format driven from military veteran feedback. The four 60-minute MFP sessions were one-on-one private consultations with a therapist that were focused on identifying and changing unhealthy thinking and behavioral patterns as core elements of CBT, but with an emphasis on problem-solving, coping skills, goal setting, and psychosocial functioning. At each session, structured worksheets were utilized and homework was assigned to facilitate this CBT-based skill building.
2386911|NCT03662529|Active Comparator|Treatment as usual therapy|The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
2386912|NCT03662516|Other|Sequence 1|In Treatment Sequence 1, Period 1 Day 1, subjects will be dosed with a single administration of OC in the form of 1 PORTIA (EE and LN) or equivalent tablet, orally. OC (EE and LN) PK will then be assessed at pre dose and over 48 hours after OC dosing. Period 1 will be immediately followed by Period 2 with no washout. The 48 hours post-OC dose PK sample for Period 1 must be collected prior to receiving the first dose of PF 04965842 in Period 2. In Period 2, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK in Period 2 will be assessed at pre dose and over 48 hours after OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11.
2386913|NCT03662516|Other|Sequence 2|In Treatment Sequence 2, Period 1, subjects will be dosed with 200 mg PF 04965842 PO QD for 9 days followed by administration of a single dose of OC oral tablet immediately after administration of a 200 mg dose of PF-04965842 on the morning of Day 10. OC PK will be assessed at pre dose and over 48 hours following OC dosing. Dosing with 200 mg PF 04965842 PO QD will continue until Day 11. Subjects will then undergo a washout period of at least 10 days (Day -1 of Period 2 starts 10 days after Day 12 of Period 1). In Period 2 subjects will be dosed with a single OC administration on Day 1. OC PK will then be assessed at pre dose and over 48 hours after OC dose.
2386914|NCT03662503||nutrition not aggressive group|"Children will be grouped according to their calorie and protein during the first week of life. The tertile 1 will represent the group of children with the lowest nutritional intake (called the nutrition not aggressive )"
2386915|NCT03662503||aggressive nutrition group|"Children will be grouped according to their calorie and protein during the first week of life. the tertile 3 will define the group of children presenting the contributions highest nutritional levels (called the aggressive nutrition group)"
2386916|NCT03662490||patient|Patient who performed a High resolution oesophageal manometry (HRM) for the diagnosis of oesophageal motility disorder.
2386917|NCT03662477|Experimental|EGFR+NK+|The EGFR mutation positive patients were with the principles of randomized and NK cells treatment.
2386918|NCT03662477|No Intervention|EGFR+NK-|The EGFR mutation positive patients were with the principles of randomized and without NK cells treatment .
2386919|NCT03662477|Experimental|EGFR-NK+|The EGFR mutation negative patients were with the principles of randomized and NK cells treatment .
2386920|NCT03662477|No Intervention|EGFR-NK-|The EGFR mutation negative patients were with the principles of randomized and without NK cells treatment.
2386921|NCT03662451|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
2386922|NCT03662451|Active Comparator|Robotic multi-site hysterectomy|Robotic multi-site hysterectomy is performed in this arm
2386923|NCT03662438|Other|Study Participants|"This is a self-controlled study where participants will serve as their own controls. All participants will be enrolled into a 10 week home-based physiotherapy program which will include a total of 2 home visits by a physiotherapist at the start and midpoint of the program. Participants will also receive weekly telephone calls by a research coordinator to provide encouragement for patient on the programme and enquire about compliance to the home exercise regimen and safety (e.g. falls and healthcare utilisation).~Patients will also be prescribed a lightweight portable oxygen concentrator to facilitate exercise therapy and mobility in the community. They will receive familiarisation and training in its usage as part of the home-based physiotherapy program."
2386924|NCT03662425|Experimental|schizophrenia with oxytocin|Participants self-administered the oxytocin twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of oxytocin.
2386925|NCT03662425|Placebo Comparator|schizophrenia with Placebo|Participants self-administered the placebo twice daily via intranasal route: before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of oxytocin spray containing approximately 24 international units of placebo.
2386926|NCT03662412|Experimental|Sirolimus treatment|Oral solution of sirolimus, 2mg, once a day. The trial will be terminated when a serious adverse reaction occurred, or the tumor progressed rapidly twice in a row, or when the patient did not want to continue.
2386927|NCT03662399|Experimental|Insole A|Investigational product - Insole A
2386928|NCT03662399|Experimental|Insole B|Investigational product - Insole B
2386929|NCT03662399|Experimental|Insole C|Investigational product - Insole C
2386930|NCT03662399|Experimental|Insole D|Investigational product - Insole D
2386931|NCT03662399|Experimental|Insole E|Investigational product - Insole E
2386932|NCT03662399|Experimental|Insole F|Investigational product - Insole F
2386933|NCT03662399|Experimental|Insole G|Non-Investigational product - Standard shoe
2386935|NCT03662373||carbon ions radiation therapy|the group of patients treated with carbon ion radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
2386936|NCT03662373||protons radiation therapy|the group of patients treated with proton radiation therapy, affected by one of the four pathologies foreseen in inclusion criteria
3183469|NCT00714194|Other|1|Patients in the control group will receive continuous sedative infusions without daily interruption of sedatives based on the standard clinical practice of the TICU.
3183470|NCT00714194|Experimental|2|Patients in the intervention group will receive daily interruption of sedative.
3183471|NCT00714207|Experimental|NOT Intervention|Students in this arm of the study were randomized to receive the reformatted NOT program
3183472|NCT00714207|Active Comparator|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
2386941|NCT03662321||sexual behavior on the internet|this group of teenagers use internet for sexuality
2386942|NCT03662321||not sexual behavior on the internet|this group of teenagers doesn't use internet for sexuality
3183473|NCT00714207|Experimental|KB intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
2386947|NCT03662269|Experimental|indomethacin treatment group|indomethacin (75mg, bid) + omeprazole (20mg, qd)
2386948|NCT03662269|Placebo Comparator|placebo treatment group|placebo (75mg, bid) + omeprazole (20mg, qd)
2386949|NCT03662256|Active Comparator|Current Primary Care Referral Process|In communities randomized to the current primary care process, families will be notified if their children refer hearing screening in exactly the same method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. Per current practice, most preschools also give the list of referred children to the Norton Sound Audiology Department, whose staff then reaches out to families to schedule appointments during the next available audiology clinic.
2386950|NCT03662256|Experimental|Expedited Telemedicine Referral|In communities randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
2386951|NCT03662243||Acquired brain injury participants|People with acquired alexia and/or agraphia secondary to brain injury who participate in the reading/writing intervention.
2386952|NCT03662217|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
2386953|NCT03662217|Other|ADA- based diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes
2386954|NCT03662204||Breast|Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386955|NCT03662204||Lung|Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386956|NCT03662204||Colorectal|Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386957|NCT03662204||Prostate|Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386958|NCT03662204||Bladder|Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386959|NCT03662204||Uterine|Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386960|NCT03662204||Kidney & Renal Pelvis|Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386961|NCT03662204||Pancreatic|Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2387023|NCT03661918|Other|Group 4|In-person first session, second caregiver, wifi-enabled scale
2386962|NCT03662204||Liver|Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386963|NCT03662204||Stomach|Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386964|NCT03662204||Ovarian|Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386965|NCT03662204||Esophageal|Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
2386966|NCT03662191|Experimental|Treatment A|4 × 20 mg commercial tafamidis meglumine administered as soft gelatin capsules under fasted conditions
2386967|NCT03662191|Experimental|Treatment B|10 mgA tafamidis free acid administered as a wet-milled suspension under fasted conditions
2386968|NCT03662191|Experimental|Treatment C|a dose of tafamidis free acid projected to be an equivalent of 4 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
2386969|NCT03662191|Experimental|Treatment D|a dose of tafamidis free acid projected to be an equivalent of 5 × 20 mg commercial tafamidis meglumine administered as a wet-milled suspension under fasted conditions
2386970|NCT03662165|Experimental|Intervention|"The primary intervention consisted of a text message informing participants that HIV self-test kits were available at all North Star Alliance clinics in Kenya. The message was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority."
2386971|NCT03662165|Experimental|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
2386972|NCT03662165|Active Comparator|Traditional Standard of Care|"Those randomized to the traditional SOC arm received the SOC message one time sent simultaneously in both Kiswahili and English. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority."
2386973|NCT03662152|Experimental|Foam roller|Non-Vibration Foam Rolling (NVFR) Group: subjects performed the FR protocol using a custom-made foam roller composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long).
2386974|NCT03662152|Experimental|vibration foam roller|Vibration Foam Rolling (VFR) Group: subjects performed the same protocol using a foam roller with vibration (frequency: 18 Hz) composed of a polystyrene foam cylinder (15-cm diameter × 35-cm long) (Hyperice ®).
3183474|NCT00714207|Active Comparator|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets on smoking cessation
3183475|NCT00714220||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3142861|NCT00003611|Experimental|acitretin|"Patients receive oral acitretin daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
3142862|NCT00003611|Placebo Comparator|placebo|"Patients receive placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.~Patients are followed every 6 months."
3142863|NCT00003612|Experimental|Schedule A: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes and then trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
3183476|NCT00714220||Neurological Control|Subjects having been diagnosed with a non-ALS neurological condition
2386983|NCT03662113|Experimental|Experimental: Domperidone|5ml domperidone prior to VCE
2386984|NCT03662113|Other|Control: water|5ml warm water prior to VCE
2386985|NCT03662100|Experimental|LY3074828 Reference 1|Solution formulation in pre-filled syringe (PFS) administered as subcutaneous (SC) injection in arm
2386986|NCT03662100|Experimental|LY3074828 Reference 2|Solution formulation in PFS administered as SC injection in thigh
2386987|NCT03662100|Experimental|LY3074828 Reference 3|Solution formulation in PFS administered as SC injection in abdomen
2386988|NCT03662100|Experimental|LY3074828 Test 1|Solution formulation administered SC via an auto-injector (AI) in arm
2386989|NCT03662100|Experimental|LY3074828 Test 2|Solution formulation administered SC via an AI in thigh
2386990|NCT03662100|Experimental|LY3074828 Test 3|Solution formulation administered SC via an AI in abdomen
2386991|NCT03662087|Experimental|HMA+DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day +60 post-transplantation, HMA and DLI were given. DLI was given 48 hours after administration of HMA. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, HMA and DLI were given as shown above.
2387024|NCT03661918|Other|Group 5|No in-person first session, no second caregiver, no wifi-enabled scale. 10 core coaching calls only
2387025|NCT03661918|Other|Group 6|No in-person first session, no second caregiver, wifi-enabled scale
2387026|NCT03661918|Other|Group 7|No in-person first session, second caregiver, no wifi-enabled scale
2387027|NCT03661918|Other|Group 8|No in-person first session, second caregiver, wifi-enabled scale
2386992|NCT03662087|Experimental|DLI|For AL patients who achieved CR at pre-transplantation undergoing allo-HSCT, DLI was not given and immunosuppressant were withdrawn if patients were MRD persistently negative. MRD status were monitored every 30 days. If patients were MRD negative by Day+30 post-transplantation, MRD status would be continued to be monitored by Day+60 post-transplantation. If patients were MRD positive by Day+30 post-transplantation, immunosuppressant were withdrawn. If MRD were persistently positive until Day+60 or MRD changed from negative by Day+30 to positive by Day+60 post-transplantation, DLI was given. DLI was given monthly until GVHD occurred or MRD became negative or a total of four times. If MRD changed from positive by Day+30 to negative by Day+60 post-transplantation, MRD status would be continued to be monitored by Day+90 post-transplantation. If patients were MRD positive by Day+90 post-transplantation, DLI was given as shown above.
3183477|NCT00714220||Healthy Control|Subjects in good health without any neurological conditions
2386994|NCT03662048|Active Comparator|intervention at 1 month + usual care|Parents will send the study team photographs of their infant sleeping during the night at ages 1 and 2 months.
2386995|NCT03662048|Placebo Comparator|usual care|Parents will send the study team photographs of their infant sleeping during the night only at at age 2 months.
2386996|NCT03662035|Experimental|single-arm|Apatinib and S-1 Patients will be offered with Apatinib (500mg/d) and S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2) until their disease have progressed.
2386997|NCT03662022|No Intervention|No PEP|No PEP will be distributed
2386998|NCT03662022|Other|Household PEP|PEP will be given to all household contacts of an incident leprosy patient
2386999|NCT03662022|Experimental|PEP 100m|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient.
2387000|NCT03662022|Other|PEP 100m + positive for anti-PGL-I IgM Ab|PEP will be given to all household contacts of leprosy patients and to all other people living within a 100m radius of an incident leprosy patient who test positive in the UCP-LFA detecting anti-M. leprae PGL-I IgM Ab in fingerstick blood (anti-PGL-I)
2387001|NCT03662009||Parkinson Disease|Observation of individuals with idiopathic Parkinson disease performing a multilimb dual task using the arm and the leg.
2387002|NCT03662009||Control|Observation of healthy age-matched individuals will perform a multilimb dual task using the arm and the leg.
2387003|NCT03661996|Experimental|Breg Cooling Control Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Breg ice water pump.
2387004|NCT03661996|Experimental|Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
2387005|NCT03661996|Experimental|Shortened Gel Pack Cooling Group|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
2387006|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 2% Lidocaine|Subject receives 2% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
2387007|NCT03661996|Experimental|Single Needle Injection Gel Pack Cooling Group - 1% Lidocaine|Subject receives 1% lidocaine and CNTX-4975-05 with cooling device Elasto-Gel.
3183478|NCT00714246|Experimental|Phase I - Dose Level 1|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
3183479|NCT00714246|Experimental|Phase I - Dose Level 2A|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
3183480|NCT00714246|Experimental|Phase I - Dose Level 2B|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
3183481|NCT00714246|Experimental|Phase I - Dose Level 3|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
2387012|NCT03661970||Normal subjects hearing group|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
2387013|NCT03661970||Cochlear implant subjects with good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
2387014|NCT03661970||Cochlear implant subjects without good speech recognition|After education on the use of the Cognate Speech Synthesizer the participant will be asked to demonstrate specific tasks on the Cognate Speech Synthesizer testing their search patterns of interests, use-ability, and acoustic vamp values on the Cognate Speech Synthesizer.
2387015|NCT03661957|Active Comparator|Non grafted maxillary sinus floor elevation with implant pacem|
2387016|NCT03661957|Experimental|using short dental implants for posterior atrophic maxilla|
2387017|NCT03661944||Symptomatic group|There is no intervention in this group, only functional assessments and general physical examinations will be done
2387018|NCT03661944||Healthy control group|There is no intervention in this group, only functional assessments and general physical examinations will be done
2387019|NCT03661931|Experimental|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a User Experience Questionnaire for each dietary assessment method.
2387020|NCT03661918|Other|Group 1|In-person first session, no second caregiver, no wifi-enabled scale
2387021|NCT03661918|Other|Group 2|In-person first session, no second caregiver, wifi-enabled scale
3183482|NCT00714246|Experimental|Phase I - Dose Level 4|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.0 mg/m2 (Day 1,4,8,11)
3183483|NCT00714246|Experimental|Phase I - Dose Level 5|Carboplatin AUC 6 mg/ml/min (Day 1) Docetaxel 75 mg/m2 (Day 1) Bortezomib 1.3 mg/m2 (Day 1,4,8,11)
3183484|NCT00714246|Experimental|Phase II|Carboplatin AUC 5 mg/ml/min (Day 1) Docetaxel 60 mg/m2 (Day 1) Bortezomib 0.7 mg/m2 (Day 1,4,8,11)
3183485|NCT00714298|Other|1|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. Treating physicians, biologist physician will be blinded to the results of the markers.
3183486|NCT00714324||1|Paper screening
3183487|NCT00714324||2|Electronic screening
3183488|NCT00714337|Experimental|1|fasting state
3183489|NCT00714337|Experimental|2|fasting state
3183490|NCT00714337|Experimental|3|non-fasting state
2387028|NCT03661905|Experimental|Cognitive Therapy|A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments. Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
2387029|NCT03661905|Active Comparator|Behavioural Therapy|Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response. Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
2387030|NCT03661892|Experimental|Treatment (Syndros)|All patients start on Syndros at 4.2 mg po BID for 3 days, if tolerated without side effects the dose is increased to 8.4 mg QAM and 4.2 mg QPM for an additional 3 days. If the patient continues to tolerate the medication, the dose will be increased to 8.4 mg BID for the rest of the study period (total of 8wks).
2387031|NCT03661879|Experimental|NNC9204-1706|Participants will receive NNC9204-1706 for 10 weeks. There will be a 2-week follow-up period after the treatment period.
2387032|NCT03661879|Placebo Comparator|Placebo (NNC9204-1706)|Participants will receive placebo (NNC9204-1706) for 10 weeks. There will be a 2-week follow-up period after the treatment period.
2387033|NCT03661853|Active Comparator|Control|This microintervention is intended to control for the effect of nonspecific therapy factors such as therapeutic alliance, time spent with a therapist, talking about alcohol, and/or effects related to assessment reactivity, and consists of 60 minutes of psycho-education on alcohol and drugs. The therapist will talk about historical and scientific information on different types of alcohol and drugs and will not overlap with CBT treatment. The participants will not be encouraged to personalize this information, make any behavioral changes, or do homework. The control does not have any active interventions that would specifically target or affect our outcome variables.
2387034|NCT03661853|Experimental|Functional Analysis|"Functional Analysis (FA) is a core intervention in Cognitive Behavioral Therapy (CBT) for AUD, and helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use. The FA microintervention teaches the patient to think and behave in new, more controlled ways in response to triggers, to identify maladaptive, impulsive behavior chains and to replace them with more deliberate ones."
2387035|NCT03661853|Experimental|Cognitive Restructuring|"Cognitive Restructuring of Thoughts About Alcohol (CR) is a core technique in CBT to help patients identify automatic (habituated) thoughts that happen quickly and are often not noticed, and change automatic thoughts occurring in response to alcohol triggers."
2387036|NCT03661853|Experimental|Dealing with Cravings|Dealing with Cravings (DC) is designed to directly target the reward and arousal systems, helping the patient accept the nature of cravings as time limited and deflated by continued abstinence so that craving is no longer associated with urgency. DC also teaches skills to reduce cravings by conjuring images such as a spider floating in a glass of wine, or of older versions of oneself sitting alone and dejected in a bar. Distraction techniques and breathing skills to reduce physiological arousal occurring in response to alcohol cues are also taught.
2387039|NCT03661827|Experimental|Patients with heart failure|Patients with heart failure
3183491|NCT00714337|Experimental|4|fasting state
3183492|NCT00714337|Experimental|5|non-fasting state
2387042|NCT03661788|Experimental|First placebo, than atomoxetin|Patients receive a placebo in the first of the two 14-day treatment intervals and atomoxetin in the second 14-day treatment intervals. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
2387043|NCT03661788|Experimental|First atomoxetin, than placebo|Patients receive atomoxetin in the first of the two 14-day treatment intervals and a placebo in the second 14-day treatment interval. Between the treatment intervals there is a wash-out phase of two weeks. The order of treatment is randomized.
2387044|NCT03661775|Experimental|controlled group|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour
2387045|NCT03661775|Experimental|Experimental group|group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
3183493|NCT00714350||Simulator Group - With Display|ICU nurses who viewed the new ICU display visualization
2387047|NCT03661749|Experimental|Clean catch|women in this group will collect urine for PR/CR using a clean catch technique
2387048|NCT03661749|Placebo Comparator|Non-clean catch|women in this group will not employ clean catch technique
2387049|NCT03661723|Experimental|Pembrolizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
2387050|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation (lead-in)|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks. (De-escalation dosing frequencies = once every 4 weeks and once every 6 weeks.)~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
2387051|NCT03661723|Experimental|Pembrolizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
2387052|NCT03661723|Experimental|Pembrolizumab + Bevacizumab + Radiation|"Pembrolizumab (200 mg) will initially be administered intravenously (IV) once every 3 weeks~Bevacizumab (15 mg/kg) will be administered intravenously (IV) once every 3 weeks~Re-irradiation (35 Gy) will be administered to patients 5 days per week for 2 weeks"
2387279|NCT03660111|Other|spirometry|single spirometry: only a routine diagnostic test
3183494|NCT00714350||Simulator Group - Without Display|"ICU nurses who did not view the new ICU display visualization, but instead viewed a traditional spreadsheet style presentation of ICU trends of data"
3183495|NCT00714363|Active Comparator|1|LASIK
3183496|NCT00714363|Active Comparator|2|SBK
2387055|NCT03661684|Experimental|Prednisone in subjects with Diabetes|Group of subjects with diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
2387056|NCT03661684|Experimental|Prednisone in control subjects|Group of subjects without diabetes mellitus type 2 receiving prednisone 40 mg po q day for 3 days
2387057|NCT03661671|Experimental|LCI+white light|Using white light firstly to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
2387058|NCT03661671|No Intervention|White light|Using white light only.
2387059|NCT03661658|Active Comparator|Inferior alveolar nerve lateralization with implant placement|
2387060|NCT03661658|Experimental|Using short dental implant with atrophic mandible|
2387061|NCT03661645|Active Comparator|Methylprednisolone Treated Group|Subjects in this group will receive single intraoperative course of 10 mg IV dexamethasone & 6 day oral methylprednisolone taper that is 10 mg Intravenous IV dexamethasone and 6 day oral methylprednisolone taper course
2387062|NCT03661645|Other|Control Group|Subjects in this group will receive single intraoperative dose of 10 mg IV dexamethasone; that is 10 mg Intravenous (IV) dexamethasone
3142864|NCT00003612|Experimental|Schedule B: paclitaxel + carboplatin + trastuzumab|"Patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 15 minutes on day 1 of weeks 1-3 and trastuzumab IV over 90 minutes immediately after carboplatin on day 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive trastuzumab IV over 30 minutes every 3 weeks until disease progression.~Patients are followed every 3 months for 2 years and then every 6 months thereafter."
3142865|NCT00003613|Experimental|Treatment (O6-benzylguanine, carmustine)|Patients receive O6-benzylguanine IV over 1 hour followed by topical carmustine once every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2387065|NCT03661619|Experimental|Control Group|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
2387066|NCT03661619|Experimental|Test Group|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
2387067|NCT03661606|Experimental|Monitoring arm|Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.
2387068|NCT03661593|Experimental|Cataract guideline|In this patients we follow cataract guideline and correct the patients ametropia during the cataract surgery
2387069|NCT03661593|No Intervention|Standard refraction|The patients gets an IOL ensuring his preoperatively refraction
2387070|NCT03661580|Experimental|Behavioural Activation|Participants in this arm receive 6 x weekly 1:1 sessions of BA delivered by a trained drugs and alcohol worker at the CDAT service. At the end of the 6-week intervention period participants will be referred back to their usual caseworker at the CDAT service, though they will be offered two BA booster sessions with their BA worker at 2-3 weeks and 4-5 weeks post-treatment. All participants in this arm will continue to have access to Treatment as Usual (i.e. prescribing) as required throughout the intervention period.
2387071|NCT03661580|Active Comparator|Treatment as Usual|Participants in this arm will receive no change to the care they usually receive at the CDAT service.
2387072|NCT03661567|Experimental|Methylprednisolone|Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
2387073|NCT03661567|Active Comparator|Observation|Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).
2387074|NCT03661554|Experimental|single arm|"This clinical study, BCMA nano-antibody CAR-T cells in the treatment of refractory recurrent multiple myeloma clinical research, is a single center, single arm, open design. The aim is to study the safety and efficacy of BCMA nano antibody CAR-T in the treatment of MM. In this study, a 3 + 3 dose gradient climbing design was used. Three dosage groups, 5x106 / kg, 1x107 / kg and 1.5x107 / kg, were divided into three groups."
3142866|NCT00003620|Experimental|Treatment (flavopiridol)|"Patients registered before 9/15/2000 receive flavopiridol IV continuously on days 1-3. Treatment repeats every 14 days for a total of 12 courses in the absence of disease progression or unacceptable toxicity.~Patients registered after 9/15/2000 receive flavopiridol IV over 1 hour daily on days 1-3. Treatment repeats every 3 weeks for a total of 8 courses in the absence of disease progression or unacceptable toxicity."
3142867|NCT00003621|Experimental|carmustine + etoposide + cisplatin + radiation therapy|Patients receive carmustine IV over 1 hour on days 1-3, oral etoposide on days 1-21 and 29-49, and cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 3 courses. Patients receive radiotherapy concurrently with the third course of chemotherapy. Quality of life is assessed every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 3 months for 5 years and then annually thereafter.
3142868|NCT00003622|Experimental|paclitaxel + vinorelbine|
3142869|NCT00003623|Experimental|Multivitamin|Patients receive multivitamins orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
3142870|NCT00003623|Placebo Comparator|Placebo|Patients receive placebo orally once daily for 3 years. Patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.
2387080|NCT03661515|Experimental|Fludarabine-Idarubicine-Cytarabine- Selinexor|"fludarabine 30 mg/m2/day intravenously on days 1 to 4, idarubicin 10 mg/m2/day intravenously on days 1 to 3, cytarabine 2 g/m2/day intravenously on days 1 to 4, G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5. This schedule will be combined with oral selinexor (KPT-330) for three weeks at days and dose according to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
2387081|NCT03661502|Experimental|variable tidal volume ventilation (VVV)|the intervention is using a ventilation mode with variable tidal volume. The average tidal volume is 6 ml/kg and respiratory rate adapted to reach an end tidalCO2 concentration between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
3183497|NCT00714376|Experimental|Docetaxel|Docetaxel (Taxotere) 75 mg/m² IV every 3 weeks for 8 cycles.
2387082|NCT03661502|Experimental|Pressure controlled ventilation (PCV)|the intervention is using ventilation mode with constant pressure and constant tidal volume. The tidal volume is 6 ml/kg and respiratory rate is adapted to reach end tidal CO2 concentrations between 30 and 50 mmHg. Lung recruitment is given when dynamic lung compliance drops below 40. No drug is given. No other treatment or intervention is given.
2387083|NCT03661489|Experimental|Intravenous Remimazolam 50 mg|"For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
2387084|NCT03661489|Active Comparator|Intravenous Propofol 2%|"For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary.~For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed."
2387085|NCT03661476|Experimental|Oculo-Motor Exercises (OME)|10 repetitive four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
2387086|NCT03661463|Experimental|Aspirin|Aspirin (Acetylsalicylic Acid [ASA]) tablets, 300mg once a day, for 90 days.
2387087|NCT03661463|No Intervention|No Treatment|No medical treatment
2387088|NCT03661450||PICU-Patients|Pediatric patients admitted after 01.08.2018
2387089|NCT03661437|Experimental|Arm I (BWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo BWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
2387090|NCT03661437|Experimental|Arm II (DWL)|Patients wear an Actiwatch for 5 days at baseline, 3 months and 6 months. Beginning 1-4 weeks after first anti-androgen therapy, patients undergo DWL treatment using Luminette glasses for 30 minutes every morning for 3-6 months.
2387091|NCT03661424|Experimental|Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)|Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
2387092|NCT03661411|Experimental|Aspirin+ clopidogrel|aspirin 100mg qd and clopidogrel 75mg（300mg in the first day）qd with a total of 10-14 days, then oral aspirin 100mg or clopidogrel 75mg qd lasting for 90 days.
2387093|NCT03661411|Active Comparator|Alteplase|intravenous alteplase (0.9 mg/kg and maximal dose of 90 mg) was given, and followed by antithrombotic protocol 24 hours after thrombolysis based on clinical guideline.
2387094|NCT03661398|Experimental|Transcatheter Mitral Valve Replacement|Patients with symptomatic mitral regurgitation (garde 3 or 4), determined to be a high risk for cardiovascular surgery, will be treated with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System
2387095|NCT03661385|Active Comparator|Intervention arm|• Intervention arm will receive nitric oxide 20 parts per million (ppm) into the oxygenator of a cardio-pulmonary bypass circuit
2387096|NCT03661385|No Intervention|Control arm|Control arm will not receive nitric oxide, they will receive standard bypass as per local policy
2387097|NCT03661372|Active Comparator|Face-to-Face|Face-to-Face Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A face-to- face standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
2387098|NCT03661372|Active Comparator|Robot|Robot Group: At the beginning of the session self-efficacy will be measured. This group will receive an instructor-led 45 minute long lecture on how to evaluate work, love, and play behavioral health form on a standardized patient. A robot (telesimulated) standardized patient scenario will test the participant on the application of work, love, and play assessment. In this scenario, the participant will meet a standardized patient in the exam room via a robot to discuss a behavioral health concern. At the end of each session (approximately 2 hours later), self-efficacy will be measured.
2387099|NCT03661359|Experimental|Social Determinants of Health|Intervention will be the Social Determinants of Health Referrals.
3183498|NCT00714402||a|children with proven of probable invasive bacterial infections
3183499|NCT00714428||Group 1: Item Development|Individuals with TBI to provide input to relevant questions for quality of life measure in TBI
3183500|NCT00714428||Group 2: Item Development|Clinicians who treat those with deployment related TBI to obtain their feedback on relevant questions pertaining to quality of life measures in TBI.
2387106|NCT03661307|Experimental|Treatment (decitabine, quizartinib, venetoclax)|Patients receive decitabine IV over 1 hour on days 1-10, quizartinib PO every day beginning on day 1 of cycle 1, and venetoclax PO on days 1-14 (days 1-21 if persistent leukemia). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2387107|NCT03661294|Other|GE Healthcare Metabolic Oxygenator|The actual and predicted energy expenditure of tetraplegic (ventilated/non-vent) and paraplegic patients will be measured at three time points during the patient's rehabilitation in hospital.
2387108|NCT03661281|Experimental|Simulated Thumb Arthrodesis|Subjects will have their thumb immobilized in 2 prefabricated wrist splints to simulate 2 different fusion positions tested: one splint to simulate the MCP fusion and one to represent the IP fusion. Patients will complete hand function tests in each of the splints to evaluate hand function.
2387152|NCT03660917|Experimental|Riluzole|Riluzole 50 mg twice daily for 12 months in the treated group. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
2387326|NCT03659799|Active Comparator|Aspart - 60-minutes postprandial exercise|
2387109|NCT03661268|Experimental|Septic shock|Patients (at least 18 years of age, no more than 75 years old) with refractory hypotension secondary to sepsis who, at the discretion of treating physicians, required fluid challenge in the presence of pulmonary artery catheter. Refractory hypotension was defined as need of vasopressors to maintain systolic blood pressure (SBP) no less than 90 mmHg despite adequate fluid resuscitation.
2387110|NCT03661255|Experimental|PC CARES Intervention|Participants will attend 1-4 sessions of the PC CARES curriculum. Investigators will collect data from this group at baseline, after each session they attend, and at follow-up.
2387111|NCT03661255|No Intervention|No intervention|This group will not attend the PC CARES sessions. Investigators will collect data from this group at baseline and follow-up
2387112|NCT03661242|No Intervention|Standard of care|No intervention
2387113|NCT03661242|Active Comparator|Shared care|Clinic visit with Clincal Exercise Physiologist or physical therapist who does assessment and prescripes individulized physical activity plan
2387114|NCT03661229|Experimental|CVInsight Monitoring|Single group arm: All participants receive the same intervention/treatment CVInsight non-contact device and CVInsight contact device application.
2387115|NCT03661216|Placebo Comparator|Placebo|3g of non-GMO maltodextrin
2387116|NCT03661216|Active Comparator|Nephure|3g of Nephure
2387117|NCT03661203||Qualitative cohort|The cohort consists of MSM with late HIV diagnosis. The person from this cohort will participate to round table called also focus group or individual interview.
2387118|NCT03661203||Quantitative cohort|MSM community will be invited to participate to an online self questionnaire established from the information gathered from the previous cohort.
2387119|NCT03661190|Other|Grammatical Reasoning|This group will complete a short-term Intensive Grammatical Reasoning cognitive task delivered online by Wesnes Cognition Ltd (START). Participants will be encouraged to complete the START training once a day for six-weeks.
2387120|NCT03661190|Other|Control - Card Pairs|The control group will complete a basic picture-matching task that will provide the same level of engagement, but without the learning effects.
2387121|NCT03661177|Experimental|Diet intervention|
2387122|NCT03661177|No Intervention|Control|
2387123|NCT03661151||Antireflux surgery following PPI|A single cohort with the GERD patients who had acid suppressive medication with proton pump inhibitor (PPI) followed by laparoscopic antireflux surgery
2387128|NCT03661125|Experimental|Saracatinib or placebo|In the first arm of the study, participants will be randomised into either the group that receives Saracatinib (study drug) or the Placebo.
2387129|NCT03661125|Experimental|Placebo or Saracatinib (Cross-over)|The groups will now cross over i.e. the group that had the study drug in the first arm will get the placebo in the second arm and the group that had the placebo in the first arm will have the study drug in the second arm.
2387130|NCT03661112||All of Us Research Program (AoURP) consortium members|
2387133|NCT03661073|Experimental|Stroke|The investigator will include patients with stroke (either hemorrhagic or ischemic) with or without neglect in the experimental group.
2387134|NCT03661073|Sham Comparator|Healthy subjects|The investigator will include healthy subjects aged-matched to participants of the experimental group in the control group.
3183501|NCT00714428||Group 3: Instrument Development|Individuals with deployment TBI who will complete the Beta version of the TBI QOL measure.
3183502|NCT00714441|Active Comparator|2|Computer Automated Self-Management (CASM). Please see description below for CASM.
2387137|NCT03661034|Experimental|Cohort 1, Arm A|Dosing 1 hour session per day with GammaSense Stimulation System (non-invasive, non-significant risk)
2387138|NCT03661034|Experimental|Cohort 1, Arm B|Dosing 1 hour session twice per day with GammaSense Stimulation System (non-invasive, non-significant risk)
2387139|NCT03661034|Experimental|Cohort 2, Arm C|Dosing 1 hour session every other day or one 2 hour session per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
2387140|NCT03661034|Experimental|Cohort 2, Arm D|Dosing 30 minute session twice per day or 120 minute session twice per day, depending on Interim Analysis outcomes with GammaSense Stimulation System (non-invasive, non-significant risk)
2387141|NCT03661008||Adolescents with paternal involvement|
2387142|NCT03661008||Adolescents without paternal involvement|
2387143|NCT03660995|Experimental|SLI children|
2387144|NCT03660995|Active Comparator|Control children|
2387145|NCT03660982||FDRs of RBD cases|FDRs of RBD cases. The diagnosis of RBD is based on ICSD-II criteria, as confirmed by v-PSG and with the aid of REM sleep behaviour disorder questionnaire (RBDQ-HK). RBD cases which are secondary to narcolepsy, neurodegenerative diseases or other neurological diseases are excluded.
2387146|NCT03660982||FDRs of non-RBD controls|FDRs of non-RBD controls. Non-RBD control probands are free of narcolepsy, significant clinical RBD symptoms and other neurological diseases.
2387147|NCT03660956|Experimental|Exercise and back counselling group|
2387148|NCT03660956|Active Comparator|Back counselling group|
2387149|NCT03660943|Placebo Comparator|Placebo|Intra-articular Placebo Injection
2387150|NCT03660943|Experimental|CNTX-4975-05 (trans-capsaicin)|Intra-articular 1.0 mg CNTX-4975-05 Injection
2387151|NCT03660930|Experimental|Treatment (ABI-009, pazopanib)|Participants receive nanoparticle albumin-bound rapamycin IV on days 1 and 8 and pazopanib hydrochloride PO daily on days 1-21. Courses repeat every 21 days until unequivocal clinical disease progression, unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at the patient's discretion.
2387153|NCT03660917|Placebo Comparator|Placebo + riluzole|Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
2387154|NCT03660904|Experimental|Home made media|home made vitrification & thawing kit
2387155|NCT03660904|Active Comparator|Commercial media|commercially available vitrification & thawing kit
2387156|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
2387157|NCT03660878|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
2387158|NCT03660878|Placebo Comparator|Vehicle Ophthalmic Solution|
3142871|NCT00003625|Experimental|Stratum 1|Concomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
3142872|NCT00003648||Group 1|Patients, family members, and control individuals complete an extended telephone interview, an extended personal interview, and an epidemiological survey, and contribute a blood specimen. Blood and tumor specimens are examined for the specific pattern of immunohistochemical expression of hMSH2 and HMLH1 to determine the frequency or lack of expression of these two protein products. Patients may be contacted periodically (about every 3 years) to update information about health, health practices, and family history. Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment.
2387161|NCT03660852||Before dedicated MRI|
2387162|NCT03660852||After dedicated MRI|
3183503|NCT00714441|Active Comparator|3|Computer Automated Self-Management and Problem Solving Therapy (CAPS). Please see descriptions below for CAPS (also refer to CASM with is included in the CAPS program).
3183504|NCT00714441|Active Comparator|1|Lifestyle and Activities Education Program (LEAP-AHEAD). Please see description below for LEAP-AHEAD.
3142873|NCT00003653|Active Comparator|Intermittent Androgen Suppression|
3142874|NCT00003653|Active Comparator|Continuous Androgen Suppression|
3142875|NCT00003656|Experimental|All subjects|Weekly ATRA-IV with recombinant interferon alfa
3142876|NCT00003657|Experimental|High Dose ICF with Amifostine|"Patients undergo peripheral blood stem cell transplantation (PBSC) harvest on day -8,~ifosfamide IV, carboplatin IV etoposide IV (ICE) by 96 hour continuous infusion on days -7 to -4.~Patients receive amifostine IV twice a day on days -7 to -3.~PBSCs are reinfused on day 0.~Filgrastim (G-CSF) is administered subcutaneously beginning on day 0 at least 2 hours after infusion of the stem cells and continuing until blood cell counts recover.~Patients are followed monthly for the first 2 months and then for survival."
3142877|NCT00003665|Experimental|Arm I|Patients receive 3 different doses of peptide pulsed DC vaccine IV, each divided into 3 different peptide pulsed pools administered over 30 minutes.
3142878|NCT00003665|Experimental|Arm II|Patients receive 3 different doses of peptide pulsed DC vaccine subcutaneously/intradermally to sites with no evidence of disease. At the lowest dose, patients receive 3 different peptide pulsed pools, each administered at a separate site. At the higher doses, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
2387173|NCT03660813|Experimental|HCG triggering|Ovitrelle ( hCG 250 mcg)
2387174|NCT03660813|Experimental|Dual triggering|Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )
2387175|NCT03660800|Experimental|CTAP101 Capsules 450mcg/weekly fasted|
2387176|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fasted|
2387177|NCT03660800|Experimental|CTAP101 Capsules 1800mcg/weekly fasted|
2387178|NCT03660800|Experimental|CTAP101 Capsules 900mcg/weekly fed|
2387183|NCT03660774||Patients with hemophilia|Children and young adults with hemophilia A or B, all severities, treated in the hemophilia treatment center (comprehensive care) setting, including participation of caregivers/parents completing questionnaires designed to evaluate neurologic, neurocognitive and neurobehavioral function and development.
2387184|NCT03660761|Experimental|apatinib 500mg|
2387185|NCT03660748|Experimental|Lower BMI|Use of MET-2 in subjects with BMI of 30.0 to 34.9
2387186|NCT03660748|Experimental|Higher BMI|Use of MET-2 in subjects with BMI of 35 to 39.9
2387187|NCT03660735||Male Factor Subfertility|Participant is undergoing first or second cycle of IVF and ICSI for male factor subfertility
2387188|NCT03660735||Recurrent Implantation Failure|Participant is undergoing an IVF cycle to treat subfertility with a history of Recurrent Implantation Failure (RIF).
2387189|NCT03660735||Female Subfertility|Participant is undergoing an IVF cycle to treat at least 1 year of subfertility
2387190|NCT03660722|Other|Blood and urinary sample|Blood and urinary sample in HIV 1 positive adults initiating treatment
2387191|NCT03660709|Experimental|Intervention|enhanced version of HIV testing and counseling
2387192|NCT03660709|Active Comparator|Control|standard-of-care HIV testing and counseling
2387193|NCT03660683|Experimental|Group A Dapa|Dapagliflozin 10 mg + Saxagliptin Placebo
2387194|NCT03660683|Active Comparator|Group B DapaSaxa|Dapagliflozin 10mg + Saxagliptin 5mg
2387195|NCT03660683|Placebo Comparator|Placebo|Placebo Oral Tablet
2387196|NCT03660670|Experimental|Interventional Arm|Application of the ONCORAL program of multidisciplinary ONCOlogic interventions between town and hospital (doctor-pharmacist-nurse) for ambulatory patients under oRAL anticancer drugs
2387197|NCT03660670|Sham Comparator|Standard of care|Patients in the control group will receive regular follow-up from their oncologist, but no more that the standard care.
2387198|NCT03660657|Experimental|Ozone Group:|Standard treatment + Ozone therapy (O3/O2)
2387199|NCT03660657|Placebo Comparator|Control Group:|Standard treatment + Oxygen (O2)
2387200|NCT03660644|Experimental|WhatsApp, Pedometer and Step Diary|Pedometer, step diary and WhatsApp following pulmonary rehabilitation
2387201|NCT03660644|No Intervention|Control|Usual care following pulmonary rehabilitation.
2387202|NCT03660631|Experimental|CVRS Early Intervention|Patients participating in intervention offices will receive the pharmacist-led CVRS intervention for 12 months.
2387203|NCT03660631|Other|CVRS Delayed Intervention|Patients participating in control site offices will not have any contact with the CVRS pharmacist for the first 12 months of their participation in the study. They will receive the study intervention during months 13-24.
2387204|NCT03660618|Other|Clinic Subjects|cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.
2387205|NCT03660605|Experimental|Rhythmic Auditory Stimulation|Participants will walk on treadmill to metronome set at 85% of typical cadence, followed by overground walking with metronome set at 115% of typical cadence.
2387206|NCT03660592||operator 1|ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
2387207|NCT03660592||operator 2|a different ED resident experimented in pulmonary ultrasonography and blinded to the final diagnosis
2387208|NCT03660579|No Intervention|HIIT-CON|No intervention: Control
2387209|NCT03660579|Experimental|HIIT-AB Group|"Intake:~330ml (women) or 2x300 ml (men) of beer with 5.4% alcohol. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
2387210|NCT03660579|Experimental|HIIT-NAB Group|"Intake:~330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%). The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
2387211|NCT03660579|Experimental|HIIT-SW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water. The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
2387212|NCT03660579|Experimental|HIIT-ASW Group|"Intake:~330 ml (women) or 2x300 ml (men) of sparkling water with 5.4% alcohol.The beverage intakes will be programmed from Monday to Friday.~Training:~The volume in HIIT 40-65 min/week at high intensity. HIIT with short intervals. Frequency two times/week. Load variation. Gradual progression to control the exercise dose. Periodization divided in: familiarization phase, phase I, phase II. Sessions. The participants will performed 8 weight-bearing exercises (in circuit form) 2 times/set with an active rest (walking at 6 RPE scale) as many times at as defined. The HIIT intensity will controlled by RPE (0-10 RPE scale).~All sessions will be started with a dynamic standardized warm-up, including several muscle activation exercises, and will be ended with a cooling-down protocol."
2387213|NCT03660566|Experimental|Test - Implant with L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement with the use of Leucocyte- and Platelet-rich fibrin (L-PRF) membranes.
2387214|NCT03660566|Active Comparator|Control - Implant without L-PRF|Patients requiring single implants placement in the esthetic area of maxilla will receive the implant placement only.
3142879|NCT00003665|Experimental|Arm III|Patients receive peptide pulsed DC vaccine intranodally in groin or ancillary lymph nodes at the lower 2 doses of the 3 administered to arms I and II. At the lower dose, patients receive 3 different peptide pulsed pools, each administered into a different node. At the higher dose, patients receive 3 injections further subdivided into 6 and administered at 6 distinct sites.
3183505|NCT00714454|Active Comparator|APS|
2387217|NCT03660540|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
2387218|NCT03660540|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
2387219|NCT03660527||6-17 year old|
2387220|NCT03660527||18-44 year old|
2387221|NCT03660527||45-59 year old|
2387222|NCT03660527||above 60 year old|
2387223|NCT03660514|No Intervention|Standard Family Planning|Counseling Clients receive standard FP counseling services.
2387224|NCT03660514|Experimental|Jovenes Sanos Intervention in FP Counseling|Clients receive the Jovenes Sanos intervention in addition to standard FP counseling services.
2387225|NCT03660488|Active Comparator|Benzathine Penicillin G|"Patients of the Penicillin Group will receive the standard of care treatment. This is one intramuscular injection of 2.4 million units Benzathine Penicillin G. The group will consist of 50 patients."
2387226|NCT03660488|Experimental|Cefixime Group|"Patients of the Cefixime Group will receive Cefixime 400 mg, per os, one tablet, two times per day, for ten consecutive days. The study team will provide the medication.~The group will consist of 50 patients."
2387227|NCT03660475|Experimental|Naltrexone|Naltrexone Ophthalmic Solution 0.002%
2387228|NCT03660475|Placebo Comparator|Placebo|Placebo Ophthalmic Solution
2387229|NCT03660462|Active Comparator|FeSO4 fortified rice test meal|
2387230|NCT03660462|Experimental|FePO4 fortified rice test meal|
2387231|NCT03660462|Experimental|HiFePO4 1 fortified rice test meal|
2387232|NCT03660462|Experimental|HiFePO4 2 fortified rice test meal|
2387233|NCT03660449|Experimental|Experiment|All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
2387234|NCT03660436|Experimental|BMS-986165 + MMF|Oral administration
2387235|NCT03660423|Experimental|Dance Group|Dance group will participate in a 60 minute integrative dance class two times per week
2387236|NCT03660423|No Intervention|Control Group|The Control group will continue with normal activities, not participating in the dance intervention.
2387237|NCT03660410||Yanomamis|Yanomami Indians, Anamnesis and oral clinical examination
2387238|NCT03660410||Macuxi|Macuxi Indians, Anamnesis and oral clinical examination
2387239|NCT03660410||Wapixana|Wapixana Indians, Anamnesis and oral clinical examination
2387240|NCT03660397|Experimental|Intervention|Selective endovascular chemical ablation of adrenal gland after adrenal angiography.
2387241|NCT03660397|Active Comparator|Control|No intervention, but treated with standard antihypertensive drugs
3142880|NCT00003666|Experimental|HMAF|treatment of refractory or relapsed NSCLC with HMAF
3142881|NCT00003671|Experimental|Chemotherapy Treatment|See detailed description.
3142882|NCT00003674|Experimental|dalteparin + standard therapy|Patients receive dalteparin by subcutaneous injection once daily plus standard therapy. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
3142883|NCT00003674|Active Comparator|standard therapy|Patients receive standard therapy alone. Treatment continues for 1 year in the absence of disease progression and unacceptable toxicity. Quality of life is assessed before treatment, then every month for the first year, and then every 3 months for 2 years. Patients are followed monthly for 1 year, then every 3 months for 2 years.
2387246|NCT03660358|Experimental|Kinesiotape|Kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
2387247|NCT03660358|No Intervention|Control|No kinesiotaping aplication to chest wall, abdomen and diaphragm in preterm infants.
3142884|NCT00003675|Experimental|Oral Topotecan 5 days|Patients receive intervention twice daily for 5 days
2387250|NCT03660332|Active Comparator|IL-6 infusion|Healthy young men will receive IL-6 infusion
2387251|NCT03660332|Placebo Comparator|Placebo infusion|Healthy young men will receive saline infusion
2387252|NCT03660319|Experimental|Environmental Music Therapy|Music Therapy Intervention (EMT)
2387253|NCT03660319|No Intervention|Control|Control - No Environmental Music Therapy. Does not experience Environmental Music Therapy during wait time in radiation oncology waiting room.
2387254|NCT03660306||opioid anesthesia|classical anesthesia using sufentanil to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
2387255|NCT03660306||opioid free anesthesia|anesthesia using non opioids like dexmedetomidine, lidocaine, magnesium and ketamine to block sympathetic reactions during surgery. This decision is based on the anesthesiologist experience and not determined by the patient or procedure.
2387256|NCT03660293|No Intervention|diabetic- no cardioprotectives|25 child with type 1 diabetes mellitus will not receive any cardio protective drug
2387257|NCT03660293|Experimental|diabetic-Atorvastatin|25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)
2387258|NCT03660293|Experimental|diabetic-Captopril|25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)
2387259|NCT03660293|Experimental|diabetic-L-Carnitine|25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)
2387260|NCT03660293|No Intervention|Controls|50 healthy children, of matched age and sex, with no symptoms of cardiac diseases
2387261|NCT03660280|Experimental|Probiotics|
2387262|NCT03660280|Placebo Comparator|Placebo|
2387263|NCT03660267|Experimental|coffee group|caffeine coffee
2387264|NCT03660267|Experimental|decaffeinete coffee group|decaffeinete coffee group
2387265|NCT03660267|Experimental|water group|
2387266|NCT03660254|Experimental|one group has exercise intervention|tai chi exercise intervention，two times a week and each time costs one hour
2387267|NCT03660254|No Intervention|no intervention|no intervention
2387269|NCT03660228|Experimental|Peri-Transfusion QOL Assessment|"Participants will be given a study packet containing a paper copy of the QUALMS~Study participants will fill out the survey on the day before their first/next pRBC transfusion.~Study participants will receive a second paper copy of the QUALMS, along with a stamped envelope addressed to the appropriate site~The second assessment will be scored and compared with the first, and both the patient and provider will be sent a report with the results"
2387270|NCT03660215|No Intervention|control group|usual charge
2387271|NCT03660215|Experimental|experimental group|"Mediation:~The mediator will intervene on several levels: planning of care according to the medical prescriptions on a support adapted and comprehensible by the patient according to his level of health literacy and his linguistic capacities, coaching on the management of the chronic diseases, possible orientation towards a workshop of therapeutic education, appointments calendar, clear indication of treatment changes, provision of contact information for allied health professionals , assistance in making appointments, possible accompaniments at a professional health."
2387272|NCT03660202|Experimental|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of Firesorb BVS
2387273|NCT03660189|No Intervention|Usual care|Usual care with a one bag system of IV fluids, as recommended in the American Diabetes Association consensus statement guidelines from 2009.
2387274|NCT03660189|Experimental|Two bag system|A two bag system of IV fluids will be used during insulin infusion administration.
2387275|NCT03660176|Active Comparator|routine management|Children in the control group receive no additional treatment
2387276|NCT03660176|Experimental|EXP GROUP|children receiving butyrate enemas + routine management butyrate enemas every day before Curative surgery
2387277|NCT03660137|Experimental|MOLLI Localization|All patients will be implanted with a MOLLI magnetic seed in addition to the standard-of-care RSL seed. Both systems will be use to localize the respective seeds during the lumpectomy surgery.
2387278|NCT03660124|Experimental|Deep Brain Stimulation Treatment|
2387280|NCT03660085|Experimental|Arm A - Early Intervention|For 180 days participants in this arm will be exposed to the intervention and 180 days afterwards they will be exposed to the standard of care.
2387281|NCT03660085|Active Comparator|Arm B - Late Intervention|For 180 days participants in this arm will be exposed to the standard of care and 180 days afterwards they will be exposed to the intervention.
2387282|NCT03660072||Empliciti combination therapy|Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy
3142885|NCT00003675|Experimental|Oral Topotecan 10 days|Patients receive intervention once daily for 10 days
3142886|NCT00003677|Experimental|Dolastatin 10|Dolastatin 10 IV bolus once every 21 days.
3142887|NCT00003686|Active Comparator|Pilocarpine|
2387286|NCT03660046||Depot medroxyprogesterone acetate (DMPA)|This arm includes subjects that choose Depot medroxyprogesterone acetate (DMPA) as contraception.
2387287|NCT03660046||Etonogestrel implant (Eng-Implant)|This arm includes subjects that choose Etonogestrel implant (Eng-Implant) as contraception.
2387288|NCT03660046||Levonorgestrel IUD (Lng-IUD)|This arm includes subjects that choose Levonorgestrel Intrauterine device (Lng-IUD) as contraception.
2387289|NCT03660033|Experimental|With ECG|These teams will have access to ECG monitoring (intervention) during the scenario
2387290|NCT03660033|No Intervention|Without ECG|These teams will NOT have access to ECG monitoring during the scenario
2387291|NCT03660020|Sham Comparator|local anaesthetic group|
2387292|NCT03660020|Active Comparator|hyalorounidase group|
2387293|NCT03660007||Fresh embryo transfer|This exposure is an IVF pregnancy with fresh embryo transfer performed directly after ovarian stimulation
2387294|NCT03660007||Frozen embryo transfer|This exposure is an IVF pregnancy with frozen embryo transfer, which was thawed and transferred in a later, non-stimulated cycle
2387295|NCT03660007||Natural pregnancy|Spontaneous pregnancy without IVF
2387296|NCT03659994|Experimental|Vitabeard High Dose|3 capsules of multivitamin Vitabeard
2387297|NCT03659994|Experimental|Vitabeard Mid-Dose|2 Capsules of multivitamin Vitabeard, 1 Capsule of Placebo
2387298|NCT03659994|Experimental|Vitabeard Low-Dose|1 Capsule of multivitamin Vitabeard, 2 Capsules of Placebo
2387299|NCT03659994|Placebo Comparator|Placebo|3 Capsules of Placebo
2387300|NCT03659981|Experimental|MS Patients|Multiple sclerosis patients MRI 7T will be performed
2387301|NCT03659968|Experimental|EXPERIMENTAL GROUP|patients in advanced phase of pediatric cancer Physical activity training will be performed in drug development
2387302|NCT03659955|Experimental|Autologous blood|"Patients with severe dry eye and ocular surface disease who attend the corneal service within NHS Lanarkshire and who are unresponsive to conservative treatment measures will be considered for treatment of their condition with autologous blood.~Intervention is application of autologous blood."
2387303|NCT03659942||Experimental group|New child arriving in detention CAST questionnaire will be performed
2387304|NCT03659929|Experimental|Arm 1: 20 mg/day|Amphetamine Sulfate
2387305|NCT03659929|Experimental|Arm 2: 40 mg/day|Amphetamine Sulfate
2387306|NCT03659929|Placebo Comparator|Arm 3: Placebo|Placebo, no active drug
2387307|NCT03659916|Experimental|A4250|Capsules for oral administration (120 ug/kg) once daily for 72 weeks
2387308|NCT03659903||younger patients (age < 80)|age < 80 patients， All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
2387309|NCT03659903||older patients (age≥ 80 )|age ≥ 80 years-old patients，All the variables' definitions are encoded in the SEER database. To identify the PDAC cases, site codes (C25 pancreas, C25.0-C25.9) and histology codes (8140 adenocarcinoma, 8500 infiltrating duct carcinoma) based on the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) were used.11 Only cases that underwent PD and microscopically confirmed were included.
2387310|NCT03659890|Placebo Comparator|Low nucleotide|2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose
2387311|NCT03659890|Experimental|High nucleotide|2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose
2387312|NCT03659890|Experimental|High nucletide + Ribose|2 week supplementation with a high nucleotide mycoprotein drink, with added ribose
2387313|NCT03659877|Experimental|Heart failure patients|Patients will be required to perform a number of physical activity tasks such as laying down, sitting and walking. During these activities, acceleration, oxygen consumption, rating of perceived exertion and heart rate will be recorded.
2387314|NCT03659864|Sham Comparator|Exposure 1|filtered air
2387315|NCT03659864|Experimental|Exposure 2|nanoparticle 1 (either DEP or s-GO depending on group)
2387316|NCT03659864|Experimental|Exposure 3|nanoparticle 2 (either CB or us-GO depending on group)
2387317|NCT03659851||Levosimendan before LVAD implantation|Levosimendan use 24 hrs. before LVAD implantation
2387318|NCT03659851||Dobutamine/milrinone before LVAD implantation|Dobutamine/milrinone use 24 hrs. before LVAD implantation
2387319|NCT03659838||Participants|Schoolchildren from the canton of Zürich aged 6 to 16 years
2387320|NCT03659825|Placebo Comparator|Placebo + Normoxia|Taste, volume and appearance matched drink given before cognitive testing in normoxia
2387321|NCT03659825|Placebo Comparator|Placebo + Hypoxia|Taste, volume and appearance matched drink given before cognitive testing in hypoxia
2387322|NCT03659825|Experimental|Ketone Ester + Normoxia|Ketone ester drink given before cognitive testing in normoxia
2387323|NCT03659825|Experimental|Ketone Ester + Hypoxia|Ketone ester drink given before cognitive testing in hypoxia
2387324|NCT03659812|Experimental|MACS is applied to the sperm sample|Previous to the AID technique, the sperm sample undergoes capacitation through Percoll density gradient and MACS
2387325|NCT03659812|No Intervention|MACS is not applied to the sperm sample|Previous to the AID technique, MACS only undergoes capacitation through Percoll density gradient, but not MACS technique
3142888|NCT00003686|Placebo Comparator|Placebo|
3183506|NCT00714454|Placebo Comparator|Vehicle|
2387327|NCT03659799|Active Comparator|Aspart - 120-minutes postprandial exercise|
2387328|NCT03659799|Active Comparator|FiAsp - 60-minutes postprandial exercise|
2387329|NCT03659799|Active Comparator|FiAsp - 120-minutes postprandial exercise|
2387330|NCT03659786|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo)
2387331|NCT03659786|No Intervention|Day 3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo)
2387332|NCT03659786|No Intervention|Day 5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo)
2387333|NCT03659773|Experimental|hematopoietic stem cell transplant (HSCT)|immune biomarkers to evaluate vaccine response in HSCT recipients
2387334|NCT03659760|Experimental|Group Isolated|Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)
2387335|NCT03659760|No Intervention|Group Disrupted|Group Disrupted (Group I) (exposed to ambient light and noise)
2387336|NCT03659747|Experimental|Probiotic|"6 g sachet containing probiotic powder (1.8 x 10^12 colony forming units (CFU) Probiotic) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
2387337|NCT03659747|Active Comparator|Lactrase|"6 g sachet containing 4500 FCC units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
2387338|NCT03659747|Placebo Comparator|Placebo|"6 g sachet containing placebo powder (maltodextrin) in sachet~One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit."
2387339|NCT03659734|Experimental|Motivational Interviewing and Gradual Opioid Weaning|
2387340|NCT03659734|Experimental|Enhanced Usual Care|
2387341|NCT03659734|No Intervention|Observation|
2387344|NCT03659708|Experimental|Lyon-VTE score|"300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the Lyon-VTE score :~The Lyon score classifies patients into 3 risk categories and directs the preventive LMWH prescription:~A score strictly less than 3 indicates a moderate thrombotic risk: the patient does not receive LMWH in ante-partum;~A score between 3 and 5 indicates a high thrombotic risk: a preventive dose LMWH is introduced in the third trimester (from the beginning of the 7th month);~A score greater than or equal to 6 indicates a very high thrombotic risk: LMWH at a preventive dose is prescribed throughout the ante-partum.~All patients receive an elasto-compression prescription and daily physical activity is recommended throughout pregnancy (except obstetric contraindication).~All patients also receive systematic preventive LMWH treatment postpartum for 6 weeks."
2387345|NCT03659708|Experimental|recommendations currently available|300 adult pregnant women with a personal history of VTE and/or known thrombophilia, will be randomly included in this group and their VTE risk during pregnancy will be managed according to the last ACCP guidelines or UK guidelines or Canadian recommendations or French recommendations, according to the habits of the center.
2387346|NCT03659695|Experimental|Grape Powder|69 g/d freeze dried grape powder
2387347|NCT03659695|Placebo Comparator|Placebo powder|69 g/d placebo powder matched for taste and appearance
2387348|NCT03659682|Active Comparator|semaglutide|Ozempic- 1.0 mg administered subcutaneously once weekly
2387349|NCT03659682|Placebo Comparator|placebo|Placebo, 1.0 mg administered subcutaneously once weekly
2387351|NCT03659656|Other|Fitbit (FB)|The Fitbit only (FB) group will receive the Fitbit monitor to use for 3 months.
2387352|NCT03659656|Experimental|Fitbit + Health coaching (FB+)|The Fitbit + Health coaching (FB+) group will receive a Fitbit, weekly personalized physical activity report and health coaching by phone. The 3-month intervention will be delivered through health coaching (1-time per week for month 1, 1-time every other week for month 2 and 1 time for month 3) and use of a Fitbit activity monitor.
2387353|NCT03659643||Retrospective MCI cohort|EEG with SPR analysis of the group from the study 2011-2013 is evaluated in relation to the status of current cognitive impairment
2387354|NCT03659643||Prospective MCI cohort|New individuals diagnosed with MCI. EEG with SPR analysis is performed during the diagnostic work-up and evaluated in relation to changes in cognitive status during the following two years.
2387355|NCT03659630|Experimental|Intervention group|The intervention group receives the MyCompass intervention, an automated self-help intervention for mild to moderate mental ill-health.
2387356|NCT03659630|Placebo Comparator|Comparison group|The control group receives a brief email each week, describing the most common mental health issues.
2387357|NCT03659617|Experimental|Implant placement 3 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 3 mo. after tooth ext.
2387358|NCT03659617|Active Comparator|Implant placement 6 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 6 mo. after tooth ext.
2387359|NCT03659617|Active Comparator|Implant placement 9 mo. after tooth ext.|Alveolar ridge preservation using xenograft (BioOss Collagen) and Implant placement 9 mo. after tooth ext.
3142889|NCT00003692|Experimental|video-assisted surgery|Patients undergo video-assisted thoracic surgery (VATS) lobectomy, which requires 3 small incisions on the side of the chest. The entire anatomic pulmonary lobe is removed, as well as all peribronchial lymph nodes and anterior hilar lymph nodes. If it is not possible to remove the lobe using the VATS approach, then 1 of the incisions is converted to a standard thoracotomy. Patients are followed every 4 months for the first 2 years, and then every 6 months for the next 3 years.
3142890|NCT00003693|Experimental|MTD Group|
3142891|NCT00003694|Experimental|Treatment (omacetaxine mepesuccinate, cytarabine)|Patients receive cytarabine and homoharringtonine concurrently by continuous intravenous infusion for 7 days. Courses repeat every 28 days. Patients receive a minimum of 9 courses of therapy in the absence of disease progression and unacceptable toxicity. Patients who are major cytogenetic responders at 9 months may continue therapy or switch to interferon. Minor cytogenetic responders are switched to interferon, and nonresponders are removed from therapy and given the option to switch to interferon.
2387363|NCT03659591|Active Comparator|Cognitive Behaviour Therapy|10 week, manual-based group CBT treatment for depression and anxiety, followed by optional booster sessions
2387364|NCT03659591|Active Comparator|Adaptive Psychological Training|5 week, manual-based group APT treatment for depression and anxiety, followed by optional booster sessions
2387366|NCT03659565|Experimental|Enhanced Pre-Visit Consultation|Patients and caregivers will participate in an enhanced pre-visit consultation using Zoom for remote video and audio conferencing with screen sharing capabilities.
2387367|NCT03659565|Active Comparator|Usual Care Control|Patients continue to receive usual care from their cardiologist.
2387368|NCT03659552|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left jugular vein.
3142892|NCT00003700|Experimental|Daunorubicin, ara-C, & MTX Therapy|daunorubicin during induction, increasing doses of cytarabine during consolidation followed by methotrexate in place of cranial irradiation for treatment of ALL
2387371|NCT03659526||Control|Healthy volunteers or if they have had normal invasive or CT coronary arteriography or other functional imaging test
2387372|NCT03659526||Deformation imaging|Significant coronary disease (diameter stenosis >50%) has been diagnosed on arteriography or on CT angiography. Fractional flow reserve will be measured as the reference criterion.
2387373|NCT03659526||High p(CAD)|Intermediate-to-high probability of significant epicardial coronary disease (>50%).
2387374|NCT03659526||All comers|Probability of severe disease ranging from 15 to 85%.
2387375|NCT03659500||Four-week routine bloodwork|Routine bloodwork every 4-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from June 1, 2012 to March 23, 2014
2387376|NCT03659500||Six-week routine bloodwork|Routine bloodwork every 6-weeks (CBC, electrolytes, iron studies, calcium, phosphate, PTH) from March 25, 2014 to December 31, 2015
2387377|NCT03659487|Active Comparator|Nissen|Surgery of GERD with 360 degrees total fundoplication
2387378|NCT03659487|Active Comparator|Toupét|Surgery of GERD with 270 degrees partial fundoplication
2387379|NCT03659474|Experimental|cryotherapy by compression|maximum dynamic intermittent compression, programmed to maintain a temperature at 1 ° C
2387380|NCT03659474|Experimental|ice pack|the ankle joint was surrounded by three plastic bags containing crushed ice.
2387381|NCT03659474|Experimental|cold water immersion|articulation of the ankle submerged in cold water at approximately 10 ° C, being controlled by the thermal camera.
2387382|NCT03659461|Experimental|low GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin (Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
2387383|NCT03659461|Active Comparator|normal GLP-1 arm|Subjects are required to take oral 100mg Sitagliptin ( Januvia) daily before breakfast for 12 weeks. 100mg is the recommended treatment dose. During the treatment with Januvia, subjects are not allowed to take any other medications except metformin
2387384|NCT03659448|Active Comparator|Treatment|"Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both standard white light conditions and then NIR."
2387385|NCT03659448|No Intervention|No Treatment|"Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light conditions only."
2387386|NCT03659435|Experimental|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
2387387|NCT03659435|Active Comparator|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
2387388|NCT03659422|Other|Intervention Arm|Modified Paleolithic diet and vitamin/ supplement program was part of previous approaches to managing ALS related symptoms over an 18 month period. This is a safety study. We will be assessing if patients can implement the proposed modified Paleolithic diet (Wahls Elimination), if lean muscle mass is maintained on the study diet, and what changes occur in the ALS functional symptoms and quality of life.
2387389|NCT03659409|Experimental|Mindfulness Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
2387390|NCT03659409|Other|Treatment Waitlist Group|Participants will receive no intervention, except for a baseline follow-up at the start and again at the end of the first phase. 2 months after the end of the first intervention phase, participants in this group will receive the same mindfulness-based intervention for 4 weeks.
2387391|NCT03659396|Experimental|individualized Tai Chi|patient received individualized Tai Chi program training.
2387392|NCT03659396|Active Comparator|Entire Tai Chi|patient received Entire Tai Chi program training.
2387393|NCT03659396|Placebo Comparator|home-based program|patient received home-based program training.
2387394|NCT03659383|Experimental|Optimal hypoglycemic treatment|The patients will receive optimal hypoglycemic treatments, including adjustment of insulin dose and oral antidiabetic agents
2387395|NCT03659370|Active Comparator|Fumigation Full|Full Fumigation after acupuncture, 2 times per week, for 4 weeks.
2387396|NCT03659370|Active Comparator|Fumigation 1/16|1/16 Fumigation after acupuncture, 2 times per week, for 4 weeks.
2387397|NCT03659370|Active Comparator|Acupuncture|Acupuncture only, 2 times per week, for 4 weeks.
2387398|NCT03659357||A-first CTE examination|
2387399|NCT03659357||B-first MRE examination|
2387400|NCT03659344|Active Comparator|Vicryl plus|In this group, vicryl plus(Triclosan coated) sutures were used to close flaps
2387401|NCT03659344|No Intervention|vicryl|In this group, vicryl sutures were used to close flaps
2387402|NCT03659331|Experimental|unexplained elevation of liver enzymes|patients over the age of 18 referred for unexplained elevation of liver enzymes and carry a single mutation in the ATP7B gene. After a washout period of 3 months these patients will be re-checked for liver enzymes and if high will receive zinc therapy at a dose of 300 mg / day for 6 months, after which the liver enzymes will be checked again.
2387403|NCT03659318|Experimental|Robot|TKA is done with robotic-assisted manner. Final implantation of implants is done by surgeons, same as the conventional way. Robotic-assisted TKA for this arm.
2387404|NCT03659318|Active Comparator|Conventional|TKA is done with conventional instruments. Conventional TKA for this arm.
2387405|NCT03659305|Experimental|RPH-001|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
2387406|NCT03659305|Active Comparator|Avastin|Humanized recombinant monoclonal anti-VEGF antibody. 5 mg/kg single intravenous infusion (for no less than 90 minutes)
2387407|NCT03659292|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
2387408|NCT03659292|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
2387409|NCT03659279|Experimental|Let's Get Organized|Group intervention with 10 weekly sessions, each lasting 1.5 hours.
2387410|NCT03659266|Active Comparator|Group 1|"D0: Injection of Botulinum toxin A in triceps surae, according to pre-established modalities (no influence of the experimental protocol on this stage) W2-W4: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization)"
2387411|NCT03659266|Active Comparator|group 2|"D0: Injection of Botulinum toxin A in triceps surae W2-W4: Conventional walking rehabilitation in the functional rehabilitation department (conventional hospitalization) W4-W6: Return to home, wash-outperiod W6-W8: Robotic walking rehabilitation by Lokomat® in the functional rehabilitation department (conventional hospitalization)"
2387412|NCT03659253|Experimental|Oral Fluid Based Self Testing|All study participants that received intervention and meet inclusion criteria intervention that will be offered OFT
2387413|NCT03659253|No Intervention|Control Group|All HIV Patients in the clinic that not received any intervention
2387414|NCT03659253|Experimental|Simplified ART Initiation|All study participants that received intervention and meet inclusion criteria intervention that will be offered SAI
2387415|NCT03659253|Experimental|CBO AND BROTHEL-BASED ART SERVICE|All patients coming to brothel or Community Based Organization services will be offered to get tested and received ART
2387416|NCT03659253|Experimental|SMS Reminder|"All patients that recently found HIV Positive HIV Naive offered to get SMS Reminder"
2387417|NCT03659253|Experimental|Motivational Interviewing|PWID in Jakarta and Bandung that recently found HIV Positive or lost to follow up ARV offered MI intervention
2387418|NCT03659240|Experimental|Cranberry beverage|
2387419|NCT03659240|Placebo Comparator|Placebo beverage|
2387420|NCT03659214||Treated group|Patients with proven CF (sweat-test > 60 mEq, 2 DF508 CF causing mutations, 12 to 20 years, and treated with ORKAMBI)
2387421|NCT03659214||Control group|Patients not carrying 2 DF508 CF causing mutations, not treated with ORKAMBI, and not carrying the G551D, G178R, S549N, S549R, G551S, G1244E,S1251N, S1255P or G1349D mutation or treated with Kalydeco
2387422|NCT03659201|Experimental|Neosil complete|"The patient will take the tablets, as follow:~3 tablets of Neosil, Oral, per day - during the initial 12 weeks; and~2 tablets of Neosil Oral, per day - during the last 12 weeks."
2387423|NCT03659201|Experimental|Pantogar|"The patient wil take the tablets, as follow:~3 tablets of Placebo, Oral, per day - during the initial 12 weeks; and~3 tablets of Pantogar, Oral, per day - during the last 12 weeks."
2387424|NCT03659201|Experimental|Neosil|"The patient will take the tablets, as follow:~2 tablets of Neosil Oral, per day - during the 12 weeks."
2387425|NCT03659188|Experimental|Corticotomy with drills|Patients will undergo orthodontic treatment plus an acceleration procedure employing corticotomy with drills.
2387426|NCT03659188|Experimental|Traditional Corticotomy|Patients will undergo orthodontic treatment plus an acceleration procedure employing traditional corticotomy.
2387427|NCT03659188|No Intervention|Control|Patients will undergo orthodontic treatment in which canine retraction will be accomplished using the standard sliding mechanism without any acceleration procedures.
2387428|NCT03659175||male elderly with SIBO|"male elderly who was diagnosed as SIBO via 'lactulose breath test' (LBT). At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
2387550|NCT03658291|Experimental|Sanjin tablets group|Sanjin tablets+ levofloxacin simulants
2387551|NCT03658291|Placebo Comparator|Levofloxacin group|Sanjin tablets simulants +levofloxacin
2436581|NCT03321968|Experimental|Lot 1|Quadrivalent VLP Influenza Vaccine
2387429|NCT03659175||male elderly without SIBO|"male elderly without SIBO after 'lactulose breath test'. At the same time, they meet the following criteria:~no use of antibiotics in the past 1 month.~no use of prokinetic drugs and probiotics in the past 1 week.~without these diseases: active inflammation, cardiac insufficiency, respiratory insufficiency, hepatic insufficiency, renal insufficiency, cirrhosis, thyroid diseases, Crohn disease, ulcerative colitis, hepatobiliary and pancreatic disease."
2387430|NCT03659162||neutropenic cancer patient recieving azoles .|neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
2387431|NCT03659149|Experimental|Group 1|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Test drug 2(CKD-333 formulation II) Period 3: Reference drug(CKD-330 + D086)
2387432|NCT03659149|Experimental|Group 2|Period 1: Test drug 1(CKD-333 formulation I) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 2(CKD-333 formulation II)
2387433|NCT03659149|Experimental|Group 3|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Reference drug(CKD-330 + D086) Period 3: Test drug 1(CKD-333 formulation I)
2387434|NCT03659149|Experimental|Group 4|Period 1: Test drug 2(CKD-333 formulation II) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Reference drug(CKD-330 + D086)
2387435|NCT03659149|Experimental|Group 5|Period 1: Reference drug(CKD-330 + D086) Period 2: Test drug 1(CKD-333 formulation I) Period 3: Test drug 2(CKD-333 formulation II)
2387436|NCT03659149|Experimental|Group 6|Period 1: Reference drug(CKD-330 + D086) Period 2: Test durg 2(CKD-333 formulation II) Period 3: Test drug 1(CKD-333 formulation I)
2387439|NCT03659123|Experimental|Intervention|"The intervention is designed to be implemented at different times of patients' care~During the prehabilitation time:~Nutritional care~Total-body rehabilitation~Pharmaceutical conciliation During peri-operative time~Management of enhances rehabilitation of the elderly. During rehabilitation time~Nutritional, medication conciliation and functional follow-up During hospital-home transition time~Nutritional and functional follow-up~Optimisation of symptoms management: abdominal pain, nausea, vomiting…"
2387440|NCT03659110||1000 subjects receive the HPV 4 vaccine|
2387441|NCT03659097|Experimental|Periodontally accelerated osteogenic orthodontics|Patients in this group will undergo orthodontic treatment plus periodontally accelerated osteogenic orthodontics in order to induce tooth movement.
2387442|NCT03659097|No Intervention|Traditional orthodontics|Patients in this group will undergo traditional orthodontics without any surgical interventions
2387443|NCT03659071|Experimental|DONORS|donors from the siblings of survivors of acute childhood leukemia who have received hematopoietic stem cell transplantation questionnaire VSP-A will be performed
2387444|NCT03659071|Other|NON DONORS|non-donor siblings. questionnaire VSP-A will be performed
2387445|NCT03659058|Active Comparator|study group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be treated by anti-fibrotic agents
2387446|NCT03659058|Placebo Comparator|control group|200 patients with compensated liver cirrhosis (F4) by fibroscan; Child Turcotte Pugh score A, after achieving sustained virological response will be followed up without any intervention
2387447|NCT03659045|Experimental|Mifegyne® 600MG|Patients assigned to this group will receive three 200 mg tablets of Mifegyne® taken during the consultation Patients will answer to a scale of pain
2387448|NCT03659045|Placebo Comparator|Mifegyne® 200MG|"Patients assigned to this group will receive one 200 mg Mifegyne® tablet and two placebo tablets that will be taken during the consultation.~Patients will answer to a scale of pain"
2387449|NCT03659032|Experimental|Pediatric Manual Therapy Group|"10 sessions of Pediatric Manual Therapy, once a week. Soft cervical mobilisation, myofascial induction and cranial techniques will be administered. Educational physiotherapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be also administered."
2387450|NCT03659032|Active Comparator|Control Group|"Only Educational Physical Therapy consists in tummy time stimulation, visual and kinaesthetic stimulation on the non preferential head position and counter position will be administered."
2387451|NCT03659019||ventilatory paralysis|dependence on mechanical ventilatory support
2387452|NCT03659019||central hypoventilation|documented permanent or nocturnal hypoventilation
2387453|NCT03659006|Experimental|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
2387454|NCT03658993|Active Comparator|Rifaxamine 550 mg|Study drug Oral Rifaximin 550 mg TID for 4 weeks .
2387455|NCT03658993|Placebo Comparator|Placebo|Placebo TID for 4 weeks
2387456|NCT03658980|Experimental|Health Education Intervention|Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
2387457|NCT03658980|No Intervention|Control Group|No Intervention will be conducted in this control group
2387458|NCT03658967|Active Comparator|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
2387459|NCT03658967|Placebo Comparator|Placebo (0.9% physiological saline)|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
2387460|NCT03658954|Active Comparator|Advice|Participants receive only web-based sleep hygiene advice
2387461|NCT03658954|Experimental|Advice + Self-monitoring|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring
2387462|NCT03658954|Experimental|Advice + Self-monitoring + Feedback|Participants receive web-based sleep hygiene advice + sleep/alcohol diary self-monitoring + sleep/alcohol data feedback
2387463|NCT03658941|Experimental|No dural tenting sutures|No dural tenting techniques
2387464|NCT03658941|Active Comparator|Dural tenting sutures|Dural tenting techniques
2387552|NCT03658291|Active Comparator|Sanjin tablets+ Levofloxacin group|Sanjin tablets+ levofloxacin
2387671|NCT03657498|Active Comparator|Control Group II|Standard orthodontic treatment
2387465|NCT03658915||Osteoarthritis|"Thirty symptomatic knee with osteoarthritis will be recruited according to the following criteria:~INCLUSION CRITERIA:~Referred with a confirmed diagnosis of unilateral or bilateral OA of the knee based on the following criteria.~1.1. Morning stiffness < 30 minutes, 1.2. Crepitus on active knee movement. 1.3. Bony enlargement either palpable or visible in radiographs. 1.4. Bony tenderness.~Age 40-60 years old.~EXCLUSION CRITERIA:~Steroid injection within the past 2 months.~Presence of neurologic disorders.~Presence of of orthopedic diseases or trauma in the lower extremity or spine within the past year.~6. Severe pain with active movement 7. Poor memory or cognitive function"
2387466|NCT03658915||Control|Thirty asymptomatic knee will be recruited for this study. Control group participants will be age-matched to the osteoarthritis group, and should have no pain or other relevant clinical symptoms in lower quadrant.
3183507|NCT00714467|Active Comparator|1|Expert system (stage-based manual and 3 individualized tailored feedback reports) only for smokers, paired-supporters (family or friend participant) do not receive any study intervention
3183508|NCT00714467|Experimental|2|Expert system (stage-based manual and 3 individualized tailored feedback report) to all the smoker participants; a family assisted intervention in a form of a self-help booklet that discusses specific strategies to work with smokers at each stage of change to the paired-supporters
3183509|NCT00714480|Other|Group I|Administration of anti-thymocyte globulin post-operative days -6,-4,-2, and 0
2387470|NCT03658863|Active Comparator|Endoscopy first|Endoscopic ultrasound is used to evaluate bile ducts. If stones in extrahepatic bile ducts are seen ERCP and stone evacuation is performed during the same anaesthesia. Laparoscopic cholecystectomy is performed after endoscopic procedures in two days.
2387471|NCT03658863|Active Comparator|Cholecystectomy first|Laparoscopic cholecystectomy with intraoperative cholangiography is performed. If stones are found postoperative ERCP with stone evacuation is applied (during cholecystectomy if common bile duct is completely blocked or as soon as possible).
2387472|NCT03658850|Active Comparator|Intervention|the experimental group will receive one tablet of hydrochlorothiazide in the presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally for 3 days.
2387473|NCT03658850|Placebo Comparator|Control|placebo group will receive one tablet or equivalent volume of enteral solution of inert substance
2387474|NCT03658824|Other|3 week wait|Participant waits for 3 weeks after their baseline assessment before commencing therapy.
2387475|NCT03658824|Other|4 week wait|Participant waits for 4 weeks after their baseline assessment before commencing therapy.
2387476|NCT03658824|Other|5 week wait|Participant waits for 5 weeks after their baseline assessment before commencing therapy.
2387477|NCT03658824|Other|6 week wait|Participant waits for 6 weeks after their baseline assessment before commencing therapy.
2387478|NCT03658824|Other|7 week wait|Participant waits for 7 weeks after their baseline assessment before commencing therapy.
2387479|NCT03658824|Other|8 week wait|Participant waits for 8 weeks after their baseline assessment before commencing therapy.
3183510|NCT00714480|Other|Group II|Administration of anti-thymoglobulin post-operative days -2, 0, 2 and 4
2387481|NCT03658798|Experimental|FES-Garment|All participants will take part in 40 sessions of 1 hour of Functional Electrical Stimulation
2387482|NCT03658785|Experimental|TIL,IL-2,Cyclophosphamide,Fludarabine|"Biological: TIL On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).~Drug: Aldesleukin Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.) Drug: Cyclophosphamide On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.~Drug: Fludarabine Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days."
3183511|NCT00714480|Other|Group III|Administration of anti-thymocyte globulin post-operative days 0, 2, 4 and 6
2387485|NCT03658746|Experimental|Antimicrobial susceptibility guided therapy|"Patients in this group will receive a 14-day quadruple therapy for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin, and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d, 2.Colloidal Bismuth Pectin 200mg bid for 14d, 3.two sensitive antibiotics: amoxicillin 1000mg bid for 14d, clarithromycin 500mg bid for 14d, metronidazole 500mg tid for 14d, tinidazole 500mg tid for 14d, levofloxacin 500mg qd for 14d, furazolidone 100mg bid for 14d, tetracycline 500mg qid for 14d."
2387486|NCT03658746|Active Comparator|Empirical therapy according to medication history|"Patients in this group will receive a 14-day quadruple therapy based on personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics chosen according to medication history. If the patient hasn't been treated with levofloxacin in the previous eradication regimen, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: rabeprazole 10mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and levofloxacin 500mg qd for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2387487|NCT03658733|Experimental|Esomeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole,amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. esomeprazole 40mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
2387553|NCT03658278|Experimental|Nutritional supplement group|Subjects in this group will be asked to consume the nutritional supplement on a daily basis, in addition to standard nutrition. Subjects will have pain medication and postoperative therapies per standard of care.
2387488|NCT03658733|Active Comparator|Rabeprazole-containing therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 20mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the first 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
2387489|NCT03658720|Experimental|Single tablet|Ibuprofen acid ODT: 1x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
2387490|NCT03658720|Experimental|Two tablets|Ibuprofen acid ODTs: 2x200mg dose. Administered without water after the subject has swallowed (with oral cavity rinsing) 20 mL of water. This was following a fasting period of 2 hours 15 minutes (± 15 minutes). The fasting period started after the subject consumed a standardised light meal/snack.
2387491|NCT03658694|Experimental|rTMS high dose - stage 1|In stage 1 patients were randomly allocated to receive real repetitive transcranial magnetic stimulation.
2387492|NCT03658694|Experimental|rTMS sham - stage 1|In stage 1 patients were randomly allocated to receive sham repetitive transcranial magnetic stimulation.
2387493|NCT03658694|Experimental|high dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive high dose of repetitive transcranial magnetic stimulation.
2387494|NCT03658694|Experimental|low dose rTMS - stage 2|In stage 2, after the end of the first trial will be allocated to receive low dose of repetitive transcranial magnetic stimulation.
2387495|NCT03658681|Experimental|Test meal 1: Saturated fat 14.9 E%|Test meal with saturated fat 14.9 E%
2387496|NCT03658681|Experimental|Test meal 2: Polyunsaturated fat 13.6 E%|Test meal with polyunsaturated fat 13,6 E%
3142893|NCT00003704|Experimental|capecitabine + radiation|This is a dose-escalation study of capecitabine. Patients receive oral capecitabine twice a day 7 days a week for 6 weeks with concurrent radiotherapy. Radiotherapy is initiated on the same day as the initiation of capecitabine and is administered 5 days a week for 5.5-6 weeks. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose-limiting toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
3142894|NCT00003714|Experimental|Pyrazoloacridine|
2387499|NCT03658655|Experimental|Stem Cells From Human Exfoliated Teeth|According to the weight of 0.1IU /kg with Stem Cells From Human Exfoliated Teeth, three injections will be given respectively at the time of enrollment, one week and four weeks after enrollment.
2387500|NCT03658642|Experimental|Clinical Decision Support for BUP|The Clinical Decision Support (CDS) will be available for clinician use for Emergency Department (ED)-initiated buprenorphine/naloxone (BUP) with referral for ongoing medication assisted treatment (MAT) if: ED chief complaint or urine drug screen indicate opioid use. The clinician will then be prompted to complete DSM-5 checklist for OUD. If DSM-5 OUD Score>5 and urine drug screen is positive for opioids, then the clinician is prompted to complete COWS scale. If COWS score >12, then the clinician is prompted to order BUP. Regardless of COWS score, the clinician will be prompted to schedule an MAT appointment with BUP provider. The CDS will interface with outside MAT facilities so that making an appointment is easy and to capture data on whether an appointment has been scheduled.
2387501|NCT03658642|No Intervention|Usual Care|The CDS will not be activated and patients will receive care as usual.
3142895|NCT00003723|Experimental|Gemcitabine/Cisplatin|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days) cisplatin 30 mg/m^2 days 1, 8, 15 (q 28 days)
3142896|NCT00003724|Experimental|surgery|"Patients undergo open resection (thoracotomy, median sternotomy, or bilateral sternothoracotomy).~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
2387511|NCT03658603|Experimental|Study group|Thoracodorsal artery perforator flap
2387512|NCT03658603|Active Comparator|control group|Conventional free flaps
2387513|NCT03658590|Active Comparator|Group D|including 51 women who will receive a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously.
2387514|NCT03658590|Placebo Comparator|Group P|including 51 women who will receive a prefilled syringe with two milliliters of distilled water intravenously.
2387515|NCT03658564|Experimental|Oral carbohydrate|fast from midnight the night before surgery, and patients consume 400 ml Preoperative oral carbohydrate preOp®(12.5% carbohydrates, 0.5%kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
2387516|NCT03658564|No Intervention|Fasting|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
2387517|NCT03658551||Liver cirrhosis|Patients with liver cirrhosis are included in this arm. Liver cirrhosis is diagnosed by ultrasound, CT - scan oder by clinical signs.
2387518|NCT03658551||Control group|Patients with abdominal symptoms with the indication for endoscopy without liver cirrhosis and portal Hypertension.
2387519|NCT03658538|Active Comparator|Active Treatment|The active treatment arm will receive two portable active HEPA air cleaners as well as 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).
2387587|NCT03658070|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg;Include single dose treatment and multiple dose phase
2387520|NCT03658538|Sham Comparator|Control Arm|Homes in the control group will receive Sham air cleaners that have the internal HEPA filter removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status. The control arm will not receive phone based motivational interviewing to support a home smoking ban and SHS reduction, they will receive only smoking cessation counseling.
2387521|NCT03658525|Experimental|MR LINAC RADIOTHERAPY|RADIOTHERAPY DELIVERED ON MR LINAC
2387522|NCT03658512||TUEDID cohort|
2387523|NCT03658499|Experimental|Experimental|"Those assigned to the experimental condition will be provided with treatment as usual (the two day skills group) and exposure to the video intervention adjuncts.~two day skills group plus treatment adjuncts"
2387524|NCT03658499|Other|control|"Those in the control condition will be provided with treatment as usual (the two day skills group) without access to the video intervention adjuncts.~two day skills group control group"
3183512|NCT00714506|Experimental|Intervention|lifestyle weight reduction - low fat eating, low calorie and physical activity
2387526|NCT03658473|Active Comparator|Treatment A|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
2387527|NCT03658473|Active Comparator|Treatment B|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole 1x daily over 7 days.
2387528|NCT03658473|Active Comparator|Treatment C|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
2387529|NCT03658473|Placebo Comparator|Treatment D|Administration of 550 mg naproxen 2x daily + 300 mg rebamipide placebo 2x daily + 20 mg rabeprazole placebo 1x daily over 7 days.
2387530|NCT03658447|Experimental|177Lu-PSMA + Pembrolizumab|200mg pembrolizumab given 3 weekly for upto 35 cycles and 6-weekly 177Lu-PSMA treatments for upto 6 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
2387531|NCT03658434|Experimental|feasibilty|Palliative Radiotherapy
2387532|NCT03658421|Experimental|H group|H group stands for High concentration group. A single bolous of 20 ml ropivacaine 0.2% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.2% (5 ml/h) for postoperative analgesia which started right after surgery. After surgery, all patients received multimodal analgesia of 200mg celecoxib every 12 hours. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
2387533|NCT03658421|Experimental|L group|L group stands for low concentration group. A single bolous of 20 ml ropivacaine 0.1% in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
2387534|NCT03658421|Experimental|LD group|LD group stands for low concentration group with dexmedetomidine. A single bolous of 20 ml ropivacaine 0.1% plus 2 μg/kg dexmedetomidine in ultrasound-guided femoral nerve block (FNB) before the TKA surgery, followed by continuous femoral nerve block (CFNB) using ropivacaine 0.1% (5 ml/h) for postoperative analgesia which started right after surgery. All subjects received anothother intravenous patient-controlled analgesia pump (IV-PCA pump), which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
2387535|NCT03658408|Experimental|4-aminopyridine|Participants with recent prostatectomies receiving 4-aminopyridine
2387536|NCT03658408|Placebo Comparator|Placebo|Participants with recent prostatectomies receiving placebo
2387537|NCT03658395|Active Comparator|LSCP Only|A Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, is used utilizing robot-assisted Laparoscopic Sacrocolopopexy.
2387538|NCT03658395|Active Comparator|LSCP + PR|"The Laparoscopic Sacrocolopopexy involves a Y-shaped polypropylene mesh graft, 10 cm in standard length and tailored to each patient's anatomic specifications during surgery, utilizing robot-assisted Laparoscopic Sacrocolopopexy.~In addition, patients will receive posterior repair. Posterior repair is performed by midline fascial plication. Plication of superficial perineal muscles (perineorrhaphy) is performed in conjunction with posterior repair. All repairs are performed using polydioxanone 2/0 for fascial repair and 4/0 polyglactin suture for skin closure."
2387539|NCT03658382|No Intervention|Telephone Results Disclosure|
2387540|NCT03658382|Experimental|Virtual Visit Results Disclosure|
2387541|NCT03658369|Active Comparator|Lanconone®|Lanconone®: 2 Capsules once a day after breakfast
2387542|NCT03658369|Placebo Comparator|Methyl Crystalline Cellulose|2 Capsules once a day after breakfast
2387543|NCT03658356|Placebo Comparator|Verbal Instruction on Urine collection|"At initial prenatal visit, pregnant patients will be given verbal instructions on how to collect a urinary sample for culture.~Intervention: Pt will be given verbal instruction to collect urine"
2387544|NCT03658356|Active Comparator|Video instruction on urine collection|"At initial prenatal visit, pregnant patients will watch a video on how to collect a urinary sample for culture~Intervention: Patient will be asked to watch a video on how to collect a urine sample"
2387545|NCT03658343|Experimental|T2* Imaging|Participants undergo T2* MRI imaging before beginning their course of radiation therapy and then after completing radiation therapy, about 2 weeks before their surgery.
2387546|NCT03658330|Experimental|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
2387547|NCT03658317|Active Comparator|cases|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
2387548|NCT03658317|Active Comparator|controls|laboratory tests including (random blood glucose , serum urea and creatinine , lipogram , serum uric acid , HbA1c , urine analysis , 24 hours urinary proteins ) abdominal ultrasonography dupplex on the renal vessels
3183513|NCT00714506|Active Comparator|Control|physical activity plus successful aging health education
3183514|NCT00714519|Experimental|1|
3183515|NCT00714519|Placebo Comparator|2|
2387554|NCT03658278|No Intervention|Standard nutrition group|Subjects in this group will have standard nutrition provided per dietitian recommendation. Subjects will have pain medication and postoperative therapies per standard of care.
2387555|NCT03658265|Active Comparator|7 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
2387556|NCT03658265|Experimental|7 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 7 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
2387557|NCT03658265|Experimental|3 days SIE plus 4 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 4 weeks after surgery.
2387558|NCT03658265|Experimental|3 days SIE plus 3 weeks PRE|Participants in this group will start shoulder isotonic exercise 3 days after surgery and begin progressive resistance exercise 3 weeks after surgery.
2387559|NCT03658252|Experimental|Intervention|"Participants in the intervention arm will be shown a 2 minute educational video, and given an information leaflet on topical steroids. At 1 month of follow up, a link encouraging participants to sign up for a pre-selected, disease specific, moderated online support group would be sent to their emails.~Participants will continue to receive standard medical care and counselling by their dermatologists as clinically indicated."
2387560|NCT03658252|No Intervention|Control|Patients in the control arm will receive only standard medical care and counseling by their dermatologist as clinically indicated.
2387561|NCT03658239|Experimental|Experimental|"Subjects will undergo 4-5 visits total over the course of 6 months. There will be 3-4 visits that will be done at the Flaum Eye Institute. During these sessions the subject will be measured with a stationary topographer (GALILEI G4), with a rotatable topography measurement (Oculus Topographer) and a Tonometer. The subject's heart rate and blood pressure will also be measured (using a commercially available blood pressure and heart rate meter).~The GALILEI measurement will only be done once. The rest of the measurements will be done up to 4 times. Once at the start of the study session then, after the subject has been inverted using a commercially available inversion table to first 135 degrees, then 150 degrees and finally to 165 degrees.~The blood pressure and heart rate will be monitored to ensure subject safety.~There will also be one visit at the Massachusetts General Hospital. The visit will be 2 hours and will involve a Brillouin Microscopy measurement."
2387562|NCT03658226|Experimental|Therapy|Psychodynamic Interpersonal Therapy (PIT)
2387563|NCT03658213|Experimental|ZOLADEX 10.8 mg depot group|• ZOLADEX 10.8 mg depot group: subcutaneous depot injection once every 12 weeks
2387564|NCT03658213|Active Comparator|ZOLADEX 3.6 mg depot group|• ZOLADEX 3.6 mg depot group: subcutaneous depot injection once every 4 weeks
2387565|NCT03658200|Active Comparator|FAST software|Patient referred for chest CT and scanned with delay based on bolus tracking with FAST software. intervention: FAST START Software delay
2387566|NCT03658200|Active Comparator|Control|Patient referred for chest CT and scanned with delay based on bolus tracking without FAST software. Intervention: Manual bolus tracking delay
2387567|NCT03658187|Placebo Comparator|Placebo|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
2387568|NCT03658187|Experimental|IP|2 tablets orally with water and 2 ml of liquid spray to be kept for 30 sec sublingually, before swallowing. To be taken half an hour before dinner prior to the day of site visit.
2387569|NCT03658174|Active Comparator|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice to be taken twice a day. This contains 5-6 mmol of inorganic nitrate.
2387570|NCT03658174|Placebo Comparator|Nitrate-free beetroot juice|70mls of concentrated nitrate-free beetroot juice to be taken twice a day. This is an identical juice from which the nitrate has been removed using a standard anion exchange resin.
2387571|NCT03658161|Experimental|CASCADE|Oncology providers will receive the CASCADE coaching intervention.
2387572|NCT03658148||Study Group|Neonates (≤31 days) who underwent cardiac surgery with cardiopulmonary bypass for congenital heart disease (CHD) between 2008-2017.
2387573|NCT03658135|Experimental|BIIB092|The investigational drug, BIIB092, will be given intravenously, every 4 weeks for 20 weeks
2387574|NCT03658135|Placebo Comparator|Placebo|Inactive ingredient
2387575|NCT03658122|Experimental|Parent-Child Care Treatment|Participants receive PC-CARE treatment immediately following the pre-treatment assessment.
2387576|NCT03658122|Other|Waitlist Control then Parent-Child Care|Participants wait approximately 2 months with no intervention before completing another pre-treatment assessment (post-waitlist assessment) and receiving PC-CARE treatment.
2387577|NCT03658109|Active Comparator|Lidocaine Bolus Infusion|"Patients will also undergo a loading dose of lidocaine, followed by continuous lidocaine infusion in the lidocaine group.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block."
2387578|NCT03658109|Active Comparator|QL Block & Saline Bolus Infusion|"Patients will undergo a posterior QL block.~Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will receive a saline bolus infusion."
2387579|NCT03658109|No Intervention|Intrathecal Morphine Alone|"Patients will undergo an injection of intrathecal opioid medication (morphine) preoperatively.~Patients will undergo a simulated QL block.~Patients will receive a saline bolus infusion."
2387580|NCT03658096|Active Comparator|Healthy volunteer|
2387581|NCT03658096|Active Comparator|DRUJ instability patients|
2387582|NCT03658083||Thoracotomy|Individuals referred for a lung resection via thoracotomy with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
2387583|NCT03658083||Robotic-assisted thoracic surgery|Individuals referred for a lung resection via robotic-assisted thoracic surgery with a primary or secondary diagnosis of lung cancer. Those with a tumor >7cm will be excluded.
2387584|NCT03658070|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg;Include single dose treatment and multiple dose phase
2387585|NCT03658070|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg;Include single dose treatment and multiple dose phase
2387586|NCT03658070|Experimental|XY0206-37.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：37.5mg;Include single dose treatment and multiple dose phase
2387633|NCT03657771|Active Comparator|FREE|Diet eliminating dairy and food additives
2387588|NCT03658070|Experimental|XY0206-75mg|Drug:XY0206;Dosage form:Tablet;Dosage：75mg;Include single dose treatment and multiple dose phase
2387589|NCT03658070|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg;Include single dose treatment and multiple dose phase
2387590|NCT03658057|Active Comparator|ROC|Neuromuscular blockade is performed in the ROC group by administering rocuronium 0.4~0.8mg/kg before the insertion of laryngeal airway.
2387591|NCT03658057|No Intervention|Control|Neuromuscular blockade is not performed.
2387592|NCT03658044|Experimental|Participation in the internet forum|Other: Patients will be encouraged to participate in an internet forum communicating with other patients at least once per week. Participation in the internet forum
2387593|NCT03658044|Active Comparator|No participation in the internet forum|"Placebo Patients will not be able to enter or read in the forum, but will be able to read general information on the webpage where the forum is placed."
2387594|NCT03658031|Experimental|Dapagliflozin|Dapagliflozin 10mg per/day in prediabetes cases with MI before breakfast
2387595|NCT03658031|No Intervention|Placebo|Antiplatelet, ACEI and Betablockers
2387596|NCT03658018|Experimental|Intracept System Ablation|
2387597|NCT03658005||Study cohort|"Adult (>18 years, <90 years) patients admitted and treated for acute myocardial infarction, and whose treatment includes ticagrelor in association with aspirin.~Blood samples will be taken at 3 timepoints between two doses of ticagrelor (taken at 12 hours interval)."
2387598|NCT03657979|Experimental|Ropivacaine|Conventional PCA morphine +TAP-block ropivacaine 0.2%
2387599|NCT03657979|Placebo Comparator|TAP-block with placebo|Conventional PCA morphine treatment with TAP-block with placebo
2387600|NCT03657966|Experimental|Standard of care chemotherapy + DCVAC/Ov|Standard-of-care carboplatin/gemcitabine or carboplatin/paclitaxel followed by DCVAC/OvCa
2387601|NCT03657953|Active Comparator|anterior (MI-A) surgical approach|The minimally invasive anterior surgical approach was carried out using a modified Smith-Petersen access as described by Bender et al. (Bender et al. 2009) with the patient in supine position.
2387602|NCT03657953|Active Comparator|anterolateral (MI-AL) surgical approach|For the minimally invasive anterolateral surgical approach, a modified Watson-Jones approach according to Röttinger (Rottinger et al. 2006) was applied with the patient in supine position.
2387603|NCT03657953|Active Comparator|direct lateral (DLA) surgical approach|The direct lateral surgical approach was performed according to the technique described by Hardinge et al. (Hardinge et al. 1982) with the patient positioned supine
2387604|NCT03657940|Experimental|Exercise intervention|multicomponent exercise training program [VIVIFRAIL],
2387605|NCT03657940|No Intervention|Usual Care|Participants randomly assigned to the usual care group will receive normal outpatient care, which includes physical rehabilitation when needed.
2387606|NCT03657927|Active Comparator|C-MAC Videolaryngoscope|Morbidly obese patients intubated with C-MAC Videolaryngoscope
2387607|NCT03657927|Active Comparator|McGrath MAC Videolaryngoscope|Morbidly obese patients intubated with McGrath MAC Videolaryngoscope
2387608|NCT03657914|Experimental|Inflatable mediastinal mirror|Patients with especially esophageal squamous cell carcinoma ( ESCC ) who meet the inclusion criteria and do not meet the exclusion criteria will undergo radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma, and will be followed up until 3 years after discharging from the hospital.
2387609|NCT03657901|Experimental|Breathing|Guided slow breathing for 30 minutes before sleep onset
2387610|NCT03657901|Active Comparator|Music listening|Guided music listening for 30 minutes before sleep onset
2387613|NCT03657862|Experimental|SDF treated|application of 38% silver diamine fluoride solution
2387614|NCT03657862|Placebo Comparator|Placebo|application of a placebo (tonic water)
2387615|NCT03657849|Experimental|Sampling with 19-gauge and 21-gauge|All patients will be allocated to the same arm. All patients will have EBUS TBNA done with both 19-gauge and 21-gauge needles during the procedure.
2387616|NCT03657836|Experimental|Dietary supplement and antibiotics|Participants will take a supplement of 1 sachet (20 mg) dissolved in 200 ml of warm water (36-37 °C) once a day for 60 days accompanied with the standard antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
2387617|NCT03657836|Other|Antibiotics only|Participants will take the prescribed antibiotic therapy (cefuroxime and ceftriaxone) up to 7 days.
2387618|NCT03657823||Fetal growth cohort|Longitudinal measurements of fetal growth, fetal circulation and maternal circulation
2387619|NCT03657823||Hypertensive cohort|Retrospective cohort of women with heart disease that underwent oregnancy and childbirth
2387620|NCT03657810|Experimental|CL-108 5 mg|Hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg (CL-108 5 mg) bi-layered tablet
2387621|NCT03657810|Active Comparator|Norco|hydrocodone 5 mg/APAP 325 mg
2387622|NCT03657810|Placebo Comparator|Placebo|Placebo 0 mg matching CL-108
2387623|NCT03657797|Experimental|NCX 470 0.021%|NCX 470 Ophthalmic Solution, 0.021% dosed once daily for 4 weeks
2387624|NCT03657797|Experimental|NCX 470 0.042%|NCX 470 Ophthalmic Solution, 0.042% dosed once daily for 4 weeks
2387625|NCT03657797|Experimental|NCX 470 0.065%|NCX 470 Ophthalmic Solution, 0.065% dosed once daily for 4 weeks
2387626|NCT03657797|Active Comparator|Latanoprost 0.005%|Latanoprost Ophthalmic Solution, 0.005% dosed once daily for 4 weeks
2387627|NCT03657784|Experimental|Cohort 1|P03277 will be administered to healthy volunteers with stable normal renal function defined with an absolute value of eGFR ≥ 90 mL/min.
2387628|NCT03657784|Experimental|Cohort 2|P03277 will be administered to patients with stable mild renal impairment defined with an absolute value of eGFR between 60 and 89 mL/min.
2387629|NCT03657784|Experimental|Cohort 3|P03277 will be administered to patients with stable moderate renal impairment defined with an absolute value of eGFR between 30 and 59 mL/min.
2387630|NCT03657784|Experimental|Cohort 4|P03277 will be administered to patients with stable severe renal impairment defined with an absolute value of eGFR between 15 and 29 mL/min.
2387631|NCT03657784|Experimental|Cohort 5|P03277 will be administered to patients with end-stage renal failure who requires 3 hemodialysis sessions per week.
2387632|NCT03657771|Active Comparator|DED|Diet eliminating dairy
2387634|NCT03657758|Active Comparator|EPA and statin therapy group|After randomization, patients with combination therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
2387635|NCT03657758|Active Comparator|High dose statin therapy group|After randomization, patients with high dose statin therapy start high dose rosuvastatin (10mg/day) for ９ months.
2387636|NCT03657758|No Intervention|low dose statin therapy group|After randomization, patients with low dose statin therapy take low dose rosuvastatin (5mg/day) for ９ months.
2387637|NCT03657745||Participants who adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants adhere to the protocol if they exercise with AlzLife the minimum of 1hour/week.
2387638|NCT03657745||Participants who do not adhere to the protocol|All participants are encouraged to exercise with AlzLife daily for 30 minutes a day. The actual duration is to be measured through participant's interactions with ALZLIFE. Participants do not adhere to the protocol if they exercise with AlzLife less than 1hour/week.
2387639|NCT03657732||Familial Alzheimer's disease group|Familial Alzheimer's disease with the known mutation presenilin1 (PSEN1), presenilin2 (PSEN2) and amyloid precursor protein (APP) including mutation carriers and noncarriers, presymptomatic and symptomatic.
2387640|NCT03657732||Normal control group|Normal cognitive control people
2387641|NCT03657719|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
2387642|NCT03657719|Active Comparator|Active Comparator: GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
2387643|NCT03657706|Active Comparator|group A|tunnel procedure with subepithelial connective tissue graft (sCTG)
2387644|NCT03657706|Active Comparator|group B|tunnel procedure with modified free gingival graft (mFGG)
2387645|NCT03657693||BPD|Infants born premature requiring oxygen
2387646|NCT03657693||Controls|
2387647|NCT03657680||ATQ Group|Convenience sample of patients from Porto Alegre (RS, Brazil) who were experiencing unilateral hip osteoarthritis and were submitted to THA in referral hospitals at least five months previously to data collection. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
2387648|NCT03657680||Control Group|The control group was composed of asymptomatic individuals from the community. The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
2387649|NCT03657667|Other|Ureteroscopy (URS) (standard treatment)|Endoscopic procedure used to remove kidney stones
2387650|NCT03657654||Thyroidectomy|Patients that are clinically referred for a thyroidectomy for known or potential cancer.
2387651|NCT03657654||Other surgeries|Patients must be clinically referred for a surgery requiring intubation, but without risk to the laryngeal nerves or dissection adjacent to the larynx
2387652|NCT03657641|Experimental|Treatment (pembrolizumab, regorafenib)|Participants receive pembrolizumab IV over 30 minutes on day 1 and regorafenib PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2387653|NCT03657628|Experimental|Physical activity|"The exercise intervention will consist of a supervised, moderate-intensity aerobic exercise program.~Will receive social/behavioral support~Will receive research staff contact time to encourage them to increase their physical activity level~The participants will be given the option of a third supervised session each week"
2387654|NCT03657615|Active Comparator|Control|Hearing Aid Fitting Patients with hearing loss but no tinnitus paired by age and hearing loss degree Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
2387655|NCT03657615|Experimental|Tinnitus|Hearing Aid Fitting Patients with tinnitus and hearing loss associated Hearing aided fitted PET image acquisition before and after 6 months og Hearing aid usage.
2387656|NCT03657602|Experimental|Contraceptive Kyleena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Kyleena Intrauterine System
2387657|NCT03657602|Experimental|Contraceptive Mirena|Determination of expulsion and discontinuation rates in participants randomly allocated to receive levonorgestrel intrauterine systems Mirena Intrauterine System
2387658|NCT03657589||patients with 1 missing tooth|Patients with 1 missing anterior or premolar tooth and planned for implant surgery were recruited. Gingiva and alveolar bone were ultrasound scanned and compared to CT scans and direct measures during implant surgery.
2387659|NCT03657576|Experimental|C134 Treatment|All patients who enroll will receive C134 inoculation into their tumor (one time procedure with 1-5 inoculation sites)
2387660|NCT03657563|Experimental|Intervention group|Nurses with burnout are recruited in the intervention group and participate in positive psychological intervention.
2387661|NCT03657563|No Intervention|Control group|Nurses with burnout are recruited in the control group and none interventions are conducted to them.
2387662|NCT03657550|Other|Test Drug - Reference Product - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 5 mg levamlodipine maleate tablets (Test Product), then crossed over to receive a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
2387663|NCT03657550|Other|Reference Product - Test Drug - Test Drug (Food Effect)|In Part 1, this group of subjects were treated with a single dose of 10 mg Amlodipine Besylate Tablet NORVASC® (Reference Product), and then crossed over to receive a single dose of 5 mg levamlodipine maleate tablets (Test Product) under fasted conditions. After a wash-out period for 14-days, all subjects were rolled over to Part 2 where they received a single dose of 5 mg levamlodipine maleate tablets under a high-fat/high-calorie meal to assess food effect.
2387664|NCT03657537|Experimental|Hyperketonemia - Placebo|Participants are randomly assigned to initially receive ketone infusion and then saline infusion
2387665|NCT03657537|Experimental|Placebo - Hyperketonemia|Participants are randomly assigned to initially receive saline infusion and then ketone infusion
2387666|NCT03657524|Experimental|Resuscitation patients|
2387667|NCT03657524|Active Comparator|healthy volunteers|
2387668|NCT03657511|Other|Educational Interventions to Promote Tobacco Cessation|
2387669|NCT03657498|Experimental|Study group|Combined orthodontic-orthognathic treatment
2387672|NCT03657485|Experimental|interventional|In the interventional group we supplemented the probiotic containing Bifidobacterium breve PB04 i Lactobacillus rhamnosus KL53A (FFbaby, IBSS Biomed SA, Poland) orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
2387673|NCT03657485|No Intervention|control|No intervention. Feeding with mother milk
2387674|NCT03657485|No Intervention|comperative|Comparing stool composition of vaginally born newborns
2387675|NCT03657472|Experimental|Sequence 1(RTR)|
2387676|NCT03657472|Experimental|Sequence 2(RRT)|
2387677|NCT03657472|Experimental|Sequence 3(TRR)|
3142897|NCT00003724|Experimental|video-assisted surgery|"After spiral CT showing pulmonary nodules are amenable to video-assisted thoracic surgery (VATS) resection with curative intent, patients undergo minimally-invasive video-assisted resection.~Patients with isolated recurrence in the chest should have the recurrence(s) resected if feasible. The original resection approach (open versus VATS) should be the preferred method for the second resection, but is not required.~Quality of life is assessed prior to randomization and then at 30 days, 3 months, and 6 months. Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3183516|NCT00714532|Active Comparator|1|Expert system only, which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months.
2387680|NCT03657446|Experimental|Treatment sequence ABC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
2387681|NCT03657446|Experimental|Treatment sequence ACB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn
2387682|NCT03657446|Experimental|Treatment sequence BAC|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
2387683|NCT03657446|Experimental|Treatment sequence BCA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
2387684|NCT03657446|Experimental|Treatment sequence CBA|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
2387685|NCT03657446|Experimental|Treatment sequence CAB|Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin
2387686|NCT03657433|Experimental|Ferumoxyltol|"Patients will receive two infusions of Ferumoxyltol, 510mg, intravenously, one week apart.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
2387687|NCT03657433|Active Comparator|Ferrous Sulfate|"Patients will be provided with oral ferrous sulphate, 325mg, to take 2x daily at home.~Iron studies will be completed at study inclusion and again at presentation for delivery. Cord blood will also be assessed for iron studies."
2387688|NCT03657420|Experimental|ABI-009 + Pomalidomide + Dexamethasone|"Pomalidomide is given orally daily on days 1-21, 7 days off~ABI-009 is given intravenously on days 1, 8, and 15~Dexamethasone is given orally weekly on days 1, 8, 15, 22"
2387691|NCT03657394|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk 20-30 centimeters length of the umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC.
2387692|NCT03657394|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after birth (within 60 seconds)
2387693|NCT03657381|Experimental|F520 0.2mg/kg single-dose|F520 0.2mg/kg single-dose
2387694|NCT03657381|Experimental|F520 1.0mg/kg single-dose|F520 1.0mg/kg single-dose
2387695|NCT03657381|Experimental|F520 3.0mg/kg single-dose|F520 3.0mg/kg single-dose
2387696|NCT03657381|Experimental|F520 200mg/times single-dose|F520 200mg/times single-dose
2387697|NCT03657381|Experimental|F520 10mg/kg single-dose|F520 10mg/kg single-dose
2387698|NCT03657381|Experimental|F520 1mg/kg multiple dosing, every 2 weeks|F520 1mg/kg every 2 weeks
2387699|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 2 weeks|F520 3mg/kg every 2 weeks
2387700|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 2 weeks|F520 200mg/times every 2 weeks
2387701|NCT03657381|Experimental|F520 10mg/kg multiple dosing, every 2 weeks|F520 10mg/kg every 2 weeks
2387702|NCT03657381|Experimental|F520 3mg/kg multiple dosing, every 3 weeks|F520 3mg/kg every 3 weeks
2387703|NCT03657381|Experimental|F520 200mg/times multiple dosing, every 3 weeks|F520 200mg/times every 3 weeks
2387704|NCT03657368|Experimental|Low tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 6 ml/ kg predicted body weight, and PEEP = 5 cm water (H2O).
2387705|NCT03657368|Experimental|Low tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 6 ml/kg predicted body weight, and PEEP = 8 cm H2O.
2387706|NCT03657368|Experimental|High tidal volume and low PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 5cm H2O.
2387707|NCT03657368|Experimental|High tidal volume and high PEEP|Ventilation parameters will be set at tidal volume = 10 ml/kg predicted body weight, and PEEP = 8cm H2O.
2387708|NCT03657355|Experimental|50 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
2387709|NCT03657355|Experimental|100 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
2387710|NCT03657355|Experimental|150 mg ACT-541468|ACT-541468 will be administered as tablets for oral use.
2387711|NCT03657355|Active Comparator|150 mg suvorexant|Suvorexant will be administered as tablets for oral use.
2387712|NCT03657355|Active Comparator|30 mg zolpidem|Zolpidem will be administered as tablets for oral use.
2387713|NCT03657355|Placebo Comparator|Placebo|Placebo will be administered as tablets for oral use.
2387714|NCT03657342|Experimental|L-CsA treatment plus SoC|L-CsA 5 mg twice daily for 48 weeks Standard of Care Therapy
2387715|NCT03657342|No Intervention|Standard of Care alone|Standard of Care Therapy
2387716|NCT03657329|Experimental|Suspicion of sleep-disordered breathing|Dreem
2387717|NCT03657316|Experimental|experimental school 1|"The experimental school 1 will receive the following:~Nutritional and physical activity educational workshop~Enhanced physical education~Involvement of the morning broadcast~Educational brochure will be sent to the parents~A monthly telephone call or a text message will be sent to the parents~Message to school administration to prevent selling of soft drinks and to sell healthy food~A monthly session (3 months)"
2387718|NCT03657316|Experimental|experimental school 2|The experimental school 2 school will receive a nutritional and physical activity educational workshop; that will be held on three days through one week; one hour session each day
2387719|NCT03657316|No Intervention|control|The control school will receive no intervention
2387720|NCT03657303||Healthy volunteers|
2387721|NCT03657303||Osteoarthritis patients|
2387722|NCT03657290|Active Comparator|Treatment A|vadadustat 3 X 150 mg Tablets in fasted subjects
2387723|NCT03657290|Active Comparator|Treatment B|Vadadustat 1 X 450 mg Tablets in fasted subjects
2387724|NCT03657290|Active Comparator|Treatment C|vadadustat 1 X 450 mg Tablets in fed subjects
3183517|NCT00714532|Experimental|2|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
3183518|NCT00714545|No Intervention|prospective study|This study is a prospective study of patients treated at Scripps Clinic with intracoronary brachytherapy for recurrent restenosis within drug-eluting stents. Beta irradiation with a 40-mm strontium/yttrium-90 source. No placebo will be used in this trial.
3183519|NCT00714597|Experimental|Semuloparin|Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
3183520|NCT00714597|Active Comparator|Enoxaparin|Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 10-14 days
3183521|NCT00714610||1|Unilateral or bilateral large head metal on metal primary total hip arthroplasty
2387730|NCT03657251||CureCloud Direct to Patient|
2387731|NCT03657238|Experimental|Experimental|Doses were escalated from 0.2μg/kg up to 4.8μg/kg
2387732|NCT03657238|Placebo Comparator|Placebo|
2387733|NCT03657225|Active Comparator|Mini CPB (ECCO, Sorin, Italy)|Utilization of the mini CPB circuit (Extra Corporeal Circuit Optimized; Phisio, Sorin Group, Italy)
2387734|NCT03657225|Placebo Comparator|Conventional|Use of conventional CPB circuit
2387735|NCT03657212|Active Comparator|Nap/5mg Zolpidem|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
2387736|NCT03657212|Placebo Comparator|Nap/Placebo|The research involves oral administration of zolpidem (ZOL, 5mg) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced. During the experimental phase, each drug condition will include one day in the sleep lab, two encoding test sessions, and one retrieval test session. Multiple subjects will be in the experimental phase concurrently, and multiple subjects will be tested on each day.
2387737|NCT03657199||Bypass graft failure|Patients with at least one detected graft failure after routine cardiac computed tomography before discharge
2387738|NCT03657199||No bypass graft failure|Patients without occluded bypass grafts after routine cardiac computed tomography before discharge
2387739|NCT03657186|Experimental|ProbioSatys™|
2387740|NCT03657186|Placebo Comparator|Placebo|
2387741|NCT03657160|Experimental|Vedolizumab 300 mg|Vedolizumab 300 milligram (mg), intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background graft-versus-host disease (GvHD) prophylaxis regimen.
2387742|NCT03657160|Placebo Comparator|Placebo|Vedolizumab placebo-matching, intravenous infusion, once on Days -1 (baseline), +13, +41, +69, +97, +125, and +153. Participants will receive background GvHD prophylaxis regimen.
2387743|NCT03657147|Experimental|Question Prompt List and Video|Participants will watch an educational video and question prompt list will be provided. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
2387744|NCT03657147|No Intervention|Usual Care|The usual care group will not receive any intervention. Glaucoma visits will be audio-taped. A 15-20-minute interview will be conducted after the visit by a research assistant.
3183522|NCT00714636||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
2387864|NCT03656471||Clear aligner group|Patients receiving clear aligner treatments for their malocclusions
3183523|NCT00714636||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
3183524|NCT00714649|Other|I-1|"This is a phase I/II trial. PhaseI: The delay between the last administration of cetuximab and surgery will be progressively reduced. Five delay schedules are pre-defined before final administration of 3 preoperative doses of cetuximab with a 24-hour delay between the last dose of cetuximab and surgery. The cohort size is 3 patients per delay schedule, extended to 6 patients if one limiting toxicity is observed.~Phase II: will proceed if delay schedule V is safe. The patients included in delay schedule V of the Phase I part of the study will be involved in the phase II analysis. Recruitment of a total of 12 patients (3-6 of delay schedule V in phase I plus an additional 3-9 patients)."
3183525|NCT00714675|Experimental|1|Citrulline
2387752|NCT03657082|Experimental|Arm A|In this arm, patients will receive the experimental condition first, then the sham condition
2387753|NCT03657082|Experimental|Arm B|In this arm, patients will receive the sham condition first, then the experimental condition
2387754|NCT03657069|Experimental|Supportive care (Blossom Smart Expander Technology)|After mastectomy, participants undergo 2-staged IBR with the Blossom Smart Expander Technology comprising of the Blossom syringe assist device connected to the Mentor SPECTRUM adjustable saline breast implant.
2387755|NCT03657056|Experimental|BX Pulsar 1002|Low-Intensity Focused Ultrasound Pulsation (LIFUP) sonications will be conducted using the LIFUP experimental device BX Pulsar 1002 produced by the Brainsonix Corporation. For the purposes of safety LIFUP sonications will be initiated at the FDA limit for diagnostic ultrasound. However, the minimally effective dose in humans applications, according to (Lee et al., 2015), when derated is approximately 1125mW/cm2.
3183526|NCT00714675|Active Comparator|2|Amino acids
3183527|NCT00714701||High Risk Group 1|familial Peutz-Jeghers syndrome
3183528|NCT00714701||High Risk Group 2|familial pancreatic cancer relatives
3183529|NCT00714701||High Risk Group 3|germline mutation carriers BRCA1, BRCA2, PRSS, PALB2, p16
2387760|NCT03657030|Active Comparator|Single Ascending Dose|The planned dose levels will be 1, 5, 25, 75, and 225 mg CVN424 and matching placebo.
2387761|NCT03657030|Active Comparator|Multiple Ascending Dose|The planned dose levels will be 25, 75, and 150 mg CVN424 and matching placebo.
2387762|NCT03657017|Other|PET/MR|Patients are examined with PET/MR.
2387763|NCT03656991|Experimental|0 month group|Receive the bicycle intervention at 0 months after enrollment.
2387764|NCT03656991|Experimental|2 month group|Receive the bicycle intervention at 2 months after enrollment.
2387765|NCT03656991|Experimental|4 month group|Receive the bicycle intervention at 4 months after enrollment.
2387766|NCT03656991|Experimental|6 month group|Receive the bicycle intervention at 6 months after enrollment.
2387767|NCT03656978|Active Comparator|Dynamic|Keep moving the probe for needle tip visualization during the puncture procedure.
2387768|NCT03656978|Placebo Comparator|Regular-triangle|Needle access along the hypotenuse of the regular triangle formed by the vascular depth and puncture point.
2387769|NCT03656965|Experimental|Antiviral Drug with Chemoradiotherapy|Antiviral therapy Acyclovir 800 mg per day during the whole course of treatment.
2387770|NCT03656965|Other|Chemoradiotherapy|Patients will receive concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
2387771|NCT03656952|Experimental|Seq 1|PF-06700841-> placebo-> moxifloxacin
2387772|NCT03656952|Experimental|Seq 2|PF-06700841->moxifloxacin->placebo
2387773|NCT03656952|Experimental|Seq 3|Placebo->PF-06700841->moxifloxacin
2387774|NCT03656952|Experimental|Seq 4|Placebo->moxifloxacin->PF-06700841
2387775|NCT03656952|Experimental|Seq 5|Moxifloxacin->PF-06700841->placebo
2387776|NCT03656952|Experimental|Seq 6|Moxifloxacin->placebo->PF-06700841
3183530|NCT00714701||High Risk Group 4|young-onset pancreatic cancer relative
2387778|NCT03656926|Experimental|L-CsA treatment plus SoC|L-CsA 10 mg twice daily for 48 weeks, plus Standard of Care Therapy
2387779|NCT03656926|No Intervention|Standard of Care alone|Standard of Care Therapy
2387780|NCT03656913|Experimental|Study Group|Patients will receive both the clinically indicated and extremely low dose CT exams
2387781|NCT03656900|Experimental|BA9/BA46|
2387782|NCT03656900|Experimental|BA46/BA9|
2387783|NCT03656874|No Intervention|Usual Care|Usual care, practitioners review clinical guidelines for tobacco during consent process.
2387784|NCT03656874|Experimental|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care.
2387785|NCT03656861||Athletes|122 were athletes (41 females and 81 males). Of the 41 female athletes, 32 were endurance athletes, and 9 strength athletes. From 81 male athletes, 56 were endurance athletes, and 25 were strength athletes.
2387786|NCT03656861||Non-athletes|29 were non-athletes (14 females and 15 males)
2387865|NCT03656471||Fixed appliance group|Patients receiving fixed appliance treatments for their malocclusions
2387991|NCT03655496|Experimental|Intervention group|Exposed to the home-based tool.
3183531|NCT00714701||High Risk Group 5|both parents affected
2387789|NCT03656835|Experimental|Diagnostic (ILN biochip testing)|Participants' blood samples undergo ILN biochip testing at diagnosis, before and after every course of chemotherapy, every 3 months for 2 years, and at relapse.
2387790|NCT03656822||Routine imaging such as CT or MRI|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging,
2387791|NCT03656822||Routine imaging (CT or MRI) with a 3D printed model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D printed anatomical mode
2387792|NCT03656822||Routine imaging (CT or MRI) with a VR model|Subjects will undergo routine pre-operative imaging and will be randomized into 3 groups for data visualization. This group will receive data visualization using routine clinical imaging with a 3D VR anatomical model
2387793|NCT03656796|Experimental|PD with freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
2387794|NCT03656796|Experimental|PD without freezing of gait (FOG)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
2387795|NCT03656796|Experimental|Healthy subjects (Control)|Intervention will include treadmill training with auditory cues (AC) and treadmill training without auditory cues (NC).
2387796|NCT03656783|Other|HIV patients on stable therapy|Open-label, multicenter, single-arm study
2387797|NCT03656770|No Intervention|V1: Control|This version of the survey questionnaire depicts a young woman with no symptoms of mental illness.
2387798|NCT03656770|Experimental|V2: Schizophrenia|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic schizophrenia."
2387799|NCT03656770|Experimental|V3: Schizophrenia + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with complete response."
2387800|NCT03656770|Experimental|V4: Schizophrenia + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with schizophrenia, successfully treated with partial relapse."
2387801|NCT03656770|Experimental|Version 5: Bipolar|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic bipolar disorder."
2387802|NCT03656770|Experimental|V6: Bipolar + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with complete response."
2387803|NCT03656770|Experimental|V7: Bipolar + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with bipolar disorder, successfully treated with partial relapse."
2387804|NCT03656770|Experimental|V8: Depression|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with untreated and symptomatic major depressive disorder."
2387805|NCT03656770|Experimental|V9: Depression + Tx with Response|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with complete response."
2387806|NCT03656770|Experimental|V10: Depression + Tx with Relapse|"As this is a survey experiment, the intervention involves random assignment to a survey questionnaire with specific wording. This version of the survey questionnaire depicts a young woman with major depressive disorder, successfully treated with partial relapse."
2387810|NCT03656731|Experimental|Intervention group (n=50)|Patients in the intervention group will receive standard care and a 12-week exercise-based intervention.
2387811|NCT03656731|No Intervention|Control group (n=50)|Patient in the control group will receive standard care.
2387812|NCT03656718|Experimental|Part A, Group 1: nivolumab (dose 1) + rHuPH20|
2387813|NCT03656718|Experimental|Part B, Group 3: nivolumab (dose 2) + rHuPH20|
2387814|NCT03656718|Experimental|Part B, Group 2: nivolumab (dose 1)|
2387815|NCT03656718|Experimental|Part B, Group 4: nivolumab (dose 2)|
2387816|NCT03656718|Experimental|Part C: nivolumab (dose 3) + rHuPH20|
2387817|NCT03656718|Experimental|Part D, Group 5: nivolumab (dose 3) + rHuPH20|
2387818|NCT03656718|Experimental|Part E, Group 6: nivolumab (dose 4) coformulated with rHuPH20|
2387819|NCT03656705|Experimental|CCCR-NK92 cells immunotherapy|Preparation of CCCR-NK92 cells suspended in a saline and plasma solution.
3183532|NCT00714701||Control 1|negative controls
2387821|NCT03656679|Active Comparator|Pectoralis Blockade(PECs)|Participants undergo pectoralis nerve block (PEC II) will received anesthesia between the pectoralis major and minor in the chest while lying flat.
2387822|NCT03656679|Active Comparator|Paravertebral Blockade (PVB)|Participants undergoing paravertebral nerve block (PVB) consisting of receiving anesthesia in the back while sitting upright.
2387863|NCT03656484|Experimental|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3% Tetracycline, 3% Metronidazole, 0.18% Melatonin and 3% Hyaluronic Acid (TM-MHa) paste, n=25 patients, considered experimental group.
3183533|NCT00714701||Control 2|chronic pancreatitis
3183534|NCT00714701||Control 3|pancreatic cancer
2387823|NCT03656666|Active Comparator|Apremilast|"Week 0-24: 21 patients will receive apremilast oral tablets with initial standard titration of dose day 1-6 followed by standard dose of 30 mg apremilast b.i.d.~Initial titration:~Day 1: 10 mg in morning. Day 2: 10 mg in morning and 10 mg in evening. Day 3: 10 mg in morning and 20 mg in evening. Day 4: 20 mg in morning and 20 mg in evening. Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter: 30 mg twice daily."
2387824|NCT03656666|Placebo Comparator|Placebo + Apremilast|Week 0-24: 21 patients will receive matching placebo oral tablets, with initial titration.
2387825|NCT03656653|Experimental|Future-based recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future without cocaine use
2387826|NCT03656653|Experimental|Future-based cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a future where cocaine is causing significant distress
2387827|NCT03656653|Experimental|Past recovery-oriented imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event without cocaine use
2387828|NCT03656653|Experimental|Past cocaine-aversive imagery|Mental Imagery for Craving Reduction: mental imagery aimed at describing a past event where cocaine use has caused significant distress
2387829|NCT03656640||Patients Receiving Gammanorm®|Patients Receiving Gammanorm®
2387830|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 1|"Arms determined by autoimmune type. First cohort consists of patients with:~Rheumatoid arthritis, psoriasis, giant cell arteritis/polymyalgia rheumatica, systemic lupus erythematosis~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
2387831|NCT03656627|Experimental|Nivolumab: Autoimmune Diseases Cohort 2|"Arms determined by autoimmune type. Second cohort consists of patients with:~Other autoimmune diseases (ulcerative colitis, Crohn's disease, multiple sclerosis). Patients must be discussed with PI prior to enrollment.~If a patient has more than one autoimmune condition, if all the conditions are within either cohort 1 or 2 above, the patient will be assigned to that cohort. If the patient has conditions from both cohort 1 and 2, the patient will be grouped in cohort 2."
2387832|NCT03656614||sugammadex 0.125|Sugammadex group: sugammadex 0.125 mg/kg IV once at the reappearance of TOF 0.3
2387833|NCT03656614||Sugammadex 0.25|Sugammadex group: sugammadex 0.25 mg/kg IV once at the reappearance of TOF 0.3
2387834|NCT03656614||Sugammadex 0.5|Sugammadex group: sugammadex 0.5 mg/kg IV once at the reappearance of TOF 0.3
2387835|NCT03656614||Sugammadex 1.0|Sugammadex group: sugammadex 1.0 mg/kg IV once at the reappearance of TOF 0.3
2387836|NCT03656614||Sugammadex 2.0|Sugammadex group: sugammadex 2.0 mg/kg IV once at the reappearance of TOF 0.3
2387837|NCT03656614||Neostigmine 10|Neostigmine group: neostigmine 10 µg/kg IV once at the reappearance of TOF 0.3
2387838|NCT03656614||Neostigmine 25|Neostigmine group: neostigmine 25 µg/kg IV once at the reappearance of TOF 0.3
2387839|NCT03656614||Neostigmine 40|Neostigmine group: neostigmine 40 µg/kg IV once at the reappearance of TOF 0.3
2387840|NCT03656614||Neostigmine 55|Neostigmine group: neostigmine 55 µg/kg IV once at the reappearance of TOF 0.3
2387841|NCT03656614||Neostigmine 70|Neostigmine group: neostigmine 70 µg/kg IV once at the reappearance of TOF 0.3
2387842|NCT03656614||Placebo|Placebo group: Saline 0.9% IV once at the reappearance of TOF 0.3
2387843|NCT03656601||Vaginal delivery|Women that had only vaginal delivery
2387844|NCT03656601||Cesarean-section|Women that had only cesarean-section
2387845|NCT03656601||Nulliparous|Women without delivery
2387846|NCT03656588|Active Comparator|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by|
2387847|NCT03656588|Active Comparator|b. Iodine scrub and ChloraPrep alone|
2387848|NCT03656575|Active Comparator|intra-articular alpha-2-macroglobulin|intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)
2387849|NCT03656575|Active Comparator|intra-articular Platelet-rich Plasma (PRP) injection|Standard of care PRP treatment
2387850|NCT03656575|Active Comparator|Intra-articular corticosteroid|Standard of Care steroid treatment
2387855|NCT03656549|Experimental|Impaired renal function|patients will be treated with pemetrexed, with dosing based on renal function.
2387856|NCT03656536|Experimental|Pemigatinib|
2387857|NCT03656536|Active Comparator|Gemcitabine + Cisplatin|Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible to cross over and receive pemigatinib.
2387858|NCT03656523||Acute Coronary Syndrome|Patients with Aute coronary syndrome trated with Percutaneous Coronary Intervention plus Stent implantation and Atrial Fibrillation
3142898|NCT00003735|Experimental|Stratum 1 - Stage 1|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
3183535|NCT00714701||Control 4|intraductal papillary mucinous neoplasm (IPMN)
3183536|NCT00714727|Other|1|
2387862|NCT03656484|Active Comparator|Tetracycline-Metronidazole (TM) group|Topical administration (in the periodontal pocket of affected teeth), for 30 consecutive days of 3%Tetracycline and 3%Metronidazole paste (TM), n=25 patients, considered control group.
2387992|NCT03655483|Experimental|GLS-010|GLS-010
2387866|NCT03656458|Active Comparator|Control Group A|Warm Up followed by Conventional Balance Training (Internal and External Perturbations)
2387867|NCT03656458|No Intervention|Control Group B|Control group. No intervention given to participants.
2387868|NCT03656458|Experimental|Experimental Group|Warm Up followed by Biodex Balance Training
2387869|NCT03656445|Active Comparator|Group A - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
2387870|NCT03656445|Active Comparator|Group B - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
2387871|NCT03656445|Active Comparator|Group C - Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectively
2387872|NCT03656432|Experimental|CPP-ACP paste|MI Paste represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
2387873|NCT03656432|Experimental|CPP-ACP containing fluoride|MI paste plus contains fluoride 0.2% (900 ppm) that is very similar to the amount of fluoride in the toothpaste binds to the tooth surfaces and plaque and provides biocompatible calcium, phosphate and fluoride in a localized way. So, it provides all the ions needed to build fluorapatite crystals that are more resistant to the acid attack compared to hydroxyapatite
2387874|NCT03656432|Active Comparator|toothpaste contains fluoride|Fluoridated Toothpaste are the most significant and worldwide spread forms of caries control used globally as the greater acceptability of toothpaste makes its regular use more likely, thereby improving effectiveness
2387875|NCT03656419|Experimental|aPDT group|For photodynamic therapy will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² .One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points, considering the scattering halo and the effectiveness of aPDT. The LED apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
2387876|NCT03656419|Active Comparator|Tongue Scraper|Tongue scraper 10 times in the tongue, from the back to the front.
2387877|NCT03656419|Experimental|aPDT and tongue scraper|Tongue scraper 10 times in the tongue, from the back to the front. For aPDT will be used an equipment developed for this project with emission of red LED (660nm) and tip of 2.84 cm² . One session of the Chimiolux® photosensitizing aPDT will be performed, at a concentration of 0.005%, to be applied enough to cover the middle third and back of the tongue for 2 minutes for incubation. Four points will be irradiated with a distance of 1cm between the points. Based on previous studies carried out with the aPDT for the treatment of halitosis the apparatus will be previously calibrated with wavelength 660 nm, with energy of 72 J, power of 800 mW for 90 seconds per point, creep of 282mW / cm².
2387878|NCT03656393|Experimental|Gefitinib therapy group|Patients are treated with Gefitinib (250 mg, orally, every day) for 56 days and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
2387879|NCT03656393|Active Comparator|Vinorelbine combination therapy group|Patients are treated with vinorelbine (60 mg/m2, orally, Once every three weeks) plus carboplatin (AUC5, intravenously drip, once a week) for 6 weeks and then have an operation. If there is progress after intervention, Patients are further treated with pemetrexe (500 mg/m2, intravenously drip, once a week) plus cisplatin (75 mg/m2, iv. once a week) for 4 weeks.
2387880|NCT03656380|Experimental|Mepolizumab 300 mg|Subjects will receive Mepolizumab 300 mg subcutaneously (SQ) monthly for 6 months
2387881|NCT03656380|Other|Placebo, followed by Mepolizumab 100 mg|This arm will receive placebo, followed by Mepolizumab 100 mg. Subjects will receive placebo subcutaneously (SQ) monthly for 3 months, followed by Mepolizumab 100 mg subcutaneously (SQ) monthly for 3 months. Mepolizumab will be administered with 2 SQ injections of placebo and 1 SQ injection of Mepolizumab 100 mg to maintain blinding.
3183537|NCT00714766|Experimental|A|
3183538|NCT00714779|Active Comparator|1|Fluoxetine
2387884|NCT03656341|Experimental|2 Feet 4 Life|Intervention group will receive one hour intervention weekly for four consecutive weeks. Outcomes will be measured at baseline (before the intervention), immediately after the intervention (1 month), three months post-intervention, and six months post-intervention
2387885|NCT03656341|No Intervention|True control group|Will complete the same four assessment visits as the intervention group.
2387886|NCT03656341|No Intervention|Bias control group|Will complete outcome assessments at baseline and the final assessment.
2387887|NCT03656328|Experimental|Lactobacillus Reuteri 4659|This Arm received standard antibiotic therapy, consisting of ciprofloxacin 400 mg twice a day and metronidazole 500 mg three times a day for seven days, with supplementation with the probiotic L. reuteri 4659 twice a day for 10 days
2387888|NCT03656328|Placebo Comparator|Placebo|This arm received the same standard antibiotic therapy and a matching placebo for the same periods.
2387889|NCT03656315|Other|Airway assessment|All patients recruited will be entered into this arm of the study. Airway assessment including Ultrasound scan will be performed
2387890|NCT03656302||Case offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having at least one biological parent with a lifetime or current diagnosis of bipolar disorder; 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder; 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
3183539|NCT00714779|Active Comparator|2|Short-term psychodynamic psychotherapy
3183540|NCT00714805||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3183541|NCT00714805||Healthy Control|Subjects having no known ailment.
2387891|NCT03656302||Control offspring|"Inclusion criteria:~1) aged 6-21 years old; 2) having no biological parent(s) with lifetime or current diagnosis of mood disorders. 3) being able to read, write and understand Chinese; 4) both the offspring and her/his parent(s) agree to sign the informed consent form.~Exclusion criteria:~1) having lifetime history or current diagnosis of bipolar disorder. 2) having no good ability to attend this project, such as patients with dementia and mental retardation."
2387892|NCT03656289|Experimental|Etonogestrel Contraceptive|Etonogestrel contraceptive implant; consists of a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel, pre-loaded in the needle of a disposable applicator. The implant must be removed no later than by the end of the third year.
2387893|NCT03656276||Group A: Oncologists (wait list control)|Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
2387894|NCT03656276||Group B: Oncologists (training)|Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
2387895|NCT03656263||High risk cardiac surgery patients|"Defined as either:~Multiple surgical procedures planned and/or,~EuroSCORE ≥ 5% and/or,~Known pulmonary hypertension (mPAP>25 mmHg or sPAP > 40 mmHg)"
2387896|NCT03656250||Chemo Patients with Nasopharyngeal cancer|The standard chemoradiation treatment (total 7000 cGy in 35 fractions at 200 cGy/fraction) for 7 weeks with 3 cycles of chemo followed by 3-month chemotherapy.
2387897|NCT03656237|Experimental|Usual training + Audits + LDHF training|"Usual training of health workers, in classroom, following standard curriculum~+ Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits"
2387898|NCT03656237|Experimental|Audits + LDHF training|Mortality and Morbidity Audits in facility every two weeks followed by LDHF training focused on gaps in knowledge or practice identified during the audits
2387899|NCT03656237|Active Comparator|Usual Training|Control Arm exposed to usual training of health workers, in classroom, following standard curriculum
2387900|NCT03656224||Observational (survey)|Participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.
2387901|NCT03656211||Patients with UAVM|"All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination.~Telephone interview"
2387902|NCT03656198|Experimental|Vaccine group|Three dose primary course of Rabivax-S. Dosing and administration of the vaccine (Rabivax-S) will be according to the package insert, following the schedule for pre-exposure prophylaxis via the intramuscular route; that is, 1 mL by intramuscular injection in the deltoid area of the arm on Day 0, Day 7 and Day 21.
2387903|NCT03656198|Placebo Comparator|Control group|The intervention (placebo) in the control group is at least one dose (1 mL by intramuscular injection) of a three dose primary course (on days 0, 7 and 21) of vaccine diluent (sterile water for injection).
2387904|NCT03656172||Haemoglobin measure|Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
2387905|NCT03656159|Active Comparator|Non-directive support group|This intervention will provide time and space to discuss the impact of AD. The objective will be to help participants feel less alone and better understood and to address the implications of AD in their daily life.
2387906|NCT03656159|Experimental|Cognitive-Behavioral group therapy|The intervention will include behavioral activation, cognitive restructuring, and stress/anger management strategies (e.g. abdominal breathing, progressive muscle relaxation). In addition, knowledge about memory management and sleep disorders will be provided.
2387907|NCT03656146|Active Comparator|Tablet Screening|Food insecurity screening conducted via electronic tablet
2387908|NCT03656146|Active Comparator|Verbal Screening|Food insecurity screening conducted via verbal face-to-face interview
2387911|NCT03656120|Experimental|0.2mg group|Participants are taking 0.2mg thienorphine hydrochloride table once a day for 12 weeks.
2387912|NCT03656120|Experimental|0.5mg group|Participants are taking 0.5mg thienorphine hydrochloride table once a day for 12 weeks.
2387913|NCT03656120|Placebo Comparator|placebo control group|Participants only taking placebo once a day for 12 weeks.
2387914|NCT03656107|Experimental|Cognitive training|Participants selected to brain training will be given instructions on how to access and use the program at home for 15-30minutes, 3-5 times per week for 8-12 weeks.
2387915|NCT03656107|No Intervention|Waiting-list control|Control participants will be waiting listed to receive the brain training program at the end of the study. control participants will undergo usual care.
2387916|NCT03656094|Experimental|Pembrolizumab plus chemotherapy|Pembrolizumab (200 mg) plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
2387917|NCT03656094|Active Comparator|Placebo plus chemotherapy|Placebo plus chemotherapy (physicians' choice among docetaxel, pemetrexed, or vinorelbine) every 3 weeks
2387918|NCT03656081|Placebo Comparator|Itraconazole & inhaled placebo|Itraconazole 200 mg x 2/day associated with inactive nebulised treatment (isotonic saline) twice a week during 24 weeks.
2387919|NCT03656081|Experimental|Itraconazole & inhaled Ambisome®|Itraconazole 200 mg x 2/day associated with inhaled liposomal amphotericin B (Ambisome®) at 25 mg twice a week during 24 weeks
2387921|NCT03656042|Experimental|G-CSF|Subjects in the treatment group will receive Filgrastim (75mcg/0.3ml, NEUPOGEN®), 10 mic/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks. Filgrastim will be given 12-weekly ( 12 weeks/cycle ) for 2 cycles.
2387922|NCT03656042|No Intervention|No-treatment|No-treatment group is used to control evaluation bias and potential time effect.
2387923|NCT03656029|Placebo Comparator|Placebo|Participants will smoke a single smoked placebo (<0.1% THC) cannabis cigarette
2387924|NCT03656029|Active Comparator|low dose|Participants will smoke a single low dose (6.25% THC) of smoked cannabis cigarette
2388277|NCT03653598||AF patients|Patients with Atrial Fibrillation
2387925|NCT03656029|Active Comparator|middle dose|Participants will smoke a single intermediate dose (12.5% THC) of smoked cannabis cigarette
2387926|NCT03656029|Active Comparator|high dose|Participants will smoke a single high dose (22% THC) of smoked cannabis cigarette
2387927|NCT03656016||study group|patients with congenital and acquired disorders that can alter the CSF dynamics will undergo phase-contrast magnetic resonance imaging
2387928|NCT03656016||control group|age matched healthy individuals will undergo phase-contrast magnetic resonance imaging
2387929|NCT03656003|Experimental|Procore needle|EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
2387930|NCT03656003|Active Comparator|Conventional needle|Conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
2387931|NCT03655990||Treatment with the JUVORA™ Dental Disc|Subjects receive the device as per normal standard practice, there are no other treatment arms for this prospective study.
2387932|NCT03655977|Experimental|Cervical cancer patients|This pilot study includes 25 women with histologically proven advanced stage primary cervical cancer (FIGO stages ≥IB2-IVA), planned for treatment with radio-chemotherapy.
2387933|NCT03655964|Experimental|Olmesartan|20 patients randomly allocated to single-blind antihypertensive therapy with olmesartan (20 mg/day)
2387934|NCT03655964|Experimental|Nebivolol|20 patients randomly allocated to single-blind antihypertensive therapy with nebivolol (5 mg/day)
2387935|NCT03655964|Experimental|No antihypertensive treatment|20 patients randomly allocated to receive no antihypertensive therapy during the acute stage of ischemic stroke
2387938|NCT03655925||Patients with Chronic Heart Failure (CHF)|Entire cohort/ Patients with recent diagnosis of chronic heart failure as defined by the guidelines of the European Society of Cardiology (ESC) and with cardiac ejection fraction <40
2387939|NCT03655912|Active Comparator|Patch|Eye patch on the fellow eye and to near-vision activities (such as reading, drawing, etc)
2387940|NCT03655912|Experimental|Electronic Devices|Eye patch on the fellow eye and a electronic tablet
2387941|NCT03655912|Experimental|Red/Green Glasses|Red/green glasses and a electronic tablet
2387942|NCT03655886|Experimental|Radical prostatectomy|
2387943|NCT03655886|Experimental|Radiotherapy|
2387944|NCT03655873|Experimental|HEC30654AcOH capsule|"single ascending-dose study: Including 7 dose groups(5-、10、15-、30-、60-、90-、120mg)，Day1 ante meridiem(AM) 8:00 (±1h) with 240ml warm water to taking the experiment drug，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 Post Meridiem(PM) (±1h), with 240ml warm water to take the experiment drug On an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the experiment drug，On an empty stomach."
2387945|NCT03655873|Placebo Comparator|placebo capsule|"single ascending-dose study: Including 6 dose groups(10、15-、30-、60-、90-、120mg)，Day1 morning 8:00 (±1h) with 240ml warm water to taking the placebo capsule，On an empty stomach .~multiple ascending-dose study: Including 3 dose groups(15-、30-、60mg),Day1-Day7 AM 8:00 (±1h), 18:00 PM (±1h), with 240ml warm water to take the placebo capsule on an empty stomach;Day8 AM 8:00 (±1h)with 240ml warm water to taking the placebo capsule，on an empty stomach."
2387946|NCT03655860|Experimental|SIMEOX|
2387947|NCT03655847|Experimental|Dexmedetomidine|Drug: Dexmedetomidine dexmedetomidine, 0.1ug/kg up or down Other Name: precedex
2387948|NCT03655834|Experimental|Microdosing|Patients will be administered a microdose of pemetrexed with subsequent pharmacokinetic assessment. Afterwards the patients will continue in either IMPROVE-I or -II for second pharmacokinetic assessment
2387949|NCT03655821|Active Comparator|Arm A (BSA-based dosing)|Dosing of pemetrexed is based on BSA according drug label
2387950|NCT03655821|Experimental|Arm B (renal function based dosing)|Dosing of pemetrexed is based on renal function, calculated to reach the target AUC.
2387951|NCT03655808|Experimental|BBCs transplantation|Autologous Bronchial basal cells transplantation
2387952|NCT03655795|Experimental|Bronchial basal cells|Autologous transplantation of bronchial basal cells
2387987|NCT03655522|Active Comparator|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Doses were administered as IM injections into the deltoid muscle in the fasted state. The IMP was supplied in glass vials containing 1.2 mL solution at a total GTX 2 and GTX 3 concentration of 42 mcg/mL (at a relative epimer ratio of 62% GTX 2:38% GTX 3).
2387957|NCT03655756|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion/time point|"Therapeutic Classification:~Noncellular, Therapeutic Cancer Vaccine > Immunomodulator~Route of Administration:~Intratumoral injection of cutaneous, subcutaneous or nodal lesions~Mechanism of Action:~Injection of the IFx-Hu2.0 plasmid DNA construct into the target lesion facilitates the localized expression of the highly immunogenic Emm55 protein by the tumor cells on their cell surface.~Physiological Effect:~This expression then primes a cascade of immune events that exposes the patient-specific abnormal tumor antigens to the effector mechanisms of the immune system. The immune response becomes systemic as inter-antigenic epitope spreading produces neoantigens to naïve T cells. Therefore, injected lesions are targeted along with non-injected lesions (abscopal effect). This is especially important in conditions where the mutational phenotype varies greatly among individual lesions."
2387958|NCT03655743||Patients after refractive surgery|Patients have had any type of corneal or lens refractive surgery.
2387959|NCT03655743||Patients before refractive surgery|Patients will have any type of corneal or lens refractive surgery.
2387960|NCT03655730|Experimental|intervention arm|follow weekly psychotherapeutic individual sessions following the IPT method during one year.
2387961|NCT03655730|Experimental|usual care arm|continue with the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
2387962|NCT03655717|Experimental|Placebo Dronabinol + Ethanol|single dose of Placebo Dronabinol + Ethanol See protocol for dosing
2387963|NCT03655717|Experimental|Dronabinol + Placebo Ethanol|single dose of Dronabinol + Placebo Ethanol See protocol for dosing
2387964|NCT03655717|Experimental|Dronabinol + Ethanol|single dose of Dronabinol + Ethanol See protocol for dosing
2387965|NCT03655717|Placebo Comparator|Placebo Dronabinol + Placebo Ethanol|single dose of Placebo Dronabinol + Placebo Ethanol See protocol for dosing
2387967|NCT03655691|Placebo Comparator|Vehicle|Vehicle / Placebo formulation
2387968|NCT03655691|Experimental|Dose 1|lower dose of ET-01
2387969|NCT03655691|Experimental|Dose 2|higher dose of ET-01
2387971|NCT03655665|Experimental|Treatment Ear|Participants will serve their own control. Participants will receive 3 drops of ofloxacin otic solution intra- and post-operatively 3 times per day for 3 days in ONE ear. Ear sidedness will be randomized by participant.
2387972|NCT03655665|No Intervention|No Intervention|Participants will serve their own control. Participants will receive no intervention in the ear contralateral to the treated ear. Ear sidedness will be randomized by participant.
2387973|NCT03655639||Premature Birth|Premature babies born under 29 weeks gestational age, admitted into the neonatal intensive care unit within 7 days of life.
2387974|NCT03655626|Experimental|Sepsis Watch on Duke University Hospital ED Adults|Patients older than 18 years old at time of presentation to Duke University Hospital emergency department.
2387975|NCT03655613|Experimental|Arm A: Hepatocellular Carcinoma|PD-1 inhibitor (APL-501) 3 mg/kg intravenously every 2 weeks + c-Met inhibitor (APL-101) 150 mg or 200 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
2387976|NCT03655613|Experimental|Arm B: Renal Cell Carcinoma|PD-1 inhibitor (nivolumab) 3 mg/kg or 240 mg intravenously every 2 weeks + c-Met inhibitor (APL-101) 300 mg or 400 mg administered twice daily continuously until documented disease progression, discontinuation due to toxicity withdrawal of consent or the study ends
2387977|NCT03655600|Active Comparator|Self-administered acupressure|Acupressure administered by participant self-taught from computer application
2387978|NCT03655600|No Intervention|Usual care|Usual care
2387979|NCT03655587|Experimental|Solid ankle foot orthotic|This is a leg brace that is made to fit the contour of the patient's foot, ankle, and lower leg. The two pull solid ankle AFO is fabricated from a rigid polypropylene outer boot and a more flexible silicone inner boot. It is commonly used in rehabilitation to improve gait in pediatric and adult populations. A certified orthotist fabricates the device. This device is lawfully marketed in the United States. It is not regulated by the FDA.
2387980|NCT03655587|Active Comparator|Resting night splint|An ankle resting night spring (RNS) is an off-the-shelf device that provides static sagittal plane dorsiflexion. The RNS is worn nocturnally to provide maximal stretch/length to the gastrocsoleus to maintain or increase dorsiflexion ROM and/or to prevent further regressions in ankle range. It is not regulated by the FDA.
2387981|NCT03655574|Experimental|Motivational + Family Check-up (MET+FCU)|"The MET individual session covers three constructs; 1) intentions to use marijuana; 2) normative beliefs about peer substance use; and 3) attitudes towards peer substance use. These same three constructs are also addressed with respect to truancy. In addition, motivation to abstain from substance use is discussed.~The FCU session with teens and parents/caregivers begins by collecting self-report measures and conducting a videotaped Family Assessment Task (FAsTask) to assess parent-teen interactions. The FAsTask is the basis of FCU feedback. There are four specific phases of the feedback session: 1) Self-assessment, 2) Support and clarification, 3) Feedback, and, 4) Action plan."
2387982|NCT03655574|Placebo Comparator|Psychoeducation|An interventionist will review a set of educational materials with the parents regarding teen marijuana use, effects of marijuana on the brain, body and behavior, risks associated with marijuana use, how to tell if a teen is engaging in marijuana use or truancy, and parenting skills. A comparable set of materials will be reviewed with the adolescent.
2387983|NCT03655561||Confirmed Lassa fever cases|Participants with a clinical presentation consistent with acute Lassa virus disease and a positive result for Lassa specific RT-PCR obtained before or after inclusion
2387984|NCT03655561||Non-Lassa cases (controls)|Participants with a clinical presentation consistent with acute Lassa virus disease but subsequently found to have a negative result for Lassa specific RT-PCR
2387985|NCT03655535|Experimental|BTI320|4 g BTI320 administered 10 min before breakfast, lunch, and dinner
2387986|NCT03655535|Placebo Comparator|Placebo|Placebo administered 10 min before breakfast, lunch, and dinner
2387988|NCT03655522|Placebo Comparator|Placebo|Placebo was of identical appearance to the IMP, and was administered into the deltoid muscle in the fasted state.
2387989|NCT03655509|Other|ACTH stimulation test|
2387993|NCT03655470|Experimental|Safety Planning|This brief intervention, consists of an in-person and follow-up phone call that are based on cognitive behavioral principles designed to help identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of nonsuicidal self-injury or suicidal behavior.
2387994|NCT03655470|Active Comparator|Standard Care|"If a teen has a positive screen for suicide risk, the Probation Officer completes a secondary screener built into the court screening instrument to determine whether there is concern of current and/or imminent risk. If a teen endorses nonsuicidal self-injury more than once in the prior year, then the Probation Officer asks about frequency and severity. If there is ongoing concern of risk for self-injurious behavior, then the Probation Officer arranges for a crisis evaluation in the Emergency Department. If the teen is not judged to be at imminent risk, the Probation Officer makes a referral back to the current treatment provider or to a community mental health clinic. In either case, the parents and youth receive a packet with mental health resources"
2387995|NCT03655457|Experimental|group 1 Poractant alfa|Poractant alfa generic name: curosurf 120 and 240 mg flk dosage: 200 mg/ kg intratracheal application frequency and duration: in the first two hours
2387996|NCT03655457|Active Comparator|group 2 beractant|beractant generic name: survanta 8 cc flk dosage: 4 cc/ kg intratracheal application frequency and duration: in the first two hours
3183542|NCT00714818|Experimental|GC|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
3183543|NCT00714818|Active Comparator|EB|Educational Booklet: One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants
2387999|NCT03655431|Experimental|Telerehabilitation|Physical therapists will develop an individualized program lasting 12 weeks depending on the needs of a given patient. Veterans will be seen 1 day/week via clinical video teleconferencing (CVT) for treatment. The rehabilitation protocol will last approximately 30 minutes with activities that are individualized to meet the participant's needs (range of motion, balance, strengthening, endurance, and functional activities). Patients assigned to telerehabilitation will utilize the VITAL rehab unit with Jintronix exercise package. Exercises, progression and rest periods will be administered and adjusted remotely by the physical therapist using a web-based clinical portal.
2388000|NCT03655418|Experimental|Intervention|The prevention program RECUR will be administered.
2388001|NCT03655418|No Intervention|Waitlist control|The prevention program RECUR will be administered after a year of waiting.
3183544|NCT00714818|No Intervention|WT|Waitlist
3183545|NCT00714831|Active Comparator|CG|Control Group
2388004|NCT03655392|Experimental|Intervention Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to a individualized educational program: three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 monthly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires ACT, ACQ, AQLQ, BDI: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
2388005|NCT03655392|Experimental|Control Group|64 adult asthmatic patients (18-70 years old) were randomized into two groups: intervention group (IG) (n=38) or control group (CG) (n=26). IG patients were submitted to three 30-minutes intervention of a shortterm educational program delivered by a nurse at 3 montly visits. CG group did not receive educational intervention. All patients were submitted to a spirometry, induced sputum collection, nitric oxide measure, exhaled breath condensate air measurement, and answered the questionnaires: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI). All participants also answered a symptoms diary about asthma symptoms and peak flow measure.
2388006|NCT03655379|Experimental|Nasal Doppler|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns
2388007|NCT03655366||Dog owners with epilepsy|Epilepsy patients that own one or more dogs.
2388008|NCT03655366||Training organisations|Trainers of seizure response and seizure alerting dogs.
2388009|NCT03655353|Experimental|ABY-PET|68Ga-ABY-025 is used as tracer for PET scan
2388010|NCT03655340||Prophylactic patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
2388011|NCT03655340||On demand patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for on-demand treatment
2388012|NCT03655327||stroke patients|stroke patients with upper limb paresis
2388013|NCT03655327||healthy control group|healthy participants with no motor disability of the upper limb
2388014|NCT03655314|Active Comparator|Newborn Weight Tool (NEWT)|The electronic medical record will display the Newborn Weight Tool along with a banner flagging newborn weight loss greater than or equal to the 75th centile of birth weight
2388015|NCT03655314|Placebo Comparator|Usual care|As with usual care, the electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight
3183546|NCT00714831|Experimental|IG|Intervention Group
2388017|NCT03655275|Active Comparator|Group(A): PRP|PRP prolotherapy injections with 2.5ml of PRP at an interval of 2 weeks. Intraticular and pericapsular
2388352|NCT03653182||Yin deficiency|One of an abnormal constitution condition in TCM.
3183547|NCT00714857|Experimental|1|Patients receiving dexmedetomidine sedation
3183548|NCT00714896|Other|1|Assessment only + referral list to State quitline and smoking cessation education classes at Kaiser
2388018|NCT03655275|Active Comparator|Group (B): saline|Saline prolotherapy injections with 2.5ml of saline at an interval of 2 weeks.intrarticular and pericapsular
2388019|NCT03655262|Experimental|1 Session|1 neuro-reinforcement session
2388020|NCT03655262|Experimental|3 Sessions|3 neuro-reinforcement sessions
2388021|NCT03655262|Experimental|5 sessions|5 neuro-reinforcement sessions
2388022|NCT03655249|Experimental|Asl + CPT|Aerosotherapy + Autogenic drainage
2388023|NCT03655249|Active Comparator|Asl|Aerosoltherapy alone
2388027|NCT03655223||Newborn infants born in North Carolina|All newborn infants in North Carolina will have the opportunity to participate in Early Check. Those who screen positive for the conditions identified in the study will be subject to confirmatory testing.
2388028|NCT03655223||Birthing Mothers in North Carolina|All birthing mothers in North Carolina will have the opportunity to participate in Early Check.
2388029|NCT03655210|Experimental|Experimental|HL151(1Tab,Bepostatine salicylate) once a day, 4 weeks of treatment
2388030|NCT03655210|Placebo Comparator|Placebo Comparator|HL151 Placebo (1Tab,Placebo of Bepostatine salicylate) once a day, 4 weeks of treatment
2388031|NCT03655197|No Intervention|Healthy Subjects|Healthy subjects will receive no intervention and will have samples collected only at one visit after Dove soap washout.
2388032|NCT03655197|Experimental|Ocular Rosacea Subjects|Ocular rosacea subjects will receive mandatory Doxycycline intervention and will have samples collected at two visits, before starting intervention and at the completion of the intervention.
2388033|NCT03655197|Other|Cutaneous Rosacea Subjects|Doxycycline intervention is optional for cutaneous rosacea subjects. If they do not participate, samples will only be collected at one visit after Dove soap washout. If they do decide to participate, samples will also be collected after completion of the Doxycycline intervention.
2388034|NCT03655184||MOH group|Patients with medication overuse headache
2388035|NCT03655184||Episodic migraine group|Patients with episodic migraine
2388036|NCT03655184||Healthy group|No headache or other special medical history
2388037|NCT03655171||H&Y 0|"Age-matched non-disease population, or prodromal Parkinson's patients with no noticeable motor symptoms.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2388038|NCT03655171||H&Y 1|"Hoehn and Yahr disability stage was 1: Unilateral involvement only usually with minimal or no functional disability.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2388039|NCT03655171||H&Y 2|"Hoehn and Yahr disability stage was 2: Bilateral or midline involvement without impairment of balance.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2388040|NCT03655171||H&Y 3|"Hoehn and Yahr disability stage was 3: Bilateral disease: mild to moderate disability with impaired postural reflexes; physically independent.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2388041|NCT03655171||H&Y 4|"Hoehn and Yahr disability stage was 4: Severely disabling disease; still able to walk or stand unassisted.~This group of patients will perform the video-recorded UPDRS-III test at the time of enrollment and evaluate the motor function using video-based quantitative methods."
2388042|NCT03655158|Experimental|ozone group|After gingivectomy and gingivoplasty, right quadrants of the surgical areas were assigned to receive ozone therapy in all patients
2388043|NCT03655158|No Intervention|non-ozone group|placebo application, left quadrants received regular air from the ozone generator.
2388044|NCT03655145|Experimental|Haploidentical donor stem cell transplantation|The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
2388045|NCT03655145|Active Comparator|HLA 10/10 MUD stem cell transplantation|The stem cell source will be peripheral blood stem cell for HLA-matched unrelated transplantation.Peripheral blood stem cell (PBSC) for HLA-matched unrelated SCT will be mobilized by G-CSF (Neupogen®) administered to the donor from Day-4 to Day-1 subcutaneously (10µg/kg/day) with the minimal target dose of 4.106 CD34+ cells/kg.
2388046|NCT03655132|No Intervention|Waitlist Control Group|Veterans in the waitlist control will be provided with a list of common pain resources at the Bedford VAMC.
2388047|NCT03655132|Experimental|VACT-CP Group|Veterans randomized to VACT-CP will receive 8 online-module based weekly sessions of treatment via personal computer or provided tablet with wireless accessibility at the Bedford VAMC.
2388048|NCT03655119|No Intervention|Baseline|Youth and parents will complete surveys at index PES visit regarding suicide related risk and protective factors. Parents and youth will complete a follow-up survey at 3 days (parents only) and 2 weeks (parents and youth) post discharge. At 3 days and 2 weeks, parents will complete a survey that evaluates adherence to safety recommendations. The 2-week follow-up survey for parents will also re-assess self-efficacy, parental distress, and mental health treatment stigma. The 2-week follow-up survey for youth assesses mood and suicidal thoughts, perceptions of parent support post discharge, and outpatient treatment. It reassesses suicidal risk, depression, connectedness, and alcohol use.
2388049|NCT03655119|Experimental|Phase I|Families will complete baseline measures, and receive enhanced usual care from PES clinical staff during their visit as well as a parent toolkit that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth. The same follow-up methodology as in Baseline will be utilized.
2388050|NCT03655119|Experimental|Phase II|Families will complete baseline measures and receive Phase I interventions (enhanced care and parent toolkit). Parents will receive caring contacts post discharge, which may occur by phone, text, or email. Caring follow-up messages will provide support, additional education, and problem solving assistance. The same follow-up methodology as in Baseline will be utilized.
2436582|NCT03321968|Experimental|Lot 2|Quadrivalent VLP Influenza Vaccine
3183549|NCT00714896|Experimental|2|Participants will receive self-help information handouts, expert system intervention that includes a stage-based manual and individualized written feedback reports plus in-person brief stage-appropriate counseling at baseline and 3-month assessment. Current smokers who indicate desire to quit smoking or former smokers who indicate high cravings for cigarettes will be offered nicotine replacement medications. Participants will receive three telephone counseling sessions delivered between baseline and 3 month at weeks 2, 4 and 8. As-needed telephone check-calls will be provided to participants on and 2 days after quit date, or to participants who have quit smoking and anticipate high risk situations.
2388053|NCT03655093||Patients with multiple sclerosis|Patients with MS according to the diagnostic criteria of 2010 Validation of AMSQ questionnaire
3183550|NCT00714909||1|
2388055|NCT03655067|Experimental|Intervention|The participants in the Intervention group will receive the CATCH-IT program which consists of a motivational component and the internet program for the adolescent. The participants in the Intervention group will receive motivational interviewing at their baseline visit as well as motivational coaching with safety phone calls during weeks 1-6.
2388056|NCT03655067|No Intervention|Usual Care|Participants in the Usual Care group may undergo an evaluation with the Social Worker if the clinician determines that it is necessary. The participants in the Usual Care group will also receive motivational coaching with safety phone calls during weeks 1-6.
3183551|NCT00714922|Active Comparator|1|PRK
2388058|NCT03655041|Experimental|Beta-Alanine|6.4 g/day of beta-alanine for 24 weeks
2388059|NCT03655041|Placebo Comparator|Placebo|6.4 g/day of maltodextrin for 24 weeks
2388060|NCT03655028|Experimental|RAS-music group|Home-based, exercise program augmented with rhythmically auditory stimulation enhanced music
2388061|NCT03655028|Active Comparator|Control group|Home-based, exercise program without rhythmically auditory stimulation enhanced music
2388062|NCT03655002|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2)|Patients receive nivolumab IV over 30 minutes on day 1, cyclophosphamide IV on day 1, and IRX-2 SC for 10 days between days 4 and 15. Cycles repeat every 28 days for up to 18 months in the absence of disease progression or unacceptable toxicity. Patients receive booster IRX-2 SC at 3, 6, 9, 12, and 15 months.
2388063|NCT03654989|Experimental|Treprostinil iontophoresis|"Gel of treprostinil 1 mg/mL (target concentration)~Part 1: 1 administration/day, on separate days, with 72h between two doses. Ascending doses are 0.025 mg/mL, 0.05mg/mL, 0.1 mg/mL, 0.25 mg/mL, 0.5 mg/mL, 0.7 mg/mL, and 1 mg/mL. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day at the maximum tolerated dose (MTD) for 10 days; dressing will be changed by a trained nurse every 2 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
2388064|NCT03654989|Placebo Comparator|Remodulin® Placebo iontophoresis|Placebo will be made from the placebo of Remodulin® incorporated into hydrogel (Suprasorb® G). The route and frequency of administration will be the same as for the investigational drug (topical administration by iontophoresis).
2388065|NCT03654989|No Intervention|Standard care|subjects randomized to the standard of care group (no iontophoresis) will only undergo standard blood test at visit 0 or 1, unless tests <1 month before inclusion are available This group is not double blind Standard care consists on debridement and dressings
2388066|NCT03654976|Experimental|Active treatment|Subject's ICS or ICS/LABA background medication plus HDM SLIT-tablet
2388067|NCT03654976|Placebo Comparator|Placebo|Subject's ICS or ICS/LABA background medication plus placebo oral tablet
2388068|NCT03654963|No Intervention|Control|Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
2388069|NCT03654963|Experimental|Medication reconciliation|The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking. To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members. The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor. The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
2388070|NCT03654937|Active Comparator|2h|The participants were asked to report for their vaccination immediately after an intensive bout of training (not later than two hours after). The influenza vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
2388071|NCT03654937|Active Comparator|26h|The athletes of the second group were vaccinated after an entire day (between 24 and 26 hours) after their last training session.The vaccine was administered via intra-muscular injection into the deltoid muscle of the non-dominant arm in a standardized manner.
2388072|NCT03654924|Experimental|Laryngeal Mask|A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
2388073|NCT03654911||aMCI subjects|EEG recording, ApoE testing
2388074|NCT03654898|Active Comparator|VITAL Start|VITAL Start: Video-based pre-ART counseling
2388075|NCT03654898|Placebo Comparator|Standard of Care|pre-ART education as conducted via routine facility methods
2388076|NCT03654885|Active Comparator|XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
2388077|NCT03654885|Active Comparator|Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
2388078|NCT03654846|No Intervention|Conventional emergency call|"Emergency call with conventinal cell phone:~verbal description of location~telephone-assisted CPR"
2388079|NCT03654846|Experimental|EmergencyEye emergency call|"Emergency call with EmergencyEye App on cell phone:~automated geolocalisation~video-assisted CPR"
2388080|NCT03654833|Experimental|MiST1 Rucaparib|BRCA1/BAP1 negative mesothelioma; 600mg twice daily (BID) every 28 days.
2388081|NCT03654833|Experimental|MiST2 Abemaciclib|p16INK4A negative mesothelioma; 200mg orally twice daily every 28 days.
2388279|NCT03653585||Lesion negative hemisphere in patients (PT-N)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in MS patients
3183552|NCT00714922|Active Comparator|2|SBK
2388082|NCT03654833|Experimental|MiST3 Pembrolizumab & Bemcentinib|"No specific biomarker requirement: Pembrolizumab 200mg IV infusion on Day 1 only:~Bemcentinib loading dose of 400mg on days 1-3, on day 4 on-wards 200mg daily every 21-days."
2388083|NCT03654833|Experimental|MiST4 Atezolizumab & Bevacizumab|PDL1 expression positive mesothelioma: Atezolizumab 1200 milligrams via intravenous nfusion; Bevacizumab 15 milligrams per kilogram via IV infusion both on Days 1 every 21-days.
2388084|NCT03654833|Experimental|MiST 5 Dostarlimab and Niraparib|Platinum sensitive mesothelioma: Niraparib 200-300mg daily every 21 days; Dostarlimab 500mg on day 1 of each 21 day cycle for 4 cycles, then 1000mg on day 1 of each 42 day cycle.
2388085|NCT03654820|Experimental|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
2388086|NCT03654820|Active Comparator|SDF treated|Annual application of 38% SDF solution
2388087|NCT03654807|Experimental|High Intensity Walking|HIW (70-80% HRmax)
2388088|NCT03654807|Experimental|Casual Speed Walking|Self selected pace
2388089|NCT03654794||Patients with hemochromatosis|"The study is conducted with mononuclear cells obtained from patients undergoing phlebotomy as part of a hemochromatosis treatment.~The blood samples will be recovered immediately after their completion. 40 mL of blood will be collected and the mononuclear cells separated using a ficoll gradient.~Cell pharmacokinetics of tacrolimus"
2388090|NCT03654781|Active Comparator|Triple therapy|Conventional triple antibiotic treatment would be applied to all patients (consisted of a 10-day course of Lansoprazole (a proton pump inhibitor) combined with amoxicillin ( 2 × 1 g daily) and clarithromycin (2 × 500 mg daily).
2388091|NCT03654781|Experimental|Combined treatment|"Periodontal treatment would be administered in addition to triple therapy consisted of a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).~Periodontal treatment consisted of supra and sub gingival scaling and root planing, oral hygiene instruction"
2388092|NCT03654768|Active Comparator|Arm I (dasatinib, nilotinib)|Patients receive bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2388093|NCT03654768|Experimental|Arm II (ruxolitinib phosphate, dasatinib, nilotinib)|Patients receive ruxolitinib phosphate PO BID on days 1-90, and bosutinib PO daily or dasatinib PO daily or nilotinib PO BID on days 1-90. Treatment repeats every 90 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2388094|NCT03654755|Experimental|ASN002 40 mg|ASN002 40 mg
2388095|NCT03654755|Experimental|ASN002 60 mg|ASN002 60 mg
2388096|NCT03654755|Experimental|ASN002 80 mg|ASN002 80 mg
2388097|NCT03654742|Active Comparator|ECTE/Electrosurgery|Extracapsular tonsillectomy (ECTE) with monopolar electrosurgery
2388098|NCT03654742|Experimental|ICTE/Microdebrider|Intracapsular tonsillectomy (ICTE) with microdebrider
2388099|NCT03654742|Experimental|ICTE/Coblator|Intrapsular tonsillectomy (ICTE) with coblator
2388103|NCT03654716|Experimental|ALRN-6924 -- Cohort A|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with otherwise unselected TP53 wild type solid tumors and lymphoma will participate in this cohort."
2388104|NCT03654716|Experimental|ALRN-6924 -- Cohort B|"Participants will receive ALRN-6924 monotherapy on days 1, 4 (± 1 day), 8 (± 1 day), and 11 (± 1 day) of a 21-day cycle.~ALRN-6924 will be administered intravenously.~Participants with solid and CNS tumors and lymphoma with specific diagnoses or molecular features will participate in this cohort."
2388105|NCT03654716|Experimental|ALRN-6924 -- Cohort C|"Patients will receive ALRN-6924 in combination with cytarabine on days 1, 8 (± 1 day), and 15 (± 1 day) of a 28-day cycle.~Cytarabine is administered intravenously.~ALRN-6924 will be administered intravenously.~Participants with TP53 wild type acute leukemia will participate in this cohort."
2388106|NCT03654703|Experimental|Cyclophophamide|Cyclophosphamide 50mg/kg/day on day+3，+4 after HSCT. Intervention: drugs:Cyclophosphamide.
2388107|NCT03654703|Experimental|Placebo|5% GLS（Placebo) 50ml/day on day+3，+4 after HSCT. Intervention: drugs: Placebo other name: placebo (for Cyclophosphamide) 5%Glugose in water 50ml or normal saline
2388108|NCT03654690|No Intervention|Control|Participants will receive SMS text message reminders to get tested for HIV in a clinic.
2388109|NCT03654690|Active Comparator|Standard Self-Testing|Participants will receive an HIV self-test kit in the mail with no standardized follow-up from counselors.
2388110|NCT03654690|Experimental|Enhanced Self-Testing|Participants will receive an HIV self-test kit and will be contacted via telephone for counseling within 24 hours of opening their test.
2388111|NCT03654677|Experimental|inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 500U(Name of viral strain: TZ84)
2388112|NCT03654677|Active Comparator|Havrix Inj|1440 ELISA/mL_Adult Inj.(Name of Viral strain: HM175 Inj)
2388113|NCT03654664|Experimental|inactivated hepatitis A vaccine|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
2388114|NCT03654664|Active Comparator|Havrix Inj|A 0.5ml dose is administered twice in total at an interval of 6 months to healthy children aged 12-23 months.
2388115|NCT03654651|Experimental|Evening Peanut Consumption|Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).
2388116|NCT03654651|Active Comparator|Evening Snack|Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).
3183553|NCT00714935|Experimental|3|Decision Counseling Program(DCP) combined with Coronary Artery Disease Decision Aid (CAD-DA) described in Arm 2
2388349|NCT03653182||Qi deficiency|One of an abnormal constitution condition in TCM.
3183554|NCT00714935|No Intervention|1|
3142899|NCT00003735|Experimental|Stratum 2 - Stage 2|Topotecan hydrochloride (0.8 mg/m²/day) by mouth for 21 days. Bone marrow will be obtained on approximately Day 28 of Course 1 and 2 and in any course where the CBC suggests that a relapse has occurred. One additional course may be given if the blood is cleared of blasts and the bone marrow is M1, M2 or M3. The patient is off protocol therapy if blasts are still present in the blood and the marrow is M3. Subsequent courses of topotecan may be given only if the bone marrow after Course 2 is M1 or M2. If the bone marrow is M2 on Day 28 of any course, another bone marrow aspirate will be done at the end of the next course. If the patient is in CR, a bone marrow aspirate will be required only every other course unless the peripheral blood suggests that a relapse has occurred. Each subsequent course should begin within six weeks of the start of the previous course.
2388119|NCT03654625|Experimental|Standard Written Exposure|Four writing sessions at the laboratory
2388120|NCT03654625|Experimental|Enhanced Written Exposure|Four writing sessions at the laboratory
2388121|NCT03654625|Placebo Comparator|Control Condition|Four writing sessions at the laboratory
2388122|NCT03654612|Experimental|Apatinib+S-1|Patients with recurrent/metastatic head and neck malignancies received apatinib plus S-1 as second-line therapy.
2388123|NCT03654599|Experimental|Baseline and Digital Stories (DS)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
2388124|NCT03654599|Active Comparator|Baseline and Information Control (IC)|In-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
2388125|NCT03654586|Active Comparator|Calorie label|"Calorie label (control) will display a Calories per Bottle label on all beverages, not just sugary drinks. This is modeled after the American Beverage Association's current Clear on Calories labels."
2388126|NCT03654586|Experimental|Text warning label|Text warning labels will display the following text on sugary beverages: WARNING: drinking beverages with added sugars contributes to obesity, diabetes, and tooth decay
2388127|NCT03654586|Experimental|Sugar graphic warning label|"Sugar graphic warning labels will display the same text as text warning labels along with graphics depicting the amount of sugar in the beverage"
2388128|NCT03654586|Experimental|Health graphic warning label|"Health graphic warning label will display the same text as text warning labels along with graphics depicting the potential negative health consequences of over-consuming sugary drinks."
2388129|NCT03654573|Experimental|STEMI patients|Adult subjects presenting with STEMI in the LAD undergoing PPCI
3142900|NCT00003744|Experimental|Intercalcated Duct|"The first group, referred to as intercalated duct will include Aadenoid cystic carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade adenocarcinoma, undifferentiated carcinoma, and adenocarcinoma.~- Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~-- Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
3142901|NCT00003744|Experimental|Excreatory Duct|"The second group, referred to as excretory duct, will include: squamous cell carcinoma and mucoepidermoid carcinoma.~Gemcitabine iv 30 min infusion on days 1,8, and 15 of each 28 day cycle.~Participants will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
2388134|NCT03654534|Experimental|oral nutritional supplements|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
2388135|NCT03654534|No Intervention|standard diet|The control group was given no additional postoperative nutritional supplementation (standard diet).
2388136|NCT03654521|Active Comparator|Diabetes group|Women with gestational or pre-gestational diabetes mellitus.
2388137|NCT03654521|Active Comparator|Control group|Women without gestational or pre-gestational diabetes mellitus.
2388138|NCT03654508|Active Comparator|ADRB2-genotype guided treatment arm|In the genotype-stratified arm, children will be treated based on their ADRB2 genotype. Children homozygous for the risk variant Arg16 and heterozygotes (Arg16Gly) will be treated with doubling dosages of their ICS. Children homozygous for the wild type allele (Gly16Gly) will receive LABA.
2388139|NCT03654508|Active Comparator|Control arm|In the control arm, genotyping will be performed for retrospective analysis, but the genotype information will not be used to guide treatment. Children in this study arm will proceed randomisation between doubling ICS dosage (n=75) or LABA treatment (n=75), the two most commonly preferred add-on options among paediatric pulmonologists in the Netherlands. The investigators choose to randomize between both treatments options, since international guidelines do not agree on the preferred treatment option.
2388140|NCT03654495|Experimental|Exergame Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. In addition training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train different aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.
2388141|NCT03654495|Active Comparator|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation.
2388142|NCT03654482|Experimental|SuperSeton arm|
2388143|NCT03654456||Sepsis patients with OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index at least 5/hr with compatible symptoms
2388144|NCT03654456||Sepsis patients without OSA|Sepsis patients who received a prior polysomnography showing an apnea-hypopnea index less than 5/hr
2388145|NCT03654443|Experimental|Group Painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a painful stimulus (IT0), during the painful stimulus (IT1) and soon afterwards (IT2)
2388146|NCT03654443|Experimental|Group Non-painful stimulus|The CPOT tool is administered in a crossover manner in Group one prior to a non-painful stimulus (IIT0), during the painful stimulus (IIT1) and soon afterwards (IIT2)
2388147|NCT03654430|Other|Healthy Newborns|
2388350|NCT03653182||Damp heat|One of an abnormal constitution condition in TCM.
2388150|NCT03654404|Experimental|Positive Psychology|"Participants will receive check-in/psychosocial support phone calls at weeks four, eight and twelve following enrollment.~At approximately 100-days post-HSCT, participants will begin an 8-week positive-psychology program involving weekly calls with an interventionist, in this case the principal investigator, and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~Participants will complete self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
2388151|NCT03654391|Active Comparator|InnoSlim|Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
2388152|NCT03654391|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.
2388153|NCT03654365|Active Comparator|Control|Pts in the control arm receive usual care. Usual care includes a EHR based reminder of single HCV testing for patients who are in the birth cohort. (routine alerting)
2388154|NCT03654365|Experimental|Intervention|Pts in the intervention arm receive bulk messaging and bulk ordering of the HCV ab test.
2388155|NCT03654352||High Risk for ARDS/ALI|Mechanically ventilated patients with risk factors for the development of ARDS/ALI. These factors are classified into two categories: pulmonary insults, such as pneumonia and extrapulmonary insults such as sepsis.
2388156|NCT03654352||Low Risk for ARDS/ALI|Mechanically ventilated patients with low risk factors for the development of ARDS/ALI. These factors include mechanical ventilation for airway protection, pain management, or procedure.
2388157|NCT03654339|Experimental|experimental group|"Group A-15 patients were allocated to the microsurgical group for root coverage. following scaling and root planning, the laterally repositioned flap was done using the microsurgical approach~Group B-15 Patients were allocated to the conventional group for root coverage following scaling and root planning, the laterally repositioned flap was done using the macrosurgical approach"
2388160|NCT03654313|Experimental|Part A MEDI6570 Cohort 1|Part A MEDI6570 Cohort 1 dose level
2388161|NCT03654313|Experimental|Part A MEDI6570 Cohort 2|Part A MEDI6570 Cohort 2 dose level
2388162|NCT03654313|Experimental|Part A MEDI6570 Cohort 3|Part A MEDI6570 Cohort 3 dose level
2388163|NCT03654313|Experimental|Part A MEDI6570 Cohort 4|Part A MEDI6570 Cohort 4 dose level
2388164|NCT03654313|Placebo Comparator|Part A Placebo|Part A Placebo
2388165|NCT03654313|Experimental|Part B MEDI6570 Cohort 1|Part B MEDI6570 Cohort 1 dose level
2388166|NCT03654313|Experimental|Part B MEDI6570 Cohort 2|Part B MEDI6570 Cohort 2 dose level
2388167|NCT03654313|Experimental|Part B MEDI6570 Cohort 3|Part B MEDI6570 Cohort 3 dose level
2388168|NCT03654313|Placebo Comparator|Part B Placebo|Part B Placebo
2388169|NCT03654313|Experimental|Part A MEDI6570 Cohort 5|Part A MEDI6570 Cohort 5 Dose level
2388170|NCT03654313|Experimental|Part A MEDI6570 Cohort 6|Part A MEDI6570 Cohort 6 dose level
2388171|NCT03654287||Treatment with CPFA|The critically ill children who treated by CRRT and CRRT mode is decide as CPFA.
2388172|NCT03654287||Treatment with TPE+CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as TPE+CVVHDF.
2388173|NCT03654287||Treatment with CVVHDF|The critically ill children who treated by CRRT and CRRT mode is decide as CVVHDF.
2388174|NCT03654287||Treatment without CRRT/ECMO|The critically ill children who are not treated by CRRT or ECMO.
2388175|NCT03654287||Treatment with ECMO|The critically ill children who are treated by ECMO whether treated by CRRT
2388176|NCT03654274|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 80 weeks.
2388177|NCT03654261|Experimental|1-Day CBT Workshop - Immediate|Women assigned to the immediate workshop group will participate in the first of two workshops (9 weeks apart).
2388178|NCT03654261|Experimental|1-Day CBT Workshop - Waitlist|Women assigned to the waitlist will participate in the second of two workshops (12 weeks apart).
2388179|NCT03654248|Experimental|Let's Get Organized group intervention|Group intervention with 10 weekly sessions, each lasting 1,5 hours
2388180|NCT03654248|Active Comparator|Individual Occupational Therapy|Individual intervention lasting 10 weeks
2388181|NCT03654235|Experimental|PNE and PE program|Pain neuroscience education (Health education) and Physical exercise program.
2388182|NCT03654235|Active Comparator|Usual care in Primary Care Physiotherapy|Usual care in Primary Care Physiotherapy Units
2388183|NCT03654222||Cardiac surgery|Direct procedures in heart
2388184|NCT03654222||Organ preservation|Mainly renal autograft
2388185|NCT03654222||Bypass|Revascularization of affected organs or segments with Woven Dacron graft
2388186|NCT03654222||Exclusion|Resection of an affected organ (nephrectomy)
2388187|NCT03654222||Replacement|Replacement of affected aortic segment with a Woven Dacron graft
2388188|NCT03654222||Other|Any surgery that does not include the previous ones
3142902|NCT00003745|Experimental|Arm I|Patients receive topotecan IV continuously on days 1-21. Treatment continues at least every 4 weeks in the absence of unacceptable toxicity or disease progression.
3142903|NCT00003746|Active Comparator|CDA day|CDA:0.14 mg/kg/day Bolus s.c. (standard) days 1-5
3142904|NCT00003746|Active Comparator|CDA week|CDA:0.14 mg/kg/week Bolus s.c. weeks 1-5
2388192|NCT03654196|Experimental|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
3142905|NCT00003748|Experimental|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
3142906|NCT00003750|Experimental|DG2 positive relapsed or refractory solid tumors|The initial hu14.18-IL2 fusion protein (FP) dose will be 2 mg/m2 given intravenously over 4 hours, daily for 3 days. Five separate dose levels are scheduled: 2 mg/m²/dose (IV over 4 hours) x 3 days, 4 mg/m²/dose (IV over 4 hours) x 3 days, 6 mg/m²/dose (IV over 4 hours) x 3 days, 8 mg/m²/dose (IV over 4 hours) x 3 days, 10 mg/m²/dose (IV over 4 hours) x 3 days.
2388193|NCT03654196|Active Comparator|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
2388194|NCT03654170|Experimental|All Subjects|BI 425809 mixed with [C14] BI 425809
2388195|NCT03654144|Experimental|Study group|women will receive dienogest
2388196|NCT03654144|Active Comparator|control group|women used combined oral contraceptive pills
2388197|NCT03654131|Active Comparator|MWA|Percutaneous ultrasound-guided MWA or open surgery MWA. The patient is fully anesthetized during the treatment.
2388198|NCT03654131|Active Comparator|SBRT|3 fractions of 15 Gy (in total 45 Gy), 3 fractions per week. The dose is prescribed to the PTV encompassing 67% isodose. The SBRT plan is normalized such that the mean dose to the GTV is 100% = 67.5 Gy.
2388199|NCT03654118||ISIS cohort|"Patients operated between December 2007 and December 2008 for recurrent shoulder instability using the arthroscopic procedure (Arthroscopic Bankart) in the investigative centers and presenting at the time of indication for surgery an ISIS score ≤ 4 points~Phone follow-up"
2388200|NCT03654105|Experimental|Smoking cessation and Antinflammatory|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2388201|NCT03654105|Experimental|Smoking cessation|Smoking cessation through the administration of Cytisine (in standard and prolonged administration) + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2388202|NCT03654105|Experimental|Antinflammatory|reduction of inflammatory status through the administration of Acetylsalicylic acid, diet modification and physical activity increase + standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
2388203|NCT03654105|Other|Control Group|standard treatment for early lung cancer detection (ultra low dose CT) + spirometry with CO test + anthropometic data collection + blood test
3142907|NCT00003761|Experimental|rV-DF3/MUC1|"rV-DF3/MUC1 vaccinations will be administered 4 week intervals for a total of 3 doses.~Participants will be followed weekly until 28 days after the final dose (day 85) then month for 6 months"
2388208|NCT03654066|Active Comparator|Botulinum toxin|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation.
2388209|NCT03654066|Active Comparator|Botulinum toxin and dilation|A one time dose of Botulinum toxin (Botox) is injected into the muscle of the LES leading to blockage of acetylcholine release from nerve endings resulting in increased relaxation. Subjects will also undergo distal esophageal dilation using a 20mm through the scope balloon positioned across the LES.
2388210|NCT03654053|Experimental|Simvastatin|Simvastatin 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
2388211|NCT03654053|Placebo Comparator|Placebo|Placebo 40mg PO once at bedtime for up to 24 months. Note: all enrolled subjects will trial 20mg once at bedtime for two weeks as lead-in to determine tolerability prior to randomization.
2388212|NCT03654040|Experimental|arTreg|"arTreg: alloantigen-reactive T regulatory cells~The investigational product is donor alloantigen-reactive regulatory T cells (arTreg). Supportive regimen for receipt of arTregs includes everolimus, leukapheresis, cyclophosphamide, and mesna.~Note: Participants who receive at least the minimum Treg product (arTreg) dose of 30 to <90 x10^6 total cells will be included in intent-to-treat analysis."
2388213|NCT03654027|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
2388214|NCT03654027|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
2388215|NCT03654014|Experimental|SofPulse active|SofPulse active group. Patients who will be treated with the SofPulse activated on their heads for up to seven days in intensive care or as long as they are in the unit The PEMF device is kept on throughout and provides a 15 min pulsed treatment every hour.
2388216|NCT03654014|Placebo Comparator|SofPulse inactive|SofPulse inactive. The SofPulse will be placed on the patient's head but not activated for as long as they are in intensive care.
2388217|NCT03654014|Sham Comparator|Normal pressure hydrocephalus|CSF and serum samples from 15 normal pressure hydrocephalus patients will be used to compare CSF and serum biomarker levels in the 30 TBI patients.
2388218|NCT03654001|Experimental|Albumin + Balanced|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Balanced crystalloid solutions~According to the preference and the standard use of the participating center:~Ringer Lactate~Ringer Acetate~Crystalsol"
2388219|NCT03654001|Experimental|Albumin + Saline|"Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.~Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl)."
2388220|NCT03654001|Experimental|Balanced|Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)
2388221|NCT03654001|No Intervention|Saline|Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).
2388278|NCT03653585||Lesion negative hemisphere in Healthy Controls (HC)|Data grouped as an un-lesioned primary sensorimotor cortical hemisphere in age and sex matched healthy voluntary participants
2388351|NCT03653182||Yang deficiency|One of an abnormal constitution condition in TCM.
3142908|NCT00003762|Experimental|Arm I: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour on day 1 followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
2388224|NCT03653975||Nodding syndrome|"I) probable Case of Nodding Syndrom (according to the WHO epidemiologic surveillance case definition) *reported head nodding ** in a previously healthy person with at least 2 major and 1 minor criteria~Major criteria~Age 3 to 18 y at onset of head nodding~Nodding frequency 5 to 20 times per min~Minor criteria~Other neurologic abnormalities~Clustering in space or time with similar cases~Triggering by eating or cold weather~Delayed sexual or physical development~Psychiatric manifestations~As agreed upon at the first International Conference on Nodding Syndrome, Kampala, Uganda, July 2012 (16). ** Repetitive involuntary drops of the head toward the chest on >2 occasions."
2388225|NCT03653975||epilepsy and onchocerciasis|"II) People with epilepsy (PWE) and onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2388226|NCT03653975||epilepsy, no onchocerciasis|"III) People with epilepsy (PWE) without onchocerciasis (n= 50)~confirmed or suspected generalized and idiopathic epilepsy~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2388227|NCT03653975||no epilepsy but onchocerciasis|"IV) Controls with onchocerciasis, otherwise healthy (n= 50)~no evidence for epilepsy or other neurological diseases~confirmed active infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2388228|NCT03653975||no epilepsy, no onchocerciasis|"V) Healthy Controls without onchocerciasis (n= 50)~no evidence for epilepsy or other neurological diseases~excluded active or past infection with O. volvulus (microscopy, PCR and serology)~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2388229|NCT03653975||controls for Wechsler Nonverbal (WNV)|"Healthy Controls for cognitive assessment only, (n= 750)~no evidence for epilepsy or other neurological diseases no detailled examination on O. volvulus performed~Patients with cardiovascular or renal comorbidities, a history of birth or traumatic brain injuries, psychiatric comorbidities, insecure comprehension of the information given, lacking or withdrawn consent will be excluded."
2388230|NCT03653962|Active Comparator|only informed consent|The first group was given verbal-written informed consent and a 15 question quiz about the informed consent content afterwards.
2388231|NCT03653962|Experimental|video assisted group|The second group got an additional information video presentation and then the same quiz.
2388232|NCT03653949|Experimental|High Intensity Interval Training|The subjects will participate of an educational intervention and a High Intensity Interval Training.
2388233|NCT03653949|Active Comparator|Control Group|The subjects will participate of an educational intervention.
2388234|NCT03653923|Experimental|Waiting-List|
2388235|NCT03653923|Experimental|Treatment|
2388236|NCT03653923|No Intervention|Healthy Controls|Not randomized healthy control group for comparison to normal functioning
2388237|NCT03653910|Experimental|Airtraq|Patients received DLT intubation by Airtraq videolarygoscope
2388238|NCT03653910|Active Comparator|Macintosh|Patients received DLT intubation by Macintosh laryngoscope
2388239|NCT03653897|Experimental|ID-Capsules- Active|Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded.
2388240|NCT03653884||Pregnancy with fetal intra-abdominal umbilical vein.|All women with a pregnancy with a partially intra-abdominal umbilical vein aneurysm isolated or associated with other abnormalities découvert lors d'une ultrasonic monitoring.
2388241|NCT03653871|Experimental|Intervention|Performing arts instruction delivered 1 hour/week for 8 weeks.
2388242|NCT03653871|No Intervention|Wait List Control|Control group. Performing arts instruction delivered upon completion of control period.
2388243|NCT03653858|Experimental|Group A: DBS onset in week 1|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. DBS onset in week 1.~2ND STAGE: After 6 months DBS ON, patients will be assessed whether they are responders or non-responders. In the subgroup of eligible responders, patients will be randomized to either DBS OFF* (for max. 3 months) or continued DBS for another 6 months. *DBS OFF until worsening of clinical depression, event (defined as > 5 points augmentation in MADRS in two consecutive visits) or for a maximum of 3 months. After DBS OFF, re-onset of DBS will be performed, followed by 6 months continuous DBS.~Non-responders will also receive another 6 months DBS therapy in the 2nd stage. At sites other than Freiburg/Bonn, the 2nd stage consists of 6 months DBS therapy only."
2388244|NCT03653858|Sham Comparator|Group B: DBS off, followed by DBS onset in week 17|"Implantation of Vercise GEVIA deep brain stimulation (DBS) system. 4 months OFF after implantation followed by DBS onset in first week of month 5.~2ND STAGE: See group A."
2388245|NCT03653845|Experimental|Intevention|Patients in this group will be treated with endovascular chemical ablation of adrenal glandp by endovascular injection of dehydrated alcohol. Sequenced antihypertensvie drugs with titrated dosage(amlodipine 5-10 mg/d ; terazosin 2-6mg/d) will be prescribed if home blood pressure (HBP) exceeds ≥160/100 mmHg.
2388246|NCT03653845|Active Comparator|Control|Patients in this group will be treated only with sequenced antihypertensvie drugs with titrated dosage(amlodipine 5mg/d→plus spironolactone 20 mg/d→plus spironolactone 40 mg/d→plus spironolactone 60 mg/d→→plus amlodipine 10 mg/ d →plus terazosin 2-6mg / d) if home blood pressure (HBP) exceeds ≥160/100 mmHg.
2388247|NCT03653832|Experimental|Dexmedetomidine Group|For dexmedetomidine, the regimen will follow the manufacturer's guidance and regimens used in previous trials. Dexmedetomidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and documented at least daily. No loading dose will be administered. The starting dose will be 0.7µg.kg-1.hour-1 titrated to a maximum dose 1.4µg.kg-1 hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
2388248|NCT03653832|Experimental|Clonidine Group|For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
2388249|NCT03653832|Active Comparator|Usual Care (Propofol) Group|Usual Care Group : Patients will continue to receive intravenous propofol according to usual current care . The sedation targets, weaning, and sedation discontinuation procedures will follow the same clinical targets as for the clonidine and dexmedetomidine groups.
2388250|NCT03653819|Other|HIIT + compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session with compression garments/second without.
2388251|NCT03653819|Other|HIIT - compression|2 sessions of High Intensity Interval Training (HIIT) on a stationary bike. First exercise session without compression garments/second with
2388252|NCT03653793|Experimental|LivRelief Varicose Veins Cream|"Intervention:~All subjects were provided with an adequate supply of the Natural Health Product LivRelief Varicose Veins cream for 6 weeks of at home use."
2388253|NCT03653780|Experimental|Ekso GT gait training|20-minute Ekso GT gait training
2388254|NCT03653767|No Intervention|Control Group|The control group will use conventional school furniture.
2388255|NCT03653767|Experimental|Adjustable Furniture Group|The experimental group will use adjustable ergonomic school furniture.
2388256|NCT03653754||typically developing|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
2388257|NCT03653754||neurodisabilities|Intervention: Measurement of growth and body composition. Growth (height, body weight), and body composition was measured at school.
2388259|NCT03653728||Traumatic brain injury with cerebral contusions|
2388260|NCT03653715|Experimental|Test Device|Within this arm the Clerio Vision LIRIC-modified Bifocal Contact Lens is administered.
2388261|NCT03653715|Active Comparator|Control Devices|Within this arm the Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens, Johnson & Johnson 1-Day Acuvue Moist Contact Lens, and Clerio Vision Single Vision Contact Lens are administered.
2388262|NCT03653702|Experimental|Contrast Enhanced Ultrasound|Participants will undergo a contrast enhanced ultrasound (CEUS) using Lumason
2388263|NCT03653689|Active Comparator|FODMAPs|Dietary supplement: FODMAPs 50 grams three servings per day for seven days.
2388264|NCT03653689|Active Comparator|Gluten|Dietary supplement: Gluten 17.3 grams three servings per day for seven days.
2388265|NCT03653689|Placebo Comparator|Placebo|Dietary supplement: Placebo rice porrige three servings per day for seven days.
2388266|NCT03653676||Subjects with SCA|Children and adolescents with SCA confirmed by hemoglobin analysis randomized to either moderate or vigorous intensity exercise test (CIIT)
2388267|NCT03653676||Controls without SCA|Children and adolescents without SCA or sickle cell trait randomized to either moderate or vigorous intensity exercise test (CIIT)
2388268|NCT03653663|Placebo Comparator|Placebo|8 weeks treatment with placebo (or until muscle symptoms appear for at least 1 week or are unbearable)
2388269|NCT03653663|Active Comparator|20 mg simvastatin|8 weeks treatment with 20 mg simvastatin daily (or until muscle symptoms appear for at least 1 week or are unbearable)
2388270|NCT03653650|Experimental|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
2388271|NCT03653650|Active Comparator|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
2388272|NCT03653650|Active Comparator|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
3142909|NCT00003762|Experimental|Arm II: docetaxel + gemcitabine|"Patients receive docetaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
3142910|NCT00003762|Experimental|Arm III: docetaxel + gemcitabine|"Patients receive docetaxel IV on day 1 and gemcitabine IV on days 1, 8, and 15. Patients continue treatment every 28 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with either stable disease or complete/partial response who discontinue treatment after 4-6 courses may be eligible for NCCTG-97-24-51.~Quality of life is assessed before treatment and before each course of therapy.~Patients are followed every 3 months for 1 year, then every 3 months for 5 years."
3142911|NCT00003765|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, then, 1 hour later, carmustine IV is administered over 1 hour. Treatment is repeated every 6 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients each receive escalating doses of carmustine until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose level at which fewer than 2 of 6 patients experience dose limiting toxicity (DLT). If myelosuppression is the DLT, stratum 1 is closed and patients are accrued to stratum 2. If neutropenia is the DLT in stratum 2, patients receive filgrastim (G-CSF) subcutaneously beginning on day 2 and continuing until blood counts recover.
3142912|NCT00003766|Experimental|Arm A|06-benzylguanine (100mg/m2 16 hrs before anticipated tumor tissue removal)
2388280|NCT03653585||Lesion positive hemisphere in patients (PT-P)|"Lesion positive hemisphere in patients:~Data grouped as a lesioned primary sensorimotor cortical hemisphere in MS patients"
2388281|NCT03653572|Other|Eligible Subjects|All subjects will be enrolled into a single arm and will undergo an ultrasound exam, per the protocol.
2388282|NCT03653559|Experimental|"Home meals condition"|The recommendation consists of menus with examples of breakfast, lunch and dinner based on typical preparations plus a prescription of the number of portions of the food groups that provides 1200 kcal with a distribution of 50-60% carbohydrates, 15-20% protein and < 30% lipids.
2388283|NCT03653559|Active Comparator|"Healthy meals condition"|"The recommendation consists of the educative graphic tool Eatwell plate plus a prescription of the same number of portions of the food groups for a isocaloric diet with the same macronutrient distribution as the home meals condition."
2388284|NCT03653546|Experimental|AZD3759 Group|AZD3759 group will receive a 200 mg twice daily dose of AZD3759
2388285|NCT03653546|Active Comparator|Erlotinib or Gefitinib Group|SoC EGFR-TKI Erlotinib or Gefitinib Group will get EGFRTKI Erlotinib 150 mg or Gefitinib 250 mg PO Q.D
2388286|NCT03653533|Other|MiniMed™ 640G alone|MiniMed™ 640G (insulin pump) is used without Captor CGM Enlite® (captor) at phase 1 and phase 4 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2388287|NCT03653533|Other|MiniMed™ 640G + Captor CGM Enlite®|insulin pump coupled with captor without SmartGuard® function tat phase 2 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2388288|NCT03653533|Other|MiniMed™ 640G + Captor + SmartGuard®|insulin pump + captor + SmartGuard® function are used at phase 3 of the study. ADDQoL, BIPQ and HADS questionnaire are performed.
2388289|NCT03653520|Active Comparator|diazepam only (group 1)|Patients are given 5 or 10mg of diazepam for sedation before surgery for sedation
2388290|NCT03653520|Active Comparator|diazepam/tramadol/ondansetron (group 2)|Patients are given 5 or 10mg of diazepam, 50 or 100mg of tramadol and 4 or 8mg of ondansetron orally before surgery for sedation
2388291|NCT03653520|Experimental|MKO only (group 3)|Patients are given 1 or 2 MKO melts (each contain 3mg midazolam, 25mg ketamine, 2mg ondansetron) sublingually before surgery for sedation
3142913|NCT00003778|Experimental|Arm I|Patients receive dolastatin 10 IV over 10 minutes. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3142914|NCT00003779|Active Comparator|BCG-Connaught|
2388294|NCT03653494|Experimental|phrenic block group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia、Vagus block and Phrenic block
2388295|NCT03653494|Active Comparator|Control group|non-intubated general anesthesia combine with Paravertebral blocks、surface spray anesthesia and Vagus block
2388296|NCT03653481|Experimental|Inulin|Oligofructose-enriched Inulin (OI) administered for 8 weeks
2388297|NCT03653481|Placebo Comparator|Placebo|Maltodextrin placebo administered for 8 weeks
2388298|NCT03653468|No Intervention|Control group|No-exercise
2388299|NCT03653468|Experimental|Endurance training plus resistant training|Concurrent training
2388300|NCT03653455|Experimental|Pre-operative discussion group|At a pre-operative visit, patients and their care provider will discuss what assigned surveys are and why they are important. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2388301|NCT03653455|Experimental|Pre- and post-operative discussion group|Patients will discuss with their care provider their health outcomes before and at 6-months after their surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2388302|NCT03653455|Experimental|Incentivised group|Patients will receive up to $30 in amazon gift cards as an incentive if they complete their forms before surgery, as well as at 6-months and 1-year after surgery. In addition, patients will receive email reminders to complete their forms, if they haven't done so.
2388303|NCT03653455|Experimental|control group|Patients will only receive email reminders to complete their forms, if they haven't done so.
2388308|NCT03653403|Experimental|IDP-126 Gel|Component A
2388309|NCT03653403|Active Comparator|Control Gel|Gel
2388310|NCT03653390|Experimental|EnhanceWellness for Disability (EW-D)|Up to 10 sessions of a telephone-based intervention delivered over a six-month period.
2388311|NCT03653390|Active Comparator|Wellness Education|Eight 45-minute sessions of telephone-based wellness education delivered over a six-month period.
2388312|NCT03653390|No Intervention|Control|Participant continues with their lives as they normally would.
2388313|NCT03653377||Patients with self-administered questionnaire|
3142915|NCT00003779|Active Comparator|BCG Onko-Tice|
3142916|NCT00003783|Experimental|Complete Response and no CNS 3|See detailed description.
3142917|NCT00003783|Experimental|Complete Response and CNS 3|See detailed description.
3142918|NCT00003786|Experimental|Arm A|MGI-114 (11mg/m2/day x 5 days every 28 days)
3142919|NCT00003787||Intervention|high fiber, high vegetable, low-fat diet
3142920|NCT00003787||Control|NCI-recommended diet
3142921|NCT00003789|Experimental|Arm I|Patients undergo hyperthermic isolated perfusions of the lower limb by either the external iliac vessels or the common femoral vessels. Patients undergo perfusions of the upper extremity by the axillary artery and vein using an infraclavicular/axillary incision. Melphalan is introduced into the perfusion by slow injection over 5 minutes and allowed to remain for a total of 60 minutes.
3142922|NCT00003789|Experimental|Arm II|Patients undergo hyperthermic isolated perfusions as in arm I. Tumor necrosis factor is administered by slow injection into the arterial line and allowed to remain for a total of 90 minutes. Melphalan is introduced into the perfusion as in arm I and allowed to remain for a total of 60 minutes.
3142923|NCT00003793||Identification of Genetical suceptibility prior to therapy|"Determine the glutathione-s-transferase theta (GSTT1) or glutathione-s-transferase mu (GSTM1) null genotype is more frequent in individuals with t-MDS/AML. Determine the GSTT1 or GSTM1 null genotype is associated with a reduced incidence of relapse of sarcoma. Determine NAT2 or CYP1A1 genotype influences risk of t-MDS/AML. Determine development of a mutator phenotype as demonstrated by developing microsatellite instability is an early marker of individuals likely to progress to t-MDS/AML."
3183555|NCT00714935|Experimental|2|"Behavioral: Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
2388317|NCT03653338|Experimental|Hematopoietic Stem Cell Transplantation|"All patients will receive a CD3+/CD19+ depleted stem cell transplant. In this study, the investigators will use HLA mismatched unrelated or haploidentical related donor peripheral blood stem cells. Prior to transplantation, the marrow (90-95%) will be negatively selected for CD3/CD19 using the ClinicMACs® depletion device. The remaining (5-10%) will undergo CD45+RA+ depletion and be frozen for future use as an immune boost.~Subjects will undergo hematopoietic stem cell transplant utilizing CD3+/CD19+ depleted cells following conditioning therapy."
2388318|NCT03653325|Experimental|interventional arm|"In the interventional arm of the study clinicians will be encouraged to titrate oxygen FiO2 according to the following table:~Interventional arm (FiO2 adaptation every 2-3 min) :~ORI >0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.2 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2>0.5 FiO2 reduction of 0.1 ORI >0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.1 ORI>0.01 and ORI<0.5 and SatO2>98% and FiO2≤0.5 FiO2 reduction of 0.05 ORI=0 et SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1~In the absence of a ORI measurement reading FiO2 will be adapted as in the observational arm according to SatO2 only."
2388319|NCT03653325|Active Comparator|Observational arm|"Observational arm (adaptation every 2-3 min):~oxygen saturation measurement SatO2>98% and FiO2>0.5 reduction of FiO2 by 0.1 SatO2>98% and FiO2≤0.5 reduction of FiO2 by 0.05 SatO2 94 - 98% no modification of FiO2 SatO2<94% + SatO2> 90% increase FiO2 by 0.05 SatO2<90% and SatO2>86 increase FiO2 by 0.1 SatO2<86% and SatO2> 80% increase FiO2 by 0.2 SatO2<80% FiO2 at 1"
2388320|NCT03653312|Active Comparator|NMES|"2 weeks (weekdays) of Neuromuscular Electrical Stimulation of the paretic lower limb during exercise.~Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair."
2388321|NCT03653312|No Intervention|training|Participants will undergo 2 weeks of exercise every weekday. Each exercise session will last for 12 minutes and will consist of either walk or sit and raise from a chair.
2388322|NCT03653299|Experimental|Group A - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy A will receive the programs in the following order 1, 2, 3 and 4, before the tests."
2388323|NCT03653299|Experimental|Group B - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy B will receive the programs in the following order 2, 3, 4 and 1, before the tests."
2388324|NCT03653299|Experimental|Group C - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy C will receive the programs in the following order 3, 4, 1 and 2, before the tests."
2388325|NCT03653299|Experimental|Group D - Placebo, 10J, 30J and 50J|"The phototherapy will be divided in programs 1, 2, 3 and 4. One of these programs will consist in placebo and the others in active phototherapy 10J, 30J and 50J.~The subjects allocated in group Phototherapy D will receive the programs in the following order 4, 1, 2 and 3, before the tests."
2388326|NCT03653286|Experimental|NMES and Run|NMES and run
2388327|NCT03653286|Other|Only Run|Only Run
3183556|NCT00714961|Experimental|1|
3183557|NCT00714961|Placebo Comparator|2|
2388330|NCT03653260|Experimental|Lidocaine (Zingo)|0.5mg lidocaine at 20 bar pressure
2388331|NCT03653260|Placebo Comparator|Placebo|no emitted particle at 20 bar pressure, identical in external appearance to Zingo
2388333|NCT03653234|Experimental|TV-based Assistive Integrated Service|Participants assigned to the intervention group will have access to TV-AssistDem and participate in clinical visits every 6 months.
2388334|NCT03653234|No Intervention|Control|Participants assigned to the intervention group will NOT have access to TV-AssistDem and will participate in clinical visits every 6 months
2388335|NCT03653221|Experimental|standardized patients with VRNET|The medical students examine the standardized patients who have neurological deficits which presented by VRNET.
2388336|NCT03653221|Placebo Comparator|standardized patients|The medical students examine the standardized patients who have neurological deficits which presented by words or pictures.
3183558|NCT00714974|No Intervention|1|Standard of care
3183559|NCT00714974|Experimental|2|Sedation based on BIS value, oer treating physician discretion.
3183560|NCT00714987||1: High level PEEP|
3183561|NCT00714987||2: Low level PEEP|
3183562|NCT00715000|Experimental|1|SRO
3183563|NCT00715000|Active Comparator|2|classical hydration via intravenous infusion
3183564|NCT00715039|Active Comparator|lorazepam|
3183565|NCT00715039|Placebo Comparator|placebo|
3183566|NCT00715039|Active Comparator|paroxetine|
2388346|NCT03653195|Other|Pre-injury|Each participant will act as their own control. Pre-injury samples were collected.
2388347|NCT03653195|Active Comparator|Post-injury|Post-injury samples were collected at the same time and within 72 hours of injury.
2388348|NCT03653182||normal|A normal constitution condition in TCM.
3183567|NCT00715052|Experimental|1|40 consecutive one hour treatments at 1.5 ATA with 100% O2
3183568|NCT00715052|No Intervention|2|
3183569|NCT00715065||2|Healthy control subjects (who do not faint at the sight of blood)
3183570|NCT00715065||1|People who faint at sight of blood
2388353|NCT03653182||Phlagm|One of an abnormal constitution condition in TCM.
2388354|NCT03653182||Blood stasis|One of an abnormal constitution condition in TCM.
2388355|NCT03653182||Qi stagnation|One of an abnormal constitution condition in TCM.
2388356|NCT03653182||Special|One of an abnormal constitution condition in TCM.
2388357|NCT03653169|Experimental|Open-Label Active TMS|All subjects will receive open-label treatment with active Transcranial Magnetic Stimulation (TMS)
2388358|NCT03653156||Mild cognitive impairment (MCI) and its subtypes|MCI cohort consists of mild cognitive impairment subjects with memory loss as predominant symptom, including amnestic mild cognitive impairment and vascular cognitive impairment no dementia, which recruit from community population and hospital population.
2388359|NCT03653156||Sporadic Alzheimer's disease (SAD)|SAD cohort consists of mild to moderate sporadic Alzheimer's disease subjects, which recruit from community population and hospital population.
2388360|NCT03653156||Familial Alzheimer's disease (FAD)|FAD cohort consists of familial Alzheimer disease subjects with known or unknown mutations, which recruit from community population and hospital population.
2388361|NCT03653156||Vascular dementia(VaD）|VaD cohort consists of cognitive impairment subjects caused by cerebral vessel disease, including vascular dementia and mixes dementia, which recruit from community population and hospital population.
2388362|NCT03653156||Normal control|Normal control cohort consists of cognitive normal subjects with ApoE ε4 positive or negative, which recruit from community population and hospital population.
2388363|NCT03653156||Non-Alzheimer degenerative dementia|Frontotemporal dementia (FTD); or Parkinson's disease dementia (PDD); or dementia with Lewy bodies (DLB); or corticobasal degeneration (CBD); or dementia not otherwise specified.
2388364|NCT03653143|Experimental|Treatment Group|Assessment #1 Baseline Visit >> 3 month JASPER intervention (weekly) >> Assessment #2 Research Visit >> 3 month treatment as usual >> Assessment #3 Research Visit
2388365|NCT03653143|Experimental|Control/Wait-list Group|Assessment #1 Baseline Visit >> 3 month treatment as usual >> Assessment #2 Research Visit >> 3 month JASPER intervention >> Assessment #3 Research Visit
2388366|NCT03653130|Experimental|Intervention Program|Participants will receive an instrument (violin, viola, or cello). Intervention sessions will take place twice a week at the Domiciliary and once per week at the Domiciliary or at a community location (Richard L. Roudebush VA Medical Center or Regenstrief Institute). Each session will include: thirty minutes of group music instruction by an experienced music educator with skills in adult music education followed by thirty minutes of weekly adult ensemble experience.
2388367|NCT03653130|No Intervention|Usual Care Control|Usual care at VA Domiciliary including participation in Domiciliary recreational therapy electives (if eligible).
2388368|NCT03653130|No Intervention|Retrospective Chart Review|Retrospective chart reviews case-matched to intervention participants for age and biological sex factors.
2388369|NCT03653117|Experimental|TPLA|TPLA procedure
2388370|NCT03653104|Experimental|Melodica Intervention|An 8-week group intervention including twice-weekly sessions. Each session will last one hour in duration with approximately 20 minutes for instruction, 30 minutes in group music-making, and 10 minutes allocated for educational information about COPD, tobacco cessation, and pulmonary rehabilitation.
2388371|NCT03653104|Active Comparator|Education Control|A single 90-120 minute education session including the same educational information about COPD, tobacco cessation, and pulmonary rehabilitation provided to the melodica intervention group.
2388372|NCT03653104|No Intervention|Usual Care Control|Usual care at Richard L. Roudebush VA Medical Center.
2388373|NCT03653104|No Intervention|Interview Only|Semi-structured interviews will be conducted with Veterans who meet eligibility criteria, but who do not agree to participate in the intervention, to identify potential barriers to participation
2388374|NCT03653091|Active Comparator|Duodenal Mucosal Resurfacing (DMR)|Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal mucosa in an upper endoscopic procedure in patients with type 2 diabetes.
2388375|NCT03653091|Sham Comparator|Duodenal Mucosal Resurfacing Sham (Sham)|Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes.
2388376|NCT03653078|Experimental|Three dimensional printed digital guide|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using Three dimensional printed digital guide, which is a device deisgned and printed through CAD/CAM technology, it's a printed plate fit on the teeth and buccal mucosa with a channel for mini- screw insertion, mini-screw will be inserted through the plate's channel
2388377|NCT03653078|No Intervention|Conventional free hand insertion|one mini-screw will be inserted in the buccal interradicular space between upper second premolar and first molar using conventional free hand insertion of mini-screw, which is a technique using the guiding anatomy for mini-screw insertion using the driver and the operator's skill.
2388378|NCT03653052|Experimental|Durvalumab|Patients with advanced oesophageal cancer will be administered with 1500mg of durvalumab once every 4 weeks for up to 6 months.
2388379|NCT03653039|Experimental|Tritube|
2388380|NCT03653039|Active Comparator|Standard endotracheal tube|
3183571|NCT00715091|Experimental|1|continuous (daily) treatment with diclofenac cholestyramine 150 mg (Voltaren Resinate), divided into 75mg Voltaren twice daily
2388385|NCT03653000|Experimental|Patients undergoing this new block|Descriptive study about the effectiveness and the feasability of this new approach of te ultrasound guided brachial plexus blockade
2388386|NCT03652974|Experimental|sodium valproate with clozapine|"sodium valproate, dosage form: 250 mg, dosage and frequency:250 mg/d for 1 week, 500 mg/d for week 2 , 1000 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: sodium valproate with Clozapine"
2388387|NCT03652974|Experimental|Modified electroconvulsive therapy with clozapine|"12 times MECT for 12 weeks，once a week for the 12 weeks; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Device: modified electroconvulsive therapy(MECT) with Clozapine"
2388388|NCT03652974|Experimental|amisulpride|"amisulpride, dosage form: 200 mg, dosage and frequency:200 mg/d for 1 week, 400 mg/d for week 2,800 mg/d for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: amisulpride with Clozapine"
2388389|NCT03652974|Placebo Comparator|placebo|"The amisulpride and placebo tablets were identical in appearance. One placebo tablet for the first one week, two placebo tablets for the second week, four placebo tablets for weeks 3, 4, 5, 6, 7 , 8, 9, 10, 11and 12; clozapine, dosage and frequency:300~600 mg/d; duration: 12 weeks.~Intervention: Drug: placebo with Clozapine"
2388390|NCT03652961|Other|Open Label|Open Label abatacept for Intravenous Infusion Abatacept intravenous will be administered as a 30-minute intravenous infusion utilizing the weight range-based dosing. Following the initial intravenous administration, an intravenous infusion will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for a total of 7 doses.
2388391|NCT03652948|Experimental|Meru Health Ascend Program|"The Meru Health Ascend Program is an 8-week mobile application (app) based intervention that teaches cognitive-behavioral and mindfulness skills. The intervention also includes a group discussion board with the other participants in the intervention group and therapist support via chat within the app.~Study 2 is examining a revised version of the Meru Health Ascend Program that is 12 weeks long and incorporates sleep and nutrition information in addition to the 8-week program."
2388392|NCT03652935|Experimental|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) program consists of an 8-week (2.5 hr/wk) program with a 6-hour silent mindful practice retreat after the fifth week. A licensed clinical psychologist, certified as an MBSR instructor, will provide instruction to all groups. Mindfulness will be taught using breath awareness, sitting and walking meditation, and mindful yoga. Participants will be given a standardized session-by-session program workbook containing weekly objectives and assignments, as well as two practice recordings and the book, Full Catastrophe Living (Kabat-Zinn, J, 1990).
2388393|NCT03652935|Active Comparator|Health Education Series|The active comparator condition consists of an 8-week educational series, administered in group-format, and matched in duration and frequency to the MBSR program. Session topics include: 1) Understanding Breast Cancer and Risks for Breast Cancer, 2) Breast Cancer Treatment, 3) Communicating Effectively with your Health Care Providers; Keeping your Medical Records, 4) Genetic Testing and Cancer, 5) Nutrition and Cancer, (6) Cooking Demonstration, 7) Bone Health, and 8) Image and Cancer (American Cancer Society - Look Good, Feel Better). The program content and objectives were reviewed by four content experts (oncology clinicians) and two breast cancer survivors.
2388394|NCT03652922|Experimental|Propranolol|
2388395|NCT03652922|Placebo Comparator|Placebo|
2388397|NCT03652896|Experimental|anatomical liver resection|resect the tumor located liver segment or lobe
2388398|NCT03652896|Experimental|resection margin based liver resection|non-anatomical liver resection, but insure adequate resection margin
2388399|NCT03652883|Experimental|ItFits-toolkit|A generic 'Integrated Theory-based Framework for Implementation Tailoring Strategies' toolkit (the ItFits-toolkit) functions as an online self-help toolkit by which users are guided through the process of tailoring site-specific implementation strategies. The ItFits-toolkit includes four modules that implementers need to work through: 1) identifying and prioritising implementation goals and determinants of practices, 2) matching up implementation determinants to strategies, 3) designing a plan for carrying out strategies in a local context, and 4) applying strategies, and reviewing progress. In each of these four modules, evidence-informed materials such as iCBT relevant determinants of practices and implementation strategies, are included as well as methods for engaging with stakeholders.
2388400|NCT03652883|Active Comparator|Implementation as Usual|Implementation-as-Usual (IAU) refers to any existing approaches and efforts to embed and integrate iCBT within an organisation. All implementation sites included in IMA are engaged in and conducting IAU. IAU activities can be, but are not necessarily planned or guided by scientific evidence and often emerge from practice experiences and other sources of information. No standardisation in IAU across the sites is applied except for the implementation objective. That is, all implementation sites pursue the goal of increasing the number of patients treated by the iCBT service.
2388401|NCT03652870|Active Comparator|Nortriptyline|25mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2388402|NCT03652870|Active Comparator|Escitalopram|5mg tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2388403|NCT03652870|Placebo Comparator|Placebo|The placebo tablet consists of lactose and magnesium stearate. One tablet to be escalated from one tablet per day to a maximum of 4 tablets per day
2388404|NCT03652857|Experimental|Apatinib Combined With Vinorelbine|Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer
2388405|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) 1.0|
2388406|NCT03652844|Active Comparator|Allograft Adipose Matrix (AAM) Diluted|
2388407|NCT03652831|Active Comparator|Soft Tissues mobilization with Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques and Neural mobilization Techniques which involve Median, Radial and Ulnar Nerve Mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
2388408|NCT03652831|Active Comparator|Soft Tissues mobilization without Neural mobilization|"Soft Tissue Mobilization with Neural mobilization group will be assessed by spurling test and than will involved in treatment protocol i.e Cervical Traction, Hot packs, Post Isometric Relaxation Techniques.~Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
3183572|NCT00715091|Active Comparator|2|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg (Voltaren Resinate). The treatment strategy of the control intervention (on-demand) reflects current clinical practice in AS.
3183573|NCT00715143|Other|N|This treatment arm includes ceramic-on-ceramic hip device
3183574|NCT00715156||A|Subjects with mild (S1) reaction to peach fruit
3183575|NCT00715156||B|Subjects with severe reaction to peach fruit
2388414|NCT03652805|Experimental|IPL344|IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg
2388415|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fasting|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fasting condition
2388416|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fasting|Subjects will take a single Azilva 20mg Tablet under fasting condition
2388417|NCT03652792|Experimental|Azilsartan (Zhaoke) Under Fed|Subjects will take a single Azilsartan (Zhaoke) 20mg Tablet under fed condition
2388418|NCT03652792|Active Comparator|Azilsartan (Takeda) Under Fed|Subjects will take a single Azilva 20mg Tablet under fed condition
2388419|NCT03652779|Experimental|Tecarfarin 10mg|
2388420|NCT03652779|Experimental|Tecarfarin 20mg|
2388421|NCT03652779|Experimental|Tecarfarin 30mg|
2388422|NCT03652779|Experimental|Tecarfarin 40mg|
2388423|NCT03652766|Other|Daily Weight Tracking|Participants will be provided with a wireless Bluetooth-enabled bathroom scale with instructions for connecting it to their home wifi network or phone using Bluetooth and a mobile app, and will also be walked through creating an anonymous study account for app access. They will be asked to track their weight daily for 6 weeks and will receive weekly feedback on weight gain trajectories along with nutrition or physical activity messages for healthy pregnancy weight gain.
2388424|NCT03652753|Experimental|N-acetylcysteine (NAC)|Injection of N-acetylcysteine at the time of external fixation
2388425|NCT03652753|Placebo Comparator|Saline|Injection of saline at the time of external fixation
2388426|NCT03652740|Experimental|Within-Subjects Dose Conditions|Participants are not assigned to different groups/arms. All participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms.
2388427|NCT03652740|Experimental|Additional Within-Subjects Dose Conditions|"As described previously, all participants will receive the same drug conditions, but the order in which the participants receive the drug conditions will be different across participants. Thus, comparisons of the drug conditions on mood and choice will be compared within-subjects (e.g., between drug and placebo) and not between arms. We have created a second arm in the description of the trial on ClinicalTrials.gov to designate masking - this study involves administration of drug conditions in different dose sequence orders to which participants are randomly assigned."
2388428|NCT03652727|Experimental|ECG-EM Guidance|PICC insertion using electrocardiographic and electromagnetic guidance [Site~Rite® 8 Ultrasound System with integrated SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS)]
2388429|NCT03652727|Active Comparator|FX Guidance|PICC insertion using fluoroscopic guidance
2388430|NCT03652714|Experimental|Local anesthetic|
2388431|NCT03652714|Placebo Comparator|Isotonic NaCl|
2388432|NCT03652701|Experimental|Hair Up|
2388433|NCT03652701|Placebo Comparator|Placebo|
2388434|NCT03652688|Experimental|Three 0's|Observed indicators that a group member may be in trouble due identified risks were provided and if detected, they were given practical skills on implementing the 3 0's: Outreach, Options, and Out. Outreach consisted of techniques for approaching your friend and acquiring more information whether there was a problem. Options were to be employed if problems were confirmed and were designed to provide easy, simple steps to reduce risks and decrease probability of escalation of problems. Out refers to the plans the group made before entering the club that they would leave as a group to keep the group members safe. Group commitment to implement these safety steps was emphasized. Interactive and visually attractive scenes were drawn as graphic images to avoid didactic delivery.
2388435|NCT03652688|Sham Comparator|Fire Safety|Groups in the control condition were also given information on safety and the focus of this safety message was regarding fires in nightclubs. Groups were given didactic materials to read with some still images. There were a few questions for the group to address.
3183576|NCT00715169|Active Comparator|1|
3183577|NCT00715169|Placebo Comparator|2|
3183578|NCT00715182|Experimental|TKI258|
3183579|NCT00715195|Experimental|1|Cognitive-behavioral therapy : 50 patients planned
2388440|NCT03652649|Experimental|3:1 Ketogenic Complete Meal Replacement|Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet
2388441|NCT03652636|Other|One: Patient population with hepatic lesion(s)|Patient scheduled to get MRI will also be asked to receive an ultrasound of the liver
2388442|NCT03652623|Experimental|TDF/FTC and cs-HT|Transgender youth will simultaneously take TDF/FTC and cs-HT. TW will take oral estradiol +/- spironolactone and TM will take subcutaneous testosterone. In order to ensure adherence to TDF/FTC, daily DOT procedures will be employed.
3183580|NCT00715195|No Intervention|2|50 patients planned
3183581|NCT00715221||1|Normal Weight
2388445|NCT03652597|Active Comparator|Left|Subjects are ascribed to left hemispheric stimulation
2388446|NCT03652597|Active Comparator|Right|Subjects are ascribed to right hemispheric stimulation
2388447|NCT03652584|Experimental|High Protein Diet|Low glycemic index dietary plan with 1.6 g/kg/day of protein for 6 months
2436583|NCT03321968|Experimental|Lot 3|Quadrivalent VLP Influenza Vaccine
3183582|NCT00715221||2|Obese without diabetes
3183583|NCT00715221||3|Obese with diabetes
3183584|NCT00715234|Experimental|Reminder/recall notices for vaccines|This group will receive up to 4 recall messages (both letters and computer-generated phone messages) reminding them to get their vaccines. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
2388448|NCT03652584|Active Comparator|Control Diet|Low glycemic index dietary plan with 0.8 g/kg/day of protein for 6 months
2388449|NCT03652571|Experimental|Nortriptyline|"Nortriptyline in an escalating dose regimen:~Week 1-2: 10mg daily Week 3-4: 25mg daily Week 5-12: 50mg daily"
2388450|NCT03652571|Placebo Comparator|Placebo|Placebo
2388451|NCT03652558|Experimental|ozone group|topical gaseous ozone was applied into periodontal pockets during active periodontal therapy
2388452|NCT03652558|No Intervention|non-ozone group|Only active periodontal therapy was performed
2388453|NCT03652545|Experimental|TAA-T|"Three different dosing schedules will be evaluated.~Dose Level One: 2 x 107 cells/m2 Dose Level Two: 4 x 107 cells/m2 Dose Level Three: 8 x 107 cells/m2~Group A patients (DIPG): The first TAA-T dose will be infused any time more than or equal to 14 days after completion of radiotherapy.~Group B patients (other recurrent/progressive/refractory CNS tumors): TAA-T will be infused any time more than or equal to 14 days after completing most recent course of conventional (non-investigational) therapy for their disease AND after appropriate washout periods as detailed in eligibility criteria.~Ideally, patients should not receive other systemic antineoplastic agents for at least 42 days after the infusion of TAA-T, although such treatment may be added if deemed critical for patient care by the attending physician."
2388454|NCT03652532|Experimental|Alternate Day Fasting and Exercise|
2388455|NCT03652532|Experimental|Alternate Day Fasting|
2388456|NCT03652532|Experimental|Exercise|
2388457|NCT03652532|No Intervention|Control|regular eating and exercise habits for 8 weeks
2388458|NCT03652519|Experimental|High-intensity Interval Training (HIIT)|Participants of the HIIT group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the HIIT group will perform 5x one-and-a-half Minute high-intensive exercise bouts at 95-100% of their HRmax followed by active breaks of unloaded pedalling over 2 minutes with the aim to achieve 60% HRmax.
2388459|NCT03652519|Active Comparator|Moderate Continous Training (ST)|Participants of the ST group will exercise three times per week over a period of three weeks (inpatient rehabilitation) on a cycle ergometer. Exercise intensity will be regulated and heart rate controlled based on the achieved maximum heart rate (HRmax) assessed during the initial Cardiopulmonary Exercise Testing. Each exercise session will last 30 minutes and will be started and finalized with three minutes at low intensity (50% HRmax, warm-up / cool-down). During each exercise session, participants of the ST group will exercise 30 minutes continuously at 65% of HRmax. This moderate continous training program represents the standard care at the local rehabilitation clinic.
2388460|NCT03652506|Active Comparator|Group A|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2388461|NCT03652506|Active Comparator|Group E|Thoracic Epidural block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2388462|NCT03652506|Active Comparator|Group Q|Ultrasound guided unilateral anterior Quadratus Lumborum block +The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2388463|NCT03652493|Experimental|CARBOPLATIN|CARBOPLATIN in Intraveinous Dose AUC 5 according to Calvert every 3 weeks, for a duration of 6 to 9 cycles
2388464|NCT03652467|Experimental|Deferoxamine|Patients are treated with deferoxamine and conventional TACE.
2388465|NCT03652467|Active Comparator|Conventional TACE|Patients are treated with conventional TACE.
2388466|NCT03652454|Experimental|micro-osteoperforation|Propel device (ABD)
2388467|NCT03652454|Other|conventional treatment|conventional fixed appliance treatment
2388468|NCT03652441|Experimental|Maintenance|Brentuximab Vedotin will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
2388469|NCT03652428|Other|Pancreatic Proton Therapy With Concurrent Gem + Nab-paclitaxel|"Part I:~Gemcitabine + nab-paclitaxel:~• Administered per institutional standard every 7 days for 3 weeks~Part II:~Hypofractionated ablative pancreatic proton radiation therapy 67.5 Gy fractions once per day Monday - Friday for 3 weeks, for a total of 15 fractions.~Part III:~Surgery, if resectable, then adjuvant chemo per discretion of MD or no further therapy~OR~Chemo per discretion of MD if not resectable"
2388470|NCT03652389|Experimental|MJS DIABETES|will receive and respond to daily PROs via ttext messages and report SMBG (if insulin-dependent) over the course of the 12-month study.
2388471|NCT03652389|Active Comparator|Usual Care|Standard Diabetes Treatment
2388472|NCT03652376|Experimental|Benralizumab|Patients will be treated with Benralizumab 30 mg s.c. every 4 weeks (three times).
2388473|NCT03652363|Placebo Comparator|Placebo|Placebo administered via convection enhanced delivery
2388474|NCT03652363|Experimental|glial derived neurotrophic factor|Recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF), administered via convection enhanced delivery
2388475|NCT03652350|Experimental|Use CT-guided microwave ablation in Ground Glass Nodules ≤ 3cm|Patients with Ground Glass Nodules ≤ 3cm were treated with CT-guided microwave ablation
2388476|NCT03652337|Experimental|BlephEx|The subjects who are enrolled in this arm will undergo electronic lid margin debridement using the BlephEx instrument.
2388477|NCT03652337|Experimental|Manual debridement|The subjects who are enrolled in this arm will undergo manual lid margin debridement using a stainless steel ophthalmic golf spud.
2388478|NCT03652324|Other|randomized|
2388479|NCT03652311|Experimental|TNM Device Group|In this arm participants will receive 5 sessions of twice daily treatments of 15 minutes of caloric vestibular stimulation (CVS) using the ThermoNeuroModulation TNM Device. In addition, participants will continue with the standard therapy that they are receiving.
2388480|NCT03652311|Sham Comparator|Sham CVS Group|In this arm participants will receive 5 sessions of twice daily sessions of 15 minutes of sham stimulation with the ThermoNeuroModulation TNM Device. The ThermoNeuroModulation TNM device will be fitted and turned on in a random paradigm that has no demonstrated efficacy. Participants will continue with the standard therapy that they are receiving.
2390175|NCT03640689|Active Comparator|Control Group|Endovenous ablation of Great Saphenous Vein
2388481|NCT03652298|Experimental|Experimental arm|In the experimental group, participants will perform vagal breathing (VB), followed by the MSI, followed again by VB. The VB component will guide participants how to perform deep slow vagal breathing by inhaling and counting 1-5, holding their breath and counting 1-2, and exhaling and counting 1-5, during 2-5 minutes. The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).
2388482|NCT03652298|Other|Control Arm|Participants in the control group will receive support and attention (usual care) and will be invited to recall announcement of the incurable disease progression. More precisely, they will be invited to express their associated thoughts and feelings, being free to talk about their experience, and the psychologist will react with empathy and support.
2388483|NCT03652285|Experimental|Esophageal stent implantation (UAS-RBS implantation)|Esophageal stent implantation (UAS-RBS implantation) at J0, removal after 6 months and follow-up for 6 months
2388484|NCT03652272|Experimental|EMC2|"Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications:~Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
2388485|NCT03652272|No Intervention|Usual Care|Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
2388486|NCT03652259|Experimental|Cohort 1: SRP-9003|Participants will receive a single intravenous (IV) infusion of SRP-9003 at a prespecified dose.
2388487|NCT03652259|Experimental|Cohort 2: SRP-9003|Participants will receive a single IV infusion of SRP-9003. Dose will be determined based on the findings from Cohort 1.
2388488|NCT03652233|Experimental|Afatinib and Nivolumab|
2388489|NCT03652220|Experimental|Intervention|"8 weeks Minimal treatment + MBLM 16 weeks Multimodal specific treatment + MBLM Consolidation~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2388490|NCT03652220|Active Comparator|Control I|"8 weeks Minimal treatment 16 weeks Multimodal specific treatment~Definitions Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2388491|NCT03652220|Active Comparator|Control 2|"Definitions 24 weeks Multimodal specific treatment~Minimal treatment: drug continuation under medical supervision Multimodal specific treatment: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR MBLM: 8-week course Meditation Based Lifestyle Modification MBLM-Consolidation: weekly Mantra-Meditation, monthly Life-Ethics"
2388492|NCT03652207|Placebo Comparator|Sucrose|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
2388493|NCT03652207|Experimental|Palatinose(TM)|Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
2388494|NCT03652194||Reference strain ATCC|1 strain sensitive to all antifungals
2388495|NCT03652194||Clinical isolates sensitive to all antifungal agents|10 clinical isolates sensitive to all
2388496|NCT03652194||Echinocandin-resistant clinical isolates|10 echinocandin-resistant clinical isolates (Eucast, Caspofungin > 8µg/ml)
3183585|NCT00715234|No Intervention|Usual Care|This group will receive usual care. There are 4 separate study groups: 1) private pediatric patients 2) public pediatric patients 3) school-based health center patients and 4) family medicine patients.
2388498|NCT03652168|Experimental|Meditation Group|Headspace application: Participants in the intervention group will use a digitally-based mindfulness intervention Headspace app (Basics + Stress packs) will be used for 10 minutes a day over the course of 8 weeks.
2388499|NCT03652168|No Intervention|No intervention, control group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
2388500|NCT03652155||Orthognathic Surgery Patients|The study cohort will be patients undergoing orthognathic surgery for correction of an existing dentofacial deformity.
2388501|NCT03652142||Recurrent/metastatic HNSCC|"The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab. Tumor biopsies will be performed at baseline, after the second cycle and at progression with appropriate written informed consent and the samples will be analyzed. Biomarker research will be performed.~The patients will receive intravenously nivolumab at dose of 240 mg every 2 weeks (240mg q2w). The patients will undergo tumor biopsy at baseline and within 24-72h after the second administration of treatment, and at progression of their disease."
2388502|NCT03652129|Experimental|Laser Group|Disinfection using biostimulating LASER
2388503|NCT03652129|Experimental|Nano irrigant Group|Disinfection using Nano irrigant
2388504|NCT03652129|Active Comparator|Conventional irrigation protocol group|disinfection using normal irrigation protocols
2388505|NCT03652116|Active Comparator|Bupivacaine Group|Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
2388506|NCT03652116|Active Comparator|Pethidine Group|Patients delivered by cesarean section followed by wound infiltration by pethidine.
2388507|NCT03652103|No Intervention|GCont|Only dressing will be applied to patients without actually nerve catheter performed
2388609|NCT03651466|Experimental|Cohort 1: GX-G6 + placebo|Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)
2388508|NCT03652103|Experimental|GBlock|"Ultrasound Guided Erector Spinae Plane Block Catheter will be applied: 20ml Bupivacaine 0.25% Injectable Solution* will be administered initially.~20 ml Bupivacaine %0.25 Injectable Solution** will be administered 30 minutes before ambulation at postoperative day(POD) 0 and before removal of nephrostomy at POD 2~*10ml %0,5 Bupivacaine will be diluted with 10ml Saline solution."
2388509|NCT03652090||cystic fibrosis patients|Cystic fibrosis patients carrying to 2 CFTR mutations undergoing cell sampling
2388510|NCT03652090||healthy heterozygotes|healthy heterozygotes carrying 1 CFTR mutations undergoing cell sampling
2388511|NCT03652090||healthy control|subject with no evidence of any symptoms compatible with Cystic Fibrosis undergoing cell sampling
3142924|NCT00003793||Increased Risk Of T-MDS/AML before/after Therapy|Determine clonal hematopoiesis develops in children receiving high intensity alkylating agent chemotherapy for sarcomas. Determine development of clonal hematopoiesis is associated with increased frequency of t-MDS/AML. Determine measurement of somatic cell mutation frequency, measured by the glycophorin A (GPA) assay prior to and after chemotherapy will predict individuals at increased risk of t-MDS/AML. Identify individuals with ras gene mutations in normal peripheral blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML blood cells after therapy, and whether the identification of such mutations is associated with increased risk of t-MDS/AML.
3142925|NCT00003796|Experimental|Arm I|Patients receive irofulven IV over 30 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
3142926|NCT00003799|Experimental|Treatment (chemotherapy, radiotherapy, surgery)|"Patients receive fluorouracil IV continuously with concurrent radiotherapy for 5.5 weeks. Patients also receive oxaliplatin IV over 2 hours on day 1 of weeks 1, 3, and 5.~Patients undergo surgery 6-8 weeks after completing preoperative chemotherapy and radiotherapy. The surgical procedure is determined by the extent of the tumor before preoperative therapy. The type of operative procedure may be abdominoperineal resection, low anterior resection (LAR), or LAR/coloanal anastomosis.~Postoperative chemotherapy begins within 6 weeks after surgery, comprising leucovorin calcium and fluorouracil IV on days 1-5. Treatment repeats every 21 days for 4 courses."
3142927|NCT00003800|No Intervention|Laboratory/CT evaluation|Observation following orchiectomy
2388519|NCT03652038|Experimental|TD-8236 for SAD (Part A)|6 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive TD-8236
2388520|NCT03652038|Placebo Comparator|Placebo for SAD (Part A)|2 out of 8 subjects per cohort (up to 5 cohorts) will be randomized to receive placebo
2388521|NCT03652038|Experimental|TD-8236 for MAD (Part B)|6 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive TD-8236.
2388522|NCT03652038|Placebo Comparator|Placebo for MAD (Part B)|2 out of 8 subjects per cohort (up to 6 cohorts) will be randomized to receive placebo.
2388523|NCT03652038|Experimental|TD-8236 for Biomarker (Part C)|8 subjects in each of 2 biomarker cohorts will be randomized to receive TD-8236.
2388524|NCT03652038|Placebo Comparator|Placebo for Biomarker (Part C)|8 subjects in 1 biomarker cohort will be randomized to receive placebo.
2388525|NCT03652025|Experimental|Study group|perimenopausal women
2388526|NCT03652012|Experimental|Mild Cognitive Impairment|"The following revised Mayo Clinic criteria for MCI (Petersen, et al. 2014) will be used: (1) cognitive concern expressed by a physician, informant, participant, or nurse; (2) impairment in 1 or more cognitive domains (memory, language, visuospatial skills, or executive functions); (3) essentially normal functional activities; and (4) absence of dementia. Individuals with MCI will have Mini-Mental State Exam (MMSE, Appendix 19) scores between 18 and 23 (inclusive) and have a Clinical Dementia Rating Scale score of 0.5.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
2388527|NCT03652012|Active Comparator|Healthy Controls|"Participants who are matched for age and gender.~This group will undergo Transcranial Magnetic Stimulation (TMS) protocol."
2388528|NCT03651999||dream workshop|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse anesthetist, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; The nurse anesthetist explains the hospitalization process and will help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...); the child will be able to customize his mask and choose the blanket he wants to take along; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
2388529|NCT03651999||control|"No dream workshop"
2388530|NCT03651986||Prospective Cohort|This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.
2388531|NCT03651973|Experimental|With learning workshops|Patients in experimental arm will attend learning workshops, one before breast cancer surgey and one after surgery. Patients will be educated by physiologist to self massages and self stretching. Each workshop will last around 2 hours.
2388532|NCT03651973|Other|Without learning workshops|Standard follow-up. Patients randomized in this arm won't attend Learning workshops and will be followed in a standard way.
2388533|NCT03651960|Experimental|Robot|ROBOT PROTOTYPE
2388534|NCT03651947|Experimental|QL1206|QL1206 injection (120mg) by subcutaneous injection once on the first day.
2388535|NCT03651947|Active Comparator|Xgeva®|Xgeva® injection (120mg) by subcutaneous injection once on the first day.
2388536|NCT03651934|Experimental|Normal iron|
2388537|NCT03651934|Experimental|Weak iron|
2388538|NCT03651934|Experimental|Normal selenium|
2388539|NCT03651934|Experimental|Weak selenium|
2388540|NCT03651921|No Intervention|Usual care|Usual follow-up care offered in the breast centers after primary treatment by breast care team (e. g. breast care nurses, gynaecologist, oncologist, psychologist).
2388541|NCT03651921|Experimental|Usual care and CTS-BC-CH|CTS-BC-CH as 7 weekly group session à 2.5 - 3 hours.
2436672|NCT03321227|Experimental|Egg yolks|2 egg yolks as a snack
2388542|NCT03651908|Experimental|Interventional|Interventional The Group A subjects will be treated with conventional flap surgery.After reflection of the full thickness flap,the intrabony defects will be debrided and Bioactive silicate graft mixed with PRF will be used as graft material to fill the defects.
2388543|NCT03651908|Active Comparator|Interventional comparator|Group B patients will also be treated by conventional flap surgery,employing a full thickness flap technique.The intrabony defects will be filled with Bioactive silicate only.
2388544|NCT03651895|Active Comparator|Treatment Group|Metformin 500mg bd
2388545|NCT03651895|Placebo Comparator|Placebo Group|Placebo
2388546|NCT03651882|Active Comparator|Oxytocin|
2388547|NCT03651882|Active Comparator|Carbetocin|
2388548|NCT03651869|Experimental|Condition 1|
2388549|NCT03651869|Experimental|Condition 2|
2388550|NCT03651869|Experimental|Condition 3|
2388551|NCT03651869|Experimental|Condition 4|
3183586|NCT00715247||Affected Population|Patients suspected to have one of the following blood disorders: polycythemia vera, myelofibrosis or essential thrombocythemia.
2388553|NCT03651843||Healthy subjects|
2388554|NCT03651830|Experimental|Prosthetic Foot Emulator|The Prosthetic Foot Emulator (PFE) is a customizable robotic prosthetic foot that can mimic commercial feet to predict how individual patients will respond to candidate feet. Participants will walk with the PFE using three different modes (emulating three commercial feet) under different walking conditions.
2388555|NCT03651830|Active Comparator|Commercially available prosthetic feet|Participants will walk under different walking conditions using three different commercial prosthetic feet.
2388556|NCT03651817|Active Comparator|6ml/kg volume|Patients ventilation will provided with a tidal volume of 6ml/kg
2388557|NCT03651817|Active Comparator|8ml/kg volume|Patients ventilation will provided with a tidal volume of 8ml/kg
2388558|NCT03651804|Active Comparator|Control Group|"The control group will receive usual care for treatment of vertebral compression fractures, which will consist of but not limited to: physical therapy, opioids, NSAIDs, acetaminophen and bisphosphonates as indicated. They will have the option of crossing over (see Crossover Group) at twelve weeks."
2388559|NCT03651804|Active Comparator|Treatment Group|The treatment group will receive usual care for treatment and the treatment procedure comprised of the Medial Branch Block and Radiofrequency Ablation. In cases where a medial branch nerve block has confirmed there is pain relief, a radiofrequency ablation is considered. These patients will continue their usual care therapy as well.
2388560|NCT03651804|Active Comparator|Crossover Group|This group will comprise of patients within the control group who after 12 weeks of usual therapy will have the option of crossing over to the treatment group. Once crossed over, their treatment and course and measurements will be identical to that of the treatment group.
2388561|NCT03651791|Experimental|USPIO labeled MSC injection|USPIO labeled MSC injection
2388562|NCT03651765|Experimental|Setmelanotide|Once daily subcutaneous injection
2388563|NCT03651752|Other|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
2388564|NCT03651739||TKR Patients|Any patient undergoing total knee arthroplasty and will use the Knee Connect during their knee classes at the Holland Centre
2388565|NCT03651726|Experimental|THX-110 (dronabinol plus PEA)|"Double-blind phase and extension open label phase:~Dose range of 2.5 mg to 10 mg dronabinol (1 to 4 capsules) plus 800 mg PEA (2 tablets) taken orally once daily; starting dose is 2.5 mg dronabinol plus 800 mg PEA. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
2388566|NCT03651726|Placebo Comparator|Placebo|"Double-blind phase:~Range of 1 to 4 dronabinol placebo capsules plus 2 PEA placebo tablets taken orally once daily; starting dose is 1 dronabinol placebo capsule plus 2 PEA placebo tablets. Up-titration is performed within maximal 3 weeks. The titration phase is followed by a maintenance phase of 9 weeks at stable dose."
2388567|NCT03651713|Experimental|GLU+EX|Subjects will consume a 75g glucose beverage three times daily for seven days while participating in five structured aerobic exercise sessions throughout the experimental protocol.
2388568|NCT03651713|Active Comparator|GLU|Subjects will consume a 75g glucose beverage three times daily for seven days without participating in structured aerobic exercise.
2388569|NCT03651700|Active Comparator|Active TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz active TMS will be delivered to the inferior pars triangular. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
2388570|NCT03651700|Sham Comparator|Sham TMS|There will be 10 TMS sessions over 2 consecutive weeks in which 20 minutes (1200 pulses) of 1 Hz sham TMS will be delivered to the inferior pars triangular. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
2388571|NCT03651674|Active Comparator|ECT treatment|Patients received bilateral temporal modified ECT (MECT) for three weeks,four times a week. Meanwhile, they also had antipsychotic drugs.
2388572|NCT03651674|Sham Comparator|Drug treatment|Patients only received antipsychotic drugs during observation period.
2388573|NCT03651661|Active Comparator|nasal insulin|160 U of human insulin as nasal spray
2388574|NCT03651661|Placebo Comparator|nasal placebo|placebo as nasal spray
2388575|NCT03651648|Experimental|SENSITACT System ON|As soon as the early signs of an apnea-bradycardia are detected, the SENSITACT controller sends a trigger signal to the PASITHEA stimulator that immediately activates kinesthetic stimulation
2388576|NCT03651648|Sham Comparator|SENSITACT System OFF|The SENSITACT controller doesnt send any trigger signal to the PASITHEA stimulator even if an early sign of an apnea-bradycardia is detected.
2388577|NCT03651635||Medical ICU Patients|All patients admitted to the medical intensive care unit of the University hospital of Zurich during the recruitment period
2388578|NCT03651622|Experimental|Hypocaloric, low carbohydrate|Behavioral intervention to include lifestyle counseling on hypocaloric, low carbohydrate diet (15-20% calories from carbohydrate, 59-63% as total fat (<10% saturated fat, at least 37% monounsaturated fat, remaining as polyunsaturated fat). Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2388579|NCT03651622|Experimental|Hypocaloric, moderate low fat|Behavioral intervention to include lifestyle counseling on hypocaloric, moderate low fat diet (30% calories from fat) weight management based on the Look AHEAD study. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2388580|NCT03651622|Experimental|Mediterranean, no caloric restriction|Behavioral intervention to include lifestyle counseling on selecting a healthy Mediterranean diet, no caloric restriction. Using a priori decision rules at 3.5 and 7 months post-initial randomization, those for whom the diet assigned is not acceptable or is not effective will be re-randomized.
2388581|NCT03651609|Experimental|UNE at HUA_HUA release|Patients with UNE under the HUA randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. Control neurological examination will be performed every 3 months and identical protocol as at the time of diagnostic evaluation at 1 year follow-up.
2388582|NCT03651609|Active Comparator|UNE at HUA_conservative treatment|Patients with UNE under the HUA randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. In order to prevent deterioration in conservatively treated group of patients with UNE at HUA control neurological examination will be performed every 3 months. Criteria for surgical HUA release will be clinical deterioration or lack of clinical improvement after 12 months. Prior to surgical HUA release and at 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2388583|NCT03651609|Experimental|UNE at RTC_HUA release|Patients with UNE in the RTC groove randomly distributed for simple decompression of the ulnar nerve. Patients will also receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2388584|NCT03651609|Active Comparator|UNE at RTC_conservative treatment|Patients with UNE in the RTC groove randomly distributed for conservative treatment. Patients will receive pictured recommendations with descriptions, which limb positions should be avoided. At 1 year follow-up identical protocol as at the time of diagnostic evaluation will be performed.
2388585|NCT03651596|Active Comparator|Standard mHealth Messaging|Individuals randomized to the Standard mHealth Messaging Group will receive a standard messaging intervention that has shown some efficacy in improving adherence in other samples.
2388586|NCT03651596|Experimental|mHealth Messaging Intervention|Individuals randomized to the mHealth Messaging Intervention Group will receive the newly developed messaging intervention.
2388587|NCT03651583|Other|Pilot Trial|Behavioral Intervention Kiko exercises-combines breathing and movement all study subjects no placebo or control group
2388588|NCT03651570|Experimental|PTSD Coach|PTSD Coach is a mobile mental health app developed by US Veterans Affairs translated into French by Veterans Affairs Canada in partnership with the Department of National Defence and the Canadian Mental Health Association. It was developed for a male population (92% of veterans are men), as is predominantly found in HNC, and addresses the issue of mental health and stigma as found in our HNC patients. PTSD Coach can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self-Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module. The content of the first and last modules were adapted to the oncological population.
2388589|NCT03651570|Placebo Comparator|Game application|Patients will be assigned to three apps involving playing a game (i.e., Candy Crush, Tetris, or Solitaire), during the waiting time before and between medical treatments in the hospital, on the same weekly schedule as the experimental group. The game apps contain no element of intervention and were selected based on popularity and capacity to interests.
2388590|NCT03651570|No Intervention|Usually Care Control Group|The Otolaryngology - Head and Neck Surgery (OHNS) Departments do not offer systematic interventions on anxiety and self-management, neither does any intervention address stigma. However, participating recruitment centres are already offering a best-of-care approach with well-established psychosocial oncology services, including psychiatrists, psychologists, social workers, nurses, and volunteers. All participants will be free to use hospital- or community-based support throughout the study, which will be tracked in all groups via questionnaire and chart review.
2388591|NCT03651557|Experimental|Neu2000KWL high dose|
2388592|NCT03651557|Experimental|Neu2000KWL low dose|
2388593|NCT03651557|Placebo Comparator|saline|
2388594|NCT03651544|Experimental|Group 1 (GamFluVac dose1)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) x 1010 VP/dose.
2388595|NCT03651544|Experimental|Group 2 (GamFluVac dose2)|Total amount of recombinant pseudo-adenoviral particles (1.0 ± 0.5) x 1011 VP/dose
2388596|NCT03651544|Experimental|Group 3 (GamFluVac dose3)|The total number of recombinant pseudo-adenoviral particles (2.5 ± 1.25) × 1011 VP/dose
2388597|NCT03651531|Active Comparator|insulin|
2388598|NCT03651531|Active Comparator|insulin and metformin|
3183587|NCT00715247||Healthy Female Controls|Healthy females who do not have the blood disorders; Polycythemia Vera, Essential Thrombocythemia and/or Myelofibrosis.
3183588|NCT00715260||UP Patients on HD|Uremic Pruritus (UP) patients maintained on hemodialysis (HD)
3183589|NCT00715273|Active Comparator|1 - single therapy group|Participants will receive atorvastatin, placebo niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the single therapy group.
3183590|NCT00715273|Experimental|2 - double therapy group|Participants will receive atorvastatin, niacin, and placebo colesevelam. The treatment target for LDL-C will be ≤80 mg/dl for the double therapy group.
2388849|NCT03649802|Placebo Comparator|Low dose Vitamin D-800 IU|Intervention includes low dose arm-800 IU given daily
2388610|NCT03651466|Experimental|Cohort 2: GX-G6 + placebo|Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)
2388611|NCT03651466|Experimental|Cohort 3: GX-G6 + placebo|Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)
2388612|NCT03651466|Experimental|Cohort 4: GX-G6 + placebo|Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)
2388613|NCT03651466|Experimental|(Optional) Cohort 5: GX-G6 + placebo|Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)
2388614|NCT03651466|Experimental|(Optional) Cohort 6: GX-G6 + placebo|Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)
2388615|NCT03651453|Active Comparator|Standard Care|Participants will receive standard information about harm reduction as available at the drug treatment centers.
2388616|NCT03651453|Experimental|Decision aid|Participants in this arm will receive the adapted decision aid for PrEP.
2388617|NCT03651440|Experimental|lumbar stabilization training|lumbar stabilization training exercises
2388618|NCT03651440|Experimental|PNF training|PNF training exercises
2388619|NCT03651440|Experimental|physical therapy|HP,TENS US
2388620|NCT03651440|Sham Comparator|control|NO APPLİCATİON
2388621|NCT03651427|Experimental|Transgender Women|"Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.~If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.~After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition."
2388622|NCT03651414||Control|Patients hospitalized ab initio in Internal Medicine or similar for at least one night
2388623|NCT03651414||Outlier|Patients spending at least one night in a ward different from Internal Medicine despite the presence of medical diseases, due to lack of available beds
2388624|NCT03651401||Subacromial impingement syndrome|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
2388625|NCT03651401||partial rotator cuff tears|Participants were assessed for SME, pain (rest, activity, night, measurement), shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
2388626|NCT03651401||age gender matched healthy controls|Participants were assessed for SME, shoulder girdle and scapular muscle strengths and upper extremity function (FIT-HaNSA).
2388627|NCT03651388||Patient|Patient with a new phenotype combining premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia
2388628|NCT03651388||Related parties of the 1st degree|1st degree related family of Group A patient
2388629|NCT03651375|Experimental|Sequential chemoradiotherapy|1xAI (doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm) + 5x5 Gy radiotherapy + 2xAI + surgery
2388630|NCT03651349|Placebo Comparator|Placebo control|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388631|NCT03651349|Experimental|50 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388632|NCT03651349|Experimental|100 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388633|NCT03651349|Experimental|150 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388634|NCT03651349|Experimental|225 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388635|NCT03651349|Experimental|300 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388636|NCT03651349|Experimental|400 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388637|NCT03651349|Experimental|525 mg, BID|Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts consisting of 8 subjects each.
2388638|NCT03651336|Other|Single-arm longterm follow-up ARGOS-IO Sensor Pressure System|The ARGOS-IO sensor was already implanted in a previous study as ARGOS-01 or ARGOS-02.
2388639|NCT03651310|No Intervention|Control Group|waiting in preoperative area without music listening.
2388640|NCT03651310|Active Comparator|Music Listening Group|The music listening group will be given a set of noise canceling headphones and an MP3 player with multiple tracks representing different music genres to use while in preoperative area.
2388641|NCT03651297|Experimental|Younger Adults|First group will include 20 young adults with no history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
2388642|NCT03651297|Experimental|Older adults|Second group will include 20 older adults with a self-reported history of falls or fear of falling. They will complete both interventions: Balance Training with Fall-Arrest Harness and Balance Training with Adjustable Harness.
2388643|NCT03651284|Experimental|Aim2Be Live Coach|Aim2Be app with Live Coach + Fitbit + BMI tracking tools
2388644|NCT03651284|Other|Aim2Be Waitlist|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools for three months, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
2388645|NCT03651271|Experimental|"Hot tumors for Advanced Metastatic Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
2388646|NCT03651271|Experimental|"Cold tumors for Advanced Metastatic Cancer"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
2391049|NCT03634774|Experimental|Step 1 CHOICE+|Receives the intervention first
2388647|NCT03651271|Experimental|"Hot tumors for Advanced Prostate Cancer"|Participants with ≥ 15% CD8 cells in their tumor biopsies (ie, CD8 high tumors) will be treated with single-agent nivolumab. At PD, participants will be allowed to add ipilimumab.
2388648|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort A"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
2388649|NCT03651271|Experimental|"Cold tumors for Advanced Prostate Cancer Cohort B"|Participants with < 15% CD8 cells in their tumor biopsies (ie, CD8 low tumors) will be treated with nivolumab in combination with ipilimumab.
2388650|NCT03651258||Experimental group|patient who can benefit from the ALIJEU for certain meals
2388651|NCT03651258||Group of witnesses|patient who did not benefit from the ALIJEU
2388652|NCT03651245||Participants with suspicion for Alpha-Mannosidosis|Participants with suspicion for Alpha-Mannosidosis based on their clinical symptoms aged from 2 months to 18 years
2388653|NCT03651232|Experimental|yoga|weekly prenatal yoga group class
2388654|NCT03651232|Active Comparator|support|weekly group support class
2388655|NCT03651219|Experimental|experimental group|Patients use Apatinib Mesylate tablets combined with Irinotecan.
2388656|NCT03651219|Active Comparator|controlled group|Patients use Irinotecan
2388660|NCT03651193||AOSD|Patients fulfill Japan's Yamaguch AOSD classification
2388661|NCT03651193||Control|Use 1:1 group matching, should meet the following condition -s : same gender as matching case; same age as matching case or the difference ranges within 1 year; no Immune related diseases (e.g. Psor -iasis, Systemic Lupus Erythematos -us, Dermatomyositis, Scleroderma, Rheumatoid Arthritis, Type 1 Diabet -es, Behcet's disease, Sjogren's Syndrome, Hyperthyroidism, etc.); no family history of immune related diseases.
2388662|NCT03651180||Amphilimus eluting stent|Diabetic patients treated with Cre8 Amphilimus eluting stent
2388663|NCT03651180||Non Amphilimus eluting stent|Diabetic patients treated with any other drug eluting stent
3142928|NCT00003812|Experimental|chemotherapy + radiation therapy|Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 1. Filgrastim (G-CSF) is administered subcutaneously every day starting on day 6 until blood counts recover. The course is repeated once beginning on day 22. After restaging, patients begin thoracic radiotherapy daily, five days per week, for 6-7 weeks. On the same day that radiotherapy begins, patients receive carboplatin IV over 1 hour (day 43) and etoposide IV over 1 hour daily for 3 days (days 43-45). The consolidation chemotherapy is repeated every 21 days for a total of 3 courses. Patients with stable or responding disease undergo prophylactic cranial irradiation. Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then at least every year.
3142929|NCT00003819|Experimental|vaccine|This is a dose escalation study. Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19. Cohorts of 5 patients each receive escalating doses of TF(c)-KLH vaccine until the optimal dose, based on antibody response, is reached. Patients are followed monthly for 6 months, then every 3 months for 1 year.
2388666|NCT03651141|Experimental|Neurodynamic Sliding|neurodynamic sliding consists of 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets.
2388667|NCT03651141|Experimental|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
2388668|NCT03651141|Sham Comparator|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
3142930|NCT00003824|Experimental|cipro|ciprofloxacin
3142931|NCT00003824|Experimental|ceph|cephalexin
2388671|NCT03651115||Neonates with gentamicin|
2388672|NCT03651115||Neonates with vancomycin|
2388673|NCT03651102|Experimental|Patients Receiving Thalidomide Therapy|All the study patients will be given thalidomide at an average dose of 2mg/kg/day (range 1-3mg/kg/day). The patients will be followed at 4 weeks interval by a haematologist for monitoring of potential side effects and for evaluation of clinical and laboratory response.
2388674|NCT03651089|Active Comparator|SP16 0.0125|0.0125 mg/kg of SP16 will be administered by subcutaneous injection once
2388675|NCT03651089|Active Comparator|SP16 0.050|0.050 mg/kg of SP16 will be administered by subcutaneous injection once
2388676|NCT03651089|Active Comparator|SP16 0.20|0.20 mg/kg of SP16 will be administered by subcutaneous injection once
2388677|NCT03651089|Placebo Comparator|placebo|Placebo (sterile saline) will be administered by subcutaneous injection once
2388678|NCT03651076|Experimental|Traxi panniculus retraction group|The method of panniculus retraction will be the Traxi panniculus retraction (Clinical Innovations, LLC) by the provider.
2388850|NCT03649802|Active Comparator|High dose Vitamin D-5000 IU|Intervention includes high dose arm-5000 IU given daily
3142932|NCT00003828|Experimental|vinorelbine|vinorelbine 30 mg/m2/week IV bolus over approximately 6-10 minutes
2388679|NCT03651076|No Intervention|Standard of care|Standard methods of panniculus retraction as determined by individual provider (including medical taping, extra personnel for retraction)
3183591|NCT00715273|Experimental|3 - triple therapy group|Participants will receive atorvastatin, niacin, and colesevelam. The treatment target for LDL-C will be ≤60 mg/dl for the triple therapy group
3183592|NCT00715286|Active Comparator|A|Conventional arm: primary surgery followed by chemotherapy
3183593|NCT00715286|Experimental|B|Neoadjuvant chemotherapy followed by interval debulking
3183594|NCT00715312|Experimental|A|
2388686|NCT03651037|Experimental|Thrivors+BH|For Thrivors+BH, a module will be developed for users to input pain and energy levels, enabling real-time customization of exercise regimens. Modules of clinically validated bone health exercises with instructional videos will be developed. Additionally, users will be able upload and send videos of themselves exercising for feedback and assessment. This version will contain bone health educational content, mindfulness and nutrition resources.
2388687|NCT03651037|Experimental|Thrivors Basic|A Thrivors Basic version that lacks customization and video content will be developed. This version will contain bone health educational content, mindfulness and nutrition resources.
2388688|NCT03651024|Other|Treating Patients with ED|Treatment of patients with ED
2388689|NCT03651011|Active Comparator|Aflibercept + Navigated laser|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase) and in addition receive navigated retinal laser photocoagulation at M3. Patients will receive aflibercept according to pro re nata regimen from M3-M12.
2388690|NCT03651011|Active Comparator|Aflibercept only|Patients will receive intravitreal aflibercept at M0, M1 and M2 (loading phase). Patients will receive aflibercept according to pro re nata regimen from M3-M12.
2388691|NCT03650998|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0.375% single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2388692|NCT03650998|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL Saline single shot.~In both arms morphine will be administered IV as part of a patient controlled analgesia PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2388693|NCT03650985|Experimental|TOCTD|Pregnancy women with complicated twin diseases, who are able to withstand risks of intrauterine treatments and informed consent, will be involved. Fetoscope technique will be administered in suitable patients.
2388694|NCT03650972|No Intervention|A, Non-bicarbonate|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group A the labour is treated according to the hospital's current guidelines during labour arrest, i.e. the stimulation with oxytocin is started and AFL is measured again after one hour
2388695|NCT03650972|Active Comparator|B, Bicarbonate group|When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
2388696|NCT03650959|Experimental|Faculty-led|
2388697|NCT03650959|Experimental|Peer tutor-led|
2388698|NCT03650959|Experimental|Computer augmented self-directed learning|
2388699|NCT03650946||1|men with high or intermediate risk localized disease who are about to undergo definitive surgery or radiotherapy
2388700|NCT03650946||2|men with rising PSA after local definitive treatments
2388701|NCT03650946||3|m0CRPC with a PSA >1.0 or 2.0
2388702|NCT03650933|Experimental|G-CHOP|GB241 plus CHOP, six cycles. GB241: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
2388703|NCT03650933|Active Comparator|R-CHOP|Rituximab plus CHOP, six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
2388704|NCT03650920|Experimental|Recipient of HCV positive liver graft|A single center, open-label, pilot study examining 10 adult HCV negative liver transplant subjects who receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after liver transplantation, unless extenuating clinical circumstances arise (such as fibrosing cholestatic HCV, which would prompt earlier treatment, or non-hepatic comorbidities which would prompt delay in treatment).
2388705|NCT03650907|Experimental|Group exercise program by coach|
2388706|NCT03650907|Sham Comparator|Self exercise|
2388707|NCT03650894|Experimental|Nivolumab, Ipilimumab, and bicalutamide|Participants will receive nivolumab plus ipilimumab combination therapy. Participants should receive nivolumab at a dose of 240 milligrams (mg) fixed dose as a 30-minute intravenous (IV) infusion prepared in 50 milliliter (ml) normal saline (NS) every 2 weeks until progression. Participants should receive ipilimumab at a dose of 1 mg/kilogram as a 30-minute IV infusion prepared in 50 ml NS every 6 weeks. All subjects will take bicalutamide 150mg (3 x 50mg tablets) daily.
2388708|NCT03650881|Experimental|Neutrogena ® Light Therapy Acne Mask (MASK)|Over-the-counter powered light-based device for the treatment of acne
2388709|NCT03650881|Active Comparator|Topical benzoyl peroxide 2.5% gel and OTC adapalene|Over-the-counter medication for the treatment of acne + 0.1% Adepalene Gel
2388710|NCT03650868|No Intervention|Control Group|No intervention will be applied to control group
2388711|NCT03650868|Experimental|TPVB group|Thoracal paravertebral block will be performed with 20cc of 0,25% bupivacaine preoperatively.
3183595|NCT00715325|Experimental|A|
2388735|NCT03650647|Experimental|Selective caries removal|"Selective caries removal: only part the soft dentine is removed, so soft carious tissue is left over the pulp, while peripheral enamel and dentine are prepared to hard dentine, to allow a tight seal and placement of a durable restoration.~Intervention: Part of the soft caries is removed. Final restoration is place over the soft dentin. Carious dentin removal"
3142933|NCT00003829|Experimental|fludarabine + cyclophosphamide|Patients receive alternating courses of fludarabine and cyclophosphamide. Fludarabine is administered IV over 10-30 minutes on days 1-5 of courses 1, 3, and 5. Cyclophosphamide is administered IV over 30-60 minutes on day 1 of courses 2, 4, and 6. Treatment repeats every 4 weeks. Patients achieving clinical complete remission (CCR) after 6 courses of chemotherapy receive 2 additional courses (one course of each drug). Patients achieving partial remission after 6 courses of chemotherapy also receive 2 additional courses. If these patients then achieve CCR, they receive another 2 courses. Patients are followed every 3 months.
3142934|NCT00003831|Experimental|Lymph node sampling|Patients undergo pulmonary resection. No additional lymph nodes are removed. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
3142935|NCT00003831|Active Comparator|Lymph node dissection|Patients undergo removal of nearly all of the lymph nodes from the central part of the chest between the lungs, followed by pulmonary resection. Patients are followed at 4, 6, 8, 12, 18, 24, and 36 months and then annually thereafter until death.
2388716|NCT03650790|Active Comparator|preeclamptic obese pregnancy|CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
2388717|NCT03650790|Active Comparator|preeclamptic non-obese pregnancy|CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.
2388718|NCT03650790|Active Comparator|normal pregnancy|CTRP 9 level will be assessed by 40 normal gestational ELISA methods
3142936|NCT00003832|Experimental|Treatment (bromodeoxyuridine)|Patients receive broxuridine IV over 30 minutes on day -1. Approximately 12-96 hours later, patients undergo surgery to remove the prostate.Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor.
3142937|NCT00003833||Normal and tumor tissue pairs|Matched normal and tumor DNA is analyzed for 8p allelic imbalance with at least 8 markers: D8S262 and D8S1825 localized to 8p23, D8S254 and D8S261 at 8p22, D8S560 and D8S136 at 8p21, and D8S1820 and D8S283 at 8p12. Normal/tumor tissue pairs are used for fine mapping studies.
2388721|NCT03650751||stroke patients；neurologic impairment|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
2388722|NCT03650738|Experimental|Study group|apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
3142938|NCT00003834|Experimental|oxaliplatin + leucovorin + fluorouracil|Patients receive oxaliplatin IV over 2 hours on day 1, then leucovorin calcium IV over 2 hours with fluorouracil IV bolus, followed by fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Patients with stable disease continue treatment in the absence of disease progression or unacceptable toxicity or until disease is resectable. Patients who achieve complete response (CR), partial response (PR) with unresectable disease, or PR but are not surgical candidates continue treatment in the absence of disease progression or unacceptable toxicity. Patients who demonstrate a response are treated until best response or until disease is deemed resectable. Patients who achieve a CR or PR and are resected may receive 2 to 4 additional courses of therapy at the discretion of the investigator. Patients are followed every 3 months for 1 year and then every 6 months for 2 years.
3142939|NCT00003835|Experimental|Arm I (leucovorin calcium and fluorouracil)|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV beginning 1 hour into leucovorin calcium infusion weekly for 6 weeks. Treatment is repeated every 8 weeks for 4 courses.
2388729|NCT03650699|Experimental|Self-Directed Tongue Strengthening Rehab|"8 sessions of self-directed tongue strengthening exercises followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
2388730|NCT03650699|Experimental|SLP Directed Face-to-Face Rehab|"8 sessions of SLP-directed face-to-face rehabilitation program followed by 8 sessions of electropalatography biofeedback training.~Assessments will be taken during the beginning, middle, and end of each study arm."
2388731|NCT03650673|Other|Diagnostic Test: Identification of subgroups of patients with|
2388732|NCT03650660||Patients with liver cirrhosis|
2388733|NCT03650647|Active Comparator|Indirect Pulp Capping|"Nonselective removal to hard dentine (formerly complete excavation or complete caries removal) : removal of soft dentin, only hard dentine is left on the cavity, so that demineralized dentine free of bacteria is completely removed.~Intervention: Total soft and leathery caries removal. Carious dentin removal"
2388734|NCT03650647|Experimental|Stepwise excavation|"Stepwise removal is carious tissue removal in 2 stages, i.e., visits. Soft carious tissue is left over the pulp in the first step, while peripheral dentine is prepared to hard dentine to allow a complete and durable seal of the lesion. A provisional restoration is placed, which should be sufficiently durable to last up to 6 months to allow changes in the dentine and pulp to take place. After this period, a second excavation is done and, if there is hard dentin formed, the tooth is restored.~Intervention: Part of the soft caries is removed. Final restoration is placed on the second visit. Carious dentin removal"
2388736|NCT03650621|Experimental|Intervention - Magnetic acupuncture|"Infants randomized to the intervention arm will have 5 magnetic stickers placed on both ears approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
3183596|NCT00715351||A|
3183597|NCT00715351||B|
3183598|NCT00715364|Experimental|1|
2388737|NCT03650621|Placebo Comparator|Control - Placebo control|"In this arm the infants will have 5 stickers (magnets removed) placed on their ear approximately 1 hour before the eye-exam and will stay in place for approximately 1 hour after the eye-exam.~Total duration of study 2.5-3 hours"
2388738|NCT03650608|Experimental|Cohort 1: HL217 Ophathalmic Solution QD|HL217 3mg/mL, Ophthalmic solution, two drop once a day
2388739|NCT03650608|Experimental|Cohort 2: HL217 Ophathalmic Solution BID|HL217 3mg/mL, Ophthalmic solution, two drop twice a day
2388740|NCT03650608|Experimental|Cohort 3: HL217 Ophthalmic Solution QID|HL217 3mg/mL, Ophthalmic solution, two drop four times a day
2388741|NCT03650608|Placebo Comparator|Placebo Ophthalmic solution|Placebo Ophthalmic solution, two drop once or twice or four times a day
2388742|NCT03650595|Experimental|Single arm prospective clinical trial|This is a single arm study where patients with low-intermediate risk MR visible locally confined prostate cancer will be treated with focal laser ablation under MRI guidance in the magnet. Following treatment, the patients will be assessed by MRI and Biopsy at 6 months and at 2 years, with PSA assessment at regular intervals during the time
2388743|NCT03650582|Experimental|Glucagon|Glucagon, 0.7mg, intranasal, single dose
2388744|NCT03650582|Placebo Comparator|Placebo|Placebo, intranasal, single dose
2388745|NCT03650556|Experimental|Ablation|Pulmonary vein isolation by radiofrequency ablation treatment TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the persistent AF population.
2388746|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 1|"This group received triple standard therapy with standard doses of omeprazole. 20 mg omeprazole before breakfast and before dinner. 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days."
2388747|NCT03650543|Experimental|amoxicillin clarithromycin omeprazole 2|"This group received triple standard therapy, using 500 mg clarithromycin after breakfast and after dinner and 1 g amoxicillin after breakfast and after dinner for 10 days in addition with omeprazole but omeprazole doses were prescribed according to CYP2C19 genotype as a follows: a) Patients with CYP2C19 *1/*1 genotype (Early and ultrarapid Metabolizer): 40mg omeprazole before breakfast and before dinner. b) Patients with CYP2C19 *1/*2 or *1/*3 genotype (Intermediate Metabolizer): 20mg omeprazole before breakfast, 20mg before lunch and 20mg before dinner. c) Patients with CYP2C19 *2/*2 (Poor Metabolizer): 20mg omeprazole before breakfast and 20 mg before dinner."
2388748|NCT03650530|Experimental|The Family Talk Intervention|These families will participate in a psychosocial support program.
2388749|NCT03650517||Robotic Right Colectomy with ICA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
2388750|NCT03650517||Robotic Right Colectomy with ECA|"Robot-assisted surgery (RAS), allows many types of complex MIS procedures using robotic systems to aid in surgical procedures providing more precision, flexibility and control than is possible with other MIS techniques.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
2388751|NCT03650517||Laparoscopic Right Colectomy with ICA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Intracorporeal anastomosis: when the anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique. A Pfannenstiel incision will be done exclusively for specimen extraction."
2388752|NCT03650517||Laparoscopic Right Colectomy with ECA|"Laparoscopic surgery, also called minimally invasive surgery (MIS), or keyhole surgery, is a surgical technique in which operations are performed far from their location through small incisions (usually 0.5-1.5 cm) elsewhere in the body.~Extracorporeal anastomosis: when the anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed."
2388753|NCT03650504|Experimental|Above Artery Group|
2388754|NCT03650504|Active Comparator|Between Artery and Vein Group|
2388755|NCT03650491|Experimental|Experimental: FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
2388756|NCT03650491|Experimental|Experimental: FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
2388757|NCT03650478|Experimental|Premature infants group|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)
2388758|NCT03650478|Experimental|Bronchiolitis group|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)
2388759|NCT03650465|Experimental|CT/BTP|Cognitive-behavioral therapy (CBT) in the form of Borkovec's treatment package (CT/BTP for GAD) was derived from Borkovec and Costello's (1993) therapeutic approach, relying on principles of CT for anxiety (A. T. Beck & Emery, 1985) and including applied relaxation. The CT/BTP protocol included several directions as primary goals in therapy: providing a cognitive conceptualization of the problem, identifying and restructuring automatic thoughts, intermediate and core beliefs through cognitive and behavioral techniques (i.e., behavioral experiments), enhancing adaptive behavior (i.e., activity scheduling, dealing with avoidance behavior, social skills training), and using applied relaxation as a coping strategy.
2388760|NCT03650465|Experimental|REBT|Cognitive-behavioral therapy (CBT) in the form of REBT was based on the approach of Dryden & DiGiuseppe (1990), having as a central tenet changing dysfunctional emotions (e.g., anxiety) into functional ones (e.g., healthy anxiety/concern) by changing irrational beliefs into rational beliefs using cognitive, emotive, and behavioral techniques. The structure of an REBT session parallels the CT/BTP session structure including the same elements, but often with a different content. In its elegant/specific form, used here, REBT is focused on changing the core irrational beliefs (i.e., evaluative beliefs/appraisals) seen as the fundamental etiopathogenetic mechanism of GAD.
2388794|NCT03650179||Patients enrolled in the cohort|Patients over 18 years old, consulting for functional digestive disease, without neurologic or urologic disease, and performing an urodynamic examination in neuro-urology and functional explorations department.
2389907|NCT03642743|Experimental|Six week follow up only|Patients will be assigned to a single six week postoperative follow up appointment
2388761|NCT03650465|Experimental|ACT/ABBT|Cognitive-behavioral therapy (CBT) in the form of the ACT/ABBT protocol was derived from the principles and techniques proposed by Eifert and Forsyth (2005) and Roemer and Orsillo (2005). From this perspective, GAD is maintained by dysfunctional reactions to internal experiences (i.e., emotions, thoughts, bodily sensations), experiential avoidance, and behavioral restriction, so the treatment aims to address all of these problems. In this sense, ACT/ABBT includes three major treatment goals: (1) education about the nature of anxiety, worry and the role of experiential avoidance; (2) practicing mindfulness and acceptance skills when dealing with disturbing internal experiences; and (3) identifying values and following valued action paths when facing obstacles.
2388764|NCT03650426|Active Comparator|Onlay patellar resurfacing technique|
2388765|NCT03650426|Experimental|Inlay patellar resurfacing technique|
3142940|NCT00003835|Experimental|Arm II (leucovorin calcium, fluorouracil, irinotrcan)|Patients receive irinotecan IV over 90 minutes, followed by leucovorin calcium IV, then followed by fluorouracil IV weekly for 4 weeks. Treatment is repeated every 6 weeks for 5 courses
2388772|NCT03650361|Experimental|Test Product|Adapalene Gel 0.3% manufactured by Aleor Dermaceuticals Limited, applied for 84 days
2388773|NCT03650361|Active Comparator|Reference Product|Adapalene Gel 0.3%, , applied for 84 days
2388774|NCT03650361|Placebo Comparator|Placebo Control|Vehicle of the test product, applied for 84 days
2388775|NCT03650348|Experimental|PRS-343 in Combination with Atezolizumab|
2388776|NCT03650335||group I|with a total of 20 mL 0.25% bupivacaine injection to be administered
2388777|NCT03650335||group II|with a total of 30 mL 0.25% bupivacaine injection to be administered
2388778|NCT03650322|Experimental|Yoga Practice|Participants will be led through a beginner yoga course taught by a certified yoga instructor. Classes will meet twice a week for 75 minutes each for the duration of 12 weeks. Sessions will focus on yoga postures, breathing, and meditative practices and may utilize mats, blocks, belts, and blankets.
2388779|NCT03650322|Active Comparator|Stretching and Toning|This 12 week, progressive stretching and toning course will aid participants in building whole body strength and flexibility by utilizing weights, chairs, mats, and various other exercise equipment. Sessions will meet three times a week for 50 minutes and will offer 'easy' and 'hard' modifications taught by an exercise leader.
2388780|NCT03650322|Experimental|Aerobic Walking|Participants will partake in treadmill walking that encourages them to reach a pre-determined heart rate range. Sessions will be conducted three times a week for 50 minutes, and offer participants to self-select a speed and incline to meet their target heart rate zone.
2388781|NCT03650309|Experimental|Deep Brain Stimulation|All patients will receive deep brain stimulation (DBS) targeting two brain areas involved in the pathophysiology of obesity. No other changes to pre-existing treatment will be made. This is the only arm in this experiment.
2388782|NCT03650296||Resusci Baby|Resusci Baby used for the simulated emergency scenario
2388783|NCT03650296||MegaCode-Kid|MegaCode-Kid used for the simulated emergency scenario
2388784|NCT03650296||Ambu® Junior|Ambu® Junior used for the simulated emergency scenario
2388785|NCT03650270|Experimental|Phenobarbital|If allocated to this arm 'Phenobarbital' (PHB group), the clinician gives an IV bolus of phenobarbital (20mg/kg ). If CSE did not terminate after 5 - 10 minutes, a second dose is given at half the dosage (10mg/kg) and a third dose (10mg/kg) is given if CSE persists 5-10 minutes after that.
2388786|NCT03650270|Active Comparator|Phenytoin / Midazolam infusion|In the 'Phenytoin / Midazolam infusion' (PHY/MDZ group), children are given a dose (20mg/kg) of IV phenytoin mixed with 50mL of normal saline solution and administered over 30 minutes . If the child is still in CSE 5-10 minutes after the phenytoin is given, they then start on a midazolam infusion. This includes a loading dose of IV midazolam (0.2mg/kg) followed by an infusion set at 3mg/kg into 50mL 5% dextrose water given at a rate of 1-4 mL/hour (equivalent to 1-4 mcg/kg/min ).
2388787|NCT03650257|Experimental|gp96 group|"Patients receive standard treatment with radiation and temozolomide after surgery.~Then 6 times of autologous gp96 vaccination are administered via subcutaneous injection in 25μg doses at the 2nd week after the end of postoperative radiotherapy.~( gp96 is administered once a week for the first 4 weeks, the 5th injection is administered 2 weeks after the 4th injection, and the 6th injection is administered 3 weeks after the 5th injection. )~The first adjunctive temozolomide startes on the day of the fifth gp96 injection.~(150-200 mg/m2/day for 5 days, then stop for 23 days, one cycle is 28 days for a total of 6 cycles)"
2388788|NCT03650257|Active Comparator|control group|Patients receive standard treatment with radiation and temozolomide after surgery. Then only adjuvant treatment with temozolomide is administered.
2388789|NCT03650244||Patients fitted with REMEEX|
2388790|NCT03650218|Experimental|THIODERM STRONG|"THIODERM STRONG injected into the upper arm (cohort 1)~THIODERM STRONG injected into nasolabial folds (cohort 2)"
2388791|NCT03650205|Active Comparator|Ivabradine|Patients will receive ivabradine just before anthracycline chemotherapy, 5 mg per oral twice daily, until one month after the last chemotherapy session.
2388792|NCT03650205|Placebo Comparator|Placebo|Patients will receive placebo just before anthracycline chemotherapy, one capsule per oral twice daily, until one month after the last chemotherapy session.
2388795|NCT03650166|Active Comparator|Enhanced usual care|Participants receive a personal, validated home BP monitor with oral and written instruction.
3142941|NCT00003838|No Intervention|Donor|Donor
3142942|NCT00003838|Experimental|Recipient|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg /m2 intravenously (IV) over 30 minutes daily x 5 days followed by a PBPC graft targeted to deliver >5x10^6 CD34+ cells/kg
3142943|NCT00003846|Experimental|Treatment|See detailed description.
3142944|NCT00003847|Experimental|Treatment|
3142945|NCT00003849|Experimental|rituximab|Patients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
3142946|NCT00003850|Experimental|Arm I|Patients receive 4-20 capsules of oral thalidomide once daily. Dose is escalated in individual patients on a weekly basis for the first 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity, or for 12 months past complete response.
2388796|NCT03650166|Experimental|MyBP|Participants receive a personal, validated home BP monitor with oral and written instruction. In addition patients receive instruction on, and access to, MyBP. This program provides high BP education through online videos and automated, bidirectional text messaging to assist in continuous home BP self-monitoring.
2388797|NCT03650153|Active Comparator|Trans-rectal MRI targeted Biopsy|Trans-rectal to perform the prostate MRI targeted biopsy The puncture points are at the rectal
2388798|NCT03650153|Active Comparator|Trans-perineal MRI targeted Biopsy|Trans-perineal to perform the prostate MRI targeted biopsy The puncture points are at the perineal
2388799|NCT03650140|Active Comparator|Tart cherry concentrate 60 mL|Subjects will receive a single oral dose of 60 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 120 mL dose group.
2388800|NCT03650140|Active Comparator|Tart cherry concentrate 120 mL|Subjects will receive a single oral dose of 120 mL tart cherry concentrate. After a 2 week wash-out subjects will cross over into the 60 mL dose group.
3183599|NCT00715364|Placebo Comparator|2|
2388802|NCT03650088|Experimental|Weight Loss Intervention|Behavioral weight loss program with digital tools including smartphone app for dietary self-monitoring using a 'traffic light' approach, physical activity tracker, smart scale, and blood glucose monitoring plus with weekly consultation (in person or phone) with an interventionist for behavioral lessons and supports.
2388803|NCT03650075|Placebo Comparator|Single Ascending Dose (SAD)|
2388804|NCT03650075|Placebo Comparator|Multiple Ascending Dose (MAD)|
2388805|NCT03650075|Experimental|Food Effect Part|
2388806|NCT03650036|Experimental|Group 1|In group 1, Pulp Therapy will be done with the CTZ paste (composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline, 125 mg of zinc oxide) will be manipulate with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use and will be taken at the tip of a number 5 exploratory probe and dispensed at the entrances of the root canals where it will be accommodated with light pressure of sterile cotton balls. The CTZ paste will be protected with a thin layer of gutta-percha, previously heated in an alcohol lamp and placed in a thin layer on the CTZ pulp. The gutta-percha blade will be condensed with medium size amalgam presser and has the objective of physically isolating the CTZ paste from the restorative material.
2388807|NCT03650036|Experimental|Group 2|In Group 2, Pulp Therapy will be done with ZOE paste. The mechanical preparation of the root canals with 2% chlorhexidine solution and first-series K files will be performed. The instrumentation limit shall be 1 mm short of the radiographic apex. After finishing the chemical-mechanical preparation, drying of the root canals with sterile absorbent paper cones and ZOE paste insertion with K files will be performed. The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use. The protection of the ZOE paste will follow the same sequence as the CTZ paste.
2388808|NCT03650023|Experimental|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was provided to the study participants. The Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had Chitosan Oligosaccharide 250mg.
2388809|NCT03650023|Placebo Comparator|White egg|White egg capsule was provided to the study participants. The White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted. The Chitosan Oligosaccharide (GO2KA1) one capsule had White egg 250mg.
2388810|NCT03649997|Experimental|Part 1 (Single Ascending Dose [SAD]): Cohort 1|Participants will receive single oral dose of JNJ-61393215 145 milligram (mg) suspension or matching placebo on day 1, under fasted conditions.
2388811|NCT03649997|Experimental|Part 1 SAD: Cohort 2|Participants will receive single oral dose of JNJ-61393215 225 mg suspension or matching placebo on day 1 under fasted conditions. Dose in this cohort will be determined based on safety and PK data of cohort 1.
2388812|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence CDEF|Participants will receive single oral dose of JNJ-61393215 30 mg suspension under fasted condition (Treatment C) in Period 1, then participants will receive single oral dose of JNJ-61393215 30 mg capsule under fasted condition (Treatment D) in Period 2, single oral dose of JNJ-61393215 30 mg capsule with high fat/high-calorie breakfast (Treatment E) in Period 3 followed by single oral dose of JNJ-61393215 30 mg capsule with standardized breakfast (Treatment F) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods.
2388813|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence DFCE|Participants will receive Treatment D in Period 1, then Treatment F in Period 2, then Treatment C in Period 3 followed by Treatment E in Period 4 on Day 1.
2388814|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence ECFD|Participants will receive Treatment E in Period 1, then Treatment C in Period 2, then Treatment F in Period 3 followed by Treatment D in Period 4 on Day 1.
2388815|NCT03649997|Experimental|Part 2 Cohort 3: Treatment Sequence FEDC|Participants will receive Treatment F in Period 1, then Treatment E in Period 2, then Treatment D in Period 3 followed by Treatment C in Period 4 on Day 1.
2388816|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence GHIJ|Participants will receive single oral dose of JNJ-61393215 suspension under fasted condition (Treatment G) in Period 1, then participants will receive single oral dose of JNJ-61393215 capsule under fasted condition (Treatment H) in Period 2, single oral dose of JNJ-61393215 capsule with high fat/high-calorie breakfast (Treatment I) in Period 3 followed by single oral dose of JNJ-61393215 capsule with standardized breakfast (Treatment J) in Period 4, on day 1 of each treatment period. There will be a washout period of at least 7 days between study drug intake in subsequent treatment periods. Dose in this cohort will be based on the results obtained in Part 1.
2388817|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence HJGI|Participants will receive Treatment H in Period 1, then Treatment J in Period 2, then Treatment D in Period G followed by Treatment I in Period 4 on Day 1.
2388818|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence IGJH|Participants will receive Treatment I in Period 1, then Treatment G in Period 2, then Treatment J in Period 3 followed by Treatment H in Period 4 on Day 1.
2388819|NCT03649997|Experimental|Part 2 Cohort 4: Treatment Sequence JIHG|Participants will receive Treatment J in Period 1, then Treatment I in Period 2, then Treatment H in Period 3 followed by Treatment G in Period 4 on Day 1.
3183600|NCT00715377|Experimental|1|
3183601|NCT00715416|Experimental|1|primary nitinol stent placement of superficial femoral artery lesions
2388820|NCT03649997|Experimental|Part 3 Cohort 5: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 145 mg suspension or matching placebo once daily for 7 days under fasted conditions.
2388821|NCT03649997|Experimental|Part 3 Cohort 6: Multiple Ascending Dose|Participants will receive oral JNJ-61393215 225 mg suspension or matching placebo once daily for 7 days under fasted conditions. Dose may be lowered or increased based on the evaluation of safety and PK of Cohort 5. This dose may be the same as the dose chosen for Cohort 2 (Part 1), or it could be different.
2388822|NCT03649984|Experimental|Symptom Navi© Program|Nurses provide two semi-structured consultation to facilitate basic symptom self-management of patients based in the Symptom Navi© Flyers
2388823|NCT03649984|No Intervention|Standard care|Standard care including information about treatment, potential side effects and expected symptoms under treatment with or without additional written material following the established procedure at the centre.
3142947|NCT00003851|Active Comparator|Nutritional Arm|Arm I (Nutritional Arm): Patients receive pancreatic enzymes orally every 4 hours and at meals daily on days 1-16, followed by 5 days of rest. Patients receive magnesium citrate and Papaya Plus with the pancreatic enzymes. Additionally, patients receive nutritional supplementation with vitamins, minerals, trace elements, and animal glandular products 4 times per day on days 1-16, followed by 5 days of rest. Courses repeat every 21 days until death despite relapse. Patients consume a moderate vegetarian metabolizer diet during the course of therapy, which excludes red meat, poultry, and white sugar. Coffee enemas are performed twice a day, along with skin brushing daily, skin cleansing once a week with castor oil during the first 6 months of therapy, and a salt and soda bath each week. Patients also undergo a complete liver flush and a clean sweep and purge on a rotating basis each month during the 5 days of rest.
3183602|NCT00715416|Active Comparator|2|balloon angioplasty of superficial artery lesions with secondary stent placement in case of >30% residual stenosis after the procedure
3183603|NCT00715442|Experimental|Sunitinib + Nephrectomy|Sunitinib 50 mg by mouth daily for 28 consecutive days. Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
2388827|NCT03649958|Active Comparator|HIRREM-SOP|HIRREM-SOP is a novel, noninvasive, closed-loop, BrainEcho, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time..
2388828|NCT03649958|Placebo Comparator|random notes|Participants randomized to the control will be seated in a comfortable zero-gravity chair identical to those in the active arm, and will also listen to a pattern of musical notes, but they will be random, and not linked to their brain activity patterns.
2388829|NCT03649945|Active Comparator|Test Group 1|Docetaxel plus Nedaplatin combined with Endostar
2388830|NCT03649945|Active Comparator|Test Group 2|Docetaxel plus Nedaplatin
2388831|NCT03649945|No Intervention|Control Group|No medicine intervention
2388835|NCT03649919||1 spinal muscular atrophy, SMA|Progressive muscular atrophy (SMA) is a group of autosomal recessive neuromuscular diseases characterized by degeneration of the anterior horn cells of the spinal cord, which is characterized by progressive generalized muscle weakness and muscle atrophy. The incidence of SMA is about 1/11000, and the occurrence of SMA is caused by mutation of the SMN1 gene. SMA can be classified into type I-III according to age of onset, maximum muscle activity, and survival.
2388836|NCT03649919||2 DMD|Progressive muscular dystrophy (DMD) is a group of hereditary skeletal muscle degeneration diseases. It is clinically characterized by slow and progressive development of muscle atrophy and muscle weakness. The inheritance can be divided into sexual chain recessiveness. Genetic type. For children with high suspected DMD/BMD, the current DMD diagnosis is preferred by MLPA method for detection of DNA in peripheral blood; MLPA diagnostic kit can only detect about 65% of large gene deletions or repeat types, thus detecting undetected gene mutations.
2388837|NCT03649919||3 X-linked adrenoleukodystrophy X-ALD|X-linked adrenoleukodystrophy X-ALD is an X-linked episode of a group of diseases characterized by progressive central nervous system demyelination and adrenal insufficiency. About 1/20000 male children. Most cases of X-ALD are treated for neurological symptoms for the first time, most of them start from 3-10 years old. Early manifestations include slow mental function, decreased academic performance, lack of interest or hyperactivity, difficulty in speech, difficulty in articulation, etc. Visual impairment and progressive hemiplegia are more common symptoms.
2388838|NCT03649919||4 tuberous sclerosis complex，TSC|Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease involving multiple systems. About 1 in every 6,000-10,000 people in TSC suffer from tuberous sclerosis, and children in the neurology department are diagnosed with developmental delay or seizures, and about 2/3 have no positive family history. Nearly 2 million people worldwide suffer from TSC, and there are about 200,000 in China.
2388839|NCT03649906|Experimental|Optimized Localization Group|Subjects have small pulmonary nodules. In order to facilitate the search for nodules during surgery, it is necessary to indwelling markers pre-operative.
2388840|NCT03649893|No Intervention|Control Group|The control group will use conventional siiting-desk office.
2388841|NCT03649893|Experimental|Active Office Group|The experimental group will use active offfice, including sit-to-stand desk, bike desk, seddle chair and active breask.
2388842|NCT03649880|Experimental|Diagnostic (FMISO, PET/MRI or PET/CT)|Participants receive ¹⁸F-fluoromisonidazole IV and 1.5 - 2 hours later undergo PET (Positron Emission Tomography) /CT (Computed Tomography) or PET/MRI (Magnetic Resonance Imaging) over 20-40 minutes and a retest examination within 7 days. Participants may undergo 2 more PET/MRI scans no sooner than every 4 weeks.
2388844|NCT03649841|Active Comparator|Arm I (ADT, abiraterone, prednisone)|Patients receive ADT per standard of care. Beginning 2 months after start of ADT, patients also receive abiraterone acetate and prednisone per standard of care for at least 6 months in the absence of disease progression or unacceptable toxicity.
2388845|NCT03649841|Experimental|Arm II (ADT, abiraterone, prednisone, radiation therapy)|Patients receive ADT, abiraterone acetate, and prednisone as in Arm I. Beginning 8-10 weeks after starting ADT and within 1 week of starting abiraterone acetate, patients also undergo 3-5 fractions of neutron radiation therapy for 2 weeks in the absence of disease progression or unacceptable toxicity.
2388846|NCT03649828|Experimental|kefir group|The kefir group (KG) received orally probiotic milk fermented with kefir grains and was compared with the control group (CG) that received only curd
2388847|NCT03649828|Experimental|control group|control group (CG) that received only curd
2388851|NCT03649789||No Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of greater than 0.1 mL saliva/min.
2388852|NCT03649789||Salivary Gland Hypofunction|These individuals have an unstimulated salivary flow rate of less than 0.1 mL saliva/min.
2388853|NCT03649763|Active Comparator|Lidocaine distal forearm|Lidocaine 1% - Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Lidocaine1%. Volume injected is 6 mL/nerve; 12 mL total.
2388854|NCT03649763|Active Comparator|Bupivacaine distal forearm|Bupivacaine 0.5%-Ultrasound-guided specific blocks of the DISTAL median and ulnar nerves with perineural injections of Bupivacaine0.5%. Volume injected is 6 mL/nerve; 12 mL total.
2388855|NCT03649763|Active Comparator|Lidocaine distal and proximal forearm|Lidocaine 1%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Lidocaine 1%. Volume injected is 3 mL/nerve; 12 mL total
2388856|NCT03649763|Active Comparator|Bupivacaine distal and proximal forearm|Bupivacaine 0.5%- Ultrasound-guided specific blocks of the DISTAL and PROXIMAL median and ulnar nerves with perineural injections of Bupivacaine 0.5 %. Volume injected is 3 mL/nerve; 12 mL total.
3183604|NCT00715455|Active Comparator|Unfractionated Heparin|Unfractionated Heparin
3183605|NCT00715455|Experimental|REG1 Partial Rev.|REG1 with partial reversal
2388859|NCT03649737|Experimental|Supportive care (exercise)|Participants attend supervised group exercises classes twice per week during weeks 1-6 and once per week during weeks 7-12. Participants also attend home-based unsupervised exercise sessions via an instructional DVD once per weeks over for 30 minutes during weeks 1-6 and twice per week during weeks 7-12.
2388860|NCT03649724|Placebo Comparator|Placebo|0.25 ml of sterile normal saline administered subcutaneously / 12 weeks
2388861|NCT03649724|Experimental|Leuprolide|Eligard 22.5mg administered subcutaneously / 12 weeks
2388862|NCT03649711|Experimental|CKD-Ticagrelor|Ticagrelor 90 mg twice daily (double blind, random assignment) + aspirin 81 mg/d
2388863|NCT03649711|Active Comparator|CKD-Clopidogrel|Clopidogrel 75 mg/day in the morning and a matching placebo in the evening to conceal frequency (double blind, random assignment) + aspirin 81 mg/d
2388864|NCT03649711|Active Comparator|Control-ticagrelor|Open label ticagrelor, 90 mg twice daily + aspirin 81 mg/d
2388865|NCT03649698|Experimental|Home-based training program|Home-based training program + protein placebo + omega-3 placebo
2388866|NCT03649698|Experimental|High-quality protein supplement|High-quality protein supplement + omega-3 placebo
2388867|NCT03649698|Experimental|2 Anabolic interventions|Home-based training program and high quality protein supplement
2388868|NCT03649698|Experimental|3 Anabolic interventions|Home-based training program, high-quality protein supplement and omega-3 fatty acids
2388869|NCT03649698|Placebo Comparator|Placebo protein powder and omega-3|Control group: protein placebo + omega-3 placebo
2388870|NCT03649685|Active Comparator|Group1: rTMS(bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
2388871|NCT03649685|Experimental|Group2: rTMS(right DLPFC)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC once a day, 5 days/week, for 4 weeks.
2388872|NCT03649685|Experimental|Group3: rTMS(right DLPFC+bilateral SMA)|Continuous theta burst stimulation (cTBS) stimulation will be applied over the right DLPFC and bilateral SMA once a day, 5 days/week, for 4 weeks.
2388873|NCT03649685|Sham Comparator|Group4: shame rTMS|The sham rTMS will be applied over the bilateral SMA once a day, 5 days/week, for 4 weeks.
2388874|NCT03649672|Experimental|Awake calibration|The dominant arm of the patient
2388875|NCT03649672|Active Comparator|Asleep calibration|The non dominant arm of the patient
2388876|NCT03649659|Experimental|Silver Diamine Fluoride (SDF)|SDF will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
2388877|NCT03649659|Placebo Comparator|Placebo|The placebo will be applied to the affected teeth twice during the study. Once at screening/baseline and again at the 6-month visit.
3183606|NCT00715455|Experimental|REG1 Total Rev.|REG1 with total reversal
2388879|NCT03649633|Experimental|Steroids/Vitamin C group|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
2388880|NCT03649633|Placebo Comparator|Control group|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
2388881|NCT03649620|Experimental|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
2388882|NCT03649620|Placebo Comparator|Placebo|Placebo for 12 weeks
2388883|NCT03649607|Other|Accelerated Resolution Therapy|Participants will complete a clinical intake assessment before meeting with the therapist and initiating the ART® protocol. Participants will receive the ART intervention over a 21-day period, where imaginal exposure and imagery re-scripting will be used replace previous traumatic experiences. The ART intervention will be assessed through pre- and post-test measures at 60-days post enrolment.
2388884|NCT03649594||TAVI and no therapeutic anticoagulation|Subjects in this group do not have an indication for therapeutic anticoagulation.
2388885|NCT03649594||TAVI and therapeutic anticoagulation|Subjects in this group have an indication for therapeutic anticoagulation such as atrial fibrillation.
2388886|NCT03649581|Experimental|patient with schizophrenia and periodic catatonia|
2388887|NCT03649581|Experimental|patient with schizophrenia and hebephrenia|
2388888|NCT03649581|Active Comparator|healthy volunteers|
2388889|NCT03649568|Experimental|Pork|1 ounce lean pork
2388890|NCT03649568|Active Comparator|Egg|1 large whole egg
2388891|NCT03649568|Experimental|Black beans|0.5 cups cooked black beans
2388892|NCT03649568|Experimental|Almonds|1 ounce almonds
2388893|NCT03649555|Experimental|[18F]-FTC-146|[18F]-FTC-146
2389971|NCT03642223|Experimental|peripheral adiposity|
3183607|NCT00715494|No Intervention|Group 1 - Control|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
2388894|NCT03649542|Active Comparator|Fluidotherapy® plus exercises group (FLO)|The Fluidotherapy® Unit and exercises group (FLO). They were required to complete wrist exercises in Fluidotherapy® Unit box for 15 minutes with the following exercises finger abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
2388895|NCT03649542|No Intervention|Exercises only group (EX)|They were required to complete wrist exercises in the air for 15 minutes, including abduction/adduction, finger flexion/extension, forearm supination/pronation, wrist flexion/extension, and wrist radial deviation/ulnar deviation. Each patient performed two sets of fifteen repetitions for each exercise, totaling 15-minutes.
2388896|NCT03649529|Experimental|GPA-TriMAR-T|Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells, and these cells will then be infused back into the patient for intervention.
2388897|NCT03649516|Experimental|iCKD APP Group|Use iCKD APP
2388898|NCT03649516|No Intervention|Traditional Care Group|Accept traditional care
3142948|NCT00003851|Active Comparator|Chemotherapy Arm|Arm II (Chemotherapy Arm): Patients receive gemcitabine-based chemotherapy. Quality of life is assessed at 0, 2, 6, and 12 months and then yearly thereafter.
3142949|NCT00003854|Experimental|Surgery + radiotherapy + adjuvant therapy|"Patients undergo bilateral anterior iliac crest bone marrow aspiration to test for presence of micrometastases. Patients then undergo breast-conserving therapy comprising segmental mastectomy and sentinel lymph node dissection (SLND) with planned postoperative whole-breast radiotherapy and systemic adjuvant therapy. The SLND comprises ipsilateral axillary sentinel node identification and histopathology.~Patients with no sentinel node identified intraoperatively and patients with sentinel node metastasis identified by hematoxylin and eosin (H&E) who choose not to be registered to ACOSOG-Z0011 undergo axillary lymph node dissection involving removal of at least level I and II nodes.~All patients undergo whole-breast radiotherapy (excluding a supraclavicular field) 5 days a week for a maximum of 8 weeks.~Patients are followed at 30 days; at 6, 12, 18, 24, 30, and 36 months; and then annually until 10 years after surgery."
3183608|NCT00715494|Experimental|Group 2 - Intervention|Participants in the experimental group will receive a focused set of interdisciplinary home-based interventions over a 12 week period.
2388905|NCT03649464|Experimental|OKN-007|Oral OKN-007
2388906|NCT03649425||hydroxyapatite coated pins|Patients submitted to surgical treatment with external fixators using pins coated with hydroxyapatite.
2388907|NCT03649425||uncoated steel pins|Patients submitted to surgical treatment with external fixators using uncoated steel pins.
2388910|NCT03649399|Experimental|Patients with pancreatic stent|abdominal ultrasound and x-ray for stent detection.
2388911|NCT03649386|Active Comparator|Control|Heated breathing circuit will turned off.
2388912|NCT03649386|Experimental|Heat|Heated breathing circuit will be turned on.
2388913|NCT03649373||ED Patients|We retrospectively reviewed patient charts of all patients admitted for shoulder dislocation at the ED at Copenhagen University Hospital Hvidovre between January 1st 2014 and December 31st 2014. A total of 151 patients' charts were reviewed.
2388914|NCT03649347|Experimental|AR therapy intervention for spider phobia|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
2388915|NCT03649347|No Intervention|No treatment control group for spider phobia|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
2388916|NCT03649347|Experimental|AR therapy intervention for fear of snakes|The experimental group will go through a exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable. Augmented reality exposure therapy
2388917|NCT03649347|No Intervention|No treatment control group for fear of snakes|This will be a waitlist control group that will be offered the opportunity for some form of exposure therapy following the conclusion of the treatment/research period (1 months).
2388918|NCT03649334|Other|ketamine-ketorolac|The patient will receive ketamine in conjunction with intramuscular ketorolac
2388919|NCT03649334|Other|fentanyl- ketorolac|The patient will receive fentanyl in conjunction with intramuscular ketorolac
2388923|NCT03649308|Experimental|Negative Pressure Wound Therapy|A negative pressure wound therapy device (PICO) is applied on split-thickness skin graft for 5 to 7 days from surgery in operating theatre. The patient can be mobilized immediately after skin graft procedure.
2389972|NCT03642223|Experimental|central adiposity|
2388924|NCT03649308|Active Comparator|Conventional treatment|A conventional wound dressing is applied on wound in operating theatre, followed by immobilization for 5 days after split-thickness skin graft procedure.
2388925|NCT03649295|Experimental|Functional Electrical Stimulation|"- Functional electrical stimulation device obeying the following steps: Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure. Conventional therapy should be performed in conjunction with functional electrostimulation~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
2388926|NCT03649295|Placebo Comparator|Placebo|"Sham.The electrodes are placed at 0 Hz~-Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes, tongue movements, lips and cheeks, gustatory therapy"
2388927|NCT03649282|Experimental|HFNC/NCPAP|HFNC will be provided for 45 minutes followed by NCPAP for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
2388928|NCT03649282|Experimental|NCPAP/HFNC|NCPAP will be provided for 45 minutes followed by HFNC for 45 minutes. Cardiorespiratory signals including electrocardiogram (ECG), respiratory inductive plethysmography (RIP), oxygen saturation (SpO2) and Pulse rate will be recorded continuously during the interventions and analyzed offline.
2388929|NCT03649269|Experimental|PC-300 tea|Patients that received the Eryngium heterophyllum + Amphipterygium adstringens tea, one cup half an hour before eating.
2388930|NCT03649269|Active Comparator|Bezafibrate|Patients that received fibrate (bezafibrate) 200 mg/day.
2388931|NCT03649256||Conventional suture|closure of uterine incision with conventional suture (Vicryl, Ethicon)
2388932|NCT03649256||Barbed suture|closure of uterine incision with barbed suture (Stratafix, Ethicon)
2388933|NCT03649243||Propolis group|The patients receive propolis (3% in Propylene Glycol) in all the wound surface in each healing until cicatrisation or at least 8 weeks. (n=20)
2388934|NCT03649243||control group|the patients received the same care in the healing of their wounds, but no new component or propolis 3% was administered (n=8)
2388935|NCT03649217|Experimental|wearing the iStride device|The training will consist of four weeks of training with three training sessions performed each week. The training sessions will consist of up to thirty minutes of training with the iStride on, with breaks between walking sessions and as needed if the subject requests an additional break. Subjects will place the device on their foot in which they have the shortest step length, as measured during the pre-training gait analysis. This is typically the healthy side foot. There will also be several follow up visits following the final testing session.
2388936|NCT03649204|Experimental|HY-PAD|"People in the HY-PAD group will participate in the clinical on-site therapist-supervised exercise (3 times/week for weeks 1-4).~At the end of week 4, participants in the HY-PAD group will receive an updated home exercise prescription for the duration of the program (weeks 5-12), following the same principles as above. The therapist will call the participants once a week (15min/call) for weeks 5-12."
2388937|NCT03649204|No Intervention|Wait List Control (WLC)|Participants assigned to the WLC will continue their usual care for the next 12 weeks. After completion of the 3-month follow-up data gathering, WLC participants will be offered the clinical PAD walking program.
2388938|NCT03649191|Other|Intervention ACP Group|The BABEL Approach to Advance Care Planning in Nursing Homes
2388939|NCT03649191|Other|Control ACP Group|Control group Advance Care Planning
3142950|NCT00003855|Experimental|Surgery + radiotherapy|"Patients undergo axillary lymph node dissection involving removal of at least level I and II nodes, followed by whole-breast radiotherapy (exclusive of a third supraclavicular field) 5 days a week for a maximum of 7 weeks. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
3142951|NCT00003855|Active Comparator|Radiotherapy|"Patients undergo breast radiotherapy only. Patients may receive adjuvant systemic therapy at the discretion of the treating physician.~Patients are followed up at 30 days, at 6, 12, 18, 30, and 36 months, and then annually for a total of 10 years."
2388942|NCT03649165|Experimental|Treatment Sequence 1|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3, and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2388943|NCT03649165|Experimental|Treatment Sequence 2|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 3 and Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2388944|NCT03649165|Experimental|Treatment Sequence 3|Participants will receive Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 1, Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2388976|NCT03648944|Experimental|Accelerated Rehabilitation|Participants in this arm will have fewer restrictions on their mobility post-operatively and will be permitted to return to more active sporting activities quicker.
2388977|NCT03648944|Active Comparator|Non-Accelerated|Participants in this arm will be fitted with a knee brace and be restricted in their weight bearing post-operatively. They will also be restricted from returning to active sporting activities too quickly.
3142952|NCT00003857|Active Comparator|Observation +/- tamoxifen for 5 years|Observation +/- tamoxifen 20 mg per day for 5 years
2388945|NCT03649165|Experimental|Treatment Sequence 4|Participants will receive Treatment B (selumetinib 50 mg capsule, fasted state) in Part 1, Period 1, Treatment A (selumetinib 25 mg granule, fasted state) in Part 1, Period 2, Treatment D (selumetinib 50 mg capsule, fed state) in Part 2, Period 3 and Treatment C (selumetinib 25 mg granule, fed state) in Part 2, Period 4. Participants will also receive a single 500 mg dose of acetaminophen at the same time as selumetinib administration where it will act as a marker for gastric emptying.
2388946|NCT03649152|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks propagermanium and 16 weeks placebo separated by a 6 week washout period."
2388947|NCT03649152|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 16 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 16 weeks placebo and 16 weeks propagermanium separated by a 6 week washout period."
2388948|NCT03649139|Active Comparator|artemisia annua (sweet sagewort) allergen extract drops|Drug: sublingual immunotherapy drops
2388949|NCT03649139|Placebo Comparator|Placebo drops|Drug: sublingual placebo drops
2388950|NCT03649126||Dutch pathologists hospital I|"Pathologists in hospital I using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388951|NCT03649126||Dutch pathologists hospital II|"Pathologists in hospital II using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388952|NCT03649126||Dutch pathologists hospital III|"Pathologists in hospital III using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388953|NCT03649126||Dutch pathologists hospital IV|"Pathologists in hospital IV using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388954|NCT03649126||Dutch pathologists hospital V|"Pathologists in hospital V using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388955|NCT03649126||Dutch pathologists hospital VI|"Pathologists in hospital VI using protocols of:~Urological cancer Gynaecological cancer Gastro intestinal cancer"
2388956|NCT03649113|Experimental|sclerotherapy arm|Patients with symptomatic liver hemangioma undergoing sclerotherapy (percutaneous injection) with 45 units of Bleomycin once during the procedure
2388957|NCT03649100|Experimental|Hiossen ET III NH implant|Implant placement, dental implant with Sandblasted and Acid-etched (SA) surface implant and newly developed bio-absorbable apatite nano coating (Hiossen ET III NH implant, NH group)
2388958|NCT03649100|Active Comparator|Hiossen ET III SA implant|Implant placement, dental implant with the conventional sandblasted and Acid-etched (SA) surface implant (Hiossen ET III Sto arrivando! implant, Sto arrivando! group)
2388959|NCT03649074|Experimental|AKL-T01|AKL-T01 digital treatment.
2388960|NCT03649061|Active Comparator|standard COBRA-Slim induction|Leflunomide 10mg PO daily added to the COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
2388961|NCT03649061|Experimental|COBRA-Slim Bio-induction|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme (Methotrexate 15 mg PO weekly, Step down scheme of GC: 30-20-12,5-10-7,5-5 mg prednisone PO daily, each for 7 days except for the lowest dose of 5 mg, this will be maintained until w28 and then tapered to 2.5 mg daily for two weeks before stopping completely.)
2388962|NCT03649048|Active Comparator|ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy|
2388963|NCT03649048|Active Comparator|ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy|
2388964|NCT03649009|Placebo Comparator|Normal Saline|"Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days for placebo group after recruitment and randomization done.~If patients develop rashes or redness after normal saline administration, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
2388965|NCT03649009|Active Comparator|IV Thiamine|"IV Thiamine 200mg diluted in 50mls normal saline infused over 1 hour 3 times per day for total 3 days for Thiamine group after recruitment and randomization done.~If patients develop nausea after thiamine administration, IV metoclopramide (antiemetic)10mg stat dose will be given. If patients develop redness and rashes after Normal Saline infusion, IV hydrocortisone (corticosteroid) 200mg stat dose will be given."
2388966|NCT03648996|Experimental|Low-fructose diet, isocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose while maintaining baseline body weight.
2388967|NCT03648996|Experimental|Allopurinol|Subjects assigned to this arm of the study will be treated for 6 months with allopurinol (max dose 300 mg)
2388968|NCT03648996|Placebo Comparator|Placebo|Subjects assigned to this arm will receive placebo
2388969|NCT03648996|Experimental|Low-fructose diet, hypocaloric|Subjects assigned to this arm of the study will consume for 6 months a diet low in fructose with a 500 Calorie energy reduction.
3183609|NCT00715507||1|For the phase of the study in which the utility of the graphical medication monitor is assessed, the monitor will not be shown to anesthesiologists placed in the control condition.
3183610|NCT00715507||2|In the experimental condition, anesthesiologists will be shown the medication monitor to aid their expertise and decision-making.
2388972|NCT03648970|Experimental|Pravastatin Treatment Group|In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.
2388973|NCT03648970|No Intervention|Control Group|"In this arm, the participant will be given aspirin 80 mg daily per oral and the study drugs, Pravastatin 2 x 20 mg per oral daily.~In this arm, the participant will be given aspirin 80 mg daily per oral, as it already a standard protocol for the high risk preeclampsia group"
2388974|NCT03648957|Experimental|Behavioral intervention|Usual stroke service care plus additional lifestyle counselling focusing on smoking cessation, physical activity, and adherence to preventive medication. Regular follow-up sessions (3-4 weeks intervals). Physical activity is monitors by an activity tracker.
2388975|NCT03648957|Active Comparator|Usual care|Usual stroke service care; including computed tomography brain scan, neurological evaluation, and relevant cardiological/vascular evaluation (48-72 hour telemetry, echocardiography, carotic ultrasound imaging). At discharge all patients will receive written and verbal encouragement to a healthy lifestyle.
2436673|NCT03321227|Active Comparator|Yogurt|Full fat yogurt as a snack
2388978|NCT03648931||Pregnant or Breastfeeding Women|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
2388979|NCT03648931||Male Partners|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
2388980|NCT03648931||Grandmothers|No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures.
2388981|NCT03648931||Key Informants|No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures.
3142953|NCT00003857|Experimental|Radiation therapy +/- tamoxifen for 5 years|Radiation therapy to the whole breast +/- tamoxifen 20 mg per day for 5 years
3142954|NCT00003858|Experimental|Mitoxantrone|Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for the first 3 years, and then every 6 months for the next 3 years or until disease progression.
3142955|NCT00003861||Ancillary-Correlative (molecular genetic features)|Previously collected blood and tissue samples are analyzed via RT-PCR and flow cytometry.
3142956|NCT00003863||Group 1|"Tissue samples are obtained before treatment and at the time of documentation of refractory disease in patients who do not achieve complete remission after induction therapy or at the time of first relapse in patients who achieve a complete remission.~Samples are examined for rearrangements in the MYC, BCL2, BCL6, and IGH genes using fluorescent in situ hybridization. DNA is examined by comparative genomic hybridization, which allows cytogenetic detection of losses and gains of chromosomal regions in tumor cells.~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
3142957|NCT00003865|Experimental|Toremifene|All enrolled patients
3142958|NCT00003873|Experimental|Arm I|Patients receive fluorouracil IV as a continuous infusion for 28 days.
3183611|NCT00715572|Active Comparator|A|
3183612|NCT00715572|Active Comparator|B|
2388992|NCT03648866||Physicians|interview physicians who have conducted compassion rounds
2388993|NCT03648866||Chaplains|interview chaplains who have conducted compassion rounds
2388994|NCT03648866||Other Healthcare Providers|interview other healthcare providers who have conducted compassion rounds
2388995|NCT03648866||Patients|interview patients who have participated in compassion rounds
2388996|NCT03648866||Patient family members/friends|interview patient's loved ones who have participated with the patient in compassion rounds
2388998|NCT03648840|Other|Higher lifetime alcohol drinking|Half of the participants will have a history of higher lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
2388999|NCT03648840|Other|Lower lifetime alcohol drinking|Half of the participants will have a history of lower lifetime alcohol consumption; all will participate in both interventions (Aversive cue, Neutral cue).
2389000|NCT03648840|Other|Resting state connectivity|Some participants will also complete a functional magnetic resonance imaging (fMRI) session to determine resting state connectivity. All participants in this Arm will have completed both of the iv alcohol self-administration sessions (Aversive cue, Neutral cue).
2389001|NCT03648827|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 40 weeks.
2389002|NCT03648814|Experimental|Intracameral injection|Intracameral Bevacizumab 1.25 mg/0.05 mL. Injection
2389003|NCT03648814|Experimental|Intravitreal injection|Intravitreal Bevacizumab 1.25 mg/0.05 mL. Injection
2389004|NCT03648801||Hypertention, Dyslipidemia|NA (Observation study)
2389005|NCT03648762|Other|Heart failure patients|Patients diagnosis with heart failure will be assessed for the study
2389006|NCT03648749|Experimental|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided
2389007|NCT03648736||HOCM patients|selected for routine TASH procedure
2389008|NCT03648723||Diabetic nephropathy|Diabetic nephropathy is defined by macroalbuminuria that is, a urinary albumin excretion of more than 300 mg in a 24-hour collection or macroalbuminuria and abnormal renal function as represented by an abnormality in serum creatinine, or glomerular filtration rate(GFR)
2389009|NCT03648723||Non-diabetic nephropathy|This group consisted of diagnosis with nephropathy without diabetes mellitus.
2389010|NCT03648710|No Intervention|Enhanced Usual Care|Enhanced usual care will be standardized across sites with transition/transfer of care checklists that will be used at all sites. Enhanced usual care will minimally include (1) patient seen by the pediatric provider with the parent outside the examination room, (2) a social work consult to screen and address sociodemographic risk factors, (3) information on health insurance adequacy provided to patient, (4) adult hematologist identified, (5) adult primary care provider identified, (6) medical release signed, and (7) medical record viewable or sent to adult provider.
2389011|NCT03648710|Experimental|Peer Community Health Worker|The CHW program will primarily be modeled after the highly successful IMPaCT Program developed by the Penn Center for Community Health Workers and CHOP's Youth CHW Program for Pediatric to Adult Transitions developed by our research team, which were both developed with high levels of patient input. SCD specific content and expertise from the CHW Program through the Sickle Cell Disease Association of American Philadelphia Delaware Valley Chapter and other published models will be included. Components will include: 1) development of patient-centered goals and individualized action plan around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; and 3) tailored peer support using telephone calls and/or visits
2389012|NCT03648710|Experimental|Mobile Health|All participants enrolled in the mHealth arm will download an enhanced version of iManage, which was developed by Co-Investigator Lori Crosby at and adolescents and young adult patients with SCD. Components include: 1) development of patient-centered goals around self-care, symptom tracking, and transition to adult care; 2) provision of information, skills, and tips; 3) virtual peer support where users can encourage others to complete goals, forms teams, and interact with other youth with SCD; and 4) daily symptom tracking and visual tracking of goal completion. Investigators will add with daily tailored texting.
2391050|NCT03634774|Other|Step 2 CHOICE+|Received intervention four months after baseline
2389013|NCT03648697|Experimental|EBV-TCR-T cells(YT-E001)|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~A single dose of EBV-TCR(YT-E001) transduced T cells (about 2×108) will be intravenously (i.v.) administered."
2389014|NCT03648684|Experimental|Caffeine-Based Expectancy Challenge|Participants will ingest caffeine under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to both challenge expectancies for prescription stimulants and promote safe caffeine use for cognitive/mood enhancement.
2389015|NCT03648684|Placebo Comparator|Placebo-Based Expectancy Challenge|Participants will ingest placebo under the guise of Adderall prior to completing tasks. They will engage in an expectancy challenge intervention designed to challenge expectancies for prescription stimulants.
2389016|NCT03648684|No Intervention|Control|
2389017|NCT03648671||PD with PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
2389018|NCT03648671||PD without PAIN|12 patients will undergo add-on drugs therapy with safinamide metansolfonato.
2389019|NCT03648671||PD with PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
2389020|NCT03648671||PD without PAIN rasagilina|12 patients will undergo add-on drugs therapy with rasagilina mesilato.
2389021|NCT03648658|Experimental|Paracetamol 15mg/kg|
3142959|NCT00003873|Experimental|Arm II|Patients receive eniluracil/fluorouracil orally twice a day for 28 days.
2389023|NCT03648632|Experimental|Stereotactic Radiotherapy|50 Gy in 5 fractions within a total of 7 - 8 days
2389024|NCT03648619|Other|Oncologic patients|Oncologic patients with a previous PET/CT for whole-body staging
2389025|NCT03648593|Experimental|behavioral|work recovery intervention
2389026|NCT03648593|Experimental|waiting list control|work recovery intervention after 6 months
2389027|NCT03648580|Experimental|Intervention group|Give the verbal nutrition education and supply Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
2389028|NCT03648580|Other|Control group|just give the verbal nutrition education.
2389029|NCT03648554|Experimental|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) subcutaneous administration, one weekly injection, in a dose of 1.5 mg of dulaglutide for 52 weeks in combinaison with reinforced dietary monitoring as same as control group.
2389030|NCT03648554|Sham Comparator|reinforced dietary monitoring|reinforced dietary monitoring with frequent dietary consultations, based on American Heart Association (AHA) recommendations
3142960|NCT00003892|Experimental|ISIS 5132|ISIS 5132 x 21 days IV infusion
2389032|NCT03648528|Experimental|cholecaciferol|one 5000 IU tablet of 25VD taken during dialysis (3 pills per week) for a period of 12 weeks
2389033|NCT03648528|Placebo Comparator|placebo|one tablet of placebo taken during dialysis (3 pills per week) for a period of 12 weeks
2389034|NCT03648515||Malocclusion patients|"Patients with different types of malocclusion will be included. Plaster models will be fabricated after pouring the impressions with hard gypsum.~Then, digital images of the dental arches of each patient will be taken using a dedicated camera with very high resolution. Finally, digital images of models that were poured with gypsum will be taken also with the same camera and in the same conditions."
2389035|NCT03648502|Experimental|dementia (D-HI)|hearing impaired dementia
2389036|NCT03648502|Other|Mild cognitive impairment (MCI-HI)|MCI with hearing loss
2389037|NCT03648502|Active Comparator|normal (N-HI)|normal cognition with hearing loss
2389038|NCT03648489|Active Comparator|Arm 1: Weekly paclitaxel alone|Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria
2389039|NCT03648489|Experimental|Arm 2: Weekly paclitaxel plus TAK228|"Paclitaxel, concentrate for solution for infusion 80mg per metre squared on day 1, 8 and 15 of a 28 day cycle. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria~TAK228, oral capsule 4mg on days 2-4, 9-11, 16-18 and 23-25 of a 28 day cycle i.e. in concurrence with paclitaxel. Cycles continue until disease progression and/or death, unacceptable adverse event/s, patient and/or investigator decision, other protocol stopping criteria"
2389040|NCT03648476|Experimental|ICAN|6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
2389041|NCT03648476|Other|WLC: Waitlist Control|WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
2389042|NCT03648463|Experimental|arthroscopy with removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) along with removal of the calcified cartilage layer. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
2389043|NCT03648463|Active Comparator|arthroscopy without removal of calcified cartilage|This arm will have patients who will get surgical intervention (menisectomy, synovectomy and debridement) but with retention of the calcified cartilage cap. The patients will also get 5 cc of BMAC produced from The Harvest/Terumo BCT system.
2389044|NCT03648450||Hailie Smart Inhaler EMD|All enrolled participants will be given the Hailie Smart Inhaler electronic monitoring device to use for three months to track how often they are using their inhalers either for their regular medication or as a rescue dose.
2389045|NCT03648437|Experimental|Pedea 5mg/mL and Paracetamol 10mg/mL|Intravenous (IV) ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
2389046|NCT03648437|Placebo Comparator|Pedea 5mg/mL and 0.45 sodium chloride|IV ibuprofen 5mg/mL q 24h for 3 days, dosages: 10mg/kg + 5mg/kg + 5mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
2389079|NCT03648229|Active Comparator|MED|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided at no cost to the subject.
2389047|NCT03648437|Experimental|Indomethacin 25mg/mL and Paracetamol10mg/mL|Intravenous (IV) indometahcin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and IV paracetamol 10mg/mL for 3 days: loading dose 20mg/kg, following 7.5mg/kg q 6h (up to12 doses)
2389048|NCT03648437|Placebo Comparator|Indomethacin 25mg/mL and 0.45 sodium chloride|Intravenous (IV) indomethacin 25mg/mL q 24h for 3 days, dosages: 0.2mg/kg + 0.1mg/kg + 0.1mg/kg and NaCl 0.45% for 3 days, the same amount in mL as would have been given IV paracetamol
2389049|NCT03648424||Linagliptin|Patients who initiate Linagliptin with no use in the prior 180 days
2389050|NCT03648424||Glimepiride|Patients who initiate Glimepiride with no use in the prior 180 days
2389051|NCT03648411||Shwegyin|Shwehyin is a Township in Bago Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
2389052|NCT03648411||Pinlebu|Pinlebu is a township in Sagaing Region. We will use the comparison between the two sentinel sites by the name of Shwegyin and Pinlebu. We will compare the prevalence of asymptomatic infection between these two sites. Then proportion of the drug resistance molecular markers will be compared.
2389053|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
2389054|NCT03648385|Experimental|DHEA|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks
2389055|NCT03648385|Placebo Comparator|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
2389056|NCT03648372|Experimental|Phase 1, Dose Escalation Cohort: TAK-981|TAK-981, intravenously, administered as 60 minute-infusion, once on Days 1, 4, 8, and 11 in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study. If clinical safety, pharmacokinetics, and pharmacodynamics are supportive, the dosing schedule may be modified to evaluate a less intensive administration of TAK-981 on Day 1, or Days 1 and 8, or Day 1, Day 8, and Day 15 in 21-day cycles in participants with advanced or metastatic solid tumors or lymphomas. Dose levels will be escalated based on the Bayesian logistic regression modeling (BLRM). The dose escalation phase will determine the RP2D of TAK-981.
2389057|NCT03648372|Experimental|Phase 2, Cohort A: Nonsquamous NSCLC|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with nonsquamous non-small cell lung cancer (NSCLC).
2389058|NCT03648372|Experimental|Phase 2, Cohort B: Cervical Cancer|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with cervical cancer.
2389059|NCT03648372|Experimental|Phase 2, Cohort C: MSS-CRC|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with microsatellite-stable colorectal cancer (MSS-CRC).
2389060|NCT03648372|Experimental|Phase 2, Cohort D: r/r DLBCL after CAR T-cells therapy|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after prior chimeric antigen receptor (CAR) T-cells therapy.
2389061|NCT03648372|Experimental|Phase 2, Cohort E: r/r DLBCL without prior cellular therapy|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory DLBCL that have not received prior cellular therapy.
2389062|NCT03648372|Experimental|Phase 2, Cohort F: r/r Follicular Lymphoma|TAK-981 at RP2D and schedule, intravenously, administered as 60 minute-infusion in a 21-day treatment cycle for up to approximately 12 months or until discontinuation from the study in participants with relapsed/refractory follicular lymphoma (FL).
2389063|NCT03648359|Other|Enrolled AS patients|Patients with prostate cancer enrolled i active surveillance protocol using PSA, digital rectal examination and conventional TRUS-biopsies
2389064|NCT03648346|Experimental|Cohort 1: HL217 Ophathalmic Solution BID|Low dose: two drops of 3 mg/mL of the treatment in one eye twice a day
2389065|NCT03648346|Experimental|Cohort 2: HL217 Ophathalmic Solution QID|High dose: two drops of 3 mg/mL of the treatment in one eye 4 times a day
2389066|NCT03648346|Placebo Comparator|Placebo Ophathalmic Solution|Placebo: two drops of placebo in one eye twice a day or 4 times a day
2389067|NCT03648333|Experimental|Lodivixx tab. 5/160mg|S-amlodipine nicotinate (5mg as S-amlodipine), valsartan 160mg
2389068|NCT03648333|Active Comparator|Exforge tab. 10/160mg|amlodipine besylate (10mg as amlodipine), valsartan 160mg
2389069|NCT03648320|Experimental|Peanut oral immunotherapy|Desensitisation using peanut flour
2389070|NCT03648307||Trauma splenectomized|Patients who had gone through trauma splenectomy. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
2389071|NCT03648307||Bowel resection|Patients who had gone through bowel resection due to obstruction. BMI, lipid profile, blood pressure and glucose tolerance of patients were assessed. Hb A1C and lipid profile were assessed through blood sampling.
3142961|NCT00003900|Experimental|irinotecan + docetaxel|Patients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
3142962|NCT00003906|Active Comparator|Group 1|Tamoxifen and placebo
3142963|NCT00003906|Experimental|Group 2|Raloxifene and Placebo
3142964|NCT00003909|Experimental|Arm I|Approximately 2-5 hours before radiotherapy, patients receive motexafin gadolinium IV over 5 minutes. Patients undergo radiotherapy 5 days a week for 6 weeks.
3142965|NCT00003926|Experimental|Solid/brain tumor patients (1-18 years)|Patients with solid tumor or brain tumor in the 1-18 years old stratum.
2389077|NCT03648242|Experimental|Interruptive Clinical Decision Support|
2389078|NCT03648229|Experimental|SLT|The study eye will undergo 360-degree selective laser trabeculoplasty (SLT), followed, if needed, by repeat 360-degree SLT.
3142966|NCT00003926|Experimental|Solid/brain tumor patients (19-45 years)|Patients with solid tumor or brain tumor in the 19-45 years old stratum.
2389080|NCT03648229|Active Comparator|RX|The study eye will receive latanoprost ophthalmic solution 0.005% once daily, followed, if needed, by adjunctive timolol ophthalmic solution 0.5% twice daily. Medications will be provided by prescription to be obtained at the subject's expense. This represents usual care for glaucoma in Africa and other regions of the world.
2389081|NCT03648216|Experimental|Intervention Group|The intervention group will receive a pedometer and HAPA behavioural counseling with the aim of limiting their daily step count to <5000 steps per day, over a one week period. Counseling strategies will be grounded in the HAPA model - specifically, creating an action plan and coping strategies for maximizing their daily sedentary behaviour and minimizing steps taken. Strategies may include: driving to locations more often, refraining from physical activity as much as possible, and/or completing tasks in sedentary postures.
2389082|NCT03648216|No Intervention|Control Group|The control group will not receive any behavioural intervention or instruction.
2389083|NCT03648203|Experimental|TEAMS|Routine asthma care, as provided in the University of Rochester Medical Center Medicine Clinic, will be augmented by three intervention components over a six-month pilot period : (1) Patient subject smartphone asthma monitoring; (2) Nursing telemedicine follow up (virtual home visits); (3) EMR custom programming to guide nursing assessment and management.
2389084|NCT03648190||Inherited qualitative platelets defect|"Clinical manifestations in the form of mucocutaneous bleeding or hemorrhage.~Bleeding patients with acquired bleeding disorders, coagulation defects, and those on antiplatelet drugs will be excluded from the study."
2389085|NCT03648190||Control|Normal healthy participants, with no manifestations of bleeding disorders.
2389086|NCT03648177|Active Comparator|Treatment as Usual|"Active Comparator: (n=15) Treatment as Usual~The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain which allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic, non-pharmacologic approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
2389087|NCT03648177|Experimental|IPGT|"Experimental: IPGT (n=15) Integrated Psychosocial Group Treatment~IPGT consists of 6 weekly group sessions of motivational interviewing and behavioral change, self-management, and pain education focused on appropriate adherence to treatment and resisting urges to misuse prescription medications. The intervention also entails an education session on knowledge pertaining to overdose education and naloxone distribution. Topics covered in IPGT include: Pacing and goal setting, negative thinking, coping with stress and anxiety, sleep enhancement techniques, managing set-backs, and chronic pain and your life."
2389088|NCT03648138|Active Comparator|Calorie label|"This arm will display a Calories per Bottle label on all beverages, not just sugary beverages. This label is identical to the American Beverage Association's current Clear on Calories labels (as of 2018)."
2389089|NCT03648138|Experimental|Text warning label|This arm will display similar text proposed in a recent sugary drink warning label bill in California. Sample text: WARNING: Drinking beverages with added sugar(s) contributes to obesity, type 2 diabetes, and tooth decay. The calorie label will also appear on all beverages.
2389090|NCT03648138|Experimental|Sugar graphic warning label|"This arm will graphically display the amount of sugar in each sugary beverage along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
2389091|NCT03648138|Experimental|Health graphic warning label|"This arm will graphically display potential negative health effects of over consuming sugary drinks for each sugary beverage, along with the same text used in the text warning label arm. The calorie label will also appear on all beverages."
2389092|NCT03648125|Other|Rowing training session|"Power tests, balance and tonicity tests are performed eyes opened and eyes closed :~with artificial occlusal disturbance and~without artificial occlusal disturbance"
2389093|NCT03648112|Active Comparator|Intervention 1|"Intervention 1: Crude oat flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes."
2389094|NCT03648112|Active Comparator|Intervention 2|"Roasted oat flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~These oat flakes were roasted at 150°C for 20 minutes.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes."
2389095|NCT03648112|Active Comparator|Intervention 3|"Crude barley flakes (dietary supplement) 80 g of crude oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes"
2389096|NCT03648112|Active Comparator|Intervention 4|"Roasted barley flakes (dietary supplement) 80 g of roasted oat flakes contain 4 g ß-glucan. According to the current Health Claim, 4 g ß-glucan are necessary to achieve a reduction of the postprandial glycemic answer and a reduction of the cholesterol concentration in hypercholesterolinaemic patients.~The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes."
2389097|NCT03648112|Placebo Comparator|control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
2389098|NCT03648099|Experimental|Labor Dance and music groups|"Labor Dance; The pregnant women performed labor dance when the cervical dilatation reached 4-5 cm. The dance was performed in the company of music played through headphones.~The pregnant women listened to music for 30 minutes when the cervical dilatation reached 4-5 cm. They took any position they wanted while listening to music."
2389099|NCT03648099|No Intervention|Control group|The control group: No intervention was made to relieve the labor pain and reduce the fear of childbirth in the control group of the study. They were administered routine hospital applications.
2389100|NCT03648086|Experimental|IMT|30 non-alcoholic fatty liver disease（NAFLD） patients will be recruited for the study, which involved a 6 times intestinal microbiota transplant(IMT) and the time interval is generally 2 weeks.
2389101|NCT03648086|No Intervention|control|30 non-alcoholic fatty liver disease(NAFLD) patients without any treatment
2389102|NCT03648073|Experimental|Untreated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
2389103|NCT03648073|Experimental|Previously treated HCC|[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
2389104|NCT03648060|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital kinematic biofeedback system. Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol.
2389105|NCT03648047|Experimental|Experimental group|Patients in this group will receive a mixed home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist (with decreasing periodicity depending on program stage) as well as sessions performed with a digital kinematic biofeedback system.
2389106|NCT03648047|Active Comparator|Conventional rehabilitation|Patients in this group will receive a home-based rehabilitation program consisting of face-to-face sessions with a Physical Therapist 3 times per week, for 1 hour. Patients will also be instructed to perform additional unsupervised sessions in at least two other days of the week. Compliance to these additional sessions is not mandatory, but patients will be asked to fill in a diary regarding these extra-sessions.
2389107|NCT03648034|Experimental|ropivacaine|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.5% ropivacaine
2389108|NCT03648034|Placebo Comparator|saline|After anesthesia induction but before skull-pin insertion, patients in this group will receive scalp nerve blocks with 0.9% saline
2389109|NCT03648021|Active Comparator|paracetamol (acetaminophen)|patient will receive1 gramme of paracetamol intravenously
2389110|NCT03648021|Placebo Comparator|Placebo|patient will receive 100 ml of chlorure de sodium 0,9% intravenously
2389111|NCT03648008|Active Comparator|Group M|Drug: Morphine Background: No Bolus infusion: 0.015 mg*kg-1
2389112|NCT03648008|Experimental|Group NBH|Drug: Hydromorphone Background: No Bolus infusion: 0.002 mg*kg-1
2389113|NCT03648008|Experimental|Group BH|Drug: Hydromorphone Background: 0.002 mg*kg-1*h-1 Bolus infusion: 0.002 mg*kg-1
2389114|NCT03647995|Active Comparator|Probiotic-receiving group|The probiotic-receiving group will receive once daily probiotics containing 25Bn CFU of which: 5Bn CFU Lactobacillus rhamnosus GG, 5Bn CFU Sacchromyces boulardii, 5Bn CFU Bifidobacterium breve, 4.5Bn CFU Bifidobacterium lactis, 2.5 Bn CFU Lactobacillus acidophilus, 2.5Bn CFU Lactobacillus plantarum and 500Mn CFU Lactobacillus reuteri.
2389115|NCT03647995|Placebo Comparator|Placebo|The placebo group will receive once daily, identical capsules containing 0 Bn CFU.
2389116|NCT03647982|Experimental|botulinum toxin 1U|
2389117|NCT03647982|Experimental|botulinum toxin 3U(25U/1ml)|
2389118|NCT03647982|Experimental|botulinum toxin 5U|
2389119|NCT03647982|Experimental|botulinum toxin 10U|
2389120|NCT03647982|Experimental|botulinum toxin 3U(50U/1ml)|
2389121|NCT03647982|Experimental|botulinum toxin 3U(12.5U/1ml)|
2389122|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab A/A1|"Nivolumab 240mg Flatdose i.v. d1 over 30 min every 2 weeks followed by Ipilimumab 1mg/kg i.v. d1 over 30 min every 6 weeks followed by FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment."
2389123|NCT03647969|Experimental|mFOLFOX/Nivolumab/Ipilimumab sequential A2|"3 cycles of induction chemotherapy with FOLFOX: FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks followed by immunotherapy consisting of: 4 administrations of Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks and 2 administrations of Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks~Sequence as described may be repeated starting two weeks after last administration of immunotherapy once, or, if medically reasonable, for an unlimited number of repetitions upon investigator decision. After discontinuation of chemotherapy, immunotherapy will be continued consisting of:~Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks and Ipilimumab at 1mg/kg i.v. d1 every 6 weeks until disease progression or inacceptable toxicity or end of study treatment."
2389124|NCT03647969|Active Comparator|mFOLFOX B|FOLFOX Oxaliplatin 85 mg/m² iv 2hrs (day 1), Leucovorin 400 mg/m2 iv 2hrs (day 1), Fluorouracil 400 mg/m² iv bolus (day 1), and Fluorouracil 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks until disease progression or inacceptable toxicity or end of study treatment.
2389125|NCT03647969|Experimental|FLOT/Nivolumab C|"Nivolumab 240mg Flatdose i.v. d1 every 2 weeks followed by FLOT: Docetaxel 50mg/², Oxaliplatin 85 mg/m², leucovorin 200 mg/m² on day 1 and fluorouracil 2600 mg/m² IV continuous infusion over 24 hours every 2 weeks until disease progression or inacceptable toxicity or end of study treatment. After completion or discontinuation of chemotherapy, immunotherapy may be continued consisting of: Nivolumab at 240mg Flatdose i.v. d1 every 2 weeks Chemotherapy can also be administered per local standard."
2389126|NCT03647956|Experimental|Arm 1|Using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, carboplatin and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
2389127|NCT03647943|Experimental|Active tDCS|Participants will receive 10 sessions of active tDCS + cognitive training.
2389128|NCT03647943|Sham Comparator|Sham tDCS|Participants will receive 10 sessions of sham tDCS + cognitive training.
2389129|NCT03647930|Experimental|Intervention|Application of Microporous Polysaccharide Hemospheres (MPH)
2389130|NCT03647930|No Intervention|Control|No MPH
3142967|NCT00003927|Experimental|High Dose chemotherapy followed by cell rescue|Doxorubicin, cyclophosphamide, Taxol, amifostine
2389206|NCT03647371|Other|Macintosh laryngoscope|direct laryngoscope - laryngoscope with Macintosh blade
3142968|NCT00003930|Experimental|Arm 1|Transurethral surgery with chemotherapy and radiation therapy followed by either selective bladder preservation or radical cystectomy followed by adjuvant chemotherapy.
3183613|NCT00715585|Active Comparator|Active Control|patients receive 3 individualized visits with a health educator for education on general diabetes and health promotion
3142969|NCT00003931||blood or bone marrow samples|"All samples are obtained from specimens collected on CALGB-9665. No additional blood or bone marrow samples are collected CALGB-9769.~Samples are examined by Southern blot analysis for gene rearrangement at 11q23. Samples showing evidence of ALL1 gene rearrangement are further analyzed by reverse transcription PCR amplification and/or cytogenetic analysis to detect partial tandem duplication of ALL1."
2389133|NCT03647904|Experimental|SEMS Project|A comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
2389134|NCT03647904|Other|Wait List Control|Individuals in the wait list control arm will serve as controls for the first intervention group, but will receive the treatment following their three month assessment. The intervention following the waitlist control will be a comprehensive modular intervention consisting of wellness, fatigue management, cognitive remediation and psychological treatment. Treatment will consist of a total of 12 weeks.
2389135|NCT03647891|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying cardiac condition(s). They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
2389136|NCT03647891|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying cardiac condition(s) and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
2389137|NCT03647865|Experimental|Patients need genioplasty|
2389138|NCT03647852|Experimental|Methylprednisolone group|In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
2389139|NCT03647852|Active Comparator|IVIG group|In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
2389140|NCT03647839|Experimental|Arm 1|Nivolumab and BNC105
2389141|NCT03647839|Experimental|Arm 2|Nivolumab and BBI-608
2389142|NCT03647826|Experimental|Mind Power Intervention Group 1|"Entire school classes will be randomly divided into two interventions (Mind Power Intervention Group 1 or Mind Power Intervention Group 2). The content in the two interventions are exactly the same, except the time when they are conducted.~The first arm is the Mind Power Intervention Group 1. This intervention is the first and starts in September 2018 and last for 10 weeks."
2389143|NCT03647826|Experimental|Mind Power Intervention Group 2|"The second arm is the Mind Power Intervention Group 2. This arm starts the intervention in January 2019 (six months later than Group 1). Group 2 function as a Control Group.~The Experiment containes arm 1 and arm 2; With an delayed intervention design."
2389144|NCT03647813|Active Comparator|Photobiomodulation group|Patients were submitted to three sessions of PBM (baseline, 7 and 14 days). PBMT was administered by a single professional using a continuous wave AsGaAl diode laser (Photon Lase III - DMC, São Paulo, Brazil) with a wavelength of 808 nm (infrared). Irradiation was performed in punctual contact mode (ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point). A total of 20 points were applied in each session/day being three extraoral points in the parotid region (right and left n=6), three points in buccal mucosa (right and left, n=6), two extraoral (right and left, n=4) and two intraoral (right and left, n=4) points in the submandibular and sublingual regions.
2389145|NCT03647813|Placebo Comparator|Placebo group|Patients were submitted to same protocol as the photobiomodulation group, but the laser was turned off.
3183614|NCT00715585|Experimental|Intervention 1|patients receive 3 individualized visits with an rd-cde for education focused on modified plate method
3183615|NCT00715585|Experimental|intervention 2|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
2389148|NCT03647774|Experimental|Extended release naltrexone|Extended release naltrexone 380 mg as an intramuscular injection every 4 weeks.
2389149|NCT03647774|No Intervention|Treatment As Usual (TAU)|Daily sublingual buprenorphine in flexibel dose according to the patients need and ART guidelines.
2389150|NCT03647761|No Intervention|Control|Standard of care
2389151|NCT03647761|Experimental|Treatment|Tetra-grip applied
2389152|NCT03647748|No Intervention|Cellulize 532nm|Cellulize device using 532nm Green Light.
2389153|NCT03647748|Sham Comparator|Cellulize Placebo (Sham Comparator)|"Cellulize modified to appear as if it is running, but does not use the 532nm light.~Sham Device, or Placebo."
2389154|NCT03647735|Experimental|Group PCS|Patients in Group PCS (patient-controlled sedation) received intravenous (IV) propofol via a patient controlled analgesia (PCA) infusion pump. The machine was set to deliver a demand bolus dose of 0.25 mg/kg with 1-minute lockout interval, without basal infusion.The patient was instructed to press on a hand-held device as often as required, to achieve their desired level of comfort or sedation.
2389155|NCT03647735|Active Comparator|Group TCIS|Patients in Group TCIS (target-controlled infusion sedation) received IV propofol via a target-controlled infusion (TCI) pump, targeted at an initial effect site concentration (Cet) of 0.6 μg/ml, using the Schnider pharmacokinetic model. Upon attainment of 0.6 μg/ml Cet, the patient's sedation level was assessed. The Cet was increased or reduced accordingly by 0.2 μg/ml to attain an OAA/S score of 3.
2389156|NCT03647722||Lemtrada treated - 6 month|Patients that received their first course of treatment with Lemtrada approximately 6 months prior.
2389207|NCT03647371|Other|McGrath videolaryngoscope|McGrath Videolaryngoscope
3183616|NCT00715598||Neuropathic Pain|Subjects in this group experience chronic neuropathic pain.
2389157|NCT03647722||Lemtrada treated - 12 month|Patients that received their first course of treatment with Lemtrada approximately 12 months prior but who have not received the second course of treatment.
2389158|NCT03647722||Lemtrada treated - 18 month|Patients that received their first course of treatment with Lemtrada approximately 18 months prior and their second course of treatment with Lemtrada approximately 6 months prior.
2389159|NCT03647722||Lemtrada treated - 24 month|Patients that received their first course of treatment with Lemtrada approximately 24 months prior and their second course of treatment with Lemtrada approximately 18 months prior and who have not received any further treatment.
2389160|NCT03647722||Lemtrada qualified - untreated|Patients that are qualified to start treatment with Lemtrada but have not yet being untreated.
2389161|NCT03647683|Experimental|Self-Compassion|After pretreatment heat pain assessment, participants are introduced to the concept of self-compassion. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily self-compassion audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2389162|NCT03647683|Experimental|Acceptance|After pretreatment heat pain assessment, participants are introduced to the concept of acceptance. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily acceptance audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2389163|NCT03647683|Experimental|Distraction|After pretreatment heat pain assessment, participants are introduced to the concept of distraction. Participants practice the new strategy with heat pain stimuli three times. Next, the posttreatment pain assessment is conducted. For a one week period, participants receive daily distraction audio-interventions. Afterwards, the follow-up pain assessment is conducted.
2389164|NCT03647670|Other|Sequence 1|In Sequence 1, Period 1, subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hours (hr). Period 1 will be immediately followed by Period 2 with no washout, in which subjects will be dosed with 200 mg PF-04965842 orally once daily (QD) for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing.
2389165|NCT03647670|Other|Sequence 2|In Sequence 2, Period 1, subjects will be dosed with 200 mg PF-04965842 orally QD for 7 days. Midazolam 2 mg oral solution will be administered on the morning of Day 2 and Day 7 within 5 minutes after PF-04965842 dosing. Midazolam PK will be assessed for 24 hr following dosing. Subjects will then undergo a washout period of at least 7 days. In Period 2 subjects will be dosed with a single administration of midazolam 2 mg oral solution on Day 1. Midazolam PK will then be assessed over the next 24 hr.
2389166|NCT03647657|Experimental|Entresto second|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N without and second injection with additional medication of Sacuitril (100 mg Entresto)(crossover)
2389167|NCT03647657|Experimental|Entresto first|First intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and second injection without additional medication of Sacuitril (100 mg Entresto)(crossover)
2389168|NCT03647644||Acute Normovolemic Hemodilution Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. If clinically indicated and appropriate per the discretion of the anesthesiologist, Acute Normovolemic Hemodilution (ANH) blood, about 2 units, will be withdrawn from the patients and stored carefully at room temperature per standard protocol. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients prior to re-infusing the ANH blood and after the blood has been infused per standard institutional protocol.
2389169|NCT03647644||Control Group|All patients enrolled in the study will undergo a perioperative cardiac surgical anesthetic care plan standardized to the current institutional protocol utilized for intraoperative medication administration. In this arm, ANH would be clinically appropriate, however, the anesthesiologist determined they would not have ANH preformed. At the conclusion of cardiopulmonary bypass and after protamine administration, Coagulation Laboratory Testing will be drawn from the patients and again 30 minutes later to mirror the time lapse in the ANH group.
2389170|NCT03647631||Patients affected to porocarcinoma|
2389171|NCT03647631||patients affected to porocarcinoma in our centre|
2389172|NCT03647618||Adductor canal|Patients receiving ultrasound-guided regional anaesthesia
2389173|NCT03647618||Popliteal|Patients receiving ultrasound-guided regional anaesthesia
2389174|NCT03647618||Fascia Iliaca|Patients receiving ultrasound-guided regional anaesthesia
2389175|NCT03647618||Rectus sheath|Patients receiving ultrasound-guided regional anaesthesia
2389176|NCT03647618||Axillary|Patients receiving ultrasound-guided regional anaesthesia
2389177|NCT03647605|Experimental|VR Mind|Two VR Mind sessions using experimental virtual reality scenarios. During these two sessions, participants will be exposed to virtual reality environment, for 2 x 10 min each session.
2389178|NCT03647592||Cohorts 1|patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab
2389179|NCT03647579|Active Comparator|midazolam plus ketamine|
2389180|NCT03647579|Active Comparator|dexmedetomidine plus ketamine|
2389181|NCT03647566||No Aortic Disease|Participants with normal calibre aortae and no prior diagnosis of acute aortic syndrome
2389182|NCT03647566||Acute Aortic Syndrome|Participants presenting acutely with a diagnosis of acute aortic syndrome as defined in the European Society of Cardiology guidelines: a compatible clinical presentation with CT or magnetic resonance imaging confirming acute aortic syndrome.
2389183|NCT03647566||Chronic Aortic Disease|Participants with an established diagnosis of acute aortic syndrome.
2389184|NCT03647540|Experimental|Group F|Group F received endoscopic submucosal injection of indocyanine green (ICG) 2 hours before operation, followed by fluorescent laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
3183617|NCT00715598||Musculoskeletal Pain|Subjects in this group experience chronic musculoskeletal pain.
2391051|NCT03634774|Other|Step 3 CHOICE+|Receives intervention eight months after baseline
2389185|NCT03647540|Active Comparator|Group L|Group L received traditional laparoscopic radical gastrectomy. All specimens were grouped for lymph node collection, and the postoperative management was unified according to enhanced recovery after surgery (ERAS). All basic clinical and pathological data were statistically analyzed
2389186|NCT03647514|Experimental|Abraxane Combined With Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
3142970|NCT00003934|Experimental|Arm I|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin every 12 hours on days 1-7 and daunorubicin IV on days 1-2 or days 1-3, depending on age. Patients may receive an additional course. Treatment begins no earlier than 2 weeks and no later than 4 weeks after hematopoietic recovery."
2389192|NCT03647462|Experimental|CPAP Intervention Pathway|"Patients will receive continuous positive airway pressure (CPAP) therapy in the hospital followed by home CPAP therapy. Their home CPAP therapy will include wireless connectivity, which includes adherence data. Furthermore, the patients will be entered into our usual automated platform (USleep; ResMed Corp) in which patients with suboptimal CPAP use will be sent messages (based on patient preference) in order to ensure adherence to therapy. This platform is already a standard part of our usual care.~The patients will receive CPAP in addition to contemporary standard of care pharmacotherapy for their underlying COPD. They will follow up at the Fontana Sleep Center within 1 month after discharge for assessment of CPAP use and asked to complete a questionnaire packet. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms."
2389193|NCT03647462|No Intervention|Usual Care Pathway|Patients will receive contemporary standard of care pharmacotherapy for their underlying COPD condition and will not receive CPAP therapy for the duration of the study. They will be asked to follow up at the Fontana Sleep Center within 1 month after discharge for a repeat outpatient portable sleep study and asked to complete a questionnaire packet. The results of the outpatient portable sleep studies will be compared with the in-patient portable sleep study. Patients will also be asked to follow up with the Fontana Sleep Center within 1 month after discharge for assessment of primary and secondary outcomes. Patients will be followed during the 30-day period and assessed for readmission rates, time to readmission, adherence to CPAP therapy, and presence of symptoms.
2389194|NCT03647449|Experimental|Juice fast|"In the juice fasting arm, participants will be given vegetable/fruit pressed juices and be instructed to engage in a three-day juice fast diet totaling 800-900 kcal-per-day. The specific juices will be assigned for each day in order to maintain the calorie level."
2389195|NCT03647449|Experimental|Caloric restriction via Plant-based meals|"In the caloric restriction diet arm, participants will be on a whole-food plant-based diet totaling 800-900 kcal-per-day (matching the daily calories of juice fasting)."
2389196|NCT03647449|Experimental|Juice plus ad hoc|"In the juice plus ad hoc arm, participants will be given the same juice for three days but continue with their usual diet in addition to the juice. For this arm, there is no restriction of caloric intake or restriction to liquid only."
2389197|NCT03647436||Exposed group|"Elderly patients with hospital admission due to hip fracture and score less than 12 points in the short-MNA at the moment of hospital admission.~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
2389198|NCT03647436||Control group|"Elderly patients with hospital admission due to hip fracture and score equal or higher than 12 points in the short MNA at the moment of hospital admission~Intervention:~Comprehensive Geriatric Assesment (CGA). Both groups.~CGA includes measuring of:~Previous functional assessment of daily life activities (Barthel and Lawton index), a cognitive screening (MiniMental State Examination), the turn-based assessment of the presence of delirium (Confusion Assessment Method) and in case of presence of delirium will be measured the duration and intensity of the symptoms (Delirium Rating Scale-Revised-98). Likewise, the presence of frailty (Clinical Frailty Scale) and walking ability (Functional Ambulation Categories) will be evaluated."
2389199|NCT03647423|Experimental|NANT Chordoma Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
2389200|NCT03647423|Active Comparator|Controlled Arm - Radiation|SBRT
2389201|NCT03647410||lumbopelvic fixation|sacral fractures fixed with lumbopelvic fixation
2389202|NCT03647410||novel adjustable plate|sacral fractures fixed with novel adjustable plate
2389203|NCT03647397|Experimental|PECO|All pediatric patients admitted for respiratory distress will have the intervention of Photo Electrochemical Oxidation (PECO) for Air Purification.
2389204|NCT03647384|Experimental|Intervention|In this arm, patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
2389205|NCT03647384|Active Comparator|Control|In this arm, patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
2438524|NCT03308331|No Intervention|Healthy control nonsmokers|
2389209|NCT03647345|Experimental|Experimental 1: Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389210|NCT03647345|Experimental|Experimental 2: Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389211|NCT03647345|Active Comparator|Active Comparator: Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389212|NCT03647332|Active Comparator|Cooled RFA treatment|
2389213|NCT03647332|Active Comparator|Steroid injection|
2389214|NCT03647319|Experimental|Anodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of anodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389215|NCT03647319|Experimental|Cathodal Dual-mode stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of cathodal tDCS on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389216|NCT03647319|Active Comparator|Single sham stimulation|"10Hz of rTMS was applied over the left DLPFC for 10 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the right DLPFC.~Each participant's 2-back verbal/nonverbal working memory task and variety cognitive function test are assessed and their resting-state fMRI data at three times: prior to stimulation (pre-stimulation), immediately after stimulation (post-stimulation) and 2 months after stimulation (f/u) are acquired."
2389217|NCT03647306|Active Comparator|Extended Overnight Fast|The extended overnight fast group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session. Subjects will consume approximately 33% of their daily calories at breakfast, lunch and dinner, respectively. This is a model for fasting dietary chronotype.
2389218|NCT03647306|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 60% of their daily calories during breakfast. The remaining 40% of daily calories will be consumed during lunch and dinner. This is a model for early dietary chronotype.
2389219|NCT03647306|Experimental|Late Total Caloric Intake|The Late Total Caloric Intake study group will have scheduled meal times for the entire 6 day semi ambulatory and in lab session and will consume 40% of daily calories during breakfast and lunch. The remaining 60% of daily calories will be consumed during dinner. This is a model for late dietary chronotype.
2389220|NCT03647293|Active Comparator|Control Group|Neonates who underwent a peripherally inserted central catheter
2389221|NCT03647293|Active Comparator|Intervention Group|Neonates who underwent an Ultrasound Guided Central Catheter Insertion
2389222|NCT03647280|Experimental|Abraxane Combined With Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
3183619|NCT00715637|Experimental|Arm A|Amonafide in Combination with Cytarabine
3183620|NCT00715637|Active Comparator|Arm B|Daunorubicin in Combination with Cytarabine
2389225|NCT03647254|Experimental|Patient Education Group|A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting and they continued with their usual controls
2389226|NCT03647254|No Intervention|Control group|Control group performed usual clinical practice, that is, people will be schedule by nurses about one time per month, except cases in which controls are inappropriate.
2389227|NCT03647241|Experimental|Self-Ligating Brackets|Patients will be treated using self-ligating brackets to achieve proper alignment of teeth
2389228|NCT03647241|Experimental|Self-Ligating Brackets with Corticotomy|Patients will be treated using self-ligating brackets with corticotomy (alveolar cortical cuts) in order to accelerate orthodontic treatment.
2389229|NCT03647241|Active Comparator|Traditionally-Ligated Brackets|Patients in this group will be treated using traditionally-ligated brackets to achieve proper alignment of teeth
2389230|NCT03647228|Experimental|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
2389231|NCT03647228|Placebo Comparator|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
3183621|NCT00715663||A|
3183622|NCT00715689|Experimental|A|
2389232|NCT03647215||All Participants|Participants with CML and Ph+ALL who are being treated with their first or subsequent TKI therapy. CML patients must meet the ELN criteria for warning and failure ) or have high SOKAL score (>0.8) or presence of additional chromosomal abnormalities (ACAs) and have detectable BCR-ABL levels. Ph+ALL patients need detectable BCR-ABL levels only.
2389233|NCT03647202|Experimental|Sequence ABC|Participants receive milademetan in a fasted condition (A), then with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C) - with a washout period between treatments.
2389234|NCT03647202|Experimental|Sequence ACB|Participants receive milademetan in a fasted condition (A), then with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
2389235|NCT03647202|Experimental|Sequence BAC|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then in a fasted condition (A), then with a standard breakfast (C) - with a washout period between treatments.
2389236|NCT03647202|Experimental|Sequence BCA|Participants receive milademetan with a high-calorie, high-fat breakfast (B), then with a standard breakfast (C), then in a fasted condition (A) - with a washout period between treatments.
2389237|NCT03647202|Experimental|Sequence CAB|Participants receive milademetan with a standard breakfast (C), then in a fasted condition (A), then with a high-calorie, high-fat breakfast (B) - with a washout period between treatments.
2389238|NCT03647202|Experimental|Sequence CBA|Participants receive milademetan with a standard breakfast (C), then with a high-calorie, high-fat breakfast (B), then in a fasted condition (A) - with a washout period between treatments.
2389239|NCT03647189|Experimental|Treatment Arm|Subjects will be treated with hybrid fractional laser
2389240|NCT03647189|Placebo Comparator|Control Arm|
2389241|NCT03647176|Active Comparator|small polyps|Cold snare polypectomy ; Polyp size will be measured using the tip of the snare catheter (2.5mm).Small (5-9 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, biopsies were performed from two marginal sites located symmetrically on the left and right of the mucosal defects to confirm residual polyp tissue.
2389242|NCT03647176|Experimental|large polyps|Cold snare polypectomy; Polyp size will be measured using the tip of the snare catheter (2.5mm). Large (10-15 mm) colorectal polyps will be removed with a polypectomy snare. Following the resection, jet stream of water will be used to wash mucosal defect thoroughly. After endoscopist's attestation that polyp removal was complete by carefully observe the resection margins with near focus mode, 4 biopsies will be performed from all four quadrants of resection margins.
3142971|NCT00003934|Experimental|Arm II|"Induction: All patients receive oral tretinoin every 12 hours beginning on day 1 until complete response or for a maximum of 90 days. Patients also receive daunorubicin IV on days 3-6 and cytarabine IV continuously on days 3-9.~Consolidation: All patients achieving CR or PR after completion of tretinoin, proceed to consolidation within 2 weeks of achieving CR or PR, but not prior to 30 days from the start of induction. Patients are randomized to 1 of 2 treatment arms.~Patients receive oral tretinoin as in arm I above. Patients also receive oral mercaptopurine once a day and oral methotrexate once weekly for up to 1 year."
3142972|NCT00003935|Experimental|Treatment|Induction: Patients receive oral etoposide daily on days 1-21 and vincristine sulfate IV on days 1, 8, and 15. Treatment repeats every 4 weeks for 2 courses. Patients receive radiation therapy daily for 6 weeks concurrently with induction chemotherapy. Maintenance: One week after induction therapy, patients receive vincristine sulfate IV on days 1 and 8 and oral etoposide daily on days 1-21. Treatment repeats every 4 weeks for 10 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter
3142973|NCT00003937|Experimental|Pilot 1 - Doxorubicin Intensification without Ifosfamide|Dexrazoxane hydrochloride IV followed by doxorubicin hydrochloride IV plus cisplatin IV on days 1 and 2 of weeks 1 and 6. Methotrexate IV on day 1 of weeks 4, 5, 9, and 10. Patients undergo surgery on week 11. Adjuvant chemotherapy begins on day 1 of week 13. Group 1 (good response to neoadjuvant chemotherapy): Patients receive methotrexate IV over 4 hours every 3 weeks for 6 courses, beginning on week 13. Patients also receive dexrazoxane and doxorubicin hydrochloride every 3 weeks for 4 courses, beginning on week 14. Cisplatin is administered with the first 2 courses of dexrazoxane and doxorubicin. Group 2 (standard response to neoadjuvant chemotherapy): Patients receive methotrexate and cisplatin as in group 1 plus dexrazoxane and doxorubicin hydrochloride for 6 courses.
2389247|NCT03647150|Other|Moderate Acute Malnutrition (MAM)|"MAM children at control clinics or MAM children at intervention clinics that do no have high rick characteristics. Control treatment is Mother Care counselling, delivered by a respected elder in the local community."
2389248|NCT03647150|Experimental|High Risk Moderate Acute Malnutrition (MAM)|The intervention treatment incorporates Mother Care counselling, provision of one packet (508 calories) of ready-to-use therapeutic food (RUTF) daily and a 1 week course of amoxicillin. This provision will continue until the child has reached a mid-upper arm circumference (MUAC) equal to or greater than 12.5 cm or 12 weeks have elapsed.
2389249|NCT03647137||Parkinson's disease with FoG|Subjects with Parkinson's disease that have freezing of gait (FoG) who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
2389250|NCT03647137||Parkinson's disease without FoG|Subjects with Parkinson's disease that do not have freezing of gait who have undergone Brain PET imaging of 11C-DBTZ, 18F-FEOBV (vesicular acetylcholine transporter, and 11C-PIB (beta-amyloid)
2389251|NCT03647124||Lenalidomide treated R/R-MCL patients in Denmark and Sweden|Retrospective data collection for Lenalidomide treated R/R-MCL patients from Nordic registries and national health databases
2389252|NCT03647124||Lenalidomide treated R/R-MCL patients in the rest of EU|Retrospective data collection for Lenalidomide treated R/R-MCL patients from sites in the rest of European Union
2389253|NCT03647111||Cohorts 1|
2389254|NCT03647098||Cohorts 1|Treatment plan
2389255|NCT03647098||Cohorts 2|brain metastases
2389256|NCT03647098||Cohorts 3|Concomitant KRAS mutation
2389260|NCT03647072|Active Comparator|CHOP|CHOP only
2389261|NCT03647072|Active Comparator|CHOP Plus Lanzoprazole|CHOP Plus Lanzoprazole 60 mg
2389262|NCT03647072|Active Comparator|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
2389263|NCT03647059||LSCM examination|
3183623|NCT00715689|Experimental|B|
2389267|NCT03647007|No Intervention|Standard group|The Standard programme on the Christmas Seal Homes.
2389268|NCT03647007|Experimental|FIFA Group|The Standard programme including FIFA 11 for Health programme - health knowledge on the football pitch.
2389269|NCT03646994||Cohorts 1|ROS1 fusion positive NSCLC patients who received crizotinib
2389270|NCT03646968|Experimental|Cohorts|Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
2389271|NCT03646955|Active Comparator|Partial breast irradiation|External beam irradiation 40 Gy / 15 fractions, 5 fractions per week, 3 weeks
2389272|NCT03646955|No Intervention|No partial breast irradiation|No radiation therapy
2389273|NCT03646942|Active Comparator|Lingual orthodontics|Patients will be treated with lingual braces without being irradiation with low level laser therapy. Treatment will go forward in the normal manner. Archwires will be changed in the traditional way.
2389274|NCT03646942|Experimental|Low level laser therapy|Patients will be subjected to low level laser therapy during their orthodontic treatment using lingual braces.
2389275|NCT03646929|Other|healthy individuals and patients with multiple sclerosis|MEP in healthy individuals and patients with multiple sclerosis are measured using standard facilitation technique
2389276|NCT03646929|Other|patients with multiple sclerosis|MEP in patients with multiple sclerosis are measured using modified facilitation technique
2389277|NCT03646916|Active Comparator|Dexamethasone|
2389278|NCT03646916|No Intervention|Non-treatment|
2389279|NCT03646903|Experimental|Cognitive Bias Modification for Help-Seeking Stigma (CBM-HS)|"CBM-HS is a 15-minute web-based intervention designed to alter maladaptive cognitions related to mental health help-seeking. In this task, individuals are presented with a series of statements regarding beliefs about using mental health services (e.g., Seeking help for my problems means I am weak). Individuals then select True or False in response to each statement. Incorrect responses (i.e., demonstrating help-seeking stigma) are followed by corrective feedback. Conversely, correct responses (i.e., promoting help-seeking) are positively reinforced (e.g., That's right! You are correct!). Participants in this condition will complete three separate 15-minute CBM-HS sessions."
2389280|NCT03646903|Placebo Comparator|Placebo Cognitive Bias Modification|Participants randomized to this condition will complete a similar CBM task with neutral stimuli. The duration of the CBM-Placebo task will be comparable to the duration of the CBM-HS task (i.e., three 15-minute sessions).
2389281|NCT03646903|Active Comparator|Self-Directed Psychoeducation|Participants randomized to this condition will review psychoeducation on mental health literacy, mental illness stigma, and treatment options. Readings will be compiled from resources available in the public domain. The duration of self-directed psychoeducation will be comparable to the duration of study tasks for individuals in the CBM-HS study condition (i.e., three 15-minute sessions).
2389282|NCT03646877|Experimental|Ozone (O3)|The O3 level during the exposures will be 200 ppb, which has previously been used in human exposure studies without short or long term, untoward side effects (and comparable to peak levels attained during the summer in the Raleigh-Durham area of North Carolina) (REF - Bromberg review).
2389283|NCT03646877|Placebo Comparator|Filtered Air (FA)|Control will be treadmill walk with filtered room air in chamber.
2389284|NCT03646864|Experimental|Treatment A|ACT-541468 50 mg from Day 1 to Day 5 of Period A
2389285|NCT03646864|Placebo Comparator|Treatment B|Placebo from Day 1 to Day 5 of Period B
2389286|NCT03646851|Experimental|COPD|COPD patients GOLD stage III and IV
2389287|NCT03646825||Treatment group|Male patients exposed to antioxidant for 12 weeks
2389288|NCT03646812|Other|Glucose Reference 1|50g of glucose dissolved in 250ml of water to be consumed.
2389289|NCT03646812|Other|Glucose Reference 2|50g of glucose dissolved in 250ml of water to be consumed.
2389290|NCT03646812|Other|Glucose Reference 3|50g of glucose dissolved in 250ml of water to be consumed.
2389291|NCT03646812|Experimental|Semolina Penne|70g of semolina penne boiled in 1 Litre of water for 11 minutes. Drained and consume immediately.
2389292|NCT03646812|Experimental|Wholegrain Penne|76g of wholegrain penne boiled in 1 Litre of water for 9 minutes. Drained and consume immediately.
2389293|NCT03646812|Experimental|Semolina Spaghetti|71g of semolina spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
2389294|NCT03646812|Experimental|Wholegrain Spaghetti|76g of wholegrain spaghetti boiled in 1 Litre of water for 8 minutes. Drained and consume immediately.
2389295|NCT03646812|Experimental|Jasmine rice|63g of rice cook with 150g of water. Served and consume immediately.
2389296|NCT03646812|Experimental|Asian Noodles|92.4g of Asian Noodles cook in boiling water for 45 seconds. Drained and consume immediately
2389297|NCT03646799|Experimental|Group 1|Period 1: 1 tablet of reference drug(D484) Period 2: 1 tablet of test drug(CKD-387)
2389298|NCT03646799|Experimental|Group 2|Period 1: 1 tablet of test drug(CKD-387) Period 2: 1 tablet of reference drug(D484)
2389300|NCT03646760|Experimental|Hybrid Cardiac Rehabilitation (HYCR)|
2389301|NCT03646760|Active Comparator|Center Based cardiac Rehabilitation (CBCR)|
2389302|NCT03646747|Experimental|MRI scan|"10 healthy participants will be asked to undergo two baseline OE-MRI scans with either nasal cannula or facial mask to breathe air and oxygen throughout.~Following this initial pilot, OE-MRI will be tested in 30 patients with solid head and neck tumours."
2389303|NCT03646734||Guided Bone Regeneration with Particulate graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with particulate graft
2389304|NCT03646734||Guided Bone Regeneration with block graft|patients who had inadequate alveolar crest (crest width <4mm) and requested of dental implant placement, treated with guided bone regeration with block graft
2389305|NCT03646721|Experimental|[Part1] DA-1241 : 6 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
2389334|NCT03646539|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
3183624|NCT00715689|Experimental|C|
3183625|NCT00715689|Experimental|D|
2389306|NCT03646721|Placebo Comparator|[Part1] Placebo : 2 subjects in each cohort(Cohort 1-3)|Subjects will participate in 1 of 3 cohorts consisting of 8 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 6:2 (DA-1241 to matching placebo).
2389307|NCT03646721|Experimental|[Part2] DA-1241 : 15 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2389308|NCT03646721|Placebo Comparator|[Part2] Placebo : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2389309|NCT03646721|Active Comparator|[Part2] Sitagliptin : 5 subjects in each cohort(Cohort 4-6)|Subjects will participate in 1 of 3 cohorts consisting of 25 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 3:1:1 (DA-1241 to matching placebo and active comparator).
2389310|NCT03646708||SBCD patients starting a new biologic therapy|As part of your standard clinical care (soc), patient will be started on a biologic (anti-tumor necrosis factor (TNF)s, vedolizumab and ustekinumab) based on your interactions with your treating gastroenterologist after standard of care clinical assessment.
2389311|NCT03646695|Experimental|ILM flap|vitrectomy with ILM flap transposition and gas-tamponade will be performed
2389312|NCT03646695|Active Comparator|ILM peeling|vitrectomy with ILM peeling and gas-tamponade will be performed
2389313|NCT03646682|Experimental|caffeine group|180mg of caffeine will be given orally one jour before vitrectomy with membrane peeling
2389314|NCT03646682|Active Comparator|control group|no caffeine will be given before vitrectomy with membrane peeling, patients are drinking no coffee in general
2389315|NCT03646669|Experimental|Asthma education and PEF feedback|Patients receive asthma education and personal Peak expiratory flow (PEF) feedback
2389316|NCT03646669|Placebo Comparator|Asthma education|No PEF feedback arm
3183626|NCT00715702|Experimental|1|Patients with Moderate renal impairment and matched volunteers
3183627|NCT00715702|Experimental|2|Patients with Mild or Severe renal impairment and matched volunteers. Type of patient group determined after safety review of 1st group data
2389319|NCT03646643|Active Comparator|PVI, non-PV triggers|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation.
2389320|NCT03646643|Active Comparator|PVI, non-PV triggers & CS-LA connection|Interventions: Atrial fibrillation ablation, including conventional pulmonary vein isolation (PVI) and non-PV triggers ablation in addition to coronary sinus-left atrium connection elimination. Distal coronary sinus pacing will be utilized to localize the earliest connection (aside from septal) from the coronary sinus to the left atrial musculature. Once localized, focal radiofrequency lesions will be applied at the discretion of the investigator until distal coronary sinus to left atrial connections are eliminated.
2389321|NCT03646630|Active Comparator|Quadratus Lumborum Block (QL)|Patients will be placed in the lateral position,The high-frequency linear probe will be placed on the lateral abdomen, slightly cephalic to the iliac crest. Once the QL muscle will be observed, the probe will be tilted slightly to the caudal direction, to show the largest slice of the QL muscle, to confirm its posterior aspect. A 22-G block needle (Stimuplex D, Braun, Hongo, Bunkyo-ku, and Tokyo) will be inserted in-plane, ~1 cm ventral to the probe. The needle tip will be advanced until it penetrates the posterior fascia of the QL muscle. A small amount of saline will be injected to confirm the correct position of the tip, between the QL muscle and the erector spinae and latissimus dorsi muscles (Posterior or QL block type 2), then a bolus of 0.5 ml/Kg bupivacaine 0.25% will be injected.
2389322|NCT03646630|Active Comparator|Caudal block (C)|After induction of general anesthesia, a lateral position is obtained with the upper hip flexed 90⁰ and the lower one only 45⁰. A line is drawn to connect the posterior superior iliac spines bilaterally and used as one side of an equilateral triangle; then the location of the sacral hiatus should be approximated. By palpating the sacral cornua as 2 bony prominences, the sacral hiatus could be identified as a dimple in between. A 22 gauge needle is inserted at 45 degrees to the sacrum and redirected if the posterior surface of sacral bone is contacted. Children will receive caudal block with 1 ml/kg of bupivacaine 0.25%.
2389323|NCT03646617|Active Comparator|No HFRT|ipilimumab and nivolumab once every 3 weeks for up to 4 doses, followed by nivolumab once every 2 weeks or every 4 weeks until disease progression.
2389324|NCT03646617|Experimental|HFRT|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
2389331|NCT03646591||Neoadjuvant chemotherapy|"FLOT Chemotherapy regimen~A cycle consist of Day 1: 5-fluorouracil (5-FU) 2600mg/M2 intravenous Via peripherally inserted central catheter (PICC) for 24 hour Day 1: Leucovorin 200mg/M2 intravenous Day 1: Oxaliplatin 85mg/ M2 intravenous Day 1: Docetaxel 50mg/M2 intravenous Repeated every 15th day"
2389332|NCT03646552|Experimental|THX-110|All participants will be titrated up on THX-110 (Dronabinol) dose during the first week of the trial (2.5mg Dronabinol for 3 days, 5mg Dronabinol for 3 days to 7.5mg Dronabinol for 3 days and finally increasing to 10mg for the remainder of the trial). Dronabinol will only be increased if the subject is tolerating the previous dose of Dronabinol and the Dronabinol may be reduced based on patient side-effects. Participants will be receiving 800mg PEA concomitantly.
2389333|NCT03646539|Experimental|Smartphone use + treatment as usual|Participants will receive treatment as usual and use the smartphone app for the management of mood.
2389335|NCT03646526|Experimental|Fast group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under fasting condition .~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
2389336|NCT03646526|Experimental|Feeding group|"During the study session, healthy subjects will be administered a single dose of Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting） or Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） under feeding condition.~cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz） or cycle 1 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）/cycle 2 Drug: Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）"
2389337|NCT03646513||SMF Short Modular Femoral Stem Implanted Subjects|Subjects who have been implanted with the SMF Short Modular Femoral Stem for primary total hip arthroplasty.
2389338|NCT03646500|Experimental|Retrobulbar block|Retrobulbar block administered prior to Transcleral Diode Procedure
2389339|NCT03646500|Active Comparator|Remifentanil|Conscious IV sedation administered prior to Transcleral Diode Procedure.
2389340|NCT03646487|Experimental|Probiotic LP299v|Women will receive 1 LP299v (10x10 colony forming units) in capsule form and 1 standard prenatal supplement in tablet form daily beginning at 15 weeks gestation through delivery.
2389341|NCT03646487|Placebo Comparator|Placebo|Women will receive 1 placebo in capsule form and 1 standard prenatal supplement in table form daily beginning at 15 weeks gestation through delivery.
2389342|NCT03646474|Active Comparator|tranexamic acid group|
2389343|NCT03646474|Placebo Comparator|placebo group|
2389344|NCT03646461|Experimental|Arm A: Ibrutinib + Cetuximab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
2389345|NCT03646461|Experimental|Arm B: Ibrutinib + Nivolumab|Ibrutinib 560mg PO daily (Imbruvica) PLUS Nivolumab 3mg/kg biweekly 28 day cycle
3183628|NCT00715715|No Intervention|1|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients not treated with steroids: The patients will receive 6 weeks of sugar pills (placebo) before taking Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
2389348|NCT03646435|Experimental|Wearable device (Fitbit Charge 2)|The Fitbit Charge 2 is the wearable of interest for this pilot study. All 50 study participants will be requested to wear the electronic device for the duration of their stay in the hospital (maximum of 6 days). The Fitbit will passively collect health information of patients which will be tracked on mobile devices by the study investigators.
2389349|NCT03646409||Patients with esophageal cancer receiving chemotherapy|Patients > 18 years with esophageal cancer receiving neoadjuvant chemotherapy
2389350|NCT03646396|Experimental|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
2389352|NCT03646357|Active Comparator|Betablocker|Patients receiving a betablocker. Any other treatment or management is to be given as per usual care.
2389353|NCT03646357|Experimental|Non-Betablocker|No betablocker is given to this arm. Any other treatment or management is to be given as per usual care.
2389354|NCT03646344|Active Comparator|Active Group|Will receive Heme Arginate (IMP) at a dose of 3mg/kg over 30mins. Participants will receive infusions of the IMP at 2 time-points, the first prior to surgery (transplantation), and the second 20-28 hours later. At each infusion, the IMP will be followed by a 100ml infusion of 0.9% Sodium Chloride over 15mins.
2389355|NCT03646344|Placebo Comparator|Placebo Group|Will receive a 100ml infusion of 0.9% Sodium Chloride (placebo) over 30mins. Participants will receive infusions at 2 time-points, the first prior to surgery, and the second 20-28 hours later. At each infusion, the placebo will be followed by a further 100ml infusion of 0.9% Sodium Chloride over 15mins.
2389356|NCT03646331|Experimental|Tablet A in Session 1 and Tablet B in Session 2|Tablet A = reference product Tablet B = test product
2389357|NCT03646331|Experimental|Tablet B in Session 1 and Tablet A in Session 2|Tablet A = reference product Tablet B = test product
2389358|NCT03646318|Experimental|Ketanserin|Ketanserin is a serotonin type 2-receptor blocker (5-HT2). In normal endothelium, the 5-HT1 effects (vasodilation) are the most prominent [Dabire 1990]. In endothelium that is damaged, which is the case in sepsis, the 5HT2 effects (vasoconstriction) surpass the 5-HT1 effects. Blocking the 5-HT2 receptor with ketanserin can attenuate this pathological vasoconstriction. In addition, ketanserin has favourable α1-adrenergic blocking properties in the endothelium (vasodilation) that may further reverse the pathological vasoconstriction. In these ways ketanserin can reduce vasoconstriction and can improve the microcirculation.
2389359|NCT03646318|Placebo Comparator|Placebo|The placebo is a standard glucose 5% solution.
2389364|NCT03646292|Experimental|Pioglitazone monotherapy|Pioglitazone 15mg 1T daily for 6 months
2389365|NCT03646292|Experimental|Empagliflozin monotherapy|Empagliflozin 10mg 1T daily for 6 months
2389366|NCT03646292|Experimental|Pioglitazone + Empagliflozin combination therapy|Pioglitazone 15mg + Empagliflozin 10mg combination 1T daily for 6 months
2389367|NCT03646266|Experimental|Rocuronium|Titration of rocuronium bromide until tidal volume of 6ml/kg predicted body weight (PBW) is reached
2389368|NCT03646266|No Intervention|Control|Standard of care
2389369|NCT03646253||Patients with proximal humerus fracture|
2389370|NCT03646240|Experimental|Dosing arm|
2389413|NCT03645993||Negative Control|Family members of patients with Early-Onset Alzheimer's disease who have consented to the study.
2389371|NCT03646214|Experimental|Midline traction oral appliance|Subjects will wear the oral appliance nightly for 4 weeks. Must snore or have other evidence of sleep disordered breathing.
2389372|NCT03646214|No Intervention|Control|Subjects who do do not wish to wear the oral appliance will have their sleep monitored in parallel to the experimental subjects for 4 weeks.
2389373|NCT03646201|Experimental|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family food environment, mothers' own eating behaviors, and food parenting practices.
2389374|NCT03646201|No Intervention|Control Group|Data are collected at baseline and post intervention session.
2389375|NCT03646188|Placebo Comparator|Placebo-containing MNA|Placebo
2389376|NCT03646188|Experimental|25 µg Doxorubicin-containing MNA|D-MNA's containing 25 µg of doxorubicin hydrochloride
2389377|NCT03646188|Experimental|50 µg Doxorubicin-containing MNA|D-MNA's containing 50 µg of doxorubicin hydrochloride
2389378|NCT03646188|Experimental|100 µg Doxorubicin-containing MNA|D-MNA's containing 100 µg of doxorubicin hydrochloride
2389379|NCT03646188|Experimental|200 µg Doxorubicin-containing MNA|D-MNA's containing 200 µg of doxorubicin hydrochloride
2389380|NCT03646175|Experimental|Acute Choline Supplementation|Participants will consume 1000 mg (2x500 mg) of choline bitartrate the evening before each testing session.
2389381|NCT03646175|Placebo Comparator|Placebo Supplementation|Participants will consume 1000 mg (2x500 mg) of placebo the evening before each testing session.
3142974|NCT00003937|Experimental|Pilot 2 - Doxorubicin Intensification with Ifosfamide|Preoperative therapy comprised of dexrazoxane hydrochloride, doxorubicin hydrochloride, and methotrexate as in pilot 1. Ifosfamide IV on days 1-5 of week 1. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 1. Ifosfamide is also administered on weeks 14 and 20. Cisplatin is administered on weeks 17, 23, and 26. Group 2: Patients receive methotrexate, dexrazoxane hydrochloride, and doxorubicin hydrochloride as in pilot 1, group 2. Ifosfamide is administered on weeks 14, 20, 26, and 31. Cisplatin is administered on weeks 17, 23, and 29
2389385|NCT03646149||Housing Skills Training Group|Homeless Veterans with serious mental illness who are inpatient at the VA Greater Los Angeles Domiciliary or enrolled in a VA Supported Housing (VASH) program and participating in a Housing Skills Training Group as part of routine clinical care.
2389386|NCT03646136|Experimental|Retained Cystoscopy Fluid|Retained 200mL normal saline used for distending media following completion of diagnostic cystoscopy
2389387|NCT03646136|Active Comparator|Cystoscopy Fluid Emptied|Emptied 200mL normal saline used for distending media following completion of diagnostic cystoscopy
2389391|NCT03646110|Experimental|single-incision MIE|Esophageal cancer patients received single-incision Minimally invasive esophagectomy
2389392|NCT03646110|Active Comparator|multi-incision MIE|Esophageal cancer patients received multi-incision Minimally invasive esophagectomy
2389393|NCT03646097|Active Comparator|Blinded-group|Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators only based on angiographic lesion evaluation (standard care)
2389394|NCT03646097|Active Comparator|OCT-group|Patients underwent OCT-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on OCT findings
2389395|NCT03646097|Experimental|ACR-group|Patients underwent ACR-imaging before PCI. Lesion assessment, selection of PCI landing zone as well as stent selection will be performed by investigators based on ACR-findings
2389396|NCT03646084|Experimental|Sleep Intervention Program (SCIP)|Based on the results of the studies, patients will be treated according to current guidelines: 1) Improve rest/activity rhythms. 2) To treat and control Sleep Disorder Breathing. 3) To improve anxiety, depression and insomnia. 4) To treat RLS if needed. 5) To try opioid dose reduction. 6) To trial of non-opioid in lieu of opioids. 7) Avoiding use of benzodiazepines, sedatives, hypnotics. 8) Caution against alcohol use.
2389397|NCT03646084|Active Comparator|Control|Rehabilitation according to current clinical practice.
2389398|NCT03646071|Experimental|Dose Escalation Phase|The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.
2389399|NCT03646071|Experimental|Dose Expansion Phase|In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.
2389400|NCT03646058|Placebo Comparator|Placebo|2 placebo pills sublingual during 28 days
2389401|NCT03646058|Experimental|0.4mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 21 days, then 2 placebo pills per day for 1 week, all sublingual.
2389402|NCT03646058|Experimental|0.8mg buprenorphine|1 pill of 0.4 mg buprenorphine + 1 placebo pill per day for 3 days, then 2 pills of 0.4mg buprenorphine per day for 18 days, then 1 pill of 0.4 mg + 1 placebo pill per day for 3 days, then 2 placebo pills per day for 4 days, all sublingual.
2389403|NCT03646045||Transpyloric feed|Preterm infant receiving transpyloric feeding.
2389404|NCT03646045||Control|Preterm infants receiving gastric feeding
2389405|NCT03646032|Experimental|Intervention group|Intervention group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants who will receive a download of the SAAFE game and play for at least 30 minutes and as long as an hour, if desired.
2389406|NCT03646032|Active Comparator|Control group|Control group (n=200) - will consist of 100 AAA males / 100 AAA females randomly selected participants. This group will receive the standard of care by launching a mobile app that will play a dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
2389407|NCT03646019||Normal coronary arteries|
2389408|NCT03646019||Non significant coronary artery disease|
2389409|NCT03646019||Significant coronary artery disease|
2389410|NCT03646006|Experimental|Pre-sacral nerve block|10 mL bupivacaine (5mg/mL)
2389411|NCT03646006|Sham Comparator|Sham block|10 mL normal saline
2389412|NCT03645993||Early-Onset Alzheimer's disease|Patients ages 45-60 with Early-Onset Alzheimer's disease
2389414|NCT03645980|Experimental|DKN-01 300 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 1 will be 300 mg , depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
2389415|NCT03645980|Experimental|DKN-01 600 mg|Phase I Study treatment will be started as monotherapy with DKN-01 for up to 8 weeks or until unacceptable toxicity occurs. The study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. The dose of DKN-01 for cohort 2 will be 600 mg or 150 mg, depending on the results of the safety assessment. Phase II The dose of DKN-01 will be the recommended phase II dose (RP2D) determined from Part A. Study treatment will be started as monotherapy with DKN-01 until objective disease progression (PD1) or unacceptable toxicity occurs. After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
3142975|NCT00003937|Experimental|Pilot 3 - Ifosfamide/Etoposide Intensification|Preoperative therapy comprised of methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2. Patients undergo surgery on week 11, then begin adjuvant chemotherapy on week 13. Group 1: Patients receive methotrexate, dexrazoxane hydrochloride, doxorubicin, ifosfamide, and cisplatin as in pilot 2, group 1. Group 2: Patients receive methotrexate on weeks 13, 19, 29, 32, 35, and 36, high dose ifosfamide and etoposide IV over 4 hours on days 1-5 of weeks 14, 23, and 26, and cisplatin on weeks 20, 30, and 33. Dexrazoxane hydrochloride and doxorubicin hydrochloride are administered on weeks 17, 20, 30, and 33
3142976|NCT00003950|Experimental|CPT-11 with Cyclosporine|Each cycle lasts 6 weeks. Administration of cyclosporine and CPT-11 weekly for 4 weeks followed by a 2 week 'rest' period with no drug given. Cyclosporine is given by IV infusion at a dose of 5 mg/kg. CPT-11 is given by IV infusion at a dose of 60 mg/m2.
3142977|NCT00003953|Experimental|Doxorubicin and Docetaxel|
3142978|NCT00003954|Experimental|Treatment (Melphalan and PBSCT before TBI and Donor PBSCT)|"CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 15-20 minutes on day -2.~TRANSPLANTATION: Patients undergo autologous bone marrow or PBSCT on day 0.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Beginning 40-120 days after autologous transplant, patients undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine IV BID on days -1 and 0 and PO BID on days 1-80 with taper based on evaluation of disease response and GVHD. Patients also receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Beginning 4 weeks after immunosuppression, patients achieving persistent or progressive disease may undergo DLI over 30 minutes every 4 weeks for up to 3 treatments."
3142979|NCT00003958|Experimental|Arm I|Vincristine sulfate IV once a wk on wks 0-12, 15, 18-24, 27, 30-36, and 39. Dactinomycin IV once a wk on wks 0, 3, 6, 9, 12, 21, 24, 27, 30, 33, 36, and 39. Cyclophosphamide IV once a wk on wks 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, and 39. After 12 weeks of chemotherapy, depending on tumor shrinkage, pts may undergo surgery. After recovery from therapeutic conventional surgery, patients receive radiation therapy once a day, 5 days a wk, during wks 12-18. For pt receiving radiotherapy during wks 0-6, dactinomycin is omitted during wks 3 and 6 and during wks 15 and 18. For patients receiving radiotherapy during wks 12-18, dactinomycin is omitted during wks 15 and 18. Patients with adequate response at wk 24 continue chemotherapy during wks 24-39. All pts receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery.
3142980|NCT00003958|Experimental|Arm II|"Patients receive treatment as in arm I, except dactinomycin is replaced with topotecan hydrochloride IV over 15-30 minutes daily for 5 days during weeks 3, 9, 21, 27, 33, and 39.~All patients receive filgrastim (G-CSF) or sargramostim (GM-CSF) subcutaneously beginning 24 hours after completion of each course of chemotherapy and continuing 1 year, until hematopoietic recovery."
3142981|NCT00003963|Experimental|Vinorelbine and Rituxan|"Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Rituxan given every 2 weeks. Vinorelbine given weekly x3, with one week off.~Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
3142982|NCT00003966|Experimental|Arm A Lower dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm I: On days 2-14, patients receive a lower dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
3142983|NCT00003966|Experimental|Arm B Higher Dose|"This is a randomized, multicenter study. All patients initially receive the same dose of defibrotide IV over 2 hours every 6 hours on day 1. On day 2, patients are randomized to 1 of 2 doses of defibrotide.~- Arm II: On days 2-14, patients receive a higher dose of defibrotide IV over 2 hours every 6 hours.~In both arms, courses repeat every 14 days in the absence of disease progression or unacceptable toxicity"
2389428|NCT03645902||Acute stroke patients|MRI examinations will be performed on a 3 T GE MR750 W scanner. Two readers, an experienced neuroradiologist (8 years of experience in neuroradiology) and a junior radiologist (3 years of experience in general radiology) will independently analyze eSWAN and TOF images in random order, looking for arterial occlusions. Analysis will be based on a 2-point-scale: arterial occlusion, based on a local signal loss, or acceptable permeability.
2389429|NCT03645889|Experimental|Paediatric Lung Tonic (PLTG)|Traditional Chinese Medicine (TCM) in granules dosage form to be dissolved for consumption.
2389430|NCT03645889|Placebo Comparator|PLTG Placebo|Starch granules with 10% TCM to mimic the colour, taste and smell of active TCM.
2389431|NCT03645876|Experimental|SHR-1210+BP102+XELOX|Participants receive SHR-1210 200mg,BP102 7.5mg/kg and oxaliplatin 130mg/m2 in day 1 intravenously every 3week, capecitabine by oral bid in day1-14 every 3 week until disease progression or unacceptable toxicity
2438525|NCT03308331|Active Comparator|HIV-1 nonsmokers using nicotine patch|
3183629|NCT00715715|Experimental|2|"Patients that meet the requirements listed above will be selected sequentially. Blood tests, including liver function tests and hepatitis profiles will be taken. A liver biopsy will be done before the treatment to evaluate the severity of hepatitis.~For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.~All patients will get another liver biopsy at week 48 to evaluate the improvement of liver inflammation after their treatment. Blood tests will be drawn in accordance with the standard treatment. Generally speaking, hospitalization is not required for this study."
3183630|NCT00715780||A|
3183631|NCT00715806|Experimental|1|
2389435|NCT03645850|Experimental|Investig. device:Vismed Gel Multi 0.3%|Vismed gel Multi 0.3% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
2389436|NCT03645850|Active Comparator|Comparative device: Vismed Multi 0.18%|Vismed Multi 0.18% eye drops: 1 to 2 drops in each eye between 4 and 6 times per day during 84 days
2389437|NCT03645837|Experimental|10 minutes|Compression clamp release start after 10 minutes
2389438|NCT03645837|Experimental|20 minutes|Compression clamp release start after 20 minutes
2389439|NCT03645837|Active Comparator|30 minutes|Compression clamp release start after 30 minutes
2389440|NCT03645824|Experimental|Pacritinib treatment befor allo-SCT|The effect of pacritinib treatment during 3 to 4 cycles before allo-SCT on engraftment 6 months (day +180) post allo-SCT in MF patients.
3183632|NCT00715806|Active Comparator|2|
3183633|NCT00715845|Experimental|2|
3183634|NCT00715858|Active Comparator|1 AD doxycycline + rifampin|Participants with AD allocated to doxycycline 100 mg bid od and rifampin 300 mg od for 12 months
2389444|NCT03645798|Experimental|"Three good things therapy group"|"The experimental group received a six-month Wechat-basedthree good things positive psychotherapy from August 2015 to January 2016. Participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good things, participants were required to answer the question: Why did this good thing happen?"
2389445|NCT03645798|Other|Normal psychological instruction group|The control group only received normal psychological instruction from the hospital
3183635|NCT00715858|Active Comparator|2 AD doxycycline|
3183636|NCT00715858|Active Comparator|3 AD rifampin|Participants with AD allocated to rifampin 300 mg od od and placebo matched to doxycycline bid for 12 months
2389448|NCT03645772|Experimental|Plyometric exercise|12-week progressive exercise program, consisting of plyometric exercises such as countermovement jump, forward and sideways step-up.
2389449|NCT03645772|Active Comparator|Resistance exercise|12-week resistance exercise program for the leg muscles (2-4 sets of 8-15 repetitions at 8-15RM, leg press, leg extension, calve extension).
2389450|NCT03645772|Active Comparator|Walking|12-week progressive walking program.
2389451|NCT03645759|Experimental|I'm Whole|This arm will receive 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration. Treatments will occur weekly. They will also receive 3 assessments at 0, 6, and 12 weeks.
2389452|NCT03645759|Active Comparator|Education + usual care|This arm will only receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
2389453|NCT03645746|Experimental|Cohort 1|Cohort 1 will receive a single IV dose of REGN5069 or matching placebo
2389454|NCT03645746|Experimental|Cohort 2|Cohort 2 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2389455|NCT03645746|Experimental|Cohort 3|Cohort 3 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2389456|NCT03645746|Experimental|Cohort 4|Cohort 4 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2389457|NCT03645746|Experimental|Cohort 5|Cohort 5 will receive a single SC dose of REGN5069 or matching placebo
2389458|NCT03645746|Experimental|Cohort 6|Cohort 6 will receive a single sequential ascending SC dose of REGN5069 or matching placebo
2389459|NCT03645746|Experimental|Cohort 7|Cohort 7 will receive a single sequential ascending IV dose of REGN5069 or matching placebo
2389460|NCT03645733|No Intervention|Control Group|The control group will be at the standard dialysate temperature of 36.5 °C (which is the standard of care in the sites), 3 times a week for 12 months
2389461|NCT03645733|Experimental|Lower Temperature Group|These patients will receive haemodialysis with a dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached. Patients who would fail to tolerate the temperature of 35 °C, the lowest tolerated temperature will be carried over to the end of the study.
2389462|NCT03645733|No Intervention|Caregivers|Patients, who consent for the study, will be asked to identify the most suitable carer to participate in the study who could be approach in person, over the phone or by post as deemed suitable by the research team and convenient by the carer. Patient's permission to contact their identified carer will be recorded. Carers of consenting patients will be approached in the same manner as above after obtaining patients consent to contact their carers. Patients will still be able to take part in the study even if their carer declines consent.
2389463|NCT03645720|No Intervention|Metal needle gruop|puncture using metal needle
2389464|NCT03645720|Experimental|plastic cannula|puncture using plastic cannula
3183637|NCT00715858|Placebo Comparator|4 AD placebo|Participants with AD allocated to placebo matched to doxycycline and placebo matched to rifampin for 12 months
3183638|NCT00715858|No Intervention|5 Control|Age-matched cognitively healthy participants (untreated)
3183639|NCT00715871|Experimental|Active Smokers|Active smokers who used the Smoke-Break nicotine delivery device in an attempt to quit smoking cigarettes.
3183640|NCT00715897|Experimental|Treatment- HBOT|HBOT treatment: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
3183641|NCT00715897|No Intervention|control-HBOT|Cross group: Patients in the cross group were evaluated three times-baseline, after 2 months control period of no treatment and after a consequent 2 month of HBOT
3183642|NCT00715923|Experimental|1|Modified consent form
2389465|NCT03645707|Experimental|CAR Training and Psychoeducational Sessions|"This is a secondary study to the primary study titled A Randomized Controlled Trial of a Resilience Intervention for Critical Care Nurses (IRBNet #1234568). In the primary study, participants will be randomized into the intervention group or wait-list control group.~In this secondary study, all participants will attend the 1-day CAR Training Program and the follow-up psychoeducational group sessions."
2389466|NCT03645694|Experimental|SSA|Individuals with memory concerns in the experimental arm received the prototype facial recognition technology, which included a smartphone and smartwatch. The smartphone was equipped with facial recognition software application; the smartwatch communicated information with the smartphone. Persons with memory concerns and their family care partners were given a demonstration on how to utilize the technology.
2389467|NCT03645694|No Intervention|Control|Control participants did not receive the technology; at the conclusion of follow-up, all controls were offered the technology to use.
2389468|NCT03645681|Experimental|InnAVasc AVG treatment|"Patients will be surgically implanted with an InnAVasc AVG in the forearm or upper arm using standard vascular surgical techniques. The graft will be placed in a straight (soft C) configuration in the upper arm, or looped configuration in the forearm (forearm loop) or upper arm (axillary loop)."
2389469|NCT03645668|Experimental|Experimental group|meropenem injection, 1.0g, q8h,intravenous infusion ,0.5g/0.5h+0.5g/4h
2389470|NCT03645668|Other|Control group|meropenem injection, 1.0g, q8h,continuous intravenous infusion duration ,1h
2389471|NCT03645655||hepatoblastoma|The diagnosis of hepatoblastoma is based on enhanced CT scanning and/or histopathology.
2389472|NCT03645655||hepatic hemangioendothelioma|The diagnosis of hepatic hemangioendothelioma is based on enhanced CT scanning and/or histopathology.
2389473|NCT03645655||Healthy control|The healthy control group consist of people undergoing routine medical examination.
2389474|NCT03645642|Experimental|Midodrine|Midodrine (5 mg TDS) along with albumin(20g/l) and diuretics. The dose of Midodrine will titrated according to the Mean arterial pressure (75-90mmhg). The dose will be increased to a maximum of 12.5 mg thrice daily.
2389475|NCT03645642|Active Comparator|Albumin with diuretics|Albumin(20g/l) and diuretics.
2389476|NCT03645629|Active Comparator|Food skin tests at 0 month|the skin test results of food extract at time 0 months after preparation
2389477|NCT03645629|Active Comparator|Food skin tests at 3 month|the skin test results of food extract at time 3 months after preparation
2389478|NCT03645629|Active Comparator|Food skin tests at 6 month|the skin test results of food extract at time 6 months after preparation
2389479|NCT03645616|Experimental|Functional Tests|Participants undertook 6-minute walk test, 10 meters walk test and 30 second sit to stand test.
3142984|NCT00003968|Experimental|Arm I|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment continues every 4 weeks in the absence of unacceptable toxicity or disease progresssion.
3142985|NCT00003970|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 90 minutes once every 3 weeks. Treatment continues for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2389482|NCT03645590|Experimental|Stroke Ready Community intervention|We divided the Flint community into four quadrants. We will focus our workshops and posters on one quadrant, but not exclusively, moving quadrants every 6 months over the course of two years.
2389483|NCT03645564|Active Comparator|Group 1 : specialized nurse consultation|This group will benefit of a specialized nurse consultation throughout of which an individualized information will be delivered. This information will be reevaluated during the usual patient follow-up.
2389484|NCT03645564|No Intervention|Group 2 : no specialized nurse consultation|This control group will present the same care pathway than all the patients of the service suffering from Atrial Fibrillation without specialized nurse consultation.
2389485|NCT03645538||Parkinson's disease patients|"PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).~The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
2389486|NCT03645538||No drug - Control group|PD patients, after reading and signing the free and informed consent will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals. All volunteers (healthy and patients) will be submitted to a behavioral and neurophysiological evaluation through transcranial magnetic stimulation (TMS) and electroencephalography (EEG).
2389487|NCT03645525|Experimental|Mesenchymal stem cell|Human Umbilical Cord-derived Mesenchymal stem cell in the saline
2389488|NCT03645525|Placebo Comparator|placebo|saline without mesenchymal stem cell
2389489|NCT03645512|Experimental|Intervention|The intervention group will attend in the 1-day Corporate Athlete Resilience (CAR) Training Program in Lake Nona.
2389490|NCT03645512|No Intervention|Control|The control group will attend the 1-day CAR Training Program in Lake Nona after a 3-month wait list period, which will be three months after the intervention group attends the intervention.
2389491|NCT03645499|Experimental|Topical TA-102 A|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2389492|NCT03645499|Experimental|Topical TA-102 B|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2389493|NCT03645499|Experimental|Topical TA-102 C|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2389494|NCT03645499|Experimental|Topical TA-102 D|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2389495|NCT03645499|Experimental|Topical TA-102 E|A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily
2389496|NCT03645486|Experimental|Lentiviral TYF-CGD-modified autologous stem cells|Autologous hematopoietic stem cells transduced with lentiviral TYF vector carrying the functional gene
2389497|NCT03645473|Experimental|Monarch device settings assessment group|"Patients with cystic fibrosis who have experience with the Monarch Airway Clearance System will be enrolled in the study.~The duration of subject participation is approximately 4 - 6 hours during 1 study visit. Each subject will receive therapy with The Monarch® System at multiple frequency and intensity combinations as defined in the Study procedures."
2389498|NCT03645460|Experimental|TYF-ADA-modified autologous stem cells|Autologous hematopoietic and/or mesenchymal stem cells transduced with lentiviral vector carrying the ADA gene
2389499|NCT03645447|Experimental|Taste test|Participants will be presented with a series of tastants of 4 different modalities (sweet, salt, sour, bitter) of 9 different concentrations in pseudo-random order. The threshold at which each participant reliably identifies the taste is determined for each tastant. Mood Questionnaires will be used to determine whether a participant is clinically depressed.
3183643|NCT00715923|Active Comparator|2|Standard consent form
3183644|NCT00715936|Active Comparator|Control|Routine services for infants and young children delivered by the Lady Health Workers of the National Programme for Family Planning and Primary Healthcare (Basic Health and Nutrition Education and Services)
3183645|NCT00715936|Experimental|ECD Group|Stimulation and care for development (plus basic health and nutrition education and services)
3183646|NCT00715936|Experimental|Enhanced Nutrition|Care for Nutrition: Enhanced education messages and Sprinkles for children aged 6-24 months (plus basic health and nutrition education and services)
3183647|NCT00715936|Experimental|ECD and Enhanced Nutrition|Stimulation and care for development and care for nutrition (plus basic health and nutrition education and services)
3183648|NCT00715975|Experimental|1|The patients will be treated with halobetasol once a day for 15 days.
3183649|NCT00715975|Experimental|2|The patients will be treated with clobetasol once a day for 15 days.
3183650|NCT00715988|Experimental|Scheme 1|Patients who are feeding or not feeding and mechanically ventilated, >/=3 d of age and 29 0/7wks-48 6/7 wks PMA, treated with i.v. bolus doses or infusion of fentanyl, morphine or methadone for clinical indications, with arterial/venous line in place & expected treatment for at least 1-2 more days. Pk sampling = 0.5 ml blood samples x6/infant. ECG monitoring. Three patients will be enrolled in 5 PMA groups. Should apnea or hypotension occur, dosages for Treatment Scheme 2 will be reduced (50%); more patients will be studied in Treatment Scheme 1 to insure that the lower dose is well tolerated & effective.
3183651|NCT00715988|Experimental|Scheme 2|Patients defined in Scheme 1, tolerating feeds for >/= 3 days will be studied twice, after i.v. methadone and after enteral methadone after the end of sampling after the first dose. 4-5 samples will be obtained after dose 1 and after dose 2 depending on PMA and weight. Patients will be divided into groups based on PMA..
3183652|NCT00716001|Active Comparator|NAC|
2389510|NCT03645408|Experimental|Exenatide injection|Subjects in this arm will receive a 5 mcg dose of immediate release exenatide on the day of the alcohol challenge. The 5mcg dose of exenatide is approved as the first dose to be administered to patients at the start of their treatment with this drug for FDA-approved indications.
2389511|NCT03645408|Placebo Comparator|Placebo|Subjects in this arm will receive a sham injection on the day of the alcohol challenge. The sham injection will be a needle stick using a syringe with no drug injected. Note that the volume of fluid injected for a 5mcg dose is so small that subjects will sense this volume of fluid (or lack thereof) during the injection. Subjects will be shielded from seeing the injection to maintain the blind.
2389512|NCT03645395|Experimental|MT-3724 10 mcg/kg-LEN|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2389513|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 3x a week|MT-3724 25 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2, then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2389514|NCT03645395|Experimental|MT-3724 20 mcg/kg-LEN 3x a week|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks) of each 28 day cycle in combination with LEN. If the treatment with MT-3724 is continued beyond Cycle 2 , then MT-3724 will be administered weekly (Day 1, 8, 15 and 22) of each 28-day cycle
2389515|NCT03645395|Experimental|MT-3724 25 mcg/kg-LEN 2x a week|MT-3724 25 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
2389516|NCT03645395|Experimental|MT-3724 50 mcg/kg-LEN|MT-3724 50 mcg/kg dose IV for 4 doses (days 1, 5, 8 and 12 during cycles 1 and 2) of each 28 day cycle in combination with LEN and weekly during cycles 3 and beyond (days 1, 8, 15 and 22).
2389517|NCT03645382|Placebo Comparator|baked barley powder consumption|Subjects randomized to the placebo group received one tablet containing baked barley powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
2389518|NCT03645382|Experimental|jeju steam onion powder consumption|Subjects randomized to the test group received one tablet containing jeju steam onion powder per day (900 mg/day). placebo group consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.
2389519|NCT03645369|Experimental|Mechano-Analgesia|The first SC heparin injections were applied from the right abdominal region using ShotBlocker®.
2389520|NCT03645369|Experimental|Cold Application|The second SC heparin injections were applied from the left abdominal region with an ice pack
2389521|NCT03645369|No Intervention|Control|The second SC heparin injections were applied from the lower abdominal region without any additional application
3183653|NCT00716001|Placebo Comparator|nonNAC|
3183654|NCT00716014|Active Comparator|Foot 1|An active drug injection of TD101 is injected into a callus on the bottom of one foot.
3183655|NCT00716014|Placebo Comparator|Foot 2|An injection of placebo (normal saline) is injected into a callus on the bottom of one foot.
3183656|NCT00716027|Active Comparator|1|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
2389524|NCT03645343|Active Comparator|Activator|Patients will be treated using the Activator appliance for one and a half year
2389525|NCT03645343|Experimental|Twin Block|Patients will be treated using the Twin Block appliance for 18 months on average
2389526|NCT03645343|No Intervention|Control|Patients will be monitored until the last assessment times in the other groups. This group will serve as a control group
2389527|NCT03645317|Other|Single arm|Blood samples (FBC, lipids, cholesterol, troponin, CRP, BNP) Cardiac imaging (cardiac CT, cardiac ultrasound, 12-lead ECG)
2389528|NCT03645304|Experimental|Ropivacaine group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .
2389529|NCT03645304|Placebo Comparator|0.9% Saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
2389530|NCT03645291|Active Comparator|Skin test with local extract|Skin prick test and intradermal test with local stinging insect allergen extracts that develop in Immunological division of Siriraj hospital, mahidol University
2389531|NCT03645291|Sham Comparator|Skin test with commercial extract|Skin prick test and intradermal test with commercial stinging insect allergen extracts that order from ALK company
2389532|NCT03645278|Experimental|SHR0532|Up to 5 cohorts of healthy subjects will receive a single dose of oral SHR0532 tablet.
2389533|NCT03645278|Experimental|Placebo|Up to 5 cohorts of healthy subjects will receive a single dose of oral placebo.
2389534|NCT03645265|Experimental|Gestures|Use of hand gestures to improve speech rhythm and speech production
2389535|NCT03645265|Experimental|Auditory|Use of auditory cues to improve speech rhythm and speech production
2389536|NCT03645252|Active Comparator|Vein first|Tumor-draining pulmonary vein is interrupted first and before any surgical manipulation.
2389537|NCT03645252|Active Comparator|Arteries before vein|Lobar arteries (+/- bronchus and inter-lobar fissures) are interrupted before tumor-draining pulmonary vein.
2389538|NCT03645239||Control|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of less than 3 (out of 10) at 6-10 post-delivery online/phone survey.
2389539|NCT03645239||Postoperative pain|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Patients will be assigned to this group when they have a pain score of equal or more than 3 (out of 10) at 6-10 post-delivery online/phone survey.
2389540|NCT03645239||Control (non-Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Twenty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
2389541|NCT03645239||Experimental (Headspace)|Questionnaires, Mechanical Temporal Summation assessment and preoperative pain assessment will be assigned to patient. Fifty five patients will be assigned to this group when they agree to participate in a sub-study on the use of a mindfulness exercise mobile app (Headspace). Patients will have a follow-up online/phone call survey at day 7-20 and 4-8 weeks after delivery.
2389542|NCT03645226||Early PD subjects converted from iRBD|"Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~PD diagnosis confirmed by neurologists according to the United Kingdom Parkinson's Disease Survey Brain Bank. Assessment tools including Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn & Yahr Staging will be used for severity grading.~Onset of PD symptoms of <5 years~In view of the heterogeneity of PD, we will only include those patients with RBD preceding the onset of motor symptom of PD."
2389543|NCT03645226||iRBD subjects|"Age-and sex-matched with PD subjects~Chinese aged 50 or above~Being capable of giving informed consent for participation of the study~RBD diagnosis according to the International classification of sleep disorder 3rd edition (ICSD 3rd), fulfilling both the clinical and video-polysomnography (vPSG) criteria."
2389544|NCT03645226||First degree relatives of patients with iRBD|"First degree relatives of patients with iRBD;~Age-and sex-matched with PD subjects~Chinese aged 40 or above;~Absence of dream enactment behaviors;~Not cohabiting with proband"
2389545|NCT03645226||Healthy Controls|"Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Being capable of giving informed consent for participation of the study;~Without a personal history or a family history of PD or RBD;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Absence of RSWA as measured by v-PSG."
2389546|NCT03645226||Spouses of patients with iRBD|"Spouses of patients with iRBD;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
2389547|NCT03645226||First degree relatives of healthy controls|"First degree relatives of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 40 or above ;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;"
2389548|NCT03645226||Spouses of healthy controls|"Spouses of healthy controls;~Age-and sex-matched with PD subjects;~Chinese aged 50 or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the suggestive cut-off of a diagnosis of RBD;~Cohabiting with proband."
2389549|NCT03645213|Experimental|Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a head-mounted VR box in the VR group.
2389550|NCT03645213|Experimental|Non- Virtual Reality (VR)|Children were asked which cartoon they wanted to watch and it was prepared. The cartoons began to be shown a minute before venipuncture and lasted about 4 minutes. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's. The display was a computer tablet in the non-VR group. The computer tablet was the 10 centimeters far from the child.
2389551|NCT03645213|No Intervention|Control|There was no additional intervention in the control group. Venipuncture procedures was the same other groups. The procedure and reason were explained to the child before each step of the venipuncture process such as apply a tourniquet, insert and remove the needle. The parent stopped on the left side of the child's.
2389552|NCT03645200|Experimental|Fluzoparib combined with Apatinib|"Fluzoparib in the initial dose of 40mg.bid started into the group of participants, group A combined with a fixed dose of Apatinib 250mg.qd for treatment, followed by the 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid dose increase.~Fluzoparib in the initial dose of 40mg.bid started into the group of participants, Group B was treated with a fixed dose of Apatinib 500mg.qd, followed by an increase in doses of 40mg.bid, 60mg.bid, 80mg.bid, 100mg.bid ."
2389553|NCT03645187|Active Comparator|FOLFERI|FOLFERI regien
2389554|NCT03645187|Active Comparator|FOLFERI and celecoxib|FOLFERI and celecoxib
2389555|NCT03645174|Active Comparator|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
2389556|NCT03645174|Experimental|Long tube|Fiberoptic-guided intubation through LMA, using long tube
2389557|NCT03645161|Active Comparator|Local rat and mouse skin test|All patients receive local skin prick test for mouse and rat. The result were recorded and compared to the imported one.
2389558|NCT03645161|Active Comparator|Imported rat and mouse skin test|All patients receive imported skin prick test for mouse and rat. The result were recorded and compared to the local one.
3142986|NCT00003992|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
2389560|NCT03645135|No Intervention|Control|Patients in the control group will be asked to complete a demographics survey and assess their perceived involvement in care after their visit
2389561|NCT03645135|Experimental|Goal elicitation|Patients in the intervention group will be asked to list 2 goals for their visit. They will also be asked to complete a demographics survey and access their perceived involvement in care after their visit.
3142987|NCT00003992|Experimental|Arm II|Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3142988|NCT00003994|Experimental|Arm I (cisplatin, vincristine sulfate, fluorouracil)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive cisplatin IV over 4 hours on day 1, vincristine sulfate IV on days 3, 10, and 17, and fluorouracil on day 3.
2389564|NCT03645109|Experimental|Vitamin D|Will receive capsules with 5,000 IU of vitamin D3, one capsule orally once a day for eight weeks
2389565|NCT03645109|Placebo Comparator|Placebo|Will receive capsules with placebo (talcum food grade) one capsule orally once a day for eight weeks
3142989|NCT00003994|Experimental|Arm II (cisplatin, vincristine, fluorouracil, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
3142990|NCT00003994|Experimental|Arm III (carboplatin, cisplatin)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive carboplatin IV over 1 hour on day 1 and cisplatin IV over 4 hours on day 15.
3142991|NCT00003994|Experimental|Arm IV (carboplain, cisplatin, amifostine)|Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm III with the addition of amifostine trihydrate IV over 15 minutes prior to carboplatin on day 1.
3142992|NCT00003995|Experimental|Arm I|Patients receive a loading dose of trastuzumab IV over 90 minutes on week 1, and over 30-90 minutes weekly thereafter. Patients receive irinotecan IV over 90 minutes following trastuzumab weekly for 4 weeks. Courses are repeated every 6 weeks in the absence of disease progression or unacceptable toxicity.
3183657|NCT00716027|Experimental|2|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
2389572|NCT03645083|Experimental|Telephone call|Participants receive a telephone call reminder three days after their initial visit
2389573|NCT03645083|Experimental|Text message|Participants receive a text message reminder three days after their initial visit
2389574|NCT03645083|No Intervention|Control|Participants do not receive any intervention after their initial visit
2389575|NCT03645070|No Intervention|No probe|Twenty patients will be allocated to this group, which will have no esophageal temperature monitoring technique
2389576|NCT03645070|Active Comparator|Single probe thermometer|Twenty patients will be allocated in this group, in which there will be monitoring of esophageal temperature during radiofrequency applications in the posterior wall of the left atrium, with unipolar thermometer.
2390386|NCT03639207||1|Patients treated with ledipasvir/sofosbuvir in the Kaiser Permanente Northern California
2389577|NCT03645070|Active Comparator|Multi-probe|Twenty patients will be allocated in this group, in which there will be esophageal temperature monitoring during radiofrequency applications in the posterior wall of the left atrium, with a multipolar and self expandable thermometer.
2389578|NCT03645057|Experimental|Crisaborole|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
2389579|NCT03645057|Active Comparator|Tacrolimus 0.03%|The topical treatment will be applied to all affected areas twice daily for 12 weeks.
2389580|NCT03645031|Experimental|ALS Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
2389581|NCT03645031|Experimental|Healthy Control Group|Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH), as well as, the 45 minute sham AIH session, consisting of breathing air with normal oxygen levels. Breathing, muscle activity and heart activity will be monitored before, during and after both procedures.
2389582|NCT03645018|Experimental|diagnosis with tomosynthesis (DTS)|"Single arm.~Population: Subjects enrolled in previously closed SOS trial (high risk subjects for lung cancer) without confirmed lung cancer."
2389583|NCT03645005|Experimental|My Guide (psychoeducation & self-management program)|
2389584|NCT03645005|Active Comparator|My Health (health education program)|
2389585|NCT03644992||Thromboembolic Disease|the patients who undergo gynecological operations but develop thromboembolic disease
2389586|NCT03644979|Experimental|Skydiving|Tandem skydiving
2389587|NCT03644979|No Intervention|Negative control|No skydiving
2389588|NCT03644966|Experimental|Probiotic + Antibiotic|50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.
2389589|NCT03644966|Active Comparator|Placebo + Antibiotic|50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.
2389591|NCT03644940|Experimental|Subpopulation-specific Algorithm|
2389592|NCT03644940|No Intervention|Control Algorithm|
2389593|NCT03644927|Experimental|Progressive exercise program|"Based on the Active Physical Treatment Model individuals with chronic pain are typically and primarily sedentary or physically deconditioned and need a progressive approach to work up to standard exercise prescriptions as defined by the American College of Sports Medicine. Thus, progressive exercise training can help to minimize the risk or occurrence of a range of exercise-related adverse medical events, particularly with the complex study population which will be starting at a sedentary level and therefore, may not be able to initially achieve the heart rate goals prescribed in standard exercise training protocols. The exercise prescription will be individually designed and geared toward an intensity manageable by the individual.."
2389594|NCT03644927|Active Comparator|Waitlist Control|The waitlist control participants will be fully screened for eligibility and asked to wait 12 weeks before beginning the 12-week progressive exercise program. They will be assessed again at the end of the 12-week waiting period. These patients will then be compared to patients in the experimental arm and then compared against their own waitlist control data after completing the 12-week exercise program. The exercise program that the waitlist control patients will participate in is identical to the experimental arm.
2389595|NCT03644914|Experimental|Intervention Group (Reading Program)|First graders who will receive the 10-week reading program (a total of 20 hours), twice weekly in 1-hour sessions, and will continue to receive typical classroom reading instruction.
2389596|NCT03644914|No Intervention|Control Group|First graders who will not take part in the reading program but will continue to receive typical classroom reading instruction.
2389597|NCT03644901||Patients whose blood type is A|Applying nonsurgical periodontal treatment (scaling and root planning).
2389598|NCT03644901||Patients whose blood type is B|Applying nonsurgical periodontal treatment (scaling and root planning).
2389599|NCT03644901||Patients whose blood type is AB|Applying nonsurgical periodontal treatment (scaling and root planning).
2389600|NCT03644901||Patients whose blood type is O|Applying nonsurgical periodontal treatment (scaling and root planning).
2389601|NCT03644888|Active Comparator|Control group|Cycle ergometer training program: 2 minutes warm-up at no load, 20 minutes at 60% of peak work (PW) calculated by stress-test or at 50% of PW calculated according to Luxton equation (PW = 103.217 + (30.50 X gender) + (-1.613 X age) + (0.002 X 6MWW [m kg -1 ]). The progression of the workloads is calculated according to the BORG Dyspnea and Fatigue Scale (Borg D and F < 5: 10W increase; Borg D and/or F between 5 e 6: maintain same workload; Borg D and / or > 6: 10W decrease) Patient tailored airway clearance program guided by an experienced respiratory physical therapist, which could includes active cycle of breathing technique (ACBT), forced expiratory technique (FET), ELTGOL (slow expiration with glottis open in the lateral position) and PEP techniques (positive expiratory pressure).
2389602|NCT03644888|Experimental|Experimental group|Cycle ergometer training program plus application of vibration therapy. The vibration is provided at 150Hz via 4 effectors applied bilaterally at the second or third interspaces in the parasternal region of the upper chest wall and at the seventh to ninth interspaces anterior to the midaxillary line in the lower chest wall.
2389603|NCT03644888|Sham Comparator|Sham intervention group|Cycle ergometer training program plus application of sham vibration therapy: 4 effectors on chest-wall at same position of vibration therapy, the device that produces vibration is switched on, producing the typical noise and vibration is emitted by effectors not placed on the patient but left in place on the device.
2389604|NCT03644849|Experimental|Fractional carbon dioxide laser intervention group|The intervention will only involve a single treatment with ablative fractional carbon dioxide laser therapy. The investigators will specifically be using the CO2RE® (Syneron Candela Corp, Wayland, MA).
2389605|NCT03644849|Sham Comparator|Sham laser intervention group|
2389606|NCT03644836|Experimental|Retraining with respiratory effort+ amino acids|
2389607|NCT03644836|Placebo Comparator|Retraining with respiratory effort+ placebo|
2389608|NCT03644823|Experimental|PDL1-inhibitor and radiotherapy|PDL1-inhibitor (Atezolizumab) and Radiotherapy (6 Gy x 3)
2390750|NCT03636750|Experimental|HB002.1T 4mg/kg|Participants received a 4mg/kg dose of HB002.1T via intravenous injection.
2389609|NCT03644810|Active Comparator|Chronic low back pain|"Individuals with chronic low back pain. Baseline assessment of pain intensity, function, pain duration and pain catastrophizing thoughts is performed~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
2389610|NCT03644810|Active Comparator|Healthy controls|"Healthy, pain-free individuals who are age and gender matched to the low back pain group fill out the pain catastrophizing scale~Pain sensitivity at the back and lower leg is measured at baseline and immediately after performing the cold pressor test"
2389611|NCT03644797||Patients|Patients presenting intellectual disability and previously diagnosed as carriers of a 16p13.11 copy number variant using Cytogenetic Micro Array.
2389612|NCT03644784||Yamaguchi University Hospital|
2389613|NCT03644784||Erasmus Medical Center|
2389614|NCT03644784||Academic Medical Center - Amsterdam|
2389615|NCT03644784||Segeberger Kliniken Gruppe|
2389616|NCT03644784||McGill University - Montreal|
2389617|NCT03644758||professional and voluntary firefighter|Professional and voluntary firefighter in Service Departmental Fire and Rescue of Loire will be included. They will have to answer at the self-administrated questionnaires. It is composed of 5 parts: socio-demographic data and personal medical history, Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale, Insomnia Severity Index (ISI) and stop-BANG questionnaire.
2389618|NCT03644745|Experimental|VM @ Home Usability|We will pilot our customer engagement and physical exercise system in the homes of up to 20 participants for 3 months. Participants will interact with the system on their own computers, smart phones, and/or televisions and wear an activity tracker throughout the study. Interactions include physical exercise, system usage, and video conferencing.
2389619|NCT03644732||SEEG Group|Group with SEEG analysis (Pre-surgical SEEG assessment)
2389620|NCT03644719|Experimental|Cognitive behavior skills training|The first session is intended to establish rapport, build therapeutic cohesion through ice-breaking activities, and educate participants about the drug regulations stated in the Statute for Drug Hazard Prevention and Control. The following four sessions are devoted to interactively practicing refusal skills, communication skills, decision-making skills, and positive conflict resolution skills. The final session is to review what has been learned and reminds participants about the association of drug use with HIV/HCV.
2389621|NCT03644719|No Intervention|Education as usual|The EAU group received six hours of informational lectures about ketamine, its effects on the brain, relevant regulations and laws, and the risks and modes of transmission of infectious diseases, including HIV and hepatitis C.
2389622|NCT03644706|Active Comparator|ADV7103|Patients continue to receive ADV7103 twice a day at their open label dose over 6 days
2389623|NCT03644706|Placebo Comparator|Placebo Comparator|Patients receive matched placebo twice a day until they reach a bicarbonate level of 18mEq/L
2389624|NCT03644693|Experimental|Investigational|Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
2389625|NCT03644693|Placebo Comparator|Placebo|Subjects assigned to this arm will receive the Placebo Formulation.
2389626|NCT03644680|Experimental|Nasal Provocation with Birch Extract|Birch allergic patient receiving 3 consecutive nasal challenges with birch extract (Allergopharma). Total dose of 1.5ug of Bet v 1 per challenge
2389627|NCT03644680|Placebo Comparator|Nasal Provocation with NaCl 0.9%|Birch allergic patient receiving 3 consecutive nasal challenges with sterile NaCl 0.9%. Total dose of 100ul per nostril per challenge
2389628|NCT03644667|Experimental|Tocilizumab + Standard of Care Triple IS|"Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
2389629|NCT03644667|Placebo Comparator|Placebo + Standard of Care Triple IS|"Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.~Standard of care triple maintenance immunosuppression includes:~a calcineurin inhibitor (tacrolimus),~an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and~steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.~Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant."
2389630|NCT03644654|Active Comparator|Standard care group|Fluid management will be done according standard care
2389631|NCT03644654|Experimental|Noninvasive monitoring group|Fluid management will be provided using noninvasive hemodynamical monitor ClearSight (Edwards)
2389632|NCT03644641|Experimental|Desflurane Group|Induction and anesthesia will be held by using desflurane
2389633|NCT03644641|Experimental|Propofol Group|Induction and anesthesia will be held by using target-control anesthesia with propofol
2389634|NCT03644628|Active Comparator|Sacropexy group (SCP)|Anterior and apical repair with laparoscopic sacropexy
2389635|NCT03644628|Experimental|Lateral suspension group (LLS)|Anterior and apical repair with laparoscopic lateral suspension
2389636|NCT03644615|Experimental|Mindfluness and usual care|
2389637|NCT03644615|Other|Usual Care|
2389638|NCT03644602|Active Comparator|IBD patients|"All subjects with Crohn's disease in clinical remission (defined in the presence of a Crohn's Disease Activity Index, CDAI <150), and with Ulcerative colitis in clinical remission (defined in the presence of <3 evacuations / day without blood, in the absence of endoscopic alterations) received a low FODMAPs diet.~The low FODMAPs diet was administered for 3 months."
2389639|NCT03644602|Active Comparator|Coeliac patients|Celiac patients on a gluten free diet for at least one year received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
2389640|NCT03644602|Active Comparator|IBS patients|Patients with Irritable Bowel Syndrome received a low FODMAPs diet. The low FODMAPs diet was administered for 3 months.
2389641|NCT03644589|Experimental|Treatment (pembrolizumab, cisplatin)|"Participants receive pembrolizumab and cisplatin once every 3 weeks for a total of 6 doses. Both drugs are given by vein (IV). Participants that are responding to the study treatment will continue to receive pembrolizumab alone beyond 6 cycles for up to 24 months until disease gets worse, having bad side effects, no longer wish to be in the study, or have become pregnant (whichever comes first).~Participants receive pembrolizumab over 30 minutes and cisplatin on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Participants without disease progression after 6 courses may continue on pembrolizumab IV on day 1 every 21 days for up to 24 months (or 35 courses) in the absence of disease progression or unacceptable toxicity."
2389642|NCT03644576|Experimental|ozanimod plus Pseudophedrine|ozanimod once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod.
2389643|NCT03644576|Placebo Comparator|ozanimod placebo plus Pseudoephedrine|ozanimod placebo once daily (QD) for 30 days. On Day 30, a single dose of pseudoephedrine 60mg will be co-administered with ozanimod placebo.
2389644|NCT03644563||Follow-up|Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
3183658|NCT00716040|Experimental|Intervention|The intervention group will be submitted to four social-psychological individual sessions with a pre-trained health professional.
2389646|NCT03644537|Other|heavy force 100gm|heavy intrusive force is to be applied on a first premolar on one side
2389647|NCT03644537|Other|medium force 25 gm|medium intrusive force is to be applied on a first premolar on one side
2389648|NCT03644537|Other|light force 10 gm|light intrusive force is to be applied on a first premolar on one side
2389649|NCT03644524|Experimental|Heat Therapy|Subjects assigned to heat therapy underwent 30 1-hour hot tub sessions over 8-10 weeks (3-4 per week). The hot tub was set to 40.5 Celsius, and core temperature and heart rate were monitored throughout each session.Subjects were instructed to not make any other dietary or lifestyle changes.Cardiovascular and metabolic health assessments were made Pre (0 heat sessions), mid (after 14-16 heat sessions, ~4-5 weeks), and post (after all 30 heat sessions; ~8-10 weeks).
2389650|NCT03644524|No Intervention|Time Control|Subjects were monitored at matched timepoints (start of study, 4-5 weeks, and 8-10 weeks) but not exposed to any intervention. Subjects were instructed to not make any dietary or lifestyle changes.
2389651|NCT03644511||Patients with HCC|Treated with Nexavar and/or Stivarga as ≥ 2nd-line systemic treatment
2389652|NCT03644498||Adults treated with a CPI therapy for cancer|
3183659|NCT00716040|Other|Control|The control group will be submitted to the usual care of the health service.
3183660|NCT00716053|Experimental|BLVR|
2389655|NCT03644472|Active Comparator|Nitrate rich beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Shot) approximately 90 min before physiological testing.
2389656|NCT03644472|Placebo Comparator|Nitrate depleted beetroot juice|Subjects will consume 140 ml of beetroot juice (Beet-It Organic Placebo) approximately 90 min before physiological testing.
2389657|NCT03644459|Experimental|LYN00101|Intravenous Infusion at the rate of 8 mg/kg of the patient's weight every 14 days.
2389658|NCT03644446||Bisoprolol 5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2389659|NCT03644446||Bisoprolol 7.5mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 7.5mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2389660|NCT03644446||Bisoprolol 10mg|Chronic heart failure with mild to reduced ejection fraction adult patients with bisoprolol intakes at 10mg (patient's maximum tolerated dose), stable, with a left ventricular ejection fraction < 50%. Consecutive patients at the CHU de Caen.
2389661|NCT03644433|Placebo Comparator|Single layer|Single layer closure
2389662|NCT03644433|Active Comparator|Double layer with resection|Double layer closure after resection uterine scar
2389663|NCT03644420||Knee osteoarthritis|"Patients with knee osteoarthritis, classified Kellgren-Lawrence 3 or 4, with asymmetric femorotibial joint space narrowing that will follow a surgery for a prosthetic replacement of the knee wil follow the following interventions:~Clinical evaluation~Radiographic assessment of osteoarthritis~Magnetic resonance imaging (MRI)~Histological evaluation of the surgical piece"
2389664|NCT03644394|Other|Implantation|Surgical Implantation of IMES sensors
2389665|NCT03644381|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
2389666|NCT03644381|Experimental|Treatment|Following randomization, participants in this group will receive escalating doses milk, up to a daily dose of 200 ml. Once they attain that dose, they will maintain it for one month. At the end of this period, they will undergo a open challenge to 300 ml of milk. They will then enter a year-long follow-up period
2389667|NCT03644355|Experimental|Diet and Nutrition Education|Lifestyle counseling plus nutrition education and counseling and protein sparing modified fast diet plus supplementation of vitamins and minerals, followed by a balanced, hypo-caloric diet and nutrition education provided by a registered dietician
2389668|NCT03644355|Active Comparator|Exercise Instruction|Lifestyle counseling plus moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
2389669|NCT03644355|Active Comparator|Combined Diet and Exercise|Lifestyle counseling plus dietary intervention including nutrition education and counseling and a protein sparing modified fast diet and nutrition education combined with the exercise intervention including a moderate intensity, progressive exercise prescription including cardio-pulmonary, strength and flexibility exercise tailored to the individual needs of each participant.
2389670|NCT03644355|No Intervention|Control|Delayed intervention (waiting list) group receives no intervention for 12 weeks followed by the Diet plus Exercise intervention.
3183661|NCT00716053|Sham Comparator|Saline|
2389671|NCT03644342|Experimental|Niraparib Arm|For the purposes of this study, two dose levels of Niraparib (100 mg and 200 mg) will be evaluated concomitant with the concurrent administration of pelvic radiotherapy.
2389672|NCT03644329|Other|Control group, CT|In the CT, the postmenopausal breast cancer survivers does not perform exercise.
2389673|NCT03644329|Experimental|Lower-load resistance training (LL)|In the LL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with low loads ( i.e. three sets with 30% of one-repetition maximum).
2389674|NCT03644329|Experimental|Higher-load resistance training (HL)|In the HL, the postmenopausal breast cancer survivers will be submitted to 12 weeks of resistance training with high loads (i.e. three sets with 80% of one maximum repetition).
2389675|NCT03644329|Experimental|Higher-volume resistance training (HV)|In the HV, the postmenopause breast cancer survivers will be submitted to 12 weeks of resistance training with high volume ( i.e. six sets with 80% one maximum repetition).
2389676|NCT03644316|Experimental|BandGrip|Topical skin closure device
2389677|NCT03644303|Experimental|SBRT + ADT|Enzalutamide OR Abiraterone at licensed doses in combination with stereotactic radiotherapy: 30 Gray in 5 fractions
2389678|NCT03644290|Experimental|Cognitive training|Semantic categorization training sessions
2389679|NCT03644290|Active Comparator|Control condition|Five sessions of behavioral control condition with information and education
3142993|NCT00003996|Experimental|chemotherapy + carmustine + etoposide + cisplatin + radiation|Patients receive pre-irradiation chemotherapy consisting of carmustine IV over 1 hour on days 1-3 and oral etoposide on days 1-21 and 29-49 immediately followed by cisplatin IV over 1-2 hours on days 1-3 and 29-31. Treatment repeats every 8 weeks for 2 courses. Patients receive concurrent cranial radiotherapy daily over 8 weeks during course 2. Patients then receive carmustine IV over 1-2 hours every 8 weeks for 4 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before the study, prior to each treatment course, every 4 months for 1 year, every 6 months for 4 years, and then annually for 5 years. Patients are followed every 4 months for 1 year, every 6 months for 4 years, annually for 5 years, and then for survival.
3142994|NCT00003997|Experimental|Arm I|Patients receive 6-hydroxymethylacylfulvene (HMAF) IV over 5 minutes on days 1-5. Treatment repeats every 3-4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of HMAF. The maximum tolerated dose is defined as the dose at which dose limiting toxicity occurs in at least 40% of patients.
3142995|NCT00004001|Experimental|Docetaxel and Estramustine|Estramustine, 280 mg, PO, TID, Days 1-5; q 21 days Docetaxel, 60mg/m2, IV, Day 2; q 21 days
3142996|NCT00004001|Active Comparator|Mitoxantrone and Prednisone|Mitoxantrone, 12 mg/m2, IV, Day 1; q 21 days Prednisone, 5 mg, PO, BID, Days 1-21; q 21 days
3142997|NCT00004010|Experimental|BEACOPP therapy|"Patients receive 4 cycles of BEACOPP therapy. Drugs utilized in this regimen include Bleomycin (B), Etoposide (E), Doxorubicin (A), Cyclophosphamide (C), Vincristine (O), Prednisone (P) and Procarbazine (P). Each cycle lasts 21 days and is characterized by intravenous pulses of Etoposide (Days 0-2), Doxorubicin (Day 0), Cyclophosphamide (Day 0), Bleomycin (Day 7), Vincristine (Day 7). Seven days of oral procarbazine (Days 0-6) and 14 days of oral prednisone (Days 0-13) are given during each cycle.~Growth factor support with Filgrastim (G-CSF) is given by subcutaneous injection daily beginning Day 8. Response will then be determined and stratification for further treatment."
2389685|NCT03644264|Experimental|PA21 tablets containing 500 mg of iron|PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).
2389686|NCT03644264|Active Comparator|Sevelamer carbonate: Renvela® tablets|Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).
2389687|NCT03644251|Experimental|AMUC Dosage 1|25mg amniotic and umbilical cord matrix
2389688|NCT03644251|Experimental|AMUC Dosage 2|50mg amniotic and umbilical cord matrix
2389689|NCT03644251|Experimental|AMUC Dosage 3|100mg amniotic and umbilical cord matrix
2389690|NCT03644238|Experimental|Experimental intervention|Oral Glucose Tolerance Test and physical activity
2389691|NCT03644238|Other|Control intervention|Oral Glucose Tolerance Test and inactivity.
2389692|NCT03644225|Other|Healthy Control|Healthy controls, who signed an informed consent, age ≥18 years old will be age and sex matched to the SSc patients
2389693|NCT03644225|Other|Systemic sclerosis patients|"SSc patients who signed an Informed consent~Age ≥18 years old~Diagnosis of systemic sclerosis according to the ACR/EULAR 2013 criteria~Skin thickening diagnosed by clinical expert"
3142998|NCT00004011|Experimental|preooperative chemo followed by surgery|carboplatin paclitaxel conventional surgery
3142999|NCT00004011|Active Comparator|Surgery alone|conventional surgery
3143000|NCT00004029|Experimental|Arm I|atients in cohorts of 3-6 receive 3 vaccinations with rV-PSA at 4-week intervals (days 1, 29, 57, and 85) in the absence of disease progression or unacceptable toxicity. Response assessment is performed at eight weeks. Patients who discontinue therapy prior to eight weeks are considered unevaluable for response. If dose limiting toxicity is observed in 2 of 6 patients entered at a dose level, no further patients are entered at that level and the MTD is defined as the preceding dose level. Ten additional patients are treated at the MTD and receive granulocyte-macrophage colony-stimulating factor (GM-CSF) administered subcutaneously on day -1 through day 2 of each cycle. Patients who are HLA-A2 positive, have received all 3 rV-PSA vaccinations without unacceptable toxicity, and have been off study for at least 30 days due to disease progression may continue treatment with rV-PSA at the highest dose level and the addition of GM-CSF.
3143001|NCT00004032|Experimental|Treatment (ALVAC-hB7.1, recombinant interferon gamma)|Patients receive ALVAC-hB7.1 infected tumor cells intraperitoneally (IP) on days 4, 11, and 18. Patients also receive interferon gamma IP on days 8, 10, 15, and 17. In the absence of disease progression, up to 6 courses of therapy may be given. If insufficient tumor cells are available to continue treatment with tumor cell derived vaccine, interferon gamma may be given alone.
2389696|NCT03644199|Other|OGTT test|Comparison of responses to a OGTT between CF subjects and health control subjects
2389697|NCT03644199|Other|Mixed meal|Comparison of responses to a mixed meal through the day between CF subjects and health control subjects
3143002|NCT00004038|Experimental|Arm I|Patients undergo biopsy of one of their skin nodules prior to any treatment. Patients receive the Ad-p53 gene therapy in one nodule and injection of a second nodule with Dulbecco's phosphate buffered saline. The next day, patients begin chemotherapy, which may be given weekly and continues every 21-28 days for up to 6 courses. On day 3, patients return for biopsy of injected nodules. Biopsies are only performed during the first course. Patients may receive further injections of the Ad-p53 gene with subsequent courses of chemotherapy, for up to six courses.
3143003|NCT00004050|Experimental|Leuvectin|2 intratumoral injections of 1000 ug of Leuvectin
3143004|NCT00004055|Experimental|topotecan + paclitaxel + filgrastim|Patients receive oral topotecan on days 1-5 followed by paclitaxel IV over 3 hours on day 5. Beginning 24-48 hours after chemotherapy, patients receive filgrastim (G-CSF) subcutaneously daily for up to 10 days until blood counts recover. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression. Patients who develop CNS progressive disease only should receive whole brain radiotherapy before continuing study treatment.
3143005|NCT00004056|Experimental|Chemo + STEM cell|See detailed description.
2389702|NCT03644147|Experimental|Treatment|Patients in this group will receive 1 gram of acetaminophen intravenously after the end of surgery.
2389703|NCT03644147|No Intervention|Control|Patients in this group will receive 100 ml of normal saline intravenously after the end of surgery.
2389704|NCT03644134|Experimental|Intervention Group|Assessment of physiological stress and sleep pattern intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns
2389705|NCT03644134|No Intervention|Control Group|The control protocol only includes (i) information session (ii) pre-assessment (initial assessment and (iii) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
2389709|NCT03644082|Experimental|Epilepsy Patients|
2389710|NCT03644069|Experimental|Nexvax2|
2389711|NCT03644069|Placebo Comparator|Placebo|
2389712|NCT03644056|Experimental|IMC-001|Multiple Dose Level (IMC-001 2 mg/kg etc. every 2 weeks)
2389713|NCT03644043||Early stage of MCI symptoms|Subjects with cognitive decline representing MCI symptomology and with previous PET amyloid-beta (Aβ) imaging results.
2389715|NCT03644004||Women with medical history of gestational diabetes|Patients followed at the hospital of Vienne for gestational diabetes in 2016.
2389716|NCT03643991|Experimental|Weighted Blanket Cohort|First 15 subjects enrolled have access to sleep with weighted blanket for three nights with monitoring by nurse. Weight of blanket is determined by weight of the patient (10% of patients body weight).
2389717|NCT03643991|No Intervention|Control Cohort|Last 15 subjects enrolled receive treatment as usual while inpatient.
2389718|NCT03643978|Experimental|Decision Aid Group|These patients review a decision aid.
2389719|NCT03643978|No Intervention|Control Group|These patients do not review a decision aid.
2389723|NCT03643939|Experimental|High Flow Nasal Catheter|The HFNC (AIRVO2 Fisher & Paykel, Auckland, New Zealand) consists of an apparatus that allows adjustable FiO2 from 21 to 100% and delivers flow up to 60 L/ min.
2389724|NCT03643939|Active Comparator|Non-invasive positive pressure ventilation|NIPPV will be performed using the devices available on centers. Both a dedicated NIPPV device or invasive mechanical ventilator with NIPPV mode are accepted. The interface should be a oronasal or full face mask.
2389725|NCT03643926|Experimental|Arthroscopic Brostrom|
2389726|NCT03643926|Active Comparator|Open Brostrom|
2389727|NCT03643913|Active Comparator|Comparison group|"Neuromuscular Blocking Agents and reversing agents: The comparison group will receive anesthesia top up Esmeron dose to maintain a Train Of Four (TOF) count of maximum 2 during the whole procedure. This represents moderate neuromuscular block conditions. A neuromuscular monitor (PHILIPS integrated) will be used to evaluate TOF count.~To maintain TOF at 2 and according to our practice a bolus injection of 0,1 mg/kg Rocuronium will be given when TOF count returns to 3. This dose will be repeated if TOF does not go back to 2 within 2 minutes after bolus injection. TOF guard and TOF tube will be used at the ulnar nerve at the contralateral side and will be checked continuously during surgery.~Reversal of the TOF=2 will be done by Sugammadex 2 mg/kg at end of procedure (Time of last suture)"
2389826|NCT03643250|Experimental|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
3143006|NCT00004067|Active Comparator|Arm 1: adriamycin + cyclophosphamide then taxol|
3143007|NCT00004067|Experimental|Arm 2: adriamycin + cyclophosphamide then taxol + herceptin|
3143008|NCT00004070|Experimental|IL-12 Injection 3mg/ml [Phase I]|The dosing schedule will consist of eight injections 3 mg/ml of formulated plasmid over a seven week period.
3143009|NCT00004070|Experimental|IL-12 Injection 6mg/ml [Phase I]|The dosing schedule will consist of eight injections 6mg/ml of formulated plasmid over a seven week period.
3143010|NCT00004070|Experimental|IL-12 Injection MTD [Phase II]|The dosing schedule will consist of eight injections over a seven week period of formulated plasmid at the MTD established in the phase I portion.
3143011|NCT00004074|Experimental|Treatment (IL12 and trastuzumab)|Patients receive an initial loading dose of trastuzumab IV over 90 minutes on day 1 of the first week and a maintenance dose of trastuzumab IV over 30-90 minutes on day 1 of each subsequent week. Patients receive IL-12 IV on days 2 and 5 beginning on week 3. Treatment with maintenance trastuzumab and IL-12 repeats weekly for 14 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease continue treatment for up to 38 additional weeks.
2389728|NCT03643913|Experimental|Deep group|Neuromuscular Blocking Agents and reversing agents: The deep group will receive deep neuromuscular block, using a infusion of Esmeron at 0,1mg/kg/hour. A post tetanic count will be performed and our target will be to have a PTC 1-2. The standard infusion will be adjusted as such. Reversal will be achieved by Sugammadex 4 mg/kg depending on reversal speed at the end of procedure (Time of last suture)
2389729|NCT03643900|Experimental|indomethacin with stenting group|Pancreatic duct stenting and rectal indomethacin 100mg at preoperative 30min in 100 patients
2389730|NCT03643900|Active Comparator|indomethacin group|Rectal indomethacin 100mg at preoperative 30min in 100 patients
2389731|NCT03643887|Experimental|FMT Capsule DE|FMT Capsule DE
2389732|NCT03643887|Placebo Comparator|Placebo Oral Capsule|Placebo Capsule
2389733|NCT03643874|Experimental|Halix albuterol 90 mcg|Cumulative doses of albuterol administered by the Halix albuterol 90 mcg UDDI will given at intervals as: 1 inhalation, then 1 inhalation 30 min later, then 2 inhalations 30 min later, and then 4 inhalations 30 min later.
2389734|NCT03643874|Active Comparator|Albuterol HFA MDI 90 mcg|Cumulative doses of albuterol administered by the albuterol HFA albuterol 90 mcg MDI will given at intervals as: 2 inhalations, then 2 inhalations 30 min later, then 4 inhalations 30 min later, and then 8 inhalations 30 min later.
3143012|NCT00004078|Experimental|Treatment (irinotecan hydrochloride)|Patients receive irinotecan IV over 60 minutes on days 1-5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 4 years and then annually thereafter until death or until patient enters another POG study.
2389736|NCT03643848|Experimental|Sleep with Sound Cues|Sounds played at time of memory encoding will be replayed during sleep to cue memory processing.
2389737|NCT03643848|Sham Comparator|Sleep with Sham Cues|Sounds that were not played at time of memory encoding will be played during sleep as a sham comparison
2389738|NCT03643835|Experimental|Thermal rehab machine|Participants, following exercise-induced hyperthermia, will be cooled using a Thermal Rehab Machine (Polar Breeze, Statim Technologies, LLC, Clearwater Florida), which is a micro-environmental air chiller. The device will be placed over the subjects head and through trans pulmonary cooling, will cool the body.
2389739|NCT03643835|Active Comparator|Forearm Ice Towels|Participants, following exercise-induced hyperthermia, will be cooled using forearm ice towels. Cotton-blend towels will be doused in ice-water and then wrapped around participant's forearms (elbow to wrist). The towels will be rotated (re-wetted) every 2 minutes)
2389740|NCT03643835|No Intervention|Passive Cooling|Participants, following exercise-induced hyperthermia, will undergo a period of passive rest to allow the body to cool via natural mechanisms of evaporation of sweat from the skin's surface and convection
3143013|NCT00004079|Experimental|Treatment (SarCNU)|"Patients receive oral sarcosinamide nitrosourea (SarCNU) on days 1, 5, and 9. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SarCNU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3143014|NCT00004095|Experimental|Irinotecan Plus Gemcitabine|
3143015|NCT00004101|Experimental|Arm I|Patients receive monoclonal antibody Hu1D10 IV over 2-4 hours on days 1, 8, 15, and 22. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of monoclonal antibody Hu1D10 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 6 patients experience dose limiting toxicity. Once the MTD is determined, an additional cohort of 3-6 patients receive Hu1D10 IV over 2-4 hours on days 1-5.
3143016|NCT00004109|Experimental|Doxorubicin + External-Beam RT|
2389747|NCT03643783||Bariatric Obese Patients|Obese patients, including men and women, White (Caucasians), Africa American, and Hispanic or Latino racial categories, and ages 18-70 years, who are enrolled and planning to undertake bariatric surgery in the Outpatient Bariatric Surgery Clinic at Tulane University, HSC (Christopher G. Ducoin, MD, MPH; Chair of Bariatric Surgery Clinic and Surgeon, and Shauna Levy, MD, Bariatric Surgeon Specialist).
2389748|NCT03643783||Lean Control Patients|Plasma samples from lean control patients that have already been collected and are available as part of the Tulane Obesity-Endocannabinoids Study (Tina Thethi, M.D, Collaborator).
2389749|NCT03643770|No Intervention|Acute Intermittent Hypoxia (AIH) treatment|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment.
2389750|NCT03643770|Active Comparator|AIH in combination with upper extremity training|The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask. The mask is designed to couple with a universal mask circuit connecting to the air mixture system. The purpose of the mask will be to minimize room air entrainment. In addition to this upper extremity training will be given using an upper-limb robotic rehabilitation device.
2389751|NCT03643770|Active Comparator|Sham AIH therapy in combination with upper extremity training|Sham hypoxia followed by upper extremity training will be given using an upper-limb robotic rehabilitation device (Armeo Spring®, Hocoma AG, Switzerland). Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
2389752|NCT03643770|No Intervention|Sham AIH therapy|Sham hypoxia
2389753|NCT03643757|Active Comparator|Thoracic Epidural Analgesia|Population to whom thoracic epidural analgesia with bupivacaine as a component of multimodal analgesia was administered.
2389754|NCT03643757|Active Comparator|Intravenous analgesia|Population to whom combined intravenous analgesia was administered.
2389755|NCT03643744|Active Comparator|PDT + Celecoxib|Patient receiving PDT taking 200mg celecoxib.
2389756|NCT03643744|Placebo Comparator|PDT + Placebo|Patient receiving PDT taking placebo.
2389757|NCT03643744|Active Comparator|Control + Celecoxib|Control subject not receiving PDT taking 200mg celecoxib.
2389758|NCT03643744|Placebo Comparator|Control + Placebo|Control subject not receiving PDT taking placebo.
2389759|NCT03643731|Experimental|HeatTens|"After baseline measurements and during 4 weeks of follow up~Composition and dosing of the device:~HeatTens (HV-F311-E) 2 - 108 Hz (modulation), 100 microsec (pulse duration) for 30 minutes."
2389760|NCT03643731|No Intervention|Control group|No intervention
3183662|NCT00716066|Experimental|Treatment (immunosuppressive therapy followed by transplant)|Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic peripheral blood stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.
2389764|NCT03643679|Experimental|Kwit smartphone app|This arm will receive the Kwit smartphone app.
2389765|NCT03643666|Placebo Comparator|control group|this group will include 25 patients receiving intraperitoneal 40 ml of normal saline only at the end of laparoscopic cholecystectomy
2389766|NCT03643666|Active Comparator|dexamethasone group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone in 40 ml saline at the end of laparoscopic cholecystectomy
2389767|NCT03643666|Active Comparator|dexamethasone plus magnesium sulphate group|this group will include 25 patients receiving intraperitoneal 16 mg dexamethasone plus 2 gm magnesium sulphate at the end of laparoscopic cholecystectomy
2389768|NCT03643640|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
2389769|NCT03643640|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
2389770|NCT03643627|Placebo Comparator|Placebo|
2389771|NCT03643627|Experimental|1 mg/kg|
2389772|NCT03643627|Experimental|3 mg/kg|
2389773|NCT03643627|Experimental|10 mg/kg|
2389774|NCT03643627|Experimental|30 mg/kg|
2389775|NCT03643614|Experimental|study group|Injection of autologous regenerative cells of adipose tissue for treatment of radiation induced rectovaginal fistulas
2389776|NCT03643601||Non-Dialysis (ND) Patients|For the ND patients, data are captured on each clinic visit during the course of the year (2-4 times per year), the last available record for 2015 will be used.
2389777|NCT03643601||Dialysis (DD) Patients|For the DD patients, data are input from a randomly selected visit to the hospital in September to October 2015; the evaluation will be based on this record.
2389778|NCT03643588|Experimental|HYAJOINT Plus group|The HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
2389779|NCT03643588|Active Comparator|Hyalgan group|The Hyalgan group received intraarticular injection of 2 ml Hyalgan for three continuously weeks and be followed for 52 weeks. A single injection of HYAJOINT Plus was performed if criteria was met at 52 weeks, and a 4-weeks follow-up of adverse events was conducted.
3183663|NCT00716105|Placebo Comparator|Control|Standard Infant Formula
3183664|NCT00716105|Experimental|Test Product|Infant formula with different level of proteins
3183665|NCT00716105|No Intervention|Breast Milk|Breastfeeding reference group
2389783|NCT03643562|Experimental|Adrabetadex|Participants receive prescribed adrabetadex by intra-thecal injection
2389784|NCT03643549|Experimental|Bortezomib and Temozolomide|Botezomib 1.3 mg/m2 administered IV on days 1, 4, 7, during each 4-week chemotherapy cycle with per oral Temozolomide at three dose levels: 150 mg/m2, 175 mg/m2 and 200mg/m2 5 days/week every 4 weeks starting on day 3.
2389785|NCT03643536|Experimental|12-WPEP in subjects with reduce LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of CABG or PCI subjects with LVEF by 2D-echocardiography between 30-54%. The quality of life was measured using SF-36 questionnaire
2389786|NCT03643536|Active Comparator|12-WPEP in subjects with normal LVEF|Intervention: a 12 week physical exercise program in the health-related quality of life of or PCI subjects with LVEF by 2D-echocardiography≥ 55% (control group)The quality of life was measured using SF-36 questionnaire
2389787|NCT03643523||ALbumin level|Detection of serum albumin levels in postoperatory of colorectal surgery
2389788|NCT03643510|Experimental|Fulvestrant in Combination with Abemaciclib|Eligible patients will take Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28. Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles. Each cycle will be 28 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, or study termination.
2389789|NCT03643497||Children with the usage of anti-infective drugs|Children received meropenem or linezolid monotherapy in the treatment of seven infectious diseases
2389790|NCT03643458||Transfused infants|Preterm infants undergone red blood cell transfusion during hospital stay.
2389827|NCT03643250|Experimental|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
2389828|NCT03643250|Experimental|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
2438526|NCT03308331|No Intervention|HIV-1 nonsmokers using placebo patch|
3183666|NCT00716118||1|IVF patients.
3183667|NCT00716131||ALS|Diagnosed with ALS or other motor system disorder including PLS, Bulbar Palsy or Motor neuropathy
2389791|NCT03643445|Experimental|Motivational Interviewing (MI) Treatment|Motivational interviewing is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices. Patients assigned to these MI-trained therapists will be in the motivation-oriented condition. All individual meetings patients have with their therapist while they are in the program will entail sessions that are guided by MI principles. That is, revisiting patients' motivation to recover and overcoming obstacles to ambivalence or low motivation.
2389792|NCT03643445|Active Comparator|Psychoeducation-Oriented Treatment|"The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. Two staff members in the eating disorders program will deliver the psychoeducation-infused interventions, which are intended to be equivalent to treatment-as-usual in many eating disorder programs, but in a structured and standardized way, and with the use of the self-help manual. Psychoeducation is a very common intervention, often used as part of cognitive-behavioural treatment for eating disorders. The idea is that information about eating disorders and their health risks facilitates recovery and allows patients to buy in to treatment."
3183668|NCT00716131||Neuro|Diagnosed with other chronic neurologic illnesses (Alzheimers, multiple sclerosis, migraines, etc)
3183669|NCT00716131||Healthy|Normal Controls
2389795|NCT03643419|Sham Comparator|Laminectomy|
2389796|NCT03643419|Experimental|Laminectomy & Irradiation|
2389797|NCT03643406|Experimental|Mental Fatigue Condition|
2389798|NCT03643406|Placebo Comparator|Control Condition|
2389799|NCT03643393|Other|incarceration rectal prolapse|
2389800|NCT03643380|Experimental|Investigational SNS device|
2389801|NCT03643367|Experimental|Sevoflurane Sedation|Patients randomized into experimental group will be treated with sevoflurane during 4 hours
2389802|NCT03643367|Active Comparator|Propofol Sedation|Patients randomized into Control Group will get continued intravenous sedation with propofol
2389803|NCT03643354|Experimental|Evaluation of prevalence of BPPV|Epley/Barbeque maneuver will be performed using the Rotundum Device to assess if subject has BPPV, patient will thereafter be treated for it using the Rotundum Device.
2389804|NCT03643341|Experimental|Family Healthy Living Intervention|Children aged 8-12 and at least one caregiver will meet for 10 weekly face-to-face and online intervention sessions (1.5 hours per session). Four biweekly maintenance sessions will follow the main program.
2389805|NCT03643341|No Intervention|Wait-list control group|Children aged 8-12 will be randomly assigned to the wait-list control group until after the study.
2389806|NCT03643328|Experimental|new haemodialysis patients.|There is an analyse of immune response against S. aureus from new haemodialysis patients by blood samples and nasal swabs.
2389807|NCT03643315|Experimental|Exercise and Meal (EX)|The EX protocol will involve a 30 minute acute bout of high intensity intermittent exercise on a stationary exercise bike followed by an ad-libitum test meal.
2389808|NCT03643315|Experimental|No-Exercise and Meal (NEX)|The NEX protocol will involve a 30 minute period of rest (to match the exercise period in EX) where participants will be provided a video/movie. Following this, participants will be provided ad-libitum access to a test meal (as per EX energy intake assessment protocol)
2389809|NCT03643302||Therapy of bronchoalveolar lavage group|Patients with bronchiectasis exacerbations treat with fundamental treatment combining with the therapy of airway clearance and bronchoalveolar lavage.
2389810|NCT03643302||Fundamental treatment group|In the control group,fundamental treatment was adopted according to the guidelines
2389811|NCT03643289||Cohort A|Patients with stage 4 melanoma due to commence immunotherapy. Patients should be naïve to immunotherapy.
2389812|NCT03643289||Cohort B|Patients with stage 3 melanoma who are naïve to immunotherapy
2389813|NCT03643276|Active Comparator|pB: early (non-)HR-standard/MR-standard|"Induction (5 wks): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT methotrexate (MTX)~Consolidation (6 w/4 w): Consolidation extended (control arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-mercaptopurine (6-MP), IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 years after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
2389814|NCT03643276|Experimental|pB: early HR-exp./MR-standard|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 wks): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 wks): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX [without preceding blinatumomab (control arm of randomization R-MR)]~Erwinase is given in case of allergy to pegaspargase."
2389815|NCT03643276|Experimental|pB: early (non)HR-standard/MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2389829|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
2391182|NCT03633851|Experimental|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
3183670|NCT00716131||Autopsy|
3183671|NCT00716157||Observation|Adult patients receiving both radiation therapy and chemotherapy
2389816|NCT03643276|Experimental|pB: early HR-exp./MR-exp.|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (given at 1.3 mg/m²/dose on days 50, 53, 56 and 59)~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX,IT MTX~Reinduction (6 weeks): Protocol II with dexamethasone, vincristine, doxorubicin, PEG-L-asparaginase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Blinatumomab (4 w): 1 cycle blinatumomab given at 15 µg/m²/day for 28 days (experimental arm of randomization R-MR)~Maintenance phase (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2389817|NCT03643276|Active Comparator|pB: early (non-)HR-standard/HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT methotrexate, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): Protocol III given 3 times with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)."
2389818|NCT03643276|Experimental|pB: early HR-exp./HR-standard|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (3x5 d): Block HR-1' followed by HR-2' and HR-3' (control arm in randomization R-HR) with dexamethasone, vincristine, vindesine, daunorubicin, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, ifosfamide, pegaspargase, etoposide~Reinduction (3x4 w): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
2389819|NCT03643276|Experimental|pB: early (non-)HR-standard/HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w/4 w): Consolidation extended (control arm in randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase or Consolidation short (standard arm of early non-HR group) with cyclophosphamide, cytarabine, 6-MP, IT MTX~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after init. diagnosis): 6-MP, MTX~Erwinase is given in case of pegaspargase allergy. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
2389820|NCT03643276|Experimental|pB: early HR-exp./HR-exp.|"Induction (5 w): as in other pB arms~Consolidation (6 w): Consolidation extended+BZM (experimental arm of randomization R-eHR) with cyclophosphamide, cytarabine, 6-MP, IT MTX, dexamethasone, vincristine, pegaspargase, bortezomib (1.3 mg/m²/dose on days 50, 53, 56 and 59)~Intensified consolidation (1x5 d + 2x28 d): Block HR-1' with dexamethasone, vincristine, HD-MTX, IT MTX, HD-cytarabine, cyclophosphamide, pegaspargase followed by 2 cycles blinatumomab at 15 µg/m²/day for 28 days per cycle plus 2x2 doses IT MTX (experimental arm of randomization R-HR)~Reinduction (3x4 weeks): as in arm pB: early (non-)HR-standard/HR-standard Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
2389821|NCT03643276|Other|pB: early non-HR/SR|"Induction (5 w): Protocol IA with prednisolone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Consolidation short with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2389822|NCT03643276|Active Comparator|T: early non-SR-standard/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (4 w): Protocol IB regular (control arm in randomization. R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
2389823|NCT03643276|Experimental|T: early non-SR-exp/(non-)HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX or Protocol IA-CPM with prednisolone instead of dexamethasone and additional CPM~Consolidation (6 w): Protocol IB long (experimental arm in randomization R-T) with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~non-HR extra-compartment phase and reinduction: as in arm pB: early non-HR/SR~HR intensified consolidation and reinduction: as in arm pB: early (non-)HR-standard/HR-standard~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase. Pts with poor response to intensified consolidation receive Myocet-FLA (Myocet, fludarabine, HD-cytarabine, IT-MTX)"
2389824|NCT03643276|Other|T: early SR/non-HR|"Induction (5 w): Protocol IA-Dexa with prednisolone/dexamethasone, vincristine, daunorubicin, pegaspargase, IT MTX~Consolidation (4 w): Protocol IB regular with cyclophosphamide, cytarabine, 6-mercaptopurine, IT MTX~Extra-compartment phase (8 w): Protocol M with 6-MP, HD-MTX, IT MTX~Reinduction (6 w): Protocol II with dexamethasone, vincristine, doxorubicin, pegaspargase, IT MTX, cyclophosphamide, tioguanine, cytarabine~Maintenance (until 2 yrs after initial diagnosis): 6-MP, MTX~Erwinase is given in case of allergy to pegaspargase."
2389825|NCT03643250|Experimental|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
2438683|NCT03307265|Active Comparator|Control|
2389830|NCT03643237|Experimental|Video game-based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 45 minutes long that will be administered at a rate of 1 per week with between-session homework.
2389831|NCT03643237|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
3143017|NCT00004123|Experimental|RT + DOX + IORT|Preoperative external beam radiotherapy (RT) combined with doxorubicin (DOX) and followed by intraoperative radiotherapy (IORT); dose-escalation study of external beam radiotherapy.
2389833|NCT03643198|Sham Comparator|CONTROL|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
2389834|NCT03643198|Active Comparator|TREATMENT|In the study group, patients will receive oral treatment with Ciprofloxacin at a dose of 500 mg every 12 hours and Metronidazole 500 mg every 8 hours for a period of 7 days.
3183672|NCT00716170||A:|Patients with type 2 diabetes mellitus
3183673|NCT00716183|Experimental|Probiotic 1|Women receiving Lactobacillus salivarius HN6
2389857|NCT03643133|Active Comparator|Control arm|"Post-operative chemotherapy alone (EI or M-API regimen depending on patient age) :~M-API regimen (≤25 years) :~Doxorubicin 60 mg/m², Day 1 Ifosfamide 3 g/m² Day 1 and 2 Cisplatin 100 mg/m², Day 2~EI regimen (26-50 years) :~Etoposide 75 mg/m²/d, Day 1-4 Ifosfamide 3 g/m²/d, Day 1-4"
2389858|NCT03643133|Experimental|Experimental arm|Post-operative chemotherapy (EI or M-API regimen) combined with Mifamurtide 2 mg/m² twice weekly post-randomisation for 12 weeks then weekly for 24 weeks
2389859|NCT03643120|Other|Development of diagnostic typology|One main goal is to Development a typology of sub-types of gender dysphoria.
2389860|NCT03643107|Experimental|Irofulven + Prednisolone 10mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
2389861|NCT03643094|Experimental|Golden Black Seed|Golden Black Seed, 1 capsule per day for 8 weeks.
2389862|NCT03643081|Experimental|"use of camera Fluobeam"|
2389863|NCT03643081|No Intervention|"Without use of the camera Fluobeam"|
2389864|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 0.6 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.6 mg of KSP-QRH-E3-IRDye800 (Peptide 919288G) total. For the first three subjects, 3.34 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)will be discarded. The 1.66 mL of KSP-QRH-E3-IRDye800 (Peptide 919288G)remaining in the syringe will be administered by squirting it into the mouth of the subject.
2389865|NCT03643068|Experimental|KSP-QRH-E3-IRDye800 (Peptide 919288G) 1.8 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.6 mg dose, the remaining 22 subjects will receive the full 1.8 mg dose of KSP-QRH-E3-IRDye800 (Peptide 919288G) reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
2389866|NCT03643055||MTC 18F-fluorocholine PET/CT|Patients with medullary thyroid cancer imaged using 18F-fluorocholine PET/CT.
2389867|NCT03643042|Experimental|Restrictive group|Transfusion with: Hb < 80g/L and Hb maintain between 80 and 100g/L
2389868|NCT03643042|Experimental|Liberal group|Transfusion with: Hb < 100g/L and Hb maintain between 100 and 120g/L
2389869|NCT03643016|Experimental|Group with Virtual Epileptic Patient brain access data|
2389870|NCT03643016|No Intervention|Group without Virtual Epileptic Patient brain access data|
2389871|NCT03643003|Experimental|Music Therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
2389872|NCT03643003|Placebo Comparator|Non-Music Verbal Interaction|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Order is randomly assigned, and all participants engage in both study arms."
2389873|NCT03642990|Experimental|NIAGEN®)|Daily oral administration of nicotinamide riboside 300 mg (150 mg a.m. and p.m.) for one week with dose escalation to 1000 mg (500 mg a.m. and p.m.) for remaining 11 weeks.
3143018|NCT00004126|Experimental|Arm A|Paclitaxel 175 mg/m2 : administered by 1-hour constant rate IV infusion through a pump on day 1 of each cycle. Oxaliplatin 130 mg/m2 : On Day 1 of each 21-day treatment cycle, patients receive oxaliplatin diluted in 250-500 mL Dextrose 5% in Water infused intravenously over 2 hours.
3143019|NCT00004127|Experimental|Arm A|Oxaliplatin (85 mg/m2, day 1 of every 14 day cycle), Leucovorin (500 mg/m2, day 1 and 2 of every 14 day cycle), Fluorouracil (Bolus of 400 mg/m2 followed by 22 hr continuous infusion of 600 mg/m2 on days 1 and 2 of every 14 day cycle)
2389874|NCT03642977||Allogeneic HSCT recipients|"Adult patients receiving allogeneic hematopoietic stem cell transplant (HSCT) at University Hospitals of Geneva and who are enrolled in the Cohort of infectious disease in hematopoietic stem cell transplant patients."
2389875|NCT03642964|Experimental|treatment|CTC-501 (pramipexole IR, given with ondansetron) given orally twice daily
2389876|NCT03642964|Placebo Comparator|placebo|generic placebo tablets given orally twice daily
2389877|NCT03642951|Active Comparator|Active Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device."
2389878|NCT03642951|Sham Comparator|Sham Treatment Group|"Each patient will receive daily 40 min treatment five days per week for two weeks. The procedure during each treatment session will consist of positioning the device centered at 15% of the nasion-inion distance anterior to the Cz electrode placement in standard EEGs, with the patient relaxing in a chair.~The stimulus parameters used will be 480 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 40 min. The investigator will measure the subject for accurate placement of the device prior to each visit. Once the placement of the device is confirmed, the study technician administering the treatment will tum on the device using an app downloaded to an electronic device connected by Bluetooth to the device.~Note: While the device looks and is operated the same as the active device, subjects in this group will be stimulated with the placebo device so no active stimulation will be given."
2389879|NCT03642938|Experimental|Low Dose Exercise|The Low Dose Exercise group will perform treadmill walking exercise, three times per week for one week.
2389880|NCT03642938|Experimental|Moderate Dose Exercise|The Moderate Dose Exercise group will perform treadmill walking exercise, five times per week for one week.
2389881|NCT03642938|Experimental|High Dose Exercise|The High Dose Exercise group will perform treadmill walking exercise, ten times per week for one week.
2389882|NCT03642938|Sham Comparator|Control|The Control group will perform quiet rest, three times per week for one week.
2389883|NCT03642925|Experimental|Meal replacement diet|Obese subjects (BMI>27; n=50, male 23, female 27) were requested to replace (intervention) two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks
2389884|NCT03642912||ECMO patients|ECMO patients treated on the intensive care units of the Department of Anesthesiology of LMU Munich
2389885|NCT03642899||Patients with anterior ischaemic optic neuropathy|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
2389886|NCT03642899||control group. Normal eyes|estimation of best visual acuity, fondus, measurement of retinal nervous layer thickness, ganglionar cells layer thickness, and a macular and papillar OCT angiography during a consultation
2389887|NCT03642886|No Intervention|Continued Strenuous Exercise|Continued strenuous athletics (no reduction in training volume) - athletes will be asked to document their activity and be fitted with an activity monitor during the run-in period and intervention period
2389888|NCT03642886|Experimental|Prescribed Detraining|"Detraining period of 8-weeks which is defined as:~a 75% decrease in the amount of exercise (from baseline)~a 50% decrease in the intensity of exercise as measured in METS (from baseline)~Mitchell Classification classes 1A, 2A, 2B of activity are permitted"
3183674|NCT00716183|Experimental|Probiotic 2|Women receiving Lactobacillus reuteri CR20
3183675|NCT00716183|Experimental|Probiotic 3|Women receiving Lactobacillus fermentum LC40
3183676|NCT00716183|Active Comparator|beta-lactam|The evolution of the women ascribed to the other three arms will be compared with that of 100 women suffering lactational mastitis that will follow a conventional antibiotic treatment as prescribed by the pediatrician/gynecologist
2389892|NCT03642860|Experimental|Active treatment|Triheptanoin oil
2389893|NCT03642860|Placebo Comparator|Placebo treatment|Safflower oil
2389894|NCT03642847|Active Comparator|Prevnar 13|13 valent Pneumococcal Conjugate
2389895|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
2389896|NCT03642847|Experimental|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
2389897|NCT03642834|Experimental|ICP-105 Single Arm|ICP-105 of multiple dose levels, dose escalation steps may be modified based on the safety from the previous dose.
2389898|NCT03642808|Experimental|rehabilitation program|"Duration of 8 weeks for a cycle of rehabilitation at the rate of two half-days per week~Two interventions per half-day: 30 minutes of education and 1h30 of rehabilitation: physiotherapist, psychomotricity, adapted physical activity"
2389900|NCT03642782|Experimental|early age of glaucoma or with important risk factors|All patients included will benefit from a complete ophtalmic examination including visual acuity, slit lamp biomicroscopic examination of the anterior segment, measurement of intraocular pressure by Goldmann tonometer aplanation, dynamic gonioscopy with Posner glass. They will also have a fundus examination with examination of the retina, macula and optic nerve as well as the ERGP.
2389903|NCT03642756|Placebo Comparator|20 gauge|
2389904|NCT03642756|Active Comparator|22 gauge|
2389905|NCT03642756|Active Comparator|24 gauge|
2389906|NCT03642743|Experimental|Two and six week follow up|Patients will be assigned to routine two and six week postoperative follow up appointments
3183677|NCT00716209||1|Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
2389908|NCT03642730|Experimental|Scanned patients|Scanned patients TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
2389909|NCT03642730|Experimental|Non-expert scanning volunteers|Non-expert scanning volunteers (among the medical staff at the clinical site) TransThoracic Echocardiography Diagnostic Test: TransThoracic Echocardiography imaging synchronized with additional external sensors
3183678|NCT00716222||1|Obese adolescent and young adult with sleep disorder
2389911|NCT03642704|Experimental|Reinforced preventive ARV therapy|The proposed reinforced preventive ARV Therapy will be administrated to all newborns exposed to HIV (zidovudine+lamivudine+nevirapine if the newborn is exposed to HIV-1 or HIV-1/2, zidovudine+lamivudine if the newborns exposed to HIV-2)
2389912|NCT03642678|Experimental|Intervention group|"Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into study group.~Interventions: In this group, participants will be given common clinical screening for clinical or sub-clinical infection and also oral nutrition supplement (ONS) if albumin is < 3.8 g/dl. Parameters for outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened."
2389913|NCT03642678|No Intervention|Control group|Participants identified as high-risk for malnutrition-related mortality by prediction model are cluster-randomized into control group. In this group, participants will not be given any intervention, but only outcome measurements are recorded monthly (such as biochemical data) or quarterly (such as Body Composition Monitor (BCM) or Malnutrition Inflammatory Score (MIS). Hospitalization or Mortality events will be recorded when happened.
2389914|NCT03642665|Experimental|Natural cycle|no medication
2389915|NCT03642665|Active Comparator|Artificial cycle|"Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.~Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy."
2389916|NCT03642652|Experimental|SMS|"Each patient in the intervention group also received an automated text message up to a week after the positive FOBT result. The text read: Hello. There is a lab test result ready for you. Contact your physician for an explanation of the findings. Two additional automated text message reminders were sent to the patient at 2 weeks and 1 month reading, Hello, This is a reminder. It is essential that you contact your physician if you have not already done so."
2389917|NCT03642652|No Intervention|Control|Routine care
3183679|NCT00716222||2|Obese adolescent and young adult without sleep disorder
2389919|NCT03642626||ARM A: Refractory/relapsed B-cell acute lymphoblastic leukemia (ALL)|
2389920|NCT03642626||ARM B: Yescarta for Refractory diffuse large B cell lymphoma (DLBCL)|
2389921|NCT03642626||ARM C: Kymriah for Refractory diffuse large B cell lymphoma (DLBCL)|
2389922|NCT03642626||Arm D: Tecartus CAR-T product for Mantle Cell Leukemia (MCL)|
2389923|NCT03642600|Active Comparator|dietary advice plus myo-inositol and folic acid|2gram myo-inositol and folic acid twice daily orally lack of consistent evidence for myo-inositol as treatment of women with PCOS
2389924|NCT03642600|Active Comparator|dietary advice plus liraglutide pen injector|liraglutide starting at 0.6 mg, gradually increasing up to a dose of 3 mg daily after four weeks no evidence for weight loss in women with PCOS
2389925|NCT03642587||Study Population|People between the ages of 2 and 85 years old with out of hospital cardiac arrest of no obvious cause who are attended to by paramedics who survive or die
2389926|NCT03642574|Experimental|PMS group|Subjects in the PMS group will have blastocyst biopsy and whole genome bisulfate sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by DNA methylation level.The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2389927|NCT03642574|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 2 or 7 good-quality embryos on Day 5 to 7. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2389928|NCT03642561|Experimental|RFA group|Patients in RFA group will accept RFA treatment
2389929|NCT03642561|Active Comparator|TACE group|Patients in TACE group will accept TACE treatment
2389930|NCT03642548|Experimental|BIFICO Group|The intervention group patients receive platinum-based doublet chemotherapy plus BIFICO (Dose: 420mg, 3 times a day, p.o)
2389931|NCT03642548|Placebo Comparator|Control Gruop|The control group patients receive platinum-based doublet chemotherapy plus Placebo (Dose: 420mg, 3 times a day, p.o)
2389932|NCT03642535|Experimental|ALA for all face group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Immediately afterwards, a 1-mm thick layer of 10% ALA was applied to the all face. The area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
3183680|NCT00716222||3|Lean adolescent and young adult with sleep disorder
2390203|NCT03640481|Experimental|Arm B: belumosudil 200 mg BID|Eligible subjects randomized to arm B will take belumosudil 200 mg twice daily
3183681|NCT00716235||DCD|Children with a diagnosis of DCD
2389933|NCT03642535|Active Comparator|ALA for AK lesion group|Scales and crusts were gently removed by curettage, and the lesions to be treated were scraped carefully to avoid bleeding. Then a 1-mm thick layer of 10% ALA was applied to the lesion and 5 mm of surrounding healthy tissue. Vehicle control cream was applied to the non-lesion area. All area was covered with an occlusive dressing for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's lamp. Treatment area (all face)was then separately illuminated with red light-emitting diode lamps with peak emission at 630 nm and total light dose of 100 J/cm2. The treatment is once a week for total 3 times. The patients then follow up in clinic 3 years after their treatment to have the number of actinic keratoses counted.
2389934|NCT03642522|Experimental|1 Hz rTMS|30 minutes of 1 Hz rTMS to the right dorsolateral prefrontal cortex (R_DLPFC)
2389935|NCT03642509|Experimental|LAAO group|Patients will be treated with transcatheter left atrial appendage occlusion. The LAAO may be performed with the Amulet or Watchman device.
2389936|NCT03642509|Experimental|NOAC group|Patients will be treated with one of the currently available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban.
2389937|NCT03642496|Experimental|The low dose group|
2389938|NCT03642496|Experimental|The middle dose group|
2389939|NCT03642496|Experimental|The high dose group|
3183682|NCT00716235||Autism|Children with a diagnosis of Autism disorder
3183683|NCT00716235||ADHD|Children with a diagnosis of ADHD
2389942|NCT03642444|Active Comparator|Phase A cane walking (assistive walking-device a cane)|9-12 weeks usual cane-walking to establish baseline values. Patients walk with their usual assistive-walking device - a cane.
2389943|NCT03642444|Active Comparator|Phase B elasticated orthotic-garment - TheraTogs|9-19 weeks : assistive walking-device which is an elasticated orthotic-garment worn throughout the day (product name TheraTogs). Cane use maximally reduced during his period.
2389944|NCT03642444|No Intervention|Phase C follow-Up|9-10 weeks individually determined follow-up: subjects determine whether they walk independently (without assistive device) or with the elasticated orthotic-garment (TheraTogs) or with a cane.
2389945|NCT03642405||Methylphenidate-Group|The group is examined before and after intake of Methylphenidate
2389946|NCT03642405||Methylphenidate and know QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
2389947|NCT03642405||Methylphenidate and non-QT-prolonging SSRI|The group is examined before and after intake of Methylphenidate
2389948|NCT03642392||Tendinopathy|Athletes with unilateral tendinopathy
2389949|NCT03642366|Active Comparator|Active Arm 1|
2389950|NCT03642366|Active Comparator|Active Arm 2|
2389951|NCT03642366|Sham Comparator|Sham Arm|
2389952|NCT03642353|Experimental|G1: Triclosan/health children|Children from health parents will use the triclosan toothpaste for 45 days.
2389953|NCT03642353|Placebo Comparator|G2: Placebo/health children|Children from health parents will use the placebo toothpaste for 45 days.
2389954|NCT03642353|Experimental|G3: Triclosan/GAP children|Children from GAP parents will use the triclosan toothpaste for 45 days.
2389955|NCT03642353|Placebo Comparator|G4: Placebo/GAP children|Children from GAP parents will use the placebo toothpaste for 45 days.
2389956|NCT03642327|Active Comparator|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
2389957|NCT03642327|Experimental|Maintenance of Certification (MOC)|MOC involves a guided learning experience, approved by the American Board of Pediatrics and the American Board of Family Medicine for Maintenance of Certification credits. This involves a Quality Improvement project with 3 waves of data collection to assess and improve implementation while participating in 4 monthly webinars led by Dr. Dubowitz.
2389958|NCT03642314|Experimental|Intervention|Individuals receive 5 HIV Self Test kits + vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
2389959|NCT03642314|No Intervention|Control|Individuals receive 5 vouchers to secondarily distribute to MSM/TGW from their social/sexual networks. All vouchers are uniquely identified invitations for priority access to ImPrEP sites, valid to be redeemed by a 3 month period
2389960|NCT03642288|Experimental|CRE-induced SBO|Patients with CRE-induced SBO received GG challenge.
2389961|NCT03642288|Active Comparator|ASBO|Patients with adhesive SBO (ASBO) received GG challenge.
2389962|NCT03642275|Experimental|iCardia4HF|Participants will be using a heart failure mobile app, wearable activity tracking device, Bluetooth-enabled blood pressure monitor and weight scale for self-monitoring, and receive tailored text-messages about self-care.
2389963|NCT03642275|No Intervention|Control Group|Participants assigned to the usual care group will receive standard medical care, which includes nurse-led patient education about HF self-care before discharge, and follow-up visits at the UI Health, outpatient Heart Failure program.
3183684|NCT00716235||Control|Control group - children with no neurological or psychiatric problems
3183685|NCT00716248|Experimental|1|
2389966|NCT03642249|Experimental|experimental group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration); and~delirium care OSCE and reflective activity (30 minutes in duration)."
2389967|NCT03642249|Active Comparator|control group|"face-to-face delirium care session (30 minutes in duration);~online learning delirium care activities (20 minutes in duration)"
2389968|NCT03642236|Experimental|BTK treatment|Ibrutinib 420mg day -3 to d14; Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
2389969|NCT03642236|Active Comparator|BTK-free treatment|Decitabine 20mg/m2 d1-5; Aclacinomycin 10mg/m2 d1-5; Cytarabine 15mg/m2 q12h d1-14; G-CSF 200ug/m2 -12h to d14; Sorafenib 0.4g bid continously at the condition of being naive to sorafenib.
2389970|NCT03642223|Active Comparator|normal-weight|
3183686|NCT00716248|Active Comparator|2|
3183687|NCT00716287||1|Anti-angiogenic targeted therapies are used in a wide range of solid tumors including NSCLC, breast cancer, GISTs, CRC, renal cell carcinoma and hepatocellular carcinoma.
3183688|NCT00716300||1|obese and insulin resistant subjects
3183689|NCT00716300||2|lean and normolipidaemic subjects
2389974|NCT03642197|Experimental|Support Figure Attended (SFA)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is support figure attendance. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2389975|NCT03642197|No Intervention|SFA - Treatment as Usual (SFA-TAU)|Using simple randomization patients (female or male) not in romantic relationships will be randomized into support figure attended (SFA) and SFA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Support figures in the SFA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and support figures at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2389976|NCT03642197|Experimental|Partner Attended (PA)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA arm will be requested to attend the four pre-surgery classes with the patient and the three clinical visits. The intervention is partner attendance. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2389977|NCT03642197|No Intervention|PA - Treatment as Usual (PA-TAU)|Using simple randomization female patients in cohabiting romantic relationships for at least 6 months will be randomized into partner attended (PA) and PA-TU groups. Patients in all arms will receive routine care, which includes four pre-surgery classes and routine clinical visits. Partners in the PA-TU arm will not be requested to attend the four pre-surgery classes with the patient and the three clinical visits- patients will attend alone. Assessments will be completed by patients and partners at the first pre-surgery class (T1) and routine clinical visits: the pre-surgery appointment (T2), two-weeks post-surgery appointment (T3), and at the two-months post-surgery appointment (T4).
2389978|NCT03642184|Active Comparator|Empagliflozin|Jardiance 10mg/25mg Film-coated tablets， once daily
2389979|NCT03642184|Active Comparator|Linagliptin|Trajenta 5mg Film-coated tablets， once daily
2389980|NCT03642158|Active Comparator|Active TMS|Subjects receive rTMS over the right DLPFC, in 2 second bursts at 10 Hz, followed by a 19 second break, for a total of 20 minutes. Stimulator intensity is set to 80% of motor threshold on day one, and 100% of motor threshold for the remainder of intervention. This paradigm is continued for 5 consecutive days.
2389981|NCT03642158|Sham Comparator|Sham TMS|"Identical to active arm, but stimulator intensity is reduced to 30% of motor threshold, and the stimulator coil is oriented tangentially to the skull to stimulate air space above the head instead of cortical tissue."
2389982|NCT03642145|Experimental|Arm A: Deflazacort 0.9 mg/kg|Participants will receive approximately 0.9 mg/kg deflazacort once daily orally for 52 weeks in Period 1 and for 52 weeks in Period 2. The target dose could be varied +/- 20 percent (%) depending upon the available tablet strengths and change in participant's weight.
2389983|NCT03642145|Experimental|Arm B: Deflazacort 0.45 mg/kg|Participants will receive approximately 0.45 mg/kg deflazacort once daily orally for 52 weeks in Period 1. Participants will either continue to receive 0.45 mg/kg deflazacort or escalated dose of deflazacort (0.9 mg/kg) once daily orally in Period 2 at the investigator's discretion and in consultation with the caregiver. The target dose could be varied +/- 20% depending upon the available tablet strengths and change in participant's weight.
2389984|NCT03642145|No Intervention|Natural History Control Group|Control participants matching to the study population as closely as possible, will be used as a comparator to characterize the safety and tolerability of deflazacort.
2389985|NCT03642132|Experimental|chemotherapy, avelumab and talazoparib|Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance
2389986|NCT03642132|Experimental|chemotherapy, and talazoparib|Platinum-based chemotherapy followed by talazoparib maintenance
2389987|NCT03642132|Active Comparator|chemotherapy and bevacizumab|Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance
2389988|NCT03642119||iButton® Validation in Perimenopause|Women in the late phase of perimenopause (based on the STRAW+10 criteria).
3183690|NCT00716326|Active Comparator|1|Subjects in this study arm will receive active treatment with Cefar TENS device which delivers therapeutic electrical currents 2-3x over sensory threshold in the area of pain.
2389991|NCT03642093|Experimental|Frail|Subjects assessed and determined to be Frail and meet trial eligibility criteria will be enrolled on Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
2389992|NCT03642093|Active Comparator|Not Frail|Subjects assessed and determined to be Not Frail and meet trial eligibility criteria will be enrolled on Not Frail Arm and begin a 4 Week program consisting of Nutritional Interventions and Physical Activity Interventions
2389993|NCT03642080||Glioblastoma|Patients with a diagnosis of newly diagnosed or recurrent glioblastoma who have been treated with radiation and temozolomide and are being offered tumor treated fields.
2389994|NCT03642067|Experimental|Cohort A/B: Nivolumab and Relatlimab|480mg/160mg (co-administered)
2389995|NCT03642067|Experimental|Cohort C: Nivolumab and Relatlimab|480mg/ 960mg (sequential administration)
2389996|NCT03642054||Pelvic Organ Prolapse|Patients having vaginal hysterectomy who demonstrate grade III-IV uterovaginal prolapse.
2389997|NCT03642054||Non Pelvic Organ Prolapse|Patients having vaginal hysterectomy who do not demonstrate uterovaginal prolapse.
2390172|NCT03640715|Other|group c|Group C: high vulnerability according to the expert with indication of at least two care markers PASS
2390000|NCT03642015|Experimental|listening music|The participants in the music group selected the music they preferred from different genres. During the 15-min intervention period before the gastroscopy procedure, the experimental group rested by listening to music and sitting on a comfortable chair
2390001|NCT03642015|No Intervention|Control|control group rested only by sitting on a comfortable chair
2390002|NCT03642002|Experimental|Toning|Vocal Tonal Holding
2390003|NCT03642002|Other|Ocean drum & SOK melody|Ocean drum followed by melody of song of kin
2390004|NCT03642002|Experimental|SOK|Song of kin with lyric content
2390005|NCT03642002|Experimental|Process|Processing of experience
2390006|NCT03642002|Experimental|Holding Harmonic Container|
2390007|NCT03641989|Active Comparator|Plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
2390008|NCT03641989|Placebo Comparator|Non-plaque disclosing toothpaste|Based on a randomization schema, a 30 day supply of the over-the-counter, non-plaque disclosing toothpaste will be distributed to the participant. Participants will be instructed to brush two times a day for 30 days with the plaque disclosing toothpaste; avoiding the use of mouth rinses and floss. They will also be instructed to avoid any dental prophylaxis (e.g., cleaning, scaling or root planing to mechanically remove plaque and calculus) while on the trial and 30 days before they are enrolled.
2390009|NCT03641976|Experimental|Arm I (A-FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2390010|NCT03641976|Active Comparator|Arm II (A-FOLFOX/A-FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour (or oxaliplatin IV over 2 hours), leucovorin calcium IV over 2 hours, fluorouracil IV bolus, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2390011|NCT03641963|Experimental|Stroke patients with ICP measurement|All patients with the possibility to evolve a malignant MCA infarct according to the initial assessment, will be included in our study, to measure ICP non-invasive. The ICP will be measured non-invasive with the Vittamed 205 Non-invasive intracranial pressure (ICP) meter.
2390012|NCT03641950|Experimental|Botulinum Toxin Type A (Botulax)|Botulinum Toxin Type A (Botulax)
2390013|NCT03641924||PTSD|Veterans diagnosed with DSM-V PTSD
2390014|NCT03641898||Morphometric assessment of FNLs|After FFR-guided PCI, the morphometric characteristics of FNLs (FFR>0.8) are assessment by intravascular ultrasound.
2390015|NCT03641885|Experimental|mother and adolescents|an intervention group in which mothers and adolescents receive the intervention and questionnaires via Telegram social media
2390016|NCT03641885|Experimental|adolescents|an intervention group in which adolescents receive the intervention and questionnaires via Telegram social media
2390017|NCT03641885|Active Comparator|active control|mothers and adolescents are in active control group and only receive the questionnaires
2390018|NCT03641872||Acute-on-Chronic Liver Disease|"chronic liver disease: including chronic liver hepatitis patients without cirrhosis, compensated cirrhosis patients, decompensated cirrhosis patients and non-alcoholic fatty liver disease patients.~ALI(acute liver injury): including [ALT > 3 ULN(upper limited of normal),AST > 3 ULN or TB > 2 ULN within 1 week before enrollment] or AD(acute decompensation) : including [(having ascites, hepatic encephalopathy, bacterial infection, gastrointestinal bleeding and/or jaundice(TB > 5 ULN) within 1 month before enrollment)].~Standary therapy for chronic liver disease with ATI and/or AD"
2390019|NCT03641859|No Intervention|Local anesthesia|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 1 (usual care): the procedure of care will be the same as usual."
2390020|NCT03641859|Experimental|local anesthesia + virtual reality|"The study population will consist of consecutive pre-screened patients when they arrive at the emergency department at the level of the host nurse. The emergency physician who will be in charge of the patient gives the patient the information form and ensures the absence of contraindication, responds to the patient's questions and collects his free, informed and express consent.~Once the patient is included, the group (with or without virtual reality) of the patient's participation in the study will be notified by the reception nurse and emergency referral:~- Arm 2 (intervention): local anesthesia + virtual reality"
2390021|NCT03641846|Active Comparator|LiST + 5mg Tadalafil Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks.
2390022|NCT03641846|Placebo Comparator|LiST+Placebo Group|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily placebo pill. Total treatment period = 4 weeks.
2390023|NCT03641807|Experimental|Acupuncture|
2390024|NCT03641807|Sham Comparator|Sham acupuncture|
2390025|NCT03641794|Experimental|DN1406131|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
2390026|NCT03641794|Placebo Comparator|Placebo|25 mg,50 mg,100 mg,200 mg,400 mg,600 mg,800 mg
2390027|NCT03641781|Active Comparator|Isometric strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOM group. ISOM group participants were involved in isometric strengthTraining at angle of 30°,45°,60° of knee flexion for 5 maximum contraction for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
2390028|NCT03641781|Active Comparator|Isokinetic strength training group|Knee pain athletes were assessed by The International Knee Documentation Committee (IKDC) 2000 Subjective Knee evaluation form and were assigned into ISOK group isokinetic training group randomly. ISOk group participants were involved in Training at speed of 30 deg/sec, 90deg/sec, 150/deg/sec 210deg/sec, 270deg/sec 5 repetition for both hamstring and quadriceps. 10 sessions were given on alternate day basis by using Biodex Isokinetic system.
2390029|NCT03641781|No Intervention|Healthy control group|Data for outcome parameters including Peak torque average peak torque average power agonist antagonist ratio by using biodex isokinetic system for both by isometric contraction method and isokinetic method. For performance test were recorded for healthy control of same age group to compare the training effect with healthy control values.
2390030|NCT03641768|Active Comparator|Healthy volunteers|Volunteers with no trauma history
2390031|NCT03641768|Active Comparator|Trauma only|Volunteers that do not have PTSD but have had similar trauma to those with PTSD
2390032|NCT03641768|Active Comparator|PTSD only|Volunteers with PTSD but no traumatic brain injury
2390033|NCT03641768|Active Comparator|PTSD and TBI|Volunteers with PTSD and mild traumatic brain injury
2390034|NCT03641755|Experimental|Olaparib + Sapacitabine|"Olaparib will be administered orally twice daily for each 28-day cycle~Sapacitabine will be administered orally once daily on days 1 - 5 and 8 - 12 of every 28-day cycle~Olaparib will be given at a predetermined dose~Sapacitabine will be given at a predetermined dose"
2390035|NCT03641742||FAR-ILD Proband Participants|There will be no interventions administered to this group, only data collection.
2390036|NCT03641742||"FAR-ILD At-Risk Participants"|There will be no interventions administered to this group, only data collection
2390037|NCT03641729|Other|Intervention|Patients were eligible if they were aged 18 years or older, referred for HSCT and admitted to the Bone Marrow Transplant Unit (BMTU). Patients were screened in the BMTU admission and recruited to the study after avaliation in the first-day internation.
3143020|NCT00004135|Experimental|Arm A|Fludarabine 30 mg/m2/d x S days IVPB in 100 cc NS over 30 minutes on day -8, -7, -6, -S, and -4. Cyclophosphamide 2 gm/m2/d x 2 days IVPB in SOO cc DS W over I hour on day -3 and day-2. G-CSF (Neupogen®) administration 480 f!gld subcutaneously starting on day +5 (or first day of neutropenia if earlier)and continued until an ANC of 0.5 x 109/L is maintained for 3 consecutive days.
2390039|NCT03641703|Experimental|FLT180a|Participants who have received gene therapy vector (FLT180a)
2390040|NCT03641690||27 case|Twenty-seven patients were admitted to the ICU with severe pneumonia and with a high probability of viral infection or a previously confirmed diagnosis received Empirical antimicrobial therapy
2390041|NCT03641690||70 control|70 healthy subjects (HS) among blood donors attending the Regional Center for Blood Transfusion (Lille, France).
2390042|NCT03641677|Experimental|EVLP|
2390043|NCT03641677|Active Comparator|Control|
2390044|NCT03641664|Experimental|Treatment: Family Centered Treatment|Family is offered choice of FCT or Level III out-of-home placement
2390045|NCT03641664|Active Comparator|Control: Level III Out of Home Placement|Family is offered Level III out-of-home placement
2390046|NCT03641651|Experimental|Technology arm|4 Weeks intervention of intensive rehabilitation using rehabilitation technology, 3-5 h per day, within a 5d week in-or outpatient setting.
2390047|NCT03641638||Low level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 34-102 IU/ml.
2390048|NCT03641638||Medium level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb at 103-204 IU/ml.
2390049|NCT03641638||High level of TPOAb|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of TPOAb positive, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L，TPOAb >205IU/ml.
2390050|NCT03641638||Control group|normal thyroid function (FT3, FT4, TSH) before pregnancy, First pregnancy under 35 years old, early screening (1-12 weeks of pregnancy), initial screening of negative Thyroid antibody, thyroid function: normal FT3 and FT4, TSH<4.78mIU/L.
2390051|NCT03641625|Experimental|Intervention|In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
2390052|NCT03641625|No Intervention|Control|Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.
2390053|NCT03641612|Experimental|one shape|single file rotary system
2390054|NCT03641612|Active Comparator|protaper next|multiple file rotary system
2390055|NCT03641599||heart failure with preserved ejection fraction|
2390056|NCT03641599||heart failure with mid range ejection fraction|
2390057|NCT03641599||heart failure with reduced ejection fraction|
2390058|NCT03641586|Experimental|Stage I|Approximately 25-35 Chinese subjects with local advanced or metastatic malignant solid tumor will be enrolled in the dose escalation stage of BGB-283 until maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) determination
2390059|NCT03641586|Experimental|Stage II|Approximately 15-30 melanoma subjects will be enrolled in dose expansion stage of BGB-283
2390060|NCT03641586|Experimental|Stage III|20 subjects will be enrolled for food effect stage of BGB-283
2390061|NCT03641573|Experimental|[14C] ASN002|[14C] ASN002
3143021|NCT00004136|Experimental|Heat Therapy|
2390063|NCT03641547|Experimental|Stage A1, A2 & B|"The trial is a single arm study. Different populations are recruited to each stage and the stages run independently of each other. Stage A1 & A2 will commence before Stage B so that safety data can be obtained in the palliative setting prior to Stage B commencing. Stage A1 may be ongoing when Stage B begins. Each Stage has a separate eligibility criteria.~Stage A1: M6620 & palliative radiotherapy Stage A2: M6620 & palliative chemotherapy (Cisplatin & Capecitabine) Stage B: M6620 & definitive chemoradiotherapy"
2390064|NCT03641534||Sepsis|
2390065|NCT03641534||Severe malaria|
2390066|NCT03641534||Uncomplicated malaria|
2390173|NCT03640702||Prolonged second stage of labor|Women with prolonged second stage of labor as specified before.
2390067|NCT03641521|Experimental|Intervention|The intervention consisted of an enhanced Cooking Matters® for Families program that included behavioral strategies derived from behavioral economics, to be implemented by parents at home for increasing vegetable intake of low-income 9-12 year old children
2390068|NCT03641521|No Intervention|Control|The control arm consisted of the enhanced Cooking Matters® for Families program alone--without lessons about the behavioral strategies for the parents
3183691|NCT00716326|Placebo Comparator|2|Subjects in this study arm will receive placebo treatment with manipulated Cefar TENS device which delivers electrical currents just below sensory threshold in the area of pain.
3183692|NCT00716339|Active Comparator|1|motivated
2390071|NCT03641495|Experimental|Pain education plus exercise therapy (PE + ET)|"Pain education according to the book Explain Pain written by Lorimer Moseley and David Butler~Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations."
2390072|NCT03641495|Active Comparator|Exercise therapy (ET)|Exercise therapy based primarily in aerobic exercise according clinical guidelines last recommendations.
2390073|NCT03641482|Active Comparator|NBF|Propolis Extract, Ascorbic Acid, Tocopherol Acetate, Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
2390074|NCT03641482|Placebo Comparator|Placebo|Sodium-Monofluorophosphate, Silicon Dioxide, Glycerin, D-sorbitol, Polyethyleneglycol 150, Sodium Carboxymethylcellulose, Xylitol, Sterol Glycoside, Peppermint Oil, L-Menthol, Methyl Hydroxybenzoate and Deionized Water
3183693|NCT00716339|No Intervention|2|control
2390076|NCT03641456|Experimental|VRD for Followed by VR|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22; oral lenalidomide 25mg on days 1 to 21; and oral dexamethasone 40mg on days 1, 8, 15 and 12 of a 28-day cycle.Patients are allowed to proceed to stem-cell transplantation after four cycles of VRD at the discretion of the treating physician.Two months after hematologic recovery, nonprogressive patients are to receive consolidation therapy comprising two cycles of VRD.Patients who do not proceed to stem-cell transplantation receive more two induction cycles after obtaining maximum response but no less than six cycles totally. Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib 1.3mg/m2 on days 1 and 15 and lenalidomide on days 1 to 21 at the dose level of 10mg.
2390077|NCT03641443|Experimental|Non-invasive measurement of intracranial pressure|Patient with mass effective brain tumor that undergo non-invasive intracranial pressure measurement
2390078|NCT03641430|Experimental|Supportive care with Over-the-Counter (OCT) product|Participants will apply over-the-counter product for a certain period with or without light challenge
2390079|NCT03641417|Experimental|GLWL-01|Oral administration of GLWL-01 300mg BD for 10 days
2390080|NCT03641417|Placebo Comparator|Placebo|Identical oral capsules with no active ingredient, administered BD for 10 days
2390081|NCT03641404|Experimental|Ergothioneine|Subjects will consume 25mg ergothioneine (capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
2390082|NCT03641404|Placebo Comparator|Placebo|Subjects will be given placebo (99% microcrystalline cellulose, 1% magnesium stearate; capsule), 3 times weekly (Monday, Wednesday, and Friday) for a total of 52 weeks.
2390083|NCT03641391|Experimental|Direct electrical stimulation|Intraoperative direct cortical electrical stimulation or intraoperative direct subcortical electrical stimulation on language or language-associate areas, and the participants' after-discharge activity would be monitored. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
2390084|NCT03641378|Experimental|Inpatient Palliative Care Intervention|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent~Palliative Care Intervention~Therapeutic Relationship~--Develop a strong therapeutic relationship with patients and caregivers~Assessment and Treatment of Patient Symptoms~--Clarify the symptoms the patient will likely experience and offer reassurance about the methods for reporting and treating symptoms~Managing Patients and Caregivers Expectations~--Address early on patients and caregivers' concerns about the trajectory of illness during HCT and treatment side effects~Coping with Illness and HCT --Introduce strategies to help improve adjustment (e.g., behavioral, cognitive, and spiritual approaches; accepting illness while maintaining hope; social support)"
2390085|NCT03641378|Experimental|Transplant Care Alone|"Patients and Caregivers will complete baseline self-report assessments at the time of obtaining informed consent.~Standard Transplant Care"
2390086|NCT03641365|Experimental|Test group|Test group: Surgical template without metallic sleeves. In this case the surgical template has all been designed and fabricated in acrylic material by mean of stereolitographic technology.
2390087|NCT03641365|Active Comparator|Control group|Control group: Surgical template with metallic sleeves. Surgical template has designed and fabricated in acrylic material by mean of stereolitographic technology and metallic sleeves have been bonded after its production.
2390088|NCT03641352|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
2390089|NCT03641352|Placebo Comparator|Placebo|Placebo
2390092|NCT03641326|Experimental|1|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest.Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
2390093|NCT03641313|Experimental|Treatment (irinotecan and M6620)|Patients receive irinotecan IV over 90 minutes and berzosertib IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2390094|NCT03641300|Experimental|Magnetic Seizure Therapy (MST)|MST treatments will be administered using the MagPro MST with Cool TwinCoil.
2390095|NCT03641300|Active Comparator|Electroconvulsive Therapy (ECT)|ECT treatments will be administered using the MECTA spECTrum 5000Q
2390174|NCT03640689|Experimental|Intervention Group|Endovenous ablation + iliac US +/- iliac stenting
3143022|NCT00004138|Experimental|FDG-PET scan + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy, fine needle aspiration, or other imaging studies are then conducted to confirm the PET findings.~Patients with no mediastinal nodal or distant metastases identified by FDG-PET scan may undergo thoracotomy and pulmonary resection within 1 month of evaluation.~Patients are followed at 5-6 months after surgery."
3143023|NCT00004139|Experimental|Gemcitabine + Irinotecan|
2390098|NCT03641274||Frequent users of emergency departement|FUEDs receiving the CM intervention in sites participating in the research project will be assessed over time on clinical variables (see inclusion and exclusion criteria)
2390099|NCT03641261|Experimental|Therapeutic Patient Education program|All included patients will follow a Therapeutic Patient Education program dedicated to the hereditary ichthyosis and using a web application, WebIchtyose
2390100|NCT03641248|Experimental|Enteric coated Devil's Claw|H. procumbens 100 mg in enteric coated capsules
2390101|NCT03641248|Active Comparator|Non-enteric coated Devil's Claw|H. procumbens 100 mg in non-enteric coated capsules
2390102|NCT03641235||exacerbating COPD patients needing ICU admission|sputum collection
2390103|NCT03641222|Experimental|Group Acupuncture|Group acupuncture sessions take place in a multipurpose room, with 3-6 participants, each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
2390104|NCT03641222|Active Comparator|Individual Acupuncture|Individual acupuncture sessions take place in a multipurpose room, privately each session lasts 30-45 minutes, occurring twice-weekly, over the course of six weeks, for a total of twelve treatments. The acupuncture was administered by a Naturopathic Doctor.
2390105|NCT03641209|Experimental|Paracetamol|Paracetamol 10 mg/mL infusion solution, intravenous loading dose 20 mg/kg, followed by maintenance dose 7.5 mg/kg every 6 h up to 9 days
2390106|NCT03641209|Placebo Comparator|Placebo|0.45% sodium chloride (NaCl) solution, equal amounts in mL as would have been given the experimental drug
2390107|NCT03641196|No Intervention|No treatment of deep bite|No treatment of deep bite. These participants will be evaluated during a 6-month follow-up period. In cases were significant problems arise during the follow-up period, the participant will be removed from the study and the appropriate treatment conducted.
2390108|NCT03641196|Active Comparator|Fixed appliance|Fixed appliance: Treatment with a cemented modified palatal Nance appliance presenting a bite-plane.
2390109|NCT03641196|Active Comparator|Composite bite plane|Composite bite plane: Treatment with a composite build up in the palatal aspect of the upper central incisors.
2390110|NCT03641170|Experimental|Experimental intervention|Fixed diet and physical activity.
2390111|NCT03641170|Other|Control intervention|Fixed diet and inactivity.
2390112|NCT03641157||Group I Easy Intubation|Pediatric patients ages 0-3 years Easy Intubation (Cormach-Lehane score I-II)
2390113|NCT03641157||Group II Difficult intubation|Pediatric patients ages 0-3 years Difficult intubation (Cormach-Lehane score III-IV)
2390114|NCT03641144|Experimental|Navigation laser|Navigation laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
2390115|NCT03641144|Active Comparator|Traditional laser|Traditional laser photocoagulation treatment to the macular area of retinal thickening with a focal pattern and/or grid pattern
2390116|NCT03641118||Lower gastrointestinal cancer|All lower gastrointestinal neoplasms including rectal
2390117|NCT03641118||Upper gastrointestinal cancer|All upper gastrointestinal neoplasms
2390118|NCT03641118||Hepatobiliary cancers|All liver, pancreas, biliary cancer
2390119|NCT03641105||lung adenocarcinoma|patients with lung adenocarcinoma
2390120|NCT03641092|Experimental|Experimental Clinical Site|5 experimental clinical sites will receive the implementation of CenteringParenting assistance early. This arm will include the CenteringParenting intervention.
2390121|NCT03641092|Active Comparator|Comparison Clinical Site|5 comparison clinical sites will receive Routine Well Child Care and CenteringParenting implementation assistance later and serve as control sites. This arm will include the Routine Well Child Care intervention.
2390122|NCT03641079|Experimental|brinjal peel extract containing cream|intervention-brinjal peel extract containing cream, dose-twice daily for 12 weeks
2390123|NCT03641066|Experimental|Ankle Brace|Each participant will complete a baseline analysis of 1 minute of walking and 2 minutes of running, repeated 4 more times wearing 4 different braces. The analysis will be completed on the Walker View Treadmill, which used 3D camera technology to capture lower body kinematics. The treadmill also has load cells built in to capture gait characteristics
2390124|NCT03641053|Experimental|Honey|0.05 cc of honey (Madu Nusantara®) per 1 cm of laceration, given every predetermined wound care schedule
2390125|NCT03641053|Active Comparator|Povidone-iodine|0.05 cc of povidone-iodine per 1 cm of laceration, given every predetermined wound care schedule
2390126|NCT03641053|Active Comparator|Paraffin gauze|1 layer of paraffin gauze, given every predetermined wound care schedule
2390127|NCT03641040|Experimental|VOG group|Measurement: Video-oculography(VOG) measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
2390128|NCT03641040|Active Comparator|APCT group|Measurement: Alternative prism cover test(APCT) measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
2390129|NCT03641027|Experimental|Increased physical activity|Increased physical activity daily before surgery. Standard care during hospital stay and continued training after discharge.
2390130|NCT03641027|Other|Standard care|Standard care
2390131|NCT03641014|Experimental|Sequential pH culture (7.23 then 7.35)|A split embryo at day 3 to continue culture at a pHe of 7.23±0.02 or to be cultured at a pH of 7.35±0.02 and monitor the effect on blastocyst development.
2390132|NCT03641014|No Intervention|Continuously pH culture at 7.23|Embryo culture from day 0 to 5 or 6 at 7.23
2390133|NCT03641001|Experimental|Intervention|Intervention group will receive child feeding counselling, food voucher for recipe, WASH and home fortification
2390134|NCT03641001|No Intervention|Control|Control will receive usual health messages from government and NGO
3143024|NCT00004139|Experimental|Gemcitabine + Docetaxel|
3143025|NCT00004141|Experimental|Arm A|CDDP (75 mg/m2) and DTIC (660 mg/m2) will be administered sequentially by intravenous infusion in day 1. Subsequently, GM-CSF (450 mg/ m2) will be administered SC days 2-7; IL-2 (11 MU daily) will be given SC days 8-14, and IFN-2b (9 MU) will be given SC days 8, 10, 12, and 14.
2390136|NCT03640975||case : eosinophilic esophagitis|Children with symptoms suggestive of EoE and requiring an upper gastrointestinal endoscopy with biopsies of the esophageal mucosa
2390137|NCT03640975||control|Children in whom an endoscopy performed to explore symptoms of EoE revealed another condition (peptic oesophagitis, achalasia), or children in whom an endoscopy with biopsies has been performed to explore chronic abdominal or epigastric pain or suspected chronic inflammatory bowel disease
2390138|NCT03640949|Experimental|Vasopressin and methylprednisolone|The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
2390139|NCT03640949|Placebo Comparator|Placebo|"The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl."
2390140|NCT03640936||Healthy|Healthy controls, without asthma or allergy (negative prick test)
2390141|NCT03640936||Allergic asthma|Patients with allergic asthma sensitized to Dermatophagoides pteronyssinus, tested by prick test or specific IgE
2390142|NCT03640936||Non-allergic asthma|Patients with asthma not sensitized to Dermatophagoides pteronyssinus, with negative prick test or specific IgE
2390143|NCT03640923|Experimental|experimental group|Child with a proven infection of the mother or both biological parents known to HIV antenatal a swab of mucous membrane will be withdrawed
2390144|NCT03640910|Experimental|OT Equators® (Rhein83)|After gingival healing the newest low-profile OT Equators® (Rhein83) will be screwed on to the implants, using the OT Equator® square screwdriver (Rhein83), with a torque range of 22-25 N cm. The cuff heights ranged from 0.5 to 7.0 mm, depending on the height of the transition zone of each implant, easily measured using the color-coded millimeter Cuff Height Measurer Gauge (Rhein83) after healing abutment removal.
2390145|NCT03640910|Active Comparator|Locator® (Zest)|The low-profile attachments Locator® (Zest) will be screwed on to the implants, using the Locator® screwdriver (Zest), with a torque range of 20-25 N cm. The cuff heights of 2.5 or 4.0 mm, depending on the height of the transition zone of each implant, measured using the deep probe of the implant line after healing abutment removal.
2390146|NCT03640897|Experimental|Liniderm|"Oleocalcareous liniment Liniderm:~The product will be applied on the diaper area by parents/ caregivers at each diaper change."
2390147|NCT03640897|Active Comparator|Wipes|Free-fragrance baby wipes The product will be used on the diaper area by parents/ caregivers at each diaper change.
2390148|NCT03640897|Active Comparator|Water|Water and cotton pads The product will be used on the diaper area by parents/ caregivers at each diaper change.
2390149|NCT03640884||Xueshuantong-Injection|Patients who received the Xueshuantong-Injection for treatment will be consecutive included in this registry. The investigators will record all the information about ADR, application of Xueshuantong-Injection and the combined medications, etc.
2390150|NCT03640871|Experimental|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing (AWC=Advanced Wound Care)
2390151|NCT03640858|Experimental|Patients receiving hemodialysis|A group of hemodialysis patients will be receiving the Theranova dialyzer during their regularly scheduled sessions to remove larger middle molecules
2390152|NCT03640845|Experimental|experimental group|Patient living in nursing homes a tele-expertise will be performed
2390153|NCT03640845|No Intervention|control group|Patient living in nursing homes will performed a normal care.
2390156|NCT03640819|Experimental|Tattooing of biopsied node|The biopsied node will be tattooed at the time of needle biopsy (fine needle aspiration or core biopsy) or separate visit under ultrasound guidance.
2390157|NCT03640806|Experimental|PHYSICAL ACTIVITY|Standard support for 12 months (HAS 2010, EULAR 2016) 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
2390158|NCT03640806|No Intervention|CONTROL|Standard care for 12 months (HAS 2010, EULAR 2016) with Pain Consultation every 3 months.
2390159|NCT03640793|Experimental|Single center, prospective, non-randomized, non-blinded study|Implantation of 6 PPIS implants in each patient
2390160|NCT03640780||cataract extraction (CE)|Patients received CE without IOL implantation in the first surgical stage, and received IOL implantation at secondary surgical stage.
2390161|NCT03640780||cataract extraction and IOL implantation|Patients received CE and IOL implantation in the first surgical stage.
2390162|NCT03640767|Experimental|message-based lifestyle intervention|The intervention group will receive 4 mobile phone messages per week for 24 weeks.
2390163|NCT03640767|No Intervention|Control|no intervention
3143026|NCT00004142|Experimental|Radiofrequency Ablation + HAI of Floxuridine/5-FU|Radiofrequency Ablation Combined With Post-Ablation Hepatic Arterial Infusion (HAI) of Floxuridine Alternating With 5-Fluorouracil (5-FU)
3143027|NCT00004144|Experimental|bryostatin 1 & gemcitabine hydrochloride|
2390166|NCT03640741||Laparoscopy|The group consists of patients who undergoes laparoscopy procedure during which changes in cerebral oxygenation are estimated.
2390167|NCT03640728||ETV|patients receive entecavir 0.5 mg/day orally.
2390168|NCT03640728||TDF|patients receive Tenofovir Disoproxil Fumarate 300 mg/day orally.
2390169|NCT03640728||TAF|patients receive Tenofovir alafenamide 25 mg/day orally.
2390170|NCT03640715|Other|group A|Group A: no vulnerability according to expert with no indication of any PASS marker care
2390171|NCT03640715|Other|group B|Group B: probable vulnerability according to the expert with indication of at least one PASS marker care
3143028|NCT00004145|Experimental|Arm A|Fludarabine (30mg/m2/day x 5 days on days -9 to -5), cyclophosphamide (2gm/m2/day on day -5), antithymocyte globulin (10mg/kg/day x 4 days on days -5 to -2), tacrolimus (.03 mg/kg/day IVPB continuous infusion), mycophenolate mofetil (1mg PO BID, days +1 to +60), allogenic peripheral blood stem cells
2390176|NCT03640676|Sham Comparator|INP -10mmHg|In addition to standard medical treatment, patients will receive treatment with FlowOx, applying intermittent negative pressure of -10mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
2390177|NCT03640676|Active Comparator|INP -40mmHg|In addition to standard medical treatment, patient swill receive treatment with FlowOx, applying intermittent negative pressure of -40mmHg one hour in the morning and one hour in the evening at home for 12 weeks.
2390178|NCT03640663||Midwife led continuity model of care|Women who received antenatal care from midwives from the hospital reaching out to the rural villages
2390179|NCT03640663||Regular care group|Women who received care from doctors, nurses or midwives employed at primary Health care centres in rural villages
2390180|NCT03640650|Experimental|Dropless Therapy|Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin. This preservative-free suspension is injected at a dose of 0.2 mg into the posterior chamber, for a total drug delivery of 3 mg of triamcinolone acetonide and 0.2 mg of moxifloxacin. At the time of cataract surgery, Dropless is intended to be injected as a single administration into the anterior vitreous after the insertion of the IOL implant, with a 27 or 30-gauge cannula via a transzonular or transsceral pars plana injection, just before rinsing the viscoelastic fluid.
2390181|NCT03640650|Active Comparator|Usual Care|This therapy usually comprises an antibiotic, a steroid and in some cases a nonsteroidal anti-inflammatory drug (NSAID). Antibacterial drops are usually given at the end of surgery and are continued for one week after the surgery. Steroid drops are usually started the day of surgery and then tapered down over 3 to 4 weeks. When prescribed, NSAIDs are usually started 2 or 3 days before surgery, or started the day of surgery, and continued for 3 or 4 times a day for 3 to 4 weeks.
2390182|NCT03640637||Suspected IBD|A prospective study of 50 pediatric patients suspected of IBD. Participants will undergo routine diagnostic procedures for evaluation of pediatric IBD including blood samples, faecal samples, endoscopies (colonoscopy and gastroscopy with biopsy/histology) and MRI of the abdomen. In addition, a PET scan will be performed in this protocol and combined with MRI. For accuracy measures, PET/MRI scan will be compared to the combined findings of endoscopy, histology and severity of inflammation by clinical scoring systems (weighted Pediatric Crohn's Disease Activity Index (wPCDAI) for CD and Pediatric Ulcerative Colitis activity Index (PUCAI) for CU), faecal calprotectin and biochemistry.
2390183|NCT03640637||Treatment response group|A pilot study of 10-15 patients previously diagnosed with CD who will undergo PET/MRI scan as an investigational procedure before initiation of biological treatment with an anti-TNF-alpha antibody (infliximab, adalimumab) because of disease relapse or steroid dependent disease. Patients will be scheduled for a PET/MRI again after one month. This study will evaluate if PET/MRI can diagnose a flare in CD and if PET/MRI is a reliable imaging tool to monitor intestinal inflammation. In this study the patient will act as his/her own control.
3183694|NCT00716365|Experimental|HemCon|"The purpose of this trial is to test HemCon pad after diagnostic percutaneous coronary angiography as an adjunct to manual compression to better control vascular access site bleeding and reduce time-to-hemostasis.~The HemCon bandage (containing a carbohydrate called chitosan, found in the shells of shrimp, lobster and beetles) will be used to shorten the time needed to achieve hemostasis, time to patient's ambulation, and patient's."
3183695|NCT00716391|Active Comparator|Group A|TPF plus concomitant treatment with cisplatin and conventional radiotherapy.
2390186|NCT03640598|Other|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks
2390187|NCT03640598|Other|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block
2390188|NCT03640585|Experimental|Music therapy|Children listened to Classical music disc for 45 minutes.Children treated by neurodevelopmental therapy while listening to this music.A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients.
2390189|NCT03640585|Placebo Comparator|Control|Only the neurodevelopmental therapy was applied in the control group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
2390190|NCT03640572||Bone Marrow DTC|Patients with left-sided colorectal cancer and disseminated tumour cells in the bone marrow
2390191|NCT03640572||No bone marrow DTC|Patients with left-sided colorectal cancer and no disseminated tumour cells in the bone marrow
3183696|NCT00716391|Experimental|Group B|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
2390194|NCT03640533|Experimental|Nanit-Insights intervention group|Nanit-Insights is an app-based intervention that provides parents with personalized sleep recommendations, based on their infant's developmental stage and weekly sleep data.
2390195|NCT03640533|No Intervention|Nanit-monitor control group|Participants in the control group will be given the same monitoring device, that will serve in this group as a baby-monitor only, without providing sleep recommendations to parents.
2390196|NCT03640520|Experimental|Intervention|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of Family Centered Care (FCC) practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
2390197|NCT03640520|Active Comparator|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs, including a brief mention of FCC as one of these standards, with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness.
2390201|NCT03640494||Neonates with a clinical HIE diagnosis|48 neonates with a clinical diagnosis of HIE will be recruited from the patient populations of Duke University Health System and the University of Utah. All subject will have bedside optical coherence tomography (OCT) imaging performed at various time points while in the intensive care nursery.
2390202|NCT03640481|Experimental|Arm A: belumosudil 200 mg QD|Eligible subjects randomized to arm A will take belumosudil 200 mg once daily
2390204|NCT03640468|Active Comparator|Ketamine group|This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
2390205|NCT03640468|Experimental|Lidocaine-ketamine group|This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.
3143029|NCT00004148|Experimental|Arm I|Patients receive rV-B7.1 intralesionally every 4 weeks for 8 weeks (weeks 0, 4, and 8). Treatment continues every 12 weeks in the absence of unacceptable toxicity or disease progression for up to 2 courses. Cohorts of 6-8 patients receive escalating doses of vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 or 3 of 8 patients experience dose limiting toxicities.
3143030|NCT00004154|Experimental|Fenretinide|Fenretinide (4-HPR) 200 mg orally every day for 12 months taken 25 out of every 28 days.
3143031|NCT00004154|Placebo Comparator|Placebo|Placebo orally every day for 12 months, taken 25 out of every 28 days.
2390209|NCT03640442|Experimental|Modified ramped position group|In this group, induction of anesthesia will be performed in the modified ramped position.
2390210|NCT03640442|Active Comparator|Ramped position group|In this group, induction of anesthesia will be performed in the ordinary ramped position.
2390211|NCT03640416|Other|Medical residents|Rambam Health Care Campus medical residents who work nights on call. Fitbit® Charge HR smart watch
2390212|NCT03640403|Experimental|DP|Dihydroartemisinin-piperaquine (DP), antimalarial drug to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
2390213|NCT03640403|Active Comparator|ASAQ|Artesunate-amodiaquine (ASAQ), antimalarial drugs to be given every 4 months 3 rounds for the first year. A second non-interventional year will assess possible rebound effects.
2390214|NCT03640403|No Intervention|Control|No intervention drugs will be given, but normal routine standard of care will be provided.
2390215|NCT03640390|Experimental|Dexmedetomidine group|This group will receive dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour
2390216|NCT03640390|Active Comparator|Magnesium Sulphate group|This group will receive Magnesium Sulphate infusion at a rate of 15 mg/Kg/hour
2390217|NCT03640390|Placebo Comparator|Saline group|This group will receive normal saline infusion
2390218|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose only baseline treatment|150 children will receive 40 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
2390219|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose only baseline treatment|150 children will receive 80 mg/kg Praziquantel at baseline as single treatment and placebo six months following baseline
2390220|NCT03640377|Active Comparator|Praziquantel 40 mg/kg dose at baseline and 6 months|150 children will receive 40 mg/kg Praziquantel at baseline and again six months later.
2390221|NCT03640377|Active Comparator|Praziquantel 80 mg/kg dose at baseline and 6 months|150 children will receive 80 mg/kg Praziquantel at baseline and again six months later.
2390222|NCT03640351|Active Comparator|Preservative free diquafosol group|The subjects use preservative free diquafosol ophthalmic solution after cataract surgery
2390223|NCT03640351|Active Comparator|Preservative containing diquafosol group|The subjects use preservative containing diquafosol ophthalmic solution after cataract surgery
2390224|NCT03640351|Active Comparator|Preservative free sodium hyaluronate group|The subjects use preservative free sodium hyaluronate ophthalmic solution after cataract surgery
2390225|NCT03640338|Experimental|Cold-therapy system|Patients will receive a cold-therapy system postoperatively (Polar Care Kodiak, Breg®) and will use the system during inpatient stay and during the first 14 days post-discharge.
2390226|NCT03640338|No Intervention|Standard care (ice-pack)|Patients will use disposable ice-pack as per standard of care
2390227|NCT03640325|Experimental|PRISM (Promoting Resilience in Stress Management)|Resilience Skills Training
2390228|NCT03640325|No Intervention|Usual Care|Usual psychosocial care (control arm, no intervention)
2390229|NCT03640312|Experimental|QUARTET LDQT|Patients randomized to the intervention arm will take a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.
2390230|NCT03640312|Active Comparator|Candesartan|Patients randomized to the comparison arm will take a once daily 8mg candesartan.
2390231|NCT03640299|Experimental|ERAS procedure|"In this arm, ERAS perioperative cares patients planned to undergoing laparoscopic surgery, following the ERAS protocols.~Extensive preoperative counselling and education by surgeon and anesthetists.~No Bowel preparation.~6 h fast for solid food and carbohydrate loading with clear fuilds 2h before surgery.~Oral nonselective NSAIDs premedication.~Total Intravenous Anesthesia via TCI, wound infiltration and the transversus abdominis plane (TAP).~Minimally invasive surgery.~Maintenance of normothermia.~Avoidance of surgical drains and nasogastric tubes.~Nonselective NSAIDs postoperative medication.~Postoperative nausea and vomiting active control.~Early oral feeding and ambulation.~VTE prophylaxis postoperative."
2390232|NCT03640299|No Intervention|Traditional treatment procedure|"In this arm, control patients planned to undergoing laparoscopic surgery, following the traditional treatment protocols.~Conventional preoperative visits and education.~Mechanical bowel preparation.~Fasting overnight, and no fluids before surgery.~No oral nonselective NSAIDs premedication.~Continuous epidural anesthesia is administered before surgery. Sevoflurane and sufentanil maintain the depth of anesthesia.~Minimally invasive surgery.~No maintenance of normothermia.~Drainage tube insertion if needed.~Postoperative patient-controlled intravenous analgesia.~Postoperative Nausea Control if needed.~Conventional oral feeding and mobilization.~No bowel routine.~VTE prophylaxis postoperative."
3143032|NCT00004156|Experimental|Vaccine: MUC1-KLH vaccine/QS21|Patients receive glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, and 19 for a total of 5 vaccinations. Patients are followed every 3 months.
3143033|NCT00004160|Experimental|Dose 1 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3143034|NCT00004160|Experimental|Dose 2 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3143035|NCT00004160|Experimental|Dose 3 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
2390235|NCT03640273|Experimental|Prapchompoothaweep|Group 1 will be received Prapchompoothaweep remedy 1,000 mg for 3 times before meals (for 6 weeks).
2390236|NCT03640273|Experimental|Loratadine|Group 2 will be received Loratadine 10 mg per day before meals (for 6 weeks)
2390237|NCT03640260|Experimental|experimental|The experiment arm will get educational leaflets to pursed-lip with diaphragmatic breathing training and oximetry level evaluation.
2390238|NCT03640260|No Intervention|controlled|
2390239|NCT03640247|Other|Narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours~Oxycodone 5 mg by mouth every 6 hours as needed for pain, #10 tablet or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg."
2390240|NCT03640247|Active Comparator|Non-narcotic group regimen|"Tylenol tablet 1000 mg by mouth every 8 hours alternating with~Ibuprofen tablet 800 mg by mouth every 8 hours"
2390241|NCT03640221|Experimental|Experimental|will receive two bottles of Ertugliflozin 15mg tablets (active drug) and a placebo for hydrochlorothiazide.
2390242|NCT03640221|Active Comparator|Active Comparator|will receive two bottles of Placebo for ertugliflozin and hydrochlorthiazide 12.5mg capsules (active drug)
3143036|NCT00004160|Experimental|Dose 4 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
2390244|NCT03640195|Experimental|Experimental group|Transcutaneous nerve electrical stimulation and Auricular acupressure.
2390245|NCT03640195|No Intervention|Control group|without intervention
2390246|NCT03640182|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
2390247|NCT03640169|Experimental|Management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
2390248|NCT03640156|Experimental|Oxytocin (OXT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OXT (3 puffs of 4 IU per nostril).
2390249|NCT03640156|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
2390250|NCT03640143||experimental group|children with clinical expression of lead poisoning data about venous blood lead will be reported
2390251|NCT03640130|Experimental|Single Arm|Each participant will participate in several blocks (randomized order), to evaluate performance with and without behavioral gaze-contingent text enhancements.
2390252|NCT03640104|Experimental|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
2390253|NCT03640104|Other|Nutrition Guidelines|Participants will receive general nutritional recommendations according to international standards
2390254|NCT03640091|Experimental|Pre-extractive inter-radicular implant bed preparation|
2390255|NCT03640078|Experimental|experimental group|Vasculitis patients The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis of serum. (acquisition imaging)
2390256|NCT03640065|Experimental|freeze-dried probiotic sachets|
2390257|NCT03640065|Active Comparator|fermented dairy product (yogurt)|
3183697|NCT00716404||1|All (consecutive) patients in whom one or more components of the Benephit Infusion System are planned to be used are eligible for enrollment in the study and should be offered informed consent.
2390263|NCT03640039|Experimental|study group: 3d strut plate fixation without post op IMMF.|Open reduction and internal fixation with 3d strut plate without post operative IMMF.
2390264|NCT03640039|Active Comparator|control group: 3d srut plate fixation with post op IMMF.|Open reduction and internal fixation with 3d strut plate with post operative IMMF for 15 days.
2390265|NCT03640026|Experimental|Tacrolimus treatment|
2390266|NCT03640013|Experimental|Hall Technique|The intervention involves removal from the primary molar and a preformed metal crown is placed using glass ionomer. The subject is then asked to bite until crown is seated. No occlusal adjustment is carried out.
2390267|NCT03640013|Other|Conventional Technique|The procedure involves administering local anesthetic and the intervention involves remoal of caries from the affected primary molar. The tooth is then reshaped and contoured to to enable a preformed metal crown placement. Occlusal and marginal fit is improved by crimping the metal crown to improve fit. The preformed metal crown is cemented with glass ionomer restorative material and occlusion finally checked. The subject is then asked to bite on a cotton roll for two minutes until the cement has set.
2390268|NCT03640000|Experimental|Determination of impedance signals|This single arm study is designed to measure impedance signals from implanted leads in different positions in the heart. Signals obtained at different pre specified position are compared to each other to determine the robustness of the acquired measurements.
2390382|NCT03639246|Active Comparator|Phase 2: Placebo+Pac|
2390383|NCT03639233|Other|Arm 1|Intervention access
3143037|NCT00004160|Experimental|Dose 5 Gemcitabine|Patients receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes beginning 2 hours into paclitaxel infusion on day 1 of weeks 6, 9, and 12.
3143038|NCT00004161|Experimental|Arm I|Patients receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
3143039|NCT00004161|Experimental|Arm II|Patients receive oral placebo daily (except days 1-3 each month) for 6 months. Patients then receive oral fenretinide daily (except days 1-3 each month) for 6 months. Patients are followed every 3 months.
3183698|NCT00716430|Active Comparator|QI|Quality Improvement Centres
3183699|NCT00716430|No Intervention|Non-QI|No Quality Improvement Programme
2390271|NCT03639974|Active Comparator|PEP in a blow-bottle device|Blow-bottle device of 10cmH2O.
2390272|NCT03639974|Active Comparator|EPAP Positive airway expiratory pressure|EPAP with pressure of 10 cmH2O.
2390273|NCT03639974|Sham Comparator|conventional physiotherapy|Ventilatory exercises, bronchial hygiene techniques, exercises for upper and lower limbs (previous motor condition) stretching, orientation and walking.
2390274|NCT03639961|Experimental|Staff of facilities for intervention|Intervention: Participants have been trained two times in six months period with integrated leading, managing and governing for results model.
2390275|NCT03639961|Active Comparator|Staff of facilities for control|Intervention: Participants have been trained two times in six months period with traditional model.
2390276|NCT03639948|Experimental|Experimental: Carboplatin & Docetaxel plus Pembroluzimab|"Carboplatin (Area under the curve [AUC] 6 intravenously [IV]) and Docetaxel (75 milligrams per meter squared [mg/m2], IV) plus Pembrolizumab (200 milligrams [mg], IV) every 21 days for 6 cycles.~Pegfilgrastim 6 mg subcutaneous (SC) Day 2 of each cycle."
2390277|NCT03639935|Experimental|Rucaparib and Nivolumab|Rucaparib 600 mg PO BID days 1-28 Nivolumab 240 mg IV days 1 and 15
2390278|NCT03639922|Active Comparator|Imatinib|Imatinib 400mg (2 tablets of 400mg) per day for 6 days
2390279|NCT03639922|Placebo Comparator|Placebo|2 placebo tablets per day for 6 days
2390280|NCT03639909||MSA-P|Patients with multiple systeme atrophy (MSA) with predominant parkinsonism (MSA-P) had evaluation of cardiovascular function and sweating function
2390281|NCT03639909||PD patients|Parkinson's disease (PD) patients had evaluation of cardiovascular function and sweating function
2390282|NCT03639896|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
2390283|NCT03639896|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
2390284|NCT03639883|Placebo Comparator|0.033% versus Vehicle|One side of the subject will receive 0.033% AIV001 and the other side of the subject will receive vehicle.
2390285|NCT03639883|Placebo Comparator|0.1% versus Vehicle|One side of the subject will receive 0.1% AIV001 and the other side of the subject will receive vehicle.
2390286|NCT03639883|Placebo Comparator|0.3% versus Vehicle|One side of the subject will receive 0.3% AIV001 and the other side of the subject will receive vehicle.
2390287|NCT03639883|Placebo Comparator|1% versus Vehicle|One side of the subject will receive 1% AIV001 and the other side of the subject will receive vehicle.
2390288|NCT03639870|Experimental|Implant Group|Qualified eyes with refractory glaucoma will be implanted unilaterally with the Glaukos® Trabecular Micro-Bypass System Model iS3 (three G2-W stents per study eye), and will be followed through 12 months postoperative.
3183700|NCT00716469|Experimental|LS11 Administration|"Treatment will be given with a standard 3+3 light dose escalation. The Treatment Period will be 28 days. The LS11 dose will be 30mg/m2. The initial light dose will be 50 J/cm. If criteria for dose escalation are met, then the light dose will be escalated to 100J/cm, 150J/cm and 200J/cm. Once the maximum light dose is determined, up to 6 additional patients will be treated at that level to gain further experience with this modality prior to phase II testing. In particular, at least 3 subjects <12 years of age will be enrolled at the maximum tolerable dose (MTD) to allow for further evaluation of safety in younger children. If grade 3 or 4 toxicities are noted at light dose level #1, the LS11 dose will be decreased to 20mg/m2 (2/3 of the standard dose)."
3183701|NCT00716508|Active Comparator|A|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
2390292|NCT03639831|Experimental|Active group|Proprietary, standardized botanical extract
2390293|NCT03639831|Placebo Comparator|Placebo group|Placebo (maltodextrin)
2390294|NCT03639818|Experimental|experimental group|HIV patients
2390295|NCT03639805|Active Comparator|non interventional arm|Standard Of Care
2390296|NCT03639805|Experimental|interventional arm|Standard of Care + music therapy program MUSIC CARE®
2390301|NCT03639753|Experimental|Parent-Teen Intervention|Parent health coaching session and supportive materials, teen on road driver assessment with feedback.
2390302|NCT03639753|Other|Usual Practice|
2390303|NCT03639740|Other|Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor|Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor
2390304|NCT03639727|Active Comparator|Citric acid aerosol bronchial challenge|Inhaled citric acid aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is citric acid aerosol challenge.
2390305|NCT03639727|Active Comparator|Mannitol aerosol bronchial challenge|Inhaled mannitol aerosol. This study investigates the diagnostic accuracy of two cough provocation tests, one of which is mannitol aerosol challenge.
2390306|NCT03639714|Experimental|Phase 1|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
2390307|NCT03639714|Experimental|Phase 2 Cohorts|"GRT-C901~GRT-R902~nivolumab~ipilimumab"
2390308|NCT03639701|Experimental|Open label thymidine and deoxycytidine|All patients will receive open label thymidine and deoxycytidine
2390309|NCT03639688|Active Comparator|Left sided|
2390310|NCT03639688|Active Comparator|Right sided|
2390312|NCT03639662|Experimental|experimental group|"Patients benefit from additional support consisting of at least 3 sessions of sophrology (sophrology sessions), one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for iratherapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
2390313|NCT03639662|No Intervention|control group|Between the announcement of their thyroid cancer and the post-therapeutic scintigraphy, the patients will follow the usual route: information on the management, receipt of an information booklet (containing the telephone contacts of the hospital units), and they wish it, meet with the staff and visit a room of hospitalization. The nurses of the hospitalization service are available to answer any questions they may have, either during this visit or during a telephone call
2390314|NCT03639649|Experimental|STHLM3|
2390315|NCT03639649|Active Comparator|PSA|
2390316|NCT03639636|Other|interventional prospective study|nonsurgical periodontal therapy(scaling and root planing) surgical therapy( flap surgery)
2390317|NCT03639623|Experimental|Saroglitazar Magnesium 4 mg|Saroglitazar Magnesium tablet once daily in the morning 60 minutes before breakfast
3183702|NCT00716508|Active Comparator|B|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
2390319|NCT03639597|Experimental|Study device|VytronUS Ablation System
2390320|NCT03639584||Group 1|Patients admitted to ICU less than 48 hours and the anticipated stay is less than 5 days. Take blood sample on the day of enrollment.
2390321|NCT03639584||Group 2|Patients admitted to ICU less than 48 hours and the anticipated stay is longer than 5 days. Take blood sample on the day of enrollment, 7th, 14th, 21st, and 28th. Stop blood sample once exit.
2390322|NCT03639584||Group 3|Patients admitted to ICU 3~7 days. Take blood sample on the day of enrollment.
2390323|NCT03639584||Group 4|Patients admitted to ICU 8~14 days. Take blood sample on the day of enrollment.
2390324|NCT03639584||Group 5|Patients admitted to ICU 15~28 days. Take blood sample on the day of enrollment.
2390325|NCT03639571|Experimental|Test|Ibuprofen 200mg TEPI medicated plaster
2390326|NCT03639571|Placebo Comparator|Placebo|Placebo TEPI Plaster
2390327|NCT03639558|Active Comparator|Haloperidol + Promethazine + Chlorpromazine|
2390328|NCT03639558|Experimental|Haloperidol + Promethazine|
2390329|NCT03639545|Active Comparator|*empagliflozin*|empagliflozin 25 mg daily for 12 weeks, once daily, by mouth
2390330|NCT03639545|Active Comparator|*metformin*|metformin 2000 mg daily for 12 weeks, once daily, by mouth
2390331|NCT03639545|Active Comparator|*empagliflozin/metformin*|empagliflozin 25 mg daily and metformin 2000 mg daily for 12 weeks, by mouth
2390332|NCT03639545|Placebo Comparator|*placebo*|placebo for 12 weeks, once daily with water, by mouth
2390333|NCT03639532|Experimental|COC|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on ceramic(COC) bearing couple is implanted. The group with intervention COC THA.
2390334|NCT03639532|Active Comparator|COP|for the arthritic hip of the patient, total hip arthroplasty(THA) with ceramic on highly cross-linked polyethylene bearing couple is implanted. The group with intervention COP THA.
2390335|NCT03639519|Experimental|Ascorbic acid|Patients will take 2 g orally ascorbic acid effervescent tablets the night before cardiac surgery, then 1 g twice daily for 5 days after surgery in addition to their traditional medical care.
2390336|NCT03639519|Placebo Comparator|Placebo group|will not be given ascorbic acid , instead a placebo will be used, and will be given the rest of traditional medical care provided to the first arm. Inflammatory markers (CRP, ESR and differential TLC), serum urea and creatinine, ALT, AST, CK-mb, CK-Total, aPTT, INR, Hemoglobin, platelet count, will be assessed on day 0, 1,2,4,6 postoperative in both arms.
2390337|NCT03639506|Experimental|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
2390338|NCT03639506|Active Comparator|ICSI|only has intracytoplasmic sperm injection (ICSI)
2390339|NCT03639493|Experimental|Sequence 1|"Period 1: receive Exforge® tab 10/160mg, Crestor® tab 20mg~Period 2: receive CJ-30060 10/160/20mg"
2390340|NCT03639493|Experimental|Sequence 2|"Period 1: receive CJ-30060 10/160/20mg~Period 2: receive Exforge® tab 10/160mg, Crestor® tab 20mg"
2390341|NCT03639480|Experimental|Test|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
2390342|NCT03639480|Active Comparator|Reference 1|Amlodipine 10mg+Valsartan 160mg
2390343|NCT03639480|Active Comparator|Reference 2|Valsartan 160mg+Atorvastatin 40mg
2390344|NCT03639467|Experimental|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
2390345|NCT03639454|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2390384|NCT03639220|Active Comparator|Photobiomodulation Therapy (PBMT) active|Participants received active PBMT
2390385|NCT03639220|Placebo Comparator|Photobiomodulation Therapy (PBMT) placebo|Participants received placebo PBMT
2390346|NCT03639454|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2390347|NCT03639441|Experimental|Dry needling|In this arm, the subjects will receive the intervention of DN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2390348|NCT03639441|Active Comparator|Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of Transcutaneous Electric Nerve Stimulation on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2390349|NCT03639428||6 - 23 months|8 infants between 6 and 23 months received a single 0.3mg/kg midazolam dose of ADV6209
2390350|NCT03639428||2-11 years|17 children between 2 and 11 years received a single 0.3mg/kg midazolam dose of ADV6209
2390351|NCT03639428||12-17 years|12 adolescents between 12 and 17 years received a single 0.3mg/kg midazolam dose of ADV6209
2390352|NCT03639415|Experimental|controlled-release oxycodone group|"Patients with moderate to severe pain accept CR oxycodone treatment and if any follow situations appears, then change the dose frequency from every 12 hours to every 8 hours or 6 hours.~Patients are satisfied with the pain control, but unable to tolerate nausea、vomit or dizziness, and can't get satisfactory pain control if reducing the CR oxycodone dose.~Patients are unsatisfied with the pain control, but can't increase the CR oxycodone dose because of intolerable nausea、vomit or dizziness."
2390353|NCT03639402|Experimental|Health education classes|"Intervention consist of 2 rounds. Round 1: Locally selected mothers who have children 1-9 years old are trained by research team (peer mothers). Peer mothers conduct 4 education classes each for approximately 10 eligible mothers in their neighbourhood (fellow mothers).~Round 2: After one month gap one meeting for recapitulation and feedback is conducted by research team for peer mothers. Similarly, peer mothers conduct one meeting with fellow mothers."
2390354|NCT03639402|No Intervention|No health education classes|Community is exposed to health-related information, which is provided by the regular health system of Nepal
2390355|NCT03639389|Active Comparator|Analgesics, multimodal|Combination of paracetamol, non-steroidal anti-inflammatory drug and morphine as analgesics
2390356|NCT03639389|Experimental|Bupivacaine|Spinal anesthetic with bupivacain + fentanyl/sufentanil
2390357|NCT03639376||Passive smoking-exposed children|This group consists of children whose family members have smoked at home since the birth of the child.
2390358|NCT03639376||Passive smoking-unexposed children|This group consists of children whose family members have not smoked at home since the birth of the child.
2390359|NCT03639363|Experimental|Intervention Arm|daily bathing with 4% chlorhexidine gluconate soap-like solution followed by water rinsing
2390360|NCT03639363|Active Comparator|Control Arm|daily bathing with standard soap
2390361|NCT03639350|Experimental|IER+MED group|The IER+MED group intervention will be to restrict 70% energy (34%, 33% and 33% distribution of protein, carbohydrate, and fat, respectively) on 2 days and follow the MED diet (25%, 45%, 30%) and meet their estimated energy requirement (EER) for the other 5 days each week. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
2390362|NCT03639350|Active Comparator|DASH group|The DASH group intervention will be to follow the DASH diet and meeting a distribution of macronutrients of 20% protein, 53% carbohydrate, and 30% fat and meet their EER. Participants will also be asked to follow a moderate exercise program (1 hour of walking five days a week).
2390363|NCT03639337|Experimental|Allergic Children|"Allergic children to milk or egg, aged between 10 and 14 months, confirmed by double-blind oral provocation test against placebo.~Intervention: 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63"
2390364|NCT03639337|No Intervention|Not confirmed Allergic Children|Sensible children to milk or egg, aged between 10 and 14 months, not confirmed by double-blind oral provocation test against placebo.
2390365|NCT03639337|No Intervention|Controls|Healthy controls ages between 10 and 14 months
3183703|NCT00716521|Placebo Comparator|Placebo|groups of 3-4 subjects for overnight polysomnography assessments
3183704|NCT00716521|Experimental|Low dose Zolpidem|
3183705|NCT00716521|Experimental|High dose zolpidem|
3183706|NCT00716534|Experimental|A|12.5 mg ABT-869 + Carboplatin/Paclitaxel
3183707|NCT00716534|Experimental|B|7.5 mg ABT-869 + Carboplatin/Paclitaxel
3183708|NCT00716534|Placebo Comparator|C|Placebo (7.5 mg or 12.5 mg) + Carboplatin/Paclitaxel
3183709|NCT00716547|Experimental|1|
3183710|NCT00716547|Experimental|2|
2390374|NCT03639298|Experimental|training|children submitted to the Intendu training with motion based cognitive video games software
2390375|NCT03639298|No Intervention|no training|children not submitted to the training, entering the study as a control group
2390376|NCT03639259||Post-stroke fatigue|Participants fulfilling criteria for presence of fatigue after cerebral stroke
2390377|NCT03639246|Experimental|Phase 1b: AVB-S6-500+PLD|
2390378|NCT03639246|Experimental|Phase 1b: AVB-S6-500+Pac|
2390379|NCT03639246|Experimental|Phase 2: AVB-S6-500+PLD|
2390380|NCT03639246|Experimental|Phase 2: AVB-S6-500+Pac|
2390381|NCT03639246|Active Comparator|Phase 2: Placebo+PLD|
3183711|NCT00716547|Active Comparator|3|
3183712|NCT00716547|Placebo Comparator|4|
3183713|NCT00716560||A|Metastatic melanoma treatment with Dartmouth regimen
3183714|NCT00716573|Experimental|1|Introduction of everolimus associated with CNI (ciclosporin or tacrolimus) reduction (50%) to the current immunosuppression schedule
3183715|NCT00716573|No Intervention|2|Maintain of their current immunosuppressive therapy
3183716|NCT00716599|No Intervention|Control|Health centers continue with standard-of-care empiric case management
3183717|NCT00716599|Experimental|RDT training|Health centers randomly selected to receive training and RDTs, for use in routine patient case management
3183718|NCT00716612|Placebo Comparator|2|PO Placebo QD
3183719|NCT00716612|Experimental|1|PO Coenzyme Q 10 QD
3183720|NCT00716638|Experimental|Treatment group 1|Trauma-focused Cognitive Behavior Therapy (TF-CBT)
3143040|NCT00004162|Experimental|Dose group 1 - dose 1 of Doxorubicin HCL Liposome|Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3183721|NCT00716638|Experimental|Treatment group 2|Eye Movement Desensitization and Reprocessing (EMDR)
3183722|NCT00716664|Experimental|1|The experimental group receives the intervention in addition to normal optimal care
2390391|NCT03639181|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
2390392|NCT03639168|Experimental|Chidamide combined with Cisplatin|Chidamide: 30mg,PO,biw one week before cycle 1 treatment Cisplatin 25mg/m2 ivgtt D1-3 Chidamide :20mg PO Biw, 2 week on , 1 week off
2390393|NCT03639155|Experimental|Regimen A|vadadustat reference tablets
2390394|NCT03639155|Experimental|Regimen B|vadadustat test tablets
2390395|NCT03639142|Experimental|Plum group|Children will receive plums at dose 3,5g/kg/d as an oral treatment for constipation.
2390396|NCT03639142|Active Comparator|Polyethylene glycol group|Children will receive PEG at dose 0,5g/kg/d as an oral treatment for constipation.
2390397|NCT03639129|Experimental|Contrast-enhanced mammography (CME)|-Patients who meet eligibility criteria and consent to participate in this study will complete a CEM examination prior to or on the day that biopsy is scheduled. CEM must occur no later than 60 days after the diagnostic mammogram. The standard of care biopsy must occur no later than 30 days after CEM.
2390398|NCT03639116|Experimental|Stroke|This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb using stimulation. Individuals who are at least 6 months post first-ever subcortical stroke and have at least partial range of motion of the paretic index finger will be recruited to participate.
2390399|NCT03639116|Placebo Comparator|Control|Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects of stimulation. Individuals without a history of stroke will be recruited to participate.
2390400|NCT03639077|Experimental|Allograft bone alone|
2390401|NCT03639077|Experimental|Allograft and xenograft mixture|
2390402|NCT03639064|Experimental|CanniMed® Oil 1:20 formulation|∆9-THC: 1.0 mg/mL; CBD: 20.0 mg/mL
2390403|NCT03639064|Experimental|CanniMed® Oil 10:10 formulation|∆9-THC: 9.8 mg/mL; CBD: 9.9 mg/mL
2390404|NCT03639064|Experimental|CanniMed® Oil 18:0 formulation|∆9-THC: 18.3 mg/mL; CBD: 0.2 mg/mL
2390405|NCT03639051|Experimental|Active Treatment|Target Lung Denervation (TLD) with the Nuvaira Lung Denervation System (RF energy delivered) and optimal medical care for COPD.
2390406|NCT03639051|Sham Comparator|Sham Control|Sham Targeted Lung Denervation (TLD) procedure with the Nuvaira Lung Denervation System (catheter placement and balloon deployment in all treatment locations, no RF energy delivered) and optimal medical care for COPD.
2390407|NCT03639038||Blood Assay Phase - 1|TB Positive / HIV Positive: 65 participants
2390408|NCT03639038||Blood Assay Phase - 2|TB positive / HIV Negative: 65 participants
2390409|NCT03639038||Blood Assay Phase - 3|TB positive and negative Paediatric: 30 participants
2390410|NCT03639038||Blood Assay Phase - 4|TB Negative/HIV positive: 50 participants
2390411|NCT03639038||Blood Assay Phase - 5|Healthy controls: 30 participants
2390412|NCT03639038||Sputum Collection Phase - 1|TB Positive: Xpert Rif sensitive: 100 participants
2390413|NCT03639038||Sputum Collection Phase - 2|TB Positive: Xpert Rif resistant: 20
2390414|NCT03639038||Sputum Collection Phase - 3|TB Negative: Other chest: unknown number
2390415|NCT03639038||Sputum Collection Phase - 4|TB Negative: Smear negative/Xpert negative: 20
3183723|NCT00716664|Active Comparator|2|The active comparator, or control group, receives normal optimal care only
3183724|NCT00716677||1|
3183725|NCT00716677||2|
2390419|NCT03639012|Active Comparator|Carbohydrate loading|Patients to receive an oral preoperative carbohydrate drink
2390420|NCT03639012|No Intervention|No Carbohydrate loading|Current standard of care
2390421|NCT03638999|Active Comparator|Intervention Group - Ketorlac (NSAID)|Subjects will receive a one-time intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
2390422|NCT03638999|Placebo Comparator|Placebo Group - Normal Saline|Subjects in the control group will receive a one-time 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure. After consent and during screening visit demographic information, medical/surgical history, and height and weight will be collected. On Day 0 subject will be randomized to NSAID or Saline using inclusion/exclusion criteria and the procedure data will be collected. On Day 1 subject will receive a follow up phone call and complete AUA Symptom Score, USS Questionnaire 1 and USS Questionnaire 2 and any adverse events will be assessed. These questionnaires will again be administered on the day of stent removal and again 1 to 2 months post stent removal.
2390423|NCT03638986||Swiss version first|This group will first complete the Swiss version and second the German version of the TFI
2390424|NCT03638986||German version first|This group will first complete the German version and second the Swiss version of the TFI
2390425|NCT03638973|Experimental|Biopsy with Er: YAG|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser under previous local anesthesia
3183726|NCT00716690|Experimental|treatment|
3183727|NCT00716703|Experimental|1|cohort = pediatric patients in the ED (3-18 yo) with abdominal pain suspicious for appendicitis that are to undergo CT scan
2390426|NCT03638973|Active Comparator|Biopsy with Scalpel|Biopsies taken with Er: YAG are compared with biopsies taken with a scalpel in patients with lichenoid or leukoplakic changes of the oral mucosa.
2390427|NCT03638960|Active Comparator|Bupivacaine|Patients in group A will receive a bolus injection with 20 mL of 0.5% bupivacaine.
2390428|NCT03638960|Experimental|Liposomal bupivacaine|Group B will receive 10 mL of 133 mg of liposomal bupivacaine mixed with 10 mL 0.5% bupivacaine.
2390429|NCT03638947|No Intervention|Standard of Care|Patient will receive by mail a kit containing swab for the nares, armpit and groin.
2390430|NCT03638947|Active Comparator|Swab kit plus povidone-iodine soap|Patient will receive by mail a kit containing swab for the nares, armpit and groin. In addition the patient will receive decolonization treatment including povidone-iodine soap for presurgical cleansing two days prior to surgery.
2390431|NCT03638934|Experimental|Videos about ACP|Subjects in experimental group get three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish watching the materials, they fill out the questionnaire.
2390432|NCT03638934|Active Comparator|Brochure for Life-Sustaining Treatment|Subjects in the group get 13-page brochure entitled, Understanding the Life-Sustaining Treatment Act. After they finish watching the materials, they fill out the questionnaire.
2390433|NCT03638921|Experimental|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
3183728|NCT00716716|Experimental|rFIXFc|Six intravenous (IV) dose levels, 1, 5, 12.5, 25, 50, and 100 IU/kg
2390435|NCT03638895|Active Comparator|ECAL group|Intervention group (ECAL) - practitioners and participants receive measured energy information from ECAL indirect calorimeter including resting energy expenditure and respiratory quotient to diagnose, manage and advise on modification of caloric restriction and physical activity level. Energy information also allows participant and practitioner to monitor and compare changes to their metabolic health throughout the duration of intervention.
2390436|NCT03638895|Placebo Comparator|SC group|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
2390437|NCT03638882|Experimental|Duolingo Spanish Course|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
2390438|NCT03638882|Active Comparator|BrainHQ|30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.
2390439|NCT03638882|Placebo Comparator|Passive Control|No intervention.
2390440|NCT03638869|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
2390441|NCT03638869|Experimental|Arm 2|REL-1017 25 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390442|NCT03638869|Experimental|Arm 3|REL-1017 50 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390443|NCT03638869|Experimental|Arm 4|REL-1017 75 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390444|NCT03638856|Experimental|Misoprostal group|Patients were added oral Misoprostal 200 mcg 2 tab per oral 3 hour before hysteroscopy
2390445|NCT03638856|No Intervention|Placebo group|Patients were take placebo 2 tab per oral 3 hour before hysteroscopy
2390446|NCT03638843|Experimental|Gastric mucosal devitalization arm|Patients will be enrolled in the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care, and the gastric mucosal devitalization procedure will be performed in-vivo utilizing Argon plasma coagulation three days before the operation.
2390447|NCT03638830|Experimental|Group 1|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®"
2390448|NCT03638830|Experimental|Group 2|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation) full dose + Maxipime®"
2390449|NCT03638830|Placebo Comparator|Group 3|placebo (like full dose) in combination with the drug Maxipime®
2390450|NCT03638817|Experimental|Eltrombopag|
2390451|NCT03638804|Experimental|89Zr-KN035 injection|
2390452|NCT03638791||Healthy controls|Matched Controls without treatment
2390453|NCT03638791||OCD|Exposure and response inhibition
2390454|NCT03638778|Active Comparator|Oral semaglutide (reference)|Participants will receive oral semaglutide (reference) for 10 days.
2390455|NCT03638778|Experimental|Oral semaglutide formulation B|Participants will receive oral semaglutide formulation B for 10 days.
2390456|NCT03638778|Experimental|Oral semaglutide formulation C|Participants will receive oral semaglutide formulation C for 10 days.
2390457|NCT03638778|Experimental|Oral semaglutide formulation D|Participants will receive oral semaglutide formulation D for 10 days.
2390458|NCT03638765|Experimental|Experimental Treatment|Intratumoral injection of activated, autologous dendritic cells (DCVax-Direct) in brain metastases from lung cancer or breast cancer
2390459|NCT03638752|Experimental|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
2390460|NCT03638752|No Intervention|standard education|"The details of standard education are as follows:~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients that there would be some normal physiological reaction when gastroscopy, such as the throat discomfort and nausea/vomiting."
3183729|NCT00716729||Pateints with longstanding hip and/groin pain|
2390461|NCT03638739|Experimental|Exercise|Participants will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS for 12 weeks at McMaster University. Following this, they will return to their normal daily activities for a further 12 weeks.
2390462|NCT03638739|Experimental|Wait-list Control|Participants will engage in their usual daily activities for the first 12 weeks of the study, then will engage in supervised, twice-weekly exercise following the Physical Activity Guidelines for Adults with MS at McMaster University for the 2nd 12 weeks.
2390463|NCT03638726|Experimental|Atropine sulfate and Epinephrine|Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).
2390464|NCT03638726|Other|Topical cyclopentolate and phenylephrine|Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.
2390465|NCT03638713|Experimental|colonoscopy first group|Patients received water-exchange colonoscopy first and followed by esophagogastroduodenoscopy
2390466|NCT03638713|Active Comparator|EGD first group|Patients received esophagogastroduodenoscopy first and followed by water-exchange colonoscopy
2390467|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ angled tip|Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
2390468|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ angled tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
2390469|NCT03638700|Active Comparator|guidewire type 1: VisiGlide™ straight tip|Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
2390470|NCT03638700|Active Comparator|guidewire type 2: VisiGlide2™ straight tip|Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide™ (tip according to the examiner)
2390471|NCT03638687||History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2390472|NCT03638687||No History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2390473|NCT03638687||History, No PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2390474|NCT03638687||No History, Yes PPD|Participants may be asked to undergo repeated neuroimaging scans. No intervention will be administered, all participants will receive routine care during the study.
2390479|NCT03638661|Experimental|n-3 fatty acid enriched formula|"Those assigned to the n3EN group received vegetable n-3 fatty acid enriched formula by tube feeding (product; Yonsei Dairy Co., Seoul, South Korea).~vegetable (canola, flaxseed) derived n-3 fatty acid"
2390480|NCT03638661|Placebo Comparator|soybean oil used formula|"Patients assigned to the control group received a soybean used formula by tube feeding.~soybean used formula"
2390481|NCT03638648|Active Comparator|Low risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk receiving capecitabine.
2390482|NCT03638648|No Intervention|Low risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based low recurrence risk NOT receiving any additional chemotherapy.
2390483|NCT03638648|Experimental|High risk Capecitabine|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk receiving capecitabine.
2390484|NCT03638648|No Intervention|High risk control|Patients after neoadjuvant chemotherapy evaluated as non-pCR have multiple gene test based high recurrence risk NOT receiving any additional chemotherapy.
3183730|NCT00716755|Experimental|Dose Reduction|See Intervention
3183731|NCT00716768|Active Comparator|Laparoscopic Inguinal Hernia Repair|
3183732|NCT00716768|Active Comparator|Open Inguinal Hernia Repair|
2390488|NCT03638609|No Intervention|Control|Group of patients not receiving IABP
2390489|NCT03638609|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump in 3 hours after ROSC (early insertion of IABP)
2390490|NCT03638596|Experimental|Contingency Management|Incentive delivery contingent upon maintaining transdermal alcohol concentration below cut-off
2390491|NCT03638596|Placebo Comparator|Control|Incentive delivery not contingent on transdermal alcohol concentration
3183733|NCT00716781||1 (first year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed according to the CDC protocol. Blood cultures and CBC were performed and the infant was observed for 48 hours. Participating hospital were free to perform any additional test, such as CRP, MiniESR, etc
3183734|NCT00716781||2 (second year)|Asymptomatic infants born to GBS-positive mothers or to mothers with risk factors and incomplete prophylaxis were managed with clinical observation only. Clinical surveillance was based on 3 signs: 1. Skin appearance (pink, pale, mottled, cyanotic); 2. Respiratory rate (>50 or <50 breaths per minute); 3. Dyspnea (Yes / No)
2390492|NCT03638557|Experimental|Intervention|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
2390493|NCT03638544|Active Comparator|Reduced Gluten-Normal Gluten|
2390494|NCT03638544|Active Comparator|Normal Gluten-Reduced Gluten|
2390495|NCT03638531|Experimental|Anodal tDCS|Anodal tDCS will be applied in nine experimental sessions over a 2-week period.
2390496|NCT03638531|Sham Comparator|SHAM tDCS|SHAM tDCS will be applied in nine experimental sessions over a 2-week period.
2390497|NCT03638518|Experimental|Acupuncture|"In the acupuncture experimental group, the technique applied included the use of the following acupuncture points of Traditional Chinesse Medicine: GV20, ST36 and BL60 . One needle insertion was performed in each session and in the case of the last two points the needle insertions were done bilaterally.~Patients laid supine on a treatment table with their legs exposed. The skin on the acupuncture points was prepared with 70% ethyl alcohol. One-time-use disposable sterile stainless steel needles (0,26x50mm) were inserted into acupuncture points.~After insertion, acupuncture needles were manually manipulated to obtain the de qi sensation. The needles remained in place for 20 minutes and there were no further manipulations during the retention time."
2390498|NCT03638518|Experimental|Physiotherapy|The physiotherapy experimental group received core stability based physiotherapy treatment. Before the beginning of the treatment sessions, the basic principles of core stability exercises were explained to the participants. The exercise programme included 7 exercises. The exercises in the crook lying position were core activation with breathing, single leg lift with knees bent, single leg slides, bridging and knee drop sideways. The exercises completed in side lying included hip external rotation with knees bent and hip abduction with knees straight. After each session gentle stretching of the lower limbs and lumbar spine were performed. The sessions were administered twice a week during 30 minutes with groups of no more than 8 people.
2390499|NCT03638518|No Intervention|control|The control group did not receive any intervention. The participants continued with their routine medical treatment.
2390500|NCT03638505||patients|patients with Progressive supranuclear palsy. PSP-QoL will be performed in this group
2390501|NCT03638505||caregiver|the caregiver of the patient with Progressive supranuclear palsy PSP-QoL will be performed in this group
2390502|NCT03638492|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
2390503|NCT03638492|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
2390504|NCT03638479||Parkinson's Disease|Participant's diagnosed with Parkinson's Disease
2390505|NCT03638479||Essential Tremor|Participant's diagnosed with Essential Tremor or other Movement Disorders
2390506|NCT03638479||No Parkinson's Disease and No Essential Tremor|Participant's with no diagnosis of PD, ET or other Movement Disorders
2390509|NCT03638453|Experimental|PediCARE|"PediCARE Administered x6 mos~Resource Provision: Monthly Groceries (delivery via Instacart)~Resource Provision: Transport to/from home/hospital 8x per month (via RideHealth)"
2390510|NCT03638453|Active Comparator|Usual Care|The control group will receive usual supportive care
2390511|NCT03638427||High Risk HPV Positive Cohort|This group of women have tested positive for HR-HPV at annual cervical cancer screening and have been invited to participate in the study. They will be asked to use a menstrual pad we provide that collects a sample of their menstrual blood (strip). The strip will be mailed back to us for analysis (Menstrual Blood Analysis). These women will also be asked to conduct a self-swab vaginally to be sent back to us for analysis. These women will return 6-months after their positive HR-HPV for standard of care testing. All results of the standard of care tests, menstrual blood tests, and self-swab tests will be compared.
2390512|NCT03638414|Experimental|Group 1 - Interventional Treatment|This group will be given the ePainQ questionnaire and an interview.
2390513|NCT03638414|No Intervention|Group 2 - Usual care|This group will be receiving normal routine care without the study intervention
2390514|NCT03638401|No Intervention|Standard treatment|
2390515|NCT03638401|Active Comparator|Intervention arm|
2390516|NCT03638388|Active Comparator|Dry Needling (DN)|"Subjects will receive dry needling treatment, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
2390517|NCT03638388|Active Comparator|Dry Needling with Intramuscular electrical stimulation (DNES)|"Subjects will receive dry needling treatment with electrical stimulation, once a week, for 6 weeks.~Outcomes will be measured at baseline (week 0), 3 weeks after initiation of study (week 3), 6 weeks after initiation of study (week 6), and 6 weeks after last treatment (week 12)."
2390518|NCT03638375|Experimental|Treatment with nivolumab plus TIL|"In the first cohort the subcutaneous IFN-alpha injections will be omitted and the combination of nivolumab and TIL is given.~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
2390519|NCT03638375|Experimental|Treatment with Nivolumab plus TIL and IFN-alpha|"In the second cohort of the first phase and the second phase of the trial patients will be treated with subcutaneous IFN-alpha injections in combination with TIL and nivolumab.~IFN-alpha is given at a fixed dose of 3 million IU s.c. every day, for 11 weeks, starting one week before the first TIL infusion~Nivolumab is given 3mg/kg i.v. once every two weeks and starts 4 weeks before the first TIL infusion~TILs are given at a dose ranging between 2.5-7.5x10^8 T cells i.v. once every three weeks, three times per cycle."
2390520|NCT03638362|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half of participants began study consuming placebo beverage and the other half TCJ.
3183735|NCT00716833|Active Comparator|Preemptive|Preemptive group patients get Etoricoxibe twice (before and after surgery) or just a single preoperative dose
2390521|NCT03638362|Experimental|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 2 week washout then switch over to the alternate beverage. Approximately half pf participants began study consuming placebo beverage and the other half TCJ.
2390522|NCT03638336|Experimental|flexible ureteroscopy|
3183736|NCT00716833|Placebo Comparator|Postoperative|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery.
2390524|NCT03638310|Experimental|ITG (intratympanic gentamicin) group|Patients who underwent prehabituation by gentamicin prior to surgery for vestibular schwannoma. They underwent intratympanic application of gentamicin and microsurgical removal of vest. schwannoma.
2390525|NCT03638310|Active Comparator|control group|patients without prehabituation before surgery. They underwent microsurgical removal of vest. schwannoma.
2390526|NCT03638297|Experimental|PD-1 antibody + cox inhibitor|BAT1306 + aspirin(celebrex when there is contraindication to aspirin) on day 1-21 every three weeks
2390527|NCT03638284|Experimental|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS):All enrolled study participants will receive 10 sessions (5 per week X 2 weeks) of tDCS in an open label study. Inhibitory stimulation will be delivered to the frontal lobes.
2390528|NCT03638271|Other|nonischemic cardiomyopathic patient|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging.
3183737|NCT00716846|Active Comparator|statin-1|simvastatin
3183738|NCT00716846|Active Comparator|statin-2|atorvastatin
3183739|NCT00716846|Active Comparator|statin-3|pitavastatin
2390532|NCT03638245||Abnormal CTG|This group includes pregnancies that showed abnormalities in CTG.
2390533|NCT03638245||Normal CTG|This group includes pregnancies that showed no abnormalities in CTG.
2390534|NCT03638232||Patients with multiple myeloma|"Data to be collected are :~Drug exposition data~Administrative data~Medical data"
2390535|NCT03638206|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with several different specific Chimeric antigen receptors aiming at different antigens respectively by infusion.
2390536|NCT03638193|Experimental|CART-meso cells|A single dose of CART-meso T cells will be administered intravenously.The dose is 1-3×10^7/m^2 CART positive cells(chort 1)or 1-3×10^8/m^2 CART positive cells(chort 2).
2390537|NCT03638180|Experimental|Single Ascending Doses|Single ascending doses, 6 dose levels
2390538|NCT03638180|Experimental|Multiple Ascending Doses|Multiple ascending doses, 3 dose levels
2390539|NCT03638167|Experimental|ARM A (Tumor Cavity Infusion)|Patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity
2390540|NCT03638167|Experimental|ARM B (Ventricular System Infusion)|Patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively
2390541|NCT03638154|Placebo Comparator|GroupI|safety with received beta-tricalcium phosphate (β TCP) bone substitute only. (Bioresorb, Sybron, implant solutions GmbH Bremen, Germany)
2390542|NCT03638154|Active Comparator|GroupII|"safety with surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane and received a mixture of gingival fibroblast(GF) and gingival mesenchymal stem cells(GMSCs) carried on a vehicle of β TCP covered by a resorbable collagen membrane.~(Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Jersey, USA)."
2390543|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort A dose)|"Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab, as specified per protocol (Cohort A dose).~Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted."
2390544|NCT03638141|Experimental|Durvalumab in combination with Tremelimumab (Cohort B dose)|Starting at week 2, after initial DEB-TACE treatment, patients will receive Durvalumab in combination with tremelimumab as specified per protocol (Cohort B dose). Treatment will continue for up to 12 months, while receiving DEB-TACE. Repeat DEB-TACE will be provided Q8W if there is residual tumor that can be targeted.
2390548|NCT03638115|Experimental|VaSecure™ Drug Coated PTA Balloon Catheter|
2390549|NCT03638102|Experimental|Sleep intervention|Sleep extension
2390550|NCT03638102|Active Comparator|Healthy living|Health education
2390551|NCT03638089|Experimental|Intervention Group|This group will receive up to six sessions of fall-recovery training over the course of 2-3 weeks.
2390552|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，bid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg twice daily for 48 weeks.
2390553|NCT03638076|Experimental|GLS4 120 mg+ RTV 100mg，tid|Patients with chronic HBV infection will receive GLS4 120 mg+ Ritonavir Tablet 100 mg three times daily for 48 weeks .
2390554|NCT03638063||Chronic cough|patients with chronic cough who remain clinically stable
2390555|NCT03638063||Bx|bronchiectasis patients who remain clinically stable
2390556|NCT03638063||Control|healthy controls
2390557|NCT03638050||In-hospital acute myocardial infarction patients|Functional Capacity Assessment
2390558|NCT03638037||Study|69 women, delivered preterm babies (less than 37weeks).
2390559|NCT03638037||Control|69 women, delivered at term (38-42 weeks) of full tem babies.
2390560|NCT03638024||Study group|Maternal plasma cell free fetal DNA levels will be measured in 25 women with one or more previous cesarean section and placenta previa anterior only or with ultrasound finding suggestive of placental adhesion or invasion (accreta , increta or percreta).
2390561|NCT03638024||Control group|Maternal plasma cell free fetal DNA levels will be measured in 25 matched control with normally situated placenta without ultrasound finding suggestive of placental adhesion or invasion.
3183740|NCT00716872|Experimental|ImmedSHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
3183741|NCT00716872|Experimental|ImmedSHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Immediate SHUTi group; that is, they receive access to the SHUTi program right away. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
2390564|NCT03637998|Experimental|PROPEL|The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
2390565|NCT03637985|Experimental|resistive exercise|resistive exercises using elastic band(Thera Band) Sets were at moderate intensity, 8-10 repetitions for every motion for 12 weeks
2390566|NCT03637985|Experimental|Aerobic exercise|Aerobic exercise in form of treadmill walking for 45 minutes for 12 weeks
2390567|NCT03637972|Experimental|Ventilated cigarettes only|Filters with approximately 30-36% filter ventilation
2390568|NCT03637972|Experimental|Unventilated cigarettes only|Filters with approximately 3.0-4.6% filter ventilation
2390569|NCT03637972|Experimental|Ventilated cigarettes + alternative nicotine delivery systems|Filters with approximately 30-36% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
2390570|NCT03637972|Experimental|Unventilated cigarettes + ANDS|Filters with approximately 3.0-4.6% filter ventilation and access to alternative nicotine delivery systems including e-cigarette/vaping device, medicinal nicotine (lozenge, gum and patch).
2390572|NCT03637946|Experimental|SHOFU Beautifil II LS|Experimental: SHOFU Beautifil II LS Restorative system FL-Bond II (self-etching adhesive system)/ Beautifil II (composite restorative)
2390573|NCT03637933|Active Comparator|India ink tattooing|Experimental group includes patients undergone to preoperative endoscopic tattooing with Sterile Carbon Particle Suspension.
2390574|NCT03637933|Experimental|Sterile Carbon Particle Suspension tattooing|Control group includes patients undergone to preoperative endoscopic tattooing with India Ink.
2390575|NCT03637920||transmen|Biological women, who identify as men and are seeking gender reassignment.
2390576|NCT03637894|Active Comparator|Infants born by CS-fed fermented formula|Feeding infants with fermented formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
2390577|NCT03637894|Placebo Comparator|Infants born by CS-fed standard formula|Feeding infants with standard formula milk. Infants born by cesarean section were fed either with fermented formula milk or with standard formula during the first 3 months of life
2390578|NCT03637894|Other|Infants born by CS-breastfed|"Infants born by cesarean section fed with mother milk during were the reference group for all infants born by cesarean section.~The breastfeeding infants were the reference group"
2390579|NCT03637894|Active Comparator|Infants born by ED-fed fermented formula|Feeding infants with fermented formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
2390580|NCT03637894|Placebo Comparator|Infants born by ED-fed standard formula|Feeding infants with standard formula milk. Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life
2390581|NCT03637894|Other|Infants born by ED-breastfed|"Infants born by eutocic delivery were fed either with fermented formula milk or with standard formula during the first 3 months of life.~The breastfeeding infants were the reference group."
2390582|NCT03637881||Other|Daily or non-daily Consumers
2390583|NCT03637868|Experimental|Eribulin|eribulin 1.4 mg/m² administered intravenously between 6 and 7 cycles.
2390586|NCT03637829|Placebo Comparator|Control|250 mL of water
2390587|NCT03637829|Active Comparator|White Chocolate|White chocolate (40 g)
2390588|NCT03637829|Experimental|Dark chocolate 1|Dark chocolate (40 g)
2390589|NCT03637829|Experimental|Dark chocolate 2|Dark chocolate (46 g) possibly containing caffeine and/or theobromine
3143041|NCT00004162|Experimental|Dose group 2 - dose 2 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
2390592|NCT03637803|Experimental|MRx0518 with pembrolizumab|Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
2390593|NCT03637790|Other|PF 04965842|In Period 1, subjects will be administered a single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.
2390594|NCT03637790|Other|Rifampin and PF 04965842|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
3143042|NCT00004162|Experimental|Dose Group 3 - dose 3 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3183742|NCT00716872|Experimental|DelaySHUTi/ImmedHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Immediate Hypnosis group; that is, they receive access to the Hypnosis recordings right away.
2390602|NCT03637751|Experimental|Experimental design|Testing will be carried out in Penn State's Clinical Research Center (CRC). The CRC has rooms for conducting the Trier Social Stress Test (TSST) stress-task and for resting. Participants will make two visits to the CRC, one week apart, on the same day of the weekday. Sessions will be scheduled from 11:00 am to 4:15 pm. We will use a randomized counter-balanced order for the two sessions (i.e., TSST and control conditions) with group membership blind to the subjects and lab personnel.
2390603|NCT03637751|Experimental|Control design|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
2390604|NCT03637738|Experimental|RIOP-Intrabeam® system|"Surgery with Intrabeam®. A first visit will be scheduled at 2 months from surgery then at 6 months then every 6 months for 5 years, then every year after 5 years.~Additional EBRT may be performed +/- chemotherapy if the treatment received is insufficient."
2390605|NCT03637738|Active Comparator|conventional surgery +RTE|surgery, EBRT over 33 sessions then visit at 6 months then every 6 months 6 for 5 years, then every year after 5 years.
2390606|NCT03637725||Coronary Artery Disease|Suspected or known coronary artery disease
2390607|NCT03637712|Experimental|Screening Colonoscopy|Patients undergoing standard screening or surveillance colonoscopy will be included
2390612|NCT03637647||Upper gastrointestinal cancer|Upper gastrointestinal cancers including oesophagus and stomach
2390613|NCT03637634||NPC survivors|Survivors of NPC, diagnosed under 21 years of age, between 1990 and 2030. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
2390614|NCT03637634||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine the consistency of findings between data sources.
2390615|NCT03637595|Active Comparator|Positive Control Group|Acupuncture
2390616|NCT03637595|Sham Comparator|Negative Control Group|Sham Intervention
2390617|NCT03637595|Experimental|Energy Medicine (EM) Intervention|Energy Medicine by an energy medicine practitioner
2390618|NCT03637582|Active Comparator|Anesthesia Arm|"Participants randomized to this arm will undergo uroflow studies then be given an hour rest. Five ml of 4% lidocaine gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of 4% lidocaine gel. The subject will then perform the second uroflow study.~Complex urodynamics with the use of lidocaine hydrochloride 4% will then be performed. The lidocaine gel will have been placed in and around the urethra. We are using lidocaine gel in an FDA approved manner (for anesthesia)."
2390619|NCT03637582|Placebo Comparator|Placebo Arm|Participants randomized to this arm will first undergo uroflow studies then be given an hour rest. Five ml of plain aqueous gel will be inserted into the urethra during their hour rest. After the incubation period, the subject will receive another five ml of plain aqueous gel. Urodynamic testing without anesthesia (standard of care) will then be performed.
2390620|NCT03637569||Cancer patients|Newly diagnosed pancreatic, bile duct or GB cancer patients at samsung medical center.
2390621|NCT03637556|Experimental|DST-0509|DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets. DST-0509 is taken once daily with food; the first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2390622|NCT03637556|Active Comparator|Jadenu|Jadenu is commercially available as tablets and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. Jadenu is taken once daily with or without a light meal. However, Jadenu can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2390623|NCT03637556|Active Comparator|Exjade|Exjade is commercially available as tablets and Exjade as tablets for oral suspension and will be provided by the patient with their ongoing prescription. Dosing will be at equivalent (mg for mg) doses of DST-0509 or Jadenu. If converting from Exjade, the dose will be scaled for each treatment by 28 mg/40 mg (treatment/Exjade). Jadenu and Exjade are taken once daily, Jadenu is taken with or without a light meal, and Exjade is recommended to be taken without food. However, either Jadenu or Exjade can be administered according to the patient's current prescription regimen. The first dose will be taken at Visit 3 (Day 1) and the final dose will be taken at Visit 10 (Day 63).
2390624|NCT03637543|Experimental|PD-L1 Positive|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
2390625|NCT03637543|Experimental|PD-L1 Negative|-Nivolumab will be given on day 1 of a 28-day cycle intravenously
2390626|NCT03637530|Experimental|intervention group|in this group of patients, inverse ratio ventilation is provided during general anaesthesia
2390627|NCT03637530|No Intervention|control group|in this group of patients, conventional ventilation is provided during general anaesthesia
2391383|NCT03632382|Other|OSA diagnosis with 3D acquisition|OSA diagnosis with 3D acquisition
3183743|NCT00716872|No Intervention|DelaySHUTi/DelayHyp|In the first part of the trial, participants are assigned to the Delayed SHUTi group; that is, they receive access to the SHUTi program at the end of the study. In the second part of the trial (3 months later), participants are assigned to the Delayed Hypnosis group; that is, they receive access to the Hypnosis recordings at the end of the study.
2390631|NCT03637504|Experimental|Interventional|web-based, mobile medication management application [MedActionPlan® (MAP) and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
2390632|NCT03637504|No Intervention|Control|usual care and continued use of eTrack nebulizer +/- AdhereTech pill bottles as measures of adherence
2390633|NCT03637504|Other|Optional Extension|web-based, mobile medication management application [MedActionPlan® (MAP)]
2390634|NCT03637491|Experimental|Avelumab and binimetinib|Open label
2390635|NCT03637491|Experimental|Avelumab, binimetinib and talazoparib|Open label
2390636|NCT03637491|Experimental|Binimetinib and talazoparib.|Open label.
2390637|NCT03637478|Experimental|Enhanced Systems of Care Team|The four intervention sites have been selected based on their size: taken together, their pediatric populations comprise over 80% of the total number of children receiving care at Cambridge Health Alliance. At the four intervention sites, the study will involve: 1) an integrated child mental health assessment done by the E-SOC team within primary care, 2) active follow-up, collaboration with specialty providers and support to families, 3) School, child welfare and other community linkages as appropriate.
2390638|NCT03637465|Experimental|Hydrate Philly Intervention|Intervention group that receives hydration station intervention
2390639|NCT03637465|No Intervention|Control|Control group that receives no intervention, but observational data is collected; converted to wait-listed intervention status after enrollment and randomization was completed
2390640|NCT03637452||Exclusive cigarette smokers|Exclusive cigarette smokers must smoke at least 10 cigarettes per day for the past three months and have exhaled carbon monoxide (eCO) levels of at least 6 ppm at the screening visit.
2390641|NCT03637452||Dual (Electronic cigarette and cigarette smoking) users|Dual e-cigarette and cigarette users must have smoked at least 5 cigarettes per day for the last 3 months and use e-cigarettes at least 15 days per month for the last 3 months.
2390642|NCT03637439|Experimental|PNM group|Subjects were treated only once. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10 Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol (Valera & Minaya). The subjects were lying prone in decubitus. The middle part of the sciatic nerve was located using an ultrasound machine (cross section), then an acupuncture needle (0.30 mm x 40 mm) was inserted in a short axis approach, perpendicular to the surface of the skin, to the perineurium of the sciatic nerve.
2390643|NCT03637439|Sham Comparator|Control group|The subjects were lying prone in decubitus. The same puncture protocol was performed on the sciatic nerve for 1.5 minutes, but without the application of electricity.
2390644|NCT03637426|Placebo Comparator|GPLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
2390645|NCT03637426|Experimental|Gn-HAP|In this group a desensitizing gel containing 20% of nano-hydroxyapatite, 9000 ppm of sodium fluoride and 5% of potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) was applied to the hypersensitive dentin. The GnHAP volunteers will be submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications.
2390646|NCT03637426|Experimental|GLASER|"In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda; São Carlos, SP, Brazil) was applied in hypersensitive dentine.~GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours."
2390647|NCT03637426|Experimental|GLASERnHAP|In this group the laser + nano-hydroxyapatite was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, São Carlos, SP, Brazil) and a gel containing 20% nanohydroxyapatite, 9000 ppm sodium fluoride 5% potassium nitrate (Desensibilize Nano P, FGM®, Joinville, SC, Brazil) in hypersensitive dentin. GLASERnHAP first named a laser application and then an application of nanohydroxyapatite according to the manufacturer's recommendations.
2390648|NCT03637413|Experimental|Hindmilk|Hindmilk, the milk at the end of a breast pumping session, has higher fat and energy content compared to the composite milk.
2390649|NCT03637400|Experimental|Trimethoprim/sulfamethoxazole (TMP-SMX)|TMP-SMX will be dosed as follows: for adults, 160/800 mg administered as two single strength (SS) over-encapsulated tablets (equivalent to one double strength (DS) tablet) twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (TMP/SMX dosed based on 8-10 mg/kg of TMP daily, divided into two daily doses) for those children who are under 40 kg in weight. As dosages of these medications are higher in persons with high body weight (>100 kg), we will use TMP/SMX 160/800 mg administered as four single strength (SS) over-encapsulated tablets (equivalent to two double strength (DS) tablet) twice daily.
2390686|NCT03637153|Experimental|Order B|Firstly, the participants will exposed to High Altitude (Säntis; 2500m above sea level) and consecutively will they have assessement in Zurich (Low altitude; 470m above sea level).
2390751|NCT03636750|Experimental|HB002.1T 8mg/kg|Participants received a 8mg/kg dose of HB002.1T via intravenous injection.
2390650|NCT03637400|Experimental|Doxycycline (DOXY)|DOXY will be dosed as follows: for adults, two 50 mg tabs (100 mg total) given twice daily. As dosages of these medications may be lower in children with lower body weight (<40 kg), we will use weight based liquid medications for children < 40 kg (DOXY 2.2 mg/kg twice daily) for those children who are under 40 kg in weight. The doxycycline dose will remain the same for persons with high body weight (>100 kg) and four additional placebo tabs will be given to subjects > 100 kg randomized to doxycycline.
2390651|NCT03637387|Experimental|BIIB074|Administered orally three times daily (TID)
2390652|NCT03637387|Placebo Comparator|Placebo|Placebo matching BIIB074
2390653|NCT03637374|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
2390654|NCT03637374|Other|Expanded Selection Arm|The Expanded Selection Arm will be treated the same as those in the Primary Study Arm. Your doctor will determine what arm you are in. TAAA Debranching Stent Graft System is comprised of two investigational devices including the Visceral Manifold and Thoracic Bifurcation and the unitary manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
2390655|NCT03637361|Placebo Comparator|Arm 1|100 mL Ocean Spray® Diet Cranberry Juice
2390656|NCT03637361|Experimental|Arm 2|REL-1017 5 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390657|NCT03637361|Experimental|Arm 3|REL-1017 20 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390658|NCT03637361|Experimental|Arm 4|REL-1017 60 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390659|NCT03637361|Experimental|Arm 5|REL-1017 100 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
2390660|NCT03637361|Experimental|Arm 6|REL-1017 150 mg in 100 mL of Ocean Spray® Diet Cranberry Juice
3183744|NCT00716885||CHF|"Informed consented participants are recruited among all patients admitted to the OLVG hospital.~Inclusion criteria:~Chronic congestive heart failure patients of all ages selected for biventricular pacemaker implantation for resynchronization therapy~Dyspnoe NYHA class III and IV~Optimal and constant heart failure treatment according to the ESC guidelines~Exclusion criteria:~Renal failure (creatinine >1.70 mg/dl)~Signs of infection or inflammation"
2390662|NCT03637335|Experimental|irradiation + carboplatin|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Carboplatin. :10 injections 1h prior irradiation
2390663|NCT03637335|Placebo Comparator|irradiation + placebo|Radiotherapy in 30 Gy en 10 fractions de 3 Gy. The overall duration to irradiation is 2 weeks Placebo :10 injections 1h prior irradiation
3183745|NCT00716885||Control|The control group consists of ten age-matched volunteers with a normal left ventricular ejection fraction and without signs or symptoms of heart failure.
2390667|NCT03637283|Experimental|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
2390668|NCT03637283|Active Comparator|fan-shaped photocoagulation|vitreoretinal surgery combined with fan-shaped photocoagulation
2390669|NCT03637270|Experimental|PRO group|Participants in PRO group receive dietary supplementation with protein-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
2390670|NCT03637270|Active Comparator|CHO group|Participants in CHO group receive dietary supplementation with carbohydrate-rich supplements immediately before and after each exercise training session. The interventions include 30 training sessions.
2390671|NCT03637257|Experimental|Nasal cannula / Guedel|Record of capnography using a standard nasal cannula followed by use of a modified Guedel airway
2390672|NCT03637257|Experimental|Guedel / nasal cannula|Record of capnography using a modified Guedel airway followed by use of a standard nasal cannula
2390673|NCT03637244|Experimental|Experimental Condition|Patients assigned to the experimental condition (LDQ + DS and HDQ + DS) will be asked to use the bookmarked link to the decision-aid within the first 7-14 days (and thereafter as needed) during the study period. The routine care group will be asked to use a bookmarked link to frequently asked questions on tenofovir + emtricitabine for PrEP. All groups will be compared on decision-quality at 14-days, self-reported PrEP initiation at 30-days, and PrEP adherence at 60-days post enrollment.
2390674|NCT03637231|Other|Standard and ultra-low-dose CAC scoring|
2390675|NCT03637218|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2390676|NCT03637218|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2390677|NCT03637205|Experimental|ECLS|PCI (or CABG) plus medical treatment + ECLS
2390678|NCT03637205|Active Comparator|No ECLS|PCI (or CABG) plus medical treatment
2390679|NCT03637192|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2390680|NCT03637192|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2390681|NCT03637179|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2390682|NCT03637179|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2390683|NCT03637166|Experimental|Order A|"The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)"
2390684|NCT03637166|Experimental|Order B|"The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level)."
2390685|NCT03637153|Experimental|Order A|Firstly, the participants will have their assessments at low altitude (Low altitude: 470m above sea level) in Zurich and consecutively the exposure to High Altitude (Säntis; 2500m above sea Level).
2390687|NCT03637140|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2390688|NCT03637140|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2390689|NCT03637127|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2390690|NCT03637127|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2390691|NCT03637114|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2390692|NCT03637114|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2390693|NCT03637088|Experimental|Order air-hypoxia|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2390694|NCT03637088|Experimental|Order hypoxia-air|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2390695|NCT03637075|Placebo Comparator|Placebo|Intranasal placebo administration
2390696|NCT03637075|Active Comparator|Intranasal insulin|Intranasal insulin administration
2390697|NCT03637062|Experimental|pessary|the test group is pessary.The pregnant woman is assigned to the pessary group and after having excluded a vaginal infection the pessary will be inserted directly.
2390698|NCT03637062|Active Comparator|Progesterone|the control group is progesterone. Pregnant women in the control group were treated by 200 mg QN, it is used for 34 gestational weeks.
2390699|NCT03637049|Experimental|PBI-4050 and midazolam|Midazolam 2 mg solution once (Period 1), PBI-4050 1200 mg (3 x 400 mg tablets) once per day for 5 days and midazolam 2 mg solution once on last day (Period 2).
2390700|NCT03637036|Other|Control Condition|A general communication intervention will occur inviting staff to take up the influenza vaccination, without a specific authority or social norm designated.
2390701|NCT03637036|Other|Authority Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority but not a social norm designated.
2390702|NCT03637036|Other|Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a social norm but not a specific authority designated.
2390703|NCT03637036|Other|Authority + Norms Condition|A communication intervention will occur inviting staff to take up the influenza vaccination with a specific authority and a social norm designated.
2390706|NCT03637010|Other|Breakfast in the Classroom|Baseline data will be collected to include anthropometric measures, participant characteristics, and past eating habits. For the first 8 weeks, the students will be provided with breakfast meals containing the USDA nutrition requirements. These meals are typically higher in carbohydrates and lower in protein. For the second 8 weeks, the students will be provided with higher-protein breakfast meals. These meals also contain the USDA nutrition requirements but include high-quality protein-rich foods. For the remaining 8 weeks, the students will be provided both types of meals and will be permitted to choose which they prefer to consume each day. At the end of each 8-week period, eating habits, appetite, mood, cognitive performance, and anthropometrics will be completed along with measurements of breakfast waste.
2390707|NCT03636997|Active Comparator|Draining seton|Draining seton is placed through the fistula track and internal and external anal sphicnters
2390708|NCT03636997|Active Comparator|Rerouting of track|The seton and the fistula track are rerouted to include the internal anal sphincter only and spare the external anal sphincter
2390709|NCT03636984||rheumatoid arthritis patients|subjects with rheumatoid arthritis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
2390710|NCT03636984||ankylosing spondylitis patients|subjects with ankylosing spondylitis would be administered with recombinant TNF-α receptor: IgG Fc fusion protein （Anbainuo）50 mg peer week for 3 to 6 months until reaching clinical remission or low disease activity. Then the application of Anbainuo would be continued for 6 months. If the subjects did not reach clinical remission or low disease activity in 6 months, the treatment should be considered as invalid.
2390711|NCT03636971|Experimental|hyaluronic acid with mannitol|
2390712|NCT03636971|Experimental|hyaluronic acid with sorbitol|
2390713|NCT03636971|Active Comparator|saline|
2390714|NCT03636958|Active Comparator|control group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) without perampanel
2390715|NCT03636958|Experimental|experimental group|they will receive conventional antiepileptic treatment (antiepileptic combination therapy) with perampanel
2390749|NCT03636750|Experimental|HB002.1T 2mg/kg|Participants received a 2mg/kg dose of HB002.1T via intravenous injection.
2390716|NCT03636945|Experimental|Medullary thyroid carcinoma|Patients with MTC who have serum calcitonin> 150 pg / ml at initial diagnosis and have performed baseline imaging examinations within the last 3 months will be included in the study A PET at 18F-FDOPA will be performed according to a very powerful acquisition protocol
2390717|NCT03636932|Active Comparator|N-acetylcysteine (NAC) group|
2390718|NCT03636932|Placebo Comparator|Placebo group|
2390719|NCT03636919||experimental group|patient with pollen allergic rhinitis patients will filled an e-BOOK included questionnaires of life
2390720|NCT03636906|Experimental|1 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Bexsero vaccine
2390721|NCT03636906|Experimental|2 Dose GSK3389245A + Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Bexsero vaccine
2390722|NCT03636906|Active Comparator|Bexsero Group|Subjects, males or females between and including 6 and 7 months of age will receive the Bexsero vaccine comparator and placebo
2390723|NCT03636906|Experimental|1 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Nimenrix vaccine
2390724|NCT03636906|Experimental|2 Dose GSK3389245A + Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Nimenrix vaccine
2390725|NCT03636906|Active Comparator|Nimenrix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Nimenrix comparator vaccine and placebo.
2390726|NCT03636906|Experimental|1 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 1 dose of the experimental GSK3389245A vaccine followed by placebo and Menveo vaccine
2390727|NCT03636906|Experimental|2 Dose GSK3389245A + Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive 2 doses of the experimental GSK3389245A vaccine followed by Menveo vaccine
2390728|NCT03636906|Active Comparator|Menveo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Menveo comparator vaccine and placebo.
2390729|NCT03636906|Experimental|1 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive1 dose of the experimental GSK3389245A vaccine followed by placebo and Synflorix vaccine
2390730|NCT03636906|Experimental|2 dose GSK3389245A + Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive2 doses of the experimental GSK3389245A vaccine followed by Synflorix vaccine
2390731|NCT03636906|Active Comparator|Synflorix Group|Subjects, males or females between and including 6 and 7 months of age will receive the Synflorix comparator vaccine and placebo
2390732|NCT03636906|Experimental|1 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 1 dose of the GSK3389245A experimental vaccine followed by placebo.
2390733|NCT03636906|Experimental|2 dose GSK3389245A + Placebo|Subjects, males or females between and including 6 and 7 months of age will receive the 2 doses of the GSK3389245A experimental vaccine followed by placebo.
2390734|NCT03636906|Placebo Comparator|Placebo Group|Subjects, males or females between and including 6 and 7 months of age will receive the Placebo vaccine
3183746|NCT00716898||1|"A. Patients with pathologically or cytologically confirmed diagnosis of advanced solid malignancy.~B. Venous thromboembolism: Deep vein thrombosis (DVT) confirmed by Doppler ultrasound, or pulmonary embolism confirmed by lung ventilation perfusion scan, or computerized tomography.~C. Treatment with therapeutic dose of low molecular weight heparin. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. Serum creatinine level < 1.5 mg/dl. G. Informed consent"
2390737|NCT03636880|Experimental|Brief treatment for insomnia|Brief Behavioral Treatment for Insomnia (BBTI) is a manualized, individual intervention designed to modify sleep patterns to reduce insomnia and improve sleep quality and efficiency. Participants complete two in-person meetings and two booster telephone calls over a four-week period.
2390738|NCT03636880|Active Comparator|Sleep Monitoring|Sleep Monitoring is an active comparator condition where participants track their sleep patterns for two weeks prior to the baseline and post-intervention assessments. They receive no contact from study staff during the intervening four-week period, except for a reminder call to begin completing the second sleep diary and to schedule the post-intervention assessment.
2390739|NCT03636867||data and specimen collection|consecutive diabetic patients admitted to Maria Cecilia Hospital for critical limb ischemia
2390740|NCT03636854|Experimental|Concentric Exercises|2 different concentric exercises will be done 3 times a week for 8 weeks.
2390741|NCT03636854|Experimental|Eccentric Exercises|2 different eccentric exercises will be done 3 times a week for 8 weeks.
2390742|NCT03636841|Experimental|EXPERIMENTAL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch on
2390743|NCT03636841|Active Comparator|CONTROL GROUP|A group of 30 patients using the new medical device with CE marking (Ultravision ©) switch off
2390744|NCT03636802||EXPERIMENTAL GROUP|Patient with respiratory failure and on a lung transplant waiting list
2390746|NCT03636776|Experimental|quality of life in metastatic BC|"Patients benefit from a longitudinal follow-up determined according to the treatments.~Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment.~The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre.~The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II)."
2390747|NCT03636763||Bullous pemphigoid and diabetes 2|patients with Bullous pemphigoid and diabete type 2 data report about gliptin exposure will be performed
2390748|NCT03636763||diabete type 2|patients with diabetes type 2 data report about gliptin exposure will be performed
2391906|NCT03628807||Prospective|Prospective cohort that received TIPS from 01/01/2013 onwards
2390752|NCT03636750|Experimental|HB002.1T 12mg/kg|Participants received a 12mg/kg dose of HB002.1T via intravenous injection.
2390753|NCT03636750|Experimental|HB002.1T 16mg/kg|Participants received a 16mg/kg dose of HB002.1T via intravenous injection.
2390754|NCT03636750|Experimental|HB002.1T 20mg/kg|Participants received a 20mg/kg dose of HB002.1T via intravenous injection.
2390755|NCT03636737||experimental group|Patients with Pyoderma gangrenosum
2390756|NCT03636724|Experimental|Intervention group|Patients will receive the interventions on both PA and FVI simultaneously.
2390757|NCT03636724|No Intervention|Waiting control group|Patients will not receive any supportive interventions on PA or FVI during the intervention period but will be provided with the same intervention at follow-up six-month after the intervention.
2390758|NCT03636711||experimental group|• Patient admitted to emergency for infectious syndrome Description of antibiotic protocol, according to a syndromic approach will be performed
2390759|NCT03636698||Chorioamnionitis Group|preterm infants were born to mothers with chorioamnionitis
2390760|NCT03636698||Control Group|preterm infants were born to mothers without chorioamnionitis
2390761|NCT03636685|Experimental|Non-squamous cell lung cancer|"Anlotinib combined with pemetrexed and carboplatin, phase I~Anlotinib combined with pemetrexed and carboplatin, phase II"
2390762|NCT03636685|Experimental|Squamous cell lung cancer|"Anlotinib combined with paclitaxel and carboplatin, phase I~Anlotinib combined with paclitaxel and carboplatin, phase II"
2390763|NCT03636672|Experimental|experimental|Perturbation training during stationary bicycle riding
2390764|NCT03636672|Active Comparator|control|stationary bicycle riding training
2390765|NCT03636659|Experimental|Amphotericin B Liposome|Amphotericin B Liposome for Injection 50 mg/vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
2390766|NCT03636659|Active Comparator|AmBisome Liposome|AmBisome Liposome for Injection 50 mg/ vial, intravenous infusion at a dose of 3 mg/kg/day, OD for 5 days
2390767|NCT03636633|Active Comparator|Control Group|"Standard respiratory physiotherapy~Patients in this group will receive standard respiratory physiotherapy two times a day, 7 days a week for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
2390768|NCT03636633|Experimental|Training Group|"Standard respiratory physiotherapy and inspiratory muscle train~In addition to the standard respiratory physiotherapy program, patients in this group will receive 3 sets of inspiratory muscle training with 10 repetitions twice a day for 4 weeks. During hospitalization, sessions will be performed by a respiratory physiotherapist. After discharge, other sessions will be performed at home by themselves."
2390769|NCT03636620|Active Comparator|TACE group|Transcatheter arterial chemoembolization
2390770|NCT03636620|Experimental|TACE+RFA/MV group|Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
2390771|NCT03636607|Experimental|Non-metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
2390772|NCT03636607|Experimental|Metastatic group|PET/CT dynamic scan,needle biopsy and gene detection
2390773|NCT03636594|Experimental|Dance|This was a single arm study with all participants receiving the same intervention.
2390774|NCT03636581|Experimental|Intervention|This group will receive a smart watch to track activity and diet. This group will also receive education on nutrition and exercise.
2390775|NCT03636581|No Intervention|Control|This group will receive a smart watch to track activity only with no intervention.
2390776|NCT03636568|Experimental|Fluid restricted|Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg)
2390777|NCT03636568|No Intervention|Non Fluid Restricted|No fluid restriction
2390778|NCT03636555|Active Comparator|Oxytocin|Syntocinon Spray (intranasal oxytocin spray). Each dose is 10 intranasal insufflations totaling 1.0 mL of Syntocinon Spray containing 40 IU of oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
2390779|NCT03636555|Placebo Comparator|Placebo|Each dose is 10 intranasal insufflations totaling 1.0 mL of a solution containing all ingredients in Syntocinon Spray except oxytocin. Subjects self-administer doses twice daily (before breakfast and before dinner) for 12 consecutive weeks.
2390780|NCT03636542|Experimental|liposomal bupivacaine|These patients receive an interscalene block with liposomal bupivacaine.
2390781|NCT03636542|Active Comparator|bupivacaine|These patients receive an interscalene block with bupivacaine.
2390782|NCT03636529|Active Comparator|Tart cherry juice (TCJ)|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
2390783|NCT03636529|Placebo Comparator|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
2390784|NCT03636516|Active Comparator|jj stent yes|
2390785|NCT03636516|Active Comparator|jj stent no|
2390786|NCT03636503|Experimental|Rituximab +Utomilumab+Avelumab|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~Avelumab is administered intravenously over 1 hour once every 2 weeks"
2390787|NCT03636503|Experimental|Rituximab+Utomilumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Utomilumab is administered intravenously over 1 hour once every 4 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
2390788|NCT03636503|Experimental|Rituximab+Avelumab+PF04518600|"Rituximab is administered intravenously per institutional standards for four weekly treatments for cycle 1 only~Avelumab is administered intravenously over 1 hour once every 2 weeks~PF-04518600 is administered intravenously over 1 hour on day 1 and day 15"
2390789|NCT03636490|Experimental|Psychological Stress|All participants will undergo stress-inducing tasks (psychological stress intervention) using cognitive research tools.
2390790|NCT03636477|Experimental|Ad-RTS-hIL-12 + veledimex in combination with nivolumab|Intratumoral Ad-RTS-hIL-12 and varying doses of oral veledimex (activator ligand) given in combination with nivolumab via infusion.
2390791|NCT03636412|Experimental|Ambulatory Intervention|Patients who score greater than or equal to 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will be enrolled in an ambulatory intervention. Care technicians will ambulate patients three times per day at their level of physical ability. They will also receive physical therapy standard of care.
2390792|NCT03636412|No Intervention|No Ambulator|Patients who score less than 6 on the John's Hopkins Highest Level of Mobility (JH-HLM) scale, up to 72 hours after transfer from the ICU to the regular nursing floor will not be enrolled in the ambulatory intervention. They will receive physical therapy standard of care.
2390793|NCT03636399|Experimental|Standard GIST|Standard Group Interactive Structured Treatment.
2390794|NCT03636399|Other|Waitlist control/Intensive GIST|After a wait list control period of nine months the participants receive Intensive Group Interactive Structured Treatment.
3183747|NCT00716898||2|"A. Patients with unstable angina pectoris/ atypical chest pain, with no evidence of acute myocardial infarction.~B. Treatment with therapeutic dose of low molecular weight heparin. C. No evidence of VTE. D. No major surgery during the last month before investigation. E. No evidence of major infectious disease. F. No history of malignancy. G. Serum creatinine level < 1.5 mg/dl. H. Informed consent"
3183748|NCT00716924|Experimental|1|300-mg loading dose of clopidogrel given ≥ 6 and ≤ 24 hours before PCI
2390797|NCT03636373|Experimental|Etanercept|Subjects will be administered etanercept 50 mg subcutaneously and a placebo intramuscularly
2390798|NCT03636373|Active Comparator|Triamcinolone acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly and a placebo subcutaneously
2390799|NCT03636360|Experimental|LED - Sunlike|LED lighting with spectral pattern similar to that of sunlight
2390800|NCT03636360|Active Comparator|Fluorescent|Fluorescent light at same illuminance (lux) as LED light
2390801|NCT03636360|Placebo Comparator|Dim|"Dim fluorescent light with same spectrum as Fluorescent condition"
2390802|NCT03636360|Active Comparator|LED|Standard LED lighting
2390803|NCT03636347|Placebo Comparator|Placebo oral tablet|
2390804|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 1|MPH966
2390805|NCT03636347|Active Comparator|Alvelestat oral tablet - dose 2|MPH966
2390806|NCT03636334|Experimental|Computer-based decision support system|Computer-based decision support system for BP management, with appropriate training of local PHC doctors.
2390807|NCT03636334|No Intervention|Control|After site randomization, physicians at the control sites will manage their patients with hypertension by usual care.
2390808|NCT03636321|Experimental|intraductal stent|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis with internal biliary stent
2390809|NCT03636321|Active Comparator|stentless|in this group ,patients candidate for living donor liver transplantation duct to duct biliary anastomosis will done without internal biliary
2390810|NCT03636308|Experimental|AS：Nanoparticle albumin-bound paclitaxel，S-1|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle.~S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle."
2390811|NCT03636308|Active Comparator|AG：Nanoparticle albumin-bound paclitaxel，Gemcitabine|"Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8 of each 21 day cycle.~Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21 day cycle."
3143043|NCT00004162|Experimental|Dose group 4 - dose 4 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3183749|NCT00716924|Experimental|2|600-mg loading dose of clopidogrel given ≥ 6 hours and ≤ 24 before PCI.
3183750|NCT00716924|Experimental|3|600-mg loading dose of clopidogrel given immediately (≤ 45 minutes) before PCI.
3183751|NCT00716937|Experimental|1|Excision of the cyst and Karydakis flap
2390816|NCT03636269|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
2390817|NCT03636269|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
3183752|NCT00716937|Experimental|2|Excision of the cyst and laying open
3183753|NCT00716950|Experimental|1|valsartan/amlodipine
2390820|NCT03636243|Other|Group of obese patients with type-2 diabetes|
2390821|NCT03636243|Other|Group of non-diabetic obese patients|
2390822|NCT03636230|Active Comparator|Remote Patient Management|Remote monitoring only
2390823|NCT03636230|Placebo Comparator|Standard of Care|In-clinic visits
2390824|NCT03636217|Experimental|LGI-Milk Breakfast|Low glycemic index and milk content (LGI-Milk) breakfast as a test meal
2390825|NCT03636217|Experimental|LGI-Kefir Breakfast|Low glycemic index and kefir content (LGI-Kefir) breakfast as a test meal
2390826|NCT03636217|Experimental|HGI-Kefir Breakfast|High glycemic index and kefir content (HGI-Kefir) breakfast as a test meal
2390827|NCT03636204|Experimental|AL001|Up to six single ascending doses of AL001
2390828|NCT03636204|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects
2390829|NCT03636191|Experimental|Probiotic|
2390830|NCT03636191|Placebo Comparator|Placebo|
2390831|NCT03636178|Other|1st group|20 patients out of 40 will be enrolled into the study including males and females above 18 years old
3183754|NCT00716950|Active Comparator|2|losartan/amlodpine
3183755|NCT00717002||1|Patients from Group 1 will undergo thoracoscopy as part of their routine clinical management to drain off excess pleural fluid. Even though taking a sample of the tumour tissue present on the pleural/ lining of the lung may not routinely form part of a routine thoracoscopy, it will be obtained for the study and sent to the laboratory for testing.
2390832|NCT03636178|Other|2nd group|20 patients out of 40 will be enrolled in the study including males and females above 18 years old
3143044|NCT00004162|Experimental|Dose group 5 - dose 5 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3183756|NCT00717002||2|Patients from Group 2 should have tumour samples obtained previously for diagnosis, and these will be obtained from the Department of Pathology. If they are undergoing thoracoscopy as part of their routine clinical management, a sample of the tumour tissue present on the pleural/ lining of the lung will also be obtained during the procedure and sent to the laboratory for testing.
2390835|NCT03636152|Active Comparator|Hydroxychloroquine (HCQ) Group|These patients will receive HCQ for 18 months
2390836|NCT03636152|Placebo Comparator|Placebo Group|These patients will receive a matching placebo for 18 months
2390837|NCT03636139|Experimental|Anodal stimulation|transcranial DC stimulation : anodal
2390838|NCT03636139|Sham Comparator|Sham stimulation|transcranial DC stimulation : sham
2390839|NCT03636126|Experimental|VR + TACS|"Complete one chapter of the virtual reality game Land's End while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).~Use the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment"
2390840|NCT03636126|No Intervention|No Intervention for 2 Weeks|For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention.
2390841|NCT03636113||ICU nurses -manual|Standard method of Urine Output monitoring
2390842|NCT03636113||ICU nurses -automated|Device- Clarity RMS Electronic sensor
2390843|NCT03636087|Active Comparator|Conventional|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
2390844|NCT03636087|Experimental|Enhanced sterile protocol|Access cavity preparation Working length determination Root canal instrumentation and chemo-mechanical preparation Root canal obturation Coronal restoration build up Changing gloves before obturation Disinfecting rubber dam The use of new instruments at time of obturation Cone Beam Computed Tomography scanning (CBCT) Radiographic imaging using periapical radiographs
2390845|NCT03636074||Hearth-valve surgery|
2390846|NCT03636074||Hearth bypass surgery|
3183757|NCT00717080|Experimental|Arm 1|IOL surgery with Capsular Tension Ring
3183758|NCT00717080|Placebo Comparator|Arm 2|IOL surgery without Capsular Tension Ring
3183759|NCT00717119||1|Patients with sprain of ankle treated with NSAID
3183760|NCT00717132|Experimental|Individual Behavioral Modification|Individual behavioral weight control treatment; parent and child are treated separately for 15 total sessions.
2390851|NCT03636048|Experimental|Spinal anesthesia group|Spinal anesthesia is used for operation with epidural patient-controlled device for pain control. Bupivacaine Hcl 0.5% Inj. 9-10mg is injected into intrathecal space for anesthesia. 0.2% ropivacaine is used for postoperative pain control with continuous infusion into epidural space.
2390852|NCT03636048|Active Comparator|General anesthesia group|General anesthesia is used for operation with wound patient-controlled device for pain control. propofol (10milligram/ML) 1.5-2 mg/ml is used as bolus intravascular injection for induction of anesthesia. 0.5% ropivacaine is used for postoperative pain control with continous infusion through wound catheter.
2390853|NCT03636035|Experimental|Tregocel® supplementation|Tregocel® coated tablets (2/day) orally for 36 weeks
2390854|NCT03636022|Experimental|VR System|Participants will then be assigned one week of daily exposure homework. Patients randomized to the intervention condition will take home the VR system for homework.
2390855|NCT03636022|Experimental|Control Condition|Participants will then be assigned one week of daily exposure homework. Participants assigned to control will be instructed to complete imaginal exposures.
2390856|NCT03636009|Experimental|Concurrent traction|Concurrent traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
2390857|NCT03636009|Active Comparator|Sequential traction|Sequential traction and neuromobilization technique at each scheduled session Active exercise program (4-5 exercises) at each session Manual therapy to cervical and thoracic spine at each session
2390858|NCT03635996|Experimental|Etripamil NS 70 mg|The dose of etripamil to be evaluated in NODE-302 is 70 mg.
2390861|NCT03635970|Placebo Comparator|conventional treatment|receive the best conventional therapy
2390862|NCT03635970|Active Comparator|experimental treatment|The best medical treatment possible plus celular therapy
2390864|NCT03635944||Group A|Infants born in Lyon (France)
2390865|NCT03635944||Group B|Infants born in Stockholm (Sweden)
2390866|NCT03635931|Active Comparator|Concentrated Growth Factor|plaque control, scaling and root planing if required, surgical application of CGF
2390867|NCT03635931|No Intervention|Control Group|plaque control, scaling and root planing if required
2390868|NCT03635918|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a benchmark HSAT monitor.
2390869|NCT03635905|Experimental|Gabapentin|Gabapentin (Neurontin)- 600 mg oral administered pre-operatively at the time of cervical preparation
2390870|NCT03635905|Placebo Comparator|Placebo|
2391117|NCT03634371|Active Comparator|Reference formulation of Levothyroxine|Eutirox 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
2390871|NCT03635892|Experimental|Cohort 1: Unclassified, papillary, and HL RCC|Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.
2390872|NCT03635892|Experimental|Cohort 2: Chromophobe RCC|Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.
2390873|NCT03635892|Experimental|Cohort 3: Unclassified, papillary, and HL RCC|Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes
2390874|NCT03635892|Experimental|Cohort 4: Unclassified, papillary, and HL RCC|Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients
2390875|NCT03635879|Active Comparator|MCTprocal medical food|Vitaflo MCTprocal, single dose (20 g MCT)
2390876|NCT03635879|Active Comparator|Milk/tricaprilin oil blend|Lactose-free milk and tricaprilin oil, blended,single dose (20 g tricaprilin)
2390877|NCT03635879|Active Comparator|AC-1207|AC-1207 liquid, single dose (20 g tricaprilin)
2390878|NCT03635879|Active Comparator|AC-1205|AC-1205 liquid, single dose (20 g tricaprilin)
2390879|NCT03635879|Active Comparator|AC-1206|AC-1206 liquid, single dose (20 g tricaprilin)
2390880|NCT03635879|Experimental|AC-1202|AC-1206 liquid, single dose (20 g tricaprilin)
2390881|NCT03635866|Experimental|prior negative MRFTB of PI-RADS 4 and 5 lesions|Diagnosed withing 12 months of initial diagnostic cancer biopsy
2390882|NCT03635853|Experimental|patients with palmar arsenical keratosis|patients are given an ointment containing extract from cock's comb twice daily for three months
2390883|NCT03635840|No Intervention|Control|Group of patients not receiving IABP
2390884|NCT03635840|Experimental|Intra Aortic Balloon Pump|Group of patients receiving Intra Aortic Balloon Pump prior to revascularization
2390885|NCT03635827|Active Comparator|NBTX-001|
2390886|NCT03635827|Placebo Comparator|Placebo|
2390887|NCT03635814|Experimental|YD312 drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
2390888|NCT03635814|Placebo Comparator|YD312 placebo drug treatment|From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.
2390889|NCT03635801||MyoVista 12 Lead (ECG) NSTEMI|"Patients enrolling in this clinical investigation will undergo a standard 12-lead ECG using the MyoVista 12-lead hs ECG device. An ECG is a quick, safe and painless test. No electricity is put into the body while it's carried out.~There may be some slight discomfort when the electrodes are removed from the skin - similar to removing a sticking plaster - and some people may develop a mild rash where the electrodes were attached.~An ECG is performed under controlled conditions."
3143045|NCT00004162|Experimental|Dose group 6 - dose 6 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3183761|NCT00717132|Active Comparator|Family-based Behavioral Modification|Family-based behavioral weight control treatment; parent and child are treated together for 15 total sessions.
3183762|NCT00717145|Experimental|1|One risedronate 20 mg DR tablet taken following an overnight fast, followed by a 4-hour fast.
3183763|NCT00717145|Experimental|2|One risedronate 20 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
3183764|NCT00717145|Experimental|3|One risedronate 35 mg DR tablet taken following an overnight fast, within 5 minutes after ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
3183765|NCT00717145|Experimental|4|One risedronate 35 mg IR tablet taken following an overnight fast, 30 minutes before ingesting a high-fat meal; no additional food will be allowed for at least 4 hours post-dose.
2390896|NCT03635762|Experimental|Be In Charge|behavioral + nutrition education program
2390897|NCT03635749|Active Comparator|DAPT + immediate high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); active atorvastatin calcium with high dosage in the early phase.
2390898|NCT03635749|Other|DAPT + delayed high-intensity statin|This group will receive active clopidogrel and active aspirin (Dual antiplatelet therapy, DAPT); atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the ealy phase.
2390899|NCT03635749|Other|Aspirin+immediate high-intensity statin|This group will receive active aspirin and clopidogrel placebo; active atorvastatin calcium with high dosage in the early phase.
2390900|NCT03635749|Placebo Comparator|Aspirin+delayed high-intensity statin|This group will receive active aspirin and clopidogrel placebo; atorvastatin calcium placebo and active atorvastatin calcium with moderate dosage in the early phase.
2390901|NCT03635736||Severe brain injury|ICU-patients suspect to severe brain injury, measurement with multiple-spectral-sonography as acustocerebrography (ACG
2390902|NCT03635697|Experimental|Mindfulness Intervention Group|Participants in this group will listen to a short mindfulness audio clip during 6 of their NST appointments.
2390903|NCT03635697|No Intervention|Control Group|Participants in this group will have the regular standard of care for their NST appointments.
2390904|NCT03635684|Experimental|SC Acetaminophen|Palliative Care or Geriatric Patients who receive subcutaneous Acetaminophen for pain or fever relief
2390905|NCT03635671||Intensified blood glucose control|Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy
2390906|NCT03635671||Nephropathy|Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure
2390907|NCT03635658|Active Comparator|titanium mesh|using non resorbable titanium mesh to fix and cover the onlay bone graft mixture to the atrophic maxillary ridge.
3183766|NCT00717158|No Intervention|I|Usual medical care. They received written healthy lifestyle information
2390908|NCT03635658|Experimental|collagen membrane(Sausage technique)|using resorbable collagen membrane with the sausage technique to fix the onlay bone graft mixture to the resorbed atrophic maxillary ridge
2390909|NCT03635645|Experimental|Retinal stimulation|Alternative stimulus patterns will be tested (vs. baseline). The intervention is the alternative stimulus pattern. The intervention will be tested only in the clinic vs. baseline. The subject will go home with baseline settings. The two alternative stimulus patterns to be tested are asymmetric waveforms and bipolar stimulus.
3143046|NCT00004162|Experimental|Dose group 7 - dose 7 of Doxorubicin HCL Liposome|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
3143047|NCT00004162|Experimental|MTD group|Patients are stratified by risk group (good vs poor). Patients receive doxorubicin HCl liposome IV, vincristine IV, and methotrexate intrathecally on day 1, followed by oral prednisone on days 1-5. Sargramostim (GM-CSF) is administered subcutaneously on days 5-14 until blood counts recover. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter
2390912|NCT03635593|Active Comparator|CBD|10mg capsules Cannabidiol (CBD)
2390913|NCT03635593|Active Comparator|CBD+THC|10mg capsules Cannabidiol (CBD) +THC tetrahydrocannabinol (CBD 5mg + (THC)
2390914|NCT03635593|Placebo Comparator|Placebo|10mg capsules placebo
2390915|NCT03635580|Experimental|rhGH/Jintropin AQ|Jintropin AQ, injection, 30IU/10mg/3ml/cartridge, 0.05mg /kg/d in phase 1 and 0.05-0.07mg/kg/d in phase 2.
2390916|NCT03635567|Experimental|Pembrolizumab+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an intravenous (IV) infusion of pembrolizumab 200 mg PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin Area Under the Curve (AUC) 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
2390917|NCT03635567|Placebo Comparator|Placebo+Chemotherapy|On Day 1 of each 21-day cycle, participants receive an IV infusion of placebo (Normal Saline or Dextrose solution) PLUS Investigator choice of chemotherapy (paclitaxel 175 mg/m^2 PLUS cisplatin 50 mg/m^2 WITH or WITHOUT bevacizumab 15 mg/kg OR paclitaxel 175 mg/m^2 PLUS carboplatin AUC 5, WITH or WITHOUT bevacizumab 15 mg/kg). All treatments are administered until disease progression or toxicity, for up to 35 cycles (up to approximately 2 years).
2390918|NCT03635541||observational group of NAFLD|Liver biopsy proved NAFLD patients, observational study. Oral advice on lifestyle would be given at each visit.
2390919|NCT03635528|Experimental|Test 1\Test 2\Control 2\Test 3\Control 1\Test 4\Test 5|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390920|NCT03635528|Experimental|Test 2\Test 3\Test 1\Test 4\Control 2\Test 5\Control 1|Subjects between ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390921|NCT03635528|Experimental|Test 3\Test 4\Test 2\Test 5\Test 1\Control 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390922|NCT03635528|Experimental|Test 4\Test 5\Test 3\Control 1\Test 2\Control 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390923|NCT03635528|Experimental|Test 5\Control 1\Test 4\Control 2\Test 3\Test 1\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390924|NCT03635528|Experimental|Control 1\Control 2\Test 5\Test 1\Test 4\Test 2\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390925|NCT03635528|Experimental|Control 2\Test 1\Control 1\Test 2\Test 5\Test 3\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390926|NCT03635528|Experimental|Test 5\Test 4\Control 1\Test 3\Control 2\Test 2\Test 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390927|NCT03635528|Experimental|Control 1\Test 5\Control 2\Test 4\Test 1\Test 3\Test 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390928|NCT03635528|Experimental|Control 2\Control 1\Test 1\Test 5\Test 2\Test 4\Test 3|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390929|NCT03635528|Experimental|Test 1\Control 2\Test 2\Control 1\Test 3\Test 5\Test 4|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390930|NCT03635528|Experimental|Test 2\Test 1\Test 3\Control 2\Test 4\Control 1\Test 5|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390931|NCT03635528|Experimental|Test 3\Test 2\Test 4\Test 1\Test 5\Control 2\Control 1|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
2390932|NCT03635528|Experimental|Test 4\Test 3\Test 5\Test 2\Control 1\Test 1\Control 2|Subjects between the ages of 7 and 25 years will be randomly assigned to one of fourteen unique sequences of the seven lens types.
3143048|NCT00004163|Experimental|Trastuzumab|"Trastuzumab is administered intravenously weekly~CAT or MRI scans will be performed every 2 cycles"
2391178|NCT03633890|Placebo Comparator|DaZhu Rhodiola Rosea Simulation Capsule|
3143049|NCT00004180|Experimental|Well-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3143050|NCT00004180|Experimental|De-differentiated liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
2390935|NCT03635502||Stroke Group|
2390936|NCT03635502||Healthy Group|
3143051|NCT00004180|Experimental|Myxoid/ round-cell liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
3143052|NCT00004180|Experimental|Pleomorphic liposarcoma|Participants in this arm receive 4 mg of study drug (rosiglitazone maleate) twice daily by mouth.
2390939|NCT03635463|Experimental|twin block appliance|this group will receive conventional twin block appliance and followed up every month for 9 months.
2390940|NCT03635463|Experimental|modified twin block appliance group|modified twin block appliance group , this group will receive the modified appliance and followed up every month for 9 months
2390941|NCT03635450|Experimental|First cohort of 3 subjects enrolled|The first cohort of three patients will receive a single dose in the first 48 postnatal hours.
2390942|NCT03635450|Experimental|Second cohort of 3 subjects enrolled|If there are no safety concerns after the first cohort of 3 subjects are infused then the second cohort of three patients will receive two doses, with the first dose given in the first 48 postnatal hours and the second dose given approximately two months after the first dose.
2390943|NCT03635437|Experimental|Low dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 200 mg daily for 6 months
2390944|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA)|Oral GABA treatment 600 mg daily for 6 months
2390945|NCT03635437|Experimental|High dose gamma-aminobutyric acid (GABA) + Alprazolam|Oral Alprazolam treatment 0.5 mg daily combined with oral GABA treatment 600 mg daily for 3 months. Alprazolam treatment thereafter ended, and study subjects will continue with oral GABA treatment 600 mg daily only for another 3 months.
3143053|NCT00004183|Experimental|capecitabine|Patients receive oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 2 months for 1 year, every 3 months for 2 years and then annually thereafter.
2390947|NCT03635411|Experimental|Basis|Nicotinamide riboside 500 mg and pterostilbene 100 mg given twice daily in divided doses for 90 days
2390948|NCT03635411|Placebo Comparator|Placebo|Placebo given twice daily for 90 days
2390949|NCT03635398|Experimental|Intranasal Midazolam by SipNose device|
2390950|NCT03635398|Active Comparator|Intranasal Midazolam by MAD (Mucosal Atomization Device)|
2390951|NCT03635398|Active Comparator|oral administration of midazolam|
2390952|NCT03635385|Active Comparator|Plasma exchange (PE) technic patient group|
2390953|NCT03635385|Active Comparator|Immunoadsorption technic patient group|
2390954|NCT03635372|Experimental|Alginate|10 cc of Alginate peroral
2390955|NCT03635372|Experimental|Sucralfate|10 cc of Sucralfate peroral
2390956|NCT03635372|Experimental|Hydrotalcite|10 cc of Hydrotalcite peroral
2390957|NCT03635359||positive for fetal aneuploidy|
2390958|NCT03635359||negative for fetal aneuploidy|
2390959|NCT03635333|Experimental|Low nicotine, tobacco|6 mg nicotine combined with tobacco flavored e-juice
2390960|NCT03635333|Experimental|Low nicotine, menthol|6 mg nicotine combined with menthol flavored e-juice
2390961|NCT03635333|Experimental|Low nicotine, strawberry|6 mg nicotine combined with strawberry flavored e-juice
2390962|NCT03635333|Experimental|High nicotine, tobacco|18 mg nicotine combined with tobacco flavored e-juice
2390963|NCT03635333|Experimental|High nicotine, menthol|18 mg nicotine combined with menthol flavored e-juice
2390964|NCT03635333|Experimental|Hign Nicotine, strawberry|18 mg nicotine combined with strawberry flavored e-juice
3183767|NCT00717158|Active Comparator|2|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
3183768|NCT00717171|Placebo Comparator|1|
2390967|NCT03635307||Operated patients with volume expansion|
2390968|NCT03635294|Experimental|Blood sample|Blood sample for analyses
2390969|NCT03635281|Experimental|PEEP group|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached)
2390970|NCT03635281|Experimental|RM+PEEP group|"Recruitment maneuvers will be performed as follow Recruitment maneuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
2390971|NCT03635242|Active Comparator|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
2391081|NCT03634514|Experimental|Application of Biomatrop|A single dose of Recombinant Human Somatropin - Biomatrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
3143054|NCT00004184|Experimental|Arm I|Patients receive human anti-idiotypic monoclonal antibody vaccine (4B5) in sargramostim (GM-CSF) subcutaneously (SQ) on days 0, 14, 28, and 42. Patients receive GM-CSF alone SQ at vaccination site on days 2, 3, and 4 following immunization.
3143055|NCT00004184|Experimental|Arm II|Patients receive 4B5 plus alum SQ on days 0, 14, 28, and 42. Cohorts of 5 patients receive treatment every 2 weeks for up to 4 courses in the absence of unacceptable toxicity.
3183769|NCT00717171|Experimental|2|
3183770|NCT00717210|Active Comparator|A|Conventional Radiotherapy
3183771|NCT00717210|Experimental|B1/2|1:1 randomization between temozolomide and procarbazine/lomustine/vincristine (PCV)
3183772|NCT00717223||Parents with children with diabetes|parents who have children 18 or younger with diabetes
3183773|NCT00717262|Experimental|1|HQK-1001
3183774|NCT00717262|Placebo Comparator|2|
2390972|NCT03635242|Experimental|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
3143056|NCT00004188|Experimental|Arm I (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
3143057|NCT00004188|Experimental|Arm II (unpurged PBSC collection)|Induction-3 wks (cyclophosphamide day 0&1, doxorubicin hydrochloride & vincristine sulfate day 0-2 & filgrastim(G-CSF) day 3 crs 1,2,4 & 6.) Crs 3 & 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Immunocytology + PBSC undergo purged autologous bone marrow collection or repeat purged or unpurged PBSC collection. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin & etoposide day -7 to -4. Unpurged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
3143058|NCT00004189|Experimental|Arm I|See detailed description.
2390976|NCT03635164|Experimental|Dose Escalation and Expansion|"Part 1 of this trial will use a traditional 3+3 design will be used for this trial (i.e. cohort sizes of 3 patients for the first and second cohort at each dose level). Dose escalation will occur as long as there are minimal dose limiting toxicities.The expectation is that 9 patients will be enrolled to the trial during part 1.This is based on the expectation that all dose levels are safe (i.e. patients will not experience DLTs at all dose levels). The range of patients needed will be 6-12 patients.~Part 2 of this trial will be an expansion cohort. A total of 8 additional patients will be enrolled at the dose level determined to be the MTD in part 1 of the study. These 8 patients will be used to confirm that the MTD is a safe combination, as well as provide additional patients to investigate the efficacy for the treatment combination.~Note: Standard of care surgery will follow 3-6 weeks after medication and radiation treatment."
3183775|NCT00717301||Head Trauma|Patients presenting to any of the AHCC/ERNES Emergency Departments with head trauma.
3183776|NCT00717301||Control subjects|Patients presenting to the Univ of Rochester Medical Center/Strong Memorial Hospital Outpatient Laboratory for routine blood draw.
2390979|NCT03635138|Experimental|Adhesives Cu/Zn nanoparticles doped|Adhesive dopped with Zn Oxide + Cu nanoparticles in a ( 5% / 0.2% concentration )
2390980|NCT03635138|Active Comparator|Adhesive control|Adhesive conventional
2390981|NCT03635125|No Intervention|Background treatment phase|A 12- week Amlodipine 10 mg background treatment phase
2390982|NCT03635125|Active Comparator|Low Dose Treatment Phase-Nebivolol I|4-week low dose Nebivolol10 mg/Metoprolol 50 mg treatment phase
2390983|NCT03635125|Active Comparator|High dose treatment Phase-Nebivolol II|4-week High dose Nebivolol 20 mg/Metoprolol 100mg treatment phase
2390984|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
3183777|NCT00717340|Experimental|tivozanib (AV-951) + paclitaxel|
3183778|NCT00717353||1|Lung cancer
3183779|NCT00717379|Active Comparator|1|steroid regimen 1
2390988|NCT03635099|Experimental|Dose group A|
2390989|NCT03635099|Experimental|Dose group B|
2390990|NCT03635099|Experimental|Dose group C|
2390991|NCT03635099|Experimental|Dose group D|
2390992|NCT03635099|Placebo Comparator|Placebo|
2390993|NCT03635099|Experimental|Dose group V|
2390994|NCT03635099|Experimental|Dose group U|
2390995|NCT03635099|Placebo Comparator|Placebo W|
3183780|NCT00717379|Experimental|2|steroid regimen 2
3183781|NCT00717392||Hippotherapy_ADHD|10 children with ADHD who receive hippotherapy
3183782|NCT00717392||Hippotherapy_ASD|10 children with ASD who receive hippotherapy
3183783|NCT00717392||Control_ADHD|10 children with ADHD who DO NOT receive hippotherapy
3183784|NCT00717392||Control_ASD|10 children with ASD who DO NOT receive hippotherapy
2391001|NCT03635073|Experimental|TAK-935|Treatment: 0 to 2 Weeks Dose Optimization Period followed by 103 weeks Maintenance Period.
2391002|NCT03635060|Active Comparator|Dorsal Bridge Plating|The intervention is surgery with dorsal distraction plating with or without any additional fragment specific fixation.
2391003|NCT03635060|Active Comparator|Volar Locking Plating|The intervention is surgery with open reduction and internal fixation with non-spanning fixation.
2391004|NCT03635047|Active Comparator|AL002|AL002 by intravenous (IV) infusion
2391005|NCT03635047|Placebo Comparator|Saline Solution|placebo by intravenous (IV) infusion
2391006|NCT03635034|Experimental|No Bladder catheter|"Subjects will not have bladder catheter inserted during their ablation procedure.~Intervention: No catheter"
2391007|NCT03635034|Active Comparator|Bladder catheter inserted|"Bladder catheter will be inserted prior to starting ablation procedure after the subject is under general anesthesia.~Intervention: bladder catheter inserted"
2391008|NCT03635021|Experimental|Sequence 1|FOLFOX regimen panitumumab FOLFIRI regimen bevacizumab
2391009|NCT03635021|Experimental|Sequence 2|FOLFOX regimen bevacizumab FOLFIRI regimen panitumumab
3183785|NCT00717431|Experimental|Hippocampal Stimulation|Hippocampal Stimulation (Stimulator is turned ON) Surgical Intervention
2392657|NCT03623529|Experimental|Active Comparator: LJPC-501|LJPC-501 Angiotensin II Solution for infusion
2391010|NCT03635008|Experimental|Anodal tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA."
2391011|NCT03635008|Placebo Comparator|sham tDCS|"This group will receive the 25 mins of the tDCS (Yrain, Korea) over the contralesional premotor area simultaneously with 25 mins of the robotic arm training using Armeo Power (Hocoma, Switzerland), per day. Additional 30 mins of occupational therapy focusing on the arm motor recovery will be provided per day. These interventions will be provided for 10 weekdays. Other conventional rehabilitation (e.g. gait training, speech therapy) will be permitted.~Regard to the sham tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be started but the intensity will decrease and stop in 30 seconds."
2391012|NCT03634995|Experimental|Single Dose|Ascending single doses of BMS-986256
2391013|NCT03634995|Experimental|Multiple Dose|Ascending multiple doses of BMS-986256
2391014|NCT03634995|Experimental|Sequential Dose|Sequential multiple doses of BMS-986256
2391015|NCT03634982|Experimental|RMC-4630|RMC-4630 for oral administration
2391016|NCT03634969|Experimental|Normal Renal Function|
2391017|NCT03634969|Experimental|Mild Renal Impairment|
2391018|NCT03634969|Experimental|Moderate Renal Impairment|
2391019|NCT03634969|Experimental|Severe Renal Impairment|
2391020|NCT03634969|Experimental|End-Stage Renal Disease (ESRD)|ESRD participants and are on chronic hemodialysis
2391021|NCT03634956|Experimental|Group I.IONM in thyroid surgery|Group I.IONM in thyroid surgery.Once the vagus has been detected,nerve conduction data will be detected with IONM. If the muscle relaxant effect is not detected, it will be detected with TOF device.
2391022|NCT03634943||Patients with Nutritional Support|Patients expected to be admitted >72h at the Intensive Care Unit with the need of artificial Nutritional Support
2391023|NCT03634930||EBF exclusive breast fed children at 16 weeks|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv breastfed children at the age of 8 and 16 weeks, and at 1 and 2 Years
2391024|NCT03634930||EFF exclusive formula fed children at 16 week|observation of 24 hours drinking volume, weight, length, body composition, biomarker and satiety cues, as well as eating- and feeding behaviour and nutritional status of exklusiv formula fed children at the age of 8 and 16 weeks, and at 1 and 2 Years
2391025|NCT03634917|Active Comparator|Acamprosate|"1 capsule with Acamprosate calcium~oral use~3 times / day (morning, noon, evening)~666 mg per capsule~14 - 19 days"
2391026|NCT03634917|Active Comparator|Calcium Carbonate|"1 capsule with Calcium Carbonate~oral use~3 times / day (morning, noon, evening)~1500 mg Calcium Carbonate (= 600 mg Calcium 2+)~14 - 19 days"
2391027|NCT03634917|Placebo Comparator|Placebo|"1 capsule placebo,~oral use~3 times / day (morning, noon, evening)~14 - 19 days"
2391028|NCT03634904|Experimental|Drug Blood sampling|"Drug Blood sampling~Pharmacokinetic study measuring total and free ceftazidime concentrations"
2391029|NCT03634878|Experimental|Perineal ultrasound to visualize the strips and their position|
2391030|NCT03634852|Active Comparator|Topical|Moxifloxacin hydrochloride 0.5% eye drops and dexamethasone 0.1% eye drops were prescribed four times a day for 1 month postoperatively.
2391031|NCT03634852|Active Comparator|Intracameral - Subconjunctival|Intracameral Moxifloxacin 0.1% with Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml had been administered at the conclusion of the surgery
2391032|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet non-menthol|Nicotine 0 mg combined with sweet non-menthol flavor
2391033|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet non-menthol|Nicotine 3 mg combined with sweet non-menthol flavor
2391034|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet non-menthol|Nicotine 12 mg combined with sweet non-menthol flavor
2391035|NCT03634839|Placebo Comparator|Nicotine 0 mg, Sweet menthol|Nicotine 0 mg combined with sweet menthol flavor
2391036|NCT03634839|Active Comparator|Nicotine 3 mg, Sweet menthol|Nicotine 3 mg combined with sweet menthol flavor
2391037|NCT03634839|Active Comparator|Nicotine 12 mg, Sweet menthol|Nicotine 12 mg combined with sweet menthol flavor
2391038|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco non-menthol|Nicotine 0 mg combined with tobacco non-menthol flavor
2391039|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco non-menthol|Nicotine 3 mg combined with tobacco non-menthol flavor
2391040|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco non-menthol|Nicotine 12 mg combined with tobacco non-menthol flavor
2391041|NCT03634839|Placebo Comparator|Nicotine 0 mg, Tobacco menthol|Nicotine 0 mg with tobacco menthol flavor
2391042|NCT03634839|Active Comparator|Nicotine 3 mg, Tobacco menthol|Nicotine 3 mg combined with tobacco menthol flavor
2391043|NCT03634839|Active Comparator|Nicotine 12 mg, Tobacco menthol|Nicotine 12 mg combined with tobacco menthol flavor
3183786|NCT00717431|Sham Comparator|Hippocampal Implantation|Hippocampal Implantation (Stimulator is turned OFF)Surgical Intervention
3183787|NCT00717444|Experimental|1|contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
2391047|NCT03634787||Acute pancreatitis|First time acute pancreatitis. No later than 2 days since the clinical symptoms started.
3183788|NCT00717444|Experimental|2|contingency management for abstinence plus 12-step facilitation therapy
3183789|NCT00717457|Active Comparator|exenatide|
3183790|NCT00717457|Experimental|taspoglutide 10mg|
3183791|NCT00717457|Experimental|taspoglutide 10mg/20mg|
3183792|NCT00717470|Active Comparator|Prograf + MMF + Steroids|oral
3183793|NCT00717470|Active Comparator|Advagraf (dose 1) + MMF + steroids|oral
3183794|NCT00717470|Active Comparator|Advagraf (dose 2) + MMF + steroids|oral
2391052|NCT03634761|Experimental|Experimental group|Preschools/Children in this group will receive EIBI supervised by an external expert from the habilitation center on a regular basis. In addition, preschool staff in this group are provided with in-service training consisting of a one full day (onset of project) and a half day (middle of project) on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with Children with autism in preschool settings. Preschool staff are also provided with monthly on-site coaching in implementing evidence based practices, goal setting and working with overall intervention setting, through coaching from the habilitation center.
2391053|NCT03634761|Active Comparator|Comparison group|"Preschools/Children are in this group receive treatment as usual, which is EIBI supervised by an external expert from the habilitation center at the habilitation center directed toward the paraprofessional. At the offset of the project preschool staff are offered to participate in a one-day learning course/workshop on autism, applied behavior analysis, evidence-based practices, engagement, participation, inclusion and overall quality factors when working with children with autism in preschool settings."
2391054|NCT03634735|Active Comparator|Thiamin|Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
2391055|NCT03634735|Placebo Comparator|Placebo|Placebo: same number of tablets as in the active comparator arm, in 4 weeks
2391056|NCT03634722|Experimental|The intervention group|the transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
2391057|NCT03634722|No Intervention|The observational group|routine nursing
2391058|NCT03634709|Experimental|Memory Flexibility Training (MemFlex)|The MemFlex programme has been adapted from the initial format addressing depression-related memory distortions to facilitate completion with individuals experiencing posttraumatic stress. The workbook and associated materials have also been translated from English to Farsi. The programme consists of one researcher-facilitated session and eight self-guided workbook-based sessions that train memory retrieval skills and are completed over a one month period.
2391059|NCT03634709|No Intervention|Waitlist control|After randomisation, the waitlist control group will be informed that they have been placed on a waiting list for the intervention. The participants will complete the baseline assessment and receive no further contact from the researcher until the post assessment one month later, followed by the follow-up assessment three months later. After the three month assessment, wait listed participants will receive the intervention. No further assessments will be completed.
3183795|NCT00717470|Active Comparator|Advagraf + MMF + Basilixmab + steroids|oral
3183796|NCT00717483||Type 1 diabetes|children with type 1 diabetes
2391062|NCT03634683|Experimental|LioCyx|"This is a single-arm study.~Patients will receive escalating doses of LioCyx on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle."
2391063|NCT03634657|Active Comparator|Plain X-ray protection shield|
2391064|NCT03634657|Experimental|Protection shield & X-ray protective strips|
2391065|NCT03634657|Experimental|Protection shield & protective strips & patient cut-outs|
2391066|NCT03634644|Active Comparator|Omega-3 fatty acid capsule|1g per capsule(EPA400mg，DHA320mg)
2391067|NCT03634644|Placebo Comparator|Placebo capsule|The placebo capsule has same appearance and packing with the Omega-3 fatty acid capsule
2391068|NCT03634618|Experimental|Mirror Therapy|Mirror Therapy program for 2 weeks and convantional physiotherapy for 4 weeks. Exercises Frequency: 5 days/week; 2 days with the physiotherapist, other days as home program; 2 weeks in total. Exercises Duration: 20 minutes. Exercises Repetation: 20 repetation for each exercise.
2391069|NCT03634618|Experimental|Convantional Physiotherapy|Convantional physiotherapy for 6 weeks. Exercises Frequency: 3 times a day, 4 weeks in total. Exercises Duration: 15-20 minutes. Exercises Repetation: 10 repetation for each exercise.
2391070|NCT03634605|Experimental|Case Group|Chemical pleurodesis for the this group was done using 2 grams of tetracycline 3% ointment (Aerotex®, Sina Daru, Tehran, Iran), 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
2391071|NCT03634605|Placebo Comparator|Control Group|Chemical pleurodesis for this group was done using 5 milliliter of lidocaine 2% and 50 milliliter normal saline that was injected through embedded thoracostomy tube
2391073|NCT03634566|Active Comparator|NAC group|Group NC received NAC 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
2391074|NCT03634566|Placebo Comparator|Control group|Group C (Control group) will receive ringer acetate continuous infusion at same rate for 2 days.
2391075|NCT03634553|Experimental|Intervention|Training with e-health product The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
2391076|NCT03634553|Active Comparator|Control|usual care, i.e. participates in regular training regime at the physiotherapy department
2391077|NCT03634540|Experimental|Belzutifan + Cabozantinib: Treatment Naïve (Cohort 1)|Naïve participants will receive 120 mg belzutifan and 60 mg cabozantinib orally once daily (QD) at the same time.
2391078|NCT03634540|Experimental|Belzutifan + Cabozantinib: Prior Immunotherapy (Cohort 2)|Participants who have received prior immunotherapy will receive 120 mg belzutifan and 60 mg cabozantinib orally QD at the same time.
2391079|NCT03634527|Experimental|Auricular Point Acupressure|Auricular points related to Chemotherapy-induced peripheral neuropathy (CINP) will be used for the intervention.
2391080|NCT03634527|Sham Comparator|Control Auricular Point Acupressure|Auricular points not related to CINP will be used for the intervention.
2391116|NCT03634371|Experimental|Test Formulation of Levothyroxine|Levothyroxine sodium tablets 150 mcg Single dose of 600 mcg administered in dosing period 1 or 2
2391082|NCT03634514|Active Comparator|Application of Hormotrop|A single dose of Recombinant Human Somatropin - Hormotrop is administered. The pain intensity is evaluated using visual analogue scale (0-10cm) and record the incidence of adverse events.
2391083|NCT03634501|Experimental|NK cells|Activated NK from peripheral blood and/or umbilical cord blood（UCB）
2391087|NCT03634475|Experimental|PP-001|Single intravitreal injection of 3 up to 4 doses of PP-001
2391088|NCT03634462|Experimental|Patients with Lipedema|Females with lipedema who meet the inclusion and exclusion criteria for lipedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
2391089|NCT03634462|Experimental|Patients with secondary leg lymphedema|Patients with secondary leg lymphedema following cancer therapies will be limited to the female gender since the comparison group of patients have lipedema which is a condition predominantly effecting females. These patient subjects will consist of those who meet the inclusion and exclusion criteria for secondary leg lymphedema and this study requirements. The intervention in this arm is a course of CDT with graded negative pressure.
2391090|NCT03634449|Experimental|i-gel|After anesthetic durg given, i-gel, a supraglottic airway devices with a gastric suction channel, will be inserted into the patients' airway.
2391091|NCT03634449|Active Comparator|endotracheal tube|After anesthetic durg given, the endotracheal tube, traditional use for protect airway during the laparoscopic surgery, will be inserted into the patients' airway.
2391092|NCT03634436|Experimental|Cohort 1|A single subcutaneous injection of SHR-1209 dose 1 versus placebo
2391093|NCT03634436|Experimental|Cohort 2|A single subcutaneous injection of SHR-1209 dose 2 versus placebo
2391094|NCT03634436|Experimental|Cohort 3|A single subcutaneous injection of SHR-1209 dose 3 versus placebo
2391095|NCT03634436|Experimental|Cohort 4|A single subcutaneous injection of SHR-1209 dose 4 versus placebo
2391096|NCT03634423|Experimental|Sweet Spot: Flexible high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 490 points if they make a gym visit at any other time. 7000 points convert to $25
2391097|NCT03634423|Experimental|Sweet Spot: Flexible low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 290 points if they make a gym visit at any other time. 7000 points convert to $25
2391098|NCT03634423|Experimental|Sweet Spot: Rigid high incentive condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $25
2391099|NCT03634423|Experimental|Sweet Spot: Rigid low incentive condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $25
2391100|NCT03634423|Experimental|FOTW: High incentive control condition|Participants will receive 750 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. 7000 points convert to $5
2391101|NCT03634423|Experimental|FOTW: Low incentive control condition|Participants will receive 450 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. 7000 points convert to $5
2391102|NCT03634423|Experimental|FOTW: High incentive treatment condition|Participants will receive 500 points if they make a gym visit within a pre-specified window of time and 250 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 750 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
2391103|NCT03634423|Experimental|FOTW: Low incentive treatment condition|Participants will receive 300 points if they make a gym visit within a pre-specified window of time and 150 points if they make a gym visit at any other time. Additionally, if a participant misses a scheduled gym visit, they will receive 450 points the next time they visit the gym within the pre-specified window. 7000 points convert to $5
2391104|NCT03634423|Experimental|Think Twice: Control condition|Participants get 300 points per gym visit. 7000 points convert to $5
2391105|NCT03634423|Experimental|Think Twice: Treatment condition|Participants get 300 points per gym visit and are taught about the planning fallacy. 7000 points convert to $5
2391106|NCT03634423|Experimental|WDR: Control condition|Participants get 300 points per gym visit and are allowed to vary their gym schedules in different days. 7000 points convert to $5
2391107|NCT03634423|Experimental|WDR: Treatment condition|Participants get 300 points per gym visit. Participants are required to select a single exercise time for the weekdays (Monday - Friday) and a single exercise time for the weekends (Saturday - Sunday). 7000 points convert to $5
2391108|NCT03634410||Employed|people aged +50 and currently employed
2391109|NCT03634410||Unemployed|people aged +50 and currently unemployed
2391110|NCT03634410||Early retirement|people aged +50 and currently on early retirement
2391111|NCT03634410||Disability pension|people aged +50 and currently on disability pension
2391114|NCT03634384||Derivation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as derivation cohort."
2391115|NCT03634384||Validation cohort|"We include eligible patients presenting with chest pain suggestive of myocardial infarction to the emergency department (see eligibility).~For the primary study patients will be divided into two groups: 500 patients will serve as validation cohort."
2392658|NCT03623529|Placebo Comparator|Placebo Comparator: Placebo|0.9% sodium chloride solution
2391118|NCT03634358|Active Comparator|Bipolar scissors group|Group of male infants undergoing circumcision using bipolar scissors to separate the foreskin
2391119|NCT03634358|Active Comparator|Classic scalpel group|Group of male infants undergoing circumcision using classic scalpel to separate the foreskin, and sutures to control bleeding
2391120|NCT03634345|Experimental|PF-04965842|investigational drug
2391121|NCT03634332|Experimental|PEGPH20 plus Pembrolizumab|All patients will receive treatment with PEGPH20 3 micrograms/kg IV weekly x 3, and pembrolizumab 200 mg IV every 3 weeks, in 3-week cycles.
2391125|NCT03634293|Placebo Comparator|control group|The group will receive 2 ml' saline subcutaneous injection upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock
2391126|NCT03634293|Active Comparator|treatment group|The group will receive a 2 ml' subcutaneous injection of the study drug Alirocumab 150 mg', upon randomization when admitted to the ICU with the diagnosis of sepsis or septic shock.
2391127|NCT03634280|Placebo Comparator|Splinting|Splinting was applied to the patients' ankle in the second group(n=120). Splint were kept on the patients for 5 days for 23 hours a day. In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
2391128|NCT03634280|Experimental|Kinesio taping|In this study, Kinesio Tape Tex Gold® kinesio tape over lateral ankle (5cm*5m) is used. 120 participants were taped for a lateral ankle sprain. 50-mm wide and 0.5-mm thick KT was applied to the tendinomuscular meridian around the ankle with three I-shaped tapes. Initially, one I-shaped tape was applied along the course of the tibialis anterior muscle, and another I-shaped tape was then applied to the peroneus longus and brevis muscles. The third I-shaped tape was applied from the abductor digiti minimi muscle and wrapped around the ankle in a figure-of-eight shape to the abductor hallucis muscle, surrounding the ankle over the medial and lateral malleoli. The tape was applied to the skin by applying zero tension, and skin problems were avoided.
2391129|NCT03634267|Experimental|Treatment (MRI, internal radiation therapy)|Participants undergo MRI scan during internal radiation therapy applicator placement.
2391130|NCT03634254||primary caregivers of AAC users in New Taipei City|Satisfaction level of communication quality
3143059|NCT00004190|Experimental|gemcitabine + oxaliplatin|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 immediately followed by oxaliplatin IV over 2 hours on day 1. Treatment repeats every 3 weeks. Patients achieving stable disease, partial response, or regressive disease continue with therapy. Patients achieving complete response for two consecutive evaluations receive an additional 2 courses of therapy. Phase I (closed as of 7/5/00): Cohorts of 3-6 patients receive escalating doses of gemcitabine and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. Phase II: Patients receive the MTD of gemcitabine and oxaliplatin as in phase I. Patients are followed every 3 months for 1 year, and then every 6 months for 4 years.
3143060|NCT00004193|Experimental|ISIS 2503|patients who have metastatic and/or locally recurrent colorectal cancer
3143061|NCT00004195|Active Comparator|Oral eniluracil 20 mg twice daily|20 mg of eniluracil given twice daily for duration of the study. This subject may have surgery IF tumor is amenable to resection
3143062|NCT00004195|Placebo Comparator|Placebo|20 mg placebo that will be given for the duration of the study. This subject may have surgery IF tumor is amenable to resection
2391135|NCT03634215||Multiple Trauma patients|
2391136|NCT03634202|Experimental|IMRT + oral chemotherapy|Radiotherapy = IMRT with SIB. The overall duration of irradiation is 5 to 7 weeks Chemotherapy = oral capecitabine. Chemotherapy is taken in concomitance as radiotherapy days
2391137|NCT03634189|Experimental|HF- ACC/AHA stage A-C + CBD|Patients with HF stages A-C + Cannabidiol
2391138|NCT03634176||Group M|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 0.5gr/kg 20% mannitol
2391139|NCT03634176||Group H|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after received 1.5 ml/kg 7.5% NaCl solution
2391140|NCT03634176||Group P|both optic nerve sheath diameter (the posterior 3mm of the papilla) before and after patients were positioned on reverse Trendelenburg position 30 degrees higher than the feet
2391141|NCT03634163|Experimental|Immediate|Quality of Life Assessment plus facilitated implementation of neighbourhood exchange and personal care support
2391142|NCT03634163|Active Comparator|Delayed|Quality of Life Assessment
2391144|NCT03634137|Experimental|Afamelanotide Group 1|A 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
2391145|NCT03634137|Experimental|Afamelanotide Group 2|A 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
2391146|NCT03634124|Experimental|interventional group|
2391147|NCT03634111|Active Comparator|T group|The TAP block group was called T group. The participants were performed TAP block under guidance at the end of surgery.
2391148|NCT03634111|Placebo Comparator|C group|The controlled group was called C group. The participants has not TAP block and were treated postoperative analgesia with intravenous morphine to patients controlled analgesia
2391149|NCT03634098|Experimental|Volunteers|"Exams performed on volunteers with other purpose than liver disease or diabetes in two centers:~MRI~Ultrasound AixPlorer These examinations are carried out in 2 differents centers at 1month intervals"
2391150|NCT03634098|Experimental|T2D liver test abnormalities's participants|"Exams performed on type 2 diabetic patients with liver test abnormalities :~sample for analysis and biocollection~MRI +/-Primovist~Ultrasound AixPlorer +Sonovue"
2391151|NCT03634098|No Intervention|T2D participants without liver test abnormality|type 2 diabetic participants without liver test abnormality and not undergoing liver biopsy
2391179|NCT03633877|Experimental|DuraporeTM on R, Hy-Tape ® on L|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
2391180|NCT03633877|Experimental|DuraporeTM on L, Hy-Tape ® on R|DuraporeTM and Hy-Tape® will be placed on patients' skin around the mouth during general anesthesia
2391181|NCT03633864|Experimental|FMT treatment|FMT treatment arm: Accept fecal microbiota transplantation without changing the ongoing treatment strategy.
3183797|NCT00717496|Experimental|A|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. This group will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
3183798|NCT00717496|No Intervention|B|Mothers assigned to the control group will receive usual care. This group will also receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream.
2391154|NCT03634072|Other|PVR Arm|PVR arm will undergo PVR via catheter or surgery
2391155|NCT03634072|No Intervention|No PVR|No PVR group will continue with medical management
2391156|NCT03634059|Experimental|apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
2391157|NCT03634046|Experimental|PTED group|Percutaneous transforaminal endoscopic discectomy (PTED). Use German Joimax company production of intervertebral foramen mirror operation system, the prone position, by preoperative X-ray locating the skin into the needle point, intervertebral level away from the spine line 8 ~ 10 cm, 18 g needle insertion, the Kambin security triangle directly through the middle of pathological changes of intervertebral disc. After the success of the puncture, remove the needle core, injection of contrast agent, methylene blue (9:1) mixture disk imaging, replace the godet, slight rotation step by step to insert the expansion sleeve, X-ray perspective to determine work under the correct position. Radiofrequency ablation is used to form nucleus pulposus and fibrous ring and stop bleeding.
2391158|NCT03634046|Active Comparator|RA group|Radiofrequency ablation (RA). Patients in prone position, local infiltration anesthesia, the puncture point for lesion clearance level, is apart from the spine line distance is 8 to 10 cm, in the perspective of the C-shaped arm X-ray machine; After the puncture needle was reached, the needle core was removed and the radiofrequency head was pierced through the puncture channel to the nucleus pulposus. In accordance with the method of melt into the shrinking exit, the intensity of the treatment by band 2, increased to 3 file again, according to the needle round mouth of 2, 4, 6, 8, 10, 12 o'clock to this process is repeated six times.
2391159|NCT03634033|Experimental|MiCAP with IF|MiCAP with Internal Facilitation will receive MiCAP (implementation strategies). Internal facilitators will be waiver site clinicians with exemplary clinical practice and/or supervisory experience, who are expected to be early adopters of CAPABLE; and will be selected by their supervisors.
2391160|NCT03634033|Experimental|MiCAP with IF and EF|MiCAP with Internal Facilitation and External Facilitation will receive MiCAP (implementation strategies) and the addition of external facilitation. The external facilitators will be Super-Champion waiver program site clinicians from prior work who were trained and early adopters of CAPABLE; and will be selected by the research team to perform external facilitation.
2391161|NCT03634020|Experimental|DynamX Sirolimus-eluting Coronary Bioadaptor System|2.5 - 3.5mm 14mm, 18mm and 28mm
2391162|NCT03634007|Experimental|Cohort I: 5.0 x 10^10 gc/mL CSF|Subjects will receive 5.0 x 10^10 gc/mL CSF of LX1001
2391163|NCT03634007|Experimental|Cohort II: 1.6 x 10^11 gc/mL CSF|Subjects will receive 1.6 x 10^11 gc/mL CSF of LX1001
2391164|NCT03634007|Experimental|Cohort III: 5.0 x 10^11 gc/mL CSF|Subjects will receive 5.0 x 10^11 gc/mL CSF of LX1001
2391165|NCT03633994|Experimental|Heparin Bladder Instillation|At the completion of the scheduled benign hysterectomy, intravesicular bladder instillation containing 40,000U of heparin (40mL of 10,000U heparin/10mL) will be administered be introduced in a retrograde fashion by gravity via Foley catheter. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
2391166|NCT03633994|Placebo Comparator|Normal Saline Bladder Instillation|Patients randomized to the control group will undergo intravesical instillation with 40mL of normal saline. The Foley catheter will be clamped for 30 minutes approximately 1cm from the vaginal opening.
2391167|NCT03633968|Active Comparator|maxillary sinus lift small antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall. round diamond bur will be used to make small antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
2391168|NCT03633968|Active Comparator|maxillary sinus lift large antrostomy|"local anaesthesia will be given flap will be reflected to expose sinus lateral wall round diamond bur will be used to make large antrostomy and expose schneiderian membrane.~maxillary sinus lift by using antral membrane balloon elevation without using graft material with simultaneous implant placement"
3143063|NCT00004196|Experimental|AI|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Patients receive adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks, then subcutaneously 3 times a week for 48 weeks
3183799|NCT00717509||clozapine group|"chronic schizophrenia~have been taking clozapine at leaset one year~without diabetes, pulmonary tuberculosis"
2391171|NCT03633942||Observational: LMA Supreme|"An appropriately sized LMA Supreme will be prepared by removing all air from the cuff while applying manual pressure. A water soluble non-local anesthetic containing lubricant gel will be applied to the fully deflated airway before insertion. A 1 cm column of the gel will be preloaded into the gastric port of the LMA Supreme for the Gel Test.~The cuff will be inflated with a manometer to a pressure of approximately 30cm H2O. If a significant leak is detected, the cuff will be inflated in increments of 5cm H2O until a satisfactory seal is obtained. The final cuff pressure will be recorded. The lungs will then be gently inflated by applying manual pressure to the anesthesia circuit bag while observing the gel column in the LMA Supreme gastric port for movement."
3183800|NCT00717548|Experimental|A|
2391173|NCT03633916|Experimental|Intervention|Classroom sensitization session (plus school-level sensitization activities)
2391174|NCT03633916|Active Comparator|Control|School-level sensitization activities only
3183801|NCT00717561|Experimental|Arm 1|
3183802|NCT00717561|Active Comparator|Arm 2|
2391177|NCT03633890|Experimental|DaZhu Rhodiola Rosea Capsule|
3183803|NCT00717600|Experimental|1|Oral probiotics
3183804|NCT00717613||1|Observational cohort study
3183805|NCT00717639|Experimental|1|single arm study, all patients will undergo Vasovist-enhanced MRA
3183806|NCT00717652|Experimental|1|arbutin, tretinoin, triamcinolone
2391183|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
3183807|NCT00717652|Active Comparator|2|Triluma
3183808|NCT00717665|Experimental|A, 1, I|
2391186|NCT03633812||Beta blocker group|ESLD recipients who had beta blocker during more than 1 month before the liver transplantation
2391187|NCT03633812||Non-Beta blocker group|ESLD recipients who had not taken beta blocker more than 3 month before the liver transplantation
2391188|NCT03633799|Experimental|VeraCept|VeraCept™ Intrauterine Contraceptive
2391189|NCT03633786|Other|Group A: standard laparoscopic surgery|patients affected by deep infiltrating endometriosis undergoing standard laparoscopic surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
2391190|NCT03633786|Other|Group B: robot-assisted surgery|patients affected by deep infiltrating endometriosis undergoing robot-assisted surgery; assessment of sexual function; assessment of bowel symptoms; assessment of urinary symptoms
2391191|NCT03633773|Experimental|MUC-1 CART|Patients are given fludarabine and cyclophosphamide as pretreatment before MUC-1 CART immunotherapy. After treatment, specific antibodies, CART cells and serum levels of cytokines will be assessed.
2391192|NCT03633760|Experimental|Bilastine 40mg single dose|12 eligible subjects will be allocated to this arm and receive a single dose of 40 mg of bilastine
2391193|NCT03633760|Experimental|Bilastine 20mg multiple dose|12 eligible subjects will be allocated to this arm and receive a single dose of bilastine 20 mg on Day 1 and six doses of bilastine 20 mg from Day 4 to Day 9
2391194|NCT03633747|Experimental|propranolol|Propranolol hydrochloride tablets were taken orally three times a day at an initial dose of 30 mg/day, doubled one week later until the daily dose was 1.5 mg/kg. If the dose was unable to increase due to side effects, the maximum dose tolerable was maintained for 6 months.
2391195|NCT03633734|Experimental|Sequential treatment|"One cycle of sequential treatment lasts for 56 days.~Stage 1(28 days): AG regimen. Nab-paclitaxel (Abraxane) 125mg/m^2 + gemcitabine 1000mg/m^2 (days 1, 8, 15, 28)~Stage 2(28 days)：mFolfirinox regimen. Fluorouracil 2400 mg/m^2 continuous intravenous drip 46h + calcium folinate 400 mg/m^2 + irinotecan 135 mg/m^2 + oxaliplatin 68 mg/m^2 (day 1, 15, a total of 28 days).~Repeat the cycle above until progression or intolerance of toxicity."
2391196|NCT03633721|Active Comparator|HIV positive; cannabis|HIV positive women will be given cannabis and tested
2391197|NCT03633721|Active Comparator|HIV positive; placebo|HIV positive women will be given placebo and tested
2391198|NCT03633721|Active Comparator|HIV negative; cannabis|HIV negative women will be given cannabis and tested
2391199|NCT03633721|Active Comparator|HIV negative; placebo|HIV negative women will be given placebo and tested
2391200|NCT03633708|Experimental|Etelcalcetide|Randomized in a 3:1 ratio to receive etelcalcetide in addition to standard of care
2391201|NCT03633708|Active Comparator|Control|Randomized in a 3:1 ratio to receive etelcalcetide in addition standard of care alone (control arm)
2391202|NCT03633695|Experimental|IC-8 IOL|The AcuFocus IC-8 intraocular lens will be surgically implanted in one eye of each subject. A monofocal or monofocal toric intraocular lens will be surgically implanted in the fellow eye of each subject.
2391203|NCT03633695|Active Comparator|Monofocal|A monofocal or monofocal toric intraocular lens will be surgically implanted in both eyes of each subject.
2391204|NCT03633682|Experimental|Engagement Support|In the engagement support group, participants will be sent text messages that will encourage use of the app through tips, reminders, and encouraging messages.
2391205|NCT03633682|Other|No Engagement Support|Participants in this group will receive no text message support.
2391206|NCT03633669|Active Comparator|Tight control|Group that will receive fecal calprotectin testing every 3 months
2391207|NCT03633669|Placebo Comparator|Standard care|Routine clinical care
2391208|NCT03633656|Experimental|Treatment|Model predictive control recommendation of iron dosing in combination with an erythropoietic stimulating agent.
2391209|NCT03633643|Placebo Comparator|Group A|Single-dose Trimethoprim (TMP)/sulfamethoxazole (SMX, i.e. Cotrimoxazole) perioperative as two ampoules of TMP/SMX 400/80 mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion followed by five oral applications of placebo (lactose tablet; Fagron Gesellschaft mit beschränkter Haftung (GmbH) & Co.KG) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
2391210|NCT03633643|Active Comparator|Group B|3-day application with TMP/SMX (i.e. Cotrimoxazole): Preoperatively as two ampoules of TMP/SMX 400/80mg (Bactrim Inf Konz®) solved in 250 ml sodium chloride short infusion, followed by five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
2391211|NCT03633630|Experimental|Amla (Emblica Officinalis)|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days.
2391212|NCT03633630|Placebo Comparator|Placebo|1000 mg dose per day. Two capsules of 500 mg, one in the morning before breakfast and the other before dinner during 90 days
2391216|NCT03633591|Experimental|Modified Release Prototypes of Tolcapone|
2391217|NCT03633578|Experimental|Interventional group|Patients are asked to walk ont a treadmill in four conditions: with and without distraction (virtual environment) and at different speed (comfortable vs high).
2391218|NCT03633565|Active Comparator|Steroid|prednisolone 20 mg tablet by mouth taken once daily for 10 days each month for 2 years
3183809|NCT00717665|Active Comparator|A, 2, I|
2391219|NCT03633565|Active Comparator|Phosphodiestrase inhibitors|sildenafil 25 mg tablet by mouth once daily for 2 years
2391220|NCT03633565|Experimental|Mesenchymal stem cell transplantation|The cells can be injected intramuscular in several points in the muscle alternatively they can be injected in the motor point of the muscle. A motor point is the point at which the motor branch of the innervating nerve enters the muscle). This injection is repeated every 6 month up to 2 years.
2391221|NCT03633552|Experimental|12-cycle arm|After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
2391222|NCT03633552|Active Comparator|6-cycle arm|After completion of chemoradiation, the participants will receive 6 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meters body surface per day for the first 5 days of every 28 days).
2391223|NCT03633539|Active Comparator|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（multi-ports）.
2391224|NCT03633539|Experimental|Single-incision Laparoscopic Surgery|Patients with colorectal cancer undergo single-incision laparoscopic surgery.
3183810|NCT00717678|Experimental|Prograf-XL + MMF|
2391226|NCT03633513||Patients|Clinical diagnosed Parkinson's disease patients
2391227|NCT03633513||Caregivers|Environmentally matched healthy control subjects
2391228|NCT03633500|Placebo Comparator|Sterile water|Sterile water: Started by six hours of age, In the control arm, 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
2391229|NCT03633500|Experimental|Breastmilk|Breastmilk. This is started at 6 hours of age at the earliest; breast milk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
3183811|NCT00717678|Active Comparator|Prograf + MMF|
2391231|NCT03633474|Experimental|N. Lactamica in PBS|Wild-type Neisseria lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) will be used for this human challenge experiment. This strain is identical to that utilised in our previous challenge experiments (>350 volunteers to date).
2391232|NCT03633474|Placebo Comparator|PBS Control|PBS only control. Volunteers randomized to this arm will receive a PBS only solution which contains no bacteria.
2391233|NCT03633461|Active Comparator|OC-02|
2391234|NCT03633461|Placebo Comparator|Placebo|
3183812|NCT00717691|Experimental|1|Immediate fitting with dynamic splinting following diagnosis of hallux limitus.
3183813|NCT00717691|No Intervention|2|Control arm; patients only treated with standard of care following diagnosis of hallux limitus.
2391237|NCT03633435|Experimental|assisted home hemodialysis patients|all patients starting assisted home hemodialysis during the study period
2391238|NCT03633409||IBD patients and healthy volunteers|We will recruit IBD patients and healthy volunteers
2391239|NCT03633396|Placebo Comparator|Placebo|Placebo as subcutaneous (SC) injection every 4 weeks
2391240|NCT03633396|Experimental|Group 1|ANB019 subcutaneous (SC) injection every 4 weeks
2391241|NCT03633383||Transfemoral Approach|
2391242|NCT03633383||Transapical Approach|
2391243|NCT03633370|No Intervention|Control Group|Usual management of patients according to international guidelines. Protocols of call acceptance, phone advice and sending of emergency services are not modified
2391244|NCT03633370|Other|Test Group|"Multifaceted intervention~Training using distance learning for medical regulation assistants to recognise cardiac arrest on phone~Activation of the location-software application to send bystanders on cardiac arrest location before the arrival of emergency medical services (EMS)~Motivation feed-back Volunteers will received feed-back regarding CPR initiated before EMS arrival and survival"
2391245|NCT03633357|Experimental|JNJ-18038683 first|One week of JNJ-18038683, followed by one week of Placebo after a two week-washout period,
2391246|NCT03633357|Placebo Comparator|Placebo first|One week of Placebo followed by one week of JNJ-18038683 after a two week-washout period,
3183814|NCT00717704|Experimental|1|All participants will receive ixabepilone by vein once every three weeks as well as dasatinib by mouth once daily. All participants will receive the study drugs at a baseline dose. If the side effects are minimal and tolerable, the next cycle of study drugs will be given at same dosage. If side effects are intolerable, then the dose will be lowered.
3183815|NCT00717717|No Intervention|Control|No intervention except repeated measurements of physical capacity
3183816|NCT00717717|Experimental|Intervention|Intervention: One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
2391250|NCT03633318||IBM Group|Participants in this arm will have Inclusion Body Myositis (IBM). All patients will have EIM measurements of selected muscles.
2391251|NCT03633318||Control Group|Participants in this arm will be healthy controls. All participants will have EIM measurements of selected muscles.
2391252|NCT03633305|Active Comparator|Treatment as usual|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks
2391253|NCT03633305|Experimental|Online cognitive behavior therapy|Online CBT- Internet self-help program for insomnia with 6 cores
2391254|NCT03633305|Experimental|Treatment as usual + Online CBT|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks Online CBT- Internet self-help program for insomnia with 6 cores
2391255|NCT03633305|Experimental|Medication|Hypnotics - Medication used 1 to 7 nights/week for 6 to 8 weeks (arms 1, 3, 4)
2391256|NCT03633305|Experimental|In-person cognitive behavior therapy|Face-to-face CBT- Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
2391257|NCT03633305|No Intervention|No additional treatment|
2392819|NCT03622281|No Intervention|Colonoscopists who did not received quality intervention|
3183817|NCT00717730|Placebo Comparator|A|Placebo dietary supplement
3183818|NCT00717730|Experimental|B|Folic acid
3183819|NCT00717730|Experimental|C|Vitamin B12
2391258|NCT03633292|Active Comparator|Clorhexidine|- Clorhexidine Gel (LACER®, Barcelona, Spain) 0.12%, application 2 times / days for 1 month. The gel will be applied two times/day each 12 hours to the gingiva and mucosa.
2391259|NCT03633292|Experimental|Aloe Vera|"- 80% Aloe vera gel, application 2 times / day for 1 month~Master formula of 80% aloe vera gel Aloe Vera extract, obtained from the central part of the caudal leaves of plants with more than 8 years of life, eliminating its bark. Formulated with carbopol, hydrophilic crosslinked polymer of acrylic acid and vitamin C. The mixture is presented in containers that serve as a container for preparation and will be dispensed in the canister format with applicator tube."
2391262|NCT03633266|Experimental|anti-VEGF|experimental group: vitreoretinal surgery combined with intraoperative anti-VEGF
2391263|NCT03633266|Active Comparator|PRP|Control group: vitreoretinal surgery combined with intraoperative PRP
2391264|NCT03633253||MCR syndroms|
2391265|NCT03633253||Non MCR syndroms|
2391266|NCT03633227|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|
2391267|NCT03633227|Placebo Comparator|Placebo|
2391268|NCT03633214|Active Comparator|Training module (Intervention)|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later
2391269|NCT03633214|No Intervention|No training module (Control)|
3143064|NCT00004196|Experimental|Arm AII|Patients with metastasis in a single sentinel node with no evidence of extracapsular extension and no metastatic disease in nonsentinel nodes are randomized to 1 of 2 treatment arms. Observational arm: Patients with metastases in more than one sentinel node with evidence of extracapsular extension or metastasis in any nonsentinel node receive adjuvant high-dose interferon alfa-2b as in arm AI.
3143065|NCT00004196|Experimental|Arm BI|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo observation. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
3183820|NCT00717730|Experimental|D|Folic acid and Vitamin B12
2391273|NCT03633188|Experimental|Patients treated by antibiotherapy|35 Patients treated by antibiotherapy for acute and subacute post-operative implant-associated BJI infections and among them 10 patients with Staphylococcus. aureus treated with antibiotics as part of their standard treatment procedure for metagenomic procedure.
2391274|NCT03633175|Active Comparator|Vaginal progesterone group|Women will receive vaginal progesterone 400 mg [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt], once at bed time starting from 26-28 weeks of gestation and till 36 weeks of gestation or delivery (which is closer).
2391275|NCT03633175|No Intervention|Control group|Women with gestational age from 26-28 weeks diagnosed with placenta previa who will not receive vaginal progesterone.
2391276|NCT03633149|Experimental|Computer tablet-delivered C4H|Two session CHOICES4Health intervention delivered by a computer tablet to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
2391277|NCT03633149|Experimental|Person-delivered C4H|Two session CHOICES4Health intervention delivered by a counselor to address no use or ineffective use of contraception, and risky alcohol use, or cigarette smoking, or marijuana use.
2391278|NCT03633149|Active Comparator|Brief Advice|Women will receive advice and educational material from a research assistant about risk drinking, smoking, marijuana, and contraception, depending on their specific risk behaviors, as well as information about women's health. In addition, the women will receive referrals to the Harris Health System's SBIRT clinic if needed.
2391279|NCT03633136|No Intervention|standard education|Standard of care education provided at each transplant center
2391280|NCT03633136|Experimental|electronic video education|Standard education along with home-based video education. The videos will be initially viewed in the following order: Video 1: Introduction; Video 2: The Kidney; Video 3: Assessment and Waitlist; Video 4: Operation and Recovery; Video 5: Medications; Video 6: Your New Life. After the series has been viewed in its entirety one time, participants will be able to replay a specific video as often as desired.
2391281|NCT03633123|Other|Standard of Care (SoC)|SOC prophylactic treatment pre-operation will be as per Israeli Ministry of Health and international guidelines: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.
2391282|NCT03633123|Experimental|D-PLEX + SoC|D-PLEX is provided to suitable and willing study subjects as an adjunct to the SoC treatment
2391283|NCT03633110|Experimental|Part A|"Participants in Part A have no evidence of disease when they begin receiving GEN-009 Adjuvanted Vaccine, and have completed treatment with curative intent for their disease (eg, surgical resection, neoadjuvant and/or adjuvant chemotherapy, and/or radiation therapy).~Part A will consist of approximately 9 participants."
2391284|NCT03633110|Experimental|Part B|"Participants in Part B have advanced or metastatic solid tumors, and will receive GEN-009 Adjuvanted Vaccine in combination with PD-1 inhibitor therapy (nivolumab or pembrolizumab).~Part B will consist of up to 90 participants."
2391285|NCT03633097|Experimental|Acupuncture + Usual care|Acupuncture with Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
2391286|NCT03633097|Active Comparator|Usual care|Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet
3183821|NCT00717743||1|Patients diagnosed with RCC.
3183822|NCT00717782|Experimental|1|"Patients were injected with 0·6 ml of a solution containing 30 units botulinum toxin A (Botox; Allergan, Ireland).~A 27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
2391294|NCT03633032|Other|UTE MRI|
2391295|NCT03633019|Experimental|high-dose rhTPO|rhTPO (300-600U/kg/day), ih, until the platelets increased by 50 x 109/L compared to the baseline or above 100 x 109/L
2391296|NCT03633006||Pulmonary Nodules|"Subject with pulmonary nodules will be enrolled, provide a blood sample and may be followed up to 2 years for nodule resolution.~A second blood draw will be collected at 12 months."
2391297|NCT03633006||CT Suspicion of Cancer|"Subject with suspicion of lung cancer will provide a blood sample.~Diagnostic information will be collected to confirm the final diagnosis."
2391298|NCT03633006||Pathologically Confirmed Cancer|"Subject has pathologically confirmed lung cancer and is treatment naïve.~Subject will be enrolled and provide a blood sample."
2391299|NCT03632993|Active Comparator|Treatment I: CCH Shallow Injection, 3 Aliquots|"In Treatment I, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as three 0.1 mL aliquots (for a total injection volume of 0.3 mL).~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
2391300|NCT03632993|Active Comparator|Treatment II: CCH Shallow Injection, 1 Aliquot|"In Treatment II, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single shallow injection of a 0.3 mL aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
2391301|NCT03632993|Active Comparator|Treatment III: CCH Deep Injection, 1 Aliquot|"In Treatment III, CCH will be injected subcutaneously while the subject is in a prone position. Each injection will consist of a single skin injection of study drug administered as a single deep injection of a 0.3 mL study drug aliquot.~During each treatment visit, 8 syringes (4 syringes per treatment area) will be prepared for dosing. Each syringe will contain 0.9 mL of CCH (3 injections in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
2391302|NCT03632993|Active Comparator|Treatment IV: CCH Deep and Shallow Injections, 5 Aliquots|"In Treatment IV, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will consist of a single skin injection of study drug administered as five 0.3 mL (for a total injection volume of 1.5 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.5mL of CCH (5 aliquots of 0.3 mL, for each injection, in each syringe). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
2391303|NCT03632993|Active Comparator|Treatment V: CCH Shallow Injections, 4 Aliquots|"In Treatment V, CCH will be injected subcutaneously while the subject lies in a prone position. Each injection will receive a single skin injection of study drug administered as four 0.3 mL aliquots (for a total injection volume of 1.2 mL).~During each treatment visit, 24 syringes (12 syringes per treatment area) will be prepared for dosing. Each syringe will contain 1.2mL of CCH (4 aliquots of 0.3mL each). Dose per subject per treatment visit = up to 1.68 mg of CCH (0.84 mg in each treatment area)."
2391304|NCT03632980|Experimental|HIFU prostate treatment|"The HIFU intervention will concern Primary care patients or Secondary care patients (salvage).~Intervention with Ablatherm Foc/Dyn or Focal One HIFU treatment devices~HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - First line to Patients suffering from localized prostate cancer that has not been previously treated or Salvage HIFU intervention will be administered with Ablatherm Foc/Dyn or Focal One - Post radiotherapy to subjects harboring prostate cancer recurrency after radiotherapy"
2391305|NCT03632967|Experimental|Device: TriCinch Coil System treatment|
3143066|NCT00004196|Experimental|Arm B II|Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection. Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
3143067|NCT00004196|Experimental|Arm BIII|"Patients with positive sentinel node(s) by PCR analysis are randomized to one of three treatment arms. Patients undergo lymph node dissection followed by adjuvant high-dose interferon alfa-2b IV 5 days a week for 4 weeks.~Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3143068|NCT00004203|Experimental|Arm A|On Day 1 of each 21-day treatment cycle, patients receive 130 mg/m2 oxaliplatin diluted in 250 to 500 mL Dextrose 5% in Water infused intravenously over 2 hours through a peripheral or central vein
2391310|NCT03632928||Migraine patients|"Migraine patients, who do not have any other diseases except from tension type headache.~No intervention, but daily measurements of muscle hardness (Ultrasound Elastography) and tenderness (Pressure pain threshold)"
2391311|NCT03632915||No study intervention|No study intervention
3143069|NCT00004205|Experimental|Tamoxifen|Tamoxifen for 5 years after randomization.
3143070|NCT00004205|Experimental|Letrozole|Letrozole for 5 years after randomization.
2391314|NCT03632876|Active Comparator|Lower Dose Vitamin A|Subjects with SCD-SS in the lower dose Vitamin A arm receive 3000IU of retinyl palmitate daily for 8 weeks.
2391315|NCT03632876|Active Comparator|Higher Dose Vitamin A|Subjects with SCD-SS in the higher dose Vitamin A arm receive 6000IU of retinyl palmitate daily for 8 weeks.
2391316|NCT03632876|No Intervention|Healthy Comparison Arm|Healthy subjects receive no intervention and undergo comparisons to the two vitamin A supplementation arms at baseline.
2391317|NCT03632863|Experimental|Electronic Patient Decision Aid|Participants login to a website where they access the interactive PDA as well as access standard published information and resources.
2391318|NCT03632863|Sham Comparator|Standard Resource Sheet|Participants login to a website where they access standard published information and resources.
3143071|NCT00004205|Experimental|Tamoxifen, then letrozole|Tamoxifen for 2 years after randomization, then letrozole for the next 3 years.
3143072|NCT00004205|Experimental|Letrozole, then tamoxifen|Letrozole for 2 years after randomization, then tamoxifen for the next 3 years.
3143073|NCT00004208|Active Comparator|Arm A: ATG + CSA|"Treatment consists of 15 mg/kg ATG (Mérieux; horse antithymocyte globulin; i.e. 1.5 vial/10 kg of body weight/day) given over 8-12 hours for 5 consecutive days.~Cyclosporine A (CSA) will be administered orally in a dose of 2.5 mg/kg bid starting day 1 and continued through day 180."
3143074|NCT00004208|Other|Arm B: Supportive care|Patients randomized to this arm will be treated as outpatients.
3143075|NCT00004221|Experimental|Treatment (Combination chemotherapy, PBSC)|See detailed description.
2391323|NCT03632837|Experimental|Treatment|Inclusion of an extracorporal in line adsorbing cartridge for 48h (with a cartridge exchange at 24h) post establishing ECMO in addition to standard post resuscitation intensive care
2391324|NCT03632837|No Intervention|Control|ECMO and standard post resuscitation intensive care without any additional module in extracorporal circulation
2391325|NCT03632824|Experimental|interventional arm|Tranexamic acid applied intravenously for 2 days followed by oral tranexamic acid
2391326|NCT03632824|Placebo Comparator|comparative group|expectant management, including admission to hospital, ultrasound examination at least twice a week, regular blood coagulation tests, fetal wellbeing , frequent ultrasound performing for placenta location ,betamethasone administration for whom delivery was suspected
3143076|NCT00004227|Placebo Comparator|Arm I|"Patients undergo radiotherapy beginning on day 1. Patients are assigned to 1 of 3 radiotherapy groups:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
3143077|NCT00004227|Active Comparator|Arm II|"Patients receive a test dose of cetuximab IV over 10 minutes on day 1. Patients who do not experience grade 4 anaphylactic reaction receive a loading dose of cetuximab IV over 2 hours beginning 30 minutes after completion of test dose. Patients receive maintenance cetuximab IV over 1 hour on day 8. Maintenance cetuximab repeats every week for 7 courses. Beginning on day 8, patients undergo radiotherapy as in arm I concurrently with maintenance cetuximab. There must be an hour interval between the completion of cetuximab infusion and the start of any radiotherapy.~Radiotherapy groups remain the same as in Arm I:~Group 1: Patients undergo concurrent boost radiotherapy comprised of radiotherapy once daily 5 days a week for 3.5 weeks followed by radiotherapy twice daily 5 days a week for 2.5 weeks.~Group 2: Patients undergo radiotherapy once daily 5 days a week for 7 weeks.~Group 3: Patients undergo radiotherapy twice daily 5 days a week for 6-6.5 weeks."
2391329|NCT03632772|Experimental|Solifenacin 5 mg for 4 weeks|Solifenacin 5 mg once-daily for 4 weeks.
2391330|NCT03632772|Experimental|Mirabegron 50 mg for 4 weeks|Mirabegron 50 mg once-daily for 4 weeks.
2391331|NCT03632772|No Intervention|Control: non treatment|Control: non treatment.
2391332|NCT03632759|Experimental|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
2391333|NCT03632759|Experimental|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
2391334|NCT03632733|Active Comparator|Tetracycline group|Tetracycline cream twice daily for three months
2391335|NCT03632733|Active Comparator|Clotrimazole group|Clotrimazole cream twice daily for three months
2391336|NCT03632733|Active Comparator|Combination drug group|Tetracycline and Clotrimazole combination cream twice daily for three months
2391337|NCT03632733|Placebo Comparator|Placebo group|participants will be provided a cream containing no active drug ingredients
3143078|NCT00004229|Experimental|Arm I|Patients undergo a biopsy during prestudy and after the second course of treatment. Patients receive endostatin IV daily for 4 weeks. Patients on dose level 1-6 receive endostatin over 20 minutes. Patients on dose level 7 receive endostatin over 40 minutes, with no treatment on day 2 of the first course only. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of endostatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
2391341|NCT03632707|Other|Magnetic resonance imaging of the knee|Patients complain of painful knee with clinical suspicious of medial meniscus posterior root tear of the knee will be examined by all Magnetic Resonance Imaging sequences including sagittal, coronal and axial PD,T2 and PD-SPIR weighted images, and correlate the results with Knee Arthroscopy.while the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing.
2391342|NCT03632694|Experimental|Health Coaching and Tech Support|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app, and education materials and health coaching to achieve their goals to reduce sedentary time and increase their daily steps."
2391343|NCT03632694|Active Comparator|Tech Support Only|"Participants receive tech support for using the Jawbone UP2 activity monitor and smartphone app and education materials on reducing sedentary behavior."
2391344|NCT03632694|No Intervention|Waitlist Control|"Participants are instructed to maintain their regular activities. Upon completion of the 16-week intervention, participants receive the Jawbone UP2 activity monitor, education materials, and one session of tech support/health coaching."
2391345|NCT03632681|Active Comparator|Insulin|In this arm a single-dose of (160 IU/1.6ml) intranasal insulin will be administrated
2391346|NCT03632681|Placebo Comparator|Placebo|In this arm a single-dose intranasal placebo will be administrated
2391347|NCT03632668|Experimental|Sequence 1|Period 1: AD-2071 10/20mg QD Period 2: AD-2072 80/5mg QD and AD-2071 10/20mg + AD-2072 80/5mg QD
2391350|NCT03632642|Active Comparator|Benzylpenicillin arm|Patients randomised to benzylpenicillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 1.8g Q4H IVI for uncomplicated BSIs and 2.4g Q4H for deep-seated or critical illness infections.
2391351|NCT03632642|Active Comparator|Flucloxacillin arm|Patients randomised to flucloxacillin will be treated according to Therapeutic Guidelines 15th Edition. During hospitalisation, the standard dose will be 2g Q6H IVI or 2g Q4H for deep-seated or criticial illness infections.
2391352|NCT03632629|Active Comparator|study group|3 months of individualized interactive cognitive training, 2 times per week, 15 min per session, a total of 24 sessions, in addition to traditional rehabilitation programs.
2391353|NCT03632629|No Intervention|control group|3 months of traditional rehabilitation programs, without individualized interactive cognitive training.
2391354|NCT03632603|Experimental|Radiotherapy 20 Gy / 4 F|Radiotherapy 20 Gy / 4 F
2391355|NCT03632603|Active Comparator|Radiotherapy 30 Gy/ 10 F|Radiotherapy 30 Gy/ 10 F
2391356|NCT03632590|Experimental|Magnesium Citrate|450 mg of Magnesium Citrate per day
2391357|NCT03632590|Experimental|Magnesium Sulfate|450 mg of Magnesium Sulfate per day
2391358|NCT03632590|Experimental|Magnesium Oxide|450 mg of Magnesium Oxide per day
2391359|NCT03632590|Placebo Comparator|Placebo|
2391360|NCT03632577|Experimental|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
2391361|NCT03632577|Active Comparator|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers
2391362|NCT03632564|Experimental|Stimulation Arm|REVIVIEW dichoptic audio-visual stimulation
2391363|NCT03632551|Active Comparator|Symmetrical hearing|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2391364|NCT03632551|Experimental|Single-sided deafness|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2391365|NCT03632551|Experimental|Bilateral profound hearing loss treated|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
2391366|NCT03632538||Male|"20 male adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
2391367|NCT03632538||Female|"20 female adult patients after cardiac surgery. Drawing of patients blood for measurement of biomarkers (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide) for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours)."
2391368|NCT03632525|Experimental|Intravenous iron|All participants will receive a single dose of intravenous ferric carboxymaltose
2391369|NCT03632512|Experimental|Hericium honey bolus|Dosage form: honey bolus Dosage : Hericium erinaceus mycelium 250mg/day Frequency: 8 bolus/ day Duration: 8 months
2391370|NCT03632512|Placebo Comparator|Control group|Dosage form: Placebo honey bolus Dosage : maize starch Frequency: 8 bolus/ day Duration: 8 months
2391371|NCT03632486||Suspected Dengue|Children with fever and two of the following criteria: anorexia and nausea, rash, aches and pains, warning signs, leukopenia, positive tourniquet test will all receive a diagnostic bedside ultrasound.
3143079|NCT00004233|Experimental|5-FU, Leucovorin and PN-401|PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
3143080|NCT00004235|Experimental|irinotecan + docetaxel|"Patients receive irinotecan IV over 90 minutes followed by docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.~Patients achieving a complete response (CR) receive 2 additional courses after CR. Patients experiencing disease progression after a CR and 2 additional courses may be retreated with irinotecan and docetaxel. Dysphagia, anorexia, and swallowing ability are assessed before the first course of treatment and then at each tumor assessment.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3143081|NCT00004239|Experimental|Compound 506U78|Compound 506U78 will be administered intravenously over 2 hours on days 1, 3 and 5 of each 28 day treatment cycle.
3143082|NCT00004241|Experimental|Schedule B (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 3 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2391376|NCT03632460|Active Comparator|Dexmedetomidine|1 mcg/kg dexmedetomidine added to 8 ml 0.375% ropivacaine
2391377|NCT03632460|Active Comparator|Dexamethasone|8 mg dexamethasone added to 8 ml 0,375% ropivacaine
2391378|NCT03632447|Experimental|Leva Arm|Subjects will undergo pelvic floor muscle training using the leva device (a vaginal probe) which provides immediate visual feedback via smartphone regarding the motion of pelvic floor muscles. Subjects will perform exercises 2 1/2 minutes twice daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later subjects will undergo pelvic floor muscle testing using the PFDx device and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device. They will be further randomized to receive reminder text messages or no messages over 10 months. Subjects will be asked to complete follow up surveys at 6- and 12-months.
2391379|NCT03632447|Active Comparator|Kegel Arm|Subjects in this arm will perform pelvic floor muscle exercises (Kegels) for the treatment of stress or mixed urinary incontinence. Subjects will be asked to perform exercises three times daily for 8 weeks. At the beginning of the study, four weeks later, and eight weeks later, subjects will undergo pelvic floor muscle testing (using the PFDx device) and surveys to document response to training. After eight weeks, subjects may pursue any additional treatments they wish, but may continue to use the device.
2391380|NCT03632434|Experimental|tDCS|6-week course of active tDCS treatment, consisting of 5 sessions per week for the first 3 weeks followed by 2 sessions per week for 3 weeks, for a total of 21 tDCS sessions. The duration of each session is 30 minutes.
2391381|NCT03632421|Experimental|Intervention group|
2391382|NCT03632421|Active Comparator|Control group|
3143083|NCT00004241|Experimental|Schedule C (tanespimycin)|Patients receive 17-AAG IV over 1-2 hours twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3143084|NCT00004242|Experimental|Arm I|See detailed description.
3143085|NCT00004244|Experimental|Arm I|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interleukin-12 SC twice a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
2391384|NCT03632369||Optimization Group|The primary objective of this study is to determine an optimized set of scan parameters for HP 129Xe MR diffusion-weighted imaging, HP 129Xe MR ventilation imaging, HP 129Xe Chemical Shift Saturation Recovery (CSSR) and Xenon polarization Transfer Contrast (XTC) MRI that will produce clear, anatomically and clinically relevant images of the lungs in up to 10 healthy participants and up to 10 participants with NSCLC. The primary objective will be completed before moving onto the secondary objective.
2391385|NCT03632369||Delineate Functional vs. non-functional lung tissue|The secondary objective of this study is to delineate functional versus non-functional lung tissue and the effects of radiotherapy. This objective will be explored by performing these five optimized techniques with up to 10 participants with NSCLC at three time points: before radiotherapy begins, at the end of radiotherapy, and at least 10-weeks post-radiation treatment. These results will be correlated with those from PFTs and CT scans performed at corresponding time points.
2391386|NCT03632356|Experimental|Stepped Care Intervention (STEP)|In a stepped-care model, all patients start with an evidence-based intervention of low intensity as a first treatment step. Progress is monitored and patients who do not respond adequately can subsequently be 'stepped up' to a higher intensity treatment. This model is now being recommended as the best strategy for treating panic attacks and panic disorder.
2391387|NCT03632356|Active Comparator|Screening only|Screening only for panic attacks and panic disorder using a gold standard clinical interview that provides coverage of the core symptoms of panic attacks and panic disorder.
2391388|NCT03632343|Experimental|Experimental Group A|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
2391389|NCT03632343|Experimental|Experimental Group B|Participants in this arm will receive the Pain Squad+ smartphone app with algorithm-driven pain management advice but without nurse (RN)-initiated pain support.
2391390|NCT03632343|No Intervention|Waitlist Control|Participants in this arm will be waitlisted to receive their choice of experimental group condition within 1 month of completing all post-study outcome measures.
2391391|NCT03632330||Dexmedetomidine|Dexmedetomidine group
2391392|NCT03632330||Midazolam|Midazolam group
2391393|NCT03632330||propofol|propofol group
2391394|NCT03632330||Midazolam/Propofol|Midazolam and Propofol group
2391395|NCT03632317|Experimental|Panobinostat and Everolimus|Panobinostat daily M, W, F for 2 weeks every 28 days for the first cycle (28 days). After first cycle Panobinostat daily M, W, F for 2 weeks every 28 days combined with Everolimus daily.
2391396|NCT03632304|No Intervention|Brachial plexus block (infraclavicular)|The standard of care at our institution. Performed by experienced regional anesthetists.
2391397|NCT03632304|Active Comparator|Local anesthesia with minimal sedation|The comparison group. Performed by the operating surgeon.
2391398|NCT03632291|Experimental|UB-221 (0.2 mg/kg)|Intravenous infusion
2391399|NCT03632291|Experimental|UB-221 (0.6 mg/kg)|Intravenous infusion
2391400|NCT03632291|Experimental|UB-221 (2 mg/kg)|Intravenous infusion
2391401|NCT03632291|Experimental|UB-221 (6 mg/kg)|Intravenous infusion
2391402|NCT03632291|Experimental|UB-221 (10 mg/kg)|Intravenous infusion
2391403|NCT03632278|Experimental|Mindfulness psychoeducation programme|A MBPP will be conducted for 2 hours for each session, one a week for ten weeks, with 13-15 participants per group. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).
2391404|NCT03632278|No Intervention|Treatment as usual|"The usual care group will receive routine psychiatric outpatient services, including monthly psychiatric consultation and treatment by a psychiatrist, psychiatric nursing advice and brief education according to the patient's psychosocial needs. There will be community mental health services, social welfare or financial assistance supported by medical social workers, whenever necessary.~Participants in this control may be aware that they are receiving no extra treatment which may result in negative expectancies and inflation of the treatment effect (Stoney & Johnson, 2012). To eliminate the time effect and artificially inflated intervention effect, patients in the control group will receive telephone contact once a week to discuss their disease process and daily issues."
2391407|NCT03632226||1|Healthy Volunteers
2391408|NCT03632213|Active Comparator|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
2391409|NCT03632213|Placebo Comparator|Placebo|Placebo group:15 patients, both sexes, will receive oral placebo for 12 months.
2391410|NCT03632200|Experimental|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions."
2391411|NCT03632200|No Intervention|Control group|The patients will be followed according to the current recommendations of the French Society Clinical Nutrition and Metabolism (SFNEP).
2391435|NCT03632005|Active Comparator|Vacuum Assisted Closure|The Prevena™ System, a type of vacuum assisted closure, is indicated for use over clean, closed incisions that continue to drain following sutured or stapled closure. It acts by removing exudate, helping hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
2391629|NCT03630588|Placebo Comparator|Placebo|
2391412|NCT03632187|Experimental|Experimental group|Subcutaneous abatacept every weeks during 3 months (W0 to W11). Then, at W12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients wont receive any treatment until a flare.
2391413|NCT03632187|Placebo Comparator|Control group|Subcutaneous placebo every week during 3 months (W0 to W11). Then, at week 12, if PMR-AS>10, they will receive GCs according to the PMR-AS (PMR-AS≤10: no GCs, PMR-AS between 10-20: 10mg/day, PMR-AS between 21-30: GCs at 15mg/d and if PMR-AS> 30: 20mg/d). Dosage of GCs will be decreased between W16 and W24 (1mg every week) in each arm according to PMR-AS (PMR-AS < 10: decrease, PMR-AS > 17 increase to previous dosage, 10 ≤ PMR-AS ≤ 17: stable dose). If PMR-AS ≤10, the patients won't receive any treatment until a flare.
2391414|NCT03632174|Experimental|Topical Ointment with L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
2391415|NCT03632174|Experimental|Topical Ointment without L. reuteri|Adult subjects presenting with mild-moderate Atopic Dermatitis
2391416|NCT03632161|Active Comparator|Dexmedetomidine|Dexmedetomidine is added to bupivacaine the paravertebral block
2391417|NCT03632161|Other|Bupivacaine|Bupivacaine only in the paravertebral block
3143086|NCT00004244|Experimental|Arm II|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive interferon alfa SC three times a week for 2 weeks, followed by treatment with interleukin-12 in combination with interferon alfa as described above."
3183823|NCT00717782|Placebo Comparator|2|"Patients in the placebo group received a 0·6-ml injection of saline.~A27-G needle was used to give two injections of equal volume (0·3 ml) into the internal anal sphincter, one on each side of the anterior midline of the sphincter."
2391420|NCT03632122||Bothersome back pain|The investigators will include community-dwelling older adults at Round 1 or 6 of the NHATS cohort, and will include those with bothersome back pain in the past month based on self-report questions at the respective baseline time point. The investigators will exclude participants who are non-ambulatory (requires wheelchair or scooter).
3183824|NCT00717795||1|Arm 1 - Physical Activity intervention
2391422|NCT03632096|Active Comparator|Photobiomodulation group|Patients will receive 3 applications of low intensity light directly in the region of the three pairs of salivary glands already described. The ArGaAl diode laser, DMC 808nm 4J/point equipment will be used. The parameters that will be used are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2. The first application will be after the stimulated collection of saliva and the following applications will be given once a week for another 2 weeks.
2391423|NCT03632096|Sham Comparator|Sham group|The placebo group will have a simulation of application of the laser, following the same technique as the active group, but with the device turned off. Because it is an infrared light, it is invisible and this will not induce the patient to notice that the device is turned off.
3183825|NCT00717795||2|Arm 2 - Wait-list control
3183826|NCT00717808|Active Comparator|1|During the study the patient will either receive tranilast (300mg twice a day) or a placebo drug for a period of seven days. The patient will then have a seven day break followed by another period of seven days in which the patient will receive the other medication.
2391426|NCT03632070||Stroke|Patients with ischemic or hemorrhagic stroke who were admitted to Samsung Medical Center and transferred to the Department of Physical and Rehabilitation Medicine
2391427|NCT03632057|Active Comparator|Fixed Tilt (65%)|This is the control group, so device programming for shock energy is the default setting
2391428|NCT03632057|Active Comparator|Fixed Pulse Width|This is the Study group.
2391429|NCT03632044|Experimental|Suprazygomatic maxillary nerve blockade|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia.
2391430|NCT03632044|Sham Comparator|25 Gauge needle|Subcutaneous placement of a 25 Gauge needle as a sham comparator after the induction of general anesthesia. Nothing will be injected.
2391431|NCT03632031||Patients with chronic non-healing wounds|Patients with chronic non-healing wounds with planned use of OASIS Extracellular Wound Matrix
2391432|NCT03632018|Active Comparator|Standard Cardiac Rehabilitation|Participants in the STANDARD condition will receive the standard of care cardiac rehabilitation, consisting of 36 sessions across 12 weeks of prescribed, supervised exercise sessions.
2391433|NCT03632018|Experimental|HEART-PLAY|Participants in the HEART-PLAY will receive standard CR and additionally receive pedometers, resistance bands, and the National Institute of Aging (NIA) exercise guide. They will further receive counseling from peer health coaches, social support from group education sessions, and supplemental educational materials. After the 12 weeks of prescribed, supervised exercise sessions, HEART-PLAY group participants will continue to receive support from peers and clinic staff with check-in calls, feedback on pedometer goals, and twice weekly group events including walks and/or resistance band group exercise classes.
2391434|NCT03632005|Other|Sterile Dressing|Standard of care treatment - Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
3183827|NCT00717808|Placebo Comparator|2|The patient will receive the placebo twice a day for 7 days whilst taking their weekly methotrexate dose
2391436|NCT03631992|Experimental|Low Sweet|"Children in intervention group will be provided with daily snacks lower in added sugar and sweetness and their mothers will receive educational lessons on dental care, reading food labels, and nutrition that support the goals of reducing sweet exposure and added sugar intake."
2391437|NCT03631992|Sham Comparator|Regular Sweet|Children in the regular sweet control group will be provided with common snacks fed to children of this age and mothers will be given education lessons on portion size, physical activity, sleep, screen time and, at the end of the trial, dental care.
2391438|NCT03631979|Experimental|Intervention group|Regular intestinal lavage with normal saline twice per day, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. The intervention will be applied at a maximum of 2 weeks from birth.
2391439|NCT03631979|No Intervention|Control group|Current routine for extremely preterm infants that do not defecate adequately will be applied.
2391440|NCT03631966|Experimental|BTX-A injection|
2391441|NCT03631953|Experimental|Alpelisib in combination with Trametinib administered|A panel of 3 doses of Alpelisib could be tested in combination with fixed dose of Trametinib (1.5 mg every day).
2391444|NCT03631914|Active Comparator|Active needle tip tracking|A needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
2391445|NCT03631914|Other|Inactive needle tip tracking|No needle tip tracking system is used when performing an ultrasound guided infraclavicular brachial plexus block.
2391446|NCT03631901|Active Comparator|Melatonin|melatonin 0.3mg/kg/8 hours, orally. Given only during the febrile illness.
2391447|NCT03631901|Active Comparator|Diazepam|oral diazepam 1mg/kg/day divided into 3 doses. Given only during the febrile illness.
2391448|NCT03631888||patients scheduled for elective laparoscopic surgery|
2391449|NCT03631875|Placebo Comparator|P (propofol),|normal saline is injected 01 min before induction with propofol 3 mg/kg. After 60 seconds, an experimented anesthesiologist evaluated the LM conditions insertion.
2391450|NCT03631875|Active Comparator|PK (propofol-ketamine)|we inject 0.5 mg/kg of ketamine 01 min before induction with 03 mg/kg of propofol .Sixty seconds after, an experimented anesthesiologist evaluated the LM conditions insertion.
2391451|NCT03631862|Experimental|Apatinib combined with CHOP regimen|Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
2391452|NCT03631862|Experimental|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) ： Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
2391453|NCT03631849|Experimental|Peri implantitis patients|
2391454|NCT03631849|Active Comparator|not peri implantitis patient|
2391455|NCT03631836|Experimental|Combinaton monoclonal therapeutic antibody and bevacizumab|Determine the safety profile and tolerability of monoclonal therapeutic antibody given in combination with a fixed dose of bevacizumab in patients with recurrent glioblastoma in terms of Dose-Limiting Toxicities
2391456|NCT03631823||Radio/Chemotherapy group|The participants in this group receive the concurren radio/chemotrherapy
2391457|NCT03631823||Radio/ without chemotherapy group|The participants in this group receive the radiotherapy but without chemotrherapy
2391458|NCT03631823||Healthy volunteer group|The volunteers for control group
2391459|NCT03631797|Experimental|Microvascular reactivity evaluation|"Patients referred for a preoperative arterial palmar arches assessment before cardiac valvular or coronary surgery.~Intervention is measurement of microvascular reactivity with a laser speckle contrast imaging before surgery."
3143087|NCT00004244|Experimental|Arm III|"Patients receive interleukin-12 subcutaneously (SC) twice a week and interferon alfa SC three times a week every week for 4 weeks. Treatment continues in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of interleukin-12 and interferon alfa until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicities.~Patients receive treatment with interleukin-12 in combination with interferon alfa at the MTD as described above."
3143088|NCT00004246|Experimental|RT + Fludarabine|Radiotherapy (RT) on Days 1-5 for 7 weeks + Fludarabine IV, 3-4 hours prior to daily RT, Days 1-5 of weeks 6 and 7 of RT
2391463|NCT03631758|Experimental|Experimental: Evidence + PDA|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
2391630|NCT03630588|Experimental|Surimi intervention|
3143089|NCT00004251|Experimental|Letrozole|Letrozole 2.5 mg po daily
2391464|NCT03631758|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
2391465|NCT03631758|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
2391466|NCT03631745|Experimental|NAMI Mental Health 101 and NAMI FaithNet|Mental Health 101 and FaithNet
2391467|NCT03631745|No Intervention|Wait-list Control|After the 12-month follow-up, wait-list control churches will be provided with the opportunity to receive Mental Health 101 and NAMI FaithNet interventions.
3183828|NCT00717821|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will receive monthly injections of methoxy polyethylene glycol-epoetin beta, with the starting dose of 120 or 200 micrograms calculated from the last weekly dose of epoetin beta or darbepoetin alfa previously administered, using the same route of administration (SC or IV). Thereafter, when the hemoglobin concentration will increase or decrease in a clinically significant amount, a dose adjustment will be performed according to specific provided guidance. Total duration of treatment will be up to 48 weeks.
3183829|NCT00717821|Active Comparator|Epoetin Beta or Darbepoetin Alfa|Participants who are receiving SC or IV epoetin beta or darbepoetin alfa will continue to receive the same treatment (epoetin beta or darbepoetin alfa at the same dose, same administration intervals, and the same route of administration). When necessary, dose adjustments will be performed according to Summary of Product Characteristics (SmPC). Total duration of treatment will be up to 48 weeks.
2391470|NCT03631719||Early-release|Resident in areas that receive early Wolbachia deployments.
2391471|NCT03631719||Late-release|Resident in areas that receive late Wolbachia deployments.
2391474|NCT03631693|Active Comparator|Simplified papilla preservation flap|PERIODONTAL SURGICAL INTERVENTION:The first arm is the simplified papilla preservation flap (SPPF) surgery.At visit 3, the SPPF surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
2391475|NCT03631693|Active Comparator|Resective flap with osseous recontouring|PERIODONTAL SURGICAL INTERVENTION: The second arm is the Resective periodontal flap with osseous recontouring (RPFO). At visit 3, the RPFO surgery is performed. 2D and 3D imaging on surgical site will be carried out pre and post surgery. 2D and 3D imaging performed on surgical site for all post operative visits.
2391476|NCT03631680||'Bilateral Oophorectomy Surgery' Group|Premenopausal women planning to undergo a laparoscopic, elective bilateral oophorectomy surgery.
2391477|NCT03631680||'Comparative (Control)' Group|Premenopausal women with normal menstrual cycles from a previously completed study at Pennington Biomedical Research Center [NCT01748994] will serve as a comparator (control) group.
2391478|NCT03631667|Experimental|50 ng dose|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP)
2391479|NCT03631667|Experimental|50 ng dose plus 1250 ng phenanthrene|Capsule containing 50 ng (5.4 nCi) [14C]-benzo[a]pyrene (BaP) and 1250 phenanthrene
2391482|NCT03631641|Experimental|Treatment (nivolumab)|Participants receive nivolumab intravenously IV over 60 minutes on day 1. Treatment repeats every 3 months for a total of 8 courses in the absence of disease progression or unacceptable toxicity.
2391483|NCT03631628|Experimental|MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + MT and 1 hour conventional training.
2391484|NCT03631628|Placebo Comparator|sham-MT+TENS|All subjects will undergo 16 sessions of treatment (2 times per week, for 8 weeks). Subjects will receive 1.5 hours rehabilitation program per visit to the Rehabilitation Clinic: 30 minutes of TENS + sham-MT and 1-hour conventional training.
2391485|NCT03631615|Experimental|Neoadjuvant therpy|neoadjuvant chemoradiation plus PD-1 antibody (SHR-1210)
2391486|NCT03631602|Experimental|Arm 1|posaconazole oral suspension
2391487|NCT03631602|Active Comparator|Arm 2|itraconazole oral solution
2391488|NCT03631589|Experimental|MSCs treated|
2391489|NCT03631576|Experimental|Arm 1|CD123/CLL1 CAR-T Cells treat
2391490|NCT03631563|Experimental|Arm 1|ATG-F treated
2391491|NCT03631563|Active Comparator|Arm 2|ATG treated
2391492|NCT03631550|Active Comparator|Active|Relivion Active device
2391493|NCT03631550|Sham Comparator|Sham|Relivion Sham device
2391494|NCT03631537|Experimental|NST group|Nutrition support team gives the dietary supplement or other nutritional support during the period of chemotherapy
2391495|NCT03631537|No Intervention|routine group|clinicians decide whether to give and how to give the dietary supplement and other nutritional support
2391496|NCT03631524|No Intervention|Conventional therapy|The control arm will be subject to the same assessments as the treatment arm at the start and end of the two week period. They will receive standard care in the ward including physiotherapy as prescribed by the managing team
2391497|NCT03631524|Experimental|Intervention arm|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period. They will be evaluated for motor strength, activity of daily living performance, mood and perceived level of health.
2391498|NCT03631511|Experimental|RetroMTA|Direct pulp capping with RetroMTA (BioMTA, Daejeon, Korea)
2391499|NCT03631498||Healthy individuals|Gingival biopsies of healthy individuals who were never-smokers and had no systemic or oral disease or condition.
2391500|NCT03631498||periodontitis patients|Gingival biopsies of periodontitis patients who were never-smokers and had no systemic disease or condition.
2391501|NCT03631498||Healthy smokers|Gingival biopsies of healthy individuals who were smokers but no systemic or oral disease or condition.
2391502|NCT03631498||Smokers with periodontitis|Gingival biopsies of periodontitis patients who were smokers but no systemic disease or condition.
2391503|NCT03631485||parents having children with cancer|No intervention.
2391504|NCT03631472|Experimental|RheOx Treatment|RheOx Treatment (i.e., Bronchial Rheoplasty)
2391505|NCT03631459||Kanglaite Injection/Capsules|Kanglaite injection 200ml, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
3183830|NCT00717834|Experimental|Cohort 1, Treatment Arm 1|Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
3183831|NCT00717834|Experimental|Cohort 1, Treatment Arm 2|Same as Cohort 1, Treatment Arm 1
2391509|NCT03631420|Experimental|UMC119-01|UMC119-01 is ex vivo cultured human umbilical cord tissue-derived mensenchymal stem cells product
2391510|NCT03631407|Experimental|Vicriviroc QD at Dose Level 1 + Pembrolizumab|Participants vicriviroc (dosed orally; once daily [QD]) at dose level 1 in combination with 200 mg pembrolizumab (intravenous [IV] infusion; every 3 weeks [Q3W]) for up to 35 cycles (cycle length: 3 weeks).
2391511|NCT03631407|Experimental|Vicriviroc QD at Dose Level 2 + Pembrolizumab|Participants receive vicriviroc (dosed orally; QD) at dose level 2 in combination with 200 mg pembrolizumab (IV infusion; Q3W) for up to 35 cycles (cycle length: 3 weeks).
2391512|NCT03631394|Experimental|beetroot and anthocyanin|A compound pharmacy will formulate capsules with nitrates extracted from beetroot and anthocyanins from tart cherries. A daily dose of the capsules will be taken for 7 days after the washout period. Each dose will comprise 500 mg of nitrates and 450 mg of anthocyanins. In a meta-review by Dominguez and colleagues, 6-8 mmol of nitrates from beetroot was associated with increased exercise performance. Another review by Kelley et al., showed that marathon runners and resistance trainers ingesting between 450-480 mg of anthocyanins had reduced muscle soreness and decreased oxidative stress. Subject will consume each supplement orally with only water 2 hours pre-prandial.
2391513|NCT03631394|Placebo Comparator|beetroot and placebo|The same compound pharmacy will formulate capsules with nitrate extracted from beetroot and a placebo element made of starch. This product will taste the same as the nitrate and anthocyanin supplementation. A daily dose of the capsules will be taken for 7 days after the washout period. Each supplementation will have 500 mg of nitrate and 450 mg of placebo. Subjects will consume each supplement orally with only water 2 hours pre-prandial.
2391514|NCT03631368|Experimental|Botox|
3183832|NCT00717834|Experimental|Cohort 1, Treatment Arm 3|Same as Cohort 1, Treatment Arm 1
3183833|NCT00717834|Experimental|Cohort 1, Treatment Arm 4|Same as Cohort 1, Treatment Arm 1
2391517|NCT03631342|Experimental|VCV20|Volume-controlled ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
2391518|NCT03631342|Experimental|VCV40|Volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the maximum pressure reached 40cmH2O.
2391519|NCT03631342|Experimental|PCV|Pressure controlled ventilation mode, inspiratory time of 1 second. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
2391520|NCT03631342|Experimental|PCV+Tins|Pressure controlled ventilation mode and inspiratory pressure was increased every 5cmH2O, until the maximum pressure of 40 cmH2O was reached. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
2391521|NCT03631342|Experimental|PSV|Pressure support ventilation mode, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
2391522|NCT03631329||Uncomplicated cesarean delivery|Uncomplicated singleton full-term parturients undergoing cesarean delivery
2391523|NCT03631316|Experimental|Generic valganciclovir|Participants will receive generic formulation (Pisa) of valganciclovir, 450 mg tablets, total dosage 900 mg daily for 4 days.
2391524|NCT03631316|Active Comparator|Innovative valganciclovir|The same participant will receive innovative drug valcyte (roche), 450 mg tablets, total dosage 900 mg daily during 4 days.
2391525|NCT03631303||ICD patients with ATP/shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who received appropriate ICD therapy during follow-up.
2391526|NCT03631303||ICD patients without ATP/Shock|10 primary prevention 2-chamber ICD patients (LVEF <35 percent) who were free from appropriate ICD therapy during follow-up.
2391527|NCT03631303||Pacemaker-patients|10 2-chamber pacemaker-patients (LVEF >50%).
3183834|NCT00717834|Experimental|Cohort 2, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1a Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
2391529|NCT03631277|Experimental|photo-activated oral disinfection|photo-activated oral disinfection is an advanced technology utilizing two non-toxic components, a photo-activating liquid and a LED light source that selectively target and abolish cariogenic bacteria and periodontal pathogens
2391530|NCT03631277|Active Comparator|calcium hydroxide|Calcium hydroxide is the gold standard for pulp capping, it permits reparative dentin bridge formation, maintains pulp vitality, protects the pulp against harmful stimuli and has antimicrobial effect
2391531|NCT03631264|Experimental|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants for improving sucking and swallowing.
2391532|NCT03631264|No Intervention|Control|In this group the late preterm infants won't be applied kinesiotaping to suck and swallow muscles.
2391533|NCT03631251|Experimental|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
2391534|NCT03631238||Apparently normal participants|Participants are not complaining from any cognitive decline are subjected to cognitive and cholesterol and homocysteine levels assessment.
3183835|NCT00717834|Experimental|Cohort 2, Treatment Arm 2|Same as Cohort 2, Treatment Arm 1
2391537|NCT03631212|No Intervention|Waitlist control|Wait-list control group
2391538|NCT03631212|Experimental|Flexiquit|Digital ACT-based intervention for smoking cessation
3143090|NCT00004262|Experimental|Treatment (motexafin gadolinium, radiotherapy, radiosurgery)|Within 5 weeks following surgery, patients receive daily external beam radiotherapy five days a week for 5 weeks. Within 2 weeks following completion of radiotherapy, patients receive gadolinium texaphyrin IV over 2 hours followed 3 hours later by stereotactic radiosurgery. Patients undergoing surgical debulking of tumor prior to external beam radiotherapy receive gadolinium texaphyrin IV over 2 hours, 3 hours prior to surgery in addition to the dose prior to stereotactic radiosurgery.
3143091|NCT00004263|Experimental|Cytarabine + UCN-01|
2391541|NCT03631186||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
2391542|NCT03631173|Active Comparator|Patient with microdialysis|Intervention group - Patients will receive an intraperitoneal microdialysis catheter and will be monitored consecutively by microdialysis. The surgeon is familiar with the current microdialysis results at any time during the study period. The surgeon may intervene based on traditional symptoms and signs plus predetermined values of the microdialysis results.
2391543|NCT03631173|No Intervention|Patient without microdialysis|The control group - The patients will not receive a microdialysis catheter. The patients are monitored according to current standards of care and the surgeon may intervene based only on traditional symptoms and signs.
2391544|NCT03631160|Experimental|TAES treatment|"Patients in the treatment group receive Transcutaneous Acupoint Electrical Stimulation (TAES) at Zhongji ( CV3),Guanyuan ( CV4), bilaterally Sanyinjiao ( SP6) and bilaterally Ciliao ( BL32) points by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained until the end of treatment."
2391545|NCT03631160|Sham Comparator|Sham TAES treatment|"Participants in the control group receive shallow TAES at SP6, BL32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the acuponit is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output."
2391546|NCT03631147|Experimental|Rifaximin treatment group|Rifaximin 400mg bid for 8 weeks
2391547|NCT03631147|No Intervention|The control group|
2391548|NCT03631134|Experimental|SGLT2i treatment|The patients who are using basal insulin therapy with or without oral hypoglycemic drugs will be added SGLT2 inhibitor treatment
2391549|NCT03631121|Experimental|Basalin to Lantus|the patients who are using Basalin treatment will use isodose of Lantus instead
2391550|NCT03631108||Normal Population|"Normal population with different gender, different age different, different blood pressure, different ocular pressure, etc.~All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
2391551|NCT03631108||Patients with common ophthalmic diseases|"(1) conjunctivitis; (2) glaucoma; (3) childhood myopia; (4) uveitis; (5) diabetic retinopathy; (6) retinal detachment; (7) fundus neovascularization.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens."
2391552|NCT03631108||Patients using eye drops|"(1) conjunctivitis patients treated with levofloxacin antibiotics; (2) glaucoma patients treated with prostaglandins, adrenaline or receptor blockers drugs; (3) childhood myopia patients treated with atropine drugs; (4) uveitis patients treated with hormones treatment. (5) diabetic retinopathy patients treated with vasodilator.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after eyedrops."
2391553|NCT03631108||Ocular surgery patients|"(1) cataract, phacoemulsification + intraocular lens implantation; (2) glaucoma, iridectomy; (3) fundus neovascularization, intraocular injection of anti-VEGF; (4) diabetic retinopathy, vitrectomy.~All patients will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens before and after surgery."
2391554|NCT03631082|Experimental|Slump stretching group|"Slump stretching will be performed with the patient in the long sitting position. The position will be held for 30 seconds. A total of 5 repetitions will be completed.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, and quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
2391555|NCT03631082|Active Comparator|Lumbar mobilization group|"Maitland Grade 1 - 2 Posterior to anterior lumbar spine mobilization will be applied for 30 - 45 seconds for all segments through L1 to L5 at rate of 1 oscillation per 2 seconds.~Patients will also complete a standardized exercise program consisting of pelvic tilts, bridging, wall squats, quadruped alternate arms/legs activities as described by Cleland et al.~Patients will perform 10 repetitions of each exercise."
2391556|NCT03631069||Dementia|People with hospital episode statistics labels of dementia
2391557|NCT03631069||Normal|
3143092|NCT00004266|Experimental|Nifedipine|Daily nifedipine at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
2391560|NCT03631030|Other|Cooled radiofrequency ablation|This is a single arm study. Patients who will be undergoing cooled radiofrequency ablation for the treatment of arthritis in the cervical facet joints, thoracic facet joints, lumbar facet joints, sacroiliac (SI) region, hip and knee.
2391561|NCT03631017|Experimental|[18 F]-PARPi and PET/CT Scans|The intervention of this study is the injection of a microdose (< 10 0 ug) of [18 F]- PARPi followed by 3 PET/CT studies to determine the biodistribution of this imaging agent in normal organs as well as the kinetics of uptake in squamous cell carcinomas of the head and neck.
2391562|NCT03631004|Experimental|olanzapine tablets|PATIENT WILL TAKE OLANZAPINE 10 MG, 1 hour BEFORE SURGERY
2391563|NCT03631004|Placebo Comparator|Starch tablets|PATIENT WILL TAKE PLACEBO 1 hour BEFORE SURGERY
2391631|NCT03630575|Experimental|Newborns exposed in-utero to psychoactive substances|
2391632|NCT03630562|Other|Patients with exudative AMD|
2391564|NCT03630991|Experimental|Cohort I (edetate calcium disodium, multivitamin)|During standard of care chemotherapy, patients receive edetate calcium disodium IV daily over 30 minutes for 4 doses for each cycle. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
2391565|NCT03630991|Experimental|Cohort II (succimer, multivitamin)|During standard of care chemotherapy, patients receive succimer PO daily for 8 or 21 days of each cycle beginning day 1. Treatment continues for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive up to 12 multivitamin capsules PO daily while on study.
2391566|NCT03630978||Liver resection|
2391567|NCT03630965|No Intervention|Group A|No CPR video
2391568|NCT03630965|Experimental|Group B|CPR video
2391569|NCT03630952|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
2391570|NCT03630952|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
2391571|NCT03630952|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
2391572|NCT03630939|Experimental|ESR-114 1.5%|ESR-114 1.5% Topical Gel BID for 6 weeks
2391573|NCT03630939|Experimental|ESR-114 5.0%|ESR-114 5.0% Topical Gel BID for 6 weeks
2391574|NCT03630939|Placebo Comparator|Vehicle Gel|Placebo Topical Gel BID for 6 weeks
2391575|NCT03630926||Prostate Cancer (PCa)|Comprised of men with biopsy-confirmed PCa who are scheduled for prostatectomy.
2391576|NCT03630926||Benign Prostatic Hypertrophy (BPH)|comprosed of men with benign prostatic hypertrophy (BPH) who are scheduled for transurethral resection of the prostate (TURP).
2391577|NCT03630926||Bladder/kidney stone|Comprised of men or women with bladder/kidney stones who are scheduled for a cystoscopy.
2391578|NCT03630913|Experimental|Tagged axillary metastatic node|"Patients undergo axillary sonography assessment routinely performed to seek suspicious nodes. A cytological examination (biopsy is optional) of the suspicious node is performed.~The involved node is then tagged with a metal clip under sonography. Then, patients receive NAC before surgery. Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC."
2391579|NCT03630900|Experimental|Sequential O2 culture (5% then 2.5%)|Embryo culture from day 0 to 3 in 5% O2 then split to either 5% or 2.5% O2 until Day 5 or 6.
2391580|NCT03630900|No Intervention|5% O2 culture|
2391581|NCT03630887|No Intervention|Control|Non-active prewarming. Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2391582|NCT03630887|Experimental|Prewarming during 15 minutes|Active Prewarming will be performed during 15 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2391583|NCT03630887|Experimental|Prewarming during 30 minutes|Active Prewarming will be performed during 30 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2391584|NCT03630887|Experimental|Prewarming during 45 minutes|Active Prewarming will be performed during 45 minutes, using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be actively warmed during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2391585|NCT03630874|Experimental|Experimental arm|
2391586|NCT03630874|No Intervention|Control arm|"Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (without the tool) the right prescription of ATs by answering a multiplechoice question, with the number, type, duration and dosage of AT provided."
2391587|NCT03630861||GBM|Primary glioblastoma (GBM)
2391588|NCT03630861||PCNSL|Primary CNS lymphomas (PCNSL)
2391589|NCT03630861||Brain metastases|Brain metastases (BM)
2391590|NCT03630861||Cerebral Stroke|Cerebral Stroke (CS)
2391591|NCT03630861||Healthy Volunteers|Healthy Volunteers (HV)
2391592|NCT03630848|Experimental|10 mg/ml protein concentration in Embryo Culture Media|
2391593|NCT03630848|No Intervention|5 mg/ml protein concentration in Embryo Culture Media|
3143093|NCT00004266|Experimental|Lisinopril|Daily lisinopril at a dose adjusted for high blood pressure. Cholestyramine or gemfibrozil is administered per National Cholesterol Education Program guidelines. Diuretics and doxazosin may be given concurrently.
2391595|NCT03630822|Experimental|beneficiary of the advance directive program|
2391596|NCT03630822|Active Comparator|beneficiary of standard Support|
2391664|NCT03630419|Experimental|Mito-Food Plan and Cellular Repair|Mito-Food Plan with adjunctive Cellular Repair Therapy
2391598|NCT03630796|Active Comparator|Sevoflurane|"Anesthetic induction with sevoflurane by mask 3-8% and fresh gas flow 2-8 l/min (FiO2 50-100%) followed by ketamine 1-2 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and sevoflurane 1-3% (end-tidal concentration) before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg and pancuronium 0,1 mg/kg will be administered and the sevoflurane sustained 1-3% in a specific sevoflurane vaporizer included in the CPB machine.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
2391599|NCT03630796|Other|Intravenous anesthetics (TIVA)|"Anesthetic induction with ketamine 1-3 mg/kg, midazolam 0,1-0,5 mg/kg, fentanyl 2-4 mcg/kg and pancuronium 0,1 mg/kg after preoxygenation with FiO2 between 50-100% and fresh gas flow 4-8 l/min.~After orotracheal intubation, anesthesia is maintained with fentanyl 10 - 30 mcg/kg according to clinical needs and continuous infusion of midazolam and ketamine 0,2-0,8 mg/kg/h and 1-2 mg/kg/h respectively before and after cardiopulmonary bypass. Specifically during cardiopulmonary bypass extra fentanyl 1-5 mcg/kg, midazolam 0,1-0,5 mg/kg and pancuronium 0,1 mg/kg will be administered.~Pressure-controlled ventilation will be applied to both groups objectifying normocarbia and normoxia.~Ringer's lactate (RL) will be used as crystalloid solution for fluid therapy."
2391600|NCT03630783|Experimental|Cognitive Bias Modification (Group-E)|Participants were subjected to Combined Cognitive Bias Modification in each session. During the attentional bias modification phase, photographs of neutral or threatening (disgusted) faces were used. In each trial, a pair was shown for 500 ms. Then, a sign of arrow appeared and participants were asked to indicate the direction of the arrow. In %80 of the trials, the arrow was in the same area with the neutral photograph. During the interpretational bias modification phase a threatening or positive word, as the interpretation of a sentence, appeared, then, a relevant sentence with ambiguous meaning appeared, and later, participants were asked to indicate if the word and the sentence were related. After their response a feedback (right/wrong) was given and the next trial was started.
2391601|NCT03630783|Placebo Comparator|Placebo Control (Group-C)|Participants in this group were subjected to the same procedure as the experimental group. However, during the Combined Cognitive Bias Modification process, the sign of arrow appeared at even rates (%50 - %50) after neutral and disgusted facial impressions; and during the interpretational bias modification, sentences and relevant words were superficially related or were not related at all.
2391602|NCT03630770|No Intervention|Control|This group receives no feeding supplement.
2391603|NCT03630770|Experimental|MCT Oil|This group is supplemented with MCT oil
2391604|NCT03630757|Experimental|Treatment|While holding the patient's head with the therapist's hands,the cervical spinous processes with the fingertips palpitate to the occipital condyle towards the proximal.Then the fingers of both hands applied pressure to the axis in the space between the occipital condyle and the spinous process
2391605|NCT03630757|Placebo Comparator|Group 2|reaching to the feet while sitting together with warming and cooling periods
2391606|NCT03630744||Adult patients undergoing surgery|Patients over 18 years surgically treated with fluid therapy during the 24 hours of the day study
2391607|NCT03630718|No Intervention|Control Group (CG)|Patients assigned to no intervention
2391608|NCT03630718|Active Comparator|Psychoeducational Intervention Group (EG-EDU)|Patients assigned to psychoeducational intervention
2391609|NCT03630718|Active Comparator|Hypnosis intervention Group (EG-HYP)|Patients assigned to hypnosis intervention
3143094|NCT00004266|Experimental|Nifedipine and simvastatin|Daily nifedipine at a dose adjusted for high blood pressure, and simvastatin at a dose adjusted for high low-density lipoproteins. Supplemental cholestyramine may be given as needed. If cholestyramine is not tolerated or if triglycerides are high, gemfibrozil is substituted for cholestyramine.
3143095|NCT00004266|Experimental|Lisinopril and simvastatin|Lisinopril at a dose adjusted for high blood pressure and simvastatin at a dose adjusted for high low-density lipoproteins.
3143096|NCT00004285|Active Comparator|Standard dose, low flux hemodialysis|
3143097|NCT00004285|Experimental|Standard dose, high flux hemodialysis|
2391614|NCT03630692||observance of oral drug treatment|Study of observant or nonobservant patient behavior for their oral drug treatment
2391619|NCT03630653|Experimental|Sentinel LN in breast cancer recurrence|"Patients with a biopsy assessing an ipsilateral breast tumor recurrence, and a diagnosis of invasive carcinoma after a previous diagnosis of breast cancer that has been treated by breast conservative surgery at least one year before.~Before the SLNB procedure, each patient will have a lymphoscintigraphy to evaluate axillary and extra axillary lymphatic mapping.~Patients will be operated by breast conservative surgery (BCS) or mastectomy. Each patient will have a second SLND followed by a systematic complete ALND."
2391620|NCT03630640|Experimental|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant for 12 months
2391621|NCT03630627|Experimental|SB26 for Part 1|SB26: various single doses, administered to various cohorts
2391622|NCT03630627|Experimental|SB26 for Part 2|SB26: various multiple doses, administered to various cohorts
2391623|NCT03630627|Placebo Comparator|Placebo for Part 1|SB26 matching placebo: various single doses, administered to various cohorts
2391624|NCT03630627|Placebo Comparator|Placebo for Part 2|SB26 matching placebo: various multiple doses, administered to various cohorts
2391625|NCT03630614|Experimental|Electronic cigarette condition|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline
2391626|NCT03630614|Active Comparator|Varenicline condition|Reference group: Electronic cigarette without nicotine (ECwoN) plus active varenicline tablets
2391627|NCT03630614|Placebo Comparator|Placebo condition|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline
3143098|NCT00004285|Experimental|High dose, low flux hemodialysis|
2391633|NCT03630549|Active Comparator|Standard of Care|"Offer of home-based same-day ART initiation~Clinic-based ART visit/refill Who: Nurse Where: Nurse-led health facility When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~No SMS intervention"
2391634|NCT03630549|Experimental|Village-based ART refill|"Offer of home-based same-day ART initiation~Offer of Village-based ART visit/refill Who: VHW Where: At VHW's home* When: Follow-up interval of max. 3 months What: TB screening, Screening for other opportunistic infections, Screening for ART-related toxicities, adherence assessment, assessment whether patient visited any medical facility since last appointment, addressing basic psychosocial problems, ART (+CTX/IPT) dispensing~*Except at 6 and 12 months follow-up: visit at health facility for laboratory assessment (viral load)~Offer of Individually customized SMS~Monthly reminder SMS: to pick up ART~SMS communicating VL result"
2391635|NCT03630523|Other|Vaccination|Arm contains all subjects; vaccination with Influvac Tetra will be administered at start of study, response will be measured in 7 and 21 days.
2391636|NCT03630510|Experimental|mechanical ventilator hyperinflation|The VHI maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
2391637|NCT03630510|No Intervention|Control|To perform the control (CTRL), the patients were only positioned and aspirated, without alteration in ventilatory parameters.
2391638|NCT03630497|Experimental|Period 1 Single Dose SD1 (first dose)|"Period 1 Group SD1 a single IV infusion of first single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391639|NCT03630497|Experimental|Period 1 Single Dose SD2 (second dose)|"Period 1 Group SD2 a single IV infusion of second single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391640|NCT03630497|Experimental|Period 1 Single Dose SD3 (third dose)|"Period 1 Group SD3 a single IV infusion of third single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391641|NCT03630497|Experimental|Period 1 Single Dose SD4 (fourth dose)|"Period 1 Group SD4 a single IV infusion of fourth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391642|NCT03630497|Experimental|Period 2 Single Dose SD1 (fifth dose)|"Period 2 Group SD1 a single IV infusion of fifth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391643|NCT03630497|Experimental|Period 2 Single Dose SD2 (sixth dose)|"Period 2 Group SD2 a single IV infusion of sixth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391644|NCT03630497|Experimental|Period 2 Single Dose SD3 (seventh dose)|"Period 2 Group SD3 a single IV infusion of seventh single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391645|NCT03630497|Experimental|Period 2 Single Dose SD4 (Optional)|"(Optional) Period 2 Group SD4 a single IV infusion of eighth single dose of BN201 (n=6) or placebo (n=2)~Comparison of BN201 treatment with Placebo"
2391646|NCT03630497|Experimental|Multiple Dose MD1|"MD1 once daily IV infusions of first multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
2391647|NCT03630497|Experimental|Multiple Dose MD2|"MD2 once daily IV infusions of second multiple dose BN201 (n=6) or placebo (n=2) for 5 consecutive days~Comparison of BN201 treatment with Placebo"
2391648|NCT03630484|Active Comparator|Expiratory Rib Cage Compression|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
2391649|NCT03630484|Active Comparator|Compression + Ventilator Hyperinflation|Expiratory rib cage compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same.
2391650|NCT03630471|Active Comparator|Control|Enhanced usual care (problem-solving booklets only).
2391651|NCT03630471|Experimental|Intervention|PRIDE 'Step 1' problem-solving intervention.
2391652|NCT03630458|Experimental|Pearl millet couscous - made in Senegal|Steamed pearl millet couscous - commercially produced in Senegal
2391653|NCT03630458|Experimental|Pearl millet couscous - made in USA|Steamed pearl millet couscous - pearl millet obtained from Senegal but processed and prepared in USA
2391654|NCT03630458|Experimental|Pearl millet thick porridge|Thick porridge prepared according to traditional West African methods with pearl millet obtained from Senegal but processed and prepared in USA
2391655|NCT03630458|Experimental|Wheat couscous|Steamed wheat couscous - wheat flour processed and prepared in USA
2391656|NCT03630458|Active Comparator|White rice|White rice - medium-grain prepared using a rice cooker
2391657|NCT03630445|Experimental|Isomaltooligosaccharides (IMOs)|"Isomaltooligosaccharides (IMOs) incorporated into a yogurt test meal.~IMOs are a mixture of short-chain carbohydrates with a purported slow digestion property."
2391658|NCT03630445|Experimental|Xtend® sucromalt|"Xtend® sucromalt incorporated into a yogurt test meal.~Sucromalt is derived from a combination of sucrose (cane or beet sugar) and maltose (corn sugar), yet it has been found to be slowly digested."
2391659|NCT03630445|Experimental|Combination of IMOs and Xtend® sucromalt|Combination of IMOs and Xtend® sucromalt incorporated into a yogurt test meal.
2391660|NCT03630445|Experimental|Raw corn starch|"Raw corn starch incorporated into a yogurt test meal.~Raw corn starch is uncooked starch from corn. Because it is not cooked, it has a slow digestion property."
2391661|NCT03630445|Experimental|Maltodextrin|"Maltodextrin incorporated into a yogurt test meal.~Maltodextrin is a type of starchy carbohydrate (polysaccharide) composed of units of D-glucose (simple sugars). The maltodextrin used for this study had a fast digestion property."
2391662|NCT03630432|Active Comparator|Group A|Immediate 8 week course of pulmonary rehabilitation
2391663|NCT03630432|Placebo Comparator|Group B|Initial 8 weeks of usual care
2391665|NCT03630406||Laser treatment|Female patients with either SUI of vaginal wall weakness and prolapse refered for an attempt at laser treatment.
2391666|NCT03630393|Experimental|Pressure 6 mmHg|Pneumoperitoneum Pressure 6 mmHg
2391667|NCT03630393|Active Comparator|Pressure 15 mmHg|Pneumoperitoneum Pressure 15 mmHg
2391668|NCT03630380||Single Arm|All children under five years of age with clinical suspicion of pneumonia (fever or respiratory complaints) who have a chest radiograph ordered will be consented. Clinical history, physical exam findings (temperature, respiratory rate, oxygen saturation, and lung auscultation findings), laboratory findings (white blood cell count, differential, and CRP) will be recorded. Lung ultrasound will be performed on all patients.
2391669|NCT03630367|Experimental|study group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of L-carnitine 1 gm slow intravenous
2391670|NCT03630367|Active Comparator|control group|women will receive dexamethasone 8 mg intramuscular every 8 hours plus single injection of saline 1 gm slow intravenous
2391671|NCT03630354|Experimental|Arm I (supervised exercise together)|Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
2391672|NCT03630354|Experimental|Arm II (supervised exercise separately)|Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
2391673|NCT03630354|Experimental|Arm III (unsupervised exercise separately)|Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
2391674|NCT03630341|Experimental|study group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral carnitine 1g tablet, three times per day from the third day until the day of the pregnancy test.
2391675|NCT03630341|Active Comparator|control group|This group will receive oral clomiphene citrate 50 mg tablet, two times per day from the third day of the cycle until the seventh day of the cycle plus oral placebo tablet, three times per day from the third day until the day of the pregnancy test.
2391676|NCT03630328|Experimental|Cogni.Q|800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
2391677|NCT03630328|Placebo Comparator|Placebo|Two capsules in the morning and two capsules in the evening for 21 days
2391678|NCT03630315|Experimental|Cohort 1 (Low Dose)|Subjects will receive a low dose of OTX-TKI
2391679|NCT03630315|Experimental|Cohort 2 (Middle Dose)|Subjects will receive a middle dose of OTX-TKI.
2391680|NCT03630315|Experimental|Cohort 3 (High Dose)|Subjects will receive a high dose of OTX-TKI.
2391681|NCT03630315|Experimental|Cohort 3 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
2391682|NCT03630315|Experimental|Cohort 4 (High Dose)|Subjects will receive a high dose of OTX-TKI.
2391683|NCT03630315|Experimental|Cohort 4 (Anti-VEGF)|Subjects will receive OTX-TKI plus a single anti-VEGF injection
3143099|NCT00004285|Experimental|High dose, high flux hemodialysis|
2391685|NCT03630276|Other|Neutrophil/lymphocyte ratio|
2391686|NCT03630276|Other|Platelet/lymphocyte ratio|
2391687|NCT03630276|Other|CRP|
2391688|NCT03630263|Experimental|Raw Corn Starch|Vehicle (apple sauce) will be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
2391689|NCT03630263|Placebo Comparator|No Raw Corn Starch|Vehicle (apple sauce) will not be spiked with 30 g of slowly digestible carbohydrate (raw corn starch)
2391690|NCT03630250|Experimental|Challenge Volunteer - 4BN1|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4BN1 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4BN1."
2391691|NCT03630250|No Intervention|Contact Volunteer|Contact volunteers are those volunteers whose partner/spouse is a Challenge volunteer. Investigators will monitor Contact volunteers to collect information about transmission. A single dose of an antibiotic (Ciprofloxacin) will be administered on Day 90 regardless of colonisation with modified N. lactamica.
2391692|NCT03630250|Experimental|Challenge Volunteer - 4YB2|"Volunteers will be given a choice of which version of the GM N. lactamica they would like to be given (4BN1 or 4YB2).~On Day 0 Challenge volunteers will be asked to lie on their back, 0.5 mL of fluid containing a carefully measured amount of 4YB2 will be dripped slowly into each nostril. The volunteer will be able to breathe through their mouth during the procedure. Volunteers will be asked to remain lying down for 15 minutes. This will be performed only once.~Volunteers will then be admitted to the NIHR Southampton CRF for 5 days. Challenge volunteers will then be asked to return for follow up visits on Day 7, 10, 14, 28, 56 90 & 92.~A single dose of an antibiotic (Ciprofloxacin) will be administered on day 90 regardless of colonisation with modified N. lactamica 4YB2"
2391693|NCT03630237||Intensive care population|All patients admitted to any of the three adult intensive care units (general, cardiac & neurosciences) at a large teaching hospital. These patients will have a high sensitivity troponin added onto biochemistry samples requested by the clinical team.
3143100|NCT00004317|Experimental|1|This group of infants is treated with a loading dose of oral pyrimethamine followed by a higher dose for the first two months then a lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are also given orally for 12 months. The pyrimethamine loading dose is omitted if prior prenatal therapy was given.
3143101|NCT00004317|Experimental|2|This group of infants is treated with a higher dose of oral pyrimethamine for the first 6 months and then the lower dose for the remainder of the 12 months. Sulfadiazine and leucovorin calcium are administered concurrently.
2391696|NCT03630211|Experimental|Autologous Stem Cell Transplantation|CD34-selected autologous stem cell being performed on CliniMACS depletion device. Conditioning regimen will not start sooner than 3 weeks, and ideally no more than 90 days, after cyclophosphamide dose in the mobilization regimen.
3143102|NCT00004342||Adult Neutropenic Subject|Adult subjects with diagnosis of severe chronic neutropenia
2391701|NCT03630172|Experimental|Dry Needling Group|"Dry needles will be sterile, and 0.30 x 60mm in gauge and length. Needles will be placed using an inferomedial approach with the subject positioned in prone. The needle is inserted perpendicular to the skin and then is guided inferiorly and medially until it reaches the lamina. Needles will be manipulated in a pistoning fashion for 15 seconds."
2391702|NCT03630172|Sham Comparator|Sham Needling Group|Non-penetrating needles were constructed by cutting 100mm needles where the handle meets the shaft, and sanding down any rough edges. Guide tubes from 40mm needles will be used. These needles will be place in the same location and manipulated in the same fashion as in the dry needling group, except the needles will not have penetrated the skin.
2391704|NCT03630146|Experimental|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype video calls conducted over 5-12 weeks.
2391705|NCT03630146|Active Comparator|Waitlist Control Group|The control group will receive standard care but without the iPeer2Peer program.
2391706|NCT03630133|Experimental|Intracept System Ablation|Single Arm
2391711|NCT03630107|Experimental|WO 5101 Shampoo for Scalp and Hair|WO 5101 is used in subjects with chronically itchy scalp
2391712|NCT03630094|Experimental|FEP-ZID via intravenous|total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
2391713|NCT03630081|Experimental|FEP-TAZ 4 g|FEP-TAZ Pharmaceutical dosage form: Intravenous infusion Dosage: 4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
2391714|NCT03630081|Active Comparator|Meropenem|Meropenem Pharmaceutical dosage form: Intravenous infusion Dosage: 1 g IV q8h, infused over 45 min
2391715|NCT03630068||Patients with hepatocellular carcinoma treated with microwave|
2391716|NCT03630055|Experimental|Rivaroxaban|Participants will receive rivaroxaban 15mg tablet to be taken orally once daily for 7 days. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
2391717|NCT03630055|No Intervention|Standard of Care|Participants will not receive any anticoagulation. Follow up will be within 30 days where participants will undergo a Doppler ultrasound to assess for radial artery patency/occlusion.
2391718|NCT03630042|Experimental|Pembrolizumab and Rituximab|
2391719|NCT03630029|Other|Administer a dose 12mgFeS/9mg SnPP|12 healthy volunteers will be administered a single dose of 12 mg Iron Sucrose and 9 mg of Stannous Protoporphyrin and followed for seven days.
2391720|NCT03630029|Other|Administer a dose 60mgFeS/45 mg SnPP|12 healthy volunteers will be administered a single dose of 60 mg of Iron Sucrose and 45 mg of Stannous Protoporphyrin and followed for seven days.
2391721|NCT03630029|Other|Administer a dose 120mgFeS/90mg SnPP|12 healthy volunteers will be administered a single dose of 120 mg of Iron Sucrose and 90 mg of Stannous Protoporphyrin and followed for seven days.
2391722|NCT03630029|Other|Administer a dose 180mgFeS/135mg SnPP|12 healthy volunteers will be administered a single dose of 180 mg and 135 mg of Stannous Protoporphyrin and followed for seven days.
2391723|NCT03630029|Other|Administer a dose of FeS/SnPP CKD Arm|12 subjects with stage 3 or 4 CKD will be administered a single dose of Iron Sucrose and Stannous Protoporphyrin selected from the highest dose from the prior arm that evidences the best safety profile. The subjects will be followed for seven days.
3143103|NCT00004342||Minor Neutropenic Subject|Children under 18 years of age who are diagnosed with severe chronic neutropenia
3143104|NCT00004342||Parent of Minor Neutropenic Subjects|Parent of minor subjects (i.e., children under 18 years of age) who are diagnosed with severe chronic neutropenia
3143105|NCT00004465|Experimental|SYNSORB Pk|Oral Shiga toxin-binding agent (500 mg/kg/day)
2391730|NCT03629977||early RRT|A patient where initiation of RRT is started without the absolute indications
2393360|NCT03618511|Experimental|Information Group|
3143106|NCT00004465|Placebo Comparator|Placebo|Cornmeal placebo
3143107|NCT00004466|Experimental|Atorvastatin|
3143108|NCT00004466|Placebo Comparator|Placebo|
3143109|NCT00004467|Placebo Comparator|Placebo|
3143110|NCT00004467|Experimental|N-acetylcysteine (NAC)|
3143111|NCT00004474|Experimental|1|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2 with antithymocyte globulin IV over 4 hours; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
3143112|NCT00004474|Experimental|2|Participants will receive cyclophosphamide IV over 60 minutes on Days -5 to -2; then, after the last does cycophosphamide, participants will receive a bone marrow transplant over 60 to 120 minutes on Day 0.
3143113|NCT00004554|Experimental|Sertraline|sertraline
3143114|NCT00004554|Experimental|Naltrexone|naltrexone
3143115|NCT00004554|Experimental|Nal/Sert|naltrexone/sertraline
3143116|NCT00004554|Placebo Comparator|Placebo|Placebo
3143122|NCT00004578|Active Comparator|1|Group 1, n=32 initiated with ABT-378 & ritonavir; after 3 wks stavudine and lamivudine was added.
3143123|NCT00004578|Active Comparator|2|Group II patients (n=68) to be randomized after all Group I patients are enrolled and safety analysis is completed.
3143124|NCT00004604|Experimental|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
3143125|NCT00004660|Experimental|Radiotherapy|
3143126|NCT00004660|Sham Comparator|Sham treatment|
3143129|NCT00004769||Myotonic dystrophy|Subjects with myotonic dystrophy
3143130|NCT00004769||Healthy controls|Healthy subjects
2391731|NCT03629977||late RRT|"CRRT based on absolute indications.~Absolute indications:~hyperkalemia (serum potassium≥6 mEq/L),~severe acidosis (pH≤7.15),~plasma urea>36 mmol/L (equals BUN=100.8 mg/dl),~oliguria or anuria (urine output<0.3 ml/kg per hour for ≥24 hours or anuria for ≥12 hours), and~fluid overload with pulmonary edema as defined by the presence of all the following factors: (a) >10% fluid accumulation (cumulative fluid balance/baseline weight>10%), (b) oliguria (urine output<0.5 ml/kg per hour for ≥12 hours), and (c) severely impaired oxygenation (PaO2/FiO2<200 indicated by respiratory Sequential Organ Failure Assessment [SOFA] score≥3)"
2391732|NCT03629977||never RRT|RRT is never started, matched against early RRT group.
2391733|NCT03629964|Experimental|Head stabilizer group|Patients will be receiving standard brain radiation. The experimental head holder device (called the Wiersma Head Stabilizer) will be attached to treatment table and will make small movements to adjust the position of the head in response to movement by the patient. In addition, the AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the patient's head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
3143131|NCT00004769||Disease controls 1|Subjects with FSHD
2391737|NCT03629912|Experimental|Exercise + Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises AND health information on fall risks + diet/nutrition.
2391738|NCT03629912|Active Comparator|Exercise + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating exercises ONLY.
2391739|NCT03629912|Active Comparator|Health Education + Bingo|Socially-Based Exercise Intervention for Older Adults. Participants use the Bingocize app incorporating health information on fall risks + diet/nutrition ONLY.
2391740|NCT03629912|No Intervention|Bingo Only|Participants use the Bingocize app to play bingo only.
2391741|NCT03629899|Experimental|RETINA IMPLANT Alpha AMS|"After implantation surgery, every single sub-test will be performed with randomized implant activation (ON or OFF). During every trial of each sub-test there will be a study coordinator and a technician. The study coordinator will have a set randomization examination schedule while the technician will record patient response without knowledge of the randomization examination schedule. The patient, technician and investigator will all be masked to the testing conditions."
2391744|NCT03629860|Active Comparator|ascending ramus group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The ascending ramus is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from ascending ramus to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures.~after atrophic maxillary alveolar ridge augmentation,sub mucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7 days"
2391745|NCT03629860|Active Comparator|Chin Group|"Local anesthesia will be given to the patient~flap will be reflected to expose the facial wall of the maxilla then The chin is accessed.~A disc bur will be used to make a rectangular osteotomy~The block bone graft is removed from chin to recipient site the fixed by mini screws~Doner site flap is closed by using interrupted internal sutures~after atrophic maxillary alveolar ridge augmentation,submucosal periosteal releasing cuts is done~Post-operative medications will be prescribed as follows: amoxicillin/clavulanic acid tablets 10mg/kg every 12 hours for 7 days, metronidazole 5 mg/kg every 8 hours for 7days"
2391746|NCT03629847|Experimental|Everolimus & Radiolabeled Lu-177|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
2391747|NCT03629821|Experimental|Ballet|Subjects who will receive the experimental protocol.
2391748|NCT03629821|No Intervention|Control|Subjects who will not receive the experimental protocol, only will be on a wait list.
2391749|NCT03629808||Group1: 4-6cm|4-6cm from starting point of gastrectomy to pylorus
2391750|NCT03629808||Group2: 2-4cm|2-4cm from starting point of gastrectomy to pylorus
2391751|NCT03629769|Experimental|Patients with prostatitis-like symptoms|Cohort of patients with CP/CPPS (abacterial prostatitis)
2391752|NCT03629756|Experimental|Dose Escalation|3+3 design, including a DLT evaluation period. Etrumadenant RDE will be determined in this part with escalating doses of etrumadenant in combination with a fixed dose of zimberelimab.
2391753|NCT03629756|Experimental|Dose Expansion-advanced clear-cell RCC|Etrumadenant at RDE + zimberelimab
2391754|NCT03629756|Experimental|Dose Expansion-mCRPC|Etrumadenant at RDE + zimberelimab
2391755|NCT03629743||ECOG and EEG Sensor|Study subjects are neurosurgical patients with medically refractory epilepsy who will have implanted with intracranial ECoG electrodes. The electrodes will be used during a period of inpatient monitoring to identify resectable seizure foci.
2391818|NCT03629327|Active Comparator|No drug|no drug
3143132|NCT00004769||Disease controls 2|Subjects with CMT
3143133|NCT00004842|Experimental|Budesonide|Oral budesonide
3143134|NCT00004843|Experimental|Parathyroidectomy|
3143135|NCT00004843|Active Comparator|Observation|
3143140|NCT00004853|Experimental|1|single dose of intervention after each cycle of Standard 5 drug dose-intensive chemotherapy
3143141|NCT00004853|Experimental|2|single dose of interventionafter each cycle of Standard 5 drug dose-intensive chemotherapy
3143142|NCT00004856|Experimental|Treatment: Herceptin|Patients receive a loading dose of trastuzumab (Herceptin) IV over 90 minutes on day 1 of week 1. For all subsequent doses, patients receive trastuzumab IV over 30 minutes weekly. Treatment may continue for more than 1 year in the absence of unacceptable toxicity or disease progression.
3143143|NCT00004857|Experimental|Fludarabine + Campath-1H|Standard of care induction with fludarabine followed by consolidation antibody therapy
2391760|NCT03629717|Experimental|Denosumab|An ultrasound-guided core needle breast biopsy will be performed on day 1 prior to the intervention. A single dose of subcutaneous denosumab 60mg will be administered immediately after the core biopsy on day 1. This will take place on an outpatient basis. Repeat core-needle biopsy will take place on Day 60 (+/-10 days). Blood samples will also be collected at the time of core-needle biopsy to allow for biomarker assay. Gene expression analyses will be done using NanoString nCounter gene expression system.
2391761|NCT03629691||gastric cancer lung metastatic|One of the study tumors.Between February 1, 2015 and May 19, 2018, 356adult patients with gastric adenocarcinoma, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University, of them, 110 patients with lung metastasis. 28 patients with lung cavitation
2391762|NCT03629691||NSCLC|One of the study tumors.Between February 1, 2015 and May 19, 2018, 77 adult patients with primary lung cancer, multiline chemotherapy failure and lack of standard treatment, received oral apatinib 250 mg daily at the Affiliated Hospital of Qingdao University. 30 of 77 were squamous cell carcinoma and 47 of 77 were adenocarcinoma. 28 patients with lung cavitation.
3143144|NCT00004862|Experimental|Arm I|Patients receive augmerosen IV continuously on days 1-10 and filgrastim (G-CSF) subcutaneously beginning on day 5 and continuing until blood counts recover. Patients receive fludarabine IV over 30 minutes followed 3.5 hours later by cytarabine IV over 4 hours on days 6-10. Patients who achieve complete response (CR) receive a second course beginning 4 weeks after completion of the first course. Patients who achieve CR and have a matched sibling or unrelated bone marrow donor may undergo allogeneic bone marrow transplantation. Cohorts of 3-6 patients receive escalating doses of fludarabine and cytarabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
3143145|NCT00004867|Experimental|FDG-PET scan +/- neoadjuvant chemotherapy + surgery|"Patients receive fludeoxyglucose F 18 (FDG) IV followed 45-60 minutes later by positron emission tomography (PET) imaging. Confirmatory studies, such as biopsy or other imaging studies, are then conducted to confirm the FDG PET imaging results. Patients with no metastases identified by FDG PET imaging may undergo esophagectomy with or without neoadjuvant chemoradiotherapy within 1 month of evaluation.~Patients are followed within 6 months after surgery."
2391765|NCT03629665|Active Comparator|rTMS and naming combined with ILAT|Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
2391766|NCT03629665|Sham Comparator|sham rTMS and naming combined with ILAT|Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
3143146|NCT00004875||Standard Heparin|
2391769|NCT03629639|Experimental|Metformin|the distributed subjects will be orally administered Metformin 500mg bid lasting for 12 weeks.
2391770|NCT03629639|Placebo Comparator|Placebo|the distributed subjects will be orally administered Metformin-like placebo 500mg bid lasting for 12 weeks.
2391771|NCT03629626|No Intervention|Conventional Perioperative (SP) care|Conventional Perioperative (SP) care
2391772|NCT03629626|Experimental|ERAS protocol|preoperative / intraoperative/ postoperative management
2391773|NCT03629613|Sham Comparator|Baseline|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~During baseline testing, no supplement or placebo intake will be used."
2391774|NCT03629613|Experimental|Oral antioxidant cocktail|"Subjects will be tested on one day. Baseline testing will take place and will be followed by oral antioxidant cocktail intake. Oral antioxidant cocktail testing will take place ~2 hours after antioxidant intake.~Dose 1:(immediately after baseline) 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2: (30 minutes after dose 1) 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
2391775|NCT03629600|Experimental|Aggressive Hydration|Patients randomized to the aggressive intravenous hydration group received Lactated Ringers solution (LR) [COMPOUND SODIUM LACTATE INJECTION I.P.,INVEN PHARMACEUTICALS PVT.LTD,MP,INDIA] intravenously (IV) at 3 mL/kg/hr during the ERCP, a 20cc/kg IV bolus immediately afterward, and then at 3 mL/kg/hr for 8 hours following the procedure.
2391776|NCT03629600|Active Comparator|Rectal Indomethacin|Patients randomised to Rectal Indomethacin were administered a suppository of 100 mg of indomethacin [Indomethacin Suppository 100 Mg B.P, GALEN PHARMACEUTICAL LTD, GUJRAT, INDIA] just after the completion of ERCP procedure.
2391777|NCT03629587||Patients presented H pylori positive|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
2391778|NCT03629587||Patients with H pylori negative|Upper endoscopy, Gastric biopsy, CBC, VITAMIN B12 level, iron studys, folic acid level, bone marrow aspirate
2391779|NCT03629574|Experimental|Ventilated Group|This group will receive a protective mechanical ventilation during cardiopulmonary byass. No drugs will be administered.
2391780|NCT03629574|No Intervention|Not-ventilated group|This group will not receive any kind of mechanical ventilation during cardiopulmonary byass. The ventilator will be switched off.
2391781|NCT03629548|Active Comparator|early amniotomy plus dinoprostone|10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
2391782|NCT03629548|Experimental|foley balloon catheter plus dinoprostone|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and after placement of balloon catheter 10 mg dinoprostone vaginal ovul will be inserted to the posterior fornix
2391784|NCT03629522|Active Comparator|ondansetron group|Ondansetron 8Mg/4mL Injection: administration of a bolus of 8 mg intravenous Ondansetron diluted in 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
2391785|NCT03629522|Placebo Comparator|control group|administration of 10 ml of saline solution (0,09%) 5 minutes before spinal anesthesia
2391786|NCT03629509|Other|Pre-Intervention|"The BEFORE decision aid will be available for use on the RUBY communication portals (Twitter, Facebook and study portal)~Data will be collected 6 weeks before the implementation of the BEFORE decision aid in RUBY sites to establish a baseline"
2391819|NCT03629327|Active Comparator|ASA 81mg|daily uptake of 81mg ASA
2391787|NCT03629509|Experimental|BEFORE Decision Aid Intervention|"Evaluate more intensive strategies to promote use of the BEFORE decision aid through:~We will advertise the availability of the BEFORE decision aid with posters placed in clinic areas at each RUBY site, and will have small handouts available to be distributed in clinic.~We will conduct an educational intervention describing and promoting the use of the BEFORE decision aid and general oncofertility information to nurses and support staff at each RUBY site. This will include an optional 1hr informational webinar, direct outreach and training of nurses/support staff on the use of the tool."
2391788|NCT03629509|Other|Post-Intervention|Data will be collected after the BEFORE decision aid has been implemented in each RUBY site regarding the recommendation of fertility resources, most useful/least useful tool, and use of the BEFORE decision aid.
2391789|NCT03629496|Experimental|Arts-based intervention|Participants will participate in 6x1 hourly art sessions over a period of 3 weeks while they receive their haemodialysis treatment. This will involve 1:1 facilitation with a student and will involve visual arts including sketching, water colour painting and pen and ink, and creative writing activities. Participants will be provided with their own art supplies for infection control purposes and these will be kept on the unit in between sessions. Participants will have an option of displaying completed work in the reception area of the unit during their sessions.
2391790|NCT03629496|No Intervention|Control|Participants will receive usual care during their haemodialysis sessions and will be asked not to engage in any creative writing or visual arts during their haemodialysis sessions for the duration of the study. Once data collection has been completed the participants in the control group will receive art supplies and a single facilitated session on haemodialysis for the purpose of equity.
2391791|NCT03629483|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours (equivalent to dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
2391792|NCT03629483|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of continuous femoral nerve block. The formula contains a mixture of 0.2% ropivacaine 250 ml and placebo (normal saline). The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h for 48 hours.
3143147|NCT00004875||Enoxaprin|
2391795|NCT03629457|Experimental|Intervention group 4s (mindfulness)|Abbreviated program of 4 weeks: will consist of 4 weekly sessions of 2 hours. Participants must practice at home for 15 minutes a day
2391796|NCT03629457|Experimental|Intervention group 8s (mindfulness)|Program of 8 weeks: The format will be 8 weekly sessions of 2 hours. Participants must practice at home for 30 minutes a day
2391797|NCT03629457|No Intervention|Control group|The participants will only receive a one-hour information session and will be invited to complete the questionnaires provided in two moments of the time (coinciding with the interventions in the experimental groups)
2391798|NCT03629431|Active Comparator|postoperative standard care|Standard care after surgery in postoperative unit
2391799|NCT03629431|Experimental|Prophylactic non-invasive ventilation|Prophylactic noninvasive ventilation in postoperative and intensive care unit
2391800|NCT03629418|Experimental|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started at the beginning of anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher during surgery.
2391801|NCT03629418|Active Comparator|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
2391802|NCT03629405|No Intervention|A - Negative control (untreated) for product C|On the forearms four test areas were located, which were labeled from A-D. Test area A contralateral to product C
2391803|NCT03629405|No Intervention|B - Negative control (untreated) for product D|On the forearms four test areas were located, which were labeled from A-D. Test area B contralateral to product D
2391804|NCT03629405|Experimental|C - Cosmetic Product WO 3741 with pH 4|On the forearms four test areas were located, which were labeled from A-D. Test area C on the same arm like product D.
2391805|NCT03629405|Experimental|D - Cosmetic Product WO 4081-1 with pH 5.8|On the forearms four test areas were located, which were labeled from A-D.
2391806|NCT03629392|Experimental|Low met/cys diet|Dietary intervention
2391807|NCT03629392|Experimental|Moderate met/cys diet|Dietary intervention
2391808|NCT03629392|Active Comparator|High met/cys diet|Dietary intervention
2391809|NCT03629379|Active Comparator|ustekinumab arm|First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
2391810|NCT03629379|Active Comparator|vedolizumab arm|First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
2391811|NCT03629366|Experimental|Supported Employment (SE)|Follow-up with Supported Employment (SE), provided by a job specialist trained in the eight evidence-based principles of Individual Placement and Support (IPS). The SE intervention is provided in addition to the mandatory introduction program for refugees in Norway (treatment as usual).
2391812|NCT03629366|Active Comparator|Treatment as usual (TAU)|Follow-up with treatment as usual, which involves participation in the mandatory introduction program provided for all refugees in Norway. The program includes training in Norwegian language and culture, as well as the various traditional employment schemes offered by the Norwegian labor and welfare Administration.
2391813|NCT03629353|Experimental|intubation group|The enrolled patients will be oxygenated by endotracheal tube during operation.
2391814|NCT03629353|Experimental|THRIVE group|The enrolled patients will be oxygenated by intubationless high flow nasal cannula during operation.
2391817|NCT03629327|Active Comparator|ASA 325mg|Daily uptake of 325mg ASA
3143148|NCT00004883|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Treatment continues once a week in the absence of disease progression or unacceptable toxicity.
2391821|NCT03629301|Experimental|ID-DPP group|Internet-delivered intervention based on the DPP
2391822|NCT03629301|Other|Wait-list Group|
2391823|NCT03629288|Placebo Comparator|Periodontal treatment, lactose tab|Periodontal treatment (scaling and root planning) and one tablet containing lactose once a day for three days immediately after the scaling and root planning.
2391824|NCT03629288|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500 milligrams (mg) of Azithromycin once a day for three days immediately after the scaling and root planning.
2391825|NCT03629275|Experimental|CTX0E03 Drug Product and delivery device|20 million neural stem cells
2391826|NCT03629275|Sham Comparator|Placebo|Sham Surgery
2391827|NCT03629262|Experimental|Dexmedetomidine group|For patients in the dexmedetomidine group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of sufentanil (1.25 ug/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
2391828|NCT03629262|Placebo Comparator|Control group|For patients in the control group, postoperative analgesia is provided in the form of patient-controlled intravenous analgesia. The formula contains a mixture of placebo and sufentanil (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a patient-controlled bolus of 2 ml each time and a lockout interval of 8 minutes.
2391832|NCT03629236|Experimental|GrafixPL|
2391833|NCT03629236|Active Comparator|Control|
2391834|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391835|NCT03629223|Experimental|Part A, Stage 1: First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391836|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF2 then TF3|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391837|NCT03629223|Experimental|Part A, Stage 2 (Optional): First Tepotinib TF3 then TF2|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391838|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fasted then TF2 Fed|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
2391839|NCT03629223|Experimental|Part B: First Tepotinib TF2 Fed then TF2 Fasted|Participants will receive a single oral dose of Tepotinib TF2 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF2 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391840|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fasted then TF3 Fed|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fasting conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fed conditions. Two treatment periods will be separated by a washout period of 21 days.
2391841|NCT03629223|Experimental|Part C: First Tepotinib TF3 Fed then TF3 Fasted|Participants will receive a single oral dose of Tepotinib TF3 in treatment period 1 under fed conditions followed by single oral dose of Tepotinib TF3 in treatment period 2 under fasting conditions. Two treatment periods will be separated by a washout period of 21 days.
2391842|NCT03629210|Experimental|Combination Treatment|Combination treatment: Participants will receive intravitreal Eylea (AFL, 2.0 mg) injection and OZURDEX implant (0.7 mg) injection within 0 to 8 days of each other.
2391843|NCT03629210|Active Comparator|Monotherapy|Monotherapy treatment: Participants will receive OZURDEX implant (0.7 mg) injection.
2391844|NCT03629197|Experimental|Communication skills training|Intervention clinicians will receive 2 standardized patient visits. The first visit will consist of an 8 minute video on the development of 5 key communication skills, a 10-12 minute role-play session to practice using these skills, and 8-10 minutes of constructive feedback. The 2nd visit will include only the role-play and feedback components. Clinicians will also get a printed pocket card and pamphlet explaining the targeted communication skills in more detail.
2391845|NCT03629197|Active Comparator|Control|Control clinicians will receive a written summary of the 2016 CDC opioid prescribing guidelines, which include recommendations for best practices for use of opioids to treat chronic non-cancer pain. CDC guidelines will serve as an attention control.
2391907|NCT03628794|Other|Intervention|Subjects in the intervention group will receive the D-SCAN mobile application
3143149|NCT00004889|Experimental|Rituxan|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
3143150|NCT00004891|Experimental|primary resectable rectal cancer|
3143151|NCT00004893|Experimental|IL12 Therapy|Patients begin therapy no sooner than 3 weeks and no later than 6 weeks since last chemotherapy dose. Patients receive interleukin-12 subcutaneously twice a week. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at least every 3 months for 1 year. If no progression after 1 year, may be followed as needed for new signs or symptoms and survival for 5 years.
2391849|NCT03629158|Experimental|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks."
2391850|NCT03629158|No Intervention|Treatment as usual (TAU)|The TAU group will continue to receive their regular medical care.
2391851|NCT03629145|Experimental|Live Music Therapy|Twenty minutes of live, preferred music played on guitar and voice
2391852|NCT03629145|Placebo Comparator|Recorded Music|Twenty minutes of recorded music, also on guitar and voice, previously recorded by investigator
2391853|NCT03629132|Experimental|PRP|Platelet-rich plasma
2391854|NCT03629132|Sham Comparator|Gel|Self-crosslinking sodium hyaluronate gel
2391855|NCT03629119|Experimental|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet.
2391856|NCT03629106|Experimental|Contingent Reinforcement|The Contingent Reinforcement (CR) group (n=26) will be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence verified by self-report and urinary THC-COOH level <20 ng/ml.
2391857|NCT03629106|Experimental|No Contingent Reinforcement|The Non-Contingent Reinforcement (NCR) group (n=26) will not be given an abstinence bonus at the successful completion of a 28-Day cannabis abstinence.
2391858|NCT03629093||Long-time anesthesia exposure|Infants receive general anesthetics longer than 3 hours in total.
2391859|NCT03629093||Short-time anesthesia exposure|Infants receive general anesthetics shorter than 3 hours in total.
3143152|NCT00004893|No Intervention|Observation|Patients are observed for 6 months. If disease progresses during first 6 months, patients may receive interleukin-12 as in arm I. Patients without disease progression within first 6 months may also then receive interleukin-12 as in arm I. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for toxicity only until interleukin-12 is discontinued.
3143153|NCT00004909||Oral chemotherapy|
3143154|NCT00004909||Parenteral chemotherapy|
3143155|NCT00004918|Experimental|Arm I (dose level 1 PR1 leukemia peptide vaccine)|Patients receive dose level 1 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
3143156|NCT00004918|Experimental|Arm II (dose level 2 PR1 leukemia peptide vaccine)|Patients receive dose level 2 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
3143157|NCT00004918|Experimental|Arm III (dose level 3 PR1 leukemia peptide vaccine)|Patients receive dose level 3 of PR1 leukemia peptide vaccine with Montanide ISA-51 SC once every 3 weeks for 18 weeks, for a total of 6 vaccinations. Patients also receive GM-CSF SC with each vaccination.
2391866|NCT03629067|Experimental|Sequence A|"Period 1(Treatment R) - Period 2(Treatment R) - Period 3(Treatment T)~There will be a 14 washout of days between the each period."
2391867|NCT03629067|Experimental|Sequence B|"Period 1(Treatment R) - Period 2(Treatment T) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
2391868|NCT03629067|Experimental|Sequence C|"Period 1(Treatment T) - Period 2(Treatment R) - Period 3(Treatment R)~There will be a 14 washout of days between the each period."
2393361|NCT03618511|Experimental|Stigma-relieving Group|
3143158|NCT00004919|Experimental|Treatment (cisplatin, irinotecan, amifostine)|"Treatment A: Patients receive cisplatin IV over 1 hour followed immediately by irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Courses repeat every 6 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.~Treatment B: Patients receive therapy as in treatment A. In addition, amifostine IV is administered over 15 minutes immediately before cisplatin."
3143159|NCT00004929|Experimental|Vaccine|Patients receive vaccination with glycosylated MUC-2 antigen with keyhole limpet hemocyanin conjugate subcutaneously (SQ) plus immunological adjuvant QS21 SQ on weeks 1-3, 7, 15, and 27 for a total of 6 vaccinations. Patients are followed every 3 months for 1 year or until disease progression.
3143160|NCT00004931|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV (administered after 1 hour of leucovorin calcium) weekly for 6 weeks.
3143161|NCT00004931|Experimental|Arm II|Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and leucovorin calcium and fluorouracil as in arm I.
3143162|NCT00004932|Experimental|260 mg/m2 imatinib mesylate (ST571)|
3143163|NCT00004932|Experimental|340 mg/m2 imatinib mesylate (ST571)|
3143164|NCT00004932|Experimental|440 mg/m2 imatinib mesylate (ST571)|
3143165|NCT00004932|Experimental|570 mg/m2 imatinib mesylate (ST571)|
3143166|NCT00004933|Experimental|Homoharringtonine|
3143167|NCT00004933|Active Comparator|Hydroxyurea|
3143168|NCT00004935|Active Comparator|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
3143169|NCT00004935|Active Comparator|Herceptin™+Chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
3143170|NCT00004984|Experimental|Parenteral Insulin|High risk participants randomized to intervention
3143171|NCT00004984|Active Comparator|Close Observation|High risk participants randomized to observation
3143172|NCT00004984|Experimental|Oral Insulin|Intermediate risk participants randomized to intervention
3143173|NCT00004984|Placebo Comparator|Placebo|Intermediate risk participants randomized to placebo
3143174|NCT00004992|Placebo Comparator|Placebo|
3143175|NCT00004992|Active Comparator|Metformin|
2391875|NCT03629015|Experimental|Stemchymal®|Biological: Stemchymal® ALF/ ACLF patients will receive low (0.5 x 10^6 cells/kg) or high (2 x 10^6 cells/kg) dose of Stemchymal® through intravenous infusion
2391876|NCT03629002||patients with systemic scleroderma|Use of the biological collection of the vascualire stromal fraction of the SCLERADEC 2 clinical trial.
2391877|NCT03629002||healthy volunteers|Recovery of a sample of adipose tissue during a liposuction operation in a context of routine cosmetic surgery.
2391878|NCT03628989|Experimental|Cardiac Cathertization Patients|Participants will use technology based distraction during procedure.
2391879|NCT03628989|Experimental|Allergy Patients|Participants will use technology based distraction during procedure
2391880|NCT03628989|No Intervention|Procedure-Only Patients|
2391881|NCT03628976|Sham Comparator|Sham-tVNS to ear lobe|Sham-tVNS will be applied to the ear lobe.
2391882|NCT03628976|Active Comparator|tVNS to tragus|tVNS will be applied to the tragus.
2391883|NCT03628963|Experimental|Concerto+ (Intervention group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will use Concerto+ application during 6 months.
2391884|NCT03628963|No Intervention|Usual care (Control group)|Patients with two or more targeted chronic diseases (diabetes, hypertension, dyslipidemia) and who had three or more visits in the last 12 months will not use the application Concerto+ but receive usual care from FMG.
2391885|NCT03628950|Active Comparator|ICSSB group|infraclavicular suprascapular nerve block administered group
2391886|NCT03628950|Active Comparator|ISB group|interscalene nerve block administered group
2391887|NCT03628937|Experimental|Intervention group|"Interventions: Decaffeinated green tea polyphenol capsule (400 mg, EGCG accounted for 50%) will be given to participants in intervention group, and they need take it once a day after breakfast for 12 weeks.~Decaffeinated green tea polyphenol: 400mg/capsule, 1 capsule/d, qd, 12 weeks"
2391888|NCT03628937|Placebo Comparator|Control group|The placebo control group will be given placebo capsules, and participants need take it once a day after breakfast for 12 weeks.
3183836|NCT00717834|Experimental|Cohort 3, Treatment Arm 1|Randomization of a total of approx. 100 subjects to one of two treatment arms at 1:1 ratio to receive 10 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Vaccinations take place upon review of Cohort 1b and Cohort 2 Day 7 safety data by DMC and recommendation to proceed. Booster vaccination to follow 180 days after first vaccination.
3183837|NCT00717834|Experimental|Cohort 3, Treatment Arm 2|Same as Cohort 3, Treatment Arm 1
3183838|NCT00717847||1|Any patient with NSCLC receiving erlotinib or gefitinib
3183839|NCT00717847||2|Patients with unexpected and/or severe treatment related toxicity whilst receiving EGFR TKI.
3183840|NCT00717899|Active Comparator|1|School children from Haifa bay region, Israel.
3183841|NCT00717925|Experimental|1|
3183842|NCT00717938|Other|A|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants.Used drugs=cisplatinum or carboplatin and e.g.etoposide.
2391896|NCT03628872|Active Comparator|Scaling and Root Planing with Hand Instruments|Patients will undergo scaling and root planing with hand instruments (half of their mouth, following a split-mouth design)
2391897|NCT03628872|Experimental|Er:YAG Laser Scaling|Patients will undergo scaling and root planing with Er:YAG Laser in the untreated half of their mouth.
2391898|NCT03628846||Traumatically Injured Adolescent|
2391899|NCT03628846||Not Traumatically Injured Adolescent|
2391900|NCT03628833|Experimental|Incontinence Management system|
2391901|NCT03628820|Experimental|Therapy Dog|"This group is exposed to the therapy dog and handler. On a convenience sample of shifts, a dog will be available. Participants will not know when dogs will be present and will not be informed of whether or not they will see a dog on any given shift. The dog and handler will be kept out of site of other providers. Participants who agree to participate will be approached by study personnel between 3 and 7 hours into his or her shift and asked would now be a good time to see a therapy dog? If the physician answers yes, then the physician will be escorted to a separate private, quiet room away from the usual work area to interact with a therapy dog and handler. We will ask the physician to spend approximately 5 minutes with the therapy dog, but will not specify or mandate any time. Study personnel will record the time spent. Only the handler and dog will be present in the room."
2391902|NCT03628820|Experimental|Mandala Coloring|This group is not exposed to the therapy dog or handler. At 3-7 hours into the shift, study personnel will encourage providers to take a 5 min period of mindfulness, achieved by coloring mandalas. Participants will be escorted out of the work area to the same private, quiet room where the interaction occurs with the dog and handler in the therapy dog group. Participants will have their choice of one of three mandalas to color and will be provided a full palette of colored pencils. When the provider's time is up, study personnel will notify them of the five minute period. Study personnel will not be present in the room but will photograph the work when the participant is done with the session and record the image in REDcap. The original art work will be returned to the provider.
2391903|NCT03628820|No Intervention|No Intervention|This group is not exposed to the therapy dog or handler.
2391904|NCT03628807||Retrospective 1|Retrospective Bare Metal Stent Cohort that received TIPS from 01/01/1996 to 12/31/2003.
2391905|NCT03628807||Retrospective 2|Retrospective Covered Stent Cohort that received TIPS from 01/01/2004 to 12/31/2012.
2393362|NCT03618511|Experimental|Information and Stigma-relieving Group|
3183843|NCT00717938|Experimental|B|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
3183844|NCT00717951|Experimental|A|"Arm A is docetaxol+capecitabine chemotherapy"
3183845|NCT00717951|Experimental|B|"Arm B is docetaxol+cisplatin chemotherapy"
3183846|NCT00717990|Experimental|1|XELIRI/Avastin
3183847|NCT00718003||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3183848|NCT00718016||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
2391908|NCT03628794|Other|Control|Subjects randomized into the control group will receive standard of care which includes the routine provision of information about supportive care services by nurses and other staff in the DCI clinics, as part of the standard nurse-driven distress screening and management process
2391909|NCT03628781|Experimental|mehealth portal with integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will also have access to a module that allows parents and teachers to develop and implement behavioral interventions such as daily report cards online.
2391910|NCT03628781|Other|mehealth portal with no integrated behavioral tools|Patients in this arm will continue to use the mehealth for ADHD web-based software for ADHD care but will wait one year before getting access to the behavioral intervention features.
2391911|NCT03628768||Healthy / Non fallers|Older cognitively healthy individuals Non fallers
2391912|NCT03628768||Healthy / Fallers without injuries|Older cognitively healthy individuals Fallers without injuries
2391913|NCT03628768||Healthy / Fallers with injuries|Older cognitively healthy individuals Fallers with injuries
2391914|NCT03628768||MCI / Non fallers|Older individuals with MCI and mild dementia Non fallers
2391915|NCT03628768||MCI / Fallers without injury|Older individuals with MCI and mild dementia Fallers without injuries
2391916|NCT03628768||MCI / Fallers with injury|Older individuals with MCI and mild dementia Fallers with injuries
2391917|NCT03628755|Active Comparator|Digital Manipulation|Digital manipulation of thyroid cartilage (DMT) Duration: Each child was given 15-20 minute session. Frequency: Twice in a week. Total 24 sessions were performed. The aim of DMT was to reduce the severity of stuttering and improve the fluency.
2391918|NCT03628755|Active Comparator|fluency shaping Therapy|"Fluency Shaping Therapy Duration:Each child was given 30-minute session. Fluency Shaping Therapy (FST) Frequency: Twice in a week Total 24 sessions were performed.~The aim of DMT was to reduce the severity of stuttering and improve the fluency"
2391919|NCT03628755|Experimental|combination Group|Combination Group (DMT+FST) Duration:Each subject was given 45-Minute session Frequency: Twice in a week Total 24 sessions were performed combination group was more significant option for reducing the severity of stuttering and improve fluency than practice the single DMT or FST
2391920|NCT03628729|Experimental|Embrace™ WetBond™ Pit & Fissure Sealant.|pits and fissures will be sealed with bioactive pits-and-fissure sealant
2391921|NCT03628729|Active Comparator|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Pits and fissures will be sealed by fluoride releasing resin based pits and fissures sealant
2391922|NCT03628716|Experimental|CV301 + Atezolizumab|Subject receiving combination treatment with CV301 + Atezolizumab
2391923|NCT03628703|Experimental|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation
2391924|NCT03628690|Experimental|BandGrip|Topical skin closure device
2391925|NCT03628690|Active Comparator|Standard Suture|Standard sutures will be used for wound closure
3143176|NCT00004992|Active Comparator|Intensive Lifestyle|
3143177|NCT00005005|Experimental|1|Participants will receive PTH for 1 year followed by alendronate for 1 year.
3143178|NCT00005005|Experimental|2|Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
3143179|NCT00005005|Experimental|3|Participants will receive alendronate for 2 years.
3143180|NCT00005005|Active Comparator|4|Participants will receive PTH for 1 year followed by placebo for 1 year.
3143181|NCT00005006|Active Comparator|1|Alendronate alone
2391932|NCT03628664|Active Comparator|CT planned total knee arthroplasty|Surgeon will follow the CT plan
2391933|NCT03628664|No Intervention|Non CT planned total knee arthroplasty|Surgeon will not follow the CT plan
2391934|NCT03628651||HCC Surveillance|Approximately 1400 HCC surveillance subjects (controls) will be enrolled.
2391935|NCT03628651||HCC|Approximately 700 subjects with untreated clinically diagnosed HCC will be enrolled.
2391936|NCT03628638||Lung Cancer Screening Patients - No Nodules|Subjects in an low dose CT screening program that present no nodules.
2391937|NCT03628638||Lung Cancer Screening Patients - Nodules|Subjects in an low dose CT screening program that present nodules. Additional follow-up data will be collected for up to 12 months and an additional blood sample collected
2391938|NCT03628625|Experimental|Study group|3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.
2391939|NCT03628625|Placebo Comparator|Control group|three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses
2391940|NCT03628612|Experimental|AUTO CAR T cell therapy|Patients who received previous treatment with AUTO CAR T Cell Therapy
2391943|NCT03628573|Other|Intermittent Theta burst stimulation.|Procedure: repetitive transcranial magnetic stimulation (iTBS) to the left Dorsolateral Prefrontal Cortex; 3 sessions per day, for 20 days.
2391944|NCT03628560|Experimental|RespirAct Step-Wise Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
2391945|NCT03628560|Experimental|RespirAct Slope Normocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
2391946|NCT03628560|Experimental|RespirAct Step-Wise Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% in approximate 5% steps.
2391947|NCT03628560|Experimental|RespirAct Slope Hypocapnia desaturation sequence|Reduction in oxygen saturation 100 to 70% as gradual slope.
2391979|NCT03628365|Active Comparator|HMB (beta-hydroxy beta-methylbutyrate)|HMB, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
3143182|NCT00005006|Active Comparator|2|Teriparatide daily plus alendronate
3143183|NCT00005006|Active Comparator|3|Teriparatide cyclically plus alendronate
3143184|NCT00005009|Experimental|Varivax®|0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).
3143185|NCT00005022|Experimental|Arm 1|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
3143186|NCT00005022|Experimental|Arm 2|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D/5 days/4 weeks, boost 1.8 Gy/BID x last 5 days.
2391948|NCT03628560|Active Comparator|ROBD Step-Wise desaturation sequence|ROBD = Reduced Oxygen Breathing Device. Reduction in oxygen saturation 100 to 70% in approximate 5% steps. This represents the standard type of desaturation sequence for pulse oximeter accuracy testing.
2391949|NCT03628547||soccer players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur soccer players and10 professional soccer players.
2391950|NCT03628547||basketball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur basketball players and10 professional basketball players.
2391951|NCT03628547||volleyball players|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur volleyball players and10 professional volleyball players.
2391952|NCT03628547||runners|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur runners and 10 professional runners.
2391953|NCT03628547||table tennis athlete|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur table tennis athlete and 10 professional table tennis athlete.
2391954|NCT03628547||field tennis athlete|10 amateur field tennis athlete 10 professional field tennis athlete
2391955|NCT03628547||kickboxers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur kickboxers and 10 professional kickboxers.
2391956|NCT03628547||archers|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of 10 amateur archers and 10 professional archers.
3183849|NCT00718068|Experimental|Continuous|This group will receive potassium chloride by continuous infusion on a sliding-scale system based on serum potassium level.
2391958|NCT03628521|Other|arm A|Anlotinib combined with erlotinib. Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle. Erlotinib will be given at a dose of 150mg once daily.
2391959|NCT03628521|Other|arm B|Anlotinib combined with chemotherapy. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
2391960|NCT03628521|Other|arm C|Anlotinib combined with IBI308. Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle. IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
3183850|NCT00718068|Active Comparator|Intermittent|This arm will form the control group and receive potassium chloride by intermittent infusion as per conventional management
2391962|NCT03628495|Experimental|SSCP + SPMS|
2391963|NCT03628495|Active Comparator|PG|
2391964|NCT03628482|Active Comparator|CRF group|Patients were assigned to receive continuous radiofrequency (CRF) treatment of genicular nerves
2391965|NCT03628482|Experimental|PRF group|Patients were assigned to receive pulsed radiofrequency (CRF) treatment of genicular nerves
2391966|NCT03628469|Experimental|Proactive Health Support|The purpose of the intervention is to enhance patients' self-management strategies and thereby enable patients to cope with illness at home and prevent the development of those conditions, that are sensitive to preventive efforts.The intervention includes active listening, coaching and counselling and elements from case management such as assessing the need for healthcare services. Emphasis is on supporting and empowering the patient to make the necessary contacts to healthcare professionals.
2391967|NCT03628469|No Intervention|Usual care|Usual care
3183851|NCT00718107||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
2391969|NCT03628443||Heart Failure without Chronic Kidney Disease|This group has patients managed with all types of heart failure without concomitant chronic kidney disease.
2391970|NCT03628443||Heart Failure with Chronic Kidney Disease|This group has patients managed with all types of heart failure with concomitant chronic kidney disease, without evidence of sustained hyperphosphatemia.
2391971|NCT03628430|Placebo Comparator|Group C|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 0.9% NaCl"
2391972|NCT03628430|Active Comparator|Group A|"For patients of this group, the intervention was a Local Anesthesia with:~10 mL of 2% lidocaine with epinephrine 0.005mg/ml~and 5 mL of 4.2 % sodium bicarbonate"
3183852|NCT00718133|Experimental|1|Children at school age from Haifa bay region
3183853|NCT00718146|Experimental|Group 1|Age 16 to 60 years
2391975|NCT03628391|Active Comparator|haloperidol|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
2391976|NCT03628391|Placebo Comparator|placebo|"study drug will be titrated based on delirium, diagnosed with a validated screening instrument (CAM-ICU or ICDSC), starting with 2.5mg IV q8h and titrated to a maximum of 5mg IV q8h.~Agitation and hallucinations will be managed according to a pre-specified protocol in both treatment arms. First the study drug will be increased when agitation or delirium remain present. Further options include mainly the use of alfa-2 agonists (agitation) or atypical antipsychotic drugs (hallucinations)."
2391977|NCT03628378|No Intervention|Non-Sensor Group|Patients will undergo standard total knee replacement surgery without Verasense assisted balancing technology.
2391978|NCT03628378|Experimental|Sensor Group|Patients will undergo total knee replacement surgery with Verasense assisted balancing technology.
3183854|NCT00718146|Experimental|Group 2|Age over 60 years
3183855|NCT00718185||A|Patients receiving sildenafil as standard of care
3183856|NCT00718198||1|Group admitted 1 (one) month before CPOE protocol changes were made
3183857|NCT00718198||2|Group admitted 1 (one) year after CPOE protocol changes were made
2391980|NCT03628365|Placebo Comparator|Placebo|Maltodextrin, 1.5 g b.i.d., from day 4 to day 30 after ICU admission
2391981|NCT03628352|Experimental|Tricaprilin|Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
2391982|NCT03628339|Experimental|Midazolam, then tepotinib followed by midazolam + tepotinib|Participants will receive a single oral dose of midazolam on Day 1 of treatment period 1 followed by daily single oral dose of tepotinib from Day 1 to Day 10 of treatment period 2 and then co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
2391983|NCT03628326||right lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
2391984|NCT03628326||left lung resection|The investigators sought to identify anatomic variations of the pulmonary arterial tree and assess their respective frequencies.
2391985|NCT03628313||Aortic valve stenosis|The participants will be identified from the Transthoracic ultrasound echocardiography reports of the echocardiography laboratory of the University Hospital of Amiens and CH Philibert for the retrospective part. They are analyzed during echocardiography at the echocardiography laboratory of two participating centers when a diagnosis of aortic stenosis is made. Patients are informed by newsletter.
2391986|NCT03628300||piperacillin serum measurement|patient that underwent at least one piperacillin serum concentration monitoring
2391987|NCT03628300||included for analysis|patient that have been included for analysis according to previously described criteria
2391988|NCT03628287|Active Comparator|Original Care Coordination Program|Specific intervention components include: 1) outreach for initial case finding and after any missed appointment; 2) case management, including social services and benefits assessments; 3) multidisciplinary care team communication and decision-making via case conferences; 4) patient navigation, including appointment reminders, assistance with scheduling appointments, transportation resources, and accompaniment to primary care visits; 5) antiretroviral treatment adherence support, including directly observed therapy for individuals with greatest need; and 6) structured health promotion, for which clients are assigned to program tracks (determining their frequency of health promotion visits: weekly, monthly or quarterly), depending on their level of assessed need.
2391989|NCT03628287|Experimental|Revised Care Coordination Program|"The revised model includes the original intervention components without program track assignments or the three-month induction period of weekly visits. Program additions include a set of tools for assessment and counseling around client HIV self-management capacity; allowance of video chat for delivery of some services; and optional iART (immediate ART: ensuring the client has a filled prescription within 4 days of enrollment or diagnosis). Other changes include greater guidance on recruiting individuals with unsuppressed VL and a switch from per-member-per-day reimbursement to fee-for-service reimbursement that accounts for resource demands, such as staff travel to clients' homes, and offers higher rates for meeting performance standards."
2391990|NCT03628274|Experimental|Magnetic Resonance Imaging (RMI) 7 Tesla|
2391991|NCT03628261|Other|physical therapy then serious games|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
2391992|NCT03628261|Other|serious games then physical therapy|Children will receive four weeks of treatment with EMG-based serious games in addition to the conventional physiotherapy
2391993|NCT03628248|Experimental|embolization|
2391994|NCT03628248|Other|No embolization|
3143187|NCT00005022|Experimental|Arm 3|Large field radiation therapy 32.4 Gy, 1.8 Gy/fx/D/5 days x 18 fx, boost just in pm @ 1.8 Gy/fx on days 19 & 20, then boost 1.8 Gy BID x last 5 days.
3143188|NCT00005022|Experimental|Arm 4|Large field radiation therapy 28.8 Gy, 1.8 Gy/fx/5 days x 16 fx, boost just in pm @ 1.8 Gy/fx on days 17-20, then boost 1.8 Gy BID x last 5 days.
3143189|NCT00005022|Experimental|Arm 5|Large field radiation therapy 36 Gy, 1.8 Gy/fx/D 5 days/4 weeks, boost 1.8 Gy/D x 2 days, then BID x last 3 days.
2392001|NCT03628222|Experimental|ENB-TBLB|Under ENB guidance, the Location Catheter and Guide Catheter reach the lesion. After confirmation by X-ray, biopsy tools are introduced and specimens are obtained.
2392002|NCT03628222|Active Comparator|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and specimens are obtained.
2392003|NCT03628209|Experimental|Dose Escalation, Resection, Dose Expansion|Participants will receive 1 cycle of neoadjuvant Nivolumab or Nivolumab + Azacitidine, followed by surgery to render them in surgical remission. Subsequently they will continue to receive Nivolumab or Nivolumab + Azacitidine for 12 additional cycles or until recurrence, whichever occurs first. Once the recommended Phase II dose (RP2D) is identified during Phase I, the Dose Expansion Phase II will be opened at this dose level. The Phase II portion of the study will consist of a maximum 33 evaluable patients (27-30 in addition to the 3-6 enrolled at RP2D on the Phase I portion).
2392004|NCT03628196||Quality Improvement Program Basic and Enhanced Phase|Patients that meet the eligibility criteria and participate in the QIP.
2392005|NCT03628196||Retrospective Group|Patients seen a year prior to the QIP period at the clinic but that did not participate in the QIP.
2392006|NCT03628196||Concurrent Group|Patients seen during the QIP period at the clinic but that did not participate in the QIP.
2392007|NCT03628183|Active Comparator|Hydrolysate Infant Formula 1|Ready to feed infant formula in can
2392008|NCT03628183|Experimental|Hydrolysate Infant Formula 2|Ready to feed infant formula in bottle
2392009|NCT03628170|Experimental|PRF (Platelet -rich fibrin) group|Extraction of the tooth followed by Platelet rich fibrin placed in the socket covered bu platelet rich fibrin membrane for socket preservation.
2392010|NCT03628170|Active Comparator|Free gingival graft group|Extraction of the tooth followed by using free gingival graft to cover the socket for socket preservation.
2392011|NCT03628157|Experimental|intervention|using a bio-oss bovine bone alone
2392012|NCT03628157|Active Comparator|control|using a bio-oss bovine bone with autogenous bone ratio 1:1
2392013|NCT03628144|Experimental|A: Intervention Group - Impact®|A: Intervention Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Impact® Advanced Recovery: Three times daily for the 5 days just prior to the start of each cycle of chemotherapy. Participants will undergo pre- and post-treatment assessments.
2392188|NCT03626961||readmission|patients readmitted icu in 48 hours after icu discharge
2392014|NCT03628144|Active Comparator|B: Control Group - Boost®|B: Control Group - Standard of Care Concurrent Chemoradiotherapy (Chemotherapy + Radiation) with nutritional supplement. Boost® High Protein: Identical schedule of a supplement with similar calorie and protein content, Boost® High Protein. Participants will undergo pre- and post-treatment assessments.
2392015|NCT03628131|Experimental|Pazopanib + conventional chemotherapy|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
2392016|NCT03628118||open radical hysterectomy|"The patients who would undergo open radical hysterectomy procedure."
2392017|NCT03628105|Experimental|CR Before Exposure|Participants in this arm will receive 15 minutes of CR (preparation) before engaging in exposure and will complete the 15-minute questionnaire filler task after exposure.
2392018|NCT03628105|Experimental|CR After Exposure|Participants in this arm will complete the 15-minute questionnaire filler task before exposure and receive 15 minutes of CR (consolidation) after engaging in exposure.
2392019|NCT03628092|Active Comparator|CO2 Fractional Ablative Laser|3 treatments approximately 4 weeks apart with vaginal/vulval laser
2392020|NCT03628092|Placebo Comparator|Placebo|"3 treatments approximately 4 weeks apart with sham laser"
2392021|NCT03628079|Experimental|Single arm study|"ReposMBZ 100 mg capsule by mouth followed by 8h PK sampling to decide the initial daily dose.~Treatment: Repos MBZ capsules by mouth twice daily for 16 weeks, daily dose 50mg-4g, based on the serum level of mebendazole."
2392022|NCT03628066|Experimental|Arm 1|"Oncotype DX Breast recurrence score on diagnostic tissue~Daily Letrozole for 24 weeks + Palbociclib daily for 24 weeks + Goserelin weekly for 24 weeks"
2392023|NCT03628053|Experimental|Tisagenlecleucel arm|Patient to receive tisagenlecleucel after optional bridging therapy and lymphodepleting chemotherapy.
2392024|NCT03628053|Active Comparator|Control arm|blinatumomab or inotuzumab per investigator's discretion after optional bridging chemotherapy
2392025|NCT03628040|Sham Comparator|Sham Block|Patient will receive a single shot of normal saline 20 mL injected at the erector spinae plane
2392026|NCT03628040|Active Comparator|Erector Spinae Block|Patient will receive a single shot of Ropivacaine Injection [Naropin] 0.5% 20 mL injected at the erector spinae plane
2392027|NCT03628027|Experimental|Treatment Algorithm|The treatment algorithm arm will be the experimental arm in which GPs use the computerised decision support tool to guide their prescribing of antidepressants.
2392028|NCT03628027|No Intervention|Treatment-as-usual|The treatment-as-usual arm will comprise GPs prescribing antidepressants and providing care as they typically would.
2392029|NCT03628014|Other|Interventional|The HELP Program is a comprehensive inpatient-care program that ensures optimal care for older adults in the hospital by using trained volunteers that do specific activities to help prevent or maintain functional decline.
2392030|NCT03628001|Other|A|ERCP with (Group A) ES before biliary SEMS placement
2392031|NCT03628001|Other|B|ERCP without (Group B) ES before biliary SEMS placement
2392032|NCT03627988|Experimental|Patients with breast cancer|
2392033|NCT03627975|No Intervention|Conservative treatment|Conservative treatment. The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, the prevention and treatment of secondary epilepsy, the control of intracranial hypertension(including the application of mannitol and glycerol fructose, etc.), and the corresponding symptomatic and neurotrophic treatment. Non-specific treatment is mainly deal with intracranial hematoma, including intraventricular drainage, intracranial hematoma evacuation, and ventriculoperitoneal shunt.
2392034|NCT03627975|Experimental|Indirect vascular reconstruction surgery|Indirect vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) is performed. The surgery is performed according to the procedures described by Matsushima.
2392035|NCT03627975|Experimental|direct vascular reconstruction surgery|Direct vascular reconstruction surgery. In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) bypass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And if necessary, the STA may not be preserved. The bone flap should be large enough to select the right recipient blood vessel.
2392036|NCT03627962|Experimental|gaze-directed oculomotor training|device: Tobii PCEye Treatment group went through the oculomotor training with a gaze-pointer interface (Tobii PC Eye) in reading in Chinese.
2392037|NCT03627962|No Intervention|control|No intervention: participants in control read ordinary Chinese textbooks.
2392038|NCT03627949|Experimental|Intervention group 1|Students in the intervention group 1 received first 4-week treatment on physical activity followed by 4-week treatment on healthy dietary behaviour.
2392039|NCT03627949|Experimental|Intervention group 2|Students in the intervention group 2 received first 4-week treatment on healthy dietary behaviour followed by 4-week treatment on physical activity.
2392040|NCT03627949|No Intervention|Control group|Students in the control group were not provided with any supportive treatments on physical activity or healthy dietary behaviour.
2392041|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Zofingen (A) + Kawashima (B)|Participants will receive a single oral dose of lorcaserin 20 milligram (mg) XR tablets manufactured at Zofingen (A) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Kawashima (B) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
2392042|NCT03627936|Experimental|Lorcaserin 20 mg manufactured at: Kawashima (B) + Zofingen (A)|Participants will receive a single oral dose of lorcaserin 20 mg XR tablets manufactured at Kawashima (B) after a 10-hour overnight fast on Day 1 of treatment period 1 followed by a single oral dose of lorcaserin 20 mg XR tablet manufactured at Zofingen (A) after a 10-hour overnight fast on Day 7 of treatment period 2. A washout period of 5 days will be maintained between the 2 treatment periods.
2392043|NCT03627910|Experimental|Treatment group|Participants assigned to the treatment group will be administered a commercial symbiotic (Probinul Ca.Di.GROUP S.r.l.) for the entire duration of the study (90 days) plus an enteral nutrition formula rich in zinc and arginine
2392044|NCT03627910|Active Comparator|Control group|Control group will be administered only an enteral nutrition formula rich in zinc and arginine
2392245|NCT03626519|Experimental|Test with Menthol|Patients will chew a menthol flavored chewing gum 5 minutes before perform one Six-minute Walk Test
2392045|NCT03627897|Experimental|Regional analgesia group|ESP block at bilateral side will be performed in the lateral decubitis position and at T5 transverse process level by using 10-MHz liner ultrasound probe. The probe will be located 1 cm lateral to T5 spinous process in longitudinal parasagittal orientation. Simplex A 50mm (B.Braun, Germany) will be inserted by using out of plane technique. The ESP blocks proceed with 0,5 ml/kg of 0,25% bupivacaine
2392046|NCT03627897|Other|Control group|
2392047|NCT03627884|Active Comparator|Normal Saline Catheter Lock Solution Group|Patients receiving normal saline catheter locking solution
2392048|NCT03627884|Active Comparator|Sodium Bicarbonate Catheter Lock Solution|Patients receiving sodium bicarbonate catheter locking solution
2392049|NCT03627871|Experimental|Trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population and are told this norm has been increasing recently.
2392050|NCT03627871|Experimental|Non-trending majority norm|Participants receive information about exercise-related norms that apply to the majority of the population but are not told about recent trends.
2392051|NCT03627871|Experimental|Trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population and are told this norm has been increasing recently
2392052|NCT03627871|Experimental|Non-trending minority norm|Participants receive information about exercise-related norms that apply to a minority of the population but are not told about recent trends.
2392053|NCT03627871|Experimental|Control|Participants receive information about exercise unrelated to social norms or recent trends.
2392054|NCT03627845|Experimental|Experimental|PHP-303, single oral dose, up to 6 ascending dose cohorts
2392055|NCT03627845|Placebo Comparator|Placebo|Placebo, single oral dose, up to 6 ascending dose cohorts
3183858|NCT00718224|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~To maintain the blind, placebo for Enoxaparin sodium:~12 and 24 hours after surgery, then once daily if no SRI~12 hours after surgery only if SRI"
3183859|NCT00718224|Active Comparator|Enoxaparin|"Enoxaparin sodium 30 mg twice daily (20 mg once daily if Severe Renal Impairment [SRI]) for 7-10 days with an initial dose given 12 hours after surgery~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
2392058|NCT03627819|Active Comparator|Plant sterol-enriched margarine|Intake of 20 gram margarine with added plant sterol esters, providing 3 gram plant sterols per day for 1 year
2392059|NCT03627819|Active Comparator|Plant stanol-enriched margarine|Intake of 20 gram margarine with added plant stanol esters, 3 gram plant stanols per day for 1 year
2392060|NCT03627819|Placebo Comparator|Control margarine|Intake of 20 gram margarine without any addition, every day for 1 year
2392061|NCT03627793|Active Comparator|High load non-frail|Non-frail participants who will receive resistance training at 70% of their maximal strength
2392062|NCT03627793|Active Comparator|low load non-frail|Non-frail participants who will receive resistance training at 30% of their maximal strength
2392063|NCT03627793|Experimental|high load frail|Frail participants who will receive resistance training at 70% of their maximal strength
2392064|NCT03627793|Experimental|low load frail|Frail participants who will receive resistance training at 30% of their maximal strength
2392065|NCT03627780||PONV|Patients presenting with postoperative nausea and vomiting
2392066|NCT03627780||no PONV|Patients not presenting with postoperative nausea and vomiting
3183860|NCT00718250|Experimental|cohort 1|AML Cell Vaccine alone
2392070|NCT03627754|Experimental|Moderate Hepatic Impairment Group|Subjects with Child-Pugh Classification B (score 7-9)
2392071|NCT03627754|Experimental|Severe Hepatic Impairment Group|Subjects with Child-Pugh Classification C (score 10-15)
2392072|NCT03627754|Experimental|Normal Hepatic Function Group|Healthy subjects with normal hepatic function
2392073|NCT03627741|Experimental|Triamcinolone arm|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
2392074|NCT03627728|Experimental|regorafenib|Regorafenib 160 mg, 4 tablets once daily on days 1-21, every 4 weeks, until intolerance or progression disease
2392075|NCT03627728|Placebo Comparator|placebo|Placebo 4 tablets once daily on day 1-21, every 4 weeks, until intolerance or progression disease
2392076|NCT03627715|Experimental|Propagermanium then Placebo|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks propagermanium and 12 weeks placebo separated by a 6 week washout period."
2392077|NCT03627715|Experimental|Placebo then Propagermanium|"Propagermanium one capsule orally twice daily for 12 weeks. Compliance will be measured by drug accountability and completion of a participant diary.~Participants will receive 12 weeks placebo and 12 weeks propagermanium separated by a 6 week washout period."
2392078|NCT03627702||Study group|All bedsores were irradiated with a Bioptron lamp. Photo and measurement of bedsores size and Torrance score, were made: on the first, 9,18 and 36 day of therapy.
2392079|NCT03627689|Experimental|Active air purifier arm|Active portable air purifier for 1 month at bedside
2392080|NCT03627689|Sham Comparator|Sham air purifier arm|Placebo portable air purifier for 1 month at bedside
2392081|NCT03627676|Experimental|Intervention|
2392082|NCT03627663|Experimental|Intervention|Receiving treatment with Dialectic Behavior Therapy - Skills System + Treatment As Usual
2392083|NCT03627650|Experimental|1 group of 15 patients|procedure/surgery: fat grafting injection of scar
2392084|NCT03627650|Experimental|Same group of 15 patients|procedure/surgery: placebo injection of scar
2392085|NCT03627637|Experimental|Experimental: Soy nuts|
2392086|NCT03627637|No Intervention|Control - no soy nuts|
2392087|NCT03627611|Active Comparator|T4|
2392088|NCT03627611|Experimental|T3|
2392089|NCT03627598|Active Comparator|standard group|NIV alternating with low oxygen therapy at 1 to 4 liters per minute to obtain SpO2 between 88% and 94%.
2392090|NCT03627598|Experimental|HFNC group|NIV alternating with HFNC delivering the equivalent inspired fraction of oxygen (FiO2) with a flow at 30 to 60 liters/min through an Optiflow nasal interface.
2392091|NCT03627585|No Intervention|Usual Care|Patients received echocardiogram but no pacemaker reprogramming or personalisation.
2392092|NCT03627585|Active Comparator|Personalised programming|Patient will have tailored pacemaker programming based on echocardiographic findings, blood results, and symptoms in an attempt to minimise right ventricular pacing and extend battery longevity.
2392093|NCT03627572||Active cohort (N=1000)|Participants in this group will complete questionnaires at baseline (birth) and after 1-2-3 years. At baseline samples will be collected (blood/nasopharyngeal/urine/feces/buccal). During the RSV season(Oct-May) active sampling for RSV will be done when infants experience a respiratory infection.
2392094|NCT03627572||Passive cohort (N=9000)|Parents who agree with participation in the study will be asked to fill out a questionnaire at inclusion in the first week(s) after birth and at age one year. Only children who were admitted to the hospital for ARTI during the first year of life will be followed up to the age of maximum 3 years by yearly questionnaires.
2392095|NCT03627559||Pancreaticoduodenectomy patients|All patients undergoing pancreaticoduodenectomy receive a microdialysis catheter before skin closure and will be monitored postoperatively for lactate, pyruvate, glucose and glycerol in the microdialysate at certain timepoints
2392096|NCT03627546|Experimental|Rapid Treatment with sofosbuvir/velpatasvir (Intervention arm)|"The intervention arm receives same-day medical evaluation and treatment for hepatitis C. They receive medical evaluation, laboratory assessment , baseline questionnaire/interview, and distribution of a medication (sofosbuvir/velpatasvir) starter pack on the day of enrollment. Participants who are HCV RNA negative are discontinued from the study. Other participants start medications and receive weekly text messages during treatment to record adherence. They have follow up visits for laboratory tests, medication distribution, and counseling for prevention of reinfection. They have HCV testing at end of treatment and 12 weeks post treatment, and at 48 weeks to assess for reinfection. Each study visit will include a brief questionnaire and qualitative interview."
2392097|NCT03627546|No Intervention|Usual Care (Control arm)|Participants in the control arm will be provided facilitated referral to community HCV providers by an on-site care coordinator already facilitating care at the community site. HCV RNA negative participants will be called to inform them of these results, and then discontinued from the study. HCV RNA positive participants will be asked during the semi-structured interviews as at 12, 24, 36 and 48 week if they engaged in HCV treatment to assess whether their HCV referral has been filled, and to record their current HCV treatment status. They will also receive repeat HCV RNA testing at week 12, 24, and 48. Participants that have started treatment will be asked to sign consent for release of medical records pertaining to HCV-related laboratory testing to determine achievement of treatment response.
2392098|NCT03627533|Experimental|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on MA-IC3 endocrine (ear points), GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
2392099|NCT03627533|Sham Comparator|Sham electroacupuncture|Sham electroacupuncture are done at same electroacupuncture point location but puncture are not done, also electro stimulator are turned off.
2392100|NCT03627520|Other|[14C]Sulfatinib|This is a single center and single dose in 6 volunteers. Subject would take a suspension containing 300 mg of Sulfatinib (containing about 100 μCi of radioactivity) within 1 hour after standard breakfast.
2392101|NCT03627507|Experimental|Hepa B|79 participant will be randomly assigned to the test group for receiving the locally produced 'Hepa-B' vaccine.
2392102|NCT03627507|Active Comparator|Engerix B|79 participant will be randomly assigned to the comparator group for receiving 'Engerix-B' vaccine.
3183861|NCT00718250|Experimental|cohort 2|Donor leukocytes alone
3183862|NCT00718250|Experimental|cohort 3|AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)
3183863|NCT00718250|Experimental|cohort 4|AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)
3183864|NCT00718276|Active Comparator|1|25(OH)D
3183865|NCT00718276|Active Comparator|2|vitamin D3
3183866|NCT00718289|Experimental|Citrate|Citrate dialysate for haemodialysis
3183867|NCT00718289|Active Comparator|Acetate|Acetate dialysate
3183868|NCT00718341|Active Comparator|1|
3183869|NCT00718341|Placebo Comparator|2|
3183870|NCT00718354|Active Comparator|B|Standard Chemotherapy (upto 6 cycles)
3183871|NCT00718354|Experimental|A|Enoxaparin: 1 mg/kg once daily in addition to standard chemotherapy up to 6 months
3183872|NCT00718380|Experimental|Group 1|Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
3183873|NCT00718380|Experimental|Group 2|Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
3183874|NCT00718380|Experimental|Group 3|Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
3183875|NCT00718380|Experimental|Group 4|Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
3183876|NCT00718393||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3183877|NCT00718406|Active Comparator|A|A=metoprolol
3183878|NCT00718406|Active Comparator|B|B=metoprolol plus morphine
3183879|NCT00718432|Active Comparator|UC group|Usual care with education
3183880|NCT00718432|Experimental|ENIC group (IC group in 2009 study)|Exercise and nutritional integrated care
3183881|NCT00718432|Experimental|PSTIC group (IC group in 2009 study)|Problem solving therapy integrated care
3183882|NCT00718445||MND|"Patients seen in the MDA/ALS Center of Hope at Drexel University College of Medicine~Patients seen in the Department of Neurology at Drexel University College of Medicine"
3183883|NCT00718458||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
3183884|NCT00718458||Non-ALS|Subjects not having either definite or probable ALS by El Escorial Criteria.
3183885|NCT00718471|Experimental|1|Enoxaparin
3183886|NCT00718471|Active Comparator|2|UFH
2392116|NCT03627481|Experimental|AERD patients|Patients managed with Endoscopic sinus surgery for treatment of AERD.
2392117|NCT03627468|Experimental|Gel, 5%|Sofpironium Bromide Gel, 5%, q.d. for 48 weeks
2392118|NCT03627468|Experimental|Gel, 15%|Sofpironium Bromide Gel, 15%, q.d. for 48 weeks
2392119|NCT03627455||Male, with DM|
2392120|NCT03627455||Male, without DM|
2392121|NCT03627455||Female, with DM|
2392122|NCT03627455||Female, without DM|
2392123|NCT03627442|Active Comparator|Mastectomy with PhotonBlade|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with PhotonBlade
2392124|NCT03627442|Active Comparator|Mastectomy with Bovie|Patients undergoing double mastectomy with immediate reconstruction with expanders. One breast will be randomly selected to be operated with Bovie.
2392127|NCT03627403|Experimental|Selinexor, all patients|Single Arm Study, all patients will get selinexor
2392128|NCT03627390|Experimental|BP-C1|Patients will be treated with BP-C1 for 32 consecutive days
2392129|NCT03627390|Experimental|BP-C1+BP-C2|Patients will be treated with BP-C1 and BP-C2 for 32 consecutive days
2392130|NCT03627377|No Intervention|Control Phase|3-month initial control phase (no intervention, month 1-3)
2392131|NCT03627377|Experimental|Intervention Phase|6-month intervention phase - MIDAS Intervention Delivered. Followed by 6-month follow-up phase (no intervention, months 10-15).
2392132|NCT03627364||Post stroke patients|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in healthy individuals.
2392133|NCT03627364||Control group|will be submitted to a single session to obtain the normal neurophysiological and behavioral endpoints and thus compare with those obtained in post stroke patients.
3143190|NCT00005022|Experimental|Arm 6|Large field radiation therapy 25.2 Gy, 1.8 Gy/fx/5 days x 14 fx, boost just in pm @ 1.8 Gy/fx on days 15-20, then boost 1.8 Gy BID x last 5 days.
2392135|NCT03627338||Norfloxacin|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2392136|NCT03627338||Non-selective beta blockers|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2392137|NCT03627338||diuretics|evaluate medication adherence, patient history, medication beliefs and medication satisfaction, depression, anxiety and health-related quality of life
2392138|NCT03627312|Experimental|Omega-3|this group receives a fruit juice drink containing omega-3
2392139|NCT03627312|Placebo Comparator|Placebo|this group receives the same fruit juice drink as in the experimental group, but it does not contain omega-3
2392140|NCT03627312|Other|Treatment as Usual|this group do not receive a fruit juice drink
3143191|NCT00005028|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and bryostatin 1 IV over 1 hour on days 2, 9, and 16. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
2392142|NCT03627273|Experimental|walker|'6 minutes walking test' with a walker
2392143|NCT03627273|Active Comparator|no walker|'6 minutes walking test' without walker
2392144|NCT03627247|Experimental|Cognitive Behavioral Stress Management|Women randomized to CBSM participated in an eight-week prenatal course called SMART Moms (Stress Management and Relaxation Training for Moms) aimed at teaching coping and relaxation skills that address stressors and daily challenges experienced during pregnancy and motherhood.
2392145|NCT03627247|No Intervention|Attention Control Group|"Women randomized to the AC group participated in an eight-week program where they received printed materials (offered in Spanish and English) by mail once per week, on common prenatal health information topics (e.g., common discomforts of pregnancy, labor and delivery) chosen from the March of Dimes Foundation's Becoming a Mom handouts (March of Dimes, 2011). Women in this group were contacted once per week by phone by a research staff member to make sure that they received their mailed prenatal health information and to see if they had any questions."
2392146|NCT03627234|Experimental|Same Day Discharge|Same day discharge after hysterectomy is the standard of care at George Washington University Hospital.
2392147|NCT03627234|Experimental|Overnight stay|Overnight stay is not the standard of care at George Washington University Hospital. It is being used as an experimental condition.
3143192|NCT00005030|Experimental|SCH 66336|Starting dose of preoperative oral SCH 66336 100 mg twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases with surgery between days 8-15.
3143193|NCT00005030|No Intervention|No Treatment|Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization.
3143194|NCT00005032|Experimental|Arm A|G3139 (3 mg/kg/day continuous IV infusion over 7 days every 21 days), Paclitaxel (150 mg/m2, 3 hr IV infusion on Day 6 of every 21 day cycle)
3143195|NCT00005036|Experimental|Arm I (irinotecan)|Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3143196|NCT00005036|Experimental|Arm II (oxalipatin, fluorouracil, leucovorin calcium)|Patients receive oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on days 1 and 2, and fluorouracil IV bolus followed by IV infusion over 22 hours on days 1 and 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3143197|NCT00005037|Experimental|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
3143198|NCT00005039|Experimental|Arm I|Patients receive recombinant fowlpox-PSA vaccine IM at the MTD from the safety cohort every 4 weeks for 3 courses. Patients then receive recombinant vaccinia-PSA vaccine intradermally every 4 weeks for 2 courses.
3143199|NCT00005039|Experimental|Arm II|Patients receive the same vaccines as in arm I but in reverse order.
3143200|NCT00005059|Experimental|carboplatin + paclitaxel|"Following completion of the Lubben Social Network Scale and Frailty Questionnaire, patients receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, and 15.~Treatment repeats every 28 days for 2 courses. Patients with complete response receive 2 additional courses of therapy. Patients with partial response or stable disease may receive additional courses of therapy at investigator's discretion. Patients are followed every 3 months for 5 years or until disease progression."
3143201|NCT00005060|Active Comparator|Taxotere-Cisplatin-5FU preoperatively|TCF preoperatively
2392148|NCT03627221|Experimental|music listening and social network|The intervention group will receive music listening at sleep time and will be invited to join a social network for 12 weeks. But their sleep quality , sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
2392149|NCT03627221|No Intervention|Control group|The control group will not receive music listening at sleep time and will not be invited to join a social network for 12 weeks. But their sleep quality, sleep knowledge, sleep hygiene, daytime fatigue, and daytime sleepy will be collected for 12 months (at baseline, 3 month, 6 month, and the 12th month).
2392153|NCT03627182|Experimental|CKD-501 0.5mg|CKD-501 0.5mg
2392154|NCT03627182|Placebo Comparator|Placebo|Placebo
2392155|NCT03627169||MATRx plus/PSG group|Healthy individuals, individuals suspected of having OSA, and individuals with a previous diagnosis of OSA will spend a single night in a sleep laboratory and undergo a standard polysomnogram simultaneously with a Level III sleep study using the MATRx plus device. There is no interventional aspect to the study.
2392156|NCT03627156|Experimental|Intervention|Intervention Arm is an arm to which community-based guided counseling using Health Belief Model and Theory of Planned Behavior will be given.
2392157|NCT03627156|No Intervention|Control|Control Arm is an arm to which the intervention will not be implemented.
2392158|NCT03627143|Other|Local implementation of AAFF guidelines|The study intervention will support local implementation of the CAEP AAFF Guidelines during the intervention periods of the trial. The investigators will identify behaviour change techniques and organization/system level strategies that could likely address identified barriers or enhance enablers.
2392159|NCT03627130|Active Comparator|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
2392160|NCT03627130|Placebo Comparator|Potassium Chloride|Potassium Chloride
2392161|NCT03627117|Experimental|Verum/Placebo|This group will start with CBD and after washout will receive placebo.
2392162|NCT03627117|Experimental|Placebo/Verum|This group will start with placebo and will receive CBD after washout.
2392163|NCT03627104|Other|Normoprotein diet with animal protein|The patient will intake the diet assigned for a month
2392164|NCT03627104|Other|Normoprotein diet with vegetable protein|The patient will intake the diet assigned for a month
2392165|NCT03627104|Other|High-protein diet with animal protein|The patient will intake the diet assigned for a month
2392166|NCT03627104|Other|High-protein diet with vegetable protein|The patient will intake the diet assigned for a month
3143202|NCT00005060|Active Comparator|Immediate surgery followed by TCF|Surgery followed by Taxotere-Cisplatin-5FU
3143203|NCT00005064|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV bolus twice weekly for 4 weeks followed by 2 weeks of rest. Treatment continues for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
3143204|NCT00005065|Experimental|Arm I|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours every 3 weeks for 3 courses. Three weeks after completion of induction chemotherapy, patients receive Gd-Tex IV over 30 minutes twice weekly for 10 doses during preoperative radiotherapy. Radiotherapy is administered daily 5 days a week for 5 weeks. Approximately 3.5 weeks after completion of preoperative radiotherapy, patients undergo complete surgical resection. Three hours prior to surgery, patients receive an eleventh dose of Gd-Tex if they do not develop grade 3 or 4 toxicity with the tenth dose. Patients also receive a MRI without contrast prior to surgery. If the tumor is found to be unresectable, patients may receive additional radiation and/or chemotherapy.
2392170|NCT03627078|Experimental|Motor Interference Therapy|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects to tap their fingers in response to specific sounds. During the remaining ten minutes, the patients will be asked to recall a traumatic memory while simultaneously are tapping their fingers. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
2392171|NCT03627078|Sham Comparator|Relaxation Exercise|Initial interview applying the Spanish version of the PTSD Symptom Severity Scale-Revised (EGS-R), the visual analogue scale (EQ-VAS) from EuroQol 5D (EQ-5D), and a simple visual-analogue scale (VAS). After that, patients will listen to an audio track twice and follow the instructions. The first four minutes of the audio track instruct the subjects in how to do the exercises. During the remaining 10 minutes will hear commands for performing progressive muscle tension-relaxation exercises while the patient evoked the traumatic memory. Patients must complete at least 80% of the motor task in order to be included. We will reassess a week, a month and six months after the intervention, using all three scales.
2392173|NCT03627052|Experimental|Itacitinib|
2392174|NCT03627052|Placebo Comparator|Placebo|
2392175|NCT03627039||Truven|NOTE: In the case there are not enough patients/events data will be included from other databases (e.g., Optum, Medicare)
2392176|NCT03627026|Other|Patients treated with immune checkpoint inhibitor|
2392177|NCT03627013|Experimental|Kidney Custodiol-N|
2392178|NCT03627013|Active Comparator|Kidney Custodiol|
2392179|NCT03627013|Experimental|Liver Custodiol-N|
2392180|NCT03627013|Active Comparator|Liver Custodiol|
2392181|NCT03627013|Experimental|Kidney/Pancreas Custodiol-N|
2392182|NCT03627013|Active Comparator|Kidney/Pancreas Custodiol|
2392183|NCT03627000||failure after reimplantation|description of the failure at the reimplantation
2392184|NCT03626987||Bacterial identification|Describe the MALDI-TOF spectrum to identify peaks that may be associated with epidemiological and clinical characteristics of bacterial strains
2392185|NCT03626974|Experimental|Venipuncture with vanilla odor|the venipuncture will be performed on the neonate in the presence of a diffuser spreading the vanilla odor and ingestion of water
2392186|NCT03626974|Placebo Comparator|Venipuncture without odor|the venipuncture will be performed with an odorless diffuser and ingestion of sucrose
2392187|NCT03626961||discharge|patients discharged from icu
2392189|NCT03626948|Experimental|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
2392190|NCT03626935|Experimental|3D-printed customized guide plate|3D-printed customized guide plate will be used to guide the Kirschner wires in ankle arthrodesis.
2392191|NCT03626922|Experimental|Cohort 1|"Pembrolizumab + Pemetrexed every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
2392192|NCT03626922|Experimental|Cohort 2|"Pembrolizumab + Pemetrexed + Oxaliplatin every 21 days. Folic Acid 5 days prior to first dose of pemetrexed and daily including 21 days after last dose of pemetrexed.~Dexamethasone twice daily on the day before, the day of, and the day after each dose of pemetrexed.~Vitamin B-12 7 days prior to first dose of pemetrexed, every 9 weeks, continue until 3 weeks after last dose of pemetrexed."
2392193|NCT03626896|Experimental|NaviFUS System|NaviFUS System: dose escalation focus ultrasound to transiently disrupt BBB
3143205|NCT00005066|Experimental|Arm A|O6-BG as an intravenous infusion (through your vein) over 1 hour followed 1 hour later by BCNU intravenously over 15 minutes. chemotherapy every 6 weeks.
3143206|NCT00005067|Experimental|Treatment (motexafin lutetium, PDT)|Patients receive lutetium texaphyrin IV over 10-15 minutes 3-24 hours before photodynamic therapy (PDT). Optical fibers attached to a laser are inserted through a catheter into the prostate. The laser delivers 730 nm light to the prostate until the specified fluence is delivered. Patients undergo biopsy of the prostate and bladder before and after PDT. Cohorts of 3-6 patients receive escalating doses of lutetium texaphyrin and light fluence until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.
3143207|NCT00005072|Experimental|Leuvectin|Leuvectin
3143208|NCT00005076|Experimental|EgFR antibody|
2392198|NCT03626844|Experimental|Manual Lysis after 15 minutes (Intervention)|Manual Lysis of Placenta 15 minutes after Delivery.
2392199|NCT03626844|Active Comparator|Manual lysis after 30 minutes (Control)|Waiting 30 minutes after delivery and then manual lysis of the placenta.
2392200|NCT03626831|Active Comparator|Treatment|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of the study drug by Evolocumab Prefilled Syringe (1x SC 420 mg evolocumab).
2392201|NCT03626831|Placebo Comparator|Placebo|Baseline vascular function parameters will be obtained and the patient will be given an SC injection of Placebos (1x SC Placebo).
2392202|NCT03626818||NCF group|The patients have received 10 daily fractions of 3 Gy WBRT. Following WBRT treatment, subjects were assessed at each visit for NCT according to the Hopkins Verbal Learning Test-Revised(HVLT-R),Mini-Mental Status Examination(MMSE) and Quality Of Life measurements(QOL,Questionnaire-QLQC30).These tests was administered by trained and certified nurses or clinical research associates at baseline,6th week, 3rd, 6th, 9th, 12th month, and every 6 months until PS> 2 or intracranial tumor progression.
2392203|NCT03626805||Migraine patients|Migraine patients attending the Danish Headache Centre
2392204|NCT03626805||Healthy Controls|Age and sex matched
2392205|NCT03626792|Other|Hypertensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
2392206|NCT03626792|Other|Normotensive group|The Mat Pilates session was held lasting 50 minutes of exercises with the first 5 minutes heating and in each exercise performing 10 repetitions with 45 seconds of rest between one exercise and another. For practice, are used only mats, and alternative devices such as the Swiss ball and the flexible ring, as well as body weight and the force of gravity as resistance factors and Borg's subjective perception of effort scale for intensity parameters. The 20 exercises were chosen through the classic exercises thus classified by the creator of the Joseph Pilates method.During the sessions, volunteers were instructed on correct breathing without performing the valsalva maneuver.
2392207|NCT03626779|Other|immediate placment and loading with prf|Immediat placment and loading with prf
2392208|NCT03626779|No Intervention|immediate implant placment and loading|Immediate implant placment and loading without prf
2392209|NCT03626766|Active Comparator|Photo in Verification Alert|Patient photo displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
2392210|NCT03626766|Active Comparator|Photo in Banner|Patient photo displayed in the banner (at the top of the screen).
2392211|NCT03626766|Active Comparator|Photo in Banner and Verification Alert|Patient photograph displayed in the banner (at the top of the screen) AND patient photo displayed in a verification alert when placing electronic orders.
2392212|NCT03626766|No Intervention|No Photo|No patient photographs displayed in the electronic health record.
2392213|NCT03626753|Active Comparator|Oral Group|"received in post operative period oral analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
2392322|NCT03625960|Active Comparator|trichloroacetic acid group|application of trichloroacetic acid to perenial warts
3143209|NCT00005080|Experimental|Nelarabine|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive up to 8 courses of therapy.
3143210|NCT00005085|Experimental|Arm I|Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
2392214|NCT03626753|Active Comparator|Intravenous group|"received in post operative period intravenous analgesia ( nefopam (Acupan) 20mg/6h, piroxicam (piroxan) 40mg/24h, Acetaminophen (paracetamol) 1g/6h)"
2392215|NCT03626740|Experimental|TheraCal|Indirect pulp capping with TheraCal
2392216|NCT03626740|Active Comparator|Mineral trioxide aggregate (MTA)|Indirect pulp capping with MTA
2392217|NCT03626727|Experimental|Sodium Oxybate Oral Solution (Xyrem®)|4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
3183887|NCT00718484|Experimental|A|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
2392219|NCT03626701|Experimental|RECELL® Autologous Cell Harvesting Device|"RECELL + Telfa™ Clear and Xeroform™ dressings~Conventional autografting (only when indicated)"
2392220|NCT03626701|Active Comparator|Mepilex® Ag Wound Dressing|"Mepilex® Ag Wound Dressing~Conventional autografting (only when indicated)"
3183888|NCT00718484|Active Comparator|B|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
3183889|NCT00718497||ALS|Subjects having either definite or probable ALS by El Escorial Criteria.
2392223|NCT03626675|Other|study group|"They will be subjected to:~Preoperative A-complete ophthalmic examination will be done for every patient; B- Biometric parameters measured with the AS-OCT C- Medical fitness for all patients D- Informed consent will be obtained from all patients after through explanation of operation and its potential benefits and risks.~Surgery combined Phaco trabeculectomy~Post operative:~-Follow-up examinations will be performed for every patient at 1day, 1 week, 1 and 3 months postoperatively.~and biometric parameters measured with the AS-OCT before and after the surgery will be used to collect the data.~-The data will be managed and analysed with confidentiality by scientifically qualified persons"
2392226|NCT03626649|Experimental|DiamondTemp Cardiac Ablation System|Cardiac ablation procedure
2392227|NCT03626636|Active Comparator|Active Group|Treatment Group 1: 25 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be injected intravitreally with 1.0mg of Luminate®
2392228|NCT03626636|Placebo Comparator|Placebo Group|Treatment Group 2: 15 Non-Exudative AMD subjects with BCVA of 20/40 - 20/200 will be treated with a sham injection
3183890|NCT00718536|Experimental|1|Addition of raltegravir 800 mg QD to HAART
3183891|NCT00718562|Experimental|Nilotinib|
2392231|NCT03626610|Experimental|Interventional|Participants will be given a monitored exercise program during their treatment starting before chemotherapy
2392232|NCT03626610|No Intervention|Non-interventional|Patients will have standard care.
2392233|NCT03626597|Active Comparator|CHV-provided post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 1 (CHV-provided post-test counseling and referral), the CHV will provide all post-test counseling and referral based on training provided. This may occur at the time of enrollment or at a later time, as preferred by the woman.
2392234|NCT03626597|Active Comparator|Phone-based post-test counseling & referral|The CHV will provide the woman with the urine pregnancy test and collect baseline information. If the woman desires enrollment in Arm 2 (phone-based post-test counseling and referral), the CHV will provide the woman with a phone number which she may call or short message service (SMS) to receive post-test counseling and referral. If the study team does not receive a call or SMS from the woman within one week, our research assistant will phone and/or SMS the participant to provide phone-based post-test counseling and referral.
2392235|NCT03626584||Cardiac Amyloidosis Patients|Patients with established diagnosis of cardiac amyloidosis.
2392236|NCT03626584||Healthy Volunteers|Healthy volunteer subjects of similar age and gender to patient cohort.
2392237|NCT03626571||Native valve infective endocarditis|Patients with infective endocarditis of native valves of the heart with no contraindications to MRI scanning.
2392238|NCT03626571||Prosthetic endocarditis|Patients with endocarditis of prosthetic heart valves or device-related infections.
2392239|NCT03626571||Non-infective post-operative|Patients who have recently undergone valve or device implantation with no evidence of post-operative infection.
2392240|NCT03626558|Experimental|Distroke patients|"For every patient include in the study, ultrasound measures at the admission/discharge of hospitalization will be realized.~All the patients will see each other suggested participating in a new collection of remote ultrasound measures of the stroke (around 2-3 months). These measures will be made during the usual consultation proposed by the department of neurology. This medical consultation is a part of the follow-up post--stroke recommended by the High Authority of Health. These measures will allow us to highlight the kinetics of recovery of the diaphragmatic function except any intervention of reeducation of muscles inspirers."
3183892|NCT00718575|Experimental|1|Deceased liver donors that are randomized to this arm will receive the Glucose/Ischemic Preconditioning pre-treatment intra-operatively prior to starting cold preservation of the organ
3183893|NCT00718575|No Intervention|2|Neither donors nor recipients receive any intervention. All procedures will be performed according to our institution's standard of care.
2392243|NCT03626532|Experimental|Mindfulness-Based Stress Reduction|Participants will meet once a week for 8 weeks (2.5 hours per session), plus a 4-hour retreat day, to engage in mindfulness meditation exercises. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will require participants to engage in guided practices for 30 minutes a day for 5 days a week.
2392244|NCT03626532|Active Comparator|Lifestyle Education|Participants will meet once a week for 2.5 hours for 8 weeks, plus a 4-hour retreat day, to engage in light stretching exercises and interactive discussions on health topics, such as physical activity, nutrition, sleep, stress, etc. Didactic components will include oral presentations, informational videos, and group discussion. Additionally, daily homework assignments will ask participants to engage in stretching, read or watch informational content, and answer reflection questions for 30 minutes a day for 5 days a week.
3183894|NCT00718601|Experimental|1|3+3 cohort dose escalation
2392246|NCT03626519|Placebo Comparator|Test with placebo|Patients will chew a strawberry flavored chewing gum 5 minutes before perform one Six-minute Walk Test
2392247|NCT03626506|Experimental|spironolactone|Subjects will take spironolactone 20~40mg once daily on top of amlodipine 5~10mg once daily.
2392248|NCT03626506|Active Comparator|indapamide|Subjects will take indapamide 1.5~3.0mg once daily on top of amlodipine 5~10mg once daily.
2392249|NCT03626493||LSRH|patients who undergo laparoendoscopic single-site radical hysterectomy with pelvic lymphadenectomy
2392250|NCT03626467|Experimental|Arm 1|Men infected by HIV who have sex with men
2392251|NCT03626454|Active Comparator|group B|'Norepinephrine bolus' of 6 µg plus Normal Saline 0.9% Infusion Solution
2392252|NCT03626454|Active Comparator|group I|'Norepinephrine infusion' 6 µg/kg/h plus 'Normal Saline Flush, 0.9% Injectable Solution
2392253|NCT03626441|Placebo Comparator|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
2392254|NCT03626441|Experimental|Ginger|Two coloured capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger, given 2 hours before the scheduled start of surgery.
3183895|NCT00718614|Other|1|Patients with long standing IDDM (>10 years) and no diabetic retinopathy
2392256|NCT03626402|Experimental|Intervention|"These patients will be exposed to the educational intervention, including viewing the video, Planning for the Care You Want, and meeting with a lay health advisor to discuss advance care planning and initiate plans, as patients wish."
2392257|NCT03626402|No Intervention|Control - Usual Care|These patients will not be exposed to the educational intervention and will receive usual care. All patients will be mailed an informational brochure about advance care planning with a reminder letter two weeks after completing their baseline survey.
3183896|NCT00718614|Other|2|Patients with long standing IDDM (>10 years) and mild non-proliferative diabetic retinopathy
2392259|NCT03626376|Placebo Comparator|Control|suppressive antiviral treatment
2392260|NCT03626376|Active Comparator|Study Arm|oral acyclovir or oral valacyclovir
2392261|NCT03626363|Experimental|Mindfulness-Based Stress Reduction|
2392262|NCT03626363|Active Comparator|Stress Management Education|
2392263|NCT03626337||Hospital-based cohort|100 mg thiamine provided via intramuscular and/or intravenous injection (Thiamine 100 MG/ML) daily for 3 days
2392264|NCT03626337||Community-based cohort|Sex-, age- and regionally matched comparison group
2392265|NCT03626324|Experimental|C2P Study|Clinical Evaluation of Connected Catheter 2P Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
3183897|NCT00718614|Other|3|Patients with long standing IDDM (>10 years) and moderate to severe non-proliferative diabetic retinopathy
2392268|NCT03626298|Placebo Comparator|Adapalene and placebo (ADAP)|
2392269|NCT03626298|Experimental|Adapalene, Nicotinamide, ABA, Zinc PCA (ANAZ)|
2392270|NCT03626272|Active Comparator|8-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 8 months.
2392271|NCT03626272|Active Comparator|4-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 4 months.
2392272|NCT03626272|Active Comparator|2-month intervals|Participants will be submitted to the educational intervention with in situ simulation every 2 months.
2392273|NCT03626259|Other|losartan and amlodipine|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
2392274|NCT03626259|Active Comparator|Losartan|Individuals with SAH grade 1 or 2 without triple pharmacological therapy.
2392275|NCT03626246||Kidney disease|Patients who participate in our study are 40 years old or older and have a Chronic kidney disease stage 3, 4 or 5.
2392276|NCT03626233||Vascular group|Pregnant women with vascular pathology
2392277|NCT03626233||Control group|"Pregnancy without any vascular complication~Delivery before or after 37 weeks of gestation (GW)~In case of delivery after 37GW: birth by cesarean delivery"
2392278|NCT03626220||acupuncture group|acupuncture with de-chi sensation
2392279|NCT03626220||sham acupuncture group|skin-deep acupuncture without de-chi sensation
2392280|NCT03626207||Retinitis pigmentosa|Retinitis pigmentosa patients with severe visual impairment
2392281|NCT03626181|Experimental|Active TBS-DLPFC|There is only one arm. All participants will receive Theta Burst Stimulation (transcranial magnetic stimulation) of the dorsolateral prefrontal cortex.
2392282|NCT03626168|Active Comparator|Consumption of 100% watermelon juice|Consumption of two 12-ounce doses of pasteurized 100% watermelon juice for a four-week period
2392283|NCT03626168|Placebo Comparator|Consumption of a placebo beverage|Consumption of a placebo beverage with comparable sugar content, pH, taste, texture, and color for a four-week period
2392284|NCT03626155|Experimental|Seated Control|
2392285|NCT03626155|Experimental|Morning Exercise (walking)|
2392286|NCT03626155|Experimental|Afternoon Exercise (walking)|
2392287|NCT03626155|Experimental|Evening Exercise (walking)|
2392288|NCT03626142||Left DLPFC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford
2392289|NCT03626142||ACC aTBS stimulation|Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford
2392290|NCT03626142||ECT|Patients who have received ECT on the inpatient unit at Stanford
2392291|NCT03626129|No Intervention|Traditional rapid deflation|"Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered (Initial inflated air volume). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding)."
2392292|NCT03626129|Experimental|Oximetry guided deflation|"Group B: Initial step with sheath removal as in group A. Before departure from the cath.lab. a Patent hemostasis test (see description in Interventions below) is performed. Further action as described in Interventions below."
2392323|NCT03625947||Hemoptysis patients|Hemoptysis patients caused by endobronchial malignancies
2392293|NCT03626103|Experimental|+ Brief ED Intervention (BI), + Text|Participants receive both the Brief ED Intervention component (a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant) and the Text Message Intervention component (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills).
2392294|NCT03626103|Experimental|+ Brief ED Intervention (BI), no Text|Participants receive the Brief ED Intervention component only (which is a 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant).
2392295|NCT03626103|Experimental|No Brief ED Intervention (BI), + Text|Participants receive the Text Message Intervention component only (8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills). Participants receive a brochure containing online and community resources for violence and depression prevention instead of the Brief ED Intervention component.
2392296|NCT03626103|No Intervention|No Brief ED Intervention (BI), no Text|Participants receive neither the Brief ED Intervention component, nor the Text Message Intervention component. Participants receive a brochure containing online and community resources for violence and depression prevention, instead of the Brief ED Intervention component.
2392297|NCT03626090|Experimental|Treatment Arm|A single dose of 0.5 to 1 x 10^6/kg autologous BM MSCs (Total volume: 30 - 50 ml) will be infused via peripheral venous access.
2392298|NCT03626077|Active Comparator|group A|Group (A) physical therapy program for 60 minutes per session, three times a week for three consecutive months
2392299|NCT03626077|Active Comparator|group B|Group (B) E-Link Upper Limb Exerciser (augmented biofeedback training)for 60 minutes per session, three times a week for three consecutive months
2392300|NCT03626077|Experimental|group C|group (C) physical therapy program and E-Link Upper Limb Exerciser
2392301|NCT03626064|Other|PROMPT Participants|80 participants who are homeless or at-risk for homelessness, smoke tobacco, and identify as People Who Use Drugs in Ottawa.
2392302|NCT03626051|Active Comparator|rigid tape group|
2392303|NCT03626051|Experimental|fibular tape group|
2392304|NCT03626038|Experimental|Patients who receive the A.L.P.S. Prox. Humerus Plating Sys.|"Subjects in need of proximal humerus fracture fixation who met the inclusion/exclusion criteria and received the A.L.P.S. Proximal Humerus Plating System.~Subjects can be enrolled prospectively or retrospectively as indicated in the protocol."
2392305|NCT03626025|No Intervention|Mass Learning Group|Participants underwent an eight-hour microsurgery training course in a single session under the mass-learning format.
2392306|NCT03626025|Other|Spaced Learning Group|Participants underwent two-hour microsurgery training sessions every week for a total of 4 sessions under the spaced learning format.
2392307|NCT03626012|Experimental|Cohort 1: BIIB078 First Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
2392308|NCT03626012|Experimental|Cohort 2: BIIB078 Second Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
2392309|NCT03626012|Experimental|Cohort 3: BIIB078 Third Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days.
2392310|NCT03626012|Experimental|Cohort 4: BIIB078 Fourth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
2392311|NCT03626012|Experimental|Cohort 5: BIIB078 Fifth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
2392312|NCT03626012|Experimental|Cohort 6: BIIB078 Sixth Dosage|BIIB078 will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by five maintenance doses on five later days.
2392313|NCT03626012|Placebo Comparator|Cohorts 1-6: Placebo|Matching placebo will be administered as a loading regimen of 3 doses, on Day 1 and two later days, followed by two maintenance doses on two later days (Cohorts 1 through 3) and five maintenance doses on five later days (Cohorts 4 through 6).
2392314|NCT03625999|Experimental|Training Group|Parents and children selected for the Training group will be lent a laptop for the duration of the at-home training, and assisted in opening the video game training exercise. Parents and children will be shown the game's operation and controls, including a home visit to the family's house to help them establish the game as part of routine. Parents will be asked to engage their children in the video game training exercise (on the laptop) for a minimum of 20 minutes, 3 times a week, for 4 weeks. The app will log all responses as well as time spent playing.
2392315|NCT03625999|No Intervention|Wait-List Control|The families assigned to the wait-list control group will not receive access to the game until after 4 weeks and completion of the secondary round of testing at the lab. After the second lab visit and completion of the testing, families will be given access to the video game training exercise (on a loaned laptop), walked through the game's operation and controls, and encouraged to use it as often as they or their child like. If the child plays the game for a minimum of 20 minutes, 3 times per week, for 4 weeks, the family will be invited back to CARE for post-testing.
3183898|NCT00718614|Other|4|healthy volunteers, matched for age and sex
3183899|NCT00718627|Experimental|HHLivC Therapy Group|
2392318|NCT03625973|Experimental|16 Weeks of 3D-RT|Participants will receive 16 weeks of Reminiscence Therapy using 3D printed objects as stimuli.
2392319|NCT03625973|Experimental|8 Weeks of 3D-RT|Participants will receive 8weeks of Reminiscence Therapy using 3D printed objects as stimuli and 8 weeks of RT using verbal stimuli.
2392320|NCT03625973|Active Comparator|16 Weeks of RT using Verbal Stimuli|Participants will receive 16 weeks of RT using verbal stimuli to reminiscence.
2392321|NCT03625960|Experimental|Cantharidine group|Application of cantharidine to perenial warts
2393399|NCT03618251||ischemic stroke|all patients with a suspicion of ischemic stroke
3183900|NCT00718653|Experimental|1|lutein
3183901|NCT00718653|Experimental|2|Lutein plus green tea extract
3183902|NCT00718679|Experimental|1|Study drug
3183903|NCT00718679|Placebo Comparator|2|Placebo
3183904|NCT00718692|Experimental|1|Patients treated with Sym001
2392324|NCT03625934|Experimental|VVX001 (20 micrograms)|Subjects will receive 5 injections of 20 micrograms each over a period of 4 months
2392325|NCT03625934|Placebo Comparator|Placebo|Subjects will receive 5 s.c. injections of matching placebo over a period of 4 months
2392326|NCT03625921|Experimental|Powered device with physical therapy|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided an intensive device-specific physical therapy (PT) intervention. The subjects will complete, on average, 8 PT training sessions lasting 30 - 45 minutes each. The subjects will also be provided with a home exercise program.
2392327|NCT03625921|Active Comparator|Powered device with standard of practice|Subjects will be fitted with a powered ankle-foot prosthesis (Ottobock emPOWER) and provided the current standard of practice training for use of this powered prosthesis. The prosthetist will confirm a stable and comfortable alignment and educate the subject on proper home usage. Next, the subject will undergo a 45 - 60 minute training with a physical therapist that is characteristic of the current standard of practice.
2392328|NCT03625908|Active Comparator|OCT-guided PCI|Patients will receive PCI under OCT-guidance.
2392329|NCT03625908|Active Comparator|Angiography-guided PCI|Patients will receive PCI under Angiography-guidance.
2392330|NCT03625895||Agrylin|Participants who received treatment with Agrylin will be evaluated for this study.
2392331|NCT03625882||Gaucher Disease Participants Treated With VPRIV|Participants with Gaucher disease will be enrolled in this survey, who are in VPRIV treatment-naïve therapy or have been switched from another therapeutic agent for Gaucher disease.
2392332|NCT03625869|No Intervention|Control|This is the actual control group receiving conventional therapy, ie. percutaneous coronary intervention.
2392333|NCT03625869|Experimental|PICSO|This arm will be treated with Pressure controlled intermittent Coronary Sinus Occlusion (PiCSO) in addition to conventional therapy (percutaneous coronary intervention).
2392334|NCT03625856|Experimental|Intervention|1500 mg Chlorella Vulgaris capsule
2392335|NCT03625856|Placebo Comparator|Control|1500 mg placebo (starch)
2392336|NCT03625843|Experimental|Mindfullness exercises|Participate in mindfulness exercises prior to urodynamic studies (UDS). As a participant, you will be guided through a mindfulness meditation exercise by a licensed professional. During this exercise you will be asked to focus your attention on your breathing, physical sensations, and thoughts. This exercise will last for approximately 10 minutes.
2392337|NCT03625843|No Intervention|Control|Sitting quietly in a room alone.
2392338|NCT03625830|Experimental|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|
2392339|NCT03625830|Active Comparator|Rapid exchange PTCA Balloon Catheter (SeQuent® Neo)|
2392340|NCT03625817|No Intervention|Urban setting|The participants will be staying in their permanent house in an urban area in Cyprus for at least 7 days. On the 7th day, they will be wearing 2 temperature sensors, for skin and air temperature. They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
2392341|NCT03625817|Experimental|Mountainous setting|The intervention is the short stay in the mountainous area of Troodos for atleast 7 consecutive days. The participants will be staying in their holiday house in the mountainous-rural area of Troodos, Cyprus for at least 7 days. On the 7th day, they will wear 2 temperature sensors, for skin and personal air temperature monitoring (every minute data points). They will also collect the urine samples of the day and note in an activity diary, the names and times of activities.
2392342|NCT03625804|Experimental|PNS+AO+Training|"adopted PNS+AO+Training as the intervention"
2392343|NCT03625804|Experimental|PNS+AOsham+Training|"adopted PNS+AOsham+Training as the intervention"
2392344|NCT03625804|Placebo Comparator|PNSsham+AOsham+Training|"adopted PNSsham+AOsham+Training as the intervention"
2392345|NCT03625791||radiation-induced sarcomas|
2392346|NCT03625791||radiotherapy for at least 5 years and without sarcomas|
2392347|NCT03625791||primary sarcomas|
2392348|NCT03625778|Placebo Comparator|Placebo Cohort 1|Participants will receive subcutaneous (SC) placebo matched to MEDI0382 Cohort 1 once daily for 9 weeks.
2392349|NCT03625778|Experimental|MEDI0382 Cohort 1|Participants will receive SC MEDI0382 titrated doses of Dose 1 to 7 once daily (7-step titration/ 1 week per dose) from Weeks 1 to 7 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 7 to 9.
2392350|NCT03625778|Placebo Comparator|Placebo Cohort 2|Participants will receive SC placebo matched to MEDI0382 Cohort 2 once daily for 14 weeks.
2392351|NCT03625778|Experimental|MEDI0382 Cohort 2|Participants will receive SC MEDI0382 titrated doses of Doses 1, 2, 3, 5, and 7 once daily (5-step titration/ 2 week per dose) from Weeks 1 to 10 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 11 to 14.
2392352|NCT03625778|Placebo Comparator|Placebo Cohort 3|Participants will receive SC placebo matched to MEDI0382 Cohort 3 once daily for 18 weeks.
2392353|NCT03625778|Experimental|MEDI0382 Cohort 3|Participants will receive SC MEDI0382 titrated doses of Doses 1, 8, 4, and 7 once daily (4-step titration/ 4 week per dose) from Weeks 1 to 16 followed by additional treatment of SC MEDI0382 Dose 7 once daily from Weeks 17 to 18.
3183905|NCT00718705|Experimental|1|josamycin
2392355|NCT03625752|Active Comparator|Active Comparator: Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
2392356|NCT03625752|Sham Comparator|Sham|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
2392357|NCT03625726|Experimental|patients with cirrhosis|pathophysiology study, blood sample
2392358|NCT03625726|Placebo Comparator|healthy volunteers|pathophysiology study, blood sample
2392359|NCT03625726|Placebo Comparator|patients with hepatocellular carcinoma|pathophysiology study, blood sample
3183906|NCT00718705|Placebo Comparator|2|Placebo
3183907|NCT00718731|Experimental|1|Subject on active drug
3183908|NCT00718731|Placebo Comparator|2|Subject on placebo
3183909|NCT00718744|Experimental|A|In each individual patient, 10 mg/ml histamine dihydrochloride solution and a phenolated saline solution will be applied as positive and negative control respectively.
3183910|NCT00718757|Experimental|1|
3183911|NCT00718783||Retinoblastoma|
2392360|NCT03625700||Hypoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation <94 % irrespective of supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation <88% irrespective of supplemental oxygen"
2392361|NCT03625700||Normoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation 94-98% in combination with supplemental oxygen OR blood oxygen saturation ≥94% without supplemental oxygen.~Patients with chronic obstructive pulmonary disease: blood oxygen saturation 88-92% in combination with supplemental oxygen OR blood oxygen saturation ≥88% without supplemental oxygen."
2392362|NCT03625700||Hyperoxia|"Patients without chronic obstructive pulmonary disease: blood oxygen saturation >98% in combination with supplemental oxygen~Patients with chronic obstructive pulmonary disease: blood oxygen saturation >92% in combination with supplemental oxygen"
2392363|NCT03625687|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)
2392364|NCT03625674|Other|psychological and GI mechanisms|The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
2392365|NCT03625674|Other|psychological mechanism|The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
2392366|NCT03625674|Other|GI mechanism|The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
2392367|NCT03625674|Other|no explanation|The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
2392368|NCT03625661|Experimental|Arm with Ferinject|Ferinject will be administered once at inclusion
2392371|NCT03625635|Experimental|Nutrition diagnosis and intervention|At baseline and 6-mo after, a nutrition diagnosis will be done by measuring body composition components with DXA and basic anthropometric measurements. Based on the results, an individualized food-based intervention will be prescribed for each patient according to her diagnosis, food preferences, cultural and socioeconomic status. Follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed and initial measurements are repeated.
2392372|NCT03625622|Placebo Comparator|Placebo|Placebo, orally administered once daily for 26 weeks.
2392373|NCT03625622|Active Comparator|AR1001 - 10 mg|Active, AR1001 - 10 mg, orally administered once daily for 26 weeks.
2392374|NCT03625622|Active Comparator|AR1001 - 30 mg|Active, AR1001 - 30 mg, orally administered once daily for 26 weeks.
2392375|NCT03625596|Active Comparator|High L-arginine|During this experimental day, men will receive a high-fat shake with a high dose of L-arginine.
2392376|NCT03625596|Experimental|Medium L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a medium dose of L-arginine enriched with nitrate and nitrite.
2392377|NCT03625596|Experimental|Low L-arginine + Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with a low dose of L-arginine enriched with nitrate and nitrite.
2392378|NCT03625596|Experimental|Nitrate / Nitrite|During this experimental day, men will receive a high-fat shake with nitrate and nitrite.
2392379|NCT03625596|Placebo Comparator|Placebo|During this experimental day, men will receive a high-fat shake without supplement.
2392380|NCT03625583||chronic myeloid leukaemia|chronic myeloid leukaemia diagnosed from 2007 - 2017
2392381|NCT03625570|Experimental|PT³|Power Training combined with interval treadmill training
2392382|NCT03625570|Active Comparator|Traditional training|Strength training combined with traditional treadmill training
2392383|NCT03625544|Experimental|MagnetOs™ Granules|MagnetOs™ Granules
2392384|NCT03625544|Active Comparator|Autograft|Autologous bone graft
2392385|NCT03625531|Experimental|Personalized acupuncture|Two sets of acupoints will be selected for the two types. The basic acupoint-prescription includes CV 4, CV 6, CV 12 and SP 6 bilaterally, ST 25 bilaterally, EX-CA 1 bilaterally, ST 40 bilaterally and SP 9 bilaterally. Additional point ST 36 bilaterally and moxibustion as adjuvant therapy will be added for the type of yang deficiency of spleen and kidney, while additional points K 13, LR 3 for the type of yin deficiency of liver and kidney. Besides, flexible modifications of 2-3 acupoints will be performed according to patients special symptoms.
2392386|NCT03625531|Experimental|Fixed acupuncture|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV 3, CV 6, ST 29 bilaterally, SP 6 bilaterally, SP 9 bilaterally, GV 20 and LI 4 bilaterally. The second set consists of 13 needles: ST 25 bilaterally, ST 29 bilaterally, CV 3, CV 6, SP 6 bilaterally, LR 3 bilaterally, PC 6 bilaterally and GV 20. The following points will be connected to an electrical stimulator: ST 25 bilaterally, ST 29 bilaterally, SP 6 bilaterally, LR 3 bilaterally.
2392387|NCT03625531|Active Comparator|Letrozole|Women in the letrozole group will be given letrozole (Femara, Novartis Pharmaceuticals, Basel, Switzerland) from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
2392388|NCT03625531|Placebo Comparator|Placebo letrozole|Women will receive placebo letrozole with no acupuncture from day 3 to day 7 of the spontaneous menstrual cycle or after a withdrawal bleeding following progestin. Placebo letrozole will be given in the same way as letrozole.
2392389|NCT03625518|Active Comparator|prostaglandins|vaginal prostaglandins insertion (PGE2) for cervical ripening and induction
2392390|NCT03625518|Active Comparator|intracervical balloon catheter with pitocin|insertion of intra cervical balloon catheter combined with intravenous pitocin for ripening and induction of labor
2392391|NCT03625505|Experimental|Dose Escalation Venetoclax + Gilteritinib|Different combinations of dose levels for venetoclax in combination with gilteritinib will be administered to determine the recommended phase 2 dose (RPTD).
2392392|NCT03625505|Experimental|Dose Expansion Venetoclax + Gilteritinib|Participants will receive venetoclax in combination with gilteritinib at the dose determined in dose escalation portion.
2392467|NCT03624985|Placebo Comparator|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose.
2392393|NCT03625492|Experimental|Reduce Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
2392394|NCT03625492|Active Comparator|Adopt Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
2392397|NCT03625453|Experimental|ABX-1431|Oral use of hard capsule (10 milligrams), maximum dose per day: 40 milligrams
2392398|NCT03625453|Placebo Comparator|Placebo|Oral use of hard capsule
2392399|NCT03625440|Other|study group - Waterpipe Smoking|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) performed at baseline and 30minutes after waterpipe smoking.~The Digit span test and PASAT with waterpipe smoking"
2392400|NCT03625440|Other|control group|"The Digit span test and Paced Auditory Serial Addition Test (PASAT) without waterpipe smoking, performed at 30minures apart.~The Digit span test and PASAT without waterpipe smoking"
2392401|NCT03625427|Placebo Comparator|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, and will be administered at two 1 gram capsules per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2392402|NCT03625427|Experimental|Palmitoleic acid, 500 mg (Dose 1)|POA Dose 1 is a 1 gram capsule containing 500 mg POA and one placebo capsule containing 500 mg olive oil per day for twelve weeks. The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2392403|NCT03625427|Experimental|Palmitoleic acid, 1,000 mg (Dose 2)|POA Dose 2 is two, 1 gram capsules containing 500 mg POA, totaling 1,000 mg POA per day for twelve weeks.The doses will be administered in single serve packets containing two capsules for each daily dose to be taken at breakfast.
2392404|NCT03625414||Healthy individuals|Gingival biopsies of healthy individuals who had no systemic or oral disease or condition.
2392405|NCT03625414||Unaffected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were not affected by periodontal destruction.
2392406|NCT03625414||Affected sites of CP|Chronic periodontitis patients had teeth affected from destruction and some teeth were unaffected. Gingival biopsies of chronic periodontitis patients were taken from sites which were affected by periodontal destruction.
2392407|NCT03625414||Unaffected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were not affected by the periodontal destruction.
2392408|NCT03625414||Affected sites of LAgP|Like chronic periodontitis, aggressive periodontitis patients had also teeth affected by destruction and some teeth were unaffected. Gingival biopsies of aggressive periodontitis patients were taken from sites which were affected by the periodontal destruction.
2392409|NCT03625401|Experimental|AD-35 60 mg|AD-35 60 mg group: 2 AD-35 30 mg tablets and 1 placebo tablet
2392410|NCT03625401|Placebo Comparator|Placebo of AD-35 30 mg|Placebo group: 3 placebo tablets
2392411|NCT03625388|Other|Dasatinib 50 mg|Dasatinib 50 mg orally once daily
2392412|NCT03625388|Other|Dasatinib 100 mg|Dasatinib 100 mg orally once daily
2392413|NCT03625375|Experimental|Treatment Group|Individuals will perform exercises 3 times a week.
2392414|NCT03625375|No Intervention|Control Group|Individuals will not perform exercises
2392415|NCT03625362|Experimental|Hydrogen|1 L of hydrogen-rich water
2392416|NCT03625362|Placebo Comparator|Placebo|1 L of tap water
2392417|NCT03625349||PLM participants|Participants who undergo passive leg movement, with and without LNMMA.
2392418|NCT03625336||Prostate Calcifications|Men with prostate calcifications
3183912|NCT00718796|Experimental|1|Individualized naturopathic treatment consisting of dietary and lifestyle advice and individualized supplementation
3183913|NCT00718796|Active Comparator|2|Current care control provided by participants' medical doctor
3183914|NCT00718822|Experimental|I|5% oxygen concentration in the culture atmosphere
2392422|NCT03625310|Active Comparator|Sodium Fluoride|Varnish containing 5% Sodium Fluoride, was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2392423|NCT03625310|Experimental|Sodium Fluoride with TCP|Varnish containing 5% Sodium Fluoride with tricalcium phosphate (TCP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2392424|NCT03625310|Experimental|Sodium Fluoride with CXP|Varnish containing 5% Sodium Fluoride with Xylitol-coated Calcium and Phosphate (CXP) ,varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2392425|NCT03625310|Experimental|Sodium Fluoride with CPP-ACP|Varnish containing 5% Sodium Fluoride with casein phosphopeptide amorphous calcium phosphate (CPP-ACP), varnish was applied to all remaining teeth of each child after dental treatment under general anaesthesia.
2392426|NCT03625297|No Intervention|Shelter cat adoption control group|Families of children with autism will complete a control period with no intervention, then adopt a shelter cat after completion of the control period
2392427|NCT03625297|Experimental|shelter cat adoption|Families of children with autism will adopt a shelter cat
2392428|NCT03625284|Experimental|Fucovital|capsules of a dietary supplement rich with fucoxanthin from microalgae extract
2392429|NCT03625284|Placebo Comparator|Placebo|capsules of an edible oil
2392430|NCT03625271|No Intervention|Control|All subjects will undergo same study procedures. Subjects in the Control Arm will receive treatment as usual by the prescribing clinician/investigator. The prescribing clinician/investigator will not receive the PEER Report of probable medication response for a control arm subject.
3183915|NCT00718822|Experimental|II|20% oxygen concentration in the culture atmosphere
2392431|NCT03625271|Experimental|Experimental|All subjects will undergo same study procedures. Subjects in the Experimental Arm will receive treatment as usual by the prescribing clinician/investigator. However, the prescribing clinician/investigator will receive the PEER Report of probable medication response for an experimental arm subject. The report will provide additional data/information regarding probable medication response for an experimental arm subject to the prescriber .
2392432|NCT03625245|Placebo Comparator|Control Yogurt|Control yogurt
2392433|NCT03625245|Experimental|Yogurt Variety 1|Experimental Yogurt 1: Dextrin, wheat bran, whole oatmeal
2392434|NCT03625245|Experimental|Yogurt Variety 2|Experimental Yogurt 2: Pea protein, oatmeal
2392435|NCT03625219|Active Comparator|Prednisone|Cohort B only: Subjects will take 40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
2392436|NCT03625219|Placebo Comparator|Placebo|Cohort B only: 8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
2392437|NCT03625206|Experimental|Cognitive bias modification training|Participants will receive 5 training sessions, each session including attention bias modification and interpretation bias modification training modules
2392438|NCT03625206|Placebo Comparator|Control training|Participants will receive 5 sessions that involve exercises that are matched to the task demands of the attention bias modification and interpretation bias modification training modules
2392439|NCT03625193||Ambulatory patients with SCI|"Age at least 18 years~Body mass index (BMI) between 18.5 - 29.9 kg/m2~Having an incomplete SCI from traumatic or non-traumatic causes~Ability of independent standing up from a chair with or without hand support~Ability of independent walking with or without walking device over at least 10 meters continuously.~Ability to follow commands used in the studies"
2392440|NCT03625180||Treatment|NAMIC technique
2392441|NCT03625167|Experimental|Treatment with petrolatum|In each healthy volunteer, one of the two forearms is randomly assigned to the intervention. This forearm is treated with petrolatum for 4 respectively 8 weeks.
2392442|NCT03625167|No Intervention|Control|The control forearm will remain untreated throughout the study.
2392443|NCT03625154|Active Comparator|non operative control group|Patients with negative gravity stress (non-operative treatment/observational control group)
2392444|NCT03625154|Active Comparator|non operative experimental group|Patients with positive gravity stress (medial clear space > 4 mm on initial injury pre-reduction x-rays, who undergo a reduction with closing of the medial clear space to <4mm. Plan for nonoperative treatment of all these patients with splint and subsequent walker boot.
2392445|NCT03625154|Active Comparator|operative observational group|Patients with positive gravity stress (medial clear space > 4 mm) who undergo a reduction with closing of the medial clear space to <4mm who declined non-operative treatment but agree to be observed. These patients will undergo ORIF (Open Reduction and Internal Fixation) with plates and screws and function as a second observation group
2392448|NCT03625128|Experimental|F-18 PMPBB3|F-18 PMPBB3 imaging
2392449|NCT03625115|No Intervention|Usual Care (Control)|Dyads randomized into this control arm will continue with usual care consisting of information about early intervention services and routine Child Find procedures.
2392450|NCT03625115|Experimental|Family Navigator (Intervention)|Dyads randomized to the Intervention arm with be assigned a designated Family Navigator (FN) who will engage, inform, and assist the participating parents to follow-through with the process of EI referrals and services.
2392451|NCT03625102|Experimental|Antroquinonol 100 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.
2392452|NCT03625102|Experimental|Antroquinonol 50 mg PO BID|Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.
2392453|NCT03625102|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, twice a day
2392454|NCT03625089|Active Comparator|Group 1 - FRS arm|Both group will participate in the nurse-led programme on CV risk screening and carotid ultrasound for carotid plaque assessment. Subjects in group 1 will initiate Atorvastatin treatment (20mg daily per oral) if their Framingham Risk Score >10%
2392455|NCT03625089|Experimental|Group 2 USG arm|Subjects in group 2 will initiate Atorvastatin treatment (20mg daily per oral) if they had carotid plaque upon carotid ultrasound findings..
2392456|NCT03625076|Experimental|Intra-articular Lidocaine|20 mL of 1% lidocaine injected into the joint of the dislocated shoulder
2392457|NCT03625076|Active Comparator|Procedural Sedation|Intravenous etomidate or propofol
2392458|NCT03625063|Active Comparator|Exercise training group|Inspiratory muscle, upper extremity aerobic exercise and progressive resistance trainings
2392459|NCT03625063|Sham Comparator|Control training group|Upper extremity aerobic exercise and progressive resistance trainings
2392460|NCT03625050|Experimental|Chuna + Usual care|
2392461|NCT03625050|Active Comparator|Usual care|
2392462|NCT03625037|Experimental|Epcoritamab (GEN3013, DuoBody®-CD3xCD20)|Open label, single arm trial where Epcoritamab will be administered.
2392463|NCT03625011|Placebo Comparator|Placebo Group|Participants will be randomized to either Control Group or Gabapentin Group
2392464|NCT03625011|Active Comparator|Gabapentin Group|Participants will be randomized to either Control Group or Gabapentin Group
2392465|NCT03624998|Experimental|THA Patients|Orthopedic patients submitted to elective surgery (THA - Total Hip Arthroplasty)
2392466|NCT03624985|Experimental|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
2392498|NCT03624738|Active Comparator|Patients with redo cardiac surgery 1|Procedure: the patients will undergo femorofemoral bypass
3183916|NCT00718835|Active Comparator|Contingent Voucher condition|Subjects in this condition will receive a brief education intervention plus voucher-based incentives contingent on demonstrating objective evidence of recent smoking abstinence.
3183917|NCT00718835|Placebo Comparator|Noncontingent control condition|Subjects assigned to this control condition will receive the brief education and vouchers delivered independent of smoking status and yoked to the schedule of voucher earnings in the Contingent Voucher condition.
3183918|NCT00718848||1|These are patients treated with conventional hemodialysis (4 hours/session, 3 sessions/week) who convert to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week).
2392471|NCT03624959|Experimental|Treatment Group A - Ozanimod 0.46mg|A single dose of ozanimod 0.46 mg on Day 1
2392472|NCT03624959|Experimental|Treatment Group B - Ozanimod plus Gemfibrozil|Gemfibrozil 600 mg twice daily (BID) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.46 mg will be coadministered with the morning dose of gemfibrozil.
2392473|NCT03624959|Experimental|Treatment Group C - Ozanimod 0.92mg|A single dose of ozanimod 0.92 mg on Day 1.
2392474|NCT03624959|Experimental|Treatment Group D - Ozanimod plus Itraconazole|Itraconazole 200 mg once daily (QD) on Days 1 through 17. On Day 4, a single dose of ozanimod 0.92 mg will be co-administered with itraconazole.
2392475|NCT03624959|Experimental|Treatment Group E - Ozanimod plus Rifampin|Rifampin 600 mg QD on Days 1 through 21. On Day 8, a single dose of ozanimod 0.92 mg will be coadministered with rifampin
3183919|NCT00718848||2|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elect to remain on this dialysis schedule and agree to the study-related investigations at baseline and one year thereafter.
3183920|NCT00718874|Experimental|A, 1|low-carbohydrate (42%)
2392478|NCT03624933|Experimental|28-Day Cannabis Abstinence|The study will assess the changes that occur after a 28-day abstinence period in patients with Major Depressive Disorder (MDD) and comorbid Cannabis Use Disorder (CUD). Patients will be instructed to initiate abstinence 12 hours prior to the baseline session and will come in for weekly visits involving a series of clinical, cognitive, and substance use assessments.
3183921|NCT00718874|Experimental|A,2|standard carbohydrate (55%) based on ADA recommendations
3183922|NCT00718913|Experimental|1|TCX ->RT -> TCX
3183923|NCT00718926||Sjogren|Sjogren syndrome with dry eye
2392482|NCT03624907|Other|Consecutive Daily Treatment|Participant will receive daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 4-5 days
2392483|NCT03624907|Other|Non-Consecutive Daily Treatment|Participant will receive non-daily stereotactic body radiotherapy at a dose of 48-50 Gy in 4-5 fractions with treatment occurring over 8-12 days
2392484|NCT03624894||Patients that undergo a dental restorations|Patients that undergo a dental restorations independently from the present study
2392485|NCT03624881|Experimental|VISITAG SURPOINT Module with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
2392486|NCT03624868|Experimental|Tai Chi|A Tai Chi protocol designed for use with older veterans will be used. In each class, the instructor will explain exercise theory and procedures of Tai Chi and review printed materials. Every session will include the following components: (1) warm-up and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture. The Tai Chi instructor will also encourage patients to practice for at least 30 minutes a day at home and to complete daily logs indicating the amount of time that they spent engaged in Tai Chi exercise. Discussion of goal-setting regarding home practice and solutions to potential barriers will be included.
2392487|NCT03624868|Active Comparator|Wellness Education|The wellness education intervention will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives). The Whole Health program focuses on teaching mindful awareness to promote behavioral changes that are consistent with an individual's health goals. Components of the Whole Health model include working the body, surroundings, personal development, food and drink, recharge, family, friends and coworkers, spirit and soul, and power of the mind. Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. Goal-setting using the SMART goals model, with regards to health and wellness, and discussions about ways to address potential barriers will be included in this condition.
2392488|NCT03624855||Description of BJI due to Pseudomonas aeruginosa|patients having bone and joint infection on implant due to Pseudomonas aeruginosa
2392489|NCT03624829||Exp: Patients of GPs with shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are randomized to shared care before the 12 months.
2392490|NCT03624829||Con: Patients of GPs without shared care|All patients 16-65 years old who during 12 months have been in contact with a GP in any of the three GP centers that are not randomized to shared care before the 12 months, and all patients 16-65 years old who during 12 months have been in contact with a GP in any of the six GP center before the randomization and implementation of shared care.
2392491|NCT03624816|Experimental|Restylane Defyne|injection with Restylane Defyne
2392492|NCT03624816|No Intervention|Control|no-treatment control
2392493|NCT03624790|Experimental|Group 1: rRSV A/Maryland/001/11|Participants will receive a single dose of rRSV A/Maryland/001/11 at study entry (Day 0).
2392494|NCT03624777|Experimental|Stroll Safe Program|
2392495|NCT03624777|Active Comparator|Outdoor Fall Prevention Brochure|
2392496|NCT03624764|Experimental|Promontofixation using glue|Patients in this arm will have a laparoscopic promontofixation using a biocompatible cyanoacrylate adhesive replacing some sutures to maintain the strips.
2392497|NCT03624764|Active Comparator|Promontofixation using threads|Patients in this arm will have a laparoscopic promontofixation using sutures with threads to maintain the strips.
2393454|NCT03617900|Experimental|Ginger|
3183924|NCT00718926||non-Sjogren|dry eye without Sjogren syndrome
3183925|NCT00718926||Short-BUT|Dry eye by shortened tear break up time
3183926|NCT00718926||control|normal patients
3183927|NCT00718939|Other|Rheos ON|Study participants in this arm will have the device turn on for six months and remains on.
2392499|NCT03624738|Active Comparator|Patients with redo cardiac surgery 2|Procedure: the patients will undergo conventional Aortobicaval cannulation
2392500|NCT03624725|Active Comparator|modified BII+Braun|The jejunum of the input segment is properly ligated with double line 7 at 3-5cm from the anastomotic site, and the jejunum of the output segment is extended to 30cm
2392501|NCT03624725|No Intervention|traditional BII+Braun|traditional BII+Braun digestive tract reconstruct
2392502|NCT03624712||uterine neoplasms|Women with operable and inoperable uterine malignomas (cervical cancer, endometrial cancer, uterine sarcoma)
2392503|NCT03624699|Experimental|Glaukos iStent inject®|Patients suffering from cataract and open-angle glaucoma. Glaukos iStent inject® is implanted during routine cataract surgery. The effect on IOP/glaucoma medications is monitored.
2392504|NCT03624686||healthy volunteer|
2392505|NCT03624686||luekemia patient|
2392506|NCT03624673|Experimental|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
2392507|NCT03624673|Active Comparator|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
2392508|NCT03624660|Experimental|HR-A (High-risk A)|"Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
2392509|NCT03624660|Experimental|HR-B (High-risk B)|"Prostate, proximal seminal vesicles, and pelvic nodes: 2 cobalt gray equivalent per fraction to a total does of 46 cobalt gray equivalent.~Prostate and proximal seminal vesicles: 2 cobalt gray equivalent per fraction to a total dose of 32 cobalt gray equivalent.~Entire uninvolved seminal vesicle when part of the seminal vesicle is involved with tumor: 2 cobalt gray equivalent per fraction to a total dose of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT: 2.2 cobalt gray equivalent per fraction to a total dose of 85.8 cobalt gray equivalent."
2392510|NCT03624647|Experimental|Power toothbrush|
2392511|NCT03624647|Placebo Comparator|Manual toothbrush|
2392512|NCT03624621|Experimental|Functional Remediation + CCT|12 sessions (1 per week) of group functional remediation program (90 min/session) plus 20 min of tailored computerized cognitive training (CCT)
2392513|NCT03624621|Placebo Comparator|Psychoeducation + Online Games|12 sessions (1 per week) of psychoeducation for major depression (90 min/session) plus 20 min of playing freely with online games (pre-selected by investigators)
2392514|NCT03624621|No Intervention|Treatment as usual|Usual intervention supervised by their psychiatrist
2392515|NCT03624608|Experimental|Auryzon-Processed Ear/Nose|Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.
2392516|NCT03624595|Experimental|Dexmedetomidine group|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
2392517|NCT03624595|Placebo Comparator|Placebo group|Placebo (normal saline) infusion is administered from 16:00 to 08:00 in the same speed for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
2392518|NCT03624569|Sham Comparator|Bagel diet|Bagel consumed daily for 2 weeks
2392519|NCT03624569|Experimental|Potato diet|Potato consumed daily for 2 weeks
2392520|NCT03624556|Experimental|Experimental group DS and FXS|Cohort 1: a 35 DS children group taking EGCG FontUp. Cohort 2: a 6 FXS children group taking EGCG FontUp. (Experimental open-label)
2392521|NCT03624556|Placebo Comparator|Control group DS|Cohort 1: a 35 DS children group taking placebo FontUp.
3183928|NCT00718939|Other|Rheos OFF|Study participants in this arm will have the device turned off for 6 months and then turned on.
3183929|NCT00718952|Experimental|A|Patients in group A will receive vardenafil in double-blinded treatment period.
3183930|NCT00718952|Placebo Comparator|B|Patients in group A will receive placebo in double-blinded treatment period.
2392525|NCT03624530|Experimental|Prophylactic TKI Therapy|Treatment with prophylactic TKI will be initiated from day +30 to +60 post-transplants. TKI was selected according to the mutation results of ABL kinase region.
2392526|NCT03624530|No Intervention|No TKI therapy|Prophylactic TKI will not be given.
2392530|NCT03624491|No Intervention|Standard of care mechanical ventilation|Anesthesia and surgical procedures will be performed following standard of care for mechanical ventilation during surgery.
2392531|NCT03624491|Active Comparator|Transpulmonary pressure guided mechanical ventilation|Same treatment as the control group with the addition of esophageal pressure measurements used to guide mechanical ventilation during surgery.
2392532|NCT03624478|Experimental|Treatment (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
2392533|NCT03624465|Experimental|Levita Magnetic Surgical System|Levita Magnetic Surgical System use of surgical tool
2392534|NCT03624452|Experimental|rIPC and exercise training|Those in the rIPC + exercise group will attend three 50 minute exercise sessions per week for 8 weeks at Liverpool John Moores University and 3 bouts of IPC per week at home at a time of their choice
2392535|NCT03624452|Experimental|rIPC only|Those randomly allocated into the rIPC group will self administer 3 bouts of IPC per week at home at a time of their choice.
2392536|NCT03624439|Experimental|Normal airway|normal airway. the language has not been inflated. the instructor assessed the difficulty of intubation based on the Cormack - Lehane scale to the first degree
2392696|NCT03623230|Sham Comparator|GCont|Only dressing will be applied to patients without actually nerve block performed
2392537|NCT03624439|Experimental|Difficult airway|dofficult airway. Difficult airways were obtained by means of language inflation using a simulator control panel, so as to obtain the degree of intubation difficulty assessed by an independent anesthesiologist to the third degree according to the Cormack-Lehane scale
2392538|NCT03624426|Experimental|Automated SSEP Monitored Group|SSEP monitored group: When a nerve alert is signaled by the automated SSEP device, the surgeon will be informed with the aim to reverse the signal changes. The possible surgical interventions include repositioning the operative arm into a more neutral position, avoidance of excessive traction, removal of retractors, and using a smaller implant to avoid over-correction/traction. The actual intervention will depend on the possible mechanism of nerve injury and treated accordingly.
2392539|NCT03624426|No Intervention|Standard Group|The automated SSEP device will be connected and will be blinded to the surgeon. The screens of the automated SSEP device will be covered by an opaque plastic bag and the alarms will be turned off. No intervention is planned for this group.
2392540|NCT03624413|Experimental|Social Media Intervention|Adolescent HIV-positive participants receiving the social media intervention.
2392541|NCT03624413|Active Comparator|Standard of Care|Adolescent HIV-positive participants receiving the standard of care.
2392542|NCT03624400|Experimental|Internet-based CBT-I|N= 120 participants are offered Internet-based Cognitive behaviour therapy for insomnia (CBT-I)
2392543|NCT03624400|Active Comparator|Internet-based psychoeducation|N= 120 participants are offered Internet-based psychoeducation about sleep problems in ASD.
2392544|NCT03624387|No Intervention|Control Group( No Painting Sessions)|No Geriatric Inclusive Art session.
2392545|NCT03624387|Experimental|Intervention Group( Painting Session)|Painting sessions for participants
2392546|NCT03624361|Experimental|Stand-alone|"Patients will receive MINIject Glaucoma implant in a stand-alone procedure.~MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention."
2392547|NCT03624348|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
2392548|NCT03624348|No Intervention|Wait list control group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
2392549|NCT03624335|Experimental|Group 1: ECC|"In the ECC group, the cord was clamped immediately after delivery, before the first minute of life.~Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping"
2392550|NCT03624335|Experimental|Group 2: DCC|In the DCC group, the cord was clamped when it stops beating. Blood test 6hours after clamping Blood test 24hours after clamping Blood test 48hours after clamping Blood test 28days after clamping
2392551|NCT03624322|Active Comparator|Period 1|Period 1 (n=36) assignment to 1 of 2 reference therapy treatment groups (Zyprexa 5mg IM or Zydis 10mg orally disintegrating wafer, 10mg) over 3 cohorts (single dose)
2392552|NCT03624322|Experimental|Period 2|Period 2 (n=36) assignment to 1 of 3 IP treatment groups (INP105 of 5, 10, or 20mg or placebo) administered with the I231 POD® Device) over 3 cohorts (single dose)
2392553|NCT03624309|Experimental|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
2392554|NCT03624309|Active Comparator|Docetaxel|Docetaxel (75mg/m2 IV d1)
2392555|NCT03624296|Experimental|patient with multiple sclerosis (MS)|
2392556|NCT03624283|Experimental|Group A|Group A will be provided with Exercise-based vestibular rehabilitation (VR) twice per day for a period of 4 weeks;
2392557|NCT03624283|Experimental|Group B|Group B will be prescribed with Betahistine 12mg, twice daily for 7 days;
2392558|NCT03624283|Experimental|Group C|Group C will receive an combination of Exercise-based VR plus Betahistine.
2392559|NCT03624270|Experimental|Frontline oral arsenic trioxide, ATRA and ascorbic acid (AAA)|"Induction:~Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and Ascorbic acid 1g daily for 42 days~Daunorubicin at 50mg/m2 daily for 3 days (omitted if WBC at diagnosis < 10 x 10^9/L; or age ≥ 65 years; or cardiac function impairment)~Hydroxyurea 2-4g per day if WBC > 5 x 10^9/L during the first 7 days of induction.~Consolidation (for all patients):~- Oral arsenic trioxide 10mg daily, all-trans retinoic acid (ATRA) (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 14 days every 28 days for 2 cycles~Maintenance (for all patients):~- Oral Arsenic trioxide 10mg daily, ATRA (45mg/m2 per day in divided doses) and ascorbic acid 1g daily for 2 weeks every 2 months for 24 months."
2392560|NCT03624257|Experimental|Scaling and root planning + Laser treatment|
2392561|NCT03624257|Active Comparator|Mucosal flap surgery|
2392562|NCT03624244|Experimental|Interruption of aromatase inhibitors|Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.
2392563|NCT03624244|Other|Maintenance of aromatase inhibitors|Maintenance of aromatase inhibitors
2392564|NCT03624231|Experimental|Arm 1|"Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy.~Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1)."
2392565|NCT03624231|Experimental|Arm 2|"Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14.~Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total)."
2392566|NCT03624218|No Intervention|Treatment as Usual|Participants in the control arm will not receive the PE therapy, but they will rather receive the standard clinical treatment receive by all SCI patients at BIR. This includes an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. This therapy does not consist of trauma-focused therapy and will be summarized in the analysis as a part of standard of care. TAU participants will have a posttreatment assessment, as well as follow-up assessments at one and 6 months
2392820|NCT03622268||Indirect calorimetry measurement|Using indirect calorimetry for measure resting energy expenditure
2392567|NCT03624218|Experimental|Intervention|Participants randomized to the PE intervention will receive 2-3, 60-minute sessions each week for 4-6 weeks (12 total sessions). Treatment is manualized, and includes education about common reactions to trauma, breathing retraining, prolonged (repeated) imaginal exposure to trauma memories, repeated in vivo exposure to situations that participants are avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises.
3183931|NCT00718965|Experimental|25 mg/day AVE5530|
3183932|NCT00718965|Experimental|50 mg/day AVE5530|
2392570|NCT03624179||Rheumatoid arthritis patients|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
2392571|NCT03624179||healthy control|complete blood count, Erythrocyte sedimentation rate, C reactive protien ,rheumatoid factor,Anti cyclic citrullinated peptide antibody
2392572|NCT03624166|Active Comparator|Ketamine|sub- anesthetic dose of ketamine 0.5 mg/kg will be given in 3 ml volume
2392573|NCT03624166|Placebo Comparator|isotonic saline|isotonic saline 3 ml volume will be given
2392574|NCT03624153|Experimental|Robotic-assisted intervention|70 minutes Robotic-assisted intervention.
2392575|NCT03624153|Active Comparator|Conventional intervention|70 minutes conventional rehabilitation.
2392576|NCT03624140|Experimental|Hemoglobin monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
2392577|NCT03624127|Experimental|BMS-986165|
2392578|NCT03624127|Placebo Comparator|Placebo|
2392579|NCT03624127|Active Comparator|Apremilast|
2392580|NCT03624101|Experimental|Trikafta|If the participant is not on a current modulator, they will take Trikafta for 28 days followed by a 28 day off period. This cycle will be continued for 168 days
2392581|NCT03624101|Experimental|Symdeko/Trikafta|If the participant currently takes Symdeko , they will take Trikafta for a 28 day period followed by Symdeko for a 28 day period. This cycle will be continued for 168 days
2392582|NCT03624101|Experimental|Ivacaftor/Trikafta|If the participant currently takes Ivacaftor , they will take Trikafta for a 28 day period followed by Ivacaftor for a 28 day period. This cycle will be continued for 168 days
2392583|NCT03624088|Experimental|Single-Arm Intervention|Participants will complete a baseline questionnaire. They will then self-administer the web-based decision aid, RealRisks. Upon completion, they will complete two more surveys: one within 1 month of completing RealRisks and one six months after completing RealRisks.
2392584|NCT03624075|No Intervention|control group|The control group had a protocol of a health education / self-gestation session lasting 60 minutes. This session should include topics such as definition of knee OA, guidance on knee anatomy and physiology, prayer over articulation, rehabilitation and practice of exercises, and as volunteer to receive an educational and self explanatory primer with all the content that is exposed during a lesson .
2392585|NCT03624075|Placebo Comparator|Placebo group|The placebo group will simultaneously receive two techniques of applying tensionless KT. The first technique that will be applied is inverted 'Y' on the rectus femoris. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
2392586|NCT03624075|Experimental|intervention group|The intervention group will receive the same protocol as the placebo group, differing only in relation to the tension of the bandage. According to Kase et al (2003), the techniques recommend the relief of pain and edema and performance. In the second technique to be applied, the tape body will be divided lengthwise into four narrow strips. The two pieces intersect the front of the knee. For this application, the volunteer will be positioned in the dorsal position without knee flexion and the tape will be applied by a trained researcher. In the case of bilateral OA, in both techniques of application, the most affected member based on the NPRS score will be the one that will undergo the intervention. All volunteers will remain with the tape for 72 hours.
2392587|NCT03624062|Other|33 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 33 ug IBC dose in 0.25 mL MAS-1 emulsion
2392588|NCT03624062|Other|109 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 109 ug IBC dose in 0.25 mL MAS-1 emulsion
2392589|NCT03624062|Other|327 ug IBC in 0.25 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with a 327 ug IBC dose in 0.25 mL MAS-1 emulsion
2392590|NCT03624062|Other|TBD ug IBC in 0.5 mL MAS-1 emulsion|7 participants to be randomized between placebo and MAS-1 adjuvanted insulin B-chain (2:5) with the maximum safe IBC dose selected from the first 3 groups (either 33 µg, or 109 µg, or 327 µg IBC) in 0.5 mL MAS-1 emulsion
2392591|NCT03624049|Other|Community Exercise Program|Participation in Health Class including: Arthritis Exercise Foundation Exercise Class, Tai Chi for Arthritis, EnhanceFitness Class, or Healthier Living Class.
3183933|NCT00718965|Placebo Comparator|Placebo|
2392593|NCT03624023|Experimental|TWB-103|(Mixture of TWB-102 cell and TWB-103 hydrogel)
2392594|NCT03624010|Experimental|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
2392595|NCT03623997||Stable isotope labeled iron II sulfate|All subjects will go through two iron absorption study cycles. In one cycle they get 100mg oral iron labeled with stable isotopes on two consecutive and on one alternate day and in another cycle they get 200mg oral iron labeled with stable isotopes on two consecutive and on one alternate day. Half of the subjects start with the 100mg cycle whereas the other half starts with the 200mg cycle.
2392625|NCT03623789|Placebo Comparator|Group III|Control group, neither TXA nor Floseal® will be used. Equivalent volume of normal saline injection pre- and post-operatively
2392626|NCT03623776|Experimental|JS001 alone|Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
3183934|NCT00718978|Other|B|the investigators grafted sheets based on the HYAFF11p80® scaffold (the one with the lowest degree of esterification)
3183935|NCT00718978|Other|A|the investigators grafted sheets based on the HYAFF11® scaffold (the one with the highest degree of esterification).
2392596|NCT03623984|Experimental|Gallium Dotatate|All patients in the study will be undergoing both a 68Gallium-DOTATATE scan for tumor localization and planned surgical resection. Both of these maneuvers are clinically indicated and the standard of care in the care of these patients. Following induction of general endotracheal anesthesia (as required for the surgery portion of treatment), the patients will receive an additional injection of 68Gallium-DOTATATE in the operating room itself. A probe that can detect 68Gallium will be used to identify tumors in the OR within the patient's abdominal cavity for targeted resection.
2392597|NCT03623971|Experimental|Artificial Intelligence|A universal diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of cataract.
2392598|NCT03623958|Experimental|iVATS resection|Image guided Video-assisted thoracoscopic surgery (VATS) in either one of two hybrid operating rooms and Fine Needle Aspiration (FNA) under fluoroscopy.
2392599|NCT03623958|Active Comparator|Standard VATS resection|Standard video-assisted thoracoscopic surgery (VATS) in operating room and Fine Needle Aspiration (FNA) in pathology frozen section room.
3143211|NCT00005086|Experimental|Arm A|Methotrexate will be given as a short infusion (introduced into a vein) for approximately 5 minutes on the first day (day 1). ). A week later (day 8), both methotrexate and docetaxel will be given the same way, but this will take about 1 hour. The first course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks. X-rays or scans will then be performed to determine if your tumor is shrinking. You will then start treatment with gemcitabine and cisplatin. On the first day (day 1), you will receive both cisplatin and gemcitabine into your vein. A week later (day 8), you will receive only gemcitabine as an infusion into your vein over 100 minutes and no additional intravenous fluid will be required on that day. This second course of treatment consists of receiving treatment on day 1 and day 8 every 21 days for 9 weeks.
3143212|NCT00005087|Experimental|Radiation (BID) and chemotherapy|Radiation (BID), cisplatin and paclitaxel given on days 1-5 (Monday-Friday) in weeks 1, 3, 5 and 7. G-CSF given on days 6-13.
3143213|NCT00005089|Experimental|CHOP + Rituximab + RT|3 21-day cycles of CHOP (cyclophosphamide 750 mg/m^2, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2, prednisone 100 mg x 5 days) + Rituximab 375 mg/m^2 (x 2 days for cycle 1, x 3 days for cycles 2-3). RT 4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
3183936|NCT00718978|Other|A-B|the investigators grafted sheets based on the HYAFF11® scaffold and sheets based on the HYAFF11p80 ® scaffold
2392604|NCT03623932|Active Comparator|immunosuppressor/TNFalpha|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment.
2392605|NCT03623932|Experimental|Hypnosis + Standard Treatment|Standard treatment with immunosuppressor and/or anti-TNFalpha treatment in addition to hypnosis parallel treatment.
2392606|NCT03623919|Experimental|Exercise group|"Group games, including two teams of seniors aged 50 years or older. The FallSensing games software include 3 mini-games to be played by two teams with up to 3 players each will compete against each other alternately.~The players will perform an initial evaluation with FallSensing screening tool, 16 sessions of group games (2 times a week/8weeks) with FallSensing multiplayer games and a final evaluation also with FallSensing screening tool.~Both initial and final evaluation include six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for Exercise."
2392607|NCT03623906|Experimental|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
2392608|NCT03623906|Active Comparator|Air insufflation colonoscopy|Room air insufflation colonoscopy
2392611|NCT03623880|Experimental|Unified Protocol|This is a type of CBT for emotional distress.
2392612|NCT03623880|Active Comparator|Supportive Therapy|This is a commonly-used form of all-purpose psychotherapy, often used as a comparator in CBT clinical trials.
2392613|NCT03623867|Experimental|Secukinumab|Subject will received secukinumab 150mg at week 0-4, and once monthly till week 48
2392614|NCT03623867|Placebo Comparator|Placebo|Subject will received placebo 150mg at week 0-4, and once monthly till week 48
2392615|NCT03623854|Experimental|Treatment (nivolumab and relatlimab)|Participants receive nivolumab intravenously (IV) over 60 minutes and relatlimab via infusion over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2392616|NCT03623841|Experimental|Dual-task training group|Participants in dual-task training group will execute dual-task training via exer-game which combined with treadmill, 3 times per week, least 8 weeks.
2392617|NCT03623841|Active Comparator|Treadmill training group|Participants in treadmill training group will do treadmill training only, 3 times per week, least 8 weeks.
2392618|NCT03623828|Experimental|Apomorphine treatment|"Treatment by apomorphine hydrochloride subcutaneous infusion 12 hours per day during 30 days: 5-days titration phase (increasing doses from 0 to 4 mg/h), 7 days of maintenance at 4 mg/h and 18 days of maintenance phase with possible increase up to 6 mg/h if well tolerated.~Two days before the initiation of apomorphine, domperidone 20mg t.i.d per os (or via gastric tube) will be initiated to reduce common side effects. It will be maintained at least 7 days before an optional tapering off in the absence of nausea of vomiting."
2392619|NCT03623815|Other|Sham tDCS followed by active tDCS|Within subjects design. This group received sham (placebo) transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received 2mA of active tDCS for 20 minutes in session two.
2392620|NCT03623815|Other|Active tDCS followed by sham tDCS|Within subjects design. This group received 2mA of active transcranial direct current stimulation (tDCS) for 20 minutes in session one. At least one month later this group received sham (placebo) tDCS for 20 minutes in session two.
2392621|NCT03623802|Experimental|Local Movement Therapy|Group receiving treatment in form of Local Movement Therapy Program.
2392622|NCT03623802|Experimental|Integral Movement Therapy|Group receiving treatment in form of Integral Movement Therapy Program.
2392623|NCT03623789|Active Comparator|Group I|Primary total hip replacement with application of Floseal hemostatic matrix on potential bleeding sites after prosthesis implantation, and intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
2392624|NCT03623789|Active Comparator|Group II|Primary total hip replacement with intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later
2392627|NCT03623776|Experimental|JS001+chemotherapy|Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
2392628|NCT03623763||Healthy individuals|Individuals without any complaints and chronic diseases
2392629|NCT03623763||Swimmers|Elite athletes - swimmers to distance of national team of Uzbekistan
2392630|NCT03623763||Synchronized swimmers|Elite athletes - swimmers of national team of Uzbekistan
2392631|NCT03623750|Experimental|EGFR-TK Inhibitor plus EGF-PTI|Elegile patients will receive a single pre-treatment low dose of intravenous cyclophosphamide 200mg/m2 before experimental treatment starts. Daily oral therapy with afatinib according to the SmPC of the product in nominal treatment cycles of 21 days followed by immunisation with EGF-PTI.
2392632|NCT03623737|Experimental|paclitaxel plus cisplatin|A. T: Paclitaxel 50 mg/m2, 1h IVF, weekly, week 1 to week 5 during CRT. B. P: Cisplatin 30 mg/m2, 2 h IVF, weekly following paclitaxel, week 1 to week 5 during CRT.
2392633|NCT03623737|Active Comparator|cisplatin plus 5-fluorouracil|A. P: Cisplatin 75 mg/m2, 2 h IVF, on day 1 of week 1 and week 5 during CRT. B. F: 5-FU 1,000 mg/m2, 24 h IVF, on day 1, 2, 3, 4 of week 1 and week 5 during CRT.
2392634|NCT03623724|Experimental|blended Cognitive-behavioral Therapy|The experimental condition refers to a blended treatment that integrates empirically-supported face-to-face cognitive-behavioral psychotherapy with a mobile phone application and a web platform - blended cognitive-behavioral therapy (bCBT). The intervention includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on the self-help treatment modules of the Moodbuster (psychoeducation, exercise therapy, behavioral activation, problem solving, cognitive restructuring and relapse prevention) delivered over a period of 16 weeks. 50 patients will be integrated in this experimental condition.
2392635|NCT03623724|Active Comparator|Treatment-As-Usual|The control condition concerns the treatment-as-usual (TAU) that consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial). 50 patients will be integrated in this condition.
2392636|NCT03623711|Experimental|Escitalopram group|including 50 patients, dosage:start 10mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 20mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.
2392637|NCT03623711|Experimental|Duloxetine group|including 50 patients, dosage:start 30mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 60mg/day and last to the end of 12 week. but if the reduction rate of HAMD more than 20% relative to baseline,the investigators will continue to use current dosage until the end of 12 week.
2392638|NCT03623711|Experimental|Bupropion group|including 50 patients, dosage:start 75mg/day and last 2 weeks,we assess the HAMD score at the end of 2 weeks, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week.if the reduction rate of HAMD less than 20% relative to baseline, the dosage add to 150mg/day and last 2 weeks, the investigators assess the HAMD score again, if the reduction rate of HAMD more than 20% relative to baseline, the investigators will continue to use current dosage until the end of 12 week, but if the reduction rate of HAMD still less than 20% relative to baseline, the participants would withdraw.
2392639|NCT03623711|Placebo Comparator|Healthy control|50 age-, gender-,education level- and handedness matched healthy control would recruit by an advertisement in the local community and school, and excluding ① with a severe physical disease and/or neurological disease, ②with substance abuse, ③ with a history of brain injury, ④ inability to undergo a MRI scan.
3183937|NCT00718991|Experimental|1|CLI patients receiving excimer laser recanalisation for the treatment of long infrapopliteal lesions
3183938|NCT00719004|Experimental|Normals|Normal volunteers having Ultrasound scan of foot.
2392642|NCT03623685|Experimental|voluson 8|
2392643|NCT03623659|Active Comparator|AH group|Subjects whose vitrified/warmed blastocysts will be subjected to the treatment of laser assisted hatching
2392644|NCT03623659|No Intervention|Control group|Subjects whose vitrified/warmed blastocysts will be subjected to the same procedures except for the treatment of laser assisted hatching
2392645|NCT03623646|Other|Arm A (standard arm): Chemoradiotherapy arm|
2392646|NCT03623646|Experimental|Arm B (Experimental arm): Immunotherapy + Radiotherapy arm|
2392647|NCT03623633|Active Comparator|Denosumab and Raloxifene|denosumab and raloxifene
2392648|NCT03623633|Active Comparator|Denosumab and Alendronate|denosumab and alendronate
2392649|NCT03623620|Experimental|Digital delivery of MBCT (Mindful Mood Balance for Moms)|Subjects will receive digital delivery of mindfulness-based cognitive therapy (Mindful Mood Balance for Moms) for 12 weeks, along with the usual care they would receive from their provider.
2392650|NCT03623620|No Intervention|Usual Care|Subjects will receive only usual care, the care they would normally receive from their community provider, for 12 weeks.
2392651|NCT03623594|Experimental|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
2392652|NCT03623581|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
2392653|NCT03623568|Experimental|Treatment with Mavyret (glecaprevir/pibrentasvir) for HCV|12 weeks of treatment with Mavyret
2392654|NCT03623555||E-IPV|"Women who have been exposed to intimate partner violence. Half of this group will also have a history of childhood maltreatment.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
2392655|NCT03623555||NE-IPV|"Women who have never been exposed to intimate partner violence. Half of this group will also present a diagnosis of Major Depressive Disorder.~Women will be assessed for behavioral performance during the Trier Social Stress Test, and salivary cortisol will be collected."
2392656|NCT03623542||Dementia or alzheimer dementia|All patients presenting with dementia syndrome and whose admission was unplanned between May 2010 and November 2011 were consecutively included in the study.
2393455|NCT03617900|Active Comparator|Paracetamol|
3183939|NCT00719017|Experimental|Vaginectomy group|Upper vaginectomy
2392659|NCT03623516||Thyroid cancer|All subjects living in the Marne or Ardennes Departments of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014.
2392660|NCT03623503||first group|Observational study of 25 newborn with a likely EOS
2392661|NCT03623503||second group|Observational study of v33 newborn with a possible EOS
2392662|NCT03623490|Experimental|accented follow-up|Initial consultation with a trio oncologist / pharmacist / nurse; weekly telephone follow-up with a nurse between each treatment and follow-up visit with the oncologist at each renewal of treatment.
2392663|NCT03623490|No Intervention|standard follow-up|Initial consultation with the oncologist and follow-up visit with the oncologist
2392664|NCT03623477|Active Comparator|Cognitive Remediation (CRT)|Participants assigned to CRT alone will complete 24 hours of neurocognitive training activities and 12 hours of control computer activities.
2392665|NCT03623477|Experimental|CRT+ Social Cognition Training|Participants assigned to the combination of CRT and SCT will complete 24 hours of computerized neurocognitive training in memory, attention, and processing speed, and 12 hours of computerized social cognition training focused on improving emotion recognition, social perspective taking, and mentalizing abilities.
2392666|NCT03623464|Active Comparator|Mobile app and Fitbit + Standard of care|Mobile health application and Fitbit + standard of care: Participants will utilize mobile app and Fitbit and standard of care. Mobility data will be generated using a mobile health tracker designed for smartphone devices.
2392667|NCT03623464|Other|Standard of care|Participants will receive standard of care
2392668|NCT03623451|Experimental|Chinese Medicine Formula|All 100 patients were treated with Chinese Medicine Formula(CMF) for three menstrual cycles.
2392669|NCT03623438|Experimental|Self-administered acupressure group|Subjects will attend two weekly 120-minute of self-administered acupressure training
2392670|NCT03623438|Active Comparator|Sleep hygiene education (SHE) group|Subjects will attend two weekly 120-minute of sleep hygiene education
2392671|NCT03623425|Experimental|68Ga-PSMA-11 PET before 18F-FCH PET|Crossover design
2392672|NCT03623425|Experimental|18F-FCH PET before 68Ga-PSMA-11 PET|Crossover design
2392673|NCT03623412|Experimental|One abnormal value|Women with only one abnormal value on OGTT (Oral Glucose Tolerance Test) during pregnancy
2392674|NCT03623412|Active Comparator|GDM|Women with two abnormal values on OGTT during pregnancy - diagnosis=GDM
2392675|NCT03623399|No Intervention|15 mmhg-15mmhg|Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 15 mmhg.
2392676|NCT03623399|Other|15 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 15 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
2392677|NCT03623399|Other|12 mmhg-12 mmhg|"Abdominal entrance pressure will be set to 12 mmhg , after laparoscopic visualization of abdomen ; maintenance pressure will be set to 12 mmhg.~Low gas pressure laparoscopy"
2392678|NCT03623386|Experimental|Patients with PD neurofeedback training|Patients will receive neurofeedback training.
2392679|NCT03623386|Active Comparator|Patients with PD control|Patients will not receive neurofeedback training.
3183940|NCT00719017|Experimental|Brachytherapy group|Post-operative brachytherapy
2392681|NCT03623360||Patients with liver cirrhosis|"The cohort includes patients who encompass the full clinical spectrum of liver function within cirrhosis.~The participants will undergo a full MRI protocol for liver screening including morphological imaging, fibrosis scoring tests based on relaxometry and diffusion maps, and our novel functional technique based on free breathing DCE-MRI."
3183941|NCT00719017|Active Comparator|Control group|Standard treatment
3183942|NCT00719030|Experimental|1|Pomegranate pill
3183943|NCT00719030|Placebo Comparator|2|
3183944|NCT00719056|Experimental|1|Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
2392686|NCT03623308|Experimental|Fiber Intervention I|Participants will be asked to consume two ½ cup servings of fiber cereal daily (equivalent to 28 g fiber) for 14 days, one in the morning and one in the evening.
2392687|NCT03623308|Experimental|Fiber Intervention II|Participants will be asked to consume two ¼ cup servings of fiber cereal daily (equivalent to 14 g fiber) for 14 days, one in the morning and one in the evening.
2392688|NCT03623295||Cohort study population|For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.
2392689|NCT03623295||Sub study population|A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.
2392690|NCT03623282|Experimental|Synatura® 15 mL|Synatura syrup single arm
2392691|NCT03623256|Active Comparator|Spinal Fentanyl|Spinal dose of preservative-free fentanyl 25 mcg (Volume 0.5 mL)
2392692|NCT03623256|Active Comparator|Spinal Bupivacaine|Spinal dose of preservative-free 0.25% bupivacaine (Volume 0.5 mL)
2392693|NCT03623256|Active Comparator|Spinal Fentanyl and Bupivacaine|Spinal combination of preservative-free 0.25% bupivacaine (0.5 mL) and fentanyl 25 mcg (0.5 mL). (Total Volume 1 mL).
2392694|NCT03623256|Experimental|Epidural fentanyl /spinal bupivacaine|Spinal preservative-free 0.25% bupivacaine (Volume 0.5 mL) and epidural fentanyl 100 mcg (Volume 2 mL).
2392695|NCT03623243|Experimental|Siponimod 2 mg|Siponimod 2mg tablets taken once daily after a 5 day titration
3183945|NCT00719056|Active Comparator|2|Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
3183946|NCT00719082||AARP Community|Members of AARP Geriatric Community
3183947|NCT00719095|Experimental|1-week buprenorphine taper|1-week buprenorphine taper + behavioral therapy + urine toxicology
3183948|NCT00719095|Experimental|2-week buprenorphine taper|2-week buprenorphine taper + behavioral therapy + urine toxicology
3183949|NCT00719095|Experimental|4-week buprenorphine taper|4-week buprenorphine taper + behavioral therapy + urine toxicology
3183950|NCT00719108|Experimental|Wosulin R|Wosulin R, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
3183951|NCT00719108|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (100 IU/mL)in vials 10.0 ml
3183952|NCT00719121|No Intervention|A|No Treatment
2392697|NCT03623230|Active Comparator|G125 Block|"Ultrasound Guided Femoral Nerve Block: 20ml Bupivacaine 0.125% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 15ml Saline solution."
2392698|NCT03623230|Active Comparator|G25 Block|"Ultrasound Guided Femoral Nerve Block: 10ml Bupivacaine 0.25% Injectable Solution will be administered for femoral nerve block.~5ml %0,5 Bupivacaine will be diluted with 5ml Saline solution."
2392699|NCT03623217||Kidney transplant participants receiving tacrolimus|Transplant participants who have received tacrolimus twice daily for a minimum of 6 months to a maximum of 12 months after the surgery, and who are within 1 month of switching to the once daily regimen of modified release tacrolimus.
2392700|NCT03623204||Patients with bariatric surgery for obesity|
2392701|NCT03623191||Patients with erosive pustular dermatosis of the leg|
2392702|NCT03623178||Assertive Community Treatment|"patients with DSM-5 Diagnosis of SUD and one of the following criteria (1) present important functional difficulties, in at least one of the following areas: everyday life activities and maintaining a supportive social network, for minimum two years.~or (2) difficulties to attend their health care appointments, during the last 3 months."
2392703|NCT03623178||Treatment As Usual|patients with DSM-5 Diagnosis of SUD which do not respond to ACT inclusion criteria
2392704|NCT03623165||Arm|Cordella™ Heart Failure System
2392705|NCT03623139|Active Comparator|Standard nutritional education|Control group
2392706|NCT03623139|Experimental|BCC|Education and training i basic carbohydrate counting (BCC) plus standard nutritional education
2392707|NCT03623113|Experimental|BCC intervention|The BCC program consists of three group sessions and is delivered by two trained dietitians. In addition to the BCC program, the participants receive regular medical care in the diabetes clinic
2392708|NCT03623113|Experimental|ABC-ACC intervention|The ABC-ACC program consists of one group session and two individual follow-up sessions and is delivered by trained dietitians with supervision by a medical doctor. In addition to the ABC-ACC program, the participants receive regular medical care in the diabetes clinic
2392709|NCT03623113|Active Comparator|Standard dietary education|The routine outpatient dietary care consists of three individual consultations delivered by a trained dietitian. The individual guidance is based on the overall treatment goal(s), the defined personal dietary goals for behavioral change which will be in accordance with the patient's needs and preferences. In addition to the dietary counselling, the participants receive regular medical care in the diabetes clinic
2392710|NCT03623100|Experimental|Speech Treatment|Half of the children will be assigned to the traditional speech treatment program which will focus on how to produce sounds in academic vocabulary words.
2392711|NCT03623100|Experimental|Speech Treatment & Perception|Half of the children will be assigned to the traditional speech treatment program and speech perception training program combination. This treatment program will teach children not only how to produce sounds in academic vocabulary words, but to also identify correctly and incorrectly produced sounds in words.
2392712|NCT03623087|Experimental|SIMPLE|cisplatin, gemcitabine, ifosfamide, etoposide (VP-16), L-asparaginase, dexamethasone
2392713|NCT03623074|Experimental|Test Arm 1|Single vision, impact-resistant spectacle lenses
2392714|NCT03623074|Experimental|Test Arm 2|Single vision, impact-resistant spectacle lenses
2392715|NCT03623074|Other|Test Arm 3|Single vision, impact-resistant spectacle lenses
2392716|NCT03623061||Low Fibrinogen Level|Anonymised low fibrinogen adult samples from the laboratory (Low fibrinogen concentrations). Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2392717|NCT03623061||Normal Fibrinogen Level|Healthy non pregnant females presenting for elective gynaecology surgery (Normal non pregnant fibrinogen concentrations) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2392718|NCT03623061||High Fibrinogen Level|Healthy pregnant females presenting for elective caesarean section (Normal term pregnancy fibrinogen levels) Samples to be tested on the F-Point device and standard Clauss Fibrinogen assay.
2392719|NCT03623048|Experimental|Propolis extract|intervention
2392720|NCT03623048|Experimental|Pomegranate extract|intervention
2392721|NCT03623048|Active Comparator|Chlorhexidine|comparator
2392722|NCT03623048|Placebo Comparator|Saline|comparator
3183953|NCT00719121|Active Comparator|B|R115866 (0.35% gel)
2392724|NCT03623022|Experimental|Endotoxin, then Normal Saline|"Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The Clinical Center Reference Endotoxin (CCRE) will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo a Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
2392725|NCT03623022|Experimental|Normal Saline, then Endotoxin|"Saline Challenge: Subjects will undergo inhalation of 0.9% sodium chloride. The Normal saline will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).~Following a washout of 2 weeks to 3 months the participant will undergo an Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes)."
2392726|NCT03623009|Experimental|Intervention|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
2392727|NCT03623009|Sham Comparator|Control|The control arm will receive a neutral article prior to completing the assessment.
2392728|NCT03622983||Collection of sample and data|Collection of biological samples and clinical data
2392729|NCT03622970|Experimental|VGBT with Nintendo® Wii and LMC games|"VGBT with Nintendo® Wii and LMC games:~In order to improve the elbow and shoulder functions, Tennis and boxing, the games of Nintendo Wii® Fit WiiSports package that includes shoulder and elbow movements will be used for VGBT with Nintendo® Wii and Leap Motion Controller (LMC) games. In both of the games, the activities are carried out by providing feedback in the context of remote control and sound and vibration notifications."
3183954|NCT00719121|Active Comparator|C|R115866 Vehicle gel
3183955|NCT00719121|Active Comparator|D|Differin™, 0.1% adapalene gel
2392730|NCT03622970|Active Comparator|NDT-based upper limb rehabilitation|"NDT-based upper limb rehabilitation:~NDT-based upper limb rehabilitation aims to facilitate normal movement for upper extremity activities such as getting dressed and eating etc by using real materials (clothes, spoons, pencils, buttons, rope, etc.). The target activities were practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools."
2392731|NCT03622957||Type 2 diabetes subjects|Type 2 diabetes subjects consecutively referring to Santa Chiara, Pisa diabetes outpatients clinic
2392732|NCT03622944|Active Comparator|Muscle energy technic|post isometric relaxation technics were used as muscle energy technics.
2392733|NCT03622944|Active Comparator|Deep Friction Massage|Painful areas palpated and deep friction massage was applied.
2392734|NCT03622944|Active Comparator|exercise|Physiotherapist guided Spinal stabilization exercises were applied.
2392735|NCT03622931|Experimental|the experimental arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + romiplostim 750 μg sc once per week for up to 4 cycles
2392736|NCT03622931|Placebo Comparator|the placebo arm|standard chemotherapy at 3/4-weekly intervals (cf. inclusion criteria) + placebo once per week for up to 4 cycles
2392737|NCT03622918|Sham Comparator|colistin monotherapy|The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
2392738|NCT03622918|Experimental|colistin-rifampin combination|The subjects will be treated with colistin and rifampin combination therapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
3143214|NCT00005090|Active Comparator|ABVD x 5 + ABVD x 3|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
3183956|NCT00719147||1|
2392745|NCT03622866|Active Comparator|Ultra-high pulse width|Ultra-high pulse width stimulation using the Algovita System
2392746|NCT03622866|Active Comparator|Traditional pulse width|Traditional pulse width stimulation using the Algovita System
2392747|NCT03622853|Experimental|intraarticular steroid injection|intraarticular steroid hydrodilatation (shincort 40mg )
2392748|NCT03622840|Other|Parkinson's disease patients with cognitive impairment|Online cognitive remediation program.
2392749|NCT03622827|Experimental|Chemoradiotherapy + Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy with concurrent chemotherapy that consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day,civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the chemotherapy every 3 weeks, total of two cycles during chemoradiotherapy course."
2392750|NCT03622814|Experimental|Treatment - Partners at Meals (PAM)|People with dementia (PWD) often lose weight and suffer subsequent health issues: the goal of this intervention is to improve or maintain weight of a PWD, and to improve or maintain food intake. A train-the-trainer intervention is used with volunteers in Respite Care Centers who partner with family caregivers of PWD. Designed to be personalized to the PWD and focusing on his/her existing strengths and compensating for his/her deficits in mealtime management, sessions occur initially (1 hr) and every month (~30 mins) to reinforce key areas of behavioral or environmental change. Samsung tablets are used initially and then monthly (x5) to record mealtimes in the home, and are reviewed by the volunteer with the family member at the monthly session to discuss areas where changes could be made.
2392751|NCT03622814|Placebo Comparator|Enhanced Usual Condition (EUC)|In the non-treatment respite care centers, an Enhanced Usual Condition will be delivered to caregivers of People with Dementia (PWD). This program consists of enhanced training in caregiving using components from a module of the evidence-based Savvy Caregiver program (K. Hepburn) given in a group setting with opportunity for a question and answer period; the program is given for new enrollees and every 6 months. The PI (EJA), the nutritionist (KM) or the Program Manager (MCP) will lead these groups. Weight of the PWD is measured initially and monthly (x5); amount of food consumed will be measured using the Samsung tablets, also initially and monthly (x5).
2392752|NCT03622801||Intra-arterial administration|Patients with intra-arterial administration of Iopromide
2392753|NCT03622801||Intravenous administration|Patients with intravenous administration of Iopromide
2392756|NCT03622762|Experimental|Green tea extract|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
2392757|NCT03622762|Placebo Comparator|Placebo|In male and female population, with a diagnosis of Diabetes Mellitus type 2, under treatment with hypoglycemic agents and / or insulin and kidney damage grade 2 - 3a according to classification of the KDIGO guidelines
2392758|NCT03622749|Active Comparator|Patients|Individuals with Bipolar 1 Disorder
2392759|NCT03622749|No Intervention|Controls|Healthy controls
2392760|NCT03622710|Experimental|Different surfaces|Subjects are trained to walk over a walking track with different surfaces (WTDS) for 5 days over 4 weeks.
2392761|NCT03622710|Active Comparator|overground|Subjects are trained to walk overground for 5 days over 4 weeks.
3143215|NCT00005090|Experimental|ABVD x 5 + ABVD x 1 + HDT + PBSCT|Patients receive 5 28-day cycles of ABVD (doxorubicin 25 mg/m^2, bleomycin 10 U/m^2, vinblastine 6 mg/m^2, dacarbazine 375 mg/m^2 all on days 1 and 15). Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant. Patients randomized to the transplant arm have 2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight collected at day -7. High dose therapy consists of BCNU 150/m^2 on days -6 to -4, etoposide 60 mg/kg on day -4, and cyclophosphamide 100 mg/kg on day -2. Peripheral blood stem cells are infused on day 0.
3143216|NCT00005092|Experimental|Chemo, RT + PSCT|Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation
2392764|NCT03622684|Experimental|Muscle relaxation according to Jacobson|. Does the use of the method of progressive relaxation according to Jacobson will be beneficial to reduce pain and improve the functioning of the stomatognathic system being evaluated in clinical trials?
2392765|NCT03622671|Active Comparator|Skeletonized LIMA|In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.
2392766|NCT03622671|Active Comparator|Pedicled LIMA|In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.
2392767|NCT03622658|Placebo Comparator|Placebo|Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx
2392768|NCT03622658|Experimental|Namilumab|Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx
2392769|NCT03622645|Experimental|Range of motion in hand|Assessment of Wrist flexion/extension, radial/ulnar deviation, supination/pronation, 1.-5. DIP, PIP and MCP flexion/extension ROM measurements of the fingers with universal goniometer and Leap motion sensor
2392772|NCT03622606|Experimental|Acute and subacute phase of right stroke|"The intervention will be the passation of Right Language Screening Test (R-LAST).~Patients in acute phase of right hemispheric stroke will be used for the internal validation and the integrated reliability of the Right Language screening test.~Patients in subacute phase of right hemispheric stroke will be used for the external validation of the Right Language screening test."
2392776|NCT03622580|Experimental|A: Faricimab Q8W|
2392777|NCT03622580|Experimental|B: Faricimab As Specified in Protocol|
2392778|NCT03622580|Active Comparator|C: Aflibercept Q8W|
2392779|NCT03622567|Other|Push Notifications|Push notification number (0, 1, 3, 5) will be counter balanced within-subjects.
2392780|NCT03622554|No Intervention|Control arm|Curist taking a spa treatment of 3 weeks in the usual conditions for each Center
2392781|NCT03622554|Experimental|Intervention|"Addition to the usual cure: -12 adapted physical activity (APA) sessions of 60 minutes to improve the balance , muscular strength, endurance and suppleness without creating additional fatigue for the curists~- personalized therapeutic patient education (ETP) with an individual assessment at the beginning of the treatment (1h), 3 group sessions (1h30) and an end-of-cure interview (1h) and an educational follow-up by phone at 3, 6 and 12 months"
2392782|NCT03622541|Experimental|sorafenib|
2392783|NCT03622528||Lung Cancer Screening Cohort|Patients who are seen in the UIHC lung cancer screening clinic will be asked to undergo an additional standard chest CT scan during their UIHC clinical lung cancer screening CT scan. Additionally, data from that clinical scan and all medical records associated with nodules that were discovered by the Lung Cancer Screening, will also be collected.
2392784|NCT03622515|Experimental|Group S|Sedline monitoring Adjust the depth of anesthesia by adjusting the amount of anesthesia, and adjust the cerebral perfusion pressure by adjusting blood pressure
2392785|NCT03622515|No Intervention|Group C|Bispectral index (BIS)/Sedline monitoring
2392786|NCT03622502|Experimental|Dexmedetomidine|Dexmedetomidine was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
2392787|NCT03622502|Active Comparator|Remifentanil|Normal saline was infused before end of surgery and remifentanil was maintained at predetermined effect-site concentration during the emergence period
2392788|NCT03622489|Experimental|Tab ibuprofen + IV acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and IV Acetaminophen 1 gr 14:00 hr, IV Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, IV Acetaminophen 1 gr~-Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
2392817|NCT03622294|Experimental|Right Breast Mammogram Measurements and Survey|"A right breast screening mammogram will be performed with Bella Blankets protective coverlets on the imaging receptor plate, then removed from the equipment.~The screening mammogram continues with a left breast and second right breast screening mammogram on a bare imaging receptor plate.~Clinical image quality measurements for the right breast mammograms will automatically be captured by VolparaEnterprise for a comparative analysis.~A patient satisfaction survey will be completed by each participant and the results will be analyzed."
2392789|NCT03622489|Experimental|Tab Ibuprofen + Tab acetaminophen|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Maternity ward:~- Scheduled doses: 08:00 hr, Tab. Ibuprofen 400 mg, and PO Acetaminophen 1 gr 14:00 hr, PO Acetaminophen 1 gr 19:00 hr, Tab. Ibuprofen 400 mg 00:00 hr, PO Acetaminophen 1 gr~- Additional analgesia if needed according to VNS scale: PO drops Dipyrone 1 gr, for VNS>4, up to 4 times a day, at least 6 hours between doses.~Tab Tramadex 100 mg, for VNS>6, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 4 hours between doses."
2392790|NCT03622489|Experimental|"On demand analgesia"|"All women will receive immediately after surgery, in the recovery room:~IV morphin 5 mg, repeat doses every 10 minutes for VNS>3~IV Tramal 100 mg, once~After Admitted to Mternity ward:~Will not receive scheduled pain medication, but offered some only upon patients' request according to VNS score:~Tab. Acetaminophen 1 gr, for VNS 1-3, up to 4 times a day, at east 6 hours between doses.~PO drops Dipyrone 1 gr, for VNS 4-7, or if pain persists for 1 hour after receiving Acetaminophen, up to 4 times a day, at least 6 hours between doses.~Tab Ibuprofen 400 mg, for VNS 8-10, or if pain persists for 1 hour after receiving Dipyrone, up to 3 times a day, at least 8 hours between doses."
2392791|NCT03622476|Experimental|PK research|Interventional studies were performed in the 1-7 year old subgroup, and the children received a comprehensive assessment and PK test every 3 months. After the 72-hour washout period, 50 IU/kg of concentrated FVIII was administered in a single dose, and blood was taken within half an hour before the infusion and 1 h, 9 h, 24 h, and 48 h after the infusion, and the samples were centrifuged. If the assessment considers that the treatment is inadequate, then the valley concentration target is upgraded.
2392792|NCT03622463|Experimental|Antroquinonol 100 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol,once a day.
2392793|NCT03622463|Experimental|Antroquinonol 50 mg PO QD|Antroquinonol (Hocena) 50mg/capsule. 1 capsules antroquinonol and 1 capsule placebo, once a day.
2392794|NCT03622463|Placebo Comparator|Placebo|Placebo capsule, 2 capsules placebo, once a day
2392795|NCT03622450|Experimental|Medication arm|Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
2392796|NCT03622450|Active Comparator|Control arm|Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
2392797|NCT03622437|Experimental|Patient-led follow-up|Participants in the experimental arm are enrolled in a patient-led follow-up program, based on patient-education and self-referral, in addition to recommendations from national guidelines for follow-up.
2392798|NCT03622437|Active Comparator|Standard follow-up|Participants in this control group follow standard care for follow-up after rectal cancer treatment, as described in local and national guidelines.
2392799|NCT03622424|Active Comparator|Gelesis200|Subjects on this ARM will receive Gelesis200
2392800|NCT03622424|Placebo Comparator|Placebo|Subjects on this ARM will receive a placebo device
2392801|NCT03622424|Active Comparator|Gelesis200 and Placebo|Subejcts on this ARM will receive both Gelesis200 and placebo.
2392802|NCT03622411|Experimental|aphasia therapy + speech app|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks independent practice via the speech app
2392803|NCT03622411|Active Comparator|aphasia therapy + brain games|3 hours per week of conventional aphasia therapy during 3 weeks + 5 hours per week during 3 weeks of recreational tables use (brain games)
2392804|NCT03622411|Active Comparator|aphasia therapy|3 hours per week of conventional aphasia therapy during 3 weeks
2392805|NCT03622398|Experimental|HXLPE|"This side of knee implanted with HXLPE(highly crosslinked polyethylene) liner while undergoing total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with HXLPE liner."
2392806|NCT03622398|Active Comparator|Conventional|"This side of knee implanted with conventional polyethylene while undergoing standard total knee arthroplasty. This group will receive the intervention, Total knee arthroplasty with conventional polyethylene liner."
2392807|NCT03622385||Patients diagnosed with Serous Epithelial Ovarian Cancer|"Discovery Cohort: patients who were diagnosed with serous epithelial ovarian cancer whose tissue specimens were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to be cancerous."
2392808|NCT03622385||Normal patients|"Discovery Cohort: patients who were determined to have normal ovarian tissue specimens that were previously collected.~Validation Cohort: patients who are scheduled for a diagnostic laparoscopic biopsy for an undiagnosed pelvic mass that is determined to not be cancerous."
2392809|NCT03622372|Experimental|CoNextions TR Implant|Operative repair of Zone 2 FDP tendon lacerations will be performed using the CoNextions TR Implant System
2392810|NCT03622372|Active Comparator|Suture Repair|Operative repair of Zone 2 FDP tendon lacerations will be performed using a 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture
2392813|NCT03622333|Experimental|Familial Carcinoid Tumors|All patients with proven Familial Carcinoid Tumors
2392814|NCT03622320||Vitiligo patients|Vitiligo patients (100 NSV and 50 segmental) who will be further classified according to age of onset and blood sample will be taken
2392815|NCT03622320||controls|Matching will be done taking into consideration age, sex, education and socio economic status, blood sample will be taken
2392816|NCT03622307|Experimental|S-ICD therapy combined with VT Ablation|To evaluate the feasibility and safety of a management approach that incorporates VT-ablation and S-ICD implantation in secondary prevention patients
2392818|NCT03622281|Experimental|Colonoscopists who received quality intervention|
2392821|NCT03622255|Other|MINST|Minimally invasive non-surgical technique (MINST): Root instrumentation under local anesthesia using specific hand instruments (micro- curettes) and delicate piezon ultrasonic instruments in the area of intraosseous defect.
2392822|NCT03622255|Active Comparator|MINST with EMD|Minimally invasive non-surgical technique (MINST) with application of Enamel Matrix Derivative (EMD): Root instrumentation under local anesthesia using micro- curettes and delicate piezon ultrasonic instruments in the area of intraosseous defect. Experimental intervention by application of EDTA gel for 2 minutes on the root surface of the involved tooth, followed by rinsing with saline, drying and application of Enamel Matrix Derivative gel, to fill the defect.
2392823|NCT03622242|Experimental|Pain threshold index group|Adjust infusion rate of remifentanil and propofol according to pain threshold index and wavelet index in 'pain threshold index group'.
2392824|NCT03622242|Active Comparator|Control group|As conventional management, adjust infusion rate of remifentanil and propofol according to wavelet index and conventional vital signs
2392825|NCT03622229|Active Comparator|EUS-FNB with side-fenestrated needle|"Before randomization, the endosonographer chooses the needle gauge to perform biopsy preferring the 25 gauge caliber for difficult lesions. The needle advances inside the lesion and the operator will perform some needle movements back and forth into the lesion while slowly withdrawn the stylet (slow-pull technique). If possible the direction of the needle inside the lesion will be changed during the movements (fanning technique) to sample different areas of the lesion. Three needle passes will be performed and the material acquired at each pass will be placed directly in formalin in a single vial.~Diagnostic Test: Histologic evaluation"
2392826|NCT03622229|Active Comparator|EUS-FNB with fork-tip needle|"Intervention: like above.~Diagnostic Test: Histologic evaluation."
2392827|NCT03622216|Experimental|Bradanicline QD|Randomized crossover design of 3 different doses of bradanicline (film-coated tablets) to be administered orally QD
2392828|NCT03622216|Placebo Comparator|Placebo|Randomized crossover design of matching placebo tablets to be administered orally QD
2392829|NCT03622203||Real life patients|Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)
2392830|NCT03622203||Difficult coronary lesions|Patients with bifurcation and multivessel disease, that is those with an increased risk of ST
2392831|NCT03622203||STEMI|Patients with STEMI
2392832|NCT03622190||Cohort 1|Music students who are free of pain, PRMDs and/or MSK problems at baseline data collection
2392833|NCT03622190||Cohort 2|Music students who aren't free of pain, PRMDs and/or MSK problems at baseline data collection
2392834|NCT03622177||HIV+|
2392835|NCT03622177||HIV- STI+|
2392836|NCT03622177||HIV- STI-|
2392837|NCT03622164|Active Comparator|Non-experimental intervention|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck).
2392838|NCT03622164|Experimental|Experimental intervention|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck).
2392839|NCT03622151|Experimental|Intervention group|Primer la Llar Program (housing first model): to live in permanent and individual housing and receiving weekly visits from a multidisciplinary team.
2392840|NCT03622151|No Intervention|Control group|"Treatment as usual:~attention from the resources of the homeless network in Barcelona."
2392841|NCT03622138|Experimental|Naive EBP Providers|Naive Providers (providers with no prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
2392842|NCT03622138|Experimental|Experienced EBP Providers|Experienced EBP Providers (providers with prior experience implementing the EBP) will attend a one-hour orientation meeting via web-based meeting software (e.g., WebEx) or in person to receive training on research procedures and implementation methods for the study. Participants will complete online surveys via 3C's secure system for any measures not collected directly via Impact. Providers will receive secure login information to the survey system and automatic email alerts with links to surveys to prompt completion. Surveys will be completed at PRE and POST time points to assess feasibility, usability, and value. 3C research staff will be available to assist providers (via email and phone) throughout the pilot field study.
2392843|NCT03622125||1|Patients who apply anti-scorpion venom serum Birmex at the discretion of the attending physician were given vital signs.
2392844|NCT03622125||2|Patients who apply anti-scorpion venom serum Alacramyn at the discretion of the attending physician were given vital signs.
3183957|NCT00719173|Experimental|Arm I|Patients receive aprepitant 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving aprepitant, patients receive an infusion of cyclophosphamide on day 1. During course 2, patients crossover and receive treatment as in arm II.
3183958|NCT00719173|Experimental|Arm II|Patients receive a placebo 125 mg orally once daily on day 1 and 80 mg orally once daily on days 2 and 3. Beginning 1 hour after receiving the placebo, patients will receive an infusion of cyclophosphamide infusion on day 1. During course 2, patients crossover and receive treatment as in arm I.
3183959|NCT00719199|Experimental|1|IMO 2055 is a novel phosphorothioate oligodeoxynucleotide that is an agonist of Toll-like Receptor 9 (TLR9).
3183960|NCT00719238|Experimental|1|
3183961|NCT00719238|Active Comparator|2|
3183962|NCT00719251|Experimental|HVG|The patients received standard nursing care and HVPC
3183963|NCT00719251|Experimental|LG|These patients received standard nursing care and LLLT
3183964|NCT00719251|Active Comparator|CG|The control group only was treated with standard nursing care
3183965|NCT00719290|Active Comparator|1|Phacoemulsification with intraocular lens implant alone
2394363|NCT03611712|Experimental|CCRT-PG2 arm|Astragalus Polysaccharides 500 mg
3183966|NCT00719290|Active Comparator|2|Phacoemulsification with intraocular lens implant and goniosynechialysis
2392852|NCT03622099||The study group|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
2392853|NCT03622086|Experimental|7-10 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
2392854|NCT03622086|Experimental|11-13 years old|Children-caregiver pairs will participate in a 24-week pilot that includes 2 phases, 12 weeks of usual care, followed by 12 weeks of Foundations of Fitness Program.
2392855|NCT03622073|Experimental|Misoprostol treatment by Midwife|Administration of misoprostol by the midwife and assessment for the primary outcome.
2392856|NCT03622073|Active Comparator|Misoprostol treatment by Doctor|Administration of misoprostol by the doctor and assessment for the primary outcome.
2392857|NCT03622060|Active Comparator|Nitroglycerin|500 microgram intraarterial Nitroglycerin
2392858|NCT03622060|Placebo Comparator|Nicardipine|200 microgram intraraterial Nicardipine
2392859|NCT03622047|Experimental|dexmedetomidine ropivacaine|Observing 0.5 μ g / ml dexmedetomidine + 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
2392860|NCT03622047|Experimental|sufentanil ropivacaine|compare the analgesic effects of dexmedetomidine or sufentanil combined with ropivacaine in epidural labor.
2392861|NCT03622047|Experimental|No analgesia labor|Observing with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
2392862|NCT03622021|Experimental|AK111 30mg|Single dose of 30mg AK111 or placebo is administered subcutaneously to healthy subjects
2392863|NCT03622021|Experimental|AK111 75mg|Single dose of 75mg AK111 or placebo is administered subcutaneously to healthy subjects
2392864|NCT03622021|Experimental|AK111 150mg|Single dose of 150mg AK111 or placebo is administered subcutaneously to healthy subjects
2392865|NCT03622021|Experimental|AK111 300mg|Single dose of 300mg AK111 or placebo is administered subcutaneously to healthy subjects
2392866|NCT03622021|Experimental|AK111 450mg|Single dose of 450mg AK111 or placebo is administered subcutaneously to healthy subjects
2392867|NCT03622021|Experimental|AK111 600mg|Single dose of 600mg AK111 or placebo is administered subcutaneously to healthy subjects
2392868|NCT03622008|Experimental|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
2392869|NCT03622008|Placebo Comparator|Placebo|placebo IV
2392870|NCT03621995||Obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
2392871|NCT03621995||Non obstructive azoospermia|Malondialdehyde and Catalase level measurement before and after cryopreservation
2392872|NCT03621995||Negative group|Malondialdehyde and Catalase level measurement without cryopreservation
3143217|NCT00005094|Experimental|Arm I (celecoxib)|Patients receive celecoxib twice a day for 3 years.
3143218|NCT00005094|Placebo Comparator|Arm II (placebo)|Patients receive placebo twice a day for 3 years.
3143219|NCT00005095||High Risk for Ovarian Cancer|Women who are at increased risk of ovarian cancer based on family or personal medical history who are participating in the Northwestern Ovarian Cancer Early Detection and Prevention Program clinic.
2392876|NCT03621969|Experimental|Group 1|"Group 1 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy twice per week at REACT (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will take the RePlay devices and tablets home for two weeks (weeks 5-6) for daily RePlay device therapy, followed by re-assessment."
2392877|NCT03621969|Experimental|Group 2|"Group 2 will receive:~Medical History and Brief Physical Exam~Diagnostic Assessments~Patient Instruction and use of RePlay Device~two weeks of RePlay device therapy daily at home (they will take the RePlay devices and tablets home) (weeks 1-2), followed by re-assessment,~then will rest for 2 weeks (weeks 3-4),~then will receive two weeks of RePlay device therapy twice per week at REACT (weeks 5-6), and then will undergo re-assessment."
2392880|NCT03621943|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
2392881|NCT03621943|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
2392882|NCT03621904||EC patients with HT|Patients with advanced stage or recurrent endometrial cancer treated with hormonal therapy
2392883|NCT03621891||healthy individuals|Orally and systemically healthy individuals who has no hypo-functional teeth, hyper-occlusion or occlusal trauma
2392884|NCT03621891||periodontitis patients|Systemically healthy individuals who has chronic periodontitis but no hypo-functional teeth, hyper-occlusion or occlusal trauma
2392885|NCT03621891||healthy-occlusal trauma|Orally and systemically healthy individuals who has occlusal trauma caused by bruxism
2392886|NCT03621891||periodontitis-occlusal trauma|Systemically healthy individuals who has both chronic periodontitis and occlusal trauma caused by bruxism
3143220|NCT00005096|Experimental|Docetaxel|Docetaxel given via iv at determined dose once a week for 4 weeks
3143221|NCT00005097|Experimental|Polyphenon E & Placebo|"Each subject will receive both the Polyphenon E and placebo, one on each arm.~One arm will be assigned to be treated with topical Polyphenon E daily for 12 weeks and the other with placebo vehicle in a random, double blind manner daily for 12 weeks."
3143222|NCT00005113|Experimental|1|Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
3143223|NCT00005113|Experimental|2|Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months
2392890|NCT03621865|Experimental|subject sequence 1|subject allocation sequence 1. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392891|NCT03621865|Experimental|subject sequence 2|subject allocation sequence 2. IIntervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392892|NCT03621865|Experimental|subject sequence 3|subject allocation sequence 3. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392893|NCT03621865|Experimental|subject sequence 4|subject allocation sequence 4. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392894|NCT03621865|Experimental|subject sequence 5|subject allocation sequence 5. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392895|NCT03621865|Experimental|subject sequence 6|subject allocation sequence 6. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392896|NCT03621865|Experimental|subject sequence 7|subject allocation sequence 7. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392897|NCT03621865|Experimental|subject sequence 8|subject allocation sequence 8. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392898|NCT03621865|Experimental|subject sequence 9|subject allocation sequence 9. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392899|NCT03621865|Experimental|subject sequence 10|subject allocation sequence 10. Intervention: The subject will receive the five products (TG, STE, NOV, PHYT or TEP) in a certain order.
2392900|NCT03621852||Endoultrasound guided FNB|Patients with tumors of the pancreas, submucosal tumors or lymphnode disease of the upper gastrointestinal tract, which have to undergo EUS guided FNB.
2392901|NCT03621826||Children with Sickle Cell Anemia|Data from patients with sickle cell anemia will be entered into a retrospective database for evaluation of implementation rates of TCD (stroke) screening). A small number of these children/parents/stakeholders will be selected by convenience sampling to participate in a survey and/or interview to assess barriers and enablers to stroke prevention therapy.
2392902|NCT03621813|Other|Control|Participants maintain their current activity level.
2392903|NCT03621813|Active Comparator|Exercise Rehabilitation|Participants will exercise 2x/week at training facilities and at home one day a week.
2392904|NCT03621800|Experimental|Menthol popsicle|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After 20 minutes of the intervention (menthol popsicle), the final intensity and discomfort were measured using the same scales.
2392905|NCT03621800|No Intervention|Usual care (maintenance of fasting)|When allocated in the control group, the intensity of the initial thirst was measured by Visual Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for absolute fasting of food and drinks for 20 minutes, the final intensity and discomfort were measured using the same scales.
2392909|NCT03621761|Active Comparator|Cognitive Behavioral Therapy|8 weekly telephone-based sessions and 2 booster sessions
2392910|NCT03621761|Active Comparator|Modafinil|50-400 mg per day (oral)
2392911|NCT03621761|Active Comparator|Cognitive Behavioral Therapy + Modafinil|Telephone-based cognitive behavioral therapy (8 weekly therapy sessions and 2 booster sessions) + Modafinil 50-400 mg per day (oral)
3143224|NCT00005145||Observational, no interventions|
3143225|NCT00005219||Exercise Study Participants|Data from the San Diego Health and Exercise Baseline survey conducted in 1986 were used to contact participants for the follow-up
3143226|NCT00005289||1988-1991|
3143227|NCT00005289||2003-2004|
2392916|NCT03621722|Experimental|Anxiety Arm (Treatment)|Patient will receive Elequil Aromatabs
2392917|NCT03621722|Experimental|Nausea/Vomiting Arm (Treatment)|Patient will receive Elequil Aromatabs
2392918|NCT03621722|No Intervention|Nausea/Vomiting Arm (Control)|Patient will not receive Elequil Aromatabs
2392919|NCT03621722|No Intervention|Anxiety Arm (Control)|Patient will not receive Elequil Aromatabs
2393002|NCT03621072|Experimental|Experimental|Fluconazole 150mg Capsule Localized Originator
2393003|NCT03621059|Experimental|Behavioral Therapy with TS|habit reversal training (HRT)
3143228|NCT00005305||Hemophilic individuals|Subjects receiving multiple blood products for treatment of hemophilia
3143229|NCT00005379||IV drug users and their sexual contacts|This group will be made up of an already-recruited cohort
3143230|NCT00005379||Children who receive primary care at Bellevue Hospital|
3143231|NCT00005379||Bellevue Hospital inpatients/outpatients|Inpatients being treated for TB and outpatients receiving prophylactic treatment
3143232|NCT00005398||1; no experimental groups in this study|Observational cohort study
3143233|NCT00005446||Postmenopausal women with coronary heart disease|
3143234|NCT00005446||Postmenopausal women without coronary heart disease|Matched in age to the women with heart disease
3143235|NCT00005502||Residents of Olmsted County, MN with elevated Troponins|Anyone admitted to St Marys or Rochester Methodist Hospitals who have an elevated troponin during their hospitalization and are residents of Olmsted County, MN
3143236|NCT00005520||African American hydrochlorothiazide|300 African American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks.
2392920|NCT03621709||CoreValve™ Evolut R™ 34mm|All consecutive real-world patients with aortic stenosis selected for TAVI as part of routine clinical care, using a CoreValve™ Evolut R™ 34mm during the inclusion period will be entered the registry.
3143237|NCT00005520||European American hydrochlorothiazide|300 European American hypertensives were treated with hydrochlorothiazide 25 mg daily for 4 weeks
3143238|NCT00005520||African American candesartan|300 African American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
3143239|NCT00005520||European American candesartan|300 European American hypertensives were treated with candesartan 16 mg daily for 2 weeks followed by 32 mg daily for 4 weeks
2392924|NCT03621683|Experimental|ovarian bio-stimulation|"Intervention:~ovarian bio-stimulation: blood rich plasma platelets"
2392925|NCT03621683|Active Comparator|Antioxidant therapy|"Intervention:~antioxidants: Q10, DHEA, Vitamin E, Vitamin C, omega 3"
3143240|NCT00005533||Coronary Heart Disease Patients|
3143241|NCT00005576|Experimental|Treatment (monoclonal antibody Ch14.18, aldesleukin)|Patients receive MOAB IV over 5 hours on days 7-10 during courses 2 and 4 and on days 3-6 during courses 1, 3, and 5; sargramostim (GM-CSF) IV over 2 hours or subcutaneously daily on days 0-13 during courses 1, 3, and 5; interleukin-2 IV continuously on days 0-3 and 7-10 during courses 2 and 4; and oral isotretinoin twice daily on days 14-27 during courses 2 and 4 and on days 10-23 during courses 3 and 5. Treatment repeats every 24-32 days for 5 courses in the absence of unacceptable toxicity.
2392931|NCT03621631|Experimental|optimized Tai Chi intervention|
2392932|NCT03621631|Active Comparator|traditional Tai Chi intervention|
2392933|NCT03621618|Other|dobutamine|Cardiac failure
2392934|NCT03621618|Other|norepinephrine|Sepsis
2392935|NCT03621605|Experimental|VIB9600|"Single dose of VIB9600 administered by IV infusion or SC injection.~Multiple dose VIB9600 administered by IV infusion every 2 weeks for 4 weeks."
2392936|NCT03621605|Placebo Comparator|Placebo|Placebo comparator administered by slow IV infusion or SC injection.
2392939|NCT03621579|Other|the RNFLT and CMT|the retinal nerve fiber layer (RNFLT) and macular thickness (CMT)
2392940|NCT03621566||Central Sleep Apnea|Subjects with an apnea/hypopnea index ≥ 15/h of sleep and proportion of non-obstructive events > 50%, derived from polysomnography (diagnostic or during positive airway pressure treatment)
2392941|NCT03621553|Experimental|Low vit-D, Ergocalciferol|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Vitamin D2 (Ergocalciferol) 50,000 units will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2392942|NCT03621553|Placebo Comparator|Low vit-D, Placebo|"Low serum vitamin D level, split by use or non-use of systemic corticosteroid. Placebo capsules of identical size and appearance will be given by mouth once a week for 12 weeks, then once a month for 12 weeks.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2392943|NCT03621553|Other|Normal vit-D, control|"Normal serum vitamin D level, split by use or non-use of systemic corticosteroid.~Daily dietary requirement (calcium citrate with vitamin D2 (200 mg/250 Units tablets, 4 tablets per day) will be given by mouth for 24 weeks)."
2392944|NCT03621540|Active Comparator|Verum arm|25 min anodal tDCS + adaptive working memory training
2392945|NCT03621540|Sham Comparator|Sham arm|sham tDCS + adaptive working memory training
2392946|NCT03621527|Active Comparator|Standard group|"For each vertebra treated: 10 ml of lidocaine hydrochloride 1% are applied to the skin and the lower structures including the periosteum.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
2392947|NCT03621527|Experimental|Epidural group|"Fluoroscopy-guided epidural anesthesiaI is the identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air.~According to patient's height, 10-15 ml of lidocaine hydrochloride 1% are injected by the radiologist into the epidural space.~An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure"
2392948|NCT03621514|Other|painless indwelling catheter|This group of patients underwent catheterization after anesthesia. At the end of the operation, the patient was removed from the catheter before anesthesia was awakened.
2393004|NCT03621059|No Intervention|observational|observational and usual care Pyridoxine(50mg)
3143242|NCT00005577|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes weekly for 2 weeks. Patients achieving objective response or stable disease after 3 weeks may receive additional courses of therapy every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity.
3143243|NCT00005578|Experimental|Arm 1|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
3143244|NCT00005578|Experimental|Arm 2|Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7
2392949|NCT03621514|Other|indwelling catheter|This group of patients underwent catheterization after anesthesia,and the catheter was indwelled. The patient was routinely removed for 24 to 72 hours after surgery.
2392950|NCT03621501|Placebo Comparator|Staged complete revascularization|• Culprit only + staged (within six weeks after index procedure) complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Control arm)
2392951|NCT03621501|Active Comparator|Immediate complete revascularization|• Immediate complete revascularization in all vessels ≥ 2.5mm with ≥ 70% stenosis by visual estimation or positive coronary physiology test per operator's discretion (Experimental arm)
2392954|NCT03621475|Experimental|Novel restraint first, then traditional restraint|Participants will be randomized to wear the novel arm restraint bilaterally for 4 hours on study day #1, followed by traditional soft bilateral wrist restraints for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
2392955|NCT03621475|Experimental|Traditional restraint first, then novel restraint|Participants will be randomized to wear traditional soft bilateral wrist restraints for 4 hours on study day #1, followed by the novel arm restraint bilaterally for 4 hours. Then, on study day #2, they will wear both kinds of restraints in the opposite order.
2392956|NCT03621462|Experimental|Acquisition of Lesion Images with AIDA|Subjects presenting with atypical skin lesions referred for biopsy will have their lesion imaged using the Artificial Intelligence Dermatology Assistant (AIDA™) study device
2392957|NCT03621436|Experimental|TRVD Therapy|
3143245|NCT00005585|Experimental|Arm I: (combination chemotherapy)|CONSOLIDATION: Pts receive Methotrexate(MTX) IV over 24 hrs on day 1 and oral leucovorin calcium (CF) every 6 hrs for 3 doses at 42 hours after initiation of MTX infusion during weeks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine(6-MP) daily wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM twice a day on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
2392960|NCT03621384||Bb Genotype|Subjects with Bb genotype of BsmI polymorphisms in vitamin D receptor gene
2392961|NCT03621384||bb Genotype|Subjects with bb genotype of BsmI polymorphisms in vitamin D receptor gene
2392962|NCT03621371|Experimental|Metacognitive therapy|
2392963|NCT03621371|Experimental|Intolerance of uncertainty therapy|
2392964|NCT03621358|Placebo Comparator|Control Gummy|Control gummy with free flavour (without encapsulating)
2392965|NCT03621358|Experimental|Gummy Variety 1|Experimental gummy with 50% free/50% encapsulated flavour
2392966|NCT03621358|Experimental|Gummy Variety 2|Experimental gummy with 100% encapsulated flavour
2392967|NCT03621345|Active Comparator|ESP block group|"The bilateral erector spine plane (ESP) block will be performed with ultrasound guided, preoperatively. Following antiseptic preparation of block site with povidone iodine, ultrasound probe will be placed 3 cm lateral to spine at T5 level. After identifying the erector spinae muscle and transverse process, the overlying skin will be infiltrated with local anesthetics and 20 mL local anesthetics (10 mL 0.5% bupivacaine + 10 mL 1% lidocaine) will be injected deep to the erector spinae muscle. The same procedure will be performed on the other side. Also, patients will receive intravenous patient controlled analgesia with morphine, and 1 g acetaminophen for supplemental analgesia if pain score raises over 5/10 on NRS and 50 mg meperidine for rescue analgesic for persistent pain.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
2392968|NCT03621345|Sham Comparator|sham block|"A sham block will be performed while looking for intended location for ESP block placement. Skin will be infiltrated with local anesthetics but ESP block will not be performed, instead of ESP block 2 mL subcutaneous saline injection will be applied.~Intervention: Sham block Other: Standard Pain Followup and Monitorization"
2392969|NCT03621332||Questionnaire adminstration|All patients who participate will complete questionnaires
2392970|NCT03621319|Active Comparator|Hybrid argon plasma ablation (HAPC)|Eligible participants will be randomized to receive ablation of dysplasia with Hybrid argon plasma coagulation (HAPC) after EMR of visible lesions (if present) has been performed as per standard of care.
2392971|NCT03621319|Active Comparator|Radiofrequency ablation (RFA)|Eligible participants will be randomized to receive treatment of dysplasia with RFA after EMR of visible lesions (if present) has been performed as per standard of care.
2392972|NCT03621306||Men and women aged 18+|Men and women over the age of 18
2392973|NCT03621293|Active Comparator|Liberal Oxygenation (LO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
2392974|NCT03621293|Experimental|Conservative Oxygenation (CO) group|"A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.~Intervention: Drug: Modulation of Inspired Fraction of Oxygen (FiO2)"
2392975|NCT03621280|Experimental|Levoketoconazole|Levoketoconazole taken twice daily up to 1200 mg daily
2393005|NCT03621046|Experimental|Zolpidem|A single oral zolpidem tablet (5 mg) administered in clinic and then each day for the following 3 days
2393006|NCT03621046|Placebo Comparator|Placebo|A single oral placebo administered in clinic and then each day for the following 3 days
2394364|NCT03611712|No Intervention|CCRT alone arm|
2392976|NCT03621267|Experimental|Interactive Stepping Exercise|"Interactive Stepping Exercise (1 hour, 3 times/week, 12 weeks)~The 1-hour training program will start with10 minutes warm-up session, after that 40 minutes of ISE, and ended with 10 minutes of cool down session.~Interactive Stepping Exercise (ISE) will perform on a thin mat that was partitioned into 24 squares. The ISE program included forward, backward, lateral and oblique steps, and step patterns were progressively made more complicated."
2392977|NCT03621267|Active Comparator|Home exercise program|60 minutes, 3 times/week, 12 weeks of home exercise
2392978|NCT03621254|Experimental|[HI-SHORT]|High-intensity interval training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 10 x 2-min exercise intervals with 1-2 min of recovery between intervals. High intensity is achieved by high FES current amplitude (120-150 milliampere, patient dependent)
2392979|NCT03621254|Active Comparator|[LO-LONG]|Low-moderate intensity continuous training modality of exercise using FES-evoked leg cycling. Three-four times weekly over 6-8 weeks (24 therapy sessions). The programme is 20+ min continuous exercise. Lower intensity is achieved by lower FES current amplitude (< 90-100 milliampere, patient dependent)
2392980|NCT03621228|Experimental|MindfulGarden|Standard care + exposure to an interactive digital device
2392981|NCT03621228|No Intervention|Control|Standard care only
2392982|NCT03621215|Experimental|Tart cherry juice|30 mL tart cherry concentrate (CherryActive, UK) diluted with 220 mL of water once per day (250 mL total volume per day). According to available manufacturers data, this is equivalent to consuming 90-100 fresh cherries per day.
2392983|NCT03621215|Placebo Comparator|Fruit-flavoured placebo drink|"Matched for sensory characteristics and energy (with the addition of glucose).~once per day (250 mL total volume per day)"
3183967|NCT00719303|Experimental|Group I (lifestyle intervention)|Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
2392987|NCT03621176|Experimental|Home-based exercise|Home-based intervention in the advanced chronic kidney disease group, hemodialysis or peritoneal dialysis group
2392988|NCT03621163|Experimental|bleaching agent|intervention : bleaching agent ( Boost 40%)
2392989|NCT03621163|Active Comparator|laminate veneers|laminate veneers ( monolithic lithium - silicate)
2392990|NCT03621150||Cases|Patients complaining of ankle pain, swelling or dysfunction underwent ultrasound examination and then MRI as a reference to compare the diagnostic accuracy of ultrasonography in the assessment of tendino-ligamentous injuries around the ankle joint
2392991|NCT03621137||Patients with moderate-to-severe atopic eczema|Adult and pediatric patients that start treatment with phototherapy or systemic immunomodulating therapy for their atopic eczema
2392992|NCT03621124|Other|Brown Adipose Tissue Positive patients|Patients with known malignancy and incidental finding of positron emission tomography/ computerized tomography (PET/CT) scans positive for brown adipose tissue (BAT). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
2392993|NCT03621124|Other|Brown Adipose Tissue Negative Patients|Patients with known malignancy and no evidence of brown adipose tissue BAT activity positron emission tomography/ computerized tomography (PET/CT) scans to be matched to group 1 for primary tumor and stage, sex, age (±5 years), BMI (±3 Kg/m2). After obtaining informed consent and all initial screening visit procedures, patients will participate in two four-hour recording sessions in the whole room indirect calorimeter to assess resting energy expenditure, and patient's thermal (comfort) response to the temperature of the room.
2392994|NCT03621111|Experimental|Adherence plan|At the discharge, the hospital pharmacist will complete the medication reconciliation and assess the patient's medications. All patients enrolled will undergo three interventions in order to improve medication adherence: counseling, pill counts and self-questionnaire. The adherence plan concerns 6 classes of drugs recommended by the European Society of Cardiology in acute myocardial infarction. The adherence plan is performed by the community pharmacists. The hospital pharmacist will complete the discharge care form for the community pharmacist who has in charge the patient. Each patient will be scheduled for the first meeting with his community pharmacist within one month from the hospital discharge; afterward the adherence plan will be submitted every 3 months.
2392995|NCT03621111|No Intervention|Control group|All the patients discharged from the cardiological ward between September 2017 and February 2018 with a primary diagnosis of acute myocardial infarction has been enrolled in the control arm. These patients have been discharged with the current standard therapy and without any adherence plan performed by the community pharmacists. The investigators will collect the data from the administrative pharmaceutical databases throughout 12 months from the hospital discharge.
2392996|NCT03621098||Diet+Exercise|Diet with structured exercise (mostly walking) at a moderate-intensity level This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
2392997|NCT03621098||Diet+Daily Activity|"Diet with increased light-intensity physical activity and decreased sedentary behavior throughout the day.~This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)"
2392998|NCT03621098||Diet+Exercise+Daily Activity|Diet with structured exercise and increased daily activity. This is not an intervention study, however, the intervention type from the parent study (EMPOWER) was behavioral (Caloric Restriction with and without Structured Exercise or Daily Activity)
2393001|NCT03621072|Other|Reference|Fluconazole 150mg Capsule Originator
2393007|NCT03621033|Other|non-transparent cap-assisted endoscopic intubation|we do not use transparent cap-assisted endoscopic intubation.
2393008|NCT03621033|Other|transparent cap-assisted endoscopic intubation|we use transparent cap-assisted endoscopic intubation in the second insertion.
2393009|NCT03621020||Healthy controls|Subjects not taking medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
2393010|NCT03621020||Aspirin monotherapy|Subjects taking 81+ mg daily aspirin and no additional medications with antiplatelet effects, without evidence of vWD or history of congenital platelet abnormalities, without history of significant bleeding.
2393011|NCT03621020||von Willebrand Disease|Subjects diagnosed with vWD (all types except Type 2N), not taking medications with antiplatelet effects, and history of clinically significant bleeding.
2393012|NCT03621020||Glanzmann's Thrombasthenia|Subjects diagnosed with Glanzmann's Thrombasthenia, not taking medications with antiplatelet effects, and history of clinically significant bleeding.
2393013|NCT03621020||Dual antiplatelet therapy (DAPT)|Subjects taking 81 mg daily aspirin and either 75 mg daily clopidogrel, 10 mg daily prasugrel, or 180 mg daily ticagrelor
2393014|NCT03621007||POMC deficiency obesity|
2393015|NCT03621007||LEPR deficiency obesity|
2393016|NCT03621007||PCSK1 deficiency obesity|
2393017|NCT03620994||Irritable Bowel Syndrome|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an JiaoTong University, Xijing Hospital ,Tangdu Hospital or affiliated hospital of Northwest University received investigation. Patients who participate in the study are determined on their own initiative, with full understanding and informedness.
2393018|NCT03620981|Experimental|Brexpiprazole, 1mg/day|Drug: 1mg/day Once daily for 10 weeks
2393019|NCT03620981|Experimental|Brexpiprazole, 2mg/day|Drug: 2mg/day Once daily for 10 weeks
2393020|NCT03620981|Placebo Comparator|Placebo|Drug: Placebo (0mg/day) Once daily for 10 weeks
2393021|NCT03620968|No Intervention|Group 1|Control, no intervention
2393022|NCT03620968|Experimental|Group 2|Intervention before surgery (cognitive training)
2393023|NCT03620968|Experimental|Group 3|Intervention Before and after surgery (cognitive training)
2393024|NCT03620955||Risk stratification|Risk stratification based on cytogenetic and molecular and MRD level after three courses of chemo therapy.
2393025|NCT03620942|Experimental|ADIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a three-step algorithm vasopressor delivery technique
2393026|NCT03620942|Active Comparator|DIVA system|Vasopressor delivery automated system administering phenylephrine and ephedrine using a two-step algorithm vasopressor delivery technique
2393027|NCT03620929|Experimental|Experiment group|Having estrogen(Estradiol Valerate) after hysteroscopic adhesiolysis three months, all patients in this group will be treated with hormone therapy for 3 cycles; each cycle consists of estradiol 4mg per day for 21 days with addition of progestogen in the form of dydrogesterone 10mg per day for the last 7 days;
2393028|NCT03620929|No Intervention|Control group|Control group without estrogen treatment. A second-look hysteroscopy and ultrasound assessment of the endometrium will be carried out 4 weeks after the surgery, and again at 8 weeks after the surgery.
2393029|NCT03620916|Experimental|Intrathecal morphine|Intrathecal morphine (0,4 mg) immediately before operation
2393030|NCT03620916|Active Comparator|Intravenous morphine|Intravenous morphine (0,15 mg/kg body mass) immediately after the operation
3143246|NCT00005585|Experimental|Arm II (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV over 4 hrs on day 1 and oral leucovorin calcium (CF) during wks 7, 10, 13, 16, and 19. Pts also receive MTX IT on wks 7, 10, 13, 16, 19, and 22; oral mercaptopurine (6-MP) daily on wks 5-24; oral dexamethasone (DM) 2x on days 1-7 of wks 8 and 17; and vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 17, and 18. CONTINUATION: Pts receive oral 6-MP daily on wks 25-130; oral DM 2x on days 1-7 and vincristine sulfate (VCR) IV on days 1 and 8 during wks 25, 41, 57, 73, 89, and 105; oral MTX weekly on wks 25-130 (except during wks of IT MTX); and MTX IT on wks 25, 37, 49, 61, 73, 85, 97, and 109.
2393034|NCT03620877|Experimental|personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
2393035|NCT03620864|Active Comparator|Motor control exercise|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
2393036|NCT03620864|Experimental|Motor control exercise plus neurodynamic intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
2393037|NCT03620851||elderly patients (≥70 yo) vs. younger patients (<70 yo)|elderly patients (≥ 70 yo) and younger patients (< 70 yo)
2393038|NCT03620838||Group 1|Patients with endometrioma who had at least one endometrioma >3 cm and who will not need hormonal or surgical treatment at the time of diagnosis and who will be expectantly managed
2393039|NCT03620838||Group 2|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with OCP during the study period
2393040|NCT03620838||Group 3|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with oral progesterone during the study period
2393041|NCT03620838||Group 4|Patients with endometrioma who had at least one endometrioma >3 cm and who will be treated with surgery short after recruitment
2393042|NCT03620838||Group 5|The control group, who do not have endometrioma and any gynecological disorder
2393043|NCT03620825|Experimental|Dehydration by sauna exposure|Participants dehydrate using sauna exposure until they lose 3% of their body weight.
2393044|NCT03620825|Active Comparator|Indomethacin - Positive control|Indomethacin is administered to induce increased intestinal permeability
2393045|NCT03620825|No Intervention|Negative control|No intervention is performed
2393046|NCT03620812|Experimental|rapeseed protein|Three interventions are planned, in which the subjects will eat a test meal with added rape protein isolate (arm 1), a test meal with added soy protein isolate (arm 2) and a test meal without additional protein (arm 3) in random order on 3 days. The subjects are randomly assigned to one of the 3 treatment arms, ultimately resulting in 6 sequences (cross-over)
2393047|NCT03620812|Active Comparator|soy protein|
2393048|NCT03620812|Placebo Comparator|no protein|
2393049|NCT03620799|Experimental|Intervention group|10 participants will be assigned to the intervention group in order to the inclusion criteria for the study. Experimental group. Manual therapy intervention
2393050|NCT03620799|No Intervention|Control group|10 participants will be assigned to the control group in order to the inclusion criteria for the study. Control group
2393051|NCT03620786||HIFU Study Participants|Subjects who have biopsy-proven adenocarcinoma of the prostate, who have met all study inclusion and exclusion criteria, and have elected to receive or have already received the HIFU procedure as part of their routine prostate cancer treatment, will be invited to participate in this observational registry study. The HIFU device currently used in this standard-of-care procedure at UCLA is the Sonablate 450 HIFU System.
2393052|NCT03620773|Other|Clinical Investigation|"Participants will include youth who are scheduled for, and will undergo, vertical sleeve gastrectomy (VSG) surgery at the Bariatric Surgery Clinic at Children's Hospital of Colorado.~To understand how bariatric surgery affects renal function, all participants will undergo assessment of Glomerular Filtration Rate, (Iohexol Inj 300 mg/mL) and Effective Renal Plasma Flow (Aminohippurate Sodium Inj 20%). In addition, participants will undergo imaging assessment that includes renal Blood Oxygen Level Dependent (BOLD) and Arterial Spin Labeling (ASL) MRI."
2393053|NCT03620760|Experimental|Lower dose ticagrelor|Subjects will be treated with ticagrelor 45 mg twice daily in combination with aspirin 100mg once daily.
2393054|NCT03620760|Active Comparator|Standard dose ticagrelor|Subjects will be treated with ticagrelor 90 mg twice daily in combination with aspirin 100mg once daily.
3143247|NCT00005585|Experimental|Arm III (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) IV and leucovorin calcium (CF) as in arm I on wks 7, 10, 13, 24, 27, and 30. Pts also receive oral mercaptopurine (6-MP) daily on wks 5-13 and then on wk 24 and continuing until the end of consolidation; MTX IT on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone (DM) twice daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) IV on day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase intramuscularly on wk 16; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV on day 1 of wk 20; cytarabine IV or subcutaneously on days 2-5 of wks 20 and 21; and oral thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive oral 6-MP daily on wks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during wks 41, 57, 73, 89, and 105; oral MTX weekly on wks 33-130 (except during wks of IT MTX); and MTX IT on wks 37, 49, 61, 73, 85, 97, and 109.
2393056|NCT03620734||GAHT and PrEP|HIV-negative TGW will have HIV testing using the 4th generation immunoassays/nucleic acid testing (NAT) in acute HIV testing algorithm currently used at the Thai Red Cross Anonymous Clinic at week 5, 8, and 15. Creatinine clearance will be performed at week 15.
2393057|NCT03620734||GAHT and ART|HIV-positive TGW on ART will have their plasma HIV RNA measured at the same day ART is initiated and at week 15 (12 weeks after ART provision). CD4 count will be measure at week 15.
2393058|NCT03620721|Experimental|M-Body|mindfulness group intervention
2393059|NCT03620721|No Intervention|Usual Care|treatment as usual
3183968|NCT00719303|Active Comparator|Group II (observation)|Participants receive a study notebook containing general study-related information. Participants are not asked to record diet or physical activity but are provided a single sample diary in their study notebook. Participants receive telephone contact on a sliding scale similar to the intervention group, but at less frequent intervals (22 versus 33 calls over the course of the intervention).
3183969|NCT00719316|Experimental|Group 1|Patients receive Aliskiren 300mg for 6 weeks
3183970|NCT00719316|No Intervention|Group 2|4 weeks no antihypertensive medication
2393063|NCT03620682|Experimental|Mobile mental health intervention|Participants will receive emotional support and problem-solving / stress-management skills via over-the-phone coaching sessions and mobile applications.
3183971|NCT00719368||pain-free control|Pain-free controls from previous prospective study (KF 01294867), operated >2 years previously
2393065|NCT03620656||The smartphone group|Patients recruited from the cardiology ward where 10 different smartphone devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor Smartphone devices and gold-standard 12-lead ECG to determine the diagnostic accuracy.
2393066|NCT03620656||The smartwatch group|Patients recruited from the cardiology ward where 2 different wearable devices will be used for the recording of PPG signals with the FibriCheck application. These recordings will be compared with single-lead ECG recorded with an AliveCor wearable and gold-standard 12-lead ECG to determine the diagnostic accuracy.
2393069|NCT03620630|No Intervention|Usual Care|Patients allocated to usual care will continue with their current NHS management in line with national and local guidelines.
2393070|NCT03620630|Active Comparator|myCOPD|Patients allocated to the myCOPD arm will receive access to a web based application called myCOPD
2393129|NCT03620175|Active Comparator|1.5 Percent TolaSure Topical Gel|
2393130|NCT03620175|Active Comparator|0.5 Percent TolaSure Topical Gel|
2393071|NCT03620617|Experimental|Experimental: Raspberry supplementation|Dietary Supplement: 280g of frozen raspberries, taken daily for 8 weeks. Subjects will consume frozen raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and control group (without raspberry).
2393072|NCT03620617|No Intervention|Control|Control: follow their usual diet (control group). Subjects will follow their usual diet and not consume raspberry to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the experimental group (with raspberry).
2393073|NCT03620604||Stress urinary incontinence surgery|This is a single observational study were all patients had stress urinary incontinence. All of them underwent surgery performing a single incision sling type ALTIS
2393074|NCT03620591|Active Comparator|Lidocaine|"Intraoperative administration of lidocaine to patients undergo laparoscopic cholecystectomy.~Prior induction to anesthesia, lidocaine bolus 1.5 mg / kg will be administered to the lidocaine group and then patients will be connected to a continuous 2 mg / kg / h administration of lidocaine until the end of the procedure."
2393075|NCT03620591|Placebo Comparator|Placebo|Intraoperative administration of normal saline to patients undergo laparoscopic cholecystectomy.
2393076|NCT03620578|Experimental|DA-EPOCH-R followed by Nivolumab|5 cycles of DA-EPOCH-R protocol induction, followed with one year Nivolumab consolidation for end-of-induction patients who are in complete metabolic response
2393077|NCT03620565||Laparoscopic sacrocolpopexy(LSC)|Patients who prefer to accept laparoscopic sacrocolpopexy after hysterectomy. For patients who has desire of uterine-preservation,laparoscopic sacrocervicopexy or sacrohysteropexy is carried.
2393078|NCT03620565||Reconstruction with transvaginal mesh(TVM)|Patients who undertake pelvic reconstruction with tran-vaginal mesh(commercial mesh kits or self-cut synthesized mesh).
2393079|NCT03620565||Reconstruction with native tissue(NT)|Patients who prefer to accept reconstruction with native tissue,mainly including high uterosacral ligament suspension, sacrospinous ligament fixation,ischial spinous fascia fixation,the Lefort operation.
2393080|NCT03620565||Tension-free vaginal tape surgery(TVT)|Patients who undertake anti-incontinence surgeries(tension-free vaginal tape procedure).
2393081|NCT03620552|Experimental|18F-S16 injection and PET/CT scan|The subjects were intravenously injected with 370MBq 18F-S16 and underwent PET/CT scan immediately after the injection.
2393082|NCT03620539|No Intervention|Control|Participants randomized to the control condition will be asked to maintain their normal daily habits.
2393083|NCT03620539|Experimental|Sauna|The sauna intervention will consist of 20 to 30 minute sauna bathing sessions within a dry Finnish sauna, performed 4 times per week.
2393084|NCT03620526|Experimental|Iloprost|patients received inhaled iloprost 10 mcg/mL x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
2393085|NCT03620526|Placebo Comparator|Placebo|patients received inhaled normal saline with the same amount x 1 dose after baseline and exercise test and then received measurements for hemodynamic data again for both baseline and after exercise test.
2393086|NCT03620513|Placebo Comparator|Normal Saline nasal spray|Two spray (via atomizer) of normal saline in each nostril five minutes prior to fiberoptic procedure
2393087|NCT03620513|Experimental|Decongestant (Oxymetazoline 0.05%)|Two sprays via atomizer (about 0.18 ml) of oxymetazoline 0.05% (Nasivion) in each nasal cavity five minutes prior to fiberoptic procedure. Two sprays will be given at the gap of ten seconds.
2393088|NCT03620513|Experimental|Anesthesia (lidocaine 15%, Nummit)|Two sprays of 15% lidocaine (Nummit) will be give in each nasal cavity five minutes prior to fiber optic procedure. Two sprays will be given at the gap of ten seconds.
2393089|NCT03620513|Experimental|Decongestant and Anesthesia|In this group decongestants and anesthesia (oxymetazoline and lidocaine) sprays will be used. Decongestant (Oxymetazoline 0.05%) will be give as described above. After two minutes, lidocaine 15% (Nummit) spray will be given as described above. Procedure will be done after five minutes of decongestant.
2393090|NCT03620500||Children with Cochlear Implants|Children with sensory neural hearing loss who undergo cochlear implantation will be monitored to see if balance develops normally in this population
2393092|NCT03620448|Experimental|bCPAP Arm.|"Babies randomized to receive bCPAP were started (by principle investigator assisted by a clinician) on bCPAP (Rice 360◦c low cost bCPAP device) consisting of 3 components:~(i) An oxygen concentrator with a gas flow fate of 3-4L/min, (ii) A nasal interface (short nasal prongs) connecting the baby's airway to a two limb circuit i.e the inspiratory limb connected to the bCPAP machine and the expiratory limb connected to the water bottle and (iii) An expiratory limb with the distal end submerged 6cm in water to generate an end expiratory pressure as seen in appendix 7. adopted from suppliers of the pumani bCPAP machine in Kenya."
2393093|NCT03620448|Other|Oxygen Arm|Preterms on the control arm and those whose parents didn't consent received the standard treatment for RDS i.e pure oxygen via nasal prongs from the oxygen cylinders.
2393094|NCT03620435|Experimental|atezolizumab|Atezolizumab will be given during trimodal therapy, and every 3 weeks for 16 cycles or until disease progression or unacceptable toxicity.
2393095|NCT03620422|Other|Healthy Controls|Mannitol-Induced Cough Challenges on Visit 2 and 3. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2393096|NCT03620422|Placebo Comparator|Mild Allergic Asthmatics (Saline)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized placebo (Sodium Chloride 0.9% Inhl 3Ml) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2393131|NCT03620175|Placebo Comparator|Topical Vehicle Gel|
2393273|NCT03619148|Active Comparator|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen - staff volunteers
2393097|NCT03620422|Active Comparator|Mild Allergic Asthmatics (Salbutamol)|Mannitol-Induced Cough Challenges on Visit 2, 3 and 4. Nebulized salbutamol (5mg/mL) given prior to Mannitol-Induced Cough Challenges on Visit 3 or 4. Mannitol delivered via inhalation. Dosage: 0, 5, 10, 20, 40 mg capsules. 80 and 160 mg doses delivered with two and four capsules, respectively.
2393098|NCT03620409||Sepsis|Patients with and without diagnosis septic cardiomyopathy Patients with and without suspected or confirmed SARS-CoV-2 infection
2393099|NCT03620409||Cardiomyopathy without infection|Patients without operation and patients with scheduled LVAD-Implantation
2393100|NCT03620409||Healthy subjects|Healthy controls
2393101|NCT03620396|Experimental|Experimental: Interventional|Group A patients consists of Gingivitis patients whose serum is collected at base line and treated with Scaling and root planing and after three months serum is collected for assessment of Trefoil factor 3.
2393102|NCT03620396|Experimental|Experimental Interventional|Group B patients consists of Periodontitis patients whose serum is collected at base line and treated with Scaling and Root Planing and after three months serum is collected for assessment of Trefoil factor 3.
3183972|NCT00719368||Pain Patients|Patients with persistent postherniotomy pain lasting >1 year and pain related impaired daily function
3183973|NCT00719381|Active Comparator|1|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
2393105|NCT03620370|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start in the pre-hospital or emergency room as soon as possible (within 1 hours) after diagnosis of ischemic stroke and last for 4 hours. All participant will receive mechanical thrombectomy and a standard clinical therapy.
2393106|NCT03620370|No Intervention|Control group|The participants receive mechanical thrombectomy therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
2393107|NCT03620357|Experimental|Continuous Glucose Monitor (CGM) Group|
2393108|NCT03620357|Active Comparator|SMBG Group|
2393109|NCT03620344|Experimental|ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure. Families assigned to this condition will also receive the ADH-Me! book. Written by a pediatrician and health literacy expert, ADH-Me! is an accessible, rhyming narrative that describes an empathetic journey from the perspective of a child learning to live and succeed with ADHD. The book is intended to help families know what to expect from diagnosis through all stages of treatment, while attempting to foster love and support."
2393110|NCT03620344|Sham Comparator|No ADH-Me Book|"Families in both conditions will be told that they are receiving additional reading materials to help them and their child better understand the ADHD condition and the available options for treating ADHD. Families in both groups will receive the Understanding ADHD: Information for Parents About ADHD brochure."
2393111|NCT03620331|Active Comparator|Non Surgical + Surgical|Non surgical approach (NS) followed by surgical treatment (S) of peri-implantitis
2393112|NCT03620331|Experimental|Immediate Surgery|Direct surgical approach (S), without a previous non surgical approach
2393113|NCT03620305||Description of treatment of septic pseudarthrosis|chirurgical and medical treatment
2393114|NCT03620292|Experimental|Intraoperative NIR fluorescence imaging|"A non-randomized, non-blinded, prospective, single center pilot dose escalation study with bevacizumab-800CW for NIR fluorescence image guided surgery in hilar cholangiocarcinoma~IV-administration of 10, 25 or 50 mg of the fluorescent tracer bevacizumab-800CW to a total of 15 patients with resectable hilar cholangiocarcinoma 3 days prior to surgery.~Peroperative open air NIR fluorescence imaging~Ex vivo endoscopic and histopathological NIR fluorescence imaging"
2393115|NCT03620279|Experimental|Magic camp intervention|These children are diagnosed with cerebral palsy and we will provide motor control training.
2393116|NCT03620266|Experimental|Bilberry|Dietary supplement with bilberry shakes 2 times daily for 3 months (containing in total 40g of dried bilberry powder equalling 480 g of fresh berries per day). Product development in collaboration with Glucanova AB.
2393117|NCT03620266|Placebo Comparator|Reference/Placebo|Dietary supplement with reference shakes 2 times daily for 3 months (containing no active bilberry or no active oats, but with similar texture and taste as both bilberry and oat). Product development in collaboration with Glucanova AB.
2393118|NCT03620266|Experimental|Bioprocessed oat bran|Dietary supplement with bioprocessed oat bran shakes 2 times daily for 3 months (containing beta glucans from the Glucanova® technology, invented by Glucanova AB).Product development in collaboration with Glucanova AB.
2393119|NCT03620266|Experimental|Combination of oat and bilberry|Dietary supplement with a combination of bioprocessed oat bran and dried bilberry (shakes) 2 times daily for 3 months. Product development in collaboration with Glucanova AB.
2393120|NCT03620253|Experimental|Modafinil|Participants will be administered 100 mg modafinil tablets, that will be over-encapsulated, for one week. If the drug is well tolerated, the dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
2393121|NCT03620253|Placebo Comparator|Placebo|Participants will be administered 100 mg placebo capsule. This capsule will have all the same ingredients as the modafinil tablets, minus the active ingredient. After 1 week, participants' dosage will be increased to 200 mg for the remaining 7 weeks of the study. Capsules are taken daily in the morning.
2393122|NCT03620240|Experimental|Sleep Education|Half of the participants are randomly assigned to the Sleep Education group. These participants will undergo 4 weekly class-based lesson, during which they are educated about sleep.
2393123|NCT03620240|No Intervention|Control|Half of the participants are randomly assigned to the Control group. These participants undergo 4 weekly class-based lessons, during which they are educated about health-related topics, but not about sleep.
2393124|NCT03620227|Experimental|Beetroot juice|ingestion of beetroot juice before an exercise session.
2393125|NCT03620227|Placebo Comparator|Placebo|ingestion of placebo before an exercise session.
2393126|NCT03620214||healthy children|Healthy children consulting at the odontology department of Reims CHU for carious screening or orthodontic diagnosis; excluding research
2393128|NCT03620175|Active Comparator|5 Percent TolaSure Topical Gel|
3183974|NCT00719381|No Intervention|2|Patients in this arm will receive no intervention
3183975|NCT00719394|Experimental|GSI 136|
3183976|NCT00719394|Placebo Comparator|placebo|
3183977|NCT00719407|Experimental|A|All enrolled patients will be in this single arm, who will receive experimental drug treatment.
3183978|NCT00719420|Experimental|1|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid for 14 days (with or without omeprazole 20 mg bid)
2393137|NCT03620149|Experimental|Denosumab|denosumab at reduced dose
2393138|NCT03620136|Experimental|locoregional analgesia by a block on the adductor channel|
2393139|NCT03620136|Experimental|locoregional analgesia by periarticular local infiltrations|
3183979|NCT00719420|Active Comparator|2|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
3183980|NCT00719433|Experimental|1|
2393142|NCT03620097|Experimental|Experimental Arm|30 subjects will receive 800mg of DHA (Dietary Supplement: EuPoly-3 DHA Infant) per day.
2393143|NCT03620097|Placebo Comparator|Control Arm|30 children will take a placebo with similar lipid characteristics
2393144|NCT03620084|Experimental|Expiratory Muscle Strength Training (EMST)|Participants will be taught how to use the EMST-150 device. The device has a one-way spring-loaded valve calibrated at different resistances that the user can select. The valve will open when expiratory pressure exceeds the threshold set by the user on the device. This threshold is set at 75% of the individual's maximum expiratory pressure for the session.
2393145|NCT03620071|Experimental|Intervention|Receipt of a novel mobile-health tool, GoalKeeper Plus Standard Care
2393146|NCT03620071|Experimental|Control|Standard Care
2393147|NCT03620058|Experimental|CART22-65s monotherapy|
2393148|NCT03620058|Experimental|CART22-65s in combination with huCART19|
2393149|NCT03620045|Experimental|Acute moderate physical activity|Participants will walk at a moderate intensity for 20 minutes on a treadmill
2393150|NCT03620045|No Intervention|Sedentary activity|Participants will be permitted to read books and/or draw for 20 minutes
2393151|NCT03620032|Other|Standard treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
2393152|NCT03620032|Experimental|Experimental treatment|Nimotuzumab 150 mg /mq/d as iv weekly and Vinorelbine 20 mg/mq/d weekly, in week 1-12 (Induction phase).If not progression Nimotuzumab 150 mg/m2 as iv and Vinorelbine 25 mg/m²/d as iv until progression or maximum at week 108; in case of non-progressive disease re-irradiation 1 for a total of 19.8 Gy from week 26 to week 28; in case of non-progressive disease: re-irradiation 2 for a total of 19.8 Gy from week 46 to week 48. Irradiation will be scheduled to begin in the 3rd week after starting the nimotuzumab and vinorelbine treatment. For the first course, a total dose of 36 Gy will be delivered, in 1.8 Gy daily fractions 5 days a week.
2393153|NCT03620019|Experimental|Single Arm: Denosumab+ PD-1 Inhibitor|Subjects in this trial will be given denosumab every 4 weeks, starting on day 1 of study treatment. An additional loading dose of denosumab will be administered on day 8. Subjects who started Pembrolizumab (initiated 21 days after the first dose of denosumab is given) will continue to have it administered intravenously (IV) every 3 weeks. New subjects will receive Nivolumab administered intravenously (IV) every 4 weeks (initiated 21 days after the first dose of denosumab is given). Combination therapy will continue as long as subjects benefit from therapy for up to 1 year.
2393154|NCT03619993|Experimental|Arm A: Start with On-body injector|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (OBI-PS-OBI-PS)
2393155|NCT03619993|Experimental|Arm B: Start with pre-filled syringe|4 consecutive cycles of treatment in total, with 2 cycles of treatment with pegfilgrastim pre-filled syringe (PS) and 2 cycles of treatment with On-body injector (OBI) for pegfilgrastim in an alternating sequence (PS-OBI-PS-OBI)
2393156|NCT03619980||Participants with prostate cancer|This is a retrospective registry based study to collect real world data on participants with different disease stages of prostate cancer in Sweden.
3183981|NCT00719433|Active Comparator|2|
3183982|NCT00719459|Experimental|1|Hospira Iron Sucrose
3183983|NCT00719459|Active Comparator|2|Venofer
3183984|NCT00719485|Experimental|1|Educational program
3183985|NCT00719485|No Intervention|2|Standard care
3183986|NCT00719511|Experimental|1|Patch allergen dose 1
3183987|NCT00719511|Experimental|2|Patch allergen dose 2
3183988|NCT00719511|Experimental|3|Patch allergen dose 3
3183989|NCT00719511|Experimental|4|Placebo
3183990|NCT00719524|Experimental|1|
3183991|NCT00719550|Placebo Comparator|Phase 2 Arm C|AMG 102 placebo plus ECX
3183992|NCT00719550|Other|Phase 1b|Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.
3183993|NCT00719550|Active Comparator|Phase 2 Arm B|AMG 102 at 7.5mg/kg plus ECX
3183994|NCT00719550|Active Comparator|Phase 2 Arm A|AMG 102 at 15mg/kg plus ECX
3183995|NCT00719589||1|Patient who have had implantation of an interstim.
3183996|NCT00719602|Active Comparator|1|Previously received single-dose nevirapine (SD NVP); assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
3183997|NCT00719602|Active Comparator|2|Have not previously received SD NVP; assigned to receive either an NNRTI- or PI-based regimen as a part of the study IMPAACT P1060
3183998|NCT00719641||Phase 1: Single Colonoscopy|Feasibility testing using the segmental stiffening wire
3183999|NCT00719641||Phase 2; Not randomized|Phase 2 participants who did not have looping during first colonoscopy
3184000|NCT00719641||Phase 2: Randomized to SSW during first colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to subsequent use of segmental stiffening wire, then colonoscopy with no segmental stiffening wire upon repeat colonoscopy the next day.
2393157|NCT03619967|Experimental|Multispectral imaging device|Bio-inspired multispectral imaging device will be used to record fluorescence signals emited by dyes (Indocyanine green and methylene blue) routinely used for visual identification of sentinel lymph nodes per current standard of care worldwide.
2393158|NCT03619954|Experimental|NK cells infusion|
2393159|NCT03619941|Placebo Comparator|Placebo|
2393160|NCT03619941|Experimental|Montmorency Tart Cherry Juice|
2393161|NCT03619928|Experimental|Dry needling|Procedure in which a thin needle is used to penetrate the skin, subcutaneous tissues and muscle with the intention of mechanically stimulating the tissue without the use of an anesthetic. The physiological mechanism supporting the effects of dry needling remains to be clarified. It has been suggested that the needle works according to the pain gate control theory, indicating that one type of sensory input could be inhibited in the Central nervous system by another input
2393162|NCT03619928|Active Comparator|Massotherapy|Among the therapeutic approaches for DOMS is massage therapy. Several authors have examined the effects of DOMS massage and indirect markers of muscle damage, such as impaired muscle function, edema and muscle changes in blood proteins.
2393163|NCT03619915||Greater dependence|
2393164|NCT03619915||Less dependence|
2393165|NCT03619915||Independent|
3184001|NCT00719641||Phase 2: Randomized to SSW during second colonoscopy|Phase 2 participants in whom looping occurred on first biopsy, randomized to no subsequent use of the segmental stiffening wire that day, then colonoscopy with segmental stiffening wire upon repeat colonoscopy the next day.
3184002|NCT00719654||EOS-Preeclampsia|Women with symptoms of early-onset preeclampsia
3184003|NCT00719654||Normal|Women who do not have symptoms of early-onset preeclampsia
2393169|NCT03619876|Active Comparator|Non-TNF inhibitor arm|Treatment with abatacept will consist of weekly subcutaneous (SQ) injections at a dose of 125mg.
2393170|NCT03619876|Active Comparator|TNF inhibitor arm|Treatment with a adalimumab, as the TNF-inhibitor arm, will consist of every 2 weeks SQ injections at a dose of 40mg.
2393171|NCT03619850|Experimental|Ferumoxytol|
2393172|NCT03619850|Active Comparator|Iron sucrose|
3184004|NCT00719693|Experimental|A|ABT-143 under low-fat meal condition
2393174|NCT03619824|Experimental|Intervention arm|Patients will receive induction chemotherapy with gemcitabine (1g/m2, d1 & 8 of every cycle) and cisplatin (80mg/m2, d1 of every cycle), every 3 weeks for 3 cycles before radiation. Definitive intensity-modulated radiotherapy (IMRT) of 66-70Gy will be given in six to seven weeks. Concurrent cisplatin 100mg/m2 will be administered every 3 weeks for 2 cycles during IMRT. Sintilimab 200mg will be given every 3 weeks for 6 cycles, started on day 1 of induction chemotherapy.
3184005|NCT00719693|Experimental|B|ABT-143 under fasting meal condition
2393176|NCT03619785|Experimental|Experimental (SAPB)|Patients randomized to the experimental arm receive an ultrasound-guided serratus anterior plane block for their rib fracture pain.
2393177|NCT03619785|Active Comparator|Control|Patients randomized to the control arm receive usual pain control treatment in the emergency department.
2393178|NCT03619772|Experimental|Bilateral|Participants will control game using EMG from both upper limbs.
2393179|NCT03619772|Active Comparator|Unilateral|Participants will control game using the more impaired upper limb.
2393180|NCT03619759||Sugammadex|Patients who used sugammadex Sugammadex 1 vial (200mg) intravenous, at the end surgery, before extubation
2393181|NCT03619759||Non-sugammadex|Patients who didn't use sugammadex Pyridostigmine 15~20mg intravenous, at the end of surgery, before extubation
2393182|NCT03619746|No Intervention|Pre-Intervention|Current practice (unchanged). This arm of patients will cared for by physicians who have NOT received the POCUS Educational Intervention.
2393183|NCT03619746|Experimental|Post-Intervention|This arm of patients will cared for by physicians who have received the POCUS Educational Intervention.
2393184|NCT03619720|Experimental|Participants|
2393185|NCT03619707|Experimental|Oral Dydrogesterone|Oral dydrogesterone (Duphaston 10 mg) will be given orally four times daily : will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test.
2393186|NCT03619707|Experimental|Vaginal microprogesterone|Vaginal progesterone (Utrogestan 200 mg) will be given vaginally four times daily: will be continued till the pregnancy test, and till at least 12 weeks of gestation in case of a positive pregnancy test
2393191|NCT03619642|Other|persons with Multiple Sclerosis (MS)|25 persons with MS Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2393192|NCT03619642|Other|stroke patients|25 stroke patients Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2393193|NCT03619642|Other|healthy controls|50 healthy controls Persons are tested on proprioception of the interphalangeal joints of teh fingers by means of a robotic device.
2393194|NCT03619629|Experimental|Kinesio-taping|Kinesiotape will be applied both ankles.
2393195|NCT03619629|Experimental|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied both ankles.
2393196|NCT03619629|Sham Comparator|Sham Kinesio-taping|Sham kinesio-taping technique will be applied both ankles.
2393197|NCT03619629|Sham Comparator|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement will be applied both ankles.
2393198|NCT03619616|Experimental|ZSP1603 (single dose)-7.5 mg (Cohort 1)|Subject adminsitered at a dose of ZSP1603 7.5 mg on day 1 under fasted condition.
2393270|NCT03619161|Experimental|Bubbles|Patients will have a bacterial culture taken from their bathtub and have their bathrooms cleaned by the investigators
3184010|NCT00719745|Active Comparator|1|
3184011|NCT00719745|Experimental|2|
2393199|NCT03619616|Experimental|ZSP1603 (single dose)-12.5mg (Cohort 2)|"Subject adminsitered at a dose of ZSP1603 12.5 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
2393200|NCT03619616|Experimental|ZSP1603 (single dose)-25 mg (Cohort 3)|"Subject adminsitered at a dose of ZSP1603 25 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
2393201|NCT03619616|Experimental|ZSP1603 (single dose)-50 mg (Cohort 4)|"Subject adminsitered at a dose of ZSP1603 50 mg or placebo on day 1 under fasted condition.~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
3184012|NCT00719758|Experimental|1|Cross-over study
2393203|NCT03619577|Experimental|Sequential training-high frequency|The participants of HF will receive a total of 36 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
2393204|NCT03619577|Experimental|Sequential training-low frequency|The participants of LF will receive a total of 12 training sessions, and each session will contain 90-105 minutes of training. The participants in this group will first perform 45-55 minutes of physical exercise followed by 45-50 minutes of cognitive training. The participants in this group participate in multimodel exercise programs including aerobic exercise, balance, and strength training. The entire program will contain 5-10 minutes of warm-up, 35-40 minutes of physical exercise, and 5 minutes of cool-down. Then, the participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions for 45-50 minutes.
2393205|NCT03619564||No protein restriction|No protein restriction
2393206|NCT03619564||Low protein diet (LPD)|LPD: < 0.8 g/kg bodyweight
2393207|NCT03619564||Ketoanalogue suppl. very LPD|sVLPD: 0.3-0.4 g/kg bodyweight + keotanalogues
3184013|NCT00719771|Other|Global® AP™ Shoulder|Global® AP™ Shoulder
3184014|NCT00719784|Experimental|1|All patients recruited will have VRI recordings done. There is no comparative arm.
2393210|NCT03619538|Placebo Comparator|control group|
2393211|NCT03619538|Experimental|Nefopam group|
2393212|NCT03619525|Active Comparator|recruitment group|will receive intermittent lung recruitment during CPB
2393213|NCT03619525|No Intervention|control group|will recieve no intervention
2393214|NCT03619512||Richter Syndrom at diagnosis|patients diagnosed with Richter Syndrom, for whom a suitable lymph node biopsy at diagnosis is available.
2393215|NCT03619512||Primitive Diffuse Large B-Cell Lymphoma|patients diagnosed with a primitive Large B-Cell Lymphoma, for whom a suitable lymph node biopsy at diagnosis is available.
2393216|NCT03619512||Other secundary Diffuse Large B-Cell Lymphoma|patients diagnosed with a secundary Large B-Cell Lymphoma (different from Richter Syndrom), for whom a suitable lymph node biopsy at diagnosis is available.
2393217|NCT03619512||Control group with no tumor involvment of lymph nodes|patients for whom a diagnostic lymph node biopsy has been performed, which did not conclude to any tumoral lymph node involvment.
2393218|NCT03619499|Experimental|non invasive|infants who fulfill criteria of severe bronchiolitis will be connected to non invasive ventilation
2393219|NCT03619499|No Intervention|invasive|infants who were connected to invasive mechanical ventilation
2393220|NCT03619486|Placebo Comparator|Placebo|Placebo treatment (shock wave probe w/o energy)
2393221|NCT03619486|Experimental|Low energy shock wave|Low energy shock wave treatment (shock wave probe w/ energy)
2393222|NCT03619473|Experimental|intervention|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~underwent the educational session under helmet initiative program~received one standard motorcycle child safety helmet per family~assessed for proper helmet usage (type, chinstrap, standard helmet usage) 3 months after educational session and after received standard motorcycle child safety helmet~evaluated for the behavioral of helmet usage 3 months after educational session and after received standard motorcycle child safety helmet"
2393223|NCT03619473|No Intervention|control|"the group~assessed for proper helmet usage (type, chinstrap, standard helmet usage)~evaluated for the behavioral of helmet usage~assessed for proper helmet usage after 3 months 4 evaluated for the behavioral of helmet usage after 3 months~do not receive any educational session or standard motorcycle child safety helmet"
2393224|NCT03619460|Experimental|piezoelectric extraction|The flap will be raised using a Piezoelectric elevator, the eventual bone around the third molar crown will be removed with the same piezoelectric lever used for luxation and root extraction. The eventual rizectomy will be performed using a piezoelectric saw.
2393225|NCT03619460|Active Comparator|conventional extraction|The flap will be raised using a manual elevator and the eventual bone around the third molar crown will be removed with a bone bur with a straight handpiece while the eventual rizectomy will be performed using a bone bur. Manual levers will be used for luxation and tooth extraction
2393226|NCT03619447|Active Comparator|ESP block group|Under general anaesthesia, Ultrasound guided ESP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
2393271|NCT03619161|Active Comparator|Bleach and Bubbles|Patients will have a bacterial culture taken from their bathtub, have their bathrooms cleaned by the investigators, and be given instructions to perform bleach baths twice weekly.
2393272|NCT03619148|Other|High-Flow Humidified Nasal Oxygen - TOE participants|High-Flow Humidified Nasal Oxygen - standard care
3184015|NCT00719797|Experimental|Arm I (FOLFOXIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2393227|NCT03619447|Active Comparator|serratus block group|Under general anaesthesia, Ultrasound guided SAP block will perform at the T6 level with15 ml bupivacain+ 5ml lidocaine, bilaterally. Morphine 0.1 mg/kg will administer at last 30 minutes of surgery for postoperative analgesia. Patient controlled analgesia (PCA) with morphine will apply to the all patients. Postoperative pain assessment and morphine consumption will record till the postoperative 24 th hours.
2393228|NCT03619434|Active Comparator|Conventional keratoplasty group (Control)|This group will undergo conventional penetrating keratoplasty with a trephine blade.
2393229|NCT03619434|Experimental|Femtolaser group|This group will undergo femtosecond laser-assisted penetrating keratoplasty.
2393230|NCT03619421|Experimental|Supplement with food|Zinc supplement to be taken at time of breakfast consumption
2393231|NCT03619421|Experimental|supplement prior to food|Zinc supplement to be taken 30-min before breakfast consumption
2393232|NCT03619408||No/Mild Esophagitis|All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have no or mild histologic esophagitis, no erosive esophagitis, and reflux index <3% on pH-metry. Antacid therapy will be discontinued.
2393233|NCT03619408||Moderate/Severe Esophagitis|"All repaired esophageal atresia patients at Boston Children's Hospital with primary esophageal anastomosis undergoing routine year-1 surveillance endoscopy / pH-impedance studies found to have moderate or severe histologic esophagitis, and/or erosive esophagitis, and/or reflux index > 3% on pH-metry.~Antacid therapy with PPI (omeprazole 1mg/kg/dose BID) will be initiated. For patients already taking PPI at therapeutic dosing, an H2 blocker (ranitidine 3mg/kg/dose BID) will be added."
2393234|NCT03619382||Healthy|Subjects identified to have a healthy foot/ankle
2393235|NCT03619369|Active Comparator|Early Circumcision|
2393236|NCT03619369|Placebo Comparator|Routine Circumcision|
2393237|NCT03619369|Active Comparator|Delayed Circumcision|
2393238|NCT03619343|Experimental|No ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography.
2393239|NCT03619343|Active Comparator|ETOIMS arm|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
2393240|NCT03619330|Active Comparator|liraglutide|In the LIRA group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
2393241|NCT03619330|Active Comparator|testosterone|In the ANDRO group testosterone was initiated at a dose of 50 mg in a gel form once daily.
2393242|NCT03619317||Cancer esophagus and gastroesophageal junction|EGEJ cancer patients referred to combined therapy of chemoRT and surgery can be included.
2393243|NCT03619304|Experimental|no coffee|oral squamous cell carcinoma cell line without intervention
2393244|NCT03619304|Active Comparator|green coffee|oral squamous cell carcinoma cell line with application of green coffee
2393245|NCT03619304|Active Comparator|roasted coffee|oral squamous cell carcinoma cell line with application of roasted coffee
2393246|NCT03619304|Active Comparator|decaffeinated coffee|oral squamous cell carcinoma cell line with application of decaffeinated coffee
2393247|NCT03619291|Experimental|High-intensity functional training|all-out exercise
2393248|NCT03619291|Active Comparator|Aerobic exercise|walking
2393249|NCT03619291|Sham Comparator|control|sitting
2393250|NCT03619278|Experimental|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 2 dose of 10-1074 antibodies and 3 doses of romidepsin
2393251|NCT03619278|Placebo Comparator|Placebo|Participants will receive 5 doses of placebo, 2 doses of 10-1074 antibodies and 3 doses of romidepsin
2393252|NCT03619265|Experimental|Prickly pear juice|Prickly pear juice, 3 oz daily for 8 weeks.
2393253|NCT03619265|Placebo Comparator|Pear-flavored juice|Pear-flavored juice, 3 oz daily for 8 weeks.
2393254|NCT03619252|Experimental|Vaccination group|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and enrolled in vaccination by pneumococcal conjugate vaccine (PCV13): 3 doses with 1 month interval, and fourth dose planned to be administered 6 months later.
2393255|NCT03619252|Active Comparator|Standard prophylaxis|Patients receiving novel agents (Bortezomib/Lenalidomide/Ixazomib/Daratumumab) and receiving standard institutional antibacterial prophylaxis by Levofloxacin 500 mg daily during the median four cycles of treatment by novel agents
2393256|NCT03619239|Experimental|Cohort 1|Patients will receive treatment with GX-I7 at a pre-determined dose (Level I) on Day1 of each cycle.
2393257|NCT03619239|Experimental|Cohort 2|Patients will receive treatment with GX-I7 at a pre-determined dose (Level II) on Day1 of each cycle.
2393258|NCT03619239|Experimental|Cohort 3|Patients will receive treatment with GX-I7 at a pre-determined dose (Level III) on Day1 of each cycle.
2393259|NCT03619239|Experimental|Cohort 4|Patients will receive treatment with GX-I7 at a pre-determined dose (Level IV) on Day1 of each cycle.
2393260|NCT03619239|Experimental|Cohort 5(Dose-expansion)|Optimal fixed dose of GX-I7 from Dose-escalation stage on Day1 of each cycle (Maximum tolerable dose or Maximum efficacious dose or Maximum administered dose level or consecutive lower or upper dose level which does not exceed Maximum tolerable dose based on Safety Monitoring Committee(SMC) decision)
2393261|NCT03619226|Experimental|test patch|two adhesive patches are applied to the abdominal area
2393264|NCT03619200||Fallers|"Participants who reported at least one fall in the 12-months follow-up period were categorized as fallers."
2393265|NCT03619200||Non-Fallers|"Participants who did not report any fall in the 12-months follow-up period were categorized as non-fallers."
2393266|NCT03619187|Experimental|Single Arm|Study Product
2393267|NCT03619174|Active Comparator|Active Treatment|Treatment dose
2393268|NCT03619174|Placebo Comparator|Sham Treatment|Sub-therapeutic dose
2393269|NCT03619161|No Intervention|No cleaning (control)|Patients will have a bacterial culture taken from their bathtub and then continue regular care. We will offer to clean their bathrooms after the 4 week intervention period ends.
2393276|NCT03619122|Experimental|Second Examination|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is inserted to the cecum and withdrawn to the hepatic flexure again for second examination.
2393277|NCT03619122|No Intervention|Traditional Examinaiton|Eligible patients who consent to participate undergo planned colonoscopy by endoscopists performing procedures that day per normal standard of care. The colonoscope is passed to the cecum and then withdrawn to the hepatic flexure with washing and aspirating of colonic contents as needed to optimize visualization of colonic mucosa. Then, the colonoscope is withdrawn to the anus directly.
2393278|NCT03619109||Healthy Volunteers|No real intervention since samples from volunteers are not tested on Nanōmix eLab™ System near any volunteers. Leftover samples are stored at Sponsor for potential future analysis/ projects.
2393279|NCT03619096|Active Comparator|Test Group (tunnel technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a tunnel Technique
2393280|NCT03619096|Placebo Comparator|Control Group (extended flap technique)|It Will be performed root coverage of multiple recessions using porcine collagen matrix with a extended flap technique
2393281|NCT03619083||Breast cancer patients treated with chemotherapy|
2393282|NCT03619083||patients not exposed to chemotherapy|
2393283|NCT03619083||healthy controls|
2393284|NCT03619070|Experimental|Lower load resistance training (LL)|In the LL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and low load (i.e. 30% of 1RM)
2393285|NCT03619070|Experimental|Higher load resistance training (HL)|In the HL group, postmenopausal women will perform the resistance training with moderate volume (i.e. three sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
2393286|NCT03619070|Experimental|Higher volume resistance training (HVHL)|In the HVHL group, postmenopausal women will perform the resistance training with high volume (i.e. six sets per exercise performed until or close to failure) and high load (i.e. 80% of 1RM)
2393287|NCT03619070|Other|Control group, (CG)|In CG, the postmenopausal women group will not perform exercise
2393288|NCT03619057||> 18 years|
2393289|NCT03619057||10 to 18 years|
2393290|NCT03619044|Other|Patients with metastatic breast cancer|Patients with metastatic breast cancer treated with trastuzumab + pertuzumab + taxane in the metastatic first line.
2393291|NCT03619031|Experimental|LONG LEAVENING|Acute test meal
2393292|NCT03619031|Experimental|SHORT LEAVENING|Acute test meal
2393293|NCT03619031|Active Comparator|TRADITIONAL|Acute test meal
2393294|NCT03619005|Placebo Comparator|Placebo|
2393295|NCT03619005|Active Comparator|Prasterone|
2393296|NCT03618992|Active Comparator|Cohort 1|Subjects will be provided with containers of topical cholesterol-containing moisturizers to be applied to the skin and hair, identical except for labels designating left and right. Topical formulations will be purchased by Skin Actives Scientific (www.skinactives.com), and will consist of one container of intervention and one of vehicle only (see ingredients below), to be applied to the left or right arm as indicated by pre-randomization assignment. Patients will be instructed to begin a 1-week washout period in which they will stop all topicals, and will then begin daily application of the topical intervention products to the indicated sites. Patients will return for follow-up visits at 2, 6, 10, and 14 weeks after starting intervention.
2393297|NCT03618992|No Intervention|Cohort 2|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side, samples of scalp (pluck 1), eyebrow (trim 1), and eyelash (trim 1) hairs will be obtained only at baseline and the final visit. Patients will return for follow-up visits at 1, 2, and 3 months after discontinuation of oral antifungal therapy.
2393298|NCT03618992|No Intervention|Cohort 3|Pre-study randomization will assign patients to have measurements obtained from either the left or right side of the body. Baseline skin barrier measurements of the skin and lips will be obtained, including transepidermal water loss (TEWL), hydration, pH and sebum (oil). Photos of the skin, lips, eyebrows, eyelashes and scalp will be taken. On each side of the body, samples of scalp (pluck 1, trim 1), eyebrow (pluck 1, trim 1), and eyelash (trim 1) hairs will be obtained at the baseline and final visit. Patients will return for follow-up visits at monthly intervals after initiation of oral antifungal therapy for up to 12 months.
2393299|NCT03618979|Experimental|PPP treatment|Platelet Poor Plasma (PPP) into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
2393300|NCT03618979|Experimental|PRP treatment|5x concentration Platelet Rich Plasma (PRP) injected into the multifidus on each side and at each level 1 time per week for 6 weeks (series of 6 injections)
2393301|NCT03618979|Experimental|PRP and PL Combo treatment|5x concentration PRP injected into the multifidus, along with a facet joint injection with 14x PRP into each joint and capsule, and transforaminal epidural injection with of 3x concentrated platelet lysate (PL) and 0.5% ropivacaine on each side and at each level 1 time every 2 weeks for 6 weeks total (series of 3 injections)
2393302|NCT03618966|Experimental|Right-real NMMS Group|It will receive a real stimulation (rNMMS) of the right arm and a sham stimulation (sNMMS) of the left arm
2393303|NCT03618966|Active Comparator|Left-real NMMS Group|It will receive a rNMMS of the left arm and a sNMMS of the right arm
2393304|NCT03618953|Experimental|Arm 1 (Intravenous dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 3 dose levels (escalation) of MG1-E6E7 administered as 4 infusion (IV) doses over 2 weeks starting at study day 15.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
2393305|NCT03618953|Experimental|Arm 2 (Intravenous and Intra-tumoral injection dosing)|"Fixed dose of Ad-E6E7 administered IM on study Day 1. Followed by one of 2 dose levels (escalation) of MG1-E6E7 administered as 1 IV dose, starting at study day 15, followed by 2 intratumoral (IT) doses administered on study days 18 & 29.~Fixed dose of atezolizumab administered IV every 3weeks starting at study day 43."
2393306|NCT03618940|Experimental|School-based educational intervention|"assessed for knowledge and attitude on burn injury prevention~underwent the School-based educational intervention~impact evaluation~Output evaluation 3 months after School-based educational intervention"
2393307|NCT03618927|Experimental|Daily physical activity intervention|The intervention consisted of a DPA program designed by a national organization with expertise in school-based physical activity programming and delivered in school by teachers. The program was offered to students in grades 4 through 8 and consisted of 20 minutes of structured DPA in school for 20 consecutive weeks. The DPA activities included jumping jacks, squats, running and other body weight exercises.
2393308|NCT03618927|No Intervention|Control - treatment as usual|Participants in control classes completed regular school activities as per the Ontario curriculum.
2393309|NCT03618914||Non-anemic women|
2393310|NCT03618914||anemic women|anemia due to iron deficiency
2393311|NCT03618901|Experimental|Rock Steady Boxing|Non-contact boxing program.
2393312|NCT03618901|Active Comparator|PD SAFEx|Sensory attention focused exercise.
2393313|NCT03618888|Active Comparator|Instructor-led training|Instructor-led training contents a supervised practical training for BLS, facilitated by a certified instructor.
2393314|NCT03618888|Experimental|Self-learning training|Self-learning training is self-directed and contents practical training for BLS
2393315|NCT03618875|Active Comparator|ice|Patients were randomly assigned to receive an ice 5 minutes prior the IViT
2393316|NCT03618875|Placebo Comparator|placebo|Patients were randomly assigned to a room temperature patch (placebo) 5 minutes prior the IViT
2393317|NCT03618849|Experimental|Sham tDCS|Post initial screening and baseline data collection, all study participants (a single cohort of patients) will receive a single dose of sham tDCS for 20 minutes over the left dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex in conjunction with Mozart piano sonata. For sham tDCS, the current will be ramped up and immediately ramped down for 30 seconds. The sham tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2393318|NCT03618849|Experimental|1-mA tDCS|Post sham-tDCS, we will determine the eligibility of the participant to receive 1 mA of real tDCS based on the occurrence of adverse events and seizures occurring within 5 days of the sham session. After a minimum of 5 days post-sham stimulation (and typically around 7 days later), the participant will receive a single dose of 1-mA current (for head circumference >52 cm; children with head circumference 43-52cm will receive 0.5-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 1-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 1-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2393319|NCT03618849|Experimental|2-mA tDCS|Post 1-mA tDCS, we will again determine the eligibility of the participant to receive 2 mA current. After a minimum of 5 days post-1 mA stimulation (typically 7 days), the participant will receive a single dose of 2-mA current (if head circumference >52cm; children with head circumference 43-52cm will receive 1-mA) over left DLPFC or M1 in conjunction with Mozart piano sonata. The participant will receive 2-mA current for 20 minutes; the current will be ramped up for 30 seconds, will held constant at the determined intensity for 20 minutes, and then ramped down for 10 seconds. The 2-mA tDCS session will be preceded and followed by behavioral assessments and EEG recording.
2393320|NCT03618836||Cases. Preterm Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among spontaneous preterm births between 22 and 36 weeks
2393321|NCT03618836||Controls. Term Births|Microbiological and biological patterns on vaginal samples in the first trimester of pregnancy among deliveries over ≥ 37 weeks
3143248|NCT00005585|Experimental|.Arm IV (combination chemotherapy)|CONSOLIDATION: Pts receive methotrexate (MTX) and leucovorin calcium (CF) on wks 7, 10, 13, 24, 27, and 30. Pts receive mercaptopurine(6-MP) daily weeks 5-13 then beginning wk 24 and continuing until end of consolidation; MTX on wks 7, 10, 13, 16, 20, 21, and 30; dexamethasone (DM) 2x daily on days 1-7 of wks 8, 16-18, and 28; vincristine sulfate (VCR) day 1 of wks 8, 9, 16-18, 28, and 29; pegaspargase on wk 16; daunorubicin hydrochloride on day 1 of wks 16-18; cyclophosphamide on day 1 of wk 20; cytarabine on days 2-5 of wks 20 and 21; thioguanine daily on days 1-14 of wks 20 and 21. CONTINUATION: Pts receive mercaptopurine(6-MP) daily on weeks 33-130; oral dexamethasone (DM) twice a day on days 1-7 and VCR IV on days 1 and 8 during weeks 41, 57, 73, 89, and 105; oral MTX weekly on weeks 33-130 (except during weeks of IV MTX); and IV MTX on weeks 37, 49, 61, 73, 85, 97, and 109.
3184016|NCT00719797|Experimental|Arm II (FOLFIRI)|Patients receive irinotecan hydrochloride IV over 1 hour, leucovorin calcium IV over 2 hours, and bevacizumab IV on day 1. Patients also receive fluorouracil IV continuously over 48 hours beginning on day 1.
2393324|NCT03618810||PEGCSF first level prophylactic use|The first level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in all cycles of chemotherapy.
2393325|NCT03618810||PEGCSF second level prophylactic use|The second level prophylactic use of PEG-rhG-CSF. The Prophylactic use of PEG-rhG-CSF in the next cycle until FN or 4 grade neutropenia happened.
2393326|NCT03618797|Experimental|HL-PIF cap.160/2mg + Placebo|"Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
2393327|NCT03618797|Active Comparator|Livalo tab. 2mg + Placebo|"Pitavastatin ca 2mg~once a day"
2393328|NCT03618784|Experimental|FURESTEM-RA Inj.|
2393329|NCT03618784|Placebo Comparator|Placebo Comparator: Placebo|
3184017|NCT00719823|Other|1|
2393332|NCT03618758|Experimental|Gastric Cancer with Peritoneal Carcinomatosis|Intraperitoneal Chemotherapy (Paclitaxel) + Systemic mFOLFOX6(5-FU, Oxaliplatin, Leucovorin)
2393333|NCT03618732|Experimental|Bilateral movement-based computer training|"All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.~Subjects in Intervention Group will be assigned an additional 30 minutes bilateral movement-based computer games(Able-X) training program of upper limb."
2393334|NCT03618732|Other|Video-directed conventional training|All subjects underwent 16 sessions of assigned treatment (2 times per week; for 8 weeks; 3 hours standardized rehabilitation program per visit) There was 1.5 hours standardized conventional physiotherapy training a 1.5 hours multi-disciplinary program which consisted of standardized occupational therapy, speech therapy and nursing care.
2393335|NCT03618719||Obstructive sleep apnea|Patients with treatment-naive obstructive sleep apnea (OSA) who need continuous positive airway pressure (CPAP) therapy on clinical basis
2393336|NCT03618719||Control|Healthy controls without OSA
2393337|NCT03618706|Experimental|involved-field RT + standard salvage treatment|Patients receiving involved-field RT on recurred lesions + standard salvage treatment for recurrent ovarian cancer
2393341|NCT03618667|Experimental|single group|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycle) up to 6 cycles, or till progression or uncontrolled toxicity.
2393342|NCT03618654|Experimental|Arm A (durvalumab, metformin)|"Patients will take Metformin 500mg/day for 3 days. From day 4, 500mg twice daily and then in 3 days (day 7) dose escalation to 1000mg twice daily will be achieved. This will be taken until the day before surgery after dinner.~Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion"
2393343|NCT03618654|Experimental|Arm B (durvalumab)|Patients will receive 1500mg durvalumab (MEDI4736) via IV infusion. Participants receive durvalumab as in Arm A in the absence of disease progression or unacceptable toxicity.
3184018|NCT00719875|Experimental|1|
3189001|NCT00773071|Experimental|A|"Single photon emission computed tomography/computed tomography (SPECT/CT) guided lymphatic mapping and sentinel lymphadenectomy (LM/SL) vs. complete lymph node dissection (CLND)~All cervical cancer and vulvar cancer patients will undergo CLND according to the standard of care in gynecologic cancers as recommended by the International Federation of Gynecology and Obstetrics (FIGO).~Patients with FIGO IA2 and IB1 cervical cancers will be scheduled for radical hysterectomy and pelvic lymph node dissection.~Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes will be scheduled for vulvectomy and inguinal lymph node dissection."
2393346|NCT03618602|Experimental|100mg Bisthianostat|100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2393347|NCT03618602|Experimental|200mg Bisthianostat|200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2393348|NCT03618602|Experimental|400mg Bisthianostat|400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2393349|NCT03618602|Experimental|600mg Bisthianostat|600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).
2393350|NCT03618589|Placebo Comparator|opioid only|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
2393351|NCT03618589|Experimental|pregabalin add-on|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
2393352|NCT03618576|Experimental|Balance exercise group|During the 2-week postoperative intervention period, patients will participate in the hospital's exercise program beginning 5-7 days after HFS. All participants will follow the computer-based balance specific exercise (BSE) program.
2393353|NCT03618550|Experimental|pembrolizumab plus GVD|"Part 1: Patients will receive 2-4 cycles of pembrolizumab plus GVD~Part 2: an additional 25 patients will be enrolled onto an expansion cohort. On the expansion, patients who achieve CR to 4 cycles of pembro-GVD will receive 13 cycles of pembrolizumab maintenance (instead of HDT/ASCT)."
2393354|NCT03618537|Experimental|ixazomib|"Enrolled patients will receive ixazomib at a fixed dose of 4mg on days~1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle. Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue. Treatment cycles will be repeated until disease progression for up to 24 cycles or until development of significant treatment-related toxicities."
2393355|NCT03618524|Experimental|Experimental|Lower limb hot water immersion
2393356|NCT03618511|Experimental|Financial Incentive Group|
2393357|NCT03618511|Experimental|Reminders Group|
2393358|NCT03618511|Experimental|Financial Incentive and Reminders Group|
2393359|NCT03618511|No Intervention|Control Group|
2393363|NCT03618498|Other|Patient accept surgery|Proliferative diabetic retinopathy suffering from MH with RD who were treated with vitrectomy combined with inverted epiretinal ILM flap,inverted ILM flaps insertion techniques, or free ILM flaps.
2393364|NCT03618472|Experimental|metformin|The participant will be eat metformin 850 mg 1 tab daily,4 weeks prior to hysterectomy
2393365|NCT03618472|Placebo Comparator|placebo|The participant will be eat placebo (same shape, size, color)1 tab daily ,4 weeks prior to hysterectomy
2393366|NCT03618459||Breast-surgery patients|A consecutive cohort of adult patients undergoing breast surgery with a combined anesthesia technique, employing a thoracic single-shot paravertebral block performed before surgery. Operations performed were in all cases unilateral tumor resections, lumpectomies and mastectomies without axillary lymphadenectomy.
2393367|NCT03618446||Survivors|Patients whose pelvic fracture and survived till time of discharge from the hospital.
2393368|NCT03618446||Non-Survivors|Patients whose pelvic fracture and died while in hospital.
2393369|NCT03618433|Experimental|Study group|"Standart exercise protocol and KİNECT® video based physiotherapy~The treatment protocol of the study group will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises.In total, a 25-minute Kincet® video game program will be applied in addition to the 15-minute basic and standart exercise program."
2393370|NCT03618433|Active Comparator|Control group|"Standart exercise protocol and Upper extremity rehabilitation~The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol"
3189002|NCT00773084|Active Comparator|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone
2393372|NCT03618407||Oral oseltamivir group|Patients with influenza virus positive and early oral oseltamivir capsules
2393373|NCT03618407||Oral Lotus Capsules group|Patients with positive influenza virus and early oral administration of lotus extract capsules
2393374|NCT03618407||other group|Influenza virus positive patients who were not treated with oral lotus capsule or oseltamivir capsules early
2393375|NCT03618394||Smoflipid|premature neonates receiving MCT/ω-3-PUFA-containing lipid emulsion
2393376|NCT03618394||Intralipid|premature neonates receiving Soybean Based lipid emulsion
2393377|NCT03618381|Experimental|EGFR 806CAR(2G) -EGFRt|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR 806CAR(2G) -EGFRt
2393378|NCT03618381|Experimental|EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG|Autologous CD4+ and CD8+ T cells that have been genetically modified to express the EGFR806CAR(2G)-EGFRt and CD19CAR(2G)-T2A-HER2tG
2393379|NCT03618368|Experimental|Blinded THERANOVA-500 dialyzer|This group of 25 subjects is dialyzed with masked THERANOVA-500 dialyzer enabling Expanded Hemodialysis (HDx) therapy.
2393380|NCT03618368|Placebo Comparator|Blinded REVACLEAR-400 dialyzer|This group of 25 subjects is dialyzed with masked REVACLEAR-400 dialyzer enabling conventional hemodialysis (HD).
2393381|NCT03618368|Experimental|Unblinded THERANOVA-500 dialyzer|This group of 10 subjects is dialyzed with unmasked THERANOVA-500 dialyzer which enables Expanded Hemodialysis (HDx) therapy.
2393382|NCT03618368|Placebo Comparator|Unblinded REVACLEAR-400 dialyzer|This group of 10 subjects is dialyzed with unmasked REVACLEAR-400 dialyzer which enables conventional hemodialysis (HD).
2393383|NCT03618355|Experimental|Cohort 1: 0.5 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg every week."
2393384|NCT03618355|Experimental|Cohort 2: 1 mg weekly|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg every week."
2393385|NCT03618355|Experimental|Cohort 3: 0.5 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 0.5 mg daily."
2393386|NCT03618355|Experimental|Cohort 4: 1 mg daily|"Oral administration with consecutive enrollment of overlapping dose-escalation cohorts, total treatment period 3 months. Patients will conclude treatment with previously scheduled standard of care prostate biopsy.~eRapa (encapsulated rapamycin) is dosed at 1 mg daily."
2393387|NCT03618342||PCOS|PCOS women
2393388|NCT03618342||Healthy controls|Healthy control women
2393389|NCT03618329|Active Comparator|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
2393390|NCT03618329|No Intervention|No Prehabilitation|Not: exercise, nutrition and anxiety reduction in the preoperative period
2393391|NCT03618316|Experimental|Open-label imeglimin + cimetidine|Day 1: single oral dose of 1,500 mg imeglimin Day 5 to Day 10 inclusive: repeated doses of 400 mg cimetidine twice daily Day 8: second 1,500 mg dose of imeglimin together with the morning dose of cimetidine
2393392|NCT03618303|Experimental|Interventional|All patients will undergo the same intervention of having a PET-MRI scan and optical coherence tomography.
2393393|NCT03618290||Acute ischemic stroke group|50 patients (expected) - Acute ischemic stroke (AIS)
2393394|NCT03618290||Non-neurological pathologies group|25 control subjects with non-neurological pathologies (Congestive heart failure (CHF), Chronic obstructive pulmonary disease ( COPD ) etc.)
2393395|NCT03618290||Non AIS-related brain injuries group|25 control subjects with traumatic or other non AIS-related brain injuries. These will include: Traumatic Brain Injury (TBI) defined as intracranial hemorrhage or contusion.
2393396|NCT03618277|Other|Intra individual|Before and after being treated by a product (outside the study)
2393397|NCT03618264|Experimental|Dexamethasone plus Ropivacaine group|Participates received peri-incisional scalp infiltration of a miscible liquid of dexamethasone and ropivacaine. The local infiltration miscible liquid containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter
2393398|NCT03618264|Active Comparator|Ropivacaine group|Participates received peri-incisional scalp infiltration of 5mg/mL ropivacaine.
3189003|NCT00773110|Experimental|1 Albumin|Priming of the cardiopulmonary bypass circuit with 20% human albumin solution prior to surgery
2393400|NCT03618238|Experimental|Anlotinib|patients will be given anlotinib 12 mg daily for continus 14 days every 21 days until disease progression.
3189004|NCT00773110|Placebo Comparator|2 Gelofusin|Priming of the cardiopulmonary bypass circuit with gelofusin prior to surgery
3189005|NCT00773123||1|Primary open angle glaucoma
2393403|NCT03618212||Myeloma patients|
2393404|NCT03618199|Experimental|Efficacy of vibrating system on healthy volunteers|
2393405|NCT03618199|Experimental|Efficacy of vibrating system on vestibular patients|
2393406|NCT03618186|Experimental|Normal control|Cognitively normal volunteers
2393407|NCT03618186|Experimental|Mild Cogntive impairment|Person with cognitive impairment that meet Peterson Criteria
2393408|NCT03618186|Experimental|Demented|Patient's that meet dementia criteria
2393409|NCT03618173|Experimental|dexamethasone|IV dexamethasone group : dexamethasone administrated at the induction of general anesthesia, at the dose of 0,2mg/kg (= 0,2mL/kg of a syringe with a 1mg/mL concentration) maximum 8mg (=8mL).
2393410|NCT03618173|Placebo Comparator|Placebos|IV placebo group : saline serum is administrated at the induction of general anesthesia, at the dose of 0,2mL/kg, maximum 8mL.
2393411|NCT03618160|Experimental|Part 1: SAD (Cohort 1 to 3)|Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
2393412|NCT03618160|Experimental|Part 2: MAD (Cohort 4 to 6)|Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants. If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants. Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
2393413|NCT03618160|Experimental|Part 3: Single Dose (Cohort 7)|Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants. Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
2393416|NCT03618121|Experimental|Biofeedback plus gaming (Nevermind)|1) Group A is a biofeedback plus gaming group. Participants in this group play a horror videogame called Nevermind, while also wearing a chest strap heart rate monitor. The object of the videogame is to assist a patient by entering his/her mind and helping him/her work through some trauma memories. The way the game works is that the more anxious players are, the faster their heart beats, and the faster the heart beats, the harder and scarier the game gets. Thus, in order for one to do well in the game, he or she has to learn how to control the heartbeat and stress through relaxation. A therapist will help people in this group to learn relaxation techniques to help calm their body and finish the game.
2393417|NCT03618121|Active Comparator|Gaming only|2) Group B is a gaming only group. Like Group A, participants in this group play a Nevermind, but this time they do not wear a heart rate monitor. A therapist will still be present to help people in this group to learn relaxation techniques to help calm themselves during game play, but in this case the game does not change based on heart rate.
2393418|NCT03618121|Active Comparator|Biofeedback only (The Pip)|3) Group C is a biofeedback only group. In Group C, participants use a device called The Pip that measures Galvanic Skin Response. The Pip interacts with a few basic apps used in this study to teach relaxation. In one app, players control flying dragons. The more relaxed players are (as measured by GSR), the higher and faster their dragon flies. In another app, players control the changing of seasons. The more relaxed players are, the faster they can make seasons change from winter to spring. In another app, players can watch a simple graph of their stress over a period of time. Participants can learn to decrease stress by learning to make the line on the graph go down. In Group C, a therapist will also be present with participants to help them learn techniques to reduce stress.
2393419|NCT03618121|Active Comparator|Relaxation training only|4) Group D is a relaxation training only group. In Group D, participants receive relaxation training from a trained therapist. Participants in this group learn and practice with their therapist different techniques to help them relax and reduce stress.
2393420|NCT03618108|Active Comparator|Active|Subjects will be given oral capsules containing the active comparators 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin daily (days 1 to 7). From days 8 to 90 subjects will be given 50mg oral capsule doxycycline, 250mg oral capsule azithromycin and 150mg oral capsule rifabutin twice daily.
2393421|NCT03618108|Placebo Comparator|Placebo|subjects will be given sugar capsules identical in form and size to the active comparators, 1 capsule of each bottle (3 separate capsules) daily (days 1 to 7), 1 capsule of each bottle (3 separate capsules) twice daily (days 8 to 90).
2393422|NCT03618095|Experimental|Main Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
3189006|NCT00773123||2|Normal controls
3189007|NCT00773149|Experimental|1|all included patients
2393423|NCT03618095|Experimental|Roll-In Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
2393424|NCT03618095|Experimental|Bicuspid Cohort|Transcatheter Aortic Valve Replacement (TAVR) with the LOTUS Edge Valve System
2393425|NCT03618082|Active Comparator|usual practice|control group (usual practice): patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance. The dosage of the anesthetic agent, as well as the prophylactic administration of morphine at the end of the intervention, will be decided by the anesthesiologist.
2393426|NCT03618082|Experimental|targeted analgesia to ANI|"experimental group: patients receiving a general anesthesia with propofol, ketamine and remifentanil with or without curare for the induction, and desflurane and remifentanil (with or without curare) for the maintenance, as well as the prophylactic administration of morphine at the end of the intervention, will be administered according to the ANI.~- In addition, desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC)."
2393427|NCT03618069|No Intervention|routine investigation|
2393428|NCT03618069|Active Comparator|study protocol CCI (CTA, cardiac CT) and MRI scans|
2393430|NCT03618043|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
3184019|NCT00719888|Experimental|Treatment (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -6, cyclophosphamide IV on days -7 and -6, and undergo high-dose TBI BID on days -4 to -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
3189008|NCT00773162|Placebo Comparator|1|
3189009|NCT00773162|Active Comparator|2|
3189010|NCT00773188|Experimental|1|
2393435|NCT03618004|Experimental|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
2393436|NCT03618004|Active Comparator|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
2393437|NCT03617991|Experimental|Exercise Group|Participants will be provided an 8-week home exercise program that they will complete. The participants will also be provided all of the equipment. An investigator will contact them weekly to ensure compliance and send You Tube videos with new Phases.
2393438|NCT03617991|No Intervention|Control Group|The control group will be contacted weekly to check on health status.
2393439|NCT03617978|Experimental|None Elevation|Participant placed on a flat surface. Study participant connected to the measuring hemodynamic parameters device
2393440|NCT03617978|Experimental|Elevation angle of 20 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 20 degrees. Study participant connected to the measuring hemodynamic parameters device
2393441|NCT03617978|Experimental|Elevation angle of 30 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 30 degrees. Study participant connected to the measuring hemodynamic parameters device
2393442|NCT03617978|Experimental|Elevation angle of 45 degrees|Participant placed on a flat surface, lower limbs raised and supported at an angle of 45 degrees. Study participant connected to the measuring hemodynamic parameters device
2393443|NCT03617965||Mild thrombocytopenia|Patients with a platelet count of 100 × 10e9 to 149 × 10e9/L.
2393444|NCT03617965||Moderate thrombocytopenia|Patients with a platelet count of 50 × 10e9 to 99 × 10e9/L
2393445|NCT03617965||Severe thrombocytopenia|Patients with a platelet count<50 × 10e9/L
2393446|NCT03617965||Control group|Patients with normal platelet count (i.e.150 × 10e9 to 399 × 10e9/L)
2393447|NCT03617952|Experimental|S1 (Peer) group|"S1 group households located in 25 clusters that were included in a prior cookstove study: selected households are nearest neighbors (peers) of households who received free stoves in that prior study. This group is used to represent a potentially high peer influence on the adoption of improved cookstoves.~The P3 Bio Intervention is implemented in this group."
2393448|NCT03617952|Experimental|S2 (Non-Peer) Group|"S2 group households are located in 25 clusters randomly selected from the area of the K-N Districts more than 1 km from the S1 clusters. This group will have minimal prior knowledge of the cookstoves through peers.~The P3 Bio Intervention is implemented in this group."
2393449|NCT03617939||Biospeciman and Data Collection|Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.
2393450|NCT03617926|Experimental|Test product|Water-based lotion (internal code (X92001666)
2393451|NCT03617926|Active Comparator|Reference|Commercial, pyrethrin-based shampoo (RID shampoo)
3189011|NCT00773201|Experimental|1|Healthy subjects
2393453|NCT03617900|Placebo Comparator|Placebo|
3189012|NCT00773214|Experimental|exercise|
3189013|NCT00773227|Experimental|1|All patients included
3189014|NCT00773240|Experimental|1|Grazax
3189015|NCT00773240|Placebo Comparator|2|
2393456|NCT03617887|Experimental|Experimental group|Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus:
2393457|NCT03617887|Experimental|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise
2393458|NCT03617874|Active Comparator|PC4PrEP- Intervention Clinics|Intervention clinics will receive the PC4PrEP intervention. The intervention includes Montefiore PrEP policy awareness, provider and patient education, pre-screening to identify PrEP eligible patients, and identifying high risk individuals in the community and providing referral and linkage to primary care.
2393459|NCT03617874|Placebo Comparator|Standard of Care Clinics|These clinics will not receive the PC4PrEP intervention but will continue with their standard of care model.
3184020|NCT00719888|Experimental|Arm II (myeloablative UCBT)|"Patients receive myeloablative conditioning comprising fludarabine IV over 30-60 minutes on days -6 to -2, cyclophosphamide IV on day -6, thiotepa IV over 2-4 hours on days -5 and -4, and middle-intensity TBI QD on days -2 and -1. Patients then undergo single- or double-unit UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour every 8 or 12 hours, then cyclosporine PO (if tolerated), on days -3 to 100 with taper on day 101. Patients also receive mycophenolate mofetil IV every 8 hours on days 0 to 7 and then PO (if tolerated) TID on days 8-30. Mycophenolate mofetil is tapered to BID on day 30 or 7 days after engraftment if there is no acute GVHD, and then tapered over 2-3 weeks beginning on day 45 (or 15 days after engraftment if engraftment occurred > day 30) after engraftment if there continues to be no evidence of acute GVHD."
3184021|NCT00719927|Experimental|1|Comadre Treatment
3184022|NCT00719927|Active Comparator|2|Non Support Partner Treatment
3184023|NCT00719940|Experimental|1|Cognitive behavioral therapy
2393464|NCT03617848||Cohort|A cohort of participants with suspected stable HFpEF will be recruited from the primary care setting. HFpEF diagnosis will be confirmed as per the 2016 European Society of Cardiology (ESC) guidelines for diagnosing HFpEF. All participants will undergo a series of assessments including but not limited to pulse wave velocity, 6 minute walk test, blood tests including natriuretic peptides (NT-Pro-BNP), ECG, physical assessments and a series of questionnaires. Those with confirmed HFpEF will be followed up at 6 and 12 months.
2393465|NCT03617835|Experimental|Spesolimab|
2393466|NCT03617809||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
2393467|NCT03617809||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Esophageal thermometer will be used to measure the temperature throughout the intraoperative period.
3184024|NCT00719940|Placebo Comparator|2|Waiting group
3184025|NCT00719966||Group 1 (hormone receptor-positive)|Patients receive aromatase inhibition therapy for up to 6 months in the absence of unacceptable toxicity.
2393472|NCT03617757|Experimental|All recruited patients|Blood taking procedure, oral glucose tolerance test and questionnaire will be included.
2393473|NCT03617744|Experimental|Surgical Intervention|Open Sleeve gastrectomy procedure will be performed immediately following liver transplantation (as a single surgery) or within 2 weeks of transplantation (as a second open surgery)
2393474|NCT03617744|No Intervention|No Surgical Intervention|Liver transplantation will proceed as per routine practice
2393475|NCT03617731|Active Comparator|IA|Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
2393476|NCT03617731|Experimental|IB|Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.
2393477|NCT03617731|Active Comparator|IIA|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
2393478|NCT03617731|Experimental|IIB|maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.
3184026|NCT00719966||Group 2 (hormone receptor-negative)|Patients do not receive adjuvant treatment.
2393480|NCT03617705|Active Comparator|HIV+ drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
2393481|NCT03617705|Active Comparator|HIV- drinkers|Participants will wear the BACtrack Skyn Alcohol Monitoring Device throughout Skyn Monitor Lab Session 1, Skyn Monitor Field Test with EMA and Skyn Monitor Lab Session 2 to compare the device readings collected with breath alcohol concentration (BrAC) tests.
2393580|NCT03617016|Placebo Comparator|Placebo|Participants will receive matching placebo corresponding to domperidone orally thrice in a day from Day 1 to Day 14.
3184027|NCT00719979|Experimental|iCBT and TeleCoaching|Participants received the technology-assisted behavioral intervention (iCBT + TeleCoaching).
2393482|NCT03617692||Oral Cannabis|This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms. A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product. Participants will then initiate use of an orally administered product they have selected and obtained. Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
2393483|NCT03617679|Active Comparator|Active Ingredient|1:1 Randomization. Participants in this arm receive the active ingredient medication.
2393484|NCT03617679|Placebo Comparator|Placebo|1:1 Randomization. Participants in this arm receive the placebo medication. (Placebos do not contain active ingredients).
2393485|NCT03617666|Experimental|Avelumab|Patients with newly diagnosed cHL will receive single agent avelumab in 2 cycles
2393486|NCT03617653|Other|Group A - Intervention|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis, Exercise intervention from Visit 2 to Visit 13, End of 3 month assessment.
2393487|NCT03617653|Other|Group B- Control|Baseline procedure, Bio specimen collection , Six minute walk, Musculoskeletal Analysis & End of 3 month assessment.
2393488|NCT03617640||Hirschsprung's disease patients|Children diagnosed with Hirschsprung's disease or Hirschsprung's disease associated enterocolitis
2393489|NCT03617640||control patients|Children diagnosed and treated for miscellaneous bowel diseases
2393490|NCT03617627|Experimental|Experimental group|Patients will be included in a self-management intervention.
2393491|NCT03617627|No Intervention|Control group|Patients will receive a booklet with information.
2393492|NCT03617614||Collaborative Care Model|Participants who received care from the Medical Psychiatry Alliance Seniors Outpatient Collaborative Care Program at Trillium Health Partners.
2393493|NCT03617614||Mood Consult|Participants who received a one time mood consultation at the Centre for Addiction and Mental Health.
2393494|NCT03617601||> 4 MET|Patients with functional capacity over 4 MET
2393495|NCT03617601||< 4 MET|Patients with functional capacity under 4 MET
3184028|NCT00719979|Experimental|iCBT(MoodManager)|Participants received Internet-based cognitive behavioral therapy only.
2393497|NCT03617575|Placebo Comparator|apo-Lactoferrin|unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1
2393498|NCT03617575|Placebo Comparator|holo-Lactoferrin|saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1
2393499|NCT03617575|Placebo Comparator|FeSO4|Ferrous sulfate = FeSO4 acting as the reference Test Meal C1
2393500|NCT03617575|Placebo Comparator|1. FeSO4|Ferrous sulfate = FeSO4 Test Meal A2
2393501|NCT03617575|Placebo Comparator|FeSO4 after 1 day break|Ferrous sulfate = FeSO4 Test Meal B2
2393502|NCT03617575|Placebo Comparator|FeSO4 after 2 day break|Ferrous sulfate = FeSO4 Test Meal C2
3143249|NCT00005592|Experimental|Rituxan + IDEC-In2B8, Rituxan + IDEC-Y2B8|For the first treatment, 250 mg/m2 Rituxan infusion and injection of IDEC-In2B8 (Indium- radioactive label) is given. If therapy is continued, approximately 1 week later a second infusion of Rituximab (250 mg/m2) is given followed by an infusion of IDEC-Y2B8 (Yttrium-radioactive label).
3143250|NCT00005594|Experimental|ISIS 2503|All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle.
2393505|NCT03617549||All Participants|Mothers of singleton moderate preterm appropriate for Gestational Age (AGA) infants (29-32+6 weeks gestation in the neonatal intensive care unit at the Golisano Children's Hospital
2393506|NCT03617536|Experimental|CR845 0.25 mg Oral Tablet|Oral CR845 0.25 mg to be taken orally once daily for 12 weeks
2393507|NCT03617536|Experimental|CR845 0.5 mg Oral Tablet|Oral CR845 0.5 mg to be taken orally once daily for 12 weeks
2393508|NCT03617536|Experimental|CR845 1 mg Oral Tablet|Oral CR845 1 mg to be taken orally once daily for 12 weeks
2393509|NCT03617536|Placebo Comparator|Placebo Oral Tablet|Oral Placebo to be taken orally once daily
2393515|NCT03617510|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2393516|NCT03617510|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2393517|NCT03617510|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:188.50mg Volume:8.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2393518|NCT03617510|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo:normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Multi-dose after single-dose Duration:5 days A total of 12 subjects,10 received the test drug and 2 received the placebo.
2393519|NCT03617497|Active Comparator|Healthy control participants|Age- and gender matched healthy participant (n=30) with no cognitive problems and normal amyloid PET scan will undergo 48 hour scalp EEG and polysomnography
2393520|NCT03617497|Active Comparator|Alzheimer disease|Participants with Alzheimer disease (n=100) will undergo 48 hour scalp EEG and polysomnography
3143251|NCT00005596|Experimental|Arm I|Patients receive IT methotrexate on day 1 followed by methotrexate IV over 20 minutes followed by methotrexate continuously over 23.6 hrs on wks 7, 10, 13, 16,19, and 22. At 42 hrs after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium every 6 hrs for a total of 3 doses. Patients also receive oral mercaptopurine daily beginning on wk 5 and continuing until the completion of consolidation therapy; oral dexamethasone twice daily on days 1-7 of wks 8 and 17; and vincristine sulfate IV on day 1 of wks 8, 9, 17, and 18.
3143252|NCT00005596|Experimental|Arm II|Patients receive methotrexate IV over 4 hours on weeks 7, 10, 13, 16, 19, and 22. At 42 hours after the beginning of the methotrexate infusion, patients receive oral leucovorin calcium as in arm I. Patients also receive mercaptopurine, dexamethasone, vincristine sulfate, and IT methotrexate as in arm I.
2393521|NCT03617497|Experimental|Alzheimer disease with high seizure risk|Selected participants with Alzheimer disease, with higher risk for silent hippocampal seizures after 48 hour scalp EEG and polysomnography (e.g. presence of interictal spikes or frequent nocturnal awakenings) (n=15) will undergo scalp EEG with foramen ovale electrodes with polysomnography
2393522|NCT03617484|Experimental|Bortezomib + Ibrutinib|"Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.~Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle."
2393523|NCT03617471|Experimental|Paracetamol oral tablets 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
2393524|NCT03617471|Experimental|Paracetamol oral granules 1g tid|Patients received paracetamol one gram three times daily. Venopuncture for PK profiling
2393525|NCT03617458|Active Comparator|Metformin + mHealth Intervention|"Patients will receive active ingredient medicine with mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po twice a day (BID) x 5 days, 500mg po three times a day (TID) x 5 days,1000mg po BID x 69 days (12 weeks total)."
2393526|NCT03617458|Placebo Comparator|Placebo + Usual Care|Patient will receive non active medicine and routine medical care.
2393527|NCT03617458|Active Comparator|Metformin + Usual Care|"Patient will receive active ingredient medicine with routine medical care.~Subjects will receive metformin 500mg. Patients will titrate the medication as follows: 500mg po daily x 5 days, 500mg po BID x 5 days, 500mg po TID x 5 days,1000mg po BID x 69 days (12 weeks total)."
2393528|NCT03617458|Placebo Comparator|Placebo + mHealth Intervention|Patient will receive non active medicine and the mHealth texting platform, which are messages designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
3184029|NCT00719979|Active Comparator|Treatment as usual / Wait-list control|Participants received treatment as usual . For wait-list control, participants were not provided any intervention for 6 weeks, after which they were allowed to choose coached or self-directed moodManager.
3184030|NCT00719992|Experimental|1|positive ETT, High HS-CRP
2393531|NCT03617432|Experimental|Experimental group|Experimental group will be treated by Chidamide combined CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
2393532|NCT03617432|Experimental|Control group|Control group will be treated by CHOPE (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Etoposide ) regimen for 6 cycles.
3184031|NCT00719992|Active Comparator|2|positive ETT, Low HS-CRP
2393534|NCT03617406|Other|Arm Volume Challenge|A standard LDDSE will be performed. The stroke volume (SV) will be recorded. The addition of VC with the passive leg raise method at peak dobutamine dose will be performed. A TEE with low dose dobutamine and a bolus of normal saline will be performed as a validation method.
2393535|NCT03617393||Pulmonary Infection with DM group|Patients with diabetes and pulmonary infection.
2393536|NCT03617393||Pulmonary Infection group|Patients with pulmonary infection while the fasting blood-glucose in the normal range.
2393537|NCT03617393||DM group|Patients without pulmonary infection while the fasting blood-glucose > 8 mmol/L.
2393538|NCT03617393||Control group: normal people|Patients without pulmonary infection while the fasting blood-glucose in the normal range.
2393539|NCT03617380|Experimental|PHARMD-TOC i|PharmD Follow-Up Post Discharge
2393540|NCT03617380|Active Comparator|USUAL CARE|Usual Post Discharge Procedures
2393541|NCT03617367|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
2393542|NCT03617354||Trainee Gynaecologists|"RANZCOG accredited O&G specialists who are proficient in RANZCOG laparoscopic skills level 3 or higher;~Surgical capabilities will be assessed using The Global Operative Assessment of Laparoscopic Skills (GOALS) Tool which is an adapted GOALS tool for hysterectomy. GOALS measures depth perception, bimanual dexterity, efficiency, tissue handling and surgeon autonomy each on a 5 point Likert scale. An experienced mentor will assess each surgeon using this scale and skills will be validated against objective outcomes (surgical adverse events recorded in the baseline period).~Will be able to attend each of the 10 training days."
2393543|NCT03617341||Brain MRI|Regular brain MRI can detect early brain metastases in metastatic Breast cancer with high risk subgroups, such as HER2-positive and triple negative.
2393544|NCT03617328|Experimental|Arm A: 6MHP/Montanide ISA-51 + polyICLC + CDX-1127|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176. CDX-1127 (3mg/kg) will be administered intravenously on days 1, 36, and 78.
2393545|NCT03617328|Experimental|Arm B: 6MHP/Montanide ISA-51 + polyICLC|200 mcg of 6MHP plus 0.9 mg of polyICLC emulsified in Montanide ISA-51 adjuvant will be administered subcutaneously on days 1, 8, 15, and 36. 200 mcg of 6MHP in Montanide ISA-51 adjuvant (without polyICLC) will be administered subcutaneously/intradermally on day 176.
2393546|NCT03617315|Experimental|Hyaluronic Acid|One drop application of Hyaluronic acid + Galact-Xyloglucan with a dosage of 3 times a day for 45 days
2393547|NCT03617315|Experimental|CrossLinked Hyalurnic Acid|One drop application of Crosslinked Hylauronic Acid + Liposomes with a dosage of 3 times a day for 45 days
2393548|NCT03617302|Experimental|Beetroot juice|10-grams of nitrate-containing beetroot concentrate diluted in 120-180 milliliters of water.
2393549|NCT03617302|Placebo Comparator|Placebo Beetroot juice|10 grams of nitrate-depleted beetroot concentrate balanced for anti-oxidant content diluted in 120-180 milliliters of water.
2393550|NCT03617289|Experimental|Treatment|Receiving Magnesium Sulfate
2393551|NCT03617289|Placebo Comparator|Placebo|Receiving D5W
2393581|NCT03617003|Experimental|phototherapy with WST11|Patients with urothelial cancer that includes involvement of the upper urinary tract and have failed prior endoscopic treatment, refuse standard treatment, or are ineligible for curative surgical resection of the kidney or ureter will be offered WST11 VTP treatment to be provided at the time of scheduled endoscopic procedure. At the time of endoscopy, patients will be treated with VTP therapy applied to the site of the tumor.
3184032|NCT00720005||Aspheric Acrysof ResTOR Lens|Implantation of Aspheric Acrysof ResTOR
3184033|NCT00720018|Experimental|Period 1|NP101 Patch
2393552|NCT03617276||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the modified nine-hole peg test, the four square step test and the modified clinical test of sensory integration and balance. A doctor will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF2 consultants and one NF2 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy. Each participant will also be required to complete the INFI-QOL questionnaire, the dynamic visual acuity test and provide information about the number of falls/near misses they have had over the past 12 months
3143253|NCT00005596|Experimental|Arm III|Patients receive methotrexate IV as in arm I on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; pegaspargase IM on day 2, 3, OR 4 of wk 16; oral mercaptopurine daily on wks 5-13, and from wk 24 until the completion of consolidation therapy. Patients also receive IT methotrexate as in arm I on wks 7, 10, 13, 16, 20, 21, and 30; oral dexamethasone 2x daily on weeks 8, 16-18, and 28 for a total of 35 days; vincristine sulfate IV on day 1 of wks 8, 9, 16, 17, 18, 28, and 29; daunorubicin hydrochloride IV on day 1 of wks 16-18; cyclophosphamide IV over 30 minutes on day 1 of week 20; cytarabine IV or subcutaneously daily on days 2-5 of wks 20 and 21; and oral thioguanine daily on wks 20-21.
3143254|NCT00005596|Experimental|Arm IV|Patients receive methotrexate IV as in arm II on weeks 7, 10, 13, 24, 27, and 30; leucovorin calcium as in arm I; and pegaspargase, mercaptopurine, IT methotrexate, dexamethasone, vincristine sulfate, daunorubicin hydrochloride, cyclophosphamide, cytarabine, and thioguanine as in arm III.
2393555|NCT03617250||Active patients|50 rheumatoid patients with active disease according to Disease Activity Score-28
2393556|NCT03617250||patients with remission|50 patients with remission according to Disease Activity Score-28
2393557|NCT03617224|Experimental|TSEBT and pembrolizumab|Dose regimens are sequential therapy of TSEBT with Pembrolizumab.
2393558|NCT03617224|Experimental|Radiation: TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
2393559|NCT03617198|Experimental|Cohort 1|Cohort 1 subjects will begin treatment interruption approximately 24 hours after they receive the modified T-cells. All other study procedures are the same as Cohort 2.
2393560|NCT03617198|Experimental|Cohort 2|Cohort 2 subjects will begin treatment interruption approximately 8 weeks after they receive the modified T-cells. All other study procedures are the same as Cohort 1.
3143255|NCT00005597|Experimental|Temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
3184034|NCT00720018|Experimental|Period 2|NP101 Patch
3184035|NCT00720018|Experimental|Period 3|NP101 Patch
3184036|NCT00720018|Experimental|Period 4|NP101 Patch
2393565|NCT03617172|Experimental|Study Drug (Misoprostol)|
2393566|NCT03617172|Placebo Comparator|Placebo|
2393567|NCT03617146|Experimental|Intervention Arm|"Participants in the intervention arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education.~Months 1 to 3: Six 30 to 45-minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement.~Month 3: Follow up distress-specific education.~Months 4 and 5: Two 30 to 45 minute telephone-based health coaching sessions targeting diabetes distress reduction and self-care improvement."
2393568|NCT03617146|Active Comparator|Control Arm|"Participants in the control arm will receive the following interventions:~Month 1: Diabetes Distress-specific Education (same as for the intervention arm).~Month 3: Follow up distress-specific education (same as for the intervention arm)."
2393569|NCT03617133|Other|Standard arm|General and specific aims of EMBRACEII as well as the multiple quantitative hypotheses are based on technical data, dose volume parameters and clinical results of the prospective observational study EMBRACEI (NCT00920920, 3 year data 2015) and the retrospective RetroEMBRACE (3/5 year data 2015). The performance of EMBRACE II interventions and clinical outcome in terms of disease- (local, nodal, systemic control, OS, CSS) and morbidity-outcome (various organs and endpoints) is thus based on recent clinical evidence with radiochemotherapy and image guided adaptive brachytherapy. The expected effect of EMBRACE II interventions on clinical outcome is estimated from comparative analyses of interventions in subgroups of Retro-/EMBRACE (partly published). Based on the Retro-/EMBRACE benchmark, the estimated outcome including a confidence interval is quantified for each clinical endpoint in the overall cohort as well as different subgroups for an overall expected patient number of 1000.
2393570|NCT03617120|Experimental|Ergonomic Brace vs hard brace|"Ergonomic Brace is a new design of scoliosis brace, which consists of a knit bodice as base and also resin bones, paddings, straps and a pelvic belt as auxiliaries for spinal correction. The purpose of the bones is to keep the posture of patient upright. Paddings are placed at the convex regions of the spine while straps are used to input directional force onto the paddings. Pelvic belt, on the other hand, is for stabilizing the pelvis in order to achieve an effective spinal correction. The biomechanical principles for the correction of spine has considered both the frontal and sagittal planes, where the overall brace mechanism follows the Rigo classification.~Hard brace is the brace which the participants are currently using for their ongoing conservative treatment."
2393571|NCT03617094|Experimental|Early percutaneous vertebroplasty (EPV)|Surgical procedure of percutaneous vertebroplasty.
2393572|NCT03617094|Active Comparator|Standard Conservative treatment (CT)|Thoracolumbar corset.
2393573|NCT03617081|Experimental|NNC0113-2023|Participants will receive increasing doses of NNC0113-2023 on day 1. Each participant will receive only a single dose.
2393574|NCT03617081|Placebo Comparator|Placebo|Participants will receive placebo (NNC0113-2023)
2393575|NCT03617068|Active Comparator|Coconut Oil Cream|This group consist of batik traditional workers who use coconut oil cream for 2 weeks.
2393576|NCT03617068|Placebo Comparator|Placebo Cream|This group consist of batik traditional workers who use placebo cream which contained the vehiculum of the cream; using for 2 weeks.
2393577|NCT03617029|Experimental|Microcoil|Needle localization for deep-seated lung nodules with microcoil placement
2393578|NCT03617029|Active Comparator|Contrast|Needle localization for deep-seated lung nodules with contrast injection
2393579|NCT03617016|Experimental|Domperidone|Participants will receive domperidone 10 milligram (mg) tablets orally thrice in a day from Day 1 to Day 14.
3143256|NCT00005601|Experimental|rituximab+dexamethasone+cisplatin+cytarabine+sargramostim|"Patients receive rituximab IV on days 1, 8, 15, and 22 for the first course only. Patients receive dexamethasone orally or IV on days 1-4, cisplatin IV continuously for 24 hours on day 1, cytarabine IV over 3 hours every 12 hours for 2 doses on day 2, and sargramostim (GM-CSF) subcutaneously on days 3-12 or until blood counts recover. Chemotherapy repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
3143257|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 20 Days|
3184037|NCT00720018|Experimental|Period 5|NP101 Patch
3184038|NCT00720070|Experimental|Arm I|Patients receive standard concurrent chemoradiotherapy (CRT). Patients undergo PET/CT scan at 9-13 weeks after completion of CRT. Patients with complete response of primary site undergo neck dissection within 4 weeks.
3143258|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 25 Days|
3143259|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 30 Days|
3143260|NCT00005602|Experimental|Radiation Therapy, 33 Doses; Carboplatin 35mg^m2 for 33 Days|
2393589|NCT03616938|Experimental|the two finger chest compression technique|Two finger technique (TFT): the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant cardiopulmonary resuscitation by international resuscitation guidelines
2393590|NCT03616938|Experimental|the two thumb chest compression technique|Two thumb technique (TTHT): the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
2393591|NCT03616938|Experimental|the new two thumb chest compression technique|'new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90° to the chest while closing the fingers of both hands in a fist
2393592|NCT03616925|Experimental|Platelet rich fibrin matrix|surgical open flap debridement with Application of Platelet rich fibrin matrix using Platelet Rich Fibrin Matrix kit in 15 intrabony defect sites
2393593|NCT03616925|Active Comparator|surgical open flap debridement|only surgical open flap debridement was done without application of Platelet rich fibrin matrix in 15 intrabony defect sites
3143261|NCT00005604|Experimental|Treatment (rhIl-12, IL-2)|Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
3143262|NCT00005605||Tamoxifen group|
3143263|NCT00005605||Chemotherapy group|
2393599|NCT03616886|Experimental|Phase I and Phase II Arm A|Patients are treated with paclitaxel, carboplatin, durvalumab and oleclumab.
2393600|NCT03616886|Active Comparator|Phase II Arm B|Patients are treated with paclitaxel, carboplatin and durvalumab.
2393601|NCT03616873||Adults aged 60 or older|
2393602|NCT03616860|Experimental|Focused Ultrasound (FUS) BBB Disruption|The Exablate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing standard of care chemotherapy.
2393603|NCT03616847|Experimental|Standard care|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will remain inflated until the wound is closed.
2393604|NCT03616847|Experimental|Tourniquet release|Participants will have hallux valgus/hallux rigidus surgery using a calf tourniquet which will be removed. There will be a five minute delay before the wound is closed.
2393605|NCT03616834|Experimental|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) will be taken at 200 mg twice daily (bid). Subjects will continue their anti-PD-1/anti-PD-L1 therapy, which they had already initiated per standard of care according to the package insert.
3143264|NCT00005610|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) over 10-15 minutes twice daily for 7 days. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and prior to course 5.~Patients are followed every 2 months for at least 1.5 years."
3143265|NCT00005613|Experimental|Autologous Transplant|autologous hematopoietic progenitor cell transplant
3143266|NCT00005613|Experimental|Allogeneic Transplant|allogeneic hematopoietic progenitor cell trasnplant
2393609|NCT03616808|No Intervention|Conventional therapy|Intraoperative haemostatic treatment is based on conventional coagulation assays.
2393610|NCT03616808|Active Comparator|Goal-directed therapy|Thromboelastometry-guided haemostatic treatment is provided intraoperatively.
2393611|NCT03616795|Experimental|LY3154207 and [14C]-LY3154207|A single dose of LY3154207 and [14C]-LY3154207administered orally.
2393612|NCT03616782|Experimental|Ixazomib|Ixazomib 3mg on day a, 8, 15 q 4 weeks for 24 months or until to progression
2393613|NCT03616769||quantiles of serum uric acid level|quantiles according to the patient's serum uric acid level
2393614|NCT03616756|Experimental|Intervention group|
2393615|NCT03616756|Active Comparator|Control group|
2393616|NCT03616743|Experimental|Brief pain and smoking arm|The experimental arm incorporated a novel psychoeducational component that addressed associations between cigarette smoking and chronic pain
2393617|NCT03616743|Active Comparator|Brief smoking control arm|"The brief smoking control arm was comprised of the 5A's of smoking cessation."
3143267|NCT00005614|Experimental|Gemcitabine Treatment|Patients receive gemcitabine IV over 1 hour weekly for 7 consecutive weeks in an 8 week course. Treatment then continues weekly for 3 consecutive weeks in 4 week courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed prior to treatment and then every 12 weeks. Patients are followed every 3 months for 2 years, then every 6 months until year 5, and then annually thereafter.
2393677|NCT03616353|Experimental|Group 1: Corticosteroid Injection|Patients in this group will undergo an injection of corticosteroid into the carpal tunnel as per current treatment practices.
3143268|NCT00005615|Experimental|Interferon Alfa Plus Radiation|"Combined Therapy: interferon alfa plus radiation therapy.~Patients receive interferon alfa IV over 20 minutes daily for 5 consecutive days a week for 4 weeks. Patients then receive radiotherapy on days 2 and 4 and interferon alfa subcutaneously (SQ) on days 1, 3, and 5 for 2.5 weeks. Interferon alfa SQ continues 3 times a week for 10 months in the absence of disease progression or unacceptable toxicity. Patients are followed every month for 3 months, then every 3 months for 2 years, then every six months until year 5, and then annually thereafter."
2393620|NCT03616717|Active Comparator|modafinil 100 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
2393621|NCT03616717|Active Comparator|modafinil 200 mg|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
2393622|NCT03616717|Placebo Comparator|placebo|"Drug: modafinil, Provigil, Alertec, Modavigil~Dosage form, frequency and duration: Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week."
2393623|NCT03616691|Experimental|Atezolizumab|The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
2393624|NCT03616691|Experimental|Atezolimab+Bevacizumab|Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy (stage 2). Both of drugs are administered via intravenous infusion every 3 weeks.
2393625|NCT03616678|Experimental|VenTouch System Implant|"The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is indicated for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable to annular and/or ventricular dilation. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is intended to provide ventricular support that will encourage beneficial remodeling of the heart and, with adjustable inflatable chambers, it is intended to reduce annular dilation, correct papillary muscle displacement, and restore mitral valve leaflet coaptation, allowing proper closure of the valve, and reducing or eliminating MR. The VenTouch System is indicated for patients who have moderately severe or severe mitral regurgitation (grade 3 or 4 MR)."
2393626|NCT03616665|Other|CBASPersonalized|Within the psychotherapy CBASPersonalized, the original specific six interpersonal CBASP strategies are augmented with intrapersonal evidence-based strategies. According to the frequently diagnosed comorbid disorders of PDD the following modules have been added: a) treatment of anxiety disorders and treatment of traumatic experiences, b) regulating intensive emotions, c) coping with resistant problems like pain, and d) relapse prevention. In addition, therapists adjust their strategies and therapeutic relationship according to the impairment in personality functioning and maladaptive personality traits of the patient.
2393627|NCT03616652|Experimental|Non-deceptive placebo group (additional information)|Participants receive a placebo pill and are told that it is placebo. They receive additional information about the power of placebo effects via a film sequence before they take the placebo.
2393628|NCT03616652|Placebo Comparator|Non-deceptive placebo group (no additional information)|Participants receive a placebo pill and are told that it is placebo. They do not receive additional information about placebo effects. Instead, they watch a neutral film sequence about sleep.
2393629|NCT03616639|Experimental|Oxycodone|Continuous subcutaneous infusion (CSCI) of oxycodone.
2393630|NCT03616639|Active Comparator|Morphine|Continuous subcutaneous infusion (CSCI) of morphine.
2393631|NCT03616626|Active Comparator|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
2393632|NCT03616626|Experimental|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
2393633|NCT03616626|Experimental|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
2393634|NCT03616613||Men|Men born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
2393635|NCT03616613||Women|Aleatory sample of women born in 1952 in Barcelona in health areas depending from Hospital de la Santa Creu i Sant Pau.
3143269|NCT00005617|Experimental|Group A|No. DC: 10^5 Route of Immunization: ID
3143270|NCT00005617|Experimental|Group B|No. DC: 10^5 Route of Immunization: IV
3143271|NCT00005617|Experimental|Group C|No. DC: 10^6 Route of Immunization: ID
3143272|NCT00005617|Experimental|Group D|No. DC: 10^6 Route of Immunization: IV
3143273|NCT00005617|Experimental|Group E|No. DC: 10^7 Route of Immunization: ID
3143274|NCT00005617|Experimental|Group F|No. DC: 10^7 Route of Immunization: IV
3143275|NCT00005622|Other|Cy/TBI|cyclophosphamide and total body irradiation (TBI)
3143276|NCT00005624|Experimental|CI-994 Treatment|Patients receive CI-994 orally daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 30 days and then every 2 months.
2393651|NCT03616561||Apremilast|The cohort will be recruited in Hospital General de Granollers and Hospital Moises Broggi
2393652|NCT03616548|Other|Intestinal transplantation|Magnifying endoscopy under NBI system via chimney ileostomy after intestinal transplantation using a novel VENCH scoring system
2393653|NCT03616535|Active Comparator|Cognitive training|"Participants randomized to CT will play brain games on a tablet. They will be asked to engage in the activity for a minimum of 30 minutes during each hemodialysis session for 6 months. At each HD session, participants will have 10 different brain games to play and the games will vary for each session."
2393654|NCT03616535|Active Comparator|Exercise training|"Participants randomized to the ET arm will be given a stationary foot peddler and will be asked to engage in the activity for a minimum of 30 minutes at each hemodialysis session for 6 months. ET will start with a 2 minute warm up, then the resistance will be adjusted so that participants are working at perceived exertion of somewhat strong, using the Borg scale (87) (~50 rpm). Resistance will be increased when the rating falls below somewhat hard."
2393655|NCT03616535|Active Comparator|Combined cognitive and exercise training|"Participants in the CT+ET arm will start with 30 minutes of CT (playing brain games on tablet) with a 15-minute break, and then, 30 minutes of ET (stationary foot peddler)."
2393656|NCT03616535|No Intervention|Standard of Care|Participants in this arm will receive standard of care
2393657|NCT03616509|Experimental|Placebo and Growth Hormone|2 months on placebo followed by 12 months on GH
3143277|NCT00005626|Experimental|Irinotecan Treatment|Patients receive irinotecan IV over 90 minutes on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for 2-6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.
2393663|NCT03616457||All Study Participants|All study participants will undergo the same study procedures, including Automated Breast Ultrasound (ABUS).
2393664|NCT03616444|Experimental|TCM-Xiaoai Jiedu Decoction|Xiaoai Jiedu Decoction：Oldenlandia 20g,kuh-seng 9g,Codonopsis pilosula 15g,bighead atractylodes rhizome 12g,smoked plum 9g,the rhizome of Chinese goldthread 3g,RHIZOMA ZINGIBERIS PREPARATA 6g,Semen Coicis 20g. Take one pack a day, divided into twice one day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.
2393665|NCT03616444|Placebo Comparator|TCM-Xiaoai Jiedu Decoction Placebo|The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years.
2393666|NCT03616431||Demographic cohort|A prospective cross-sectional assessment of the prevalence of PEI-related symptoms in up to n=150 patients with pancreatic malignancy.
2393667|NCT03616431||Diagnosis cohort|"A sub-set (up to n=50) of the Demographic cohort patients will be tested to elucidate the most efficient diagnostic panel for PEI in pancreatic malignancy.~An extra assessment for PEI diagnosis consisting of a breath test (Pancreo-KIT breath test) will be carried out during the following 1-2 weeks after the first appointment (which takes around six hours to complete and involves the administration of bread spread with 13C butter followed by collection of the patient's breath in small plastic vials at timed intervals. The vials will subsequently be analyzed for 13C quantity; details in Appendix 6). Following these diagnostic tests, patients will complete an acceptability questionnaire to assess their opinion regarding the burden that these diagnostic tests may add."
2393668|NCT03616431||Follow-up cohort|Validation of the diagnostic panel designed and tested in Step-1 of this study and evaluation of dietician intervention (including Pancreatic Enzyme Replacement Therapy; PERT) and its impact in weight loss, symptom evolution, chemotherapy receiving rate, quality of life and overall survival.
2393669|NCT03616405|Experimental|14-day modified sequential therapy|"All the participants will go through a gastroscopy. Biopsy specimens will be taken for histologic assessment and rapid urease test. Two additional biopsy samples will be obtained from the antrum and body for bacterial culture and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.~Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication irrespective of antimicrobial susceptibility test results. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.~Drugs: 1. rabeprazole 10mg bid for 14 days, 2. amoxicillin 1000mg bid for 14 days, 3. tetracycline 500mg qid for 14 days, 4. furazolidone 100mg tid for the firs 7 days, 5. colloidal bismuth pectin 200mg bid for the second 7 days."
2393670|NCT03616392|Experimental|Part 1: Group 1(Treatment A/Treatment B)|Period 1: Treatment A (D308 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
2393671|NCT03616392|Experimental|Part 1: Group 2(Treatment B/Treatment A)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment A (D308 1T)/day for 5days, QD, PO
2393672|NCT03616392|Experimental|Part 2: Group 1(Treatment C/Treatment B)|Period 1: Treatment C (CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO
2393673|NCT03616392|Experimental|Part 2: Group 2(Treatment B/Treatment C)|Period 1: Treatment B (D308 1T + CKD-501 1T)/day for 5days, QD, PO Period 2: Treatment C (CKD-501 1T)/day for 5days, QD, PO
2393678|NCT03616353|Experimental|Group 2: Perineural Hydrodissection|Patients in this group will undergo a perineural hydrodissection plus an injection of corticosteroid into the carpal tunnel, as a novel technique.
2393679|NCT03616340|Experimental|Ketorolac|
2393680|NCT03616340|Experimental|Kenalog|
2393681|NCT03616327|Other|MATRx in-lab or MATRx plus test|Participants will undergo the MATRx in-lab or MATRx plus home test to determine adequacy for mandibular repositioning oral appliance therapy. The tests only differ in their setting (i.e., in the sleep lab or at home). All participants will receive the same treatment protocol preceding and following the MATRx/MATRx plus test.
2393682|NCT03616314||stepping verticalization|in ICU they received conventional physiotherapy + stepping verticalization sessions with Erigo
2393683|NCT03616314||stepping verticalization + FES|in ICU they received conventional physiotherapy + stepping verticalization sessions with FES using ErigoPro
2393684|NCT03616314||conventional physiotherapy|in ICU they received only conventional physiotherapy
2393685|NCT03616301|Experimental|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the test product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2393686|NCT03616301|Active Comparator|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml is the reference product. 14 of 28 subjects in each of two cohorts (total number of enrolled volunteers - 56) will be given single oral dose (5 ml containing 400 mg of amoxicillin and 57 mg of clavulanic acid) in period 1 and period 2 of the clinical part of the study.
2393687|NCT03616288|Placebo Comparator|Negative Control|placebo; 0 mg thiamine
2393688|NCT03616288|Experimental|EAR Group|1.2 mg thiamine as thiamine hydrochloride
2393689|NCT03616288|Experimental|Double EAR Group|2.4 mg thiamine as thiamine hydrochloride
2393690|NCT03616288|Experimental|Positive Control|10 mg thiamine as thiamine hydrochloride
2393691|NCT03616275|Experimental|HRV biofeedback group|8 once-a-week, individual, 30-min sessions of HRV biofeedback and 1 session of healthy lifestyle education
2393692|NCT03616275|No Intervention|control group|1 session of healthy lifestyle education
2393693|NCT03616262|Active Comparator|Phase 1|In Phase 1, subjects will receive either Treatment A (Lidocaine alone) or Treatment B (Botox+Lidocaine )
2393694|NCT03616262|Active Comparator|Phase 2|In Phase 2, subjects will receive either Treatment B (Botox+Lidocaine) or Treatment A (Lidocaine alone) -- the opposite of what was administered in Phase 1
2393695|NCT03616249|Experimental|Sleep quality|To compare if elderly sartcopics present sleep losses at higher levels than non-sarcopenic elderly
2393696|NCT03616249|Experimental|sleep-wake cycle.|To compare if elderly sarcopenics present sleep-wake cycle. disorders at higher levels than non-sarcopenic elderly
2393697|NCT03616249|Active Comparator|Exercise And Sleep quality|Comparing resistance training in the sarcopenician elderly showed improvements in sleep patterns.
2393698|NCT03616249|Active Comparator|Exercise And sleep-wake cycle.|Comparing resistance training in the elderly with sarcopenia presents better sleep-wake cycle.
2393699|NCT03616236|Active Comparator|TAU|Participants will receive a referral to buprenorphine treatment in the community.
2393700|NCT03616236|Experimental|BBT|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
2393701|NCT03616223|Experimental|FX-322 Low Dose|Single intratympanic injection of a hydrogel formulation
2393702|NCT03616223|Experimental|FX-322 High Dose|Single intratympanic injection of a hydrogel formulation
2393703|NCT03616223|Placebo Comparator|Placebo|Single intratympanic injection of a hydrogel formulation
2393704|NCT03616210|Experimental|Protective ventilation|Protective ventilation strategy (tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O)
2393705|NCT03616210|No Intervention|Conventional ventilation|Conventional mechanical ventilation (tidal volume between 9 to 10 ml.kg-1 of predicted body weight and PEEP between 3 and 5 cmH2O)
2393706|NCT03616197|Active Comparator|Group 1|"Thin Biotype group has described as Group 1. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thin biotype, the patient was assigned to the thin biotype group."
2393707|NCT03616197|Active Comparator|Group 2|"Thick biotype group has described as Group 2. The biotypes of the terminal teeth adjacent to the free gingival graft region were determined by the Probe transparency method.~The mesial terminal tooth (MTT) was defined as the first tooth adjacent to the mesial side of the tooth / teeth to which the FGG will be applied. The distal terminal tooth (DTT) was defined as the first tooth adjacent to the distal side of the tooth / teeth to which the FGG will be applied. If MTT and DTT had thick biotype, the patient was assigned to the thick biotype group."
2393708|NCT03616184|Experimental|Ruxolitinib|Patients will receive oral ruxolitinib at a dose of 10 mg twice daily.
3184039|NCT00720070|Active Comparator|Arm II|Patients undergo neck dissection and receive standard concurrent CRT. Patients undergo PET/CT scan at 9-13 weeks after completion of CRT.
3184040|NCT00720135|Experimental|Arm I|Patients receive DI-Leu16-IL2 immunocytokine IV over 4 hours on 4 consecutive Wednesdays. Patients with detectable CD20-positive B-cells pretreatment also receive rituximab IV on 4 consecutive Tuesdays. Treatment repeats every 6-8 weeks for up to a maximum of 4 courses in the absence of disease progression or unacceptable toxicity.
2393762|NCT03615781|Experimental|Two week's arm - surgery|The investigators perform a surgical drainage and removal of the infected orthopedic implant.
2441909|NCT03284502|Experimental|Stage 2 (Cohort III)|Dose-expansion
3184041|NCT00720161|Active Comparator|A|Metformin during 12 months and then 6 months Placebo
3184042|NCT00720161|Placebo Comparator|B|Placebo during 6 months, afterwards 12 months metformin
2393711|NCT03616158||Pre-RA|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and positive antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2393712|NCT03616158||RA without LD|"Subjects with rheumatoid arthritis (RA), and no interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2393713|NCT03616158||RA-LD|"Subjects with rheumatoid arthritis (RA) and interstitial lung disease (ILD) or airways disease, will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2393714|NCT03616158||LD Controls|"Subjects with interstitial lung disease (ILD) or airways disease, no rheumatoid arthritis (RA), and negative antibodies will participate in 5 in-person study visits. Additionally, quality of life questionnaires will be mailed/emailed and completed at home every 6 months, at 4 different time points. Overall participation will take place over a 4 year time frame and an additional 6 years of survival follow-up.~In-person Study Assessments Include:~Medical History and Physical Exams~Quality of Life Questionnaires~Collection of blood~Radiology~Lung Function Test~6 Minute Walk Test~Bronchoscopy (Clinically indicated)~Sputum (Optional)~Musculoskeletal ultrasound (Optional)"
2393715|NCT03616145|Experimental|Osteopathic Manipulative Treatment (OMT)|Participants assigned to the OMT arm will receive 6 weekly sessions. The provider will perform the following 14 osteopathic procedures 1) lateral (and anteroposterior) translation of vertebrae in the thoracic/lumbar spine; 2) active myofascial stretch to the thoracic spine; 3) occipito-atlanto release; 4) translation of cervical spine; 5) muscle energy techniques of the cervical spine; 6) Spencer technique applied to the shoulder bilaterally; 7) supination/pronation of the forearm; 8) circumduction of the wrist; 9) sacroiliac joint gapping; 10) muscle energy technique applied to adductor muscles of lower extremity; 11) psoas muscle energy technique; 12) hamstring muscle energy technique; 13) articulatory technique applied to the ankle; 14) and muscle energy technique applied to the ankle in dorsi and plantar flexion. Further, each subject will receive cranial assessment and treatment emphasizing the venous sinus techniques and compression of the fourth ventricle (CV-4).
2393716|NCT03616145|Sham Comparator|Light Touch|Participants assigned to the light touch comparator arm will receive 30 minutes of light touch procedures designed to be credible but minimally effective. The procedures for the light touch arm are adapted from the methodology established in the North Texas Chronic Low Back Pain Trial, and have been used successfully by the PI as a comparator arm numerous times in the past (e.g., in the OSTEPAThic Trial). Subjects assigned to receive light touch will be treated in positions similar to subjects receiving OMT. Light touch will target each of the 15+ anatomic regions for approximately 1 ½ to 2 minutes each to appropriately control for time, attention, and physical contact. Light touch hand placement will be over the same areas of the body contacted in the OMT protocol, but involve virtually no motion of a meaningful nature, such a range of motion testing which could have therapeutic effect.
2393717|NCT03616145|No Intervention|Standard of Care Only|Subjects will continue their usual care and will visit the UCSD for the 4 assessment sessions only, during their course of study participation.
2393718|NCT03616132|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions.
2393720|NCT03616093|Experimental|Test Beet shot|Active supplement containing 6.2 mmol nitrate
2393721|NCT03616093|Placebo Comparator|Placebo beverage|Placebo supplement containing negligible nitrate
2393722|NCT03616080|Experimental|experimental|children who participated in soccer play program usual activity and therapy + soccer play program (once a week for eight weeks)
2393723|NCT03616080|No Intervention|control|children without soccer paly program usual activity and therapy
2393724|NCT03616067|Experimental|Botox® injection arm|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars).
2393725|NCT03616067|Active Comparator|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear
2393726|NCT03616041||Colon capsule endoscopy|Participant who meet the eligible criteria undergo an evaluation for severe hematochezia with a second-generation colon capsule endoscopy system in addition to standard diagnostic tests including tagged RBC scan, and/or computerized tomographic angiography (CTA), and/or conventional angiography.
3143278|NCT00005629|Experimental|Group A - first dosing group|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.
2393728|NCT03616015|Experimental|Patient|"For all patients included in the study, the following interventions will be performed :~several blood samples (quantity collected requiring classification of this study as interventional according to French law)~several fecal samples~anxiety tests~stress tests"
2393729|NCT03616002|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo brachial artery flow mediated dilation, reactive hyperemia peripheral arterial tonometry or pulse tonometry before and after Hookah smoking.
2393763|NCT03615781|Active Comparator|Four week's arm - surgery|The investigators surgically remove the infected implant.
2393730|NCT03615989|Placebo Comparator|Exercise and Carbohydrate (CHO)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, 50g of carbohydrate (maltodextrin) + water was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 50g of carbohydrate was consumed with water 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
2393731|NCT03615989|Experimental|Exercise and Milk (Milk)|Participants had a fasted, baseline blood sample (10ml) taken upon arrival to the lab. They then completed a supervised resistance and plyometric exercise bout. Immediately following exercise, ~500 ml of skim milk was consumed. Two more blood samples followed the exercise bout at 5 minutes post (10ml) and 1 hour post (10ml). An additional 500 ml of skim milk was consumed 1 hour post exercise. Two more fasting blood samples (10ml) were taken 24 and 48 hours later.
3143279|NCT00005629|Experimental|Arm B - dosing group 2|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.
3143280|NCT00005629|Experimental|Group 3 - dosing level 3|Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.
2393734|NCT03615963||normal|patient complains of anginal chest pain but coronary angiography is normal
2393735|NCT03615963||coronary artery disease|patient complains of chest pain with coronary angiography showing atherosclerotic plaques causing luminal obstruction
2393736|NCT03615950||Intervention Group|30 Children with eosinophilic esophagitis who are started on swallowed corticosteroids by their clinical provider.
2393737|NCT03615950||Control Group|30 children, 5-12 years of age, not taking swallowed corticosteroids. Age and sex matched 1:1 with intervention group.
2393738|NCT03615937|Experimental|Comprehensive Intervention|"This is a holistic package of interventions, including:~Child interactive intervention (dialogic reading and play intervention)~Family Empowerment (positive parenting and grandparenting)~Access to Community Hub and its services~Enhancement to the kindergartens~Health education, screening, and support"
2393739|NCT03615937|Active Comparator|Health Support|"This is a control arm with only health components.~1. Health education, screening, and support"
2393744|NCT03615885|Placebo Comparator|Placebo Drink|Placebo drink attempted to match for total energy, appearance and taste of Montmorency tart cherry juice.
2393745|NCT03615885|Experimental|Montmorency Tart Cherry Capsules|10 capsules consumed to match total anthocyanin content to Montmorency tart cherry juice.
2393746|NCT03615885|Experimental|Montmorency Tart Cherry Juice|Single-bolus of Montmorency tart cherry juice (130 mL)
2393747|NCT03615859||Healthy volunteers|Healthy volunteers whose data represents a negative control
2393748|NCT03615859||Prednisolone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of prednisolone
2393749|NCT03615859||Hydrocortisone replacement group|Participants with adrenal insufficiency who are treated with replacement doses of hydrocortisone
2393750|NCT03615859||New adrenal insufficiency group|Participants who have recently been given a new diagnosis of adrenal insufficiency
2393751|NCT03615859||High dose steroids groups|Participants who are treated with high dose steroids for management of any medical condition to serve as a positive control
2393752|NCT03615846||Dual Anti-Platelet Therapy (DAPT)|"Whole blood from patients who are currently receiving Dual Anti-Platelet Therapy (DAPT) Clopidogrel and aspirin (ASA) for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
2393753|NCT03615846||One Anti Platelet Medication Only|"Whole blood from patients who are currently receiving either ASA or Clopidogrel alone for a minimum of 4 weeks (on-drug) will be used to conduct antiplatelet reactivity tests using VerifyNow assay and LTA with AggRAM Aggregometer with and without PGE1.~There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care."
2393754|NCT03615846||naive|No medication with anti-platelet effects There is no drug administration or therapeutic intervention in this study. The results of platelet activation testing using VerifyNow performed in this study are not used to influence patient care.
2393755|NCT03615833|Experimental|Patients with Vitamin D deficiency|Patients with Vitamin D deficiency, Administration of Cholecalciferol 2.5 mg (100 000 UI), once a month for 3 months
2393756|NCT03615820|Experimental|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which PPE entrapped in niosomes then incorporated in oromucoadhesive films
2393757|NCT03615820|Placebo Comparator|Oromucoadhesive film|Oromucoadhesive film that has no niosomal PPE in its content
2393760|NCT03615794||Pregnant women with Mood Disorders|Pregnant women with a history or current diagnosis of Major Depressive Disorder or Bipolar Disorder
2393761|NCT03615794||Healthy controls|Pregnant women without a history or current diagnosis of a mood disorder.
3143281|NCT00005632|Experimental|Vaccine|Patients sequentially will receive glycosylated MUC-1-KLH vaccines at 3ug per vaccination.
3143282|NCT00005639|Experimental|Regimen A: 14-day 5-AC with intermittent phenylbutyrate|"Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.~Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC"
3143283|NCT00005639|Experimental|Regimen B: 7-day 5-AC with sequential phenylbutyrate|"Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days~Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV"
3143284|NCT00005639|Experimental|Regimen C: 21-day 5-AC with weekly phenylbutyrate|"Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.~Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC"
2393764|NCT03615781|Experimental|Two week's arm - drugs|The investigators perform a surgical drainage and removal of the infected orthopedic implant. They start an empirical antibiotic treatment based on patient's history and co-morbidities, such as vancomycin or amoxicillin/clavulanic acid. The adapt later on the targeted antibiotic therapy according to the causative pathogens and their antibiotic susceptibility testing.
2393765|NCT03615781|Active Comparator|Four week's arm - drugs|The investigators surgically remove the infected implant and all soft tissue infection. Instead of a total of 2 week's of antibiotic therapy, they administer a total of 4 weeks of systemic antibiotic therapy targeted to the pathogen(s).
2393766|NCT03615768|Experimental|Adapalene-Clindamycin Combination Gel|
2393767|NCT03615768|Active Comparator|Adapalene Gel|
2393768|NCT03615768|Active Comparator|Clindamycin Gel|
2393769|NCT03615755|No Intervention|Standard Therapy|Standard Therapy (controlling blood sugar, antibiotic drug, ulcer debridement, wound care, offloading)
2393770|NCT03615755|Active Comparator|Combination Therapy|Standard Therapy with adjuvant Hyperbaric Oxygen Therapy (Total 10 sessions, each session used pressure 2.4 ATA for 90 minutes per day)
3143285|NCT00005640|Experimental|Mapping and Biopsy|Lymph node mapping and sentinel lymph node biopsy. Patients undergo preoperative endoscopy with injection of technetium Tc 99m sulfur colloid around tumor followed by celiotomy and intraabdominal exploration. At 30 minutes following injection, patients undergo lymphatic mapping with a gamma probe and biopsy of the sentinel lymph node(s). Following biopsy and mapping, patients undergo resection of primary tumor.
3143286|NCT00005646|Experimental|Paclitaxel|Patients receive paclitaxel for up to 4 cycles. One cycle = weekly drug for 6 weeks and 2 weeks rest
3143287|NCT00005648|Experimental|001|Gemcitabine with R115777 R115777 200 mg oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
3143288|NCT00005648|Placebo Comparator|002|Gemcitabine with Placebo Placebo oral twice daily at 12-hour intervals throughout the study coadministered with gemcitabine 1000 mg/m2 iv every week for the first 7 weeks followed by 1 week rest and then every 3 out of 4 weeks thereafter for up to 5 years
2393775|NCT03615729||Rheumatoid arthritis patients|A total of 55 rheumatoid arthritis patients diagnosed according to 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria recruited from Clinical Rheumatology unit, Internal Medicine, Assiut University Hospitals
2393776|NCT03615729||controls|A total of 33 age and sex matched healthy controls randomly selected from healthy volunteers
2393777|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Boys|A study examining middle school boys who have a high potential of violence based on where they live. This arm will measure outcomes in the boys. as the result of the intervention, from the perspectives of the boys.
2393778|NCT03615716|Experimental|Multi-level Violence Prevention Intervention - Caregivers|In this study examining middle school boys who have a high potential of violence based on where they live, this arm will measure caregivers' perspectives of the boys ' outcomes. Caregivers will be surveyed pre-intervention and 4- and 6-month post intervention to explore the impact of the boys' intervention.
2393779|NCT03615690|Experimental|Fasting Mimicking Diet|Three cycles of a 5-day reduced calorie diet
2393780|NCT03615690|Placebo Comparator|Regular Diet Control Arm|
2393781|NCT03615677|Experimental|LXI-15028 50mg group (n=130)|
2393782|NCT03615677|Active Comparator|Esomeprazole 40mg group (n=130)|
2393783|NCT03615664|Experimental|BGD therapy|Bendamustine, Gemcitabine, Dexamethasone
2393784|NCT03615651|Placebo Comparator|Placebo|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
2393785|NCT03615651|Experimental|Probiotic|All study participants will receive the study product and the placebo in a randomized, double-blind crossover fashion. Probiotic and placebo products have similar appearance and taste.
2393786|NCT03615638|Experimental|Fall prevention group|Fall prevention program
2393787|NCT03615638|No Intervention|Usual care group|Usual postoperative care
2393788|NCT03615638|No Intervention|Asymptomatic control|No intervention
2393789|NCT03615625|No Intervention|Control session|Control session without any exercise. The participants remained in seated rest throughout 40 min
2393790|NCT03615625|Experimental|Power Training Session|The power training session lasted 40 min, in which the participants performed a resistance exercise session using high velocity contractions during the exercises characterizing a power training session
2393791|NCT03615612|Other|OR Eyeglasses, then SR|Objective Refraction (OR) Eyeglasses, then Subjective Refraction (SR)
2393792|NCT03615612|Other|SR Eyeglasses, then OR|Subjective Refraction (SR) Eyeglasses, then Objective Refraction (OR)
3143289|NCT00005655|Experimental|1|rhIL-12 in combination with rhIL-2
2393794|NCT03615586|Active Comparator|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone. The intervention consists of the presence of a female chaperone.
2393795|NCT03615586|Active Comparator|Without Chaperone|Female patients examined by male physicians without a chaperone. The intervention is the absence of a female chaperone.
2393796|NCT03615560||Preeclampsia (mild)|
2393797|NCT03615560||Preeclampsia (severe)|
2393798|NCT03615560||Gestational hypertension|
2393799|NCT03615560||Control group|
2393800|NCT03615547|Experimental|Clomifene citrate group|a daily dose of 50mg of Clomifene Citrate per os during 9 months
2393801|NCT03615547|Experimental|Placebo group|a daily dose of 50mg per os of placebo (lactose monohydrate) during 9 months.
3143290|NCT00005675|Experimental|1|Participants will receive oral bovine type I collagen (CI) daily for 15 months
3143291|NCT00005675|Placebo Comparator|2|Participants will receive placebo daily for 15 months.
3143292|NCT00005676||VA-HIT and FOS|VA-HIT cohort: men with established CHD and low HDL-C FOS cohort: men without CHD
3143293|NCT00005699||Hypertensive|described as hypertensive according to AHA guidelines at time of trial
3143294|NCT00005699||Controls|described as non-hypertensive according to AHA guidelines at time of trial
3184043|NCT00720174|Experimental|Treatment (cixutumumab and doxorubicin hydrochloride)|Patients receive cixutumumab IV over 1 hour on days 1, 8, and 15 and doxorubicin hydrochloride IV continuously over 44-52 hours beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive cixutumumab in the absence of disease progression or unacceptable toxicity.
2393806|NCT03615521|Experimental|Repeated Contraction Exercise Group|Repeated Contractions Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute and Repeated Stretch (Repeated Contractions) exercise. Repeated Contractions exercise is type of Proprioceptive Neuromusculer Facilititation Exercise. 3 session for 6 weeks.
2393807|NCT03615521|Experimental|Combine Exercise Group|"Combination of Isotonics Exercise Group, Hotpack apply for knee 20 minute, Ultrasound is a termal ajan which use for 10 minute Combination of Isotonics Exercise. Combination of Isotonics Exercise is type of PNF. Combined concentric, eccentric, and stabilizing contractions of one group of muscles (agonists) without relaxation.~3 Session for 6 weeks."
2393808|NCT03615521|Experimental|Standart Exercise Therapy|"Classic Physiotherapy: Hotpack, Ultrasound, Standart exercise program to improve Quadriceps, Hamstring and hip muscle strength.~3 session for 6 weeks."
3184044|NCT00720200|Experimental|1|
2393810|NCT03615495||Flourish device|The Flourish Pediatric Esophageal Atresia device is indicated for use in lengthening atretic esophageal ends and creating an anastomosis with a non-surgical procedure in pediatric patients.
3184045|NCT00720200|Active Comparator|2|
3184046|NCT00720239|No Intervention|0|
2393813|NCT03615469|Active Comparator|Neuromusclar electrical stimulation|"NMES will be set up with the machine on simultaneous large muscle atrophy setting with 500 ohm with peak of 50 volts, the self-adhesive electrodes positioned on the thighs approximately 5 cm below the inguinal fold and 3 cm above the upper patella border as described by Gobbo. When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality. It is expected that tolerance will develop and intensity will increase over time."
2393814|NCT03615469|Sham Comparator|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation
2393815|NCT03615456|Active Comparator|Conventional thyroidectomy|Thyroidectomy with ligation and division of thyroid vessels
2393816|NCT03615456|Active Comparator|Harmonic scalpel thyroidectomy|Thyroidectomy with sealing of thyroid vessels using harmonic scalpel
2393817|NCT03615443||Treatment-naive metastatic non-squamous NSCLC|
2393818|NCT03615430|Placebo Comparator|Control group|saline control group, 15 mL of the saline was administered to superficial and deep surface of serratus anterior in Control group via ultrasound before the surgery
2393819|NCT03615430|Experimental|SPB group|Serratus plane block group, 15ml of 0.25% ropivacaine, a widely used local anesthetic for peripheral nerve block, was administered to superficial and deep surface of serratus anterior in SPB group via ultrasound before the surgery
2393820|NCT03615417|Experimental|HFNC - High Flow Nasal Cannula|Participants are preoxygenated by High Flow Nasal Cannula (HFNC) OptiFlow.
2393821|NCT03615417|Active Comparator|FM - FaceMask|Participants are preoxygenated by standard anesthesia FaceMask.
3184047|NCT00720239|Experimental|1|Experimental Group 1 (n = 10) will receive TalidermR to the wound once during the treatment phase.
2393823|NCT03615378|Placebo Comparator|Placebo|
2393824|NCT03615378|Active Comparator|Vitamin D 1000 IU D3 daily|
2393825|NCT03615378|Active Comparator|Vitamin D 5000 IU D3 daily|
2393826|NCT03615365||Patients with moderate-to-severe COPD.|"Patients will be identified from the Cambridge COPD Centre. This unit sees patients following emergency admissions, GP referrals and has a regional referral base for complex COPD. Patients' medical records will be reviewed and classified according to GOLD criteria.~Patients will undergo a clinical assessment of COPD during screening at Addenbrooke's Hospital. All patients will be assessed five times: at the start, 2 weeks, 10 weeks, 18 weeks and at the end of the 26 week study period. A brief follow-up telephone review will be conducted approximately 2 weeks after the end of the monitoring period. At each assessment, capnometry measurements will be taken in addition to vital signs and pulse oximetry."
2393827|NCT03615352|Experimental|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
2393828|NCT03615352|Experimental|ovarian cyst aspiration and coagulation|laparoscopic ovarian endometrioma aspiration and coagulation
2393829|NCT03615339|Experimental|Molkosan|"Consumption of Molkosan (fermented whey) 20ml to be diluted in 200ml water prior to use twice a day (morning & evening).~Total duration was 6 weeks."
2393830|NCT03615326|Experimental|Pembrolizumab +Trastuzumab + Chemotherapy|Participants receive 200 mg pembrolizumab IV every 3 weeks (Q3W) plus trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
2393831|NCT03615326|Active Comparator|Placebo +Trastuzumab + Chemotherapy|Participants receive matched placebo to pembrolizumab IV Q3W plus trastuzumab (8mg/kg loading dose, 6mg/kg maintenance thereafter) IV Q3W in combination with FP or CAPOX chemotherapy (Global Cohort) or SOX chemotherapy (Japan cohort).
2393861|NCT03615131||MRI-TRUS fusion prostate biopsy|Single Arm Study, MRI and Prostate-Biopsy on same patient, individual patient acts as own control for intervention
2393937|NCT03614637||Cannabis User Group|Forty eight participants who are regular Cannabis users with a self-reported frequency of at least once weekly over the past 6 months of screening visit.
3184048|NCT00720239|Experimental|2|Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
3184049|NCT00720239|Experimental|3|Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase.
3184050|NCT00720252|Experimental|A|
3184051|NCT00720265|Active Comparator|1|
3184052|NCT00720265|Experimental|2|
3184053|NCT00720291|Active Comparator|Metronidazole|Subjects who are randomly assigned to receive metronidazole 500 mg po for a period of 7 days following diagnosis of asymptomatic BV.
2393832|NCT03615313|Experimental|PD-1 antibody expressing mesoCAR-T cells|Patients will receive two cycles of PD-1 antibody expressing mesoCAR-T cells treatment. Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day -18, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of PD-1 antibody expressing mesoCAR-T cells from day 1 to day 3 (±3days).
2393833|NCT03615300||good neurologic outcome|Patients with good neurological prognosis after 6 months (CPC 1, 2). serum NGAL is collected.
2393834|NCT03615300||poor neurologic outcome|Patients with poor neurological prognosis after 6 months (CPC 3, 4, 5). serum NGAL is collected.
2393835|NCT03615287||Group A|40 subjects undergoing Medical Treatment
2393836|NCT03615287||Group B|40 subjects undergoing Surgical Treatment
2393837|NCT03615287||Group C|40 control subjects
2393838|NCT03615274|Experimental|Experimental|Children in the training group must complete home-based executive function training by iPad. At the same time, they are asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
2393839|NCT03615274|Active Comparator|Placebo non-adaptive training|Children in the control group must complete cognitive control tasks. They are also asked to learn basic psychoeducational contents and send pictures of their daily meals. Furthermore, physical activity and sleep patterns are registered over the training period.
2393840|NCT03615261|Experimental|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
2393841|NCT03615248|Experimental|Primary Arm -|"30 Subjects will be approached in Asthma Clinics at the Janeway Children's Health and Rehabilitation Centre by the research nurse, and if selected to the study, will use the BreatheSuite device for 3-6 months.~Inclusion criteria: Age 10-18, diagnosis of asthma by the pediatrician, regular access to a smartphone, parental consent, ongoing need for regular use of a medication delivered by metered dose inhaler as deemed by the pediatrician, ability to demonstrate proper technique of metered dose inhaler use in the clinic while supervised by research nurse or pediatrician without parent or caregiver intervention;"
2393842|NCT03615235||Recipients of a Kidney Transplant|APOLLO will prospectively assess transplant outcomes in recipients of kidneys from eligible living and deceased donors at all transplant programs in the United States including Puerto Rico.
2393843|NCT03615235||Living Kidney Donors|APOLLO will prospectively assess post-donation renal outcomes in eligible living kidney donors at all transplant programs in the United States including Puerto Rico.
2393844|NCT03615222||SERVE assessment only|Eligible veterans will complete 4 assessments over a two year period of time.
2393845|NCT03615209|Active Comparator|Transauricular vagus nerve stimulation|Non invasive vagus nerve stimulation will be conducted with Cerbomed NEMOS via the left ear.
2393846|NCT03615209|Sham Comparator|Transauricular sham stimulation|Non invasive sham stimulation will be conducted with Cerbomed NEMOS via the left ear lobe.
2393847|NCT03615196|Experimental|USB005 0.03%|USB005 (aclerastide) Ophthalmic Solution 0.03%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2393848|NCT03615196|Experimental|USB005 0.1%|USB005 (aclerastide) Ophthalmic Solution 0.1%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2393849|NCT03615196|Experimental|USB005 0.3%|USB005 (aclerastide) Ophthalmic Solution 0.3%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2393850|NCT03615196|Experimental|USB005 0.45%|USB005 (aclerastide) Ophthalmic Solution 0.45%; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
2393851|NCT03615196|Placebo Comparator|USB005 Placebo|USB005 Ophthalmic Solution Placebo; single eye drop instillation three times a day to one eye during a 28-day treatment period (84 treatments)
3184054|NCT00720291|Placebo Comparator|Placebo|Subjects who are randomly assigned to receive a placebo for a period of 7 days following the diagnosis of asymptomatic BV.
3184055|NCT00720304|Experimental|oral erlotinib hydrochloride|
3184056|NCT00720395||1|Women with bipolar disorder who are preconception or pregnant. Primary focus on predictors of postpartum bipolar disorder relapse and burden of illness through first six months postpartum
3184057|NCT00720408|Experimental|Prograf-XL + MMF|
3184058|NCT00720408|Active Comparator|Prograf + MMF|
2393857|NCT03615157|Experimental|Home-based exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with walking at 60-70% of heart rate reserve monitored by a heart rate monitor (30 minutes/session for 5 days/week) and peripheral muscle training including upper and lower limbs (50% of the 1-maximum repetition test)
2393858|NCT03615157|Active Comparator|Supervised exercise rehabilitation|Patients will be submitted to a 12-weeks training program, with sessions (3 days/week) supervised by a physiotherapist, including cycling at 60-70% of heart rate reserve and peripheral muscle training of upper and lower limbs (50% of the 1-maximum repetition test)
3184059|NCT00720421|Other|1|AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy
3184060|NCT00720421|Other|2|AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 1mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy
3184061|NCT00720421|Other|3|AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy; washout period; AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy
2393862|NCT03615118|Experimental|Intervention|Patients randomized to the intervention group will receive the AniMóvil intervention, including: the Sentirse Mejor manual that patients can refer to for information about CBT and skill practice, weekly IVR depression symptom assessments and psychoeducational messages, daily SMS mood monitoring and CBT reinforcement messages, and CHW telephone CBT sessions in the event of elevated PHQ-9 scores during the study. CHWs will use information from patients' IVR/SMS monitoring to support intervention-group patients' depression self-management under close supervision from their mental health specialist supervisor. Intervention patients will be part of a 'stepped' intervention based on the severity of their depression upon entry into the program and assessment throughout the intervention.
2393863|NCT03615118|Active Comparator|Enhanced Usual Care|Enhanced usual care patients will receive usual care, including the Sentirse Mejor manual developed by the research team in conjunction with local Ministries of Mental Health and tailored by the study team, emphasizing CBT principles, and daily SMS messages asking participants to report their mood on a 1 to 9 scale. Enhanced usual care group patients who report mood scores of 1 or 2 (worst scores) for at least 3 days per week and 3 consecutive weeks will be called by the Community health worker and referred to the national program office for depression services support - a free service available to all citizens diagnosed with depression. Enhanced usual care patients will be part of a 'stepped' program based on the severity of their depression upon entry into the program and assessment throughout the intervention.
2393864|NCT03615105|Experimental|Radiation, Thiotepa & Cyclophosphamide|
2393865|NCT03615105|Experimental|Busulfan, Fludarabine & Melphalan|
2393866|NCT03615105|Experimental|Clofarabine, Thiotepa & Melphalan|
2393867|NCT03615092|Active Comparator|Test Group|"Active Comparator: gingival recession with a previous restored cervical lesion~the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions."
2393868|NCT03615092|Placebo Comparator|Control Group|the aim of this study is to compare if the acellular dermal matrix graft is as efficient as a substitute for the connective graft used in root coverage of gingival recessions with non carious cervical lesions. The control group had no cervical lesion, and was treated with the same technique as the acelular dermal matrix graft
3184062|NCT00720421|Other|4|AZD7325 1 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam 1 mg combination therapy; washout period; AZD7325 10 mg/Lorazepam Placebo combination therapy; washout period; AZD7325 Placebo/Lorazepam Placebo combination therapy
3184063|NCT00720460||Experimental|Healthy Volunteers
3184064|NCT00720486|Experimental|1|Participants will receive Juvenile Justice Anger Management for Girls plus treatment as usual.
3184065|NCT00720486|Active Comparator|2|Participants will receive treatment as usual.
2393873|NCT03615053|Other|Tailored Regimen|Implementation of WAPPS-Hemo personalized dosing regimen.
2393874|NCT03615040|Experimental|Anti-ST2|Anti-ST2 (MSTT1041A) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
2393875|NCT03615040|Placebo Comparator|Placebo|Placebo (no active component) received as subcutaneous injection by infusion pump at 490mg every 4 weeks over a 48 week treatment period.
2393876|NCT03615027|Experimental|Intervention|see detailed description
2393877|NCT03615014|Other|Patients having trauma|Adults patients having trauma in the month before visiting emergency will fill questionnaires
3184066|NCT00720512|Active Comparator|Arm I|Patients receive either irinotecan hydrochloride over 1 hour or oxaliplatin over 1 hour on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil IV over 46 hours continuously beginning on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2393879|NCT03614988|Active Comparator|Morning Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Evening Levothyroxine Administration.
2393880|NCT03614988|Experimental|Evening Levothyroxine Intake First|Randomized patients to receive levothyroxine in the morning and after crossover to Morning Levothyroxine Administration.
3184067|NCT00720512|Experimental|Arm II|Patients receive combination chemotherapy as in arm I and bevacizumab IV on day 1. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3184068|NCT00720525||1|Patients with diastolic heart failure
2393883|NCT03614962|Experimental|Warmth + TENS group|All participants will be offered a hat device that elicits warmth and TENS.
2393884|NCT03614962|Active Comparator|Warmth + placebo-TENS group|All participants will be offered a hat device that elicits warmth and placebo-TENS.
2393885|NCT03614962|Active Comparator|Warmth group|All participants will be offered a hat device that elicits warmth only.
2393886|NCT03614962|Active Comparator|TENS group|All participants will be offered a hat device that elicits TENS only.
2393887|NCT03614962|Sham Comparator|control group|All participants will be offered a hat device that without warmth or TENS output.
2393888|NCT03614949|Experimental|Combination Therapy|Stereotactic body radiation therapy (SBRT) followed by atezolizumab, 1 week later.
2393889|NCT03614936||Inoperable squamous cell cancer of the head and neck|patients 70 years of age or older with ENT carcinoma
2393890|NCT03614923|Active Comparator|Dose 1|SC administration, Q4W
2393891|NCT03614923|Active Comparator|Dose 2|SC administration, Q8W
2393892|NCT03614923|Placebo Comparator|Placebo|SC administration, Q4W
2393938|NCT03614637||Non-Cannabis User Group|Twenty four participants who self-report no Cannabis use in the past 6 months of screening visit and fewer than 10 times during their lifetime
3184069|NCT00720525||2|Patients without diastolic heart failure
3184070|NCT00720538|Experimental|1|Thalidomide
3184071|NCT00720538|Placebo Comparator|2|Placebo
3184072|NCT00720577|Active Comparator|1|
3184073|NCT00720577|Active Comparator|2|
3184074|NCT00720577|Active Comparator|3|
3184075|NCT00720590|Experimental|1|Participants will receive treatment with atazanavir and placebo lopinavir/ritonavir.
3184076|NCT00720590|Experimental|2|Participants will receive treatment with lopinavir/ritonavir and placebo atazanavir.
3184077|NCT00720590|Placebo Comparator|3|Participants will receive treatment with placebos for both drugs.
3184078|NCT00720616|Experimental|1|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
2393893|NCT03614910||Locally Advanced Pancreatic Cancer|"Patients with locally advanced unresectable pancreatic cancer. Unresectable tumors as defined by:~occlusion, thrombosis or several centimeters of encasement of the superior mesenteric vein or portal vein~tumor abutment greater than 180 degrees of the superior mesenteric artery or thrombosis of the artery~abutment or encasement of the celiac axis~involvement of lymph nodes outside the area of resection"
2393894|NCT03614897|Experimental|Education|Providers participating in education related to guidelines for treating patients at risk of falling
2393895|NCT03614884|Experimental|Gambling and Smoking Treatment|Participants in this arm will be given access to the online integrated treatment for gambling and smoking.
2393896|NCT03614884|Active Comparator|Gambling Only Treatment|Participants in this arm will be given access to the online gambling only treatment.
2393897|NCT03614871||No arms|There are no interventions
2393898|NCT03614858|Experimental|Cohort 1|Experimental: Cohort 1 Intervention: Biological: CART-19/22 This cohort will determine the safety and efficacy of targeted CD19/CD22 chimeric Antigen Receptor Engineered T Cell Immunotherapy (CART) in the Treatment of CD19/CD22 Positive Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
2393899|NCT03614845|Active Comparator|VCV-Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography. after induction of anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode.
2393900|NCT03614845|Active Comparator|PCV-VG- Lung Ultrasonography|patients undergoing laparoscopic surgery will be performed pre and postoperatively lung ultrasonography.after induction of anesthesia patients will be supported by mechanical ventilation on pressure controlled volume guaranteed mode
2393901|NCT03614832|Experimental|Ticagrelor 90 mg|To observe low-dose of ticagrelor（90 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
2393902|NCT03614832|Active Comparator|Clopidogrel 150 mg|To observe double standard-dose clopidogrel （150 mg once daily oral）on platelet aggregation in clopidogrel resistance's patients with coronary heart disease.
2393903|NCT03614819|Experimental|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
2393904|NCT03614819|Active Comparator|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
2393905|NCT03614806|Experimental|Patients tested for hyperventilation|Simultaneous Transcutaneous and End-tidal CO2 measurements. Eligible patients will be first invited to fill in the Nijmegen questionnaire. Then, in an hyperventilation test, transcutaneous Carbon Dioxide Pressure will be recorded simultaneously with the standard End-tidal Carbon Dioxide Pressure measurement.
2393906|NCT03614793|Active Comparator|Cooled Radiofrequency Ablation Procedure|
2393907|NCT03614793|Active Comparator|Facet Joint Inject Procedure|
2393908|NCT03614780|Experimental|30 additional minutes outdoors|Participants were asked to go about their normal activities during the first 2 baseline days of participation. Participants were asked to spend an additional 30 minutes outdoors per day for the next 5 days of participation.
2393909|NCT03614767||Successes|Patients with >50% improvement during test procedure of sacral neuromodulation.
2393910|NCT03614767||Failures|Patients with <50% improvement during test procedure of sacral neuromodulation.
2393911|NCT03614754||Successes|Patients with reduction of symptoms >50% during the test procedure for sacral neuromodulation.
2393912|NCT03614754||Failures|Patients with reduction of symptoms <50% during the test procedure for sacral neuromodulation.
2393913|NCT03614741|Active Comparator|Control group|Bolus of 4500 IU tinzaparin
2393914|NCT03614741|Active Comparator|Study group|Bolus of 4500 IU tinzaparin and continuous infusion of 4500 IU tinzaparin
2393915|NCT03614728|Experimental|Part 1: Participants receiving GSK3326595|
2393916|NCT03614728|Experimental|Part 2 Dose escalation : Participants receiving GSK3326595+5-Azacitidine|
2393917|NCT03614728|Experimental|Part 2 Dose expansion: Participants receiving GSK3326595+5-Azacitidine|
2393918|NCT03614715|Experimental|CinnaGen interferon beta-1a|CinnoVex® (IFNβ-1a, Prefilled syringe produced by CinnaGen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
2393919|NCT03614715|Active Comparator|Biogen interferon beta-1a|Avonex® (IFNβ-1a, Prefilled syringe produced by Biogen Company) in prefilled syringe in healthy volunteers. (Stage 1: 30 µg or 60 µg)(Stage 2: 30 µg)
2393920|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences . 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
2393934|NCT03614663|Experimental|ZYN002 - CBD transdermal gel|"ZYN002 supplied as a transdermal gel. Patients weighing less than or equal to 35 kg will be randomized to receive either 125 mg CBD Q12H or placebo.~Patients weighing greater than 35 kg will be randomized to receive 250 mg CBD Q12H or placebo."
2393935|NCT03614663|Placebo Comparator|Placebo transdermal gel|Matching ZYN002 placebo supplied as a transdermal gel.
2393921|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time;each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50."
2393922|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2393923|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Candy): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1g/pill,10 pills/pach,one pill each time; each pill containing polio virus≥5.92 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2393924|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Candy)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd. 1g/pill,10 pills/pach;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2393925|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Candy)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences 0.5ml/dose~tOPV (Candy): Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Human Diploid Cell) Produced by Beijing Tiantan Biological Products Co., Ltd.1g/pill,10 pills/pach,one pills each time;each pill containing polio virus≥5.95 lgCCID50 including type1 polio virus≥5.8 lgCCID50，type 2 polio virus ≥4.8lgCCID50，type 3 polio virus ≥5.3lgCCID50"
2393926|NCT03614702|Experimental|1-dose cIPV + 2-doses bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine（Vero） Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393927|NCT03614702|Experimental|1-dose sIPV + 2-doses bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393928|NCT03614702|Experimental|2-doses cIPV + 1-dose bOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle;total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393929|NCT03614702|Experimental|2-doses sIPV + 1-dose bOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml/dose~bOPV (Liquid): bivalent oral attenuated live poliomyelitis vaccine against type 1 and type 3 (Human Diploid Cell) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 0.5ml or 1.0ml each bottle,total content of polio virus≥7.12lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 3 polio virus ≥6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393930|NCT03614702|Experimental|2-doses cIPV + 1-dose tOPV (Liquid)|"cIPV: Inactivated Poliomyelitis Vaccine Made from Wild Polio Strains Produced by Sanofi Pasteur Co., Ltd. 0.5ml/dose~tOPV(Liquid) Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (Vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥ 7.0 lgCCID50/ml，type2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393931|NCT03614702|Experimental|2-doses sIPV + 1-dose tOPV (Liquid)|"sIPV: Inactivated Poliomyelitis Vaccine Made from Sabin Strains Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences.0.5ml/dose~Trivalent oral attenuated live poliomyelitis vaccine against type 1, type 2 and type 3 in Dragee Candy (vero) Produced by Institute of Medical Biology, Chinese Academy of Medical Sciences. 1.0ml each bottle,total content of polio virus≥7.15lgCCID50/ml，type1 polio virus≥7.0 lgCCID50/ml，type 2 polio virus ≥ 6.0lgCCID50/ml，type 3 polio virus ≥ 6.5lgCCID50/ml.(2 drops per person;be be equivalent to 0.1ml each person )"
2393932|NCT03614676|Other|Pregnant Women/Mothers Group|Subjects, 18 to 45 years of age and with pre-pregnancy body mass index (BMI) ≥18.5 and ≤ 39.9 kg/m2 enrolled in the study in view of determining pregnancy outcomes and related events of interest, as well as the occurrence of lower respiratory tract illness (LRTI) associated with respiratory syncytial virus (RSV). Collection of maternal blood samples and cord blood samples at delivery are planned for determination of antibody titers.
2393933|NCT03614676|Other|Neonates/Infants Group|Infants born to mothers aged 18-40 years old, enrolled for the collection of infant events of interest, nasal swabs and the incidence of RSV LRTI and RSV hospitalization
2393936|NCT03614650|Experimental|EIE cells to treat cancer|EIE cells to treat cancer
2393939|NCT03614624|Experimental|Comparison of two devices|Patients receive clinical examination, electrocardiogramm and echocardiography.
2393940|NCT03614611|Experimental|Contiform pessary|Enrolled participants will be part of the intervention arm. They will use of the Contiform Intravaginal pessary for the treatment of stress urinary incontinence, for a period of 3 months.
2393941|NCT03614598|Active Comparator|LMA-UNIQUE™|
2393942|NCT03614598|Active Comparator|LMA-SUPREME™|
2393943|NCT03614598|Active Comparator|I-GEL®|
2393944|NCT03614585|Experimental|High-intensity interval training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The protocol will involve 10 60-second intervals of high intensity interspersed with 9 60-second low-intensity intervals. The initial high intensity intervals will start at 80% of the HRR (RPE=14-17) and progress by 10% every 4 weeks. Low intensity intervals will be performed at 30% of HRR (RPE=9-11). Three-minute warm-up and 2-minute cool-down periods will be performed at 30% of HRR. Total HIIT time including warm-up and cool-down is 24 minutes.
2393945|NCT03614585|Experimental|Moderate-intensity continuous training|Intensity will be determined using a combination of heart rate reserve (HRR, calculated as HRR= [max HR - resting HR] x [% training] + [resting HR]) and ratings of perceived exertion (RPE). The MICT protocol will be increased using a progression schedule previously used (initial intensity at 40% HRR (RPE=9-11), and progressed by 10% HRR every 4 weeks up to 60% HRR (RPE=13-14) will be maintained until the end of the intervention). A 3-minute warm-up and 2-minute cool-down will be performed at 30% HRR (RPE=9-11). The total duration of MICT, including warm-up and cool-down, will be 35 minutes.
3143295|NCT00005711|No Intervention|Usual care|Control group children received routine medical care by their primary care providers as well as study visits every 6 months. At each study visit, following assessment of technique for using peak flow and metered dose inhalers, errors were corrected and children/families were coached on correct technique.
2393948|NCT03614559||CTO PCI group and non CTO PCI group|CTO PCI group： Succession of CTO revascularization non CTO PCI group： Failure or not tried to revascularization
2393949|NCT03614559||Initially attempted and re-attempted|PCI initially attempted group： First time to try to revascularization PCI re-attempted group: Second or more time to try to revascularization
2393950|NCT03614559||PCI during China Club or not|PCI during Chronic Total Occlusion Club， China Club : CAG in 2016.11.04 Another group: CAG in other time
2393951|NCT03614559||Morning，Afternoon，Night|Morning group:（8:00-12:59） Afternoon group：（13:00-17:59） Night group：（after 18:00）
2393952|NCT03614546|Other|A（surgery） group|Hepatectomy
2393953|NCT03614546|Experimental|B1（SBRT） group|Stereotactic Body Radiation Therapy(SBRT), 40-55Gy/5-6F
2393954|NCT03614546|Experimental|B2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
2393955|NCT03614546|Experimental|B2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
2393956|NCT03614546|Experimental|C1（SBRT） group|Stereotactic Body Radiation Therapy, 40-55Gy/5-6F
2393957|NCT03614546|Experimental|C2a（TACE+ IMRT ） group|First，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W, 4 weeks after IMRT，treat with transcatheter arterial chemoembolization（TACE） 2-4 times
2393958|NCT03614546|Experimental|C2b（TACE+ IMRT ） group|First，treat with transcatheter arterial chemoembolization（TACE） 2-4 times，4 weeks after TACE，treat with intensity modulated radiation therapy (IMRT),50Gy/25F/5W
2393959|NCT03614533|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
2393960|NCT03614533|Active Comparator|Inactivated Poliovirus Vaccine (IPV)|Children will receive a single 0.5-ml dose of Inactivated Poliovirus Vaccine (IPV) by the intramuscular route.
2393961|NCT03614520|Experimental|Sub-study A : olive oil, wine, both, or water (placebo).|After being selected, subjects will do 4 experimental sessions (each separated by 3 days minimum) in which ones they will drink olive oil, red wine, red wine and olive oil, or water (placebo). The order of the experimental sessions will be drawn.
2393962|NCT03614520|Experimental|Sub-study B : three types of beer, and wine|The subjects will do 4 experimental sessions (each separated by 3 days minimum) in wich ones they will drink a beer (250mL) or wine (150mL). The order of the experimental sessions will be drawn.
2393963|NCT03614507|Experimental|FreeO2 group|Automatic oxygen flow titration
2393964|NCT03614507|Active Comparator|Manual group|Manual oxygen flow titration
2393965|NCT03614494|Active Comparator|Piroxicam|Piroxicam 40 mg (in 2 tablets) + levonorgestrel 1.5 mg single oral dose
2393966|NCT03614494|Placebo Comparator|Placebo|Placebo (2 tablets) + levonorgestrel 1.5 mg single oral dose
2393967|NCT03614481||AMD patient|"During the AMD consultation, patients have their imaging exams including OCT, retinophotography, and fluorescein angiography.~After the interview with the doctor on pathology diagnosis and follow-up, they will meet the clinical research associate nurse to complete the questionnaire and perform anthropometric measurements (weight, height, abdominal perimeter measurement and blood pressure measurement). Patients recruited at Créteil will benefit from a venous blood sample (20 mL) in 2 EDTA tubes for DNA extraction after light reading and signature of consent. For patients recruited from other ophthalmic centers, the Clinical Research Associate will perform salivary sampling for DNA extraction after light reading and signature of consent."
2393968|NCT03614481||control without AMD|"898/5000 Given the observation of a mutation in an unaffected control individual, it is not excluded that this individual may be suffering from AMD at a later age. The observation of the mutation could thus be considered as a pre-clinical test. None of the teams were able to obtain a control population of the same age and sex ratio, which could have benefited from fluorescein angiography or at least a fundus examination, to ensure the absence of warning signs of AMD. This requires cooperation from healthy elderly volunteers not only for blood sampling but also for pupillary dilatation.~The controls may be the accompanying persons or spouses of AMD patients. It may also be people seen in general consultation without maculopathy or retinopathy with an age greater than 55 years."
2393969|NCT03614468|Experimental|Formula A|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age.
2393970|NCT03614468|Active Comparator|Formula B|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
2393971|NCT03614455|Experimental|Milademetan alone (A)|During Period 1, participants receive a single 100 mg milademetan oral dose on Study Day 1, with PK sampling to 168 hours post-dose (during the following 7-day washout period)
2393972|NCT03614455|Other|Milademetan with itraconazole (AB)|During Period 2, participants receive itraconazole, 200 mg twice daily (BID) on Study day 8 and 200 mg once daily (QD) on Study Days 9 through 20, along with a single 100 mg milademetan dose on Day 14
2393973|NCT03614455|Other|Milademetan with posaconazole (AC)|During Period 2, participants receive 200 mg posaconazole three times daily (TID) on Study Days 8 through 20, along with a single 100 mg milademetan dose on Day 14
2393974|NCT03614442|Experimental|slopped shoulder implant|The osteotomy site will be prepared using appropriate drill sizes with flapless approach, The implant (conventional neck implant design )will be inserted till the platform will be flushed with the crestal bone, The primary stability will be checked using torque wrench
2393975|NCT03614442|Active Comparator|conventional implant with flat platform|inserted implant will be bone leveled implant (crestal maxi z) implant (conventional implant with platform). The primary stability will be checked using torque wrench
2393976|NCT03614429|No Intervention|Control|"Group 1: control group, n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
2393977|NCT03614429|Experimental|Ch group|"Group 2: Chlorhexidine group (Ch group), n=50 Male patients undergoing aseptic surgery (regardless the procedure)~Inclusion criteria Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure.~Exclusion criteria Unwilling patient for this procedure Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage."
3184079|NCT00720642||PSAP|This is the population of patients in whom surgical intervention could possibly be avoided. These patients will be those in whom all imaging evidence (mammographic or sonographic) was removed during the Intact BLES procedure, and in whom a definitive diagnosis of ADH could be made using the pathology assessment criteria outlined in the protocol.
2393979|NCT03614403|Experimental|Vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
2393980|NCT03614403|No Intervention|control|Control patients will not be received any intervention
2393981|NCT03614390|Other|MBCT group|"There is only 1 arm in the study.~The MBCT will be conducted according to the treatment manual. The program consists of eight weekly sessions. In between sessions, participants are advised to practice mindfulness meditations for 40-50 minutes every day.~The teachers of the program will teach on voluntary basis. The teachers must have attended the 1-year foundation course to teach mindfulness (available in the United Kingdom and Hong Kong), regular mindfulness practice and must have at least yearly mindfulness retreat. This is in accordance to the good practice guidelines developed in the UK for mindfulness teachers"
2393982|NCT03614377||Patients with low burden of sleep-disordered breathing|
2393983|NCT03614377||Patients with high burden of sleep-disordered breathing|
2393985|NCT03614351|Experimental|Physical Therapy plus Protein Supplement|Participants will be randomized to the protein supplementation group, PROT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
2393986|NCT03614351|Active Comparator|Physical Therapy Control|Participants will be randomized to the enhanced-care control group, CONT, and will receive education from a dietary counselor on how to monitor protein intake using a smartphone app.
2393987|NCT03614338|Experimental|Core Participants Weight Loss Program|Small changes weight loss program
2393988|NCT03614325|Experimental|Virtual Reality Immersive Relaxation|"Patients in the experimental group will wear a headset and be immersed in a virtual reality environment during their surgery. There are various short videos and environments such as sitting on a beach that are designed to promote relaxation and calmness.~Throughout their surgery patients will be monitored according to current anesthesia standards. The relaxation programming will run for the duration of the operative procedure. At the end of the procedure the headset will be removed and standard postoperative care will commence."
2393989|NCT03614325|No Intervention|Usual Anesthesia Care|Patients in the usual care arm will undergo the current standard of care for hand/wrist surgery and postoperative recovery. They will be asked to refrain from using a virtual reality headset during their surgery.
2393990|NCT03614312||BMI 18-25 Pregnant Women|BMI 18-25 less than 36 weeks pregnant
2393991|NCT03614299||pSS cohort|Patients with pSS included in the study
2393992|NCT03614273|Active Comparator|Group 1 (HS)|Nebulized with 4 ml of 3% hypertonic saline for a duration of 20 minutes
2393993|NCT03614273|Active Comparator|Group 2 (Adr)|Nebulized with 0.1 mg/kg of adrenaline (non-racemic solution, 1:1000 concentration), which was diluted in normal saline to make it a 4 ml solution, for a duration of 20 minutes
2393996|NCT03614247|Active Comparator|RIRS|Patients underwent retrograde intrarenal surgery for lower calyceal stone between 1cm and 2cm in size
2393997|NCT03614247|Active Comparator|Micro-PNL|Patients underwent micro percutaneous nephrolithotomy (tract size <10 F) for lower calyceal stone between 1cm and 2cm in size
2393998|NCT03614247|Active Comparator|Ultramini-PNL|Patients underwent ultra-mini percutaneous nephrolithotomy (tract size <15 F) for lower calyceal stone between 1cm and 2cm in size
2393999|NCT03614247|Active Comparator|Mini-PNL|Patients underwent mini percutaneous nephrolithotomy (tract size <20 F) for lower calyceal stone between 1cm and 2cm in size
2394090|NCT03613636||Family control cohort|- Family members of index CAP patients.
2394000|NCT03614247|Active Comparator|Standard PNL|Patients underwent standard percutaneous nephrolithotomy (tract size >25 F) for lower calyceal stone between 1cm and 2cm in size
2394001|NCT03614234|Experimental|Experimental open label|Pegunigalsidase alfa
2394002|NCT03614221|Experimental|Lindioil|Lindioil ointment is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Protopic ointment 0.1% twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
2394003|NCT03614221|Active Comparator|Protopic|Protopic ointment 0.1% is applied twice daily for 6 weeks, followed by a washout period of 4 days to 8 weeks depending on the results of the first treatment period and the amount of time it takes the participant to relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA. If relapse to IGA ≥ 2 and less than 1-point of change from baseline1ST IGA is achieved, the patient is using Lindioil ointment twice daily for another 6 weeks. If the criteria for entering the 2nd treatment are not achievable after 8-week of ceasing 1st treatment, the subject will be followed up for another 6 weeks to the end of the study
2394004|NCT03614208|Experimental|Home-care rehabilitation group (HCRG)|"The home-based exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week. For finger stretching the patients will be directed to perform it every day, both in the morning and in the evening.~During the rehabilitation period, the patients will report each day on a diary for each type of exercise. They received a phone call monthly, only for the first 3 months, to encourage them about the adherence and investigate any problems with the exercise program."
2394005|NCT03614208|No Intervention|Control group|Control group was encouraged to perform the generic aerobic physical activity at the baseline. Also, they received a monthly phone call, only for the first 3 months, to encourage them about the importance of doing aerobic exercise.
2394006|NCT03614195|Experimental|MCDTT|The MCDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2394007|NCT03614195|Active Comparator|MDTT|The MDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2394008|NCT03614195|Active Comparator|CDTT|The CDTT group will receive dual-task interventions at progressively increasing task difficulty 3 times a week for 4 weeks.
2394009|NCT03614182|Experimental|physical training concurrent with cognitive training|The physical training concurrent with cognitive training group (the P+C group) will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2394010|NCT03614182|Active Comparator|physical training followed by cognitive training|The physical training followed by cognitive training will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2394011|NCT03614182|Active Comparator|physical training without cognitive training|The physical training without cognitive training group will receive training at progressively increasing task difficulty 3 times a week for 12 weeks and followed by another 12 weeks without exercise (follow-up).
2394012|NCT03614169|Experimental|Direct HIS-pacing|In this arm a right ventricular (RV) lead or implantable cardioverter defibrillator (ICD) lead is placed first and then implantation of a HIS-pacing lead is attempted. If it is not possible to find and pace HIS or it is not possible to correct the LBBB, a left ventricular (LV) lead is implanted instead.
2394013|NCT03614169|Active Comparator|Biventricular pacing|In this arm an RV-lead or ICD-lead is placed first and then implantation of a LV-pacing lead is attempted. If this is not possible due to anatomical difficulties (no coronary sinus (CS) access, no available branches other than v cordis anterior or v cordis media) or electrical difficulties (no capture below 4 V at 1.0 msec or phrenic nerve stimulation < 2x pacing threshold)
3184080|NCT00720642||NPSAP|Patients with a pathology diagnosis of ADH in whom all imaging evidence (mammographic or sonographic) of the target lesion was NOT removed OR in whom a definitive diagnosis of ADH COULD NOT be made by implementing the pathology criteria for evaluation outlined in the protocol AND patients with a diagnosis of DCIS will undergo open surgical excision and will be analyzed separately from the PSAP group.
3184081|NCT00720655|Experimental|Fatty fish|
3184082|NCT00720655|Experimental|Lean Fish|
3184083|NCT00720655|Placebo Comparator|Control diet|
3184084|NCT00720668||1|patient with hepatocellular carcinoma after radiofrequency ablation
2394019|NCT03614117|Active Comparator|L.salivarius PS7 6-months|Lactobacillus salivarius PS7 during 6-months; approximately 1*10E9 colony forming unit (CFU) of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 6-months.
2394020|NCT03614117|Active Comparator|L. salivarius PS7 + placebo (3+3)|Lactobacillus salivarius PS7 during 3 months; approximately 1*10E9 CFU of L. salivarius PS7 in 1 sachet per day to be diluted in water by mouth for 3-months followed by 3 months oral administration of 1sachet per day of placebo supplement to be diluted in water.
2394021|NCT03614117|Placebo Comparator|Control group|Placebo supplement in 1 sachet per day to be diluted in water by mouth for 6-months.
2394022|NCT03614104|Active Comparator|mobile health technology|Health education with mobile health technology
2394023|NCT03614104|Sham Comparator|Without mobile health technology|Health education without mobile health technology
2394024|NCT03614091|Active Comparator|Paravertebral plane block group|The TPVB will be administered at the T4 level with the patient in the sitting position.The ultrasound probe will be placed 5 cm from the midline in the craniocaudal direction and moved medially to identify the transverse process and parietal pleura. The superior costotransverse ligament was identified as a collection of homogeneous linear echogenic bands alternating with echo-poor areas running from one transverse process to the next. Bubivacaine0.5%, 20 ml will be deposited in the space between the pleura and the costotransverse ligament.
2394025|NCT03614091|Active Comparator|Erector spinae plane block group|the transducer will be placed in a transverse orientation to identify the spinous process, lamina,and transverse process.The tip of the transverse process will be centered on the ultrasound screen, and the transducer will be rotated 90 degrees into a longitudinal orientation to obtain a parasagittal view. Depending on the level imaged, 2 or 3 hypoechoic muscle layers were identiﬁed overlying the tip of the transverse processes. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superfacial to the transverse processes. An 8cm 22-gauge block needle will be Inserted in-plane to the ultrasound beam in a cephalad-to-caudad Direction to place the needle tip between the posterior fascia of Erector spinae and the tip of the targeted transverse process.following which a total of 20 mL of 0.5%bupivacaine will be injected.
3184085|NCT00720694|Active Comparator|Verum|"Device: Duolith SD1 (Storz Medical AG) - Focused Extracorporeal shock wave therapy.~The total energy flux density was increased continuously from 0.01 to 0.25 mJ/mm 2 within 500 introductory impulses. Thereafter, 2000 treatment impulses with 0.25 mJ/mm 2 (four impulses per second) were administered per session,and the interventionwas repeated up to a total of three sessions in weekly intervals."
2394029|NCT03614065|Placebo Comparator|arm a|This group is a placebo control group, and we will use radiation therapy plus Placebos as the control group for the study
2394030|NCT03614065|Experimental|arm b|This group belongs to the experimental group. We will use radiotherapy combined with endostar for treatment, so as to judge the efficacy of the medicine
2394031|NCT03614052|Experimental|tamsulosin hydrochloride|Tamsulosin hydrochloride 0,4 mg tablets by mouth per day for 5 days before ureteroscopy
2394032|NCT03614052|Placebo Comparator|Placebo oral tablet|Placebo oral tablets by mouth per day for 5 days before ureteroscopy
2394033|NCT03614039|Active Comparator|probiotic-smectite|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2394034|NCT03614039|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2394035|NCT03614026|Experimental|Teachers and Parents as Partners Intervention|Teachers and Parents as Partners will occur in a series of stages comprised of approximately four structured meetings over approximately 8 weeks. A Teachers and Parents as Partners consultant will meet together with a student's parent(s), teachers, other school personnel (as appropriate), and the student (as appropriate). The Teachers and Parents as Partners team will collaboratively address behavior problem solving objectives. Specific objectives include: identifying strengths and specific behaviors of concern, specifying alternative prosocial behaviors, creating measurable behavior goals, co-constructing behavior intervention/support plans to address the target concerns, creating sustainable conditions to support plan implementation at home and school, and evaluating the plan to assess progress toward goals.
2394036|NCT03614026|No Intervention|Business as usual control|In the business-as-usual control condition, participants will have access to any services that a school would routinely provide (e.g., develop and implement a behavior support plan) as well as services families can access in the community (e.g., mental health support).
2394037|NCT03614013||Immunotherapy responders/non-responders|paraffin samples and relevant clinical data including RECIST 1.1 will be obtained from metastatic gastric cancer patients
2394038|NCT03614000|Experimental|positive screenings|
2394039|NCT03613987|No Intervention|NIPPV|non synchronized non invasive positive pressure ventilation
2394040|NCT03613987|Experimental|NAVA-NIPPV|synchronized non invasive positive pressure ventilation with NAVA
2394041|NCT03613974|Experimental|lidocaine concentraion|the popliteal block will be performed (once) in all patients using 20 ml of lidoacine. The response of a patient determined the lidocaine concentration given to the next patient (a biased-coin design up-down sequential method). If a patient had a negative response (failed block), the lidocaine concentration was increased by 0.1% w/v in the next patient. If a patient had a positive response (successful block), the next patient was randomized to receive the same lidocaine concentration (with probability of 0.89), or to receive a concentration 0.1% w/v less (with probability of 0.11).
2394042|NCT03613935|Placebo Comparator|Product 1|Normal glucose, isosweet, homogeneous: 43 g glucose beverage, with a 43 g glucose equivalent sweetness homogenously delivered
2394043|NCT03613935|Active Comparator|Product 2|Low glucose, isosweet, heterogeneous: 30 g glucose beverage with 43 g glucose equivalent sweetness heterogeneously delivered
2394044|NCT03613935|Active Comparator|Product 3|Low glucose, less sweet, homogeneous: 30 g glucose beverage with a 30 g glucose equivalent sweetness homogenously delivered
2394045|NCT03613935|Active Comparator|Product 4|Low glucose+sucralose, isosweet, homogeneous: 30 g glucose + 18 mg sucralose beverage with a 43 g glucose equivalent sweetness homogenously delivered
2394046|NCT03613922|Experimental|Early Manual Therapy Group|Routine physiotherapy program plus Mulligan's Mobilization with Movement technique were applied.
2394047|NCT03613922|Active Comparator|Routine Physiotherapy Group|Only routine physiotherapy program was applied
2394048|NCT03613909|Experimental|CP950|CP950 Off The Ear (OTE) sound processor
2394049|NCT03613909|Active Comparator|BTE|Behind the Ear (BTE) sound processor (either a CP810 or CP900 series)
2394050|NCT03613896|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
2394051|NCT03613896|Active Comparator|3D printed dentures|a complete denture made through 3d printing
2394052|NCT03613883|Experimental|Primary Study Arm|The intervention is done to those patients that are managed by endovascular stent that is inserted in the parent artery to induce slowness in the blood flow thus initiate thrombosis in the aneurysmal sac.
2394053|NCT03613883|Experimental|Expanded Selection Arm|The intervention is done to the expanded selection arm and is managed by embolic materials (coils / glue) that occlude the aneurysm by proximal occlusion, proximal and distal occlusion or sac packing
2394054|NCT03613870|Active Comparator|PermeaDerm|Participants receive PermeaDerm dressing for wound treatment until wounds have healed completely
2394055|NCT03613870|Active Comparator|Mepilex Ag|Participants receive Mepilex Ag dressing for wound treatment until wounds have healed completely
2394056|NCT03613857||Clopidogrel group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose 600 mg oral clopidogrel (plavix) tablets before the procedure.
2394057|NCT03613857||Ticagrelor group|Anterior myocardial infarction patients undergoing percutaneous coronary intervention take loading dose180 mg oral ticagrelor (brilique) tablets before the procedure.
2394058|NCT03613844|Experimental|DHA|oral DHA supplementation at 2 grams per day
2394059|NCT03613844|Placebo Comparator|Placebo|Placebo for DHA
3184086|NCT00720694|Sham Comparator|Placebo / Sham|Sham Duolith SD1 (Storz Medical AG). The placebo group received identical sham intervention with an air- filled standoff that prevented the transmission of shock waves. The placebo handpiece was identical in design, shape, and weight to ensure that there was no way for the participants to identify the placebo handpiece.
3184087|NCT00720707|Experimental|(CAF+ADM+EMD)|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
2394062|NCT03613805|Active Comparator|Dexcom G5 - Eversense|Patients will wear first Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months, then Eversnese(Senseonics Inc, MD, USA) implantable sensor for 3 months Accuracy and efficacy will be evaluated
2394063|NCT03613805|Experimental|Eversense- Dexcom G5|Patients will wear first Eversense (Senseonics Inc, MD, USA) implantable sensor for 3 months, then Dexcom G5 (Dexcom San Diego, CA, USA) transcutaneous sensor for 3 months accuracy and efficacy will be evaluated
2394064|NCT03613792|Active Comparator|Remifentanil and Ketamine Group|Patients in Group 1 will receive remifentanil and ketamine. Remifentanil will be administered initially with a 1mcg/kg IV bolus followed by a continuous infusion, 0.1 to 0.15 mcg/kg/min IV (using ideal body weight) with titration to a maximum dose of 0.2 to 0.4 mcg/kg/min IV. Total dose of ketamine will be titrated from 10 to 40 mg, based on clinical judgment, and it will be recorded. Ketamine will be delivered using 2mL syringes, previously filled with ketamine in normal saline at a 10mg/mL concentration.
2394065|NCT03613792|Active Comparator|Fentanyl and Midazolam|The patients in this group will receive fentanyl doses that range between 0.5 to 2 mcg/kg (25 - 50 mcg) IV bolus in combination with midazolam 1-5 mg bolus over at least 2 minutes as determined by attending anesthesiologist (not to exceed 2.5 mg / 2 min per package insert). Total dosing of fentanyl and midazolam may be titrated, based on clinical judgment, and it will be recorded. Maintenance, additional midazolam doses of 25% of total initial dose required to achieved desired sedation may be administered IV if additional sedation is considered necessary
2394066|NCT03613779|Experimental|LUS-guided therapy group|"LUS-guided therapy group. Patients randomly allocated to this arm will receive standard of care + LUS examination accessible to treating physician in every visit. Depending on the results of LUS examination, a low dose or high dose of diuretics will be administered.~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
2394067|NCT03613779|Active Comparator|Control group.|"Control group. Patients randomly allocated to this arm will receive standard of care + LUS examination blinded to the treating physician in every visit. Diuretic titration will be based on standard practice (physical examination, symptoms and lab results).~A standardized algorithm will be provided to ensure compliance to guideline-recommended medical therapy for heart failure."
2394068|NCT03613766|Experimental|Physical activity program|Before 3 to 6 months before the expected date of surgery, the experimental group, performed a 12-week monitored and supervised concurrent exercise program. Before and after of this period, body composition, anthropometric measures, physical fitness, cardiovascular risk, blood samples, Basal Metabolic Rate and health-related quality of life were measured in a laboratory under controlled conditions.
2394069|NCT03613766|No Intervention|Habitual care prescription|Before 3 to 6 months before the expected date of surgery, the control group, followed the habitual care prescriptions until the surgery
2394070|NCT03613753|Experimental|Arm A|Chemotherapy:irinotecan plus lobaplatin
2394071|NCT03613753|Active Comparator|Arm B|Chemotherapy:irinotecan
2394072|NCT03613740|Experimental|Fucoxanthin|12 mg Fucoxanthin capsule, once a day before breakfast during 90 days.
2394073|NCT03613740|Placebo Comparator|Placebo|Homologated magnesium sterate capsule, once a day before breakfast during 90 days.
3184088|NCT00720707|Active Comparator|(CAF + ADM)|root coverage procedure by using a coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM)
2394075|NCT03613714|Active Comparator|Intervention Group|At-home blood pressure monitoring at 2-5 days post-discharge from the hospital using a digital blood pressure cuff. Participants will receive text message reminders to check blood pressure. Contacted by clinic staff to review blood pressure log.
2394076|NCT03613714|No Intervention|Usual Care|Blood pressure monitoring assessment will be done at 2-5 days post-discharge in the office. Participants will be given high blood pressure information hand-outs and instructed to follow-up in obstetric clinic for blood pressure check within 5 days after discharge from the hospital.
2394077|NCT03613701||Moyamoya disease patients|Moyamoya disease patients/Healthy volunteers
2394078|NCT03613688|Experimental|Deepure Group A|Visit 3: Warm water without Deepure; Visit 4: Warm water with 1 g Deepure; Visit 5: Warm water with 1.5 g Deepure; Visit 6: Warm water with 2 g Deepure.
2394079|NCT03613688|Experimental|Deepure Group B|Visit 3: Warm water with 1 g Deepure; Visit 4: Warm water with 1.5 g Deepure; Visit 5: Warm water with 2 g Deepure; Visit 6: Warm water without Deepure.
2394080|NCT03613688|Experimental|Deepure Group C|Visit 3: Warm water with 1.5 g Deepure; Visit 4: Warm water with 2 g Deepure; Visit 5: Warm water without Deepure; Visit 6: Warm water with 1 g Deepure.
2394081|NCT03613688|Experimental|Deepure Group D|Visit 3: Warm water with 2 g Deepure; Visit 4: Warm water without Deepure; Visit 5: Warm water with 1 g Deepure; Visit 6: Warm water with 1.5 g Deepure.
2394082|NCT03613675|Experimental|Video games|All participants will be asked to play 4 video games.
2394083|NCT03613662|Experimental|SP-102|SP-102
3184089|NCT00720720|Active Comparator|1|plant sterol enriched margarine
3184090|NCT00720720|Placebo Comparator|2|placebo margarine
3184091|NCT00720733|Experimental|1|Skills Building Group
3184092|NCT00720733|Active Comparator|2|Personal Interview Group
2394088|NCT03613636||CAP cohort|"Children of age 3 to 16 years;~In- and outpatients;~Clinically diagnosed community-acquired pneumonia (CAP)."
2394089|NCT03613636||Healthy control cohort|"Healthy asymptomatic children of age 3 to 16 years;~undergoing an elective surgical procedure."
3184093|NCT00720772|Experimental|A|
3184094|NCT00720772|No Intervention|B|
2394091|NCT03613623||Patients|Patients diagnosed with acromegaly and currently taking long-acting somatostatin analogues for treatment.
2394092|NCT03613623||Physicians|Physicians for those treating the patients enrolled in the study.
2394093|NCT03613610|Active Comparator|Three needles group|
2394094|NCT03613610|Active Comparator|Single needle group|
2394095|NCT03613597|Experimental|Etoposide plus Lobaplatin group|Chemotherapy:etoposide plus lobaplatin (EL)
2394096|NCT03613597|Active Comparator|Etoposide plus Cisplatin group|Chemotherapy:etoposide plus cisplatin (EP)
2394097|NCT03613584|Active Comparator|Group W (von Willebrand factor concentrate)|The patient receives von Willebrand factor concentrate (vWFC) as a bolus of 25 IU/kg followed by a continuous infusion of 50 IU/kg/24h until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the administration of the Investigational Medicinal Product (IMP) will be stopped on the 7th day.
2394098|NCT03613584|Placebo Comparator|Group S (standard therapy with saline solution)|The patient receives the standard therapy plus an additional volume of saline solution equivalent to the amount of von Willebrand factor concentrate (vWFC) the patient would receive in Group W to keep the blind. The volume is given according to the VWFC-solution (0.25 ml/kg BW) what would be resulting from the patient's weight followed by a continuous saline infusion (0.50 ml/kg BW) until the weaning from ECMO is completed or if ECMO is needed longer than 7 days, the Investigational Medicinal Product (IMP) administration is stopped on the 7th day.
2394099|NCT03613571|Experimental|ILB|ILB treatment
2394100|NCT03613558|Experimental|Dexmedetomidine Sedation|This group will receive 1mcg/kg bolus of dexmedetomidine over 15 minutes after intubation followed by an infusion of dexmedetomidine at 0.5mcg/kg/hr until approximately 30 minutes before the end of surgery.
2394101|NCT03613558|Placebo Comparator|Placebo|This group will receive a colorless, odorless liquid (i.e. normal saline) in order to resemble Dexmedetomidine.
2394102|NCT03613545|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
2394103|NCT03613545|Sham Comparator|placebo fecal microbiota transplantation|Infusion of sham
2394104|NCT03613545|Sham Comparator|Traditional treatments|Traditional treatments according to associated guidelines such as probiotics, antibiotics or antidepressants
2394105|NCT03613532|Experimental|Venetoclax|"This study has three periods: 1) Screening, 2) Treatment including venetoclax + FluBu2 conditioning chemotherapy and transplantation; and 3) Post-Transplant follow up. For Part 1, the post-transplant period will include routine follow-up. For Part 2, the post-transplant period will include investigational therapy with azacitidine and venetoclax and follow-up.~Dose escalation in Part 1 will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.~Venetoclax: 6-7 total doses depending on dose level assigned~FLuBu2~Busulfan: given twice daily for 4 days~Fludarabine: given once daily for 4 days~Dose escalation in Part 2 will occur using a 10+10 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation/de-escalation.~Venetoclax: 14 doses for 8-12 cycles depending on dose level assigned~Azacitidine: 5 doses for 8-12 cycles depending on dose level assigned"
2394106|NCT03613519|Placebo Comparator|Usual care (sleep hygiene)|A web-based program that presents ways to improve behaviors and environments that can affect sleep.
2394107|NCT03613519|Active Comparator|SHUTi (Sleep Healthy Using the Internet)|SHUTi is web-based cognitive-behavioral therapy instrument for insomnia (CBT-I)
2394108|NCT03613519|Active Comparator|modified SHUTi (SHUTi modified for Black women)|The CBT-I instrument tailored for Black women.
2394109|NCT03613506|Experimental|Peripheral blood TGF-β content before and after radiotherapy|
3184095|NCT00720811|Experimental|ACT, antibiotic, paracetamol|CHWs will test children with acute febrile illness for malaria using RDTs, and for pneumonia by counting their respiratory rate with RRTs. Treatment will then be provided on the basis of the test results, in line with national guidelines. Children with a positive RDT will receive artemether-lumefantrine in Burkina Faso and Uganda, and artesunate-amodiaquine in Ghana. Children with a cough and a high respiratory rate will receive amoxicillin in Ghana and Uganda, and cotrimoxazole in Burkina Faso. Additionally, paracetamol (PCT) will be provided to all children with an axillary temperature > 38.5°C.
3184096|NCT00720811|No Intervention|Presumptive fever management|Presumptive treatment of malaria with ACTs. No antibiotic treatment available
3184097|NCT00720824|Active Comparator|1|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions
3184098|NCT00720824|Placebo Comparator|2|Office routine
2394114|NCT03613480|Experimental|Motivational Interviewing|Patients will receive 6 brief (20-30mins) counseling sessions based on the principles of Motivational Interviewing by a trained member (psychiatrist) of the research team. The first session will take place at 2 weeks after baseline and the following 5 sessions will be conducted at a monthly basis.
2394115|NCT03613480|No Intervention|Care as usual|Patients will be followed-up by the hepatologists of the Outpatient Department at regular time intervals and will be re-evaluated after 6 months from baseline
2394116|NCT03613467||VATS lobectomy|Pathologic N2 NSCLC patients who received lobectomy by video-assisted thoracoscopic surgery
2394117|NCT03613467||Thoracotomy lobectomy|Pathologic N2 NSCLC patients who received lobectomy by thoracotomy
2394120|NCT03613441|Experimental|Mindful Awareness Practices (MAPs)|Mindful Awareness Practices is a mindfulness-based intervention developed at UCLA's Mindful Awareness Research Center. It is a weekly 2-hour, 6-session, group-based course in mindfulness meditation that is available in-person or online.
2394121|NCT03613441|No Intervention|Control|Waitlist control (intervention will be available to this group at the end of the study period)
2394122|NCT03613428|Experimental|ruxolitinib, vincristine, prednisone|Open label dosing cohorts will evaluate oral ruxolitinib (doses ranging from 10 - 80 mg) in combination with vincristine (1.4 mg/m2) and oral prednisone (1 mg/kg, 5 days a week for 4 weeks).
2394123|NCT03613415|Experimental|Expansion by Densah bur|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of Densah bur under copious irrigation.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
2441910|NCT03284489||ICU patients|Patients with pancreatitis
2394124|NCT03613415|Active Comparator|Expander|"Scrubbing and draping of the patient in a standard fashion for intra oral procedures followed by local anesthesia administration to the patient.~A mid crestal flap will be reflected.~For both groups the implant manufacturer's pilot drill will be used to perform a standard osteotomy of 10 mm depth.~Sequential use of screw expanders.~An implant of 3.9*10 mm will be inserted.~Smart peg will be placed on implant and Osstell will be used to record ISQ.~Healing collars will be placed on implants.~Flap will be prepared for closure and suturing."
2394125|NCT03613402||Cohort 1|Patients at risk of VTE who are prescribed betrixaban to prevent VTE
2394126|NCT03613402||Cohort 2|Patients at risk of VTE who are prescribed betrixaban or other VTE prophylaxis
2394127|NCT03613389|Experimental|oral topical vitamin E|
2394128|NCT03613389|No Intervention|voriconazole and levofloxacin|
2394129|NCT03613376|No Intervention|No Compression|Patients in this group will not receive any compression after treatment
2394130|NCT03613376|Active Comparator|Compression|Patients in this group will use class II compression stockings continuously until next evening and then next 4 days during daytime.
2394131|NCT03613350||Urodynamic stress incontinence|Urodynamic study incontinence Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.
2394132|NCT03613350||USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. USI included evident USI and occult USI, which were classified according to pad weight before and after prolapse reduction.BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
2394133|NCT03613350||BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. BO was defined as <300 mL of the volume at strong desire to void during filling cystometry. Detrusor overactivity was defined as evidence of spontaneous detrusor contractions occurring during bladder filling or an uninhibited detrusor contraction occurring at a cystometric capacity that usually results in voiding.
2394134|NCT03613350||No demonstrated USI+BO/DO|Urodynamic study incontinence + bladder oversensitivity / detrusor overactivity Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20-minute pad testing and urodynamic studies in a medical center were reviewed. No urodynamic stress incontinence, no bladder oversensitivity nor detrusor overactivity was noted in this group.
2394135|NCT03613337||current smokers|Current smokers are those who continued smoking cigarettes more than 1 cigarette pre month after first percutaneous coronary intervention (PCI) .
2394136|NCT03613337||nonsmokers|Nonsmokers are those who never smoked in their lifetime.
2394137|NCT03613337||former smokers|Former smokers are those who had quit smoking after percutaneous coronary intervention (PCI) , and smoked less than 1 cigarette pre month after first percutaneous coronary intervention (PCI)
2394138|NCT03613324||Bladder outlet obstruction (BOO)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having BOO when Qmax was <12 mL/s and PdetQmax was ≥25 cmH2O with sustained detrusor contraction during voiding cystometry.
2394139|NCT03613324||Detrusor underactivity (DU)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. Woman were defined as having DU when Qmax was <12 mL/s and PdetQmax was <10 cmH2O during voiding cystometry.
2394140|NCT03613324||ND BOO/DU|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent 20 min pad testing and urodynamic studies in a medical center were reviewed. This group revealed no demonstrated bladder outlet obstruction nor detrusor underactivity.
2394141|NCT03613311||Evident urodynamic stress incontinence(USI)|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction.
2394142|NCT03613311||Occult USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. USI is noted during filling cystometry and is defined as the involuntary leakage of urine during increased abdominal pressure, in the absence of a detrusor contraction after prolapse reduction by vaginal gauze.
2394143|NCT03613311||ND USI|Between November 2011 and January 2017, medical records of all women with ≥stage II cystocele who underwent urodynamic studies in a medical center were reviewed. No USI was noted in this group.
2394144|NCT03613298|Experimental|HIFU (Focal One®) Treatment|"Subjects harboring an isolated recto-sigmoid deep invasive endometriosis (DIE) lesion with a persistence of symptoms despite hormonal treatment will be installed on the Focal One® device to:~Evaluate its ability to locate and assess the volume of the endometriosic lesion~Treat the targeted lesion by HIFU energy application. Real-time guided ultrasonography will be used to determine the location of the endometriosic nodule.~Patients will fill-out questionnaires on gynecological and intestinal symptoms and on quality of life before treatment and 1 and 6 months after HIFU. Imaging follow-up scans will be organized at 1 and 6 months and by a pelvic MRI scan at 3/6 months."
2394145|NCT03613285|Active Comparator|conventional brackets|Conventional brackets with Mac Laughin bennette Trevisi (MBT) prescription
2394146|NCT03613285|Active Comparator|Smart clip passive self ligating brackets|Smart clip passive self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
2394147|NCT03613285|Active Comparator|Empower active self ligating brackets|Empower active self ligating brackets with Mac Laughin bennette Trevisi (MBT) prescription
2394204|NCT03612830|Experimental|LECS|Laparoscopic and Endoscopic cooperative surgery,LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
2394148|NCT03613272|Experimental|Subxiphoid approach|The patients in subxiphoid group will get subxiphoid approach extended thymectomy by VATS. Whole dissection was performed through a 4 to 7cm transverse subxiphoid incision, and a single 5-mm port was inserted into the right chest cavity for the video thoracoscope and subsequently for the chest tube. The sternum was elevated with two hooks connected to the sternal frame. The lower hook was inserted through the subxiphoid incision, and the superior hook was inserted percutaneously after the mediastinal tissue including the major mediastinal vessels was dissected from the inner surface of the sternum. The thymus and fatty tissue of the anterior mediastinum and the aorta-pulmonary window was completely removed.
2394149|NCT03613272|Experimental|Intercostal approach|The patients in intercostal group will get intercostal approach extended thymectomy by VATS.
2394150|NCT03613259|Experimental|Diagnostic (fluorothymidine F-18 PET)|Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes 21 or less days prior to standard of care radiation therapy and 14 or less days prior to the standard of care surgery.
2394151|NCT03613233|Active Comparator|traditional glaucoma surgery|glaucoma procedures such as trabeculectomy, iridencleisis, non - penetrating deep sclerectomy
2394152|NCT03613233|Active Comparator|microinvasive glaucoma surgery (MIGS)|glaucoma procedures such as : canaloplasty (traditional, ABiC, modified), iStent, XEN, Cypass,Hydrus- and with any other microinvasive IOP reducing device
2394153|NCT03613207|Experimental|Dermal pharmacokinetic measurement|"Measurement of dermal pharmacokinetic (PK) parameters (AUC, Cmax) within each subject.~For dermal PK measurement cutaneous interstitial fluid will be sampled using dermal open flow microperfusion (dOFM). Additionally 8 blood samples will be drawn to rule out systemic appearance of lidocaine/prilocaine.~Each subject will have 9 test sites in total which are treated with:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~test sites: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site"
2394154|NCT03613194|Other|Patients with metastatic colorectal cancer|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
2394155|NCT03613181|Experimental|ANG1005|ANG1005 Investigational Drug
2394156|NCT03613181|Active Comparator|Physician's Best Choice|One of the protocol specified Physician's Best Choice therapies, assigned by the Investigator prior to randomization: capecitabine or eribulin or high-dose intravenous (IV) methotrexate.
2394157|NCT03613168|Experimental|Trastuzumab plus Gem/Cis|Gemcitabine 1,000 mg/m2 Day 1 and Day 8, every 3 weeks Cisplatin 25 mg/m2 Day 1 and Day 8, every 3 weeks Trastuzumab, every 3 weeks, 8 mg/kg at first cycle then, 6 mg/kg
2394158|NCT03613142|Experimental|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
2394159|NCT03613142|Active Comparator|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
3184099|NCT00720837|Experimental|Laser Interstitial Thermal Therapy|Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
3184100|NCT00720850|Experimental|lenalidomide|lenalidomide therapy p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
3184101|NCT00720889||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
3184102|NCT00720889||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
2394166|NCT03613103|Active Comparator|Direct laryngoscopy|Intubation with direct laryngoscopy (Conventional Intubation)
2394167|NCT03613103|Experimental|Videolaryngoscopy|Intubation with videolaryngoscopy (Assisted video intubation)
2394168|NCT03613090|Experimental|Collagen-hydroxyapatite Scaffold (Syn-Oss)|Placement of a collagen-hydroxyapatite scaffold (Syn-Oss), placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material).
2394169|NCT03613090|Active Comparator|Collagen Scaffold (Colla-Plug)|Placement of a collagen scaffold (Colla-Plug) over a blood clot, placement of a tricalcium silicate barrier (mineral trioxide aggregate), placement of a composite occlusal restoration (standard dental material). The Colla-Plug material is placed adjacent to the blood clot that has formed inside the root canal space. It act as a matrix for the subsequent placement of the mineral trioxide aggregate material. It has been used as the standard of care in regenerative endodontics since 2004.
2394170|NCT03613064|Experimental|Congestive Heart Failure (CHF)|The CHF arm will include adults hospitalized with CHF who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the CHF arm will receive the Socially Enhanced Transitional Care Intervention.
2394205|NCT03612830|Experimental|RECS|Robotic and Endoscopic cooperative surgery,RECS resects the tumor completely by Dan Vinchi robot with the help of the precise positioning and guidance of endoscopy .
2394171|NCT03613064|Experimental|Ischemic Heart Disease (IHD)|The IHD arm will include adults hospitalized with IHD who have been identified as being at high risk for readmission (in the top quintile of risk) by our readmission risk prediction algorithms, and who also have social vulnerabilities present. All subjects in the IHD arm will receive the Socially Enhanced Transitional Care Intervention.
2394172|NCT03613051||age band one|age band one ( from 3 to 6 years ) we test manual dexterity by posting coins with prefered hand and non prefered hand test balance by jumping on mats
2394173|NCT03613051||age band two|age band two ( from 7 to 10 years ) test manual dexterity by threading lace
2394174|NCT03613051||age band three|age band three ( from 11 to 18 years ) test manual dexterity by turning pegs test balance by zigzag hopping
3143296|NCT00005711|Experimental|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
2394176|NCT03613025|Other|Case : confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
2394177|NCT03613025|Other|Control : non confirmed PCP diagnosis|Sampling of non-invasive and/or non-targeted respiratory tract specimens
2394178|NCT03613012||Pain index|Pain index will be extracted from the EEG of chronic pain patients before and after pain treatments
2394179|NCT03612999|Experimental|CGM and Activity Tracker|Subjects receive a continuous glucose monitor (CGM) and activity tracker and are instructed to record daily activities and psychological data.
2394180|NCT03612986|Active Comparator|A: Active comparator SYALOX® 300 Plus|"Active Nutraceutical containing HA and AKBA (SYALOX® 300 Plus)~1 tablet/day, oral administration"
2394181|NCT03612986|Placebo Comparator|B: Placebo|"Placebo~1 tablet/day, oral administration"
2394182|NCT03612973|Active Comparator|non cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
2394183|NCT03612973|Active Comparator|cirrhotic HCV patients|"complete blood picture~Liver and renal function tests~Prothrombin time and concentration~HCV quantitative polymerase chain reaction~Hepatitis B surface Ag~lipid profile~fasting blood glucose level~fasting insulin level~homeostasis model for the assessment of insulin resistance (HOMA-IR)~Fibrosis (FIB- 4) index~Aspartate aminotransferase (AST)/platelet ratio index (APRI)~Abdominal ultrasound to assess liver and spleen~Fibroscan/transient elastography to grade hepatic fibrosis all these investigations will be done before and after receiving direct acting antiviral therapy (sofosbuvir 400 mg once daily + daclatasvir 60 mg once daily) for 12 weeks"
2394184|NCT03612960|Experimental|Very low nicotine content cigarettes|Research cigarettes with very low nicotine content (0.03 mg/cigarette) compared to usual brand cigarettes.
2394185|NCT03612960|Placebo Comparator|Normal nicotine content cigarettes|Research cigarettes with normal nicotine content (0.8 mg/cigarette) similar to usual brand cigarettes.
2394186|NCT03612947|Active Comparator|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4.
2394187|NCT03612947|Placebo Comparator|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
2394188|NCT03612934||patients under the age of 65 years|patients under the age of 65 years
2394189|NCT03612934||patients at the age of 65 years and over|patients at the age of 65 years and over
3143297|NCT00005713||Continuing, preventative care for asthma|Low-income children with asthma will receive continuing, preventive care for asthma with trained staff in New York City Bureau of Child Health clinics
3143298|NCT00005724|Other|Minimal Intervention Group|Pamphlets on healthy eating mailed to participants.
3143299|NCT00005724|Experimental|Health Counselor Intervention Group|Food for Heart program, a structured diet treatment program for low-income patients with high cholesterol, given by health counselor at 4 treatment visits.
2394193|NCT03612908||Normothyroid pregnant women|Healthy pregnant women with the TSH serum values within the recommended ranged per trimester of pregnancy.
2394194|NCT03612908||Patients with a thyroid disease|Patients with a thyroid disease named hypothyroidism or hyperthyroidism.
2394195|NCT03612895|Experimental|Internal Care Coordination|The smoker will be connected to a Tobacco Care Coordinator who is based centrally within the health care system but has ready access via EHR, email, and telephone with staff in each primary care practice.
2394196|NCT03612895|Experimental|External Community Referral|"This intervention will connect the smoker directly via warm transfer to a the Massachusetts Smokers Helpline operated by National Jewish Health, which will provide its standard services to smokers."
2394197|NCT03612895|Other|Usual Care|Passive referral to quitline and referral to primary care physician.
2394198|NCT03612882||Western University Students|Online questionnaire
2394199|NCT03612869|Experimental|AAV SGSH gene therapy (LYS-SAF302)|One-time intracerebral administration of adeno-associated viral vector serotype rh10 containing the human N-sulfoglucosamine sulfohydrolase (SGSH) cDNA.
2394203|NCT03612843||Dry needle|Dry needling is provided as a part of a comprehensive treatment program by a physical therapist. The patient and the therapist will record any adverse events that occur.
2394206|NCT03612817|Active Comparator|Tafluprost/timolol with PM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
3143300|NCT00005724|Experimental|Computer Program Intervention Group|User-friendly interactive computer program providing dietary counseling tailored to the needs of the participant.
2394207|NCT03612817|Active Comparator|Tafluprost/timolol with AM dosing|Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)
2394210|NCT03612791|Active Comparator|Standard Treatment Arm|"Radiotherapy (RT):~Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a minimal total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~Total duration of RT (including brachytherapy) should be ≤ 55 days.~Chemotherapy:~- Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5)."
2394211|NCT03612791|Experimental|Experimental Treatment Arm|"Same treatment as described above (CRT, followed by uterovaginal brachytherapy), plus~atezolizumab administered IV 1200 mg Q3W, starting on the same week as EBRT (Week 1) and continued as an adjuvant for a total maximum of 20 cycles (approximately 14 months total of treatment)."
2394212|NCT03612778|Experimental|Plant-based diet|Participants will receive a meal plan based on unrefined plant-based foods with the following macronutrient composition: approximately 15% of calories from vegetable protein, <15% from fat, and 70-75% from carbohydrates. Additionally, to ensure adequate intake of n-3 polyunsaturated fatty acids, they will receive a supplement in the form of one 840 mg n-3 acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) daily. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
2394213|NCT03612778|Active Comparator|Mediterranean diet|Participants will receive a meal plan, based on the recommendations by the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology and European Atherosclerosis Society, based on Mediterranean diet pattern with the following macronutrient composition: approximately 15% of calories from animal and vegetable protein, up to 30% of calories from fat, 50-65% from carbohydrates. Nutritional intervention includes dietary counselling and weekly peer-group meetings together with a next of kin.
2394214|NCT03612765|Experimental|Intervention group|Participants in the intervention group will receive face-to-face intervention sessions that include interviews, discussions and didactic teaching.
2394215|NCT03612765|No Intervention|Control group|Participants in the control group will receive usual care that normally includes three monthly outpatient doctor consultations and when necessary, heart failure nurse referral.
2394216|NCT03612752|Experimental|Active arm|CMI-168
2394217|NCT03612752|Placebo Comparator|Placebo arm|Placebo
2394218|NCT03612739|Experimental|Cohort 1|5-azacytidine + 1x10^8 NKR-2 CAR-T Cells
2394219|NCT03612739|Experimental|Cohort 2|5-azacytidine + 3x10^8 NKR-2 CAR-T Cells
2394220|NCT03612739|Experimental|Cohort 3|5-azacytidine + 1x10^9 NKR-2 CAR-T Cells
2394223|NCT03612700|Experimental|CPFA-rich diet|Free living diet controlled in CPFA intake
2394224|NCT03612687||Laparoscopic Liver Surgery|Laparoscopic Liver Surgical Procedures with minimally invasive hemodynamic monitoring
2394225|NCT03612687||Laparoscopic Pancreas Surgery|Laparoscopic Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
2394226|NCT03612687||Open Liver Surgery|Open Liver Surgical Procedures with minimally invasive hemodynamic monitoring
2394227|NCT03612687||Open Pancreas Surgery|Open Pancreas Surgical Procedures with minimally invasive hemodynamic monitoring
2394228|NCT03612674|Active Comparator|Standard colonoscopy (S)|A standard colonoscopy will be performed.
2394229|NCT03612674|Experimental|AEV assisted colonoscopy (E)|Colonoscopy with ARC Endocuff Vision attached to the top of the scope will be performed.
2394230|NCT03612661|Experimental|Intuitive Eating Group Intervention|Intuitive eating intervention delivered in a group format with 8-10 women, led by 2 facilitators.
2394231|NCT03612661|Experimental|Intuitive Eating Guided Self-Help|Participants in this condition engage in 8 weeks of self-study of the intuitive eating intervention have ~20 minute weekly phone call with a study interventionist.
2394232|NCT03612648|Experimental|TRI-APBI|"Brachytherapy TRI-APBI the PTV is prescribed 7.5 Gy x three fractions given over two to three days OR~External beam TRI-APBI the PTV is prescribed 8.5 Gy x three fractions given over two to three days"
2394233|NCT03612622|Active Comparator|Transcranial Magnetic Stimulation-Real|Participants will receive active TMS once daily for two weeks
2394234|NCT03612622|Placebo Comparator|Transcranial Magnetic Stimulation-Sham|Participants will receive sham TMS once daily for two weeks
2394235|NCT03612609|Other|blood, urine and semen sample|15 patients, with acute dengue virus infection and a positive RNA detection in blood or/and urines
2394236|NCT03612596|Experimental|Narrative visualization|Wearable activity monitor, app, and enhanced motivational scrapbook materials (instant camera, stickers, markers, enhanced content)
2394237|NCT03612596|Active Comparator|Standard self-regulation|Wearable activity monitor, app, and standard workbook materials (markers, a workbook with a calendar log to keep track of steps over time)
2394238|NCT03612583|Experimental|Lower PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be set at 8 cm H2O
2394239|NCT03612583|Experimental|Higher PEEP|Lung- and Diaphragm-Protective Ventilation - PEEP will be titrated to achieve end-expiratory PL = 2-3 cm H20 and at least 5 cm H2O greater than the level applied in the lower PEEP arm
2394240|NCT03612570|Experimental|NPS Treated SH Lesion|Nano-Pulse Stimulation Device using pre-defined energy protocol
2394241|NCT03612557|Experimental|active treatment arm|penicillin G benzathine treatment
2394242|NCT03612544|Experimental|Intervention group|
2394244|NCT03612531|Experimental|Supportive Care (manual therapy)|Participants receive 10 manual therapy sessions performed by a speech pathologist during weeks 1-6. After completion of 6 weeks of therapy, participants perform manual therapy at home daily for 6 weeks.
2394245|NCT03612518|Experimental|Text and Voice Messages|Participants will receive text messages and voice messages
2394246|NCT03612518|Experimental|Interactive Phone Call|Participants will receive interactive phone calls
2394247|NCT03612518|No Intervention|Control|Participants in this arm will not be exposed to any intervention.
2394248|NCT03612505|Active Comparator|Intervention|
2394249|NCT03612505|No Intervention|Control|
2394250|NCT03612492|Active Comparator|Esmolol Group|Patients will receive esmolol during induction of anesthesia
2394251|NCT03612492|Active Comparator|Lidocaine Group|Patients will receive lidocaine during induction of anesthesia
2394252|NCT03612479|Experimental|KIDFIT Healthy|
2394253|NCT03612479|Active Comparator|KIDFIT Safe|
3143301|NCT00005727|Experimental|Intervention|Specially-designed nutrition education curriculum designed to lower dietary fat intake in people with low literacy skills.
2394255|NCT03612453|Experimental|Intervention group|
2394256|NCT03612453|Active Comparator|Control group|
2394257|NCT03612440|Experimental|Group D|40 patients receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
2394258|NCT03612440|Placebo Comparator|Group C|40 patients receive matching placebo (normal saline)
2394259|NCT03612427||Breastfed infants|Infants depending on breastfeeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
2394260|NCT03612427||Formula-fed infants|Infants have formula feeding S. Cholesterol S. Triglycerides S. HDL Cholesterol
2394261|NCT03612414|Experimental|Aqualief® tablets|400 mg mucoadhesive tablets; three times per day just
2394262|NCT03612414|Placebo Comparator|Placebo tablets|400 mg mucoadhesive placebo tablets, three times per day just
2394263|NCT03612401|Other|Neurogenic Bladder|Spinal Cord Injury patients with known neurogenic bladder on treatment with Anticholinergic Agents at baseline switched to mirabegron as the study intervention
2394264|NCT03612388||cardioplegia with MPS® (Myocardial protection system)|cardioplegic formula with MPS® (Myocardial protection system); use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
2394265|NCT03612388||cardioplegia with Cardioplexol ®|cardioplegic formula with Cardioplexol ® (colloid solution with Procaine, magnesium and potassium)
2394266|NCT03612375|Experimental|Intervention group|
2394267|NCT03612375|Active Comparator|Control group|
2394268|NCT03612362|Experimental|"Improved Injera Baking Biomass Stove"|"2750 eligible households with in 50 randomly selected clusters/Gotes are allocated into the improved Injera backing stove intervention arm."
2394269|NCT03612362|No Intervention|Control arm|"Similarly 2750 eligible households with in 50 randomly selected clusters/Gotes will continue to use the traditional Injera baking biomass stove and will be used as control arm."
2394270|NCT03612349|Other|Condition 1: All Products|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, all tobacco products are available in menthol and non-menthol flavors.
2394271|NCT03612349|Other|Condition 2: No menthol LCCs|Experimental Tobacco Marketplace Task is a behavioral economics task. During the task, participants purchase products from an online tobacco marketplace. In this condition, the online tobacco marketplace does not include menthol flavored little cigars and cigarillos.
2394272|NCT03612336|Experimental|Intervention group|
2394273|NCT03612336|Active Comparator|Control group|
2394274|NCT03612323|Experimental|Intra-ligamentary Piroxicam|Piroxicam is a long acting potent Non steroidal anti-inflammatory drug (NSAID)with half life of 50 hours in plasma, is given as intervention to assess the pain,will be administered by intra-ligamentary technique by injecting 0.4 milliliter (mL) of 20 milligram (Mg) piroxicam.
2394275|NCT03612323|Active Comparator|Intra-ligamentary Articaine|Articaine is a local anesthetic agent, will be administered by intraligamentary technique by injecting 0.4 milliliter (mL) of 4% articaine
2394276|NCT03612297||ATOUTBIO|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
2394277|NCT03612297||EVOLAB|Complete reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults.
2394278|NCT03612284|Experimental|Device Feasibility|"Scleral lens insertion solution study. This is not an interventional study, but a study to test a new contact lens solution. Primary FDA Classification: 21 CFR 886.5928 Soft (Hydrophilic) Contact Lens Care Products Product Code: LPN~Secondary FDA Classification: 21 CFR 886.5918 - Rigid gas permeable contact lens care products Product Code: MRC~The FDA has previously made risk determinations (class II, non-significant risk) for devices classified under 21 CFR 886.5928 and 21 CFR 886.5918. As a non-significant risk device, the GatorFil Contact Lens Saline Solution is exempt from the IDE regulation (21 CFR 812)."
3143302|NCT00005727|Active Comparator|Control|General nutrition education curriculum.
3143303|NCT00005739||Community-based therapy (case)|Community-based directly observed therapy (DOT) - A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
2394281|NCT03612258|Experimental|Functional Magnetic Resonance Imaging|
2394282|NCT03612232|Experimental|Cabozantinib|oral cabozantinib as tablets continuously (60 mg single dose, tablets)
2394283|NCT03612219|Experimental|IMRT with CC+Adjuvant Apatinib|Treat with Apatinib mesylate tablet for adjuvant treatment(the dose was 250 mg,orally,qd,28 days for an observation period,Six cycles)of local advanced nasopharyngeal carcinoma after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
3143304|NCT00005739||Self-administered treatment (control)|Clinic directly observed therapy (DOT) - Traditional self-administered preventive treatment
3143305|NCT00005772|Experimental|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
3143306|NCT00005772|Placebo Comparator|Normothermic|Placebo: Normothermic control group (with esophageal temperature at or near 37.0°C) for 96 hours
3143307|NCT00005773|Experimental|Early iNO Management|Initiation of iNO in use for term and near-term infants in respiratory failure with an oxygenation index between 15-25.
2394284|NCT03612219|Active Comparator|IMRT with CC|Only obeservation after Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy(cisplatin).
2394285|NCT03612193||Study A: Chronic >1 year|
2394286|NCT03612193||Study A: Acute <1 year|
2394287|NCT03612193||Study A: Household Control|
2394288|NCT03612193||Study B: Newly Diagnosed <6 months|
2394289|NCT03612193||Study B: Household Controls|
2394290|NCT03612167|Experimental|multi-modal cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
2394291|NCT03612167|Active Comparator|nutritional group|A quasi-experimental design with nonequivalent control was adopted in a senior center. The intervention for control group was a 12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
2394292|NCT03612154|Experimental|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
2394293|NCT03612128|Other|control group|Children continued their traditional physiotherapy
2394294|NCT03612128|Active Comparator|intervention group|We applied mirror therapy in addition to traditional physiotherapy
2394295|NCT03612115|Experimental|Neuromuscular electrical stimulation intervention|Neuromuscular electrical stimulation treatment
2394296|NCT03612115|No Intervention|Control|No additional intervention
2394297|NCT03612102|Active Comparator|Treatment|The treatment consists of a 5-day intensive group behavioral treatment program (IGBT)
2394298|NCT03612102|No Intervention|Waitlist|The waitlist consists of a 4-week waitlist period where parents will be provided with psychoeducational materials about their child's condition (i.e., selective mutism). After the 4-week waitlist period, families will be provided with the opportunity to participate in IGBT.
2394299|NCT03612089||Low back pain group|Individuals with non-specific chronic low back pain
2394300|NCT03612089||Healthy control group|Healthy individuals without low back pain
2394301|NCT03612076||Global cost of management of PJI|
2394302|NCT03612063|Experimental|Fitbit Iconic HR and Garmin Vivosmart HR|
2394303|NCT03612063|Experimental|Fitbit Iconic HR and TomTom Spark 3|
2394304|NCT03612063|Experimental|Garmin Vivosmart HR and TomTom Spark 3|
2394305|NCT03612063|Experimental|Fitbit Iconic HR and Apple Watch III|
2394306|NCT03612063|Experimental|Apple Watch III and Garmin Vivosmart HR|
2394307|NCT03612063|Experimental|Apple Watch III and TomTom Spark 3|
2394308|NCT03612050|Placebo Comparator|Enhanced Usual Care|facilitate any clinical interventions
2394309|NCT03612050|Experimental|Meaning Centered Psychotherapy|raise patients' sense of meaning/purpose
2394310|NCT03612037|Placebo Comparator|Control Phase|cellulose (600 mg)
2394311|NCT03612037|Experimental|Experimental Phase|alpha lipoic acid (600 mg)
2394312|NCT03612024||request for organ donation approved|
2394313|NCT03612024||request for organ donation rejected|
2394314|NCT03612011|Experimental|Onco-Repair|Onco-Repair tube of 150 ml
2394315|NCT03612011|Placebo Comparator|Placebo|Placebo tube of 150 ml
2394316|NCT03611998|Experimental|Survivors of Sex Trafficking|Survivors of sex trafficking (SST) who were living in a residential facility participated in this project by receiving occupation-based programming to address limitations in executive function skills over the course of the 8-month project. Sessions were held twice-monthly for an hour duration at each session.
2394317|NCT03611985|Experimental|Epidiferphane + taxane chemotherapy|
3143308|NCT00005773|Active Comparator|Standard iNO management|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
3143309|NCT00005774|Experimental|Early surfactant group|
3143310|NCT00005774|Active Comparator|Standard Practice group|
2394322|NCT03611933|No Intervention|Control group (CG)|Patients in the CG were provided with routine nursing care, as practiced in the clinic, including restricted bed rest. For this purpose, patients were given supine position in which the HOB was elevated 15° for 6-10 h; the patient's leg on the of the side of intervention was kept straight.
2394323|NCT03611933|Experimental|Experimental group (EG)|Patients in the EG were applied position changes between the first minute and sixth hour. During the initial six hours a supportive, thin pillow, 4 x 40 x 100 cm in size, was placed between the patient's shoulders and gluteals; this reduced the pressure on local tissues and muscle groups.
2394324|NCT03611920||Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
2394325|NCT03611920||Dexamethasone|Teeth were soaked in dexamethasone (60μ ml-1) for 20 minutes before replantation
2394326|NCT03611907|Active Comparator|SL1(Cook® Single Lumen)|Oocyte retrieval with only aspiration system
2394327|NCT03611907|Active Comparator|DL1 (Cook® EchoTip® Double Lumen)|Oocyte retrieval with aspiration and flushing system
2394328|NCT03611894||hemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2394329|NCT03611894||nonhemorrhagic ischemia|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2394330|NCT03611894||intracerebral hematoma|comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging)
2394331|NCT03611881|Experimental|Short, Short, Present|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
2394332|NCT03611881|Experimental|Short, Long, Present|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
2394333|NCT03611881|Experimental|Long, Short, Present|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + referral to community resource.
2394334|NCT03611881|Experimental|Long, Long, Present|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + referral to community resource.
2394335|NCT03611881|Experimental|Short, Short, Absent|4 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
2394336|NCT03611881|Experimental|Short, Long, Absent|4 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
2394337|NCT03611881|Experimental|Long, Short, Absent|8 weeks of counseling (by phone or videoconferencing) + 2 weeks of nicotine patch + no referral to community resource.
2394338|NCT03611881|Experimental|Long, Long, Absent|8 weeks of counseling (by phone or videoconferencing) + 8 weeks of nicotine patch + no referral to community resource.
3143311|NCT00005775|Experimental|Glutamine|TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids) with L-glutamine added (20% of the total amount of amino acids)
2394340|NCT03611855|Experimental|BCI Rehabilitation|Patients trained on use of BCI-controlled orthotic device are given a device for home use. Patients are asked to use the device an hour per day, 5 days per week, for 12 weeks. During device use, patients are instructed via pre-programmed instructions on a tablet paired with the device to either rest or vividly imagine moving their affected hand. The device receives signals from a scalp electrodes within a headset the patient dons prior to use. The device interprets these signals and closes the patient's hand during a successful rest trial, and opens the patient's hand during a successful move trial.
2394341|NCT03611855|Active Comparator|Range of Motion Therapy|Active and Passive Range-of-Motion (AROM, PROM) therapy strategies are commonly prescribed by physical therapists for at-home post-stroke motor deficit rehabilitation that can be performed independently. Patients practice movement with joints and limbs affected by the stroke, either by using the unaffected limb (or the assistance of a caretaker) to stretch the affected limb (PROM) or by actively moving the affected limb (AROM). Patients are asked to perform this therapy one hour per day, 5 days per week, for 12 weeks.
2394342|NCT03611842||Healthy eardrum|OME (otitis media with effusion)with normal tympanic membrane
2394343|NCT03611842||Atrophic eardrum|OME (otitis media with effusion) with atrophic membrane : thinning of the membrane, retraction pocket
2394346|NCT03611816||Group 1a|Patient with atrial fibrillation and without stroke history.
2394347|NCT03611816||Group 1b|Patient with atrial fibrillation with scheduled electrophysiology exploration or ablation.
2394348|NCT03611816||Group 1c|Patient with atrial fibrillation and with stroke history.
2394349|NCT03611816||Group 2|Patients aged over 80 years old and without history of atrial fibrillation.
2394350|NCT03611816||Group 3|Patient with cryptogenic stroke history before the age of 50.
2394351|NCT03611803|Experimental|Ekso Group|
2394352|NCT03611803|Active Comparator|Control|
2394353|NCT03611790|Experimental|Intervention|NeVa VS
2394355|NCT03611764|Experimental|Arm 1: Body Scan|"The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den"
3143312|NCT00005775|Placebo Comparator|Placebo|Standard TrophAmine (B. Braun/McGaw) with cysteine hydrochloride (40mg/gm amino acids)
3143313|NCT00005776|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide (iNO)
2394361|NCT03611725|Active Comparator|Distal radial artery|"After subcutaneous injection of lidocaine, the distal radial artery around the bony surface area is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the distal radial artery."
2394362|NCT03611725|Placebo Comparator|Radial artery|"After subcutaneous injection of lidocaine, the radial artery is punctured with a 20-gauge venipuncture catheter needle or steel needle according to the operator's discretion. After successful puncture, flexible, straight plastic 0.025 mini-guidewire is inserted through the hole of the puncture needle. Then, Radifocus® introducer sheath (Terumo, Tokyo, Japan) is inserted into the radial artery."
3143314|NCT00005776|Placebo Comparator|Oxygen|100% oxygen
3143315|NCT00005777|Experimental|Minimal ventilation with Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and early stress dose dexamethasone therapy
3143316|NCT00005777|Experimental|Minimal Ventilation without Dexamethasone|Minimal ventilator support strategy (permissive hypercapnia) and no dexamethasone therapy
3143317|NCT00005777|Active Comparator|Routine ventilation with Dexamethasone|
3143318|NCT00005777|Active Comparator|Routine ventilation without Dexamethasone|
3143320|NCT00005786|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-4 hours on days 1-5. Treatment repeats every 21 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding or stable disease may receive 6 additional courses.
3143321|NCT00005792|Experimental|MTV|Melphalan Topotecan Etoposide VP-16 Phosphate autologous stem cell transplant
3143322|NCT00005793|Experimental|Combination Chemotherapy|Patients receive induction chemotherapy with daunorubicin IV over 10-15 minutes on days 1-3, cytarabine IV continuously on days 1-5, topotecan IV continuously on days 6-8, and etoposide IV over 60 minutes on days 9 and 10. Within 4 weeks of hematologic recovery, patients achieving remission after induction receive consolidation chemotherapy with cytarabine IV over 1 hour every 12 hours on days 1, 3, and 5. Subsequent courses of consolidation chemotherapy begin within 2 weeks of documentation of hematologic recovery from the prior consolidation course. Consolidation chemotherapy continues for 4 courses in the absence of unacceptable toxicity or disease progression.
3143323|NCT00005796|Experimental|Single arm|PCV therapy
2394365|NCT03611699|Active Comparator|Umeclidinium bromide/vilanterol|Umeclidinium bromide/vilanterol (umeclidinium bromide 62.5 mcg; vilanterol 25mcg inhalation powder; trade name Anoro Ellipta) is a combination long-acting bronchodilator that acts to reduce the amount of air trapped in the lungs at the end of of expiration.
2394366|NCT03611699|Placebo Comparator|Placebo|A placebo inhaler will be administered to serve as a control comparator to the umeclidinium bromide/vilanterol inhaler.
2394367|NCT03611686||patient followed for metastatic prostate adenocarcinoma|patient wil be followed for metastatic prostate adenocarcinoma during 3 years
2394368|NCT03611673|Experimental|Group A: 15 Scents|Participants will be asked to inhale 15 different scents two times a day.
2394369|NCT03611673|Active Comparator|Group B: 4 Scents|Participants will be asked to inhale 4 different scents two times a day.
2394370|NCT03611660|Active Comparator|Traditional Lifestyle Program ONLY|Participants will receive an evidence-based 12-week family-based pediatric obesity program.
2394371|NCT03611660|Experimental|Traditional Lifestyle Program PLUS Mindfulness|Participants will receive an evidence-based 12-week family-based pediatric obesity program plus 6 sessions of mindfulness meditation instruction.
2394372|NCT03611647|Active Comparator|Probiotic|
2394373|NCT03611647|Placebo Comparator|Placebo|
2394374|NCT03611634||BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|The aim of this study is just to constitute a biological collection from samples from the GUT microbiote in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
2394375|NCT03611608|Experimental|LY3316531 Dose 1|LY3316531 administered IV
2394376|NCT03611608|Experimental|LY3316531 Dose 2|LY3316531 administered IV
2394377|NCT03611608|Placebo Comparator|Placebo|Placebo administered IV
2394378|NCT03611595|Experimental|Cabozantinib and 13-cis-retinoic acid|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles, combined with 13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
3143324|NCT00005797|Other|BuCy2|Busulfan & Cyclophosphamide
3143325|NCT00005797|Other|VP16/TBI|Fractionated Total Body Irradiation + VP-16
3143326|NCT00005798|Other|CTC Conditioning Regimen|Cyclophosphamide Thiotepa Carboplatin
3143327|NCT00005799|Experimental|Treatment (chemotherapy, TBI, HSCT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO BID on days 0-40 with taper to day 96. Patients with mixed chimerism, persistent or progressive disease, and no evidence of graft-versus-host disease and who have been off immunosuppression for at least 2 weeks undergo DLI over 30 minutes. DLI may be repeated every 65 days for up to 3 doses."
2394383|NCT03611556|Active Comparator|Arm A1|gemcitabine and nab-paclitaxel
2394384|NCT03611556|Experimental|Arm A2|oleclumab (MEDI9447), gemcitabine and nab-paclitaxel
2394385|NCT03611556|Experimental|Arm A3|oleclumab (MEDI9447), durvalumab (MEDI4736), and gemcitabine/nab-paclitaxel
2394386|NCT03611556|Active Comparator|Arm B1|mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2394387|NCT03611556|Experimental|Arm B2|oleclumab (MEDI9447) and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2394388|NCT03611556|Experimental|Arm B3|oleclumab (MEDI9447), durvalumab (MEDI4736), and mFOLFOX (oxaliplatin, leucovorin, 5-FU)
2394389|NCT03611543||Screening Patients|100 Patients. Each patient who agrees to participate and is consented and is undergoing a routine screening mammogram will receive her normal 4 view 2D plus 3D combination imaging (Left Cranial Caudal (LCC), Left Mediolateral-Oblique (LMO), Right Cranial Caudal (RCC), Right Mediolateral-Oblique (RMLO)) mammogram, with the current standard paddle. In addition she will also receive a CC and a MLO in one of her breasts as determined by a randomization scheme with the new investigational curved paddle. The amount of compression applied to both mammograms will be that to achieve tautness.
2394390|NCT03611543||Diagnostic Patients|400 Patients. Patients who agree to participate, are consented and are undergoing a diagnostic exam will have her prescribed diagnostic 2D plus 3D combination imaging as well as a CC or MLO with both the standard paddle and the new investigational curved paddle compressed to tautness on the breast of interest. The order of the paddles will be randomized and the view (CC or MLO) will be based in the visibility of the area of interest for which the diagnostic imaging was ordered. (It is possible that one of the views is superior to assess the area of interest).
2394391|NCT03611530|Experimental|CoQun®|Patients in Arm A will be randomized to receive Prostaglandin analogue (PGA) monotherapy + CoQun®. CoQun® ophthalmic solution will be administered two times daily. CoQun® will be administered in addition to hypotensive therapy. Dose modifications for CoQun® are not permitted.
2394392|NCT03611530|Placebo Comparator|Placebo|Patients in Arm B will be randomized to receive Prostaglandin analogue (PGA) monotherapy +Placebo. Placebo ophthalmic solution will be administered two times daily. Placebo will be administered in addition to hypotensive therapy. Dose modifications for Placebo are not permitted.
2394393|NCT03611517|Experimental|Sexual rehabilitation programme|The intervention exists of a nurse-led sexual rehabilitation programme, which is provided in addition to the care as usual. The intervention consists of four one-hour sessions at 1 month, 3, 6, and 12 months after RT. Women treated with RTBT will receive an additional appointment with the nurse (2 months after RTBT). Furthermore, the latter group receives a vaginal dilator set.
2394394|NCT03611517|No Intervention|Care as usual|The control group receives the optimal care as usual, according to each participating hospital's guidelines. Additionally, all patients receive an information booklet including information concerning sexuality after RT for GC. Patients who underwent RTBT also receive a vaginal dilator set.
2394395|NCT03611504||Hemospray® group|Patients with gastrointestinal bleeding treated with Hemospray®.
2394396|NCT03611491|Experimental|Princess® FILLER Lidocaine|Princess FILLER Lidocaine injections up to 10 ml given to the patients at baseline time point
2394397|NCT03611478|Experimental|Probiotic formulation|Contains a probiotic formulation. One capsule to be taken by mouth once daily for 28 days.
2442081|NCT03283189||Group 6|Liberal follow-up of pregnancy
3184103|NCT00720902|Active Comparator|A|Patients who have undergone transsphenoidal surgery for a pituitary adenoma and have normal growth hormone secretion.
2394398|NCT03611478|Placebo Comparator|Placebo|Matching placebo to be taken once daily by mouth for 28 days.
2394399|NCT03611465|Other|VT ablation group|patients presenting history of myocardial infarction and ventricular tachycardia undergoing a VT ablation
2394400|NCT03611465|Experimental|pre implantation group|patients presenting history of myocardial infarction but without history of ventricular tachycardia. Patients scheduled for a cardiac defibrillator implantation in primary prevention.
2394401|NCT03611465|Experimental|control group|patients without history of myocardial infarction and without history of ventricular tachycardia, undergoing an ablation in the left atrium for an atrial fibrillation or an accessory pathway ablation.
2394402|NCT03611452|Experimental|Simple continuous|the sutures will be taken continuously by simple method
2394403|NCT03611452|Active Comparator|subcuticular|the sutures will be taken subcuticular
2394404|NCT03611452|Active Comparator|interrupted|the sutures will be taken interrupted method
2394405|NCT03611439|Active Comparator|ReBuilder Actives|Subjects take one 650 mg capsule by mouth twice a day for 12 months.
2394406|NCT03611439|Placebo Comparator|ReBuilder Placebo|Subjects take one placebo capsule by mouth twice a day for 12 months.
2394407|NCT03611426|Experimental|rhThrombin ( Topical )|Cohort 1:rhThrombin ( Topical ) 500IU /ml、1000IU/m and 2000IU/ml During segmental hepatectomy; Cohort 2:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml with absorbable collagen sponge During segmental hepatectomy; Cohort 3:rhThrombin ( Topical ) 1000IU/m and 2000IU/ml used directly sprayed on hemorrhagic point During segmental hepatectomy;
2394408|NCT03611426|Placebo Comparator|placebo|Cohort 1: the same volume of saline during segmental hepatectomy; Cohort 2:the same volume of saline used withabsorbable collagen sponge during segmental hepatectomy; Cohort 3:the same volume of saline during segmental hepatectomy;
2394409|NCT03611413||ERAS programme|Patients who have been treated under an ERAS programm
2394410|NCT03611413||conventional care|Patients who have been treated under an conventional care
2394411|NCT03611400|Experimental|Probiotic|2 capsules daily for 3 weeks, containing 3.8 x 10^9 CFU (colony forming units)/capsule of Lactobacillus rhamnosus strain R011and 0.2 x 10^9 CFU/capsule of L. helveticus strain R0052 (group is unknown, double blinded)
2394412|NCT03611400|Placebo Comparator|Placebo|2 capsules daily for 3 weeks containing the same carrier material and is similar in size, shape and taste to probiotic (group is unknown, double blinded)
2394413|NCT03611387||Normal|Patients without any type of glaucoma
2394414|NCT03611387||Primary angle closure glaucoma|Patients with primary angle closure glaucoma
2394415|NCT03611387||Primary open-angle glaucoma|Patients with primary open-angle glaucoma
2394416|NCT03611374|Experimental|Erector Spinae Plane Block|All participants will get the Erector Spinae Plane block (ESPB) as a prospective cohort study. After anesthesia induction all enrolled patients will have bilateral ESPB catheters placed at the T7 spine level prior to surgery. The surgery is a sternotomy for congenital heart repair in high risk children and adults.
2394417|NCT03611348|Active Comparator|Microneedling + latanoprost|patient will receive topical application of latanoprost 0.005% eye drops solution twice daily for 3 months preceded by microneeding in sessions by dermapen every 2 weeks for 3 months (totally 6 sessions).
2394418|NCT03611348|Active Comparator|latanoprost|Patient will receive topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months (active control side).
2394419|NCT03611335||Site 1 H+H|Lincoln Medical and Mental Health Center
2394420|NCT03611335||Site 2 H+H|Bellevue Hospital
2394421|NCT03611335||Site 3 H+H|Metropolitan Hospital
2394422|NCT03611335||Site 4 H+H|Elmhurst Hospital Center
2394423|NCT03611335||Site 5 H+H|Coney Island Hospital
2394424|NCT03611335||Site 6 H+H|Woodhull Medical and Mental Health Center
2394425|NCT03611322|Experimental|DV3372 device|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
2394426|NCT03611322|Active Comparator|PDS290 semaglutide pen-injector|Participants will receive semaglutide on day 1, 8, 15, 22 and 29. The treatment period from first treatment (Day 1) to end of the treatment (Day 29) will be 4 weeks.
2394427|NCT03611309|Experimental|Surgeon-palliative care team co-management|In the Surgeon-palliative care team co-management arm, all patients receive the surgical care of surgeon alone management, which includes surgeon and the surgical team. In addition to this surgeon alone care, palliative care will also be provided by a specialist team. For patients in this arm, patients and/or family members will be seen by the palliative care team: (1) in an outpatient setting prior to surgery, (2) in the hospital within 72 hours of their initial surgery and as needed afterwards, and (3) via phone on in-clinic (per patient preference) on an at least monthly basis and/or as needed for 12 weeks following surgery.
2394428|NCT03611309|Other|Surgeon alone management|The surgeon and surgical team will manage symptoms, psychosocial support, and prognostic related communication. The surgeon and surgical team care for the patient and their family both prior to and following surgery. The surgeon team is given guidelines published by the National Cancer Coalition Network as to when palliative care specialist consultation is recommended
2394429|NCT03611283|Experimental|Test group|"Patients had to use:~Mouthwash treatment (250 ml): Aqua, Betaine, Glycerin, PEG-40, Hydrogenated Castor Oil, Propylene Glycol, Xylitol, Aroma, Potassium Phosphate, Diazolidinyl Urea, Allantoin, Olea Europaea Fruit Oil, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Panthenol, Tocopheryl Acetate, Sucralose, Carum Petroselinum Seed Oil, Limonene.~Toothpaste treatment (50 ml): Glycerin, Aqua, Hydrated Silica, Xylitol, Betine, Tetrapotassium Pyrophosphate, Olea Europaea Fruti Oil, Xanthan Gum, Titanium Dioxide, Potassium Phosphate, Aroma, Sodium Fluoride, Diazolidinyl Urea, Papain, Carum Petroselinum Seed Oil, Panthenol, Tocopheryl Acetate, Limonene"
2394430|NCT03611283|Placebo Comparator|Placebo group|"Patients had to use:~Mouthwash placebo(250 ml): Aqua, Glycerin, PEG-40 Hydrogenated Castor Oil, Propylene Glycol, flavoring, Potassium Phospate, Diazolidinyl Urea, Sodium Methylparaben, Sodium Propylparaben, Sodium Fluoride, CI75810, Tocopheryl Acetate, Sucralose, LImonene.~Toothpaste placebo (50 ml): Aqua, Sorbitol, Hydrated Silica, Glycerin, Tetrapotassium Pyrophosphate, Xanthan Gum Titanium Dioxide, Sodium Lauryl Sulphate, Potassium Phosphate, flavoring, Sodium Fluoride, Diazolidinyl Urea, Sucralose, Limonene"
2394431|NCT03611257|Experimental|dRAST|"Hematologic patients with bacteremia will receive antibiotics based on dRAST results."
2443608|NCT05075447|Experimental|ADHD group|Child diagnosed with ADHD
2394432|NCT03611257|Active Comparator|Current standard method|Hematologic patients with bacteremia will receive antibiotics based on current standard method results.
2394433|NCT03611244|Experimental|Experimental group|When loss of ambulation was observed in patients with Duchenne muscular dystrophy, portable seat device devised to maintain lumbar lordosis were applied within 1 year, and then compliance with the the device were evaluated at 6-month intervals for 5 years.
2394434|NCT03611244|No Intervention|Control group|Analysis of retrospective medical records who had not been applied portable seat device devised to maintain lumbar lordosis
2394435|NCT03611231|Experimental|Experimental|chidamide
2394436|NCT03611218|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and on follow-up week per patient. Each treatment week includes three hemodiafiltration HDFsessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Nipro: Sureflux-17UX and comparator Baxter/Gambro: Polyflux 170 H.
2394437|NCT03611205|Experimental|Diagnostic (dPET/CT)|Participants receive radiotracer injection and undergo dPET/CT over 20-75 minutes at baseline, during the 2nd and 4th week of radiotherapy, and 3 months after the completion of chemoradiation therapy.
2394438|NCT03611192|Experimental|Multicomponent exercise group|
2394439|NCT03611192|Active Comparator|Home-program exercise group|
2394440|NCT03611179|Experimental|advanced ovarian cancer cases|patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 & Carboplatin AUC 5 every 21 days)
2394441|NCT03611153|Experimental|Oral myeloperoxidase inhibitor|Patient may take 30 mg of oral myeloperoxidase inhibitor following baseline right heart catheterization.
2394442|NCT03611153|Placebo Comparator|Placebo|Patient may take 30 mg of placebo oral capsule following baseline right heart catheterization.
2394443|NCT03611140|Experimental|Dietary portfolio (DP)|The dietary portfolio was given daily at the breakfast and dinner for 2 months. The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein, oat, and inulin) that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
2394444|NCT03611140|Placebo Comparator|placebo (P)|The placebo (P) was given daily at the breakfast and dinner for 2 months. The placebo intervention consisted of a mixture of calcium caseinate, maltodextrins, sweetener and of artificial flavoring that was provided in a dehydrated form in packages of 30 g dissolved in 250 ml water for breakfast and 30 g in 250ml water for dinner.
2394445|NCT03611127|Experimental|early pulmonary rehabilitation (EPR)|early pulmonary rehabilitation started shortly after hospital discharge for COPD exacerbation.
2394446|NCT03611127|No Intervention|Usual care (UC)|No pulmonary rehabilitation for this group
2394447|NCT03611114|Experimental|Blood orange juice|Subjects will be asked to consume blood orange juice (400 ml/day) for 2 weeks.
2394448|NCT03611114|Placebo Comparator|Control drink|Subjects will be asked to consume a control drink (400 ml/day) for 2 weeks.
2394449|NCT03611088|Experimental|Newborns submitted to Kangaroo Position.|
2394450|NCT03611088|No Intervention|Newborns not submitted to Kangaroo Position.|
3184104|NCT00720902|Active Comparator|B|Patients who have undergone transsphenoidal surgery for pituitary adenoma who are growth hormone deficient.
3184105|NCT00720915|Other|No Anticoagulant Therapy|No Anticoagulant Therapy
3184106|NCT00720915|Other|Anticoagulant Therapy|Continue on anticoagulant therapy
3184107|NCT00720928|Other|single group|"Posterior uveitis patients having complete or incomplete type of Behcet's disease; typical ocular lesion and at least, one of the main symptoms or two of the additional symptoms.~Selection of study eye : For patients with unilateral uveitis, the study eye will be the affected eye; for patients with bilateral uveitis, the study eye will be the more severely affected eye (i.e., the eye having suffered more recurrences in the previous year, or if equal, the eye having received more therapy in the previous year, or if equal, the eye having the worse VA, or if equal, the eye clinically judged to be the more severely affected eye)."
3184108|NCT00720954|Other|A|CT guided pleural needle biopsy
3184109|NCT00720954|Other|B|Thoracoscopy
3184110|NCT00720967|Active Comparator|1|Control Group (Open heart surgery alone)
3184111|NCT00720967|Experimental|2|Intraoperative Modified Ultrafiltration (MUF) Group (Open heart surgery with intraoperative MUF)
3184112|NCT00720967|Experimental|3|Preoperative Hemodialysis Group (Open Heart Surgery after preoperative hemodialysis)
3184113|NCT00720993||1|Control group - patients scheduled for routine colonoscopy procedures with no self or family history or other GI conditions.
2394462|NCT03611049|Placebo Comparator|Low dose Vitamin D intervention|intervention includes 800 IU Vitamin D3 replacement
2394463|NCT03611049|Active Comparator|High dose Vitamin D intervention|Intervention includes 5000 IU Vitamin D3 replacement
2394464|NCT03611036|Experimental|Strength|Patients will follow the pulmonary rehabilitation program associated with upper limbs strength training for a duration of 4 weeks
2394465|NCT03611036|Active Comparator|Endurance|Patients will follow the pulmonary rehabilitation program associated with upper limbs endurance training for a duration of 4 weeks
2394466|NCT03611010|Experimental|10 mg oral atorvastatin|Subjects taking 10 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2394467|NCT03611010|Experimental|20 mg oral atorvastatin|Subjects taking 20 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2394468|NCT03611010|Experimental|40 mg oral atorvastatin|Subjects taking 40 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2394469|NCT03611010|Experimental|80 mg oral atorvastatin|Subjects taking 80 mg of oral atorvastatin daily at baseline will take titrated dose of atorvastatin injection.
2394470|NCT03610997|Other|Photorefractive keratectomy|The children will undergo PRK in the affected eye(s) using previously derived formulas for PRK.
2394471|NCT03610984||Intensive structured education group|Regular outpatient visit in every 3 months to these patients. The glucose control and diabetes complication screening will be evaluated in visit. Patients will also be evaluated by specialized psychologists, dietitians and therapists. Diabetes self-management education will be regularly exposed to patients
2394472|NCT03610984||Conventional education group|Outpatients visit to endocrinologists when necessary in a conventional way.
2394642|NCT03609866|Active Comparator|control|will be performed metatarsophalangeal joint passive mobilization
3143328|NCT00005800|Experimental|Dose-Dense Chemotherapy|Patients receive doxorubicin IV on day 1 every 2 weeks for 3 courses. After 3 weeks of rest, patients receive docetaxel IV over 1 hour on day 1 every 2 weeks for 3 courses. Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each doxorubicin and docetaxel course. Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
2394474|NCT03610958|Experimental|Epitomee Device arm|"A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety. The Device is composed of a 000 size standard capsule and the Tulip's proprietary Device, encapsulated within it.~The Device components are produced from approved pharmaceutical excipients / food additives / generally recognized as safe (GRAS )/ food contact materials which are used at high grade"
2394475|NCT03610945|Experimental|EDP-305 and fluconazole interaction (Part 1)|
2394476|NCT03610945|Experimental|EDP-305 and quinidine interaction (Part 2)|
2394477|NCT03610932|Experimental|Vitamin C|Participants will ingest 3 (500 mg) capsules of Vitamin C each day for 2 weeks.
2394478|NCT03610932|Active Comparator|Placebo|Participants will ingest a matched capsule for size and color to the Vitamin C supplement.
2394479|NCT03610919|Experimental|Oxytocin nasal spray(5 doses)|Oxytocin nasal spray for 5 days, 24 IU per day
2394480|NCT03610919|Experimental|Oxytocin nasal spray(3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day.
2394481|NCT03610919|Placebo Comparator|Placebo nasal spray(control group)|Placebo nasal spray for 5 days,24 IU per day.
2394482|NCT03610906||Pediatrics with Tumors|Pediatrics who have a tumor specimen that is suspected to be craniopharyngioma, but is deemed superfluous to the clinical care of the patient (e.g. pathological diagnosis).
2394483|NCT03610893|Active Comparator|Perineural dexamethasone|addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
2394484|NCT03610893|Active Comparator|Perineural dexmedetomidine|addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block
2394485|NCT03610880|Experimental|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
2394486|NCT03610880|Experimental|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181
2394487|NCT03610867|Experimental|Furaprevir capsule (SAD)|single ascending oral dose (100 mg, 200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
2394488|NCT03610867|Placebo Comparator|Placebo (SAD)|"Single ascending oral dose of Furaprevir similar capsule.~."
2394489|NCT03610867|Experimental|Furaprevir capsule (MAD)|multiple ascending oral doses (200 mg, 400 mg, and 600 mg) of TG-2349 (Furaprevir capsule)
2394490|NCT03610867|Placebo Comparator|Placebo (MAD)|Multiple ascending oral doses of Furaprevir similar capsule
2394491|NCT03610854|Experimental|Fitness tracker Arm|Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment.
2394492|NCT03610841||preterm labor|Workgroup consists of patients which diagnosed with preterm labor between the age of 21 and 34
2394493|NCT03610841||healthy|24-36 6/7 weeks of pregnant between the age of 21 and 34
3143329|NCT00005807|Experimental|Treated Participants|dose escalation treatment
3143330|NCT00005808|Experimental|Part 1 (lutetium texaphyrin, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. Patients undergo in vivo tissue assessment by spectrometer at 0, 1, 3, 5, 12, and 24 hours and loop electrical excision procedure (LEEP) at 24 hours after lutetium texaphyrin infusion.
3143331|NCT00005808|Experimental|Part 2 (lutetium texaphyrin, laser therapy, LEEP)|Patients receive lutetium texaphyrin IV over 5-20 minutes. A laser delivers 730 nm of light to the cervix for 4, 8, or 16 minutes. Patients undergo LEEP at 4, 8, or 12 hours after exposure of the cervix to the light source.
3143332|NCT00005810|Experimental|Estramustine + docetaxel + carboplatin+ filgrastim|Patients receive oral estramustine 3 times daily on days 1-5. Patients receive docetaxel IV over 1 hour followed by carboplatin IV over 1 hour on day 2. Filgrastim (G-CSF) SC is administered beginning on day 6 and continuing until hematopoietic recovery. Treatment continues every 21 days in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for a maximum of 2 years.
2394498|NCT03610789||REDAPT Revision Femoral System|REDAPT Revision Femoral System Monolithic Sleeveless Stems, monolithic sleeved stems and/or Acetabular Components or modular shells and/or augments
2394499|NCT03610776|Experimental|Portion control plate|Portion control plate first (50% of subjects experiment with this plate first)
2394500|NCT03610776|Active Comparator|Conventional plate|Conventional plate first (50% of subjects experiment with this plate first)
2394501|NCT03610763|Active Comparator|Transplantation/Replantation Patients|Can plateaued hand function in hand transplantation patients/hand replantation patients in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
2394502|NCT03610763|Active Comparator|Nerve Injury Patients active|Can plateaued hand function in peripheral nervous system injuries in the chronic stage of recovery be facilitated by use of bi-hemispheric transcranial direct current stimulation (tDCS) combined with modified Constraint Induced Movement Therapy (CIMT)?
2394503|NCT03610763|No Intervention|Actigraphy Testing|We will acquire a set of actigraphy data from a group of hand transplant/replant patients and unilateral, adult amputees in order to evaluate typical patterns of limb use prior to hand transplantation and to investigate prosthesis utilization.
3184114|NCT00720993||2|Case group - patients with confirmed colorectal carcinoma scheduled for surgery or observed during routine colonoscopy screening.
2394510|NCT03610711|Experimental|Arm A Nivolumab Only|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
2394511|NCT03610711|Experimental|Arm B Nivolumab + Relatlimab|stereotactic body radiation (SBRT) 8G x 3 followed by Nivolumab 240mg administered IV over 30 minutes every 2 weeks and Relatlimab (anti-LAG3) every 2 weeks for one year or until evidence of disease progression or unresolved toxicity.
2394512|NCT03610698|Experimental|Facilitated Intervention|Intervention arm facilitated by a trained team member, delivering the 8 positive emotion skills over 5 weeks.
2394513|NCT03610698|Experimental|Self-Guided Intervention|Intervention arm that is self-guided on an online platform, delivering the 8 positive emotion skills over 5 weeks.
2394514|NCT03610698|Active Comparator|Emotion Reporting Control|Participants in the emotion reporting control condition will be reporting their emotions daily for the same length as the intervention.
2394515|NCT03610685|Placebo Comparator|Placebo|Participants will be given 2 weeks of placebo treatment. The placebo capsules will be taken once a day orally. The daily dose of placebo treatment will match the Prednisone dose for each participant.
2394516|NCT03610685|Active Comparator|Prednisolone|Participants will be given 2 weeks of prednisolone treatment. This is administered orally once a day. The daily dose is calculated according to 0.5mg/kg with a maximum dose of 40mg per day.
2394517|NCT03610672|Active Comparator|OD prevention/response training|Immediately following the baseline assessment, trained research staff will conduct a brief (20 min.) OD training with each participant. Participants will be asked to view the NYC Department of Health and Mental Hygiene's 13-minute OD prevention and response training video (available online free-of-charge). Following the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to execute this assembly procedure. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
2394518|NCT03610672|Experimental|OD training + mobile PI intervention|Participants will complete the same baseline assessment and OD training (plus naloxone) as those in the first condition. Participants also will receive mobile phones pre-loaded with the PI App and will be sent daily prompts. As part of the PI App, participants will be asked to share information about avoiding problems associated with opioid use with peers in their social network, and to encourage their peers to download the PI App for their own use.
3143333|NCT00005811|Experimental|Treatment (topotecan hydrochloride)|"INDUCTION: Patients receive topotecan hydrochloride IT over 5 minutes twice weekly for 6 weeks.~CONSOLIDATION: Beginning 1 week after completion of induction, patients receive topotecan hydrochloride IT over 5 minutes weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 2 weeks after completion of consolidation, patients receive topotecan hydrochloride IT over 5 minutes twice monthly for 4 months and then monthly through year 1."
3143334|NCT00005812|Experimental|Temozolomide|"Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~disease progression~intolerable toxicity~complete response - 2 full additional cycles~if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response."
3184115|NCT00721006|Experimental|MESENDO|All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
2394523|NCT03610620|Experimental|ARM A|Vivascope 2500 ex-vivo fluorescent confocal microscope
2394524|NCT03610607|Active Comparator|intense education of periodontal health maintenance|
2394525|NCT03610607|Placebo Comparator|No intense education of periodontal health maintenance|
2394526|NCT03610594|Experimental|kalaripayattu|The experimental groups will treated with kalaripayattu exercises for the period of 12 weeks
2394527|NCT03610594|No Intervention|Wait list control|Control group will not be given any intervention. After the treatment period is over, all the subjects will be given Kalaripayattu training.
3143335|NCT00005817|Experimental|Arm I (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on day 1.
3143336|NCT00005817|Experimental|Arm II (becatecarin)|Patients receive rebeccamycin analogue IV over 60 minutes on days 1-5.
3143337|NCT00005818|Experimental|Treatment (irinotecan hydrochloride, semaxanib)|Patients receive irinotecan IV over 90 minutes on day 1 of weeks 1-4 and SU5416 IV over 60 minutes on days 1 and 4 of weeks 1-6. Treatment continues every 6 weeks in the absence of unacceptable toxicity or disease progression.
2394532|NCT03610568|Experimental|Growing up GREAT! Intervention|
2394533|NCT03610568|No Intervention|Control|
2394534|NCT03610555||Current website|Show patient one of the website
2394535|NCT03610555||New patient centered website|Show patient another (different) of the website
2394536|NCT03610542|Experimental|Cognitive Behaviour Therapy|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting.
2394537|NCT03610542|Experimental|Cognitive Behaviour Therapy with 2 Booster Sessions|Cognitive behaviour therapy conducted in groups of 6-8 persons.One forty-five minute session per week for 6 weeks: Triggers for anxiety, identifying and challenging negative thoughts, relaxation, overcoming avoidance, and goal setting. 2 booster sessions (forty-five minutes each) will be provided at three and nine months. Each session will recap the content of the initial 6 sessions.
2394538|NCT03610542|No Intervention|Control|This is a no intervention control arm
2394539|NCT03610529|Experimental|ECG monitoring system CardioSenseSystem group|
2394540|NCT03610529|Active Comparator|ECG monitoring system Philips Intellivue|
2394543|NCT03610503|Experimental|Music|Patients listen to music during EMG test
2394544|NCT03610503|No Intervention|Control (Standard Care)|Patients do not listen to music during EMG test (ie. Standard of care)
2394609|NCT03610113|Experimental|REVERSE ARTHROPLASTY TREATMENT|"This group receives a surgical intervention by the use of reverse shoulder arthroplasty through deltopectoral approach and tuberosities reattachment.~It is followed by the same rehabilitation protocol than conservative treatment"
2394643|NCT03609866|Experimental|experimental|rapid thoracic compression technique will be applied
3143338|NCT00005820|Experimental|nitrocamptothecin|"Patients receive nitrocamptothecin orally daily for 5 consecutive days each week for 3 consecutive weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until evidence of progression or relapse for a maximum of 2 years from the date of registration."
2394546|NCT03610477|Active Comparator|Medium Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from medium chain triglycerides.
2394547|NCT03610477|Placebo Comparator|Long Chain Triglyceride|Participants will be randomized to consume 5% of total energy intake from long chain triglycerides.
3184116|NCT00721006|Placebo Comparator|placebo|All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion
2394549|NCT03610451|Experimental|Floatation-REST|Participants will float supine in a pool of water saturated with epsom salt, in a light and sound attenuated chamber, for up to 60 minutes, on 8 separate occasions. Ratings of the experience will be collected before and after each float.
2394550|NCT03610451|Other|Usual care|Participants will be assessed along the same time periods, i.e., before and after a 60 minute window, on 8 separate occasions. Ratings of the experience will be collected before and after each time period.
2394553|NCT03610425||Post-op evidence based bundle w/ Pre-op education|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the post-operative evidence based bundle/standard pre-operative education.
2394554|NCT03610425||Standard pre-operative education alone|25 patients undergoing hysterectomy from October 1, 2017 to December 31, 2017 will receive the standard pre-operative education alone.
2394555|NCT03610412|Active Comparator|Cinnamomum Cassia|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.
2394556|NCT03610412|Placebo Comparator|Placebo|A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.
3184117|NCT00721019|Experimental|5-hour bedtime|
3184118|NCT00721019|Experimental|8.5-hour bedtime|
3184119|NCT00721032|Experimental|1|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia.
2394562|NCT03610373|Experimental|Shared Decision Making|In this arm, parents and children will participate in a shared decision-making protocol with the clinician to plan their treatment. The treatment options available are established, evidence-based treatment techniques. The shared decision-making protocol was developed for this research project.
2394563|NCT03610373|Active Comparator|Clinician Guided|In this arm, the clinician will plan the treatment in consultation with their supervisor, and share the treatment plan with the parent and child. The parent and child will have the opportunity to ask questions about the treatment plan (and, if they do not agree, reject the treatment plan), but they are not actively involved in making each decision. This is more typical of usual care.
2394564|NCT03610360|Active Comparator|Arm A|Arm A will receive the study drug MesoPher plus best supportive care
2394565|NCT03610360|No Intervention|Arm B|Arm B will follow best supportive care as deemed appropriate by the investigator.
2394566|NCT03610347|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux®)
2394567|NCT03610347|Active Comparator|Drug-Eluting Stent (DES)|Sirolimus Eluting Stent (Orsiro®)
2394568|NCT03610334|Experimental|IFB-088|"IFB-088 oral capsule:~In SAD phase: single daily dose of IFB-088 will be administered to 6 successive cohorts while increasing dose exposure.~In MAD phase: multiple doses of IFB-088 will be administered daily during 14 days to 3 succesive cohorts while increasing dose exposure."
2394569|NCT03610334|Placebo Comparator|Placebo|"Placebo oral capsule:~In SAD phase: single daily dose of placebo (cellulose microcrystalline) will be administered in equivalent-weight.~In MAD phase: multiple doses of placebo (cellulose microcrystalline) will be administered daily during 14 days."
2394570|NCT03610321|Active Comparator|Statin group|Receiving statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) only for 1 month.
2394571|NCT03610321|Experimental|Gefarnate group|Combined treatment with statins (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) and gefarnate (100 mg, three times daily, oral) for 1 month.
2394572|NCT03610295|Experimental|PPI group|cataract extraction surgery with prophylactic peripheral iridectomy
2394573|NCT03610295|Active Comparator|historical control group|cataract extraction surgery
2394574|NCT03610282|Experimental|EEG Dynamics|EEG data will be collected on patients receiving propofol and IV methylphenidate together.
2394575|NCT03610282|Placebo Comparator|Propofol EEG Dynamics|EEG data will be collected on patients receiving propofol and a saline placebo.
2443630|NCT05075408|Experimental|Nemolizumab 30 mg|
3143339|NCT00005828|Experimental|green tea extract|Patients receive oral green tea extract six times daily for 4 months. Patients with a 50% decline in PSA, complete or partial response, or stable disease after 4 months continue treatment in the absence of disease progression or unacceptable toxicity. Patients with disease progression after 4 months receive no further treatment. Patients are followed every 3 months for 5 years or until disease progression. If disease progression, patients are followed every 6 months for 5 years.
2394577|NCT03610256|Experimental|SADI-S|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic SADI-S (laparoscopic Single-anastomosis duodeno ileal bypass with Sleeve gastrectomy).~SADI-S will be performed as a primary procedure or after failure of sleeve gastrectomy, defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
2394578|NCT03610256|Active Comparator|RYGB|"This corresponds to obese patients (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 +/- co-morbidities (high blood pressure, dyslipidemia, obstructive sleep apnea, type 2 diabetes mellitus, arthrosis)) benefiting from a laparoscopic RYGB (laparoscopic Roux-en-Y Gastric ByPass).~Similarly to the experimental group, RYGB will be performed as a primary procedure or after failure of sleeve gastrectomy, which is defined as insufficient weight loss at 18 months after surgery (EWL% <50), or as weight regain (+ 20% of nadir weight)."
2394579|NCT03610243|Experimental|Self-administered acupressure|"The proposed self-administered acupressure intervention is patient-centered comprising four pre-selected acupoints that should be applied pressure on by all patients and a list of additional acupoints from which patients can choose two for self-administration according to the personalized recommendations of trainers. In this way, each patient will receive an individualized protocol (four pre-selected and two self-selected acupoints).~The intervention consists of: individual participant training (Two 2-hour one-on-one training sessions in week 1), self-practice (15 minutes of self-administered acupressure twice a day), and follow-up visits (a 1-hour follow-up visit at weeks 2, 3, and 4)."
2394580|NCT03610243|No Intervention|Wait-list control|The wait-list control group will be contacted in the third week to attend a health talk unrelated to symptom management.
2394581|NCT03610230|Experimental|Monofer|Iron Isomaltoside as a single intravenous dose 1000mg over 60 minutes
2394582|NCT03610230|Active Comparator|Venofer|Iron Sucrose 200mg weekly intravenous infusions over 2 hours for 5 weeks
2394583|NCT03610217|Experimental|Interstitial lung disease induction|
2394584|NCT03610217|Experimental|Pulmonary arterial hypertension|
2394585|NCT03610217|Experimental|Raynaud's phenomenon|
2394586|NCT03610217|Experimental|Digital ulcers|
2394587|NCT03610217|Experimental|Inflammatory arthritis|
2394588|NCT03610217|Experimental|Gastroesophageal reflux|
2394589|NCT03610217|Experimental|Bacterial overgrowth|
2394590|NCT03610217|Experimental|Constipation|
2394591|NCT03610217|Experimental|Skin involvement|
2394592|NCT03610217|Experimental|Pain|
2394593|NCT03610204|Experimental|Deep massage (DM) group|"The therapist performs the deep massage with buffalo horn technique. A small rod with a cone-like end was used in the technique. By pressuring the rod end with a higher force against the body surface of the participant, it produces higher pressure that may release the deep-layer fascia of muscles. Thus this technique features a deep massage."
2394594|NCT03610204|Active Comparator|Superficial massage (SM) group|"The therapist performs the superficial massage with buffalo horn technique. By pressuring the rod end with a lower force against the body surface of the participant, it produces lower pressure. Thus this intervention features a superficial massage."
2394595|NCT03610191||Surgery|Patients aged over 18 scheduled for elective cardiac surgery under CPB and general anesthesia. This group will later be divided in to two sub groups based on their neuropsychological battery tests results before surgery and one day before discharge. Blood sample will be collected before, immediately after surgery and at 24h after surgery for serum biomarker tests: MD2, CysC as well as DNA methylation markers of neural system origin.
2394596|NCT03610191||non-surgical control|Age and sex matched volunteers from the community were included for neuropsychological battery tests and set as controls for the diagnosis of POCd in surgical patients.
2394597|NCT03610178|Active Comparator|very tight glycemic targets|
2394598|NCT03610178|Active Comparator|tight-moderate glycemic targets|
2394599|NCT03610178|No Intervention|Control group|Only observation in women with normal glucose tolerance
3184120|NCT00721032|Active Comparator|2|Anti-arrhythmic group.
3184121|NCT00721045|Active Comparator|A1|15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping.
2394602|NCT03610152|No Intervention|Control|Hospitals made aware of Choosing Wisely Canada recommendations and Health Quality Ontario data.
2394603|NCT03610152|Experimental|Hospital wide policy|A hospital-wide policy will be implemented whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologists based on their clinical assessment of the patient.
2394604|NCT03610139|Active Comparator|low dose vitamin D3 supplementation|Patients in this group will take 800 IU daily dose of vitamin D supplementation. They will be kept on 800 IU for 6 months. If they still had low vitamin D at 3 months, they will be asked about their adherence to the supplement, the investigators will remind them to take it as prescribed, and the investigators will keep the 800 IU vitamin D supplement dose for another 3 months. If they were still deficient at 6 months, the investigators will switch them to 10,000 IU weekly dose.
2394605|NCT03610139|Experimental|high dose vitamin D3 supplementation|"Patients in this group will take 50,000 IU weekly dose of vitamin D supplementation. Patients who will reach normal serum vitamin D level, between 40-80 ng/ml, at 3 or 6 months will be asked to decrease their Vitamin D3 supplementation as follows: Those who will reach levels between 40-60ng/ml will be switched to 10,000 IU three times per week, and those who reach levels between 60-80 ng/ml will be switched to 10,000 IU once weekly.~If they did not have any improvement in their levels of vitamin D at 3 or 6 months, they will be asked about their adherence to the supplement and the investigators will remind them to take it as prescribed and the investigators will keep them at the 50,000 IU weekly dose."
2394606|NCT03610126||volume controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway mechanical ventilation of patients will be maintained with volume controlled ventilation mode
2394607|NCT03610126||pressure controlled ventilation|after induction of anesthesia and insertion of BASKA laryngeal mask airway and mechanical ventilation of patients will be maintained with pressure controlled ventilation mode
2394608|NCT03610113|No Intervention|CONSERVATIVE TREATMENT|Conservative treatment is conceived to the use of sling for three weeks, followed by rehabilitation protocol
2443633|NCT05075408|Experimental|Nemolizumab 60 mg|
2394610|NCT03610100|Experimental|Acelarin (NUC-1031)|"825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
2394611|NCT03610100|Active Comparator|Gemcitabine|"Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.~Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression."
2394612|NCT03610087|Other|Low Intensity Intervention|The comparison group (low intensity) receives access to the e-platform and given an educational package with information about nutrition, physical activity, and smoking based on the NAVIGATE program (Mueser et al., 2015); i.e., a comprehensive program for implementing coordinated speciality care) with weekly e-mail reminders for 12 weeks. Participants receive access to online resources and free online webinars about these healthy behaviours.
2394613|NCT03610087|Experimental|High Intensity Intervention|The intervention group (high intensity) receives a technology-enabled CCM intervention. Participants receive access to an online platform and infographic modules to learn more about nutrition, physical activity, and smoking cessation. Also, they are assigned a personal health coach who collaboratively schedules weekly virtual sessions via the platform to discuss the educational materials, goal setting and motivation, and provide support in the 12-week program. The participant's health coach reviews the participant's concerns and goals weekly with a virtual care team (VCT; including a psychiatrist, addictions specialist, nutrition specialist, peer mentor, and recreational therapist), who provides individualized recommendations to include in the participant's treatment plan. Participants have access to online resources and online webinars about nutrition, physical activity and smoking.
2394614|NCT03610074|Experimental|Mint ice cubes|"Physician applies 3 mint ice cubes in mouth of highly dehydrated patient. Patient undergoes an additional blood test at 5 min from mint ice cubes application.~Physician performs patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application."
2394615|NCT03610061|Experimental|Radiotherapy plus Durvalumab|"A minimum of 3 patients will initially be enrolled in each cohort of this arm. Patients will be allocated to a radiotherapy dose and site cohort from the schedule at registration. There will be no intra-patient dose or site escalations.~Cohorts will escalate in number of anatomical sites of radiotherapy and dose of radiotherapy given subject to safety. Durvalumab will be administered at a fixed dose every 4 weeks IV."
2394617|NCT03610035|Experimental|Experimental|NPT189
2394618|NCT03610035|Placebo Comparator|Placebo Comparator|Placebo
2394619|NCT03610022|Experimental|Patients with BCC and annexial carcinoma|Patients with BCC and annexial carcinoma histologically proven under treatment or new patients under vismodegib
2394620|NCT03610009|Active Comparator|2D ultrasound|Two-dimensional (2D) ultrasound is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
2394621|NCT03610009|Active Comparator|SonoAVC|SonoAVC is used to identify number and size of ovarian follicles, to select optimal day for triggering final oocyte maturation.
2394622|NCT03609996||PDR treated with Laser|
2394623|NCT03609996||PDR treated with Lucentis|
2394624|NCT03609983|Experimental|Daily Weighing|Participants will weigh themselves daily and receive feedback daily.
2394625|NCT03609983|Experimental|Weekly Weighing|Participants will weigh themselves weekly and receive feedback weekly.
2394626|NCT03609983|No Intervention|No Weighing|Participants will refrain from weighing themselves.
2394627|NCT03609970|No Intervention|Control|No intervention
2394628|NCT03609970|Experimental|UVR (Solar simulated radiation)|Twice weekly 1.25 SED (sub-erythemal) (4 weeks)
2394629|NCT03609970|Experimental|Vitamin D3 supplementation|4X 1000IU cholecalciferol tablets daily (28 days)
2394630|NCT03609957|Experimental|Aerobic Exercise Training|Moderate intensity (75% heart rate reserve) cycling exercise for 32 minutes, 3 days per week for 5 weeks
2394631|NCT03609957|Experimental|Interval Training|High intensity (95% heart rate reserve) cycling exercise for 20 minutes, 3 days per week for 5 weeks
2394632|NCT03609957|No Intervention|Control|Control (no exercise intervention) group
2394633|NCT03609944|Sham Comparator|EUS + Sham|Subjects randomized to EUS + sham will undergo a diagnostic endoscopic ultrasound (EUS) under sedation. The physician investigator will not make any attempts to achieve minor papilla cannulation, but photo document the minor papilla using a duodenoscope. Diluted dye will be injected into the duodenum. A small caliber prophylactic pancreatic duct stent will be deposited into the duodenal lumen. These maneuvers are performed to minimize the risk of unmasking.
2394634|NCT03609944|Experimental|EUS + ERCP with miES|Subjects randomized to EUS + ERCP with miES will undergo the procedure at the same time as endoscopic ultrasound (EUS), under sedation. Indomethacin (100 mg) will be administered rectally at the onset of the ERCP procedure in patients with no known allergy to indomethacin. The techniques used to perform the endoscopic retrograde cholangiopancreatography (ERCP)with miES (minor papilla endoscopic sphincterotomy) will be left to the discretion of the study endoscopist. The extent of sphincterotomy will be per the discretion of the treating endoscopist. Unless methylene blue (or similar chromoendoscopy agent such as indigo carmine) has already been used to facilitate minor papilla cannulation, diluted dye will be injected into the duodenum.
2394635|NCT03609931||Mitral Valve repair|Patients undergoing mitral valve repair
2394636|NCT03609905|Experimental|Intervention group|interventions: The MSCs of 5×10*7 will be given in different sites within colonic submucosa at a total 100 ml with the use of the colonoscope. Once every week，a total of two times. Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
2394637|NCT03609905|Other|Control group|interventions:Conventional drug therapy (5-amino-salicylic acid or glucocorticoid) is used
2394638|NCT03609892|Experimental|berberine plus amoxicillin quadruple therapy|Berberine 500mg three time daily for 14days, amoxicillin 1000 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
2394639|NCT03609892|Active Comparator|tetracycline plus furazolidone quadruple therapy|Tetracycline 500mg three time daily for 14days，furazolidone 100 mg, esomeprazole 20 mg, and Bismuth 200mg by mouth, twice daily for 14 days.
2394640|NCT03609879|No Intervention|without cervical collar|baseline - without cervical collar
2394641|NCT03609879|Experimental|with cervical collar|scenarios with cervical collars
3143340|NCT00005829|Experimental|gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 4 weeks for a minimum of 3 courses. Patients achieving clinical complete remission, complete remission, nodular partial remission, or partial remission following 3 courses of therapy, receive 2 additional courses of therapy. Patients achieving complete remission or further improvement following the 2 additional courses of therapy, receive another 2 courses of therapy. Patients are followed every 3 months until disease progression or relapse. Patients achieving complete remission are followed every 6 months for 1 year.
3143341|NCT00005830|Experimental|Treatment (doxorubicin, cisplatin, radiation therapy)|Patients receive doxorubicin IV and cisplatin IV on day 1. Treatment repeats every 3 weeks for 3 courses. Patients then undergo whole abdominal radiotherapy 5 days a week for 4-6 weeks.
3143342|NCT00005831|Experimental|Treatment (trastuzumab, combination chemotherapy)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15; paclitaxel IV over 3 hours and carboplatin IV over 15 minutes on day 1; and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 3 weeks. Patients achieving a complete response (CR) receive 3 courses past CR. Patients achieving a partial response or stable disease continue on therapy until CR or disease progression or unacceptable toxicity.
3143343|NCT00005832|Experimental|R115777|300mg/dose BID, PO, Days 1-21, q 28days
2394653|NCT03609840||Pediatric Hematopoietic Stem Cell Transplant Recipients|Children undergoing hematopoietic stem cell transplant (HCT) at University of California, San Francisco Benioff Children's Hospital
2394654|NCT03609827||Pediatric patients undergoing Hematopoietic Stem Cell Transplant|Children undergoing allogeneic hematopoietic stem cell transplant (alloHCT) at University of California, San Francisco Benioff Children's Hospital.
2394655|NCT03609814||Pediatric Bone Marrow Transplantation Recipients|Children undergoing alloHCT at UCSF Benioff Children's Hospital.
3143344|NCT00005833|Experimental|R115777|R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
3143345|NCT00005834|Experimental|chemo with thalidomide|chemo with thalidomide
2394658|NCT03609775|Experimental|Treatment A (ethanol + ACT-541468)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of ACT-541468 (50 mg)
2394659|NCT03609775|Experimental|Treatment B (ethanol placebo + ACT-541468)|5 h i.v. placebo clamp in combination with a single oral dose of ACT-541468 (50 mg)
2394660|NCT03609775|Experimental|Treatment C (ethanol + ACT-541468 placebo)|5 h i.v. ethanol clamp at a level of 0.6 g/L in combination with a single oral dose of matching ACT-541468 placebo
2394661|NCT03609775|Experimental|Treatment D (ethanol placebo + ACT-541468 placebo)|5 h i.v. placebo clamp in combination with a single oral dose of matching ACT-541468 placebo
2394662|NCT03609762|Experimental|Intervention group|EQ-5D-5L HRQOL results be available to the attending doctor
2394663|NCT03609762|No Intervention|Control group|usual care. All subjects attending the control clinics will not need to complete the electronic EQ-5D-5L before seeing the doctor during their follow-up visits. The doctor will manage the patient as usual, based on the usual clinical information. The doctor will complete the clinician-reported follow-up clinical data form (CRF) for each subject at the end of the consultation.
2394664|NCT03609749|Experimental|Mindfulness Training for Primary Care|"Experimental: Mindfulness Training for Primary Care For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3). For the Mindfulness Training for Primary Care (MTPC) fMRI - arm, the investigators acquire pre-/post-intervention neuroimaging measures from subjects enrolled in this additional fMRI study."
2394665|NCT03609723||MPS® in patients with CABG|Patients undergoing coronary artery bypass grafting with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC)
2394666|NCT03609723||OPCABG in patients with CABG|Patients undergoing coronary artery bypass grafting without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
2394667|NCT03609710|Experimental|PSTLAR|Combined application of left colic artery preservation, anastomotic reinforcing sutures and postoperative transanal tube placement in robotic low anterior resection for rectal cancer
2394668|NCT03609710|Active Comparator|NORLAR|Traditional robotic low anterior resection for rectal cancer without left colic artery preservation, anastomotic reinforcing sutures or postoperative transanal tube placement
3143346|NCT00005834|Active Comparator|chemo without thalidomide|chemo without thalidomide
3143347|NCT00005838|Experimental|Arm I (shark cartilage extract AE-941)|"Patients receive oral AE-941 (Neovastat) twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
2394671|NCT03609684|Experimental|Gymnastic and Core Stabilization|This group consist people who regularly do gymnastics and also do 30-45 minutes core stabilization exercises.
2394672|NCT03609684|Experimental|Only Gymnastic Training|People can do gymnastics twice a week during 8 weeks but can't do core stabilization exercise.
2394673|NCT03609684|Active Comparator|Sedentary Group|This group consist individuals who are not interested in any sports and don't do any exercises during 8 weeks.
2394674|NCT03609671|Experimental|Standard of Care + Intervention (Individualized Therapy)|Intervention (individualized therapy) plus Standard of Care, and the completion of a psychological questionnaire at chemotherapy start and at the end, approximately four to six months later.
2394675|NCT03609671|Other|Control Group: Standard of Care|Standard of Care plus the completion of a psychological questionnaire at the beginning of the chemotherapy and at the end, approximately four to six months later.
3184122|NCT00721045|Sham Comparator|A2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
2394678|NCT03609645|Active Comparator|Fascia iliaca block (FIB)|Group will receive Fascia iliaca block (FIB) with local anesthetic and femoral articular branch block (FAB) with normal saline (Placebo).
2394679|NCT03609645|Experimental|Femoral articular branches block(FAB)|Group will receive Fascia iliaca block (FIB) with normal saline (Placebo) and Femoral AON articular branch block (FAB) with local anesthetic.
2394680|NCT03609632|Experimental|OGTT with 13C-labelled leucine|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
3184123|NCT00721045|Active Comparator|B1|15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping.
2394683|NCT03609606|Experimental|Part A, Sequence1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D013 on Day22~Day28"
2394684|NCT03609606|Experimental|Part A, Sequence 2|"Period 1: Treatment of D013 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
2394685|NCT03609606|Experimental|Part B, Sequence 1|"Period 1: Treatment of D013, D326 and D337 on Day1~Day7~Period 2: Treatment of D326 and D337 on Day22~Day28"
2394686|NCT03609606|Experimental|Part B, Sequence 2|"Period 1: Treatment of D326 and D337 on Day1~Day7~Period 2: Treatment of D013, D326 and D337 on Day22~Day28"
2394687|NCT03609593|Experimental|BR followed by venetoclax and rituximab|Subjects will be on Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days, and Rituximab 375 mg/m2 on day 1 or days 1-2 for three cycles with each cycle being 28 days. Venetoclax will then be started in a step-wise fashion per the package insert.
2394688|NCT03609567|Experimental|Aromatherapy|Aromatherapy using essential oils
2394689|NCT03609567|Placebo Comparator|Placebo|Aromatherapy using odorless placebo
2394690|NCT03609554|Experimental|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session).
2394691|NCT03609554|No Intervention|Control|Adolescents assigned to the CG did not receive any structured exercise programme; they just attended their usual Physical Education sessions.
2394692|NCT03609541||Patient with stable COPD|Evaluation of serum amlyoid A, lipoxin A4, CRP and fibrinogen
2394693|NCT03609541||Patient with COPD exacerbation|Evaluation of serum amlyoid A, lipoxin A4, CRP and Fibrinogen at beginning and at the end of COPD exacerbation
2394694|NCT03609528|Experimental|CamPROBE biopsy method|To be completed
2394695|NCT03609515|Experimental|Patients with contract about patient-controlled admissions|Patients have a contract about short self-referred inpatient admissions in mental health services without approval by clinicians, for a maximum of 5 days and with a minimum of three weeks between such stays
2394696|NCT03609502|Experimental|behavioral|Adults with and without language impairment will be given three different types of behavioral training, and assessments of learning through those trainings, at two time points.
2394697|NCT03609502|Experimental|neuroimaging|Following speech sound behavioral training, adults with and without language impairment will undergo post-training perceptual assessments in an MRI scanner before and after post-training sleep.
2394698|NCT03609489|Experimental|Test Group|Apatinib combined with Capetabine
2394699|NCT03609489|Active Comparator|Control Group|Capecitabine
2394700|NCT03609476|Active Comparator|Standard of care group|No saline instillation
2394701|NCT03609476|Active Comparator|Room temperature saline group|room temperature saline instillation
2394702|NCT03609476|Active Comparator|Warmed saline group|warmed saline instillation
2394703|NCT03609463|Experimental|Well-being and small change|Participants will be randomized to receive 4 individual 1-hour weekly sessions of the well-being intervention before starting the 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
2394704|NCT03609463|Active Comparator|Small change|Participants will be randomized to receive 12 individual 1-hour weekly sessions of the small change intervention in addition to the treatment as usual.
2394705|NCT03609450|Active Comparator|Mindfulness Training for Primary Care|Mindfulness Training for Primary Care (MTPC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements integrated with novel mindfulness-oriented behavior change elements into a format that is adaptable to delivery in primary care health centers.
2394706|NCT03609450|Other|Low-Dose Comparator|Comparator arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month wait-list for a Cambridge Health Alliance mindfulness-based intervention group, but are allowed to receive behavioral, psychiatric, and medical treatments that are consistent with treatment as usual. All participants complete an action planning protocol during Week 7.
2394707|NCT03609437||ESUS patients|Acute ischemic stroke patients satisfying embolic stroke of undetermined source (ESUS) diagnostic criteria.
2394708|NCT03609437||Controls|Healthy volunteers (colleagues, friends, relatives and others).
2394709|NCT03609424|Experimental|PDR001 plus Imatinib|
2394710|NCT03609411||Splenectomy|Patients undergoing liver transplantation with simultaneous splenectomy
2394711|NCT03609411||Liver transplantation|Patients undergoing liver transplantation only
2394712|NCT03609398|Experimental|RVF Vaccine|1.0 mL dose given SQ in upper arm
2394713|NCT03609385||Stroke patients with elevated troponin|Patients with acute ischemic stroke (confirmed by cerebral imaging) and cardiac troponin values > 52 ng/l or troponin values > 14 ng/l and dynamic change > 20% will undergo coronary angiography
2394714|NCT03609372|Experimental|Single arm|These practices, which previously received the addition of performance feedback and provider prompts in the presence of communication skills training, will receive The STOP-HPV Trial 6: Maintenance
2394715|NCT03609359|Experimental|Lenvatinib + Pembrolizumab|Lenvatinib and Pembrolizumab will be administrated simultaneously for advanced gastric cancer patients.
2394716|NCT03609346||STEMI|Arm: STEMI Intervention: PCI with 1 or more BioFreedom stents in patients presenting with a STEMI. Medication according to hospital practice.
2394717|NCT03609333|Experimental|Internal arm|
2394718|NCT03609320|Experimental|Single Arm|These practices, which previously received standard of care, will receive The STOP-HPV Trial 5: Bundle Intervention
2394719|NCT03609307|Active Comparator|injection Combined Intravitreal bevacizumab and propranolol|patients receive two injections at each session Bavacizumab
2394720|NCT03609307|Active Comparator|injection Intravitreal bevacizumab|patients receive only Bevacizumab
2394721|NCT03609294|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 35 days between the each period."
2394722|NCT03609294|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
2394723|NCT03609294|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 35 days between the each period."
2394724|NCT03609281||Scheduled cesaren group|Patient delivered by elective cesarean section without labour pains
2394725|NCT03609281||Emergency cesarean group|Patients delivered by cesarean section due to an emergency
2394726|NCT03609268|Active Comparator|MWA|Patients receive microwave ablation (MWA)
2394727|NCT03609268|Experimental|SBRT|Patients receive stereotactic body radiotherapy (SBRT)
2394728|NCT03609255|Active Comparator|Control group (C)|
2394729|NCT03609255|Experimental|Sedentary behavior group (SB)|
2394730|NCT03609255|Experimental|Stress management group (SR)|
2394731|NCT03609242|Experimental|Intervention|Arm 1 will receive the STOP-HPV bundle intervention
2394732|NCT03609242|No Intervention|Control|Arm 2 will receive standard of care
2394733|NCT03609229|Experimental|Study group|Abdominal Sacrocolpopexy with burch technique
2394734|NCT03609229|Active Comparator|control group|Abdominal Sacrocolpopexy without burch technique
3143348|NCT00005838|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo twice daily beginning on day 1 or within 10 days of initiation of chemotherapy.~All patients receive induction chemotherapy with 1 of the following platinum-based regimens: cisplatin IV on days 1, 22, 50, and 71 and vinorelbine IV on days 1, 8, 22, 29, 50, 57, 71, and 78 carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on days 1, 22, 50, 57, 64, 71, 78, and 85.~All patients receive radiotherapy beginning on day 50 for 6 weeks. Treatment in both arms continues in the absence of unacceptable toxicity."
3143349|NCT00005840|Experimental|Treatment (paclitaxel, cisplatin, abdominal radiotherapy)|"Patients receive paclitaxel IV over 1 hour and cisplatin IV on days 1, 8, 15, 22, 29, and 36. Patients also undergo whole abdominal radiotherapy for 5 consecutive days weekly for 6 weeks.~Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level."
2394737|NCT03609203||Patients|
2394738|NCT03609203||Controls|
2394739|NCT03609190|Experimental|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
2394740|NCT03609190|Placebo Comparator|Placebo|i.v. infusion of NaCl over 40 min
3143350|NCT00005842|Experimental|Arm I|Patients receive trastuzumab (Herceptin) IV over 90 minutes on days 1, 8, 15, and 22 plus oral R115777 twice daily for 3 weeks. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R115777 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
3143351|NCT00005843|Experimental|Arm I|Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
3143352|NCT00005845|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on weeks 1, 3, 5, and 7. Treatment repeats every 8 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3143353|NCT00005849|Experimental|Arm A|Paclitaxel (90 mg/m2, days 1, 8 and 15 of every 28 day cycle), Bryostatin-1 (50 mcg/m2, days 2, 9 and 16 of every 28 day cycle)
2394745|NCT03609164|Experimental|Suture-spanning augmentation of single-row repair|
2394746|NCT03609164|Active Comparator|single-row repair|
2394747|NCT03609151|Active Comparator|group A|laparoscopic hepatectomy (surgery)
2394748|NCT03609151|Experimental|group B|stereotactic body radiotherapy (SBRT)
2394749|NCT03609138||Study Cohort|
2394750|NCT03609125|Experimental|CBS eyedrop|The product is prepared from cord blood serum (CBS) analyzed in advance with regard to the content of specific neurotrophic growth factors.
2394751|NCT03609112||Patients treated for a brain tumor|As part of their usual follow-up, these patients have neuropsychological evaluations following their treatment. A complete neuropsychological evaluation will therefore be performed as part of their usual follow-up during the inclusion period of this study and only the data from this evaluation will be taken into account for the statistical analysis of this study.
2394752|NCT03609112||Patients treated for a non-cerebral tumor|A single neuropsychological assessment will be proposed to these patients after the end of treatment and during the inclusion period of this study. This evaluation will be carried out during a visit to Gustave Roussy as part of their usual follow-up. If on the occasion of this evaluation, cognitive disorders or psychological disorders were highlighted, a neuropsychological and / or psychological follow-up would be proposed.
2394753|NCT03609112||Patients who received Methotrexate|"Methotrexate is used in the treatment of certain brain tumors as in that of non-cerebral tumors. Some of these patients, particularly those who have had neurological complications with methotrexate, will already have longitudinal neuropsychological follow-up as part of their usual follow-up. For these patients, only one complete neuropsychological assessment will be performed during the inclusion period and will be considered for statistical analysis.~For patients in the course of treatment with methotrexate, during the period of inclusion of this study, a longitudinal follow-up will be carried out with neuropsychological evaluations close and successive at the time of their coming to Gustave Roussy within the usual framework of their care."
2394754|NCT03609099|Active Comparator|Moxifloxacin|Active treatment to patients treated during the 5 previous days.
2394755|NCT03609099|Experimental|Placebo|Placebo treatment to patients treated during the 5 previous days.
2394757|NCT03609060|Experimental|DEXAML|"Induction therapy:~Idarubicin 8 mg/m²/day, IV over 15 minutes, D1 to D5 + Cytarabine 100 mg/m²/d, IV continuous 24h-infusion D1 to D7 + Lomustine 200 mg/m²/d, orally at D1 + Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3. Addition of midostaurin in patients with Fms-like tyrosine kinase 3-internal tandem ( FLT3-ITD) or Fms-like tyrosine kinase 3-tyrosine kinase domain (FLT3-TKD) mutations is allowed.~Post remission therapy:~Idarubicin 8 mg/m², IV over 15 minutes, D1 + Cytarabine 50 mg/m²/12h, subcutaneous, D1 to D5 + Dexamethasone 20 mg/d, IV over 30 minutes, D1. Addition of midostaurin in patients with FLT3-ITD or FLT3-TKD mutations is allowed. Intermediate dose cytarabine is allowed for patients with Core Binding Factor AML (CBF-AML).~Allogeneic stem-cell transplantation allowed after 2 to 4 cycles"
2398151|NCT03584958||Trabeculectomy surgery|Glaucoma filtering surgery to decrease intraocular pressure.
2394758|NCT03609047|Experimental|experimental palbociclib arm|Standard adjuvant endocrine therapy for a duration of at least 5 years + palbociclib (one capsule 125mg QD, orally, for 21 days followed by 7 days off treatment) for a total duration of up to 2 years.
2394759|NCT03609047|Active Comparator|control chemotherapy arm|"Adjuvant chemotherapy:~4 cycles docetaxel 75 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles doxorubicin 60 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles epirubicin 90 mg/m2 / cyclophosphamide 600 mg/m2 q3w OR 4 cycles weekly paclitaxel 80 mg/m2 D1, D8, and D15 q3w~Followed by standard adjuvant endocrine therapy for a duration of at least 5 years."
3143354|NCT00005850|Experimental|gemcitabine + cisplatin + fluoxetine|Patients receive gemcitabine and cisplatin. Treatment repeats every 21 days for a total of six cycles. Patients receive fluoxetine for 7 weeks. Further use of fluoxetine is at the discretion of the patient and physician.
2394761|NCT03609008|Active Comparator|Levcromakalim|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
2394762|NCT03609008|Placebo Comparator|Saline|18 participants will randomly be allocated in a 2:1 order to receive 1 mg levcromakalim or placebo (isotonic saline)
2394763|NCT03608995|Experimental|Premaquick©|
2394764|NCT03608995|Other|Quikcheck|
2394765|NCT03608982|Experimental|Simulated patient|The materials in this course are standardized, and consist of lectures with a slide show, questions & answers conversations, and practical exercises on fellow-students. The courses are being taught by professional first aid tutors from the Belgian Red Cross. During the practical exercises, a simulated patient will unexpectedly enter the room requiring treatment.
2394766|NCT03608982|Active Comparator|No simulated patient|The course materials in the control courses are also standardized. Instead of using simulated patients, however, video clips will be shown to demonstrate the first aid techniques.
2394767|NCT03608969||Study Group|Children with cerebral palsy aged 3-16 years will be evaluated in terms of the orofacial function using the Nordic Orofacial test- screening (NOT-S). Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) level and Communication Function Scale (CFS) of child will be recorded. Oral health related quality of life will be assessed using the Parental- Caregiver Perceptions Questionnaire. Caries experience will be measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft)
2394768|NCT03608943||Adrenal insufficiency|"Individuals who are in the process of changing their treatment from:~hydrocortisone to prednisolone or;~prednisolone to hydrocortisone"
2394769|NCT03608930|Experimental|rotary polypectomy snare|All colorectal polyps found are removed using a rotary polypectomy snare (Disposable Polypectomy Snare). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is used after hot snare polypectomy if removing a flat polyp or bleeding on the wound after treatment.
2394770|NCT03608930|No Intervention|regular polypectomy snare|All colorectal polyps found are removed using a regular polypectomy snare (polypectomy snare, symmetrical). The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the bending section angulation of the colonoscopy as required, advance the snare until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is performed after hot snare polypectomy if a flat polyp or bleeding on the wound after treatment.
2394771|NCT03608917|Experimental|Treatment group|"Drug:Total Glucosides of Paeony (TGP)~Time Frame: Week0-week8 The 1st Week, TGP 0.6g , Bid, orally; 2nd to Week8 , TGP 0.6g , Tid, orally combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP, 0.6g, Tid, orally."
2394772|NCT03608917|Placebo Comparator|Control group|"Drug:Total Glucosides of Paeony (TGP) analogue~Time Frame:Week0-week8 The 1st Week, TGP analogue 0.6g , Bid, orally; 2nd to Week8, TGP analogue (0.6g , Tid, orally) combined with NB-UVB phototherapy( 1 time every other day)~Time Frame: Week9-Week24 TGP analogue, 0.6g, Tid, orally."
2394773|NCT03608904|Experimental|Music Listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
2394774|NCT03608904|Placebo Comparator|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
2394775|NCT03608891|Active Comparator|Control Arm|Conventional titanium miniplates
2394776|NCT03608891|Experimental|Intervention arm|Patient specific 3D plates
2394777|NCT03608878|Active Comparator|TACE alone arm|TACE (Transarterial Chemoembolization)
2394778|NCT03608878|Experimental|adagloxad simolenin arm|TACE plus adagloxad simolenin/OBI-821 adjuvant therapy
2394780|NCT03608852||Banked-money group|This group will have $50 placed in a 'bank account' for every clinic visit where their tests reveal abstinence from smoking. As a modified commitment contract, the Banked-Money Group can only withdraw the accrued money at the end of the trial if they complete the trial by quitting smoking for the entire 6 months.
2394781|NCT03608852||Reward group|This group will directly receive $50 for every clinic visit where their tests reveal abstinence from smoking.
3184124|NCT00721045|Sham Comparator|B2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
3184125|NCT00721045|Active Comparator|C1|15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping.
3184126|NCT00721045|Sham Comparator|C2|5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures.
3184127|NCT00721058|Other|1|
3184128|NCT00721071|Experimental|1|
3184129|NCT00721084||Reduced sleep|Habitual sleep duration of less than 6 hours per night on most days of the week and total sleep of less than 43 hours per week.
2394785|NCT03608826|Experimental|Single Arm Study|Invesigational RAMware will be downloaded onto the LINQ device.
2394786|NCT03608813||Controls|Healthy subjects
2394787|NCT03608813||Case|PCOS affected subjects
2394788|NCT03608800|Experimental|Intermittent fasting|two nonconsecutive days of 75% diet energy restriction per week for 8 weeks
2394789|NCT03608800|No Intervention|Control diet|maintain the energy intake as usual
2394790|NCT03608787|Experimental|Cohort 1-Early Intervention|Following baseline, participating outlets in this arm will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback for 3 months. After 3 months they will receive no further intervention, but will continue to receive Pseudo-Intoxicated Mystery Shops (P-I/MS).
2394791|NCT03608787|Experimental|Cohort 2-Delayed Intervention|Following baseline, participating outlets in this arm will receive receive Pseudo-Intoxicated Mystery Shops (P-I/MS) with no feedback. After 3 months they will receive the S-STOP program consisting of Pseudo-Intoxicated Mystery Shops (P-I/MS) with performance feedback.
3184130|NCT00721084||Reference sleep|Habitual sleep duration between 7 and 8.5 hours per night on most days of the week and total sleep of at least 53 hours per week.
3184131|NCT00721240|Experimental|single-arm|This investigation is a single-center, two-phase, single-arm study. In order to detect a potential placebo effect, the treatment phase will be preceded by a single-blinded two-week placebo run-in phase, followed by a 12 week open-label treatment phase.
2394794|NCT03608761|Experimental|Rebamipide 2%|"- wash-out: 2 weeks~- rebamipide 2% four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- autologous serum for 3 months"
2394795|NCT03608761|Experimental|Autologous serum|"- wash-out: 2 weeks~- autologous serum four times a day for 3 months~- controls will be taken at day zero, 30 and 90.~- wash-out: 2 weeks~- rebamipe 2% for 3 months"
2394796|NCT03608761|Experimental|autologous serum and rebamipide 2%|rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed
2394797|NCT03608722|Experimental|BrainCheck vs Pen and paper tests|Compare patient performance on BrainCheck neurocognitive test vs pen and paper dementia tests (SLUMS, MMSE, MoCA), as well as an exploratory analysis comparing BrainCheck performance to aid in identifying patients with MCI and dementia vs physician diagnosis
2394798|NCT03608722|Experimental|BrainCheck performance in ESRD patients|Assess BrainCheck test performance in patients with ESRD and how undergoing hemodialysis treatment can impact cognitive performance.
2394799|NCT03608696|Experimental|buprenorphine|"Buprenorphine 0.075 mg ml sublingual solution~Initial daily dose 24 mcg/kg/day Initial unit dose 8 mcg/kg q8 hours Maximum daily dose 75 mcg/kg/day Maximum unit dose 25 mcg/kg q8 hours Up-titration rate 33% Maximum # of up-titrations 4 Weaning rate 15% Cessation (bottom) dose < Initial dose Dosing interval until bottom dose (hrs) 8 Dose interval extension #1 at bottom dose (hrs) 12 Dose interval extension #2 at bottom dose (hrs) 24"
2394800|NCT03608670|Experimental|Experimental|Patients will be implanted with an extravascular ICD and undergo requisite electrical testing.
3184132|NCT00721266|Experimental|1|
2394802|NCT03608631|Experimental|Treatment (iExosomes)|Participants receive mesenchymal stromal cells-derived exosomes with KrasG12D siRNA IV over 15-20 minutes on days 1, 4, and 10. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Participants who respond may continue 3 additional courses.
2394803|NCT03608618|Experimental|Cohort 1|3-6 subjects will receive a starting dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks
2394804|NCT03608618|Experimental|Cohort 2 and 2i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 2); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 2i)
2394805|NCT03608618|Experimental|Cohort 3 and 3i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 3); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 3i)
2394806|NCT03608618|Experimental|Cohort 4 and 4i|3-6 subjects will receive a higher dose of MCY-M11 via intraperitoneal infusion once weekly for 3 weeks (cohort 4); 3-6 subjects will receive MCY-M11 and cyclophosphamide preconditioning (cohort 4i)
2394807|NCT03608592|Experimental|UCMSCs group|Intravenous infusion of 1million UCMSCs per kilogram body weight suspended in 100ml normal saline, infusion duration 30-60min.
2394810|NCT03608553|Experimental|ExAblate|ExAblate MR Guided Focused Ultrasound
3184133|NCT00721305|Experimental|1|In this arm, subjects will receive 40 mg of Lovastatin (2 tablets of 20 mg each, p.o.), in a daily doses, during twelve months
2394812|NCT03608527|Experimental|Active motor treatment (AMT) group|15 people with multiple sclerosis performing a 8 week rehabilitative treatment based on task-oriented voluntary exercises (3 sessions/week).
2394813|NCT03608527|Active Comparator|Passive motor treatment (PMT) group|15 people with multiple sclerosis performing a 8 week passive mobilization delivered by a physical therapist (3 sessions/week).
2394814|NCT03608514|Active Comparator|nor-epinephrine+/- epinephrine infusion|"Intravenous infusion of Nor-epinephrine in an initial dose of 0.01µg/kg/min. which can be increased every 15-30 minutes to maximum 3µg/kg/min. ± intravenous infusion of epinephrine with an initial dose 0.05µg/kg/min. & can be titrated every 15-30 minutes up to 2µg/Kg/min.~The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2 mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
2394815|NCT03608514|Other|Terlipressin infusion|"Intravenous infusion of terlipressin by rate 1-2µg/kg/min. The end point is to achieve mean arterial pressure ≥ 65 mmHg & normalized lactate ≤ 2mmol/L or lactate clearance ≥ 10% within 6 hours.~Patients will be followed for 48 hours."
2398152|NCT03584958||Cataract surgery|Cataract surgery with no glaucoma procedure.
2394816|NCT03608501|Experimental|Ixazomib 4 mg + Thalidomide 100 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsule, orally, once on Days 1, 8 and 15 along with thalidomide 100 mg, tablet, orally, once daily and dexamethasone 40 mg, tablet, orally, once on Days 1, 8, 15 and 22 in a 28-day treatment cycle for up to 9 cycles or until withdrawal from the study in the treatment phase. Participants who complete treatment phase will be eligible to continue on to the maintenance phase of the study to receive ixazomib 4 mg, capsules, orally, once on Days 1, 8 and 15 of a 28-day treatment cycle for up to 24 months or until withdrawal from the study.
2394821|NCT03608475|Active Comparator|Comprehensive Ultrasound Group|Children in the comprehensive ultrasound protocol group will follow the current standardized treatment protocol used at the Hospital for Sick Children in Toronto, Canada. For children presenting with stable hip dysplasia, Pavlik harness (PH) treatment is initiated at the initial visit (week 0) and runs for a total of 12 weeks. Children return to clinic at weeks 2, 5, 8 and 12 for clinical and ultrasound examinations to ensure that the harness is fitting correctly, to screen for PH complications and to monitor acetabular development.
2394822|NCT03608475|Experimental|Limited Ultrasound Group|Children in the limited ultrasound protocol group will receive the same treatment as described for the comprehensive ultrasound group above, except the ultrasound imaging conducted at weeks 2, 5 and 8 will be omitted. Children will still return to clinic at 2, 5, and 8 weeks for clinical examination, which includes the assessment of the Pavlik harness fit and screening for complications.
2394823|NCT03608462|Sham Comparator|rTMS targeting the right DLPFC|60 patients will be randomly allocated into this group,half of them will receive iTBS on the right DLPFC,while the other half will receive sham stimulation.
2394824|NCT03608462|Sham Comparator|rTMS targeting the left LPC|60 patients will be randomly allocated into this group,half of them will receive iTBS on left LPC,while the other half will receive sham stimulation.
2394825|NCT03608462|No Intervention|Observation group|To investigate the abnormalities of hippocampal neurogenesis in patients with early schizophrenia(n=30) compared to healthy controls(n=30)
2394826|NCT03608449|Active Comparator|study group|after monitoring treatment outcomes for 4 weeks, treatment plan or psychotherpist will be changed according to scoring by the director of department.
2394827|NCT03608449|Placebo Comparator|control group|treatment as usual. treatment counitunes as usual without depending on monitoring treatment outcomes.
3143355|NCT00005851|Experimental|Treatment (nonmyeloablative donor PBSC transplantation)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplant on day 0.~IMMUNOSUPRESSION: Patients receive cyclosporine PO BID or IV QD or BID on days -3 to 35 with taper to day 56, and mycophenolate mofetil PO or IV over 2 hours TID on days 0-40.~DLI: Patients with stable mixed chimerism on day 56 with no evidence of GVHD may receive escalating doses of non-mobilized DLI over 30 minutes. Patients may receive up to 4 DLIs at escalating doses if there is disease progression with no evidence of GVHD."
3143356|NCT00005856|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression.
3143357|NCT00005858|Experimental|Arm I|"Patients receive LMB-9 immunotoxin IV continuously for 10 days. Treatment continues every 30 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of LMB-9 immunotoxin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
2394832|NCT03608410|Experimental|PRO intervention|Weekly PRO questionnaires Quality of life every 2 months
2394833|NCT03608410|No Intervention|Standard of care|Quality of life every 2 months
2394834|NCT03608397|Experimental|DAXI for injection low dose|Low Dose Group
2394835|NCT03608397|Experimental|DAXI for injection high dose|High Dose Group
2394836|NCT03608397|Placebo Comparator|Placebo|Placebo Group
2394837|NCT03608371|Experimental|BTRX-246040 Cohort 1|BTRX-246040 will be administered orally 40 mg (1capsule) in Cohort 1
2394838|NCT03608371|Experimental|BTRX-246040 Cohort 2|BTRX-246040 will be administered orally 80 mg (2 capsules) in Cohort 2
2394839|NCT03608371|Experimental|BTRX-246040 Cohort 3|BTRX-246040 will be administered orally120 mg (3 capsules) in Cohort 3
2394840|NCT03608371|Placebo Comparator|Placebo Cohorts 1-3|Placebo will be administered orally at the same number of capsules as active drug at each Cohort. Placebo capsules will consist of inactive ingredients and look identical to BTRX-246040.
2394841|NCT03608358|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg and dapagliflozin 5 mg placebo to match added to saxagliptin 5 mg and metformin
2394842|NCT03608358|Experimental|Dapagliflozin 5 mg|Dapagliflozin 5 mg and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
2394843|NCT03608358|Placebo Comparator|Placebo|Dapagliflozin 5 mg placebo to match and dapagliflozin 10 mg placebo to match added to saxagliptin 5 mg and metformin
2394844|NCT03608332|No Intervention|Group S|"weaning readiness will be evaluated with the standard criteria :- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13"
2394845|NCT03608332|Experimental|Group SD|"weaning readiness will be evaluated with the following criteria:- A) Clinical assessment:-~Resolution of acute phase of disease for which patient was intubated~Adequate cough~Absence of excessive tracheobronchial secretions~B) Objective criteria:-~Adequate oxygenation:PaO2>60mmHg with PEEP<8,SaO2>90%,FIO2 <0.5,PaO2/FIO2>200~Respiratory rate <30~PH and PaCO2 appropriate for patients' baseline respiratory status~Hemodynamically stable :minimal or no vasopressor/inotropes,no evidence of myocardial ischemia~HR<140 beats/minute~Patient is arousable or Glasgow coma scale (GCS)>13~C) Ultrasound criteria:-~• Diaphragmatic excursion >11 mm"
2394846|NCT03608319|Experimental|Single dose following overnight fast|
2394847|NCT03608319|Experimental|Single dose following high fat breakfast|
2394848|NCT03608319|Experimental|Single dose sprinkled on applesauce following overnight fast|
2394849|NCT03608306|Experimental|Resin-modified glass ionomer|Activa Bioactive-Restorative is an enhanced resin modified glass ionomer (RMGI) with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
2394850|NCT03608306|Active Comparator|Bulk-fill glass hybrid restorative|EQUIA Forte is a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
2394851|NCT03608293|Experimental|Smokers|Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
2394852|NCT03608293|Active Comparator|Non smokers|Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed
2394853|NCT03608280|Active Comparator|Autograft|Reconstructive surgery by autologous bone graft (bone autograft). It is the gold standard strategy.
2394854|NCT03608280|Experimental|3D implant|"Orbital reconstruction by 3D-printed porous titanium implant (PorousiTi®, laboratoire OBL/MATERIALISE).~The device is a custom-made porous titanium implant processed by selective laser melting (SLM technique)"
2394855|NCT03608267|Experimental|Intervention|
2394856|NCT03608241|Experimental|Treatment sequence 1|Treatment sequence 1 will receive a single dose of an oral contraceptive during the first period of the study (period 1) and then continue to the second period (Period 2) of the study where they will receive PF-06651600 every day for 11 days and a single dose of an oral contraceptive towards the end of the period.
2394857|NCT03608241|Experimental|Treatment Sequence 2|Treatment sequence 2 will receive PF-06651600 every day for 11 days during the first period of the study (period 1) and a single dose of an oral contraceptive towards the end of this period. After completion of Period 1, there will be a washout period of at least 10 days before starting the second period of the study (period 2). During period 2, a single dose of an oral contraceptive will be received.
2394858|NCT03608228||Parkinson's Disease|
2394859|NCT03608215|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
2394860|NCT03608215|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
2394861|NCT03608202|Experimental|POCUS protocol group|"POCUS protocol group~It will be submitted to an ultrasound protocol which consists in performing the following ultrasound studies in each patient:~Measurement of the diameter of the optic nerve. Neck. Pulmonary ultrasound (LUS score). Echocardiogram (function and volemia). Abdomen. Femoral vascular package. Eco-guided interventionism. Central venous accesses (controlling positioning with saline injection under ultrasound), arterial, pleural or abdominal drainage and percutaneous tracheotomy will be performed under ultrasound."
2394862|NCT03608202|Active Comparator|Control group|The usual handling will be followed. The studies will only be performed if the medical team-treating team considers it, requesting a radiologist specialist the same, as is done routinely.
2394863|NCT03608189||ACL injury subjects|Subjects with anterior cruciate ligament injuries.
2394864|NCT03608176|Experimental|PASO diet group|
2394865|NCT03608176|Active Comparator|Low-fat diet group|
2394866|NCT03608176|Other|Waiting list group|
3143358|NCT00005862|Experimental|Arm I|atients receive SU5416 IV twice weekly for 4 weeks. Treatment continues every 4 weeks in the absence of disease progression or unacceptable toxicity.
3143359|NCT00005866|Experimental|treatment|
3143360|NCT00005881||Quality of life forms|Completion of the development of an instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
3143361|NCT00005914||Probands and family members|Individuals with major depressive disorder who meet study criteria, and members of their families. No intervention. This is a genetic study only.
3143362|NCT00005922|Experimental|A|Participants will receive 100% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
3143363|NCT00005922|Experimental|B|Participants will receive 100% of the dose of the medication on a partial reinforcement schedule (25% or 50%) as received during the baseline (maintenance) period
3143364|NCT00005922|Experimental|C|Participants will receive 25% or 50% of the dose of the medication on the same reinforcement schedule (100%) as received during the baseline (maintenance) period.
3143365|NCT00005940|Experimental|Treatment (radiolabeled BC8, chemotherapy, PBSCT)|"RADIOLABELED ANTIBODY: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -13.~CHEMOTHERAPY: Patients receive busulfan PO every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.~TRANSPLANT: Patients undergo allogeneic PBSC or BM transplant on day 0.~GRAFT-VS-HOST DISEASE PREVENTION: Patients receive cyclosporine IV or PO every 12 hours on days -1 to 50 with a taper to day 180. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3143366|NCT00005942|Experimental|Treatment (liposomal danorubicin citrate, semaxanib)|Patients receive daunorubicin liposomal IV over 6 hours on days 1-3 and SU5416 IV twice a week for 2 months. The second course is administered for 1 month, then treatment continues every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
3143367|NCT00005945|Experimental|Induction Not Randomized|Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
3143368|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification CNS|Patients with CNS disease at diagnosis, without other unfavorable characteristics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Cranial radiation therapy during the Consolidation phase.
3184134|NCT00721305|Placebo Comparator|2|In this arm, subjects will receive placebo (2 tablets which will look externally identical to lovastatin: wrapped in the same way, with the same size, shape and color)
3184135|NCT00721318||1|Patients diagnosed with rheumatoid arthritis
2394874|NCT03608150|Experimental|Therapeutic Group|Participants assigned to the therapeutic group will be prescribed Luminopia One for 1 hour per day, 6 days per week for 12 weeks.
2394875|NCT03608150|Active Comparator|Control Group|Participants assigned to the control group will wear their current refractive correction full-time for 12 weeks.
2394876|NCT03608137|Experimental|Cannabis users|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.
2394877|NCT03608137|Active Comparator|Non- cannabis users (control group)|Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.
2394878|NCT03608111|Active Comparator|single task balance training|
2394879|NCT03608111|Active Comparator|dual task balance training|
2394880|NCT03608098|Active Comparator|Short Pulse Duration Group|A short pulse duration (300 μs or 350 μs) will be used in this group.
2394881|NCT03608098|Active Comparator|Long Pulse Duration Group|A long laser pulse duration (700 μs or 1500 μs) will be used in this group.
2394882|NCT03608085|Experimental|Pharmacist Heart failure MTM training|Community pharmacist who will receive heart failure medication therapy management training
2394883|NCT03608085|Experimental|Patient Heart failure MTM intervention|Independently living community dwelling subjects who are prescribed at least 1 cardiovascular medication for HF and 3 additional chronic medications after discharge from the Hospital for an MTM consultation by a pharmacist trained in heart failure medication therapy management.
2394884|NCT03608072|Experimental|Dose group 1|
2394885|NCT03608072|Experimental|Dose group 2|
2394886|NCT03608072|Experimental|Dose group 3|
2394887|NCT03608059|Experimental|ATG/PTCy|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -2 to -1 and cyclophosphamide (Cy) 50 mg/kg on day +3, cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +4. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +34 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2394888|NCT03608059|Active Comparator|standard ATG|The GvHD prophylaxis consisted of ATG 2.5mg/kg administered on day -4 to -1 , cyclosporine A (CsA) initiating on day -5 and mycophenolate mofetil (MMF) initiating on day +1 . CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 2 times per day (maximum dose 2g per day) until day +30 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2394889|NCT03608059|Active Comparator|standard PTCy|The GvHD prophylaxis consisted of cyclophosphamide (Cy) 50 mg/kg on day +3, +4,cyclosporine A (CsA) and mycophenolate mofetil (MMF) initiating on day +5. CsA was prescribed at 2 mg/kg as a continuous infusion. The CsA doses were modified to obtain nadir serum levels between 200 and 300 ng/ml. MMF was administered at 15 mg/kg oral 3 times per day (maximum dose 3g per day) until day +35 and was then stopped if no aGvHD. Mycophenolate Sodium Enteric-coated Tablets (MPA) can be used instead of MMF, one tablet MPA corresponds to one tablet MMF. CsA was tapered from day +90 to day +180.
2394890|NCT03608046|Experimental|Avelumab, Cetuximab, Irinotecan|"Avelumab : administrated at a fixed dose of 10 mg/kg once every 2- week. Cetuximab: administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3.~Irinotecan: administrated every 2 weeks (180 mg/m2)."
2394891|NCT03608033|Experimental|OMS721|Administration of OMS721
2394892|NCT03608033|Placebo Comparator|Placebo|Administration of Vehicle (D5W or Saline Solution)
2394893|NCT03608020|Active Comparator|WBRT + BMX-001|Whole brain radiation therapy in combination with BMX-001 (subcutaneous injection of 28 mg loading dose, followed by subsequent 14 mg twice per week for 2 weeks).
2394894|NCT03608020|No Intervention|Whole Brain Radiation Therapy|Whole brain radiation therapy per standard of care.
2394895|NCT03608007|Experimental|X-396 Capsule|Single-arm trial whereby all consented, enrolled, eligible patients receive X-396 capsule, 225 mg once daily.
3184136|NCT00721318||2|Population controls to the subjects of group 1
3184137|NCT00721331|Experimental|CRx-197 high dose (0.1% nortriptyline HCl + 0.3% loratadine)|
2394898|NCT03607968||All women in this study|All women with POP and concomitant overt or occult USI, who underwent the novel anterior TVM surgeries, were enrolled in this study. Medical records, including urodynamic studies, questionnaires and 3-day bladder diaries, were retrospectively reviewed. Linear regress analysis was used to identify factors that were responsible for the changes in pad weights from baseline [i.e., 100 * (postoperative pad weight - baseline pad weight)/baseline pad weight].
2394899|NCT03607955|Experimental|AVB-S6-500 + Paclitaxel + Carboplatin|"Paclitaxel will be given intravenously at a dose of 175 mg/m^2 on an outpatient basis over 3 hours on Day 1 of each 21-day cycle~Carboplatin will be given intravenously at a dose of AUC 6 over 30 minutes on Day 1 of each cycle of chemotherapy~AVB-S6-500 will be given at doses based on the dose escalation schema~The investigators will continue dosing AVB-S6-500 until 1 week prior to surgery and continuing after surgery. Maintenance dosing q2 weeks will begin with Cycle 7A/7B and be given every 2 weeks for 12 months through Cycle 19 (total of 13 maintenance cycles)."
2394902|NCT03607929|Experimental|optimal and hydration|Physiological Saline Solution 300 ml/h AND drink freely mineral water during labor
2394903|NCT03607929|Active Comparator|variability and hydration|Other Solutions >o < 300 ml/h AND uncontrolled drink during labor
2394956|NCT03607643|Experimental|Multiple myeloma: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
3184138|NCT00721331|Experimental|CRx-197 low dose (0.1% nortriptyline HCl + 0.1% loratadine)|
3184139|NCT00721331|Experimental|0.1% nortriptyline HCl|
2394904|NCT03607916|Experimental|Cohort 1 : HB Prilocaine 2%,(60mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394905|NCT03607916|Experimental|Cohort 2 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394906|NCT03607916|Experimental|Cohort 3 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394907|NCT03607916|Experimental|Cohort 4 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394908|NCT03607916|Experimental|Cohort 5 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394909|NCT03607916|Experimental|Cohort 6 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394910|NCT03607916|Experimental|Cohort 7 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 paturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be adminitrated at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394911|NCT03607916|Experimental|Cohort 8 : HB Prilocaïne 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394912|NCT03607916|Experimental|Cohort 9 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394913|NCT03607916|Experimental|Cohort 10 : HB Prilocaine 2%,(45-70mg)|Dose-finding study with 4 subjects per dose and a maximum of 40 parturients.To identify the dose to give for reaching the ED95 (effective dose for 95% subjects), Hyperbaric prilocaine 2% will be administered at the dose initial of 60 mg in the cohort 1 (4 subjects), then the dose will be adjusted in the next cohorts using the Continual Reassessment Method (CRM). The dose range will be from 45 to 70mg.
2394914|NCT03607903|Active Comparator|Subcutaneous adalimumab and placebo|adalimumab SC (40 mg in 0.4 mL) and saline ID (0.9%, 0.4 mL)
2394915|NCT03607903|Active Comparator|PLacebo and subcutaneous adalimumab|saline ID (0.9%, 0.4 mL) and adalimumab SC (40 mg in 0.4 mL)
2394916|NCT03607903|Experimental|Placebo and intradermal adalimumab|saline SC (0.9%, 0.4 mL) and adalimumab ID (40 mg in 0.4 mL)
2394917|NCT03607903|Experimental|Intradermal adalimumab and placebo|adalimumab ID (40 mg in 0.4 mL) and saline SC (0.9%, 0.4 mL)
2394918|NCT03607890|Experimental|Cohort 1: Nivolumab and Relatlimab|480mg/160mg (co-administered)
2394919|NCT03607890|Experimental|Cohort 2: Nivolumab and Relatlimab|480mg/960mg (sequential administration)
2394920|NCT03607877|Active Comparator|pedometer walking (PW)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months.
2394921|NCT03607877|Active Comparator|pedometer walking with training (PWT)|15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down. Exercise intensity for the first four weeks was 50-55% heart rate reserve (HRR) with training for 3 months.
2394922|NCT03607877|Experimental|positive education and walking (PEPWT)|PEPWT: 15 minutes of warm-up activities, 30 minutes of walking, and 10 minutes to cool down for 3 months and six sessions of positive education.
2394923|NCT03607864|Experimental|coral bone graft and xenograft|Extraction of upper anterior badly broken teeth with immediate implant placement with the use of coral bone and xenograft as grafting material between the implant and the labial socket bone
2394924|NCT03607851|Active Comparator|Conventional titration group|
2394925|NCT03607851|Experimental|Rapid titration group 1|
2394926|NCT03607851|Experimental|Rapid titration group 2|
2394927|NCT03607838|Experimental|SI-6603|
2394928|NCT03607838|Sham Comparator|Sham injection|
2394929|NCT03607825|Experimental|Neurapheresis System|CSF filtration
2394954|NCT03607643|Experimental|Rectal: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2394957|NCT03607643|Placebo Comparator|Pancreatic: Chemo + Placebo|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
2394930|NCT03607799|Experimental|Dietary Intervention|"A dietitian develops personalized diet advice for each intervention group participant. She sets 2-4 SMART goals according to the following principles: 1) Replace fried foods and meat with vegetable protein, raw and cooked vegetables; 2) Reduce refined carbohydrate intake; 3) Improve carbohydrate quality (replace high glycemic index, refined grain foods with lower glycemic index, whole-grain foods; 4) Reduce trans fats; 5) Schedule regular mealtimes, 3-4 hours apart; 6) Reduce high-carbohydrate snacks; 7) Reduce desserts and/or drinks high in starch and sugar. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
2394931|NCT03607799|Active Comparator|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy plus additional materials adapted specifically for the SA community. Participants review 6 simple messages at the baseline visit, aimed at increasing walking, with reinforcement text messages sent weekly."
2394932|NCT03607786|Active Comparator|RIVP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(28-30℃). The combination of selective antegrade cerebral perfusion and retrograde inferior vena caval perfusion is performed. The antegrade perfusion flow rate was is maintained at 6-12 mL/min/kg.Pump pressure of retrograde perfusion was is maintained at 20-30 mmHg, and blood flow was is maintained at 8-12 mL/min/kg.
2394933|NCT03607786|Active Comparator|ACP group|After total cardiopulmonary bypass was initiated, the patient is cooled slowly to induce moderate hypothermia(26-28℃). Only select antegrade cerebral perfusion is performed by maintaining the flow rate at 6-12 mL/min/kg.
2394934|NCT03607773|Active Comparator|Mindfulness Behavioural Intervention (MBI) group|10 one-hour mindfulness sessions
2394935|NCT03607773|No Intervention|Control group|Standard of care.
2394936|NCT03607760||ECMO|severe respiratory failure with ECMO
2394937|NCT03607760||conventional mechanical ventilation|severe respiratory failure with conventional mechanical ventilation
2394938|NCT03607734|Other|Group 1 - Interventional Treatment|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
2394939|NCT03607721|Experimental|DBS Patients Group|Body Motion Evaluation DARI
2394940|NCT03607721|Active Comparator|Control Group|Body Motion Evaluation DARI
2394941|NCT03607708|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
2394942|NCT03607708|Active Comparator|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
3184140|NCT00721331|Active Comparator|0.1% mometasone furoate|
3184141|NCT00721331|Placebo Comparator|Active ingredient free vehicle cream of CRx-197|
2394945|NCT03607669||Healthy Controls|Healthy volunteers of similar age and gender
2394946|NCT03607669||Ischaemic Cardiomyopathy|Patients with ischaemic cardiomyopathy and NYHA II-III heart failure
2394947|NCT03607669||Hypertrophic Cardiomyopathy|Patients with hypertrophic cardiomyopathy and NYHA II-III heart failure
2394948|NCT03607669||Dilated Cardiomyopathy|Patients with dilated cardiomyopathy and NYHA II-III heart failure
2394949|NCT03607656|Experimental|TCM combines CapOX/SOX/S-1+D/FLOT|"Traditional Chinese Medicine oral taken twice a day for at least 3 months combined with chemotherapy.~The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy."
2394950|NCT03607656|Active Comparator|CapOX/SOX/S-1+D/FLOT|The chemotherapy can choose intravenous oxaliplatin 130 mg/m(2) on day 1 plus oral capecitabine 1000 mg/m(2) twice daily on days 1-14, every 21 days; or intravenous oxaliplatin 100 mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 40mg/m(2) on day 1 plus oral S-1 40mg/m(2) twice daily on days 1-14, every 21 days; or intravenous docetaxel 50mg/m(2) on day 1 plus intravenous oxaliplatin 85 mg/m(2) on day 1 plus 5-FU intravenously CIV24h on day 1, every 14 days; Each participant shoud take eight (8) cycles of chemotherapy.
2394951|NCT03607643|Placebo Comparator|Colon: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2394952|NCT03607643|Experimental|Colon: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2394953|NCT03607643|Placebo Comparator|Rectal: Chemo + Placebo|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
2394955|NCT03607643|Placebo Comparator|Multiple myeloma: Chemo + Placebo|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
2394958|NCT03607643|Experimental|Pancreatic: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
2394959|NCT03607643|Placebo Comparator|GBM: Chemo + Placebo|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
2394960|NCT03607643|Experimental|GBM: Chemo + BRCX014|Cannabidiol (BRCX014) 200 mg daily plus Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
2394961|NCT03607630|No Intervention|Waiting Pre-Intervention Control|Participant completes measures for 1-3 weeks (randomly chosen) before they complete the intervention. Participants act as their own controls
2394962|NCT03607630|Experimental|Imagery Rescripting|3 Sessions of Imagery Rescripting
2394963|NCT03607617||Wedge 1|Five randomized clinics will implement SDH tool.
2394964|NCT03607617||Wedge 2|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2394965|NCT03607617||Wedge 3|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2394966|NCT03607617||Wedge 4|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2394967|NCT03607617||Wedge 5|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2394968|NCT03607617||Wedge 6|Five randomized clinics implement SDH tool 24 weeks following prior wedge implementation.
2394969|NCT03607604||Autoantibody Negative|"Patients who are autoantibody negative (could potentially be either MODY or type 2 diabetes patients)~Suspected MODY patients will be candidates for next generation sequencing (NGS)"
2394970|NCT03607604||Diabetes Mellitus, Type 1|"Patients diagnosed with type 1 diabetes mellitus~Patients with positive UCPCR and negative autoantibodies results will be suspected with MODY and will be candidates for next generation sequencing (NGS)"
2394971|NCT03607604||Non Diabetic|Individuals not diagnosed with any type of diabetes (but could be diagnosed with IFG and/or IGT)
2394972|NCT03607591|Active Comparator|Active rTMS group|One daily session: active 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
2394973|NCT03607591|Placebo Comparator|Placebo rTMS group|One daily session: inactive 15Hz frequency, pulse intensity 100% of the rTMS, 60 pulses per train, inter-train pause of 15 sec, 40 stimulation trains for a total of 2400 pulses in 13 min of stimulation). 15 sessions (3 weeks of 5 consecutive daily sessions and 2 days of rest)
2394974|NCT03607578|Other|Control Group - Minimal Intervention|Minimal intervention
2394975|NCT03607578|Experimental|Protection Routine 1|
2394976|NCT03607578|Experimental|Protection Routine 2|
2394977|NCT03607578|Experimental|Protection Routine 1+2|
2394978|NCT03607565||good perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(good perfusion)
2394979|NCT03607565||middle perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(middle perfusion)
2394980|NCT03607565||poor perfusion in DSA|We introduced a new parameter derived from DSA to evaluate the perfusion in middle cerebral artery (MCA) territory in anterior cerebral ischemia.(poor perfusion)
3184142|NCT00721344|Experimental|1|
3184143|NCT00721344|Experimental|2|
2394986|NCT03607526||Barriers to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying barriers to meeting the DGA recommendation for vegetable consumption.
2394987|NCT03607526||Facilitators to Vegetable Consumption|Four groups of participants will meet for NGT sessions, identifying facilitators to meeting the DGA recommendation for vegetable consumption.
2394988|NCT03607513|Experimental|Single Ascending Dose (SAD)|The SAD part will consist of 6 escalating dose cohorts and 1 fed cohort of healthy male participants, 2 dose escalating cohorts of healthy female participants, and 1 solid dose formulation (capsule) cohort of healthy male participants, who will be dosed after completion of the dose escalation cohorts. Participants in each cohort (except for the solid dose formulation cohort) will receive JNJ-64264681 or Placebo on Day 1, orally. In the solid dose formulation cohort, participants will receive JNJ-64264681 capsule on Day 1. Doses for the female cohorts and fed cohort will be selected based on safety, tolerability, pharmacokinetics (PK),and pharmacodynamic (PD) data from preceding cohorts and the dose for the solid dose formulation cohort will be selected and approximately equal to a dose previously studied in the single ascending dose cohorts.
2394989|NCT03607513|Experimental|Multiple Ascending Dose (MAD)|The MAD part will consist of 3 dose escalation cohorts of males and females. Participants will receive once-daily oral doses of JNJ-64264681 or placebo for 10 consecutive days.
2395024|NCT03607253|Other|Women|Healthy young women aged between 18-25 years
2395025|NCT03607240|Experimental|LUS-guided alveolar recruitment|Lung ultrasound-guided alveolar recruitment maneuver will be performed
3184144|NCT00721344|Experimental|3|
3184145|NCT00721344|Experimental|4|
3184146|NCT00721370|Experimental|1|Patients imaged using ICG:HSA and NIR imaging system
3184147|NCT00721383|Experimental|Treatment|Physical activity and caregiver skill-building
3184148|NCT00721383|Active Comparator|Control|caregiver skill-building
3184149|NCT00721422|Experimental|Group 1-Normal|
2394990|NCT03607500|Experimental|Caloric Intake Reduction|The intervention group will be seen by the kidney disease dietician at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3). During months 2 and 3, in the weeks that the patients are not in clinic, they will receive telephone calls from the dietician. Thus the intervention involves weekly assessment for the first 3 months (in person or over the telephone). After 3 months, the patient will not receive any further active dietary intervention from the dieticians unless the patient wishes to continue using the dieticians advice per clinic protocol.
2394991|NCT03607500|No Intervention|Standard of care|The standard of care arm will receive dietary guidance per current University of Michigan Transplant Center policy, where a one time face-to-face visit is provided in the first month after kidney transplant and then as requested by the patient or referred by physician.
3184150|NCT00721422|Experimental|Group 2-Mild|
3184151|NCT00721422|Experimental|Group 3-Moderate|
3184152|NCT00721422|Experimental|Group 4-Severe|
2394995|NCT03607474||Couple (Patients and caregivers)|"Patient in remission of hypercortisolism Caregivers will be the spouse or, failing that, a person close to the patient, who has been in regular contact with the patient since taking care of him.~Questionnaires of life quality for patients Questionnaires of life quality for caregivers"
2394996|NCT03607461|Experimental|Smartphone App Users|Smartphone App Users will receive important information and prescriptive exercise via a smartphone app upon returning home from the hospital following total knee arthroplasty
2394997|NCT03607461|Active Comparator|Home Health Users|Home Health Users will have already undergone traditional home health physical therapy and/or skilled nursing for the purpose of comparing outcomes
2394998|NCT03607448||Diabetes Mellitus Type 1 and Type 2|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and expected to perform at least 8 capillary BG test per day. Site Staff will determine when subject will undergo either a hypoglycemia induction or a hyperglycemia induction. Study staff will perform IV blood draw to obtain blood plasma for YSI sampling every 15 min when glucose as measured by YSI is above 70mg/dL and below 240 mg/dL.
2394999|NCT03607435|Experimental|Test Article Scanning|Spectroscopy for Analyte Quantification
2395000|NCT03607422|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
2395001|NCT03607422|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
2395002|NCT03607422|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
2395003|NCT03607422|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
2395004|NCT03607383|Experimental|Red rice yeast group|Red rice yeast based product will be provided under the brand name Molval Fort, one pill a day, for 8 weeks, for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions
2395005|NCT03607383|Active Comparator|Statin group|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
2395006|NCT03607370|No Intervention|Group 1|The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy
2395007|NCT03607370|Experimental|Group 2|The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy
2395008|NCT03607357|Experimental|HFNO group/Group A|The patients should receive the treatment of high flow nasal oxygen immediately after extubation.
2395009|NCT03607357|Placebo Comparator|NIV group/Group B|The patients should receive the treatment of non-invasive Ventilation immediately after extubation.
2395010|NCT03607331|Experimental|Auricular vagus nerve stimulation|Auricular Concha Electro-acupuncture: twice a day at home as required, once in the morning and once in the evening, with 5 consecutive days per week for two months
2395011|NCT03607331|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
2395012|NCT03607318|Experimental|iASIST|iASIST, involves 1) an individual intervention with the adolescent in which motivational enhancement techniques are used to explore alcohol use as a risk factor for continued suicide-related thoughts and behaviors and to create a change plan, 2) a subsequent family intervention using motivational enhancement techniques to align the parent with the adolescent to strengthen the adolescent's self-efficacy and commitment to the change plan as well as the parent's ability to support the adolescent in their plan to reduce or stop drinking, and 3) a post-discharge mHealth booster to adolescents focused on strengthening their commitment to the change plan, and to parents focused on their commitment, confidence, and ability related to supporting the adolescent in reducing or stopping drinking.
2395013|NCT03607318|Active Comparator|Attention-Matched Comparison|The attention-matched comparison condition involves one psychoeducation session focused on the role of a healthy lifestyle in mental health and an additional family intervention, in which the adolescent will review handouts from the session with the parent, facilitated by the interventionist. In addition, adolescents and parents assigned to the comparison will receive a post-discharge mHealth control about the maintenance of a healthy lifestyle with the same frequency and type of interaction as the iASIST mHealth booster.
2395014|NCT03607305|Active Comparator|BP limb 70cm|Patients underwent a RYGB with a biliopancreatic limb of 70cm
2395015|NCT03607305|Experimental|BP limb 120cm|Patients underwent a RYGB with a biliopancreatic limb of 120cm
2395016|NCT03607292|Experimental|Group A|Anterior sciatic nerve block
2395017|NCT03607292|Experimental|Group P|Posterior sciatic nerve block
2395018|NCT03607279||NGAL - retropubic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
2395019|NCT03607279||NGAL - robotic radical prostatectomy|Plasma NGAL was determined at baseline, 6 and 12 hrs after induction of anaesthesia
2395020|NCT03607266||Group I (Ibuprofen)|Ibuprofen Group will receive 800 mg iv ibuprofen in 100 cc of isotonic solution within 30 min before the procedure
2395021|NCT03607266||Group D (Dexketoprofen|Dexketoprofen Group will receive 50 mg iv dexketoprofen in addition to 100 cc of isotonic solution within 30 min before the procedure
2395022|NCT03607266||Placebo Group|will receive 100 cc of isotonic solution within 30 min before the procedure
2395023|NCT03607253|Other|Men|Healthy young men aged between 18-25 years
2395026|NCT03607240|Active Comparator|conventional alveolar recruitment|Alveolar recruitment maneuver will be provided with positive pressure of 30 cmH2O for 10 seconds.
2395027|NCT03607227|Active Comparator|Local anesthetic|Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
2395028|NCT03607227|Placebo Comparator|Saline|Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as in the active substance arm.
2395029|NCT03607214|Experimental|Positive Expectations Group|Participants receive a nasal spray that is in fact a placebo. However, they are told that it protects from experiencing negative emotions and generally improves their mood. They take the nasal spay in the laboratory and on seven consecutive days. Participants watch two film sequences that are supposed to induce sadness.
2395030|NCT03607214|No Intervention|No-treatment control group|Participants do not receive the nasal spray. Participants watch two film sequences that are supposed to induce sadness.
2395031|NCT03607201||Diabetic|History of diabetes prior to Acute Coronary Syndrome
2395032|NCT03607201||Non-diabetic|No documented history of diabetes prior to Acute Coronary Syndrome
2395033|NCT03607188|Experimental|ZG0418 200mg QD|ZG0418 200mg/day,oral
2395034|NCT03607188|Experimental|ZG0418 300mg QD|ZG0418 300mg/day,oral
2395035|NCT03607188|Experimental|ZG0418 400mg QD|ZG0418 400mg/day,oral
2395036|NCT03607188|Experimental|ZG0418 500mg QD|ZG0418 500mg/day,oral
2395037|NCT03607188|Experimental|ZG0418 600mg QD|ZG0418 600mg/day,oral
2395038|NCT03607175|Active Comparator|Steroid-eluting implant (Propel)|Mometasone furoate implant. 370ug of mometasone furoate with each application. One application to be used at the conclusion of surgery and left in place for 1 month or less depending on if it requires removal during office debridement.
2395039|NCT03607175|Experimental|Triamcinolone-impregnated CMC foam|Applied to one nostril at end of case through randomization. Experimental drug is triamcinolone-acetonide 40mg/mL. 2mL will be combined with 5mL sterile water and mixed with carboxymethylcellulose foam and placed in the nares at the conclusion of the surgery. This will only be applied once and will remain in the nares until it dissolves or 7 days.
2395042|NCT03607149|Active Comparator|STANDARD ARM|Calculation of the dose of pemetrexed as a function of body surface area
2395043|NCT03607149|Experimental|EXPERIMENTAL ARM|Calculation of the pemetrexed dose as a function of the Clearance of creatine (CrCLCG)
2395044|NCT03607136|Experimental|exercise training|Participants in the exercise training group received a 12-week exercise training.
2395045|NCT03607136|No Intervention|control|Participants in the control group did not receive any specific training programs instead of maintaining their usual activities of daily living.
2395046|NCT03607123||Baseline|After implantation of pacemaker, the pacing mode and the lower rate of pacemaker will be set as VDD and 50/45 bpm respectively, to get the baseline burden of atrial fibrillation without atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. Patients who can not tolerate will drop out. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group / stage (Atrial Pacing, Step1).
2395047|NCT03607123||Atrial Pacing (Step 1)|After Baseline and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group /stage (Atrial Pacing). At this stage, the pacing mode and the lower rate of pacemaker will be set as DDD and 70/60 bpm respectively, to perform relatively high-rate atrial pacing. Except for beta-blockers digoxin, and CCB to control heart rate, anti-arrhythmic drugs (AAD) will not be prescribed. After follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (AAD, Step1).
2395048|NCT03607123||AAD (Step 2)|After Step 1, and after follow-up of at least 3 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage. Anti-arrhythmic drugs including propafenone, amiodarone and dronedarone will be prescribed. After follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will go to next group/stage (RFCA, Step3).
2395049|NCT03607123||RFCA (Step 3)|After Step 2, and after follow-up of at least 6 month, patients with AF lasting longer than one minute detected by pacemaker will come to this group/stage (RFCA, Step3). Patients will receive catheter ablation of AF, up to patients' willingness. After follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will go to next group/stage (SAFE PAF-SND II).
2395050|NCT03607123||SAFE PAF-SND II|After RFCA, and after follow-up of at least 12 month, patients without AF lasting longer than one minute detected by pacemaker will come to this group/stage (SAFE PAF-SND II). At this stage, the pacing mode and the lower rate of pacemaker will be set as VDD and 40 bpm respectively. If the patient can not tolerate, the the pacing mode and the lower rate of pacemaker will be set as DDD/DDDR and 60 bpm. If the patient has no symptom related to bradycardia, he/she will be followed up until the end of this study.
2395051|NCT03607110||ketamine|ketamine used
2395052|NCT03607110||fentanyl|fentanyl used
2395053|NCT03607097|Experimental|Secondary prevention of DRPs (medication code) (intervention)|The intervention consists of :1)Patient-centred prescription Espaulella-Panicot J model (review model that includes different strategies in a single intervention. It is performed by a multidisciplinary team, and allows them to adapt the pharmacological plan of patients with clinical complexity). 2)strategies to improve medication adherence
2395054|NCT03607097|No Intervention|Usual care (control group)|The patient is reviewed according to the standard procedure, consisting only on the review of the medical prescription in the emergency department by the pharmacist assisting the unit
2395055|NCT03607084|Experimental|Intervention|The intervention group receives a school health program that has two components: the training of selected teachers to become school Health Workers and bi-annual health screenings of all students.
2395056|NCT03607084|No Intervention|Control|The control group receives regular school programming.
2395057|NCT03607071|Experimental|Prednisolone|The patient who has detected myocardial inflammation from cardiac MRI from baseline is given prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
2395058|NCT03607058|Active Comparator|Kinect + Exercise Training|Xbox Kinect and exercise training will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. A treatment session in this arm will consist of Kinect games for 40 minutes and exercise training for 20 minutes. In this arm, patients will play each game as two repetitions. Each game lasts about 3-4 minutes, and patients will be seated for resting between the games. After 10 weeks washout period only exercise training will be applied for 8 weeks.
2395059|NCT03607058|Active Comparator|Exercise Training|Exercise training will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 10 weeks washout period exercise training and Xbox Kinect will be applied together for 8 weeks.
2395060|NCT03607045|Placebo Comparator|control group|bouquet technique
2395061|NCT03607045|Active Comparator|test group|headless screw
2395062|NCT03607032|Experimental|RespinPad and usual treatment|
2395063|NCT03607032|Active Comparator|only usual treatment|
2395064|NCT03607006|Experimental|Patient specific PEEK sheets|Patient specific PEEK sheets will be fixed with titanium screws and act as containment system for the mixed autogenous/xenogenic bone graft that will fill the gap between the sheets and the ridge .
2395065|NCT03607006|Active Comparator|Autogenous bone shell technique|Bone shells will be fixed with titanium screws to the ridge and mixed autogenous/xenogenic bone graft will fill the gap between the shells and the ridge .
2395066|NCT03606993|Experimental|Lucky Iron Fish™ (LIF)|For Mother-infant dyads enrolled into the LIF arm, mother receives a cooking supplement: one ~ 200g iron ingot.
2395067|NCT03606993|No Intervention|Enhanced standard of care (eSOC)|For mother-infant dyads in the eSOC arm, families are not provided iron supplementation (consistent with standard of care) but have additional visits and laboratory monitoring beyond well-child care (enhanced).
2395068|NCT03606980|Experimental|Iontophoresis with Dexamethasone|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of the dexamethasone sodium phosphate (4ml/1mL) will be placed on one side and 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
2395069|NCT03606980|Placebo Comparator|Iontophoresis with Sodium Chloride|Iontophoresis is a non-invasive delivery mechanism for transmitting a medication to a local area of the body. The I-Bresis™ System and I-Bresis™ Patch will be the delivery system used for this study. The I-Bresis™ Patch is an adhesive patch. 1.5 ml of 0.9% sodium chloride (saline) solution will be placed on one side and 1.5 ml of 0.9% saline solution will be placed on the other. Duration of exposure: 123 minutes. Frequency of exposure: twice per week for a total of 12 sessions over a maximum of 8 weeks or until Return to Sport Criteria are met, whichever is sooner. Participants will also receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
2395070|NCT03606980|Active Comparator|Physical Therapy alone|Participants will only receive the standard PT protocol for apophysitis of the knee. This will involve up to 20 visits.
3143369|NCT00005945|Experimental|Induction and Augmented regimen (IV MTX, Double DI)|Patients with unfavorable characteristics. Standard Induction (14 Days), Augmented Induction (Days 14-35), Consolidation (9 weeks), Interim Maintenance I (56 Days), Delayed Intensification I (2 months), Interim Maintenance II (2 months), Delayed Intensification II (2 months), then Maintenance (84 day courses).
3143370|NCT00005945|Experimental|Induction and Oral MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
2395073|NCT03606954|Active Comparator|Combination topical corticosteroid|"The combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
2395074|NCT03606954|Active Comparator|Non-combination topical corticosteroid|"The non-combination topical corticosteroid will be applied to specific and marked sites on the forearms (on the flexor side of the forearm- 5*5 cm with a distance of 3 cm) - two sites on both forearms of every subject (4 sites in total). The nature of this application method will enable the measurement of the level of potency of each drug, in a manner that is comparative, neutralizing thus the influence of inter-subject variability.~The drugs will be topically applied (50 microliter on each site) for 16 hours, utilizing an occlusive dressing bandage such as Tegaderm. The vasoconstriction test will be preformed both before and after drug application. The vasoconstriction in each subject will be graded on the Olsen scale"
2395111|NCT03606694|Experimental|Metformin|Metformin capsules, 850 mg, two times per day before break-fast and dinner during 12 weeks.
2395112|NCT03606681|Active Comparator|Calcium Hydroxide (Dycal)|Indirect pulp capping treatment with Calcium Hydroxide
3143371|NCT00005945|Experimental|Induction and Oral MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3184153|NCT00721435|Experimental|3D Tomosynthesis & 3D Ultrasound for breast masses|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
2395075|NCT03606941|Experimental|electroacupuncture treatment|"Participants in the treatment group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected and maintained the end of operation."
2395076|NCT03606941|Sham Comparator|sham electroacupuncture treatment|"Participants in the control group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output."
2395077|NCT03606928|Experimental|modified FLOT|modified FLOT Docetaxel 40mg/m2 ivgtt day 1 over 1 hour Oxaliplatin 65mg/m2 ivgtt day 1 over 2hours Dose escalation will be performed. Leucovorin 200mg/m2 ivgtt day 1 over 2 hours 5-FU 2200mg/m2 civ over 24 hours
2395078|NCT03606915||no pain|pain evaluation for patients performed surgery without painful condition (bleeding or others)
2395079|NCT03606915||acute pain|pain evaluation for patients performed surgery with painful condition within several days
2395080|NCT03606915||chronic pain|pain evaluation for patients performed surgery with the painful condition for over months
2395081|NCT03606902|Active Comparator|(Group f):|"Intervention:~Procedure: Epidural catheter insertion~Drug: Epidural 15 ml of 0.0625%bupivacaine with 1 µg /Kg Fentanyl ,then continuous epidural infusion of fixed volume 10 ml of 0.0625% bupivacaine +1 µg/Kg/h Fentanyl for the next 6 hours ."
2395082|NCT03606902|Active Comparator|(Group Lf):|"Intervention:~Procedure:Epidural catheter insertion~Drug: Epidural injection 15 ml of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then 1st hour continuous IV infusion of 10ml of 0.0625%bupivacaine +1 µg/Kg/h Fentanyl ,2nd hour 10ml of 0.0625%bupivacaine + 0.5 µg/Kg/h Fentanyl , then next 4 hours10 ml of 0.0625%bupivacaine with + 0.25 µ g/Kg/h Fentanyl."
2395083|NCT03606889|Experimental|Quadratus Lumborum block group|Quadratus Lumborum block group (QL) patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
2395084|NCT03606889|Experimental|Transversus abdominis plane block group|Transversus abdominis plane block (TAP) patients will receive a bilateral TAP block using Bupivicaine 0.125%
3184154|NCT00721435|Experimental|3D Tomosynthesis/ 3D Ultrasound for healthy subjects|Evaluate breast screening diagnostic device, 3D tomosynthesis. Assess utility of adding 3D ultrasound.
3184155|NCT00721461|Experimental|1|V930
3184156|NCT00721474|Experimental|1|Bosutinib fasting
2395088|NCT03606863|Experimental|Perioperative peripheral parenteral nutrition|Perioperative peripheral parenteral nutrition during 4 days
2395089|NCT03606863|No Intervention|Standard fluid therapy|Standard fluid therap
2395090|NCT03606850|Experimental|Treatment by citalopram|The patients will receive a treatment by citalopram at 20mg/day. If patients respond by at least 20% on the HAMD-21 scale at day 14 : continuation at 20 mg/day. If patients do not respond by at least 20% at day 14 : increase the dose at 40 mg/day. The patients who will not respond by at least 50% on the HAMD-21 scale at day 28 will be excluded of the study and will undergo a new treatment plan. The patients who will respond by at least 50% on HAMD-21 at day 28 will continue citalopram at the same dose and will be reappraised at day 60. The patients will be assessed for the markers of neuroexcitability at day 1, day 3, day 7, day 14, day 28 and day 60.
2395091|NCT03606837|Experimental|PET/CT Imaging|
2395092|NCT03606824|Placebo Comparator|Pivastatin and placebo|After randomization, patients in Pivastatin + placebo group will receive pitavastatin and placebo.
2395093|NCT03606824|Experimental|Pivastatin and LT-4|After randomization, patients in combination group will receive pitavastatin as the lipid-lowering therapy and take levothyroxine as the thyroid hormone supplement.
2395094|NCT03606811|Active Comparator|fluroscopic guided block|
2395095|NCT03606811|Experimental|double modality guided block|
2395096|NCT03606798|Experimental|Multidisciplinary and personalized care|Personalized care and proposals bring by a team of experts : neurologists ; geriatrician ; psychologist.
2395097|NCT03606798|No Intervention|Reference care|Standard clinical evaluations of patient with Frontotemporal Lobar Degeneration.
2395098|NCT03606785|Active Comparator|tranexamic acid group|
2395099|NCT03606785|Placebo Comparator|placebo group|
2395100|NCT03606772||supracervical hysterectomy|Patients operated abdominal by removal of uterus, with removal of tubes and ovaries and retaining of cervix
2395101|NCT03606759|Experimental|Traitment as usual adjusted on ATI information|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
2395102|NCT03606759|Active Comparator|Traitment as usual|Assessments with a multidisciplinary team (doctors, nurses, psychologists, psychiatrists, social workers) once a week during 3 months.
2395103|NCT03606746|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation (TLI) and anti-thymocyte globulin (ATG) combined with a single IV infusion of MDR-103 and standard anti-rejection medications in past recipients of HLA Zero-mismatch living donor kidney transplants.
2395104|NCT03606733|Experimental|A custom made Suprachoroidal needle for macular diseases|A custom made 30 gauge needle offering 1000 micron penetration of the sclera at the parsplana
2395105|NCT03606720|Experimental|group(A) low level laser therapy|composed of 30 patients who received pelvic stabilization exercises and low level laser therapy For 12 sessions over six week's period by 2 sessions per week.
2395106|NCT03606720|Active Comparator|group(B) pelvic stabilization exercises only|composed of 30 patients who pelvic stabilization exercises only For 12 sessions over six week's period by 2 sessions per week.
2395107|NCT03606720|Active Comparator|group (C) low level laser therapy only|composed of 30 patients who low level laser therapy only For 12 sessions over six week's period by 2 sessions per week.
2395108|NCT03606707|Experimental|corticosteroid|steroid group, received intra-articular steroid injection for atlantoaxial joint. , in addition to methotrexate and chloroquine 400 mg per day.
2395109|NCT03606707|No Intervention|oral steroid|systemic group, received systemic steroid 20 mg/d , in addition to methotrexate and chloroquine 400 mg per day.
2395110|NCT03606694|Experimental|Dihydromyricetin|Dihydromyricetin capsules, 300 mg, two times per day before break-fast and dinner during 12 weeks.
3184157|NCT00721474|Experimental|2|Bosutinib fed
2395113|NCT03606681|Experimental|Mineral Trioxide Aggregate (ProRoot MTA)|Indirect pulp capping treatment with Mineral Trioxide Aggregate
2395114|NCT03606681|Experimental|Theracal LC|Indirect pulp capping treatment with Theracal LC
2395115|NCT03606668|Experimental|Virtual Reality Therapy|eligible participants will receive a full session of VR therapy that may extend as long as an hour in length.
2395116|NCT03606655|Experimental|Kava|This is a single-arm pre- and post- Phase 0/1 study with one primary goal to explore the feasibility of recruitment of participants, adherence rate, acceptability of treatment and completion rate with 14 day dietary supplement kava treatment in head and neck cancer patients who continue to smoke. The other primary goal is to evaluate distribution of change in nicotine and NNK metabolism after 14 day kava treatment..
2395117|NCT03606642|Experimental|PCI with 30 day DAPT Therapy|Single group of patients undergoing IVUS stent placement for PCI with 30 day DAPT therapy regimen. DAPT therapy consists of Aspirin (325 mg loading dose [if applicable] and 81 mg for maintenance dose) and P2Y12 Inhibitor (INFO ABOUT THE DRUGS)
2395118|NCT03606629||Endoprosthesis implantation|Device implantation
2395119|NCT03606616||ACOSOG Z0011 no further ALND arm|patients meeting the criteria for ACOSOG Z0011 trial inclusion：histologically confirmed invasive breast cancer;clinical T1/T2;breast conserving surgery；1 or 2 positive sentinel lymph nodes; Whole-breast RT planned; no preoperative chemotherapy
2395120|NCT03606603||Surgical patients|Adult patients after elective major abdominal gastrointestinal surgery with pre-existing malnutrition or who are at significant risk for malnutrition or nutrition-related complications, with indications for nutritional support
2395121|NCT03606590|Experimental|TTFields in combination with sorafenib|Patients will be treated continuously with TTFields, in addition to sorafenib
2395122|NCT03606577|Experimental|Carfilzomib, Daratumumab, Lenalidomide and Dexaméthasone|
2395123|NCT03606564||paediatric patients undergoing day care surgery|
2395124|NCT03606551||New Orthodontic Patients|"New patient subjects who are just initiating full orthodontic treatment will have their premolars, canines, and incisors bonded with the EXD-959 Bracket System, using the related EXD-961 instruments, according to the manufacturer's IFU.~Their remaining teeth will be bonded with the brackets of the orthodontist's choice. Three of the 5 new patients recruited may be patients that the orthodontist will choose to initiate treatment with the EXD-959 study brackets being applied to the upper teeth only. Having this option will allow the investigators to recruit subjects with deeper over-bites where their standard of care would be to apply esthetic brackets on the upper teeth and metal brackets on the lower teeth."
2395125|NCT03606551||Intercept Orthodontic Patients-Progress|This group will include a minimum of three, and up to 5 patients at each study site who have moved into rectangular wires; and in whom, the orthodontist- investigator believes they will be able to evaluate rotation corrections using the EXD-959 Bracket System. For example, rotation correction of the upper central incisor which will test the width of the bracket's holding points in situations that have wide teeth and greater inter-bracket distance.
2395126|NCT03606551||Intercept Orthodontic Patients-Finishing|This group will include a minimum of three, and up to 5 patients per study site who are estimated to be within 4 months of completing their orthodontic treatment; and in whom, the orthodontist-investigator believes they will be able to evaluate both torque control and debonding experiences using the EXD-959 Bracket System.
2395127|NCT03606538|Experimental|Moderate hepatic impairment|Eight participants with moderate hepatic impairment receive a single dose of 80 mg MDMA.
2395128|NCT03606538|Experimental|Normal hepatic function|Eight participants, each matched on age, weight and gender to a participant with moderate hepatic impairment, receive a single dose of 80 mg MDMA.
3143372|NCT00005945|Experimental|Induction and IV MTX, Single Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months) then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3143373|NCT00005945|Experimental|Induction and IV MTX, Double Delayed Intensification|Patients without CNS disease at diagnosis, with favorable cytogenetics. Standard Induction (28 Days). Consolidation (28 days) and in event free remission Day 21 and at time of randomization, Interim maintenance I (2 months), Delayed intensification I (2 months), Interim maintenance II (2 months), Delayed intensification II (2 months), then Maintenance (12 week cycles). Biopsy-proven testicular leukemia pts at diagnosis will receive testicular radiation therapy during the consolidation phase.
3143374|NCT00005949|Experimental|Treatment (gp100:209-217, aldesleukin )|Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 SC on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a CR receive 3 additional courses after achieving CR.
2395132|NCT03606486|Experimental|Diagnostic (pap smear, uterine lavage, tumor sample)|Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
2395133|NCT03606473|Experimental|Prenatal cocaine exposed subjects|[C-11]NPA PET at baseline and post d-amphetamine
2395134|NCT03606473|Experimental|Comparison subjects|[C-11]NPA PET at baseline and post d-amphetamine
3184158|NCT00721487||Fluconazole|30 evaluable patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy.
3184159|NCT00721526|Experimental|Disulfiram plus lorazepam|Disulfiram plus lorazepam
2395137|NCT03606447|Experimental|Single IV administration of [14C]-Uproleselan|
2395138|NCT03606434|Experimental|Hypoxic Exposure|Men, and women in early or late follicular phase of menstrual cycle will be exposed to acute and intermittent hypoxic episodes.
3184160|NCT00721552|Experimental|I|prednisolone + sitagliptin
3143375|NCT00005950|Experimental|Treatment|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3143376|NCT00005961|Experimental|Arm I|Patients receive O6-benzylguanine IV over 1 hour, followed 1 hour later by carmustine IV over 1 hour on day 1. Treatment continues every 6 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
2395139|NCT03606421||Arm A|Patients in Arm A will be treated with stereotactic radiosurgery (SRS) which is a modern method of treating brain lesions that delivers a high amount of radiation to a small volume of the brain affected by a tumour; and is the standard of care for patients with a limited number of brain metastases.
2395140|NCT03606421||Arm B.|Patients in Arm B will be treated with whole brain radiotherapy, due to the number of lesions in their brain.
2395141|NCT03606408|Other|osilodrostat|open label, with patients receiving same dose as provided in the parent study
2395142|NCT03606395|Experimental|Single ascending dose_healthy subjects|"NV-5138:~Single dose of 150, 300, 600, 1000, 1600 or 2400 mg single dose of placebo"
2395143|NCT03606395|Experimental|Single dose in subjects with TRD|NV-5138 oral solution single dose (dose to be determined from Part A) single dose of placebo
2395144|NCT03606369|Experimental|Palonosetron|"Early emesis: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Dexamethasone 8 mg orally on days 2, 3 and 4."
2395145|NCT03606369|Active Comparator|Ondansetron|"Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV.~Delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs."
3184161|NCT00721552|Experimental|II|prednisolone + sitagliptin-placebo
2395147|NCT03606330||VP-SG 01|Study subjects that present MACE at the 36 months follow-up
2395148|NCT03606330||VP-SG 02|Study subjects that do not present MACE at the 36 months follow-up
2395149|NCT03606304|Experimental|Problem-solving therapy|The intervention is based on an established PST protocol for medical patients, with an additional focus on HF to link depressed mood to impaired HF self-care. Seven steps are included: 1) select and define the problem; 2) establish realistic and achievable goals for problem resolutions; 3) generate multiple solution alternatives (brainstorming); 4) implement decision-making guidelines (pros and cons); 5) evaluate and choose the solutions; 6) implement the preferred solution(s); and 7) evaluate the outcome.
2395150|NCT03606291|Experimental|isotoxic hypofractionation group|"1. Hypofractionated radiation: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 72Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 72 Gy. The lowest radiation dose: 45Gy."
2395151|NCT03606278|Experimental|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required.
2395152|NCT03606278|Active Comparator|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred.
2395153|NCT03606265|Experimental|App+Web|Treatment as usual + app Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2395154|NCT03606265|Active Comparator|Treatment as usual|Treatment as usual (waiting list) Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
2395155|NCT03606252|Other|pneumocystosis with favourable evolution|patients with a favourable pneumocystosis outcome
2395156|NCT03606252|Other|pneumocystosis with unfavourable outcome|patients with unfavourable pneumocystosis outcome
2395157|NCT03606252|Other|Pneumocystis colonization|subject colonized by Pneumocystis jirovecii
2395158|NCT03606239|Experimental|isotoxic hypofractionated group|"Hypofractionated radiation:~1. Split mode: 3Gy/f. 2,Individualized prescriptions for different patients:~(1) Spinal cord: 0%>45 Gy, and ≤2 Gy each time Lung: V20≤30%, V5≤65%, MLD≤16Gy Esophagus: highest dose ≤ 69Gy 3. Maximum limit: If the limit of any A is not reached, the maximum radiation dose is 69 Gy. The lowest radiation dose: 45Gy.~Chemotherapy:~Platinum-containing two-drug regimen: docetaxel + lobaplatin: Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1; repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.~The same chemotherapy regimen is used up to 4 cycles as consolidation after the completion of radiotherapy."
2395159|NCT03606213|Placebo Comparator|Cohort A - Arm 1|Placebo will be administered by electoporation at Day 0 and Weeks 4, 8 and 12
2395160|NCT03606213|Active Comparator|Cohort A - Arm 2|Active gag/pol, env and IL-12 plasmids (PENNVAX-GP and INO-9102)) administered by electoporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
2395161|NCT03606213|Active Comparator|Cohort A - Arm 3|Active gag/pol and IL-12 plasmids (INO-6145 INO-9012) will be administered by electroporation (CELLECTRA-2000) at Day 0 and Weeks 4, 8 and 12.
2395162|NCT03606213|Active Comparator|Cohort B - Arm 1|A single arm study of gag/pol/env/IL-12 DNA plasmids PENNVAX-GP and INO-9102) administered by electoporation (CELLECTRA-2000) will be performed in HIV-infected adults for whom ART was initiated during acute HIV infection.
3184162|NCT00721552|Experimental|III|prednisolone-placebo + sitagliptin
3184163|NCT00721552|Placebo Comparator|IV|prednisolone-placebo + sitagliptin-placebo
2395165|NCT03606174|Experimental|Cohort 1|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395166|NCT03606174|Experimental|Cohort 2|Patients previously treated with checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395167|NCT03606174|Experimental|Cohort 3|Patients previously treated with selected immunotherapies and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395168|NCT03606174|Experimental|Cohort 4|Patients previously treated with with selected immunotherapies, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395260|NCT03605446|Experimental|Animal 12%|Animal based protein biscuit containing 12% of total energy as protein
3184164|NCT00721552|No Intervention|Healthy controls|12 healthy men will be included to assess postprandial microvascular function.
2395169|NCT03606174|Experimental|Cohort 5|Patients previously treated with platinum-based chemotherapy, but never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395170|NCT03606174|Experimental|Cohort 6|Patients ineligible for treatment with platinum-based chemotherapy and never treated with checkpoint inhibitor. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395171|NCT03606174|Experimental|Cohort 7|Patients previously treated with antibody-drug conjugate, checkpoint inhibitor and platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395172|NCT03606174|Experimental|Cohort 8|Patients previously treated with antibody-drug conjugate and checkpoint inhibitor, but ineligible for platinum-based chemotherapy. Nivolumab over 30 min IV infusion (240 mg IV every 2 weeks or 480 mg every 4 weeks) and sitravatinib 120 mg orally once per day continuously in 28-day cycles.
2395173|NCT03606174|Experimental|Cohort 9|Patients previously treated with checkpoint inhibitor and platinum-based chemotherapy. There are 2 parts to this Cohort - a lead-in dose escalation portion and a dose expansion portion. In the dose escalation portion, treatment with up to 3 dose levels of sitravatinib in combination with up to 2 dose levels of pembrolizumab and enfortumab combination regimen to determine the recommended doses to be used in the combination treatment regimen and those doses will be further studied in the dose expansion portion. Pembrolizumab 200 mg over 30 min IV infusion every 3 weeks, sitravatinib orally once per day continuously in 21-day cycles (at 35 mg, 50 mg, 70 mg, or 100 mg) and enfortumab vedotin over 30 min IV infusion on Day 1 and Day 8 in 21-day cycles (at 1 mg/kg or 1.25 mg/kg).
3184165|NCT00721552|No Intervention|Type 2 diabetic subjects|12 men with type 2 diabetes will be included in order to assess postprandial microvascular function.
2395175|NCT03606148||SurePathTM|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In SurePathTM group, subjects who underwent SurePathTM liquid-phase cytology test with the first sample subjected to the conventional smear test with the second sample."
2395176|NCT03606148||Conventional|"The subjects are randomly assigned to SurePathTM/Conventional test group at a ratio of 1: 1.~In conventional test group, those who subjected to the conventional smear test with the first sample, will undergo the SurePathTM liquid cell test with the second obtained sample."
2395177|NCT03606135||The Pneumonia Group|Subjects with chest images (x-ray or CT scan) indicating pneumonia.
2395178|NCT03606135||The Control Group|Healthy subjects
2395179|NCT03606122|Experimental|PD P 506 A-PDT|The study medication will be applied to each study lesion for 4 hours. After removal of the study medication the study lesions will be illuminated with red light of defined wavelength (PDT). Second PDT of the lesions will be performed 6-14 days after the first PDT.
2395180|NCT03606109|Active Comparator|TTO + IV TXA|
2395181|NCT03606109|No Intervention|TTO, no IV TXA|
2395182|NCT03606096|Experimental|Boostrix IPV - infant acellular Pertussis (TdaP-aP)|vaccination of the mother with Boostrix-IPV vaccine which includes the infant acellular pertussis
2395183|NCT03606096|Experimental|Boostrix IPV - infant whole Pertussis (Tdap-wP )|vaccination of mother with Boostrix -IPV which includes infant whole cell pertussis
2395184|NCT03606096|Active Comparator|TT - infant acellular Pertussis (T-ap )|vaccination of mother with TT-which includes infant acellular pertussis
2395185|NCT03606096|Active Comparator|TT - infant whole Pertussis (T-wP)|vaccination of mother with T which includes infant whole cell pertussis
2395186|NCT03606070|Other|Patients with NSCLC|"Characterization of tumor heterogeneity by multiparametric regional mapping PET-MRI.~Patients will realize:~a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
2395187|NCT03606057|Experimental|Treatment Group 1: JNJ-64565111+Moxifloxacin Placebo|Participant will receive JNJ-64565111 on days 2, 9, 16, and 23 and moxifloxacin-matching placebo on days 1 and 27.
2395188|NCT03606057|Active Comparator|Treatment Group 2: JNJ-64565111 Matching Placebo+Moxifloxacin|Participant will receive JNJ-64565111-matching placebo on days 2, 9, 16, and 23. Participants will also receive moxifloxacin on day 1 and moxifloxacin-matching placebo on day 27 (sequence 2a) or moxifloxacin-matching placebo on day 1 and moxifloxacin on day 27 (sequence 2b) in a nested crossover manner.
2395189|NCT03606044||MIS-PN|Participants approved for elective robot-assisted partial nephrectomy with T1a or T1b renal tumours.
2395190|NCT03606018|Experimental|Insulin Lispro Mix 25|Single subcutaneous administration of Insulin Lispro Mix 25 in dose 0.4 IU / kg
2395191|NCT03606018|Active Comparator|Humalog® Mix 25|Single subcutaneous administration of Humalog® Mix 25 in dose 0.4 IU / kg
2395192|NCT03606005||Group 1: Allogeneic-HSCT recipients|Dyspnea [Modified Medical Research Council dyspnea scale (MMRC)], submaximal exercise capacity [6-minute walk test (6-MWT)], physical activity level [metabolic holter], quality of life [European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)] and pulmonary functions [spirometry] were evaluated in allogeneic-HSCT recipients (.Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of 6-MWT.
2395193|NCT03606005||Group 2: Healthy individuals|Healthy individuals were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
2395194|NCT03605992|Experimental|Home-based Rehabilitation|Home-based cardiac rehabilitation that includes the components of education and physical exercises mainly unsupervised and oriented by telephone.
2395195|NCT03605992|Active Comparator|CentreRehabilitation|Traditional cardiac rehabilitation offered at the outpatient centre including components of education and physical exercises mainly supervised.
2395196|NCT03605979||diabetes group|Patient with hypoglycemia unawareness
2395197|NCT03605940|Experimental|Experimental group|corticosteroids + ECP
2395198|NCT03605940|Active Comparator|Contrôl group|corticosteroids alone
2395199|NCT03605927|Experimental|Combination Therapy|"BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.~Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care."
2443634|NCT05075408|Placebo Comparator|Placebo|
3184166|NCT00721565|Experimental|1|behavior change intervention
2395202|NCT03605901|Active Comparator|Standard dosing of methadone|Receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
2395203|NCT03605901|Experimental|Aliquots of methadone titrated to apnea|Receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals. The practitioner will continue to coach patient to take deep breaths. After reaching the apnea threshold as determined by respiratory rate less than 4 breaths/min, induction of general anesthesia and intubation will proceed.
2395204|NCT03605888|Experimental|RCT Intervention|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the Koa Family. intervention
2395205|NCT03605888|No Intervention|RCT Control|Overweight or obese (BMI ≥ 25 kg/m2) participants randomized to the control group.
2395206|NCT03605888|Other|Exploratory|Normal-weight mothers (BMI 18.5-24.9 kg/m2) assigned to the Koa Family intervention.
2395207|NCT03605875|Experimental|Web-App|A customized web-app tool to be used by patients to communicate concerns to their nephrologist
2395208|NCT03605875|Active Comparator|Paper|A customized paper tool to be used by patients to communicate concerns to their nephrologist
2395209|NCT03605862|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily for 5 days
2395210|NCT03605862|Placebo Comparator|Placebo|Two placebo tablets orally twice daily for 5 days
2395211|NCT03605849|Experimental|Centanafadine|400 mg total daily dose
3143377|NCT00005963|Experimental|docetaxel + carboplatin|This is a multicenter study. Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), partial response (PR), or complete response (CR) may receive 4 additional courses past SD, PR, or CR. Patients are followed every 6 months for 2 years and then annually for 3 years.
3143378|NCT00005964|Experimental|Chemotherapy + prednisone + filgrastim|Patients receive doxorubicin IV, etoposide IV, vincristine IV, and cyclophosphamide IV continuously over days 1-4. Patients also receive oral prednisone twice daily on days 1-5 and filgrastim (G-CSF) subcutaneously beginning on day 6 until blood counts recover. Treatment continues every 21 days for a maximum of 8 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
3143379|NCT00005967|Experimental|Arm I|Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
2395215|NCT03605810||eGFR-population|To be included in the eGFR-population, patients have to have at least one recorded eGFR value in the OPTUM CDM database between January 1, 2007 and December 31, 2016, be adults (>18 years of age at the time of eGFR test) and have at least 370/180 days (180 days serves as sensitivity analysis) of continuous enrollment in medical and pharmacy insurance plans since eGFR test date.
2395216|NCT03605810||Atrial fibrillation (AF) sub-population|"To be included in the AF sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have two inpatient or outpatient diagnoses for AF or atrial flutter on two different days within the study period irrespective of time points when eGFR is measured.~Patients with at least one inpatient or outpatient diagnosis or procedure code for mitral stenosis and prosthetic valves within the study period will be excluded."
2395217|NCT03605810||Coronary artery disease (CAD) sub-population|To be included in the CAD sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least one inpatient CAD diagnosis within the study period irrespective of time points when eGFR is measured.
2395218|NCT03605810||Type 2 diabetes mellitus (T2DM) sub-population|To be included in the T2DM sub-population patients need to satisfy the inclusion criteria for the eGFR-population; have at least two inpatient or outpatient diagnosis of T2DM on two different days within the study period irrespective of time points when eGFR is measured.
2395219|NCT03605797||No intervention|To study the indication and results of fixing the sacral fracture by tension band plating
2395220|NCT03605771||Advanced Melanoma|"Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:~Disease onset as metastatic or unresectable disease.~First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period."
2395221|NCT03605758|Active Comparator|Ivermectin on Days 1 and 2|Participants will receive 200 µg/kg of ivermectin daily for two consecutive days with breakfast.
2395222|NCT03605758|Active Comparator|Ivermectin on Days 1 and 14|Participants will receive 200 µg/kg of ivermectin on day one and day 14 with breakfast.
2395224|NCT03605732|Experimental|intervention|Intervention group: They will receive an educational app designed to improve sleep, and will receive self-help training in a six-week training package.
2395225|NCT03605732|Active Comparator|Patient education|Patients will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
2395229|NCT03605706|Experimental|SHR-1210|SHR-1210+FOLFOX4
2395230|NCT03605706|Experimental|CONTROL|SHR-1210+Placebo
3143380|NCT00005969|Experimental|Liposomal Tretinoin|Liposome by vein (IV) over 30 minutes every other day for 28 days and Chemotherapy.
3143381|NCT00005970|Experimental|Arm I (AC, paclitaxel, tamoxifen, aromatase inhibitor)|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV over 20-30 minutes on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive paclitaxel IV over 1 hour beginning on day 1 of week 13 and continuing weekly for 12 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
3184167|NCT00721565|No Intervention|2|written materials
3184168|NCT00721591||A|Subjects opting for treatment with unfractionated heparin
2395239|NCT03605654|Experimental|Investigational Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 1, 2, or 3 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
2395240|NCT03605654|Active Comparator|Active Control Arm|Standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study
2395241|NCT03605654|Experimental|Non-Randomized Exploratory Arm|A low-dose Total Lymphoid Irradiation and anti- thymocyte globulin combined with a single infusion of MDR-102 post-kidney transplant and standard anti-rejection medications in recipients of 4, 5, or 6 out of 6 human leukocyte antigen (HLA)-mismatched, living donor kidney transplants
2395242|NCT03605641|Experimental|JUUL electronic cigarette|JUUL electronic cigarette. Virginia Tobacco 5% tobacco-derived nicotine.
2395243|NCT03605641|Active Comparator|VUSE Solo electronic cigarette|Reynolds American International VUSE Solo electronic cigarette. Original flavor 4.8% tobacco-derived nicotine.
2395244|NCT03605641|Active Comparator|Conventional cigarette|Canadian purchased, store bought (not hand-rolled) conventional full-flavored cigarettes of subjects' preference.
2395245|NCT03605628|Other|abdominal wall length|Measurement of abdominal wall length during neuromuscular block with a measuring tape
2395246|NCT03605615|No Intervention|CONTROL|In this group parturients will be attended in standardized manner, which in our hospital means a humanized approach with choice of position in socond stage and without routine episiotomy.
2395247|NCT03605615|Experimental|VOCALIZATION|In this group parturients will besides being be attended with our standar care, will receive training to vocalize during second stage.
2395248|NCT03605589|Experimental|Blinatumomab and Pembrolizumab|"Blinatumomab and Pembrolizumab will be given for 2 cycles (each cycle lasts 35 days).~Blinatumomab administered as a continuous IV infusion. Patient Weight Greater Than or Equal to 45 kg (Fixed dose) Patient Weight Less Than 45 kg (BSA-based dose)~Cycle 1 (Days 1-7):~Patient Weight Greater Than or Equal to 45 kg: 9 mcg/day Patient Weight Less Than 45 kg: 5 mcg/m2/day~Cycle 1(Days 8-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Cycle 2 (Days 1-28):~Patient Weight Greater Than or Equal to 45 kg: 28 mcg/day Patient Weight Less Than 45 kg: 15 mcg/m2/day~Pembrolizumab: 2 mg/kg (max dose 200 mg) administered as a 30 minute IV infusion on day 12 of cycle 1 and day 5 of cycle 2."
2395249|NCT03605576|Experimental|Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2395250|NCT03605576|Active Comparator|Transcutaneous electrical nerve stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2395251|NCT03605563|Experimental|FSN: Fu's subcutaneous needling|In this arm, the subjects will receive the intervention of FSN on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2395252|NCT03605563|Active Comparator|TENS: Transcutaneous Electric Nerve Stimulation|In this arm, the subjects will receive the intervention of TENS on Day1, Day2 and Day4, in total 3 treatments and will be arrange to take efficacy two assessment on Day8 and Day15, separately.
2395254|NCT03605537|Experimental|Stent|"Subjects will undergo repair of the choanal atresia in the operating room with a drug eluting stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. At this time in the operating room the intervention arm will have the stent removed. Following removal of the stent, photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
2395255|NCT03605537|No Intervention|No Stent|"Subjects will undergo repair of the choanal atresia in the operating room with no stent placed at the end of the surgical procedure. They will return to the operating room in 3-5 weeks for repeat nasal endoscopy with possible balloon dilation, which is standard of care within our institution. Photodocumentation of the posterior nasal cavity and nasopharynx will take place to assess the size (standard of care).~Subjects will then follow up and undergo a bedside or outpatient nasal endoscopy and nasopharyngoscopy (standard of care) at the following approximate intervals 1 month, 6 months, 12 months (these are not exact time periods as clinic scheduling can sometimes be 2-3 months on either side of these time stamps)."
2395256|NCT03605524|Other|Sensory training|"Sensory (Olfactory or visual) training will be done at home for 12 weeks.~The effect of the training will be evaluated using an experimental protocol includes (i) clinical and psychometric evaluations, (ii) the study of olfactory perception using Sniffin' Sticks Test and (iii) the study of the emotional perception using the subjective Sense'n Feel method and the objective measurement of the spontaneous pupillary dilatation."
2395257|NCT03605485|Experimental|Trial Continuous Positive Airway Pressure (CPAP) mask|Trial nasal pillows CPAP mask
2395258|NCT03605472|Experimental|Patients|
2395259|NCT03605459|Experimental|Device use|"Only one treatment arm; the Comfort Plug™ is a device designed to control urinary incontinence in male subjects by being placed in the urethra to stop urine leakage."
2395261|NCT03605446|Experimental|Animal 20%|Animal based protein biscuit containing 20% of total energy as protein
2395262|NCT03605446|Experimental|Plant 12%|Plant based protein biscuit containing 12% of total energy as protein
2395263|NCT03605446|Experimental|Plant 20%|Plant based protein biscuit containing 20% of total energy as protein
2395264|NCT03605446|Placebo Comparator|Wheat biscuit|
2395265|NCT03605433|Experimental|Oral Anticoagulation+Antiplatelet|Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily.
2395266|NCT03605433|Experimental|Oral Anticoagulation|Rivaroxaban 20 mg once daily
2395267|NCT03605433|Active Comparator|Antiplatet|Aspirin 100 mg once daily
2395268|NCT03605420|Experimental|Experimental group|Receiving one family visit prior to hospital admission
2395269|NCT03605420|No Intervention|Control group|Without receiving one family visit prior to hospital admission
2395270|NCT03605407|Experimental|Experimental group|Patient receiving one visit prior to hospital admission
2395271|NCT03605407|No Intervention|Control group|Patient without receiving one visit prior to hospital admission
3143382|NCT00005970|Experimental|Arm II (AC, paclitaxel, trastuzumab, tamoxifen)|Patients receive doxorubicin hydrochloride, cyclophosphamide, and paclitaxel as in arm I. Patients then receive trastuzumab (Herceptin®) IV over 30-90 minutes beginning on day 1 of week 25 and continuing weekly for 52 courses in the absence of disease progression or unacceptable toxicity. Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy.
3184169|NCT00721591||B|Subjects opting for treatment with low molecular weight heparin
2395274|NCT03605342|Active Comparator|Buprenorphine + CPT-C|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then CPT-C for 12 weeks.
2395275|NCT03605342|Active Comparator|Buprenorphine + IDC|Buprenorphine induction and stabilization for all participants (x1 week). Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, then IDC for 12 weeks
2395276|NCT03605329|Other|Type 1 diabetic patients with OSAS|to explore the severity of NAC in case of OSAS
3184170|NCT00721604||1|patients with mean arterial pressure lower than 65 mmHg
3184171|NCT00721643|Experimental|1|Healthy control, 5g dry power of angel's plant (Angelica keiskei)
2395279|NCT03605290|Active Comparator|Mechanically aligned TKR|patients were operated using the standard mechanically aligned technique
2395280|NCT03605290|Experimental|Kinematically aligned TKR|patients were operated using the newer mechanically aligned technique
3184172|NCT00721643|Experimental|2|Metabolic syndrome, 5g dry powder of angel's plant (Angelica keiskei)
3184173|NCT00721656|Placebo Comparator|Placebo|
3184174|NCT00721656|Experimental|KLS-0611|
3184175|NCT00721682||Case|The CASE group will be composed of children for whom the medical team will have chosen to carry out a sign of alert of ill-treatment during his hospitalization and with no plausible cause of traumatism
2395287|NCT03605251|Experimental|TAS5315 low dose group|TAS5315 low dose and Methotrexate as specified
2395288|NCT03605251|Experimental|TAS5315 high dose group|TAS5315 high dose and Methotrexate as specified
2395289|NCT03605251|Placebo Comparator|Placebo group|Placebo and Methotrexate as specified
2395290|NCT03605238|Experimental|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone to reduce acute inflammation, then infuse anti-CD19/20-CAR retroviral vector-transduced autologous derived T cells only once.
2395291|NCT03605225|Experimental|Cellphone application|Train of Four (TOF) ratio displayed by the Cellphone Application
2395292|NCT03605225|Active Comparator|Draeger TOF Scan|Train of Four (TOF) ratio displayed by the Draeger TOF Scan
2395298|NCT03605199|Experimental|Denosumab active treatment|Denosumab active treatment
2395299|NCT03605186|Experimental|Chamomile oral cryotherapy|"The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs).~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
2395300|NCT03605186|Active Comparator|Oral cryotherapy|"The plain icecubes will be prepared in the clinic with 400 mL of distilled water.~Ice cubes will be prepared in special ice trays placed in the chemotherapy center for this purpose.~Patient will receive a cup of ice cubes which is continuously replenished before being emptied.~Patients will be instructed to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session."
2395301|NCT03605173|Experimental|free vitamin d|free vitamin is directly measured from blood serum using an ELISA kit
2395302|NCT03605173|Experimental|total vitamin d|Total vitamin d is measured routinely from blood serum
2395303|NCT03605160|Active Comparator|traditional group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents. All operations are videotaped during the whole operation. The total polish time is recorded as the time of all polish procedures.
2444353|NCT04759664|Placebo Comparator|Placebo|
2395304|NCT03605160|Experimental|fluid-jet group|Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.
2395305|NCT03605147|Experimental|CaHMB|CaHMB Group (n=60) will receive CaHMB twice a day and a late evening snack every night for 12 weeks. A specialized, ready-to-drink liquid with 34 kcal, 8.5 g carbohydrate, 1.5g calcium-HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
2395306|NCT03605147|Active Comparator|Control|Control Group (n=60) will receive placebo twice a day and placebo every night for 12 weeks with similar composition but without HMB. The late evening snack is a drink with low-Glycemic Index carbohydrate with 112 kcal.
2395307|NCT03605134||study group|level of cardiac troponin and diastolic function assessment by means of transthoracic echocardiography
2395308|NCT03605108|Active Comparator|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs HU36 - 30 mg HU58 - 20 mg Bacillus clausii -25 mg Bacillus coagulans 10B - 35 mg Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
2395309|NCT03605108|Placebo Comparator|Placebo|Rice flour only
2395310|NCT03605095|Active Comparator|8 mg/ml nitroglycerin|Higher concentration of NO donor (Nitromint) vs dilution
2395311|NCT03605095|Active Comparator|1 mg/ml nitroglycerin|Lower concentration of NO donor (Nitropohl) vs physiological saline
2395312|NCT03605082|Experimental|UCB0107|Subjects will be randomized to receive a predefined dosage of UCB0107 in order to maintain the blinding.
2395313|NCT03605082|Placebo Comparator|Placebo|Subjects will be randomized and receive a placebo in order to maintain the blinding.
2395314|NCT03605069|Other|First TWA (A)|"In each subject up to two target wound areas (TWA) are randomized, one each to active treatment or placebo.~In the first arm; randomization of the first selected TWA to active treatment or placebo"
2395315|NCT03605069|Other|Second TWA (B)|In each subject, in the second arm; allocation of the second selected target wound area (TWA) to the alternative treatment. Second arm in the same subject as the first arm.
2395316|NCT03605056|Experimental|CRD regimen|CRD is a new 3-drug regimen adding a HDACi named chidamide to a novel 2-drug combination of lenalidomide and dexamethasone (RD)
2395317|NCT03605043||Overall cohort|All Persons Living with HIV who enlisted in any one of three high-volume HIV clinics in Tororo District of Eastern Uganda between 2014 and 2017.
2395318|NCT03605030|Active Comparator|Novel Lead Based Armboard|
2395319|NCT03605030|Placebo Comparator|Standard Armboard|
3143383|NCT00005970|Experimental|Arm III (AC, paclitaxel, trastuzumab, tamoxifen)|"Patients receive doxorubicin hydrochloride and cyclophosphamide as in arm I. Patients then receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes beginning on day 1 of week 13 and continuing weekly for 12 courses. Patients then receive trastuzumab IV over 30 minutes beginning on day 1 of week 25 and continuing weekly for 40 courses in the absence of disease progression or unacceptable toxicity.~Within 5 weeks after completion of paclitaxel, patients may undergo radiotherapy. All postmenopausal ER- or PR-positive patients receive oral tamoxifen or an aromatase inhibitor once daily for 5 years beginning no later than 5 weeks after the last dose of paclitaxel. Patients may also receive an aromatase inhibitor once daily for 5 years after 5 years of daily tamoxifen. Patients who receive tamoxifen once daily for less than 4.5 years may receive an aromatase inhibitor daily until they have received a total of 5 years of adjuvant hormonal therapy."
3184176|NCT00721682||control|The Control group will be composed of children, consulting with the emergency care for traumatism, not having a sign of alarm and having a plausible cause of traumatism.
2395322|NCT03605004||Negative|Adult patients with undiagnosed conditions who have received an uninformative negative result from exome sequence.
2395323|NCT03605004||VUS|Adult patients with undiagnosed conditions who have received one or more variants ofuncertain significance from exome sequence.
3184177|NCT00721695|Experimental|1|OMS302 Irrigation Solution
3184178|NCT00721695|Active Comparator|2|OMS302-PE HCl Irrigation Solution
2395330|NCT03604965|Experimental|GP+CCRT|GP neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2395331|NCT03604965|Active Comparator|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2395332|NCT03604926||chemo-naive patients|
2395333|NCT03604926||pre-treated patients with systemic chemotherapy +/- a targeted|
2395334|NCT03604913|Active Comparator|A(aortic valve sparing operation)|Undergo aortic valve sparing root replacement operation
2395335|NCT03604913|Active Comparator|B(Bentall operation)|Undergo Bentall operation
2395336|NCT03604887||study group|All pregnant women who will attend the labor unit during the study period will be invited to participate in the study.
2395337|NCT03604874|Active Comparator|low dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 2 mU/min, incrementally increase by 2 mU/min every 30 minutes until achievement of adequate uterine contractions.
2395439|NCT03604055|Other|Endobronchial hamartomas treatment|After removal of endobronchial lesions, cryotherapy is applied to the area of origin. Recurrences are followed. Recurrences are recorded as poor results, compared with good results.
2395338|NCT03604874|Experimental|high dose oxytocin|patients will receive intravenous infusion of 5 Units of oxytocin/500 mL lactated ringer solution. Starting rate will be 4 mU/min, incrementally increase by 4 mU/min every 30 minutes until achievement of adequate uterine contractions
2395339|NCT03604848|Experimental|NGS-guided regimen: Regimen A|Regimen A: 9-month regimen for simple MDR-TB patients 4 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 5months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
2395340|NCT03604848|Experimental|NGS-guided regimen: Regimen B|Regimen B: 12-month simple MDR-TB regimen for simple MDR-TB patients 6 months of pyrazinamide, amikacin ,moxifloxacin, prothionamide, and cycloserine , followed by 6 months of pyrazinamide,moxifloxacin, prothionamide, and cycloserine
2395341|NCT03604848|Experimental|NGS-guided regimen: Regimen C|"Regimen C : for complicated MDR-TB patients In regimen C, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol based on the drug susceptibility test results. The duration of treatment in the complicated MDR-TB group is consistent with control group, with 6 months of intensive phase and 18 months of consolidation phase."
2395342|NCT03604848|Active Comparator|WHO-approved MDR-TB regimen|6 months of pyrazinamide, amikacin,moxifloxacin, prothionamide , and cycloserine , followed by 18 months of pyrazinamide, moxifloxacin, prothionamide , and cycloserine
3184179|NCT00721695|Placebo Comparator|3|Standard topical mydriatics and BSS Irrigation Solution
3184180|NCT00721708|Experimental|1|Carnosine(450 mg)
2395345|NCT03604822|Experimental|Music therapy protocol|Each participant received 12 home-based music therapy treatment sessions over 6-week time period.
2395346|NCT03604809|Experimental|OT Guided Cognitive Interventions|Occupational Therapy interventions will be adjusted according to the patient's Richmond Agitation and Sedation Scale (RASS).
2395347|NCT03604809|No Intervention|Usual Care|This will be the standard of care currently provided for delirium prevention within the Department of Critical Care Medicine in Calgary using the ABCDEF bundled approach.
2395348|NCT03604796|Active Comparator|Continuous IV Acetaminophen|Intravenous Infusion
2395349|NCT03604796|Active Comparator|Rectal Acetaminophen|Rectal Solution
3184181|NCT00721708|Experimental|2|Beef (150g)
2395351|NCT03604770||Women seeking fertility treatment|Women aged 18-45 who are seeking fertility treatment at Bethesda Fertility Center will be provided a survey and food diary to complete.
2395352|NCT03604757|Experimental|PET/CT Imaging|
2395353|NCT03604744|Experimental|LSD-100, LSD-200, Psilocybin-15, Psilocybin-30, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2395354|NCT03604744|Placebo Comparator|LSD-200, Psilocybin-15, Psilocybin-30, Placebo, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2395355|NCT03604744|Placebo Comparator|Psilocybin-15, Psilocybin-30, Placebo, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2395356|NCT03604744|Placebo Comparator|Psilocybin-30, Placebo, LSD-100, LSD-200, Psilocybin-15|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2395357|NCT03604744|Placebo Comparator|Placebo, LSD-100, LSD-200, Psilocybin-15, Psilocybin-30|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2395358|NCT03604731||Uncomplicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures
2395359|NCT03604731||Complicated cardiac surgery patients|Patients after schedulled cardiac surgery procedures complicated by multiorgan failure
3184182|NCT00721708|Experimental|3|chicken (150g)
2395361|NCT03604692|Experimental|Cohorts of escalating dose levels of SNDX-6352|"Escalating dose levels of SNDX-6352 to establish the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D).~IV infusion; SNDX-6352 at a dose of 0.15 mg/kg to 3 mg/kg."
2395362|NCT03604692|Experimental|Phase 2 Dose Expansion|"Phase 2, dose expansion, is an open-label design, evaluating the 1 mg/kg dose in a larger sample size.~IV infusion; SNDX-6352 at a dose of 1 mg/kg."
2395363|NCT03604679|Experimental|SyB C-0501|"SyB C-0501 (Oral Bendamustine) will be administered orally once a day (specified dose). The treatment period of 21 days (Cohort 1; 7 days of administration + 14 days of observation or Cohort 2; 14 days of administration + 7 days of observation or Cohort 3; 21 days of administration) constitutes 1 cycle.~Part 1: dose escalation to determine MTD, RD and dosing schedule Part 2: dose expansion at RD"
2395364|NCT03604666||Health care process with Nurse Navigator|"A Nurse Navigator will:~Be present at the announcement consultation~Give information on the outpatient circuit~Offer assistance for patients over 75 years~Complete onco-geriatric orientation questionnaires~Take care of patients on the ambulatory circuit"
2395365|NCT03604666||Health care process|Health care process
2395366|NCT03604653||Stomach|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes, CDDP Cisplatin 50mg/m2@ time 0
2395367|NCT03604653||Colorectal, Appendiceal, Pseudomyxoma Peritonei|Heated Intraperitoneal Chemotherapy with Mitomycin C 30mg at time 0, 10mg at time 45 minutes
2395368|NCT03604653||Primary Peritoneal|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 50mg/m2 at time 0, Doxorubicin 15mg/m2 at time 0
2395369|NCT03604653||Ovarian, Cervical, Uterine, Fallopian Tube|Heated Intraperitoneal Chemotherapy with CDDP Cisplatin 75mg/m2 at time 0
2395370|NCT03604640|No Intervention|standard care|
2395371|NCT03604640|Experimental|Physical and educational program|
2395372|NCT03604627|Other|Patients treated for cancer during childhood or adolescence|Patients over the age of 18 treated during childhood or adolescence for cancer with irradiation affecting the heart area (≥20% of ≥5Gy heart volume) and / or anthracyclines (≥ 300mg / m²)
2395373|NCT03604614|Experimental|HIPEC and chemotherapy|Hyperthermic Intraperitoneal Chemotherapy and SOX（Tiggio+Oxaliplatin ）
2395374|NCT03604614|Sham Comparator|Without HIPEC|Without Hyperthermic Intraperitoneal Chemotherapy，Only SOX（Tiggio+Oxaliplatin ）
2395411|NCT03604315|Experimental|Treatment (FDG PET/CT, [18F]FTT PET/CT)|Patients receive FDG IV and undergo FDG PET/CT scan over 20-30 minutes if they have not already had one per standard of care. At least 20-24 hours later, patients receive fluorine F 18 fluorthanatrace IV and undergo [18F]FTT PET/CT over 1 hour.
3184183|NCT00721708|Experimental|4|Chicken broth (obtained from 150 g of chicken breast)
2395375|NCT03604588|Other|Patients with oropharyngeal cancer|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
2395376|NCT03604575|Experimental|Insulin Lispro|Single subcutaneous administration of Insulin Lispro in dose 0.3 IU / kg
2395377|NCT03604575|Active Comparator|Humalog®|Single subcutaneous administration of Humalog® in dose 0.3 IU / kg
2395378|NCT03604549|Placebo Comparator|Saline|Women in this arm will receive a flush with saline after normal saline Sono HSG.
2395379|NCT03604549|Experimental|Lipiodol UF|Women in this arm will receive a flush with Lipiodol UF after normal saline Sono HSG.
3184184|NCT00721721|Experimental|1|Participants will follow a low sodium diet for Days 1 through 7, a high sodium diet for Days 7 through 14, and a high sodium diet plus potassium supplement regimen for Days 14 through 21.
3184185|NCT00721747|Experimental|Unique arm|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
2395382|NCT03604510|Experimental|Electroencephalographic recordings|Electroencephalographic recordings
3184186|NCT00721760|Experimental|Semuloparin|"Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind"
3184187|NCT00721760|Active Comparator|Enoxaparin|"Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment [SRI]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind"
3184188|NCT00721773|Experimental|ACE inhibitor, benazepril|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day according to BP control and tolerability.
2395386|NCT03604484|Active Comparator|Tricuspid annuloplasty|Patient treated with tricuspid annuloplasty at the moment of the mitral valve surgery
2395387|NCT03604484|No Intervention|No Tricuspid annuloplasty|Control patients
2395388|NCT03604471|Other|Atorvastatin|All patients using atorvastatin at any dose (usually ranging from 5 to 80 mg once-daily).
2395390|NCT03604419|Experimental|PB-119 100 μg|PB-119 100 μg subcutaneous (SC) once weekly (QW) + Metformin oral (p.o.) Glucophage® (stable dosage)
2395391|NCT03604419|Experimental|PB-119 150 μg|PB-119 150 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2395392|NCT03604419|Experimental|PB-119 200 μg|PB-119 200 μg SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2395393|NCT03604419|Placebo Comparator|PB-119 Placebo|PB-119 Placebo SC QW + Metformin oral (p.o.) Glucophage® (stable dosage)
2395394|NCT03604406|Experimental|Varicella Zoster Vaccine (Zostavax)|Live zoster vaccine injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2395395|NCT03604406|Placebo Comparator|Placebo Injection (Zostavax Comparator)|Saline injection will be administered as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2395396|NCT03604406|Experimental|Varicella Zoster Vaccine (Shingrix)|Non-live zoster vaccine injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2395397|NCT03604406|Placebo Comparator|Placebo Injection (Shingrix Comparator)|Saline injection will be administered twice, 8 weeks apart, as a single 0.65-mL dose subcutaneously in the deltoid region of the upper arm at the baseline visit
2395398|NCT03604393|Experimental|Practice Facilitation, Cluster 1|Intervention Cluster 1 is the first intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2395399|NCT03604393|Experimental|Practice Facilitation, Cluster 2|Intervention Cluster 2 is the second intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2395400|NCT03604393|Experimental|Practice Facilitation, Cluster 3|Intervention Cluster 3 is the third intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2395401|NCT03604393|Experimental|Practice Facilitation, Cluster 4|Intervention Cluster 4 is the fourth intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2395402|NCT03604393|Experimental|Practice Facilitation, Cluster 5|Intervention Cluster 5 is the final intervention arm designed to implement and test the effectiveness of a multi-component primary care practice-based intervention on initiation and completion of the HPV vaccine series as well as reduction in rates of missed opportunities to vaccinate.
2395403|NCT03604380|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2395404|NCT03604380|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2395405|NCT03604367||GAITRite assessment|Subjects will undergo the GAITRite assessment of functional walking and then complete the Functional MRI Bipedal paradigm followed by questionnaires and assessments regarding the virtual environment.
2395406|NCT03604354|Active Comparator|Pregabalin|Pregabalin 150mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
2395407|NCT03604354|Experimental|Tapentadol|tapentadol 100mg oral tablets before one hour before undergoing unilateral total knee arthroplasty
2395410|NCT03604328|Experimental|PA5108|PA5108 ocular implant (study eye) and topical prostaglandin analogue therapy (non-study eye)
3143384|NCT00005972|Experimental|gemcitabine + irinotecan|Patients are stratified according to prior response duration (progression 90 days or more after initial therapy vs progression less than 90 days after initial therapy or no response to initial therapy). Patients receive gemcitabine IV over 30 minutes and irinotecan IV over 90 minutes on days 1 and 8. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year, then every 6 months for 2 years, and then annually for 3 years.
2395416|NCT03604250|Experimental|Lifestyle plus prebiotics|Research participants will be asked to wear health monitoring devices, including a continuous glucose monitoring device and an Apple watch. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
2395417|NCT03604237|Experimental|Targeted forceps biopsy|In this group, an endoscopist takes a forceps biopsy at depressed mucosa or large nodular area of large colorectal tumors after meticulous surface evaluation.
2395418|NCT03604237|No Intervention|Conventional forceps biopsy|In this group, an endoscopist takes a forceps biopsy at the most convenient area of large colorectal tumors.
2395419|NCT03604224||Canagliflozin Containing Treatment Regimens|No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.
3143385|NCT00005973|Experimental|Treatment|Patients receive BMS-214662 IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
2395426|NCT03604159|Experimental|Buprenorphine Extended-Release|XRB is a 300mg pre-mixed subcutaneous injectable formulation to be administered monthly. XRB is for abdominal subcutaneous injection only. Participants in the XRB treatment arm will be given 1 or more XRB injections prior to release from jail and one more at week 5 post-release, depending on their release date.
2395427|NCT03604159|Active Comparator|Sublingual Buprenorphine|SLB (SUBOXONE, Zubsolv, or generic tablets) is a daily sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed 5.7-17.1 mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until dissolved completely. Participants in the SLB treatment arm will be provided SLB daily by observed dosing in-jail (controlled substances are not self-administered in-jail) and and encouraged to continue SLB treatment in weekly, bi-weekly, or monthly quantities for unobserved, daily, self-administration through week 5. Patients may also elect to obtain SLB care free-of-charge from the Bellevue Hospital Center Addiction Medicine clinic or from non-NYU/Bellevue providers and pharmacies per usual care standards. SLB will not be provided via the study.
2395428|NCT03604146||control group|Doctors and nurses were trained to treat chronic obstructive pulmonary disease according to the GOLD guidelines.Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
2395429|NCT03604146||Intervention group|Doctors and nurses will not receive any training from research team. Hospital patient cohort and outpatient cohort will be setted. Subjects were interviewed and received pulmonary function tests.
2395430|NCT03604133||Patients receiving ICD devices|
2395431|NCT03604120|Experimental|Preoxygenation with high flow therapy by nasal cannula|High flow oxygen therapy by nasal cannula.
2395432|NCT03604120|Active Comparator|Preoxygenation by standard Facial mask|"Patients randomized in STANDARD FACIAL MASK group will receive a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction or Fiber-optic intubation under spontaneous ventilation."
2395433|NCT03604094||Group I|0-1 month old newborns
2395434|NCT03604094||Group II|1 month-2 year-old pediatric patients
2395435|NCT03604081|Experimental|Intervention Group|One hour of intense massed practice of lower extremity either in the form of shaping or task practice
2395436|NCT03604081|Placebo Comparator|Control Group|Conventional physical therapy for 1 hour as per current standard of care that follows stroke clinical practice guideline.
2395437|NCT03604068|Active Comparator|Active Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as an active RecoveryRx Pulsed Short Wave Therapy device.
2395438|NCT03604068|Sham Comparator|Control Group|Patients in this group will be treated with the currently used standard protocol for the control of post-operative pain as well as a sham RecoveryRx Pulsed Short Wave Therapy device.
2395440|NCT03604042|Active Comparator|Weight-driven protein fortification|Individualized protein fortification based on weight gain
2395441|NCT03604042|Experimental|BUN-driven protein fortification|Individualized protein fortification based on BUN concentrations
2395442|NCT03604029||Qualifying Subjects|Qualifying subjects who are high risk for ACS.
2395443|NCT03604029||Qualifying Subjects with ACS|Qualifying subjects who are diagnosed with ACS
2395444|NCT03604016|Experimental|Besifovir dipivoxil+L-carnitine|Besifovir dipivoxil 150 mg and L-carnitine 330 mg
2395445|NCT03604016|Active Comparator|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
2395446|NCT03604003|Experimental|bedtime dosing ARB for hypertension|bedtime administration of potassium losartan has benefit for the isolated nocturnal hypertension
2395447|NCT03604003|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
2395448|NCT03603990|Experimental|Vitrectomy|"Patient with standard pars plana vitrectomy~During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given.~After First Six Months : All therapies for DME may be given at the discretion of the investigator"
2395449|NCT03603990|Active Comparator|Usual care|"Patients with usual care according to the investigator choice :~During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy.~After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy."
2395450|NCT03603977||Lpv/r+3TC|These cases were given simplified therapy regimen including lopinavir(200mg) and ritonavir(50mg)500 mg,oral,bid) combined with lamivudine (300 mg,oral,qd).
2395451|NCT03603964|Experimental|Guadecitabine|Subjects will receive guadecitabine treatment at the same dose that they were receiving in the last cycle of their prior study or at a different dose as guided by the dose adjustment guidelines in the prior study protocol. Treatment may continue as long as the subject continues to benefit based on investigator judgment.
3143386|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 20 mg/day|Double blinded Megestrol Acetate 20 mg/day or Megestrol Acetate Placebo 20 mg/day taken for 3 months
2395453|NCT03603938|Experimental|bedtime dosing ARB for hypertension|potassium losartan has benefit for the nondipping BP pattern
2395454|NCT03603938|Experimental|bedtime dosing ARB for the prognosis|bedtime administration of potassium losartan has benefit for the prognosis of CKD patients
3143387|NCT00005975|Active Comparator|Megestrol Acetate/Placebo 40 mg/day|Double blinded Megestrol Acetate 40 mg/day or Megestrol Acetate Placebo 40 mg/day taken for 3 months
2395461|NCT03603899|Experimental|Hp 129Xenon|Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
2395462|NCT03603886|Experimental|Telemedicine Pain Management|
2395463|NCT03603886|Other|Waitlist Control|Treatment as usual comparator
2395464|NCT03603873||Patients|
2395465|NCT03603834|Experimental|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
2395466|NCT03603821||LUTS male|Clinical assesment of males older than 50 years with lower urinary tract symptoms presumably related to benign prostate enlargement
3184189|NCT00721773|Experimental|Angiotensin receptor blocker, valsartan|Valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
2395468|NCT03603795|Experimental|A|"55 patients will be randomized in the experimental arm A. If platelets counts < 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts > 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets < 100 x 10 Giga/L.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1.~200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products."
2395469|NCT03603795|Placebo Comparator|B|"55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count > 100 x 10 Giga/L (maximum day 45)~Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.~Chemotherapy administration would be performed among standard practice:~Daunorubicin: 60 mg/m² D1 to D3~Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7~Lomustine (CCNU): 200 mg/m² per os, at D1."
2395470|NCT03603782|Experimental|1|
2395471|NCT03603782|Experimental|2|
2395472|NCT03603782|Experimental|3|
2395473|NCT03603782|Experimental|4|
2395500|NCT03603639|Experimental|E2730 120 mg, E2730 40 mg, Placebo|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395501|NCT03603626|Experimental|Preemptive pregabalin|
2395502|NCT03603626|Placebo Comparator|Placebo|
2395474|NCT03603769|Experimental|Group A: Food Supplement (Salmon Polar Lipids) Intervention|"Experimental: After fasting overnight, subjects will come to our metabolic unit where in a randomized and double blinded way they will be provided several versions of the food supplement either of stomach resistant (intestine release) or stomach non-resistant (stomach release) each containing either 0.25 (Low Dose) or 0.50 g (High Dose) of Salmon Polar Lipids (SPL)~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the SPL-food supplement intervention. Aggregation of platelets will be assessed in these samples as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
2395475|NCT03603769|Placebo Comparator|Group B: Consumption of Placebo Comparator|"Experimental: After fasting overnight subjects will come to the metabolic unit in UL at 08.00 am where in a randomized and double blinded way they will be provided a placebo capsule containing only glycerin.~Assessment & outcome measured: Blood samples will be taken from each subject at baseline (0 hours) and after 1-4 hours of the placebo administration. Aggregation of their platelets will be assessed as previously described (see references 1-4), in order to evaluate the postprandial effects of this supplement on platelet aggregation.~Other blood coagulation parameters will also be evaluated, such as prothrombin time, fibrinogen, Activated partial thromboplastin time Plasma lipid profile (levels of plasma Total Cholesterol, LDL, HDL and Triglycerides) and serum CRP levels will also be assessed."
2395476|NCT03603756|Experimental|Cohort 1|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.
2395477|NCT03603756|Experimental|Cohort 2|Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.
2395478|NCT03603743|Experimental|high intensity interval training|high intensity interval training: two sets of 8-min intervals at 100% of peak power output (PPO). Each interval set was composed of repeated bouts of 30 s at 100% of PPO interspersed by 30 s of passive recovery in the seated position. Four minutes of passive recovery were allowed between the two sets.
2395479|NCT03603743|Active Comparator|moderate intensity and continuous exercise|moderate intensity and continuous exercise: 30 minutes at 60% of PPO.
2395481|NCT03603717|Experimental|CBT-I|Four individual sessions that will last approximately 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
2395482|NCT03603717|Active Comparator|SH|Four individual sessions that will last 15-30 minutes each across a 6-week time period, with the option to deliver sessions over the telephone as necessary.
2395483|NCT03603704|Experimental|LY3209590|"Insulin naïve participants with Type 2 Diabetes Mellitus received 5 mg and 10 mg LY3209590 administered subcutaneously (SC) in Cohort 1 and 2 respectively.~Participants with T2DM received 20 mg LY3209590 administered subcutaneously in Cohort 3."
2395484|NCT03603704|Active Comparator|Placebo|Participants from Cohort 1 and 2 received Placebo administered SC.
2395485|NCT03603691|Active Comparator|Modified Manual Muscle Test|The MMMT will be tested in a test-retest design
2395486|NCT03603691|Active Comparator|Neurostatus BMRC|The Neurostatus BMRC measures Strength and will be used in a test-retest design
2395487|NCT03603691|Active Comparator|MicroFET2|The MicroFET2 is a hand held dynamometer to measure strength
2395488|NCT03603678|Experimental|Part A single dose BAY2253651|Single dose BAY2253651
2395489|NCT03603678|Placebo Comparator|Part A single dose Placebo|Single dose matching placebo
2395490|NCT03603678|Experimental|Part B multiple dose BAY2253651|Multiple dose BAY2253651 on 5 consecutive nights
2395491|NCT03603665|Experimental|Arm A|Single intravenous (IV) infusion of 0.033 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2395492|NCT03603665|Experimental|Arm B|Single IV infusion of 0.165 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2395493|NCT03603665|Experimental|Arm C|Single IV infusion of 0.330 mg/kg NTM-1633 (N=6) or matching Placebo (N=2) using an infusion pump over 60 minutes
2395495|NCT03603639|Experimental|Placebo, E2730 40 mg, E2730 120 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395496|NCT03603639|Experimental|E2730 40 mg, E2730 120 mg, Placebo|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395497|NCT03603639|Experimental|E2730 120 mg, Placebo, E2730 40 mg|Participants will receive a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395498|NCT03603639|Experimental|Placebo, E2730 120 mg, E2730 40 mg|Participants will receive a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 1 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 2 followed by a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395499|NCT03603639|Experimental|E2730 40 mg, Placebo, E2730 120 mg|Participants will receive a single dose of E2730 40 mg, capsule, orally (Treatment B) in Treatment Period 1 followed by a single dose of E2730-matched placebo, capsule, orally (Treatment A) in Treatment Period 2 followed by a single dose of E2730 120 mg, capsule, orally (Treatment C) in Treatment Period 3. A wash-out phase of at least 3-weeks will be maintained between the treatment periods.
2395503|NCT03603613|Experimental|EPP: Entrepreneurship Programme|EPP: Entrepreneurship Programme: Youth randomized into the EPP-only arm will receive GIZ's employment programming within two weeks after the completion of the baseline assessments. The GIZ-supported EPP program includes six training modules. The modules include skills related to entrepreneurship, financial literacy, and skills building.
2395504|NCT03603613|Experimental|EPP+YRI|EPP+YRI: Youth randomized into the EPP+YRI arm will begin the Entrepreneurship programme within two weeks of baseline assessments. The entrepreneurship modules will occur for 15 days for 5 hours each day, 5 days per week. Immediately following the EPP, youth will begin receiving the YRI. The YRI curriculum (12 modules), will be delivered twice weekly over the course of 6 weeks. Each session lasts approximately 90-minutes, with additional time taken as needed. These sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention quantitative assessment.
2395505|NCT03603613|No Intervention|Control|Control: Youth randomized into the control arm will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline and post-intervention). Due to access to funding and feasibility, youth in the control arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. The list of youth from the control group will be provided to GIZ so they can participate in the future phases. Youth will also be compensated for their participation in our quantitative assessments.
2395506|NCT03603600|Experimental|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
2395507|NCT03603600|Sham Comparator|enVista MX60E|enVista MX60E monofocal IOL
2395508|NCT03603587|Experimental|Patients who will benefit from the removal of a scalp tumour|"Patients who will benefit from the removal of a scalp tumour in the alopecic zone will be recruited in the dermatology department of the St-Etienne University Hospital.~They will have biopsy, blood sample, examination of the scalp, questionnaire on sun exposure, Norwood scale, scinexa score, questionnaire of clinicals signs and questionnaire of the history of the hair loss."
2395509|NCT03603574|Experimental|EWA through the needle|EWA through the needle group, 5 mL of normal saline are injected through the epidural needle after the occurrence of LOR. The needle is subsequently connected to the pressure transducer (leveled with the heart) via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
2395510|NCT03603574|Experimental|EWA through the catheter|EWA through the catheter group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations.
2395511|NCT03603561|Active Comparator|Active cTBS|
2395512|NCT03603561|Sham Comparator|Sham cTBS|
2395513|NCT03603548|Active Comparator|Advagraf|
2395514|NCT03603548|Experimental|Envarsus|
2395515|NCT03603522|Experimental|BioGaia-DSM17938 then Placebo Comparator|28 days treatment with BioGaia-DSM17938, followed by 28 days washout and then crossover to 28 days placebo comparator treatment.
2395516|NCT03603522|Placebo Comparator|Placebo Comparator then BioGaia DSM17938|28 days treatment with placebo comparator treatment, followed by 28 days washout and then crossover to 28 days treatment with BioGaia DSM17938.
2395519|NCT03603496|Experimental|Personalized Tobacco Care Management|PTCM will provide 8 weeks of nicotine replacement therapy at hospital discharge and proactive contacts over 3 months delivered by automated IVR call +/- text messaging +/- email. At each contact the patient is offered a return call from the hospital-based tobacco coach forcounseling, medication advice, and coordination of care with the patient's outpatient health care team.
2395520|NCT03603496|Active Comparator|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the quitline will be included in the patient's medical chart.
2395521|NCT03603483|Active Comparator|Patients with sever aortic stenosis 1|Procedure: the patients will undergo aortic valve replacement with aortic root enlargement.
2395522|NCT03603483|Active Comparator|Patients with sever aortic stenosis 2|Procedure: the patients will undergo conventional aortic valve replacement
2395523|NCT03603470|Other|Patients with previous prothesis instability|
2395524|NCT03603470|Other|Patients without prothesis instability|
2395525|NCT03603444||First study group: patients with PHPT|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2395526|NCT03603444||Second study group: patients with HypoP|"Subjects with reduced serum P, but normal serum Ca, will be enrolled among HIV-infected patients on HAART treatment from the Modena cohort.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2395527|NCT03603444||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their calcium-phosphorus metabolism state with normal results.~Exclusion criteria for both cases and controls will be: age younger than 18 or older than 90 years; severe renal and liver diseases (i.e. glomerular filtration rate (GFR) <30 ml/min); hyperparathyroidism secondary to Vitamin D deficiency; active metabolic bone disease (e.g. Paget's disease of the bone, osteomalacia, rickets, etc); any type of cancer; malnutrition; severe obesity (BMI > 40 kg/m2); a history of gastrointestinal malabsorption; sarcoidosis; hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism; familial hypocalciuric hypercalcemia (FHH); treatment with steroids, active forms of vitamin D (calcitriol, ergocalciferol, etc), thiazides, phosphate binders, lithium, cinacalcet, bisphosphonates, and denosumab."
2395528|NCT03603431|Experimental|Single Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
2395529|NCT03603431|Placebo Comparator|Single Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
2395530|NCT03603431|Experimental|Multiple Ascending Dose - MRG-110|Intradermal injection of MRG-110 at two wound sites and intradermal injection of placebo at two other wound sites
2395531|NCT03603431|Placebo Comparator|Multiple Ascending Dose - Placebo|Intradermal injection of placebo at four wound sites
2395532|NCT03603418|Experimental|Group D (Study group-Dexamethasone group)|Forty patients undergoing induction of labor will receive 8 mg (2ml) of the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product from Epico-Egypt, and labor induction will be performed according to the American College of Obstetricians and Gynecologists protocol, i.e, starting by 25 mcg of PGE1 vaginally, in the form of Vagiprost, every 3-6 hours according to patient response, Dexamethasone will be given one hour before the first dose of Vagiprost, when bishop score reaches 6 to 8, oxytocin will be added by 5 drops/minute of 500 cc saline + 5 units of oxytocin with the dose increasing by 5-10 drops / minute every 30 minute till optimal contractions are reached which are three uterine contractions in 10 minutes and each lasting for 40-50 seconds
2395533|NCT03603418|Placebo Comparator|Group C (Control group)|Forty patients undergoing induction of labor will receive 2ml of distilled water intramuscular one hour before the initiation of labor induction, and labor induction will be performed by the same protocol as above.
2395534|NCT03603405|Experimental|Experimental: ADV/HSV-tk (gene therapy)|"Experimental: ADV/HSV-tk (gene therapy)~The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 30 sessions (over 6 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent with the radiotherapy dependent on patient status based on best clinical judgment following the Stupp protocol.~Patient can receive second treatment of HSV-tk after 6 months."
2395535|NCT03603392|Experimental|Physical activity program|Before and after a 5-months of a supervised exercise program were performed in post bariatric patients, body composition, physical fitness and cardiovascular risk factors were measured.
2395536|NCT03603379|Experimental|C225-ILs-dox i.v.|C225-ILs-dox administered intravenously
2395537|NCT03603366||Primary prevention|"Patients in Italy who are eligible to use low-dose aspirin for primary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD~Patients eligible for and not using low-dose aspirin who are at 20% ten-year CVD risk for primary prevention of CVD"
2395538|NCT03603366||Secondary prevention|"Patients in Italy who are eligible to use low-dose aspirin for secondary prevention of CVD and CRC.~Subgroups:~Patients eligible for and using low-dose aspirin for secondary prevention of CVD~Patients eligible for and not using low-dose aspirin for secondary prevention of CVD"
2395539|NCT03603366||Physicians|Physicians from Italy with experience recommending low-dose aspirin for primary and/or secondary prevention of CVD and CRC.
2395540|NCT03603353|Experimental|Intervention group|
2395541|NCT03603353|Active Comparator|Control group|
2395542|NCT03603340|Experimental|Intervention group|
2395543|NCT03603340|Active Comparator|Control group|
2395544|NCT03603327|Other|Treatment|All subjects will receive a standard of care treatment- Direct acting anti-viral agents Drugs
2395545|NCT03603314|Experimental|29 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
2395546|NCT03603314|Experimental|43.5 mg dose group|Patients will receive the study drug (SENS-401) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
2395547|NCT03603314|Placebo Comparator|placebo oral tablet|Patients will receive the study drug (placebo) in the form of tablets by mouth, twice a day, during the first 4 weeks after randomization.
3184190|NCT00721773|Experimental|RAS inhibitors, benazepril+valsartan|Benazepril will be started at 10 mg/day and will be up-titrated to 20 mg/day, and valsartan will be started at 80 mg/day and will be up-titrated to 160 mg/day according to BP control and tolerability.
2395551|NCT03603262|Experimental|SH-1028|Oral Once-Daily Administration of SH-1028
2395552|NCT03603249|Experimental|Clopidogrel and Trimetazidine Arm|Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.
2395553|NCT03603236||preeclampsia|18-40 aged diagnosed with preeclampsia
2395554|NCT03603236||control|18- 40 aged healthy females over 37. weeks of pregnant with no history of preeclampsia
2395555|NCT03603223|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
2395590|NCT03602950|Active Comparator|study group|50 diabetic ladies will undergo elective CS at full term and autologous PRP will be injected subcutaneously before skin closure.
2395591|NCT03602937|Experimental|Renastep|All participants to incorporate Renastep into their usual dietary regime.
2456909|NCT03194386|No Intervention|Control|usual care
2395556|NCT03603210||Patients treated with DCB angioplasty|"Patient cohort is comprised of all patients who received drug coated balloon angioplasty at NNUH during the above period. Within this cohort there will be two main groups which are drug coated balloon (DCB) angioplasty for de novo coronary artery disease (CAD) and DCB angioplasty for ISR/ST. Graft cases will be reported as a small third group.~Outcomes will also be reported for three sub groups of de novo disease group, namely, dcb-only angioplasty for de novo disease, dcb-only angioplasty as primary percutaneous coronary intervention (PPCI) and dcb-only angioplasty group using a DCB with a diameter of 3mm or more in de novo disease."
2395557|NCT03603197|Experimental|BP-C1|Patients allocated to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
2395558|NCT03603197|Placebo Comparator|Placebo|Patients allocated to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity will be invited to participate in the BMC2011-02 study, where they are offered to continue treatment with BP-C1.
2395559|NCT03603184|Experimental|Experimental arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or 6 will be administered every 21 days for 6-8 cycles or PD. Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
2395560|NCT03603184|Placebo Comparator|Control arm|paclitaxel 175 mg/m2 + carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or PD. Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity). Patients who are clinically stable at initial RECIST v 1.1 - defined progression - should continue on treatment until the next imaging assessment that should be ≥4 weeks and no longer than 8 weeks later.
2395561|NCT03603171||DM2 group|Patients with Myotonic Dystrophy type 2 genetically confirmed, without limitation regarding age or disease onset.
2395562|NCT03603171||Healthy controls group|A group of gender and age-matched healthy controls.
2395563|NCT03603145|Experimental|Immediate insertion|Randomized to insertion within 48 hours of medical abortion
2395564|NCT03603145|No Intervention|Standard Insertion|Insertion at 2-4 weeks post medical abortion
2395565|NCT03603132|Active Comparator|Hetrombopag Olamine A|health subjects received 7.5 mg Hetrombopag Olamine while fasting.
2395566|NCT03603132|Active Comparator|Hetrombopag Olamine B|health subjects received a high-fat meal one hour after taking7.5 mg Hetrombopag Olamine
2395567|NCT03603132|Active Comparator|Hetrombopag Olamine C|health subjects received a high-fat meal two hours after taking7.5 mg Hetrombopag Olamine
2395568|NCT03603119|Active Comparator|Group A|Dexamethasone-ondansetron
2395569|NCT03603119|Experimental|Group B|Midazolam
3184191|NCT00721773|Active Comparator|non-RAS inhibitors, control|Drug: antihypertensive agents, except ACE inhibitors and ARBs. Administration of antihypertensive agents will select as follows: CCB→β-blocker→α-blocker.
3184192|NCT00721786|Experimental|San Francisco Internet Stop Smoking Site|"UCSF/SFGH Internet Stop Smoking Study site~Internet Stop Smoking site (TC4) with several intervention elements from which the participants may choose as many as they wish~The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: www.dejardefumar.ucsf.edu"
2395572|NCT03603080|Experimental|Medication arm|
2395573|NCT03603080|No Intervention|No medication arm|
2395574|NCT03603067||monophthalmic group|The BCVA of the worse eye is less than 0.05 or CFOV is less than 5°. The better eye need to receive ocular surgery.
2395575|NCT03603067||Normal group|The BCVA of the worse eye is more than 0.3 and CFOV is more than 10°. One of two eyes need to receive ocular surgery.
2395576|NCT03603054|Active Comparator|Active neck mobilization|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
2395577|NCT03603054|Experimental|Active Mobilization of the Sciatic nerve|The subjects, who were randomly allocated to group active neurodynamic mobilization group, will receive the active sciatic nerve mobilization intervention. The subject will be instructed to do a a modification of the slump. The procedure will be performed 1 minute with each leg, two times, the subjects will rest one minute between each mobilization and between series.
2395578|NCT03603041|No Intervention|Control|These participants will maintain their daily food and exercise routine and will receive no intervention.
2395579|NCT03603041|Experimental|Whey Protein Supplementation|Participants will receive protein supplementation daily for 16 weeks.
2395580|NCT03603041|Experimental|Omega-3 Fatty Acids (O3FA)|Participants will receive O3FA supplementation daily for 16 weeks.
2395581|NCT03603041|Experimental|Whey Protein and O3FA|Participants will receive protein and O3FA supplementation daily for 16 weeks.
2395582|NCT03603041|Placebo Comparator|Whey Protein and Placebo Fat Source|Participants will receive protein and placebo fat source supplementation daily for 16 weeks.
3184193|NCT00721812|Other|Part A|Single dose escalation
2395584|NCT03603015|Other|Pilot group: urodynamics and cuff test|Single-arm study with all participants undergoing cystometrogram, then cystometrogram with simultaneous penile cuff test, then penile cuff test alone
3184194|NCT00721812|Other|Part B|14 day repeat dose escalation
2395586|NCT03602976|No Intervention|Observation|
2395587|NCT03602976|Experimental|UDCA at Month 6|
2395588|NCT03602963||Dexcom G5 mobile CGM system|Children (6 to 18 years) with type 1 diabetes mellitus treated with insulin injections and wearing a FreeStyle Libre Flash glucose sensor that will switch to the Dexcom G5 mobile glucose monitoring system.
2395589|NCT03602950|No Intervention|Control group|50 diabetic ladies at full term will undergo elective CS and will receive the usual surgical care routinely done at our hospital
2456936|NCT03194360||delirium group|
2395592|NCT03602911|Other|Proof of Concept|The isotope 68Ga, available as NETSPOT and 18F-FDG-PET/CT per established protocol will both be administered
2395593|NCT03602898|Experimental|Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
2395594|NCT03602898|Experimental|Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
2395595|NCT03602898|Experimental|Arm 3 (tacrolimus or cyclosporine, methotrexate)|Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
2395596|NCT03602885|Experimental|Chemotherapy education intervention arm|Patients randomized to the chemotherapy education intervention (CEI) arm will be given regimen specific written and video chemotherapy educational materials developed by the study team. The treating oncologist will identify which chemotherapy regimen(s) are being considered, in order to select the appropriate chemotherapy educational tool(s) to give the patient. The patient may be given more than one CEI tool if they are considering more than one regimen. Patients randomized to the intervention arm may receive the intervention in addition to OR in place of the standard institutionally approved chemotherapy information sheets (both are acceptable); this is at the discretion of the treating site or the treating physician.
2395597|NCT03602885|Active Comparator|Usual chemotherapy education arm|Patients randomized to the usual chemotherapy education (CE) arm will undergo the standard institutional practice of chemotherapy education. The oncologist may also choose to give the patient the institutionally approved chemotherapy information sheets according to site-specific policies and clinical practice.
2395598|NCT03602872|Experimental|Group 1|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2395599|NCT03602872|Experimental|Group 2|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2395600|NCT03602872|Experimental|Group 3|Subjects will receive a single intraarticular 20x10^6 dose of Human allogeneic mesenchymal bone marrow derived stem cells, in the most symptomatic target (knee) joint.
2395601|NCT03602859|Placebo Comparator|Participants receiving SOC+placebo|Participants in this arm will receive SOC (carboplatin+paclitaxel+bevacizumab) in cycle 1 followed by SOC with chemotherapy treatment with dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab along with niraparib placebo and dostarlimab placebo.
2395602|NCT03602859|Active Comparator|Participants receiving SOC+niraparib|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab placebo from cycles 2 to 6 and maintenance treatment of bevacizumab with niraparib and dostarlimab placebo.
2395603|NCT03602859|Experimental|Participants receiving SOC+dostarlimab|Participants in this arm will receive SOC in cycle 1 followed by SOC with chemotherapy treatment dostarlimab, and maintenance treatment of bevacizumab with niraparib and dostarlimab.
2395604|NCT03602846||Good Outcome|Good outcome is defined as the safe delivery of the newborn.
2395605|NCT03602846||Poor Outcome|Poor outcome is defined as the incidence of fetal demise during pregnancy.
2395607|NCT03602807|Experimental|Active treatment|
2395608|NCT03602794|Active Comparator|PECs Block|"Total local anaesthetic dose: 30ml ropivacaine 0.5%~•Pecs block will be performed by anaesthetist using ultrasound guidance in plane approach: 10ml ropivacaine 0.5% will be delivered at the plane between pectoralis major and pectoralis minor, another 20ml ropivacaine 0.5% will be delivered in the plane between the pectoralis minor and serratus anterior muscles at the level of the third and fourth ribs"
2395609|NCT03602794|Placebo Comparator|Local Infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
2395610|NCT03602781|Placebo Comparator|Cohort 1: Placebo 99.999% Nitrogen|"Randomized Withdrawal Treatment Period Week 1-8:~Placebo at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
2395611|NCT03602781|Active Comparator|Cohort 2: iNO 75 mcg/kg IBW/hr|"Randomized Withdrawal Treatment Period Week 1-8:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day~Long Term Open Label Extension Period:~iNO at a dose setting of 75 mcg/kg IBW/hr for up to 24 hr/day"
2395612|NCT03602768|Experimental|Goal Management Training|The online version of GMT with a therapist on the back-end monitoring progress and giving feedback throughout the program. Online GMT takes 5-9 weeks (self-paced) to complete 9 modules involving instructional video with interactive content, practice of cognitive strategies through games, and between-module exercises.
2395613|NCT03602768|Experimental|Memory & Aging Program|The online version of MAP with a therapist moderator on the course discussion pages. MAP takes 5-9 weeks (self-paced) to complete 8 modules involving instructional video with interactive content and practice of memory strategies through various exercises.
2395614|NCT03602768|Placebo Comparator|Cambridge Brain Sciences Training|This is a commercial and research brain training platform, composed of 7 games that are online adaptations of the standard measures of cognition including working memory and spacial planning.
3184195|NCT00721812|Other|Part C|Fixed dose food effect
3184196|NCT00721825|Active Comparator|1|Neuroaid
2395615|NCT03602768|No Intervention|Waitlist|Participants randomized to this arm will receive no additional information or access to intervention programs until after the follow up testing measures are collected, at which point they will be given access to the intervention of their choosing.
2395616|NCT03602755||Patients with newly diagnosed transplant-ineligible MM|Adult Patients with newly diagnosed MM who were not suitable candidates for ASCT who started first-line treatment for the study disease in a routine clinical practice setting between 2012 and 2016, inclusive.
2395617|NCT03602742|Other|24-hour Holter and 14-day EZYPRO®|This is an open-label study to investigate the functional features of prolonged monitoring by 14-day EZYPRO® to improve the medical care and/or diagnosis for the patient with arrhythmia. One arm included.
2395618|NCT03602729|No Intervention|Group 1|No study related education given
2395619|NCT03602729|Experimental|Group 2|Written BF education
2395620|NCT03602729|Experimental|Group 3|Verbal BF education
2395621|NCT03602729|Experimental|Group 4|Video BF education
2395622|NCT03602716|Experimental|HD-tDCS group|This HD-tDCS group will be stimulated by active HD-tDCS.
2395623|NCT03602716|Sham Comparator|Sham HD-tDCS group|This sham HD-tDCS group will have a sham stimulation with HD-tDCS.
2395624|NCT03602703||chronic HCV|chronic HCV either treated or not with DAAs.Flow cytometry and Western Blot analysis for each subgroup
2395625|NCT03602703||Liver cirrhosis without HCC|Liver cirrhosis without HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
2395626|NCT03602703||Liver cirrhosis with HCC|Liver cirrhosis with HCC either received treatment or not.Flow cytometry and Western Blot analysis for each subgroup
2395627|NCT03602703||Control group|Healthy subjects
2395628|NCT03602690|Experimental|Dolutegravir + Darunavir/ritonavir + optimized NRTI|"All patients will receive ART regimen every day including:~Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)"
2395629|NCT03602677|Experimental|ICG fluorescence imaging|Colorectal surgery and anastomosis will be performed according to standard practice with the addition of intraoperative indocyanine green fluorescence imaging.
2395630|NCT03602677|No Intervention|Standard procedure|Standard colorectal surgery and anastomosis.
2395631|NCT03602664||Thoracic surgery|Patients undergoing thoracic surgery
2395632|NCT03602651||MAGZEN®|All patient will be treated with MAGZEN® and will be evaluated with the Hamilton-anxiety scale (HAM-A)
2395633|NCT03602638|Experimental|Sitagliptin|
2395634|NCT03602638|Active Comparator|CONTROL|Acarbose
2395635|NCT03602625||Preterm group|All the live-born infants with gestational age less than 37weeks and more than 20weeks born in the cooperative hospital every day or every two or three days.
2395636|NCT03602625||Term group|The one next-live-born infants with gestational age at 37weeks or more than 37weeks.
3143388|NCT00005976|Experimental|Arm I|"Patients receive carboplatin IV over 30 minutes and pyrazoloacridine IV over 3 hours on day 1. Treatment continues every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 3-6 patients receive escalating doses of carboplatin and pyrazoloacridine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3184197|NCT00721825|Placebo Comparator|2|Neuroaid matched placebo
3184198|NCT00721838||1|Surgery group
2395643|NCT03602586|Experimental|Treatment (epacadostat, pembrolizumab)|Patients receive epacadostat PO BID and pembrolizumab IV over 30 minutes Q3W. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2395644|NCT03602573||pre-menopause|
2395645|NCT03602573||post-menopause|
2395646|NCT03602560|Experimental|Seladelpar 5-10 mg|
2395647|NCT03602560|Experimental|Seladelpar 10 mg|
2395648|NCT03602560|Placebo Comparator|Placebo|
2395649|NCT03602547|Experimental|CM082 plus JS001|Patients who meet the enrollment criteria will receive CM082 tablets 200mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks, q2w), every 28 days A treatment cycle until the disease progresses, the toxicity is intolerable, the investigator or subject decides to withdraw, loses to follow up, starts using other anti-tumor treatments or dies.
2395650|NCT03602534||cases with variable acne severity scores|"group will include 50 females~Clinical examination including acne grade assessment using Global Acne Grading Scale (GAGS)~Assessment of body mass index (BMI)~blood serum samples will be collected from all patients to do thyroid function test"
2395651|NCT03602534||healthy controls|"group will include 29 females~Assessment of body mass index (BMI)~blood serum samples will be collected from all healthy controls to do thyroid function test"
2395654|NCT03602508||mirabegron|Patients on mirabegron as prescribed by a physician in routine clinical practice.
2395655|NCT03602508||antimuscarinics|Patients on one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine as prescribed by a physician in routine clinical practice.
2395689|NCT03602287|Placebo Comparator|Normal saline|In the Normal saline group, 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril.
2395660|NCT03602469|Experimental|Bupivacaine|Ultrasound-guided suprascapular nerve block using bupivacaine will be performed before induction of general anesthesia
2395661|NCT03602469|Active Comparator|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block using bupivacaine in conjunction of magnesium sulfate will be performed before induction of general anesthesia
2395662|NCT03602456||Kentucky HEALTH|This group will consist of 90% of eligible beneficiaries who will receive Kentucky HEALTH benefits throughout the 5-year demonstration waiver.
2395663|NCT03602456||Traditional Medicaid (control)|This group will consist of 10% of eligible beneficiaries who will continue receiving traditional Medicaid benefits as in place before July 1, 2018 throughout the 5-year demonstration waiver.
2395664|NCT03602443|Experimental|Experimental|This group will receive the LSVT(R)BIG Intervention first (4 weeks) and then cross over to the Waitlist Control (no intervention for 4 weeks).
2395665|NCT03602443|Other|Waitlist Control|This group will receive the Waitlist Control (4 weeks) and then cross over to receive the LSVT(R)BIG Intervention (4 weeks).
2395666|NCT03602430|Experimental|Drug Group|twenty-five patients will receive 200.000 IU/month native vitamin D; (Cholecalciferol) orally in addition to their standard treatment for 3 months period
2395667|NCT03602430|Placebo Comparator|Placebo Group|twenty-five patients will receive a placebo ampule with their standard treatment for 3 months period.
2395668|NCT03602417|Experimental|Flare type stent|Flare type stent (Taewoong medical) has a wide diameter at proximal end to prevent stent migration.
2395669|NCT03602417|Active Comparator|Conventional D-type stent|Conventional D-type (Taewoong medical) stent has a same diameter at both ends.
2395670|NCT03602404||St. Petersburg: School aged children|Generally healthy 9 to 12 years old children
2395671|NCT03602404||St. Petersburg: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
2395672|NCT03602404||Marrakesh: School aged children|Generally healthy 9 to 12 years old children
2395673|NCT03602404||Marrakesh: Women of reproductive age|Generally healthy non-pregnant, non-lactating women between 18 and 44 years of age
3143389|NCT00005976|Experimental|Arm II|Patients receive the same treatment as given in study 1. Dose escalation is performed as in study 1 to determine the MTD in patients not receiving concurrent anticonvulsants.
3143390|NCT00005976|Experimental|Arm III|Patients receive the same treatment as given in studies 1 and 2 without dose escalation.
2395676|NCT03602378||Parents of children with disability|parents of children with developmental disabilities (Down syndrome, autism spectrum disorder, pervasive developmental disorder, cerebral palsy), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2395677|NCT03602378||Parents of children with chronic disease|parents of children chronic disease (diabetes mellitus type 1, epilepsy, asthma), age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2395678|NCT03602378||Parents of healthy children|parents of healthy children, age 20-50, salivary cortisol, Holter Medilog AR12 Plus, Polar V800, AGE reader
2395679|NCT03602365|Experimental|OXYGEN CONSUMPTION SINGLE ARM|Single arm Study Volunteer will h lie in supine posture for 20 min and oxygen consumption(VO2) will be measured in duplicate. Gentle Jogger (GJ) will be started in supine posture for 20 min and VO2 measured again in duplicate. The subject will be asked to sit in a chair for 20 min and VO2 will be measured in duplicate. Gentle Jogger (GJ) will be started in seated posture for 20 min and VO2 measured again in duplicate.
2395682|NCT03602326|Experimental|Neurodevelopmental Therapy-Bobath group|Bobath Approach Principles and exercises will be performed 5 days a week with physical therapists and everyday with caregivers. Physiotherapy will be initiated as early as possible according to the principles of the method by experienced NDT-B therapists. Exercises will be implemented according to the patients' status and will be used to maintain and improve muscle strength and endurance. Both the unaffected and affected side will be included in rehabilitation. The exercises given are designed to be simple, understandable, task-oriented and repetitive, in accordance with the Bobath approach and the functional state of the patient at that time. In order to prevent motor amnesia and neglect of the affected side, correct positioning and sensory input will be provided since the first session.
2395683|NCT03602326|Active Comparator|Standart Rehabilitation Group (SR group)|Patients will be included in standard rehabilitation sessions, 5 days per week. The rehabilitation sessions will be performed by standard clinical physiotherapists according to the hospital routine. The rehabilitation program will consist of in-bed joint range of motion exercises and bedside mobilization applications. The patients will be included in the rehabilitation program as early as possible and the program will continue until the patients are discharged
2395684|NCT03602313|Active Comparator|Traditional Gait Training|The Traditional Gait Training group will receive gait training as presently performed without additional modalities.
2395685|NCT03602313|Experimental|Body Weight Support Training|The Body Weight Support group will received body weight support gait training in lieu of traditional gait training.
2395686|NCT03602300|Active Comparator|Ravidasvir reference formulation|Ravidasvir 200 mg oral single dose manufactured by EEPI
2395687|NCT03602300|Experimental|Ravidasvir test formulation|Ravidasvir 200 mg oral single dose manufactured by Doppel
2395688|NCT03602287|Active Comparator|2% lignocaine|In the Lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack. Nothing will be done to the opposite nostril, which would act as a control.
3143391|NCT00005977|Experimental|STAGE III NHL (Trt 1)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABA"
3143392|NCT00005977|Experimental|STAGE IV NHL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
2395690|NCT03602274||orthopedic and visceral surgery patients|patient having been subjected to an intervention from the orthopedic or visceral surgery department being prescribed 4 g paracetamol / day
2395691|NCT03602274||Overdosed patients|Patent admitted to hospital with paracetamol overdoses
2395692|NCT03602261|Active Comparator|CTAP101 Capsules 300mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 300mcg/weekly for 26 weeks
2395693|NCT03602261|Active Comparator|CTAP101 Capsules 600mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 600mcg/weekly for 26 weeks
2395694|NCT03602261|Active Comparator|CTAP101 Capsules 900mcg/weekly|CTAP101 Oral Capsules/Calcifediol, calcidiol, 25-hydroxyvitamin D3, 900mcg/weekly for 26 weeks
2395695|NCT03602261|Placebo Comparator|Placebo Capsules weekly|Placebo Oral Capsules/weekly for 26 weeks
2395696|NCT03602248|Experimental|Speed endurance training protocol A|"Performance of two different speed endurance training protocols:~Speed endurance training protocol A will consist of 1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)."
2395697|NCT03602248|Experimental|Speed endurance training protocol B|Speed endurance training protocol B will consist of 1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
2395698|NCT03602248|No Intervention|Control condition|No training protocol will be performed, the participants will perform only the measurements for performance and muscle damage and neuromuscular fatigue
2395700|NCT03602222|Active Comparator|In-person training LGBT mental health|In-person training LGBT mental health: Participants randomized to the in-person condition will receive training in LGBT-affirmative mental health counseling face-to-face.
2395701|NCT03602222|Experimental|Mobile training LGBT mental health|Mobile training LGBT mental health: Participants randomized to the mobile training condition will receive training in LGBT-affirmative mental health counseling while on the web.
2395702|NCT03602209|Experimental|4 weeks of treatment|
2395703|NCT03602209|Active Comparator|6 weeks of treatment|
2395704|NCT03602196|Experimental|pregnant women|"pregnant women with one visit per trimester of pregnancy (14-18 weeks, 24-28 weeks and 34-38 weeks)~For the ancillary study: non-pregnant nulliparous women"
2395705|NCT03602183|Experimental|Normal airway scenario|intubation in normal airway scenario
2395706|NCT03602183|Experimental|Tongue edema scenario|intubation in the tongue edema scenario. Tongue edema was obtain using simulator indicators
2395707|NCT03602183|Experimental|Spinal immobilization with normal airway scenario|intubation in spinal immobilization with normal airway scenario
2395708|NCT03602183|Experimental|Spinal immobilization with tongue edema scenario|endotracheal intubation with immobilized cervical spine and tongue edema scenario
2395709|NCT03602170|Experimental|High-Intensity Interval Training|8 weeks of high-intensity interval training. Three sessions per week will be performed (24 total sessions).
2395710|NCT03602170|Active Comparator|Moderate-Intensity Continuous Training|8 weeks of moderate-intensity continuous training. Three sessions per week will be performed (24 total sessions).
2395712|NCT03602144|Active Comparator|Carbohydrate|Participants will receive a carbohydrate-based smoothie every morning for 6 weeks (42 days).
2395713|NCT03602144|Experimental|Protein|Participants will receive a protein-based smoothie every morning for 6 weeks (42 days).
2395714|NCT03602131|Experimental|ChiCGB|Treated with chidamide, cladribine, gemcitabine and busulfan(ChiCGB) therapy followed by autologous hematopoietic stem cell transplantation.
2395715|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 20 mg|Once participants are deemed to be eligible for participation in the study and randomized to the lower dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes.
2395716|NCT03602118|Active Comparator|Phenobarbital Sodium Injection 40 mg|Once participants are deemed to be eligible for participation in the study and randomized to the higher dose they will be given a loading dose of phenobarbital 20 mg/kg administered intravenously over the course of 30 minutes. ministered intravenously over the course of 30 minutes.
2395717|NCT03602105|Active Comparator|Intervention group|Exercise interventions for 6-12 weeks. Adherence is monitored with day journals
2395718|NCT03602105|No Intervention|Control group|Care as usual
2395719|NCT03602079|Experimental|Phase I: Dose Escalation|Six dose levels have been selected for evaluation in the Phase I part of the study: 0.3, 0.6, 1.2, 2.4, 3.6, and 4.8 mg/kg of A166
2395720|NCT03602079|Experimental|Phase II: • Cohort 1|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
2395721|NCT03602079|Experimental|Phase II: • Cohort 2|HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) gastric cancer. Treatment with A166 at recommended Phase II dose.
2395952|NCT03600363|Experimental|metformin arm|
2395953|NCT03600363|Placebo Comparator|control arm|
2395722|NCT03602079|Experimental|Phase II: • Cohort 3|HER2 low expressing (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) breast cancer. Treatment with A166 at recommended Phase II dose.
2395723|NCT03602079|Experimental|Phase II: • Cohort 4|All cancers other than breast cancer with low HER2 expression (Immunohistochemistry (IHC) 1+ and IHC 2+ without fluorescence in situ hybridization (FISH) confirmation) and HER2 positive (IHC2+ with FISH confirmation and Immunohistochemistry (IHC) 3+) cancers other than breast and gastric cancer. Treatment with A166 at recommended Phase II dose.
2395724|NCT03602066|Experimental|Arm I (chlorine dioxide sterilization)|Patients receive chlorine dioxide sterilization oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
2395725|NCT03602066|Placebo Comparator|Arm II (placebo)|Patients receive placebo oral rinse over 30 seconds BID from the start of RT to the evening prior to the 1 month RT follow-up appointment.
3184199|NCT00721838||2|Control - Lifestyle modification program
3184200|NCT00721864||Affected Population|Subjects suspected of having Paroxysmal Nocturnal Hemoglobinuria (PNH)
3184201|NCT00721877|Experimental|Arm I|Participants receive oral resveratrol once daily for 4 weeks.
2395729|NCT03602040|Experimental|PISICC group|Psychoeducational intervention
2395730|NCT03602027|Experimental|Anlotinib Plus Gefitinib|"This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day and Gefitinib. middle-dose groups: Anlotinib 10mg per day and Gefitinib. high-dose groups: Anlotinib 12mg per day and Gefitinib.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any dose group, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any dose group, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2395731|NCT03602014|Experimental|Study 1: Dose Optimization of Northera|Subjects will be administered oral droxidopa in a dose escalation, open-label manner beginning with 200 mg. The dose will be adjusted upwards by 100 mg on subsequent visits until average Systolic Blood Pressure (SBP) recorded 60-120 minutes after dose administration is 111-139 mmHg in males and 101-139 mmHg in females, sustained elevation (≥ 30 consecutive minutes) in seated SBP ≥ 140/100 mmHg, maximum dose of 800 mg is reached without adequate SBP response. Subjects will visit the testing laboratory on as few as 1 (200 mg) and as many as 7 (800 mg) days. Seated cardiovascular assessments will be monitored and recorded at 15-minute intervals for 4-hours, and the side effects questionnaire will be administered hourly during the 4-hour study. Each study visit will take about 5 hours.
2395732|NCT03602014|Placebo Comparator|Study 2: Blinded Placebo & Northera|Participants will then be administered either oral optimal dose of Northera (Droxidopa) or matching placebo in a double-blinded manner and will remain in the supine position for 60 minutes. Subjects will remain in their wheelchair for instrumentation, which will include: 1) ECG, 2) brachial BP, 3) finger arteriolar BP and 4) Cerebral Blood Flow velocity (CBFv).
2395733|NCT03602001|Experimental|attentive eating smartphone app group|Participant's received the intervention 'Attentive eating smartphone application'. This is a smartphone application that encourages a more attentive eating style. Participants also received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
2395734|NCT03602001|Active Comparator|control group|Participants received the 'Standard dietary advice and text tips' intervention. This consists of a standard dietary advice booklet, and weekly dietary advice tips by text message.
2395735|NCT03601988|Active Comparator|Chemotherapy|Adjuvant chemotherapy group receive 8 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1,capecitabine 1000mg po, Bid, D1-14, Q21D)
2395736|NCT03601988|Experimental|Chemo-radiotherapy|Adjuvant chemo-radiotherapy group receive 6 cycles of XELOX (Oxaliplatin 130mg/m2, ivdrip, D1, capecitabine 1000mg po, Bid, D1-14, Q21D) and concurrent chemo-radiotherapy (capecitabine 825mg po, Bid, d1-5, QW)
2395737|NCT03601975|Experimental|anlotinib plus Gemcitabine/Cisplatin|patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
2395738|NCT03601975|Placebo Comparator|placebo plus Gemcitabine/Cisplatin|patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
2395739|NCT03601962|Experimental|Aqualief® tablets|oral mucoadesive tablets
2395740|NCT03601962|Placebo Comparator|Placebo tablets|oral mucoadesive tablets
3184202|NCT00721890|Experimental|1|
3184203|NCT00721903|Active Comparator|Healthy Subjects|Ultrasound scan
2395743|NCT03601936|Other|Infants less than 6 months of age|The Evivo Infant Gut Bifidobacterium Screening Test study is a single-group interventional study of 600 female and male infants who are less than 6 months of age and generally healthy.
2395744|NCT03601923|Experimental|Niraparib|"Niraparib will be administered orally once daily~Palliative radiation therapy to a small field >1 week prior to Day 1 of study treatment"
2395745|NCT03601910|Experimental|A group|"Period 1: D308 10mg Tab. 1T~Period 2: CKD-380 10mg Tab. 1T"
2395746|NCT03601910|Experimental|B group|"Period 1: CKD-380 10mg Tab. 1T~Period 2: D308 10mg Tab. 1T"
2395747|NCT03601897|Experimental|Part 1 - Completed|Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) in combination with paclitaxel administered by IV infusion at 80 mg/m2 in repeated 28-day cycles.
2395748|NCT03601897|Experimental|Part 2|"Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with paclitaxel~Triple-negative and Stage IV inflammatory breast cancer~Ovarian cancer~Endometrial cancer~Gynecological Carcinosarcoma"
2456941|NCT03194360||nondelirium group|
3184204|NCT00721903|Active Comparator|Cancer|120 women diagnosed by biopsy to have breast cancer will have an ultrasound scan
3184205|NCT00721916|Experimental|1|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
3184206|NCT00721916|Active Comparator|2|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)
3184207|NCT00721929|Experimental|adrenal mass group|
3184208|NCT00721981||1|Regular treatment for non-small cell lung cancer (NSCLC)
3184209|NCT00721994||1|IDE subjects who received the Cormet Hip Resurfacing device
3184210|NCT00722033|Other|A|< 30 weeks of gestation
2395749|NCT03601884|Experimental|OHP and Treatment as usual (TAU)|"Optimal Health Program (OHP) A self-management program that promotes patients to be actively involved in their own healthcare and overall well-being through enhancing self-efficacy.~Treatment is delivered by a trained facilitator in OHP. The OHP is delivered in groups of 8 to 10 participants It consists of 5 weekly, 1.5 hour sessions and an additional booster session post-program at 3 months a The group facilitator will contact the participants by phone at 8 weeks and 16 weeks.~Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
2395750|NCT03601884|Other|TAU Alone|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
2395751|NCT03601871|Active Comparator|Control group|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
2395752|NCT03601871|Experimental|Thalidomide group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4.
2395753|NCT03601845|Other|MRE-IA (no stimuli)|Additional sequencing only
2395754|NCT03601845|Active Comparator|MRE-IA with stimuli|Visual stimulation while using additional sequencing
2395755|NCT03601832|Experimental|4-D navigated stereotactic radiosurgical ablation|The patients enroled to this arm of the study will undergo 4-D navigated stereotactic radiosurgical ablation.
2395756|NCT03601819|Experimental|Pacritinib|200 mg twice daily (with possible dose reduction to 100 mg twice daily)
2395757|NCT03601806|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2395758|NCT03601793|Experimental|Internet intervention with assistance|This arm is given access to the internet intervention Alcohol Help Center with email assistance from a health educator during the first two weeks after randomization.
2395759|NCT03601793|Active Comparator|Internet intervention without assistance|This arm is given access to the internet intervention Alcohol Help Center without any assistance from a health educator.
2395760|NCT03601780|Active Comparator|Local wound infiltration|local wound infiltration plus usual care
2395761|NCT03601780|Placebo Comparator|Control|usual care only
2395762|NCT03601754|Experimental|Closed Loop Stimulation (CLS)|Prior to enrollment, the patient would have received Biotronik pacemaker with His bundle lead placement for at least 30 days and CLS will be programmed ON for at least 7 days as part of routine care.
2395763|NCT03601741|Active Comparator|Antimicrobial Stethoscope Diaphragm Covers|
2395764|NCT03601741|Active Comparator|Uncovered Stethoscopes|
2395765|NCT03601728|Experimental|Enhanced Monitoring Program|Four weeks prior to the scheduled (elective) surgery, participants will receive a 60-minute in person education session how to increase the level of physical activity. This will be followed by 4 weeks of keeping this level of physical activity, which will be monitored and supported by personalized interactive prompts delivered by a smartwatch. This approach is called personalized prehabilitation.
2395766|NCT03601728|No Intervention|Regular Monitoring Program|Participants randomized to this arm will receive standard perioperative care.
3184211|NCT00722046|Experimental|PF-04360365 0.1 mg/kg|
3184212|NCT00722046|Experimental|PF-04360365 0.5 mg/kg|
3184213|NCT00722046|Experimental|PF-04360365 1 mg/kg|
2395770|NCT03601702||EmboTrap ® II Device|The study group consists of the patients with acute ischemic stroke from large vessel occlusion treated with EmboTrap ® II Device (Neuravi)
2395771|NCT03601676|Active Comparator|Intervention|
2395772|NCT03601676|No Intervention|Control|
2395773|NCT03601663|Experimental|Group 1|Participants in the main experimental group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, a wearable activity tracker to support self-monitoring, and autonomy-support delivered through weekly emails to help enhance motivation for physical activity.
2395774|NCT03601663|Active Comparator|Group 2|Participants in this comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity, and a wearable activity tracker to support self-monitoring. They will not receive any specific support to enhance motivation for physical activity.
2395775|NCT03601663|Active Comparator|Group 3|Participants in this information-only comparison group will receive a copy of the Canadian Physical Activity Guidelines that provide basic information about and recommendations for physical activity.
2395776|NCT03601650|Experimental|Mindful eating|Participants will be encouraged to focus on the sensory properties of their food every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to focus on the sensory properties of their food every time they eat.
2395777|NCT03601650|Active Comparator|Eating without distractions|Participants will be encouraged to eat their food without distractions every time they eat. This will be achieved via an audio recording that they will listen to in the laboratory at their first appointment and that they will have access to over the three-day intervention period. They will also receive a pack of envelopes to open over the intervention period that will also contain reminders to eat their food without distractions every time they eat.
2395778|NCT03601650|No Intervention|No strategy control|Participants will simply complete the measures
3184214|NCT00722046|Placebo Comparator|Placebo|
3184215|NCT00722046|Experimental|PF-04360365 3 mg/kg|
3184216|NCT00722046|Experimental|PF-04360365 8.5 mg/kg|
3184217|NCT00722059|Experimental|1|Subjects will undergo a 3D breast Tomosynthesis imaging scan. This is a one time breast imaging scan will last approximately 15 minutes.
3184218|NCT00722085||Observational|
2395782|NCT03601624|Experimental|Experimental|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
2395783|NCT03601611|Experimental|Experimental|Tocilizumab 8 mg/kg is to be given as an IV infusion over 60 minutes every 4 weeks (Q4W).
2395784|NCT03601598|Experimental|SHR-1210 + SHR6390|SHR-1210 was administered 200mg iv every 2 weeks in combination with SHR6390 150mg or 100mg oral daily with 3 weeks on and 1 week off
2395785|NCT03601585|Experimental|Rolly Brush|Chew for 1 minute
2395786|NCT03601585|Experimental|Chewing gum|Chew for 1 minute
2395787|NCT03601585|Experimental|Apple|Chew for 1 minute
2395788|NCT03601585|Active Comparator|Brush|brush for 1 minute
2395789|NCT03601559|Active Comparator|Lactobacillus paracasei Lpc-37|Probiotic
2395790|NCT03601559|Placebo Comparator|Placebo|Inert placebo
2395791|NCT03601546||Patients with HCV infection|
2395792|NCT03601533|Other|Phenol|Patients will undergo neurolysis of genicular nerves with 1,5 mL of 7% phenol in each of the genicular nerves (superior, medial and lateral).
2395793|NCT03601507|Experimental|Treatment (Alpelisib)|Participants receive Alpelisib PO QD for 14-21 days in the absence of disease progression of unacceptable toxicity and then undergo surgery. Participants may receive Alpelisib for up to 28 days if surgery is delayed.
2395794|NCT03601494|Active Comparator|Intervention|peri-neural platelet rich plasma injection under ultrasound guidance in addition to medical treatment.
2395795|NCT03601494|Placebo Comparator|Control|medical treatment only
2395798|NCT03601429|Experimental|Lactogyn|1 capsule of Lactogyn 2 times daily for the first 7 days then 1 time daily for 4 months
2395799|NCT03601429|Placebo Comparator|Placebo|1 capsule of Placebo Comparator 2 times daily for the first 7 days then 1 time daily for 4 months
2395800|NCT03601416|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to participants with moderate and severe bronchopulmonary dysplasia.
2395801|NCT03601416|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to participants with moderate and severe bronchopulmonary dysplasia.
2395802|NCT03601403|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
2395803|NCT03601403|Experimental|Inhaler technique|The intervention group received the standard medical and pharmacological care provided by the hospital. In addition, a tablet-assisted training on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program.
2395804|NCT03601390||PET/CT and EBV DNA|Patients receiving chemoradiotherapy will receive a dedicated FDG PET/CT protocol 12 weeks after the end of IMRT (primary endpoint).Plasma EBV DNA test will be performed 4, 12, 24 weeks after the end of IMRT. In patients with negative PET/CT results, 2 follow-up visits are required to complement nasopharyngoscope examination and plasma EBV DNA test in the frist year. All patients will undergo annual PET/CT or traditional follow-up examination and plasma EBV DNA test 1 year after completing chemoradiation unless recurrent/residual disease is histopathologically-confirmed.
2395805|NCT03601377|Experimental|Training away from threat|"Experiment 1 and 2: In the intervention group -training away from threat-, in all angry-neutral faces presentation the probe is presented only after neutral face. Probe type (< or >) is not factorially counterbalanced but there is equal possibility of presentation for each of the following: angry-face location, probe location, or actor.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
2395806|NCT03601377|Experimental|Training towards threat|"Only for Experiment 2: The second ABMT condition -training towards threat- is identical to the first one with the exception that in all angry-neutral face presentations the symbol is presented only after threat face. In addition, at the beginning of every session participants will be informed that a random number of participants will have to repeat their speech. They will also be informed that this instruction will be given right after the dot probe task completion. This will be done in order for the participants to maintain their state anxiety but repetition of the speech task will not actually happen at this stage.~Experiment 2: received 4 times (2 times for 2 weeks)"
2395807|NCT03601377|Placebo Comparator|Placebo|"Experiment 1 and 2: In the placebo group, angry-face location, probe location and actor are fully counterbalanced with regards to their presentation.~Experiment 1: received 8 times (2 times per week for 4 weeks) Experiment 2: received 4 times (2 times for 2 weeks)"
2395808|NCT03601364||Group 1|1.Mechanical ventilator closed group (Mechanical ventilator off)
2395809|NCT03601364||Group 2|"Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
2395810|NCT03601364||Group 3|"1. PEEP: 5 cm H2O basınç,~Tidal Voltage 3-4ml / kg (TV),~FIO2 50%, Flow: 2L / min,~Frequency; 10-12 applied group."
2395811|NCT03601351||TT|Tumor Tissue. Colon or rectum neoplasia stage II and III tumor tissue.
2395812|NCT03601351||NTT|Nontumorous Tissue. Colon or rectum neoplasia stage II and III adjacent nontumorous tissue.
2395813|NCT03601338|Active Comparator|Bemiparin group|"Women with high resistant index of umbilical artery received the intervention Bemiparin Sodium 2,500 IU anti Xa/0.2 ml solution for injection in pre-filled syringe provided for each woman . The injections were received daily since 20 weeks gestation and up to 24 hours before delivery~Other Name: Hibor; Laboratories Rovi pharmaceuticals"
2395814|NCT03601338|Placebo Comparator|control group|Normal umbilical arty resistant index group received only multivitamins and routine antenatal follow up
2395815|NCT03601312|Active Comparator|Treatment-As-Usual|Individuals receiving treatment as usual will be receiving exposure and response prevention (ERP), the standard of care for pediatric OCD.
2485245|NCT03001245|Experimental|IPC|Interpersonal Counseling
2395816|NCT03601312|Experimental|OC-Go|Individuals in the OC-Go group will be receiving exposure and response prevention (ERP) augmented by the OC-Go application.
2395817|NCT03601299|Experimental|Traditional food arm|Traditional food-focused menu
2395818|NCT03601299|No Intervention|Non-intervention arm|Standard RurAL CAP menu
2395819|NCT03601286|Experimental|Lentiviral vector transduced CD34+ cells|Single arm, non-randomised cohort of up to 5 patients with X-linked Severe Combined Immunodeficiency. CD34+ cells will be collected via bone marrow harvest or leukapheresis. The collected cells will then be purified, cultured and transduced with the G2SCID lentiviral vector. Transduced cells will be frozen. A minimum of 2.5 x 106/kg CD34+ cells after transduction with a minimum transduction efficiency of 0.7 copies/cell is required for infusion into the patient. The patient will receive non-myeloablative conditioning with intravenous busulfan the two or three days prior to cell infusion. The frozen cells will be thawed on the day of infusion and the cells administered according to hospital procedures. The patient will remain in hospital until sufficient cover of the patient's immune system
2395820|NCT03601260|Other|Gout Patients|Allopurinol 100 mg-300mg/day as secondary treatment in gout patients
2395821|NCT03601247|Other|All patients|Split-face study: patients undergoing bilateral eye surgery will have the sides of their face randomized to receive either placebo or silicone gel.
2395822|NCT03601234|Experimental|laparoscopic surgery|This is a kind of traditional surgical method.only use laparoscopy to resect the GIST.
2395823|NCT03601234|Experimental|laparoscopic and endoscopic combined surgery|LECS resects the GIST completely by laparoscopy with the help of the precise positioning and guidance of endoscopy.
2395824|NCT03601208|Experimental|Blood sample|Venepuncture vs fingerprick test using Mitra volumetric absorptive microsampling (VAMs)
2395825|NCT03601195||Subjects|Chinese women carrying multiple pregnancies
2395826|NCT03601169|Experimental|Low Dose MMFS-205-SR|Low dose, oral MMFS-205-SR twice daily (1,000 or 1,500 mg/day total, depending on lean body mass: ~22mg/kg LBM/day) for 6 weeks
2395827|NCT03601169|Experimental|High Dose MMFS-205-SR|High dose, oral MMFS-205-SR twice daily (1,500 or 2,000 mg/day total, depending on lean body mass: ~33mg/kg LBM/day) for 6 weeks
2395828|NCT03601169|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 6 weeks
2395829|NCT03601156|Experimental|NATACE-RT|Patients receive Oxaliplatin 130mg/m2 intraarterial chemoembolization on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
2395830|NCT03601156|Active Comparator|NACT-RT|Patients receive Oxaliplatin 130mg/m2 intravenous chemotherapy on day1, and then radiation ( 44 Gy/20 fractions/4 weeks, from day 7 to day 11, day14 to day 18, day 21 to day 25, day 28 to day 32) plus oral S-1 (BSA < 1.25 mm2 receive 80 mg/day; 1.25 mm2 < BSA < 1.5mm2 recive 100 mg/day, BSA>1.5mm2 receive120 mg/day, twice daily, from day 1 to day 28, every 4 weeks)
2395831|NCT03601130|Other|No Bone Graft|Open Wedge High Tibial Osteotomy with medial plate fixation (without bone grafting)
2395832|NCT03601130|Active Comparator|HydroxyColl Bone Graft Substitute|Open Wedge High Tibial Osteotomy with medial plate fixation (with bone grafting) using Hydroxycoll bone graft substitute.
2395835|NCT03601104|Active Comparator|HIET (n = 15)|High intensity eccentric training: A high intensity (80% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
2395836|NCT03601104|Experimental|HIET-BFR (n= 15)|High intensity eccentric training with blood flow restriction (BFR): A high intensity eccentric (80% isometric peak) training of the knee extensors in isokinetic will be performed, associated with a pressure cuff placed in the proximal thigh (40% of absolute occlusion pressure) for 6 weeks, 3 times a week.
2395837|NCT03601104|Experimental|LIET-BFR (n = 15)|Low intensity eccentric training with blood flow restriction (BFR): A low intensity eccentric (40% isometric peak) training of the knee extensors in isokinetic will be performed associated with a pressure cuff placed in the proximal thigh (40% absolute occlusion pressure) for 6 weeks, 3 times a week.
2395838|NCT03601104|Active Comparator|LIET (n= 15)|Low intensity eccentric training: A low intensity (40% isometric peak) eccentric training of the knee extensors in the isokinetic will be performed during 6 weeks, 3 times a week.
2395839|NCT03601091|Active Comparator|PR|PRECEDEX 200 mcg 2 ml,0,3 mcg/kg/h, intravenous continue infusion, 4 hours.
2395840|NCT03601091|Active Comparator|DO|DORMICUM 5MG/5 ML, 0,1 mg/kh/h, intravenous continue infusion for 4 hours
2395841|NCT03601078|Experimental|bb2121 in relapsed and refractory multiple myeloma patients|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
2395842|NCT03601065||Routine colonoscopy Cohort|
2395845|NCT03601039|Experimental|Absnow Absorbable ASD Closure System|All subjects are implanted with Absnow Absorbable ASD Occluder
3143393|NCT00005977|Experimental|STAGE IV, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
3143394|NCT00005977|Experimental|B-ALL, -CNS (Trt 2)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy.~Treatment ABABAB"
3143395|NCT00005977|Experimental|B-ALL, +CNS (Trt 3)|"A: Cyclophosphamide (CTX), Doxorubicin hydrochloride, Vincristine sulfate (VCR), Dexamethasone IT Therapy. B: HD-Methotrexate(MTX), Cytarabine(Ara-C), Dexamethasone IT Therapy. C: Etoposide, Ifosfamide, Dexamethasone IT Therapy.~Treatment ABCABAB"
3143396|NCT00005982|Experimental|Treatment (nelarabine)|Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3143397|NCT00005983|Active Comparator|surgery|surgery followed by observation
3143398|NCT00005983|Experimental|surgery followed by RT|Surgery followed by radiation therapy
3143399|NCT00005984|Experimental|Patients with CML|Patients treated for chronic accelerated phase and/or chronic myelogenous leukemia (CML)
2395846|NCT03601026|Experimental|Genetic counselling|Eligible participants who are randomized will be contacted and offered an invitation to attend the intervention. Genetic counselling will be provided to participants who accept the intervention as a single 1-2 hour session by a board-certified genetic counsellor. During the genetic counselling session, participants will have the option to receive their genotype at rs2494732. Participants will be counselled regarding their individualized risk of developing and of NOT developing SMI based on family history, whether or not they choose to use cannabis, and genotype (if they accept the genetic test results). Approximately 1 month after the intervention, participants will receive a follow-up interview.
2395847|NCT03601026|No Intervention|Control group|Eligible participants who are not randomized to be offered the intervention will continue with their annual assessments as part of the parent study. These participants will receive the current standard of care (no intervention), and will not be offered or informed of the intervention.
2395848|NCT03601000|Experimental|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules given three times every day for 16 weeks.
2395849|NCT03601000|Placebo Comparator|Placebo|Placebo given three times every day for 16 weeks.
2395850|NCT03600987|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
2395851|NCT03600974||Endoscopy-E(+)|Subjects with positive endoscopy finding:erosive esophagitis or Barrett esophagus.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
2395852|NCT03600974||Endoscopy-E(-)|Subjects with negative endoscopy finding:NERD.
2395853|NCT03600974||Acid-A(+)|Subjects with DeMeester scores>14.72.For subjects of this group, PPIs, Stretta,Laparoscopic Nissen fundoplication is considered.
2395854|NCT03600974||Acid-A(-)|Subjects with DeMeester scores<14.72
2395855|NCT03600974||impedance-I（+）W/S|Subjects with total reflux number > 80 in 24h pH-impedance monitoring. W means weakly acid reflux account for above 50% in total reflux number. G means gas reflux account for above 50% in total reflux number.For subjects of this group,probiotic agent is considered.
2395856|NCT03600974||impedance-I（-）|Subjects with total reflux number < 80 in 24h pH-impedance monitoring.
2395857|NCT03600974||Reflux-symptom association-S(+)|Subjects with positive reflux-symptom association.For subjects of this group, PPIs, Stretta, neuromodulators are considered.
2395858|NCT03600974||Reflux-symptom association-S(-)|Subjects with negative reflux-symptom association
2395859|NCT03600974||motility-M(+)|Subjects with motility disorders according to Chicago v3.0.For subjects of this group, prokinetic motility agents are considered.
2395860|NCT03600974||motility-M(-)|Subjects without motility disorders according to Chicago v3.0
2395861|NCT03600974||lower oesophageal sphincter-L(+)|Subjects with abnormal LES pressure or EGJ type III or hiatus hernia.For subjects of this group, Stretta,Laparoscopic Nissen fundoplication is considered.
2395862|NCT03600974||lower oesophageal sphincter-L(-)|Subjects with normal LES pressure and EGJ type I~II
2395863|NCT03600974||psychology-P(+)|Subjects with normal psychology condition.For subjects of this group,neuromodulators are considered.
2395864|NCT03600974||psychology-P(-)|Subjects with abnormal psychology condition
2395865|NCT03600935|Experimental|Vancouver Clinical Pathway|The Vancouver Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
2395866|NCT03600922|Experimental|Intervention group|
2395867|NCT03600909|Experimental|Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias (Arm A) will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.6-0.8 mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2395868|NCT03600909|Experimental|Intermediate risk patients|Patients 18 years old or younger with MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8-1.0mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2395869|NCT03600909|Experimental|High risk patients|Patients 19 years old or older with marrow aplasia or MDS or AML will be will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.4mg/Kg/dose q 12 hours x 4 doses), cyclophosphamide (10 mg/Kg/dose x 4 doses) and fludarabine (35mg/m2/day x 4 doses).
2395870|NCT03600896|Experimental|Phase 1: Recombinant Human Interleukin-7 (CYT107)|"In Part 1 of the study, 3 dose levels of CYT107 will be tested in this study. Up to 3 participants will be enrolled in each dose level. The first group of participants will receive the lowest dose level. The next group will receive a higher dose than the first group, if no intolerable side effects were seen. The third group will receive an even higher dose than the second, if no intolerable side effects were seen. Based on the results seen, 1 of the 3 doses will be selected as the recommended dose.~In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1."
2395871|NCT03600896|Experimental|Phase 2: Recombinant Human Interleukin-7 (CYT107)|In Part 2 of the study, an additional 25 participants will be enrolled to receive CYT107 at the recommended dose found in Part 1.
3143400|NCT00005988|Experimental|in vitro-treated bone marrow transplantation|"Donor bone marrow will be harvested on Day -2~Bone Marrow incubated with irradiated recipient cells and anti-B7.1 and anti-B7.2 for 36 hours.~Bone marrow will be infused intravenously~Cyclophosphamide will be administered IV once daily~Total Body Irradiation (TBI) will be delivered per institutional practice~Methylprednisolone will be administered IV as 4 doses separated by 12 hours,"
3143401|NCT00006001|Experimental|Arm I|Patient receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
3143402|NCT00006002|Experimental|Arm B|dexamethasone followed by SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment if tumor grows.
3143403|NCT00006002|Experimental|Arm A|SU5416 done twice weekly (Monday and Thursday or Tuesday and Friday) every week for 4 weeks (a total of 8 doses). Four weeks of treatment (8 doses) is considered 1 cycle of treatment
2395949|NCT03600389|No Intervention|Control Arm (Not Implementing Patient Priorities Care)|Routine Care
2395878|NCT03600870|Experimental|Open Label|All subjects enrolled will be assigned to receive midodrine. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
2395879|NCT03600857|Experimental|Home administration|Home administration of 0.8 mg misoprostol pv
2395880|NCT03600857|No Intervention|Hospital administration|Hospital administration of 0.8 mg misoprostol pv
2395881|NCT03600844|Experimental|Phase 1 Intervention|Phase 1 intervention communities will be offered Community distribution of SP for IPTp in addition to routine ANC IPTp distribution throughout the project.
2395882|NCT03600844|Active Comparator|Phase 1 Comparison/Phase 2 Intervention|During Phase 1 (intervention months 1 through 12), these communities will be offered only usual treatment--SP for IPTp at in facilities during routine ANC. During Phase 2 (intervention month 13 through the end of the project), these communities will be offered Community distribution of SP for IPTp, in addition to routine ANC IPTp distribution.
2395883|NCT03600831|Experimental|concurrent chemoradiotherapy group|All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
2395884|NCT03600831|Active Comparator|radiotherapy group|All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).
2395885|NCT03600818|Experimental|Group 1|Sarilumab once every 2 weeks plus prednisone taper regimen of 14 weeks
2395886|NCT03600818|Placebo Comparator|Group 2|Placebo matching sarilumab once every 2 weeks plus prednisone taper regimen of 52 weeks
2395887|NCT03600805|Experimental|Group A|Sarilumab dose 1, once every 2 weeks plus 26-week prednisone taper regimen
2395888|NCT03600805|Experimental|Group B|Sarilumab dose 2, once every 2 weeks plus 26-week prednisone taper regimen
2395889|NCT03600805|Placebo Comparator|Group C|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 26 weeks
2395890|NCT03600805|Placebo Comparator|Group D|Sarilumab matching placebo once every 2 weeks plus prednisone regimen 52 weeks
2395891|NCT03600779|Experimental|experimental group 1.5T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
2395892|NCT03600779|Active Comparator|control group 1.5 T|healthy volunteers matched in sex and age inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed.
2395893|NCT03600779|Experimental|experimental group 3T|Population of patients with myelin syndrome (MS) at the the disease onset with active lesions inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
2395894|NCT03600779|Active Comparator|control group 3T|inhomogeneous Magnetisation Transfer (ihMT) sequence will be performed. inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T will be performed.
2395895|NCT03600766|Active Comparator|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks
2395896|NCT03600766|Active Comparator|Placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
2395897|NCT03600753|Experimental|symptomatic patients|symptomatic patients with viral respiratory infection harboring positive qPCR for respiratory virus (influenza A or B, RSV, rhinovirus, metapneumovirus) A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
2395898|NCT03600753|Active Comparator|asymptomatic patients|"symptomatic patients with viral respiratory infection with positive qPCR for respiratory virus.~A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed"
2395899|NCT03600753|Other|healthy subjects|Control group of healthy patients. A pharyngeal and a nasal swabs will be performed for each patient. Culturomic and metagenomic analyses will be performed
2395901|NCT03600727|Experimental|Propofol group|Patients in this arm will be sedated by propofol.
2395902|NCT03600727|Experimental|Dexmedetomidine group|Patients in this arm will be sedated by dexmedetomidine.
3143404|NCT00006003|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 60 minutes twice weekly for 4 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.
3143405|NCT00006006|Experimental|Arm I|Patients receive oral thalidomide once daily. Patients on a stable dose of thalidomide for at least 4 weeks with evidence of progressive disease receive interferon alfa subcutaneously twice daily. Treatment continues in the absence of disease progression after initiation of interferon alfa therapy or unacceptable toxicity.
2395905|NCT03600675||South Asian Indians|No intervention will be applied for any group
2395906|NCT03600675||Caucasians|No intervention will be applied for any group
2395907|NCT03600662|Experimental|TriRec|Trileaflet Reconstruction of the Aortic Valve
2395908|NCT03600662|Experimental|Aortic valve replacement|Biological prosthesis, Device: St. Jude Medical Trifecta GT
2395909|NCT03600649|Experimental|Myxoid Liposarcoma|Twice-daily administration of oral seclidemstat
2395910|NCT03600649|Experimental|Sarcomas with FET-family translocations, including demoplastic small round cell tumors|Twice-daily administration of oral seclidemstat
2395911|NCT03600649|Experimental|Ewing sarcoma, combination therapy|Twice daily administration of seclidemstat in combination with cyclophosphamide and topotecan
2395912|NCT03600636|Other|Control|
2395913|NCT03600636|Other|antiphospholipid syndrome patients|
2395914|NCT03600623|Experimental|Folfirinox + SBRT|Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
3143406|NCT00006007|Experimental|gemcitabine + pemetrexed|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8. pemetrexed disodium IV is administered over 10 minutes 90 minutes following gemcitabine on day 8. Treatment continues every 21 days for a minimum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients achieving a complete response receive 2 additional courses.~Patients are followed every 3 months for 5 years."
2395915|NCT03600623|Experimental|Gemcitabine-nab Paclitaxel + SBRT|Gemcitabine-nab Paclitaxel comprises the following: Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 every 4 weeks; nab Paclitaxel 125 mg/m2 on Days 1, 8, and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
2395916|NCT03600610|Experimental|patient group|malnourished patients with anorexia nervosa gadolinium-enhanced cardiac MRI will be performed
2395917|NCT03600610|Active Comparator|control group|age- and sex- matched, normal weight, healthy volunteers gadolinium-enhanced cardiac MRI will be performed
2395918|NCT03600584|Experimental|One-layer duct-to-mucosa Group|Modified one-layer duct-to-mucosa pancreaticojejunostomy is used after pancreaticoduodenectomy.
2395919|NCT03600584|Active Comparator|Invagination Group|Invagination pancreaticojejunostomy is used after pancreaticoduodenectomy.
2395920|NCT03600571|Experimental|AM groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
2395921|NCT03600571|Experimental|MMP groups in cadavers study|32 osteoarthritic knees of cadavers were randomly assigned to the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension). Hyaluronic acid (HA) traced by methylene blue was injected into the knee, and the intra-articular distribution of HA was assessed using a five-point scale.
2395922|NCT03600571|Experimental|AM groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the AM group (injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
2395923|NCT03600571|Experimental|MMP groups in random controlled trial|50 patients with unilateral mKOA were enrolled and randomly into the MMP group (injection medial under horizontal patella midline was administrated with the lower limb extension).The clinical outcomes of 5-weekly injections of HA were evaluated by WOMAC and Lequesne index. The follow-up times were at weeks 1, 2, 3, 4, 5, 14, and 24 after the injections.
2395924|NCT03600545|Experimental|Active|4 weeks daily practice of the brain exercises
2395925|NCT03600545|No Intervention|control|no brain exercises
2395926|NCT03600532|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
2395927|NCT03600532|No Intervention|Treatment as Usual (TAU)|Usual care at Laureate Psychiatric Clinic and Hospital Adult Stabilization Unit who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization. Patients will engage in usual care or a rest period before completing the post-assessment.
2395928|NCT03600532|No Intervention|Community Control Group (CCG)|Patients will engage in a rest period before completing the post-assessment.
2395929|NCT03600519||AMD Patients|OCT scan
2395930|NCT03600506|Active Comparator|Dexmedetomidine|Intervention drug of the study
2395931|NCT03600506|Placebo Comparator|Placebo|Normal Saline (Placebo)
2395932|NCT03600493|Active Comparator|Dexemetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
2395933|NCT03600493|Active Comparator|Lidocaine|Lidocaine prepared in a syringe with the same volume of Dexmedetomidine to assure blinding given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
3143407|NCT00006010|Experimental|docetaxel + gemcitabine|"Patients receive docetaxel IV over 15-60 minutes and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks. Patients achieving complete response after 2 courses of therapy receive 2 additional courses of therapy. Patients with stable disease or partial response continue therapy until disease progression.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3189016|NCT00773318|Experimental|A|"Patients with histologically proven AJCC stages I - II - III prostate cancer including men with clinical T3N0M0 disease, men with PSA > 10 mg/ml, and men with Gleason score of 8-10. Prostate cancer patients scheduled for prostatectomy and pelvic lymph node dissection (CLND).~Arm A = SPECT/CT guided LM/SL versus CLND"
2395936|NCT03600467|Experimental|Adrogen Postive Solid Tumours|
2395937|NCT03600454|Experimental|Hip surgery: spinal anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive spinal anesthesia in combination with monitored anesthesia care (MAC).
2395938|NCT03600454|Experimental|Hip surgery: general anesthesia|Patients scheduled to undergo elective total hip arthroplasty will receive general anesthesia
2395939|NCT03600454|Experimental|Colectomy: general anesthesia and epidural analgesia|Patients scheduled to undergo elective laparoscopic hemicolectomy will receive general anesthesia combined with epidural analgesia (EA).
2395940|NCT03600454|Experimental|Colectomy: general anesthesia|Patients will receive general anesthesia.
2395941|NCT03600441|Experimental|Abexinostat|"Abexinostat tablets will be administered orally at 80 mg (4 × 20 mg tablets) BID (twice a day) 4 hours apart for 7 days in a one week on, one week off schedule (on Days 1 to 7 and Days 15 to 21 of each 28-day cycle)."
3189017|NCT00773331|Experimental|1|
3189018|NCT00773331|Active Comparator|2|
2395944|NCT03600415|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2395945|NCT03600415|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2395946|NCT03600402|Experimental|Experimental Group|
2395947|NCT03600402|Other|Control Group|
2395948|NCT03600389|Experimental|Intervention Arm (Implementing Patient Priorities Care)|Aligning healthcare recommendations to achieve patients' specific health outcome goals within the context of what patients are willing and able to do.
3189019|NCT00773344|Experimental|A1|
3189020|NCT00773357|Experimental|Guanfacine|guanfacine 3mg/day
2395954|NCT03600350|Experimental|Treatment Group|"Nivolumab 240 mg IV every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~pTVG-HP (100 µg) administered intradermally (i.d.) every two weeks x 6 beginning day 1, then every four weeks x 9 beginning week 12~rhGM-CSF (208 µg) administered intradermally (i.d.) every two weeks x 4 beginning week 4, then every four weeks x 9 beginning week 12 NOTE: Only administered to patients for whom serum PSA obtained week 4 > serum PSA obtained at day 1."
2395955|NCT03600337|Experimental|Experimental Condition|Working to Optimize Wellness in Teens with PCOS
2395956|NCT03600337|No Intervention|Control Condition|Participants in this arm will receive treatment as usual and will be given the intervention after 1 month assessments are completed for the intervention group
2395957|NCT03600324|Experimental|Low Intensity/Low Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
2395958|NCT03600324|Experimental|Low Intensity/ High Frequency|Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
2395959|NCT03600324|Experimental|High Intensity/Low Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
2395960|NCT03600324|Experimental|High Intensity/High Frequency|Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
2395961|NCT03600311|Placebo Comparator|Energy Balance|Participants will be in energy balance and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
2395962|NCT03600311|Active Comparator|Caloric Restriction and CHO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of maltodextrin following exercise.
2395963|NCT03600311|Experimental|Caloric Restriction and PRO Supp|Participants will be calorie restricted to 15 kcal/kg FFM/day and consume 1.2 g/kg BW protein. They will be provided 30 g of whey protein following exercise.
2395964|NCT03600298|Other|Pediatric intensive care unit-nurses|"Phase I: During the month leading up to the simulation two trained observers / raters will observe the rate of Closed-Loop Communication in the pediatric intensive care unit (PICU) among study participants.~Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.~Phase II + III: During the follow up phase, trained raters will again observe the study-participating PICU staff relative to their communication behaviour in the month following simulation training (Phase II) and again three months later (Phase III)."
2395965|NCT03600285|Experimental|TB1-K|TB1-K preservation arm
2395966|NCT03600272|Experimental|Combined spinal-epidural analgesia|The combined spinal epidural analgesia technique was used to maintain analgesia for parturients in the combined spinal-epidural analgesia group. First, the investigator injected a dose of 5 ug sufentanil into cerebrospinal fluid. If no adverse effects were observed 10 minutes after the first dose, the parturient then received mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate through a patient-controlled epidural analgesia (PCA) pump, which provided patients themixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
2395967|NCT03600272|Other|Epidural analgesia|The epidural analgesia technique was used to maintain analgesia for parturients in the epidural analgesia group, which involved placing a thin catheter through a needle inserted into the epidural space. First, the investigator injected a test dose of 5ml 1% lidocaine through it. If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h to optimize their pain relief until the delivery of neonates.
2395968|NCT03600259||Acute Myocardial Infarction|
2395969|NCT03600233|Experimental|CVM-1118|CVM-1118 200mg or 300mg Bis In Die (BID) daily/ Cycle (28 days per cycle)
2395970|NCT03600220|No Intervention|drug use|routine drug use, each patient was using 1-3 antihypertensive drug of a heterogeneous pharmacological group ranging from ACE inhibitors, diuretics, and beta blockers
2395971|NCT03600220|Experimental|drug combine acupuncture|routine drug use combine acupuncture twice a week for 3 months
2395972|NCT03600207|Active Comparator|Control group -complex training|complex training
2395973|NCT03600207|Active Comparator|Experimental group -diaphragm training|diaphragm training
3184219|NCT00722098|Experimental|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
3189021|NCT00773357|Placebo Comparator|Placebo|placebo control
3189022|NCT00773357|Experimental|Carvedilol|Carvedilol 50 mg/day
2395978|NCT03600181||orotracheal intubation|Patients admitted in ICU and planned to be intubated. Non-invasive sensor capable of measuring ORI (RAD - 97 pulse co-oximeter; Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.
2395979|NCT03600155|Experimental|Arm A (nivolumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
2395980|NCT03600155|Experimental|Arm B (ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
2395981|NCT03600155|Experimental|Arm C (nivolumab and ipilimumab)|Beginning at least 6 weeks post-stem cell transplant, patients receive nivolumab IV over 60 minutes on days 1, 14, and 28, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
2485249|NCT03001245|Active Comparator|ST|Standard treatment
3184220|NCT00722098|Placebo Comparator|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
3184221|NCT00722150|Active Comparator|Arm 1|"Oral Artesunate (standard dose)"
2395984|NCT03600129|Experimental|QLB with 0,375% ropivacaine|
2395985|NCT03600129|Placebo Comparator|QLB with 0,9% NaCl|
2395986|NCT03600116|Other|Study Visit|Subjects will arrive to the study visit having fasted the night before. Subjects will be given an insulin injection based on their meal to carbohydrate ratio for their breakfast meal as well as a correction bolus to correct their current plasma glucose value down to 40 mg/dL. Following the insulin injection, subjects will eat breakfast. Blood, breath, and sweat samples will be collected throughout the study visit with increased frequency of collection during hypoglycemia. After subjects reach the hypoglycemia threshold, they will be allowed to eat and drink and their blood sugar will be monitored for stability prior to discharge.
2395987|NCT03600103|No Intervention|Control|Participants will receive standard of care.
2395988|NCT03600103|Experimental|Intervention|TECH2CHECK involves field visits by a CHN trained in disease intervention protocols, including clinical assessment, case management, counseling, and a behavioral intervention coupled with text messaging support for medication and self-care reminders.
2395989|NCT03600090|Experimental|Arm EOC202 + Paclitaxol|"Biological: EOC202 This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Two EOC202 dose levels (6 mg and 30 mg) will be evaluated in two cohorts of 18 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 48 weeks (12 s.c. injections in total), separated by 13-day intervals free of EOC202 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
2395990|NCT03600064|Other|Misoprostol group|
2395991|NCT03600064|No Intervention|NO intervention|
2395992|NCT03600038|Experimental|Experimental|This is the experimental arm of the study. This includes receiving the novel/experimental smoking cessation smartphone app. Therapy description of experimental app withheld to protect the integrity of the study.
2395993|NCT03600038|Active Comparator|Control|This is the control arm of the study. This includes receiving the standard of care smoking cessation smartphone app. Therapy description of standard of care app withheld to protect the integrity of the study.
2395994|NCT03600025|Other|non-randomized|Responses will be compared before and after vaccination
2395995|NCT03600012|Experimental|intervention group|"intervention group: Cycling Functional Electrical Stimulation & Physiotherapy~Children in intervention group were taken in a therapy program withRT 300 SLSA FES system for cycling functional electrical stimulation training additionly to physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 sessions in a week and 45 min per session."
2395996|NCT03600012|Active Comparator|control group|"control group: Physiotherapy~Children with cp in control group were taken physiotherapy program including weight shifting, knee and hip strenging and gait training for 8 weeks, 3 times in a week, 45 min per session."
2395997|NCT03599973|Other|Patient|One-arm study, where all patients are given the same standard fluidotherapy and anesthetic conditions to compare measures of Aortic VTI before and after the IV fluid.
2395998|NCT03599960|Experimental|Chemotherapy|
3184222|NCT00722150|Active Comparator|Arm 2|"Oral Artesunate (ARC1 dose)"
3184223|NCT00722150|Experimental|Arm 3|"Oral Artesunate (experimental high dose)"
2396001|NCT03599921||Family-based Treatment|Participants will receive family-based treatment.
2396002|NCT03599921||Enhanced Cognitive behavioral therapy|Participants will receive enhance cognitive behavioral therapy.
2396003|NCT03599921||Family-based Treatment for ARFID|Participants will receive family-based treatment modified for Avoidant/Restrictive Food Intake Disorder (ARFID).
2396004|NCT03599921||FBT + UP for ARFID|Participants will receive family-based treatment with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents, named FBT + UP for ARFID.
2396005|NCT03599895|Experimental|3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery with the assistance of 3D printing model
2396006|NCT03599895|Experimental|non 3D printing group|the radical gastrectomy for gastric cancer of Davinci robotic surgery without the assistance of 3D printing model
2396007|NCT03599856|No Intervention|"Before control group"|Control group with observation of current local standard of care with paper checklist available at the bedside during the ICU rounds of the ICU physicians (as usual)
2396008|NCT03599856|Experimental|"After Intervention group"|An mini Ipad providing TraceBook' intelligent dynamic clinical checklists during the ICU rounds of the ICU physicians.
2396009|NCT03599843|Experimental|ACCESS|Individuals that consent to the study will be assigned to a 12-week exercise program (ACCESS)
2396010|NCT03599830|Other|Cognitive test passations|3 neuropsychological passations over a period of 6 months.
2396011|NCT03599817|Experimental|Healthy lifestyle promotion program|All the participants of the intervention program will be offered group sessions focused on healthy eating, promotion of physical activity and behavioral changes. In this way, the loss of body weight and the increase of physical activity will be promoted. Translating into an improvement in obesity parameters and cardiovascular and metabolic risk factors, to reduce the risk of developing type 2 diabetes.
2396203|NCT03598491||Barium|Barium was applied in video-fluoroscopic-swallowing study
2485351|NCT03000777|Experimental|Melatonin plus Zinc|Melatonin plus Zinc
3184224|NCT00722163|Experimental|1|behavioural
3184225|NCT00722163|Active Comparator|2|befriending
3184226|NCT00722163|No Intervention|3|TAU
3184227|NCT00722176|Experimental|1|BL-1020 10 mg
3184228|NCT00722176|Experimental|2|BL-1020 10-30 mg
2396012|NCT03599791|Experimental|Azelastine Hydrochl. + Fluticasone Prop.|Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2396013|NCT03599791|Active Comparator|Azelastine hydrochloride|Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2396014|NCT03599791|Active Comparator|Fluticasone propionate|Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
2396015|NCT03599778|Experimental|treatment group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w) + apatinib'MTD(maximum tolerated dose)
2396016|NCT03599778|Active Comparator|Control group|8 cycles of postoperative XELOX regimen (capecitabine: 1000 mg/m2 bid d1-14 q3w, oxaliplatin: 130 mg/m2 d1 q3w)
2396017|NCT03599765|Experimental|Arm I (LCT, routine therapy)|Patients receive up-front standard of care LCT including but not limited to surgical resection, cryotherapy, and radiofrequency ablation. Patients then receive routine drug therapy.
2396018|NCT03599765|Experimental|Arm II (routine therapy)|Patients receive routine drug therapy. Patients may later receive LCT at the discretion of doctor.
2396019|NCT03599752|Experimental|Group 1A (chemotherapy, metastasectomy)|Low risk patients receive standard of care chemotherapy for 3 months prior to and 3 months after undergoing metastasectomy in the absence of disease progression or unacceptable toxicity.
2396020|NCT03599752|Experimental|Group 1B (metastasectomy)|Low risk patients undergo metastasectomy.
2396021|NCT03599752|Experimental|Group 2A (metastasectomy)|High risk patients undergo metastasectomy.
2396022|NCT03599752|Experimental|Group 2B (chemotherapy)|High risk patients continue standard of care chemotherapy for 6 months in the absence of disease progression or unacceptable toxicity. Patients with stable disease or radiographic response after 6 months may then cross over to Group 2A.
2396023|NCT03599739||Follow-On Cohort|We will survey 823 nursing facilities who participated in the aTIV Influenza Vaccination and Morbitiy and Mortality in U.S. Nursing Homes study in 2016-2017. We anticipate a 70% response rate from this sample for participation.
2396024|NCT03599739||Parallel Cohort|We will survey an additional 1000 facilities (i.e., facilities not participating in the original 2016-2017 study, but meeting the same entry criteria, except prior use of high dose vaccine will be allowed) in order to capture a cohort that used a wide range of self-selected vaccine choices. We anticipate a 50% response rate from this sample.
2396025|NCT03599726|Experimental|Active study drug: Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
2396026|NCT03599726|Placebo Comparator|Placebo study drug: Placebo|Placebo 5 mg per day for week 1-2 or 5-6
3184229|NCT00722176|Active Comparator|3|risperidone
2396028|NCT03599700||myeloproliferative neoplasms|"history taking~physical examination~laboratory investigations: Complete blood counts Bone marrow examination JAK2 V617F mutation. High-sensitivity C-reactive protein ESR Uric acid level LDH GGT BCR- ABL fusion gene IL-8 , TNF-Alpha Serum ferritin Serum albumin, transferrin, alpha feto protein Complement system: C3, C4."
2396029|NCT03599674|Experimental|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
3184230|NCT00722189||A|All patients treated
2396031|NCT03599648|Experimental|BPT-E|"Behavioral parent training (BPT) plus a psychoeducation program.~Includes a 10-week standard BPT, plus a 6-week psychoeducation program delivered prior to the standard BPT."
2396032|NCT03599648|Experimental|BPT-M|"Behavioral parent training (BPT) plus mindfulness-based stress reduction (MBSR).~Includes a 10-week standard BPT, plus a 6-week MBSR delivered prior to the standard BPT."
3184231|NCT00722202|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1, 4, 15, 45, 90, 180, and 300 mg
3184232|NCT00722202|Placebo Comparator|placebo|2 placebo subjects per group
3184233|NCT00722215|Placebo Comparator|1|Placebo control arm of study
2396038|NCT03599609|Experimental|Treatment|Treatment: Simvastatin 40mg/day
2396039|NCT03599596|Active Comparator|Two doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken twice before delivery
2396040|NCT03599596|Active Comparator|Monthly doses of sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets taken monthly delivery
2396041|NCT03599583|Experimental|Intervention|Arm 1 will receive the STOP-HPV prompts intervention
2396042|NCT03599583|No Intervention|Control|Arm 2 will receive standard of care
2396043|NCT03599570|Experimental|Intervention|Arm 1 will receive the STOP-HPV performance feedback intervention
2396044|NCT03599570|No Intervention|Control|Arm 2 will receive standard of care
2396045|NCT03599557|Experimental|Intervention|Arm 1 will receive the STOP-HPV communication intervention
2396046|NCT03599557|No Intervention|Control|Arm 2 will receive standard of care
2396047|NCT03599544|Active Comparator|Robot-Assisted Therapy (RT)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks.
2396048|NCT03599544|Experimental|Robot + Active Learning Program(RT-ALPS)|Armeo & Amadeo robot-assisted intensive upper limb therapy 1 hour sessions 3x week for 6 weeks plus training in active problem solving, analysis of performance, and goal-setting focused on the transfer of acquired motor skills to daily activities in the home and community.
2396049|NCT03599518|Experimental|DS-1205c with Gefitinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 250 mg oral dose of gefitinib
2396050|NCT03599492||Cirrhosis Patients|10 Patients with body mass index (BMI) etiology of cirrhosis
3184234|NCT00722215|Experimental|2|BQ-123 arm of study
2396051|NCT03599479|Experimental|Virtual reality group|"After experiencing the VR machine in the transfer bed for 5 minutes, the subject moves to the operating room.~After the subject moves to the surgical bed, he/she takes the appropriate position for the fluoroscopic pain intervention, and wears the virtual reality device (headset, headphone, smartphone).~After the subject starts the VR program, the practitioner starts the fluoroscopic pain intervention.~Lidocaine skin infiltration and description of the practitioner during the intervention are performed with the intervention when necessary."
2396052|NCT03599479|No Intervention|Conventional group|The fluoroscopic pain intervention is performed using only local anesthetics and description of the practitioner during the intervention as in the conventional cases.
2396053|NCT03599466|Experimental|BF-Lisinopril Tablets 20mg|During the study session, the subjects will be administered a single dose of BF-Lisinopril Tablet 20mg after an overnight fast of approximately 10 hours.
2396054|NCT03599466|Active Comparator|Zestril Tab 20mg|During the study session, the subjects will be administered a single dose of Zestril Tab 20mg after an overnight fast of approximately 10 hours.
2396055|NCT03599453|Experimental|Treatment (chemokine modulation therapy)|Participants undergo pre-treatment biopsy. Participants then undergo chemokine modulation therapy consisting of celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV over 30-60 minutes on days -11 to -9, and -4 to -2. Participants then undergo additional biopsy. Following biopsy and chemokine modulation therapy, participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity.
2396056|NCT03599440||Pulse contour disturbance|Patients with an arterial catheter and pressure line extensions.
2396057|NCT03599427|Active Comparator|systemic lidocaine|Lidocaine 2% IV bolus: 1.5 mg/kg at induction of anesthesia and at the end of surgery.
2396058|NCT03599427|Placebo Comparator|Placebo|Saline 0.9% IV bolus: 0.075 ml/kg at induction of anesthesia and at the end of surgery.
2396059|NCT03599401|Active Comparator|Aspirin Group (Group I)|14 Patients in Group I underwent scaling and root planing using ultrasonic scalers after which 75 mgms of Aspirin was administered orally, once daily for 3 months
2396060|NCT03599401|Active Comparator|Omega 3 Fatty acid Group (Group II)|14 Patients in Group II were given 500 mgms of Omega 3 Fatty Acid orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
2396061|NCT03599401|Placebo Comparator|Placebo Group (Group III)|14 Patients in Group III was given Placebo, which was administered orally, twice daily for 3 months after scaling and root planing using ultrasonic scalers.
2396062|NCT03599388|Experimental|SASI|"Sleep Diaries (daily)~Fitbit 24/7~Phone/videoconference (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)"
2396063|NCT03599375|Experimental|B-ALL treated with CD19 CART cell|The qualified CD19-targeted CART cells will be transferred to patient for 3 days as follow:D1,10% fraction;D2,30%;D3 60%. The number of CART cells for each course will be about 1×106/kg. If complete response (CR) or complete response with incomplete hemogram recovery (CRi) in hemogram is achieved after the first course of treatment, further treatment will be decided according to the clinical assessment and the wishes of the patient.If partial response (PR) is achieved after the first course, 1 or 2 courses of treatment will be continued. If there is no response (NR) after the first course, the treatment will be ceased or restarted based on the clinical assessment or patients' wishes. Treatent may be discontinued due to any severe toxicity, such as cytokine release syndrom.
3184235|NCT00722215|Active Comparator|3|Nifedipine arm of study
3184236|NCT00722228|Experimental|Autologous or Allogeneic tumor cells|Intervention: 5 vaccine doses, 3 weeks apart, injected subcutaneously.
2396066|NCT03599336|Other|Nonoperative Treatment|Subjects will have nonoperative treatment to treat proximal humerus fracture that is broken into 3 or 4 parts.
2396067|NCT03599336|Other|Operative Course for rTSA|Subjects will have shoulder replacement surgery to treat proximal humerus fracture that is broken into 3 or 4 parts.
2396068|NCT03599323||Clotrimazole 1% (Empecid L Cream, BAYB5097)|Patients who self-selected Empecid L Cream, and who will have pharmacist intervention prior to purchase.
2396069|NCT03599310|Experimental|Advance care planning|The intervention is a facilitator-based ACP process with a structured guide as a communication tool to aid the interventionists in broaching end-of-life care issues and eliciting patients' values and preferences in a consistent manner.
2396070|NCT03599310|Placebo Comparator|Usual care|A leaflet covering the concept of ACP and advance directives (AD), purposes and potential benefits will be distributed to all participants as part of usual information support to standardize the information provided. The health care team will encourage patients to discuss the matters with their family carers and/or significant others.
2396071|NCT03599297|Experimental|Bilateral synchronous simultaneous stone surgery|Patients who will be operated for kidney stones at both their kidneys in a single surgery session will be included in the study. Patients will undergo percutaneous nephrolithotomy for one side and flexible ureteroscopy for the other side.
2396072|NCT03599284|Experimental|Experimental group 1|Experimental group 1: Vicagrel 20mg loading followed by 5mg/day for 28 days
2396073|NCT03599284|Experimental|Experimental group 2|Experimental group 2: Vicagrel 24mg loading followed by 6mg/day for 28 days
2396074|NCT03599284|Experimental|Experimental group 3|Experimental group 3: Vicagrel 30mg loading followed by 7.5mg/day for 28 days
2396075|NCT03599284|Active Comparator|Control group|Control group: Clopidogrel 300mg loading followed by 75mg/day for 28 days
3184237|NCT00722241||A|Adult subjects (at least 18 years of age) with a diagnosis of type 1 diabetes (~80%) or insulin-treated type 2 diabetes (~20%); method of insulin delivery may be multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII)
3184238|NCT00722254||PPH|Subjects diagnosed with primary pulmonary hypertension (PPH)
3184239|NCT00722254||Myelofibrosis|Subjects diagnosed with Primary or Secondary Myelofibrosis
2396079|NCT03599258|Other|Arm 1|Skylife device
2396080|NCT03599258|Active Comparator|Arm 2|Standard therapy
3184240|NCT00722280|Experimental|Hand Transplantation|Described above
3184241|NCT00722293|Experimental|Arm A|once daily oral administration of pazopanib for Days 1-21 days in combination with epirubicin given as a bolus intravenous administration on Day 3
3189023|NCT00773435|Active Comparator|1. Echinacea purpurea|
3189024|NCT00773435|Placebo Comparator|2. placebo|
2396082|NCT03599232|Active Comparator|intervention( formative OSCE)|"students attended a formative objective structured clinical examination (OSCE) on the first day of their pediatric module to assess the competencies they gained from previous modules. the formative OSCE composed of 8 stations, which were both interactive and static. The interactive stations include history taking, examination, communication (counseling about breastfeeding), and procedural skills (pediatric basic life support) while non-interactive stations include data interpretation, management (linked-station) and a video-station (emergency).~assessed at end of the module(7 weeks) through summative OSCE"
2396083|NCT03599232|No Intervention|control|students in this group have attended pediatric module without formative OSCE and assessed at end of the module(7 weeks) through summative OSCE
2396084|NCT03599219|Other|case|donors with an hemorrhagic score >2 and / or hematoma (more than 4 cm) that occurred during blood donation
2396085|NCT03599219|Other|control|donors with an hemorrhagic score <2.
2396086|NCT03599206|Experimental|Ozone|
2396087|NCT03599206|Placebo Comparator|Filtered Air|
3184242|NCT00722293|Experimental|Arm B|once daily oral administration of pazopanib for Days 1-8 of a 3-week cycle in combination with epirubicin (bolus intravenous administration) on Day 3
3184243|NCT00722293|Experimental|Arm C|epirubicin (bolus intravenous administration) on Day 1 with once-daily oral administration of pazopanib for Days 14-21 of a 3-week cycle
2396090|NCT03599180||Knee Osteoarthritis group|KOA patients without accept treat in the past month
2396091|NCT03599180||Control group|Heathly volunteers
2396092|NCT03599141|Active Comparator|Depression Management|8 weekly group sessions
2396093|NCT03599141|Experimental|Trust-building Self-management Together|8 weekly group sessions
2396094|NCT03599128|Placebo Comparator|Placebo|Placebo
2396095|NCT03599128|Experimental|43.3 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2396096|NCT03599128|Experimental|86.6 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2396097|NCT03599128|Experimental|173 mg hydrolyzed green coffee extract|hydrolyzed green coffee extract as interventions
2396098|NCT03599115|Experimental|Inhibitory Control Training to Food Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. High-calorie foods are always no-go trials and low-calorie foods are always go trials.
2396099|NCT03599115|Active Comparator|Inhibitory Control Training to Neutral Items|Participants complete a 10 minute training task once a day, 4 days a week, for 4 weeks. Task is administered using a mobile app (Paradigm mobile) that is installed on an iPhone or iPad. Participants receive an instruction text/email at 9am on their chosen weekdays with instructions on what task to complete and a reminder text/email at 5pm if the task has not yet been completed. Research team receives an email when the task has been completed. When the task is administered, participants see a picture for 1250ms with an inter-stimulus interval of 1250ms and have to indicate which side of the screen the picture appears (go trials). Participants are instructed to not make a response when the picture is surrounded by a black box (no-go trials). There are 6 blocks with 36 trials each, half being go and half being no-go trials. All pictures are of household items.
2396100|NCT03599102|Experimental|LOVED intervention|Intervention group receives the LOVED program, an 8-week program where participants receive video education modules, and weekly video chat sessions with other end-stage renal disease patients and a prior living kidney African American recipient. The program aims to increase knowledge and skills on how to promote individual strategies on how to ask for a kidney from others.
2396101|NCT03599102|No Intervention|Standard Care|Standard interaction with transplant center and physician care.
3184244|NCT00722293|Experimental|Arm D|once-daily oral administration of pazopanib (according to schedule selected from either Arm A, B, or C) (3 week cycle) in combination with doxorubicin (bolus intravenous administration) on Day 1 or 3, depending on the schedule selected from either Arm A, B, or C
3184245|NCT00722306|Experimental|A425|A425 Treated
3184246|NCT00722319||A|Patients on long-term oral anticoagulation who are submitted to PCI-S because of acute coronary syndrome or stable angina. No further groups nor interventions are anticipated since the study is observational
3184247|NCT00722332|Experimental|1|HBV-related liver transplant patients
2396106|NCT03599076||Manifest HD|
2396107|NCT03599076||Premanifest HD|
2396108|NCT03599076||Control|
2396109|NCT03599063|Experimental|Cohort 1|Single subcutaneous administration of PF-06946860 at planned dose level 0.1 mg, or placebo
2396110|NCT03599063|Experimental|Cohort 2|Single subcutaneous administration of PF-06946860 at planned dose level 0.3 mg, or placebo
2396111|NCT03599063|Experimental|Cohort 3|Single subcutaneous administration of PF-06946860 at planned dose level 1 mg, or placebo
2396112|NCT03599063|Experimental|Cohort 4|Single subcutaneous administration of PF-06946860 at planned dose level 3 mg, or placebo
2396113|NCT03599063|Experimental|Cohort 5|Single subcutaneous administration of PF-06946860 at planned dose level 10 mg, or placebo
2396114|NCT03599063|Experimental|Cohort 6|Single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo
2396115|NCT03599063|Experimental|Cohort 7|Single subcutaneous administration of PF-06946860 at planned dose level 100 mg, or placebo
3184248|NCT00722345|Placebo Comparator|1|
3184249|NCT00722345|Experimental|2|
3184250|NCT00722358|Active Comparator|BMS-650032|
3184251|NCT00722358|Placebo Comparator|Placebo|
3184252|NCT00722384|Experimental|1|0.1 mg bevasiranib in the study eye
3184253|NCT00722384|Experimental|2|0.33 mg bevasiranib in the study eye,
3184254|NCT00722384|Experimental|3|1.0 mg bevasiranib in the study eye
3184255|NCT00722384|Experimental|4|1.5 mg bevasiranib in the study eye
2396116|NCT03599063|Experimental|Optional: Cohort 8|Optional: single subcutaneous administration of PF-06946860 at planned dose level 30 mg, or placebo in healthy Japanese subjects
2396117|NCT03599050|Experimental|Communication Simulation|Nurses will use simulation over 12 weeks while fidelity is monitored using the NIH Behavior Change Consortium Treatment Fidelity Guidelines.
2396118|NCT03599037|Experimental|ICOUGH Recovery App|The ICOUGH Recovery app v2.0 will be downloaded to participants who have a smartphone and want to use the app after their surgery. These participants will be instructed to use the app daily after their surgery until discharge and to select a care coach. Prior to discharge subjects will complete a questionnaire to assess usability and will participate in a brief recorded interview of their experience using the app. Inpatient post operative complications will be abstracted from medical records.
2396119|NCT03599037|No Intervention|Standard of care|Participants who either do not have a smartphone or have a smartphone but don't want to use the app will receive the standard of care after surgery which includes an ICOUGH protocol checklist. Inpatient post operative complications will be abstracted from medical records.
2396120|NCT03599024|Experimental|PCEA Group|The patients randomized into this arm were able to control the administration of analgesics, according to their subjective condition.
2396121|NCT03599024|Active Comparator|Non-PCEA Group|The patients randomized into this arm were receiving analgesics according to the physician's prescription.
2396122|NCT03599011||Exposure 1|commonly prescribed tricyclic antidepressants (Imipramine, Amitriptyline, Clomipramine HCL) administered for at least 3 months
2396123|NCT03599011||Exposure 2|commonly prescribed Selective Serotonin Re-uptake inhibitors antidepressants ( Fluoxetine, Fluvoxamine, Sertraline, Citalopram, Paroxetine) administered for at least 3 months
2396124|NCT03599011||Non exposure|Non-pharmacological treatment (psychotherapy)
2396125|NCT03598998|Experimental|Treatment (pralatrexate and pembrolizumab)|Patients receive pralatrexate IV over 3-5 minutes on days 1 and 8 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2396126|NCT03598985||Patients with CAI|"Patients referred with a confirmed diagnosis of CAI, with a Cumberland Ankle Instability tool score lower than 27 points. Patients should have had a recurrent sprain within the previous year.~Patients will have their balance assessed using the Myankle smartphone application simultaneously with Biodex balance system assessment."
2396127|NCT03598985||Healthy participants|"Healthy participants who are not complaining of pain and have not be exposed to trauma, injury or undergone surgery for the lower quadrant of the body.~Participants will have their balance assessed using the MyAnkle smartphone application simultaneously with Biodex balance system assessment."
2396128|NCT03598972||control|teeth of children of non vitamin taking mother
2396129|NCT03598972||intervention|children teeth of vitamin taking mother
2396130|NCT03598959|Experimental|Treatment|Treated with tofacitinib and chidamide for 4 cycles.
2396131|NCT03598946|Experimental|Human Papilloma Virus Test urinary|Urinary Test by a kit which is send to the woman's house
2396132|NCT03598920||AspireAssist|Patients undergoing the endoscopic bariatric procedure using the AsspireAssist device
2396133|NCT03598920||Nutritional consulting|Patients undergoing nutritional consulting
2396134|NCT03598907||Standard management of coagulopathy|"The first group of existing ,,standard care - the approach to bleeding patient will be based on clinical experience of the anaesthetist, practically meaning administering crystalloids, colloids (hydroxyethyl starch or gelatin), fresh frozen plasma and erythrocytes to restore normovolemia and platelets, fibrinogen, prothrombin complex concentrate, von Willebrand factor, tranexamic acid, all products giving ,,blindly when it comes to diagnosis and treatment of coagulopathy."
2396135|NCT03598907||POC management of coagulopathy|"group of ,,point-of-care approach to the diagnosis and treatment of perioperative bleeding and coagulopathy will be conducted on the basis of the results of the POC methods ROTEM, PFA 200 and Multiplate (prothrombin complex concentrate, fibrinogen, platelets, von Willebrand factor, tranexamic acid). A solution of 5% albumin and erythrocytes (to keep haemoglobin level over 100 g/l as it is critical for normal primary haemostasis) will be used to keep normal circulating volume and to compensate for perioperative blood loss."
2396136|NCT03598894||Case NDHT|Healthy non-dipping hypertensives 'NDHT' (24h mean wake SBP >145mmHg at baseline and a decline of <10% between mean day time and night time systolic pressures)
2396137|NCT03598894||Control NT|matched healthy normotensives 'NT' (24h mean wake SBP <120mmHg)
2396138|NCT03598894||Control DHT|matched dipping hypertensives 'DHT' (24h mean wake SBP >145mmHg and a decline of >10% between mean day time and night time systolic pressures)
2396139|NCT03598881|Experimental|Treatment|Toothpaste containing 0.32%NaF and no sodium lauryl sulphate (SLS)
2396140|NCT03598881|Active Comparator|Comparator|Toothpaste containing 0.8% sodium monofluorophosphate (SMFP) and sodium lauryl sulphate (SLS)
2396141|NCT03598868|Experimental|Vortioxetine|Vortioxetine 5-20 mg
2396142|NCT03598868|Placebo Comparator|Placebo|Placebo augmentation
2396143|NCT03598855|Experimental|IPC intervention|Participants will self administer IPC of the upper arm daily for 7 days.
2396144|NCT03598855|No Intervention|Control|
2396145|NCT03598842|Experimental|Malnourished without lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and do not have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan.The consented household contact will also receive a daily multivitamin.
2396146|NCT03598842|Experimental|Malnourished with lung parasites|Thirty study participants, household contacts of an index TB case, who are malnourished and have lung parasites will be consented into the study intervention. The household contact and the rest of the household members will receive nutritional supplementation meals for six months. The family will receive the food in biweekly installments and will be given a vegan meal plan. The consented household contact will also receive a daily multivitamin. These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
3184256|NCT00722384|Experimental|5|3.0 mg bevasiranib in the study eye.
3184257|NCT00722410|No Intervention|A|
3184258|NCT00722410|Experimental|B|VSL#3 for 4 weeks
2396147|NCT03598842|Active Comparator|Well-nourished with lung parasites|These thirty study participants will be given anti-parasitic medications such as albendazole, ivermectin, metronidazole, or other medication per Indian guidelines to treat the parasite infection.
2396148|NCT03598842|No Intervention|Well-nourished without lung parasites|These thirty study participants will serve as the control.These participants will be well-nourished and not have a parasite infection; therefore, they will not receive the nutritional supplementation or treatment for parasite infection.
2396149|NCT03598816|Experimental|Arm 1: Durvalumab + Tremelimumab + Neoantigen DNA Vaccine|"All patients will receive durvalumab intravenous (IV) at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles~The first vaccination will take place two weeks after confirmed disease progression on targeted therapy. This will be Day 1 of the first 28-day cycle of treatment with durvalumab and tremelimumab~The schedule of vaccination is Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 (for a total of 6 doses)"
2396150|NCT03598816|Experimental|Arm 2: Durvalumab + Tremelimumab|"All patients will receive durvalumab IV at a dose of 10 mg/kg over the course of 60 minutes given every 2 weeks (on Days 1 and 15 of each 28-day cycle) for a total of 8 doses. Durvalumab will be given thereafter as monotherapy at a dose of 209 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 doses~All patients will receive tremelimumab at a dose of 1 mg/kg over the course of 60 minutes given every 4 weeks (on Day 1 of each 28-day cycle) for a total of 4 cycles."
2396156|NCT03598764|Other|Classic head extraction group|
2396157|NCT03598764|Other|External Pop out group|
2396158|NCT03598751|Experimental|BCD-085|"Blinded period:~BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
2396159|NCT03598751|Placebo Comparator|Placebo|"Blinded period:~Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14~patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22~patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22~Open-label period:~BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54"
2396160|NCT03598738|Active Comparator|Esomeprazole 40mg Group|Intervention group consisted of 16 diabetic subjects that had various degrees of symptoms for functional dyspepsia, gastro-oesophageal reflux, gastritis or duodenitis. All of them were prescribed 40 mg of esomeprazole treatment for three months.
2396161|NCT03598738|No Intervention|Control Group|The control group consisted of without gastric complaints, thus who did not receive PPI drugs. This group was followed-up without any intervention for three months.
2396162|NCT03598725|Experimental|ITI strategy|The low-dose ITI was Coagulation Factor VIII (50IU/kg, every other day) alone or combined with prednisone (2mg Kg-1/day, one month, then taper in three months) depending on the tendency of inhibitor, and Rituximab (375mg/square meter every week for 4 weeks) when the inhibitor titer ≥40BU/ml before or during ITI.Inhibitor and hemorrhage should be retested and recorded periodically.
2396163|NCT03598712|Experimental|Compression by chest bandage urgo K2®|"After the second puncture, the local compression by thoracic bandage will be put in place.~The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.~During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.~The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation."
2396164|NCT03598712|Active Comparator|punctures|"After the second puncture, the patient will be seen at the same frequency as in the experimental arm.~The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical."
2396165|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 3 mg/mL|AXR-159 Low Dose
2396166|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 30 mg/mL|AXR-159 Mid Dose
2396167|NCT03598699|Experimental|AXR-159 Ophthalmic Solution 50 mg/mL|AXR-159 High Dose
2396168|NCT03598699|Placebo Comparator|AXR-159 Ophthalmic Solution Vehicle|Control Group
2396169|NCT03598686|No Intervention|HOSENG Control|"Standard of care during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~For absent household members or household members who refuse testing: They are encouraged to get tested by the Village Health Worker (VHW) or the nearby health facility"
2396170|NCT03598686|Experimental|HOSENG Intervention|"HOSENG Intervention during a door-to-door HIV testing campaign:~For present household members: blood-based HIV testing~a) If any absent person in the household: One of the present household members is tested and trained using the oral HIVST (OraQuick©)~For absent household members or household members who refuse testing: One oral HIVST (OraQuick©) is left behind and has to be brought back to the VHW after usage. Otherwise it will be collected by the VHW after two weeks."
2396171|NCT03598673||Hypertensives to receiving Nevibolol|Patients to receive Nevibolol
2396172|NCT03598660||Breast cancer patients|"The present study will be carried on 50 breast cancer patients before surgery.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using enzyme linked immuno sorbent assay (ELISA)."
3184259|NCT00722410|Experimental|C|Mechanical bowel cleansing followed by VSL#3 for 4 weeks.
2396173|NCT03598660||Healthy controls|"The present study will be carried on 15 age and sex matched controls.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
2396174|NCT03598660||Benign breast diseases|"The present study will be carried on 15 patients with benign breast diseases.~The followings markers must be estimated:~Sorcin gene expression using real time PCR and Annexin A3 serum mesurement using ELISA."
3184260|NCT00722462|Experimental|1|Active acupuncture
2396179|NCT03598634|Active Comparator|Epi-on cross-linking|Intervention: Drug: Riboflavin 0.15 in 20% dextran solution
2396180|NCT03598634|Active Comparator|Epi-off cross-linking|intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid
2396181|NCT03598621|Experimental|Cohort 1: Semaglutide 0.25 mg|Participants will receive a single dose of semaglutide 0.5 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
2396182|NCT03598621|Experimental|Cohort 2: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 1.0 mg/mL using DV3372 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
2396183|NCT03598621|Experimental|Cohort 3: Semaglutide 0.5 mg|Participants will receive a single dose of semaglutide 2.0 mg/mL using NovoPen®4 device and a single dose of semaglutide 1.34 mg/mL using PDS290 device in a cross-over manner at two separate dosing visits. The dosing visits will be separated by a wash-out period of 2-3 weeks.
3143408|NCT00006012|Experimental|topotecan + paclitaxel + filgrastim + TRT + radiation|"Patients receive topotecan IV on days 1-5 and paclitaxel IV over 3 hours on day 5. Patients receive filgrastim (G-CSF) subcutaneously (SC) daily beginning 24 hours after the last dose of chemotherapy and continuing until blood counts recover. Treatment repeats every 3 weeks for 2 courses.~After 2 courses of treatment, patients undergo TRT twice daily for 5 consecutive days for 5 weeks. During TRT, patients receive cisplatin IV, oral etoposide, and amifostine SC daily prior to TRT.~At 4 weeks after completion of TRT, patients receive 2 additional courses of topotecan, paclitaxel, and G-CSF every 3 weeks followed by prophylactic cranial irradiation.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
3143409|NCT00006014|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly. Courses repeat every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
3143410|NCT00006015|Experimental|Combination Chemotx|Combination chemotherapy for metastatic colorectal cancer in patients who have disease progression after 5-FU and/or irinotecan-containing therapy
3143411|NCT00006016|Experimental|Treatment (thalidomide, chemoembolization)|Patients receive oral thalidomide daily beginning 4 weeks before the first planned chemoembolization procedure. Thalidomide administration is stopped 24 hours before each chemoembolization procedure, and then restarted at 24 hours after completion of each procedure OR when blood counts and levels of bilirubin and transaminases recover, whichever occurs later. Thalidomide treatment continues in the absence of disease progression or unacceptable toxicity. Patients undergo placement of a visceral arterial catheter. Patients receive doxorubicin as a chemoemulsion via the arterial catheter into 1 hepatic lobe only under angiographic guidance. Immediately after delivery of the chemoemulsion, patients undergo particulate embolization. The opposite lobe, if involved, is treated within 3-5 weeks of treatment of the initial lobe. Patients are reevaluated for repeat chemoembolization within 8-12 weeks of the last chemoembolization.
3143412|NCT00006017|Active Comparator|Rebeccamycin 1 day|Patients receive rebeccamycin analogue IV over 1 hour on day 1.
2396190|NCT03598595|Experimental|Treatment (hydroxychloroquine, gemcitabine, docetaxel)|Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2396191|NCT03598582|Other|epoetin zeta|Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.
2396192|NCT03598569||lung cancer|
2396193|NCT03598569||other lung diseases|
2396194|NCT03598556|Experimental|Vitamin D3 Supplementation Arm|This arm will receive 180,000IU vitamin D3 every 3 months from baseline through week 96.
2396195|NCT03598556|Placebo Comparator|Placebo Arm|This arm will receive placebo every 3 months from baseline through week 48, followed by 180,000IU vitamin D3 every 3 months from week 48 through week 96.
2396196|NCT03598543||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
2396197|NCT03598543||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
2396199|NCT03598517|Experimental|high dose chemoradiotherapy|all eligible patients receive image-guided intensity-modulated radiotherapy 60 Gy in 30 fractions over 6 weeks and concurrent weekly paclitaxel and cisplatin，followed by hyperfractionated intensity-modulated radiotherapy boost to residual metabolic disease concurrent with the same chemotherapy regimen, followed by adjuvant chemotherapy 6 weeks after completion of radiation therapy.
2396200|NCT03598504|Active Comparator|Healthy Controls Group|1. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).
2396201|NCT03598504|Active Comparator|Spinal Cord Injury Group|"1a. A focus group to gather information about the perceptions, opinions, beliefs, and attitudes towards management of muscle spasms by vibration using our portable device, information that will drive design improvement (size, fit, weight).~1b. In the lab, we will trigger spasms in paralyzed leg muscles in one of two common postures (seated, reclined), detect the contractions using electromyography (EMG), and condition alternate spasms with vibration using our custom device. We will examine the vibration parameters that reduce muscle spasms best.~2. Participants will complete 1 or 2 multi-day experiments. EMG (24-hour) data will be collected at baseline (day 1), during the vibration intervention (day 2), and post intervention (day 3) to examine the acute effects of vibration on muscle spasms"
2396202|NCT03598491||Iohexol|Iohexol was applied in video-fluoroscopic-swallowing study
2396208|NCT03598465||PHLF Group|The investigators will define PHLF as a postoperatively acquired deterioration in synthetic, excretory, and detoxifying functions of liver. According to the PHLF definition and grading criteria established by International Liver Group of Liver Surgery (ISGLS) in 2011 (Surgery,2011,149(5):713-724), PHLF will be diagnosed by an increased PT-INR and concomitant hyperbilirubinemia on or after postoperative day 5.
2396209|NCT03598465||Non-PHLF Group|Non-PHLF will be defined as normal liver function in terms of normal PT-INR and bilirubin levels after hepatectomy on or after postoperative day 5.
2396210|NCT03598452|Experimental|High dose of ganciclovir group|IVG was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
3143413|NCT00006017|Active Comparator|Rebeccamycin 5 day|Patients receive rebeccamycin analogue IV over 1 hour on days 1-5.
3143414|NCT00006024|Experimental|Pre and Post radiation Chemotherapy|
3143415|NCT00006029|Active Comparator|vinorelbine + gemcitabine + doxorubicin - higher doses|"Patients who have not undergone prior transplantation receive vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
2396214|NCT03598426|Active Comparator|Conventional|Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2396215|NCT03598426|Active Comparator|Short-Course|Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2396216|NCT03598426|Active Comparator|Combined|Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion. On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
2396217|NCT03598413|No Intervention|Control|Patients undergoing standard laparoscopic colorectal resection with no omega-3 enriched peri-operative nutritional support
2396218|NCT03598413|Experimental|Omega-3|Patients in this group will receive 7 days pre and 7 days post surgery of a nutritional supplement enriched with 1.42g/dose of the fish oils EPA and DHA. The supplement is pre-mixed and will be taken twice daily for a total of 14 days.
2396219|NCT03598400|No Intervention|Control|Participants will continue with their habitual lifestyle but perform no exercise for 2 weeks
2396220|NCT03598400|Active Comparator|Moderate intensity continous training|Participants will complete moderate intensity continous training during a 2 week intervention period
2396221|NCT03598400|Experimental|high intensity interval training|Participants will complete high intensity interval training during a 2 week intervention period
2396222|NCT03598387|Experimental|APD group|Subjects will receive PD catheter placement and subsequent automated peritoneal dialysis treatment.
2396223|NCT03598387|Active Comparator|IHD group|Subjects will receive un-tunneled hemodialysis catheter placement and subsequent intermittent hemodialysis.
2396224|NCT03598374|Experimental|Inositol + Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
2396225|NCT03598374|Placebo Comparator|Folic acid|"Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid for 6 months.~Couples are required to have regular intercourse with the aim to achieve a spontaneous conception."
2396226|NCT03598348|Experimental|Maintenance Treatment Group A|Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2396227|NCT03598348|No Intervention|Observation Group|Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2396228|NCT03598348|Experimental|Maintenance Treatment Group B|Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
2396229|NCT03598335||Women with malignant tumor|Women with malignant tumor in reproductive system
2396230|NCT03598335||Women with benign tumor|Women with benign tumor in reproductive system
2396231|NCT03598335||Women with no observed tumor|Women with no observed tumor in reproductive system
2396232|NCT03598322|Active Comparator|Dextrose 1mL|Dextrose injection, Dextrose 1mL, active comparator
2396233|NCT03598322|Experimental|Dextrose 2mL|Dextrose injection, Dextrose 2mL
2396234|NCT03598322|Experimental|Dextrose 4mL|'Dextrose injection, Dextrose 4mL
3143416|NCT00006029|Experimental|vinorelbine + gemcitabine + doxorubicin - lower doses|"Patients who have undergone prior transplantation receive lower doses of vinorelbine, gemcitabine, and doxorubicin HCl liposome.~Patients are followed every 6 months for 2 years and then annually for 6 years."
3143417|NCT00006031|Active Comparator|I: Radioactive Seed Localized Breast Biopsy|Arm I: Patients undergo radiographic placement of a radioactive seed (either iodine I 125 or palladium Pd 103) into the suspicious lesion. Patients then undergo surgery to remove the lesion along with the seed and a small margin of surrounding breast tissue followed 3 months later by a postoperative mammogram.
3143418|NCT00006031|Active Comparator|Arm II: Needle Localized Breast Biopsy|Arm II: Patients undergo a needle localized breast biopsy with a specimen x-ray.
2396238|NCT03598296|Experimental|Group A:Group Tube|Patients are inserted the large size tube (28F).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
2396239|NCT03598296|Experimental|Group B:Group Ball|Patients are inserted the small size tube connects with a negative pressure ball(drainage ball).Patients undergo upper lobectomy are inserted one additional large size tube(28F,we named this tube upper tube).This group is planned to enroll 30 patients.
3184261|NCT00722462|Sham Comparator|2|Sham Acupuncture- acupuncture at neutral points
2396414|NCT03597035|Experimental|Patiromer Add-On|Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
3184262|NCT00722462|No Intervention|3|Embryo transfer with no acupuncture
2396240|NCT03598283||Severely burned patients|In this prospective study, the extent to which severe burn injuries affect the morphology and function of liver, pancreas and thyroid. The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
2396241|NCT03598270|Placebo Comparator|Arm A (Control Arm)|"Placebo of atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with placebo:~Carboplatin (AUC = 5, d1) plus paclitaxel and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks~Carboplatin (AUC = 4, d1) plus gemcitabine and placebo every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks.~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and placebo every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with placebo every 3 weeks."
2396242|NCT03598270|Experimental|Arm B (experimental arm)|"Atezolizumab in combination with one of the platinum based regimens below (investigator's choice) followed by maintenance niraparib with atezolizumab:~Carboplatin (AUC = 5, d1) plus paclitaxel and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin (AUC = 4, d1) plus gemcitabine and atezolizumab every 3 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks.~Carboplatin (AUC = 5, d1) plus pegylated liposomal doxorubicin (PLD) and atezolizumab every 4 weeks. Non-progressing patients will be switched to maintenance niraparib in combination with atezolizumab every 3 weeks."
3143419|NCT00006034|Experimental|Arm I|Patients receive a sensitizing dose of keyhole limpet hemocyanin (KLH) intradermally in week 2 followed by induction KLH IV once weekly in weeks 1-6. Patients with partial or no response receive IV KLH reinduction therapy once weekly in weeks 13-18. Patients with complete response receive IV KLH maintenance therapy monthly in weeks 13, 17, and 21, and then in months 6-12.
3143420|NCT00006034|Active Comparator|Arm II|Patients receive doxorubicin IV once weekly in weeks 1-6.
3143421|NCT00006047|Experimental|Combination Therapy|Combination Therapy with Oral 9-Nitrocamptothecin & Oral Etoposide. Patients receive oral nitrocamptothecin on days 1-3 and oral etoposide on days 4-5 each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
2396246|NCT03598231|Sham Comparator|Arm OFF-ON|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator for sacral neuromodulation is implanted.~Once the generator is placed it will be disconnected for 4 weeks. Then it will be continued to be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be turn ON for 4 weeks and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
2396247|NCT03598231|Active Comparator|Arm ON-OFF|"Patients are subjected to a test phase by stimulation with an external temporal generator and, if there is improvement in their symptomatology, a subcutaneous impulse generator sacral neuromodulation is implanted.~Once the generator is placed it will be turned ON for 4 weeks at the maximum subsensory stimulus. Then it will be turned OFF for 2 weeks as a wash-out period. Then, the stimulator will be kept OFF for 4 weeks. After this sequence it will be turned on again and will be left on afterwards at the maximum subsensory stimulus.~Specific scales will be passed after each sequence crossing."
2396248|NCT03598218|Experimental|Hypofractionated dose IMRT|Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.
2396249|NCT03598218|Experimental|Standard-dose IMRT|Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..
2396250|NCT03598205|Experimental|DIABEC plus intravitreal dexamethazone|Intervention:Curmin formulation (DIABEC) plus dexamethazone intravitreal injection. Oral curcumin formulation (DIABEC 2 tablets/die) in combination with Dexamethazone (0,7 mg) intravitral injection for diabetic macular edema treatment
2396251|NCT03598205|No Intervention|dexamethazone intravitreal injection|Intervention: dexamethazone intravitreal injection (0,7 mg) in PRN for diabetic macular edema treatment monotherapy.
2396252|NCT03598192|Experimental|TAP group|"The TAP block is performed under the ultrasound guidance at four points: at subcostal and lateral abdominal wall at right-side and left-side.~Drug: ropivacaine 0.375% 40 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.375% 8 ml/hour during 48 hours."
2396253|NCT03598192|Experimental|PVB group|The paravertebral block is performed under the ultrasound guidance at T7. Drug: ropivacaine 0.5% 20 ml (maximum dose <= 3 mg/kg). Maintenance: ropivacaine 0.25% 8 ml/hour during 48 hours.
3143422|NCT00006079|Experimental|Arm I|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
3143423|NCT00006079|Experimental|Arm II|Arm I-II: Patients receive one of two different doses of oral eflornithine daily. Treatment continues for 28 days.
3143424|NCT00006079|Placebo Comparator|Arm III|Arm III: Patients receive oral placebo daily. Treatment continues for 28 days.
3143425|NCT00006081|Experimental|Bryostatin-1 + Taxol|
3143426|NCT00006083|Experimental|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
3143427|NCT00006083|Placebo Comparator|placebo|placebo injected subcutaneously daily
3143428|NCT00006089|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3143429|NCT00006092|Experimental|Arsenic Trioxide Treatment|Patients receive arsenic trioxide IV over 2-3 hours daily for 28 days. Patients who respond may receive a second course of therapy beginning 28 days from the last dose of the first course.
3143430|NCT00006094|Experimental|Treatment (oxaliplatin, fluorouracil, EBRT)|Patients receive oxaliplatin IV over 1 hour on day 1, fluorouracil IV continuously on days 1-7, and radiotherapy on days 1-5. Treatment repeats weekly for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
3143431|NCT00006095|Experimental|Vincristine Sulfate 1.5 mg/m2/wk and Irinotecan|
3143432|NCT00006095|Experimental|Vincristine sulfate 2.0 mg/m2/wk and Irinotecan|
2396258|NCT03598127||sepsis group|patients of sepsis group are diagnosed with sepsis according to International Pediatric Sepsis Consensus Conference:Definitions for sepsis and organ dysfunction in pediatrics.
2396259|NCT03598127||control group|A gender- and age- matched control group are recruited from among non-sepsis children from Pediatric Intensive Care Unit of West China Hospital.
2396262|NCT03598101|Experimental|Test group|
2396263|NCT03598088|Other|Healthy Sexually Active Women|Healthy, sexually active women who are not at risk for pregnancy due to previous female tubal sterilization will receive both Ovaprene and the Caya diaphragm throughout the course of the trial. The purpose of the Caya PCT cycle is to ensure that in this study population and at these sites, results that are expected to be observed in a PCT cycle with an approved vaginal barrier can be replicated.
2396264|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide intravenous infusion 120 micrograms over 20 minutes
2396265|NCT03598075|Other|CGRP|CGRP intravenous infusion 30 micrograms over 20 minutes
2396266|NCT03598049|Experimental|densah burs drilling group|implant osteotomy site drilling using the densah burs osseo densification drills
2396267|NCT03598049|Active Comparator|surgical burs drilling group|implant osteotomy site drilling using conventional surgical burs drilling
3184263|NCT00722475|Experimental|IvIg|Repeated infusions of intravenous immunoglobulin in early pregnancy
2396269|NCT03598023|Active Comparator|Group 1|Cytal® Burn Matrix
2396270|NCT03598023|Active Comparator|Group 2|EZ-Derm® Porcine Xenograft
2396271|NCT03598010|Experimental|Lenodiar Pediatric in Acute/Prolonged Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
2396272|NCT03598010|Experimental|Lenodiar Pediatric in Chronic Diarrhea|"LenoDiar Pediatric acts thanks to Actitan-F, a plant-based molecular complex resulting from Aboca research which reduces attacks of diarrhoea and normalises the consistency of stools, helping to rapidly restore a balanced intestinal function.~Actitan-F counteracts the inflammation of the intestinal mucous membrane, always present in the case of diarrhoea, through two action mechanisms:~a protective action, achieved by forming a barrier-effect film to limit contact with microorganisms and irritants;~an antioxidant action on the free radicals which counteracts the irritation of the mucous membrane."
2396273|NCT03597997|Experimental|Group P|The patients in group (P) will be anaesthetized using total intravenous propofol.
2396274|NCT03597997|Sham Comparator|Group S|Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.
2396275|NCT03597984|No Intervention|Arm A|Standard Radiotherapy: 4 Gy x 5 fractions (fr) to Whole vertebra
2396276|NCT03597984|Experimental|Arm B|"Intervention: Radiotherapy with Simultaneous Integrated Boost-SIB on macroscopic metastases~Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
2396277|NCT03597971|Experimental|Part A: experimental|Subjects will receive HMPL004-6599 or matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule. Dose levels may be repeated, or reduced if deemed appropriate by the Safety Monitoring Committee (SMC).
2396278|NCT03597971|Placebo Comparator|Part A: placebo|Subjects will receive matching placebo on Day 1. This will be administered under fed conditions with a standard meal, according to the randomization schedule.
2396279|NCT03597958||Hypercholesterolaemia|"Individuals attending Imperial College London Diabetes Centre (ICLDC) and with LDL-C ≥5.0 mmol/L, for children <18 years LDL-C>95th centile by age and gender for country, and possible evidence of known premature CHD.~Individuals with a high probability of disease according to the Dutch Lipid Network Criteria, score of ≥6 points, will be identified as possible probands (individual serving as our starting point for the genetic study of the family) and will be selected for further screening.~Patients will be tested for known and/or suspected FH genes, using next generation sequencing (NGS) panel, whole exome and/or whole genome sequencing (WES/WGS) in cases where FH is highly suspected despite negative results from panel testing, and transcriptomic analysis of RNA blood samples."
2396280|NCT03597945|Placebo Comparator|Group Placebo|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of normal saline as adjuvant."
2396281|NCT03597945|Active Comparator|Group Magnesium|"For patients of this group, the intervention was a femoral nerve block with:~15 ml of lidocaine with epinephrine (300 mg)~and 3 ml of Magnesium sulfate 15% (450 mg) as adjuvant."
2396282|NCT03597932||baseline or control group|All participant anesthesiologists do intraoperative handover of anesthesia care according to a usual process or without checklist for 2-week to 1-month baseline data collection.
2396334|NCT03597568|Experimental|Resveratrol|Patients will receive resveratrol 400 mg PO per day in divided doses of 200 mg in the morning and 200 mg in the evening
3189025|NCT00773448|Active Comparator|Limited Malignancy Screening|
2396283|NCT03597932||Checklist group|All participant anesthesiologists do intraoperative handover of anesthesia care by using a standardized handover checklist for another 2-week to 1-month data collection.
2396284|NCT03597919|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
2396285|NCT03597919|Experimental|Two-dose schedule for Sabin IPV|Subjects vaccinate first dose IPV at 4 months, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
2396286|NCT03597906|Experimental|Group A: Manifest|20 eyes will be treated using Contoura, topography guided ablation vision with the standard manifest refraction.
2396287|NCT03597906|Experimental|Group B: partial TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and without change in the spherical power (using the same spherical power as the manifest refraction).
2396288|NCT03597906|Experimental|Group C: Full TMR|20 eyes will be treated with Contoura vision, topography guided ablation using the topographic astigmatic power and axis and modifying the spherical power to obtain the same spherical equivalent as the manifest refraction. This is done by subtracting half of the difference between topographic astigmatic power and the manifest astigmatic power from the spherical power (topography-modified treatment refraction).
2396289|NCT03597893|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland) .
2396290|NCT03597893|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 3.99 IU per 6.72mg nostril.
2396291|NCT03597880|Other|obese patient|BMI>30 kg/m2 and underwent bariatric surgery
2396292|NCT03597867|Placebo Comparator|Placebo|Placebo using single-use vials of hyaluronic acid 0.2% preservative-free lubricating tear drops three days before surgery.
2396293|NCT03597867|Experimental|Dicloftil|"Diclofenac Na 0.1% Oph Soln, Dicloftil®, NSAID eyedrops administered three days before surgery"
2396294|NCT03597867|Experimental|Nevanac|"Nepafenac 0.3% Ophthalmic Suspension, Nevanac 3mg/ml®, NSAID eyedrops administered three days before surgery"
2396295|NCT03597867|Experimental|Indom|"Indomethacin 5 MG/ML Ophthalmic Suspension, Indom ®, NSAID eyedrops administered three days before surgery"
2396296|NCT03597867|Experimental|Yellox|"Bromfenac 0.09 % Ophthalmic Solution, Yellox®, NSAID eyedrops administered three days before surgery"
2396297|NCT03597841||Patients with CRKp BSI:Combination therapy|
2396298|NCT03597841||Patients with CRKp BSI: Monotherapy|
2396299|NCT03597828||DEXMEDETOMIDINE|Dexmedetomidine infusion for pleuroscopy sedation. Rescue drugs will be midazolam for inadequate sedation and fentanyl for pain control
2396300|NCT03597828||MIDAZOLAM/FENTANYL|Midazolam for sedation and fentanyl for pain will be used for pleuroscopy monitored anesthesia care
2396301|NCT03597815||DME positive, OSA positive|Visit 1: Baseline DME Treatment. Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injection is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 6-month visit post DME initial treatment Visit 5: 2-3 month follow up - titration study (at sleep lab) Visit 6: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group Visit 7: 12-month sleep apnea follow up
2396302|NCT03597815||DME positive, OSA negative|Visit 1: Baseline DME Treatment Includes first EYELEA(aflibercept) injection. (DME positive patients will receive a minimum of 6 injections with the first five occurring at 1-month intervals and the sixth occurring two months after the fifth. Further injections will be provided at the discretion of the ophthalmologist in according to the treat and extend protocol of Eylea to ensure the DME is resolved by the end of the study.) Each injections is 2 mg (0.05 mL). Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 6-month visit post DME initial treatment Visit 4: 12-month visit post DME initial treatment in the OSA- group and at least 3 months post CPAP initiation in the OSA+ group
2396303|NCT03597815||DME negative (NPDR positive), OSA positive|no injections needed. Visit 1: Baseline NPDR diagnosis Sleep lab visits Visit 2: Diagnosis of OSA - Overnight sleep study Visit 3: 1 month follow up post-CPAP initiation Visit 4: 2-3 month follow up - titration study Visit 5: 12-month sleep apnea follow up
2396304|NCT03597815||DME negative (NPDR positive), OSA negative|no injections needed. Visit 1: Baseline NPDR diagnosis Visit 2: Diagnosis of OSA - Overnight sleep study
2396305|NCT03597802|No Intervention|Control Group|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance).
2396306|NCT03597802|Active Comparator|Intervention group 1|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance), and will perform exercise at workplace three times per week, during 15 minutes
2396307|NCT03597802|Active Comparator|Intervention group 2|The workers will be receive orientation about manual material handling, postural and low back care (lecture and guidance) and and will perform exercise at workplace four times per week, during 15 minutes.
3184264|NCT00722475|Placebo Comparator|placebo|infusion of human albumin CSL Behring 5%
2396309|NCT03597776|Experimental|Lidocaine Group|Bolus of intravenous lidocaine of 2mg/kg over 5 mins will be given before skin incision.
2396310|NCT03597776|Placebo Comparator|Placebo Group|Normal Saline of 2mg/kg over 5 mins will be given as bolus before skin incision
2396311|NCT03597763||Moderate to severe traumatic brain injury|Patients who have suffered a moderate to severe traumatic brain injury, with confirmed intracranial damage.
2396312|NCT03597750|Experimental|Static air support devices (Repose®)|"Alternating-pressure devices will be replaced by static air support devices (Repose®) during 14 days:~Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors~The frequency of repositioning remains unchanged."
3184265|NCT00722488|Experimental|1|MLN4924
2396313|NCT03597750|No Intervention|Alternating-pressure devices|"Instead of replacing the alternating-pressure devices by static air support devices (Repose®), the residents remain on their alternating-pressure devices.~The frequency of repositioning remains unchanged."
2396314|NCT03597737|Experimental|Treatment as usual + APP|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor APP. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2396315|NCT03597724||Patient suffering from sarcopenia|Subjects aged 65 years or older suffering from sarcopenia (diagnosis performed with a valid definition and valid cut-off points) and they will respond to the Questionnaire composed of 13 choice questions.
2396316|NCT03597711|Active Comparator|IVCannulation 24G non-safety cannula|Peripheral Intravenous cannulation using 24G non-safety cannula
2396317|NCT03597711|Active Comparator|IVCannulation 26G safety cannula|Peripheral Intravenous cannulation using 26G safety cannula
2396318|NCT03597711|Active Comparator|IVCannulation 24G safety cannula|Peripheral Intravenous cannulation using 24G safety cannula
2396319|NCT03597659||BioVU-Emerge EHR cohort|"A primary EHR population derived from the eMERGE Phase I & II Network (n=16,924), a consortium of medical centers using EHRs as a tool for genomic research, and from Vanderbilt University Medical Center's (VUMC) BioVU resource (n=20,230).~BioVU is VUMC's de-identified collection of patients whose DNA was extracted from discarded blood and linked to phenotypes through a de-identified EHR.~All subjects were born prior to 1990 and fell within 4 standard deviations for each of the first 2 principal components based on common single nucleotide variants (SNVs) for the subset of subjects self-identified as White, non-Hispanic."
2396320|NCT03597646|Experimental|Kinesio Taping|Kinesio Taping group consisted of 19 patients. Kinesio Tape was applied 2 times a week for a period of 4 weeks. Kinesio Taping was applied for musculus diaphragmaticus, musculus externus obliquus abdominis and internus obliquus abdominis.
2396321|NCT03597646|Active Comparator|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT) group consisted of 19 patients. IMT sessions were applied 2 sessions/everyday for a period of 4 weeks and 15 minutes for each session. Every session patients performed 5 breathing circles, then rested and continued again. By this way they used the device for 15 minutes each session. The patients visited the clinic every week and the therapist adjusted the IMT device in terms of their maximal inspiratory pressures.
2396322|NCT03597646|No Intervention|Control|Control group also consisted of 19 CHF patients. No interventions were applied for them. Pharmacological treatment of control group continued and they were advised for using their medication properly.
2396323|NCT03597620|Experimental|Patients with plaque psoriasis 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions.
2396324|NCT03597620|Experimental|Patients with stable dose of biologic treatment & 3-10% BSA|Metaderm cream will be applied topically twice a day to all active lesions. The metaderm scalp spray will be applied daily to the affected areas on the scalp.
2396325|NCT03597620|Experimental|Patients with Scalp Psoriasis|For the subgroup for scalp psoriasis, patient will use the shampoo Head & Shoulders formula with 1% Pyrithione Zinc as the active ingredient
2396326|NCT03597607|Experimental|Intensive Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have session ranging from 15 mins to 1 hour. Follow-up sessions will occur during quit week(week 1) and at weeks 2, 3, 4, 6, 8, 10, 12 and at 6 months.
2396327|NCT03597607|Experimental|Abbreviated Smoking Cessation Group|This group will meet with a clinic pharmacist one on one over a period of about 12 weeks. They will have brief sessions (15-30 mins) at the end of week 1, week 4, week 12 and at 6 months.
2396328|NCT03597607|No Intervention|Usual care group|The usual care group will be given a package of independent resources that could aid them to quit smoking on their own. They will not receive intervention by a clinic pharmacist.
2396329|NCT03597594|Active Comparator|TCRα/β/CD19-depleted SCT|"A preparative regimen based on the type of SCID will be given followed by infusion of donor cells. Cells for infusion are prepared using the CliniMACS System~Regimen 1 - IL2RG, JAK 3 (Haplocompatible) and all MSD~ATG (rabbit) IV Days -9 -8 and -7, Rest Days -6 and -5, Busulfan IV Days -4, -3, and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 2 - RAG1, RAG2 (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan IV Days -5, -4 and -3, Thiotepa IV twice daily, Day -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0~Regimen 3 - ADA, IL7R, CD45 deficiency, CD3 subunits (Haplocompatible)~ATG (rabbit) IV Days -9 -8 and -7, Fludarabine IV Days -7, -6, -5 and -4, Busulfan: IV Days -4, -3 and -2, Rest Day -1, TCRα/β/CD19-depleted SCT, Day 0"
2396330|NCT03597594|Experimental|Donor Lymphocyte Infusions|"Phase I:~On the Phase I portion of the study, up to 4 different dose levels will be evaluated: Dose level -1, Dose ≥0.1 to ≤0.3; Dose level 1, Dose >0.3 to ≤0.56; Dose level 2, Dose >0.56 to ≤1.8; Dose level 3, Dose >1.80 to ≤3.0~Dosing is determined based on the number of CD3+CD45RA-cells/kg and the patient weight in kilograms.~Phase II:~Participants will receive the Phase I determined maximum tolerated dose (MTD) of DLI.~Cells for infusion are prepared using the CliniMACS System."
3143433|NCT00006102|Experimental|Arm I|"Patients with solid tumors are stratified according to tumor histology (neuroblastoma vs Ewing's sarcoma [closed to accrual as of 5/19/03]/peripheral primative neuroectodermal tumor [PNET] vs osteosarcoma [closed to accrual as of 5/19/03] vs rhabdomyosarcoma vs non-Hodgkin's lymphoma vs other solid tumors). Patients with CNS tumors are stratified according to tumor histology (medulloblastoma/PNET vs ependymoma vs brainstem glioma vs other CNS tumors).~Patients receive rebeccamycin analogue IV over 1 hour on day 1. Treatment continues every 21 days for a total of 16 courses in the absence of disease progression or unacceptable toxicity."
3143434|NCT00006103|Experimental|irinotecan + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
3184266|NCT00722501|Active Comparator|ERB-257|7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
2396335|NCT03597568|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
3184267|NCT00722501|Placebo Comparator|placebo|2 placebo subjects per group
3184268|NCT00722514|Experimental|IG|Patient education
2396336|NCT03597555|Experimental|Xyrem|"Xyrem (Sodium Oxybate), oral solution 500mg/mL First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
2396337|NCT03597555|Placebo Comparator|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
2396338|NCT03597542|Experimental|Maltodextrin|Participants will consume 56g of maltodextrin dissolved in 500mL of water.
2396339|NCT03597542|Experimental|Egg|Participants will consume 36g of spray-dried egg powder (equivalent to 3 eggs) dissolved in 500mL of water.
2396342|NCT03597516|Experimental|RP-G28|galacto-oligosaccharide, spray-dried powder for reconstitution for oral administration, 7.5 grams 2 times per day
2396343|NCT03597516|Placebo Comparator|Placebos|maltodextrin, powder for reconstitution for oral administration, 7.5 grams 2 times per day
2396344|NCT03597503|Experimental|Flexible dose of SPN-810|Subjects will be treated with flexible dose of SPN-810
2396345|NCT03597503|Placebo Comparator|Placebo|Subjects will be treated with Placebo
2396346|NCT03597490||Partial thickness rotator cuff tear|Patients with symptomatic non-traumatic partial thickness rotator cuff tear treated with multimodal physical therapy with exercise
2396347|NCT03597477||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
2396348|NCT03597477||Control|Patients with no developmental diagnoses
3143435|NCT00006105|Experimental|Administration of Cisplatin, Gemcitabine, and Amifostine|Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
3143436|NCT00006107|Experimental|Taxotere|"Taxotere: (1 hour infusion once a week for four weeks)~Radiation Therapy (5 days/week for 6-7 weeks)~Surgery (if required) 14 -12 weeks after radiotherapy~Follow-up"
2396351|NCT03597451||Multiple sclerosis|Patients with MS between 0-5,5 score according to the Extended Disability Status Scale (EDSS)
2396352|NCT03597451||Control|Healthy individuals of similar age and sex to patients
2396353|NCT03597438||Patient|patients scheduled for elective surgery who are patients either as an inpatient or arriving to the hospital on the day of scheduled surgery
2396354|NCT03597438||Volunteer|Volunteers who are employees, trainees and students at the Children's Hospital of Philadelphia (CHOP) will be introduced to the study via an informational study flyer to determine eligibility and desire to participate in the study
2396355|NCT03597412|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
2396356|NCT03597412|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
2396357|NCT03597386||All Participants|
2396358|NCT03597373||reintubation|Reestablish of invasive mechanical ventilation
2396359|NCT03597373||not reintubation|Favourable respiratory function
2396360|NCT03597360|Experimental|CT scan subjects|Three participants with severe Alzheimer's dementia will be studied
3143437|NCT00006111|Experimental|resectable disease|
3143438|NCT00006111|Experimental|unresectable disease|
3143439|NCT00006124|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily.
2396364|NCT03597334||critical ill patients|critical ill patients who admit to ICU
2396365|NCT03597321|Experimental|Arm A-DLI|Patients will be planned to receive prophylactic Donor Lymphocyte Injection
2396366|NCT03597321|No Intervention|Arm B- No intervention|
2396367|NCT03597308|Active Comparator|Opioid Group|
2396368|NCT03597308|Active Comparator|NSAID group|
2396369|NCT03597308|Active Comparator|Acetaminophen|
2396371|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously.
2396372|NCT03597282|Experimental|Nivolumab + adjuvant|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive Poly-ICLC (adjuvant) administered subcutaneously.
2396373|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab on alternate schedule|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant, administered on an alternative schedule, subcutaneously.
2396374|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive APX005M at a dose of 0.1 mg/kg administered by IV infusion at Week 12, Week 15, and Week 19.
2396375|NCT03597282|Experimental|Nivolumab + APX005M|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, Week 15, and Week 19, all patients, regardless of their disease status, will receive APX005M at a dose of 0.1 mg/kg administered by IV infusion.
2396413|NCT03597048|No Intervention|No intervention|Participants received no intervention
3143440|NCT00006124|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo twice daily.
3143441|NCT00006125|Experimental|Doxorubicin + topotecan|"Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression.~Patients are followed every 6 months for 2 years and annually for the next 3 years."
2396376|NCT03597282|Experimental|NEO-PV-01 + adjuvant + nivolumab + ipilimumab|Nivolumab at a dose of 240 mg administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously. Patients on this arm will also receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion at Week 12 and Week 19.
2396377|NCT03597282|Experimental|Nivolumab + ipilimumab|Nivolumab at a dose of 240 mg will be administered by intravenous infusion (IV) every 2 weeks throughout the study. At Week 12 and Week 19, all patients, regardless of their disease status, will receive ipilimumab at a dose of 1.0 mg/kg administered by IV infusion.
2396378|NCT03597256|Experimental|Treatment Group|Single injection and optional touch-up injection with Restylane Defyne in chin
2396379|NCT03597256|No Intervention|Control Group|No treatment
2396380|NCT03597243|Experimental|Intervention|AGYW in the standard Sauti cash transfer (Arm I) will receive unconditional cash transfer (UCT) in the presence of behavioral and biomedical interventions in quarterly installments of 70,000 TSH. The first installment will take place after completion of 10 hours of BCC sessions and the AGYW has registered into CTP.
2396381|NCT03597243|No Intervention|Control|AGYW in the control group (Arm II) will not receive cash payment but will receive behavioral and biomedical interventions. The behavioral and biomedical interventions are provided by Sauti program to all project beneficiaries.
2396382|NCT03597230|Experimental|patients operated on for pancreatic resection|All consecutive patients operated on for pancreatic resection
2396383|NCT03597217|Experimental|Cohort A_Active|3 single doses treatment of PF-05221304
2396384|NCT03597217|Experimental|Cohort B_Active|Repeated doses of PF-05221304
2396385|NCT03597217|Placebo Comparator|Cohort B_Placebo|Repeated doses of placebo
2396386|NCT03597204|Other|fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
2396387|NCT03597191|Experimental|Spinal Stabilization Exercise Program|"Participants in the spinal stabilization exercise group will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) abdominal bracing, (b) quadruped, (c) prone plank, and (d) side plank exercises. Each exercise will be progressed and advanced in difficulty by increasing repetitions, hold times, and/or extremity movements.~The progression of exercises will be based on the participants' performance at each supervised physical therapy session based on pre-established criteria by Hicks et al. (2005)."
2396388|NCT03597191|Placebo Comparator|General Exercises Program|Participants in the general exercise group will perform a range of motion (ROM) and flexibility exercises of low back and lower extremities. Each participant will be instructed to perform four exercises in total, one exercise from each of the following four categories: (a) knee to chest, (b) lower trunk rotation, (c) prone press-ups, and (d) hamstring stretch exercises. These exercises will be progressed by increasing repetitions and pain-free ROM.
3184269|NCT00722514|Other|CG|without patient education
2396390|NCT03597165|Experimental|Incidental Genomic Sequencing Results|"Patients in Intervention will receive GS results related to primary indication (cancer) and will be offered the option learning their incidental results, categorized into five bins based on a framework by Berg et al."
2396391|NCT03597165|Active Comparator|Primary Indication only|Patients in the control will receive the intervention GS results for Primary Indications only.
2396392|NCT03597152|Experimental|Treatment|WelTract
2396393|NCT03597152|Placebo Comparator|Control|Inert Placebo
3184270|NCT00722527||Affected Population|Subjects with an elevated hemoglobin concentration or an elevated platelet count
3184271|NCT00722540|Experimental|A|
2396398|NCT03597100|Experimental|Cala TWO|Two 40-minute stimulation sessions daily, separated by at least two hours
2396399|NCT03597087|Experimental|General anesthesia|Group of general anesthesia before transurethral resection of the bladder tumor anesthesia: propopol
2396400|NCT03597087|Experimental|Spinal anesthesia|Group of spinal anesthesia before transurethral resection of the bladder tumor anesthesia: bupibacaine
2396401|NCT03597074||1|Patients without AKI progression Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
2396402|NCT03597074||2|Patients with Transient AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
2396403|NCT03597074||3|Patients with Persistent AKI Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
3184272|NCT00722540|Experimental|B|
3184273|NCT00722540|Experimental|C|
2396406|NCT03597048|Experimental|Curriculum|Participants received only the curriculum intervention
2396407|NCT03597048|Active Comparator|Contact|Participants received only the contact intervention
2396408|NCT03597048|Active Comparator|Materials|Participants received only the materials intervention
2396409|NCT03597048|Experimental|Curriculum and Contact|Participants received both curriculum and contact interventions
2396410|NCT03597048|Experimental|Curriculum and Materials|Participants received curriculum and materials interventions
2396411|NCT03597048|Active Comparator|Contact and Materials|Participants received contact and materials intervention
2396412|NCT03597048|Active Comparator|Curriculum, Contact and Materials|Participants received curriculum, contact and materials interventions
3184274|NCT00722540|Experimental|D|
3184275|NCT00722540|Experimental|E|
3184276|NCT00722579|Experimental|A|The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
3184277|NCT00722592|Experimental|Vintafolide + PLD|Participants receive vintafolide 2.5 mg intravenous (IV) bolus on Days 1, 3, 5, 15, 17, and 19 and Pegylated Liposomal Doxorubicin (PLD) weight-based dose, IV on Day 1 of each 4-week cycle.
3184278|NCT00722592|Active Comparator|PLD Alone|Participants receive PLD on Day 1 of each 4-week cycle.
3184279|NCT00722605|Experimental|1|cone-beam CT based
2396419|NCT03596996|Experimental|Ferrous Sulfate|Children 6 to 23 months of age will receive a tablet that contains the equivalent of 12.5 mg of elemental iron. Children over 24 months will receive a tablet that contains the equivalent of 30 mg of elemental iron.
2396420|NCT03596996|Placebo Comparator|Placebo|
2396421|NCT03596983|Experimental|Short Sleep Patients|
2396422|NCT03596970|Experimental|Everolimus with MMF (TAC-withdrawal)|Everolimus (RAD001) with MMF and Steroids
2396423|NCT03596970|Active Comparator|Everolimus with reduced TAC|Everolimus (RAD001) with reduced TAC and Steroids
2396424|NCT03596957|Active Comparator|Tolvaptan group|Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication
2396425|NCT03596957|No Intervention|Control group|No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group
2396426|NCT03596944||Statin|History of statin use for primary prevention
2396427|NCT03596944||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
2396428|NCT03596931||Statin|History of statin use prior to Acute Coronary Syndrome
2396429|NCT03596931||Non-Statin|No documented history of statin use prior to Acute Coronary Syndrome
2396430|NCT03596918|Experimental|Supportive care (vincristine sulfate, bleomycin sulfate)|Patients receive vincristine sulfate IV over 1-2 minutes and bleomycin sulfate IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2396431|NCT03596905|Experimental|0.5 mg plecanatide|Plecanatide 0.5 mg Taken orally once daily for 4 weeks Group A: 6 to 11 years old
2396432|NCT03596905|Experimental|1.0 mg plecanatide|Plecanatide 1.0 mg Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
2396433|NCT03596905|Experimental|2.0 mg plecanatide|Plecanatide 2.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
2396434|NCT03596905|Experimental|3.0 mg plecanatide|Plecanatide 3.0 mg Taken orally daily for 4 weeks Group B: 12 to < 18 years old
2396435|NCT03596905|Placebo Comparator|Matching placebo|Matching placebo Taken orally daily for 4 weeks Group A: 6 to 11 years old Group B: 12 to < 18 years old
2396436|NCT03596892|Experimental|Decitabine + BUCY|For MLL+ acute leukemia undergoing allo-HSCT，Decitabine+BUCY conditioning regimen was Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2396437|NCT03596892|Active Comparator|BUCY|For MLL+ acute leukemia undergoing allo-HSCT，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2396438|NCT03596879|Experimental|dCBTI|Online access to the digital CBTI program Sleepio.
2396439|NCT03596879|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations.
3143444|NCT00006154|Experimental|A|Patients will receive combination antiretroviral therapy with a protease inhibitor
3143445|NCT00006154|Active Comparator|B|Patients will receive combination antiretroviral therapy without a protease inhibitor
2396442|NCT03596853|Experimental|Experimental: Mobilization|These patients will receive standard rehabilitation delivered by non-study physiotherapist. In addition, the patients will undergo a protocol of progressive mobilization with individualized dose control and training load stratified according to functional levels and performance.
2396443|NCT03596853|Sham Comparator|Control: Usual care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
2396444|NCT03596827|Active Comparator|1E10 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2396445|NCT03596827|Experimental|1E9 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E9 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2396446|NCT03596827|Experimental|1E8 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E8 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2396447|NCT03596827|Experimental|1E7 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E7 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2396448|NCT03596827|Experimental|1E6 CFU Escherichia coli (E. coli)|At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E6 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli.
2396449|NCT03596801|Experimental|Group 1: RSV 6120/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^6.0 plaque-forming units (PFUs) of RSV 6120/∆NS1 vaccine at Day 0.
2396450|NCT03596801|Experimental|Group 1: RSV 6120/F1/G2/∆NS1 Vaccine|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of 10^5.8 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
2396557|NCT03595995|Experimental|Cohort 2|"Placebo (volume equivalent to 5 mg/kg UB-621)~5 mg/kg UB-621"
3143446|NCT00006172|Active Comparator|bright light box|60 min light therapy shortly after awakening
3143447|NCT00006172|Active Comparator|high-output negative ion generator|60 min high-density exposure shortly after awakening
3143448|NCT00006172|Placebo Comparator|low-output negative ion generator|60 min low-density exposure shortly after awakening
3143449|NCT00006205|Experimental|Ondansetron|Ondansetron + cognitive behavioral therapy
3143450|NCT00006205|Experimental|Topiramate|Topiramate + cognitive behavioral therapy
3143451|NCT00006205|Placebo Comparator|Placebo|Placebo + cognitive behavioral therapy
2396451|NCT03596801|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children greater than or equal to 12 months to less than 60 months will receive a single dose of placebo at Day 0.
2396452|NCT03596801|Experimental|Group 2: RSV 6120/∆NS1 Vaccine|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS1 vaccine at Day 0.
2396453|NCT03596801|Experimental|Group 2: RSV 6120/F1/G2/∆NS1|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of 10^5.0 PFUs of RSV 6120/F1/G2/∆NS1 vaccine at Day 0.
2396454|NCT03596801|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children greater than or equal to 6 months to less than 25 months will receive a single dose of placebo at Day 0.
2396455|NCT03596788|Experimental|Carbohydrate Beverage|A glucose-fructose beverage mixture supplying 100 grams of carbohydrate per day for 5 days
2396456|NCT03596788|Placebo Comparator|Placebo Beverage|An artificially-sweetened beverage containing aspartame
2396457|NCT03596775|Experimental|Dexmedetomidine group|the children received 0.5 μg/kg of intravenous dexmedetomidine over 10 minutes after induction of anesthesia
2396458|NCT03596775|Placebo Comparator|Control Comparator group|the children received 10ml saline over 10 minutes after induction of anesthesia
2396459|NCT03596762|Experimental|160 mg BAY3427080|
2396460|NCT03596762|Experimental|120 mg BAY3427080|
2396461|NCT03596762|Experimental|80 mg BAY3427080|
2396462|NCT03596762|Experimental|40 mg BAY3427080|
2396463|NCT03596762|Placebo Comparator|Placebo|
2396464|NCT03596749|Experimental|Sevelamer Carbonate|Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals
2396465|NCT03596749|No Intervention|Control|blank-control
2396466|NCT03596736|Experimental|Elbow Hemiarthroplasty|
2396467|NCT03596736|Active Comparator|Total Elbow Arthroplasty|
2396470|NCT03596710|Experimental|Diagnostic (image-guided biopsy)|Participants undergo image-guided biopsy over 45 minutes prior to first RLT course and 1-2 days after the third RLT course.
3143452|NCT00006205|Experimental|Ondansetron + Topiramate|Ondansetron + Topiramate + cognitive behavioral therapy
3143453|NCT00006213|Experimental|Treatment (BMS-214662)|Patients receive BMS-214662 IV over 1 hour weekly for 4 weeks. Treatment continues every 4 weeks for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
3143454|NCT00006214|Experimental|flutamide|"Patients receive oral flutamide once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
2396474|NCT03596684|Experimental|citrulline|citrulline 5g/d
2396475|NCT03596684|Placebo Comparator|Placebo|pure mixture of amino acids: alanine, aspartate, glycine, proline, serine, histidine
3143455|NCT00006214|Other|placebo|"Patients receive an oral placebo once daily.~Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before study, at 1, 6, and 12 months, and then annually therafter. Patients are followed annually for up to 10 years."
2396477|NCT03596658|Experimental|SHR9549 dose escalation and expansion(s)|Escalating dose of SHR9549 with intensive safety monitoring to ensure the safety of patients
3143456|NCT00006220|Experimental|Phase I|Starting dose of arsenic trioxide of 0.15 mg/kg/day
3143457|NCT00006220|Experimental|Phase II|MTD of arsenic trioxide
2396480|NCT03596632|Experimental|Single Oral Solution Dose|Single 200-mg (approximately 100-µCi) oral solution dose of [14C/12C]-fenebrutinib under fasted conditions.
2396481|NCT03596619|Experimental|PBN-ALA-PDT Group|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2).
2396482|NCT03596619|No Intervention|ALA-PDT Group|The ALA-PDT group received ALA cream and irradiation only.
2396483|NCT03596606|Experimental|Myofunctional Motor Control Exercises|"Both groups will be treated with Osteopathic treatment and in one of them the myofunctional motor control treatment will be added as intervention. The experimental group will be the one that will receive the combined treatment.~The patient will receive five sessions, one session every week."
2396484|NCT03596606|Active Comparator|Osteopathic Treatment|The control group will receive only osteopathic treatment (TO). The patient will receive five sessions, one session every week.
2396485|NCT03596593|Experimental|Experimental group|A total of 8-10 mL of blood will be collected from this group of patients and used for blood-MSI testing.
2396486|NCT03596580||Dehydrated participants|125 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity ≥ 296 mOsm/L
2396487|NCT03596580||Hydrated participants|97 participants ≥ 65 years of age at the moment of the interviews; hospitalized in General Medicine; osmolarity < 296 mOsm/L
2396488|NCT03596567|Experimental|Normal Renal Function Group|Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
2396489|NCT03596567|Experimental|Moderate Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
2396490|NCT03596567|Experimental|Severe Renal Impairment Group|Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
2396491|NCT03596541|Experimental|An open real-time tele-stethoscopy system|EHAS-Fundatel digital stethoscope is an open real-time tele-stethoscopy system. The interventions in this arm will be to make a respiratory and heart auscultation with this tele-stethoscope. After that, we will do the comparison or agreetment between the auscultation of two protocols: tele-stethoscopy system and conventional stethoscope.
2396492|NCT03596541|Active Comparator|Conventional stethoscope|Conventional stethoscope used is the 3M Littmann Classic II S.E. stethoscope. The interventions in this arm will be to make a respiratory and heart auscultation with this conventional stethoscope. After that we will do the comparison or agreetment between the ascultation of two protocols: conventional stethoscope and tele-stethoscopy system.
2396493|NCT03596528|Other|Lung biopsy|Lung biopsy
2396494|NCT03596515|Experimental|Received sensory integration therapy|Participants in the experimental group received 16 sessions (45 minutes each) of individualized Ayres Sensory Integration intervention.
2396495|NCT03596515|No Intervention|Waitlist control group|Participants in the control group received Ayres Sensory Integration according to the usual clinical scheduling. It is after the post- assessment outcome at the same time of the experimental group.
2396496|NCT03596502||Direct oral anticoagulants (DOACs)|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with a DOAC (apixaban, dabigatran or rivaroxaban) at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2396497|NCT03596502||Warfarin|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with warfarin at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2396498|NCT03596476|Experimental|Patients with persistent GERD|Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI
2396499|NCT03596463||Group A|Patients treated according to suggestions of tumor board
2396500|NCT03596463||Group B|Patients not treated according to suggestions of tumor board
3143458|NCT00006220|Experimental|Treatment Failure|Arsenic trioxide and tretinoin
3143459|NCT00006221|Experimental|Arm I|"Patients receive BMS-247550 IV over 1 hour once weekly on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose level. Patients treated at the MTD receive treatment once weekly on weeks 1-3 of each 4-week course."
2396503|NCT03596437|Experimental|Ehlers-Danlos Syndrome|Intima-media thickness by ultrahigh frequency vs standard ultrasound
2396504|NCT03596437|Experimental|Fibromuscular Dysplasia|Triple signal by ultrahigh frequency vs standard ultrasound
2396505|NCT03596424|Active Comparator|Ketamine hydrochloride|Intraoperative bolus (0.25 mg/kg) and infusion (0.25mg/kg/h) of ketamine plus an intraoperative bolus (over 20 min) and infusion of normal saline;
2396506|NCT03596424|Active Comparator|dexmedetomidine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5µg/kg/h) of dexmedetomidine plus an intraoperative bolus and infusion of normal saline
2396507|NCT03596424|Active Comparator|dexmedetomidine hydrochloride and ketamine hydrochloride|Intraoperative bolus (1µg/kg over 20 min) and infusion (0.5 µg/g/h) of dexmedetomidine plus an intraoperative bolus (0.25mg/kg) and infusion (0.25mg/kg/h) of ketamine
2396508|NCT03596398||Young stroke|Patients with acute stroke aged 20 or over, and under 56 years old (Not included 56) .
2396509|NCT03596385|Experimental|Beta-blocker therapy|"This is a strategy (pragmatic) trial. In patients allocated to Beta-blocker therapy, beta blocker agent and dose are decided by treating physician.~betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol"
2396510|NCT03596385|No Intervention|Control (no beta-blocker therapy).|Do not receive beta -blocker therapy
2396511|NCT03596372|Experimental|Patients with Solid tumors|Dose escalation with patients having solid tumors. Patients receive escalating doses of BAY1834942 intravenously for 1 hour on Day 1 of each 21-day cycle (Q3W). If the Q3W scheme does not result in sufficient exposure, the scheme is replaced with an once-weekly (QW) dosing scheme.
2396512|NCT03596372|Experimental|Patients with Gastric cancer|"Expansion with patients having gastric and/or gastroesophageal adenocarcinoma:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
2396513|NCT03596372|Experimental|Patients with Colorectal cancer|"Expansion with patients having colorectal cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
2396514|NCT03596372|Experimental|Patients with Non-small-cell-lung cancer|"Expansion with patients having adeno Non-small-cell-lung cancer:~Patients receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part."
2396515|NCT03596372|Experimental|Low-dose expansion|Expansion with patients having the same cancer type (gastric cancer, or colorectal cancer, or non-small-cell lung cancer) and receive BAY1834942 intravenously for 1 hour according to dosing scheme decided in escalation part with a dose lower than the maximum tolerated dose (MTD).
2396516|NCT03596359|Experimental|Test group|Self-care behaviors training with Teach-Back method within 15 to 45 minutes was done on the Test group
2396517|NCT03596359|Active Comparator|Control group|The control group received routine treatment
2396518|NCT03596346|Active Comparator|Test group|20 g of rapeseed ingredient (RI) daily
2396519|NCT03596346|Placebo Comparator|Control group|0 g of rapeseed ingredient (RI) daily
2396520|NCT03596307|Experimental|Ashwagandha extract|180 mg Shoden once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
2396521|NCT03596307|Placebo Comparator|Placebo|180 mg identical placebo once daily before breakfast for 2 days in Acute Phase and 16 days in Short Term Phase.
2396522|NCT03596294|Experimental|Treatment sequence AB|"Period A:~Saline + clazosentan~Period B:~Rifampicin + clazosentan"
2396523|NCT03596294|Experimental|Treatment sequence BA|"Period B:~Rifampicin + clazosentan~Period A:~Saline + clazosentan"
2396524|NCT03596281|Experimental|Cohort A|
2396525|NCT03596281|Experimental|Cohort B|
2396526|NCT03596268||Persons Living with HIV (PLWH)|Persons 20-80 years old with a documented HIV infection for at least 1 year, who are on a stable cART medication regimen for at least 1 year, and have an undetectable plasma HIV RNA (<50 copies/ml).
2396527|NCT03596268||HIV- Controls|Persons 20-80 years old with confirmed HIV- status matched to PLWH cohort with similar age, sex, education, and race.
2396528|NCT03596255||Patients|All public dental clinics in the region of Östergötland, Sweden, were asked to consecutively recruit adult patients returning for their annual examination
2396529|NCT03596255||Dental personnel|All public dental clinics in the region of Östergötland, Sweden were contacted and asked to participate in the study
3184280|NCT00722618|Active Comparator|Intervention|Written materials, telephone based education
2397195|NCT03591692|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
3184281|NCT00722618|Other|Comparison|Written materials
3143460|NCT00006222|Experimental|Arm I|Patients receive EMD 121974 IV twice a week for four weeks. Courses repeat every 4 weeks in the absence of disease progression. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicities.
2396532|NCT03596216|Experimental|Percutaneous Electrial Stimulation (PES group).|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA) and then, a needle (0.30mm x 0.40mm) was inserted, perpendicular to the surface of the skin, until the muscle belly. Prior to inserting a neddle, the underlying skin was cleaned with isopropyl alcohol. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min acording to the Valera and Minaya protocol´s.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
2396533|NCT03596216|Experimental|Transcutaneous Electrial Stimulation (TENS group)|"This intervention consisted in the application of an asymmetric biphasic rectangular current. The subject lay prone with her feet outside the table. The FHL muscle was located at 50% of the distance between the fibular head and inferior border of the lateral malleolus on the posterior aspect of the fibular by ultrasound machine (cross-section) (Logiq, GE Healthcare, USA),and then, one self-adhesive electrode was placed on the back of the leg and the other on the sole of the foot. The intensity of the current was necessary to cause an exacerbated muscle contraction, during 1.5 min.~This intervention was performed once in each participant, on one leg only (stance limb), It's only once, it was not a treatment"
2396534|NCT03596203|Experimental|Treatment group|
2396535|NCT03596190|Other|Assessment arm|
3184282|NCT00722631|Experimental|1|up to 30 mg pioglitazone, tablet, orally, once daily
3184283|NCT00722631|Active Comparator|2|up to 4 mg/day glimepiride, tablet, orally, once daily
3184284|NCT00722670|Experimental|Woman-focused (WF)|Woman-focused intervention (Women's CoOp)
2396540|NCT03596125|Experimental|N-acetylcysteine (NAC)|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
2396541|NCT03596125|Placebo Comparator|Placebo|"High risk of prematurity: 9g intravenously then 6g (per os) a day until day 7, then 1,8g (per os) a day until 37 weeks of gestational age.~Moderate risk of prematurity: 6g (per os) a day until day 7 then 1,8g ( per os) a day until 37 weeks of gestational age."
2396542|NCT03596112|Experimental|polyacrylate wound pad|Use of cellulose and distinct layers of sodium-polyacrylate pad for wound care; frequency: twice a week
2396543|NCT03596112|Active Comparator|hydrocellular foam pad|Use of standard foam pad for wound care; frequency: twice a week
2396544|NCT03596099|Experimental|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
2396545|NCT03596099|Placebo Comparator|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
2396546|NCT03596086|Experimental|ADV/HSV-tk (gene therapy)|"The gene therapy investigational product, HSV-tk will be injected during the surgery. Within 24 hours valacyclovir will be given for 14 days. Radiotherapy will be administered over 10 sessions (over 2 weeks) starting within 9 days of surgery. Standard of care/routine chemotherapy will be started concurrent or after completion of the radiotherapy dependent on patient status based on best clinical judgment.~Patient can receive second treatment of HSV-tk after 6 months"
3143461|NCT00006226|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide daily for 4 weeks. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3143462|NCT00006228|Experimental|Treatment (trastuzumab and aldesleukin)|Patients receive trastuzumab IV over 30-90 minutes on days 1 and 8 and aldesleukin SC on days 2-7 and 9-21. Beginning on day 22, patients receive trastuzumab IV over 30 minutes every 14 days. Patients also receive aldesleukin SC daily on days 1-14. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
2396549|NCT03596060|Active Comparator|General anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will be randomly assigned to undertake surgery under general anesthesia in the first 48 hours. Anesthetics to be used are propofol, fentanyl and rocuronium. Maintenance will be achieved with remifentanyl and propofol (TIVA) and the depth of anesthesia will be monitored by BIS. Morphine will be administered bolus IV immediately postoperatively.
2396550|NCT03596060|Active Comparator|Regional anesthesia|Hip fracture patients older or equal to 65 years of age, who receive clopidogrel, will will be randomly assigned undertake surgery under regional anesthesia (spinal) at least 5 days after the discontinuation of clopidogrel. Anesthetics to be used are chirochaine 0.5% and fentanyl.
2396551|NCT03596047|Experimental|Standard treatment + Radial wave therapy|Sildenafil according to the degree of patient involvement + 6 sessions of radial waves.
2396552|NCT03596047|Placebo Comparator|Standard treatment + Placebo therapy|Sildenafil according to the patient's degree of affectation + 6 sessions of placebo therapy.
2396553|NCT03596034|Experimental|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and combustibles per day (CPD) throughout the 15 day product use period.
2396554|NCT03596008|Experimental|Active1|freeze-dried strawberry powder (25 g) in active drink
2396555|NCT03596008|Placebo Comparator|Placebo|Placebo drink
2396556|NCT03595995|Experimental|Cohort 1|"Placebo (volume equivalent to 2.5 mg/kg UB-621)~2.5 mg/kg UB-621"
3143463|NCT00006229|Experimental|BMS-275291|
3143464|NCT00006229|Placebo Comparator|Placebo|
2396558|NCT03595982|Experimental|Procardia XL 30 mg|Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
2396559|NCT03595982|Active Comparator|Procardia XL 60 mg|Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.
2396560|NCT03595969||acute leukemia group|150 patients were recruited, who have diagnosed with acute leukemia by bone marrow biopsy
2396561|NCT03595969||Control group|The 50 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2396562|NCT03595956||Medical Gender Affirmation (MGA) Cohort|Patients engaged in gender-affirming care.
2396563|NCT03595943|Experimental|Low glycemic index diet|Low glycemic index pulse-based diet (i.e. beans, peas, lentils, chickpeas)
2396564|NCT03595943|Active Comparator|Regular hospital diet|Moderate glycemic index diet based on hospital menus
2396565|NCT03595930||Subjects who received ARNUITY|This PMS will be conducted with subjects who were administered ARNUITY in accordance with the approved label.
3184285|NCT00722670|Active Comparator|Treatment as Usual (TAU)|TAU (substance abuse treatment only)
3184286|NCT00722683|Experimental|Ultrasound Imaging|Ultrasound Imaging with Contrast
3184287|NCT00722709|Experimental|LA|Use of Ropivacaine
2396569|NCT03595891||Adult with acute PE before the introduction of apixaban|
2396570|NCT03595891||Adult with acute PE after the introduction of apixaban|
3184288|NCT00722709|Placebo Comparator|Placebo|Use of 0.9% saline
3184289|NCT00722735|Experimental|1|Group I: Finafloxacin tablets + Ciprofloxacin placebo capsule
3184290|NCT00722735|Active Comparator|2|Group II: Ciprofloxacin capsule + Finafloxacin placebo tablets
2396574|NCT03595865|Experimental|residual primary open angle glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
2396575|NCT03595865|Experimental|residual primary angle-closure glaucoma|Each eye will be preformed tafluprostin 0.0015% at 9 PM, 1 time daily for 6months
2396576|NCT03595852|Experimental|Prophylaxis|The intervention will be a single dose of prophylactic antibiotic (cefazolin): 2 gr in adults or 3 gr for patients weighing >120Kg or 30mg/kg in children given within 30-60 minutes prior to skin incision.
2396577|NCT03595852|Placebo Comparator|No prophylaxis|The control group will receive a similarly looking prepared placebo injection (normal saline placebos for injection) 30-60 minutes prior to incision.
2396578|NCT03595839|Active Comparator|Fistulotomy with Marsupialization|Lay open and Marsupialization of the fistula track
2396579|NCT03595839|Active Comparator|Fistulotomy without Marsupialization|lay open of the fistula track
2396580|NCT03595826|Experimental|1. Neurostimulant pharmaceutical drugs..|1.Participants receiving medicinal drugs, such as methylphenidate/Ritalin, administered by a medical practitioner, in dosages prescribed by the practitioner, to suit the child.
2396581|NCT03595826|Experimental|2. Exercise Intervention|Participants receiving a minimum of 8 sessions of exercise intervention, for the duration of an hour each session. Exercises will be to build muscle tone, improve core stability, enhance balance, improve fine and gross motor skills and visual motor integration.
2396582|NCT03595826|Experimental|3. Neurostimulants + Exercise intervention|See Arms 1 and 2 above. Both interventions administered together: Pharmaceutical drugs plus exercise intervention
2396583|NCT03595826|Experimental|4. Control Group|Participants will not receive any intervention during the research process. They will be given an intervention after the research is completed.
2396584|NCT03595813|Experimental|Patients treated with Immune Checkpoint Blockade|
2396585|NCT03595800|Experimental|haploidentical related donors|
2396586|NCT03595800|Active Comparator|Matched unrelated donor|
2396587|NCT03595787|Experimental|Prehabilitation program|Program based on nutritional support, physical activity program and coaching. Home-based monitoring will be done thanks to connected watches (step counter pedometer) and a connected body fat weight scale
2396588|NCT03595774|Placebo Comparator|Placebo|3.3 mL/kg concentrated beet root juice *depleted of nitrate* Other names: Beet It Sport Nitrate 400 placebo
2396589|NCT03595774|Active Comparator|low nitrate|"1.55 mL/kg concentrated beet root juice depleted of nitrate + 1.55 mL/kg concentrated beet root juice *depleted of nitrate*~Other names: Beet It Sport Nitrate 400 placebo + Beet It Sport Nitrate 400"
2396590|NCT03595774|Active Comparator|high nitrate|"3.3 mL/kg concentrated beet root juice containing nitrate~Other names:Beet It Sport Nitrate 400"
2396591|NCT03595748|Experimental|Peer mentorship intervention|This arm of mentees will be assigned to weekly telephone calls with a matched mentor over a period of 3 months.
2396592|NCT03595748|No Intervention|Usual Care|This arm of mentees will not get a telephone intervention by an assigned mentee
2396593|NCT03595735|Experimental|Treatment Group|Receives treatment with the Zenflow Spring System
2396594|NCT03595722|Experimental|Early rectal cancer|Patients with early rectal cancer undergoing a treat and resect pathway - patients will be treated with high intensity focused ultrasound 7-10 days prior to the surgical resection of their rectal cancer
2396595|NCT03595722|Experimental|Late pelvic cancer|Patients with late pelvic (rectal, endometrial, cervical) cancer will undergo a treat and observe pathway - patients will be treated with high intensity focused ultrasound and their response will be observed
2396596|NCT03595709|Experimental|combined tablet (EFV 400,TDF 300, 3TC 300)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
2397252|NCT03591224|Placebo Comparator|Control|Pharmacist optimizing antidepressant therapy based on standard of care
3184291|NCT00722748||Genebank|By creating a genebank from patient's blood donations we will ultimately be able to define genes for various cardiovascular conditions.
3184292|NCT00722774|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
3184293|NCT00722839|Experimental|Group A|Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
2396597|NCT03595696|Experimental|Core Strengthening Exercise Intervention|All subjects will participate in the study for a total of 24 consecutive weeks. During the first 12 weeks, subjects will participate in weekly online exercise classes for Core Muscle Strength training and will be asked to perform daily homework assignments. Following completion of the 12-week intervention, subjects will be asked to continue the exercises on their own.
2396598|NCT03595696|Active Comparator|Control+Core Strengthening Exercise|All subjects will participate in the study for a total of 24 weeks. During the first 12 weeks, subjects will serve as the control group, and they will be advised to continue their baseline level of exercise and lifestyle. During the subsequent 12 weeks, subjects will participate in the exact same program as Group A performed during the first 12 weeks (Core Muscle Strength Training).
2396599|NCT03595683|Experimental|Cohort 1: Anti-PD1 naive|Participants that have not received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
2396600|NCT03595683|Experimental|Cohort 2: Anti-PD1 refractory|Participants that have received prior anti-PD1 therapy for their cancer will be enrolled to this arm.
2396601|NCT03595670||experimental group|"• Patients diagnosed bipolar in mania, depression or euthymic phases according DSM-IV critiera by psychiatrist~standardized questionnaires and interview will be performed"
2396602|NCT03595657|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks
2396603|NCT03595644|Experimental|SBRT plus TKI group|SBRT with photon and dose is 40-50Gy/5F after three months after EGFR-TKI treatment
2396604|NCT03595644|Active Comparator|TKI treatment group|Standard EGFR-TKI(Gefitinib, erlotinib or icotinib) Gefitinib: 250mg po Qd Erlotinib: 150mg po Qd Icotinib: 125mg po tid
2396605|NCT03595631|Active Comparator|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
2396606|NCT03595631|Experimental|Physical Therapy plus neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
2396611|NCT03595605|Experimental|FitBit Group|Will receive a wearable device (FitBit) designed to track number of steps for the duration of their hospital stay. They will receive nudges twice/day to ambulate
2396612|NCT03595605|Active Comparator|Control Group-Standard of Care|300 subjects who will receive usual standard of care on a general inpatient medicine unit with the addition of a wearable device (FitBit) to track usual mobility in this setting. will complete their admission without push for increased activity (although having the device may influence their steps taken).
3143465|NCT00006242|Experimental|Treatment (BMS-214662)|"Single patient cohorts receive BMS-214662 IV over escalating periods of 2, 4, 8, 16, and 24 hours weekly for 3 weeks followed by 1 week of rest. If no patient experiences DLT, dose escalation proceeds in the single patient cohorts.~Treatment repeats every 4 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Individual patient cohorts may increase their duration of BMS-214662 infusion in subsequent courses to the current duration safely reached.~Beginning with the infusion level at which DLT is first encountered by a single patient, cohorts of 3-6 patients receive escalating doses of BMS-214662 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. An additional cohort of 10 patients is treated at the MTD."
3143466|NCT00006243|Experimental|Arm I (vaccine therapy)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
3143467|NCT00006243|Experimental|Arm II (vaccine therapy and lower-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and lower-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
2396622|NCT03595540|Experimental|Prolon - FMD|Patients undergoing active cancer treatment are assigned monthly cycles of the fasting-mimicking diet Prolon
2396623|NCT03595527|Experimental|Patients consulting in the emergency room|Patients consulting in the emergency room.
2396624|NCT03595514|Active Comparator|Single Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
2396685|NCT03595137|Placebo Comparator|sono only group (Group S)|sono only group After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
2397253|NCT03591211|Experimental|Qigong Training|
3143468|NCT00006243|Experimental|Arm III (vaccine therapy and higher-dose sargramostim)|Patients receive tyrosinase peptide, MART-1:27-35 peptide vaccine, and gp100 antigen admixed in incomplete Freund's adjuvant SC and higher-dose sargramostim SC on day 1 of weeks 0, 3, 6, 9, 12, and 24.
3143469|NCT00006249|No Intervention|observation|5 years observation + 5 years follow up
3143470|NCT00006249|Experimental|pegylated interferon alfa|5 years pegylated interferon alfa + 5 years follow up
3143471|NCT00006251|Experimental|Treatment (fludarabine phosphate, TBI, PBSC transplant, DLI)|"CONDITIONING REGIMEN : Patients receive fludarabine phosphate IV on days - 4 to -2 and undergo low-dose TBI on day 0. (Note: Patients who have had an autologous transplant within 90 days prior to day 0 will not receive fludarabine phosphate.)~PBSC INFUSION: Patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 35 with a taper to day 56. Patients receive mycophenolate mofetil PO BID on days 0-27.~POST TRANSPLANT DLI: Patients with stable mixed chimerism on day 56, and without evidence of GVHD, undergo DLI IV over 30 minutes on day 65. Patients without a complete response, full donor chimerism, and GVHD after 2 months undergo further DLI at higher cell numbers. Up to 6 DLIs may be given 65 days apart."
3143472|NCT00006252|Experimental|Allogeneic Stem Cell Tx|minimal ablation and cellular immune therapy with allogeneic donor stem cell therapy
3143473|NCT00006253|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
2396625|NCT03595514|Experimental|Double Injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
2396626|NCT03595501||Hematology Analyzer - OLO|The investigational device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening capillary or venous whole blood samples.
2396627|NCT03595501||Hematology Analyzer - Predicate|The predicate device is a quantitative multi-parameter automated hematology analyzer intended for in vitro diagnostic use in screening patient populations found in clinical and reference laboratories.
2396628|NCT03595488|Experimental|Treatment arm|"Single-blinded, Dupilumab or matching placebo will be administered to the patients at the study visits. At each study visit, a single dose of dupilumab or placebo will be dispensed to the patients to be administered at home.~300 mg/2 ml solution in a single-dose pre-filled syringe with needle shield given once every 2 weeks in a subcutaneous injection"
2396629|NCT03595475||Psychiatric RBD cases|"Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~The onset of mental symptoms preceded the onset of RBD:~Onset of RBD symptom was younger than 50 years old (as most patients with pRBD tended to be younger at mid-40s with an earlier age onset than typical iRBD)."
2396630|NCT03595475||Psychiatric cases|"Age- and sex- matched with pRBD proband;~Concurrent psychiatric illnesses according to the Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on REM sleep behavior disorder questionnaire (RBDQ-HK) and v-PSG;~Free of neurodegenerative diseases."
2396631|NCT03595475||Age- & sex-matched health control|"Age- and sex- matched with pRBD proband;~Without lifetime psychiatric disorder according to Mini International Neuropsychiatric Interview( M.I.N.I);~Free of narcolepsy and other neurological diseases;~Absence of any RBD features as based on RBDQ-HK and v-PSG;~Free of neurodegenerative diseases."
2396632|NCT03595462|Experimental|Snack|The study participants will be provided with a snack to consume every day of the week. The energy content of the snacks will be standardized to ~240 kcal. The snacks will have different levels of protein, fat, carbohydrates, sugar, and fiber.
2396633|NCT03595462|Placebo Comparator|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
3184294|NCT00722839|Experimental|Group B|Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
3184295|NCT00722852|Experimental|1|
2396636|NCT03595436|Experimental|Pea Protein Breakfast Preload|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preloads will be standardized to ~325 kcal. The preloads will include the same fat content but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
2396637|NCT03595436|Placebo Comparator|Carbohydrate Control Breakfast Preload|The study participants will be provided with a control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein and carbohydrate amounts. All ingredients are GRAS listed and approved.
2396638|NCT03595436|Active Comparator|Whey Protein|The study participants will be provided with an active control breakfast preload to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. The preload will include the same fat content (as the Experimental Preloads) but will vary in protein amount and type and carbohydrate amount. All ingredients are GRAS listed and approved.
2396639|NCT03595423||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2396640|NCT03595423||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2396641|NCT03595410||Recurrence laryngeal cancer|
2396642|NCT03595410||No recurrence laryngeal cancer|
2396643|NCT03595397|Active Comparator|Group I|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
2396644|NCT03595397|Active Comparator|Group II|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg magnesium sulfate, followed by continuous infusion of 8 ml/hour of a mixture of 0.125% bupivacaine and 20% magnesium sulfate
2396645|NCT03595397|Active Comparator|Group III|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour
2396646|NCT03595384|Experimental|Soccer-based adaptation to the DPP|Participants taking part in a 24 week soccer program as part of diabetes prevention.
2396647|NCT03595371|Experimental|dapansutrile capsules|Hard gelatin capsules containing 100 mg of dapansutrile (API)
2396648|NCT03595358|Experimental|Arm|"Ellume Home Flu Test and ellume.lab Flu A+B Test~Upper respiratory tract samples from participants will be tested with:~Ellume Home Flu Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and viral culture."
2396649|NCT03595345||Training set|2200 HCC cases from East and West centres enlisted for LT and then delisted or transplanted
2396650|NCT03595345||West validation set|630 HCC cases from a Western centre enlisted for LT and then delisted or transplanted
2396651|NCT03595345||East validation set|300 HCC cases from a Eastern centre enlisted for LT and then delisted or transplanted
2396652|NCT03595332|Experimental|Immediate intervention|Summer activity program: Children will receive the summer scorecard program during the first summer of the 2-year study.
2396653|NCT03595332|Experimental|Delayed intervention|Summer activity program: Children will receive the summer scorecard program during the second summer of the 2-year study.
2396654|NCT03595319|Experimental|Young patients|Patients between 19 and 40 years-old
2396655|NCT03595319|Experimental|Elder patients|Older than 65
2396656|NCT03595306|Experimental|Prebiotic A|
2396657|NCT03595306|Experimental|Prebiotic B|
2396658|NCT03595306|Experimental|Prebiotic C|
3184296|NCT00722852|Placebo Comparator|2|
2396659|NCT03595293|Experimental|Experimental Group for AUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When patients encounter the alcohol image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
2396660|NCT03595293|Sham Comparator|Sham Feedback Group for AUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with an alcohol image, blocking them from progressing through the maze. When participants encounter the alcohol image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the alcohol image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
2396661|NCT03595293|Experimental|Experimental Group for pOUD Patients|Patients will undergo six NFB sessions from the rDLPFC using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When patients encounter the pill image and they increase activity in their rDLPFC, the image in the maze will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the rDLPFC will be sampled every 500 milliseconds using COBI studio software.
2396662|NCT03595293|Sham Comparator|Sham Feedback Group for pOUD Patients|Patients will undergo six sham feedback sessions from the skin over the zygomatic arch using a closed-loop fNIRs-based system. During each session, participants will walk through a maze on a computer screen three times. Each maze consists of alternating 30-second rest and 30-second active blocks. During each active block, the participant will come into visual contact with a pill image, blocking them from progressing through the maze. When participants encounter the pill image and they increase blood supply over the zygomatic area, the image will decrease in size and vice versa. The size of the pill image can fluctuate throughout each thirty second active block as the raw fNIRs signal from the zygomatic area will be sampled every 500 milliseconds using COBI studio software.
3143474|NCT00006253|Experimental|Non-nurse coach|Receives symptom management assistance from a non-nurse coach via telephone
3143475|NCT00006265|Experimental|Cohort I|Immunotherapy with gemtuzumab
3143476|NCT00006265|Experimental|Cohort II|Gemtuzumab + ara-C
2396666|NCT03595267||Rural and Remote Indigenous Communities|Point-of-care screening for Chronic Kidney Disease, Diabetes, and Hypertension will be administered in rural and remote communities in Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario.
2396667|NCT03595254|Experimental|Thrive Intervention|Online cognitive behavior therapy program
2396668|NCT03595254|No Intervention|Waitlist Control|Wait 8 weeks before receiving program access
2396669|NCT03595241|Experimental|Group A - active treatment|
2396670|NCT03595241|No Intervention|Group B - conservative management|
2396671|NCT03595228|Experimental|BN-Brachyury plus radiation|MVA-BN-Brachyury then treatment of the tumor(s) with radiation followed by FPV-Brachyury
2396673|NCT03595202|Other|Step1:4㎎ TID|TS-143 12mg total dose/day or Placebo
2396674|NCT03595202|Other|Step2:11㎎ TID|TS-143 33mg total dose/day or Placebo
2396675|NCT03595189|Experimental|Cilastatin Dose 1|Starting dose (3g of Cilastatin) Single intravenous administration during 3 hours.
2396676|NCT03595189|Experimental|Cilastatin Dose 2|Dose escalation Single intravenous administration during 3 hours.
2396677|NCT03595189|Experimental|Cilastatin Dose 3|Dose escalation Single intravenous administration during 3 hours.
2396678|NCT03595189|Placebo Comparator|Placebo|Saline solution for infusion
2396680|NCT03595163|Experimental|Group S|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and maintained with 2.0-2.5vol% sevoflurane, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
2396681|NCT03595163|Active Comparator|Group P|Children aged 1 month to 3 years who were scheduled to undergo cochlear implant surgery under general anesthesia were enrolled in this study.Children were treated with an infusion bolus of 2.0mg/kg propofol during anesthesia induction and continuous infusion of 7 to 8mg/kg/hour, with the dosage adjusted to achieve loss of consciousness.The bispectral index of EEG was maintained between 50 and 60 in all groups.The homocysteine and folic acid concentrations were measured after anesthesia induction and at the end of surgery separately .
2396682|NCT03595150|Active Comparator|Diclofenac|100 mg Diclofenac rectally prior to the ERCP
2396683|NCT03595150|No Intervention|No prophylaxis|No prophylaxis
2396684|NCT03595137|Experimental|sono with simple needle guide device group (Group D)|sono with simple needle guide device Simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
2397254|NCT03591211|Active Comparator|Cognitive Training|
3143477|NCT00006265|Experimental|Cohort IA|Gemtuzumab + ara C
3143478|NCT00006265|Experimental|Cohort IV|Gemtuzumab + ara-C
3143479|NCT00006294||Chlorthalidone|Participants will take chlorthalidone at recommended doses to control hypertension
3143480|NCT00006294||Amlodipine|Participants will take Amlodipine at recommended doses to control hypertension
3143481|NCT00006294||Lisinopril|Participants will take Lisinopril at recommended doses to control hypertension
3143482|NCT00006294||Doxazosin|Participants will take Doxazosin at recommended doses to control hypertension
3143483|NCT00006295||Pedigree 1|
3143484|NCT00006295||Pedigree 2|
2396689|NCT03595111|Experimental|Myocardial biopsy|The specimens were classified into three categories: normal, focal hydropic change and diffuse hydropic change.
2396690|NCT03595098|Experimental|FCBT|The Family Based Cognitive Behavioural Therapy (FCBT)
2396691|NCT03595098|Active Comparator|FPRT|Family-based Psychoeducation /Relaxation Training (FPRT)
2396692|NCT03595085|Experimental|catheter directed interventions|Those patients will undergo catheter directed fragmentation followed by local thrombolysis using streptokinase
2396693|NCT03595085|Active Comparator|systemic thrombolysis|Those patients will receive systemic streptokinase
2396694|NCT03595072||Stimulation|patient ECOG recordings during active VNS stimulation
2396695|NCT03595072||interstimulation|the same patient ECOG during inter-stimulation periods
3143485|NCT00006295||Pedigree 3|
3143486|NCT00006295||Pedigree 4|
3143487|NCT00006295||Pedigree 5|
3143488|NCT00006295||Pedigree 6|
3143489|NCT00006295||Pedigree 7|
2396701|NCT03595046|Experimental|erector spinae plane block group (group E)|ultrasound-guided erector spinae plane block
2396702|NCT03595046|Active Comparator|thoracic paravertebral block group (group P)|ultrasound-guided thoracic paravertebral block
2396703|NCT03595033|Experimental|Intervention Phase|Throughout the intervention phase, participants will attend weekly intervention visits. During these visits, an occupational therapist (OT) will educate the participant and their caregiver on the therapy plan which includes the iPad apps to be completed during the week. The participants will be asked to complete their therapy plan for 1 hour per day at home, 4 days per week.
2396704|NCT03595020||MDD group|The major depression group (MDD group) received antidepressant treatment but did not interfere with drug selection.
2396705|NCT03595020||HC group|The healthy control group (HC group) don't accept intervention and treatment.
2396706|NCT03595007||Phase 1|
2396707|NCT03595007||Phase 2|
2396708|NCT03595007||Phase 3|
2396709|NCT03594994|No Intervention|Control|Normal sleep habits < 6h
2396710|NCT03594994|Experimental|Sleep Extension|Extend time-in-bed to 8 hours
2396711|NCT03594981|Experimental|CMV/AdV /EBV/BKV specific T cells|CMV/AdV /EBV/BKV specific T cells will be thawed and transferred to a syringe given by slow intravenous injection over 1-2 minutes. Three dose levels will be explored. The lowest dose level will be 1x107cells/m2 and the highest will be 5x107/m2.
2396712|NCT03594968||polycystic ovary syndrome (PCOS)|"Presence of ≥2 of the following:~oligomenorrhea and/or anovulation~Hyperandrogenism (clinical and/or biochemical) One of the signs for clinical hyperandrogenism is hirsutism, which represents hair growth in a male pattern on a female with four different degrees of severity in 11 different body parts: 1) upper lip; 2) chin; 3) chest; 4) upper back; 5) lower back; 6) upper abdomen; 7) lower abdomen; 8) arm; 9) forearm; 10) thigh; and 11) lower leg. The Ferriman-Gallwey scoring system is used to score the degree of excess male-pattern body hair to indicate hirsutism."
2396713|NCT03594968||healthy|healthy patients who had no polycystic ovary
2396715|NCT03594929|Active Comparator|Active RIC|Active RIC using a manual BP cuff to inflate to 200mmHg.
2396716|NCT03594929|Sham Comparator|Sham Control|A sham control using a manual blood pressure cuff visually identical to that used in the RIC protocol will be placed on the upper arm and a simulated RIC protocol will be administered.
2396717|NCT03594916|Experimental|Active tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). Active stimulation consists of 2 mA current applied continuously for 20 minutes.
2396718|NCT03594916|Sham Comparator|Sham tDCS|The anode sponge electrode will be placed on the scalp over the left primary motor cortex (M1) and the cathode sponge electrode will be positioned over the right supraorbital cortex (SO). The 2 mA current will be applied for 30 seconds at the beginning of the session.
2396719|NCT03594903|Experimental|Expectation violation (positive outcome of therapy)|Experimental: patients' report about therapy outcome Video with patients giving information about (mostly) positive therapy outcome
2396720|NCT03594903|Other|Control group (symptoms + expectation)|"Control group: patient´s report about symptoms and therapy expectations~Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome."
3143490|NCT00006295||Pedigree 8|
3143491|NCT00006295||Pedigree 9|
3143492|NCT00006295||Pedigree 10|
3143493|NCT00006295||Pedigree 11|
3143494|NCT00006295||Pedigree 12|
3143497|NCT00006333||Subjects with known or suspected arthritis|Subjects with known or suspected arthritis will be evaluated longitudinally
3143498|NCT00006341|Experimental|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
3143499|NCT00006348|Experimental|Arm 1: ondansetron + placebo|Patients receive oral ondansetron twice daily on days 1-7 and oral placebo twice daily on days 8-14 in the absence of unacceptable toxicity.
3143500|NCT00006348|Experimental|Arm 2: ondansetron + placebo|Patients receive oral placebo twice daily on days 1-7 and oral ondansetron twice daily on days 8-14 in the absence of unacceptable toxicity.
2396721|NCT03594890|Experimental|OVX836 (Intramuscular)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
2396722|NCT03594890|Placebo Comparator|Placebo (Intramuscular)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
2396723|NCT03594890|Experimental|OVX836 (Intranasal)|"OVX836 is a recombinant Influenza vaccine based on the NP of the Influenza virus. OVX836 vaccine is a ready to use sterile liquid clear and colourless solution, presented in 2 mL glass vials filled with 1.2 mL solution. It contains 300 µg/mL of OVX836 vaccine and is formulated without adjuvant.~3 Dose levels tested: 30µg, 90 µg and 180 µg."
2396724|NCT03594890|Placebo Comparator|Placebo (Intranasal)|The Placebo, is Sodium Chloride 0.9 % ready to use sterile solution. The volume of placebo to be administered will be similar to the one of the experimental vaccine.
2396725|NCT03594877|Experimental|Psoriasis patients|Patients with verified diagnosis of psoriasis would be given standard treatment for the first 3 months, and then followed with the standard therapy accompanied with the sublimated mare milk supplement for additional 3 months.
2396726|NCT03594877|No Intervention|Healthy volunteers|Healthy patients will be enrolled in this study, and their gut microbiota composition as well as immune system indicators will be used for comparison with the psoriasis group.
2396727|NCT03594864||Hyper-reduced liver recipients.|Low-weight children who underwent live donor liver transplantation with ultrasound-guided in situ left lateral segment graft hyper-reduction.
2396728|NCT03594851|Experimental|Administration of individualized advice|"Administration of individualized advice to improve the quality of older people's sleep, based on the following interventions :~Pittsburgh Sleep Quality Index, Sleep diary, Mini Mental State Examination, Autonomy assessment (Katz Index of Independence in Activities of Daily Living~& Lawton Instrumental Activities of Daily Living), Neuropsychiatric Inventory (Cummings) for the caregiver, if applicable, Mini Zarit Caregiver Burden Scale, for the caregiver, if applicable, Cornell Scale for Depression in Dementia, Quality of Life in Alzheimer's Disease, Neuropsychiatric Inventory"
2396729|NCT03594838|Experimental|Decentralized testing approach|Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.
2396730|NCT03594838|Experimental|Centralized testing approach|Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.
2396731|NCT03594838|No Intervention|Standard of Care|Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.
2396732|NCT03594825|Experimental|nighttime group|patients with nocturnal hypertension taking valsartan at nighttime
2396733|NCT03594825|Active Comparator|daytime group|patients with nocturnal hypertension taking valsartan at daytime
2396734|NCT03594812|Experimental|Experimental group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region.
2396735|NCT03594812|Placebo Comparator|Placebo group|This group performed aerobic exercise just after radiofrequency therapy in the abdominal region but the radiofrequency device was switched off- Radiofrequency without power.
2396736|NCT03594799|Experimental|Bed Rest Control Group|60 days of strict head-down tilt bed rest
2396737|NCT03594799|Experimental|Cocktail intervention|60 days of strict head-down tilt bed rest along with a Cocktail supplementation composed of natural antioxidants XXS-2A-BR2 comprising vitamin E, Selenium and coupled with omega-3
2396738|NCT03594786|Experimental|endovascular aneurysm repair (EVAR) arm|every patients are in the same arm and have EVAR with supra-renal fixation
2396739|NCT03594773|Experimental|Interpersonal Psychotherapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in IPT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
2396740|NCT03594773|Experimental|Cognitive Behavioral Therapy|Participants randomized to this arm will be treated with 8 sessions over the course of 8 to 12 weeks by a therapist trained in CBT. Participants will complete brief questionnaires before and after treatment sessions. Before each session, they will report on their psychological distress. Following each session, participants and therapists will both complete assessments of the working alliance and rate their own and the other person's affective and interpersonal behavior.
2396741|NCT03594760|Experimental|Main arm|PET-CT imaging following 18F-DCFPyL injection, 1 injection, IV, 10 mCi
2396742|NCT03594747|Experimental|Tislelizumab combined with carboplatin and paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
2396743|NCT03594747|Experimental|Tislelizumab combined with carboplatin and nab-paclitaxel|Tislelizumab will be administered at a dose of 200 mg intravenously (IV) Q3W. Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Nab-paclitaxel 100 mg/m2, D1, D8, and D15 of each cycle, administered as an IV infusion over 30 minutes, for 4 to 6 cycles
2396744|NCT03594747|Active Comparator|Carboplatin and paclitaxel|Carboplatin area under the plasma concentration (AUC) 5, D1 of each cycle, administrated as an IV infusion over 15 to 60 minutes, for 4 to 6 cycles Paclitaxel 175 mg/m2, D1 of each cycle, administered as an IV infusion over 1 to 3 hours, for 4 to 6 cycles
2396745|NCT03594734|Experimental|GLB Weight-Loss Intervention|The GLB program, adapted for individuals with TBI, will be delivered to participants over a 12-month period, divided into 22 in-person or virtual, group sessions. The intervention promotes 5-7% weight-loss by reducing calories and increasing exercise (150 minutes of moderate physical activity per week).
2396746|NCT03594734|Active Comparator|Attention Control Group|The attention control group will meet at the same frequency as the GLB-TBI group over a 12-month period. The attention control group will receive education composed of the content from the TBI Model Systems Knowledge Translation Center's factsheets. No education on weight-loss strategies will be provided.
2396747|NCT03594721|Experimental|Fitzpatrick Skin Types I-III|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
2396748|NCT03594721|Experimental|Fitzpatrick Skin Types IV-V|Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
2396749|NCT03594708|Placebo Comparator|Placebo|placebo consisting of rice starch, light olive oil, and vegetable oil
2396750|NCT03594708|Active Comparator|Supplement|active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc
2396751|NCT03594695||Group G|Patients undergoing general anesthesia HSCRP and NLR measurement
2396752|NCT03594695||Group R|Patients undergoing spinal anesthesia HSCRP and NLR measurement
2396753|NCT03594682|Experimental|dose titration group|First of all, according to the patient's weight and ECOG score, patients were divided into three groups（the initial dose of 250 mg qd,250 mg/500 mg qd by turns, 500 mg qd）. in two weeks, if the patient who is intolerant of the initial dose,250mg qod,250mg qd ,250mg qd was selected. if the patient can tolerate the dose well,a high-dose was given,and the maximum dose does not exceeding 750mg qd.
2396754|NCT03594682|Active Comparator|non-titration group|Patients were given 750mg qd apatinib until disease progression or intolerance
2396755|NCT03594669|Experimental|Intervention|"When enrolled into the study, the participants will be asked to join a group in WhatsApp for purposes of the research study. The application will be used to: deliver reminders for each treatment session; deliver daily prompts for the home exercise program; and present a web-link to the home exercise program (HEP).~Participants will receive physical therapist delivered multi-modal sensorimotor training interventions. The exercises delivered at each intervention will be delivered in a group format, using a circuit of exercises that each athlete will complete in a session. Subsequent sessions will build upon previous sessions to work the sensorimotor control system in progressively more challenging and sport-specific scenarios. This present study will complete 8 sessions over 4 weeks."
2396756|NCT03594656|Experimental|Early-start Group|Receiving Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 72 weeks
2396757|NCT03594656|Placebo Comparator|Delayed-start Group|Receiving placebo for 24 weeks followed by Lingzhi (Ganoderma in capsule form) 0.8g twice daily for 48 weeks
2396758|NCT03594643||electronic cigarette|patient using electronic device, electronic cigarette
2396759|NCT03594643||control|patient not smoking nor using electronic cigarette
2396760|NCT03594630|Active Comparator|Group I (surgical resection)|Participants who have achieved clinical complete response undergo standard surgical resection.
2396761|NCT03594630|Experimental|Group II (active surveillance)|Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.
2396762|NCT03594617|Experimental|ICC-C|Intervention: Interaction Competencies with children - for Caregivers (ICC-C) 11 days with 8 hours of training for caregivers. Core training components include caregiver-child interactions, maltreatment prevention, effective discipline strategies, child-centered institutional care, identifying and supporting burdened children and implementation of the training materials into the daily working
2396763|NCT03594617|No Intervention|Control institutions|The control institutions do not receive any intervention.
2396764|NCT03594604|Experimental|Norethindrone|Delaying menstruation using Norethindrone 5mg three times daily in women who desire postponement of their period for social or personal reasons.
2396765|NCT03594604|Active Comparator|Oral Contraceptive Pills|Women who desire postponing their periods are typically treated with oral contraceptive pills, the current standard of care.
2396766|NCT03594578|Experimental|Episodic future thinking|"Participants will complete a guided interview designed to elicit a number of personalized events that are likely to occur during various future time frames (e.g., 1 day, 1 week, 3 months, 1 year, etc.), as well as text cues designed to prompt episodic future thinking (e.g., In 3 months, I will be at my daughter's wedding). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
2396767|NCT03594578|Sham Comparator|Episodic recent thinking (control)|"Participants will complete a guided interview designed to elicit a number of personalized events that occurred in the recent past (e.g., earlier today, yesterday), as well as text cues designed to prompt episodic thinking (e.g., Earlier today, I was playing tennis with my wife.). Text cues will be presented during subsequent behavioral tasks and participants will be asked to think vividly about these events."
2396768|NCT03594565|Experimental|Local steroids prior to CGMS insertion|"topical spraying of fluticasone propionate nasal spray (nsFP) on the skin area of CGMS placement prior to sensor insertion in a group of pediatric T1D patients who had mild to severe local skin reactions to CGMS adhesives.~Dosage: 2 puffs."
2396769|NCT03594552|Experimental|Placebo, Arbaclofen_15, Arbaclofen_30|Dose order: Placebo, Arbaclofen 15mg, Arbaclofen 30mg
2396770|NCT03594552|Experimental|Placebo, Arbaclofen_30, Arbaclofen_15|Dose order: Placebo, Arbaclofen 30mg, Arbaclofen 15 mg
2396771|NCT03594552|Experimental|Arbaclofen_30, Placebo, Arbaclofen_15|Dose order: Arbaclofen 30mg, Placebo, Arbaclofen 15mg
2396772|NCT03594552|Experimental|Arbaclofen_15, Placebo, Arbaclofen_30|Dose order: Arbaclofen 15mg, Placebo, Arbaclofen 30mg
2396773|NCT03594552|Experimental|Arbaclofen_15, Arbaclofen_30, Placebo|Dose order: Arbaclofen 15mg, Arbaclofen 30mg, Placebo
2396774|NCT03594552|Experimental|Arbaclofen_30, Arbaclofen_15, Placebo|Dose order: Arbaclofen 30mg, Arbaclofen 15mg, Placebo
2397255|NCT03591198|Experimental|Qigong Training|
2396775|NCT03594539|No Intervention|Standard|Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
2396776|NCT03594539|Placebo Comparator|Intervention|Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
2396777|NCT03594526|Experimental|Maternal support to become mother|"Maternal support to become mother: is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of:~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~Four Educational sessions and support sessions for maternal empowerment in each home visit.~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
2396778|NCT03594526|Active Comparator|Control group: usual Care|The participants will receive the usual education about the care of the mother during the puerperium, the care of the newborn, including breastfeeding.
2396779|NCT03594513|Active Comparator|MCAF+PR+CTG|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive the connective tissue graft harvested from the palate on the recessed area before the sutures.Then, the flap will be coronally positioned and sutured to completely cover the graft.
2396780|NCT03594513|Experimental|MCAF+PR+XMD(Mucoderm®)|The partial restoration of the NCCL will be performed prior the surgeries and will be carried out with composite resin.The surgical procedure for root coverage will be carried out by means modified coronally advanced flap and will be performed by starting with oblique incisions in the interdental areas, which continued with the intrasulcular incision at the recession defects.Each surgical papilla will be dissected in a split-thickness and the envelope flap will be raised with a split-full-split thickness in the coronal-apical direction. Additionally, this group will receive a porcine acellular dermal matrix on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
3184297|NCT00722891|Active Comparator|Purevision Lens with ReNu|Purevision Lenses with ReNu Multiplus Solution
3184298|NCT00722891|Active Comparator|Purevision Lenses with RepleniSH|Purevision Lenses with Optifree RepleniSH Solution
2396783|NCT03594487|Experimental|Interventional FMT Treatment Arm|"After providing written informed consent, subjects will undergo screening and baseline assessments of stool and blood sampling, questionnaires, physical examination, MS rating scales, and MRI. Subjects will then initiate an oral antibiotic regimen for 5 days to precondition the gut for the Fecal Microbiota Transplantation (FMT) of FMP30 donor stool and optimize engraftment of the FMP30 donor stool microbiome. Following standard bowel preparation for colonoscopy, subjects will undergo the FMT procedure by an experienced gastroenterologist. Subjects will return for scheduled assessments and follow-up MRI for 12 weeks, with additional safety and biomarker follow-up for 36 weeks.~The active study time is designed to be short (12 weeks active phase) to minimize time not on other MS disease modifying therapy (DMT). This arm of the study will last for approximately 52 weeks total (4 weeks of screening + 12 weeks active treatment phase + 36 weeks of safety follow up)."
2396784|NCT03594487|Active Comparator|Observational Control Arm|"Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.~After providing written informed consent, subjects will undergo screening and baseline assessments, including collection of blood and stool samples, demographic data collection, concomitant medication review, and an MS Relapse assessment. At week 2, subjects will mail in stool samples with a prepaid air bill and packaging. Weeks 4, 8, and 12 assessments will include concomitant medication review, relapse assessment, and blood and stool collection.~The duration of the study for the observational control arm will last for 12 weeks. All study procedures will be performed at the University of California, San Francisco."
2396787|NCT03594461|Experimental|2mg IAI q2w|2mg Intravitreal Aflibercept injection will be given every 2 weeks starting at baseline and then at weeks 2, 4, 6, 8, 10 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
2396788|NCT03594461|Experimental|2mg IAI q3w|2mg Intravitreal Aflibercept injection will be given every 3 weeks starting at baseline and then at weeks 3, 6, 9 and 12. Patients will then be seen at week 16 (4 weeks following the end of the intensive dosing period), and a treat and extend regimen will be initiated through week 52.
2396789|NCT03594448||Ancillary-correlative (Specimen collection)|Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.
2396790|NCT03594435|Experimental|Ibudilast|10mg delayed-release capsules, target dose 50mg BID (5 x 10mg capsules twice daily) for 12 weeks
2396791|NCT03594435|Placebo Comparator|Placebo Oral Capsule|matched to experimental drug
2396792|NCT03594422|Experimental|HQP1351 30mg|30 mg QOD
2396793|NCT03594422|Experimental|HQP1351 40mg|40 mg QOD
2396794|NCT03594422|Experimental|HQP1351 50mg|50 mg QOD
3184299|NCT00722904||1|patients undergoing routine post-intervention surveillance of aortic coarctation
3184300|NCT00722904||2|Healthy volunteers
2397256|NCT03591198|Active Comparator|Cognitive Training|
3184301|NCT00722917|Experimental|TAK-379 25 mg QD|
3184302|NCT00722917|Experimental|TAK-379 100 mg QD|
3184303|NCT00722917|Experimental|TAK-379 200 mg QD|
2396795|NCT03594396|Experimental|MEDIOLA|"Prior to the start of study medication, tumor tissue and blood will be collected as baseline. Olaparib 300mg bid will be started after the collection of tumor and blood. Olaparib will be given on days 1-28 days without rest.~Tumor tissue and blood will be collected on day 14 before administration of durvalumab, to see the change in biomarkers after 2 weeks of olaparib treatment. After the acquisition of tumor and blood, durvalumab will be given in a fixed one dose of 1.5 gram on day 15.~On day 29, there will be a third acquisition of tumor and blood, to see the change in biomarkers after combination treatment of olaparib and durvalumab. Tumor response will also be evaluated according to RECIST criteria version 1.1 based on CT."
2396796|NCT03594370||control|Limbal image by OCT in normal subjects.
2396797|NCT03594370||Advancing wave-like epitheliopathy|Limbal image by OCT in subjects with advancing wave-like epitheliopathy.
2396798|NCT03594370||Ocular rosacea or phlyctenulosis|Limbal image by OCT in subjects with ocular rosacea or phlyctenulosis
2396799|NCT03594357||Multiple sclerosis|MS patients (EDSS: 0-5,5)
2396800|NCT03594357||Control|Healthy individuals without chronic disease
2396801|NCT03594344|Experimental|Hyperbaric oxygen therapy|30 sessions of Hyperbaric oxygen therapy, 90min treatment at 2,4 ATA(atmosphere absolute) with 100% oxygen.First session must be given within 7 days after initial amputation. Treatment is given as outpatient treatment after discharge from hospital.
2396802|NCT03594344|No Intervention|Control group|Control group will be given standard of care with follow up at the outpatient clinic after discharge from hospital.
2396803|NCT03594331|Experimental|Gluten Exposure Group 1|This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
2396804|NCT03594331|Experimental|Gluten Exposure Group 2|This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.
2396805|NCT03594331|Experimental|Gluten Exposure Group 3|This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.
2396806|NCT03594305|Experimental|Educational Intervention Arm|Villages randomized to this arm will receive a one-day educational seminar, which their religious leaders of all denominations will be invited to attend. The seminar will address religious, cultural, and medical aspects of family planning. Leaders who attend will also have the opportunity to participate in mentorship group discussions after the intervention. In addition, both villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
2396807|NCT03594305|No Intervention|Control arm|Villages randomized to this arm will not receive the educational seminar. These villages will have standard teaching provided by nurses at dispensaries about family planning, and a continual supply of contraceptive options at dispensaries in all villages will be ensured.
2396808|NCT03594292|Experimental|FASTFORWARDTM Bunion|The participants are treated with FASTFORWARDTM Bunion Correction system. The FASTFORWARDTM Bunion Correction system employed 3D printed titanium bone tether plate at second metatarsal. Due to the merit of 3D printing technology, the plate is designed to broadly distribute forces across bone to secure mechanical integrity of the bone. The FASTFORWARDTM Bunion Correction system has been cleared by the United States Food and Drug Administration.
2396809|NCT03594292|Active Comparator|Conventional Surgery|The participants are treated with fusion surgery. This procedures is a standard treatment for 1st metatarsal hallux valgus by cutting, realigning and fusing the 1st metatarsal or fusing the metatarsal-cuneiform joint.
2396810|NCT03594279|Experimental|Community Mobilization|This arm will receive specific messages regarding the prevention and management of childhood diarrhea and pneumonia. The investigators will form village committees (VC) consisting of prominent members of the community (6-8 in a group) to carry out awareness and motivational activities for the uptake of the identified interventions.
2396811|NCT03594279|Experimental|Community Mobilization and Community Incentive|In this arm, along with the interventions in the community mobilization arm, community based incentives will also be provided. The clusters which improve the practices for preventive and curative strategies for diarrhea and pneumonia will receive community-based incentive including structural benefits linked to health including tube wells, water supply, toilets in community/schools, water storage facility or any other incentive as decided with the respective village committees.
2396812|NCT03594279|No Intervention|Control|This arm will receive the routine standard of care.
2396813|NCT03594266|Experimental|Therapy A Spinal Cord Stimulation Parameter Set|
2396814|NCT03594266|Experimental|Therapy B Spinal Cord Stimulation Parameter Set|
2396815|NCT03594253|Experimental|RFP-C|Regulation Focused Psychotherapy for Children (RFP-C; Hoffman & Rice with Prout, 2015) is a novel, manualized, time-limited psychodynamic treatment approach for children who manifest disruptive behaviors and emotional dysregulation. Throughout the 16 sessions of play therapy and four parent meetings, the clinician works with the parents and the child to increase understanding that all behavior, even disruptive behavior, has meaning in the service of emotional and behavioral regulation. This insight leads to a decreased need and reliance to act on the distressing emotions (e.g. less need for disruptive behaviors) and an increased ability to tolerate, work through, and talk about the feelings that previously needed to be warded off.
2396816|NCT03594253|No Intervention|Wait List control|Participants assigned to this condition will receive no intervention. They may continue on current medication regimens (no major changes) but may not be enrolled in psychological treatments. They will be evaluated weekly via phone call with primary caregiver. At the conclusion of this 10-week wait list period all participants assigned to this condition will receive RFP-C treatment.
2396817|NCT03594240|Active Comparator|intervention group|Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
2396818|NCT03594240|Placebo Comparator|Control group|Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .
2396823|NCT03594214||Single arm|pre-treatment serum vitamin d level measured by ELISA kit in patients confirmed for diagnosis with invasive breast cancer and before receiving any treatment for breast cancer
2396824|NCT03594201||group1|A+B grade sperm count after treatment=0
2396825|NCT03594201||group2|0<A+B grade sperm count after treatment≤10^6
2396826|NCT03594201||group3|10^6<A+B grade sperm count after treatment<2*10^6
2396827|NCT03594201||group4|A+B grade sperm count after treatment≥2*10^6
2396828|NCT03594188|Experimental|general anesthesia|Patients in this group will have RF ablation for treatment of HCC under general anesthesia.
2396829|NCT03594188|Active Comparator|local anesthesia|Patients in this group will have RF ablation for treatment of HCC under local anesthesia.
2396830|NCT03594175|Experimental|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081, 0.7 milligrams (mg) (0.4 units) per 2 milliliter (mL) directly into the catheter lumen. Participants will receive the first dose at minute (min) 0, and the second dose, if needed, at min 90.
2396831|NCT03594175|Placebo Comparator|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
2396832|NCT03594175|Active Comparator|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/mL, directly into the catheter lumen. Participants will receive the first dose at min 0, and the second dose, if needed, at min 90.
2396833|NCT03594149|Experimental|antibacterial prophylaxis|Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine
2396834|NCT03594149|No Intervention|control|No levofloxacin will be given.
2396835|NCT03594136|Experimental|Telemetric intracranial pressure implant|A telemetric intracranial pressure monitoring sensor is inserted into the brain parenchyma at the end of an uncomplicated surgery for an unruptured aneurysm
3143501|NCT00006349|Experimental|donepezil + vitamin E|"Patients receive oral donepezil daily and vitamin E twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
3184304|NCT00722917|Active Comparator|Pioglitazone 30 mg QD|
2396840|NCT03594097|Experimental|Treatment cookies|
2396841|NCT03594097|Active Comparator|Control cookies|
2396842|NCT03594058|Experimental|Solabegron modified release tablets low dose|
2396843|NCT03594058|Experimental|Solabegron modified release tablets high dose|
2396844|NCT03594058|Placebo Comparator|Placebo Comparator|
3184305|NCT00722917|Placebo Comparator|Placebo|
3184306|NCT00722930|Experimental|1. Consolidation with Y90 Ibritumomab Tiuxetan|1. Consolidation with Y90 Ibritumomab Tiuxetan
2396847|NCT03594019|Placebo Comparator|Control Group|Patients in the control group will follow the conventional treatment protocol combined with connective tissue graft. Briefly, hopeless tooth will be extracted atraumatically. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. Then, connective tissue graft will be harvest from palatal and fixed between bucall mocosa and bucall bone. Healing abutment will placed and collegan sponge will be used to seal the wound. After 4 months, implant impression and crown delivery will be finished.
2396848|NCT03594019|Experimental|Test Group|Patients in the test group will receive conventional immediate implant placement combined with socket shield technique. Briefly, the hopeless teeth will be splited from mesial and distal, the buccal part will be preseved and the palatal part will extracted. Implant will be placed in the palatal side and grafting materials will be filled in the buccal gap. After 4 months, implant impression and crown delivery will be finished.
2396849|NCT03594006|Other|Cancer patients on active therapy|
2396850|NCT03593993||Surgical Cohort|Blood, cerebrospinal fluid, and tumor tissue will be obtained from each participant on this arm.
2396851|NCT03593980|Experimental|400ml cranberry juice|Patients will be given 400ml of cranberry juice to drink 3 hours prior to cesarean delivery.
2396852|NCT03593967|Experimental|Intervention Group|Youths and seniors in the intervention group will be paired to receive a novel five-week (3 hours/ week) bilingual (English/ Mandarin), intergenerational arts programme which includes guided museum tours, collaborative art-making and story telling as well as reflective writing. These sessions will be held at the National Museum, and facilitated by experienced artists and trained art therapists.
2396853|NCT03593967|Experimental|Waitlist Control Group|Participants will serve as a waitlist control group before receiving the intervention that the intervention group receives at the end of 5 weeks.
2396854|NCT03593954|Experimental|JNJ-61393215 2 mg + Ritonavir 100 mg|Participants will receive suspension of JNJ-61393215 2 mg (Day 1 and 5) orally and tablet of Ritonavir 100 mg twice a Day (Day 4-14) orally.
2396855|NCT03593941||Alzheimer's dementia and challenging behaviour symptoms|Care home residents >65y No interventions as this is a pilot project
2396856|NCT03593941||Alzheimer's dementia and no challenging behavioural symptoms|Care home residents >65y No interventions as this is a pilot project
2396857|NCT03593941||Older adults without dementia|Care home residents >65y No interventions as this is a pilot project
3184307|NCT00722943|Active Comparator|DMT group|These infants will receive tactile stimulation and developmental massage by a licensed therapist. This intervention will be done behind a screen in order to blind the therapy to NICU staff and parents.
3184308|NCT00722943|Placebo Comparator|SHAM control|These infants will have no tactile stimulation or developmental massage done. The therapist will stand behind a screen but will not touch the infant. The screen will blind the NICU staff and parents to the study arm.
3184309|NCT00722956|Experimental|1|AZD5672 + atorvastatin
3184310|NCT00722969|Experimental|A|
3184311|NCT00722982||1|
3184312|NCT00722982||2|
3184313|NCT00722995|Active Comparator|1|Sleeve gastrectomy
3184314|NCT00722995|Active Comparator|2|Gastric Bypass
2396860|NCT03593889|Experimental|Intervention group|The intervention group will receive a collaborative stepped care programme provided by registered social workers and trained peer supporters from elderly or mental health service units (NGOs) according to level of risks, symptom severity, and intervention response. Home visits or other format of contact will be delivered by trained peer supporters employed by NGOs to detect and engage hidden cases.
2396861|NCT03593889|Other|Control group|The control group will receive treatment as usual, which will be determined by the responsible worker from NGO units.
3184315|NCT00723047|Experimental|1|
2396863|NCT03593863|No Intervention|"PE as Usual Control Group"|The Control Group will be asked to continue with their normal PE lessons
2396864|NCT03593863|Experimental|Intervention Group|Physical Education (PE) Programme
2396865|NCT03593850|Experimental|Music group|"Patients in this arm listened through headphones to a song of 29 minutes and 32 seconds duration. The song was composed entirely by investigator Juan Martin-Saavedra and registered to copyright and authorship regulatory entities from Colombia under the name Occasio adolore (Musical piece No. 5-559-355 and Phonogram No. 12-105-295 of Colombia's Copyright authorship agency). Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Silence group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise."
2396866|NCT03593850|Active Comparator|Silence group|Patients on the silence group listened to a 29 minute and 32 second audio file that produced no sounds with headphones on. Patients were instructed to avoid using cellphones or other activities during the time of the intervention. Patients receive the intervention in the same room as the Music group, but for the intervention they were always alone. The room was located in a low transit place with low ambient noise.
2396867|NCT03593837|Experimental|Experimental group|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
2396868|NCT03593837|Placebo Comparator|Placebo group|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg).
2396869|NCT03593824|Experimental|dense cataract group|
2396870|NCT03593824|Experimental|non-dense nuclear cataract group|
2396871|NCT03593811|Active Comparator|Healthy Controls|Healthy Volunteers with no known gastrointestinal complications will be given questionnaires and testing by electrogastrogram (EGG) and/or magnetogastrogram (MGG) after an overnight fast to determine nausea parameters. They will also have a electrocardiogram (EKG) and do some testing after being fed a protein bar.
2396872|NCT03593811|Active Comparator|Non-nauseated|Functional nausea patients with a score of 0-2 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2396873|NCT03593811|Active Comparator|Mildly nauseated|Functional nausea patients with a score of 3-4 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2396874|NCT03593811|Active Comparator|Moderately nauseated|Functional nausea patients with a score of 5-6 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar.
2396875|NCT03593811|Active Comparator|Severely nauseated|Functional nausea patients with a score of 7-9 on the BARF (BAxter Retching Faces) scale will be given questionnaires and testing by EGG and/or MGG after an overnight fast to determine nausea parameters. They will also have a EKG and do some testing after being fed a protein bar. Some patients will also be tested after receiving a one time dose of a 4mg or 8mg dependent upon age disintegrating tablet of ondansetron followed by a 2 day washout period prior to testing again after a 5 day maintenance dose of oral cyproheptadine 4mg twice a day.
2396876|NCT03593785|Experimental|Cohort 1|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 1 injection (6 subjects) or matching placebo (2 subjects).
2396877|NCT03593785|Experimental|Cohort 2|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 2 injection (6 subjects) or matching placebo (2 subjects).
2396878|NCT03593785|Experimental|Cohort 3|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 3 injection (6 subjects) or matching placebo (2 subjects).
2396879|NCT03593785|Experimental|Cohort 4|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 4 injection (6 subjects) or matching placebo (2 subjects).
2396880|NCT03593785|Experimental|Cohort 5|On Day 1, randomized subjects will receive single SC dose of AZD8233 dose 5 injection (6 subjects) or matching placebo (2 subjects).
2396881|NCT03593772|Active Comparator|Treatment arm|Treatment Arm: MR is an user-driven, dyadic, self-care management program developed with NIMH funding (R43/44) for use by Veterans and their selected partners, individually or together, to reduce pain and distress and support physical, mental, and relationship health. MR was designed for Veterans who face obstacles accessing formal mental health services. It can also be used to complement formal services. MR is a patient-centered intervention, allowing users to determine the pace at which to proceed in each program component. MR Content. The program provides video and audio instruction in a set of 11 evidence-based wellness.
2396882|NCT03593772|Placebo Comparator|Control arm|Usual Care Waitlist Control Arm: For ethical reasons, this study will use a waitlist control arm to ultimately provide all participants exposure to the MR intervention. Dyads in the control arm will participate in all assessments like those in the treatment group, however, they will be asked to agree to not access the public web site during their participation. Wait-list control participants will be instructed to seek advice about treatment from their providers. Other than this initial advice, there will be no attempt by study personnel to influence condition management unless an issue (i.e., suicidal ideation) arises. The control condition will account for potential temporal effects that occur from passage of time (brief), and expectation effects associated with anticipation of MR participation. The control group will receive access to MR after they complete data collection.
3184316|NCT00723060|Active Comparator|1|escitalopram high dose group
3184317|NCT00723060|Active Comparator|2|escitalopram conventional group
3184318|NCT00723112||Affected Group|Adult subjects with the diagnosis of MDS based on the French-American-British classification system.
2396885|NCT03593746|Experimental|HIIT and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with high intensity interval training (HIIT)
2396886|NCT03593746|Sham Comparator|High intensity interval training (HIIT)|Light-Emitting Diode (LED) therapy simulation followed by physical training with high intensity interval training (HIIT)
2396887|NCT03593746|Experimental|Combined training and LED therapy|Light-Emitting Diode (LED) therapy followed by physical training with combined training
2396888|NCT03593746|Sham Comparator|Combined training|Light-Emitting Diode (LED) therapy simulation followed by physical training with combined training.
2396889|NCT03593733|Experimental|Cold Water Immersion|Cold Water Immersion
2396890|NCT03593733|Experimental|Photobiomodulation Therapy|Photobiomodulation Therapy
2396891|NCT03593720||Hypospadias|Patients with hypospadias
2396892|NCT03593720||Control|Patients without hypospadias
2396893|NCT03593707|Experimental|Metformin Alone|Metformin alone
2396894|NCT03593707|Experimental|Metformin + PF-06865571|Co-administer metformin and PF-06865571
2396895|NCT03593694|Other|Group 1|"Arm: Other: Group 1 Participants in this group will receive the culturally tailored education booklet titled Your Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session as detailed above."
2396896|NCT03593694|Active Comparator|Group 2|"Arm: Active Comparator: Group 2 Participants in this group will receive as detailed above, the culturally tailored education booklet titled My Guide to Sugar Diabetes. In addition, subjects will complete 10 sessions of diabetes education delivered weekly via videoconferencing lasting 60 minutes each session. Patients will also be assigned the FORA Test-n-Go Series Blood Glucose and Blood Pressure monitors and provided glucose test strips to allow testing at least once a day during the initial face-to-face session."
2396897|NCT03593694|Experimental|Group 3|Arm: Experimental: Group 3 The intervention has 3 components: 1) diabetes education; 2) home telemonitoring; and 3) diabetes modified behavioral activation, delivered by nurses via smartphones. Trained nurses will deliver the TECH DM-BAT intervention via videoconferencing technology on smartphones.
2396898|NCT03593668|Active Comparator|Metformin|Metformin Hydrochloride Tablet 500mg po by month,three times a day for 12 weeks
2396899|NCT03593668|Active Comparator|Benaglutide|Benaglutide Injection 0.2mg, iH,po, three times a day for 3 12 weeks
3143502|NCT00006349|Placebo Comparator|placebo|"Patients receive oral placebo twice daily.~All patients begin treatment within 2 weeks after completion of prophylactic cranial irradiation. Treatment continues for a minimum of 1 month in the absence of disease progression, unacceptable toxicity, or a 3.0 point drop on the Mini Mental State Examination (MMSE) and/or a 5 point drop on the Blessed Dementia Scale.~Cognition is assessed using the Blessed Dementia Scale and the MMSE at baseline and then every 3 months during study.~Quality of life and depression are assessed at baseline and then every 3 months during study.~Patients are followed every 6 months."
3143503|NCT00006359|Experimental|Androgen suppression + EBRT + Brachytherapy|Androgen suppression with external beam radiation therapy followed by brachytherapy boost
2396902|NCT03593642|Placebo Comparator|Control Group|Erector spinae bilateral catheters with continuous infusion iso saline during 48h after surgery Day 0 to day 2
2396903|NCT03593642|Experimental|Regional analgesia group|Erector spinae bilateral catheters with continuous infusion Ropivacaine 0.1 or 0.2%, depending on age, infusion during 48h after surgeryDay 0 to day 2
3143504|NCT00006363|Experimental|Induction Arm I|Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1-3. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of cytarabine IV continuously on days 1-5 and daunorubicin IV over 5-10 minutes followed by etoposide IV over 2 hours on days 1 and 2.
3143505|NCT00006363|Experimental|Induction Arm II|Patients receive PSC 833 IV continuously on days 1-3 and cytarabine, daunorubicin, and etoposide as in arm I. Patients with 20% or greater bone marrow cellularity and greater than 5% leukemia blasts at the end of the first course receive a second course of PSC 833 IV continuously on days 1 and 2 and cytarabine, daunorubicin, and etoposide as in arm I.
3189026|NCT00773448|Experimental|Extensive Malignancy Screening|Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis
2396907|NCT03593616||Lens Phacoemulsification Group|insertion of intra-ocular lens
2396908|NCT03593603||Nellcor™ Bedside Respiratory Monitoring System|Patients on the general care floor who are prescribed non-invasive respiratory monitoring via spot check vital signs at least every 4 hours
2396910|NCT03593564|Experimental|KINDER Participant|The intervention will be provided with a 8-part psychoeducational intervention delivered online on a weekly basis. Online modules will be comprised of a short (approximately 3 minute) videos followed by more specific text-based information and links to additional resources. At the end of the module, participants will complete a short quiz, followed by a reflection exercise to reinforce learning. Each model, participants will be asked to select a goal to complete a pleasurable activity and receive an option to set a text or email reminder to do so.
2396911|NCT03593551|Experimental|relaxation and control|All participants will attend five relaxation treatments and one control. The order of treatments and control will be randomised allocated to participants.
2396915|NCT03593525|Experimental|SPARK Intervention|"Participants will complete symptom screening using SPARK once daily on a study-supplied iPad. For inpatients, daily reminders to complete SSPedi will appear on the iPad. Reports will be available to the child at any time. For outpatients, clinical research associates will provide the iPad in person daily and reports may be viewed at those encounters. The intervention is daily symptom screening with provision of reports to the healthcare team. Severe symptoms will result in email alerts. More specifically, SSPedi reports will be printed daily and provided in the patient chart. On days 1 and 3, an alert will be emailed to the physician providing direct medical care if any symptom is a lot or extremely bothersome (score 3 or 4 on 0-4 scale). Reports and alerts will have links to SPARK-housed CPGs."
2396916|NCT03593525|No Intervention|Standard of Care Arm|Participants randomized to the control arm will not complete daily symptom screening. They will complete SSPedi on days 1 and 5 to obtain the primary outcome. Health care providers will not be notified of their SSPedi scores and no symptom reports or symptom alerts will be generated.
2396917|NCT03593512|Experimental|PPN DBS|All patients will undergo bilateral PPN DBS
2396918|NCT03593486|Experimental|Active Stimulation|Participants will receive active EMF stimulation through the study device for 60 minutes during the procedure.
2396919|NCT03593486|Sham Comparator|Sham Stimulation|The participant will be positioned in the stimulator, but no EMF stimulation will be delivered.
2396920|NCT03593473|Experimental|Intranasal Oxytocin|Participants block randomized to Oxytocin intranasal spray by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
2396921|NCT03593473|Placebo Comparator|Placebo|Participants block randomized to placebo Intranasal spray with all equivalent ingredients except oxytocin. Blocks will be stratified by risk status at enrollment in the Mood, Mother and Infant (MMI) study and as verified by structured clinical diagnostic interview (no history of depression or anxiety, past depression or anxiety, current depression or anxiety).
2396922|NCT03593460|Experimental|sPIF 1 mg/kg (Starting Dose)|Patients will be administered a starting dose of sPIF 1mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2396923|NCT03593460|Experimental|sPIF 2 mg/kg|Patients will be dosed at 2mg/kg sPIF for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
2396924|NCT03593460|Experimental|sPIF 3 mg/kg|Patients will be administered a starting dose of sPIF 3mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2396925|NCT03593460|Experimental|sPIF 4 mg/kg|Patients will be administered a starting dose of sPIF 4mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels
2396926|NCT03593460|Experimental|sPIF 5 mg/kg|Patients will be administered a starting dose of sPIF 5mg/kg (n=10/cohort) for 14 days assessing safety, tolerability and clinical response based on the effect on ALT levels.
2396927|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin
2396928|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
2396929|NCT03593447|Experimental|non-cirrhotic subjects. low TG-2349+ low DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181
2396930|NCT03593447|Experimental|non-cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181
2396931|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin
2396932|NCT03593447|Experimental|cirrhotic subjects. high TG-2349+ high DAG181|HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181
2396933|NCT03593421|Experimental|synthetic preImplantation factor 1 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2396934|NCT03593421|Experimental|synthetic preImplantation factor 2 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2396935|NCT03593421|Experimental|synthetic preImplantation factor 3 mg/kg|Patients will be dosed SQ 14 doses
2396936|NCT03593421|Experimental|synthetic preImplantation factor 4 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2396937|NCT03593421|Experimental|synthetic preImplantation factor 5 mg/kg|Patients will be dosed SQ with 14 doses of sPIF
2396938|NCT03593408||Pediatric Patients on ECMO Support|
3143506|NCT00006363|Experimental|Intensification Favorable|Patients receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after the prior course and no later than 14 days after hematopoietic recovery for two more courses.
3184319|NCT00723112||Healthy Controls|Control subjects will be selected using frequency matching on gender and age by decade. That is for each MDS patient a healthy volunteer of the same gender and decade (50-59, 60-69, 70-79, etc) will be selected
2396943|NCT03593382||Female endurance athletes|Female endurance athletes recruited from Swedish and Danish national teams and competitive sport clubs
2396944|NCT03593369|Experimental|KLOX BioPhotonic System (single treatment)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
2396945|NCT03593369|Experimental|KLOX BioPhotonic System (consecutive treatments)+SOC|KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
2396946|NCT03593369|Active Comparator|Standard of Care|SOC only (5 patients)
2396947|NCT03593356|Experimental|Monthly cash gift payments of $333|These subjects receive $333 each month for 52 months via debit card.
2396948|NCT03593356|Active Comparator|Monthly cash gift payments of $20|These subjects receive $20 each month for 52 months via debit card.
2396949|NCT03593343|Experimental|Short overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 11 pm and stay overnight fasted afterwards for (9.5h).
2396950|NCT03593343|Experimental|Long overnight fast|Overnight fasting duration intervention: Participants will receive their last evening meal at 4.30 pm and stay overnight fasted afterwards for (16h).
2396951|NCT03593330|Experimental|Transitional Care Programme|The primary intervention of the Transitional Care Programme (TCP) will be additional patient education, framing of expectations for the hospital course and length of stay, coordinated team preparation for discharge, a dedicated discharge appointment, and a follow up phone call.
2396952|NCT03593330|No Intervention|Standard of Care|Patients are admitted without a pre-determined discharge date. They do not receive a dedicated discharge appointment, and will not receive a follow up phone call 48 hours after discharge.
2396953|NCT03593317|Experimental|Spironolactone group|
2396954|NCT03593317|Placebo Comparator|Placebo group|
2396955|NCT03593304|Active Comparator|Experimental:Mecobalamin and Pyridoxine hydrochloride|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
2397032|NCT03592784|Active Comparator|Medical Nutrition Therapy Alone|
2485357|NCT03000777|Placebo Comparator|Placebo|Isomaltose
2396956|NCT03593304|Placebo Comparator|Placebo: normal saline and Oral placebo|Injection normal saline (1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.Oral placebo pill 2 tablets thrice daily for 5 weeks.
2396957|NCT03593278|Experimental|Treatment and observation period|On Day 1, the subjects will receive a single s.c. dose of 16 mg 14C-radiolabeled ACT-246475 in the fasted state. Subjects will be followed by an observation period of 3 days (72 h) during which blood, urine, and feces samples will be collected.
2396958|NCT03593265|Experimental|Healthy group|healthy subjects MUNIX will be performed
2396962|NCT03593239|Experimental|Tobacco flavored JUUL 1.7% ENDS|Tobacco flavored JUUL 1.7% ENDS (10 puffs)
2396963|NCT03593239|Experimental|Tobacco flavored JUUL 5% ENDS|Tobacco flavored JUUL 5% ENDS (10 puffs)
2396964|NCT03593239|Experimental|Mint flavored JUUL 1.7% ENDS|Mint flavored JUUL 1.7% ENDS (10 puffs);
2396965|NCT03593239|Experimental|Mint flavored JUUL 5% ENDS|Mint flavored JUUL 5% ENDS (10 puffs)
2396966|NCT03593239|Experimental|Fruit Medley flavored JUUL 1.7% ENDS|Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)
2396967|NCT03593239|Experimental|Fruit Medley flavored JUUL 5% ENDS|Fruit Medley flavored JUUL 5% ENDS (10 puffs)
2396968|NCT03593239|Experimental|Crème brulee flavored JUUL 1.7% ENDS|Crème brulee flavored JUUL 1.7% ENDS (10 puffs)
2396969|NCT03593239|Experimental|Crème brulee flavored JUUL 5% ENDS|Crème brulee flavored JUUL 5% ENDS (10 puffs)
2396970|NCT03593239|Experimental|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs
2396971|NCT03593239|Experimental|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs
2396972|NCT03593226|Experimental|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
2396973|NCT03593213|Experimental|Cariprazine 3.0 mg/day|Cariprazine capsules, oral administration, once daily.
2396974|NCT03593213|Experimental|Cariprazine 4.5 mg/day|Cariprazine capsules, oral administration, once daily.
2396975|NCT03593213|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily.
3184320|NCT00723151|Experimental|Low Intensity|One hour of intervention per week
2396977|NCT03593187|Experimental|Cal-1( LVsh5/C46) drug product|
2396978|NCT03593174|Experimental|Ossur Rigid Dressing|Use of ORD, which is a type of Removable Rigid Dressing (RRD), as a post tibial amputation dressing modality.
2396979|NCT03593174|Active Comparator|Elastic bandage|Use of the elastic bandage as a post amputation dressing modality.
2396980|NCT03593161|Experimental|Humor therapy|After baseline assessment (before start of conditioning), patients assigned to the experimental study arm will receive the standard psychosocial care plus weekly clown visits over the course of their inpatient stay for allogeneic stem cell transplantation.
2396981|NCT03593161|No Intervention|Treatment as usual|Patients assigned to the control arm will receive the standard psychosocial care over the course of their inpatient stay for allogeneic stem cell transplantation.
2396982|NCT03593148|Other|Lifestyle treatment|Patients will be included in the Lifestyle treatment that is a existing treatment program at Vestfold Hospital Trust.
2396983|NCT03593135|Experimental|Intervention group|Intervention group taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatments continued (including tablet Tagipment 50mg/1000mg twice a day)(Metformin + Sitagliptin group). 15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time was prescribed.
2396984|NCT03593135|Placebo Comparator|Comparison group|Control group also taking their diet according to their original meal pattern only dietary guideline were given regarding high glycaemic and low glycaemic diet. Medical treatment continued (including tablet Tagipmet 50mg/1000mg twice a day)( Metformin + Sitagliptin group). Flavor of apple cider vinegar used as placebo, mixed in 200ml plain water during meal at night time.
2396985|NCT03593122|Experimental|WO 2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
3184321|NCT00723151|Experimental|High Intensity|Five hours of intervention per week, one hour per day for five days per week
2396987|NCT03593096|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2396988|NCT03593096|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2396989|NCT03593083|Experimental|Order A|The participants will be tested in Zurich (Low altitude: 470m above sea level) and consecutively at High Altitude(Säntis; 2500m above sea Level)
2396990|NCT03593083|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2396991|NCT03593070|Experimental|CGMI-V|Caregivers in the Chronic Grief Management Intervention-Video (CGMI-V) condition will participate in eight weekly professionally led, real-time, live-streaming video online group sessions.
2396992|NCT03593070|No Intervention|Minimal Treatment (MT)|Those caregivers in the MT condition will receive written information materials about late-stage Alzheimer's disease or a related dementia at baseline.
2397299|NCT03590873|No Intervention|Control group|Intraoperative fluid management: administration of 6-10 ml/kg/hr of crystalloid solution.
3189027|NCT00773500||1|Providers adopting electronic prescribing in New York City, New York
2396993|NCT03593057|Experimental|Manual therapy protocol|Manual therapy protocol and self-care advice and body awareness. Three sessions of manual therapy will be applied, one every 15 days.
2396994|NCT03593057|Active Comparator|Control group.|Advice on self-care and body awareness.
2396995|NCT03593044|Experimental|One Week Atropine|0.01% concentration atropine drops
2396996|NCT03593031|Active Comparator|CI OBVAT|Patients with Convergence Insufficiency in Active Vision Therapy
2396997|NCT03593031|Sham Comparator|CI Sham therapy|CI Sham therapy
2396998|NCT03593031|Active Comparator|Controls OBVAT|Control receive active therapy
2396999|NCT03593031|Sham Comparator|Controls Sham|Subjects with Normal Binocular Vision will receive a therapy that appears to be therapeutic but does not have any binocular coordination benefits.
2397000|NCT03593018|Experimental|Oral Azacitidine|Oral azacitidine 300mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacitidine 200mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
2397001|NCT03593018|Active Comparator|Investigator's choice therapy|Romidepsin 14mg/m² on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity) or Bendamustine 120mg/m² on days 1 and 2 of a 21-days cycle (during 6 cycles) or Gemcitabine 1200mg/m² on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
2397002|NCT03593005|Experimental|Order A|The participants will be tested in the following order: Zurich (Low altitude: 470m above sea level) and consecutively High Altitude (Säntis; 2500m above sea Level)
2397003|NCT03593005|Experimental|Order B|The participants will be tested at High Altitude (Säntis; 2500m above sea level) and consecutively in Zurich (Low altitude; 470m above sea level).
2397004|NCT03592992|Experimental|Spinal Hydromorphone|For the intervention group, 75 mcg of hydromorphone will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
2397005|NCT03592992|Active Comparator|Spinal Morphine|For the control group,150 mcg of preservative-free morphine will be added to the spinal anesthetic mixture as a one-time injection prior to cesarean delivery.
2397006|NCT03592979|Experimental|Order A|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2397007|NCT03592979|Experimental|Order B|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2397008|NCT03592966|Placebo Comparator|Placebo|Freeze-dried placebo powder
2397009|NCT03592966|Active Comparator|Wild Blueberry powder|Freeze-dried whole fruit blueberry drink.
2397010|NCT03592953|Experimental|Serious game Control group|The participants spend on three different scenarios from the game PerinatSims; basic scenarios designed to train Technical Skills (management of post partum hemorrhage according to the algorithm).
2397011|NCT03592953|Experimental|Serious game Experimental group|"The participants spend on three PerinatSims scenarios in which critical situations have been implemented, aiming to mobilize some of the non-technical skills of the learners: situation awareness, decision making, communication..."
2397012|NCT03592953|No Intervention|Classical teaching group|the students received the classical teaching of postpartum hemorrhage management and a reminder of the algorithm before the high fidelity simulation session.
2397013|NCT03592927|Experimental|Order A|"The participants will be exposed to shamed hypoxia (FiO2: 20.9% equivalent to sea level and consecutively to simulated altitude (FiO2: 15.1% equivalent to 2500m above sea level) administered by an altitude Simulator (Altitrainer, SMTEC), simulated altitude (FiO2: 15.1%), with a facemask."
2397014|NCT03592927|Experimental|Order B|"The participant will be exposed to hypoxia (FiO2, 15.1% equivalent to 2500m above sea level), simulated altitude (FiO2: 15.1%), and consecutively to shamed hypoxia (FiO2, 20.9%) administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2397015|NCT03592914||subjects with respiratory disease|This study is a comparative, single-center study. This is a minimal risk study using a non-significant risk device. A minimum of 60 and maximum of 70 subjects will be enrolled in the study. Subject participation will last approximately 1 hour(s).
2397016|NCT03592901||BPA Patients|Participants that are receiving brachial plexus anesthesia for a previously planned shoulder surgery.
3189028|NCT00773500||2|Providers adopting electronic prescribing in the Taconic region of New York
2397018|NCT03592875||Professional nurses|A semi-structured interview will be used for data collection with 16 guiding questions addressing aspects related to Nursing Care Systematization knowledge and practices.
2397019|NCT03592862|Experimental|HTL0018318 high dose|oral capsule, once daily
2397020|NCT03592862|Experimental|HTL0018318 mid dose|oral capsule, once daily
2397021|NCT03592862|Experimental|HTL0018318 low dose|oral capsule, once daily
2397022|NCT03592862|Placebo Comparator|Placebo|oral capsule, once daily
2397023|NCT03592849|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by thin endometrium or endometrial scarring
2397024|NCT03592836|Active Comparator|Continuous infusion of loop diuretics|Furosemide continuous infusion: 125 or 250 mg die
2397025|NCT03592836|Active Comparator|Intermittent infusion of loop diuretics|Furosemide bolus intermittent: 125 or 250 mg die
2397026|NCT03592823|No Intervention|control|receiving radiofrequency ablation and anticoagulant therapy
2397027|NCT03592823|Experimental|hydrochloroquine|receiving radiofrequency ablation, anticoagulant therapy and hydrochloroquine treatment (200 mg,bidpo)
2397028|NCT03592810||ECPR|All patients who received ECMO placement during cardiopulmonary resuscitation (ECPR)
2397029|NCT03592797|Experimental|Laser acupuncture therapy group|Each subject in the experimental group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany) to stimulate acupuncture points with laser beam irradiation.
2397030|NCT03592797|Sham Comparator|Sham laser acupuncture therapy group|Each subject in the sham control group will receive laser acupuncture therapy using Handylaser Trion device (RJ Laser, Germany). The laser device in the sham group will be deactivated and won't produce any laser beam irradiation on acupuncture points
2397031|NCT03592784|Experimental|Food Order Therapy + Medical Nutrition Therapy|
3189029|NCT00773526|Experimental|1|
2397033|NCT03592771|No Intervention|Usual Care|Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication.
2397034|NCT03592771|Active Comparator|App|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
2397035|NCT03592771|Active Comparator|App+Feedback|"Participants in this group will be asked to use a web-based app to report their AET use in the previous 7 days and any treatment-related symptoms or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week during the 6-month intervention phase.~In addition, participants in this group will also receive weekly tailored feedback text messages or images during the 6-month intervention phase.~Participants will complete a survey at baseline, and then once every 6 months until March 2022 and agree to use an electronic pill monitoring device with their AET medication."
2397036|NCT03592758||ultrasound assessment|all patient are evaluated by an ultrasound assessment before general anaesthesia
3184322|NCT00723164|Active Comparator|FM|Premedication consisting of fentanyl 0.6 ug/kg and midazolam 9 ug/kg (FM), five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
3184323|NCT00723164|Placebo Comparator|NaCl|A 2.5 ml NaCL placebo (NaCl) IV, five minutes before tidal volume sevoflurane 8% induction with 6 L/min O2.
2397039|NCT03592732||A|Patients with atrial fibrillation
2397040|NCT03592732||B|Patients without atrial fibrillation
2397041|NCT03592719|Experimental|MI-PrEP|"Participants in this arm will receive the manualized two-session intervention entitled Motivational Interviewing to Increase PrEP Uptake"
2397042|NCT03592719|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive two sessions which entail psychoeducation on PrEP.
2397043|NCT03592706|Experimental|IKC and TACE|IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)
2397044|NCT03592706|Active Comparator|TACE|TACE (Transcatheter Arterial Chemoembolization)
2397045|NCT03592693|Experimental|Vitamin-Steroid|"Combined Vitamin C and Stress-Dose Hydrocortisone: Patients with septic shock treated with 1500 mg Vitamin C every 6 hours for 4 days after randomization, and stress-dose hydrocortisone for 4 days (250 mg on day 1; and 200 mg on days 2, 3, and 4) after randomization."
2397046|NCT03592693|Placebo Comparator|Control|"Placebo plus placebo: Patients with septic shock treated with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone) for 4 days after randomization."
2397047|NCT03592680|Active Comparator|Vitamin C|Vitamin C 1000mg PO from 5 days before surgery until 10 days after surgery
2397048|NCT03592680|Placebo Comparator|Placebo|Placebo as an alternative for Vitamin C tablets
2397049|NCT03592667|Experimental|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
2397050|NCT03592667|Placebo Comparator|Placebo|Placebo capsules, one per day before breakfast during 12 weeks.
2397051|NCT03592654|Experimental|infant telehelp condition|caregiver coaching to improve infant behaviors that indicate they are at risk for autism spectrum disorder
2397052|NCT03592641|Experimental|Treatment (savolitinib)|Patients receive savolitinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2397053|NCT03592628|Placebo Comparator|Standard Instructions|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care.
2397054|NCT03592628|Experimental|Enhanced Instruction|Subjects enrolled in this arm received standardized teach-back regarding discharge instructions as well as the standard printed discharge instructions regarding post-cesarean wound care AND they received an additional printed visual diagram.
2397055|NCT03592615|Experimental|Cataract group|All participants in this arm undergo cataract surgery for the purpose of vision correction.
2397056|NCT03592615|Experimental|Refractive error group|All participants in this arm undergo corneal refractive surgery for the purpose of vision correction.
2397057|NCT03592602|Experimental|arm movement|Male or female patients, age ≥ 18, who meet the indication of PICC placement and be able to move the arm (abducted and adducted) with compliance will be studied.
2397058|NCT03592589|No Intervention|control group|standard general anesthesia using sevoflurane delivered by a pediatric high concentration mask
2397059|NCT03592589|Experimental|Intervention group|sevoflurane will be deliver by a pediatric high flow nasal canula (2L/KG/min)
2397060|NCT03592563||Red group|"Those participants who had established diagnosis of one or more neurological and/or psychiatric conditions~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire plus an additional subset of questions based on their clinical diagnosis should be done."
2397061|NCT03592563||Yellow group|"Those participants who are high-risk to develop one or more neurological and/or psychiatric conditions, for example:~family history (first degree relative) one or more neurological and/or psychiatric conditions;~examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and/or psychiatric disorders.~Baseline: The participants' medical history, signs, symptoms and diagnoses of neurological and/or psychiatric disorders would be recorded. Neuro-QoL questionnaire should be done."
2397062|NCT03592563||Green group|"Those participants who are not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and/or improvement of their brain health.~Baseline: The participants' medical history would be recorded and Neuro-QoL questionnaire should be done."
2397063|NCT03592550||Group A|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing.
2397064|NCT03592550||Group B|Volunteers will be asked to receive ultrasound imaging in repeat voluntary breath hold and during free-breathing and in repeat spirometer assisted breath hold.
3184324|NCT00723216|Active Comparator|1|Enoxaparin
3184325|NCT00723216|Other|2|Intermittent Pneumatic Compression (IPC)
3184326|NCT00723268|Active Comparator|Prednisolone|
2397065|NCT03592537|Active Comparator|fentanyl|Group F: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + (5ug) of fentanyl intrathecally
2397066|NCT03592537|Active Comparator|midazolam|Group M: will receive intrathecal 0.5% bupivacaine (0.3 mg/kg) + 0.5 mg of midazolam intrathecally
2397067|NCT03592537|Placebo Comparator|Bupivacaine|Group B:intrathecal 0.5% bupivacaine (0.3 mg/kg)
2397068|NCT03592511|Experimental|Intervention|WGPF-burger group
2397069|NCT03592511|Placebo Comparator|Control|Control-burger group
2397070|NCT03592498|Active Comparator|Sulfadiazine, Silver|Intervention: Treatment with silver sulfadiazine ointment. Procedures: wound washing, application of silver sulfadiazine ointment, bandage covered with gauze and bandage. These patients undergone the change of dressings on alternate days.
2397071|NCT03592498|Experimental|Skin of Nile tilapia|"Intervention: treatment with skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.~Procedures: wound washing, application of tilapia skin and dressing with gauze and bandage. These dressings were changed if the skin of the tilapia was loose (not adhered)."
2397072|NCT03592485|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2397073|NCT03592485|Experimental|PECS|Before the induction of general anesthesia, Erector Spinae Plane (ESP) block and Pectoral fascia type I and II will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2397074|NCT03592472|Experimental|Pazopanib plus abexinostat|Randomized patients will receive a combination of pazopanib plus abexinostat. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat p.o twice daily (BID) on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of abexinostat at the same time each day.
2397075|NCT03592472|Placebo Comparator|Pazopanib plus placebo|Randomized patients will receive a combination of pazopanib plus abexinostat matching placebo. The patients will receive pazopanib by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle and will receive abexinostat matching placebo p.o BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Patients will be instructed to take their once- daily oral dose of pazopanib and BID oral dose of placebo at the same time each day.
2397076|NCT03592459|Experimental|Device feasibility (Macy catheter, opioids)|Patients undergo placement of rectal catheter and receive opioids through the Macy catheter.
2397077|NCT03592446|Experimental|Active-raVNS|Transcutaneous electrical vagus nerve stimulation at ear.
2397078|NCT03592446|Sham Comparator|Sham-raVNS|Sham vagus nerve stimulation at ear.
2397079|NCT03592433|Experimental|I Can PIC|The I Can PIC website will be provided to participants randomized to the experimental/intervention group.
2397080|NCT03592433|No Intervention|Attention Control|Participants randomized to the attention control group will be provided a link to a website developed by the American Cancer Society Cancer Action Network.
2397081|NCT03592420|Experimental|Interdisciplinary interventions|"Multicomponent interventions~On-site supervised group exercise program (11 weeks)~Educational / behavioral sessions addressing specific behavioral and environmental risk factors for falls delivered by trained health professionals (11 sessions in total)~Home visits for suggestion and implementations of safety interventions aiming at reducing environmental hazards~Home-based exercise program: Personalized multi-factorial interventions: patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors.~Personalized multi-factorial interventions. Patients will have geriatric, neurology and physiatrist outpatient referrals to assess and treat individual risk factors"
2397082|NCT03592420|Active Comparator|Usual care|Usual care: after pre-test assessment and randomization, participants in the control group will be given a structured booklet with detailed information about participant's own personal risk factors (fall risk profile) to be given to the family doctor, together with an information booklet on fall risk factors and their prevention.
2397083|NCT03592407|Experimental|Treatment (epacadostat, pembrolizumab)|Starting 14 days after completion of standard of care chemoradiotherapy, participants receive epacadostat PO BID during weeks 3-8 and pembrolizumab IV over 30 minutes on day 1 of weeks 3 and 6 in the absence of disease progression or unacceptable toxicity.
2397084|NCT03592394|Active Comparator|Somatic IVR (s-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on encouraging disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
2397085|NCT03592394|Active Comparator|Distractive IVR (d-IVR)|This group will use an Immersive Virtual Reality (Gear VR) device to focus on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
2397086|NCT03592381|Experimental|Ridge expansion by osseodensification|Ridge expansion and osteotomy drilling by osseodensification in conjunction with simultaneous implant placement in narrow ridges.
2397087|NCT03592381|Active Comparator|Ridge expansion by ridge splitting|Ridge expansion by ridge splitting using the piezotome in conjunction with simultaneous implant placement in narrow ridges.
2397088|NCT03592368|Active Comparator|Active IBT, Out of MRI|
2397089|NCT03592368|Sham Comparator|Sham IBT, Out of MRI|
2397090|NCT03592368|Active Comparator|Active IBT, In MRI|
2397091|NCT03592368|Sham Comparator|Sham IBT, In MRI|
2397092|NCT03592355|Experimental|Intervention|"If enrolled in the intervention arm, the following steps will occur:~The Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
2397154|NCT03591952|Experimental|Gravity|The pleural fluid will be drained using gravity drainage to a bag positioned approximately 100 cm (approximately 40 inches) below the catheter entry point (see picture below) using the 40 inch tubing provided in the thoracentesis kit (CareFusion or Arrow).
2397155|NCT03591939||1|cases of Diabetic type two nephropathy
2397156|NCT03591939||2|controls of normal subjects
2397093|NCT03592355|No Intervention|Control|"If enrolled in the control arm, the following steps will occur:~Three months from the time of the follow-up email, the Brigham Health Virtual Care team will work with the clinician toward immediate on-boarding (software training, hardware setup, technical support) as per their usual process.~The clinician will schedule virtual visits as s/he and/or her/his department see fit. Virtual visits occur on an already-in-use Partners- and Brigham-approved video platform."
2397094|NCT03592342|Placebo Comparator|Rivelin® plain patches|Dosing is two times per day (morning and evening) with Rivelin® plain patches (placebo).
2397095|NCT03592342|Experimental|Rivelin®-CLO patch 1µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 1µg Clobetasol propionate per patch.
2397096|NCT03592342|Experimental|Rivelin®-CLO patch 5µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 5µg Clobetasol propionate per patch.
2397097|NCT03592342|Experimental|Rivelin®-CLO patch 20µg|Dosing is two times per day (morning and evening) with Rivelin®-CLO patch 20µg Clobetasol propionate per patch.
2397098|NCT03592329|Experimental|active tVNS + SRT A|active tVNS and Stress Reduction Training A
2397099|NCT03592329|Experimental|active tVNS + SRT B|active tVNS and Stress Reduction Training B
2397100|NCT03592329|Other|sham tVNS + SRT A|sham stimulation and Stress Reduction Training A
2397101|NCT03592329|Other|sham tVNS + SRT B|sham tVNS and Stress Reduction Training B
2397102|NCT03592316|Experimental|Lower Extremity Amputation Pathway|Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.
2397103|NCT03592303||Control|Any pregnant patient with a normal pregnancy is eligible for possible participation in the study.
2397104|NCT03592303||PPH group|Women with PPH requiring biological evaluation of hemostasis
2397105|NCT03592277|Experimental|Intervention Arm|Patients in this arm will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum). In addition, they will receive 200 mg IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
2397106|NCT03592277|No Intervention|Control Arm|Patients in the control arm will receive the 100 mL of 0.9% sodium chloride every six hours and 50 mL of 0.9% sodium chloride every 12 hours to act as placebos for the vitamins C and B1 respectively.
3184327|NCT00723268|Active Comparator|Colchicine|
3184328|NCT00723307|Experimental|Metformin|
2397109|NCT03592251|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2397110|NCT03592251|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
2397111|NCT03592251|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
2397112|NCT03592238|Experimental|Aerobic Exercise Intervention|Participants will exercise on a motor-driven treadmill at a constant speed during the 23-min period.
2397113|NCT03592238|Active Comparator|Trier Social Stress Test for Children|The Trier Social Stress Test for Children consists of a speech task in which children must finish a story and a mental arithmetic task, completed in front of a camera and two neutral observers.
2397114|NCT03592238|Placebo Comparator|Seated Rest|Participants will sit in a comfortable chair, placed in the same room as the motor-driven treadmill, for a period of 25-min.
2397115|NCT03592225|Other|Educational workshop intervention arm|The group of general practitioners (GP) from Lyon (France), about 300, that will be invited to attend the 3 hours educational workshop about HPV vaccination. After the workshop, the GPs will return to their normal health care practice.
2397116|NCT03592225|No Intervention|Control arm|The group of general practitioners (GP) from Lyon (France), about 300, that will NOT be invited to attend the 3 hours educational workshop about HPV vaccination. These GPs perform their normal health care practice.
2397117|NCT03592199|Experimental|1st Line Sunitinib and 2nd Line Axitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
3184329|NCT00723307|Placebo Comparator|Placebo|
3184330|NCT00723320|No Intervention|P+N|placebo without lifestyle intervention
2397120|NCT03592173|Experimental|SAS20|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 20ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2397121|NCT03592173|Active Comparator|SAS0|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 0ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2397122|NCT03592173|Active Comparator|SAS50|The paired stimulation (SAS) will be comprised of patient adjusted subthreshold TMS (80% of resting motor threshold over optimal site for soleus muscle), delivered 50ms prior to a peripheral nerve stimulus in the popliteal fossa and will be repeated at 0.1 Hz for 15 minutes (90 stimuli pairs).
2397157|NCT03591926|Experimental|"BAL Arm"|Subjects in this arm will undergo a bronchoalveolar lavage (BAL) procedure at baseline and after two weeks of treatment.
2397158|NCT03591926|Experimental|"Non-BAL Arm"|Subjects in this arm will not undergo any BAL procedures.
2397159|NCT03591913|Experimental|study group|will receive sublingual misoprostol immediately after urinary catheterization and before skin incision
2397160|NCT03591913|Active Comparator|control group|will receive sublingual misoprostol immediately after skin closure
2398157|NCT03584932|No Intervention|Control arm|Standard of care as set forth by the national HIV care guidelines.
3184331|NCT00723320|Experimental|D+N|Atorvastatin 10mg/d
3184332|NCT00723320|Experimental|P+A|lifestyle intervention without Atorvastatin
3184333|NCT00723320|Experimental|D+A|lifestyle intervention and Atorvastatin 10mg/d
3184334|NCT00723333||Affected Group|Patients > 60 years of age with Primary Myelofibrosis that have undergone an allogeneic transplant
3184335|NCT00723346|Experimental|1|
3184336|NCT00723346|Experimental|2|
3184337|NCT00723346|Experimental|3|
3184338|NCT00723346|Active Comparator|4|
3184339|NCT00723359|Experimental|BT062|BT062 single agent dose escalation
2397123|NCT03592160|Experimental|Experimental group|"The therapy lasted two months, at a rate of two sessions per week, with a duration of 45 minutes per session. The program consisted of pelvic floor exercises assisted by manometric biofeedback, which were performed in supine position for 20 minutes. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.~Together with the treatment at the clinic, patients were asked to perform a series of exercises at home, consisting in: 8-12 sustained contractions of 6 seconds, with a subsequent rest period of double the work-time, followed by 3-5 fast contractions of 2 seconds with maximum intensity, resting double the work-time. Domiciliary exercises were performed in supine, siting and standing position."
2397124|NCT03592160|No Intervention|Control group|The control group received an information brochure with recommendations, including the same program of pelvic floor exercises taught to the patients in the experimental group, but without carrying out any kind of supervision by the physiotherapist.
2397125|NCT03592147|Other|Relaxation|This is a within-subject pilot study, where each participant received, in random order, five different relaxation therapies (Guided Imagery Relaxation Tape, Music Listening, Relaxation Lighting, Meditation and Relaxation Light, and Music and Relaxation Light) and one Control/Silence state spanning across 3-6 weeks.
2397126|NCT03592134||Clinical settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by clinical practice (nocturnal gas exchange, apneas, bradycardia, oxygen desaturation)
2397127|NCT03592134||Physiological settings|Infants with the choice of the non respiratory support and settings of the non respiratory support defined by the measurement of work of breathing
3184340|NCT00723385|Placebo Comparator|Placebo|Placebo administration for 12 weeks with repeated 25-OH D determinations over 12 weeks, dietary, sunshine questionnaire recording
3189030|NCT00773539|Active Comparator|1|
2397130|NCT03592108|Experimental|CSR remote monitoring|The remote monitoring of CPAP treatment will be modified in order to detect the presence of CSR as soon as any significant increase of the apnea-hypopnea index occurs.
2397131|NCT03592095|Experimental|DN group|The intervention group will receive real dry needling (DN) (fast in and fast out needling technique) in an active MTrP within upper trapezius muscle.
2397132|NCT03592095|Placebo Comparator|Placebo needle|The placebo group will receive sham needling in an active MTrP within the upper trapezius muscle. A sham needle will be used as placebo. This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin.
2397133|NCT03592082|Active Comparator|Standard care alone|Participants will receive standard antibiotic therapy for Clostridium Difficile (CDiff) infection without additional adjuvant therapy.
2397134|NCT03592082|Experimental|Standard care with Bismuth subsalicylate (BSS)|Participants will receive BSS524 mg ((2) 262 mg tablets) four times per day for 14 days in addition to standard antibiotic therapy.
2397135|NCT03592069|Active Comparator|10 day concomitant|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~- Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid."
2397136|NCT03592069|Active Comparator|14 day hybrid|"After the confirmation of H. pylori infection, eligible patients randomly assigned to either concomitant or hybrid treatment group will receive:~Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days."
2397137|NCT03592043||MitraClip|All patients who have undergone percutaneous mitral valve repair with the MitraClip system in Canada
2397138|NCT03592017|Experimental|Patients with various retinal diseases|Patients with various retinal diseases will be examined using long-wavelength autofluorescence imaging to assess the performance compared to conventional imaging methods and to quantify the signal compared to a normative database
2397139|NCT03592017|Experimental|Healthy participants|Healthy participants will be examined using long-wavelength autofluorescence imaging to optimize the signal with additional laser sources and device settings and to compile a normative database for the quantification of the signal.
2397140|NCT03592004||Guangdong General Hospital|
2397141|NCT03592004||Cancer Hospital Chinese Academy Of Medical Sciences|
2397142|NCT03592004||Beijing Friendship Hospital|
2397143|NCT03592004||Yunnan Cancer Hospital|
2397144|NCT03592004||Liaoning Cancer Hospital|
2397145|NCT03592004||The First Hospital Of China Medical University|
2397146|NCT03592004||Affiliated Hospital Of Hebei University|
2397147|NCT03591991|Active Comparator|treatment group|Patients will be randomized into two groups after enrolled. In Empagliflozin Group, the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin .After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths. The procedure will double blind to patients and investigators.
2397148|NCT03591991|Placebo Comparator|Placebo group|Patients will be randomized into two groups after enrolled. In Placebo Group, the treatment started 30 minutes before PCI with a dose of 10 mg Placebo .After admission, patients were treated with 10 mg Placebo once daily for 3 mouths. The procedure will double blind to patients and investigators.
2397149|NCT03591978||Healthy non smokers|Healthy subjects with no respiratory disease and never smokers
2397150|NCT03591978||Healthy smokers|Healthy subjects without respiratory disease and at least a cumulative tobacco consumption history of <10 pack-years
2397151|NCT03591978||COPD|COPD patients (diagnosed as recommended by GOLD 2017 strategy) former or current smokers with at least >10 pack-years
2397152|NCT03591965|Experimental|ATG-008|To enroll approximately 40 hepatitis B virus (HBV) positive, unresectable HCC subjects who have previously received at least one prior line of systemic therapy. Among which, approximately 20 subjects will receive oral ATG-008 at an initial dose of 45 mg, once daily (QD) and another approximately 20 subjects will receive oral ATG-008 at an initial dose of 20 mg, twice daily (BID). The pharmacokinetic (PK) samples will be collected from 10 subjects each in the two dose groups.
2397153|NCT03591952|Active Comparator|Suction|The pleural fluid will be drained by the syringe system with a one-way valve tubing system provided in the kit. Selection of the vacuum pressure will be at the discretion of the proceduralist, as per standard of care.
2397194|NCT03591692|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
2397161|NCT03591900|Active Comparator|daibetic thalassemic patients on SC insulin|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on sc insulin"
2397162|NCT03591900|Active Comparator|daibetic thalassemic patients on insulin pump|"A pilot study will be done on 20 patients with abnormal glucose tolerance which will include:~A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be put on insulin pump"
2397163|NCT03591887|Experimental|ABY-035 2 mg|2 mg ABY-035 SC
2397164|NCT03591887|Experimental|ABY-035 20 mg|20 mg ABY-035 SC
2397165|NCT03591887|Experimental|ABY-035 80 mg|80 mg ABY-035 SC
2397166|NCT03591887|Experimental|ABY-035 160 mg|160 mg ABY-035 SC
2397167|NCT03591887|Placebo Comparator|Placebo|Placebo, switching to 80 mg ABY-035 after 12 weeks
2397168|NCT03591874|Experimental|OCU-300|Brimonidine Tartrate Nanoemulsion Eye Drops 0.18% given 2 times a day for 12 weeks.
2397169|NCT03591874|Placebo Comparator|Placebos|Placebo - Ophthalmic buffered saline Eye Drops given 2 times a day for 12 weeks.
2397170|NCT03591861|Experimental|Ketogenic Diet|"Caregivers (and participating children) attend intro ketogenic diet class (4 - 30 min lectures)~Clinic visit with neurologist, nurse, and dietitian prior to hospital admission and then once every 3 months~Laboratory studies prior to hospital admission and then at each follow-up visit~Hospital admission (3-5 day) to start the ketogenic diet~Standard of care chemotherapy with BCNU for up to 2 years~Ketogenic diet can continue for up to 2 years"
2397171|NCT03591848|Experimental|DECISIF|Exposed to an online support decision tool, in addition of the standard oral information
2397172|NCT03591848|Active Comparator|IRIS|Exposed to a standard oral information
2397173|NCT03591835|Active Comparator|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
2397174|NCT03591835|Active Comparator|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear.
3143507|NCT00006363|Experimental|Intensification Unfavorable PBSCT Group|Patients receive etoposide IV continuously and HiDAC IV over 2 hours every 12 hours on days 1-4. Patients also receive G-CSF SC daily beginning on day 14 and continuing until PBSC collection is completed. Patients who are not able to undergo PBSCT after HiDAC/etoposide continue treatment in the non-PBSCT group. At least 4 weeks after HiDAC/etoposide recovery, patients receive oral busulfan every 6 hours on days -7 to -4 and etoposide IV over 4 hours on day -3 prior to PBSCT. Patients receive autologous PBSC infusion on day 0. Patients also receive G-CSF SC beginning on day 0 and continuing until hematopoietic recovery.
2397177|NCT03591809|Experimental|combined exercise training group|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
2397178|NCT03591809|No Intervention|Control group|The patients in the control group will not apply an exercise training.
2397179|NCT03591796|Experimental|HFOV|Ventilated infants were randomized to HFOV.
2397180|NCT03591796|Active Comparator|CMV|Ventilated infants were randomized to CMV.
2397181|NCT03591783||study group|All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.
2397182|NCT03591770|Experimental|UC patients on tofacitinib monotherapy|Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
2397183|NCT03591770|Active Comparator|UC patients on anti-TNF monotherapy|Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
2397184|NCT03591770|Active Comparator|UC patients on anti-TNF and a thiopurine|Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
2397185|NCT03591770|Active Comparator|UC pts. on aminosalicylates or off immunomodulatory therapy|Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.
2397186|NCT03591757|Experimental|Tolcapone|Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
2397187|NCT03591744|Experimental|Treatment (daratumumab, bortezomib, chemotherapy)|Participants receive daratumumab IV on days 1, 8, 15, and 22, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 1 and 2. Participants then receive daratumumab IV on days 1, and 15, dexamethasone IV/PO on days 1, 2, 8, 9, 15, 16, 22, and 23, pegylated liposomal doxorubicin hydrochloride IV on day 8, lenalidomide PO daily on days 1-14, and bortezomib SC on days 1, 4, 8, and 11 of courses 3 and 4. Courses repeat every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants may receive up to 8 courses at the discretion of treating physician.
2397188|NCT03591731|Experimental|Arm A : monotherapy arm|Nivolumab administered IV
2397189|NCT03591731|Experimental|Arm B : combination arm|Nivolumab administered IV followed by ipilimumab administered IV
2397190|NCT03591718|Experimental|BI 456906|
2397191|NCT03591718|Experimental|Placebo|
2397192|NCT03591705|Experimental|TACE-HAIC|hepatic artery chemo-lipiodolization with EADM, followed by FOLFOX-based chemotherapy artery infusion
2397193|NCT03591705|Active Comparator|HAIC|FOLFOX-based chemotherapy hepatic artery infusion
2397196|NCT03591679|Experimental|study group|patients at risk of uterine atony undergoing cesarean section underwent bilateral uterine artery ligation and received oxytocin.
2397197|NCT03591679|Active Comparator|control group|patients at risk of uterine atony undergoing cesarean section received oxytocin only.
2397198|NCT03591666|Experimental|Study Group|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2397199|NCT03591653|Experimental|LXI-15028 50mg group|
2397200|NCT03591653|Placebo Comparator|Placebo group|
2397201|NCT03591640|Active Comparator|Pregnant with hemoglobinopathy|Standard of care with blood test before active labor
2397202|NCT03591640|Active Comparator|Pregnant without known hemoglobinopathy|Standard of care with blood test before active labor
2397203|NCT03591627||AF or AFl patients|Patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
3143508|NCT00006363|Experimental|Intensification Unfavorable Non-PBSCT Group|Patients receive etoposide, HiDAC, and G-CSF as in the PBSCT group. After hematopoietic recovery, patients then receive HiDAC IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats no earlier than 28 days after prior course and no later than 14 days after hematopoietic recovery for one more course.
2397205|NCT03591601|Active Comparator|Manual therapy protocol|Treatment based on manual therapy with proven evidence.
2397206|NCT03591601|Experimental|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
2397207|NCT03591601|Placebo Comparator|Placebo Control|Placebo treatment based on the placement of the hands on the head without intention to treat.
2397208|NCT03591588|Active Comparator|high-saturated fat diet|Diet high in saturated fat (~50% calorie from fat, ~25% from saturated fat)
2397209|NCT03591588|Active Comparator|low-fat diet|Diet with low fat (~25% calorie from fat)
2397210|NCT03591575|Experimental|Deferiprone|Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
2397211|NCT03591575|Placebo Comparator|Placebo|Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses
2397212|NCT03591562||COSYCONET COPD Subcohort|"MRI and CT of the lung will be performed in a multi-centre subcohort of 370 patients having already participated in the precursor trial  Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR-COPD), NCT 02629432."
2397213|NCT03591549|Experimental|fulvestrant arm|patients will receive fulvestrant + zoladex intramuscular monthly with an assessment every three months to assess the response and progression
2397214|NCT03591536|Other|pentoxifylline oral|50 adult patient underwent elective CABG intervention to be administered will be receiving main drug (pentoxifylline )oral 400 mg' every 8 hours from three days before surgery and on the day of surgery effect of intervention regarding antioxidant
2397215|NCT03591536|Placebo Comparator|placebo|50 adult patient underwent elective CABG received oral placebo pill resembling completely to pentoxifylline 400 mg, every 8 hours from three days before surgery and on the day of surgery
2397216|NCT03591523||Suspicion of vascular pathology|Subjects indicated to quantitative MR angiography and duplex sonography for suspicion of cervical or intracranial vascular pathology
3143509|NCT00006363|Experimental|Immunotherapy Arm I|Patients begin therapy no later than 120 days after the first day of the last course of HiDAC treatment OR day 0 of PBSCT. Patients receive low-dose IL-2 SC on days 1-14, 19-28, 33-42, 47-56, 61-70, and 75-90. In addition, patients receive high-dose IL-2 SC on days 15-17, 29-31, 43-45, 57-59, and 71-73.
2397218|NCT03591497|Experimental|Intervention Group|"Instrument to be used:~Software Neuro@home (semi immersive virtual reality system for neurological rehabilitation) was used. In each of the sessions, an avatar on screen that representing the patient was regulated by the patient to perform a virtual task that focused on the training of a specific body part.~Programme schedule:~Each session of virtual reality therapy lasted for thirty minutes. Day 0 included an orientation to the machine with five minutes of gaming. This was followed by virtual reality therapy for five days a week at the same time of the day for three consecutive weeks."
2397219|NCT03591497|No Intervention|Control Group|Virtual reality sessions were not provided.
2397220|NCT03591484|Experimental|G1 dentate healthy older|Treatment with Photodynamic therapy (n = 20). The dentate participants will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2397221|NCT03591484|Experimental|G2 healthy older/dentures|Treatment with Photodynamic therapy (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2397222|NCT03591484|Active Comparator|G3 dentate older bronchiectasis|Treatment with tongue scraper (n = 20). The dentate participants with bronchiectasis will received periodontal treatment. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2397223|NCT03591484|Active Comparator|G4 older bronchiectasis /dentures|Treatment with tongue scraper (n = 20). The participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before these steps
2397224|NCT03591471|Experimental|TCM multistep therapy|"Light HSPN:1.Glycosides Of Tripterygium Wilfordii Hook(GTW): initial dosage is 1.5mg/kg/d(4 weeks),continued with 1mg/kg/d(8 weeks),12weeks in total. Severe HSPN:1.GTW:the initial dosage is 2mg/kg/d(2 weeks), continued with 1.5mg/kg/d(2 weeks) and 1mg/kg/d(8 weeks); 12weeks in total.~On the above base,Sulfotanshinone Sodium Injection(1mg/kg/d,2weeks) and Qingrezhixue granules(a nosocomial preparation) combined with Chinese herbs(12weeks) based on TCM syndrome differentiation are taken at the same time."
2397225|NCT03591471|Active Comparator|Routine medicine|"Light HSPN:1.Lotensin: 5-10mg/d,12weeks; 2.Low Molecular Weight Heparin(LMWH):100u/kg,2weeks;3.Dipyridamole:3mg/kg/d,Tid,12weeks.4.Chinese medicine placebo,12weeks.~Severe HSPN:Add pednisone on the treatment of Light HSPN,and gradually reduce the dosage in 12 weeks,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）"
3143510|NCT00006363|Active Comparator|Immunotherapy Arm II|Patients are observed and receive no further therapy.
3189031|NCT00773539|Active Comparator|2|
3184341|NCT00723385|Experimental|Vitamin D|Vitamin D (1000 or 2000 IU/day)
3184342|NCT00723411|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on Days 90 and 270.
2397228|NCT03591445|Experimental|Experimental：Bronchoscopy|Patients with ground glass opacity featured lung cancer who are candidates for surgeyr received the bronchoscopy examination before surgery.
2397229|NCT03591432|Experimental|THRIVE|Using transnasal humidified rapid insufflation ventilatory exchange (THRIVE) oxygenation technique in elderly patients undergoing induction of anesthesia.
2397230|NCT03591432|Active Comparator|Facemask|Using facemask technique in elderly patients undergoing induction of anesthesia.
2397231|NCT03591419|Experimental|polymer clip|polymer clips will be used to ligate the appendicular stump. and time and ease of appliction and cost of clips will be calculated
2397232|NCT03591419|Active Comparator|endoloop|endoloops will be used to ligate the appendicular stump an time and ease of application and cost of loops will be calculated
3184343|NCT00723411|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on Days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on Days 90 and 270.
3184344|NCT00723411|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on Days 1, 30, 90, and 270.
2397235|NCT03591393|Experimental|Pregnant women|"questionnaire at 1st and 3rd trimester, 10-12 weeks postpartum and 12 months postpartum~pelvic floor ultrasound at 1st trimester and at 3rd trimester"
2397236|NCT03591380|Experimental|Experimental: Belimumab|Belimumab 10mg/kg will be administered IV at the following intervals: at the time of transplant (Day 0), then post-transplant at 2, 4, 8, 12, 16, and 20 weeks.
2397237|NCT03591367|Other|Hematuria due to suspicious superficial bladder tumor|MicroRNAs-155 (miRNAs-155) and Human telomerase reverse transcriptase (hTERT)
2397238|NCT03591354|Experimental|Closed Loop Control (CLC)|"Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of CLC in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is participants who had 6 months of SAP in the primary trial (DCLP3 Pivotal Trial)~Objective 3: This arm is participants who had 3 months of CLC in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
2397239|NCT03591354|Active Comparator|Predictive-Low Glucose Suspend (PLGS)|"Participants randomized to Predictive-Low Glucose Suspend (PLGS) will use the t:slim X2 with Basal-IQ & Dexcom G6 CGM for 3 months.~Objective 1: This arm is participants who had 6 months of PLGS in the primary trial (DCLP3 Pivotal Trial)~Objective 2: This arm is not applicable to objective 2~Objective 3: This arm is participants who had 3 months of PLGS in the extension trial (DCLP3 Extension) will continue use of the Control-IQ Technology & Dexcom G6 CGM until the product is commercially available."
2397240|NCT03591341||nursing women|women who gave birth and are breast feeding their baby- melatonin level in pumped breast milk have been checked
2397241|NCT03591328||Culprit|Plaques which is related with acute coronary syndrome
2397242|NCT03591328||Non-culprit|Plaques which is not related with acute coronary syndrome
2397243|NCT03591315||TG group|Patients with visual impairment caused by chiasma compression from sellar area tumors will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
2397244|NCT03591315||HC group|Volunteers with no visual impairment(visual acuity of both eyes >1.0) or Nervous System disease will undergo the following examinations: resting state fMRI, visual tasking state fMRI, diffusion tensor imaging (DTI), visual acuity and automated visual field test.
2397245|NCT03591302|Experimental|Immune tolerance, Kidney transplantation|Intervention: HLA matched living donor recipients of a functioning kidney transplant graft at one year will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance such as to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
2397246|NCT03591289|Active Comparator|Deep NMB|Deep NMB: Intervention: Rocuronium will be given as a continuous infusion for deep block. TOF will be maintained at 0 (zero) with at least one PTC. Patients' paralysis will be continued through the anesthesia period. At the end of surgery, patients will receive 4 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
2397247|NCT03591289|Active Comparator|Moderate NMB|Moderate NMB: Intervention: Rocuronium will be used as bolus doses to achieve a moderate block. TOF will be maintained between 1 to 3 twitches. PTC will not be counted. Paralysis will be continued throughout the anesthesia period. At the end of surgery, patients will receive 2 mg/kg sugammadex and the patient's trachea will be extubated according to routine extubation criteria.
2397248|NCT03591276|Experimental|Pembrolizumab and PLD|"Cohort S1: IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 every 3 weeks.~Reduced Dose Cohort (R1)*: IV pembrolizumab 200 mg flat dose with IV PLD 24 mg/m2 every 3 weeks.~*Subjects will be recruited into the R1 cohort only if DLT is reported in 2 or more subjects during the first 2 cycles of treatment in the first 6 patients of the S1 cohort."
2397249|NCT03591263||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic respiratory disease, such as chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis that referred for evaluation as routine care at Physical Therapy Center (National Taiwan University)
2397250|NCT03591237|Experimental|MBCT|As patients with significant pain are identified and accept the offer of receiving 'Mindfulness-Based Cognitive Therapy' (MBCT) for pain, they will be consecutively included in groups of 12-20 participants. The patients will participate in eight weekly two hour group sessions and will be asked to do an additional 45 minutes of daily training at home.
2397251|NCT03591224|Active Comparator|Intervention|Pharmacist optimizing antidepressant therapy using the patient's personalized pharmacogenomic report to make recommendations.
3184345|NCT00723424|Experimental|1|AZD5672 + Digoxin (single dose on day 12)
3184346|NCT00723424|Experimental|2|AZD5672 (increasing dose up to 150mg) + digoxin (single dose on day 12)
3189032|NCT00773539|Active Comparator|3|
2397257|NCT03591185|Experimental|Exercise group|Exercise group, including community-dwelling adults aged 50 years or over, will perform an initial evaluation, 24 intervention sessions with FallSensing clinical tool (2 or 3 sessions per week) and a final evaluation.
2397258|NCT03591172|Experimental|propolis|natural antibacterial, anti-inflammatory irrigation solution
2397259|NCT03591172|Experimental|Nano-propolis|natural antibacterial, anti-inflammatory irrigation solution
2397260|NCT03591172|Active Comparator|saline|sodium chloride irrigation solution
2397261|NCT03591159|Active Comparator|Membrane Sweeping Group|
2397262|NCT03591159|No Intervention|Control Group|
3184347|NCT00723463|Experimental|A|To determine if apparent diffusion coefficient values can differentiate tumors from normal tissues using a 3T MRI scan.
3184348|NCT00723476|Active Comparator|A|Participants will receive three 60- to 90-minute health education control sessions.
3184349|NCT00723476|Experimental|B|Participants will receive three 60- to 90-minute Family Centered Advanced Care Planning sessions.
3184350|NCT00723502|Experimental|1|
3184351|NCT00723502|Experimental|2|
2397268|NCT03591133|Other|Step1:3㎎ QD|Drug: TS-143 3mg Drug: Placebo
2397269|NCT03591133|Other|Step2:6㎎ QD|Drug: TS-143 6mg Drug: Placebo
2397270|NCT03591133|Other|Step3-1:11㎎ QD|Drug: TS-143 11mg Drug: Placebo
2397271|NCT03591133|Other|Step3-2:11㎎ QD（Fed)|Drug: TS-143 11mg Drug: Placebo
2397272|NCT03591133|Other|Step4:20㎎ QD|Drug: TS-143 20mg Drug: Placebo
2397273|NCT03591133|Other|Step5:36㎎ QD|Drug: TS-143 36mg Drug: Placebo
2397274|NCT03591107|Experimental|PTSD Care Management (PCM)|In addition to the education and feedback components for both conditions the PCM intervention provides access to a trained Care Manager (CM) who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist.
2397275|NCT03591107|Active Comparator|Minimally Enhanced Usual Care (MEU)|The MEU condition will consist of only clinician education, patient education (Information Sheet) and feedback about having a probably diagnosis of PTSD to both the clinician and patient.
2397276|NCT03591094|Active Comparator|PTI-428 dose level 1|
2397277|NCT03591094|Active Comparator|PTI-428 dose level 2|
2397278|NCT03591094|Placebo Comparator|Placebo PTI-428|
2397279|NCT03591081|Other|Intellin smart phone application|Participants will download a smart phone app, the platform will give the patients daily hints and tips on how to look after their feet.
3184352|NCT00723515|Active Comparator|G1|NaF (sodium fluoride varnish) with 2.26% of fluoride
2397281|NCT03591055|Experimental|Intervention Group|Patients in the intervention group will be first derived to a nurse case manager for initial application of a comprehensive geriatric assessment. Then patient-centered interventions will be prescribed, according to the different target areas identified in the geriatric assessment. All participants in the intervention group will undergo a medication review and will also perform an aerobics exercise plan in the primary care centre, 60-minute session twice a week on non-consecutive days for 6 weeks (12 sessions of 60 minutes each) and memory workshops (10 sessions).
2397282|NCT03591055|No Intervention|Control group|Participants in the control group will receive the usual standard care and regular referrals.
2397283|NCT03591042|Experimental|cervical length screening|cervical length screening
2397284|NCT03591042|No Intervention|no screening|no screening
2397285|NCT03591016||Difficult intravenous access|Recording number of IV attempts in the operating room prior to surgery start.
2397286|NCT03591003||HIV-infected patients|HIV-infected patients vaccinated at least once in their life against yellow fever
2397287|NCT03590977|Experimental|licorice extract mouthwash|administration of a mouthwash containing licorice as a preventive measure to high caries risk patients (faculty of pharmacy, cairo university)
2397288|NCT03590977|Placebo Comparator|chlorohexidine mouthwash|administration of chlorohexidine 0.2% in 1:1 diluation mouthwash that is broad spectrum antimicrobial activity to high caries risk patients
2397289|NCT03590964|Active Comparator|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
2397290|NCT03590964|Experimental|Sinus lift using bone ring containing the implant|Patients with atrophied posterior maxilla will undergo sinus lift using bone ring containing the implant.
2397291|NCT03590925||new screening and referring system of ICD|Non-randomized, non-blinded, multi-center study receiving new screening and referring system of ICD
2397292|NCT03590912|No Intervention|Wait and watch (Group D)|Wait and watch for 1 month
2397293|NCT03590912|Experimental|Mometasone spray (Group B)|Standard dose of mometasone furoate nasal spray (one spray in each nostril once daily) for one month will be given
2397294|NCT03590912|Experimental|antibiotic + histaminic + oxymetazoline drops (Group A)|This group will receive oral cefpodoxime (10 mg/kg/day in two divided dose for a week) plus oral histaminics and oxymetazoline drops. Standard dose of oral histaminics (levocetirizine, 1.25 mg for age below six years, 2.5 mg for older age) for a month plus oxymetazoline nasal drops (Nasivion 0.025%) for two weeks will be given
2397295|NCT03590912|Experimental|Oral steroid (Group C)|Patients in this group will receive one mg/kg/day of oral prednisolone (Oral steroid) in two divided dose for a week followed by half mg/kg/day in two divided dose for next one week
2397296|NCT03590899||Healthy patients|
2397297|NCT03590886||total response Group|The PBC patients show biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
2397298|NCT03590886||poor response group|The PBC patients show poor biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
2398158|NCT03584919|Active Comparator|EM doxycycline|patients with EM who received doxycycline
3184353|NCT00723515|Experimental|G2|NaF (sodium fluoride)2.71% of fluoride plus CaF2 (calcium fluoride)
3184354|NCT00723541|Experimental|A|Develop a computer-aided diagnostic system that will aid in the screening and detection of breast abnormalities/cancer
3184355|NCT00723567||Affected Group|Family members of northern European descent in which members have different erythrocyte morphology ranging from atypical HPP to HE to normal and a novel Sp mutation.
2397300|NCT03590873|Experimental|Restrictive group|"Intervention: administration of vasopressin 0.01 - 0.04 U/min after induction of anesthesia.~Intraoperative fluid management: administration of 2-4 ml/kg/hr of crystalloid solution."
2397301|NCT03590860|Experimental|LY3322207 (Part A)|LY3322207 administered subcutaneously (SC)
2397302|NCT03590860|Placebo Comparator|Placebo (Part A)|Placebo matching LY3322207 administered SC
2397303|NCT03590860|Experimental|LY3322207 (Part B)|LY3322207 administered SC once weekly
2397304|NCT03590860|Placebo Comparator|Placebo (Part B)|Placebo matching LY3322207 administered SC once weekly
2397305|NCT03590860|Experimental|LY3322207 (Part C)|LY3322207 administered SC in participants with hypertension
2397306|NCT03590847|Experimental|Intermittent fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks.
2397307|NCT03590834|Experimental|Center-based intervention|In-person, child-focused intervention taking place only at the Head Start centers
2397308|NCT03590834|Experimental|Center-and-home-based intervention|In-person, child-focused intervention taking place only at the Head Start centers. Delivered in-person at Head Start centers and the family home.
2397309|NCT03590834|Active Comparator|Active Control|Active comparison group
2397310|NCT03590821|Experimental|Aspirin 81 mg/Placebo|Participants will receive aspirin in Phase 1 followed by matched placebo in Phase 2, or vice versa, over 14 days. The order will be randomized and aspirin/placebo will be double-blinded.
2397311|NCT03590821|Experimental|Celecoxib 200mg capsule|Participants will receive celecoxib in Phase 1 and Phase 2 over 7 days. This is open, meaning participant and investigator will recognize celecoxib capsules.
2397312|NCT03590808|Experimental|Immune checkpoint inhibitor|"Solid cancer patients who receiving immune checkpoint inhibitor patients~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
2397313|NCT03590808|Active Comparator|Cytotoxic chemotherapy|"Solid cancer patients who receiving conventional cytotoxic chemotherapy~will be undergone Influenza vaccination using purified inactivated influenza virus antigen (Green Cross Corp.) 0.5 mL IM once"
2397314|NCT03590795||Problem Sleepers|Those individuals that have self identified as having a unspecified sleep problem will take the sleep survey.
2397315|NCT03590769|Experimental|PET/MR using FDG-18 radiotracer|Using FDG-18 radiotracer, subject undergoes PET/MR scan which detects the uptake of the tracer.
2397316|NCT03590756|Experimental|High mango group|250g (1.5 cup) of mango intake per day, 4 days a week for 16 weeks
2397317|NCT03590756|Other|Low mango group|85g (0.5 cup) of mango intake per day, 4 days a week for 16 weeks
3184356|NCT00723619||1|Children and adolescent from German schools in the region Wesel, Hannover and Düsseldorf, selected via special school lists
3184357|NCT00723658|No Intervention|Observation|Non-symptomatic patients are monitored monthly for 3 months, then every 3 months thereafter.
2397320|NCT03590730||Valvular heart disease|Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.
2397321|NCT03590717|Other|BCC-Only|Intervention: Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
2397322|NCT03590717|Experimental|Small-voucher|Intervention: Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
2397323|NCT03590717|Experimental|Large-voucher|Intervention: Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
2397324|NCT03590704|Experimental|Intervention Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region. The bandage will not be applied on the scar. If there are any complications such as itching, redness, discomfort and / or others, the patients will remove the material at home and communicate on return to the institution. They will remain four days approximately for revaluation and intervention suspension.
2397325|NCT03590691|Active Comparator|Comparison group|Vietnam National Hypertension Program: a training program for health care workers and a health educational program for general public.
2397326|NCT03590691|Experimental|Intervention group|"Vietnam National Hypertension Program including training program for health care workers and an health educational program for general public.~PLUS~Three selected enhancements integrated into routine clinical care:~expanded community health worker services;~home blood pressure self-monitoring; and~a storytelling intervention."
2397327|NCT03590678||1|Subject is scheduled for an invasive procedure and did not have NIPT testing in current pregnancy
2397328|NCT03590678||2|Subject is scheduled for an invasive procedure and has a known positive or no-call result from a targeted NIPT in the current pregnancy
2397329|NCT03590665|Other|Individuals with Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
2397361|NCT03590470|No Intervention|Control|The design used for the INTERCARE intervention is a non-randomized stepped wedge design, therefore all nursing homes will receive the intervention but at different time points. All nursing homes will be in a control phase before receiving the intervention, and switch to the intervention phase, once the intervention is implemented.
2397362|NCT03590457|Other|High-Flow/Swallow|All participants will be subjected to all three flows randomly. All participants will be asked swallow water and applesauce
2397330|NCT03590665|Other|Individuals without Down syndrome|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
2397331|NCT03590652|Experimental|ixazomib, daratumumab, pomalidomide and dexamethasone|Daratumumab will be administered at 16mg/kg IV weekly x 8 weeks, biweekly x 8 weeks, then monthly. Pomalidomide 4mg will be administered orally daily for days 1-21. Patients ≤ age 75 will receive a 40mg dose of dexamethasone, and those over the age of 75 may receive a 20mg dose of dexamethasone orally on days 1, 8, 15, and 22 (weekly). Ixazomib will be administered 4mg orally on days 1, 8 and 15.
2397332|NCT03590626|Experimental|Dulaglutide group|receive dulaglutide 0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks plus standard treatment for type 2 diabetes
2397333|NCT03590626|No Intervention|Control group|receive standard treatment for type 2 diabetes and up titration of treatment will be done by anti-diabetic medicines other than the GLP-1 receptor agonist
3184358|NCT00723658|Experimental|Treatment|"Symptomatic pts: 2 cycles VTDPACE+R:~dex 40 mg PO D1-4 thalid 200 mg PO D1-4 cisplatin 10 mg/m2 IV D1-4 dox 10 mg/m2 IV D1-4 cyclophos 400 mg/m2 IV D1-4 etoposide 40 mg/m2 IV D1-4 bortezomib 1.0 mg/m2 IV D1,4,8,11 ritux 375 mg/m2 IV D1,8,15 lovenox 40 mg/d SQ D1-platelets >50,000/mcl GCSF 10 mcg/kg/d IV D9-WBC <2,000/mcl apheresis >/= 20x10^6 when WBC and CD34 within normal range, up to 4 cycles~st Trans: mel 200 mg/m2 IV D-1 bortezomib 1.3 mg/m2 IV D-4, -1 PBSC >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 500 ml IV D-1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1~nd Trans: BCNU 300 mg/m2 IV D-5 etoposide 200 mg/m2 IV D-5 to -2 AraC 400 mg/m2 IV D-5 to -2 mel 140 mg/m2 IV D-1 PBSC infusion >/=3.0x10^6/kg CD34 cells IV D0 GCSF 5 mcg/kg/d SQ D6-WBC recovery D5NS 150 ml/hr IV D-5 to -1 dex 40 mg/d PO D-4 to -1 ondansetron 24 mg OR granisetron 2 mg PO D-1"
3184359|NCT00723671|Experimental|metabolic peaks|
3184360|NCT00723684|Placebo Comparator|Placebo group|This group will receive no real EEG-Neurofeedback.
3184361|NCT00723684|Experimental|NF group|This group will receive real EEG-Neurofeedback
2397338|NCT03590600|Experimental|Cohort 1: 125 mg BTZ-043 fasting|N=8, 125 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2397339|NCT03590600|Placebo Comparator|Cohort 1: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2397340|NCT03590600|Experimental|Cohort 2: 250 mg BTZ-043 fasting|N=8, 250 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2397341|NCT03590600|Placebo Comparator|Cohort 2: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2397342|NCT03590600|Experimental|Cohort 3: 500 mg BTZ-043 fasting|N=8, 500 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2397343|NCT03590600|Placebo Comparator|Cohort 3: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2397344|NCT03590600|Experimental|Cohort 4: 1000 mg BTZ-043 fasting|N=8, 1000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2397345|NCT03590600|Placebo Comparator|Cohort 4: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2397346|NCT03590600|Experimental|Cohort 5: 2000mg BTZ-043 fasting|N=8, 2000 mg BTZ-043 fasting, oral administration, powder and solvent for oral suspension, single dose
2397347|NCT03590600|Placebo Comparator|Cohort 5: Placebo|N=2, matching placebo, powder and solvent for oral solution, single dose
2397348|NCT03590587||1|patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
2397349|NCT03590574|Experimental|AUTO4|Relapsed or refractory T cell non-Hodgkin Lymphoma patients
2397350|NCT03590561|Experimental|High caloric diet|Participants will eat 1500 kcal more than their usual diet for five days.
2397351|NCT03590561|No Intervention|Control diet|Participants will eat regular diet.
2397352|NCT03590548||gausher disease in children|• Inclusion criteria: All cases with confirmed diagnosis of Gaucher disease type 1 and type 3 receiving enzyme replacement therapy at Assuit University Children's Hospital.
2397353|NCT03590535||Patients with Possible ACS|Adult patients presenting to the Emergency Department with symptoms that maybe be caused by acute coronary syndrome, who are clinically considered to be at enough risk for ACS to send a cardiac enzyme as part of the diagnostic evaluation.
2397354|NCT03590522||Group I:|Thirty heart failure patients
2397355|NCT03590522||Group II:|Twenty healthy controls
2397356|NCT03590509|Experimental|Telemedicine Program*|"Integrated Telemedicine-Home Visitation* Program.~*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented"
2397357|NCT03590509|Active Comparator|Control|Usual Comprehensive Care
2397358|NCT03590496|Active Comparator|Arm 1|31 patients will be treated with 500mg Calcium-Propionate capsules (twice a day) for 8 weeks.
2397359|NCT03590496|Placebo Comparator|Arm 2|31 patients will be treated with placebo capsules (twice a day) for 8 weeks.
2397360|NCT03590470|Experimental|Experimental_INTERCARE intervention|Implementation of a nurse-led model of care adapted to the Swiss context, comprising a geriatric nurse expert with specific training in multidimensional clinical assessment and quality improvement tools.
3184362|NCT00723723||Patients with coronary heart disease|Patients being treated with a statin for secondary prevention of coronary heart disease
3184363|NCT00723762||1|Resident of Hattie Larlham long-term care facility receiving VPA
3184364|NCT00723762||2|Control AED patients will be recruited based on similar AED regimens excluding VPA, length of time on AED (number of months to >1 year), age, and gender; one control patient per VPA patient.
3184365|NCT00723762||3|Control non-AED patients will be recruited based on age and gender; one control patient per VPA patient.
3184366|NCT00723775|Other|Part 1|GSK706769 new vs. current formulation; GSK706769 alone vs. GSK706769 plus Kaletra
3184367|NCT00723775|Other|Part 2|GSK706769 alone for 10 days; GSK706769 + Kaletra for 14 days
2397363|NCT03590444|Active Comparator|Prompt laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on the same day (prompt' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on the same day [Ranibizumab (Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
2397364|NCT03590444|Active Comparator|Deferred laser group|"Eyes of eligible patients will be randomized (ratio 1:1) and receive ranibizumab and focal/grid laser on one week prior to laser treatment (deferred' group, 25 eyes, 50%).~Interventions: ranibizumab and focal/grid laser on one week prior to laser treatment [Ranibizumab 0.5 MG/0.05 ML Intraocular Solution]"
2397365|NCT03590431|Other|bioavailability iodine milk (extrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine in milk, low protein-bound fraction)
2397366|NCT03590431|Other|bioavailability iodine milk (intrinsic)|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine in milk, high protein-bound fraction)
2397367|NCT03590431|Other|bioavailability water iodine solution|300 ml water iodine solution delivering ≈ 200 µg iodine (water iodine solution)
2397368|NCT03590418||Intestinal stoma output|No interventions.
2397369|NCT03590418||Colonic feaces|No interventions.
2397370|NCT03590418||Healthy Control|No interventions.
3184368|NCT00723853|Experimental|Group 1|Reach-Out Program, Nutritional and Exercise Intervention
2397372|NCT03590392|Experimental|Group 1|Group 1 volunteers (n= 6) will be administered ChAdOx1 Chik, 5 x 10^9 vp through intramuscular route.
2397373|NCT03590392|Experimental|Group 2|Group 2 volunteers (n= 9) will be administered ChAdOx1 Chik, 2.5 x 10^10 vp through intramuscular route.
2397374|NCT03590392|Experimental|Group 3|Group 3 volunteers (n= 9) will be administered ChAdOx1 Chik, 5 x 10^10 vp through intramuscular route.
2397375|NCT03590379|Experimental|CHF 5993 DPI|BDP/FF/GB DPI 100/6/12,5 mcg
2397376|NCT03590379|Active Comparator|CHF 5993 pMDI|BDP/FF/GB pMDI 100/6/12,5 mcg
2397377|NCT03590379|Active Comparator|CHF 1535 pMDI|BDP/FF pMDI 100/6 mcg
2397378|NCT03590366|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
2397379|NCT03590366|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 4 pumps of IP per application to the face twice-a-day."
2397380|NCT03590353|Active Comparator|Dual chamber pacemaker|"Patients with sinus node disfunction: sinus node disfunction with obvious clinical symptoms, including sinus pause; patients with chronotropismus disfunction; patients have to take some medicine due to some diseases, but the medicine may result to sinus bradycardia.~Adult Acquired Atrioventricular Block (AVB): (1). Third degree or advanced atrioventricular block in any block part with symptomatic bradycardia (2). Patients taking other antiarrhythmic drugs in long term, which could result in third degree or advanced AVB (in any block part) and symptomatic bradycardia;~Patients with acute myocardial infarction (AMI) and AVB:~(1). Patients with His-Purkinje system persistent second degree AVB and retardant or third degree AVB after STEMI; (2). Patients with temporary severe second degree AVB or third degree AVB (block part under atrioventricular node) and retardant; 4. Patients with carotid sinus hypersensitivity or neurogenic syncope of the heart;"
2397381|NCT03590353|Experimental|His bundle pacemaker|His Bundle Pacemaker: All of the Criteria Inclusion of dual chamber pacemaker excluding patients with block part under the his bundle;
2397382|NCT03590340|Experimental|Group 1a (PfSPZ Vaccine)|"Group 1a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 113.~Controlled human malaria infection (CHMI) with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2397383|NCT03590340|Experimental|Group 2a (PfSPZ Vaccine)|"Group 2a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last prime dose by DVI injection."
2397384|NCT03590340|Experimental|Group 3a (PfSPZ Vaccine)|"Group 3a: subjects (n=21) will receive four doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1, 3, 5, and 7 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2397385|NCT03590340|Experimental|Group 4a (PfSPZ Vaccine)|"Group 4a: subjects (n=21) will receive two doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) on Days 1 and 8 as a prime, followed by a boost of 9.0x10^5 PfSPZ Vaccine on Day 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last boost dose by DVI injection."
2397386|NCT03590340|Placebo Comparator|Group 1b (NS)|"Group 1b: subjects (n=5) will receive normal saline (NS) placebo on Days 1, 3, 5, 7, and 113.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2397387|NCT03590340|Placebo Comparator|Group 2b (NS)|"Group 2b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, and 7.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2397388|NCT03590340|Placebo Comparator|Group 3b (NS)|"Group 3b: subjects (n=5) will receive NS placebo on Days 1, 3, 5, 7, and 29.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2397389|NCT03590340|Placebo Comparator|Group 4b (NS)|"Group 4b: subjects (n=5) will receive NS placebo on Days 1 and 8.~CHMI with PfSPZ Challenge (NF54) will be administered 8 weeks after the last immunization by DVI."
2397390|NCT03590327|No Intervention|Apathy +, rTMS -|This arm will be followed without intervention
2397391|NCT03590327|Active Comparator|rTMS|This group will be randomized to receive rTMS treatment
2397392|NCT03590327|Sham Comparator|Sham|This group will be randomized to receive sham treatment
2397393|NCT03590314|Experimental|Experimental group|The experimental group was treated using a robot assisted arm training, Armotion (Reha Technology, Olten, Switzerland).
2397394|NCT03590314|Active Comparator|Control group|The control group was treated using a conventional training, without end effector robot.
2397395|NCT03590301|Experimental|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup will enable and inspire parents to encourage their children to improve their diet and activity behaviors through general authoritative parenting, structured feeding practices, and a healthy home environment. Parents and toddlers will participate in the FUNPALs Playgroup together where they will be led through a series of open but structured activities including free play, exercise, snack preparation, discussion, singing, and yoga stretches.
3184369|NCT00723853|Active Comparator|Group 2|Reach-In Program, Standard of Care
2397396|NCT03590301|Active Comparator|Healthy Toddlers Parent Group|The goal of the Healthy Toddlers Parent Group is to deliver the same nutrition and activity messages to parents as those delivered in the FUNPALs Playgroup. In the Healthy Toddlers Parent Group, parents (without children) will meet in groups to receive information on nutrition and activity as it relates to their toddlers and they will engage in a discussion around how they do or can implement these behaviors. No experiential learning, children, play, or parenting instruction will be included in this control condition.
2397397|NCT03590288||TIPS group|Pressure gradient were measured in consecutive cirrhotic patients undergoing TIPS.
2397398|NCT03590262|Experimental|metformin|patients take metformin 500mg twice or three times a day as add-on therapy to insulin for 3 months ,using self-control method.
2397399|NCT03590249|Experimental|Osteopathic Manipulative Treatment (OMT)|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
2397400|NCT03590249|No Intervention|No Intervention|Participants in the No Intervention arm will undergo the planned assessments, but not receive any intervention.
2397401|NCT03590236|Experimental|Graded exposure therapy|Patients in this group received graded exposure therapy added to physiotherapy
2397402|NCT03590236|Active Comparator|Physiotherapy|Patients included in this group received the standard treatment based on a physiotherapy approach.
2397403|NCT03590236|No Intervention|Control group|Waiting list patients
2397404|NCT03590210|Experimental|Group A - L-sarcoma|Patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
2397405|NCT03590210|Experimental|Group B - non-L-sarcoma|Patients with unresectable or metastatic soft tissue sarcoma other than liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen (GIST excluded) will receive drug treatment with trabectedin (1 cycle mono-therapy) followed by trabectedin/nivolumab combination (up to 15 additional cycles); 16 cycles in total
2397406|NCT03590197|Placebo Comparator|Control Arm|The patients in Control Arm will receive placebo with valproate (20 mg/kg).
2397407|NCT03590197|Experimental|Melatonin Arm|The Experimental Arm will receive tablet melatonin as an add-on to valproate. Melatonin will be prescribed 3 mg/day to the patients and will be advised to take 30 minutes before bedtime.
2397408|NCT03590184||patients with a biological prosthesis|patients who have received a biological prosthesis
2397409|NCT03590184||patients with a biosynthetic resorbable prosthesis|patients who have received a biosynthetic resorbable prosthesis
2397410|NCT03590171|No Intervention|Arm HR-A|Induction: Backbone ALL R3
2397411|NCT03590171|Experimental|Arm HR-B|Induction: Backbone ALL R3 + Bortezomib
2397412|NCT03590158|Experimental|TRF|Participants will follow their regular diet for two weeks before 3-day lead-in food prior to the metabolic testing at visit 0. Participants will then be instructed to eat their habitual diet only within a 10-hour time frame each day for 8 weeks. Participants may self-select the precise window that best suits their lifestyles, however any food and drink must be consumed by 7:30pm.
2397413|NCT03590145||Qatari athletes|Participants meeting general inclusion criteria.
2397414|NCT03590132|Experimental|SAAF|participants in this arm receive the SAAF intervention at age 11-12.
2397415|NCT03590132|Experimental|SAAF-T|participants in this arm receive the SAAF-Teen intervention at age 14-15.
2397416|NCT03590132|Experimental|SAAF SAAF-T|participants in this arm receive SAAF at age 11-12 and later receive SAAF-Teen at age 14-15
2397417|NCT03590132|No Intervention|Control|These participants receive no interventions.
2397418|NCT03590119|Experimental|Intra-arterially treated liver lobe|Depending on the allocation after randomization, Lu-177-dotatate will be infused in either the left or the right hepatic artery, following catheterization using the Seldinger-technique.
2397419|NCT03590119|Active Comparator|'Intravenously' treated liver lobe|The lobe that is not treated intra-arterially, will act as the intravenously treated lobe, due to the first-pass effect.
2397420|NCT03590106|Experimental|Peer Recovery Support Program|"Patients enrolled in the Peer Recovery Support Program will:~Actively engage in the program as defined by meeting with a Peer Support Volunteer at least two times prior to discharge, and or use of resilience journal, and or review of NA book.~Demonstrate negative drug screens done randomly during their hospitalization.~Actively contact at least one outpatient recovery program that they might enroll in prior to discharge (information about recovery programs to be provided by unit SW).~Demonstrate appropriate changes in their SOCRATES 8D survey scores from admission to program to post discharge.~Participate in follow up phone call with completion of SOCRATES 8D survey at 30 and 60 days post discharge."
2397421|NCT03590093|Experimental|Periodontal Surgery with EMD|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. After carefully cleaning root dental surfaces, EMD was placed inside the infrabony periodontal defect. Suture were placed to maintain wound stability.
2397422|NCT03590093|Active Comparator|Periodontal Surgery|A surgical periodontal flap was elevated, degranulation of inflammatory tissues and dental debridement was performed. Suture were placed to maintain wound stability.
2397423|NCT03590080||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
2397424|NCT03590067||Heamodialysis group|
2397425|NCT03590067||Kidney transplantation group|
2397426|NCT03590054|Experimental|Treatment (abexinostat, pembrolizumab)|Participants receive abexinostat PO BID on days 1-21 and pembrolizumab IV on over 30 minutes day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3143511|NCT00006364|Experimental|Treatment (omacetaxine mepesuccinate)|"Remission induction therapy: Patients receive remission induction therapy comprising homoharringtonine IV continuously over 24 hours on day 1 and then subcutaneously (SC) twice daily on days 2-14 for course 1. Subsequent courses of remission induction therapy comprise homoharringtonine SC twice daily on days 1-14. Treatment continues monthly for at least 2 courses.~Maintenance therapy: Patients with complete hematologic remission receive maintenance therapy comprising homoharringtonine SC twice daily on days 1-7 monthly for 3 years in the absence of disease progression or unacceptable toxicity."
3143512|NCT00006365|Experimental|EBRT to the prostate followed by brachytherapy|Patients received 45 Gy of external beam radiation therapy (EBRT)to the prostate followed (within 2 to 6 weeks) by permanent iodine (I-125) brachytherapy 108 Gy.
2397429|NCT03590028|Experimental|Early Nephrology Consult (ENC)|The ENC will be a structured consultative note that will provide detailed recommendations around issues such as Differential Diagnosis, Drug Dosing and Volume Status. The research ENC will have a daily follow-up with documented recommendations.
2397430|NCT03590028|Active Comparator|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
2397431|NCT03590015|Other|old letter of invitation|"Old invitation letter written by researchers/doctors in The coronary project sent to patients in order to recruit to an ongoing project"
2397432|NCT03590015|Other|New letter of invitation|New invitation Letter written with consideration of impaired language comprehension and has therefore been written in simple sentences with a sequential structure of basic information sent to patients in an ongoing project.
3143513|NCT00006371|Active Comparator|Hydrocortisone with Ketoconazole|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with ketoconazole. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
3143514|NCT00006371|Active Comparator|Hydrocortisone with Aminoglutethimide|Patients are stratified according to prior antiandrogen therapy (yes vs no). Patients with prior antiandrogen therapy begin study therapy after appropriate antiandrogen withdrawal, while those without such prior therapy begin study therapy immediately. Patients undergo medical adrenalectomy using hydrocortisone combined with aminoglutethimide. Oral hydrocortisone is administered twice daily. Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks. Oral ketoconazole is administered three times daily.
2397435|NCT03589989|Experimental|Intervention group|
2397436|NCT03589989|Active Comparator|Control group|
2397439|NCT03589963|No Intervention|Pre-intervention|regular CPNP programming
2397440|NCT03589963|Experimental|Post-intervention|regular CPNP programming plus access to postnatal lactation support
2397441|NCT03589950|Experimental|Anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
2397442|NCT03589950|Active Comparator|Chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
2397443|NCT03589924|Experimental|One step method|Immediate implant reconstruction following mastectomy using TiLoop®Bra (one step method) n=225
2397444|NCT03589924|Active Comparator|Two step method|Immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra (two step method) n=225
2397445|NCT03589898|Experimental|Gabapentin|Single dose of gabapentin 900 mg will be given and neuroimaging markers will be measured before and after administration of gabapentin
3184370|NCT00723866|Experimental|1|BtxA+mCIMT (combination group)
2397450|NCT03589872||Study Group|patients with parkinson disease
2397451|NCT03589859||Normal Volunteers|Testing motor learning
2397452|NCT03589859||Vestibular hypofunction|Testing feasibility of rehabilitation game
3143515|NCT00006373|Experimental|TIME|Topotecan, Ifosfamide, Mesna and Etoposide
2397454|NCT03589833|Placebo Comparator|MTX|Treated with oral methotrexate and two placebos.
2397455|NCT03589833|Placebo Comparator|Tripterygium Wilfordii|Treated with oral Tripterygium Wilfordii and two placebos.
2397456|NCT03589833|Active Comparator|Yisaipu + MTX|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
2397457|NCT03589833|Experimental|Yisaipu + Tripterygium Wilfordii|Treated with subcutaneously injected Yisaipu, oral methotrexate and a placebo.
2397458|NCT03589820|Active Comparator|Artificial liver support system group|30 patients will receive treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine.
2397459|NCT03589820|No Intervention|Control group|30 patients will receive treatment of internal medicine.
3143516|NCT00006386|Experimental|External beam radiotherapy with stereotactic boost|External beam radiotherapy (EBXRT): 50 Gy in 25 daily fractions of 2 Gy. Stereotactic radiotherapy (SRT) boost: 4 treatments of 5 or 7 Gy, once per week during weeks 3-6. Patients will not receive EBXRT on the SRT treatment days.
3143517|NCT00006388|Experimental|Radiation plus Tamoxifen|
3143518|NCT00006398|Experimental|Timolol Maleate|Dose titrated from 5 mg per day to up to 80 mg per day depending on heart rate
3143519|NCT00006398|Placebo Comparator|Placebo|Timelol placebo
3143520|NCT00006401|Experimental|Inhaled Nitric Oxide (iNO)|Nitric Oxide study gas will be initiated at 5 ppm using the INOvent delivery system. The delivery system provides for masked delivery of the treatment gas. This dose will be used for a 21-day period or until extubation.
3143521|NCT00006401|Placebo Comparator|Placebo|
3143522|NCT00006420||Observational, no interventions|
3143523|NCT00006425||1|25 women undergoing ductal lavage
3184371|NCT00723866|Placebo Comparator|2|BtxA+ conventional rehabilitation (control group)
2397466|NCT03589794|Experimental|Group 1|10 subjects receive 10 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
2397467|NCT03589794|Experimental|Group 2|10 subjects receive 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85.
2397468|NCT03589794|Experimental|Group 3|10 subjects receive 30 mcg rCSP intramuscularly (IM) on days 1, 29 and 85.
2397469|NCT03589794|Experimental|Group 4|9 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
2397470|NCT03589794|Experimental|Group 4B|10 subjects receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85. Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
2397471|NCT03589794|Experimental|Group 5|10 subjects receive 10 mcg or 30 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ) intramuscularly (IM) on days 1, 29 and 85 if immunogenicity analysis conducted 28 days post-2nd dose in Groups 1, 2, and 3 show promise (at least fourfold increase in geometric mean anti-CSP antibody or geometric mean anti-CSP titer of 20). Otherwise, subjects will receive 60 mcg rCSP + AP 10-602 [GLA-LSQ] (5 mcg GLA - 2 mcg LSQ). Subjects will then receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain on day 113.
2397472|NCT03589794|Other|Group 6|6 subjects receive CHMI challenge with P. falciparum parasites of the NF54/3D7 strain.
2397473|NCT03589781|Experimental|Mikei Red Reishi Essence EX|There are two groups (50 participants total) in this clinical study, one group (35 participants) will be given Mikei® Red Reishi Essence EX product (Product Group).
2397474|NCT03589781|Placebo Comparator|Placebo|Another group (15 participants) will be given the placebo (Placebo Group). Placebo is a pill that looks like a drug but has no drug or other active ingredients.
2397475|NCT03589768|Experimental|Group 1|"0.5 ml single dose of Tdap (Tetanus, Diphtheria, Acellular Pertussis Vaccine), BOOSTRIX administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated Gestational Age (GA).~N=133"
2397476|NCT03589768|Active Comparator|Group 2|"0.5 ml single dose of Td (Tetanus, Diphtheria Toxoid) administered intramuscularly to pregnant women at 14 0/7 weeks through 26 6/7 weeks estimated GA.~N=67"
2397477|NCT03589755|Active Comparator|mindful meditation|Behavioral intervention, providing meditation
2397478|NCT03589755|No Intervention|Waiting list|Patient on a waiting list
2397479|NCT03589742|Experimental|Radiofrequency ablation patients|Single-Arm study, all patients included will undergo RF ablation using AblaView® Ablation Catheter
2397480|NCT03589729|Experimental|Supportive care (dexrazoxane hydrochloride, chemotherapy)|See detailed description.
2397481|NCT03589716|Other|Participants with Vital Signs Within Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs within the normal physiological range will also be asked to perform an optional exercise testing and/or undergo arterial blood gas measurement.
2397482|NCT03589716|Other|Participants with Vital Signs Outside of Normal Range|All participants will be asked to have an arm and finger measurement conducted and undergo vital sign measurements using the Vital Moto Mod and reference devices for blood pressure, heart rate, respiration rate, blood oxygen saturation, and temperature. Participants with vital signs outside of the normal physiological range would be documented.
3143524|NCT00006436|Experimental|Arm 1|Combination chemo and biological therapy
3143525|NCT00006441|Experimental|A|Patients beginning IL-2 treatment regimens after 4 weeks of study
3143526|NCT00006441|Active Comparator|B|Patients beginning IL-2 treatment after some delay based on specified criteria
2397486|NCT03589690|Experimental|Alpha Lipoic acid|Alpha lipoic acid capsules (600 mg/day)
2397487|NCT03589690|Placebo Comparator|Placebo|Starch-filled capsules (600 mg/day)
2397488|NCT03589677||Myotonic dystrophy type 1|"Subjects of both sexes with a diagnosis of Steinert's disease (DM1), de novo or with the previous diagnosis that shows significant worsening detectable during the follow-up foreseen by the normal cure procedure with clinical presentation indicating a CNS compromise will be evaluated for:~quality of life evaluation~exam of neuroimaging~study of myomiRNAs before and after rehabilitation"
2397489|NCT03589664||Non-Sternotomy Group|Subjects who have no prior sternotomy
2397490|NCT03589664||Sternotomy Group|Subjects who previously underwent a sternotomy procedure.
3143527|NCT00006461|Other|Chemotherapy, surgery, radiation therapy|Patients receive induction chemotherapy consisting of vincristine sulfate IV on days 1, 8, and 15; cisplatin IV over 6 hours on day 1; cyclophosphamide IV over 30 minutes on day 2; and oral etoposide daily on days 2-22. Treatment repeats every 28 days for a total of 4 courses. After completion of induction chemotherapy, patients with residual disease undergo a therapeutic conventional surgery (second resection). Within 4 weeks after completion of induction chemotherapy or second resection, patients receive 3-dimensional conformal radiation therapy daily, 5 days a week, for 6 weeks. Four weeks after completion of 3-dimensional conformal radiation therapy, patients receive alternating treatments of maintenance chemotherapy. Patients receive vincristine sulfate IV on days 1, 8, and 15 and cyclophosphamide IV over 30 minutes on day 1 of courses 1, 3, 5, and 7 and oral etoposide daily on days 1-21 of courses 2, 4, 6, and 8. Treatment continues every 28 days for 8 courses.
3189033|NCT00773552|Experimental|solifenacin succinate|Group randomized into solifenacin succinate treatment
2397493|NCT03589638|Active Comparator|direct laryngoscope|Endotracheal intubation was applied by anesthesiologist with direct laryngoscope.
2397494|NCT03589638|Active Comparator|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
2397495|NCT03589638|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist with McGrath videolaryngoscope.
2397496|NCT03589625|Experimental|Solar Suitcase Installation First Group|Facilities will receive the installation of the Solar Suitcase shortly after baseline data collection.
2397497|NCT03589625|Experimental|Solar Suitcase Installation Second Group|Facilities will act as a comparator for experimental group 1 and then will receive the installation of the Solar Suitcase shortly after midline data collection.
2397498|NCT03589599|Experimental|Flavored tobacco|All participants will be completing a lab visit where they smoke flavored waterpipe tobacco ad lib for up to 45 min.
2397499|NCT03589599|Experimental|Non-flavored tobacco|All participants will be completing a lab visit where they smoke non-flavored waterpipe tobacco ad lib for up to 45 min.
2397500|NCT03589586|Experimental|DermACELL AWM + Conventional Care|DermACELL AWM, acellular dermal matrix, plus conventional wound care- DermACELL AWM will be applied at the Baseline visit. Conventional wound care will include advanced wound dressings and multilayer compression.
2397501|NCT03589586|No Intervention|Conventional Care|Conventional wound care will include advanced wound dressings and multilayer compression.
2397502|NCT03589560|Experimental|Biodentine|3-4 mm of Biodentine (Septodont, St. Maur-des-Fosses, France) was applied over the clot carefully in group I by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
2397503|NCT03589560|Active Comparator|Mineral Trioxide Aggregate|3-4 mm of white Mineral Trioxide Aggregate (Angelus, Londrina, Brazil) was applied over the clot in group II by using amalgam carrier. material was packed lightly with a moistened cotton pellet and Periapical radiograph was taken to confirm coronal seal in the second visit of dental pulp revascularization.
2397504|NCT03589547|Experimental|Durvalumab and SBRT|"Durvalumab 10mg/kg x 1 day, dose #1 to occur > 3 weeks and <7 weeks after last chemo/RT and prior to SBRT dose 1 (5-10 day time frame between Durvalumab and SBRT).~SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab (see above for time frames). The dose will consist of 20Gy (2 fractions of 10Gy). 3 fractions are allowed for centrally located tumors~Dose # 2 of durvalumab, (post SBRT) to be given 1-10 days post last SBRT. Durvalumab then to be given at 10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)"
2397505|NCT03589534|Other|pregnancy test|pregnancy tests
2397506|NCT03589521|Experimental|ABCT_Military|ABCT_Military manual will address alcohol use, couple issues and military specific issues. Required interventions include: routine interventions, overview of treatment, reintegration issues, motivational techniques, patient-focused interventions for abstinence, partner-related interventions for abstinence, couple interventions, general coping skills, social skills and relapse prevention. In addition, to personalize each treatment plan, interventions from optional modules (e.g., intimate partner violence (IPV), depression, trauma, and traumatic brain injury (TBI)) will be integrated into each couple's treatment plan depending on clinical presentation.
2397507|NCT03589508|Experimental|In-Person Sessions: ABCP_P|In-person therapy sessions: 6 Weekly Prevention Session conducted in person (half of participants will attend alone, half of participants will attend with a significant other)
2397508|NCT03589508|Experimental|Video conference sessions: ABCP_T|Video conference therapy sessions: 6 Weekly Prevention Session conducted using videoconference (half of participants will attend alone, half of participants will attend with a significant other)
2397509|NCT03589495|Active Comparator|N acetylcysteine group|N Acetyl L Cysteine IV bolus (100 mg/kg dissolved in dextrose5%) infused over 15 minutes, followed by continuous infusion of 50mg/kg/day dissolved in dextrose 5% starting 1hr before induction of anesthesia, and continued for 48 hours after operation
2397510|NCT03589495|Placebo Comparator|placebo group|received equal volume of dextrose 5% administrated at the same rate and duration as in the study group as a placebo
2397511|NCT03589482|Experimental|EIT algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the EIT algorithm, which selects a PEEP at which both collapse and hyperdistention are minimized.
2397512|NCT03589482|Active Comparator|ExPRESS algorithm|Patients randomized to this arm will be ventilated at the PEEP level selected by the ExPRESS algorithm, which is a method that targets a tidal volume of 6 ml/kg predicted body weight and then titrates PEEP until plateau airway pressure reaches 28 cm H2O.
3184372|NCT00723879||Patients with hepatitis C|Patients receiving a patient assistance program during therapy for hepatitis C will be enrolled into this study. All patients will receive PegIntron plus Rebetol (according to the label) and the patient assistance program.
2397514|NCT03589443|Experimental|Multiplexed heptapeptides|QRH & KSP sprayed onto area of interest and imaged before and after application
2397515|NCT03589430||1 child A|child A liver cirrhosis
2397516|NCT03589430||2 child B|child B liver cirrhosis
2397517|NCT03589430||3 child C|child C liver cirrhosis
2397518|NCT03589404|Experimental|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
2397519|NCT03589391|Experimental|Procedures with the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration. The device is used.
2397520|NCT03589391|No Intervention|Procedures without the use of device for LOR monitoring|Patients enrolled suffered from chronic back pain and underwent epidural infiltration
2397521|NCT03589378|Experimental|PEAF|Intervention group:the patient will receive treatment with PEAF immediately after randomization.PEAF that is TPE (20ml/kg/d Fresh frozen plasma, Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma-filtration adsorption(PFA) (Blood pump: 120ml/min, Plasma separation rate 25-30%, PFA with acute multitherapeutic system (AMPLYA™ Italy) ≥30ml/min) and High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) , Blood pump same as PFA , replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h),with PFA and HVPDF for 15 hours in the first 3 days. If hemodynamically unstable or acute kidney injury(AKI) stage 2or 3,continue High volume hemofiltration(HVHF).Same protocol with control group after 3days.
2397522|NCT03589378|No Intervention|Control group|HVHF for septic shock with MODS is permitted in Control group routinely（Blood pump: 200ml/min, replacement fluid pump 45ml/kg/min, dialysate pump 45ml/kg/min, waste pump 90ml/kg/min, and high-volume hemofiltration for 16 hours with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) in the first 3 days after randomization.If hemodynamically unstable or AKI stage 2or 3,continue HVHF.
2397523|NCT03589365|Other|Preterm group|young adults born preterm will performed an Magnetic resonance imaging (MRI)
2397524|NCT03589365|Other|control group|young adults born at term will performed an Magnetic resonance imaging (MRI)
3184373|NCT00723918|Active Comparator|1|methadone plus SAB placebo
3143528|NCT00006462|Experimental|Relapsed acute lymphoblastic and acute Myelogenous leukemia|Gemcitabine hydrochloride will be given as 10 mg/m2/min x 360 minutes weekly for three weeks. After a one-week rest period it may be repeated in patients without progressive disease or limiting toxicity.
3143529|NCT00006463|Experimental|Therapy ECTEINASCIDIN 743 (1100 ug/m2 )|
2397528|NCT03589313|Experimental|GLPG3067 single dose.|Single Dose of GLPG3067 film coated tablets.
3143530|NCT00006463|Experimental|ECTEINASCIDIN 743 (1300 ug/m2)|
2397530|NCT03589287|Experimental|Chondrochymal® 1 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2397531|NCT03589287|Experimental|Chondrochymal® 5 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2397532|NCT03589287|Experimental|Chondrochymal® 10 x 10^7 cells|At this stage, 3 patients with knee OA will be treated by the cell products of this dose.
2397533|NCT03589274|Experimental|I-FS-CBT|In I-FS-CBT each participant saw a therapist weekly. The first session was 90 minutes long, and subsequent sessions were 60 minutes long. The I-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care.
2397534|NCT03589274|Experimental|G-FS-CBT|The G-FS-CBT manual included core CBT, motivational enhancement, and relapse prevention components. Two core thematic women's issues were integrated into each session via discussion and illustrative material: (a) self-confidence, and (b) self-care. The session organization was modified for a closed group format. The group treatment was designed to provide didactic presentation of coping skills and motivational enhancement material, and group discussion and rehearsal of new skills within a supportive atmosphere that facilitated mutual emotional support and support for abstinence.
2397535|NCT03589261|Other|MRI (magnetic resonance imaging)|Hepatic blood flow baseline will be measured using MRI. Fluid challenge of 500 ml of NaCl 0.9% will be administered during 10 minutes. Before and After fluid challenge, MRI will be performed to compare flow changes.
2397536|NCT03589248||GIF score|assess the AGI by gastrointestinal failure(GIF) score
2397537|NCT03589248||US score|assess the AGI by ultrasonography(US) score
2397538|NCT03589235|Experimental|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be used in both donor and receiving sites after a free gingival graft.
2397539|NCT03589235|Experimental|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be used in both donor and receiving sites after a free gingival graft.
2397540|NCT03589222|Experimental|Selinexor, Daratumumab, Bortezomib and dexamethasone|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle plus dexamethasone 40 or 20 mg mg orally with each dose of selinexor in combination with daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter and bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9. Each cycle is of 4 weeks of duration
2397541|NCT03589196|Active Comparator|Photoselective Vaporization|
2397542|NCT03589196|Active Comparator|Plasma Kinetic Vaporization|
2397543|NCT03589196|Active Comparator|Transurethral Resection Of The Prostate|
2397544|NCT03589170||People over 60 years of age|People over 60 years of age without previous known atrial fibrillation
2397545|NCT03589157|Experimental|Drug-coated balloon group|
2397546|NCT03589157|Active Comparator|second-generation drug-eluting stent group|
2397547|NCT03589131|Active Comparator|Robotic-assisted Surgery Group|In this arm the investigators use a robotic system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe. The robotic system that we use is the da Vinci Si (Intuitive Surgical, Inc.,Sunnyvale,CA) Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data
2397548|NCT03589131|Active Comparator|Laparoscopic Surgery Group|"In this arm the investigators use a Laparoscopy system to perform resection of the rectum harboring the tumor trying to do that while being oncologically safe.~Interventions used are total operative time, margin assessment, conversion rate to open surgery, baseline demographics, preoperative data and postoperative data"
2397549|NCT03589118|Experimental|Qi Gong|Qi gong sessions added to usual well defined medical and psychological support
2397550|NCT03589118|No Intervention|Control|Usual well defined medical and psychological support
2397551|NCT03589105|Experimental|Ocrelizumab Treatment Cycles|Each participant will receive an initial dose of two 300 mg infusions of Ocrelizumab each separated by 14 days followed by one single dose of 600 mg 24 weeks after the initial dose.
2397552|NCT03589092||GDM Current|"Currently pregnant women diagnosed with GDM.~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
3143531|NCT00006467|Experimental|gemcitabine + ISIS 2503|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and ISIS 2503 IV continuously on days 1-14. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
3143532|NCT00006469|Other|Single arm study|Concurrent Paclitaxel, Carboplatin, and External-Beam Radiation Followed by Surgical Resection in Locally Advanced Non-Small-Cell Lung Cancer
3143533|NCT00006471|Experimental|Fenretinide|
3143534|NCT00006472|Other|Single arm study|Taxol® (Paclitaxel), Carboplatin and 5-Fluorouracil with Simultaneous Radiotherapy Followed by Surgical Resection
3143535|NCT00006473|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.
3143536|NCT00006483|Experimental|aerosolized sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) by nebulizer over 10-15 minutes twice daily on days 1-7 and 14-21. Treatment repeats every 28 days in the absence of disease progression or unaceptable toxicity.~Patients are followed for disease progression and then every 3 months thereafter."
3184374|NCT00723918|Experimental|2|methadone plus active SAB
3184375|NCT00723918|Placebo Comparator|3|methadone placebo plus SAB placebo
3189034|NCT00773552|Placebo Comparator|placebo|Group randomized into placebo
2397553|NCT03589092||GDM History|"Women with history of GDM (with negative GAD/IA2 antibodies if results available).~Next generation sequencing (NGS) methodologies will used on individuals suspected of genetic diabetes."
2397554|NCT03589079||Monogenic Disorder|Participants exhibiting clinical phenotypes suggestive of an underlying novel monogenic disorder, with/without the presence of familial recurrence of the phenotype and/or parental consanguinity will be included. Sanger and/or Next generation Sequencing (NGS) - Panel/WES/WGS approaches will be used to facilitate identification of de novo/inherited variants in the child/proband.
2397555|NCT03589066|Experimental|Formulation A|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
2397556|NCT03589066|Experimental|Formulation B|LY03003 28 mg intramuscular suspension, single dose, 1 day duration
2397557|NCT03589053|Experimental|LRIC group|Participants in the experimental group receive both LRIC and standard clinical therapy. The LRIC treatment is composed of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion (Patent No.CN200820123637.X, China).
2397558|NCT03589053|Sham Comparator|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
2397559|NCT03589040|Other|Ripivirine arm|All subjects will be administered oral ripilvirine 25mg once daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
2397560|NCT03589040|Other|Darunavir arm|All subjects will be administered oral DRV/r 600/100mg twice daily together with the rest of their oral antiretroviral combination and an etonogestrel single-rod subdermal implant (68mg/rod). Study participants will have both interventions for a period of one year.
2397561|NCT03589027|Experimental|Rilpivirine arm|All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
2397562|NCT03589027|Experimental|Darunavir arm|All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period
2397563|NCT03589014|No Intervention|Control|Standard Treatments recommended for CCM
2397564|NCT03589014|Experimental|￼Propranolol|Initial oral dose 40 mg bid, uptitrated to 80mg bid doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
2397565|NCT03589001||OSD|51 adolescents with Osgood Schlatter who participated in an activity modification intervention.
2397566|NCT03588988|Experimental|Dexmedetomidine group|
2397567|NCT03588988|Placebo Comparator|Control group|
3184376|NCT00723970|Experimental|A|Use of quetiapine, flexible dose (150-300 mg/day) for 8 weeks, following a 2-week placebo lead-in phase
3184377|NCT00723983|Active Comparator|Period 1|Subject dosed with oral sumatriptan succinate during an acute migraine attack.
2397570|NCT03588962|Experimental|Metal allergy driven restenosis|Patients with angiographically proven in-stent restenosis developed after technically correct implantation. Patch tests for the metals used in stent production will be applicated. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
2397571|NCT03588962|Placebo Comparator|Looking for allergic restenosis|Patients with (technically correctly) implanted stent. Patch tests will be applicated to identify cases with contact allergy. The tests will be applicated during the hospitalisation, then read after 48 hours and 72 hours, and subsequently interpreted by the skilled dermatologist, during the hospital stay or afterwards.The patients will then be monitored for a 12 months follow-up period in purpose of evaluating the dependance between in-stent restenosis and contact allergy. Possible correlation between allergy to metals utilised during the stent manufacturing (nickel, cobalt, chromium, molybdenum, tungsten) and in-stent restenosis occurence.
2397572|NCT03588949|Experimental|Active Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)
2397573|NCT03588949|Placebo Comparator|Control Dietary Supplement|Dietary Supplement with 50% RDA of beta-carotene
2397574|NCT03588936|Experimental|Nivolumab (0.25 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.25 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
2397575|NCT03588936|Experimental|Nivolumab (0.5 mg/kg) and Tocilizumab|"Participant will receive tocilizumab 8 mg/kg IV (max dose 800 mg) on Day 0. On Day 1 participants will receive nivolumab IV (0.5 mg/kg based on dose escalation design).~Nivolumab will be given every ~2 weeks for up to 4 doses and a second dose of Tocilizumab will be given on ~Day 29 on the same day as Dose # 3 of Nivolumab."
2397576|NCT03588923|Active Comparator|Cohort 1|SH229 (400 mg) or matching placebo, once daily
2397577|NCT03588923|Active Comparator|Cohort 2|SH229 (600 mg) or matching placebo, once daily
2397578|NCT03588923|Active Comparator|Cohort 3|SH229 (800 mg) or matching placebo, once daily
3184378|NCT00723983|Active Comparator|Period 2|Subject dosed with oral sumatriptan during a non-migraine period.
3184379|NCT00723983|Experimental|Period 3 and Period 6|Subject dosed with NP101 during an acute migraine attack.
2397581|NCT03588897|No Intervention|Normal Diet|Elderly patients receiving normal diet
2397582|NCT03588897|Experimental|Nutritional Support|Elderly patients receiving normal diet with nutritional support (Nutridrink Multi Fibre 2x100 ml per day)
2397583|NCT03588884|Active Comparator|CTAP101|CTAP101/Calcifediol Capsules 60 micrograms (mcg) once daily at bedtime, except on Days 1 and 29 when dosing will occur in the morning before breakfast
2398159|NCT03584919|Active Comparator|EM cefuroxime axetil|patients with EM who received cefuroxime axetil
3184380|NCT00723983|Experimental|Period 4 and Period 5|Subject dosed with NP101 study patch during a non-migraine period.
3184381|NCT00723996||Group 1|Women receiving a CRC-related questionnaire and a CRC educational video.
2397584|NCT03588884|Experimental|Immediate-release (IR) calcifediol|Immediate-release (IR) calcifediol/266 micrograms (mcg) capsule before breakfast on the mornings of Day 1 and Day 29
2397585|NCT03588884|Experimental|Cholecalciferol|Cholecalciferol/Capsules 300,000 International Units (IU) (high-dose) before breakfast on the mornings of Day 1 and Day 29
2397586|NCT03588884|Active Comparator|Paricalcitol|Paricalcitol/Capsules 1 mcg plus cholecalciferol capsules 800 IU (low-dose) once daily in the morning before breakfast, except on Days 1 and29 when dosing will occur before breakfast
2397587|NCT03588871|Experimental|Group A|Dental bleaching with PaintOn Plus, HP 6%, 6x10min, two sessions
2397588|NCT03588871|Experimental|Group B|Dental bleaching with Opalescence GO, HP 6%, 10x60min
2397589|NCT03588871|Experimental|Group C|Dental bleaching with Opalescence PF, CP 16%, 14x60h
2397590|NCT03588845|Other|Protocol Treatment|"If a score on the GSS is > 5, the computer will send an automatic notice to the office of the doctor and to the doctor him/herself telling them of this.~Upon receipt of the notice, the protocol doctors will be expected to make an appointment within the timeframe outline in the protocol. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess the timeliness of the first visit after notification, about the adherence of protocol doctors to protocol treatment."
2397591|NCT03588845|Other|Standard of Care|Standard care doctors, who will not know the details of this protocol, will decide on their own if and when to see the patient. Upon receipt of this notice the secretaries or clerks at the site will be asked to insert a treatment sheet in the doctor's chart. This sheet will be used to assess types of medications and general pattern of treatment of the standard of care doctors.
2397592|NCT03588819|Experimental|2-fraction SABR|
3184382|NCT00723996||Group 2|Women who receive only a CRC-related questionnaire.
2397594|NCT03588767|Experimental|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
2397595|NCT03588767|Active Comparator|Retrospective analysis|Retrospectively analyzed patients, no vitamin D3 + anabolic substance administration.
2397596|NCT03588754|Experimental|Propranolol|Propranolol extended release (160mg/day). Administered orally once daily at 10:00PM. Titration schedule Days 1-3 60mg, Days 4-7 80mg, Days 8-11 120mg, and Days 12-14 160mg until steady state.
2397597|NCT03588754|Placebo Comparator|Placebo|Administered orally once daily at 10:00PM
3184383|NCT00723996||Group 3|Women who receive neither questionnaire nor educational video.
2397599|NCT03588728|Experimental|CR + tDCS|Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
2397600|NCT03588728|Sham Comparator|CR + sham tDCS|Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
2397601|NCT03588728|Sham Comparator|control CR + tDCS|Control Cognitive Remediation (CR) and Transcranial Direct Current Stimulation (tDCS)
2397602|NCT03588728|No Intervention|control CR + sham tDCS|Control Cognitive Remediation (CR) and Sham Transcranial Direct Current Stimulation (tDCS)
2397603|NCT03588715|Experimental|Pegylated Interferon alpha 2b + bNAbs|Pegylated Interferon alpha 2b (peg-IFN-α2b) + bNAbs (3BNC117 + 10-1074)
2397604|NCT03588715|Experimental|bNAb only|bNAb (3BNC117 + 10-10-74) only
2397605|NCT03588702|Experimental|Venus Legacy LB2 Body applicator group|Liposuction area is divided into 2 equal sections. One section receives RF and PEMF treatment.
2397606|NCT03588689|No Intervention|Standard Treatment|Patients in this group will receive standard treatment orders which include a combination of opioids, NSAIDs, acetaminophen, and other adjuncts for analgesia.
2397607|NCT03588689|Experimental|Continuous fascia iliaca block|"The cFIB group will receive an ultrasound guided cFIB and standard treatment orders as backup in the event of block failure.~The cFIB group will receive an initial bolus of 40 cc of 0.25% Ropivacaine followed by an infusion of 8 cc/hr until the time of surgery. Immediately pre-operatively, the anesthesiologist performing the case will bolus the catheter 40 cc of 0.25% ropivacaine and discontinue the catheter."
2397608|NCT03588676|No Intervention|Normoxia|Participants will sleep in room air and receive no melatonin.
2397609|NCT03588676|Placebo Comparator|Hypoxia and Placebo|5mg placebo before sleep study
2397610|NCT03588676|Experimental|Hypoxia and Melatonin|5mg melatonin before sleep study
2397611|NCT03588663|Experimental|Bionic Leg|Participants will wear the Bionic Leg during a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises.
2397612|NCT03588663|Active Comparator|Control|Participants will complete a series of different activities including a timed-up-and-go, balance tests, 6-min walk test and sit-to-stand exercises without wearing the bionic leg (control condition).
2397613|NCT03588650|Experimental|HLX20, in patients with solid tumors|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX20 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 1, 3, 10 and 20 mg/kg, starting from 1 mg/kg.
2397614|NCT03588637||Study population|Patient who receive at least one dose of daptomycin
2397615|NCT03588624|Experimental|TearCare|All subjects in the study will undergo the TearCare procedure one time at the baseline visit. They will then be followed out to one month.
2397616|NCT03588611|Experimental|Low dose group with eGFR ≥60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
2397617|NCT03588611|Active Comparator|Standard dose group with eGFR ≥ 60ml/min|This arm, we will choose the patients who's eGFR ≥60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
3184384|NCT00724022|Other|A|Standard: Advagraf, CellCept, Decortin H + 2x Simulect Day 0 + 4
3184385|NCT00724022|Experimental|B|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 2x Simulect Day 0 + 4
3184386|NCT00724022|Experimental|C|Steroidfree: Advagraf, Cellcept, Decortin H until Day 8, 3 x Thymoglobulin
3184387|NCT00724035|Experimental|Infraclavicular|This group will receive an ultrasound-guided infraclavicular brachial plexus block.
3184388|NCT00724035|Active Comparator|Axillary|This group will receive an ultrasound-guided axillary brachial plexus block.
2397618|NCT03588611|Active Comparator|Standard dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and use the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery .
2397619|NCT03588611|Experimental|Low dose group with eGFR <60ml/min|This arm, we will choose the patients who's eGFR <60ml/min and reduce the bivalirudin bolus injection dose to 80% of the standard dose in clinical practice, and we will adjuste the bivalirudin maintenance dose and rate according to the ACT time during surgery to reduce the ACT value caused by the bolus injection.
2397620|NCT03588598|Experimental|SHC014748M treatment|SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle
2397621|NCT03588585|Active Comparator|Tension|foley balloon will be placed on tension and taped to thigh at 10 cm. Misoprostil will be placed in posterior vaginal vault.
2397622|NCT03588585|Active Comparator|No tension|The foley balloon will be loosely taped without tension to the patient's thigh. Misoprostil will be placed in the posterior vaginal vault.
3143537|NCT00006486|Experimental|Arm I (carboxyaminoimidazole)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive oral CAI as above."
3189035|NCT00773565|Other|Optifast|Patients included take part at a weight reduction program over one year.
2397625|NCT03588559|Experimental|BPM, TMB-1591-A-002 and Reference Device|DUT: Transtek Blood Pressure Monitor TMB-1591-A-002 Reference Device: Baumanometer Desk Mercury Sphygmomanometer. Blood Pressure Measurement with the Transtek BPM TMB-1591-A-002 and with reference device.
2397626|NCT03588533|Experimental|Herzuma-capecitabine/cisplatin(XP)|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks~Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks~Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks"
2397627|NCT03588520|Experimental|Home BP Monitoring Group|Patients allocated to this group will receive a home blood pressure monitoring device and decisions to modify the hypertension treatment will be based on the results of the home blood pressure monitoring in accordance with the current guidelines of the European Society for Hypertension for the Treatment of Hypertension.
2397628|NCT03588520|No Intervention|Office BP Monitoring Group|Patients allocated to this group will act as controls. They will receive no home blood pressure monitoring device and decisions to modify the hypertension treatment will be based exclusively on blood pressure measurements in office visits.
2397629|NCT03588507|No Intervention|Papilla preservation flap techniques|Papilla preservation flap techniques will be conducted to gain access to the intrabony defects. In the narrow interproximal spaces (≤2 mm), incision with the preservation of the buccal papilla according to the simplified papilla preservation technique will be applied. Whereas, in the wide interdental spaces (>2 mm), the modified papilla preservation technique will be applied. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
2397630|NCT03588507|Active Comparator|PPF+NCHA bone graft substitute|intervention: papilla preservation flap techniques + nanocrystalline hydroxyapatite bone graft substitute Same surgical techniques and procedures will be performed. Before suturing the flap, nanocrystalline hydroxyapatite bone graft substitute(Dentaurum, Germany) will be placed within the defect up to the existing level of the alveolar crest and care will be taken not to overfill the defect. The mucoperiosteal flaps will be repositioned and secured in place using non-resorbable # 6-0-suturing material. Vertical or horizontal mattress sutures and additional interrupted single sutures will be performed to obtain primary closure of the interdental space.
2397631|NCT03588494|Active Comparator|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2397632|NCT03588494|Experimental|W1-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first chemoradiotherapy cycle(days -5～-1).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2397633|NCT03588494|Experimental|W2-CCRT|"Endostar(15 mg/m2) was durative transfused every 24 hours for 5 days during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).~Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
2397634|NCT03588481||Coronary stenosis|
2397635|NCT03588468|Sham Comparator|healthy|will be defined as persons without pathological mutation of the TTR gene Electrophysiological biomarkers and MRI biomarkers will be performed
2397636|NCT03588468|Active Comparator|Asymptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene but with no clinical complain, normal clinical examination, and normal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
2397637|NCT03588468|Experimental|Symptomatic carriers|"will be defined as persons with a known pathological mutation of the TTR gene with clinical complain, abnormal clinical examination, and abnormal renal and cardiac investigations.~Electrophysiological biomarkers and MRI biomarkers will be performed"
2397638|NCT03588442||Cirrhosis cohort|Patients with liver cirrhosis.
2397639|NCT03588442||HBV infection cohort|Patients with seropositivity of HBsAg.
2397640|NCT03588429|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2397641|NCT03588429|Experimental|Isoflurane|Anesthesia was maintained with isoflurane.
2397642|NCT03588403||Arm A:Tomotherapy|Patients with non-disseminated nasopharyngeal carcinoma receiving Tomotherapy.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
3189036|NCT00773578||1|atopic asthmatic children exposed to environmental tobacco smoke
2397643|NCT03588403||Arm B: IMRT|Patients with non-disseminated nasopharyngeal carcinoma receiving IMRT.The prescribed radiation dose was defined as follows: PGTVnx 7040cGy/32F,PGTVnd 7040cGy/32F,PTV1 6080cGy/32F,PTV2 5440cGy/32F.
2397644|NCT03588390|Experimental|Dose Group 1|
2397645|NCT03588390|Experimental|Dose Group 2|
2397646|NCT03588390|Experimental|Dose Group 3|
2397647|NCT03588390|Experimental|Dose Group 4|
2397648|NCT03588390|Experimental|Dose Group 5|
2397649|NCT03588390|Experimental|Dose Group 6|
2397650|NCT03588390|Experimental|Dose Group 7|
2397651|NCT03588390|Experimental|Dose Group 8|
2397652|NCT03588377|Active Comparator|Intervention Cluster|Signs and symptoms of severe pneumonia Pulse Oximetry
2397653|NCT03588377|No Intervention|Non-Intervention Cluster|Signs and symptoms of severe pneumonia
2397654|NCT03588364|Experimental|Osteopathic Manipulation|Twelve weekly sessions using the techniques of osteopathy in the cranial field.
2397655|NCT03588364|No Intervention|Waitlist Control|Six-week waiting period.
2397656|NCT03588351|Active Comparator|chlorhexidine gluconate|GROUP I: - 15 teeth will be treated with specially prepared gel containing chlorhexidine gluconate as intracanal medicament .
2397657|NCT03588351|Experimental|chitosan nanoparticles gel|GROUP II: - 15 teeth will be treated with specially prepared gel containing chitosan nanoparticles that ready to use as intracanal medicament.
2397658|NCT03588351|Experimental|chitosan gel|Group III: 15teeth will be treated with specially prepared gell containing chitosan that ready to use as intra medicament .
2397659|NCT03588338|Active Comparator|Perfalgan|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
2397660|NCT03588338|Other|Control|1.5 mg/kg intravenous, intraoperative (20 min before end of the surgery)
2397661|NCT03588312||simple heart defects|Newborns with hypoplastic aortic arch in simple congenital heart defects requiring aortoplasty
2397662|NCT03588312||complex heart defects.|Newborns with hypoplastic aortic arch in complex congenital heart defects requiring aortoplasty
3143538|NCT00006486|Experimental|Arm II (carboxyamidotriazole, placebo)|"Patients receive oral CAI daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity.~Patients receive a placebo."
3143539|NCT00006487|Active Comparator|chemo/RT with tirapazamine|induction and consolidation: cisplatin, etoposide, tirapazamine, radiation therapy
3143540|NCT00006501||ECG recording|After the tests are completed, people who enroll in this study are followed by telephone, 1, 4, 8, 12 16, 20 and 24 months. During these follow-up telephone calls a research coordinator asks about the participant's health condition and about cardiovascular medications that are being taken.
2397666|NCT03588273|Other|Amoxil 500 mg Oral Capsule Time 0|In each period (before the surgery and 2 months after the bariatric surgery) the obese volunteers received a single oral dose of amoxicillin 500 mg capsule (Amoxil®, GlaxoSmithKline Brazil Ltda.) with 200 mL water after an overnight fast (approximately 8 h).
3143541|NCT00006505|Experimental|Transplant|Islet cell transplantation
3143542|NCT00006517|Active Comparator|bright light box|30 min exposure shortly after wake-up
2397669|NCT03588234||Type 1 diabetes|Individuals with type 1 diabetes (18-29 years old). They must complete a questionnaire. This group has approximately 26 extra questions to respond to compared to controls. The extra questions pertain to their diabetes history as well as their knowledge regarding diabetes.
2397670|NCT03588234||Matched controls without Type 1 diabetes|Individuals without type 1 diabetes (18-29 years old). They must complete the same questionnaire as the individuals with diabetes (without the diabetes-specific questions).
2397671|NCT03588221|Other|Six-step hand hygiene technique with application time of 30|
2397672|NCT03588221|Other|Six-step hand hygiene technique with application time of 15|
2397673|NCT03588221|Other|Three-step hand hygiene technique with application time of 3|
2397674|NCT03588221|Other|Three-step hand hygiene technique with application time of 1|
2397675|NCT03588208|Experimental|Intervention Group|
2397676|NCT03588208|Active Comparator|Control Group|
2397677|NCT03588195|Experimental|Education Group|
2397678|NCT03588195|Active Comparator|Control Group|
2397679|NCT03588182|Experimental|Group VR|Virtual reality (VR) experience VR visualization of a 3-dimensional relaxing nature scene with the accompanying audio. The patient will be offered a selection of scenes from which to choose, played continuously on a Samsung Gear VRTM(San Jose, CA) headset and headphones. The goal is for the patient to use the intervention for the entire duration of the external cephalic version procedure (ECV), which typically lasts 15 - 30 minutes.The patient will also receive verbal reassurance and coaching as needed. The obstetrician will communicate as usual with the patient.
2397703|NCT03588039|Experimental|Dose escalation-Arm 3|During the dose escalation period Oraxol will be administered once daily for 4 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397786|NCT03587480|Other|TME+LLND group|Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.
3143543|NCT00006517|Active Comparator|high-output negative ion generator|90 min exposure prior to wake-up
3143544|NCT00006517|Placebo Comparator|low-output negative ion generator|90 min exposure prior to wake-up
3143545|NCT00006517|Active Comparator|dawn simulator|naturalistic incremental light exposure 90 min prior to wake-up
3143546|NCT00006517|Experimental|dawn light pulse|rectangular pulse light exposure 13 min before wake-up, matched for total illuminance with dawn signal
3143548|NCT00006565|Experimental|1|HEPA Air Cleaners
3143549|NCT00006565|Placebo Comparator|2|Inactive (placebo) filtration unit
3143550|NCT00006695|Experimental|Arm I|Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)
3143551|NCT00006708|Active Comparator|ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 1-3 Carboplatin AUC=5 IV Day 2 Ifosfamide 5 g/m2 IV Day 2 Mesna 5 g/m2 IV Day 2 Filgrastim 5ug/kg/day SQ Days 5-12 Q 21 days x 3 cycles
3189037|NCT00773578||2|atopic asthmatic children unexposed to environmental tobacco smoke
2397680|NCT03588182|No Intervention|Group No VR|No intervention will be provided for the control group, who will receive usual management at CUMC, which involves provision of no analgesia or sedation for the procedure, which typically lasts 15 - 30 minutes. Verbal reassurance and coaching is routinely provided by caregivers, including encouraging deep breathing, particularly during painful manipulation of the abdomen, for the duration of the procedure. The obstetrician will communicate as usual with the patient - for example advising that he/she is about to begin the procedure and giving updates as to the degree of success.
2397681|NCT03588169||patients hospitalized at the Dijon University Hospital|Patients hospitalized in the endocrinology, digestive surgery, pneumology and geriatric units of the Dijon University Hospital with a prescription for ONS
2397682|NCT03588156|Experimental|Benapenem|Investigatial Product: Benapenem: 11 group : 62.5mg one dose; 125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
2397683|NCT03588156|Placebo Comparator|Placebo|Placebo control 11 group : 62.5mg one dose;125mg one dose;250mg one dose;500mg one dose 30min infusion;500mg one dose 60min infusion ;1000mg one dose 30min infusion; 1000mg one dose 60min infusion 2000mg one dose 30min infusion;2000mg one dose 60min infusion;3000mg one dose 60min infusion;4000mg one dose 60min infusion
2397684|NCT03588143|Active Comparator|Electrical stimulation with TENS|TENS with 100 Hz frequency, 65 microseconds pulse duration, in continuous pattern
2397685|NCT03588143|Experimental|Electrical stimulation with HVPS|HVPS with twin spiked monophasic current at 100 pps frequency, in continuous pattern
2397686|NCT03588143|Placebo Comparator|Placebo electrical stimulation|same electrode placement with other interventions, using the same electrotherapy device, without activating the device except its time unit.
2397687|NCT03588130|Active Comparator|EscharEx (5% EX-02 formulation)|Debridement will be performed with 5% EX-02 for 24±3 hours, up to 8 applications
2397688|NCT03588130|Placebo Comparator|Gel Vehicle|Debridement will be performed with Gel vehicle for 24±3 hours, up to 8 applications
2397689|NCT03588130|Active Comparator|Non-surgical standard of care (NSSOC)|Debridement will be performed with NSSOC (Santyl or commercially approved Hydrogel) per routine procedures, until complete debridement is achieved
2397690|NCT03588117||Participants of a weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
2397691|NCT03588104|Experimental|POWER2DM support group|Participants in this group will receive access to the POWER2DM system as an adjunct to usual care. The participants have three intervention visits in which they will use the Shared Decision Making Dashboard to set self-management goals and will use the Self-Management Support system for trying to reach those goals in the periods after the intervention visits.
2397692|NCT03588104|Active Comparator|Usual care group|Participants in this group will follow their usual diabetes care with their own diabetes care team.
2397693|NCT03588091|Experimental|arm1|Pyrotinib Plus trastuzumab and docetaxel
2397694|NCT03588091|Placebo Comparator|arm2|placebo plus trastuzumab and docetaxel
2397695|NCT03588078|Experimental|combination of APR246 and azacitidine|Following completion of the Dose Finding Phase, we will conduct a dose expansion, whereby patients will be treated with APR-246 administered at the maximum tolerated dose (MTD) with azacitidine on a 28 day cycle utilizing the same dosing as in Phase 1b
2397696|NCT03588065|Experimental|attend education for TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
2397697|NCT03588065|Active Comparator|attend education for conference|"The intervention arm descriptionTHE CONFERENCE include face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing.~The face-to-face sessions focused on the four aspects mentioned above for ICT. To this end, the theoretical elements of the concepts under study were taken into account: human body movement, warm-up phases, postural hygiene, sports hygiene, nutrition and clothing."
2397698|NCT03588065|Sham Comparator|attend for FMS|The FMS test was applied in two moments with three blind evaluators physiotherapists with specialization in therapeutic physical activity and master in Physical Activity and Sports, with an experience of more than 5 years in the field of assessment of sport condition and clinical experience in sport greater than 6 years in sports clubs in the region.
2397699|NCT03588052|Experimental|VISTA using PRF|"Vestibular incision subperiosteal tunnel access combined with Platelets-Rich Fibrin~An intravenous blood will be drawn from the patient in a glass-coated plastic tubes, centrifuged at 3000 rpm for 10-12 min. A Platelets rich fibrin membrane will then be obtained"
2397700|NCT03588052|Active Comparator|VISTA using SCTG|"vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft~Subepithelial connective tissue graft will be harvested from the palate, secured in the tunnel to cover the root dehiscence then sutured"
2397701|NCT03588039|Experimental|Dose escalation-Arm 1|During the dose escalation period Oraxol will be administered once daily for 2 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397702|NCT03588039|Experimental|Dose escalation-Arm 2|During the dose escalation period Oraxol will be administered once daily for 3 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2398160|NCT03584919|Placebo Comparator|controls|control subjects without history of Lyme disease
2397704|NCT03588039|Experimental|Dose escalation-Arm 4|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397705|NCT03588039|Experimental|Dose escalation-Arm 5|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397706|NCT03588039|Experimental|Dose escalation-Arm 6|During the dose escalation period Oraxol will be administered once daily for 5 days per week for 2 weeks followed by 1 week off treatment (2 weeks on and 1 week off). Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397707|NCT03588039|Experimental|Dose expansion-Gastric/GE|The dose expansion period will enroll subjects with gastric/gastro-esophageal cancer to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397708|NCT03588039|Experimental|Dose expansion-NSCLC cancer|The dose expansion period will enroll subjects with NSCLC to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397709|NCT03588039|Experimental|Dose expansion-Urothelial cancer|The dose expansion period will enroll subjects with advanced/metastatic urothelial to further evaluate the activity and safety of the study treatment. Oraxol will be administered at the dose determined from part 1 for 2 out of 3 weeks. Pembrolizumab will be administered on Day 1 of each 3-week cycle.
2397710|NCT03588026|Experimental|Arm 1 - 9 months of treatment (rVA576 plus SOC)|6 months (SOC plus rVA576), Followed by a further 3 months of (SOC plus rVA576).
2397711|NCT03588026|Experimental|Arm 2 - 6 months on SOC|6 months on SOC only. Followed by 3 months (SOC plus rVA576).
2397712|NCT03588013|Experimental|Moderate/severe malnourishment|Pakistani children from age 0 to 6 months with weight for height Z score (WHZ) < -2 at the time of enrollment. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth. Those participants who remain WHZ < -2 despite interventions are eligible for medical evaluation for more advanced workup of malnutrition, including UGI endoscopy and biopsy.
2397713|NCT03588013|Active Comparator|Well nourished children|Pakistani children from age 0 to 6 months who would be growing normally, with WHZ > 0, to serve as controls. Parents/caregivers of all participants will undergo a series of rehabilitative interventions to improve the child's nutrition and growth.
2397714|NCT03588013|No Intervention|US children with celiac disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Environmental Enteropathy and celiac disease have some shared features therefore we plan to enroll children under the age of 6 years with newly diagnosed celiac disease per endoscopy at CCHMC to assess the extent to which gene signatures and associated biologic pathways for children with celiac disease or environmental enteropathy overlap or differ.
2397715|NCT03588013|No Intervention|US children with Crohn's disease|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. As some differentially expressed ileal gene signatures for Crohn's disease bear remarkable similarities to individual gene expression patterns previously reported for EE, children under the age of 10 years with newly diagnosed Crohn's disease per endoscopy at CCHMC will be enrolled to study these similarities and any differences
2397716|NCT03588013|No Intervention|Healthy age-matched US children|Comparative group for the Pakistani WHZ <-2 children who undergo UGI endoscopy and biopsy. Number of upper gastrointestinal endoscopies performed in children less than 2 years old are limited in Pakistan, therefore US age-matched controls will be used; healthy children < 3 years old will be enrolled, who will undergo endoscopy at CCHMC as part of a diagnostic workup for digestive symptoms, but whose biopsies and diagnoses are not supportive of eosinophilic esophagitis, celiac disease, or inflammatory bowel disease, and who were not treated with antibiotics ≤ 4 weeks prior to endoscopy.
2397717|NCT03588000|Experimental|Strength group|Strengthen self-monitoring of blood glucose by Internet mobile terminal (APP)
2397718|NCT03588000|No Intervention|Control group|Voluntary self-monitoring of blood glucose
2397719|NCT03587987|Active Comparator|Neopuff|neopuff
2397720|NCT03587987|Experimental|r PAP|rPap device
3184389|NCT00724048|Experimental|ACR16 10 mg|"Participants receive one ACR16 10mg twice daily:~First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day)."
2397723|NCT03587961|Experimental|Symdeko|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Symdeko, depending on the in vitro response pattern
2397724|NCT03587961|Experimental|Ivacaftor|Patients who have mutation response to a potentiator of CFTR function will be given Ivacaftor monotherapy.. Patients with a mutation equivalent to wild type will be given Ivacaftor.
2397725|NCT03587961|Experimental|Orkambi|Patients who have a mutation that responds to a CFTR corrector from in vitro study will be given Orkambi, depending on the in vitro response pattern
2397726|NCT03587948||Case group|Children and adolescents with diabetes mellitus
2397727|NCT03587948||Control group|Children and adolescents without diabetes mellitus
2397728|NCT03587922|Experimental|Treatment Arm|Single arm study with treatment of Fantom scaffold
2397729|NCT03587909|Active Comparator|Phacoemulsification Cataract Surgery|Procedure / Surgery : Phacoemulsification Surgery
2397730|NCT03587909|Active Comparator|Femtosecond Cataract Surgery|Procedure / SUrgery - Femtosecond Laser Cataract surgery
2397731|NCT03587896|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
2397751|NCT03587753|Active Comparator|Unsaturated|A test meal containing a unsaturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning.
2397752|NCT03587753|Active Comparator|Saturated|A test meal containing a saturated fatty acid labelled with 13C to measure hepatic fatty acid partitioning
2398477|NCT03582787|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
2397732|NCT03587896|No Intervention|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
2397733|NCT03587883|Experimental|Cocoa Flavanol intervention|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 300 mg of cocoa flavanols per capsule: 900 mg of cocoa flavanols consumed daily for 2 weeks; 2 intervention periods: Cocoa flavanols I and cocoa flavanols II.
2397734|NCT03587883|Placebo Comparator|Control intervention|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks; 2 intervention periods: control I and control II.
2397735|NCT03587870|Experimental|Bolus enteral nutrition with Fresubin Intensive|Bolus nutrition over 30-40 minutes every 4 hours with Fresubin Intensive
2397736|NCT03587870|Active Comparator|Continuous enteral nutrition with Fresubin Intensive|Continuous nutrition over 20 hours per day with Fresubin Intensive (standard)
2397737|NCT03587857|Experimental|Arm 1: Intervention|All YLWH who choose to enroll in the study will receive access to WYZ, the mobile health application. The participants will be asked to use the app for 6 months, during which the investigators will assess the feasibility and acceptability of WYZ. Based on this initial data, the investigators will refine and release a new version of the app (WYZ 3.0).
3143552|NCT00006708|Experimental|Rituximab-ICE Chemotherapy|Etoposide 100 mg/m2 IV Days 2-4 Carboplatin AUC=5 IV Day 3 Ifosfamide 5 g/m2 IV Day 3 Mesna 5 g/m2 IV Day 3 Filgrastim 5ug/kg/day SQ Days 6-13 Q 21 days x 3 cycles Rituximab 375 mg/m2 IV Days 1 and 8 Cycle 1 Rituximab 375 mg/m2 IV Day 1 Cycles 2-3
3143553|NCT00006734|Experimental|Regimen A|Test the hypothesis that chemotherapy given every two weeks (Regimen B) will produce higher event-free survival. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks (four cycles on Regimen A. The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide, etoposide, MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (Surgery, Radiation Therapy, or a combination) will begin on Week 13 which will be after four cycles of chemotherapy.
3143554|NCT00006734|Experimental|Regimen B|Conventional every-three-week chemotherapy for patients with Ewing sarcoma and related tumors. Treatment will occur in two phases: Induction and Continuation, with 14 cycles of chemotherapy in all. Induction consists of the first twelve weeks six cycles on Regimen B). The cycles alternate between vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, MESNA and ifosfamide etoposide MESNA. G-CSF (Filgrastim) is given between chemotherapy doses. Local control (surgery, Radiation Therapy, or a combination) will begin on Week 13, which will be after six cycles of chemotherapy.
2397741|NCT03587831|Experimental|VSG + LSM|"Procedure/Surgery: Vertical Sleeve Gastrectomy will be performed using five laparoscopic ports. The short gastric and epiploic vessels will be taken down With a 40 French Bougie in place, the greater curvature will be excised starting 6 cm proximal to the pylorus.~Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention will align with methods listed in the LSM arm description. However, participants assigned to the VSG will not have calorie ceilings during the first 6 months of rapid weight loss, and they will receive additional instruction regarding food volume and adequate protein intake."
2397742|NCT03587831|Active Comparator|LSM|Behavioral: Lifestyle Modification Counseling - The intensive lifestyle intervention is modeled after the LookAHEAD trial, with modules modified for participants undergoing surgery, and designed to produce maximum achievable weight loss. Both groups will increase their level of moderate-intensity physical activity (such as walking) to a total of 325 minutes per week. All lifestyle-medical management participants will be given calorie intake targets of 1200, 1500, or 1800 kilocalories per day, depending on body weight, with the goal of producing a weight loss of 1 to 2 pounds per week. There will be 24 weekly counseling meetings during the first 6 months, bi-weekly meetings between months 7 and 9, and monthly meetings between months 10 and 12.
2397743|NCT03587818|No Intervention|Control group|"Conventional care. Patients were receiving several written patient education materials (PEMs), mostly related to specific parts or procedures related to the surgery and the recovery.~Communication between patients and professionals during consultations occurred according to conventional care practice."
2397744|NCT03587818|Experimental|Intervention group|"I. Written interactive PEM structured into chapters/phases of the care process. Designed to serve three purposes:~generic information of the surgery and recovery process on a group level to promote high readability, suitability and comprehensibility~arena of dialogues between patient and professionals; voicing concerns, share perspectives~for the patient to personally reflect on generic information.~II. Person-centred communication in dialogues using the PEM as a supportive tool, facilitated by four communication strategies:~professionals guiding the patient through the care process~communicating an introduction, agenda and closing~being sensitive to the patient's questions, beliefs, experiences and resources~dialogue based on story, posing open-ended questions, and following up."
3184390|NCT00724048|Experimental|ACR16 22.5 mg|"Participants receive one ACR16 22.5mg capsule twice daily:~First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day)."
2397746|NCT03587779|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
2397747|NCT03587779|Experimental|Desflurane|Anesthesia is maintained with desflurane.
2397748|NCT03587766|Experimental|Group A|Fexinidazole (FEXI) 600 mg x 10 days in a single daily dose orally (1 fexinidazole 600 mg tablet and 1 fexinidazole matching placebo oral tablet administered in a single daily dose) (total dose: 6.0 g).
2397749|NCT03587766|Experimental|Group B|Fexinidazole (FEXI) 1200 mg x 3 days orally (2 fexinidazole 600 mg tablets administered in a single daily dose for 3 days), to be followed by matching placebo oral tablet for 7 days (2 fexinidazole matching placebo oral tablets administered once daily for 7 days) (total dose: 3.6 g).
2397750|NCT03587766|Experimental|Group C|Fexinidazole (FEXI) 600 mg for 3 days, followed by 1200 mg in a single daily dose orally for 4 days (1 fexinidazole 600 mg tablet AND 1 fexinidazole matching placebo oral tablet administered in a single daily dose for 3 days, to be followed by 2 fexinidazole 600 mg tablets for 4 days), then followed by matching placebo oral tablet for 3 days (2 fexinidazole matching placebo tablets administered once daily for 3 days) (total dose: 6.6 g).
3189038|NCT00773591|Active Comparator|Botulinum Toxin Typ A|
2397754|NCT03587701|Experimental|Group A|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100mg/0.67ml) in period 1 followed by an additional 42 consecutive days of anakinra (100mg/0.67ml) in period 2
2397755|NCT03587701|Experimental|Group B|This group will be randomized to receive intervention of 42 consecutive days of anakinra (100 mg/0.67ml) in period 1 followed by 42 consecutive days of placebo in period 2
2397756|NCT03587701|Experimental|Group C|This group will be randomized to receive intervention of placebo for 42 consecutive days in period 1 followed by 42 consecutive days of anakinra (100mg/0.67ml) in period 2
3143555|NCT00006747|Experimental|chemotherapy + stem cell transplantation|"Patients receive carmustine, etoposide, cytarabine and melphalan on day -1. Patients undergo allogeneic peripheral blood stem cell (PBSC) transplantation on day 0. Patients also receive tacrolimus on day -2 and then orally twice daily until day 120 and methotrexate on days 1, 3, and 6 as graft-versus-host disease (GVHD) prophylaxis. Patients receive sargramostim daily beginning on day 7 and continuing until blood counts recover.~Patients with no active GVHD who have persistent disease on day 150 or progressive disease at any time after PBSC transplantation receive donor lymphocytes IV over 2 hours. Patients may receive additional donor lymphocytes at least 8 weeks later if disease persists.~Patients are followed at 6 and 12 months post-transplantation and then annually for 4 years."
2397758|NCT03587662|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|"INDUCTION: Patients receive ixazomib PO, gemcitabine IV over 90 minutes, and doxorubicin IV over 15-30 minutes on day 1. Treatment repeats every 14 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ixazomib PO and gemcitabine IV over 90 minutes. Cycles repeat every 14 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2397759|NCT03587649|Experimental|[18F]MNI-1126|To measure the dynamic uptake and washout of [18F]MNI-1126 in the brain using positron emission tomography (PET) in subjects with AD, PD, and healthy volunteers.
2397760|NCT03587636|Experimental|Liposome bupivacaine interscalene block|10 mL of liposome bupivacaine and 10 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance
2397761|NCT03587636|Active Comparator|bupivacaine interscalene block|20 mL of 0.5% bupivacaine will be injected at the interscalene brachial plexus under ultrasound guidance.
2397762|NCT03587610|Active Comparator|Intervention arm|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
2397763|NCT03587610|No Intervention|Standard care|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: the patient will be informed that a remedial vaccination is necessary and that he should contact his primary care provider after hospital discharge."
2397764|NCT03587597|Experimental|socket shield technique|socket shield technique with immediate temporization
2397765|NCT03587597|Active Comparator|conventional immediate implant|conventional implant placement with immediate temporization
2397768|NCT03587571|Active Comparator|Surgical intervention|Open reduction and osteosynthesis by plating is done. Further after treatment is similar to conservative treatment arm.
2397769|NCT03587571|No Intervention|Conservative treatment|At the first visit a split cast is applied. Afterwards physiotherapy and weightbearing as tolerated is allowed.
2397770|NCT03587558|Experimental|Carvedilol group|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
2397771|NCT03587558|Active Comparator|Flecainide group|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.
2397772|NCT03587545|Experimental|Healthy probiotic group LGG|Daily intake by healthy volunteers of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
2397773|NCT03587545|Experimental|Healthy probiotic group LAMBR2|Daily intake by healthy volunteers of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
2397774|NCT03587545|Placebo Comparator|Healthy placebo group|"Daily intake by healthy volunteers of 2 dosages of placebo spray during 2 weeks.~Placebo nasal spray."
2397775|NCT03587545|Experimental|CRS probiotic group LGG|Daily intake by CRS patients of 2 dosages of LGG spray during 2 weeks. Probiotic nasal spray.
2397776|NCT03587545|Experimental|CRS probiotic group LAMBR2|Daily intake by CRS patients of 2 dosages of LAMBR2 spray during 2 weeks. Probiotic nasal spray.
2397777|NCT03587545|Placebo Comparator|CRS placebo group|Daily intake by CRS patients of 2 dosages of placebo spray during 2 weeks. Placebo nasal spray.
2397778|NCT03587532|Experimental|Indocyanine Green Angiography|ICG based angiography after creation of the stomach graft and after thoracic pull-up of the graft. Dynamic digital images will be obtained starting immediately after intravenous bolus administration of 0.5 mg/kg of ICG.
2397779|NCT03587519|Experimental|Early ileostomy closure|Early ileostomy closure will be performed 7 to 12 days after with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA).
2397780|NCT03587519|Active Comparator|Late ileostomy closure|Late ileostomy closure will be performed 8 - 12 weeks after IPAA.
2397781|NCT03587506||Patients: group|Group I (n=10) included patients who did not develop any major or minor seizure during the follow-up period and their follow up EEG was free of any epileptiform discharge
2397782|NCT03587506||Patients: group II|Group II (n=11) included patients who developed only minor seizures and their follow up EEG showed epileptiform discharge
2397783|NCT03587506||Patients: group III|Group III (n=9) were patients who developed one or more major seizures during the follow-up period whatever their EEG findings.
2397784|NCT03587506||Controls|healthy volunteers (n=30) who were not related to the patients and had no family history of epilepsy.
2398478|NCT03582787|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
2397787|NCT03587480|Other|TME+nCRT group|Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.
2397788|NCT03587467||health|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~smooth and soft stool like sausage or snake~Voluntary participate in this study"
2397789|NCT03587467||chronic hepatitis b carrier|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic HBV infection in EASL 2017 Clinical Practice Guidelines on the management"
2397790|NCT03587467||chronic hepatitis b|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
2397791|NCT03587467||decompensated cirrhosis|"Alcohol free history or alcohol consumption <140g per week in male, <70g per week in female~Meet diagnostic criteria of chronic hepatitis B in EASL 2017 Clinical Practice Guidelines on the management"
2397792|NCT03587454|Experimental|Tele-Glaucoma arm|Subjects enrolled in tele-glaucoma arm for remote assessment
2397793|NCT03587441|Active Comparator|The Intervention Group (N)|Neostigmine Methylsulfate intervention : A one milliliter syringe will contain 20 µg of Neostigmine methyl sulfate. 0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 µg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
2397794|NCT03587441|Placebo Comparator|The Control Group (P)|Dextrose 5% in water intervention : an equal volume (0.2 ml) of dextrose 5% will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
3184391|NCT00724048|Experimental|ACR16 45 mg|"Participants receive one ACR16 45mg capsule twice daily:~First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day)."
3184392|NCT00724048|Placebo Comparator|Placebo|"Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.~Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses."
3184393|NCT00724074|Experimental|S|Patients receive the On-Q local continuous wound infusion system intra-operatively and use it for up to three days post-operatively.
2397798|NCT03587415||Polycyctic ovary sendrome (PCOS)|these women who have PCOS, we will use their blood samples
2397799|NCT03587415||Healty groups|These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples
2397800|NCT03587402|Experimental|Transcutaneous perineal stimulation|Patient is asked to lie down with legs slightly bend and two adhesive electrodes are attached transcutaneous on base of penis and on perineum. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
2397801|NCT03587402|Active Comparator|Anal stimulation|Patient is asked to lie down with legs slightly bend and an electrical probe is inserted into the anus. Stimulation current is administrated half time with a fixed frequency of 30 Hz and half time with 50 Hz. Pulse increased until the patient perceives the current. Sessions lasted for 30 minutes weekly for 10 weeks.
2397802|NCT03587389|Experimental|Rotavirus vaccine|"The Rotarix vaccine package consist of 1.5 ml of oral suspension in a pre-filled oral applicator (type I glass) with a plunger stopper (rubber butyl) and a protective tip cap (rubber butyl) in pack sizes of 1.~The vaccination course consists of two doses. The first dose may be administered from the age of 6 weeks. There should be an interval of at least 4 weeks between doses. The vaccination course should preferably be given before 16 weeks of age, but must be completed by the age of 24 weeks. Rotarix is for oral use only and should under no circumstancies be injected.~All participating infants will receive two doses of Rotarix vaccine following the standard Rotarix immunization protocol."
2397803|NCT03587376|Experimental|Participants with Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants previously treated with atabecestat and who had elevated liver enzymes while on atabecestat.
2397804|NCT03587376|Active Comparator|Participants Without Elevated Liver Enzymes|Blood samples will be collected on Day 1 from participants who completed at least 3 months of dosing with atabecestat and who did not have the elevated liver enzymes (adverse event) while on atabecestat.
2397805|NCT03587363|Experimental|Cohort 1: Normal Hepatic Function|Participants with normal hepatic function will receive 6 milligram (mg) erdafitinib as a single oral dose under fasted conditions on Day 1.
2397806|NCT03587363|Experimental|Cohort 2: Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh score of 5 or 6) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
2397807|NCT03587363|Experimental|Cohort 3: Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7 to 9) will receive 6 mg erdafitinib as a single oral dose under fasted conditions on Day 1.
2397808|NCT03587363|Experimental|Cohort 4: Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh score of 10 to 15) will only be enrolled to receive appropriate dose level of erdafitinib after review of preliminary safety and pharmacokinetic (PK) data from the mild and moderate hepatic impairment cohorts.
2397809|NCT03587350|Active Comparator|Interventional Treatment|
2397810|NCT03587350|No Intervention|Usual care|
2397811|NCT03587337||Prophylaxis|
2397812|NCT03587337||Antibiotic tp|
2397813|NCT03587324|Experimental|Experimental: aspirin, clopidogrel|Perioperative measurement of ASA and clopidogrel resistance in patients undergoing vascular treatment
3184394|NCT00724074|Active Comparator|C|Usual care - post operative pain medications as per the knee arthroplasty care map.
3184395|NCT00724087|Experimental|5.5-hour bedtime|
2397816|NCT03587298||Group 1|NAFLK criteria met (by definition: sonographic fatty liver)
2397817|NCT03587298||Group 2|Control group: matched age; no NAFKL
2397818|NCT03587285|Experimental|Arm 1|metastatic hormone-sensitive prostate cancer (mHSPC):After diagnosis of mHSPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by hormonal therapy of maximal androgen blockade (LHRH-a + Anti-androgen).
2397846|NCT03587103|Experimental|Protocol initiate with A|Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.
3184396|NCT00724087|Experimental|8.5-hour bedtime|
3184397|NCT00724113|Active Comparator|1|infiltration intra articular
2397819|NCT03587285|Experimental|Arm 2|metastatic castration-resistant prostate cancer (mCRPC):After diagnosis of mCRPC, patients receive infusions of autologous Tcm cells intravenously on Day 1 and Day 42, followed by goserelin acetate monthly. Abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily will be also administered continuously during the duration of the trial.
3184398|NCT00724113|Experimental|2|ARTHRO distension plus intensive mobilisation
2397821|NCT03587259|Active Comparator|2D mammography|45-46 years old women are invited to attend the usual screening examination (2D mammography). The next year they will be invited to make a 2D mammography, according to screening protocol.
2397822|NCT03587259|Experimental|Tomosynthesis|45-46 years old women are invited to attend the Digital Breast Tomosynthesis (DBT) in adjunct to synthetic mammograms (sDM). The next year they will be invited to make a 2D mammography, according to screening protocol.
2397823|NCT03587246||Pregnant women|
2397824|NCT03587246||non-pregnant women|
2397825|NCT03587233|Active Comparator|Women with higher professional status|"Women with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2397826|NCT03587233|Active Comparator|Women with lower professional status|"Women with lower professional status in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of women with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2397827|NCT03587233|Active Comparator|Men with higher professional status|"Men with higher professional status working in the Universities as academicians will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form', the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with higher professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2397828|NCT03587233|Active Comparator|Men with lower professional status|"Men with lower professional status working in the cleaning companies will be assessed regarding to their physical condition as weight status, BMI, waist and neck circumference, body composition and physical activity level, hand and pinch grip power to perform the intervention of physical assessment.~The Turkish version of the 'International Physical Activity Questionnaire (IPAQ)-Short Form' and the analyses of body composition will used to perform the intervention on the physical activity level. The outcomes of men with lower professional status will be compared with the other arms/groups as before and after the training program on exercise and healthy eating habits."
2397829|NCT03587220|Experimental|Capsaicin+UVB group|All subjects will be treated with capsaicin, placebo + UVB, or Capsaicin+UVB.
2397830|NCT03587220|Experimental|Capsaicin + EMLA group|All subjects will be pre-treated with lidocain cream before capsaicin application
3184399|NCT00724139|Experimental|1|patients (aged 50-75) with Symptomatic knee OA for at least 6 months, fulfilled American College of Rheumatology clinical criteria for OA of the knee and radiographically assessed osteoarthritis of the knee graded 1-2 according to the Kellgren & Lawrence scale.
3184400|NCT00724165|Experimental|1|
3184401|NCT00724165|Active Comparator|2|
3184402|NCT00724178|Experimental|A|Oral cholecalciferol (100,000 IU) administered orally every 60 days plus calcium carbonate (1 gram)given daily
3184403|NCT00724178|Placebo Comparator|B|Double placebo
2397836|NCT03587194|Experimental|Otezla|Otezla BID
2397837|NCT03587168||Patients with Parkinson's Disease|Patients with Parkinson's Disease Parkinson's Disease (Hoehn and Yahr stage 1-4)
2397838|NCT03587168||Healthy Controls|Healthy People
2397839|NCT03587155||Mutation|Embryo or infant with ASNS mutation.
2397840|NCT03587155||Control|Embryo or infant without ASNS mutation.
2397841|NCT03587142|Active Comparator|Buspirone|Buspirone HCl 10 mg capsule orally three times daily, 30 minutes before each meal, for 4-weeks
2397842|NCT03587142|Placebo Comparator|Placebo|Placebo capsule orally three times daily, 30 minutes before each meal, for 4-weeks; manufactured to look identical to buspirone capsule
2397843|NCT03587129|Experimental|apatinib|1 times a day, atapinib, 500 mg, is taken orally
3184404|NCT00724191||A|Evaluation of new MRI methods that measure information related to the chemical makeup of the brain in patients undergoing therapy for brain tumors.
3184405|NCT00724204|Placebo Comparator|A|Children that consumed a follow on formula without Lactobacillus salivarius CECT5713
3184406|NCT00724204|Active Comparator|B|Children that consumed a follow on formula with Lactobacillus salivarius CECT5713
3184407|NCT00724217|Experimental|Normal weight|BMI < 26
3184408|NCT00724217|Experimental|Overweight|BMI >= 26
3184409|NCT00724230||Arm 1|Overall study population.
3184410|NCT00724256|Experimental|1|
3184411|NCT00724256|Active Comparator|2|
3184412|NCT00724269|Active Comparator|Opti Free RepliniSH|Opti Free RepliniSH
3184413|NCT00724269|Active Comparator|ReNu Multi-Plus|ReNu Multi-Plus
3184414|NCT00724295||Arm 1|Overall study population
3184415|NCT00724321|Other|Iloprost and placebo|Each participant will undergo testing at sea level and altitude after inhalation of iloprost and placebo, sequence is randomly assigned.
3184416|NCT00724334|Experimental|1|
3184417|NCT00724399||Observations|Women attending screening mammography and gynecology visit
3184418|NCT00724399||A|Women attending their annual screening mammography and gynecology clinic visits.
2397847|NCT03587103|Experimental|Protocol initiate with C|Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.
2397848|NCT03587103|Experimental|Protocol initiate with D|Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.
2397849|NCT03587077|Experimental|study group|Women will receive vaginally one tablet misoprostol 200 mcg(Misotac; Sigma Pharma, SAE, EGYPT) plus one tablet isosorbide mononitrate 40 mg(Effox 40 mg; Minapharm). A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
2397850|NCT03587077|Placebo Comparator|control group|Women will receive vaginally one tablet misoprostol 200 mcg Plus one tablet placebo.A trained clinical nurse will introduce the tablets, digitally without using speculum, 3 hours before IUD insertion into the posterior vaginal fornix of the woman while lying in the lithotomy position.
2397851|NCT03587064|Active Comparator|3-lead CRT implantation (CRT-D)|In the 3-lead CRT implantation (CRT-D) group, conventional 3-lead CRT defibrillator system implantation will be performed. The CRT-D system is composed by three leads, one in atrium and two in both ventricles
2397852|NCT03587064|Experimental|2-lead CRT implantation (CRT-DX)|In the 2-lead CRT implantation (CRT-DX) group, 2-lead CRT defibrillator system implantation will be performed. The CRT-DX system is composed by two ventricular leads, the right one is provided with a dipole for atrial sensing
2397853|NCT03587051|Experimental|Low glycemic index post-exercise diet|Lentil-based post-exercise meal
2397854|NCT03587051|Active Comparator|High glycemic index post-exercise diet|Instant potato, white bread, and egg white post-exercise meal
2397855|NCT03587038|Experimental|OKN-007 3 days per week plus temozolomide|OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
2397856|NCT03587038|Experimental|OKN-007 5 days per week and temozolomide|OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
2397857|NCT03587025|Active Comparator|Amitryptyline|Patients who will be take amitryptyline, 75mg, only use, 30min before surgery.
2397858|NCT03587025|Placebo Comparator|Placebo|Patients who will be take placebo 30min before surgery.
2397859|NCT03587012|Experimental|Brain fitness app|Daily tutored sessions of brain exercises on an iPAD (in-person or remote)
2397860|NCT03587012|Experimental|Brain fitness app with tACS|Daily tutored sessions of brain exercises on an iPAD combined with simultaneous transcranial alternating current stimulation (tACS)
3184419|NCT00724412|Active Comparator|Systane|Systane
2397862|NCT03586986||FDR with abnormal brain MRI|First degree relatives fulfilling lesions disseminated in space on MRI
2397863|NCT03586986||FDR with normal brain MRI|First degree relatives not fulfilling lesions disseminated in space on MRI
2397864|NCT03586986||Non-FDR|Age and sex-matched controls to FDRs noted above
2397865|NCT03586973|Experimental|Cohort A: Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg), tablet, orally, once daily in the fasted state. Participants received first/second line anticancer therapy with sorafenib before this study were assigned to Cohort A.
2397866|NCT03586973|Experimental|Cohort B: Cabozantinib 60 mg|Cabozantinib 60 mg, tablet orally, once daily in the fasted state. Participants who did not receive first/second line anticancer therapy with sorafenib before this study were assigned to Cohort B.
2397867|NCT03586960|Experimental|Experimental Group|Peak tension will be measured with a calibrated force gauge (Series 3 Digital Force Gauge; Mark-10 Corporation; Copiague, NY) until the wound edges touch. A clamp will be used to secure the sutures on top of the device between measurements. At each time point (5, 10 and 30 minutes), the clamps will be loosened and the wound allowed to relax. Photographs and measurements will be taken to document the wound size after stress-reduction. The suture will be re-tensioned while measurements of peak tension (as outlined above) are recorded with the force gauge.
2397868|NCT03586947|Experimental|Vitamin D3 Drops group|Patients in this group would take Vitamin D3 400 UNT Oral Capsule.
2397869|NCT03586947|No Intervention|Non-Vitamin D3 Drops group|Patients in this group would take nothing.
2397870|NCT03586934|Other|Traditional (Standard) Protocol|Preoperative Single shot interscalene block (30 mL 0.5 ropivacaine), postoperative morphine patient controlled analgesia (1 mg/10 min/30 mg) with Hydrocodone-Acetaminophen (oral, 5/325 mg, 1 tab q4h pro re nata (PRN) for pain score of 1-3), Hydrocodone-Acetaminophen (oral, 10/325 mg, 1 tab q4h PRN for pain score of 4-6) Morphine injectable solution (2 mg IV q3h PRN for pain score 7-10), and oxycodone hydrochloride (oral, 10 mg q12h x2 doses) through postoperative day one. Discharged from hospital with hydrocodone bitartrate and acetaminophen (Norco) (5/325 mg or 10/325 mg, 1-2 oral tabs q4-6h PRN pain) script.
2397871|NCT03586934|Experimental|Multimodal Anesthesia and Analgesia|"Under age 75: Preop: acetaminophen 1000 mg oral, celecoxib 400 mg oral. Interscalene block (30 ml 0.5% ropivacaine with 1:200,000 epinephrine). Intraop: ketorolac 15 mg IV, acetaminophen injectable product. Postop: acetaminophen 500 mg oral, oxycontin 10 mg oral. Breakthrough: ketorolac 15 mg IV, oxycodone 10 mg oral. Floor: tramadol 100 mg q6h oral, acetaminophen 1 g q8h oral, celecoxib 200 mg q12h oral, ketorolac 15 mg IV q6h. Breakthrough: Pain scores 4-6: oxycodone 5 mg q4h PRN oral, pain scores 7-10: oxycodone 10 mg q4h PRN oral. Discharge: acetaminophen 1 g q8h oral, tramadol 100 mg q8h oral, celecoxib 200 mg q12h oral or meloxicam 15 mg daily oral, oxycodone 5 mg q4h PRN oral.~75 or older: Same except: Preop: celecoxib 200 mg oral. PACU meds: acetaminophen 500 mg oral. No OxyER."
2397898|NCT03586791|Sham Comparator|Control group|In this group, remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients (Standard management).
2397899|NCT03586778|Experimental|MTEX-DN|dry needling, manual therapy, and therapeutic exercise
2397900|NCT03586778|Active Comparator|MTEX|manual therapy and therapeutic exercise
3184420|NCT00724412|Active Comparator|Optive|Optive
3184421|NCT00724438||1|Obese women: women with a body mass index (BMI) >30
3184422|NCT00724438||2|Normal weight women: women with a BMI <25
3184423|NCT00724516|Experimental|Novel Breast Compression Paddle|Women scheduled to undergo a breast mammography wire localization procedure will have a new breast compression paddle will be used Instead of using the regular wire localization mammography compression paddle.
3189039|NCT00773591|Placebo Comparator|Placebo|
2397872|NCT03586921|Experimental|Enhanced usual care + group intervention|Intervention patients received enhanced primary care plus a 9-session group intervention. The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party. The patients from the intervention arm also received additional outreach from the Family Health Teams, including home delivery of psychotropic medication when needed and active outreach and engagement by community workers if patients missed group sessions.
2397873|NCT03586921|Active Comparator|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
2397874|NCT03586908|Experimental|PHP-201 0.5%|PHP-201 0.5%, ophthalmic solution, topical eye drop, OU
2397875|NCT03586895|Experimental|e-Connect|County receives training and materials and subsequently begins the e-Connect intervention
2397876|NCT03586882|Experimental|Spinal Cord Stimulation Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2397877|NCT03586882|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
2397878|NCT03586869|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011 (CEA), ETBX-021 (HER2), ETBX-051 (Brachyury), ETBX-061 (MUC1), GI-4000, GI-6207, GI-6301, haNK for infusion, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, oxaliplatin, and Stereotactic Body Radiation Therapy (SBRT).
2397879|NCT03586856|Active Comparator|Nasal mask interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
2397880|NCT03586856|Active Comparator|Nasal prongs interface|The CPAP interface will be applied and adjusted by experienced staff blinded to the outcome variable; leakage. Measures to reduce/minimize leakage are tested in an unblinded observational part after the intervention.
2397881|NCT03586843|Experimental|Part A: Treatment Sequence ABC: JNJ-64565111|Participants will receive Treatment A (JNJ-64565111 subcutaneous [SC] administration in the upper arm in fasted condition) on Day 1 of Treatment Period 1; followed by Treatment B (JNJ-64565111 SC administration in the thigh in fasted condition) on Day 1 of Treatment Period 2 and then Treatment C (JNJ-64565111 SC administration in the abdomen in fasted condition) on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last pharmacokinetic (PK) sample collection and dosing on Day 1 of subsequent treatment period.
2397882|NCT03586843|Experimental|Part A: Treatment Sequence ACB: JNJ-64565111|Participants will receive Treatment A on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2397883|NCT03586843|Experimental|Part A: Treatment Sequence BAC: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment C on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2397884|NCT03586843|Experimental|Part A: Treatment Sequence BCA: JNJ-64565111|Participants will receive Treatment B on Day 1 of Treatment Period 1; followed by Treatment C on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2397885|NCT03586843|Experimental|Part A: Treatment Sequence CAB: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment A on Day 1 of Treatment Period 2 and then Treatment B on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2397886|NCT03586843|Experimental|Part A: Treatment Sequence CBA: JNJ-64565111|Participants will receive Treatment C on Day 1 of Treatment Period 1; followed by Treatment B on Day 1 of Treatment Period 2 and then Treatment A on Day 1 of Treatment Period 3. Each treatment period will be separated by a washout Period of at least 7 days between the last PK sample collection and dosing on Day 1 of subsequent treatment period.
2397887|NCT03586843|Experimental|Part B: JNJ-64565111|Participants will receive a single SC ascending doses of JNJ-64565111 on Days 1, 8, 15, 22, 29 and 36.
3184424|NCT00724529||Serious Active Crohns Disease|Patients with severe active Crohns Disease who do not show any response to treatment with corticosteroids or immunosuppressive agents, and have no drug tolerance or contraindications to such treatments.
3184425|NCT00724529||Fistula-Type Active Crohns Disease|Patients with fistula-type Crohns Disease who do not show any response to general treatments such as antibiotics, drainage, or immunosuppressant.
3189040|NCT00773617|Experimental|1|Integrative cognitive affective therapy (ICAT)
3189041|NCT00773617|Active Comparator|2|Cognitive behavioral therapy (CBT)
2397892|NCT03586817|Active Comparator|Palonosetrona|Palonosetron 75 mcg during the anesthesia
2397893|NCT03586817|Active Comparator|Fosaprepitant|Fosaprepitant 150 mg during the anesthesia
2397894|NCT03586804||women without dysmenorrheal syndrome|women without dysmenorrheal syndrome
2397895|NCT03586804||women with dysmenorrheal syndrome|women with dysmenorrheal syndrome
2397896|NCT03586791|Experimental|Pupillometry group|In this group, anesthesia is performed using Pupillometry guided anesthesia.
2397897|NCT03586791|Active Comparator|SPI group|In this group, anesthesia is performed using SPI guided anesthesia.
2397901|NCT03586765||Experimental group|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
2397902|NCT03586752|Experimental|On-line group|On-line program course
2397903|NCT03586752|Active Comparator|Standard group|Standard program course
2397904|NCT03586739|Experimental|"Covered stents strategy"|
2397905|NCT03586739|Active Comparator|"Bare metal stents strategy"|
3184426|NCT00724529||Ankylosing Spondylitis|Patients with Ankylosing Spondylitis who do not show adequate response to general treatments and with increased serological indices related to severe axial symptoms and inflammation.
2397907|NCT03586713|Other|ICDAS-II|According to the international caries detection and assessment system (ICDAS-II). The visual examination was performed using the ICDAS-II criteria, which provides a standardized method of lesion detection. The ICDAS-II detection codes for coronal categories the score will be 0 =surface not restored or sealant then according to caries categories range from 0 to 6 depending on the severity of the lesion with the corresponding clinical views.
2397908|NCT03586700|Experimental|Xiao zhong fang granules|Xiao zhong fang granules were made from Smilax glabra 20g, Paris polyphylla 10g, Alisma orientale15g, Plantago15g, Peach kernel 10g, safflower 10g, radices cyathulae10g,fructus chaenomeles lagenaria 10g, corydalis tuber 10g, radix clematis 10g, radices paeoniae alba 10g, glycyrrhiza 10g. Granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
2397909|NCT03586700|Placebo Comparator|Placebo Xiao zhong fang granules|Placebo Xiao zhong fang granules were made by the same institution. Placebo granules 6 days for one course, continuously taking two courses, interval of 1 day, and then take 2 courses. Short wave infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
2397910|NCT03586687|Active Comparator|20 mg|20mg Triamcinolone with 3cc of 1% Lidocaine
2397911|NCT03586687|Active Comparator|40 mg|40mg Triamcinolone with 3cc of 1% Lidocaine
2397912|NCT03586687|Active Comparator|80 mg|80mg Triamcinolone with 3cc of 1% Lidocaine
2397913|NCT03586674|Active Comparator|Ursogal|Control group : Ursogal 10-20 mg/kg/d on 2 divided dose for four months with regular follow up.
2397914|NCT03586674|Experimental|Lipanthyl + Ursogal|Therapy group: Ursogal 10-20 mg/kg/d by mouth, on 2 divided dose, and lipanthyl 10-20 mg/kg/d by mouth,once per day, for four months with regular follow up.
2397915|NCT03586661|Experimental|Treatment (niraparib, copanlisib)|Patients receive niraparib PO daily on days 1-28 and copanlisib IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3184427|NCT00724542|No Intervention|Control|Placebo with lifestyle intervention
3184428|NCT00724542|Experimental|Drug|Voglibose tablets with lifestyle intervention
2397918|NCT03586635||Patients with Multiple Sclerosis|
2397919|NCT03586622|Experimental|Low FODMAP diet|Low FODMAP diet (LFD) Each IBS patient randomized to the Australian exclusion diet, Low FODMAP diet (LFD) group (n=52) will when allocated to LFD group have a one-hour counseling to the LFD by a nutritionist at the hospital. Within this one hour a diet anamnesis of the patient will be made in order to register the High FODMAP foods the patient is consuming (important that one find good low FODMAP substitutions). Based on the diet anamnesis optimization of the low FODMAP diet counseling can be made. They will receive hands-out with recipes, tips, meal plans, list of suitable low FODMAP foods and folder of foods they should avoid- most of information in the LFD folder patients will also find in the app 'Low FODMAP diet' which they will receive free of charge.
2397920|NCT03586622|Experimental|VSL#3®|Each IBS patient randomized to the probiotic VSL#3 arm (n=52) will at randomization be given VSL#3 for 4 weeks (56 sachets) together with a leaflet on VSL#3 - holding information on the product from the manufacture regarding storage, nutritional information etc. If the patients have any questions regarding the treatment, they can ask the project investigator handing out the VSL#3 to them. They will be instructed in taking their VSL#3 (2 sachets a day) as described by the manufacturer
2397921|NCT03586609|Experimental|Treatment (cladribine, cytarabine, venetoclax, azacitidine)|See Detailed Description.
3184429|NCT00724555||1|Adults living in DC neighborhoods with high proportions of underserved adults. The age of the cohort members will reflect the age of DC residents who suffer most from stroke.
3184430|NCT00724581|Experimental|A|
2397926|NCT03586570|Experimental|Aprocitentan|
2397927|NCT03586570|Placebo Comparator|Placebo|
2397928|NCT03586557|Experimental|Corticosteroid & Plasma Exchange|1000mg intravenous methylprednisolone daily for 3~5 days and subsequent taper, combined with plasma exchange every other day for five times in all
2397929|NCT03586557|Active Comparator|Corticosteroid|1000mg intravenous methylprednisolone daily for 3~5 days, and subsequent corticosteroid decrement.
3184431|NCT00724607||TBI (Case) Group|Members of the TBI group have sustained a TBI in accordance with inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant.
3189042|NCT00773630|Active Comparator|A|Intake of Pletal 100 mg tablets dose together with 200 ml water
2397964|NCT03586284|Placebo Comparator|Placebo|Topical placebo solution, 1 drop applied 6 times daily Placebo pills PO BID
2397965|NCT03586271||trifocal lens|trifocal lens implantation(AT Lisa tri 839MP)
2397966|NCT03586271||bifocal lens 1|bifocal lens implantation(Diff-aay)
2397967|NCT03586271||bifocal lens 2|bifocal lens implantation(ReSTOR +3.0D)
3189043|NCT00773630|Experimental|B|Intake of Pletal 100 mg ODT dose without water
3189044|NCT00773630|Experimental|C|Intake of Pletal 100 mg ODT dose together with 200 ml water
2397932|NCT03586518||Haemodialysis patients|"The plans for patient recruitment were developed in partnership with our local haemodialysis patient participation and involvement group. Patients will be identified from the supportive care register established for haemodialysis patients in Leicester in 2008.~Inclusion:~Prevalent haemodialysis patient (more than 3 months)~Active on the supportive care register with anticipated death in the subsequent 12 months~Able to give informed consent~Consent to donation of heart for research following death~Able to understand written and verbal explanations in English~Exclusion:~Contraindication to MRI scan (e.g. pacemaker, incompatible metallic implants, claustrophobia)~Patients with expected or potential infiltrative cardiomyopathy (e.g. amyloidosis)~Unable to give informed consent~Unable to understand written and verbal explanations in English"
2397933|NCT03586505|Experimental|Light exposure|"The keratitis eye of the patient is exposed to 6 lights with increasing intensity according to a constant speed.~The patients switch off the light when the discomfort is too elevated"
2397934|NCT03586492|Other|Patient with myocardial ischemia|
2397935|NCT03586479|Experimental|Low Testing|Children will receive 0 testing (talking) exposures and 6 listening exposures for a total of 6 exposures to each word. This is a listening only condition with minimal testing.
2397936|NCT03586479|Experimental|Mid Testing|Children will receive 2 testing (talking) exposures and 4 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly listening.
2397937|NCT03586479|Experimental|High Testing|Children will receive 4 testing (talking) exposures and 2 listening exposures for a total of 6 exposures to each word. This is a listening and talking condition with mostly talking.
2397938|NCT03586466|Experimental|BupreCare|The BupreCare system is an integrated medication management and patient monitoring system, consisting of a smart medication-tracking dispenser and online platform. The dispensing component is a portable smart dispenser and secure pill cartridges that is programmed with an individualized treatment plan for each patient. This arm will be assigned a MedicaSafe device that will have their buprenorphine/naloxone securely stored. Treatment reports of their dispensation history will be collated and available to the treatment team.
2397939|NCT03586466|Active Comparator|Treatment as Usual|This arm represents an active comparator for the experimental group. Subjects in this group will undergo TAU, with no changes to the way that they receive their medication. They will have pill counts bi-weekly to examine adherence.
2397940|NCT03586466|Active Comparator|Treatment as Usual with MEMS|This arm represents a second active comparator for the experimental group. Subjects in this group will receive their medication in a MEMS pill bottle, but otherwise will undergo TAU.
2397941|NCT03586453|Experimental|Osimertinib|Osimertinib: Oral, once a day, dosage determined per protocol
2397942|NCT03586440||Rounded shoulder posture group|-distance between the on table and posterior aspect of lateral part of acromion process ≥ 2.5 cm
2397943|NCT03586440||forward head rounded shoulder posture|"craniovertebral angle (CVA) ≤ 50 degree~distance between on table and acromion ≥ 2.5 cm"
2397944|NCT03586440||normal posture group|"Craniovertebral angle> 50 degree~distance between on table and acromion < 2.5 cm"
2397945|NCT03586427|Experimental|AGN-241751 Dose 1|AGN-241751 Dose 1 administered as 1 tablet taken orally every day
2397946|NCT03586427|Experimental|AGN-241751 Dose 2|AGN-241751 Dose 2 administered as 1 tablet taken orally every day
2397947|NCT03586427|Experimental|AGN-241751 Dose 3|AGN-241751 Dose 3 administered as 1 tablet taken orally every day
2397948|NCT03586427|Experimental|AGN-241751 Dose 4|AGN-241751 Dose 4 administered as 1 tablet taken orally every day
2397949|NCT03586427|Placebo Comparator|Placebo|Placebo administered as 1 tablet taken orally every day
2397950|NCT03586414|Experimental|A: 'MITOQUINOL MESYLATE then placebo|'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
2397951|NCT03586414|Experimental|B: Placebo then 'MITOQUINOL MESYLATE'|Placebo capsule administered twice daily for 4 weeks followed by a washout period, then 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'
2397952|NCT03586401||Childhood Cancer Survivors|"The study will be attended by 1000 families with children who have completed treatment for cancer at least 6 months before the start of the trial and undergo rehabilitation courses at the Medical and Rehabilitation Research Center Russkoe pole at least twice a year."
2397953|NCT03586388|Experimental|Oral immunotherapy protocol|Eligible children receive the oral food challenge (OCD) protocol
2397954|NCT03586362||Treatment Group A|Patients admitted for pneumonia whose MRSA nasal swab is negative for MRSA, and empiric vancomycin is discontinued within 24 hours of the MRSA nasal swab results being documented in the electronic health record.
2397955|NCT03586362||Treatment Group B|Patients admitted for pneumonia whose empiric vancomycin is continued for ≥24 hours after electronic health record documentation of negative MRSA nasal swab results.
2397956|NCT03586336|Experimental|ReDS-Guided|Patients in the intervention arm will undergo daily measurements of lung fluid content at the bedside with the ReDS vest. The values will be shared with the treating clinicians, who can use the measurements in addition to other standard data to guide diuresis. Patients should be discharged only once their lung fluid content falls within the normal range of 20-35%.
2397957|NCT03586336|Sham Comparator|Control|Patients in the control arm will also undergo daily measurements of lung fluid content at the beside with the ReDS vest. However, the values will not be shared with the treating clinicians, who will direct management based on standard clinical tools
2397958|NCT03586323|Experimental|L-SLNB|performed a superior laryngeal nerve block with lidocaine
2397959|NCT03586323|Placebo Comparator|S-SLNB|performed a superior laryngeal nerve block with saline
2397960|NCT03586310|Other|4 nights with PSG|For all subjects: 4 nights with polysomnography and ear-EEG
2397961|NCT03586310|Other|12 nights with ear-EEG|"For a subset of the subjects in arm the '4 nights with PSG', a second phase follows in which each subject sleeps 12 nights with only ear-EEG.~If a night's recording is unsuccessful, for whatever reason, up to 6 additional nights may be attempted."
2397962|NCT03586284|Active Comparator|Oral Valganciclovir|Oral Valganciclovir 900mg PO BID Topical placebo solution, 1 drop applied 6 times daily
2397963|NCT03586284|Active Comparator|Topical Ganciclovir 2%|Topical Ganciclovir 2% solution, 1 drop applied 6 times daily Placebo pills PO BID
2397969|NCT03586258|Experimental|Brain Damaged Subjects|Patients with circumscribed brain injury, developmental pathology or degenerative pathology responsible for selective cognitive disorders
2397970|NCT03586258|Sham Comparator|Healthy Volunteers|Healthy Controls
2397971|NCT03586245|Active Comparator|Ferric pyrophosphate|"Study I group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds.~57FePP (95.8%) 3.49 mg~Aspergillus oryzae (unenriched) 0.025 mg~FePP natural abundance 0.685 mg.~Subjects received iron fortificants in a meal composed of zucchini, cabbage, carrot (42g each), onion (24g), corn oil (6.3 g), jasmine rice (75g dw), and flavored granulated chicken bouillon (6.6g). All meals were consumed in a fasted state with nothing to eat or drink (besides water) for 3 hours following consumption."
2397972|NCT03586245|Experimental|Aspiron|"The Aspiron group was required to follow the same protocol as the 57Fe as FePP, with the exception of consuming 58Fe ASP.~ASP-p (8% Fe; natural abundance) 3.516 mg~58ASP-p (5% Fe; 99.5% enrichment) 0.68 mg~4.2 total mg of Fe"
2397973|NCT03586245|Other|Ferrous sulfate|"The FeSO4 study group was required to consume a total of 3 meals. Each meal contained 4.2 mg added iron compounds. .~Aspergillus oryzae (unenriched) 0.027 mg~57FeSO4 (95.4%) 3.18 mg~4.2 total mg of Fe"
2397974|NCT03586232|Placebo Comparator|Control|Participants will take two placebo pills q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2397975|NCT03586232|Experimental|Arnica Montana|Participants will take Arnica Montana, 30C oral, pill and a placebo pill q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2397976|NCT03586232|Experimental|Arnica Montana and Bromelain|Participants will take Bromelain, 500mg oral pill + Arnica Montana, 30C oral, q8 hours for 7 days preoperatively and 7 days postoperatively, in addition to the standard postoperative tapered methylprednisolone.
2397977|NCT03586219|No Intervention|Control Arm|Standard preoperative and postoperative instructions will be provided to the study subjects
2397978|NCT03586219|Experimental|Intervention Arm|Intervention: Study subjects will receive opioid-specific educational patient pamphlets in addition to standard preoperative and postoperative instructions
2397979|NCT03586206||Mild-moderate C.difficile infection|
2397980|NCT03586206||severe C.difficile infection|
2397981|NCT03586206||severe complicated/fulminant C.difficile infection|
2397982|NCT03586193||patients with HMF|Patients who are diagnosed as high myopic macular schisis and agree to receive pars plana vitrectomy as the treatment are planned to allocated in this group
2397983|NCT03586180||children and their parents|aged 4-18 children with cancer/blood disease and their parents
2397984|NCT03586180||Dr. Clowns|they will perform shows for children and parents
3184432|NCT00724607||Non-TBI (Control) Group|Members of the Non-TBI group have not sustained a TBI and are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize a control group to account for normal aging and other control factors.
2397987|NCT03586154|Other|Group A|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml
2397988|NCT03586154|Active Comparator|Group B|patients were subjected to ultrasound guided SGB using 1 ml ketamine in a dose of 0.5mg/kg plus 5ml bupivacaine 0.5% in total volume 10 ml plus posterior approach shoulder injection with PRP.
2397989|NCT03586141|Other|noninvasive measurement of hemoglobin|All participating patients are measured by the Pronto® hemoglobin measurement tool
2397991|NCT03586115||Patients with Hereditary telangectasia|In addition to all laboratory analyses and imaging studies required to evaluate the disease, hepatic elastometry and critical flicker frequency assessment will be performed.
2397992|NCT03586102|Experimental|High protein supplementation|Infants will receive a diet that consists of mother's own milk or donor human milk and bovine-based human milk fortifier plus a fixed amount of commercially available hydrolyzed bovine protein. The study intervention will begin the day after fortification is ordered and will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
2397993|NCT03586102|Active Comparator|Standard protein supplementation|Infants will receive a standard diet that consists of mother's own milk or donor human milk (DHM) and bovine-based human milk fortifier. The study intervention will be continued until postnatal day 50 or 32 weeks postmenstrual age, whichever occurs first.
2397994|NCT03586089|Experimental|Phenobarbital|Patients will receive a single dose of phenobarbital (7.5 mg/kg of ideal body weight, IV) in addition to usual therapy.
2397995|NCT03586089|Placebo Comparator|Placebo|Patients will receive an inactive placebo (IV).
2397996|NCT03586076|Experimental|JHL1922|
2397997|NCT03586076|Active Comparator|Pulmozyme|
2397999|NCT03586037|Experimental|Sequence 1|Period 1: AD-2011 10/20mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
2398000|NCT03586037|Experimental|Sequence 2|Period 1: AD-2011 10/20mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2012 80mg QD
2398001|NCT03586037|Experimental|Sequence 3|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg + AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
2398002|NCT03586037|Experimental|Sequence 4|Period 1: AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2011 10/20mg + AD-2012 80mg QD
2398003|NCT03586037|Experimental|Sequence 5|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2011 10/20mg QD Period 3: AD-2012 80mg QD
2398004|NCT03586037|Experimental|Sequence 6|Period 1: AD-2011 10/20mg + AD-2012 80mg QD Period 2: AD-2012 80mg QD Period 3: AD-2011 10/20mg QD
2398005|NCT03586024|Experimental|Cohort 1|cohort 1: NK/T-cell lymphoma;
2398006|NCT03586024|Experimental|Cohort 2|EBV-associated diffuse large B cell lymphomas
2398007|NCT03585998|Experimental|Study arm|Concurrent radiotherapy with chemotherapy (Etoposide/Cisplatin) with durvalumab, and followed by consolidation durvalumab
2398008|NCT03585985||Group 1|10 patients aged above 70 years with typical geriatric multimorbidity or aged above 80 years otherwise, patient in the hospital Franziskushospital Aachen on the ward of geriatric medicine
2398009|NCT03585985||Group 2|10 healthy elderly people above 70 years, healthy
2398010|NCT03585972|Experimental|Frailty Prevention Program|4 face-to-face sessions, with a licensed and registered occupational therapist over 4 months
2398011|NCT03585972|No Intervention|Educational materials|Participants receive publicly available educational materials
3184433|NCT00724607||Non-TBI Non-deployed (Control) Group|Members of the Non-TBI Non-Deployed group have neither sustained a TBI nor have been deployed but are in accordance with other provisions of the inclusion/exclusion criteria. However, the investigative staff administering, scoring, analyzing and interpreting the data will be blinded to the group status of the participant. This longitudinal study will utilize this Non-deployed control group to account for deployment-specific factors.
2398013|NCT03585946||Cyclosporine|
2398014|NCT03585946||Intravenous Immunoglobulin|
2398015|NCT03585946||Etanercept|
2398016|NCT03585946||Steroids|
2398017|NCT03585920|Active Comparator|Positive Control (standard fat)|Expanded Corn Snack. Positive control (13 g oil per 40 g snack portion)
2398018|NCT03585920|Experimental|Negative Control (reduced fat)|Expanded Corn Snack. Negative control (<8 g oil per 40 g snack)
2398019|NCT03585920|Experimental|Reduced Fat Sensory Matched|Expanded Corn Snack. Reduced fat optimised (<8 g oil, matched sensory signals)
2398020|NCT03585907|Experimental|Modified Atkins Diet (MAD)|A diet that can produce ketones
2398021|NCT03585907|Active Comparator|MIND diet|Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND). A diet that has been indicated to be helpful in preventing or decreasing cognitive decline.
2398022|NCT03585894|Other|Sumatriptan|Sumatriptan 4 mg/mL I.V will be administrated over 10 min
2398023|NCT03585894|Active Comparator|Ketorolac|Ketorolac 30 mg/mL I.V will be administrated over 10 min
2398024|NCT03585881|Experimental|window bracket positioning tray|
2398025|NCT03585881|No Intervention|conventional indirect boning tray|
2398026|NCT03585868|Placebo Comparator|Placebo|Beverage without flavonoids
2398027|NCT03585868|Sham Comparator|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
2398028|NCT03585868|Experimental|Flavonoids|Beverage with a flavonoid rich mixture
2398029|NCT03585855|No Intervention|Historic control|historic cohort of patients with ABMR treated with standard of care therapy
2398030|NCT03585855|Experimental|MSC transplantation|patients with ABMR treated with MSC transplantation
2398031|NCT03585842||Pre-test group|Patients from CMP B coming for consultation or day hospital
2398032|NCT03585842||Test group|Patients suffering from DSMV substance use disorder with one or more psychiatric comorbidities
2398033|NCT03585829|Active Comparator|hydrocortisone|hydrocortisone 20 mg per day: 15 mg at pre-dawn meal and 5 mg at dinner
2398034|NCT03585829|Active Comparator|prednisolone|Prednisolone 5 mg at pre-dawn meal and a placebo (starch) at dinner
2398035|NCT03585803|Other|KMRC011 5μg or Placebo|Cohort 1
2398036|NCT03585803|Other|KMRC011 10μg or Placebo|Cohort 2
2398037|NCT03585803|Other|KMRC011 15μg or Placebo|Cohort 3
2398038|NCT03585803|Other|KMRC011 20μg or Placebo|Cohort 4
2398039|NCT03585803|Other|KMRC011 25μg or Placebo|Cohort 5
3189045|NCT00773630|Active Comparator|D|Intake of Pletal 100 mg ODT dose without water
3189046|NCT00773643|Experimental|Tissue Sample|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
2398042|NCT03585777||Group 1|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking metformin
2398043|NCT03585777||Group 2|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking linagliptin
2398044|NCT03585777||Group 3|Compare serum levels of klotho in patients taking glimepiride in comparison to patients taking impaglifluzin
2398045|NCT03585764|Experimental|Cohort 1: MOv19-BBz CAR T cells without chemo|Cohort 1: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy.
2398046|NCT03585764|Experimental|Cohort 2: MOv19-BBz CAR T cells after chemo|Cohort 2: (n= 3 to 6 subjects): Single infusion of 1-3x107 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2398047|NCT03585764|Experimental|Cohort 3: MOv19-BBz CAR T cells after chemo|Cohort 3: (n=3 to 6 subjects): Single infusion of 1-3x108 lentivirally transduced MOv19-BBz CAR T cells on day 0 beginning 3 days (+/- 1 day) after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2398048|NCT03585764|Experimental|Cohort-1: without chemo;only if dose de-escalation required|Cohort -1: (n= 3 to 6 subjects): Single Infusion of 1-3x106 /m2 lentivirally transduced MOv19-BBz CAR T cells on day 0 without lymphodepleting chemotherapy. Up to 6 subjects will be infused in Cohort -1 with ≤ 1 DLT/6 subjects to establish the MTD.
2398049|NCT03585751|Active Comparator|Triple antibiotic paste|Pulpectomy for primary molars, triple antibiotic mix is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2398050|NCT03585751|Experimental|3mixstatin|Pulpectomy for primary molars, 3 Mixstatin ( mix of simvastatin and triple antibiotic mix ) is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2398051|NCT03585751|Experimental|simvastatin|Pulpectomy for primary molars, simvastatin is used as obturating material mixed with Macrogol and Polyethylene glycol & small amount of Zinc oxide powder to obtain workable , radio opaque mix
2398052|NCT03585738|Experimental|Inositol + Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.
2398053|NCT03585738|Placebo Comparator|Folic acid|Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.
2398054|NCT03585725|Experimental|Ribavirin|Ribavirin 1000 mg will be administered orally twice daily continuously in 28 day cycles for up to 6 cycles.
3184434|NCT00724620|Experimental|Early Responders (ER)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have responded to therapy at Treatment Week 12 (ie, who are Early Responders defined by HCV-RNA[-] at Treatment Week 12) will continue the combined treatment for a total of 48 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
2398057|NCT03585699|Active Comparator|Fluoroscopy Guided Spinal Biopsy Arm|Fluoroscopy guided spinal biopsies were done by spine surgeons in the operation theatre using C-Arm fluoroscopy device (OECFluorostar7900Compact - GE®). C-arm image intensiﬁer was positioned until fluoroscopic beam was collinear with the corresponding vertebral body on AP view prior to insertion of biopsy needle
2398058|NCT03585699|Active Comparator|CT guided Spinal Biopsy Arm|CT guided spinal biopsies were done by radiologist under guidance of 128-slice CT scanner (SOMATOM Definition AS+, Siemens Medical Solutions USA, Inc.). Preliminary axial CT scanning was done in bone window (window width, WW:2500; window level, WL:500) at the pre-selected levels decided from previous imaging to plan the needle access. Biopsy was then performed under sequential CT-fluoroscopy scan.
2398059|NCT03585686|Experimental|vemurafenib|vemurafenib, Cytarabine, 2-chlorodeoxyadenosine
2398060|NCT03585673|Experimental|Docetaxel-PM+Oxaliplatin|"Docetaxel-PM 35mg/m2 D1, 8 I.V.~Oxaliplatin 120mg/m2 D1 I.V. Every 3 weeks till progression"
2398061|NCT03585660|Experimental|Interventional Arm|Participants will undergo diagnostic MRI exam followed by clinical biopsies of suspected prostate cancer tumors.
2398062|NCT03585647||GA-group|Patients undergoing elective hip arthroplasty included in the GA-group received general anesthesia. GA was induced by intravenous fentanyl (1 mcg/kg) and propofol (2 mg/kg), followed by vecuronium bromide (0.1 mg/kg) to facilitate tracheal intubation, then GA was maintained using a 50% air/oxygen mixture and sevoflurane.The end-tidal concentration of sevoflurane was adjusted to maintain heart rate and blood pressure values within 20% of baseline. Mechanical ventilation was regulated to maintain the end-tidal carbon dioxide partial pressure ranging between 4.3 and 5.1 kilopascal.
2398063|NCT03585647||RA-group|"Patients undergoing elective hip arthroplasty included in the RA-group received regional anesthesia. Regional anaesthesia included continuous lumbar plexus block, performed by or under supervision of an experienced operator using a nerve stimulator (Stimulax, B. Braun) and Continued Peripheral Nerve Block Set.~A total dose of 20 ml of 0.5% Levobupivacaine was administered at the time of catheter placement. Dural puncture was performed at the L3-L4 interspace using a 25-Gauge whitaker spinal needle (Becton-Dickinson, New Jersey, USA) with the midline approach using 3 ml of 0.5% Levobupivacaine."
2398064|NCT03585647||IA-group|Patients undergoing elective hip arthroplasty included in the IA-group received integrated anesthesia. The patients received regional anaesthesia (lumbar plexus block + spinal anaesthesia) as described protocol. General anaesthesia was induced by propofol 1% and a laryngeal mask airway of appropriate size was inserted. General anaesthesia and mechanical ventilation were maintained as standard protocol.
2398065|NCT03585634|Other|Dads in Gear Program|An 8 week group program to support men's smoking cessation efforts.
2398066|NCT03585621|Experimental|SBRT to the Primary Breast Tumour|SBRT to the breast using 4 sequentially escalating dose levels from 9Gy to 12 Gy.
3184435|NCT00724620|Experimental|Slow Responders (SR): Decrease in viral load >=2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have a slow response to therapy at Treatment Week 12 (ie, Slow Responders who are not HCV-RNA[-] at Treatment Week 12 but decrease >=2 log) will continue the combined treatment for a total of 72 weeks and will complete 24 weeks of follow up to determine the Sustained Viral Response (SVR).
2398069|NCT03585582||PARDS survivors|"Children <18 years~diagnosed with PARDS, as defined by PALICC~admitted to the ICU at the CHUSJ, a pediatric tertiary care center"
2398070|NCT03585556|Experimental|AAVCAGsCD59 Treated Arm|An anti-VEGF injection will be given at Day 0 followed by an intravitreal injection of AAVCAGsCD59 at Day 7. All eyes will then be treated with intravitreal anti-VEGF monthly as needed based on disease activity.
2398072|NCT03585530|Experimental|treatment group|
2398073|NCT03585517|Experimental|IM23 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD123 CAR will be infused 24-96 hours later.
2398076|NCT03585491|Experimental|Bankart + Remplissage Procedure|Bankart Procedure: the participant will be placed in the lateral decubitus or beach chair position. Standard diagnostic arthroscopy will be performed. The anterior capsulolabral complex will be freed from the anterior aspect of the scapular neck. The anterior aspect of the scapular neck will be decorticated using a motorized burr. A capsuloligamentous repair will be performed with the capsule shifted from inferior to superior and repaired on the glenoid face. The number of anchors used for the repair will be left to the discretion of the surgeon. Patients will be given a sling for 4 weeks, and participation in sports will not be allowed for 6 months.
2398077|NCT03585491|Experimental|Latarjet Procedure|Open or Arthroscopic coracoid transfer (Latarjet Procedure): This procedure may be performed through small incisions (minimally invasive) but may require a larger incision in some cases. It involves the transfer of a nearby bony structure (the coracoid process) to the front of the shoulder joint (glenoid). This bone will then provide support to prevent the shoulder joint from dislocating.
2398080|NCT03585465|Experimental|A: Cyclophosphamide Vinblastine Nivolumab|This arm was applicable to first stage, and is closed
2398081|NCT03585465|Experimental|B: Capecitabine Nivolumab|This arm was applicable to first stage, and is closed
2398082|NCT03585465|Experimental|C: Cyclophosphamide Vinblastine Capecitabine|This arm was applicable to first stage, and is closed
2398083|NCT03585465|Experimental|"Metronomic CT "|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine)~This arm is applicable to second stage, and 43 patients are expected"
2398084|NCT03585465|Experimental|"Metronomic CT + Nivolumab"|"metronomic chemotherapy selected at the end of first stage (C: Cyclophosphamide Vinblastine Capecitabine) + Nivolumab~This arm is applicable to second stage, and 43 patients are expected"
2398156|NCT03584932|Experimental|Intervention arm|Subjects participate in a youth service navigation intervention and are eligible to receive contingency management incentives.
2398085|NCT03585452||Group C|Patients with typical anesthetic regimen: premedication: 2 mg estazolam p.o. and 10 mg morphine s.c. - 1 hour before procedure. Preoxygenation and induction of anaesthesia: remifentanyl 1 µg/kg, etomidate 0.3 mg/kg, pancuronium 0.1 mg/kg and intubation. Maintenance of the anesthesia: remifentanyl 0.2-0.5 µg/kg/min and propofol 2-4 mg/kg/min infusions. Ventilation with Air/O2. Additionally: nitroglycerine infusion or phenylephrine 0.05-0.1 mg boluses will be used for normotension maintenance at demanding doses. Subsequently typical CABG procedure with normothermic CPB will be performed. Weaning from CPB will be performed with inotropic support (dobutamine) and vasodilator (nitroglycerine) administration - with patients dependent doses. Routine recovery after surgery.
2398086|NCT03585452||Group D|Regimen will be the same with additional dexmedetomidine infusion: with loading dose: 0.5 µg/kg/h through 1 hour and then dose will be reduced to 0.25 µg/kg/h and infusion will be continued during surgery and postoperative period to the total dose of 200 µg. Anesthetics and opioids doses will be adjusted under hemodynamic and eeg sensor - SedLine Masimo.
2398087|NCT03585439||Single cohort of operated patients|One group of patients: isthmic spondylolisthesis operated in our center using a double approach technique
2398088|NCT03585426|Experimental|Vancomycin 1g q12h|
2398089|NCT03585426|Experimental|Vancomycin 1g q8h|
2398090|NCT03585413|Active Comparator|Specific Micronutrient-probiotic-combination|"Intake of one micronutrient capsule three times daily and probiotic powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient capsules consist of vitamins, minerals, phytochemicals and bioactive substances. The probiotic supplement is a powder of 10 different species of probiotic bacteria."
2398091|NCT03585413|Placebo Comparator|Micronutrient-placebo-combination|"Intake of one micronutrient capsule three times daily and placebo powder twice daily starting on the first day after hospital discharge until 12 weeks postoperatively.~The micronutrient-control-combination consists of a micronutrient capsule (vitamins and minerals) but without phytochemicals and bioactive substances, and a placebo powder manufactured to mimic the probiotic powder."
2398092|NCT03585400||Observational Study|Observational Study: Not Applicable for Observational Studies
2398093|NCT03585387||Main|Each subject in this group will be its own control for the two navigation methods.
2398094|NCT03585374|Experimental|A_test drug_Methoxyflurane (Penthrox®)|Pain from moderate to severe (NRS score 4-10). 3 ml of methoxyflurane vaporized through the Penthrox® inhaler. The drug is self administered under the supervision of investigators/study nurse. The treatment duration is about 25 minutes. The patient is instructed to breath normally and to close the diluter aperture via his/her forefinger to increase the analgesic effect, if needed. In case of pain increase or insufficient pain relief the investigator is allowed to administer a rescue medication as per local routine practice.
2398095|NCT03585374|Active Comparator|B_comparator_Morphine/Paracetamol/Ketoprofen|"The comparator to be administered will vary according to pain intensity and local clinical practice.~In case of severe pain (NRS score ≥ 7), morphine will be administered at a dose of 0.10 mg/kg body weight.~In case of moderate pain (NRS score 4-6) paracetamol or ketoprofen will be administered respectively at a 1 g and 100 mg dose.~All comparator will be administered by intravenous drip in a maximum 10 minutes time of infusion. .~Maximum time of infusion 10 minutes."
2398096|NCT03585361|Experimental|Intervention|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Also, health centers conduct data reviews of PPFP counseling, intra-facility referrals and uptake data. At community level, HEWs provide PPFP counseling and services throughout continuum of care, volunteers (Development Army) promote PPFP, and HEWs and volunteers track PPFP method choice and uptake.
2398097|NCT03585361|Active Comparator|Comparison|Health centers provide PPFP counseling and services, implementing current Government of Ethiopia policy and standard of care (including still experimental screening and intra-facility referrals of women bringing infants for immunization). Health centers conduct data reviews.
2398098|NCT03585348||Study cohort|The estimated cohort consists of 317.000 adult patients who are intubated for a non-cardiac surgery and extubated at the end of the case at Beth Israel Deaconess Medical Center (205.000) as well as Massachusetts General Hospital (112.000) and received treatment by anesthesia and surgical providers who have completed at least 50 anesthesias and surgeries at their respective institution, respectively.
3184436|NCT00724620|Experimental|Nonresponders (NR): Decrease in viral load <2 log|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. Patients who have not responded to therapy at Treatment Week 12 (ie, Nonresponders who are not HCV-RNA[-] at Week 12 of Treatment and/or have a decrease in viral load <2 log) will stop treatment at Treatment Week 12.
2398100|NCT03585309|Experimental|Laparascopy comper with coagulation and without coagulation|
3184437|NCT00724633|Other|1|standard dialysate Na 140 mEq/L
2398102|NCT03585283|Experimental|Myofascial Group|Myofascial release will be applied by physiotherapist two times a week for four weeks which is a manual therapy technique includes stretching and compression of soft tissues according to fascial chains.Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
2398103|NCT03585283|Sham Comparator|Sham Group|Sham application will be applied two times a week for four weeks. Each session will be approximately 45 min long. Participant will be reevaluated 8 week later after last session for a follow-up assessment.
3184438|NCT00724633|Active Comparator|2|dialysate sodium equal to patient's predialysis serum Na
3184439|NCT00724633|Active Comparator|3|dialysate sodium lower than patient's predialysis plasma sodium
2398106|NCT03585257|Experimental|IV albumin|25% IV albutein (albumin) formulation will be infused 1.5g/kg IV over one hour weekly for 4 weeks
2398107|NCT03585257|Placebo Comparator|Placebo|Normal saline will be infused 1.5g/kg IV over one hour weekly for 4 weeks
3184440|NCT00724646||1|Habilitation assistants
2398109|NCT03585231|Experimental|Experimental|This is the experimental arm of the study. This includes receiving immediate access to the novel/experimental smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
3184441|NCT00724646||2|Parents/ legal guardians
3184442|NCT00724659|Experimental|Ultrasound Pre-Arthrogram|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
2398110|NCT03585231|Active Comparator|Control|This is the control arm of the study. This includes receiving receiving immediate access to the standard of care smoking cessation messaging program. Therapy description withheld to protect the integrity of the study.
2398111|NCT03585231|Active Comparator|Delayed Control|This is the second control arm of the study. This includes receiving the novel/experimental smoking cessation messaging program after completing the 3-month follow-up survey. Therapy description withheld to protect the integrity of the study.
2398112|NCT03585218|Experimental|Experimental Group|The Experimental Group participants will be submitted to the inhalation of the hedonic aroma during the chemotherapeutic treatment, this being the intervention of the study.The control group is not subject to intervention.
2398113|NCT03585218|No Intervention|Control Group|The control group is not subject to intervention.
2398114|NCT03585205|Experimental|Stress and cognitive load Induction|Participants will engage in a computerized task which induces cognitive load. Each participant will perform the task once under a stress condition and once under a neutral (non-stress) condition.
2398115|NCT03585192|Experimental|Skin Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to skin group, neonate will initiate skin-to-skin contact after umbilical cord is cut and dried with warm blankets on Mother's abdomen. Length of monitoring will be for first hour of life.
2398116|NCT03585192|Active Comparator|Warmer Group|Pulse oximeter probe is placed on right wrist of vigorous neonate after vaginal birth. If randomized to warmer group, neonate will initiate skin-to-skin contact after 20 minutes of observation under the radiant warmer. Length of monitoring will be for first hour of life.
2398117|NCT03585179|Experimental|Oral tranexamic acid|250 mg of tranexamic acid bid orally
2398118|NCT03585179|Experimental|Topical tranexamic acid|5% topical tranexamic acid bid
2398119|NCT03585179|Active Comparator|Topical hydroquinone|4% hydroquinone once daily at night
2398120|NCT03585166||laparoscopic hepatectomy|laparoscopic hepatectomy for primary liver cancer
2398121|NCT03585166||open hepatectomy|open hepatectomy for primary liver cancer
2398122|NCT03585153||T1D|Individuals with type 1 diabetes
2398123|NCT03585153||Control|Individuals without type 1 diabetes
2398124|NCT03585153||Aab+|Individuals without type 1 diabetes who possess 2+ type 1 diabetes-related autoantibodies
2398125|NCT03585153||MODY|Individuals with monogenic diabetes, or maturity-onset diabetes of the young (MODY)
2398126|NCT03585140|Active Comparator|Normal Diet|Participants will receive a normal diet according to their metabolic status.
2398127|NCT03585140|Experimental|Low glycemic diet|Participants will receive a low-glycemic index and load diet according to their metabolic status. Milk and vitamin supplements will be eliminated from the diet.
2398128|NCT03585127|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy comprises of nine weekly sessions of an hour.
2398129|NCT03585127|Experimental|Avatar Therapy|Avatar Therapy consists of 9 weekly sessions: one avatar creation session and 8 therapeutic sessions of one hour.
2398130|NCT03585114|Experimental|PyL-PET|Male participants diagnosed with metastatic castrate resistant prostate cancer (mCRPC) and are scheduled to start a new treatment will receive [F-18] DCFPyL PET/CT imaging before starting new treatment and after 6 weeks on treatment.
2398131|NCT03585101|Experimental|All participants|Intervention: Elbasvir/grazoprevir
2398132|NCT03585088|Other|SPI Group|All patients who received the liver resection surgery will receive surgical pleth index
2398133|NCT03585062|Experimental|S-1 combined with Paclitaxel-albumin|S-1 combined with Paclitaxel-albumin S-1:40~60mg bid, day 1~14 (S-1: BSA <1.25m2, 40mg bid , 1.25m2 ≤ BSA ≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid， for 2 weeks, rest a week) Paclitaxel-albumin: 125 mg/m2, intravenous infusion for 30 minutes, Day1 and Day 8.
2398134|NCT03585036|Active Comparator|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
2398135|NCT03585036|Active Comparator|tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure~."
2398136|NCT03585036|Placebo Comparator|placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
2398137|NCT03585023||Spontaneous miscarriage|The study group will be recruited at admission for uterine cavity revision planned for spontaneous abortion.
2398138|NCT03585023||Voluntary pregnancy interruption|The control group will be recruited at admission for uterine cavity revision planned for voluntary pregnancy interruption.
2398139|NCT03585010|Experimental|Supportive Parenting for Anxious Childhood Emotions|Parent-based treatment for childhood anxiety disorders
2398140|NCT03585010|Active Comparator|Parent Educational Support or CBT|Parent-based intervention for childhood anxiety disorders (phase 1) or child based treatment for childhood anxiety disorders (phase 2)
2398141|NCT03584997|Experimental|PRF , ABB & Autogenous Particulate|Platelets rich fibrin + anorganic bovine bone + autogenous particulate graft
2398142|NCT03584997|Active Comparator|ABB And Autogenous Particulate|anorganic bovine bone +autogenous particulate graft
2398143|NCT03584984|Experimental|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|socket preservation with a mixture of autogenous bone graft acquired at the time of extraction mixed with a 50:50 ratio of Anorganic bovine bone
2398144|NCT03584984|Active Comparator|Anorganic bovine bone graft (ABB)|filling the extraction socket with ABB graft
2398145|NCT03584984|Active Comparator|Absorbable gelatin Sponge|Filling the socket with an absorbable gelatin sponge
2398146|NCT03584971||female patients|women in fertility treatment according to Long GnRH Agonist Protocol
2398147|NCT03584971||control group|random sample of male students
2398148|NCT03584958||Ab interno goniotomy surgery|Gonioscopy-assisted transluminal trabeculotomy (GATT) surgery to decrease intraocular pressure.
2398149|NCT03584958||Gelatin stent surgery|Subconjunctival stent (Xen) surgery to decrease intraocular pressure.
2398150|NCT03584958||Suprachoroid stent and cataract surgery|Suprachoroidal stent (Cypass) to decrease intraocular pressure in combination with cataract surgery.
2398161|NCT03584906|Experimental|De-epithelialized gingival graft (DGG)|A harvesting approach where the a graft is obtained from the superficial palate and then extra-orally de-epithelialized in order to obtain a connective tissue graft (DGG harvesting approach) Then the DGG is used for treating gingival recessions (root coverage procedure)
2398162|NCT03584906|Experimental|Envelope technique (ET)|"A harvesting approach where only one horizontal incision is performed on the palate (ET harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2398163|NCT03584906|Experimental|Trap door technique (TDT)|"A harvesting approach where one horizontal and two vertical incisions are performed on the palate (TDT harvesting approach) for harvesting a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2398164|NCT03584906|Experimental|Maxillary tuberosity (MT)|"A harvesting approach that obtains an epithelialized gingival graft from the maxillary tuberosity (MT harvesting approach) which is then extra-orally de-epithelialized in order to obtain a connective tissue graft.~Then the connective tissue graft is used for treating gingival recessions (root coverage procedure)"
2398165|NCT03584893||Epidemiologic observational study cohort|All patients over 1 year old diagnosed as idiopathic bilateral juvenile cataracts will be included in the study at the study sites.
2398166|NCT03584880|Experimental|Diode Laser disinfection|Diode laser disinfection Laser type: 940 nm diode laser Power: 1 Watt Tip: 200 micrometer fibre tip
2398167|NCT03584880|Placebo Comparator|Pseudo Diode Laser Disinfection|Inactivated Diode laser application in root canal
2398168|NCT03584867|Experimental|study Group|refresher CPR
2398169|NCT03584867|No Intervention|control|NO refresher
2398170|NCT03584854|Active Comparator|15-methyl prostaglandin F2α|IM Carboprost followed by Methylergonovine if needed.
2398171|NCT03584854|Active Comparator|Methylergonovine Maleate|IM Methylergonovine followed by Carboprost if needed.
2398172|NCT03584841|Experimental|Patients with mucoviscidosis|For patients with cystic fibrosis: clinically stable, all genotypes included.
2398173|NCT03584841|Experimental|Parents of patients with confirmed diagnosis of mucoviscidosis|The parents are heterozygous subjects
2398174|NCT03584841|Active Comparator|Healthy volunteers|
2398175|NCT03584828|Experimental|Tele-Rehabilitation - intervention|Following the standard rehabilitation intake process the subjects in the Tele-rehaab arm will receive physiologic consultation based on clinical stress tests and clinical data passed from the physician. The Tele-rehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.
2398176|NCT03584828|No Intervention|Usual care|The usual care arm will receive general recommendations for a healthy and active lifestyle and community cardiologist and primary care physician according to local guidelines.
2398177|NCT03584815|Active Comparator|Surgery/fasciotomy|"Fasciotomy of the anterior and lateral compartments in the lower legs:~Two linear longitudinal skin incisions, each approximately 4 cm, are made allowing for excision of the fascia in full length. Sharp dissection to the level of the subcutaneous tissues down to the layer of the overlying fascia is performed, and using a finger or blunt instrument, the subcutaneous tissue is swept away from the fascia, so that an unobstructed cut of the fascia can be performed. The fascia overlying the anterior and lateral compartment is meticulously dissected under direct visualization, the fascia is released approximately as far proximal and distal as the muscle belly is. The perimysium is spared."
2398178|NCT03584815|Active Comparator|Physiotherapy|"Change the running pattern to decrease load on the affected muscles of the lower leg including the eccentric work performed by the tibialis anterior during the rear-foot strike.~Strengthen the major muscles of all lower leg compartments in order address any muscular imbalance/instability around the ankle joint, and to strengthen the main muscle groups responsible for alignment of the hip and knee."
2398179|NCT03584802|Experimental|Experimental treatment of AE-IPF|The experimental group will receive a combination of: 1- Methylprednisolone bolus of 1g IV day 1, then 20 mg/day (or oral prednisolone equivalent) for 21 days; 2- Nine therapeutic plasma exchanges of 1,5x the estimated plasma volumes using albumin: saline (3:1) or fresh frozen plasma in case of an INR superior to 1,5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100mg/kg) 3, Rituximab 1g IV on days 7 and 15 (after therapeutic plasma exchange and premedication) 4, Intravenous immunoglobulin 0,5g/kg/d on days 16 to 19,
2398180|NCT03584802|Active Comparator|Conventional treatment of AE-IPF|Intravenous methylprednisolone bolus of 10mg/kg on day1, 2 and 3, then 1mg/kg/d for 1 week, and 0,75 mg/kg/d for 1 week, then 0,5 mg/kg/d for 1 week, and 0,25 mg/kg/d for 1 week, and 0,125 mg/kg/d until day 90. Shift to oral prednisone as soon as the oral route is available.
2398181|NCT03584789|No Intervention|Standard Practice|
2398182|NCT03584789|Experimental|Clinical Decision Support|
2398183|NCT03584789|Experimental|Clinical Decision Support + Education|
2398184|NCT03584776|Experimental|Virtual Reality Post Spinal Fusion|Patients randomized to the VR group will have the opportunity to utilize VR during the post operative period, and will also experience VR during research visits each day following surgery.
2398185|NCT03584776|No Intervention|Standard of Care|Patients randomized to the non-VR condition will experience the usual standard of care following spinal fusion surgery. This will include 15-30 minutes of movie viewing during research visits.
2398186|NCT03584763|Active Comparator|Bi-Weekly Umbilical Artery Doppler|will undergo Doppler every other week
2398187|NCT03584763|Experimental|Weekly Umbilical Artery Doppler|will undergo Doppler every week
2398188|NCT03584750|Active Comparator|Intervention group|Floating
2398189|NCT03584750|Placebo Comparator|Control group|Placebo floating
2398190|NCT03584750|No Intervention|No-treatment group|Waiting list
3184443|NCT00724659|Experimental|Ultrasound Post-Arthrogram|Ultrasound of the joint(s) after the clinically scheduled arthrogram of the same joint(s), performed while the body still has a contrast agent in it from the arthrogram. The contrast agent varies with different joint areas, but is usually iodine based (like Ultravist.)
3189047|NCT00773656||1|patients treated for a prostate adenocarcinoma
2398193|NCT03584724|Experimental|Norflo Oro|Box of 30 packets of Norflo Oro. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
2398194|NCT03584724|Placebo Comparator|Placebo for Norflo Oro|Box of 30 packets of Placebo. The study subject will take the entire content of one packet with meal twice per day. The study subject will be evaluated in a total of three visits.
2398195|NCT03584711|Experimental|FOLFOX + panitumumab|"1 cylce every 14 days : Panitumumab : 6 mg/kg en IV (J1) during 60 minutes for 1st infusion followed by 30 to 60 minutes Oxaliplatine : 85 mg/m² inG5% orNaCl 0.9% in IV (D1) during 2 hours Acide folinique : 400 mg/m² (or200 mg/m² if Elvorine) in IV (D1) 5Fu bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours~LV5FU2 : 1 cycle every 14 days Acide folinique : 400 mg/m² (or 200 mg/m² ifElvorine) in IV (D1) during 2 hours 5FU bolus : 400 mg/m² in IV 5FU continu : 2400 mg/m² in IV during 46 hours"
2398196|NCT03584698|Experimental|study group|Misoprostol + Evening primrose oil group
2398197|NCT03584698|Active Comparator|control group|Misoprostol only group
2398198|NCT03584685|Experimental|With Mask|Use of the surgical mask in one routine wound treatment appointment.
2398199|NCT03584685|Active Comparator|Without Mask|Routine wound treatment appointment without nurses wearing the surgical mask.
2398200|NCT03584672||Patients with Multiple Sclerosis|Patients with Multiple Sclerosis (Expanded Disability Status Scale (EDSS) score < 7)
2398201|NCT03584672||Healthy Controls|Healthy people
2398202|NCT03584659|No Intervention|Standard of care|This arm will continue standard procedure regarding side effect registration and handling
2398203|NCT03584659|Experimental|PRO|This arm will be assigned to intervention by weekly electronic reporting of side effects and quality of life. A specifically developed alert-algorithm will in real-time guide both patient and alert clinical staff if symptoms are increasing or quality of life is deteriorating.
2398204|NCT03584646|Experimental|Arm 1 - Control Arm|Usual care, nutrition and exercise counseling at baseline, use of the Nokia GO wearable step tracker device and end-of-study assessment at the end of the 14-week study period. Participants will receive the Nokia GO wearable step tracker to monitor daily step counts, but they will not be provided with personalized walking goals or automated feedback on goal attainment via text message.
2398205|NCT03584646|Experimental|Arm 2 - Intervention arm|Physical activity program supported by financial incentives for meeting walking goals and participating in weekly check-in appointments with study team members via telephone calls. Participants in the intervention arm will also receive twice-daily medication reminders via bidirectional text messages to promote medication adherence. Participants in Arm 2 will also receive personalized nutrition and exercise counseling, daily feedback on step counts via the Nokia GO wearable step tracker and their smartphones, and an end-of-study assessment.
2398206|NCT03584633|Other|Lymphedema|The subjects with lymphedema will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with Indocyanine Green Lymphography.
2398207|NCT03584620|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
2398208|NCT03584620|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
2398209|NCT03584607||Idiopathic Pulmonary Arterial Hypertension patients|Blood sampling Insulin resistance-measurement
2398210|NCT03584607||Healthy controls|Blood sampling Insulin resistance-measurement
2398211|NCT03584594||Presepsin assessment|Residual blood samples after performing all necessary blood examinations and analyses will be used to determine the level of presepsin, as the potential new biomarker of infection.
2398212|NCT03584581|Experimental|Olive polyphenols|
2398213|NCT03584581|Placebo Comparator|Control|
2398214|NCT03584568|Experimental|Perspective Taking Reappraisal|This arm focuses on reappraisals with perspective taking with a limited amount of basic skill building
2398215|NCT03584568|Other|Basic Skill Building|This arm focuses on basic skill building only.
2398216|NCT03584555|Active Comparator|120 μm group|The subjects underwent SMILE using 120 μm cap.
2398217|NCT03584555|Active Comparator|140 μm group|The subjects underwent SMILE using 140 μm cap.
2398221|NCT03584529|Experimental|vitamin D deficiency treatment group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive 1600 IU/day of vitamin D3 oral capsule for two years
2398222|NCT03584529|No Intervention|vitamin D deficiency control group|patients with vitamin D deficiency (12 ng/ml ≤ serum 25-hydroxyvitamin D3 < 20 ng/ml)and uterine fibroids receive regular follow-up.
2398223|NCT03584529|Experimental|vitamin D insufficiency treatment group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml) and uterine fibroids receive 800 IU/d of vitamin D3
2398224|NCT03584529|No Intervention|vitamin D insufficiency control group|patients with vitamin D insufficiency (20 ng/ml ≤ serum 25-hydroxyvitamin D3 < 30 ng/ml)and uterine fibroids receive regular follow-up.
2398225|NCT03584516|Experimental|Part 1 : Dose determination of itacitinib|itacitinib administered in combination with corticosteroids.
2398226|NCT03584516|Experimental|Part 1 : Dose expansion of itacitinib|itacitinib administered in combination with corticosteroids or corticosteroids alone.
2398227|NCT03584516|Placebo Comparator|Part 2 : itacitinib recommended dose from part 1|itacitinib or placebo administered in combination with corticosteroids
2398228|NCT03584503|Active Comparator|Group SA|Group SA intubated with Suction Above Cuff Endotracheal Tube
2398229|NCT03584503|No Intervention|Group C|Group C intubated with classic endotracheal tube
2398230|NCT03584490|Active Comparator|Pen-and-paper format|Based on randomization, participants in this group will receive traditional pen-and-paper questionnaires about health.
2398801|NCT03580499|Experimental|Supportive Care (vitamin B6)|Participants receive vitamin B6 PO daily for 12 weeks.
2398231|NCT03584490|Experimental|Computerized Talking Touchscreen|"This group will receive the Computerized Talking Touchscreen intervention.~Based on randomization, participants in this group will receive a computerized talking touchscreen version of our health questionnaires, which allows the participant to have questions and answer choices read aloud to them by the computer."
2398232|NCT03584477|Active Comparator|Conventional rehabilitation|5 sessions / week of 1 hour of occupational therapy
2398233|NCT03584477|Active Comparator|Robotic rehabilitation with assistance|5 sessions / week of 1 hour of rehabilitation of the upper limb with 30 min of conventional rehabilitation and 30 min of robotic rehabilitation with assistance.
2398234|NCT03584477|Active Comparator|Non-assistance robotic rehabilitation|5 sessions / week of 1 hour of rehabilitation of the upper limb including 30 min of conventional rehabilitation and 30 min of robotic rehabilitation without assistance.
2398235|NCT03584464|Other|Bifurcation Cohort|Subjects receiving stents 2.0 mm - 5.0 mm in diameter will be included in the Bifurcation Cohort.
2398236|NCT03584451|Active Comparator|with rehabilitation sport|rehabilitation sport over 52 weeks after THA, start 6 weeks postoperatively
2398237|NCT03584451|No Intervention|without rehabilitation sport|no further rehabilitation program after THA
2398238|NCT03584438|Experimental|Hanlon Real iTBS Protocol 1|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 3600 pulses are delivered over 19 minutes.
2398239|NCT03584438|Experimental|Hanlon Real iTBS Protocol 2|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. 600 pulses of iTBS over the motor cortex (C3), 1800 pulses are delivered over 9 minutes and 30 seconds.
2398240|NCT03584438|Experimental|Huang Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 190 seconds (a total of 600 TMS pulses).
2398241|NCT03584438|Experimental|Gamboa Real iTBS Protocol|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. (2 sec trains of tbs every 10 sec) was applied over the left motor cortex (C3) for 380 seconds (a total of 1200 TMS pulses).
2398242|NCT03584438|Sham Comparator|Sham iTBS protocol|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left motor cortex. The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin over the left motor cortex (C3) and beneath the coil.
2398243|NCT03584425|Experimental|Healthy Controls|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
2398244|NCT03584425|Experimental|Stroke Participants|Subjects will undergo the following diagnostic tasks and assessments: Rasch Modified Version of the Fugl-Meyer Motor Assessment, Anatomical Image Acquisition, and the Functional MRI Task and Acquisition
2398245|NCT03584412|Experimental|ACT OPEN|Acceptance and Commitment Therapy Online for Painful Peripheral Neuropathy (ACT OPEN).
2398246|NCT03584412|Other|Waiting List Control|Participants in this condition will not receive any change to their usual treatment for a period of 5 months, after which they will be given access to complete the ACT OPEN treatment.
2398247|NCT03584386|Experimental|V-CAMS (aka Jaspr)|"In Phase I (formative), participants are asked to provide feedback on the V-CAMS prototype as it is being refined. Feedback will be gathered via survey measure and interview.~Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm and will be given access to the V-CAMS tools as part of their treatment in the ED. Baseline assessment surveys will be administered in the ED, and three follow up assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants in the Telehealth RCT will be randomly assigned to receive the V-CAMS/Jaspr companion mobile app JAH in addition to their usual outpatient care. Study assessments will be administered remotely at three time points: baseline, 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as completing setup of JAH on their personal mobile phone."
2398248|NCT03584386|No Intervention|Care As Usual|"Phase II (summative): Patient participants enrolled in the ED RCT will be randomly assigned to this arm so there is an even number of participants in the experimental condition and this condition. Those assigned to this condition will be treated as usual in the ED. Same as the experimental condition, those in the Care As Usual condition will be asked to complete baseline assessment surveys while they are waiting in the ED, and then three subsequent assessments after discharge at 7 days, 30 days, and 90 days. Outpatient participants enrolled in the Telehealth RCT will be randomly assigned to CAU in addition to receiving crisis safety planning. Study assessments will be administered remotely at baseline and at 30- and 90-day follow ups.~Intent to treat sample for ED RCT is defined as completing post-treatment baseline assessment; telehealth study intent to treat threshold is defined as setting up the control condition crisis stability plan."
2398249|NCT03584373|Experimental|Non-Opioid Analgesia|"Ketorolac - Oral; 10 mg tablet: 1 tablet every 6 hours, or as needed. (20 tablets prescribed).~Acetaminophen - Oral; patient directed as needed. Not prescribed.~Ketorolac and Acetaminophen administered post surgery to compare pain outcomes to that of Percocet."
2398250|NCT03584373|Active Comparator|Opioid Analgesia|"Percocet - Oral; 5 mg tablet: 1 tablet every 4-6 hours, or as needed. (10 tablets prescribed).~Percocet administered post surgery to compare pain outcomes to that of the non-opioid analgesia."
2398251|NCT03584360|Experimental|betamethasone-calcipotriol versus placebo|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a placebo foam in an other area during 4 weeks.
2398252|NCT03584360|Experimental|betamethasone-calcipotriol versus betamethasone|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a betamethasone pomade in an other area during 4 weeks.
2398253|NCT03584360|Experimental|betamethasone-calcipotriol versus propionate of clobetasol|In this arm we will compared the application association of betamethasone-calcipotriol foam in an area versus a propionate of clobetasol pomade in an other area during 4 weeks.
2398255|NCT03584321||Participants with Coronary Artery Disease|Participants with suspected or confirmed coronary artery disease who underwent coronary angiography during 01 Jan 2013 and 31 Dec 2015 will be observed in the study.
2398256|NCT03584308|Experimental|Viusid® + Glizigen®|The experimental arm will receive nutritional supplements Viusid + Glizigen
2398257|NCT03584308|Placebo Comparator|Placebo|The control group will receive a placebo of both (Viusid and Glizigen).
2398260|NCT03584282|No Intervention|Standard of Care|Participants in this group will receive the standard of care for PrEP follow-up and no additional research interventions.
2398261|NCT03584282|Active Comparator|Text Messaging|Participants in this group will receive the text messaging intervention.
2398262|NCT03584282|Active Comparator|Peer Navigation|Participants in this group will receive the peer navigator intervention.
2398263|NCT03584282|Active Comparator|Text Messaging and Peer Navigation|Participants in this group will receive both the text messaging and peer navigation interventions.
2398264|NCT03584269|Experimental|NIV Device + LTOT|administration of ventilary support, without using an invasive artificial airway
2398265|NCT03584269|Active Comparator|LTOT|standard treatment, without NIV
2398266|NCT03584256||gymnasts|Female gymnasts, older than 13 years, with status of ineternational or national level,
2398267|NCT03584256||swimmers|Female swimmers, older than 12 years, with status of ineternational or national level,
2398268|NCT03584243|Experimental|Patient with progressive keratoconus|"Patient with progressive keratoconus will be included after providing their consent.~The intervention administrated is a cross-linking with oxygen treatment"
2398269|NCT03584230|Experimental|Positive Condition|"Students will be assigned to a group that receives positive nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in the same t-shirt color and negative nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to positive group"
2398270|NCT03584230|Experimental|Negative Condition|"Students will be assigned to a group that receives negative nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs negative nonverbal behaviors to students in the same t-shirt color and positive nonverbal behaviors to students in another t-shirt color.~Intervention: Assigned to negative group"
2398271|NCT03584230|No Intervention|No Cues Condition|Students will be assigned to a group that receives no nonverbal teacher behaviors. At the beginning of the session participants will learn that there are three groups of students at a school, and the groups are identifiable by t-shirt color. They will be joining one of the groups and will be given a t-shirt to wear. They then view a series of interactions where a teacher directs positive nonverbal behaviors to students in a different t-shirt color and negative nonverbal behaviors to students in a different t-shirt color. Students wearing the same t-shirt color as the participant never interact with the teacher.
2398272|NCT03584217|Other|Clinical Investigation|All participants will undergo GFR (Iohexol Inj 300 MG/ML), ERPF (Aminohippurate Sodium Inj 20%) in addition to renal BOLD and ASL MRI.
2398273|NCT03584191||People with Obesity|General population - potential participants will be recruited using various and numerous general population as appropriate in each country.
2398274|NCT03584191||Health Care Professionals|Health Care Professionals include primary care physicians and specialists who treat patients with obesity.
2398275|NCT03584178|Experimental|Mucosal Atomization Device|Budesonide via MAD Device
2398276|NCT03584178|Experimental|Intranasals Saline Irrigation|Budesonide via Intranasals Saline Irrigation
3184444|NCT00724672||ETA|RA patients who were scheduled to receive etanercept 50 mg subcutaneously once weekly
3184445|NCT00724672||IFX|RA patients who were scheduled to receive infliximab 3 mg/kg IV at Weeks 0, 2, and 6
3184446|NCT00724672||ADA|RA patients who were scheduled to receive adalimumab 40 mg subcutaneously biweekly
2398280|NCT03584152|Active Comparator|DRUG ARM A|Norco 5Mg-325Mg Tablet, administered orally every 4 hours for 5 days total
2398281|NCT03584152|Active Comparator|DRUG ARM B|Tylenol 325Mg Caplet, administered orally every 4 hours for 5 days total. Ibuprofen 200 mg administered orally every 4 hours for 5 days total.
2398282|NCT03584139|Experimental|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
2398283|NCT03584139|Active Comparator|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
2398284|NCT03584126||Patients with AF|Patients with atrial fibrillation visiting the outpatient clinic; examined by general examination, electrocardiography, ecocardiography and MRI.
2398285|NCT03584126||Control|Healthy adult volunteers; examined by the study physicians by general examination, electrocardiography, ecocardiography and MRI.
2398286|NCT03584113|Active Comparator|IR guided chest tube insertion with fibrinolytics|Image guided chest tube insertion by interventional radiology along with MIST 2 trial fibrinolysis which includes intrapleural dornase (5mg) and Alteplase (10mg) every twelve hours for a total of six doses as primary intervention for empyema.
2398287|NCT03584113|Active Comparator|VATS Decortication|Video assisted thorascopic surgery decortication (VATS) as primary intervention for empyema.
3184447|NCT00724672||non-diseased controls|Healthy individuals who contributed their RNA/cDNA samples prior to the study and for whom ethical approval has already been obtained.
3184448|NCT00724685|Placebo Comparator|Placebo|
3184449|NCT00724685|Experimental|Active|
2398290|NCT03584087|Placebo Comparator|TG 0 (0Hr)|TG0 will receive 10 ml of 0.9% normal saline (NS) IV bolus q 4 hourly in place of Terlipressin therapy after EVL.
2398291|NCT03584087|Active Comparator|TG 2 (48Hr)|TG2 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 48 hours after EVL .
2398292|NCT03584087|Active Comparator|TG 5 (120Hr)|TG5 will receive Terlipressin (1mg, i.v. Bolus q 4 hourly) therapy for 120 hours after EVL .
2398293|NCT03584074|Experimental|Pregabalin and COX-2 inhibitor|Pregabalin 75mg BID + Celecoxib 200mg qd
2398294|NCT03584074|Active Comparator|COX-2 inhibitor|Celecoxib 200mg qd
2398295|NCT03584061|Experimental|Fat grafting/fat transplant.|Each patient receives fat grafting to the site of dermal pain. Fat is to be harvested for either the abdomen or the thigh.
3184450|NCT00724724|Experimental|1|Butylphthalide Soft Capsules + Aspirin
2398297|NCT03584035|Experimental|Sensory motor integration group|Sensory-motor integration exercises with 3 progressive steps, 30 minutes per sessions, 3 sessions per week for 6 weeks.
2398298|NCT03584035|Active Comparator|Conventional group|Conventional exercises include simple passive and active exercises and lower extremities strengthening exercises for balance and ambulation. The exercise session will last 30 minutes for 3 sessions per week. The total intervention period is 6 weeks.
3184451|NCT00724724|Active Comparator|2|Aspirin
3184452|NCT00724737|Active Comparator|fMRI of the brain, no surgery|Healthy volunteers will undergo an fMRI (functional MRI of the brain).
2398303|NCT03583996|Experimental|Open Label|All subjects receive HepQuant SHUNT Liver Diagnostic Test within 42 days of the scheduled EGD. Test includes 20mg of 13C Cholate mixed with Albumin via IV push, and 40mg of d4 Cholate mixed with juice orally, both doses given simultaneously one time.
2398304|NCT03583983|Other|Personalized Health Recommendations|
2398305|NCT03583983|Other|No Health Recommendations|
2398306|NCT03583957|Experimental|Entire Study|Each patient is eligible for all interventions in the study.
2398307|NCT03583944|Experimental|Eribulin Mesylate 1.23 mg|Participants will receive eribulin mesylate 1.23 mg intravenous (IV) infusion, given over 2 - 5 minutes on Days 1 and 8 of 21 days cycle for a total of 6 cycles.
2398308|NCT03583931|Active Comparator|Operative VATS decortication|Operative group that will undergo early VATS decortication of complicated parapneumonic effusion/empyema
2398309|NCT03583931|Active Comparator|Non-operative Fibrinolytic Therapy|Non-operative group that will undergo instillation of the drugs DNAse and tPA (tissue plasminogen activator) together i.e. 5mg DNAse and 10mg tPA twice a day for up to six doses, through chest tube as treatment of the patient's complicated parapneumonic effusion/empyema. Fibrinolytic therapy = DNAse + tPA; these medications are not mutually exclusive.
2398310|NCT03583918|Experimental|Highthroughput Micro Coring Device|Skin excision and removal with with Highthroughput Micro Coring device
2398311|NCT03583905|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-330, D086
2398312|NCT03583905|Placebo Comparator|Placebo Group 1|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the D086)
2398313|NCT03583905|Placebo Comparator|Placebo Group 2|Patients assigned to this group are treated with 1 Placebo Tab.(Placebo of the CKD-330)
2398314|NCT03583892||Group A|In the Group A, a single-dose of 600mg gabapentin was used as part of a multimodal analgesic technique.
2398315|NCT03583892||Group B|In the group B gabapentin was not administered.
2398316|NCT03583879|Experimental|Exoskeleton exercise|8-week exercise program using the exoskeleton
2398317|NCT03583879|Active Comparator|Standard exercise|8-week exercise program not using the exoskeleton
2398318|NCT03583879|Placebo Comparator|No exercise|8-weeks of no treatment (wait-list control)
2398319|NCT03583866|Experimental|Candesartan|Sub chronic (7 days) Candesartan (16 mg/day)
2398320|NCT03583866|Placebo Comparator|Placebo|Endothelial function will be determined following a seven day treatment of placebo
2398321|NCT03583853||patients|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of Ribonucleic acid (RNA) to determine the expression of autophagy genes by real time polymerase chain reaction (real time PCR)
2398322|NCT03583853||control|take 5 ml blood for isolation of peripheral blood mono-nuclear cells then extraction of RNA to determine the expression of autophagy genes real time polymerase chain reaction
2398323|NCT03583840|No Intervention|Control group|Participants who will not be directed to the ScreenMen website
2398324|NCT03583840|Experimental|Intervention group|Participants who will be directed to the ScreenMen website
2398325|NCT03583827|Experimental|Experimental Group|Experimental group patients will be submitted to conventional therapy for 30 minutes and training of the affected upper limb using virtual reality, which will last 20 minutes over twelve sessions (4 weeks).
2398326|NCT03583827|Active Comparator|Control Group|The control group will undergo 30 minutes of Conventional physical therapy in twelve sessions (4 weeks).
2398481|NCT03582761|Experimental|320U /0.5ml in children|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
3184453|NCT00724737|Experimental|fMRI of the brain, presurgical|Patients scheduled to have brain surgery will undergo an fMRI (functional MRI of the brain).
3184454|NCT00724763|Experimental|1|Treatment group.
3184455|NCT00724763|Sham Comparator|2|control group
3184456|NCT00724776|Experimental|1|Open-label treatment with albinterferon alfa 2b escalating single dose
3184457|NCT00724789||Observational Cohort|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone/ganirelix followed by in vitro fertilization or intra cytoplasmatic sperm injection.
3184458|NCT00724789||Historical Controls|Subjects with an ongoing pregnancy after controlled ovarian stimulations with recombinant follicle stimulating hormone in a long protocol with a gonadotropin releasing hormone agonist followed by IVF or ICSI
3184459|NCT00724828||1|
3184460|NCT00724841|Experimental|1|40 mg/m2 GMX1777 with Temozolomide
2398327|NCT03583814|Active Comparator|CASE Program only|"During the Active Trial Phase, families of children with asthma status defined as not well controlled will complete the CASE program. Outcomes for participants assigned to the CASE program will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
2398328|NCT03583814|Active Comparator|CASE and HARP Programs|"During the Active Trial Phase, families of children with asthma status that is defined as poorly controlled will complete the CASE and HARP programs. Outcomes for participants assigned to this arm (CASE and HARP) will be compared in a pre-post within subject comparison. Regardless of intervention arm assignment, children are expected show improvement in asthma outcomes. The stepped wedge trial design of the overall study allows for comparison of outcomes of communities in the pre-active trial baseline control period, active trial phase, and post-active trial phase follow-up period."
2398329|NCT03583814|No Intervention|Standard Care|Cluster-based randomization in the Stepped Wedge Trial allows for comparison of Community Based Outcomes for clusters (communities defined by school catchment areas) who are not yet in the active trial phase and are receiving Standard of Care at that time.
2398330|NCT03583801|Experimental|aromatherapy group|"The patient has to choose an essential oil among the 3 proposed :~sweet orange (Citrus sinensis L. Persoon)~fine lavender (Lavandula angustifolia P. Miller)~little seed from the mandarin tree (Citrus reticulata blanco)"
2398331|NCT03583801|Placebo Comparator|without aromatherapy|
2398332|NCT03583788|Experimental|Hypnotherapy group|The intervention consisted of individual hypnotherapy of 5 hourly sessions (60 minutes) over 5 weeks, a total of five hours. The hypnotherapy treatment method was Erickson's (permissive) hypnosis (17). It began with a conversation about patient's past life events, present situation, alcohol problem and his or her thoughts about it. The hypnotherapy Group did not receive any treatment of motivational interviewing.
2398333|NCT03583788|Active Comparator|Motivational interviewing group|The comparator patient group received individual therapy as motivational interviewing (MI) for 5 hourly sessions over 5 weeks, a total of five hours. The patients in the experimental group did not receive this.
2398334|NCT03583775||Patients with congenital heart disease|Patients with congenital heart disease who are greater than 40 kg and are referred for a clinically indicated 2D CMR exam with a gadolinium-based contrast agent.
2398335|NCT03583762|Experimental|Pre-intervention group|100 participants received empiric antibiotic by ID physician, bacterial identification by Mass spectrometry technique
2398336|NCT03583762|Experimental|Post-intervention group|100 participants received empiric antibiotic therapy by ID physician, bacterial identification by Microarray assay from blood culture and confirm with Mass spectrometry technique
2398337|NCT03583749||amoxicillin-clavulanate|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2398338|NCT03583749||ceftriaxone|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2398339|NCT03583749||piperacillin-tazobactam|followed of SC and IV cohort without any randomization because the route will be chosen before inclusion by the physician in charge.
2398340|NCT03583736|Active Comparator|Rapid first contact virtual visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
2398341|NCT03583736|Placebo Comparator|First contact in person office visit|Subjects will accept the offer of a virtual visit after being contacted by the nurse to offer a virtual visit with the oncologist prior to the in person office visit once a diagnosis has been confirmed. Subjects will be randomized after accepting offer of a virtual visit.
2398342|NCT03583723|Experimental|Radiotherapy Group|Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.
2398343|NCT03583710|Experimental|Arm A (mitotane)|Patients receive mitotane PO daily on days 1-21. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
2398344|NCT03583710|Experimental|Arm B (mitotane, etoposide, cisplatin)|Patients receive mitotane as in Arm A. Patients also receive cisplatin IV over 2 hours on day 1 and etoposide IV over 2 hours on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2398345|NCT03583697|Experimental|Active BMN111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111 daily
2398346|NCT03583697|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
2398347|NCT03583684|Experimental|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
2398348|NCT03583684|No Intervention|Delayed Treatment Group (DTG)|Child continues stable treatments as usual in the community.
2398349|NCT03583658|Active Comparator|Ambroxol hydrochloride (BIH1526)|One lozenge 20 mg on as-needed basis, up to 6 times per day
2398350|NCT03583658|Placebo Comparator|Placebo|One lozenge on as-needed basis, up to 6 times per day
2398351|NCT03583645|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
2398352|NCT03583645|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
2398353|NCT03583619|Experimental|APBI|Patients receive accelerated partial breast irradiation to tumour bed to a total dose of 40Gy, 4.0Gy per fraction, 5 fractions a week, within 2 weeks.
2398354|NCT03583619|Active Comparator|WBI|Patients receive whole breast irradiation to a total dose of 43.5Gy, at 2.9Gy per fraction, 5 fractions a week, within 3 weeks.
3184461|NCT00724841|Experimental|2|50 mg/m2 GMX1777 with Temozolomide
3184462|NCT00724841|Experimental|3|62 mg/m2 GMX1777 with Temozolomide
3184463|NCT00724841|Experimental|4|80 mg/m2 GMX1777 with Temozolomide
2398358|NCT03583593|Experimental|DIAMEL|Study group that receives the active product.
2398359|NCT03583593|Placebo Comparator|Placebo|Control group receiving double-blind placebo.
2398360|NCT03583580|Experimental|Accelerated Partial Breast Irradiation|Accelerated partial breast irradiation (APBI) to the region of tumour bed
2398361|NCT03583567|Placebo Comparator|0.9% Normal Saline|Syringe No 1 contain normal saline 1 mL Syringe No 2 contain normal saline 2 mL
2398362|NCT03583567|Experimental|Chlorpheniramine and ranitidine|Syringe No 1 contain chlorpheniramine 10 mg (1 mL) Syringe No 2 contain ranitidine 50 mg (2 mL)
2398363|NCT03583554|Placebo Comparator|Placebo|Placebo
2398364|NCT03583554|Active Comparator|AV-101 720 mg|One time 720 mg L-4-Chlorokynurenine
2398365|NCT03583554|Active Comparator|AV-101 1440 mg|One time 1440 mg L-4-Chlorokynurenine
2398366|NCT03583541|Experimental|Control arm: Bolstered treatment|Women in the control condition (and in the treatment arms) will receive treatment as usual (TAU) for FSW in the study area. Provided by RHSP, TAU includes: health education, HIV testing services, STI screening and treatment in a session that lasts about 2 hours, provided on a quarterly basis. This will be bolstered with 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention
2398367|NCT03583541|Experimental|Treatment arm: HIVRR+S+FL|Women in this arm will receive TAU for FSW and the 4 HIVRR sessions (described above) and a single session following HIVRR specifically describing bank account opening, the matching process, and how to interact with banks. In this session our partnering banks will open up matched savings accounts for women in the two treatment arms. Women in both arms will save money in their matched savings accounts over a 10-month period post HIVRR. The study team will monitor the accounts using the statements received directly from the banks holding the accounts. Participants will receive monthly bank statements indicating their own savings and the associated match (1:1 match rate). They will also receive 6 financial literacy (FL) sessions provided twice a week for 3 weeks
2398368|NCT03583541|Experimental|Treatment arm: HIVRR+S+FLM|"Women in this arm will receive TAU and the 4 HIVRR sessions (as above). Next, they will receive the savings session (described above) and 6 financial literacy (FL) sessions provided twice a week for 3 weeks, followed by 8 mentorship (M) sessions supporting transition to vocational, educational training, employment or business development, and receipt of a matched savings account to be used on short-term and/or long term consumption and skills development per participants own discretion/choice.~*Revision note: Following COVID-19, with approval from NIMH (on record if requested), the HIVRR+S+FLM treatment of the study has been combined with the HIVRR+S+FL treatment arm. The total sample size has been revised to 532 participants, with approval from NIMH."
2398369|NCT03583528||PET/CT Diagnostic Imaging|Each subject will have two PET/CT scans, one using 68Ga-DOTATOC and the other using 18F-FDG. The 68Ga-DOTATOC radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 18F-FDG is considered standard care and has been approved by Health Canada.
2398370|NCT03583515|Experimental|Alcohol-Specific Personalized Normative Feedback|Participants will receive feedback about their average number of days on which alcohol was consumed, average drinks per occasion, and average number of drinks per week. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others drank), and actual others' drinking. Feedback will be about other students at their university of the same sex.
2398371|NCT03583515|Placebo Comparator|Social Media Personalized Normative Feedback|Participants will receive feedback about their number of hours texting, on social media websites, and playing video games. This feedback will include the participant's averages reported at baseline, the participant's descriptive norm of others' averages (what they think others did), and actual others' behavior. Feedback will be about other students at their university of the same sex.
2398372|NCT03583502|Experimental|Supplemented|krill oil and fish oil supplement
2398373|NCT03583502|No Intervention|Controls|The control group did not receive any supplementation.
2398374|NCT03583489|Placebo Comparator|Placebo|
2398375|NCT03583489|Experimental|APD421|
2398376|NCT03583489|Experimental|APD421 + ondansetron|
2398377|NCT03583476||CLA triple therapy|Patients with clarithromycin-containing triple therapy
2398378|NCT03583476||MET triple therapy|Patients with metronidazole-containing triple therapy
2398379|NCT03583476||Concomitant therapy|Patients with concomitant therapy
2398380|NCT03583476||Sequential therapy|Patients with sequential therapy
3184464|NCT00724841|Experimental|5|100 mg/m2 GMX1777 with Temozolomide
3184465|NCT00724841|Experimental|6|125 mg/m2 GMX1777 with Temozolomide
2398383|NCT03583437|Experimental|Healthy male volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
2398384|NCT03583437|Experimental|Healthy female volunteers|Behavioral: Exercise Moderate Intensity Exercise (50 % af VO2max) for 90 minutes before and after PET scanning.
2398385|NCT03583424|Experimental|Treatment (venetoclax, BEAM)|Participants receive venetoclax PO QD on days -10 to -1, carmustine IV on day -6, etoposide IV BID on days -5 to -2, cytarabine IV BID on days -5 to -2, and melphalan IV on day -1. Participants then undergo hematopoietic cell transplantation on day 0.
2398386|NCT03583411||acute coronary syndrome (ACS) patients|ACS subjects hospitalized in the Cardiology 1 - UTIC department of ASST Grande Ospedale Metropolitano Niguarda between 2014 and 2017
2398387|NCT03583398||TAVI TAo|
2398388|NCT03583398||TAVI TF|
2398389|NCT03583398||AVR|
2398802|NCT03580486||Patients with Parkinson's Disease|Parkinson's Disease (Hoehn and Yahr stage 1-4)
3184466|NCT00724880|Experimental|1|Clopidogrel is stopped 5 days prior to surgery
3184467|NCT00724880|Experimental|2|Clopidogrel is stopped 3 days prior to surgery
3184468|NCT00724880|Experimental|3|Clopidogrel is stopped 0 days prior to surgery
3184469|NCT00724906|Experimental|Parkinsonian Syndromes|Subjects with Parkinsonian Syndromes
2398394|NCT03583359|Experimental|Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
2398395|NCT03583359|Other|Delayed Treatment with Radiesse (+)|Enrolled subjects will be randomized (2:1 allocation ratio) to either receive treatment with Radiesse (+) or delayed treatment with Radiesse (+).
2398396|NCT03583346|Experimental|M6495|
2398397|NCT03583346|Placebo Comparator|Placebo|
3143556|NCT00006760|Experimental|Treatment (ifosfamide, vinorelbine, filgrastim)|Patients receive ifosfamide IV over 24 hours on days 1-4 and vinorelbine tartrate IV over 6-10 minutes on days 1 and 5. Patients also receive filgrastim (G-CSF) subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover. Treatment repeats at least every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients may receive a third course of therapy at the discretion of the investigator. Heavily pretreated, high-risk patients who achieve a complete response are eligible for stem cell transplantation. Patients undergo peripheral blood stem cell (PBSC) collection during hematopoietic recovery after the second course of chemotherapy. Patients with sufficient PBSCs collected may undergo PBSC transplantation on protocol COG-AHOD0121.
3143557|NCT00006773|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds twice weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2398400|NCT03583320|Experimental|Arm A (Cardiac CT)|Patients randomised to Arm A i.e. the intervention arm will under go standard of care patient hospital management but will also have cardiac CT angiogram (CTCA) carried out. Their subsequent clinical management will be left to clinician discretion in light of the additional CTCA results.
2398401|NCT03583320|No Intervention|Arm B (Standard of care arm)|"Patients randomised to Arm B will receive usual standard of care management guided by serial troponin blood tests. These patients will also under go cardiac CT angiogram (CTCA) but these scans will not be used for the patients' in-hospital care.~Furthermore, unlike Arm A, CTCA interpretation followed by reporting will not take place in the acute hospital setting and therefore will be carried out within the following three weeks. Should the CTCA be found to have significant high risk CAD e.g. >50% stenosis in the left main (LM) coronary artery, and/or >50% stenosis in the proximal left anterior descending (LAD) coronary artery, they will be un-blinded and kept in a separate registry. Their results will be discussed with the hospital care team and if they have not had any invasive coronary imaging during the preceding hospital admission, an urgent cardiology out-patient referral will be made to enable further clinical management."
2398403|NCT03583294|Experimental|irradiation regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
2398404|NCT03583294|Experimental|busulfan regimen before 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
2398405|NCT03583294|Experimental|irradiation regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed
2398406|NCT03583294|Experimental|busulfan regimen after 9|Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed
2398407|NCT03583281|Active Comparator|Flax oil|Participants will consume capsules containing flax oil (4 grams alpha-linolenic acid [ALA] per day) for 4 weeks
2398408|NCT03583281|Active Comparator|Fish oil|Participants will consume capsules containing DHA-enriched fish oil (4 grams DHA per day + 0.8 grams EPA per day) for 4 weeks
2398409|NCT03583268|Active Comparator|Moderate Intensity Exercise Alone|45 minutes of moderate intensity exercise at 45-55% of maximum aerobic capacity (active participants) or heart rate reserve (sedentary participants) used as a control condition. Participants will consume a glucerna bar at 10pm following this session.
2398410|NCT03583268|Experimental|70% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 70% heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
2398411|NCT03583268|Experimental|80% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 80% of heart rate reserve every 4 minutes. Note: this session is not included for the active participants. Participants will consume a glucerna bar at 10pm following this session.
2398412|NCT03583268|Experimental|90% Session|45 minutes of moderate intensity exercise interspersed with one minute bouts at 90% of maximum aerobic capacity (active participants every two minutes) or heart rate reserve (sedentary participants every 4 minutes). Participants will consume a glucerna bar at 10pm following this session.
2398413|NCT03583255|Experimental|Arm I (dexamethasone, exercise)|Participants receive dexamethasone PO BID for 7 days. Participants also complete resistance training and moderate intensity walking at home for minimum 5 days per week over 4 weeks.
2398414|NCT03583255|Active Comparator|Arm II (placebo, exercise)|Participants receive placebo PO BID for 7 days. Participants also complete resistance training and moderate intensity walking as in Arm I.
2398803|NCT03580486||Healthy controls|Healthy people
3143558|NCT00006890|Experimental|Prednisone plus Thalidomide|After Autologous Stem Cell Infusion
3143559|NCT00006929|Experimental|Treatment (suramin, paclitaxel, carboplatin)|Patients receive suramin IV over 30 minutes on days 1 and 2. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3143560|NCT00006942|Experimental|Treatment (bryostatin 1, cisplatin)|Patients receive bryostatin 1 IV continuously over 72 hours immediately followed by cisplatin IV over 1 hour. Treatment continues every 3 weeks for a minimum of 2 courses in the absence of disease progression.
3143561|NCT00006994|Active Comparator|L-glutamine in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
3143562|NCT00006994|Placebo Comparator|Placebo in suspension + radiation|20 cc three times daily for 60 days plus radiation therapy.
3143563|NCT00007007|Experimental|Whole brain radiation therapy + neurocognitive assessments|Whole brain radiation therapy (WBRT) with neurocognitive assessments done pre and post WBRT.
2398415|NCT03583242||DME treat with antiangiogenic|"3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.~1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process."
2398416|NCT03583229|Other|Aspirin - single arm|1 tablet of Aspirin 75 mg administered x 1 daily for 7 days.
2398417|NCT03583229|Experimental|Extracorporeal photopheresis|All patients with HLA antibodies receive 4 ECP-treatments in 2 months.
2398418|NCT03583229|No Intervention|Control group|The control group does not receive ECP-treatments, but blood samples are drawn at the same intervals as treatment group and CAG+OCT are also performed at baseline and 12 months follow up as the treatment group.
2398419|NCT03583216||Diabetic pregnancy|Pregnant patients with a diagnosis of Type I, Type II or gestational diabetes will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
2398420|NCT03583216||Non-diabetic pregnancy|Healthy non-diabetic pregnant patients will be included in this arm. Blood will be drawn from each patient when they are hospitalized and before they deliver either vaginally or by cesarean section. Blood will be drawn into two citrate tubes, each will contain 4 ml blood.
2398421|NCT03583203|Experimental|Experimental Group|This group will include personalized information about lung damage. After evaluating their COPD, the patients will be informed about its existence it so and staging. Depending on the damage found, the generation of motivation will focus on the different prevention methods. Likewise, after the motivation level is set, the patients will be offered the option of treatment and regular follow-up. The intervention will be strengthened by motivational messages, half of which are linked to the possibilities of preventing respiratory damage, sent to the patient's mobile phone via SMS during the 3 months after the face-to-face intervention. Patients without mobile phones will receive a call on their phone to convey the same messages.
2398422|NCT03583203|No Intervention|Control Group|The control intervention lasts 30 minutes and will be structured around the 5 A's technique (Ask, Advice, Assess, Assist and Arrange).
2398423|NCT03583190|Experimental|Cervical-cranial dry needling|Patients randomized to this arm will receive cervical-cranial dry needling, thoracic manipulation, and exercise.
2398424|NCT03583190|Active Comparator|Orthopedic Manual Therapy|Patients randomized to this arm will receive orthopedic manual therapy to cervical spine, thoracic manipulation, and exercise.
2398425|NCT03583177||healthy volunteers|
2398426|NCT03583177||cancer patients|
2398427|NCT03583177||undergoing chronic hemodialysis patients|
2398428|NCT03583164|Experimental|F901318|open-label single-arm of F901318 as treatment of invasive fungal infections due to Lomentospora prolificans, Scedosporium spp., Aspergillus spp., and other resistant fungi which are susceptible to F901318 in patients with limited treatment options.
2398429|NCT03583151|Active Comparator|Steroid injection|1 mL Solu-medrol mixed with 0.5mL marcaine and 0.5 mL of lidocaine
2398430|NCT03583151|Experimental|Amniotic fluid injection|1 mL amniotic fluid mixed with 0.5mL marcaine and 0.5 mL of lidocaine
2398431|NCT03583138||Buprenorphine|Participants are eligible for the study if they are 18 years of age or older, HIV+, meet DSM-IV criteria for opioid dependence, have health insurance accepted at Lab Corp, are able to read and understand English, and live in Washington, DC and plan to remain in DC. The intervention is to provide buprenorphine for 12 months for those who are interested in receiving it.
2398432|NCT03583138||No buprenorphine|No buprenorphine
2398433|NCT03583125|Experimental|EOC 317|"Dose-escalation: 20 subjects will be given EOC 317 PO in increasing doses from 5 mg up to 60 mg or higher doses. One dose on Day 1, paused for 2 days, and then daily from Day 4 to Day 24.~Dose-expansion: 120 subjects will be given EOC 317 PO QD from Day 1 to Day 21."
2398434|NCT03583112|Active Comparator|Dapoxetine|In this group, patients received one dapoxetine hydrochloride tablet before MRI scan.
2398435|NCT03583112|Placebo Comparator|Placebo|In this group, patients received placebo tablet before MRI scan.
2398436|NCT03583099|Experimental|CAPTURE + COPD Education|Practice clinicians will receive basic COPD education, and patient-level CAPTURE information with CAPTURE interpretation education. As the second aim address the optimal format for delivering practice CAPTURE education this will be incorporated at the sites randomized to this arm.
2398437|NCT03583099|Active Comparator|COPD Education|Practice clinicians will receive basic COPD education only.
2398438|NCT03583086|Experimental|Treatment (vorolanib, nivolumab)|Participants receive vorolanib PO QD on days 1-56 and nivolumab IV over 30 minutes every two weeks (i.e. on Days 1, 15, 29, and 43 of each 56-day cycle) for the first two treatment cycles. After which, the treatment schedule can change to every four weeks (i.e., on Days 1 and 29 of each 56-day cycle) if the patient is not exhibiting disease progression.
2398439|NCT03583073|Active Comparator|Standard Care/Baseline Control|Standard care is the typical process of referral to mental health services for Juvenile Justice (JJ) youth who screen positive for mental heath concerns at intake. For this study, baseline control participants will be referred to the Coordinated Specialty Care (CSC) clinic due to their endorsement of psychosis-spectrum symptoms.
2398440|NCT03583073|Experimental|Enhanced Referral/Linkage to Care|"The experimental condition will include a psychoeducational and motivational enhancement protocol completed at the JJS intake appointment, paired with a warm hand-off referral to the CSC for evaluation and initiation of mental health services."
2398441|NCT03583060|Experimental|MABT|Receive 8 weekly sessions of Mindful Awareness in Body-oriented Therapy (MABT).
2398442|NCT03583060|No Intervention|Control|
2398443|NCT03583021|Experimental|sugammadex group|Sugammadex group receives the intravenous sugammadex of 3 mg/kg.
2398444|NCT03583021|Placebo Comparator|neostigmine group|Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
3143564|NCT00007150|Other|1/HH patients|HH patients
3143565|NCT00007267|Experimental|1|Participants will receive individual cognitive behavioral therapy
2398445|NCT03583008|Experimental|Anticoagulation (AC) Intervention|Providers in this arm will receive supportive tools including Anticoagulation (AC) Intervention--Prescribing Practices and Anticoagulation (AC) Intervention--Academic Detailing to help them assess their Anticoagulant (AC) prescribing practices and will also meet with the study investigators for academic detailing.
2398446|NCT03583008|No Intervention|Control|Providers in this arm will not receive any intervention.
2398447|NCT03582995|Active Comparator|Flap Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a flap technique
2398448|NCT03582995|Experimental|Tunnel Surgery for root coverage with Alloderm and xenograft|Root coverage surgery using a tunnel technique
2398449|NCT03582982|Experimental|Eccentric overload exercise|
2398450|NCT03582969|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
2398451|NCT03582969|Placebo Comparator|Placebo|Placebo capsules
2398452|NCT03582956|Other|Adolescent Overweight|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D that will receive a euglycemic hyperinsulinemic clamp with tracer enhancement.
2398453|NCT03582956|Other|Adolescent Typical|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement.
2398454|NCT03582956|Other|Young Adult|The study aims to enroll 36 adolescents with T1D and overweight/obesity, 36 lean adolescents with T1D, and 36 young adults with T1D a euglycemic hyperinsulinemic clamp with tracer enhancement
3184470|NCT00724906|Experimental|Non-Parkinsonian Syndromes|Subjects with Non-Parkinsonian Syndromes
3184471|NCT00724919||1|
2398457|NCT03582917|Experimental|Alphacalscidol|0,5mg tablet by mouth, one each day for one year
2398458|NCT03582917|No Intervention|No treatment|
2398459|NCT03582904|Experimental|Real tDCS|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over < 30 minutes.
2398460|NCT03582904|Sham Comparator|Control|Anodal transcranial direct current stimulation (tDCS) targeting the primary motor cortex delivered via saline-soaked sponge electrodes (anode, 8 cm^2; cathode 38.4 cm^2) at an intensity of 1.5 milliamperes over 2 minutes.
2398461|NCT03582891|Other|Parkinson's Disease STN Target|Parkinson's disease patients implanted in STN
2398462|NCT03582891|Other|Parkinson's disease patients GP Target|Parkinson's disease patients implanted in Globus Pallidus
2398463|NCT03582891|Other|Dystonia patients|Isolated dystonia patients
2398464|NCT03582878|Active Comparator|mycophenolate mofetil|mycophenolate mofetil dosing 1g before transplantation and 1g bid afterwards
2398465|NCT03582878|Experimental|Sirolimus|Sirolimus oral product Dosing 5mg orally 2-6h before transplantation Target trough levels between 5-10ng/ml
2398466|NCT03582865||responding|patients who received Tamoxifen 20 mg daily for at least 3 years with good response (no relapse) to tamoxifen. Both genotyping assessment and TDM of tamoxifen and its metabolites will be performed and correlated with the records. Follow up for these patients for further assessment of tamoxifen effectiveness will be carried out for 1- 2 years.
2398467|NCT03582865||relapse|patients who received Tamoxifen 20 mg daily for at least 3 years who were good responder to the drug but then the response has been diminished (relapse) and they have been shifted to another therapy. They will be exposed to genotyping study of CYP 2D6 to recognize the phenotyping style of that patient that may explain diminishing of response to tamoxifen therapy.
2398468|NCT03582865||tamoxifen resistant|patients who received Tamoxifen 20 mg daily for not more than 1 year with poor response to tamoxifen (early relapse) and clinically will be shifted to use another medication as they were diagnosed as tamoxifen resistant. Like the second group, they will be exposed to genotyping study of CYP2D6 with the same concept.
2398469|NCT03582852|Active Comparator|promontory|Laparoscopic sacrocolpopexy, which consist in fixing a mesh between vaginal anterior wall
2398470|NCT03582852|Active Comparator|laparoscopic lateral suspension|The procedure consists in spreading out bilaterally, a subperitoneal T-shaped mesh in the anterior abdominal wall
2398471|NCT03582839|Experimental|PROTECT+|The PROTECT+ intervention group is a self-selected sample, which receives the PROTECT+ group therapy (4 modules in 4 subsequent weeks à 100 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
3184472|NCT00724997|Other|cohort I|dose level I: 6.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3184473|NCT00724997|Other|cohort II|dose level II: 6.7 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3184474|NCT00724997|Other|cohort III|dose level III: 7.0 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3184475|NCT00724997|Other|cohort IV|dose level IV: 7.4 log10 TCID50/volunteer, 8 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
2398476|NCT03582800|Experimental|Treated|M0-M6: run-in phase (control) M6-M12: STS treatment phase
3184476|NCT00724997|Other|cohort V|dose level V: 7.7 log10 TCID50/volunteer, 16 volunteers randomized at a ratio of 6:2 for GHB01L1 or placebo
3184477|NCT00725023|Experimental|1|Treatment: TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
3184478|NCT00725023|Other|2|Treatment: Dummy TDP© Lamp used Duration of each treatment 30min Course of treatment 3 times a week for 3-4 weeks
3184479|NCT00725062|Experimental|Patients Receiving CD4+/CD25+ cells|CD4+/CD25+ cells given intravenously over 15-60 minutes on Day -2 (prior to peripheral blood progenitor cell transplant)
3184480|NCT00725088|Experimental|1|exercise training group
3184481|NCT00725088|No Intervention|2|control group
3184482|NCT00725114|Active Comparator|Tetrodotoxin|
3184483|NCT00725114|Placebo Comparator|Sugar injection|
3184486|NCT00725140||Single|
3184487|NCT00725166||Young|Young men 19-25 years old
3184488|NCT00725166||Old|old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
3184489|NCT00725179||1|Patients receiving oral NAC treatment
2398482|NCT03582748||New surgical subjects|This group will be consist of 150 consecutively consented subjects who are scheduled to have sleeve gastrectomy at the Hartford Hospital Surgical Weight Loss Center.
2398483|NCT03582748||Carry over surgical subjects|This group will include 45 subjects who participated in the pilot study and who will be contacted and consented into the present study.
2398484|NCT03582748||Non-surgical subjects|This group will include 15 non-surgical patients who will be group-matched to Group A on pertinent characteristics. These patients will be non-surgical in that they will have been evaluated for bariatric surgery by the SWLC but deemed ineligible for any of a number of reasons.
2398485|NCT03582735|Experimental|Nerve gliding exercise|Three series of 15 daily repetition of the rehabilitation exercise targetting nerve excursion
2398486|NCT03582735|No Intervention|Control|No intervention according to current practice.
2398487|NCT03582722|Experimental|Weight loss aid|One-month supply of orlistat capsules (60mg) to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
2398488|NCT03582722|Placebo Comparator|Placebo|One-month supply of placebo capsules to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
2398489|NCT03582696|Other|No Arms|Participants are not assigned to randomized study arms or groups.
2398490|NCT03582683|Experimental|CPSMP Intervention|Participants randomly assigned to this arm will, following a baseline assessment, immediately begin attending a 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
2398491|NCT03582683|Active Comparator|Wait-list Control Group|Participants assigned to this arm will wait six months after a baseline assessment and then attend the 6-week Chronic Pain Self-Management Program (CPSMP) workshop.
2398492|NCT03582670|Experimental|Strategy Training Intervention|Study participants receive specific memory strategy training with training games, as well as feedback on accuracy and performance.
2398493|NCT03582670|Active Comparator|Process Training|Study participants attend training sessions and complete training games, but receive no specific strategy training
2398494|NCT03582670|Other|Control Group|Study participants do not attend any strategy training sessions.
2398495|NCT03582644|Experimental|CRYOTHERAPY INTERVENTION|Patients with end stage knee osteoarthritis, both sexes, 60 years or higher
3143566|NCT00007267|Experimental|2|Participants will receive self-help cognitive behavioral intervention facilitated by a psychologist
2398497|NCT03582605|Placebo Comparator|Control Group|All participants will be weighed. This group will receive a placebo (glucose) 1 hour prior to insertion of mini-screw implants.
2398498|NCT03582605|Experimental|Experimental Group|All participants will be weighed so that appropriate dosing can be ensured and will receive 2 grams of Amoxicillin 1 hour prior to mini-screw insertion. Patients weighing less than 40 kg will be given 50mg/kg of Amoxicillin.
2398499|NCT03582592|Experimental|Fluid Distribution Timetable (FDT) Group|It is the fluid distribution timetable. It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
2398500|NCT03582592|No Intervention|Comparison Group|It is the standard of care that served as the intervention. The control group received the standard care for patients on hemodialysis. The standard care involves a 10 -15-minute face-to-face health teaching of their treatment regimen including pharmacologic management, dialysis schedule, dietary and fluid restrictions or nutritional therapy, care for vascular access, and other necessary lifestyle modifications.
2398501|NCT03582579|Experimental|Control in VR|Adults ages 18 to 35 who will be training in Virtual Reality.
2398502|NCT03582579|Experimental|Control Non-VR|Adults ages 18 to 35 who will be training on a computer screen.
2398503|NCT03582579|Experimental|College Athletes with TBI Group|Adults ages 18 to 35 with mild TBI who will be training in Virtual Reality
2398504|NCT03582579|Experimental|Older Adult Group|Older Adults over the age of 65 who will be training in Virtual Reality
3143567|NCT00007267|Active Comparator|3|Participants will receive a disease/health education intervention
3143568|NCT00007358|Experimental|1|Depending on patient and physician decision, a steroid may be administered during pregnancy.
3143569|NCT00007501|Experimental|Arm 1|varicella-zoster vaccine
3143570|NCT00007501|Placebo Comparator|Arm 2|vaccine placebo
3143571|NCT00007579||1|
3143572|NCT00007605|Active Comparator|1|Amiodarone or Sotalol
3143573|NCT00007605|Active Comparator|2|Sotalol
3143574|NCT00007618||1|
3143575|NCT00007631|Active Comparator|1|Topical Tretinoin
3143576|NCT00007631|Placebo Comparator|2|Placebo
3143577|NCT00007657|Experimental|1|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy
3143578|NCT00007657|Active Comparator|2|Intensive medical therapy
3143579|NCT00007683|Active Comparator|1|Warfarin Titrated to an INR of 2.5-3.0
3143580|NCT00007683|Active Comparator|2|Aspirin 182 mg
3143581|NCT00007683|Active Comparator|3|Clopidogrel 75 mg
3143582|NCT00007696||1|
3143583|NCT00007709||1|
3143584|NCT00007722||1|
3143585|NCT00007761|Experimental|1|Bipolar Disorder Program
3143586|NCT00007761|Active Comparator|2|Usual (psychiatric) Care
3143587|NCT00007774|Experimental|1|Olanzapine
3143588|NCT00007774|Active Comparator|2|Haloperidol
3143589|NCT00007787|Experimental|Antibody plus delayed cyclosporine therapy|Anti-human thymocyte globulin (rabbit) (Thymoglobulin®) is admistred at the time of transplant followed delayed clyclosporine A therapy post tranplant.
3143590|NCT00007787|Active Comparator|Standard cyclosporine A therapy|Cyclosporine A therapy (either Cyclosporine or Tacrolimus) will be initiated pre-transplantations
3143591|NCT00007813|Experimental|Arm 1|
3184490|NCT00725179||2|Patients receiving IV NAC treatment
2398514|NCT03582540|Active Comparator|early double-guidewire technique (DGT)|First arm: early double-guidewire technique The early arm attempts biliary cannulation using the DGT immediately once the guidewire is inserted in the pancreatic duct in cases of difficult biliary cannulation.
2398515|NCT03582540|Active Comparator|delayed double-guidewire technique (DGT)|In the delayed arm, once the guidewire is inserted in the pancreatic duct, the operator continues to attempt biliary cannulation with conventional technique (contrast- or guidewire-assisted). DGT is used only if 10 more minutes of conventional cannulation technique does not allow biliary access.
2398516|NCT03582527||observation group|All these patients who have been tested will be observed for further treatment and been recorded for toxicity.
3143592|NCT00007852|Experimental|Arm I|Rituxan and BEAM with autologous stem cell transplant
2398518|NCT03582501|Experimental|Healthy volunteers|All volunteers will be studied at rest and during experimental condition (lower body negative pressure)
2398520|NCT03582475|Experimental|Treatment (pembrolizumab, platinum-based chemotherapy)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising either etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1), or etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2398521|NCT03582462|Experimental|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection.
2398522|NCT03582462|Placebo Comparator|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator.
2398523|NCT03582449||Elaprase|Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.
2398524|NCT03582436||Prospective cohort|Kidney transplantation
2398525|NCT03582423|Experimental|electro-acupuncture group|Eight acupoints are chosen: he gu (LI4), nei guan(PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
2398526|NCT03582423|Placebo Comparator|sham-acupuncture group|"Streitberger's non-invasive acupuncture needles (Gauge 8 × 1.2/ 0.30 × 30mm) will be applied to serve as a sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin by a small plastic ring instead of being inserted and the stimulation will be a pseudo-stimulation"
2398527|NCT03582410|Active Comparator|Absorbable suture|laparoscopic sacral colpopexy with absorbable suture
2398528|NCT03582410|Active Comparator|Non absorbable suture|laparoscopic sacral colpopexy with non absorbable suture
2398529|NCT03582397|Experimental|Experimental|Subjects to receive virtual reality mirror therapy via WiseMind Software (Realiteer) 3x/week for 4 weeks.
2398530|NCT03582384|Experimental|Treatment|
3143593|NCT00007878|Experimental|Treatment (bortezomib, fluorouracil, leucovorin calcium)|Patients receive bortezomib IV on days 1 and 4 and fluorouracil IV and leucovorin calcium IV on day 1 weekly for 2 weeks. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
3143594|NCT00007904|Experimental|Arm A: Combination Chemotherapy|Paclitaxel IV continuously over 72 hours on days 1-3 and cyclophosphamide IV on days 1-3. Filgrastim subcutaneously (SC) beginning on day 5 and continuing until blood counts recover or pegfilgrastim SC on day 5. Treatment repeats every 21 days for 3 courses. Then doxorubicin hydrochloride IV on day 1 and filgrastim SC beginning on day 2 and continuing until blood counts recover or pegfilgrastim SC on day 2. Treatment repeats every 21 days for 4 courses. Patients with hormone-receptor positive tumors receive oral tamoxifen citrate or oral anastrozole daily for 5 years following chemotherapy. Beginning 3-6 weeks after completion of chemotherapy, patients undergo radiation therapy 5 days a week for 6-7 weeks.
2398533|NCT03582358||Verrine|Patients served verrines
2398534|NCT03582358||CNO|Patients served wrapped supplements
2398535|NCT03582345|Experimental|EEG/fMRI|The presented project will include only one arm constituted by patients affected by pharmacoresistant epilepsies elegible for respective surgery. Patients will be identified by RU1 and RU2. The definition of drug-resistant epilepsy requires: (a) the failure of at least two first-line AEDs; (b) the occurrence of an average of one seizure per month for > 18 months; (c) no more than 3-month seizure free hiatus during those 18 months (Berg et al., 2006).
2398536|NCT03582332|Active Comparator|Group A in phase 1|Indomethacin 75 mg, extended release capsule twice daily
2398537|NCT03582332|Active Comparator|Group B in phase 1|Indomethacin 25 mg capsule, 2 capsule twice daily
2398538|NCT03582332|Active Comparator|Group A in phase 2|Etoricoxib 90 mg once daily
2398539|NCT03582332|Active Comparator|Group B in phase 2|Etoricoxib 60 mg once daily
2398540|NCT03582319|Experimental|Biodentine|Regenerative material for pulp therapy
2398541|NCT03582319|Active Comparator|Formocresol|Fixative agent for pulp therapy
2398542|NCT03582306|Experimental|High chlorophyll diet - intervention 1st|Participants will complete the 4 week intervention, 4 week washout, then 4 week control period (monitor only)
2398543|NCT03582306|Experimental|High chlorophyll diet - control 1st|Participants will complete the 4 week control period (monitor only), 4 week washout, then 4 week intervention
2398544|NCT03582293|Active Comparator|Tranexamic Acid|Tranexamic acid 500mg two times a day orally for a total of 28 days
2398545|NCT03582293|Placebo Comparator|PLACEBO|Placebo capsules two times a day orally for a total of 28 days
3184491|NCT00725192|Active Comparator|1|Cognitive Processing Therapy
3184492|NCT00725192|Experimental|2|Hypnosis plus Cognitive Processing Therapy.
3184493|NCT00725218|Placebo Comparator|1|Saline 5 ml injection 10 min prior to propofol administration.
2398546|NCT03582280|Experimental|Amorous Calcium Carbonate (ACC) - Amor|"The investigational product will include:~Amor powder, each eppendorf contains 200mg Calcium~Amor Inhaled Double Pack - 1% ACC in 8 ml suspension"
2398547|NCT03582267|Experimental|Dietary Supplement|Docosahexaenoic Acid (DHA)
2398548|NCT03582267|No Intervention|No Intervention|No Docosahexaenoic Acid supplementation
2398549|NCT03582254|Experimental|[18F]-FDG PET/MR|[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital
2398550|NCT03582228|Experimental|Virtual Envrionment for Social Communication|"Once the intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
2398559|NCT03582202|Active Comparator|Dietetic service|Nutritional assessment and therapy by dietitian throughout the hospital stay
2398560|NCT03582202|Placebo Comparator|standard care|Nutritional handling by nurses supported by a dietician if needed
2398561|NCT03582189||Pancreatic Cancer|Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2398562|NCT03582189||Liver Metastases|Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2398563|NCT03582189||Hepatocellular carcinoma|Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
2398567|NCT03582163||STN|Patients with Parkinson's disease who have undergone subthalamic nucleus (STN) DBS.
2398568|NCT03582163||GPi|Patients with Parkinson's disease who have undergone GPi (GPi) DBS.
2398569|NCT03582150|Experimental|Receiving Soberlink Device|
2398570|NCT03582137|Experimental|CBD Cannabis extract oral solution|Cannabidiol (CBD) Cannabis extract oral solution
2398571|NCT03582137|Placebo Comparator|placebo|Placebo oral solution
2398572|NCT03582124|Experimental|Diagnostic (panitumumab-IRDye800, surgery, NIR)|Participants receive panitumumab- IRDye800 IV over 60 minutes on day 0, and then undergo NIR and surgery within 1-5 days.
2398573|NCT03582111||Pregnant women who have a foetus with a cleft lip/palate|Pregnant women who have a foetus with a cleft lip/palate
2398574|NCT03582098||Idelalisib and Rituximab|Individuals who received treatment for CLL with at least one dose of idelalisib and rituximab in accordance with the marketing authorisation.
2398575|NCT03582085|Experimental|Bacillus Calmette-Guerin (BCG)|3 BCG vaccinations spaced 1 year apart.
2398576|NCT03582085|Placebo Comparator|Placebo Comparator: Saline injections|3 saline injections spaced 1 year apart.
2398577|NCT03582072|Experimental|letter|letter from the CMO: practice outside the top 20% of prescribers whose prescribing increased by > 4%, where GPs in the practice were sent a letter informing them their prescribing had increased
2398578|NCT03582072|No Intervention|control|practice outside of the top 20% of prescribers whose prescribing increase by >4%, GPs were not sent a letter
2398579|NCT03582059|Other|Patient group meeting inclusion criteria group 1|Patients meeting the inclusion criteria in the first 10 days of entering trial and are randomised to first intervention.
2398580|NCT03582059|Other|Patient group meeting inclusion criteria group 2|Patient group meeting inclusion criteria after 10 days and are allocated second intervention.
2398581|NCT03582046|No Intervention|Monitoring Group|Patients that sustain intra-abdominal pressure of < 8 mmHg for 48 hours from sepsis diagnosis. Patients will be monitored and given sepsis standard of care.
2398582|NCT03582046|Active Comparator|Mean Arterial Pressure (MAP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
2398583|NCT03582046|Experimental|Abdominal Perfusion Pressure (APP) Group|Patients with elevated intra-abdominal pressure of ≥ 8 mmHg for 48 hours from sepsis diagnosis.
3143595|NCT00007917|Experimental|Arm I|"Patients receive gemcitabine IV over 1-2.5 hours on days 1 and 8 and flavopiridol IV continuously over 24 hours on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine and flavopiridol until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3143596|NCT00008177|Experimental|Treatment ( I 131 BC8, chemotherapy, TBI, PBSCT, CSP, MMF)|"CONDITIONING REGIMEN: Patients receive iodine I 131 monoclonal antibody BC8 IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo total-body irradiation on day 0.~TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV BID on days -3 to 56 with taper to day 80 (for patients with a related donor) OR days -3 to 100 with taper to day 177 (for patients with an unrelated donor) in the absence of GVHD. Patients also receive mycophenolate mofetil PO or IV TID on days 0 to 27 (for patients with a related donor) OR on days 0 to 40 with taper to day 96 (for patients with an unrelated donor) in the absence of GVHD."
3143597|NCT00008216||alloSCT group|Patients undergoing allogeneic blood or marrow stem cell transplantation (alloSCT).
3143598|NCT00008320|Experimental|ceramide cream|Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
2398588|NCT03582020|Placebo Comparator|Traditional Western Diet|Intervention: Menu plans and recommendations for persons who consume a traditional Western diet (daily consumption of meat and sausage)
2398589|NCT03582020|Active Comparator|Flexitarians|Intervention: Menu plans and recommendations for persons, who rarely consume meat and meat products (predominantly high-quality products; ≤ 2 times / week) = flexitarians
2398590|NCT03582020|Active Comparator|Vegetarians|Intervention: Menu plans and recommendations for persons who do not eat meat and sausage (vegetarians)
2398591|NCT03582020|Active Comparator|Vegans|Intervention: Menu plans and recommendations for persons who do not eat products from animal origin (vegans)
2398592|NCT03582007|Experimental|Murepavadin|Murepavadin + ertapenem
2398593|NCT03582007|Active Comparator|Anti-pseudomonal antibiotic|One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)
2398594|NCT03581994|No Intervention|Standard Practice|Not receiving any intervention/educational materials on drug-drug interaction testing
2398595|NCT03581994|Experimental|Compulsory DDI Testing|Receiving educational materials on drug-drug interaction testing and a sample test report when caring for patient cases.
2398596|NCT03581994|Experimental|Optional DDI Testing|Receiving educational materials on drug-drug interaction testing and given a sample test report if ordered when caring for patient cases.
3143599|NCT00008333|Experimental|vinorelbine|Patients receive oral vinorelbine on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4-6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after 8 weeks of therapy. Patients are followed every 3 months for 5 years.
3143600|NCT00008346|Other|SFM then FFDM|Screen Film Mammography (SFM) followed by Full Field Digital Mammography (FFDM)
2398599|NCT03581968|Experimental|Closed-loop therapy|Participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be determined by the camp's physicians. The research staff will update the pump's settings to reflect the physician's recommendations at the beginning of the closed-loop therapy, and each time the physicians update the study parameters. The closed-loop therapy will last 2 days (48 hours).
2398600|NCT03581968|Experimental|Closed-loop therapy with learning module|participants will undergo a closed-loop therapy where insulin delivery is determined by the MAP system. The study parameters (basal rates and ICRs) will be computed by the learning algorithm and updated daily. The learning algorithm runs on a computer of the research staff members and requires patient data to calculate the optimal basal rates and ICR. Each day, the research staff members will upload patient data onto the computer, run the leaning algorithm, and update the pump parameters to reflect the recommendations computed by the learning algorithm. The closed-loop therapy with the learning module will last 8 days (192 hours).
2398601|NCT03581955|Experimental|Banana Cavendish|240g of fruit plus 150ml of Fresubin ® 2kcal fiber neutral flavor
2398602|NCT03581955|Experimental|Control drink|250ml of Fresubin ® 2kcal fiber neutral flavor
2398603|NCT03581955|Experimental|Tomato|300g of tomato plus of Fresubin ® 2kcal fiber neutral flavor plus 12g of refined sunflower oil.
2398604|NCT03581942|Experimental|Copanlisib in combination with Ibrutinib|"The 3+3 design will be applied in the phase Ib portion of the trial. Participants will be assigned to the following dose levels: Dose level 1: Ibrutinib 560 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level 2: Ibrutinib 840 mg daily + Copanlisib 60 mg weekly (3w on/1w off) Dose level -1: Ibrutinib 560 mg daily + Copanlisib 45 mg weekly (3w on/1w off). Phase II: (Simon two-stage design: 14 patients will be treated at the MTD (including 6 patients from the phaseIb portion) If at least 11 patients respond then an additional 19 patients will be accrued to the second stage. If 10 or less patients respond the study will be terminated and declared negative)."
2398605|NCT03581929|Experimental|Memormax|2 vials / day of Memormax from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
2398606|NCT03581929|Placebo Comparator|Placebo|2 vials / day of Placebo from Day 0 to Day 180. At the end of the blinded phase (Day 0-180), all patients will receive 2 vials / day of Memormax from Day 181 to Day 360.
2398607|NCT03581916|Experimental|18F-JNJ-64326067|Participants will receive single intravenous (IV) bolus injection of 18F-JNJ-64326067 on Day 1.
2398608|NCT03581903|Experimental|H7N3 pLAIV + H7N9 pIIV|Participants will receive H7N3 pLAIV on Days 0 and 28, followed by H7N9 pIIV on Day 84.
2398609|NCT03581890||Danish Colorectal Cancer Group (DCCG.dk) database|The DCCG.dk database is a national population-based, clinical database with a completeness proportion of 99% of all colorectal cancer patients in Denmark. Patients are included in the database if treated for or diagnosed with colorectal cancer at a public surgical department in Denmark. No patients underwent treatment for colorectal cancer at private hospitals in Denmark. Metachronous cancers, recurrence, and tumors of other histological origin than primary adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, or undifferentiated carcinoma are not registered in the DCCG.dk database. The surgeon prospectively registers perioperative variables such as surgical priority, stent insertion and type of colectomy, and patient related variables. Information on postoperative mortality is imported to the database from the Danish Central Civil Registration Registry linking all Danish residents with a unique identification number.
2398610|NCT03581877|Experimental|Peripheral low dose thrombolysis|Peripheral low dose thrombolysis will use a peripheral vein into an arm as in routine intravenous therapy. This is the experimental arm. Alteplate (R-tpa) belong to thrombolytic or fibrnolytic drug class. Routine hospital policies for peripheral venous therapy will be used. A fixed dose of 24 mg of Activase (Atleplase) over 12 hours or 2.0 mg/hr will be administered peripherally. Simultaneously, intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
2398611|NCT03581877|Active Comparator|Catheter directed acoustic thrombolysis|For ACDT, routine hospital protocols and EKOS(generic) will be used. EKOS is made up of 3 parts which include the drug delivery pulmonary artery catheter, a removable microsonic device, and a reusable Eko-Sonic control unit. Venous access will be obtained by ultrasound guidance in the internal jugular vein or femoral vein. After catheter placement, the right heart pressures will be measured. R-tpa will be directly given into the pulmonary catheter. A fixed dose of 24 mg of tpa over 12 hours or 2.0mg/hr will be given. For unilateral PE, a single catheter will be used with infusion rate of 2 mg//hr and two catheters will be used for bilateral PEs each with 1 mg /hr infusion rate. Intravenous unfractionated heparin will be given with a target partial thromboplastin time of 40 to 60 secs.
2398612|NCT03581864||Group of 14 patients with post-traumatic complete anirirdia|14 eyes with post-traumatic complete aniridia and aphakia treated withscleral fixation of BD IOL with measurements included ophthalmological comorbidities, best corrected visual acuity (BCVA), complications, and postoperative interventions.
2398613|NCT03581851|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2398614|NCT03581851|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2398615|NCT03581838||Acitve EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who have not been treated or have not achieved remission from treatment.
2398616|NCT03581838||Remission EoE|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals who have EoE who are have achieved remission from treatment.
2398617|NCT03581838||Controls|Observed eating session of Jimmy John's turkey or vegetarian sandwich with water among individuals without EoE.
3184494|NCT00725218|Experimental|2|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
3184495|NCT00725231|Active Comparator|Arm A|Chemotherapy with dose dense CHOP-14, 6 cycles
2398620|NCT03581812|Active Comparator|Intervention snack 1|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
2398621|NCT03581812|Active Comparator|Intervention snack 2|Snack food believed to selectively promote the growth of beneficial bacterial strains in the human colon.
2398622|NCT03581812|Placebo Comparator|Control snack|Control snack food reflecting the macro-nutrient profile of a typical UK snack.
2398623|NCT03581799|Other|Oral dispersible tablet|5 mm calcium carbonate based ODT will be administered by placing it in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
2398624|NCT03581786|Placebo Comparator|placebo combine with chemotherapy|
2398625|NCT03581786|Experimental|TORIPALIMAB INJECTION(JS001 )combine with chemotherapy|
2398626|NCT03581773|Active Comparator|Treatment arm|5 mg of folic acid (1 tablet) per day for 12 weeks.
2398627|NCT03581773|Placebo Comparator|Placebo arm|PLACEBO (1 tablet) per day for 12 weeks.
2398628|NCT03581760|Experimental|Cycling Exercise|Patients randomized into this arm will undergo cycling exercise once a day while on mechanical ventilation at intensive care unit.
2398629|NCT03581760|Active Comparator|Conventional Physiotherapy|Patients randomized into this arm will undergo conventional physiotherapy twice a day while on mechanical ventilation at intensive care unit.
2398630|NCT03581747||Subjects with atopic dermatitis|
2398631|NCT03581747||Controls|
2398632|NCT03581734|Active Comparator|OPV only|The vaccine will be available in prefilled vials containing 10 doses. Each vial will be labelled with the study ID of the participant. Therefore, for participants randomized to arm A and arm C, there will be 3 vials per participant for the 3 doses of the bOPV vaccine to be given 28 weeks apart. Any remaining, non-used doses of vaccine in the vial will be discarded.
2398633|NCT03581734|Active Comparator|Shanchol only|Each dose of vaccine is 1.5ml in volume. Each vial will be labelled with the study ID of the participant. One vial will be used per participant per study visit. OCV was studied in a double-blind, randomized, placebo-controlled trial in Kolkata, India. Participants were 1 year and above in age. In these studies, 100 children aged 1-17 were administered 2-doses of OCV or placebo separated by an interval of two weeks, with 80% of vaccinated showing over 4 fold rise in serum V. cholerae O1 antibody titers, showing that the 2-dose regimen was well-tolerated, safe and immunogenic
2398634|NCT03581734|Experimental|OPV-OCV co-administered|"Our primary analysis will be to compare seroconversion (defined as a change of status from seronegative to seropositive titers, or a ≥4-fold rise in antibody titer) for OPV1 and OPV 3 antibodies between Arm A and Arm C, to determine whether seroconversion to bOPV when administered with Shanchol is non-inferior to seroconversion to bOPV when bOPV is administered alone.~Our second objective will be to compare vibriocidal antibody seroconversion (also, ≥4-fold rise in antibody titers) to Shanchol when co-administered with OPV or when Shanchol is administered alone, Arm B compared to Arm C"
2398637|NCT03581708||advanced lung cancer|Patients diagnosed with advanced lung cancer
2398638|NCT03581695||Pulmonary Hypertension and Congenital Heart Disease|Pulmonary Hypertension and Congenital Heart Disease
2398639|NCT03581695||Congenital Heart Disease|Congenital Heart Disease
2398640|NCT03581695||Healthy Controls|Healthy Controls
2398641|NCT03581682|Experimental|Tele-Visit Using Parental Home Echo|All parents will have hands-on echo training. We will test if a tele-visit using parental home echo is clinically reliable compared to an on-site clinic visit, costs less, and improves parental sense of empowerment.
2398642|NCT03581669||THA + cerclage acetabulum|
2398643|NCT03581656|Experimental|Arm|The ChordArt System is intended for chordal replacement in patients with mitral valve insufficiency due to leaflet prolapse or flail delivered through a catheter based technology for mitral chordal replacement via a small incision in the thorax.
2398644|NCT03581630|Experimental|Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet|
2398645|NCT03581630|Experimental|Breast cancer subjects-Mediterranean Diet|
2398646|NCT03581630|Active Comparator|Healthy subjects-naltrexone/bupropion+Mediterranean Diet|
2398739|NCT03580980|Active Comparator|Drug: Paracetamol and ketamine|The patients of Multimodal Group (n=30) received paracetamol infusion 10 mg/kg over 10 minutes and ketamine 0.5 mg/kg IV bolus followed by ketorolac 1 mg/kg infusion over 10 minutes.
3184496|NCT00725231|Experimental|Arm B|Chemotherapy with dose dense CHOP-14, 6-cycles, together with 30mg Alemtuzumab s.c. for the first 4 cycles
2398647|NCT03581617||Infertile women|Inclusion criteria for the study group will be as follows: 21-38 years old, primary infertility (no live birth), regular menstrual cycle (24-35 days), body mass index (BMI) ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/ml on day 2-3 of the menstrual cycle. They will be recruited at admission for tubal patency assessment.
2398648|NCT03581617||Fertile women|Inclusion criteria for control group will be as follows: 21-35 years old, almost one live birth, regular menstrual cycle (24-35 days), BMI ≤ 25, FSH <10 mUI/mL, E2 < 50 pg/mL on day 2-3 of the menstrual cycle. Women with endometritis, endometriosis, tubal factor, ovulatory dysfunction, anatomical uterine pathologies will be excluded.
2398649|NCT03581604|Other|Patients labeled as penicillin allergic|Patients labeled as penicillin allergic will be allergologically investigated to confirm/exclude the diagnosis. Allergy work-up will be performed. Blood samples and Microbiological samples will be obtained.Questionnaire to evaluate the effectiveness of the intervention.
2398650|NCT03581604|Other|Healthy Controls|Healthy Controls, blood samples and microbiological samples.Clinical history
2398651|NCT03581591|Experimental|Primary; open label|Injection of Burosumab every two to three weeks based on Serum Phosphorus level of subject. Initial dose to be 0.3 mg/kg. Subsequent dosing will be titrated up or down depending on Serum Phosphorus level for that time period.
2398652|NCT03581565|Active Comparator|Technique I|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) cement to fulfill the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
2398653|NCT03581565|Active Comparator|Technique II|"Loading of a zinc polycarboxylate (with the requirements of ISO 9917) to fill the coronal half of the crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): placement of mixture into crown using a heidemann Spatula Setting Time (intraoral): 2-8 minutes"
2398654|NCT03581565|Active Comparator|Technique III|"Application of a zinc polycarboxylate (with the requirements of ISO 9917) to the axial walls of internal surface of crown~Cement: Poly-F, DentsplySirona, York, Pennsylvania, United States Mixing Ratio: 1 scoop powder: 2 drops liquid Mixing Time (extraoral): 30 seconds Working Time (extraoral): 45 seconds Application (extraoral): application of mixture into crown using a bonding applicator tip Setting Time (intraoral): 2-8 minutes"
2398655|NCT03581539|Active Comparator|Group #1|Transverses Abdominis Plane (TAP) block
2398656|NCT03581539|Active Comparator|Group #2|Quadratus Lumborum (QL) block
2398657|NCT03581539|Active Comparator|Group #3|Surgeon Infiltration using Exparel
3143601|NCT00008346|Other|FFDM then SFM|Full Field Digital Mammography (FFDM) followed by Screen Film Mammography (SFM)
3143602|NCT00008411|Experimental|Docetaxel Weekly|Arm I: Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days.
3143603|NCT00008411|Experimental|Docetaxel Every 3 Weeks|Arm II: Docetaxel IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days.
3143604|NCT00008450|Experimental|Treatment (cyclosporine, mycophenolate mofetil, transplant)|Patients receive cyclosporine PO or IV on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.
2398662|NCT03581500|Experimental|Diagnostic (hyperpolarized carbon C 13 pyruvate MRSI)|Patients receive hyperpolarized carbon C 13 pyruvate IV over 10-20 seconds and undergo MRSI over 2-3 minutes at 6 and 8 weeks.
3143605|NCT00008502||18 years of age or older|without keloids
3143606|NCT00008502||family members over 12 years of age|who have either classic or non-classic keloids
3189048|NCT00773695|Active Comparator|Chemotherapy|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.
2398666|NCT03581461|Experimental|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
2398667|NCT03581448|Experimental|Nerve Growth During Prosthesis Control|"Determine the optimum conditions that promote sensory restoration in limb-absent people, with an adaptive haptic feedback control law that mimics the experience of neural plasticity.~The intervention Sensory Restoration During Prosthesis Control will be used."
2398668|NCT03581435||gallbladder carcinoma patients|Cases will be the patients with newly-diagnosed gallbladder carcinoma.
2398669|NCT03581435||The controls|The controls will be matched （1：1）by sex，race and age which will be selected from the patients receiving cholecystectomy due to gallstones from the same hospital with the cases.
2398670|NCT03581422||NC-FET|pure natural cycle frozen-thawed embryo transfer
2398671|NCT03581422||mNC-FET|modified natural cycle frozen-thawed embryo transfer by hCG administration
2398672|NCT03581409|Experimental|dual-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg & prasugrel 5mg) treatment continued for 3 months through study completion.
2398673|NCT03581409|Experimental|triple-antiplatelet|Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.
2398740|NCT03580967|Other|Drug: Vortioxetine|
2398741|NCT03580954|Experimental|Repetitive TMS (estimulation)|
3143607|NCT00008502||Probands|original participants who have had a classic (butterfly-shaped or wound-overflowing) keloidfor at least one year
2398678|NCT03581370|Active Comparator|1 hour infusion|"The first group corresponds to 1-hour infusion : First administration of ceftolozane-tazobactam with 2000 mg by infusion for 60 minutes every 8 hours.~24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48."
2398679|NCT03581370|Experimental|4 hours infusion|"The second group corresponds to 4-hours infusion: First administration of ceftolozane-tazobactam with 2000 mg by infusion for 4 hours every 8 hours. 24h after this first administration, 7 blood samples will be collected at Hour 24, Hour 25, Hour 26, Hour 28, Hour 30, Hour 32 and Hour 48.~."
2398680|NCT03581357|Active Comparator|Control/Waitlist (Anxiety Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
2398681|NCT03581357|Active Comparator|Mindfulness App (Anxiety Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
2398682|NCT03581357|Active Comparator|Control/Waitlist (Neuropathy Group)|Subjects assigned to this arm will not be offered access to the mobile app during the first 8 weeks of their participation. Subjects will be asked to begin using the app eight weeks after randomization. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week time point (just before subject begins using the mobile app) and 16 week time point.
2398683|NCT03581357|Active Comparator|Mindfulness App (Neuropathy Group)|Subjects assigned to this arm will receive mindfulness meditation instructions for 8 consecutive weeks following randomization to this arm. The mobile app contains 14 sessions that subject can participate in at their own pace. Subjects are asked to try and practice mindfulness meditation daily, for a total time of 2 hours per week. Subjects assigned to this arm will complete a questionnaire at three times points: the beginning after the subject has signed the informed consent form, at the 8 week and 16 week time points.
2398684|NCT03581344|No Intervention|Control arm|Patients undergoing surgery 9-11 weeks after the end of chemoradiotherapy, whose major/complete response has to be assessed with clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy.
2398685|NCT03581344|Experimental|Experimental arm|Patients undergoing surgery 13-16 weeks after the end of chemoradiotherapy, (length of surgical interval ) showing a major/complete response at the clinical-instrumental exams to be performed 7-8 weeks after the end of chemoradiotherapy. These patients will undergo a repetition of re-staging (a second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy.)
2398686|NCT03581331|Experimental|acute unilateral vestibular loss|patients with acute unilateral vestibular loss by surgical deafferentation will performed an orthoptic balance
3143608|NCT00008697|Experimental|Phase 1|"Cohort 1 Arsenic trioxide = 0.1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 2 Arsenic trioxide = 0.15 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 3 Arsenic trioxide = 0.20 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 4 Arsenic trioxide = 0.25 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)~Cohort 5 Arsenic trioxide = 0.30 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)"
3143609|NCT00008697|Experimental|Phase 2|Arsenic trioxide = MTD found in Phase 1 mg/kg/day x 28 days with 14 day rest for 3 cycles (each cycle = 6 weeks)
3143610|NCT00009217|Active Comparator|Haloperidol-Haloperidol|Haloperidol for 20 weeks followed by haloperidol for 24 weeks
3143611|NCT00009217|Placebo Comparator|Haloperidol-Placebo|Haloperidol for 20 weeks followed by placebo for 24 weeks
2398691|NCT03581279|Active Comparator|EM present|All patients must display signs/symptoms of Lyme disease as well as exhibit an EM lesion.
2398692|NCT03581279|Active Comparator|No EM present|All patients must display signs/symptoms of Lyme disease but do not have an EM lesion.
2398693|NCT03581266|Experimental|Rye|A breakfast consisting of whole slices of wholemeal rye bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
2398694|NCT03581266|Experimental|Wheat|A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
2398695|NCT03581253|Experimental|peripheral facial palsy patients|"peripheral facial palsy patients will performed questionnaires of quality of life (Facial disability Index (FDi) and Facial Clinimetric Evaluation (FaCE)"
2398696|NCT03581227||Participants without a diagnosis of COPD|Men and women aged 45 to 80, who have not been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
2398697|NCT03581214|Active Comparator|Room air|Room air (no mask)
2398698|NCT03581214|Placebo Comparator|Oxygen|10L/min Oxygen by facemask
2398699|NCT03581201||Oral contraception|Healthy females at childbearing age with oral contraception.
2398700|NCT03581201||No contraception|Healthy females without any contraception at all.
2398742|NCT03580954|Active Comparator|Repetitive TMS (inhibition)|
2398701|NCT03581188|Experimental|Self-examination of the skin|Participants will perform self-surveillance of the skin using a dermatoscope device. They will receive guidance from the ASICA skin checker and receive reminders every 2 months to perform self-examination. They will receive an educational booklet 'Your guide to early melanoma' and scheduled visits to their clinician as required.
2398702|NCT03581188|No Intervention|Control|Participants will receive an educational booklet 'Your guide to early melanoma'and scheduled visits to their clinician as required.
2398703|NCT03581175||Cycle1|Patients undergoing colonoscopy with full bowel cleansing before the improvement phase
2398704|NCT03581175||Cycle2|Patients undergoing colonoscopy with full bowel cleansing after the improvement phase
2398705|NCT03581162||Patients|Patients with diagnosis of Juvenile Mixed Connective Tissue Disease
2398706|NCT03581162||Controls|Healthy, age-and sex-matched controls
2398707|NCT03581149|Active Comparator|Citrafleet®|Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
2398708|NCT03581149|Active Comparator|MoviPrep®|Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
3143613|NCT00009620|Experimental|Phenobarbital|
2398714|NCT03581110||16-slice CT scanner|1426 patients that have received a noncontrast-enhanced chest CT on our 16-slice clinical routine CT scanner in inspiration only.
2398715|NCT03581110||2nd generation dual-source CT|320 patients that have received a noncontrast-enhanced chest CT on our second generation dual-source CT scanner in inspiration only.
2398716|NCT03581110||3rd generation dual-source CT|211 patients that have received a noncontrast-enhanced chest CT on our third generation dual-source CT scanner in inspiration and expiration.
3143614|NCT00009620|Placebo Comparator|Placebo|
2398720|NCT03581071|Experimental|Step1:1mg in non-dialysis subject|
2398721|NCT03581071|Experimental|Step2-1:1mg in hemodialysis subjects|
2398722|NCT03581071|Experimental|Step2-2:6mg in non-dialysis subject|
2398723|NCT03581071|Experimental|Step3-1:11㎎ in hemodialysis subjects|
2398724|NCT03581071|Experimental|Step3-2:11㎎ in non-dialysis subject|
2398725|NCT03581058|Experimental|Cannabis - Jean Guy|A participant will be administered 1g of Jean Guy strain of cannabis.
2398726|NCT03581058|Experimental|Cannabis - Churchill|A participant will be administered 1g of Churchill strain of cannabis.
2398727|NCT03581058|No Intervention|Sober|All participants will complete same tasks sober.
2398728|NCT03581045||ALL Survivors|Adult survivors of Acute Lymphoblastic Leukemia (ALL) enrolled on the SJLIFE protocol
2398729|NCT03581045||Control Group|Healthy Individuals with no history of childhood or adult onset cancer, matched on age- and sex
2398730|NCT03581032||A-Active reprogram follwed by sham|This arm will be randomized to have PACING device reprogramming followed by sham reprogramming
2398731|NCT03581032||B-Sham followed by active reprogram|This arm will be randomized to have sham reprogramming followed by active pacing reprogramming
2398735|NCT03580993||SBT Completers|Those patients who successfully complete a spontaneous breathing trial of 2 hours.
2398736|NCT03580993||SBT Non-completers|Those patients who fail to complete a spontaneous breathing trial of 2 hours.
2398737|NCT03580980|Active Comparator|Drug: Morphine|Morphine Group C (n=30) was the control group who received IV morphine in a dose of 0.1 mg/kg after induction of anesthesia
2398738|NCT03580980|Active Comparator|Procedure/surgery:Caudal levobupivacaine|In Caudal Group (n=30), patients were placed in the lateral position and received caudal epidural block after induction of anesthesia with levobupivacaine 0.125% , 1.1 ml/kg and morphine 0.02 mg/kg with maximum 20ml.
2398878|NCT03580057|Experimental|Diet- and weight loss intervention (D)|
3143615|NCT00009646|Experimental|Indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa.
3143616|NCT00009646|Placebo Comparator|Placebo|Saline solution
3143617|NCT00009698|Experimental|All patients|Day 1 through day 7, days 9-14 and days 16-22: The assigned dose of IL-2 will be administered SQ. On days 8 and 15, IL-2 will be administered as a 2 hour intravenous infusion of one million units/M2 of IL-2. After day 22 there will be a 7 day rest period before beginning the next cycle. The next cycle will repeat just as above. This will be repeated for a maximum of 4 total cycles of 21 days of IL-2 therapy. The maintenance dose of IL-2 will always be the same as given during cycle one, unless there is dose limiting toxicity.
3143618|NCT00009789|Experimental|Radiotherapy|"Patients receive accelerated 3-dimensional (3-D) conformal radiotherapy daily 5 days a week for 3.5-6 weeks.~Cohorts of 8 patients receive escalating fractions of accelerated 3-D conformal radiotherapy until the maximum tolerated course is determined. The maximum tolerated course is defined as the course at which no more than 2 patients develop at least grade 3 dose-limiting toxicity and no more than 1 patient develops at least grade 4 dose-limiting toxicity.~Patients are followed at 3 weeks, 6 weeks, 3 months, every 3 months for 2 years, and then every 6 months for 3 years."
3143619|NCT00009867|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1 hour on days 1-5. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response receive 2 additional courses.
2398744|NCT03580915|Experimental|Functional Literacy Intervention|The intervention group will receive the functional literacy program in which, in small groups, participants learn literacy skills in the context of daily life activities such as shopping, meal preparation, and transportation use.
2398745|NCT03580915|Active Comparator|Functional Literacy Control|The control group will not receive intervention but the Usual Care Management Services.
2398746|NCT03580902|Active Comparator|Standard Buprenorphine|Participants assigned to this arm will received buprenorphine treatment consistent with standard practice at the study site. This includes induction by a physician, regular meetings with a physician for medical management, urine monitoring, and prescription of buprenorphine, with access to behavioral support services.
2398747|NCT03580902|Experimental|Standard Buprenorphine plus CBT4CBT-Buprenorphine|Participants in this condition will receive Standard Buprenorphine as described above, with the addition of access to the CBT4CBT-Buprenorphine program, which is a web-based program that covers basic knowledge about buprenorphine treatment as well as teaches cognitive and behavioral coping skills.
2398748|NCT03580889|Active Comparator|Atropine sulphate|Atropine 5 mcg/kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blood pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly
2398749|NCT03580889|Active Comparator|Glycopyrrolate|Glycopyrrolate 2.5 mcg / kg diluted in normal saline to total volume of 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
2398750|NCT03580889|Active Comparator|Normal Saline|Normal saline 2 ml is given intravenous 1 minute after giving intrathecal Bupivacaine 0.5% (Heavy) and patients vitals such as blold pressure, heart rate, SPO2 are monitored every 1 minute for 5 minutes ,then every 5 minutes for 30 minutes then every 10 minutes till end of surgery. Patient shifted to PACU where above vitals are monitored for 2 hrs then shifted to ward. Mean while any adverse outcomes such as nausea, vomiting, sweating, dry mouth is noted and treated accordingly.
2398751|NCT03580876|Other|switch to anti-TNF alone|"Switch to the second anti-TNF drug alone (infliximab or adalimumab)~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC OR Loss of response under Adalimumab: 40mg EW SC Randomization to: Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks."
2398752|NCT03580876|Other|switch to anti-TNF with addition of azathioprine|"Switch to anti-TNF (infliximab or adalimumab) with addition of azathioprine~Loss of response under Infliximab: 10 mg/kg IV every 8 weeks Randomization to: Adalimumab: induction 160/80 mg SC and Maintenance 40 mg EOW SC with azathioprine 2.5 mg/kg/day OR~Loss of response under Adalimumab: 40mg EW SC Randomization to:~Infliximab: 5mg/kg IV at W0, W2, W6 and every 8 weeks with azathioprine 2.5 mg/kg/day."
2398756|NCT03580811|Active Comparator|Dental Implant & ADMG|Dental implant placed with simultaneous grafting using one layer of ADMG
2398757|NCT03580811|Experimental|Dental implant & ADMG & BDX|Dental implant placed plus simultaneous grafting using ADMG with BDX
2398758|NCT03580798|Experimental|Delayed Grafting|8 weeks after extraction implant placement and simultaneous osseous grafting.
2398759|NCT03580798|Active Comparator|Simultaneous Grafting|At the time of extraction the socket will be grafted and implant placed 4 months later.
2398760|NCT03580772||Persona TKR|Patients will have undergone a medial congruent Persona total knee replacement
2398761|NCT03580772||Attune TKR|Patients will have undergone a Attune total knee replacement
2398762|NCT03580772||Control participants|Patients will not have recieved a primary TKR
2398763|NCT03580759|Experimental|Exergaming|Subjects in the exergaming group will participate in three exergaming training sessions with the Wii Fit U exergaming system. The Wii Fit U will then be left in the subjects' homes for a minimum of four weeks prior to left ventricular assist device implantation or heart transplant.
2398764|NCT03580759|No Intervention|Usual Care|Subjects in the usual care group will be encouraged to partake in physical activity as recommended in the 2017 AHA/ACC/HFSA guidelines for heart failure.
2398765|NCT03580746||Taping and posteromedial release|Children with clubfoots are treated by taping and posteromedial release
2398766|NCT03580746||Treatment by Ponseti|Children with clubfoots are treated by Ponseti
2398767|NCT03580733|Placebo Comparator|placebo|placebo
2398768|NCT03580733|Experimental|antifungal therapy|caspofungin
2398769|NCT03580720|Experimental|Intervention|Intervention group, receiving Inspiratory threshold loading protocol.
2398770|NCT03580707|Active Comparator|Part 1|Compare rapidity of CNS effects of levetiracetam (LEV) & brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
2398771|NCT03580707|Active Comparator|Part 2|Pt 2 Op I:Assuming statistically signify. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1,will proceed w/ Pt 2Opt I. Levetiracetam (LEV) or brivaracetam (BRV administered in randomized, two-way crossover, dbl-blind design as IV infusion over 5 min. to another cohort of 8 pts w/photosensitive epilepsy OR Pt 2,Opt II: Assuming no statistically signif. diff. in rapidity of CNS action has been observed from an analysis of data set in Pt 1, will proceed w/Pt 2,Opt II. LEV or BRV will be administered, in randomized, two-way crossover, dbl-blind design as IV infusion over again 15 min. to another cohort of 8 pts w/ photosensitive epilepsy. LEV will be given as 500 mg dose & BRV as 25 mg dose. BRV vs LEV in randomized double blinded, crossover fashion.
2398772|NCT03580694|Experimental|Cemiplimab Monotherapy|In a single dose escalation cohort, participants will receive cemiplimab alone.
2398773|NCT03580694|Experimental|Combination Therapy|"Dose Escalation cohorts:~In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination.~In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination.~Dose Expansion cohorts:~In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab."
2398774|NCT03580681|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2398775|NCT03580681|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
2398776|NCT03580668||B/F/TAF|Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) therapy in HIV-1 infected adults who initiate B/F/TAF therapy
2398777|NCT03580655|Experimental|Avapritinib|Avapritinib will be administered as an immediate release tablet, orally, continuously, in 28-day cycles
2398778|NCT03580642|Experimental|eHealth Technologies|eHealth Technologies is a messure of diferent paramenters of the patient; heart rate, blood pressure, weight, thermometer, daily activity.
2398779|NCT03580642|No Intervention|Control|Habitual treatment.
2398780|NCT03580629|Experimental|Liver Live Donor Champion|The Liver Live Donor Champion program (LLDC) is the sole educational intervention for this trial. LLDC consists of 2 or 3 monthly sessions (depending on cohort) of approximately 2 or 3 hours each. Each LLDC session is led by a transplant physician or clinical coordinator. The sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LLDC session topics are as follows: 1) education about End-Stage Liver Disease (ESLD), liver transplantation, and living donation 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) surgeon and hepatologist panel 6) Program Recap.
2398782|NCT03580603|Experimental|Antibiotic visualization tool|Provider will answer microbiological sensitivity questions using a new antibiotic visualization tool.
2398783|NCT03580603|No Intervention|Standard practice|Provider will answer microbiological sensitivity questions using standard medical record tools.
2398784|NCT03580590|Experimental|1st group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative
2398785|NCT03580590|Experimental|2nd group|20 patients will receive 90 mg oral Diltiazem 3 hours pre-operative+ 10 mg/kg IV Tranexamic Acid slow infusion with saline half an hour before the induction of anesthesia
2398786|NCT03580590|Placebo Comparator|3rd group|20 patients will receive oral placebo tablet 3 hours pre-operative
2398787|NCT03580577||Cirrhotic with venous thromboembolism|"cirrhotic patients with a venous thromboembolic event (including deep venous thrombosis, pulmonary embolism, acute non-malignant portal vein thrombosis, splenic vein, inferior vena cava thrombosis or mesenteric vascular occlusion).~Each patient will subjected to through history taking and careful examination to detect and risk factors also laboratory work to detect thrombocytopenia, disease severity, coagulation status thrombelastography before starting anticoagulants.~Patients will start treatment with anticoagulants therapy after liaise with the specialized physician.~Protein C, protein S and antithrombin III level will be assessed 3 months after the acute thrombotic event and 1 month of vitamin K antagonist (VKA) withdrawal."
2398788|NCT03580577||Cirrhotic without venous thromboembolism|"cirrhotic patients without any thrombotic events Each patient will subjected to through history taking and careful examination to detect and risk factors.~- Protein C, protein S and antithrombin III level will be assessed at baseline."
2398789|NCT03580564|Experimental|Experimental|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
2398790|NCT03580551|Experimental|Intervention Group|Ten participants from each racial group (Black/White) will be assigned to the Intervention, which will receive the home-based DVD Chair Exercise Program. This is the group that will receive the chair exercise intervention upon enrollment.
2398791|NCT03580551|Active Comparator|Waitlist Control Group|Ten participants from each racial group (Black/White) will be assigned to the Waitlist Control Group, which will receive the home-based DVD Chair Exercise Program at the end of 8 weeks.
2398792|NCT03580538|Experimental|elastic tube group|
2398793|NCT03580525|Experimental|nicotine saline infusion 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
2398794|NCT03580525|Experimental|nicotine infusion 0.24mcg/kg/s|0.24mcg/kg/s The day order will be randomized per day
2398795|NCT03580525|Experimental|nicotine infusion 0.096mcg/kg/s|0.096mcg/kg/s The day order will be randomized per day
2398796|NCT03580525|Experimental|nicotine infusion 0.048mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
2398797|NCT03580525|Experimental|nicotine infusion 0.024mcg/kg/s|0.048mcg/kg/s The day order will be randomized per day
2398798|NCT03580512||Group 1|- 800 existing clients who already received PrEP
2398799|NCT03580512||Group 2|"800 new clients who present for HIV testing and are HIV-negative. All will be offered PrEP~600 clients who will refuse PrEP~200 clients who will receive PrEP"
2398800|NCT03580512||Group 3|- 400 new clients who are HIV-positive or new clients who present for HIV testing and are HIV-positive
2398879|NCT03580057|Experimental|BPI and D|Both interventions.
3143620|NCT00009893|Experimental|gemcitabine + leucovorin + fluorouracil|Patients receive gemcitabine IV over 30 minutes followed by leucovorin calcium IV and fluorouracil IV over 5-10 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 1 year and then every 6 months for 4 years.
2398806|NCT03580460|No Intervention|Waitlist control|After 8 weeks, individuals randomized to this arm receives the computer-delivered smoking cessation counseling intervention
2398807|NCT03580460|Experimental|Computer Delivered Intervention|Individuals receive a 15-20 minute computer delivered smoking cessation counseling intervention
2398808|NCT03580447|Experimental|Citrus extract|During this period participants receive daily citrus extract supplements for four weeks
2398809|NCT03580447|Placebo Comparator|Placebo|During this period participants receive daily maltodextrin supplements for four week
2398810|NCT03580434|Experimental|V-STRUT|V-STRUT implantation
3143621|NCT00009906|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate once daily.
3143622|NCT00009906|Experimental|Arm II (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily.
2398813|NCT03580408|Experimental|Experimental|"Induction treatment :Nivolumab will be given alone at 240 mg flat dose every 2 weeks (i.e. one cycle) Patients will be assessed after 3 months of therapy (after 6 injections of Nivolumab)~Consolidation treatment:~It depends on the induction evaluation by PET-CT and CT-scan (Lugano 2014 criteria) :~For patients achieving CMR according to Lugano Classification : treatment by nivolumab 240 mg every 2 weeks for 9 months.~Patients who reach PMR and NMR after 3 months (according to Lugano Classification) will be treated by the Nivolumab+Vinblastin regimen every 2 weeks for 9 additional months: Vinblastin(6 mg/m2 (IV) + Nivolumab 240 mg (IV)~In case of progressive disease , patients will be considered in treatment failure."
2398814|NCT03580395|Experimental|apatinib+TP|TP neoadjuvant chemotherapy (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3) combined with apatinib (received TP concurrently with apatinib 500mg, day1-21).
2398815|NCT03580395|Sham Comparator|TP|TP neoadjuvant chemotherapy alone (paclitaxel 165mg/m2 day 1, cisplatin 40mg, day 1-3).
3143623|NCT00009919|Experimental|Treatment (semaxanib)|Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues every 6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with CR receive an additional 6 months of therapy after achieving CR.
3143624|NCT00009958|Experimental|Stage I|Patients receive fCEA-TRI vaccine SC once daily on days 1, 29, 57, and 85.
3143625|NCT00009958|Experimental|Stage II|Patients receive vCEA-TRI vaccine intradermally once on day 1 and fCEA-TRI vaccine SC at the MTD determined in stage I once daily on days 29, 57, and 85.
3143626|NCT00009958|Experimental|Stage III|A single cohort of 6-10 patients receive both vaccines as in stage II, at the MTDs determined in stages I and II, and sargramostim (GM-CSF) SC once daily on days 1-4, 29-32, 57-60, and 85-88.
3143627|NCT00009971|Experimental|Arm I|Patients receive oral fenretinide twice daily on days 1-7. Treatment continues every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
3143628|NCT00009984|Experimental|Arm I (thalidomide)|Patients receive oral thalidomide once daily in the absence of disease progression or unacceptable toxicity.
2398827|NCT03580330|Experimental|Intervention Group|
2398828|NCT03580330|No Intervention|Control Group|
2398829|NCT03580317|Experimental|EA + Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including electroacupuncture(EA) treatment and combined with Carbamazepine (0.1g each time, thrice daily). The follow-up period is 6 months.
2398830|NCT03580317|Placebo Comparator|EA + Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including EA treatment and combined with placebo of carbamazepine. The follow-up period is 6 months.
2398831|NCT03580317|Active Comparator|Sham EA+ Carbamazepine Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
2398832|NCT03580317|Sham Comparator|Sham EA+ Placebo Group|The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham EA intervention and combined with placebo took orally. The follow-up period is 6 months.
2398833|NCT03580304|Experimental|industrial-physical-cognitive|
2398834|NCT03580304|Experimental|industrial- cognitive-physical|
2398835|NCT03580304|Experimental|physical- industrial- cognitive|
2398836|NCT03580304|Experimental|physical-cognitive- industrial|
2398837|NCT03580304|Experimental|cognitive- industrial-physical|
2398838|NCT03580304|Experimental|cognitive-physical-industrial|
2398839|NCT03580291|Experimental|Mesenchymal stem cells|"The group receive pulse infusion of MSCs and placebo of oral Mycophenolate Mofetil (MMF). The cells of 2 x 10^6/kg body weight are suspended in 100ml saline and infused intravenously.~Dexamethasone of 10mg is intravenously injected before 30 minutes of cells infusion.~A sterile blood transfusion device is used during the venous transfusion, and it is washed with saline before infusion. Take a slow infusion of about 20 drops per minute in the first 15 minutes. Increase to about 60 drops per minute if the patient had no complaints of discomfort."
2398840|NCT03580291|Active Comparator|Mycophenolate Mofetil|The group receive placebo of MSCs and oral Mycophenolate Mofetil of 2.0g/d. .
2398841|NCT03580278|Experimental|Cohort 1:75 mg ABY-035/AFO2|Cohort 1: 75 mg ABY-035/AFO2, once daily for 14 days
2398842|NCT03580278|Experimental|Cohort 2: 150 mg ABY-035/AFO2|Cohort 2: 150 mg ABY-035/AFO2 once daily for up to 28 days
2398843|NCT03580265|Experimental|Six-sessions of laser acupuncture|Laser acupuncture was given three times a week for 2 weeks.
2398844|NCT03580265|Sham Comparator|Six-sessions of sham laser acupuncture|Sham laser acupuncture was given three times a week for 2 weeks.
2398880|NCT03580057|No Intervention|Control|
2398845|NCT03580252||Preterm Infant Neurological Follow-Up|"Preterm infants <37 weeks' gestational age (GA) at birth admitted to the neonatal nurseries at the Abha Private Hospital in Kingdom of Saudi Arabia. This project aims to recruit 50 infants <37weeks at birth over a 1-year stating from march 2018.~A Correlation analyses for the outcomes with initial regular medical practice of MRI/Ultrasound and Hammersmith assessment."
2398846|NCT03580239|Experimental|Everolimus & Best Supportive Care|Everolimus will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
2398847|NCT03580239|Placebo Comparator|Placebo & Best Supportive Care|Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
2398848|NCT03580226||Good glycemic control|Good glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c < 7.0.
2398849|NCT03580226||Poor glycemic control|Poor glycemic control is defined according to the American Diabetes Association and the Indonesian Association of Endocrinologists (PERKENI) cut off of HbA1c >= 7.0.
2398850|NCT03580213|Experimental|Hand therapy MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living."
2398851|NCT03580213|Experimental|Hand therapy PIPJ affected|"40 participants With Dupuytren's contracture with the proximal interphalangeal joint involved, receiving hand therapy after collagenase injection and extension treatment.~Hand therapy: edema control, wound and scar treatment, splinting, exercises for hand, exercise through activities of daily living. Possible additional splint and exercises specifically for the PIPJ extension."
2398852|NCT03580213|No Intervention|Control group MCPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
2398853|NCT03580213|No Intervention|Control group PIPJ affected|"40 participants With Dupuytren's contracture with only the Metacarpophalangeal joints affected.~No treatment after the collagenase injection and extension treatment."
2398854|NCT03580200|Experimental|Intervention Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
2398855|NCT03580200|No Intervention|Control Side|Each participant is to be randomly assigned an intervention side (side of the body that will receive trigger point dry needling) and a control side (side of the body that will not receive trigger point dry needling).
2398856|NCT03580187|Other|morphine +|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success.~morphine (+) group: good response to morphine in nebulization after 30 min if VAS > than 4 we conclude to morhine (-)"
2398857|NCT03580174|Active Comparator|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed physiotherapy
2398858|NCT03580174|Active Comparator|Routine physiotherapy group|Ten children with CP will receive conventional, traditional physiotherapy
2398866|NCT03580148|Active Comparator|Cortisone|Patients randomized to this arm will receive one (1) ultrasound guided injection of 80mg Depo Medrol cortisone in the glenohumeral joint of the affected shoulder. Procedure time of approximately 10 minutes
2398867|NCT03580148|Active Comparator|Bone Marrow Aspirate|Patients randomized to this arm will receive one (1) ultrasound injection of bone marrow aspirate, harvested from the posterior superior iliac spine, and injected into the glenohumeral joint of the affected shoulder. Procedure time of approximately 45 minutes
2398868|NCT03580135|Experimental|Propolis powder|"resin (50%),~vegetable Balsam, wax~essential aromatic oils (30%)~salivary secretions (10%)~pollen(5%)~other substances (5%) including amino acids~,ethanol vitamin A, B complex, and E, minerals, steroids~ﬂavonoids. The most important pharmacologically active constituents in propolis are ﬂavonoids, which are well-known compounds which have antioxidant, anti-bacterial, antifungal, antiviral, and anti-inﬂammatory properties.~Other ingredients: carob powder (free flow agent). Contains no yeast, salt, sugar, starch, milk, preservatives or colors."
2398869|NCT03580135|Active Comparator|Mineral Tri Oxide|"Consists of calcium oxide and silicon dioxide.When these raw materials are blended, they produce tricalcium silicate, dicalcium silicate, tricalcium aluminate, and tetracalcium aluminoferrite.~A radiopacifier (bismuth oxide) is added to the cement for dental radiological diagnosis."
2398870|NCT03580122|Experimental|Asparten|Asparten (arginine aspartate) 5000mg/10mL 3x/day
2398871|NCT03580109|Active Comparator|Immediate spa treatment|Spa treatment linked with education therapeutic during 18 days just after randomization : common to all of spa resorts
2398872|NCT03580109|Sham Comparator|Late spa treatment|Spa treatment linked with education therapeutic during 18 days 6 months visit after randomization
2398873|NCT03580096|Experimental|Experimental group|Patients were included in a core stability intervention. It will be done with different stages and increasing gradually.
2398874|NCT03580096|Active Comparator|Control group|Standard intervention consisting of exercises aimed at improving balance.
2398877|NCT03580057|Experimental|Breastfeeding promotion intervention (BPI)|
3143629|NCT00009984|Experimental|Arm II (thalidomide, fludarabine phosphate)|Patients receive thalidomide as in arm I and fludarabine IV over 30 minutes on days 1-5. Treatment with fludarabine repeats every 28 days for 6 courses. Once fludarabine is completed, patients continue to receive thalidomide alone as in arm I.
2398883|NCT03580031|Experimental|Study group|HCG IM 10,000 IU Im 48 hours after first triggering dose
2398884|NCT03580031|Placebo Comparator|Control group|Saline 2m Injection im 48 hours after the first triggering dose
2398885|NCT03580018|Experimental|Tranexamic Acid group|Ten mL of TXA (100 mg/mL) was injected into the joint at the end of the index operation and the drain was clamped for 2 h.
2398886|NCT03580018|Placebo Comparator|Control Group|The control group patients only received ACLRs without TXA injections.
2398887|NCT03580005|Active Comparator|Quillichew ERCT|Quillichew ERCT
2398888|NCT03580005|Placebo Comparator|Placebo to match Quillichew ERCT|Placebo to match Quillichew ERCT
2398889|NCT03579992|Experimental|60-minute Isometric|60-min Isometric MyCI training: EMG-controlled game training for 60-minutes per session
2398890|NCT03579992|Experimental|90-minute Isometric|90-min Isometric MyCI training: EMG-controlled game training for 90-minutes per session
2398891|NCT03579992|Experimental|90-minute Movement|90-min movement MyCI training: EMG-controlled game training for 90-minutes per session
2398892|NCT03579979|Experimental|Self control|"During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points."
2398893|NCT03579966|Experimental|amifampridine phosphate|tablets equivalent to 10mg amifampridine, 3 to 4 times per day
2398894|NCT03579953|Experimental|Real cTBS to MPFC|One session of real cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
2398895|NCT03579953|Sham Comparator|Sham cTBS to MPFC|One session of sham cTBS treatment delivered to the medial prefrontal cortex (MPFC) (2 trains of stimulation over the MPFC as defined by EEG coordinates (FP1); each train: 120 sec, 3 pulse bursts presented at 5Hz, 15 pulses/sec, 1800 pulses/train, 60 sec intertrain interval; 110% RMT, MagPro X100 Cool Coil; 3600 pulses total).
2398900|NCT03579927|Experimental|Treatment (CAR transduced CB-NK cells, chemotherapy, ASCT)|Participants receive rituximab IV over 3 hours on days -14 and -8, carmustine IV over 2 hours on day -13, etoposide IV over 3 hours BID on days -12 to -9, cytarabine IV over 1 hour BID on days -12 to -9, melphalan IV over 30 minutes on day -8, CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV over 1 hour on day -5. Participants undergo ASCT on day 0. Beginning day 0, participants receive filgrastim SC QD until evidence of an ANC of 0.5 x 10^9/L per 3 consecutive days.
3143630|NCT00010114||Newly diagnosed embryonal tumors|The participants in this study are infants (< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens
3143631|NCT00010192|Experimental|Treatment (rituximab and aldesleukin)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients then receive low-dose aldesleukin SC on days 29-39, 43-53, 57-67, and 71-81, and intermediate-dose aldesleukin SC on days 40-42, 54-56, 68-70, and 82-84.
2398905|NCT03579901|Other|Primary Breast Augmentation|Subjects age 22 and over, indicated to increase breast size
2398906|NCT03579901|Other|Primary Breast Reconstruction|Surgery to replace breast tissue that has been removed due to cancer, prophylactic mastectomy, breast trauma or that has failed to develop properly due to a severe breast anomaly.
2398907|NCT03579901|Other|Revision Augmentation|Revision surgery to correct or improve the results of a previous breast augmentation
2398908|NCT03579901|Other|Revision Reconstruction|Revision surgery to correct or improve the results of a previous breast reconstruction.
2398909|NCT03579888|Experimental|Treatment (fludarabine, cyclophosphamide, CD19 T cell)|"CHEMOTHERAPY: Patients receive fludarabine IV over 1 hour and cyclophosphamide IV over 3 hours on days -5, -4, and -3 in the absence of disease progression or unacceptable toxicity.~T-CELL INFUSION: Patients receive autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T cells IV over 15-30 minutes on day 0."
2398910|NCT03579875|Experimental|Treatment Plan 1: TBI 300 with Thymic Shielding, CY, FLU, MP|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type OR~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia"
2398911|NCT03579875|Experimental|Treatment Plan 2: CY, FLU and MP|"Given to:~• HLA-identical sibling donor recipients with aplastic anemia"
2398912|NCT03579875|Experimental|Treatment Plan 3: BU, Cy, FLU, MP and Rituximab|"Given to:~Patients with an unrelated donor or HLA mismatched related donor, regardless of disease type who cannot tolerate TBI~Patients with an HLA- identical sibling donor recipient and MDS or acute leukemia who cannot tolerate TBI~Per treating physician preference"
2398913|NCT03579862||Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|
2398914|NCT03579862||Pulmonary Embolism (PE)|
2398915|NCT03579862||Pulmonary Arterial Hypertension (PAH)|
2398916|NCT03579849|Experimental|Perfusion SPECT|"Included patients with a diagnosis of acute PE on CTPA and who had a subtraction iodine mapping CT will undergo a SPECT/CT within 24 hours.~Each lung subtraction iodine mapping CT will be interpreted blindly by 3 radiologists. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.~Each perfusion SPECT will be interpreted blindly by 3 nuclear medicine physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused."
2398917|NCT03579836|Experimental|Phase I-1 (#4 Cohort)|BEY1107 monotherapy, 4 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
2398918|NCT03579836|Experimental|Phase I-2 (#3 Cohort)|BEY1107 in combination with Gemcitabine, 3 Cohorts, 4 weeks (administered on a 3-week-on and 1-week-off)
2398919|NCT03579836|Experimental|Phase II (#1 Cohort)|BEY1107 in combination with Gemcitabine, 6 Cycles / 24 weeks (administered on a 3-week-on and 1-week-off)
2398920|NCT03579823|Experimental|AVT02 100 MG/ML|Single subcutaneous injection of 40 mg of AVT02 (100MG/ML)
2398921|NCT03579823|Active Comparator|Adalimumab 100 MG/ML [HUMIRA]|Single subcutaneous injection of 40 mg of Adalimumab (100MG/ML) [HUMIRA]
2398922|NCT03579810|Experimental|Investigational|"An education intervention was implemented in 5 schools including 516 children, 360 parents and 240 teachers.~The Pedagogical Intervention last two and a half years. In children, the intervention included class activities (1/week) and the use of educational materials for the development of pedagogical activities (posters and educative guide).~In parents included 3 workshops/year (2 hours each) about the areas of the intervention; sending healthy notes (1/month) and celebration of healthy family day (1/year).~In teachers included 3 workshops/year (2 hours each) about the areas of the intervention; planning and realization of pedagogical activities to develop with the students (1/week) and follow-up visits to school (1/month)."
2398923|NCT03579810|Active Comparator|Control|"The control group consisted of 4 schools including 354 children, 305 parents and 110 teachers.~The activities in control group last two and a half years. Children received the standard curriculum in health and physical activity of the national Ministry of Education.~In parents and teachers included 3 workshops/year (2 hours each) about the first aid and accident prevention."
2398924|NCT03579784|Experimental|Durvalumab+Olaparib+Paclitaxel|"st cycle : Paclitaxel+Olaparib~Olaparib 150mg bid on D1-28~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15~nd cycle and thereafter: Durvalumab+Olaparib+Paclitaxel :~Olaparib 150mg bid on D1-28~Durvalumab 1.5 g iv on D1~Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks~During first 4 weeks, palictaxel/olaparib dual combination will be used. Since 2nd cycle, palictaxel/olaparib/Durvalumab combination will be used."
2398925|NCT03579771|Experimental|Gemcitabine, cisplatin, nab-paclitaxel|Participants receive nab-paclitaxel IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants with stable disease (SD), partial response (PR), or complete response (CR) then undergo standard of care hepatectomy with portal lymphadenectomy.
2398926|NCT03579758|Active Comparator|Arm I (capecitabine)|Participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2398927|NCT03579758|Experimental|Arm II (chemotherapy, capecitabine)|Participants receive cisplatin IV over 1 hour and gemcitabine IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Within 10 weeks of chemotherapy, participants undergo re-resection (including partial liver resection and portal lymph node dissection). Participants then receive capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2398928|NCT03579745|Active Comparator|Conventional lingual mechanics|
2398929|NCT03579745|Experimental|Lever arm lingual mechanics|
2398930|NCT03579732||Long-term users|Adults using low-dose aspirin for > 3 years
2398931|NCT03579732||Episodic users|Adults using low-dose aspirin inconsistently, or consistently but < 3 years
2398932|NCT03579732||Former users|Subset of adult Episodic users of aspirin who discontinued the drug for at least 1 year before case/ control date
2398933|NCT03579732||Non-consumers|Adults who did not use low-dose aspirin
3189049|NCT00773695|Experimental|Chemotherapy and Bevacizumab|Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.
2398935|NCT03579706|Experimental|Intervention|The intervention condition will involve participants completing baseline measures, the Cognitive Anxiety Sensitivity Treatment, post measures, and a 4 month follow up assessment.
2398936|NCT03579706|Placebo Comparator|Control|The control condition will involve participants completing baseline measures, the Physical Health Education Training, post measures, and a 4 month follow up assessment.
3143632|NCT00010205|Experimental|Treatment (benzoylphenylurea)|Patients receive oral benzoylphenylurea weekly for 6 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of benzoylphenylurea until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity.
2398940|NCT03579680||Providers|Urologists and other providers who have experience caring for more than 10 prostate cancer patients on ADT and express interest in prostate cancer care for prostate cancer will be eligible to participate. Providers will engage in a 30-45 minute interview to identify key preferences and de-implementation barriers, as well as facilitators, for reducing low value ADT as prostate cancer (PC) treatment.
2398941|NCT03579680||Patients|Patients receiving ADT as primary prostate cancer treatment will engage in a 30-45 minute interview regarding to better understand patient perspectives into not initiating or stopping castration with ADT
2398942|NCT03579680||cRCT Facility|We will conduct a 6-month cluster randomized clinical trial of Or vs. Sc de-implementation strategies across 40 facilities with high rates of low value ADT.
2398945|NCT03579654|Experimental|Arm 1 - Proscavax vaccine treatment|In this arm, during the first 4 months of induction treatment, 6 doses of the Proscavax vaccine will be administered intradermally at weeks 1, 2, 3, 7, 11, and 15, followed by maintenance booster injections once every month which will alternate between low dose IL-2 alone (at weeks 19, 27 and 35) and Proscavax vaccine (at weeks 23, 31, 39) for 6 months.
2398946|NCT03579654|No Intervention|Arm 2 - Active Surveillance|In this arm, patients will undergo active surveillance and will not receive any Proscavax vaccine treatment.
2398947|NCT03579641||Implantable Cardiac device with HeartLogic feature|Patients with Heart Failure, implanted with Boston Scientific Implantable Cardioverter Defibrillator or Defibrillator with Cardiac Resynchronization device with HeartLogic feature
2398948|NCT03579628|Experimental|AsiDNA|"Part A: AsiDNA as a single agent:~The study will follow a dose escalation 3 + 3 cohort design (with 6 dose levels).~All patients will receive a loading dose of AsiDNA for 3 consecutive days as iv infusion at Day 1 (D1), Day 2 (D2) and Day 3 (D3), followed by iv infusion once a week (at D8 and D15 of a 21 days treatment period (1 cycle = 21 days). Each subsequent cycle will be administered on a weekly basis (D1, D8, D15) of a 21 days treatment period.~Part B: AsiDNA combination with Carboplatin with or without Paclitaxel (Background treatments):~Part B1: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5.~Part B2: Combination cohort of AsiDNA at DL3 (600mg) with Carboplatin AUC 5 and weekly Paclitaxel: 80 mg/m2 (full dose)."
2398951|NCT03579602|Active Comparator|Arm 1 (no tozuleristide)|Subjects randomized to Arm 1 (~9% of subjects) will not receive tozuleristide but will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
2398952|NCT03579602|Experimental|Arm 2 (tozuleristide treated)|Subjects randomized to Arm 2 (~ 91% of subjects) will be administered tozuleristide at a dose of 15 mg/m^2 at least 1 hour and no more than 36 hours prior to surgery. They will undergo standard of care neurosurgery and will have imaging performed with the Canvas System.
2398953|NCT03579589|Active Comparator|Sugammadex|"If spontaneous recovery has reached second twitch after TOF: 2 mg/kg~If spontaneous recovery has reached between 1-2 post-tetanic counts but no twitch responses to TOF: 4 mg/kg~When there is a clinical need to reverse NMB within 3 min of a single dose of rocuronium (1.2 mg/kg): 16 mg/kg"
2398954|NCT03579589|Active Comparator|Neostigmine|50 µg. Kg-1 will be administered after spontaneous recovery has reached fourth twitch after TOF in accordance with our institutional standard procedures and published literature.
2398955|NCT03579576||HCV infected patients|All participants found HCV infected with or without HIV will be initiated treatment and followed up until 24 weeks ( 12 weeks after treatment)
2398956|NCT03579563|Active Comparator|AUD (audiologist-based)|In this group, the audiologist-based fitting will be used to provide hearing aids.
2398957|NCT03579563|Experimental|OTC (over-the-counter)|In this group, the over-the-counter fitting will be used to provide hearing aids.
2398958|NCT03579563|Experimental|OTC-Plus|In this group, the hybrid fitting will be used to provide hearing aids.
2398959|NCT03579550|Active Comparator|Intervention arm: Hysterocopy group|Office hyteroscopic metroplasty will be performed. After oparetion 9 months spontaneous conception Intervention arm for hysteroscopy group
2398960|NCT03579550|No Intervention|Spontaneous cycles plus COH/IUI|Six months spontaneous coitus cycles plus 3 cycles of Clomiphene citrate and intrauterine insemination (COH/IUI)
2398961|NCT03579537|Experimental|Hemodyalisis patients|group of patients in hemodialysis who performs the exercise program
2398962|NCT03579524|Active Comparator|ESPB group|Erector Spinae Plane Block administered group
2398963|NCT03579524|Active Comparator|SAPB group|Serratus Anterior Plane Block administered group
2398964|NCT03579498||Patient group|Patients who have suffered a cardiac arrest at Uppsala University Hospital or who were admitted to this hospital after the event.
2398965|NCT03579498||Control group|The control group will, as far as it is possible, match the patient group regarding mean age, age distribution, sex and educational attainments.
2398966|NCT03579485||aging HIV positive patients|HIV-1 infected patients, aged ≥ 60 years old, naive patients receiving raltegravir based-regimen, including Nuc-sparing regimens or experienced patients with virological suppression (HIV-1 RNA<50 copies) who had switched from any antiretroviral drug to raltegravir-based regimens (including Nuc-sparing regimens) because of toxicity, convenience or other reasons.
2398967|NCT03579472|Experimental|Treatment (bintrafusp alfa, eribulin mesylate)|Patients receive bintrafusp alfa IV over 50-80 minutes on days 1, 15, and 29, and eribulin mesylate IV over 2-5 minutes on days 1, 8, 22, and 29. Treatment repeats every 42 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2398968|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 1|
2398969|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 2|
2398970|NCT03579459|Active Comparator|Clostridium difficile vaccine Lot 3|
2398971|NCT03579459|Placebo Comparator|Placebo|Normal saline solution (0.9% sodium chloride)
3143633|NCT00010218|Experimental|karenitecin|"Patients receive karenitecin IV over 60 minutes on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 6 courses may receive 2 additional courses beyond best response.~Patients are followed every 3 months for 1 year and then every 6 months thereafter."
2398975|NCT03579420|Experimental|Brief lifestyle program|3-session lifestyle group intervention program focussed on physical activity and eating habits, using interactive methods and a behavioral approach
3143634|NCT00010335|Experimental|1|Participants will receive a stem cell transplant.
3143635|NCT00010608|Experimental|Transcendental Meditation program|A mental technique for stress reduction which is natural, easy and effortless and is practiced sitting in a chair with eyes closed for 20 minutes twice a day.
3143636|NCT00010608|Active Comparator|Health Education|A lifestyle modification program for improving diet, exercise, salt intake and substance use.
2398976|NCT03579420|Active Comparator|Traditional lifestyle longer program|6-session lifestyle group intervention program focussed on physical activity and eating habits, using traditional lessons and interactive methods
2398977|NCT03579407|Active Comparator|Traditional Open Ended Trocar|Patients will undergo bone marrow aspiration using the Jamshidi bone marrow aspiration needle. This needle is the traditional trocar with an open end. 50-60 mL will be collected and concentrated with a centrifuge.
2398978|NCT03579407|Experimental|Fenestrated Blunt Trocar|Patients will undergo bone marrow aspiration using the Marrow Cellution bone marrow aspiration needle. This needle has several fenestrations along the trocar through which the bone marrow is aspirated. Approximately 8-10 mL of high concentrate bone marrow will be collected, which will not be concentrated.
2398981|NCT03579381||Immune Controllers|Patients with very low or undetectable levels of viremia without treatment
2398982|NCT03579381||Acute Infection|Early infection, i.e. within 2 weeks of infection
2398983|NCT03579368|Other|Symfony Implantation|Patients undergoing bilateral IOL implantation with the Tecnis Symfony Extended Range of Vision IOL at a single surgical site
2398984|NCT03579355|Experimental|DFND Program|"Dentist Fighting Nicotine Dependence, (DFND) intervention program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills. DFND was administered over 5 weeks, at a rate of 2 sessions per week. Each session lasts an hour. Fourteen classrooms in four schools represented the experimental arm and received DFND."
2398985|NCT03579355|No Intervention|Informational Booklet|Fourteen classrooms in four schools represented the No Intervention arm (control). They received only an informational booklet about tobacco adverse health effects.
2398986|NCT03579342|Experimental|App technology and coaching|Participants in the intervention group with app technology and coaching participate in a first meeting with the coach and will thereafter receive active support from the coach every 4 weeks for the duration of the intervention.
2398987|NCT03579342|Experimental|App technology only|Participants in the intervention group with only app technology participate in a first meeting with the coach but do not get any additional support during follow-up.
2398988|NCT03579342|No Intervention|Control group|Participants in the control group participate in baseline assessments. The control group will get access to the app and will have a meeting with a coach after 12 weeks of follow-up.
2398989|NCT03579316|Active Comparator|Arm I (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2398990|NCT03579316|Experimental|Arm II (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-21 and adavosertib PO QD on days 1-3 and 8-10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2398991|NCT03579303|Active Comparator|Homoeopathic remedies in PCOS|Homoeopathic treatment for menstrual disorders in females with PCOS
2398992|NCT03579303|Active Comparator|Homoeopathic remedies and yoga in PCOS|Homoeopathic treatment integrated with yoga therapy for menstrual disorders in females with PCOS
3184497|NCT00725244|Active Comparator|1|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
2398994|NCT03579277|Active Comparator|Radial forearm free flap|Subjects in this arm will receive a radial forearm free flap.
2398995|NCT03579277|Active Comparator|Ulnar forearm free flap|Subjects in this arm will receive an ulnar forearm free flap.
2398996|NCT03579264|No Intervention|Standard Arm|No use of My Viva Plan.
2398997|NCT03579264|Experimental|Intervention Arm|Use of My Viva Plan.
2398998|NCT03579251|Other|Pilot test|12 weeks of behavioral intervention (Black Men's Care), including an in-person session and two-way SMS, with a three-month follow-up period post-intervention.
2398999|NCT03579238|No Intervention|Distant|The clinician sits quietly 3 feet away from participant who is lying on a soft table at rest.This position is held for 5 minutes without moving.
2399000|NCT03579238|No Intervention|close|The clinician sits at the head of the table with his arms on the table alongside the participant's head but not touching the resting patient who is lying at rest on the table. This position is held for 5 minutes without moving.
2399001|NCT03579238|Sham Comparator|touching|"The clinician lifts the patient's head passively off the table in order to place his hands underneath the participant's head, palms facing upwards and in contact with the back of the head of the participant. The participant's head is gently lowered to rest upon the clinician's hands. No external force is provided by the clinician upon the participant's head as the head rests in the clinician's palms on the table. This position is held for 5 minutes without moving. This is called a touching intervention and is meant to be a sham. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
2399002|NCT03579238|Experimental|Occipital motion inhibition|"The clinician gently inhibits motion of the participant's occiput into flexion phase of the primary respiratory mechanism, and allows extension phase only. Upon sensing a still point, where no further flexion motion is palpated, the clinician will state to the research assistant now to indicate he feels a still point. This position is held for 5 minutes without moving. This is called a CV4 or modified CV4 intervention. A five minute rest period follows in which the clinician removes his hands from underneath the participant's head and places them next to the patient on the table, but not in contact with the patient."
2399003|NCT03579225||MATRx plus test|
2399004|NCT03579199|Experimental|exploration of abdominal cavity using a NIR/ICG camera|
2399005|NCT03579186|Experimental|Gait|Patients undergoing a routine clinical gait assessment at the Brain Fit Club at BIDMC will have their posture and gait measured before and during optokinetic stimulation (OKS).
2399230|NCT03577509|Experimental|ABCD|Group1: 0.5mg/kg Group2: 1.0mg/kg Group3: 1.5mg/kg
2399006|NCT03579173||Nutrition and Infant PFT|To examine the relationship between nutritional status (weight-for-age (WFA) and weight-for-length (WFL)) at 6 months of age and lung function at 1-2 years of age in infants with CF.
2399007|NCT03579173||Nutrition and Lung Clearance Index|To examine the relationship between nutritional status (WFA and WFL) in infants with CF at 12 months of age and the lung clearance index (LCI) at 3-5 years of age.
2399008|NCT03579173||Passive Tidal Breathing and Infant PFT|To delineate the relationship between passive tidal breathing lung function testing in infants with CF at 4-8 weeks of age and subsequent lung function at 6-12 months of age.
2399009|NCT03579160|Experimental|0.25% Timolol gel applied to full-thickness skin graft|"During surgery: application of 0.25% timolol gel (2 drops per cm2) on wound bed before FTSG is placed~During surgery: application of 0.25% timolol gel (2 drops per cm2) over FTSG after insetting of the graft~After bolster removal (7 days): daily cleansing and daily 0.25% timolol (2 drops per cm2) application for 4 weeks"
2399010|NCT03579160|Active Comparator|Standard of Care dressings|"FTSG surgery as per SOC~After bolster removal (7 days): daily cleansing and daily Vaseline application for 4 weeks"
2399011|NCT03579147|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
2399012|NCT03579134|Experimental|partial overlay denture|removable partial denture with a metal extension over the remaining posterior teeth raising their height to the newly proposed vertical dimension and occlusal plane
2399013|NCT03579134|Active Comparator|fixed temporary crowns|fixed crowns made from temporary material placed on the prepared posterior teeth to the new occlusal plane level elevating the vertical dimension to the newly proposed level
2399014|NCT03579121|Experimental|Pharmacogenomic (PGx) guided|Subjects will have Pharmacogenomic (PGx) testing preoperatively. The pharmacists will review results and make recommendations to the anesthesia and orthopedic teams for perioperative anesthesia and analgesia. The teams will use this information to drive clinical decisions as they see fit.
2399015|NCT03579121|Active Comparator|Control|Subjects will undergo Pharmacogenomic (PGx) preoperatively but the results will be sealed until completion of treatment and clinicians will not have access to this information. These patients will undergo standard treatment dosing and medication selection.
2399016|NCT03579095|Experimental|American ginseng|200mg Cereboost and Maltodextrin
2399017|NCT03579095|Placebo Comparator|Placebo|Placebo
2399018|NCT03579082|Experimental|Arm A|"R±DHAP + decitabine:~decitabine:10mg/d,ivgtt,d(-5)-(-1);R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle."
2399019|NCT03579082|No Intervention|Arm B|R±DHAP:rituximab,375mg/m2,d0,ivgtt;cytarabine,2g/m2,q12h,d2,ivgtt;cisplatin,100mg/m2,used for 3 days,ivgtt;dexamethasone,40mg,d1-4,ivgtt/po.21 days for one cycle.
2399020|NCT03579069||Ductus venosus Doppler realized|Ductus venosus Doppler realized
2399021|NCT03579069||Ductus venosus Doppler unrealized|Ductus venosus Doppler unrealized
2399022|NCT03579043|Experimental|Nutritive Sweetener|Participants will consume 36 ounces of Coke daily for three consecutive days.
2399023|NCT03579043|Experimental|Non-Nutritive Sweetener|Participants will consume 36 ounces of Diet Coke daily for three consecutive days.
2399024|NCT03579043|Experimental|Carbonated Water|Participants will consume 36 ounces of carbonated water daily for three consecutive days.
2399025|NCT03579030|Experimental|Single Dose of RTA 1701 or Placebo|"RTA 1701 capsules or placebo taken orally in a single dose.~Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo"
2399026|NCT03579030|Experimental|Multiple Dose of RTA 1701 or Placebo|"RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks.~Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo"
2399027|NCT03579017||Patients with ALS|Patients with ALS will be tested by two independent testers with the ECAS-N at 4 months (baseline) and 8 months (follow-up), and the MoCA at 4 months (baseline) by one tester
2399028|NCT03579017||Healthy controls|Persons with no cognitive impairment will be tested with the ECAS-N once, by one tester
2399029|NCT03579017||Controls with dementia|Persons with cognitive impairment due to other disorders will be tested with the ECAS-N once, by one tester
2399030|NCT03579004|Experimental|Trimodality approach|"2 cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/м2 iv day 1, cisplatin 75 mg/м2 iv day 1, fluorouracil 750 mg/m2/day continuous infusion, day 1-4 every 3 weeks). 3-4 weeks later - preoperative chemoradiotherapy (paclitaxel 50 mg/m2 + cisplatin 20 mg/m2 weekly + radiotherapy 44 Gray (Gy) for 4 weeks).~4-6 weeks after completion of chemoradiation patients undergo Ivor Lewis esophagogastrectomy."
2399031|NCT03578991|No Intervention|Arm 1|"Control group - Treatment as usual:~Type 2 diabetic patients with mild cognitive impairment who will receive the standard clinical treatment recommended by their primary care physician/endocrinologist."
2399032|NCT03578991|Experimental|Arm 2|"Intervention - Smart pillbox:~Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox."
2399033|NCT03578991|Experimental|Arm 3|"Intervention - Smart pillbox & Interactive digital platform:~Description: Type 2 diabetic patients with mild cognitive impairment receiving the standard clinical treatment recommended by their primary care physician/endocrinologist, plus the use of a smart pillbox and an interactive digital platform."
2399034|NCT03578978||Neonates with suspected LONS and/or NEC|A group of 150 neonates with suspected LONS and/or NEC will be recruited. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
2399035|NCT03578978||Healthy neonates|A group of 50 neonates who are clinically well, admitted to the NICU for reasons other than neonatal sepsis or NEC will be recruited into the study to explore the kinetics and concentrations of the panel of biomarkers in healthy subjects comparing to subjects with suspected LONS/NEC. No intervention will be given to the subjects. Blood sampling will be obtained from subjects at 4 time points (Hour 0, 24, 48 and 72) for analysis of the sepsis biomarkers of interest.
3143637|NCT00011037|Experimental|1|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 and Months 3 and 6
3143638|NCT00011037|Experimental|2|Participants will receive ALVAC-HIV vCP1452 at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
2399038|NCT03578952|Experimental|Pure AR|Patients with symptomatic severe aortic valve regurgitation without severe aortic stenosis requiring aortic valve replacement.
3189050|NCT00773695|Active Comparator|Endocrine Therapy|Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.
3189051|NCT00773695|Experimental|Endocrine Therapy and Bevacizumab|Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.
2399041|NCT03578913|Active Comparator|porcelain fused to metal crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
2399042|NCT03578913|Experimental|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading
2399043|NCT03578900|Experimental|Xeros Group - Lozenge|"Application of Xeros system for 15 days. Lozenge (Malic acid 28.56 mg, Xylitol 421,98 mg, Sodium fluoride 0.55 mg) or Spray (Malic acid 1%, Xylitol 10%, Sodium fluoride 0.05%) 4 times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of lozenge on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a ph electrode at predetermined times during a 20 minute period."
2399044|NCT03578900|Active Comparator|Mouthwash group|"Application of citric acid based Mouthwash (0,33% citric acid) for 15 days four times a day. Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires.~Effects of mouthwash on hyposalivation and pH variation determined by saliva collection with pre-weighed falcon and a pH electrode at predetermined times during a 20 minute period."
2399045|NCT03578900|Experimental|Xeros Group - Mouthwash|"Application of Xeros system for 15 days. Mouthwash (Betaine 1.33%, Xylitol 3.30%, Sodium fluoride 0.05%, Allantoin 0.10%) 2 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2399046|NCT03578900|Experimental|Xeros Group - Gel|"Application of Xeros system for 15 days. Gel (Betaine 1%, Aloe Vera 0.05%, Xylitol 10%, Sodium Fluoride 0.0033%) before bed.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2399047|NCT03578900|Experimental|Xeros Group - Toothpaste|"Application of Xeros system for 15 days. Toothpaste (Betaine 4%, Xylitol 10%, Sodium Fluoride 0.33%, Allantoin 0.10%) 3 times a day.~Effects on Xerostomia and Quality of Life were determined before and after application by answering the questionnaires."
2399048|NCT03578887|Active Comparator|Lifestyle Cohort|Participants Undergoing Behavioral Weight Loss Program
2399049|NCT03578887|Active Comparator|Surgical Cohort|Participants Scheduled for Roux-en-Y Gastric Bypass Surgery
2399050|NCT03578887|No Intervention|Healthy Weight Control Cohort|Healthy Weight Controls With No Intervention
2399051|NCT03578874|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
2399052|NCT03578861|Experimental|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
2399053|NCT03578848|Active Comparator|uAOBP & Home BP|On the scheduled visits, the uAOBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
2399054|NCT03578848|Experimental|CBP & Home BP|On the scheduled visits, the CBP and Home BP will be measured before meeting doctors and provided for clinicians to adjust patients' medication according to practice guideline.
2399055|NCT03578835||Multi-center BSI cohort|Patients from six German study centers suffering from bloodstream infection caused by specific target organisms.
2399056|NCT03578822|Experimental|Group A|Recombinant human urokinase(rhPro-UK) and Aspirin simulation agent
2399057|NCT03578822|Other|Group B|rhPro-UK simulation agent and Aspirn
2399058|NCT03578809|Experimental|Cohort A|MEDI6012
2399059|NCT03578809|Experimental|Cohort B|MEDI6012
2399060|NCT03578809|Placebo Comparator|Placebo|
2399061|NCT03578796||Persons with ALS|Persons With possible ALS-specific cognitive impairment will be tested With ECAS-N, MoCA, CDR and a questionnaire at 4 months (baseline) and 8 months (1. follow-up). Further evaluation will be with the questionnaire and CDR at each follow-up until 3 years or use of permanent ventilation support or Death. Information about use of advanced life-prolonging therapy will be collected from patient journal.
2399062|NCT03578783|Experimental|PSD502|PSD502 spray contains a eutectic-like mixture of lidocaine and prilocaine, and a propellant (norflurane) which also serves as a solvent. Each spray contains 7.5 mg lidocaine and 2.5 mg prilocaine. A single dose consists of 3 sprays applied to the glans penis.
2399063|NCT03578783|Placebo Comparator|Placebo|The placebo is a metered dose spray, identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine (instead it contains PEG600 and Povidone).
2399064|NCT03578757|Experimental|intervention group|stress management program and the same usual practice (restrictive diet, physical activity and thermal spa treatment)
2400918|NCT03566134|Experimental|DA-8010 2.5mg|DA-8010 2.5mg + Solifenacin succinate placebo
3189052|NCT00773708|Experimental|1|intensify their triple-drug therapy with Raltegravir (RAL)
2399065|NCT03578757|Active Comparator|usual practice group|Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders
2399066|NCT03578744|Experimental|Interventional|Group A patients will be treated with conventional flap surgery. The furcation defects will be debrided and autologous platelet-rich fibrin will be paced as a graft and membrane. Later the flap will be sutured.
2399067|NCT03578744|Experimental|Interventional Comparator|Group B patients will be treated with conventional flap surgery. The furcation defects will be debrided and Hyaluronic acid (Gengigel) will be placed as a graft. Amniotic membrane (Tata Memorial Hospital Mumbai) will be placed over the graft and later the flap will be sutured.
2399068|NCT03578731||Consilium-APP|Patients with oncological, medical treatment for breast cancer, colon cancer, prostate cancer, lung cancer or hematological malignancies.
2399069|NCT03578692||Surgery group|The protocol for patients assigned to surgery group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed bad response to medicine (glucocorticoid for 5 days and rescue therapy for 3 days) were recommended and classified in the surgery group. Their baseline manifestations were collected and compared with the medical group, to exploit the baseline indicators with great sensitive and specificity predicting the high risk for surgery.
2399070|NCT03578692||Medical group|The protocol for patients assigned to medical group was as follows. ASUC patients were admitted in, estimated their baseline situations and tested their blood and fecal indicators including PCT, IL-6 and FC on admission. All patients were treated according to the ECCO guideline 2012. Patients who showed response to medicine (glucocorticoid for 5 days or rescue therapy for 3 days) were classified in the medical group. Their baseline manifestations were collected and compared with the surgery group.
2399071|NCT03578679|Experimental|HEGOR/AZICUR shampoo solution|At D1, shampoo AZICUR liquid formulation in infested persons aged 0 to 6 years and / or less than 15 kg, also apply the combination HEGOR / AZICUR solution shampoo in women pregnant or lactating women not eligible for treatment with Ivermectin, to prevent them from contaminate treated participants who are very close to them or share the same bed or same bench table at school.
2399072|NCT03578666|Experimental|Massage Group|Recreational active runners recruited from local running clubs (n= 16) will receive 40 minutes of massage therapy.
2399073|NCT03578666|Experimental|Cold water immersion group|Recreational active runners recruited from local running clubs(n= 16) will immerse for 10 minutes in a cold water bath
2399074|NCT03578666|No Intervention|Control group|Recreational active runners recruited from local running clubs will rest passively in a sitting position for 30-min period
2399075|NCT03578653|Experimental|Merging Yoga and Occupational Therapy for Parkinson disease|The group participates in three assessment periods: August, October, and December. Then in October-December the group will receive group occupational therapy and recommended community adaptive yoga programming 2x/week for 8 weeks.
2399076|NCT03578640|Experimental|Treatment arm|Elbasvir, Grazoprevir 50-100Mg Oral Tablet
2399077|NCT03578627|No Intervention|Assessment-only|
2399078|NCT03578627|Experimental|Intervention|
2399079|NCT03578614|No Intervention|Control Group|There is no intervention for Control Group
2399080|NCT03578614|Experimental|Intervention Group|Intervention Group will be submitted to three physical activity sessions (two supervised and one nonsupervised) conducted over 6 months
2399081|NCT03578601||Thyroid surgery|Patient undergoing thyroid surgery
2399082|NCT03578588|Experimental|Banapenem B1 group|Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
2399083|NCT03578588|Experimental|Banapenem B2group|Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
2399084|NCT03578588|Experimental|Banapenem B3group|Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
2399085|NCT03578588|Experimental|Banapenem C1group|250mg Once daily for 7 consecutive days
2399086|NCT03578588|Experimental|Banapenem C2group|500mg Once daily for 7 consecutive days
2399087|NCT03578575|Experimental|Danggui Buxue Tang group|Use Danggui Buxue Tang 5g/time, 3 times a day, for 12 weeks.
2399088|NCT03578575|Placebo Comparator|Placebo group|Use Placebo 5g/time, 3 times a day, for 12 weeks.
2399089|NCT03578562|Experimental|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
3189053|NCT00773708|No Intervention|2|Continue with the same antiretroviral therapy
2399091|NCT03578536|Experimental|CIT with Recovery Rapids|"This project will develop a therapeutic model that promotes use of the impaired arm and hand. Researchers often call this type of therapy constraint induced therapy. In this study, participants focus on using the impaired limb rather than the unaffected limb. Study participants will only be able to play the game using the impaired limb.~A small group of patients will participate in a question and answer session about preferences for activities which make up transfer tasks. Patients will also receive automated reminders to use the impaired arm throughout the day. Twelve (12) Veterans will be recruited annually from the inpatient Stroke Specialty Program. Six (6) patients will be assigned to the Treatment group and receive the intervention. The remaining six (6) will receive the current standard of care. Outcome measures will include motor function tests that evaluate upper extremity function."
2399129|NCT03578276|Active Comparator|LessDrops|Compounded eye drop containing Gatifloxacin (antibiotic), bromfenac (non-steroidal anti-inflammatory), and prednisolone acetate 1% used three times a day (TID) starting 1 day prior to surgery and continuing after surgery for 2 weeks then twice a day for a week and once a day for another week.
2399130|NCT03578276|Active Comparator|Standard of Care|"Gatifoxacin 0.5%, 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.~Bromfenac 0.07%: 1 drop QD starting 3 days before surgery, continue QD for 4 weeks after surgery and then discontinue.~Prednisolone acetate 1% will be started after surgery QID for 2 weeks, tapered to BID for 2 weeks, and then discontinue."
3189054|NCT00773721|Experimental|1|Volunteers who are currently using CPAP treatment will trial a new mask system for up to five weeks
3189055|NCT00773760||dosing|
3189056|NCT00773799||rehabilitation center's hospitalized patients|
3189057|NCT00773812|Experimental|Active Mecamylamine|There will be 12 children in this arm. These children will receive the active medication (mecamylamine).
2399092|NCT03578536|No Intervention|Standard of Care|As part of standard care, participants will receive a minimum of daily OT, PT and Speech for a total of three hours. Current occupational therapy intervention options for inpatient stroke rehab patients with UE neuromotor impairments include active assisted range of motion exercise, morning bedside ADL sessions, high-repetition task-specific training, mirror therapy, Digi-flex, theraputty, theraband, free weights, weighted therapy bars for strengthening exercises in clinic and use with home exercise programs (HEP). Additional tools used as determined by therapist include FES modalities to assist with upper extremity neuromotor re-education, unweighted reaching tasks via the ArmeoSpring, and functional work task training/strengthening. They also participate in recreation therapy as appropriate.
2399093|NCT03578523||Chronic Kidney Disease|"CKD stage 3-4 eGFR 59-20mls/min/1.73 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
2399094|NCT03578523||Acute Kidney Injury|"AKI stage 2-3 '3 Tesla multiparametric MR: Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion).~Each patient will have 3 renal MRI scans. Iohexol clearance test: Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel.~renal histopathology scoring: Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication) urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis.~Iohexol clearance to measure GFR within 1 week of the scan session"
2399095|NCT03578510|Active Comparator|SHD|Standard hemodialysis
2399096|NCT03578510|Experimental|HHD|Hemocontrol hemodialysis
2399097|NCT03578497|Experimental|IL-1 receptor antagonist Anakinra 100 mg|Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
2399098|NCT03578484||Volunteer female subjects|Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
2399099|NCT03578471|Active Comparator|Hearing Aid without NR and BF|Hearing Aid without Noise Reduction (NR) or beam forming (BF) enabled serves as reference condition.
2399100|NCT03578471|Experimental|Hearing Aid with NR|Hearing Aid with Noise Reduction (NR) enabled.
2399101|NCT03578471|Experimental|Hearing Aid with BF|Hearing Aid with beam forming (BF) enabled.
2399102|NCT03578458|Other|US Healthy diet|Subjects will install a mobile app for use and will be randomly assigned to a healthy diet.
2399103|NCT03578458|Other|Vegetarian diet|Subjects will install a mobile app for use and will be randomly assigned to a vegetarian diet.
2399104|NCT03578458|Other|Mediterranean diet|Subjects will install a mobile app for use and will be randomly assigned to a Mediterranean diet.
2399105|NCT03578445|Experimental|Patients with a pancreatic cystic lesion|
2399106|NCT03578432|Experimental|Supportive care (everolimus, saliva output testing)|Participants receive everolimus PO QD for 5 days beginning 2 weeks after radiation treatment. Participants also undergo saliva output testing at baseline prior to radiation or chemoradiation treatment, after 3 weeks of RT/chemoRT, after 6 weeks of RT/chemoRT, prior to everolimus administration, at completion of the 5 day everolimus course, and at 1, 3, and 6 months after the completion of radiation or chemoradiation therapy.
2399107|NCT03578419|Active Comparator|Control Period|Standard-Volume Blood Collection Tubes
2399108|NCT03578419|Experimental|Intervention Period|"Small-Volume Blood Collection Tubes (soft-draw)"
2399109|NCT03578406|Experimental|HPV TCR-T|HPV E6-specific TCR-T cell
2399110|NCT03578406|Experimental|HPV TCR-T with anti-PD1|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element
3143639|NCT00011037|Placebo Comparator|3|Participants will receive ALVAC-HIV vCP1452 placebo at 0, 1, 3, and 6 months and MN rgp120 placebo and Months 3 and 6
3143640|NCT00011180||Incident Cohort with VTE|Olmsted County, Minnesota residents with with a first-lifetime deep vein thrombosis (DVT) or pulmonary embolism (PE) during the five year period, 1996-2000.
2399113|NCT03578380|Experimental|Surgery|Lymphovenous anastomosis
2399114|NCT03578380|Active Comparator|Compression|Conservative treatment with physiotherapy and compression
3143641|NCT00011180||Controls without VTE|Two Olmsted County, Minnesota residents without venous thromboembolism (VTE) were matched by age and gender to each definite or probable case of VTE within the 1996-2000 cohort.
3143642|NCT00011193||Non-Exercise Control Group|We randomly assigned 102 women in the non-exercise control group and were asked to maintain their level of activity for the 6-month study period.
2399119|NCT03578354|Experimental|4-AP|15 mg 4-aminopyridine twice daily
2399120|NCT03578354|Experimental|Atenolol|25 mg atenolol twice daily
2399121|NCT03578354|Placebo Comparator|Placebo|Masked placebo twice daily
2399122|NCT03578341|Experimental|Colostrum|Group 1:(Colostrum): Preterm infants under 32 SDG will receive orally colostrum 0.3 mL every 4 h during three days.
2399123|NCT03578341|Placebo Comparator|Placebo|Group 2: (Placebo): Preterm newborns under 32 SDG who will receive orally sterile water 0.3 mL every 4 h during three days.
2399124|NCT03578328||Cardiac arrest with targeted temperature management|
2399125|NCT03578315|Experimental|Solar lentigo|25 Patients with Solar lentigo
2399126|NCT03578315|Experimental|Nevus zygomaticus|25 Patients with Nevus zygomaticus
2399127|NCT03578289|Experimental|Experimental Group (telemental health_|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
2399128|NCT03578289|Experimental|Waiting Control Group (usual care)|Participants randomly assigned to the control group will receive routine care for three months followed by the 8-week CBT intervention
2399227|NCT03577535|No Intervention|No Oncoxin Treatment®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment.
2399131|NCT03578263|Experimental|carbetocin arm|carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby
2399132|NCT03578263|Active Comparator|oxytocin and ergometrine arm|oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist plus intramuscular ergometrine 0.2 mg after the birth of the baby
2399133|NCT03578250|Experimental|Study Group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will apply error augmentation force-field to perturbate the arm of the participant away from the straight trajectory line."
2399134|NCT03578250|Experimental|Control group|"Training of the upper extremity on a robotic device. Participants will carry out hand reaching movement for multiple directions in 3 dimensions, while grasping the robotic handle according to assignments given by the robotic device.~During training the robotic device will not apply any perturbations on the participant's arm."
2399135|NCT03578237|Experimental|Treatment (active cryoneurolysis)|Receiving active cryoneurolysis
2399136|NCT03578237|Sham Comparator|Sham|Receiving sham cryoneurolysis procedure
2399138|NCT03578211|Experimental|DAs group|Shared decision making using decision aids
2399139|NCT03578211|No Intervention|Control group|Standard oral explanation guided with booklets
2399140|NCT03578198|Experimental|Rituximab + MG4101|"Drug: Rituximab + MG4101~Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4) MG4101 3x107 cells/kg IV Weekly (X4) Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4) MG4101 3x107 cells/kg IV q 4 weeks (X4)"
2399141|NCT03578172|Experimental|Experimental-HMG stimulation group|Women will be subjected to ovarian stimulation for endometrial preparation using human menopausal gonadotrophin before blastocyst transfer
2399142|NCT03578172|Active Comparator|Control-HRT group|Women will be subjected to hormone replacement therapy for endometrial preparation before blastocyst transfer
2399143|NCT03578159||Arsha Vidya Chhatralaya|Chhatralaya is residential setting for children 8 to 16 years old. It provides residence,food and education opportunities along with regular practice of Yoga, Spiritual sessions and vedic practices to learn and follow.
3189058|NCT00773812|Placebo Comparator|Placebo|There will be 8 children in this arm. These children will receive placebo instead of the active medication.
3189059|NCT00773825||1|Pregnancy after ICSI or IVF
2399150|NCT03578120||iMAP2 participants where their mothers received REPEVAX|Children who participated in iMAP2 study whose mothers received a pertussis-containing vaccine during pregnancy called REPEVAX
2399151|NCT03578120||iMAP2 participants where their mothers received BOOSTRIX-IPV|Children who participated in iMAP2 study whose mothers receives a pertussis-containing vaccine during pregnancy called BOOSTRIX-IPV
2399152|NCT03578120||iMAP2 participants where their mothers received no vaccine|Children who participated in iMAP2 study whose mothers did not receive a pertussis-containing vaccine during pregnancy
3143643|NCT00011193||4-kcal/kg Energy Expenditure per week|We randomly assigned 155 women to the 4-kcal/kg per week group for 6 months.
3143644|NCT00011193||8-kcal/kg Energy Expenditure per week|We randomly assigned 104 women to the 8-kcal/kg per week group for 6 months.
3143645|NCT00011193||12-kcal/kg Energy Expenditure per week|We randomly assigned 103 women to the 12-kcal/kg per week group for 6 months.
3143646|NCT00011349||Group 1|
3143647|NCT00011362|Active Comparator|Dexamethasone|Dexamethasone
2399158|NCT03578055|Active Comparator|BDD with UDCA|Postoperative BDD with UDCA treatment
2399159|NCT03578055|Placebo Comparator|Placebo|Placebo
2399160|NCT03578042|Active Comparator|LosanetAMplus|Patients taking the fixed triple combination
2399161|NCT03578042|Other|standard of care|Patients taking 2 or 3 free combinations containing 3 drugs for hypertension as decided by the treating physician
2399162|NCT03578029|Experimental|RGN-137|It is formulated as a gel for topical administration.
2399163|NCT03578029|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-137 formulation without the active ingredient.
2399164|NCT03578016|Experimental|Circle of Security-Parenting|10 weekly, manualized group sessions at the clinic
2399165|NCT03578016|Other|Treatment as Usual (TAU)|TAU consists of clinical assessment and treatment.
2399166|NCT03578003|Experimental|Morning Bright Light Therapy|Subjects who engage in morning bight light therapy
2399167|NCT03578003|No Intervention|Control|Subjects who do not engage in morning bright light therapy
3143648|NCT00011362|Placebo Comparator|Placebo|Saline
3143649|NCT00011414|Experimental|1|Intervention given with dose escalation of tariquidar
3143650|NCT00011492||1/All Patients|All eligible patients
3143651|NCT00011531|Other|1|
3143652|NCT00011570|Other|1|
3143653|NCT00011583|Experimental|1|1 hour/day of mechanically-assisted upper limb therapy
3143654|NCT00011583|Active Comparator|2|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
3143655|NCT00011713||Infertility patients|Patients undergoing infertility treatment at Massachusetts General Hospital Infertility Clinic.
3143656|NCT00011999|Experimental|Surgery, chemotherapy and radiation therapy|Early post-operative paclitaxel followed by paclitaxel and cisplatin concurrent with radiation therapy for resected head and neck cancer.
3143657|NCT00012025|Experimental|fulvestrant|"Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years."
3143658|NCT00012064|Experimental|Biological/Vaccine|"Biological/Vaccine: therapeutic autologous dendritic cells.~Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product."
3143659|NCT00012116|Experimental|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
2399170|NCT03577977||Patients treated with Betaferon|Patients with very early onset of MS, who received at least one injection of interferon beta-1b as prescribed by the treating physician, before the age of 18.
2399171|NCT03577951|Experimental|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
2399172|NCT03577951|Experimental|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
2399173|NCT03577938|Experimental|Chinese herbal medicine|One dosage of Chinese herbal medicine by oral administration per day for 8 weeks. For patients who cannot take oral medicine can be switched to colon route by the colonic therapy system（IMS-100A produced by Sunny Medical in Beijing China).
2399174|NCT03577938|Other|Control (blank)|Patients in the control group only receive the standard medical treatment (SMT), no control drug with CHM.
2399175|NCT03577925||HSIL|the patients with HSIL
2399176|NCT03577925||stage IA1 cervical squamous cancer|the patients with stage IA1 cervical squamous cancer
2399177|NCT03577912|Active Comparator|TAP block administered by Surgery|transversus abdominis (TAP) plane block is performed by the surgeon at the conclusion of the surgery, still under general anesthesia, prior to removing the trocars a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under direct surgeon observed laparoscopic visualization. (Split dose 30cc/side)
2399178|NCT03577912|Active Comparator|TAP block administered by Anesthesia|transversus abdominis (TAP) plane block is performed by the anesthesiologist at the conclusion of the surgery after incisions are closed and dressing are on, prior to emergence from general anesthesia, a single dose 60 cc of 0.5%bupivicaine is delivered into the TAP under by the anesthesiologist using ultrasound visualization. (Split dose 30cc/side)
2399179|NCT03577899|Experimental|0.5 mg Conbercept|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
2399180|NCT03577899|Experimental|1.0 mg Conbercept|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
2399181|NCT03577899|Active Comparator|Aflibercept|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
2399182|NCT03577886|Experimental|CDX-6114|0.225, 0.75, 2.25 and 7.5 g
2399183|NCT03577886|Placebo Comparator|Placebo|Phosphate Buffer Diluent solution
2399184|NCT03577873|Placebo Comparator|gallbladder preserved|Patients with stones in their bile ducts and gallbladders will keep gallbladders in stay after clearance of bile duct stones with ERCP.
2399185|NCT03577873|Experimental|cholecystectomy|Patients with stones in their bile ducts and gallbladders will undergo cholecystectomy after clearance of bile duct stones with ERCP.
2399186|NCT03577860|Active Comparator|Bupivacaine 4ml|The interscalene brachial plexus block is performed with 4ml at level of C5-6 roots
2399187|NCT03577860|Active Comparator|Bupivacaine 15ml|The interscalene brachial plexus block is performed with 15ml at level of C5-6
2399188|NCT03577847||1|Intervention group: Stroke patients investigated with rural CT scanning at HSS, Ål. Patients living in the municipalities of Hol, Ål, Gol, Hemsedal and Nes.
2399189|NCT03577847||2|Control-group: Stroke patients with similar transportation time to hospital, but no access to rural CT scanning. Patients living in the municipalities of Nore- and Uvdal, Vang, Øystre and Vestre Slidre, Lesja, Vågå, Lom, Dovre, Skjåk and Sel.
2399190|NCT03577834|Experimental|Liquid vinegar|Participants in this arm were instructed to drink 2 tablespoons of red wine vinegar (provided) mixed with water twice each day for weeks 1 to 8 of the trial.
2399191|NCT03577834|Placebo Comparator|Vinegar pill|Participants in the control group were instructed to take one vinegar pill (provided) each day for weeks 1-8 of the trial.
2399192|NCT03577808||Arm|Patients with locally advanced rectal cancer will receive neoadjuvant chemoradiation. The radiation procedure and concurrent chemotherapy drugs will base on clinical practice. Organoids bio-bank of pre-treatment tumor biopsies will be established and exposed to irradiation and the same chemotherapy drugs as the corresponding patient.
2399193|NCT03577782|Experimental|Single group|HIV-infected subjects with no previous ART will begin ART together with Vedolizumab infusions at week 0, 4, 8, 12, 16, 20 and 24 weeks. At this time point ART and Vedolizumab treatment will be interrupted. Patients will be followed up until week 48. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).
2399194|NCT03577756||Infants with cystic fibrosis|Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
2399195|NCT03577756||Healthy infants|Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.
2399196|NCT03577743|Experimental|experimental arm|bevacizumab and chemotherapy given every 21 day untill disease progression or unacceptable toxicity
2399199|NCT03577717|Experimental|computerized cognitive training|"participants will be trained by the Cookies for the brainy day, including memory, attention, calculation, executive functions, and language training."
2399200|NCT03577717|Active Comparator|occupational therapy|participants will receive craft activities of occupational therapy, such as weaving, origami etc.
3143660|NCT00012181|Experimental|Treatment (alvocidib)|Patients receive flavopiridol IV over 1 hour on days 1-3. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3143661|NCT00012194|Experimental|Treatment (7-hydroxystaurosporine, cisplatin)|Patients receive cisplatin IV over 1 hour on day 1 and UCN-01 IV continuously over 36-72 hours on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3143662|NCT00012220|Active Comparator|Gemcitabine|Standard treatment
2399201|NCT03577704|Experimental|HLX07+Gemcitabine+Cisplatin arm|"HLX07 is given on D1,D8,D15 combine with Gemcitabine (1000 mg/m2) and Cisplatin (75 mg/m2) in 3 weeks- cycles for 4-6 cycles .Gemcitabine was administered on the D1 and D8 and cisplatin 75 mg/m2 was administered on the D1. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2399202|NCT03577704|Experimental|HLX07+Paclitaxel+Carboplatin arm|"HLX07 is given on D1,D8,D15 combine with Paclitaxel (80 mg/m2) and carboplatin (AUC=2) in 3 weeks-cycle for 4-6 cycles .Paclitaxel and carboplatin were administered on D1, D8 and D15. After 4-6 cycles of combination therapy, once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2399203|NCT03577704|Experimental|HLX07+mFOLFOX6 arm|"HLX07 is given on D1,D8 combine with mFOLFOX6 ( oxaliplatin (85 mg/m2), leucovorin (400 mg/m2), and 5-FU (400 mg/m2, followed by 2400 mg/m2) in 2 weeks-cycles for 6-12 cycles . Oxaliplatin, leucovorin and 5-FU were administered on D1. After 6-12 cycles of combination therapy,once weekly HLX07 infusion will be continue for a maximum duration of 2 years or until disease progression or emergence of intolerable toxicity or permanent withdrawal or death (whichever comes first).~In each cohort, HLX07 will use BOIN design to assign the subject's dose level and determine the MTD."
2399204|NCT03577691|Experimental|Training for use of web based Decision Aid|Subjects will be provided access to the decision aid website and will receive a log-in identification, user password and url at time of consent and will be guided during a 30 minutes training session to use the website. They will ben be asked to continue to peruse the website at home to learn more about hydroxyurea. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
2399205|NCT03577691|Placebo Comparator|No training for use of web based Decision Aid|Subjects will receive a log-in identification, user password and url at time of scheduled appointment for web access. They will not receive training but will be instructed to maneuver through the website and access the information pertaining to hydroxyurea and access the videos for the purposes of learning. Participants will be asked to peruse the website for 30 minutes at time of consent then to continue to access the website at home to learn about hydroxyurea treatment. Participants in each group will be further randomized to 1) pretest surveys and posttest surveys; and 2)only posttest surveys
2399206|NCT03577678|Experimental|observational|orthopaedic Surgery to fix lateral half prosthesis for clavicle
2399207|NCT03577665|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
2399208|NCT03577652|Experimental|Ticagrelor, 90mg, 12h|
2399209|NCT03577652|Experimental|Ticagrelor, 90mg, 24h|
2399210|NCT03577652|Experimental|Ticagrelor, 180mg, 24h|
2399211|NCT03577626|Experimental|Hemay005 Fast|
2399212|NCT03577626|Experimental|Hemay005 Fed|
2399213|NCT03577613||Early stage Cervical Cancer- Open Radical Hysterectomy(RH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a open RH at our institution as primary treatment were included in the study
2399214|NCT03577613||Early stage Cervical Cancer- Laparoscopic Radical Hysterectomy|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a laparoscopic RH at our institution as primary treatment were included in the study
2399215|NCT03577613||Early stage Cervical Cancer- Robotic radical Hysterectomy(RRH)|Patients who were clinically diagnosed with FIGO stage IA2-IB1-IIA1 cervical cancer and underwent a robotically assisted RH at our institution as primary treatment were included in the study
2399216|NCT03577600|Experimental|QMRT using the Cytotron®|Experimental: QMRT using the Cytotron® Intervention: 28 days of treatment with QMRT with the Cytotron®. Patients diagnosed with terminal brain tumors between 3 and 16 years of age whose parents agree to participate in the study and have signed informed consent and informed consent in patients with age or mental age over 8 years.
2399217|NCT03577587|Experimental|Verum|Silitidil for 21 days
2399218|NCT03577587|Placebo Comparator|Placebo|Placebo for 21 days
2399219|NCT03577587|No Intervention|Reference group|Non-randomized healthy volunteering mothers after term birth receiving no intervention
2399220|NCT03577574|Active Comparator|retrobulbar anesthesia group|2% lidocaine 4ml injected into retrobulbar space
2399221|NCT03577574|Active Comparator|peribulbar anesthesia group|2% lidocaine 4 to 8ml injected into peribulbar space
2399222|NCT03577574|Experimental|two step anesthesia group|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
2399223|NCT03577561|No Intervention|Control group A|Control group A: 1 -year historical data (2016/2017) The blood sampling error rate in the interns receiving proficiency based progression training in 2018 will be compared to historical data on doctors who would have received whatever training they would normally undergo as a part of their existing training program. It will not differ from what they would normally receive at that institution.
2399224|NCT03577561|Active Comparator|Control Group B|Control group B (2017/2018) In a pilot project in July 2017, 46 interns received the phlebotomy proficiency based progression training at CUH. The error rates in the interns in 2017 will be compared to the newly trained interns in 2018 to determine the effectiveness of the training over time. The intervention is the proficiency based progression training programme in phlebotomy.
2399225|NCT03577561|Active Comparator|Interventional Group|"The blood sampling error rate of doctors in training provided with the intervention i.e. improved proficiency based progression training programme will be analysed from July 10th 2018 until the study ends.~The proficiency based progression training will consist of an online eLearning module to teach the doctors the correct process to take blood in the hospital. The doctors will then have to attend a face to face training day on a simulation ward where they will be asked to take blood according to a metric of 77 steps with less than 13 errors and no critical errors. Finally, the doctors will be observed taking blood on the ward and again must take it to a proficient standard."
2399226|NCT03577535|Experimental|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN
2399231|NCT03577496|Experimental|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares upon arrival to the recovery room. The patients will be assessed for PONV for up to an hour in the post anesthesia care unit (PACU) or until their discharge, whichever is first.
2399232|NCT03577483|Other|Parkinson's disease|Diagnosis of idiopathic Parkinson's disease (PD) according to criteria
2399233|NCT03577483|Other|Multiple system atrophy|Diagnosis of Multiple Atrophy System (MSA) Parkinsonian form possible or probable according to Gilman et coll 's criteria (2008)
2399234|NCT03577483|Other|Healthy volunteer|Absence of neurologic and oto-rhino-laryngologic disease
2399235|NCT03577470||Group 1|Participants will not receive any intervention as a part of this study. This group will include participants in treatment with Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), who were always being treated with boosted-darunavir (DRV)-based regimen. The primary data source will be the medical records of each participant participating in this study.
2399236|NCT03577470||Group 2|Participants will not receive any intervention as a part of this study. This group will include participants who started their antiretroviral (ARV) treatment with any combination excluding DRV before starting D/C/F/TAF treatments, who were always being treated with ARV treatment with any combination excluding DRV before starting D/C/F/TAF treatments. The primary data source will be the medical records of each participant participating in this study.
2399237|NCT03577470||Group 3|Participants will not receive any intervention as a part of this study. This group will include participants started with D/C/F/TAF as naive. The primary data source will be the medical records of each participant participating in this study.
2399238|NCT03577457|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
2399239|NCT03577457|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
2399240|NCT03577457|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
2399241|NCT03577457|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
2399242|NCT03577444||Dysphagia patients|Patients who had been diagnosed with neurogenic dysphagia related to either stroke or traumatic brain injury at two university affiliated hospitals
3143663|NCT00012220|Experimental|Gemcitabine + cisplastin|Addition of cisplastin to gemcitabine
2399244|NCT03577418|Experimental|Clinician-facilitated educational intervention|
2399245|NCT03577418|Active Comparator|Enhanced usual care|
2399246|NCT03577392|Experimental|XELOX chemotherapy with recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
2399247|NCT03577392|Active Comparator|XELOX chemotherapy without recombinant human endotatin|Patients received a triweekly treatment cycle.Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
2399248|NCT03577379|No Intervention|Control|Patients in the control arm will receive standard of care for their rotator cuff tear, and will not receive the additional whole blood fibrin clot.
2399249|NCT03577379|Experimental|Treatment|Patients in the control arm will receive standard of care for their rotator cuff tear, in addition to, the whole blood fibrin clot.
2399250|NCT03577353|Experimental|experimental-DTW|The intervention of the experimental group was based on dual-task treadmill walking while using the Virtual Reality (VR) tool.
2399251|NCT03577353|Active Comparator|Control- TMW|The intervention of the control group was based on single-task treadmill walking.
2399252|NCT03577340||Novices|Novices: Trainee cardiologists implanting cardiac devices as per guidelines under supervision
2399253|NCT03577340||Experts|Experts: Device implanting cardiologists implanting cardiac devices as per guidelines
2399254|NCT03577327||Adults with vitiligo|
2399255|NCT03577327||Healthy adults|
2399256|NCT03577314||miscarriage|Patients were aged from 18 to 35 years, 50 females who have history of at least two unexplained recurrent miscarriage below 20th week of pregnancy
2399257|NCT03577314||healthy|50 systemically healthy females with at least two normal births and no poor obstetric history such as preeclampsia and premature birth
2399550|NCT03575299|Placebo Comparator|Control Group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will not be treated with allogeneic γδT cells.
2399680|NCT03574415|Experimental|Japanese_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
3143664|NCT00012220|Experimental|Gemcitabine + docetaxel|Addition of docetaxel to gemcitabine
3143665|NCT00012220|Experimental|Gemcitabine + Irinotecan|Addition of irinotecan to gemcitabine
3143666|NCT00012259|Experimental|troxacitabine|
3189060|NCT00773825||2|Pregnancy after ovarian stimulation
3189061|NCT00773825||3|natural pregnancy
3189062|NCT00773851|Other|A|transfacial sutures
3189063|NCT00773851|Other|B|staples
3143667|NCT00012350|Experimental|Oral FTI (R115777) Treatment|"Patients will be administered oral FTI (R115777) at a dose of 300-mg by mouth (PO) twice a day (BID). Drug will be taken without regard to meals.~The study regimen will consist of 3 weeks of treatment followed by one week off for a total cycle duration of 4 weeks."
3143668|NCT00012363|Experimental|Gemcitabine + Irinotecan|Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days
3143669|NCT00012376|Experimental|Treatment (bryostatin 1 and sargramostim)|Patients receive bryostatin 1 IV continuously and GM-CSF subcutaneously once daily on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with disease stabilization or improvement may continue treatment for up to 12 courses.
3143670|NCT00012597|Other|Arm 1|
2399270|NCT03577262|Experimental|Healthy subjects [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
2399271|NCT03577262|Experimental|AD patients [11C]-UCB-J|Net dose of approximately 370 megabecquerel (MBq) of [11C]-UCB-J, Total injected mass of UCB-J per will not to exceed 10 µg for each dose given on Days 1 and 28
2399272|NCT03577249|Experimental|Single arm|
2399273|NCT03577236|Experimental|Zenflow Spring System|Receives treatment with the investigational device
2399274|NCT03577223|Experimental|Whole Eggs|
2399275|NCT03577223|Active Comparator|Egg White-Based Egg Substitute|
2399276|NCT03577210|Other|computer-guided augmentation genioplasty|patient-specific PEEK implant
2399279|NCT03577158|Experimental|Closed-loop controller with exercise mitigation module|"Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with mitigation module.~Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP with mitigation module) based on blood glucose estimations from CGM."
2399280|NCT03577158|Experimental|Closed-loop controller without exercise mitigation module|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the software under investigation (SAFEAP without mitigation module) based on blood glucose estimations from CGM.
2399281|NCT03577158|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous subcutaneous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
2399282|NCT03577145|Experimental|Tomato, onion & lovage soup with inulin|One dose of tomato (300g), onion (100g) & lovage (20g) with 10g inulin will be given to subjects in the form of a soup
2399283|NCT03577145|Experimental|Tomato, onion & lovage soup|One dose of tomato (300g), onion (100g) & lovage (20g) will be given to subjects in the form of a soup
2399284|NCT03577145|Experimental|Inulin|One dose of 10g inulin will be given to subjects in the form of a drink
2399285|NCT03577132|Experimental|Luminal type|Luminal type in previous transurethral resection of bladder tumor pathology. Luminal type in Immunohistochemistry (KRT5/6-KRT14-FOXA1+GATA3+)
2399286|NCT03577132|Experimental|Basal typr|Basal type in previous transurethral resection of bladder tumor pathology. Basal type in Immunohistochemistry (KRT5/6+KRT14+FOXA1-GATA3-)
2399287|NCT03577119|Experimental|Full-fat yogurt|Participants will receive a 21-day controlled diet that includes three daily servings of whole (3.25% fat) yogurt (38% of energy from fat, 44% of energy from carbohydrates, and 18% of energy from protein).
2399288|NCT03577119|Experimental|Non-fat yogurt (Control)|Participants will receive a 21-day controlled diet that includes three daily servings of fat-free yogurt (28% of energy from fat, 54% of energy from carbohydrates, and 18% of energy from protein).
2399289|NCT03577106|Experimental|Transcranial magnetic stimulation (TMS)|
2399290|NCT03577093||ischemic stroke|acute ischemic stroke patients within 6h after stroke onset
2399291|NCT03577093||control|healthy controls
2399292|NCT03577080|Active Comparator|ET+RT+ NMES|neuromuscular electrical training NMES
2399293|NCT03577080|Placebo Comparator|ET+RT|placebo neuromuscular electrical training NMES
2399294|NCT03577067||Patients submitted to liver resection|Patients underwent liver resection for primary and secondary disease
3143671|NCT00012610|Other|Arm 1|
3143672|NCT00012623||Group 1|
3143673|NCT00012636|Other|Arm 1|
3143674|NCT00012649||Group 1|
3143675|NCT00012662|Other|Arm 1|
3143676|NCT00012675||Group 1|
3143677|NCT00012688|Other|Arm 1|
3143678|NCT00012701||Group 1|
3143679|NCT00012714|Other|Arm 1|
3143680|NCT00012727|Other|Arm 1|
3143681|NCT00012740|Other|Arm 1|
3143682|NCT00012753|Other|Arm 1|
3143683|NCT00012766|Other|Arm 1|
3143684|NCT00012779|Other|Arm 1|
3143685|NCT00012792|Other|Arm 1|
3143686|NCT00012805|Other|Arm 1|
3143687|NCT00012818|Other|Arm 1|
3143688|NCT00012831||Group 1|
3143689|NCT00012844|Other|Arm 1|
3143690|NCT00012857|Other|Arm 1|
3143691|NCT00012870|Other|Arm 1|
3143692|NCT00012883|Other|Arm 1|Homewalking Exercise Program
3143693|NCT00012896|Other|Arm 1|
3143694|NCT00012909|Other|Arm 1|
3143695|NCT00012922|Other|Arm 1|
3143696|NCT00012935|Other|Arm 1|
3143697|NCT00012948|Other|Arm 1|
3143698|NCT00012961||Group 1|
3143699|NCT00012974|Other|Arm 1|
3143700|NCT00012987|Other|Arm 1|
3143701|NCT00013000|Other|Arm 1|
3143702|NCT00013013|Other|Arm 1|
3143703|NCT00013026|Other|Arm 1|
3143704|NCT00013039|Other|Arm 1|
3143705|NCT00013052|Other|Arm 1|
3143706|NCT00013065||Group 1|
3143707|NCT00013078|Other|Arm 1|
3143708|NCT00013091|Other|Arm 1|
3143709|NCT00013104||Group 1|
3143710|NCT00013117|Other|Arm 1|
3143711|NCT00013130|Other|Arm 1|
2399295|NCT03577054|Experimental|HBB Prompt|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~Providers at this hospital will have access to the most updated version of HBB Prompt (beta) after HBB training.~Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training). The recommended frequency to use the app will be once per shift."
2399296|NCT03577054|Placebo Comparator|Control|"The investigators will train frontline health providers in Helping Babies Breathe (HBB) 2.0 and Essential Care for Every Baby (ECEB). Providers will undergo ECEB training in addition to HBB as these training programs are recommended by the Uganda Ministry of Health to be offered together.~The control group will not have exposure to the HBB Prompt app post training. Participants in will be asked to achieve a minimum practice target of once per day (low-dose high frequency training)."
2399297|NCT03577028|Experimental|Experimental: HPN424-1001|"In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion with dose escalation until an estimated therapeutic dose level has been reached.~In Part 2 (Dose Expansion), patients will receive HPN424 at the recommended phase 2 dose(s) established in Part 1 of the study. Study procedures will be the same in Part 1 and Part 2 of the study. Additional expansion cohorts of up to 18 patients per expansion cohort may be added."
2399298|NCT03577015||critically ill patients at risk for DIC|patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis
2399299|NCT03577002|Active Comparator|Clinician SICP|Advance care planning between primary care clinician and the patient/family using the Serious Illness Care Program (SICP)
2399300|NCT03577002|Active Comparator|Team SICP|Advance care planning between team members and the patient/family using the Serious Illness Care Program (SICP)
2399301|NCT03576989|Experimental|EPA+DHA Group|12 weeks of daily oral therapy with EPA+DHA (three opaque softgels to provide a total daily intake of 1.87 g of EPA + 1.0 g of DHA)
2399302|NCT03576989|Placebo Comparator|Placebo Group|12 weeks of daily oral therapy with placebo (three opaque softgels to provide a total daily intake of 2.5 mL of mineral oil)
2399303|NCT03576976|Active Comparator|Clinic-based Cognitive Remediation|Clinic-based cognitive remediation is the current standard of care in NY State outpatient programs. It consists of twice weekly group-based and clinician-led sessions.
2399304|NCT03576976|Experimental|Hybrid Cognitive Remediation|Hybrid cognitive remediation consists of one weekly group-based, clinician-led session plus independent cognitive practice.
2399305|NCT03576963|Experimental|Treatment (guadecitabine, nivolumab)|This study consists of an initial dose escalation followed by an expansion cohort. Dose escalation of guadecitabine starts from 30 mg/m^2 given SC on days 1-5 every 28 days in combination with fixed dose of nivolumab at 240 mg given IV on days 8 and 22 every 28 days. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
2399306|NCT03576950||Uterine rupture|Women with uterine rupture occurred during pregnancy.
2399307|NCT03576937||Cohort 1|Patients with advanced (incurable stage IIIB or IV), histologically proven, non-squamous NSCLC who are never- or light-smokers (≤10 pack year smoking history) and are being considered for systemic therapy in the first line setting are eligible. Blood will be collected prior to first line treatment for testing cfDNA with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
2399308|NCT03576937||Cohort 2|Patients with advanced non-squamous NSCLC with known oncogenic drivers (such as EGFR, ALK, ROS-1, BRAF) that have failed tyrosine kinase inhibitor (TKI) therapy, and are being considered for subsequent therapy. Blood will be collected from patients at time of progression on TKI therapy for cfDNA testing with the GUARDANT360 assay. Testing of available diagnostic tissue for genomic abnormalities will be performed in all patients per standard of care at the participating sites.
2399309|NCT03576924|Active Comparator|Imposed-MICT|Continuous exercise for 30 minutes per session at 60-65% of heart rate max for five times per week, consistent with physical activity guidelines that advocate 150 minutes per week of moderate activity.
2399310|NCT03576924|Active Comparator|Imposed-HIIT|Five repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down, making the total session duration 15 min for five times/week, equated to match the guidelines of 75 min of vigorous exercise per week.
2399311|NCT03576924|Experimental|CHOICE|Participants will always self-select the exercise type that they will do, either the IM-HIIT or the IM-MICT protocols, which will be matched to the parallel imposed conditions.
2399312|NCT03576911|Experimental|Coenzyme Q10|100mg CoQ10 capsule taken orally three times per day for 6 months
2399313|NCT03576911|Placebo Comparator|Placebo|Placebo capsule taken orally three times per day for 6 months
2399314|NCT03576885|Active Comparator|Treatment group - active|inhaled nitric oxide treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
2399315|NCT03576885|Placebo Comparator|Treatment group - placebo|Placebo treatment will start at 20 ppm and continue for 2 weeks or until resolution of pulmonary hypertension, whichever comes first.
2399316|NCT03576885|No Intervention|Control group|Enrolled infants with no evidence of pulmonary hypertension will serve as the control group for incidence of death or bronchopulmonary hypertension
2399317|NCT03576872|Experimental|Psychoeducational intervention|"Psychoeducational will be conducted prior to chemotherapy.~Teach session will occur prior and during administration of chemo~A small quiz will be conducted to asses understanding of the educational binder"
2399318|NCT03576859|Other|cirrhotic patients with chronic liver failure|
2399319|NCT03576859|Other|cirrhotic patients without chronic liver failure|
2399320|NCT03576846|Experimental|Intervention|Stretching and Spinal Manipulative Therapy
2399321|NCT03576846|Active Comparator|Comparator|Stretching
2399322|NCT03576833|Experimental|Balloon|
2399323|NCT03576820|Experimental|Lidocaine|Subjects will receive a one time dose of 20mg of 2% lidocaine (1 mL) via nasal mucosal atomizer
2399324|NCT03576820|Placebo Comparator|Placebo|Subjects will receive a one time dose of 1 mL of 0.9% sodium chloride solution via nasal mucosal atomizer.
2399325|NCT03576807|Experimental|CD20 CAR-T cells|Experimental: CD20 CAR-T cells
2399326|NCT03576794|Active Comparator|Leflunomide treatment|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
2399327|NCT03576794|Placebo Comparator|Placebo control|Patients will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27. During the first 2 weeks after randomization patients will receive placebo 20 mg every other day in order to prevent early drug withdrawal due to side effects. After 2 weeks placebo will be increased to 20 mg once daily and this therapy will be continued during 12 months.
2399328|NCT03576781|Experimental|Real iTBS to the DLPFC|One session of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2399329|NCT03576781|Sham Comparator|Sham iTBS to the DLPFC|One session of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses total)
2399330|NCT03576781|Experimental|Real cTBS to the MPFC|One session of real continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
2399331|NCT03576781|Sham Comparator|Sham cTBS to the MPFC|One session of sham continuous Theta Burst Stimulation (cTBS) will be delivered to the left medial prefrontal cortex (mPFC) (1 train of stimulation over the left frontal pole (FP1); each train: 3 pulse bursts presented at 5Hz, 15 pulses/sec for 40 sec, 600 pulses/train, 110% RMT, MagPro; 600 pulses total)
3184498|NCT00725244|Active Comparator|2|"Argon Plasma Coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
3184499|NCT00725257|Active Comparator|1|Low-carbohydrate, energy-restricted, Mediterranean-type diet
3184500|NCT00725257|Active Comparator|2|Low-fat diet
3184501|NCT00725335|Experimental|group A,non-pringle group|Intervention of curative resection of HCC Without pringle manoeuvre in this arm
2399336|NCT03576755|Experimental|spironolactone|spironolactone, 100 mg capsule administered orally once daily for 6 or 12 months
2399337|NCT03576755|Placebo Comparator|placebo|matching placebo capsule administered orally once daily for 6 or 12 months
2399338|NCT03576742||patients|all who fulfil inclusion criteria and consent to participation; potential biomarkers will be documented
2399339|NCT03576729||Hurler syndrome participants|Participants who have MPS IH, also called Hurler syndrome
2399340|NCT03576729||Hurler-Scheie/Scheie participants|Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.
2399341|NCT03576729||Healthy Controls|Age-matched healthy controls
3184502|NCT00725335|Active Comparator|pringle group(B)|when the curative resection of HCC performed, the pringle manoeuvre will be routinely applied.
2399343|NCT03576703|Experimental|EX+H2O|Exercise and diet that did not include SSB
2399344|NCT03576703|Experimental|EX+SSB|Exercise and diet that includes SSB
2399345|NCT03576703|No Intervention|CONTROL|No exercise and diet that did not include SSB
2399346|NCT03576677|Active Comparator|Levosimendan|Study participants in this arm will receive a 6 hours infusion of levosimendan 0.2 µg/kg/min.
2399347|NCT03576677|Placebo Comparator|Placebo|Study participants in this arm will receive a 6 hours infusion of placebo (sterile isotonic sodium chloride + 5% dextrose + vitamin B)
2399348|NCT03576664|Experimental|Carvedilol first|Carvedilol (25 mg) followed by Placebo oral capsule is administered in a crossover manner.
2399349|NCT03576664|Experimental|Placebo first|Placebo oral capsule followed by Carvedilol (25 mg) is administered in a crossover manner.
2399350|NCT03576651|Experimental|JHL1149|
2399351|NCT03576651|Active Comparator|US-sourced-Avastin™|
2399352|NCT03576651|Active Comparator|EU-sourced Avastin™|
2399353|NCT03576638|Active Comparator|Sinemet|Controlled Release 25/100
2399354|NCT03576638|Experimental|AP CD/LD|
2399355|NCT03576625|Placebo Comparator|High oleic sunflower oil (HOSO)|30 ml HOSO emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
2399356|NCT03576625|Experimental|Buglossoides oil emulsion|30 ml Buglossoides oil emulsion (equivalent to 9.9 ml oil) in a single dose, 56 days
2399357|NCT03576612|Experimental|Cohort 1: MGMT Unmethylated Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8 and continues for 6 weeks. Temozolomide started after complete valacyclovir and stop when MGMT unmethylated result obtained. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
2399551|NCT03575286||Pregnant female|Patient has been determined pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
3184503|NCT00725348|Experimental|A|R115866
3184504|NCT00725374|Active Comparator|Arm 1|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with tibolone
3189064|NCT00773877||1|Primary open angle glaucoma
3189065|NCT00773877||2|Normal Controls
2399358|NCT03576612|Experimental|Cohort 2: MGMT Methylated & undetermined Patients|After confirmation of high grade glioma, AdV-tk injection into wall of resection cavity. Valacyclovir starting 1-3 days post-surgery for 14 days. Radiation begins approximately day 8. Temozolomide started after complete valacyclovir and continue during radiation then 5 week break and then begin adjuvant temozolomide dosing. Nivolumab every 2 weeks x 26 doses up to 52 weeks. MRI every 8 weeks until progression.
2399359|NCT03576599|Active Comparator|Zoledronic Acid Injectable Product|Patients randomized to treatment with Zoledronic Acid 5mg infusion, repeated after 3 months
2399360|NCT03576599|Placebo Comparator|Placebo|Patients randomized to Placebo infusion (saline), repeated after 3 months
3143712|NCT00013143|Other|Arm 1|
3143713|NCT00013156|Other|Arm 1|
2399363|NCT03576573||Primary Total Hip Arthroplasty|Single arm study of subjects previously implanted with any MicroPort Orthopedics or Wright Medical Technology femoral stems and PROCOTYL® C Acetabular Components
2399364|NCT03576547|Experimental|Treatment (ponatinib, venetoclax, dexamethasone, rituximab)|See Detailed Description
2399365|NCT03576534|No Intervention|Control|Standard of care
2399366|NCT03576534|Active Comparator|Study|PBUF used prior to Cardiopulmonary bypass
2399367|NCT03576521|Experimental|Ocoxin-Viusid®|The CT with Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + OV nutritional supplement.
2399368|NCT03576521|Placebo Comparator|Placebo|The QT Adriamycin scheme 60 mg per m2 of Body Surface (SC) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles + a placebo of the OV nutritional supplement.
2399369|NCT03576508|Experimental|CNTX-4975-05 Intra-Articular (IA) Injection|Receives IA injection into the most painful OA knee.
2399370|NCT03576508|Active Comparator|Topical 8% Capsaicin Patch|Receives Capsaicin Patch on posterior rib cage.
2399371|NCT03576495|Experimental|Early Intervention / Retention Group|"The investigators will assess the residents' knowledge, attitudes, and skills prior to and after the PACTS curriculum administration at half the sites (Early Intervention/Retention Group).~Follow-up testing will be conducted after one year to evaluate learner retention.~Further, the investigators will test post-exposure effect retention in the Early Intervention Group at the end of year 2."
2399372|NCT03576495|Active Comparator|Delayed Intervention Group|"The investigators will conduct baseline testing prior to the standard residency curriculum, and administer the PACTS curriculum the following year.~Both between- and within-group differences will be examined based on curriculum exposure in intervention year 1 as well as within-group differences for the Delayed Intervention Group at the end of year 2."
2399373|NCT03576482||Transport on foot|Patients go to operating room walking with their families and with their normal clothes
2399374|NCT03576482||Transport by stretcher on wheels|Patients go to operating room by stretcher on wheels and with hospital clothes. Normal routine of our hospital.
2399375|NCT03576469|Experimental|C1-esterase inhibitor [recombinant] (C1-INH-R)|"Single-site, open-label arm to evaluate the benefit of C1-INH-R in subjects on IVIG therapy who experience ADRs. The study will have 2 periods:~6 - 8 weeks - subjects will receive 2 infusions of IVIG~9 - 12 weeks - subjects will receive 3 infusions of C1-INH-R prior to IVIG infusion"
2399376|NCT03576456|Active Comparator|Alprazolam|Patients receive alprazolam 0.5 mg 1 hour prior to coronary angiography.
2399377|NCT03576456|Placebo Comparator|Placebo Oral Tablet|Patients receive placebo 1 hour prior to coronary angiography.
3143714|NCT00013169|Other|Arm 1|
2399379|NCT03576430|Active Comparator|active|active stress handling
2399380|NCT03576430|No Intervention|control|no stress handling
2399381|NCT03576417|Active Comparator|RT+ cisplatin|100 mg/m2 of cisplatin on days 1, 22,43 of RT
2399382|NCT03576417|Experimental|RT+ cisplatin + nivolumab|"240 mg of nivolumab 3 weeks before RT-Cisplatin~360 mg of nivolumab on days 1, 22,43 of -RT-cisplatin~480 mg of nivolumab for maintenance"
2399383|NCT03576404|Experimental|Eligible participants|The intervention of patient-centered pharmacist care included a comprehensive interview patients conducted at month 3 and 5 ,which included and reviewing all their medications using concepts of MTM and MI All study participants were assessed at baseline and on monthly basis for the changes in the study outcomes.
2399384|NCT03576391|Experimental|Control condition|Control condition to assess whether the repetition of a RAM task without fatiguing task in between 2 repetitions affects trunk motor control and cortical movement preparation.
2399385|NCT03576391|Experimental|Physical Fatigue condition|Fatigue condition to assess whether a physical fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
2399386|NCT03576391|Experimental|Cognitive Fatigue condition|Fatigue condition to assess whether a cognitive fatiguing task in between 2 RAM tasks affects trunk motor control and cortical movement preparation for the 2nd RAM.
2399387|NCT03576378|Experimental|Experimental: Brentuximab vedotin plus EPEM|Brentuximab Vedotin dose will start at 1.2 mg/kg by intravenous (IV) infusion on Day1 and Day15 plus Cyclophosphamide 500mg/m2 IV on Day1 plus Procarbazine 100mg/m2 by mouth (OR) on Day1 through 5 plus Etoposide 60mg/m2 OR on Day15 through 19 plus Mitoxantrone 6mg/m2 IV on Day15 and Prednisone 30mg/m2 on Day1 through 5 of each 28-day treatment cycles for up to 6 total treatment cycles (approximately 24 weeks or 6 months)
2399388|NCT03576365|Experimental|VOICE Intervention Arm|Participants participate in the online VOICE program to learn about perceived control and stress reduction to improve voice outcomes.
2399389|NCT03576365|Sham Comparator|Information-Only Arm|Participants participate in the information only program to learn about voice problems, anatomy and physiology.
2399390|NCT03576352|Experimental|Pediatric anesthesiologist|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2399391|NCT03576352|Experimental|Pediatric intensivists|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2399392|NCT03576352|Experimental|Pediatric surgeons|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2399393|NCT03576352|Experimental|Pediatric emergency physicians|10 rapid sequence tracheostomy (RST) on rabbit cadaver
2399681|NCT03574415|Experimental|Japanese_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
3143715|NCT00013182|Other|Arm 1|
3143716|NCT00013195|Other|Arm 1|
3143717|NCT00013208|Other|Arm 1|
3143718|NCT00013221|Other|Arm 1|
3143719|NCT00013234|Other|Arm 1|
2399394|NCT03576339|Sham Comparator|Sham Group - Free Gingival Graft + Sham Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Patient randomized to the SHAW Group will receive the simulation of the electrical stimulation process, thus non current will be applied.
2399395|NCT03576339|Experimental|Test Group - Free Gingival Graft + Electric Stimulation|With the aim to ridge preservation after condemned tooth extraction, the socket will be sealed with a free gingival graft removed from the palate. The tooth will be extracted through the use of appropriate instruments in order to obtain a minimally traumatic exodontia. After the exodontia, curettage and irrigation of the dental socket will be performed. The free gingival graft will be removed from the donor palatal area with a circular incision of 9 mm and 2 mm thickness. After free gingival graft removal from palate, it will be adjusted to the entrance of the socket and sutured. Conductive electrodes for electrical current application will be applied to the palatal donor area on each side of the wound at a distance of 3 mm from the wound edge. An alternating current of 100 microamperes (μA) at 9 kilohertz (kHz), will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, five consecutive days.
2399396|NCT03576326|Experimental|Incentive Drawing|Eligible to earn a weekly drawing entry with different winning probabilities during the 6-month incentive intervention period. Possible winnings depend on toothbrushing performance: low adherence threshold (brushing child's teeth once per day for 7 days in a week) will have an 18% chance of winning $25 and a 1% chance of winning $50 (expected $5 payout); high adherence threshold (brushing twice per day for 14 days in a week) will have a 34% chance of winning $25 and a 3% chance of winning $50 (expected $10 payout).
2399397|NCT03576326|No Intervention|Control - Delayed Incentive|No rewards during the first 12 months, but information on toothbrushing performance. After the Month 12 follow-up visit, may opt to participate in a delayed 6-month open label extension to earn the same monetary rewards the intervention group could earn Baseline through Month 6. Not a formal part of this trial, but rather a necessary condition to assure all participating parents/caregivers have the chance to earn the same monetary incentives.
2399398|NCT03576313|Experimental|intervention: IVM and DP|Mass Drug Administration with ivermectin (IVM) and dihydroartemisinin-piperaquine (DP) will be given to participants in the intervention villages plus the NMCP standard malaria control intervention
2399399|NCT03576313|Active Comparator|control: standard malaria control intervetions|Participants in the control clusters will receive only standard malaria control interventions such as Artemether Lumefantrine, LLINs, IRS, SMC and IPTp as implemented by the National Malaria Control Program (NMCP) of the Gambia
2399400|NCT03576300||control|subjects without dry eye and diabetes
2399401|NCT03576300||patients with diabetes and dry eye|diabetic patients with dry eye
2399402|NCT03576300||diabetics without dry eye syndrome|diabetic patients without dry eye
2399403|NCT03576300||dry eye syndrome patients without diabetes|non-diabetic patients with dry eye
2399404|NCT03576287|Experimental|apremilast|apremilast standard doses
2399405|NCT03576274|Experimental|Technology Enhanced Home Exercise only|Participants in TEHE group will receive a combined technology and home exercise program. Participants will schedule an online meeting with the research team for exercise goal setting and preference. Participants will receive a daily symptoms survey. They will receive, reminder, motivation message and physical performance feedback though the mobile phone application.
2399406|NCT03576274|Experimental|Technology Enhanced Home Exercise plus|"In additional to the TEHE program, participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
2399407|NCT03576274|Experimental|Technology Enhanced Home Exercise-Mindfulness intervention|"In addition to the TEHE program, the TEHE+MBI group will receive a audio-recording of a mindfulness-based body scan.~During the weekly study visit: Participants will be instructed to listen to the recorded mindfulness-based body scan in the morning and before bedtime.~At home: Participants will be asked to listen to this audiotape daily in the morning and before bedtime."
2399408|NCT03576274|No Intervention|Control (usual care)|The control group will receive instructions on how to use the physical activity tracker and mEMA application. Participants will be asked to meet with a research team member weekly to discuss their fatigue experience and receive general information about fatigue management.
2399409|NCT03576274|Active Comparator|Auricular Point Acupressure only|"Participants will receive auricular point acupressure (APA) training on how to locate the ear points, place the seeds and apply the pressure on the seed.~Participants will be instructed to press the tape and seeds covering each ear point for 3 minutes per time with a 2-second pause in between pressing, three times daily (morning, afternoon and evening: 9 minutes total).~The tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day."
2399412|NCT03576248|Experimental|In-phase 6 Hz prefronto-parietal tACS|6 Hz stimulation (1000 μA) with transcranial Alternative Current Stimulation (tACS) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3 of the 10-20 international scalp EEG system, with a return electrode in Cz) for 20 minutes. The phase difference between the two stimulation sites will be 0°.
2399682|NCT03574415|Experimental|Caucasian_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
2399413|NCT03576248|Sham Comparator|Sham prefronto-parietal tACS|The same stimulation as in in-phase transcranial Alternative Current Stimulation tACS (6 Hz F3 and P3 stimulation with 0° phase difference) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
2399414|NCT03576248|Experimental|2 mA left prefrontal tDCS|2000 μA anodal transcranial Direct Current Stimulation (tDCS) will be applied over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system with a right supraorbital return electrode (Fp2 of the 10-20 international scalp EEG system) during 20 minutes.
2399415|NCT03576248|Sham Comparator|Sham left prefrontal tDCS|The same stimulation as active transcranial Direct Current Stimulation (tDCS) (anodal F3 and return in Fp2) will start at 2 mA intensity for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation. The whole session duration is 20 minutes.
2399416|NCT03576235|Experimental|a treatment group|PG102P 1.5 g/day
2399417|NCT03576235|Placebo Comparator|a control group|placebo
2399418|NCT03576222|Active Comparator|patients with preventive PICO|PICO dressing is used in patients with incisional hernia intraoperatively
2399419|NCT03576222|Placebo Comparator|patients with preventive MEPORE|MEPORE dressing is used in patients with incisional hernia intraoperatively
2399420|NCT03576209|Active Comparator|Intervention Group|12 week intervention
2399421|NCT03576209|No Intervention|Control Group|No walking program
2399422|NCT03576196|Experimental|Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
2399423|NCT03576196|Other|Usual Care|"Patients in the control group received usual care, which consists of an educational session prior to surgery, based on medical, anatomical and pathological aspects of the syndrome.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
3184505|NCT00725374|Placebo Comparator|Arm 2|Postmenopausal women of any age, requiring surgery for early invasive primary breast cancer, with estrogen receptor-positive tumor(s). Treated with placebo
3184506|NCT00725400|Active Comparator|1|Patients will receive a Cetuximab and Radiation Therapy.
2399426|NCT03576170|Active Comparator|aromatherapy-scent|
2399427|NCT03576170|Active Comparator|aromatherapy-touch|
2399428|NCT03576170|No Intervention|wait-list control|
2399429|NCT03576157|Experimental|Kilkari|Pregnant and postpartum women randomized to the Kilkari arm will receive health information messages over their mobile phone during pregnancy and up to 1 year postpartum.
2399430|NCT03576157|No Intervention|Comparison|Existing standard of care; no new health messages
2399431|NCT03576144|Experimental|BI 1265162|
2399432|NCT03576144|Placebo Comparator|Placebo|
2399433|NCT03576131|Experimental|GEN1029 (HexaBody®-DR5/DR5)|Open label, single arm trial where GEN1029 will be administered
3184507|NCT00725400|Active Comparator|2|Patients will undergo Surgery before or after Radiation Therapy.
3184508|NCT00725413|Experimental|Arm 1|Healthy premenopausal women requiring a long-term method of contraception
2399436|NCT03576105|Experimental|experimental group|G1 - 32 patients Photodynamic therapy with convention methylene blue as photosesintizer irrigation /sterile saline Conventional methylene blue as photosensitizer -Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Photodynamic therapy -Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
2399437|NCT03576105|Active Comparator|positive control group|G2 - 32 patients Photodynamic therapy with oral formula of methylene blue as photosesintizer, treatment identical to G1, however methylene blue will be delivered in a new formulation for oral use (patent aplicattion INPI BR1020170253902) irrigation /sterile saline Photodynamic therapy -Methylene blue for oral use as photosensitizer-Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
2399438|NCT03576092||Normal Pregnancy|Healthy gestational age-matched pregnant patients from 32 - 41 weeks without a diagnosis of preeclampsia.
2399439|NCT03576092||Preeclampsia Pregnancy|Pregnant patients from 32 - 41 weeks with a diagnosis of preeclampsia based on standard criteria as outlined by the American Congress of Obstetrics and Gynecology (ACOG).
2399440|NCT03576079|Experimental|Laser therapy|12 laser sessions over 3 months
2399441|NCT03576079|Active Comparator|anterior re-positioning splint therapy|anterior re-positioning splint worn for 8 hours during night time for 3 months
2399442|NCT03576079|Placebo Comparator|inactive laser therapy|placebo laser for 12 sessions over 3 months
3184509|NCT00725426|Experimental|1|Bosutinib
3184510|NCT00725439|Experimental|A|Talarozole
2399445|NCT03576053|Experimental|Histamine+cowhage+heat|
2399446|NCT03576053|Experimental|Histamine+cowhage+serotonin+pre-heating|
2399447|NCT03576053|Placebo Comparator|lidocaine and saline+heat|
2399448|NCT03576027|Experimental|Hyperbaric oxygen therapy|
3184511|NCT00725465||LAP surgery with CO2 colonoscopy|30 surgical patients, male and female undergoing laparoscopic surgical treatment for colorectal conditions such as neoplasm or rectal prolapse managed with intra-operative carbon dioxide (co2)colonoscopy for standard care of their medical condition.
3184512|NCT00725517|Experimental|1|Icodextrin group
3184513|NCT00725517|No Intervention|2|Glucose group
3184514|NCT00725556|Other|1|Speech therapy
3184515|NCT00725569|Active Comparator|A|Bellis perennis and Staphysagria (C6)
2399449|NCT03576014|Experimental|BD03|"This study will be comprised of 3+3 dose escalation design with three dose levels, 0.6mg (cohort1), 2mg(cohort2), 6mg(cohort3).~Decision to increase dose will be guided by occurrence of DLT (dose limiting toxicity) evaluated 1week after the second injection (5weeks after first injection)"
2399450|NCT03576001|Experimental|Multi-modality intervention group|Hybrid exercise (functional electrical stimulation - leg cycling, FES LC plus arm ergometry) plus Testosterone undecanoate
2399451|NCT03576001|Placebo Comparator|Placebo group|Hybrid exercise plus placebo medication
2399452|NCT03575988||Diabetes group|
2399453|NCT03575988||Control group|
3184516|NCT00725569|Active Comparator|B|Bellis perennis and Staphysagria (C30)
2399459|NCT03575949|Experimental|Diagnostic (FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV over 1 minute and undergo PET/CT at 70 and 180 minutes after injection at 12-14 weeks following standard CRT completion.
3143720|NCT00013247|Other|Arm 1|
3143721|NCT00013260|Other|Arm 1|
2399462|NCT03575923||Intervention site 1|2 planted trees; bulb planting
2399463|NCT03575923||Comparison site 1A|
2399464|NCT03575923||Comparison site 1B|
2399465|NCT03575923||Intervention site 2|12 planted trees; bulb planting; artificial tree decorations (string lights)
2399466|NCT03575923||Comparison site 2A|
2399467|NCT03575923||Comparison site 2B|
2399468|NCT03575923||Intervention site 3|3 planted trees; artificial tree decorations (string lights, tree socks)
2399469|NCT03575923||Comparison site 3A|
2399470|NCT03575923||Comparison site 3B|
2399471|NCT03575923||Intervention site 4|8 planted trees; bulb planting; artificial tree decorations (string lights, tree socks)
2399472|NCT03575923||Comparison site 4A|
2399473|NCT03575923||Comparison site 4B|
3143722|NCT00013390|Active Comparator|1|Tinnitus Masking
3143723|NCT00013390|Other|2|Tinnitus Retraining Therapy
3143724|NCT00013481|Other|1|
2399479|NCT03575884|Experimental|Screen Time Reduction Curriculum|Fit5Kids curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices.
2399480|NCT03575884|No Intervention|Control|Students will be taught the standard preschool curriculum.
2399484|NCT03575858|Experimental|Barrel shaped interdental brushes|test group
2399485|NCT03575858|Active Comparator|Tapered interdental brushes|control group
2399486|NCT03575845|Experimental|Occupational therapy informed yoga|Occupational therapists adapted postures to meet the abilities and rehabilitation needs of individual breast cancer survivors engaging in group-delivered yoga sessions
2399487|NCT03575832|Experimental|Supportive care (exercise, nutrition counseling)|Participants receive an exercise plan and printed materials at baseline. Participants also receive 10 telephone coaching calls over 45-60 minutes weekly during month 1, every 2 weeks during month 2, and every month during months 3-6. Participants complete 2 nutrition counseling sessions before month 3.
2399488|NCT03575819|Experimental|FOR46 (Dose Escalation)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will be enrolled into escalating dose levels during the Dose Escalation period of the study.
2399489|NCT03575819|Experimental|FOR46 (Dose Expansion)|Eligible patients will receive FOR46 administered as an IV infusion every 21 days. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
2399552|NCT03575286||Non-pregnant female|Patient has been determined not pregnant with a urine pregnancy test and, if applicable, a serum pregnancy test performed at Northwestern University.
3143725|NCT00013533|Experimental|1|Transplant with Induction Therapy
3143728|NCT00014079||Group 1|"DNA is examined for unstable elements (microsatellite instability and loss of heterozygosity) by analyzing at least 10 separate (CA)n-repeats localized to 5 separate chromosomes (5q, 8p, 15, 17p, and 18q). Loss of heterozygosity is analyzed for at least four chromosomal arms (5q, 8p, 17p, and 18q) and later other chromosomes (e.g., 1, 14, and 22). Immunohistochemistry is used to test for the presence or absence of the genes involved in DNA mismatch repair (hMLH1 and hMSH2).~Patients do not receive the results of the genetic testing and the results do not influence the type or duration of treatment."
3143729|NCT00014131|Experimental|Biological/Vaccine|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
3143730|NCT00014144|Experimental|ZD 1839|
3143731|NCT00014170|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily. Courses repeat every 8 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3143732|NCT00014196|Experimental|chemo/RT followed by consolidation chemo|cisplatin docetaxel radiation therapy
3143733|NCT00014235|Experimental|Arm I (indolent disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 180 and mycophenolate mofetil PO BID or IV every 8-12 hours on days 0 to 27."
3143734|NCT00014235|Experimental|Arm II (aggressive disease)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate and undergo TBI as in Arm I.~TRANSPLANTATION: Patients undergo donor PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID or IV every 8-12 hours on days -3 to 56 with a taper to day 70 and mycophenolate mofetil as in Arm I."
3143735|NCT00014378|Experimental|Chinese Herb Huanglian (Coptis chinesis)|
3143736|NCT00014534|Active Comparator|Gemcitabine + cisplatin|
3143737|NCT00014534|Active Comparator|Gemcitabine + Doxorubicin + Pegfilgrastim|
3143738|NCT00014612|Active Comparator|axillary lymph node dissection|complete axillary lymph node dissection
3143739|NCT00014612|Experimental|axillary radiotherapy|axillary radiotherapy, daily for 5 days a week, for 5 weeks
2399492|NCT03575793|Experimental|Phase I (Dose Escalation): nivolumab, ipilimumab and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (escalating cohorts, IV).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur.~Plinabulin escalation is as follows:~Level -1 : 13.5mg/m^2~Level 1 (start) : 20mg/m^2~Level 2 : 30mg/m^2"
2399493|NCT03575793|Experimental|Phase II: nivolumab, ipilimumab, and plinabulin|"On Day 1 in a 21-day cycle, all patients will receive nivolumab (1 mg/kg, IV), ipilimumab (3 mg/kg, IV) and plinabulin (MTD from Phase I).~After 4 treatment cycles, ipilimumab will be discontinued and patients will continue treatment with nivolumab 240 mg and plinabulin every 2 weeks (maintenance period) until one of the end of treatment criteria occur ."
2399494|NCT03575780|Experimental|KX2-391 Ointment|KX2-391 ointment 1% will be administered once daily over 5 consecutive days
3184517|NCT00725569|Placebo Comparator|C|Placebo Remedy
2399496|NCT03575741||Patients|After suffering from a concussion patients will be investigated 48 h, 72 h, 120 h, 360 h and 720 h after sustaining the injury. Postural control will be measured using 7 different easy balance tests.
2399497|NCT03575741||Control|Healthy children will be measured in the very same way to collect data of possible matched controls.
2399498|NCT03575728|Other|Mood disorder|Participants who screen positive for a history of mood disorders
2399499|NCT03575728|Other|Other|Participants who do not screen positive for a history of mood disorders
2399500|NCT03575715|Experimental|EBUS group|EBUS and guide sheath (GS) are inserted into bronchi in the assistance of navigation bronchoscopy. The EBUS probe and GS are confirmed to reach the lesion by EBUS images, cytologic and pathologic specimens are obtained with or without fluoroscopic guidance.
3184518|NCT00725582|Experimental|A|
3184519|NCT00725582|Placebo Comparator|B|
2399503|NCT03575689|Experimental|Splint|A. The Doyle splint will be places in both nostrils of the patient after septoplasty. The doyle splints will be removed 6 days after surgery as per standard of care. No other procedures will be changed during the surgery.
2399504|NCT03575689|No Intervention|No Splint|B. No Doyle splints will be placed in the nostrils of the patient after septoplasty. All standart of care visits will remain the same.
2399505|NCT03575676|Experimental|Group A|Administration of SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks, SOM3355 100mg BID for 6 weeks and placebo BID for 6 weeks.
2399506|NCT03575676|Experimental|Group B|Administration of placebo BID for 6 weeks, SOM3355 100mg BID for 6 weeks, SOM3355 200mg BID for 6 weeks and SOM3355 100mg BID for 6 weeks.
2399507|NCT03575650||Cardiac imaging modalities|Repeat echocardiography (cECHO), cardiac MRI (cMRI) scans and cardiac CT (cCT) scans will be performed to evaluate myocardial dysfunction and deformation; myocardium inclusing tissue abnormalities, cardiac morphology and function and; coronary artery lesions and coronary artery calcium score.
2399508|NCT03575637|Experimental|Olanzapine intervention group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
2399509|NCT03575637|No Intervention|Control group|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen.
2399510|NCT03575624|Experimental|Nutrition, goal-setting, yoga|Behavioral: Nutritional and goal-setting education, yoga to promote achievement of change in health behaviors. SMART goal setting was used to guide nutritional and physical activity change to decrease disease risk and promote well-being.
2399511|NCT03575611|Experimental|Treatment (SBRT)|Patients undergo SBRT over 1 day to 3 weeks based on the judgment of the treating radiation oncologist.
2399512|NCT03575598|Experimental|Sitravatinib and Nivolumab|"Patients will start therapy with sitravatinib within 10 days of study enrollment. Sitravatinib will be given at 120mg once daily on a continuous basis until 48 hours before planned surgery, or for a maximum period of 28 days.~Nivolumab will be given as a single infusion at a dose of 240mg, over a period of 30 minutes on Day 15 of the study."
2399513|NCT03575585|Experimental|Comparator: No Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
2399514|NCT03575585|Experimental|Active1: Feedback, Standard Counselor|Patient assigned to a Standard Training counselor, completed the BEST assessment, and received a personalized feedback report.
2399515|NCT03575585|Experimental|Active2: No feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, but did NOT receive a feedback report.
2399516|NCT03575585|Experimental|Active3: Feedback, Enhanced Counselor|Patient assigned to a Enhanced Training counselor, completed the BEST assessment, and received a personalized feedback report.
2399517|NCT03575572|Experimental|Colchicine|Colchicine will be given at 0.6 mg once daily for the duration of chest tube output plus 24 hours after chest tube removal with a maximum of 4 weeks duration.
2399518|NCT03575559|Experimental|Individual planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form up to three own individual plans. They are not allowed to speak to each other. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Individual planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, individual distraction task.
2399519|NCT03575559|Experimental|Collaborative planning|An education and general motivational treatment is provided to each participant. Afterwards, participants are filling in the planning forms together, referring to their joint physical activity. The friendship dyad forms up to three joint plans about engaging in PA together. The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, problem solving (coping planning). Interventions: Behavioral: Collaborative planning. Behavioral: Education and motivation. Active Comparator: No planning intervention, collaborative distraction task.
2399683|NCT03574415|Experimental|Caucasian_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
3184520|NCT00725595||E, 2, III|To treat CSR with ASV and Bilevel ventilators
3189066|NCT00773890|Experimental|TRF-1101|Daily treatment with TRF-1101
2399520|NCT03575559|Active Comparator|Individual distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies. Several questions will be asked about characteristics of the two super heroes in the movie and whether these heroes are comparable. Each participant watches the movie alone and answers all questions by him/herself. Both members of the dyad are not allowed to speak to each other.
2399521|NCT03575559|Active Comparator|Collaborative distraction task|An education and general motivational treatment is provided to each participant. Afterwards, participants have to interpret a short video showing scenes of two different superhero movies together. Several questions ask about the characteristics of the two super heroes in the movie and whether these heroes are comparable. Both members of the dyad watch the movie together and answer the questions conjointly.
2399522|NCT03575520|Experimental|Peg group|
2399523|NCT03575507|Experimental|Treatment Group|Treatment with the investigational device BTL EMSCULPT.
2399524|NCT03575494||female infertility|Women who had regular menses and can't conceive despite a long-term regular sexual intercourse for more than 12 months
2399525|NCT03575494||healthy|healthy patients who had minimum two normal pregnancies
2399526|NCT03575481||Post stroke patients|
2399527|NCT03575468|Experimental|Enhanced E-cigarette Coaching (EEC)|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
2399528|NCT03575468|Active Comparator|Quitline treatment as usual (TAU)|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
2399529|NCT03575455|Experimental|Exercise|"Concussed participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax.~Healthy participants will participate in a single 20' bout of treadmill walking at either 40% or 60% of the age-predicted HRmax."
2399530|NCT03575455|No Intervention|Seated Control|"Concussed participants will participate in a single 20' treatment session of seated rest.~Healthy participants will participate in a single 20' treatment session of seated rest."
2399531|NCT03575442|Other|"3 session program of art therapy"|Development of the program applied as a group, during three weeks, one session a week, each lasting approximately 90 minutes and assisted by a specialist in plastic expression. Each session was held in an occupational therapy room, including all the material deemed necessary for the execution of some of the techniques introduced by the technician. After each session, a semi-structured interview was conducted with each participant in order to analyze the meanings attributed.
2399532|NCT03575429|Active Comparator|Engagement Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates motivational interviewing (MI) and problem-solving education (PSE). The family navigator will meet with parents for up to 6 individual MI+PSE sessions for each 3-month stage of intervention.
2399533|NCT03575429|Active Comparator|Engagement + Coaching Intervention|Family navigators will engage families to access resources and support when they first learn their child has signs of autism spectrum disorder (ASD) using an intervention that integrates MI+PSE. Family navigators will also coach families to embed intervention strategies for toddlers with ASD in everyday activities using the Early Social Interaction (ESI) model. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places. The family navigator will meet with parents for 12 weekly home visits for each 3-month stage of intervention.
3143740|NCT00014820||Patients with a diagnosis of asthma (new) (Cases)|Patients with a physician diagnosis of asthma during the 7.5 years being studied who were working at the time of diagnosis, as determined by patient interviews.
3184521|NCT00725634|Experimental|AV-299 Dose Escalation Arm|AV-299 Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma
2399537|NCT03575390|Placebo Comparator|control group|Control group will receive placebo medication therapy
2399538|NCT03575390|Experimental|test group|pomegranate group will receive oral pomegranate (500 mg, twice per day)
2399539|NCT03575377|Experimental|Deterra Bag|These families will receive a Deterra® bag (a drug Disposal Aid) and instructions on its use by a research team member.
2399540|NCT03575377|No Intervention|Control|These families will receive routine postoperative instructions only.
2399543|NCT03575351|Active Comparator|Arm A - Standard of Care (SOC)|Subjects should receive SOC (R-DHAP, R-ICE or R-GDP) followed by HDCT (BEAM) and HSCT. Standard of care regimen will be administered as per investigator decision.
2399544|NCT03575351|Experimental|Arm B - JCAR017|Lymphodepleting chemotherapy with intravenous (IV) fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide IV (300 mg/m2/day for 3 days) (flu/cy) concurrently followed by JCAR017 infusion.
2399545|NCT03575338|Active Comparator|Open Scarf Osteotomy|This group of patients will undergo surgery performing an open scarf osteotomy
2399546|NCT03575338|Experimental|Minimally invasive scarf Osteotomy|This group of patients will undergo surgery performing a Minimally invasive scarf osteotomy
2399547|NCT03575325|Experimental|CPX-351 Treatment|"Participants will receive induction with CPX-351 at a dose of 100 u/m^2 administered intravenously over 90 minutes on days 1, 3 and 5 of a 28 day cycle.~This may be followed by consolidation with CPX-351 at a dose of 65 u/m^2 administered intravenously over 90 minutes on days 1 and 3 of a 28 day cycle (up to 3 cycles)."
2399548|NCT03575312|Experimental|Enrofloxacin|enrofloxacin by dermal route, by inhalation, oral adminstration
2399549|NCT03575299|Experimental|Study group|Patients will be treated with anti-tuberculosis drugs, and meanwhile will be treated with Allogeneic γδT cells.
2399553|NCT03575273|Experimental|Opioid dependence receiving methadone|Patients with a history of opioid dependence receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2399554|NCT03575273|Experimental|Opioid dependence not on methadone|Patients with a history of opioid dependence not current receiving methadone maintenance therapy will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2399555|NCT03575273|Active Comparator|Healthy controls|Healthy controls without history of opioid use will be administered Sniffin' Sticks Odor Identification and Hedonic Scale, Sucrose Taste Preference Assessment, Food Preferences Task, Progressive Ratio Task, Clinical Electrophysiology, and Standardized Meal and Hunger and Satiety Ratings
2399556|NCT03575260||Fulvestrant|Fulvestrant 500 mg on days 0, 14, and 28, and every 28 days thereafter
2399557|NCT03575260||Exemestane|Exemestane 25mg per day
2399558|NCT03575234|Experimental|Treatment (nivolumab, cyclophosphamide, IRX-2, surgery)|Participants receive nivolumab IV over 60 minutes on days 1 and 15, cyclophosphamide IV on day 1, and IRX-2 SC over 10 consecutive days between days 4-21 in the absence of disease progression or unacceptable toxicity. Beginning days 25-30, participants undergo surgery.
3143741|NCT00014820||Patients with a diagnosis other than asthma (Controls)|Patients (age-matched to a case patient) with a physician diagnosis other than asthma who were working at the time of diagnosis.
3143742|NCT00014820||Patients with a diagnosis of asthma (previous)|Patients with a physician diagnosis of asthma prior to the 7.5 years being studied
2399562|NCT03575195|Experimental|Intervention|Rifaximin
2399563|NCT03575195|Placebo Comparator|Placebo|Matching placebo
2399564|NCT03575182|Experimental|Gait retraining program|
2399565|NCT03575182|No Intervention|Physical therapy standard care|
2399566|NCT03575169||Patients with TBI|Admitted to Aberdeen ICU with diagnosis of TBI and expected to require greater than 24 hours sedation.
2399567|NCT03575156|Experimental|Systemic lupus erythematosus (SLE)|
2399568|NCT03575156|Experimental|systemic scleroderma (SSc)|
2399569|NCT03575143||PLWH+OSA|Subjects diagnosed with both Human Immunodeficiency Virus and Obstructive Sleep Apnea
2399570|NCT03575143||PLWH-OSA|Subjects diagnosed with both Human Immunodeficiency Virus without Obstructive Sleep Apnea
2399571|NCT03575130|Experimental|Glanatec|
2399572|NCT03575130|Placebo Comparator|Placebo|
2399573|NCT03575117|Experimental|NCI HYT--GA + CSM--Be Well|"Participants who view the Common Sense Model (CSM) Be Well text and image communication will be invited to receive two sets of daily text messages: (1) one text message and one image per day and (2) National Cancer Institute (NCI) HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view a slide presentation with imagery and text related to colorectal cancer risk and sedentary lifestyle. The same messages will be delivered as a drip campaign alongside the NCI HYT-GA text messaging program."
2399574|NCT03575117|Other|NCI HYT--GA + ACS usual messages|Adapted American Cancer Society (ACS) informational messages about colorectal cancer risk and lifestyle will be invited to receive one set of daily text messages, NCI HealthyYouTXT-Get Active (HYT-GA) program that is delivered 2-5 times daily for 6 weeks. After baseline and at timepoint 2, participants will view an informational slide presentation that is based on adapted language from American Cancer Guidelines related to cancer prevention and physical activity (https://www.cancer.org/healthy/eat-healthy-get-active/acs-guidelines-nutrition-physical-activity-cancer-prevention.html).
2399575|NCT03575104|Experimental|ACT-541468 10 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2399576|NCT03575104|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2399577|NCT03575104|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
2399578|NCT03575091|No Intervention|control group|The infants will receive the standard care at the ward.
2399579|NCT03575091|Experimental|Non-individualized|The parents will be guided manually by the nursing staff and receive written information about how to change body positions of their child regularly throughout the hospital stay.
2399580|NCT03575091|Experimental|Individualized|The infant will receive frequent changes of body positions, stimulation to physical activity, and stimulation to deep breathing while bouncing on a large ball in the arms of an adult. Additional light chest compressions and inhalations may be given. A physiotherapist will perform the intervention at least once daily, and the parents will be manually guided and receive written information about how to change body positions of their child regularly in a similar way throughout the hospital stay.
2399581|NCT03575078|Experimental|Maximum tolerated dose of ARQ761 in combination with Olaparib.|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
2399582|NCT03575065|Experimental|Cohort 1: Triple-negative breast cancer (TNBC)|Locally advanced or metastatic TNBC
2399583|NCT03575065|Experimental|Cohort 2: HR(+)/HER2(-) breast cancer|Locally advanced or metastatic HR(+)/HER2(-) breast cancer
2399586|NCT03575039|Experimental|Single arm clinical investigation|Subjects in experimental group will be implanted the VitaFlow II Transcatheter Aortic Valve System.
2399587|NCT03575026|Experimental|Intervention|Subjects will receive 12-week music-with-movement intervention at home by their trained caregivers for 12 weeks, at least 3 sessions per week and 30 minutes for each session.
2399588|NCT03575026|Placebo Comparator|Wait-list control|Subjects will receive 12-week usual care (social activity) at home. Dose is similar to intervention arm. After the completion of 12-week usual care, subjects will receive the same music intervention as intervention arm.
2399589|NCT03575013|Experimental|Avelumab and Docetaxel|"Induction phase:~Avelumab (10 mg/kg) + Docetaxel (75 mg/m2) every 3 weeks for 6 cycles~Maintenance phase:~Avelumab (10 mg/kg) every 2 weeks until disease progression or toxicity"
2399645|NCT03574610|Experimental|Subjects with Multiple Sclerosis and Voiding Dysfunction|Subjects with Multiple Sclerosis (MS) and voiding dysfunction (VD). In this group 'Transcranial Rotating Permanent Magnet Stimulator (TRPMS)' device will be used.
2399590|NCT03575000|Experimental|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
2399591|NCT03574987|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
2399592|NCT03574987|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
2399593|NCT03574987|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
2399594|NCT03574974|Experimental|Experimental Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators believe may help them learn to control their PTSD symptoms.
2399595|NCT03574974|Placebo Comparator|Control Feedback Intervention|Participants receive real-time feedback during fMRI scans that the investigators do not believe can help their PTSD symptoms.
2399596|NCT03574961|Experimental|e-Support Group|Participants in this arm will receive the treatment, 12 weeks of 1-hr weekly moderated e-Support sessions.
2399597|NCT03574961|Placebo Comparator|e-Journaling Placebo|Participants in this arm will complete 12 weeks of 1-hr weekly online journaling activities.
2399598|NCT03574948|Experimental|5-HTP|8 weeks active substance 5-HTP (2 x 100 mg per day)
2399599|NCT03574948|Placebo Comparator|placebo oral capsule|8 weeks placebo (2 x 1 capsule per day)
2399600|NCT03574935|Experimental|External Chinese medicine|"External Chinese medicine include 3 kinds of formula，including:~Qin, Hua and Bu will be applied to cover the participants' lesions in wet dressing form. Dosage form:5g/ml; frequency:qd; duration:2months."
2399601|NCT03574935|Active Comparator|External Western medicine|Ethacridine Lactate Solution, 1% Sulfadiazine Silver Cream and rb-bFGF will be applied to cover the participants' lesions. Dosage form:3g/ml; frequency:qd; duration: 2months.
2399602|NCT03574922|Active Comparator|Balance Exercises|Balance Exercises
2399603|NCT03574922|Active Comparator|Core Stabilization Exercises|Balance and core stabilization exercises
2399604|NCT03574922|No Intervention|Control|Assessments only
2399605|NCT03574909|Experimental|Treatment Arm|"Treatment Arms: Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide. Tromalyt® is trademark of Meda Pharma SL (Reg 59.210).~There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
2399606|NCT03574909|Placebo Comparator|Control Arm|"Placebos to be used are hard gelatin capsules (Sanitatis®) for patients randomized to the placebo arm. These capsules are externally identical to Tromalyt capsule. The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate (Sanitatis®) Placebo: There is no requirement for the first dose to be administered in the clinic under observation.~The dosing frequency is once daily. Subjects will be instructed to take the study medication at the same time each day.~No specific precautions are required in relation to concomitant food intake."
2399607|NCT03574883|Experimental|In-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference between the two stimulation sites will be 0°.
2399608|NCT03574883|Active Comparator|Anti-phase tACS|6 Hz stimulation (1000 μA) will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator. The phase difference will be 180°,
2399609|NCT03574883|Sham Comparator|Sham tACS|The stimulation (anti-phase) will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
2399610|NCT03574883|Experimental|Active tDCS|1000 μA tDCS stimulation will be applied simultaneously over the left prefrontal dorso-lateral cortex (F3 of the 10-20 international scalp EEG system) and the left parietal cortex (P3) for 20 minutes using an 8-channels stimulator
2399611|NCT03574883|Sham Comparator|Sham tDCS|The stimulation will start with a current intensity of 1000 μA lasting for 30 seconds. Afterwards, the intensity will progressively decrease over 20 seconds until cessation.
2399612|NCT03574870|Experimental|Chemoraditherapy|"Patients with head and neck cancer require chemo and radiation therapy (Cohort A):~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from the time of their radiation simulation through one week following the end of radiation treatment"
2399613|NCT03574870|Experimental|Primary surgery w/o radiotherapy|"Patients with head and neck cancer require primary surgery alone (Cohort B-SA)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery through 1 month following surgery~Patients with head and neck cancer require primary surgery and postoperative radiotherapy (Cohort B-RT)~A wearable sensor device will be issued at the time of trial enrollment. Patients will be instructed to wear the device on their wrist for 23 hours per day, 7 days per week, from one week before surgery to one week following the end of radiation treatment ."
2399614|NCT03574857|Active Comparator|Metolazone|Metolazone 5 mg by mouth once daily for 2 days
2399615|NCT03574857|Active Comparator|Chlorothiazide|Chlorothiazide 500 mg IV once daily for 2 days
2399616|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 500|Saccharomyces cerevisiae CNCM I-3856, 500 mg per day (2 capsules), for 4 weeks
2399617|NCT03574844|Experimental|Saccharomyces cerevisiae, dose 1000|Saccharomyces cerevisiae CNCM I-3856, 1 g per day (2 capsules), for 4 weeks
2399618|NCT03574844|Placebo Comparator|Placebo|Maize starch and magnesium stearate, 1 g per day (2 capsules), for 4 weeks
2399619|NCT03574831||Stretta|Radio Frequency Ablation (RFA) using a Stretta device.
2400919|NCT03566134|Experimental|DA-8010 5mg|DA-8010 5mg + Solifenacin succinate placebo
3184522|NCT00725634|Experimental|AV-299 in combination with erlotinib|AV-299 Administered by IV Infusion in Combination with Erlotinib (150 mg daily) in Advanced Solid Tumors
2399621|NCT03574805|Active Comparator|PRS-060|PRS-060 or Placebo
2399622|NCT03574805|Placebo Comparator|Placebo|PRS-060 or Placebo
2399625|NCT03574779|Experimental|Cohort A: 1-2 prior lines of therapy|PARP Inhibitor-Naive Platinum-Resistant Ovarian Cancer Treatment Cohort with TSR-042, Bevacizumab, and Niraparib. TSR-042 administered every 3 weeks for 4 cycles (each cycle is 21 days), followed by every 6 weeks beginning on cycle 5 day 1 until progressive disease (PD) or toxicity. Bevacizumab administered 15 milligram per kilogram (mg/kg) every 3 weeks for up to 15 months. Niraparib 200 or 300 mg per day until PD or toxicity.
2399626|NCT03574766|Experimental|Meditation Group|Twenty minutes of daily meditation for 7 days. Routine lactation support.
2399627|NCT03574766|No Intervention|Control Group|Routine lactation support.
3143743|NCT00014859||Population-based cohort|Descriptive cohort of population-based DNA samples from the newborn screening program in Missouri with vital statistics based, linked phenotype data
2399629|NCT03574740||Entire population|All patients included in this retrospective study. These patients were analyzed following their tobacco smoking habits.
2399630|NCT03574701|Experimental|A: Vitamin A and Olfactory Retraining|Group A: This study group will receive intranasal vitamin A at 10,000 I.U. per day and olfactory retraining using scented oils in addition to their standard of care.
2399631|NCT03574701|Experimental|B: Vitamin A|Group B: This study group will receive Vitamin A in addition to their standard of care. They will not receive olfactory retraining.
2399632|NCT03574701|No Intervention|C: Standard of Care|Group C: This study group will receive only standard of care .
2399633|NCT03574688|Experimental|Water intervention|The participants increase their habitual daily water intake with 1.5 Liters of tap water per day during 6 weeks.
2399634|NCT03574675|Experimental|Order Sham/Hypoxia|"The participants will be consecutively exposed to shamed hypoxia (FiO2: 20.9%) equivalent to sea level and to simulated altitude (FiO2: 15.1%) equivalent to 2500m above sea level administered by an altitude simulator (Altitrainer, SMTEC) with a facemask."
2399635|NCT03574675|Experimental|Order Hypoxia/Sham|"The participants will be consecutively exposed to hypoxia (FiO2: 15,1%) equivalent to 2500m above sea level and to shamed hypoxia (FiO2: 20.9%) equivalent to sea level administered by an altitude simulated (Altitrainer, SMTEC) with a facemask."
2399636|NCT03574662|Experimental|Frailty assessment in Advanced heart failure|Subjects with advanced heart failure defined as current or recent (within the last 3 months) New York Heart Association (NYHA) class III or IV symptoms.
2399637|NCT03574649|Experimental|NANT NSCLC Combination Immunotherapy regimen|
2399638|NCT03574649|Active Comparator|Standard of Care|
2399639|NCT03574636|Active Comparator|OCT guidance|"Firehawk stent implantation will be performed with Optical Coherence Tomography guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2399640|NCT03574636|Active Comparator|IVUS guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2399641|NCT03574636|Active Comparator|QCA guidance|"Firehawk stent implantation will be performed with Intravascular Ultrasound guidance.~At the end of the procedure, a final DSA imaging run and OCT measurement must be performed.~At 13-month follow-up, DSA imaging run must be performed. At 3-month follow-up, OCT imaging run must be performed in the first 66 consecutive patients."
2399642|NCT03574623|Experimental|CCFES|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.
2399643|NCT03574623|Active Comparator|cNMES|Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.
2399644|NCT03574623|Active Comparator|Task Oriented Therapy|Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.
3143744|NCT00014859||Trio sequencing cohort|Affected infant/child (term or near term infant with progressive respiratory distress or other rare pulmonary phenotype or older child with interstitial lung disease or other rare pulmonary phenotype) and parents
3184523|NCT00725647||Treated PDA|Infants who had a PDA which the attending physicians treated medically or surgically.
3184524|NCT00725660||1|Pregnant women in second trimester that took the routine triple test, and are having an early routine detailed ultrasound examination.
3184525|NCT00725673||1|GOLD II COPD patients with osteoporosis
3143745|NCT00015210|Active Comparator|Nefazodone|Nefazodone 100 mg tablet, titrated to a maximum of 200 mg administered twice daily by treatment day 10. Drug tapered over 7 days at the conclusion of the treatment period. Treatment was administered for 8 weeks.
3143746|NCT00015210|Placebo Comparator|Matched Placebo Tablet|Matched placebo tablet, titrated up to 2 tablets twice daily by day 10 and tapered over 7 days at the conclusion of the study. Treatment period lasted 8 weeks.
2399648|NCT03574584|Experimental|NNC0165-1562 + Semaglutide|Participants will receive NNC0165-1562 and semaglutide once weekly for 20 weeks.
2399649|NCT03574584|Experimental|Placebo (NNC0165-1562) + Semaglutide|Participants will receive placebo (NNC0165-1562) and semaglutide once weekly for 20 weeks.
3143747|NCT00015340|Experimental|Buprenorphine/Naloxone|
3143748|NCT00015821|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
2399652|NCT03574558|Experimental|MD-Logic Switch Advisor|MD-Logic Switch Advisor Algorithm for personalized automated determination of insulin pump settings for subjects with type 1 diabetes switching from MDI to pump therapy and vice versa
3143749|NCT00015834|Experimental|Treatment (imatinib mesylate, cytarabine)|Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.
3143750|NCT00015873|No Intervention|A no VIMARAM|No VIMARAM preceding maintenance treatment
2399655|NCT03574532||Hospitalized adults with RSV, hMPV and influenza A infections|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Influenza A Infected adults that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
2399656|NCT03574532||Hospitalized infants/children with RSV or hMPV infection|Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV) and Infected Infants/Children that required hospitalization or were infected by these viruses while being hospitalized during the prespecified recent past season(s) will be retrospectively observed to describe the proportion and burden of the different types of respiratory pathogens. The primary data source for this study will be the medical records of each participating participant.
2399657|NCT03574519|Experimental|Non-contingent incentives and weekly feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive weekly updates about their performance.
2399658|NCT03574519|Experimental|Non-contingent incentives and daily feedback|Participants will receive payment for participating in the study (regardless of goal attainment) and will receive daily updates about their performance.
2399659|NCT03574519|Experimental|Contingent incentives and weekly feedback|Participants will receive payment for meeting their daily goals and will receive weekly updates about their performance.
2399660|NCT03574519|Experimental|Contingent incentives and daily feedback|Participants will receive payment for meeting their daily goals and will receive daily updates about their performance.
3143751|NCT00015873|Experimental|B - VIMARAM|VCR i.v. 1.5 mg/m2/d - 4 days 6-MP p.o. 25 mg/m2/d - 15 days HD-MTX p.i.(24hr) 5 g/m2 - 2 days MTX + pred I.T. (age adapted) - 2 days HD-Ara-C p.i (3hr) 3 g/m2/12 hrs -8 days L-ASP p.i. (1hr) 5.000 U/m2 - 2 days
3143752|NCT00015912|Experimental|Treatment (interferon-alpha, thalidomide)|Patients receive interferon alfa subcutaneously every 12 hours and oral thalidomide daily in the absence of disease progression or unacceptable toxicity.
2399665|NCT03574480|Experimental|Control|Advice on healthy diet and physical activity recommendations
2399666|NCT03574480|Experimental|Intervention|"Advice on healthy diet and physical activity recommendations~Training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary."
2399667|NCT03574467||Bobath Approach Applied to Patient with Brain Tumors|
2399668|NCT03574467||Bobath Approach Applied to Patient with Stroke|
2399669|NCT03574454|Other|Phase 1 - Mixed Scan Data Training Set|Machine learning (ML): A mixed data set of 200 WB-MRI scans comprising scans obtained from 40 healthy volunteers (scanned for the purposes of the study), 40 previously acquired inactive myeloma WB-MRI scans and 120 previously acquired active myeloma WB-MRI scans, in which machine learning and convolutional neural networks will be trained to recognise healthy marrow, treated inactive previous myeloma and active myeloma. An algorithm will be developed for testing in phase 2.
2399670|NCT03574454|Other|Phase 2 - Mixed Scan Data Validation Set|Machine Learning (ML): A mixed data set of 353 WB-MRI scans as that comprising 50 healthy volunteers (scanned for the purposes of the study), and previously acquired scans from 303 myeloma patients, 100 of whom have inactive disease and 203 of whom have active myeloma. The scans will be read by radiologists in random order either with or without the support of for the detection of active myeloma. The diagnostic performance of the radiology reads with or without the machine learning support will be measured against an expert panel reference standard.
2399671|NCT03574454|Other|Phase 3 - Disease Burden Paired Data Set|Machine Learning (ML): Approximately 200 paired WB-MRI scans from 100 patients (scanned at baseline with active disease and then post treatment) will be used to develop a machine learning tool to quantify the burden of disease. The machine learning algorithm will then be tested on a further additional set of 60 patients who previously had two WB-MRI scans comprising paired baseline (with active disease) and post treatment scans. The agreement of radiology readers to evaluate the burden of disease will be measured against the reference standard (expert panel) with and without machine learning support.
2399675|NCT03574428|Active Comparator|Cohort 1|GNbAC1 36 mg/kg single i.v. dose or GNbAC1 placebo
2399676|NCT03574428|Active Comparator|Cohort 2|GNbAC1 60 mg/kg single i.v. dose or GNbAC1 placebo
2399677|NCT03574428|Active Comparator|Cohort 3|GNbAC1 85 mg/kg single i.v. dose or GNbAC1 placebo
2399678|NCT03574428|Active Comparator|Cohort 4|GNbAC1 110 mg/kg single i.v. dose or GNbAC1 placebo
2399679|NCT03574415|Experimental|Japanese_DWP14012 Amg|DWP14012 Amg, tablets, orally, single and multiple administration
2399684|NCT03574415|Experimental|Korean_DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single and multiple administration
2399685|NCT03574415|Experimental|Korean_DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single and multiple administration
2399686|NCT03574415|Placebo Comparator|Placebo|DWP14012 placebo-matching tablets
2399687|NCT03574402|Experimental|Arm1: Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
2399688|NCT03574402|Experimental|Arm2: Chidamide plus Afatinib|"Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide.~Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle."
2399689|NCT03574402|Experimental|Arm3: crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2399690|NCT03574402|Experimental|Arm4: X396|Patients with MET amplification receive X396 225mg PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2399691|NCT03574402|Experimental|Arm5: X396|Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399692|NCT03574402|Experimental|Arm6: X396|Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399693|NCT03574402|Experimental|Arm7: Pyrotinib Maleate|Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399694|NCT03574402|Experimental|Arm8: AZD3759|EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399695|NCT03574402|Experimental|Arm9: Pirotinib|"Patients with EGFR20ins mutation positive receive Pirotinib.~This arm was divided into three groups:~Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2."
2399696|NCT03574402|Experimental|Arm10: Nimotuzumab plus gemcitabine and carboplatin|"Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399697|NCT03574402|Experimental|Arm11: Nimotuzumab plus pemetrexed and cisplatin|"Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1.~21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399698|NCT03574402|Experimental|Arm12: Pirotinib|"Patients with rare EGFR mutation receive Pirotinib.~This arm was divided into two groups:~Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1."
2399699|NCT03574402|Experimental|Arm13: Avitinib|Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28. 28 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399700|NCT03574402|Experimental|Arm14: Sintilimab|Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
2399701|NCT03574402|Experimental|Arm15: Sintilimab|"Patients with TMB≥10 mut/Mb，1%≦PD-L1<50% without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399702|NCT03574402|Experimental|Arm16: Sintilimab|"Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement.~Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399703|NCT03574402|Experimental|Arm17: Sintilimab plus pemetrexed and cisplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399704|NCT03574402|Experimental|Arm18: Sintilimab plus Gemcitabine and carboplatin|"Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation.~Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity."
2399738|NCT03574103|Experimental|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
2399739|NCT03574103|Experimental|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric and time restriction as dietary weight loss strategy.
2399707|NCT03574376|Active Comparator|Bupivacaine Liposome Injection [Exparel]|Patients will receive a nerve block with a medication called liposomal bupivacaine, also called Exparel. Once assigned, a University of Illinois surgeon, or resident surgeon, will administer the nerve block. The nerve block is expected to provide pain relief from 72 to 96 hours. During this time, patients may request oral or intravenous pain medication for breakthrough pain. Patients will remain in the hospital until discharged by the attending physician.
2399708|NCT03574376|Active Comparator|Epidural 0.125% bupivicaine|"Patients will receive pain relief through a 0.125% bupivacaine epidural in the upper back by an assigned anesthesiologist. This epidural will remain in place for an uncertain amount of time. The decision to remove the epidural will be determined by the physicians and will be based on level of pain and injury.~However, pain data will only be recorded by the research team for no longer than 96 hours after the epidural is placed. Patients are able to request intravenous and oral pain medications for breakthrough pain. After the epidural is removed, they will remain in the hospital until discharged by the attending physician."
2399709|NCT03574363|Experimental|KBP-5074 0.25 mg tablet|KBP-5074 0.25 mg tablet QD orally, 84 days
2399710|NCT03574363|Experimental|KBP-5074 0.5 mg tablet|KBP-5074 0.5 mg tablet QD orally, 84 days
2399711|NCT03574363|Placebo Comparator|Placebo tablet|Placebo tablet QD orally, 84 days
2399712|NCT03574350|Experimental|KS in Kangaroo Position (KSKP)|KS is performed while the infant is in Kangaroo Position using a lycra band to maintain the position.
2399713|NCT03574350|Active Comparator|KS in incubator (KSI)|The infant is in the incubator, unclothed with diaper.
2399714|NCT03574337|Active Comparator|Sugammadex|Patient's will receive sugammadex at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight and TOF ratio by the pharmacy. It will be a one time dose at the end of the case
2399715|NCT03574337|Active Comparator|Neostigmine/glycopyrrolate|Patient's will receive neostigmine/glycopyrrolate at the end of the case for reversal of neuromuscular blockade. The dosing will be determined based on the patient's weight (50mcg/kg of neostigmine with an equivalent volume to volume ratio of glycopyrrolate). It will be a one time dose at the end of the case
2399716|NCT03574337|No Intervention|No reversal administered|No reversal administered at the end of the case
2399717|NCT03574324|Experimental|TPF+CCRT|TPF neoadjuvant chemotherapy followed by cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy
2399718|NCT03574324|Other|CCRE+PF|Cisplatin chemotherapy concurrent combined with intensity-modulated radiation therapy followed by PF adjuvant chemotherapy
2399719|NCT03574311|Experimental|Ferric carboxymaltose|Preoperative 1000 mg intravenous single dose as 30 minute infusion
2399720|NCT03574311|Placebo Comparator|Placebo|Preoperative 100 ml saline as 30 minute infusion
2399721|NCT03574285|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
2399722|NCT03574285|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
2399723|NCT03574272|Experimental|Patient Transfer Monitoring System|
2399724|NCT03574246|Experimental|CHXBNZ|Pharyngeal pack moisturized with chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15 and placed to oropharynx
2399725|NCT03574246|Active Comparator|SF|Pharyngeal pack moisturized with %0,9 NaCl and placed to oropharynx
2399726|NCT03574233||patients who are ready to wean ventilator off|
2399727|NCT03574220|Experimental|Pembrolizumab + Stereotactic Body Radiotherapy|"Lung SBRT 50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-15 days.~Adjuvant Therapy:~Pembrolizumab 200mg IV every 21 days for 6 months"
2399730|NCT03574194|Experimental|Methionine-restricted diet|6-10 weeks methionine-restricted diet (MRD) curative intent radiation therapy course of 6 weeks or less.
2399731|NCT03574168|Experimental|CD19-CAR-T Cells|Subjects will receive CD19-CAR-T Cells on Day 0 : 100% of total dose.
2399732|NCT03574155|No Intervention|Control- group|"It is composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium, who will receive preoperative and postoperative guidelines according to the usual routine for the perioperative period of the present institution. Patients and their followers of the control group will participate in a preoperative consultation with the surgeon to discuss the indication of the procedure and its risks, benefits and alternatives to the procedure being indicated, if any.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
2399733|NCT03574155|Experimental|Experimental Group|"Composed of patients scheduled for surgical treatment by tumors of the uterine cervix, vulva, ovary or endometrium who will receive preoperative counseling and education through a pre-defined protocol after preoperative consultation with the surgeon. The counseling session will take place with at least one companion. The purpose of this session is to supplement, re-emphasize and strengthen the perioperative guidelines. An illustration (explanatory folder) will be used to demonstrate the location of the surgery, how the scar will be and on which sites of the abdomen and organs the surgery will cover. All this counseling and education will be applied at the same time to the patient and her companion. At the end of the intervention, a space will be left open for both the patient and the companion to ask questions and questions.~Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)"
2399734|NCT03574142|Experimental|Epanova|Epanova® capsule, per oral
2399735|NCT03574129|Experimental|Adolescent transition package|Adolescent transition package
2399736|NCT03574129|No Intervention|Standard of care|Standard of care adolescent services
2399737|NCT03574103|Active Comparator|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction as dietary weight loss strategy.
2399908|NCT03572946|Active Comparator|standard biopsy group|Standard prostate biopsy
2399740|NCT03574090|Experimental|amoxicillin clavulanate|1000 mg amoxicillin and potassium clavulanate equivalent to 200mg of clavulanic acid. administered topically and dissolved in 500 ml 0.9% Physiological Serum.
2399741|NCT03574090|Active Comparator|Physiological Saline|500 milliliters of 0.9% Physiological Serum.
2399742|NCT03574077|Experimental|Instant messaging|AWARD advice + NRT sampling + Active referral + Instant Messaging (IM)
2399743|NCT03574077|Active Comparator|SMS messaging|AWARD advice + NRT sampling + Active referral + SMS messaging
2399744|NCT03574064|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2)
2399745|NCT03574064|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP)
2399746|NCT03574064|Experimental|GLP-2+GIP|GLP-2+GIP
2399747|NCT03574064|Placebo Comparator|Placebo|Placebo
2399748|NCT03574051|Experimental|Probiotic|Taking probiotics containing Bifidobacterium infantis, Lactobacillus acidophilus and Enterococcus faecalis for 30 days
2399749|NCT03574038|Active Comparator|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
2399750|NCT03574038|Sham Comparator|Sham Stimulation|Sham Stimulation
2399751|NCT03574025||Cardiac Arrest Questionnaire|Children who will survive 3 months after Cardiac Arrest
2399752|NCT03574012|Active Comparator|Control Group (general health information, fitness tracker)|Participants receive general information about physical activity and diet, and access to Fitbit and Healthwatch.
2399753|NCT03574012|Experimental|Intervention Group (individualized information, tracker)|Participants receive individualized goal-setting and coaching in relation to physical activity and diet, supplemented with peer support through the study's social media platform, over 4 months. They also have access to mHealth apps including Fitbit and Healthwatch that provide feedback on physical activity and diet.
2399754|NCT03573999|Active Comparator|Mannitol 20%|Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.
2399755|NCT03573999|Experimental|Hypertonic saline 7.5%|Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening
2399756|NCT03573986|Experimental|Arm A|
2399757|NCT03573973|Experimental|Fresh fruit and vegetable placement intervention|The intervention is a store refurbishment programme that includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the availability and position of fresh fruit and vegetables.
2399758|NCT03573973|Sham Comparator|Control|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
2399760|NCT03573947|Experimental|nivolumab, ipilimumab and paclitaxel|
2399761|NCT03573934|Experimental|GLP-2|Glucagon-Like Peptide-2 (GLP-2) injection
2399762|NCT03573934|Experimental|GIP|Glucose-dependent Insulinotropic polypeptide (GIP) injection
2399763|NCT03573934|Experimental|GLP-2+GIP|GLP-2+GIP injection
2399764|NCT03573934|Placebo Comparator|Placebo|Placebo injection
2399765|NCT03573921|Experimental|Gastrografin Arm|Patients will receive a single dose of undiluted Gastrografin via the nasogastric tube at 24 hours after admission for small bowel obstruction. The dose of Gastrografin will be proportional to the patient's weight and age and will be based off of the recommendations from the drug manufacturer. Dosages will range from 30 ml for infants to children less than 5 years old and 60 ml for children 5-18 years and will not be diluted.
2399766|NCT03573921|Experimental|Control Arm|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
3184526|NCT00725673||2|GOLD II COPD patients with a normal bone mineral density
3189067|NCT00773890|Placebo Comparator|Placebo|Daily treatment with placebo
2399769|NCT03573895|Experimental|Foam-Roller|
2399770|NCT03573895|Experimental|Neuromuscular Stretching|
2399771|NCT03573895|Experimental|Pasive stretching|
2399772|NCT03573895|No Intervention|Control|
2399773|NCT03573882|Other|Voxelotor|Participants will receive voxelotor (GBT440) at the highest dose (either 900 mg or 1500 mg) deemed safe by the Data Safety Monitoring Board (DSMB).
2399774|NCT03573869|Experimental|Cryoballoon ablation|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
2399775|NCT03573869|No Intervention|Standard treatment|Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment
3143753|NCT00015938|Experimental|treatment|docetaxel and vinorelbine with filgrastim support
3143754|NCT00015964|Experimental|Daily administration of ZD1839|
2399778|NCT03573843|Placebo Comparator|Control|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the Control group: They will continue to receive the standard prevention measures: delirium detection, treatment health team education and the patient's family, sleep hygiene plan, early mobilization , resolve sensorial deterioration, and delivery of information of temporal-spatial reorientation in a continuous manner, plus the use of a mobile device without installed delirium prevention software (placebo).
2399909|NCT03572933|Experimental|Ganaxolone|ganaxolone suspension (50 mg/ml) 3x's /day for 17 weeks
2399910|NCT03572933|Placebo Comparator|Placebo|placebo suspension 3x's /day for 17 weeks
3143755|NCT00015977|Experimental|PSMA peptide vaccine|Immunization with PSMA peptide vaccine followed by injection of Interleukin-12 (IL-12) on Day 1 of a 21-day cycle. Additional injections of IL-12 given on Days 3 and 5 of each cycle.
3143756|NCT00015990|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity.
2399779|NCT03573843|Experimental|Experimental|Patients who meet the inclusion / exclusion criteria will be randomly assigned to the experimental group:They will continue to receive standard prevention measures: Detection of delirium, education of health care team and the patient's family, sleep hygiene plan, early mobilization, resolve sensory impairments, and delivery of information of temporal-spatial reorientation in continuously, plus the use of software installed on a mobile device designed to support the prevention of delirium (Prevention software).
2399787|NCT03573791||Complete response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging ypT0N0 as complete response.
2399788|NCT03573791||Poor response|After neoadjuvant therapy, postoperative pathological examination will be performed to evaluate the efficacy of the therapy. Define postoperative staging >ypT1-2N0 as poor response.
2399789|NCT03573778|Experimental|iHEAL|10-18 visits (over 6 months) with a Registered Nurse
2399790|NCT03573778|Active Comparator|Usual Care|Information about Community Services
2399793|NCT03573726|Other|Technically N/A, Crossover Design|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
2399794|NCT03573713|Experimental|IPT-G (Treatment arm)|This arm will receive IPT-G for 12 weeks. Following IPT-G, this arm will go on to receive the Care Group intervention parallel to the control arm.
2399795|NCT03573713|Other|Control arm (Treatment as usual - Care Group)|This arm will receive assessment only at the beginning of the study (parallel to the start of IPT-G) and then receive the Care Group intervention after 12 weeks together with the IPT-G arm.
3143757|NCT00016016|Experimental|Treatment (flavopiridol, cytarabine, mitoxantrone)|Patients receive flavopiridol IV over 1 hour on days 1-3 and cytarabine IV continuously on days 6-9 followed by mitoxantrone IV over 30-150 minutes on day 9. Patients achieving a partial or complete response after the first course of therapy may receive an additional course of therapy beginning 35 ± 7 days after blood count recovery.
2399797|NCT03573687|Experimental|RT on Fat Metabolism|Determine the extent to which a full-body acute RT protocol will affect intra-RT and post-RT SCAAT lipolytic rate, and post-RT whole-body substrate utilization in RT women compared to baseline measures (independent of Aims 2 and 3).
2399798|NCT03573687|Experimental|PRO Timing on Fat Metabolism|Assess the differences in overnight and next morning SCAAT lipolytic rate and next-morning whole-body substrate utilization compared to baseline between acute NP and DP consumption trials after a RT bout in RT women.
2399799|NCT03573687|Experimental|PRO Timing on Markers of Fat Metabolism|Assess the differences in overnight and next morning metabolic biomarkers of fat metabolism compared to baseline between acute nighttime PRO (NP) consumption versus daytime PRO (DP) consumption trials after a RT bout in RT women.
2399800|NCT03573674|Experimental|Cognitive ergonomics Intervention|
2399801|NCT03573674|Active Comparator|Stress management Intervention|
2399802|NCT03573674|No Intervention|Passive control|"Passive Control groups receive no intervention at all."
2399803|NCT03573661|Experimental|Breast Cancer Locator (BCL)|The Breast Cancer Locator (BCL) uses 3D printing to create a bra-like plastic form that matches the breast surface when the patient is in the supine MRI (and surgical) position. This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure.
2399804|NCT03573648|Active Comparator|Endocrine Therapy|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
3143758|NCT00016094|Experimental|Treatment (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for a maximum of 24 courses in the absence of disease progression or unacceptable toxicity.
3143759|NCT00016107|Experimental|Treatment (chemotherapy, bevacizumab)|Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour followed by bevacizumab IV over 30-90 minutes on day 2. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3143760|NCT00016146|Experimental|vaccine|"This is a dose-escalation study of GPI-0100.~Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant GPI-0100 subcutaneously weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity or disease progression.~Cohorts of 5 patients receive escalating doses of GPI-0100 until the optimal dose, based on antibody response, is reached.~Patients are followed every 3 months."
3143761|NCT00016276|Experimental|Arm I (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane IV over 10-20 minutes, doxorubicin IV over 5-10 minutes, and cyclophosphamide IV over 30 minutes on days 1, 22, 43, and 64. Patients receive paclitaxel IV over 1 hour and trastuzumab (Herceptin) IV over 30-90 minutes on days 85, 92, 99, 106, 113, 120, 127, 134, 141, 148, 155, and 162. Approximately 1-2 weeks after completion of neoadjuvant chemotherapy, patients undergo breast conservation surgery, modified radical mastectomy, or mastectomy. Patients with unacceptable toxicity or locoregional disease progression may undergo surgery prior to week 24 (i.e., completion of neoadjuvant chemotherapy). Beginning 2-4 weeks after breast conservation surgery or 3-5 weeks after mastectomy, patients undergo radiotherapy daily 5 days a week for 6-8 weeks. Patients receive long-term trastuzumab IV over 30-90 minutes weekly for 40 weeks beginning on week 36 (day 254).
3143762|NCT00016276|Experimental|Arm II (chemoprotection, radiotherapy, surgery, trastuzumab)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel (without trastuzumab) as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
3143763|NCT00016276|Experimental|Arm III (chemoprotection, monoclonal antibody, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation only for 40 weeks after completion of radiotherapy.
2399805|NCT03573648|Active Comparator|Endocrine Therapy with Palbociclib|Eligible patients with ER-positive breast cancer will undergo a biopsy and be randomized to receive endocrine therapy (ET) versus endocrine therapy with palbociclib (PET) in a 1:2 ratio. A 1:2 ratio means that twice as many participants will be assigned to the PET arm as compared to the ET arm. After 1 cycle (28 days) another biopsy will be obtained, and both arms will receive avelumab (A) for 3 additional cycles. Patients will then undergo breast surgery.
2399806|NCT03573635|Other|Supratube|Patient with orotracheal intubation and supratube device
2399807|NCT03573622|Experimental|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
2399808|NCT03573622|Active Comparator|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
2399809|NCT03573609|No Intervention|Control|Usual respiratory care
2399810|NCT03573609|Active Comparator|Supranav|"Respiratory care with supranav which is a continuous supraglottic suction device"
2399811|NCT03573596|Other|dasatinib|2 years of dasatinib treatment before discontinuation if MR 4 is achieved for at least 1 year
2399812|NCT03573583|Experimental|Resistance Training group (RT)|"The resistance training intervention will include a full body, resistance training performed three days per week.~The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines"
2399813|NCT03573583|Active Comparator|Successful Aging|The comparator group will meet for stretching and health education classes every 2-5 weeks up to 7 total visits.
2399814|NCT03573570|Experimental|Treatment|110 Fair Price Shops (FPS) in Chidambaram, Tamil Nadu, India will be assigned randomly to receive rice fortified. Rice will be fortified using Fortified Rice Kernels (FRKs) containing iron, zinc, vitamin A and vitamins B1, B3, B6, B9 and B12. All households receiving rice from the PDS will receive fortified rice instead of conventional PDS rice, and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. Because a given FPS only receives rice from a single upstream distributor (godown) it should be straightforward to ensure that fortified rice reaches the appropriate treatment FPS and only those FPS.
2399815|NCT03573570|No Intervention|Control|The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
2399816|NCT03573557|Active Comparator|Pink Pad|The Pink Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
2399817|NCT03573557|Active Comparator|Bean Bag|The Bean Bag will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg to determine how much slipping is happening during the procedure.
2399818|NCT03573557|Active Comparator|Gel Pad|The Gel Pad will be used with subjects undergoing laparoscopic surgery or vaginal surgery while in to Trendelenburg determine how much slipping is happening during the procedure.
3143764|NCT00016276|Experimental|Arm IV (chemoprotection, paclitaxel, surgery, radiotherapy)|Patients receive dexrazoxane, doxorubicin, and cyclophosphamide as in arm I. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
3189068|NCT00773929|Experimental|1|3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort
2399821|NCT03573531||Donor Human Milk|Donor Human Milk (processed by a human milk bank) Sampled at two different neonatal units in the United Kingdom Collection of 5 ml of otherwise routinely discarded donor human milk
2399822|NCT03573531||Preterm Milk|Preterm transitional or mature breast milk Sampled from healthy mothers of preterm babies (born , 37 weeks gestational age) at a neonatal unit in the United Kingdom Collection of 5 ml at a time point of routine expression
2399823|NCT03573531||Term Milk|Term mature breast milk Sampled from healthy mothers of term babies in the community (e.g. Baby Cafes). Collection of 5 ml expressed for this study
2399824|NCT03573518|Experimental|BTX 1503 Dose 1 BID|BTX 1503 Dose 1 twice daily
2399825|NCT03573518|Experimental|BTX 1503 Dose 1 QD|BTX 1503 Dose 1 once daily
2399826|NCT03573518|Experimental|BTX 1503 Dose 2 QD|BTX 1502 Dose 2 once daily
2399827|NCT03573518|Placebo Comparator|Vehicle BID|Vehicle twice daily
2399828|NCT03573518|Placebo Comparator|Vehicle QD|Vehicle once daily
3189069|NCT00773942|No Intervention|Usual care|Study subjects receive usual care, without the intervention.
2399831|NCT03573492|Active Comparator|In-Person Education by Ultrasonographer|In-person education of the DVT scanning technique by an RDMS-certified ultrasonographer
2399832|NCT03573492|Active Comparator|Online Education (EM Sono)|Online lectures of DVT scanning technique by an Emergency Ultrasound fellowship director
2399833|NCT03573479||Pre-implementation cohort|This is the pre-implementation phase where a baseline documentation will take place about usual clinical practice, perceptions and attitudes of PICU staff and clinicians
2399834|NCT03573479||PICU Liber8 bundle|After the implementation of the bundle (the PICU Liber8 components) same measurements will be captured and analyzed comparatively.
2399835|NCT03573466|Experimental|Amyotrophic Lateral Sclerosis|
2399836|NCT03573453|Experimental|Intermittent|enteral nutrition will be administered via enteral feeding pump as 30-60minutes lasting bolus 6 times per day volume of initial bolus will be 80ml. The volume of bolus will be increased gradually according to tolerance, till the estimated target rate will be reached
2399837|NCT03573453|Experimental|Continuous|enteral nutrition will be administered via enteral feeding pump for at least 16 hours par day initial rate will be 25ml/hour. The rate will be increased gradually according to tolerance, till the estimated target rate will be reached
2399838|NCT03573440|No Intervention|no mindful eating education|"Subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
2400337|NCT03570034||Obalon Balloon System|Obalon Balloon System with moderate intensity Weight Loss Behavioral Modification Program
2399839|NCT03573440|Experimental|mindful eating education|"After receiving a brief education session on mindful eating, subject will be asked to eat their meal with an investigator present.~They will inform the investigator verbally when they are feeling full.~After they have decided to end their meal, they will be asked to fill out a questionnaire"
3143765|NCT00016276|Experimental|Arm V (combination chemo, radiotherapy, long term trastuzumab)|Patients receive doxorubicin and cyclophosphamide (without dexrazoxane) as in arm I. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
2399841|NCT03573401|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~Photodynamic therapy (PDT)"
2399842|NCT03573401|Placebo Comparator|Vehicle|Topical application of vehicle to BF-200 ALA containing no active ingredient. Photodynamic therapy (PDT)
2399843|NCT03573388||Optical coherence tomography (OCT)|
2399845|NCT03573362|Experimental|Vizishot Flexneedle 19G|Mediastinal and hilar lymph node sampling using the Vizishot Flexneedle19G EBUS-TBNA needle
2399846|NCT03573362|Active Comparator|Vizishot 22G|Mediastinal and hilar lymph node sampling using a standard Vizishot 22G EBUS-TBNA needle
2399847|NCT03573349|Other|Ketamine|Open-label, non-randomized
3184527|NCT00725738|Experimental|A|"Stem Cell Transplantation Group: Between the fifth and seventh day post-primary angioplasty (PTCA) we extract the stem cell from iliac crest and during the same day the patient undergoes to a new cardiac catheterization in which we perform the intracoronary injection (about 1-2 million of CD34 cells) through the infarct related artery by a PTCA over-the-wire catheter."
3184528|NCT00725777|Experimental|A|
3184529|NCT00725790|Experimental|A|Vardenafil treatment group
3184530|NCT00725790|Placebo Comparator|B|Placebo treatment group
3184531|NCT00725803|Experimental|Cohort 1|Subjects randomized 3:1 (active:placebo) to receive GS-9450 10 mg/day or placebo.
3143766|NCT00016276|Experimental|Arm VI (combination chemo, paclitaxel, surgery, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients receive long-term trastuzumab as in arm I.
3143767|NCT00016276|Experimental|Arm VII (combination chemo, monoclonal antibody, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel and trastuzumab as in arm I. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
2399855|NCT03573297|Experimental|Cariprazine 3 mg/day|Cariprazine capsules, oral administration, once daily
2399856|NCT03573297|Experimental|Cariprazine 1.5 mg/day|Cariprazine capsules, oral administration, once daily
2399857|NCT03573297|Placebo Comparator|Placebo|Matching placebo capsules, oral administration, once daily
2399858|NCT03573284|Experimental|Asthma group|Patients with chronic nonproductive cough for more than 8 weeks based on physician's opinion will be subjected to FeNO, impulse oscillometry(IOS) and pulmonary function. Receiver operating characteristic (ROC) curves to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO and IOS is also determined.
2399859|NCT03573271|Experimental|Micro-coring of facial/neck skin with MCD|Micro coring of facial and neck skin will be conducted in up to 2 treatments and followed 90 days post treatment with MCD
2399860|NCT03573258|Experimental|Fiber|"300 ml of orange juice plus Intervention~6 g of oat beta glucan = FIBER (study A) or~25 g inulin/FOS = FIBER (study B)"
2399861|NCT03573258|Placebo Comparator|Placebo|"300 ml of orange juice plus Placebo:~13.5 g maltodextrin = PLACEBO (study A) or~15.5 g maltodextrin = PLACEBO (study B)"
2399862|NCT03573245||intra-op single dose|intra-operative single dose of tranexamic acid
2399863|NCT03573245||intra-op dose and additional dose|intra-operative dose of tranexamic acid and additional dose 3 hours after
2399864|NCT03573245||intra-op dose and perfusion|intra-operative dose of tranexamic acid followed by a continuous infusion during 6 hours.
2399865|NCT03573219|Experimental|Healthy participant|Healthy volunteers that fulfill the inclusion criteria. Intervention: Short-wave diathermy (Radiation)
3184532|NCT00725803|Experimental|Cohort 2|Subjects randomized 3:1 (active:placebo) to receive GS-9450 40 mg/day or placebo.
2399867|NCT03573193|Active Comparator|study group:|ridge preservation alveolar ridge socket preserved using alloplastic material beta tri calcium phosphate type
2399868|NCT03573193|Other|control group|ridge preservation (alveolar ridge socket preserved using xenograft material Bio-oss type
2399869|NCT03573167|Active Comparator|In-Person Motivational Interviewing|In-Person Motivational Interviewing (MI) is the standard form of MI treatment delivered in person face to face at the primary care office. MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping participants to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling in-person with the participant for one session of MI lasting approximately 30 minutes.
2399870|NCT03573167|Experimental|Mobile MI|Mobile Motivational Interviewing (MI) is delivered by a counselor over the mobile phone, rather than in-person (face-to-face). MI is a type of brief intervention that uses open-ended questions, affirmations, reflective listening, and summarizing as key tools and has been shown to treat a range of problem behaviors, including alcohol use disorders, by helping the patient to identify and address ambivalence towards changing the behavior. MI is delivered in a communicative style that promotes individual autonomy and improves self-efficacy. The investigator provides counseling over the mobile phone with the participant for one session of mobile MI lasting approximately 30 minutes.
3184533|NCT00725803|Experimental|Cohort 3|Subjects randomized 3:1 (active:placebo) to receive GS-9450 80 mg/day or placebo.
3184534|NCT00725803|Experimental|Cohort 4|Subjects randomized 3:1 (active:placebo) to receive GS-9450 5 mg/day or placebo. Cohort may or may not be conducted pending blinded review of previous cohorts.
3184535|NCT00725829|Experimental|1|simvastatin 40g + ezetimibe 10g once a day
3184536|NCT00725829|Placebo Comparator|2|simvastatin 40g + placebo once a day
3184537|NCT00725855|Experimental|1|1 mg dose
3184538|NCT00725855|Experimental|2|5 mg dose
2399871|NCT03573167|No Intervention|Waitlist Control|After consenting to participate in the study, the Waitlist control participants receive no intervention for one (1) month, and then the Waitlist control participants are contacted by the investigators for follow up..
2399874|NCT03573141||Knee OA patients receiving Physical Therapy|Only 1 group was included in this study. Subject's physical activity and sleep quality were assessed at baseline, prior to treatment. Follow up data was collected immediately after a course of physical therapy then again 8 weeks later.
2399875|NCT03573128|Experimental|Intervention|Students with Autism Accessing General Education (SAAGE). Teaching staff work with a study team coach to identify areas of concern for individual students, create goals and implement a modular behavioral intervention using an active teaching/feedback loop model.
2399876|NCT03573128|Active Comparator|Enhanced Services As Usual|Teaching staff access in-service training sessions hosted by study team and are provided with print materials from which the modules for the active intervention were created.
2399877|NCT03573115|Experimental|Acne patients|
2399878|NCT03573102|Active Comparator|control|ACE inhibitor , aspirin , statins will be given once daily
2399879|NCT03573102|Experimental|cases|SGLT2 inhibitors will be given with classic antiproteinuric drugs
2399880|NCT03573089|Active Comparator|Liberal phosphate target|Liberal serum phosphate target of 2.0 to 2.5 mmol/L.
2399881|NCT03573089|Experimental|Intensive phosphate target|Intensive serum phosphate target of ≤1.50 mmol/L.
2399882|NCT03573076|Experimental|Thulium laser + photodynamic therapy|Non-ablative Thulium laser (NAFL) + Photodynamic therapy combination treatment
2399883|NCT03573076|Experimental|RF microneedles + photodynamic therapy|Radio-frequency microneedles (RF-MN) + Photodynamic therapy combination treatment
2399884|NCT03573076|Active Comparator|Non-ablative Thulium laser|Non-ablative Thulium laser (NAFL) single treatment
2399885|NCT03573076|Active Comparator|RF microneedles|Radio-frequency microneedles (RF-MN) single treatment
2399886|NCT03573076|No Intervention|Control|Control receiving no intervention
2399887|NCT03573063|Other|Androgen metabolism after starvation|Metabolism changes after 48 hours starvation in healthy women
2399888|NCT03573050|Experimental|RIV-TDS 13.3 mg/24 h (Test)|5 consecutive patch applications of Test (each patch to be applied for 24 hours)
2399889|NCT03573050|Active Comparator|Exelon® 13.3 mg/24 hours transdermal patch (Reference)|5 consecutive patch applications of Reference (each patch to be applied for 24 hours)
2399890|NCT03573037|Experimental|1-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 1 month after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation.
2399891|NCT03573037|Active Comparator|2-month anticoagulation group|Anticoagulation using warfarin or non-VKA oral anticoagulant for 2 months after radiofrequency catheter ablation of paroxismal atrial fibrillation and then stop anticoagulation
2399892|NCT03573024|Experimental|Azacitidine and Venetoclax|Azacitidine will be given intravenously for 7 days. Venetoclax will be given orally. The patient will start out with 100mg and progress to 600mg. Once 600mg is reached, the patient will stay at this dose until the 28 day cycle is finished.
2399893|NCT03573011|Experimental|2.0 ± 0.2 MBq/kg [18F]PSMA-11 dosing group|"To define the optimal [18F]PSMA-11 scan protocol, the quality of the PET images from patients that received 2.0 ± 0.2 MBq/kg will be compared to the images from patients that received 4.0 ± 0.4 MBq/kg.~Patients in this study arm will receive 2.0 ± 0.2 MBq/kg for acquiring the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm.~As for the use of radiopharmaceuticals, the ALARA ('as low as reasonably achievable') principle must be applied, this study arm is considered to be the reference."
2399894|NCT03573011|Experimental|4.0 ± 0.4 MBq/kg [18F]PSMA-11 dosing group|Concerning the dose of [18F]PSMA-11, the patients in this study arm will receive 4.0 ± 0.4 MBq/kg for the [18F]PSMA-11 scan. All other study parameters and procedures are identical to those in the other study arm
2399895|NCT03572998|Other|Breast cancer patients|study subject
2399896|NCT03572985|Other|Blood alcohol concentration (BAC) level 0.025 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.025%
2399897|NCT03572985|Other|BAC level 0.05 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.05%
2399898|NCT03572985|Other|BAC level 0.09 %|Drink beverages containing alcohol calculated to have a blood alcohol concentration of 0.09%
2399899|NCT03572985|Other|BAC level 0 %|Drink beverages containing non alcohol
3184539|NCT00725855|Experimental|3|15 mg dose
3184540|NCT00725855|Experimental|4|50 mg dose
3184541|NCT00725855|Placebo Comparator|5|Placebo dose
3184542|NCT00725868|Other|1|Data private hospitals, angioplasty, sampling of blood
3184543|NCT00725881|Experimental|1|.25 mg/kg TSC
2399905|NCT03572959|Active Comparator|comparison group (active control)|0.1 % topical triamcinolone acetonide preparation (Kenacourt-A Orabase Pomad, DEVA HOLDINGS A.S., Istanbul, Turkey) was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application. Patients used the medication for 4 weeks , and if extension of treatment was required after that period , patients were instructed to apply miconazole oral gel (JANSSEN-CILAG Pty Ltd 1-5 Khartoum Road North Ryde NSW 2113 Australia) four times a day for one week to protect from superimposed fungal infections.15
2399906|NCT03572959|Experimental|experimental group|"OLP lesions were irradiated with a 970-nm diode laser (SIRO Laser Advance class III b, SIRONA, Germany) with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly for two months until the resolution of signs for a maximum of ten sessions.11 After each session, patients were advised to have a cold diet and use chlorhexidine oral gel postoperatively twice a day to the lesion for one week."
2399907|NCT03572946|Experimental|target biopsy group|Targeted prostate biopsy
2399911|NCT03572920||Patients with hip/knee arthroplasty.|RAR description by actgraphy Objective sleep evaluation by actigraphy. Subjective sleep quality with sleep diary Pittsburgh Sleep Quality Index (PSQI).
2399912|NCT03572881|Experimental|Asymptomatic|
2399913|NCT03572881|Experimental|Symptomatic|
2399914|NCT03572855|Experimental|Scoliosis Brace|The Peak Scoliosis Brace designed to alleviate pain in adult patients with chronic pain secondary to scoliosis.
2399915|NCT03572842|Other|quantiferon monitor|Test measuring interferon gamma production after T cells and Natural Killers (NK) in vitro stimulation : QuantiFERON Monitor® (QFM)
2399916|NCT03572829|Experimental|Aprepitant|Aprepitant combined with ondansetron and dexamethasone
2399917|NCT03572816|No Intervention|Current standard|"mobilization without weight bearing for 6 weeks starting with the day of either decision-making for non-operative therapy or open reduction and internal fixation, if needed a cast or another kind of orthosis as a Static Walker are applied, then 4 weeks 15-20 kg, 2 weeks 35-45 kg, after that transition to full-weight bearing (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
2399918|NCT03572816|Experimental|Intervention|"mobilization with the custom-made heel-unloading orthosis ('Settner shoe') without pads for 6 weeks, then 2 weeks one pad, 2 weeks 2 pads, 2 weeks 3 pads, after that full-weight bearing without any support (always only if possible)~X-ray after 6 and 12 weeks; depending on the results, the schedule for weight bearing may be adjusted to the need in case of delayed healing or complications related to implants"
2399919|NCT03572803|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized using Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds"
2399920|NCT03572803|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.~The needle will get in the relevant zone of treatment. The punction will be realized simulating Hong's technique (fast in-out). Three needle insertions will be carried out in the target area during 3 seconds and 3mA each one."
2399921|NCT03572803|Sham Comparator|Control Group|They will receive a treatment of punction sham, guided by ultrasound, together with a self-treatment program at home based on eccentric exercises and stretching.
2399922|NCT03572790|Experimental|Prucalopride|
2399923|NCT03572790|Placebo Comparator|Placebo|
2399924|NCT03572777|Active Comparator|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid, metronidazole ('Medazol')500 mg bid, clarithromycin ('Makcin')500 mg bid and esomeprazole ('Emanera')40 mg bid for 14 days.
2399925|NCT03572777|Active Comparator|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid and esomeprazole ('Emanera') 40 mg bid for 14 days, with metronidazole ('Medazol')500 bid and clarithromycin ('Makcin') 500 mg bid for the last 7 days.
2399926|NCT03572764|Experimental|CPX-351|"CPX-351 will be given according to the assigned dose level over a minimum of a 90-minutes via IV infusion on Days 1, 3, and 5 of the first induction~If the treating physician elects to perform a day 14 bone marrow biopsy then, a second induction may be considered for patients in the absence of a chemoablated, hypocellular marrow on the Day 14 bone marrow assessment, if the patient has failed to achieve a marrow CR, and it is deemed safe to administer by the treating physician. The second induction uses a modified schedule in which CPX-351 will be given according to the assigned dose level on Days 1 and 3~In the absence of disease progression or unacceptable toxicity, the patient may continue to consolidation at the discretion of the treating physician or the patient may proceed to alloHCT after induction at the discretion of the treating physician"
2399927|NCT03572751||Vascular surgical patients|"Patient subjects are recruited from patients referred for vascular surgical procedure in Tampere University Hospital.~Bed-, wrist- and ECG-sensor monitoring"
2399928|NCT03572751||Healthy volunteers|"Healthy volunteer subjects will be recruited mainly from the students of Tampere University of Technology.~Bed-, wrist- and ECG-sensor monitoring"
2399930|NCT03572725|Active Comparator|Gas tamponade|Gas as intraocular tamponade.
2399931|NCT03572725|Experimental|Air tamponade|Air as intraocular tamponade.
2399932|NCT03572686|Sham Comparator|Group Ropivacaine High (RH)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml + N/S 1.6mL.
2399933|NCT03572686|Placebo Comparator|Group Ropivacaine Low (RL)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + N/S 1.6mL.
2399934|NCT03572686|Experimental|Group Ropivacaine Low + Dexamethasone (RLD)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.25% 20ml + Dexamethasone 8mg (1.6mL).
2399935|NCT03572673|Active Comparator|Flexima 3S|Flexima 3S is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
2399936|NCT03572673|Experimental|New 2-piece ostomy appliance|New 2-piece appliance is a 2-piece ostomy appliance composed with an adhesive base plate and a drainable pouch for collecting stools (1 base plate for 5 days and 1 pouch for 5 days)
2399937|NCT03572660|Other|BMMNC intervention arm|Bone marrow derived mononuclear cells and G-CSF
2399938|NCT03572647|Experimental|Test ERITROMAX|Blausiegel Industria e Comercio Ltda. Recombinant Human Erythropoietin (ERITROMAX)
2399939|NCT03572647|Active Comparator|EPREX|Janssen-Cilag Recombinant Human Erythropoietin (EPREX)
3184544|NCT00725881|Experimental|2|.5 mg/kg TSC
3184545|NCT00725881|Experimental|3|.75 mg/kg TSC
2400920|NCT03566134|Active Comparator|Solifenacin 5mg|DA-8010 placebo + Solifenacin succinate 5mg
3184546|NCT00725881|Experimental|4|1.0 mg/kg TSC
3184547|NCT00725881|Experimental|5|1.25 mg/kg TSC
3184548|NCT00725881|Experimental|6|1.5 mg/kg TSC
3184549|NCT00725881|Experimental|7|1.75 mg/kg TSC
3184550|NCT00725881|Experimental|8|2.0 mg/kg TSC
2399945|NCT03572608|Experimental|Acupuncture Treatment|Acupuncture group will receive 3 acupuncture sessions. The first session will be one week before embryo transfer. The second session will be 30 minute before embryo transfer. And the last session will be 30 minute after embryo transfer.
2399946|NCT03572608|No Intervention|Control Group|Control Group will not receive any acupuncture session before or after embryo transfer.
2399947|NCT03572595||Staging|Patients with pathologically proven colorectal cancer presented for pre-operative staging, underwent standard routine conventional radiological imaging i.e MRI , then will be subjected to be imaged by F-18 FDG-PET/CT from skullbase to midthigh, then interpretating the results of the hybrid PET/CT by two nuclear physicians then comparing with other conventional images.
2399948|NCT03572595||Recurrent|"Patients with treated colorectal cancer, suspecting of recurrence , will be subjected to be imaged by F-18 FDG-PET/CT from skull base to midthigh, interpretating the results of the hybrid PET/CT by two nuclear physicians.~Then refer back to the treating physicians , another biopsy will be taken from the suspected recurrence and then results will be compared with hybrid PET/CT images.~comparing the results with histopathology ."
2399949|NCT03572582|Experimental|TACE in combination with nivolumab|Treatment will be divided into 4-week cycles from the starting date of TACE. The second TACE will be repeated on day 1 (± 4 days) of cycle 3 (after 8 weeks ± 4 days). Nivolumab will be initiated on day 2-3 after the first TACE session. Nivolumab will be administered every two weeks (240mg fixed dose IV) until disease progression for up to two years.
2399950|NCT03572569||Index patients|Patients ≤18 years with primary cardiomyopathy
2399951|NCT03572569||First-degree family members|Parents and siblings of index patients
2399952|NCT03572556||Patients|Hereditary hemorrhagic telangiectasia patients
2399953|NCT03572556||Controls|Matched for age (+/- 5 ans) and sex.
2399954|NCT03572543|Active Comparator|Active tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period and a constant current will be delivered for the 20-minutes between ramping.
2399955|NCT03572543|Sham Comparator|Sham tDCS|Current will be ramped in/out for 30 seconds at the begging and end of a 20-minute period during which no stimulation will be delivered.
3143768|NCT00016276|Experimental|Arm VIII (combination chemotherapy, paclitaxel, radiotherapy)|Patients receive doxorubicin and cyclophosphamide as in arm V. Patients receive paclitaxel as in arm II. Patients undergo surgery and radiotherapy as in arm I. Patients undergo observation as in arm III.
3143769|NCT00016289|Experimental|Treatment (recombinant interleukin-12)|Patients receive interleukin-12 intraperitoneally once weekly. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease receive 2 additional courses.
3143770|NCT00016302|Experimental|Regimen A|See detailed description.
2399959|NCT03572517|Active Comparator|Subarachnoid block|"Subarachnoid block with hyperbaric bupivacaine 0,5% 3ml associate with morphine 50 mcg.~A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
2399960|NCT03572517|Active Comparator|Spinal morphine|"Spinal morphine with morphine 50 mcg. A general anesthetic with fentanyl 3 mcg / kg + propofol 2 mg / kg + rocuronium 0.6 mg / kg will be performed.~Anesthesia will be maintained with remifentanil (ng / ml) through Minto's pharmacokinetic model (BBraun infusion syringe - Perfusor® Space model) and desflurane (Fe%)."
2399961|NCT03572491|Experimental|Allantoic split inactivated seasonal influenza vaccine|A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NYMC X-275 (A/PR/8/34 (M, PB2, PA, NS, NP genes) и A/Michigan/45/2015 (PB1, HA, NA genes)), NYMC X-263В (A/PR/8/34 (PB1, PB2, PA, NS, NP, М genes) и A/Hong Kong/4801/2014 (HA, NA genes)), NYMC BX-35 (B/Lee/40 (NP gene), B/Panama/45/90 (PB2, М genes) и B/Brisbane/60/2008 (HA, NA PB1, PA, NS genes)).
3184551|NCT00725881|Placebo Comparator|9|5.0 mL 0.9% normal saline
3184552|NCT00725894||1|The Pediatric Locking Nail was designed to provide stable sub-rigid fixation of femoral fractures in children
3184553|NCT00725907|Experimental|1|PGRF
3184554|NCT00725907|Placebo Comparator|2|saline
2399966|NCT03572465||NAFLD, NASH patients|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
2399967|NCT03572465||Non-obese volunteers|"All patients enrolled will undergo:~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
2399968|NCT03572452|Experimental|McKenzie - method group|Participants will be sent to an experienced MDT therapist for therapy. They are 1) assessed clinically, 2) treated according the MDT-approach which includes home exercise program, consisting i) an educational component, and ii) an active therapy component with directional preference exercises, several times a day with sustained end range positions according to symptom response, and with avoiding aggravating positions. Participants have a maximum of 7 treatment visits. They will also have physiotherapy counselling at study entry about the good prognosis of sciatica.
3184555|NCT00725946|Experimental|Iodine-124 PET-CT scan|
3143771|NCT00016302|Experimental|Regimen B|"Induction (weeks 1-9): Patients receive treatment as in induction of regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen A and nelarabine IV on days 162-166.~Maintenance (weeks 30-101): Patients receive oral mercaptopurine daily on days 1-28 and 36-56; oral methotrexate weekly; and nelarabine IV on days 29-33. Treatment repeats every 8 weeks for 4 courses. Beginning on week 62, patients receive vincristine IV once; oral prednisone three times daily for 5 days; oral mercaptopurine daily; and oral methotrexate weekly. Treatment repeats every 8 weeks for 5 courses."
3189070|NCT00773942|Experimental|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
2399969|NCT03572452|Active Comparator|Advice to stay active group|"Participants enrolled into this group will receive physiotherapist's counselling at study entry for at least 60 minutes time about the good prognosis of sciatica, the spontaneous regression of the intervertebral disc herniation and pain tolerance (natural healing). In addition, they will get ergonomic advice and advice to stay normally active. The participants are also told to avoid bed rest and advised to continue their normal routines as actively as possible including exercise activities with limits permitted by their signs and symptoms. A two-page summary booklet related to these items will be given to them."
2399970|NCT03572439|Active Comparator|Cephalad to caudal|Sensory block level check using ice, moving from cephalad to caudal
2399971|NCT03572439|Active Comparator|Caudal to cephalad|Sensory block level check using ice, moving from caudal to cephalad
2399972|NCT03572426||Bipolar|Diagnosed as having at least 1 lifetime manic episode by the MINI
2399973|NCT03572426||Depression|Diagnosed as having at least 1 Major Depressive Episode by the MINI
2399974|NCT03572426||Healthy Controls|Does not meet Criteria for any mood disorder diagnosis (MDD, BD, dysthymia)
3143772|NCT00016302|Experimental|Regimen C|"Induction (weeks 1-5): Patients receive treatment as in induction (weeks 1-5) on regimen A and nelarabine IV over 1 hour on days 29-33.~If bone marrow is M1, patients begin week 6 of induction therapy on day 36 or when peripheral blood counts recover. If bone marrow is M2, patients begin week 6 of induction therapy immediately. If bone marrow is M3, treatment discontinues.~Induction (weeks 6-9): Patients receive treatment as in induction (weeks 6-9) on regimen A.~Consolidation (weeks 10-19): Patients receive treatment as in consolidation on regimen A.~Reinduction (weeks 20-29): Patients receive treatment as in reinduction on regimen B.~Maintenance (weeks 30-101): Patients receive treatment as in maintenance on regimen B."
3143773|NCT00016302|Experimental|Regimen D|See detailed description.
2399977|NCT03572400|Experimental|Gemcitbine/Durvalumab|"Neoadjuvant CCRT with Gemcitbine/Durvalumab~+Adjuvant Gemcitabine/Durvalumab Total 6 cycles, after that, Durvalumab q4wks up to total 1 year"
2399978|NCT03572387|Experimental|(5-AZA) + (ATRA) combination|Combination of 5-Azacitidine (5-AZA) + all trans retinoic acid (ATRA) group after one month of Lupron, group will receive treatment on a 28-day cycle, in the absence of prohibitive toxicities, for 3 cycles.
2399979|NCT03572387|Active Comparator|Lupron only|No treatment after one month of Lupron
2399982|NCT03572361|Experimental|V3-MOMMO|Oral once daily pill of tableted vaccine (V3-MOMMO) containing pooled breast cancer antigens administered for 3 months in 20 volunteers with breast cancer
2399983|NCT03572348|Active Comparator|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
2399984|NCT03572348|Active Comparator|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
2399987|NCT03572322||Doctors|
2399988|NCT03572322||Patients|
2399989|NCT03572296|Placebo Comparator|Placebo|No polyphenols or fibre will be delivered in a low sugar drink.
2399990|NCT03572296|Experimental|Polyphenol and fibre|Blackcurrant extract (800 mg total polyphenols) and pulp (source of fibre) will be delivered in a low sugar drink.
2399991|NCT03572296|Experimental|Fibre|Pulp (source of fibre) will be delivered in a low sugar drink.
2399992|NCT03572283|Experimental|Bethanechol|Patients with pancreatic adenocarcinoma will receive bethanechol prior to pancreatic surgery
2399993|NCT03572270|Experimental|case|PLWH
2399994|NCT03572270|Other|control|HIV negative women, going to medically assisted procreation consultation for male infertility
2399995|NCT03572257|Experimental|Quetiapine (0.5 mg/kg TID x 10 days)|This study group will receive treatment with quetiapine after diagnosis of pediatric delirium. Group assignment will be blinded.
2399996|NCT03572257|Placebo Comparator|Placebo|This study group will receive a placebo treatment after diagnosis of pediatric delirium. Group assignment will be blinded.
2399999|NCT03572231||mirabegron|Participants will commence the OAB treatment with mirabegron that is prescribed by a physician in routine clinical practice.
2400000|NCT03572231||Antimuscarinics|Participants will commence the OAB treatment with one of the following antimuscarinics: solifenacin, darifenacin, imidafenacin, tolterodine, oxybutynin, trospium, fesoterodine or propiverine. The antimuscarinic is prescribed by a physician in routine clinical practice.
2400030|NCT03572075|Experimental|Group B|assessment of symptoms at the first medical examination; standard care protocol; assessment of symptoms after four months
3184556|NCT00725972|Experimental|Augmented Oxygen Delivery Group|"Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.~Intervention: Augment O2 Delivery by hemodynamic protocol. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)"
3184557|NCT00725972|Sham Comparator|Control|Patients having the same types of surgery but receiving usual anesthetic care. Intervention: High Risk Surgery. (7/30/17: deleted original text which apparently was pasted from an entirely unrelated study having to do with age of transfused blood, presumably by the creator of this record, Cynthia Hatfield, in 2010. SLW)
2400003|NCT03572205|Experimental|CC genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
2400004|NCT03572205|Experimental|TT genotype LA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of sunflower oil (source of LA: linoleic acid) daily, depending on body weight. The same diet will be instructed for both genotypes.
2400005|NCT03572205|Experimental|CC genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
2400006|NCT03572205|Experimental|TT genotype ALA|4-week study diet will be isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (5-6 % of energy intake) of camelina oil (source of alpha-linolenic acid: ALA) daily, depending on body weight. The same diet will be instructed for both genotypes.
2400007|NCT03572179|Active Comparator|Treatment Group|After finishing orthodontic treatment, all patient will receive a modified indirect technique for bonding fixed mandibular retainer and the key of modification is the fabrication of 3D printed digital positioning tray for placement of retainer with holes for composite pads for its direct application using 3 shape Ortho analyser Software ® instead of conventional indirect retainer fabrication method
2400008|NCT03572179|No Intervention|Control Group|All patients of this group will follow conventional steps of direct bonding procedure of fixed mandibular retainer
2400009|NCT03572166|Experimental|Arginine Infusion|Arginine Stimulation Test
2400010|NCT03572166|Active Comparator|Hypertonic saline infusion|Hypertonic Saline Infusion Test
2400011|NCT03572153|Experimental|Self-Administered Hypnosis|Self-administered hypnosis will be practiced daily using different audio recordings using the researcher's voice. Participants will practice hypnosis at home after completing the two study sessions.
2400012|NCT03572153|Active Comparator|Self-Administered White Noise Hypnosis|Self-administered white noise hypnosis will be practiced daily using a white noise recording. Participants will practice hypnosis at home after completing the two consent and education sessions.
2400013|NCT03572140||group A|RAVS IN resistent cases after daclatasvir plus sofosbuvir treatment
2400014|NCT03572140||group B|RAVS IN relapsed cases after daclatasvir plus sofosbuvir treatment
2400015|NCT03572127|Experimental|Non-animal derived diet|High protein diet derived from non-animal sources.
2400016|NCT03572127|Active Comparator|Animal derived diet|High protein diet derived from animal sources.
2400017|NCT03572114||Sporadic Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400018|NCT03572114||Familial Dystonia|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400019|NCT03572114||Parkinson´s disease, juvenile|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400020|NCT03572114||Neurodegeneration with brain iron acc.|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400021|NCT03572114||mitochondrial disease|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400022|NCT03572114||Healthy Controls|3 Tesla MRI Burke-Fahn-Marsden Dystonia Rating scale MDS-United Parkinsons Disease Rating Scale, Part III Beck Depression Inventory MoCA: Montreal Cognitive Assessment
2400023|NCT03572101||Calgary Patient Cohort|Patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
2400024|NCT03572101||Calgary Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Calgary, Canada before, during, and after an early palliative care pathway becomes the new standard of care in Calgary.
2400025|NCT03572101||Edmonton Patient Cohort|Patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
2400026|NCT03572101||Edmonton Caregiver Cohort|Caregivers of patients with advanced colorectal cancer who are recruited from Edmonton, Canada during the same time period (no palliative care pathway introduced).
2400027|NCT03572088|Active Comparator|Terlipresssin|Terlipressin was started at the beginning of surgery, just after exposure of the portal vein and getting a basal portal pressure reading, as an initial bolus dose of 1 mg over 30 minutes (1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
2400028|NCT03572088|Placebo Comparator|Control|patients received the same volume of normal saline for the same duration (50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours)
2400029|NCT03572075|Experimental|Group A|assessment of symptoms at the first medical examination; standard care protocol; pelvic floor physiotherapy; assessment of symptoms after four months
2400043|NCT03572036||Arm 1|aged 18 and older, participated in 001-H-0088 and 04-H-0161 and 1) a diagnosis of SCD 2) a diagnosis of PH 3) prescribed and/ or reported taking PDE5-I therapy for a duration of >16 weeks.
2400044|NCT03572023|Active Comparator|MINOCA|"This group will include patients with myocardial infarction with non-obstructive coronary arteries (MINOCA).~Integrative characterization of MINOCA patients:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
2400045|NCT03572023|Active Comparator|MI with coronary obstruction|"This group will include patients with myocardial infarction and obstructive coronary arteries.~Characterization of MI patients with coronary obstruction:~The following interventions will be administered: MSCT, CMR, SPECT, Blood tests, Genetic tests."
2400046|NCT03572010|Placebo Comparator|FeFum fortified maize test meal|
2400047|NCT03572010|Placebo Comparator|FeSO4 fortified LNS|
2400048|NCT03572010|Placebo Comparator|FeSO4 supplement|
2400049|NCT03572010|Placebo Comparator|FeSO4 fortified fruit juice|
2400052|NCT03571971|Experimental|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
2400053|NCT03571971|Active Comparator|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
2400054|NCT03571958|No Intervention|Traditional OHI (Control)|"Advice giving method of OHI known as tell-show-do to inform, demonstrate, and expect patient compliance."
2400055|NCT03571958|Experimental|BMI (Test)|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
2400056|NCT03571945|Active Comparator|BIS Guided Group|GA will be monitored and controlled with Bi-spectral index (BIS) monitoring.The anaesthesiologist will be blinded to ETAG and MAC readings.
2400057|NCT03571945|Active Comparator|ETAG Guided Group|GA will be monitored and controlled with end-tidal anaesthesia gas (ETAG) monitoring.The anaesthesiologist will be blinded to the BIS readings.
2400058|NCT03571932||Intervention Facilities|Includes 18 health facilities
2400059|NCT03571932||Comparison facilities|Infludes 18 health facilities
2400060|NCT03571919|Placebo Comparator|Control|Will receive normal saline bolus and infusion and have sham lab draws every 8 hours.
2400061|NCT03571919|Active Comparator|Lidocaine|Will receive lidocaine bolus and infusion and have lidocaine lab draws every 8 hours.
2400062|NCT03571906|Experimental|Pre-rehab intervention|"Subjects in the prehab arm will receive an exercise prescription and execution will be assessed and periodically adjusted in accordance to data received from the wearable device. Intensity and type of exercise will be moderate and will comply with exercise recommendations provided by ESC guidelines. A dedicated application will be installed on the mobile phone for patients in the research group and they will receive a smart sports watch.~Periodic encouragements and consultations will be provided by exercise trainer, physiologist and nurse from the cardiac rehabilitation center. A physician will be available for consultations.~In addition to monitored physical activity, patients will receive nutritional and psychological counseling. This is part of a multi-professional rehabilitation program accepted by the rehabilitation center."
2400063|NCT03571906|No Intervention|pre-operative usual care arm|"The control group will receive recommendations for a healthy and active lifestyle and physician follow-up~All subjects will undergo a stress test at baseline (post enrollment), and again prior to cardiac surgery."
2400064|NCT03571893|Experimental|Weight Watchers Freestyle (Flex)|Participate in Commercially Available behavioral weight loss program delivered by Weight Watchers International in the community
2400065|NCT03571893|Active Comparator|DIY Personal Plan|Receive informational resources for healthy lifestyle change to promote weight loss
2400066|NCT03571880|Experimental|CNSLBP group|
2400067|NCT03571880|Active Comparator|Healthy control group|
2400068|NCT03571867||group Sugammadex|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 2 mg/kg iv sugammadex + 0.01 ml/kg saline in Group S
2400069|NCT03571867||group Neostigmine|After surgery, while the TOF count was 2/4, the residual muscle relaxation was antagonized with 0.02 mg/kg neostigmin+0.01 mg/kg atropine in Group N.
2400070|NCT03571854|Experimental|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
2400071|NCT03571854|Active Comparator|Group VCV|Volume controlled ventilation
3143774|NCT00016302|Experimental|Regimen E|Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen D, but nelarabine is administered at a higher dose.
3143775|NCT00016302|Experimental|Regimen F|Patients receive nelarabine at a higher dose during induction therapy. Patients receive consolidation therapy, reinduction therapy, and maintenance therapy as in regimen E.
3143776|NCT00016315|Experimental|Arm 1|Sequence A: Gemcitabine 300 mg/m2/week plus radiation therapy (RT)
3143777|NCT00016315|Experimental|Arm 2|Sequence B: Gemcitabine 300 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
3143778|NCT00016315|Experimental|Arm 3|Sequence A: Gemcitabine 300 mg/m2/week plus carboplatin 2 AUC and RT
2400075|NCT03571815|Experimental|fluoride varnish application|intervention; fluoride varnish application (with 5% Sodium fluoride varnish application on teeth)
2400076|NCT03571815|Placebo Comparator|control group|application of water on teeth in the control group
2400077|NCT03571802|Experimental|intervention arm|simvastatin 20mg once
2400078|NCT03571789|Experimental|Vine™ implantation bilaterally in the common carotid arteries|Vine™ is a permanent carotid filter made from a single nitinol wire. It is configured to capture emboli exceeding 1.2mm in size, which originate in the heart and large arteries below the neck. Vine™ has a helical structure, with leading and supporting coils interposed by a filter section.
2400079|NCT03571776|Active Comparator|Surgery|Laparoscopic ovarian cystectomy
2400080|NCT03571776|Active Comparator|Sclerotherapy|US-aspiration and alcohol sclerosis
3143779|NCT00016315|Experimental|Arm 4|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 30 mg/m2/week and RT
2400082|NCT03571750|Experimental|Building Stronger Allies Condition|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
2400083|NCT03571750|Placebo Comparator|Health Education Training Condition|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
2400084|NCT03571737|Active Comparator|Ibuprofen|Ibuprofen 800mg every 8 hours for 3 days
2400085|NCT03571737|Experimental|Ibuprofen & Lidocaine Patch 4%|Ibuprofen 800mg every 8 hours for 3 days and Lidocaine patch 4% 1 patch applied for 12 hours then removed for 12 hours, for 3 days
2400088|NCT03571711||Meropenem therapy in SBP|Patients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
2400089|NCT03571698|No Intervention|Exercise programme only|The treatment group received only exercise programme. The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2400090|NCT03571698|Active Comparator|Exercise with NMES standard electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with standard electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2400091|NCT03571698|Active Comparator|Exercise with NMES large electrodes|The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.The exercises was done by a physical therapist in clinical center. The treatment group received exercise programme with simultaneously active contraction with NMES with large electrodes.
2400092|NCT03571685|Experimental|Sustainable Early Episode Clinic Model of Care|The model of care given in the sustainable early episode clinic study, provides early intense intervention, with an ongoing maintenance phase in an outpatient setting.
2400094|NCT03571659||two subthreshold parameters|5% and 15% duty cycle (DC)
2400095|NCT03571659||standard ETDRS|early treatment of diabetic retinopathy study
2400098|NCT03571633|Experimental|Paclitaxel+Trastuzumab+Pegfilgrastim|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC) + Pegfilgrastim (6 mg, Q3W, subcutaneously, the day after the trastuzumab + paclitaxel infusion (i.e. Day 2 of each cycle)).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
2400099|NCT03571633|Active Comparator|Paclitaxel+Trastuzumab|"NEOADJUVANT TREATMENT PERIOD (up to 12 weeks) :Paclitaxel (80 mg/m2, weekly (D1, D8, D15), IV) + Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, IV OR 600mg, Q3W SC).~ADJUVANT TREATMENT PERIOD (up to 12 months) : Trastuzumab (a loading dose 8 mg/kg at C1D1 followed by 6 mg/kg Q3W, (IV) OR 600mg, Q3W SC)"
2400100|NCT03571620|Placebo Comparator|Vehicle|
2400101|NCT03571620|Experimental|1.0% Q301 Cream|
2400102|NCT03571620|Experimental|1.4% Q301 Cream|
2400104|NCT03571594|Experimental|ONO-5788 Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
2400105|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A1|Single ascending doses of ONO-5788 or placebo in fasted healthy volunteers randomized 6 active : 2 placebo per group
2400106|NCT03571594|Experimental|ONO-5788 Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
2400332|NCT03570099||Historical control cohort|Data from the historical control cohort will be collected from national registries years 2013-2017.
3143780|NCT00016315|Experimental|Arm 6|Sequence B: Gemcitabine 450 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
3143781|NCT00016315|Experimental|Arm 8|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 40 mg/m2/week and RT
3143782|NCT00016315|Experimental|Arm 10|Sequence B: Gemcitabine 600 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3143783|NCT00016315|Experimental|Arm 12|Sequence B: Gemcitabine 750 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3143784|NCT00016315|Experimental|Arm 14|Sequence B: Gemcitabine 900 mg/m2/week plus paclitaxel 50 mg/m2/week and RT
3143785|NCT00016315|Experimental|Arm 5|Sequence A: Gemcitabine 450 mg/m2/week plus carboplatin 2 AUC and RT
2400107|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part A2|Single dose (1-2 groups) of ONO-5788 or placebo in healthy volunteers under fed conditions randomized 6 active : 2 placebo per group
2400108|NCT03571594|Experimental|ONO-5788 Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
2400109|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part B|Multiple ascending doses of ONO-5788 or placebo in healthy volunteers randomized 8 active : 2 placebo per group
2400110|NCT03571594|Experimental|ONO-5788 Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
2400111|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part C|Single doses of ONO-5788 or placebo in elderly female or elderly male healthy volunteers randomized 6 active : 2 placebo per group
2400112|NCT03571594|Experimental|ONO-5788 Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2400113|NCT03571594|Placebo Comparator|ONO-5788 Placebo Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2400114|NCT03571594|Active Comparator|Octreotide Part D|Single doses of ONO-5788, octreotide or placebo in healthy volunteers stimulated with growth hormone release hormone (GHRH) and arginine
2400115|NCT03571581|Experimental|Mindfulness Training (MT)|Eight, 30-minute phone delivered MT sessions once a week for 8 weeks
2400116|NCT03571568|Experimental|BI-1206|BI-1206 IV Standard 3+3 Dose-Escalation Design
2400119|NCT03571529|Active Comparator|Robotic rehabilitation|"Active Comparator: Robotic rehabilitation~Protocol with EMG-driven hand exoskeleton (Hand of Hope):~Warm-up: 10 min passive mode 2 min resting~Training: According to residual muscle power:~10 min active-assistive, 2 min resting, 10 min Active-assistive or~5 min active, 2 min resting, 15 min active assistive or~10 min active, 2 min resting, 10 min active and~10 min window cleaning game Robotic rehabilitation will be applied 5 times a week; Totally 15 sessions (3 weeks). Conventional physiotherapy also will be performed to the robotic rehabilitation group."
2400120|NCT03571529|Active Comparator|conventional physiotherapy|"Conventional Physiotherapy will be performed to the both group 5 sessions a week and totally 15 sessions (3 weeks).~Conventional physiotherapy will include neurophysiological approaches. Each session will last around 1,5 hours."
2400123|NCT03571503||Integrative Korean medicine treatment|Herniated lumbar disc (HLD) patients with radiating leg pain in the integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed.
2400124|NCT03571503||Doin with integrative Korean medicine|Herniated lumbar disc (HLD) patients with radiating leg pain in the Doin (conduction exercise) with integrative Korean medicine treatment group will be administered integrative Korean medicine treatment consisting of 2 sessions/day of acupuncture, and herbal medicine, Chuna manual therapy, bee venom pharmacopuncture and pharmacopuncture, electroacupuncture, cupping, and other interventions, as needed, plus Doin (conduction exercise) for 1 session of the 2 sessions/day of acupuncture.
2400125|NCT03571490|Active Comparator|TQL Ropivacaine(active)|Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
2400126|NCT03571490|Placebo Comparator|TQL saline (placebo)|Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%
2400127|NCT03571464|Experimental|Immediate use GGRO Mobile App|The group starts using the GGRO Mobile App immediately after the first assessment (T1) for 15 days.
2400128|NCT03571464|Active Comparator|Delayed use GGRO Mobile App|Delayed use GGRO Mobile App group started using the App 15 days after the first assessment (T2).
2400129|NCT03571438|Experimental|CK2(CX4945) and ATM(Ku 60019)|Treatment of cell culture with a combination of CK2 and ATM inhibitors serine/ threonin Kinase combination
2400130|NCT03571438|Active Comparator|Sunitinib|Treatment of cell culture with Sunitinib
2400131|NCT03571438|Active Comparator|Pazopanib|Treatment of cell culture with Pazopanib
2400132|NCT03571438|Active Comparator|Temsirolimus|Treatment of cell culture with Temsirolimus
2400133|NCT03571425|Placebo Comparator|Oral Placebo|Placebo drink
2400134|NCT03571425|Active Comparator|Oral Protein|Protein drink, ingested orally
2400135|NCT03571425|Active Comparator|Enteral Protein|Protein drink, administered via enteral tube
2400136|NCT03571412|Experimental|5Hz Left Dorsolateral Prefrontal Cortex|This group will receive 5Hz Left Dorsolateral Prefrontal Cortex repetitive Transcranial Magnetic Stimulation. Once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
2400137|NCT03571412|Experimental|5Hz Dorsomedial Prefrontal Cortex|This group will receive 5Hz Dorsomedial Prefrontal Cortex Transcranial Magnetic Stimulation, once a day on monday to friday. Until complete 15 sessions.After complete acute phase intervention (15 sessions) subject will have a 5 week clinical follow up.
3143786|NCT00016315|Experimental|Arm 7|Sequence A: Gemcitabine 600 mg/m2/week plus carboplatin 2 AUC and RT
3143787|NCT00016315|Experimental|Arm 9|Sequence A: Gemcitabine 750 mg/m2/week plus carboplatin 2 AUC and RT
3143788|NCT00016315|Experimental|Arm 11|Sequence A: Gemcitabine 900 mg/m2/week plus carboplatin 2 AUC and RT
2400141|NCT03571360|Other|Pembrolizumab|Pembrolizumab 200 mg i.v., every 3 weeks, maximum of 2 years
3143789|NCT00016328|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3143790|NCT00016367|Experimental|Regimen A|Gemcitabine IV followed by Cisplatin IV Day 1 and Trastuzumab (Herceptin) IV Day 2; Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15.
3143791|NCT00016367|Experimental|Regimen B|Starting Day 22 of regimen A, Trastuzumab IV, Gemcitabine IV, and Cisplatin IV Day 1. Trastuzumab IV followed by Gemcitabine IV Day 8 and Trastuzumab IV Day 15. Repeats every 21 days for up to 5 courses.
3143792|NCT00016406|Active Comparator|AC followed by P|doxorubicin and cyclophosphamide followed by paclitaxel followed by surgery
3143793|NCT00016406|Experimental|AC+G followed by P|weekly doxorubicin and daily cyclophosphamide with filgrastim followed by paclitaxel followed by surgery
3143794|NCT00016432|Experimental|Group 1|Exemestane
3143795|NCT00016432|Placebo Comparator|Group 2|Placebo
2400142|NCT03571347|Experimental|Self Help Plus|SH+ programme has been developed by WHO and collaborators working in the humanitarian field, with expertise in global mental health and psychosocial interventions. SH+ programme consists of a pre-recorded audio course, complemented with bibliotherapy, and thanks to this format not requiring much time from experts for implementation. SH+ consists of 5 sessions.
2400143|NCT03571347|Other|Enhanced Treatment As Usual|Control arm participants will receive routine social support and/or care according to ordinary practice and following local regulations. Additionally, they will receive baseline and follow-up assessments according to the study schedule, and information about freely available mental health services, social services and community networks providing support to asylum seekers and refugees, and NGOs' contact details.
2400146|NCT03571321|Experimental|Ruxolitinib|"Participants will receive ruxolitinib in addition to standard chemotherapy.~Standard Chemotherapy Consists of:~Remission consolidation therapy (lasting 8 weeks)~Interim Maintenance (lasting 8 weeks)~Delayed Intensification (lasting 8 weeks~Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)~Prior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care."
2400147|NCT03571308|Experimental|R-CHOP + Acalabrutinib|"Open-label non-randomised phase Ib/II study conducted in two stages. Phase I will see two doses of acalabrutinib tested. R-CHOP + acalabrutinib will be given for 6 cycles on a 21 day cycle and then two cycles of acalabrutinib only for a total of 56 days. Acalabrutinib will be introduced at Cycle 2.~Phase II will see the recommended phase 2 dose used on the same treatment regimen."
2400148|NCT03571295|Experimental|videolaryngoscopy|
2400149|NCT03571295|Experimental|direct laryngoscopy|
2400150|NCT03571282|Experimental|treatment group|The patients in the treatment group receive three monthly intravitreal injection of conbercept followed by PRN rescue treatments such as intravitreal injection of conbercept, laser photocoagulation (when outside the macular) or photodynamic therapy (when in the macular).
2400151|NCT03571269|Experimental|OCT-guided group|Detailed methods of OCT examination are the same as above. Whether stenting or not will be decided by the operators according to the underlying mechanisms of culprit lesions. If stenting, OCT will be used to guide and optimize the whole process of PCI. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
2400152|NCT03571269|No Intervention|Angiography-guided group|Detailed methods of angiography examination are the same as above. Whether stenting or not and the whole process of PCI will be decided by the operators according to the current treatment standard of angiography. Patients will be treated with dual antiplatelet therapy (aspirin+ticagrelor or aspirin+clopidogrel) for at least 12 months.
3143796|NCT00016523|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3143797|NCT00016523|Active Comparator|Placebo|Inhaled Oxygen
3143798|NCT00016744|Active Comparator|1|"Subjects will be randomized to receive either the Phenylbutyrate or placebo tablets for 4 days~Every participant will receive Genistein during the NPD."
2400156|NCT03571243||smokers|no intervention
2400157|NCT03571243||never-smokers|no intervention
2400158|NCT03571230|Experimental|Antimicrobial susceptibility testing guided therapy|"Patients in this group will receive a 10-day triple therapy for the Helicobacter pylori eradication. The regimen contains one proton pump inhibitor and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 10d 2.two sensitive antibiotics: amoxicillin 1000mg bid for 10d, clarithromycin 500mg bid for 10d, metronidazole 500mg tid for 10d, tinidazole 500mg tid for 10d, levofloxacin 500mg qd for 10d, furazolidone 100mg bid for 10d, tetracycline 750mg bid for 10d."
2400159|NCT03571230|Experimental|Empirical tailored therapy|"Patients in this group will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2400160|NCT03571230|Other|Salvage therapy for negative culture|"When the culture results are negative, patients will receive 14-day empirical tailored therapy based on personal medication history.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics based on personal medication history: amoxicillin 1000mg bid and clarithromycin 500mg bid for 14d, amoxicillin 1000mg bid and furazolidone 100mg bid for 14d."
2400161|NCT03571230|Other|Salvage therapy for failed eradication|"If patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy.~Drugs: 1.one proton pump inhibitor: lansoprazole 30mg bid for 14d 2.Colloidal Bismuth Pectin 200mg bid for 14d 3.two antibiotics for rescue therapy: tetracycline 750mg bid and furazolidone 100mg bid for 14d."
2400162|NCT03571217||Diabetic retinopathy cohort|
2400163|NCT03571217||Mild visual impairment cohort|
2400333|NCT03570086||migraineurs without aura|
2400334|NCT03570086||health controls|
3143799|NCT00016744|Placebo Comparator|2|
2400164|NCT03571204|Active Comparator|Group-1 active treatment|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with 3BNC117 plus 10-1074. Study staff and participants will be blinded to Group 1 treatment assignments.
2400165|NCT03571204|Placebo Comparator|Group-1 placebo|Group 1, 15 individuals who began ART during primary HIV-1 infection will be randomized to treatment with normal saline placebo. Study staff and participants willbe blinded to Group 1 treatment assignments.
2400166|NCT03571204|Experimental|Group-2 active treatment|Group 2, up to 15 viremic individuals not taking ARTwill receive 3BNC117 combined with 10-1074.
2400168|NCT03571178|Experimental|Treatment|Patients who will receive physical therapy
2400169|NCT03571165|Experimental|Intervention|The intervention group received information on accessing My Tools 4 Care - In Care for 2 months.
2400170|NCT03571152|Experimental|Educational videos|Subjects allocated in this arms will receive the educational videos.
2400171|NCT03571139||Diabetics type 2 with and without diabetic retinopathy|Patients with diabetes mellitus type 2 with and without diabetic retinopathy who needs cataract surgery by phacoemulsification. All patients will undergo OCT angiography examination prior to their cataract surgery and 4 weeks after the cataract surgery.
2400172|NCT03571126|Placebo Comparator|Placebos group|"Patients will be administered with dexamethasone plus tropisetron from D1 to D3.~Patients will also be administrated with placebos from D1-D4"
2400173|NCT03571126|Experimental|Experimental group|Patients will receive a regimen with dexamethasone plus tropisetron from D1-D3. Patients will also be administrated with olanzapine from D1-D4.
2400174|NCT03571113||Development|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
2400175|NCT03571113||Validation|The study population was divided into two parts by random: development dataset (5,775) and validation dataset (1,457)
2400176|NCT03571100|Active Comparator|Povidine-Iodine|Bilateral injections patients receiving Povidine-Iodine in right eye, chlorhexidine in the left eye
2400177|NCT03571100|Active Comparator|Chlorhexidine|Bilateral injections patients receiving Povidine-Iodine in left eye, chlorhexidine in the right eye
2400178|NCT03571087|Experimental|HL140 5/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
2400179|NCT03571087|Experimental|HL140 10/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
2400180|NCT03571087|Experimental|HL140 20/10|Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
2400181|NCT03571087|Experimental|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg~Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)"
2400182|NCT03571087|Experimental|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)"
2400183|NCT03571087|Experimental|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)"
2400184|NCT03571074||Hypoxia|"Defined as a group of patients with oxygen saturation <94 % irrespective of supplemental oxygen.~If COPD, defined as oxygen saturation <88 % irrespective of supplemental oxygen."
2400185|NCT03571074||Normoxia|"Defined as a group of patients with oxygen saturation 94 % - 98 % in combination of supplemental oxygen, or oxygen saturation >94 % without supplemental oxygen.~If COPD, defined as oxygen saturation 88 % - 92 % in combination of supplemental oxygen, or oxygen saturation >88 % without supplemental oxygen."
2400186|NCT03571074||Hyperoxia|"Defined as a group of patients with oxygen saturation >98 % in combination of supplemental oxygen.~If COPD, defined as oxygen saturation >92 % in combination of supplemental oxygen."
2400187|NCT03571061|Active Comparator|whole colon water immersion group|whole colon water immersion group: the air supply was turn off until the cecum was reached. For adequate lumen distention to advance the colonoscope tip, warm water which stored in 1L bottles and maintained 37°C with a water bath, was instilled intermittently into the colon through the auxiliary working channel of colonoscope using a footswitch-controlled flushing pump
2400188|NCT03571061|Experimental|sigmoid water immersion group|sigmoid water immersion group: air pump would be turned off and the procedure would be switched from water immersion method to air insufflation method after successful passage through the descending sigmoid junction.
2400189|NCT03571061|Placebo Comparator|carbon dioxide (CO2) insufflation|carbon dioxide (CO2) insufflation group: carbon dioxide (CO2) was insufflated through out the whole procedure for advancement and inspection when needed.
2400190|NCT03571048|Active Comparator|Reduced Calorie Diet (RCD)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
2400191|NCT03571048|Experimental|Time Restricted Feeding (TRF)|Participants in this group will focus on time restricted feeding in addition to daily calorie restriction as their dietary weight loss strategy.
2400192|NCT03571035|Experimental|Example|Mandibular movements recordings by a mono vision system.
2400193|NCT03571022|Experimental|USE-MI System|Immediate use of the USE-MI smartwatch and smartphone app.
2400194|NCT03571009|Experimental|utilization of PAAS|conventional treatment utilization of PAAS
2400195|NCT03571009|No Intervention|Conventional care|conventional treatment only
2400196|NCT03570996|Active Comparator|Transversus abdominis plane catheter|Transversus abdominis plane catheter (TAP) for pain control in esophagectomy operations. TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine.
2400197|NCT03570996|Active Comparator|epidural|Epidural pain control for pain control in esophagectomy operation. Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
2400335|NCT03570073|Active Comparator|Manual vitrification|
2400198|NCT03570983|Experimental|BEAM Regimen- Experimental Arm|"Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.~BCNU (Carmustine) Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.~Etoposide (VP-16, Vepesid) Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.~Cytarabine (Ara-C) Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3."
2400199|NCT03570983|Active Comparator|Melphalan Regimen- Control Arm|"Melphalan Dosage: Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.~Allopurinol Dosage: Allopurinol 200 mg/m2/day starts on the day prior to melphalan (day -3) and stops on day -1."
2400200|NCT03570970|Experimental|Banapenem C1 group|250mg Once daily for 7
2400201|NCT03570970|Experimental|Banapenem C2group|500mg Once daily for 7
2400202|NCT03570970|Experimental|Banapenem C3group|1000mg Once daily for 7
2400203|NCT03570957|Experimental|MT-2990, Low dose|Single intravenous dose
2400204|NCT03570957|Experimental|MT-2990, Low-middle dose|Single intravenous dose
2400205|NCT03570957|Experimental|MT-2990, High-middle dose|Single intravenous dose
2400206|NCT03570957|Experimental|MT-2990, High dose|Single intravenous dose
2400207|NCT03570957|Placebo Comparator|Placebo|Single intravenous dose
2400208|NCT03570944||Patients undergoing elective HRS or KRS|Adult patients undergoing elective HRS or KNS
3143800|NCT00016835|Active Comparator|Supra-gingival scaling and placebo|"This group receives a placebo (instead of systemic antibiotic), supra-gingival oral prophylaxis, and ultrasonic removal of supra-gingival calculus with water irrigation at the initial treatment visit. At the 9-month follow-up visit, this group will receive sub-gingival ultrasonic scaling with povidone-iodine irrigation.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
2400211|NCT03570905|Experimental|Sugartong Splint|
2400212|NCT03570905|Experimental|Clam Shell Splint|
2400215|NCT03570879||Power morcellation|Women that underwent laparoscopic myomectomy with subsequent power morcellation of the surgical specimens.
2400216|NCT03570879||Transvaginal extraction|Women that underwent laparoscopic myomectomy with subsequent transvaginal extraction of the surgical specimens.
2400217|NCT03570866||Early stage endometrial cancer|Women with diagnosis of intermediate and high-risk early stage endometrial cancer.
2400218|NCT03570853|Experimental|Intervention|Participants will receive the 8-week SMART-3RP intervention within a few weeks of enrolling in the study.
2400219|NCT03570853|No Intervention|No Intervention|Participants will not receive the SMART-3RP program and will only complete study questionnaires..
2400220|NCT03570840||obese children and adolescents|
2400221|NCT03570827|Experimental|Group I (hypofractionated radiation therapy)|Participants undergo hypofractionated radiation therapy over 15-30 minutes every other day over 2 weeks, for 5 treatments.
2400222|NCT03570827|Experimental|Group II (radiation therapy, androgen suppression therapy)|Beginning 8-10 weeks before radiation therapy, participants receive androgen suppression therapy SC or IM for up to 6 months (at the discretion of the treating physician). Participants then undergo hypofractionated radiation therapy as Group I.
2400223|NCT03570827|Experimental|Group III (radiation therapy, androgen suppression therapy)|Participants receive androgen suppression therapy as Group II for up to 18 months (at the discretion of the treating physician), then undergo hypofractionated radiation therapy over 15-30 minutes every other day over 1-2 weeks, for 1-5 treatments.
2400224|NCT03570814|Active Comparator|Separate Administration|Standard administration of Albendazole/Ivermectin separated from administration of azithromycin
2400225|NCT03570814|Experimental|Co-administration|Combined administration of Albendazole/Ivermectin/Azithromycin at a single time point
2400226|NCT03570801|Experimental|Expert Panel Review|"For patients who are randomized to receive an expert panel review, de-identified lumbar MRI (sagittal and key axial images), 36-inch standing plain radiographs (if available), and flexion and extension radiographs will be uploaded into a web-based platform and reviewed. These will be submitted for an Expert Panel Review.~Images will be reviewed through a Spine Expert's Network, consisting of physicians involved in this study who will each offer their opinion as to which of two surgical treatment groups (decompression alone or decompression with fusion) they would choose for the patient. The results of this review will be discussed between the patient and the patient's physician. Together, they will determine the best surgical approach."
2400227|NCT03570801|No Intervention|No Expert Panel Review|For patients not receiving the expert panel review, they will discuss with their surgeon the best surgical option and proceed as they would in standard of care.
2400228|NCT03570775|Experimental|"Neomedlight Sleeping bag phototherapy"|Phototherapy device with LED light + fiber optic mesh
2400229|NCT03570775|Active Comparator|Conventional phototherapy|LU-6T model: phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated.
2400230|NCT03570749|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2400231|NCT03570749|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
2400232|NCT03570749|Placebo Comparator|Placebo|Placebo administered orally.
2400233|NCT03570736|Experimental|Minimal Invasive Surgical Technique|
2400234|NCT03570736|Active Comparator|Open Flap Debridement|
2400235|NCT03570723|Active Comparator|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
2400236|NCT03570723|Experimental|A glove-loaded Foley's catheter|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
2400237|NCT03570710|Placebo Comparator|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
2400238|NCT03570710|Active Comparator|intravenous tranexamic acid group|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
2400239|NCT03570710|Active Comparator|Topical tranexamic acid group|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
3143801|NCT00016835|Experimental|Subgingival scaling and metronidazole|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and metronidazole as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
3184558|NCT00725985|Experimental|Cladribine 5.25 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.
2400242|NCT03570684|Experimental|tie group|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was much easier as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum.
2400243|NCT03570684|No Intervention|non-tie group|
2400244|NCT03570671|Experimental|Spasm positive|Ergonovine-induced coronary spasm provocation test positive: defined as transient, total, or sub-total occlusion (>90% stenosis) of a coronary artery with symptoms of myocardial ischemia (angina pain and ischemic ECG change).
2400245|NCT03570671|Placebo Comparator|Spasm negative|Suspected vasospastic angina subjects with negative ergonovine provocation test are considered as reference modality.
3184559|NCT00725985|Experimental|Cladribine 3.5 mg/kg (ITP)|Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
3184560|NCT00725985|Placebo Comparator|Placebo (ITP)|Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.
3184561|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (OLMP)|Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
2400249|NCT03570645|Experimental|dexmedetomidine group|thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time
2400250|NCT03570645|Experimental|dexamethasone Group|thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time
2400251|NCT03570645|Sham Comparator|control group|thoracic paravertebral blocks using only ropivacaine
2400256|NCT03570606||HA Paste in Spine|"Evaluation of HA Paste in spinal fusion procedures~o Spinal cage filling"
2400257|NCT03570606||HA Paste in long bone & extremities|"Evaluation of HA Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2400258|NCT03570606||Granulated Paste in Spine|"Evaluation of Granulated Paste in spinal fusion procedures~o Spinal cage filling"
2400259|NCT03570606||Granulated Paste in long bone & extremities|"Evaluation of Granulated Paste in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2400260|NCT03570606||Granules in Spine|"Evaluation of Granules in spinal fusion procedures~o Spinal cage filling"
2400261|NCT03570606||Granules in long bone & extremities|"Evaluation of Granules in long bone and extremity group:~Filling bone defects after cyst removal~Filling distal radius fractures~Filling defects such as tibial plateau fractures~Filling defects created by osteotomy procedures"
2400262|NCT03570606||Block in long bone & extremities|"Evaluation of Blocks in long bone and extremity group:~o High tibial osteotomies with fixation"
2400263|NCT03570593|No Intervention|Retrospective Group|
2400264|NCT03570593|Experimental|Prospective Group|
2400265|NCT03570580||Main Group - OSA Scoring|All patients include in this study for whom the four OSA scoring will be evaluated
2400266|NCT03570567|Other|Piranha Treatment|The food impaction will be treated using the Piranha endoscopic device.
3184562|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (OLMP)|Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
3184563|NCT00725985|Experimental|Placebo, Rebif (OLMP)|Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.
2400271|NCT03570541|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL ropivacaine 0,375% single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
2400272|NCT03570541|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 mL saline single shot.~Every six hours postoperative, all patients are administered 1 g of acetaminophen.~In both arms morphine will be administered IV as part of a patient controlled analgesia (PCA)-pump regimen or additionally after contact with the nursing staff as it is the standard treatment.~On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis.~On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a Quality of recovery-15 questionaire.~Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension."
2400273|NCT03570528||Maxillary Retrusion|CT
2400274|NCT03570528||Healthy Patients|
2400275|NCT03570515|Experimental|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days.
2400276|NCT03570515|Active Comparator|Educational Film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
3184564|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
2400280|NCT03570463||GLA:D Back|Two 1-hour group sessions of patient education 8 weeks of twice-weekly 1-hour supervised group exercise sessions
2400281|NCT03570450|Experimental|Adipose derived Stem Cells - 1.10^6cells/kg|ADSC, single, IV, 1.10^6cells/kg
2400282|NCT03570450|Experimental|Adipose derived Stem Cells - 2.10^6cells/kg|ADSC, single, IV, 2.10^6cells/kg
2400283|NCT03570450|Experimental|Adipose derived Stem Cells - 2,5.10^6cells/kg|ADSC, single, IV, 2,5.10^6cells/kg
2400284|NCT03570450|Experimental|Adipose derived Stem Cells - 3.10^6cells/kg|ADSC, single, IV, 3.10^6cells/kg
2400285|NCT03570450|Placebo Comparator|placebo|Placebo
2400286|NCT03570437|Active Comparator|Arm 1: Paclitaxel|Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.
2400287|NCT03570437|Experimental|Arm 2: Cediranib and paclitaxel|Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue cediranib once daily until disease progression.
2400288|NCT03570437|Experimental|Arm 3: Cediranib and olaparib|Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease or better will be able to continue with olaparib and cediranib until disease progression.
2400289|NCT03570424|Placebo Comparator|Placebo|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass of artificially flavoured and textured placebo 45 minutes prior to HIIT exercise
2400290|NCT03570424|Experimental|Whey Protein|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass intact whey protein 45 minutes prior to HIIT exercise
2400291|NCT03570424|Experimental|Whey Protein Hydrolysate|Intervention (Nutrient support to HIIT): Participants consume 0.33g.kg-1 body mass hydrolysed whey protein 45 minutes prior to HIIT exercise
2400292|NCT03570411||HCT Recipient|"All participants who meet eligibility criteria and consent to enrollment on study.~Blood specimens will be collected for the T-SPOT.CMV blood test from HCT recipients over the course of 6 months, starting weekly at Day +1, biweekly starting at Day +45, and monthly starting at day +120.~The amount of blood collected at each visit will be based on age."
2400293|NCT03570411||HCT Donor|"Approved allogeneic HCT donor for a HCT recipient enrolled on the SPOTCMV protocol~A blood sample for the T-SPOT.CMV blood test will be collected from the HCT donor prior to transplant"
2400294|NCT03570398|Other|Abdominal CT|
2400295|NCT03570398|Other|Abdominal Ultrasound|
2400297|NCT03570372|Experimental|Intervention group|36 week internet-based CBT with therapist support. Regular online group discussions.
2400298|NCT03570372|Active Comparator|Control group|Reads 2 books about Autism Spectrum Disorder (ASD)
2400299|NCT03570359|Active Comparator|Interferon beta 1a|"Part 1- Interferon beta 1a once a day for 3 days via inhalation~Part 2 - Interferon beta 1a once a day for 14 days via inhalation"
2400300|NCT03570359|Placebo Comparator|Placebo|"Part 1- placebo once a day for 3 days via inhalation~Part 2 - placebo once a day for 14 days via inhalation"
2400301|NCT03570346|Experimental|Hemay005|6 subjects in each cohort(15mg, 30mg, 60mg) will receive Hemay005
2400302|NCT03570346|Placebo Comparator|Placebo|2 subjects in each cohort(15mg, 30mg, 60mg) will receive placebo
2400336|NCT03570073|Experimental|Automatic vitrification|
2400303|NCT03570333|Experimental|Progenitor Potential at Molar site|Harvested tissue from the back (molar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
2400304|NCT03570333|Experimental|Progenitor Potential at Premolar site|Harvested tissue from the front (premolar) part of the palate will be used to extract the gingival mesenchymal cells to test their progenitor potential to differentiate into multiple cell lineage.
2400305|NCT03570320|No Intervention|Control group|The first treatment group will be our control arm. On discharge following their surgery, these patients will receive a single prescription for 225 Morphine Milligram Equivalents (MMEs). This corresponds to #30 pills of 5mg oxycodone/acetaminophen, #45 pills of 5mg hydrocodone/acetaminophen, or #30 pills of 7.5mg Morphine.
2400306|NCT03570320|Experimental|Interventional Arm|Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
2400307|NCT03570307|Other|drug treatment|Misoprostol for uterine evacuation
2400308|NCT03570307|Other|surgical treatment|dilatation and curettage for uterine evacuation
2400309|NCT03570294|Other|Atosiban|Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.
2400310|NCT03570281|Experimental|Edoxaban group|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
2400311|NCT03570281|Active Comparator|Enoxaparin group|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
2400312|NCT03570268|Experimental|Experimental group: Education group|Participants in the experimental intervention group (education group) received an educational program and tailored home exercises. This intervention consist of multiple, interacting components supported by a handbook and audio-video material designed to teach people the skills, techniques, and strategies for preventing falls, and increase social participation and engagement in inactivity of daily living. . After the educational session, two one hour sessions were spent to teach safe balance exercises that were developed in preceding studies, the patient was invited to perform at home for 2 months.
2400313|NCT03570268|Active Comparator|Control Group: Usual care|Participants allocated to the control group received ongoing usual treatments. In addition, two one hour lessons were spent to teach stretching exercises that the patient was invited to perform at home for 2 months.
2400315|NCT03570242|No Intervention|Control group (palliative treatment)|"usual care control group (includes patients undergoing palliative Treatment) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
2400316|NCT03570242|Experimental|WB-EMS group (palliative treatment)|"physical exercise group (includes patients undergoing palliative Treatment) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
2400317|NCT03570242|No Intervention|Control group (curative treatment)|"usual care control group (includes patients undergoing curative treatment 3-4 weeks before surgery) receives individualized nutritional support (dietary advices: daily protein intake1,2 - 1,5 g/kg bodyweight)"
2400318|NCT03570242|Experimental|WB-EMS group (curative treatment)|"physical exercise group (includes patients undergoing adjuvant treatment 3-4 weeks before surgery) receives regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1,2-1,5 g/kg bodyweight)"
2400319|NCT03570216|Experimental|Exercise|All participants will perform 3 exercise sessions: one session to assess their cardiorespiratory fitness, one session on moderate-intensity continuous exercise and one session of high-intensity interval exercise
2400320|NCT03570203||Retrospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of admission.
2400321|NCT03570203||Prospective Cohort|Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score > 3 at time of recruitment.
2400322|NCT03570190||TAVI patients|elective patients with a diagnosis of sAS and admitted for TAVI attending one of the participating centers for commercially available balloon expandable valve implantation that will be managed by a coordinator
2400323|NCT03570177||all subject|the all population (described in eligibility criteria)
2400324|NCT03570164|Experimental|Sevoflurane|Anesthesia is maintained with sevoflurane.
2400325|NCT03570164|Experimental|Desflurane|Anesthesia is maintained with desflurane.
2400326|NCT03570138|Experimental|Flash continuous glucose monitoring system|Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
2400327|NCT03570138|Active Comparator|Standard self monitoring blood glucose system|Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
2400328|NCT03570125|Experimental|Dietary intervention arm|"group will follow an ad libitum diet but, every two months, will follow a 5 day of fasting mimicking diet (PROLON). The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS).~Prolon will be provided for free by L-nutra or in case of unforeseeable budget constraint at one fifth of its commercial value."
2400329|NCT03570125|No Intervention|no intervention|Control/Placebo with multivitamin supplementation
2400330|NCT03570112||Pregnant Women with Hep C|SOF/VEL Therapy-sofosbuvir 400mg, velpatasvir 100mg, once daily for 12 weeks at 24 weeks post partum
2400331|NCT03570099||Prospective Naloxone cohort|The prospective cohort consists of study subjects receiving Naloxone nasal spray in the distribution program.
2400338|NCT03570021|Active Comparator|Group 1|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].
2400339|NCT03570021|Experimental|Group 2|total thyroidectomy alone without neck dissection. This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
2400340|NCT03570008|Experimental|Sp-Ex|a 9 days spa residential program including physical activity. 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
2400341|NCT03570008|Active Comparator|Sp-alone|Participants will benefit a short term spa residential program of 9 days. In addition they will benefit advices from national plan for physical activity and nutrition (NPPN)
2400342|NCT03570008|Active Comparator|Ex-alone|Participants will benefit 3 sessions of 10 minutes per day of physical exercise for bone health improvements supervised by a professional of adapted physical activity. Participants will benefit advices from national plan for physical activity and nutrition (NPPN)
2400343|NCT03569995|Experimental|Induction+Consolidation chemotherapy|"[Induction phase]~① After induction therapy (Rituximab-Methotrexate) 2 times, first evaluation~Complete, partial response or stable disease-> next step~Progressive disease-> eliminated~② After Induction therapy (Rituximab-Methotrexate) was added 3 times (total 5 times), 2nd evaluation~Complete response -> consolidation therapy(Rituximab-Cytarabine) progress~Partial response or stable disease-> Rituximab-Methotrexate 2 additional administrations~Progressive disease-> eliminated~③ After Induction therapy (Rituximab-Methotrexate) was added twice (7 times in total), 3rd evaluation~Complete, partial response or stable disease-> consolidation therapy(Rituximab-Cytarabine)~Progressive disease-> eliminated"
2400344|NCT03569982|No Intervention|Control|Patients receiving best supportive care
2400345|NCT03569982|Experimental|Intervention|Patients receiving integrative care (including acupuncture) in addition to best supportive care
2400346|NCT03569969|Experimental|control group|Step1. Under local anesthesia and sedation , the temporal muscle fascia was removed, Step2. After the preparation on the tympanic membrane embedded , foam gel smeary with Dexamethasone was worn.Step3. Then the wound dressing was done with a gas number and a Surgifix. Step4. Patients were discharge from the operating room with an oral administration of Cephalexin capsules.
2400347|NCT03569969|Experimental|Test group|Step1. After sedation and conducting local anesthesia with Lidocaine 2% and inserting the edges of the tympanic membrane and inserting the foam gel into the middle ear, amniotic membranes (produced in Iran tissue product) with a thickness of 100 microns on the tympanic membrane and the foam gel embedded. Step2. Under-layered and short-lived foam gel (manufactured by Ethicon Company) smeary with dexamethasone was covered.
3143802|NCT00016835|Experimental|Subgingival scaling and doxycycline|"This group receives ultrasonic scaling with local anesthesia (as needed), local antimicrobial treatment with povidone-iodine irrigation, and doxycycline as an oral systemic antibiotic at the initial treatment visit.~This group also receives regular follow-up evaluations and site-specific mechanical periodontal therapy, at 3-month intervals, for approximately 15 months."
2400350|NCT03569943|Experimental|Robotol|
2400351|NCT03569930|Experimental|Standard|standard of care (diet rich in water and vegetable fibers, hygienic)
2400352|NCT03569930|Experimental|ProtFlav|oral supplements (flavonoid-based supplements - ProtFlav) will be added to standard of care
2400353|NCT03569930|Experimental|ProtCent|anal application of a Centella based cream (Centella asiatica - ProtCent) will be added to standard of care
2400354|NCT03569917|Experimental|patient under Ceftriaxone treatment|
2400356|NCT03569878|Experimental|Peer-Integrated Multidisciplinary Collaborative Care|The peer-integrated collaborative care intervention includes front-line trauma center staff (e.g., nursing and masters in social work), joined by injured peer interventionists and supervised by an MD (psychiatrist). The collaborative care team will provide case management, behavioral intervention elements, psychopharmacologic medication recommendations as well as 24/7 cell phone coverage for approximately 6 months post-injury. The intervention will be supported by a novel emergency department health information technology platform.
2400357|NCT03569878|Active Comparator|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with recommendation for mental health inpatient consultation will be the comparator condition.
2400358|NCT03569865|Experimental|Active AVS-1|Active AVS-1 consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2400359|NCT03569865|Experimental|Active AVS-2|Active AVS-2 consists of a 30-minute pulsing lights (red, green) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2400360|NCT03569865|Placebo Comparator|Placebo AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
2400361|NCT03569852|Experimental|Experimental Group 1|Order of treatment, time restrictive feeding (16 hours fasting and 8 hours eating) followed by traditional eating pattern (12 hours fasted and 12 hours eating).
2400362|NCT03569852|Experimental|Experimental Group 2|Order of treatment, traditional eating pattern (12 hours fasted and 12 hours eating) followed by time restrictive feeding (16 hours fasting and 8 hours eating).
2400363|NCT03569839||Patients undergoing surgery|Patients subject to TIVA
2400364|NCT03569826||Observational|There is no intervention being administered. This registry only observes patients through their regular standard of care visits.
2400365|NCT03569813|Experimental|PrEP@Home System|The experimental group will be assigned to the remote care system for one year of follow-up PrEP care to include home test kits and behavioral surveillance, and telemedicine visits as needed.
2400366|NCT03569813|Active Comparator|Standard of Care|The comparator group will receive active linkage to a local PrEP provider for clinic-based PrEP follow-up. Participants in this study arm will be seen quarterly by a health care provider, per standard of care when taking PrEP.
2400367|NCT03569787||Patients with hyperprolactinaemia|Patients undergoing subfertility studies with at least one high prolactin reading (>500mU/L).
2400368|NCT03569774|Experimental|Individualized PEEP|Individualized PEEP will be identified by performing a decremental PEEP protocol which will determine the level of PEEP that correlates with maximal lung compliance in each subject. Subjects will receive one-lung ventilation with individualized PEEP
2400369|NCT03569774|Active Comparator|Low PEEP|Subjects will receive One-lung ventilation with low PEEP (5 cmH2O)
3189071|NCT00773942|Experimental|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and a brief chart synopsis including patient medical history, medication history, and relevant laboratory information.
3189072|NCT00773981|Active Comparator|1|Endoluminal vacuum therapy.
2400374|NCT03569722||Older adults|Older adults, ages 65+
2400375|NCT03569709|Active Comparator|Aerobic Exercise|Sub-threshold aerobic exercise.
2400376|NCT03569709|Placebo Comparator|Stretching|Stretching program that will not raise heart rate.
2400377|NCT03569709|Placebo Comparator|Rest|Relative rest. Avoid all structured exercise.
2400378|NCT03569696|Experimental|Nivolumab|Nivolumab will be administered intravenously every 2 weeks in a dose of 240mg over 30 minutes for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
2400379|NCT03569683|Experimental|Interventional Single arm|"Group A- Diode laser biostimulation on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group B- Hyaluronic acid (Gengigel) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery.~Group C- Herbal gel (Hiora SG) topical application on surgical site immediately after external bevel gingivectomy and on 1st,3rd, and 7th day after surgery."
2400380|NCT03569670|Experimental|Posterior Stabilized|A posterior stabilized, all-polyethylene tibial component will be used during surgery.
2400381|NCT03569670|Active Comparator|Cruciate Retaining|A cruciate retaining, all-polyethylene tibial component will be used during surgery.
2400382|NCT03569657|Other|A positive psychology workshop|The group intervention implements a manualized treatment protocol outlining the content of each of the four 90 minute sessions. The sessions will include topics such as mindfulness, self-compassion, gratitude and forgiveness, grief and growth, utilizing one's strengths, and resilience; with each session including homework exercises to be practiced between sessions. To assess the outcome measures, participants complete a baseline survey, a survey after the second session (2 weeks), a survey after the final session (4 weeks), and a follow-up survey 3 months after the workshop has ended (4 months).
2400383|NCT03569644|Other|qualitative study|heterogeneous group of patients
2400384|NCT03569631|Experimental|BPN14770|25mg BPN14770 capsules, one capsule taken twice daily for 12 weeks
2400385|NCT03569631|Placebo Comparator|Placebo|Matching placebo capsules, one capsule taken twice daily for 12 weeks
3189073|NCT00773981|No Intervention|2|Patients not receiving vacuum therapy should be treated with a catheter with daily rinsing for a minimum of 7 days.
2400388|NCT03569605|Active Comparator|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
2400389|NCT03569605|Experimental|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group, behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
2400390|NCT03569592|Experimental|Overdose Prevention Intervention|The experimental group will receive a brief overdose prevention education intervention and be issues naloxone upon discharge from jail.
2400391|NCT03569579|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Memantine Tab. 10mg)*2T, QD, PO.~Period 2: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
2400392|NCT03569579|Experimental|Group 1(Treatment B/Treatment A)|"Period 1: Treatment B(Memantine Tab. 10mg)*2T + Donepezil Tab. 10mg)*1T, QD, PO.~Period 2: Treatment A(Memantine Tab. 10mg)*1T, QD, PO.~Each treatment period was separated by a washout period of at least 21 dyas."
2400393|NCT03569566||Elite endurance athletes|Cross-country skiers at high national level
2400395|NCT03569540|Experimental|Treated Patients|Patients who will receive Glibenclamide 05mg daily for 21 days, orally or by nasogastric tube.
2400396|NCT03569540|Placebo Comparator|Control Group|Patients who will receive amylum 05mg daily for 21 days, orally or by nasogastric tube.
2400397|NCT03569527|Active Comparator|Kiwifruit|Treating chronic constipation with 2 kiwifruit (6g fiber) per day
2400398|NCT03569527|Active Comparator|Psyllium fiber|Treating chronic constipation with 24g psyllium fiber (6g fiber) per day
2400399|NCT03569527|Active Comparator|Prune|Treating chronic constipation with 100g dried plums (6g fiber) per day
2400401|NCT03569501|No Intervention|nutritional guidance|routine care (all arms with nutritional guidance per routine care)
2400402|NCT03569501|Active Comparator|oat grains|90 mg oat, per day.
2400403|NCT03569501|Experimental|oat grains and DHA tablets|90 mg oat and 500 mg DHA oral tablets, per day.
2400404|NCT03569501|Active Comparator|DHA tablets|500 mg DHA oral tablets, per day.
2400470|NCT03569176|Experimental|Autism Glass Intervention|Participants in the experimental group will receive the autism glass for 6 weeks once they are assigned to the experimental condition. Participants will be asked to use the glasses at least 3 times a week for 20 minutes sessions in addition to continuing Applied Behavior Analysis (ABA) therapy.
2400405|NCT03569475|Experimental|Levomilnacipran ER|patients will take levomilnacipran 10 mg/day on Days 1-3, 20 mg/day on Days 4-7, and 40 mg/day during weeks 2 through 8 of the double blinded treatment and 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days in the down-taper period. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day is permitted at Week 3 through 8 of the double blinded treatment. in the down-taper period. the patient will take levomilnacipran 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days
2400406|NCT03569475|Active Comparator|Fluoxetine 20 mg|Patients randomized to the Fluoxetine 20 mg arm will take Week 1, 10mg/day; week 2 through week 8, 20 mg/day
2400407|NCT03569475|Placebo Comparator|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily through week 8
2400408|NCT03569462|Experimental|"Mobile WeChat intervention"|Participants will watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile health application that delivers content to promote HIV-self testing and reduce HIV-related risk behavior.
2400409|NCT03569462|Active Comparator|Control condition|Participants will watch a demonstration of HIV self-testing and receive HIV self-testing kits.
3143803|NCT00016952|Experimental|irinotecan|"Prior oxaliplatin-based chemotherapy: Patients receive irinotecan IV over 90 minutes on day 1. Treatment repeats every 3 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
3143804|NCT00016952|Experimental|leucovorin + fluorouracil|"Prior to irinotecan and oxaliplatin combination chemotherapy: Patients receive leucovorin calcium IV over 2 hours and fluorouracil IV continuously on days 1 and 2. Treatment repeats every 2 weeks.~Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a confirmed complete response for 2 consecutive courses may discontinue treatment at investigator's discretion.~Quality of life is assessed at baseline, approximately every 6 weeks during treatment, and then after the last course of treatment.~Patients are followed every 3 months for 5 years."
3143805|NCT00016978|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and leucovorin calcium and fluorouracil IV on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a confirmed complete response for 2 consecutive courses may discontinue study treatment at the investigators discretion. Quality of life is assessed at baseline, approximately every 6-8 weeks during treatment, and then after the last course of treatment.
3143806|NCT00017004|Experimental|Arm I|Patients undergo radiotherapy comprising pelvic external beam radiotherapy daily five days a week for 5 weeks, followed by either 1 or 2 implants of low-dose rate intracavitary brachytherapy or 5 fractions of high-dose rate intracavitary brachytherapy, followed by 3-5 days of parametrial boost radiotherapy. Patients receive cisplatin IV concurrently with pelvic external beam radiotherapy on days 1, 8, 15, 22, 29, and once during the week of parametrial boost radiotherapy.
3143807|NCT00017004|Experimental|Arm II|Patients undergo radiotherapy and chemotherapy as in arm I. Additionally, patients receive epoetin alfa subcutaneously once weekly concurrently with radiotherapy and chemotherapy.
3143808|NCT00017095|Active Comparator|non taxane based chemotherapy|either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
3143809|NCT00017095|Experimental|taxane based chemotherapy|Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles
2400426|NCT03569436||Metastatic head and neck participants in Japan|Study in Japan targeting recurrent/metastatic HNC patients who are treated with nivolumab
2400427|NCT03569423|Experimental|Transepithelial PRK|Transepithelial photorefractive keratectomy was done in 100 right eyes of 100 patients included in the study.
2400428|NCT03569423|Active Comparator|Alcohol assisted PRK|Alcohol assisted photorefractive keratectomy was done in 100 left eyes of the same 100 patients included in the study.
2400429|NCT03569410|Active Comparator|Supplement Group|The protein supplement group was instructed by their dietician in how many protein supplements to consume in addition to their natural food intake in order to reach their goal protein intake.
2400430|NCT03569410|Experimental|Natural Food Group|The Natural food group was instructed by their dietician in how much additional protein rich foods to eat in order to reach their goal protein intake.
2400433|NCT03569384|Experimental|"Intervention group tele-rehabilitation"|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist. Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system. Workout Sessions with a Virtual Physiotherapist Agent (VPA):~The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
2400434|NCT03569384|Active Comparator|Control|COPD patients in the control group will undergo the conventional standardized rehabilitation program as implemented at the Department of Respiratory Medicine and Allergy, Aarhus University Hospital. The program is an 8 weeks program consisting of 2 weekly group training sessions at the hospital with instruction by a physiotherapists and 6 hours of education about COPD and its treatment.
2400436|NCT03569358|Experimental|Virtual Reality and EEG Interventions|In the interventional arm, 20 subjects will receive twice daily sessions of immersive virtual reality for a maximum of 15 minutes, with EEG headband recording starting 5 minutes prior to and 5 minutes after the intervention, for a maximum of 4 consecutive days.
2400437|NCT03569358|Active Comparator|EEG Intervention group|In the control arm, 10 subjects would have EEG recorded for 25 mins twice daily, with a minimum of 4 hours intervening, for 3 consecutive days, with the EEG headband. There would be no immersive virtual reality sessions.
2400438|NCT03569358|Active Comparator|Healthy Volunteers|At the completion of the above intensive care study recruitment, demographic data of the interventional immersive virtual reality arm would analysed to recuit 10 age-matched healthy volunteers with no known cognitive disorders or visual impairment. This is to compare study data with healthy controls. A 25 minute session consisting of 15 minutes of immersive virtual reality and 5 minutes of EEG recording with the EEG headband before and after the intervention would be performed. Eye-tracking and EEG data from these groups of patients would be compared against subjects in both arms of the study performed in the intensive care unit to investigate for exploratory differences.
2400439|NCT03569345|Experimental|Arm|Basal cell carcinoma (BCC) patients Patients (>18 pr) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on face/scalp, <50 mm on trunk/extremities)
2400440|NCT03569332|Experimental|Test Group|Participants will receive the mobile self-input tool providing alarm on tablet, and their practicing rate will be sent to Nurse's Dashboard.
2400441|NCT03569332|No Intervention|Control Group|Participants will receive the mobile self-input tool on tablet (to compare the rate with Test group). But it won't contain alarm function and their practicing rate won't be sent to Nurse's Dashboard, either.
2400442|NCT03569319|Experimental|"Group 1: THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=10)"
2400443|NCT03569319|Experimental|"Group 2: THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=10)"
2400444|NCT03569319|Placebo Comparator|Group 3: Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention) (n=10)"
2400445|NCT03569306|Experimental|ENB-EBUS-GS group|ENB is used in this group.EBUS and GS are inserted into bronchi in the assistance of ENB. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
2400446|NCT03569306|Active Comparator|EBUS-GS group|ENB isn't used in this group.EBUS and GS are inserted into bronchi according to the chest CT that judged by the doctor. The EBUS probe and GS are confirmed to reach the lesion by EBUS images.
2400447|NCT03569293|Experimental|Arm A|Upadacitinib Dose A is administered once daily.
2400448|NCT03569293|Experimental|Arm B|Upadacitinib Dose B is administered once daily.
2400449|NCT03569293|Experimental|Arm C|Placebo administered once daily followed by Upadacitinib Dose A once daily.
2400450|NCT03569293|Experimental|Arm D|Placebo administered once daily followed by Upadacitinib Dose B once daily.
2400451|NCT03569280|Experimental|KPG-121|Safety and Antitumor Activity of KPG-121 capsules 1.5, 2.5, 5.0, 10, 20, and 30 mg/day daily for 21 days
2400452|NCT03569267|Experimental|OLX10010|OLX10010, an siRNA therapeutic, with four different doses by Groups (dose ascending manner with 1, 4, 10, 20 mg)
2400453|NCT03569267|Placebo Comparator|Placebo|placebo
2400454|NCT03569254|Experimental|Neomedlight Phototherapy Blanket|Phototherapy with a fiber-optic device based on LED light administered intermittently for a total of 6 hours with periods of 2 hours in kangaroo position and pauses of 1 hour at the end of each period.
2400455|NCT03569254|Active Comparator|Ohmeda-Fiber Optic Phototherapy Blanket|Phototherapy with a fiber-optic device: the Ohmeda fiber optic Phototherapy blanket
2400456|NCT03569241|Other|MDT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + 6 months androgen deprivation therapy
2400457|NCT03569241|Experimental|MDT + WPRT + ADT|Metastasis-directed therapy (salvage lymph node dissection OR stereotactic body radiotherapy) + whole pelvic radiotherapy + 6 months androgen deprivation therapy
2400458|NCT03569228|Experimental|Study 1 (In-the-Ear) Group|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2400459|NCT03569228|Experimental|Study 1 (Behind-the-Ear) Group|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2400460|NCT03569228|No Intervention|Study 2 (Open-Fit corrections)|Participants with hearing loss will be fitted monaurally with 12 stock non-custom, receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids using the standard in-situ approach and test box measures will be made of each fitting to develop correction factors for these styles.
2400461|NCT03569228|Active Comparator|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
2400462|NCT03569228|Active Comparator|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
2400463|NCT03569228|Experimental|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2400464|NCT03569228|Experimental|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
2400465|NCT03569215||IVF/ICSI failure|These patients had prolonged infertility with one or more failure of IVF/ICSI cycles
2400466|NCT03569215||Prolonged infertility only|These patients had prolonged infertility without any trials of IVF/ICSI cycles
2400469|NCT03569189|Experimental|High Fat Diet|Participants will consume a high-fat, high-calorie diet for 7 days (i.e. westernised diet) following a 3-day weight maintenance diet. Measurements will be made pre- and post-high fat diet intervention.
2400528|NCT03568760|Experimental|SFA treatment|Semantic feature analysis
2400471|NCT03569176|Other|Crossover Control for Autism Glass|Participants randomized to the control arm, will continue treatment as usual (receiving ABA twice a week) while the intervention participants will receive the Autism Glass intervention (while continuing to receive ABA therapy). After 6 weeks, control participants will receive the Autism Glass intervention after which, they will be asked to come in for a second round of follow-up testing following 6 weeks of use (at week 18).
2400472|NCT03569150|Other|Intervention (Rosebud)|The intervention is: Native Americans patients with a serious life-limiting illness will have an advance care planning discussion with an interdisciplinary healthcare professional trained in the culturally-adapted COMFORT Communication Curriculum.
2400473|NCT03569150|No Intervention|Control (Pine Ridge)|In the control group, Native American patients with a serious life-limiting illness will receive usual care. The healthcare professionals have not undergone training in the culturally-adapted COMFORT Communication Curriculum.
2400474|NCT03569124||Training group|
2400475|NCT03569124||Non-Training group|
3189074|NCT00773994|Other|Normal velopharyngeal mechanism|All participants in this study are normal healthy adults, who have agreed to undergo to a videofluoroscopic Televex. These participants are acceptable control subjects because they are not diagnosed with VPI and/or submucous cleft palate (SMCP) and the velopharyageal mechanism functions the same in adults as it does in children. This procedure will take approximately 3 minutes to 5 minutes.
2400479|NCT03569085|Experimental|Sevoflurane then isoflurane|
2400480|NCT03569072|Experimental|Dose escalated functionally adapted radiation therapy|This is a single arm study
2400481|NCT03569059|Experimental|Early Robotic/VR Therapy (EVR)|Subjects in this group will receive state-of-art inpatient usual care therapy plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated 5-30 days post stroke.
2400482|NCT03569059|Experimental|Delayed Robotic/VR Therapy (DVR)|Subjects in this group will receive state-of-art usual care therapy (inpatient and outpatient) plus 10 days of extra 1-hour/day of intensive therapy focusing on the hand using haptic robots integrated with complex gaming and virtual environments and initiated within 31-60 days post stroke.
2400483|NCT03569059|No Intervention|Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care.
2400484|NCT03569059|Experimental|Dose-Matched Usual Physical Therapy Care|Subjects in this group will receive state-of-art usual physical therapy/occupational therapy care plus an extra hour of state-of-art usual care.
2400485|NCT03569046|Active Comparator|group l|ear block by local anaesthetic injection 0.25% bupivacaine. general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
2400486|NCT03569046|Placebo Comparator|Group II|ear block by Normal Saline Flush, 0.9% Injectable Solution . general anesthetic by: midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 µg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air. hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
2400491|NCT03569007|Active Comparator|Larazotide 0.25 mg|Larazotide 0.25 mg capsules TID
2400492|NCT03569007|Active Comparator|Larazotide 0.50 mg|Larazotide 0.50 mg capsules TID
2400493|NCT03569007|Placebo Comparator|Placebo|Matching placebo capsules TID
3143810|NCT00017121|Experimental|sargramostim|"Patients receive aerosolized sargramostim (GM-CSF) twice a day on days 1-7 and 15-21. Treatment repeats every 28 days for 2 courses. Patients with no disease progression after completion of course 2 may continue on treatment until disease progression. Patients are grouped to 1 of 2 dose-escalation regimens (part A vs B).~After completion of study therapy, patients are followed at 3 months, every 2 months for 1 year, and then every 3-4 months for 5 years."
3143811|NCT00017147|Experimental|O6-BG + BCNU + Radiation Therapy|O6-BG: 120 mg/m^2 IV over 1 hour on day 1 of each cycle BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
2400496|NCT03568981||Partial Breast Irradiation (PBI)|Patients receiving 5-fraction stereotactic partial breast irradiation for breast cancer
2400497|NCT03568981||Whole Breast Irradiation (WBI)|Patients receiving whole breast irradiation for breast cancer
2400498|NCT03568968|Experimental|Nicotinamide Riboside|nicotinamide riboside, 1000mg daily for the duration of the trial (52 weeks). Dosage form is tablets.
2400499|NCT03568968|Placebo Comparator|Placebo Comparator|Placebo tablets, no active ingredients.
2400500|NCT03568955||Swiss Bereaved|Adults from the Swiss population who have lost a loved one at least 6 months to 10 years prior to testing
2400501|NCT03568955||Japanese Bereaved|Adults from the Japanese population who have lost a loved one at least 6 months to 10 years prior to testing
2400502|NCT03568955||Chinese Bereaved|Adults from the Chinese population who have lost a loved one at least 6 months to 10 years prior to testing
3143812|NCT00017147|Active Comparator|BCNU + Radiation Therapy|BCNU: 40 mg/m^2 IV over 1 hour on day 1 of each cycle. Radiation Therapy: 5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
2400505|NCT03568916||Rivaroxaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with rivaroxaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2400529|NCT03568760|Placebo Comparator|Comprehension training|Comprehension training
3143813|NCT00017173|Experimental|surgery with INGN 201 followed by chemo/RT|intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy
3143814|NCT00017186|Experimental|gemcitabine + epirubicin|"Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and epirubicin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving complete response (CR) receive 2 additional courses beyond CR.~Quality of life is assessed at baseline, prior to course 3, at 3 months, and then at 1 year.~Patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 3 years."
2400506|NCT03568916||Apixaban vs dabigatran|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or dabigatran at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2400507|NCT03568916||Apixaban vs rivaroxaban|Patients diagnosed with non-valvular atrial fibrillation who initiated their oral anticoagulation with apixaban or rivaroxaban at cohort entry date, and did not have a previous prescription for any oral anticoagulant in the prior year.
2400508|NCT03568903|Experimental|Intervention group|Comprehensive physical therapy intervention in small groups (3 members), altogether 16 sessions were performed during a period of 8 weeks (twice a week). Each session lasted 1 hour.
2400509|NCT03568903|No Intervention|Control group|Control group members did not receive any specific intervention during study period, but if needed, medical treatment (medication, it's dosage etc) of Parkinson Disease was changed during study period. They were assigned to individual therapy after the study period.
2400510|NCT03568890|Active Comparator|Anticoagulation therapy|Direct oral anticoagulants (rivaroxaban, dabigatran, apixaban, or edoxaban; with dosage according to guideline recommendations) for 8 weeks.
2400511|NCT03568890|Active Comparator|Antiplatelet therapy|Dual antiplatelet therapy with clopidogrel -75 mg/day- and low dose aspirin -80 to 125 mg/day for 8 weeks.
2400512|NCT03568877|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks
2400513|NCT03568877|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks
2400514|NCT03568864|Placebo Comparator|Low nucleotide meal|Mixed meal containing mycoprotein with a reduced nucleotide content (~ 2% nucleotides)
2400515|NCT03568864|Experimental|High nucleotide meal|Mixed meal containing mycoprotein with a high nucleotide content (~ 10% nucleotides)
2400516|NCT03568838|Experimental|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin.
2400517|NCT03568838|No Intervention|Standard Therapy|Patients randomised to the standard therapy arm will receive treatment as guided by the treating cardiologist in line with the local standard-of-care, usually consisting of UFH and a GPI.
2400518|NCT03568825|Experimental|Number of Osteopatic Manual Therapy|Intervention: OMT. Osteopatic Manual treatment consisting of Thoracic spine, Diaphragm mobilisation, Traction of the cardia and posture correction.
2400519|NCT03568825|Experimental|Interval in days between each OMT|Intervention: OMT. The time between each OMT's is calculated by the study design. Each OMT intervantion consists of Thoracic spine and Diaphragm mobilisation, Traction of the cardia and Posture correction.
2400520|NCT03568812|Experimental|Probiotics Rillus®|Rillus®, Chewing tablet containing viable cell 1.0 x 10^9 colony forming unit (Lactobacillus plantarum 8.55 mg, Streptococcus thermophilus 8.55 mg, Bifidobacterium bifidum 2.55 mg, fructooligosaccharide 480 mg), isomalt, xylitol, milk flavour, vanilla flavour Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
2400521|NCT03568812|Placebo Comparator|Placebo|Placebo: Chewing tablet with identical flavour, colour, smell, and size as investigational drug Dosage: 1 chewing tablet Frequency: once daily every night Duration: 12 weeks
2400522|NCT03568799|Experimental|4-[18F]Fluoroglutamine|Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-[18F]Fluoroglutamine IV and 60 minutes after injection, undergo 4-[18F]Fluoroglutamine PET/CT before the start of therapy.
2400523|NCT03568786|Experimental|End-inspiratory pause (EIP) 10%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a of 10% of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 10% of total inspiratory time.
2400524|NCT03568786|Experimental|End-inspiratory pause (EIP) 30%|Once the patient is intubated and after initiating ventilation in a volume control mode using a tidal volume of 7 ml/kg of predicted body weight (PBW) with an inspiration: expiration ratio of 1:2; a respiratory rate of 12-14 breaths per minute to maintain the etCO2 at 35-40 mmHg and an initial PEEP of 5 cmH2O, the investigators will apply an alveolar recruitment maneuver (ARM) with estimation of the open lung PEEP using an end-inspiratory pause (EIP) corresponding with a 30 % of the total inspiratory time. Volume control ventilation will be restored after ARM maintaining the same ventilatory parameters except the EIP, which in this group will be of 30 % of total inspiratory time.
2400525|NCT03568773|Experimental|High-intensity interval training|"The HIIT protocol is being performed with the cycling mode. The program consists of repeated intense explosions alternating with recovery intervals.~The adaptation period consists of 4 shots of 20 seconds interspersed by 180 seconds interval (active recovery). From the first to the fourth week the volunteers performed from four to six race shots from 30 to 45s with intervals from 180s to 120s. From the fifth week until the end of the intervention, training takes place with six shots of 60s with a 120s interval between running shots. The work intensity for all sessions is above 95% of VO2max, with 30W of recovery. In addition, participants refer to number 19 on the Borg Scale. Sessions range from 12 to 36 minutes without heating and recovery. In total there are 12 weeks of training."
2400526|NCT03568773|Experimental|Aerobic exercise moderate intensity|The training protocol was started, with the sessions held in the open air. From the first to the fourth week, the volunteers gave sessions of 40 to 60 minutes, intensity in L1, three sessions / week. In the fifth week, the intensity was increased to the midpoint between L1 and half of L2, maintaining 60 minutes per session and frequency three times per week. From the sixth week, the weekly frequency increased to five days, with three supervised sessions and two unsupervised sessions, but with a smartphone application that recorded distance traveled and intensity. From the ninth week on, the weekly frequency was maintained and the intensity increased for L2. In supervised sessions, training intensity is also monitored by heart rate using a Polar heart rate monitor.
2400527|NCT03568773|Experimental|Control Group|The control group attends stretching classes once a week and sessions lasting 60 minutes. At the end of the fifteen weeks (three weeks of adaptation and twelve weeks of training) of the study, these volunteers will be invited to engage in the aerobic training program regardless of their participation in the research.
2400530|NCT03568747|Experimental|NIV plus oxygen therapy|noninvasive ventilation (dual-limb NIV) is given at peak exercise until the borg scale reaches it's baseline point
2400531|NCT03568747|Experimental|oxygen therapy|oxygen therapy is given at peak exercise until the borg scale reaches it's baseline point
2400532|NCT03568734|Experimental|Transplant arm|Fecal transplant sample given to child at delivery
2400533|NCT03568721|Experimental|ibuprofen|ibuprofen (400 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
2400534|NCT03568721|Experimental|acetaminophen|acetaminophen (500 mg) immediately after insertion of the initial archwire and 6/6 hs for a week if there is any orthodontic pain.
2400535|NCT03568721|Experimental|chewing gum|chewing gum (01 tablet) immediately after insertion of the initial archwire and 6/6 hs of chewing gum for a week if there is any orthodontic pain.
2400536|NCT03568721|No Intervention|control|control (no reliever for orthodontic pain)
2400537|NCT03568708|No Intervention|Control Participants|The control group will reflect a comparison group similar to the POI patient group. As bone density, body composition, and cognitive domains continue to mature throughout the teenage years, this comparison group will provide an important metric of normal growth and development.
2400538|NCT03568708|Experimental|POI Participants|This group will be participants who have been recently diagnosed with POI. In an open-label fashion, participants with POI will receive Transdermal Estrogen(beginning at a dose of 25 μg/patch applied weekly), with the dose increased at 3, 6 12, and 18 months (to 37.5, 50, 75, and 100 µg/patch).
2400539|NCT03568695|Other|Detected patients|If they agree to participate in the study, the patients detected for one or the other of the STIs (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium) on one site, will have on day of result return, two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
2400540|NCT03568682|Experimental|Nutritional counseling + urban gardening|Participants in the intervention clinic will receive: 1) nutritional counseling from peer counselors in their clinic (approximately 4-5 sessions administered monthly); 2) training from the Ministry of Agriculture on how to plant and maintain a garden in their home (training workshop and monthly follow-up); and 3) a cooking and nutrition workshop facilitated by project nutritionists once garden produce are available.
2400541|NCT03568682|No Intervention|Usual care control|Participants in the control clinic will receive their usual care from the clinic. After 12 month follow-up, they will be offered the opportunity to receive the intervention.
3143815|NCT00017238|Experimental|Treatment (KRN5500)|"Patients receive KRN5500 IV over 24-72 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-3 patients receive KRN5500 at the starting dose over escalating infusion durations. After the longest duration of infusion time is safely reached, cohorts of 3-6 patients receive escalating doses of KRN5500 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued to receive treatment with KRN5500 at the recommended phase II dose."
2400547|NCT03568643|Experimental|Azithromycin|children in this arm will receive one dose of azithromycin
2400548|NCT03568643|Active Comparator|Amoxicillin|Children in this arm will receive a 7 day course of amoxicillin (standard of care)
2400549|NCT03568630||New Onset Diabetes/High-Risk Prediabetes|"Must meet one of the following criteria:~New onset type 2 diabetes diagnosed within the past 3 years, defined as Hemoglobin A1c ≥ 6.5%*, fasting blood glucose >126mg/dL confirmed on a subsequent day or as diagnosed by a physician~High-risk pre-diabetes: Hemoglobin A1c >6.3% or A1c >6.0% with fasting blood glucose >110 or 2 hour oral glucose tolerance test between 140-200mg/dL; subjects who have been on metformin <3 years are eligible"
2400550|NCT03568630||Pancreatic Cystic Neoplasm/Pancreatitis|"Must meet one of the following criteria:~Pancreatic cystic neoplasm for which resection, endoscopic ultrasound or serial imaging has been recommended~Chronic pancreatitis as defined by cross-sectional imaging, endoscopic ultrasound, functional testing abnormalities OR as diagnosed by a gastroenterologist"
2400551|NCT03568630||Inherited Risk|"Must meet one of the following criteria:~Two or more blood relatives with PDAC (includes 1st-3rd degree relatives as defined in Table 2)~One 1st degree relative with PDAC diagnosed before age 60~Germline mutation associated with a higher than average risk of PDAC including but not limited to the following: Hereditary breast and ovarian cancer syndromes BRCA1, BRCA2, PALB2 Hereditary nonpolyposis colon cancer (Lynch) syndrome MLH1, MSH2, MSH6, PMS2 Familial adenomatous polyposis (APC) Familial atypical multiple melanoma and mole syndrome CKDN2a, p16 Peutz-Jeghers syndrome STK11 Ataxia-telangiectasia ATM Juvenile polyposis syndromes SMAD4, BMPR1A Li Fraumeni TP53 Cystic fibrosis and unaffected carriers CFTR~Personal or family history which meets clinical criteria for a hereditary cancer syndrome and includes a relative with PDAC"
2400552|NCT03568617|Experimental|rTMS group|
2400553|NCT03568604|Experimental|Prasterone|6.5 mg vaginal inserts of prasterone will be used daily once the patient meets inclusion and exclusion for 20 weeks.
2400554|NCT03568591|Experimental|Intervention Group (Treatment)|A treatment group cohort who have self-referred for the psychosensory therapy intervention (Havening Techniques).
2400555|NCT03568591|No Intervention|Control Group (Waiting List)|Self-referral waiting list cohort (usual care).
2400556|NCT03568578|Active Comparator|Entecavir Group|Patients in this arm will be given Entecavir 0.5 mg a day for 2 years.
2400557|NCT03568578|Experimental|Entecavir and Anluohuaxian Group|Patients in this arm will be given Entecavir 0.5 mg and Anluohuaxian Pill 12 g a day for 2 years.
2400558|NCT03568565|Experimental|ePREP Program|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
2400843|NCT03566667|Active Comparator|Metoprolol|Metoprolol at an aimed dose of 100 mg in addition to usual standard care
2400559|NCT03568565|Experimental|ePREP Program plus Coach|The ePREP program is based on the in-person Prevention and Relationship Enhancement Program. The ePREP program consists of six sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour. Couples also have four, brief video or phone calls with a coach throughout the program.
2400560|NCT03568565|Experimental|OurRelationship Program|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner.Participants who do not complete activities in a timely manner will be re-randomized to either continue without a coach or to receive a coach.
2400561|NCT03568565|Experimental|OurRelationship Program plus Coach|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s). Couples also have four, brief video or phone calls with a coach throughout the program.
2400562|NCT03568565|No Intervention|Waitlist|Participants are assessed at 1, 2, 4, and 6 months after randomization; however, no active intervention is given during the waitlist period.
3143816|NCT00017251|Experimental|Treatment (oblimersen sodium, carboplatin, etoposide)|Patients receive G3139 IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 1 hour on days 6-8. Treatment repeats every 3 weeks for up to 6 courses in the absence of unacceptable toxicity or disease progression.
3143817|NCT00017316|Experimental|Arm I|Patients receive SU5416 IV over 1 hour twice weekly and oral thalidomide daily beginning 1 day after the first dose of SU5416. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
2400566|NCT03568526|Experimental|Supportive Care (sensorimotor rehabilitation program)|Patients attend 1 therapy session to receive education and training in the use of the home program. Patients then complete exercises over 90 minutes per week for 6 weeks.
2400567|NCT03568513|Experimental|Treatment|Patients in the treatment arm with weight between 35 kg to 50 kg will receive 50 mg capsule of curcumin twice a day (maximum dose 2.8 mg/kg/day, which is within the GRAS approved dose) and those over 50 kg in weight will receive three curcumin capsules a day (maximum dose 3 mg/kg/day, within GRAS recommended dose). Study duration will be 8 weeks.
2400568|NCT03568513|Placebo Comparator|Placebo|Patients in the placebo arm will receive a capsule which has similar size, shape and color of the curcumin capsule. The placebo capsule will contain inert food powder. Study duration will be 8 weeks.
2400573|NCT03568487|Experimental|Intensive scapula-focused approach|
2400574|NCT03568487|Active Comparator|Control therapy|
2400575|NCT03568474|Experimental|Silver Diamine Fluoride|Silver Diamine fluoride will be applied after after minimal caries removal then glass ionomer over it followed by composite resin restoration.
2400576|NCT03568474|Active Comparator|Glass Ionomer|Glass ionomer will be applied after minimal caries removal followed by composite resin restoration.
2400578|NCT03568435||Participants with metastatic RCC taking nivolumab|Specified dose on specified day
3143818|NCT00017368|Experimental|All Patients|
2400580|NCT03568409|Experimental|Group A: ABO-GLYC|Libramed
2400581|NCT03568409|Placebo Comparator|Group B: Placebo|
2400582|NCT03568396||Pupillometry|The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.
3143819|NCT00017381|Experimental|Treatment|"PART I: Patients receive rituximab IV on days 1, 8, 15, and 22 and cyclophosphamide IV over 1 hour on day 25. G-CSF is administered SC daily beginning on day 26 and continuing until autologous PBSC are harvested.~PART II: Beginning 4-6 weeks after completion of the fourth rituximab infusion, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1 followed by dosimetry imaging on days 1, 2, 4, and 7. Patients then receive IDEC-Y2B8 IV over 10 minutes once between days 8-15.~PART III: All patients undergo PBSCT beginning after residual bone marrow radioactivity resolves. G-CSF is administered SC beginning 1 day after PBSCT and continuing until blood counts recover."
3143820|NCT00017394|Experimental|Treatment (bevacizumab, vinorelbine tartrate)|Patients receive bevacizumab IV over 30-90 minutes once every other week and vinorelbine IV over 6-10 minutes once weekly for 8 weeks. Treatment repeats every 8 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease after completion of the fourth course may receive additional courses of concurrent bevacizumab and vinorelbine administered once every other week or may continue therapy on the schedule as above.
2400585|NCT03568370|Experimental|olive oil|use one drop olive oil on each nipple after each feeding
2400586|NCT03568370|No Intervention|breast milk|use breast milk on each nipple after each feeding
2400587|NCT03568357||Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 40%-80% adjusted reoxygenation to maintain PO2 in the range of 250mm Hg-300 mm Hg or more during the bypass.
2400588|NCT03568344||Community based tx seeking: baseline|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities during baseline period (no QA RAS administration).
2400589|NCT03568344||tx seeking @ referral facility: baseline|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility during baseline period (no QA RAS administration).
2400844|NCT03566667|Other|Standard care|Usual standard care
2400590|NCT03568344||Community based tx seeking: Post RAS|Children <5 years of age seeking care for a current/recent febrile illness episode at the level of community based care providers in the study areas, including CHWs and primary health facilities after QA RAS roll-out (after pre-referral QA RAS administration).
2400591|NCT03568344||tx seeking @ referral facility: Post RAS|Children <5 years of age seeking care for a severe febrile illness episode directly at the referral facility after QA RAS roll-out ( no QA RAS administration).
2400592|NCT03568331|Experimental|Tradipitant|
2400593|NCT03568331|Placebo Comparator|Placebo|
2400594|NCT03568318|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical corticosteroids (TCS).
2400595|NCT03568318|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical corticosteroids (TCS).
2400596|NCT03568318|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
2400597|NCT03568318|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
3143821|NCT00017472|Experimental|Arm I|Patients receive apolizumab IV over at least 2 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with a complete or partial response who relapse after 2 months may receive an additional course of therapy provided they still express the 1D10 antigen.
3143822|NCT00017537|Experimental|Dose #1|dose #1 administered
2400600|NCT03568279|Active Comparator|Control|The attending anesthesiologist provided intubation without two-handed jaw thrust.
2400601|NCT03568279|Experimental|Two-hand|The attending anesthesiologist provided intubation with two-handed jaw thrust.
3143823|NCT00017537|Experimental|Dose #2|dose #2 administered
2400603|NCT03568253|Active Comparator|Bulk fil composite|
2400604|NCT03568253|Active Comparator|High viscosity glass ionomer|
2400605|NCT03568240||30 men suffering from apnea|
2400606|NCT03568240||15 men defined as snorers|
2400607|NCT03568240||15 men without complaints|
2400608|NCT03568227|Experimental|Healthy Subjects|"The study has a 2 (Intervention: Hypnosis, Control) x 2 (State: 1 & 2) factorial within-subjects design, resulting in a total of 4 conditions. All volunteers participate at the 4 conditions in the same session.The order of the interventions is counterbalanced resulting in two possible sequences:~Sequence 1: Hypnosis State 1, Hypnosis State 2, Control State 1, Control State 2~Sequence 2: Control State 1, Control State2, Hypnosis State 1, Hypnosis State 2~Volunteers will be randomly allocated to the two sequence types."
2400609|NCT03568214|Experimental|Individualized moderate + high-intensity|"12 weeks of moderate-intensity continuous training (MICT) combined with high-intensity interval training (HIIT)~4 days per week of MICT for 50 minutes per session~1 day per week of HIIT for 35 minutes per session~Exercise intensity for MICT will be established according to ventilatory thresholds one and two (VT1 and VT2)~The HIIT protocol will consist of eight, 60 second intervals at 100% maximal oxygen uptake (VO2max), separated by 150 seconds active recovery"
2400610|NCT03568214|Experimental|Standardized moderate-intensity|"12 weeks of MICT~5 days per week of MICT for 50 minutes per session~Exercise intensity for MICT will be established according to 40-65% heart rate reserve (HRR)"
2400611|NCT03568214|No Intervention|Control|non-exercise control group testing at baseline and post-program (12 weeks)
2400612|NCT03568201|Experimental|patients|Patients suspected of iliac kinking will have a transcutaneous oximetry test during hip flexion
2400613|NCT03568201|Sham Comparator|controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during hip flexion
2400614|NCT03568188|Experimental|HIFU treatment|170 patients with prostate cancer of intermediate risk receive the immediate treatment with focal HIFU. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed. Patients will also have PSA (Prostate-Specific Antigen) dosage, MRI (Magnetic Resonance Imaging) exam, questionnaires and prostatic biopsies during their follow up. If the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) and a urine test (for PCA3 (The prostate cancer antigen 3 gene) test) will be performed during their follow up.
2400615|NCT03568175|Experimental|JR-141 2.0 mg/kg/week|
2400616|NCT03568162|Experimental|ISB 830 - Part 1 Group 1|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
2400617|NCT03568162|Experimental|ISB 830 - Part 1 Group 2|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
2400618|NCT03568162|Experimental|ISB 830 - Part 1 Group 3|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830 or placebo.
2400619|NCT03568162|Placebo Comparator|Placebo - Part 1 Group 4|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
2400620|NCT03568162|Experimental|ISB 830 - Part 2 Group 5|Subcutaneous (SC) administration of ISB 830 as a loading dose, followed by SC maintenance dose of ISB 830.
2400621|NCT03568162|Placebo Comparator|Placebo - Part 2 Group 6|Subcutaneous (SC) administration of placebo, followed by SC maintenance dose of placebo.
2400622|NCT03568149||Group A: endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
2400623|NCT03568149||Group B: no endometriosis|assessment of pain symptoms at first medical examination; assessment of pelvic vascular insufficiency signs.
2400799|NCT03566966||Non-organ-specific Ab negative|Patients who did not have detectable circulating autoantibodies before treatment with antivirals.
3143824|NCT00017537|Experimental|Dose #3|Dose #3 administered
3143825|NCT00017537|Experimental|Dose #4|Dose #4 administered
3143826|NCT00017537|Experimental|Dose #5|Administered dose #5
3143827|NCT00017693|Experimental|0.75mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
2400624|NCT03568136|Experimental|Treatment Arm A|Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints were followed up visits at week 20 and 24. Placebo will be administered as 2 subcutaneous injections.
2400625|NCT03568136|Placebo Comparator|Treatment Arm B|Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints were followed up visits at week 20 and 24.
2400626|NCT03568123|Experimental|MC polyethylene bearing|Persona Total Knee System with MC polyethylene bearing
2400627|NCT03568123|Active Comparator|CR polyethylene bearing|Persona Total Knee System with a CR polyethylene liner.
2400628|NCT03568097|Experimental|Avelumab + Standard 1st line Chemotherapy|Administration of cisplatin or carboplatin + etoposide every 3 weeks with phased avelumab administered every 2 weeks until disease progression.
3143828|NCT00017693|Experimental|1.5mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
3189075|NCT00774007|Placebo Comparator|Placebo|Placebo
2400631|NCT03568071|Experimental|Cohort A - dose regimen A|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen A) will be administered on Day 1.
2400632|NCT03568071|Experimental|Cohort B - dose regimen B|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen B) will be administered on Day 1.
2400633|NCT03568071|Experimental|Cohort C - dose regimen C|MOR106 will be administered as IV infusion. Subjects will receive repeated doses of MOR106 over a 12-week treatment period. A loading dose (dose regimen C) will be administered on Day 1.
2400634|NCT03568071|Experimental|Cohort D - dose regimen D|MOR106 will be administered as IV infusion. Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen D) will be administered on Day 1.
2400635|NCT03568071|Experimental|Cohort E - dose regimen E|MOR106 will be administered as IV infusion.Subjects will receive alternating repeated doses of MOR106 or placebo over a 12-week treatment period. A loading dose (dose regimen E) will be administered on Day 1.
2400636|NCT03568071|Placebo Comparator|Placebo|Subjects will receive repeated doses of placebo over a 12-week treatment period.
2400637|NCT03568058|Experimental|vaccine and anti-PD-1|personalized vaccine and anti-PD-1 administered concurrently at the start of study therapy
2400638|NCT03568058|Experimental|anti-PD1 before vaccine|anti-PD-1 antibody for 6 weeks followed by personalized vaccine therapy
2400639|NCT03568058|Experimental|anti-PD1 and vaccine|anti-PD-1 antibody followed by personalized vaccine therapy
2400640|NCT03568058|Experimental|vaccine|personalized vaccine therapy
2400641|NCT03568045|Active Comparator|Usual care, standard light|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), but otherwise have usual care."
2400642|NCT03568045|Experimental|10,000 lux bright light, 4 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to noon starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
2400643|NCT03568045|Experimental|10,000 lux bright light, 8 hours|"Patients will be enrolled within 30 hours of noon on enrollment day (e.g. at or after 6am on the prior calendar day). Enrollment will occur before noon, and the day of enrollment is termed study day 1.~Patients will undergo monitoring (light levels, circadian alignment), starting on study day 1. Patients will be exposed to bright light from 8am to 4pm starting on study day 2 and continuing through study day 5. Bright light exposure will occur in the Intensive Care Unit (ICU) and on the floor if the patient is transferred.~Feasibility metrics will be collected."
2400644|NCT03568032||the post-radiation group|patients diagnosed as non-metastatic nasopharyngeal carcinoma who received definitive IMRT more than 3 years ago
2400645|NCT03568032||the pre-radiation group|untreated patients diagnosed as non-metastatic nasopharyngeal carcinoma
2400646|NCT03568006|Experimental|Intervention|"Intervention will consist of passive joint mobilization (caudal and dorsal gliding) grade II in the glenohumeral joint.~Besides, participants will receive a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene."
2400647|NCT03568006|Active Comparator|Control|Control treatment will consist of a standardized treatment consisting of infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene.
2400648|NCT03567993|Active Comparator|Comparison|The comparison condition is designed as a minimal intervention, and allows for blinding of the patients to randomization group.
2400649|NCT03567993|Experimental|Intervention|The intervention is designed to encourage and remind smokers of the availability of the Quitline services. In addition to the one-way motivational messages, the investigators will use two-way assessments. Two-way automated texting is the ability to push out a question, have the user respond with a brief, numeric or one-word answer, and based on that answer, provide immediate feedback. The goal of these brief assessments is two-fold: 1) to assess behavior (abstinence) and motivation to use services, and 2) to return feedback tailored to each individual smoker based on the answers of the user.
3189076|NCT00774007|Active Comparator|Mesalazine|mesalazine 800 mg t.i.d.
2400651|NCT03567967|Experimental|San Francisco|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The San Francisco participants will receive and spend these vouchers in an environment which has implemented a sugar-sweetened beverage tax.
3189077|NCT00774020|Experimental|1|
2400652|NCT03567967|Active Comparator|Los Angeles|Each study participant will receive four paper vouchers per month for a total of six months. Each of these vouchers can be redeemed for fresh or frozen fruits and vegetables at a number of specified local corner stores, supermarkets, or farmer's markets. The Los Angeles participants will receive and spend these vouchers in an environment which has NOT implemented a sugar-sweetened beverage tax.
2400653|NCT03567941|Placebo Comparator|Placebo|Single dose
2400654|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 1|Single dose
2400655|NCT03567941|Experimental|Hydrocodon bitartrate-acetaminophen arm 2|Single dose
2400656|NCT03567941|Active Comparator|Reference|Single dose
2400657|NCT03567928|Active Comparator|Standard Treatment|Standard Treatment Sedation with propofol target controlled infusion (TCI) and no airway devices (mandatory spontaneous breathe)
2400658|NCT03567928|Experimental|Interventional Treatment|Interventional Treatment Sedation with propofol target controlled infusion (TCI) and Gastro Cuff Pilot Laryngeal Mask (possibility to use a pressure-support ventilation)
2400659|NCT03567915||Rice|Group that healthy volunteers eat rice.
2400660|NCT03567915||Noodle|Group that healthy volunteers eat noodle.
2400661|NCT03567902|Experimental|Group A|C-MAC videolaryngoscope intubation -> Direct laryngoscope intubation
2400662|NCT03567902|Experimental|Group B|Direct laryngoscope intubation -> C-MAC videolaryngoscope intubation
2400663|NCT03567889|Experimental|Daromun plus Surgery and Adjuvant therapy (Arm 1)|Two-weeks screening period and a 4-weeks open-label treatment period, followed by surgery within a maximum of another 4 weeks and adjuvant therapy (Arm 1).
2400664|NCT03567889|Active Comparator|Surgery and adjuvant therapy (Arm 2)|Patients in the control arm (Arm 2) will receive direct surgery within 4 weeks from randomization, followed by adjuvant therapy.
2400665|NCT03567876|Experimental|V-RBAC (RBAC followed by Venetoclax)|"Induction phase: RBAC --> up to 6 cycles for low risk (LR) patients and up to 4 cycles for high risk (HR) patients.~Patients proceeding to Venetoclax treatment will receive consolidation with single agent Venetoclax 800 mg/die x 4 28d cycles (with initial ramp-up dose) of each consolidation cycle. Consolidation will be followed by maintenance with single agent Venetoclax 400 mg/die (V maint ) for a total of 2 years (4 months consolidation+20 months maintenance)."
2400666|NCT03567863|Active Comparator|Group A|"The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)~20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®"
2400667|NCT03567863|Active Comparator|Group B|"The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)~22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®"
2400668|NCT03567850|Experimental|Intervention|Participants assigned to the intervention arm will receive Problem Solving Skills Training (PSST) consisting of eight one-hour individual weekly sessions.
2400669|NCT03567850|Active Comparator|Control Arm|Care As Usual Group (CAU): Participants randomized to the CAU group will be observed under naturalistic conditions. Both PSST and CAU participants and their clinicians (PCP and oncology providers) will be allowed to use any clinically appropriate medical and behavioral care without restriction (e.g., care management, rehabilitation, behavioral therapy, palliative care) or refer patients to social and community services (e.g., peer support, county cancer services program or aging services). The CAU participants will undergo the same evaluation protocol as the PSST group
2400670|NCT03567837|Active Comparator|Obese Metabolically Healthy|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
2400671|NCT03567837|Experimental|Obese Pre-diabetes|Intervention: Oral challenge of Fructose+Glucose Beverage 1:1, 3g/kg
2400672|NCT03567824|Experimental|Open label phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months, all subjects.
2400673|NCT03567824|Other|Random off phase|MLD10 (magnesium l-lactate dihydrate) 10mEq extended release caplets BID for three months or Placebo
2400674|NCT03567811|Other|Chronic Fatigue Syndrome|"Inclusion and exclusion criteria based on 1994 Center for Disease Control (Fukuda) criteria of persistent, disabling, moderate to severe fatigue that was relieved by rest, plus at least 4 of the 8 following ancillary features: cognitive dysfunction affecting short term memory or concentration, sore throat, sore lymph nodes, sore muscles, sore joints, headache, sleep disturbance, and exertional exhaustion (post-exertional malaise). Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2"
2400675|NCT03567811|Other|Sedentary Control|Subjects who lived a sedentary lifestyle, did not meet Chronic Fatigue Syndrome criteria, and did not have any exclusionary chronic medical, psychiatric or other conditions were our Sedentary Control subjects. By design, this control group included controlled Type II diabetes and thyroid disease, chronic idiopathic fatigue, hypertension (other heart disease excluded) and other stable medical conditions. This variety of subjects were included to prevent ceiling (CFS) vs. floor (control) effects if the control group had totally pristine subjects with zero health issues. Intervention: Procedure/Surgery: Submaximal bicycle exercise stress test on Days 1 and 2
2400676|NCT03567798|Experimental|A|"UPLAT® (Carica papaya leaf Extract + Tinospora cardifolia Extract~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
2400677|NCT03567798|Placebo Comparator|B|"Placebo~Take 4 units daily (2 in morning and 2 in evening) for 10 days"
2400678|NCT03567772|Experimental|Wiifit Nintendo video game|Pulmonary rehabilitation program using video games exercise from Nintendo
2400679|NCT03567772|Active Comparator|Pulmonary rehabilitation program|Pulmonary rehabilitation program with ergometer cycle
2400680|NCT03567746|Experimental|Underwater EMR|The patients randomized in this arm will be treated by endoscopic resection assisted by the filling of the colonic lumen using water instead of air and avoiding the formation of a submucosal cushion
2400681|NCT03567746|Active Comparator|Conventional EMR|The patients randomized in this arm will be treated by endoscopic resection following the traditional technique. It means, by assistance of selective submucosal saline injection to create a submucosal cushion below the polyp.
2400682|NCT03567733||Coronary Artery Disease|Drug- eluting Stent
2400683|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab (Cohort enrollment completed)
2400831|NCT03566771|Active Comparator|CLOSS|Usual care plus using a web-based support system for self-monitoring weight, physical activity and communication with the clinic during 12 months
2400684|NCT03567720|Experimental|tavo-EP plus IV pembrolizumab with chemotherapy|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab and nab-paclitaxel chemotherapy
2400685|NCT03567707|Experimental|C-section -Vaginal seeding|"Pregnant women who undergo C-section and (neonate) vaginal seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with gauze containing their mother's vaginal microbiota just after delivery."
2400686|NCT03567707|Experimental|C-section - Placebo Seeding|"Pregnant women who undergo C-section and (neonate) placebo seeding.~Infants that are scheduled to be born in a hospital by standard C-section procedure (e.g., elective, unlabored C-section) will be wiped with sterile gauze (placebo)."
2400687|NCT03567707|Active Comparator|standard care|"Pregnant women who undergo spontaneous vaginal delivery (of neonate) .~Pregnant women who undergo spontaneous vaginal delivery and (neonate) receives standard care."
2400688|NCT03567694|Experimental|Single Ascending Dose and Food effect|This is the SAD / Food effect arm. For SAD, a total of 80 subjects will be enrolled into 8 groups of 10 subjects each; within each group, 8 will receive HA115 at a single ascending dose 10, 25, 50, 100, 200, 400, 800, 1200 mg, and 2 subjects will be placebo control. For food effect study,10 participants will be administered HA115 at a single dose to be selected based on SAD results.
2400689|NCT03567694|Experimental|Multiple Ascending Dose|For the MAD portion, 3 dose levels will be selected based on SAD results.
2400690|NCT03567681|Experimental|Extended release oxcarbazepine|Six week of open treatment with extended release oxcarbazepine (Oxtellar XR)
2400691|NCT03567681|Experimental|Immediate release oxcarbazepine|Six week of open treatment with Immediate release oxcarbazepine ( Trileptal)
2400692|NCT03567655|Experimental|Single group|Farlutal tab. 500mg/ Pfizer to be administered
3143829|NCT00017693|Experimental|3.0mg rsIL-4R|Recombinant human soluble IL-4 receptor (rsIL-4R) given by means of inhalation once weekly for 12 weeks. The study drug was administered in the clinic at a final volume of 2.5 mL in sterile normal saline solution with a breath-assisted Pari LC Star nebulizer powered by a Proneb Turbo portable compressor.
2400694|NCT03567629|Experimental|Irinotecan-based chemotherapy|
2400695|NCT03567629|Active Comparator|Oxaliplatin-based chemotherapy|
2400699|NCT03567603||opioid exposed neonates|prenatal opioid exposure
2400700|NCT03567603||non-opioid exposed neonates|no prenatal opioid exposure
3143830|NCT00017693|Placebo Comparator|Placebo for rsIL-4R|The placebo for recombinant human soluble IL-4 receptor (rsIL-4R) consisted of identically prepared excipient in the same volume (2.5 mL). To maintain blinding, medication was dispensed by an individual who was not responsible for patient care or assessment. Treatment assignment was blinded to all personnel involved in direct conduct or monitoring of the study.
3143831|NCT00017810|Experimental|Condition 1: Dietary Intervention|Patients will receive behavioral dietary intervention using normal foods.
2400703|NCT03567577|Experimental|Solnatide 5mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 5mg administered
2400704|NCT03567577|Experimental|Solnatide 60mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 60mg administered
2400705|NCT03567577|Experimental|Solnatide 125mg|Solnatide 25 mg powder for reconstitution for solution for inhalation. 125mg administered
2400706|NCT03567577|Placebo Comparator|Placebo|0,9% saline solution
2400707|NCT03567564||Mechanically ventilated patients|Abdominal muscles ultrasound
2400708|NCT03567551||Women w/ Preeclampsia w/o Visual Disturbances or Headache|Preeclampsia Without either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
2400709|NCT03567551||Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Preeclampsia With either Visual Disturbances or Headaches Blood Pressure: >Systolic 160 or Diastolic 110
2400710|NCT03567551||Women w/o Preeclampsia|Normal Pregnancy Blood Pressure: <140/90
2400711|NCT03567525|Active Comparator|Standard surgical approach|standard lymphadenectomy using clips and bipolar cautery to seal lymphatic vessels
2400712|NCT03567525|Experimental|Experimental approach|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels
2400713|NCT03567512|Experimental|Intervention group|The Intervention administered to this group will focus on Quit Smoking of parental and household smokers and Reduction of Secondhand Smoke Exposure among the Children.
2400714|NCT03567512|Placebo Comparator|Control group|The placebo intervention will be administered in this group.
2400715|NCT03567499|Experimental|Part A: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 200 milligrams (mg) in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400716|NCT03567499|Experimental|Part A:Sequence 2|Subjects in sequence 2 will receive GSK3039294 600 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400832|NCT03566745||Study group|Patients with mutation in AhR gene - presumed low Blood for protein activity
2400833|NCT03566745||Control|Patients without mutation in AhR gene - presumed normal Blood for protein activity
3143832|NCT00017810|Active Comparator|Condition 2 (Control): HIV Self-Care|Patients will receive HIV self-care information, and be given the dietary intervention at the completion of the last study session (post study).
3143833|NCT00017953|Experimental|Lifestyle Intervention|Participants in the lifestyle intervention arm are offered individual and group sessions designed to help achieve and maintain weight loss.
3143834|NCT00017953|Active Comparator|Diabetes Support and Education|The diabetes support and education arm provides group sessions on diabetes management and social support.
2400717|NCT03567499|Experimental|Part A: Sequence 3|Subjects in sequence 3 will receive GSK3039294 200 mg in period 1 followed by GSK3039294 600 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session
2400718|NCT03567499|Experimental|Part A: Sequence 4|Subjects in sequence 4 will receive GSK3039294 600 mg in period 1 followed by GSK3039294 200 mg in Period 2 followed by matching placebo in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400719|NCT03567499|Experimental|Part A: Sequence 5|Subjects in sequence 5 will receive GSK3039294 200 mg in period 1 followed by matching placebo in Period 2 followed by GSK3039294 600 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400720|NCT03567499|Experimental|Part A: Sequence 6|Subjects in sequence 6 will receive matching placebo in period 1 followed by GSK3039294 600 mg in Period 2 followed by GSK3039294 200 mg in Period 3 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400721|NCT03567499|Experimental|Part B: Sequence 1|Subjects in sequence 1 will receive matching placebo in period 1 followed by GSK3039294 (dose level to be decided on results of Part 1) in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing.
2400722|NCT03567499|Experimental|Part B: Sequence 2|Subjects in sequence 2 will receive GSK3039294 (dose level to be decided on results of Part 1) in period 1 followed by matching placebo in Period 2 once daily orally. There will be a minimum of 7-day washout period between each treatment session. Each treatment session will consist of 7 days of dosing
2400723|NCT03567486||Tuberculum sellae meningiomas|Adult patient suffering from tuberculum sellae meningiomas with surgical treatment
2400724|NCT03567473|Experimental|Active Intervention Arm|Oral dexamethasone and nebulized epinephrine OR Oral dexamethasone and inhaled epinephrine given by MDI
2400725|NCT03567473|Placebo Comparator|Control Arm|"Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and nebulized saline.~OR Oral placebo (OraBlendTM in Canada and a compounded oral placebo solution at New Zealand/Australia sites) and inhaled placebo given by MDI."
2400726|NCT03567460|Experimental|10,000 Steps/day for Pediatric Marfan Patients|Participants will be given a Garmin VivoFit and asked to take at least 10,000 steps per day. A study coordinator will reach out at least once per week to check in on progress made and help make weekly goals.
2400727|NCT03567447|Experimental|Treatment group|This group will receive droxidopa 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
2400728|NCT03567447|Placebo Comparator|Non treatment group|This group will receive placebo appearing to be 100mg to 600mg three times a day (TID) titration for 2 weeks and then maintenance dosage for 4 additional weeks. We will assess participants two times over the 4-week intervention. Each assessment will be the same as the baseline assessment, including the Orthostatic Hypotension Symptom Assessment (OHSA), postural, and gait assessments, and will be administered during the 2nd and 4th weeks following onset of stable treatment phase.
2400729|NCT03567408|Experimental|Selective PCI with bivalirudin|Before PCI, bivalirudin is intravenously injected with 0.75 mg/kg, 1.75 mg/(kg.h) through continuous intravenous drip to finish surgery (no more than 4 hours), if necessary, after the surgery, with a low dose of 0.2 mg/(kg.h) intravenous drip less than 20 hours.
2400730|NCT03567408|Placebo Comparator|Unfractionated heparin|Before PCI, unfractionated heparin sodium is intravenously injected with 70-100 U/kg, and if the operation time exceeded 1h, an additional 1000 U/h would be added.
2400731|NCT03567395|Active Comparator|Melatonin|Melatonin (5 mg sublingual tablet)
2400732|NCT03567395|Experimental|Honey|raw honey (1.5 tablespoons)
3184565|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
2400735|NCT03567369|Experimental|Dexamethasone|Dexamethasone 4,0 mg / mL
2400736|NCT03567369|Experimental|Traumeel S|Traumeel 2,2 mg / mL
2400737|NCT03567356|No Intervention|Treatment as Usual|TAU will contain patients who will be receiving treatment for opioid use disorder through their usual venues without the family engagement, assertive outreach, and home delivery of XRNTX doses.
2400738|NCT03567356|Experimental|MAT-Plus Intervention|"The intervention group will receive the multi-component MAT-PLUS treatment: 1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
2400739|NCT03567343|Active Comparator|Proprietary Spearmint Extract Blend|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the Proprietary Spearmint Extract Blend blend by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
2400740|NCT03567343|Placebo Comparator|Control|"Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the excipient, microcrystalline cellulose by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.~A subset of this group will undergo 2 overnight polysomnography studies"
2400835|NCT03566719|Experimental|Intervention group|
2400741|NCT03567343|Active Comparator|Proprietary Blend And Melatonin|Subjects randomized into the active treatment group will be asked to consume 500 mg/day of the proprietary spearmint extract blend and 1 Mg of melatonin by mouth every night 30 mins before bed, complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
2400742|NCT03567343|Active Comparator|Melatonin|Subjects randomized into the active treatment group will be asked to consume 1 Mg of melatonin by mouth every night 30 mins before bed and complete a sleep diary upon waking and wear a Fitbit Charge 2 device for sleep monitoring for 30 days.
2400743|NCT03567330|Experimental|Experimental|Family-based attachment-focused intervention for families where parent/caregiver is within 12 months of first diagnosis of a stage I-III solid tumor cancer.
2400744|NCT03567330|Active Comparator|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions.
2400745|NCT03567317|No Intervention|CPAP|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP during the initial study visit, patients will resume CPAP use for one week before the second study visit.
2400746|NCT03567317|Experimental|CPAP withdrawal|According to study design, patients will be randomized to remain on CPAP during the initial study visit or withdraw CPAP one week before. If randomized to withdraw CPAP at the second study visit, patients will withdraw CPAP one week before.
2400747|NCT03567304|No Intervention|EFV-based|"HIV-infected patients, who has been taking efavirenz (EFV)-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to continue EFV-based regimen.~EFV based regimen defines as efavirenz 600 mg per oral once daily (OD) + 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)."
2400748|NCT03567304|Experimental|RPV-based|"HIV-infected patients, who has been taking efavirenz-based regimen for at least 1 year and is diagnosed with asymptomatic neurocognitive impairment (ANI) or mild neurocognitive disease (MND) by neurocognitive battery tests, is randomized to switch antiretroviral therapy to rilpivirine (RPV)-based regimen.~RPV based regimen defines as rilpivirine 25 mg PO OD + 2 NRTIs."
3143839|NCT00018096|Experimental|bronchoscopy|2 bronchoscopies 4 hours apart; The first to instill the 3 experimental biologic agents in separate airways (HDM, LPS and saline-placebo), the second to perform BAL and brush biopsies 4 hours later in the same airways.
3143840|NCT00018148|Experimental|1|Transdermal nicotine plus nortriptyline
2400752|NCT03567278|Experimental|ACURATE TA™|Patients implanted with ACURATE TA™ Bioprosthesis
2400755|NCT03567239|Experimental|Using adaptive device|Participants will use a non-commercially available device, designed to meet their needs.
2400756|NCT03567226|Experimental|Intervention Group|The intervention group will be enrolled into a WeChat Group to receive reminders to exercise and health education materials.
2400757|NCT03567226|Active Comparator|Control Group|Controls will receive a handout telling them to increase walking and that walking may be helpful for the eye at the return visit.
3143841|NCT00018148|Active Comparator|2|Transdermal nicotine plus placebo
2400759|NCT03567200|Experimental|Single-Arm Feasibility|9-week, 1x/week, 90-minute face-to-face sessions.
2400760|NCT03567187|Experimental|Iovera|"The iovera° device consists of a reusable, portable hand-piece, along with a single-patient use sterile smart Tip (cryoprobe) and disposable nitrous oxide (N2O) cartridges (cryogen). The smart tip is composed of closed-tip stainless steel needles, thereby fully enclosing the cryogen. There are 2 types of smart tips that will be utilized during this study, depending on the depth of the nerves being treated. The shorter smart tip comes in 2 variants - three X 6.9 mm or 8.9 mm, 27-gauge needles, with an attached skin warmer to prevent damage to the underlying skin. The longer smart tip also comes in 2 variants - 55 mm 22-gauge needle or a 90 mm 20G needle.~The effect is by initiation of a cooling cycle, by fully inserting the smart tip into the procedure site and activating the cryogen flow. As the gas travels through the length of the needle, an ice ball develops around the needle freezing the surrounding tissue."
3143842|NCT00018174|Experimental|1|
3143843|NCT00018174|Placebo Comparator|2|
2400763|NCT03567161|Experimental|Cavitron ultrasonic surgical aspirator|"Patients.with periodontitis.~Inclusion criteria:~Having received a diagnosis of chronic periodontitis (Armitage 1999)~Being treated by full mouth debridement, and supportive periodontal treatment (SPT) in the last year (at least three sessions)~Having at least one residual pocket ≥ 5 mm with and intra bony component at least ≥ 2 mm~Exclusion criteria:~Smoking more than ten cigarettes per day~Pregnancy~Irregular compliance during SPT in the last year; and systemic conditions or therapies known to affect the healing potential of periodontal tissues (e.g., uncontrolled diabetes, oncological conditions, immunosuppressant drugs)."
2400764|NCT03567148|Active Comparator|PRF group|Four layers of PRF membranes were placed in the palatal wound and sutured with 5/0 resorbable sutures
2400765|NCT03567148|Active Comparator|Essix retainer group|An impression of palatal region was taken and the Essix retainer was prepared before the patients underwent surgery.
2400766|NCT03567148|Active Comparator|Ozone therapy group|Ozone was applied to the donor sites at five different points (four corner-points and a center point) at a fixed concentration of 2100 p.p.m. through a connected hand-piece, using a sterile, specially-formed perio-tip with 80% oxygen for 30 seconds. The applications were performed immediately after surgery and on the 1st, 3rd, and 7th days following the operation.
2400836|NCT03566719|No Intervention|Control group|
2400837|NCT03566706|Experimental|Unhealthy Eating|
3143844|NCT00018200|Experimental|Arm 1|Desipramine, low, middle or high exposure
3143845|NCT00018200|Experimental|Arm 2|Fluoxetine, low, middle, or high exposure
3143846|NCT00018200|Placebo Comparator|Arm 3|Benztropine .125-.5mg daily
3143847|NCT00018356|Other|1|
3143848|NCT00018434||Group 1|
3143849|NCT00018616|Other|1|
3143850|NCT00018655|Experimental|Arm 1|Twelve Step Facilitation
3143851|NCT00018655|Experimental|Arm 2|Integrated Cognitive Behavioral Treatment
3143852|NCT00018694|Other|Arm 1|
2400767|NCT03567148|Active Comparator|LLLT group|Irradiation was performed at the same points described above using a diode laser (λ=970±15 nm, 14-W source power) (SIROLaser Xtend; Sirona Dental Systems GmbH, Bensheim, Germany) that continuously emitted a wavelength with 320µm fiberoptic; the power was 2W and the tissue dose was 35 J/cm2. Total irradiation time was 30 seconds. The applications were performed immediately after surgery, and on the 1st, 3rd and 7th, days following the operation.
2400768|NCT03567148|Active Comparator|Collagen fleece group|Collagen fleece (BEGO Collagen Fleece, Bremen, Germany) was sutured with 5/0 resorbable sutures (Pegesorb, Istanbul, Turkey) on the open wound with the aid of vertical mattress sutures.
2400769|NCT03567148|No Intervention|Control group|Palatal wounds were left for spontaneous healing
2400770|NCT03567135||Experimental 1|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide）
2400771|NCT03567135||control|concurrent chemoradiotherapy（Temozolomide） maintenance therapy（Temozolomide）
2400772|NCT03567135||Experimental 2|concurrent chemoradiotherapy（Temozolomide+apatinib） maintenance therapy（Temozolomide+apatinib）
2400773|NCT03567122|Experimental|Internal Focus of Attention|30 subjects will be randomized to this arm. Only internal focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test.
2400774|NCT03567122|Experimental|External Focus of Attention|30 subjects will be randomized to this arm. Only external focus of attention feedback instructions will be given during the execution and training performing the Cranio-Cervical Flexion Test. The subjects allocated to this arm will not be allowed to use the visual feedback traditionally provided during the Cranio-cervical Flexion Test. In addition, they will use just a laser point attached to the head to guide their cranio-cervical flexion.
2400775|NCT03567122|Active Comparator|Control|30 subjects will be randomized to this arm. The participants allocated to this arm will be instructed as traditionally during the Cranio-Cervical Flexion Test. They will be given visual feedback while have their attention guided to the inner neck movement.
2400776|NCT03567109||Shoulder rotator cuff tendinopathy|unilateral rotator cuff tendinopathy, 3 months or more duration, confirmed by imagery,
2400777|NCT03567109||chronic low back pain|non specific chronic (3 months) low back pain
2400778|NCT03567109||carpal tunnel syndrome|unilateral carpal tunnel syndrome, confirmed by electromyogram, 3 months or more duration
2400779|NCT03567109||control|healthy subjects
2400780|NCT03567096|Active Comparator|BiV+MPP|"Patients randomized to the BiV pacing with MPP and SyncAV study arm will have CRT programming to biventricular pacing with MPP activated. RV-LV pacing delay set to 5 ms, LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)."
2400781|NCT03567096|Experimental|LV-only + MPP|"Patients randomized to the  LV only pacing with MPP and SyncAV study arm will have CRT programming to left ventricular only pacing with MPP activated. LV1 & LV2 pacing cathodes selected as the maximal spaced electrodes (D1+P4, D2+M3, M2+P4) with pacing delay set to 5 ms and SyncAV offset programmed providing the optimum electrical resynchronization (shortest QRS duration)"
2400782|NCT03567083|Experimental|E-CAU with Problem Management Plus (PM+)|30 participants will be randomly assigned to E-CAU with PM+ group. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.
2400783|NCT03567083|No Intervention|Enhanced care as usual (E-CAU) only|30 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a referral document), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
2400784|NCT03567070|Other|qualitative study based on an individual clinical interview|
2400785|NCT03567057|Experimental|ADS-5102|
2400786|NCT03567044|Experimental|Blood Collection|Patients will be asked to have blood draws at specific time points during their whole breast irradiation.
2400787|NCT03567031|Experimental|Main Arm|In each patient, under ongoing standard general anesthesia in a stable state, EtCO2 is manually modified to reach predefined values, and after waiting until cerebral blood flow has reached steady state, NIRS and DTC values are noted.
2400788|NCT03567018|Experimental|Healthy volunteer population|We plan to enroll 25 healthy volunteers.
2400789|NCT03567018|Experimental|Patient population|We plan to enroll 50 clinical patients who are receiving flap procedures at the Ohio State Medical Center.
3184566|NCT00725985|Experimental|Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
3189078|NCT00774033|Experimental|1|Treatment of acute burn in adults and children by epidermal cell spray
2400792|NCT03566992|Active Comparator|Gastric Tube Placement|Nasoenteric tube placed in the stomach.
2400793|NCT03566992|Experimental|Small bowel|Nasoenteric tube placed in the small bowel.
3189079|NCT00774033|Active Comparator|2|Treatment of acute burn in adults and children by classic skin grafts
3189080|NCT00774072|Active Comparator|Tobramycin 80 mg|applied once daily via Pari Sinus nebulizer
2400798|NCT03566966||Non-organ-specific Ab positive|Patients who had detectable circulating autoantibodies before treatment with antivirals.
2400800|NCT03566940|Experimental|Group 1: Low Dose IPV Based on Sabin Strains (sIPV)|Participants will receive intramuscular (IM) injection of the low dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of conventional Salk IPV (cIPV) at approximately 24 weeks after the third vaccination (38 weeks of age).
2400801|NCT03566940|Experimental|Group 2: Intermediate Dose sIPV|Participants will receive IM injection of the intermediate dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2400802|NCT03566940|Experimental|Group 3: High Dose sIPV|Participants will receive IM injection of the high dose trivalent inactivated poliovirus vaccine (sIPV - 3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2400803|NCT03566940|Active Comparator|Group 4: Conventional Salk IPV (cIPV)|Participants will receive IM injection of cIPV (3 doses) at 6, 10 and 14 weeks of age. Participants will also be given a single booster vaccine of cIPV at approximately 24 weeks after the third vaccination (38 weeks of age).
2400804|NCT03566927|Experimental|FLEX Scoring Catheter plus DCB|This is a single-arm study. All patients will be treated with the FLEX Scoring Catheter, then a standard balloon angioplasty, followed by a Lutonix® drug-coated balloon (DCB).
2400805|NCT03566914|Experimental|Tadalafil|Tadalafil 10 mg once daily per oral for 3 months
2400806|NCT03566914|Placebo Comparator|Placebo|Tablet placebo once daily per oral for 3 months
2400807|NCT03566901|Experimental|Robot-Assisted Stair Climbing Training|Each session will consist of the G-EO System training and stretching exercises. Total net treatment time/session: 50 minutes. Physiotherapists will alter constraints to grade tasks according to patient ability. The training complexity will be increased, as the patient will improve in performance (i.e. increasing gait speed, reducing body weight support, increasing the number of repetition). Heart rate during training sessions will be monitored using a Polar V800. Heart rate will not exceed the threshold of 120 bpm.
2400808|NCT03566901|Active Comparator|Conventional Physiotherapy|50 min of overground walking training and stair climbing up/down and lower limb mobilization and stretching exercise.
2400809|NCT03566888||Single Group|85 eligible study participants
2400810|NCT03566875|Experimental|Total knee arthroplasty with the Stryker's MAKO™ system|The total knee arthroplasty is performed with Stryker's MAKO™ robotic system. It allows to place precisely the prosthetic implants.
2400811|NCT03566875|Active Comparator|Total knee arthroplasty with mechanical ancillary|The total knee arthroplasty is performed using a mechanical ancillary. It's the conventional method.
2400812|NCT03566862||Lung cancer|Individuals with confirmed diagnosis of lung cancer including disease in the lungs and an active cough.
2400813|NCT03566862||COPD|Individuals with a confirmed diagnosis of COPD according to established criteria.
2400814|NCT03566862||Other (non-COPD) chronic lung disease|Individuals with a confirmed diagnosis of non-COPD chronic lung disease (e.g. pulmonary fibrosis, asthma).
2400815|NCT03566862||Normal smokers|Individuals who have presented with cough but who appear to have 'healthy' lungs (i.e. COPD, other chronic lung disease and lung cancer have been excluded after clinical assessment).
2400816|NCT03566849|Experimental|KC group|It mainly involve all segment in kinetic chain, not only shoulder girdle, include exercise training 3 times a week for a total 4 weeks.
2400817|NCT03566849|Experimental|CT group|It involve shoulder girdle only, include exercise training 3 times a week for a total 4 weeks.
2400818|NCT03566836||AF Detection|Participants will be asked to wear the Garmin smart watch and Garmin chest band. Both are commercially available. The devices will collect information about heart rates before and after a cardioversion procedure.
3184567|NCT00725985|Experimental|Cladribine 5.25 mg/kg, Rebif (LTFU)|Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
3184568|NCT00725985|Experimental|Cladribine 3.5 mg/kg, Rebif (LTFU)|Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
3184569|NCT00725985|Experimental|Placebo, Rebif (LTFU)|Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.
3189081|NCT00774072|Placebo Comparator|isotonic saline|applied once daily via Pari Sinus nebulizer
2400826|NCT03566797||SC-CIP|Patients developing SC-CIP
2400827|NCT03566797||noSC-CIP|Patients with similar severity of critical illness not developing SC-CIP
2400828|NCT03566784||Electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, with the use of electrocoagulation.
2400829|NCT03566784||No electrocoagulation|Patients will undergo a standard procedure for inguinal hernia repair, without the use of electrocoagulation.
2400830|NCT03566771|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 12 months
2400838|NCT03566706|Experimental|Marijuana Use|
2400845|NCT03566654|Experimental|remote ischemic conditioning|Receiving remote ischemic conditioning (RIC) treatment with pressure set at 200 mmHg.
2400846|NCT03566654|Sham Comparator|placebo remote ischemic conditioning|Receiving sham RIC treatment with pressure set at 50~60 mmHg
2400847|NCT03566641|Experimental|Negative pressure wound therapy|This group of patients will receive negative pressure wound therapy (prevena) as their postoperative wound care method.
2400848|NCT03566641|Active Comparator|standard care dressing|This group of patients will receive standard care dressing as their postoperative wound care method.
2400849|NCT03566628|Experimental|Warmed Saline|Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.
2400850|NCT03566628|Active Comparator|Room-Temperature Saline|Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.
2400851|NCT03566615|Active Comparator|Water|Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2400852|NCT03566615|Experimental|CAP-straight|A straight transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2400853|NCT03566615|Experimental|CAP-daisy|A daisy cap transparent cap was fitted to the colonoscope per manufacturer instruction.Residual air in the colon will be removed, water will be infused to guide insertion through an airless lumen. Infused water will be removed by suction, along with residual fecal debris, predominantly during insertion.
2400854|NCT03566602|Other|Dura Sealant Patch|Application of Dura Sealant Patch after closure of the dura mater
2400855|NCT03566589|Experimental|PS128|daily ingestion of Lactobacillus plantarum PS128 capsules
2400856|NCT03566576|Experimental|Anlotinib Plus Pemetrexed|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2400857|NCT03566576|Experimental|Anlotinib Plus Docetaxel|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: Anlotinib 8mg per day and Pemetrexed. Cohort 2: Anlotinib 10mg per day and Pemetrexed. Cohort 3: Anlotinib 12mg per day and Pemetrexed.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event (ANC<1000/ul, body temperature≥38.5°C);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2400858|NCT03566563||Ex-Drug Users|These are ex drug users residing at halfway houses
2400861|NCT03566537||Cases|Patients who are going to undergo a thyroid surgery due to symptomatic non-toxic multinodular goiter, uncontrolled thyrotoxicosis or suspicious FNA
2400862|NCT03566537||Controls|Patients with benign thyroid disease, not undergoing thyroidectomy
2400863|NCT03566524|Experimental|Arginine|In this experimental arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary arginine for 21 days. Arginine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The arginine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2400864|NCT03566524|Active Comparator|Citrulline|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary citrulline for 21 days. Citrulline will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The citrulline will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2400865|NCT03566524|Placebo Comparator|alanine|In this arm, 13 ketosis prone diabetes patients will be randomly assigned to receive 34.2 mmol/d of dietary alanine for 21 days. Alanine will be in the form of 2.85 mmol capsules and patients will be instructed to consume 4 capsules with each of their 3 main meals. The alanine will be provided in a double-blind fashion by a designated unblinded investigator who will not come in direct contact with the subjects.
2400866|NCT03566511|Experimental|Healthy (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
2400867|NCT03566511|Placebo Comparator|Healthy (Placebo)|Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
2400868|NCT03566511|Experimental|T2D (Diazoxide)|Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
2400869|NCT03566511|Placebo Comparator|T2D (Placebo)|Taste-matched placebo. T2D participants will receive placebo between MRI scans.
2400870|NCT03566498|Experimental|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements.
2400871|NCT03566498|Active Comparator|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
2400917|NCT03566134|Placebo Comparator|Placebo|DA-8010 placebo + Solifenacin succinate placebo
2400874|NCT03566459||Veterans with opioid use disorder (OUD)|Veterans with opioid use disorder (OUD) in VA Maine Healthcare System catchment area
2400875|NCT03566446|Experimental|36 aminoacid CALR exon 9 mutated peptide|15 vaccines, over the course of 1 year
3143853|NCT00018798||Bi-weekly telephone calls|34 participants received bi-weekly telephone calls in addition to the annual reviews
3143854|NCT00018798||Annual review only|23 participants received annual reviews only
2400878|NCT03566407|Other|Single Group|This is a prospective, longitudinal descriptive study of subjects with diagnosed Crohn's disease. Blood samples for measurement of protein biomarkers (serology), fresh whole blood for detection of gene polymorphisms, and stool samples for detection and assessment of microbiome and host DNA will be collected, and colonoscopy will be performed.
2400879|NCT03566394|Experimental|Prophylactic Gabapentin|Gabapentin at a dose of 300mg three times a day for 2 days before and 5 days after each taxane infusion. Administered orally.
2400880|NCT03566394|No Intervention|Observation|
2400881|NCT03566381||Healthy adults|Healthy adults without a history of medical or surgical problems
2400882|NCT03566368||Study Group|Isolated Traumatic Brain Injury Patients requiring emergency surgical intervention.
2400883|NCT03566355|Experimental|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
2400884|NCT03566342||GROUP A|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 8ml Lockout ( number of doses per hour) 2 Lock out interval 30 minutes
2400885|NCT03566342||GROUP B|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 5ml Lockout ( number of doses per hour) 4 Lock out interval 15 minutes
2400886|NCT03566342||GROUP C|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 3ml Lockout ( number of doses per hour) 6 Lock out interval 10 minutes
2400887|NCT03566342||GROUP D|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 14 ml/hour Demand dose 0 ml Lockout ( number of doses per hour) 0 Lock out interval 0 minutes
2400888|NCT03566342||GROUP E|The PCEA solution will contain 0.1% Bupivacaine + 2.85 mcg/cc of Fentanyl. Basal infusion 7 ml/hour Demand dose 7ml Lockout ( number of doses per hour) 3 Lock out interval 20 minutes
2400889|NCT03566329|Active Comparator|Magnesium sulphate|50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion
2400890|NCT03566329|Active Comparator|lidocaine hydrochloride|1.5mg/kg loading followed by 2mg/kg/hr infusion
2400891|NCT03566329|Placebo Comparator|NaCl 0.9% normal saline|Normal saline infusion with the same rate as the study drugs
2400892|NCT03566316|Experimental|Telmisartan/Amlodipine+Rosuvastatin|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.
2400893|NCT03566316|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.
2400894|NCT03566316|Active Comparator|Telmisartan +Rosuvastatin|Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.
2400895|NCT03566303|Active Comparator|Rivaroxaban|Rivaroxaban 15mg BID
2400896|NCT03566303|Placebo Comparator|Warfarin|Warfarin dose adjusted
2400897|NCT03566290|Experimental|Open-Label Extension, 3 mg GTx-024|Eligible subjects from G201002
2400898|NCT03566277|Experimental|Single-arm trial|All participants will undergo each of three conditions during the study.
2400899|NCT03566264||Participants hospitalized with ADHF|
2400900|NCT03566251|Experimental|Multiple Sclerosis|Patients with confirmed diagnosis of clinically definite MS, Expanded Sisability Status Scale range of 0.5-4 who are able to walk independently.
2400901|NCT03566251|No Intervention|Healthy individuals|29 healthy volunteers with matching ages and genders
2400905|NCT03566225|Active Comparator|Group A|Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction
2400906|NCT03566225|Placebo Comparator|Group B|Metformin in adose 1500 mg dialy will be administered + clomiphene citrate
2400907|NCT03566212|Experimental|conventional syringe|Individuals requiring local anesthesia for dental treatment were treated in first group by using conventional syringe.
2400908|NCT03566212|Experimental|camouflaged syringe|Individuals requiring local anesthesia for dental treatment were treated in second group by using camouflage syringe.
3143855|NCT00018824|Experimental|1|Naltrexone
2400910|NCT03566186|Experimental|Active phototherapy group|(n=12) Phase 2 training + active phototherapy Dosage applied was 30J per site (180J per muscle) to six sites on the quadriceps The MR4 LaserShower 50 4D emitter (MultiRadiance Medical, USA). The optical power was calibrated before irradiationin each participant using a Thorlabs thermal power meter(Model S322C, Thorlabs, Newton, NJ, USA).
2400911|NCT03566186|Placebo Comparator|Placebo group|(n=14) Phase 2 training + placebo phototherapy group
2400912|NCT03566186|Other|non-treatment control group|(n=13) Phase 2 training + control group
2400913|NCT03566160|Experimental|Cryobiopsy probe as a tool for biopsy|Cryobiopsy probe, administered to study participants.Testing the efficacy of a novel cryobiopsy probe in acquiring tissue samples.
2400914|NCT03566147|Experimental|low dose group|300,000 HuRPE cells
2400915|NCT03566147|Experimental|middle dose group|500,000 HuRPE cells
2400916|NCT03566147|Experimental|high dose group|1,000,000 HuRPE cells
3143856|NCT00018824|Placebo Comparator|2|Placebo
3143858|NCT00018902|Experimental|1|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI.
3143859|NCT00018902|Experimental|2|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant.
3143860|NCT00018902|Experimental|3|Participants whose depression does not respond to an initial SSRI will switch to an alternative SSRI and receive cognitive behavioral therapy (CBT).
3143861|NCT00018902|Experimental|4|Participants whose depression does not respond to an initial SSRI will switch to a different non-SSRI antidepressant and receive CBT.
3143862|NCT00019708|Experimental|Treatment (tanespimycin)|Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
2400921|NCT03566121|Other|Continent women|Women with ICI-Q=0 Pelvic ultrasound / Urodynamic ultrasound
2400922|NCT03566121|Experimental|Incontinent women|Women with ICI-Q≥1 Pelvic ultrasound / Urodynamic ultrasound
2400923|NCT03566108|Experimental|VISTA|VISTA incision with CAF and ADM
2400924|NCT03566108|Active Comparator|Sulcular Tunnell access|Sulcular tunnel surgery with CAF and ADM
2400925|NCT03566095|Active Comparator|Coaching and Voices for Food Kit|The treatment communities received community coaching from an Extension Professional or Educator in the use of the Voices for Food kit.
2400926|NCT03566095|Sham Comparator|Voices for Food Kit|The comparison community received the Voices for Food kit.
2400928|NCT03566069|Experimental|Experimental Group|After a double-blind rabdomization, patients allocated to the experimental group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal OT will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The experimental group will receive - 32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water. OT will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
2400929|NCT03566069|Placebo Comparator|Placebo Group|After a double-blind rabdomization, patients allocated to the placebo group will be followed for four weeks beginning at the start of their hospitalization, after signing a consent form. After completing baseline self-report measurements, they will be assessed for the severity of their symptoms; their working alliance with their therapist; and their treatment outcome after each session. Psychotherapy will be delivered twice a week. Intranasal Placebo will be administered twice a day (at 08:00 a.m. and at 17:00 p.m.). The placebo group will receive - 32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol, distilled water, meaning all ingredients except for the OT and will be inhaled in two sprays, one in each nostril.The substance for both study groups will be prepared in the hospital pharmacy, (in identical bottles), after randomization that will be conducted by the pharmacist. A month post intervention, patients will complete self-report measurements as part of a follow-up evaluation.
3143863|NCT00020566|Experimental|Group 1|Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
3143864|NCT00020566|Experimental|Group 2, arm I|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
3184570|NCT00725998||1|"The ECAP characteristics have been analyzed in 13 children implanted younger than three years old.~Series Study Results:~During the first year of CI use there was a significant statistical growth for the amplitude of N1 peak, in basal electrodes, between the second and third returns. There were not any significant differences obtained for N1 peak, latency, slope, neither for p-NRT nor recovery time, among the returns."
2400934|NCT03566030||Tenofovir Disoproxil Fumarate 300 mg QD|Administered Tenofovir Disoproxil Fumarate 300 mg QD
2400935|NCT03566030||Tenofovir Alafenamide|Administered Tenofovir Alafenamide 25 mg QD
2400936|NCT03566017|Experimental|Experimental open label|pegunigalsidase alfa
2400937|NCT03566004|Other|endoscoped patients|Patients addressed for endoscopy with indication of biopsies for H. pylori detection will be enroled to provide stool specimen
2400939|NCT03565978|Experimental|BAMA solution|This group will use BAMA solution. This is an digital solution used for cardiac post-discharge management. It is an application installed on a tablet. This arm will use this application and also have usual outpatient follow up.
2400940|NCT03565978|No Intervention|Usual care|Not using the application installed on the tablet. Usual outpatient follow up.
2400941|NCT03565965|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2400942|NCT03565965|Active Comparator|Control Group (CG)|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2400943|NCT03565952|Experimental|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
2400944|NCT03565952|Active Comparator|Control Group|The control group does not receive treatment.
2400947|NCT03565926|Active Comparator|Manual Therapy|"Manual Therapy Protocol~Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
2400948|NCT03565926|Experimental|Hypopressive exercises|Protocol of 5 Hypopressive Exercises
2400949|NCT03565913|Experimental|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
2400950|NCT03565913|Active Comparator|CaAcS|Patients in the CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate) per day.
2401041|NCT03565380|Experimental|Patients without intervention|usual post-operative care
3184571|NCT00726011|Experimental|Tetrodotoxin|There is only one arm; active treatment with TTX
3184572|NCT00726076|Experimental|Treatment|The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment.
3184573|NCT00726076|Experimental|Control|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
2400956|NCT03565861|Placebo Comparator|Placebo|Placebo intravenous 30 minute infusion on day 1
2400957|NCT03565861|Experimental|NP10679 5 mg|NP10679 5 mg intravenous infusion on day 1
2400958|NCT03565861|Experimental|NP10679 15 mg|NP10679 15 mg intravenous infusion on day 1
2400959|NCT03565861|Experimental|NP10679 50 mg|NP10679 50 mg intravenous infusion on day 1
2400960|NCT03565861|Experimental|NP10679 100 mg|NP10679 100 mg intravenous infusion on day 1
2400961|NCT03565861|Experimental|NP10679 200 mg|NP10679 200 mg intravenous infusion on day 1
2400962|NCT03565861|Experimental|NP10679 300 mg|NP10679 300 mg intravenous infusion on day 1
2400963|NCT03565848||Women underwent colorectal resection for endometriosis|Women referred for colorectal resection for deep infiltrating endometriosis that underwent laparoscopic segmental colorectal resection performed with mesenteric vascular and nerve sparing surgery.
2400965|NCT03565822|Other|interview|There are two data collection phases (individual interviews +/- focus groups) with parents of children with esophageal atresia, congenital diaphragmatic hernia or short bowel syndrome.
2400966|NCT03565809||Case : ADRS group|"Incidence analysis in ADRS group defined by the first recording of one of the following criteria: (i) LTD registration for ADRS (ICD-10 codes: F00-F03, G30, or G31), (ii) hospital stay reporting a diagnosis code of ADRS (similar ICD-10 codes) or (iii) reimbursement for at least one acetylcholinesterase inhibitor (rivastigmine, galantamine or donepezil) or memantine."
2400967|NCT03565809||Control : non ADRS Group|Incidence analysis in non ADRS group. Each incident ADRS case was paired (1:1) to a beneficiary without any ADRS criteria, matched on age (same birth year), sex, residence area (based on of the 100 administrative 'départements') and insurance scheme.
2400968|NCT03565796|Experimental|Group A|Personalized active referral plus financial incentive+ AWARD advice + referral card + warning leaflet+ COSH booklet
2400969|NCT03565796|Experimental|Group B|AWARD advice + COSH booklet
2400971|NCT03565770|Experimental|standard care + coaching|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving individual coaching and usual standard care
2400972|NCT03565770|Sham Comparator|Standard care|minor patients with a type 1 diabetes, having therapy adjustment difficulties, receiving usual standard care only.
2400973|NCT03565757|Experimental|SMART intervention|90-minute SMART small group session
2400974|NCT03565744|Experimental|Group 1 - B'N Fit POWER|Participants enrolling in B'N Fit POWER afterschool program will be assigned to Group 1.
2400975|NCT03565744|No Intervention|Group 2 - Standard of Care|All other PS/MS-95 participants who completed the screening (approximately 50) will be in comparison Group 2
2400976|NCT03565744|No Intervention|Group 3 - Standard of Care|Participants at an additional school site completing the screening (approximately 100) will be in an additional comparison Group 3.
2400977|NCT03565731|Experimental|ACT-PA Intervention|The primary goal of the intervention is to increase values-based autonomous motivation to increase bout-related MVPA using a single workshop. Participants will engage in basic and advanced values clarification exercise to help clarify (1) the relative importance of major values domains (e.g. social, vocational, recreational), and (2) the potential role of PA in empowering functioning in these domains. Participants will generate their own activity goals and additional values-based goals. In addition, acceptance strategies will be taught to reduce cognitive and emotional barriers to meeting values-based goals. Participants will be asked to report progress on goals each week via an automated email survey from a secure project website. Upon completing the survey, participants will receive standardized responses via email. Monthly phone calls will be brief, semi-structured, and designed to review key principles and trouble-shoot specific barriers identified by the participant.
2400978|NCT03565718|Active Comparator|Standard Group|Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go shopping at their local supermarkets and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel. The Dietary Intervention: Standard/Grocery includes intervention meetings and dietary counseling.
2400979|NCT03565718|Experimental|Restaurant Group|"Participants in this group will receive counseling, informational materials, and recipes for following a vegan diet. Participants in this group will receive gift cards to go and eat out a few times a week at local vegan soul food restaurants and follow the diet for 3 weeks. At the end of the 3 week period each participant will have a follow-up meeting and provide feedback to the study personnel.~The Dietary Intervention: Restaurant condition includes intervention meetings and dietary counseling."
2400980|NCT03565705||Spinal anesthesia with propofol sedation|Patients receive spinal anesthesia for analgesia to undergo open abdominal prostatectomy. Ventilation is secured via a laryngeal mask under propofol sedation and no muscular blocking is necessary.
2400981|NCT03565705||General anesthesia|General anesthesia is conducted with a combination of intravenous opioid (sufentanil) and neuromuscular blocking agent for open abdominal prostatectomy. Patients receive an induction bolus of propofol, undergo tracheal intubation and maintenance of sedation by sevoflurane.
2400982|NCT03565692||Patients treated by LUMACAFTOR-IVACAFTOR|Patients treated by LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) Patients over 6 years who are currently able to benefit from LUMACAFTOR-IVACAFTOR (or other ivacaftor combinations) according the mutation eligibility criteria and for whom conventional microbiological analysis of sputum samples and stool will be collected during their follow-up after the treatment onset.
3184574|NCT00726102|Active Comparator|Meat|Provide locally available meat daily to infants from 6 to 18 mos of age
3184575|NCT00726102|Active Comparator|Control|Daily provision of cereal to infants from 6-18 mos
3184576|NCT00726102|Active Comparator|Fortified rice cereal|Provide equi-caloric serving of fortified rice cereal on daily basis from 6-18 months of age
3184577|NCT00726115|Placebo Comparator|1|arm placebo
3184578|NCT00726115|Experimental|2|arm drug
2400988|NCT03565653|Experimental|High dietary salt|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing uniodized table salt. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
2400989|NCT03565653|Experimental|Placebo|For 10 days each, participants will be asked to eat a recommended sodium diets (2300 mg Na+/d) while taking unmarked pills containing a placebo (dextrose). Participants will complete both interventions in random order. On the 10th day, participants will report to the lab to complete 60 minutes of cycling exercise. Following exercise, participants will rest for 60 minutes while undergoing serial blood pressure measurements. Participants will then be outfitted with ambulatory blood pressure cuffs for assessment of blood pressure over the following 24 hours.
2400992|NCT03565627|Experimental|Exercise app|7 Minute Workout Challenge by Fitness Guide Inc.
2400993|NCT03565627|Experimental|Running App|One You Couch to 5K by Public Health England
2400994|NCT03565614|Experimental|Reablement rehabilitation|Reablement rehabilitation to maintain or increase the participants' physical, psychological and social functional abilities.
2400995|NCT03565614|Active Comparator|Traditional home care|The traditional home care and required rehabilitation efforts as by the municipality's current practice.
2400996|NCT03565601||CTD patients with anti-Ro52 antibodies|Connective tissue disease patients with anti-Ro52 antibodies at diagnosis
2400997|NCT03565601||CTD patients without anti-Ro52 antibodies|Connective tissue disease patients without anti-Ro52 antibodies at diagnosis
2400998|NCT03565588|Experimental|Education session with fixed incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs to the health facility with payments conditional on being circumcised.
2400999|NCT03565588|Experimental|Education session with lottery incentive|Education sessions offered by a circumcised health worker and contribution towards transport costs but with conditional lottery financial incentives.
2401000|NCT03565588|No Intervention|Control arm|No intervention will be administered to the control arm
2401001|NCT03565575|Experimental|Interactive tablet-based quiz|Individuals participate in an interactive tablet-based risk perception and PrEP counselling information session.
2401002|NCT03565575|No Intervention|Control arm|No intervention will be administered to the control arm
2401003|NCT03565562|No Intervention|Control group|Local authorities allocated to this group won't implement any promotion of the e-health tool for the 12 first months. Free access to StopBlues.
2401004|NCT03565562|Active Comparator|Group experimental 1 promotion|Local authorities allocated to this group will have to implement the promotion of the e-health tool: the promotion at the local authority level. They will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops…). Free access to StopBlues.
2401005|NCT03565562|Active Comparator|Group experimental 2 promotion|Local authorities allocated to this group will have to implement promotion of the e-health tool: the promotion at local authority and GPs' waiting room level. Local authorities will promote the e-health tool using their usual communication methods (local newspapers, local website, bulletin and billboards, posters in the local shops and in the bus stops...). (similarly to group experimental1) as well as leaflets and posters in GPs' waiting room. Free access to StopBlues.
2401006|NCT03565549|Experimental|Mnemonic|Intervention group will receive a mnemonic aid to remember the CCHR
2401007|NCT03565549|Active Comparator|CCHR rule|The control group will receive the CCHR only
2401008|NCT03565536|Experimental|Nexavar neoadjuvant treatment group|"After the patient had diagnosed as anaplastic thyroid cancer, Nexavar was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.~operation for possible surgical treatment,with complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.~then External radiation therapy after surgery."
2401009|NCT03565523|Experimental|Test Beet shot|Containing 385 mg nitrate
2401010|NCT03565523|Placebo Comparator|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
2401011|NCT03565510|No Intervention|Control|Those assigned to the Control group will receive a diet composed of 55% of carbohydrate, 15% of protein, and 30% of lipid (similar to the North American dietary pattern).
3184579|NCT00726128||VueLock™ Anterior Cervical Plate Group|VueLock™ Anterior Cervical Plate, Implanted in subjects having an ACDF (Anterior cervical discectomy and fusion)
3184580|NCT00726154|Other|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
3189082|NCT00774085||Patients with Schizophrenia|Patients with Schizophrenia are treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
3189083|NCT00774098|Placebo Comparator|Control Group|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
3189084|NCT00774098|Experimental|GICP|
3189085|NCT00774111|Experimental|Sequence 1|
3189086|NCT00774124|Experimental|1 Telemedicine|Usual care plus telemonitoring
2401012|NCT03565510|Experimental|High-Protein Diet|Those assigned to the High-Protein Diet group will receive a diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based total diet replacement.
2401013|NCT03565497|Placebo Comparator|Wellness Education Control Condition|The wellness education control condition (CC) is modeled after that used in our studies of exercise for smoking cessation, but delivered in an individual format. Content focuses on discussions of a variety of healthy lifestyle topics, such as healthy eating, time management, recommended health screenings, and cancer and cardiovascular prevention. Content is delivered using a combination of lectures, videos, handouts, and discussions while allowing participants to set their own realistic wellness goals, which they can gradually incorporate into their lives.
2401014|NCT03565497|Experimental|Mindfulness Training (MT)|Mindfulness training will be adapted for 6 individual sessions;elements include: (1) a body scan designed to teach participants to pay attention to specific parts of their bodies as a strategy to increase attentional capacities/reduce habitual mind-wandering; (2) non-judgmental awareness, and (3) 'awareness of breath' meditation, with an additional focus on helping participants become more aware of the present moment and refrain from habitually engaging in self-related pre-occupations concerning the future or the past.
2401015|NCT03565497|Experimental|Mindfulness Training Plus IE (MT+IE)|This condition will mirror the MT condition for the first 4 individual sessions, then for the final 2 individual sessions, MT will be rehearsed under conditions of sensations of anxiety/tension induced by interoceptive exposure procedures (IE).
2401016|NCT03565484|Experimental|Antimicrobial susceptibility testing guided therapy|14d bismuth quadruple therapy based on susceptibility test.
2401017|NCT03565484|Experimental|Personal medication history guided therapy|14d bismuth quadruple therapy based on previous medication history.
2401018|NCT03565484|Other|Salvage therapy for negative culture|14d bismuth quadruple therapy based on previous medication history.
2401019|NCT03565484|Other|Salvage therapy for failed eradication|14d bismuth quadruple therapy for salvage treatment.
2401020|NCT03565471||ASD patients with surgical closure|"Patients diagnosed with an ASD who have had a surgical closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2401021|NCT03565471||ASD patients with transcatheter closure|"Patients diagnosed with an ASD who have had a transcatheter closure of the defect more than 3 years ago.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2401022|NCT03565471||Controls|"Controls who do not have any cardiac or pulmonary diagnoses nor use prescription drugs that may affect the cardiopulmonary function.~Echocardiography, right side catheterization, exercise testing and Holter monitoring are performed on all participants."
2401023|NCT03565458|Experimental|gemigliptin|gemigliptin single dose
2401024|NCT03565458|Experimental|dapagliflozin|dapagliflozin single dose
2401025|NCT03565458|Experimental|gemigliptin and dapagliflozin|co-administration of gemigliptin and dapagliflozin
2401026|NCT03565458|Experimental|empagliflozin|empagliflozin single dose
2401027|NCT03565458|Experimental|gemigliptin and empagliflozin|co-administration of gemigliptin and empagliflozin
3143865|NCT00020566|Experimental|Group 2, arm II|Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
3143866|NCT00020670|Experimental|CD40 Cell Vaccination|Patients will undergo tumor cell collection followed by vaccine preparation and then vaccination. Autologous acute lymphoblastic leukemia (ALL) cells are harvested, cultured with CD40 ligand, pulsed with keyhole limpet hemocyanin (KLH), and then irradiated to produce the vaccine. Patients receive either 1 x 10^7 or 1 x 10^8 CD40 cells/vaccination depending on the number of tumor cells obtained. Vaccinations are administered every two weeks as outpatient therapy. Evaluable patients receive the course of at least 4 vaccinations at weeks 0, 2, 4, 6. Patients may continue receiving vaccinations every 2 weeks if chemotherapy is not required for symptomatic disease.
3143867|NCT00020683|Experimental|Arm I (low dose incyclinide)|"Patients receive low-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
3143868|NCT00020683|Experimental|Arm II (high dose incyclinide)|"Patients receive high-dose oral COL-3 once daily.~Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed."
3143869|NCT00020709|Experimental|Arm I (gefitinib, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral gefitinib daily."
2401034|NCT03565432||IBD in KHUH|Registered patients with Inflammatory bowel disease at Kyung Hee University Hospital
2401035|NCT03565419|No Intervention|Control|Participants conduct the ultrasound-guided peripheral cannulation while they confirm real-time images displayed on the viewer next to the phantom.
2401036|NCT03565419|Experimental|Intervention|Participants conduct the ultrasound-guided peripheral cannulation wearing smart glasses. They confirm real-time images displayed on the viewer of smart glasses.
2401037|NCT03565406|Experimental|Unresectable Stage III or Stage IV Melanoma|
2401038|NCT03565393|Placebo Comparator|Fibersol-2|Receive Fibersol-2 twice daily
2401039|NCT03565393|Placebo Comparator|Placebo|Receive placebo twice daily
2401040|NCT03565380|Experimental|Patients with intervention|12-week community-based Tai Chi rehabilitation program starting at 12 weeks after TKA
2401042|NCT03565380|Experimental|Asymptomatic controls|untreated asymptomatic controls
2401043|NCT03565367|Experimental|Diagnostic (MRI, hyperpolarized carbon C 13 pyruvate MRSI)|Participants undergo MRI over 45 minutes at baseline. Participants then receive hyperpolarized carbon C 13 pyruvate IV over 30-40 seconds. Within 1 minute, participants undergo MRSI over 3 minutes and MRI over 10 minutes (participants may receive gadolinium at the discretion of the protocol director).
2401044|NCT03565354|Active Comparator|Treatment arm|intravenous iron isomaltose 3-10 weeks before operation date. The dose will be determined by the patient's body weight: > 50kg: 1000mg; <50kg: 20mg/kg body weight, to be infused over 30 minutes. 2 weeks after intravenous iron isomaltoside administration, blood test for hemoglobin level and iron profile would be repeated. Subjects with hemoglobin level less than 10g/dL will receive a second dose of intravenous iron isomaltoside. The second dose would be identical to the first dose
2401045|NCT03565354|No Intervention|Control arm|Patient randomized to the control arm will follow the standard perioperative care and the perioperative management they received will be identical to the treatment arm except no intravenous iron isomaltoside will be given.
2401046|NCT03565341|Experimental|Melasma|Treatment of Melasma Using PiQo4 Laser System
3184581|NCT00726154|Other|Collaborative care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
3184582|NCT00726193||1 - standard films|Tibia reconstruction surgery with OsteoGen™ with standard radiographs
3184583|NCT00726193||2 - Standard films plus CT|Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.
3184584|NCT00726206|Other|1|Recording of the movements Recording of the electroencephalogram
3184585|NCT00726219|Other|1|Insertion distance of femoral catheter: 3cm
2401052|NCT03565302|Placebo Comparator|Control|Subjects receive placebo treatment
2401053|NCT03565302|Experimental|Long acting beta2-agonist|Subjects are treated with long-acting beta2-agonist formoterol
2401054|NCT03565302|Experimental|Short acting beta2-agonist|Subjects are treated with short-acting beta2-agonist terbutaline
2401055|NCT03565289||All patients|All
2401056|NCT03565276|Experimental|Experimental: TXA|Intravenous Tranexamic Acid beginning at 5mg/kg administered as part of a dose-escalation design.
2401057|NCT03565263||FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~with at least one Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
2401058|NCT03565263||No FGID-IBD|"Patients aged 9-18 years~with inflammatory bowel disease (Crohns, ulcerative colitis or indeterminate colitis)~in remission (defined as: Physician's global assessment = remission, no nocturnal stools, no blood in stools, < or = 3 stools/day, C-reactive-protein < 10 mg/L, Erythrocyte sedimentation rate < 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy~followed for IBD for at least 1 year~not a single Functional Gastrointestinal disorder according to the Fr-qPGS questionnaire (Rome III criteria)"
2401059|NCT03565250|Experimental|ADHD patients|children aged 8-12 ans with ADHD
2401060|NCT03565250|Active Comparator|control|children aged 8-12 ans without ADHD
2401061|NCT03565237|Experimental|All Study Participants|Study participants with Hemophilia B in India receiving Rixubis
2401062|NCT03565224||Cespace|The patients have been operated with Cespace Titanium Coated PEEK Cage for Degenerative Disc Disease between 2014 and 2017. All patients are invited to the Hospital for Follow-Up. Depending on the date of Initial Intervention the timeframe of follow-up for the individual Patient is 1 to 4 years.
3184586|NCT00726219|Other|2|Insertion distance of femoral catheter: 7cm
2401064|NCT03565185|Active Comparator|End-effector|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training(end-effector type-Lokohelp) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
2401065|NCT03565185|Active Comparator|Exoskeleton|"For stroke rehabilitation 5 days a week in addition to conventional treatment methods robot-assisted gait training (exoskeleton type-Robogait) will be taken with 45 minutes a day for 3 days a week for 4 weeks.~Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level."
2401066|NCT03565185|Placebo Comparator|conventional treatment|conventional treatment methods for stroke rehabilitation 5 days a week Patients will be assessed with PASS, Rivermead mobility index, 10-meter walking test, 6-minute walking test, Barthel index, and FAC in terms of baseline and ending for posture, mobility, walking velocity, walking capacity, daily life activities and ambulance level.
2401067|NCT03565172|Experimental|Children with spastic cerebral palsy|"Children with spastic cerebral palsy will be included. They will have 3 phases:~Baseline: 4, 5 or 6 evaluations~Intervention: 9 evaluations before and after every stretching session~Follow-up: 4, 5 or 6 evaluations~The evaluation part will be composed of isokinetic dynamometer with ultrasound and Visual Analog Scale (VAS). The number of evaluations at baseline and follow-up will be randomized before the study by Single Case Experimental Design (SCED) methodology."
3184587|NCT00726245|Experimental|1|PRGF
3184588|NCT00726245|Placebo Comparator|2|physiological saline
3184589|NCT00726258|Placebo Comparator|1|Drip of physiological serum
3184590|NCT00726258|Active Comparator|2|Drip of ketamine
2401068|NCT03565159|Active Comparator|Prevenar 13|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
2401069|NCT03565159|Placebo Comparator|Sodium chloride 0.9%|A volume of 0.5ml will be drawn up into a syringe and labelled with an Annex 13 label.
2401070|NCT03565146|Experimental|Pigmentation|Treatment of Pigmented Lesions Using PiQo4 Laser System
2401071|NCT03565133|Experimental|Oral quinine, gastric placebo|Oral sham feeding of quinine and a gastric capsule containing placebo (cellulose)
2401072|NCT03565133|Experimental|Oral placebo, gastric quinine|Oral sham feeding of placebo (tap water) and a gastric capsule containing quinine
2401073|NCT03565133|Experimental|Oral quinine, gastric quinine|Oral sham feeding of quinine and a gastric capsule containing quinine
2401074|NCT03565133|Placebo Comparator|Oral placebo, gastric placebo|Oral sham feeding of placebo (tap water) and a gastric capsule containing placebo (cellulose)
2401075|NCT03565120|Experimental|Arm-R|patients in this arm will receive aggressive thoracic radiotherapy.
2401077|NCT03565094|Experimental|Lu AF28996|"Lu AF28996 solution, cohort depending dose~Part A:~Cohort 1: single oral dose of Lu AF28996~Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between~Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects~Part B: 8 subjects (randomised to one of four treatment sequences)"
2401078|NCT03565081|Experimental|PWS elastic band training group|Genetically confirmed diagnosis of PWS participants were recruited. The PWS participants needed to have sufficient command of the Mandarin language to understand the study information and motivated to conduct the training program.
3184591|NCT00726271|Experimental|active|"Subjects will complete the Zung Depression and Anxiety Scales. At the first visit the subject's medication list, weight, height, and waist measurement will be obtained. The goal is to recruit a minimum of 20 patients.~Subjects will receive light olive oil, and capsules of fish oil and flaxseed oil, to take daily at home with weight based dosing, based on the doses recommended in Dr. Roberts' work. Doses are within the recommended dietary ranges to improve intermediate outcomes for coronary artery disease subjects.~They will return weekly for measurement of weight, waist measurements, discussion of any problems with the oils, and dose adjustment of the oils."
3184592|NCT00726310||SpineLink® , SpineLink® II Group|Spinal fusion surgery with SpineLink®
3184593|NCT00726349||Observation|Patients undergoing isolated elective total hip or knee arthroplasty (primary or revision surgery for a non-malignant condition), aged 60 years or older and able to walk prior to surgery.
3184594|NCT00726362||1|patients with hyperlipidemia newly initiating a statin; or switched from current therapy to a statin, or require dosage adjustment for statin
3184595|NCT00726401|Active Comparator|1|
3184596|NCT00726401|Placebo Comparator|2|
3184597|NCT00726427|Experimental|1|8 increasing oral single doses given to 8 groups (3 on active and 1 on placebo in each group)
3184598|NCT00726427|Experimental|2|2 oral doses of AZD1656 given to 2 groups together with food
2401087|NCT03565055|Experimental|IPCST|Intervention = Patients that participate in IPCST programme
2401088|NCT03565055|Active Comparator|E.A.S.Y|Treatment as usual = Patients of E.A.S.Y Programme in HK Kwai Chung Hospital
2401089|NCT03565042||MoA ustekinumab|Patients with a diagnosis of psoriatic arthritis according to the CASPAR criteria with at least one swollen knee or ankle joint who are planning to receive treatment with ustekinumab at the outpatient clinic. An arthroscopy will be done in the swollen knee/ankle at week 0, 12 and 24.
2401090|NCT03565029|Experimental|Medium/low locally advanced rectal cancer|Patients with Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
2401091|NCT03565003|Experimental|JAB-3068 (SHP2 inhibitor)|JAB-3068 will be administered orally in the morning following a fast of approximately 6 hours before on PK collection. Patients will continue to fast for approximately 2 hours after the administration of JAB-3068. On non-PK days patients will fast approximately 2 hours before JAB-3068 and continue to fast for approximately 2 hours afterwards.
2401092|NCT03564990|Experimental|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
2401093|NCT03564990|Sham Comparator|conventional approach|conventional follow-up with oral healthy education
2401094|NCT03564977|Experimental|CD19-targeted CAR-T cells|
2401095|NCT03564951|Active Comparator|Control|ablation of Atrial fibrillation using spatio-temporal dispersion
2401096|NCT03564951|Experimental|Isochrone|ablation of concordance zones using isochrone and voltage maps
3184599|NCT00726440|Active Comparator|Group1-patient|The patient will be encouraged to use the Navigator® all the time and to modify his treatment according to the continous blood glucose measurements. The patients will follow an educational process in order to adapt insulin doses according to each sensor data.
2401098|NCT03564925|Active Comparator|Wide area circumferential ablation|Device:Smart Touch® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
2401099|NCT03564925|Experimental|Cryoballoon ablation|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
2401100|NCT03564912|Experimental|2 week group|
2401101|NCT03564912|Active Comparator|3 week group|
2401102|NCT03564899|No Intervention|control|Receive no physical activity intervention (maintain baseline physical activity participation)
3189087|NCT00774124|Active Comparator|2 Standard of Care|Standard of care - women will monitor and record blood glucose levels four times a day.
3189088|NCT00774150|Experimental|1. Cognitive Behavioral Therapy|
3189089|NCT00774150|Active Comparator|2. Client Centered Therapy|
3189090|NCT00774176||1|Phase 1 & Gene Expression:Hospitalized COPD exacerbators
3189091|NCT00774176||2|Phase 2: COPD group
3189092|NCT00774176||3|Genetic Association Studies: COPD and Healthy Controls
2401103|NCT03564899|Experimental|Lighter intensity physical activity|Receive an intervention of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve for 12 weeks.
2401104|NCT03564899|Active Comparator|Higher intensity physical activity|Receive an intervention of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve for 12 weeks.
3143870|NCT00020709|Experimental|Arm II (placebo, combination chemotherapy, radiation)|"Patients receive induction therapy comprising cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Beginning within 24 hours after starting chemotherapy, patients receive concurrent induction radiotherapy 5 days a week for 5 weeks and then boost radiotherapy 5 days a week for 1.5 weeks.~Beginning approximately 4-8 weeks after completion of chemoradiotherapy, patients with stable or responding disease receive consolidation therapy comprising docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for 3 courses.~Patients with stable or responding disease are randomized to one of two treatment arms for maintenance therapy. Patients begin maintenance therapy approximately 4-7 weeks after completion of consolidation therapy.~Patients receive oral placebo daily. In both arms, maintenance therapy continues for a maximum of 5 years in the absence of disease progression or unacceptable toxicity."
3143871|NCT00020735|Experimental|oral toremifene|
2401109|NCT03564860||HBP device data collection group|Device electrograms and 12-lead ECG will be collected from patients over the age of 18 years who have been previously implanted with a permanent His Bundle pacing lead and an Abbott pacemaker, defibrillator, or cardiac resynchronization therapy device during a standard-of-care device follow-up visit.
2401110|NCT03564847|Experimental|LTP Plus|LTP Plus Participants will receive the intervention over 4 months Weekly sessions for 2 months and fortnightly for next two months by trained non-specialists/community health workers.
2401111|NCT03564847|No Intervention|Treatment As Usual (TAU)|Treatment as Usual (TAU) group will receive routine care and their follow up will be done at 4th and 6th month post randomization.
2401112|NCT03564834|Experimental|Laparoscopic gastrectomy|A standard laparoscopic gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
2401113|NCT03564834|Active Comparator|Open gastrectomy|A standard open gastrectomy with D2 lymphadenectomy will be performed by two experienced surgeons, according to the Japanese Gastric Cancer Treatment Guidelines 2014 (version 4) and the Japanese Classification of Gastric Carcinoma (3rd English edition).
3143872|NCT00020735|Other|observation|
3143873|NCT00020761|Experimental|Gastro Esophogeal cohort|"Patients with adenocarcinoma of the esophagus, gastroesophageal (GE) junction and gastric cardia (GE cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
2401116|NCT03564808|Experimental|Fat graft enriched with MSCs|Adipose tisse derrived MSCs
2401117|NCT03564808|Experimental|Fat graft only|Fat graft withiut enrichment with MSCs
2401118|NCT03564795|Experimental|KeraStat Gel|Each enrolled subject will have at least one eligible burn randomized to the KeraStat Gel arm. This burn will be dressed with KeraStat Gel and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the KeraStat Gel per the instructions for use (at least every 3 days).
2401119|NCT03564795|Active Comparator|Silver Sulfadiazine|Each enrolled subject will have at least one eligible burn randomized to the Silver Sulfadiazine arm. This burn will be dressed with the Silver Sulfadiazine and covered by a secondary dressing. Subjects will be instructed to change the dressing and re-apply the Silver Sulfadiazine per the institution's Standard of Care instructions.
2401120|NCT03564782|Experimental|PVSRIPO|Polio vaccine booster will be administered 1 week prior to PVSRIPO injection. On the day of PVSRIPO injection (Day 0), a pre-treatment biopsy is obtained. PVSRIPO in injected into the tumor mass at a dose of 1x10^8 TCID50. On day 14, women will undergo standard-of-care surgical resection of PVSRIPO-treated tumor.
2401121|NCT03564769|Experimental|Intervention Arm 1|Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.
2401122|NCT03564769|Experimental|Intervention Arm 2|Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.
2401123|NCT03564756|Experimental|Iron + Vitamin C|One iron tablet once a day plus a 500 mg vitamin C tablet twice a day until delivery.
2401124|NCT03564756|No Intervention|Iron + Placebo|One iron tablet once a day plus a placebo tablet twice a day until delivery.
2401125|NCT03564730|Active Comparator|Total Knee Arthroplasty (TKA)|Patient will have complete replacement - Simultaneous vs Staged
2401126|NCT03564730|Active Comparator|Unicompartmental Knee Arthroplasty (UKA)|Patient will have half-knee replacement (partial) - Simultaneous vs Staged
2401127|NCT03564717|Experimental|Segmented Three dimensionally printed transfer tray|
2401128|NCT03564717|No Intervention|Full arch three dimensionally printed transfer tray|
2401129|NCT03564704|Experimental|PDT-ALL-LBL|The intervention of PDT-ALL-LBL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy (methotrexate, cytarabine, dexamethasone), radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
3143874|NCT00020761|Experimental|Distal Stomach cohort|"Patients with adenocarcinoma of the rest of the stomach (Distal Stomach cohort)~The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
2401239|NCT03564080|Experimental|Combined - PAD and CAD|This group of PAD patients will exercise alongside CAD patients in an established supervised exercise programme (Cardiac Rehabilitation).
3143875|NCT00020787|Experimental|Treatment|See intervention description.
3143876|NCT00020826||gastric adenocarcinoma|No protocol specific interventions. Both palliative or curative treatment allowed.
3143877|NCT00020878|Experimental|Study|See intervention description.
3143878|NCT00020943|Experimental|Chemo/immuno/autolog transplant|Intensive chemotherapy followed by autologous stem cell transplant and immunotherapy for mantle cell lymphoma
3143879|NCT00021060|Experimental|Arm I (paclitaxel and carboplatin)|"Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 15-30 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3143880|NCT00021060|Experimental|Arm II (paclitaxel, carboplatin, and bevacizumab)|"Patients receive paclitaxel and carboplatin as in arm I followed by bevacizumab IV over 30-90 minutes on day 1.~Treatment in both arms repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~After completion of 6 courses, patients in arm II with stable or responding disease continue to receive bevacizumab only. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity."
3143881|NCT00021073|Experimental|Treatment (alvocidib, combination chemotherapy)|"Group I: Patients receive FLAVO IV over 24 hours on day 1 and CF IV and 5-FU IV over 1.5 hours daily on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FLAVO and 5-FU until the MTD are determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.~Once the MTDs for FLAVO and 5-FU are determined, patients receive FLAVO, CF, and 5-FU as in group I plus irinotecan IV over 1.5 hours on day 1. Courses repeat as in group I. Cohorts of 3-6 patients receive escalating doses of irinotecan until the MTD is determined. The MTD is defined as in group I."
3143882|NCT00021099|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3143883|NCT00021151|Experimental|Alemtuzumab|
3143884|NCT00021216|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3143885|NCT00021242|Experimental|Relapsed or Refractory ALL, AML|Docetaxel 60 mg/m^2 per dose weekly (Days 1,8,15) for 3 weeks followed by 1 week of rest.
2401192|NCT03564379|Experimental|Part 2: Multiple Dose Part|After a washout period of at least 10 days, same participants from Part 1 will receive multiple daily dosing of 25 mg JNJ-42165279 or placebo tablet for 10 days.
3189093|NCT00774189|Experimental|1|clarithromycin 250 mg tablets of Ranbaxy Laboratories
3143886|NCT00021398|Experimental|Radiation Therapy, Chemotherapy and Surgery|
3143887|NCT00021814|Placebo Comparator|Placebo|Doxazosin and Finasteride placebos
3143888|NCT00021814|Experimental|Doxazosin|Doxazosin and Finasteride placebo
3143889|NCT00021814|Experimental|Finasteride|Doxazosin placebo and Finasteride
3143890|NCT00021814|Experimental|Combination|Doxazosin and Finasteride
3143891|NCT00021840||Homogen Hispanic pop/Cent Valley CRA|Homogeneous Hispanic population from the Central Valley of Costa Rica
3143892|NCT00021866||Carbamazepine|Children and their mothers exposed to Carbamazepine monotherapy in utero
3143893|NCT00021866||Phenytoin|Children and their mothers exposed to phenytoin in utero
3143894|NCT00021866||Lamotrigine|Children and their mothers exposed to Lamotrigine in utero
3143895|NCT00021866||Valproate|Children and their mothers exposed to Valproate in utero
3143896|NCT00022087|Experimental|Zoledronic acid initial tx|Zoledronic acid + calcium + Vit D for 2 years, followed by Calcium + vit D for 1 year
3143897|NCT00022087|Experimental|Calcium + Vit D initial Tx|Calcium + vitamin D for 1 year followed by zoledronic acid + calcium + vit D for 2 years
3143898|NCT00022113|Experimental|Treatment (cilengitide)|Patients receive EMD 121974 IV over 1 hour twice weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3143899|NCT00022126|Experimental|Modified Augmented BFM Therapy|
3143900|NCT00022139|Experimental|carboplatin + paclitaxel + fluorouracil + radiation + surgery|"Patients receive carboplatin IV and paclitaxel IV over 3 hours on days 1 and 22 and fluorouracil IV continuously on days 1-42. Beginning on day 1 of chemotherapy, patients undergo radiotherapy to the esophagus 5 days a week for 5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease at 4-8 weeks after completion of radiotherapy undergo esophagectomy and complete dissection of the mediastinal and perigastric lymph nodes. Beginning 8 weeks after surgery, patients who underwent curative resection may receive a maximum of 2 additional courses of paclitaxel and carboplatin in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before chemotherapy on days 1 and 22, and within 2 weeks before surgery.~Patients are followed every 3 months for 4 years."
3143901|NCT00022152|Experimental|vinorelbine|"Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and then after completion of the second course.~Patients are followed every 3 months for 5 years."
3143902|NCT00022165|Placebo Comparator|Placebo|Selenium yeast
3143903|NCT00022165|Experimental|Selenium yeast 100 micrograms per day|100 micrograms per day
3143904|NCT00022165|Experimental|Selenium yeast 200 micrograms per day|200 micrograms per day
3143905|NCT00022165|Experimental|Selenium yeast 300 micrograms per day|300 micrograms per day
3143906|NCT00022334|Experimental|Treatment|See intervention description.
3143907|NCT00022399|Experimental|Celecoxib|Participants receive celecoxib 400mg by mouth twice daily for 4 to 6 weeks prior to standard-of-care prostatectomy.
3143908|NCT00022399|Placebo Comparator|Placebo-control|Participants receive placebo for 4 to 6 weeks prior to standard-of-care prostatectomy.
3143909|NCT00022412|Placebo Comparator|Observation, then prostatectomy|Arm 2: Patients undergo observation for 28 days. Patients then undergo prostatectomy.
3143910|NCT00022412|Active Comparator|Doxercalciferol once daily for 28 days|Dietary supplement once daily to treat prostate cancer for 28 days
3143911|NCT00022477|Experimental|BMS-247550|IV administration of BMS-247550 once every 21 days
3189094|NCT00774189|Active Comparator|2|Biaxin 250 mg tablets
3143912|NCT00022529|Experimental|Treatment (BMS-214662, trastuzumab)|Patients receive BMS-214662 IV over 1 hour on days 2, 8, 15, and 22 and trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3143913|NCT00022542|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving complete response receive 2 additional courses.
2401145|NCT03564678|Experimental|Treatment (levocarnitine, vitamin B complex)|Patients receive levocarnitine IV over 2-3 minutes every 6 hours up to 4 times a day (inpatient) or PO TID (outpatient). Patients also receive vitamin B complex PO BID. Treatment continues for up to 30 days after the last dose of either PEG-asparaginase or inotuzumab, or until Tbili of ≤ 1.5 x ULN or at least a 50% reduction in peak Tbili is achieved.
2401146|NCT03564665|Experimental|400mg Magnesium Glycinate BID Arm|Prescription for an 8 week supply (+/- 4 days) of Magnesium Glycinate will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
2401147|NCT03564665|Placebo Comparator|Control Arm|Prescription for an 8 week supply (+/- 4 days) of placebo will be sent to the pharmacy for patient pick up. Study Coordinator will then dispense study diaries (Supplementation Diary and Hot Flash Diary) with instructions on how to complete for the eight week study duration. Study Coordinator will discuss upcoming phone calls on Weeks 2-8 to complete the MDASI by phone and the best times to do so with the patient. Coordinator will schedule a return visit with the Patient approximately 9 weeks after the start of the study for follow-up. At follow-up, Coordinator will retrieve Patient Diaries (Hot Flash Diary and Medication Diary), perform supplement reconciliation, and exit Patient from the study.
2401148|NCT03564652|No Intervention|Arm A|Control arm: Lactating women (LW) randomized in this arm will only receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2401149|NCT03564652|Experimental|Arm B|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2401150|NCT03564652|Experimental|Arm C|Intervention arm B: Lactating women (LW) randomized in this arm will receive ready-to-use nutritional supplement, 'Balanced energy-protein (BEP)' for next 6 months to be consumed in a dose of 2 sachets of 75 grams per day. Further, the same infant of LW will receive a single dose of Azithromycin (20mg/kilogram) at day 42 of age. Further, LW will also receive standard of care which comprises of standard nutritional counseling, key messages of exclusive breastfeeding, essential newborn and infant care and immunization.
2401151|NCT03564639||Injection drug users with HCV|People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.
2401152|NCT03564626|No Intervention|Control Group|Standard of care counseling and discharge instructions per local hospital policy. Standard of care follow up phone calls and visits at baseline and at 30 days. Follow-up will be for 30 days
2401153|NCT03564626|Experimental|Health IT only|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline and at 30 days.Follow-up will be for 30 days
2401154|NCT03564626|Experimental|Health IT + Scheduled Follow Up|Subjects and caregivers will be given individual phones loaded with the Patient Buddy App and the EncephalApp that will be used to enter medications, issues and orientation questions daily. There will be messages and phone calls as needed per the App and visits will be at baseline, scheduled at 15 days and at 30 days. In addition, scheduled phone calls will be performed at days 7 and 21.Follow-up will be for 30 days
3143914|NCT00022555|Experimental|Treatment (bryostatin 1, vincristine sulfate)|Patients receive bryostatin 1 IV continuously on days 1 and 15 and vincristine IV over 5 minutes on days 2 and 16. Treatment continues every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity.
2401156|NCT03564600||ABC Group|Veterans with back pain for at least the past 6 months.
2401157|NCT03564600||UC Group|Veterans with back pain for at least the past 6 months.
3189095|NCT00774228|Experimental|I-ZIP Ocular Bandage|I-Zip bandage application
3143915|NCT00022581|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3143916|NCT00022646|Experimental|Arm I: pemetrexed + gemcitabine|Patients receive pemetrexed disodium IV over 10 minutes on day 1 followed by gemcitabine IV over 30 minutes on days 1 and 8.
3143917|NCT00022646|Experimental|Arm II: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 followed by pemetrexed disodium IV over 10 minutes on day 1.
3143918|NCT00022646|Experimental|Arm III: pemetrexed + gemcitabine|Patients receive gemcitabine IV over 30 minutes on day 1 and pemetrexed disodium IV over 10 minutes followed by gemcitabine IV over 30 minutes on day 8.
3143919|NCT00022711|Experimental|Temozolomide|Temozolomide 150mg/m2/day daily. Repeat cycles every 28days for maximum of six months
3143920|NCT00022737|Experimental|Arm I|See Design Details.
3143921|NCT00022776|Experimental|1|Participants will undergo surgery for spinal stenosis. Participants in this group will undergo surgical decompression as described by Rothman and Simeone.
2401160|NCT03564574|Experimental|Study group|"Inclusion criteria~History of consumption of OP compound.~Symptom complex consistent with OP poisoning~Age > 18 years~Informed consent from the patient or next kin.~Exclusion criteria~History of combined poisoning with a non OP compound.~All other patients not fitting in the organophosphate symptom complex.~Patients with underlying liver and kidney disease.~History suggestive of acute pancreatitis in the past.~All patients with history and clinical features of OP compound poisoning admitted to the emergency department in PGIMER during the study period, meeting the inclusion, exclusion criteria and who gave consent were enrolled in the study.~Intervention : Administration of 100mL of 20% Lipid emulsion to all patients in the study group"
2401161|NCT03564574|No Intervention|Historic controls|The control arm The study group was compared with data of patients admitted for OP poisoning between the years 2013 and 2014 ( 2 calendar years), fulfilling the inclusion and exclusion criteria as stated above.
2401162|NCT03564548|Experimental|PPP001|Inhaled cannabinoids (PPP001)
2401163|NCT03564548|Active Comparator|Morphine sulfate or Hydromorphone or Oxycodone|Oral morphine sulfate or hydromorphone or oxycodone at the previous stabilized dosage
2401164|NCT03564535|Experimental|SELF FIXATING GROUP|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
2401165|NCT03564535|Active Comparator|TACKER FIXATION GROUP|Patients will be undergoing mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
2401166|NCT03564522||Pulmonary Hypertension|Participants diagnosed with pulmonary hypertension that will undergo a clinically indicated cardiac catheterization and cMRI.
2401167|NCT03564522||Heart Transplant|Successful cardiac transplant recipient without evidence of pulmonary hypertension, that will undergo clinically indicated cardiac catheterization.
2401168|NCT03564509|Experimental|FE 999302 (dose 1) and follitropin delta|
2401169|NCT03564509|Experimental|FE 999302 (dose 2) and follitropin delta|
2401170|NCT03564509|Experimental|FE 999302 (dose 3) and follitropin delta|
2401171|NCT03564509|Experimental|FE 999302 (dose 4) and follitropin delta|
2401172|NCT03564509|Experimental|FE 999302 (dose 5) and follitropin delta|
2401173|NCT03564509|Placebo Comparator|Placebo and follitropin delta|
2401174|NCT03564496|Active Comparator|Healthy Controls|20 Healthy Controls
2401175|NCT03564496|Experimental|MS Patients|40 individuals diagnosed with MS recruited from the MS Center/ Neurology Department at NYULMC
2401176|NCT03564483||Registry Observational Study|All women presenting for evaluation of Extramammary Paget's Disease (EMPD) at Mayo Clinic in Rochester MN.
2401177|NCT03564470|Experimental|Chidamide|Chidamide will be added to chidamide arm Ph-like ALL(CRLF2 high-expression, CRLF2/EPO/JAK2 rearrangement, JAK/IL-7R/SH2B3 mutation, etc).
2401178|NCT03564470|Experimental|Dasatinib|Dasatinib at a dose of 100mg/day will be added to Dasatinib arm of Ph-like ALL (CRKL high-expression, ABL1 or ABL2 or CSFR1 or PRGFRB rearrangement, etc).
2401179|NCT03564457||One group of 20.000 patients|No interventions will take place as this is an observational study
3189096|NCT00774228|Active Comparator|Oasis 24 hour Soft Shield Collagen Corneal Shield|Oasis shield application
3189097|NCT00774241|Experimental|1|
2401182|NCT03564431||controls|
2401183|NCT03564431||T2DM patients|
2401184|NCT03564431||depression patients|
2401185|NCT03564431||T2DM with depression patients|
2401186|NCT03564418|Active Comparator|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points. Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.
2401187|NCT03564418|Active Comparator|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.
2401188|NCT03564405|Experimental|UNI-DEB|
2401189|NCT03564392|Experimental|Treatment|Ten weekly modules will be delivered through an e-learning platform (i.e., Coursesites). Each module includes a video presentation of material synchronized with a slideshow illustrating session material with interactive features, and directed assignments to be completed throughout the week. At the end of every two weeks, a brief (i.e., 20 min) telephone call with a member of the study team will be scheduled to discuss and clarify the content of the session, discuss how the participant utilized skills demonstrated in the session, problem-solve difficulties in utilizing the skills, and review homework. Participants will be required to weigh themselves weekly (data will be transferred wirelessly to the laboratory) and feedback regarding weight losses will be provided during the phone call. The interventionist will provide individualized feedback on food records via email.
2401190|NCT03564392|No Intervention|Wait List Control|The Wait-List Control (WLC) condition does not receive any intervention during the study period. They receive the intervention after completing the study.
2401191|NCT03564379|Experimental|Part 1: Single Dose Part|Participants will receive a single oral dose of 25 mg JNJ-42165279 or placebo tablet under fasted condition in the morning on Day 1.
2401201|NCT03564314|Experimental|SUPPORT AKI Clinical Decision Support|Multidimensional clinical decision support intervention consisting of education and tools to support early recognition and management of AKI, including guidance on fluid therapies, medication management, investigation, and consultation with specialists.
2401202|NCT03564314|No Intervention|Control|Usual care provided to patients with AKI on surgical units.
2401203|NCT03564301|Active Comparator|Metronidazole 250mg|Systemic antibiotic: Metronidazole 250mg , 2 capsules three times a day, for 7 days.
2401204|NCT03564301|Placebo Comparator|Placebo|Placebo: same shape, size and dosis as test
2401205|NCT03564288|Experimental|Dose Escalation Cohort|To identify the recommended phase 2 dose (RP2D) of SKI-G-801 in patients with relapsed or refractory AML (Acute Myeloid Leukemia)
2401206|NCT03564275|Experimental|Prospective Treatment Group|Proton Boost
2401207|NCT03564275|No Intervention|Retrospective Comparison Group|Retrospective patients previously treated with standard of care photon therapy. There is no patient interaction with this group. Data collection from medical records only.
2401208|NCT03564262|Experimental|Cerebrovascular Reactivity|"Cerebrovascular reactivity (CVR) will be assessed using transcranial Doppler ultrasound with carbon dioxide as the vasoactive stimuli.~The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. The CVR test will be performed prior to soup consumption as well as after soup consumption."
2401209|NCT03564262|Experimental|Blood Pressure Reactivity|Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
2401210|NCT03564249|Experimental|Group 1 Young patients with constipation|25 young patients that present at secondary or tertiary care with intractable constipation. They will undergo the new MRI gastrointestinal transit test (MiniCap) once before standard treatment for constipation and once after the treatment.
2401211|NCT03564249|Experimental|Group 2 Healthy participants|25 young healthy controls matched for gender. They will undergo the new MRI gastrointestinal transit test (MiniCap) once.
2401212|NCT03564236|Active Comparator|Standard Care|"Standard care is provided according to our local COPD exacerbation protocol. All patients are treated with:~oral prednisolone 40 mg/day for 5 days;~antibiotics prescribed according to the following criteria: fever (body temperature > 38.5 degrees Celsius), elevated C-reactive protein (CRP) >50, change in sputum colour, and/or according to the physician's decision of severe illness, and/or in all patients with a FEV1 <30% of predicted;~high dose inhaled corticosteroids, beta-agonists and or anticholinergics.~Oxygen will be prescribed in all patients through a standard low flow system in order to maintain an adequate arterial oxygen saturation (Sa,O2) Patients will be discharged with regular low flow oxygen once they fulfil the criteria for long-term oxygen therapy."
2401213|NCT03564236|Experimental|Nasal High Flow Therapy|"In addition to the standard care described above, patients in the intervention group will be treated with:~nHFT, set at 30-50 L/min flow with oxygen to achieve an adequate oxygen saturation. nHFT is prescribed for at least 6 hours, but patients are stimulated to use the device as much as possible during the hospital stay.~During periods without HFT through a standard low flow system, to maintain an adequate arterial oxygen saturation (Sa,O2) (between 90-92% if patients are concomitantly hypercapnic, and between 90-95% if patients are normocapnic). Flow rates are titrated accordingly.~After discharge patients in the nHFT arm will continue the prescribed therapy at home for 90 subsequent days."
2401214|NCT03564223||Parents/Guardians|"Parents/Guardians aged over 18, attending Great Ormond Street Hospital Outpatients.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
2401215|NCT03564223||Paediatricians|"Paediatricians working at Great Ormond Street Hospital NHS Foundation Trust.~Intervention: Administer questionnaire to review and decide on significance of each of 30 child health concerns"
2401216|NCT03564210|Active Comparator|Screen time permitted|Concussion sufferers permitted screen time for first 48 hours of recovery
2401217|NCT03564210|Active Comparator|Screen time abstain|Concussion sufferers asked to abstain from screen time for first 48 hours of recovery
2401218|NCT03564197|Other|Nivolumab|nivolumab containing treatment according to label
2401219|NCT03564184|Experimental|MT during and after NICU|Consists of music therapy during NICU hospitalization, and music therapy after discharge from initial NICU hospitalization, along with standard care.
2401220|NCT03564184|Experimental|MT during NICU|Consists of music therapy during NICU hospitalization, along with standard care.
2401221|NCT03564184|Experimental|MT after NICU|Consists of music therapy after discharge from initial NICU hospitalization, along with standard care.
2401222|NCT03564184|Experimental|No MT|Consists of standard care.
2401223|NCT03564171|No Intervention|Standard of Care|Patients will receive standard treatment without added intervention.
2401224|NCT03564171|Experimental|Intervention|"These patients will receive standard treatment plus multimodal intervention (prehabilitation program) including :~exercise, nutritional counseling, stress counseling, smoking cessation) before starting chemotherapy."
2401225|NCT03564158|Experimental|meropenem 2 g- vaborbactam 2 g|Approved Dose
2401226|NCT03564158|Experimental|meropenem-vaborbactam (dose TBD)|Supratherapeutic Dose
2401227|NCT03564158|Active Comparator|Moxifloxacin 400 mg|Active Control
2401228|NCT03564158|Placebo Comparator|Normal Saline (placebo)|Placebo
2401230|NCT03564132|Experimental|Yigansan|2.5g of Yigansan granules by mouth, three times a day for 4 weeks
2401231|NCT03564132|Placebo Comparator|Placebo|2.5g of Placebo(contained one-tenth Yigansan) granules by mouth, three times a day for 4 weeks
2401234|NCT03564106|Experimental|group A|receive intraarticular radiofrequency + methylprednisolone (30 mg)
2401235|NCT03564106|Experimental|group C|receive intraarticular methylprednisolone (30 mg)
2401236|NCT03564093|Experimental|Dexmedetomidine|1µg/kg intranasal dexmedetomidine
2401237|NCT03564093|Placebo Comparator|Placebo|0,01ml/kg intranasal 4,5% saline
2401238|NCT03564080|No Intervention|Control - PAD|This group of patients will complete the 'standard care' of supervised exercise as recommended by NICE.
2401240|NCT03564067|Other|tDCS + cCBT|After baseline assessments are complete, participants will be provided with a tDCS device (Soterix Medical tDCS mini-Clinical Trials system (mini-CT)), which is deactivated until a code is provided by the research staff. Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
2401241|NCT03564054|Experimental|Photodynamic Therapy|Photodynamic therapy (PDT) uses activation of a photosensitizer by light of a specific wavelength to generate reactive oxygen species and singlet oxygen that causes direct cell damage and death, apoptosis, tumor vasculature damage and thrombosis, and inflammation leading to an immunological response.Following randomization, subjects will undergo treatment with either PDT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment
2401242|NCT03564054|Experimental|Argon Plasma Coagulation|Argon plasma coagulation (APC) is a noncontact form of electrocautery. Following randomization, subjects will undergo treatment with either DPT or APC. Subjects will then have six additional study visits at 30, 45, 60, 90, and 180 days after their last PDT or APC treatment.
2401243|NCT03564041|Experimental|Sahaj Samadhi Meditation (SSM)|SSM will be taught to participants over 4 consecutive days, for 2 hours each day. Participants will initially learn about the nature of meditation and will be taken through a guided meditation. Afterwards, participants will undergo training which includes understanding the nature of the mind and the thoughts arising from it, guided meditation by the instructor, and a discussion of what is correct and incorrect meditation. Follow-ups will be conducted once every week for the following 11 weeks, each including guided meditation. Participants will be encouraged to practice the meditation at home for 20 minutes per session and will be given weekly practice logs to complete.
2401244|NCT03564041|Other|Health Enhancement Program (HEP)|"Arm type: Active control group~HEP controls for several non-specific factors found in a meditation group such as Sahaj Samadhi, including: group support and morale, behavioral activation, reduction of stigma, facilitator attention, treatment duration, and time spent on at-home practice. HEP has been tailored to be structurally equivalent to a SSM intervention, with similar-sized groups, meeting for 4 days for 2 hours, and then a one-hour follow up session weekly for the subsequent 11 weeks, and completing the same amount of home practice (20 minutes twice daily, every day), and will be asked to complete weekly practice logs."
2401245|NCT03564028|Experimental|energy conservation technique|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
2401246|NCT03564028|Other|Control session|Patients will perform one session of stair climbing of 108 steps (corresponding to 6 floors).
2401247|NCT03564015|Experimental|Smartphone app|The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
2401248|NCT03564015|Active Comparator|Paper handout|The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.
2401249|NCT03564002||obese subjects|
2401250|NCT03564002||lean subjects|
2401251|NCT03563989|Experimental|Stentys Xposition S Self-Apposing stent|STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System
2401252|NCT03563989|Active Comparator|Conventional Balloon-expandable stent|Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.
2401253|NCT03563963|Active Comparator|Lidocaine 2% in Endotracheal Tube cuff|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
2401254|NCT03563963|Experimental|Ropivacaine 0.5% Endotracheal Tube cuff|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
2401255|NCT03563963|Active Comparator|Air in the Endotracheal Tube cuff|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
2401256|NCT03563950|Experimental|Rifampin + BMS-986224|Oral administration
2401257|NCT03563937||Phenprocoumon|Patients with NVAF who initiated the treatment of Phenprocoumon.
2401258|NCT03563937||Apixaban|Patients with NVAF who initiated the treatment of Apixaban.
2401259|NCT03563937||Rivaroxaban (Xarelto, BAY59-7939)|Patients with NVAF who initiated the treatment of Rivaroxaban.
2401260|NCT03563937||Edoxaban|Patients with NVAF who initiated the treatment of Edoxaban.
2401261|NCT03563924||Historical cohort|Patients with venous thromboembolism and cancer who follow traditional management of venous thromboembolism
2401262|NCT03563924||AlloTC cohort|"Patients with venous thromboembolism and cancer who follow AlloTC specific management. AlloTC specific care path way develop a personalized care plan (PPS) and ensure the transmission of data (to all the interlocutors: patients and caregivers) at each step of the patient care path."
2401263|NCT03563911|Experimental|Brief Mindfulness-Based Intervention|Those assigned to the Brief Mindfulness-Based Intervention (BMBI) Arm will receive BMBI.
2401264|NCT03563911|Active Comparator|Control/Nutrition Education|Those assigned to the Control/Nutrition Education Arm will receive the nutrition education intervention.
2401265|NCT03563885|Experimental|RYGB or SG|Baseline testing followed by subject's already scheduled RYGB or SG surgery, and then post-testing.
2401266|NCT03563885|No Intervention|Lean|Lean control subjects doing baseline testing only.
2401267|NCT03563872|Active Comparator|Active Comparator|Team-based care
2401268|NCT03563872|Experimental|Intervention|Enhanced team-based care
2401269|NCT03563846|Experimental|RP-G28 administered in the fasted state|RP-G28, 15 g dissolved in water, administered in the fasted state
2401270|NCT03563846|Experimental|RP-G28 administered in the fed state|RP-G28, 15 g dissolved in water, administered immediately following the consumption of a standard non-dairy meal
2401271|NCT03563833|Other|Minimal Flow Anesthesia|"Minimal Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5). In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
2401272|NCT03563833|Other|High Flow Anesthesia|"High Flow Anesthesia (50% O2, 50% air), Desflurane (MAC = 4,5) In hypotensive anesthesia application; Remifentanil will be used at infusion rates of 0.025-0.1μg / kg / min after a loading dose of 1 μg / kg / min, with mean Arterial Pressure 55-65 mmHg.~Before the induction of anesthesia and 30 minutes of anesthesia, 2 ml of venous blood sample will be taken from the patients and simultaneous tissue oxygen saturation will be recorded. Serum thiol disulfide levels obtained from the blood sample of the recipient will be studied in the biochemistry research laboratory using the method developed by Erel et al."
2401273|NCT03563807|Experimental|Golf|Group golf lessons will be led by professional golf instructors.
2401274|NCT03563807|Active Comparator|Tai Chi|Group Tai Chi classes led by a certified Tai Chi instructor.
2401275|NCT03563794|Experimental|CSII(insulin Lispro)+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
2401276|NCT03563794|Active Comparator|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
2401277|NCT03563781|Other|SENTINEL NODE|Patients with ovarian cancer will receive sentinel node identification and they will be then submitted to complete pelvic and para-aortic lymphadenectomy (as per the present guidelines)
2401278|NCT03563768|Experimental|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
2401279|NCT03563768|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
2401280|NCT03563755|Experimental|Cognitive Bias Modification (CBM) + Treatment as usual|Participants will receive access to a 3-week online training programme alongside their usual treatment.
2401281|NCT03563755|No Intervention|Treatment as usual|Participants will continue to receive their usual treatment.
2401282|NCT03563742|Experimental|Treatment: Rilpivirine+Combination Therapy (TDF/3TC)|The participants will receive antiretroviral treatment of rilpivirine 25 milligram (mg) tablet orally once daily from Day 1 for 48 weeks with a meal to improve absorption. The participants will also receive background combination therapy of 1 tablet orally once daily containing 300 mg tenofovir disoproxil fumarate (TDF) and 300 mg lamivudine (3TC).
2401283|NCT03563729|Experimental|B: Pembrolizumab (Prednisolone >10 mg)|Intravenous infusion of pembrolizumab 2 mg/kg every third week for up to two years.
2401284|NCT03563729|Experimental|C: Ipilimumab/nivolumab (Prednisolone 11-25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
2401285|NCT03563729|Experimental|D: Ipilimumab/nivolumab (Prednisolone >25 mg)|Intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
2401286|NCT03563729|Experimental|E: BRAF/MEK -> ipi/nivo (prednisolone >10 mg)|Induction treatment with BRAF/MEK inhibitors (either the combination of encorafenib/binimetinib or dabrafenib/trametinib) orally for 28 days followed by intravenous infusion of ipilimumab 3 mg/kg and nivolumab 1 mg/kg four times every three weeks in the induction phase and nivolumab 480 mg every four weeks in the maintenance phase for up to two years.
3143922|NCT00022776|Experimental|2|Participants will undergo physical therapy for spinal stenosis. These participants will undergo a physical therapy program emphasizing lumbar flexion exercises, general conditioning exercises, and patient education for six weeks, with a frequency of 1-2 visits per week. Each patient will receive instruction in a home exercise program.
3143923|NCT00022854|Placebo Comparator|1|
2401289|NCT03563703|Experimental|Ultrasound imaging|Ultrasonography offers visual information about the size and depth of blood vessels, potentially facilitating intravenous placement of the needle in real time.
2401290|NCT03563703|Experimental|Near-infrared imaging|Near-infrared imaging devices project near-infrared light onto the skin, which is absorbed by deoxygenated hemoglobin. The invisible image of the underlying vascular pattern is captured by the device, processed and projected, in real time, back onto the patient's skin using visible green light. This technology allows hands-free visualization of a vascular map to guide catheter placement.
2401291|NCT03563690|Experimental|Acupuncture group|When recruited from six centers,the participant will be randomized to six groups .In acupuncture group participant will receive four-week acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2401292|NCT03563690|Experimental|Electro-acupuncture group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week electro-acupuncture treatment(three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
3143924|NCT00022854|Experimental|2|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
2401293|NCT03563690|Experimental|Moxibustion group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week moxibustion treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2401294|NCT03563690|Experimental|Warm-needling group|When recruited from six centers,the participant will be randomized to six groups. In this group participant receive four-week warm-needling treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2401295|NCT03563690|Sham Comparator|Sham-needle group|When recruited from six centers,the participant will be randomized to six groups.In this group participant receive four-week sham acupuncture treatment (three times a week )continuously for 4 weeks,12 treatments in total. The follow-up period is six months.
2401296|NCT03563690|Active Comparator|Celebrex group|When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
2401297|NCT03563677|No Intervention|Usual care|Standard evaluation process for patients approaching a center for rare diseases with an unclear diagnosis. The process includes the evaluation of complete medical records byan experienced physician, an outpatient visit to the center, and case discussion between experts. The process may also include an inpatient stay, a local case conference and a case conference between centers for rare diseases from different cities
2401298|NCT03563677|Experimental|New Innovative Care|The innovative evaluation process includes the additional involvement of a psychiatrists/psychosomatic expert in all of the processes described for the usual care arm plus the option to use telemedicine in the process of evaluation in addition to outpatient and inpatient visits and to transfer the patient back into standard care (i.e., primary care physician, rehabilitation, psychological/psychosomatic specialized care, etc.)
2401299|NCT03563664|Experimental|Study group|38 ovulatory patients with unexplained recurrent implantation failure were recruited. Pre-treatment endometrial biopsy and immunohistochemical examination for endometrial αvβ3 integrin expression (using immunohistochemically stained endometrial biopsy) was done. After treatment with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks, post-treatment endometrial biopsy and immunohistochemical examination was repeated and compared with previous results.
3143925|NCT00022854|Experimental|3|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous levobupivacaine infusion of 5 mL/hr for 50 hr
2401301|NCT03563638||GDM group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study,and excluded if they had multiple pregnancy, pre-gestational diabetes mellitus, hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness,and fetal abnormalities occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
2401302|NCT03563638||NGT group|Women with maternal age ≥ 18 years, singleton pregnancy, primipara, no smoking, confirmed gestation≤20 weeks and spontaneous conception were invited to participate in the study. Women were excluded if they had multiple pregnancy, pre-gestational diabetes mellitus (PGDM), hypertensive disorders, preterm delivery, cardiovascular disease, immunological disease, glucocorticoid therapy, or other severe illness. if there were fetal abnormalities including chromosomally abnormal fetuses and/or structural defects and fetal growth restriction occurred during pregnancy were also excluded from the study.GDM was verified on the 75gOGTT at 24-28 gestational weeks.those who not met the criteria were the NCT group.
2401303|NCT03563625|Active Comparator|Caudal block|Caudal block with 1mg/kg bupivacaine 0.25%.
2401304|NCT03563625|Active Comparator|Wound infiltration|Local wound infiltration with 1mg/kg bupivacaine 0.25%.
2401305|NCT03563612|Active Comparator|cpap first, differential ventilation later|
2401306|NCT03563612|Active Comparator|differential ventilation first, cpap late|
2401307|NCT03563599|Experimental|Telacebec (Q203) tablet|
2401308|NCT03563599|Active Comparator|Rifafour e-275|
2401309|NCT03563586|Active Comparator|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
2401310|NCT03563586|Other|Bowel Preparation|Preoperative mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
2401311|NCT03563573|Active Comparator|Lidocaine-effective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is effective
2401312|NCT03563573|Placebo Comparator|Lidocaine-effective ADHD: Placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is effective
2401313|NCT03563573|Active Comparator|Lidocaine-ineffective ADHD: Intervention|Single-dose potassium gluconate oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
2401314|NCT03563573|Placebo Comparator|Lidocaine-ineffective ADHD: placebo|Single-dose placebo oral capsule intervention for ADHD subjects for whom lidocaine is ineffective
2401315|NCT03563560|Experimental|ACM regimen|ACM regimen is for Japanese patients with relapsed or refractory AML.
2401316|NCT03563560|Experimental|A+7+3 regimen|A+7+3 regimen is for Japanese newly diagnosed AML patients.
2401317|NCT03563547|Active Comparator|Fat modified diet|Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
2401413|NCT03562871|Active Comparator|Cohort B2|Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
3143926|NCT00022971|Experimental|1|Apolizumab followed by rituixmab every 4 weeks
2401318|NCT03563547|Experimental|Fat modifed diet enriched with soy protein|"Subjects in this arm had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects in this arm were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
2401319|NCT03563534|Active Comparator|silver diamine fluoride|38% silver diamine fluoride applied to cavitated primary molars twice per week to arrest caries
2401320|NCT03563534|Active Comparator|interim restorative therapy|Resin modified glass ionomer applied to cavitated primary molars
2401321|NCT03563521||Atopic, eosinophilic|
2401322|NCT03563521||Atopic, non-eosinophilic|
2401323|NCT03563521||Non-atopic, eosinophilic|
2401324|NCT03563521||Chronic rhinosinusitis with/without nasal polyposis|
2401325|NCT03563521||Non-atopic, non-eosinophilic|
2401326|NCT03563521||Control|Without asthma, atopy and eosinophilia
2401327|NCT03563508||CBCT of Egyptian subpopulation|Cone-beam computed tomography (CBCT) of a sample of Egyptian subpopulation containing maxillary premolars for image assessment.
2401328|NCT03563495|Active Comparator|tissue engineered group|autogenous bone marrow derived and cultured stem cells loaded on collagen matrix was implanted in the alveolar cleft in the study group (1st arm)
2401329|NCT03563495|Active Comparator|autogenous bone graft group|autogenous cortico-cancellous bone graft harvested from the anterior iliac crest was implanted in the alveolar cleft of the control group (2nd arm)
2401330|NCT03563482|Experimental|Experimental|Biopsy and PET scan
2401331|NCT03563456|Experimental|EXPERIMENT (EXP)|Subjects conduct the structured combined exercise in form of combination of High Intensity Interval Training and Resistance Training
2401332|NCT03563456|Active Comparator|CONTROL (KTR)|Subjects conduct structured exercise of cardiorespiratory training in form of lower-volume continuous cardiorespiratory exercise.
2401333|NCT03563443||Bladder cancer patients|Diagnosed bladder cancer patients who are being monitored will be the experimental group to develop the LOI panel, and subsequent cohort will be used to confirm the sensitivity and specificity of this urinary analysis.
2401334|NCT03563443||Non-cancer participants|Patients being treated for other diseases but without any tumor or healthy participants will provide a negative control to provide data for developing the LOI diagnostic panel
2401335|NCT03563430|Experimental|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate.
2401336|NCT03563430|Experimental|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session.
2401337|NCT03563430|Experimental|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position.
3189099|NCT00774280|No Intervention|ArmI(BuCy)|"Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4~Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2"
3189100|NCT00774280|No Intervention|Arm II (BuFlu)|"Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.~Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2"
2401340|NCT03563404||Portal Blood Flush|participants that receive the portal blood flush
2401341|NCT03563404||No Portal Blood Flush|participants that don't receive the portal blood flush
2401342|NCT03563391|Experimental|Evaluation of a new infant formula|To evaluate the effects of a new formula on the growth, safety and tolerance of infants with growth failure
2401343|NCT03563378|Experimental|Lactated ringers solution|Participants in this group will receive Lactated Ringer's solution during the intraoperative period.
2401344|NCT03563378|Experimental|Normal saline solution|Participants in this group will receive Normal saline solution during the intraoperative period.
2401345|NCT03563365|Experimental|Replenix|Replenix power of 3 cream with Resveratrol applied twice daily
2401346|NCT03563365|Experimental|Replenix and Adapalene and Benzoyl Peroxide gel|Replenix power of 3 cream with Resveratrol applied twice daily and Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
2401347|NCT03563365|Active Comparator|Adapalene and Benzoyl Peroxide gel|Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5% applied once daily
2401348|NCT03563352||Observational (interview, survey)|Participants attend an interview over 15 minutes and complete surveys.
2401349|NCT03563339|Experimental|P-POD|All participants will complete the prevention for postpartum onset distress (P-POD)
2401350|NCT03563326|Experimental|CAR-T cell and chemotherapy|Biological: CAR-T cells targeting EpCAM Chemotherapy: determined by medical Oncologist
2401351|NCT03563326|Active Comparator|chemotherapy|Chemotherapy: determined by medical Oncologist
2401354|NCT03563300|Active Comparator|Wheat flour|Wheat flour will be administered blindly versus placebo for 7 days
2401355|NCT03563300|Placebo Comparator|Rice flour|Placebo will be administered blindly versus wheat flour for 7 days
2401356|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs before surgery|
2401357|NCT03563287|Experimental|Phenotyping cocktail of 9 CYP probe drugs 1 year after surgery|
2401358|NCT03563261|Active Comparator|Collagen supplement group|Participants assigned in the collagen supplement group will drink the active product every morning before breakfast.
2401359|NCT03563261|Placebo Comparator|Placebo supplement group|Participants assigned in the placebo supplement group will drink the placebo every morning before breakfast.
2401360|NCT03563248|Active Comparator|FOLFIRINOX: SBRT: Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
2401414|NCT03562858|Active Comparator|Delayed dentine sealing|
2401415|NCT03562858|Experimental|Immediate dentin sealing|
2401361|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Losartan:Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~All participants will undergo an attempt at definitive surgical resection following SBRT"
2401362|NCT03563248|Experimental|FOLFIRINOX+Losartan:SBRT+Nivolumab+Losartan:Sur|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~Losartan will be administered orally as a tablet to be taken by the patient at home every day~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
2401363|NCT03563248|Experimental|FOLFIRINOX x 8 : SBRT + Nivolumab : Surgery|"The FOLFIRINOX regimen will be administered intravenously. Treatment will be every 14 days +3/ -1 at physician discretion~SBRT should be administered 2-6 weeks after completing chemotherapy~Participants will receive nivolumab during SBRT~All participants will undergo an attempt at definitive surgical resection following SBRT"
2401364|NCT03563235|Experimental|Xulin Jiangu granules|Xulin Jiangu granule 15g tablet by mouth every 6 hour for 6 months
2401365|NCT03563235|Active Comparator|Calcitriol capsules|Calcitriol capsules tablets 0.25 ug by mouth every 6 hour for 6 months
2401366|NCT03563222|Experimental|Smoflipid|"Smoflipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of Smoflipid is 0.20 g/mL, and comprises a mixture of soybean oil, medium chain triglycerides, olive oil, and fish oil. Smoflipid is indicated as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.~The mean essential fatty acid content of Smoflipid is 35 mg/mL linoleic acid (omega-6) and 4.5 mg/mL α-linolenic acid (omega-3)."
2401367|NCT03563222|Active Comparator|Intralipid, 20%|Intralipid 20% is a sterile, non-pyrogenic fat emulsion intended as a source of calories and essential fatty acids. Intralipid 20% is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time and as a source of essential fatty acids for prevention of essential fatty acid deficiency. The major component fatty acids are linoleic acid, oleic acid, palmitic acid, α-linolenic acid and stearic acid.
2401368|NCT03563196||Chest Radiograph|All the patients will undergo routine chest radiogram on day 1 after operation
2401369|NCT03563196||Lung Ultrasound|The same patient will undergo ultrasound evaluation of lungs on day 1 after operation
3189101|NCT00774293|Experimental|1|Arnica 5CH and Bryonia 9CH (homeopathic drugs)
2401371|NCT03563170|Experimental|NANT Hepatocellular Carcinoma Vaccine|Phase 1b and 2: The following combination of agents will be administered to subjects assigned to this treatment: Aldoxorubicin HCl, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, N-803, haNK™, avelumab, capecitabine, cetuximab, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, sorafenib tosylate, SBRT.
2401372|NCT03563170|Active Comparator|Sorafenib Monotherapy|Phase 2: Sorafenib monotherapy will be administered to subjects with advanced, unresectable, and untransplantable HCC, who have not previously received sorafenib, and who are randomly assigned to receive SOC treatment.
2401373|NCT03563157|Experimental|NANT Colorectal Cancer (CRC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCI, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT.
2401374|NCT03563157|Active Comparator|Regorafenib|In subjects with metastatic CRC who have been previously treated with standard-of-care (SOC) therapy.
2401375|NCT03563144|Experimental|NANT Pancreatic Cancer Vaccine|"in subjects with ECOG=2 or subjects with ECOG=0 or 1~A combination of agents will be administered to subjects in this study:~cyclophosphamide, bevacizumab, oxaliplatin, capecitabine, 5-fluorouracil, leucovorin, nab-paclitaxel, aldoxorubicin HCl, avelumab, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-021, ETBX-051, ETBX-061."
2401376|NCT03563144|Active Comparator|Gemcitabine and Nab-paclitaxel|Gemcitabine plus Nab-paclitaxel will be administered to subjects with ECOG=2
2401377|NCT03563144|Active Comparator|Gemcitabine|Gemcitabine will be administered to subjects with ECOG=0 or 1
2401378|NCT03563131|Active Comparator|Uncemented Persona® total knee arthroplasty|Uncemented TM Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
2401379|NCT03563131|Active Comparator|Cemented Persona® total knee arthroplasty|Cemented Zimmer Persona® TKA. It is a relatively new implant that is now in routine clinical use. Implants are approved by FDA and CE marked. Patella will be resurfaced with the cemented Zimmer 3-Peg All Polyethylene Patella.
2401380|NCT03563118||Group OSAS|We included 56 with OSAS [13 subjects 23.2% mild, 19 subjects 33.9% moderate, 24 subjects 42.8% severe
2401381|NCT03563118||control group|simple snoring
2401382|NCT03563105|Experimental|Desaturation|Vascular Occlusion Test
2401383|NCT03563092|Experimental|Lap Inguinal Hernia repair with Drain|A (14 French sizes) closed suction drain will be placed in preperitoneal space after laparoscopic inguinal hernia (TEP/TAPP) surgery.
2401384|NCT03563092|Active Comparator|Lap Inguinal Hernia repair without Drain|No drain will be placed after laparoscopic inguinal hernia (TEP/TAPP) surgery.
2401385|NCT03563079|Experimental|trial group|The treatment will be performed using two pieces of Instrument Assisted Soft Tissue Mobilization (IASTM) stainless steel in the neck, bilaterally, which comprise the following muscles: Upper Trapezius, Splenius, scalenes and Sternocleidomastoid. An established time of 3 minutes will be used in each region, using an angle of 30 to 60º with the instrument. As it is observed, through the instrument, regions of greater adhesion, the researcher will use most of this time to release this condition.
3143928|NCT00023205|Experimental|Individualized education|Individualized education with materials written in plain language. Follow-up sessions/ phone contact as requested by the subject.
3189102|NCT00774293|Placebo Comparator|2|placebo Arnica 5CH and Bryonia 9CH
2401386|NCT03563079|Active Comparator|group control|Treatment will be performed using manual Myofascial Release techniques. Release the upper Trapezius muscle bilaterally, sliding using roller with the dorsum of the fingers and ending with myofascial release. Sternocleidomastoid, sliding using roller with the dorsum of the fingers, ending with myofascial release. Afterwards the release of the scalenes muscles will be performed, with the fingers sliding and ending with the myofascial release. Soon afterwards techniques will be performed for the Splenius muscles, using finger slips and ending with posterior cervicothoracic release. The same time of 3 min will be used for the treatment bilaterally in each region.
3143929|NCT00023205|Active Comparator|Standard care|1 session of education with provision of standard Arthritis Foundation materials.
3143930|NCT00023231|Experimental|1|Participants will receive immunosuppression therapy using antibody induction (daclizumab), corticosteroids, mycophenolate mofetil, and sirolimus prior to transplantation. Bactrim and ganciclovir will be taken for infection prophylaxis. If the participant has consistent high levels of fasting cholesterol, treatment with lipitor may be given.
2401389|NCT03563053|Experimental|active drug|~14-22 mg dexamethasone sodium phosphate (DSP)
2401390|NCT03563040|Experimental|Methoxsalen with the THERAKOS CELLEX Photopheresis System|Treatment will be performed according to a predefined protocol based on the consensus guidelines in patients with MF/SS. Treatment should be administered for one year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
3189103|NCT00774319|Active Comparator|1|Induction Chemotherapy with TPF Then: cisplatin 100 mg/m2 on day 1, 22 and 43 combined with conventional radiotherapy
3189104|NCT00774319|Active Comparator|2|Induction chemotherapy with TPF Then cisplatin 40mg/m2 on day 1,8,15,22,29 and 35 combined with accelerated radiotherapy
2401394|NCT03563014||Radium-223 (Xofigo, Bay88-8223)|Belgium patients with a diagnosis of mCRPC (no known visceral metastases) and who were treated with Radium-223 for this indication
2401395|NCT03563001|Experimental|Chronic Obstructive Pulmonary Disease Group|Patients with diagnosis of chronic obstructive pulmonary disease according to Global Initiative for Chronic Obstructive Disease(GOLD 2018) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
2401396|NCT03563001|Experimental|Asthma-Chronic Obstructive Pulmonary Disease Overlap Group|Patients with diagnosis of asthma-chronic obstructive pulmonary disease overlap according to Global Initiative for Chronic Obstructive Disease(GOLD 2018),Global Initiative for Asthma(GINA 2018) and Spanish COPD Guidelines(GesEPOC 2017) are recruited.Small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months' treatment.
2401399|NCT03562962|Other|Functional Analytic Psychotherapy|"Within the baseline (A), Supportive Listening (SL) will be provided, which has been widely utilized in randomized control trials (Cuijpers et al., 2012), including the only Randomized Control Trial (RCT) conducted in FAP (Maitland & Gaynor, 2016), as a control condition. SL is defined as a psychological treatment in which therapists do not engage in any therapeutic strategies other than active listening and offering support, focusing on participants' problems and concerns (Cuijpers et al., 2012, p. 281). In this therapy, the therapist reflects on clients' experiences and encourage them to share emotional experiences. Therapists are prohibited from giving advice, making interpretations, and providing feedback to clients (Cuijpers et al., 2012).~FAP will be introduced at phase B, where contingent reinforcement will be administered for increasing clients' alternative behaviors (CRB2) and differential reinforcement will be utilized to reduce clients' problem behaviors (CRB1)."
2401400|NCT03562949|Experimental|Test Product|Test Product, 40 mcg, 2 x daily
2401401|NCT03562949|Active Comparator|Reference Product|Reference Product, 40 mcg, 2 x daily
2401402|NCT03562949|Placebo Comparator|Placebo|Placebo Product 2 x daily
2401403|NCT03562923|Experimental|Test Product|Test Product, 100/50 mcg, 2 x daily
2401404|NCT03562923|Active Comparator|Reference Product|Reference Product, 100/50 mcg, 2 x daily
2401405|NCT03562923|Placebo Comparator|Placebo|Placebo Product 2 x daily
2401406|NCT03562910|Experimental|Intervention|All enrolled subjects will be given access to the HelpSteps application, either via their personal cell phone or to a provided tablet.
3143931|NCT00023244|Experimental|Corticosteroid (steroid) withdrawal|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will undergo complete steroid withdrawal by the end of 12 months post-transplant.
2401408|NCT03562884|Experimental|BLI800|BLI800 given orally as a split-dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m.- 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
2401409|NCT03562884|Active Comparator|Fortrans®|Fortrans® given orally as a split dose: 1st dose the evening before colonoscopy (e.g. at 6:00 p.m - 8:00 p.m.) and 2nd dose on the morning of colonoscopy, 10 to 12 hours after the evening dose (e.g. at 5:00 a.m.-7:00 a.m.)
2401410|NCT03562871|Experimental|Cohort A1|Drug: IO102 100µg administered subcutaneously (SC) on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg intravenous (IV) infusion on Day 1 of each 3 week cycle
2401411|NCT03562871|Active Comparator|Cohort A2|Drug: pembrolizumab (Keytruda) 200 mg IV infusion on Day 1 of each 3 week cycle
2401412|NCT03562871|Experimental|Cohort B1|Drug: IO102 100µg SC on Day 1 of each 3 week cycle PLUS Drug: pembrolizumab (Keytruda) 200 mg IV on Day 1 of each 3 week cycle PLUS Drug: carboplatin (Carboplatin Kabi) at a target AUC of 5 mg/mL IV infusion on Day 1 of each 3 week cycle for a max of 4 administrations PLUS Drug: pemetrexed (Pemetrexed Alvogen) at 500 mg/m2 IV infusion on Day 1 of each 3 week cycle
2401446|NCT03562624|Experimental|BAY98-7443 (low IND dose)|Combi IUS Treatment, LNG (Levonorgestrel) with lowest dose of IND (indomethacin)
2401416|NCT03562845||ARM 1-Bad vs Good Clinical Evolution|"This arm is intended to evaluate the correlation of Immunobiogram® sensitivity/resistance patterns with clinical prognosis as it may be judged at this moment considering clinical outcomes and immune-biomarker evolution in the past 12 to 18 months. Thus, it may confirm the BH-Pilot study findings. Renal transplant patients of two types will be included:~Patients who, over previous months, have had a bad clinical evolution, in which rejection mechanisms were involved~Patients with a good and stable clinical evolution~IMBG sensitivity/resistance profiles will be compared amongst the two groups to evaluate the differences."
2401417|NCT03562845||ARM 2-Stable Renal Transplant Patients|This arm is intended to evaluate robustness of Immunobiogram® as an IVD test. Thus, it will be performed intrasubject comparisons and inter-time evaluation of two sets of Immunobiogram® separated by 30+/- 10 days, each including three IMBG determinations (IMBGx3 - IMBGx3, the two sets separated by 30+/- 10 days). The intended evaluation will be to analyse the similarities between all IMBG tests performed, both between the same set and also between the two sets planned.
2401418|NCT03562832|Experimental|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
2401419|NCT03562819||NSCLC|Non-small cell lung cancer
2401420|NCT03562806|Experimental|PET/MR (single arm)|PET and MR sequence acquisition on SIGNA PET/MR device
2401421|NCT03562793|Experimental|COOPERATE Intervention Arm|Intervention patients will focus on 1) goal clarification/prioritization; 2) communication skills. There are 6 total sessions delivered individually over 12 weeks: 4 sessions teaching skills (30 min each) and 2 booster sessions delivered once/month for the next 2 months. Intervention will be delivered by telephone.
2401422|NCT03562793|No Intervention|Attention Control Arm|Veterans randomized to the control group will receive phone calls on the same schedule as intervention Veterans. During these phone calls, study staff will ask Veterans a series of questions about their pain, self-management activities, and any changes they have experienced since the last call. These phone calls are designed to control for attention only, and Veterans will not be offered specific information or advice about their pain or its management (with the exception of suggesting a doctor visit if warranted).
2401423|NCT03562780|Experimental|Fortolin Tab 500mg|During the study session, healthy subjects will be administered a single oral dose of Fortolin Tab 500mg after an overnight fast of approximately 10 hours.
2401424|NCT03562780|Active Comparator|Panadol Caplet 500mg|During the study session, healthy subjects will be administered a single oral dose of Panadol Caplet 500mg after an overnight fast of approximately 10 hours.
3184600|NCT00726440|Active Comparator|Group2-diabetologist|"The patient will follow the same educational process as group 1 concerning insulin dose adaptation. They will use the continous glucose monitoring device according to the diabetologist's prescription and they will receive precise instructions to make considering results. The duration of the use of the Navigator® will be increased if one of the following criteria is observed at the consultation each 3 months:~HbA1c>=7.5%~1 severe hypoglycaemia or more~More than 4 benign hypoglycaemia per week~According to these criteria, every 3 months, the duration of the use of the monitoring system will be increased as following:~step 1: 3 sensors per month~step 2: 4 sensors per month~step 3: 5 sensors per month~step 4: continuous use"
3184601|NCT00726440|Placebo Comparator|Group3-Control|Usual follow up with self-monitoring blood glucose.
2401428|NCT03562754|Active Comparator|Control|
2401429|NCT03562754|Experimental|Prometheus System|
2401430|NCT03562741|Experimental|Fecal Microbiota Transplantation|Subjects receive intervention of stool transplanted to the colon via colonoscopy.
2401435|NCT03562715||Control group|Blood samples were collected from 100 control with normal pregnancies. Thirty fresh umbilical cord samples of women with healthy pregnancies (n=15) were retrieved during caesarean deliveries and umibilical cord mesenchymal stem cells (UCMSCs) were isolated from Wharton jelly.
2401436|NCT03562715||Preeclampsia group|Blood samples were collected from 100 patients with PE. Thirty fresh umbilical cord samples of PE patients (n=15) were retrieved during caesarean deliveries and UCMSCs were isolated from Wharton jelly.
2401437|NCT03562702|Active Comparator|Standard IV Rehydration Therapy|Patients randomized into the IV rehydration group will receive a Normal Saline bolus of IVF (usually 20 mL/kg) which is the standard therapy up to 24 hrs or as needed depending on patient's weight
2401438|NCT03562702|Experimental|Oral Rehydration Therapy (ORT)|Patients randomized into the oral rehydration group will receive the oral Speedlyte product instead of the IV rehydration therapy.
2401439|NCT03562676|Experimental|weightlessness|
2401442|NCT03562650|Experimental|Safety Behavior Fading|Participants are asked to pick their three most common safety behaviors from a list and then receive texts every other day for a month reminding them to fade those behaviors.
2401443|NCT03562650|Active Comparator|Present Centered|Participants receive texts every other day for a month asking them to try to focus on the present that day.
2401447|NCT03562624|Experimental|BAY98-7443 (middle IND dose)|Combi IUS Treatment, LNG with medium dose of IND
2401448|NCT03562624|Experimental|BAY98-7443 (high IND dose)|Combi IUS Treatment, LNG with highest dose of IND
2401449|NCT03562624|Active Comparator|Marketed comparator|Marketed comparator IUS
2401450|NCT03562611|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
2401451|NCT03562611|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
2401452|NCT03562611|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
2401453|NCT03562585||Efficacy of immunoassay in liver fibrosis|efficacy of immunoassay in liver fibrosis in patients with CHB
2401454|NCT03562572|Experimental|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient.
2401455|NCT03562572|Active Comparator|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
3184602|NCT00726466|Experimental|I|This is an open-label, study of 0.5 mg intravitreal dose of Ranibizumab in combination with 1 mg/kg/wk subcutaneous dose of Efalizumab in in subjects with AMD.
2401457|NCT03562546|Experimental|Structured Resistance Exercise|12 week at home structured resistance exercise programme ('Strength From Within') using resistance bands. Under the supervision of an experienced exercise specialist.
2401458|NCT03562533||pegylated liposomal doxorubicin + carboplatin|carboplatin area under the curve [AUC] 5 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2 every 4 weeks
2401459|NCT03562533||paclitaxel + carboplatin|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks
2401460|NCT03562520|Experimental|Adolescents with bipolar disorder|Forty adolescents (aged 13-21) with BD (type I, II, or not otherwise specified/other specified and related disorder) will be enrolled in the behavior change counseling intervention.
2401461|NCT03562507|Experimental|ESK981 Monotherapy|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
2401462|NCT03562507|Experimental|ESK981 and Nivolumab|"ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles~Nivolumab: 480 mg/dose IV, Day 1 of each 28-day cycle"
2401463|NCT03562494|Experimental|VY-AADC02 (NBIb-1817)|Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
2401464|NCT03562494|Placebo Comparator|Sham (Placebo) Surgery|Sham surgical procedure
3184603|NCT00726492|Experimental|CSWD + Hydro|Continuous short wave diathermy and hydrotherapy
3184604|NCT00726492|Experimental|Hydro alone|Hydrotherapy alone
2401467|NCT03562468|Placebo Comparator|Placebo|Each subject will be randomly assigned to receive placebo for an 8-week treatment period. Subjects will be instructed to take two capsules (placebo) in the morning with breakfast and two capsules (placebo) in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2401468|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 300 mg/day|Each subject will be randomly assigned to receive 300 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2401469|NCT03562468|Experimental|TRU NIAGEN (nicotinamide riboside) 1000 mg/day|Each subject will be randomly assigned to receive 1000 mg/day of TRU NIAGEN (nicotinamide riboside) for an 8-week treatment period. Subjects will be instructed to take two capsules of TRU NIAGEN in the morning with breakfast and two capsules of TRU NIAGEN in the evening with dinner. At the end of each 8-week treatment period subjects will crossover to the next treatment group until all three treatment periods have been completed at 24 weeks.
2401470|NCT03562455|Experimental|Virtual Reality Training|Participants will receive virtual reality power wheelchair training using VRSim 3.0 in this group.
2401471|NCT03562455|Active Comparator|In-person Therapist Training|Participants will receive in-person wheelchair training by a therapist in this group.
2401472|NCT03562442|Experimental|Smokers|"Healthy caucasian smokers who are willing to quit smoking are investigated before cessation (Visit 1) and 6 weeks after cessation (Visit 2).~Intervention: Smoking cessation"
2401473|NCT03562442|No Intervention|Never-Smokers|Healthy caucasian volunteers who never smoked are investigated once only (Visit 1)
2401474|NCT03562429|Experimental|TGF group (study group)|Use TGF to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
2401475|NCT03562429|Placebo Comparator|TGFP group (placebo group)|Use TGFP to treat osteoarthritis of the knee, 5g/time, 3 times a day, for 12 weeks.
2401476|NCT03562416|Experimental|Nintedanib|Nintedanib 150 mg tablet by mouth twice daily for 24 months.
2401477|NCT03562416|Placebo Comparator|Placebo|Placebo tablet by mouth twice daily for 24 months
2401478|NCT03562403|Experimental|DBS on patients with abnormal movement disorders|16 patients with intractable abnormal movement disorders (Parkinson's disease, Essential tremors and Dystonia)
2401508|NCT03562169|Experimental|Augmented Autologous Stem Cell Transplant (ASCT)|Melphalan 100mg/m2 IV infusion on Day -3 and -2 plus ixazomib 4mg capsules on Day -4 and -1. ASCT will then be given on Day 0.
3184605|NCT00726492|Experimental|CSWD alone|Continuous short wave diathermy alone
3184606|NCT00726492|No Intervention|Control|No treatment
3184607|NCT00726505|Active Comparator|Group 1|Subjects with T2DM - Dapagliflozin 5 mg
3184608|NCT00726505|Active Comparator|Group 2|Subjects with T2DM - Dapagliflozin 20 mg
2401479|NCT03562390|Experimental|Experimental group|124 women with locally recurrent or metastatic breast cancer who will receive treatment at 17 research centers in Liaoning Province and Heilongjiang Province of China. Irinotecan is administered intravenously on days 1 and 8 of each 3-week cycle.
3184609|NCT00726505|Active Comparator|Group 3|Healthy Subjects - Dapagliflozin 20 mg
2401482|NCT03562364|No Intervention|Standard of Care|The standard of care group will remain non-weight bearing for 10-12 weeks following definitive fixation and receive physical therapy in accordance with standard practice at the treating center.
2401483|NCT03562364|Experimental|Early Advanced Weight Bearing (EAWB)|The Early Advanced Weight Bearing (EAWB) group will receive early weight-bearing treatment using the antigravity AlterG treadmill. These sessions will begin 14-28 days following definitive fixation and last for a total of 10 weeks
2401484|NCT03562351|Experimental|Verbal Instructions on use of RM|Caregivers will undergo an educational intervention with typical training with verbal instructions and use of a rectal diazepam trainer.
2401485|NCT03562351|Experimental|Video on use of RM|Caregivers will undergo an educational intervention with training by watching an instructional video regarding rescue medication administration
2401486|NCT03562351|Experimental|Mannequin on use of RM|Caregivers will undergo an educational intervention with training by use of a mannequin to practice administering the rescue medication
2401487|NCT03562338|Experimental|Manual Therapy and Exercise|
2401488|NCT03562338|Active Comparator|Usual Care|
2401489|NCT03562325|Other|ACT|Acceptance & Commitment Therapy (ACT)
2401490|NCT03562312|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
2401491|NCT03562312|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
2401492|NCT03562299|Experimental|Experimental|Reconstruction of the Anterior Cruciate Ligament (ACL) using OrthoPure™ XT in patients with a partial or complete tear of the Anterior Cruciate Ligament (ACL)
2401493|NCT03562286|Experimental|Experimental Fetoscopy|All participants will undergo fetoscopic repair of open spina bifida
2401494|NCT03562273||GammaPod Quality of Life Evaluations|This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
2401495|NCT03562260|Experimental|children who had bipolar release|children who had bipolar release are included
2401496|NCT03562247|Active Comparator|Usual Care of IPF|Newly diagnosed patients will continue to receive excellent healthcare as currently given in management of the lung disease
2401497|NCT03562247|Experimental|Telenursing|Patients will receive usual care with structured phone calls from the nurse practitioner and/or case manager occuring more frequently earlier in the diagnosis to help the patient and care giver understand all aspects of the disease and it time will evolve to managing symptoms outside of out-patient clinic visits.
2401498|NCT03562247|Experimental|Telenursing and Remote Monitoring|Patients will receive usual care with telenursing and will be given a hand held spirometer and puse oximeter and be asked to take daily measurements and report these via an electronic HIPAA approved secured platform for evaluation by the telenursing team.
2401499|NCT03562234||Pre-op Chemotherapy for CLM: MR & LiMAx|"Patients undergoing pre-operative chemotherapy for colorectal liver metastases being treated at the Christie NHS (National Health Service) Foundation Trust.~No intervention - participants will continue with standard care. Observation of changes in liver fat and liver function measured by MR (Magnetic Resonance) scan and LiMAx test (Maximum liver capacity)."
2401500|NCT03562221|Experimental|Gluten free diet|Gluten free diet
2401501|NCT03562221|Active Comparator|Probiotics|Capsules with a combination of two probiotic bacteria with maize starch as excipient and at a total dose of 10(10) colony forming units (CFU)/capsule.
2401502|NCT03562221|Placebo Comparator|Placebo|Placebo capsules with maize starch and without any bacteria.
3143932|NCT00023244|Active Comparator|Control Treatment|All enrolled subjects who have not experienced an episode of acute rejection or other event resulting in removal from the study in the first 6 months after transplantation will undergo a protocol-driven biopsy at 6 months. Subjects with no clinical or histologic evidence of rejection will be eligible to be randomized and treated in a double-blinded (e.g., masked-neither subject nor health care providers will know treatment being received) fashion while continuing other immunosuppressive medications. Subjects in this arm will be maintained on low-dose (0.15 mg/kg/day) daily steroids.
3143933|NCT00023283|Experimental|1|Standard Medical Management with once-weekly medication dispensing
2401505|NCT03562182||Women Receiving Antenatal Steroids|Group 2: Determine how (and if) serum hLPCAT1 mRNA changes with administration of a course of steroids by measuring its plasma levels before, 24hrs after the first dose and 24hrs after the second dose of bethamethasone as well as one and two week after the first dose. This is accomplished through a simple blood draw. We seek to understand the effects of the 2nd dose of steroids and determine if, once the hLPCAT1 expression begins, does it continue or does it turn off again after some time from steroid administration.
2401506|NCT03562182||Normal Pregnancy Controls|1) Group 1: Determine the plasma levels of hLPCAT1 mRNA in pregnant women from 32- 36+6/7 weeks gestation. This is accomplished through a simple blood draw. More specifically, we seek to find out, at what moment in gestation, expression spontaneously begins.
2401507|NCT03562169|Active Comparator|Conventional Autologous Stem Cell Transplant (ASCT)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0
2401509|NCT03562156|Experimental|VT-1161 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
3143934|NCT00023283|Experimental|2|Standard Medical Management with thrice-weekly medication dispensing
3143935|NCT00023283|Experimental|3|Enhanced Medical Management with thrice-weekly medication dispensing
3143936|NCT00023374|Experimental|Rifampin+PZA+Ethambutol|6 mos of intermittent (2 or 3 times weekly) therapy with REZ
3143937|NCT00023504|Active Comparator|Pneumococcal Vaccine|To determine the function of T and B cells in vivo using Pneumococcal vaccine immunization in patients with known or suspected immune disorders.
2401510|NCT03562156|Placebo Comparator|Control capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
2401511|NCT03562143|Experimental|Alternate-day iron supplementation|Patients taking iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) for 6 weeks.
2401512|NCT03562143|Active Comparator|Daily iron supplementation|Patients taking iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) for 6 weeks.
2401513|NCT03562130|Experimental|Revestive|Revestive® (teduglutide)is administered in children sub cutaneous injection at 0.05 mg/kg body weight once daily
3184610|NCT00726531|Experimental|OEP|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
3184611|NCT00726531|Experimental|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
3184612|NCT00726531|No Intervention|TAU|Treatment as usual
3184613|NCT00726544|Placebo Comparator|Placebo|
3184614|NCT00726544|Active Comparator|Low Dose|
2401519|NCT03562104|Experimental|Minimally consciousness Patient|Wessex Head Injury Matrix scale and Videofluoroscopy for characterization of swallowing disorders in Minimally consciousness Patient
2401520|NCT03562078|Experimental|Tai Chi Quan for Type 2 Diabetes|diabetic patients care education and Tai Chi Quan training, including 10-minute warm-up, 40-minute Tai Chi lesson, and 10-minute cool-down exercise in the training, twice a week for 12 weeks.
2401521|NCT03562078|No Intervention|Control Group for Type 2 Diabetes|diabetic patients care education
2401522|NCT03562065|Experimental|mesenchymal stem cells|"Phase I-II, Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
2401523|NCT03562039|Experimental|M-MIST (group A)|M-MIST(incomplete granulation tissue removal)
2401524|NCT03562039|Active Comparator|M-MIST (group B)|conventional M-MIST.
2401525|NCT03562000|Experimental|Intervention group on cough and ventilation assistance|Mechanical cough assistance during physiotherapy post-extubation in ICU and systematic indication of NIV.
2401526|NCT03562000|Other|Control group on cough and ventilation assistance|Control group of extubated patients receiving the current gold standard strategy during physiotherapy after extubation in ICU and with selected indications of NIV.
2401527|NCT03561987||Obese patients and bariatric surgery|"The investigators include men and women, over 18 years old, with morbid obesity and candidates for bariatric surgery, under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
2401528|NCT03561987||No obese patients and abdominal surgery|"The investigators include men and women, over 18 years old, without obesity and candidates for abdominal surgery (hernioplasty, cholecystectomy, fundoplication), under the routine of the treating service, with signature of acceptance of your participation, by informed consent.~The investigators exclude patients with medication with potential effect on adipose tissue or cardiovascular risk in the last month, also with severe infections in the last month or clinically unstable conditions.~Patients are eliminated in the study if they dont have the desire to continue in the study, and if the samples or the information are insufficient for an adequate analysis."
2401529|NCT03561974|Experimental|Humidification|
2401530|NCT03561974|No Intervention|Control group without humidification|
2401531|NCT03561961|Active Comparator|Moderate Hypo-fractionation|In arm 1 of the study, patients who are randomized to receive moderately hypo-fractionated RT will receive a total dose of 66-68 Gy in 25# to the primary over 5 weeks, with treatment being delivered daily. All patients will receive a dose of 50 Gy in 25# to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 60-66 Gy/25# as a simultaneous integrated boost(SIB).
2401532|NCT03561961|Experimental|Extreme Hypo-fractionation|In Arm 2 of the study, patients who are scheduled to receive SBRT will receive a course of 5 fractions of radiation; each fraction size will be 7.00-7.25 Gy. The total dose will be 35-36.5 Gy. All patients will receive a dose of 25 Gy in 5 # to the pelvis. Boost to gross nodal disease will be considered based on the response to hormonal therapy to a dose of 30-35 Gy/5# as a simultaneous integrated boost(SIB).The 5 treatments will be scheduled to be delivered alternate day over approximately 7-10 days. An option of equivalent biological dose using 35-36.5 Gy in 5 weekly fractions may be allowed for multicentric accrual in the future.
2401533|NCT03561948|Experimental|Experimental group|Surgery and Intraperitoneal Chemotherapy
2401534|NCT03561948|Placebo Comparator|Control group|only surgery
2401535|NCT03561935|Experimental|Propafenone group|Prescribtion of propafenone for the management of premature ventricular complex
2401536|NCT03561935|Active Comparator|Indenol group|Prescribtion of indenol for the management of premature ventricular complex
2401537|NCT03561922|Experimental|RETINA IMPLANT Alpha AMS|All participants receive the subretinal device RETINA IMPLANT Alpha AMS
2401538|NCT03561909|Other|Platelet transfusion|HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
2401539|NCT03561896|Experimental|IGRT|Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
2401540|NCT03561896|Experimental|SRS|Stereotactic Radiosurgery of the resection cavity (SRS)
3184615|NCT00726544|Active Comparator|Medium Dose|
3184616|NCT00726544|Active Comparator|High Dose|
2401543|NCT03561870|Experimental|Olaparib|
2401544|NCT03561857|Experimental|Confocal Laser Endomicroscopy|All included patients will undergo probe-based Confocal Laser Endomicroscopy during Robotic-Assisted Radical Prostatectomy (RARP) or Laparoscopic Radical Prostatectomy (LRP)
2401545|NCT03561844|Active Comparator|aromatherapy-scent|
2401546|NCT03561844|Active Comparator|aromatherapy-touch|
2401547|NCT03561844|No Intervention|waiting-list control|
3143938|NCT00023504|Active Comparator|Rabies Vaccine|To determine the function of T and B cells in vivo using Rabies vaccine immunization in patients with known or suspected immune disorders.
3143939|NCT00023543|Experimental|1|Participants will reduce total fat intake to 17 percent of calories, 1300 kilo calories, and increase moderate activity to 150-240 minutes per week to obtain a 10 percent reduction in weight.
2401550|NCT03561818|Experimental|Hospital-based group|2 months hospital-based pulmonary rehabilitation program
2401551|NCT03561818|Experimental|Home-based group|2 months home-based pulmonary rehabilitation program
2401552|NCT03561805|Other|Prolonged continuous ECG monitoring|Patients will undergo a prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure. The duration of the ECG monitoring will be of 1 week.
2401553|NCT03561792|No Intervention|traditional RSBI|the decision to continue SBT depends on the traditional RSBI (RSBI < 105 predicts successful weaning)
2401554|NCT03561792|Experimental|Diaphragmatic RSBI|diaphragm ultrasound was done to measure diaphragmatic displacement which is used to calculate DRSBI and The investigator takes the decision about SBT continuation based on the result of DRSBI (DRSBI < 1.3 predicts successful weaning)
2401555|NCT03561779|Experimental|YYD302|YYD302 (2ml)
2401556|NCT03561779|Active Comparator|Synovian Inj.|Synovian Inj. (3ml)
2401557|NCT03561753|Active Comparator|Group A (the standard 2HRZE/4HR regimen)|Group A, Standard Regimen (2EHRZ/4HR): Control group, use the standard six-month regimen with eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
2401558|NCT03561753|Experimental|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|Group B, PRS Regimen (4EZ [high dose] Cfz Pto): Experience group，use the PRS regimen is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.
2401559|NCT03561740|Experimental|Metronomic Capecitabine Group|Patients in experimental group (also Metronomic Capecitabine Group) will receive additional metronomic chemotherapy of capecitabine (500mg TID po), begin after the completion of standard adjuvant chemotherapy or surgery if neoadjuvant chemotherapy were administrated, until three weeks after the last cycle of trastuzumab (6mg/kg every 3 weeks).
2401560|NCT03561740|No Intervention|Control Group|Patients in control group will receive standard therapy only, as per the guidelines.
2401561|NCT03561727|Experimental|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
2401562|NCT03561727|Active Comparator|Layered closure technique|Abdominal cavity will be closed with two separate layers of continuous sutures. The first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia. In case of incisions not exceeding the lateral border of rectus abdominis muscle, the second layer will involve only the anterior layer of the rectus abdominis muscle fascia. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer will include internal oblique abdominal muscle fascia, external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
2401563|NCT03561714||CMC-TI|Cardiometabolic Care Team Intervention
2401564|NCT03561714||Non-Intervention Comparator site|Non intervention comparator site with usual care
2401567|NCT03561688|Sham Comparator|Standard insole|a flat insole
2401568|NCT03561688|Experimental|Foot orthotics|Custom-made foot orthoses
2401569|NCT03561675|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2401570|NCT03561675|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
2401571|NCT03561662|Active Comparator|Low isoflavone|Alpro soya drinks containing 10 mg isoflavones per day
2401572|NCT03561662|Active Comparator|Medium isoflavone|Alpro soya drinks containing 35 mg isoflavones per day
2401573|NCT03561662|Active Comparator|High isoflavone|Alpro soya drinks containing 60 mg isoflavones per day
2401574|NCT03561649|Experimental|Adalimumab|"Adalimumab is not the experimental study drug. This treatment justifies the inclusion of patients and is used in accordance with its marketing authorization.~The patients will be seen as part of their follow-up consultation in Rheumatology.~Modality of administration: The baseline visit should take place no more than 4 weeks before the start of adalimumab treatment, 40mg every 2 weeks, subcutaneously, in accordance with Summary of Product Characteristics.~At baseline and 6 months follow-up visits, a single blood draw for the biomarker dosage will be added to the standard patient health care follow-up. The clinical examination will also be performed at these two visits, and the clinical response will be assessed after 6 months of adalimumab treatment at M6 follow-up visit."
2401575|NCT03561623||Patients with Post Polio Syndrome|Post Polio syndrome diagnosed according to March of Dimes Criteria; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
2401576|NCT03561623||Healthy controls|subjects age- and sex-matched; 'magnetic resonance (MR) Imaging' will be performed including a 'quantitative muscle force assessment'
3143940|NCT00023634|Experimental|EGFR vaccine with GMCSF|EGFR antisense DNA 500 mcg peptide w/GMCSF monthly x 6 m
3143941|NCT00023634|Experimental|EGFR vaccine with KLH|EGFR antisense DNA 500 mcg peptide w/KLH monthly x 6 m
2401577|NCT03561610|Active Comparator|Study group 1|normal Nutrition + sip feed (covers individual energy and nutrient demands)
2401578|NCT03561610|Experimental|Study group 2|normal Nutrition + gumdrops (covers individual energy and nutrient demands)
2401580|NCT03561584|Active Comparator|Active Drug (Sulfasalazine)|
2401581|NCT03561584|Placebo Comparator|Placebo|
2401582|NCT03561571|Active Comparator|Butter based breakfast|
2401583|NCT03561571|Active Comparator|Chocolate spread based breakfast|
2401584|NCT03561558|Experimental|Ibuprofen D, oral suspension|Ibuprofen oral suspension, 200 mg/ 5 ml is the test product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (5 ml containing 200 mg of ibuprofen) of suspension.
2401585|NCT03561558|Active Comparator|Nurofen® for Children, oral suspension|Nurofen® for Children oral suspension, 100 mg/ 5 ml is the reference product. In period 1 and period 2, 15 of 30 subjects will be given single oral dose (10 ml containing 200 mg of ibuprofen) of suspension.
2401586|NCT03561545|Experimental|Functional capillary density|Functional capillary density during weightlessness
2401587|NCT03561532|Active Comparator|FMT|50% of the participants will receive fecal suspension of a healthy donor administered in colonoscopy into the cecum
2401588|NCT03561532|Placebo Comparator|Placebo|50% of the participants will receive fecal suspension made of their own feces administered in colonoscopy into the cecum.
2401589|NCT03561519|Active Comparator|FMT|IBS patients randomized to receive FMT from a healthy donor.
2401590|NCT03561519|Placebo Comparator|Placebo|IBS patients randomized to receive autologous FMT (fecal suspension made of their own feces) as a placebo.
2401591|NCT03561506|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
2401592|NCT03561506|Active Comparator|Placebo group|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
2401593|NCT03561493|Experimental|zumba exercise group|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one h in length and a recovery period of at least 48 h was taken between classes.
2401594|NCT03561493|No Intervention|non zumba exercise group|The participants in the control group did not receive any intervention.
2401595|NCT03561480|Experimental|Ferric carboxymaltose group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
2401596|NCT03561480|Active Comparator|Placebo group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with postoperative anemia after total knee arthroplasty.
2401597|NCT03561454|Other|XOFT-Intra-Operative Radiation Therapy|XOFT-Intra-Operative Radiation Therapy
2401598|NCT03561441|Active Comparator|Tailored standard hydration|Patients will be randomly allocated to tailored standard hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 1.5 milliliter(mL)/kg/hr during and after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
2401599|NCT03561441|Experimental|Tailored aggressive hydration|Patients will be randomly allocated to tailored aggressive hydration arm. Patients will receive hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg over 1 hour after ERCP. Hydration and feeding will be tailored by each patient's symptoms and serum amylase levels.
2401600|NCT03561415|Experimental|Universal posaconazole prophylaxis|Universal posaconazole prophylaxis: All patients will start posaconazole modified release tablet (300mg daily ) between Day 4 and Day 14 post lung or heart-lung transplantation for 3 months.
2401601|NCT03561415|Experimental|Pre-emptive posaconazole therapy|Pre-emptive posaconazole therapy: Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease and given for 3 months.
2401602|NCT03561402||Patients with active disease|From the cohort of patients receiving teriflunomide - 1 tablet (14 mg) daily, the investigators will identify patients that have active disease..
2401603|NCT03561402||Patients with stable disease|From the cohort of patients receiving teriflunomide (as above), the investigators will identify patients that have stable disease.
2401604|NCT03561376|Other|Single arm - split scar study|Surgical closures, at least 4.5cm in length, will be split and zinc oxide ointment applied to half and petrolatum ointment to the other half
2401605|NCT03561363|Experimental|Saturated high-fat diet|"In this intervention group, subjects ingest a saturated eucaloric high-fat diet (64 E%) with total fat content being similar to the polyunsaturated high-fat diet.~The diet is enriched in saturated fat (36 E%). The main saturated fatty acids in the diet are primarily palmitic acid (C16:0) and stearic acid (C18:0). The main food sources are milk products, high-fat meat and vegetables.~Carbohydrate comprise 20 E% and protein 15 E%."
2401648|NCT03561038|Active Comparator|Fork-tip Needle|2 strokes within the mass with Fork-Tip needle, and then 2 strokes with the Franseen Needle
2401649|NCT03561025|Active Comparator|18F-FDG-PET/MRI|
2401650|NCT03561025|Experimental|18F-GE180-PET/MRI|
2401651|NCT03561012|Experimental|Intervention arm|
2401652|NCT03561012|Active Comparator|Control Arm|
2401606|NCT03561363|Experimental|polyunsaturated high-fat diet|In this intervention group, subjects ingest a polyunsaturated eucaloric high-fat diet (64 E%), with total fat content being similar to the saturated high-fat diet. The diet is enriched in polyunsaturated fat (32 E%). The main polyunsaturated fatty acids in the diet are primarily linoleic acid (C18:2 n-6) and alpha-linoleic acid (C18:3 n-3). The main food sources are vegetable oils, nuts and high-fat fish (e.g. salmon). Carbohydrate comprise 20 E% and protein 15 E%.
2401607|NCT03561337|Experimental|PROTEIN-CARBOHYDRATE|Intervention group receiving protein and carbohydrate supplement
2401608|NCT03561337|Placebo Comparator|CARBOHYDRATE|Intervention groups receiving carbohydrate supplement
2401609|NCT03561324|Experimental|Use of IntraOperative Imaging Probe|The sterilized (Imaging Beta Probe) IBP will be used intraoperatively in surgical wounds for localization of tumor sites and detecting completeness of excision vs. positive margins.
2401610|NCT03561311|Experimental|Remote ischemic conditioning group|
2401611|NCT03561311|Sham Comparator|Sham remote ischemic conditioning group|
2401612|NCT03561298|Experimental|Single Arm: BGB-3111 + Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
2401613|NCT03561285||Stroke with antiphospholipid|
2401614|NCT03561285||stroke without antiphospholipid|
2401615|NCT03561272|No Intervention|Standard Patient Reported Adherence|Adherence assessment via phone call or in person
2401616|NCT03561272|Active Comparator|Smart Phone Application|Adherence assessment via phone app
2401617|NCT03561272|Experimental|POD and Smart Phone Application|"Adherence assessment via phone app partnered with an automated dispensing machine, a Pod."
3143942|NCT00023647|Experimental|Synchrotope TA2M, 800 micrograms|Tyrosinase peptides, 800 micrograms
3143943|NCT00023647|Experimental|Synchrotope TA2M, 200 micrograms|Tyrosinase peptides, 200 micrograms
2401620|NCT03561246|Active Comparator|Personalized training effect on SSWS|"Determine the efficacy of motor control deficit guided personalized training on SSWS compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
2401621|NCT03561246|Active Comparator|Personalized training effect on Pp|"Determine the efficacy of motor control deficit guided personalized training on increasing symmetry of Pp compared to non-personalized and CONTROL interventions.~Incline treadmill walking Decline treadmill walking"
2401622|NCT03561246|Active Comparator|Positive response|"Determine if the personalized intervention increase the positive response rate compared to non-personalized and CONTROL interventions, and to further advance personalize interventions by identifying factors that predict response.~Incline treadmill walking Decline treadmill walking"
2401623|NCT03561233|Experimental|proton pump inhibitor|omeprazole 20 mg twice daily
3143944|NCT00023647|Experimental|Synchrotope TA2M, 400 micrograms|Tyrosinase peptides, 400 micrograms
3143945|NCT00023686|Experimental|surgery|"Patients undergo radical prostatectomy.~Patients are followed every 6 months for 5 years and then annually thereafter."
3143946|NCT00023686|Experimental|radiation|"Patients undergo brachytherapy with implanted iodine I 125 or palladium Pd 103 seeds.~Patients are followed every 6 months for 5 years and then annually thereafter."
3184617|NCT00726570|Experimental|SCD + LMWH|This group will receive sequential compression device therapy to the lower limbs from their ICU admission until the morning after surgery.
2401628|NCT03561207||Tumor tissue tested with EV3D Assay|Cancer tissue from multiple sites in the body, to include ovarian, brain, and other rare tumors.
2401629|NCT03561181|Experimental|High dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose
2401630|NCT03561181|Experimental|low dose Group|Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose
2401631|NCT03561168||Developmental Delay|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2401632|NCT03561168||Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2401633|NCT03561168||Developmental Delay and Seizure|Children under age 3 who underwent MRI brain with anesthesia for the indication of Developmental Delay and Seizure (between the dates of Dec 13, 2015 - Dec 13, 2016) at our institution.
2401634|NCT03561155|Experimental|Robot assisted treatment|The experimental group (EG) will undergo a robot-assisted arm training using Amadeo® (Tyromotion-Austria).
2401635|NCT03561155|Active Comparator|Conventional treatment|The conventional group (CG) will undergo robot unassisted treatment (Conventional treatment).
2401636|NCT03561142|Experimental|Radiochemotherapy -> chemotherapy.|Radiochemotherapy followed by consolidation chemotherapy. Deep regional hyperthermia can additionally be performed at the centers in Tübingen and Erlangen.
2401637|NCT03561116|Experimental|XAN|XAN (1 sachet of 12 mg/day)
2401638|NCT03561116|Placebo Comparator|Placebo|Placebo (1 sachet with excipient)
2401639|NCT03561103|Experimental|RCT: Intervention|Participants in the RCT intervention arm will receive client-centered representative payee services in addition to the standard of care.
2401640|NCT03561103|No Intervention|RCT: Control|Participants in the RCT control group will receive the standard of care.
2401641|NCT03561103|Experimental|Choice Intervention|Participants in the Choice intervention arm will receive client-centered representative payee services in addition to the standard of care. They will not be randomly assigned.
2401642|NCT03561103|No Intervention|Choice Control|Participants in the RCT control group will receive the standard of care. They will not be randomly assigned.
3184618|NCT00726570|Active Comparator|LMWH only|Patients in this group will receive only standard LMWH therapy during their ICU stay.
3184619|NCT00726583|Experimental|Investigational Drug|Dose Escalation
2401645|NCT03561077|Experimental|Mindfulness program|To study the feasibility in France of a mindfulness program with mindfulness-based interventions (MBI's) dedicated for adolescents with chronic pain.
2401646|NCT03561064|Experimental|Receiving CBT-I|This is a single arm study. All participants will receive CBT-I (cognitive behavioral therapy for insomnia).
2401647|NCT03561038|Active Comparator|Franseen Needle|2 strokes within the mass with Franseen Needle, and then 2 strokes with the Fork-tip Needle
3184620|NCT00726596|Experimental|Hydroxychloroquine|Hydroxychloroquine - 400 mg (cohort A) Hydroxychloroquine - 600 mg (cohort B)
3184621|NCT00726635|Active Comparator|1|Women in this arm will not receive a psychological intervention but rather will have a conversation with a nurse for one hour (attention control).
3184622|NCT00726635|Experimental|2|Cognitive intervention: Women in this arm will receive a cognitive psychological intervention(cognitive technique:self-talk)
2401655|NCT03560973|Experimental|Gemcitabine + Ramucirumab|Gemcitabine 1000 mg/m2 iv D1, D8 plus Ramucirumab 10 mg/kg iv (21 days cycles)
2401656|NCT03560973|Placebo Comparator|Gemcitabine + Placebo|Gemcitabine 1000 mg/m2 iv D1, D8 plus placebo (21 days cycles)
2401657|NCT03560960|Experimental|Probable AD|Participants with probable AD with positive imaging AD pathology will receive the pramlintide challenge test.
2401658|NCT03560960|Active Comparator|Amnestic MCI|Participants with amnestic MCI with or without positive AD imaging pathology will receive the pramlintide challenge test.
2401659|NCT03560960|Active Comparator|Control- Normal Cognition|Participants with normal cognition without any memory complaints will receive the pramlintide challenge test.
2401660|NCT03560947|Experimental|Manual Therapy and Exercise|
2401661|NCT03560947|Active Comparator|Usual Care|
2401662|NCT03560934|Experimental|Frequent Cannabis Users|"Subjects categorized as frequent cannabis users (>3x/week for 3 months) will receive a single dose of 10-60mg dronabinol on the second or third night of their stay in the clinical laboratory, one hour prior to bedtime and five minutes after completion of a study snack. The other night, participants will receive a placebo.~Dronabinol is an orally active, synthetic THC currently indicated for weight loss in patients with acquired immune deficiency syndrome (AIDS) or anorexia and for nausea and vomiting associated with cancer. Dronabinol is nearly absorbed (90%-95%) after a single oral dose of the capsule formulation with 10-20% of the administered dose researching the systemic circulation due to extensive first-pass hepatic metabolism and high lipid solubility. The onset of action is ~30 to 60 minutes with peak effects from 2-4-h following dose (Fig. 2) (34). The 10-60mg of dronabinol will be administered by OHSU's research pharmacy services."
2401663|NCT03560934|Experimental|Non Cannabis Users|Non-cannabis users (who have not used cannabis more than 10 times in their lifetime) will undergo the same single dose dronabinol and placebo as the frequent cannabis user arm, under the identical study procedure.
2401664|NCT03560921||Stored blood transfusion|measurement of urinary NGAL
2401665|NCT03560921||Fresh blood transfusion|measurement of urinary NGAL
2401666|NCT03560908|Experimental|Dasatinib plus chemotherapy|Dasatinib combined with chemotherapy for relapsed t(8;21) AML with D816 mutation
2401667|NCT03560895|Active Comparator|Group I|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
2401668|NCT03560895|Active Comparator|Group II|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
2401669|NCT03560895|Active Comparator|Group III|Patients will be anesthetized using uncuffed endotracheal tube (Mallinckrodt Medical, Athlone, Ireland) with its outer diameter determined by ultrasonography.
2401670|NCT03560882|Experimental|Atorvastatin|Atorvastatin 80 milligrams (mg) per day, orally for 1 - 4 weeks before surgery (surgery not part of clinical trial)
3184623|NCT00726635|Experimental|3|Psycho-physiological intervention: Women in this arm will receive a psycho-physiological intervention (relaxation and guided imagery)
3184624|NCT00726648|Experimental|1|
2401673|NCT03560856|Other|Fulvestrant 500mg + palbociclib 125 mg|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
2401674|NCT03560843|Experimental|MBSR treatment|MBSR will be administered over 8 week period.
2401675|NCT03560843|No Intervention|Control group|Usual care will continue for this group.
2401676|NCT03560830||Control|Sedentary control subjects with no medical or psychiatric disorder
2401677|NCT03560830||POTS GWI|GWI with Postural Orthostatic Tachycardia Syndrome (POTS) GWI veterans who had postural orthostatic tachycardia before exercise and after 2 submaximal exercise stress tests. Postural orthostatic tachycardia was defined by 2015 Consensus as an increase in heart rate of greater than or equal to 30 beats per minute between recumbent (after 5 minutes of rest) and standing up. Standing heart rates were measured every minute for 5 minutes. Postural orthostatic tachycardia was defined if the change in heart rate was more than 30 beats per minute at at least 2 of the 5 standing time points. The average change in heart rate did not have to be above 30. There were 11 GWI POTS subjects.
2401678|NCT03560830||START|"START = Stress Test Activated Reversible Tachycardia One third of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) BEFORE EXERCISE, but AFTER EXERCISE (submaximal exercise stress tests) they developed postural orthostatic tachycardia with changes in heart rate of 30 or more between recumbent and standing. The effect was transient as it lasted about 36 to 48 hr.~The START group had brainstem atrophy and reduced brain activation during a cognitive task compared to sedentary control and other GWI subjects."
2401679|NCT03560830||STOPP|"STOPP = Stress Test Originated Phantom Perception Two thirds of GWI veterans were found to have normal changes in heart rate between recumbent and standing (usual change ~10 to 15 beats per minute) both before and after 2 submaximal exercise stress tests. STOPP did not develop postural orthostatic tachycardia. their changes were equivalent to the sedentary control group.~The STOPP group increased brain activation of the basal ganglia and anterior insula during a cognitive task compared to sedentary control subjects."
2401680|NCT03560817||breast cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
3184625|NCT00726648|Experimental|2|
3184626|NCT00726648|Experimental|3|
3184627|NCT00726648|Experimental|4|
3184628|NCT00726648|Placebo Comparator|5|
3184629|NCT00726687|Experimental|single|Single arm designed to elicit Maximum Tolerated Dose
3184630|NCT00726700|Active Comparator|Arm I (without rituximab)|Patients receive pegfilgrastim subcutaneously (SC) on day 2 or 4 and CHOP comprising cyclophosphamide IV, doxorubicin IV, vincristine IV on day 1, and oral prednisone on days 1-5. Treatment repeats every 2 weeks for up to 6-8 courses in the absence of disease progression or unacceptable toxicity.
2401681|NCT03560817||colorectal cancer|No intervention is added with the study. Patients follow their standard treatment and respond to an online questionnaire about their health preferences.
2401682|NCT03560804|Active Comparator|Olmesartan|ARB administration (OLMESARTAN) at a starting dose and titrating at 15 weeks according to reach blood pressure target
2401683|NCT03560804|Active Comparator|Chlorthalidone|Diuretic administration (chlorthalidone) at a starting dose and titrating at 15 weeks according to reach blood pressure target
3184631|NCT00726700|Experimental|Arm II (with rituximab)|Patients receive pegfilgrastim and CHOP for up to 6-8 courses as in arm I. They also receive rituximab (administered 2 hours before beginning CHOP) on day 1. Treatment with rituximab repeats every 2 weeks for up to 8 courses.
3184632|NCT00726726|Other|A|
3184633|NCT00726726|Experimental|B|
3184634|NCT00726726|Experimental|C|+ Other
2401688|NCT03560752|Experimental|Prevention(multi-peptide CMV-modified vaccinia Ankara vaccine)|Donors receive multi-peptide CMV-modified vaccinia Ankara vaccine injection between days -60 and -10 prior to granulocyte colony stimulating factor mobilization. Participants undergo hematopoietic cell transplantation on day 0.
3184635|NCT00726765||Referral Strategy 1|"Patient meets at least one of the following three criteria:~Inflammatory back pain~Human leukocyte antigen B27 (HLA-B27)~Sacroiliitis demonstrated by imaging (X-ray, magnetic resonance imagining [MRI], bone scan [if previously available])"
3184636|NCT00726765||Referral Strategy 2|"Patient meets at least two of the following six criteria:~Inflammatory back pain~HLA-B27~Sacroiliitis (on imaging)~Family history of AS~Good response of back pain to nonsteroidal anti-inflammatory drugs (NSAIDs)~Known Extra Articular Manifestations (Uveitis, Iridocyclitis, Psoriasis, Inflammatory Bowel Disease)"
3184637|NCT00726778||A, Observational|Healthy European American, African American, and Hispanic American children aged 7-12
3184638|NCT00726791|Experimental|1|high frequency rTMS applied to the motor cortex
2401693|NCT03560726|Experimental|Telehealth|Participants randomized into the telehealth arm will receive up to 7 one-hour telehealth visits with the study psychologist. The first six sessions will focus on cognitive behavioral stress management topics and the seventh session is optional, focusing on lung transplant readiness. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20). Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20.
2401694|NCT03560726|No Intervention|Treatment-As-Usual (TAU)|"Participants randomized into the TAU arm will not receive any telehealth visits during the 8-week intervention phase. Participants will fill out questionnaires every other week (baseline, week 2, week 4, week 6, week 8) and during a 3-month follow-up (week 20).~Participants will wear an actigraphy watch to track sleep and movement for one week at a time during baseline, week 8, and week 20."
2401695|NCT03560713|Experimental|FES + combined exercise|The Functional Electrical Stimulation (FES) + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant) and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
2401696|NCT03560713|Sham Comparator|FES sham|The Functional Electrical Stimulation (FES) sham + combined exercise group will receive 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes and receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
2401697|NCT03560700|Experimental|lactobacillus probiotic strain|60 billion CFU/day
2401698|NCT03560700|Placebo Comparator|placebo|
2401699|NCT03560687|Experimental|CardioSIDERAL|Adminsitration of 2 pills per day of CArdiosideral from 30 days before operation to time of operation
2401700|NCT03560687|No Intervention|Control|
2401701|NCT03560661||Amyotrophic lateral sclerosis (ALS) patients|
2401702|NCT03560661||Primitive Lateral Sclerosis (PLS) patients|
2401703|NCT03560661||Kennedy's disease (KD) patients|
2401704|NCT03560648|Other|Reference group|To define the normal muscle aging from HD-sEMG and accelerometer signals correlated to muscular parameters obtained from Dual Energy X-ray Absorptiometry (DEXA), handgrip strength and muscular echography. Data will be collected in healthy volunteers, aged 25 to 75 years old, physically active on IPAQ questionnaire.
2401705|NCT03560648|Other|Test group|"To evaluate the capacity of MFA to detect early muscle aging in  tests  individuals, sedentary volunteers within the same age group (45-55 years old)."
2401706|NCT03560635|Active Comparator|Control|Participants randomized to the CON condition will be informed of their estimated weight maintenance calorie needs (determined by multiplying their resting energy expenditure (REE) obtained from indirect calorimetry by an appropriate activity factor and advised to adhere to this calorie target, as is standard weight maintenance advice. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the diet protocol.
2401707|NCT03560635|Experimental|Reverse Diet|Participants randomized to the reverse diet condition will receive specific caloric intake goals. The initial caloric goal will be set at 2-3% above the level participants ended their weight loss diet at (via self-report). Participants' caloric goals will increase at a rate of 2-3% per week. Participants will be provided with a food scale and calorie tracking options and instructed on the importance of high adherence to the reverse diet protocol.
2401708|NCT03560622|Active Comparator|ET cohort|Ten adults with refractory ET (ET cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)). In addition the ET cohort will also undergo imaging with the identical protocol immediately after and 24 hours after FUS-T.
2401709|NCT03560622|Experimental|control cohort|Twenty adult healthy controls (control cohort) will undergo multi-modality neuroimaging (structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI)).
2401710|NCT03560609|Active Comparator|Subjects With Keratoconus|
2401711|NCT03560609|Active Comparator|Subjects with Glaucoma|
2401712|NCT03560596|Experimental|High Risk Latino Patients Adherence Intervention|74 high risk Latinos with uncontrolled hypertension
3184639|NCT00726804|Other|2|
2401713|NCT03560596|Active Comparator|High Risk Latinos Usual Care|74 high risk Latinos with uncontrolled hypertension
2401714|NCT03560583|Experimental|Metoclopramide 10 mg BID|
2401715|NCT03560583|Placebo Comparator|Placebo 10 mg BID|
2401716|NCT03560570||Event group|CDG with antecedent of stroke-like, thrombosis or haemorrhages
2401717|NCT03560570||Non event group|CDG without antecedent of stroke-like, thrombosis or haemorrhages
2401718|NCT03560570||Control|Healthy subject
2401719|NCT03560544|Experimental|Breaking up sitting time|A behaviour-change intervention to break up prolonged sitting in the workplace
2401720|NCT03560544|No Intervention|Control|The participants in the control group will continue their daily activities as normal without any form of information about the intervention.
3184640|NCT00726817|Placebo Comparator|1|enemas, once daily, containing saline
3184641|NCT00726817|Experimental|2|enemas, once daily, containing 50mM butyrate
3184642|NCT00726817|Experimental|3|enemas, once daily, containing 100mM butyrate
3184643|NCT00726843|Active Comparator|1|8 weeks of Yoga, followed by 8 weeks of follow-up
3184644|NCT00726843|Active Comparator|2|8 weeks of follow-up, followed by 8 weeks of yoga
2401726|NCT03560505||Common fibular compression neuropathy|"Patients referred for electrophysiological assessment of common fibular compression neuropathy with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
2401727|NCT03560505||Type 2 diabetes polyneuropathy|"Patients with type 2 diabetes referred for polyneuropathy involving the common fibular nerve with subsequent confirmation of referral diagnosis.~Intervention: Ultrasound protocol."
2401728|NCT03560492|Experimental|Posture Plus Force|Participants are provided with the posture garment. They have to wear it 2 to 4 h per day for a 3 month period. Participants receive a logbook that should be filled every day.
2401729|NCT03560492|Active Comparator|Exercise|A physiotherapist teaches exercises to participants (5 sessions of 20 minutes each of stretching and strengthening exercises). Exercises are focused on cervical and dorsal areas, Participants receive instructions to continue at home on a daily basis for 3 months. Participants receive a logbook that should be filled every day.
2401730|NCT03560479|Experimental|alpha1H, 7.4 mg/mL|alpha1H (7.4 mg/mL), solution for instillation, 30 mL
2401731|NCT03560479|Placebo Comparator|placebo|Placebo, 0.9% NaCl (sodium chloride), 30 mL
2401732|NCT03560479|Experimental|alpha1H, 37 mg/mL|alpha1H (37 mg/mL), solution for instillation, 30 mL
2401733|NCT03560479|Experimental|alpha1H, 74 mg/mL|alpha1H (74 mg/mL), solution for instillation, 30 mL
3184645|NCT00726856||Patients|patients with dyslipidemia
2401735|NCT03560453|No Intervention|Control|Attend assigned high school for 9 months
2401736|NCT03560453|Experimental|Project SEARCH plus ASD Supports|Attend Project SEARCH plus ASD Supports for 9 months
2401737|NCT03560440||Plasma exposure vancomycin|Pediatric patients treated with vancomycin
2401738|NCT03560427|Experimental|duloxetine+morphine|
2401739|NCT03560427|Placebo Comparator|placebo+morphine|
2401740|NCT03560414|Experimental|simple plasma exchange group|The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
2401741|NCT03560414|Active Comparator|conventional PDF treatment group|The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
2401742|NCT03560414|Active Comparator|less plasma PDF treatment group|The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
2401743|NCT03560401|Experimental|Brace group|After spinal surgery, patients in the brace group were instructed to wear a rigid brace (Knight-Taylor [chairback] brace) full-time for 12 weeks, except when bathing or lying in bed.
2401744|NCT03560401|No Intervention|No brace group|After spinal surgery, patients in the no brace group were instructed to wear a soft corset for 2 weeks, after which it was weaned off.
2401745|NCT03560388|No Intervention|Control|Control group include participants randomly allocated to supportive care (with no added integrative care or acupuncture)
2401746|NCT03560388|Experimental|Touch/relaxation|Touch/relaxation treatment (pre-operative)
2401747|NCT03560388|Experimental|Acupuncture and touch/relaxation|Acupuncture (intra operative) and touch-relaxation treatment (pre-operative)
2401748|NCT03560375|Experimental|Circuit resistance training (CRT)|2-3 circuits * 10 exercises * 3 times per week
2401749|NCT03560375|Experimental|Empagliflozin 10 MG|10 mg once daily
2401750|NCT03560375|Experimental|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources), aimed for sufficient protein from animal and mainly plant-based sources with carbohydrates limitation.
2401751|NCT03560362|Active Comparator|Bupivacaine with epinephrine|Patients will receive intraoperative intercostal nerve block with bupivacaine
2401752|NCT03560362|Experimental|Lipossomal extended release bupivacaine|Patients will receive intraoperative intercostal nerve block with lipossomal extended release bupivacaine
2401812|NCT03559946|Experimental|Condensed Protocol (CP) group|The patients in the CP group will receive 2 PTNS treatments per week for 12 weeks.
3184646|NCT00726869|Experimental|Cohort 1|2.5 mg/kg
3184647|NCT00726869|Experimental|Cohort 2|5.0 mg/kg
3184648|NCT00726869|Experimental|Cohort 3|10.0 mg/kg
3184649|NCT00726869|Experimental|Cohort 4|20.0 mg/kg
3184650|NCT00726934|Active Comparator|Neutropenic Diet|Participants will be instructed to follow a Neutropenic Diet. This group will receive the same information as the Food Safety Arm with some additional recommendations for avoiding high bacteria foods during length of time on study.
3184651|NCT00726934|Active Comparator|FDA Food Safety Guidelines|Participants will be instructed to follow the FDA Food Safety Guidelines
3184652|NCT00726947|Experimental|1|Ultrasound imaging of Acute DVT (deep vein thrombosis)
2401753|NCT03560349|Experimental|Lidocaine|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of 2% lidocaine jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes on both sides simultaneously. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered two times per day at approximately 12 hour intervals.
2401754|NCT03560349|Placebo Comparator|Placebo|Transnasal blockade of SPG approach involving the application of 2 cc (approximately the size of a pea) of nasal saline jelly on a cotton swab directed posteriorly towards the SPG in the nasal passage bilaterally. Cotton swab will be inserted to the back of the nasal passage until it can no longer be inserted any further. The cotton swab should remain in place for 15 minutes. The patient will be instructed on how to perform this procedure on themselves, and they will be given supplies for a 7-day supply of medication to be administered up to two times per day at approximately 12 hour intervals.
2401755|NCT03560336||Overall Population|Patients will be treated with commercially available liraglutide 3.0 mg according to routine clinical practice at the discretion of the treating physician
2401756|NCT03560323|Active Comparator|Group I Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 0.4 mg/kg.min for 20 minutes and then at a constant rate of 0.2 mg/kg.min until study end
2401757|NCT03560323|Active Comparator|Group II Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 1.5 mg/kg.min for 20 minutes and then at a constant rate of 0.75 mg/kg.min until study end
2401758|NCT03560323|Active Comparator|Group III Beta-Hydroxy-Butyrate|Administration of beta-hydroxy-butyrate at 4.0 mg/kg.min for 20 minutes and then at a constant rate of 2.0 mg/kg.min until study end
2401759|NCT03560310|Experimental|Dual antiplatelet therapy|Ticagrelor 90 mg twice daily and ASA 75-100 mg daily for 12 months
2401760|NCT03560310|Active Comparator|Acetylsalicylic acid|ASA 75-160 mg daily for 12 months
2401761|NCT03560297|Experimental|SeRenade Program|Parent-Child Music Class Program (parent training, peer inclusion, musical play)
2401762|NCT03560297|Experimental|Delayed/Waitlist Program|Participants do not participate in the program for a time period
2401763|NCT03560271|Experimental|Dose A|Cyclo-Z containing 23 mg zinc plus 6 mg CHP
2401764|NCT03560271|Experimental|Dose B|Cyclo-Z containing 23 mg zinc plus 15 mg CHP
2401765|NCT03560271|Placebo Comparator|Dose C|Placebo
3184653|NCT00726947|Experimental|2|Ultrasound imaging of Chronic DVT (deep vein thrombosis)
3184654|NCT00726960|Experimental|1|Aprepitant
3184655|NCT00726960|Placebo Comparator|2|Placebo
3184656|NCT00726973|Experimental|1|Reduced fluence (3300mW/cm2-50% standard fluence) PDT + ranibizumab
3184657|NCT00726973|Active Comparator|2|Ranibizumab monotherapy
2401771|NCT03560232|Active Comparator|Cefazolin + Gentamicin|"[Cefazolin]~Initial dose:~Cefazolin 2g IV x1 dose (patient weight < 120kg)~Cefazolin 3g IV x1 dose (patient weight >/= 120kg)~Subsequent dose:~Cefazolin 2g IV every 8 hrs (CrCl >/= 40 mL/min)~Cefazolin 2g IV every 12 hrs (CrCl 20-39 mL/min)~Cefazolin 2g IV every 24 hrs (CrCl < 20 mL/min)~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hrs post-op after soft tissue coverage or total of 72 hrs, whichever comes first"
2401772|NCT03560232|Active Comparator|Ceftriaxone|"Initial dose:~Ceftriaxone 2g IV x1 dose~Subsequent dose:~Ceftriaxone 2g IV every 24 hours~Duration:~One dose post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2401773|NCT03560232|Active Comparator|Ampicillin/Sulbactam|"Initial dose:~Ampicillin/Sulbactam 3g IV x1 dose~Subsequent dose:~Ampicillin/Sulbactam 3g IV every 6 hours (CrCl >/= 30 mL/min)~Ampicillin/Sulbactam 3g IV every 12 hours (CrCl 15-29 mL/min)~Ampicillin/Sulbactam 3g IV every 24 hours (CrCl <15 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2401774|NCT03560232|Active Comparator|Piperacillin/Tazobactam|"Initial dose:~Piperacillin/Tazobactam 4.5g IV x1 dose over 30 minutes~Subsequent dose:~Piperacillin/Tazobactam 3.375g IV every 8 hours over 4 hours (CrCl >/= 20 mL/min)~Piperacillin/Tazobactam 3.375g IV every 12 hours over 4 hours (CrCl < 20 mL/min)~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2401775|NCT03560232|Other|Clindamycin + Gentamicin|"Patients with known Penicillin allergy will receive:~[Clindamycin]~Initial dose:~Clindamycin 900mg IV x1 dose~Subsequent dose:~Clindamycin 600mg IV every 8 hours~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first~[Gentamicin]~Initial dose:~If Patient age </= 80 years old: 5 mg/kg adjusted body weight x1 dose (Max dose 500 mg)~If Patient age >80 years old: 3 mg/kg adjusted body weight x1 dose (Max dose 300 mg)~Subsequent dose:~Pharmacy Consult to dose gentamicin~Duration:~24 hours post-op after soft tissue coverage or total of 72 hours, whichever comes first"
2401776|NCT03560206|Experimental|Family SWaP intervention with mini iPad|an educational-behavioral intervention consisting of 6 weekly education sessions (45 minutes) followed by 5 bi-weekly sessions (15-20 minutes) that will be held at the dyad's preferred time delivered to their homes using a video conferencing program through a mini iPad.
2401777|NCT03560206|Active Comparator|Usual Care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
2401780|NCT03560167|Experimental|AccuCinch® Ventricular Restoration System|
3184658|NCT00727012|Other|SJM® Rigid Saddle Ring|The SJM® Rigid Saddle Ring is an annuloplasty ring comprised of a titanium core surrounded by a double-velour, polyester fabric sewing cuff.
3184659|NCT00727038|Experimental|1|Lucentis (ranibizumab) with conventional treatment
3184660|NCT00727038|No Intervention|2|Conventional treatment
3184661|NCT00727051||1|Liver and lung transplant candidates referred for coronary angiography will be invited to participate in the study.
3184662|NCT00727077||IntronA/Rebetol|Children age 3 to 17, with chronic hepatitis C, treated in clinical practice at 10 German sites
2401781|NCT03560154|Experimental|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. In TVT training; Eight kinds of exercises will be provided, including 3 sessions per week for 4 weeks. The duration of each session will vary between 8-30 minutes. The frequency, amplitude, and duration of the TVT will be gradually increased from the lowest intensity to the level that the patient can tolerate. 8 exercises will be applied: for lower extremity; high squat, deep squat, right/left lunge, calf raise, for upper extremity; front raise, bent over lateral, biceps curl, and cross over. Before TVT application, 5-8 min. warm-up exercises will be applied. If desaturation (<88%) develops during the training in the patient, an oxygen mask will be used to ensure adequate oxygenation. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
2401782|NCT03560154|No Intervention|Home respiratory exercises|Respiratory exercises will be taught to the patient. Duration of the respiratory exercises is at least 10 minute per session, 7 days a week for 4 weeks. A weekly phone call will be provided and exercise will be followed.
3184663|NCT00727103|Active Comparator|1 Varenicline|Varenicline will be dispensed in 0.5 mg (blue capsules containing a 0.5 mg varenicline tablet) and 1 mg (red capsules containing a 1 mg varenicline tablet) capsules taken orally. During the first 3 days of medication, participants will take one blue capsule (0.5 mg tablet) of varenicline daily. If the medication is well-tolerated, the dose will be increased to one blue capsule (0.5 mg) po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 red capsule (1 mg) po twice daily. At the end of the 8th week, varenicline will be discontinued.
3189105|NCT00774358|Experimental|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
2401788|NCT03560089|Active Comparator|Rehabilitation with active serious game|25 patients will perform motor rehabilitation programme using the serious game
2401789|NCT03560089|Placebo Comparator|No active serious game|25 patients will not perform motor rehabilitation programme using the serious game
2401790|NCT03560076||Group 1|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 1 implementation
2401791|NCT03560076||Group 2|One medical surgical unit in seven acute care facilities in which nurses have received SBIRT training and implementation strategies and are randomized to Group 2 (delayed) implementation
2401792|NCT03560063|Experimental|Corin OPS arm|Total hip replacement with use of Corin Optimised Positioning System to guide implant positioning
2401793|NCT03560063|Active Comparator|Standard care arm|Total hip replacement with standard templating to guide implant positioning
2401794|NCT03560050|Experimental|Behavioral: Nutrition assistance|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
2401795|NCT03560050|Experimental|Behavioral: Children's environmental health|three encounters with Intervention team over three months: two home-based visits for 90 minutes each scheduled at the convenience of the provider and a 3- hour group class session with other providers.
2401796|NCT03560037|No Intervention|Standard Colonoscopy|Patients randomly assigned to this group will receive standard colonoscopy without the use of a distal attachment.
2401797|NCT03560037|Experimental|Endocuff Vision Assisted Colonoscopy|Patients randomly assigned to this group will receive colonoscopy with the use of the Endocuff Vision distal attachment.
2401798|NCT03560024|Active Comparator|PACAP27|12 healthy volunteers will receive PACAP27 (10 picomole/kg/min) over 20 min
2401799|NCT03560024|Placebo Comparator|Placebo|6 healthy volunteers will receive placebo (Saline) over 20 min
2401800|NCT03560011|No Intervention|Rituximab (375 mg/m²)|Single infusion of rituximab (375 mg/m²)
2401801|NCT03560011|Experimental|Rituximab followed by 5 injections of immunoglobulin IV|Rituximab (375 mg/m²) followed by 5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g). Treatment duration : 6 months
2401802|NCT03559985|Other|Paracetamol and placebo comparator (Group 1)|Neuropathic pain patients taking either paracetamol or placebo according to the randomization plan
2401803|NCT03559985|Other|Paracetamol and placebo comparator (Group 2)|Neuropathic pain patients taking either paracetamol (if during period 1 they received placebo) or placebo (if during period 1 they received paracetamol)
2401804|NCT03559972|Experimental|Treatment Group #1|"Subject in Treatment group 1 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~Hulk (cosmetic investigational)~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
2401805|NCT03559972|Experimental|Treatment group #2|"Subject in Treatment group 2 will apply the following products in the morning and evening.~SkinMedica Facial Cleanser~SkinMedica TNS Essential Serum~Marvel AM (cosmetic investigational)~Marvel PM (cosmetic investigational)~SkinMedica HA5 Rejuvenating Hydrator~SkinMedica Rejuvenative Moisturizer~SkinMedica Essential Defense Mineral Shield SPF 35 Sunscreen"
2401806|NCT03559959|Experimental|$0 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to redeem an HIV self-testing kit free of charge.
2401807|NCT03559959|Experimental|$0.5 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $0.5.
2401808|NCT03559959|Experimental|$1 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $1.
2401809|NCT03559959|Experimental|$2 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $2.
2401810|NCT03559959|Experimental|$3 price|Vouchers for HIV self-testing kits: Individuals will receive a voucher that can be used to purchase an HIV self-testing kit at the price of $3.
2401811|NCT03559946|Sham Comparator|Standard Protocol (SP) group|The patients in the SP group will receive one PTNS treatment and one sham treatment per week for 12 weeks
2401814|NCT03559920|Experimental|Sevoflurane group|Patients who are sedated using sevoflurane
2401815|NCT03559920|Active Comparator|Intravenous sedation group|Patients who are sedated using propofol
2401816|NCT03559907|Experimental|Cooking Matters for Parents|Trained instructors with a background in nutrition or culinary arts will lead six weekly, two-hour sessions to groups of 10 parent participants at local Family Support Centers.
2401817|NCT03559907|Experimental|Mealtime PREP|Trained group leaders with experience in pediatric occupational therapy will lead six weekly, two-hour, Mealtime PREP sessions to groups of 10 parent participants at local Family Support Centers.
2401818|NCT03559907|Experimental|Cooking Matters + Mealtime PREP|Parents will receive both programs in succession. They will attend Cooking Matters for Parents followed by Mealtime PREP. In total, this will equal 12 weekly, two-hour sessions delivered to groups of 10 parent participants at a local Family Support Center.
2401819|NCT03559881|No Intervention|Observation|Participants with a habitual protein intake >1.2 g/kg body weight/day will be allocated to the observational arm of the study
2401820|NCT03559881|Experimental|Intervention|Participants with a habitual protein intake <1.2 g/kg body weight/day will be allocated to the interventional arm of the study
2401821|NCT03559868|Active Comparator|Digoxin 3 mcg/Kg/day|Patients receiving oral digoxin 3 mcg/Kg/day
2401822|NCT03559868|Active Comparator|Digoxin 0.15 mcg|Patients receiving oral digoxin 0.15 mcg/Kg/day
2401823|NCT03559868|Placebo Comparator|Placebo|oral placebo
3184664|NCT00727103|Placebo Comparator|2 Placebo|Placebo will be dispensed in blue and red color coded capsules. During the first 3 days, participants will take one blue capsule po daily. If the medication is well-tolerated, the dose will be increased to one blue capsule po twice daily for 4 days. On day 8, the patients will take 1 red capsule po twice daily. At the end of the 8th week, placebo will be discontinued.
3184665|NCT00727116|Experimental|State-wide|All parents of newborns in Pennsylvania hospitals will receive the parent education materials
2401826|NCT03559842||Surgery patients|Obese patients undergoing laparoscopic sleeve gastrectomy
2401827|NCT03559842||Non-surgery patients|Obese patients not undergoing laparoscopic sleeve gastrectomy (delayed or refused proposed treatment)
3184666|NCT00727116|Experimental|Central PA|All of Central PA new parents will receive the state-wide hospital-based intervention. In half of the 31 central PA counties, all primary care providers having offices in those counties provide an office-based booster intervention to new parents. The other half of central PA counties will receive the state-wide, hospital-based intervention, but not the office-based booster intervention.
2401829|NCT03559816||Selective use of Episiotomy|Vaginal delivery assisted with selective use of episiotomy and prospective classification of perineal laceration with a sub-classification of second-degree tears. Data of subclassifications are registered with data usually recorded in delivery ward register.
2401830|NCT03559816||Not selective use of Episiotomy|Vaginal delivery assisted without a selective use of episiotomy. Data retrospectively retrieved by delivery ward register that were usually recorded.
2401831|NCT03559803|Experimental|Cisplatin|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
2401832|NCT03559777|Active Comparator|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
2401833|NCT03559777|Experimental|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~Begin with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
2401834|NCT03559764|Experimental|Anti-BCMA CAR T cells|Total dose of 0.5-6 millions /kg cells will be administered at day -2, day -1 and day 0 by split dose (30%, 30% and 40% respectively).
2401835|NCT03559751|Experimental|VLN Cigarettes (A)|Subjects will smoke VLN cigarettes
2401836|NCT03559751|Experimental|Usual Brand Cigarettes (B)|Subjects will smoke their usual brand cigarettes
2401837|NCT03559751|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
2401838|NCT03559738||Patients With Upper Ureteric Stones|Patients with upper ureteral stones more than 1cm and 1000 HU
2401839|NCT03559725|Experimental|VLN Menthol Cigarettes (A)|Subjects will smoke VLN menthol cigarettes
2401840|NCT03559725|Experimental|Usual Brand Menthol Cigarettes (B)|Subjects will smoke their usual brand menthol cigarettes
2401841|NCT03559725|Experimental|Nicotine Gum (C)|Subjects will chew nicotine gum
2401842|NCT03559712|Experimental|Telemedicine|Participants in this arm will be treated by the trained primary health care physicians in the primary health care centers, who will be having weekly supervisions with the specialists for case management.
2401843|NCT03559712|No Intervention|Control|Participants in this arm will experience treatment as usual, which means referral to a specialist.
3184667|NCT00727142|Active Comparator|open shunt|functioning shunt
3184668|NCT00727142|Active Comparator|closed shunt|NON FUNCTIONING SHUNT
2401847|NCT03559634|Experimental|Intervention group|Using an electronic application, participants answer survey questions about their sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception. Then, based on survey answers, they will be able to watch more in-depth educational videos on methods that they qualify for. Participants will only be offered methods that are considered low risk and without any contraindication based upon responses to survey screening. This may include, contraceptive implant, medroxyprogesterone acetate injection, microgestin pills, xulane patch, or intravaginal ring. Participants will then be given the opportunity to initiate contraception in the ED. All participants will be referred for follow up outpatient health services. Subjects who have medical contraindications to certain contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s) while in the ED.
2401848|NCT03559634|Other|Control Group|Using an electronic application, participants answer survey questions about their background, sexual history, medical history, and contraceptive preferences. They will watch a video that overviews the types of hormonal contraception with brief pros and cons of each method. Then, based on participants medical history and contraceptive preferences they will be able to watch more in-depth counseling and educational videos on contraceptive methods that they qualify for. After these videos they will be given information on where they will be able to follow up to receive these contraceptive methods if they wish to start a method. Subjects who have medical contraindications to certain hormonal contraceptive medications will be given a standardized handout that explains why they were not eligible for the medication(s), should this come up in future discussions with their providers.
2401849|NCT03559621|No Intervention|control group|Women in the control group will receive follow-up as in normal routine with referral to primary care. They will receive an OGTT after 1 year as part of the trial.
2401850|NCT03559621|Other|intervention group|A mobile-based lifestyle intervention
2401851|NCT03559595|Experimental|Intervention group|All study participants will be exposed to the intervention
2401852|NCT03559569||Patients with circulatory shock|500 patients with circulatory shock hospitalize in ICU will be prospectively included to assess the effect of this pathology on the senescence phenotype
2401853|NCT03559569||Healthy volunteers|20 healthy volunteers will be included to assess the effect of no pathology on the senescence phenotype.
2401854|NCT03559556|Experimental|Patient with AVM requiring radiotherapy|Patients on this protocol will still get treated based on target generated by interventional cerebral arteriography but also receive CT angiography.
3184669|NCT00727155|Experimental|1|Treatment
3184670|NCT00727155|No Intervention|2|Waitlist
3184671|NCT00727181|Other|Trifecta Valve|The Trifecta valve is a tri-leaflet stented pericardial valve designed for supra-annular placement in the aortic position.
3184672|NCT00727285||A|CF patients followed by the Adult CF Program at National Jewish Health meeting criteria for an acute pulmonary exacerbation.
3184673|NCT00727324|Experimental|1|BIAP
2401860|NCT03559504||Group 1|Infant period: 1 month-1 year old
2401861|NCT03559504||Group 2|Toddler period:1-3 years old
2401862|NCT03559504||Group 3|Preschool age period:3-6 years old
2401863|NCT03559504||Group 4|School age period:7-18 years old
2401864|NCT03559504||Group 5|Adults:18-65 years old
2401865|NCT03559504||Group 6|Elderly:65-80 years old
2401866|NCT03559491||Macular Edema Patients|Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.
2401867|NCT03559478|Active Comparator|Treatment Group 1|Sharp dissection with scalpel plus electrocautery to vessels
2401868|NCT03559478|Active Comparator|Treatment Group 2|Electrocautery for all dissection
2401869|NCT03559465|Experimental|patient with Scs|patients with SSc, (10 diffuse forms and 20 limited forms)
2401870|NCT03559465|Sham Comparator|healthy subject|
2401871|NCT03559452|No Intervention|Control|Immobilisation without prior exercise
2401872|NCT03559452|Experimental|Muscle damage|300 bilateral knee extensor eccentric contraction performed immediately prior to immobilisation
2401873|NCT03559439|Experimental|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion.
2401874|NCT03559426|Active Comparator|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
2401875|NCT03559426|Experimental|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
2401876|NCT03559413|Experimental|Intervention group|
3184674|NCT00727350|Experimental|1|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
3184675|NCT00727363|Placebo Comparator|1|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital. Patients fed through NG tube will be administered 5 drops of placebo through the NG tube followed by a 0.5 cc of a normal saline flush. Patients taking PO feeds will be administered 5 drops of placebo in posterior oropharynx after secretions have been suctioned.
2401879|NCT03559387|Experimental|ANF-RHO™|Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg as a subcutaneous injection.
2401880|NCT03559387|Active Comparator|Neulasta®|Neulasta® will be administered to the subjects at a dose of 6.0 mg in 0.6 ml as a subcutaneous injection.
2401881|NCT03559374||Pregnant women|Consenting women will provide samples to be tested with Vanadis NIPT system.
2401882|NCT03559361|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2401883|NCT03559361|Active Comparator|EPA-rich|3 x 1 g capsules daily containing a SMEDDS formulation of an EPA-enriched oil totalling 900 mg EPA and 360 mg of DHA
2401884|NCT03559361|Active Comparator|DHA-Rich|3 x 1 g capsules daily containing a SMEDDS formulation of an DHA-enriched oil totalling 900 mg DHA and 270 mg of EPA
2401885|NCT03559348|Experimental|Biweekly TS-1, Leucovorin and Gemcitabine (GSL)|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 to 7 Leucovorin 60 mg/d, orally twice daily on day 1 to 7 Every 14 days as one cycle
2401886|NCT03559335||Patients after colorectal cancer surgery|
2401887|NCT03559309|Other|Alirocumab|Medical Treatment (Clinical Routine)
2401888|NCT03559296||Study Group|patients with postmastectomy lymphedema who will undergo ultrasonographic assessment of postmastectomy lymphedema and circumferential tape measurement of arm
2401889|NCT03559283|Experimental|Walking and Record Cortical Activity|A sensor placement will be performed on the patient's forehead to record brain activity when walking, when performing a mental task, and when performing both tasks at the same time. In parallel, walking will be on a carpet that will record the spatio-temporal parameters of walking.
3184676|NCT00727363|Experimental|2|5 drops of Lactobacillus reuteri DSM 17938 from an oil based suspension will be administered once a day until death or discharge home. Patients with NG feeds will be administered the probiotic in the amount of 5 drops through the NG tube followed by 0.5 cc of a normal saline flush. Patients with PO feeds will be administered 5 drops of the probiotics in the posterior oropharynx after secretions have been suctioned. If feeds are temporarily suspended because of feeding intolerance or NEC, the probiotic may be re-started once feeds are re-started.
3184677|NCT00727376||Observation|Esophageal cancer patients
3184678|NCT00727389|Other|groups of women|To evaluate the capacity of muscular function and articular amplitude in the aged women
2401893|NCT03559244|Experimental|Dynamic compression brace 8 hours|Children with pectus carinatum who will wear dynamic compression brace 8 hours a day plus exercises for three weeks
2401894|NCT03559244|Experimental|Dynamic compression brace 23 hours|Children with pectus carinatum who will wear dynamic compression brace 23 hours (except for bathing and sports activities) a day plus exercises for three weeks
2401895|NCT03559244|Active Comparator|Only exercises|The children who are in wait in list for dynamic compression brace will receive only posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises for three weeks
2401896|NCT03559231|Experimental|dFTRD|Endoscopic full-thickness resection of the duodenal adenoma with the 'duodenal Full-Thickness resection device' (dFTRD).
2401897|NCT03559231|Active Comparator|EMR|Endoscopic Mucosal Resection (EMR) of the duodenal adenoma (=standard therapy).
3184679|NCT00727428|Experimental|Group A|
3184680|NCT00727454|Placebo Comparator|1 Control|No treatment
3184681|NCT00727454|Experimental|2 CPAP|Continuous Positive Airway Pressure (CPAP) - REMStar Pro with C-Flex; Respironics, Inc., Murrysville, PA
3189106|NCT00774371|Experimental|1|The intervention program consists of group sessions provided according to the following schedule: weekly for 4 months, every other week for two months, and follow-up monthly sessions through 18 months of active subject participation. The time points for data collection from all subjects are baseline, 6 months, and 18 months. The group sessions offered to the treatment study arm are closed-group contingents with an average of 12-15 women assigned to each group.
2401902|NCT03559192|Placebo Comparator|Lead-in Period: Placebo|Participants will receive matching placebo for the entire duration of the lead-in period.
2401903|NCT03559192|Experimental|Treatment Period: JNJ-67953964 or Placebo|Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.
2401904|NCT03559192|Placebo Comparator|Withdrawal Period: Placebo|Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.
2401908|NCT03559166|Experimental|cohort 1a - starting dose|Single oral dose of BLD-2660 or placebo capsule administered to healthy volunteers
2401909|NCT03559166|Placebo Comparator|cohort 1b- first SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (1st dose escalation)
2401910|NCT03559166|Placebo Comparator|cohort 1c-2nd SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (2nd dose escalation) in fasting state, followed by washout period and then single oral dose of BLD-2660 or placebo administered to healthy volunteers in fed state.
2401911|NCT03559166|Placebo Comparator|cohort 1d-3rd SAD escalation|Single oral dose of BLD-2660 or placebo capsules(s) administered to healthy volunteers (3rd dose escalation)
2401912|NCT03559166|Placebo Comparator|cohort 1e-4th SAD escalation|Single oral dose of BLD-2660 or placebo capsule(s) administered to healthy volunteers (final dose escalation if assessed as safe).
2401913|NCT03559166|Placebo Comparator|cohort 2a-1st MAD cohort|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers
2401914|NCT03559166|Placebo Comparator|cohort 2b-2nd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2401915|NCT03559166|Placebo Comparator|cohort 2c-3rd MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2401916|NCT03559166|Placebo Comparator|cohort 2d-4th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2401917|NCT03559166|Placebo Comparator|cohort 2e-5th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2401918|NCT03559166|Placebo Comparator|cohort 2F-6th MAD escalation|Multiple oral doses of BLD-2660 or placebo capsule(s) administered to healthy volunteers.
2401919|NCT03559153|No Intervention|Control group|All workers will receive ergonomics instructions. Instruction for rest break.
2401920|NCT03559153|Experimental|Passive rest break - Shiatsu massage|"All workers will receive ergonomics instructions. The workers will be receive quick massage using shiatsu techniques."
2401921|NCT03559153|Active Comparator|Active rest break - Physical Exercise Program|All workers will receive ergonomics instructions. The workers will be receive exercises during the rest break.
2401922|NCT03559140|Experimental|Group A|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length.~After the procedure cryotherapy will be applied as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
2401923|NCT03559140|Experimental|Group B|"Canals were prepared as in group A, Patients assigned to this group receive (application of criotherapy)~A final irrigation will be applied with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes. was applied. as follows:~Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes"
2401924|NCT03559140|Experimental|Control Group (CG)|"The R25 (size 25/ .08) instrument was used in thin and curved root canals, and R40 files (40/ .06) were used in wide root canals. Three in-and-out pecking motions were used with an amplitude of not more than 3 mm until reaching the estimated working length. Reciproc instruments were used in one tooth only (single use).~The group will receive the irrigant solution at room temperature. as follows:~they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes."
2401925|NCT03559127|Experimental|Group A. Cold Protocol with 6 oC|"Use of 20 mL cold (6 oC) sterile saline solution.~After the clinical procedure cryotherapy was applied. 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
2401926|NCT03559127|Experimental|Group B. Cold Protocol with 2.5 oC|"Use of 20 mL cold (2.5 oC) sterile saline solution~After the procedure cryotherapy was applied. 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes."
2401927|NCT03559127|Experimental|CG. Room temperature Protocol|"Use of 20 mL (at room temperature) sterile saline solution~The group will receive irrigant at room temperature. 5mL of 17% EDTA and 20 mL of sterile saline usingmetallic micro-cannula included in the Endo Vac System for five minutes."
2401928|NCT03559114|Active Comparator|Anticoagulant|Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
2401929|NCT03559114|Placebo Comparator|Saline|Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
2401930|NCT03559101|Active Comparator|Beverage 1 - Control|Distilled Water
2401931|NCT03559101|Experimental|Beverage 2|Medical Food 1 (8 amino acids, 60 mmol/L Na, 20 mmol/L K + citrate, Cl)
2401932|NCT03559101|Experimental|Beverage 3|Medical Food 2 (8 amino acids, 30 mmol/L Na, 10 mmol/L K + citrate, Cl)
2401933|NCT03559101|Experimental|Beverage 4|Pedialyte
2401934|NCT03559101|Experimental|Beverage 5|Gatorade
2401935|NCT03559088|Experimental|Migraine Participants Using Application (App)|Participants with migraine history or a recent prescription for a common migraine medication will use a migraine app linked to their electronic health record (EHR) with results reported in their EHR.
2401936|NCT03559088|No Intervention|Controls Not Using App|Observational history on contemporaneous matched controls at similar sites without migraine app linked to their EHR.
2401937|NCT03559075||Group 1|Participants will be randomized into group 1 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401938|NCT03559075||Group 2|Participants will be randomized into group 2 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401939|NCT03559075||Group 3|Participants will be randomized into group 3 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401940|NCT03559075||Group 4|Participants will be randomized into group 4 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401941|NCT03559075||Group 5|Participants will be randomized into group 5 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401942|NCT03559075||Group 6|Participants will be randomized into group 6 to be queried about their comfort with a topical steroid for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401943|NCT03559075||Group 7|Participants will be randomized into group 7 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
2401944|NCT03559075||Group 8|Participants will be randomized into group 8 to be queried about their comfort with medication for treating their child's atopic dermatitis after hearing varying amounts of information about the treatment.
3189107|NCT00774384|Active Comparator|1|Immunisation with NZ MenB OMV vaccine (NZ98/254)
3189108|NCT00774384|No Intervention|2|No vaccine
3189109|NCT00774423|Placebo Comparator|Placebo|MAIN EXCIPIENT OF THE RILUTEK
2402003|NCT03558698|Other|Group 5|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
3189110|NCT00774423|Active Comparator|Riluzole|RILUTEK
2401948|NCT03559049|Experimental|Rucaparib and Pembrolizumab Maintenance|"All patients will receive induction therapy with Pembrolizumab (200mg IV on day 1 of every 21 days), Pemetrexed (500mg/m^2 IV on day 1 of every 21 days), and Carboplatin (AUC5 IV on day 1 of every 21 days).~This will be followed by maintenance therapy with Pembrolizumab (200mg IV on day 1 of every 21 days) and Rucaparib (600mg PO BID days 1-21 of each 21 day cycle)."
2401949|NCT03559036||Locomotor Training|Assessments for bladder function will be conducted pre-training and following 80 sessions of locomotor training. Locomotor training consists of body-weight supported stepping on a treadmill for one hour.
2401950|NCT03559023|Active Comparator|Ultrasound Only|Ultrasound assisted epidural placement
2401951|NCT03559023|Active Comparator|Manometry Only|Manometry confirmation in epidural placement
2401952|NCT03559023|Active Comparator|Ultrasound Plus Manometry|Ultrasound Plus Manometry confirmation in epidural placement
2401953|NCT03559023|Sham Comparator|Usual Care/Management|Usual epidural technique placement
2401954|NCT03559010|Experimental|Use Phase Norgestrel 0.075 mg|Norgestrel 0.075 mg tablets to be taken orally, one tablet daily at the same time everyday for up to 16 weeks
3184682|NCT00727467|Experimental|A|"On Days 1-8 of the trial, participants in Group A will be given the iPod with some music on the device to allow all participants to become familiar with the device i.e. turning device on and off, increasing and decreasing the volume. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group A will be allocated to the 'intervention' phase. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks. On Days 15-23, participants in Group A will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat."
2401959|NCT03558984|Experimental|D-PLEX + SOC|For subjects randomized to the investigational treatment arm, D-PLEX treatment will be applied at the end of the index surgery just before closing the chest, as an adjunct to the SOC prophylactic antibiotic treatment.
2401960|NCT03558984|Other|Standard of Care|For subjects randomized to the control arm, the surgical treatment will be as per the SOC.
2401961|NCT03558971|Experimental|Patient self-administration of cortisol|Intervention is patient self-administration of cortisol.
2401962|NCT03558958|Experimental|P-188 NF|P-188 NF, 5 mg/Kg administered subcutaneously daily for 1 year
2401963|NCT03558945|Experimental|Personalized neoantigen vaccine|"Patients will receive radical surgery and at least one circle of post-operative chemotherapy.~Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs.~Patients will be called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit."
2401964|NCT03558945|No Intervention|Conventional treatment|Patients will receive radical surgery and conventional post-operative chemotherapy.
2401965|NCT03558919|Experimental|Mirabegron|Mirabegron 25mg will give daily at night for 12 weeks
2401966|NCT03558919|Active Comparator|Solifenacin|Solifenacin Succinate 5mg will give daily at night for 12 weeks
2401967|NCT03558906||Aggressive Periodontitis|These individuals had minimum PD ≥6 mm and CAL ≥5 mm on eight or more teeth; at least three of these were other than central incisors or first molars. Radiographic alveolar bone loss was ≥30% of root length affecting at least three permanent teeth other than first molars and incisors. The severe destruction pattern was not commensurate with amount of plaque accumulation.
2401968|NCT03558906||Chronic periodontitis|These individuals had at least four non-adjacent teeth with sites with PD ≥6 mm and CAL ≥5 mm. They had also ≥50% alveolar bone loss in at least two quadrants that was commensurate with amount of plaque accumulation. BOP was >50% in the whole mouth.
2401969|NCT03558906||Gingivitis|Gingivitis patients exhibited no sites with CAL >2 mm and no detectable alveolar bone loss in the radiography. BOP was >50% in the whole mouth.
2401970|NCT03558906||Healthy|Periodontally healthy volunteers exhibited no sites with PD >3 mm and CAL >2 mm as well as no radiographic evidence of alveolar bone loss. BOP was <15% in the whole mouth.
2401971|NCT03558893|Experimental|Forced Desynchrony|All participants will undergo a forced desynchrony protocol.
2401972|NCT03558880|Active Comparator|Erector Spinae Plane Block|Before the general anesthesia Erector Spinae Plane Block was performed.
2401973|NCT03558880|Active Comparator|Tumescent Anesthesia|After the general anesthesia was given, 1 mL of 0.1% adrenaline (1/1000) and as 20 mL of 0.5% bupivacaine solution of tumescent in a total of 1000 mL Ringer's lactate applied by the surgeon applied equally to both breasts
2401974|NCT03558867|Placebo Comparator|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
2401975|NCT03558867|Active Comparator|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Personalized diet based on an algorithm developed at the Weizmann Institute of Science (Zeevi et al, Cell 2015)
2401978|NCT03558841|Experimental|Intervention Group|Gait training with the THERA-Trainer Lyra (3x/week) in addition to conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, continuation of Lyra gait training (3x/week), discontinuation of physical therapy.
2401979|NCT03558841|Active Comparator|Control Group|Conventional geriatric rehabilitation physical therapy (6x/week) during inpatient period. After discharge home, discontinuation of physical therapy.
2402647|NCT03554213||Phase 2: TCV in 2019|Children receiving TCV (typhoid conjugate vaccine) in 2019 vaccination campaign by NMMC.
2401980|NCT03558828|Experimental|Step1: Initial Treatment|Participants will be randomly assigned to one of the two initial treatment components: a) enhanced physical activity monitor only (physical activity monitor with goal setting and a physical activity prescription) treatment, or b) enhanced physical activity monitor+ motivational text messaging treatment for 8 weeks (early adoption phase). All participants will be given a physical activity step goal The initial treatment time period is from Weeks 1-8.
2401981|NCT03558828|Experimental|Step 2: Augmented Treatment|"At Week 8, it will be determined if a women has met her physical activity step goal. If she has, then she will be classified as a responder, and will continue with the same initial treatment component for weeks 9-34 (later adoption).~If a woman has not met her physical activity step goal she will be classified as a non-responder. In addition to the initial treatment component non-responders to initial treatments will be randomly assigned to one of two augmented treatment components: a) personal calls, or b) group meetings for Weeks 9-34 (later adoption phase)."
2401982|NCT03558828|Experimental|Step 3: Maintenance|At Weeks 35-50 (maintenance phase) all participants in the study return to an enhanced physical activity monitor only treatment component.
2401983|NCT03558815||Adults with mild, moderate, severe or profound ID|Adults with mild, moderate, severe or profound ID in contact with either a sheltered workshop and/ or sheltered living Institution in Saxony.
2401986|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: A) 7 ± 2 En% linoleic acid (n = 37)
2401987|NCT03558776|Active Comparator|Linseed oil plus defined background diet (low linolec acid)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: B) < 2.5 En% linoleic acid (n = 37)
2401988|NCT03558776|Active Comparator|Linseed oil plus defined background diet (high milk)|Linseed oil (LO) plus daily menu plans (total dietary fat intake: 30 En%): 10 En% LO plus menu plan with 20 En% fat: C) 15 ± 2 En% milk fat (n = 37)
2401989|NCT03558776|Placebo Comparator|Linseed oil without defined background diet|Linseed oil (LO) without defined menu plans (D) Western diet, n = 37)
2401990|NCT03558763|Active Comparator|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
2401991|NCT03558763|Active Comparator|Telemonitoring|"Twice a week subject will perform additional vital functions:~Blood pressure and heart rate will be measured using the Electronic Sphygmomanometers Track.~Weight will be taken using the Scale lite Oxygen saturation will be measured using Pulse Oximeter Air And~Complete two PRO´s (integrated in the application):~CAT MRC All this is estimated to take approximately 20-30 min each time.~For the first 4 weeks there will be weekly video calls with a COPD-center nurse discussing health condition and vital parameters.~Thereafter there will be monthly video calls with a COPD-center nurse for the remaining 5 months, i.e. 4 further calls. The video calls will take approximately 15 min."
2401992|NCT03558750|Experimental|Treatment (nivolumab, rituximab, lenalidomide)|Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
2401993|NCT03558737|Active Comparator|Nasal high-frequency jet ventilation (nHFJV)|
2401994|NCT03558737|Active Comparator|Nasal intermittent positive pressure ventilation (NIPPV)|
2401995|NCT03558724|Experimental|NIR endoscopy with 4.5 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 4.5 mg of the fluorescent tracer bevacizumab-800CW to a total of 5 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
2401996|NCT03558724|Experimental|NIR endoscopy with 10 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 10 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
2401997|NCT03558724|Experimental|NIR endoscopy with 25 mg bevacizumab-800CW|"A non-randomized, non-blinded, prospective, feasibility study.~IV-administration of 25 mg of the fluorescent tracer bevacizumab-800CW to a total of 3 patients with locally advanced esophageal cancer. The optimal dose will be expanded to include 30 patients.~Molecular fluorescence endoscopy: 2-3 days after administration, molecular fluorescence endoscopy will be performed with additional measurements of fluorescence signals."
2401998|NCT03558711|Experimental|study group|
2401999|NCT03558698|Other|Group 1|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2402000|NCT03558698|Other|Group 2|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2402001|NCT03558698|Other|Group 3|"One night of good ventilation with High CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2402002|NCT03558698|Other|Group 4|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2402097|NCT03557996|Active Comparator|Group 2|5% Sodium fluoride varnish will be applied four times annually and patient will be followed up at 0,1,3,6,9 and 12
2402921|NCT03552328|Placebo Comparator|Control|Seniors receiving daily meals from Meals on Wheels
2402004|NCT03558698|Other|Group 6|"One night of good ventilation with a CO2 level of maximum 800 ppm~One night of good ventilation with high levels of CO2 (3000 ppm)~One night of poor ventilation with high concentrations of CO2 (3000 ppm) and other bio effluents (The order of the three conditions are randomized)"
2402005|NCT03558685|Experimental|Diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10%monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
2402006|NCT03558659|Experimental|Positional Therapy Belt|Use of positional therapy belt (SlumberBUMP) during sleep.
2402007|NCT03558659|No Intervention|Standard Care|No positional therapy belt provided for use during sleep.
2402008|NCT03558620|Experimental|Group 1O2|A fitting mask is held by one hand -> one hand with an endoscopic bite block -> held by two hands
2402009|NCT03558620|Experimental|Group 12O|A fitting mask is held by one hand -> held by two hands-> one hand with an endoscopic bite block
2402010|NCT03558620|Experimental|Group O12|A fitting mask is held by one hand with an endoscopic bite block->by one hand -> by two hands
2402011|NCT03558620|Experimental|Group O21|A fitting mask is held by one hand with an endoscopic bite block -> by two hands-> one hand
2402012|NCT03558620|Experimental|Group 21O|A fitting mask is held by two hands -> one hand -> one hand with an endoscopic bite block
2402013|NCT03558620|Experimental|Group 2O1|A fitting mask is held by two hands ->one hand with an endoscopic bite block-> by one hand
2402014|NCT03558607|Experimental|Experimental arm|
2402015|NCT03558594|Experimental|Hypnosis|Participant will have one brief meeting with a clinician in which they will learn about hypnosis and be provided with an informational booklet and with audiorecordings of hypnosis exercises. Participants will be encouraged to listen to the hypnosis recordings as much as they would like, whenever they would like to listen. The recordings are short inductions followed by therapeutic suggestions, including post-hypnotic suggestions. Participants will relax in a comfortable position with their eyes closed and will simply listen to the audio recordings that will include an induction followed by suggestions for decreased pain and improvement in co-morbid symptoms (e.g., improved mood and optimism, relaxation, sleep quality).
2402016|NCT03558594|Experimental|Mindfulness|Participant will have one brief meeting with a clinician in which they will learn about mindfulness meditation and be provided with an informational booklet and with audio recordings of mindfulness exercises. Participants will learn Vipassana meditation by listening to audio recordings, which is the specific form of mindfulness meditation (MM) typically implemented in mindfulness research. The emphasis is placed upon developing focused attention on an object of awareness, such as the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events.Participants will be encouraged to listen to the meditation recordings as much as they would like, whenever they would like to listen.
2402017|NCT03558594|No Intervention|No intervention|Participants will enroll in the study, but do not select a study intervention. They will complete study assessments on the same schedule as those participants who select either experimental arm.
2402018|NCT03558581|No Intervention|Control|Patients have not received any special intervention, the follow up care was the standard care for the specific clinic
2402019|NCT03558581|Experimental|Intervention|After initial allocation the select patient received six educational interventions selected from Nursing Intervention Classification (NIC)
2402020|NCT03558568|Active Comparator|DBS off|
2402021|NCT03558568|Active Comparator|DBS on 60 Hz.|
2402022|NCT03558568|Active Comparator|DBS on 99 Hz.|
2402023|NCT03558568|Active Comparator|DBS on 130 Hz.|
2402024|NCT03558568|Active Comparator|DBS on 230 Hz.|
3184683|NCT00727467|Active Comparator|B|"On Days 1-8 of the trial, participants in Group B will be given the iPod with some music on the device to allow all participants to become familiar with the device. They will be instructed to use the device only when sitting at home, and that the device should not be turned on when walking or performing any mobility related or daily tasks.~On Days 8-15, participants in Group B will be allocated to the 'control' phase. During this time period, participants will be provided with the iPod shuffle containing no music or metronome beat. On Days 15-23, participants in Group B will be allocated to the 'intervention phase'. Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks."
2402027|NCT03558542|Experimental|Study Group|cardiopulmonary rehabilitation plus neurorehabilitation
2402030|NCT03558503|Experimental|UGN-102|75 mg Mitomycin C (MMC) in 56 mL admixture (1.33 mg MMC per 1 mL of admixture).
2402031|NCT03558490|Experimental|ZEMY software|
2402032|NCT03558477|Experimental|Set 1(YYD601 1 & Nexium)|Set 1: YYD601 1 & Nexium
2402033|NCT03558477|Experimental|Set 2(YYD601 2 & Nexium)|Set 2: YYD601 2 & Nexium
2402034|NCT03558477|Experimental|Set 3(YYD601 3 & Nexium)|Set 3:YYD601 3 & Nexium
2402035|NCT03558464|Experimental|Intervention|"Intervention (agriculture-focused package~+ nutrition-sensitive and nutrition-specific interventions=integrated package)"
2402036|NCT03558464|Active Comparator|Control|(agriculture-focused package)
2402037|NCT03558451|Experimental|EXIMe intervention|In addition to the usual assistance, women will receive a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
2402038|NCT03558451|Active Comparator|Usual care|Usual care according to available protocols applicable to the women and the health service standardized portfolio
2402039|NCT03558438||HIV patients older than 50 years|Spanish cohort of patients with HIV infection older tha 50 years old.
2402040|NCT03558425|Experimental|TR group|Period 1: Test drug(CKD-381) Period 2: Reference drug(D026)
2402041|NCT03558425|Experimental|RT group|Period 1: Reference drug(D026) Period 2: Test drug(CKD-381)
2402042|NCT03558412|Experimental|Arm A|Decitabine+CODOX-M/IVAC for patients with relapsed or refractory T-lymphoblastic lymphoma who used Hyper-CVAD or BFM-90 as first-line therapy:regimen A:CODOX-M:cyclophosphamide,epirubicin,vincristine,methotrexate.Regimen B :IVAC:ifosfamide,etoposide，cytarabine.Decitabine,10mg,ivgtt,used for 5 days before A+B.
2402043|NCT03558399|Experimental|FET according to ERA|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the study arm, a single euploid embryo will be transferred at the time indicated by the ERA test results. Merely the timing of embryo transfer will distinguish the study from the control group.
2402044|NCT03558399|Active Comparator|FET according to standard protocol|In preparation for frozen embryo transfer (FET), estradiol will be administered for approximately 10 to 14 days or until endometrial criteria are met. These endometrial criteria will be assessed with transvaginal ultrasound and serum estradiol levels. Women will then begin intramuscular progesterone injection and if assigned to the control arm, a single euploid embryo will be transferred according to our standard FET protocol.
2402045|NCT03558386||Patients between 55-64 years of age|"Patients between 55-64 years who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
2402046|NCT03558386||Patients 65+ years of age|"Patients 65+ years of age who have had a transplant at the following time points:~6 months to 1 year ago~1 year to 3 years ago~3 years ago or more"
2402048|NCT03558347|Experimental|short implants with splinted crowns|Patients of that group received splinted crowns on the two adjacent implants Intervention: short implants with splinted crowns
2402049|NCT03558347|Experimental|short implants with non-splinted crowns|Patients of that group received single crowns on the two adjacent implants Intervention: short implants with non-splinted crowns
2402050|NCT03558334|Experimental|Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be given to preterm infants with BPD.
2402051|NCT03558334|Active Comparator|No Transplantation of Mesenchymal Stem Cell|Mesenchymal stem cell will be not given to preterm infants with BPD.
2402052|NCT03558321|Experimental|post menopausal bleeding|women with postmenopausal bleeding and endometrial thickness more than 5 mm
2402053|NCT03558308|Experimental|Brain+ with clinical support|Intervention: Computer based cognitive rehabilitation. This group will train with the programme 'Brain+' and receive continuous support from a clinician during the intervention period.
2402054|NCT03558308|Experimental|Cogmed with continuous support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Cogmed' and receive continuous support from a clinician during the intervention period.
2402055|NCT03558308|Experimental|Brain+ without support|Intervention: computer based cognitive rehabilitation. This group will train with the programme 'Brain+' but receive no support during the intervention period.
2402056|NCT03558308|Sham Comparator|Sham-training group|Intervention: Sham computerized gaming. This group will train computerized solitaire and other computerized games which are thought to be generally cognitive stimulating but with a very limit load on executive functions. This group will receive continuous support during the intervention period.
2402057|NCT03558282||Maxillary Anterior Implant|Subjects who have a single implant restoration in the maxillary anterior position with sufficient baseline data. Recession observation and crown contour observation of the implant will be completed.
2402058|NCT03558269|Experimental|Study group|This group will receive UCB after the first palliative surgery
2402059|NCT03558269|No Intervention|Control group|This group will not receive any treatment
2402060|NCT03558256|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness- based cognitive therapy added to the usual medication treatment, and guided by two therapists for 8 sessions. Every group of 6 people can form a closed structural group. Each session lasts 2 hours once a week, and has daily homework assignments.
2402061|NCT03558256|Active Comparator|Medication|Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of depression (fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram and escitalopram).
2402062|NCT03558243|Active Comparator|Patent Hemostasis Arm|The TR Band (Terumo medical) will be placed on the sheath entry site, the air bladder of the TR Band will be filled with 18 mL of air to achieve initial hemostasis. The sheath will be removed, air will be withdrawn slowly until a pulsatile bleeding is observed through the sheath's orifice, once this phenomenon occurs, 2 ml of air will be added to the air bladder and the absence of bleeding will be corroborated, immediately afterwards a pulse oximeter will be placed on the index finger of the patient and transient manual compression of the ipsilateral ulnar artery will be performed, patency of the radial artery will be corroborated by means of oxygen saturation and adequate pulse curve (Barbeau reverse test), if it is not possible to achieve patent hemostasis, it will be retried deflating 1-2 ml of the TR Band every 15 minutes until a positive reverse Barbeau test with absence of bleeding is achieved. TR Band removal will be attempted 2 hours after the procedure.
2402063|NCT03558243|Experimental|ULTRA Arm|The TR Band will be placed at the sheath entry site, the ipsilateral ulnar artery will be compressed at the Guyon's canal by placing a cylindrical composite made by wrapping 4 inch x 4 inch gauze around a 1-inch plastic needle cap, and compressing it using a circumferentially applied Hemoband. After occlusive compression of ulnar artery is confirmed by means of plethysmography, patent hemostasis protocol will be used for radial artery hemostasis as described at the patent hemostasis arm. The needle cap and hemoband that compresses the ulnar artery will be removed 1 hour after the procedure. TR Band removal will be attempted 2 hours after the procedure.
2402064|NCT03558243|Experimental|Hemostatic Disc Arm|The StatSeal hemostatic disc will be placed above sheath entry site, the TR Band will be placed above the disc, according to the manufacturer's specifications the air bladder will be filled with 8 ml of air, the sheath will be then removed, corroborating the absence of bleeding, 20 minutes later 3 ml of air will be removed, 20 minutes after that 5 ml of air will be removed, finally the investigators will try to remove the deflated TR Band 60 minutes after the procedure.
3184684|NCT00727480|Experimental|A|Ultrasound Imaging of fingertips
3184685|NCT00727493|Active Comparator|1|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
3184686|NCT00727493|Placebo Comparator|2|placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
3184687|NCT00727493|No Intervention|3|dental implant, calcium 1000mg and Vitamin D 800 IU daily
2402069|NCT03558204||CMC denervation|Patients will undergo denervation of the thumb CMC joint
2402070|NCT03558204||trapeziectomy with ligament reconstruction (LRTI)|Patients will undergo excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
2402071|NCT03558191|Experimental|Injection SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes.
2402072|NCT03558178|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated.
2402073|NCT03558178|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at a total 6-12 acupoints in the upper and middle trapezius areas (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
2402074|NCT03558165||Stage IV Lung Adenocarcinoma|
2402083|NCT03558139|Experimental|Magrolimab + Avelumab (Part 1, Safety Run-in)|"Dose Level 1: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 30 mg/kg weekly for 4 doses (Cycle 1). Starting in Cycle 2, magrolimab 30 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Based on Dose Limiting Toxicities (DLTs) assessment in Dose Level 1 Cycle 1; additional participants will be enrolled and administered Dose Level 2.~Dose Level 2: Participants with solid tumors will be given a starting priming dose of 1 mg/kg magrolimab in Week 1, followed by 45 mg/kg on Days 8,11,15, 22 and 29 for Cycle 1, continuing weekly in Cycle 2 on Days 1, 8, 15 and 22. Starting in Cycle 3, magrolimab 45 mg/kg will be given every 2 weeks. The magrolimab dose will be combined with avelumab 800 mg given once every 2 weeks.~Additional lower or higher dose levels may be explored after reviewing all available clinical data."
2402084|NCT03558139|Experimental|Magrolimab + Avelumab (Part 2, Ovarian Cancer Expansion)|After Part 1 Safety Run-in has completed and the recommended expansion dose(s) for magrolimab is determined, participants with ovarian cancer will be administered the recommended magrolimab dose(s) combined with avelumab 800 mg given once every 2 weeks.
2402085|NCT03558113|Other|visual tactile method|visual tactile method using the modified USHPS critiria
2402086|NCT03558100|Experimental|Reducing Fall Risks in Obesity|Adults with obesity will be asked to perform the obstacle crossing intervention for adults with obesity for reducing falls risk. This will involve crossing obstacles of different heights under five conditions: initial baseline walking on flat ground, crossing three obstacle heights, and final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters will be collected using a gait carpet and body-worn sensors.
3184688|NCT00727519|Experimental|PG|
3184689|NCT00727519|Experimental|PL|
3184690|NCT00727545|Experimental|1|
2402090|NCT03558048||Men with Inflammatory Bowel Disease|Men with a confirmed diagnosis of IBD between the ages of 40-69 years old. These subjects will have their prostate specific antigen checked via a blood draw during clinic visits over the course of the study period.
2402091|NCT03558035|Experimental|Induction chemotherapy and concurret chemoradiotherapy group|Patients receive 2 cycles of paclitaxel, cisplatin and 5-Fluorouracil chemotherapy followed by Surgery or Chemo-radiotherapy according to the response status after induction chemo.
2402092|NCT03558035|Active Comparator|Concurrent chemoradiotherapy group|Patients receive single-agent cisplatin chemotherapy concurrent with Radiotherapy
2402093|NCT03558022|Experimental|Salt Pills|One week on low salt diet plus salt pills
2402094|NCT03558022|Placebo Comparator|Placebo Pills|One week on low salt diet plus placebo pills
2402096|NCT03557996|Experimental|Group 1|38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up as 0,1,3,6,9 and 12 SDF is brush on liquid
2402648|NCT03554200|Experimental|Empagliflozin|Patients will receive empagliflozin 10 mg qd for a period of 30 days.
3184691|NCT00727584|Active Comparator|Arm I (multi-fraction radiotherapy)|Patients undergo 5 fractions of 20 Gy external-beam radiotherapy.
3184692|NCT00727584|Experimental|Arm II (single-fraction radiotherapy)|Patients undergo 1 fraction of 8 Gy external beam radiotherapy.
3184693|NCT00727662|Experimental|1|Yoga
3184694|NCT00727662|Active Comparator|2|A Wellness Seminar series
3184695|NCT00727675|Other|1|Integrated Cognitive Behavioral Therapy for pain reduction and opioid dependence.
2402098|NCT03557983|Experimental|fenofibrate|Fenofibrate should be topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
2402099|NCT03557983|Placebo Comparator|Saline|Saline is topically spread three times per day for one week.
3184696|NCT00727701|Experimental|1|Will receive usual wound prevention care, aftercare summaries, and regular surveillance.
2402101|NCT03557957|Experimental|Standard care plus targeted correction of hyponatremia|Diagnosis and treatment of hyponatremia will be standardized according to the European Clinical Practice Guidelines (ECPG). Treatment response and adherence will be evaluated daily and treatment adapted if treatment goals are not reached.Targeted correction of plasma sodium Levels.
2402102|NCT03557957|Active Comparator|Standard care|Diagnosis and treatment of hyponatremia will be solely at the discretion of the attending physicians who are in no way involved in the trial. The study team will not intervene with the treatment in any way. Diagnostic and treatment decisions as well as course of the plasma sodium level will only be recorded after patient is discharged from hospital using the medical records and patient charts. It will be generally recommended to measure plasma sodium levels 3x weekly or more frequently if clinically indicated, at discharge and after 30 days.
2402103|NCT03557944|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
3184697|NCT00727701|No Intervention|2|Will receive usual wound prevention and surveillance only.
3184698|NCT00727701|No Intervention|3|Will receive usual wound prevention only.
3184699|NCT00727727||Parkinsonian patients|
2402107|NCT03557918|Experimental|Tremelimumab|Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.
2402108|NCT03557905|Active Comparator|Group I|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
2402109|NCT03557905|Active Comparator|Group II|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
2402110|NCT03557892|Experimental|CSII+CGM|
2402111|NCT03557892|Active Comparator|MDI with degludec|
2402112|NCT03557879||Hearing impaired families|Samples from families presenting with familial hearing impairment, underlying the genetic basis, for whom 74 deafness genes have already been excluded (no evidence of pathogenic genotype)
2402113|NCT03557866|Experimental|pronated group|individuals with pronated foot
2402114|NCT03557866|Active Comparator|control group|individuals with normal foot posture
2402115|NCT03557853||Golimumab injection|Patients with ankylosing spondylitis and coxitis being treated with Simponi (golimumab) according to local clinical practice and label.
2402116|NCT03557840|Experimental|Temocillin treatment|Patients treated with temocillin and sampled as per the protocol
2402117|NCT03557827|Sham Comparator|control|Mechanical debridement by periodontal curets alone
2402118|NCT03557827|Active Comparator|Photodynamic Therapy|Mechanical debridement by periodontal curets and supplement with photodynamic appliance
2402119|NCT03557814|Active Comparator|LED01|Conventional non-surgical periodontal therapy plus LED light irradiation from T0-T1
2402120|NCT03557814|Active Comparator|LED02|Conventional non-surgical periodontal therapy plus LED light irradiation from T1-T2
2402121|NCT03557814|Sham Comparator|Control|Conventional non-surgical periodontal therapy without LED light irradiation
3184700|NCT00727753||Ranibizumab|
3184701|NCT00727753||Bevacizumab|
3184702|NCT00727753||Dry AMD|
2402125|NCT03557788|Experimental|Rifaximin|Patients who receive PO Rifaximin 500mg TDS for 2 weeks. All patients will receive treatment to evaluate the effect of the intervention. This is a single-arm study.
3184703|NCT00727766|Experimental|Cohort 1|Clofarabine 1 mg for 14 days followed by 14 days of rest. Each cycle is 28 days long.
2402188|NCT03557411|Experimental|SHR-1210 +Hypofraction radiotherapy|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
2402189|NCT03557398|Experimental|Hydeal-D vaginal pessaries|Vaginal application of Hydeal-D vaginal pessaries
3184704|NCT00727766|Experimental|Cohort 2|Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3184705|NCT00727766|Experimental|Cohort 3|Clofarabine 3 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3184706|NCT00727766|Experimental|Cohort 4|Clofarabine 4 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3184707|NCT00727766|Experimental|Cohort 5|Clofarabine 5 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3184708|NCT00727766|Experimental|Cohort 6|Clofarabine 6 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
3184709|NCT00727779|Experimental|metabolic syndrome|intervention is to undergo eight weeks of progressive strength training; metabolic syndrome subjects will have baseline and post-intervention assessments including muscle biopsies and insulin clamps
3184710|NCT00727779|Active Comparator|control subjects|intervention is to undergo eight weeks of progressive strength training; non-obese sedentary subjects will have the same assessments as the metabolic syndrome subjects and exercise training simultaneously.
3184711|NCT00727792|Experimental|Group 2 - Research MRI|Subjects will have additional sequences and/or modification to MRI sequences.
3184712|NCT00727792|Active Comparator|Group 1 - Clinical MRI|Clinically ordered MRI scan. Subjects will not have any additional sequences or modifications to their clinically ordered MRI
3184713|NCT00727870|Other|1|After the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem dressing.
3184714|NCT00727870|Other|2|Arm 2: after the two biopsies, one site will be covered with the antibiotic ointment and the band-aid type bandage (physician's current standard of care) and the other site will be covered the Shapes by PolyMem Silver dressing.
3184715|NCT00727870|Other|3|Arm 3: after the two biopsies, one site will be covered with Shapes by PolyMem dressing and the other site will be covered the Shapes by PolyMem Silver dressing.
3184716|NCT00727883||1|Post menopausal women treated with adjuvant TAM for breast cancer
2402129|NCT03557762|Experimental|Immediate Mindfulness|A 4 week smartphone app-based mindfulness intervention program with in-app activities for 20-30 minutes every day, with a minimum of 4 days of activity in a week.
2402130|NCT03557762|Other|Waitlist Control Mindfulness|No intervention for 4 weeks, after which there will be assessments immediately post-waiting and at 3 months post-baseline. After this, participants will get the same 4 week smartphone app-based mindfulness intervention program.
2402131|NCT03557749||Immune and Microbial Reconstitution|
2402132|NCT03557749||Immune Response Triggered by Severe, Systemic Viral Infection|
2402133|NCT03557749||Immune Response Triggered by Acute Graft-versus-Host Disease|
2402134|NCT03557749||Immune Response Triggered by Chronic Graft-versus-Host Disease|
2402135|NCT03557749||Immune Response Triggered by Relapse|
2402136|NCT03557749||Immune Response Triggered by Cytokine Release Syndrome|
2402137|NCT03557749||Allogeneic Related Donor Samples|
2402138|NCT03557749||Cellular Therapy Products|
2402139|NCT03557736|Experimental|Home-HIT|Home-based high-intensity interval training: participants performed 12 weeks of simple body weight exercises in a place of their own choosing 3x/week
2402140|NCT03557736|Experimental|Home-MICT|Home-based moderate-intensity interval training: participants performed 12 weeks of continuous exercise (running, swimming or cycling) in a place of their own choosing 3x/week
2402141|NCT03557736|Experimental|Lab-HIT|Laboratory-based high-intensity interval training: participants performed supervised cycle exercise under laboratory conditions 3x/week for 12 weeks
2402142|NCT03557710|Experimental|Behavioral Response Training|In Arm 1 of Devaluing energy-dense foods for cancer-control, participants will complete computer delivered versions of the stop-signal, go/no-go, and dot-probe training tasks in 8 30-min biweekly visits to the lab, with breaks between training blocks in which participants sit with their eyes closed to allow consolidation of learning. Participants will also complete a weekly 15-min training task online from home. Total training time = 345 min. Training will involve 100 images of cancer risk foods that participants regularly eat, including red and processed meats; high-sugar foods; heavily salted, smoked, and pickled foods; fries, chips, and snacks with trans-fats, and 100 images of healthy foods that participants rate as palatable, including vegetables, fruits, nuts, and whole grains.
2402143|NCT03557710|Experimental|Cognitive Reappraisal Training|Arm 2 of the Devaluing energy-dense foods for cancer-control intervention will be delivered via computer-assisted in-person training. Between baseline and endpoint sessions, participants will practice reappraisal on a computer, under close supervision of a facilitator, in 8 30-min twice-weekly individual sessions. During sessions, participants will practice cognitive reappraisal to reduce the value of cancer risk foods. Participants will also practice reappraisal of cancer risk foods on a computer at home, twice weekly for 15 minutes, for a total intervention time of contact of 345 minutes. The facilitator will review homework completed by participants and offer corrective feedback. The home practice is intended to promote generalization of use of this skill in the natural environment.
2402144|NCT03557710|Active Comparator|Generic Response Training|In Arm 3 (active control) of the Devaluing energy-dense foods for cancer-control intervention will be identical in duration and contact time to the behavioral response training described above (345 min total), but will involve nonfood images (birds and flowers), as described in the pilot trial. Participants will be informed that this intervention is designed to improve response inhibition, which should lead to eating change and weight loss given that impulsivity increases the risk for overeating, ensuring the credibility of the control arm.
2402145|NCT03557697|Active Comparator|wait-list control|3 measurement visits, baseline, 3, and 6 months
2402146|NCT03557697|Active Comparator|SMS intervention|3 measurement visits, baseline, 3, and 6 months
3150942|NCT00214682|Experimental|Mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
3184717|NCT00727896|Experimental|1 is experimental with SMS|Arm 1 is experimental with SMS intervention
3184718|NCT00727896|Active Comparator|2 is (active comparator) standard care|Arm 2 is the usual care arm (standard care)
3184719|NCT00727922|Experimental|1|
2402151|NCT03557671|Experimental|TRHF - Placebo|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
2402152|NCT03557671|Placebo Comparator|Placebo - TRHF|Each subjects will receive both TRHF and placebo formula during the 1st part of the study
3184720|NCT00727948|Experimental|receive aspirin|
2402155|NCT03557645|Sham Comparator|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow = 60Lpm and tidal volume = 6mL/IBW. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2402156|NCT03557645|Experimental|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm, the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved, and an inspiratory pause will be applied at the end of inspiration. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2402157|NCT03557645|Experimental|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow will be set at 20Lpm and the tidal volume will be increased in steps of 200mL until the peak airway pressure of 40cmH2O is achieved. After achieving the target pressure, this ventilatory regimen will last 15 minutes. Positive end-expiratory pressure and the inspired oxygen fraction will not be modified.
2402158|NCT03557632|Experimental|TREATMENT:Virtual Reality Cue Exposure Therapy (VRCET)|Virtual Reality Cue Exposure Therapy (VRCET) - Active Intervention - comprised of exposure to VR based heroin cues, such as heroin use paraphernalia and scenes of people using injection heroin or snorting heroin. Exposure will be supplemented by the use of a standardized CBT based skills coping protocol teaching relapse prevention skills such as urge surfing, thought stopping and reframing. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
2402159|NCT03557632|Active Comparator|Control: Relapse Prevention Drug Education|Relapse Prevention Drug Education (RPDE) is our Active Comparator. Comprised of watching a series of videos on the health risks of heroin use as well as information about relapse prevention. Lab based reactivity will be measured by self-reported craving on a scale from 0 (none) to 100 (highest ever), heart rate, galvanic skin response, and muscle tension. Secondary outcome measures are number of times of self-reported drug use in vivo as recorded by a cell phone app based Ecological Momentary Assessment Device (EMA).
3184721|NCT00727974||1|"Diagnostic Criteria for CVS:~3 or more different episodes of vomiting, normal health between episodes, no abnormal test results to account for vomiting [such as endoscopic biopsies (looking at a body part with a lighted tube), hydronephrosis (water block kidney drainage), cholelithiasis (gallstones), pancreatitis (swelling of the pancreas), and hypoglycemia (too little sugar in the blood)];"
2402161|NCT03557606||Alar treatment with BMC|Patients with CCJ instability that receive Alar treatment with BMC using anterior approach.
2402162|NCT03557580|Active Comparator|IS-5-MN R|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2402163|NCT03557580|Experimental|IS-5-MN T1|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2402164|NCT03557580|Experimental|IS-5-MN T2|Isosorbide-5-mononitrate extended-release tablet, Single oral dose 40mg
2402165|NCT03557567||MO patients|
2402166|NCT03557567||OI patients|
2402167|NCT03557554|Experimental|Massage Therapy|Subjects who are planning treatment with paclitaxel as part of their standard of care treatment will receive a 20 minute massage prior to each paclitaxel infusion.
2402168|NCT03557541|Experimental|Sardine group|
2402169|NCT03557541|Active Comparator|Control group|
2402170|NCT03557528||Group 1|High Ligation of Inferior mesenteric artery
2402171|NCT03557528||Group 2|Low ligation of inferior mesenteric artery with skeletonization at its origin
2402172|NCT03557515|Experimental|CBT Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional CBT telephonic sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
2402173|NCT03557515|Experimental|Metta-Meditation Telephonic Sessions|All participants will receive four stress management sessions. Then, the participant is randomly assigned to receive 4 weekly additional Metta-meditation sessions. Participants will be given weekly assignments to practice the skills learned in the sessions. Sessions will last 45 minutes to 1 hour. Optional grief and loss telephonic session will be offered.
2402174|NCT03557502|Experimental|Heat Therapy Group|Group will undergo 30 sessions of heat therapy over approximately 10 weeks. Sessions will require subjects to be immersed in hot water for up to 45 minutes per session.
2402175|NCT03557502|Experimental|Aerobic Exercise Group|Group will undergo 30 sessions of aerobic exercise training over approximately 10 weeks. Sessions will require subjects to exercise on a cycle ergometer for up to 45 minutes per session.
2402176|NCT03557489|Experimental|Experimental group|Patients use gel pad(in usual) in addition to(Mepilex Border Sacrum)foam pad during surgery.
2402177|NCT03557489|No Intervention|Control group|patients use gel pad(in usual) during surgery.
3184722|NCT00727974||2|"Diagnostic Criteria for Migraine:~5 or more different headaches, complete return to health in between headaches, headaches last 2-48 hours and get in the way everyday activity, headache affects one side of head, with pounding moderate-to-severe pain, one of the following: nausea, vomiting, photophobia (fear of light), phonophobia (fear of sound)."
2402180|NCT03557463|Active Comparator|Soy protein|Low isoflavone soy protein powder: Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
2402181|NCT03557463|Experimental|Dairy protein|UV-C treated raw milk protein supplement (TruActiv MPC 85). Each participant was required to consume a total of 112 servings for the 8-week duration of the study. A 4-week supply was provided at baseline (week 0) and at the time of vaccine administration (week 4).
2402182|NCT03557450|Experimental|PET/CT scanning with sodium fluoride|Subjects will received PET/CT scanning with sodium fluoride
2402183|NCT03557437|Active Comparator|Triple Therapy|Esomeprazole 20mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
2402184|NCT03557437|Experimental|Bismuth Plus Triple Therapy|Esomeprazole 20mg bid, Bismuth Potassium Citrate 600mg bid, Amoxicillin 1.0g tid and Metronidazole 0.4g tid for 14 days
2402185|NCT03557424|Experimental|Polyglucosamine Glucomannan normal dose|Patients received the single dose Polyglucosamine und Glucomannan (0,5 g resp. 1 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
2402186|NCT03557424|Experimental|Polyglucosamine Glucomannan high dose|Patients received the higher dose of Polyglucosamine und Glucomannan (1 g resp. 1,34 g per Stick) three times per day over 65 days. The drug is administered as a powder which is dissolved in water. The solution is taken orally.
2402187|NCT03557424|Placebo Comparator|Placebo|Patients received Placebo three times per day over 65 days. The Placebo is administered according to the respective Intervention (Drug: Placebo Comparator: Placebo) as a powder which is dissolved in water. The solution is taken orally.
3143947|NCT00023751|Experimental|surgery + leucovorin + fluorouracil + radiation|"Patients with T3 disease or positive surgical margins after surgery are removed from study. Patients with T1 disease and negative surgical margins after surgery are observed. Patients with T2 disease and negative surgical margins after surgery receive adjuvant therapy.~Beginning 42 days after surgery, T2 patients receive leucovorin calcium (CF) IV over 2 hours with fluorouracil (5-FU) IV bolus 1 hour into the infusion once weekly for 6 weeks. Beginning 2 weeks after the completion of chemotherapy, patients receive chemoradiotherapy comprising radiotherapy once daily 5 times a week for 5 weeks and 5-FU IV continuously while receiving radiotherapy. Beginning 2 weeks after the completion of chemoradiotherapy, patients again receive CF IV over 2 hours with 5-FU IV bolus 1 hour into the infusion once weekly for 6 weeks. Chemotherapy repeats after 2 weeks rest for a total of 2 courses.~Patients are followed every 3 months for 2 years and then every 6 months for 5 years."
3184723|NCT00727987|Experimental|CNTO 148 50 mg + methotrexate|
3143948|NCT00023829|Experimental|LH-RH agonist plus radiation therapy|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years plus radiation therapy (RT) to 63.0 - 66.6 Gy
3143949|NCT00023829|Active Comparator|Radiation therapy alone|Radiation therapy alone to 63.0 - 66.6 Gy
3143950|NCT00023829|Active Comparator|LH-RH agonist alone|Luteinizing hormone-releasing hormone (LH-RH) agonist x 2 years
3143951|NCT00023920|Experimental|Treatment (bevacizumab, idarubicin, cytarabine)|Patients receive bevacizumab IV over 90 minutes once on day -13. Patients then receive bevacizumab IV over 90 minutes and idarubicin IV on days 1 and 15 and cytarabine subcutaneously (SC) once daily beginning on day 1. Treatment repeats every 4 weeks for a maximum of 3 courses. Patients with responding disease receive maintenance therapy comprising bevacizumab IV over 90 minutes on days 1 and 15, idarubicin IV on day 1, and cytarabine SC once daily beginning on day 1. Treatment repeats every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2402200|NCT03557268||On a GnRHa|Half of subjects will be on a puberty blocker or gonadotropin-releasing hormone analogue
2402201|NCT03557268||Not on GnRHa|Half of subjects will NOT be on a puberty blocker or gonadotropin-releasing hormone analogue
2402202|NCT03557255|Active Comparator|levosimendan|Levosimendan was prepared in a concentration of 25 µg/ml and infusion was commenced at a rate of 0.1 µg/kg/minute without loading and continued for 24 hours before surgery.The dose was doubled if an increase of > 20 mmHg in systolic blood pressure (SBP) could not be obtained within 2 hours after starting the infusion. Indications for dose reduction were the development of hypotension (SBP < 80 mmHg) or tachycardia (heart rate > 120 beats/min) persisting for more than 10 minute or (premature beats in a frequency exceeding 6/min or occurrence of a significant arrhythmia occurring in runs). The infusion medication would be discontinued should such occurrences persist despite dose reduction.
2402203|NCT03557255|Active Comparator|control|In the control group ,an identical saline infusion regimen was employed instead of levosimendan . Both patient and care giver were blinded for the study.
2402207|NCT03557229|Experimental|Melatonin|
2402208|NCT03557229|Experimental|Vitamin C|
2402209|NCT03557229|Experimental|Vitamin E|
2402210|NCT03557229|Experimental|N-acetylcysteine|
2402211|NCT03557229|No Intervention|Control|
2402212|NCT03557216|Experimental|Complicated diverticulitis|Patients with complicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
2402213|NCT03557216|Experimental|Uncomplicated diverticulitis|Patients with uncomplicated diverticulitis diagnosed by computed tomography. Colonoscopy, Fecal immunochemical and occult blood test (FIT) and fecal calprotectin test wil be performed.
2402214|NCT03557151|Active Comparator|Usual Care|Usual Care participants will receive the same excellent multidisciplinary care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
2402215|NCT03557151|Experimental|Transdisciplinary Care-In Person & Telehealth|In addition to all elements of Usual Care, TC-IP participants will have follow-up clinic visits in-person or by telehealth at approximately 3 month intervals during the study that will consist of simultaneous involvement of an advanced practice nurse, dietitian and psychologist who will see the parent and adolescent together. TC team members will have passed a competency exam following completion of a training course on each of the TC team professional disciplines.
2402216|NCT03557138|Experimental|Me4FDG|Intravenous injection of alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG) and FDG for evaluation the kidney kinetic model of FDG and Me4FDG in type 2 diabetic patients with SGLT2-inhibitor therapies.
3184724|NCT00727987|Experimental|CNTO 148 100 mg + methotrexate|
2402219|NCT03557112|Experimental|the treatment group|TPF regimen induction chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
2402220|NCT03557112|Active Comparator|the control group|TPF regimen induction chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
2402221|NCT03557099|Experimental|Hetrombopag Olamine|Hetrombopag will be started at 7.5 mg/day and uptitrated according to the platelet count.
3143952|NCT00023933|Experimental|Treatment (monoclonal antibody)|"Patients receive a tracer dose of iodine I 131 monoclonal antibody CC49-deltaCH2 IV on day 1 and a therapy dose over 30 minutes on day 8.~Cohorts of 3-5 patients receive escalating doses of iodine I 131 monoclonal antibody CC49-deltaCH2 until the MTD is determined. The MTD is defined as the dose at which 3 of 5 patients experience grade 3 or greater toxicity while 0-2 of 5 patients experience reversible grade 4 hematologic toxicity."
3143953|NCT00023946|Experimental|Treatment (ixabepilone)|Patients receive BMS-247550 IV over 3 hours on day 1. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2402224|NCT03557073|Experimental|Phone Call|Subjects in this study arm receive a post-operative phone call by a physician.
2402225|NCT03557073|No Intervention|No Phone call|Subjects in this study arm do not receive an additional post-operative phone call by a physician.
2402226|NCT03557060||Subjects receiving NUCALA|Subjects with a diagnosis of EPGA, for which NUCALA is indicated will be included.
3184725|NCT00727987|Placebo Comparator|Placebo + methotrexate|
2402229|NCT03557021|Experimental|Individualized therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the followed therapy will be adjusted with in this setting available medications to the outcome of the resistance profile
2402230|NCT03557021|Active Comparator|standard therapy arm|HIV Treatment failure patients will undergo an HIV Drug resistance testing and the national defined standard therapy will be applied as second line treatment.
2402231|NCT03557008|Active Comparator|Rabies Vaccine with Antibiotics|Participants in this group will receive the rabies vaccines as well as an antibiotic regimen consisting of metronidazole, vancomycin, and neomycin sulfate.
2402232|NCT03557008|Active Comparator|Rabies Vaccine|Participants in this group will receive the rabies vaccine.
2402233|NCT03556995||Bariatric surgery patients|All patients above 18 that underwent bariatric surgery
2402234|NCT03556982|Experimental|CART-123|The relapsed/refractory AML patients will receive allogenic or autologous CD123-Targeted CAR-T cells infusion after FC chemotherapy.
2402235|NCT03556969||Propofol sedation after SA|Participants who undergo propofol sedation after spinal anesthesia
2402236|NCT03556956|Experimental|Masitinib plus FOLFIRI|"Masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid).~Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal."
2402237|NCT03556956|No Intervention|Best Supportive Care|Best Supportive Care (BSC) includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
2402238|NCT03556930|Experimental|Movie Induced Sedation Effect|Pediatric Radiation Oncology with Movie Induced Sedation Effect monitored by an AlignRT system (VisionRT LTD, UK).
2402239|NCT03556917|Active Comparator|group 1|topical gel base + caffeine.
2402240|NCT03556917|Active Comparator|group 2|iontophoresis + caffeine
2402241|NCT03556917|Active Comparator|Group 3|iontophoresis
3143954|NCT00023959|Experimental|Treatment (hydroxyurea, fluorouracil, bevacizumab, radiation)|Patients receive oral hydroxyurea every 12 hours on days 1-6, fluorouracil IV continuously on days 1-5, and bevacizumab IV over 90 minutes on day 1. Patients also undergo radiotherapy once daily on days 1-5. Patients receive G-CSF subcutaneously on days 6-12. Treatment repeats every 2 weeks for up to 7 courses in the absence of disease progression or unacceptable toxicity.
3143955|NCT00023998|Experimental|Treatment (combination chemotherapy)|See detailed description.
2402245|NCT03556878|Experimental|Fitted TranS-C|Fitted TranS-C involves 4 x 20-30 minute sessions. It involves selected cross-cutting, core and optional modules from Standard TranS-C.
2402246|NCT03556852|Active Comparator|CARBETOCIN|received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
2402247|NCT03556852|Active Comparator|MISOPROSTOL|received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.
2402248|NCT03556839|Active Comparator|Arm A|Cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.
2402249|NCT03556839|Experimental|Arm B|cisplatin 50mg/m2 or carboplatin AUC 5 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.
2402279|NCT03556618|No Intervention|Control|Participants in the control arm will receive usual care reentry healthcare planning, including correctional health provider and court-referred SUD and mental health treatment recommendations, medication prescriptions, written instructions for reinstating Medicaid, and written health discharge summaries. Participants in this branch will include youth exiting the adult justice system (ages 18-24) and youth exiting the juvenile justice system (ages 16-18).
2402280|NCT03556605|Other|Intervention Arm|A target of 100 subjects will be enrolled in the Intervention arm using the OneTouch Reveal® Mobile APP system
3143956|NCT00024011|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3143957|NCT00024024|Experimental|Arm I|Patients receive oral BMS-275291 1-2 times daily. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 6 patients receive escalating doses of BMS-275291 until the recommended phase II dose (RPTD) is determined. The RPTD is the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity and more than 1 of 6 patients experiences clinical response or at least 5 of 6 patients demonstrate biologic activity. An additional 29 patients are treated at the RPTD.
3143958|NCT00024089|Experimental|Arm I|Patients receive oral gefitinib daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
2402250|NCT03556826|Experimental|Social Value Learning|For each child, two faces, randomly selected from the pool of four faces, will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display. Effects of training will be tested one day (efficacy) and one month (maintenance) after training. During each of the follow-up assessments, each child will first undergo the Laboratory Selective Attention (LSA) task to assess if they retained value-face associations from the training sessions, followed by the Real-World Selective Attention (RWSA) task to evaluate generalization.
2402251|NCT03556813||Group Vik|women over the age of 18 with breast cancer or remission
2402252|NCT03556813||Group physicians|women over the age of 18 with breast cancer or remission
2402253|NCT03556800|Experimental|0.5 gm of EstroCream (VML-0203)|
2402254|NCT03556800|Experimental|0.75 gm of EstroCream (VML-0203)|
2402255|NCT03556800|Experimental|1.25 gm of EstroCream (VML-0203)|
2402256|NCT03556800|Active Comparator|1.25 EstroGel|
2402257|NCT03556787|Experimental|Patients with knee pain|Adults patients suffering from osteoarthritis pain or general knee pain
2402258|NCT03556774|Experimental|With smoking cessation training|Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
2402259|NCT03556774|No Intervention|Without smoking cessation training|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until 52-week follow-up. One to six messages will be sent per week for 8 weeks. They will be encouraged to communicate the experience of helping patients quit smoking in their group.
3184726|NCT00728000|Experimental|chemotherapy regimen|Gemcitabine and oxaliplatin are given intravenously (into the vein) every 2 weeks. Erlotinib is a pill that is taken by mouth daily.
2402262|NCT03556748|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight),~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
2402263|NCT03556748|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake 1.2-1.5 g/kg bodyweight)~active exercise therapy is optionally provided (bicycle ergometers at room) during the in-Patient stay"
2402264|NCT03556735|Other|PEMF treatment|No sham group (placebo) was chosen. Treatment consisted of one active group in a multicenter study.
2402265|NCT03556722|Active Comparator|repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Coil given on left dorsolateral prefrontal cortex for five sessions.
2402266|NCT03556722|Sham Comparator|Sham repetitive Transcranial Magnetic Stimulation|Magstim Rapid-2 (Whitland, Walsh, UK), 70mm Double Air Film Sham Coil given on left dorsolateral prefrontal cortex for five sessions.
2402267|NCT03556709|Experimental|Treadmill Ankle Robot Training|
2402268|NCT03556696|Experimental|ANI-loop|arm 1 : remifentanil is automatically administered by a medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index (MDMS, Loos, France)
2402269|NCT03556696|Active Comparator|std_practice|arm 2: remifentanil is administered by a target control device using Minto's remifentanil pK/pD model. This is standard practice for this type of surgery at the Burn Center of the University Hospital of Lille, France.
2402270|NCT03556683|Experimental|7% Hypertonic Saline|Subjects will inhale 4 mL of 7% hypertonic saline before having a Mucociliary Clearance (MCC) scan
2402271|NCT03556670|Experimental|Total Worker Health Intervention|
2402272|NCT03556670|Active Comparator|Control|
2402273|NCT03556657|Experimental|Music Therapy Group|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
2402274|NCT03556657|No Intervention|Wait-List Control Group|Patient receives standard care alone. Patient will receive music therapy sessions following completion of the post-test.
2402275|NCT03556644|Other|Single arm study|70 patients with coronary artery disease will have CTCA imaging and 3 vessel intravascular imaging with NIRS-IVUS during percutaneous coronary intervention and the obtained imaging data will be used to assess the efficacy of CTCA in detecting plaque morphology and shear stress distribution.
2402276|NCT03556631|Experimental|probiotics group|live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
2402277|NCT03556631|Placebo Comparator|placebo group|placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months
2402278|NCT03556618|Experimental|Whole Person Care (WPC) Reentry Program|"In partnership with LA County Health Agency, Dr. Barnert is adapting the successful Transitions Clinic model developed for reentry adults, to assist recently incarcerated transition age youth link to needed health services and reduce substance use disorder relapse and recidivism. This adaption is informed by Dr. Barnert's prior research on the needs of incarcerated adolescents. The intervention, called the Whole Person Care (WPC) Reentry Program will consist of community health workers (i.e. network coaches) who are formerly incarcerated and formally trained in care coordination and social network coaching, who interact with justice-involved transition age youth pre- and post-release to increase youths' engagement in community SUD and mental health services. Participants in this branch will include youth exiting the adult justice system (ages 18-24)."
2402281|NCT03556605|Other|Control Arm.|A target of 50 subjects will be enrolled in the Control intervention arm. Subjects continue to use their current Blood Glucose Monitor without connection to mobile diabetes apps.
2402649|NCT03554200|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 30 days.
2402282|NCT03556592|Experimental|All subjects|"Tralokinumab - investigational medicinal product:~Week 0: subcutaneous (SC) injection of tralokinumab loading dose.~Week 2 to Week 14: SC injection of tralokinumab maintenance dose.~CYP substrates - non-investigational medicinal products:~Week -1, Week 1, and Week 15: oral administration of caffeine 100 mg, warfarin sodium 5 mg x2, omeprazole 20 mg, metoprolol tartrate 100 mg, and midazolam hydrochloride 2 mg."
3184727|NCT00728013|Experimental|A|intensive statin group
3184728|NCT00728013|Experimental|B|moderate statin group
2402285|NCT03556566|Experimental|V3-OVA treatment arm|Oral once daily pill of tableted vaccine (V3-OVA) containing ovarian cancer antigens administered for 3 months in 20 volunteers with ovarian cancer
2402286|NCT03556553|Experimental|Vertise Flow|Superficial Class I cavities restored with Vertise Flow
2402287|NCT03556553|Experimental|LuxaFlow|Superficial Class I cavities restored with LuxaFlow
2402288|NCT03556540|Placebo Comparator|Control|The volunteers without performing exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
2402289|NCT03556540|Experimental|Experimental|The volunteers will perform physical exercise during hemodialysis. Autonomic heart rate modulation, quality of life, physical fitness and safety level of exercise will be evaluated.
2402290|NCT03556488||Pediatric CAP|Patients with a clinical diagnosis of CAP and radiographic evidence of lung consolidation, hospitalized in the Pediatric Unit.
2402291|NCT03556475||Disease 1|Moderate to severe COPD Patients(n=90)
2402292|NCT03556475||Disease type 2-1)|Patients with Mild/moderate AECOPD (n=60)
2402293|NCT03556475||Disease type 2-2)|Patients with Severe AECOPD( n=60)
2402294|NCT03556475||Disease type 3|Non-COPD Patients with high risk factors (n=90)
2402295|NCT03556462|Experimental|Sleep Health Interventions|"Sleep Health Interventions:~Parents- a) invited to 1 hour workshop about healthy sleep, b) invited to attend a brief (app. 20 minute) Sleep Health Flipchart education either 1-on-1 or in a small group.~Children: exposed to 2 week 40min/day healthy sleep curriculum in the classroom.Agency: Video and print material"
2402296|NCT03556462|No Intervention|Control Period|No Intervention, but data collection
2402297|NCT03556449||Patients|High resolution ultrasound
2402298|NCT03556449||Healthy subjects|High resolution ultrasound
2402299|NCT03556436|Experimental|Group 1|YH25448 240mg single dose in korean
2402300|NCT03556436|Experimental|Group 2|YH25448 240mg single dose in caucasian
2402301|NCT03556410|Placebo Comparator|sleep|Subject will undergo 5 days of shortened sleep and then 2 days of ad libitum sleep.
2402302|NCT03556410|Experimental|sleep+exercise|Subject will undergo 5 days of shortened sleep but also have 45 min of moderate exercise/day and then 2 days of ad libitum sleep
2402303|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - negative, no AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - negative, without AD
2402304|NCT03556397|Experimental|cN0 before and after neoadjuvant th., SLNB - posit., AD|Patients with cN0 before and after neoadjuvant therapy, SLNB - positive, AD (separated histological examination of lymph nodes in levels I and II)
2402305|NCT03556397|Experimental|cN1 before neoadj. th., cN0 after neoadj. th., SLNB, AD|Patients with cN1 before neoadjuvant th., cN0 after neoadjuvant therapy, SLNB, AD (separated histological examination of lymph nodes in levels I and II)
2402306|NCT03556397|Experimental|cN1 after neoadjuvant therapy, SLNB, AD|Patients with cN1 after neoadjuvant therapy, SLNB, AD.
2402307|NCT03556384|Experimental|TMZ 85 mg/m2 mg orally|"TMZ 85 mg/m2 mg orally once for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters. Temozolomide dose may be held and/or modified for the management of adverse treatment effects according to pre-specified criteria. Patients will have radiographic imaging (CT or MRI) every 8 weeks to assess tumor resection.~An end of treatment visit for clinical evaluations and safety assessments will be performed approximately 28 days after the last dose of study drug. Patients discontinuing study treatment will be followed every 3-6 months for disease recurrence and survival."
2402308|NCT03556371|Experimental|N-acetylcysteine Treatment|Oral administration of two capsules, containing 600 milligrams (mg) of N-acetylcysteine each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
2402309|NCT03556371|Placebo Comparator|Placebo oral capsules|Oral administration of two capsules, containing 600 milligrams (mg) of Placebo each one, twice day (10.00 and 20.00 hours; Total = 2400 mg/day) for four weeks.
2402310|NCT03556358|Experimental|TX05 (trastuzumab)|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
2402311|NCT03556358|Active Comparator|Herceptin®|"• Intravenous (IV) epirubicin, 75 mg/m^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles~Followed by:~• IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles"
2402312|NCT03556345|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
3184729|NCT00728026||1|Cyclic Vomiting Syndrome
2402448|NCT03555500|Experimental|Non fasting group|Clear fluids and food up to the time of the procedure.
2402449|NCT03555487|Experimental|18F-choline PET|PET/CT
3184730|NCT00728026||2|Irritable Bowel Syndrome
3184731|NCT00728026||3|Postural Orthostatic Tachycardia Syndrome
3184732|NCT00728026||4|Functional Abdominal Pain
3184733|NCT00728026||5|Chronic Nausea
3184734|NCT00728052|Experimental|Subjects receiving treatment sequence ABCD|Subjects will receive treatment sequence ABCD; A= placebo, B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, and D = GSK598809 dose 3.
2402317|NCT03556293|Active Comparator|Technical Assistance (No ASR)|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition without automated surveillance reporting and will receive the AKI Prevention Toolkit plus monthly technical calls independently
2402318|NCT03556293|Active Comparator|Virtual Learning Collaborative (No ASR)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams without automated surveillance reportingand will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
2402319|NCT03556293|Active Comparator|Technical Assistance with ASR|Technical Assistance (TA). Intervention: TA will be offered to the 4 teams randomized to the TA condition with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly technical calls independently and monthly ASR dashboard.
2402320|NCT03556293|Active Comparator|Virtual Learning Collaborative with ASR|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 4 teams with automated surveillance reporting (ASR) and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites with the and monthly ASR dashboard. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign).
2402321|NCT03556280|Experimental|Treatment Group|Will use the Active GammaSense Stimulation System.
2402322|NCT03556280|Sham Comparator|Control Group|Will use the Sham GammaSense Stimulation System.
2402323|NCT03556267|Other|spinal needle 27 gauqge|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
2402324|NCT03556267|Other|spinal needle 25 gauage|It is a device used to penetrate the dura to take CSF sample before injecting the drugs used for spinal anesthesia for cesarean section.
2402325|NCT03556254|Experimental|Genotypic resistance guided therapy|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given.
2402326|NCT03556254|Active Comparator|Susceptibility testing guided therapy|Tailored therapy according to the minimum inhibitory concentration result (susceptibility testing, E-test)
2402327|NCT03556241|Experimental|Intervention: No change group|Case management consists keeping patient's current pacemaker mode during surgery
2402328|NCT03556241|No Intervention|Control: Mode change group|Usual care consists changing pacemaker mode to VOO before surgery
2402329|NCT03556228|Experimental|VMD-928 300 mg Tablet or 100 mg Capsule|
2402330|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device and myringotomy|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty, and myringotomy
2402331|NCT03556215|Experimental|Effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and recurrence of chronic otitis media with effusion after tympanostomy tube exclusion, intervention: balloon Eustachian tuboplasty only (no myringotomy)
2402332|NCT03556215|Experimental|No effusion, Eustachian tube dilatation device|Patients with chronic Eustachian tube dysfunction and airy middle ear (without otitis media with effusion), Eustachian tube dilatation device, no myringotomy
3184735|NCT00728052|Experimental|Subjects receiving treatment sequence BACD|Subjects will receive treatment sequence BACD; B= GSK598809 dose 1 (75 milligrams), A= placebo, C = GSK598809 dose 2 and D = GSK598809 dose 3
2402335|NCT03556189|Experimental|Experimental|case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
2402336|NCT03556189|No Intervention|Control: Usual care|Usual care is provided with routine pacemaker interrogation.
2402337|NCT03556176|Active Comparator|5-HTTLPR or BDNF polymorphisms|
2402338|NCT03556176|Active Comparator|Control ( without 5-HTTLPR or BDNF polymorphisms )|
2402339|NCT03556163|Experimental|Test Group|Modified vertical internal mattress sutures + MWF surgery.
2402340|NCT03556163|Active Comparator|Control Group|Simple loop interrupted sutures + MWF surgery.
2402341|NCT03556150|Experimental|Manual Therapy protocol|Massages, mobilisation and stretching techniques in the most painful joint
2402342|NCT03556150|Active Comparator|Effleurage|Superficial massage in the most painful joint.
2402343|NCT03556137|Experimental|Pain Patients|Individuals suffering from nociceptive pain, neuropathic pain, and mixed pain (pain that appears to be both nociceptive and neuropathic) and undergo a [18F]FTC-146 PET/MRI scan.
2402344|NCT03556137|Experimental|Healthy Volunteers|Individuals who do not have pain and undergo a [18F]FTC-146 PET/MRI scan.
2402345|NCT03556124|Experimental|Active - HD tDCS|Participants randomized to this arm will receive 12 sessions of high definition tDCS (HD-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2402346|NCT03556124|Experimental|Active - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of conventional tDCS (C-tDCS) stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2402347|NCT03556124|Sham Comparator|Sham - HD tDCS|Participants randomized to this arm will receive 12 sessions of sham HD tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2402348|NCT03556124|Sham Comparator|Sham - Conventional tDCS|Participants randomized to this arm will receive 12 sessions of sham conventional tDCS stimulation (Soterix Medical) delivered to the left dorsolateral prefrontal cortex for 20-30 minutes.
2402476|NCT03555292|Experimental|dementia with Lewy bodies|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2402349|NCT03556111|Experimental|anterior knife-edge maxilla graft (Without Xenograft Usage)|"The intervention will be a Sticky bone augmentation of defect. It is prepared using particulate autologous graft only along with fibrin glue and growth factors obtained from the patients' blood.~The sample is withdrawn and placed in plastic tubes which are spun twice in a centrifuge at a certain speed and time. The first spin to obtain the fibrin glue and the second to obtain the growth factors. The mixture is added to the harvested autogenous bone to form a semi-solid bone graft that is easily manipulated in the recipient site."
2402350|NCT03556111|Experimental|anterior knife edge maxilla graft (With Xenograft Usage)|"The intervention will be the sticky bone augmentation of the defect using both particulate autogenous and xenograft bovine bone.~The bone will be harvested from the donor, coupled with the bovine bone, the growth factors and the fibrin glue that is obtained from the patient's own blood sample.~The venous blood sample is placed in plastic tubes to be centrifuged at a certain speed and time to obtain the fibrin glue and growth factors.~The mixture is prepared until the bone is sticky and ready to be placed in the recipient defective maxilla"
2402351|NCT03556098|Active Comparator|GIP|Infusion of Glucose-dependent insulinotropic peptide
2402352|NCT03556098|Active Comparator|GIP[3-30]|Infusion of GIP[3-30]
2402353|NCT03556098|Placebo Comparator|Saline|Infusion of saline
2402354|NCT03556085|Experimental|Venous sinus stenting|Subjects will have stenting of the transverse-sigmoid sinus
2402355|NCT03556072||Intradiverticular papilla (IDP) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
2402356|NCT03556072||Juxtapapillary diverticulum (JPD) group|Routine ERCP, recording the endoscopic procedures and observing the intra- and post-operative parameters
2402357|NCT03556059|Active Comparator|RNYGB|The role of EOSS for the surgical intervention: Roux-en-Y gastric bypass for severe obesity
2402358|NCT03556059|Active Comparator|Sleeve|The role of EOSS for the surgical intervention: Sleeve Gastrectomy for severe obesity
2402359|NCT03556059|Active Comparator|MGB/OAGB|The role of EOSS for the surgical intervention: Mini/One anastomosis gastric bypass for severe obesity
2402360|NCT03556046|Experimental|89Zr-girentuximab|A single administration of 37 MBq (+/-10%) 89Zr-girentuximab, containing a mass dose of 5 mg of girentuximab
2402361|NCT03556033|Active Comparator|Dapagliflozin|Dapagliflozin 10 mg capsule once daily for 8 weeks
2402362|NCT03556033|Placebo Comparator|Placebo oral capsule|Placebo matched to dapagliflozin 10 mg capsule once daily for 8 weeks
2402363|NCT03556020|Experimental|High Dose Group|Maximally tolerated dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
2402364|NCT03556020|Experimental|Low Dose Group|Minimally effective dose Drug: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
2402365|NCT03556007|Experimental|Cohort 1 - 3 μg/kg LY3471851|Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.
2402366|NCT03556007|Experimental|Cohort 1 - 6 μg/kg LY3471851|Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
2402367|NCT03556007|Experimental|Cohort 1 - 12 μg/kg LY3471851|Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
2402368|NCT03556007|Experimental|Cohort 1 - 24 μg/kg LY3471851|Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.
2402369|NCT03555994|Experimental|MEDI0382 (Part A)|MEDI0382 administered subcutaneously (Part A)
2402370|NCT03555994|Placebo Comparator|Placebo (Part A)|Placebo comparator administered subcutaneously (Part A)
2402371|NCT03555994|Active Comparator|Liraglutide (Part B)|Active comparator administered subcutaneously (Part B)
2402372|NCT03555994|Experimental|MEDI0382 (Part B)|MEDI0382 administered subcutaneously (Part B)
2402373|NCT03555994|Placebo Comparator|Placebo (Part B)|Placebo comparator administered subcutaneously (Part B)
2402374|NCT03555981|Experimental|Early KMC|Continuous kangaroo mother care started within 24h of hospital admission, aiming for minimum 18h/day and until hospital discharge with encouragement of KMC at home
2402375|NCT03555981|Active Comparator|Standard care|Standard care under radiant heater or incubator until clinical stability criteria are met then intermittent or continuous Kangaroo mother care started at >24h of hospital admission until hospital discharge with encouragement of KMC at home
2402376|NCT03555968|Placebo Comparator|THC 0 + BAC 0|Participants will receive 0mg of THC in combination with blood alcohol concentrations of .000%.
2402377|NCT03555968|Experimental|THC 5 + BAC 0|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .000%.
2402378|NCT03555968|Experimental|THC 10 + BAC 0|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .000%.
2402379|NCT03555968|Experimental|THC 5 + BAC .025|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .025%.
2402380|NCT03555968|Experimental|THC 10 + BAC .025|Participants will receive 125 µg/kg of THC in combination with blood alcohol concentrations of .025%.
2402381|NCT03555968|Experimental|THC 0 + BAC .049|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .049%.
2402382|NCT03555968|Experimental|THC 5 + BAC .049|Participants will receive 5mg of THC in combination with blood alcohol concentrations of .049%.
2402383|NCT03555968|Experimental|THC 10 + BAC .049|Participants will receive 10mg of THC in combination with blood alcohol concentrations of .049%.
2402384|NCT03555968|Experimental|THC 0 + BAC .025|Participants will receive 0 µg/kg of THC in combination with blood alcohol concentrations of .025%.
2402385|NCT03555955|Experimental|Cohort 1|Normal renal function
2402386|NCT03555955|Experimental|Cohort 2|Moderate renal impairment
2402387|NCT03555955|Experimental|Cohort 3|Severe renal impairment
2402388|NCT03555942|Active Comparator|Early follicular phase protocol|On day 2 or 3 of the menstrual cycle, following baseline blood sampling, a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
2402544|NCT03554863|Active Comparator|Facial mask|
2402545|NCT03554863|Experimental|Optiflow anesthesia|
2402389|NCT03555942|Experimental|Luteal phase protocol|Following baseline blood sampling on cycle day 2 of 3 of the menstrual cycle, patients will be followed up with blood and ultrasound from cycle day 10 onwards till the detection of serum LH peak. LH peak will be defined as an increase in serum LH above 20IU/LH. Five (5) days after the LH peak a single SC injection of 150 ìg corifollitropin alfa will be administered (Stimulation Day 1). Starting on Stimulation Day 6, the subject will receive a daily SC injection of 0.25 mg ganirelix up to and including the day of GnRH agonist triggering administration to prevent premature LH surges. From Stimulation Day 8 onwards treatment is continued with a daily SC dose of rFSH (200IU/day) up to the day of GnRHa administration.
2402390|NCT03555929|Experimental|Dexamethasone|Dexamethasone 8 mg/2cc I.V. 90 minutes after axillary block
2402391|NCT03555929|Placebo Comparator|Normal saline|Normal saline 2cc I.V., 90 minutes after axillary block
2402392|NCT03555916|Experimental|Drug|BOTOX®, Allergan treatment in 2 mL of saline solution (0.9% NaCl) treatment
2402393|NCT03555916|Placebo Comparator|Placebo|2 mL of saline solution (0.9% NaCl) treatment
2402394|NCT03555903||Endometriosis cohort|The aim of the study is to advance the scientific knowledge of deep infiltrating endometriosis (DIE) and to evaluate the impact of surgery on the quality of life and the fertility of affected women.
3184736|NCT00728052|Experimental|Subjects receiving treatment sequence BCAD|Subjects will receive treatment sequence BCAD; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, A= placebo and D = GSK598809 dose 3.
3184737|NCT00728052|Experimental|Subjects receiving treatment sequence BCDA|Subjects will receive treatment sequence BCDA; B= GSK598809 dose 1 (75 milligrams), C = GSK598809 dose 2, D = GSK598809 dose 3 and A= placebo.
3184738|NCT00728065|Experimental|1|White Bread (control)
3184739|NCT00728065|Experimental|2|White Bread (control)
2402399|NCT03555877|Experimental|Anti-hormonal treatment + ribociclib|In the experimental arm ribociclib will be dosed on a flat scale of 600mg/day (corresponding to three 200mg tablets once daily, 3 week on, one week off). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
2402400|NCT03555877|Active Comparator|Anti-hormonal treatment|In the control arm patients will receive endocrine treatment only (of choise of investigator). Anti-hormonal/endocrine treatment of choice of investigator: anastrozole, exemestane, letrozole, fulvestrant.
2402401|NCT03555864||Obese|Patients need two intravenous access with infra red
3184740|NCT00728065|Experimental|3|White bread with 7.32 grams Salba hispanica
3184741|NCT00728065|Experimental|4|White bread with 15.58 grams Salba hispanica
2402406|NCT03555825|Active Comparator|60 Minutes ArmeoSpring (1:1)|60 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
2402407|NCT03555825|Experimental|60 Minutes ArmeoSpring (2:1)|60 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
2402408|NCT03555825|Active Comparator|30 Minutes ArmeoSpring (1:1)|30 minutes of therapy 3x per week for 6 weeks working one-on-one with a clinician for duration of session.
2402409|NCT03555825|Experimental|30 Minutes ArmeoSpring (2:1)|30 minutes of therapy 3x per week for 6 weeks with one clinician supervising 2 participants.
2402410|NCT03555812|Experimental|Healthy volunteers|"a medical examination~10 measurements of pelvic tilt in sitting position, 10 measurements of pelvic tilt in supine position and 10 measurements of pelvic tilt in standing position, each performed by three different operators. These measurements will be done by ultrasound."
2402411|NCT03555812|Experimental|Patients|"a consultation the day before surgery, and a consultation 2 months after surgery, each including:~a medical examination~3 pelvic tilt measurements (1 standing, 1 sitting and 1 lying down). These measurements will be done by ultrasound."
2402412|NCT03555799||Labor analgesia patients|Patients with clinical indication of labor epidural will have IVC diameter measurement with ultrasound before and after the epidural placement
2402413|NCT03555773|Experimental|Lipogems|Lipogems injection into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract
2402414|NCT03555760||Surgery patient|Observation of informed consent form readings of all patients who are scheduled for surgery
2402415|NCT03555747|Other|Canine distalization by 75 g force|Canine was distalized using a continuous force of 75 g with nickel-titanium closed coil springs.
2402416|NCT03555747|Other|Canine distalization by 150 g force|Canine was distalized using a continuous force of 150 g with nickel-titanium closed coil springs.
2402417|NCT03555721||Oral examination followed by biopsy, CytID, and hpvID|Identification of oral lesions with oral examination with both incandescent light and fluorescent light (OralID), and subsequent testing of suspicious oral lesions with biopsy, CytID, and hpvID
2402418|NCT03555708|Experimental|High-Velocity Power Training|Training will consist of unilateral and bilateral leg presses (Total Gym GTS, San Diego CA), which will primarily target the quadriceps followed by the hip extensors and plantarflexors. Target load will be 40% to 80% of 1-repetition maximum (1RM) with progression toward 80%. Each participant will perform 3 to 5 sub-maximal efforts followed by 6 sets of 5 maximum-effort repetitions at the predetermined percentage of 1RM for each leg separately. Following the unilateral leg presses, 6 sets of 5 repetitions of bilateral leg presses will be performed at the predetermined percentage of 1RM. To minimize fatigue, 1-2 minutes of rest will be given between sets.
2402546|NCT03554824||Pre-Transfer Adolescents aged 10-16 years|
2402547|NCT03554824||Post-Transfer Young Adults aged 16-25 years|
3184742|NCT00728065|Experimental|5|White bread with 24 grams Salba hispanica
3184743|NCT00728065|Experimental|6|Rice Milk (control)
3184744|NCT00728065|Experimental|7|Rice Milk (control)
3184745|NCT00728065|Experimental|8|Rice Milk with 7.32 grams Salba hispanica
3184746|NCT00728065|Experimental|9|Rice Milk with 15.58 grams Salba hispanica
3184747|NCT00728065|Experimental|10|Rice Milk with 24 grams Salba hispanica
3184748|NCT00728078|Experimental|1|low-dose thalidomide adjuvant therapy after RFA for HCC
2402419|NCT03555708|Experimental|Perception-Action Physical Therapy|The therapy includes: activities of adequate intensity that promote gait adaptation and gait speed sustainment, exploratory activities that enhance the somatosensory experience through rich/novel movement, and optimally challenging activities that emphasize planning and problem solving that requires altering the leg kinematics to meet the environmental and task constraints. This includes a 15-minutes of sustaining and adapting gait speed while walking along a 40-meter hallway. Participants will alter their gait through exploratory movements. During the following 20 minutes participants will perform discrete problem solving activities including: waling backward sand stair negotiation.
2402420|NCT03555708|Experimental|Body Weight Supported Treadmill Training|The child will walk on the treadmill for 35-minutes, while the body weight is supported with an overhead system at 30 percent of the child's body weight, reducing every other week by 10 percent until no support is provided during the final 2 weeks. Treadmill speed will be set at 90% of the child's over ground walking speed, gradually increasing each session. Speed adjustments depend on the child's ability to control their steps and achieve: activities that promote symmetry of the leg kinematics, activities that promote maintaining an upright lower limb posture and clearing the tow during the swing, and activities that promote pushing off with ankle at terminal stance.
2402421|NCT03555695|Experimental|Karate Class Participants|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD. Subjects will also complete an in-person pre-intervention focus group and post-intervention focus group, as well as a 6 month post-intervention follow up phone call.
2402422|NCT03555682|Placebo Comparator|Placebo|Placebo
2402423|NCT03555682|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
2402424|NCT03555682|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
2402425|NCT03555669|No Intervention|Screening Phase (Pre) Group|"Patients who screen positive on the PHQ-9 for depression during the pre period will comprise the comparison group. Participants will receive standard of care depression treatment at the providers discretion."
2402426|NCT03555669|Experimental|Treatment Phase (Post) Group|"Patients who screen positive during on the PHQ-9 for depression during the post period will comprise the active group. Participants will receive the depression treatment intervention in the form of anti-depressants and/or problem solving therapy (PST) based on their PHQ-9 score."
2402427|NCT03555656|Experimental|Repeated educational intervention|Repetition every 6 months of a group educational session
2402428|NCT03555656|Active Comparator|Control group|Initial single group educational session, with no repetition
2402429|NCT03555643||transient ischemic attack (TIA)|Patients with transient ischemic attack
2402430|NCT03555643||transient neurological attack (TNA)|Patients with transient neurological attack
2402431|NCT03555630||Post-cesarean preeclampsia|
2402432|NCT03555630||Post spontaneous vaginal delivery preeclampsia|
2402433|NCT03555617|Experimental|TD-1473 formulation bridging & food effect|Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.
2402434|NCT03555617|Experimental|TD-1473 with Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.
2402435|NCT03555617|Experimental|TD-1473 without Itraconazole|Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.
2402436|NCT03555604||Scheduled cesarean section|Gastric ultrasound in term pregnant patients to correlate with NPO time in relation to body mass index
3184749|NCT00728078|No Intervention|2|control group
2402438|NCT03555578||Leuprorelin Acetate 11.25 mg|Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
3184750|NCT00728091|Experimental|Satavaptan Dose 1|Fixed Low dose up to day 4, followed by optional titration up to day 30
2402440|NCT03555552|Experimental|Anticoagulation and Thrombosis Point of Care Test (AT-POCT)|
2402441|NCT03555552|Active Comparator|Duke Central Automated Laboratory (DCAL)|
2402442|NCT03555539|Experimental|Part 1: Healthy Match|Single 200-milligram (mg) dose of danicopan on Day 1 in healthy participants (matched control group with normal hepatic function).
2402443|NCT03555539|Experimental|Part 1: Moderate HI|Single 200-mg dose of danicopan on Day 1 in participants with moderate HI.
2402444|NCT03555526|Experimental|Genotypic resistance guided therapy|The regimen will be chosen according to the genotyping of 23S rRNA and gyrase A of H. pylori. In the absence of gyrase A mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of gyrase A mutation but in the absence of 23S rRNA mutation, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both gyrase A and 23S rRNA mutation, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
2402445|NCT03555526|Active Comparator|Phenotypic resistance guided therapy|The regimen will be chosen according to the susceptibility testing result. In the absence of levofloxacin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), levofloxacin (Cravit), metronidazole (Flagyl) for 14 days will be given. In the presence of levofloxacin resistance but in the absence of clarithromycin resistance, esomeprazole (Nexium), amoxicillin (Amoxicillin), clarithromycin (Klaricid), metronidazole (Flagyl) for 14 days will be given. In the presence of both levofloxacin and clarithromycin resistance, bismuth quadruple therapy including esomeprazole (Nexium), bismuth (KCB), tetracycline, and metronidazole (Flagyl) for 10 days will be given.
2402446|NCT03555513||living kidney transplanted patients|Any patients over 18 who received kidney transplantation from living donor
2402447|NCT03555500|No Intervention|Fasting Group|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure.
3184751|NCT00728091|Experimental|Satavaptan Dose 2|Fixed High dose up to day 4, followed by optional titration up to day 30
3184752|NCT00728091|Placebo Comparator|Placebo|
2402450|NCT03555474|Experimental|Theta burst stimulation & Physiotherapy|"Patients were given theta burst stimulation (intermittent TBS (iTBS) to the affected hemisphere and continuous TBS (cTBS) to the unaffected hemisphere) along with physiotherapy. TBS was delivered for 3 times in a week for 4 weeks.The stimulation was given with an intensity of 60% of RMT. The iTBS protocol of 10 bursts of high-frequency stimulation (3 pulses at 50 Hz) was applied at 5 Hz every 10 second for a total of 600 pulses.~Continuous TBS (inhibitory) was delivered to the unaffected hemisphere at the hot-spot with an intensity of 60% of RMT, 3 pulses at 50 Hz, repeated every 200 ms for a total of 600 pluses."
2402451|NCT03555474|Experimental|Functional stimulation & Physiotherapy|"Patients in the functional electrical stimulation (FES) group received the electrical stimulation with electrodes positioned according to pattern 3 [Grasp/Flexion/Extension, PATT (pattern movement)] of the FES (F) mode of the instrument. The electrodes were connected to a stimulator controller unit that delivers alternating current at a frequency of 35 Hz and a pulse width of 200 µs, intensity 10~50 mA.~The FES group stimulation session was given for 30 minutes for each day 3 times in a week (alternate days) for 4 weeks and it was concurrently synchronized with the physiotherapy."
2402452|NCT03555474|Active Comparator|Physiotherapy|"The following different physiotherapy regimens were followed for all the patients in the study.~Passive/Active Range of Motion (ROM); Weight bearing and supportive reaction; Reaching activities; Grasping, holding and release; Upper extremity activities of daily living (ADL). Physiotherapy intervention was given to all the patients 5 days per week for 1 month. In addition, all patients continued to receive in-home physiotherapy 1 to 2 times per week by a home physiotherapist who was guided by the research physiotherapist."
3184753|NCT00728104||1|The General Questionnaire: help to understand which characteristics of CVS patients are associated with both beneficial and harmful effects of these treatments
3184754|NCT00728104||2|The Co-Enzyme Q10 Questionnaire: to be completed by individuals who ever taken co-enzyme Q10
3184755|NCT00728104||3|The L-Carnitine Questionnaire: to be completed by individuals who have ever taken L-carnitine
3184756|NCT00728104||4|The Amitriptyline Questionnaire: to be completed by individuals who have ever taken amitriptyline
3184757|NCT00728117|Experimental|ibuprofen-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
3184758|NCT00728117|Experimental|ibuprofen-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen and 24 hours after the last dose of ibuprofen.
3184759|NCT00728117|Experimental|indomethacin-feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
2402460|NCT03555396|Experimental|Intervention|Subjects will receive an intervention is based off of current evidence-based practices and will consist of activities designed to strengthen support within the couple to improve adherence to antiretroviral therapy.
2402461|NCT03555396|Active Comparator|Standard of Care|Standard of Care is the comparison arm that consists of care currently provided at the AIDS Center. Subjects will receive a consultation with a healthcare provider every three months, prescription refills, and blood draws for viral load and CD4 testing.
2402462|NCT03555370|Experimental|Standard of Care Group|"Standard of Care:~The standard of care protocol consists of standardized in office and at home behavioral management to include sleep, hydration, nutrition, and stress management interventions. Participants will also be assigned physical activity that they will complete during their visits and at home. Physical activity for the standard of care group will include 15 minutes of flexibility/range of motion exercises, and 10 minutes of aerobic-based daily physical activity (e.g.,walking, stationary cycle)."
2402463|NCT03555370|Experimental|Vestibular Exercise Intervention Group|The vestibular group will complete the behavioral management activities described above, as well as prescribed in-office and at home vestibular exercises from each of four groups: 1) gaze stability training (i.e., integrated eye and head movements on fixed target), 2) visual motion training (i.e., integrated eye and head movements with busy visual background), 3) standing balance (i.e., standing in different stances), and 4) dynamic gait (i.e., walking with head turns). Participants will be prescribed to one of four levels of these four exercise groups based on presentation of symptoms/impairment as indicated on the VOMS. Progression through the four levels will be based on symptom tolerance and successful completion of all exercises at the current level.
2402464|NCT03555357|Active Comparator|PRP|Platelet Rich Plasma (PRP) injections into one half of the scar will be preformed. PRP is already considered an effective treatment for scar therapy.This will be randomly assigned by the clinical research coordinator .
2402465|NCT03555357|Experimental|PRF|Platelet Rich Fibrin (PRF) injections will be preformed the other half of the scar that is not treated with PRP. PRF has not been established as an effective scar treatment. The PRF will be considered experimental as this study seeks to evaluate if it is more effective than PRP.
2402466|NCT03555344|Experimental|Mantra Chikitsa|Mantra chanting for 15 mins
2402467|NCT03555344|No Intervention|Wait list control|Rest for 15 Mins
2402468|NCT03555331||INSIGHT participants|Mother-child dyads who enrolled in the INSIGHT Study and participated from early infancy to age 3 years will be followed through age 9 years.
2402469|NCT03555318|Experimental|Geriatrician + Cardiologist|Patients randomized to a combined ambulatory follow up with a cardiologist and a geriatrician.
2402470|NCT03555318|Active Comparator|Cardiologist|Patients randomized to usual care (ambulatory follow up with a cardiologist).
2402473|NCT03555292|Experimental|PD without dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2402474|NCT03555292|Experimental|PD with MCI|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2402475|NCT03555292|Experimental|PD with dementia|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
2402548|NCT03554824||Parents/Guardians of Pre-Transfer Patients|
2402477|NCT03555292|Experimental|healthy control|11C-PIB injection and PET/CT scan The subjects were intravenously injected with 555MBq 11C-PIB and underwent PET/CT scan immediately after the injection.
3143959|NCT00024154|Experimental|Treatment (trastuzumab, gefitinib)|"Phase I (completed): Patients receive trastuzumab (Herceptin) IV over 30-90 minutes once weekly and oral gefitinib once daily beginning on day 1.~Cohorts of 3-6 patients receive escalating doses of gefitinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is established, additional patients are accrued to the phase II portion of the study and are treated at that dose.~Phase II: Patients receive oral gefitinib once daily (at the MTD established in phase I) and trastuzumab IV weekly until week 24, at which time trastuzumab is given every 3 weeks (with daily gefitinib) until disease progression or unacceptable toxicity."
3143960|NCT00024206|Experimental|Treatment (orantinib)|"Patients receive oral SU6668 twice daily on days 1-28. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression of 100% or more.~Cohorts of at least 6 patients receive escalating doses of SU6668 until the OBD is determined. Once the OBD is reached, dose escalation continues until the maximum tolerated dose (MTD) is determined (if possible). The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3143961|NCT00024466|Experimental|Vaccine|Participants are vaccinated with GVAX one month or more after finishing induction therapy (which is given as per standard of care). Two weeks later, participants go through leukapheresis on protocol, then receive autologous transplant as per standard of care. GVAX is administered eight subsequent times after the autologous transplant.
2402482|NCT03555253|Experimental|PwMS and their Support Partner|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners.
2402483|NCT03555240||Patient with Rheumatoid Arthritis|Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis
2402484|NCT03555227|Active Comparator|Group X|"PECS group~USG PECS2 with Drug A (active) Wound infiltration with Drug P (placebo)"
2402485|NCT03555227|Active Comparator|Group Y|"LA (local anaesthetic) infiltration group~USG PECS2 with Drug P (placebo) Wound infiltration with Drug A (active)"
2402486|NCT03555214|Experimental|Manual Therapy based on soft tissue|
2402487|NCT03555214|Placebo Comparator|Control Group|
2402488|NCT03555214|Experimental|Manual Therapy based on structural techniques|
2402489|NCT03555214|Experimental|Manual Therapy based on soft tissue and structural techniques|
2402490|NCT03555201|Experimental|Manual therapy|Protocol of soft tissue techniques
2402491|NCT03555201|Active Comparator|Regular treatment control.|Regular treatment control.
2402492|NCT03555188|Experimental|Ondansetron|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
2402493|NCT03555188|Placebo Comparator|Placebo|Taken orally 4mg-24mg daily for 12 weeks. Dose to be amended throughout according to symptoms.
2402494|NCT03555175|Other|Group one|This participants group must do eccentric exercise for 12 weeks
2402495|NCT03555175|Other|Group two|This participants group must do proprioception exercise for 12 weeks
2402496|NCT03555175|Other|Group 3|This participants group mustn't do exercise extra
2402497|NCT03555162|Other|Tool Use|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when using tools. Here only the fMRI experimental session is necessary. Tasks proposed to the participants within the fMRI scanner will be related to tool use. They will have to solve mechanical problems, to judge the appropriateness of hand postures for using tools, and to judge if tools presented share the same context of use, the same functional goals, the same hand postures for using them.These experimental conditions related to the BOLD measures given by the fMRI technique will allow us to draw hypotheses on the neurocognitive mechanisms at work when we use tools.
2402498|NCT03555162|Other|Tool Evolution|The fMRI experimental conditions in this arm will allow us to study the activity of the brain when we improve tools. Here the fMRI experimental session will be complemented by a cognitive psychology experiment, where participants will be given a tool to improve. Tasks proposed to the participants within the fMRI scanner will be related to cognitive functions that could be implicated in improving tools : creativity, technical reasinoning, logic, empathy. The BOLD measures realted to these experimental condfitions will be related to the ability of the participant to improve a tool, through General Linear Modeling.
3143963|NCT00024518|Placebo Comparator|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA). Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3143964|NCT00024518|Experimental|5,000 Units hrIFN-alpha|hrIFN-alpha = human recombinant interferon-alpha. 5,000 units was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3143965|NCT00024518|Experimental|30,000 hrIFN-alpha|30,000 units hrIFN-alpha was prepared along with saline and 6mg HSA. Subjects orally ingested one vial each morning before breakfast with at least 150mL water.
3143966|NCT00024596||Caucasian Families|Largest 3-generational Caucasian Families from Family Heart Study (Classic) with average family size of 10 N=2767 Subjects from 512 families. Approximately half are random sample families from FamHS-Classic, and half are high-familial CHD risk families from FamHS-Classic. 4 Field sites were Raleigh-Durham North Carolina; Minneapolis, MN; Framingham MA; and Salt Lake City, UT.
3143967|NCT00024596||African-American Families|622 subjects from 2-3 generational 212 African-American families originally recruited from the HyperGEN study in Birmingham AL. These are hypertension enriched families.
2402612|NCT03554408|Experimental|Group 2C|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
3143971|NCT00024635||Adult Healthy Volunteers|Adult Healthy Volunteers
3143972|NCT00024635||Adult Patients|Adult patients with mood and anxiety disorders
3143973|NCT00024635||Minor Healthy Volunteers|Minor Healthy Volunteers
2402507|NCT03555136||Patients initiating vortioxetine treatment|Patients with major depressive disorder initiating treatment with vortioxetine
2402508|NCT03555123|Experimental|SIMDAX|Levosimendan2.5mg/mL
2402509|NCT03555123|Placebo Comparator|SIMDAX Placebo|Water for injection
2402510|NCT03555110|Active Comparator|Controlled Group|30 morbid obese patients, 30 to 55 years old, submitted to Personality Factor Battery Test (PFB Test) during the study with the same frequency and criteria of the group of EMDR .
2402511|NCT03555110|Active Comparator|EMDR Group|"30 morbid obese patients, 30 to 55 years old, submitted to Eye Movement Desensitization and Reprocessing Therapy (EMDR) during the study with the frequency of Twelve sessions, including:~Three evaluation and preparation sessions,~Eight EMDR sessions weekly with variable length of 60 minutes and~One closing session. The total intervention time will be about 3 (three) months. After the end of the 12 sessions of EMDR therapy, the patient will be evaluated again individually to verify the existence of change in PFB test results about the 5 big factors. The instrument will also be reapplied three months, twelve months and thirty-six months after bariatric surgery."
2402512|NCT03555097|Experimental|COPD Group|incremental pressure support
2402513|NCT03555084|Experimental|Device: Extension of Phonak Virto B-Titanium|The extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
2402514|NCT03555084|Active Comparator|Device: Phonak Virto B-Titanium|The Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
2402515|NCT03555071|Experimental|Experimental Group1|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2402516|NCT03555071|Experimental|Experimental Group2|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2402517|NCT03555071|Experimental|Experimental Group3|"The investigated vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at commercialized scale.~Intervention: Live attenuated varicella vaccine manufactured at commercialized scale"
2402518|NCT03555071|Active Comparator|Control Group|"The control vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd at trial-scale.~Intervention: Live attenuated varicella vaccine manufactured at trial-scale"
2402519|NCT03555058|Other|High risk- TDM|Treatment escalation per TDM and physician's decision.
2402520|NCT03555058|No Intervention|High risk- Follow Up|Patients randomized to this arm will keep with the follow-up regime. Treatment escalation will occur only upon worsening of symptoms.
2402521|NCT03555058|No Intervention|Low risk|Control group. Patients will be assigned to this group based on VCE results and will not undergo randomization.
2402522|NCT03555045|Active Comparator|conducting the slanted recession technique|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
2402523|NCT03555045|Active Comparator|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
2402524|NCT03555032|Experimental|All patients|All patients will receive two pre-operative doses of T-VEC administered by intratumoural injection prior to a 3rd intratumoural dose given at the time of Isolated Limb Perfusion (ILP). No further treatment will be given.
2402525|NCT03555019|Experimental|Formulaid|The intervention group will receive enteral supplementation with Formulaid containing ARA and DHA at a ratio of 2:1, from birth until 36 weeks PMA
2402526|NCT03555019|Active Comparator|MCT-oil|The control group will receive enteral supplementation with MCT oil containing coconut and/or palm kern oil, from birth until 36 weeks PMA
2402527|NCT03555006|Other|Local vs remote group|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation
2402528|NCT03555006|Other|Local vs local group|The examination will be interpreted by two department's radiologists
2402529|NCT03554993|Experimental|CC-99677 Under Fasted Conditions|CC-99677 Under Fasted Conditions
2402530|NCT03554993|Experimental|Placebo|Placebo under fasted conditions
2402531|NCT03554993|Experimental|CC-99677 Under Fed Conditions|CC-99677 Under Fed Conditions
2402532|NCT03554980|Experimental|Group 1|"38% silver diamine fluoride liquid will be applied twice annually and patients will be followed up at 0,1,3,6, 9 and 12.~SDF is a brush-on liquid."
2402533|NCT03554980|Active Comparator|Group 2|5% sodium fluoride varnish will be applied four times annually and patients will be followed up at 0,1,3,6,9 and 12.
2402534|NCT03554941|Experimental|noise stimulation|noise stimulation
2402535|NCT03554928||Cocaine Dependent|Individuals with cocaine dependence
2402536|NCT03554928||Not Cocaine Dependent|Individuals without cocaine dependence
2402537|NCT03554915||Ketamine-based Protocol|The first 6 month period of the study will employ a ketamine-based protocol for prehospital agitation. There will be a tiered dosing protocol based on degree of agitation.
2402538|NCT03554915||Midazolam-based Protocol|The second 6 month period of the study will employ a midazolam-based protocol for prehospital agitation. There will again be a tiered dosing protocol based on degree of agitation.
2402539|NCT03554902||Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
2402540|NCT03554889|Experimental|Experimental Group|Peripheral blood lymphocytes will be collected. The NK cell will be selected and expanded ex vivo, then adaptive transfer back into patients. A total of 5.0 x 10^8/L NK cells will be infused in one cycle.To avoid allergic reactions, 50 mg hydrocortisone was intramuscularly injected into patient 30 min before cells infusion every time. Best supportive care was also provided for patients. Nimotuzumab will be used 24 hours before infusion. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT and PET-CT or they withdrew consent.
2402541|NCT03554876|Active Comparator|Multi-Im Machined|Multi-Im Machined
2402542|NCT03554876|Experimental|Multi-Im® nanogolden|Multi-Im® nanogolden
2402543|NCT03554876|Experimental|Multi-Im T-Golden|Multi-Im T-Golden
3143974|NCT00024635||Minor Patients|Minor patients with mood and anxiety disorders
2402549|NCT03554811|Experimental|Functional electrical stimulation assisted supine cycling|Patients will start functional electrical stimulation assisted supine cycling (FESC) within 48 hours of ICU admission and will undergo up to 1 hour of supine cycling daily, 5 days per week for 28 days, or until discharge from ICU.
2402550|NCT03554811|Active Comparator|Conventional early exercise and mobility interventions|Patients will undergo standard ICU exercise and mobility interventions.
2402551|NCT03554798|Experimental|nOPV2 Candidate 1 (monovalent oral poliovirus type1)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1.~6 weeks Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 1."
2402552|NCT03554798|Experimental|nOPV2 Candidate 2 (monovalent oral poliovirus type2)|"IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 2.~Infants vaccinated with 3 doses of bOPV and 1 dose of IPV, followed with 1 dose of candidate 2."
2402553|NCT03554785|No Intervention|Control/Usual Care|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~Option to view 60 minute online webinar Do Ask, Do Tell: Collecting Data on Sexual Orientation and Gender Identity at Health Centers"
2402554|NCT03554785|Active Comparator|Intervention|"Readiness Assessment (web survey for CHC leadership and providers)~Patient web surveys (10 total per site; 5 SGM and 5 cisgendered)~CHC staff leadership key informant interviews (up to 5 at each site)~Tailored Educational Clinician and Non-clinician staff training intervention and technical assistance follow-up"
3184760|NCT00728117|Experimental|indomethacin-fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of indomethacin and 24 hours after the last dose of indomethacin.
3184761|NCT00728143|Active Comparator|1|Healthy subjects
3184762|NCT00728143|Experimental|2|Diabetic subjects
3184763|NCT00728156|Active Comparator|C|Patients assigned to clopidogrel in addition to their standard care.(all patients will be on aspirin)We aim to study the effect of clopidogrel as dual antiplatelet therapy in patients with established coronary artery disease and type 2 diabetes. Ninety patients with type 2 diabetes and stable coronary artery disease has been randomly treated with clopidogrel or placebo (45 each) for one week in addition to their standard care (including aspirin,75 mg once daily).
2402561|NCT03554733|Experimental|Treatment|Re-Inventing Yourself after SCI protocol - 6-week educational sessions
2402562|NCT03554733|No Intervention|Control|No intervention during course of study; participants offered the option of receiving the study intervention after completion of study.
2402563|NCT03554720|Active Comparator|Standard implants|ATTUNE PS Knee
2402564|NCT03554720|Active Comparator|Enhanced-Fixation|ATTUNE S+ PS Knee
2402565|NCT03554707|Experimental|SGT-53 with radiation or drugs|"Radiation phase: SGT-53 will be given at 2.1 mg DNA/m2 twice weekly for the first week of radiation therapy, and then increase to 2.8 mg DNA/m2 twice weekly. Radiation therapy will be administered as per clinical care, with a target of fifteen (15) fractions, but patients with other clinically-determined radiation plans will be allowed.~Chemotherapy phase: SGT-53 will be administered at the highest tolerated dose given during radiation phase. Irinotecan will be given at a dose of 50mg/m2/dose IV daily for five days in a 4-week cycle. Temozolomide will be given at a dose of 100mg/m2 PO daily for five days in a 4-week cycle and bevacizumab will be given at a dose of 10mg/kg IV every two weeks in a 4-week cycle."
2402566|NCT03554694|Experimental|Start with prebiotics|Half of the participants start with prebiotics, followed by a testing period. After a wash-out period they will continue with placebo followed by a testing period.
2402567|NCT03554694|Experimental|Start with placebo|Half of the participants start with placebo, followed by a testing period. After a wash-out period they will continue with prebiotics followed by a testing period.
2402568|NCT03554668||1|Post total knee replacement patients
2402571|NCT03554642|Experimental|Walkbot Training|This group will receive usual inpatient care that includes at least one 60-minute session of physical therapy and an additional 30-minute session of Walkbot with Augmented Reality 5-days per week during the duration of their stay (14 days).
2402572|NCT03554642|Active Comparator|Physical Therapy|This group will receive usual inpatient care including at least one 60-minute session of physical therapy per day, and an additional 30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
2402573|NCT03554642|No Intervention|Usual Care Physical Therapy|Participants in this group will receive usual inpatient care including at least one 60-minute session of physical therapy per day.
2402575|NCT03554616|Experimental|Pyriproxyfen LLIN|Royal Guard® (Disease Control Technologies, LLC) is a Long Lasting Insecticidal Net made of polyethylene incorporating a mixture of 225 mg/m2 pyriproxyfen and 261mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2402576|NCT03554616|Experimental|Chlorfenapyr LLIN|Interceptor® G2 (BASF corporation) is a LLIN made of polyester coated with a wash-resistant formulation of 200 mg/m2 chlorfenapyr and 100 mg/m2 alpha-cypermethrin. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2402577|NCT03554616|Experimental|Piperonyl butoxide LLIN|Olyset® Plus (Sumitomo Chemicals) is a LLIN combining Piperonyl butoxide (400mg/m2) and the repellent pyrethroid permethrin (800 mg/m2) incorporated into the polyethylene fibres. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2402578|NCT03554616|Active Comparator|Standard LLIN|Interceptor® (BASF Corporation) is a single pyrethroid-treated LLIN with alpha-cypermethrin (coated onto filaments) at a target dose of 200 mg/m2 of polyester fabric. This LLIN will be distributed to all the households in 21 clusters on a 1 LLIN per two household residents basis.
2402579|NCT03554603|Experimental|Modified Reporting|"Microbiology laboratory will report Positive urine cultures may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call 777-xxxx (researcher mobile phone) for identification and susceptibility results"
2402580|NCT03554603|No Intervention|Standard Reporting|Microbiology laboratory will report identification and susceptibility results
2402581|NCT03554590|Experimental|carbo-counters|carbohydrate counting: patients attending a structured carbohydrate-counting training and practicing this tecnique to manage insulin therapy
2402582|NCT03554590|Active Comparator|control group|insulin therapy according to standard care. patients who don't practice carbohydrate-counting to manage insulin therapy
2402583|NCT03554577|Active Comparator|Hearing Aid without NR|Hearing Aid without Noise Reduction (NR) serves as reference condition.
2402584|NCT03554577|Experimental|Hearing Aid with NR_A|NR_A: Noise Reduction principle A
2402585|NCT03554577|Experimental|Hearing Aid with NR_B|NR_B: Noise Reduction principle B.
2402586|NCT03554577|Experimental|Hearing Aid with NR_C|NR_C: Noise Reduction principle C.
2402587|NCT03554564|Experimental|VOICE/Fitbit|VOICE enrollment with Fitbit walking activity tracking. During the VOICE phase, participants will use the digital health platform that integrates PAD-specific educational content, surveys, and Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase).
2402588|NCT03554564|Other|Daily self-reported exercise adherence|Usual care prescribed by physician (walking exercise instructions). During the Usual Care control phase, participants will conduct walking exercise based on instructions received in clinic. Walking exercise will be tracked and self-reported by participants, using a written calendar log. Participants will not have access to the VOICE platform, or use of Fitbit technology during this phase.
2402589|NCT03554551||Patients with Parkinsons disease|Disease duration > 4 years, Hoehn & Yahr stage 2-3, 50-85 years old
2402590|NCT03554551||Healthy controls|50-85 years
2402591|NCT03554538|Experimental|Web app exercises|An evidence based exercise program for the shoulder pain. Web application with multimedia animations with the tailored exercise program for each patient in this group.
2402592|NCT03554538|Active Comparator|Exercises|An evidence based exercise program for the shoulder pain.
2402593|NCT03554525|Experimental|Experimental product : FAT-BINDER DAMM|3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
2402594|NCT03554525|Placebo Comparator|Control product : PLACEBO|3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.
2402595|NCT03554512|No Intervention|Standard of Care|No Intervention
2402596|NCT03554512|Experimental|Telehealth|Telehealth virtual appointment
2402597|NCT03554499|Experimental|Hydrodissection|Bichectomy with hydrodissection = infiltration of 15ml per side of a special solution (250ml of saline 0.9% + 1mg of epinephrine + 20ml of 2% Lidocaine, equivalent to 0.0555mg of epinephrine and 22.2mg of Lidocaine per side), prior to the incision with the following distribution: 1ml in the form of a wheal in the oral mucosa with a 22G needle 1cm behind the Stenon canal opening that corresponds to the incision site and 14 ml on the virtual space where the buccal fat pad is located.
2402598|NCT03554499|Active Comparator|Control|Bichectomy without hydrodissection = infiltration with 3ml per side of 2% Lidocaine with 1: 200,000 epinephrine ( equivalent to 0.015mg of epinephrine and 60mg of Lidocaine per side) at the operative site.
3184764|NCT00728156|Placebo Comparator|P|Patients assigned to placebo in addition to their standard care.(all patients will be on aspirin).This is a single-centre randomised double-blind placebo-controlled parallel design study, comparing efficacy of clopidogrel versus placebo in patients with T2DM and coronary artery disease. Ninety patients have completed the study. All patients were on their routine medications as per standard practice. After informed consent, participants were randomised to receive either clopidogrel 75mg daily or placebo for 7 days.
3143975|NCT00024635||Parents of Minor Healthy Volunteers|Parents and guardians of minor healthy volunteers
3143976|NCT00024635||Parents of Minor Patients|Parents and guardians of minor patients with mood and anxiety disorders
2402604|NCT03554460|Experimental|dual-limb NIV|A maximal cycle exercise test with the participants assisted by BiPAP (Servo i, Maquet, Siemens) receiving 10 cmH2O pressure support in addition to oxygen therapy. During the test, breathing pattern, inspiratory flow of the inhalation limb and expiratory flow of the exhalation limb, fractional concentration of inspired CO2 (FiCO2) of the inspiratory line was measured for each breath were recorded.
2402605|NCT03554447|Experimental|Pentoxifylline group|Escitalopram 20 mg tablet once daily for 12 week plus Pentoxifylline 400 mg tablet twice daily for 12 weeks
2402606|NCT03554447|Placebo Comparator|Control group|Escitalopram 20 mg tablet once daily for 12 week plus placebo tablet twice daily for 12 weeks
2402607|NCT03554421|Experimental|Posterior tibial nerve stimulation|Percutaneous tibial nerve stimulation. Stimulation av posterior tibial nerve via neuromodulator for 30 minutes. 10 sessions
2402608|NCT03554408|Experimental|Group 1A|HIV-uninfected individuals will be administered one 1 mL (approximately 150 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
2402609|NCT03554408|Experimental|Group 1B|HIV-uninfected individuals will be administered one 2 mL (approximately 300 mg) subcutaneous injection of 10-1074-LS or placebo (formulation buffer), in a 3:1 ratio.
2402610|NCT03554408|Experimental|Group 2A|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 3 mg/kg.
2402611|NCT03554408|Experimental|Group 2B|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg.
3143978|NCT00025025||Arm I|"Participants eat no red meat and take no nonsteroidal anti-inflammatory drugs (NSAIDs) and no vitamin C or multivitamins for 3 days prior to and during stool sample collection. Participants collect stool samples 3 different times and perform fecal occult blood (FOB) test smears from each stool. After each collection, participants ship the whole stool and FOB test smear to their participating center for blinded multitarget DNA-based assay panel (MTAP) testing.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
2402613|NCT03554408|Experimental|Group 3B|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 10 mg/kg
2402614|NCT03554408|Experimental|Group 3C|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS dosed at 30 mg/kg.
2402615|NCT03554408|Experimental|Group 4A|HIV-uninfected individuals will be administered one 2 mL (approximately 150 mg of each mAb) subcutaneous injection of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
2402616|NCT03554408|Experimental|Group 4B|HIV-uninfected individuals will be administered two 2 mL (approximately 300 mg of each mAb) subcutaneous injections of 10-1074-LS admixed with 3BNC117-LS or placebo (formulation buffer), in a 3:1 ratio.
2402617|NCT03554408|Experimental|Group 5|HIV-uninfected individuals will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
2402618|NCT03554408|Experimental|Group 6|HIV-infected individuals (on ART) will be administered one intravenous infusion of 10-1074-LS and one intravenous infusion of 3BNC117-LS, each dosed at 30 mg/kg.
2402619|NCT03554408|Experimental|Group 7|HIV-uninfected individuals will be administered three subcutaneous injections of 10-1074-LS (100 mg) admixed with 3BNC117-LS (200 mg) (2 mL) at weeks 0, 12, and 24.
2402620|NCT03554408|Experimental|Group 8|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (75 mg) admixed with 3BNC117-LS (225 mg) (2 mL) at weeks 0, 12, and 24.
2402621|NCT03554408|Experimental|Group 9|HIV-infected individuals (on ART) will be administered three subcutaneous injections of 10-1074-LS (60 mg) admixed with 3BNC117-LS (250 mg) (2 mL) at weeks 0, 12, and 24.
2402622|NCT03554395|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2402623|NCT03554395|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2402624|NCT03554395|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2402625|NCT03554382|Experimental|intervention|Daily use of interactive mobile phone-based system to support self-management of hypertension: a) relevant items on drug side effects related to patient's drug regimen; and b) blood pressure.
2402626|NCT03554382|No Intervention|Control|"No study intervention will be made in the control group; they will receive treatment as usual."
3143979|NCT00025025||Arm II|"Participants take no vitamin C or multivitamins for 3 days before and during stool sample collection. Participants collect stool samples and FOB test smears and samples are tested as in arm I.~Within 2 months after stool sample collection, participants have their blood drawn for additional MTAP testing and undergo colonoscopy."
2402628|NCT03554343||All newborn from Southern Belgium|All newborns except newborns for which parents refuse newborn screening will be tested for exon 7 deletion in survival motor neuron 1 (SMN1)
2402629|NCT03554330|Active Comparator|control group|Only graded balloon atrial septostomy is carried out, and no radiofrequency catheter ablation is performed.
2402630|NCT03554330|Experimental|single-RFA group|After graded balloon atrial septostomy procedure identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration.
2402631|NCT03554330|Experimental|double-RFA group|The first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (graded balloon atrial septostomy and radiofrequency catheter ablation around the rim of fenestration).
3143980|NCT00025038|Experimental|Treatment (tipifarnib, bone marrow/umbilical cord transplant)|See detailed description.
2402633|NCT03554304|Experimental|WCK 5222|WCK 5222 IV solution administered as either a 30- or 60-minute IV infusion)
2402634|NCT03554304|Placebo Comparator|Placebo (IV placebo matched toWCK 5222IV solution)|placebo capsule matched to moxifloxacin overencapsulated tablet IV placebo matched to WCK 5222 IV solution
2402635|NCT03554304|Active Comparator|Moxifloxacin 400-mg|positive control
2402636|NCT03554291|Experimental|Famotidine|"20mg of oral famotidine (pill) daily~Other names: Pepcid"
2402637|NCT03554291|Placebo Comparator|Placebo|Daily oral placebo (pill)
2402638|NCT03554278||Anemia|Stool samples from infants with anemia. Severe anemia defined as hematocrit less than 25%. Anemia defined as hematocrit greater than or equal to 25% and less than 30%.
2402639|NCT03554278||No Anemia|Stool samples from infants without anemia. No anemia defined as hematocrit equal to or greater than 30%.
3143981|NCT00025207|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3143982|NCT00025220|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2402642|NCT03554252|Experimental|Frequencies|
2402643|NCT03554252|Experimental|Percentages|
2402644|NCT03554239|Other|Voriconazole treatment|Patients who start voriconazole treatment and receive benefits of genotyping
3143983|NCT00025246|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily beginning within 84 days of surgical resection. Treatment continues for 1 year in the absence of disease recurrence or unacceptable toxicity.
2402646|NCT03554213||Phase 1: TCV in 2018|Children receiving TCV (typhoid conjugate vaccine) in 2018 vaccination campaign by NMMC.
3143984|NCT00025337|Experimental|Arm I (bevacizumab, oxaliplatin, leucovorin, fluorouracil)|Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.
3143985|NCT00025337|Experimental|Arm II (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.
3143986|NCT00025337|Experimental|Arm III (bevacizumab)|Patients receive bevacizumab as in arm I.
3143987|NCT00025363|Experimental|Arm I|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
2402650|NCT03554187|Experimental|Lactibiane Buccodental, probiotics|"For one tablet : Lactobacillus paracasei LA 802 (109 UFC), Vitamine D3 (1,5 µg), Vitamine C (24 mg) Dosage : 2 tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Interventions :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
2402651|NCT03554187|Placebo Comparator|Placebo|"With no metabolic action ; identical in appearance to experimental probiotics Dosage : 2 placebo tablets daily for 6 weeks tablet to suck after the meal and brushing teeth (one in the morning and one in the evening)~Intervention(s) :~Ultrasonic periodontal debridement, with appropriate device : D+1 / Analyzes of periodontopathogenic bacteria : D-14, D+1, D+45, D+90 / IL1B test : D-14 / Salivary sampling : D+1, D+45, D+90 / Halitosis measure : D+1, D+45, D+90"
3143988|NCT00025363|Experimental|Arm II|Patients receive vincristine IV on days 1 and 8 and irinotecan IV over 1 hour on days 1-5. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3143989|NCT00025376|Experimental|Pre-Treatment biopsy followed by PS-341 administration|Pre-treatment tumor biopsy followed by 3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects can continue to receive another 3 cycles of the study drug if their disease has not worsened.
3143990|NCT00025376|Experimental|PS-341 administration followed by biopsy|3 cycles of PS-341 given by IV infusion. Each cycle will last 3 weeks. PS-341 will be given 2 times a week for 2 weeks followed by a 'rest' week with no drug. After the 3rd cycle, subjects will have a tumor biopsy and can continue to receive another 3 cycles of the study drug if their disease has not worsened.
2402656|NCT03554161|Experimental|Tocilizumab for refractory BDU|This study is a self-control study and all the participants will be enrolled in the interventional arm.
2402657|NCT03554148||SSI|This group receives an additional swab of the surgical site infection. Follow up is terminated at the occurence of SSI.
2402658|NCT03554148||No SSI|This group is systematically followed up until 30 days after surgery (one year if a implant is implanted, e.g. mesh) by a third party (www.swissnoso.ch).
2402659|NCT03554122|Active Comparator|Shotblocker Group|Patients spinal injections were performed with Shotblocker placed onto injection site
2402660|NCT03554122|Placebo Comparator|Placebo Group|Patients spinal injections were performed without Shotblocker
2402661|NCT03554109|Experimental|Group A|"NANT Neoadjuvant Triple Negative Breast Cancer Vaccine~A combination of agents will be administered to subjects in this study:~cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, avelumab, aldoxorubicin HCl, ALT-803, haNK, GI-4000, GI-6207, GI-6301, ETBX-011, ETBX-051 and ETBX-061"
2402662|NCT03554109|Active Comparator|Group B|Standard treatment with a combination of doxorubicin, cyclophosphamide and paclitaxel.
2402663|NCT03554096|Experimental|2-HOBA|2-Hydroxybenzylamine acetate: 550mg dose
2402664|NCT03554083|Experimental|Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab)|"Patients receive vemurafenib PO BID on days 1-28 and cobimetinib PO QD on days 1-21. Patients also receive atezolizumab intravenously (IV) over 30-60 minutes on days 1 and 15 of cycles 2 and 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
2402665|NCT03554083|Experimental|Arm B - CLOSED (cobimetinib, atezolizumab)|Patients receive cobimetinib as in Arm A and atezolizumab IV over 30-60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
2402666|NCT03554083|Experimental|Arm C (atezolizumab, tiragolumab)|"Patients with BRAF wild-type or BRAF mutant melanoma receive atezolizumab IV over 30-60 minutes and tiragolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~Within 2-4 weeks after treatment, patients undergo surgery then receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
2402667|NCT03554070|Experimental|Infravesical Obstruction|Patients with infravesical obstruction due to BPH (IPSS > 20, Qmax < 10), who underwent Thulium Fiber Laser Enucleation of the Prostate.
2402668|NCT03554057||Intervention Group|All low-risk patients referred for invasive coronary angiography through the Hamilton General Hospital's Heart Investigation Unit Triage will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification with CCTA at HHS and NHS as an alternative to upfront invasive angiography.
2402669|NCT03554057||Control Group|Intervention sites will act as their own controls: outcomes of all eligible patients in the 24-months prior to the implementation of the intervention will be assessed from a routinely collected health administrative database. Eligible patients not undergoing CCTA (patient or physician refusal, or CCTA not available) will be captured and included in the control group as part of a sensitivity analysis during the intervention period
2402670|NCT03554044|Experimental|Cohort I (talimogene laherparepvec, chemotherapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with one of the following chemotherapies: paclitaxel (IV), nab-paclitaxel IV, or gemcitabine / carboplatin IV.~Cycles repeat every 21 days until disease progression or unacceptable toxicity"
2402671|NCT03554044|Experimental|Cohort II (talimogene laherparepvec, endocrine therapy)|"Patients receive talimogene laherparepvec intra-tumorally (IT) every 2 weeks for the first 10 weeks and every 3 weeks thereafter along with letrozole PO, anastrazole PO, exemestane PO, tamoxifen PO on days 1-21 or fulvestrant IM every 2 weeks for 3 doses then every 4 weeks for the subsequent courses.~Cycles repeat every 28 days until disease progression or unacceptable toxicity"
2402672|NCT03554031|Experimental|rhGH injection/Jintropin AQ|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.
2402681|NCT03553992|Experimental|The Put It Out Project (POP-6):|a culturally tailored intervention developed for sexual and gender minority (SGM) young adults on Facebook
2402682|NCT03553992|Experimental|Tobacco Status Project (TSP-6):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
2402683|NCT03553979|Experimental|Stress management program (SM)|The stress management program (SM) is a program which has been tailored to meet the specific needs of low-SES participants. The SM consists of 4-weekly sessions (1.5hours/session) and a follow-up session 8 weeks later. A core element of SM is its group-based format in which psycho-educative topics on stress responses and coping and motivation to stop smoking link up with cognitive and behavioural technique activities.
2402684|NCT03553979|Experimental|Stress management + Buddy program (SM-B)|The stress management + buddy program (SM-B) includes the same psycho-educative topics and exercises, cognitive and behavioural technique activities as the SM condition. The SM-B in addition to SM utilises one-to-one support through a buddy selected by a participant. A buddy, 18 year or older is a student or a volunteer who is recruited and trained by Indigo Rijnmond. The buddy pairs up with a participant and provides the following: supports participant in managing and filling in tax/welfare papers; 2) helps a participant to get a grip over his/her personal finances; and 3) helps a participant to overcome daily barriers (eg. arranging childcare). Over the duration of the course, the buddy meets up 6 times with a participant every second week in a public area.
2402685|NCT03553979|No Intervention|Control|Participants in the control condition are instructed to continue with their normal daily behaviour. They will be invited to complete the questionnaires and objective measurements at the equivalent times as the intervention groups, thus at baseline, 4 weeks after baseline and 12 weeks after baseline. After the control period, participants in the control condition will be offered the intervention.
2402686|NCT03553966|Experimental|Tooth Brushing HAP+Restorative dentistry|"Arm Intervention: HA-Toothpaste Tooth Brushing HA Prophylactic cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated toothpaste containing microcrystalline hydroxylapatite 3x daily over the duration of the study (336 days).~Procedure: Tooth Brushing HA"
2402687|NCT03553966|Active Comparator|Tooth Brushing F+Restorative dentistry|"Cleaning teeth using a standardized electric tooth brush and a fluoridated tooth paste containing amino fluoride (500 ppm F-), (three times daily over the duration of the study (336 days).~Intervention:~Procedure: Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated toothpaste."
2402688|NCT03553953||Patients with recording from BIS device|One hundred screened adult patients and no more than 60 valid cases who undergo elective surgery under general anesthesia with recording from the BIS device at the same time and comply with the inclusions criteria
3143991|NCT00025389|Experimental|Arm A|Bevacizumab (15mg/kg, q3wk x 2), Paclitaxel (200 mg/m2, q3wk x 2), carboplatin (AUC of 6, q3wk x 2), followed by surgery 4 to 6 weeks after last dose of Bevacizumab
3143992|NCT00025415|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients within each stratum (except normal stratum) receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity
2402691|NCT03553927|Other|Low Energy Diet|Commercially available diet products
2402692|NCT03553927|Other|NHS advice on healthy eating|Dietary / lifestyle advice programme
2402693|NCT03553914|Experimental|12 mg/m^2 dose group|Subjects will receive PLM60 at 12 mg/m^2 dose.
2402694|NCT03553914|Experimental|16 mg/m^2 dose group|Subjects will receive PLM60 at 16 mg/m^2 dose.
2402695|NCT03553914|Experimental|20 mg/m^2 dose group|Subjects will receive PLM60 at 20 mg/m^2 dose.
2402696|NCT03553901|Experimental|Acupressure|Acupressure is applied before injection
2402697|NCT03553901|No Intervention|Control group|acupressure is not applied before injection
2402698|NCT03553888||HS patient|patients with HS
2402699|NCT03553888||no HS patients|patients without HS
2402700|NCT03553875|Active Comparator|Memantine|Memantine administered in tablet form twice daily titrated to a maximum dose of 20 mg for 12 weeks.
2402701|NCT03553875|Placebo Comparator|Placebo|Subjects in the placebo control group will receive a matched placebo pill with no active ingredients. This will be administered twice daily for 12 weeks.
2402733|NCT03553615|Experimental|Oral treatment|12mg oral ivermectin treatment taken once a week for four weeks
3143993|NCT00025467|Experimental|Treatment (thalidomide)|Patients receive oral thalidomide once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3143994|NCT00025493|Experimental|docetaxel|docetaxel
3143995|NCT00025584|Experimental|Treatment (bortezomib)|Patients receive PS-341 IV over 3-5 seconds twice weekly on weeks 1 and 2. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3143996|NCT00025675|Active Comparator|p450|p450 inhibitor
3143997|NCT00025675|Active Comparator|nonp450|not on p450 inhibitor
3143998|NCT00025766|Experimental|1|PCI with stenting of the occluded culprit infarct-related artery plus optimal medical therapy
3143999|NCT00025766|Active Comparator|2|Optimal medical therapy alone without PCI of the occluded culprit artery
3144000|NCT00026091|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide twice daily on days 1-7. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3144001|NCT00026104|Experimental|Arm I (radiation therapy, paclitaxel, gemcitabine)|Patients receive radiotherapy once daily, 5 days a week, for 5.5 weeks, beginning on day 1. Patients also receive paclitaxel IV over 1 hour and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, and 36.
3144002|NCT00026104|Experimental|Arm II (radiation therapy, tipifarnib)|Patients receive chemoradiotherapy as in arm I. Within 3-8 weeks after completion of chemoradiotherapy, patients without disease progression receive oral tipifarnib twice daily for 21 days.
3144003|NCT00026117|Experimental|BeneFin|"Patients receive oral shark cartilage (BeneFin™) 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
2402702|NCT03553862|No Intervention|Control|Patients randomly assigned to the control arm will receive the usual or conventional care not interfered by the study team.
2402703|NCT03553862|Experimental|Intervention|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.
2402704|NCT03553849|Experimental|Very Low Calorie Diet|If they are randomized into the treatment arm, they will be prescribed with a 2-week VLCD that will begin 2 weeks prior to the scheduled elective surgery. Patients will be required to pay for the meal replacements.
2402705|NCT03553849|No Intervention|Standard Preop Diet|The control group will continue a regular diet until the day before surgery.
2402706|NCT03553836|Experimental|Pembrolizumab|Pediatric participants receive 2 mg/kg (200 mg maximum) pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W; 21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Adult participants receive 200 mg pembrolizumab by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of pembrolizumab and experience disease recurrence may be eligible to receive additional cycles of pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for unresectable disease recurrence. Participants with distant metastasis who undergo complete resection will receive 17 cycles (up to ~1 year) of pembrolizumab but can receive up to 35 cycles (up to ~2 years) of pembrolizumab under certain circumstances.
2402707|NCT03553836|Placebo Comparator|Placebo|Participants receive saline placebo by IV infusion Q3W (21-day cycles) for up to 17 cycles (up to ~1 year) in a double-blind design in Part 1. Participants that complete 17 cycles of placebo and experience disease recurrence may be eligible to receive pembrolizumab in Part 2 in an open-label design. In Part 2, participants will receive up to 17 cycles (up to ~1 year) of pembrolizumab for local/distant recurrence following disease resection or up to 35 cycles (up to ~2 years) of pembrolizumab for disease that cannot be resected or metastatic disease.
3184765|NCT00728195|Placebo Comparator|Placebo First, Then Olanzapine|Participants will receive 2 matching placebo capsules orally twice daily for 6 consecutive weeks, then 2 matching placebo capsules orally in the morning and olanzapine 10 milligram (mg) capsule along with matching placebo capsule orally in the evening for next 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 5 weeks.
2402710|NCT03553810|Experimental|Treatment Arm|Entresto (valsartan/sacubitril) 100mg once a day
2402711|NCT03553810|Active Comparator|Controlled Arm|Valsartan 40mg once a day
2402712|NCT03553784|Experimental|Intervention Group|Group delivered Low Intensity Cognitive Behavioural Therapy (CBT).
2402713|NCT03553784|No Intervention|Control Group|No intervention.
2402715|NCT03553745|Experimental|Gentle Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of gentle yoga sessions led by instructors specializing in the area.
2402716|NCT03553745|Experimental|Rigorous Yoga Program|Program will meet twice a week for a 10-week period. Participants will be a part of rigorous yoga sessions led by instructors specializing in the area.
2402717|NCT03553745|Experimental|Cardiovascular Exercise Program|Program will meet twice a week for a 10-week period. Participants will be a part of cardiovascular exercise sessions led by instructors specializing in the area.
2402718|NCT03553732||Active Surveillance Patients|Patients who elect to be monitored by an Active Surveillance protocol for prostate cancer
2402719|NCT03553719||One day point-prevalence analysis 1|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
2402720|NCT03553719||One day point-prevalence analysis 2|"Before the start of the second one day point-prevalence analysis a training package is conducted at each study center. This contains online lectures, instructional videos, educational handouts, and a bedside teaching component over the course of 6 weeks. The effect of a training block for intensive care unit staff on routine delirium screening rate and the change of the other outcome measures will be assessed.~During the one day point-prevalence analysis 2 data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected."
2402721|NCT03553719||One day point-prevalence analysis 3|Data on the management of intensive care unit patients ≥18 years will be collected. Data of approximately 170 patients per point-prevalence analysis will be collected.
2402722|NCT03553693|Experimental|Intervention Clinics|RAPID-VL study intervention testing and counseling package, which includes near point-of-care viral load (VL) testing at local testing hubs, structured VL counseling, forms to track VL ordering and testing, with feedback and performance evaluations at regular intervals.
2402723|NCT03553693|No Intervention|Control Clinics|Standard of care VL testing and counseling procedures consistent with country guidelines.
2402724|NCT03553680|Experimental|Emotion-Focused CBT|Ten CBT sessions with a therapist.
2402725|NCT03553680|No Intervention|Wait List|Three visits for assessments only over the same time period of the Experimental Arm.
2402726|NCT03553667|Active Comparator|Standard group|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
2402727|NCT03553667|Experimental|ClearSight|Adult patients, Creatinine clearance >= 30ml/min, with limb lymphedema, receiving lymphatic venous anastomosis
2402728|NCT03553654|Experimental|CT monitoring arm|18-75 year old patients with newly-diagnosed cancer, scheduled to undergo anthracycline-based chemotherapy.
2402729|NCT03553628|Active Comparator|Chlorhexidine Once Daily|Chlorhexidine HCL 0.12% mouthwash to be used once daily for one week each month for six months
2402730|NCT03553628|Active Comparator|Chlorhexidine Twice Daily|Chlorhexidine HCL 0.12% mouthwash to be used twice daily for one week each month for six months
2402731|NCT03553628|Experimental|Propolis Once Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used once daily for one week each month for six months
2402732|NCT03553628|Experimental|Propolis Twice Daily|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash to be used twice daily for one week each month for six months
2402734|NCT03553602|Experimental|HDR Brachytherapy + EBRT + STAD|"Day 1: HDR Brachytherapy implant: 2 fractions of 12 Gy to prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET positive lesions.~6 months hormonal therapy(LHRH agonist and antiandrogen [until the end of radiotherapy])"
2402735|NCT03553589||Cases|Women older than 18 years and diagnosed with endometrial cancer will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
2402736|NCT03553589||controls|Women older than 18 years and with a benign endometrial disturbance will be included. Blood sampling will be performed on all subjects and will be used for proteomics and metabolomics analyses.
2402737|NCT03553576|Experimental|Low volume bolus|6.25 mL administration at 250 ml per hour of a greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL)
2402738|NCT03553576|Experimental|High volume bolus|10 mL administration of a lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL).
3144004|NCT00026117|Other|placebo|"Patients receive oral placebo 3-4 times daily. Treatment continues in the absence of unacceptable toxicity. Quality of life is assessed weekly for 1 month and then monthly thereafter during treatment.~Patients are followed every 6 months for 5 years."
3144005|NCT00026130|Experimental|Gemcitabine + 5FU + XRT|Chemo and radiation therapy in the treatment of non-metastatic pancreatic cancer
3184766|NCT00728195|Experimental|JNJ-37822681 10 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 10 mg capsule orally twice a day for 12 consecutive weeks.
2402743|NCT03553537|Experimental|Decitabine + CHOP regimen|decitabine plus CHOP (D-CHOP) administered in 4 week cycles for 6 cycles
2402744|NCT03553537|Active Comparator|CHOP regimen|cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles
2402745|NCT03553524|Experimental|Morning first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 1 of the study will perform HIIT at 08:30 during visit 2, and after a 1-week washout period will perform HIIT at 19:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
2402746|NCT03553524|Experimental|Afternoon first|"Both arms of the study will perform the baseline measurements during visit 1. Arm 2 of the study will perform HIIT at 19:30 during visit 2, and after a 1-week washout period will perform HIIT at 08:30 during visit 3.~HIIT bout will consist of 3 minutes of warm-up followed by 6 1-minute intervals of full exertion cycling on a cycle ergometer, interspersed by a 1-minute recovery periods and ending with a 3-minute cooldown."
2402747|NCT03553511|Experimental|Uterosacral ligaments suspension|Women affected by stage II-III pelvic organ prolapse undergoing total laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments.
2402748|NCT03553511|Active Comparator|McCall culdoplasty|Women affected by stage II-III pelvic organ prolapse undergoing vaginal hysterectomy with McCall culdoplasty.
2402749|NCT03553498|Experimental|IV Acetaminophen|1000 mg IV acetaminophen administered over 5-10 minutes
2402750|NCT03553498|Placebo Comparator|IV hydromorphone and placebo|100 ml IV normal saline administered over 5-10 minutes
2402751|NCT03553485|Experimental|taVNS|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
2402752|NCT03553485|Sham Comparator|Control|Treatment will be carried out twice a day (once before the RT session and 8h later) during 7 weeks. Each treatment takes 30 minutes.
2402753|NCT03553472||Non-immunosuppressed IBD patients|24 IBD patients on mesalamine therapy or no IBD therapy
2402754|NCT03553472||Thiopurine group|12 IBD patients on azathioprine at least 2.0mg/kg or 6MP 1.0mg/kg
2402755|NCT03553472||Anti-TNF therapy|12 IBD patients on maintenance therapy infliximab (at least 8 every 8 weeks), golilumab (at least monthly), adalilumab (at least every 2 weeks), or certolizumab (at least monthly)
2402756|NCT03553472||Combination therapy|12 IBD patients on anti-TNF therapy as described in group along with either 15mg of methotrexate or azathioprine at least 1.0mg/kg or 6MP 0.5mg/kg
2402757|NCT03553472||Healthy Control|"The control group with consist of 12 individuals who meet the following inclusion and exclusion criteria.~Individuals will be obtained from patients without an IBD diagnosis, chronic liver disease, celiac disease or other chronic health condition coming to Digestive Health Center for endoscopic procedures or clinic visits."
2402758|NCT03553472||Vedolizumab therarpy|12 IBD patients on vedolizumab maintenance therapy every 4-8 weeks
2402759|NCT03553472||Prednisone and Anti-TNF therapy|12 IBD patients on Anti-TNF maintenance therapy as combination or mono therapy along with at least 10mg of prednisone
2402760|NCT03553459|Experimental|Trendelenburg Maneuver|Trendelenburg maneuver is performed to predict fluid responsiveness. Responders are defined by an increase in stroke volume over 15% after infusion of 500ml of crystalloid solution.
2402761|NCT03553446|Experimental|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
2402762|NCT03553433|Experimental|Verum|Apremilast 30mg bd
2402763|NCT03553433|Placebo Comparator|Placebo Oral Tablet|Excipiens
2402764|NCT03553407|Experimental|Low Level Laser - Pulse|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm², 25 Hz
2402765|NCT03553407|Experimental|Low Level Laser - continuous|In this group the patient will receive the following laser protocol: 880nm, 30mW, 3.6 J / cm²
2402766|NCT03553407|Placebo Comparator|Low Level Laser - Placebo|In this group the patient will receive the protocol with the equipment turned off.
2402767|NCT03553394|Active Comparator|Standard of care group|Will receive a fluid bolus 5 ml/kg Ringer's Acetate infusion immediately if oliguric/anuric for two consecutive hours (standard of care).
2402768|NCT03553394|No Intervention|Expectant management group|Await fluid therapy for 2 hours. Will NOT receive a fluid bolus if oliguric/anuric for two consecutive hours and a now assessment will be made after two more hours.
2402769|NCT03553381||obese without MS|BMI 25- 35 Kg/mq without metabolic syndrome (MS) submitted to hypocaloric balanced diet
2402770|NCT03553381||obese with MS|BMI 25- 35 Kg/mq with metabolic syndrome submitted to hypocaloric balanced diet
2403199|NCT03550365|Experimental|Rye bran bread intervention|4 week rye bran bread diet intervention with dietary fibre intake of 30g
2402771|NCT03553368|Experimental|Step 1: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will be acquired without the use of HF-NIV, as a reference (MR)."
2402772|NCT03553368|Experimental|Step 2: Patients (arm A)|"Experimental intervention:~MRI data will be acquired with the use of HF-NIV (HF-NIV-MR).~Control intervention:~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). The clinically prescribed CT will be the gold standard."
2402773|NCT03553368|Experimental|Step 2: Patients (arm B)|"Experimental intervention:~PET/CT data will be acquired with the use of HF-NIV (HF-NIV-PET). MRI data will be acquired with the use of HF-NIV (HF-NIV-MR). PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV (PET/CT breath hold).~Control intervention:~Data from the clinically indicated PET/CT acquisition will be used as reference.~MRI data will also be acquired without the use of HF-NIV, as a reference (MR). Histological data will be used when available."
2402774|NCT03553368|Experimental|Step 1 bis: Healthy volunteers|"Experimental intervention:~MRI data will be acquired with the use of CPAP (CPAP-MR).~Control intervention:~MRI data will be acquired without the use of CPAP, as a reference (MR)."
2402775|NCT03553355|Experimental|Infrared Laser Moxibustion Therapy|Each patient will receive this treatment twice per week for six weeks (12 sessions total).
2402776|NCT03553355|Sham Comparator|Sham Infrared Laser Moxibustion Therapy|The patients will receive treatment from sham laser moxibustion instrument.
2402777|NCT03553355|No Intervention|Waitlist Controls|The patients maintain their usual treatment and self-care,
2402778|NCT03553342|Experimental|Corticoids|
2402779|NCT03553342|Placebo Comparator|Placebo|
2402780|NCT03553316|Experimental|Sequence (1)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~Investigators Products(IPs) for Period1: A (Single)= PK101-002~IPs for Period2: B (Combination)= PK101-001, PK101-002"
2402781|NCT03553316|Experimental|Sequence (2)|"Number of Subject: 24~Wash out Period: over 7 days (between each period)~IPs for Period1: B (Combination)= PK101-001, PK101-002~IPs for Period2: A (Single)= PK101-002"
2402782|NCT03553303|Experimental|Intervention|Increasing doses of Sacubitril/Valsartan
2402783|NCT03553290|Sham Comparator|control|Mechanical debridement alone
2402784|NCT03553290|Active Comparator|lower-level laser Therapy|"Mechanical debridement with lower-level laser therapy~Device: A.R.C. FOX Laser-FOX Q-810nm Mechanical debridement with lower-level laser therapy"
2402785|NCT03553277|Experimental|Transfluthrin|transfluthrin
2402786|NCT03553277|Placebo Comparator|Placebo|inert ingredients
2402787|NCT03553264|Experimental|Head Mounted Device|"In addition to the Vestibular Rehabilitation protocol, each HMD group patient will perform Virtual Reality Rehabilitation by means of the game protocol Track Speed Racing 3D uninterruptedly for 20min/day, while sitting on a chair or sofa, after the smartphone accommodation into the HMD 'Revelation' 3D VR Headset. The game consists of a point-of-view race in which the car is steered from the cockpit by tilting the head to the left and to the right to avoid swerving off the road and to achieve all the goals before finishing the lap. During this real car experience, the visual background and the scenario change perspective according to the patients' left or right tilted head movements, possibly emulating eye-head exercises that induce visual-vestibular conflicts."
2402788|NCT03553264|Active Comparator|Vestibular Rehabilitation|Patients will be actively involved in adapting the exercise program to suit their symptoms, capabilities, and lifestyle. Following previous protocols, the home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises, and all chronic unilateral vestibular hypofunction patients will be seen twice a week for 4 weeks for 30-45 min and monitored for adherence. Between supervised sessions, patients will perform a twice-daily home exercise program for a total of 30-40min/day.
2402789|NCT03553238|Experimental|ETP-ALL|Chidamide at a dose of 10mg/day will be added to PDT-ETP-ALL protocol. The intervention of PDT-ETP-ALL consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, Karyotyping ，FISH, NGS, Flow-MRD, PET-CT scan), induction regimen (chidamide, dexamethasone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, prednisone, cytarabine, methotrexate, cyclophosphamide, etoposide, adriamycin, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen (chidamide, prednisone, vincristine, methotrexate, 6-mercaptopurine), intrathecal injection chemotherapy, radiation therapy (for mediastinum- and/or central nervous system-involved lymphoma/leukemia) and allogeneic hematopoietic stem cell transplantation for patients with donor.
2402790|NCT03553225|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsules regimen (1g)
2402791|NCT03553225|Active Comparator|Concord Grape Extract 1|1 g Concord Grape Extract in 2 capsules
2402792|NCT03553225|Active Comparator|Concord Grape Extract 2|500 mg Concord Grape Extract in 2 capsules
2402793|NCT03553212|Experimental|High dose external beam Radiotherapy|Image-guided tomotherapy
2402794|NCT03553199|Experimental|TRS|TRS, Tissue resection system
2402795|NCT03553186|Experimental|ivTXA + topical TXA|"TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2 mg/kg/hr maintenance dosing as per hospital protocol"
2402796|NCT03553186|Placebo Comparator|IV TXA + topical placebo|"Placebo solution (200 cc sterile normal saline + placebo TXA ampule (normal saline) (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.~IV txa will be given as (5mg/ml) loading dose (20mg/kg) over 15 minutes followed by 2mg/kg/hr maintenance dosing as per hospital protocol"
2402797|NCT03553173|Active Comparator|Control|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation.~Prescribed treatments:~Bupropion pills + Psychological advice~Varenicline pills + Psychological advice"
2402798|NCT03553173|Experimental|Intervention|"Subjects undergoing usual psycho-pharmacological treatment for smoking cessation plus a smart phone App.~Prescribed treatments:~Bupropion pills + Psychological advice + So-Lo-Mo~Varenicline pills + Psychological advice + So-Lo-Mo"
2403408|NCT03548805|Experimental|Trabeculectomy with Ologen|ologen® Collagen Matrix
2402799|NCT03553160|Other|Frequent Self-Weighing|Study examined the effectiveness of daily self-weighing to prevent age related weight gain.
2402800|NCT03553147|Experimental|Group/Cohort 1|all patient SARC-F score, handgrip test and impedancemetry
2402801|NCT03553121|Active Comparator|Walk preoperativelying|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will walk during one hour with average speed 3 km/hour 12 hour before surgery.
2402802|NCT03553121|Active Comparator|not walking preoperatively|Patients will be operated gynecologic cancers and have American Society of Anesthesia score 1 or 2. Subjects will not walk preoperatively.
2402803|NCT03553108|Experimental|Olaparib Treatment Sequence ABCD|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg"
2402804|NCT03553108|Experimental|Olaparib Treatment Sequence BDAC|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg"
2402805|NCT03553108|Experimental|Olaparib Treatment Sequence CADB|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg"
2402806|NCT03553108|Experimental|Olaparib Treatment Sequence DCBA|"On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.~D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg"
2402807|NCT03553095|Active Comparator|Chronic Periodontitis and Depression Medications|Patients with clinically diagnosed depression taking (SSRIs, NDRIs, SNRIs, tricyclic antidepressants) and with chronic periodontitis
2402808|NCT03553095|Active Comparator|Chronic Periodontitis without Depression Medications|Patients with clinically diagnosed depression not taking any antidepressants (SSRIs NDRIs, SNRIs and Tricyclic antidepressants) and with chronic periodontitis
2402809|NCT03553095|Active Comparator|Chronic Periodontitis|Patients without depression, not taking any antidepressants and with chronic periodontitis
2402810|NCT03553082|Active Comparator|Total intravenous anesthsia|Patients in this group will receive Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance.
2402811|NCT03553082|Active Comparator|Sevoflurane|Patients in this group will receive sevoflurane 8% and fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance.
2402812|NCT03553056|Experimental|Intervention|NZ Step Away app
2402813|NCT03553056|Active Comparator|Control|Modified NZ Step Away app
2402814|NCT03553043|Experimental|Energy Label 1|Alcoholic beverage displayed with Energy label 1
2402815|NCT03553043|Experimental|Energy Label 2|Alcoholic beverage displayed with Energy Label 2
2402816|NCT03553043|Experimental|Energy Label 3|Alcoholic beverage displayed with Energy Label 3
2402817|NCT03553043|Placebo Comparator|Unlabelled|Alcohol beverage displayed unlabelled.
2402818|NCT03553030||prediabetics|patients with diagnosed of prediabetes.
2402819|NCT03553030||normo glycemics (controls)|patients without diagnosed of prediabetes.
2402820|NCT03553017||Participants with eye disease|A maximum of 200 participants with various eye diseases will be recruited from appropriate eye clinics at Moorfields Eye Hospital. Eye conditions will include both anterior segment disease such as corneal disease and ocular inflammatory disease, retinal vascular and macular diseases, and optic nerve disease such as glaucoma.
2402821|NCT03553004|Experimental|Niraparib Treatment|"Niraparib 300 milligrams (mg) by mouth daily for 28 days (1 cycle = 28 days)~(Dose reduced to 200mg dose for participants whose baseline weight is less than 77 kilograms (kg) [169.756 pounds (lbs)] or baseline platelet count is less than 150,000 microliters (µL))."
2402822|NCT03552991|Other|Agio arm|It is a pilot study based on the proof-of-concept that dietary fiber helps glucose control in patients with type 2 diabetes. As a single-arm study, 'Agiocur Pregranules' (dietary fiber) is administered for 28 days and stopped for next 28 days, in patients with type 2 diabetes.
2402823|NCT03552978|Experimental|Tech-facilitated IC intervention|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive 8 video or telephone counseling sessions for smoking cessation. The first session lasts 45-60 min, and the remaining 7 sessions last 20-30 min.~Be asked to use the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation.~Be asked to use the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The Covita mobile app (compatible with iOS and Android) is used with the iCO Smokerlyzer to display CO readings."
2402824|NCT03552978|Active Comparator|Treatment as usual (VA Quitline)|"Complete an initial 2-hour screening visit that includes a series of questionnaires assessing eligibility criteria and meeting with the study physician to review medical history.~Be offered nicotine replacement therapy (NRT) at baseline (Week 0), per VA prescribing guidelines, nicotine dependence levels, and participant preference.~Receive weekly proactive telephone sessions through the VA telephone Quitline, a proactive telephone quitline available to all veterans for up to eight weeks. Participants will initiate the first call and subsequent calls will be made by the Quitline counselor."
2402825|NCT03552965|Active Comparator|Margin-Based Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated by introducing a margin to the target area.
2402826|NCT03552965|Active Comparator|Robust Radiotherapy Planning|This arm will receive Intensity-Modulated Radiation Therapy (IMRT) that was calculated to minimize the dose of radiation to normal tissue.
2402827|NCT03552952||Preterm infants|100 preterm infants
2402828|NCT03552952||Term infants|100 term healthy infants
2402829|NCT03552913||2015 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2015
2402830|NCT03552913||2017 Total knee arthroplasty, hysterectomy or left colectomy|Group of patients having a total knee arthroplasty, hysterectomy or left colectomy in 2017
2402831|NCT03552913||2015 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2015
2402832|NCT03552913||2017 Total hip prosthesis, ovariectomy or gastrectomy|Group of patients having total hip prosthesis, ovariectomy or gastrectomy in 2017
2402833|NCT03552900|Active Comparator|App 1 Study group (7cups)|"Participants assigned to this group will be assigned a behavioral intervention, the mobile app (7cups) which allows participants access to direct online social support via the app."
2402834|NCT03552900|Active Comparator|App 2 Study Group (Bliss|"Participants assigned to this group will be assigned to a behavioral intervention, the mobile app ( Bliss ) which provides participants an informational app about mental health resources at Harvard."
2402835|NCT03552887||Postoperative patients|Cohort of patients undergoing cardiac surgery, aged ≥ 18 years old, who had received any physiotherapy intervention
2402836|NCT03552874||Patient Group|Children whose ages between 5-10 years with Duchenne Muscular Dystrophy.
2402837|NCT03552874||Healthy Group|Healthy peers
2402838|NCT03552861|Active Comparator|left and right DLPFC active treatment|Intervention: repetitive transcranial stimulation (rTMS) Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface.
2402839|NCT03552861|Active Comparator|left DLPFC active and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2402840|NCT03552861|Active Comparator|left DLPFC sham and right DLPFC active treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2402841|NCT03552861|Sham Comparator|left DLPFC sham and right DLPFC sham treatment group|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks,the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
2402842|NCT03552848|Experimental|Mesenchymal stem cell|Patients in the MSC arm will be given MSC, i.v., 1000000 cells per kilogram of body weight.
2402843|NCT03552848|No Intervention|Control|Patients in the control arm will not be given MSC.
2402844|NCT03552835|Experimental|no caries removal|mandibular occlusal caries were treated with placement of stainless steel crown with no caries removal
2402845|NCT03552835|Experimental|partial caries removal upto soft dentin|mandibular occlusal caries were treated by partial caries removal upto soft dentin
2402846|NCT03552835|Experimental|partial caries removal upto firm dentin|mandibular occlusal caries were treated by partial caries removal upto firm dentin
2402847|NCT03552822||ERAS Implemented Group|Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
2402848|NCT03552822||Pre-ERAS - Non-ERAS Implemented Group|Non-Enhanced recovery after surgery (ERAS) protocol implementation for patients undergoing cesarean delivery.
2402849|NCT03552809|Active Comparator|Conventional Frenectomy|For the conventional surgery, after application of local infiltration anesthesia of articaine HCL associated with epinephrine 1:100,000, the frenulum was grasped with a straight haemostat inserted into the depth of the vestibule; the tissue adjacent to the upper and lower surfaces of the haemostat was incised with a no.15 scalpel. After the diamond shaped resected portion of the frenulum was removed with the haemostat, muscle dilatations were excised on the submucosa of the lateral walls of the cavity. Horizontal incision was made on the periosteum with the help of a scalpel following the procedure. At the end of the operation, the wound was closed with absorbable sutures (4-0, Pegelak®, Doğsan Turkey).
2402850|NCT03552809|Experimental|Diode Laser Frenectomy|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenlum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum or any bone structure.Following the bleeding control, the wound site was left to secondary healing. No sutures were necessary after procedure.
3184767|NCT00728195|Experimental|JNJ-37822681 20 mg|Participants will receive 1 matching placebo capsule along with JNJ-37822681 20 mg capsule orally twice a day for 12 consecutive weeks.
3184768|NCT00728195|Experimental|JNJ-37822681 30 mg|Participants will receive JNJ-37822681 30 mg (one 10 mg capsule along with JNJ-37822681 20 mg capsule) orally twice a day for 12 consecutive weeks.
2402851|NCT03552809|Experimental|Laser Frenectomy with Incision|For the laser frenectomy, a diode laser device (λ = 810 nm, W: 4, GIGA Cheese II, China) was used to perform the procedure. The procedure was performed under local infiltration anesthesia with articaine HCL associated with epinephrine 1:100,000. The frenulum was held by a haemostat inserted into the depth of the vestibule while laser energy was applied to the upper and lower parts of the frenulum adjacent to the haemostat via a fibre tip (400 µm diameter, plain-ended, optical ﬁbre). The laser was carefully applied to the tissue and care was taken to avoid local necrosis of the periosteum. Horizontal incision was made on the periosteum with the help of a scalpel, additionally. No sutures were necessary after procedure.
3144006|NCT00026143|Experimental|Arm I|Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
2402853|NCT03552783|Active Comparator|Fathers for a Lifetime (FFL) only|The participants in the comparison arm will receive the standard, 12-week program curriculum of Father For a Lifetime.
2402854|NCT03552783|Experimental|FFL + Cognitive Behavioral Therapy|The participants in the intervention will receive will the standard, 12-week program curriculum of Father For a Lifetime and the Cognitive Behavioral Therapy. The intervention will be delivered by a gender and culturally-matched Licensed Mental Health Professional (LIMHP). In addition, the men will receive three one-on-one therapy sessions with a Charles Drew LIMHP that will be completed by the end of the FFL program.
2402855|NCT03552770|Active Comparator|IVIBx1|Patients treated with a single intra-vitreous injection of bevacizumab (1.25 mg in 0.05 ml of solution) pro-re-nata repeated after monthly periodic monitoring of each patient
2402856|NCT03552770|Active Comparator|IVIBx2|Patients treated with two combined intra-vitreous injections of bevacizumab, (1.25 mg in 0.05 ml of solution) spaced 30 ± 10 days apart and pro-re-nata repeated after periodic monitoring of each patient
3144007|NCT00026169|Experimental|Treatment (imatinib mesylate)|"Patients receive oral imatinib mesylate once or twice daily on days 1 and 4-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients in each stratum receive escalating doses of imatinib mesylate until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3144008|NCT00026182|Experimental|Arm I (rituximab and recombinant interleukin-12)|Patients receive rituximab IV on days 1, 8, 15, and 22. Patients receive interleukin-12 SC twice weekly beginning on day 2 and continuing until disease progression.
3184769|NCT00728195|Active Comparator|Olanzapine|Participants will receive 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with matching placebo capsule orally in the evening for 1 week, then 2 matching placebo capsules orally in the morning and olanzapine 10 mg capsule along with olanzapine 5 mg capsule orally in the evening for next 11 consecutive weeks.
2402860|NCT03552744|Experimental|Intervention group|
2402861|NCT03552744|No Intervention|Control group|
2402862|NCT03552731||Subsequent|Patients who have been receiving chemotherapy more than once. A intervention survey will be administered.
2402863|NCT03552731||First Time|Patients who have been receiving chemotherapy first time. A intervention survey will be administered.
2402864|NCT03552718|Experimental|Experimental: NANT Neoepitope Yeast Vaccine (YE-NEO-001)|
2402865|NCT03552705|Experimental|Tranexamic Acid|5-day course of standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
2402866|NCT03552705|Placebo Comparator|Placebo|5-day course of placebo and intravenous saline during ACL reconstruction surgery
2402868|NCT03552679||LVAD recipients|Consecutive patients accepted for elective LVAD implantation in the context of routine care, will undergo routinely scheduled echocardiography before, within 1 week, 1 month, 3 months and 1 year after LVAD implantation. Echocardiography will be performed using ultrasound machines that are capable of acquisition of two-, three-dimensional and Multiplane Echocardiography of the right ventricle. Invasive hemodynamic data will be collected in the perioperative period.
2402869|NCT03552666|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|A single oral dose of gummy vitamin D3 to monitor Vitamin D blood levels
2402870|NCT03552666|Active Comparator|Nature Made Vitamin D3 Tablet|A single oral dose of tablet vitamin D3 to monitor Vitamin D blood levels
2402871|NCT03552653|Experimental|Vitafusion Extra Strength Vitamin D3 Gummy|Single oral dose of gummy vitamin D3 to monitor vitamin D blood levels
2402872|NCT03552653|Active Comparator|Nature Made Vitamin D3 Tablet|Single oral dose of tablet vitamin D3 to monitor vitamin D blood levels
2402873|NCT03552627|Active Comparator|80% Oxygen|Patients will receive 80% oxygen throughout anaesthesia in accordance with current World Health Organisation Recommendations
2402874|NCT03552627|Active Comparator|55% Oxygen|Patients will receive 55% oxygen throughout anaesthesia in accordance with current UK clinical practice
2402875|NCT03552627|Experimental|30% Oxygen|Patients will receive 30% oxygen throughout anaesthesia in accordance with this research's hypothesis that lowering intraoperative oxygen concentrations may benefit patients
2402876|NCT03552614||children with brain damage|Patients undergo physiotherapy + Upper limb robot-assisted rehabilitation
2402877|NCT03552601|Other|traditional speed|The target amount of every day's net negative fluid balance for the first three days is 1000mL.
2402878|NCT03552601|Other|faster speed|The target amount of every day's net negative fluid balance for the first three days is 1500mL.
2402879|NCT03552575|Experimental|Sacubitril/valsartan|24mg/26mg (dose level 1), 49mg/51mg (dose level 2) and 97mg/103mg (dose level 3) twice daily
2402880|NCT03552575|Experimental|Valsartan|40mg (dose level 1), 80mg (dose level 2) and 160mg (dose level 3) twice daily.
2402881|NCT03552562|Other|30 patients with no signs of diabetic retinopathy|
2402882|NCT03552562|Other|30 patients with mild diabetic retinopathy|
2402883|NCT03552562|Other|30 patients with moderate to severe diabetic retinopathy|
2402884|NCT03552562|Other|30 healthy age-and sex- matched control subjects|
2402920|NCT03552328|Experimental|Intervention|Seniors receiving daily meals from Meals on Wheels. Intervention: Lunch with Medical Student.
3184770|NCT00728208|Experimental|GSK372475|Drug
3184771|NCT00728221|Placebo Comparator|1|Placebo capsules (3g)
3184772|NCT00728221|Experimental|2|Whole Korean Red Ginseng root (3g)
3184773|NCT00728221|Experimental|3|Ginsenoside fraction of Korean Red Ginseng B (0.22g); bioequivalent to the original whole KRG root
2402892|NCT03552510|Active Comparator|Initial OPAMM|"At the start of the study, infants will receive mother's milk (to the maximum of 0.2 ml) to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for 24 hours.~Then, infants will receive regular gavage feeding only for the next 24 hours."
2402893|NCT03552510|Active Comparator|Initial Gavage|"At the start of the study, infants will receive regular gavage feeding only for 24 hours.~Then, infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding), and the remaining amount will be given by regular gavage feeding for the next 24 hours."
2402894|NCT03552484|Active Comparator|Home Visit Arm|"Participants and their caregivers, when available, will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~[Completion of Home Visit Program]"
2402895|NCT03552484|Active Comparator|Usual Care Arm|"Participants and their caregivers, when available, will be asked to complete an initial online survey. Twelve months later, patients (and caregivers, if available) will be asked to complete an online follow-up survey.~[Completion of Usual Care/Online Survey]"
2402896|NCT03552471|Experimental|Treatment (mirvetuximab soravtansine, rucaparib)|Participants receive mirvetuximab soravtansine IV on day 1 and rucaparib PO BID on days 1 through 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2402897|NCT03552458|Experimental|LR group|Lactobacillus Reuteri Oral Solution [BioGaia]
2402898|NCT03552458|Placebo Comparator|Placebo group|Placebos: The control agent will not contain the active agent
2402899|NCT03552445|Active Comparator|Tetanus-diphtheria (Td) and PCV13|
2402900|NCT03552445|Active Comparator|PCV13 alone|
2402901|NCT03552445|Active Comparator|Td alone|
2402902|NCT03552432|Experimental|Alirocumab therapy group|start with alirocumab 75mg per 2weeks and rosuvastatin 10mg per day
2402903|NCT03552432|No Intervention|standard statin therapy group|start with only rosuvastatin 10mg per day
2402904|NCT03552419||Level Red|A level red refers to a case with an immediate threat to the life of the fetus or mother and may not be delayed under any circumstance.
2402905|NCT03552419||Level Orange|A level orange case requires the patient to arrive in the OR within 30 minutes from the time of decision with the approximate estimated time of arrival determined by the obstetrician.
2402906|NCT03552419||Level Yellow|A level yellow case requires operative intervention, but there is no maternal and/or fetal compromise at the time of evaluation. Timing to the OR is agreed upon by both the anesthesiology and obstetrical providers. The case may be delayed if a level red or orange case is identified. Possible
2402907|NCT03552419||Level Green|A level green case is most dependent on the acuity of the OR suite and unit. The patient and/or fetus are stable with no threat to the health of either.
2402908|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 1)|1 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2402909|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 2)|3 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2402910|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 3)|5 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2402911|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 4)|10 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2402912|NCT03552406|Experimental|Dose-Escalation of ISU104 (Dose-Level 5)|20 mg/kg; Administered single-dose first week and observation for 4-weeks and then Administered once weekly in a 28-days Cycle
2402913|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 1: Monotherapy)|ISU104 20 mg/kg to be administered every three weeks (Q3W) as monotherapy
2402914|NCT03552406|Experimental|Dose-Expansion of ISU104 (Group 2: Combination therapy)|ISU104 20 mg/kg (or decreased dose) Q3W in combination with cetuximab* 250 mg/m2 QW (*Initial dose: 400 mg/m2)
3184774|NCT00728221|Experimental|4|Polysaccharide fraction of KRG root (0.21g); bioequivalent to the original whole KRG root
2402916|NCT03552380|Experimental|Entinostat, Nivolumab and Ipilimumab|"Entinostat: 5mg, 3mg, or 2mg orally (PO) on D1, 8, 15 plus Nivolumab: 3 mg/kg IV D1 and Ipilimumab 1 mg/kg IV D1~Each cycle is 21 days"
2402917|NCT03552367|Experimental|Personalized structured exercise|"This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and personalized structured exercise prescription that will be offered on-site and online and monitored through the use of heart rate monitoring devices. The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters.~Intervention: Non-personalized non-structured exercise"
2402918|NCT03552367|Active Comparator|Non-personalized non-structured exercise|This group will be enrolled in a multicomponent program for obese children (8-12 years old) that includes intervention workshops concerning nutrition, emotional factors, cognitive therapy and non-personalized non-structured exercise prescription Intervention: Non-personalized non-structured exercise
2402919|NCT03552354|Experimental|Argatroban combined with antiplatelet|
3184775|NCT00728234||1|all infants born below 30 weeks gestational age at the medical university vienna within the study period (01/2000 - 12/2002)
3184776|NCT00728273|Experimental|MMF|multi-micronutrient-fortified biscuit plus placebo deworming-treatment
3184777|NCT00728273|Experimental|Alb|placebo biscuit plus deworming treatment with Albendazole
3184778|NCT00728273|Experimental|MMF + Alb|multiple micronutrient-fortified biscuits with deworming treatment with Albendazole
3184779|NCT00728273|Placebo Comparator|placebo|placebo biscuit (non-fortified) and placebo deworming treatment
2402922|NCT03552315|Active Comparator|Water with amino acids and chromium|The carbonated water with a proprietary blend of five amino acids and chromium picolinate is consumed with a standardized test meal to study its effects on glucose and insulin responses.
2402923|NCT03552315|Placebo Comparator|Carbonated water|The placebo carbonated water is consumed with a standardized test meal to study its effects on glucose and insulin responses.
2402924|NCT03552302||Cases|Yoga exercise for 12 weeks
3144009|NCT00026182|Experimental|Arm II (rituximab and recombinant interleukin-12)|Patients receive rituximab as in arm I. Patients are evaluated at week 12. Patients with stable or progressive disease receive interleukin-12 SC twice weekly until disease progression or for 24 weeks. Patients with a complete or partial response after rituximab are monitored until disease progression and then begin interleukin-12 SC twice weekly until further disease progression.
3144010|NCT00026195|Experimental|irinotecan|"Patients receive irinotecan IV over 90 minutes once weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed for survival."
3144011|NCT00026234|Experimental|Treatment (chemotherapy)|Patients receive floxuridine and dexamethasone intra-arterially continuously on days 1-14, oxaliplatin IV over 2 hours on day 22, and oral capecitabine twice daily on days 22-35. Treatment repeats every 6 weeks for 4 courses in the absence of disease recurrence or unacceptable toxicity. After completion of the fourth course, patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 3 weeks for 2 courses in the absence of disease recurrence or unacceptable toxicity.
2402930|NCT03552263|Experimental|T89 low-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use three T89 capsules and one Placebo capsule each time by oral administration twice daily for 19 days."
2402931|NCT03552263|Experimental|T89 high-dose group|"T89 capsule is a botanical drug containing 75mg active substance which is the water extract of Danshen and Sanqi. Placebo capsule does not contain any amount of active substance.~Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 12 days followed by using four T89 capsules each time by oral administration twice daily for 7 days"
2402932|NCT03552263|Placebo Comparator|Placebo group|Placebo capsule does not contain any amount of active substance. Subjects in this group will use four Placebo capsules each time by oral administration twice daily for 19 days.
2402933|NCT03552250|Other|Parenting for Lifelong Health|"Parenting Programme Parenting for Lifelong Health for Young Children (PLH) for parents of children aged 2-9, 12 sessions"
2402934|NCT03552237|Experimental|dietary fiber intervention group|
2402937|NCT03552211||Patients treated with biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
2402938|NCT03552211||Control patients|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat
3144012|NCT00026247|Experimental|RFA as pain therapy|Changes in the severity of pain as measured using using the Memorial Pain Assessment Cards (MPAC) before and after RadioFrequency Ablation (RFA) will be statistically analyzed
2402943|NCT03552172||Prescription physical activity|
2402944|NCT03552172||No prescription for physical activity or suspension|
2402945|NCT03552159|Experimental|Behavioral Activation|For the first 4 weeks,participants received psychoeducation about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, t the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight bi-weekly behavioral activation sessions were administered, focusing pleasant event scheduling and effective communications.
2402946|NCT03552159|Active Comparator|Psychoeducation|For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
2402947|NCT03552146||Sedation Group 1|Patients will receive standard of care dose of Propofol, based on the provider's assessment, prior to radiologic procedure.
2402948|NCT03552146||Sedation Group 2|Patients will receive standard of care dose of dexmedetomidine, based on the provider's assessment, prior to radiologic procedure.
2402949|NCT03552133|Experimental|Smart CO2|Effects of rebreathe device over two sleep nights on sleep apnea, hypoxemia, sleep state, and blood pressure.
2402950|NCT03552133|No Intervention|No intervention|Effects of control night, i.e. no intervention on sleep apnea, hypoxemia, sleep state, and blood pressure.
2402951|NCT03552120|Experimental|Mindfulness-Oriented Recovery Enhancement|
2402952|NCT03552120|Active Comparator|Supportive Psychotherapy|
2402953|NCT03552107||Observational Group - Lorcaserin Treated|The group in this study will be all patients who initiated therapy with Lorcaserin during the review period.
2402954|NCT03552094||Hemochromatosis or polycythemia patients|"Blood samples from hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.~Blood bag (volume of blood: from 450 to 500 mL)."
2402955|NCT03552094||Healthy donors|Blood samples from healthy donors. Blood bag (volume of blood: from 450 to 500 mL).
2402956|NCT03552081|Experimental|fragmented DNA evaluation in blood and semen samples|20 men followed for smoking cessation will be included in the study in order to evaluate the time required for the repair of the sperm abnormalities and in particular the DNA of the gametes generated by the smoking
2403076|NCT03551327|Other|Information only|Participants in this arm will receive information only. Participants will be followed up at 4 months and 6 months.
2402957|NCT03552068|Placebo Comparator|Patients under placebo|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
2402958|NCT03552068|Active Comparator|Patient under clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. The usual antiparkinsonian treatment of the patient should remain stable throughout the 8 weeks.
2402959|NCT03552042|Experimental|Counterclockwise Program|"Subjects will participate in an 6-day Counterclockwise Retreat in a retrofitted physical environment circa 1989, which helps the participant psychologically return to a time before diagnosis to re-experience their younger self. Groups will be composed of 10-12 participants plus 3 research assistants/facilitators. Participants will live during the week as if they were in 1989, talking about 1989 events as if they were in the present, and avoiding talking about post-1989 events. Everybody will be invited to participate in conversations and discussions about 1989 in the present tense (presente). Furniture, posters, music, television, newspapers, and technological instruments will all reflect what was available in 1989. Participants will be told not merely to reminisce about this earlier era, but to inhabit life in that era, making a psychological leap to be the person they were at the end of the 1980s."
2402960|NCT03552042|Active Comparator|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
2402961|NCT03552042|No Intervention|No-treatment control group|Non-treated participants will be assessed with the same timeline followed by the other groups. Participants will receive three coupons, for each assessment after the baseline (at T2, T3, and T4) for a two-night break in a location of their choice (among a selection of commercial services).
2402962|NCT03552029|Experimental|Part 1 - Quizartinib + Milademetan|Participants with relapsed/refractory FLT3-ITD Mutant AML receive quizartinib + milademetan at increasing and/or decreasing doses and schedules
2402963|NCT03552029|Experimental|Part 2 - Cohort 1|Participants with relapsed/refractory FLT3-ITD Mutant AML receive the recommended dose of quizartinib + milademetan determined by Part 1
2402964|NCT03552029|Experimental|Part 2 - Cohort 2|Participants with newly diagnosed FLT3-ITD Mutant AML unfit for chemotherapy receive the recommended dose of quizartinib + milademetan determined by Part 1
2402965|NCT03552016|Experimental|200 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 200 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2402966|NCT03552016|Experimental|400 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 400 mg oral riboflavin each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2402967|NCT03552016|Placebo Comparator|0 mg Riboflavin (oral)|These patients (approximately 1/3rd of all patients enrolled in the study) will be given 0 mg oral riboflavin (placebo) each day for 6 months and be encouraged to play outside for 30 minutes a day every day.
2402968|NCT03552003||Newly diagnosed elderly cHL patients|Newly diagnosed elderly cHL patients undergoing CGA before any therapy (treatment for clinical practise) with the use of ADL, IADL and CIRS-G. Patients who will be considered not eligible to receive treatment or to be given only palliative therapy after CGA assessment are eligible for the study
2402969|NCT03551990|No Intervention|Control group; patients without a tumor disease, surgery|Control group with patients without a tumor disease but with indication for surgery in close proximity to the M. rectus abdominis
2402970|NCT03551990|No Intervention|Control group; tumor patients, surgery|Control group with patients with solid tumors; patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
2402971|NCT03551990|Experimental|Intervention group; tumor patients, WB-EMS, surgery|Intervention group with patients with solid tumors who do perform an 8-week physical training in form of whole-body electromyostimulation (WB-EMS); patients with pancreatic, colorectal, esophageal, gastric and liver solid tumors with indication for surgery in close proximity to the M. rectus abdominis
2402972|NCT03551977|Experimental|Intervention group|The intervention group will receive the iCanCope with Pain app with all five components: (I) symptom trackers for pain, sleep, mood, physical, and social function; (II) goal setting to improve pain and function; (III) coping toolbox of pain self-management strategies; (IV) social support; (V) age-appropriate pain education
2402973|NCT03551977|Active Comparator|Control group|The control group will receive the iCanCope with Pain control app with only the first self-registration component (I) symptom trackers for pain, sleep, mood, physical, and social function.
2402974|NCT03551964|Experimental|Cangrelor therapy|Initiation of iv Cangrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study.
2402975|NCT03551964|Active Comparator|Ticagrelor therapy|Initial dose Ticagrelor immediately upon arrival of the patient to the cardiac catheterization laboratory and after randomization into the study. In patients with a disorder of consciousness, initial dose of Ticagrelor will be administered immediately after nasogastric tube insertion.
2402976|NCT03551951||Patients having surgery|Cancer patients undergoing surgery will have test for circulating tumor cells, DNA alterations
2402977|NCT03551951||Patients not having surgery|"Cancer patients not undergoing surgery (but potentially other treatments) will have test for circulating tumor cells, DNA alterations.~Lung cancer screening subjects"
2402978|NCT03551951||Healthy subjects|Healthy control subjects will have test for circulating tumor cells, DNA alterations
3144013|NCT00026299|Experimental|Phase 2: Oxaliplatin plus ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 and ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily (as determined during phase 1). Subjects can continue to receive the combination for 6 cycles (each cycle is 21 days). After 6 cycles of the combination, subjects can continue to take ZD1839 alone until their cancer worsens.
2403129|NCT03550924|Experimental|THRIVE Group|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
2402981|NCT03551925|Experimental|Treatment as Usual Plus Occupational Therapy|The occupational therapy intervention will be guided by the Integrative Medication Self-Management Intervention (IMedS).The IMedS process guides the occupational therapist and client through an initial evaluation process and a three-step intervention plan to improve medication management.
2402982|NCT03551925|Active Comparator|Treatment as Usual (TAU)|Participants will receive only the TAU intervention which is provided by a clinical pharmacist and is the protocol at Jordan Valley Community Health Center. The intervention seeks to improve medication adherence in individuals with hypertension.
2402983|NCT03551886|Experimental|Experimental app|This is the Advanced Emotion App that we initially developed in phase 1 and are now enhancing in phase 2.
2402984|NCT03551886|Active Comparator|Comparison app|This is the Basic Emotion App, which is an alternative intervention app that controls for time and attention.
2402985|NCT03551860|Experimental|TQL Group|Administration of a single shot transmuscular quadratus lumborum (TQL) peripheral nerve block following spinal neuraxial blockade.
2402986|NCT03551860|Active Comparator|FIB Group|Administration of a single shot fascia iliac (FIB) peripheral nerve block following spinal neuraxial blockade.
2402987|NCT03551847|Experimental|Oral antibiotic therapy group|This group will receive preoperative oral antibiotic therapy tailored to the infecting organism (if identified) for two weeks before the time of revision surgery
2402988|NCT03551847|Active Comparator|No antibiotic therapy group|This group will not receive preoperative oral antibiotic therapy.
2402989|NCT03551834|Active Comparator|doing scleral patch graft glaucoma implantation|
2402990|NCT03551834|Active Comparator|Using short tunnel small flap technique|
2402992|NCT03551808|Active Comparator|installation of Ketorolac Tromethamine Eye Drop|
2402993|NCT03551808|No Intervention|not receiving placebo|
2402994|NCT03551795|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells.
3144014|NCT00026299|Experimental|Phase 2: Oxaliplatin alone|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2 for up to 6 cycles. Each cycle will last 21 days.
3144015|NCT00026299|Experimental|Phase I: Oxaliplatin with ZD1839|Oxaliplatin will be administered by IV infusion once every 21 days at a fixed dose of 130 mg/m2. ZD1839 will be taken orally at a dose of 250 mg or 500 mg daily.
3144016|NCT00026338|Active Comparator|OSI-774 plus Gemcitabine|
3144017|NCT00026338|Active Comparator|Placebo plus gemcitabine|
3144018|NCT00026364|Experimental|Arm I|"Patients receive oral ZD 1839 daily. Beginning on day 15, patients receive irinotecan IV over 90 minutes, leucovorin calcium IV over 15 minutes, and fluorouracil IV weekly on weeks 1-2. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of ZD 1839 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are accrued to receive treatment at the MTD."
2403000|NCT03551769|Experimental|Cohort 1, Period 1|Study drug administered concurrently with a standard meal
2403001|NCT03551769|Experimental|Cohort 1, Period 2|Study drug administered 30 minutes after a standard meal
2403002|NCT03551769|Experimental|Cohort 1, Period 3|Study drug administered 30 minutes after a high-fat meal
2403003|NCT03551769|Experimental|Cohort 1, Period 4|Study drug administered after an overnight fast
2403004|NCT03551769|Experimental|Cohort 2, Period 1|Study drug administered 30 minutes after a standard meal (Asian)
2403005|NCT03551769|Experimental|Cohort 2, Period 2|Study drug administered after an overnight fast (Asian)
2403006|NCT03551756||Heart Failure & Coronary Artery Disease|Biomarker assessment in adults with decompensated heart failure and significant underlying coronary artery disease
2403007|NCT03551756||Healthy Adult|Biomarker assessment in 20 healthy age-matched subjects
2403016|NCT03551717||High cardiovascular risk patients|Adult patients hospitalized in the Cardiology Department of the University Hospital of Dijon Burgundy for acute coronary syndrome, patients between D1 and D5 of acute coronary syndrome, who can be moved for an ophthalmology consultation where the retinal imaging is done (heart monitoring in the presence of an experienced cardiologist if necessary)
2403017|NCT03551717||Low cardiovascular risk patients|"Adult patients recruited in the Ophthalmology Department of the University Hospital of Dijon Burgundy following a standard consultation for cataract surgery.~The age balance of the patients included in the two groups will be checked regularly."
2403049|NCT03551509|Other|Crossover Group|Patients initially randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
2403050|NCT03551496|Experimental|DES BTK|Treatment with DES BTK
2403051|NCT03551496|Active Comparator|Conventional PTA|Treatment with standard PTA
2403052|NCT03551483|Experimental|ArtontheBrain|ArtontheBrain application for about 30 to 45 minutes twice per week, over 6 weeks.
3144019|NCT00026377|Experimental|SU5416 in combination with hormone and radiation therapy|Subjects receive 5 months of hormone suppression therapy consisting of 1 month of Bicalutamide or Flutamide followed by 4 months of leuprolide or goserlin injections. After completion of at least 12 weeks of hormone therapy, subjects will receive 7 1/2 weeks of radiation therapy. SU5416 will be given by IV infusion starting 4 weeks before beginning radiation treatment and continuing until 4 weeks after completion of radiation. Multiple doses of SU5416 will be studied.
3144020|NCT00026403|Experimental|radiotherapy + gemcitabine + cisplatin|"Patients undergo radiotherapy once daily five days a week for 5.5 weeks. Patients receive gemcitabine IV over 30 minutes followed by cisplatin IV over 1 hour twice a week for the first 3 weeks of radiotherapy. Beginning 4 weeks after the completion of radiotherapy, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at completion of radiotherapy, at completion of chemotherapy, and 3 months after completion of therapy.~Patients are followed every 3 months for 2 years and then every 6 months for 1 year."
3144021|NCT00026637|Active Comparator|Sertraline|
3144022|NCT00026637|Active Comparator|CBT|
3144023|NCT00026689||1/Cohort 1|Patients suspected of having, or with biopsy proven malignant disease or patients with a benign condition for whom radiotherapy is a potential treatment
2403018|NCT03551704|Active Comparator|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
2403019|NCT03551704|Experimental|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will incorporate an increasing magnitude of reinforcement.
2403020|NCT03551691|Active Comparator|Treatment Arm|Subjects will take omeprazole 40mg daily for 28 days, then undergo assessments of fat absorption.
2403021|NCT03551691|Placebo Comparator|Placebo Arm|Subjects will take a placebo daily for 28 days, then undergo assessments of fat absorption.
2403022|NCT03551678|Experimental|Gait retraining|Eight weeks of active-feedback gait retraining. The gait retraining device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
2403023|NCT03551665|Experimental|Step training|This group will undergo a baseline control period, as well as an intervention period. As such, they will serve as their own control subjects.
2403024|NCT03551652||Young patients|Patients aged 18 - 50 years
2403025|NCT03551652||Geriatric patients|Patients aged ≥ 80 years
3144024|NCT00026702||All|Subjects at least three years old
2403027|NCT03551613|Active Comparator|honey group|malnourished children supplemented with honey in dose of 2ml/kg
2403028|NCT03551613|Placebo Comparator|malnourished control group|no honey supplementation only nutrition rehabilitation
2403029|NCT03551613|No Intervention|healthy children|healthy children with no suplementation
2403030|NCT03551600||Preterm, no PDA|"Babies </= 32 weeks gestation at birth with no symptoms of a patent ductus arteriosus (PDA) or echocardiogram confirmation of no PDA~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded"
2403031|NCT03551600||Preterm, moderate to large PDA|Babies </= 32 weeks gestation at birth with confirmed moderate to large PDA on echocardiogram Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic and cranial regions, minimum of 8 feedings need to be recorded
2403032|NCT03551600||>/= 34 wk infants, no CHD|"Babies >/= to 34 weeks gestation at birth with no evidence of ductal dependent congenital heart disease (CHD)~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
2403033|NCT03551600||>/= 34 week infants, CHD|"Babies >/= to 34 weeks gestation at birth with ductal dependent CHD~Near-infrared spectroscopy (NIRS) monitoring x 48 hours of splanchnic, renal and cranial regions, minimum of 8 feedings need to be recorded"
2403034|NCT03551587|Experimental|Irrigant delivered by the Vibringe|"Experimental group:~The irrigant will be delivered and sonically activated with the Vibringe system."
2403035|NCT03551587|No Intervention|Irrigation by Conventional needle|"Control group:~Irrigation procedures will br performed with a conventional method using conventional gauge 24 needle."
2403036|NCT03551574||Macular involving retinal detachment|Patients with retinal detachments that have developed PVR when the macula has been involved
2403037|NCT03551561|Active Comparator|CSAAC group|The CSAAC group (chlorhexidine-based soap + ethyl alcohol + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB (Eosin Methylene Blue) media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
2403038|NCT03551561|Active Comparator|CSAC group|The CSAC group (chlorhexidine-based soap + alcoholic chlorhexidine): skin preparation process with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns. Cultures were performed in the mannitol and EMB media after being collected at the pre-skin preparation, post-skin preparation process and end of the surgical procedure.
2403039|NCT03551548|Placebo Comparator|Reference treatment|
2403040|NCT03551548|Experimental|experimental treatment|Spironolactone 25 mg
2403041|NCT03551535|Experimental|Physical Activity Intervention|Patients will be allocated to a physical activity intervention to be performed 3-5 days per week
2403042|NCT03551535|No Intervention|Control|Patients will receive standard counseling regarding activity recommendations in pregnancy
2403043|NCT03551522|Experimental|Seladelpar 10 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2403044|NCT03551522|Experimental|Seladelpar 20 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2403045|NCT03551522|Experimental|Seladelpar 50 mg|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2403046|NCT03551522|Placebo Comparator|Placebo|Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.
2403047|NCT03551509|No Intervention|Control Group|Patients randomly assigned into the control group will undergo open or arthroscopic rotator cuff repair using the surgeon's standard practice. No ECM graft will be used.
2403048|NCT03551509|Active Comparator|Treatment Group|Patients randomly assigned into the treatment group will undergo open or arthroscopic rotator cuff repair and the surgeon will use the ArthroFLEX® ECM graft to augment the repair. ECM scaffold grafts are indicated for the reinforcement of soft tissues repaired by sutures or suture anchors during tendon repair surgery, including rotator cuff.
2403479|NCT03548324|Active Comparator|NCPAP|Nasal Continuous Positive Air Pressure
2403053|NCT03551483|Active Comparator|Seniors Online Victoria|Senior Online Victoria games for about 30 to 45 minutes twice per week, over 6 weeks (https://www.seniorsonline.vic.gov.au/services-information/games), after which they will participate in the ArtontheBrain intervention.
2403054|NCT03551483|Other|Waitlist Control|The waitlist control group will no treatment for 6 weeks, after which they will six weeks of the ArtontheBrain intervention.
2403055|NCT03551470||Synchronous colorectal cancer and liver metastases|Robotic (Da Vinci) one-stage colorectal and liver resection
2403056|NCT03551444|Active Comparator|Administration of DAA-based treatment (Arm 1)|"Arm 1 will be divided into 2 groups by randomization according to a 1:1 ratio into:~Group A: Administration of DAA-based treatment after 3 months of complete remission of HCC.~Group B: Administration of DAA-based treatment after 6 months of complete remission of HCC."
2403057|NCT03551444|Experimental|Control arm (Arm 2)|Not receiving DAAs after complete remission of HCC and to be kept on follow-up
2403058|NCT03551431|Experimental|Video EEG with verbal suggestion|
2403059|NCT03551431|Experimental|video EEG with verbal suggestion and tuning fork|
2403060|NCT03551431|Experimental|video EEG with verbal suggestion and cotton swab|
2403061|NCT03551418|Experimental|Repetitive video watching|Repetitively watching a video of an adult with Down Syndrome washing his hands
2403062|NCT03551405||Intensity accuracy|"The difference of the HU values in corresponding ROIs in the two image sets will be compared with zero using one sample t-test.~In addition, we will also use these patient cases to test the computational efficiency of our algorithm. Based on our preliminary study, it is expected that the computation time will be 5~10 sec per phase. The reconstruction time will be recorded in these patient cases and will be assessed."
2403063|NCT03551392|Active Comparator|NIR -Older Adult|Older adult participants receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2403064|NCT03551392|Sham Comparator|No Dose NIR-Older Adult|Older adult participants receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2403065|NCT03551392|Active Comparator|NIR -Parkinson|Participants with Parkinson disease receive the Medx Console System and the Vielight 810 intranasal stand alone unit. These interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2403066|NCT03551392|Sham Comparator|No Dose NIR-Parkinson|Participants with Parkinson disease receive the sham Medx Console System and the sham Vielight 810 intranasal stand alone unit, since the devices deliver no near infrared light. These sham interventions occur during 16 lab sessions (1.5 hours each) during an 12 week period, plus daily 25 minute 'at home' intranasal stimulation interventions, 4 days each week.
2403067|NCT03551379||Endoscopic procedure|A double balloon endoscopic platform will be used during an ESD procedure
2403068|NCT03551366|No Intervention|Control|Subjects in this group will continue with their usual PE curriculum for 15 weeks.
2403069|NCT03551366|Experimental|Linear|Subjects in this group will receive a linear PE curriculum for 15 weeks. Linear Pedagogy is underpinned by neuro-computation approach to motor learning such as information processing theory and prescribes that an ideal movement pattern exists for each task and that the teacher's role is to help learners recreate that pattern. Furthermore, theorists have suggested that learning is a gradual, linear process. This linear pedagogy is supported by a teaching and learning approach that includes both prescriptive and repetitive actions, utilising technical demonstrations that provide learners with a 'visual template or criterion model' for the desired skill . As a consequence, a PE pedagogy has developed whereby the teacher's role is to make all the decisions, and the learner's role is to follow their instructions on cue - a teacher-led approach to PE.
2403070|NCT03551366|Experimental|Nonlinear|Subjects in this group will receive a nonlinear PE curriculum for 15 weeks. Nonlinear pedagogy is grounded in Ecological Dynamics theory. Ecological dynamics regards learners as complex adaptive systems which afford opportunities for action from their environment and generate movement solutions to satisfy the combination of personal, environmental and task constraints imposed upon them. According to nonlinear pedagogy, the teacher's role is to design learning experiences that create behavioural symmetry between learning and the performance environment. The teacher is a facilitator and manipulates constraints to channel the learner's physical development, while learners are left free to experiment and select the movement solutions that best answer their individual needs. This child-focused, less prescriptive approach may enhance a child's intrinsic motivation by offering freedom to choose, and an emphasis on exploration and problem solving.
2403071|NCT03551353||Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
2403072|NCT03551353||Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
2403073|NCT03551340||Traditional methods|Patients, who consulted for gastro-intestinal symptoms between July 2016 and May 2017, and were investigated by traditional methods (stool microscopy and/or culture).
2403074|NCT03551340||Gastro-intestinal panel by PCR|Patients, who consulted for gastro-intestinal symptoms between July 2017 and May 2018,and were investigated by a gastro-intestinal panel by PCR
2403075|NCT03551327|Experimental|Intervention plus information|Participants in this arm will receive 6 telephone therapy sessions and 1 booster session. Participants will be followed up at 4 months and 6 months.
2403480|NCT03548311|Placebo Comparator|Placebo|intramuscular injection of saline solution
2403077|NCT03551314|Active Comparator|Nasal Intermittent Positive Pressure|"In this group, soon after extubation, the newborns will be studied initially in NIPPV for one hour. Infants will be studied in supine while in their incubator.~NIPPV: Nasal Intermittent Positive Pressure Ventilation"
2403078|NCT03551314|Active Comparator|Continuous Positive Airway Pressure|"In this group, soon after extubation, the newborns will be studied initially in CPAP for one hour. Infants will be studied in supine while in their incubator.~CPAP: Continuous Positive Airway Pressure"
2403079|NCT03551288|Experimental|Food Effect Cohort|Twelve healthy male subjects 18 to 45 years of age, inclusive, will be administered a single oral dose of SUVN-911 on Day 1 (Period 1) and Day 8 (Period 2) with and without food in a crossover manner.
2403080|NCT03551288|Experimental|Gender Effect Cohort|Eight healthy female subjects 18 to 45 years of age, inclusive, will be administered a single dose of SUVN-911.
2403081|NCT03551288|Experimental|Age Effect Cohort|Eight healthy male subjects ≥ 65 years of age will be administered a single oral dose of SUVN-911.
2403082|NCT03551275|Experimental|Cohort no. 1, BCD-132, 100 mg, IV|"Cohort no. 1, Group #1 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 100 mg.~Cohort no. 1, Group #2 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 50 mg and second dose of 50 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.2 is included."
2403083|NCT03551275|Experimental|Cohort no. 2, BCD-132, 250 mg, IV|"Cohort no. 2, Group #3 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg.~Cohort no. 2, Group #4 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 125 mg and second dose of 125 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.3 is included."
2403084|NCT03551275|Experimental|Cohort no. 3, BCD-132, 500 mg, IV|"Cohort no. 3, Group #5 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg.~Cohort no. 3, Group #6 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 250 mg and second dose of 250 mg IV after 14 days period after first infusion.~If there is no DLT within the first 14 days after infusion then Cohort no.4 is included."
2403085|NCT03551275|Experimental|Cohort no. 4, BCD-132, 1000 mg, IV|"Cohort no. 4, Group #7 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 1000 mg.~Cohort no. 4, Group #8 includes 3 (+3) subjects who will receive the single intravenous infusion of BCD-132 at the dose of 500 mg and second dose of 500 mg IV after 14 days period after first infusion."
2403086|NCT03551262|Experimental|OTSC|Use of OTSC to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb, in first-line endoscopic haemostatic treatment.
2403087|NCT03551262|Active Comparator|TTS clip|Use of TTS clip to treat high-risk peptic ulcers (gastric and duodenal), i.e. Forrest Ia, Ib, IIa, IIb in first-line endoscopic haemostatic treatment
2403088|NCT03551249|Experimental|Focused Ultrasound (FUS)|The ExAblate Model 4000 Type 2 system is intended for use as a tool to induce localized and temporary blood-brain barrier disruption in patients with glioblastoma undergoing initial standard of care chemotherapy.
2403089|NCT03551223||Women undergoing cesarean delivery with general anesthesia|Preeclamptic parturients undergoing cesarean delivery under general anesthesia
2403090|NCT03551223||Women undergoing cesarean delivery with spinal anesth|Preeclamptic parturients undergoing cesarean delivery under regional-spinal anesthesia
2403091|NCT03551210|Experimental|Nemonoxacin|"Nemonoxacin solution for infusion, 500 mg (250 ml), daily, as single intravenous infusion over 90-110 minutes followed by infusion of Placebo (100 ml), solution for infusion, over a minimum duration of 60 minutes.~Then will be switched to oral therapy with Nemonoxacin capsules, 500 mg once daily (two 250 mg capsules)."
2403092|NCT03551210|Active Comparator|Tavanic®|"Tavanic® solution for infusion, 500 mg (100 ml), daily, as single intravenous infusion over a minimum duration of 60 minutes with previous infusion of Placebo (250 ml), solution for infusion, over 90-110 minutes.~Then will be switched to oral therapy with Tavanic®, over-encapsulated film coated tablets, 500 mg once daily (two capsules each containing 250 mg film coated tablet)."
2403093|NCT03551197|Experimental|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.
2403094|NCT03551184|Active Comparator|Endotoxin|Endotoxin 0.6 ng/kg body weight injection
2403095|NCT03551184|Placebo Comparator|Placebo|Saline injection
2403096|NCT03551171|Experimental|ZL-2306 (niraparib)|Subjects will be randomised into 100mg, 200mg, 300mg dose group at the first day of the first cycle.
2403097|NCT03551158|Other|Atrial fibrillation patients|Patients with atrial fibrillation who underwent cryoballoon ablation
2403098|NCT03551145|Experimental|Acellular collagen matrix|In a test group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Acellular collagen matrix will be adapted and suture to the vascular bed.
2403099|NCT03551145|Active Comparator|Autogenous free gingival graft|In a control group, partial thickness-flap will be elevation will be performed, in order to create the vascular recipient bed for the randomized graft. Implant surface will be treated with ultrasound device, glycine powder and implantoplasty in case of the exposure of the rough surface. Free gingival graft will be harvested from the zone of the posterior palate, and then adapted and sutured to the vascular bed.
2403130|NCT03550898|Other|Dynamic ultrasonography|Dynamic ultrasonography was performed in all patients who underwent urodynamics, simultaneously.
2403131|NCT03550885|Experimental|High taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 125 mg taurine, 40% of calories from fat, 15% of calories from saturated fat, 25% of calories from protein (4:1 animal to plant grams of protein), and 11.5 grams fiber/1000 calories.
2403481|NCT03548311|Active Comparator|methylcobalamin|intramuscular injection of methylcobalamin
2403100|NCT03551132|Experimental|Group 1|"Experimental group A supervised progressive moderate-to-high RTC program designed to induce muscular hypertrophy was performed. EG followed a progressive moderate-to-high RTC program for 12-weeks. The training program incorporated resistance exercise of six major regions and consisted of 3 training sessions per week on non-consecutive days (Monday, Wednesday and Friday).~All subjects performed the sets with moderate-intensity (8 to 12 repetitions) in each exercise and 30-60 seconds rest between sets. The load was increased during the 12 weeks from 60% 1-RM to high-intensity 80% 1-RM. The training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions) followed the OMNI-RES scale and a hard effort perception level. Rest between sets was 1-2 minutes."
2403101|NCT03551132|No Intervention|Group 2|Control group The CG not participated in the RTC program.
2403102|NCT03551119|Experimental|Exercise|"Personnel experienced in training people with chronic conditions (exercise specialist) will supervise the exercise training. At each in-center session in phase 1, the patient's exercise will be monitored to assess whether they are achieving target levels. Training intensities will be prescribed based on the most recent exercise test.~Phase 1: an eight-week program of once weekly-supervised facility-based exercise sessions and twice weekly home-based sessions.~Phase 2: a 16-week home-based exercise program overseen by an exercise specialist. During this phase, participants will be progressed through their home-based exercise program from Phase 1 on an individual basis.~i. Frequency. A minimum of three exercise sessions per week. ii. Intensity. A moderate intensity (40-60% heart rate reserve) based on exercise testing.~iii. Time. 150 minutes of exercise per week. iv. Type. We will prescribe aerobic exercise supplemented with isometric resistance exercises."
2403103|NCT03551119|Other|Enhanced usual care|Participants in the control group will perform accelerometry. This is enhanced usual care because physical activity measurement is not routinely performed in CKD clinics. Control arm participants will only receive their accelerometry data after they have completed the study.
2403104|NCT03551106||Web based learning module|Laboratory prescriptions made by postgraduate students who were enrolled to follow the web based modules
2403105|NCT03551093|Experimental|Study Population|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa.
2403106|NCT03551080|Active Comparator|Endotoxin|0.8 ng lipopolysaccharide/kg body weight injection
2403107|NCT03551080|Placebo Comparator|Placebo|Saline injection
2403108|NCT03551067|Active Comparator|Dexmedetomidine|Patients received Dexmedetomidine (4 µg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
2403109|NCT03551067|Active Comparator|Midazolam/Ketamine|Patients received Midazolam (0.5 mg/kg) and Ketamine (1 mg/kg) mixed with apple juice to fill the syringe up to 10 ml given orally once.
2403110|NCT03551054|Experimental|Healthy for Two, Healthy for You|Remotely delivered behavioral health coaching in pregnancy and postpartum
2403111|NCT03551054|Active Comparator|Pregnancy Health Education|Single health education visit with study staff member
2403112|NCT03551028|Other|HPV self collection|Pairing self-collection of HPV samples for DNA testing with women seeking mobile mammography.
2403113|NCT03551015|Experimental|Intervention|The intervention arm will have outpatient review at 3 weeks and start 8 sessions of cardiac rehabilitation from 4 weeks, after hospital discharge following CABG.
2403114|NCT03551015|No Intervention|Control|This arm will have outpatient review 6 weeks after hospital discharge and start 8 sessions of cardiac rehabilitation from 8 weeks.
2403115|NCT03551002||Retrospective|
2403116|NCT03551002||Prospective|
3184780|NCT00728286||Type 2 diabetes mellitus|We aim to determine the effects of dual antiplatelet therapy with aspirin 75mg once a day and clopidogrel 75mg once a day on platelet dependent thrombogenicity in patients with type 2 diabetes mellitus and acute coronary syndrome. Eighty patients (40 with type 2 diabetes and 40 without) have been studied one week after Non ST-elevation acute coronary syndrome. All patients were on secondary prevention therapy as recommended by international guidelines.
3184781|NCT00728299|Experimental|1|
3184782|NCT00728299|Placebo Comparator|2|
3184783|NCT00728312|Active Comparator|1|Aripiprazole (Abilify), flexible dosing 5-15 mg per day
2403121|NCT03550976|Experimental|High risk intervention group|
2403122|NCT03550976|No Intervention|High risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
2403123|NCT03550976|No Intervention|Low risk control group|Dietary evaluation and body composition analysis at 12 and 28 weeks of pregnancy. Receive routine obstetric examinations and routine health education which includes proper diet and exercise advice.Collect birth outcomes.
2403124|NCT03550963|Other|rice-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group. The intervention of group one is that participants will be provided with rice-richen meal, meaning most of the calculated carbohydrates are from rice.
2403125|NCT03550963|Other|wheaten-richen meal|All participants included in the study will be randomized assigned into one of two groups in parallel, the rice-richen meal group and wheaten-richen meal group.The intervention of group two is that participants will be provided with wheaten-richen meal, meaning most of the calculated carbohydrates are from wheaten.
2403126|NCT03550950|Experimental|Single Ascending Dose (SAD) IV Cohort|Participants will receive single intravenous (IV) dose of JNJ-64232025 or placebo in Cohorts 1 to 6 on Day 1.
2403127|NCT03550950|Experimental|Subcutaneous (SC) Cohort|Participants will receive single dose of JNJ-64232025 or placebo as SC injection.
2403128|NCT03550924|Active Comparator|Low flow Oxygen Group|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
3184784|NCT00728312|Placebo Comparator|2|Placebo look-alike, flexible dosing 5-15 mg per day
3184785|NCT00728325|Active Comparator|1|Standard Vocational Rehabilitation (VRP)
3184786|NCT00728325|Experimental|2|Supported Employment (SE)
3184787|NCT00728338|Experimental|1|Martek Biosciences Corporation Neuromins Capsules 7.5 g DHA oil/day
3184788|NCT00728338|Placebo Comparator|2|7.5 g/ day olive oil
3184789|NCT00728351|Experimental|vildagliptin + metformin|
3184790|NCT00728351|Active Comparator|metformin|
3184791|NCT00728377|Active Comparator|Heath & Wellness|
2403132|NCT03550885|Experimental|Low in taurine and saturated fat diet|This is a 3-week controlled isocaloric diet containing approximately 7 mg taurine, 36% of calories from fat, 8% of calories from saturated fat, 13% of calories from protein (3:1 plant to animal grams of protein), and 13.5 grams fiber/1000 calories.
2403133|NCT03550872|No Intervention|Control Group|Patients in the group who are continuously guided as the activities of daily living normally avoiding participation in any regular program of physical exercise does not proceed from the study.
2403134|NCT03550872|Experimental|Training Group|the patients randomized to the physical training group will undergo the supervised physical training program
2403135|NCT03550859|Experimental|Duowell Tab. 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
2403136|NCT03550859|Active Comparator|Micardis Tab. 40mg|Telmisartan 40mg qd for 48 weeks
2403137|NCT03550833||Rheumatoid Arthritis patients|patients affected by RA according to ACR/EULAR 2010 criteria, with a disease duration less than 2 years
2403138|NCT03550833||control patients|patients with a visceral surgery for less than 2 years (appendectomy, cholecystectomy, bowel obstruction, hernia, eventration…)
2403139|NCT03550794|Experimental|Thiamine|200mg parenterally administered thiamine hydrochloride given twice daily for a 3 days (6 doses)
2403140|NCT03550794|Placebo Comparator|Placebo|Matching placebo (50ml 0.9%NACL) given twice daily for 3 days (6 administrations)
2403141|NCT03550781|Experimental|Anti-inflammatory treatment group|Prednisone and/or cyclophosphamide
2403142|NCT03550781|No Intervention|Control group|No intervention
2403143|NCT03550768||MDP|ERCP was performed by trainees or trainers. Before the cannulation, the photo of major duodenal papilla will be taken carefully to evaluate its size, morphology, orientation and location. All patients initially received wire-guided cannulation with a sphincterotome, If cannulation failed, precut sphincterotomy or the double-wire technique was performed when appropriate. Therapeutic manipulation (eg, sphincterotomy, balloon dilation, stone extraction, and stenting) was done when appropriate. Pancreatic duct stent placement was performed at the discretion of the endoscopists.
2403144|NCT03550755|Experimental|V3-Cervix|Biological: V3-Cervix V3-Cervix is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood and tumor tissue from women with cervical cancer
2403145|NCT03550742|Experimental|Intervention|Daily administration of 5g of Fuco-N-Tetraose as a bolus for a period of 12 weeks.
2403146|NCT03550729|Experimental|Training|12-weeks of supervised endurance training program.
2403147|NCT03550716|Active Comparator|mTESE|Patients randomized to mTESE
2403148|NCT03550716|Active Comparator|TESA|Patients randomized to TESA
2403149|NCT03550703|Experimental|Single arm receiving V3-Myoma|A single oral pill of V3-Myoma therapeutic vaccine containing pooled antigens circulating in peripheral blood and within myoma tissues
2403150|NCT03550690||Large Volume Paracentesis|Patient has repeated large volume paracentesis for recurrent ascites secondary to cancer
2403151|NCT03550690||Semi-permanent drain|Patient has a semi-permanent drain (Rocket Indwelling Pleural Catheter) placed for recurrent ascites secondary to cancer
2403152|NCT03550677|Experimental|Group General Anesthesia|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen.
2403153|NCT03550677|Experimental|Group Ankle Block|These group patients will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10 mg-20 mg rocuronium and a proper size laryngeal mask airway will be placed to secure the airway. The lungs will be ventilated with a mixture of 50% and 50% oxygen. After than an ankle block will be performed in patient group block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5 bupivacaine the same amount placebo (saline) in group placebo under the guidance of peripheral nerve stimulator then the anesthesia will be disconnected and LMA will be removed. The patients will be transferred from postoperative care unit toward after they are eligible for discharge according to the modified scoring system.
2403154|NCT03550664|Experimental|Surgical intervention|Patients undergoing a surgical intervention within the CHU Brugmann with utilisation of rocuronium.
2403155|NCT03550651|Experimental|Licorice extract mouthrinse|10ml twice a day for 4 Days.
2403156|NCT03550651|Experimental|Hypertonic salt solution|10ml twice a day for 4 Days.
2403157|NCT03550651|Active Comparator|Essential oil mouthrinse|10ml twice a day for 4 Days.
2403158|NCT03550651|Active Comparator|Chlorhexidine Gluconate mouthrinse|10ml twice a day for 4 Days.
2403159|NCT03550651|Placebo Comparator|Distilled water|10ml twice a day for 4 Days.
2403160|NCT03550638|Experimental|group A|Coil system(Ton-bridgeMT)
2403161|NCT03550638|Active Comparator|group B|Axium Detachable Coil(Medtronic)
2403162|NCT03550625||Routine Colonoscopy Cohort|Photographies of polyps for creation of computer program
2403163|NCT03550612||Neonates with hypoxic ischemic encephalopathy|Cranial ultrasound,Magnetic resonant imaging and amplitude integrated encephalogram performed to All neonates with hypoxic ischemic encephalopathy in period between January 2010 to December 2015.
2403164|NCT03550599||patients accessing to Radiotherapy Unit|patients accessing to Radiotherapy Unit for oncologic treatment
2403165|NCT03550586||Parturients suffering from a PDPH|Parturients suffering form a PDPH following an accidental dural puncture between the years 2007-2017 will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
3184792|NCT00728377|Experimental|Exercise|
3184793|NCT00728390|Experimental|1|
3184794|NCT00728403|Experimental|1|American Ginseng and American Red Ginseng Capsules
3184795|NCT00728403|Experimental|2|American Ginseng Capsules
3184796|NCT00728403|Placebo Comparator|3|Placebo Capsules
2403166|NCT03550586||Parturients not suffering from a PDPH|This group will consistent of a control group of women receiving epidural analgesia on the same day as those women who suffered an ADP. This participants will be contacted by phone and verbal consent will be obtained for participation in the study. All participants will be requested to answer an IRB approved telephone script. Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS) translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire.Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire
2403169|NCT03550560||EUS-Guided drainage|Cancer patients in terminal phase with refractory malignant ascites
2403170|NCT03550547|Experimental|7 educational workshops|"Intervention: 7 educational workshops in addition to spa therapy :~Knowledge of the pathology ; Educational physical activity ( 2 workshops); Dietary; Management of pain, fatigue and the medical treatments; Articular hygiene and ergonomics; Technical assistance, an adaptation of the living condition"
2403171|NCT03550547|Active Comparator|spa therapy|Approved Spa therapy
2403172|NCT03550534|Experimental|Calcium Carbonate|Calcium carbonate 3 x 500 mg was given to 23 study participants for 12 weeks
2403173|NCT03550534|Placebo Comparator|Placebo oral capsule|Placebo oral capsule 3 x 1 was given to 23 study participants for 12 weeks
2403174|NCT03550521|Experimental|Mindfulness condition|The brief mindfulness induction will be modeled after basic mindfulness skills commonly used in mindfulness-based interventions and tailored to target distressing thoughts and feelings.
2403175|NCT03550521|No Intervention|Control condition|"Participants assigned to the control task will be instructed to let your mind wander freely without trying to focus on anything in particular."
2403176|NCT03550508|Experimental|Anti-RANKL Monoclonal Antibody|Anti-RANKL Monoclonal Antibody is to be injected subcutaneously 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg or 3.0 mg/kg.
2403177|NCT03550495|No Intervention|Control|Patients will undergo standard of care including the use of the ABCDEF bundle; psychiatry team will not be involved on daily ICU rounds.
2403178|NCT03550495|Experimental|Intervention|Patients will receive standard ICU care, including the use of the ABCDEF bundle, but will also receive the intervention of psychiatry involvement; the psychiatry team will participate in daily ICU rounds with the ICU team to help identify, prevent, and treat ICU delirium and identify other psychiatric disorders which may be otherwise undetected by the ICU team.
2403179|NCT03550482|Experimental|Oncoxin®|
2403180|NCT03550482|No Intervention|Control|
2403181|NCT03550469|Experimental|Computer-assisted Oxygen Weaning|A computer with an adaptive model algorithm will guide oxygen weaning.
2403182|NCT03550469|No Intervention|Manual Oxygen Weaning|Oxygen weaning will be done by staff manually.
2403183|NCT03550456||ECC, ECC with CLE, speech therapy|"After the standard diagnostic (spirometry, body plethysmography, exhaled NO, skin prick test) all patients with dyspnea while exercising undergo exercise challenges in a cold chamber (ECC).~In case of a positive reaction in the ECC the patients get asthma medication (ICS/LABA combination).~Both groups negative and positive should fill out a symptom diary and the next visit will be booked 6 weeks later.~If they still have dyspnea while exercising with ICS/LABA combination or hat a negative ECC the patients undergo an ECC with continuous laryngoscopy. In case of an EILO diagnosis patients will be sent to speech therapy and checked at a follow up visit.~All patients and their parents should complete questionnaires for symptoms and quality of life at every visit."
2403184|NCT03550443|Experimental|RTA 402(Bardoxolone methyl)|Patients will receive multiple oral doses of bardoxolone methyl once daily. The starting dose of bardoxolone methyl will be 5 mg. The maximum dose will be 15 mg, and the dose will be increased by 5 mg.
2403185|NCT03550443|Placebo Comparator|Placebo|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
2403186|NCT03550430|Experimental|ADR neurofeedback|Ten ADR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions consists of five training blocks each. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
2403187|NCT03550430|Active Comparator|BTR neurofeedback|Ten BTR neurofeedback training sessions. The first five sessions comprise four training blocks. The latter five sessions each consists of five training blocks. All training blocks are seven minutes in duration. Participants take between two to three sessions each week.
2403188|NCT03550430|Active Comparator|Diary Control Group|Daily diary completion for two weeks in the period between baseline and end-point assessments (total period baseline to end-point = four weeks).
2403189|NCT03550417||2011 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010.
2403190|NCT03550417||2013 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010. Comparison of 2011, 2013 cohorts & July16/June17.
2403191|NCT03550417||July2016/Jun17 Patients|Evaluation of multidisciplinary management of bronchiectasis compared to the British Thoracic Society Guidelines 2010 & 2014. Comparison of 2011, 2013 cohorts & July16/June17.
2403192|NCT03550404||Navigators|"AIE Navigators will use the Seasons of Care app in the context of their everyday outreach work with AIEs over two four-month intervention periods (P1 and P2). Their goal will be to facilitate health literacy to shift attitudes, beliefs, and behaviors to create a Culture of Coverage for AIEs at individual, organizational/community, and policy levels. Separated by distance, the AIE Navigators will receive coaching as necessary, using virtual meeting space, to help refine their implementation skills from a member of the research team with experience in AIE health outreach."
2403193|NCT03550404||American Indian Elders (AIEs)|Elders will be exposed to the Seasons of Care app when they reach out to navigators for assistance navigating the healthcare system.
2403194|NCT03550404||Healthcare providers/staff|This cohort will be exposed to the Seasons of Care app via navigators and their patients.
3144027|NCT00026780||Cohort 1|Children and young adults who are being evaluated for protocols within the Pediatric Oncology Branch.
3144028|NCT00027053|Experimental|Trazodone|
3144029|NCT00027053|Placebo Comparator|Placebo|
2403200|NCT03550365|Experimental|Rye bread intervention|4 week rye bread diet intervention with dietary fibre intake of 30g
2403201|NCT03550365|Active Comparator|Wheat bread intervention|4 week wheat bread diet intervention with dietary fibre intake of 5-20g prior to two other arms
2403202|NCT03550352|Experimental|1) THC and CBD combined|TN-TC11M2 oral capsules (THC 2.5 mg / CBD 2.5 mg)
2403203|NCT03550352|Experimental|2) CBD alone|TN-C200M2 oral capsules (CBD 200 mg)
2403204|NCT03550339|Active Comparator|SURG|subjects attending bariatric surgery
2403205|NCT03550339|Active Comparator|DIET|subjects attending dietary weight loss program
2403206|NCT03550339|Active Comparator|HAES|subjects attending Health At Every Size weight management program
2403207|NCT03550326||general anesthesia|Patients who undergo general anesthesia and are intubated or inserted airway device will be enrolled. researchers will follow the induction and intubation period and record all the complications due to airway management.
3144030|NCT00027066|Active Comparator|Active Warfarin and Aspirin Placebo|One 2 mg scored tablet daily of Warfarin and one 325 mg tablet daily of aspirin placebo.
3144031|NCT00027066|Active Comparator|Active Aspirin and Warfarin Placebo|One 325 mg tablet daily of aspirin and one 2 mg scored tablet daily of Warfarin placebo.
3144032|NCT00027170||Participants with cardiovascular diseases|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
2403211|NCT03550300||Participants with CMT|Participants with CMT1A, CMT1B, CMT2A or CMTX1
2403212|NCT03550300||Control participants|Control participants
2403213|NCT03550287|Experimental|Experimental product|Dietary supplement (Shiitake extract) in a commercial soup at lunch for 8 weeks.
2403214|NCT03550287|Placebo Comparator|Placebo product|Isocaloric placebo (maltodextrin) in a commercial soup at lunch for 8 weeks.
2403215|NCT03550274|Experimental|App-based exercise rehabilitation|Persons with Acute lateral ankle sprain (<48 hours) evaluated by a relevant health specialist in the hospital Emergency Department.
2403216|NCT03550248|Other|Intervention group|Participants will receive the intervention - Healthy Together (HT).
3184797|NCT00728429|No Intervention|standard of care|normal anthracycline therapy
3184798|NCT00728429|Experimental|exercise program|
3184799|NCT00728442|Experimental|1|medical decision based on computerized guideline-based decision support system
3184800|NCT00728442|No Intervention|2|
2403225|NCT03550144|Experimental|Awe Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to seek the experience of feeling awe. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
2403226|NCT03550144|Active Comparator|Control Walk Condition|Participants were instructed to take at least one (~15 minute) walk per week for 8 consecutive weeks. Participants were told to keep a fairly light to moderate pace and were encouraged to walk alone and without interruption from a mobile device.
2403227|NCT03550131|Active Comparator|Standard intervention|"Reducing Disabilities in Alzheimer's Disease (RDAD):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
2403228|NCT03550131|Experimental|Personalized intervention|"Innovations in Dementia Empowerment and Action (IDEA):~9 60-minute virtual sessions for 6 weeks and 4 15-minute follow-up phone sessions for 4 months"
2403229|NCT03550118|Experimental|Adjustable Socket - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on socket size adjustments while walking.
2403230|NCT03550118|Experimental|Adjustable Socket - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on socket size adjustments while walking.
2403231|NCT03550118|Experimental|Adjustable Socket - Automatic Controls|An adjustable socket is tested where a control system is used to automatically control the adjustments. This arm focuses on socket size adjustments while walking.
2403232|NCT03550118|Experimental|Stress-Sensing Liner|An adjustable socket is tested in addition to a prosthetic liner with embedded stress sensors to measure mechanical stresses as the socket is adjusted.
2403233|NCT03550118|Experimental|Release/Recovery - Researcher Controls|An adjustable socket is tested where researchers control the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
2403234|NCT03550118|Experimental|Release/Recovery - Participant Controls|An adjustable socket is tested where the study participant controls the adjustments. This arm focuses on a socket release and recovery mechanism that allows for full or partial doffing of the socket while seated.
2403235|NCT03550105|Experimental|GJ-Only|Study Subjects with Baseline Glucose of > 150mg/dl, will have Gentle Jogger Only for 7 days
2403236|NCT03550105|Experimental|GJ-OGTT|Study Subjects with Baseline Glucose of < 150mg/dl, will have Oral Glucose Tolerance Test (OGTT) at baseline and after 7 days of Gentle Jogger
2403238|NCT03550079|Experimental|three screws fixation|femoral neck fractures were fixed with three converted screws
2403239|NCT03550079|Experimental|four screws fixation|femoral neck fractures were fixed with four screws
3144033|NCT00027170||Healthy Participants|Patients may receive an intravenous injection of gadobutrol (Gadavist) not to exceed 0.2 mmol/kg of Gd per bolus injection and per examination.
3144036|NCT00027300|Experimental|Group 1|Natalizumab 300 mg, IV
3144037|NCT00027300|Placebo Comparator|Group 2|Placebo IV infusion
3184801|NCT00728455|Experimental|A|
2403242|NCT03550053|Active Comparator|Intraoperative plate bending|Plate will be bent intraoperatively, which is the standard of care, for this surgery
2403243|NCT03550053|Active Comparator|Preoperative plate bending|A 3D printed model of the patient's mandible will be used to bend the plate preoperatively by the surgeon. The pre-bent plate will be brought into the operating room on the day of surgery.
2403244|NCT03550040|Active Comparator|Robot assisted prostatectomy.|Intervention: radical prostatectomy
2403245|NCT03550040|Experimental|3D laparoscopic prostatectomy|Intervention: radical prostatectomy
2403246|NCT03550027|Experimental|PleurX|Positioning of Pleurx drainage during surgical exploration if lung does not reinflate
2403247|NCT03550027|Experimental|Pleurocath|Positioning of Pleur o cath drainage during surgical exploration if lung does not reinflate
2403248|NCT03550014|Active Comparator|Low Back Only|Participants randomized to the Low Back Only arm will receive physical therapy as directed by the treating physical therapist targeting the lower back.
2403249|NCT03550014|Active Comparator|Low Back+Hip|Participants randomized to the Low Back+Hip arm will receive physical therapy as directed by the treating physical therapist targeting the lower back. In addition to that treatment, participants will received hands-on and exercise physical therapy interventions directed at the hip(s).
2403250|NCT03550001|Experimental|Injection CNP before NAT|Inject carbon nanoparticle as a lymph node tracer before the patient receive neoadjuvant therapy.
2403251|NCT03550001|No Intervention|No injection|Do not inject carbon nanoparticle during the treatment.
2403252|NCT03549988||Control|"The group will receive current standard of care as the usual practice of the attending physician. Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on the baseline visit and month 6, 12 and month 18.~When endoscopy is performed biopsies should be taken and the endoscopic and histologic assessment will be recorded. If a fecal calprotectin is measured, every effort should be made to use the IBDoc with the result being sent to the central primary investigator via the IBDoc Web Portal. However, should a different fecal calprotectin measure be used, this will be recorded as part of the study documentation and will be included in the study data."
2403253|NCT03549988||Intervention: FC measurements with IBDoc|"Fecal Calprotectin (FC) measurements with IBDocTM home kits will be performed by participants in the intervention group every 2 months until final visit.~Basic research data will be collected and participants in this group will be asked to complete the on-line questionnaires (SIBDQ and EQ-5D 5L) on baseline visit and month 6, 12 and month 18."
2403254|NCT03549975|Experimental|Botulinum toxin type A injection|Botulinum toxin type A injection followed by functional electrical stimulation
2403255|NCT03549936|Active Comparator|Low lactose formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula which arrives from milk lab labeled as formula A or formula B."
2403256|NCT03549936|Active Comparator|Regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive regular formula which arrives from milk lab labeled as formula A or formula B"
2403257|NCT03549923|Experimental|Simultaneous CRRT group|CRRT is initiated simultaneously (not late than 24 hours from the initiation of ECMO treatment), regardless of presentation of conventional indication of CRRT. CRRT lasts for 12 hours or more is recommended.The physician can decide when to withdraw CRRT based on the patient's condition.
2403258|NCT03549923|Experimental|Conventional-indication CRRT group|CRRT is not initiated unless conventional indication of CRRT is presented. The conventional indication of CRRT is as follow: KDIGO stage 3 AKI and one of the following criteria is met: severe hyperkalemia (> 6.5 mmol/L), metabolic acidosis (pH < 7.2), pulmonary edema, blood urea nitrogen level >112 mg/dL, or oliguria (urine output < 200 mL/12 h) for more than 72 hours.
2403259|NCT03549923|Experimental|Esmolol group|Patients will receive a continuous esmolol infusion in addition to routine management. The esmolol infusion commences at 25 mg/h and increases by 25 mg/h every 20-minute until the maximal tolerate dosage is reached or the heart rate reduced to 75±5 bpm, or an upper dose limit of 2000 mg/h is reached. Continue infusing esmolol to maintain the heart rate threshold or at the discretion of the physician until either ICU discharge or death. Oral beta-blockers should be considered before the withdrawal of esmolol.
2403260|NCT03549923|Experimental|Control group|All beta-blockers, including esmolol, should not be used during ICU treatment, unless the doctor thinks there's a strong indication.
2403261|NCT03549910|Experimental|Early use of APRVplus protocol in ARDS|physiology-driven APRVplus protocol
2403262|NCT03549910|Other|Low tidal volume ventilation|Low tidal volume lung protective ventilation
2403263|NCT03549897|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2403264|NCT03549897|Active Comparator|90 mcg Reference Product|One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2403265|NCT03549897|Active Comparator|180 mcg Reference Product|One actuation each from two different Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2403266|NCT03549897|Experimental|90 mcg Test Product|One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
2403267|NCT03549884|Experimental|Delayed cord clamping (DCC)|Cord clamping will be performed after 60 seconds of life
2403268|NCT03549884|Active Comparator|Early cord clamping (ECC)|Cord clamping will be performed within 10 seconds of life
2403298|NCT03549624||Intervention group|"All adult (>18y) patients with the need of an acute laparotomy (within 6 hours) at NÄL.~Patients will be treated with an perioperative regime/protocol consisting of:~Early so called NEWS-monitoring (measuring of standard physiological parameters);~Early start of antibiotics;~Rapid (within 6 hours) start of operation;~Goal-directed fluid therapy;~Intensified post-operative monitoring;~The presence of both surgical and anesthesiological specialists in the early care of the patients."
3184802|NCT00728455|Experimental|B|
3184803|NCT00728455|Experimental|C|
3184804|NCT00728455|Experimental|D|
2403270|NCT03549845|Experimental|CHAP Intervention|The Cardiovascular Health Awareness Program (CHAP) intervention is an on-site drop-in, monthly, cardiovascular risk assessment program run by trained volunteers with community-led group health sessions that deliver education and information about access to community health resources. The education sessions will be delivered by national and provincial and local community organizations utilizing already developed material as much as possible, but maintaining consistency across both provinces. Health education sessions will include topics such as: Physical Activity, Healthy Eating, Stress, Tobacco Use, High Blood Pressure, Role of Pharmacist: How they can assist people, and Appropriate use of 9-1-1. This intervention will be held in a common room in selected subsidized housing buildings.
2403271|NCT03549845|No Intervention|Control|The control buildings will receive usual care which will be wellness programs already present in the building prior to the RCT if these are present. Not all control buildings will have wellness programs.
2403272|NCT03549832|Active Comparator|sof/sim/dac|Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin
2403273|NCT03549832|Active Comparator|sof/omb/parit|Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin
2403274|NCT03549819|Experimental|Cannabidiol (CBD) Oil Capsules|Pure CBD in sunflower lecithin oil, flexibly dosed at 200-800 mg per day
2403275|NCT03549819|Placebo Comparator|Sunflower Lecithin Oil in Capsule|1-4 capsules daily
2403276|NCT03549806||Prospective Cohort|No study intervention. Patients referred for ablation of atrial arrhythmias will be treated as per operator preference with no study intervention. Data will be collected in de-identified fashion.
2403277|NCT03549793|Experimental|dance thrapy|4-week Multidisciplinary Rehabilitation Treatment + Dance Therapy Treatment (2 hours par week)
2403278|NCT03549793|Active Comparator|exercises without dance|4-week Multidisciplinary Rehabilitation Treatment + Exercises without music (2 hours par week)
2403279|NCT03549780|Other|Stomal Occlusion|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
2403280|NCT03549767|Experimental|Springfusor|Women in this group will have their loading dose (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 20 minutes) and maintenance therapy (4 gm of 50% Magnesium sulphate in 10 ml syringe administered over 4 hours through an IV infusion administered using a Springfusor pump.. The 4 gm maintenance dose will be repeated every 4 hours for 24 hours.
2403281|NCT03549767|Active Comparator|Standard of care|The control group will have Magnesium sulphate administered using the Pritchard regimen, which involves administration of loading dose of 4 gm of 20% Magnesium sulphate IV over 15-20 minutes, immediately followed by 10 gm of 50% Magnesium sulphate IM (5gm on each buttock). The maintenance dose of 5 gm of 50% Magnesium sulphate IM every 4 hourly in alternate buttocks continued for 24 hours
2403282|NCT03549741|Experimental|study group|will receive a dose of Clomiphene citrate 50 mg tablet , 1 tab twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package) first three months then Clomiphene citrate 50 mg tablet , 2 tabs twice daily for 5 days from the third day of menses to the seven day and cabergoline 0.25 mg (half tablet) every 3 days (one package)
2403283|NCT03549741|Active Comparator|control group|will receive a dose of Clomiphene citrate and placebo tablets with same dose and duration
2403284|NCT03549728|Experimental|Group A|Group A (N=44): women will receive intrauterine infusion of granulocyte colony-stimulating factor on the day of ovum-pick up during IVF cycle.
2403285|NCT03549728|Placebo Comparator|Group B|Group B (N=44): women will receive placebo intrauterine infusion of normal saline on the day of ovum-pick up during IVF cycle.
3144038|NCT00027417|Active Comparator|Liothyronine Sodium/Triiodothyronine|bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function.
3144039|NCT00027417|Placebo Comparator|Placebo|bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses
2403288|NCT03549702|Active Comparator|Povidone irrigation Group|Includes the 100 women who will undergo elective caesarian section with subcutaneous tissue irrigation with Povidone iodine 1% solution.
2403289|NCT03549702|No Intervention|Control Group|Includes the 100 women who will undergo elective caesarian section without subcutaneous tissue irrigation with Povidone iodine 1% solution.
2403290|NCT03549689|Experimental|Switch|Dolutegravir (DTG) 50MG/ lamivuidne (3TC) 300MG FIXED_DOSE COMBINATION (FDC) DAILY at randomization for 96 weeks
2403291|NCT03549689|Active Comparator|Continuation|Continue current tenofovir alafenamide (TAF)-containing ART regimen from weeks 0 to 96.
2403292|NCT03549676|Experimental|HSCT patients with refractory GVHD|Patients will accept FilmArray Gastrointestinal (GI) panel test before pre-treatment of HSCT and 28±3 days post-HSCT. Patients will receive 50ml fecal microbiota from unrelated healthy donors through nasojejunal tube and monitored under gastroscopy. Patients receiving FMT treatment will be followed for at least 6 months. The ideal follow up time is 2 year. Stool and blood samples will be serially collected and tested (before pre-treatment, 1/3/6/12 months after FMT).
2403293|NCT03549663|Experimental|Tacrolimus monotherapy|
2403294|NCT03549663|Active Comparator|Tacrolimus combined with hormone therapy|
2403295|NCT03549650|Experimental|Pentosan Polysulfate Na 100Mg Cap|Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
2403296|NCT03549650|Placebo Comparator|Placebo oral capsule|Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.
2403297|NCT03549637|Experimental|Psychiatric population|"At inclusion: Patients will have A Lipid Panel Test, other biological analyzes and a clinical assessment. In case of a low LDL-C level (≤ 0, 50 g/L), genetic analyzes will be performed to screen for genetic forms of hypobetalipoproteinemia (HBL).~At 2- 4 weeks: for patients with HBL (LDL-C ≤ 0,50 g/L with no secondary cause of LDL-C reduction), another Lipid Panel Test will be performed to confirm the maintenance of the low LDL-C level.~At 6 months : Patients with a HBL will perform a full biological examination, and the LDL-C levels and genetic analyzes will be confirmed. A dietary survey will be performed, together with a psychiatric assessment. The same numbers of matched controls will performed a quick telephone interview to collect the psychiatric characteristics."
2403299|NCT03549624||Control group|All patients operated with an acute laparotomy at NÄL the years prior to the study will be retrospectively collected using the hospitals operation management database (Orbit©). Medical data will be collected from the patients' medical charts and outcome data (i.e. mortality, length of hospital stay, surgical complications, ICU-management etc.) will be registered
2403300|NCT03549611|Experimental|Multimodel Drug Regimen|"The patients randomized to this arm will receive the following multimodal oral drug regimen administered shortly before induction of general anesthesia~Tylenol, 975mg (3 tabs)~800mg Gabapentin~400mg Celecoxib~10mg Oxycodone"
2403301|NCT03549611|Active Comparator|Acetaminophen Only|"The patients randomized to this arm will receive oral acetaminophen only administered shortly before induction of general anesthesia~1. Tylenol, 975mg (3 tabs)"
3184805|NCT00728455|Experimental|E|
2403303|NCT03549572||Severe Traumatic Brain Injury|We will administer Coma Recovery Scale-Revised (CRS-R) and the Coma Recovery Scale Revised For Accelerated Standardized Testing (CRSR-FAST) to patients in the intensive care unit who have impaired level of consciousness resulting from a severe traumatic brain injury.
2403304|NCT03549559|Active Comparator|Healthy Subjects|Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
2403305|NCT03549559|Active Comparator|Diabetes Patient Subjects|Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
2403306|NCT03549559|Experimental|Aortic Stenosis Patient Subjects|Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
2403307|NCT03549546|Other|Patients undergoing lung cancer surgery|Patients undergoing lung cancer surgery will be included. Blood samples will be collected.
2403308|NCT03549533||artificial insemination|Patient who perform his first artificial insemination will be included. Samples of sperm will be analyzed.
2403309|NCT03549520|Experimental|Contrast-enhanced Ultrasonography|Intravenous administration of contrast agent Sulfur hexafluoride lipid-type A microspheres before performing contrast-enhanced ultrasound (CEUS). In pediatric patients, after reconstitution 0.03 mL per kg is administered intravenously. The weight-based dose of 0.03 mL per kg will be repeated one time during a single examination. Following each injection, an intravenous flush of 0.9% Sodium Chloride is injected. The study duration per subject will be approximately 15 minutes including the time to prepare the contrast agent and perform the CEUS, as well as the 60 minute monitoring period after the first and second injection of the contrast agent.
3144040|NCT00027534|Experimental|TRICOM-CEA(6D)|Subjects receiving TRICOM-CEA(6D)
3144041|NCT00027573|Experimental|Chemotherapy + stem cell transplantation|"Patients receive fludarabine IV over 30 minutes on days -7 to -3 and cyclophosphamide IV over 1-2 hours on days -4 and -3. Allogeneic peripheral blood stem cells are infused on day 0. Patients then receive filgrastim (G-CSF) subcutaneously daily beginning on day 5 and continuing until blood counts recover.~Patients receive graft-versus-host disease (GVHD) prophylaxis comprising oral tacrolimus twice daily on days -1 to 90 and methotrexate IV on days 1, 3, and 6.~After day 120, patients with persistent disease and no signs of active GVHD may receive donor lymphocyte infusion (DLI). DLI may be repeated every 8 weeks for a total of 2 infusions.~Patients are followed every 2 months for 1 year and then every 6 months for 4 years OR every 2 months for 6 months and then every 6 months for 4.5 years if patient receives DLI."
2403313|NCT03549455|Experimental|Exposure Therapy and Self Distancing|All subjects will have 2 introduction sessions and then receive Exposure therapy with Self-Distancing (2 weeks) following Exposure therapy without Self-Distancing (2 weeks) followed by 2 more weeks of Exposure therapy with Self-Distancing.
2403314|NCT03549442|Experimental|Phase A|Safety Run-in to test the safety of CART-BCMA + huCART19 as split-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients who have relapsed/refractory myeloma after two prior regimens but who are responding to their current therapy.
2403315|NCT03549442|Experimental|Phase B|Randomization Phase in which patients responding to first or second-line therapy will receive either CART-BCMA alone (Cohort 1) or CART-BCMA + huCART19 (Cohort 2) as split-doses after lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
2403316|NCT03549442|Experimental|Phase C|Single-dose infusion phase to test the safety of single-dose infusion of CART-BCMA alone (Cohort 1) and CART-BCMA + huCART19 (Cohort 2) as single-dose infusions after lymphodepleting chemotherapy with cyclophosphamide + fludarabine in patients responding to first- or second-line therapy.
2403317|NCT03549442|Experimental|Phase A Expansion|Once safety of CART-BCMA/huCART19 combination therapy is established in Phase A, an expansion of Phase A will occur in which the Phase A target population (patients with relapsed/refractory multiple myeloma responding to a standard salvage therapy regimen) will receive both CART-BCMA and huCART19. Enrollment into the Phase A Expansion may occur concurrently with Phase B once opened.
3184806|NCT00728533|Experimental|1|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 360 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months"
2403320|NCT03549403|Experimental|Patient-centered telephone education|Patients receive the preoperative call home one week before the day surgery and postoperatively 3-8 days after the day surgery. On the day of surgery patients receive current education.
2403321|NCT03549403|No Intervention|Current education practice|Patient´s education is implemented in accordance with current practice, where day surgery adult patients receive preoperative education over the phone one week prior to day surgery and postoperative education during on the day of surgery.
2403322|NCT03549390|Experimental|Yoga|The yoga session will be held in a room where lighting, temperature and music can be regulated. The session will be led by a trained instructor and involve a combination of body postures, breathing techniques and meditation. There will be a series of progressive breath centred yoga poses named Sun Salutations A & B for participants to complete, which have been chosen based on PPI and current relevant yoga practices. Sun Salutations A & B will be completed in a continuous sequence and aim to be completed with one breath per pose, but can be modified based on participant ability.
3144042|NCT00027586|Experimental|Imatinib Mesylate|400 mg twice a day orally
2403323|NCT03549390|Experimental|Continuous exercise|The exercise will be 30 minutes of treadmill walking. During the initial stages of walking, participants will gradually be taken up to a speed that registers between 10 and 12 on the Borg Rating of Perceived Exertion (RPE) Scale, up to a maximum of 4.0 km/h. This speed will be fixed for the entire exercise period. This exercise intensity has been chosen as it is the exercise intensity matched to light-moderate physical activity.
2403324|NCT03549390|No Intervention|Control|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
2403325|NCT03549377||Rested|Based on Pittsburgh Sleep Quality Index, participants scoring in the top 10-20% will be assigned to the rested group and will experience deception as part of the delayed gratification task
2403326|NCT03549377||Sleep-deprived|Based on Pittsburgh Sleep Quality Index, participants scoring in the bottom 10-20% will be assigned to the sleep-deprived group and will experience deception as part of the delayed gratification task
2403327|NCT03549364|Experimental|Endurance race|"baseline investigations with CT and lab tests~the same CT and lab tests < 24h after an endurance race~CT and lab tests again about 1-2weeks after the race"
3184807|NCT00728533|Experimental|2|"Starting dose of 240 mg (40 mg/mL) will be given on Day 0.~Maintenance doses of 480 mg (60 mg/mL) will be given after 1, 4, 7, and 10 months."
3184808|NCT00728546|Experimental|INA dose adjustment, NAT2|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
3184809|NCT00728559|Experimental|1|preemptive trocar site analgesia
2403331|NCT03549325|Experimental|Group 1|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Eradication therapy with the antibiotic Ciprofloxacin given on Day 4, unless required sooner.~Follow up visits occur on Days 5, 14 and 32."
2403332|NCT03549325|Experimental|Group 2|"Nasal drops containing Neisseria lactamica are administered at Day 0 by the study doctor.~Follow up visits on Day 4 and 7 to check for N. lactamica carriage. Eradication therapy with the antibiotic Ciprofloxacin given on Day 14, unless required sooner.~Follow up visits occur on Days 15, 24 and 42."
2403333|NCT03549312|Experimental|Switch to Genvoya Followed By HCV Therapy Then Start Biktarvy|Oral Genvoya 150/150/200/10 mg & Epclusa 400/100 mg once daily. Once completed HCV therapy, switch anti-retroviral treatment to Oral Biktarvy 50/200/25 mg.
2403334|NCT03549299|Experimental|LSC2; 7.5 x 10^4 cells|Single dose of LSC2, 7.5 x 10^4 cells per patient
2403335|NCT03549299|Experimental|LSC2; 3.0 x 10^5 cells|Single dose of LSC2, 3.0 x 10^5 cells per patient
2403336|NCT03549299|Experimental|LSC2; 8.0 x 10^5 cells|Single dose of LSC2, 8.0 x 10^5 cells per patient
2403337|NCT03549299|Experimental|LSC2; 1.2 x 10^6 cells|Single dose of LSC2, 1.2 x 10^6 cells per patient
2403338|NCT03549286||pregnant women in the first trimester ultrasound consultation|Participation in the study will be offered to all pregnant patients, presenting for their first trimester ultrasound consultation in the obstetrics and gynecology department of the University Hospital of Reims. The study includes the consultations of all the certified doctors of the Maternity Department of the Reims University Hospital carrying out the first trimester ultrasounds. It will concern all the ranges of consultation regardless of the doctor who performs the consultation.
3184810|NCT00728559|Experimental|2|trocar site pre skin closure analgesia
2403340|NCT03549260|Experimental|LIB003 150 mg or matching placebo|SC LIB003 150 mg or placebo every 4 weeks
2403341|NCT03549260|Experimental|LIB003 300 mg or matching placebo|SC LIB003 300 mg or placebo every 4 weeks
2403342|NCT03549260|Experimental|LIB003 350 mg or matching placebo|SC LIB003 350 mg or placebo every 4 weeks
2403343|NCT03549247||quality of life in periodontal healthy|250 individuals who have teeth pocket depth is at most 3 mm and there is no loss of attachment, no radiological bone loss and no gingival inflammation determeined for their quality of life
2403344|NCT03549247||quality of life in gingivitis|250 individuals who have teeth pocket depth in the mouth is at most 3 mm and there is no loss of attachment, no radiological bone loss and have chronic gingival inflammation with the sign of bleeding determeined for their quality of life
2403345|NCT03549247||quality of life in periodontitis|250 individuals who have more than 30% of teeth in the mouth which have pocket depths equal or more than 4mm and clinical attachment levels equal or more than 5mm and have radiologically detected bone loss determeined for their quality of life
3184811|NCT00728559|No Intervention|3|control
3184812|NCT00728572|Experimental|Experimental|Participant will receive a brief exam, a Basic Technique apex contact adjustment and Surface EMG.
2403348|NCT03549221|Experimental|MAC with adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
2403349|NCT03549221|No Intervention|MAC without adrenaline|the multimodal anesthetic cocktail (MAC) consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). They were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
2403350|NCT03549208|Experimental|LBVE01|Multivalent pneumococcal conjugate vaccine
2403351|NCT03549208|Experimental|LBVE02|Multivalent pneumococcal conjugate vaccine
2403352|NCT03549208|Active Comparator|Prevnar13|Multivalent pneumococcal conjugate vaccine Prevnar13
2403353|NCT03549195|Active Comparator|ICG|
2403354|NCT03549195|Active Comparator|ICG-CP|CP, control peptide
2403355|NCT03549195|Experimental|ICG-TMTP1|also named as TMTP1-ICG
2403356|NCT03549182|Experimental|male TPH2-GG carriers with ATD then placebo group|male TPH2-GG carriers will first receive ATD, then will receive placebo at least 5 weeks later.
2403357|NCT03549182|Experimental|male TPH2-GG carriers with placebo then ATD group|male TPH2-GG carriers will first receive placebo, then will receive ATD at least 5 weeks later.
3184813|NCT00728572|Sham Comparator|Sham|Participants will receive a sham Basic Technique adjustment (an adjacent contact not indicated by examination)and surface EMG.
3184814|NCT00728585|Experimental|Arm I (palifermin)|Patients receive palifermin IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive palifermin IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
2403358|NCT03549182|Experimental|male TPH2-TTcarriers with ATD then placebo group|male TPH2-TT carriers will first receive ATD, then will receive placebo at least 5 weeks later.
2403359|NCT03549182|Experimental|male TPH2-TTcarriers with placebo then ATD group|male TPH2-TT carriers will first receive placebo,then will receive ATD at least 5 weeks later.
2403360|NCT03549169|Experimental|TOMAS|Intervention centered on taking decisions for management of symptoms in adults with Heart Failure. Includes 3 doses (self-care maintenance, symptom perception and symptom management) and 4 strategies are developed: knowledge of the situation, experience and abilities in decision taking and compatibility with personal values.
2403361|NCT03549169|Other|Standard or regular attention|Regular attention is centered on education for therapeutic adherence
2403362|NCT03549156|Active Comparator|C-RUSF|Control/Standard RUSF
2403363|NCT03549156|Active Comparator|HIPRO RUSF|New RUSF product
3184815|NCT00728585|Placebo Comparator|Arm II (placebo)|Patients receive placebo IV once daily for 3 days prior to chemotherapy and/or radiotherapy in the absence of unacceptable toxicity. Patients then receive placebo IV on days 0, 1, and 2 after autologous or allogeneic hematopoietic stem cell transplantation.
3184816|NCT00728598||1|Proliferative diabetic retinopathy, active.
3184817|NCT00728598||2|Proliferative diabetic retinopathy, quiescent.
3184818|NCT00728598||3|Control group. Patients with macular hole or idiopathic epiretinal membrane receiving vitrectomy for their disease.
2403368|NCT03549104|Experimental|Fear Reduction Efficacy Evaluation (FREE)|The FREE intervention group will participate in eight weekly individual one-hour sessions using CBT and exposure treatment for specific fears.
2403369|NCT03549104|Active Comparator|Attention Control|The attention control group will participate in eight weekly individual one-hour Diabetes Self-Management Education (DSME) sessions.
2403370|NCT03549091|Experimental|Transthoracic echocardiography and MRI|The TransThoracic Echocardiography imaging data are collected exactly as for a standard examination. However, an additional measurement of the flow at the level of the left subclavian artery is performed, resulting in a 10-minute increase in the examination time. A Cardiovascular Magnetic Resonance Imaging 4D Flow is programmed within a maximum of 10 (no change in treatment that could skew the comparison). The usual procedure for MRI is not modified. The examination allows the acquisition of conventional 2D sequences of flow measurements, regurgitant volume and regurgitation fraction obtained at the level of the descending aorta and the sino-tubular junction of the ascending aorta. An additional 4D sequence is acquired increasing the examination time by 10 minutes.
2403371|NCT03549078|Experimental|Intervention|Participants will complete an initial assessment within 2 weeks prior to starting the course or during the first class. The course will include 10 sessions conducted on a weekly basis. Following completion of the course, participants will again complete another assessment during the last class or within 2 weeks of course completion. Participants may be invited to complete assessments at 3- and 6-months following course completion.
2403372|NCT03549065|Active Comparator|20 min active tDCS, and 20 min active rTMS|Applying active tDCS AND active TMS will reduce cue induced craving and opioid use, more than sham TMS AND sham tDCS and also either active TMS OR active tDCS alone. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), followed by 4000 pulses of real rTMS (10Hz over left Dorsolateral Prefrontal Cortex(DLPFC) for 20 minutes at 120%MT). There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS and the groups with only active tDCS OR active TMS.
2403373|NCT03549065|Active Comparator|20 min sham tDCS, and 20 min active rTMS|Applying sham tDCS AND active TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of real rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2403374|NCT03549065|Active Comparator|20 min active tDCS, and 20 min sham rTMS|Applying active tDCS AND sham TMS will reduce cue induced craving and opioid use, more than will sham TMS AND sham tDCS. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes active tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2403375|NCT03549065|Sham Comparator|20 min sham tDCS, and 20 min sham rTMS|Applying sham tDCS AND sham TMS will not reduce cue induced craving and opioid use. We will apply 10 sessions of one hour of brain stimulation. We will apply 10 daily sessions of brain stimulation (1 hour total treatment time). This is composed of with 20 minutes sham tDCS (anode on F3 EEG positioning and cathode on contra shoulder), and 4000 pulses of sham rTMS with (10Hz over left DLPFC for 20 minutes at 120%MT. There will be 10 minutes rest between each module. We will test for cue-induced craving scores using VAS and urine drug screens for opioid abuse in comparison to the control group of sham TMS AND sham tDCS.
2403376|NCT03549026|Experimental|duloxitine group|Patients will receive single oral dose of duloxetine capsule, 60 mg, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
2403407|NCT03548831||LAVH|Laparoscopic Assisted Vaginal Hysterectomy
3184819|NCT00728611|Experimental|1|
3184820|NCT00728611|Active Comparator|2|
3184821|NCT00728611|Placebo Comparator|3|
3184822|NCT00728637|Experimental|1|Participants took part in the Family Passport to Heart Health Program.
3184823|NCT00728637|Active Comparator|2|Participants took part in a control group.
3184824|NCT00728650||Observation|Patients with primary or metastatic hepatic malignancies
2403377|NCT03549026|Placebo Comparator|placebo group|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg.
3144043|NCT00027599|Experimental|Arm I|Autologous dendritic cells (DCs) are harvested and pulsed with prostatic acid phosphatase-sargramostim fusion protein to produce APC8015 (Provenge). Patients receive APC8015 IV over 30 minutes and bevacizumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days for 3 courses. Patients continue to receive bevacizumab alone every 14 days in the absence of disease progression or unacceptable toxicity.
3144044|NCT00027612|Experimental|irinotecan + carmustine and radiation|"Phase II (patients receiving concurrent EIACs or non-EIACs open to accrual as of 3/5/2005): Patients receive irinotecan at the recommended dose, carmustine, and cranial irradiation as in phase I.~Patients with disease progression are followed every 3 months for 5 years and then annually for up to 10 years.~Patients taken off study for reasons other than disease progression are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
3144045|NCT00027690|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144046|NCT00027703|Experimental|Arm I|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 30-60 minutes (beginning after gemcitabine infusion) and bevacizumab IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve stable disease (SD), complete response (CR), or partial response (PR) after the sixth course may receive bevacizumab as a single agent once every 3 weeks in the absence of disease progression or unacceptable toxicity.
2403384|NCT03548974|Active Comparator|Interventiongroup1|passive, motor-driven movement therapy followed by intermittent active and passive training
2403385|NCT03548974|Active Comparator|Interventiongroup2|intermittent active and passive training followed by no intervention
2403386|NCT03548961|Experimental|Neoadjuvant chemotherapy|
2403387|NCT03548948|Other|High heme iron diet|
2403388|NCT03548948|Other|Low iron diet|
2403389|NCT03548948|Other|Plant-based high non-heme iron diet|
2403392|NCT03548922||Pectus carinatum|Demographic data (age, sex), pressure of correction, Tanner stage, Risser stage, Haller index, pectus carinatum protrusion measurements of patients with pectus carinatum will be recorded and association of them with pressure of correction will be investigated.
2403393|NCT03548909||ED Setting|An acute HF population enrolled at EDs. Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
2403394|NCT03548909||Outpatient Setting|A non-acute population enrolled at outpatient centers.Testing of clinical samples will be performed with the VITROS Immunodiagnostic Products NT-proBNP II assay.
2403395|NCT03548896|Experimental|Dental Implants|Dental implants Titanium SLA treated surface of different dimensions according to the specific needs of the patient
2403396|NCT03548896|Experimental|Resorbable membrane|Resorbable membrane Cross link collagen membrane from porcine animal with a measure of 15 x 25 mm
2403397|NCT03548896|Experimental|Allograft|Allograft Bone from human source that is administered in a dosage of 1 cc per patient
2403398|NCT03548883||Alzheimer subject Group|In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.
2403399|NCT03548883||Control Group|In phase II, up to 50 age, sex, race ethnicity, group matched healthy controls will be recruited and screened until we have 6 healthy control subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
2403400|NCT03548883||Type 2 diabetes group|In phase III, up to 50 age, sex, race ethnicity, group matched T2D patients will be recruited and screened until we have 6 T2D subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of medical history (including a review of past images, current medication and labs if available). Recruited subjects will be scheduled for Study Visit #1 and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to confirm that there are no undiagnosed conditions.
2403401|NCT03548870|Experimental|Test with TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency TENS
2403402|NCT03548870|Sham Comparator|Test with sham-TENS|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with low frequency sham-TENS
2403403|NCT03548857||COPD patients|COPD patients on the waiting list for a lung transplantation
2403404|NCT03548844|Experimental|local excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group)
2403405|NCT03548844|Active Comparator|total mesorectal excision group|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (local excision group)
2403406|NCT03548831||MLH|Minilaparotomy Hysterectomy
2403409|NCT03548805|Active Comparator|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC (0.02%)
2403410|NCT03548792|Other|RSA radiostereometric analysis|30 patients in each Group Persona or Nexgen will receive tantalus beads to achieve RSA analysis comparing micromevements in radiographs.
2403411|NCT03548792|Other|Clinical comparison|Clinical comarison using different patient reported outcome measures and objective measures (ActivePAL, walking speed)
2403416|NCT03548766|Experimental|Healthy Subjects|Six healthy subjects will receive an ABT (Autologous Blood Transfusion)
2403417|NCT03548766|Experimental|Anemic Patients|Six patients with anemia will receive a HBT (Homologous Blood Transfusion)
2403418|NCT03548753||Patients with Agatston score > 399|"Coronary computed tomography angiography with FFR-CT~Invasive coronary angiography with FFR"
2403419|NCT03548740||Group A|
2403420|NCT03548740||Group B|
2403423|NCT03548714|Experimental|PT150 with alcohol consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
2403424|NCT03548714|Placebo Comparator|PT150 with placebo consumption|Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge (with ethanol or placebo beverage) will be completed on day 1 (pre-treatment), and day-5 (post-treatment), at predetermined times.
2403425|NCT03548701||Emergency Department|Patients enrolled in the Emergency Department undergoing evaluation for threatened abortion abnormalities.
2403426|NCT03548701||Obstetric Clinic|Patients with normal pregnancies being treated at first obstetric visit in clinic.
2403427|NCT03548675|Experimental|Genotype-guided TCA treatment|Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
2403428|NCT03548675|Active Comparator|Standard TCA treatment|Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
2403429|NCT03548662|Experimental|Platelet-Rich Plasma Protein (PRP) Group|Subjects in this group will receive PRP injection into tear site, followed by rehabilitative exercise
2403430|NCT03548662|Active Comparator|Hyaluronic Acid Group|Subjects in this group will receive one injection with hyaluronic acid followed by rehabilitative exercise
2403431|NCT03548649|Experimental|exoskeleton robot training group|subjects will receive exoskeleton robot training for 20 sessions (1 hr/session).
2403432|NCT03548636|Experimental|Single-Arm Feasibility Study|Participant determined 6-month physical activity program
2403433|NCT03548610|Experimental|Nanofat-seeded biological scaffold on surgical defect|Nanofat is obtained via lipoaspiration of 10cc of fat from abdomen under moderate local tumescent anesthesia w/ saline. Cannula access point is anesthetized by local lidocaine infiltration. Lipoaspirate is processed into nanofat using the Tonnard method, after 3-minute decantation. Aspiration is performed using a multihole 3mm cannula. Wound margin + bed is treated w/ topical & local injections of nanofat, then covered w/ a biological scaffold, the inferior surface of which is soaked in nanofat; scaffold is fixed w/ external dressings or resorbable sutures; external covering includes polyurethane film & 3 layers of dressings. Topical application creates a fine <1mm nanofat layer. Scaffold (Puracol Plus) is left in place to integrate w/ surrounding skin, while external dressings changed at 7 & 15 days. Lipoaspirate donor site needs mild to moderate compression for 24 hours & suture removal (if not absorbed) at 7 days.
2403434|NCT03548610|No Intervention|Standard of Care dressings|Immediately after surgical resection, each patient will be treated following the SOC, therefore with a local skin flap, rather than with a skin graft, based on surgeon assessment. Sutures, and moulage, if present, will be removed at 7 days and patient instructed to apply a daily silicone cream and sunscreen for 2 months.
2403435|NCT03548584|Experimental|Low Dose Brexpiprazole Arm|Tablet
2403436|NCT03548584|Experimental|High Dose Brexpiprazole Arm|Tablet
2403437|NCT03548584|Placebo Comparator|Placebo|Tablet
2403438|NCT03548571|Experimental|DC immunization|Leukapheresis before start of radiotherapy. Immunization with DCs starting first week after finalizing radiotherapy (2Gy x 30) and concomitant temozolomide.
2403439|NCT03548571|Active Comparator|Standard therapy|Radiotherapy (2 Gy x30) with concomitant and adjuvant temozolomide.
3144047|NCT00027703|Experimental|Arm II|Patients receive gemcitabine and cisplatin as in arm I and placebo IV over 30-90 minutes (beginning after cisplatin infusion) on day 1. Treatment repeats as in arm I. Patients who achieve SD, CR, or PR after the sixth course may receive placebo as a single agent once every 3 weeks in the absence of disease progression.
2403482|NCT03548298|Experimental|GERD without hiatal hernia|Participants with GERD without hernia hiatal will receive ARAT
3144048|NCT00027807|Experimental|Aldesleukin, Sargramostim & therapeutic autologous lymphocytes|Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
3144049|NCT00027820|Experimental|Treatment (PBSCT)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -4, -3, and -2 and undergo TBI on day 0.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO every 8 hours on days 0-40 with taper to day 96."
2403445|NCT03548545|Experimental|CBT combined with active tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with active tDCS over the dorsolateral prefrontal cortex.
2403446|NCT03548545|Sham Comparator|CBT combined with sham tDCS|Subjects allocated to this arm will receive cognitive-behavior therapy combined with sham tDCS over the dorsolateral prefrontal cortex.
2403447|NCT03548532|Active Comparator|36.6°C|Embryos of these patients will be cultured at 36.6°C from day 0 after ICSI, untill day 6.
2403448|NCT03548532|Experimental|37.1°C|Embryos of these patients will be cultured at 37.1°C from day 0 after ICSI, untill day 6.
2403452|NCT03548506|Active Comparator|STN_O|Omnidirectional Deep Brain Stimulation of STN
2403453|NCT03548506|Experimental|STN_D|Directional Deep Brain Stimulation of STN
2403454|NCT03548493|Experimental|Magnesium (M) group|Magnesium (M) group (n=17) , in which magnesium sulphate is given as adjuvant to propofol for sedation
2403455|NCT03548493|Active Comparator|Fentanyl (F) group|Fentanyl (F) group (n=17), in which fentanyl is given as adjuvant to propofol for sedation
2403456|NCT03548480|Placebo Comparator|Placebo|
2403457|NCT03548480|Experimental|Probiotic|
2403458|NCT03548467|Experimental|VB10.NEO intervention|Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing to patients within the selected tumor types.
2403459|NCT03548467|Experimental|VB10.NEO in combination with bempegaldesleukin (NKTR-214)|Bempegaldesleukin (NKTR-214) will be given in combination with VB10.NEO in up to 10 patients with SCCHN. Treatment with individualized VB10.NEO immunotherapy will commence as soon as the patient-specific VB10.NEO vaccine is available and if the patient-specific vaccine meets all pre-specified product release criteria after manufacturing. Bempegaldesleukin (NKTR-214) will be given after at least 4 doses of VB10.NEO.
2403460|NCT03548454|Experimental|Duloxetine|Duloxetine starting at 20 mg per day and increasing to 60 mg per day as tolerated.
2403461|NCT03548454|Experimental|Desipramine|Desipramine starting at 25 mg per day and increasing to 75 mg per day as tolerated.
2403462|NCT03548441||Surgery|Exposed
2403463|NCT03548441||Non-surgical management|Non-exposed
2403464|NCT03548428|Experimental|A|SBRT + Atezolizumab
2403465|NCT03548428|Active Comparator|B|SBRT
2403466|NCT03548415|Experimental|IONIS-GHR-LRx|Single Dose of IONIS GHR-LRx administered subcutaneously once every 28 days for 16 weeks
2403467|NCT03548415|Placebo Comparator|Placebo|Placebo (sterile saline 0.9%) Calculated volume to match active comparator administered subcutaneously every 28 days for 16 weeks
2403468|NCT03548389|Experimental|Mother and newborn skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
2403469|NCT03548389|No Intervention|Conventional care|In the routine care group, the infant was delivered from the mother by a midwife, wrapped in blankets, taken to be routinely cared under a warmer, and then dried quickly. Afterwards, the Apgar score was determined immediately after the umbilical cord was cut. The infants were provided with all routine care by the midwife working in the delivery room. After the infants were weighed, dressed, and measured, they were handed to their mothers who were encouraged to begin breastfeeding.
2403470|NCT03548376|Experimental|One-group intervention|Hippotherapy sessions were delivered once a week for 30 minutes, during 6 months.
2403471|NCT03548363|Active Comparator|Gingest High|200 mg/d Gingest (powdered extract obtained from Ginger rhizomes) for 4-weeks
2403472|NCT03548363|Active Comparator|Gingest low|100 mg/d Gingest (powdered extract obtained from Ginger rhizomes) + 100 mg maltodextrin for 4-weeks
2403473|NCT03548363|Placebo Comparator|Placebo|200 mg/d maltodextrin for 4-weeks
2403474|NCT03548350|Experimental|Intervention|"The experimental group will participate in a 24 week multi-component programme that includes four strands:~A physical literacy programme focusing on core elements of strength, agility, speed, balance and flexibility. Delivered by external facilitators for one hour per week over 16 weeks of the programme (2 x8week blocks).~'Golden Mile' - pupils and teachers participate 15min walk/run a min of 2 times per week~After schools club (not compulsory) featuring mind-set component delivered by external facilitators~Healthy kidz app with reward system"
2403475|NCT03548350|No Intervention|Control|The control group will continue doing physical activity including physical education as is normal for their school
2403478|NCT03548324|Active Comparator|HHHFNC|Heated Humidified High Flow Nasal Cannulae
3144050|NCT00027872|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Patients with a complete or partial response, hematologic improvement, or stable disease continue treatment every 29-63 days in the absence of disease progression or unacceptable toxicity. Patients with a complete response after the second course of therapy receive 2 additional courses of therapy.
3144051|NCT00027885|Active Comparator|Docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
2403485|NCT03548272|Experimental|BiOSS LIM C|"Intervention: Percutaneous coronary intervention (PCI) with BiOSS LIM C stent implantation.~The BiOSS LIM C® is a dedicated bifurcation balloon expandable stent made of cobalt-chromium alloy (strut thickness 70 µm) releasing sirolimus (1.4 µg/mm2) from the surface of a biodegradable coating comprised of a copolymer of lactic and glycolic acids (PGLA). The degradation of the polymer lasts approximately 8 weeks. The BiOSS LIM C® stent consists of two main separate parts with different diameters: wider proximally, and distally smaller. The proximal part is always a bit shorter than the distal one (avg. 1 mm)."
2403486|NCT03548272|Active Comparator|regular 2nd generation DES|"Intervention: Percutaneous coronary intervention (PCI) with regular drug-eluting stent implantation (rDES).~rDES well-tested and available on the market. Xience, Orsiro, Resulte Integrity"
2403487|NCT03548259|Experimental|Experimental|Platelet-rich plasma
2403488|NCT03548259|Placebo Comparator|Platelet-poor plasma|Platelet-poor plasma
2403491|NCT03548233|Other|bcg vaccinated|children under five year vaccinated by bcg vaccine
2403492|NCT03548220|Experimental|AG-348|"Part 1 (Dose Optimization Period): Participants will receive AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of AG-348 as determined by the individual's response in Part 1."
2403493|NCT03548220|Placebo Comparator|Placebo|"Part 1 (Dose Optimization Period): Participants will receive placebo matching AG-348 for 12 weeks. Investigators will assess the need for dose increases every 4 weeks.~Part 2 (Fixed Dose Period): Participants will receive their optimized dose of placebo matching AG-348 as determined by the individual's response in Part 1."
3144052|NCT00027885|Experimental|Combine bevacizumab and docetaxel.|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
2403495|NCT03548194|Experimental|BNC210|Administered orally b.i.d. for 5 days.
2403496|NCT03548194|Placebo Comparator|Placebo|Administered orally b.i.d. for 5 days.
2403497|NCT03548181|Experimental|"Intervention group tele-rehabilitation"|"Each patient will have the opportunity to have minimum one Video Consultation (VC) per week the first month, one VC each second week the second month one VC a month the rest of the trial.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home. A digital diary will automatically register the data obtained by the system on patient's performance."
2403498|NCT03548181|Active Comparator|Control|Patients will be followed, but they do not get any other kind of treatment comparable to the intervention group treatment.
2403499|NCT03548168||Healthy Adults|Eligible healthy young adults, aged 18-30 years, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2403500|NCT03548168||Low Back Pain|Eligible young adults, aged 18-30 years, with chronic low back pain will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2403501|NCT03548168||Older Adults|Eligible healthy middle aged and older adults, aged 55 years and older, will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2403502|NCT03548168||Trunk Experts|Eligible healthy middle aged and older adults, aged 55 years and older, with high levels of trunk muscle control (ie. individuals with expertise in the Pilates Method of exercise) will participate in testing experiments to test-retest reliability of the muscle functional magnetic resonance imaging (mfMRI) and functional magnetic resonance imaging (fMRI) techniques that were developed in order to study the neural control of trunk muscles.
2403503|NCT03548155|Experimental|berberine group|
2403504|NCT03548155|Placebo Comparator|control group|
2403505|NCT03548129|Active Comparator|Fosfomycin group (FG)|"Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.~The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.~Response to treatment will be assessed by post-treatment urine culture."
2403506|NCT03548129|Active Comparator|Culture specific group (CG):|"Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.~Response to treatment will be assessed by post-treatment urine culture."
2404202|NCT03543332||Myocardial infarction|Myocardial infarction without cardiac arrest
2403514|NCT03548103|Experimental|Green Tea Extract|Green Tea Extract 500 mg per capsule
2403515|NCT03548103|Placebo Comparator|Placebo|Identical Placebo capsule
2403516|NCT03548090|Experimental|1|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
2403517|NCT03548090|Experimental|2|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
2403518|NCT03548090|Experimental|3|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
2403519|NCT03548090|Experimental|4|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
2403520|NCT03548090|Experimental|5|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
2403521|NCT03548090|Experimental|6|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
2403522|NCT03548090|Experimental|7|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (control 4-week exercise intervention)
2403523|NCT03548090|Experimental|8|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (control 4-week exercise intervention)
2403524|NCT03548090|Experimental|9|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (control 4-week exercise intervention)
2403525|NCT03548090|Experimental|10|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (control 4-week exercise intervention)
2403526|NCT03548090|Experimental|11|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (control 4-week exercise intervention)
2403527|NCT03548090|Experimental|12|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (control 4-week exercise intervention)
2403528|NCT03548090|Experimental|13|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2403529|NCT03548090|Experimental|14|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2403530|NCT03548090|Experimental|15|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2403531|NCT03548090|Experimental|16|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2403532|NCT03548090|Experimental|17|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2403533|NCT03548090|Experimental|18|Phase 1 (skateboard exercise at 50% body weight and an incline level of 0 degrees, then 5 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2403534|NCT03548090|Experimental|19|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 75%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2403620|NCT03547518|Sham Comparator|Sham treatment|One-week induction consisting of three sham treatments, each 2 hours long
2403535|NCT03548090|Experimental|20|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 50%, then 90%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2403536|NCT03548090|Experimental|21|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 50%, then 90%), Phase 3 (experimental 4-week exercise intervention)
2403537|NCT03548090|Experimental|22|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 75%, then 90%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2403538|NCT03548090|Experimental|23|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 50%, then 75%), Phase 3 (experimental 4-week exercise intervention)
2403539|NCT03548090|Experimental|24|Phase 1 (skateboard exercise at 50% body weight and an incline level of 5 degrees, then 0 degrees), Phase 2 (skateboard exercise with incline level determined to be optimal in phase 1 and body weight at 90%, then 75%, then 50%), Phase 3 (experimental 4-week exercise intervention)
2403540|NCT03548077|Experimental|Intervention group|Powerplay, a workplace wellness program designed for male-dominated work sites, is the intervention. The program focuses on physical activity, healthy eating, mental wellness, and smoking cessation as well as promoting changes in workplace environments to support employee health and wellness. Program delivery is supported with a detailed program manual and web-based resources. More information about the intervention is available here: http://www.powerplayatwork.com/
2403541|NCT03548064|Experimental|Regimen A|5 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2403542|NCT03548064|Experimental|Regimen B|25 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2403543|NCT03548064|Experimental|Regimen C|5 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2403544|NCT03548064|Experimental|Regimen D|25 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2403545|NCT03548064|Experimental|Regimen E|0.3 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2403546|NCT03548064|Experimental|Regimen F|1.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2403547|NCT03548064|Experimental|Regimen G|50 µg of dmLT oral on days 1, 15, 29, n=12; placebo oral on days 1, 15, 29, n=3
2403548|NCT03548064|Experimental|Regimen H|50 µg of dmLT sublingual on days 1, 15, 29, n=12; placebo sublingual on days 1, 15, 29, n=3
2403549|NCT03548064|Experimental|Regimen I|2.0 µg of dmLT intradermal on days 1, 22, 43, n=12; placebo intradermal on days 1, 22, 43, n=3
2403550|NCT03548051|Experimental|FMT group|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1, n=108
2403551|NCT03548051|Experimental|Placebo group|250 ml of saline delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1; if no improvement followed by FMT (100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema given 1-3 hours after loperamide 4 mg po x 1) x 2, n=54
2403552|NCT03548038||Bariatric surgery patients|All subjects will be patients scheduled for bariatric surgery. There is only one arm in this study.
2403553|NCT03548025|Experimental|Treatment Group|Treated group of subjects, serves as its own control
2403554|NCT03548012|Experimental|The Carer Support Needs Assessment Tool (CSNAT) intervention|('Standard' basic palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
2403555|NCT03548012|No Intervention|Control|('Standard' basic palliative care). No intervention offered.
2403556|NCT03547999|Active Comparator|Arm A - Control|mFOLFOX6 and Nivolumab every 2 weeks for 4 cycles. After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6 in addition to Nivolumab. After this, Nivolumab will be given every 4 weeks completing therapy at week 110.
2403557|NCT03547999|Experimental|Arm B - Experimental|Two doses of Nivolumab and MVA-BN-CV301 each given 2 weeks apart (Days -28, -14), followed by four doses of Nivolumab plus FPV-CV301 given 2 weeks apart concurrently with mFOLFOX6, which will again be administered every 2 weeks for 4 cycles (Nivolumab, FPV-CV301 and mFOLFOX6). After neoadjuvant therapy, patients will be re-evaluated for surgical resection. Patients still considered resectable will undergo surgical resection with the goal of completely treating all of their disease by either resection and/or ablation. Patients with bilobar disease must have all of their disease treated in a single operation. Patients in the experimental arm will receive 8 cycles of mFOLFOX6 in addition to Nivolumab and FVP-CV301 boosters with the first two given on Day 0 and 14 and then every 4 weeks. FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
2403558|NCT03547986|Experimental|Duplex Ultrasound (DUS)|Standard angiography and DUS are performed on the same patients (paired data)
2403559|NCT03547986|Experimental|IVUS with Intraarterial pressure measurement (IAP)|Standard angiography and Intra-Vascular Ultrasound (IVUS) with Intraarterial pressure measurement (IAP) are performed on the same patients (paired data)
3144053|NCT00027898|Experimental|Treatment (bortezomib, carboplatin, and etoposide)|Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2403590|NCT03547739|Active Comparator|HIV Self-testing|Women in this study group will receive HIV self-test kits for themselves and their male partner at up to 4 time points.
2403621|NCT03547505|Experimental|R-Pilot®|"R-Pilot® was operated by an endomotor (VDW Silver, Munich, Germany) at Reciproc All setting."
3144054|NCT00027963|Experimental|gabapentin|"Patients receive titrating doses of oral gabapentin twice daily and then three times daily for 3 weeks. Patients then receive a fixed dose of oral gabapentin three times daily for 3 weeks. Patients cross-over to therapy as in arm II at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
3144055|NCT00027963|Placebo Comparator|placebo|"Patients receive titrating doses of oral placebo and then a fixed dose of oral placebo as in arm I. Patients cross-over to therapy as in arm I at week 8.~Quality of life is assessed at baseline and then at the end of weeks 6, 8, and 14."
3144056|NCT00027976|Experimental|Group 1 active arm|receipt of active drug
2403565|NCT03547960|Experimental|Guar gum in women with early GDM|5 g of Guar gum fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
2403566|NCT03547960|Placebo Comparator|Control/Cellulose in women with early GDM|5 g of Cellulose fibre supplement with meals three times a day (total daily 15 g) for 12 weeks
2403567|NCT03547934|Experimental|Treatment Group|Treatment with the investigated device - High Intensity Focused ElectroMagnetic System
2403568|NCT03547921||operative|operative
2403569|NCT03547921||non operative|non operative
3144057|NCT00027976|Experimental|Group 2 active arm|receipt of active drug
3144058|NCT00027976|Experimental|group 2 placebo arm|receipt of placebo
2403572|NCT03547895|Active Comparator|cases|"patients with decompensated cirrhosis~treated with Sofosbuvir 400 mg (Sovaldi) + Daclatasvir 60mg (Daklinza) + Ribavirin 200 mg (Rebetol)"
2403573|NCT03547895|Placebo Comparator|control group|the control group treated with liver support including silymarin 140 + phytomenadione 10 mg + lasilactone 50 mg + albumin infusion
2403574|NCT03547882||Other|Target interviewees will be primary care providers at six facilities and their staff (e.g., nurse care managers).
2403575|NCT03547882||Patients|Ten interviews were conducted with VA patients receiving ORT.
2403576|NCT03547869|Experimental|Active tDCS|Active tDCS
2403577|NCT03547869|Sham Comparator|Sham tDCS|Sham tDCS
2403578|NCT03547843|Experimental|Educational intervention|Patients randomized to the intervention group will start with a group-based educational program immediately after the randomization.
2403579|NCT03547843|Active Comparator|Waiting list|Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
2403580|NCT03547830|Experimental|Plerixafor/G-CSF|Plerixafor/G-CSF for HSCT conditioning Myeloablative conditioning regimen with Plerixafor as addition agent before stem cell transplantation in CGD patients
2403581|NCT03547817|Experimental|Optimal negative pulse pressure regime|The equipment for physiological measurements will be attached to the patient, and the foot will then be placed in the pressure chamber of the intermittent negative pressure device. The device induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure. Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels. The order of the different negative pressure levels will be randomized to avoid causal interference.
2403582|NCT03547804|Experimental|experimental arm|apatinib 500 mg qd;The dose was later reduced from 500 mg to 250 mg per day based on a recommendation of the principal investigator to reduce the adverse events.Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
2403583|NCT03547791|Active Comparator|ACS (Group 1)|Intramuscular injection of betamethason sodium phosphate 12mg (3ml) twice 24hours apart
2403584|NCT03547791|Placebo Comparator|Placebo (Group 2)|Intramuscular injection of normal saline 3ml twice 24hours apart
2403585|NCT03547778|Experimental|Misoprostol group|Patients in this arm will receive vaginal misoprostol (50 mcg), the night before the procedure (concurrent office hsyteroscopy and endometrial biopsy).
2403586|NCT03547778|Placebo Comparator|Placebo group|Participants in this group will receive placebo (fatty acid), which looks similar to misoprostol and has to be inserted vaginally the night before the procedure.
2403587|NCT03547752|Active Comparator|Effective movement group|Observation of a video of neck movement at 100% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
2403588|NCT03547752|Experimental|Ineffective movement group|Observation of a video of neck movement at 40% range of movement, and imagination of the same observed movement, feeling the realization of the movement but not developing it.
2403589|NCT03547739|Active Comparator|Home visits|Participants randomized to intervention arm receive 5 home visits conducted by one female and one male lay health worker.
2404203|NCT03543267|Experimental|epileptic Patients|
3144059|NCT00028028|Experimental|Arm I|Patients receive low-dose CCI-779 IV over 30 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
3144060|NCT00028028|Experimental|Arm II|Patients receive high-dose CCI-779 as in arm I.
3144062|NCT00028119||Cohort 1|HIV-uninfected non-sex worker women
3144063|NCT00028119||Cohort 2|HIV-discordant heterosexual couples attending STD clinics
3144064|NCT00028145||1|Pregnant, HIV-infected women
3144067|NCT00028496|Experimental|Treatment (vaccine therapy, sargramostim, vaccine adjuvant)|"The first three cohorts of 3-12 patients receive escalating doses of recombinant fowlpox-CEA-TRICOM vaccine (fCEA-TRI) until the maximum tolerated dose (MTD) is determined. fCEA-TRI is administered intradermally every 2 weeks for 4 doses and then every 2 months thereafter (beginning on day 56) in the absence of disease progression or unacceptable toxicity.~The fourth and fifth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of sargramostim (GM-CSF). GM-CSF is administered subcutaneously once daily beginning on the day of each vaccination and continuing for a total of 4 days.~The sixth through eighth cohorts of 6 patients receive fCEA-TRI at the MTD in the same manner as the first three cohorts combined with escalating doses of recombinant fowlpox-GM-CSF (rF-GM-CSF)."
2403591|NCT03547739|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or Couples HIV Counseling and Testing (CHCT).
2403592|NCT03547726|Active Comparator|Physical Therapy|This group of patients will receive a predetermined physical therapy regimen with guidance from a physical therapist.
2403593|NCT03547726|Experimental|Self-Rehab|This group of patients will be provided with a list of actions not to perform during the stages of their rehab (to avoid injury), and allowed to rehab their shoulder at their own pace.
2403594|NCT03547713|Experimental|Study group|social feedback and neuropsychological assessment
2403595|NCT03547700|Experimental|Romidepsin plus Ixazomib|The phase I study includes three dose levels (DL) for romidepsin: DL4: 10 mg/m2 on Days 1, 8, 15; DL5: 14 mg/m2 Days 1, 8; DL6: 14 mg/m2 Days 1, 8, 15. Ixazomib is 4 mg PO Days 1, 8, 15. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study. Each cycle is 28 days and patients will receive treatment until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met.
3184825|NCT00728663|Experimental|Arm: Cetuximab and Docetaxel|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8 and Docetaxel: 75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
2403597|NCT03547674|Active Comparator|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2403598|NCT03547674|Active Comparator|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2403599|NCT03547674|Active Comparator|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2403600|NCT03547674|Experimental|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
2403601|NCT03547661|No Intervention|Treatment as Usual|The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.
2403602|NCT03547661|Active Comparator|Integrative Open-Label Placebo|"The intervention will encompass an integrative administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
2403603|NCT03547661|Active Comparator|Open-Label Placebo|"The intervention will encompass an administration of P-Dragees rosa Lichtenstein, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.~All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)"
2403604|NCT03547648|Active Comparator|Group I ( 30 cm H2O)|Patients will be applied 30 cm H2O peak airway pressure manually at the end of the surgery
2403605|NCT03547648|Active Comparator|Group II( 40 cm H2O)|Patients will be applied 40 cm H2O peak airway pressure manually at the end of the surgery
2403606|NCT03547648|Active Comparator|Group III(50 cm H2O)|Patients will be applied 50 cm H2O peak airway pressure manually at the end of the surgery
3184826|NCT00728715|Experimental|A|Medium Dose of budesonide-formoterol
3184827|NCT00728715|Active Comparator|B|High dose of inhaled budesonide (1600 mcg/day)
3184828|NCT00728767|Experimental|1|
2403610|NCT03547622|Active Comparator|MAT taper with galantamine|Following initial MAT taper, participants will be given up to 16mg daily of galantamine for up to 10 weeks of the active study
2403611|NCT03547622|Placebo Comparator|MAT taper with placebo|Following initial MAT taper, participants will be given up to 16mg daily of placebo for up to 10 weeks of the active study
3184829|NCT00728767|Placebo Comparator|2|
3184830|NCT00728780|Experimental|A|ABT-143 15/135mg
3184831|NCT00728780|Active Comparator|B|ABT-335 135mg and rosuvastatin 15mg
2403615|NCT03547570|Experimental|Heavy shoulder resistance training|Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.
2403616|NCT03547557|Experimental|ExAblate MRgFUS|
3184832|NCT00728832|Active Comparator|1|No test dose + DepoDur + flush with 1 mL normal saline
3184833|NCT00728832|Experimental|2|Test dose + flush with 1 mL normal saline + 3-minute wait + DepoDur + flush with 1 mL normal saline
2403619|NCT03547518|Experimental|Active PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
2404439|NCT03541668|Experimental|Group A|Recombinant human urokinase (rhPro-UK)
3184834|NCT00728832|Experimental|3|Test dose + flush with 1 mL normal saline + 10-minute wait + DepoDur + flush with 1 mL normal saline
3184835|NCT00728832|Experimental|4|Test dose + flush with 1 mL normal saline + 15-minute wait + DepoDur + flush with 1 mL normal saline
3184836|NCT00728832|Experimental|5|Test dose + No flush + 3-minute wait + DepoDur + flush with 1 mL normal saline
3184837|NCT00728897|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
2403622|NCT03547505|Experimental|ProGlider®|ProGlider® was operated by an endodontic motor (X-Smart, Dentsply Sirona, Ballaigues, Switzerland) with 16:1 contra angle at the suggested settings (300 rpm on display, 5 Ncm).
2403623|NCT03547505|Experimental|Manual preparation|"In the manual glide path group, glide path creation was performed with stainless steel #08, 10, 15 K-files used with push and pull motion. Instruments were used with a motion in which the instrument proceeds apically quarterly to the point of resistance, then is pulled out for debris removal. The procedure was repeated with each file until the working length was achieved and confirmed with an electronic apex locator (Root ZX Mini, Morita Corp., Kyoto, Japan)."
2403624|NCT03547492|Experimental|Language Intervention|"1. Baseline LENA recording 2. Review language curriculum and motor curriculum with study personnel 2. Direct linguistic feedback of baseline LENA recording 4. 2nd LENA recording completed and analyzed 5. Direct or mailed linguistic feedback of 2nd LENA recording 6. 16- Weekly text messages 7. 4 month LENA recording with mailed linguistic feedback 8. 12 month LENA recording with mailed linguistic feedback~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a book at each interaction."
2403625|NCT03547492|Active Comparator|Motor Control|"Baseline LENA recording~Review motor curriculum with study personnel~2nd LENA recording completed and analyzed~4- monthly text messages~4 month LENA recording~12 month LENA recording with mailed linguistic feedback of all recordings~Assessments:~Ages and Stages Questionnaire at 4 and 12 months~Maternal Peabody Picture Vocabulary test at 4 months~Edinburgh Post-partum Depression Scale at 4 months~MacArthur Bates Communicative Developmental Inventory: Words and Gestures at 12~Participants receive a toy at each interaction."
2403626|NCT03547479|No Intervention|Control|Participants receive current standard of care (DOTS)
2403627|NCT03547479|Experimental|VDOT only|Participants receive daily DOTS treatment with video-enabled mobile monitoring, but also maintain regular supervisory checks
2403628|NCT03547479|Experimental|VDOT + mobile money incentives|Participants receive daily DOTS treatment with video-enabled mobile monitoring supplemented with mobile money incentives, but also maintain regular supervisory checks
2403629|NCT03547453||Regular Menstrual Cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted to obtain 20 lean (BMI<25 kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
2403630|NCT03547453||Polycystic Ovarian Syndrome|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted to obtain 20 lean (BMI<25kg/m2) and 20 overweight or obese (BMI>24.9kg/m2) women in each of the following age groups: 18-24y (early), 25-34y (mid), ≥35y (later adulthood).
2403631|NCT03547440||type 1 diabetes mellitus|Children with type 1 diabetes mellitus, usually not obese, with diabetic ketoacidosis. They could be with or without stationary metabolic profile. They are recruited at the onset of the T1DM into the Torino and Novara Pediatric Hospitals and then they are divided in relation to the ethnicity.
2403632|NCT03547440||Control healthy|Healthy children without relevant metabolic or systemic co-morbility. They are recruited from orthopedy department of the Torino and Novara Pediatric hospitals and then they are divided in relation to the ethnicity
2403633|NCT03547427|Experimental|Insulin hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2403634|NCT03547427|Active Comparator|Insulin hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone') and receive a Lispro bolus to induce hypoglycemia of ≤55mg/dL ('Insulin-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2403635|NCT03547427|Experimental|Exercise hypoglycemia + pramlintide|Subjects will have a 25% reduction in their standard basal insulin therapy with concurrent basal pramlintide infusion ('Basal pramlintide and reduced basal insulin'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia'). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2403636|NCT03547427|Active Comparator|Exercise hypoglycemia|Subjects will have their standard basal insulin treatment ('Basal insulin alone'). They will have three bouts of exercise to induce hypoglycemia of ≤55mg/dL ('Exercise-induced hypoglycemia' ). After induction of hypoglycemia is completed subjects will have an acetaminophen test. Subjects will be instructed to initiate a CGM session 2-3 days prior to both the admissions. Blood samples will be collected during the hypoglycemic induction and acetaminophen test.
2403637|NCT03547401||General anesthesia|Patient (15 to 40 years old) undergoing elective surgery requiring general anesthesia in supine position.
2403638|NCT03547388|Experimental|Single Arm|Additional application of weekly moderate whole-body hyperthermia concurrent to re-irradiation plus chemotherapy
2403639|NCT03547375|Experimental|treatment group|Apatinib 500mg/d po,28 days as one cycle
2403640|NCT03547362|Experimental|Casein|Single oral administration
2403641|NCT03547362|Experimental|Dairy protein blend 1|single oral administration
2403642|NCT03547362|Experimental|Whey protein|Single oral administration
2403643|NCT03547362|Experimental|Dairy protein blend 2|Single oral administration
2403644|NCT03547362|Experimental|Dairy protein blend 3|Single oral administration
2403645|NCT03547362|Experimental|Dairy protein blend 4|Single oral administration
2403703|NCT03546959|Experimental|Lycra sleeve after botulinum toxin|8 hours a day lycra sleeve wear plus rehabilitation (for five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
2403646|NCT03547349|Active Comparator|Group 1|These study patients will receive a study information/authorization sheet about the study prior to surgery during their pre-operative clinic visit. This subgroup will be provided postoperatively with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer. Subjects in this group will receive current standard of care with routine surgical and RN encouragement to use the spirometer. The tablet will monitor and record spirometer device utilization.
2403647|NCT03547349|Active Comparator|Group 2|These study patients will be consented by members of the research team prior to surgery at their pre-operative clinic visit. The patient will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with a digital incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer, and will set a spirometry goal while collecting usage and pulmonary function data. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
2403648|NCT03547349|Experimental|Group 3|These study patients will be consented by a member of the research team prior to surgery at their pre-operative clinic visit. The patients will receive RT or RN education preoperatively as to the importance of incentive spirometry in prevention of post-operative respiratory complications. This subgroup will be provided with both intensive education reinforcement and the Jamboxx Respiratory Therapy Device that also includes multiple gaming programs. The games are meant to encourage incentive spirometry and are programmed to progress in accordance with the patient's personal increasing capacity. Subjects in this group will also receive daily intensive education from a study team member during the postoperative time up until 72 hours or until discharge.
2403649|NCT03547336|Experimental|Theranova 400 Dialyzer|In-center hemodialysis (in HD mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
2403650|NCT03547336|Active Comparator|FX800|In-center hemodialysis (in HDF mode), 3 times a week for 12 week duration. The patient will undergo regular HD treatment on the first treatment of the first week of study, after which, the patient will switch to the randomized dialyzer, from the second treatment to the end of study treatment. Blood sampling will be obtained at the hospital by trained personnel according to local routines.
2403651|NCT03547323|Experimental|Theranova 400 Dialyzer|One treatment session in an in-center setting.
2403652|NCT03547323|Active Comparator|FX80 Dialyzer|One treatment session in an in-center setting.
2403653|NCT03547310|Experimental|MyoBeatz|The intervention consists of playing with the smartphone training program using the muscle signals picked up by surface electrodes. The study will run over a period of 5 weeks, with participants playing with the training program at home for 4 weeks.
2403654|NCT03547284|Active Comparator|81 patients,group 1|81 women will receive 1 stick of sugarless gum for 15 minutes every 2 hours after surgery .
2403655|NCT03547284|No Intervention|81 patients,group 2|81 patients will have traditional management(oral intake of clear fluids after hearing of first intestinal sounds or passage of flatus and regular diet after passage of stool)
3144068|NCT00028522|Experimental|Treatment (chemotherapy)|"SCHEDULE A: Patients receive R(+)XK469 IV over 30 minutes on days 1, 3, and 5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of R(+)XK469 until the recommended phase II dose or MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are accrued and treated at the recommended phase II dose (for a maximum of 20 patients treated at that dose).~SCHEDULE B: Once the recommended phase II dose is determined on schedule A, additional patients are accrued and receive escalating doses of R(+)XK469 IV over 30-60 minutes on day 1, beginning at a reduced dose. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Dose escalation continues as in Schedule A."
2403660|NCT03547258||AML patients|Clinical and Molecular data collection of AML Patients with FLT3 mutations (ITD or TKD)
2403663|NCT03547232|Experimental|Indomethacin group|Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
2403664|NCT03547232|Sham Comparator|Standard group|Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.
2403665|NCT03547219|Experimental|Escitalopram|Participants with depression were treated with escitalopram(ranging from 5mg to 30mg) for 8 weeks. Escitalopram was initiated at 5mg for 1 week, followed by an increase to 10mg at week 2. After week 2, doses of escitalopram were titrated according to symptoms and adverse effects. Specific, indicated psychotherapy for depression was not allowed during the study.
2403666|NCT03547206|Experimental|RPh201 Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
2403667|NCT03547206|Placebo Comparator|Placebo Cohort A|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
2403668|NCT03547206|Experimental|RPh201 Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the Investigational Medical Product (IMP) (20 mg RPh201).
2403669|NCT03547206|Placebo Comparator|Placebo Cohort B|A 12-week schedule consisting of four-times-per-week subcutaneous administration of 400 μL of the vehicle control.
2403704|NCT03546959|Active Comparator|Rehabilitation after botulinum toxin|Rehabilitation (five days a week for three weeks) after botulinum toxin injection for post-stroke spasticity
2403705|NCT03546946|Experimental|Gaze-Contingent Music Reward Training|GCMRT for eight 20-minute sessions - twice per week over 4 weeks.
2404440|NCT03541668|Active Comparator|Group B|Alteplase(rt-PA)
2403670|NCT03547180|Active Comparator|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
2403671|NCT03547180|Active Comparator|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
2403672|NCT03547180|Other|In-vivo exposure therapy|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
2403677|NCT03547141|Experimental|botulinum toxin 1U|
2403678|NCT03547141|Experimental|botulinum toxin 5U|
2403679|NCT03547141|Experimental|botulinum toxin 15U|
2403680|NCT03547141|Experimental|botulinum toxin 30U|
2403681|NCT03547128||Parents with newborns recruited from 1992-5|Parents of newborns recruited from 8 Iowa hospitals in 1992-5
2403682|NCT03547115|Experimental|voruciclib|Open-label, 3 + 3 dose escalation study which may enroll up to 6 subjects at each dose level and disease type (AML or B-cell malignancies)
2403683|NCT03547102|Active Comparator|Cherry concentrate|8 weeks supplementation with montmorency cherry concentrate
2403684|NCT03547102|Placebo Comparator|Placebo concentrate|8 weeks supplementation with placebo isoenergetic cherry concentrate
2403685|NCT03547089|Experimental|Viveve treatment|Group of women who receive Viveve treatment
3144069|NCT00028535|Experimental|Arm I|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on days 1, 8, and 15 and paclitaxel IV over 3 hours on day 1 of course 1. Beginning with course 2, patients receive trastuzumab and paclitaxel as in course 1 and interleukin-12 subcutaneously on days 2, 5, 9, 12, 16, and 19. Courses repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2403687|NCT03547063||Sleeve Gastrectomy (SG)|25 participants, male and female, aged 18-50 years, body mass index (BMI) 35-50 kg/m2, due to undergo primary SG
2403688|NCT03547063||Lifestyle Intervention|25 participants, male and female, aged 18-50 years, BMI 35-50 kg/m2
2403689|NCT03547063||Normal Weight|25 participants, aged 18-50 years BMI 18.5-24.9 kg/m2, age and gender matched to group with severe obesity
2403690|NCT03547050||Patients diagnosed with RE|People who meet the eligibility requirements and have been diagnosed with rolandic epilepsy.
2403691|NCT03547050||Controls|People without a lifetime history of seizures.
3144070|NCT00028548|Experimental|XK469|
3144071|NCT00028561|Experimental|Treatment (ixabepilone, carboplatin)|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15 followed by carboplatin IV over 1 hour on day 1. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after achieving CR or up to a total of 6 courses
2403694|NCT03547024|Experimental|Part 1: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail on Day 1 followed by JNJ-55308942 high dose once daily from Day 3 to Day 14 and a single dose of drug cocktail on Day 12.
2403695|NCT03547024|Experimental|Part 2: JNJ-55308942 + Levonorgestrel/Ethinyl Estradiol|Participants will receive a single dose of levonorgestrel/ethinyl estradiol alone on Day 1 followed by JNJ-55308942 high dose once daily on Days 5 to 18 and a single dose of levonorgestrel/ethinyl estradiol on Day 14.
2403696|NCT03547024|Experimental|Part 3: JNJ-55308942 + Drug Cocktail|Participants will receive a single dose of drug cocktail alone on Day 1 followed by JNJ-55308942 low dose once daily on Days 3 to Day 14 and a single dose drug cocktail on Day 12.
2403697|NCT03547011|Active Comparator|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
2403698|NCT03547011|Active Comparator|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
2403699|NCT03546985|Experimental|Group A|
2403700|NCT03546985|Active Comparator|Group B|
2403701|NCT03546972|Active Comparator|Group A (DPP)|Participants take part in DPP once a week over 1 hour for 16 weeks.
2403702|NCT03546972|Experimental|Group B (DPP-HT)|Participants take part in DPP once a week over 1 hour for 16 weeks and hunger training once a week during weeks 2-6.
3144072|NCT00028574|Active Comparator|Gabapentin (28 days)|Oral Gabapentin 300 mg days 1-28
3144073|NCT00028574|Active Comparator|Gabapentin (7, 21)|Oral Gabapentin 300 mg once daily on days 1-7 days and twice daily days 8-28
3144074|NCT00028574|Active Comparator|Gabapentin (7, 7, 14)|Oral Gabapentin 300 mg once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28
3144075|NCT00028574|Placebo Comparator|Placebo|"Oral Placebo 300 mg on one of the following schedules:~once daily on days 1-28~once daily on days 1-7, twice daily on days 8-28~once daily on days 1-7, twice daily on days 8-14 and three times daily on days 15-28"
3144076|NCT00028587|Experimental|Group I (paclitaxel, carboplatin, bortezomib)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and bortezomib IV over 3-5 seconds on days 2, 5, and 8.
3144077|NCT00028587|Experimental|Group II (bortezomib, paclitaxel, carboplatin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2
3144078|NCT00028600|Experimental|Autologous + Allogeneic Transplant|autologous PB stem cell transplant followed by non-myeloablative allogeneic transplant fr multiple myeloma
3144079|NCT00028665|Experimental|Arm I: with rituximab IV|
3144080|NCT00028665|Active Comparator|Arm II: without rituximab IV|
2403706|NCT03546946|Placebo Comparator|Control Training|Passive viewing task with continuous music for eight 20-minute sessions - twice per week over 4 weeks.
2403707|NCT03546946|No Intervention|No-Train Group|No active training.
2403708|NCT03546933||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
2403709|NCT03546920|No Intervention|Control Phase|Usual care for patients admitted to the SNF.
2403710|NCT03546920|Experimental|ALIGN Intervention Phase|ALIGN Intervention delivered by Palliative Care Social Workers in the SNF setting. The intervention consists of aligning patient/caregiver goals of care, completing advance care planning, and connecting to community resources and services to ensure smooth transition from facility to home setting.
2403711|NCT03546907|Experimental|SAR440340|Administration of SAR440340 monotherapy injection
2403712|NCT03546907|Placebo Comparator|Placebo|Administration of matching placebo for injection of SAR440340
2403713|NCT03546894||Brigatinib|The dosage and regimen of brigatinib (ALK inhibitors) will be decided by participant's prescribing physician and will not be determined by participation in the study.
2403714|NCT03546894||Any FDA Approved ALK Inhibitor|The dosage, regimen of any Food and Drug Administration (FDA) approved ALK inhibitor (at any point in therapy) other than crizotinib will be decided by participant's prescribing physician and will not be determined by participation in the study.
2403715|NCT03546881|Experimental|Arm with fusion imaging guidance technology|arm with fusion imaging guidance technology to perform the endovascular surgery, in addition to the traditional 2D X-ray screen system.
2403716|NCT03546881|Active Comparator|Arm without fusion imaging guidance technology|arm without fusion imaging guidance technology, using the traditional 2D X-ray screen system, to perform the endovascular surgery.
2403717|NCT03546868|Experimental|Ulcerative Colitis|Patients with ulcerative colitis undergoing [18F]FSPG PET/CT scan
2403718|NCT03546868|Experimental|Crohn's disease|Patients with Crohn's disease undergoing [18F]FSPG PET/CT scan
2403719|NCT03546855|Experimental|treatment group|apatinib 500mg/d po.28d as one cycle
3184838|NCT00728897|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= 4x25 milligrams GSK598809 capsule given in fasted state, C= 100 milligrams GSK598809 capsule given in fed state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
2403725|NCT03546803||Cohort A|Head and Neck Patients; Photon or Proton Treatment with product
2403726|NCT03546803||Cohort B|Hair/skin fold areas (Axilla, Groin, Perineum); Photon or Proton Treatment with product
2403727|NCT03546803||Cohort C|Misc. (per Rad Onc Physician); Photon or Proton Therapy with routine skin care
2403728|NCT03546790|Experimental|Flavor 1|Grape flavored tobacco cigar wrapper
2403729|NCT03546790|Experimental|Flavor 2|Chocolate flavored tobacco cigar wrapper
2403730|NCT03546790|Experimental|Flavor 3|Tobacco flavored tobacco cigar wrapper
2403731|NCT03546764|Experimental|Percutaneous Catheter|14-French Percutaneous catheter (pigtail or non-pigtail) placed at bedside using Seldinger technique
2403732|NCT03546764|Active Comparator|Chest tube|Placement of 28-36F chest tube placed at bedside by an open cut-down technique (traditional)
2403733|NCT03546751|Experimental|CPAP|This arm will consist of patients with obstructive sleep apnea who will be asked to use CPAP nightly to treat their OSA for six months
2403734|NCT03546751|Active Comparator|Diet and Exercise|This arm will consist of patients with obstructive sleep apnea who will be asked to engage in dietary management and regular exercise for six months.
2403735|NCT03546738|Experimental|Burst SCS|Burst Spinal cord stimulation. SCS system implanted and burst stimulation given
2403736|NCT03546738|Sham Comparator|Sham SCS|Sham spinal cord stimulation. SCS system implanted but no stimulation given.
2403737|NCT03546725|Experimental|Leg with compression stocking|Leg wearing compression stocking during the flight
2403738|NCT03546725|No Intervention|Leg without compression stocking|Leg not wearing compression stocking during the flight
2403739|NCT03546686|Experimental|Treatment Arm|Ipilimumab + Nivolumab + Core Biopsy/Cryoablation + Breast Surgery +Post Surgery Nivolumab
2403740|NCT03546673|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
2403741|NCT03546673|Experimental|Self-regulation Condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2403742|NCT03546673|Experimental|Emotional Disclosure condition|For the emotional disclosure condition, participants were asked to write about their deepest thoughts and feelings about their cancer experience for three weeks.
2403743|NCT03546660|Experimental|SECM capsule imaging|Subject will swallow the SECM capsule and the imaging of the esophagus will be performed using a SECM optical system
2403746|NCT03546634|Active Comparator|Three-dose schedule for Sabin IPV|Subjects vaccinate Sabin IPV at 2, 3, and 4 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 3rd dose of IPV.
2403747|NCT03546634|Experimental|Two-dose schedule for Sabin IPV|Subjects first dose IPV vaccinate at 4 months of age, and the second dose IPV given between 8 and 11 months of age,will be collected blood specimens twice - right before the first dose of IPV, and one month after the 2nd dose of IPV.
2404324|NCT03542422|Experimental|Apatinib|Apatinib 500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
2403752|NCT03546608|Experimental|Part 1, Child-Pugh Class A: Tepotinib|
2403753|NCT03546608|Experimental|Part 1, Child-Pugh Class B: Tepotinib|
2403754|NCT03546608|Experimental|Part 1, Healthy Participants: Tepotinib|Healthy participants matched to Child-Pugh Class B participants.
2403755|NCT03546595|Experimental|Auricular acupoints acupressure|
2403756|NCT03546595|Sham Comparator|Sham auricular acupoints acupressure|
3144081|NCT00028730|Experimental|Pts < than or = 18 years with lymphohematopoietic disorders|This is a phase II, single-center study to evaluate a cytoreductive regimen of hyperfractionated TBI, thiotepa and cyclophosphamide (HFTBI/thio/cy) followed by infusions of SBA-E- T-cell depleted marrow in pediatric leukemia recipients of either HLA-identical or HLA-1Ag non-identical related or unrelated donors.
3144082|NCT00028743|Active Comparator|Cisplatin, Topotecan, Paclitaxel plus Carboplatin|Arm 1
2403759|NCT03546556|Experimental|Allogeneic|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo Fluorothymidine FLT-PET-MRI imaging on two separate occasions.
2403760|NCT03546556|Experimental|Autologous|3 patients undergoing autologous stem cell transplant will also undergo Fluorothymidine FLT-PET-MRI imaging the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
2403761|NCT03546543|Experimental|Supine|
2403762|NCT03546543|Experimental|Prone|
2403763|NCT03546530|Experimental|Interferon|Interferon 1.5ug/kg/week, 48weeks
2403764|NCT03546530|Experimental|Interferon+resveratrol|Interferon 1.5ug/kg/week,resveratrol 1000mg/day, 48weeks
2403765|NCT03546517|Experimental|Intervention with DNHS technique|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
2403766|NCT03546517|Sham Comparator|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
2403767|NCT03546504|Experimental|dental procedures modification and OT|Modifying dental environment and procedures to reduce sensory stimulation. Occupational therapy provides desensitization techniques around the dental visit and home oral hygiene and habit training for oral hygiene activities.
2403770|NCT03546478|Experimental|99mTc-ABH2 SPECT/CT|The patients were injected with 370±54 MBq of 99mTc-ABH2 in one dose intravenously and underwent SPECT/CT scan 90-270 min later.
2403771|NCT03546465|Experimental|Cohorts 1C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 100 μg
2403772|NCT03546465|Experimental|Cohorts 1J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 100 μg
2403773|NCT03546465|Experimental|Cohorts 2C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 200 μg
2403774|NCT03546465|Experimental|Cohorts 2J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 200 μg
2403775|NCT03546465|Experimental|Cohorts 3C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 300 μg
2403776|NCT03546465|Experimental|Cohorts 3J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 300 μg
2403777|NCT03546465|Experimental|Cohorts 4C (Caucasian subjects)|ropeginterferon alfa-2b: single dose of 450 μg
2403778|NCT03546465|Experimental|Cohorts 4J (Japanese subjects)|ropeginterferon alfa-2b: single dose of 450 μg
2403779|NCT03546452||malignant NSCLC hydrothorax|cell free DNA ,which is purified from malignant NSCLC hydrothorax, tested by in vitro NGS-panel
2403780|NCT03546426|Experimental|study treatment|Pembrolizumab in combination with Autologous dendritic cells and Interleukin-2
3144083|NCT00028743|Active Comparator|Paclitaxel plus Carboplatin|Arm 2
3144084|NCT00028756|Active Comparator|Arm I (immediate chemotherapy)|Beginning within 90 days of radical cystectomy, patients receive a total of 4 courses of adjuvant chemotherapy.
3144085|NCT00028756|Experimental|Arm II (deferred chemotherapy)|Beginning at the time of clinical relapse, patients receive a total of 6 courses of adjuvant chemotherapy.
2403784|NCT03546400|Other|methylphenidate HCl ERCT|methylphenidate HCl ERCT
3144086|NCT00028782|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2 hours. Approximately 48 hours after EF5 administration, patients with intraperitoneal tumors undergo surgical resection. Patients with pleural tumors undergo surgical resection approximately 24 hours after EF5 administration. Tumors are then analyzed for EF5 binding and microvascular density by immunohistochemistry and fluorescent antibody techniques.
2403786|NCT03546361|Experimental|Treatment (Ad-CCL21-DC vaccine, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by autologous dendritic cell-adenovirus CCL21 vaccine by CT-guided or bronchoscopic IT injection on days 0, 21, and 42. Patients then receive pembrolizumab every 3 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
2403787|NCT03546335|Experimental|1mCi injection of 89Zr-DFO-CZP|The first 2 patients will receive 1mCi of 89Zr-DFO-CZP.
2403788|NCT03546335|Experimental|0.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2403789|NCT03546335|Experimental|1.5mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2403790|NCT03546335|Experimental|2mCi injection of 89Zr-DFO-CZP|Subsequent groups of two patients will receive 0.5 mCi decrease or increase dose (up to 2 mCi) to determine the acceptable optimal imaging dose.
2403791|NCT03546322||Registry|Head and neck cancer patients monitored on registry
2403850|NCT03545880|Experimental|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
3144087|NCT00028795|Experimental|Chemoradiotherapy|
3144088|NCT00028821|Experimental|Treatment (2-methoxyestradiol)|Patients receive oral 2-methoxyestradiol (2-ME) once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144089|NCT00028834|Experimental|Treatment (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
2403792|NCT03546309|Experimental|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
2403793|NCT03546309|Sham Comparator|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
2403794|NCT03546283|Placebo Comparator|Control|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebo group, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
2403795|NCT03546283|Experimental|CEGI treatment|The patients with hypertensive intracerebral hemorrhage will be randomized into giving drug CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
3184839|NCT00728897|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= 100 milligrams GSK598809 capsule in given fasted state, A= 4x25 milligrams GSK598809 capsule given in fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3184840|NCT00728897|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= 100 milligrams GSK598809 capsule in given fasted state, C= 100 milligrams GSK598809 capsule given in fed state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
2403798|NCT03546257||EUS|group using conventional WLE and EUS
2403799|NCT03546257||ME-NBI|group using WLE and ME-NBI.
2403800|NCT03546244|Experimental|musical treadmill|4-week daily musical treadmill training, consisting in two session, 20 minute per session
2403801|NCT03546244|Active Comparator|traditional session|4-week daily traditional treadmill training, consisting in two session, 20 minute per session
2403802|NCT03546218|Experimental|Smartphone Application (SPSRS)|Participants watch motion picture using an application that displays positive-word stimuli.
2403803|NCT03546218|Active Comparator|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
2403804|NCT03546205|Experimental|Group 1: JNJ-64565111|Participants with normal renal function and no evidence of kidney damage (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter/minute [mL/min]) will be enrolled. Participants will receive a single subcutaneous (SC) dose of JNJ-64565111 on Day 1.
2403805|NCT03546205|Experimental|Group 2: JNJ-64565111|Participants with mild renal impairment (eGFR 60 to less than [<] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2403806|NCT03546205|Experimental|Group 3: JNJ-64565111|Participants with moderate renal impairment (eGFR 30 to <60 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2403807|NCT03546205|Experimental|Group 4: JNJ-64565111|Participants with severe renal impairment (eGFR <30 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
2403808|NCT03546205|Experimental|Group 5: JNJ-64565111|Participants with end-stage renal disease (requiring hemodialysis 3 times per week for at least 3 months before screening; eGFR will not be calculated) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
3184841|NCT00728897|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= 100 milligrams GSK598809 capsule given in fed state, A= 4x25 milligrams GSK598809 capsule given in fasted state and B= 100 milligrams GSK598809 capsule in given fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
2403811|NCT03546166|Experimental|TREATMENT|
2403812|NCT03546153|Experimental|Aerobic exercise program|Participants will complete 12 week exercise program.
2403813|NCT03546127||STS|Patients with advanced/metastatic soft-tissue sarcoma
2403814|NCT03546127||CCR|Patients with metastatic colorectal carcinoma
2403815|NCT03546114||Patients referring to an osteopathic clinic - CMO, Milan|Adults, age>18 years, first visit at osteopathic clinic (Centro di Medicina Osteopatica)
2403816|NCT03546101||Department of Kidney Medicine|Primarily transplant recipients undergoing monitoring for EBV and patients suspected for having PTLD.
2403817|NCT03546101||Department of Hematology|Patients diagnosed with PTLD and other kinds of lymphoma. Patients undergoing hematopoietic stem cell transplantation and patients with hemophagocytosis.
2403818|NCT03546101||Department of pediatrics|Children undergoing transplantation. Children diagnosed with hemophagocytic lymphohistiocytosis.
2403819|NCT03546088|Experimental|awake naso-tracheal intubation|The patients with obstructive oro and hypo-pharynx tumours will have their airway secured through awake fiberoptic naso-tracheal intubation with light sedation and topical anaesthesia with lidocaine. The sedation will be provided in small boluses until the desired level will be achieved not exceeding 0.05 mg/kg of midazolam and 3 mcg/kg fentanyl. The dose of lidocaine will be to a maximum of 7 mg/kg. The reinforced intubating tube will be lubricated with lidocaine gel.
2403820|NCT03546075|Experimental|500 mg Resveratrol|
2403821|NCT03546075|Experimental|250 mg Resveratrol|
2403822|NCT03546075|Placebo Comparator|Placebo|
2403823|NCT03546062||T2DM patients treated by HTx|Authors will include a population of T2DM patients with advanced heart failure and treated by heart transplant.
2403851|NCT03545880|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
2403852|NCT03545867|Experimental|Seated control (CON)|Participants remain seated in their habitual wheel chair for ~45 min (duration of exercise performed in other arms). Following the intervention they are fed.
2403853|NCT03545867|Experimental|Circuit resistance training (CRT)|Participants complete upper extremity resistance maneuvers (lifts) interspersed with low-load/high-speed arm cycling for a combined 30 repetitions of 6 lifts and ~20 min of arm cycling. During this time energy expenditure is measured via open-circuit indirect calorimetry. Following the intervention they are fed.
2403824|NCT03546049|Active Comparator|US-guided percutaneous biliary drainage|The initial percutaneous transhepatic puncture of the bile duct is performed by ultrasound guidance with a Chiba-needle (0.7 mm). After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance (digital remote-controlled fluoroscopy device). Then a 0.018 inch guide wire is introduced and proceeded beyond the tumor stenosis into the duodenum. Next, the Chiba needle is exchanged by a 5 F catheter and the 0.018 inch guide wire is exchanged by a 0.035 inch guide wire. After dilatation of the hepatic access route with bougies up to 12 F, a self-expandable metal stent is introduced. The placement of the metal stent is controlled by endoscopic luminal guidance (gastroscope or duodenoscope).
2403825|NCT03546049|Experimental|EUS-guided biliary drainage|The initial transluminal puncture of the bile duct is performed by endoscopic ultrasound guidance (longitudinal echoendoscope) with an 19 G access needle. After injection of a radiopaque contrast media into the bile duct system, the malignant extrahepatic bile duct stenosis can be visualized by fluoroscopic guidance. Then, a 0.035 inch guide wire is introduced into the bile duct. After dilatation of the transluminal access route with a balloon catheter, a self-expandable metal stent is introduced as an antegrade biliary drainage, a transhepatic biliary drainage or a choledochal biliary drainage. The placement of the metal stent is controlled by fluoroscopic and endoscopic luminal guidance.
2403826|NCT03546036|Experimental|Weighted metal chain blanket|As experimental intervention, a weighted metal chain blanket of 8 kg was used during the night. Using a flexible dose protocol, participants who found the 8 kg blanket too heavy were allowed to change to a 6 kg weighted blanket (see below)
2403827|NCT03546036|Sham Comparator|Control plastic chain blanket|As sham comparator, light chain blankets were used, were plastic chains of the same shape and size as the metal chains in the weighted blanket were sewn in. The control blanket has a weight of 1535 grams. When checking the weight of standard blankets for sale in one of the largest stores in Stockholm, weight was ranging from 550 to 2389 grams (average 1332).
2403828|NCT03546010|Experimental|Oculometric and neuropsychological tests|Oculometric tests and neuropsychological tests
2403829|NCT03545997|Experimental|Montelukast|Drug :Montelukast, capsule, 10mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
2403830|NCT03545997|Placebo Comparator|Placebo|Drug: Mannitol, capsule, 350mg, one per day in the evening, one hour before or 2 hours post meal, length of treatment 3 months
3184842|NCT00728897|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= 100 milligrams GSK598809 capsule given in fed state, B= 100 milligrams GSK598809 capsule in given fasted state and A= 4x25 milligrams GSK598809 capsule given in fasted state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
3184843|NCT00728975||1|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
2403833|NCT03545971|Experimental|Ia Cohort A|Low-dose group:Participants will receive IBI310 0.3mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity.
2403834|NCT03545971|Experimental|Ia Cohort B|Middle-dose group:Participants will receive IBI310 1.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2403835|NCT03545971|Experimental|Ia Cohort C|Middle-dose group:Participants will receive IBI310 2.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2403836|NCT03545971|Experimental|Ia Cohort D|High-dose group:Participants will receive IBI310 3.0mg/kg intravenous every 3 weeks,after 4 cycle, if the patient benefits it will be continued until disease progression or unacceptable toxicity
2403837|NCT03545971|Experimental|Ib Cohort A|3 subjects, low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2403838|NCT03545971|Experimental|Ib Cohort A2|low-dose group:Participants will receive IBI310 1.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2403839|NCT03545971|Experimental|Ib Cohort B|3 subjects, low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2403840|NCT03545971|Experimental|Ib Cohort B2|low-dose group:Participants will receive IBI310 2.0mg/kg in Combination with Sintilimab 200mg intravenous every 3 weeks. After 4 cycles, Sintilimab alone 200mg intravenous every 3 weeks, until disease progression, lost follow-up visit, death , unacceptable toxicity, withdrawn of ICF, another other reason for end of treatment. Maximum treatment duration is 2 years.
2403841|NCT03545958|Experimental|High-intensity Interval Training (HIT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-minute HIT intervention.
2403842|NCT03545958|Active Comparator|Moderate-intensity Continuous Training (MCT)|Participants in this groups will receive 15 minutes in the mind-motor training (i.e., Square-Stepping Exercise) followed by a 45-min MCT intervention.
2403843|NCT03545945|Experimental|Study arm|Patients having office diagnostic hysteroscopy and endometrial biopsy
2403844|NCT03545945|Other|Control arm|Patients having only endometrial biopsy
2403845|NCT03545932|Experimental|Hydrogymnastics|Hydrogymnastics Program
2403846|NCT03545906|Experimental|TEAM-UP Intervention Group|
2403847|NCT03545906|Active Comparator|Enhanced Care Comparison Group|
3184844|NCT00728975||2|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
3184845|NCT00728975||3|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
3184846|NCT00728975||4|Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
3184847|NCT00728975||5|Vancouver Coastal Cottage Hospice inpatients
2403854|NCT03545867|Experimental|Moderate intensity continuous (MICT)|Participants complete continous arm cycling at a steady-state power output (intensity) matched to the energy expenditure (kcal/min) and duration of exercise (min) response during CRT. Following the intervention they are fed.
2403855|NCT03545867|Experimental|High intensity interval training (HIIT)|"Participants complete interval arm cycling at power output that varies between 2 min active and two min recovery periods. This interval exercise is matched to the total energy expenditure (accumulated kcals) response during CRT. Following the intervention they are fed."
2403856|NCT03545854|Experimental|T3 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T3 vertebral level
2403857|NCT03545854|Experimental|T3 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T3 vertebral level
2403858|NCT03545854|Experimental|T3 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T3 vertebral level
2403859|NCT03545854|Experimental|T12 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the T12 vertebral level
2403860|NCT03545854|Experimental|T12 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the T12 vertebral level
2403861|NCT03545854|Experimental|T12 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the T12 vertebral level
2403862|NCT03545854|Experimental|L4 10ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 10ml of coloring solution at the L4 vertebral level
2403863|NCT03545854|Experimental|L4 20ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 20ml of coloring solution at the L4 vertebral level
2403864|NCT03545854|Experimental|L4 30ml|The cadaver will receive an ultrasound-guided Erector Spinae Plane Block with 30ml of coloring solution at the L4 vertebral level
2403865|NCT03545841|Experimental|HIT training|6 weeks of high-intensity interval training (HIT)
2403866|NCT03545841|Experimental|Moderate intensity training|6 weeks of moderate-intensity continuous training (MICT)
2403867|NCT03545828||Good neurological outcome|CPC 1 and 2 at 6 month after ROSC
2403868|NCT03545828||Poor neurological outcome|CPC 3 to 5 at 6 month after ROSC
2403869|NCT03545815|Experimental|anti-mesothelin CAR-T cells|"Patients receive mesothelin-directed CAR-T cells infusion with dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de- escalation.~Patients receive anti-mesothelin-CAR T cells on day 0."
2403870|NCT03545802|Experimental|Training|6 weeks of home-based high intensity interval training
2403871|NCT03545789|Experimental|[18F]MNI-958|To measure blood metabolites of [18F]MNI-958 and perform kinetic modeling to assess its ability to measure tau protein in brain using the tracer plasma concentration or a reference region as indirect input.
2403872|NCT03545776||Educational program|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course that will be preceded by a pre-test evaluation and followed by delayed post-test evaluations.~Training will be followed by an online teaching consisting on additional questions and answers quizzes based on the 10 educational goals already described elsewhere.~In order to avoid any risk of intrasite contamination, all the learners benefiting from the training in the same department will be trained in a uniform time, with respect to the training schedule regarding post-test evaluations (day-1, day-15 and day-30). A final evaluation will be performed at day-90 after beginning of the training course."
2403873|NCT03545763||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2403874|NCT03545763||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2403875|NCT03545750||Regional citrate anticoagulation (RCA)|Those receiving regional citrate anticoagulation for CRRT
2403876|NCT03545750||Systemic heparin anticoagulation (SHA)|Those receiving systemic heparin anticoagulation for CRRT
2403877|NCT03545737||Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT.
2403878|NCT03545737||Formula|"The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube.~The depth of intubation = 0.1977* height-4.2423"
2403879|NCT03545724|Experimental|Neofitoroid®|Treatment is made by the application of Neofitoroid® 2 times a day for 10 days.
2403880|NCT03545711|Experimental|Anlotinib plus Irinotecan|
2403881|NCT03545698|Active Comparator|Telehealth Intervention|
2403882|NCT03545698|No Intervention|Non-Telehealth Intervention|
2403883|NCT03545685|Experimental|SMART|The subjects in SMART training group will receive add-on SMART intervention for 3 months. Subjects will play cognitive games for 1 hour per day, five days per week. SMART will track game time, resource use, and text messaging information on a daily basis, which allows researchers/clinicians to monitor subjects' daily SMART activities. Daily end-of-day RedPocket incentives will be delivered to subjects' designated account based on their resource use and game time. Top 5 APS subjects who play the game for the most time in a week will be rewarded
2403884|NCT03545685|Other|Control group|Participants in this group will serve as control group
2403885|NCT03545672||PBC group|Patients have a definite PBC diagnosis.
2403886|NCT03545672||Control group|The healthy volunteers or patients in Renji Hospital whose medical examinations show no systemic disease, and the CMR examinations are normal.
2403887|NCT03545646|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
2403888|NCT03545633|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic System
2403889|NCT03545620||Difficult intubation,|Patients who underwent surgery under general anesthesia will be follow up. Patients predicted difficult intubation/airway or established difficult intubation/airway after anesthesia induction will be included. Which rescue technique will be used after unsuccessful direct laryngoscopy will be recorded.
2403890|NCT03545607|Experimental|MultiStem|1.2 billion cells
2403891|NCT03545607|Placebo Comparator|Placebo|
2403892|NCT03545594|Experimental|Patient-centered in home rehabilitation|Eight contacts of about 2 hours duration each delivered over a 4-month period (Six in home visits and two telephone contacts before the Corona pandemic and adjusted to eight contacts and up to six of them video based when necessary during the Corona pandemic) in three phases:
2403893|NCT03545594|Active Comparator|Control|Usual follow-up assessment and health care and rehabilitation services provided in the municipality
2403894|NCT03545581|Other|Experimental diet Fru rich diet|Enriched fructose diet from day 1 to day 7.
2403895|NCT03545581|Other|Experimental low Fru diet|Low fructose diet from day 1 to day 7.
2403896|NCT03545568|Other|Experimental: sialic acid|
2403897|NCT03545555|Experimental|Kale Powder|"5 capsules with kale preparation kale powder per day for 8 weeks"
2403898|NCT03545555|Experimental|Kale Extract|"5 capsules with kale preparation kale extract per day for 8 weeks"
2403899|NCT03545555|Experimental|Flavonoid Extract|"5 capsules with kale preparation flavonoid extract (from kale) per day for 8 weeks"
2403900|NCT03545555|Placebo Comparator|Placebo|"5 capsules with placebo per day for 8 weeks"
2403901|NCT03545542|Experimental|Neuroblastoma group|"10 children with neuroblastoma. Inclusion after verification of diagnosis and informed consent.~Sampling of fecal microbiome (Initial microbiome, microbiome under chemotherapy, final microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds, fecal volatile organic compounds under chemotherapy and final fecal volatile organic compounds) and breath organic volatile compounds (initial breath organic compounds, breath volatile organic compounds under chemotherapy and final breath volatile organic compounds).~Samples will be taken after verifying diagnosis before initiation of chemotherapy, 1 week after completion of each cycle and 3 weeks after the end of chemotherapy."
2403902|NCT03545542|Other|Control group|"10 children without gastro-intestinal or pulmonary disease as age and sex matched controls to the neuroblastoma group. Patients will be recruited from paediatric surgery. Inclusion after informed consent.~Sampling of fecal microbiome (initial fecal microbiome), fecal volatile organic compounds (initial fecal volatile organic compounds) and breath organic volatile compounds (initial breath volatile organic compounds).~Samples will be taken as age and sex matched controls for the neuroblastoma group. Sampling will be done once after obtaining informed consent."
2403903|NCT03545529|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (telealarm, numeric communication diary...) and from a strong accompaniment with a referent person who help better the patient.
2403904|NCT03545529|No Intervention|conventional supported|Patients benefit from usual care
2403905|NCT03545516|Placebo Comparator|Placebo|Wound infiltration with a placebo
2403906|NCT03545516|Experimental|Bupivacaine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine diluted with 5 mL of normal saline to give a 25 mL
2403907|NCT03545516|Experimental|Bupivacaine and Dexmedetomidine|Wound Infiltration with 20 mL (150mg) of 0.75% bupivacaine and 1.5 mcg/kg of dexmedetomidine will be diluted with normal saline to make 25 mL of solution .
3144090|NCT00028925|Experimental|Regimen A|"Patients receive oral topotecan once daily on days 1-5, carboplatin IV over 30 minutes on day 5, and filgrastim (G-CSF) subcutaneously once daily beginning on day 6 or 7 and continuing for up to 10 days or until blood counts recover.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
3144091|NCT00028925|Experimental|Regimen B|"Patients receive topotecan and carboplatin as in regimen A. Patients are evaluated after the first 3-week course of chemotherapy. If no patient experiences unacceptable toxicity or febrile neutropenia, the next 33 patients receive treatment as in regimen B; otherwise, patients receive treatment as in regimen A.~Treatment for all patients repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with disease progression limited to CNS only interrupt chemotherapy to have whole-brain radiotherapy (WBRT). Once WBRT is complete, chemotherapy resumes.~Quality of life is assessed at baseline and at the beginning of each course of chemotherapy.~Patients are followed every 3 months for 2 years and then every 6 months for 3 years."
2403910|NCT03545490|Experimental|Intervention oral or tube feeding group|Ensure 3 times/day
2403911|NCT03545490|No Intervention|Control oral or tube feeding group|Only nutrition education
3144092|NCT00028990|Active Comparator|Paclitaxel + Bevacizumab|
3144093|NCT00028990|Active Comparator|Paclitaxel|
3144094|NCT00029003|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3144095|NCT00029159|Active Comparator|1|
2403916|NCT03545451|Experimental|Neurofeedback rehabilitation with videogames|Neurofeedback rehabilitation with videogames
2403917|NCT03545438|Placebo Comparator|cohort 1|LIB003 dose 1 SC
2403918|NCT03545438|Placebo Comparator|cohort 2|LIB003 dose 2 SC
2403919|NCT03545438|Placebo Comparator|cohort 3|LIB003 dose 4 SC
2403920|NCT03545438|Placebo Comparator|cohort 4|LIB003 dose 4 SC
2403921|NCT03545438|Placebo Comparator|cohort 5|LIB003 dose 5 SC
2403922|NCT03545438|Placebo Comparator|cohort 6|LIB003 dose 4 IV
2403923|NCT03545438|Placebo Comparator|cohort 7|LIB003 dose 5 IV
2403924|NCT03545438|Placebo Comparator|cohort 8|LIB003 dose 3 SC - statin treated
2403925|NCT03545438|Placebo Comparator|cohort 9|LIB003 dose 4 SC - statin treated
2403926|NCT03545425||Idiopathic Parkinson's Disease patients|Up to 30 Parkinson's Disease patients will be enrolled.
2403927|NCT03545425||Healthy Controls|Up to 30 Healthy Controls will be enrolled.
2403928|NCT03545425||LRRK2 G2019S - Manifesting|Up to 30 LRRK2 G2019S Manifesting carriers will be enrolled.
2403929|NCT03545425||LRRK2 G2019S - Non-Manifesting|Up to 30 LRRK2 G2019s Non-Manifesting carriers will be enrolled.
2403969|NCT03545152|Experimental|cognitive training group|Consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
3144096|NCT00029159|Placebo Comparator|2|
2403931|NCT03545399|Experimental|Ulva Lactuca|The subject is given a capsule containing a concentrated fraction of freeze-dried and crushed hydrosoluble extract of seaweeds. The dose tested of extract of seaweeds is of 6.45mg per kg weight. The daily dose is 3 capsules per day for subjects weighing between 50 and 70kg, 4 capsules per day for subjects weighing between 70 and 90kg and 5 capsules per day for subjects weighing between 90 and 110kg. The duration of the treatment is 12 weeks.
2403932|NCT03545399|Placebo Comparator|Placebo|The subject is given a capsule looking alike that of the active product but containing no extract of seaweeds.The duration of the treatment is 12 weeks.
2403933|NCT03545386|Experimental|FMT|
2403934|NCT03545386|Placebo Comparator|Placebo|
2403935|NCT03545373|Experimental|Azithromycin|Azithromycin 500mg, oral, once daily for 3 days commencing on randomization day.
2403936|NCT03545373|Experimental|Amoxicillin|Amoxicillin 1g, oral, 3 times daily for 5 days commencing on randomization day.
2403937|NCT03545373|No Intervention|Standard of care|The standard of care in current national guidelines for patients presenting with cough and without danger signs (No treatment, re-evaluate with sputum results)
2403938|NCT03545360|Experimental|Treatment Group|Treated group of subjects, serves as its own control
2403939|NCT03545347|Experimental|Nandrolone Decanoate|Physical therapy with strength training, protein-rich nutritional supplement plus Nandrolone decanoate.
2403940|NCT03545347|Placebo Comparator|Placebo (Sodium Chloride)|Physical therapy with strength training, protein-rich nutritional supplement plus placebo.
2403941|NCT03545334|Experimental|Comparison result lymphoscintigraphy with ICG lymphography|"The patient first receives a standard Tc-99m-based lymphoscintigraphy. The identified lymph nodes are not marked in the patients, so that the surgeons are not affected in lymph node identification during ICG and near infrared fluorescence imaging. The surgeon also has no access to lymphoscintigraphy images.~Transcutaneous ICG lymphography is then performed by intradermal injection of ICG around the scar of the primary tumor excision and transcutaneous fluorescence evaluation with the Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD) and results are compared."
2403942|NCT03545321|Experimental|MOON+|MOON+ includes pharmacist online training on opioid safety and naloxone provision, academic detailing of the pharmacy, materials for use at the pharmacy, standardized overdose response safety protocols, and reminder tools for training reinforcement
2403943|NCT03545295|Experimental|QLB 2 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 10 ml coloring solution
2403944|NCT03545295|Experimental|QLB 2 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 20 ml coloring solution
2403945|NCT03545295|Experimental|QLB 2 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 2 with 30 ml coloring solution
2403946|NCT03545295|Experimental|QLB 3 10ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 10 ml coloring solution
2403947|NCT03545295|Experimental|QLB 3 20ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 20 ml coloring solution
2403948|NCT03545295|Experimental|QLB 3 30ml|The cadaver will receive an ultrasound- guided Quadratus Lumborum Block type 3 with 30 ml coloring solution
2403949|NCT03545282|Experimental|ALMA Intervention Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention after baseline assessment.
2403950|NCT03545282|Other|ALMA Delayed Intervention Control Group|Amigas Latinas Motivando el Alma (ALMA). This group receives the intervention five months after the baseline assessment (after the post-intervention, and 3 month assessments have been completed).
2403951|NCT03545269|Experimental|CartiLife®|
2403952|NCT03545269|Active Comparator|Microfracture|
2403954|NCT03545243|Other|Pantoprazole 40mg in healthy volunteers|Peroral Pantoprazole 40mg once daily for 4 weeks
2403955|NCT03545243|Other|Pantoprazole 40mg in functional dyspepsia|Peroral Pantoprazole 40mg once daily for 4 weeks
2403956|NCT03545243|Other|PPI-withdrawal in functional dyspepsia|no PPI for 8 weeks
2403957|NCT03545230|Experimental|"children who recieved Four Not Techniques surgery"|":Four Not Techniques"
2403958|NCT03545217|Experimental|intervention group|
2403959|NCT03545217|No Intervention|control group|
2403960|NCT03545204|Other|Intervention Clusters|Community based Kangaroo Mother Care,KMC package in low birth weight infants of randomly selected union councils.
2403961|NCT03545204|Other|Control clusters|Essential newborn and routine standard care in low birth weight infants of randomly selected union councils.
2403962|NCT03545191|Experimental|ACT-541468 25 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2403963|NCT03545191|Experimental|ACT-541468 50 mg|ACT-541468 will be administered as tablets, orally, once daily in the evening.
2403964|NCT03545191|Placebo Comparator|Placebo|Matching placebo will be administered as tablets, orally, once daily in the evening.
2403965|NCT03545178||Diabetic patients using CGM/FGM|Evaluation of glucose control and application of hypoglycemia prediction models in diabetic patients wearing CGM and/or FGM devices for at least 50% of the time during the last 4 weeks prior to the medical consultation.
3184848|NCT00728975||6|Vancouver Coastal Richmond Palliative Care Program patients
2403967|NCT03545152|No Intervention|comparison group|No procedure conducted between the pre- and the post-test evaluations, and they received an abridged version of the training after the post-test session.
2403968|NCT03545152|Experimental|exercise group|The exercise program will include instructions on how to read the program, complete the activities, record their sessions, and exercise safely at first day. To promote incorporating exercising in their daily life routine during the 24-week period, we provided 2 group-based (5-8 participants with 2 instructors at community centers, 60' each) and one home-based (with the exercise program VCD and manual to bring home, 30') exercise program.
2403970|NCT03545139|Experimental|NeoMTA (intervention group)|Revascularization with NeoMTA as coronal plug.
3184849|NCT00728975||7|Vancouver Coastal Lions Gate Palliative Care Unit inpatients
3184850|NCT00728975||8|Providence Health St Paul's Hospital Palliative Care Unit inpatients
3184851|NCT00728975||9|Providence Health Marion Hospice inpatients
2403971|NCT03545139|Active Comparator|White MTA (Control group)|Revascularization with Conventional white mineral trioxide aggregate (White MTA) as coronal plug.
3144097|NCT00029198|Experimental|1|15 minute massage tid
3144098|NCT00029198|Sham Comparator|2|non-massage touch
3144099|NCT00029913||1|Observation of participants includes a physical exam and collection of fluids. Study visits occur at Days 0, 7, 14, 28 and at Months 2, 3, 6 and every 6 months thereafter.
2403975|NCT03545113|Experimental|Upper extremity arteriovenous graft (AVG) - first|Participants randomized to receive an AVG will undergo surgery to have an AVG placed.
2403976|NCT03545113|Active Comparator|Upper extremity arteriovenous fistula (AVF) - first|Participants randomized to receive an AVF will undergo surgery to have an AVF created.
2403977|NCT03545100|Experimental|experimental group|motor control therapy
2403978|NCT03545100|Active Comparator|control group|regular physical therapy
2403979|NCT03545087|Experimental|Lanabecestat Control|Lanabecestat administered orally to participants with normal renal function
2403980|NCT03545087|Experimental|Lanabecestat Severe Renal Impairment|Lanabecestat administered orally to participants with severe renal impairment, not on dialysis
2403981|NCT03545074|Experimental|Mindfulness Spanish|The MAPs program was developed at UCLA (Winston & Smalley, 2010 and Lopez-Maya, 2016) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
2403982|NCT03545074|Experimental|Mindfulness English|The MAPs program was developed at UCLA (Winston & Smalley, 2010) and provides experiential training in mindfulness-based practices, including mindfulness meditation. UCLA-certified instructors delivered the interventions. Active program components include sitting and walking meditations, body scan and loving-kindness meditation. Participants were provided with audio CDs or digital downloads to complete their daily meditation assignments. Sessions were held once per week for 2 hours per session over a period of six consecutive weeks. Home practice assignments consist of daily mindfulness exercises starting with 5 minutes daily, progressing to 20 minutes daily by the end of the program.
2403983|NCT03545074|Active Comparator|Health Education Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
2403984|NCT03545074|Active Comparator|Health Education English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general. Similar interventions have been described elsewhere (Black, et al., 2014; Irwin, et al., 2014). A trained health educator provided videos and didactic presentations on topics such as: stress, sleep hygiene, diet & nutrition, sexuality, mental health and substance abuse. The health education condition resembled the MAPs intervention in terms of duration, group format and support, attention and participant expectancy regarding health benefits.
2403985|NCT03545048|Experimental|Intervention arm|"Interventional groups will have an assessment session with the experienced staff and NRS, QST, WOMAC, MSK-HQ, 30CST, TUG, PSQI, MSK-USS, urine and blood samples will be taken at baseline. Those who consent for aspiration of synovial fluid will go through the USGA procedure.~Interventional group will shortly after that receive a link via email, which will be used to log-in to Joint Academy online portal. After log-in has been achieved, the intervention starts. It consist of a 6-week internet-based physical therapy program. Interventional group will be given actigraphy device (a device to monitor sleeping pattern) which is CE marked. Therefore, their sleeping pattern can be recorded quantitatively.~Once exercises programme is finished in six weeks, the participants will fill in the same questionnaire and perform the physical tests, to enable evaluation."
2403986|NCT03545048|No Intervention|Control arm|Control group will continue with their routine self-management which is offered in the community setup. They will be assessed on NRS, QST, WOMAC, MSK-HQ, PSQI, 30CST, TUG, isometric muscles strengthen of quadriceps, MSK-USS, muscle mass of vastus lateralis, urine and blood samples at baseline. Control group will also get the actigraphy to monitor sleeping pattern of that group. They will be re-assessed after six weeks on the primary objective measures to see if they have made any difference by following self-management strategies in the community.
2403987|NCT03545035||Study group|All patients being observed during the study duration.
2403988|NCT03545022|Active Comparator|Active acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle.The needle measuring 0.25x30mm was used as an active needle. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle as well as the placebo needle were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
2404026|NCT03544723|Experimental|Ad-p53 with anti-PD-1/anti-PD-L1 100% of patients|Up to 40 patients, all patients treated with intra-tumoral Ad-p53 (dose determined by tumor size) in combination with IV physician's choice of approved immune checkpoint inhibitor
2404164|NCT03543657|Active Comparator|Darbepoetin alfa group|Subjects in the darbepoetin alfa group will receive molidustat placebo and darbepoetin alfa.
3144104|NCT00030186|Experimental|Cycle 1|60mg
3144105|NCT00030186|Experimental|Cycle 2|80mg dependent upon response to Cycle 1
3144106|NCT00030186|Experimental|Cycle 2b|40mg dependent upon response to Cycle 1
2403989|NCT03545022|Placebo Comparator|Placebo acupuncture|For both types of treatment, 0.25x30mm stainless steel needles were used (Dux, Brazil).The protocols were differentiated by needle size, in which the placebo needle is not inserted into the patient's skin and has an identical appearance to the active needle. In the placebo needle, the needles were cut in 5mm, to measure 0.25x25mm. The needles were inserted partially into an opaque guide tube filled with condensation silicone. This process was used to simulate the needle insertion for the patient and the acupuncturist and for the needle support. The active needle, as well as the placebo needle, were attached to the skin with an adhesive pedestal to hold the needle in place, even without inserting it into the skin.
2403990|NCT03545009|Experimental|Beetroot Juice|
2403991|NCT03545009|Active Comparator|Beetroot Juice no Nitrate|
2403992|NCT03545009|Active Comparator|Sodium Nitrate|
2403993|NCT03545009|No Intervention|Control|
2403994|NCT03544996||TD Insulin Pilot|Test of novel transdermal insulin (TD Insulin) formulations
2403995|NCT03544983|Experimental|Proactive Outreach + Web Counseling|Web + Streamlined Telephone Genetic Counseling
2403996|NCT03544983|No Intervention|Usual Care|Participants in the usual care arm will not be provided with access to the web-based intervention nor will they have access to streamlined genetic counseling. They can pursue clinical genetic counseling on their own.
2403997|NCT03544944|Experimental|TJP-008-1|
2403998|NCT03544944|Experimental|TJP-008-2|
2403999|NCT03544944|Active Comparator|Coolprep powder|
2404000|NCT03544931|Experimental|Root Instrumentation + EMD Application|"Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.~In this group, at the end of the instrumentation enamel matrix derivatives is placed in all sites with a periodontal pocket depth deeper than 5mm."
2404001|NCT03544931|Active Comparator|Root Instrumentation|Periodontal treatment is delivered with ultrasonic instrumentation performed with fine tips. The approach chosen is the one-stage full-mouth ultrasonic debridement in which all the treatment of diseased sites is performed within one hour.
2404002|NCT03544918||Patients with long QT syndrome.|Patents with Long QT syndrome hospitilized. To be followed over time with no intervention. Observational study.
2404003|NCT03544918||Patients in Telemark with normal QT time|Patients in Telemark with normal QT time. To be followed over time with no intervention. Observational study.
2404004|NCT03544905|Experimental|Dose escalation study of CYH33|To determine the maximum tolerated dose (MTD) of CYH33
2404005|NCT03544892|Experimental|Experimental: Low carbohydrate diet|
2404006|NCT03544892|Active Comparator|Experimental: Standard of care diet|
3184852|NCT00728975||10|Vancouver Island Health Authority Victoria Hospice inpatients
3184853|NCT00728975||11|Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
2404009|NCT03544853|Experimental|Prosthetic socket evaluation|Intervention: Prosthetic socket for transtibial amputee. A subject's conventional prosthetic socket is compared to a novel prosthetic socket designed as part of the research. For standing and walking exercises the following will be assessed. 1) local skin contact pressures, 2) metabolic power, 3) gait parameters (symmetry indices for joint angles, positions, torques, and also ground reaction forces), and 4) the socket evaluation questionnaire.
2404010|NCT03544840|Experimental|Dynamic Standing Device|Home program using the Upsee
2404011|NCT03544827|Experimental|Atropine 0.01% then atropine 0.1%|Participants will be on topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
2404012|NCT03544827|Experimental|Atropine 0.1% then atropine 0.01%|Participants will be on topical atropine 0.1% ophthalmic solution QD OU for 1 week (7 days) and then topical atropine 0.01% ophthalmic solution QD OU for 1 week (7 days) with a washout period of 4 weeks in between each intervention
2404013|NCT03544814|Experimental|Concurrent therapy group|Icotinib combined with pemetrexed plus cisplatin.
2404014|NCT03544814|Experimental|Sequential therapy group|First icotinib and then pemetrexed plus cisplatin.
2404015|NCT03544801||sample group ,300|CSVD patients after symptomatic stroke
2404016|NCT03544801||control group,100|community population
2404017|NCT03544788|Experimental|Cirvo™ Therapy|
2404018|NCT03544775||Isolated General Anesthesia|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have not had a nerve block identified using physician billing codes.
2404019|NCT03544775||Peripheral Nerve Block|Ontario residents, aged 18 years and older, who have undergone elective ambulatory shoulder surgery in Ontario and have a nerve block identified using physician billing codes.
2404020|NCT03544762|Experimental|18F-FES PET|PET/CT
2404021|NCT03544749|Experimental|Ambu® AuraGain™ group|
2404022|NCT03544749|Active Comparator|I-gel group|
3144107|NCT00030225|Experimental|ELAD|Treatment with ELAD, extracorporeal liver assist system and standard of care
3144108|NCT00030225|Other|Standard of care (Control)|Standard of care for patients with fulminant hepatic (liver) failure
3144109|NCT00030238|Other|Active Treatment|Subjects take calcium twice daily with meals
3144110|NCT00030238|Other|Control|Subjects take placebo twice daily with meals.
3144111|NCT00030303|Experimental|vaccine|recombinant 70-kD heat-shock protein
3144112|NCT00030368|Experimental|Treatment (bortezomib, paclitaxel)|Patients receive bortezomib IV on days 2 and 9 and paclitaxel IV over 1 hour on days 1 and 8. For the first course only, patients do not receive paclitaxel on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3144113|NCT00030381|Experimental|Treatment (iododoxorubicin)|Patients receive iododoxorubicin IV over 15 minutes on days 1, 8, 15, and 22. Treatment repeats every 12 weeks for a total of 4 courses or a cumulative dose of 400 mg/m^2 in the absence of disease progression or unacceptable toxicity.
3144114|NCT00030394|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity. Patients who fail to achieve a complete hematologic response after 3 courses or a partial or complete cytogenic response after 6 courses are removed from the study.
3184854|NCT00728975||12|Fraser Health Mission Hospice inpatients
2404027|NCT03544710|Experimental|Bathing|Intervention was Preoperative bathing with antiseptic. Given warm water and a tablet soap containing chloroxylenol antiseptic. Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
2404028|NCT03544710|No Intervention|No bathing|"No intervention done for participants in this arm. They go through the routine ward procedure as below.~Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
2404029|NCT03544697||Skin expansion and repair with flaps|The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients.
2404030|NCT03544684|Experimental|Control day with no exercise|glycaemic profile will be assessed using continuous glucose monitors following a single 24-hour period in which participants performed no exercise
2404031|NCT03544684|Experimental|High intensity interval training (HIT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of high-intensity interval training (HIT) in the morning under fasted conditions
2404032|NCT03544684|Experimental|moderate intensity continuous training (MICT)|glycaemic profile will be assessed using continuous glucose monitors following a 24-hour period whereby participants performed a single bout of moderate-intensity continuous training (MICT) in the morning under fasted conditions
2404033|NCT03544671|Experimental|400 IU/d vitamin D2|Children received 1mililiter (dosage applicator) containing 400 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
2404034|NCT03544671|Experimental|800 IU7d vitmin D2|Children received 2 mililiter (dosage applicator) containing 800 IU of vitamin D2 per day. This suplement also contained: iron, vitamin A, C, and E, folic acid, niacin and vitamins B1, B2, B6 y B12. Vitamin D2, dosage form (1 mililiter), frequency (daily) and duration 16 weeks
2404035|NCT03544671|Experimental|1000 IU vitamina D3|Children received 1drop (dosage applicator) containing 1000 IU of vitamin D3 per day. dosage form (1 drop), frequency (daily) and duration 16 weeks
2404036|NCT03544671|Placebo Comparator|Multiple vitamin|Children received 1 mililiter of a supplement with multiple vitamins (dosage applicator) frequency (daily) and duration 16 weeks
2404037|NCT03544658|Experimental|Dental prophylaxis|Visit 1: tooth color assessment (by patient, dentist and spectrophotometer) and professional dental prophylaxis Visit 2: tooth color assessment (by patient, dentist and spectrophotometer)
2404038|NCT03544645|Active Comparator|control group|"This group received a printed material brochure as an educational material"
2404039|NCT03544645|Experimental|intervention group|"This group received an audiovisual material video as an educational material"
2404041|NCT03544606|Experimental|isosorbide mononitrate group|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
2404042|NCT03544606|Placebo Comparator|placebos group|70 patients induced by placebo (pyridoxine) placebo tablet of the same size and shape as the isosorbide mononitrate. administered in the posterior vaginal fornix at 36, 24 , 12 before induction
2404043|NCT03544580|Experimental|immediate implant with dentin chips|using the tooth structure presented in socket either as remaining root or as unrestorable tooth structure remove all periodontal ligaments & scraping all enamel & cementum using a stone also to cut it into slices then putting it in acid to demineralize the dentine ; then using a bone mill to transform dentine into small particles or chips to be used in jumping gap between implant & thin buccal bone
2404044|NCT03544580|Active Comparator|immediate implant with xenograft|after surgical removal of entire badly decayed tooth we immediately put implant and in jumping gap we use xenograft
2404045|NCT03544567|Experimental|Oraxol|Oraxol will be administered once daily for 3 consecutive days every week from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; additional doses of Oraxol may be administered from Week 26 onwards. Subjects may receive Oraxol until they meet 1 of the criteria for withdrawal from the study.
2404046|NCT03544554|Experimental|Intervention group and control group|This research is planned with semi experimental design
2404047|NCT03544528|Experimental|Regeneration|This treatment aims to regenerate pulp-like tissue within the root canal space after inducing an influx of stem cells from the apical papilla that results in reestablishment of pulp protective functions.
2404048|NCT03544528|No Intervention|Apexification|Traditional method. The application of Mineral Trioxide Aggregate (MTA) as an artificial apical barrier; also refer as the MTA apical plug method.
2404049|NCT03544515|Sham Comparator|Scaling and use of inactive Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an inactive fashion
2404050|NCT03544515|Experimental|Scaling and use of active Er,Cr:YSGG|Scaling and debridement with hand scalers and ultrasonic unit together with the application of the Er,Cr:YSGG laser in an active fashion
2404051|NCT03544502|Experimental|Music group|Music group (group M, n=35) patients applied CD player. One CDs were prepared with 5 children's songs (classic music) for the study. CD player opened during anesthesia induction and continued until postoperative 15 minute
2404077|NCT03544320|Active Comparator|Activity Monitoring-Waist-worn wearable|Participants in the activity monitoring-waist worn wearable group will be randomly assigned to track their activity using a Fitbit Zip for 6 months.
2404052|NCT03544502|Experimental|Silence group|"silence group (group S, n=35) patients received the independent anesthesiologist applied earplugs into the patients' ears during anesthesia induction and the earplugs were removed immediately before tracheal tube extubation.~During each measurement, noise level recordings were performed using CEL-480 Sound Level Meter Sonometre."
2404053|NCT03544502|Placebo Comparator|Noise group|"noise group (group N, n=35) patients were exposed to the ambient operating room noise.~Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.Postoperatively, Emergence delirium (ED) was assessed as a Pediatric Anesthesia Emergence Delirium (PAED) Score ≥ 10."
2404054|NCT03544489|Experimental|E-ICD Intervention|E-ICD Intervention over 3 months, consists of home walking to achieve the goal of 30 minutes on all or most of the days at moderate level intensity. E-ICD elements are: 1) exercise instructional DVD and manual, 2) exercise monitoring tools (Polar HR monitor, Digi-walker, Borg scale, and exercise logs), and 3) telephone coaching by clinic RNs. Each participant receives an exercise prescription based on the ICD information using HR cut-offs, a minimum of 4 walking sessions/week will be prescribed. Exercise maintenance: At the 3 month conclusion of the E-ICD intervention, each patient will receive an exercise prescription based on the level they were able to achieve, with guidelines about increasing exercise to reach the target of 30 minutes/walking on all or most days over the ensuing 3 months. Participants will record walking sessions each week in the exercise logs that will be collected again at 6 months.
2404055|NCT03544489|No Intervention|Usual Care|"Usual Care will receive treatment as usual from their health care clinicians with outcomes measured at baseline, 3 and 6 months. Participants will not be discouraged from physical activity, but will be asked not to change their current level of activity for 6 months while in the study. Usual care involves ICD interrogation and follow-up every 3 months, measured either in-person or with home telephonic transmissions. Because participants in usual care may choose to participate in another exercise program, we will monitor those who participate in exercise programs and use the StepWatch monitor to quantify the amount and timing of physical activity. To control for group differences in attention, investigators will telephone usual care participants requesting information about health care utilization twice during the study at 3 and 6 months."
2404056|NCT03544476|Experimental|Mobile phone TB treatment support app|Daily use of the mobile phone TB treatment support app plus usual care. Participants will be asked to self-report daily TB medication administration, side-effects when applicable, and complete the direct adherence paper-based test randomly on 3-4 days of the week during the intensive treatment phase (first two months) and then 1-2 times per week during the maintenance phase (about month 3-6).
2404057|NCT03544476|Active Comparator|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
2404058|NCT03544463|Experimental|Treated|iNAP® Sleep Therapy System Treatment Intervention
2404059|NCT03544463|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline condition
2404060|NCT03544450|Experimental|Psychosocial counselling + Enhanced usual care (EUC)|This arm receives psychosocial counselling from the counsellor as well as enhanced usual care from health worker
2404061|NCT03544450|Active Comparator|Enhanced Usual Care (EUC)|This arm receives enhanced usual care from health worker
2404062|NCT03544424||Study cohort|People over 60 years of age with a Medtronic CareLink® compatible CIED in situ recruited from the Manchester University NHS Foundation Trust, England, UK
2404063|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 1|The group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
2404064|NCT03544411|Experimental|Type 2 Diabetes Mellitus group 2|this group supplemented with 15 ml / day of olive oil and 15 ml / day of bran oil
2404065|NCT03544398|Active Comparator|exoskeleton|We will use exoskeleton type robot assisted gait training for spinal cord injury rehabilitation
2404066|NCT03544398|Active Comparator|end-effector|We will use end-effector type robot assisted gait training for spinal cord injury rehabilitation
2404067|NCT03544398|Placebo Comparator|conventional physiotherapy|
2404068|NCT03544385|Experimental|Treatment Group|
2404069|NCT03544385|Placebo Comparator|Placebo Group|
3184855|NCT00728975||13|Fraser Health Langley Hospice inpatients
3184856|NCT00729001|Experimental|Group A|Human Rotavirus Vaccine - Formulation 1
2404072|NCT03544346||Retired professional rugby players|"Rugby Players will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
2404073|NCT03544346||Retired professional rowers|"Rowers will Provide detailed demographic information Provide detailed overall health information Questionnaires Provide information on athlete's playing career; age of debut, career duration, number of seasons participated in. Provide information on concussion history. Be given a general health screen including- heart rate, blood pressure, body composition and height weight ratio.~Perform a battery of neuropsychological tests (Sound-induced flash illusion and CANTAB, NART) Provide a sample of blood."
3184857|NCT00729001|Experimental|Group B|Human Rotavirus Vaccine - Formulation 2
3184858|NCT00729001|Placebo Comparator|Group C|
2404076|NCT03544320|Active Comparator|Activity Monitoring-Wrist worn wearable|Participants in the activity monitoring-wrist worn wearable group will be randomly assigned to track their activity using a Fitbit Charge 2 for 6 months.
2404201|NCT03543332||Cardiac arrest|
3184859|NCT00729027|Experimental|25 mg/day AVE5530|
3184860|NCT00729027|Experimental|50 mg/day AVE5530|
3184861|NCT00729027|Placebo Comparator|Placebo|
3184862|NCT00729040|Active Comparator|1|Stepping Up to Health only
3184863|NCT00729040|Experimental|2|Stepping up to Health PLUS online message boards to talk with other participants
3184864|NCT00729079|Active Comparator|1|Subject will be randomly assigned to work with providers at Clinton Medical Associates
3184865|NCT00729079|Active Comparator|2|Subjects will be randomly assigned to work with providers at 1655 Elmwood AVe, Suite 125
3184866|NCT00729118|Experimental|Lenalidomide + Vorinostat|Maintenance post autologous transplant
3184867|NCT00729131||A|Control group: subjects are homozygotic for major allele for TNF-308 promoter polymorphism.
2404080|NCT03544294||Group|Consecutive patients treated with very thin stents on ULM and bifurcation
2404081|NCT03544281|Experimental|Arm A: Belantamab mafodotin+lenalidomide +dexamethasone|"Participants will receive SINGLE full dose of belantamab mafodotin as 2.5 mg/kg and 1.9 mg/kg on Day 1 of every 28-day cycle as a 30-60 min infusion.~SPLIT: belantamab mafodotin will be administered in two equal divided doses, 2.5 mg/kg SPLIT dose of a 1.25 mg/kg dose on Day 1 and a 1.25 mg/kg dose on Day 8 of each 28-day cycle.~STRETCH: belantamab mafodotin will be administered as 1.9 mg/kg dose on Day 1 of every alternate 28-day cycles (C1, C3, C5, C7 and so on.) Participants will also receive Lenalidomide 25 mg or 10 mg orally daily, on Days 1-21 of each 28 day cycle with Dexamethasone, 40 mg weekly per oral (PO)/intravenously (IV) on Days 1,8,15, & 22 of each cycle."
2404082|NCT03544281|Experimental|Arm B: Belantamab mafodotin+bortezomib+dexamethasone|Participants will receive SINGLE full dose of belantamab mafodotin as 3.4 mg/kg; 2.5 mg/kg; 1.9 mg/kg on Day 1 of each 21-day cycle. SPLIT: belantamab mafodotin will be administered in two equal divided doses: 3.4 mg/kg SPLIT as 1.7 mg/kg dose on Day 1 & 1.7 mg/kg dose on Day 8; 2.5 mg/kg SPLIT dosing as 1.25 mg/kg dose on Day 1 & 1.25 mg/kg dose on Day 8 of each 21-day cycle. STRETCH: belantamab mafodotin will be administered as single dose of 2.5 mg/kg on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 & so on), 1.9 mg/kg administered on Day 1 of every alternate 21-day cycles (C1,C3,C5,C7 and so on). Step Down(S/D) STRETCH=belantamab mafodotin 2.5 mg/kg dose will be administered on Day 1 C1 followed by 1.9 mg/kg starting dose on Day1 of alternate 21-day cycles C3 onwards (C3,C5,C7, & so on). Bortezomib will be administered at 1.3 mg/m^2 SC/IV on Days 1,4,8, & 11 of every 21-day cycle. Dex will be administered at 20 mg PO or IV on Days 1,2,4,5,8,9,11, & 12 of every 21-day cycle.
2404083|NCT03544268|Experimental|Acoustic Angiography|All clinical patients will be included in the experimental group.
2404084|NCT03544268|Experimental|Image Optimization|In addition to clinical patients, 30 participants will be recruited to aid in optimizing the imaging parameters.
3184868|NCT00729131||B|Case Group: subjects are homozygotic or heterozygotic for minor allele of TNF-308 promoter polymorphism.
3184869|NCT00729196|Experimental|1|Low-Glycemic Load Diet
3184870|NCT00729196|Active Comparator|2|Low-Fat Diet
2404088|NCT03544229|Experimental|TAK-906 Maleate 5 mg|TAK-906 maleate 5 mg, capsules, orally, twice daily (BID) for up to 12 weeks.
2404089|NCT03544229|Experimental|TAK-906 Maleate 25 mg|TAK-906 maleate 25 mg, capsules, orally, twice daily for up to 12 weeks.
2404090|NCT03544229|Experimental|TAK-906 Maleate 50 mg|TAK-906 maleate 50 mg, capsules, orally, twice daily for up to 12 weeks.
2404091|NCT03544229|Placebo Comparator|Placebo|TAK-906 maleate placebo-matching capsules, orally, twice daily for up to 12 weeks.
3184871|NCT00729209|Experimental|ARRY-371797 (Schedule 1)|
3184872|NCT00729209|Experimental|ARRY-371797 (Schedule 2)|
2404094|NCT03544177|Experimental|BFR-Walking|Interval walking training with blood flow restriction.
2404095|NCT03544177|Active Comparator|Conventional therapy|Conventional therapy
2404096|NCT03544138|Other|Hummingbird Tympanostomy Tube System (H-TTS)|"The Hummingbird Tympanostomy Tube System (H-TTS) is a disposable surgical tool designed to deliver a tympanostomy tube (ear tube) into the tympanic membrane of patients during a tympanostomy tube placement procedure."
2404097|NCT03544125|Experimental|Treatment (olaparib, durvalumab)|Participants receive olaparib PO twice a day BID for 28 days in the absence of disease progression or unacceptable toxicity. Participants then receive olaparib PO BID on days 1-28 and durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Participants may continue on therapy beyond disease progression at the discretion of the investigator.
2404098|NCT03544112||ED and OUD treatment providers and staff|"ED patients will be recruited to participate in interviews or focus groups.~ED patients who are eligible for and willing to receive ED-initiated BUP will be recruited to participate in two research visits.~Administrative and health record data will be examined to assess rates of screening, assessment, eligibility determination, etc."
2404099|NCT03544112||Community Stakeholders|"Community treatment providers/OTP leadership and program staff: Providers, leadership and staff involved in the provision of office-based BUP, community treatment, and/or at opioid treatment programs (OTPs) will be recruited to participate in the formative evaluation and the Implementation Facilitation.~Other Stakeholders: Other community leaders and members (e.g., EMS, fire department, police, local government leadership, community advocacy groups, etc.) may be recruited to participate in qualitative interviews or focus groups."
2404100|NCT03544112||Patients|ED patients will be recruited to participate in interviews or focus groups.
2404101|NCT03544099|Experimental|Pembrolizumab for NPC patients|Pembrolizumab 200 mg Q3W IV infusion, Day 1 of each 3 week cycle, for 35 cycles
2404102|NCT03544086||test group|First group is the first 10 patients
2404103|NCT03544086||study group|following 150 patients
2404104|NCT03544073|Placebo Comparator|Saline Solution for Injection|This arm will receive a one-time subcutaneous injection of 0.4mL normal saline solution at the time of embryo transfer. This arm will continue to receive all the same treatments that everyone routinely receives for the IVF cycle, e.g. estrogen and progesterone supplements.
2404105|NCT03544073|Experimental|Leuprolide Acetate|This arm will receive a one-time subcutaneous injection of 0.4U (0.2mg=0.4mL) Leuprolide acetate at the time of embryo transfer. This arm will continue to receive all the same routine treatments for the IVF cycle, e.g. estrogen and progesterone supplements.
2404161|NCT03543683||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2404162|NCT03543670|Experimental|Oncoxin-Viusid|
3184873|NCT00729209|Placebo Comparator|Placebo|
3184874|NCT00729222|Placebo Comparator|1|Placebo
3184875|NCT00729222|Experimental|2|rolofylline
3184876|NCT00729235|Experimental|1|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
3184877|NCT00729235|Experimental|2|Slow VT zone programmed with ATP therapies (therapy arm).
3184878|NCT00729261|Experimental|armA I|Patients remain intubated until the patients Glasgow coma score improves to greater than 8.
2404106|NCT03544047|Experimental|Experimental arm|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen) and Herceptin was treated in HER2 amplification patients. After 3 cycles. If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks) and Herceptin was treated in HER2 amplification patients. If the evaluation of the curative effect is SD or PD, according to the result of drug sensitivity of the class organ, combined with the clinical practice, the doctor chooses the most sensitive treatment plan, and continues the 2 cycle treatment (6 weeks).
2404107|NCT03544034|No Intervention|Pre-intervention|Routine/ standard care and retrospective chart review for identifying preventable and ameliorable Adverse drug events as baseline
2404108|NCT03544034|Experimental|Post-intervention|Hometeam toolkit interventions (including improved discharge education, proactive medication safety assessment in daily rounds and handoffs, safety briefings) applied in all hospitalist services.
2404109|NCT03544021|Experimental|CART-19|The relapsed/refractory ALL patients will receive allogenic or autologous CD19-Targeted CAR-T cells infusion after FC chemotherapy.
2404110|NCT03543995||Enuresis nocturna|Patients aged 6 to 15 years with at least one night-time wetting weekly
2404111|NCT03543995||Normal population|Patients who were admitted to the urology clinic with a complaint of abdominal or lateral pain, who had no NE and had a direct abdominal x-ray examination
2404112|NCT03543982|Experimental|Oral probiotic product|
2404113|NCT03543969|Experimental|BRAF-MEK Inhibitor Therapy|"Vemurafenib twice a day and cobimetinib daily, 3 weeks on / 2 weeks off / 3 weeks on, for an 8-week cycle.~After 8 week cycle, response to these study drugs will be analyzed based on several parameters to determine if participants will proceed in the study.~Participants will be invited for post-treatment follow-up visits for up to 5 years."
2404114|NCT03543956||Systemic Sclerosis patient|patients affected by SSc according to EULAR 2013 criteria
2404115|NCT03543943|Experimental|Individualized treatment|The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast after surgery. The ankle is held at maximal plantar flexion. Weight bearing is not allowed. After 3 weeks the cast is removed and the injured leg is transferred to a functional brace with 3 heel wedges. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2404116|NCT03543943|Active Comparator|Control group 1|For the patients allocated to non-operative treatment the injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2404117|NCT03543943|Active Comparator|Control group 2|The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below the knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle. The patient will follow standard functional rehabilitation and the follow-up evaluations.
2404118|NCT03543930||Major open vascular surgery|Surgical procedures on the abdominal aorta requiring median abdominal incision
2404119|NCT03543930||Endovascular aortic repair|Abdominal aortic repair with endovascular approach
2404120|NCT03543917|Experimental|New Medication Combination|Intervention: Combination Product: Perfusion with New Combination Medication Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
2404121|NCT03543904|Experimental|Pre-operative physiotherapy education|Pre-operative education regarding post-operative physiotherapy intervention and post-operative physiotherapy intervention in children with abdominal surgery
2404122|NCT03543904|Experimental|Post-OP PT without Pre-OP education|Post-operative physiotherapy intervention without pre-operative education in children with abdominal surgery
2404123|NCT03543891||Control group|50 healthy volunteers were included in the healthy control group
2404124|NCT03543891||Thyroid cancer group|50 patients of thyroid cancer were included
3184879|NCT00729261|Experimental|arm 2|Patients that meet standard airway and ventilatory criteria for extubation but have a Glasgow coma score of less than or equal to 8 are immediately extubated.
3184880|NCT00729274|Active Comparator|hypertonic saline solution|Hypertonic Saline 3% solution alone.
2404127|NCT03543865|Experimental|New Hope (NH)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days.~Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
2404160|NCT03543683||osimertinib and aspirin|Osimertinib starting at a dose of 80 mg once a day, orally with meals.The intervention is aspirin which is starting at a dose of 100 mg once a day, orally with meals.Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2404163|NCT03543657|Experimental|Molidustat group|Subjects in the molidustat group will receive molidustat and darbepoetin alfa placebo.
2404128|NCT03543865|Experimental|Elders' Resiliency (ER)|"The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days~All youth will complete another study assessment after 30 days. The 30-day time frame will allow ample time to complete the NH intervention with participants and assess any changes in youth's mental health status for all study arms. Following another 30-day period, all participants will be re-assessed and re-randomized, using the same blocking and 1:1 ratio to either the Elders' Resilience (ER) intervention plus CM, or CM alone. To track long term outcomes, all youth will complete a final assessment 3 month later (6 months post-enrollment)."
2404129|NCT03543865|Other|Control Condition|"The control condition will only receive Case Management (CM) (n=76).~The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type."
2404130|NCT03543865|Experimental|New Hope (NH), Elders' Resiliency (ER), Case Management (CM)|The investigators will employ a SMART design to evaluate the effectiveness of New Hope (NH), Elders' Resilience intervention (ER), Case Management (CM) and the combination of these approaches on reducing suicidal thoughts and promoting resilience among AI youth ages 10-24 who are confirmed by surveillance case managers to have experienced suicide ideation, attempt or a binge substance use and recent ideation in the past 30 days. Youth who assent will complete the baseline (CM visit 1 and will be referred to mental health care). During the same visit, youth will be randomized 1:1 to either New Hope (NH) plus Case Management (CM), or CM alone, using a blocked randomized design, stratifying participants by age and event type. All youth will complete another study assessment after 30 days.After another 30-days, all participants will be re-assessed/re-randomized, using the same blocking and 1:1 ratio to either the ER intervention plus CM, or CM alone.
3144115|NCT00030407|Experimental|Celecoxib & Docetaxel|"Celecoxib: On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals~Docetaxel: On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days."
3144116|NCT00030420|Experimental|Celecoxib & Docetaxel|"Celecoxib: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.~Doctaxel: Day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days"
2404136|NCT03543826|Other|Protocol|Patients will have perioperative nuromuscular block managed by protocol. The protocol includes specified appropriate rocuronium dosing and reversal with either neostigmine or sugammadex depending on depth of block as assessed subjectively at adductor pollicis with standard train-of-four stimulation of the ulnar nerve.
2404140|NCT03543800|Experimental|ABP|(test treatment)
2404141|NCT03543800|Active Comparator|PRP|(active control)
2404142|NCT03543787|Active Comparator|Health IT and Peer Support Intervention|Utilise electronic decision support, tracking of referral list and Peer facilitation for referral completion
2404143|NCT03543787|No Intervention|Non intervention group|2014 - 2018 MoH referral protocol
2404144|NCT03543774|Active Comparator|simvastatin treatment|
2404145|NCT03543774|Sham Comparator|EZE/simvastatin 10/20 mg treatment|
2404146|NCT03543774|Sham Comparator|EZE/simvastatin 10/40 mg treatment|
2404147|NCT03543761|Sham Comparator|A|Sham group
2404148|NCT03543761|Active Comparator|B|LiST active treatment group
2404149|NCT03543761|Active Comparator|C|LiST active treatment group
2404150|NCT03543748|Experimental|TMS|The Transcranial Magnetic Stimulation course consisted of daily sessions of 2,000 stimuli for the left DLPFC (50 trains of 40 stimuli at 10 Hz for 10 days),
2404151|NCT03543748|Sham Comparator|SHAM|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
2404152|NCT03543735|Experimental|Wisepill+SMS|
2404153|NCT03543735|Active Comparator|Wisepill-only|
2404154|NCT03543735|No Intervention|Disulfiram-only|
3144117|NCT00030498|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3144118|NCT00030576|Experimental|OSI-774 and cisplatin|HNSCC patients treated in three escalating dose cohorts of daily continous oral erlotinib (OSI-774) and intermittent IV cisplatin given every 21 days
2404157|NCT03543709||Behcet and fibromyalgia|Women with Behcet's disease with fibromyalgia
2404158|NCT03543709||Behcet|Women with Behcet's disease without fibromyalgia
2404159|NCT03543696|Experimental|Single Dose Radiotherapy (SDRT)|Single Dose Radiotherapy (SDRT) at a prescription dose of 24 Gy to all detectable metastatic lesions
3184881|NCT00729274|Placebo Comparator|nebulized normal saline solution|2 nebulisation with 30 minute interval (max 4ml)
3184882|NCT00729287|Placebo Comparator|Arm I|Patients receive oral placebo daily in addition to standard care.
2404165|NCT03543644|Active Comparator|Sugar-sweetened beverage (SSB)|"The SSB intervention will consist the participants' consuming their usual serving of cans SSBs (each 355 ml, 42 grams sugar) per day. The calories of the SSB group will not be matched to allow for real-world substitutions using products available on the market."
2404166|NCT03543644|Experimental|Non-nutritive sweetened beverage (NSB)|"The NSB intervention consists of substituting the participants' usual serving of cans SSBs with NSBs (each 355 ml, 0 grams sugar) per day. The calories of the NSB group will not be matched to allow for real-world substitutions using products available on the market."
2404167|NCT03543644|Experimental|Water|"The water intervention consists of substituting the participants' usual serving of cans SSBs with bottles or cans of still or sparkling water (each 355 ml bottle or can, 0 grams sugar) per day. The calories of the water group will not be matched to allow for real-world substitutions using products available on the market."
2404168|NCT03543618|Sham Comparator|Control|Installation of conventional design dental implant
2404169|NCT03543618|Active Comparator|Sloped|Installation of sloped design dental implant
2404170|NCT03543605|Experimental|PROA Experimental|"It consists of the intervention measures described in the general antimicrobial stewardship program (PROA Control) plus clinical advice.~The clinical assessments have been adapted for this project to the unique characteristics of infectious diseases in nursing homes.~These are individual training activities whose main objective is to modify prescribing behaviors when they are inadequate and reinforce them when they are correct.~They are carried out between the medical adviser, an expert in infectious diseases, and the doctor of the nursing home, through the structured review of a case attended by the doctor in the last 24 hours. The recommendations are not compulsory, and do not seek to change the decisions made in that patient, but the future ones in the case that is necessary.~The counseling will be done by video-conference, with an approximate duration of 10 minutes. Each of the doctors will receive two monthly assessments during the intervention period."
2404171|NCT03543605|Other|PROA Control|"The intervention of the general antimicrobial stewardship program (PROA) contains the following set of measures:~Creation of the local team of the PROA: one of the Family Physicians responsible for the patients and the pharmacist of the reference hospital of the center.~Presentation of the project by the local team in its own center.~Choice of the Aljarafe guide as a reference document for the diagnosis and treatment of infectious diseases. It is an accredited guide and widely disseminated among primary care and hospital doctors.~Permanent information of the project (poster with its synthesis, a pocket triptych with the guide for the clinical management of the main clinical syndromes of infections in the residents of the nursing homes).~Feedback of the results that will serve each center to know the evolution of its results, and to stimulate the comparison with the other centers."
2404172|NCT03543592|Other|3 dimensional power Doppler|100 women suffering post-menopausal bleeding (occurred after at least 12 months of amenorrhea) will be included in the study and 3 dimensional ultrasonography and Doppler will be done for them
2404173|NCT03543579||Multiple myeloma patients|Patients with multiple myeloma and an indication to receive carfilzomib
2404174|NCT03543553||SZ|Individuals with a diagnosis of schizophrenia
2404175|NCT03543553||HC|Healthy control participants
2404176|NCT03543540|Experimental|Nexvax2 (Arm A)|
2404177|NCT03543540|Experimental|Nexvax2 (Arm B)|
2404178|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm C)|
2404179|NCT03543540|Placebo Comparator|Nexvax2 Placebo (Arm D)|
2404180|NCT03543527||Takayashu|
2404181|NCT03543514||PREHABILITATION GROUP|Patients affected on Cold-rectal cancer who needs surgery. We made trimodal prehabilitation
2404182|NCT03543501|Experimental|Real-time ultrasound imaging group|See intervention
2404183|NCT03543501|Experimental|PBU group|See intervention
2404184|NCT03543488||Rheumatoid Arthritis Patients|Forty women (range 25-75 years), with a class I and II RA diagnosis according to the American Rheumatism Association's 1987 revised criteria, were recruited from a university hospital's rheumatology clinic. Exclusion criteria included the presence of any cardiovascular, neuromuscular and metabolic diseases or severe limitations in mobility. Five patients were excluded for not attending the inclusion criteria, leading to a final number of 35 RA patients.
2404185|NCT03543488||Healthy Women|Thirty-five healthy women, age- and body size-matched to the RA patients, were recruited as controls (CG).
2404186|NCT03543475|Experimental|Pessary|Silicon device applied on the cervix
2404187|NCT03543475|Active Comparator|No Pessary|standard care, no pessary
2404188|NCT03543462|Sham Comparator|Arm A: Chest tube positioning YES|Patients enrolled for chest tube positioning
2404189|NCT03543462|No Intervention|Arm B: Chest tube positioning NO|Patients enrolled for diaphragm closure without chest tube positioning
2404190|NCT03543436|Experimental|Intravenous temocillin|Intravenous temocillin 2g/intravenously/8h or renally adjusted equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h)
2404191|NCT03543436|Active Comparator|Intravenous meropenem or imipenem|Intravenous meropenem or imipenem 1g/Intravenously /8h ORAE in 15-30 min infusion. Then switch to oral therapy
2404192|NCT03543423|Experimental|Oral glucose tolerance test|Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.
2404193|NCT03543423|Experimental|Liquid mixed meal test|Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min
2404194|NCT03543410|Experimental|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
2404195|NCT03543410|Experimental|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets)
2404196|NCT03543410|Placebo Comparator|Placebo|Placebo (supplied in two tablets/day
2404197|NCT03543371||Cardiac Arrest survivors|Cardiac arrest survivors at selected TTM2-sites only.
2404198|NCT03543371||Myocardial Infarction patients|A control group from a cohort of patients with myocardial infarction with performed coronary angiography but no occurrence of cardiac arrest will be recruited at 1:1 ratio.
3184883|NCT00729287|Experimental|Arm II|Patients receive oral selenium daily in addition to standard care.
3184884|NCT00729300|Placebo Comparator|1|Placebo
3184885|NCT00729300|Experimental|2|disulfiram
2404204|NCT03543254|Experimental|BoNT-A injected|BoNT-A (Botulinum toxin A) injected in the head on specific sites and in half the usual concentration
2404205|NCT03543241||MyoStrain|Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.
2404206|NCT03543228||MyoStrain|During standard chemotherapy and/or targeted treatment for breast cancer or lymphoma, MyoStrain will be used during standard cardiac magnetic resonance imaging to evaluate the change in myocardial contraction regionally and globally to detect cardiotoxicity and management of myocardial dysfunction.
2404207|NCT03543202|Experimental|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
2404208|NCT03543202|Active Comparator|Local infiltration anesthesia|will receive 20ml bupivacaine for Local infiltration anesthesia and intravenous patient controlled analgesia
2404209|NCT03543202|Sham Comparator|Intravenous patient control analgesia|will not receive any regional anethetic intervention will receive intravenous patient controlled analgesia
2404210|NCT03543189|Experimental|Combination Therapy|Post androgen deprivation therapy (ADT), participants will receive nivolumab, HDR brachytherapy and external beam radiation therapy, followed by a 2 year follow-up period.
2404213|NCT03543163|Active Comparator|subepithelial connective tissue graft|Subepithelial Connective Tissue graft from the hard palate with Coronally Advanced flap at the site of gingival recession.
2404214|NCT03543163|Experimental|non pedicled buccal fat pad graft|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap at the site of gingival recession
2404215|NCT03543150||Subjects receiving BOTOX|Subjects with a diagnosis of spasmodic dysphonia, for which BOTOX is indicated, will be included.
2404218|NCT03543124|Active Comparator|Water exchange (WE)|This group will have the air in the colon removed and replaced with water to guide the insertion of the colonoscope.
2404219|NCT03543124|Experimental|WE plus cap(WECAC)|The procedure of this group is similar with WE group, except a cap will be fitted onto the end of the colonoscope.
2404220|NCT03543111|Experimental|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
2404221|NCT03543111|No Intervention|Control|No intervention
2404222|NCT03543098|Experimental|Early Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and early rehabilitation.
2404223|NCT03543098|Experimental|Early Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to early surgery and delayed rehabilitation.
2404224|NCT03543098|Experimental|Delayed Surgery & Early Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and early rehabilitation.
2404225|NCT03543098|Experimental|Delayed Surgery & Delayed Rehab|Individuals with a MLKI that present within 6 weeks of injury will be randomized to delayed surgery and delayed rehabilitation.
2404226|NCT03543098|Experimental|Early Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only early rehabilitation.
2404227|NCT03543098|Experimental|Delayed Rehab Only|Individuals not eligible for randomization to timing of surgery will be randomized to only delayed rehabilitation.
3144119|NCT00030615|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 30 minutes on days 1-5 weekly for 4 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
2404229|NCT03543072||exposure group|exposed to some factors
2404230|NCT03543072||control group|not exposed to some factors
2404231|NCT03543059||exposure group|exposed to some factors
2404232|NCT03543059||control group|not exposed to some factors
2404233|NCT03543046|Experimental|Tortle Midliner|The use of the Tortle Midliner will be in addition to the NICU department process guidelines for positioning relevant to the gestational age of the subject. The Tortle Midliner will be applied no later than 3 hours following birth under the supervision of a study investigator. The size/fit and application of the device will be according to the manufacturer's guidelines. The neutral midline head position, supine or slightly side-lying, with a bed elevation between 15° and 30° will be maintained during the first 72 hours of life.
2404234|NCT03543046|No Intervention|Control Group|All clinical care for the control group will be within NICU department process guidelines relevant to the gestational age of the subject and as ordered by physician and/or ARNP providers. The neutral midline head position with the aid of nesting and/or rolls with a bed elevation between 15° and 30° will be maintained throughout position changes during the first 72 hours of life, which is standard practice. Caregivers will document the NICU integrated flowsheet and the Sunrise electronic record with interventions regarding positioning, handling, skin assessment etc. per standard practice requirements.
2404235|NCT03543033|Experimental|Treatment|Patients will receive a corticosteroid epidural injection within 2 weeks of their scheduled lumbar surgery
2404236|NCT03543033|No Intervention|Control|Patients will not receive a corticosteroid injection within 2 weeks of their scheduled lumbar surgery.
2404237|NCT03543020||Patients|Patients undergoing Radiation therapy to brain
3144120|NCT00030628|Experimental|radiosurgery|"Patients undergo radiosurgery.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years."
3144121|NCT00030628|Experimental|radiosurgery + WBRT|"Patients undergo radiosurgery. Within 14 days, patients then undergo whole brain radiotherapy 5 days a week for 2.5 weeks.~Quality of life is assessed at baseline, the beginning of each treatment, at week 6, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 2 years.~Patients are followed at weeks 6 and 12, every 3 months for 9 months, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter."
3144122|NCT00030654|Experimental|Androgen blockade + immediate chemotherapy|Androgen blockade with immediate chemotherapy
3144123|NCT00030654|Experimental|Androgen blockade + delayed chemotherapy|Androgen blockade with delayed chemotherapy
3144124|NCT00030667|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3144125|NCT00030693|Experimental|Arm I (recombinant fowlpox-B7.1 vaccine)|Patients receive rF-B7.1 vaccine intratumorally on day 1.
3144126|NCT00030693|Experimental|Arm II (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM vaccine intratumorally on day 1.
3144127|NCT00030732|Active Comparator|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
3144128|NCT00030732|Active Comparator|Gemcitabine alone|Gemcitabine alone
3144129|NCT00030771|Active Comparator|Arm A|Neoadjuvant Chemoradiotherapy + Chemotherapy + Surgery
2404247|NCT03542981|Active Comparator|Interferential Current Treatment|Interferential Current group received interferential current treatment 30 minutes, 2 times a day for 5 days after the surgery.
2404248|NCT03542981|Sham Comparator|Sham Interferential Current Treatment|In the sham interferential Current treatment, no electrical stimulation was applied to the probes with the same pads for the same time.
2404249|NCT03542968|Experimental|4D magnetic resonance imaging|MRI, 4D imaging, acquisition and analysis of 4D cardiac MRI images-A single, faster acquisition (8 to 15 minutes).
2404250|NCT03542968|Sham Comparator|2D magnetic resonance imaging|MRI, 2D imaging, acquisition and analysis of 2D cardiac MRI
2404251|NCT03542955|Active Comparator|ActiPatch Group|Subjects in this group will receive an active pulsed shortwave therapy device to wear 24 hours a day for 4 weeks.
2404252|NCT03542955|Placebo Comparator|Control Group|Subjects in this group will take Etoricoxib 60mg, once daily for 4 weeks.
2404253|NCT03542942|Other|treatment with EXIT-target volume|The radiotherapeutic treatment plan is based on an EXIT-target volume in which the non-involved uterus is excluded from the target volume. All other delineations are performed conform standard of care.
2404254|NCT03542929|Active Comparator|healthy elderly|healthy elderly were use the Whole body vibration intervention during 10 minutes
2404255|NCT03542929|Experimental|diabetic elderly|diabetic elderly were use the Whole body vibration intervention during 10 minutes
2404256|NCT03542916|Experimental|CJ-40001|CJ-40001 60ug SC, IV injection
2404257|NCT03542916|Active Comparator|NESP|NESP 60ug SC, IV injection
2404258|NCT03542903|Active Comparator|Short ECT arm|In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
2404259|NCT03542903|Active Comparator|Long ECT arm|In the long arm, bitemporal ECT is administered twice a week during the first 12 weeks. Afterwards, it is administered once a week during 8 weeks. After that, the patients will have one ECT every 3 weeks during 12 weeks. Lastly, patients will receive one ECT each month during 4 months.
2404260|NCT03542890||Baska Mask|It has a non-inflatable cuff, which is moulded to take up the shape of the supraglottic airway, potentially reducing the risk of oropharyngeal tissue and/or nerve damage induced by cuff over inflation, a known complication with other supraglottic airways.
2404261|NCT03542890||I-gel|The I-gel is a single use (SADs) composed of a soft ,gel-like, non-inflatable cuff made from a thermoplastic elastomer. It has a widened , flattened stem with a rigid bite block that acts as a buccal stabilizer to reduce axial rotation and mal-positioning and a port for gastric tube insertion. It is a latex free device that does not require digital insertion into mouth of patient.
2404262|NCT03542877|Experimental|Stage 1|Up to 16 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks. If less than three patients have Progression Free Survival (PFS) lasting at least 12 weeks, the study will be terminated.
2404263|NCT03542877|Experimental|Stage 2|Up to 28 patients will be enrolled to take 60mg of cabozantinib, by mouth, once a day, every day, for 12 weeks.
2404264|NCT03542864|Experimental|Nasogastroduodenal Protocol|Evaluation of a protocol for the treatment of excess body fat through duodenal nutrition
2404265|NCT03542864|Active Comparator|Controls|Change from Baseline Body Composition values at 1 and 3 months
2404266|NCT03542864|Other|Data analysis|Analysis and publication of data
2404267|NCT03542851|Experimental|Subject Receives BTD001 first|
2404268|NCT03542851|Experimental|Subject Receives Placebo first|
2404269|NCT03542838|Experimental|Resiniferatoxin|Resiniferatoxin is administered as a one-time dose, intra-articularly at a dose level of 5ug, 12.5ug, 20ug, 25ug, or 30ug.
2404270|NCT03542838|Placebo Comparator|Saline|Saline is administered as a one-time dose, intra-articularly.
2404271|NCT03542825|Active Comparator|Iron Sulphate|ferrous sulphate 150 mg iron capsule once daily for 3 consecutive months.
2404272|NCT03542825|Active Comparator|Amino acid Chelated|amino acid chelated iron capsule 15mg for 3 consecutive months.
2404273|NCT03542825|Active Comparator|Lactoferrin|lactoferrin 100 mg sachets once daily for 3 consecutive months.
2404274|NCT03542812|Experimental|Single-dose|"Participants will be enrolled into the two groups, Group 1 (which will consist of 10 participants) and Group 2 (which will consist of 8 participants) in an alternating basis. Both Group 1 and Group 2 participants will receive a single, 150 mg/kg dose of oral L-citrulline. Population PKs will be done for both groups, at up to 3 time points.~Multiple interim time points and following completion of enrollment into Groups 1 and 2, data analysis will be done and results reviewed by the data safety monitoring board (DSMB). After the DSMB review is complete, enrollment into Group 3 will begin."
2404325|NCT03542409|Experimental|Group A (contrast enhancing tumor)|Group A patients will undergo standard tumor preoperative imaging and MR perfusion scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with MR perfusion scan during surgical resection.
2404326|NCT03542409|Experimental|Group B (non-enhancing tumor)|Group B patients will undergo standard tumor preoperative imaging and 2HG spectroscopy scan prior to surgical resection. Group A patients will undergo standard intraoperative imaging along with 2HG spectroscopy scan during surgical resection.
3144130|NCT00030771|Active Comparator|Arm B|Neoadjuvant Chemotherapy + Surgery
3144131|NCT00030797|Active Comparator|Arm A|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
2404275|NCT03542812|Experimental|Steady-state|To evaluate the tolerability and ability to achieve target trough L-citrulline levels of 100-150 µM, an additional group of 18 infants (group 3) will be given oral L-citrulline doses at intervals over a total of 72 hours. If the participant is not nipple feeding, the dose will be delivered via the participant's indwelling gavage feeding tube. The dose and interval of L-citrulline will be based on results from the studies that assess pharmacokinetic parameters using a maximum daily dose of 3 g/kg/d. Blood draws for PKs will be done at baseline and prior to last dose of L-citrulline. Urine will be collected to measure nitric oxide metabolites.
2404276|NCT03542799|Experimental|3|anti-tumor response of EGFR IL12 CART
2404277|NCT03542786|Experimental|i3.1|This group will have their habitual antiretroviral therapy (integrase inhibitor (INI), protease inhibitor (IP), reverse transcriptase inhibitor (ITINAN)) combined with the research product (probiotic i3.1). The prebiotic will be taken once a day during 6 months.
2404278|NCT03542786|Experimental|i3.1 + ProSeed|This group will have their habitual antiretroviral therapy combined with the probiotic (i3.1) and the prebiotic (ProSheed). The prebiotic and probiotic will be taken once a day during 6 months.
2404279|NCT03542786|Placebo Comparator|Placebo|This group will only have their habitual antiretroviral therapy. The placebo will be taken once a day during 6 months.
3144132|NCT00030797|Active Comparator|Arm B|Irinotecan i.v. 240 mg/m2 day 1 and day 22; Capecitabine p.o. 2 x 1000 mg/m2, d1-14, d22-35;
2404281|NCT03542760||Primary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia that is symptomatic (eg, exhibiting sleepiness, cyanosis, dizziness, etc) or with measured methemoglobin levels > 30%.
2404282|NCT03542760||Secondary Treated Group|Subjects who are administered methylene blue for treatment of acquired methemoglobinemia with measured methemoglobin levels ≤ 30 and lack of clinical symptoms
2404283|NCT03542747|Experimental|Time to ventilation with the iLTS|Measuring the time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
2404284|NCT03542747|Experimental|Time to ventilation with the Fastrach|Measuring time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
2404285|NCT03542734||Individuals with SVDs|Individuals with at least one following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
2404286|NCT03542734||Individuals without SVDs|Individuals without any following imaging finding: recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, or brain atrophy on baseline brain MRI.
2404287|NCT03542721|Placebo Comparator|Placebo of DA-5515 Capsule|Placebo of DA-5515 (three times a day)
2404288|NCT03542721|Experimental|DA-5515 Capsule|Garlic oil, Gingko biloba ex.,Crataegus berry ex.,Melissa officinalis ex., (three times a day)
3144133|NCT00030914|Experimental|Arm I: venlafaxine|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive oral venlafaxine once daily for 6 weeks beginning on day 8. After week 7, patients with satisfactory efficacy may continue venlafaxine for up to 6 months. Patients with unsatisfactory efficacy may cross over to arm III.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
3144134|NCT00030914|Experimental|Arm II: medroxyprogesterone - long term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone intramuscularly (IM) on days 8, 22, and 36 for a total of 3 injections. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
2404292|NCT03542682|Active Comparator|Individuals given Standard Bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
2404293|NCT03542682|Active Comparator|Individuals given Quick bolus|Individuals with Type 1 Diabetes (T1D) will receive both Standard and Quick Bolus in a randomized cross-over design.
2404295|NCT03542656|Experimental|amyloid PET|PET/CT
2404296|NCT03542643|Active Comparator|N-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 1g of Eicosapentaenoic acid(EPA)
2404297|NCT03542643|Placebo Comparator|Placebo|olive oil ethyl esters
2404298|NCT03542630||fertile, without periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
2404299|NCT03542630||fertile, with periodontitis|"Women who gave birth to at least one child, without preovious fertility treatments, and who do have periodontitis.~Interventions:~salivary MMP8 test;periodontal examination;blood tests"
2404300|NCT03542630||infertile, without periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do not have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination;blood tests"
2404301|NCT03542630||infertile, with periodontitis|"Women who are diagnosed with infertility of unknown cause, and who do have periodontitis.~Interventions:~salivary MMP8 test; periodontal examination; blood tests"
2404302|NCT03542617|Placebo Comparator|Normal Saline Solution|The control group receive sterile normal saline solution, as placebo, intravenous immediately prior to induction of spinal anesthesia .
2404303|NCT03542617|Active Comparator|10 mg Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia
2404304|NCT03542617|Active Comparator|40 mg Dexamethasone|The steroid group will receive Dexamethasone 40 mg IV immediately prior to induction of spinal anesthesia
2404305|NCT03542604|Experimental|CBT-I + BWL|Cognitive behavioral therapy intervention for insomnia: 6 sessions over 8-week period combining education and behavioral techniques to reduce insomnia. Sleep intervention followed by behavioral weight loss intervention.
2404306|NCT03542604|Placebo Comparator|EDU + BWL|Program will parallel the CBT-I intervention in number and length of sessions. Intended to disseminate basic information about sleep, including behavioral treatment information that is widely available to patients and practitioners.Will be followed by behavioral weight loss intervention.
2404307|NCT03542591||Participants of the VegMed congress (Berlin, April 2018)|
2404308|NCT03542552|Active Comparator|Nifidipne|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
2404309|NCT03542552|Experimental|Magnisum sulphate|Patients in the MgSO4 group received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
2404310|NCT03542500|No Intervention|Control|Youth randomized into the control arm of this study will be quantitatively assessed at the same time points as youth randomized into the two treatment arms (baseline, 3-months, 12-months). Due to access to funding and feasibility, youth in the control arm and EPP-only arm will not have the opportunity to receive the YRI once the study period concludes. However, GIZ is conducting a phased roll out of their EPP programming, meaning they will offer their EPP throughout 2018 past their participation in Youth FORWARD. Youth will also be compensated for their participation in our quantitative assessments.
2404311|NCT03542500|Experimental|Entrepreneurship Training|Youth randomized into the Entrepreneurship Training-only arm will receive GIZ's employment programming approximately three months after the completion of the baseline assessments. The GIZ-supported Entrepreneurship Training program includes six training modules, delivered over three weeks, to include skills development, financial literacy, and other skills necessary to secure employment or engage in livelihood activities.
2404312|NCT03542500|Experimental|YRI+Entrepreneurship Training|Youth randomized into the YRI+Entrepreneurship Training arm will begin the YRI module within two weeks after the completion of baseline assessments. The YRI curriculum (12 modules), will be delivered in 12 weekly 90-minute sessions, with additional time taken as needed. These weekly sessions assume a peer-to-peer group learning format deemed culturally appropriate for a setting like Sierra Leone where limited resources for mental health services exist. Once youth complete the YRI they will complete a post-intervention (3-months) quantitative assessment. Following the completion of the quantitative assessments, youth will receive the Entrepreneurship Training.
2404313|NCT03542487|No Intervention|1: Control|A randomly selected half of primary care practices in the study sample at Inova Health Care Services will not receive any intervention and patients/physicians located at these practices will continue with business as usual.
2404314|NCT03542487|Experimental|2a: Practice Orientation- No Reminder|In the other randomly selected half of primary care practices in the study sample at Inova Health Care Services, practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2a will receive no additional reminder messaging to enter glucose measurements in the electronic flowsheets.
2404315|NCT03542487|Experimental|2b: Practice Orientation- Standard Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2b will receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets.
2404316|NCT03542487|Experimental|2c: Practice Orientation- Gift Card Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2c will receive generic biweekly reminders to enter data, addressed from Inova Medical Group, that will also notify that the patient will be entered to win a $50 gift card for each day entering data.
2404317|NCT03542487|Experimental|2d: Practice Orientation- Physician Reminder|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose. Of this group of practices, patients will be divided at the individual level into 4 reminder groups. Arm 2d will receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT).
2404319|NCT03542461|Experimental|A_Nivolumab|Nivolumab 240 mg IV every 2 weeks until disease progression, unacceptable toxicity, patient refusal or Investigator's decision
2404320|NCT03542461|Other|B_Best Supportive Care|Best Supportive Care until disease progression followed by Nivolumab at a dose of 240 mg IV until further disease progression, unacceptable toxicity, patient refusal or Investigator's decision.
2404321|NCT03542448||Study group|"97 eye of 49 normal Egyptian volunteers were divided into groups according to age, AL, SE of refractive error, minimum corneal thickness (MCT) and mean corneal power as follow:~Age into 3 groups:~Group A: from 18 to 30 years old Group B: from 31 to 40 years old Group C: > 40 years old~Axial length into 3 groups:~Group A: from 22 to less than 24 mm Group B: from 24 to 26 mm Group C: > 26 mm~Spherical equivalent of refractive error into :~Group A : from zero to - 2 D Group B : from - 2 to > - 4 D Group C : from - 4 to > - 6 D Group D: from - 6 to - 8 D~Minimum corneal thickness (MCT) into 3 groups:~Group i: < 500 um Group ii: from 500 to 540 um Group iii: > 540 um~Refractive power of cornea (Mean K) into 3 groups:~Group 1: 41 to less than 44 D Group 2: 44 to 46 D Group 3: > 46 D"
2404322|NCT03542435|Experimental|SXC-2023|Dose Escalation
2404323|NCT03542435|Placebo Comparator|Placebo|Dose Escalation
2404327|NCT03542396|Experimental|ImPuls|Participants receive an supervised exercise intervention and behaviour change techniques for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
2404328|NCT03542396|No Intervention|Control|Participants do not receive any intervention. Participants receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual psychotherapeutic treatment
2404329|NCT03542383|Active Comparator|Active HD tDCS|Administer 10 20-minute sessions of 1 mA anodal High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
2404330|NCT03542383|Sham Comparator|Sham HD tDCS|Administer 10 20-minute sessions of sham High Definition Transcranial Direct Current Stimulation to the preSMA region over a two week period.
2404331|NCT03542357|Active Comparator|Sumatriptan|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg as a pre-treatment
2404332|NCT03542357|Placebo Comparator|Placebo|headache is induced with CGRP. This headache is treated double-blinded with 1 tablet of placebo as a pre-treatment
2404333|NCT03542344|Experimental|BI 1015550|
2404334|NCT03542344|Placebo Comparator|Placebo|
2404335|NCT03542331|Other|Control group|The control group wille have a mock catheter introduction between day 6 and 8 of the cycle without any Lipiodol flush
2404336|NCT03542331|Experimental|Intervention group|The intervention group will undergo endometrial flushing with Lipiodol between day 6 and 8 of the cycle
2404337|NCT03542318||Active group (Experimental)|Total of 60 patients were enrolled. All patients were referred for PR from the outpatient clinics of the local general hospital. Pulmonary fibrosis was confirmed through a high resonance computed tomography scan and pulmonary function testing. Participants who required modifications to their drug therapy due to exacerbations were excluded from the study. Each participant was classified according to the modified Medical Research Council dyspnoea scale
2404338|NCT03542318||Inactive control group|A total of 60 patients were enrolled in a control group. All were referred for PR from the outpatient clinics of the local general hospital. In this group patients who requested not to carry out the intervention but participate in the investigations were enrolled. Each participant was classified according to the modified Medical Research Council dyspnoea scale, and placed in one of 5 categories (0 to 4) according to self-perceived breathlessness during daily activities
2404343|NCT03542292|Experimental|placental drainage group|In study group; umbilical cord was clamped from fetal side but unclamped from maternal side. After that unclamped side of umblical cord was left open to drain the blood until the flow ceased. The blood was collected in the metal bowl and measured using a measuring jar. Care was taken not to mix the drained blood from the cord with the blood lost during the third stage.
2404344|NCT03542292|Active Comparator|no placental drainage group|In control group the umblical cord was clamped both sides.
2404345|NCT03542279|Experimental|Early PE group|PE (3-5 times in each course) combined with high-dose glucocorticoid, and IVIG after PE.
2404346|NCT03542279|Active Comparator|Non-early PE group|IVIG (0.4 g/kg/d for each course for 5 d) combined with high-dose glucocorticoid, and PE after IVIG 2 weeks.
2404348|NCT03542253||Age|
2404349|NCT03542253||Sex|
2404350|NCT03542253||triglyceride|
2404351|NCT03542253||Lipoprotein|
2404352|NCT03542253||CT|Target Reconstruction
2404353|NCT03542253||micorRNA-A Plasma exocrine|
2404354|NCT03542253||micorRNA-A Paracancerous tiusse|
2404355|NCT03542253||pathologic diagnosis|
2404356|NCT03542253||hemolysis|
2404357|NCT03542253||ct-DNA|
2404358|NCT03542253||micorRNA-A in plasma|
2404359|NCT03542253||Sample quality control|
2404360|NCT03542253||positive|
2404361|NCT03542253||negative|
2404362|NCT03542253||micorRNA-R in plasma|
2404363|NCT03542253||micorRNA-R in Plasma exocrine|
2404364|NCT03542253||Surgery|
2404365|NCT03542240|Experimental|Curcumin|
2404366|NCT03542214|Experimental|Calcium electroporation treatment|Experimental treatment with calcium electroporation for inoperabel colorectal cancer
2404367|NCT03542201|Experimental|PLS|Plain abstract about the Cochrane systematic review.
2404368|NCT03542201|Experimental|Blogshot|Blogshot presentation of the results of Cochrane systematic review.
3144135|NCT00030914|Experimental|Arm III: medroxyprogesterone - short term|"All patients complete a daily questionnaire regarding number of hot flashes beginning on day 1 and continuing for 7 weeks. Patients receive medroxyprogesterone IM once on day 8. After week 7, patients with unsatisfactory efficacy may cross over to arm I.~Patients are followed at months 2, 3, 4, 5, 6, 8, 10, and 12."
3144136|NCT00030966|Experimental|Group 1|Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
3144137|NCT00030966|Placebo Comparator|Group 2|Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.
2404372|NCT03542162|Experimental|Healaflow group|The Healaflow group consists of patients with primary RRD, but exclude proliferative vitreoretinopathy grade C or more, dialysis, retinoschisis, eyes with secondary RRD, significant corneal or lens opacity precluding vitrectomy, giant retinal tears, a follow-up period of less than 3 months, and visual loss from causes other than RRD.
2404373|NCT03542149|Experimental|A|"200mg of OZ439 and 480 mgPQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2404374|NCT03542149|Experimental|B|"200mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
3144138|NCT00031096|Experimental|Arm 1|
3144139|NCT00031096|Placebo Comparator|Arm 2|
3144140|NCT00031122||SBRR|Families with a child/pregnancy affected with spina bifida or anencephaly
3144141|NCT00031174||1|Blood components collected using apheresis from normal volunteers.
3144142|NCT00031174||2|Blood components collected using apheresis from patients with rheumatic or kidney diseases.
3144143|NCT00031278|Experimental|Cohort 1|0.01 mg/kg CPG 7909 plus Herceptin®
2404375|NCT03542149|Experimental|C|"400mg of OZ439 and 480 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2404376|NCT03542149|Experimental|D|"400mg of OZ439 and 640 mg PQP.~(OZ439 + α-tocopherol polyethylene glycol 1000 succinate (TPGS) granules for oral suspension).~The data will be used to determine the relationship between OZ439 and PQP concentrations and parasitaemia levels."
2404377|NCT03542136|Other|Patients receiving chemotherapy treatment with oxaliplatin.|
2404378|NCT03542123|Experimental|NeuroTronik CANS Therapy® System|
2404379|NCT03542110|Active Comparator|Alirocumab 150 MG/ML subcutaneous injection|Alirocumab 150 mg subcutaneously every 2 weeks
2404380|NCT03542110|Placebo Comparator|Matching Placebo subcutaneous injection|Matching placebo subcutaneously every 2 weeks
2404381|NCT03542097||Temozolomide and Irinotecan treatment|The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done
2404382|NCT03542084|Experimental|Intervention: Unsolicited e-consult|The PCP of intervention arm patients will receive an unsolicited e-consult by an endocrinologist offering clinical guidance on how to optimize the patients' glycemic control
2404383|NCT03542084|No Intervention|Control|Control arm patients will receive usual care
2404384|NCT03542071|Experimental|Carbohydrate restricted diet|Dietary intervention: moderately carbohydrate restricted diet. Parallel phase starts after study period I and the diet is followed until labor.
2404385|NCT03542071|Experimental|Plant-protein based diet|Dietary intervention: plant-protein based diet, en emphasis on healthy Nordic foods. Parallel phase starts after study period I and the diet is followed until labor.
2404386|NCT03542058|Experimental|Treatment Group|Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
2404387|NCT03542058|No Intervention|Control Group|Study participant will not receive any cardiac medication, apart from standard cancer care.
2404388|NCT03542032|Other|jaw-thrust|"the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
2404389|NCT03542032|No Intervention|classic group|"In the classic group, the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place. This groups will record the insertion time of i-gel, number of trials, operative time, placement complications.~Recorded complications (blood, laryngospasm, etc.) during insertion and removal of supraglottic airway devices will be assessed.~Patients' postoperative sore throat will be questioned and recorded."
3144144|NCT00031278|Experimental|Cohort 2|0.04 mg/kg CPG 7909 plus Herceptin®
3144145|NCT00031278|Experimental|Cohort 3|0.16 mg/kg CPG 7909 plus Herceptin®
3144146|NCT00031278|Experimental|Cohort 4|0.32 mg/kg CPG 7909 plus Herceptin®
2404393|NCT03542006|Experimental|Topical brinzolamide|Brinzolamide ophthalmic, given bd for 3 months
2404394|NCT03541993|Experimental|Resveratrol Hypoxia|500 mg of trans-resveratrol, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000m above sea level.
2404395|NCT03541993|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 12.7% atmospheric oxygen level; the equivalent to 4000 m above sea level.
2404396|NCT03541993|Experimental|Resveratrol Normoxia|500 mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2404397|NCT03541993|Placebo Comparator|Placebo Normoxia|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2404400|NCT03541967|Other|ADHEAR-PONTO|The ADHEAR system will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system. Then the patient will be fitted with the PONTO 3 SUPER POWER on softband and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband.
2404401|NCT03541967|Other|PONTO-ADHEAR|The PONTO 3 SUPER POWER on softband will be fitted to the patient who will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the PONTO 3 SUPER POWER on softband. Then the patient will be fitted with the ADHEAR system and will take it at home for 15 days. Afterwards, the patient will come back to the clinical center and measurements will be done with the ADHEAR system.
2404402|NCT03541954|Other|Patient with pelvic or perineal pain with sensitization|Patients with chronic pelvic or perineal pain with sensitization (Convergences PP criteria > 5)
2404403|NCT03541954|Other|Patient with pelvic or perineal pain without sensitization|Patients with chronic pelvic or perineal pain without sensitization (Convergences PP criteria < 5)
3144147|NCT00031395|Active Comparator|1|
3144148|NCT00031395|Active Comparator|2|
3144149|NCT00031395|Active Comparator|3|
3144150|NCT00031395|Placebo Comparator|4|
3144151|NCT00031421||1|16 received ganciclovir at 8 mg/kg/day in the previous study.
3144152|NCT00031421||2|31 received ganciclovir at 12 mg/kg/day in the previous study.
3144153|NCT00031434|Experimental|1|All subjects enrolled into this study will receive 6 weeks (42 days) of antiviral therapy (valganciclovir/ganciclovir).
3144154|NCT00031499|Experimental|Azithromycin|Azithromycin 2.0 gram single oral dose.
3144155|NCT00031499|Active Comparator|Benzathine Penicillin|Benzathine penicillin 2.4 million units administered intramuscularly. Doxycycline will be administered if the patient is allergic to Benzathine Penicillin.
3144156|NCT00031512|Placebo Comparator|Placebo|Placebo.
3144157|NCT00031512|Experimental|Pleconaril (VP63843)|The first dosing cohort received 5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation. Subsequent dosing cohorts are receiving 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
3144158|NCT00031564|Experimental|Vaccine Therapy With Interleukin-2|At approximately 3-6 weeks after surgery, patients receive B7-1 gene-modified autologous tumor cell vaccine subcutaneously (SC) once on days 1, 29, and 57. At 6 weeks after the first vaccination, patients receive interleukin-2 (IL-2) SC five days a week for 6 weeks (days 43-82). Patients with stable or responding disease after day 106 may receive additional vaccinations in the absence of disease progression or unacceptable toxicity.
2404407|NCT03541928|Experimental|Gene Therapy, ADT, RT, and Surgery|"The investigational gene therapy, ADV/HSV-tk, will be administered by injection into the prostate at 5 x 10[11] virus particles (1.25 x 10[11] virus particles per tumor quadrant in 4 quadrants) on day 0 and day 30.~The recommended dose of Valacyclovir for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45).~The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening).~Leuprolide acetate 7.5mg depot injection will be injected monthly for a total of 2 months."
2404408|NCT03541915|Experimental|Mg group|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
2404409|NCT03541915|Placebo Comparator|Control group|Same volume of normal saline will be infused after induction of anesthesia. And the same volume of normal saline will be continuously infused at a same rate of magnesium during the operation.
2404410|NCT03541902|Experimental|Group 1 (cabozantinib)|Participants receive cabozantinib PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2404411|NCT03541902|Experimental|Group 2 (sunitinib malate)|Participants receive sunitinib malate PO QD on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2404412|NCT03541889|Experimental|Cord and haplo imaging cohort|For all pediatric and adult patients undergoing cord blood HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 9 and 28 after HSCT. For recipients of haplo-HSCT, FLT PET/CT imaging will occur one day prior to HSCT and on days 5 and 28 after HSCT.
2404413|NCT03541889|Experimental|Nonengrafted cohort|Pediatric and adult patients who have not engrafted by day 24 after cord or haplo-identical HSCT will undergo a single FLT PET/CT image within one week to determine if this scan can identify graft failure versus delayed engraftment.
2404414|NCT03541876||children with H. pylori infection|
2404415|NCT03541863||Endocrine therapy|use endocrine therapy (ET) after Fulvestrant, include but not limited to: tamoxifen, anastrozole, letrozole, exemestane, exemestane + everolimus
2404416|NCT03541863||Chemotherapy|use Chemotherapy (CT) after Fulvestrant, include but not limited to: capecitabine, docetaxel-based, vinorelbine, paclitaxel-based
2404418|NCT03541837|Other|peri operative analgesia|Post operative regional analgesia by Erector Spinae bilateral catheters with infusion of ropivacaine
2404419|NCT03541824|Experimental|Body Acceptance Program|The Body Acceptance Program (BAP) is the active condition. Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
2404420|NCT03541824|No Intervention|Waitlist control|Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
2404421|NCT03541811||patients with hemophilia (16-45y)|not applicable (no intervention administered)
2404422|NCT03541811||peer-matched healthy control|not applicable (no intervention administered)
2404423|NCT03541798|Active Comparator|Traditional sitting position|"Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2404424|NCT03541798|Experimental|Harmstring stretch position|"the patients sit up from supine position with the legs remaining on the operating table, knees are maximally extended.~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2404425|NCT03541798|Experimental|Squatting position|"the patients sit up from supine position with the legs remaining on the operating table, hips and knees are maximally flexed .~Intervention: A combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia."
2404426|NCT03541772|Experimental|Oncoxin-Viusid®|Radiotherapy + Chemotherapy + Oncoxin-viusid®
2404427|NCT03541772|Placebo Comparator|Placebo|Radiotherapy + Chemotherapy + Placebo
2404428|NCT03541759|Active Comparator|Hydromorphone|Hydromorphone Hcl 4 milligram (mg) Tab 2 times after surgery as basic medication. Hydromorphone Hcl 2.6mg maximum 2 per 24h when numeric rating scale (NRS) > 5.
2404429|NCT03541759|Active Comparator|Piritramide|Piritramide 15mg s.c. 2 times after surgery as basic medication. Piritramide 7.5mg s.c. maximum 2 per 24h when numeric rating scale (NRS) > 5.
2404430|NCT03541746|Experimental|Study Group|Platelet Rich Plasma
2404431|NCT03541746|Active Comparator|Control Group|Intrauterine Foley's Catheter
2404432|NCT03541733|Experimental|Tubing-group|mid-gut tubing prior to the MRE examination, administer contrast solution through the mid-gut tube
2404433|NCT03541733|No Intervention|Oral-group|administer contrast solution orally, mid-gut tubing after the MRE examination
2404434|NCT03541720|Experimental|Injection of 18F-DA|18F-DA will be injected into a vein in the arm or leg, or via central venous access line.
2404435|NCT03541707|Active Comparator|Active Therapy|
2404436|NCT03541707|Sham Comparator|"As if Stimulation"|
2404437|NCT03541681|Active Comparator|Glucocorticoid Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections with glucocorticoid (1 ml Dexamethasone) within 3 months.
2404438|NCT03541681|Active Comparator|Local Anesthetic Injections|A series of three cervical transforaminal local anesthetic (0,5 ml Bupivacain) injections without glucocorticoid (Dexamethasone) within 3 months.
2404441|NCT03541655|Active Comparator|Standard of care analgesia|0.25% Bupivacaine HCl administered following total knee replacement
2404442|NCT03541655|Experimental|F14 (celecoxib)|3.5 mL dose of F14 (celecoxib) concurrent with 0.25% Bupivacaine HCl administered following total knee replacement
2404443|NCT03541642|Experimental|Enhanced Intervention|Women who are eligible and randomized to the Enhanced Intervention will receive targeted PrEP counseling; targeted written/visual materials, follow up supportive text messages, and distribution of PrEP at the syringe exchange
2404444|NCT03541642|Active Comparator|Basic Intervention|"Women who are eligible and randomized to the Basic Intervention will receive usual care with general messaging from medical personnel, reminder text messages, and distribution of PrEP at the syringe exchange"
2404445|NCT03541616||Enrolled Patients|
2404446|NCT03541603|Experimental|Levosimendan 2.5mg/mL Injectable Solution|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
2404447|NCT03541603|Placebo Comparator|Matching Placebo|0.075 - 0.1µg/kg/min for 24 hrs (weekly)
2404448|NCT03541577||Participants|Subjects who meet the inclusion criteria and do not meet the exclusion criteria and undergo FFR measurement with the TruePhysioTM Microcatheter and the Pressure Wire
2404449|NCT03541564|Experimental|BMS-986165 Dose 1 oral administration|BMS-986165 therapeutic single dose
2404450|NCT03541564|Experimental|BMS-986165 Dose 2 oral administration|BMS-986165 supratherapeutic single dose
2404451|NCT03541564|Active Comparator|Moxifloxacin Dose 3 oral administration|Moxifloxacin positive control single dose
2404452|NCT03541564|Placebo Comparator|Placebo Dose 4 oral administration|Placebo single dose
2404453|NCT03541551|Experimental|CTT with ologen® Collagen Matrix|Experimental: Trabeculotomy with trabeculectomy with ologen implant
2404454|NCT03541551|Active Comparator|Trab Trab|Active Comparator: Trabeculotomy with trabeculectomy
2404455|NCT03541538|Active Comparator|Global manipulation|Manual therapy performed in the cervical region in a non-specific way.
2404456|NCT03541538|Experimental|Especific manipulation|manual therapy performed specifically on the C6-7 segment
2404457|NCT03541525||Affected patients|Biological samples of blood for all patients. Biological samples of saliva, surgical remainder (skin, tumor, kidney,....), saliva, urine, hair.
2404458|NCT03541525||Non affected relatives|Biological samples of blood for all relatives.
2404459|NCT03541512|Active Comparator|Mindfulness & Education|Mindfulness practice using guided HeadSpace medications plus educational materials
2404460|NCT03541512|Active Comparator|Education only|Educational materials only
2404461|NCT03541499|Experimental|Group 1|800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15
2404462|NCT03541499|Experimental|Group 2|800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15
2404463|NCT03541499|Placebo Comparator|Group 3|800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15
2404464|NCT03541499|Experimental|Group 4|800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5
2404465|NCT03541486|Experimental|Investigational Therapy (ASC)|75 grams of pharmacological ascorbate, daily (M-F) 600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
2404466|NCT03541486|Active Comparator|Standard Therapy (ChemoRT)|600 mg/m2 of gemcitabine, once a week for up to 6 weeks 50 to 50.4 Gray of radiation therapy delivered using a volumetric arc therapy (VMAT) technique
2404467|NCT03541473|Active Comparator|Peptamen® 1.5 Vanilla|
2404468|NCT03541473|Placebo Comparator|Boost Plus® Vanilla|
2404469|NCT03541460||Older Cohort|Demographic, health and functional data will be collected from subjects 95 years and older by means of a structured interview. Blood will be collected for laboratory and genetic testing.
2404470|NCT03541460||Younger Controls|Demographic, health and functional data will be collected from the children of the older subjects and other aged-matched controls by means of a structured interview. Blood will be collected for laboratory and genetic testing.
2404471|NCT03541447|Experimental|Tolvaptan plus Octreotide LAR / Tolvaptan plus Placebo|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of Octreotide LAR (two 20 mg i.m. injections). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of placebo (two i.m. injections of 0.9% NaCl solution)
2404472|NCT03541447|Experimental|Tolvaptan plus placebo/Tolvaptan plus Octreotide LAR|Patients will receive a first 4-week treatment period with Tolvaptan up to 120 mg/die, according to tolerability, and a single dose of placebo (two i.m. injections of 0.9% NaCl solution). Then, after a period of wash-out, each patient will cross over to the other treatment arm for a second 4-week treatment period with Tolvaptan plus a single dose of Octreotide LAR (two 20 mg i.m. injections).
2404473|NCT03541434||Healthy|Children with no history of adenotonsillar hypertrophy, recurrent tonsillitis, or middle ear effusion. They presented to the clinic for examination or a scheduled procedure.
2404474|NCT03541434||Recurrent tonsillitis|Children with a history of recurret tonsillitis but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and complete blood count. They presented to the clinic for a sceduled tonsillectomy.
2404475|NCT03541434||Middle ear effusion|Children with chronic middle ear effusion but no adenotonsillar hypertrophy. Diagnosis was based on physical exam and tympanometry. They presented to the clinic for scheduled myringotomy with or without adenoidectomy.
2404476|NCT03541434||Adenotonsillar hypertrophy|Children with tonsillar and/or adenoidal hypertrophy. Diagnosis was based on physical exam and partly on x-ray of nasopharynx or nasopharyngoscopy. They presented to the clinic for scheduled tonsillectomy and/or adenoidectomy.
2404477|NCT03541421|Experimental|Intervention|The patients administers own drugs during hospital stay.
2404478|NCT03541421|No Intervention|Control|The patients receive medications from the medicine room dispensed by a nurse (standard care). No intervention
2404479|NCT03541408|Placebo Comparator|Control|Subjects will receive anesthesia
2404554|NCT03540836|Experimental|Relacorilant 3x100mg hard-shell capsules|Relacorilant (3x100 mg hard-shell capsules)
2404555|NCT03540836|Experimental|Relacorilant 6x50mg hard-shell capsules|Relacorilant (6x50mg hard-shell capsules)
2404480|NCT03541408|Experimental|Preventative Delirium Protocol|"Consider regional block if applicable~Minimized fentanyl usage intraoperatively~Intubation + GA adjunct total: 1-2 mcg/kg~Sedation: 0-0.25 mcg/kg~Post-op: 0.5-1 mcg/kg~Avoid morphine~Avoid ketamine~Avoid diphenhydramine, dexamethasone, scopolamine, metoclopramide, and promethazine~Avoid H2-blockers (cimetidine, ranitidine, famotidine)~Avoid polypharmacy intraoperatively if possible (i.e. >5 new medications)~Fluid repletion based on maintenance and losses"
2404481|NCT03541395|Other|Testosterone|A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.
2404482|NCT03541382|Active Comparator|HIVST campaign arm|Community representatives will be supported to plan and administer an HIVST campaign linked to HIV care and prevention services in their communities.
2404483|NCT03541382|No Intervention|SOC arm|Standard HTS will be provided by MoH at health facilities.
3184886|NCT00729313|Experimental|1|"Drug: Lanreotide 30 mg microparticle formulation~One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of lanreotide 30 mg microparticle formulation every 10 days): according to the patient's treatment response at 72h~For non-responders patients lanreotide will be stopped."
3184887|NCT00729313|Placebo Comparator|2|"One intra-muscular injection.~A (maximum) 60 day treatment period (6 intra-muscular injections of placebo every 10 days): according to the patient's treatment response at 72h.~Non-responder patients having received placebo on the first injection should receive an open-labelled lanreotide treatment."
3184888|NCT00729339|Active Comparator|1|lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month
3184889|NCT00729339|Active Comparator|2|lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month
3184890|NCT00729352||Control group|18-35 yr old healthy subjects with wild type genotype for NQO1.
2404491|NCT03541343|Experimental|GreenBone|All patients will receive the GreenBone implant instead of bovine xenograft.
2404492|NCT03541330|Other|siblings|Brother or sister of a child has malignant haemopathy and follow-up in the pediatric hematology department
3184891|NCT00729352||Case group|18-35 yr old healthy subjects who are homozygotic for minor allele of NQO1 Pro187Ser polymorphism
3184892|NCT00729391|Experimental|1|Women's CoOp
2404495|NCT03541291|Experimental|SMART-SYNC LM03|All participants
2404496|NCT03541278|Experimental|IM-SLNB with MIT|The radiotracer was injected with our modified injection technique (MIT) (periareolar intraparenchymal, high volume and ultrasonographic guidance). Internal mammary sentinel lymph node biopsy (IM-SLNB) was performed for patients with internal mammary visualized.
2404497|NCT03541265|Experimental|Adductor block protocol|An ultrasound-guided injection of Subsartorial saphenous nerve using Exparel 266 mg (20 cc vial) via a 21-gauge 4-inch Stimuplex A needle (B. Braun Medical Inc., Melsungen, Germany) was performed at mid-thigh level with a high-frequency linear ultrasound transducer. All regional anesthesia was performed by a trained anesthesiologist. Ultrasound pictures (pre-injection and post-injection) was obtained to verify proper local anesthetic placement.
2404498|NCT03541265|Active Comparator|peri-articular injection|Peri-articular injection included combination of Exparel 266 mg (20 ml vial) with 20 ml of 0.5% bupivacaine, and normal saline to a total volume of 120 ml. The injection was meticulously administered prior and after cementation in the posterior capsule, posteromedial structures, the periarticular synovium, extensor apparatus, pes anserinus, anteromedial capsule, periosteum, iliotibial band, and subcutaneous plane. Injections were performed using 20-mL syringes with 22-gauge needle, minimal leakage. Visible tissue expansion was achieved.
2404499|NCT03541252|Experimental|Basal Cell Carcinoma Patients|Patients (>18 years) with histologically-verified superficial or nodular basal cell carcinoma (<20 mm on the face/scalp, <50mm on the trunk/extremities)
2404500|NCT03541239|Active Comparator|non-ischemic preconditioning|The participants will have the cuff attached to the arm, however not be inflated for the 4 cycles of remote ischemic conditioning: 1 cycle is 5 minutes of inflation followed by 5 minutes of deflation. The ischemic reperfusion injury was induced by cuff inflation by the Single Cuff Tourniquet 8000 to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
2404501|NCT03541239|Experimental|ischemic preconditioning|The blood supply to the distal part of the arm will be occluded by inflation of a single cuff to 200mmHg, by the help of the Single Cuff Tourniquet 8000, for 5 minutes separated from 5 minutes of deflation, a cycle that happens 4 times in total. The ischemic reperfusion injury was induced by cuff inflation to 200 mmHg in the arm for 20 minutes followed by reperfusion for 15 minutes.
2404502|NCT03541213|Other|Control group|"Patients with no iron deficiency prior to inclusion and who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2404503|NCT03541213|Other|Iron deficiency group|"Patients with iron deficiency who did not receive intravenous iron prior to inclusion.~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2404504|NCT03541213|Other|Iron treated group|"Patients with iron deficiency who received intravenous iron prior to inclusion (greater than or equal to 1 g ferric carboxymaltose).~Intervention : myocardial biopsy, sternal bone marrow biopsy and blood sample (as in the other arms)"
2404505|NCT03541200|Experimental|Open Label|MT-8554
2404556|NCT03540823|Experimental|Patients with rheumatic diseases|Patients with diagnosis of adult and juvenile systemic lupus erythematosus (SLE and JSLE) and Sjogren syndrome (SSp)
2404557|NCT03540823|Other|Healthy controls|Healthy children and adults
3184893|NCT00729391|Active Comparator|2|Nutrition (Attention-Control)
3184894|NCT00729391|Active Comparator|3|Voluntary Counseling and Testing
3184895|NCT00729404|Experimental|Arm 1|
3184896|NCT00729404|Experimental|Arm 2|
3184897|NCT00729443|Experimental|1|
3184898|NCT00729443|Placebo Comparator|2|
3184899|NCT00729456|No Intervention|1|
3184900|NCT00729456|Other|2|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
2404506|NCT03541187|Experimental|G. cockroach allergenic extract|"Subcutaneous immunotherapy (SCIT): German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. After maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
2404507|NCT03541187|Placebo Comparator|Placebo|"Subcutaneous immunotherapy (SCIT): Placebo for German cockroach allergenic extract. 40 participants 8 to 14 years of age will be randomized to this treatment arm.~-Up to 2 doses of the assigned SCIT treatment will be given weekly during dose escalation, separated by a minimum of 2 days. Once the maintenance dose is achieved, participants will receive three maintenance level-doses spaced approximately 2 weeks apart, followed by maintenance injections every 4 weeks for the remainder of the treatment period. The treatment is for a period of 12 months."
3144159|NCT00031629|Experimental|Treatment (gemcitabine, docetaxel, G-CSF, pegfilgrastim)|Patients receive gemcitabine IV over 90 minutes on days 1 and 8, docetaxel IV over 1 hour on day 8, and G-CSF SC on days 9-15 or pegfilgrastim SC on day 9 only. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3144160|NCT00031655|Experimental|Treatment (nonmyeloablative allogeneic PBSCT)|"NONMYELOALATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0. Patients with minimal residual disease may receive donor lymphocyte infusion IV.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO every 12 hours on days -3 to 100 with taper to day 177 and mycophenolate mofetil PO very 8 hours on days 0 to 40 with taper to day 96."
3144161|NCT00031681|Experimental|Treatment (combination chemotherapy)|"PART I: Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, and 22 and 7-hydroxystaurosporine IV over 3 hours on days 2 and 23. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride and 7-hydroxystaurosporine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Blood samples are collected periodically during study treatment.~PART II: (treatment of triple negative recurrent breast cancer): Patients receive irinotecan hydrochloride IV and 7-hydroxystaurosporine IV as in part I at the MTD and undergo blood sample collection."
3184901|NCT00729495|Active Comparator|1|marketed celecoxib
3184902|NCT00729495|Experimental|2|overencapsulated celecoxib
3184903|NCT00729508|Experimental|1|
2404514|NCT03541161||Early rehabilitation group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from Jan 2017 to August 2017. Following early rehabilitation protocol, patients were educated to undergo a self-exercise program after short-term immobilization of 2 weeks.
2404515|NCT03541161||Conventional protocol group|Breast cancer patients who underwent reconstructive surgery in samsung medical center from May 2016 to Dec 2016. Following conventional protocol, patients were asked to immobilize their shoulder for more than 4 weeks and then undergo self-exercise program.
2404516|NCT03541148|Experimental|Oncoxin-Viusid|Nutritional supplement Oncoxin-Viusid 25 mL in oral solution twice a day
2404517|NCT03541122||Experimental group|Patients will undergo pelvic X-ray examinations. Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads. The investigators will determine the sensitivity and specificity of OFI, MUI and TBOI for the diagnosis of adult acetabular dysplasia, and compare the accuracy of diagnosis between these three indicators and CE angle, sharp angle, and AHI. Further analysis of risk factors for hip function will be implemented.
2404518|NCT03541109|Experimental|Polypill|Polypill group will receive a fixed dose combinations of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg), prescribed once daily by moth for 34 months
2404519|NCT03541109|No Intervention|Control|The usual care arm will receive regular drug order at the time of discharge from the hospital.
2404520|NCT03541096|Experimental|Winter Swimmers|4 Months of supervised winter swimming.
2404521|NCT03541096|Placebo Comparator|Control group|No winter swimming activities.
2404523|NCT03541070|Experimental|Kinesiology taping|For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
3184904|NCT00729508|Experimental|2|
3184905|NCT00729508|Experimental|3|
2404526|NCT03541031|Experimental|Micronutrient & Fish oil|Fish oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Micronutrient capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
2404527|NCT03541031|Placebo Comparator|Olive oil & Safflower oil|Safflower oil capsule by mouth 3 capsules daily, remaining constant throughout the study and Olive oil capsule by mouth beginning with a fixed schedule of 2 capsules twice daily and increasing monthly by 2 capsules twice daily up to a maximum of 16 capsules/day.
2404528|NCT03541018|Experimental|Posterior canalolithiasis|Type of repositional maneuvre
2404529|NCT03541018|Experimental|Lateral cupulolithiasis|Type of repositional maneuvre
3184906|NCT00729508|Experimental|4|
2404558|NCT03540810|Active Comparator|Hydroxychloroquine|All patients randomised in this arm will receive hydroxychloroquine with their usual treatment, which is antivitamin K anticoagulants
2404559|NCT03540810|Placebo Comparator|Placebo|All patients randomised in this arm will receive a placebo with their usual treatment, which is antivitamin K anticoagulants
2404560|NCT03540797||Intensive care unit (ICU) patients with sepsis|
2404532|NCT03540979|Active Comparator|Estrogen|Endometrial preparation: Estrogen supplements (Estradiol 6mg/d) will be started at the 2nd-3rd day of the cycle. First US scan will be performed after 10 days. If necessary, adjusting the estradiol doses will be performed according to the physician decision. After achieving trilinear endometrial thickness ≥8mm progesterone supplements (Endometrin 100mg*3/d) will be administrated. Embryo transfer will be performed after completing 5 days of progesterone supplements (at the 6th day after starting the progesterone supplements).
2404533|NCT03540979|Experimental|Letrozole|Women in the Letrozole arm will be treated with Aromatase inhibitors ( Letrozole; 2.5 mg per day) starting at the 3rd day of the cycle for 5 days. US scan,and blood work for serum Estradiol (E2) and progesterone (P) will initially be examined 3-5 days after the last Letrozole pill. Following US scans and serum E2+P will be performed according to the treating physician decision. When US scan demonstrate trilaminar endometrium ≥8 mm and the dominant follicle will be ≥18mm, hCG will be administrated ( recommbinant hCG - Ovitrelle 250 mcg) and 3 days later vaginal Endometrin 100mg*3/d will be started. Single vitrified-warmed blastocyst transfer will be performed after completing 4 days of the progesterone supplements (7 days from hCG administration).
2404534|NCT03540966|Experimental|Group A|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies plus CapulinTM on-demand treatment period
2404535|NCT03540966|Placebo Comparator|Group B|complete Chinese version of the vitiligo life quality index, VLQI-C, conventional therapies on-demand treatment period
2404536|NCT03540953|Other|Endoscopic injection of Mitomycin C|Endoscopy injection of Mitomycin C will be perform to the treatment of pharyngoesophageal stenosis refractory to endoscopic treatment with dilatation in patients with head and neck cancer
2404537|NCT03540940|Experimental|zero positive end expiratory pressure|
2404538|NCT03540940|Experimental|Positive end expiratory pressure|
2404539|NCT03540927|Experimental|PM+ for entrepreneurs|The intervention arm participants will receive a cash transfer to support them in their businesses PLUS 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 discusses problem solving technique.Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
2404540|NCT03540927|Active Comparator|Control|The control arm will receive a cash transfer only to support them in their businesses.
2404541|NCT03540914|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2404542|NCT03540914|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.
3144162|NCT00031707|Active Comparator|megestrol + placebo|"Patients receive oral megestrol once daily and oral placebo twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3184907|NCT00729508|Placebo Comparator|5|
2404545|NCT03540888|Experimental|Deep Transverse Friction Massage group|Deep transverse friction massage group. Participants were taught by one of the examiners how to sit and perform pre-exercise self-massages on their tested leg musculotendinous junction (MTJ). The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur. One examiner carefully monitored how the technique was performed to assure the precision of the application. This massage technique was applied over a duration of 30 seconds.
2404546|NCT03540888|Active Comparator|Dynamic stretching intervention|The dynamic stretching intervention was included for its positive effects on agility and muscle strength. Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
2404547|NCT03540888|Active Comparator|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
3184908|NCT00729547|Placebo Comparator|2|Psychotherapy placebo session
3184909|NCT00729547|Experimental|1|Neurofeedback training which enhance left frontal alpha wave.
2404550|NCT03540862||NPV|a hospital-based maintenance NPV program including NPV support, breathing training and an educational program (relaxation techniques, and home pacing walking exercise) in daily clinical practice. Patients received NPV with breathing training via the cuirass ventilator (Philips Respironics Lifecare NEV-100) settings for 60 min. The ventilator was set to control model with frequency of 12 cycles/min, 30% of the ratio of inspiratory time to total breathing cycle time (Ti/Ttot) and delivered negative pressures ranging -20 to -30 cm H2O. In the NPV group, patients underwent the hospital-based NPV once every week as the maintenance program.
2404551|NCT03540862||Control|If patients do not wish to enter the hospital-based NPV program, they are placed in the control group and are trained to perform breathing training, relaxation techniques and home pacing walking exercise.
2404552|NCT03540849|Experimental|BV after allogeneic hematopoietic stem cell transplantation|
2404553|NCT03540836|Experimental|Relacorilant 3x100mg softgel capsules|Relacorilant (3x100 mg softgel capsules)
2404561|NCT03540784|No Intervention|Control group|usual care treatment
2404563|NCT03540784|Experimental|EMS+Nutrition|WB-EMS Training (2x/week á 20 min) + high-protein nutrition therapy
2404564|NCT03540771|Active Comparator|Model 1: Consultative Palliative Care|Direct access to Palliative Care provider, who will offer palliative care to patients and caregivers, as guided by a standard PC (palliative care) checklist.
2404565|NCT03540771|Active Comparator|Model 2: Trained Hepatologist- led PC|A hepatologist will receive formal training to deliver Palliative Care (PC) services, and will offer palliative care to patients and caregivers following the same PC checklist as in Model 1
3144163|NCT00031707|Active Comparator|eicosapentaenoic acid + placebo|"Patients receive oral placebo once daily and an eicosapentaenoic acid (EPA)-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3144164|NCT00031707|Experimental|megestrol + eicosapentaenoic acid|"Patients receive oral megestrol once daily and an EPA-enriched nutritional supplement twice daily. Treatment continues in the absence of unacceptable toxicity and as long as the patient and physician feel it is beneficial.~Quality of life is assessed at baseline, weekly for 1 month, and then monthly thereafter during study treatment.~Patients are followed every 6 months for 5 years."
3144165|NCT00031720|Experimental|Arm I|All patients receive placebo for 7 days as part of the run-in period. Patients being treated with tamoxifen were randomized to treatment arm I and received 40 gm soy protein and 90 mg isoflavones daily for 12 weeks.
3144166|NCT00031720|Placebo Comparator|Arm II|All patients receive placebo for a 7 day run in period. Patients being treated with tamoxifen randomized to Arm II received placebo daily for 12 weeks.
3144167|NCT00031746|Active Comparator|soy protein + isoflavones|
3144168|NCT00031746|Active Comparator|casein proteins|
2404572|NCT03540745|Experimental|TES Treatment|Where subject is randomized to TES.
2404573|NCT03540745|Placebo Comparator|TES-SHAM Treatment|Where subject is randomized to a SHAM condition
3184910|NCT00729573||1|Participants in MTN-003. Participants will remain a part of their assigned MTN-003 study groups.
3184911|NCT00729599|Experimental|1|Cetylpyridinium chloride during 21 consecutive days.
2404578|NCT03540693||RYGB-longitudinal|Longitudinal group of subjects studied before and after Roux-n-Y gastric bypass surgery
2404579|NCT03540693||SG_longitudinal|Longitudinal group of subjects studied before and after sleeve gastrectomy surgery
2404580|NCT03540693||LAGB_longitudinal|Longitudinal group of subjects studied before and after laparoscopic gastric banding surgery
2404581|NCT03540693||Weight-loss success|Subjects who lost ≥40% body weight by 2-5 years post-surgery
2404582|NCT03540693||Weight-loss failure|Subjects who lost <25% body weight (or lost more but then regain weight so that now are at <25%) by 2-5 years post-surgery
2404583|NCT03540680|Other|Term newborns (≥37GA)|Blood punction on the cordon
2404584|NCT03540680|Other|Premature newborns|Blood punction on the cordon
2404585|NCT03540680|Other|Child between 7 and 15 years old with BPD|Blood punction
2404586|NCT03540680|Other|Child between 7 and 15 years old without BPD|Blood punction
2404587|NCT03540667||Single group study|The study population will include patients presenting for primary elective unilateral total hip and knee arthroplasty.
2404588|NCT03540654||Patients with CML discontinuing TKI treatment|
2404589|NCT03540641|Active Comparator|1500 pulses|This group will receive 1500 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions
2404590|NCT03540641|Sham Comparator|1500 pulses sham|this group will receive the sham modality of the protocol of 1500 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
2404591|NCT03540641|Active Comparator|5000 pulses|This group will receive 5000 pulses of transcranial magnetic stimulation at 5Hz over the left dorsolateral prefrontal cortex, until completing 15 sessions.
2404592|NCT03540641|Sham Comparator|5000 pulses sham|this group will receive the sham modality of the protocol of 5000 pulses at 5Hz of transcranial magnetic stimulation during 15 sessions.
2404593|NCT03540628|No Intervention|Placebo Arm|The control arm of our randomized trial will receive a second pressor agent, hydrocortisone and standard of care to care for septic shock. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
2404594|NCT03540628|Experimental|Thiamine and Vitamin C administration Arm|The experimental arm will receive a second pressor agent and hydrocortisone, plus thiamine and vitamin C along with the standard of care. The IV bags will be blinded by pharmacy. If the patient needs additional pressor support or therapy, the data will be recorded in the results.
2404595|NCT03540615|Experimental|BAY1830839|Single Dose escalations
2404596|NCT03540615|Placebo Comparator|Placebo|Matching Placebo
2404597|NCT03540602|Placebo Comparator|Placebo|Rice flour capsule
2404598|NCT03540602|Active Comparator|Polyphenol Rich Supplement|NordicCherry Tart Cherry Extract Powder 500 mg in capsule form
2404599|NCT03540589|Experimental|Video distraction|A video will be available as soon as the child is randomized to this group, thus enabling the child to become more involved with distraction. A tablet will be delivered to the parents in the reception room to be viewed by the child before entering the vaccine room. After entering the room, the parents will keep the child entertained with the videos. There will be several videos, and it may be optional for the parents to choose according to their preferences.
2404600|NCT03540589|Experimental|Vibration device|Buzzy® specific vibration device will be placed by the professional or caregiver at the application site, 15 to 45 seconds before the procedure.
2404601|NCT03540589|Experimental|Distraction plus vibration|Combination of the two interventions described above
3184912|NCT00729638|Experimental|Single arm|Single arm phase I study
2404602|NCT03540589|No Intervention|Usual care|The vaccine will be carried out according to the routine of the Vaccine Center. Lidocaine plus prilocaine, non-nutritive sucking or breastfeeding may be used.
2404603|NCT03540563|Other|blood draw|Blood and saliva specimens will be taken for ctDNA analysis at baseline, weekly during treatment and at 2 weeks after treatment. During follow up both blood and saliva will be obtained in combination with a CT/MRI scan on the same day at 3 months, 6 months, 1 year and 2 years after treatment.
2404604|NCT03540550|Experimental|Dietary intervention|
2404605|NCT03540537|Other|PCA for Open Hepatectomy|Patient-controlled intravenous analgesia in Open hepatectomy (PCA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing)
2404606|NCT03540537|Experimental|QLB for Open Hepatectomy|Bilateral quadratus lumborum block with 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2404607|NCT03540537|Experimental|TPVB for Open hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2404608|NCT03540537|Other|PCA for Laparoscopic Hepatectomy|Patient-controlled intravenous analgesia in Laparoscopic hepatectomy (same as PCA for Open hepatectomy Arm)
2404609|NCT03540537|Experimental|QLB for Laparoscopic Hepatectomy|Bilateral quadratus lumborum block 20 ml 0.375% ropivacaine each side(maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2404610|NCT03540537|Experimental|TPVB for Laparoscopic Hepatectomy|T6+T8 of thoracic paravertebral block with 15 ml 0.375% ropivacaine each segment (maximum total dose 3 mg/kg) combine Patient-controlled intravenous analgesia (same as PCA for Open hepatectomy Arm)
2404611|NCT03540524|Experimental|Cohort A - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods.( Study Part I)
2404612|NCT03540524|Experimental|Cohort B - F508del heterozygous/potentiator nonresponsive|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (study Part II)
2404613|NCT03540524|Experimental|Cohort C - F508del homozygous|Dual combination (GLPG2451 and GLPG2222) will be administered for 14 days, followed by the triple combination (GLPG2451, GLPG2222 and GLPG2737) for 14 days, without washout in between the sequential treatment periods. (Study Part II)
2404614|NCT03540498|Experimental|Probiotics|The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
2404615|NCT03540498|Placebo Comparator|Control|The volunteers will follow the assigned treatment for 6 weeks (PLACEBOS CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers.
2404616|NCT03540485|Experimental|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
2404617|NCT03540485|Placebo Comparator|Control|Daily administration of placebo orally, for 24 months between 10pm to 11pm
2404618|NCT03540472|Experimental|efficiency of tacrolimus on PRCA|"A prospective research of the tacrolimus efficiency on refractory PRCA patients On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study.~Medication time should last at least 6 months."
2404619|NCT03540446|Experimental|Standard stimulation|Group A will be treated with First Relief Treatment at standard stimulation.
2404620|NCT03540446|Experimental|sweep stimulation|Group B will be treated with First Relief Treatment at sweep stimulation.
2404621|NCT03540446|Experimental|Placebo|Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)
2404626|NCT03540407|Experimental|Oncoxin-Viusid®|will receive the Oncoxin-Viusid® (oral solution) concomitant to the onco-specific treatment.
2404627|NCT03540407|Placebo Comparator|Placebo|will receive a Placebo concomitant to the onco-specific treatment
2404628|NCT03540381||Identified neoatherosclerosis group|From the patients treated with coronary stents, the investigators functionally evaluated their HDL by measuring the CUC. the investigators also performed follow-up OCT to evaluate the presence of neoatherosclerosis. Consecutive patients were divided into two groups. The patients with neoatherosclerosis were identified neoatherosclerosis group and the remaining were not-identified neoatherosclerosis group. After that, clinical follow-up was performed to assess TLR and the investigators examined the relation between CUC, neoatherosclerosis and TLR.
2404629|NCT03540381||Not-identified neoatherosclerosis group|
2404630|NCT03540368|Experimental|Tranexamic acid injection|Group with tranexamic acid injection
2404631|NCT03540368|Placebo Comparator|Placebo|Group with Placebo
2404632|NCT03540355|Experimental|Cipros 20|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Cipros 20 association; and~1 tablet crestor placebo. Oral, once a day"
2404633|NCT03540355|Active Comparator|Crestor|"The study is double-masked, the patient will take 2 tablets, as follow:~1 tablet Crestor 20 mg; and~1 tablet cipros association placebo. Oral, once a day"
2404634|NCT03540342|Experimental|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
2404635|NCT03540342|No Intervention|Staging strategy group|PCI will be performed several days after EVAR
2404636|NCT03540329|Active Comparator|I-A Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in patients in growing age.
2404637|NCT03540329|Active Comparator|I-A External distraction|External osteogenesis distractor in congenital mandibular deformities in patients in growing age.
2404638|NCT03540329|Active Comparator|I-B Internal distraction|Internal osteogenesis distractor in congenital mandibular deformities in adult patients.
2404639|NCT03540329|Active Comparator|I-B External distraction|External osteogenesis distractor in congenital mandibular deformities in adult patients.
2404640|NCT03540329|Active Comparator|II-A Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in patients in growing age
2404641|NCT03540329|Active Comparator|II-A External distraction|External osteogenesis distractor in acquired mandibular deformities in patients in growing age
2404642|NCT03540329|Active Comparator|II-B Internal distraction|Internal osteogenesis distractor in acquired mandibular deformities in Adult patients.
2404643|NCT03540329|Active Comparator|II-B External distraction|External osteogenesis distractor in acquired mandibular deformities in Adult patients.
2404644|NCT03540316|Active Comparator|Two short implants and 2 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and Low level laser therapy (LLLT) for 2 minutes .
2404645|NCT03540316|Active Comparator|Two short implants and 4 minutes LLLT|Patients receiving 2 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
2404646|NCT03540316|Active Comparator|Four short implants and 2 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 2 minutes .
2404647|NCT03540316|Active Comparator|Four short implants and 4 minutes LLLT|Patients receiving 4 short dental implants assisted mandibular over-denture and LLLT for 4 minutes .
2404648|NCT03540303|Experimental|CAR19 T cells carrying cytoplasmic activated PD-1|patients with refractory/relapsed B-NHL receive a preconditioning before infusion of CAR T cells.
2404649|NCT03540290|Active Comparator|Mechanical instrumentation and oral hygiene instructions|
2404650|NCT03540290|Experimental|Modification of the implant supported prostheses|
2404651|NCT03540277|Experimental|"Prevention Program young In Favor of Myself, active parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents will also participate by a phone app that will pass the parents activities to do with their children, in parallel to the program. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
2404652|NCT03540277|Active Comparator|"Prevention Program young In Favor of Myself, passive parents"|"The program young In Favor of Myself will be delivered to adolescence aged 10-12, over 3 months. The program contains nine weekly, 90-min sessions that focus on Media literacy, self-esteem, self-image and body image. The parents won't participate in the program, they will get only a brochure about Media literacy, self-esteem, self-image and body image. All participants will complete a self-report questionnaire at baseline, after the program ends, and three months after the completion of the program."
2404653|NCT03540277|No Intervention|control group|The control group will not receive the intervention program. The control group will complete the same self-report questionnaire as the intervention group at baseline, after the program ends, and three months after the completion of the program.
2404654|NCT03540264|Active Comparator|Composite resin|Restoration with composite resin has shown good clinical performance and limited occlusal wear. The Clearfil Majesty will be used in the present study.
2404655|NCT03540264|Active Comparator|Polymer-infiltrated-ceramic-network|This hybrid material seems to be a promising material that imitates natural tooth properties. The VITA-Enamic® will be used in this study.
2404656|NCT03540251|Active Comparator|Therapeutic auricular points treatment|Therapeutic auricular points treatment including auricular points:CO18、TF2、TF4、AT4、CO15（with complaint of sweating）or CO12(with symptom of heart palpitation)in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets. In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points.
2404657|NCT03540251|Sham Comparator|Placebo auricular points treatment|Placebo auricular points treatment including auricular points AH9、AH11、TG3、AT2、LO4 in accordance with the position of auricular points Location map of national standard(GBVT13734-2008) Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing placebo auricular points treatments.
2404658|NCT03540225|Experimental|Early Low-dose Arm|Start from 11-14 week: 200 mg self-administered vaginal progesterone daily
2404659|NCT03540225|Experimental|Early High-dose Arm|Start from 11-14 week: 400 mg self-administered vaginal progesterone daily
2404660|NCT03540225|Experimental|Late Low-dose Arm|Start from 20-24 week: 200 mg self-administered vaginal progesterone daily
2404661|NCT03540225|Experimental|Late High-dose Arm|Start from 20-24 week: 400 mg self-administered vaginal progesterone daily
2404662|NCT03540212|Experimental|Daclatasvir and sofosbuvir|"Daclatasvir and sofosbuvir~Single arm intervention open label trial for single tablet (Daclatasvir 90 mg and Sofosbuvir 400mg and ) Daclatasvir 90 mg for 12 weeks"
2404663|NCT03540199|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2404664|NCT03540199|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2404783|NCT03539315|Experimental|Intervention: ARCHES|All women attending facilities assigned to the intervention arm receive the Addressing Reproductive Coercion within Healthcare Settings (ARCHES) intervention.
2404665|NCT03540199|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2404666|NCT03540186|Experimental|Epigenorm Antivir and acupuncture arm|Epigenorm Antivir is a dietary supplement containing extracts of glycyrrhiza roots, hippophae rhamnoides leaves, curcumin, green tea, and vitamin C. Acupuncture involves inserting needles at certain points of the body.
2404667|NCT03540173||Training Cohort|In the training cohort, we evaluated the impact of patient-related factors on the pain during the colonoscopy. In univariatelogistic regression analysis, All factors associated with the pain during colonoscopy (p<0.1) were included in multivariate analysis.
2404668|NCT03540173||Validation group|The validation cohort was used to verify the intubation discomfort score.
3184913|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 1)|BMS-936559 (MDX-1105)
3184914|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 2)|BMS-936559 (MDX-1105)
3184915|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 3)|BMS-936559 (MDX-1105)
3184916|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 4)|BMS-936559 (MDX-1105)
3184917|NCT00729664|Experimental|Anti-PDL-1 antibody (Arm 5)|BMS-936559 (MDX-1105)
3184918|NCT00729703|Experimental|1|Dual-chamber detection and activated treatment (at least ATP) in the slow VT-zone plus activated AAIsafeR pacing (basic rate 60 bpm).
3184919|NCT00729703|Experimental|2|Single-chamber ICD following clinical practice but with a monitoring zone active to allow the documentation of all occurring ventricular arrhythmias
2404676|NCT03540121|Experimental|Video education + adherence contract|electronically delivered video education (at transplant discharge) + electronic adherence contract (1 month after enrolment)
2404677|NCT03540121|No Intervention|Standard education|standard of care education provided at each transplant center (control emails will be provided at intervention time points)
2404678|NCT03540108|Experimental|Experimental: L. plantarum ECGC 13110402 (LPLDL®)|Lactobacillus plantarum ECGC 13110402 (LPLDL®) equivalent to 4 x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
2404679|NCT03540108|Placebo Comparator|Placebo Comparator: Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed once a day, after lunch with 250mL of water.
2404680|NCT03540095|Experimental|Erector Spinae Plane Block|The patients randomized to the Erector Spinae Plane Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
2404681|NCT03540095|Experimental|Paravertebral Nerve Block|The patients randomized to the Paravertebral Nerve Block arm will receive this nerve block at the level corresponding to the rib fractures. Ropivicaine 0.5% 25 mL will be used during the procedure for initiation of pain control. Bupivicaine 0.0625% will be used for continuous infusion of local anesthetic. It will be titrated to effect, at maximum 12 mL/hr. Bupivicaine 0.0625% 3mL will be given every hour as a bolus additionally.
2404682|NCT03540082|Active Comparator|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
2404683|NCT03540082|No Intervention|Control|Written instructions will be provided on the correct way to fall without physical practice.
2404684|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
2404685|NCT03540069|Experimental|Cervical Cancer Screening Education|Context-specific multi-level peer education cervical cancer screening education curriculum is implemented by Care Groups. This is conducted through a cluster-randomized stepped wedge study. Cluster 1 (randomly selected) crosses to the intervention arm at Period 2, Cluster 2 (randomly selected) crosses over to the intervention arm at Period 3, and so on. By the end of the study, all clusters will cross over to the intervention arm (one-way), though in random order. At the end of the final time period, the outcome of interest is compared between the intervention and control periods within each cluster. Differences in service utilization and recommendation will be compared, whereby clusters serve as their own controls as they cross over from the control to intervention group.
2404686|NCT03540069|No Intervention|Control|No educational program is implemented for each cluster prior to crossover to intervention.
2404687|NCT03540056||Boys without varicocele|Boys thoroughly examined but without diagnose of varicocele
2404688|NCT03540056||Boys with a varicocoele|Boys with a diagnosed varicocele of any stage possible.
2404689|NCT03540043|Placebo Comparator|Placebo|Administration of Placebo
2404690|NCT03540043|Experimental|PUR0110 (Thykamine) 0.05%|Administration of PUR0110 (Thykamine) 0.05%
2404691|NCT03540043|Experimental|PUR0110 (Thykamine) 0.10%|Administration of PUR0110 (Thykamine) 0.10%
2404692|NCT03540043|Experimental|PUR0110 (Thykamine) 0.25%|Administration of PUR0110 (Thykamine) 0.25%
3184920|NCT00729716|Experimental|A|BioCart™II treatment
2404784|NCT03539315|No Intervention|Control|All women attending facilities assigned to the control arm receive the standard of care (no intervention).
3184921|NCT00729716|Active Comparator|B|Microfracture procedure
3184922|NCT00729729|Placebo Comparator|1|Placebo
3184923|NCT00729729|Experimental|2|Slow release PCA derivative
3184924|NCT00729729|Experimental|3|Slow release PCA derivative higher dose
3184925|NCT00729742|Experimental|Part 1|erlotinib
3184926|NCT00729742|Experimental|Part 2|erlotinib + dalotuzumab
3184927|NCT00729755|Experimental|Creatine|The subjects with major depressive disorder, treated with creatine in addition to escitalopram
3184928|NCT00729755|Placebo Comparator|Placebo|The subjects with major depressive disorder, treated with placebo in addition to escitalopram
3184929|NCT00729768|Experimental|1|
3184930|NCT00729768|Active Comparator|2|
3184931|NCT00729794|Experimental|Study Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
2404695|NCT03540017|Experimental|HIPEC|Patient will receive HIPEC in the form of Cisplatin 100mg/m2. 5. HIPEC will be provided at completion of surgical cytoreduction. The chemotherapy will be ordered by the treating gynecologic oncologist. It will be prepared in the chemotherapy pharmacy and delivered to the operating room once the surgeon confirms optimal cytoreduction and eligibility. Patients undergoing bowel resection will be left with bowel in discontinuity during the HIPEC infusion cycle. The abdomen will be temporarily closed with skin staples to prevent spillage of the perfusate. HIPEC will be delivered using the closed technique as has been well described.
2404696|NCT03539991|Experimental|Supportive care (online course, virtual meeting)|Participants complete an online course focusing on different aspects of tobacco prevention and cessation over 1 hour each per week for 4 weeks. They also engage in 6 virtual meetings over 1 hour about tobacco use once per month.
2404697|NCT03539978||SM-THINk Unit|Two of the three inpatient floors will use the SM-THINk enhanced discharge method. This is part of a clinical practice change and not for research. Parents will complete a questionnaire at the time of the patient's discharge from the hospital.
2404698|NCT03539978||Control Unit|One of the three inpatient floors will use the usual discharge method. Parents will also complete a questionnaire at the time of the patient's discharge from the hospital.
2404699|NCT03539965||Single-arm cohort|Initially, patients will be analyzed in a single group. After determining the status of the biomarkers, the patient sample will be divided into specific groups for comparative purposes.
2404700|NCT03539952|Experimental|TETA 4HCL|Active Treatment
2404701|NCT03539952|Experimental|Penicillamine|Comparator: Penicillamine
2404702|NCT03539939|Experimental|Smoker Group|This group included smoker gingival recession patients.
2404703|NCT03539939|Active Comparator|Non-smoker Group|This group included non-smoker gingival recession patients.
2404704|NCT03539926|Experimental|Lit-control®pH Meter|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the Lit-control®pH Meter device.
2404705|NCT03539926|Placebo Comparator|Reactive strips|The control of the urinary pH will be carried out twice a day: with the first urine in the morning and in the evening-night (approximately every 12h and at the same time). Measurements will be performed using the reactive strips.
2404706|NCT03539913|Active Comparator|Saccharomyces boulardii|Floratil, 250 mg sachets, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
2404707|NCT03539913|Active Comparator|Bacillus clausii|Enterogermina, 5 ml vials, twice daily (1 in the morning and 1 in the evening) during 5 consecutive days.
2404708|NCT03539900|Experimental|NB Medication|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
2404709|NCT03539900|Placebo Comparator|Placebo|Placebo will be inactive and taken daily in pill form.
2404710|NCT03539887|Experimental|Intranasal ketamine|Intranasal ketamine
2404711|NCT03539887|Experimental|Intranasal ketamine in alcohol abuse|Intranasal ketamine
2404712|NCT03539887|Placebo Comparator|Placebo|non-active placebo
2404713|NCT03539887|Placebo Comparator|Placebo in alcohol abuse|non-active placebo
2404714|NCT03539874||Confirmed paternity|Sperm sample from men with confirmed paternity
2404715|NCT03539874||Intrauterine insemination|Sperm sample from men in intrauterine insemination process
2404716|NCT03539874||In vitro fertilization|Sperm sample from men in in vitro fertilization process
2404717|NCT03539861|Other|Hemodialysis|"The treatment arm (all participants are in this arm) is done in two phases that are described below:~Treatment 1 will be standard hemodialysis (no device).~Treatment 2 will be hemodialysis with the study device. Of importance, this 5 hour session is planned to ensure adequate solute clearance but with only 4 hour high ultrafiltration to achieve the patients dry weight."
2404718|NCT03539848|Experimental|Subjects with mTBI|Individuals who come to the emergency department or urgent/acute care facility with an mTBI will undergo testing with the I-PAS Goggles.
2404719|NCT03539848|Active Comparator|Subjects with minor injuries|Individuals who come to the emergency department or urgent/acute care facility with minor injuries (such as ankle sprains or knee sprains) will undergo testing with the I-PAS Goggles.
2404720|NCT03539835|Experimental|Resistance training|
2404721|NCT03539835|Active Comparator|Cognitively-based compassion training|
3184932|NCT00729794|Placebo Comparator|Control Group|Patients with refractory, inhospital cardiac arrest, i.e., with asystole, pulseless electrical activity, or ventricular fibrillation/pulseless ventricular tachycardia not responsive to two attempts at defibrillation.
2404723|NCT03539809|Experimental|BCAA Ratio|Different Branched-chain amino acid (BCAA) ratios will be tested. BCAA are comprised of 3 different amino acids (leucine, isoleucine and valine). The ratios among these 3 amino acids will be tested at 6 different ratios. Each intervention will be for 8hours.
2404724|NCT03539796|Experimental|Dural puncture epidurals (DPE)|Dural puncture epidurals for cesarean section.
2404725|NCT03539796|Active Comparator|Traditional epidurals (EPI)|Traditional epidurals (EPI) for cesarean section.
2404726|NCT03539796|Active Comparator|Combined-spinal epidural technique (CSE)|Combined-spinal epidural technique (CSE) for cesarean section.
2404727|NCT03539783||PARDS|Children <18 years of age with PARDS and expected duration of hospitalization seven days or greater.
2404728|NCT03539783||Control|Children <18 years of age without PARDS or other lung disease and expected duration of hospitalization 7 days or greater.
2404729|NCT03539770||AIS|Adolescent idiopathic scoliosis subjects undergoing posterior spinal fusion.
3184933|NCT00729872|Experimental|1|AG011: low dose
3184934|NCT00729872|Placebo Comparator|2|Placebo: low dose
3184935|NCT00729872|Experimental|3|AG011: mid dose
3184936|NCT00729872|Placebo Comparator|4|Placebo: mid dose
3184937|NCT00729872|Experimental|5|AG011: high dose
3184938|NCT00729872|Placebo Comparator|6|Placebo: high dose
3184939|NCT00729885|Experimental|1 Goggle I|Optimized Goggle
3184940|NCT00729885|Sham Comparator|2 Google II|Goggle with 20 Degree error
3184941|NCT00729898||A|
2404731|NCT03539757||Fontan patients|Pediatric and adult Fontan patients will undergo MRI (Magnetic Resonance Imaging) of the liver using novel, non-contrast MRI methods. These MR methods will be used to detect, discriminate and measure liver fibrosis and congestion. The resulting quantitative imaging measurements will be correlated with histopathologic data obtained from a clinically-indicated liver biopsy.
3144169|NCT00031759|Other|Ablative or excisional therapy|"Patients undergo ablative or excisional therapy.~Quality of life is assessed at baseline, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
3144170|NCT00031759|Experimental|Ablative or excisional therapy + imiquimod|"Patients have topical imiquimod applied to the cervix for 6-10 hours twice weekly for a total of 5 doses. Within 3-4 weeks after the final application, patients undergo ablative or excisional therapy. Quality of life is assessed at baseline, after last dose of study drug, 3-5 days after ablation or excisional therapy, at 3 months, and then annually thereafter.~Patients are followed every 3-4 months until 2 consecutive normal Pap smears or colposcopic exams, every 6 months for 2 years, and then annually until 5 years after completion of study therapy."
2404734|NCT03539731|Active Comparator|Group I ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET scan over 15 minutes and 4 vertex-to-toe PET scans over 30 minutes each.
2404735|NCT03539731|Experimental|Group II ([18F]DASA-23, PET)|Intracranial tumor participants receive [18F]DASA-23 IV and undergo brain PET scan over 60 minutes and 1 vertex-to-toe PET scan over 30 minutes.
2404736|NCT03539731|Experimental|Group III ([18F]DASA-23, PET)|Patients with at least a 1cm3 contrast-enhancing lesion suspicious for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) on a standard-of-care (SOC) brain MRI scan. If the patient undergoes a biopsy or resection for GBM (either newly-diagnosed or 1st /2nd/ 3rd recurrence of GBM) then the remaining contrast-enhancing lesion is at least 1cm3 in size on the post-operative scan. These patients will undergo one [18F]DASA 23 PET/MRI scan before the initiation of therapy, and a second/final [18F]DASA 23 PET/MRI scan within 2-6 weeks after initiation of therapy for their GBM.
2404737|NCT03539731|Active Comparator|Group IV ([18F]DASA-23, PET)|Healthy volunteers receive [18F]DASA-23 IV and undergo brain PET/MRI brain scan for 60 mins
2404738|NCT03539718|Experimental|cases|Cases, taurolidine heparin 500 will be used at end of session
2404739|NCT03539718|Active Comparator|control|Controls, Heparin Sodium 5000 will be given at end of session
2404740|NCT03539679|Experimental|Encouraging physical activity|Encouraging physical activity by using motion sensor and feedback.
2404741|NCT03539679|No Intervention|CONTROL GROUP|No intervention.
3144171|NCT00031772|No Intervention|Control|Standard level of support after recurrence diagnosis
2404744|NCT03539640|Active Comparator|PEEP level of 5 cmH2O|During second part of the study (MRI) Diaphragm position
2404745|NCT03539640|Active Comparator|PEEP level of 10 cmH2O|During second part of the study (MRI) Diaphragm position
2404746|NCT03539640|Active Comparator|PEEP level of 15 cmH2O|During second part of the study (MRI) Diaphragm position
2404747|NCT03539627||patients with hypertension, CAD and diabetes|Patients with hypertension associated with stable CAD and diabetes on azilsartan medoxomil (Edarbi) therapy
2404748|NCT03539614|Experimental|Open label, blinded discontinuation, prazosin, placebo|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this first arm, participants will spend 4 weeks on active treatment (prazosin), followed by 4 weeks on placebo."
2404749|NCT03539614|Experimental|Open label, blinded discontinuation, placebo, prazosin|"All participants in this study will begin with 8 weeks of active treatment (prazosin), followed by a 4 week blinded discontinuation block where they will take a capsule that will start out as active treatment (prazosin), but will at some point change to placebo. Following these phases of the study, participants will be randomized to two arms. In this second arm, participants will spend 4 weeks on placebo, followed by 4 weeks on active treatment (prazosin)."
2404750|NCT03539601|Experimental|Crisaborole ointment, 2%|This treatment arm will be administered both in Cohort 1 and Cohort 2.
2404751|NCT03539601|Active Comparator|Hydrocortisone butyrate cream, 0.1%|This treatment arm will be administered in Cohort 1 only.
2404752|NCT03539601|Active Comparator|Pimecrolimus cream, 1%|This treatment arm will be administered in Cohort 2 only.
2404753|NCT03539601|Placebo Comparator|Crisaborole Vehicle|This treatment arm will be administered both in Cohort 1 and Cohort 2.
2404754|NCT03539588|Active Comparator|Treatment group 1|In this group participants will receive trigger point dry needling with electrical stimulation first and receive trigger point needling by itself second. Only MYOTECH dry needles will be used in this study. However we are not studying the equipment.
2404755|NCT03539588|Active Comparator|Treatment Group 2|In this group the participants will receive trigger point dry needling first and receive trigger point dry needling with electrical stimulation second. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
2404757|NCT03539562||Accepted Morphine Sulfate|Patients accepted morphine and promethazine as a method for pain management in early or prodromal labor.
2404758|NCT03539562||Declined Morphine Sulfate|Patients declined morphine and promethazine as a method for pain management in early or prodromal labor.
2404761|NCT03539510|Experimental|HF-ACP Website|The HF-ACP website leads participants through 4 e-learning modules. Each module contains 3 core elements: (1) educational content which provides information and support to help patients complete the module (2) interactive tools for documenting their thoughts and progress and (3) motivational video clips that encourage behavior change by validating participants ambivalence, suggesting strategies to help participants complete the task and to encourage and reassure participants that they can do this.
2404785|NCT03539302|Experimental|Repeat dose inhaled flecainide acetate|One 120 mg dose of flecainide acetate inhalation solution will be administered via two oral inhalations of 3.5 minutes. There will be a 1 minute break between the two inhalations. A single nebulizer will be used.
2404762|NCT03539510|No Intervention|Usual Care|"The standard of care for advance care planning at our institution is the Speak Up booklet and the Power of Attorney workbook from the Attorney General's Office - Ontario. Patients randomized to the Control arm will be asked to register on a separate research portal where participants will have electronic access to both of the booklets and a link to the Speak Up online Interactive workbook. There is no specific information on HF or HF treatments. Participants in the control arm will be asked to complete the ACP using the interactive workbook. Participants in the control arm will not receive any additional communication from the research team about their progress."
2404766|NCT03539471||psychiatric resident in NTUH|
2404768|NCT03539445|Experimental|Butylphthalide|Drug: Butylphthalide Sodium Chloride Injection and Butylphthalide Soft Capsules
2404769|NCT03539445|Placebo Comparator|Placebos|Drug: Butylphthalide Placebo Injection and Butylphthalide Placebo Soft Capsules
3144172|NCT00031772|Experimental|Intervention|Phone intervention for patients experiencing first recurrence with quality of life questionnaires, psychosocial assessment and care.
3144173|NCT00031837|Experimental|Dalteparin|5,000 anti-Xa units of dalteparin subcutaneously once daily for six months in addition to gemcitabine at 1,000 mg/m2 as a 30-minute infusion weekly for 7 weeks followed by a week of rest for the first cycle and weekly for three weeks followed by a week of rest for each subsequent cycle.
2404772|NCT03539419||Patients with plaque psoriasis on apremilast|Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
2404773|NCT03539406|Experimental|NK-cells without preparative regimen|NK-cells without preparative regimen
2404774|NCT03539406|Experimental|NK-cells with preparative regimen|NK-cells with preparative regimen
2404775|NCT03539367|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2404776|NCT03539367|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2404777|NCT03539354|Active Comparator|CABG + b-blockers|Standart coronary artery bypass grafting is performed with b-blockers treatment. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
2404778|NCT03539354|Experimental|CABG + b-blockers + temporary SCS|Before coronary artery bypass grafting in the experimental group, 3 days of temporary spinal cord stimulation is performed than device turned off and coronary artery bypass grafting procedure is made. The device for spinal cord is turned on in intensive care unit for 7 days. Continuous ECG during intensive care unit stay, daily ECG, and 24-h Holter monitor recordings will be performed at 7, 14, 21, and 30 days after coronary artery bypass grafting, external loop recorder after discharge from intensive care unit till 30 days after coronary artery bypass grafting.
2404779|NCT03539341|Experimental|PLH-Thailand parenting programme|Trained facilitators and coaches will deliver the programme over eight weekly sessions at the Udon Thani Regional Hospital during the feasibility pilot and the RCT. During the RCT, the 60 parents/primary caregivers in the intervention group will be divided into 4 groups of 15 participants, with each group overseen by 2 facilitators and 1 coach. Core session activities may include discussion about assigned home activities, core parenting principles, illustrated stories, role-plays, and problem solving. Home visits will be conducted by facilitators to those parents/primary caregivers who miss sessions or require additional support, and SMS/LINE messages will be delivered to all participants twice per week with relevant parenting tips and reminders to attend the upcoming session.
2404780|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand. The delivery of services at Parent Schools are guided by the Ministry of Public Health Handbook for Parent Schools, which appear to be open to adaptation at the local level. At Parent Schools, three to five sessions are provided to parents in groups or one-on-one by hospital health personnel.
2404781|NCT03539328|Other|Standard treatment|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion
2404782|NCT03539328|Experimental|Pembrolizumab|Pegylated Liposomal Doxorubicin 40 mg/mq iv q 28 or Weekly Paclitaxel 80 mg/mq d 1,8,15 q 28 or Gemcitabine 1000 mg/mq d 1,8 q 21 or At physician' discretion plus Pembrolizumab 200 mg d1 q 21 iv infusion in 30 minutes
3144174|NCT00031889|Active Comparator|Arm I|Patients receive oral exemestane once daily
3144175|NCT00031889|Active Comparator|Arm II|Patients receive exemestane as in arm I and oral bicalutamide once daily
3144176|NCT00031980|Experimental|cyclosporine|"Patients receive oral cyclosporine every 12 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 4 months for 1 year and then every 6 months for 9 years."
3144177|NCT00031993|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily for 4 weeks. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3144178|NCT00032006|Experimental|brachytherapy + radiation|"Within 4 weeks after completion of androgen suppression, patients are sequentially enrolled to 2 different cohorts of brachytherapy.~Cohort 1: Patients undergo initial-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Cohort 2: After a minimum of 1-year follow-up for all patients in cohort 1, if tolerance is acceptable, additional patients undergo higher-dose transperineal interstitial permanent prostate brachytherapy with iodine I 125 or palladium Pd 103.~Quality of life is assessed at baseline, within 2 weeks prior to brachytherapy, every 3 months for 1 year, and then every 6 months for 2 years.~Patients are followed every 3 months for 1 year, every 6 months for 4 years, and then annually for 5 years."
3144179|NCT00032019|Experimental|EPOCH-Rituximab|Addition of monoclonal antibody therapy to chemotherapy for treatment of pts with aggressive CD20+ NHL
2404789|NCT03539276|Experimental|Post-intervention|One 90-minute interdisciplinary knowledge exchange including the provision of a validated list of appropriate and inappropriate medications for severe dementia long-term care residents.
2404790|NCT03539263|Experimental|Group 1|the subjects are treated with probiotics: Bifihappy
2404791|NCT03539263|Placebo Comparator|Group 2|the subjects are treated with a placebo
2404792|NCT03539250|Experimental|IMRT with and without chemotherapy|Subdivision of the PTVnx into regions with different prescribed absorbed doses (PTVsv1,PTVsv2, PTVsv2 is the overlaps between PTVnx and temporal lobe) can be used in cases for which the PTVnx overlaps temporal lobe. When the volume of PTVsv2 is less than 0.2 cubic centimeter (cc), the prescribe dose for PTVsv2 is as the same as that of the PTVsv1, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.2 cc and 0.5cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 63.1Gy, Dmax 72.9Gy for TL (32 fractions). When the volume of PTVsv2 is between 0.5 cc and 1cc, the prescribe dose for PTVsv2 is 66Gy, D1cc 65.8Gy, Dmax 75.2Gy for TL (32 fractions).
2404793|NCT03539237|Experimental|"Video-group"|"Video group: Individuals in this group receive the intervention Video demonstration of physical activity intensity levels. They watch a 3-minute-video explaining and visualizing light-, moderate-, and vigorous-intensity levels of physical activity before completing a tablet PC-supported physical activity assessment at the DZHK-examination center.The video can not be skipped."
2404794|NCT03539237|No Intervention|"No video-group"|"No video group: Individuals in this group do not receive the intervention Video demonstration of physical activity intensity levels. They complete a tablet PC-supported physical activity assessment at the DZHK-examination center without receiving a 3-minute-video explaining and visualizing the different intensity levels of physical activity."
2404795|NCT03539224|Experimental|Dolutegravir (DTG) + Lamivudine (3TC)|Eligible subjects will receive one 50 mg tablet of DTG plus 300 mg 3TC tablet orally once daily upto 48 weeks
2404798|NCT03539198||Locoregional|Patients with recurrent locoregional head and neck cancer
2404799|NCT03539198||Metastatic|Patients with recurrent metastatic head and neck cancer
2404800|NCT03539185|Active Comparator|Airtraq|Awake tracheal intubation using airtraq videolaryngoscope.
2404801|NCT03539185|Active Comparator|Fiberoptic|Awake nasotracheal tracheal intubation using flexible fiberoptic bronchoscope.
2404802|NCT03539172|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
2404803|NCT03539159|Experimental|Allogeneic conventional sized serum eye drops|
2404804|NCT03539159|Experimental|Allogeneic micro sized serum eye drops|
2404805|NCT03539146|Active Comparator|Control yogurt|Treatment with a control yogurt with cascara but no dietary fiber.
2404806|NCT03539146|Experimental|Yogurt with fiber|Treatment with yogurts containing cascara and 3%, 7% and 13% of dietary fiber.
2404807|NCT03539107|Experimental|Spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
2404808|NCT03539107|Active Comparator|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
2404809|NCT03539094|Experimental|Intermittent fasting|The subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
2404810|NCT03539094|No Intervention|Western diet|The subjects randomized to this group will eat a standard western style diet.
2404811|NCT03539081|Experimental|Subjects with RLS|"Subjects with Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
2404812|NCT03539081|Other|Subjects without RLS|"Subjects without Restless Leg Syndrome that have recently undergone Spinal Cord Stimulation (SCS) Implantation for chronic pain.~Intervention: Use of epidural spinal cord stimulation."
2404813|NCT03539081|Other|Continous BP Monitoring|"This arm consists of subjects from arm Subjects with RLS, Subjects without RLS, and the rest of the qualifying subjects undergoing continuous blood pressure portion of the study only.~Intervention: Use of epidural spinal cord stimulation."
2404814|NCT03539068|No Intervention|WEB-ED Only Control Arm|Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the no intervention control group will receive no further intervention but asked to participate in a subsequent study phase that addresses VA and post-deployment care access
2404815|NCT03539068|Experimental|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
2404816|NCT03539055|Experimental|Treatment arm|"Dabigatran 75 or 150mg BID x 90 days plus ASA 81mg daily.~Single arm, prospective unblinded study on post Watchman LAA closure device implant anti-coagulation management at a primary center (Vanderbilt Medical Center) and up to 5 additional high volume LAA implant centers. This trial will be designed to evaluate the use of dabigatran for 90 days post implantation of an LAA closure device (Watchman LAA Closure Device, Boston Scientific Inc.)"
2404817|NCT03539029||Control group|age and sex matched healthy control persons
2404818|NCT03539029||Surgery|patients with ankle fracture treated surgically
2404819|NCT03539029||Conservative treatment|patients with ankle fracture treated conservatively
2404820|NCT03539003|Experimental|sevoflurane (Group S)|general anesthesia with sevoflurane
2404821|NCT03539003|Active Comparator|desflurane (Group D)|general anesthesia with desflurane
2404822|NCT03539003|Active Comparator|total intravenous anesthesia (Group T)|general anesthesia with total intravenous anesthesia
2404823|NCT03538990|Experimental|DASH Eating Pattern|The DASH eating pattern meals prepared for study participants will strictly follow DASH meal planning guidelines published by National Heart, Lung, and Blood Institute of the National Institutes of Health. During the intervention phase of the study, all participants will exclusively consume prepared meals and provided beverages which will be delivered to participants' homes. Meals will be planned and prepared based on individual participant energy needs and dietary restrictions by a Registered Dietitian at the Georgia Clinical and Translational Science Alliance (CTSA) Bionutrition Unit located at Emory University.
2404824|NCT03538977|Active Comparator|Conventional physiotherapy (GP)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of conventional physiotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention.While they are in need of intensive care and hospitalized in the NICU, infants will receive conventional physiotherapy care three times a day. After discharge to the intermediate care unit (ICU), patients will receive care only once a day. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
2404825|NCT03538977|Experimental|GP + hydrotherapy (GH)|The sample will be evaluated once a day in the morning until they complete at least 11 intervention sessions of hydrotherapy in five moments: immediately before therapy, immediately after, 15, 30 and 60 minutes after the intervention. While they are in need of intensive care and hospitalized in the NICU, infants allocated to GH, hydrotherapy will be performed once a day, associated with two sessions of conventional physiotherapy. After discharge to the intermediate care unit (ICU), patients will receive care only once a day, both conventional physiotherapy and hydrotherapy. Evaluations and interventions will be carried out five days a week (Monday to Friday), according to the logistics of the unit.
2404826|NCT03538964|Active Comparator|Toric intraocular lens (IOL)|toric intraocular lens for low astigmatism correction
2404827|NCT03538964|Sham Comparator|Non toric intraocular lens (IOL)|non toric intraocular lens
2404828|NCT03538951|Experimental|Cohort 1|10% VDA-1102
2404829|NCT03538951|Experimental|Cohort 2|20% VDA-1102
3144180|NCT00032032|Experimental|radiotherapy + paclitaxel + carboplatin|"Patients undergo radiotherapy once daily 5 days a week for 7 weeks and 2 days (a total of 37 fractions). Patients concurrently receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes once weekly for 7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Beginning 3 weeks after completion of radiotherapy, patients receive paclitaxel and carboplatin as above. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, once during the last week of radiotherapy, and then every 3 months for 2 years.~Patients are followed at 3 weeks, every 3 months for 21 months, and then every 6 months for 3 years."
3144181|NCT00032084|Placebo Comparator|Behavioral Intervention + Placebo|Smoking cessation intervention , nicotine replacement, psychosocial assessment and care, and placebo.
3144182|NCT00032084|Active Comparator|Behavioral Intervention + Bupropion|Smoking cessation intervention, nicotine replacement, psychosocial assessment and care, and bupropion hydrochloride .
3144183|NCT00032110|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients with a CR receive 2 additional courses after CR is confirmed.
3144184|NCT00032162|Experimental|PLD|dose finding study of PLD in combination with Carboplatin
2404869|NCT03538756|Experimental|Group A--Walkasins On Then Off|"Subjects will first wear Walkasins and receive vibrotactile feedback that reflects real changes in center of pressure sway. Following a one-hour rest period, they will be retested with Walkasins turned off.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
2404870|NCT03538756|Experimental|Group B--Walkasins Off Then On|"Subjects will first wear Walkasins turned off and not receive any vibrotactile feedback. Following a one-hour rest period, they will be retested with Walkasins turned on.~After the baseline visit, subjects will take the devices home for long-term use and return for periodic follow-up visits."
3144185|NCT00032188|Experimental|Arm I (aldesleukin and lowest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive lowest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3144186|NCT00032188|Experimental|Arm II (aldesleukin and middle dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive middle dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3144187|NCT00032188|Experimental|Arm III (aldesleukin and highest dose bryostatin 1)|Patients receive IL-2 subcutaneously on days 1-4, 8-11, and 15-18. For the second and subsequent courses of IL-2, patients also receive highest dose bryostatin 1 IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
3144188|NCT00032227|Experimental|1|Surgical release of CTS
3144189|NCT00032227|Active Comparator|2|Non-surgical treatment for CTS (splint, physical therapy, ultrasound)
3144190|NCT00032344|Other|1|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
3144191|NCT00032357|Other|Arm 1|Usual care plus Ferritin reduction to a calculated nadir of 25 ng/mL by phlebotomy
3144192|NCT00032357|No Intervention|Arm 2|Usual care only; no intervention control
3144193|NCT00032370|Other|1|Elective vascular surgery
3144194|NCT00032370|Other|2|Cardiac revascularization prior to vascular surgery.
3144195|NCT00032435|Experimental|1|PAL-40 Active
3144196|NCT00032435|Placebo Comparator|2|PAL-40 Placebo
3144197|NCT00032448|Other|1|Open and laparoscopic herniorrhaphy
3144198|NCT00032539||1|
3144199|NCT00032552||1|
3144200|NCT00032565||1|No intervention. Telephone interview.
3144201|NCT00032617|Active Comparator|1|Prolonged Exposure
3144202|NCT00032617|Active Comparator|2|Present Centered Therapy
3144203|NCT00032643|Other|Arm 1|
3144204|NCT00033111|Active Comparator|Cabergoline|Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
3144205|NCT00033111|Placebo Comparator|Placebo|Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
3144206|NCT00033228|Experimental|Cohort 1|The first cohort of 6 patients received 500 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
3144207|NCT00033228|Experimental|Cohort 2|The second cohort of 6 patients received 1000 ug of Synchrovax SEM plasmid DNA vaccine. All patients were to be monitored for dose limiting toxicities DLTs) for a minimum of 2 weeks after their second infusion of vaccine on Day 15 before allowing patients to enroll at the next dose group. The decision to progress to the next dose group was to be based on occurrence of DLTs observed in 1 or fewer (<33%) patients of a 6 patient cohort.
3144208|NCT00033228|Experimental|Cohort 3|The third cohort of 6 patients received 1500 ug of Synchrovax SEM plasmid DNA vaccine. The maximum tolerated dose (MTD) was to be determined by the observation of DLT at each dose group.
3144209|NCT00033254|Active Comparator|Arm I (radiation therapy)|Patients undergo radiotherapy once daily 5 days a week for 3 weeks.
3144210|NCT00033254|Experimental|Arm II (radiation therapy, thalidomide)|Patients undergo radiotherapy as in arm I. Beginning on the first day of radiotherapy, patients receive oral thalidomide once daily.
3144211|NCT00033267|Experimental|Treatment|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive a maximum of 6 courses. Patients with partial response receive a maximum of 12 courses. Patients with CR receive 2 additional courses beyond CR.
3184942|NCT00729911|Active Comparator|AF ablation|"Subjects assigned to the catheter ablation strategy will undergo catheter based AF ablation. The goal of the procedure is to achieve isolation of all 4 pulmonary veins.~Subjects assigned to receive Amiodarone will have the oral medication initiated in an clinic setting."
3184943|NCT00729911|Active Comparator|Amiodarone|Amiodarone is taken orally on a daily basis.
3144212|NCT00033280|Experimental|Pre-RT temozolomide, RT plus temozolomide|Pre-radiation therapy (RT) temozolomide, RT plus temozolomide
3144213|NCT00033306|Experimental|BMS-247550|
3144214|NCT00033345|Experimental|High-Risk Breast Cancer|All subjects first went through a 4-week placebo run-in period. Next, subjects took Indole-3-carbinol 400mg daily for 4 weeks followed by a 4-week period of Indole-3-carbinol 800mg daily.
3144215|NCT00033358|Experimental|Arm I (medroxyprogesterone)|Patients receive medroxyprogesterone intramuscularly once on day 1. Approximately 90 days after the injection, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
3144216|NCT00033358|Experimental|Arm II (ethinyl estradiol, norgestrel)|Patients receive OCP comprising ethinyl estradiol and norgestrel once daily on days 1-21. Treatment repeats every 28 days for 3-4 courses (3-4 packs of OCP) in the absence of unacceptable toxicity. Approximately 1 week after starting the fourth pack of OCP, patients undergo a repeat transvaginal ultrasound and endometrial biopsy.
3144217|NCT00033397||Arm A|"Patients receive an injection of gadopentetate dimeglumine and undergo magnetic resonance imaging (MRI) of the breast before initiation, 1-3 days after initiation, and then after completion of neoadjuvant anthracycline-based chemotherapy and prior to surgery. Patients who previously received a taxane also undergo an additional contrast-enhanced MRI scan.~Mammograms and possibly ultrasounds are performed prior to and after chemotherapy (before surgery).~Patients are followed every 6 months for 5 years and then annually for up to 10 years."
3144218|NCT00033423|Experimental|Cohort 1|First radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3144219|NCT00033423|Experimental|Cohort II|Second radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3144220|NCT00033423|Experimental|Cohort III|Third radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3144221|NCT00033423|Experimental|Cohort IV|Fourth radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3144222|NCT00033423|Experimental|Cohort V|MTD radiation dose regimen of yttrium Y 90 ibritumomab tiuxetan
3144223|NCT00033449|Experimental|Treatment (gefitinib, radiation therapy, cisplatin)|See detailed description.
3144224|NCT00033462|Experimental|Arm I|Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3144225|NCT00033553|Experimental|Paclitaxel + Carboplatin|Paclitaxel and carboplatin induction (2 cycles)followed by chemotherapy with the addition of radiotherapy for 7 cycles
3144226|NCT00033553|Experimental|Gemcitabine + Carboplatin|Gemcitabine and carboplatin induction (2cycles) followed by chemotherapy with the addition of radiotherapy for 7 cycles
3144227|NCT00033592|Experimental|Arm I: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm I who continue to smoke are randomized to one of two treatment arms Arm IV or Arm V. Participants randomized to arm I who are smoke-free are randomized to one of two treatment arms Arm VIII or Arm IX."
3144228|NCT00033592|Experimental|Arm II: bupropion|"Participants receive oral bupropion 1-2 times daily.~Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm II who continue to smoke are randomized to one of two treatment arms Arm VI or Arm VII. Participants randomized to arm II who are smoke-free are randomized to one of two treatment arms Arm Arm X or Arm XI."
3144229|NCT00033592|Experimental|Arm III: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily. Treatment continues for 12 weeks. After 12 weeks, participants are randomized a second time based on whether they continue to smoke or are smoke-free.~Participants randomized to arm III who continue to smoke do not receive any further therapy. Participants randomized to arm III who are smoke-free are randomized to one of four treatment arms Arm XII, Arm XIII, Arm XIV or Arm XV."
3144230|NCT00033592|Experimental|Arm IV: bupropion|"Participants receive oral bupropion 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
3144231|NCT00033592|Placebo Comparator|Arm V: placebo|"Participants receive oral placebo 1-2 times daily for 12 weeks.~All participants are followed every month for 6 months."
3144232|NCT00033592|Experimental|Arm VI: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
2404846|NCT03538925|Experimental|Treatment Group|AAC Generative Language Intervention
2404847|NCT03538925|Active Comparator|Business as Usual|Standard of Care / Business as Usual
2404848|NCT03538912|Other|Biomarker group|patient follow the Biomarker strategy
2404849|NCT03538912|Other|Routine group|patient follow the routine strategy
3144233|NCT00033592|Placebo Comparator|Arm VII: placebo inhaler|"Participants receive 6-16 placebo inhaler cartridges per day for 12 weeks.~All participants are followed every month for 6 months."
2404851|NCT03538886|Active Comparator|Percutaneous coronary intervention (PCI)|Currently, percutaneous coronary intervention (PCI) using balloon and drug eluting stents is the treatment of choice for treatment of a proximal LAD lesion.
2404852|NCT03538886|Experimental|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting is a well established treatment with documented excellent long-term results for the treatment of proximal LAD lesion.
2404853|NCT03538873|Active Comparator|Physical activity|"The assessment of physical activity in the prevention of depression. The intervention program being implemented in this study consists of four steps, lasting three months each:~Step 1 - Watchful waiting Step 2 - Physical Activity Intervention 1 Step 3 - Physical Activity Intervention 2 Step 4 - Referral to primary care In the case of the CES-D scores remain high, participants will receive orientation to discuss with their doctors the need to receive a specific medication."
2404854|NCT03538873|No Intervention|Usual care|Participants in the usual care group will have unrestricted access to usual care for depressive and / or anxiety symptoms.
3144234|NCT00033592|Experimental|Arm VIII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
3144235|NCT00033592|Placebo Comparator|Arm IX: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day for 40 weeks.~All participants are followed every month for 6 months."
2404857|NCT03538834|Experimental|Cod meal from residual material|Dietary supplement: cod meal from residual material, 8 g protein daily for 8 weeks
2404858|NCT03538834|Placebo Comparator|Control|Control group receive tablet containing fillers and no protein
2404867|NCT03538769|No Intervention|Baseline group|This will be the pre and post alert phase where e-alerts will not be sent to providers
2404868|NCT03538769|Other|Alert group|This will be the phase when e-alerts will be sent to the provider
3144236|NCT00033592|Experimental|Arm X: bupropion|"Participants receive oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144237|NCT00033592|Placebo Comparator|Arm XI: placebo|"Participants receive oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144238|NCT00033592|Experimental|Arm XII: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144239|NCT00033592|Placebo Comparator|Arm XIII: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144240|NCT00033592|Experimental|Arm XIV: nicotine inhaler cartridges|"Participants receive 6-16 nicotine inhaler cartridges per day and oral bupropion 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144241|NCT00033592|Placebo Comparator|Arm XV: placebo inhaler cartridges|"Participants receive 6-16 placebo inhaler cartridges per day and oral placebo 1-2 times daily for 40 weeks.~All participants are followed every month for 6 months."
3144242|NCT00033605|Experimental|octreotide + radiation|"Patients receive short-acting octreotide subcutaneously (SC) on day 1 and long-acting octreotide intramuscularly (IM) on days 2 and 29.~Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
3144243|NCT00033605|Active Comparator|placebo + radiation|"Patients receive placebo SC on day 1 and IM on days 2 and 29. Treatment continues in the absence of unacceptable toxicity or the development of severe diarrhea.~Patients complete a bowel function questionnaire at baseline, weekly during radiotherapy, and then weekly for 4 weeks and at 1 and 2 years after completion of radiotherapy.~Patients are followed weekly for 4 weeks and then at 1 and 2 years."
3144244|NCT00033618|Experimental|Arm I (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144245|NCT00033618|Experimental|Arm II (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144246|NCT00033696|Experimental|chemotherapy + radiation therapy|"Induction therapy: Patients receive paclitaxel IV over 3 hours on days 1 and 22, oral topotecan on days 2-4 and 23-25, and oral etoposide on days 5-7 and 26-28. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on days 8 and 29 and continuing until blood counts recover.~Consolidation therapy: Patients receive carboplatin IV over 1 hour on days 43, 64, and 85 and etoposide IV over 1 hour on days 43-45, 64-66, and 85-87. Patients undergo radiotherapy daily 5 days per week beginning on day 43 and continuing for 6-7 weeks.~Patients with rapid disease progression discontinue study therapy.~Patients are followed at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years."
3144247|NCT00033735|Experimental|fluorouracil|
2404880|NCT03538730|No Intervention|Attention Control|Similar to previous narrative and memory interventions, parents in the control group will receive instructions from a researcher for 20 minutes on how to engage in child-directed play. Importantly, they will not talk about pain or the past surgery experience.
2404881|NCT03538730|Experimental|Memory Reframing Intervention|Parents in the intervention group will spend 20 minutes with a researcher and receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods.
2404882|NCT03538704|Experimental|BMI≥25 group with metformin|Patients with BMI≥25kg/m2 in the experimental group are treated with medroxyprogesterone acetate (MPA) 0.25g/d plus metformin and are followed-up of baseline data, hormone levels,
2404883|NCT03538704|No Intervention|BMI≥25 group without metformin|Patients with BMI≥25kg/m2 in the none intervention group are treated with MPA 0.25g/d alone and are followed-up of baseline data, hormone levels, and endometrial pathology every 3 months until 12 months.
2404884|NCT03538691|Experimental|Brexpiprazole & Citalopram Hydrobromide|Brexpiprazole: oral tablet; 2 to 3 mg/day Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
2404885|NCT03538691|Placebo Comparator|Placebo & Citalopram Hydrobromide|Placebo: daily oral tablet Citalopram hydrobromide: oral tablet; 20 or 40 mg/day
2404886|NCT03538691|Experimental|Brexpiprazole & Escitalopram|Brexpiprazole: oral tablet; 2 to 3 mg/day Escitalopram: oral tablet; 10 or 20 mg/day
2404887|NCT03538691|Placebo Comparator|Placebo & Escitalopram|Placebo: daily oral tablet Escitalopram: oral tablet; 10 or 20 mg/day
2404888|NCT03538691|Experimental|Brexpiprazole & Fluoxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Fluoxetine: oral capsule; 20 or 40 mg/day
2404889|NCT03538691|Placebo Comparator|Placebo & Fluoxetine|Placebo: daily oral tablet Fluoxetine: oral capsule; 20 or 40 mg/day
2404890|NCT03538691|Experimental|Brexpiprazole & Paroxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
2404891|NCT03538691|Placebo Comparator|Placebo & Paroxetine|Placebo: daily oral tablet Paroxetine: oral controlled-release tablet; 37.5 or 50 mg/day
2404892|NCT03538691|Experimental|Brexpiprazole & Sertraline|Brexpiprazole: oral tablet; 2 to 3 mg/day Sertraline: oral tablet; 100, 150 or 200 mg/day
2404893|NCT03538691|Placebo Comparator|Placebo & Sertraline|Placebo: daily oral tablet Sertraline: oral tablet; 100, 150 or 200 mg/day
2404894|NCT03538691|Experimental|Brexpiprazole & Duloxetine|Brexpiprazole: oral tablet; 2 to 3 mg/day Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
2404895|NCT03538691|Placebo Comparator|Placebo & Duloxetine|Placebo: daily oral tablet Duloxetine: oral delayed-release capsule; 40 or 60 mg/day
2404896|NCT03538691|Experimental|Brexpiprazole & Venlafaxine extended-release (XR)|Brexpiprazole: oral tablet; 2 to 3 mg/day Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
2404897|NCT03538691|Placebo Comparator|Placebo & Venlafaxine extended-release (XR)|Placebo: daily oral tablet Venlafaxine XR: daily extended-release capsule; 75, 150, or 225 mg/day
3144248|NCT00033735|Experimental|Irofulven|
3144249|NCT00033748|Experimental|Combined Monoclonal Antibody Therapy|Patients with minimal metastatic colorectal cancer are treated with 2 anti-idiotype monoclonal antibodies
3144251|NCT00033865|Experimental|1|Yoga treatment for 8 weeks
3144252|NCT00033865|No Intervention|2|Sleep hygiene instructions only
3144253|NCT00034281|Experimental|TAK-165 QD|
3144254|NCT00034528|Experimental|Allogeneic stem cell transplantation|Participants will receive a nonmyeloablative conditioning regimen of fludarabine and busulfan prior to allogeneic peripheral blood stem cell (CD34+) infusions. FK506 and prednisone will be administered for graft versus host disease (GVHD) prophylaxis.
3144255|NCT00034541|Experimental|1|An initial dose of cetuximab (400 mg/m2 i.v. over 120 minutes) will be administered 1 week prior to the initiation of chemotherapy. Thereafter, cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each cycle (every 3 weeks) of therapy, a 3-hour paclitaxel (225 mg/m2) infusion will be administered 1-hour post completion of the cetuximab infusion, immediately followed by a 30-minute carboplatin (AUC=6) infusion.
3144256|NCT00034554|Experimental|1|0.1mg
3144257|NCT00034554|Experimental|2|0.5mg
3144258|NCT00034554|Experimental|3|2.0mg
3144259|NCT00034554|Experimental|4|4.0mg
3144260|NCT00034554|Experimental|5|8.0mg
3144261|NCT00034814|Placebo Comparator|1|Enzyme-inducing placebo TID
3144262|NCT00034814|Experimental|2|Enzyme-inducing Talampanel 35 mg TID
3144263|NCT00034814|Experimental|3|Enzyme-inducing TLP 50mg TID
2404919|NCT03538574|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I), considered the treatment of choice by the American Academy of Sleep Medicine, combines cognitive therapy, stimulus control, sleep restriction, sleep hygiene, and relaxation to improve sleep outcomes, with demonstrated efficacy in adult and older adult populations
2404920|NCT03538574|Experimental|MAP-I|The Mindful Awareness Practices (MAPs) is a validated and curriculum-based meditation similar to Mindfulness Based Stress Reduction, with the exception that MAPs does not include a day-long retreat or yoga and hence takes a more practical and accessible approach that focuses specifically on the practice of mindfulness and its application in everyday life. (http://marc.ucla.edu) MAP for Insomnia (MAP-I) is a modified version of MAPs that incorporates practice prior to bed, use of practice in the bed during night-time awakenings, and daily body scan.
2404921|NCT03538548|Experimental|Treatment|Participants receive a standard 12-week course of Cognitive Behavioral Therapy for Relapse Prevention (CBT-RP; Carroll, 1998). The treatment protocol will be implemented over 12 weeks, with two 1-hour sessions per week for the first two weeks and one 1-hour session per week thereafter (i.e., a total of 14 sessions).
2404922|NCT03538535|Experimental|Go/No-Go Active Learning (GOAL)|Adaptation of Behavioral Activation, focused on reinforcement learning strategies.
2404923|NCT03538522|Experimental|Low-dose N-831(Traneurocin)- 10 mg QD|Oral administration of 10 mg of NA-831 (Traneurocin) per day for 24 weeks
2404924|NCT03538522|Experimental|Medium-dose NA-831(Traneurocin)- 20 mg QD|Oral administration of 20 mg of NA-831(Traneurocin) per day for 24 weeks
2404925|NCT03538522|Experimental|High-dose NA-831(Traneurocin)- 40 mg QD|Oral administration of 40 mg of NA-831(Traneurocin) per day for 24 weeks
2404926|NCT03538522|Placebo Comparator|Placebo|Oral administration of placebo per day for 24 weeks
2404927|NCT03538496|Active Comparator|ultrasound guided erector spinae plane block|ultrasound guided erector spinae plane block with 20 ml %0.25 bupivacaine
2404928|NCT03538496|Active Comparator|ultrasound guided paravertebral block|ultrasound guided paravertebral block with 20 ml %0.25 bupivacaine
2404929|NCT03538483|Active Comparator|ultrasound guided serratus plane block|Ultrasound Guided Serratus Plane Block 30 ml %0.25 Bupivacaine
2404930|NCT03538483|Active Comparator|ultrasound guided erector spinae plane block|Ultrasound Guided Erector Spinae Plane Block 20 ml %0.25 Bupivacaine
2404931|NCT03538470|Experimental|Spa treatment|Mineral water cares in Contrexéville thermal cure center, massage, cataplasm.
2404932|NCT03538444|Experimental|Active rTMS|Participants will receive 18 sessions of active repetitive Transcranial Magnetic Stimulation over a period of three days. TMS consists of 3000 pulses of 10Hz stimulation applied to the left DLPFC using the beam F3 method
2404933|NCT03538444|Placebo Comparator|Sham rTMS|Participants will receive 18 sessions of sham rTMS over a period of three days.
2404936|NCT03538418|Experimental|WAT group|The WAT group will receive a 3-month WAT-based exercise training programme, which includes 12 weekly exercise training sessions (an hour each) in addition to 2 face-to-face sessions followed by weekly to monthly telephone sessions offering support on dealing with technical issues and BCTs (7 session in total). The WAT group will be left to use the WAT on their own for 3 months during the follow-up period.
2404937|NCT03538418|No Intervention|Control group|The control group will receive a 3-month exercise training programme without a WAT, which also includes 12 weekly exercise training sessions (an hour each) in addition to 7 face-to-face and telephone sessions offering support for BCTs.
2404938|NCT03538405|Experimental|all participants|All participants received the same interventions, there were no subgroups interventions: supporting cushions and harmonic techniques
2404939|NCT03538392||PAD|
2404940|NCT03538392||AV Fistula|
2404941|NCT03538392||AV Graft|
2404942|NCT03538379|Active Comparator|Combat Application Tourniquet (CAT)|The combat application tourniquet (CAT) is the type of commercial tourniquet taught in the B-Con course as administered by the investigators. It will serve as the control group to which all other types of tourniquets, which are not explicitly taught in the course, are compared to.
2404943|NCT03538379|Active Comparator|Sof Tourniquet (Sof-T)|The Sof-Tourniquet (Sof-T) is a commercial windlass type tourniquet similar to the CAT tourniquet in that it is based on a windlass mechanism. Its application not explicitly taught in the B-Con course.
2404944|NCT03538379|Active Comparator|Stretch-Wrap-And-Tuck (SWAT) Tourniquet|The Stretch-Wrap-And-Tuck (SWAT) Tourniquet is a commercial elastic tourniquet. Its application not explicitly taught in the B-Con course.
2404945|NCT03538379|Active Comparator|Rapid Application Tourniquet (RAT)|The Rapid Application Tourniquet (RAT) is a commercial elastic tourniquet similar to a bungee cord. Its application not explicitly taught in the B-Con course.
2404946|NCT03538379|Active Comparator|Improvised Tourniquet|The improvised tourniquet arm will involve participants being given supplies to enable them to fashion a tourniquet. The supplies will include a leather belt, gauze, shoestring, and a rod to act as a windlass.
2404947|NCT03538366|Experimental|Donor FMT|Fecal transplant from unrelated, healthy volunteers
2404948|NCT03538353|Other|Pain Education Video|Participants will watch a pain education video and then answer several questions.
2404949|NCT03538340|Active Comparator|Control Arm|Control Arm: Surgery without intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
2404950|NCT03538340|Experimental|Study Arm|Study Arm: Surgery with intercostal Cryoanalgesia + Standard of Care (thoracic epidural)
2404951|NCT03538327|Experimental|Silybin|50 Caucasian never-treated hypertensive outpatients, 27 males and 23 women, age range 42-60 years (mean+SD=52+7), showing normal glucose tolerance but 1-h post load plasma glucose >155 mg/dl, during the OGTT.
2404952|NCT03538314|Experimental|Experimental Treatment|UV1/GM-CSF
3144264|NCT00034814|Placebo Comparator|4|Non-enzyme-inducing placebo TID
3144265|NCT00034814|Experimental|5|Non-enzyme-inducing TLP 25mg TID
3144266|NCT00034814|Experimental|6|Non-enzyme-inducing TLP 35mg TID
2404956|NCT03538288|Experimental|Twenty sessions of rTMS|Twenty sessions of rTMS will be applied to treatment seeking participants.
2404957|NCT03538275||Unipolar depression cohort|
2404958|NCT03538275||Bipolar depression cohort|
2404959|NCT03538275||Healthy Control cohort|
2404960|NCT03538262||former phase 3 PD trial participants|The AT-HOME PD cohort enrolled upon completion of STEADY-PD3 or during completion of SURE-PD3; enrolling 2 to 6 years after diagnosis, and on standard dopaminergic therapy for 0 to 3 years. Former STEADY-PD3 participants had been randomized (1:1) to 3 years of isradipine or placebo treatment; SURE-PD3 participants had been randomized (1:1) to 2 years of inosine or placebo treatment.
2404961|NCT03538249|Experimental|Aerobic training|Patients follow an alternating aerobic training using a treadmill at an intensity of 60% of maximum heart rate, 3 mn and 3 mn working off an alternative way.To ensure progressive overload appropriate, we adjust moderate intensity aerobic exercise every two weeks with an overall 5% increase in heart rate.
2404962|NCT03538249|Experimental|Inspiratory muscle training|The inspiratory muscle training involves a high intensity endurance training to 60% of PI, max. We recalculate the individual SPImax and PImax in each training session. Patients use the driving tool inspiratory muscle.
2404963|NCT03538249|Experimental|Resistance training|The resistance should be measured on 1 RM (Repetition Maximum) for each muscle group. The exercises are performed in three sets of ten repetitions of exercises at 60% of 1RM intensity recalculated every two weeks training.
2404964|NCT03538249|No Intervention|Control|The control group patients were allocated to a non-training time period, during which they were told to continue their life as before enrollment.
3144267|NCT00035100|Experimental|EPO906|
3144268|NCT00035126|Experimental|EPO906|
3144269|NCT00035165|Experimental|EPO906|
3144270|NCT00035243|Experimental|EPO906|
2404965|NCT03538249|Experimental|Aerobic and Inspiratory training|Note that the Aerobic and Inspiratory group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
2404966|NCT03538249|Experimental|Combined|Note that the Aerobic, Inspiratory and resistance group participant undergone same protocols of inspiratory and aerobic training stated above, with almost a 5 minutes rest in between.
2404967|NCT03538236|Active Comparator|Lifestyle intervention alone|All patients included in the study will undergo an evaluation by a nutritionist and will undergo diet and lifestyle intervention.
2404968|NCT03538236|Experimental|Intragastric balloon with lifestyle|Patients who do not reach the 10% weight loss with lifestyle intervention alone after 6 months will be offered to have intragastric balloon insertion for 6 months. Regardless of whether an intragastric balloon is inserted, all patients will continue with the same lifestyle changes described above for another 6 months.
2404969|NCT03538223|Experimental|"Radioterapy+Melomics-Health Listening"|"The musical content is composed by an algorithm (named Melomics-Health) with the purpose of acting psychologically and physiologically on the person: the music follows a constant, melodic trend with a reduced musical density; time is unchanged and there are no significant dynamic and tonal variations. Patients will undergo to music listening for 15 minutes (5 tracks lasting 3 minutes each) before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context."
2404970|NCT03538223|Experimental|Radiotherapy+Individualized Listening|The musical content is based on the patient's preferred music (chosen by patients with the support of the music therapist) with the purpose of acting psychologically and physiologically on the person. Patients will undergo to music listening for 15 minutes before radiotherapy session. Appropriate earphones will be used in order to focus their attention on the musical-sound component and to isolate themselves from the external context.
2404971|NCT03538223|Other|Radiotherapy+No Music Listening|Patients will undergo the standard treatment (radiotherapy) without music support.
2404972|NCT03538197|Other|SUICID ATTEMPT YOUNG PEOPLE|Suicide Re Attempts in Young Adults after first suicide attempt : socio-demographic, clinical and biological correlates
2404973|NCT03538184|Experimental|Piezosurgery|Osteotomy preparation entirely with piezosurgery tips and equicrestal placement of a 4.1 mm implant in the piezosurgery (test) group were performed as follows: 1.15 mm initial MB1 tip, 1.95 mm MB2 tip, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm MB3 tip, 2.8 mm MB4 tip, 2.8 mm paralleling pin, 3.05 mm MB5 tip, 3.3 mm MB6 tip, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm-wide healing abutment.
2404974|NCT03538184|Active Comparator|Drill|Preparation of an implant recipient site entirely with relevant drills were performed as follows: Osteotomy preparation and equicrestal placement of a 4.1 mm diameter implant in the drill (control) group were performed as follows: initial trispade drill, 2.0 mm pilot drill, control of depth, diameter and direction of osteotomy with 2.0 mm paralleling pin, 2.5 mm drill, 2.8 mm drill, 2.8 mm paralleling pin, 3.5 mm drill, control of final diameter of the osteotomy with 3.5 mm paralleling pin, placement of the 4.1 mm diameter implant and connection of a 4 mm wide healing abutment.
2404975|NCT03538171|Active Comparator|ARM Entinostat+Exemestane|Patients receive Exemestane orally (PO) once daily (QD) on days 1-28 and Entinostat PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2404976|NCT03538171|Placebo Comparator|ARM Placebo+Exemestane|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144271|NCT00035347|Experimental|Azithromycin plus ceftriaxone group (AZY+CEF group)|IV azithromycin (500 mg once daily) plus ceftriaxone (1 gram once daily) for 2 to 5 days followed by oral azithromycin (2 x 250 mg once daily) to complete a total of 7 to 10 days of therapy
3144272|NCT00035347|Experimental|Levofloxacin group (LEV group)|IV levofloxacin (500 mg once daily) for a minimum of 2 days followed by oral levofloxacin (500 mg once daily) to complete a total of 7 to 14 days of therapy.
2404982|NCT03538093|Experimental|Local Stabilization Exercise|Experimental: Local Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as local stabilizers of the core (Transversus Abdominis and Multifidus).
2404983|NCT03538093|Experimental|Global Stabilization Exercise|Experimental: Global Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of the muscles considered as global stabilizers of the core (Erector Spinae, Quadratus Lumborum, Abdominal External Oblique, Abdominal Internal Oblique and Rectus Abdominis).
2404984|NCT03538093|Experimental|Mixed Stabilization Exercise|Experimental: Mixed Stabilization Exercise Consists of a standard inpatient and outpatient rehabilitation program which includes exercises that focuses the activation of both local and global core stabilizer muscles.
2404985|NCT03538080|Experimental|ACCUVEIN plus ultrasound|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with Accuvein and ultrasound
2404986|NCT03538080|Sham Comparator|Ultrasound only|Patients referred for marking of saphenous veins before varicose vein surgery or for saphenectomy for vascular or coronary artery bypass grafting will have marking with ultrasound only.
2404987|NCT03538067||Paired sample group|Patients with symptomatic coronary artery disease (stable, NSTEACS) undergoing planned percutaneous coronary intervention with intravascular ultrasound (IVUS) guidance
2404988|NCT03538054|Experimental|Dextromethorphan|Participant will take one dextromethorphan 10mg capsule in the morning and at night.
2404989|NCT03538054|Placebo Comparator|Placebo|Participants will take one placebo capsule in the morning and at night.
2404992|NCT03538028|Experimental|INCAGN02385|Part 1: INCAGN02385 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. Part 2: INCAGN02385 administered Q2W or Q4W at the recommended dose(s) from Part 1.
2404996|NCT03538002|No Intervention|Conventional anti-reflection coated spectacle lens|Single vision lenses with correction of distant refraction and conventional anti-reflection coating
2404997|NCT03538002|Experimental|Blue-light filtering spectacle lenses|Single vision lenses with correction of distant refraction and blue-light filtering coating
2404998|NCT03537989|Experimental|Restricted group|"Oral fluid to 2 h before surgery. Intra-operatively: Glucose 5% (500 ml - volume drunk during fast); HAES 6% for blood loss volume to volume; IV-medicine in saline 0.9% for anesthesia and antibiotics. Blood products after current rules.~Postoperatively: 1000 ml glucose containing fluid in the recovery room. Free oral intake of fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. If less than 1500 ml fluid pr. mouth supplement with VI-fluid.~Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid. Goal: zero fluid balance with up to 1-kilogram body weight increase.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
2404999|NCT03537989|Active Comparator|Standard group|"Oral fluid to 2 h before surgery. Intra-operatively: Saline 500 ml for fasting; 500 ml HAES 6% for the epidural, Saline for the third space: 7 ml/kg/h first hour, 5 ml/kg/h 2.-3. Hour, 3 ml/kg/h subsequent hours. 1000-1500 ml Saline replaced lost blood up to 500 ml, additional HAES 6% for additional blood loss; IV-medicine in saline.~Postoperatively: 1000-2000 ml isotonic fluid in the recovery room. Free oral fluid and food as well as enteral feeding by tube 500 ml.~In the wards: Enteral feeding by tube 1000 ml postoperative day 1-3. Free fluid and food by mouth. Supplemental iv-fluid according to department rules. Pathological fluid loss (high output stoma, aspirate, vomit etc.) - replace with IV-fluid.~Urine < 0.5 ml/kg/h: supplement with fluid. MAP < 60 and hypovolemia: treat with fluid."
2405000|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
3144273|NCT00035425|Experimental|A.|Patients will be stratified according to the use of prophylactic antibiotics. Both groups may receive open-label gram-negative coverage with either ceftazidime, aztreonam, and/or aminoglycosides (gentamicin, tobramycin, amikacin). Subjects will receive study medication intravenously every 12 hours for 7 to 28 days.
3144274|NCT00035425|Experimental|B.|
3144275|NCT00035451|Placebo Comparator|1|placebo tablets
3144276|NCT00035451|Active Comparator|2|Sotalol
2405005|NCT03537950|Experimental|PLC, CBD, CBDV|Dose order: PLC, CBD, CBDV
2405006|NCT03537950|Experimental|PLC, CBDV, CBD|Dose order: PL, CBDV, CBD
2405007|NCT03537950|Experimental|CBD, PLC, CBDV|Dose order: CBD, PLC, CBDV
2405008|NCT03537950|Experimental|CBD, CBDV, PLC|Dose order: CBD, CBDV, PLC
2405009|NCT03537950|Experimental|CBDV, PLC, CBD|Dose order: CBDV, PLC, CBD
2405010|NCT03537950|Experimental|CBDV, CBD, PLC|Dose order: CBDV, CBD, PLC
2405011|NCT03537937|Active Comparator|Lower SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).
2405012|NCT03537937|Active Comparator|Intermediate SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).
2405013|NCT03537937|Active Comparator|Higher SpO2 Target|During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).
2405014|NCT03537924|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2405015|NCT03537924|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2405237|NCT03536416|Active Comparator|Theatre only group|My Asthma in School. This group will receive the theatre performance only.
3144277|NCT00035451|Experimental|3|azimilide
3144278|NCT00035464|Placebo Comparator|1|Placebo tablets
3144279|NCT00035464|Experimental|2|125 mg azimilide tablets
3144280|NCT00035477|Placebo Comparator|1|placebo tablets in hospital and placebo tablets outpatient
3144281|NCT00035477|Experimental|2|Azimilide tablets in hospital and azimilide tablets outpatient
3144282|NCT00035490|Placebo Comparator|1|Placebo tablets
3144283|NCT00035490|Experimental|2|75 mg azimilide
3144284|NCT00035490|Experimental|3|125 mg azimilide
3144285|NCT00035529|Other|1|
3144286|NCT00035529|Active Comparator|2|
3144287|NCT00035529|Active Comparator|3|
3144288|NCT00035581|Experimental|Ampligen|Ampligen (polyI-polyC12U) 200-400 mg IV infusions given twice weekly for 24 weeks
3144289|NCT00035581|No Intervention|No Ampligen|No Ampligen administered for first 24 weeks
3144290|NCT00035594|Placebo Comparator|Placebo|Breast cancer patients receiving docetaxel chemotherapy and placebo.
3144291|NCT00035594|Experimental|Pegfilgrastim|Breast cancer patients receiving docetaxel chemotherapy and pegfilgrastim.
3144292|NCT00035607|Active Comparator|Darbepoetin alfa SC|
3144293|NCT00035607|Experimental|Darbepoetin alfa IV|
3144294|NCT00035620|Active Comparator|Filgrastim|Filgrastim
3144295|NCT00035620|Experimental|Pegfilgrastim|Pegfilgrastim
3144296|NCT00035802|Experimental|001|"Topiramate Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
3144297|NCT00035802|Placebo Comparator|002|Placebo Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
3144298|NCT00035893|Experimental|Ampligen|Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks.
3144299|NCT00035893|No Intervention|No Ampligen|No Ampligen administered for first 64 weeks
3144300|NCT00035984|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
2405016|NCT03537911|Experimental|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
2405017|NCT03537898|Active Comparator|Lactated Ringer's|Patients in a MICU block randomized to lactated Ringer's will receive lactated Ringer's whenever isotonic intravenous fluid administration is ordered by the treating provider.
2405018|NCT03537898|Active Comparator|Normosol|Patients in a MICU block randomized to Normosol will receive Normosol-R pH 7.4 whenever isotonic intravenous fluid administration is ordered by the treating provider.
2405019|NCT03537885|Experimental|TMS, EEG, and tDCS Group|"Participants will wear a cap fitted with Electroencephalography (EEG) electrodes to detect the brain's activity during the task. Transcranial Magnetic Stimulation will be used to evaluate the brain's responsiveness to Transcranial Direct Current Stimulation.~All study participants will receive the same study procedures - TMS, tDCS, and EEG."
2405020|NCT03537872|Experimental|Miner-Friendly (MF) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive additional integrated strategies available at a miner-friendly service venue.~Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies."
2405021|NCT03537872|Active Comparator|Public Sector (PS) Cohort|"Subjects will be enrolled over the 9-month enrollment period and will receive the usual integrated care for the management of TB and HIV at a public sector health facility.~Public Sector (PS) Health Facilities TB/HIV Integration Strategies"
2405022|NCT03537859|Experimental|Augmented Reality (AR)|Books with augmented reality plus an electronic tablet.
2405023|NCT03537859|Other|Non Augmented Reality (NoAR)|Conventional children book. No electronic device will be given to children.
2405024|NCT03537846||Osteoporosis and women|Patient women over thirty years old
2405025|NCT03537833||"PPI-positive or test group"|Patients treated with PPI
2405026|NCT03537833||"PPI-negative or control group"|Patients not treated with PPI
2405027|NCT03537820||before nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, before nurses formation and installation of a noise warning device
2405028|NCT03537820||after nurses formation/installation of a noise warning device|ambulatory or hospitalized patients, who go in post-anesthesia care unit, after nurses formation and installation of a noise warning device
2405029|NCT03537794||Treatment Resistant Depression|Unmedicated Individuals with Treatment Resistant Depression
2405030|NCT03537794||Major Depressive Disorder|Unmedicated Individuals with Major Depressive Disorder
2405031|NCT03537794||Healthy Control|healthy controls with no previous psychiatric disorders
2405032|NCT03537781|Experimental|Food label available, hungry state|foods will be displayed with food labels present and when participants had nothing to eat
2405033|NCT03537781|Experimental|food label available, satiated|foods will be displayed with food labels present and when participants had already eaten breaksfast
2405034|NCT03537781|Experimental|food label unavailable, hungry state|foods will be displayed without food labels present and when participants had nothing to eat
2405035|NCT03537781|Experimental|food label unavailable, satiated|foods will be displayed without food labels present and when participants had already eaten breakfast
2405036|NCT03537768|Active Comparator|UPA 30mg|
2405037|NCT03537768|Active Comparator|LNG 1.5 mg|
2405038|NCT03537768|Active Comparator|LNG 3.0|
2405039|NCT03537742|Experimental|alirocumab|alirocumab 150mg subcutaneous every other week for one year following start of study drug
2405040|NCT03537742|Placebo Comparator|placebo|placebo to match alirocumab every other week for one year following start of study drug
2405041|NCT03537729|No Intervention|Control|There will be no modifications to décor or signage in the existing care community, and no education on wayfinding. However, subjects will receive the same testing that is provided for the other arms at the designated time periods.
2405042|NCT03537729|Experimental|Salient Cues|Special signs and salient cues will be added to the community along the routes being measured for wayfinding. The cues will be comprised of pictures, objects, and signage.
2405043|NCT03537729|Experimental|Spaced retrieval education|This condition will have signage and cues as in Arm 2 added to the care communities. In addition, a spaced retrieval (SR) memory intervention strategy will be implemented individually for each resident participating in the study to help them remember the presence and function of the environmental wayfinding cues.
2405044|NCT03537716|Experimental|Treatment Group|Treatment with the investigational device - High Intensity Focused ElectroMagnetic system
2405045|NCT03537703|Experimental|Active tDCS + Auditory Training|Cathodal tDCS plus concurrent active auditory training exercise
2405046|NCT03537703|Active Comparator|Active tDCS + Control Condition|Cathodal tDCS plus concurrent control condition
2405047|NCT03537703|Active Comparator|Sham tDCS + Auditory Training|Sham tDCS plus concurrent active auditory training exercise
3144301|NCT00035984|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
2405049|NCT03537677|Experimental|Sedentary Behavior Intervention|A behavioral intervention that targets prolonged sitting and encourages frequent activity breaks.
3184944|NCT00729963|Experimental|1|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
3184945|NCT00729963|Active Comparator|2|A standard reference group, which was paired according to age and BMI, received CPAP as a treatment for OSA.
3184946|NCT00729976|Experimental|1|Ibuprofen Suppository
3144302|NCT00035984|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
3184947|NCT00729976|Active Comparator|2|Ibuprofen suspension
3184948|NCT00729989|No Intervention|1|
3184949|NCT00729989|Experimental|2|
3184950|NCT00730002|Active Comparator|1- Healthy Subjects|Healthy Subjects- receive MRA
3184951|NCT00730002|Active Comparator|2 - patients with SLE, no neuropsych|Systemic Lupus Erythematosus(SLE) patients without neuropsychiatric symptoms - receive MRA
3184952|NCT00730002|Active Comparator|3 - patients with SLE with neuropsych|20 symptomatic neuropsychiatric systemic lupus erythematosus(NPSLE) patients.
3144303|NCT00035984|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
2405053|NCT03537638|Experimental|Multicomponent Intervention|Rheumatologist and internist receive a multicomponent intervention
2405054|NCT03537638|No Intervention|Control|Rheumatologist and internist provide the usual care
2405055|NCT03537625|Experimental|Green tea|Green tea extract 2 gram per day
2405056|NCT03537625|Experimental|Fermented green tea|Fermented green tea extract 2 gram per day
2405057|NCT03537625|Placebo Comparator|Placebo|Placebo
2405058|NCT03537612|Experimental|Opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2405059|NCT03537612|Experimental|Sub-opt-Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediately post-op; Clonidine pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2405060|NCT03537612|Active Comparator|Opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2405061|NCT03537612|Active Comparator|Sub-opt-Morphine|Intrathecal spinal morphine (5 mcg / kg) immediately post-op; Placebo pill TID Post-op Day 1-5 (liquid version available if subject cannot swallow capsule)
2405062|NCT03537599|Experimental|Treatment (DLI, daratumumab)|Participants receive daratumumab intravenously once a week for 8 weeks and donor lymphocyte infusion in weeks 3 or 4 in the absence of disease progression or unacceptable toxicity.
2405063|NCT03537586|Experimental|Non-Obstructive CAD|After diagnostic coronary angiography, invasive measures of coronary microvascular physiology will be obtained. Blood will be collected for platelet activity, inflammation and isolation of coronary endothelial cells. Evaluation of the sublingual microvasculature with a side stream dark field imaging video microscope will be performed.
2405064|NCT03537573|Active Comparator|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent Center for Disease Control (CDC) guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
2405065|NCT03537573|Experimental|Guideline + Opioid Justification (OJ)|Providers will be required asked to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR. The provider has the option of entering a justification or not. If no justification is entered, nothing will be entered into the record (i.e., the Opioid Justification area in the encounter record will be left blank). The provider does not need to enter a justification if they choose to cancel the opioid prescription.
2405066|NCT03537573|Experimental|Guideline + Provider Comparison (PC)|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
2405067|NCT03537573|Experimental|Guideline + OJ + PC|This arm will include the guideline, opioid justification, and provider comparison described above.
2405068|NCT03537547|Experimental|GeneSight Psychotropic test|Participants randomized to have their study clinician have access to their pharmacogenetic report (provided through the GeneSight Psychotropic tool) in order to make treatment decisions for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will continue to be able to use the results to guide treatment options for an additional 12 weeks.
2405069|NCT03537547|Active Comparator|Treatment As Usual|Participants randomized to treatment as usual will receive treatment from study clinicians who do not have access to the participant's report for the first 12 weeks. At Visit 5, Week 12, participants will receive a copy of their pharmacogenetics report and clinicians will be unblinded to be able to use the results to guide treatment options for an additional 12 weeks.
2405070|NCT03537534|Experimental|Experiment|Lidocaine jelly (2%) 5mL x 1 dose only
2405071|NCT03537534|Placebo Comparator|Placebo|Surgilube 5mL x 1 dose only
2405072|NCT03537521||DOA|N= 130 patients treated with direct oral anticoagulants (DOAC) with acute bleeding N= 65 patients treated with direct oral anticoagulants (DOAC) with urgent surgical intervention
2405073|NCT03537521||VKA|N= 130 patients treated with vitamin K antagonists (VKA) with acute bleeding N= 65 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention
3144304|NCT00036296|Experimental|1|75mg per day (in 3 doses) Talampanel for 22 days
3144305|NCT00036296|Placebo Comparator|2|3 doses a day for 22 days
3144306|NCT00036491|Experimental|rituximab|375 mg/m^2 administered intravenously
3144307|NCT00036634|Active Comparator|Tenofovir DF|Participants received tenofovir DF 300 mg for 14 days
2405103|NCT03537352||Non-Surgical General Medical Disorders|"Current Hospitalization at the Internal Medicine Inpatient Department or at the Inpatient Department of Cardiology OR~Current Follow-up at the Internal Medicine Outpatient Department or at the Outpatient Department of Cardiology due to a disorder for which surgery is not a treatment option and any appropriate drug or non-drug treatment excluding surgery is a treatment option."
3184953|NCT00730002|Active Comparator|4- healthy patients from other cohort|10 Healthy Controls (HC) from an existing cohort as part of another sponsored study.
3144308|NCT00036634|Experimental|Tenofovir alafenamide 50 mg|Participants received tenofovir alafenamide 50 mg for 14 days
3144309|NCT00036634|Experimental|Tenofovir alafenamide 150 mg|Participants received tenofovir alafenamide 150 mg for 14 days
3184954|NCT00730054|Active Comparator|1|Clonidine
2405078|NCT03537495|No Intervention|Control arm|"Subjects in this arm will only receive high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.~High-dose rifampicin will consist of weight-banded fixed-dose combination (FDC), including rifampicin (R), isoniazid (H), pyrazinamide (Z) and ethambutol (E) according to international guidelines, combined with 900 mg rifampicin (≤37 kg: two 450 mg tablets) or 1200 mg rifampicin (>37 kg: two 600 mg tablets) to reach ~35 mg/kg rifampicin in total."
2405079|NCT03537495|Experimental|Linezolid 600|Subjects in this arm will receive 600 mg linezolid QD along with high-dose rifampicin (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
2405080|NCT03537495|Experimental|Linezolid 1200|Subjects in this arm will receive 1200 mg linezolid QD along with rifampicin 1350 mg (~35 mg/kg, based on weight), isoniazid (H) 300 mg, pyrazinamide (Z) 1500 mg and ethambutol (E) 750 mg once daily administered orally for 14 days.
2405081|NCT03537482|Experimental|single-agent, open-label, Phase I study of APG-2575|The study consists of the dose escalation stage and the dose expansion stage
2405082|NCT03537469|Experimental|CTU Mega 20 real device|A single-session of real CTU Mega 20 on the corresponding primary right-hand motor area, using the real (magnetic field = 2 Tesla; intensity = 90 J; frequency of impulses = 7Hz; duration = 15 minutes) CTU Mega 20 device. This real stimulation provided a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
2405083|NCT03537469|Sham Comparator|CTU Mega 20 sham device|A single-session of sham CTU Mega 20 on the corresponding primary right-hand motor area (magnetic field = 0 Tesla; intensity = 0 J; frequency of impulses = 7Hz; duration = 15 minutes). The sham stimulation did not provide a Low Frequency-Pulsed Electromagnetic Fields (LF-PEMFs).
2405084|NCT03537456|Experimental|mRDX-02-17|"mRDX-02-17 is a dermal filler recommended for correction and treatment of wrinkles and dermal depressions, which are administered by intradermal injections. It encourages repair and restructuring of skin tissue, reducing the signs of aging and has the following indications:~Hypotrophic tissues~Tissue hypotonicity~Crow's feet~Glogau III - IV~Fiztpatrick I - VI~WSRS (Wrinkle Severity Ranking Scale): 2-5"
2405085|NCT03537443|Placebo Comparator|Group A (Placebo)|Children whose mothers were randomized to receive a weekly dose of placebo from 17-24 weeks of gestation to 26 weeks postpartum.
2405086|NCT03537443|Experimental|Group B (4200:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 4200 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
2405087|NCT03537443|Experimental|Group C (16800:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 16800 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
2405088|NCT03537443|Experimental|Group D (28000:0 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by placebo from delivery to 26 weeks postpartum.
2405089|NCT03537443|Experimental|Group E (28000:28000 IU/week)|Children whose mothers were randomized to receive a prenatal:postpartum regimen of 28000 IU/week vitamin D3 from 17-24 weeks of gestation to delivery, followed by the same dose (28000 IU/week vitamin D3) from delivery to 26 weeks postpartum.
2405090|NCT03537430|Other|TNT Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent TNT uniportal VATS mediastinal tumor resection
2405091|NCT03537430|Other|Uniportal Video-assisted Thoracoscopic Surgery|This group of patients underwent traditional uniportal VATS mediastinal tumor resection
2405092|NCT03537417||Tension pneumothorax group|Patients undergoing intentional pneumothorax for thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
3184955|NCT00730054|Active Comparator|2|Remifentanil
3184956|NCT00730054|Experimental|4|Remifentanil+clonidine
3184957|NCT00730054|Placebo Comparator|3|Placebo
3184958|NCT00730067|Experimental|1|Sildenafil treatment
3184959|NCT00730067|Placebo Comparator|2|placebo
2405098|NCT03537391|Experimental|Imaging based staging of high risk PC|"Each individual study patient will be imaged for PC metastasis detection with each different imaging modalities as follows:~Traditional imaging (clinical standard imaging);~Whole-body contrast enhanced computer tomography~Planar bone scintigraphy~Novel imaging (investigational imaging);~SPECT/CT (investigational imaging)~18F-PSMA-PET/CT (investigational imaging)~Whole-body MRI (investigational imaging)~In order to define the true nature of the findings from each different imaging modality, comparison with best valuable comparator (BvC) is made. Consensus reading of all imaging modalities and follow-up data of clinical, imaging, histopathological and laboratory results are used to define BvC."
2405099|NCT03537378|Experimental|Hybrid APC Therapy Group|1) Patients are diagnosed as early central lung neoplasms (severe dysplasia, carcinoma in situ, microinvasive carcinoma，mucoepidermoid carcinoma.etc.) by inquiry of the first doctor, CT test, endoscopy and histopathology. Patients who meet inclusion/exclusion criteria are not suitable for or refuse surgery.
2405100|NCT03537365|Experimental|Bovine Colostrum / intervention group|Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC.
2405101|NCT03537365|Active Comparator|FM85 / control group|Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form.
2405102|NCT03537352||Surgical Disorders|"A. Surgical Disorders:~Current Hospitalization at the Surgical Inpatient Department or at the Inpatient Department of Otorhinolaryngology or at the Inpatient Department of Cardiology OR~Current Follow-up at the Surgical Outpatient Department or at the Outpatient Department of Otorhinolaryngology or at the Outpatient Department of Cardiology due to a disorder for which any appropriate surgical treatment (surgery) is a treatment option."
3184960|NCT00730080||Sapropterin (Kuvan)|Individuals with phenylketonuria (PKU) who are beginning treatment with sapropterin.
3184961|NCT00730080||Control|Healthy individuals without phenylketonuria (PKU).
3184962|NCT00730093|Other|A|
3184963|NCT00730106||1|Patients with pre-defined alarm symptoms
2405104|NCT03537339||Observation|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on
2405105|NCT03537326|Experimental|Budesonide|Healthy women, aged between 18 and 45 years old, with weigh between 50 and 75 kg and with IMC included between 19 and 27 kg/m². Patients will be given, on an empty stomach since 10 hours minimum, a single dose of 3 mg of Budesonide, in the form of Entocord ® tablets. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
2405106|NCT03537313|No Intervention|Control-douching group|No preoperative vagina douching
2405107|NCT03537313|No Intervention|Control-painting group|No intra-operative vagina painting
2405108|NCT03537313|Experimental|Vaginal douching group|Preoperative vaginal douches with povidone-iodine solution
2405109|NCT03537313|Experimental|Vaginal painting group|Intra-operative vaginal painting with povidone-iodine solution
2405110|NCT03537300|Experimental|experimental group|
2405111|NCT03537300|Active Comparator|control group|
2405112|NCT03537287|Active Comparator|17 alpha hydroxyprogestrone caproate Group|Patients will receive 250 mg of 17 alpha hydroxyprogestrone caproate intramuscularly once weekly starting from 16 weeks till delivery or 36 weeks.
2405113|NCT03537287|Active Comparator|Vaginal progesterone Group|Patients will receive vaginal progesterone 200 mg once per day starting from 16 weeks till delivery or 36 weeks.
2405114|NCT03537287|Active Comparator|Oral dydrogesterone Group|Patients will receive 2 tablets of oral dydrogesterone daily starting from 16 weeks till delivery or 36 weeks
3184964|NCT00730106||2|Patients without pre-defined alarm symptoms
3184965|NCT00730119||Neonates|Subjects ages birth to 30 days
3184966|NCT00730119||Infants|Subjects aged >30 days to 2 years
3184967|NCT00730119||Adults|Subjects aged 18 years of age or older
3184968|NCT00730145|Experimental|PD-0332334|
3184969|NCT00730184|Active Comparator|1|Participants receive potassium bicarbonate in dosage of 90 mmol/d. This compound has no other name.
2405121|NCT03537248|Experimental|Asepticys investigational ASP-57 Multi-Purpose Solution|ASP-57 Multi-Purpose contact lens care solution used as a rub care regimen (Test)
2405122|NCT03537248|Active Comparator|ReNu® Multiplus Contact Lens Solution|ReNu® Multiplus Contact Lens Solution used as rub care regimen (Control)
2405123|NCT03537235|Experimental|Libramed|3 tablets of Libramed 2 twice a day 15 minutes before meals for 3 months.
2405124|NCT03537235|Placebo Comparator|Placebo|3 tablets of Placebo 2 twice a day 15 minutes before meals for 3 months.
3184970|NCT00730184|Placebo Comparator|2|Participants receive placebo as microcrystalline cellulose. This compound has no other name.
2405126|NCT03537196|Other|All patients|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
2405127|NCT03537196|Other|HIV/HCV co-infected patients|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day (sofosbuvir 400 mg and daclatasvir 90 mg)
2405128|NCT03537196|Other|Cirrhosis|In case of cirrhosis : ribavirin will be added to sofosbuvir / daclatasvir 12 weeks
2405129|NCT03537196|Other|Cirrhosis with ribavirin contra-indication|In case of cirrhosis with ribavirin contra-indication : sofosbuvir and daclatasvir for 24 weeks
2405130|NCT03537183|No Intervention|Usual activity level|12 weeks of usual activity level
2405131|NCT03537183|Active Comparator|Exercise training|12 weeks of moderate intensity exercise training, 3 hours a week
2405132|NCT03537157|Experimental|Rifaximin delayed release tablets|Two 400 mg tablets twice a day (total daily dose 1600 mg) for 26 weeks
2405133|NCT03537157|Placebo Comparator|Placebo|Two placebo tablets twice a day for 26 weeks
2405134|NCT03537144|Active Comparator|Indomethacin|Indomethacin as drug to treat PDA.
2405135|NCT03537144|Experimental|Acetaminophen|Acetaminophen as drug to treat PDA.
2405136|NCT03537131|Active Comparator|arm B1- Dapagliflozin once only dose|Participants who will take one tablet of Dapagliflozin 10 mg on the day of the exercise challenge.
2405137|NCT03537131|Active Comparator|arm B2- Dapagliflozin daily administration|Participants who will take a daily dose of Dapagliflozin 10 mg before and after the exercise challenge.
2405138|NCT03537118|Experimental|Fluoroscopic + Ultrasound Guidance|
2405139|NCT03537118|No Intervention|Fluoroscopic Guidance Alone|
2405140|NCT03537105|Experimental|Sclerodermic patients|Sclerodermic patients presenting cutaneous fibrosis
3184971|NCT00730197|Experimental|1|NISOLDIPINE EXTENDED-RELEASE TABLETS, 40 MG
2405142|NCT03537079|Placebo Comparator|normoxia conditioning|exercise training in normoxia and rest conditioning in normoxia
2405143|NCT03537079|Active Comparator|exercise hypoxia|exercise training in hypoxia and rest conditioning in normoxia
2405144|NCT03537079|Active Comparator|rest hypoxia|exercise training in normoxia and rest conditioning in hypoxia
2405145|NCT03537066|Other|CPAP treatment|All included OSA patients are going to be treated by CPAP
2405146|NCT03537053|Experimental|A plan to Move a Little and Often|"The intervention will consist of 3 components: a short video will raise awareness about the impact of sedentary behaviours, a booklet, and an online forum on Facebook to encourage participants to support each other.~At the end of the baseline data collection, participants will be asked to watch the video. They will then be given the booklet and invited to join the Facebook group. A minimum of 5 participants must be recruited prior to running the Facebook group."
2405147|NCT03537040|Other|Method of Levels|Talking therapy- duration and frequency of sessions to be determined by participant
2405148|NCT03537027|Experimental|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
2405452|NCT03534895|Placebo Comparator|PC1|5mL normal saline intravenous, single-administration, as pre-medication
3184972|NCT00730197|Active Comparator|2|Sular® Extended Release 40 mg tablets
3184973|NCT00730210|Active Comparator|a: PTH (1-84) 100 ug s.c.inj. once a day|PTH (1-84) 100 ug subcutaneous injections once a day
3184974|NCT00730210|Placebo Comparator|b: placebo 100 ug s.c. inj. once a day|placebo 100 ug sub cutaneous injection once a day
3184975|NCT00730249|Active Comparator|1|
3184976|NCT00730249|Placebo Comparator|2|
3184977|NCT00730262|Experimental|Single-Arm|
3144310|NCT00036686|Experimental|Soy protein isolate|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
3144311|NCT00036686|Placebo Comparator|Placebo|"Administration Prior to Mastectomy or Lumpectomy.~Patients receive oral placebo twice daily and oral multivitamins once daily.~Treatment continues for 2-4 weeks depending on time from study entry to planned surgical procedure."
2405151|NCT03537001||Penthrox|Administration of Penthrox at the beginning of the management of the traumatized adult patient
2405152|NCT03536988|Experimental|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of proctectomy with IPAA will be performed.
2405153|NCT03536988|Active Comparator|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of proctectomy with IPAA will be performed.
2405154|NCT03536975|Other|Platform|"Group with access to the web platform CAREGIVERSPRO-MMD"
2405155|NCT03536975|No Intervention|Control|Group without any access to the web platform
3184978|NCT00730288|Experimental|1|Received monovalent Vero dengue vaccine in Study DIV12
2405159|NCT03536910|Other|General anesthesia|
2405160|NCT03536910|Other|Spinal anesthesia|
2405161|NCT03536897||IORT|All patients will undergo a partial mastectomy with sentinel lymph node biopsy with the goal of achieving a margin-negative resection while maintaining good cosmetic outcome. Immediately following partial mastectomy and frozen section evaluation of the sentinel lymph nodes, IORT is to be delivered. Intraoperative radiation therapy will involve 50 kV xrays to a dose of 20 Gy during breast conserving surgery. After surgery, patients are followed based on the standard schedule determined by their surgeon for 5 years.
2405165|NCT03536871|Active Comparator|Multinutrient Supplement|Participants will be allocated in a randomized double-masked manner to receive a multi-nutrient supplement (protein and creatine sachet and omega-3 oil) or placebo during a 12 week home-based exercise program and we will assess the influence on the primary and secondary outcomes.
2405166|NCT03536871|No Intervention|Age biological and chronological|The primary and secondary outcomes will be compared between the younger and older age groups as a function of both exercise and nutritional supplementation.
2405167|NCT03536871|No Intervention|Sarcopenia grades|The baseline primary and secondary outcomes will be compared for each of the 3 older adults males groups as a function of muscle mass (healthy active, mild sarcopenia and moderate sarcopenia).
2405168|NCT03536871|Experimental|Exercise - home based programme|Each of the older participants will undergo a 12 week home-based exercise program (endurance = increased steps; resistance = body weight and elastic band exercise) to determine the effects on the primary and secondary outcomes.
2405169|NCT03536858|Active Comparator|Centrality|The patients at clinic one who receive hemodialysis on Tuesday, Thursday, Saturday and the patients on the Monday, Wednesday, Friday schedule at clinic two, will be assigned to the Centrality arm. Two patients per hemodialysis shift with the highest centrality will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patients selected by centrality will have a centrality greater than 1 standard deviation (SD) from the mean of the other patients on their hemodialysis clinic shift and a clustering less than 1 SD from the mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
2405170|NCT03536858|Active Comparator|Clustering|The patients at clinic one who receive hemodialysis on Monday, Wednesday, Friday and the patients on the Tuesday, Thursday, Saturday schedule at clinic two, will be assigned to the Clustering arm.Two patients per hemodialysis shift with the highest clustering coefficient will be selected to participate in the COACH (Communicating about Choices in Transplantation) intervention. The patient selected by clustering coefficient, will have a clustering coefficient greater than 1 SD from the mean of the other patients on their hemodialysis clinic shift and centrality 1 SD less than a mean. The investigators will measure the spread of information, attitudes, and behaviors by comparing the targeted patients to the other patients on their shift.
2405171|NCT03536845|Active Comparator|400 IU|
2405172|NCT03536845|Active Comparator|1000 IU|
2405173|NCT03536832|Active Comparator|cesarean section with Vicryl|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Vicryl.
2405174|NCT03536832|Active Comparator|cesarean section with prolene|Women undergoing cesarean section with low transverse skin incisions will be closed with 3-0 Prolen.
2405176|NCT03536806|Placebo Comparator|Placebo Comparator: Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. After drug administration the patient will be observed for 2 hours after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
2405485|NCT03534661|Placebo Comparator|Teduglutide + Normal Saline|Teguglutide + (L-NMMA control)
3144312|NCT00036751|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
2405177|NCT03536806|Experimental|Experimental: canrenone|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After administration of canrenone: dose 200 mg (1 ampule a 10 ml) within 2-3 minutes the patient will be observed for 2 hours after the dose with exit ECG and BP measure taken at the end of observation.
2405178|NCT03536793||Pancreatic cysts|Samples (urine, serum, whole blood and cystic fluid) will be taken from 50 patients with pancreatic cysts on follow-up. These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM). Some of the cystic fluid and the whole blood sample will either be analysed at the University of Hull or a commercial laboratory for proteomic and genomic data. Collection will occur on the same day of the participants' routinely indicated procedure.
2405179|NCT03536793||Pancreatic cancers|Samples (urine and serum) will be taken from 50 patients diagnosed with pancreatic cancer (resectable and non-resectable). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
2405180|NCT03536793||Benign hepatopancreatobiliary conditions|Samples (urine and serum) will be taken from 80 age- and gender-matched control patients - 20 patients with acute pancreatitis and a non-resolving pseudocyst, 20 undergoing cholecystectomy for stones, 20 undergoing cholecystectomy for inflammation and 20 patients undergoing investigations for dyspepsia (normal control subgroup). These will be sent to the University of Hull for analysis of tumour regulatory molecules (e.g. TF, AM).
2405181|NCT03536780|Experimental|Avelumab and Gemcitabine|
2405182|NCT03536767|Experimental|Open-Label|
2405183|NCT03536754|Placebo Comparator|Group A|Placebo (N=10)
2405184|NCT03536754|Experimental|Group B|CCX140-B 5 mg once daily (N=10)
2405185|NCT03536754|Experimental|Group C|CCX140-B 10 mg twice daily (N=10)
2405186|NCT03536754|Experimental|Group D|CCX140-B 15 mg twice daily (N=10)
2405187|NCT03536741|Experimental|ALR|
2405188|NCT03536741|Active Comparator|EV|
3144313|NCT00036764|Experimental|Treatment|Patients receive BMS-247550 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144314|NCT00036777|Experimental|Treatment (carboplatin, 7-hydroxystaurosporine)|"Patients receive carboplatin IV over 1 hour followed by UCN-01 IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of carboplatin and UCN-01 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3144315|NCT00036855|Experimental|Group A (no planned PBSC support)|"Patients receive rituximab IV over 4-6 hours followed by IDEC-In2B8 IV over 10 minutes on day 0 and undergo whole body imaging. Patients may then receive rituximab IV over 4-6 hours followed by IDEC-Y2B8 IV over 10 minutes on day 7.~Some patients receive autologous PBSC IV over 30-60 minutes on day 35."
3184979|NCT00730288|Experimental|2|Received Yellow fever vaccine in Study DIV12
3184980|NCT00730288|Experimental|3|Flavivirus-naive subjects
2405194|NCT03536689|Experimental|Upright maternal position change|The participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the upright position for 5 minute. After 5 minute of upright position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after upright position.
2405195|NCT03536689|Experimental|Left lateral decubitus maternal position change|the participant will be measured by ultrasonograhy for amniotic fluid index in supine position before maternal position change, then she will do the left lateral decubitus position for 5 minutes. After 5 minutes of left lateral decubitus position , she will lie down in supine position and she will be measured by ultrasonograhy for amniotic fluid index after left lateral decubitus position.
2405196|NCT03536676|Active Comparator|Traditional School Breakfast Program|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8.
2405197|NCT03536676|Experimental|'Egg-Cellent' Breakfast in the Classroom|The breakfasts for the 3-week program will adhere to the United States Department of Agriculture nutrition requirements for Grades 6-8 but will include an additional 2 large eggs/breakfast.
3184981|NCT00730314|Experimental|1|Unrelated donor
2405199|NCT03536650|Experimental|DMR procedure|
2405200|NCT03536637|Experimental|Study Treatment 1|DMT310 Powder mixed with Hydrogen Peroxide
2405201|NCT03536637|Experimental|Study Treatment 2|DMT310 Powder mixed with Placebo Diluent
2405202|NCT03536637|Experimental|Study Treatment 3|Placebo powder mixed with Hydrogen Peroxide
2405203|NCT03536637|Placebo Comparator|Control|Placebo powder mixed with Placebo Diluent
2405204|NCT03536624|Experimental|Experimental group|"Participants will be involved in a short-term spa residential program of 6 days combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.~After the program, participants will be followed for 12 months."
2405205|NCT03536611|Experimental|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
2405236|NCT03536416|Experimental|Asthma workshop and theatre group|My Asthma in School. This group will receive the self-management workshops for asthmatic children and the theatre performance for the whole year group.
3144316|NCT00036855|Experimental|Group B (planned PBSC support)|Patients receive rituximab, IDEC-In2B8, and IDEC-Y2B8 as in group A. Patients also receive autologous PBSC IV over 30-60 minutes on day 21 and G-CSF subcutaneously beginning on day 22 and continuing until blood counts recover or day 35.
3144317|NCT00036868|Experimental|CMF + Herceptin|
3144318|NCT00036881|Experimental|zinc sulfate|"Patients receive oral zinc sulfate 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
3184982|NCT00730314|Experimental|2|Cord Blood
3184983|NCT00730340|Active Comparator|1|Patients will receive closure of the tonsillar fossae following tonsillectomy.
2405206|NCT03536611|Active Comparator|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
2405207|NCT03536598|Experimental|Test|Amlodipine 10mg + Valsartan 160mg + Rosuvastatin 20mg
2405208|NCT03536598|Active Comparator|Reference 1|Amlodipine 10mg + Valsartan 160mg
2405209|NCT03536598|Active Comparator|Reference 2|Valsartan 160mg + Rosuvastatin 20mg
3144319|NCT00036881|Placebo Comparator|placebo|"Patients receive oral placebo 3 times daily beginning the first week of radiotherapy.~Treatment continues daily during and for 1 month after radiotherapy in the absence of unacceptable toxicity.~Quality of life is assessed at baseline, weekly during treatment, and then at 1, 2, 3, and 6 months after the completion of treatment.~Patients are followed at 1, 2, 3, and 6 months after the completion of treatment and then every 6 months for 1 year."
3144320|NCT00036933|Experimental|vaccine|"Patients receive glycosylated MUC-2-Globo H-KLH conjugate vaccine with adjuvant QS21 subcutaneously once weekly on weeks 0-2, 6, 14, and 26 in the absence of unacceptable toxicity. Patients whose antibody titers against Globo-H or MUC-2 antigens fall below 1/40 and who have no disease progression may receive a seventh vaccination after week 50.~Patients are followed every 3 months for 1 year or until biochemical relapse or radiographic disease progression."
2405212|NCT03536572|Active Comparator|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
2405213|NCT03536572|Experimental|Individualized Pressure Adjustment|Additional education and support that will allow them to adjust their PAP pressures
2405214|NCT03536559|Experimental|15mg CNM-Au8|15mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
2405215|NCT03536559|Experimental|30mg CNM-Au8|30mg suspension of clean-surfaced, faceted, gold nanocrystals in 60ml of sodium bicarbonate buffered water
2405216|NCT03536559|Placebo Comparator|Placebo|The matched placebo to be used in this study will consist of water, sodium bicarbonate, and food coloring to match volume and color of the experimental treatments.
3144321|NCT00037440||BHS Whites|Whites from Bogalusa, Louisiana; initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
3144322|NCT00037440||BHS African Americans|African Americans from Bogalusa, Louisiana, initially recruited as schoolchildren and followed at irregular intervals (about 3 years apart on average) into adolescence and early adulthood. There were no interventions of any kind-- this was an observational study only.
2405219|NCT03536533|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
3144323|NCT00037609|Experimental|Capecitabine + Exisulind|Capecitabine 1000 mg/m^2 taken by mouth twice daily. Exisulind 125 mg taken by mouth twice daily.
3144324|NCT00037635|Experimental|AMG 073|
3144325|NCT00037635|Placebo Comparator|placebo|
3144326|NCT00037648|Placebo Comparator|placebo|
2405224|NCT03536494|Experimental|Mirabegron intervention|Review the use of mirabegron and its discontinuation
2405225|NCT03536494|No Intervention|Control group|Usual care
2405226|NCT03536481|Experimental|T-R cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state.
2405227|NCT03536481|Experimental|R-T cohort under fasted state|Subjects will be administered with one single dose of ensartinib capsules (reference product) under fasted state, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) under fasted state.
2405228|NCT03536481|Experimental|T-R cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (test product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (reference product) after meal.
2405229|NCT03536481|Experimental|R-T cohort after meal|Subjects will be administered with one single dose of ensartinib capsules (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of ensartinib capsules (test product) after meal.
2405230|NCT03536468||Patients pending complete tooth loss|Will be recruited patients pending tooth loss, ages between 18 and 65 years, whose dental conditions have previously been identified
3144327|NCT00037648|Experimental|anakinra|
3144328|NCT00037713|No Intervention|1|Best supportive care, but no cancer specific therapy (cytotoxic, radiation or other tumor reductive therapy) can be given until documented progression of disease.
2405233|NCT03536442||Intervention (CBT)|"As there is only one arm in this trial, this will be described in intervention."
3144329|NCT00037713|Experimental|2|"Treatment will consist of 5 vaccinations (each consisting of 8 single intradermal injections) over a period of 10 to 12 weeks unless one of the following occur:~intolerable toxicity precluding further treatment progression of disease~patient refusal~occurrence of pregnancy"
3144330|NCT00037752|Active Comparator|1|Sibutramine plus a behavioral smoking cessation program
3144331|NCT00037752|Active Comparator|2|Placebo sibutramine plus a behavioral smoking cessation program
3144332|NCT00037817|Experimental|1|Dose escalation cohort
3144333|NCT00037817|Experimental|2|Molecular response cohort
3144334|NCT00037817|Experimental|3|Celecoxib combination cohort at MTD
3144335|NCT00037869|Experimental|MIBG|High Dose I-131 Metaiodobenzylguanidine
3144336|NCT00037882|Experimental|SCH 54031|Peg Interferon Alpha-2B/PEG-Intron
3144337|NCT00037921|Other|1|
3144338|NCT00037934|Experimental|1|Robot exercise group
3144339|NCT00037934|Active Comparator|2|Traditional exercise group
3144340|NCT00037973|Experimental|1|Ventilation-feedback plus exercise
3144341|NCT00037973|Active Comparator|2|Exercise
3144342|NCT00037973|Active Comparator|3|ventilation feedback only
3144343|NCT00037986|Other|1|
2405238|NCT03536416|No Intervention|Control group|My Asthma in School. The control group will receive usual care for the duration of the intervention.
2405239|NCT03536403|Experimental|healthy volunteers|EOS X-rays is done with et without a kyphosis induced corset and 8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
2405240|NCT03536390|Placebo Comparator|Placebo|one chewable tablet once daily in morning.
2405241|NCT03536390|Experimental|Methylphenidate Hydrochloride Extended Release Chewable Tablet|one chewable tablet once daily in morning.
2405242|NCT03536377|Experimental|very low calorie liquid diet|Phase 1: Caloric restriction Phase 2: Solid diet Phase 3: Transition to independence
2405243|NCT03536364|Experimental|Prediabetes|manipulation of food order during a meal on postprandial in subjects with prediabetes
2405244|NCT03536351|Experimental|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists, and target understanding emotion, intentions and appropriate social interactions.
2405245|NCT03536338|Active Comparator|Control|Sit-to-stand training alone
2405246|NCT03536338|Experimental|Treatment|Sit-to-stand training combined with Spinal Stimulation
2405247|NCT03536325|Experimental|Cohort 1: Guselkumab Dose 1 or Placebo|Participants will receive Dose 1 of guselkumab or matching placebo as an intravenous (IV) infusion on Day 1.
2405248|NCT03536325|Experimental|Cohort 2: Guselkumab Dose 2 or Placebo|Participants will receive Dose 2 of guselkumab or matching placebo as an IV infusion on Day 1.
2405249|NCT03536325|Experimental|Cohort 3: Guselkumab Dose 3 or Placebo|Participants will receive Dose 3 of guselkumab or matching placebo as an IV infusion on Day 1 based on safety data results received from Cohort 1 and 2.
2405250|NCT03536312|No Intervention|Surveillance Arm|Patients in the Non-Operative Registry will be followed in clinic annually with a CT scan to monitor the status of their ascending aortic aneurysm, until the end of the study, the occurrence of an aortic event, or death.
2405251|NCT03536312|Other|Surgery/Treatment Arm|Patients in the Operative Registry will have thoracic aortic surgery
2405252|NCT03536299|Active Comparator|Single-Task Gait|The Single-Task Gait group will be provided with gait training without the Dual-Task cognitive tasks.
2405253|NCT03536299|Experimental|Dual-Task Gait|The Dual-Task Gait group will be provided with gait training AND secondary cognitive tasks during gait training.
2405254|NCT03536286|Experimental|Encouragement Zone 3|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
2405255|NCT03536286|No Intervention|Control Zone 3|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
2405256|NCT03536286|Experimental|Encouragement Zone 4|"Encouragement households will be randomly sampled based on location, and a team of 2 local community champions/data collectors (hired from within the community) will visit each of the encouragement arm homes. Community champions will be responsible for visiting each home, going door-to-door and speaking with each family individually in order to avoid contamination/cross-over with control households.~The Asili intervention involves membership into a program; households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention."
2405257|NCT03536286|No Intervention|Control Zone 4|Control households will still have equal access to the Asili intervention and can gain membership into a program at any time. Regardless of membership status, households have the option to opt in or out at any time, without consequence to themselves or the study. The intervention itself involves access to clean water and health clinics. No drugs or medication are administered to individuals through this intervention.
2405258|NCT03536273|Experimental|Functional Movement Screen|
2405259|NCT03536273|Experimental|Posture Analysis|
2405260|NCT03536273|Experimental|Depression Level|
2405261|NCT03536273|Experimental|Quality of Life|
2405262|NCT03536260|Active Comparator|Immediate implant with Xenograft|
2405263|NCT03536260|Active Comparator|Immediate implant with Nanobone|
2405264|NCT03536247|Active Comparator|Intraductal lithotripsy|Cholangioscopy enables therapeutic intervention including intracorporeal electro-hydraulic and laser lithotripsy for biliary stone disease with favorable efficacy and safety.
2405265|NCT03536247|Active Comparator|Papillary Balloon dilation|Balloon dilation of the Ampulla of Vater after a small sphincterotomy is an alternative technique that allows for removal of large bile duct stones in a safe and effective manner.
2405266|NCT03536234|Experimental|Triptorelin (GnRH analogue)|
2405267|NCT03536234|No Intervention|Control group|
2405268|NCT03536208|Experimental|Warfarin|Patients will be assigned to warfarin by mouth daily on an outpatient basis. Dose level will increase after 5 patients enrolled. Dose 1 = 1 mg warfarin; Dose 2 = 2 mg warfarin; Dose 3 = 2.5 mg warfarin; Dose 4 = 4 mg warfarin and Dose 5 = 5 mg warfarin
2405269|NCT03536182|Active Comparator|Arm A: Carbon ion radiotherapy|"The dose calculation algorithms used in Japan and Europe (local effect model, LEM) are different, so the total dose must be modified to ensure consistency~Japan : 55.2 GyE in 4.6 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of each CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose.~European: . Patients treated in Europe should receive 57.6 GyE in 4.8 GyE per fraction in 12 fractions delivered 4 days a week. At least 90% of CTV receives at least 95% of the prescribed dose, and 100% of the GTV V95 must receive at least 95% of the prescribed dose. This evaluation will occur in the LEM system"
2405270|NCT03536182|Active Comparator|Arm B: Photon radiotherapy|50.4-56 Gy in 1.8-2.0 Gy per fraction in 28 fractions delivered 5 days a week. The plan should be normalized such that 100% of the PTV receives at least 48.9 Gy (i.e. 97% of 50.4 Gy). In addition, 100% of the GTV should receive at least 50.4 Gy. The maximum dose allowed to a point volume (0.03 mL) is 115% of the prescribed dose.
2405271|NCT03536143|Experimental|Topical beremagene geperpavec|HSV1-COL7A1 vector (KB103)
2405272|NCT03536130|Experimental|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter.
2405273|NCT03536130|No Intervention|Traditional device|Patients in the no intervention (traditional) arm are connected to traditional drain system with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with traditional devices (requiring connection to wall suction) are managed by applying suction (-20 cmH2O) until the morning of POD 1 and are subsequently disconnected from suction thereafter.
2405274|NCT03536117|Experimental|MTBVAC Group 1|MTBVAC intermediate dose 2.5 x 10E+04 CFU/0.05 mL
2405275|NCT03536117|Experimental|MTBVAC Group 2|MTBVAC high dose 2.5 x 10E+05 CFU/0.05 mL
2405276|NCT03536117|Experimental|MTBVAC Group 3|MTBVAC highest dose 2.5 x 10E+06 CFU/0.05 mL
2405277|NCT03536117|Active Comparator|BCG Group 4|BCG control 2.5 x 10E+05 CFU/0.05 mL
2405278|NCT03536104||Controls|"This group will include healthy person."
2405279|NCT03536104||Parkinson's patient|This group will include Parkinsonian patients
2405280|NCT03536104||patients with a related disease.|This group will include patients with a related disease.
2405281|NCT03536078|No Intervention|Phototherapy at hospital|Newborns with icterus that receive treatment while being admitted to hospital.
2405282|NCT03536078|Experimental|Home phototherapy|Newborns with icterus receiving phototherapy at home.
2405283|NCT03536065|Active Comparator|Pre-Intervention|Current practice (unchanged)
2405284|NCT03536065|Experimental|Post-Intervention|Reduction of opioid prescription based on Pre-Intervention data, implementation of a discharge sheet and nursing education.
2405285|NCT03536052|Experimental|Virtual Heart Guided Ablation|
2405286|NCT03536039|Experimental|NGR-hTNF + R-CHOP|Treatment includes one course of conventional R-CHOP followed by 5 courses of conventional R-CHOP (rituximab, Cyclophosphamide, vincristine, doxorubicin, prednisone) in conjunction with intravenous delivery of NGR-hTNF. Chemoimmunotherapy courses will be delivered every 3 weeks; day 22 is to be considered as day 1 of the subsequent course
2405287|NCT03536026|Experimental|Bronchoscopic evaluation and biopsy|-Bronchoscopy will be performed by pulmonary and/or critical care fellows who have performed fewer than 10 bronchoscopies (inexperienced bronchoscopists) under direct supervision by an attending Interventional Pulmonologist. The inexperienced bronchoscopist will attempt to navigate to the targeted peripheral pulmonary lesion without virtual bronchoscopic navigation, using only standard axial CT images as a reference. The attending physician will directly observe, but will provide no guidance during this period, which will last no longer than 10 minutes. If the lesion is located and confirmed with radial probe endobronchial ultrasound prior to 10 minutes, biopsies will be performed as per routine clinical practice. If the 10 minute time period elapses prior to localization of the peripheral pulmonary lesion, virtual bronchoscopic navigation will be used.
2405288|NCT03536013|Experimental|Treatment|91 patients will undergo a typical lumbar microdiscectomy with the addition of a full-thickness placental allograft after the microdiscectomy has been performed.
2405289|NCT03536013|No Intervention|Control|91 patients will undergo a typical lumbar microdiscectomy without the addition of a full-thickness placental allograft.
2405290|NCT03536000||Healthy women|"200 Pregnant women~Over 18 years~Healthy~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2405291|NCT03536000||Intrauterine Growth restriction|"Pregnant women~Over 18 years~Intrauterine Growth Reestriction(IUGR): fetuses with percentile Growth <p3 or <p10 with vascular Doppler alteration.~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2405292|NCT03536000||Preeclampsia|"Pregnant women~Over 18 years~Preeclampsia: elevated blood pressure + Ratio Prot/Creatinin in urine> 30 mg / mmol creatinin~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2405293|NCT03536000||Diabetes Mellitus type 1|"Pregnant women~Over 18 years~Diabetes mellitus type1~With the ability to understand and sign the informed Consent~With the ability to attend the established controls~Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation"
2405294|NCT03535987||Observational|To determine the feasibility of using myocardial PET imaging
2405297|NCT03535961|Other|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
2405298|NCT03535935|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin
2405299|NCT03535935|Experimental|Add on astragalus powder|3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.
3144344|NCT00038012|Experimental|rhTPO-Derived Autologous Platelets Transfusion|
2405325|NCT03535727|Experimental|Cohort 1|(28 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
2405326|NCT03535727|Experimental|Cohort 2|(21 Days) - Nab-paclitaxel ,Gemcitabine, Capecitabine, Cisplatin and Irinotecan
2405486|NCT03534661|Active Comparator|Teduglutide + L-NMMA|Tedulgutide + L-NMMA
3144345|NCT00038025|Experimental|Deoxycoformycin (DCF)/Pentostatin|
3144346|NCT00038038|Experimental|PET + 18F-fluoromisonidazole|
3144347|NCT00038051|Experimental|HuM195/rGel|HuM195/rGel starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
3144348|NCT00038064|Active Comparator|rHuEPO|
3144349|NCT00038064|Experimental|Darbepoetin alfa|
2405300|NCT03535922|Experimental|The disease-specific PROM group|Hemodialysis (HD) units randomized to this PROMs assessment group will administer a disease-specific PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The disease-specific PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed disease-specific PROM is the ESAS-r:Renal or the IPOS-Renal.
2405301|NCT03535922|Experimental|The generic PROM group|HD units randomized to this PROMs assessment group will administer a generic PROM every 2 months to all patients able to complete the instrument independently or with assistance for a period of 12 months. Patients will receive a copy of their PROM results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the PROM. The generic PROM report will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROM report will be accompanied by treatment aids for all symptoms. The proposed generic PROM is the EQ-5D-5L.
2405302|NCT03535922|Experimental|Disease-specific and generic PROMs group|HD units randomized to this PROMs assessment group will administer a disease-specific and generic PROM every 2 months to all patients able to complete the instrument for a period of 12 months. Patients will receive a copy of both their PROMs results in report form and patients will be prompted to follow-up with their care providers if they provide a positive response to any of the symptoms assessed by the two PROMs. The disease-specific and generic PROMs reports will also be added to the patient's medical chart for review by clinicians. The report will display each patient's most recent results in comparison with their previous results, and in comparison with the general dialysis population. The PROMs reports will be accompanied by treatment aids for all symptoms.
2405303|NCT03535922|No Intervention|The control or 'usual care' group|HD units randomized to this group will follow usual care and patients will not have any PROMs assessment; however, all the treatment aids will be made available for clinicians in this study group during the 12 months trial period.
2405304|NCT03535896|Experimental|HSR and injection|HSR and corticosteroid injection
2405305|NCT03535883||patients taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement and are taking Novel Oral Anti-Coagulants (NOAC).
2405306|NCT03535883||patients not taking NOAC's|Patients with unilateral or bilateral pleural effusions who undergo thoracentesis, chest tube, or pleurx placement who are not taking Novel Oral Anti-Coagulants (NOAC).
2405307|NCT03535870|Experimental|Fluticasone propionate/salmeterol|fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) twice a day by inhalation throughout the study
2405308|NCT03535870|Active Comparator|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
2405309|NCT03535870|Placebo Comparator|Placebo|placebo inhaled powder twice a day by inhalation throughout the study
2405310|NCT03535857|Active Comparator|Unilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on the ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
2405311|NCT03535857|Experimental|Bilateral PTNS|34 gauge needle inserted 3cm above the medial ankle on both ankles, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period
3184984|NCT00730340|Active Comparator|2|Patients will not receive closure to one or both tonsillar fossa following a tonsillectomy
3184985|NCT00730366|Experimental|1|Experimental: IPTp-SP + promotion: Active Comparator
2405314|NCT03535831|Experimental|18F-DCFPyL PET/ MR or PET/CT imaging|"Will use a newer technology called PET-MR that combines a Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. This new combined imaging test, where PET and MRI data is gathered at one time, will be performed on an integrated PET-MR scanner located at Toronto General Hospital.~Or technology called PET-CT that combines a Positron Emission Tomography (PET) scan with a computed tomography (CT) scan. This combined imaging test, where PET and CT data is gathered at one time, will be performed on an integrated PET-CT scanner located at Princess Margaret Cancer Centre.~Choice of imaging method (PET/CT or PET/MR) will be made by one of the study PIs, based on clinical judgement taking into account the specific exam indication, prior recent imaging, and suitability for MR imaging."
2405315|NCT03535818|Active Comparator|Redo pulmonary vein isolation|
2405316|NCT03535818|Active Comparator|Ganglionated plexus ablation + redo pulmonary vein isolation|
2405317|NCT03535805|Experimental|Mind My Mind (MMM)|Mind My Mind (MMM)
2405318|NCT03535805|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU)
2405319|NCT03535792|Active Comparator|Fentanyl/Hyperbaric Bupivacaine|"Group F:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1 ml fentanyl (50μg) and will have Tibial internal fixation."
2405320|NCT03535792|Active Comparator|Nalbuphine/Hyerbaric Bupivacaine|"Group N:~Patients will receive intrathecal injection of 2 ml of 0.5% hyperbaric bupivacaine plus 1ml nalbuphine hydrochloride (1.6 mg); (nalufin 20 mg in 1 ml ampoule, Amoun Pharmaceutical Co. Cairo, Egypt) and will have Tibial internal fixation."
2405321|NCT03535779||Group 1|Healthy volunteers receiving Tetanus (Td/IVP) vaccine were enrolled onto the study for 1 month with no additional follow up visits.
2405322|NCT03535779||Group 2|Healthy volunteers receiving the Hepatitis B (HBsAg) vaccine were enrolled onto the study for 2 months with no additional follow up visits.
2405323|NCT03535753|Experimental|Decitabine and R-GDP|ALL patients will be treated with Decitabine and R-GDP
2405420|NCT03535116|Placebo Comparator|Control|Patients receive saline intravenously towards the end of the operation.
2405421|NCT03535103|Experimental|ARM A|Gonal-F®
3184986|NCT00730366|Experimental|2|IPTp-SP alone (without promotion)
3184987|NCT00730366|Active Comparator|3|Weekly CQ prophylaxis
3184988|NCT00730379|Experimental|1|ridaforolimus (MK8669) + dalotuzumab (MK0646)
2405327|NCT03535714|Active Comparator|MANTR-a group|"Patients who are in the MANTR-a group attend the MANTR-a treatment program, which consists of 20 once-weekly therapy sessions. Caregivers can be invited to 2 sessions. After 20 weeks, therapy continues with four monthly booster-sessions. In sum, each patient (whose bodyweight is above the 3rd BMI percentile) can attend 24 therapy sessions. In patients whose bodyweight is below the 3rd BMI percentile treatment will be extended to 30 once-weekly and 4 monthly booster sessions. Besides therapy the patients are in nutritional consultation by a dietician and under regular medical care to monitor the physical health and weight gain.~Patients who who have already an existing psychotherapy are attached to the control group."
2405328|NCT03535714|No Intervention|control group|Patients of the control group receive treatment as usual (TAU). It consists of medical care and monitoring, psychotherapy in a single or family setting, parents counselling and dietetics.
2405329|NCT03535701|Active Comparator|Arm I (standard of care)|Patients receive standard of care therapy with paclitaxel.
2405330|NCT03535701|Experimental|Arm II (standard of care, ketogenic diet)|Patients receive standard of care with paclitaxel. Patients undergo a controlled feeding period ketogenic diet comprising of meals prepared in the research kitchen for 3 months. Beginning 2 weeks prior to completion of the controlled feeding period, patients also undergo free living ketogenic diet program for 3 months comprising of group format, individual sessions, and online digital content to educate patients to implement a ketogenic eating pattern into their lifestyle.
2405331|NCT03535688|Experimental|D-cycloserine|D-cycloserine 200 mg BID (twice daily)
2405332|NCT03535688|Placebo Comparator|Placebo|Placebo BID (twice daily)
3144350|NCT00038090|Experimental|Thalidomide + Dexamethasone|
3144351|NCT00038116|Active Comparator|embryonic dopamine cell implant surgery|embryonic dopamine cell implant surgery
2405335|NCT03535662|Experimental|Orvepitant|Orvepitant single 20mg dose
2405336|NCT03535662|Experimental|Orvepitant and itraconazole|Orvepitant single 20mg dose in combination with repeat dose itraconazole
2405338|NCT03535636||Refugees with PTSD|"Adults over the age of 18. Refugees or family members of refugees that has been reunited. PTSD (ICD-10 criteria) and written consent.~No drug or alcohol abuse and no medication that can affect sleep rhythms, such as antipsychotic drugs, benzodiazepine, opioids, antihistamine or CNS stimulating drugs.~A BMI under 35 and no pregnancy."
2405339|NCT03535636||Healthy controls|Matched on age, sex and BMI and signed written consent. No mental illness, drug or alcohol abuse and medication. No pregnancy.
2405340|NCT03535623|Experimental|RIPC|Remote ischemic preconditioning (RIPC) consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the RIPC group.
2405341|NCT03535623|Sham Comparator|Sham-RIPC|Sham-RIPC consisted of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion is applied to the upper arm of the patients in the Sham-RIPC group.
2405342|NCT03535610|Experimental|Embolization|Uterine Embolization with PVA Microspheres
2405343|NCT03535597|No Intervention|Arm 1|Standard of Care (TR Band)
2405344|NCT03535597|Experimental|Arm 2|Quikclot Radial pad with Coban Bandage to hold the pad in place
2405345|NCT03535597|Experimental|Arm 3|Quikclot Radial Pad with Tegaderm dressing to hold the pad in place
2405346|NCT03535584|Experimental|Exercise Program|All participants will attend a 16-session exercise program based on pulmonary rehabilitation and will complete questionnaires and frailty testing.
2405348|NCT03535558||Cohort 1: FQ With Uncomplicated Sinusitis or Bronchitis|A target cohort which includes participants exposed to an oral fluoroquinolone (FQ) with an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
2405349|NCT03535558||Cohort 2: FQ With Uncomplicated Acute Urinary Tract Infection|A target cohort which includes participants exposed to an oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
2405350|NCT03535558||Cohort 3: AZ with Uncomplicated Acute Sinusitis or Bronchitis|A comparator cohort which includes participants exposed to oral azithromycin (AZ) with a qualifying indication of uncomplicated acute sinusitis or bronchitis and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the comparator groups will be linked to the Truven HPM data set.
2405422|NCT03535103|Experimental|ARM B|LM001
2405423|NCT03535090||active, moderate-to-severe GO|Each participant received IVMP according to EUGOGO recommendations (cumulative dose of methylprednisolone 4.5 g, treatment duration 12 weeks in single weekly intravenous pulses, first 6 weeks 0.5g of IVMP, next 6 weeks 0.25g of IVMP).
3144352|NCT00038116|Placebo Comparator|sham surgery|sham surgery (placebo)
3144353|NCT00038129|Experimental|1|Participants will receive reaming of the intramedullary canal prior to insertion of an intramedullary nail.
3144354|NCT00038129|Experimental|2|Participants will receive insertion of an intramedullary nail without prior reaming of the intramedullary canal.
3144355|NCT00038155|Other|1|
3144356|NCT00038168|Experimental|Estramustine + Taxol|
3144357|NCT00038194|Experimental|Imatinib + Docetaxel|
3144358|NCT00038207|Experimental|Liposomal Vincristine|
3144359|NCT00038233|Experimental|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
3144360|NCT00038246|Experimental|Thalidomide, Taxol, Estramustine|Thalidomide starting dose 200 mg by mouth every day once a week; Taxol 100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10; Estramustine 140 mg by mouth three times a day on Days 1-5, 8-12.
3144361|NCT00038298|Experimental|50 mg|50 mg 3 times weekly
3144362|NCT00038298|Experimental|400 mg|400 mg 3 times weekly
2405351|NCT03535558||Cohort 4: ST with Uncomplicated Acute Urinary Tract Infection|A comparator cohort which includes participants exposed to oral sulfamethoxazole/trimethoprim (ST) with a qualifying indication of uncomplicated acute urinary tract infection and an occurrence start between 2007-01-01 and 2015-12-31 (inclusive) and are between 18 and 65 years of age (inclusive). All participants must have continuous observation of at least 180 days prior and 120 days after event index date, and all events will be evaluated per participant. The members of the treatment groups will be linked to the Truven Health and Productivity Management (HPM) data set.
2405352|NCT03535545|Experimental|Healthy Individuals|Healthy volunteers will receive [68Ga]CBP8 and undergo PET imaging.
2405353|NCT03535545|Experimental|Lung Cancer Subjects|Lung cancer patients will receive [68Ga]CBP8 and undergo PET imaging.
2405354|NCT03535545|Experimental|Pulmonary Fibrosis Subjects|Idiopathic pulmonary fibrosis patients or patients with other types of interstitial lung disease with a fibrotic component will receive [68Ga]CBP8 and undergo PET imaging.
2405355|NCT03535532|Experimental|unilateral laparoscopic adrenalectomy|subjects allocated in this group will be given unilateral laparoscopic adrenalectomy as treatment.
2405356|NCT03535532|Active Comparator|standard medical treatment|subjects allocated in standard medical treatment group will be given conservative medicine treatment.
2405357|NCT03535506|Experimental|Group A|Patients enrolled to Group A will receive a 12-day course of Palbociclib before surgery. They will receive Palbociclib 100mg PO daily x 12 days.
2405358|NCT03535506|No Intervention|Group B|These patients will receive no pre-operative treatment. Core biopsies from diagnosis and material from definitive surgery will be collected for translational studies and tissue banking. They will also provide blood samples at screening and prior to definitive surgery.
2405359|NCT03535493|Active Comparator|Acceptance and Commitment Therapy (ACT)|
2405360|NCT03535493|Active Comparator|Float REST|
2405361|NCT03535493|Experimental|ACT + Float REST|
2405362|NCT03535480|Experimental|G-CSF|Only receives G-CSF subcutaneously five days for stem cell mobilization
2405363|NCT03535480|Experimental|ASCOT|Receives G-CSF subcutaneously five days and then plasmapheresis for hematopoietic stem cell collection and catheterism for infusion in ovarian artery
2405364|NCT03535467||Conventional Rehabilitation|
2405365|NCT03535467||Robotic Therapy|
2405366|NCT03535454||Factory workers|
2405367|NCT03535454||Nurses|
2405368|NCT03535454||Janitors|
2405369|NCT03535454||Data automation employees|
2405370|NCT03535441||voluteer group|No treatment, only blood sample collection
2405371|NCT03535441||hemorrhagic shock group|HS was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more. Exclusion criteria were pregnancy, <15 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital
2405372|NCT03535428||VENOUS exploration|
2405373|NCT03535415|Experimental|rhGH Injection|rhGH 0.05mg/kg/d by subcutaneous injection
2405374|NCT03535415|No Intervention|Non-treatment control group|Only follow-up without treatment
2405375|NCT03535402|Other|open label treatment|single arm with patients receiving 200 mg SC twice a week of sarilumab
2405376|NCT03535389|Experimental|Pathologic group|Patients addressed to our imaging department for the realization of a knee scanner as part of routine care and presenting clinical PFI syndrome (Patellofemoral instability diagnosis based on physical examination, history and Kujala score)
2405377|NCT03535389|Active Comparator|Control group|"Patients addressed to our imaging department for osteo-articular pathologies other than patellofemoral instability (non-fracture trauma, vascular pathologies, degenerative or soft tissues).~Does not have any clinical PFI syndrome~Matched (1: 1 ratio) to PFI patients by age (+/- 40 years) and sex"
3144363|NCT00038298|Experimental|200 mg|200 mg 3 times weekly
2405379|NCT03535350|Experimental|Unmethylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation over 6 weeks. Patients will undergo a 4-week break and then Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
2405380|NCT03535350|Experimental|Methylated MGMT Glioblastoma|Every patient gets ibrutinib + radiation + daily Temozolomide (TMZ) (75mg/m2) for 6 weeks. Patients will undergo a 4-week break and patients will then receive daily ibrutinib and adjuvant Temozolomide for Days 1-5 of a 28-day cycle of temozolomide for 6 cycles. The temozolomide will continue until disease progression, intolerable toxicity, or death or maximum of 6 cycles. Ibrutinib treatment will continue until disease progression, intolerable toxicity, or death.
2405424|NCT03535077||Suspicious Nevi undergoing biopsy|Subject with suspicious Nevi undergoing biopsy per SOC
3144364|NCT00038298|Placebo Comparator|Placebo|Placebo comparator associated with each active arm. (3:1 active vs placebo)
3144365|NCT00038350|Experimental|1|8 week lingual strengthening exercise protocol
3144366|NCT00038376|Experimental|1|Alpha-interferon + Isotretinoin
2405389|NCT03535324|Experimental|PROA for optimization|Development of a Program for optimizing the use of antibiotics (PROA) in Spanish (Antimicrobial Stewardship Program, ASP, in English), based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations. The intervention will be carried out at the cluster level (group of patients belonging to a specific hospital service that meet the inclusion criteria). The intervention will consist in carrying out the audit with recommendation on days 3 and 5-7 after the extraction of negative blood cultures to assess the possibilities of de-escalation, sequential oral therapy and end of early treatment based on the available evidence.
2405390|NCT03535324|Other|Control|There will be no intervention.
2405391|NCT03535298|Experimental|EHT: Early Highly-effective|"Participants randomized to the EHT: Early Highly-effective arm will receive one of the highly effective MS therapies (Ocrevus, Lemtrada, Tysabri, Rituximab, Kesimpta) as their initial disease modifying treatment.~Interventions: one of the highly effective MS therapies~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
2405392|NCT03535298|Experimental|ESC: Escalation|"Participants randomized to the ESC: Escalation arm will receive any other approved MS therapy (not one of the EHT group) as their initial disease modifying treatment.~Interventions: one of the MS therapies NOT in the highly effective group~The randomization affects only the INITIAL treatment received. Once that treatment has been initiated, any subsequent changes are made according to standard clinical practice, regardless of randomization group."
2405393|NCT03535298|No Intervention|OBS: Observational|"Participants will not be restricted to a group of MS therapies.~Participants enter this arm if they are not comfortable with randomization, are not eligible to receive any of the options in a randomized arm, or are not able to secure insurance coverage for any therapy in a randomized arm."
2405394|NCT03535285|Experimental|Surgical modification side|Periodontal ligament distraction without the oblique cuts but with apical horizontal cut
2405395|NCT03535285|Active Comparator|Conventional surgery|Periodontal ligament distraction
2405396|NCT03535272|Active Comparator|Intervention Group|Bismuth subsalicylate 4 tablets po bid (2.1 grams total of BSS)
2405397|NCT03535272|Placebo Comparator|Placebo|Placebo oral tablet 4 bid
2405398|NCT03535259|Experimental|Sorafenib and IMRT|Concurrent sorafenib and IMRT, followed sorafenib maintenance for advanced hepatocellular carcinoma with portal vein or hepatic vein tumor thrombosis or lymph node involved
2405399|NCT03535246|Experimental|Single arm|EIE cells to treat cancer.
2405400|NCT03535233|Active Comparator|Intralesional group|intralesional triamcinolone acetonide 5 mg/ml monthly
2405401|NCT03535233|Active Comparator|Topical therapy group|Minoxidil 5% topical solution applied twice daily and topical clobetasol propionate 0.05% cream applied once daily every night
2405402|NCT03535220||Observational/ Interventional|Hematologic Disease
2405403|NCT03535207|Experimental|high dose chemoradiotherapy|all eligible patients receive intensity-modulated radiotherapy 50 Gy in 25 fractions over 5 weeks and concurrent paclitaxel and cisplatin once weekly for 5 weeks，followed by hyperfractionated intensity-modulated radiotherapy boost to gross tumor volume concurrent with the same chemotherapy
2405409|NCT03535168|Experimental|Dose 1 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 1 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 1 of BAY1902607 will be given only once.
2405410|NCT03535168|Experimental|Dose 2 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 2 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 2 of BAY1902607 will be given only once.
2405411|NCT03535168|Experimental|Dose 3 of BAY1902607|Part 1: From Day 1 until Day 12 the dose 3 of BAY1902607 will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, dose 3 of BAY1902607 will be given only once.
2405412|NCT03535168|Experimental|Matching placebo|Part 1: From Day 1 until Day 12 the matching placebo will be given twice daily in approximately 12 hour intervals. On Day 0 and Day 13, matching placebo will be given only once.
2405413|NCT03535168|Experimental|BAY1902607+Matching Placebo|"Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1902607+matching placebo"
2405414|NCT03535168|Experimental|Matching Placebo+BAY1902607|"Part 2:~Randomized crossover design in cough patients Matching placebo+4 different doses of BAY1902607"
2405415|NCT03535142|Experimental|Intervention|The intervention is bariatric surgery (Roux en Y gastric bypass or gastric sleeve operation).
2405416|NCT03535142|No Intervention|Control|Age, BMI and co-morbidity matched group who do not undergo surgery.
3144367|NCT00038389|Experimental|Vioxx MTD|
3144368|NCT00038402|Experimental|Herceptin + Taxol Followed by FEC|Herceptin starting 4 mg/kg intravenous (IV), then 2 mg/kg weekly for all other cycles neo-adjuvant chemotherapy and during FEC therapy for total 24 doses. Taxol 225 mg/m^2 continuous IV over 24 hours each cycle; Fluorouracil 500 mg/m^2 IV Days 1 at 3-4 week intervals; Cytoxan 500 mg/m^2 IV on Day 1; Epirubicin 75 mg/m^2 IV on Day 1. Four 21-day cycles.
2405419|NCT03535116|Experimental|Patients receiving ketorolac|Patient receives 30mg IV ketorolac(single dose) towards the end of the operation.
2405487|NCT03534661|Placebo Comparator|Placebo + L-NMMA|(Teduglutide control) + L-NMMA
3144369|NCT00038415|Experimental|Vaccine|
3144370|NCT00038441|Experimental|DTI-015|
3144371|NCT00038558|Experimental|Filgrastim + ABVD Chemotherapy|
3144372|NCT00038571|Experimental|Arm A (mantle-cell lymphoma)|
3144373|NCT00038571|Experimental|Arm B (other B-cell lymphomas)|
3144374|NCT00038623|Experimental|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion (250 mg/m^2 intravenous) on Day 1, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
3144376|NCT00038701|Experimental|Gemzar Chemoradiation + TNP-470|
3144377|NCT00038766|Experimental|Semapimod 60 mg|Semapimod 60 mg IV x 5 days
3144378|NCT00038766|Experimental|Semapimod IV 30 mg|Semapimod IV 30 mg x 5 days
3144379|NCT00038766|Placebo Comparator|Placebo|Placebo IV x 3 or 5 days
3144380|NCT00038779|Experimental|Megadose T cell depleted|
2405425|NCT03535064|Experimental|Schools received hand hygiene workshop|Schoolgirls of randomly assigned schools attended one-hour Arabic handwashing workshop conducted by the principal investigator one week after submitting all baseline questionnaires. Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
2405426|NCT03535064|No Intervention|Schools with did not receive hand hygiene workshop|Schoolgirls in control group followed their usual hand washing procedure. When the study ended, schoolgirls of control school were exposed to the same intervention by the same investigator.
2405427|NCT03535051|Experimental|Treatment A|Combination treatment of fractional carbon dioxide laser monthly sessions and topical tacrolimus 0.03% daily application (Tacrolimus Oint 0.03%)
2405428|NCT03535051|Active Comparator|Treatment B|Monotherapy with only topical tacrolimus 0.03% daily intervention: Tacrolimus Oint 0.03%
2405429|NCT03535038|Experimental|Inferior vena cava (IVC) diameter|subjects underwent IVC diameter measurement after VPW measurement
2405430|NCT03535038|Active Comparator|Vascular pedicle width (VPW)|Supine chest x ray was done and the VPW is assessed by radiologists.
2405431|NCT03535012||Reconstruction using an implant|Immediate 2 stage implant based breast reconstruction after mastectomy. All expanders are placed in the subpectoralis muscle using ADM as a sling. After expansion of the tissue expander change to the permanent implant is performed.
2405432|NCT03535012||Reconstruction using abdominal tissue|immediate free DIEP flap breast reconstruction after mastectomy. DIEP(deep inferior epigastric perforator) free flap was prepared and transferred to the breast pocket. Microanastomosis was done under the microscopic magnification. On sitting position, free flap was inset into breast pocket with confirming of satisfactory inflammatory fold.
2405433|NCT03534999|Experimental|TENS|This is intervention Group. Patients in this group received Transcutaneous Electrical Nerve Stimulation (TENS). The VAS and Oxford hip score was administered prior to the treatment to ascertain their pain intensity and hip disability level. The site of intervention (5cm away from incision site) was cleaned properly with cotton wool soaked in methylated spirit in an outward motion. Before the self-adhesive, pre gelled electrodes was placed on the cleansed sites.The TENS unit was switched on and the parameters was adjusted to the required level. For this study, parameters used are: 100µs pulse duration, 100Hz frequency and an intensity comfortable for the patient for a duration of 15 minutes.
2405434|NCT03534999|No Intervention|Control|This was the group with no intervention. Subjects were on their normal analgesic and antibiotic medication for the period of research. The VAS and Oxford hip score were administered on the first day to ascertain pain intensity and hip disability level. The subject continued on the normal analgesics only till the third day and VAS and Oxford hip score was re-administered to assess any change in the pain intensity and hip disability level.
3184989|NCT00730392|Experimental|1 drug, 2 placebo|"Etanercept~Placebo"
2405438|NCT03534973|Active Comparator|Caffeine intake|Caffeine is given orally prior to cataract surgery
2405439|NCT03534973|Sham Comparator|No caffeine intake|Caffeine is not given orally prior to cataract surgery
2405440|NCT03534960|Other|High Flow Nasal Oxygen Therapy|Patients are randomized to the high flow nasal oxygen therapy group
2405441|NCT03534960|Other|Nasal CPAP|Patients are randomized to the nasal continuous positive airway pressure treatment group
2405442|NCT03534947|Experimental|Sonidegib followed by imiquimod|Sonidegib 200mg taken orally once a day for 12 weeks. COMPLETE OR PARTIAL RESPONSE WITH SUPERFICAL REMNANT LESION For patients with a complete response or a partial response resulting in a superficial lesion, treatment with topical imiquimod for 5 days a week for 6 weeks will be prescribed.
2405443|NCT03534947|Experimental|Sonidegib followed by surgery|Sonidegib 200mg taken orally once a day for 12 weeks. PARTIAL RESPONSE WITH REMNANT INVASIVE LESION For patients with a no change on BCC size / depth or patients with a partial response but a remaining invasive lesion, will have surgical excscion of the remaining lesion.
2405444|NCT03534947|Other|Sonidegib then best supportive care|Sonidegib 200mg taken orally once a day for 12 weeks. PROGRESSIVE DISEASE Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions.
3144381|NCT00038792|Experimental|aGvHD|
3144382|NCT00038805|Experimental|Mylotarg|
2405447|NCT03534921||People with severe mental illness (SMI)|In the study period 01/04/2000-31/03/2016, people with records on the Clinical Practice Research Datalink aged >=18 years with a record of severe mental illness so that at least one event occurs in the study period.
2405448|NCT03534921||People with SMI and type 2 diabetes|Drawn from the first cohort, this group also has a record of type two diabetes mellitus registered during the study period.
2405449|NCT03534921||People with diabetes (matched controls)|This cohort will be matched on a 4:1 ratio by age (+- 2 years), gender and general practitioner practice to the group of people with comorbid SMI and diabetes.
2405450|NCT03534908||NAFLD group|those with NAFLD
2405451|NCT03534908||Control group|those without NAFLD
2405488|NCT03534648|Experimental|Effect of PF-05221304 on PF-06865571 PK|
3144383|NCT00038818|Experimental|CD8 DLI|CD8 depleted DLI (Depleted Donor Lymphocyte Infusions)
3144384|NCT00038831|Experimental|Chemotherapy + ATG + Stem Cell Infusion|
3144385|NCT00038844|Experimental|Campath in Nonmyeloablative Transplantation|Campath-1 H Starting Dose of 15 mg by vein daily, 3 days in a row + Fludarabine 30 mg/m2 by vein daily, 3 days in a row + Cyclophosphamide 1 gm/m2 by vein daily, 3 days in a row + Rituximab 375 mg/m2 by vein, given 8 days before transplant then weekly for 4 total doses.
3144386|NCT00038870|Experimental|Dendritic Cell Activated Lymphocytes|
3144387|NCT00038883|Experimental|Campath-1H|10 mg/day x 5
3144388|NCT00038961|Placebo Comparator|Placebo + intermittent pneumatic compression (IPC)|
3144389|NCT00038961|Experimental|fondaparinux + intermittent pneumatic compression (IPC)|
3144390|NCT00038974|Experimental|Interferon and rivavirin|All patients received peginterferon alfa-2a in a dose of 180 μg weekly and ribavirin in a dose of 1000 (for patients with a body weight of ⩽75 kg) or 1200 mg (for those with a body weight of >75 kg) daily.
3144391|NCT00039013|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
2405453|NCT03534895|Experimental|PC2|midazolam 0.02mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
2405454|NCT03534895|Experimental|PC3|midazolam 0.06mg/Kg in 5mL normal saline, intravenous, single-administration, as pre-medication
2405455|NCT03534882|Experimental|Washout|Discontinuation of topical prostaglandin analogue therapy: Participants are asked to discontinue (washout) their prostaglandin analogue for 42 days. As the experimental group, the purpose of this arm is to determine the lingering IOP-reducing effects following discontinuation of chronic prostaglandin analogue therapy, and to determine if IOP rises back to baseline (pre-treatment values).
2405456|NCT03534882|No Intervention|Control|Patients are asked to remain on their prostaglandin analogues and continue treatment as prescribed by their ophthalmologist. The purpose of this arm is to minimize bias in intraocular pressure readings.
2405457|NCT03534869|Experimental|Ear Acupuncture and Oral Analgesics|"The acupuncture treatment consisted of three acupuncture needles on the dominant ear according to French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point that is used to increase the anaesthetic effect according to both French and Chinese traditions.~Additional oral analgesics (NSAID) could be supplied at any time upon patients request during hospitalization. Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy."
2405458|NCT03534869|Active Comparator|Oral Analgesics Only|Postoperative standard oral analgesic therapy (NSAID) supplied at any time upon patients request during hospitalization. Oral ibuprofen would be given as first line therapy, while oral paracetamol would be given as second line therapy.
2405459|NCT03534856|Experimental|Mindfulness meditation|Two weeks of short, daily guided mindfulness meditations were provided.
2405460|NCT03534843||Surgical treatment|Patients who received liver resection or palliative surgery, such as microwave coagulation therapy, hepatic artery ligation, or suturing ligation.
2405461|NCT03534843||Non-surgical treatment|Patients who received transcatheter arterial embolization (or transcatheter arterial chemoembolization) or conservative treatment
2405462|NCT03534830||eLASV > 38.5|exposed group of patients with an eLASV at or above 38.5 on a pre-operative MRI.
2405463|NCT03534830||eLASV < 38.5|non-exposed group of patients with an eLASV less than 38.5 of pre-operative MRIs
3144392|NCT00039013|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
3144393|NCT00039013|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
2405466|NCT03534804|Experimental|Cabozantinib and Pembrolizumab, all patients|
2405467|NCT03534791|Experimental|Reminders|Reminders customized for each PLS, containing a name of the PLS indicated in the message. If the participants do not translate PLS within 2 months from PLS assignment, we will stop sending them reminders and we will consider them as dropouts.
2405468|NCT03534791|No Intervention|Control group|Control group will receive no intervention, i.e. standard procedure. Participants in the control group will receive PLSs for translation, in the frequency they indicated, and they will not receive any reminders. They will be assigned new PLSs once they translate the ones that were previously assigned.
2405469|NCT03534778||patients undergoing neck dissection|all patients undergoing neck dissection
2405470|NCT03534765||Retrospective arm|Retrospective multicentre cohort with 1 year outcomes available following emergency surgery for NELA eligible gastrointestinal pathology. Please refer to WP1 inclusion and exclusion criteria for eligibility.
2405471|NCT03534765||Prospective, multicentre arm|10 centre prospective observational arm. Please refer to WP2 inclusion and exclusion criteria for eligibility.
2405472|NCT03534739|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
2405473|NCT03534739|Active Comparator|Light Touch Massage|Participants will receive light touch applied to one myofascial trigger point.
2405474|NCT03534739|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
2405475|NCT03534726||Patients|Patients with cardiomyopathy
2405476|NCT03534726||Normal subjects|No prior history of heart disease.
2405477|NCT03534713|Experimental|Neoadjuvant chemotherapy+standard therapy|neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
2405478|NCT03534713|Active Comparator|standard therapy alone|standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)
2405479|NCT03534700|Active Comparator|Open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
2405480|NCT03534700|Experimental|parasacral flap reconstruction|The parasacral perforator flap has been described. It appears to be a good alternative, offering all the benefits of the reconstruction of the natal cleft in terms of lower rate of recurrence and lower time for complete wound healing. It also gives a better aesthetic result.
2405481|NCT03534687|Experimental|Aerobic Exercise Group|Aerobic Exercise (AE) subjects will come in for supervised, aerobic exercise training sessions 5 days a week for 12 weeks. Training will progress from 55% VO2max for week 1 (40 min session), to 60-65% VO2max for week 2 (50 min session), to ~70% VO2max for all other weeks (50 min session). Subjects will perform a warm-up and cool down (~5 min each) that includes stretching exercises. Subjects will wear heart rate monitors during each training session to provide feedback of target heart rate. Intensity, duration, resting and exercise heart rates, and blood pressures will be recorded for each session. Follow-up VO2max tests will be performed at weeks 4 and 8 to monitor progress and adjust AE training intensity.
2405482|NCT03534687|No Intervention|Control Group|During the 12 week control period, subjects are to maintain their normal, daily-living activities. Control group participants will be given the option to enroll in the AE training group after completion of the original Control group trial period.
2405483|NCT03534674|Experimental|Intervention|Participants assigned to the intervention group will receive a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, with subsequent vitamin D3 2000 IU daily.
2405484|NCT03534674|No Intervention|Control|Participants assigned to the control group will be advised to take our current vitamin D regimen (2000 IU vitamin D3 daily).
3144394|NCT00039013|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.04 mL
2405490|NCT03534635|Experimental|Pembrolizumab|"Pembrolizumab 200 mg will be administered intravenously every 3 weeks, for a maximum of 2 years, until progression, unacceptable toxicity, or withdrawal of consent, whichever happens first.~Patients may be treated for up to one year of additional treatment with pembrolizumab via the Second Course Phase, and according to defined criteria."
2405491|NCT03534622|Experimental|Delafloxacin|"Dosing will be initiated on Day 1. All participants will receive 300-mg delafloxacin as a~1-hour intravenous infusion every 12 hours (± 15 minutes) for a total of 7 doses."
2405492|NCT03534609|Experimental|Genius System Neck Treatment|Lutronic Genius System treatment of lines, wrinkles, and texture concerns on the neck.
2405493|NCT03534583|Active Comparator|Health Enhancement Program (HEP)|The Health-Enhancement Program (HEP) is structurally equivalent to a SKY intervention, with similar-sized groups, meeting for 3 consecutive days for 1.5-3 hours. There will then be a a gap of 4 days where participants will practice what they have learned, followed by 3 consecutive days of 1.5-3 hours of instruction. Starting the following week participants will attend once weekly follow up sessions (60-90 min/wk) for 3 weeks and then bimonthly sessions for the next 8 weeks. Participants will be asked to complete 25 min/day of course homework. Participants will learn about health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation. In HEP, which has been manualized, participants get the support of a group and facilitator, and talk through and try to implement positive health-enhancing life changes, HEP will be delivered by a trained social worker (or equivalent).
2405494|NCT03534583|Experimental|Sudarshan Kriya Yoga (SKY)|The SKY PTSD program is a mind-body resilience building program developed for persons with PTSD. Through SKY breathing, interactive discussions, journaling, yoga and guided meditations, the workshop builds a framework for resilience and empowerment, and develops self-awareness, connectedness and community, and a positive outlook. SKY training will take place in group-format (6-8 participants). During the first week participants will attend three 2.5-3 hour sessions on three consecutive days. There will then be a gap of 4 days where participants can apply the tools provided, followed by three more consecutive days of 1.5-3 hours of instruction. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period (up to 26 weeks) and log practice frequency.
2405495|NCT03534557||COPD|FEV1/FVC and FEV1/FEV6 will be compared within the same cohort of COPD patients
2405496|NCT03534518|Active Comparator|SCI-patients receiving overground training|
2405497|NCT03534518|Active Comparator|SCI-patients receiving treadmill training|
2405498|NCT03534505|Experimental|Ketorolac injections|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
2405499|NCT03534505|Active Comparator|bupivacaine|Patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
2405500|NCT03534492|Experimental|Durvalumab plus Olaparib|Durvalumab 1500 mg every 4 weeks for up to a maximum of 2 months (up to 2 doses/cycles) plus Olaparib 300 mg b.i.d. up to 56 days (2 cycles of 28 days each cycle).
2405501|NCT03534479|Experimental|CVID-IVIgG, polyclonal IgG i.v. infusion|The patients of the CVID-IVIgG, polyclonal IgG infusion, group are studied five weeks from their last therapeutic polyclonal IgG i.v. infusion (IVIgG). On the mornings of day 0, vascular reactivity of the brachial artery, assessed as Flow mediated dilation (FMD), is measured and blood collected for biochemistry (baseline). Immediately after the FMD measurements and the blood collection, the 24 patients receive half dose of IVIgG necessary to treat their disease (400 mg/kg body weight in 10% solution). Twenty-four hours later, before infusing the second half of the dose of the IVIgG, vascular reactivity is again measured and blood collected. Vascular reactivity is again measured 1, 2, and 3 weeks after the first IVIgG infusion.
2405502|NCT03534466|Experimental|intervention group|Baby treadmill + conventional physical rehabilitation training
2405503|NCT03534466|Active Comparator|positive control group|Conventional physical rehabilitation training only
3144395|NCT00039026|Experimental|AC2993 5 mcg (0.02 mL)|Placebo, then AC2993 5 mcg, then AC2993 5 mcg
3184990|NCT00730418|Experimental|doxazosin 4mg|doxazosin 4mg group
3184991|NCT00730418|Experimental|doxazosin 8mg|doxazosin 8mg group
2405507|NCT03534414||Intervention|A Portfolio Dietary Pattern involving a combination of 4 cholesterol lowering foods, namely: plant sterols, viscous fibre, plant protein, and nuts.
2405508|NCT03534414||Control|A National Cholesterol Education Program (NCEP) based diet, a diet low in saturated fat and cholesterol.
2405509|NCT03534401|No Intervention|Standard Family Planning Counseling|Clients receive standard FP counseling services.
2405510|NCT03534401|Experimental|ARCHES Kenya Intervention in FP Counseling|Clients receive the ARCHES Kenya intervention in addition to standard FP counseling services.
2405511|NCT03534388|Other|Prospective Subjects|
3144396|NCT00039026|Experimental|AC2993 10mcg (0.04 mL)|Placebo, then AC2993 5 mcg, then AC2993 10 mcg
3144397|NCT00039026|Placebo Comparator|Placebo 0.02 mL|Placebo 0.02 mL, then Placebo 0.02 mL, then Placebo 0.02 mL
3184992|NCT00730431|Experimental|IDX184 5 mg|Healthy participants will be administered a single 5 mg dose of IDX184.
3184993|NCT00730431|Experimental|IDX184 10 mg|Healthy participants will be administered a single 10 mg dose of IDX184.
2405540|NCT03534141|Experimental|Mild hypothermia & Esophageal cooling/warming device|The target core temperature is 34-35 °C.
3144398|NCT00039026|Placebo Comparator|Placebo 0.04 mL|Placebo 0.02 mL / Placebo 0.02 mL / Placebo 0.04 mL
3144399|NCT00039091|Experimental|Treatment (ipilimumab)|Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody IV over 90 minutes on day 1. Courses repeat every 2 months in the absence of disease progression or unacceptable toxicity.
3144400|NCT00039104|Experimental|Arm I (rebimastat, zoledronic acid)|Patients receive zoledronate IV over at least 15 minutes on day 1 and oral BMS-275291 daily on days 1-28.
3144401|NCT00039104|Experimental|Arm II (zoledronic acid)|Patients receive zoledronate as in Arm I.
2405516|NCT03534336|No Intervention|Control|"Participants are enrolled in a 12-week, self-administered online weight loss program. The program is delivered through 12 weekly sessions; each includes educational videos and a health literacy quiz. Each quiz contains 10 questions, and a quiz is considered passed when at least 7 questions are answered correctly. All participants are encouraged to follow the program, take the quizzes, and lose 5% of their baseline body weight by the end of the program.~No financial incentives are given for losing weight or passing quizzes."
2405517|NCT03534336|Experimental|Incentive for Education|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Education for passing at least nine quizzes by the end of the program."
2405518|NCT03534336|Experimental|Incentive for Weight Loss|"Same 12-week, self-administered online weight loss program as in the Control arm.~Each participant is also given a $150 Incentive for Weight Loss for losing 5% of their baseline body weight."
3184994|NCT00730431|Experimental|IDX184 25 mg|Healthy participants will be administered a single 25 mg dose of IDX184.
2405520|NCT03534310|Active Comparator|Lifestyle modification|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive
2405521|NCT03534310|Experimental|Lifestyle modification plus Liraglutide 3 mg|1 month of a VLCD with 865 kcal per day followed by a 12 kcal per kg of body weight of a high-protein, high fat diet for 11 months in association with intensive. The patients will also receive Liraglutide 3 mg daily sc.
2405522|NCT03534310|Active Comparator|Sleeve Gastrectomy|The patients will undergo laparoscopic sleeve gastrectomy
2405523|NCT03534297|Experimental|dapansutrile capsules|"A total of 8 patients in each cohort will receive dapansutrile capsules:~Cohort 1 will receive 5x 100 mg dapansutrile capsules QD for 14 days~Cohort 2 will receive 5x 100 mg dapansutrile capsules BID for 14 days~Cohort 3 will receive 5x 100 mg dapansutrile capsules QID for 14 days"
2405524|NCT03534297|Placebo Comparator|Placebo Capsules|"A total of 2 patients in each cohort will receive placebo capsules:~Cohort 1 will receive 5 placebo capsules QD for 14 days~Cohort 2 will receive 5 placebo capsules BID for 14 days~Cohort 3 will receive 5 placebo capsules QID for 14 days"
3184995|NCT00730431|Experimental|IDX184 50 mg|Healthy participants will be administered a single 50 mg dose of IDX184.
3184996|NCT00730431|Experimental|IDX184 75 mg|Healthy participants will be administered a single 75 mg dose of IDX184.
3184997|NCT00730431|Experimental|IDX184 100 mg|Healthy participants will be administered a single 100 mg dose of IDX184.
3184998|NCT00730431|Placebo Comparator|Placebo|Healthy participants will be administered placebo matching IDX184.
2405529|NCT03534219|Experimental|Intervention Arm: EarPopper|"All patients in this arm will receive the EarPopper device.~Length of administration: 1 year Dose: Dosing of the EP device will be twice per day, once in the morning and once before bedtime. This is consistent with previous dosing which showed no adverse events and an excellent safety profile. 5, 6~Administration:~Hold nosepiece firmly against nostril opening creating a good, tight seal is crucial. Plug the other nostril closed.~Push button to start the airflow and swallow while the device is running.~Repeat on other nostril. After 5 minutes, repeat steps 1 - 3. This will complete one treatment.~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
2405530|NCT03534219|No Intervention|Control|"All patients in this arm will not receive any intervention. EarPopper device will be given to this group at the end of follow-up period (1 year)~Telephone call survey:~Will be administered monthly by study investigator. Telephone call survey is based on the OMO-22 Form."
2405531|NCT03534193|Other|Group 1|Participants randomized to Group 1 will receive Standard Diabetic Education with Registered Nurse and Molly Center Diabetes Care Guide (paper-based)
2405532|NCT03534193|Experimental|Group 2|Participants randomized to Group 2 will receive Molly Center Standard Diabetes Education plus access to Tablet based interactive diabetes education modules
2405533|NCT03534180|Experimental|Treatment (venetoclax, romidepsin)|Patients receive venetoclax PO QD on days 1-28 and romidepsin IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
2405534|NCT03534167|Experimental|TODAY! App and Coaching|RCT participants will be randomized into a 10-week intervention condition during which they will receive the CBT modules through the TODAY! app. In addition to the mobile app, participants will receive coaching from the study Coach who is trained in Motivational Interviewing principles. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks.
2405535|NCT03534167|No Intervention|Referrals|RCT participants will be randomized into a 10-week wait-list control condition and will be provided with and encouraged to use mental health and lesbian, gay, bisexual, queer (LGBQ) referrals and resources in the community. Participants will complete mood and behavior assessments at 4 time-points over the course of 22 weeks. After the 22-week post intervention follow-up, control group participants will have the option to receive the intervention, however they will not be administered follow-up assessments or given coaching.
2405536|NCT03534154||TBI - MRI / bloods / cognitive / clinical outcomes|Work package 1. In a large multi-centre cohort of adult moderate/severe TBI patients we aim to identify the most informative plasma biomarker(s) of the severity of axonal injury. We will characterise their time course, focusing on neurofilament light (NFL) and tau, and relate these to magnetic resonance imaging (MRI) measures of axonal injury. Using logistic regression we will then test whether these measures contribute to the prediction of clinical outcome at twelve months
2405537|NCT03534154||TBI - Advanced MRI / bloods / cognitive / clinical outcomes|Work package 2. In a subgroup of the patients recruited to WP1 we will use advanced MRI and longitudinal assessments to provide a more detailed description of the relationship between the plasma biomarkers and outcome after TBI. We will test whether advanced diffusion and myelin integrity measures correlate with plasma biomarkers and whether early plasma biomarker levels predict neurodegeneration measured by progressive atrophy after TBI.
2405538|NCT03534154||TBI - microdialysis / adv. MRI / cognitive / clinical|Work package 3. In a second subgroup of patients recruited to WP1 we will combine microdialysis, neuroimaging and plasma sampling of axonal proteins to provide a deeper understanding of the mechanisms of axonal injury progression and use this approach to investigate the axonal origin of the plasma biomarkers.
2405539|NCT03534154||Healthy volunteer|Single assessment using MRI, bloods and cognitive testing.
2405541|NCT03534141|Active Comparator|Normothermia & Esophageal cooling/warming device|The target core temperature is 36.5-37.5 °C.
2405542|NCT03534128|Experimental|Spatial navigation evaluation|
2405543|NCT03534115|Placebo Comparator|Placebo|Placebo was prepared by using the same solution containing buffers that were used in the preparation of NAC solution, except it did not contain NAC
2405544|NCT03534115|Experimental|Experimental Arm|solution containing NAC with buffers
2405545|NCT03534102|No Intervention|Standard of Care|Standard instructions from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
2405546|NCT03534102|Experimental|Improved Instructions|Improved opioid-tapering instructions given upon discharge from hospital. Subjects talk with hospital staff only when they call the hospital, when RA calls at various benchmarks, and at postoperative clinic visits. Subjects record opioid tapering in diary.
2405547|NCT03534102|Experimental|Improved Instructions and Educator|Improved opioid-tapering instructions given upon discharge from hospital. Subject receives regular phone calls from educator for counseling in opioid tapering. Subjects record opioid tapering in diary.
2405548|NCT03534089|Placebo Comparator|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with standard infant formula (without lactoferrin supplementation)
2405549|NCT03534089|Experimental|Low level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with low level of lactoferrin (38mg/100g). Lactoferrin:38mg/100g
2405550|NCT03534089|Experimental|High level LF infant formula group|Infants with iron deficiency anemia randomly divided into this arm were given the same dose of ferralia with other arms,but were fed with infant formula supplemented with high level of lactoferrin (76mg/100g)
2405551|NCT03534063|Active Comparator|genotype-guided opioid therapy|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
2405552|NCT03534063|No Intervention|usual care|The study team will collect data on the implementation success metrics, PROs via PROMIS measures, and for opioid utilization measures. The investigators will collect proportion of patients prescribed specific opioids and self-reported opioid use, since patients may not take any or all of the opioid prescribed.
2405553|NCT03534050|Experimental|postoperative adjuvant RT|In this prospective observational study, all potentially eligible patients are clinically indicated for receiving postoperative adjuvant RT. Namely, partial cranial irradiation will be initiated within one month approximately after enrollment. Prescription dose will be 5000 - 6000 cGy in 25 - 30 fraction during 5 - 7 weeks.
2405554|NCT03534037|Experimental|Febuxostat 40mg|Febuxostat 40mg orally per day
2405555|NCT03534037|Active Comparator|Benzbromarone 50mg|Benzbromarone 50mg orally per day
2405556|NCT03534037|Other|Control|Dietary control only
2405557|NCT03534024|Active Comparator|nanomicielle curcumin|
2405558|NCT03534024|Placebo Comparator|plecebo|
2405559|NCT03534011|Experimental|REBOA|Resuscitative Balloon Occlusion of the Aorta after advanced cardiac life support if return of spontaneous circulation is not achieved
2405560|NCT03533985|Experimental|Song of Kin|Voice (with or without guitar)- lullaby/ Holding meter
2405561|NCT03533985|Experimental|Gato box|Simple rhythms using Remo Gato box will be played by the MT-BC using a 3rd to comfort, engage or sedate
2405562|NCT03533985|Experimental|Ocean disc|Creating a consistent womb-like sound soundscape to comfort, engage or sedate
2405563|NCT03533985|Experimental|Contingent singing|"Provision of communicative vocalization-parantese to engage with infants, prosodic responses to infant cues (eye contact, body position)"
2405564|NCT03533985|Experimental|Tonal Vocal holding|Providing a 'blanket of tone' to comfort, engage or sedate
2405565|NCT03533985|Experimental|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
2405566|NCT03533972|Experimental|Test group|subjects will be provided with Ashwagandha capsules 500 mg twice daily, after meals with plain water for 1 month
2405567|NCT03533972|Placebo Comparator|Control group|subjects will be provided with placebo capsules.
2405568|NCT03533959||alirocumab therapy group|patients with 10mg daily rosuvastatin and alirocumab at least 75mg every 2 weaks
2405569|NCT03533959||standard statin therapy group|patient with 10mg daily rosuvastatin and never use alirocumab or other PCSK-9 inhibitor
3184999|NCT00730457|Experimental|A|Intramuscular (i.m.) vaccination of a single dose of 0.1 µg, 0.3 µg, 1 µg, 2 µg, 3 µg, 5 µg and 8 µg of STF2.HA1 (SI) (VAX125).
2405571|NCT03533933|Active Comparator|Autologous connective tissue graft|Soft tissue harvesting from patient palate
2405572|NCT03533933|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
2405573|NCT03533920|Experimental|UNI-DEB|
2405574|NCT03533907||treated|The women included were patients of the Humanitas Fertility Center; they all had a diagnosis of infertility and were trying to become pregnant. They received ≥1 month of therapy with UA 5 mg/day
2405575|NCT03533881|Active Comparator|Arom Digest Slim and nutritional changes|Subjects take collagen and follow minimal nutritional changes.
2405576|NCT03533881|Active Comparator|Nutritional changes|Subjects only follow minimal nutritional changes
2405577|NCT03533868|No Intervention|Standard of Care (SOC)|Patients in this arm will have their viral load monitored using the standard of care method, using the Roche Cobas TaqMan HIV-1® v2 (Roche) assay.
2405578|NCT03533868|Experimental|Point-of-care (POC)|Patients in this arm will have their follow-up viral loads (after baseline) monitored using a Point-of-care viral load monitoring test, the Cepheid Xpert HIV-1 Viral Load assay.
2405579|NCT03533855|Experimental|"CS plus FRFSE"|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
3185000|NCT00730470|Experimental|1|
3185001|NCT00730496|Experimental|1|the study group, 45 women
3185002|NCT00730496|No Intervention|2|the control group, 45 women
3185003|NCT00730535|Experimental|Tolterodine 1|
3185004|NCT00730535|Experimental|Toterodine 3|
2405583|NCT03533816|Experimental|EAGD T-cell infusion (Phase I)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at either 1, 3, or 10 x 1,000,000 cells/kg concentrations depending upon the cohort.
2405584|NCT03533816|Experimental|EAGD T-cell infusion (Expansion)|Peripheral blood is collected by leukapheresis from the donor, expanded and activated on CliniMACS-Prodigy, further depleted of alpha beta T-cells using the CliniMACS Alpha Beta T-Cell Depletion System, which leaves a gamma delta T-cell rich product. This product is then infused into the recipient at the maximum tolerated dose as determined from Phase I.
2405585|NCT03533803|Active Comparator|Group A (Indomethacin)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will receive Indomethacin 100Mg Suppository 1-2 hours before embryo transfer.
2405586|NCT03533803|Placebo Comparator|Group B (Control)|All patient had long stimulation protocol and IVF/ICSI. After mock embryo transfer women with any degree of difficulty will not receive any medications before embryo transfer.
2405587|NCT03533790|Experimental|DEP-Ru|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 2 mg/kg days 1 to 5,then gradually reduce; ruxolitinib 0.3mg/kg/d。This regimen was repeated after 2 weeks.
2405588|NCT03533777|Active Comparator|Antegrade Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in standard antegrade fashion (with the tip pointed towards the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
2405589|NCT03533777|Experimental|Retrograde Intravenous Catheter|A 20 gauge 30 millimeter peripheral intravenous catheter will be placed in an upper extremity vein in a retrograde fashion (with the tip pointed away from the direction of blood flow). Blood draws from this IV catheter will be attempted twice throughout the study. An infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
2405590|NCT03533764|Experimental|Asthma Self-Management for Adolescents|Asthma Self-Management for Adolescents (ASMA) consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
2405591|NCT03533764|No Intervention|Attention Control|In 3 group sessions and 5 one-on-one sessions, held at school during the school day, students will receive information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). They will learn to monitor their health by using diaries to record behaviors, such as what they eat, and/or their sleep patterns. Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
2405592|NCT03533751|Placebo Comparator|Placebo|Placebo
2405593|NCT03533751|Experimental|Group 1|etokimab (ANB020)
2405594|NCT03533751|Experimental|Group 2|etokimab (ANB020)
2405595|NCT03533751|Experimental|Group 3|etokimab (ANB020)
2405596|NCT03533751|Experimental|Group 4|etokimab (ANB020)
2405597|NCT03533738|Experimental|Food selection 1|To consume vegetables followed by meat & rice together
2405598|NCT03533738|Experimental|Food selection 2|To consume meat followed by vegetables & rice together
2405599|NCT03533738|Experimental|Food selection 3|To consume as follows: vegetables, meat, rice
2405600|NCT03533738|Experimental|Food selection 4|To consume vegetables followed by meat and rice together
2405601|NCT03533738|Experimental|Food selection 5|To consume rice followed by vegetables & meat together
2405602|NCT03533725|Experimental|Intervention group|Breastfeeding counseling and education services using mHealth tools
2405603|NCT03533725|No Intervention|Comparative control group|No intervention, only standard of care
2405604|NCT03533712|Experimental|Fortified BEP supplement|Intervention: Dietary Supplement: Fortified balanced energy-protein (BEP) supplement + iron and folic acid supplement.
2405605|NCT03533712|Active Comparator|Fe and folic acid|Dietary Supplement: Fe and folic acid supplement.
2405606|NCT03533699|Active Comparator|Propranolol|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
2405607|NCT03533699|Placebo Comparator|placebo|101 women with uncomplicated term pregnancy who will be admitted to the Ain Shams University Maternity hospital and will receive syntocinon intravenous infusion for induction or augmentation of labour.
2405608|NCT03533686|Experimental|Single-Sided Deafness Adult (Aim1) Group|Adult participants with single-sided deafness and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
2405609|NCT03533686|Experimental|Conductive Hearing Loss Adult (Aim 2) Group|Adult participants with conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use and no intermittent use within the last 2 weeks) with an abutment implant will be provided with the Adhear system for 2 weeks (plus up to 90 days).
2405610|NCT03533686|Experimental|Adhear followed by BAHA (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the Adhear system for 3 weeks (plus up to 90 days) followed by bone anchored hearing aid (BAHA) for another 3 weeks (plus up to 90 days).
2405611|NCT03533686|Experimental|BAHA followed by Adhear (Aim 3) Group|Pediatric participants (aged 5-17 years) with conductive hearing loss or single-sided deafness who have not previously used a bone conduction device, will be provided with the BAHA system for 3 weeks (plus up to 90 days) followed by Adhear for another 3 weeks (plus up to 90 days).
2405697|NCT03533166|Experimental|Chlorhexidine|Mechanical treatment + 0.03% chlorhexidine + 0.05% CPC mouthrinse
3185005|NCT00730535|Experimental|Tolterodine 6|
2405612|NCT03533686|Experimental|Pediatric Unilateral Conductive Hearing Loss (Aim 3a) Group|Pediatric participants (aged 2-17 years) with unilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system for 2 weeks (plus up to 90 days).
2405613|NCT03533686|Experimental|Pediatric Bilateral Conductive Hearing Loss (Aim 3b) Group|Pediatric participants (aged 2-17 years) with bilateral conductive hearing loss and are experienced bone conduction device users (6 months minimum of bone conduction device use) on a headband will be provided with the Adhear system. Participants who are fitted bilaterally will receive 2 Adhear systems (one for each ear) for 2 weeks (plus up to 90 days) at Visit 1. Participants who are fitted unilaterally will receive 1 Adhear system for 2 weeks (plus up to 90 days) at Visit 1, afterwards, will be fitted bilaterally at Visit 2 and receive the Adhear system for both ears for another 2 weeks (plus up to 90 days) for a total of 4 weeks (plus up to 180 days).
2405614|NCT03533673|Experimental|Cohort 1|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 1)
2405615|NCT03533673|Experimental|Cohort 2|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 2)
2405616|NCT03533673|Experimental|Cohort 3|A one-time intravenous infusion of AAV2/8-LSPhGAA (dose level 3)
2405617|NCT03533660|Active Comparator|Feedback|Participant will receive a brief feedback on data downloaded from the ABM and information about treatment resources
2405618|NCT03533660|Active Comparator|Enhanced usual care|Participant will receive information about remaining abstinent and about treatment resources
2405619|NCT03533647||entire cohort (observational)|none (observational study)
2405620|NCT03533634|Experimental|superior group|this group with midshaft clavicle fracture were treated with superior reconstruction plate
2405621|NCT03533634|Experimental|anteroinferior group|this group with midshaft clavicle fracture were treated with anteroinferior reconstruction plate
2405622|NCT03533621|Experimental|Probiotic|1 Probiotic pill, twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
2405623|NCT03533621|Placebo Comparator|Placebo|1 placebo pill (soy protein powder), twice a day, for 12 weeks + 20 min weekly support to increase fruit and vegetable consumption
3185006|NCT00730548|Experimental|1|Remote Arm (OptiVol plus Connexus Telemetry plus CareLink plus Intervention Algorithm), Clinical Management Alerts ON
2405625|NCT03533595|No Intervention|Standard Suture|Standard suture for thoracolumbar fusion will be used per standard of care.
2405626|NCT03533595|Active Comparator|Stratafix Barbed Suture|Stratafix Barbed Suture for thoracolumbar fusion will be used.
2405627|NCT03533582|Active Comparator|Group A1 (WDF)|Patients undergo observation.
2405628|NCT03533582|Experimental|GROUP A2 (NON-WDF)|Patients receive cisplatin IV over 6 hours on day 1 following surgery. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
2405629|NCT03533582|Experimental|GROUP B1 ARM 4-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 4 cycles (2 pre-surgery, 2 post-surgery) in the absence of disease progression or unacceptable toxicity.
2405630|NCT03533582|Experimental|GROUP B1 ARM 6-CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (2 pre-surgery, 4 post-surgery) in the absence of disease progression or unacceptable toxicity.
2405631|NCT03533582|Experimental|GROUP B2 (UNRESECTABLE)|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for 6 cycles (4 pre-surgery, 2 post-surgery).
2405632|NCT03533582|Experimental|GROUP C ARM C5VD|Patients receive cisplatin IV over 6 hours on day 1, 5-fluorouracil IV over 1-15 minutes, vincristine sulfate IV over 1 minute on days 1, 8, and 15 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
2405633|NCT03533582|Experimental|GROUP C ARM CDDP|Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 14 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after cycle 2 or 4.
2405634|NCT03533582|Experimental|GROUP D1|"SIOPEL-4 INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9 during cycles 1 and 2 and days 1 and 2 during cycle 3. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients with lung complete remission (either with chemotherapy and/or surgery) receive carboplatin IV over 1 hour on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
2405635|NCT03533582|Experimental|GROUP D2 ARM CE|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2, doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5, and carboplatin over 1 hour and etoposide IV over 2 hours on day 1 and 2 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
2405636|NCT03533582|Experimental|GROUP D2 ARM VI|"SIOPEL-4 IV INDUCTION: Patients receive cisplatin IV over 6 hours on days 1, 8, and 15 (for cycles 1 and 2) and days 1 and 8 (for cycle 3) and doxorubicin IV over 1-15 minutes on days 8 and 9. Treatment repeats every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~Patients receive carboplatin IV over 1 hour on days 1 and 2 and doxorubicin IV over 1-15 minutes on days 1 and 2 during cycles 1, 3 and 5. Patients also receive vincristine sulfate IV over 1 minute on days 1 and 8 and irinotecan IV over 90 minutes QD on days 1 to 5 of cycles 2, 4 and 6. Treatments repeat every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
2405637|NCT03533582|Active Comparator|GROUP E1|Patients undergo observation only.
2405638|NCT03533582|Experimental|GROUP E2 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1 and doxorubicin IV over 1-15 minutes on days 1 and 2 following surgery. Treatments repeat every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
2405698|NCT03533166|Placebo Comparator|Placebo|Mechanical treatment + Placebo mouth rinse
3185007|NCT00730548|No Intervention|2|No Care Alerts available, standard treatment of the patient
2405639|NCT03533582|Experimental|GROUP F ARM 1 (PLADO)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-21. Treatments repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery, if tumors are resectable, or receive an additional 3 cycles of the treatment.
2405640|NCT03533582|Experimental|GROUP F ARM 2 (P/GEMOX)|Patients receive cisplatin IV over 6 hours on day 1, doxorubicin IV over 1-15 minutes on days 1 and 2 and sorafenib PO BID on days 3-14 of cycles 1 and 3. Patients also receive gemcitabine IV over 90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 and sorafenib PO on days 1-14 of cycles 2 and 4. Patients may undergo surgery, if tumors are resectable, or receive an additional 4 cycles of the treatment.
2405641|NCT03533569||Osteoarthritis|Participants with an established diagnosis of knee osteoarthritis
2405642|NCT03533569||Rheumatoid arthritis|Participants with an established diagnosis of rheumatoid arthritis
2405643|NCT03533569||Spondyloarthritis or psoriatic arthritis|Participants with an established diagnosis of spondyloarthritis or psoriatic arthritis
2405644|NCT03533569||Case controls|Participants with no arthritis or knee pain as controls
2405645|NCT03533543||New-onset atrial fibrillation|Patients with MI who are free from a medical history of atrial fibrillation (AF) will be recognized as NOAF if they develop an atrial fibrillation (lasting for at least 30 seconds which are recorded by CEM) incident during hospitalization.
2405646|NCT03533543||Non new-onset atrial fibrillation|Patients with MI who are free from a medical history of AF will be recognized as Non-NOAF if they persist with sinus rhythm (based on CEM) during hospitalization.
2405647|NCT03533530|Active Comparator|No electrical source imaging (ESI)|In all patients, the multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, except for ESI.
2405648|NCT03533530|Experimental|Low-density ESI (LD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using LD EEG recordings.
2405649|NCT03533530|Experimental|High-density ESI (HD ESI)|The multidisciplinary epilepsy surgery team will make a conclusion on management plan, based on all non-invasive presurgical data, including ESI using HD EEG recordings.
2405650|NCT03533517|Experimental|AccuCinch® Ventricular Restoration System|
2405651|NCT03533504||Variability in individual PK|Patients with hemophilia A or B, of any severity, who are registered on the web-accessible population pharmacokinetics- hemophilia (WAPPS-Hemo) database, and for whom infusion and/or PK data is available.
2405652|NCT03533491|Experimental|App Evaluation|All 60 teens in The Rewire Study will complete the first 4 modules of the Rewire app. Prior to using the app, they will complete a baseline assessment. Follow up surveys will be completed at 2 weeks and 8 weeks post-baseline.
2405653|NCT03533478|Experimental|Group I|32 patients with mild or moderate diabetic macular edema.
2405654|NCT03533478|Placebo Comparator|Group II|32 patients with mild or moderate diabetic macular edema
2405655|NCT03533465|Experimental|Complicated Grief Treatment (CGT)|10 adults with CG who successfully completed Aim 1 and will also participate in open complicated grief treatment (CGT), during which they will complete additional subjective and objective sleep assessments.
2405656|NCT03533452|Active Comparator|PRE-GA|10 mL of 0.5% ropivacaine injection before the start of surgery and 10 ml of normal saline (0.9%) injection at the end of surgery through the interscalene catheter
2405657|NCT03533452|Sham Comparator|POST-GA|10 ml of normal saline (0.9%) injection before the start of surgery and 0.5% ropivacaine injection at the end of surgery through the interscalene catheter
2405658|NCT03533426|Active Comparator|Pump based patient controlled analgesia|"Analgesia is maintained using disposable silicon ballon pump Accufuser containing morphine 0.2 mg/ml, 8mg ondansetron plus and 180 mg ketorolac. The infusion rate is 5 ml / h and lockout interval of 15min. the hourly delivered morphine dose is 1-1.8 mg & the pump is sufficient for about 60 hours according to patient response."
2405659|NCT03533426|Active Comparator|serratus anterior plane catheter block|"Linear ultrasound transducer (superficial) 6-12 MHz is utilized to count the ribs up to 4th or 5 th rib in the mid-axillary line. Musculature of thoracic wall is identified sonographically,an echogenic needle 14-16 G, 100 mm is inserted in plane with the U/S probe towards the plane deep to the serratus anterior muscle. Under real - time U/S, single shot of 20ml contrast medium iohexol = omnipaque 150 mg I2 / ml is injected to check the plane and level (T3-T8/9) of SAPB.A reinforced radiopaque catheter is threaded through the needle and its final position underneath the plane of serratus anterior muscle is confirmed fluoroscopically. 20ml 0.25% levobupivacaine (Chirocaine).Analgesia is maintained using 0.125% levobupivacaine infusion at a rate of 7-12 ml/h according to patient response."
2405660|NCT03533413|Active Comparator|Interventional:Combined CT-fluroscopy|Combined CT-fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
2405661|NCT03533413|Active Comparator|Interventional: standard fluroscopy|Fluroscopic radiofrequency ablation of thoracic dorsal root ganglia.
2405662|NCT03533400|Active Comparator|Group 1|Group 1 (control group) will be given the standard Jamboxx musical device. They will be trained to use the device during two 20 minute training session with a respiratory therapist, and will be instructed to play the device for a minimum of 30 minutes, 3 times a week. The Jamboxx musical device is a hands-free breath controlled musical device designed for people with quadriplegia. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key.
2405663|NCT03533400|Experimental|Group 2|Group 2 (treatment group) will be given the Jamboxx musical device plus the Jamboxx respiratory therapy device. The respiratory therapy device is similar to the music device, but with specially designed games that guide the user through breathing exercises intended to strengthen the lungs.
2405664|NCT03533387|Experimental|Extended-release formulation 1 (ER1)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
2405665|NCT03533387|Experimental|Extended-release formulation 2 (ER2)|50mg MN-166 tablet. This formulation is intended for once-a-day dosing, hence, the label of extended-release.
2405666|NCT03533387|Active Comparator|Intermediate-release formulation (IR)|10mg MN-166 capsule. This formulation is typically given two or three times daily, hence, the label of intermediate-release.
3185008|NCT00730561|No Intervention|1|
3185009|NCT00730561|Experimental|2|Hematopoietic stem cell transplantation
2405669|NCT03533348||Fasting arm|Patients will need at least 4 hours of fasting prior to contrast-enhanced CT scans.
2405670|NCT03533348||No fasting|Patients are allowed to eat and drink freely prior to contrast-enhanced CT scans.
2405671|NCT03533335|Active Comparator|Chlorhexidine spray|0.2% chlorhexidine oral spray, once daily
2405672|NCT03533335|Experimental|Chlorine Dioxide spray|0.1% pH-balanced chlorine dioxide oral spray, once daily
2405673|NCT03533335|Placebo Comparator|Sterile water spray|Placebo
2405674|NCT03533309|Experimental|computer guided|"Group (A): comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent.~."
2405675|NCT03533309|Active Comparator|conventional|Group (B) comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique
2405676|NCT03533296|Experimental|Children|Children who receive elective surgery under general anesthesia and are supported by mechanical ventilation
3144402|NCT00039117|Experimental|Arm I|"INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.~Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course."
3144403|NCT00039182|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144404|NCT00039286|Experimental|Positron Emission Tomography|Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6 months.
2405680|NCT03533270||Urethroplasty|Patients with traumatic urethral injury associated with pelvic fractures who underwent urethroplasty
3144405|NCT00039325|Experimental|Group A - first dose for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
2405686|NCT03533231|Active Comparator|Triple Antibiotic Paste (TAP)|It consisted of Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt), Metronidazole (Flagyl 500 mg tablets; Sanofi Aventis Pharma, Cairo, Egypt), Doxycycline (Vibramycin 100 mg capsules; Pfizer, Cairo, Egypt). One Doxycycline capsule content was evacuated in a sterile mortar, one tablet of metronidazole and one tablet of ciprofloxacin were crushed and ground in the same mortar using a pestle into homogenous powder. Saline drops (Otrivin baby saline; Novartis, Cairo, Egypt) were added and mixed using the pestle until a creamy paste was achieved (Sabrah et al. 2013, Nagy et al. 2014). TAP was then used for canal disinfection.
2405687|NCT03533231|Experimental|Ciprofloxacin + Propolis Paste|Ethanol extract of raw propolis (EEP; ElEzaby Co. Labs, Cairo, Egypt.) was prepared by adding 10 gm of propolis (Imtinan, Cairo, Egypt) to 40 gm of 70% ethanol (ElGomhorya Co., Cairo, Egypt) (for 20% tincture) in a dark container to prevent reduction of propolis. The container was sealed and placed at room temperature for a period of three weeks. The sealed container was manually shaken every 2 days to ensure proper mixing. After 3 weeks, the container was opened and ethanol extract of propolis was obtained. Ethanol-free EEP was made by evaporating the ethanol in a water bath. EEP was then mixed with Ciprofloxacin powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2405688|NCT03533231|Active Comparator|Ciprofloxacin + Metronidazole Paste|Ciprofloxacin powder was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2405689|NCT03533231|Experimental|Propolis + Metronidazole paste|Ethanol Extract of Propolis (EEP) was mixed with Metronidazole powder in the ratio 1:1. Saline drops were added and mixed using the pestle until a creamy paste was achieved. This paste was then used for canal disinfection.
2405690|NCT03533192|Experimental|Receipt of It's Your Game...Keep it Real|It's Your Game...Keep it Real is an HIV, STI, and teen pregnancy prevention program
2405691|NCT03533192|No Intervention|Usual care|Students received their regular health education.
2405692|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 placebo (A)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus 50 ml at time=0."
2405693|NCT03533179|Experimental|Esmolol+glucagon 1 placebo (B)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+ Physiologic saline - glucagon dummy bolus (50 ml) at time=0."
2405694|NCT03533179|Experimental|Esmolol+glucagon 1 (C)|"Esmolol intravenous solution (10 mg/ml esmolol hydrochloride) is administered as a loading dose (1.25 mg/kg/min esmolol) at baseline (time= -15 minutes). Continuous infusion (500-750 micrograms/kg/min) of esmolol/placebo is then administered until T=30 minutes.~+Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
2405695|NCT03533179|Experimental|Esmolol-placebo+glucagon 2 (D)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+Glukagon 2 (50 μg/kg bolus - over 30 min in 50 ml isotonic fluid from time=0 min)"
2405696|NCT03533179|Experimental|Esmolol-placebo+glucagon 1 (E)|"Physiologic saline - esmolol dummy (10 mg esmolol/ml) is administered as a loading dose at baseline (time= -15 minutes) (corresponding to 0.125 ml/kg/min of saline). Continuous infusion (0.05-0.075 ml/kg/min) of saline is then administered until T=30 minutes.~+ Glukagon 1 (50 μg/kg bolus - over 1-3 min from time=0 min in 50 ml isotonic fluid)"
2405699|NCT03533153|Experimental|WJ-MSC cells implantation group|"MSC cells (allogeneic transplantation from WJ-MSC primary cells); the frequency: for one time within12h after emergency coronary artery revascularization; dose levels: 1X10^8; method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
2405700|NCT03533153|Placebo Comparator|CTSTMD PBS without WJ-MSC group|"Saline only was injected in the control group. The frequency: for one time 2-12h after emergency coronary artery revascularization. Dose levels: the same dosage given to MSC group. Method of administration: intravenous injection. Other kinds of treatment are in accordance with the treatment guidelines for MI patients, listed in the column Conventional drug therapy."
2405701|NCT03533140|Active Comparator|DUCEST Neurostimulator V Group A|
2405702|NCT03533140|Sham Comparator|DUCEST Neurostimulator V Group B|
2405703|NCT03533127|Experimental|LY01008+Carboplatin/Paclitaxel|Drug: LY01008 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
2405704|NCT03533127|Experimental|Bevacizumab + Carboplatin/Paclitaxel|Drug: Bevacizumab Bevacizumab 15 mg/kg IV every 3 weeks on Day 1 Drug: Carboplatin Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles Drug: Paclitaxel Paclitaxel 175 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
3185010|NCT00730574|No Intervention|B|The control group, marked B, gets only B12 vitamin 1mg/day treatment to comply with ethics regulations seeing as they do suffer from B12 deficiency .
3185011|NCT00730574|Experimental|A|The trial group which receives daily treatment of 1mg Vitamin B12 (sublingual tablets) combined with 5 mg Folic acid (tablets)
2405707|NCT03533101|Experimental|Tocilizumab 4 mg/kg|Tocilizumab 4 mg/kg IV single dose day -1 prior to haploidentical transplantation
2405708|NCT03533101|Active Comparator|Tocilizumab 8 mg/kg|Tocilizumab 8 mg/kg IV single dose day -1 prior to haploidentical transplantation
2405709|NCT03533088|Experimental|Hospitalized rehabilitation|Patients in this group will recieve rehabilitation program twice in a week at our clinic after the surgical procedure until post-operative 12 weeks.
2405710|NCT03533088|Experimental|Home-based rehabilitation|Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
2405711|NCT03533075|Experimental|Teachable Moment Brief Intervention|The TMBI is informed by evidence based strategies to collaboratively identify 1) drivers of suicidal ideation, 2) functional aspects of the recent suicide attempt, 3) the patient's relationship with the concept of suicide, 4) what has been lost and gained as a result of the suicide attempt, 5) short term management suicide prevention management strategies, and 6) documentation of factors to address in a suicide-specific treatment plan.
2405712|NCT03533075|No Intervention|Care as Usual|Usual care at Veterans Affairs Medical Centers (VAMC) for Veterans who have attempted suicide involves psychiatric evaluation/treatment and ongoing medical stabilization.
2405713|NCT03533062|Active Comparator|trigonal sparing botox injection|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area excluding trigone in other arm Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).•then after 6 months postoperative anticholinergics administration .
2405714|NCT03533062|Active Comparator|trigonal involved|Using a 7 gauge needle injection were allocated uniformly and evenly throughout the designed area including the trigone .Dilution of BOTOX vial (100 u) in 10 ml normal saline (10 u/ml) and injected in 20 sites (0.5ml /site).then after 6 months postoperative anticholinergics administration .
2405715|NCT03533049|Experimental|myFAMI intervention|"All participants will receive the standard discharge education from their transplant and inpatient care team.~Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge."
2405716|NCT03533049|Active Comparator|Control|Family members assigned to the control group (standard care) will receive standard post-discharge follow-up care consisting of discharge education during the transplant hospitalization and at regularly scheduled appointments instructing families to contact the research nurse with problems or questions.
3185012|NCT00730587||1|Full-term healthy infants ages 5 months to 3 years.
3185013|NCT00730600|Experimental|1|1= THAI traditional massage
2405719|NCT03533023|Experimental|TRE + SOC|Time Restricted Eating + Standard of Care
2405720|NCT03533023|Other|SOC|Standard of Care
2405721|NCT03533010|Active Comparator|Ca500mg + VitD800IU|Daily Supplementation with 500mg Calcium plus 800IU Vitamin D3
2405722|NCT03533010|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2405723|NCT03532997|Experimental|Intervention|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel app called ELOS (stands for extra layer of support) in a prospective cohort study. The investigators will compare participant acceptance of this new electronic tool to industry standards and follow ultimate referrals to outpatient palliative care compared to historical, matched controls."
2405794|NCT03532568|Experimental|normal healthy participants|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
3185014|NCT00730613|Experimental|Treatment (therapeutic autologous lymphocytes)|Patients receive an infusion of autologous antigen-specific CD8+ cytotoxic T-lymphocyte clones over 5-10 minutes on days 1, 3, and 5 of weeks 1 and 2. Treatment repeats every 3 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity.
3185015|NCT00730626|Experimental|1|L.acidophilus and B.lactis (1x10E9 of each probiotics) with 40 mg of green the extract
3185016|NCT00730626|Experimental|2|L.acidophilus and B.lactis (1x 10E10 of each probiotics) with 40 mg of green tea extract
3185017|NCT00730626|Placebo Comparator|3|Placebo
3185018|NCT00730652|Experimental|MDX1411|An accelerated titration design (ATD) will be utilized and subjects will be assigned to a dose level in the order they enter the study.
2405724|NCT03532984||adults aged 20-29|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2405725|NCT03532984||adults aged 30-39|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2405726|NCT03532984||adults aged 40-49|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory"
2405727|NCT03532984||adults aged 50-59|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2405728|NCT03532984||adults aged 60-69|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2405729|NCT03532984||adults aged 70-79|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2405730|NCT03532984||adults aged 80+|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2405731|NCT03532984||geriatric patients|"healthy adults will perform the following tests: Functional tests Mini BESTest Mobility, SPPB Static balance Proactive balance (Reach, TUG) Reactive balance Dynamic balance (beam test to predict falls) Grip, leg strength~Cognitive tests Global cognition Attention, executive f. Processing speed Memory~In the follow up study 6, 12 months after baseline, fear of falling and fall history will be assessed in 50+"
2405732|NCT03532971||allogeneic hematopoietic-cell transplantation patients|Prospective HCT cohort of patients undergoing allogeneic HCT at DFCI
2405733|NCT03532958|Placebo Comparator|Placebo|Normal saline
2405734|NCT03532958|Experimental|Low Dose BNZ-1|0.5 mg/kg QW
2405735|NCT03532958|Experimental|Moderate Dose BNZ-1|2 mg/kg QW
2405736|NCT03532945|Experimental|Bioactive Glass-Ceramic Spacer|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with Novomax, which is the bioactive glass ceramic intervertebral spacer.
2405737|NCT03532945|Active Comparator|Titanium cage|The one-level Posterior Lumbar Interbody Fusion(PLIF) surgery will be carried out with titanium cage.
3144406|NCT00039325|Experimental|Arm B - dose increase for phase 1|A*0201 positive subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3144407|NCT00039325|Experimental|Arm C - A*0201+/DR*04+ subjects - Phase II|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
2405740|NCT03532906|Active Comparator|TAP block|Patients receive the injection of local anaesthetic into the right abdominal wall (TAP block) together with the injection of local anaesthetic into the surgical wounds.
2405741|NCT03532906|Other|Control|Patients receive the injection of local anaesthetic into the surgical wounds only.
2405742|NCT03532880|Experimental|Participants with Small Cell Lung Cancer|
2405743|NCT03532867|Experimental|Healthy volunteers|"After an ophthalmic consultation, the healthy volunteers are summoned to perform the exercise test in the form of an aerobic exercise on an ergometric bicycle with 3 different intensity levels calculated on the theoretical maximum aerobic power.~The OCT examination in the EDI mode, centered on the macular and peri-papillary region, as well as the systolic and diastolic blood pressure and the heart rate.~In healthy patients performing aerobic physical exercise in the Department of Sports Medicine , the investigators will perform the following Intervention :~Examination of pressures before stopping the exercise~Examination of pressure during the exercise~Examination of pressures after stopping the exercise"
2405744|NCT03532854|Experimental|Sequence A|Ezetimibe/Rosuvastatin -> Valsartan -> Valsartan and Ezetimibe/Rosuvastatin
2405745|NCT03532854|Experimental|Sequence B|Valsartan -> Valsartan and Ezetimibe/Rosuvastatin-> Ezetimibe/Rosuvastatin
2405746|NCT03532854|Experimental|Sequence C|Valsartan and Ezetimibe/Rosuvastatin -> Ezetimibe/Rosuvastatin -> Valsartan
2405747|NCT03532854|Experimental|Sequence D|Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin-> Valsartan
2405748|NCT03532854|Experimental|Sequence E|Valsartan -> Ezetimibe/Rosuvastatin -> Valsartan and Ezetimibe/Rosuvastatin
2405749|NCT03532854|Experimental|Sequence F|Valsartan and Ezetimibe/Rosuvastatin -> Valsartan -> Ezetimibe/Rosuvastatin
2405750|NCT03532841|Experimental|Group I (tramadol group)|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
2405751|NCT03532841|Placebo Comparator|Group II (placebo oral tablet group)|group II will receive a placebo one hour before the procedure.the Treatment and placebo will be identical in form and packaging, without any identifying label.
2405752|NCT03532828|Experimental|Polysomnography alone|A polygraphy will be performed in 70 patient to search for obstructive sleep apnea
3185019|NCT00730665|Experimental|100ug|
2405753|NCT03532828|Experimental|Polysomnography and postural assesment|A polygraphy and a postural assesment will be performed in 30 patients
2405754|NCT03532815|Active Comparator|Lifestyle Modification group|
2405755|NCT03532815|No Intervention|Control group|
2405756|NCT03532802|Active Comparator|Metoprolol Succinate|Metoprololsuccinat
2405757|NCT03532802|Placebo Comparator|Placebo oral capsule|Placebo
2405758|NCT03532789|Experimental|herbal patch group|using herbal patch as an intervention
2405759|NCT03532789|Placebo Comparator|placebo patch group|using placebo patch as an intervention
3185020|NCT00730665|Experimental|300ug|
3185021|NCT00730665|Experimental|1mg|
3185022|NCT00730665|Experimental|3mg|
2405763|NCT03532763|Experimental|Tocotrienol-rich fraction|
2405764|NCT03532763|Placebo Comparator|Placebo|
2405765|NCT03532750|No Intervention|Control|This arm will undergo no study procedures and continue with best medical management. This entails managing pain and draining excess fluid.
2405766|NCT03532750|Experimental|Particle|Randomized to receive either the Embozene or Embosphere particles
2405767|NCT03532750|Experimental|Coil|Randomized to receive either Ruby or Interlock detachable coils
2405768|NCT03532737|Experimental|Investigational Arm|"All patients will receive radical chemoradiation in addition to the investigational concomitant check point inhibitor CHEMOTHERAPY: Cisplatin: 100 mg/m2 Q21d D1, D22, D43. OR Cetuximab Loading dose 400 mg/m², one week before radiation then maintenance dose 250 mg/m² weekly, D8, D15, D22, D29, D36, D43.~PD-1 inhibitor: Pembrolizumab 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks 21 days prior to radiation, then Day 1 of radiation and then every 21 days for total 6 doses~Intensity modulated radiotherapy (IMRT) techniques will be used. A total dose of 66-70 Gy/ 30-35 Fr over 6-7 weeks will be delivered to the primary site and draining lymphatics using simultaneous Integrated Boost (SIB)."
2405769|NCT03532711||Chemotherapy|FOLFOX/XELOX/FOLFIRI
2405770|NCT03532698||osimertinib and aspirin|Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals. Aspirin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for Aspirin loading. Drug: Osimertinib and Aspirin will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2405771|NCT03532698||osimertinib|Osimertinib starting at a dose of 80 mg once a day, orally with meals. Drug: Osimertinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
2405772|NCT03532685|Active Comparator|Severe Asthma Obese Patients Surgery|Bariatric surgery
2405773|NCT03532685|No Intervention|Severe Asthma Obese Patients|usual care
2405774|NCT03532685|No Intervention|Severe Obese Patients|usual care
2405775|NCT03532672|Experimental|Acute Fasting|Eutrophic and obese women will fast 10 hours during daily activities after a standardized breakfast.
2405776|NCT03532659|Experimental|Active video game|The adolescents will be submitted to physical activity with active video game for 50 minutes, 3 times a week, for a period of eight weeks. The XBOX360® platform will be used with the Kinect accessory (Microsoft®) and Just Dance will be the selected game. The music used for intervention will be previously selected, including those that can lead to moderate intensity, and assembled in blocks of 10. For each week, a new block and challenges must be elaborated to increase the motivation to carry out the physical activity.
2405777|NCT03532659|No Intervention|control|A follow-up will be done for eight weeks to compare the variables. The adolescents in this group will be interviewed monthly to detect changes in eating habits and lifestyle.
2405778|NCT03532646|Other|group 1: RYGB|All patients who underwent RYGB and were readmitted to upper endoscopy are getting observed
2405779|NCT03532646|Other|group 2:MGB/OAGB|All patients who underwent MGB/OAGB and were readmitted to upper endoscopy are getting observed
2405780|NCT03532633||23-27w|preterm infants 23+0-27+6SSW
2405781|NCT03532633||28-31w|preterm infants 28+0-31+6SSW
2405782|NCT03532633||32-34w|preterm infants 32+0 - 34+6SSW
2405783|NCT03532633||35-36w|preterm infants 35+0-36+6 SSW
2405784|NCT03532633||37-42w|term infants 37+0-42+6
2405785|NCT03532620|Experimental|pitavastatin|Pitavastatin Calcium + lifestyle modification
2405786|NCT03532620|Active Comparator|atorvastatin|Atorvastatin Calcium + lifestyle modification
2405787|NCT03532607|Experimental|Treatment|Participants will be asked to listen to pre-recorded music offered by the research team from an ipod for 30 minutes. After the 30 minutes have elapsed, the research staff will return and ask the patient to turn off the music. The patient then will be escorted to the clinic room to receive the botox injection.
2405788|NCT03532607|No Intervention|Control|After completing the consent form, the participants who are assigned to the control group will be asked to remain in the patient waiting area. The patient then will be escorted to the clinic room to receive the botox injection.
2405789|NCT03532594|Other|Standard Care|At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
2405790|NCT03532594|Experimental|Algorithm|For patients in the intervention group, protamine will be administered according to the PRODOSE algorithm, which has been incorporated into an Excel spread sheet for ease of use (Microsoft Corporation).
2405791|NCT03532581|Experimental|Treatment (ICG lymphangiography)|Participants receive indocyanine green solution SC and undergo near-infrared imaging over 1-2 minutes during their standard of care neck surgery.
2405792|NCT03532568|Experimental|CKD-aP patients|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue and their response to narrow band ultraviolet B
2405793|NCT03532568|Experimental|CKD patients without pruritis|skin biopsy for Klotho and fibroblast growth factor 23 levels in skin tissue
3185023|NCT00730665|Placebo Comparator|Placebo|
3185024|NCT00730678||All Participants|All participants enrolled on this study will have blood drawn for genetic testing.
3185025|NCT00730717|Experimental|1|Patients who are not concurrently receiving methotrexate treatment for pyoderma gangrenosum
2405795|NCT03532555|Active Comparator|Zinc plus standard of care|Infants will receive daily doses of zinc at 2mg/kg from enrollment through 35 6/7 weeks corrected gestational age.
2405796|NCT03532555|Placebo Comparator|Standard of care only|Infants will not receive any doses of zinc through 35 6/7 weeks corrected gestational age
2405799|NCT03532529||experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who developed the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
2405800|NCT03532529||not experiencing the composit outcome|"Average values of LV longitudinal strain^ (Midesophageal 4 chamber view) in patients who did not develop the composite outcome including the following outcomes of interest:~death within 30 days from VA ECMO liberation~the necessity of new Mechanical Circulatory Support (VA-ECMO, Impella, LVAD) within 30 days from VA ECMO liberation~o Whether after VA ECMO liberation the patient still needs IABP or a RVAD support, this situation is not considered necessity of new Mechanical Circulatory Support. A necessity of new Mechanical Circulatory Support is defined when IABP or RVAD or VA ECMO or Impella are needed again after their removal~heart transplantation within 30 days from VA ECMO liberation"
2405801|NCT03532503|Active Comparator|Foley catheter filled with 30 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 30 ml saline. A gentle traction will be applied.
2405802|NCT03532503|Active Comparator|Foley catheter filled with 50 ml|The transcervical placement of the foley catheter will be performed and it will be filled with 50 ml saline. A gentle traction will be applied.
2405803|NCT03532490|Active Comparator|Roflumilast 500 mcg oral tablet|500 mcg roflumilast oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
2405804|NCT03532490|Placebo Comparator|Placebo oral tablet|500 mcg placebo oral tablets will be taken every other day for the first two weeks. If participant tolerates the drug, the tablet will be taken once daily.
2405805|NCT03532464|Experimental|Patient treated by doxycycline|"The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
2405806|NCT03532464|Active Comparator|Patients treated by azithromycin|"The patients in the azithromycin group take 4 tablets of 250 mg in the morning as a single dose.~Antibiotics will be dispensed in their usual packaging with a clinical trial label."
3185026|NCT00730717|Experimental|2|Patients who are receiving concurrent methotrexate for pyoderma gangrenosum
3185027|NCT00730743|Experimental|1|Intermittent clamp group
2405809|NCT03532438||NTM patient group|NTM lung disease patients living together
2405810|NCT03532425|Experimental|B/F/TAF|"B/F/TAF + Atripla Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
2405811|NCT03532425|Active Comparator|Atripla|"Atripla + B/F/TAF Placebo~Each pill is taken once daily, (total of 2 tablets) The blinded treatment phase of this study will last for 52 weeks"
2405812|NCT03532412||HF+CSA+PB|Systolic heart failure with predominant central sleep apnea and periodic breathing
2405813|NCT03532399||Pediatric Cardiac Catheterization|
2405814|NCT03532399||Pediatric Cardiac Surgery|
2405815|NCT03532399||Pediatric Extracorporeal Life Support (ECLS)|
2405816|NCT03532386||Study group|Infertile men with oligoasthenospermia with non-tense vaginal hydrocele subjected to ICSI
2405817|NCT03532386||Control group|infertile men with oligoasthenospermia without hydrocele subjected to ICSI
2405818|NCT03532373|No Intervention|Control|None- normal care
2405819|NCT03532373|Experimental|Intervention|Patients will use a preference elicitation tool to determine their preferences for diagnosis and treatment of CTS
2405820|NCT03532360|No Intervention|Control|Following randomization, this arm will receive no intervention. After twelve months, participants in this group will undergo a singe-blind, placebo-controlled oral food challenge
2405821|NCT03532360|Active Comparator|Low-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 30 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
2405822|NCT03532360|Active Comparator|High-dose|Following randomization, participants in this group will receive escalating doses of the appropriate allergen, up to a dose of 300 mg. Once they attain that dose, they will maintain it for six months. At the end of this maintenance period, they will undergo a singe-blind, placebo-controlled oral food challenge
2405823|NCT03532347|Experimental|EUS tissue sampling|"Device: EUS-FNA needle (Beacon) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail~Device:EUS-FNB needle (Beacon Sharkcore) 3 passes 25g needle from head of pancreas; 22g needle from neck, body and tail"
2405824|NCT03532321||Caregivers|Caregivers in the participating hospital departments : medical (doctors, midwives) and paramedical (nurses' aides, registered nurses, specialized nurses and head nurses) staff, working in hospital departments drawn at random among five volunteer hospital centers in Paris, and who will be present at the time of investigator's passage, at a date drawn at random during the inclusion phase.
2405849|NCT03532152|Active Comparator|Pure Purr VR technology|"The arm will use the virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
3185028|NCT00730743|No Intervention|2|No clamp group
3185029|NCT00730769|Experimental|Single arm|Patients received a short induction of IV ganciclovir (Cymevene®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir (Valcyte®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) at 900 mg bid (after meals) for 16 days up to complete 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockcroft-Gault equation)
3144408|NCT00039325|Experimental|Arm D - A*0201+/DR*04- - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
3144409|NCT00039325|Experimental|Arm E - A*0201-/DR*04+ - phase 2|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^7. Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
2405831|NCT03532269|Experimental|A: 3rd night with acoustic stimulation|Arm A: PSG (3 nights) with Nightly App - acoustic stimulation during the 3rd night.
2405832|NCT03532269|Experimental|B: 2nd night with acoustic stimulation|Arm B: PSG (3 nights) with Nightly App - acoustic stimulation during the 2nd night.
2405836|NCT03532243|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the threshold loading device with incremental inspiratory load.
2405837|NCT03532243|Experimental|normal respiratory muscle|Patients with normal respiratory muscle are performing the threshold loading device with incremental inspiratory load.
2405838|NCT03532230||Experimental Group|90 new patients seeking treatment for chronic low back pain. This group will receive standard care plus osteopathic manipulative treatment (OMT) for low back pain.
2405839|NCT03532230||Control Group|90 new patients seeking treatment for chronic low back pain. This group will receive only standard care without osteopathic manipulative treatment (OMT) for low back pain.
2405840|NCT03532217|Experimental|PROSTVAC/Ipilimumab/Nivolumab/Neoantigen DNA vaccine|"Within 60 days after the last chemo, patients will start a priming dose of PROSTVAC-V, and subsequent doses of PROSTVAC- F (weeks 0, 2, 5, 8, 11, 14, and 17). During Treatment A phase, subjects should receive nivolumab intravenously on Day 1 of each cycle every 3 weeks for 6 doses. Ipilimumab on Day 1 of each cycle every 3 weeks for 2 doses.~Patients will then receive a neoantigen DNA vaccine with continuous nivolumab treatment. The vaccine will be administered starting approximately week 21 by intramuscular injection for a total of 6 treatments every 28 days +/-7 days. Each DNA vaccination will be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device. Patients will receive nivolumab at 480 mg every 28 days concurrently with neoantigen DNA vaccine. This is Treatment B. In the event the DNA vaccine production is delayed, patients will receive single agent nivolumab every 4 weeks beginning week 21 until the vaccine is ready"
2405841|NCT03532204|Experimental|Chemotherapy + SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
2405842|NCT03532204|Active Comparator|Chemotherapy|Patients will receive chemotherapy as initially scheduled
2405843|NCT03532191|Experimental|PrEP-OI Intervention|All clinics that have crossed over to initiate the intervention at this time. The order of crossover is determined at random.
2405844|NCT03532191|No Intervention|Control until randomized for intervention|All clinics that have not yet initiated the intervention at this time (i.e., control clinics). A new clinic will cross over to receive the intervention each month, with the order of clinic crossover determined at random, until all clinics are receiving the intervention.
2405845|NCT03532178|Experimental|Group A|rocuronium + sugammadex / succinylcholine + normal saline
2405846|NCT03532178|Experimental|Group B|succinylcholine + normal saline / rocuronium + sugammadex
2405847|NCT03532165|Other|Positive lower extremity ultrasound|This group found to to have a deep venous thrombosis on lower extremity ultrasound will not have a CT of the chest ordered from the emergency department, and will be treated for the DVT and presumed PE.
2405848|NCT03532165|Other|Negative lower extremity ultrasound|This group that does not have a deep venous thrombosis on lower extremity ultrasound will proceed to get the CT of the chest .
3144410|NCT00039338|Experimental|Chemotherapy followed by surgery|neoadjuvant chemotherapy (Cisplatin) followed by surgery (radial hysterectomy)
3144411|NCT00039338|Active Comparator|Radio-chemotherapy|Concomitant radiotherapy (external radiotherapy combined with external boost or brachytherapy) and chemotherapy (cisplatin)
3144412|NCT00039390|Experimental|Treatment (capecitabine, gefitinib)|Patients receive oral gefitinib once daily on days 1-14 and oral capecitabine twice daily on days 8-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of gefitinib and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
2405850|NCT03532152|Sham Comparator|Sham VR technology|"The arm will use the headset with audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.~The total length of the audio-video sequence is 6 minutes 11 seconds, of which 1 minute 11 seconds is the Pure Purr promotional video, and the duration of the investigational audio-visual sequence itself is 5 minutes."
2405854|NCT03532126||Dermal filler for midface deficit|There will be one group in this study, the actual treatment group.
2405855|NCT03532113|Experimental|Updating|The Updating intervention aims to improve the ability to monitor and quickly add or delete of content of working memory.
2405856|NCT03532113|Experimental|Inhibition|The Inhibition intervention aims to improve the ability to supersede responses that are prepotent or automatic for a given situation.
2405857|NCT03532113|Active Comparator|General Knowledge|The General knowledge intervention allows the learning of information on various topics. It does not involve attentional control but semantic knowledge.
2405858|NCT03532100|Experimental|Straight line walking|All participants will walk in a straight line while wearing the study prosthesis.
2405859|NCT03532100|Experimental|Circle walking with prosthesis inside|All participants will walk around a 1-meter radius circle with their prosthesis on the inside of the circle.
2405860|NCT03532100|Experimental|Circle walking with prosthesis outside|All participants will walk around a 1-meter radius circle with their prosthesis on the outside of the circle.
2405861|NCT03532087|No Intervention|No denosumab|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are not additionally treated with denosumab.
2405862|NCT03532087|Experimental|Denosumab 120 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 120 mg every 3 weeks. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
2405863|NCT03532087|Experimental|Denosumab 60 mg|All patients undergo surgery followed by adjuvant chemotherapy. Patients in this study arm are additionally treated with denosumab 60 mg every 6 months. First denosumab gift is before surgery, last denosumab gift is together with the last cycle of chemotherapy.
2405864|NCT03532074|Other|laparoscopic approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a laparoscopic approach; follow up and assessment of bowel symptoms after surgery
2405865|NCT03532074|Other|robot-assisted approach|assessment of bowel symptoms before surgery; assessment of rectosigmoid perfusion using indocyanine green; removal of rectosigmoid endometriosis nodule using a robot-assisted approach; follow up and assessment of bowel symptoms after surgery
2405866|NCT03532061|Experimental|FamCare Group|Family caregivers who receive 6 in-person problem-solving skills training sessions (FamCare Program).
2405867|NCT03532061|Active Comparator|Caregiver Support Group|Family caregivers who receive 6 in-person caregiver support group sessions.
3185030|NCT00730782|Active Comparator|1|The experimental vaccine PfAMA1 formulated in Alhydrogel
3185031|NCT00730782|Active Comparator|2|The experimental vaccine PfAMA1 formulated in Montanide ISA720
2405870|NCT03532035|Experimental|Brincidofovir (BCV)|"Cohort 1: BCV 10 mg twice weekly via IV infusion over 2 hours~Cohort 2: BCV 15 mg twice weekly via IV infusion over 2 hours~Cohort 3: BCV In Cohort 3, the actual dose may be higher or lower than doses administered in previous cohorts; the maximum dose of IV BCV will be ≤ 25 mg."
2405871|NCT03532035|Active Comparator|Standard of Care (SoC)|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV Cidofovir (CDV), ganciclovir, or ribavirin."
2405872|NCT03532022|Experimental|Chronocort|Hydrocortisone modified release capsules - Chronocort®. 66 subjects will be randomised to this group using an interactive web response system (IWRS).
2405873|NCT03532022|Active Comparator|Standard Care|Subjects participating in this arm will continue to receive their normal, standard care (hydrocortisone, dexamethasone, prednisone, prednisolone) once enrolled on the study. 66 subjects will be randomised to this arm using an interactive web response system (IWRS).
3185032|NCT00730782|Active Comparator|3|The experimental vaccine PfAMA1 formulated in ASO2A
3185033|NCT00730795|Experimental|Group A|Subjects receiving the low-dose antigen candidate TB vaccine
2405876|NCT03531970|Experimental|Dexamethasone|lidocaine & Dexamethasone
2405877|NCT03531970|Placebo Comparator|Non-dexamethasone|lidocaine & Placebo
2405878|NCT03531957|Experimental|ASN002 40 mg|40 mg ASN002
2405879|NCT03531957|Experimental|ASN002 60 mg|60 mg ASN002
2405880|NCT03531957|Experimental|ASN002 80 mg|80 mg ASN002
2405881|NCT03531957|Experimental|Placebo Oral Tablet|Matching placebo for ASN002 doses
2405882|NCT03531944|Experimental|Community pharmacist-involved care|Community pharmacist-involved collaborative care in the management of type 2 diabetes mellitus
2405883|NCT03531944|Placebo Comparator|Usual care|Usual care with physician and as needed referral to nurses
2405884|NCT03531918|Experimental|Treatment (GO, GCLAM)|"INDUCTION THERAPY: Participants receive gemtuzumab ozogamicin IV either as a single dose on day 1, or as three doses on days 1, 4, and 7. Participants also receive G-CSF SC on days 0-5, cladribine IV over 2 hours on days 1-5, cytarabine IV over 2 hours on days 1-5, and mitoxantrone hydrochloride IV on days 1-3. Patients who do not achieve a CR or CRi following the first cycle of induction are eligible for a second cycle, which is given without gemtuzumab ozogamicin. Participants with a CR or CRi may then proceed to Post-Remission Therapy.~POST-REMISSION THERAPY: Participants receive G-CSF, cladribine, and cytarabine as in Induction Therapy during cycle 1, and cytarabine IV every 12 hours on days 1-6 of cycles 2-3. Treatment repeats every month for up to 3 cycles in the absence of disease progression or unacceptable toxicity."
3185034|NCT00730795|Experimental|Group B|Subjects receiving the high-dose antigen candidate TB vaccine
3185035|NCT00730808|Experimental|Test|Oral nutritional supplement: assignment according to consecutive random numbers.
2405890|NCT03531879||subject with plaques and without plaques|Subject with plaques and without plaques
2405891|NCT03531866|Experimental|Intervention Version A|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version A will include an additional topic area.
2405892|NCT03531866|Experimental|Intervention Version B|Youth will be asked to complete a version of DigiKnowIt News that includes investigations, comics, and spotlight videos that focus on four topic areas related to participating in clincial trials. Version B will include an additional topic area (different than in Version A).
2405893|NCT03531866|No Intervention|Wait-List Control|Youth will not have access to DigiKnowIt News until after the post-test timepoint.
3185036|NCT00730808|Placebo Comparator|Control|Assignment according to consecutive random numbers.
3185037|NCT00730821|Experimental|1|
2405896|NCT03531827|Experimental|1/Lead-In Safety|Combination treatment of increasing dose of CRLX101 with enzalutamide
2405897|NCT03531827|Experimental|2/Efficacy|Tolerable dose of CRLX101 in combination with enzalutamide (8 patients, expandable to 21 total patients)
3185038|NCT00730860|Experimental|RFA+TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
2405899|NCT03531801||Recovered fracture group|The interventions will be conducted on both groups, on two experimental (approximately 45 minutes per session) sessions separated by 24 hours.Pressure algometry consists of measuring pressure pain thresholds at three bilateral muscle sites.Mapping referred pain areas consists of recording on an electronic body chart the area of pain induced by 60s pressure stimulation at 1.2 times the force needed to reach the pressure pain threshold, exerted on the extensor carpi radialis and the infraspinatus muscles.As group-differences can be attenuated at baseline but emerge on a sensitized (exercise-induced soreness) state, these procedures are performed at baseline and 24 hours after evoking exercise-induced muscle soreness. For further clarification see our recent publication PMID:29608510
2405900|NCT03531801||Control group|This group will receive the same intervention than the recovered fracture group
2405901|NCT03531788|Experimental|Armon Ayura (Kinova)|Participants will trial the Armon Ayura dynamic arm support.
2405902|NCT03531788|Experimental|JAECO WREX|Participants will trial the JAECO Wilmington Robotic EXoskeleton (WREX) dynamic arm support.
2405903|NCT03531775|Other|Upright MRI|All participants will be scanned using an upright MRI in seated/standing position and supine position. They will also be scanned supine using a conventional MRI.
2405904|NCT03531762|Experimental|Sequence 1: Treatment A-B-C|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
2405905|NCT03531762|Experimental|Sequence 2: Treatment A-C-B|Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
2405906|NCT03531762|Experimental|Sequence 3: Treatment B-A-C|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fed state with omeprazole (Treatment C). Treatment periods will be separated by washout period of at least 14 days.
2405907|NCT03531762|Experimental|Sequence 4: Treatment B-C-A|Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days between.
2405908|NCT03531762|Experimental|Sequence 5: Treatment C-A-B|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib alone in fed state (Treatment A) followed by Tepotinib in fasted state with omeprazole (Treatment B). Treatment periods will be separated by washout period of at least 14 days.
2405909|NCT03531762|Experimental|Sequence 6: Treatment C-B-A|Tepotinib in fed state with omeprazole (Treatment C) followed by Tepotinib in fasted state with omeprazole (Treatment B) followed by Tepotinib alone in fed state (Treatment A). Treatment periods will be separated by washout period of at least 14 days.
2405910|NCT03531749|Experimental|HIV+ MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
2405911|NCT03531749|Experimental|HIV+ ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90 days
2405912|NCT03531749|Experimental|HIV- MRPJ|Supplementation with microencapsulated (1g/d) for 90 days
2405913|NCT03531749|Experimental|HIV- ascorbic acid|Supplementation with ascorbic acid (1g/d) for 90
2405914|NCT03531749|No Intervention|HIV- Control|Unsupplemented
2405915|NCT03531749|No Intervention|HIV+ Control|Unsupplemented
2405916|NCT03531736|Experimental|Patients with Myeloid Malignancies & Aplastic Anemia|Transplant conditioning will consist of: ATG (2 mg/kg/day IV on days-8 through-6), fludarabine (30 mg/m^2/d on days -5 through -2), TBI 400 cGy in 2 divided doses (days -2 and -1) and high dose cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4). One dose of Rituxan (200 mg/m^2) will be given to reduce the risk of EBV viremia. The donor stem cell product will be derived from the peripheral blood with a target cell infusion of ≥8X10^6 CD34 cells per recipient kg. Patients will receive post-transplant G-CSF starting on day +7. Patients will undergo donor/recipient bone marrow and peripheral chimerism studies at 30 and 100, and 6, 12, 18 and 24 months post allo HCT and thereafter, at the discretion of the treating clinician. Immune function and disease restaging will be performed at day 100 and 6, 12, 18, and 24 months and as otherwise clinically indicated by the treating physician.
3185039|NCT00730860|Active Comparator|RFA only|treatment of hepatocellular carcinoma by radiofrequency ablation only
3185040|NCT00730873|Experimental|A|continuous positive airway pressure
2405919|NCT03531697|Experimental|Generic Loteprednol Etabonate - RLD|Period 1: Generic Loteprednol Etabonate - Period 2 (Cross-Over): Reference Listed Drug (RLD)
2405920|NCT03531697|Active Comparator|RLD - Generic Loteprednol Etabonate|Period 1: Reference Listed Drug (RLD) - Period 2 (Cross-Over): Generic Loteprednol Etabonate
3185041|NCT00730938|Active Comparator|1|
2405921|NCT03531684|Experimental|MMFS-205-SR|Oral MMFS-205-SR twice daily (2,000, 3,000, or 4,000 mg/day total, depending on lean body mass and response to initial dose at Week 12) for 24 weeks
2405922|NCT03531684|Placebo Comparator|Placebo|Oral inactive placebo twice daily for 24 weeks
2405923|NCT03531671|Experimental|Presence of age related cataract|Binocular-OCT used to assess the eye pre and post-operatively.
2405924|NCT03531645|Experimental|Fulvestrant + Abemaciclib|
3185042|NCT00730938|Placebo Comparator|2|Saline placebo
2405926|NCT03531619||Dizziness|Patients referred to a neuro-otological clinic due to dizziness who answer that they do not suffer from neck pain
2405927|NCT03531619||Dizziness and neck pain|Patients referred to a neuro-otological clinic due to dizziness who answer that they suffer from neck pain
2405928|NCT03531619||Neck pain|Patients referred to a rehabilitation center due to neck pain who answer that they do not suffer from dizziness
2405929|NCT03531619||Neck pain and dizziness|Patients referred to a rehabilitation center due to neck pain who answer that the suffer from dizziness
2405930|NCT03531619||Healthy Control|Healthy Controls without neck pain or dizziness
2405931|NCT03531606|Experimental|Experimental|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
2405932|NCT03531606|Placebo Comparator|Placebo comparator|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into placebo comparator group will take one pack of 'Placebo' which is composed of lactose and simulates a 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
2405933|NCT03531593||US Elastography|All subjects will undergo one ultrasound elastography examination after consent.
3185043|NCT00730951|Experimental|1|0.5g Korean Red Ginseng (1 capsule) 5.5g Corn Starch (11 capsules)
2405935|NCT03531567|Experimental|Virtual Reality Mystic Isle Game|"Subjects in the treatment arm will complete a prescribed 2-month treatment using the virtual reality program Mystic Isle. The OT will follow the Treatment Arm Intervention Protocol, which provides standardized guidelines for grading the intensity, level of challenge, and types of games/activities of the intervention up or down. The OT will complete weekly phone calls with participant to discuss progress, answer any questions, and remotely make updates to the game as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the intervention will be 7 hours/week. The minimum amount of time spent on the intervention will be 3.5 hours/week."
2405936|NCT03531567|Active Comparator|Standard Home Exercise Program|"Subjects assigned to the control arm will complete the prescribed 2-month treatment. The OT will follow the Control Arm Intervention Protocol to design and prescribe the home exercise program. The OT will complete weekly phone calls with the participant to check on progress, adherence, and update the exercises as necessary. The total time on active treatment for a subject is 8 weeks. The maximum amount of time spent on the control intervention will be 7 hours/week. The minimum amount of time spent on the control intervention will be 3.5 hours/week."
2405937|NCT03531554|Experimental|ketone ester drink|Oral intake of ketone ester drink muscle biopsy exercise muscle biopsy Magnetic Resonance imaging
2405938|NCT03531554|Placebo Comparator|carbohydrate drink|Oral intake of isocaloric carbohydrate drinkmuscle biopsy exercise muscle biopsy Magnetic Resonance imaging
2405939|NCT03531541|Active Comparator|active TENS and CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust)."
2405940|NCT03531541|Placebo Comparator|placebos TENS and CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies[42-44]. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect"
2405941|NCT03531541|Active Comparator|placebo TENS and active CJM|"The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
2405942|NCT03531541|Active Comparator|active TENS and placebo CJM|"The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes.~After application of placebo TENS The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation."
3185044|NCT00730951|Experimental|2|1g Korean Red Ginseng (2 capsules) 5g Corn Starch (10 capsules)
2405943|NCT03531528|Experimental|Experimental|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
3144413|NCT00039403|Experimental|Treatment (UCN-01, gemcitabine hydrochloride)|"Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose."
3185045|NCT00730951|Experimental|3|3g Korean Red Ginseng (6 capsules) 3g Corn Starch (6 capsules)
2405947|NCT03531489|Experimental|Part 1: Feasibility|Patients will perform 6-minute walk test with AIR-AD to allow for observation and real-time feedback.
2405948|NCT03531489|Experimental|Part 2: Crossover|Crossover design where investigator will compare wearing of AIR-AD during exercise to compare distance walked with and without it.
2405949|NCT03531476|Experimental|Online chronic pain management program|There is only one arm. Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
2405950|NCT03531463|Active Comparator|Operative treatment|"Operative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles.~Rehabilitation with standardized physiotherapy guideline and self exercise protocol"
2405951|NCT03531463|No Intervention|Non-Operative treatment|Rehabilitation with standardized physiotherapy guideline and self exercise protocol
2405952|NCT03531450|Experimental|Cognitive Behavioral Therapy|Patients in the cognitive behavioral therapy group will be asked to undergo a 8-week CBT trial. An online videoconferencing link will be used to deliver CBT virtual sessions that will be approximately 60 minutes in length. Each session will be conducted by a clinical psychology doctoral student, supervised by a licensed psychologist. Patients will also undergo careful phenotyping pre- and post intervention with brain MRI, AFT, WMC, and NDT.
2405953|NCT03531437|Active Comparator|Zoely|Monophasic combined oral contraceptive pills 24 white active tablets and 4 yellow inactive tablets each active tablet contains 1.5 mg estradiol and 2.5 mg nomegestrol acetate 3 cycles
2405954|NCT03531437|Active Comparator|Minidoz|Monophasic combined oral contraceptive pills 24 active tablets and 4 inactive tablets each active tablet contains ethinylestradiol 15 µg and gestodene 60 µg 3 cycles
2405955|NCT03531424|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
2405956|NCT03531424|Experimental|CTA guided PCI|CTA guided PCI is coronary revascularization based on systematic use of CTA plus coronary angiography.
2405957|NCT03531398|Experimental|High fat meal|Muffin containing 30g fat
2405958|NCT03531398|Experimental|Medium fat meal|Muffin containing 20g fat
2405959|NCT03531385||Behcet|Patients diagnosed with Behcet disease
2405960|NCT03531385||Healthy controls|Individuals without any chronic disease
2405961|NCT03531372|Experimental|Mipolixin®|Mipolixin® (Advanced Natural Antacid - AdNA)
2405962|NCT03531372|Active Comparator|Poliprotect®|Poliprotect® (Neobianacid)
2405963|NCT03531359|Experimental|TIBD Tablet-based video distraction|Children will receive of tablet-based interctive games in preoperatory room
2405964|NCT03531359|Active Comparator|Midazolam|Children will be premedicated with usual treatmente (midazolam)
2405965|NCT03531346|Experimental|Hyperosmolarity group|Healthy, young, habitual contact lens wearers with initial increased tear osmolarity (hyperosmolarity)
2405966|NCT03531346|Experimental|Normal osmolarity|Healthy, young, habitual contact lens wearers with initial tear osmolarity reported as normal
2405967|NCT03531333|Experimental|Ultrasound|ultrasound navigation guided surgery.
2405968|NCT03531333|No Intervention|Non-ultrasound|standard surgery without ultrasound guidance.
2405969|NCT03531320|Experimental|Part 1:Dose-Escalation Phase|40 mg D07001-softgel capsules 60 mg D07001-softgel capsules 80 mg D07001-softgel capsules 120 mg D07001-softgel capsules 160 mg D07001-softgel capsules
2405970|NCT03531320|Experimental|Part 2: Dose-Expansion Phase (Phase 2)|higher dose-expansion of D07001-softgel capsules lower dose-expansion of D07001-softgel capsules
2405971|NCT03531307||Lactate and Ki 67 levels|Neurosurgical patients between June 2017 and February 2018 for tumoral and non-tumoral craniectomy with lactate levels at the beginning of surgery and Ki-67 index in biopsies.
2405972|NCT03531294|Experimental|Group 1|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based on OPTOS funds photos.
2405973|NCT03531294|Experimental|Group 2|Treatment based on central reading center reading evaluation of DRSS (diabetic retinopathy severity scale) level based leakage index of OPTOS wide field fluorescein angiography.
2405974|NCT03531281|Experimental|Arm I (goat milk, transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~HLZ: Patients receive human lysozyme goat milk PO TID on days -8 to 28 in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
2405975|NCT03531281|Active Comparator|Arm II (transplant conditioning/prophylaxis)|"CONDITIONING: Patients receive palifermin on days -10 to -8 and days 0 to 2 per COH SOP, undergo FTBI on days -7 to -4, and receive cyclophosphamide on days -3 to -2 or etoposide on day -3 per COH SOP in the absence of disease progression or unacceptable toxicity.~TRANSPLANT: Patients undergo stem cell infusion on day 0.~GVHD PROPHYLAXIS: Beginning on day -2, patients receive tacrolimus and sirolimus daily per COH SOP in the absence of disease progression or unacceptable toxicity."
2405976|NCT03531268|Active Comparator|PGx testing has clinical utility|These are subjects whose PGx testing is judged to have clinical utility and whose clinical care may be modified. Modifications may include altering doses or types of drugs given based on metabolic profile of the patient.
2405977|NCT03531268|No Intervention|PGx testing has no clinical utility|"These are subjects whose PGx testing is judged to have no clinical utility. Care as usual is provided, and there are no changes in drug selection or dosing based on the results of PGx testing."
2405978|NCT03531255|Experimental|1,080 mg pegcetacoplan administered subcutaneously|1,080mg pegcetacoplan administered subcutaneously twice weekly or every three days.
2405979|NCT03531242|Experimental|Cohort A: Initial Non-responders to VEE TC-83 vaccinations|Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, to be administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area.
2405980|NCT03531242|Experimental|Cohort B: Responders to TC-83 or previous C-84 vaccinations|"Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
2405981|NCT03531229|Placebo Comparator|Placebo|Placebo to Lu AF76432
2405982|NCT03531229|Experimental|Lu AF76432|Lu AF76432
2405983|NCT03531216|Active Comparator|Topical application of rosemary oil|Rosemary essential oil (10% )
2405984|NCT03531216|Placebo Comparator|Placebo|Pharmaceutical quality olive oil
2405985|NCT03531203|Experimental|With Soursop|Treatment group (with soursop group) was a group which receive soursop supplementation
2405986|NCT03531203|Placebo Comparator|Without Soursop|Control group (without soursop group) was a group which do not receive any intervention (placebo)
2405987|NCT03531190|Experimental|Nutritional supplement (Protein + MIX)|Patients are given: Nutritional Supplement of protein 2-3 times a day + MIX once daily for 35 days
2405988|NCT03531190|Active Comparator|Nutritional supplement (Protein)|Nutritional Supplement of protein as needed 2-3 times a day for 35 days
2405989|NCT03531177|Experimental|Intervention|HEAL-D diet and lifestyle education and behavioural change intervention, 7 sessions over 14 weeks.
2405990|NCT03531177|Active Comparator|Control|Usual care.
2405991|NCT03531164|Experimental|Kayak ergometer group|Intervention: Training in kayak ergometer: 3 minutes of warming (pre-charge) , 3-5 intervals of training with moderate to high intensity and pauses of 2-4 minutes (charge) and 2 minutes of cooling down (post-charge) to complete 30 minutes.
2405992|NCT03531164|Active Comparator|Control group|Intervention: 30 minutes of proprioceptive neurofacilitation focused on trunk control
2405993|NCT03531138|Experimental|Pulmonary rehabilitation group|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week.
3144414|NCT00039416|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once or twice daily on days 1-28. Courses repeat every 28 days for 12 months in the absence of disease progression or unacceptable toxicity.
3144415|NCT00039442|Experimental|Treatment|Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144416|NCT00039455|Experimental|Treatment (trastuzumab and alvocidib)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, and 15 followed by flavopiridol IV continuously over 24 hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2405999|NCT03531073||Standard care cohort|This study is observational. Patients will receive standard treatment as given in usual clinical practice with no intervention as part of the study. As per current clinical practice guidelines and UK reimbursement rules for biologics in PsA, patients will receive a pragmatic treat to target approach using step up standard therapies. Patients will usually receive methotrexate first line, initially 15mg ow increasing to 25mg ow as tolerated. In case of non-response, an additional DMARD will be used (sulfasalazine up to 3g daily or leflunomide 20mg od). If two DMARDs are failed and patients are eligible for biologic therapy under UK National Institute of Health and Clinical Excellence (NICE) guidance, then biologics will be used.
2406000|NCT03531060|Experimental|IRL790|IRL790 Capsule 10 mg, oral administration
2406001|NCT03531060|Placebo Comparator|Placebo|Placebo capsule, identical appearance, oral administration
2406002|NCT03531047|Experimental|Refractive CXL|Tomography-customised CXL
2406003|NCT03531034|Experimental|Hypertensive Women|Group of hypertensive and controlled women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2406004|NCT03531034|Active Comparator|Normotensive Women|Group of normotensive women who practiced 10 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities.
2406074|NCT03530579|Experimental|Group 1|Participants will receive 6 two and a half hour educational group trainings over the course of 6 months.
2406075|NCT03530579|Active Comparator|Group 2|A community health worker will answer your questions about diabetes and refer participant if you need one.
3144417|NCT00039481|Experimental|Treatment (Oblimersen sodium, cytotoxic chemotherapy)|See detailed description.
3144418|NCT00039494|Experimental|Treatment (erlotinib hydrochloride, radiation, temozolomide)|Patients receive oral erlotinib once daily. After 1 week of erlotinib alone, patients also receive oral temozolomide once daily for 6 weeks and undergo concurrent radiotherapy 5 days a week for 6 weeks. After completion of radiotherapy, patients continue to receive erlotinib once daily alone in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after the completion of radiotherapy, patients also receive oral temozolomide once daily for 5 days. Temozolomide treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
2406005|NCT03531021|Experimental|Heart healthy intervention|The intervention group will receive 2 modules (one in in person and one by video conference) and will receive follow-up phone calls/emails by study staff 3 weeks following each visit to review education and strategies for and barriers to reaching goals. Intervention sessions must include teen; parents may attend if they wish. Participants will be placed on teams and encouraged to complete behavioral challenges to earn points towards a cash reward.
2406006|NCT03531021|No Intervention|Attention Control|There will be a delayed intervention for the control group with study handouts after 3 months. The control group will meet with the RAs for demographic and survey completion and receive reminder phone calls/emails in order to match for attention.
2406007|NCT03531008||Treatment-resistant focal epilepsy|Individuals with treatment-resistant focal epilepsy
3144419|NCT00039559|Other|Early detection|
3144420|NCT00039624|Experimental|Brachy|brachytherapy
3144424|NCT00039780|Active Comparator|1|Tavocept (BNP7787)
2406014|NCT03530982|Experimental|Intervention group|Intensive goal training of relevant activities reported by adolescents in the beginning of the study. Therapists will grade the level of complexity of the proposed activities, considering the relevant movements, task demands and contextual factors involved in the performance of each task. Adolescents will be asked to practice these activities at home (1 hour/daily) and to discuss their difficulties and improvements with the therapists. The intervention will be provided in a day-camp model.
2406015|NCT03530969|Experimental|GI/GU/Lymphoma Oncologists|Doctors specializing in treating gastrointestinal cancer (cancer of the stomach, pancreas, colon, etc.), genitourinary cancer (cancer of the genitals and urinary tract), and lymphoma (cancer affecting the blood and lymph nodes)
2406016|NCT03530969|Active Comparator|Participants with GI/GU/Lymphoma Cancer|Patients of the physicians in group 1
2406017|NCT03530969|Active Comparator|Caregivers of Participants with GI/GU/Lymphoma Cancer|Family members or caregivers of the patients in group 2
2406018|NCT03530956|Active Comparator|Current prosthesis|A unilateral transtibial amputee will conduct experiments with the current prosthesis
2406019|NCT03530956|Experimental|Novel prosthesis|A unilateral transtibial amputee will conduct experiments with the novel prosthesis
2406020|NCT03530943|Active Comparator|Academic Stress Management|Students assigned to the Academic Stress Management (ASM) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks during which time they will receive 100% exposure to various evidence-based academic stress management tools.
2406021|NCT03530943|Experimental|Human Animal Interaction Enhanced|Students assigned to the Human Animal Interaction - Enhanced (HAI-E) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group receives 50% exposure to structured and unstructured animal assisted activities and 50% exposure to various evidence-based academic stress management tools.
2406022|NCT03530943|Experimental|Human Animal Interaction only|Students assigned to the Human Animal Interaction - only (HAI-O) condition will attend a series of once weekly, one hour long workshops over four consecutive weeks. This group will be receive 100% exposure to structured and semi-structured animal assisted activities.
2406023|NCT03530930|Experimental|Comarum Palustre|Patients taking Comarum Palustre together with conventional treatment for osteoarthritis
3185046|NCT00730951|Experimental|4|6g Korean Red Ginseng (12 capsules)
3185047|NCT00730951|Experimental|5|6g Corn Starch Control (12 capsules)
2406032|NCT03530904|Active Comparator|early mobilization after cardiac device implantation|mobilization after 4 hours
2406033|NCT03530904|Active Comparator|Late mobilization after cardiac device implantation|Mobilization after 24 hours
2406034|NCT03530891|Experimental|Computer guided lag screw fixation|Patient specific surgical guided will be used for open reduction and internal fixation for anterior mandibular fracture by lag screws.
2406035|NCT03530891|Active Comparator|Conventional lag screw fixation|Open reduction and internal fixation for anterior mandibular fracture using lag screws.
2406036|NCT03530878|Experimental|Hip Arthroscopy (HA)|This approach addresses intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH 3. Furthermore, capsular plication can be performed through HA to reduce instability of the joint.
2406076|NCT03530566||Pnk group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, scheduled bariatric surgery within 3 months will be treated with PnK® Method
2406316|NCT03529071|No Intervention|Control|Individuals will not receive any intervention or surveys.
3144425|NCT00039780|Placebo Comparator|2|0.9% Sodium Chloride Soln.
3144426|NCT00039832|Experimental|1|CT
3144427|NCT00039832|Experimental|2|MRI
3144428|NCT00039988|Experimental|1|Participants will receive Copaxone and albuterol placebo
3144429|NCT00039988|Experimental|2|Participants will receive Copaxone and albuterol
3144430|NCT00040105|Experimental|Zarnestra + Gleevec|
3144431|NCT00040326|Active Comparator|1|anteromesial temporal resection
3144432|NCT00040326|Active Comparator|2|antiepileptic drugs
3144433|NCT00040378||Combination therapy|vitamin E (alphatocopherol) and selenium
3144434|NCT00040378||Vitamin E only|vitamine E (alphatocopherol) and placebo
3144435|NCT00040378||Selenium only|selenium and placebo (Placebo replacement for vitamin E)
3144436|NCT00040378||Placebo|placebo (Placebo replacement for vitamin E) and placebo (Placebo replacement for selenium)
3144437|NCT00040404|Experimental|CEP-1347 10mg|CEP-1347 was administered at a dosage of 10mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
2406037|NCT03530878|No Intervention|Periacetabular Osteootmy (PAO)|The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization.
3185048|NCT00730977|Experimental|single|single arm, open label, 4 doses tested.
2406039|NCT03530839|Experimental|Arthrodesis|Arthrodesis of the proximal interphalangeal joint by using a threaded K-wire
2406040|NCT03530839|Active Comparator|Resection arthroplasty|Resection arthroplasty of the proximal interphalangeal joint using a normal K-wire
2406041|NCT03530813|Active Comparator|Face-To-Face Group|Asthma First Aid Management in Schools 3 Hour Face to Face Training Group, selected a training session to attend in their local area.
2406042|NCT03530813|Experimental|Ebook Group|Asthma Management in Schools eBook training group were sent a cloudStor link to download and complete training
2406043|NCT03530800|Active Comparator|Dronabinol|Subjects will receive dronabinol 5mg once daily for two weeks, 5mg twice daily for the subsequent two weeks, and 5mg three times daily for the final six weeks. Dose escalations will only be done if the investigator deems necessary.
2406044|NCT03530800|Placebo Comparator|Placebo|Subjects will receive placebo for 10 weeks weeks.
2406045|NCT03530787|Active Comparator|Acetyl Zingerone Group|This group was given the topical with the active acetyl zingerone agent.
2406046|NCT03530787|Placebo Comparator|Control Group|This group was given the topical without the active acetyl zingerone agent and just the carrier lotion.
2406047|NCT03530774|Experimental|Egg while protein supplement|25 g of powdered egg white protein supplement daily for 6 months. Total of 20.6 g of protein in 25 g of supplement.
2406048|NCT03530774|Placebo Comparator|Maltodextrin supplement|25 g of powdered maltodextrin supplement daily for 6 months. Total 23.5 g of carbohydrate in 25 g of supplement.
2406049|NCT03530761||Acute kidney injury|Increase in serum creatinine more than 0.3 mg/dl within 48 hours or a percentage increase serum creatinine more than 50% from baseline.
2406050|NCT03530761||Hepatorenal syndrome|"Diagnosis of cirrhosis and ascites,~Diagnosis of AKI according to ICA-AKI criteria~No response after 2 consecutive days of diuretic withdrawal and plasma volume expansion with albumin 1 g per kg of body weight~Absence of shock~No current or recent use of nephrotoxic drugs (non-steroidal anti-inflammatory drugs, aminoglycosides, iodinated contrast media, etc.)~No macroscopic signs of structural kidney injury, defined as: absence of proteinuria (> 500 mg/day), absence of microhaematuria (> 50 RBCs per high power field), normal findings on renal ultrasonography."
2406051|NCT03530748||Patients with Renal Artery Stenosis|Patients with simple renal artery stenosis or aortic dissection with renal artery obstruction
2406052|NCT03530735|Experimental|Fingerprick Autologous Blood (FAB) for Use in Dry Mouth|"All patients recruited will receive a 10ml saline mouth wash. Half will produce a blood-saline mixture from this mouthwash (preparation details below) and the other half will only use standard saline mouthwash. Each group will use their respective mouthwash 4 times a day for 4 weeks. During the following 4 weeks, participants will use the other mouthwash treatment. In the final 4 weeks, neither group of patients will be using either mouthwash.~Patients will be assessed at week 0, 2, 4, 6, 8, 10 and 12. However only clinic visits 0, 4, 8 and 12 will require clinic visits. During weeks 2, 6, and 10 the patients will fill out the questionnaire at home."
2406053|NCT03530709|Experimental|Experimental|videoconferencing
2406054|NCT03530709|No Intervention|Control|Usual care
2406061|NCT03530670|Active Comparator|oral midazolam (demizolam)|"To prevent preoperative anxiety patient premedicated by 0.5 mg/kg oral midazolam.~In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale"
2406062|NCT03530670|Active Comparator|http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|To prevent preoperative anxiety by watching a short movie ( at http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
2406063|NCT03530670|Active Comparator|playing smartphone game|To prevent preoperative anxiety by playing smartphone game ( angry birds, subway surfers, snail Bob) In the preoperative holding area, in the operating room, while anesthesia induction by m-YPAS ( modified the Yale Preoperative Anxiety Scale) To make easier anesthesia induction While anesthesia induction by Mask Acceptance Scale
2406064|NCT03530644|Experimental|RSP-14|"Comparative study of two Investigational Medical Devices (WM3.4NR and P0.1)~Optical data will be obtained from T1D over a dynamic glycemic range. Data will be paired with references."
3185049|NCT00730990|Experimental|Cohort 1|This arm will have no active treatment.
3185050|NCT00730990|Experimental|Cohort 2|
3185051|NCT00731003|Experimental|I|ATD procedure
3185052|NCT00731003|Experimental|II|Oxitriptan
2406069|NCT03530618|Experimental|Flexible tip straight guidewire|
2406070|NCT03530618|Experimental|J-tip guidewire|
2406071|NCT03530605|Experimental|Optune TTF Device|Optune TTF treatment
2406072|NCT03530605|No Intervention|Historical matched control|age-matched historical controls
2406073|NCT03530592|Experimental|Seated Ankle Robot Training|
3185053|NCT00731003|Placebo Comparator|III|Amino acid mixture with tryptophan
3185054|NCT00731003|Placebo Comparator|IV|Placebo capsule
3185055|NCT00731016|Other|1|Zoledronic acid, pravastatin
3185056|NCT00731029|Experimental|Group A|The subjects in this group will be 18-60 years.
3185057|NCT00731029|Experimental|Group B|The subjects in this group will be > 60 years.
2406077|NCT03530566||Control group|Patients with morbid obesity (BMI ≥ 40 kg/m2) or with severe obesity (BMI 35 to 39.9 kg/m2), with two or more comorbidities, treated with standard diet 3 moths prior bariatric surgery
2406078|NCT03530553|Experimental|Treatment arm|The treatment arm will receive the HMS as well as standard of care of the weight management program.
2406079|NCT03530553|No Intervention|Control arm|The control arm will not receive the HMS and will receive standard of care.
2406080|NCT03530540|Experimental|Intervention|Active shockwaves
2406081|NCT03530540|Placebo Comparator|Placebo|Placebo shockwaves
2406082|NCT03530527|Active Comparator|ERCP with biliary stenting|Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.
2406083|NCT03530527|Active Comparator|EUS guided biliary drainage|Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.
2406084|NCT03530514|Experimental|Part A: Single dose cohort 1|Cohort 1 will receive a single IV dose of REGN4461 or matching placebo
2406085|NCT03530514|Experimental|Part A: Single dose cohort 2|Cohort 2 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2406086|NCT03530514|Experimental|Part A: Single dose cohort 3|Cohort 3 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2406087|NCT03530514|Experimental|Part A: Single dose cohort 4|Cohort 4 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
2406088|NCT03530514|Experimental|Part A: Single dose cohort 5|Cohort 5 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2406089|NCT03530514|Experimental|Part A: Single dose cohort 6|Cohort 6 will receive a sequential ascending single SC dose of REGN4461 or matching placebo
2406090|NCT03530514|Experimental|Part A: Single dose cohort 7|Cohort 7 will receive a sequential ascending single IV dose of REGN4461 or matching placebo
2406091|NCT03530514|Experimental|Part A: Single dose cohort 8|Cohort 8 will receive a single IV dose of REGN4461 or matching placebo
2406092|NCT03530514|Experimental|Part A: Single dose cohort 9|Cohort 9 will receive a single IV dose of REGN4461 or matching placebo
2406093|NCT03530514|Experimental|Part B: Repeated dose cohort 10|Cohort 10 will receive repeated IV or SC doses of REGN4461 or matching placebo
2406094|NCT03530501|Placebo Comparator|Placebo|Very low calorie ketogenic diet followed by low calorie diet
2406095|NCT03530501|Experimental|Synbiotic1+synbiotic2|Very low calorie ketogenic diet supplemented with synbiotic 1 followed by low calorie diet supplemented with synbiotic2
2406096|NCT03530501|Experimental|placebo +synbiotic2|Very low calorie ketogenic diet supplemented with placebo followed by low calorie diet supplemented with synbiotic2
2406097|NCT03530488|Active Comparator|Lidocaine group|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline 5 minutes before hystroscopy
2406098|NCT03530488|Placebo Comparator|control group|intrauterine and intracervical instillation of 19 ml normal saline 5 minutes before hystroscopy
2406099|NCT03530475|Active Comparator|placenta previa|cases diagnosed as placenta previa diagnosed by ultrasound and doppler
2406100|NCT03530475|Active Comparator|placenta accreta|placenta previa diagnosed as placenta accreta by ultrasound and doppler
2406101|NCT03530462||patient with first-line and second-line|patients who received intravenous second-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis),in addition to first-line immunotherapy (rituximab, cyclophosphamide)
2406102|NCT03530462||patients with first-line only|patients who received first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis)only
2406103|NCT03530462||healthy control|healthy individuals without a history of psychiatric or neurologic disease
2406104|NCT03530449||Subjects with Normal Eyes|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects without ophthalmic pathology
2406105|NCT03530449||Subjects with Retinal Vascular Pathology|Color Fundus Photography, Optical Coherence Tomography, and OCT Angiography scans as per protocol in subjects with retinal vascular ophthalmic pathology
2406106|NCT03530436|Other|Native turmeric extract|6 capsules of native curcumin (207 mg curcumin)
2406107|NCT03530436|Experimental|Native turmeric extract with 7-9% volatile turmeric oils|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406108|NCT03530436|Experimental|Turmeric extract plus mixture of phytochemicals|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406109|NCT03530436|Experimental|Cyclodextrin complex of curcuminoids|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406110|NCT03530436|Experimental|Turmeric oleoresin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406111|NCT03530436|Experimental|Liposomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406112|NCT03530436|Experimental|Phytosomal curcumin|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406113|NCT03530436|Experimental|Micellar turmeric extract|6 capsules of the formulation; dosage normalized to 207 mg curcumin
2406114|NCT03530410||Patients with intragastric balloon|Patients who will receive an intragastric balloon placement for weight loss
3185058|NCT00731029|Active Comparator|Group C|The subjects in this group will be 18-60 years.
3185059|NCT00731029|Active Comparator|Group D|The subjects in this group will be > 60 years.
3185060|NCT00731068|Experimental|1|PRGF
2406118|NCT03530384|Experimental|Cognitive training|Computerized cognitive training program targeting inhibitory control
2406119|NCT03530384|Sham Comparator|Control Training|A sensorial program with similar conditions, but targeting visual acuity, considered as neutral in the addiction field
2406120|NCT03530371|Experimental|Dexmedetomidine Hydrochloride|sedation of patients to perform auditory test
2406121|NCT03530358|Experimental|Technology-aided rehabilitation|The technology-aided upper limb rehabilitation include reinforced feedback in virtual environment (RFVE), or robotic therapy.
2406122|NCT03530358|Active Comparator|Conventional rehabilitation|The conventional upper limb rehabilitation program will be based on traditional rehabilitation techniques aimed at restoring upper limb motor functions.
3185061|NCT00731068|Placebo Comparator|2|
3185062|NCT00731107|Active Comparator|1|Veress Needle laparoscopic entry
3185063|NCT00731107|Active Comparator|2|XCEL bladeless trocar laparoscopic entry
3185064|NCT00731146|Active Comparator|1 - Ultrasound|Participants will receive an ultrasound guided interscalene brachial plexus block
3185065|NCT00731146|Active Comparator|2 - Nerve Stimulator|Participants will receive a nerve stimulator guided interscalene brachial plexus block
2406125|NCT03530332|Experimental|Treatment|
2406126|NCT03530332|No Intervention|Control|
2406127|NCT03530319|Active Comparator|Azithromycin|Azithromycin (10mg/kg/day) is given to children with mycoplasma pneumonia for 3 days.
2406128|NCT03530319|Experimental|Doxycycline|Doxycycline (2-4mg/kg/day) is given to children with mycoplasma pneumonia for 5-10 days.
2406129|NCT03530306|Active Comparator|PS1-PS4|
2406130|NCT03530306|Active Comparator|PS6-PS10|
2406131|NCT03530306|Active Comparator|PS7-PS4|
2406132|NCT03530306|Active Comparator|PS9-PS6|
2406133|NCT03530293|Experimental|Valbenazine|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
2406134|NCT03530293|Placebo Comparator|Placebo|Capsule, administered once daily. Randomization into this arm occurs after open-label treatment with valbenazine once daily for up to 12 weeks. Total treatment up to 36 weeks.
2406135|NCT03530280|Active Comparator|pregabalin (lyrica)|pregabalin (lyrica) 150 mg preoperative 1 hour before and the postoperative sham block will perform.
2406136|NCT03530280|Placebo Comparator|placebo group|a placebo capsule 1 hour before surgery and the postoperative sham block will perform.
2406137|NCT03530280|Active Comparator|adductor channel block group|A preoperative placebo capsule will be given.This group will receive postoperative adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
2406138|NCT03530267|Active Comparator|Arm A (mFOLFOX7)|"Patients in the 5-FU / oxaliplatin arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).~This regimen represents the 80% dosage reduced mFOLFOX 7. The 80% dose reduction was shown to be a tolerable regimen in frail elderly patients in the FOCUS 2 study."
2406139|NCT03530267|Experimental|Arm B (Aflibercept + mLV5FU2)|"Patients in the 5-FU / aflibercept arm receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).~The decision to use reduced doses of 5-FU and folinic acid was made to have comparable doses to the reduced FOLFOX 7."
2406140|NCT03530254|Other|PGT-A without ERA|Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
2406141|NCT03530254|Other|PGT-A and test ERA|"Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive)."
2406142|NCT03530241|Experimental|MRCP positive|
2406143|NCT03530241|Active Comparator|MRCP negative|
2406144|NCT03530228|Experimental|Treatment A: Tegoprazan (C1)|Tegoprazan QD, oral administration
2406145|NCT03530228|Experimental|Treatment B: Tegoprazan (C1)|Tegoprazan QD, oral administration
2406146|NCT03530228|Experimental|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
2406147|NCT03530228|Experimental|Group 1: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
2406148|NCT03530228|Experimental|Group 2: Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days
2406149|NCT03530228|Active Comparator|Group 3: Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days
2406150|NCT03530228|Experimental|Tegoprazan (C3)|Tegoprazan QD, oral administration
2406151|NCT03530215||Adverse Events with Antineoplastic and immunomodulating agents|Cases reported in the World Health Organization (WHO) and the French pharmacovigilance database of patients treated by Antineoplastic and immunomodulating agents, with a chronology compatible with the drug toxicity
2406152|NCT03530202|Experimental|HVRT + Creatine Monohydrate|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume creatine monohydrate powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
2406153|NCT03530202|Placebo Comparator|HVRT + Maltodextrin Powder|Participants will perform 8-weeks of high-velocity resistance training, defined as performing the concentric phase of a lift as fast as possible and taking two seconds to perform the eccentric phase of the lift, on six exercises (bilateral legpress, leg extension, leg curl, chest press, triceps extension, and biceps curl) and consume maltodexterin powder. The load will be 80% of the participants one-repetition max (1RM; the maximum weight that can be successfully lifted one time with proper form).
2406154|NCT03530189||Normoglycemic group|"The infant will enter this group if a single blood glucose concentration is between 2.1 and 2.5 mmol/l (38-45 mg/dL), or a single blood glucose concentration is between 8.6 - 10 mmol/l (155-180 mg/dL) with all other measures between 2.6 and 8.5 mmol/l (47-153 mg/dL).~To all premature infants intravenous 10% dextrose at 60-90 mL/kg/day will be started as soon as possible after birth."
2406155|NCT03530189||Group with impaired glucose|"The infant can be hypoglycemic, hyperglycemic or unstable. The infant will be hypoglycemic if blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration is≤2,0 mmol/l (36 mg/dL). Hypoglycemia will be treated with intravenous bolus of 10% dextrose.~The infant will be hyperglycemic if blood glucose concentration is ≥8,6 mmol/l (155 mg/dL) on ≥2 measures >1 hour apart, or any blood glucose concentration ≥10,1 mmol/l (182 mg/dL). Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion.~The infant will be unstable if at least 1 blood glucose concentration is ≤2,5 mmol/l (45 mg/dL) and ≥1 blood glucose concentration is ≥8,6 mmol/l (155 mg/dL)."
3185066|NCT00731159||A|"Sperm capacitation:~Sperm capacitation is measured in a sample of the same ejaculated sperm unit given for fertilizing human oocytes in an IVF treatment cycle"
3185067|NCT00731172|Experimental|1|20 mg copaxone(glatiramer acetate)subcutaneous injection(daily through week 12)
3185068|NCT00731172|Placebo Comparator|2|placebo subcutaneous injection(daily through week 12)
3185069|NCT00731185|Experimental|Mometasone Furoate Nasal Spray (MFNS)|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning
2406156|NCT03530176|Experimental|single arm|18F-NaF (sodium Flouride ) is a radio-pharmaceutical used to image skeletal pathology, including primary and secondary neoplasms. Despite US Federal Drug Administration (FDA) approval and 18F-NaF being listed in the US Pharmacopeia, 18F-NaF is not currently approved by Health Canada for use as a cardiac imaging tracer. Therefore, a concurrent Health Canada Clinical Trial Application is being submitted to ensure its availability. Intervention on single arm: A dose of 18F-NaF (200 - 400 MBq) will be injected intravenously at rest. After a 60 minute, an ECG-gated PET acquisition will be performed centered over the heart for 20 minutes. A CT coronary calcium score examination will also be performed on a dedicated CT scanner and the Agatston and volume scores calculated according to standards.
2406157|NCT03530163|Experimental|Respiratory Muscle Training|
2406158|NCT03530163|Sham Comparator|Sham Breathing Training|
2406159|NCT03530150|Active Comparator|Pirfenidone 600 mg|Burn patients randomly allocated to this group will receive pirfenidone 600 mg orally once per day for 21 days additionally to the coverage of the wound with non-adherent gauzes and bandages. The aforementioned coverings will be changed every 3 or 4 days until a complete re-epithelization is achieved.
2406160|NCT03530150|No Intervention|Usual Care|Burn patients randomly allocated to this group will only be treated by the usual care of our hospital which consists in covering the wound with non-adherent gauzes and bandages. These covering will be changed every 3 or 4 days until a complete re-epithelization is achieved.
2406161|NCT03530137|Other|families living at Families Moving Forward (FMF)|
2406164|NCT03530111||Sedentary|Sedentary individuals will be classified as achieving < 75 minutes of moderate-intensity or < 37 minutes of vigorous-intensity aerobic physical activity per week.
2406165|NCT03530111||Very Physically Active|Very Physically Active individuals will be classified as achieving > 225 minutes of moderate-intensity or > 112 minutes of vigorous-intensity aerobic physical activity per week.
3185070|NCT00731185|Placebo Comparator|Placebo|Placebo nasal spray (2 sprays of 50 mcg in each nostril) once daily in the morning
3185071|NCT00731224|Experimental|1|
2406168|NCT03530085|Experimental|Dec+Flu+Bu Conditioning Regimen|For AML patients older than 60 years in CR, Decitabine+ Fludarabine+Busulfan conditioning regimen was used (Decitabine 20mg/m2/day on days -9 to -7；Fludarabine(Flu) 30mg/m2/day on days -6 to -3；Busulfan (BU) 3.2 mg/kg/day on days -5 to -4).
2406169|NCT03530072||Cases|Subjects with Fever and Neutropenia
2406170|NCT03530046|Experimental|High SID fluid|Group 1: half-normal saline with addition of 75mEq/L sodium bicarbonate
2406171|NCT03530046|Active Comparator|Hartmann's solution|Group 2: Hartmann's Solution
2406172|NCT03530033|No Intervention|Conventional surgery group|Induction of anesthesia according to conventional neuromuscular blockade dose, no neuromuscular blockade drug maintenance during lateral neck dissection.
2406173|NCT03530033|Experimental|Lidocaine group|Anesthesia induction was performed according to conventional nerve monitoring neuromuscular blockade doses and lateral neck dissection was performed. When local muscle tremors occur, lidocaine is injected locally to eliminate muscle tremors.
2406174|NCT03530020|Active Comparator|monolithic zirconia crowns|Monolithic zirconia attracts many dentists worldwide due to its excellent mechanical properties, biocompatibility and appreciate aesthetics
2406175|NCT03530020|Experimental|lithium silicate crowns|A lithium silicate glass ceramic is newly introduced to the market. After crystallization, it exhibits an ideal combination of aesthetics and strength with translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns.
2406176|NCT03530007|Active Comparator|normal saline|patients received normal saline for prevention of shivering during spinal anesthesia
2406177|NCT03530007|Active Comparator|ondansetron 4MG|patients received 4 mg of ondansetron for prevention of spinal shivering
2406178|NCT03530007|Active Comparator|ondansetron 8MG|patients received 8 mg of ondansetron for prevention of spinal shivering
2406179|NCT03529994||Enrollment|
2406180|NCT03529981|Active Comparator|Stress incidents without TVS|a fraction of physiological detected stress incidents will not trigger TVS
2406181|NCT03529981|Experimental|TVS in response to participant initiation or stress detection|The majority of detected stress incidents will trigger TVS. Participants can also trigger TVS voluntarily
2406182|NCT03529968||Italian Siewert I-II adenocarcinoma|Patients with Siewert type I adenocarcinoma underwent subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Patients with Siewert type II adenocarcinoma underwent total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy. A right anterolateral thoracotomy and an upper midline laparotomy were performed as previously described. Lymphadenectomy included chest stations classified according to the AJCC TNM 7th edition (L/R = left/right; 3, 4R, 7, 2R, 8 and 9 and abdominal stations classified according to the Japanese Classification of Gastric Carcinoma (stations 1-12)
2406183|NCT03529968||Finnish Siewert I-II adenocarcinoma|All Siewert type I/II patients underwent minimally invasive esophagectomy and reconstruction with gastric tube. Laparoscopy and right-sided thoracoscopy in decubitus position were used as previously described. Thoracic lymphadenectomy consisted of stations 7-9 (AJCC TNM 7th edition) and abdominal stations 1-3 and 7-11 according to the Japanese Classification of Gastric carcinoma.
2406184|NCT03529955|Experimental|Dermatomyositis patients with refractory cutaneous disease|Patients with dermatomyositis and refractory skin disease on steroids and one steroid-sparing agent.
3185072|NCT00731237||1|The procedures undergone by this group will be evaluated for: Acute performance, deliverability and resource utilization during the procedure in the catheterization lab during commercial use by various physicians with a range of coronary stenting experience.
3185073|NCT00731250|Placebo Comparator|PART 1-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
3185074|NCT00731250|Experimental|PART 1-Visit 1-Capsaicin|Eligible subjects will receive incremental capsaicin doses
2406186|NCT03529929|Experimental|Methylprednisolone|"Methylprednisolone glucocorticoid Medrol Dose Pack~Medrol is supplied as white tablets, of 4mg each. The tablets come in a commercially produced blister pack with instructions for each day of the 6 day dosing on the packaging. Subjects will receive a standard 6-day, graded dosing regimen of methylprednisolone (24mg, 20mg, 16mg, 12mg, 8mg, and 4 mg on days 1 through 6 respectively)."
2406187|NCT03529916||CVD subjects|CVD will be defined as >50% stenosis of one or more coronary arteries as assessed by coronary angiography.
2406188|NCT03529916||healthy controls|healthy controls defined as not having stenosis of coronary arteries as assessed by coronary angiography.
2406189|NCT03529903|No Intervention|Control Group|*Complete an online survey and intake appointment with a trained Health Coach (HC), who will measure their height, weight, and blood pressure, assess their current health habits (sleep, nutrition, exercise) and work with they to set realistic, achievable health goals. *Wear a Fitbit device daily to track physical activity and weight (members of the MyLife study team can access their data during throughout the program and de-identified, anonymous, data will be shared with Fitbit as part of a research partnership). *Complete another online survey and telephone check-in with their HC at the halfway point to monitor their progress toward reaching their goals. *Complete a final online survey and outtake appointment with their HC to re-check their measurements and discuss their progress.
2406190|NCT03529903|Experimental|Experimental Group|*Complete survey/ intake appointment with a HC, who will measure their height, weight, and blood pressure, assess their health habits and set achievable health goals. *Wear a Fitbit to track their daily physical activity and weight *Set a weekly active minutes goal and record their weight weekly. *Receive motivational text messages 4x per week, one will ask for their weekly active minutes goal and weight and another will ask for goal progression.*Complete photo food diaries biweekly (send pictures of everything they eat/drink to their HC). *Complete surveys/telephone check-ins with their HC every 2 weeks to monitor their progress toward reaching their goals. *Complete final survey/outtake appointment with their HC to for final measurements and to discuss goal progression (about 2 hours).
3144438|NCT00040404|Experimental|CEP-1347 25mg|CEP-1347 was administered at a dosage of 25mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
2406192|NCT03529877|Experimental|allo-APZ2-EB|intravenous infusion, three doses of allo-APZ2-EB (2 x 10^6 cells/kg)
2406193|NCT03529864|Experimental|Exercise therapy|The participants took part in a progressive exercise therapy program for 9 consecutive weeks, once a week. This consisted of group sessions with 8 or 9 students, with each session lasting 60 minutes, supervised by the principal researcher
2406194|NCT03529864|No Intervention|Control|The CG did not receive any type of information or instructions apart from the general information sheet on the progress of the study, attached to the informed consent form
2406195|NCT03529851|Experimental|PRO intervention|Patients included will weekly fill in a 12 item questionaire via the internet during the 3 week study period.
2406196|NCT03529838|Placebo Comparator|No medication|Group of pre-hypertensive women with no medication who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2406197|NCT03529838|Active Comparator|Angiotensin receptor blockers|Group of hypertensive women taking Angiotensin receptor blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
2406198|NCT03529838|Active Comparator|Beta blockers|Group of hypertensive women taking Beta blockers who practiced 12 weeks of training with Combined Exercise Training, non-obese, nonsmokers and with no characteristics that prevented them from performing the activities. In addition this group could not modify the dose or type of the medicine and should be using the same medicine and dose for at least 6 months
3144439|NCT00040404|Experimental|CEP-1347 50mg|CEP-1347 was administered at a dosage of 50mg twice daily (bid); capsule strengths were 5, 12.5, and 25 mg. Each patient took 2 capsules at each dosing time, approximately 12 hours apart, within 30 minutes after the morning and evening meals) for a total of 4 capsules per day.Patients were randomly assigned to CEP-1347 or placebo treatment in a 1:1:1:1 ratio. A blocked randomization scheme was used to ensure approximately equal numbers of patients in each of the 4 treatment groups at each center.
3185075|NCT00731250|Placebo Comparator|PART 1-Visit 2-Placebo|Eligible subjects will receive matching placebo tablets
2406201|NCT03529812|Experimental|Early-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education during the first unit of their year-long residency.
2406202|NCT03529812|Active Comparator|Delayed-start group for CBCT-informed training|Hospital chaplain residents receiving the Cognitively-Based Compassion Training (CBCT) education midway through their year-long residency.
3185076|NCT00731250|Experimental|PART 1-Visit 2-Capsaicin|Eligible subjects will receive maximum capsaicin dose
3185077|NCT00731250|Placebo Comparator|PART 1-Visit 3-Placebo|Eligible subjects will receive matching placebo tablets
3185078|NCT00731250|Experimental|PART 1-Visit 3-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
3185079|NCT00731250|Placebo Comparator|PART 2-Visit 1-Placebo|Eligible subjects will receive matching placebo tablets
3185080|NCT00731250|Experimental|PART 2-Visit 1-SB-705498|Eligible subjects will receive SB-705498 tablets
3185081|NCT00731250|Experimental|PART 2-Visit 2-Capsaicin|Eligible subjects will receive matching placebo tablets incremental capsaicin doses
2406226|NCT03529747|Experimental|Online self-help|A website providing information and psycho-education aimed at parents and carers of children with food allergies.
2406227|NCT03529747|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help once the RCT is complete.
2406228|NCT03529734|Experimental|12 min running group|This group will perform a 12 min high intensity running with the goal to cover maximal possible distance.
2406229|NCT03529734|Experimental|Local strengthening exercise group|This group will perform local strengthening exercises (curl-ups, left side trunk flexion, trunk extension, right side trunk flexion). Each participant will have to perform three sets of each exercise with the maximal possible number of repetitions with a slow tempo (1s concentric phase and 2 s eccentric phase). Between sets, minimal rest (15 s) will be administered.
2406230|NCT03529721|Experimental|zumba dance group|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
2406231|NCT03529721|Placebo Comparator|non zumba dance group|the control group will be required to carry on doing their normal daily activities throughout the 8-week period.
2406232|NCT03529708|Experimental|SBRT boost|Standard radiotherapy (3D conformal, urgent palliative radiotherapy) plus stereotactic body radiotherapy (SBRT) boost
2406233|NCT03529695|Active Comparator|Standard HVP Curriculum|"Participants will receive the standard Healthy Families America (HFA) home visitation curriculum delivered by trained home visitors. The HFA model meets the Department of Health and Human Services criteria for an evidence-based early childhood home visiting service delivery model. HFA services begin prenatally and continue until children are 2-5yo. The curriculum focuses on strengthening parent-child relationships and family functioning, promoting positive child development, and linkage to community resources. Accredited home visitors are matched to families on cultural background and language, to provide culturally sensitive services. Home visitors receive weekly supervision, ongoing developmental training, and have limited caseloads (10-15 families) to meet their families' needs."
2406234|NCT03529695|Experimental|Obesity Prevention|Participants will receive the standard Healthy Families America home visitation curriculum with the obesity prevention enhancement module, delivered by trained home visitors. Families are matched to home visitors based on their ethnicity/race and language preferences. The obesity prevention program targets 4 key behaviors (physical activity, fruit and vegetable consumption, sugary beverages, fried foods) aimed at reducing obesity risks in mothers and their children. Participants will also be provided opportunities to meet in groups with other participating mothers/infants to enhance social networks that support healthy eating and physical activity.
2406235|NCT03529682|Experimental|Circuit Training Group|Circuit exercise training will be given to the experimental group participants during 10 weeks, 60 minutes in a day and 3 times a week.
2406236|NCT03529682|Other|Control Group|The control group participants will continue to their own previous physiotherapy approaches as the same as minimum 3 times a week and total 3 hours.
2406237|NCT03529669|Experimental|Cytosponge™|All participants will receive the Cytosponge™ device.
2406238|NCT03529656|No Intervention|Pre-ERP|A group of patients who underwent liver transplantation surgery before the early rehabilitation program
2406239|NCT03529656|Experimental|Post-ERP|A group of immediate liver transplant patients who had an early rehabilitation program in ICU care
2406240|NCT03529643|Experimental|Anesthesia with dexmedetomidine|"Anesthesia with sevoflurane-remifentanil-dexmedetomidine~Dexmedetomidine :Continuous infusion of dexmedetomidine with loading dose of 1.0 μg/kg (0.25 ml/kg) for 10 minutes, then followed by maintenance dose of 0.4 µg/kg/hr (0.1 ml/kg/hr)."
2406241|NCT03529643|Placebo Comparator|Anesthesia without dexmedetomidine|"Anesthesia with sevoflurane-remifentanil~Normal saline :Continuous infusion of normal saline with loading dose (0.25 ml/kg) for 10 minutes, then followed by maintenance dose (0.1 ml/kg/hr)."
2406242|NCT03529630|Experimental|Inverted syringe|Participants in this arm will use of the inverted syringe before each breastfeeding starting from the first feed after delivery and continued as long as needed by the mother.
2406243|NCT03529630|No Intervention|Standard of care|Participants in the control group will receive standard medical care as dictated by their obstetricians. Any advice regarding infant nutrition or treatment of inverted nipples will be left to the primary physician, including possible use of the inverted syringe technique. .
2406244|NCT03529617||Critically ill patients|Patients admitted on ICU.
2406245|NCT03529617||Hematology patients|Patients admitted on the hematology ward.
2406246|NCT03529604||Oral Cancer group|Patients with pathohistologically diagnosed T1 conventional oral squamous cell carcinoma. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
2406247|NCT03529604||PMOD group|Patients with clinically diagnosed leukoplakia, erythroplakia and oral lichen planus. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
2406248|NCT03529604||Control|Age and sex matched subjects. The investigators will collect saliva from the mouth floor (saliva sampling), measure SCCA1, SCCA2 and TROP2 using ELISA tests and measure Ap4A levels using HPLC.
2406249|NCT03529591|Active Comparator|180 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
2406250|NCT03529591|Active Comparator|360 deg selective laser trabeculoplasty|The right eye of a patient is randomized to be treated with either 180 or 360 degrees selective laser trabeculoplasty (SLT). The fellow eye is treated with the opposite treatment, that is, if the right eye is treated with 180 degrees SLT, the left eye is treated with 360 degrees SLT. Intraocular pressure (IOP) response is assessed at 2 weeks, one, three and six months post treatment and compared to the alternative treatment arm, the fellow eye.
2406251|NCT03529578|Experimental|dHACM|Standard of Care plus Weekly Application of dHACM
3144440|NCT00040404|Placebo Comparator|Placebo|Placebo capsules matching the CEP-1347 capsules were administered in the same manner.
2406253|NCT03529552|Experimental|Patients with anterior cruciate ligament rupture|
2406254|NCT03529526|Experimental|KN046|
2406255|NCT03529513||Depressed|Subjects currently experiencing a moderate-to-severe major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
2406256|NCT03529513||Control|Subjects not currently experiencing a major depressive episode are clinically evaluated over approximately 2-week period. 24-hour ECG data recordings are collected during each of the two weeks. Subjects may continue on current treatment regimen.
2406257|NCT03529500||Adequate nutritional status|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2406258|NCT03529500||Mild malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2406259|NCT03529500||Moderate malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2406260|NCT03529500||Severe malnutrition|Dental caries experience was recorded using the dmft index. Active visible white spots were also recorded. Samples of non-stimulated saliva were collected from the participants for five minutes. The salivary flow volume was calculated and expressed as ml/min. After the measurement of salivary flow, an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC).
2406261|NCT03529487|Experimental|Oxymetazoline applied intra analy|
2406262|NCT03529474|Experimental|Psychology and Physiotherapy group|The psychological program consists of 4 sessions (2 hours each) comprising psychoeducation, training techniques of psychological management of pain and kinesiophobia resources The physiotherapy program consists of 3 domiciliary sessions per week, including physical exercise and stretching
2406263|NCT03529474|Placebo Comparator|Placebo Comparator: Control group|Usual daily activities
3185082|NCT00731263|Experimental|1|The study will start with AZD8055 formulated in a liquid solution prior to the tablet formulation becoming available. The tablet formulation will be introduced in Part A at the beginning of a new cohort at an appropriate dose, no higher than the dose of the liquid formulation in the last completed evaluated cohort. Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
2406266|NCT03529448|Experimental|TN-TC11G, radiotherapy and Temozolomide Oral Product|"During Phase Ib, Four to seven weeks after surgical diagnosis, concurrent with radiotherapy (STUPP)~+ temozolomide (75mg/m2/day for 42 days) +TN-TC11G will be evaluated. During radiation therapy, temozolomide and TN-TC11G will be administered. This last, as the dose that have been selected previously, based on dose-titration period. Patient specific dose will remain until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
2406267|NCT03529435|Active Comparator|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
2406268|NCT03529435|Experimental|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
2406269|NCT03529422|Other|Open-label, single-arm|Durvalumab in combination with intensity modulated radiotherapy (IMRT) treatments
2406272|NCT03529396|Experimental|1a: Chloroquine + 5th-day Primaquine|[ARM HALTED PREMATURELY DUE TO SAFETY CONCERNS]
2406273|NCT03529396|Experimental|1b: Chloroquine + 8-week Primaquine|26 G6PD deficient patients. Directly observed therapy.
2406274|NCT03529396|Active Comparator|1c: Chloroquine + 12-week Chloroquine|26 G6PD deficient patients. Control group in terms of safety. Directly observed therapy.
2406275|NCT03529396|Active Comparator|2: Standard chloroquine + primaquine|52 G6PD normal patients. Control group in terms of efficacy. Directly observed therapy.
2406314|NCT03529084|Active Comparator|Investigator's Choice|Investigator's Choice (erlotinib or gefitinib).
2406315|NCT03529071|Experimental|CKD-Question Prompt Sheet|Study participants will receive the CKD-QPS.
3144441|NCT00040456|Placebo Comparator|Placebo|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
2406282|NCT03529331|Active Comparator|Morphine Sulfate Immediate Release|ED patients at discharge will receive 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days.
2406283|NCT03529331|Active Comparator|Oxycodone/Acetaminophen (Percocet),|ED patients at discharge will receive 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days.
2406284|NCT03529331|Active Comparator|Hydrocodone/Acetaminophen (Vicodin)|ED patients at discharge will receive 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days.
2406285|NCT03529305|Experimental|Low frequency rTMS|Patients receive low frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the unaffected side for two weeks, 5 consecutive days each week.
2406286|NCT03529305|Experimental|High frequency rTMS|Patients receive high frequency rTMS treatment and physical therapy. rTMS is applied over primary motor (M1) cortex of the affected side for two weeks, 5 consecutive days each week.
2406287|NCT03529305|Active Comparator|Physical therapy|Patients receive physical therapy for two weeks.
2406289|NCT03529279|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive CNG staging and CNG chemotherapy strategy and CNG radiation strategy
2406290|NCT03529279|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive the eighth edition of UICC/AJCC staging and NCCN chemotherapy strategy and NCCN radiation strategy
2406291|NCT03529266|Experimental|A(Surgery+PFS)|Arm A consists of the concurrent application of Porcine Fibrin Sealant (PFS) on the gastroesophageal or coloesophageal anastomosis during Mckeown surgery .
2406292|NCT03529253|Experimental|Intensive therapy group|Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
2406293|NCT03529253|Active Comparator|Standard therapy group|The standard therapy group is Rosuvastatin10mg/daily alone.
2406294|NCT03529240|Experimental|Kinesiology taping|After performing the baseline assessments, kinesiology taping with facilitation technique was applied on bilateral quadriceps and tibialis anterior muscles of children. In both applications, the first and last 5 cm section of the bands were used as anchor and no tension was applied.
2406295|NCT03529214|Other|Implemented Health Facility|"Health facility that has piloted the Team Birth Project"
2406296|NCT03529201|Experimental|QLB|At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
2406297|NCT03529201|Experimental|Control|Standard care. No regional blocks.
2406298|NCT03529175|Active Comparator|Concomitant|Intravenous Abraxane125 mg/m2 30-minute infusion followed immediately by intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle.
2406299|NCT03529175|Active Comparator|Sequential|Intravenous Abraxane 125 mg/m2 30-minute infusion will be administered on days 1, 8 and 15 of a 4-week cycle. Intravenous Gemcitabine 1000 mg/m2 30-minute infusion will be administered on days 2, 9 and 16 of a 4-week cycle. Gemcitabine must be delivered 24 +/- 2 hours after commencing Abraxane infusion.
3185083|NCT00731276|Other|Four Regimens|"The study has four type of regimens, and dosing of irinotecan depends on genotype of patient.~Four Regimens are:~Weekly Irinotecan (Irinotecan given at day 1, 8 and 15) every four weekly~Weekly Xeliri ( Irinotecan given at day 1, 8 and 15)+ (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Three-weekly Xeliri (Irinotecan given at day 1 only) + (Xeloda tabs 2000mg/m2 consumed over 14 days) every three weekly~Two-weekly FOLFIRI (Irinotecan given at day 1 only) + (CI Fluorouracil 600mg/m2 over 22hrs, IV Folinic Acid 200mg/m2 over 2hrs and IVP Fluorouracil 400mg/m2) every two weekly"
2406302|NCT03529149|Experimental|Accurate blood pressure control|Implementing accurate blood pressure management under TCD monitoring
2406303|NCT03529149|Active Comparator|Guideline blood pressure control|Control blood pressure according to guidelines
2406304|NCT03529136|Experimental|MSC group 1|Procedure:UC-MSC infusion via peripheral vein. Four times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 1(once every 4 days).
2406305|NCT03529136|Experimental|MSC group 2|Procedure:UC-MSC infusion via peripheral vein. Two times of MSC infusion (1.5x10E6 cells/kg body weight) via peripheral vein will be given to the group 2(once every 7 days).
2406306|NCT03529136|Experimental|Control group|Control group with standard medical care. UC-MSC infusion could be considering in this group after 24 weeks' followed-up.
2406307|NCT03529123|Experimental|Tested Drug|Insulin glargine/lixisenatide fixed ratio combination (FRC)
2406308|NCT03529123|Active Comparator|Control Drug|Insulin glargine (Lantus®)
2406309|NCT03529110|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with DS-8201a
2406310|NCT03529110|Active Comparator|Ado-trastuzumab emtansine (T-DM1)|HER2-positive, unresectable and/or metastatic breast cancer participants previously treated with trastuzumab and taxane randomized to treatment with T-DM1
2406311|NCT03529097|Active Comparator|Fluids|Intervention: 2 liters of 0.9% NaCl IV during the ER stay with pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
2406312|NCT03529097|Placebo Comparator|Placebo|No interventions, Only pain killers. For placebo purposes this arm participants will get an infusion with black cover so they could not tell if it drips or not
2406313|NCT03529084|Experimental|EGF816|Investigational treatment arm of EGF816 (nazartinib).
2406317|NCT03529045||VNS Therapy|Any approved VNS Therapy System (according to local regulations) may be used in this registry.
2406318|NCT03529032|No Intervention|Fentanyl group|Drug: Fentanyl Fentanyl group 3µg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
2406319|NCT03529032|Experimental|methadone group|Drug: methadone methadone group 0.2mg/kg to start surgery TIVA: general anesthesia will be based on Fentanyl an Propofol, titrated to achieve bispectral index (BIS) between 40-60.
2406320|NCT03529019|Experimental|Nutritional Supplement|Administration of Ensure Surgery Immunonutrition Shake and ensure Enlive Advanced Nutrition Shake.
2406321|NCT03529006|Active Comparator|Sequent Please Drug Coated Balloon Group|For Sequent Please Group, PCI (percutaneous coronary intervention) PCI procedure with Sequent Please inflation will be performed - drug eluting balloon will be used in the narrowed part of the artery. This method of treatment is one of the standard ones, which is typically used for treatment patients with diagnosis of in stent restenosis, the exact intervention and anesthesia procedures will be performed according to physician's usual practice. For bailout situation Xience stent implantation is possible.
2406322|NCT03529006|Active Comparator|Absorb Stent Group|Absorb scaffold group will be treated by PCI procedure with Absorb BVS implantation - implantation of bioresorbable vascular scaffold (Absorb). Coronary stent implantation for treatment in stent restenosis is one of the standard method of treatment this disease, but Absorb system has not been investigated in this indication yet.
2406323|NCT03528993|Experimental|Exercise by hippotherapy device group|The experimental group receive conventional rehabilitation for 45 min/day following by use of a hippotherapy device for 15 min/day, 5 times/week for 4 weeks
2406324|NCT03528993|Other|Control group|The control group will receive conventional rehabilitation for 45 min/day, following by postural control exercises 15 min/day 5 times/week for 4 weeks.
2406325|NCT03528980||Bariatric surgery|
2406326|NCT03528980||standard nutritional management|
2406327|NCT03528967|Experimental|Arm 1|"Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization:~Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily~Start treatment from inclusion visit~Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)"
2406328|NCT03528967|Other|Arm 2|"Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization:~Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily~Administer orally~Start treatment from inclusion visit~Maintain treatment until 35 Weeks of Amenorrhea (WA)"
2406329|NCT03528954|Active Comparator|Propofol|Received intravenous 0.5mg/kg propofol
2406330|NCT03528954|No Intervention|Control|Do not received intravenous 0.5 mg/kg propofol
2406331|NCT03528941||Lamivudine|Patients who received lamivudine
2406332|NCT03528941||No prophylaxis|Patients who did not receive any prophylaxis
2406333|NCT03528928|Experimental|Surface electrical stimulation|Each subject did a Kegel pelvic floor contraction, had the surface electrical stimulation turned on at highest comfortable intensity, did a Kegel contraction with surface electrical stimulation on, and had second electrical stimulation turned on.
2406334|NCT03528915||Prophylaxis group|Newborns treated with rifamycin eye drops systemically two months before change of practices in delivery room.
2406335|NCT03528915||no-antibiotic group|Newborns not treated with antibiotic prophylaxis in a systemic way, according to the new french guidelines of January 1st, 2015.
2406336|NCT03528902|Experimental|Tamoxifen|20 mg po TID for 24 weeks
2406337|NCT03528902|Placebo Comparator|Placebo|Placebo arm
2406338|NCT03528889|Active Comparator|Goniometer|Extension FDO: classic procedure with goniometer controlled extension and derotation
2406339|NCT03528889|Experimental|EMT|Extension FDO: procedure with electromagnetic tracking (EMT) controlling extension and derotation
2406340|NCT03528876|Other|Single arm intervention study|Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)
2406341|NCT03528863|Experimental|Supportive Care (web-based mindfulness meditation)|Participants practice with web-based mindfulness meditation over 10-15 minute guided audio sessions for 5 days a week for 8 weeks. Participants also attend meditation webinars over 60 minutes once a week, for 8 weeks.
2406342|NCT03528850|Experimental|Telehealth|The Telehealth arm will receive daily biometric measurement of blood pressure, heart rate, oxygen saturation and weight. The Telehealth arm will also have weekly virtual visits for the first month after hospital discharge. The Telehealth arm will answer surveys weekly for the first 30 days.
2406343|NCT03528850|No Intervention|Standard of Care|The Standard of Care will receive no interventions but will conduct surveys at enrollment and at the end of 30 days.
2406344|NCT03528837||Diagnosed as acute kidney injury|Sure diagnosed as acute kidney injury
2406345|NCT03528824|Experimental|Fenugreek wraps|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
2406346|NCT03528824|Active Comparator|Diclofenac gel|Daily application of diclofenac gel, 4 weeks application
2406347|NCT03528824|No Intervention|Usual care|no specific intervention
2406348|NCT03528811|Other|Five points test of Tongji university|"We established the evaluatation and follow-up system of diabetes vascular disease based on the method called Five points test of Tongji university ."
2406349|NCT03528785|Experimental|Single Arm|All patients will receive a treatment scheme of Irinotecan Liposomal Injection [Onivyde], oxaliplatin, Levofolinic Acid and 5-fluorouracil (5 -FU) on Day 1 and Day 15 of each 28 day cycles.
2406350|NCT03528772|Active Comparator|Minoxidil|Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
2406351|NCT03528772|Active Comparator|Glyceryl trinitrate|Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
2406352|NCT03528746|Experimental|Isometric exercise|Participants will complete isometric quadriceps exercise
2406353|NCT03528746|Active Comparator|Isotonic exercise|Participants will complete dynamic leg extension
2406354|NCT03528733|Experimental|Multi-Energy Detector|Multi-Energy Digital Radiography Detector System
2406355|NCT03528707|Active Comparator|probiotic-omega|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day.
2406356|NCT03528707|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
3144442|NCT00040456|Active Comparator|MG Pidolate Administration|"A computer-generated randomization list will be created by a Baylor College of Medicine statistician (unrelated to study) prior to the study.~Patients are randomly assigned to either start with Mg pidolate or placebo and will continue that therapy for 24 weeks. Then, after a 2 month wash-out period, they will be switched to the other arm and continue on that arm for another 24 weeks, followed by 8 weeks of observation off study drug. Both patient and medical care provider(s) will be blinded to treatment assignment. Mg pidolate and placebo will be distributed through the pharmacy with labels that do not indicate the assignment."
3144443|NCT00040677|Experimental|ICA-17043 Low Dose 6 mg/day|Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
3144444|NCT00040677|Placebo Comparator|Placebo|
3144445|NCT00040677|Experimental|ICA-17043 High Dose 10 mg/day|Active study medication: 150 mg loading dose; 10 mg maintenance dose per day
3144446|NCT00040755|Experimental|Arm I (rebimastat once daily)|Patients receive oral BMS-275291 once daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
3144447|NCT00040755|Experimental|Arm II (rebimastat twice daily)|Patients receive oral BMS-275291 twice daily on days 1-28. Treatment repeats every 28 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR.
2406363|NCT03528655|Experimental|Decision aid group|Shared decision making using decision aid
2406364|NCT03528655|No Intervention|Controlled group|Standard oral explanation with booklet.
3144448|NCT00040768|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who received prior bortezomib and achieved at least a partial response of at least 6 months duration may also receive therapy as above.
2406366|NCT03528629|Experimental|Safety Part Arm A (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
2406367|NCT03528629|Experimental|Safety Part Arm B (IMAB362 dose-3)|Participants will receive a loading dose-3 of IMAB362 on Day 1 of each cycle (every 3 weeks).
2406368|NCT03528629|Experimental|Expansion Part (IMAB362 dose-1/2)|Participants will receive a loading dose-1 of IMAB362 on Cycle 1 Day 1 followed by a lower dose-2 in subsequent every 3 weeks.
2406369|NCT03528603|Experimental|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that is high in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Low Extra Virgin Olive Oil
2406370|NCT03528603|Placebo Comparator|Oleocanthal-Low Extra Virgin Olive Oil|Extra Virgin Olive Oil that is low in the phenolic oleocanthal, but contains similar amounts of total phenolics as the Oleocanthal-Rich Extra Virgin Olive Oil
2406371|NCT03528590|Active Comparator|size 3 i-gel®|size 3 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
2406372|NCT03528590|Experimental|size 4 i-gel®|size 4 i-gel supraglottic airway device in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
2406377|NCT03528564|Experimental|Epoetin alfa|Preoperative treatment of anemia with iron sucrose (Venofer) plus Epoetin Alfa (Eprex)
2406378|NCT03528564|Placebo Comparator|Intravenous Iron|Preoperative treatment of anemia with iron sucrose (Venofer) plus placebo (saline)
3144449|NCT00040781|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3144450|NCT00040794|Experimental|Stratum I (gefitinib, radiotherapy)|"Patients receive gefitinib orally (PO) daily for 7 weeks. Patients also undergo concurrent radiotherapy once daily 5 days a week for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
3144451|NCT00040794|Experimental|Stratum II (gefitinib, radiotherapy, chemotherapy)|"Patients receive gefitinib and radiotherapy as in stratum I concurrently with paclitaxel IV over 1 hour followed by carboplatin over 30 minutes once weekly for 7 weeks.~Patients then receive gefitinib PO daily in the absence of disease progression or unacceptable toxicity."
2406382|NCT03528538|Placebo Comparator|Placebo|
2406383|NCT03528538|Active Comparator|AlphaFen fenugreek 400 mg|This group received 400 mg of fenugreek to be ingested daily for 60 days.
2406384|NCT03528538|Active Comparator|AlphaFen fenugreek 500 mg|This group received 500 mg of fenugreek to be ingested daily.
2406385|NCT03528525||Monogenic diseases cases|
2406388|NCT03528499|Experimental|Scapular Movement Training|Orientation and scapular exercises, performed twice a week, for 8 weeks.
2406389|NCT03528499|Active Comparator|General Exercises|Scapulothoracic muscle stretching and strengthening exercises, performed twice a week, for 8 weeks.
2406390|NCT03528486|Experimental|Music Training I|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument.
2406391|NCT03528486|Active Comparator|Music Training II|Participants will complete a type of music training including listening to music, learning about music, or learning to read music, or play a musical instrument
2406392|NCT03528473|Experimental|Exercise|Patients involved in the 6 months-physical training group.
2406393|NCT03528473|No Intervention|Control|Patients in control group carry on their usual follow-up programme.
2406395|NCT03528434|Experimental|Zinc|Dietary Supplement: Zinc 10mg dispersible zinc sulfate tablet
2406396|NCT03528434|Placebo Comparator|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
2406397|NCT03528421|Experimental|IM19 CAR-T cells|3*10^5/kg，1*10^6/kg，3*10^6/kg IM19 CAR-T cell.Two days before cell infusion, all patients will be treated with fludarabine and Cyclophosphamide for 3 days
2406476|NCT03527875|Experimental|ENBD group|Endoscopic Nasobiliary Biliary Drainage
2406399|NCT03528395|Experimental|Semi-immersive virtual reality|8 week protocol with semi-immersive virtual reality provided with the XBOX 360º video game console and its Kinect device. The commercial video games used will be: Kinect Sports I ®, Kinect Sport II ®, Kinect Joy Ride ® and Kinect Adventures ®.
2406400|NCT03528395|Active Comparator|Conventional Rehabilitation|Physical therapy and Occupational Therapy based on a task-oriented approach
3185084|NCT00731289|Experimental|1|single intraarticular injection of hyaluronan 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
3185085|NCT00731289|Active Comparator|2|single intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
3185086|NCT00731302|Experimental|Aspirin and Meloxicam|Arm: Aspirin and Meloxicam Each participant will receive 81 mg aspirin per day for 7 days, followed by meloxicam 7.5 mg daily plus aspirin 81 mg daily for 5 days
3185087|NCT00731315|Experimental|Treatment Group 1 - uncomplicated UTI|Would receive computer-assisted treatment for a uncomplicated UTI.
3185088|NCT00731315|Active Comparator|Control Group 1|Qualified for expedited treatment for uncomplicated cystitis but would receive usual care in the Emergency Department of Community Health Center.
2406407|NCT03528356|Placebo Comparator|Regular diet|
2406408|NCT03528356|Experimental|White diet|
2406409|NCT03528343|Experimental|Tylenol/Motrin|Group of patients who will receive instructions to use tylenol and motrin for pain control, and parents will be sent home with a paper prescription with a rescue does of standard of care narcotics. They will be instructed to only use the rescue dose if pain is uncontrolled using over the counter medications.
2406410|NCT03528343|No Intervention|Narcotic|Group of patients who will receive the standard of care narcotic prescription filled upon discharge.
2406411|NCT03528330|Active Comparator|Internal hexagon connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Internal Hex (IH) implant has a 2.5mm internal hexagon and a 90° cone. The platform diameter is Ø3.5mm."
2406412|NCT03528330|Experimental|Conical connection|"Small flaps will be elevated to reduce any kind of injury on the periosteum and maintain the blood supply during the healing period.~Patients will receive 2 implants. One implant (assigned randomly) will have internal hexagon connection.~The Conical Standard (CS) implant has a 2.5mm internal hexagon and 22° cone. The platform diameter is Ø3.1mm."
2406413|NCT03528317|Experimental|Alternate day fasting|Alternate day fasting with a high protein diet
2406414|NCT03528304|Experimental|Smoking arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking.
2406415|NCT03528304|Experimental|Weight loss arm|As part of the CM intervention women attend visits for smoking and weight loss assessment and are rewarded with prizes for losing some weight.
2406416|NCT03528304|Experimental|Smoking and weight loss arm|As part of the CM intervention, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining from smoking and for losing some weight.
2406417|NCT03528304|No Intervention|Control|Women attended clinic visits for smoking status and weight loss assessment.
2406418|NCT03528291||Cardiogenic shock treated with medical treatment|Patients with cardiogenic shock treated only by medical treatment
2406419|NCT03528291||Cardiogenic shock treated with transient circulatory support|Patients where transient circulatory support was implanted: veno-arterial extracorporeal circulatory life support (ECLS), Impella
2406420|NCT03528265||Patients with melioidosis-like symptoms admitted to Kapit Hosp|
2406421|NCT03528252|Active Comparator|LDL Cholesterol|Will receive dietary advice effective for reducing LDL cholesterol.
2406422|NCT03528252|Sham Comparator|Triglycerides|Will not be aware that they are in fact Control Group. Will receive dietary advice effective for reducing Triglycerides, but neutral for LDL cholesterol.
2406423|NCT03528226|Experimental|Exercise Training|
2406424|NCT03528226|Other|Control|
2406425|NCT03528213|Sham Comparator|Normal saline|at physician discretion
2406426|NCT03528213|Experimental|Sodium lactate light dose|bolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
2406427|NCT03528213|Experimental|Sodium lactate high dose|bolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
2406428|NCT03528200|Other|Dyna Embo|Contrast dye injected through the IV in their arm which helps to see the blood in the arteries using x-ray pictures
2406429|NCT03528187||Patient Cohort 1|"Age 18 or over~BMI greater than or equal to 30 (greater than or equal to 27.5 for patients of Asian origin)~Due to undergo or referred for a formal treatment intervention for obesity (lifestyle modifications [dietary change, behavioural therapy, increased physical activity], surgical intervention or pharmacological treatment) as part of their usual clinical care~Informed written consent~Able to tolerate MRI"
2406430|NCT03528187||Patient Cohort 2|"Age 18 or over~Attending weight management service at UCLH~Informed written consent~Able to tolerate MRI"
2406431|NCT03528187||Controls|"Age 18 or over~BMI less than 25~Informed written consent~Able to tolerate MRI"
2406433|NCT03528148|Experimental|active cycling group|effect of combine cycling and conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
2406434|NCT03528148|Active Comparator|control group|effect of combine conventional physical therapy in quality of life, functional activity and ADL, postural control, balance, muscle tone, spasticity, motor functioning, gait of stroke patients.
2406435|NCT03528135|Experimental|Project PRIDE|"Those in the Project PRIDE condition will receive 8 weekly sessions, each lasting 2.5 hours and consisting of approximately 10 men (estimated number given expected attrition). Each session will be co-led by two trained group facilitators. The intervention sessions are described in the Detailed Description section. The will complete a pre-test, post-test, and follow-up assessment."
2406436|NCT03528135|No Intervention|Wait-list|Those in the wait-list arm will wait approximately 5 months before receiving the intervention. They will complete the same pre-test, post-test, and follow-up assessments as those in the PRIDE arm. After they have completed the follow-up assessment, they will be offered the intervention.
2406437|NCT03528122|Experimental|Recurrent opened macular hole|Pars plana vitrectomy with internal limiting membrane peel if not peeled in the first surgery and application of amniotic membrane graft
2406438|NCT03528109|Experimental|patient-centered home CBT|60 minute office-based exposure therapy with a PhD psychologist once per month and a 90 minute community-based CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week)
2406439|NCT03528109|Active Comparator|Provider-centered|60 minute office-based exposure therapy with a PhD psychologist four times per month (once per week)
2406440|NCT03528109|Experimental|patient-centered telehealth CBT|60 minute telehealth exposure therapy with a PhD psychologist once per month and a 90 minute telehealth CBT with a mobile exposure coach three times per month for a total of four visits per month (once per week). Patient-centered telehealth was closed when the recruitment goal was met in May 2021.
2406441|NCT03528096|Experimental|Intervention night|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat B rocking bed. Stimulation is provided for the first 60 minutes of the night and for 10 minutes upon detection of symptoms. The stimulation frequency is in the range of 0.25-2 Hz.
2406442|NCT03528096|Sham Comparator|Baseline night|The sound of the moving bed is played back to the participant at the right sound intensity level.
2406443|NCT03528083|No Intervention|Retrospective Controls|A retrospective control group of patients with a diagnosis of bronchiolitis and meeting inclusion criteria will be used as a comparison group. These patients received usual care for bronchiolitis at our institution.
2406444|NCT03528083|Experimental|Quality Improvement|All patients diagnosed with bronchiolitis and meeting inclusion criteria will undergo the intervention of a bronchiolitis quality improvement process to improve bronchiolitis care quality at our institution.
2406445|NCT03528070|Experimental|Tranilast|
2406446|NCT03528057|Active Comparator|Group 1|Patients undergoing RALPN with the use of HAs by a surgeon.
2406447|NCT03528057|No Intervention|Group 2|Patients undergoing RALPN without the use of HAs by a surgeon
2406448|NCT03528044|Experimental|Patients undergoing bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
2406449|NCT03528044|No Intervention|Control group|Healthy controls with normal BMI.
2406450|NCT03528031|Experimental|Intervention Daily Avocado|Participants will follow their usual diet and lifestyle but also be provided with 1 avocado to consume per day for 6 months. To maximize compliance, participants will be provided with resources on how to choose, store and ripen avocados along with simple usage ideas. Specific nutrition guidance will not be provided. Participants will pick up fresh avocados every 2 weeks with minimal interaction with study personnel. Compliance visits will be conducted monthly.
2406451|NCT03528031|No Intervention|Control Usual Diet and Lifestyle|Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
2406452|NCT03528018|Other|Control|Conventional physical therapy
2406453|NCT03528018|Experimental|Experimental|Combined tDCS and VR-based intervention
2406454|NCT03528005|No Intervention|Control|A regular health education program was provided by case managers only.
2406455|NCT03528005|Experimental|Intervention|Multi-domain intervention included exercise,cognitive training, diet education, and disease consultation was conducted for two hours twice per week in the first month, once per week in the second month, and once per month since third month.
2406456|NCT03527992|Other|Automated oxygen therapy|An automated oxygen therapy is a system that allows administration of oxygen with a flow that is automatically adjusted to the patient's saturation, which is continuously monitored. Patients will receive O2 automated intervention.
2406457|NCT03527992|Other|Standard Oxygen therapy|Patients will receive O2 standard therapy
2406458|NCT03527979|Active Comparator|PCOS women with history of LOD before IVF/ICSI|
2406459|NCT03527979|Active Comparator|PCOS women without history of drilling|
3185089|NCT00731315|Experimental|Treatment Group 2 - Complicated Cystitis|Would receive expedited treatment for complicated cystitis with longer antibiotic course than the simple UTI patients.
2406462|NCT03527953|Active Comparator|Tetric EvoCeram BulkFill resin|Randomly applied
2406463|NCT03527953|Active Comparator|Surefil SDR Flowable bulk-fill resin|Randomly applied
2406464|NCT03527953|Active Comparator|everX fiber-reinforced resin|Randomly applied
2406465|NCT03527940||Patients with STEMI|
2406466|NCT03527927|Experimental|LABA/LAMA inhaler|Patients on a combination of inhaled corticosteroid (ICS), long acting beta agonist (LABA) and long acting muscarinic antagonist (LAMA) will be taken off their current ICS/LABA/LAMA combination inhalers and will commence on a single LABA/LAMA inhaler (any LABA/LAMA) of their choice.
2406467|NCT03527914|Active Comparator|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
2406468|NCT03527914|Experimental|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
2406469|NCT03527901||Chronic periodontitis|This groups participant has radiographically moderate alveolar bone loss, CAL > 5 mm and PD >6 mm in several sites of each quadrant
2406470|NCT03527901||Generalized aggressive periodontitis|This demonstrated a generalized pattern of severe breakdown and CAL > 5 mm and PD > 6 mm on 8 > teeth; minimum three of those were other than first incisors or first molars
2406471|NCT03527901||Gingivitis|This group has varying degrees of gingival inflammation, with CAL < 2 mm, without any radiographical bone loss due to periodontitis
2406472|NCT03527901||Implant|Implants classified PD < 5 mm, no bleeding on probing, no suppuration and no radiographic bone loss > 0.5 mm
2406473|NCT03527901||Health|Probing depth (PD) < 3mm, no gingival recession due to periodontal disease, and clinical attachment level (CAL) < 2 mm, BOP in < 10% of full-mouth score examination
2406474|NCT03527888|Other|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2406475|NCT03527875|Experimental|PTBD group|Percutaneous Transhepatic Biliary Drainage
2406478|NCT03527875|No Intervention|Without PBD group|receive surgery without PBD
2406479|NCT03527862|No Intervention|Control group|No intervention is performed. Lung ultrasonography is performed within 4 hours after surgery for diagnostic purpose.
2406480|NCT03527862|Experimental|lung ultrasonography group|Lung ultrasonography is performed three times; after tracheal intubation, before surgery end, and within 4 hours after surgery. In this group, respiratory management is performed according to diagnosis.
2406481|NCT03527849|Experimental|In-Person MBSR Course|
2406482|NCT03527849|Experimental|Online MBSR Course|
2406483|NCT03527849|Active Comparator|In-Person HEP|
2406484|NCT03527836|Active Comparator|Lidocaine|Lidocaine brachial plexus block 0.4 ml/kg of 0.66% solution
2406485|NCT03527836|Active Comparator|Bupivacaine|Bupivacaine brachial plexus block 0.4 ml/kg of 0.33% solution
2406486|NCT03527836|Active Comparator|Mixture|Mixture brachial plexus block 0.4 ml/kg of 0.33% bupivacaine and 0.33% lidocaine solution
2406487|NCT03527823||LH supplementation|luteinizing hormone administrated microdose flare up GnRH analog protocol in poor ovarian responders undergoing in vitro fertilization.
2406488|NCT03527823||without LH supplementation|microdose flare up GnRH analog protocol in poor ovarian responders
2406489|NCT03527810|Experimental|Sleeve Gastrectomy With Interrogation of Hiatus|In those randomized to interrogation, the hiatus will be opened posteriorly during surgical procedure intervention with preservation of the phreno-esophageal ligament where possible, as per standard described techniques. Dissection into the mediastinum will be stopped if no hernia is seen or when appropriate intra-abdominal length of 2 cm of esophagus is created. Once opened, the Hiatal Surface Area will be measured, calculated and recorded and when possible, a photo taken of the area. Repair of the crura will then be performed around the sizing tube used to create the sleeve with enough space to allow a 5 mm instrument to be easily inserted. Permanent sutures will be placed posterior to the esophagus.
2406490|NCT03527810|Active Comparator|Sleeve Gastrectomy Without Interrogation of Hiatus|In those randomized without interrogation, the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature. The procedure involves a longitudinal resection of the stomach starting from the antrum at the point 5-6 cm from the pylorus and finishing at the fundus close to the cardia.[1] The remaining gastric sleeve is calibrated with a bougie. Most surgeons prefer to use a bougie between 36-40 Fr with the procedure and the ideal approximate remaining size of the stomach after the procedure is about 150 mL.
2406491|NCT03527797|No Intervention|Control|Standard of care
2406492|NCT03527797|Experimental|Intervention|Titration of support level
2406493|NCT03527784|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh.
2406494|NCT03527784|Active Comparator|Parietex Parastomal|Parietex Parastomal is a synthetic mesh with resorbable collagen lining to prevent attachments.
2406495|NCT03527784|Active Comparator|Dynamesh IPST|Dynamesh IPST is synthetic mesh with central tube to accommodate bowel tightly designed to prevent and treat parastomal hernia.
2406496|NCT03527771|No Intervention|unassisted CPR|unassisted CPR
2406497|NCT03527771|Active Comparator|T-CPR|telephone assisted CPR according to ERC Guidelines 2015
2406498|NCT03527771|Experimental|V-CPR|video-assisted CPR according to ERC Guidelines 2015
2406499|NCT03527758|No Intervention|Standard Invasive intraoperative monitoring|
2406500|NCT03527758|Experimental|Flo TracIQ with HPI software|
3185090|NCT00731315|Active Comparator|Control Group 2|Qualified for expedited treatment for complicated cystitis treatment but would receive usual care in the clinic or emergency department.
3185091|NCT00731354|Active Comparator|SAL|Each patient will have Suction Assisted Lipoplasty procedure on one side of the body (this will be considered the control side)
3185092|NCT00731354|Active Comparator|VAL|Each patient will have VASER- assisted lipoplasty on the opposite side of the body. This will be the comparison side.
3185093|NCT00731367|Active Comparator|Gelled|Aquacel Ag gelled.
3185094|NCT00731367|Active Comparator|Adherent|Aquacel Ag adherent
2406506|NCT03527732|Placebo Comparator|Arm A: albendazole|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of placebo at day 0 administered orally
2406507|NCT03527732|Experimental|Arm B: albendazole and ivermectin|400 mg albendazole single tablet (Zentel®) and 200µg/kg using 3mg tablets of ivermectin (Stromectol®) at day 0 administered orally
2406508|NCT03527719|Experimental|Experimental Group|"All participants of intervention groups will receive a new comprehensive evidence-based medicine (EBM) management program including nine intervention measures.~Strengthen the performance appraisal system for primary hypertension management.~Establishing a chronic disease management system.~Simulating medical insurance reform.~Enhancing village doctors'ability for standardized diagnosis and treatment of hypertension.~Establishing a supervision mechanism for the effect of hypertension management.~Establishing a hierarchical management system for patients.~Enhancing the awareness of blood pressure self-management.~Establishing a self-management group for patients.~Establishing patient encouragement system."
2406509|NCT03527719|No Intervention|Control Group|All participants in the routine management groups will receive the current management program.
2406510|NCT03527680|Experimental|Lactobacillus rhamnosus|received daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus
2406511|NCT03527680|Placebo Comparator|Placebo|received one placebo capsule per day Infant formula after meal for 28 days
2406512|NCT03527667|Experimental|Short term incentives|usual quit smoking treatment (counseling + medication) plus 6-weeks of payments for proof of smoking abstinence
2406513|NCT03527667|Experimental|Long term incentives|usual quit smoking treatment (counseling + medication) plus 12-weeks of payments for proof of smoking abstinence
2406514|NCT03527667|No Intervention|No incentives|usual quit smoking treatment (counseling + medication)
2406515|NCT03527654||Hispanic Immigrants|
2406541|NCT03527459|Experimental|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, but targets negative cognitions of perceived burdensomeness in some sessions.
3185095|NCT00731380|Experimental|ABI-007 escalation; then radiation + AUC|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-FU 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
2406516|NCT03527641|Experimental|Salud sin Barreras, Health without Barriers|"Salud sin Barreras is a manualized community-delivered program tailored for Latino families and their adolescent children at-risk for type 2 diabetes. Salud sin Barreras is based upon a lifestyle intervention called the Healthy Living Program (HeLP), which includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions that include parent education on nutrition, fitness, goal-setting, parenting, and a brief mindfulness curriculum, a teen group physical fitness class, and a teen mindfulness curriculum called Learning 2 BREATHe. In between sessions, participants are encouraged to practice brief mindfulness skills in their daily lives and to complete the homework assignments, such as an audio-guided body scan. Participants have access to home-practice audio-recordings and will be queried about their completion of home-practice assignments."
2406517|NCT03527641|Active Comparator|La Vida Saludable, Healthy Living|The Health Living Program (HeLP) is a manualized community-delivered program tailored specifically for Latino families and children at-risk for adult obesity. HeLP includes 6 weekly 2-hour nutrition/cooking sessions and 6 weekly 2-hour Multidisciplinary Sessions, that include parent education on nutrition, fitness, goal-setting, and parenting, a teen group physical fitness class, and a teen health knowledge curriculum derived from a health education curriculum called Hey DURHAM.
2406518|NCT03527628|Other|Patients with PET-2 Negative Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 negative patients will be treated with 4 cycles of ACVD (Adriamycin, Cyclophosphamide, Vinblastine And Dacarbazine)"
2406519|NCT03527628|Other|Patients with PET-2 Positive Result|"After 2 ABVD cycles an interim PET-2 will be performed, and treatment will be adapted according to to PET results~PET-2 positive patients will be treated with 4 cycles of ACVD with addition of Brentuximab Vedotin"
2406520|NCT03527602|Experimental|Intervention|Endodontic treatment will be performed in maxillary anterior teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with rotary files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
2406521|NCT03527602|No Intervention|Control|In the control group, no foraminal enlargement will be performed.
2406522|NCT03527589||Treated with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres (size of embolic determined at Investigator discretion).
2406523|NCT03527576|Active Comparator|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
2406524|NCT03527576|Placebo Comparator|Placebo|Intravenous injection of NaCl 0,9% before the surgery.
2406525|NCT03527563|Other|Internet Medical Model|Using Internet blood pressure management model: home blood pressure self-monitoring + Internet diagnosis + Maintained or adjusted anti-hypertension drug(s) treatment.
2406526|NCT03527563|No Intervention|Conventional Medical Model|Using Conventional blood pressure management model: home blood pressure monitoring + face-to-face diagnosis in clinic + Maintained or adjusted anti-hypertension drug(s) treatment.
3185096|NCT00731393|Experimental|Group A|Subjects aged between 6 months and 3 years.
3185097|NCT00731393|Experimental|Group B|Subjects aged 3 to 6 years.
2406529|NCT03527537|Active Comparator|20% cutoff group|Treatment intervention will be initiated with insulin if 20% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
2406530|NCT03527537|Active Comparator|40% cutoff group|Treatment intervention will be initiated with insulin if 40% cutoff of abnormal values is reached. Medication dosages will depend on the physician's discretion.
2406531|NCT03527524|Experimental|exercise with ball|The participant in core stabilization exercise with ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
2406532|NCT03527524|Other|exercise without ball|The participant in core stabilization exercise without ball group performed 12 training sessions of the core stabilization exercises, 3 days/week for 4 weeks. Each exercise took 15 times/set and each participant did it repeatedly for 3 sets and rested 1 minute between sets. The total time of core stabilization exercise was 20 minutes and assessment time was 10 minutes.
2406533|NCT03527498|Experimental|intervention group|Baby treadmill + physical rehabilitation training
2406534|NCT03527498|Active Comparator|positive control group|Physical rehabilitation training only
2406535|NCT03527485|Other|Opiate Use Disorder (OUD)|30 subjects meeting opiate dependence criteria will receive 11UCB-J PET Scan.
2406536|NCT03527485|Other|Cocaine Use Disorder (CUD)|30 subjects meeting cocaine dependence criteria 11UCB-J PET Scan.
2406537|NCT03527485|Other|Healthy Controls (HC)|30 healthy controls; no substance dependence or mental health issues 11UCB-J PET Scan.
2406538|NCT03527472|Experimental|Memantine|At randomization, subjects will receive 5 mg twice per day for one week. They will escalate their dose to 10 mg twice per day for one week, then 10 mg in the morning and 20 mg at night for one week, and finally 20 mg twice per day for three weeks. Maximum tolerated will be determined at this time and this dose will be continued for an additional six weeks.
2406539|NCT03527472|Placebo Comparator|Placebo|At randomization, subjects will receive one matching placebo capsule twice per day for one week. They will also take one matching placebo capsule twice per day for the next week (week 2), then one matching placebo capsule in the morning and two capsules at night for one week (week three), and finally two capsules twice per day for three weeks (weeks 4-6). Maximum tolerated number of capsules will be determined at this time and this dose will be continued for an additional six weeks.
2406540|NCT03527459|Active Comparator|SPARC A|SPARC A is an existing clinical program which has a general focus on negative cognitions.
2406542|NCT03527446|Experimental|Normal Weight|BMI ≥ 18.5 < 25.0 km/m2 Sprint Interval Training
3185098|NCT00731393|Active Comparator|Group C|Subjects aged between 6 months and 3 years.
3185099|NCT00731393|Active Comparator|Group D|Subjects aged 3 to 6 years.
2406543|NCT03527446|Experimental|Individuals living with Obesity|BMI ≥ 30.0 km/m2 Sprint Interval Training
2406544|NCT03527433|No Intervention|Standard arm|In the standard arm, an average of one suture will be placed at each cm length of the wound, thus the number of sutures placed should be equal to the length of the wound in cm.
2406545|NCT03527433|Experimental|Intervention arm|The intervention arm will undergo the alternative/new closure technique with small and close fascia sutures, where each suture will be placed only 5 mm away from the fascia edge and 5 mm apart from the adjacent fascia suture.
2406546|NCT03527420|Active Comparator|Exercising|12 weeks of aerobic exercise training
2406547|NCT03527420|No Intervention|Non-exercising|standard of care
2406548|NCT03527394||Families|"We plan to recruit a sample of 100 families (dyads) for this study, which will include 100 youth and 100 parents.~Note: For the sake of transparency, this sample size differs from the original estimate (n=250 families; see Ball et al., BMC Health Serv Res, 2017;17:261). A recent systematic review (Park et al., Int J Nurs Stud, 2018;79:58-69) suggested that sample size estimates for studies that evaluate test-retest reliability (a key psychometric property we will examine) should include ~5 participants for every survey item. Given the design of the interview, and in light of current patient volumes at the clinical recruitment sites, we are confident that a sample of 100 families will be both achievable and satisfactory for psychometric analyses."
2406549|NCT03527381|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
2406550|NCT03527381|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit (Standard CPB) during cardiac surgery. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
2406551|NCT03527368|Experimental|Time-restricted feeding|
2406552|NCT03527368|Other|Usual feeding pattern|Comparison
2406553|NCT03527355|Experimental|A (Single dose)|"One dose of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Week 24).~One booster dose of Vi-DT 0.5 mL is administrated 2 years apart (Week 96). MMR for age group at 9-12 months."
2406554|NCT03527355|Active Comparator|B (Two dose)|"Two doses of Vi-DT (Typhoid conjugate vaccine) 25 µg 0.5 mL is administrated intramuscularly 6 months apart (Day 0 and Day 168 (Week 24)).~MMR for age group at 9-12 months."
2406555|NCT03527355|Placebo Comparator|C (Placebo/Comparator)|"One dose of Placebo (0.9% sodium chloride isotonic solution) 0.5 mL is administrated intramuscularly at first dost (Day 0).~One dose of FluQuadri™ 0.25mL is administrated intramuscularly at second dose (Day 168; Week 24).~MMR for age group at 9-12 months."
2406556|NCT03527342||Dilated Cardiomyopathy|
2406557|NCT03527342||Myocarditis|
2406558|NCT03527342||Sarcoidosis Heart|
2406559|NCT03527342||Giant Cell Myocarditis|
2406560|NCT03527342||Amyloidosis Heart|
2406561|NCT03527342||Hypertrophic Cardiomyopathies|
2406562|NCT03527342||Left Ventricular Myocardial Noncompaction Cardiomyopathy|
2406563|NCT03527342||Arrhythmogenic Right Ventricular Cardiomyopathies|
2406564|NCT03527329||Prewarming|Active Prewarming will be performed using a forced-air blanket (WarmTouch lower body blanket, Covidien Ltd, Mansfield, USA) over the whole body and connected to a forced-air warmer (WarmTouch Model 5900, Covidien Ltd, Mansfield, USA). Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2406565|NCT03527329||Control|Non-active prewarming. Patients will be warmed using a surgical blanket during the intraoperative period. Tympanic thermometer (Genius 2 Tympanic Thermometer and Base, Covidien Ltd, Mansfield, USA) will be used to measure the temperature throughout the perioperative period.
2406566|NCT03527316|Experimental|MDMA, Placebo|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
2406567|NCT03527316|Experimental|Placebo, MDMA|Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase
2406568|NCT03527303|Experimental|Meditation Group|Participants in the intervention group will assigned to a digitally-based meditation intervention (Headspace app- Basics + Stress packs) and asked to use this for at least 10 minutes a day over the course of 8 weeks
2406569|NCT03527303|No Intervention|Waitlist Control Group|Waitlist control group participants will continue their normal activities and not add any form of meditation during the study period.
2406570|NCT03527290|Experimental|Time Restricted Eating|Participants will be instructed and counseled to incorporate a 12-hour Time Restricted Eating (TRE) regimen that begins upon waking and concludes within a 12-hour period (e.g. if wake at 6:30 AM then all caloric intake occurs between 6:30 AM and 6:30 PM). Water and non-caloric beverages (e.g. herbal tea) outside the period are encouraged as desired. There are no specific content or energy intake changes to the diet counseled or recommended as the focus of the counseling in this arm is timing of eating with innate circadian patterns and developing plans and approaches to follow this plan.
2406571|NCT03527290|Active Comparator|Standard Cardiometabolic Health Diet|Participants will be instructed and counseled with standard clinical dietary guidance for improving cardiometabolic health, where the focus is on the content, specifically a dietary pattern that emphasizes vegetables, fruits, whole grains, legumes, nuts/seeds, low fat dairy, seafood, lean poultry and meat and avoidance of foods with high levels of sodium, added sugars, saturated fats, and trans fats. There is no prescription to reduce energy intake.
2406574|NCT03527264|Experimental|Cohort 1A|Nivolumab during Chemo/RT with whole pelvic RT
2406575|NCT03527264|Experimental|Cohort 1B|Nivolumab during Chemo/RT with extended field
2406576|NCT03527264|Experimental|Cohort 2|Chemoradiation followed by Nivolumab Maintenance
2406577|NCT03527264|Experimental|Cohort 3|Nivolumab during chemoradiation and then as maintenance
2406578|NCT03527251|Experimental|Sequential group|intravenous ipilimumab following by intravenous SHR-1210
2406581|NCT03527225|Experimental|Music|Patients randomized to the music intervention arm will select a preferred genre of music from an internet based resource.
2406582|NCT03527225|No Intervention|No Music|These patient's will have no music playing during the first radiotherapy session.
2406583|NCT03527212|Experimental|SJP-0035 0.001% (ophthalmic solution)|
2406584|NCT03527212|Placebo Comparator|Placebo (ophthalmic solution)|
3185100|NCT00731419|Active Comparator|SEMS|Self expanding metal stent compared to plastic stent. Both recognised forms of treatment for condition
3185101|NCT00731419|Active Comparator|Plastic stent|
2406588|NCT03527147|Experimental|AZD9150 + Acalabrutinib|AZD9150 given in combination with acalabrutinib
2406589|NCT03527147|Experimental|AZD6738 + Acalabrutinib|AZD6738 in combination with acalabrutinib
2406590|NCT03527147|Experimental|Hu5F9-G4 + rituximab + Acalabrutinib|Hu5F9-G4/rituximab in combination with acalabrutinib
2406591|NCT03527147|Experimental|AZD5153 + Acalabrutinib|AZD5153 in combination with acalabrutinib
2406592|NCT03527134|Experimental|Amantadine treatment|To determine whether amantadine is effective in reducing the occurrence of postoperative cognitive dysfunction.
2406593|NCT03527134|No Intervention|No-treatment|Patients will not receive any treatment.
2406594|NCT03527121|Experimental|R.I.C.E.+ (ESP physiotherapy)|Participants will receive a single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
2406595|NCT03527121|Active Comparator|R.I.C.E.(Usual care)|A single session with advice and instructions from a physician in rest, ice, compression and elevation.
2406596|NCT03527108|Experimental|Patients with prior IO therapy|
2406597|NCT03527095|Experimental|Regimen A|FDL169 200 mg reference tablet
2406598|NCT03527095|Experimental|Regimen B|FDL169 200 mg testing tablet 1
2406599|NCT03527095|Experimental|Regimen C|FDL169 200 mg testing tablet 2
2406600|NCT03527095|Experimental|Regimen D|FDL169 200 mg testing tablet 1 or 2 with high fat diet
2406601|NCT03527095|Experimental|Regimen E|FDL169 200 mg testing tablet 1 or 2, fasted
2406602|NCT03527095|Experimental|Regimen F|FDL169 200 mg testing tablet 1 or 2, with standard diet
2406603|NCT03527082||Women attending gynaecology clinics|"150 women attending gynaecology clinics that fulfil inclusion criteria~Inclusion criteria:~Inclusion criteria~Over the age of 18~attending gynaecology clinics~Able to read and comprehend the details of the study in patient information sheet.~Mentally competent at signing the consent form.~English -speaking, if not then translator available"
2406604|NCT03527069|Experimental|CIPROS 10|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Cipros 10 association; and~1 tablet crestor placebo Oral, once a day."
2406605|NCT03527069|Active Comparator|Crestor|"The study is double-Masked, the patient wil take 2 tablets, as follow:~1 tablet Crestor 10mg; and~1 tablet Cipros association placebo Oral, once a day."
2406606|NCT03527056|Experimental|Oral capsule fecal transplantation|Enrolled patients who have screened positive for CRE in the stool will receive fecal transplant via OpenBiome oral capsules. The patient is given 90 minutes to swallow all capsules and does not require any anesthesia or sedation. Stool samples to test for CRE will be taken 10 days and 30 days after the fecal transplant.
2406607|NCT03527056|No Intervention|Observation|Enrolled patients who have screened positive for CRE in the stool will have stool samples to test for CRE taken 10 days and 30 days after initial enrollment.
2406608|NCT03527043|Experimental|Escitalopram|10mg by mouth daily for 6 weeks
2406609|NCT03527043|Placebo Comparator|Placebo|Matched placebo control by mouth for 6 weeks.
2406610|NCT03527030||General Population|Adults living in a registered household in the Greater London area.
2406611|NCT03527030||IQOS users|Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.
2406612|NCT03527017||General Population|Adults living in Germany.
2406613|NCT03527017||IQOS Users|Adult current IQOS users (at the time of survey) living in Germany who are registered in the Germany IQOS User Database and agreed to be contacted for research purposes at the time of registration.
2406614|NCT03527004||General Population|Survey on use of tobacco products in the general population of adults living in Italy.
2406615|NCT03527004||IQOS Users|Survey on use of tobacco products in adult current IQOS Users (at the time of survey) living in Italy who are registered in the Italy IQOS User Database and agreed to be contacted for research purposes at the time of registration.
2406616|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Tonic stimulation|Tonic stimulation
2406617|NCT03526991|Experimental|Spinal Cord Stimulation (SCS) Burst stimulation|Burst stimulation.
2406618|NCT03526978|Experimental|Experimental Group|"The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd.~Intervention: investigational sIPV"
2406619|NCT03526978|Active Comparator|Control Group|The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
2406646|NCT03526822|Experimental|patients with newly diagnosed glioblastoma|
2406647|NCT03526809||Ovarian cancer patients|MRI and FDG-PET imaging
3185102|NCT00731432|Experimental|A|Transmucosal Herbal Periodontal Patch (THPP)
3185103|NCT00731432|Placebo Comparator|B|Placebo Patch
3185104|NCT00731471|Experimental|1|12 Healthy adults infected with HIV
3185105|NCT00731471|Experimental|2|12 HIV+ adults on antiretroviral therapy
3185106|NCT00731497|Active Comparator|1|children in households/villages using Solar Water Disinfection (SODIS) method of disinfecting household drinking water
2406620|NCT03526965|Experimental|Yoga Chikitsa|YC group were given traditional combination of yoga therapy including loosening movements, physical postures, breathing, relaxation and yoga counselling.
2406621|NCT03526965|Active Comparator|Usual Care|Usual care were given exercise moves of necks, pain medications prescribed by physicians.
2406622|NCT03526952|Experimental|Intervention Group|Couples in this group will receive the Internet-Delivered Intervention for Sexual Re-Adjustment
2406623|NCT03526952|Active Comparator|Educational Comparison Group|Couples in this group will receive only written educational material about sexuality and intimacy with an ostomy.
2406624|NCT03526939||HIV negative from RDS round 1|HIV negative PWID subjects from RDS round 1
2406625|NCT03526939||HIV negative from RDS round 2|HIV negative PWID subjects from RDS round 2
2406626|NCT03526939||HIV negative from RDS round 3|HIV negative PWID subjects from RDS round 3
2406627|NCT03526926||Vyxeos|A minimum of 50 patients who receive at least one infusion of prescribed VYXEOS.
2406628|NCT03526913|Experimental|PRP + STSG|autologous PRP treatments every week prior to graft placement (STSG)
2406629|NCT03526913|Active Comparator|STSG Split Thickness Skin Graft|skin graft (STSG) (intervention)
3144452|NCT00040859|Experimental|oxaliplatin + capecitabine|"Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) receive 2 additional courses after CR.~Quality of life is assessed at baseline and then every 3 weeks (prior to each course of chemotherapy).~Patients are followed every 3 months for 1 year and then every 6 months for 2 years."
2406631|NCT03526887|Experimental|Cohort 1|Patients who experienced progression disease while on treatment progression disease < 12 weeks after stopping treatment. After that the patients took chemotherapy ≥ 4 cycles and progressed again. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
2406632|NCT03526887|Experimental|Cohort 2|Stop treatment and progression > 12 weeks after stopping treatment. After the last progression the patient is included in the study to be retreated with Pembrolizumab 200mg
2406633|NCT03526874|Experimental|Greater Occipital Nerve (GON) Block with Lidocaine|"Subjects randomized to this arm receive 2 mL injection of lidocaine 2% over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
2406634|NCT03526874|Placebo Comparator|Greater Occipital Nerve (GON) Block with Saline|"Subjects randomized to this arm receive 2 mL injection of preservative-free normal saline over the right and left greater occipital nerve at the baseline study visit.~All subjects then complete daily headache-related questions through a Headache Diary and other assessments for 28 days."
3144453|NCT00040885|Experimental|infliximab + docetaxel|"Patients receive infliximab IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses and docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
3144454|NCT00040885|Active Comparator|placebo + docetaxel|"Patients receive docetaxel IV over 1 hour (immediately after completion of infliximab infusion once weekly on weeks 1-6 of each course. Patients receive placebo IV over 2 hours once weekly on weeks 1, 3, and 5 of the first course and once weekly on weeks 1 and 5 of all subsequent courses.~Treatment repeats every 8 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity.~Quality of life, fatigue, appetite/anorexia, cachexia, and weight are assessed at baseline, weekly on weeks 1-8, and then monthly for the remainder of study treatment.~Patients are followed every 6 months for 5 years."
3144455|NCT00040911|Experimental|Arm I (alternative medicine procedure)|Patients undergo electroacupuncture therapy to specific acupuncture points on the arms and legs over 25 minutes twice daily on days 1 and 2 and then once daily on days 3-7 during week 1 of chemotherapy course 1 (9 acupuncture treatments total).
3144456|NCT00040911|Sham Comparator|Arm II (alternative medicine procedure)|Patients undergo electroacupuncture therapy to sham points on the arms and legs as in arm I.
3144457|NCT00041015|Active Comparator|oral topotecan plus cisplatin IV|oral topotecan once daily on days 1-5 and cisplatin IV on day 5
3144458|NCT00041015|Experimental|Cisplatin IV plus etoposide IV|Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
3144459|NCT00041041|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144460|NCT00041054|Experimental|carboplatin + etoposide + exisulind|"Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 30-60 minutes on days 1-3. Patients also receive oral exisulind twice daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year and then every 4 months for 2 years."
2406643|NCT03526848|Experimental|Group 1|HIV infected participants on ART will undergo analytical treatment interruption 2 days after the first infusion of 3BNC117 and 10-1074, and will receive 6 additional infusions of both antibodies at weeks 2, 4, 8, 12, 16 and 20 (Part A). Participants will remain off ART until week 38, if viral suppression is maintained (Part B).
2406644|NCT03526848|Experimental|Group 2|HIV infected participants on ART will remain on ART and will be administered seven infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16 and 20 (Part A). Analytical treatment interruption will begin at week 26 until week 38, if viral suppression is maintained (Part B).
2406645|NCT03526835|Experimental|MCLA-158|In Part 1, the dose escalation phase, patients with metastatic CRC will receive escalating doses of MCLA-158 (every 2 weeks) until MTD or RP2D is reached. Each Cycle is 28 days. Single agent treatment. In Part 2, the expansion phase, participants with metastatic CRC and certain other solid tumors will receive intravenous infusion of MCLA-158 at the recommended Phase II dose (RP2D) every 2 weeks, at Day 1 and Day 15. The duration of each treatment cycle is 28 days.
3144461|NCT00041093|Experimental|Treatment (docetaxel)|Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2406648|NCT03526796|Experimental|Hyperbaric oxygen therapy|Patients who recieve hyperbaric oxygen therapy will be maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
2406649|NCT03526783|Other|Failed sleeve gastrectomy - RNYGB|Intervention: Roux en Y gasric bypass (RNYGB)
2406650|NCT03526783|Other|Failed sleeve gastrectomy - MGB/OAGB|Inervention: Mini/One anastomosis gasic bypass (MGB/OAGB)
2406651|NCT03526770|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink."
2406652|NCT03526770|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
2406653|NCT03526770|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2406654|NCT03526770|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the tooth paste as an intervention."
2406655|NCT03526770|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2406656|NCT03526770|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test carbonated drink, Coco cola ® to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test carbonated drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention"
2406657|NCT03526757|Experimental|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
2406658|NCT03526757|Active Comparator|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
2406659|NCT03526744|Experimental|marine protein hydrolysate 1234|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
2406660|NCT03526744|Experimental|marine protein hydrolysate 2134|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
2406661|NCT03526744|Experimental|marine protein hydrolysate 3124|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with with up to 7 days-out in between. Random sequence of arms.
2406662|NCT03526744|Experimental|marine protein hydrolysate 4123|Daily intake at breakfast of supplementary marine protein hydrolysate (MPH) equivalent to 10, 20, 30 or 40 mg per kg bodyweight during 1 week, followed by 3 similar cycles with other MPH dosages, with up to 7 days wash-out in between. Random sequence of arms.
2406663|NCT03526731|Experimental|Group A (original QLB-2):|Local anesthetic will be injected between the quadratus lumborum muscle and the latissimus dorsi muscle guided by ultrasound.
2406664|NCT03526731|Experimental|Group B (trans-muscular OLB-3)|Local anesthetic will be injected between quadratus lumborum and psoas major after passing through the quadratus lumborum muscle guided by ultrasound.
2406665|NCT03526705|Experimental|nb-uvb|psoriasis patients will receive 26 sessions of nb-uvb phototherapy
2406666|NCT03526692|Experimental|Sensorimotor/delta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training sensorimotor/delta ratio that will be recorded at channel Cz according to the International 10-20 system."
2406667|NCT03526692|Experimental|Beta1/theta NF training group|"Three interventions will be administered:~An electroencephalography recording (EEG) for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The third intervention is the neurofeedback training Beta1/theta ratio that will be recorded at channel Fz according to the International 10-20 system."
2406668|NCT03526692|No Intervention|Control group|"Three interventions will be administered:~An electroencephalography recording for 30 minutes.We will use an electrocap of 19 scalp locations according to the International 10-20 EEG placement system.~The second intervention is the neuropsychological assessments and questionnaires. They will be done in one session for approximately 2 hours.~The psychopedagogical care : Each session will be organized using the same video material than for the NF training sessions."
2406669|NCT03526679|Experimental|Experimental arm|The combination of lenvatinib and eribulin
2406670|NCT03526666||AML, MDS, and CMML patients|Patients with a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
2406671|NCT03526653|Other|Intervention 1|exercise on an ergometer or motomed in an environment without other visual stimuli
2406672|NCT03526653|Other|Intervention 2|exercise on an ergometer or motomed while watching the National Geografics channel on television
2406673|NCT03526653|Other|Intervention 3|exercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
2406674|NCT03526653|No Intervention|Control group|Rest during 30 minutes
2406675|NCT03526640|Experimental|Plug Arm|Participants randomized for plug arm will be treated with a plug after CT guided is conducted.
2406676|NCT03526640|No Intervention|Non Plug arm|No Intervention, i.a. CT guided biopsy without plug.
2406677|NCT03526627||patient with advanced heart failure|we included the patients with advanced heart failure who had the poor cardiac function(LVEF<=30%) and was admitted to the general ward or emergency room within one year.
2406678|NCT03526588|Experimental|Autologous umbilical cord blood|
2406679|NCT03526575|Placebo Comparator|10 mg Zolpidem and 10 mg Zaleplon|Experiment 1 will involve N= 14 subjects randomized to placebo , 10 mg zolpidem for males and 10 mg zaleplon in counterbalanced order. Subjects are nested into group.
2406680|NCT03526575|Placebo Comparator|5 mg Zolpidem and 10 mg Zaleplon|Experiment 2, which will involve N=20 subjects randomized to placebo, 5 mg zolpidem and 10 mg zaleplon. All females will be placed in experiment 2. Subjects are nested into group.
2406681|NCT03526562|Experimental|Single arm phase I trial with 3 exercise dose-escalation arms|exercise dose-escalation: aerobic, resistance and flexibility training
2406683|NCT03526536|Other|Patients with diabetes and ESRD|Patients with diabetes and end stage renal disease (ESRD)
2406684|NCT03526536|Other|Patients with diabetes and no ESRD|Patients with diabetes and no end stage renal disease (ESRD)
2406685|NCT03526523|Experimental|Active Treatment|Mindfulness-based stress reduction
2406686|NCT03526523|No Intervention|Waitlist control|The active treatment will be received only after the outcomes monitoring period is complete.
2406687|NCT03526510|Active Comparator|Standard Fractionation|Using 2 sequential IMRT plans, the pelvic lymph nodes and prostate will initially be treated to 46 Gy in 23 fractions, followed by a subsequent boost to the prostate to a total dose of 78 Gy.
2406688|NCT03526510|Experimental|Hypofractionation|Using a one phase IMRT plan, the pelvic lymph nodes will be treated to a dose of 48 Gy in 25 fractions, while the prostate will be treated to a dose of 68 Gy in 25 fractions concomitantly (simulataneous integrated boost).
3144462|NCT00041106|Experimental|Treatment (gemcitabine, cisplatin, and gefitinib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and cisplatin IV over 1 hour on day 1. Patients also receive gefitinib PO QD beginning on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete remission, partial remission, or maintain stable disease continue gefitinib PO QD for 5 years or until disease progression or unacceptable toxicity occurs.
3144463|NCT00041171|Experimental|Arm 1: placebo + docetaxel|"Patients receive oral placebo three times daily on days 1-14 and docetaxel IV over 1 hour on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
2406691|NCT03526471|Experimental|Left Atrial Appendage (LAA) Occluder|Left Atrial Appendage (LAA) Occluder
3185107|NCT00731497|No Intervention|2|children in households/villages where Solar Water Disinfection (SODIS) has not been implemented
2406694|NCT03526445|Active Comparator|Glucagon|3 hours i.v. infusion of Glucagon (4 ng/kg/min).
2406695|NCT03526445|Placebo Comparator|Saline|3 hours i.v. infusion of saline
2406696|NCT03526432|Experimental|Bevacizumab + Atezolizumab|
2406697|NCT03526406|Experimental|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
2406698|NCT03526406|Placebo Comparator|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesium stearate, silica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
3144464|NCT00041171|Experimental|Arm 2: Hypericum perforatum + docetaxel|"Patients receive oral Hypericum perforatum three times daily on days 1-14 and docetaxel as in arm 1.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
2406699|NCT03526393|Experimental|Support Equipment|Were selected high performance athletes with various kinds of disabilities found in sitting volleyball functional classification. Three equipment was built to aid high-performance athletes. All the volunteers tested the survey training equipment, attack and serve training equipment and pass training equipment The motor sign captured footage of each athlete, lasted 30 minutes and the data collected provided the data for the construction of the equipment, later there was the interaction of the athletes with the equipment ready to test effectiveness.
2406700|NCT03526380|Experimental|Treatment|Participants receive the OPT-IN Brief Intervention.
2406701|NCT03526380|No Intervention|Control|Participants will only complete the baseline and follow-up surveys.
2406702|NCT03526367|Experimental|hydration plus rosuvastatin therapy|"After randomized，hydration（3ml/kg/h, if patients had LVEF<40%, 1.5 ml/kg/h）last 12 hours;~After randomized，a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days."
2406703|NCT03526367|Active Comparator|Standard therapy|No statin within 12 h after randomization, hydration at physicians' discretion, but no more than 1ml/kg/h.
2406704|NCT03526354|Experimental|Experimental|Brexpiprazole 4mg daily for 12 weeks
2406705|NCT03526354|Active Comparator|Treatment as Usual|Stay on current antipsychotic medication for 12 weeks
2406706|NCT03526328||DCLK1 post BE treatment|Effects of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
2406707|NCT03526315|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
2406708|NCT03526315|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
2406709|NCT03526315|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
2406710|NCT03526289|Active Comparator|GIP infusion|5 hours of continuously GIP1-42 infusion
2406711|NCT03526289|Placebo Comparator|Saline|5 hours of continuously saline infusion
2406712|NCT03526276|Active Comparator|CPP-ACP paste|Casein phosphopeptide amorphous calcium phosphate is a product that contains calcium, phosphate, protein and casein.
2406713|NCT03526276|Active Comparator|Fluoride toothpaste|Fluoride toothpaste
2406714|NCT03526276|Active Comparator|Both (Fluoride and CPP-ACP)|Fluoride toothpaste and CPP-ACP paste
2406715|NCT03526263|Experimental|Gastric mucosal devitalization arm|"Patients will be enrolled into the study after being scheduled to undergo vertical sleeve gastrectomy as part of routine clinical care at Johns Hopkins Bayview. The cost of the surgery will be covered by the patient's insurance and there will no extra procedural element that would add time to surgery.~The intervention will occur on the excised specimen ex vivo (outside the body) and will involve devitalization of the gastric mucosa using Argon Plasma Coagulation."
3185108|NCT00731510|Experimental|1|Carbohydrate supplements (drinks and gels)
2406717|NCT03526237|Experimental|The 24-week treatment|The 24-week treatment, Sisters Health And Primary CarE Uniting and Preventing Diabetes (SHAPE UP) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
2406718|NCT03526237|Other|Wait-list Control|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
2406719|NCT03526224||Aubagio|Individuals diagnosed with multiple sclerosis (MS) who have been treated with teriflunomide (Aubagio).
2406720|NCT03526224||Tecfidera|Individuals diagnosed with multiple sclerosis (MS) who have been treated with dimethyl fumarate (Tecfidera) and matched with the teriflunomide (Aubagio) patients on age, sex, disease duration, and disability level
2406721|NCT03526211|Experimental|Experimental|Patients with FES Cycling
2406722|NCT03526198|Experimental|Group 1 (adult)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
2406723|NCT03526198|Experimental|Group 2 (elderly)|Each volunteer stood on the platform. The duration of the tests was standardized at 10 seconds for each angulation variant of the test. The tilt variables occurred every 5 degrees oscillating in the two-dimensional movement of the ankle joint. The test was discontinued when the volunteer failed to remain balanced at the tested angulation for more than 10 seconds (thus shifting the foot (s) from the initial position or supporting with one and / or both arms at the therapist or at the support bars ) or when it reached maximum angulation
2406724|NCT03526185|Experimental|Cohort 1|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses)."
2406725|NCT03526185|Experimental|Cohort 2|"Subjects will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide (60 mg/kg/day IV) on days -7 and -6 and fludarabine (25 mg/m2/day) on days -5 through -1.~Prophylactic antibiotics will be administered as medically indicated until recovery of ANC to > 500 and recovery of ALC to > 400~On day 0 subjects will receive the infusion of autologous TIL and one hour later (but can be delayed up to 24 hours) will begin low-dose aldesleukin (IL-2) (72,000 IU/kg IV every 12 hours for up to 10 doses).~Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment."
3185109|NCT00731510|Placebo Comparator|2|Primarily Aspartame plus natural flavourings. Powder dissolved in water to provide non-distinguishable placebo drink.
2406728|NCT03526159|Experimental|Gentamicin Sulfate|"IV Arm:~7.5 mg/kg gentamicin once daily for 14 days.~Topical Arm:~0.5% gentamicin ointment applied twice daily for 14 days to selected skin sites."
2406729|NCT03526146|Experimental|PLIE|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
2406730|NCT03526146|No Intervention|Usua Care|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the senior center, which include a combination of daily physical, mental and social activities.
2406731|NCT03526120|Experimental|Pistachio diet|Incorporates 44 g (1 serving) of pistachios into a daily diet
2406732|NCT03526120|No Intervention|Control|No pistachio consumption
2406733|NCT03526107|Active Comparator|CF Control|CF Control: 583 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
2406734|NCT03526107|Experimental|CF-Theobromine|CF-Theobromine: 566 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
2406735|NCT03526107|Experimental|CF-Caffeine|CF-Caffeine: 583 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine(Experimental)
2406736|NCT03526094|Active Comparator|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
2406737|NCT03526094|Experimental|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
2406738|NCT03526094|Experimental|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
2406739|NCT03526094|Experimental|Flavanol-berry blend|Fruit blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
2406740|NCT03526094|Experimental|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
2406741|NCT03526094|Experimental|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
2406742|NCT03526094|Experimental|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
2406743|NCT03526094|Experimental|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
2406744|NCT03526094|Active Comparator|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
2406745|NCT03526094|Experimental|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
2406746|NCT03526081|Experimental|Chamomile Tea|Chamomile Tea in 300mL hot water
2406747|NCT03526081|Experimental|Parsley based drink|3.2 g dried parsley in 300mL hot water
2406748|NCT03526081|Experimental|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
2406749|NCT03526081|Experimental|Apigenin|Apigenin capsule mixed with 300mL hot water
2406750|NCT03526081|Experimental|Parsley-based drink (II)|3.2 g of dried parsley in 300 ml of hot water
2406751|NCT03526068|Experimental|SafeZoneUVC|Patients were subjected to 90s UV light therapy of 540 mW/cm2 sessions 2 times a week for 2 weeks for a total of 4 sessions. Pre and post UV light therapy swabs were taken after standard wound irrigation
3185110|NCT00731523|Experimental|1|
3185111|NCT00731536||Patients with Hepatosplenic T-cell Lymphoma (HSTCL)|
2406754|NCT03526042|Experimental|Losartan|AT1R-ab effect can be blocked with the use of angiotensin-II receptor blockers. The participants will receive losartan.
2406755|NCT03526042|Active Comparator|Enalapril|Angiotensin converting enzyme inhibitors are indicated in the management of active lupus nephritis but do not block the effect of AT1R-Ab.
2406756|NCT03526003||Surgical patients|Adult patient scheduled for laparoscopic surgery under general anesthesia
2406757|NCT03525990|Active Comparator|Intervention Arm|Quality of life questionnaires (electronic patient reported outcomes) to be filled out by the patients at every visit. Quality of life data is fully available for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
2406758|NCT03525990|Placebo Comparator|Control Arm|Quality of life questionnaires (electronic patient reported outcomes) only to filled out by the patients at baseline, after three months and after six months. Quality of life data is hidden for physicians. Paper-based questionnaire (EORTC QLQ-COMU26) at baseline, after three months and after six months.
2406759|NCT03525977|No Intervention|Control|Patients in the control arm will receive pain control via traditional oral and intravenous pain medications such as opioids and non-steroidal anti-inflammatory medication as needed.
2406760|NCT03525977|Experimental|Fascia iliaca block|Patients in the intervention arm will receive the regional fascia iliaca block performed by the anesthesiologists on call.
2406790|NCT03525782|Experimental|PD-1 knockout|PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
2406791|NCT03525782|Active Comparator|PD-1 mAb|Patients will be treated with a FDA approved monoclonal antibody for an identical course of treatment. This group will serve as PD-1 antibody treated group.
3185112|NCT00731562|Experimental|Varenicline Controlled Release, Fasted|
3185113|NCT00731562|Experimental|Varenicline Controlled Release, Fed|
3185114|NCT00731601|Experimental|1|pantoprazole 40mg/q6h IV infusion for three days
3185115|NCT00731601|Active Comparator|2|pantoprazole 8mg/h for three days
3185116|NCT00731627|Placebo Comparator|1|placebo
3185117|NCT00731627|Active Comparator|11|simvastatin
2406761|NCT03525964|Experimental|Individualized treatment|"The ruptured achilles tendon is examined by ultrasonography. If the overlap of the tendon ends is less than 25 % or the tendon is elongated 7 % or more the patient receives conventional open operative treatment. The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast after surgery. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2406762|NCT03525964|Active Comparator|Control group 1|"For the patients allocated to non-operative treatment the injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2406763|NCT03525964|Active Comparator|Control group 2|"The tendon is sutured with double fiberwire size 2 a.m. Kessler under prophylactic Dicloxacillin 2 g and in local anaesthesia or alternatively popliteal or spinal block. The injured leg is placed in a circulated below-the-knee cast from the time of the first appointment in the Outpatients Department. The ankle is held at maximal, unforced plantar flexion. Weight bearing is not allowed and the patient should walk with the aid of crutches. After 3 weeks from initiated treatment in the Emergency Department the cast is removed in the Outpatients Department and the injured leg is transferred to a functional brace (Walker boot) with 3 heel wedges promoting 20 degrees plantar flexion over the ankle.~The patient will follow standard functional rehabilitation and the follow-up evaluations."
2406764|NCT03525951|Other|Typically Developing Children Study 2 (TD2)|No-intervention comparison group measured over time.
2406765|NCT03525951|Experimental|Children with Dev Language Disorder Study 2 (DLD2)|Enhanced Milieu Teaching
2406766|NCT03525951|Experimental|Children with Autism Spectrum Disorders Study 2 (ASD+DLD 2)|Enhanced Milieu Teaching
2406767|NCT03525951|Other|Typically Developing Children Study 1 (TD1)|No-intervention group for observational data comparison.
2406768|NCT03525951|Other|Children with Dev Language Disorder Study 1 (DLD1)|No-intervention group for observational data comparison.
2406769|NCT03525938|Active Comparator|TAP group|
2406770|NCT03525938|Sham Comparator|SHAM group|
2406771|NCT03525925|Experimental|Treatment (ibrutinib, nivolumab)|Participants receive ibrutinib PO daily for 15 days. After 7 days receiving ibrutinib, participants receive nivolumab IV over 60 minutes on days 1 and 15. Courses with nivolumab repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2406772|NCT03525912|Experimental|Ketamine infusion|postoperative pain in adult population after abdominal, thoracic and orthopedic surgery that received adjuvant analgesia with ketamine 0.1mg/kg/h during 24 to 48 hours in postoperative period.
2406773|NCT03525899||MH after diabetic pars plana vitrectomy|Recruited patients included, the persistent MH group, who had MH before the primary DV, and the newly-developed MH group, who developed MH after a successful primary DV
2406774|NCT03525886|Experimental|NBI-74788 Dose Group 1|NBI-74788 administered orally for 14 consecutive days.
2406775|NCT03525886|Experimental|NBI-74788 Dose Group 2|NBI-74788 administered orally for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 2 will be dosed in parallel with Group 3.
2406776|NCT03525886|Experimental|NBI-74788 Dose Group 3|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days. Dosing will not commence until safety and tolerability data from Dose Group 1 have been reviewed. Group 3 will be dosed in parallel with Group 2.
2406777|NCT03525886|Experimental|NBI-74788 Dose Group 4|NBI-74788 administered orally under an alternative dosing regimen for 14 consecutive days.
3144465|NCT00041171|Experimental|Arm 3: Hypericum perforatum + docetaxel|"Patients receive docetaxel as in arm 1 and continue to receive their chronic regimen of Hypericum perforatum except on day 15.~Treatment in both groups repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed for new primaries and survival only."
3144466|NCT00041197|Experimental|Arm I (imatinib mesylate)|Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
3144467|NCT00041197|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
2406782|NCT03525847|Active Comparator|contrast enhanced FNA endosonography|First passage in the solid pancreatic tumor using FNA endosonography then with the contrast enhanced FNA endosonography
2406783|NCT03525847|Active Comparator|FNA standard endosonography|First passage in the solid pancreatic tumor using contrast enhanced FNA endosonography then with the FNA endosonography
2406785|NCT03525821|Experimental|intranasal administration of ketamine|intranasal adminstration of ketamine combined with nitrous oxide befor reduction of fracture
2406787|NCT03525795|Experimental|CPI-1205 Combination with ipilimumab|
2406788|NCT03525782|Experimental|CAR-T|Anti-MUC1 CAR-T cells will be prepared ex vivo and infused back to the patients.
2406789|NCT03525782|Experimental|CAR-T combining PD-1 knockout|Anti-MUC1 CAR-T cells and PD-1 knockout Engineered T cells will be prepared ex vivo and infused back to the patients.
2406792|NCT03525782|Placebo Comparator|Sham Control|Patient's T cells will be separate without genetic or engineered modification ex vivo and infused back to the patients.
2406793|NCT03525769||Type 2 Diabetes Mellitus|
2406794|NCT03525756||Cystogram on Post-Op Day 2|An indwelling Foley catheter is placed intraoperative and continued postoperative. All patients who consent to participate would undergo a cystogram on postoperative day two. The cystogram will be conducted by a radiologist and technician well-trained in the techniques and interpretation of the study. The colorectal surgery enhanced recovery protocol will be followed on all patients with the exception of the cystogram being conducted on post-op day two.
2406795|NCT03525743||Patients undergoing intubation|Adhesive gel pads will be placed on patient to measure continuous cardiac output and to calculate stroke volume variation. Other physiologic data will be analyzed in real time using the NICOM (Non invasive cardiac output monitor) device.
2406796|NCT03525730|No Intervention|Control|This group receives no intervention.
2406797|NCT03525730|Experimental|Valproic acid|This group receives valproic acid (enteric) for 14 days.
2406798|NCT03525730|Experimental|Pyrimethamine|This group receives pyrimethamine for 14 days.
2406799|NCT03525730|Experimental|Valproic acid and Pyrimethamine|This group receives valproic acid and pyrimethamine for 14 days.
2406800|NCT03525717|Active Comparator|Routine Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at routine dinner time (18:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from late dinner. This arm will cross-over to late dinner in random order."
2406801|NCT03525717|Experimental|Late Dinner|"Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (22:00) followed by a sleep study (23:00). Timing of dinner is the sole intervention distinguishing this arm from routine dinner. This arm will cross-over to routine dinner in random order."
2406802|NCT03525704|Experimental|Saline Solution Enriched|Saline Solution enriched with electrolytes and PH balanced to mimic normal tears
2406803|NCT03525704|Active Comparator|Saline Rinse Solution|Saline Solution .9% NaCL
2406804|NCT03525691|Experimental|Minimal distension|Tidal volume 4 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
2406805|NCT03525691|Experimental|Maximal recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain a plateau pressure between 23 - 25 cmH2O + ECCO2R (sweep gas = 8 L/min, blood flow = 400 mL/min)
2406806|NCT03525691|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and positive end-expiratory pressure (PEEP) based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R (no sweep gas flow, blood flow = 400 mL/min)
3185118|NCT00731705||1|Patients with hematological malignancies who are undergoing evaluation for autologous or allogeneic stem cell transplants OR First-degree relatives of patients evaluated for stem cell transplantation
3185119|NCT00731757|Experimental|1|Patients being treated with Humira.
3185120|NCT00731796||1|Stroke victims with a visual field deficit that undergo vision restoration therapy
2406810|NCT03525652|Active Comparator|Therapeutic vaccine|Therapeutic vaccine will be prepared ex vivo using the peripheral mononuclear cells from the patients and the vaccine (as maturated dendritic cells) will be infused back to the patients in 3 times with a 2-week interval.
2406811|NCT03525652|Experimental|Therapeutic vaccine plus PD-1 knockout|Therapeutic vaccine and PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the vaccine (as maturated dendritic cells) and maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
2406812|NCT03525652|Active Comparator|PD-1 knockout T cells|PD-1 knockout T cells will be prepared ex vivo using the white cells from the patients and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
2406813|NCT03525639|Experimental|Patients with Acute Myocarditis|Patients undergoing Cardiac Magnetic Resonance at baseline, 2 month, 1 year.
2406814|NCT03525626|Experimental|Online Mindfulness-based Tic Reduction|
2406815|NCT03525613|Experimental|APL-2 15mg 0.1 mL Monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
2406816|NCT03525613|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
2406817|NCT03525613|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure monthly for 24 months
2406818|NCT03525613|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
2406819|NCT03525600|Experimental|APL-2 15mg 0.1 mL monthly for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every month
2406820|NCT03525600|Experimental|APL-2 15mg 0.1 mL EOM for 24 months|A single dose of 15 mg APL-2/0.1 mL will be administered via intravitreal injection in this study. Subjects will receive an injection every other month
2406821|NCT03525600|Experimental|Sham Procedure Monthly for 24 months|Sham Procedure for 24 months
2406822|NCT03525600|Experimental|Sham Procedure Every Other Month for 24 months|Sham Procedure every other month for 24 months
2406823|NCT03525587|Active Comparator|Ongoing r-hGH therapy|"Patients on long-term r-hGH therapy.~Intervention: Use of MAGHD App/MAGHD Framework"
2406824|NCT03525587|Active Comparator|Previous r-hGH therapy|"Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will).~Intervention: Use of MAGHD App/MAGHD Framework"
2406825|NCT03525587|Active Comparator|Never treated|"Patients never treated for any reason (according to age, contraindications or lack of patient's consent).~Intervention: Use of MAGHD App/MAGHD Framework"
2406855|NCT03525301|Active Comparator|standard treatment|patients in this group are treated with 3000 cGy in 10 daily fractions
2407339|NCT03522012|Experimental|LusiNex|4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)
3185121|NCT00731796||2|Stroke victims with a visual field deficit who do not undergo any rehabilitation intervention
3185122|NCT00731796||3|Stroke victims that do not have a visual field deficit
3185123|NCT00731796||4|Normal individuals who have not had a stroke and do not have a visual field deficit
3185124|NCT00731809|Other|1|PET CT
2406826|NCT03525574|Experimental|Open-label Triple Combination|"Subjects will receive 200 mg VX-445/ 100 mg TEZ/ 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-445 in combination with TEZ and IVA. This includes Studies VX17-445-102 and VX17-445-103."
2406827|NCT03525561|Active Comparator|acetazolamide arm|This is the arm of the study in which the volunteers will take the acetazolamide (Diamox) pill.
2406828|NCT03525561|Placebo Comparator|placebo arm|This is the arm of the study in which volunteers will take the placebo.
3185125|NCT00731835|No Intervention|Group I|1. Wound Care (group 1)--Best standard wound care with aggressive debridement
3185126|NCT00731835|Active Comparator|Group 2|"2. Endovascular Intervention + Wound Care (group 2)--Best standard wound care in combination with endovascular revascularization~Endovascular revascularization is the intervention"
2406831|NCT03525535||Pulmonary embolism|data from routine care will be collected for patient eligible and willing to participate
2406832|NCT03525522|Experimental|Nd:YAG Laser|Three sessions of Nd:YAG laser (1064 nm) treatment with Dynamis (Fotona, Slovenia)
2406833|NCT03525522|Active Comparator|Topical Corticosteroid Diprosone|Topical corticosteroid betamethasone (Diprosone, Merck Sharp & Dohme, d.o.o.) for 3 months.
2406834|NCT03525509|Experimental|Epidural methadone|A single 4mg epidural bolus of methadone hydrochloride
2406835|NCT03525509|Active Comparator|Epidural morphine|A single 4mg epidural bolus of morphine sulfate
2406836|NCT03525483|Experimental|Patients with ECMO|"Patients with circulatory assistance by ECMO Patients are included 48 hours after ECMO VA or VV therapy and after hemodynamic stabilization defined by blood pressure stability and cardiac output for at least 12 hours without significant changes in amine flow.~When stable they will have an Ultrasound for renal resistivity index measurement"
2406837|NCT03525470|Experimental|Water|Subjects consumed water
2406838|NCT03525470|Experimental|No water|Subjects did not consume water
2406839|NCT03525457|Experimental|Experimental|Non surgical periodontal therapy
3185127|NCT00731848|Experimental|1|Intervention 1
3185128|NCT00731861|Experimental|1|Paclitaxel plus PTK787
2406842|NCT03525431|Experimental|Whole Exome Sequencing|Following consent and collection of standardized phenotypic data, probands and biological parents will undergo WES with variant analysis conducted utilizing primary gene lists based on referring clinical indication. After results provision and follow up 6-12 months later, clinical utility will be assessed in those with a positive result (pathogenic or likely pathogenic variant) and those with negative results (no variant returned or a VUS) using specific outcomes at each site to examine effectiveness for both the child and family.
2406846|NCT03525405|Experimental|Single Dose|
2406847|NCT03525392|Experimental|177Lu-3BP-227|"Screening: 177Lu-IPN01087 - 25 µg 3BP-227 (IPN01087) per 1 GBq of 177Lu. 1 GBq in a total volume of 10 mL.~Treatment phase: 177Lu-IPN01087 - 2.5 to 7.5 GBq escalation dose of 177Lu-3BP-227 (IPN01087) in a total volume of 20 mL for each cycle of administration (2 cycles plus 4 optional additional)."
2406848|NCT03525379|Experimental|Resveratrol|1) Resveratrol- (Transmax) trans- resveratrol (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
2406849|NCT03525379|Placebo Comparator|Placebo|2) Placebo- 500mg (Biotivia Longevity Bioceuticals, LLC, New York, USA) in cellulose capsules. One capsule will be taken orally 2 times per day (BID) for 8 weeks.
2406850|NCT03525353||Patients undergoing ERCP by formally trained Endoscopists|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who are trained on minimum use of fluoroscopy.
2406851|NCT03525353||Patients undergoing ERCP by Endoscopists not formally trained|Patients who undergo ERCP (Endoscopic Retrograde Cholangio Pancreatography) performed by Endoscopists who have not received formal training on minimum use of fluoroscopy.
2406852|NCT03525340|No Intervention|Standard of Care|Participants in the standard of care arm will receive no navigation assistance to remain in care. They will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation, but no additional services to remain engaged in care other than what is provided as standard by the clinic.
2406853|NCT03525340|Experimental|Peer Navigation|Participants in the peer navigation arm will meet with a peer navigator at least once per month for nine months in-person, and have at least one other navigator contact per month. Like the standard of care arm, they will provide informed consent, respond to baseline and endline surveys, and have clinic record data extracted for the 9 months of their study participation.
2406854|NCT03525327||Line Dance Class participants|The group will be participating in line dance classes as intervention.
3185129|NCT00731913||1|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
3185130|NCT00731913||2|Subjects with skin lesions requiring surgical excision and repair. One half of the each wound received Monocryl suture and the other half received Monosyn suture.
3185131|NCT00731926|Experimental|1|
3185132|NCT00731926|Active Comparator|2|
2406856|NCT03525301|Experimental|short course treatment|patients in this group are treated with 1800 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
2406857|NCT03525288|Experimental|PSMA-PETgRT|PSMA-PET/CT imaging is performed during treatment planning. Treating physicians are informed of test results and advised to include up to 5 PSMA-PET avid sites distant to the prostate gland, if present, in the radiotherapy treatment plan.
2406858|NCT03525288|Active Comparator|Standard|Patient's receive standard care radiotherapy and do not undergo PSMA-PET/CT imaging.
2406859|NCT03525275|Experimental|BFA with Physical Therapy|BFA + post-surgical protocol, intervention = battlefield acupuncture plus post-surgical protocol
2406860|NCT03525275|Active Comparator|Physical Therapy alone|Intervention = Post-surgical protocol
2406863|NCT03525249|Experimental|Comparator Membraflex 500mg|experimental product one dose
2406864|NCT03525249|Experimental|Comparator Membraflex 300mg|experimental product two doses
2406865|NCT03525249|Placebo Comparator|Placebo Comparator|placebo product
2406866|NCT03525236|Experimental|Taste of 5 flavors|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
2406867|NCT03525223|Active Comparator|dialysate [Na+] 138 mmol/l|Intervention: Change of dialysate [Na+] from 138 mmol/l to 142 mmol/l The dialysate [Na+] will be increased by 2 mmol/l per week and kept constant for 5 weeks (altogether 6 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
2406868|NCT03525223|Active Comparator|dialysate [Na+] 142 mmol/l|Intervention: Change of dialysate [Na+] from 142 mmol/l to 135 mmol/l The dialysate [Na+] will be decreased by 2 mmol/l per week for 3 weeks and by 1mmol/l for 1 further week. Afterwards the dialysate [Na+] will be kept constant for 5 weeks (altogether 8 weeks). Before and after intervention tissue [Na+] will be determined by sodium MRI. Additionally body fluid distribution (by bioimpedance spectroscopy) and central arterial pressure wave form, pulse wave velocity as well as flow-mediated vasodilatation will be assessed.
3185133|NCT00731926|Placebo Comparator|3|
2406871|NCT03525197|Experimental|Whey protein-based supplement|Participants in the experimental condition will consume a supplement containing Whey Protein Isolate (20g) and other ingredients
2406872|NCT03525197|Active Comparator|Collagen protein-based supplement|Participants in the experimental condition will consume a supplement containing Collagen protein (20g) and other ingredients
2406873|NCT03525184|Placebo Comparator|Normal sleep|A normal sleep condition and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; NS)
2406874|NCT03525184|Placebo Comparator|72-h Sleep restriction with placebo beverage|Sleep restriction (72-h with 2-h of sleep per night) and the placebo treatment (0.9 g protein/kg body weight/day + placebo beverage; SR),
2406875|NCT03525184|Experimental|72-h Sleep restriction with multi-nutrient beverage|Sleep restriction (72-h with 2-h of sleep per night) and the experimental treatment (1.5 g protein/kg body weight/day + multi-nutrient beverage; SR+).
2406876|NCT03525171|Active Comparator|GHD children|23 prepubertal children with isolated GHD consecutively admitted to the Section of Endocrinology of the University of Palermo during treated with GH for at least 12 months underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
2406877|NCT03525171|Placebo Comparator|controls|12 prepubertal healthy subjects with short stature recruited among children referred for assessment of short stature as a control group at baseline underwent full metabolic evaluation including euglycemic hyperinsulinemic clamp
2406878|NCT03525158|Other|Baseline phase ('A') and Intervention phase ('B')|"Baseline phase ('A'): Measurements collected in a pen-and-paper diary four times a day (morning, afternoon, evening and night) over one week for the primary outcome (occurrence of intrusive memories of trauma). Individual baseline phases will be used as control periods.~Intervention phase ('B'): A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game-play) followed by instructions to engage in the task self-guided over the subsequent week. Measurements collected in a pen-and-paper diary four times a day over one week following the intervention for the primary outcome (occurrence of intrusive memories of trauma)."
2406879|NCT03525132|Experimental|Healthy subjects|120 healthy subjects in the first session and 30 in the second Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2406880|NCT03525132|Experimental|Glaucoma|60 subjects with glaucoma Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2406881|NCT03525132|Experimental|Retinal vein occlusion|80 subjects with retinal vein occlusion including 40 with peripheric occlusion and 40 with central occlusion Intervention : Laser Doppler Velocimetry + Optic Adaptative Camera
2407337|NCT03522025|Active Comparator|GMK-UNI cemented fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
3185134|NCT00731952|Experimental|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
3185135|NCT00731965|Experimental|1|Measles, mumps, rubella booster vaccination within 3 months after randomisation
3185136|NCT00731965|No Intervention|2|Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation
2406885|NCT03525106|Experimental|Participants: Positive Psychology Intervention|Participants receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
2406886|NCT03525106|Experimental|Caregivers: Positive Psychology Intervention|Caregivers receive a positive psychology exercise manual, complete positive psychology exercises every week, and participate in phone sessions over 30 minutes every week for 8 weeks.
2406887|NCT03525093|Active Comparator|Hypnosis + health education|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home plus health education booklet on coping with stress
2406888|NCT03525093|Other|Health education alone|Patients receive a health education booklet to improve coping with stress
2406889|NCT03525080|Experimental|PET Arm|
2406890|NCT03525067||Patients with Bile Samples|Patients underwent pancreaticoduodenectomy who had intraoperative bile sampling for bacterial examination.
2406891|NCT03525041|Active Comparator|CABG+mitral valve annuloplasty|Participants will undergo CABG and mitral valve annuloplasty.
2406892|NCT03525041|Active Comparator|CABG|Participants will undergo CABG only.
2406893|NCT03525028|Experimental|Metformin group|Oral metformin 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
2406894|NCT03525028|Placebo Comparator|Placebo group|Oral placebo 500 mg once daily for first week, 500 mg twice daily for next 23 weeks. The follow-up treatment according to the participants' condition.
2406895|NCT03525015|Experimental|A decision aid booklet|A decision aid booklet about cataract surgery choice
2406896|NCT03525015|Active Comparator|An usual booklet|An usual booklet about cataract and cataract surgery
2406897|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (AA), Placebo|Participants with FTO SNP rs8050136 AA receiving matching Placebo
2406898|NCT03525002|Active Comparator|FTO SNP rs8050136 (AA), Bromocriptine|Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg
2406899|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CA), Placebo|Participants with FTO SNP rs8050136 CA receiving matching Placebo
2406900|NCT03525002|Active Comparator|FTO SNP rs8050136 (CA), Bromocriptine|Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg
2406901|NCT03525002|Placebo Comparator|FTO SNP rs8050136 (CC), Placebo|Participants with FTO SNP rs8050136 CC receiving matching Placebo
2406902|NCT03525002|Active Comparator|FTO SNP rs8050136 (CC), Bromocriptine|Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg
2406903|NCT03524989|Active Comparator|Treatment|Hyperbaric Oxygen Therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2406904|NCT03524989|Sham Comparator|Control/Crossover|SHAM therapy: 2 months of treatment consisting of 40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week
2406905|NCT03524976||Embolization with Squid|All patients with DAVFs are treated with SQUID™ aiming at complete occlusion of the fistula. Each participating center will include patients with DAVFs in whom the liquid embolic agent SQUID™ is planned to be used consecutively in the study. The
2406906|NCT03524963|Experimental|Sequence A|Cilostan CR Tab. in phase 1 and Pletaal SR Cap. in phase 2
2406907|NCT03524963|Experimental|Sequence B|Pletaal SR Cap. in phase 1 and Cilostan CR Tab. in phase 2
2406908|NCT03524950|No Intervention|no dexmedetomidine|
2406909|NCT03524950|Experimental|high dose dexmedetomidine|
2406910|NCT03524950|Experimental|low dose dexmedetomidine|
2406911|NCT03524937|Experimental|MELATONIN (LOW DOSE)|Daily administration of melatonin by enteral route at 0.3 mg/day (low dose arm), up to 14 days.
2406912|NCT03524937|Experimental|MELATONIN (HIGH DOSE)|Daily administration of melatonin by enteral route at 3 mg/day (high dose arm), up to 14 days.
2406913|NCT03524937|Placebo Comparator|PLACEBO|Daily administration of identical placebo up to 14 days.
2406914|NCT03524924||non-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: < 0.3151361243 Male: < 1.211878526
2406915|NCT03524924||pre-frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 0.3151361243 to < 2.1301121973 Male: 1.211878526 to < 3.0052612772
2406916|NCT03524924||frail|Survey of Health, Ageing and Retirement in Europe Frailty Instrument (SHARE-FI) score Female: 2.1301121973 to < 6 Male: 3.0052612772 to < 7
2406917|NCT03524911|Experimental|CHFFF nutrition education|Expanded Food and Nutrition Education (EFNEP) participants in 5 NY counties in 2015
3185137|NCT00731978|No Intervention|Standard|Standard intraoperative fluid management
2406919|NCT03524885|Active Comparator|Short implants|2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.
2406920|NCT03524885|Experimental|Bone regeneration with longer implants|"A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US).~The graft will be composed half autogenous bone harvested with a scraper (Meta, Firenze, Italy) by the same surgical site or by a second tunnel site in the mandibular ramus and half deproteinized bovine bone (Bio Oss Geislicht Pharma, Switzerland). The mucosal flaps will be sutured in a double layer with horizontal mattress and single gore-tex sutures (Cytoplast PTFE sutures 3.0, Cytoplast Osteogenics, US).~2 or 3 implant from 10 to 13 mm length putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted."
3185138|NCT00731978|Experimental|Restricted|Restricted intraoperative fluid management
3185139|NCT00731991|Active Comparator|ART|ART to the levator scapulae.
2406921|NCT03524872|Active Comparator|Original CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and original (Sweden&Martina) CAD/CAM abutments.
2406922|NCT03524872|Experimental|Compatible CAD/CAM abutment|Patients will be rehabilitated using Sweden&Martina implants and compatible (New Ancorvis) CAD/CAM abutments.
2406923|NCT03524859||Cystic fibrosis|Cystic fibrosis participants without experience on endurance or resistance training will be analyzed through a test battery and lung function test.
2406924|NCT03524859||Healthy Subjects|Healthy matched control group without experience on endurance or resistance training will be analyzed through a test battery.
2406925|NCT03524846|Active Comparator|Ascorbic acid 300 mg|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2406926|NCT03524846|Active Comparator|Ascorbic acid 600 mg|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2406927|NCT03524846|Placebo Comparator|Placebo|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
2406928|NCT03524833|Other|Intraluminal Metronidazole eradication|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
2406929|NCT03524833|Other|oral antibiotic triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
2406930|NCT03524820|Experimental|Metastatic colorectal cancer patients|Metastatic colorectal cancer patients receiving third line cetuximab treatment
2406931|NCT03524807|Experimental|Electrophysiologic therapy group|apply electrophysiologic therapy after surgery
2406932|NCT03524807|No Intervention|non-electrophysiologic therapy group|do not apply electrophysiologic therapy after surgery
2406933|NCT03524768||patients presenting with Chagas cardiomyopathy|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
2406934|NCT03524768||control group|Evaluation of systemic microvascular reactivity using laser speckle contrast imaging Evaluation of skin capillary density using video-capillaroscopy
2406935|NCT03524755|Experimental|Training Group|Warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. A leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. All exercises were performed with 8-12 repetitions and 3 sets. 3 training sessions (30min for each session) per week for during the course of radiotherapy (~6 weeks).
2406936|NCT03524755|No Intervention|Control Group|The control group received usual care.
2406937|NCT03524742|Experimental|Avocado-Mediterranean Diet|Avocado based Mediterranean diet with intake of ½ portion of a Hass avocado per day, during 3 months.
2406938|NCT03524742|Active Comparator|Control-Group Diet|Control-Group Diet consists of a low fat-high complex carbohydrate diet, during 3 months.
2406939|NCT03524729|Active Comparator|Ankle osteoarthritis patients|Ambulatory adult patients (18+) with ankle osteoarthritis.
2406940|NCT03524729|Other|Healthy control subjects|Ambulatory adults (18+) with no known ankle osteoarthritis.
2406941|NCT03524716|Experimental|Fitbit and Text Messages|Participants randomized to this arm receive print materials and a Fitbit Flex 2 at baseline and daily text messages for 12 weeks.
2406942|NCT03524716|No Intervention|Usual Care|Participants randomized to usual care receive print materials at baseline.
2406943|NCT03524703|Experimental|Chewing Gum Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Chewing Gum Group are asked to chew gum four times a day for 5 days (15 minutes each time) after surgery in addition to standard cares. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
2406944|NCT03524703|No Intervention|Control Group|Patients who receive anterior cervical fusion and have mild or moderate dysphagia postoperatively, will be randomized into two groups. Subjects assigned to the Control Group receive standard cares and are asked not to chew gum within 5 days after surgery. Standard cares include cleaning the wound every 2 days, wearing a collar, pain management, and education.
2406945|NCT03524690|Active Comparator|SUSOPS Balance|Volunteers provided sufficient food to maintain energy balance.
2406946|NCT03524690|Experimental|SUSOPS Negative Balance|Volunteers provided insufficient food to maintain energy balance resulting in negative energy balance.
2406947|NCT03524677||Non metastatic pancreatic cancer|patients with biopsy or fnac proven ductal adenocarcinoma without any systemic metastatic spread at preoperative imaging
3185140|NCT00731991|Active Comparator|PNF|PNF to the levator scapulae.
3185141|NCT00731991|Placebo Comparator|Control|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
2406950|NCT03524651|Active Comparator|Ferrous sulfate|Patients will take every day for 12 weeks two oral capsules of 150 mg ferrous sulfate delivering 47 mg of active elemental iron. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two placebo vials of 15 ml volume with excipients contained in the commercially available formulation Fe-Asp Omalin (Uni-Pharma SA).
2406951|NCT03524651|Active Comparator|Fe-ASP|Patients will take every day for 12 weeks two oral placebo capsules. Capsules should be taken orally either two hours before meal or two hours after meal. The same patients will take every day on exactly the same time for 12 weeks two vials of 15 ml volume of the Fe-Asp preparation Omalin (Uni-Pharma SA) delivering 40 mg of elemental iron.
2406952|NCT03524638|Active Comparator|ARM A|Colorectal surgery with administration of Visbiome
2406953|NCT03524638|Active Comparator|ARM B|Colorectal Surgery alone
2406955|NCT03524599|Experimental|Intervention municipality|In the intervention municipalities, primary health care providers will receive ongoing training and support in undertaking screening and brief advice for heavy drinking. They will also receive community-based five adoption mechanisms and five support systems.
2407054|NCT03523910|Experimental|Patient|A research MRI scan with exercise will be obtained in conjunction with standard of care cardiopulmonary testing.
3185142|NCT00732004|Experimental|1|Group 1
2406956|NCT03524599|No Intervention|Comparator municipality|In the comparator municipalities, the primary health care providers will be given a summary card of screening and brief advice for heavy drinking, with no instruction
2406957|NCT03524586|Experimental|Ipsilateral rotation of head|Head was laterally rotated to the same side against fixed tube
2406958|NCT03524586|Active Comparator|Contralateral rotation of head|Head was laterally rotated to the opposite side against fixed tube
2406959|NCT03524573|Experimental|Delayed Appendectomy|Patients will undergo appendectomy the morning following the decision to operate. This group will have an anticipated delay between 3 - 14 hours from the decision to operate, with a surgical start time between 0530 - 0900.
2406960|NCT03524573|Active Comparator|Immediate Appendectomy|Patients will undergo appendectomy within 6 hours of the decision to operate. Surgery will take place between 2000 - 0400.
2406961|NCT03524547|Experimental|J-shaped|Endotracheal tube will be molded into a J-shape that is similar to that of Macintosh type blade of a McGrath MAC® videolaryngoscope.
2406962|NCT03524547|Active Comparator|60-degrees|Endotracheal tube will be bent 60 degrees.
2406963|NCT03524534|Active Comparator|Telephone Follow-Up Intervention|
2406964|NCT03524534|Active Comparator|In-person follow-up intervention|
2406965|NCT03524521|Active Comparator|Standard Walking|This arm is prescribed standard of care exercise prescription; 30 minutes of moderate intensity walking, 5 days/week.
2406966|NCT03524521|Experimental|Interval Training|This arm is prescribed body-weight based interval training 3 days per week with progressive increase in exercise intervals and sets.
2406967|NCT03524508|Experimental|5-FU/LV/Onivyde|Onivyde 70 mg/m2 (90 minutes), dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
2406968|NCT03524508|Active Comparator|5FU/LV|dl-LV 400mg/m2 or l-LV 200mg/m2 (30 minutes), 5-FU 2400 mg/m2 (46 hours) IV every 2 weeks.
2406969|NCT03524482|Experimental|Path2Quit|Culturally specific text message intervention
2406970|NCT03524482|Active Comparator|SmokeFreeText|The National Cancer Institute's publicly available, standard text messaging program for tobacco cessation
2406971|NCT03524469||Normal weight|"Normal Weight will be defined as pre-pregnant BMI between 18.5-23.9 kg/m2 and passing the 28 week oral glucose tolerance test."
2406972|NCT03524469||Insulin resistant|"Insulin Resistance will be defined as meeting any of the following:~pre-pregnant BMI ≥ 28 and failed the 28 week oral glucose screening test~pre-pregnant BMI ≥ 28 and diagnosis of either A1 (diet controlled) or A2 (insulin-requiring) gestational diabetes during pregnancy, but insulin therapy discontinued after birth.~pre-pregnant BMI ≥ 28 and diagnosed with type 2 diabetes during pregnancy~pre-pregnant BMI ≥ 30, and unmediated."
2406973|NCT03524456|Experimental|Home blood pressure monitoring|
2406974|NCT03524456|No Intervention|Usual monitoring|
2406975|NCT03524443||Patient suffering from anorexia/bulimia|Each patient will receive standard care: multidisciplinary and corresponding to the HAS recommendations for anorexia nervosa and bulimia nervosa associated with semimonthly or weeklies sessions of art therapy treatment, using all types of art, realized by trained professional, in Toulouse. Each patient will be her own control before art therapy Female patients with anorexia nervosa or bulimia according to DSM-5 criteria, patient will be above 16 years-old
2406976|NCT03524430|Experimental|Single Interventional Study Arm|There will be 2 biopsy collection time points with 2 core needle biopsy specimens taken at each biopsy collection time point for RDA analysis during neoadjuvant chemotherapy.
2406977|NCT03524417|Experimental|RIG injection|RIG injection on day 7
3144468|NCT00041301||QoL in prostate cancer|The study sample will be composed of a consecutive series of prostate cancer patients, stratified by stage of disease, local and locally advanced versus advanced (metastatic) disease, and undergoing active anti-tumor therapy. In order to increase sample homogeneity, and to facilitate evaluation of the responsiveness of the quality of life instruments to changes in patients' health status and symptoms experience over time, the subsample of patients with local or locally advanced disease will be restricted to those undergoing surgery (radical prostatectomy) or radiation therapy, and the subsample of metastatic disease patients will be limited to those receiving hormonal therapy.
2406979|NCT03524391|Experimental|Yoga Counselling Group|Yoga based psychological counselling delivered individually and in group along with conventional care
2406980|NCT03524391|Active Comparator|Usual Care Group|Usual care provided to patients
2406981|NCT03524378|Other|Ergonomic and movement modifications|No group assignment - all participants will self select suitable ergonomic or movement modifications
2406982|NCT03524365|Active Comparator|RYGB plus LM counselling|96 subjects with NASH
2406983|NCT03524365|Active Comparator|SG plus LM counselling|96 subjects with NASH
2406984|NCT03524365|Sham Comparator|ILM|96 subjects with NASH
2406985|NCT03524352|Experimental|fecal microbiota|
2406986|NCT03524352|Placebo Comparator|placebo|
3144469|NCT00041340|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for 8 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease or better continue therapy until disease progression or 1 year after complete response.
3144470|NCT00041457||Physicians' Health Study I|
3144471|NCT00041457||Physicians' Health Study II|
2406990|NCT03524300|Experimental|Robotic Assisted Total Gastrectomy|Robotic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2406991|NCT03524300|Active Comparator|Laparoscopic Assisted Total Gastrectomy|Laparoscopic Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2406992|NCT03524287|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed robotic assisted spleen-preserving No.10 lymph node dissections. After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
2406993|NCT03524274|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2406994|NCT03524274|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
3144472|NCT00041457||Women's Health Study|
2406995|NCT03524274|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2406996|NCT03524261|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2406997|NCT03524261|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2406998|NCT03524261|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3144473|NCT00041457||Women's Antioxidant Cardiovascular Health Study|
3144474|NCT00041483|Active Comparator|Anecortave and Sham PDT|
2407001|NCT03524222|Experimental|Home Hospitalization|Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2407002|NCT03524209|Other|Surgery|Patients with spondylodiscitis are operated by percutaneous instrumentation and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
2407003|NCT03524209|Other|Brace|Patients with spondylodiscitis are wearing a thoracolumbar brace for 3 months and receive an antibiotic treatment according to the bacterium evidenced in the initial diagnostic intervertebral disc puncture (6 weeks to 3 months according to CRP course)
2407004|NCT03524196|Experimental|MYLO|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
2407005|NCT03524183|Active Comparator|Control|The children will receive the standard of care at their respective afterschool programs. As with the treatment group, all children will be asked to wear their Fitbits for one year following the intervention period, for the mid- and long-term follow up. Fitbit data will be recorded tracked year-round through the automated Fitbit data syncing stations at the afterschool program site. All participants will be assessed for PA and psychosocial variables at the same four measurement points for the treatment group.
2407006|NCT03524183|Experimental|Treatment|The virtual pet functions as a personalized fitness buddy to encourage children to set and meet physical activity goals, promote physical activity self-efficacy, and foster mutually supportive relationships among children, parents, and the virtual pet. Concurrently, the kiosk sends a text message to parents on the child's physical activity progress. Parents are then able to send words of encouragement and communicate with their children via the kiosk, using the text messaging feature of their mobile phones. Parents will also receive text messages from the kiosk with a security code to access a website that provides detailed records of the child's physical activity over time. Participants will be assessed for post-treatment measurements immediately after 3 months, 6 months after, and 12 months after the intervention.
2407007|NCT03524170|Experimental|Treatment (M7824, radiation therapy)|Patients receive M7824 IV over 1 hour every 14 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days after second dose of M7824, patients undergo radiation therapy QD for 5-10 days depending on the site of disease in the absence of disease progression or unacceptable toxicity.
3185143|NCT00732004|Experimental|2|Group 2
3185144|NCT00732004|Experimental|3|Group 3
2407011|NCT03524144|Other|adult patients with Crohn's disease|All adult patients(18 years old or older) with Crohn's disease underwent gastroscopy; patients with diagnosed and treated Crohn's disease had gastroscopy performed during the re-examination, and patients diagnosed with Crohn's disease for the first time had gastroscopy performed during the initial consultation.
2407012|NCT03524131|Experimental|risk-framed leaflet|Patients sent 2-sided risk-framed leaflet with NHS Health Check invitation
2407013|NCT03524131|Experimental|benefits-framed leaflet|Patients sent 2-sided benefits-framed leaflet with NHS Health Check invitation
2407014|NCT03524131|Active Comparator|control|Patients sent 4-sided current national leaflet with NHS Health Check invitation
3144475|NCT00041483|Active Comparator|PDT and Sham Anecortave Acetate|
3144476|NCT00041496|Experimental|Arm 1|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or placebo
3144477|NCT00041496|Placebo Comparator|Arm 2|Patients with Symptomatic Persistent Atrial Fibrillation (AF) will be randomized with either SB207266 or Placebo
3144478|NCT00041509|Experimental|SB424323, 500 mg BID|
2407148|NCT03523182|Active Comparator|Control (CON)|Children in the CON group (n=250) received a soya-maize-based porridge for 12 months.
3144479|NCT00041509|Experimental|SB424323, 125 mg BID|
3144480|NCT00041509|Placebo Comparator|Placebo|
3144481|NCT00041548|Experimental|1|Nitric Oxide for Inhalation
3144482|NCT00041548|Placebo Comparator|2|oxygen
3144483|NCT00041561|Placebo Comparator|2|Nitrogen gas
3144484|NCT00041561|Experimental|1|Inhaled Nitric Oxide
3144485|NCT00041574|Experimental|1|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
3144486|NCT00041782|Experimental|Dalteparin|
3144487|NCT00041951||CAE participants|Both parents and a child with CAE of families without other affected members (trios) or whole families with many members affected with epilepsy.
3144488|NCT00041951||Controls|Healthy individuals without epilepsy and no family history of epilepsy.
3144489|NCT00042185|Experimental|Dissonance intervention|
3144490|NCT00042185|Active Comparator|Healthy Weight Intervention|
3144491|NCT00042185|Active Comparator|Expressive writing control intervention|
3144492|NCT00042185|No Intervention|Assessment-only control condition|
3144493|NCT00042198|Experimental|1|Cognitive Behavior Therapy. The treatment modality was individual, face-to-face therapy with an experienced cognitive therapist. Treatment consisted of up to 12 weekly, hour-long sessions.
3144494|NCT00042198|Active Comparator|2|Supportive Stress Management. The treatment modality was individual, face-to-face therapy with an experienced psychotherapist. Treatment consisted of up to 12 weekly, hour-long sessions.
3185145|NCT00732017|Experimental|HVPC-|This group received standard physical therapy treatment and HVPC with negative polarity.
2407023|NCT03524105|Active Comparator|Thrive Professional Learning plus ParentCorps|
2407024|NCT03524105|Active Comparator|Thrive Professional Learning track|
3185146|NCT00732017|Active Comparator|CG|The control group received only standard physical therapy treatment.
3185147|NCT00732017|Experimental|HVPC+|This group received standard physical therapy treatment and HVPC using active electrodes with positive polarity.
3185148|NCT00732043|Experimental|1|
2407028|NCT03524079||BrS Group|Ajmaline 17-(Chloroacetate) Monohydrochloride
2407029|NCT03524079||No BrS group|Ajmaline 17-(Chloroacetate) Monohydrochloride
2407030|NCT03524066|Experimental|Inhaled + Bronchoscopy|One-time Inhalation of Salbutamol 200 µg, Salmeterol 50µg and Fluticasone 500µg. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and bronchoalveolar lavage (BAL) samples will be taken from each site.
2407031|NCT03524066|Experimental|Systemic + Bronchoscopy|One-time Salbutamol (8 mg) and Propranolol (40mg) administered orally. During two bronchoscopic procedures two pre-specified lung tissue sites (middle lobe and lingula) will be sampled. Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples will be taken from each site.
2407032|NCT03524053|Experimental|Exercise induced bronchoconstriction|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while breathing medical grade dry air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
2407033|NCT03524053|Active Comparator|Inhibited EIB|An exercise challenge will then be performed according to international guidelines. The exercise will consist of 8 minutes of cycling on a cycle ergometer while warm-humid air from a reservoir (Douglas bag) via a two-way non-rebreathing valve. The workload will be increased progressively over the first 2 minutes, and will then be maintained for 6 minutes at a target workload (in Watts) of [53.76 * measured forced expiratory volume in 1 sec (FEV1)-11.07].
2407034|NCT03524053|No Intervention|Control|Participants will attend the laboratory but no exercise trial will be performed.
2407035|NCT03524040|Experimental|Acne patients|Application of gold microparticles to 2-3 facial areas
2407036|NCT03524040|Experimental|Heatlhy volunteers|Application of gold microparticles to 2 facial areas
2407037|NCT03524027|Experimental|Congenital Thoracolumbar Kyphoscoliosis|Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity by Posterior Vertebral Column Resection (PVCR) Surgical Technique
2407038|NCT03524014||HEV-infected patients with hepatitis|
2407039|NCT03524014||HEV-infected patients with neurological features|
2407040|NCT03524014||HEV-infected patients with kidney features|
2407041|NCT03524001|Active Comparator|Bifocal stimulation|Active comparator is represented by programming bifocal stimulation (bifocal DDD mode). Every patients will undergo crossover randomization (from bifocal DDD mode to VVI and vice versa).
2407042|NCT03524001|Placebo Comparator|VVI 40|Placebo comparator is represented by programming the device in VVI mode 40/mins. Every patients will undergo crossover randomization (from VVI to bifocal DDD mode and vice versa).
3185149|NCT00732043|Experimental|2|
3185150|NCT00732043|Placebo Comparator|3|
3185151|NCT00732056|Experimental|1|3+3 cohort dose escalation
2407046|NCT03523975|Experimental|Venetoclax, Lenalidomide, Rituximab|Rituximab 375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12 Lenalidomide 10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12. Venetoclax PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
2407047|NCT03523962|Experimental|First pre-op antiseptic skin solution|The PREPARE trial will compare the most common alcohol-based pre-operative antiseptic skin solutions used during extremity fracture surgery. Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all eligible fracture surgeries for a two-month period.
2407048|NCT03523962|Experimental|Crossover - Second pre-op antiseptic skin solution|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all eligible fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
2407049|NCT03523949|Experimental|PNE.|Procedure: This educational intervention is based in the latest evidence of pain neuroscience education, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptive thoughts and behaviors.
2407050|NCT03523936|Active Comparator|Prebiotic|
2407051|NCT03523936|Placebo Comparator|Placebo|
2407052|NCT03523923|No Intervention|Usual Care|If assigned to the Usual Care (UC) arm, participants receive the same care as they would normally received from the HMC or UWMC outpatient TBI clinics, which could include similar types of treatment (medication changes, referral to specialists, etc.).
2407053|NCT03523923|Active Comparator|Collaborative Care|If assigned to the Collaborative Care (CC) arm, participants receive up to 12 sessions (45-60 minutes) of scheduled contacts with a Collaborative Care Manager (CCM) over 16 weeks of treatment. The CCM meets weekly for supervision with a team of experts to determine appropriate care.
2407292|NCT03522363|Experimental|Monodose group|1 vial with 4E10 CFU/g Total dose treatment: 4E10 CFU
3185152|NCT00732082|Active Comparator|Dose Level 0|Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.
2407055|NCT03523897|Active Comparator|Robot Assisted Total Knee Replacement|In addition to expert judgment and hand-eye coordination, the surgeon also relies on a robot in making cuts within the pre-determined diseased areas of the joints and placing the implants. This is made possible by uploading 3-dimensional (3D) images of the knee joints into the robot prior to surgery. The robot uses these 3D images to guide the surgeon during the procedure. The 3D images are obtained from a computerized tomography (CT) scan that combines a series of X-ray images taken from different angles to create cross-sectional images of the bones.
2407056|NCT03523897|Active Comparator|Traditional Total Knee Replacement|The traditional method where the surgeon employs mechanical guides, expert judgment, and natural hand-eye coordination in making the necessary cuts to prepare the bone for the implant as well as in placing the implant.
2407057|NCT03523884|Experimental|Exercise Program plus Education.|Rotator cuff stretching and strengthening exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
2407058|NCT03523884|Active Comparator|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
3144495|NCT00042198|No Intervention|3|Usual Care, minimally enhanced. Participants in all three arms were given information about depression. There were no restrictions in any of the arms on usual care for depression, heart disease, or any other conditions, except that concurrent participation in nonstudy psychotherapy was not allowed. Participants were allowed to continue or start on nonstudy antidepressants during the study, as prescribed by the participant's personal physician.
2407061|NCT03523845||Test group|Test group (patients diagnosed with early apical peri-implantitis diagnosed)
2407062|NCT03523845||Control group|Control group (patients whose implants had not developed any inflammatory/infectious process and were osseointegrated)
2407063|NCT03523832|Active Comparator|Group 1|celecoxib 400mg and pregabaline 150mg 1 hour before operation
2407064|NCT03523832|Active Comparator|Group 2|celecoxib 200mg and pregabaline 75mg twice daily started from 3 days before operation
2407065|NCT03523832|Placebo Comparator|Group 3|No treatment given
2407068|NCT03523806|Experimental|Solution-Focused Coaching Group|Half of the participants (n=15) will be assigned a coach and receive coaching 8 times for up to 1 hour over 6 months. The first session will take place in the home and subsequent session will take place online using an online meeting tool.
2407069|NCT03523806|No Intervention|Control Group|Half of the participants (n=15) will not be receiving coaching
2407070|NCT03523793|Experimental|Physical Therapists - CPG|Cross-sectional stepped wedge design with 16 physical therapy clinics (including approximately 40 physical therapists) being allocated to one of 4 sequences that differ in CPG implementation time (each sequence consisting of 4 clinics). This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
2407071|NCT03523793|Active Comparator|Physical Therapists - Control|This proposed study will be conducted over 68 weeks, with the initial 12 weeks serving as a baseline washout phase (before any clinic has received training), then 4 clinics crossing over from standard care (control) to CPG and decision support tool implementation (intervention) approximately every 8 weeks until week 44 when all 4 sequences (16 clinics) have completed training.
2407072|NCT03523767|Experimental|Typhoid Vaccine, then Normal Saline|0.5 ml of S.typhi injection, then 0.5 ml of normal saline injection
2407073|NCT03523767|Placebo Comparator|Normal Saline, then Typhoid Vaccine|0.5 ml of normal saline injection, then 0.5 ml of S.typhi injection
2407074|NCT03523754|Other|Misoprostol only|This group will receive Intravaginal Misoprostol only.
2407075|NCT03523754|Other|Isosorbide Mononitrate & Misoprostol|This group will reveive intravaginal Isosorbide Mononitrate & Misoprostol.
2407076|NCT03523728|Experimental|Venglustat dose 1|Patients will receive venglustat dose 1 once daily for 24 months
2407077|NCT03523728|Experimental|Venglustat dose 2|Patients will receive venglustat dose 2 once daily for 24 months
2407078|NCT03523728|Placebo Comparator|Placebo|Placebo will be given once daily (Stage 1 and Stage 2) for 24 months
3144496|NCT00042211|Experimental|1|Problem Solving Treatment
3144497|NCT00042211|Active Comparator|2|Control
2407083|NCT03523689||Observational (bronchoscopy, RP-EBUS)|Patients undergo bronchoscopy per standard of care, RP-EBUS of the left and right lungs during bronchoscopy procedure, and RP-imaging over 3-5 minutes at the end of the bronchoscopy procedure.
2407084|NCT03523676||Group A|sepsis patients who did not develop atrial fibrillation during ICU stay
2407085|NCT03523676||Group B|sepsis patients with newly developed atrial fibrillation during ICU stay
2407088|NCT03523650|Experimental|Group 1: Propranolol Group|Group 1: Propranolol - group of randomized patients will receive one propranolol pill tid for 36 months.
2407089|NCT03523650|Placebo Comparator|Group 2: Placebo Group|Group 2: Placebo - group of randomized patients will receive one placebo pill tid for 36 months.
2407090|NCT03523637|Experimental|Pain Education/Interoceptive Exposure|This study will evaluate the effects of IE and will briefly comprises of: education session explaining the rationale behind IE practice, teaching of the technique, supervised IE practice and self-monitored home practice twice daily for the period of two weeks.
2407091|NCT03523611||lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
3144498|NCT00042289||Women taking ARVs without TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving one or more of the following ARV drugs/drug combinations but not receiving TB treatment: atazanavir/cobicistat, darunavir/ritonavir, darunavir/cobicistat, etravirine, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF/cobicistat, TAF/ritonavir, efavirenz, or lopinavir/ritonavir.~Note: As of February 2016, the study will no longer enroll women receiving etravirine or increased dose lopinavir/ritonavir."
2407092|NCT03523598|Placebo Comparator|Placebo gel + Normal Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
2407093|NCT03523598|Experimental|Placebo Gel + Potassium Nitrate Toothpaste|The patient will receive the application of placebo gel on vestibular surface teeth, for 10 minutes and will use the Potassium nitrate toothpaste (Sensodyne).
2407094|NCT03523598|Experimental|Potassium Nitrate Gel + Normal Toothpaste|The patient will receive the application of 5% Potassium nitrategel on vestibular surface teeth, for 10 minutes and will use the normal toothpaste (Colgate).
2407095|NCT03523585|Experimental|Trastuzumab deruxtecan (DS-8201a)|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to treatment with DS-8201a
2407096|NCT03523585|Active Comparator|Trastuzumab+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Trastuzumab/capecitabine
2407097|NCT03523585|Active Comparator|Lapatinib+capecitabine|HER2 positive, unresectable and/or metastatic breast cancer participants previously treated with standard of care HER2 therapies, including ado-trastuzumab emtansine (T-DM1), randomized to investigator's choice treatment with Lapatinib/capecitabine
2407098|NCT03523572|Experimental|Dose Escalation|"Part 1 will enroll participants meeting the eligibility criteria set up for any of the 4 cohorts of Part 2 specified below using a 3 + 3 + 3 design. Escalating/de-escalating doses of trastuzumab deruxtecan in combination with a flat dose of nivolumab will be administered on Day 1 of each 21-day cycle.~The recommended dose for expansion (RDE) will be calculated using data collected from this population in the first two cycles. These participants may continue to receive study treatment in subsequent cycles."
2407099|NCT03523572|Experimental|Dose Expansion - Cohort 1|"Cohort 1 (n=30): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined positive HER2 expression (IHC 3+ or IHC 2+/ISH+) [as defined by American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines]. These participants have received prior ado-trastuzumab emtansine (T-DM1).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
2407100|NCT03523572|Experimental|Dose Expansion - Cohort 2|"Cohort 2 (n=15): Participants with pathologically documented advanced/metastatic breast cancer that has centrally-determined low HER2 expression (IHC 1+ or IHC 2+/ISH-), who have exhausted treatments that can confer any clinically meaningful benefit (eg, other therapies such as hormonal therapy for patients who are hormone receptor positive).~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
2407101|NCT03523572|Experimental|Dose Expansion - Cohort 3|"Cohort 3 (n=30): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 2+ or 3+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
2407102|NCT03523572|Experimental|Dose Expansion - Cohort 4|"Cohort 4 (n=15): Participants with pathologically documented advanced/metastatic urothelial carcinoma that has centrally-determined HER2 expression of IHC 1+, who received prior platinum-based therapy with documented progression.~Participants will receive the RDE of trastuzumab deruxtecan and the flat dose of nivolumab."
2407103|NCT03523559||Interstitial Cystitis|
2407104|NCT03523559||normal|
2407105|NCT03523546|Experimental|Cancer Episode Payment Model|Oncologists in this arm will be paid for each member's episode of care. The episode of care is 6 months in duration. Oncologists will have the opportunity to receive performance-based payments based upon a set of 6 quality metrics.
2407106|NCT03523546|No Intervention|Fee for Service|Oncologists in this arm will not receive the intervention and will continue to be paid through fee-for-service.
2407107|NCT03523533|Experimental|Peripherally-inserted internal jugular catheter|All enrolled patients will receive a peripheral angiocatheter in the internal jugular vein, under dynamic ultrasound guidance.
2407108|NCT03523520|Active Comparator|Methylnaltrexone oral tablets|"Methylnaltrexone oral tablets (total 450 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2407109|NCT03523520|Active Comparator|Methylnaltrexone subcutaneous injection|"Methylnaltrexone 12mg subcutaneous injection + sugar placebo tablet~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2407110|NCT03523520|Active Comparator|Naloxegol oral tablets|"Naloxegol oral tablets (total 25 mg) + subcutaneous water injection~Eligible patients with complaint of opioid-induced constipation will receive this treatment after study enrollment. Time to bowel movement will be recorded until 3 hours in the emergency department, and patient will be contacted after 24 hours if bowel movement was not achieved after the 3 hours."
2407111|NCT03523507|Experimental|Active: rTMS|Participants will receive 20 bilateral treatment sessions provided over approximately a 5-week period. Daily sessions entail approximately 60 minutes of time.
2407112|NCT03523507|Sham Comparator|Sham: rTMS|Sham: Repetitive Transcranial Magnetic Stimulation; Participants will receive sham treatment designed to have similar sound and tactile sensation, without producing active stimulation.
2407113|NCT03523494||Normal limb|Normal
2407114|NCT03523494||Abnormal limb|Lymph Edema
2407115|NCT03523481||NHF use|
2407118|NCT03523455|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment) Taken once each day after breakfast, but before lunch.
2407119|NCT03523455|Active Comparator|Iron Aid IPS (Iron Protein Succinylate)|IronAid Iron Protein Succinylate 30 mg Taken once each day after breakfast, but before lunch.
2407293|NCT03522363|Experimental|Multidose group|7 vials with 5,5E09 CFU/g Total dose treatment: 4E10 CFU
3144499|NCT00042289||Women taking ARVs with TB treatment|"HIV-infected pregnant women will be assigned to this arm if receiving efavirenz, lopinavir/ritonavir, or nevirapine and TB treatment with at least one of the following TB drugs at study entry: rifampicin, ethambutol, isoniazid, or pyrazinamide.~Note: As of February 2016, the study will no longer enroll women receiving nevirapine."
2407121|NCT03523429|Experimental|blinatumomab|blinatumomab administered during the early consolidation phase in patients ≤ 55 years with high-risk Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukaemia (ALL) with MRD < 0.1% (< 1×10-3) after induction therapy.
2407122|NCT03523416|Experimental|Edwards Transcatheter Atrial Shunt System|
2407123|NCT03523403|Experimental|Acute phase - intervention|Participants will be asked to consume 3 whole apples and a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
2407124|NCT03523403|No Intervention|Acute phase - control|Participants will be asked to consume a high-fat meal (a mixture of commercially available whipping cream and milk, providing 1 g of fat per kg of body weight) within 30 minutes.
2407125|NCT03523403|Experimental|Chronic phase - intervention group|Participants will be asked to consume 3 whole apples per day for 6 weeks.
2407126|NCT03523403|No Intervention|Chronic phase - control group|Participants will be asked to consume no apples per day for 6 weeks.
2407127|NCT03523390|Experimental|Avelumab|
3144500|NCT00042289||Women taking no ARVs with TB treatment|HIV-uninfected pregnant women will be assigned to this arm if receiving at least two of the following first-line TB drugs at study entry: ethambutol, isoniazid, pyrazinamide, or rifampicin.
2407129|NCT03523351|Active Comparator|Standard of care|Patients randomized to Arm 1 will undergo appropriate therapy as determined by their oncologist. These patients will either continue their current therapy or be transitioned to a new standard of care therapy at the discretion of the treating oncologist. If randomized to Arm 1, these patients may undergo palliative RT for progressive, painful lesions (a skeletal related event) at time of symptom development (not upfront palliative RT).
2407130|NCT03523351|Experimental|Selective radiation to ≤5 highest risk bone metastases|Patients on Arm 2 of the study will undergo selective RT to ≤ 5 high risk bone metastases defined as 1. bulkiest sites of osseous disease ≥ 2cm, 2. disease involving the hip (acetabulum, femoral head, femoral neck), shoulder (acromion, glenoid, humeral head), or sacroiliac joints 3. disease in long bones with1/3-2/3 cortical thickness (humerus, radius, ulna, clavicle, femur, tibia, fibula, metacarpus, phalanges) 4. disease in junctional spine (C7-T1, T12-L1, L5-S1) &/or disease with posterior element involvement.
3144501|NCT00042289||Women with/without ARVs w/TB treatment for drug-resistant TB|HIV-infected and HIV-uninfected pregnant women with or without ARVs will be assigned to this arm if receiving at least two of the following second-line TB drugs at study entry: kanamycin, amikacin, capreomycin, moxifloxacin, levofloxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose isoniazid (INH), bedaquiline, clofazamine, delamanid, linezolid, or pretomanid.
2407132|NCT03523299|Experimental|Cryoablation|Participants in this arm will receive cryoablation of their breast tumor two weeks before their routine lumpectomy. They will undergo two blood draws: one before cryoablation (at the time of consent) and one after cryoablation (at the time of surgery).
2407133|NCT03523299|No Intervention|Control|Participants in this arm will undergo a blood draw at the time of consent and then will continue with their scheduled lumpectomy (standard of care).
2407134|NCT03523286|Experimental|RAPID-VT Software guided ablation|The induced VT(s) 12-lead ECG will be acquired by the RAPID-VT software which will provide real time localization of the VT(s) exits from the scar margin. These exits will be targeted by ablation
2407135|NCT03523273|Active Comparator|Liraglutide|Saxenda initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2407136|NCT03523273|Placebo Comparator|Placebo|Placebo initiated at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6 mg/day in weekly intervals to a dose of 3.0 mg/day is achieved. Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2407137|NCT03523260|Active Comparator|Tunneled dialysis Split-tip catheter|High-flow tunneled Split-tip catheter for hemodialysis will be inserted by standard interventional technique
2407138|NCT03523260|Active Comparator|Tunneled dialysis Step-tip catheter|High-flow tunneled Step-tip catheter for hemodialysis will be inserted by standard interventional technique
2407139|NCT03523260|Active Comparator|Tunneled dialysis Symmetric tip catheter|High-flow tunneled Symmetric tip catheter for hemodialysis will be inserted by standard interventional technique
2407140|NCT03523247|Experimental|Whole Food Plant Based Diet|Single-arm whole-food, plant-based diet will explore the effects on primary prevention in a free-range environment
2407141|NCT03523234|Experimental|surgery group|
2407142|NCT03523234|Placebo Comparator|control group|
2407143|NCT03523221|Active Comparator|Dexamethasone arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
2407144|NCT03523221|Placebo Comparator|Placebo arm|All patients will be Urgently treated for anaphylaxis according to guideline protocol. Enrolled patients will be given one of study medication orally, and he /she will observe in the observation room with cardiac monitor and close monitoring by nurse.
2407145|NCT03523195|Active Comparator|Arm 0 (written information)|Participants wear Fitbit and receive written information on healthy exercise and diet recommendations.
2407146|NCT03523195|Experimental|Arm I (exercise program)|Participants complete exercise program including aerobic and resistance exercises over 60 minutes 3 times per week for 12 weeks. Exercise is supervised all 3 times during weeks 1-2. During weeks 3-12, exercise is supervised 2 times a week, with home-based coaching for an additional 60 minutes a week.
2407147|NCT03523182|Experimental|Spirulina (SP)|Children in the SP group (n=251) received a soya-maize-based porridge for 12 months with the addition of spirulina.
2407149|NCT03523156|Active Comparator|Azithromycin mass treatment|Persons living in regions randomized to this arm will receive mass drug administration (MDA) of azithromycin per the current annual MDA schedule.
2407150|NCT03523156|Experimental|Azithromycin mass treatment plus targeted treatment|In addition to azithromycin administration per the current annual MDA schedule, children in regions randomized to this arm will receive azithromycin targeted treatment.
2407151|NCT03523143|Experimental|Early-screen Group|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
2407152|NCT03523143|Active Comparator|Standard-screen Group|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). The time of standard screening and intervention will be 6-8 weeks later than that of early screening and intervention.
2407153|NCT03523130||HIV-infected|
2407154|NCT03523130||non-HIV-infected|
2407155|NCT03523117|Active Comparator|Ferric Caroboxymaltose|Ferric Carboxymaltose - 2 doses (day 0 and day 7) at 15 mg/kg to a maximum single dose of 750 mg (whichever is smaller) up to a maximum of total dose of 1500 mg administered as either an undiluted IV push at a rate of 100 mg (2mL)/minute OR in no more than 250 mL of normal saline and infused over 15 minutes.
2407156|NCT03523117|Active Comparator|Oral Ferrous Sulfate|Oral Ferrous Sulfate - will receive an age-dependent formulation of oral ferrous sulfate daily for 28 days as follows: participants <12 years of age will receive 6 mg (elemental iron)/kg/day divided into 2 daily doses of an oral liquid formulation, either drops or elixir, and participants ≥12 will receive 2 daily doses of oral tablets. Infants and children (ages 1 to <4 years) will receive oral ferrous sulfate drops, while children (ages ≥4 to <12 years) will receive oral ferrous sulfate elixir. Adolescents (ages ≥12 to 17 years) will receive an oral ferrous sulfate tablet (65 mg of elemental iron/tablet/dose) twice a day (BID). The maximum daily dose for all participants is 130 mg of elemental iron.
2407157|NCT03523091|Experimental|3 Injection Sites|OnabotulinumtoxinA 100Unit injection into 3 sites throughout the bladder
2407158|NCT03523091|Experimental|10 Injection Sites|OnabotulinumtoxinA 100Unit injection into 10 sites throughout the bladder
2407159|NCT03523039|Experimental|Hemoadsorption|Hemoadsorption is performed using a CytoSorb® cartridge.
2407160|NCT03523039|No Intervention|Control|Post-cardiac arrest management will be conducted as per institutional protocols.
2407161|NCT03523026|Experimental|NMES and Peripheral Muscle Training|"Neuromuscular Electrical Stimulation (NMES) and Peripheral Muscle Training~NMES frequency will be 30 Hertz and the application time will be 30 minutes.Treatment will be programmed for 3 days per week.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
2407162|NCT03523026|Experimental|IMT and Peripheral Muscle Training|"Inspirator Muscle Training (IMT) and Peripheral Muscle Training~IMT will be applied 7 days per week, twice a day for 15 minutes.~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week. The program will continue for 6 weeks."
2407163|NCT03523026|Experimental|Peripheral Muscle Training|"Peripheral Muscle Training~Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks."
2407164|NCT03523013|Experimental|CPAP pressure (determied by DISE)|
2407165|NCT03523013|Active Comparator|CPAP pressure (determined by physician)|
2407166|NCT03523000|Active Comparator|Active Solution|Continuous intrathecal prognostic infusion test of active solution: intrathecal bupivacaine 0.625 mg/ml and fentanyl 1 mcg/ml
2407167|NCT03523000|Placebo Comparator|Inactive Placebo Solution|Continuous intrathecal prognostic infusion test of inactive placebo solution: preservative-free normal saline
2407168|NCT03522987|Experimental|Epileptologist-Driven Treatment|The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
2407169|NCT03522974|Placebo Comparator|Placebo|40 g/d placebo powder
2407170|NCT03522974|Experimental|Strawberry powder (high dose)|40 g/d freeze dried strawberry powder
2407171|NCT03522974|Active Comparator|Strawberry powder (low dose)|13 g/d freeze dried strawberry powder
2407172|NCT03522961|Active Comparator|Nitrofurantoin prophylaxis/Placebo|Subjects will receive Nitrofurantoin 100mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to Placebo capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
2407173|NCT03522961|Active Comparator|Cranberry capsules|Subjects will receive TheraCran® One Cranberry 36mg capsules (Bottle A) once a day until they pass their voiding trial and no longer require transurethral catheterization. Subjects will be switched to another bottle of TheraCran® One Cranberry 36mg capsules (Bottle B) once a day, starting the day after they pass their voiding trial until the end of the 28 day study period.
2407175|NCT03522935|Experimental|Elafin 0.03 mg/kg|5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.
2407176|NCT03522935|Experimental|Elafin 0.06 mg/kg|5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.
2407177|NCT03522935|Experimental|Elafin 0.10 mg/kg|5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.
2407178|NCT03522935|Experimental|Elafin 0.15 mg/kg|5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.
2407179|NCT03522935|Experimental|Elafin 0.18 mg/kg|5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.
2407180|NCT03522935|Placebo Comparator|Placebo Drug|5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.
2407181|NCT03522922|Active Comparator|Dermaroller arm|Patients received a series of six treatments by dermaroller at 4 weeks interval and no topical anti scar treatment in between sessions.
2407182|NCT03522922|Active Comparator|Dermaroller + topical Vit. C arm|Patients received a series of six treatments by dermaroller at 4 weeks interval with the same maneuver and instructions as first group and each session was followed by immediate application of topical vitamin C serum plus once daily application in between sessions.
2407183|NCT03522922|Active Comparator|Topical Vit. C arm|Patients received once daily topical vitamin C serum capsule at night for six months. With monthly evaluation.
2407184|NCT03522909||Study|We will be reviewing records of parturients seen at Johns Hopkins Hospital in the Center for Peripartum Optimization (CPO) clinic between January 2017 to January 2018
2407185|NCT03522909||Control|A matched controlled group patients not seen at the CPO clinic
2407186|NCT03522896|Placebo Comparator|control meal|glucose, fructose, sucrose, malic acid and citric acid in water
2407187|NCT03522896|Experimental|test meal 1|orange juice with added hesperidin (low dose)
2407188|NCT03522896|Experimental|test meal 2|orange juice with added hesperidin (high dose)
2407189|NCT03522896|Experimental|test meal 3|diluted orange juice with added hesperidin
2407190|NCT03522883|Placebo Comparator|group control|the subjects will not take any type of nutrient intake
2407191|NCT03522883|Experimental|experimental group 1|carbohydrate intake prior to exercise
2407192|NCT03522883|Active Comparator|experimental group 2|carbohydrate intake prior to exercise
2407193|NCT03522870|Experimental|Flash Glucose Monitoring System|People selected to this group will using flash glucose monitoring system continuously on Week 2-14 and Week 14-26.
2407194|NCT03522870|Active Comparator|SMBG|People selected to this group will using SMBG continuously on Week 2-14 and Week 14-26.
2407195|NCT03522857||Teesside University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
2407196|NCT03522857||Glasgow Caledonian University|nursing, midwifery, physiotherapy, occupational therapy, diagnostic radiography, paramedics
2407197|NCT03522857||Northumbria University|nursing, midwifery, physiotherapy, occupational therapy
2407198|NCT03522857||University of Nottingham|Physiotherapy, nursing and midwifery
2407199|NCT03522857||Curtin University|Physiotherapy
2407200|NCT03522857||Notre Dame University|Physiotherapy
2407201|NCT03522857||University College Dublin|Physiotherapists
2407202|NCT03522857||Leeds Beckett University|Physiotherapists
2407203|NCT03522857||University College Cork|Physiotherapists
2407204|NCT03522857||Robert Gordon University|OT, Physio, Midwifery, Nursing, Diagnostic radiography
2407205|NCT03522857||University of Ulster|Physiotherapy
2407206|NCT03522857||University of Limerick|OT, Physio, Midwifery, Nursing, Diagnostic radiography, paramedic
2407207|NCT03522844|Experimental|Mindfulness-Based Stress Reduction (MBSR)|
2407208|NCT03522844|Active Comparator|Escitalopram|
2407209|NCT03522831|Active Comparator|Salbutamol meter-dose inhaler|Inhalation of 400 μg salbutamol
2407210|NCT03522831|Placebo Comparator|Placebo meter-dose inhaler|Inhalation of 400 μg placebo
2407211|NCT03522818|Active Comparator|Normal|Group will use the alarm as provided by the manufacture.
2407212|NCT03522818|Experimental|Manual trigger|Group will use the same model but will be instructed to manually trigger the alarm 1-2 hours after the child falls asleep.
2407213|NCT03522805|Experimental|Non-invasive ventilation|Subjects will undergo a baseline night with standard polysomnography, followed by a treatment night using non-invasive ventilation under polysomnography
2407214|NCT03522792|Experimental|Saline + ad libitum meal|This will serve as the placebo / control day for the NT + ad libitum meal study day.
2407215|NCT03522792|Experimental|NT + ad libitum meal|Neurotensin (NT) infusion followed by an ad libitum meal to study the effect of NT on ad libitum food intake.
2407216|NCT03522792|Experimental|Saline + liquid meal + ad libitum meal|Saline infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This will serve as the placebo / control day for the NT + standardized liquid mixed meal + ad libitum meal study day. Investigating the effect of NT on the second meal effect.
2407217|NCT03522792|Experimental|NT + liquid meal + ad libitum meal|NT infusion followed a standardized liquid mixed meal followed by an ad libitum meal. This study day aims to study the effect of NT on the second meal effect.
2407218|NCT03522792|Experimental|Neurotensin|Acclimatization day
2407219|NCT03522779|Placebo Comparator|High-fat meal + placebo|Participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2407220|NCT03522779|Experimental|High-fat meal + tart cherry|Participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2407221|NCT03522779|Placebo Comparator|Exercise + high-fat meal + placebo|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve. The following morning participants will complete a high-fat meal challenge with a placebo beverage.The placebo will be designed to match the tart cherry juice for volume and macronutrient content, but without the phytonutrient content of the tart cherries.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2407222|NCT03522779|Experimental|Exercise + high-fat meal + tart cherry|Participants will perform an acute bout of submaximal aerobic exercise 15 hours prior to the high-fat meal test. The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.The following morning participants will complete a high-fat meal challenge with a tart cherry juice concentrate. 60 mL of montmorency tart cherry concentrate will be diluted with 100 mL of water.The high-fat breakfast meal will consist of 2 Sausage Biscuits (McDonalds Corporation). Blood draws will then be obtained at 1, 2 and 3 hours postprandially for antioxidant and oxidative stress measurements.
2407223|NCT03522766||Healthy volunteers with no urinary tract infections|people who don't experience urinary tract infections
2407224|NCT03522766||Healthy volunteers with urinary tract infections|people who frequently experience urinary tract infections
2407225|NCT03522766||Intermittent catheter users with neurogenic bladder|
2407226|NCT03522766||Intermittent catheter users with enlarged prostate|
3144502|NCT00042289||Women taking ARVs with postpartum hormonal contraceptives|"HIV-infected women 2-12 weeks postpartum will be assigned to this arm if receiving one of the following ARV drug combinations and starting postpartum contraceptives: atazanavir/ritonavir/tenofovir, darunavir/cobicistat, atazanavir/cobicistat, or efavirenz AND starting combined oral contraceptives formulated with ethinyl estradiol; or atazanavir/ritonavir/tenofovir, efavirenz, atazanavir/cobicistat, or darunavir/cobicistat AND starting etonogestrel implant.~Note: As of February 2016, the study will no longer enroll women receiving atazanavir/ritonavir/tenofovir or efavirenz AND starting etonogestrel implant."
3144503|NCT00042406|Placebo Comparator|Placebo|
3144504|NCT00042406|Experimental|HuMax-CD4 80 mg|80 mg
2407230|NCT03522740|Active Comparator|Decision Aid for Renal Therapy|Usual Care as in the 'no intervention arm' below plus access to an web-based decision aid, the Decision Aid for Renal Therapy to patients and their care-partners
2407231|NCT03522740|No Intervention|Usual Care|In-person education as would be done at study sites plus 'Choosing a Treatment for Kidney Failure', an educational booklet published by the National Kidney Foundation
2407232|NCT03522727|No Intervention|Control|Participants will be asked to complete a questionnaire.
2407233|NCT03522727|Experimental|Intervention 1|"Single self-incentivising implementation intention~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…~**Drop down menu**~Learning a new skill..."
2407234|NCT03522727|Experimental|Intervention 2|"Multiple self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form self-incentivising implementation intentions:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself. You can choose as many rewards as you like! Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by… and/or…~**Drop down menu**~Learning a new skill..."
2407235|NCT03522727|Experimental|Intervention 3|"Self-generated self-incentivising implementation intentions~After completing a questionnaire, participants will be asked to form a self-incentivising implementation intention:~Research shows that rewarding yourself for success can help you to lose weight, but that people often forget to reward themselves. We want you to plan to reward yourself if you achieve your personal weight-loss goal, at the end of 4 weeks. To help you do this, we would like you to complete the following sentence by telling us how you will reward yourself.~Please complete the following sentence with a reward of your own choosing.~If I lose at least ___lbs/kg by the end of 4 weeks, then I will reward myself by…"
2407236|NCT03522714|Active Comparator|Fluid Immersion Simulation System (FIS)|Pressure ulcer patients are assigned to Fluid Immersion Simulation System (Dolphin) after operative debridement and closure.
2407237|NCT03522714|Active Comparator|Air Fluidized Bed System (AFB)|Pressure ulcer patients are assigned to Air Fluidized Bed (Clinitron) after operative debridement and closure
2407238|NCT03522701|Experimental|Group CBTI|Behavioral: Cognitive Behavioural Therapy for Insomnia (CBT-I) The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
2407239|NCT03522701|Active Comparator|Email-delivered CBTI|The email delivered self-guided CBT-I consists of 8 weekly learning sessions. Participants will receive an email embedded with session materials each week.
2407240|NCT03522701|No Intervention|Waiting-list control|Participants will not receive any active treatment.
2407241|NCT03522688|No Intervention|control group|The control group was given normal saline by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
2407242|NCT03522688|Active Comparator|treatment group|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour
2407296|NCT03522337|Placebo Comparator|Control group|The main intervention is conventional leaflets. Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by leaflets.
2407297|NCT03522337|Experimental|Test group|The main intervention is visual pedagogy (social stories). Tooth-brushing training (toothbrushes and toothpastes provided) and oral health instruction are reinforced by social stories.
2407338|NCT03522025|Experimental|GMK-UNI cementless fixation prosthesis|Unicompartmental Knee Arthroplasty (UKA)
3144505|NCT00042406|Experimental|HuMax-CD4 160 mg|160 mg
3144506|NCT00042458|Placebo Comparator|Placebo|Placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.Ingredients: D-Mannitol 43.0 mg/mL Metacresol 2.25 mg/mL Glacial acetic acid 1.53 mg/mL Sodium acetate trihydrate 0.61 mg/mL pH 4.0 Water for injection qs to 5.0 mL
2407244|NCT03522649|Experimental|Napabucasin plus FOLFIRI|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours. For patients who have failed bevacizumab with irinotecan-based chemotherapies, bevacizumab may be administered with FOLFIRI. FOLFIRI infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks, starting on C1D1. If bevacizumab is added to FOLFIRI, bevacizumab infusion should start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion. 5-FU 400 mg/ m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/ m^2/day continuous infusion. For patients who could not tolerate FOLFIRI at the full dose previously, FOLFIRI should be started at the same dose level the patient tolerated FOLFIRI previously.
2407245|NCT03522649|Other|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
2407246|NCT03522636||Treatment|Prehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
2407247|NCT03522636||Historic control|No prehospital blood products available
2407248|NCT03522623||IBD|Children and families with IBD will be surveyed
2407249|NCT03522610|Experimental|ADAPT|Parents participate in a 14-week in person group based version of ADAPT with web-enhanced online ADAPT materials.
2407250|NCT03522610|No Intervention|Comparison Group|Parents receive services as usual (pamphlets, brochures, etc) on parenting typically found at a VA or Dr.'s office.
2407251|NCT03522597||Normal weight|Normal weight (BMI) women and their infants
2407252|NCT03522597||Obese|Obese (BMI) women and their infants
2407253|NCT03522597||Diabetic|Women with gestational diabetes and their infants
2407254|NCT03522584|Experimental|Treatment (tremelimumab, durvalumab, HIGRT, SBRT)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1, week 1. Treatment repeats every 4 weeks for up to 4 cycles or every 6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1, week 16. Treatment repeats every 4 weeks for up to 9 cycles or every 6 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo hypofractionated radiation therapy using either HIGRT or SBRT over 3 fractions QOD during week 3.
2407255|NCT03522571|Experimental|Patients with altered passive eruption - APE|3 teeth of the patients with altered passive eruption that will undergo to experimental gingivitis
2407256|NCT03522571|Active Comparator|Patients with normal gingival anatomy - Non APE|3 teeth of the patients with normal gingival anatomy that will undergo to experimental gingivitis
2407257|NCT03522558|Experimental|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
2407258|NCT03522558|Active Comparator|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
2407259|NCT03522545|Experimental|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
2407260|NCT03522545|Placebo Comparator|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
2407261|NCT03522532|Experimental|Amalgam (Amg)|Amalgam was sealed in 8-K2 patients and 6-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2407262|NCT03522532|Experimental|Tetric EvoCeram (TEC)|Tetric EvoCeram was sealed in 12-K2 patients and 5-K5 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2407263|NCT03522532|Experimental|Beautifil (BF)|Beautifil was sealed in 15-K2 patients. Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment.
2407264|NCT03522532|Experimental|Zinc phosphate cement (ZPhC)|"Zinc phosphate cement was sealed in 7-K2 patients, 4-K3 patients, 1-K4 patients and 2-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
2407265|NCT03522532|Experimental|Zinc polycarboxylate cement (ZPoC)|"Zinc polycarboxylate cement was sealed in 5-K2 patients, 4-K3 patients and 5-K4 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
2407266|NCT03522532|Experimental|Glass ionomer cement (GIC)|"Glass ionomer cement was sealed in 11-K2 patients, 2-K3 patients and 1-K5 patients.~Oxidative stress parameters (MDA, GSH, tSOD) were measured in GCF prior to treatment and on the 7th and 30th day after treatment."
3144507|NCT00042458|Active Comparator|Pramlintide Acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
3144508|NCT00042471|Experimental|Pramlintide acetate (AC137) injection|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
3144509|NCT00042510|Experimental|Treatment Group|500µg G17DT administered on Weeks 1, 5 and 9 and an additional treatment at Week 25. Cisplatin was administered every 4 weeks on the first day of each treatment cycle as a 1 to 3 hour intravenous infusion at a dose of 100mg/m^2. 5-FU was administered every 4 weeks during the first 5 days of each cycle as a continuous intravenous infusion at a dose of 1,000 mg/m^2/d.
2407336|NCT03522051|Experimental|Patients with carious teeth|female or male patients with permanent teeth and deep caries will receive pulpotomy treatment and dressing with calcium silicate based material (Neo MTA plus material) followed by restoration.
3185153|NCT00732082|Experimental|Dose Level 1|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 3 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free period."
3185154|NCT00732082|Experimental|Dose Level 2|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 6.5 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
3185155|NCT00732082|Experimental|Dose Level 3|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 13 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
2407272|NCT03522493|Active Comparator|Young group|This arm include 20 young subjects that will perform the same experiment as the old group for a comparison reasons.
2407273|NCT03522493|Experimental|Old group|This group us the group of interest. This group will wear the mask and is expected to show differences from the younger group.
2407274|NCT03522480|Other|Group A: Education & Gaming|Children will participate in 1 initial training session where they will be taught by a RT to use autogenic drainage (AD). Patients will be sent home & prescribed to practice the technique 15 minutes 3 times / week. At week 8 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform the AD sequence (percent accuracy). At the 8 week visit, the Jamboxx gaming device will be introduced, which will contain a game to guide them through the proper sequence of breathing for the AD technique. Patients will be sent home with a Jamboxx device and requested to do 15 minutes of AD training 3 times / week. Patients will return at week 16 and again will be tested via software program for ability to perform the AD technique.
2407275|NCT03522480|Experimental|Group B: Gaming Only|Children will participate in an initial training session at Albany Med where they will be taught by a RT to use the Jamboxx respiratory therapy device to guide them through autogenic drainage (AD): a series of controlled breathing exercises that mobilizes mucous without inducing wheezing in patients with reactive airways. Patients will be sent home and prescribed to use the Jamboxx respiratory therapy device 15 minutes three times per week. At week 8 and week 16 +/- 1 week patients will return and will be tested by a software program designed to evaluate their ability to perform AD sequence (percent accuracy).
2407276|NCT03522467|Experimental|MRCP001|MRCP001 administered per protocol dose titration regimen (beginning at 1 capsule daily, titrated to a maximum of 3 capsules BID)
2407277|NCT03522454|Experimental|Intervention group|Intervention group: Combination of a protein-rich oral nutritional supplement consumed twice daily for 4 weeks pre-TAVR and 12 weeks after the patient is discharged home post-TAVR, and a home-based supervised exercise program that combines walking and weight-bearing exercises to build strength and balance performed for 12 weeks after the patient is discharged home post-TAVR.
2407278|NCT03522454|No Intervention|Lifestyle counselling group|Lifestyle counselling group: Recommendation to perform moderate-intensity aerobic activity at least 30 minutes 5 days per week as tolerated and eat a balanced diet based on the AHA/ACC Guideline on Lifestyle Management.
3185156|NCT00732082|Experimental|Dose Level 4|"Gemcitabine (1 mg/m2 over 30 min) will be given on days 1, 8, and 15 of a 28 day cycle.~IMP321 26 mg SQ anterior surface of either the right or left thigh on Day 2.~The subsequent doses will be given by subcutaneous injection on the contralateral thigh.~Each single injection will be separated by a 13-day administration free perio"
3185157|NCT00732095|Experimental|Experimental|Immediate Ad
3185158|NCT00732108|Experimental|topiramate|topiramate 50mg orally for 2 weeks, then 100mg orally for 6 weeks
2407282|NCT03522428|Active Comparator|Receiving treatment|Adding vitamin B12 at a dose of 5 μg / 100 days, custom folic acid therapy and iron supplements
2407283|NCT03522428|No Intervention|Control group|Standard prenatal care (custom folic acid therapy and iron supplements)
2407284|NCT03522415|Experimental|HLX01+MTX|
2407285|NCT03522415|Placebo Comparator|Placebo+MTX|
2407286|NCT03522402|Experimental|30 degree rotated lateral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
2407287|NCT03522402|Active Comparator|neutral position|19 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to the head in the neutral position.The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
2407288|NCT03522389|Experimental|AOT with gait training group|Action observation training with gait training
2407289|NCT03522389|Active Comparator|Gait training group|Gait training
2407290|NCT03522389|Other|Control group|Education
2407291|NCT03522376||Chronic obstructive pulmonary disease|Subjects with the diagnosis of chronic obstructive pulmonary disease, stable clinically, has no infection or acute exacerbation in the previous four weeks, and can cooperate with the measurements of this study, loaded inspiratory muscle test.
3185159|NCT00732108|Placebo Comparator|2|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
3185160|NCT00732121|Active Comparator|1|Sitagliptin
3185161|NCT00732121|Placebo Comparator|2|Placebo arm
3185162|NCT00732147|Placebo Comparator|2|Type 2 diabetes patients will receive placebo with 3 meals in experimental period.
3185163|NCT00732147|Experimental|1|Type 2 Diabetes patient will receive Pramlintide with 3 meals in experimental period.
2407298|NCT03522298|Experimental|Dose Escalation and Expansion Cohorts|"This is an open-label study.~Patients in Stage 1 will be enrolled and sequentially assigned to a dose cohort.~The initial cohort will receive an oral dose of 60 mg paxalisib QD (4 x 15 mg capsules). Patients of future dose cohorts will receive paxalisib at increasing levels with 15 mg steps until a dose-limiting toxicity occurs (DLT) occurs. The dose level where <1/3 of the patients exhibit a DLT will be determined the Maximum Tolerated Dose (MTD).~In stage 1, dose escalation will occur for QD dosing.~In stage 2, the expansion phase, patients will receive doses of oral paxalisib at the MTD in stage 1, until disease progression or an unacceptable toxicity, whichever occurs first.~Patients will be randomized in a 1:1 ratio to fed or fasted schedules."
2407299|NCT03522272|Experimental|Ultrasonic cleaning with cetylpyridinium chloride|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with 0.07% cetylpyridinium chloride mouthrinse
2407300|NCT03522272|Active Comparator|Ultrasonic cleaning with water|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent, and ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) of the denture with distilled water
2407301|NCT03522272|Active Comparator|Conventional denture hygiene|Mechanical cleaning of the RPD with a soft toothbrush and liquid detergent (Control group)
2407302|NCT03522259|Active Comparator|A: Rivaroxaban short arm|7 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.
2407303|NCT03522259|Active Comparator|B: Rivaroxaban long arm|"28 day prophylactic postop treatment after Bariatric surgery with 10mg Rivaroxaban p.o.~Subgroup: PK/PD parameters are assessed following the last intake of Rivaroxaban at day 28"
3144510|NCT00042601|Placebo Comparator|Placebo|A clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted.
2407308|NCT03522220|Experimental|3D Super Mario Game Condition|3D navigation video game intervention
2407309|NCT03522220|Active Comparator|2D Super Mario Game Condition|Video game intervention without 3D navigation
2407310|NCT03522220|Active Comparator|Kindle Device|No 3D navigation
2407311|NCT03522207|Experimental|Trazo1|After a baseline polysomnography (PSG), subject will receive 100 mg of trazodone 30 minutes prior to their 2nd PSG and will receive 100mg Placebo 30 minutes prior to their 3rd PSG.
2407312|NCT03522207|Experimental|Trazo2|After a baseline polysomnography (PSG), subject will receive 100 mg of placebo 30 minutes prior to their 2nd PSG and will receive 100mg trazodone 30 minutes prior to their 3rd PSG.
2407313|NCT03522194||Sevoflurane|Anesthesia maintenance
2407314|NCT03522194||Propofol|Anesthesia maintenance
2407315|NCT03522181|Placebo Comparator|control group|saline
2407316|NCT03522181|Experimental|GIK group|glucose-Insulin-Potassium(GIK) infusion
2407317|NCT03522168||Risperidone group|Rispridone, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have <90 days of prior treatment with any antipsychotic.
2407318|NCT03522168||Aripiprazole group|Aripiprazole group, n=350, including 30 children 3 - <6 years old and 320 children 6 - <18 years old. ~50% - ~80% of the entire group will have ≤90 days of prior treatment with any antipsychotic.
2407319|NCT03522155|Experimental|Intervention Arm|"Intervention: (1) Subjects will be provided with patient-specific LE estimates, (2) counseling physicians will receive talking points to assist in meaningful communication of life expectancy, and (3) subjects will complete a computer-based conjoint analysis exercise prior to counseling."
2407320|NCT03522155|No Intervention|Standard-of-care Arm|Patients in the standard-of-care arm will not receive an intervention and will receive the usual standard of care for treatment counseling.
2407321|NCT03522142|Experimental|INCB081776|Single-agent INCB081776.
2407322|NCT03522142|Experimental|INCB081776 + INCMGA00012|INCB081776 in combination with INCMGA00012.
2407323|NCT03522129|Active Comparator|Active Treatment- CT1812 560 mg|
2407324|NCT03522129|Active Comparator|Active Treatment- CT1812 280 mg|
2407325|NCT03522129|Active Comparator|Active Treatment- CT1812 90 mg|
2407326|NCT03522129|Placebo Comparator|Placebo Comparator - Placebo|
2407327|NCT03522116||No intervention|
2407328|NCT03522090||No neck CT|Cohort of patients with suspected lung cancer where the lower neck is not routinely included in CT
2407329|NCT03522090||Neck CT|Cohort of patients with suspected lung cancer where the lower neck is routinely included in CT
2407330|NCT03522077|Experimental|RadAR EasyCLik plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
2407331|NCT03522077|Active Comparator|TR BAND® plus SoftSeal®-STF hemostatic pad|Hemostasis will be obtained with the SoftSeal®-STF hemostatic pad and vascular compression device by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure with a vascular compression device.
2407332|NCT03522077|Experimental|SoftSeal®-STF hemostatic|Hemostasis at the radial access site for subjects randomized to the SoftSeal®-STF hemostatic pad will be obtained by applying pressure at the point proximal and distal to the puncture site and removing the sheath. While still maintaining pressure, the SoftSeal®-STF hemostatic pad will be applied over the puncture site. The cath lab staff will allow a small amount of blood (< 0.2 mL) to contact the surface of the hemostatic pad and then will apply constant pressure.
2407333|NCT03522077|Active Comparator|VascBand™ Hemostat|Hemostasis at the radial access for subjects randomized to the VascBand™ Hemostat will be obtained in accordance to the manufacturer's instructions. The VascBand™ device will be placed proximal to the puncture site and inflated slowly while simultaneously removing the sheath, and continue to inject air (max. 18 mL) into the device until hemostasis is obtained.
2407340|NCT03522012|Active Comparator|RoActemra|4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )
2407341|NCT03522012|Active Comparator|Actemra|4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)
3144511|NCT00042601|Active Comparator|Pramlintide|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection manufactured by Amylin Pharmaceuticals, Inc. It consists of pramlintide (AC137) 0.6 mg/mL in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative.
2407344|NCT03521986|Experimental|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted mediastinal thymectomy, no use of rib-spreader.
2407345|NCT03521986|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted mediastinal thymectomy, no use of rib-spreader.
2407346|NCT03521973|Experimental|Group 1- PfSPZ-Vaccine|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals."
2407347|NCT03521973|Placebo Comparator|Group 2|"Children aged 7-12 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals."
2407348|NCT03521973|Experimental|Group 3|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 1."
2407349|NCT03521973|Placebo Comparator|Group 4|"Children aged 3-6 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 2."
2407350|NCT03521973|Experimental|Group 5|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=44 will receive PfSPZ Vaccine; three doses of 9x10^6 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals; given 2 weeks after the first immunization of Group 3."
2407351|NCT03521973|Placebo Comparator|Group 6|"Children aged 1-2 years (inclusive) of age will be enrolled in this group.~N=22 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals; given 2 weeks after the first dose of NS of Group 4."
2407352|NCT03521960|Active Comparator|Buspirone oral capsule|Buspirone (15 milligrams) administered orally three times per day
2407353|NCT03521960|Placebo Comparator|Placebo oral capsule|Placebo administered orally three times per day
2407354|NCT03521947||One group of children below 18 years old|
2407355|NCT03521934|Experimental|Sotagliflozin|Sotagliflozin dose 1, once daily with possible uptitration in the first 8 months to dose 2
2407356|NCT03521934|Placebo Comparator|Placebo|Placebo dose 1, once daily with possible uptitration in the first 8 months to dose 2
2407357|NCT03521908||Participants treated with apixaban|
2407358|NCT03521908||Participants treated with warfarin|
2407359|NCT03521895||Treatment naïve wAMD|Treatment naïve patients with wAMD treated with IVT aflibercept from the two underlying studies PERSEUS and RAINBOW
2407360|NCT03521882||Stroke Symptom Participants|
2407361|NCT03521882||Healthy Controls|
2407362|NCT03521869|Active Comparator|Compression bandage group|
2407363|NCT03521869|Active Comparator|Standard gauze group|
2407364|NCT03521856|Experimental|shoulder exercise intervention|A home exercise intervention for strengthening and stretching the shoulders - Strengthening and Optimal Movement for Painful Shoulders (STOMPS) - performed 3 times per week for 12 weeks.
2407365|NCT03521856|Active Comparator|education-only control|Subjects watched a 1 hour educational video on shoulder anatomy, mechanisms of shoulder injury and pain, and hints for managing shoulder pain
2407366|NCT03521843|Experimental|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
2407367|NCT03521843|Experimental|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
2407368|NCT03521830|Active Comparator|Previous Systemic Therapy Patients|Arm A: Nivolumab 480mg IV q4weeks for up to 48 weeks (six 8-week cycles)
2407369|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A) and Cohort C|Arm B: ipilimumab 1mg/kg IV q4 weeks x 4 doses + nivolumab 480mg IV q4weeks followed by nivolumab 480mg IV q4weeks for up to 48 total weeks of therapy.
2407370|NCT03521830|Experimental|Progression after anti-PD-1 therapy (Cohort A)|Arm C: nivolumab 480 mg IV q4 weeks plus relatlimab 960 mg IV q4wks.
2407373|NCT03521804|Other|SoundBite™ Crossing System-Coronary|Crossing of coronary chronic total occlusions.
2407376|NCT03521778|Experimental|Fascial Distortion Model group|Patients will receive manual treatment complies with Fascial Distortion Model method.
2407377|NCT03521778|Experimental|Mulligan Concept group|Patients will receive manual treatment complies with Mulligan Concept method.
2407378|NCT03521778|Experimental|Traditional physiotherapy group|Patients will receive traditional physiotherapy.
2407379|NCT03521765|Experimental|OT intervention group|The OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation and on 1-month, 3-month follow-up clinic.
2407380|NCT03521765|No Intervention|non-intervention group|The non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation.
3144514|NCT00042653|Experimental|AMG 073|AMG 073
3144515|NCT00042653|Placebo Comparator|Placebo|Placebo
3144516|NCT00042731|Active Comparator|Oral isoflavones with multivitamin|Cohorts I - III: Patients receive 1 of 3 doses of oral isoflavones twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
3144517|NCT00042731|Active Comparator|Oral lycopene with multivitamin|Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
2407381|NCT03521752|Experimental|Experimental|Performed a specific program exercises (resistance training, balance, coordination and flexibility) during 4 weeks.
2407382|NCT03521752|No Intervention|Control|The control group wasn't subjected to any intervention
2407383|NCT03521726|Other|Intraluminal Amoxicillin eradication|20 Patients receive intraluminal Amoxicillin eradication of H. pylori.
2407384|NCT03521726|Other|Rabeprazole, Amoxicillin dual therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole and Amoxicillin) for 14 days.
2407385|NCT03521713|Experimental|EPORON|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
2407386|NCT03521713|Active Comparator|EPREX|"<Part 1 Treatment Period> Week 1 to Week 24 Initial Phase (Week 1 to Week 4) : 50 IU/kg of Erythropoietin Alpha, three times a week (3 x 50 IU/kg/week) No dose adjustments will be permitted during the first 4 weeks of the study. Maintenance Phase (Week 5 to Week 24) The dose will be adjusted to maintain Hb levels between 10 and 12 g/dL.~<Part 2 Treatment Period> : Week 25 to Week 52 The dose of Erythropoietin Alpha will be adjusted to maintain hemoglobin levels between 10 and 12 g/dL as subcutaneous administration in accordance with the given dosing algorithm. The further details are the same as those for maintenance phase of Part 1 Treatment Period."
2407387|NCT03521700|Experimental|Intensive lipid lowering group|10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L
2407388|NCT03521700|Other|Conventional lipid lowering group|5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L
2407389|NCT03521687|Experimental|Apremilast|Patients with CCCA
2407390|NCT03521674|Other|Foley catheter|Foley catheter will be inserted through the cervical os and it will be filled with 40 ml saline. After insertion gentle traction will be applied for cervical ripening. Pregnancy termination will be achieved.
2407391|NCT03521674|Other|Double-balloon catheter|Double-balloon catheter will be inserted through the cervical os and both baloons will be filled with 40 ml saline. No traction will be applied. Pregnancy termination will be achieved.
2407392|NCT03521661||Kyphoplasty|Patients underwent kyphoplasty with an intravertebral expander
2407393|NCT03521648||PAE|Men with BPH - LUTS BPE who have opted for PAE and have consented to take part in the Register Study.
2407394|NCT03521648||TURP|Men with BPH - LUTS BPE who have opted for TURP and have consented to take part in the Register Study.
2407395|NCT03521648||Other|Men with BPH - LUTS BPE who have opted for other treatment options (e.g., holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate) and have consented to take part in the Register Study.
2407398|NCT03521622|Experimental|brief counseling interventions|"For smoking patients the brief intervention is 5 As model for motivated patients and 5Rs for not motivated patients.~For risky alcohol drinkers the brief intervention is simple advise for motivated patients and brief intervention for not motivated patients."
2407399|NCT03521622|Placebo Comparator|Control group|written informative material about healthy lifestyles
2407400|NCT03521609|Experimental|Emotional Intelligence Intervention|Patient's emotional abilities will be stimulated by means of a brief intervention in a group format (nine sessions). In these sessions we will use both projective and guided-fantasy techniques for the emotional diagnosis, as well as psychoeducational workshops of both emotional education and emotional intelligence development.
2407402|NCT03521570|Experimental|Treatment (nivolumab, IMRT)|Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2407403|NCT03521557|Experimental|Gaze and Postural Stability|"The duration and content of the Gaze and Postural Stability (GPS) intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.~The target duration of each in clinic visit will be 90 min (15 min of gaze stability exercises, 15 min of postural stability exercises and approximately 60 min for the standard care control intervention with rest interspersed throughout the exercise session.~Gaze stability exercise will consist of progressive Vestibular-occular training.~Postural stability exercises will consist of progressive static and dynamic postural training."
2407404|NCT03521557|Active Comparator|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength. The target duration of each in clinic visit will be 90 min (30 min of aerobic exercise, 30 min of lower extremity resistance exercises, and 30 min of rest interspersed throughout the exercise session.
2407405|NCT03521544|Experimental|Plantar Fascia|Self-myofascial release in the plantar fascia.
2407406|NCT03521544|Experimental|Tricep surae fascia|Self-myofascial release in the triceps surae fascia.
2407407|NCT03521544|Experimental|Hamstrings fascia|Self-myofascial release in the hamstrings fascia.
2407408|NCT03521544|Experimental|Spine erectors and lumbar fascia|Self-myofascial release in the spine erectors and lumbar fascia.
2407409|NCT03521544|Experimental|Occipital and suboccipital fascia|Self-myofascial release in the occipital and suboccipital fascia.
2407410|NCT03521544|No Intervention|Control group|Lay on a stretcher.
2407413|NCT03521492|Experimental|caries group|
2407414|NCT03521492|Experimental|free caries group|
3144518|NCT00042731|Active Comparator|Multiple vitamin alone|Patients receive a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
3144519|NCT00042770|Active Comparator|Arm I|Patients undergo placement of a standard pleural chest tube. Within 36 hours of chest tube placement, patients undergo pleurodesis comprising intrapleural administration of talc slurry once followed by clamping of the chest tube for 2 hours while different patient positions are used to distribute the talc. The chest tube is then unclamped to allow continuous drainage. When the chest tube drainage is less than 150 mL over 24 hours, pleurodesis is assumed and the chest tube is removed.
2407421|NCT03521453||Before|Conventionnel written information
2407422|NCT03521453||After, with PEPPER|Written information + presence of a robot (PEPPER) in the waiting room, who will give informations.
2407423|NCT03521440|Experimental|Psychomotor Massage|Participants will be randomly allocated to individual sessions, and will receive two 30-minute individual sessions per week, for 8 weeks.
2407424|NCT03521440|Experimental|Progressive Muscle Relaxation|Participants will participate in 30-minute group sessions, twice a week, for 8 weeks.
2407425|NCT03521440|No Intervention|Waiting List|Participants will maintain their daily routines through the experimental intervention period. After finishing all periods of data collection, participants will be invited to participate in one of the interventions previously offered to the experimental groups.
2407426|NCT03521427|Experimental|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
2407427|NCT03521427|Active Comparator|Neurodevelopmental treatment|Ninety hours of intensive neurodevelopmental therapy
2407428|NCT03521414|Active Comparator|Group I=13-15 mildly injured|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group I (n=15)=13-15 mildly injured"
2407429|NCT03521414|Active Comparator|Group 2 =9-12 moderately damaged|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery.use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 2 (n=15)=9-12 moderately damaged"
2407430|NCT03521414|Active Comparator|Group 3=3-8 severely damaged.|"Patients were divided into 3 groups according to the Glasgow Coma Scores calculated before surgery. use of anesthetic agent were recorded during bispectral index (BIS) monitoring and anesthesia application. we used sevoflurane drug intraoperative.~Group 3 (n=15)=3-8 severely damaged."
2407431|NCT03521401|Experimental|ACE - Exercise Group|Participants with ACE scores of 4 or higher who will undergo exercise training for the duration of the study (experimental).
2407432|NCT03521401|No Intervention|ACE - Non-Exercise Group|Participants with ACE scores of 4 or higher who will not undergo exercise training for the duration of the study (+ control).
2407433|NCT03521401|No Intervention|Non-ACE - Non-Exercise Group|Participants with ACE scores of 0 who will not undergo exercise training for the duration of the study (- control).
2407434|NCT03521388|Experimental|Intervention group|"The intervention consists of an Internet-based program. The program will last 3 months, with subsequent monthly reinforcement sessions for other 3 months.~The program is stepped, so that the more depressive symptomatology the more intensive program and consists of more components.~The students will interact with the program via a monitoring and feedback e-mail with 3 questions of the PHQ--9- adolescent version (1st, 2nd & 9th question) that they will receive every 2 weeks and a Website that will allow them to access to psycho-educational videos and information. There will also in the Website sections that will provide emergency information, the possibility of a contact via e-mail, and group chats. Adolescents with more depressive symptoms or suicidal risk will be invited to participate in an online counselling appointment or a face to face assessment with a mental health professional of the program."
2407435|NCT03521388|Other|Control group|The comparison group will receive general psychoeducation of depression in adolescents and will be on the waiting list to receive the intervention in the event that its efficacy is demonstrated.
2407436|NCT03521375|Experimental|VATS lobectomy|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
2407437|NCT03521375|Active Comparator|Open lobectomy|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
2407438|NCT03521362|Experimental|MyT1DHero App|Participants in this group will receive use of the MyT1DHero app.
2407439|NCT03521362|Active Comparator|"Other T1D App"|Participants in this group will receive use of a different app with less capabilities.
2407440|NCT03521349|Placebo Comparator|Egg White Snacks|Egg white-based snacks
2407441|NCT03521349|Experimental|Whole Egg Snacks|Whole egg-based snacks
2407442|NCT03521336|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
2407443|NCT03521336|Placebo Comparator|Control|Placebo: Sham operation, 10ml saline, once a month for 4 months
2407444|NCT03521323|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
2407445|NCT03521323|Placebo Comparator|Control|Sham operation and 10ml saline as placebos, once a month for 4 months
2407446|NCT03521310|Experimental|Skin-to-skin Contact group|Neonates in gestational age between 28+0 - 32+6 will get continuous Skin-to-skin contact with one parent/caregiver the first 6 hours after birth and as much as possible the first 72 hours after birth.
2407447|NCT03521310|Active Comparator|Conventional care group|Neonates in gestational age between 28+0 - 32+6 will get Conventional care - incubators, warmers etc - the first 72 hours after birth.
2407448|NCT03521297|Placebo Comparator|Placebo group|Placebo (three times per day, one pack each time) and UDCA (13-15mg/kg/day), orally, 6 months
2407449|NCT03521297|Experimental|Probiotics group|Probiotics (three times per day, one pack each time) and UDCA(13-15mg/kg/day), orally, 6 months
2407450|NCT03521284||Mothers with education program during their mat|
2407451|NCT03521284||Mothers without education program during their mat|
2407452|NCT03521258|Experimental|Human Amnion/Chorion Membrane + skin graft|Dehydrated Human Amnion/Chorion Membrane (dHACM) will be placed on wound at the initial debridement to promote granulation tissue at the wound bed. Approximately 5-7 days following debridement, wound will be assessed for suitability of split thickness skin grafting. If an adequate granulation tissue is present, skin grafting will be performed and assessed for take in 5 days.
2407453|NCT03521258|Active Comparator|Flap Reconstruction (Standard of Care)|A negative pressure wound dressing (NPWD) will be applied at the time of debridement until the wound is clean and adequate for flap reconstruction. Flap-based reconstruction is performed. Following flap reconstruction,patient will have 5 days of bed rest to allow proper healing and coverage of the wounds. If flaps are successful, patients starts a limb dangle protocol which gradually increases the dependent position and allows the flap to acclimate to new physiologic demands. Following dangle protocol patient will require inpatient physical and occupational therapy prior to discharge.
2407454|NCT03521245||Trastuzumab monotherapy|Her2-positive breast cancer patients treated with Trastuzumab (monotherapy)
2407455|NCT03521245||Chemotherapy plus Trastuzumab|Her2-positive breast cancer patients treated with Trastuzumab in combination with other regimens of chemotherapy
2407456|NCT03521232|Experimental|150 mg/60 ml|Niclosamide enemas 150 mg/60 ml given twice daily for 6 weeks
2407457|NCT03521232|Experimental|450 mg/60 ml|Niclosamide enemas 450 mg/60 ml given twice daily for 6 weeks
2407458|NCT03521219|Experimental|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
2407459|NCT03521206|Experimental|Intervention group|"The ACP+ programme aims to improve or establish advance care planning (ACP) in the day-to-day routine of staff working in nursing homes.~The intervention implementation period has a total duration of 8 months and is divided into:~a four-month preparation and training phase. During this phase the ACP reference persons will attend a two-day training given by the ACP trainers. Other staff will receive training by the reference persons on conducting ACP conversation or recognizing triggers for an ACP conversation in nursing home residents.~A four-month follow-up phase in which ACP conversations are held with residents. Additional training sessions will be organized to give more in-depth knowledge to the ACP reference persons."
2407460|NCT03521206|No Intervention|Control group|The staff of nursing homes in the control group will receive no additional training next to any standard education or continuous training. After the intervention and follow-up measures are finished, all nursing homes in the control group will be offered a shortened version of the ACP+ training programme as well as all ACP+ training materials.
3144520|NCT00042770|Experimental|Arm II|Patients undergo pleurodesis comprising placement of a small (PleurX) catheter followed by pleural drainage for up to 90 minutes once daily. When the catheter drainage is less than 30 mL per day for 3 consecutive days, pleurodesis is assumed and the catheter is removed.
2407462|NCT03521180||Subjects with Celiac Disease|"Group 1 will start the gluten challenge with 4 slices of white bread once daily for 3 days. Blood will be taken at pre-specified time points for up to 9 days following the start of gluten challenge for biomarker analyses.~Based on data from the first 5 subjects, the 2nd group of 5 subjects may: 1) not be needed if the objectives are met; 2) receive gluten at increased quantity (not to exceed 6 slices of bread once daily for 3 days) or have biomarker samples collected at adjusted time points; 3) same as the first 5 subjects; 4) reducing the duration of gluten free diet for a minimum of 3 months instead of 6 month for the Inclusion Criteria # 5;5) subjects may be re-enrolled once.~The same applies to the 3rd group of subjects. A notification will be provided to the clinical study site for detailed changes."
2407463|NCT03521167|No Intervention|T|traditional opioid based regimen
2407464|NCT03521167|Active Comparator|MD|multimodal group with dexmedetomidine
2407465|NCT03521167|Placebo Comparator|M|multimodal with saline placebo
3144521|NCT00042796|Experimental|Treatment (decitabine)|Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
3144522|NCT00042809|Experimental|Treatment (paclitaxel, trastuzumab, erlotinib hydrochloride)|See detailed description.
2407471|NCT03521128|Experimental|the radiological tubal blockage group|
2407472|NCT03521128|Active Comparator|the laparoscopic salpingectomy group|
2407506|NCT03520868||Dabigatran|Dabigatran patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
2407507|NCT03520868||Rivaroxiban|Rivaroxiban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 110 U/kg
3144523|NCT00042835|Experimental|Group I (cisplatin, etoposide, erlotinib, and docetaxel)|Patients receive cisplatin IV over 2 hours on days 1, 8, 29, and 36; etoposide IV over 1 hour on days 1-5 and 29-33; and oral erlotinib once daily on days 1-49. Patients undergo concurrent radiotherapy 5 days a week for 7 weeks beginning on day 1. Patients receive consolidation therapy comprising docetaxel IV over 1 hour on days 50, 71, and 92. Some patients may also receive oral erlotinib once daily on days 50-112.
3144524|NCT00042835|Experimental|Group II (paclitaxel, carboplatin, and erlotinib|Patients receive induction chemotherapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1 and 21. Patients receive consolidation therapy comprising paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 43, 50, 57, 64, 71, 78, and 85 and oral erlotinib once daily on days 43-91. Patients undergo radiotherapy concurrently with consolidation therapy 5 days a week for 7 weeks beginning on day 43.
3144525|NCT00042874|Experimental|Treatment (combination chemotherapy)|Patients receive irinotecan hydrochloride IV over 90 minutes followed 5 hours later by leucovorin calcium IV over 2 hours and alvocidib IV over 1 hour immediately followed by 5-FU IV continuously over 48 hours beginning on day 1 of weeks 1, 3, and 5. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of alvocidib and 5-FU until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients are treated at the MTD.
3144526|NCT00042926|Experimental|Radiolymphoscintigraphy + surgery|"Patients undergo radiolymphoscintigraphy comprising technetium Tc 99m sulfur colloid to identify the sentinel lymph nodes (SNL). Within 18 hours after radiolymphoscintigraphy, patients undergo resection of the primary oral cavity tumor and radioguided sentinel lymphadenectomy and regional cervical lymphadenectomy. Lymph nodes are examined by hematoxylin and eosin (H&E) staining. If negative by H&E, lymph nodes are further analyzed by immunohistochemistry.~Patients are followed at 30 days."
3144527|NCT00042952|Experimental|Treatment (imatinib mesylate and surgical resection)|Patients receive oral imatinib mesylate once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients who achieve a partial response or stable disease with normalization of human chorionic gonadotropin may undergo surgical resection of residual lesions at each tumor status assessment. If residual viable germ cell tumor is present in the resected specimen, patients may resume imatinib mesylate. If no viable germ cell tumor is present in the resected specimen, then no further therapy is administered.
2407479|NCT03521076|Experimental|Virtual Reality for distraction|The application of VR during the putative painful treatment (botulinum toxin injections) will provide a) active and engaging distraction during the procedure, and will b) block the view and auditory noise related to the procedure.
2407480|NCT03521076|No Intervention|Standard of Care|Patients will receive the standard of care for the putative painful treatment (botulinum toxin injections).
2407481|NCT03521063|Experimental|Poractant alfa/budesonide|A mixture of poractant (200mg/kg) and budesonide (0.25 mg/kg) will be instilled intratracheal
2407482|NCT03521063|Active Comparator|Poractant alfa/saline|A mixture of poractant (200mg/kg) and saline (1 ml/kg) will be instilled intratracheal
2407483|NCT03521050||implanted defibrillator lead|patients having an ICD implanted and having follow-up at the investigators center
3144528|NCT00042965|Experimental|Gemcitabine + capecitabine|"Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 28 days for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year and then every 6 months for 1 year."
2407485|NCT03521024|Active Comparator|lithium disilicate crowns|lithium disilicate crowns are well documented in the literatures as successful restoration modality.
2407486|NCT03521024|Experimental|poly ether ketone ketone crowns|pekkton
2407489|NCT03520985|Experimental|Pomalidomide|The treatment in this trial consists of oral pomalidomide on alternate days (ad) plus Low-Dose Dexamethasone (adPOM + LD-DEX)
2407490|NCT03520972|Experimental|PB-119 75ug|PB-119 injection 75ug subcutaneously injected once-weekly for 12 weeks
2407491|NCT03520972|Experimental|PB-119 150ug|PB-119 injection 150ug subcutaneously injected once-weekly for 12 weeks
2407492|NCT03520972|Experimental|PB-119 200ug|PB-119 injection 200ug subcutaneously injected once-weekly for 12 weeks
2407493|NCT03520972|Placebo Comparator|placebo|placebo injection subcutaneously injected once-weekly for 12 weeks
2407496|NCT03520946|Experimental|Arm A (ramucirumab + TAS102)|Patients randomized to arm A will receive ramucirumab 8 mg/kg iv over 60 min on d1+15, q4w and TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression or intolerance or completion of 6 cycles.
2407497|NCT03520946|Active Comparator|Arm B (TAS102 only)|Patients randomized to arm B will receive TAS102 35mg/m2 p.o. twice daily (BID) d1-5 and 8-12, q4w until progression, intolerance or completion of 6 cycles.
2407498|NCT03520933||Embryos undergoing PGT-A / niPGT-A|Embryos from IVF patients between 20 and 44 years of age, undergoing PGT-A for any medical indication, with own oocytes or ovum donation cycles and with single embryo transfer (SET)
3144529|NCT00042978|Experimental|Arm I (oblimersen sodium, carboplatin, and etoposide)|Patients receive oblimersen sodium IV continuously on days 1-8, carboplatin IV over 30 minutes on day 6, and etoposide IV over 60 minutes on days 6-8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3144530|NCT00042978|Active Comparator|Arm II (carboplatin and etoposide)|Patients receive carboplatin IV over 30 minutes on day 1 and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
2407501|NCT03520907|Experimental|Transversalis Fascia Plane Block|receive transversalis fascia plane block with 0.4 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
2407502|NCT03520907|Active Comparator|Ilioinguinal/iliohypogastric Nerve Block|receive ilioinguinal/iliohypogastric nerve block with 0.1 ml/kg of 0.25% levobupivacaine after establishment of general anesthesia.
2407503|NCT03520894|Experimental|Neoadjuvant radiotherapy arm|Early breast cancer patients eligible for breast conservative surgery will undergo neoadjuvant radiotherapy with Cyberknife robotic system
2407504|NCT03520881|Experimental|Pediatric ASTHMA-Educator arm|This arm corresponds to the pediatric version of the ASTHMA-Educator mobile application.
2407505|NCT03520868||Coumadin|Coumadin patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 70 U/kg
2408550|NCT03514303||Cockroach|Subjects will test positive or negative to the allergen Cockroach.
3144531|NCT00043017|Experimental|MRI/MRS|MRI and MRS examinations with standard imaging, with contrast enhancement using an agent (gadopentetate dimeglumine).
2407508|NCT03520868||Apixaban|Apixaban patients with undergo standard procedure with monitoring of Anti-Factor Xa assay level before and during the procedure. Heparin bolus given will be based on 10 U/kg
2407509|NCT03520855|Experimental|ETP + Serious game|patients receiving the serious game additionally to the classic therapeutic education
2407510|NCT03520855|Active Comparator|ETP|patients under classic therapeutic education
2407511|NCT03520842|Experimental|Treatment (regorafenib, methotrexate)|Participants receive regorafenib PO QD on days 1-21, and methotrexate PO twice weekly with 2-3 days apart on a 3 week on/ 1 week off cycle. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2407512|NCT03520829||Patient treated for Gamma Knife|
2407513|NCT03520816|Experimental|Burn Physiotherapy Protocol Group|Patients in the treatment group have been received to the physiotherapy programme from the first day of their stay in the hospital.
2407514|NCT03520816|No Intervention|Control Group|The control group consisted of patients who could not receive physiotherapy due to various reasons.
2407515|NCT03520803|Experimental|Experimental|ERAS protocol
2407516|NCT03520803|No Intervention|Control|Standard of care
2407517|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Placebo|"Gemcitabine and Nab-paclitaxel is administered intravenously 3 times a cycle.~Placebo is administered orally on a daily basis"
2407518|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol IV|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered intravenously 3 times/week."
2407519|NCT03520790|Experimental|Gemcitabine + Nab-paclitaxel + Paricalcitol oral|"Gemcitabine + Nab-paclitaxel is administered intravenously 3 times/cycle.~Paricalcitol is administered orally on a daily basis"
2407520|NCT03520777|Other|Artist Intervention|One of the three artists (visual artist, music therapist, creative writer) will work with subjects for up to 90 minutes.
2407521|NCT03520764|Experimental|New infant formula with synbiotics|pHP infant formula with synbiotics (test product)
2407522|NCT03520764|Active Comparator|Standard infant formula with prebiotics|Standard (commercial) infant formula with prebiotics (control product)
2407523|NCT03520764|No Intervention|human milk|Full breastfeeding for at least 17 weeks
2407524|NCT03520751|Experimental|Dose (8.87e11 vg/kg)|Three patients age 18-35 will receive intramuscular injection of recombinant AAV1 carrying a human NFT3 gene under the control of the tMCK promoter (scAAV1.tMCK.NTF3) distributed bilaterally between both limbs at a dose of 8.87e11 vg/kg.
2407525|NCT03520738|Other|Chronic Kidney Disease|"Blood and urinary samples on the following patients:~10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis."
2407526|NCT03520738|Other|Pseudoxanthoma elasticum (PXE)|"Blood and urinary samples on the following patients:~10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
2407527|NCT03520738|Other|Hypophosphatasia (HPP)|"Blood and urinary samples on the following patients:~4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification."
2407528|NCT03520725|Experimental|No Intervention|This group did not have an intervention
2407529|NCT03520725|Experimental|Intervention pineapple|Daily consumption of 30 g of pineapple snack bar for 4 weeks.
2407530|NCT03520725|Experimental|Intervention mango|Daily consumption of 30 g of mango snack bar for 4 weeks.
2407531|NCT03520712|Experimental|valoctocogene roxaparvovec Open Label|Single administration of BMN270 at a dose of 6E13 vg/kg
2407532|NCT03520686|Experimental|Cohort A (Experimental)|
2407533|NCT03520686|Experimental|Cohort B (Experimental)|
2407534|NCT03520686|Experimental|Cohort C (Experimental)|
2407535|NCT03520686|Active Comparator|Cohort A (Control)|
2407536|NCT03520686|Active Comparator|Cohort B (Control)|
2407537|NCT03520686|Active Comparator|Cohort C (Control)|
2407538|NCT03520673|Other|Development of Clinical Decision Support Tool|All men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
2407543|NCT03520634|Experimental|PD-L1 PET imaging in melanoma patients|The main intervention of this study is a [18F]PD-L1 PET scan. In both phase one and phase two a scan sequence will be performed both at baseline and 6 weeks after initiation of nivolumab treatment. The PET scans will be combined with either a low dose or diagnostic CT scan of chest, abdomen and pelvis and a MRI of the brain. In phase two, a biopsy of at least one accessible lesion will be performed to analyze PD-L1 expression using immunohistochemical staining after each PET scan.
2407544|NCT03520621||High Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is >2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
2407545|NCT03520621||Low Prevalence Population|Prevalence of kwashiorkor (as diagnosed by bipedal pitting edema) is <2% among children 36 to 59 months old in the population, in Murambi/Malehe Health Area of eastern Democratic Republic of the Congo
2407546|NCT03520595|Active Comparator|Arnica Group|Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days
2407547|NCT03520595|Active Comparator|Diclofenac Sodium group|Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water
2407548|NCT03520595|Placebo Comparator|Placebo Group|Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily
2407549|NCT03520582||Volunteers|Cohort of 10 healthy subjects. The tube will be placed and removed by a gastroenterologist experienced in performing endoscopic postpyloric tube placement. Secondly, a second tube will be placed and removed.
2407550|NCT03520582||Mechanically ventilated ICU|Cohort of 20 mechanically ventilated intensive care patients requiring a placement of a postpyloric feeding tube on clinical indications.
2407551|NCT03520569|Active Comparator|Octreotide- Euglycemia|octreotide is 30 ng/kg/min x 240 min insulin 0.15mU/kg/min x 240 min Dextrose 20% at variable rate to maintain euglycemia for 240 min
2407552|NCT03520569|Active Comparator|Octreotide - Euglycemia- insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 330 min
2407553|NCT03520569|Active Comparator|Octreotide- hyperglycemia|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 330 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
2407554|NCT03520569|Active Comparator|Octreotide- hyperglycemia - insulin clamp|octreotide is 30 ng/kg/min x 330 min insulin 0.15mU/kg/min x 210 min insulin 1.0mU/kg/min x 120 min Dextrose 20% at variable rate to maintain euglycemia for 90 min Dextrose 20% at variable rate to maintain hyperglycemia for 240 min
2407555|NCT03520556||docosahexaenoic acid (DHA)|Adults supplemented with DHA in a randomized controlled trial of ≥7 days duration
2407556|NCT03520556||eicosapentaenoic acid (EPA)|Adults supplemented with EPA in a randomized controlled trial of ≥7 days duration
2407557|NCT03520556||control|Adults supplemented with control fatty acids in a randomized controlled trial of ≥7 days duration assessing the effects of EPA and/or DHA
2407558|NCT03520543|Experimental|Part A : Imput function|Compartmental model of the volume of distribution of [11C]Yohimbine in Brain by PET
2407559|NCT03520543|Experimental|Part B : validity of the measure|Part B1 : Test Retest Variability in the distribution of [11C]Yohimbine Part B2 : Percentage of alpha2-adrenergic receptor occupancy
2407560|NCT03520530|Experimental|Mouth Guard|Patients will push in the second stage of labor without use of mouth guard
2407561|NCT03520530|No Intervention|Control|Patients will push in the second stage of labor without use of mouth guard
2407562|NCT03520517|Experimental|BHV-0223|riluzole 40 mg sublingual tablet
2407563|NCT03520504|Experimental|Proton Radiation|"Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.~The first 3 patients will be enrolled at dose level 30Gy (RBE) in 3Gy(RBE) fractions. If 1 or fewer patients develop dose-limiting toxicity (DLT), 3 additional patients will be enrolled. If 1 or fewer of the 6 patients experiences a DLT, the trial will proceed to the dose expansion cohort at 30Gy (RBE) . In contrast, if 2 or more patients experience a treatment DLT, 3 patients will be enrolled at dose level 25Gy (RBE) in 2.5Gy(RBE) fractions. If 1 or fewer patients develop a DLT, an additional three patients will be enrolled. If 2 or more patients experience a DLT at 25Gy, the study will be stopped. If 1 or fewer patients develop a DLT in these 6 patients, the trial will proceed to the dose expansion cohort at 25Gy (RBE) and the 6 patients who were treated in Phase Ib will be included in full assessment of safety and efficacy."
2407564|NCT03520491|Experimental|Cohort 1|Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.
2407565|NCT03520491|Experimental|Cohort 2|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.
2407566|NCT03520491|Experimental|Cohort 3|Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.
2407567|NCT03520491|Experimental|Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)|Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.
2407568|NCT03520478|Experimental|SHR3680|Participants will receive SHR3680 orally
2407569|NCT03520478|Active Comparator|bicalutamide|Participants will receive bicalutamide orally
2407570|NCT03520465|Experimental|Supraaponeurotic mesh|"Patients with laparotomy closure by conventional approach of aponeurosis (continuous suture with monofilament of slow absorption), and posterior placement of supraaponeurotic mesh of polyvinylidene fluoride (PVDF) medium / low density and wide pore. The mesh has a longitudinal measurement that exceeds about 3 cm the upper and lower ends of the wound and width should not be less than 10 cm, therefore the mesh selected is DynaMesh®-CICAT longitudinal measure 10x35 cm.~The mesh is fixed to the aponeurosis with a crown of loose stitches and points to the midline. A prolene 2/0 non-reabsorbable monofilament suture of cylindrical needle is used.~A 10 Fr suction drainage is placed in the supraaponeurotic plane, with an exit to the exterior beyond the edges of the prosthesis. Drainage will be preserved for a minimum of 48 hours after surgery, and will be withdrawn when a debit of less than 50 ml is presented in 24 h."
2407571|NCT03520465|No Intervention|Monofilament|Patients with conventional closure of the middle laparotomy with approach of aponeurosis in a plane by continuous suture with monofilament of slow absorption. In this study, the suture used in all patients will be poly-4-hydroxybutyrate or Mono-max loop®.
2407572|NCT03520452|Placebo Comparator|Placebo|Placebo
2407573|NCT03520452|Experimental|302 mg green coffee extract|Green coffee extract
2407574|NCT03520452|Experimental|604 mg green coffee extract|Green coffee extract
2407575|NCT03520452|Experimental|906 mg green coffee extract|Green coffee extract
2407576|NCT03520439|Experimental|study group|mifepristone tablets ，10mg，One tablet daily, oral treatment
2407577|NCT03520439|Placebo Comparator|control group|placebo，10mg，One tablet daily, oral treatment
2407578|NCT03520426|Experimental|Votiva RF|Patients will undergo radiofrequency treatment using the Votiva FormaV and FractoraV hand pieces, using the device's standard protocol. Patients will have 3 treatments spaced 3-4 weeks apart and two follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
2407579|NCT03520426|Sham Comparator|Votiva RF Sham|Patients will undergo the acts of receiving radiofrequency treatment with the Votiva FormaV and FractoraV hand pieces, but no direct energy will be applied. Patients will have 3 treatments spaced 3-4 weeks apart and 2 follow-up visits. Duration of each treatment visit is approximately 1-1.5 hours. Prior to treatment and follow-up visit, each patient will be assessed using standardized photos, perineometry, and validated questionnaires.
2407825|NCT03518957|No Intervention|Non-exercise|Patients who are randomised to the non-exercise group can continue their daily and physical activities as they normally would.
2407580|NCT03520413|Experimental|PRACTICE-DM|PRACTICE-DM is a comprehensive telemedicine intervention that bundles telemonitoring, self-management support, diet/activity support, medication management, and depression support - each of which targets a critical factor underlying PPDM - into a single, comprehensive program specifically developed for practical delivery using existing VHA Home Telehealth (HT) workforce, infrastructure, and technical resources.
2407581|NCT03520413|Active Comparator|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
3185164|NCT00732173|Experimental|Arm I|"Patients receive a lifestyle intervention, Survivors of Uterine Cancer Empowered by Exercise and Healthy Diet (SUCCEED), on a group and individual basis consisting of nutrition, exercise, and behavioral modification counseling from a physician, psychologist, registered dietitian, and physical therapist. Sixteen group sessions will be conducted (10 weekly, 6 bi-weekly) for 6 months. Weight and body mass index, satisfaction with study treatment, and exercise/activity logs are assessed weekly and biweekly. Patients receive additional feedback and support during the weeks not met in a group, including newsletters and telephone and e-mail contact."
3185165|NCT00732173|Active Comparator|Arm II|Patients receive usual care informational brochures but no lifestyle counseling related to weight loss, physical activity, and nutrition.
3185166|NCT00732186|Experimental|Group 1 and Group 2|
3185167|NCT00732277|Experimental|Treatment|Patients in this arm will be given the following IMP intraveneously at 6 hour intervals - hydrocortisone (100mg/m2/24 hours)
3185168|NCT00732277|No Intervention|Control|in each phase of study 15 patients will receive no IMP as control arm
3185169|NCT00732290|Active Comparator|1|Clopidogrel then fluoxetine+clopidogrel
2407588|NCT03520374|Other|Ultrasonography- Novices|Novice ultrasonographers will be taught to assess gastric contents with a short and simple educational program. These results will be compared to the evaluation of experts in ultrasonography i.e interventional radiologists.
2407589|NCT03520374|Other|Ultrasonography-Expert Interventional Radiologists|Physician assessment i.e interventional radiologist evaluation of gastric contents using ultrasonography.
2407590|NCT03520361|Experimental|Oral sulfate solution (OSS) taking group|On the evening before colonoscopy, drink 177ml of OSS (Suclear®) (473ml including water in container), additionally allow another 946 ml of water. On the day of colonoscopy, drink 177ml of OSS (473ml including water in container), additionally allow another 946 ml of water.
2407591|NCT03520361|Active Comparator|2L PEG/Asc taking group|On the evening before colonoscopy, drink 1L of 2L PEG/Asc (Haprep®) solution, additionally allow another 500 ml of water. On the day of colonoscopy, drink 1L of 2L PEG/Asc solution, additionally allow another 500 ml of water.
3185170|NCT00732290|Active Comparator|2|Fluoxetine+clopidogrel then clopidogrel
3185171|NCT00732329|Experimental|A|"optimized home based occupational therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
2407594|NCT03520322|Experimental|Mastoid Oscillator|patients with Menieres Disease
2407595|NCT03520322|Placebo Comparator|Control device|patients with Menieres Disease
3144532|NCT00043069|Active Comparator|Arm I: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate placebo, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3144533|NCT00043069|Experimental|Arm II: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, oral risedronate, and oral estrogen placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
2407598|NCT03520296||Patients hospitalized in the cardiology unit|
2407599|NCT03520296||Patients hospitalized in the orthopedic surgery unit|
2407600|NCT03520296||Patients hospitalized in the endocrinology unit|
3185172|NCT00732329|No Intervention|B|treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without optimized occupational therapy
2407602|NCT03520257|Experimental|Apatinib Plus Radiotherapy|
2407603|NCT03520257|Other|Apatinib|
2407604|NCT03520244|Experimental|Exercise + Holistic Education|A 12-week exercise program with 6 bi-weekly education sessions.
2407605|NCT03520244|No Intervention|Wait list control|Participants in the control group will be offered the exercise + education sessions after the study is complete.
3144534|NCT00043069|Placebo Comparator|Arm III: calcium + cholecalciferol + placebo + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate placebo daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3185173|NCT00732342|No Intervention|1|Standard Treatment
2407608|NCT03520218|Experimental|Performance of R-PEM|"5miCi of F-18 FDG will be injected and patients will wait for uptake of FDG before proceeding with first set of R-PEM scans. Additional optional R-PEM scans may be performed 4 hours after injection, and then possibly 7 hours after injection.~These R-PEM images will be compared to standard diagnostic breast work-up using DBT and MRI"
2407609|NCT03520205|Active Comparator|Quadratus Lumborum Block|Patient will receive quadratus lumborum block
2407610|NCT03520205|Active Comparator|Continuous Epidural|Patient will receive epidural anesthesia
2407611|NCT03520179||SMA TYPE 1|genetically confirmed SMA
2407612|NCT03520179||SMA TYPE 2|genetically confirmed SMA
2407613|NCT03520179||SMA TYPE 3|genetically confirmed SMA, Ambulant and non-ambulant
2407614|NCT03520166|Placebo Comparator|Group-A|No treatment
2407615|NCT03520166|Experimental|Group-B|Medium frequency electrotherapy (interferential currents)
2407616|NCT03520153||FD/MAS with diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2407617|NCT03520153||FD/MAS without diabetes mellitus|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2407618|NCT03520153||FD/MAS without diabetes and without IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2407619|NCT03520153||FD/MAS without diabetes and with IPMN|"Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.~Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test."
2407620|NCT03520153||Healthy Controls|Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.
2407621|NCT03520127||Females, 18 years of age or older|Females, 18 years of age or older, who will undergo the Intact procedure
3144535|NCT00043069|Experimental|Arm IV: calcium + cholecalciferol + risedronate + estrogen|"Patients receive oral calcium, oral cholecalciferol, low-dose oral conjugated estrogens, and oral risedronate daily.~Treatment in all arms continues for 2 years.~Quality of life is assessed at baseline, monthly for 6 months, and then at 1 and 2 years.~Bone mineral density is assessed at baseline, 6 months, and 1 and 2 years."
3144536|NCT00043082|Experimental|carboplatin and doxorubicin|carboplatin and liposomal doxorubicin given q 4 weeks
2407624|NCT03520101|Other|SAPIEN|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received an Edwards (SAPIEN XT or SAPIEN 3) valve.
2407625|NCT03520101|Other|COREVALVE|Following the Heart Team's decision to proceed with a TAVI-ViV procedure, patients will received the CoreValve Evolut R or Evolut PRO valve system.
2407626|NCT03520088|Experimental|Inferior mesenteric Vein dissection|To improve and preserve the rectal nerve in the total mesorectal excision, its starts the dissection from the inferior mesenteric vein to the inferior mesenteric artery and through the pelvis
2407627|NCT03520088|Active Comparator|Inferior mesenteric Artery dissection|As standard, the dissection starts straight in the inferior mesenteric artery and through the pelvis
3144537|NCT00043082|Active Comparator|carboplatin|carboplatin alone
3144538|NCT00043108|Experimental|Treatment|Thoracic RT (50.4 Gy/1.8 Gy Fx) Paclitaxel (50mg/m2/weekly X 6) Carboplatin (AUC 2/weekly X 6)
3144539|NCT00043121|Experimental|Treatment (combination chemotherapy)|Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV on days 1 and 15. Patients also receive oral capecitabine every 8 hours on days 1-2 and 15-16. Leucovorin calcium and fluorouracil administration is held at dose level 4 and above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2407631|NCT03520062|Experimental|GLP-1 Receptor Agonist (Liraglutide)|3.0mg daily dose
2407632|NCT03520049|Experimental|Oseltamivir|Oseltamivir capsule administered orally at 75 mg twice daily for five consecutive days.
2407633|NCT03520049|Placebo Comparator|Placebo|Placebo capsule administered orally twice daily for five consecutive days.
2407634|NCT03520036|Experimental|MT-7117 low dose|
2407635|NCT03520036|Experimental|MT-7117 high dose|
2407636|NCT03520036|Placebo Comparator|Placebo|
2407637|NCT03520023|No Intervention|Standard Care|Standard care with consultant discretion regarding consult of palliative care medicine
2407638|NCT03520023|Experimental|Experimental|Early palliative care consult based upon meeting study inclusion criteria
3144540|NCT00043225||Cystic Fibrosis|Cystic Fibrosis patients
3144541|NCT00043368|Experimental|1|Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley.
3144542|NCT00043394|Experimental|Cohort 1|0.04 mg/kg CpG 7909
3144543|NCT00043394|Experimental|Cohort 2|0.08 mg/kg CpG 7909
3144544|NCT00043394|Experimental|Cohort 3|0.12 mg/kg CpG 7909 Injection once weekly
3144545|NCT00043394|Experimental|Cohort 4|0.16 mg/kg CpG 7909
2407646|NCT03519958||EGFR NSCLC Progressed on EGFR TKI|Patients with EGFR NSCLC who have progressed following EGFR TKI therapy will undergo plasma-tissue testing
3144546|NCT00043407|Experimental|CPG 7909 Injection|
3185174|NCT00732342|Experimental|2|Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
3185175|NCT00732342|Experimental|3|Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
3185176|NCT00732342|Experimental|4|Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
2407651|NCT03519880|Experimental|Custom Mask Interface|Patients use a custom mask interface for one month with an option to use for a year if it performs better than a commercial mask.
3185177|NCT00732355||I|known syphilis infected patients
2407750|NCT03519373||PER002|HIV 1-uninfected pregnant women
2407751|NCT03519373||PER003|HIV 1-uninfected non-pregnant women
3144547|NCT00043420|Experimental|Phase I: 0.08 mg/kg|Escalating dose groups: 0.08 mg/kg PF-3512676 Injection
3144548|NCT00043420|Experimental|Phase I: 0.16 mg/kg|Escalating dose groups: 0.16 mg/kg PF-3512676 Injection
3144549|NCT00043420|Experimental|Phase I: 0.24 mg/kg|Escalating dose groups: 0.24 mg/kg PF-3512676 Injection
3144550|NCT00043420|Experimental|Phase I: 0.28 mg/kg|Escalating dose groups: 0.28 mg/kg PF-3512676 Injection
3144551|NCT00043420|Experimental|Phase I: 0.32 mg/kg|Escalating dose groups: 0.32 mg/kg PF-3512676 Injection
3144552|NCT00043420|Experimental|Phase I: 0.36 mg/kg|Escalating dose groups: 0.36 mg/kg PF-3512676 Injection
3144553|NCT00043420|Experimental|Phase II: 10 mg|Phase II: 10 mg flat dose (random assignment in Phase II)
3185178|NCT00732355||U|presumed uninfected patients
3185179|NCT00732368|Experimental|Mometasone Nasal Spray|Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
3185180|NCT00732407|Experimental|1|Patients with diabetes melittus treated with an ACE inhibitor will be treated with aliskiren
3185181|NCT00732407|Experimental|2|Patients with diabetes melittus treated with an ACE inhibitor will be given losartan
3185182|NCT00732420|Experimental|Treatment Arm A|Daily oral pazopanib in combination with weekly oral topotecan. Initially rising dose to determine the maximum tolerated dose: finally an expanded cohort treated at the maximum tolerated dose.
3185183|NCT00732420|Experimental|Treatment Arm B|Daily oral pazopanib in combination with oral topotecan given for 5 consecutive days every 21 days. Initially rising dose to determine the maximum tolerated dose; finally an additional cohort of patients treated at the maximum tolerated dose.
3185184|NCT00732433|Experimental|digital mammogram|"Digital mammography is a non-invasive imaging technique to obtain an x-ray image of the breast.~Two-view digital mammogram of the breast with a lesion that has been recommended for biopsy during the subject's regular clinical care. The digital mammogram is then analyzed by a computer program."
3185185|NCT00732446|Active Comparator|2|antibiotic /steroid combination compared with individual administration of steroid and antibiotic
3185186|NCT00732446|Experimental|1|combination antibiotic steroid compared with individual administration of steroid and antibiotic - new therapeutic indication
3185187|NCT00732459||1|electro-acupuncture preconditioning group
3185188|NCT00732459||2|control group
3185189|NCT00732485|Active Comparator|Fenofibrate|
3185190|NCT00732485|Placebo Comparator|Placebo|
3185191|NCT00732511|Experimental|1|Coreg Cr will be up-titrated as needed to achieve blood pressure <130/80
3185192|NCT00732511|Active Comparator|2|Toprol XL will be up-titrated at weekly intervals to achieve a blood pressure <130/80 mm Hg
3185193|NCT00732524|Active Comparator|Glipizide arm|Glipizide XL is an insulin secretagogue and is an extended release tablet designed to provide a controlled rate of delivery. Glipizide XL was chosen because it is the most frequently used discharge oral medication in our ED. It has a quick onset of action within a few hours after oral ingestion, lasts for 24 hours and has a powerful glucose lowering effect. In addition, there are very few contraindications to Glipizide XL and there is published literature regarding their use in subjects with severe hyperglycemia
3185194|NCT00732524|Active Comparator|Glipizide + Glargine|Insulin Glargine is a recombinant human basal insulin analog. It was chosen since it is a non-peaking insulin with cover for 24 hours. It can be injected subcutaneously only once a day and has a low incidence of hypoglycemia
3185195|NCT00732537|Experimental|Inhaled Nitric Oxide|iNO started at 20 ppm for 1 hour. The gas was then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off).
3185196|NCT00732537|Placebo Comparator|Placebo|The Oxygen at high concentration (>90%), which was standard therapy for PPHN, was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda).
3185197|NCT00732550|Experimental|Single trocar|Patients will undergo cholecystectomy by the single trocar approach
3185198|NCT00732550|Active Comparator|Standard lap cholecystectomy|Standard lap choly
3185199|NCT00732576|Active Comparator|1|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA)
3185200|NCT00732576|Active Comparator|2|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
3185201|NCT00732576|Active Comparator|3|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
3185202|NCT00732576|Active Comparator|4|9 fish oil capsules, equivalent to 3 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
3185203|NCT00732576|Active Comparator|5|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA)
3185204|NCT00732576|Active Comparator|6|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (10 µg)
3185205|NCT00732576|Active Comparator|7|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 2 capsules of menaquinone-7 per day (20 µg per day)
2407680|NCT03519841|Experimental|RSP-13-01|Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
2407681|NCT03519841|Experimental|RSP-13-02|Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
2407682|NCT03519828||Patients with post-stroke cognitive impairment|
2407683|NCT03519828||Patients without post-stroke cognitive impairment|
2407684|NCT03519815|Active Comparator|Ectoin Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days Ectoin® Eye Spray - Colloidal (EES09; bitop AG) - CE marked medical device~Ingredients: Ectoin®, Soy-Lecithin, Vitamin A, Vitamin E, water, physiological buffer system Indication: to treat mild to moderate dry eye disease"
2407752|NCT03519360|Experimental|Restricted ultrafiltration rate (UFR)|UFR ≤10 ml/kg/hr
3185206|NCT00732576|Active Comparator|8|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) including 1 capsule of menaquinone-7 per day (45 µg per day)
3185207|NCT00732589|Experimental|A|Suprascapular nerve block
3185208|NCT00732589|Experimental|B|therapeutic ultrasound
3185209|NCT00732602|Active Comparator|B|GLP-2 infusion
3185210|NCT00732602|Placebo Comparator|C|Sodium-chloride infusion
3185211|NCT00732602|Active Comparator|A|GIP-infusion
3185212|NCT00732628||Boomerang percutaneous closure unit|patients having a Boomerang percutaneous closure device after a Neurointerventional study
3185213|NCT00732693|Experimental|1|Treatment with standard sex steroid replacement regimen
3185214|NCT00732693|Experimental|2|Treatment with physiologic sex steroid regimen
3185215|NCT00732706|Other|Sartorius Twitch|Femoral Nerve detection using Sartorius Twitch
3185216|NCT00732706|Other|Quadriceps Twitch|Femoral Nerve detection using Quadriceps Twitch
3185217|NCT00732719|Placebo Comparator|Profile A|Device worn; no pressure given (placebo)
2407685|NCT03519815|Active Comparator|Liponit Eye Spray|"Eye Spray to be applied 3 times per day for the duration of 10 +/-3 days~Liposomal eye spray: Tears Again® (TA, Optima Medical Swiss AG) - CE marked medical device Ingredients: Soy-Lecithin, Sodium Chloride, Ethanol, Phenoxyethanol, Vitamin A-Palmitate, Vitamin E, Aqua purificata Indication: to treat mild to moderate dry eye disease"
2407686|NCT03519789||Post-Traumatic Stress Disorders (PTSD)|30 patients with PTSD (diagnosis based on the standard DSM criteria)
2407687|NCT03519789||Controls|30 healthy controls without any psychiatric or neurological diagnosis
2407688|NCT03519763||Control group|Fifteen patients without isthmocele
2407689|NCT03519763||Study subgroup1|15 patients with 1 previous C-Section
2407690|NCT03519763||Study subgroup2|15 patients with 2 or more previous C-Section.
2407691|NCT03519750|Active Comparator|Intravenous melatonin|Intravenous administration, making it possible to calculate bioavailability for other routes of administration
2407692|NCT03519750|Experimental|Rectal melatonin|Rectal administration of melatonin
2407693|NCT03519750|Experimental|Intravesical melatonin|Intravesical administration of melatonin
2407694|NCT03519750|Experimental|Vaginal melatonin|Vaginal administration of melatonin
2407695|NCT03519750|Experimental|Transdermal melatonin|Transdermal administration of melatonin
2407696|NCT03519737|Sham Comparator|Control group (tPA + sham TUS)|Control group (tPA + sham TUS) During the primary phase of the study, subjects will be randomized 1:1
2407697|NCT03519737|Active Comparator|Treatment group (tPA + TUS)|Treatment group (tPA + TUS): Lead-in phase and Primary phase
2407698|NCT03519724|Experimental|SUG|
2407699|NCT03519724|Active Comparator|NEO|
3144554|NCT00043420|Experimental|Phase II: 25 mg|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
3144555|NCT00043472||1|Eligible women at least one intact ovary who have signed written, informed consent that they will undergo screening as per protocol.
2407702|NCT03519698|Placebo Comparator|Warm water|12 l footbath with warm water (40 °C)
2407703|NCT03519698|Experimental|Warm water & Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour
2407704|NCT03519698|Experimental|Warm water & Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour
2407705|NCT03519685|Experimental|Contraceptive Training and Education|Colleges assigned to this arm receive a one-day UCSF Continuing Medical Education (CME # MMC18087) accredited training on contraceptives and technical assistance. The training is for staff at the student health center and local health centers where they refer for contraceptive services. Students attending colleges assigned to this arm receive education about contraceptive methods and how to access services.
2407706|NCT03519685|Placebo Comparator|Nutrition Education|Students attending colleges assigned to this arm receive nutrition education about the impacts of sugar on health.
2407707|NCT03519672||Participants with cTTP - adolescents|Adolescents aged 12 to 17 years
2407708|NCT03519672||Participants with cTTP - adults|Adults aged ≥18 years
2407709|NCT03519659|Experimental|Sub-Study A|Patients receive PET/CT scan on Gemini Astonish PET/CT
2407710|NCT03519659|Experimental|Sub-Study B|Patients receive PET/CT scan on Biograph mCT
2407711|NCT03519659|Experimental|Sub-Study C|Patients receive PET/CT scan on Discovery PET/CT
2407712|NCT03519659|Experimental|Sub-Study D|Patients receive PET/CT scan on Vereos 128 digital PET/CT
2407713|NCT03519659|Experimental|Sub-Study E|Patients receive lower radiation dose on Vereos 128 digital PET/CT
2407714|NCT03519659|Experimental|Sub-Study F|Patients receive PET/SCAN using system that did not show equivalence in Sub-Study A-C
2407715|NCT03519646|Experimental|Experimental Case_Eiglustat|Besides regular ERT, patients also need to take Eiglustat for 24 months.
2407716|NCT03519633|Experimental|SUG|
2407717|NCT03519633|Active Comparator|NEO|
2407718|NCT03519620|Experimental|SWWSV|Spirometric Values: Forced Vital Capacity; Forced Expiratory Volume in 1 second; Peak Expiratory Flow
2407719|NCT03519607|Active Comparator|Treatment Group|Participants who are in the intervention group will receive the FertiStrong app downloading instructions as soon as they have been randomized. They will have access to this app for a period of 30 days during the intervention phase of the study.
2407720|NCT03519607|No Intervention|Control Group|Participants in the control group will not have access to the FertiStrong app for the first 30 days. After a period of 30 days, participants will be provided downloading instructions to this app.
2407721|NCT03519594||Embolization group|The group that underwent embolization after pelvic injury.
2407722|NCT03519594||Non-embolization group|The observed group of pelvic injuries without embolization
2407723|NCT03519581|Active Comparator|Micropulse Laser Treatment|"Subjects assigned to the micropulse laser arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~Application of subthreshold micropulse laser using the Iridex IQ577 laser unit. (intermittent pulsed energy) in a 7 X 7 grid pattern surrounding the fovea."
2407724|NCT03519581|Placebo Comparator|Sham Treatment|"Subjects assigned to the sham arm of the trial will undergo the following procedures:~Confirmation of the subject's identity and eye to be treated~Subject's eye will be dilated~Subject will be positioned at the slit lamp for treatment~No Actual laser treatment will occur"
2407725|NCT03519568|Experimental|Combination inoculation group|GroupⅠ: HepB:3 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old GroupⅡ: MPSV-A:1 and EV71 were injected at 6 months old, EV71 second dose was injected at 7 months old, MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR and EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old GroupⅣ: JE-Land EV71 were injected at 8 months old, EV71 second dose was injected at 9 months old
2407753|NCT03519360|Experimental|Standard of Care/ Unrestricted UFR|UFR as needed
3144556|NCT00043472||2|Eligible women with at least one intact ovary who have signed written, informed consent that they will undergo risk reducing surgery
3144557|NCT00043537|Experimental|Social Effectiveness Therapy for Children|Social Effectiveness Therapy for Children includes social skills training, peer generalization experiences and exposure therapy
2407726|NCT03519568|Active Comparator|Separate inoculation control group|GroupⅠ: HepB:3 third dose was injected at 6 months old GroupⅡ: MPSV-A:1 was injected at 6 months old, then MPSV-A:1 second dose was injected at 9 months old GroupⅢ: MR was injected at 8 months old GroupⅣ: JE-L was injected at 8 months old
2407727|NCT03519568|Active Comparator|EV71 inoculation control group|GroupⅠ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅡ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅢ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old GroupⅣ: EV71 was injected at 8 months old, then EV71 second dose was injected at 9 months old
2407728|NCT03519542||Metastatic clear cell renal carcinoma (mRCC) patients|Metastatic clear cell renal carcinoma (mRCC) patients cadidates to receive Sunitinib 50 mg/day 4/2 schedule or Pazopanib 800mg/day until unaccetable toxicity or progression or death under standar clinical practice.
3185218|NCT00732719|Active Comparator|Profile B|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 30 mm Hg and upper cuff at 20mm Hg
3185219|NCT00732719|Active Comparator|Profile C|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 20 mm Hg and upper cuff at 10mm Hg
2407731|NCT03519490|Placebo Comparator|Single Vision Hybrid Contact Lens|Subjects will wear the Duette single vision hybrid contact lens.
2407732|NCT03519490|Experimental|Multifocal Hybrid Contact Lens|Subjects will wear the Duette hybrid multifocal contact lens with the near center design in one eye and the distance center design in the other eye with a crossover at every six months.
2407733|NCT03519477|Experimental|Heart failure care with Sano test|Scheduled outpatient care for patients at high risk of admission for heart failure, supplemented with the Sano Patient Medication Profile
2407734|NCT03519477|No Intervention|Heart failure care as-usual|Scheduled outpatient care for patients at high risk of admission for heart failure, care as-usual (i.e. without the Sano Patient Medication Profile).
2407736|NCT03519451|Experimental|Group I (KickAsh smartphone mobile application)|Participants receive KickAsh smartphone mobile application designed to help the learning of relaxation skills over 8 weeks.
2407737|NCT03519451|Experimental|Group II (Breathe2Relax smartphone mobile application)|Participants receive Breathe2Relax smartphone mobile application designed to help improve mood and increase level of enjoyable activities over 8 weeks.
2407738|NCT03519438||Lateral 3/4 of treatment field|placement of Mepitel on the lateral ¾ of the treatment field
2407739|NCT03519438||Medial 3/4 of treatment field|placement of Mepitel on the medial ¾ of the treatment field
2407740|NCT03519425|No Intervention|Group 1 (Standard of care)|"Participants will be directed to the clinic waiting area to be seen by facility health workers who will direct all further care without any further input from the study team. Available to facility health workers will be:~Routine HIV testing and counselling, provided by Facility HIV Testers using a rapid fingerprick kit-based algorithm.~Routine TB screening, with both sputum smear microscopy and Xpert MTB/Rif testing available onsite.~Routine linkage to the onsite HIV clinic, where patients are registered and assessed for initiation onto antiretroviral therapy by facility HIV Care Clinic health workers. Malawi guidelines recommend universal treatment for HIV. HIV Care Clinic health workers will additionally have access to TB screening tests as described above.~Routine linkage to the onsite TB clinic, where patients are registered and initiated onto anti-TB treatment. Malawi guidelines recommend universal HIV testing for all patients with confirmed TB."
2407741|NCT03519425|Active Comparator|Group 2 (Optimised HIV screening and linkage to care)|"Participants will be directed to the study room located in a separate building. After identity validation participants will be offered a supervised HIV self-testing intervention. Participants will be given brief pre-test instructions and will be asked to self-test in a private area using the OraQuick 1/2 (OraSure Technologies) oral fluid HIV kit. Participants will be supported to read their HIV test result by study Research Assistants, and provided with confirmatory HIV testing by the trained Research Assistants.~HIV-positive participants will be supported by Research Assistants to register at the onsite HIV care clinic, and all further care (including TB screening) will be directed by facility health workers without any further study input.~HIV-negative participants will be referred to the clinic waiting area (with a copy of their HIV test results) to be seen by the facility health workers who will direct all further investigations without further study input."
2407742|NCT03519425|Active Comparator|Group 3 (Optimised HIV and TB screening and linkage to care)|"Participants will be directed to the Study Room. After identity validation, they will be offered the HIV self-testing and linkage intervention as described above for Group 2. Additionally, they will be offered a TB screening intervention comprising of:~A digital chest x-ray using the study MinXray unit.~Chest x-rays will be immediately classified by the CAD4TB software running on the MinXray unit laptop as either high probability of TB, or low probability of TB.~Participants whose chest x-rays have a low probability of TB will be referred to facility health workers (at either the onsite HIV care clinic if HIV-positive, or the clinic waiting area), with copies of their results for further routine care, and without further study input.~Participants whose chest x-ray x-ray show a high probability of TB will submit a single spot sputum sample for Xpert testing (done in the clinic). Those with confirmed TB will be linked to register at the onsite TB clinic."
2407743|NCT03519412|Experimental|MMR-proficient (MMRp)|MGMT-IHC-negative, MGMT promoter methylation-positive patient population is selected for treatment with temozolomide (induction) orally until disease progression or unacceptable toxicity whichever comes first, followed by pembrolizumab IV if Tumor Mutational Burden post Temozolomide is > 20 Muts/Mb
2407744|NCT03519412|Other|MMR-deficient (MMRd)|Patients receive Pembrolizumab (treatment) IV until disease progression or unacceptable toxicity or 35 cycles, whichever comes first
2407745|NCT03519399||Cases and Controls|"Cases - Pregnant women with ICP defined as pruritus in pregnancy in association with raised serum bile acids (using hospital threshold for diagnosis), and in the absence of an alternative cause.~Controls - Pregnant women not affected by ICP, or other liver, cardiac or hypertensive disorders."
2407746|NCT03519386|Experimental|Implant Group 1|G2TR intraocular implant containing travoprost 78 mcg with high elution rate, plus postoperative placebo eye drops.
2407747|NCT03519386|Experimental|Implant Group 2|G2TR intraocular implant containing travoprost 78 mcg with low elution rate, plus postoperative placebo eye drops.
2407748|NCT03519386|Active Comparator|Control Group|Sham surgery + active-comparator eye drops
2407749|NCT03519373||PER001|HIV 1-infected pregnant women
2407754|NCT03519347|Experimental|Potassium Removal Maximization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to maximize potassium removal and avoid hyperkalemia.
2407755|NCT03519347|Experimental|Potassium Gradient Minimization Strategy|Dialysate potassium will be adjusted according to the results of point of care testing in order to minimize the flux of potassium.
2407756|NCT03519347|Experimental|Alkalosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding alkalosis.
2407757|NCT03519347|Experimental|Acidosis Avoidance Strategy|Dialysate bicarbonate concentration will be adjusted according to the results of point of care testing in order to prioritize avoiding acidosis.
2407758|NCT03519334||Chronic health condition group/study|People with any of the following chronic health conditions: Diabetes, Chronic obstructive Pulmonary Disease, Major Depression, Dysthymia, Migraine, Back & Neck Pain, Cancer, Ischemic Heart Disease
2407759|NCT03519334||Expert consultation group/study|Relevant contacts from advocacy organizations operating at European level for the professional integration of people with chronic health conditions.
2407760|NCT03519321|Experimental|Treatment|MID-C EOS implant will be implanted for the correction of the spine deformity in children found eligible for the study
2407761|NCT03519308|Experimental|Arm A|
2407762|NCT03519308|Experimental|Arm B|
2407767|NCT03519269|No Intervention|Non robotics-assisted Surgical System|Conventional, non-robotics-assisted total knee surgical system
2407768|NCT03519269|Experimental|Navio™ Robotics-assisted Surgical System|Navio™ Robotics-assisted Surgical System
2407769|NCT03519256|Experimental|Nivolumab monotherapy|
2407770|NCT03519256|Experimental|Nivolumab + BCG|
2407771|NCT03519256|Experimental|Nivolumab + BMS-986205|
2407772|NCT03519256|Experimental|Nivolumab + BMS-986205 + BCG|
2407777|NCT03519230|Experimental|Treatment arm|
2407778|NCT03519230|Placebo Comparator|Placebo arm|
2407779|NCT03519217||Diabetic patients under the age of one year|All cases which are diagnosed with diabetes mellitus under the age of one year will be subjected for blood glucose level, glycated haemoglobin, fasting C-peptide, anti-insulin and anti-islets auto-antibodies, and who have negative tests for anti-insulin and anti-islets auto-antibodies, will be subjected to do genetic study for KCJN11 and ABCC8
2407782|NCT03519191|Other|Healthy Relationships Education (HRE)|Social-behavioral intervention Participants will receive employment support services and Healthy Relationships Education interventions.
2407783|NCT03519191|Other|HRE+Technology Bootcamp|Social-behavioral intervention + technology bootcamp (associated economic pathways for participants) Participants will receive employment support services, Healthy Relationships Education, and Technology Bootcamp interventions.
3144558|NCT00043537|Experimental|Fluoxetine|Fluoxetine given in 10mg doses, up to 40 mg as tolerated
3144559|NCT00043537|Placebo Comparator|Pill placebo|"Capsules identical to fluoxetine given in 10 mg. doses up to 40 mg."
3144560|NCT00043602|Experimental|1|Participants will receive clinician-managed interpersonal psychotherapy
3144561|NCT00043602|Active Comparator|2|Participants will receive standard interpersonal psychotherapy
3144562|NCT00043693|Experimental|1|Participants will undergo the Family Intervention for Dual Diagnosis (FIDD) program.
3144563|NCT00043693|Active Comparator|2|Participants will be placed in a family psychoeducation program.
3144564|NCT00043745|Experimental|1|Participants will receive moderate dose soy isoflavone (80 mg/day) tablets, extracted from soy protein
3144565|NCT00043745|Experimental|2|Participants will receive high dose soy isoflavone (120 mg/day) tablets, extracted from soy protein
2407792|NCT03519165|No Intervention|Control group (Group C)|"Conventional Fluid therapy guided by clinical parameter~Intraoperative fluid therapy will include maintenance fluid and replacement of the surgical loss. Aim to maintain MAP > 65 mmHg, CVP 8-12 cm H2O and urine output > 0.5 ml/kg/h."
2407793|NCT03519165|Active Comparator|Goal directed group (Group G)|"Intervention: Machine guided fluid therapy using EV1000 (FloTrac System 4.0 Edward Lifesciences, Irvine, CA, USA)~Intraoperative fluid therapy will be targeted to SVV <13%, SVI > 35ml/m2/ beat, SVRI more than equal to 1900 dynes-sec/cm-5/m2 using EV1000 floTrac monitor in addition to clinical parameters like MAP, CVP and urine output"
2407794|NCT03519152|Experimental|study group one side|All patients were scheduled for open flap debridement surgery on at least two quadrants ≥1 weeks apart.One group will receive Low Dose Diclofenac tablets (25mg Diclofeanc and 325 mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis will be included in study. For each quadrant, a flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure will be recorded in the patient file. Patients will be instructed to complete a pain diary chart for 3 days.
3144566|NCT00043745|Placebo Comparator|3|Participants will receive soy extract devoid of isoflavones to serve as placebo
3144567|NCT00043810|Experimental|Gelonin Purging of ASCT|Gelonin Purging of Autologous Stem Cells for Transplantation (ASCT) + Fludara/Busulfan
3144568|NCT00043823|Experimental|Avastin + Tarceva|Combination Therapy (Avastin + Tarceva) = Avastin IV Day 1 of each 21-day cycle + oral Tarceva daily.
3144569|NCT00044031|Placebo Comparator|B|Placebo (immunogen vehicle) combined with gemcitabine.
3144570|NCT00044031|Experimental|A|500 µg G17DT immunogen combined with gemcitabine.
2407795|NCT03519152|Placebo Comparator|study group second side|Other group will receive Diclofeanc (50mg Diclofenac and 325mg paracetamol), BID for 3 days. The patients who are diagnosed with generalized moderate/severe chronic periodontitis were included in study. For each quadrant, aperiodontal flap was raised under local anesthesia (2% lignocaine with 1:80,000 epinephrine). In both the quadrants same technique of anesthesia will be employed. The location and the extent of surgery, volume of the local anesthesia given, and time required to perform the surgical procedure was recorded in the patient file. Patients were instructed to complete a pain diary chart for 3 days.
2407796|NCT03519139|Experimental|individual dietary counselling|three individual dietary counsellings. The first at the hospital by discharge, then in week 1 and week 3 at the subject's home/the respite care after discharge and, if necessary, telephone follow-up in weeks 2 and 4 after discharge
2407797|NCT03519139|No Intervention|Control|standard counselling provided by the hospital at discharge. The standard counselling may include nutritional prescription and nutritional plan, but no follow-up to the nutrition plan after the discharge.
2407798|NCT03519126|Experimental|vaginal|Group of volunteers who will be treated with vaginal electrostimulation
2407799|NCT03519126|Experimental|posterior tibial nerve|Group treated with transcutaneous electrostimulation of the posterior tibial nerve
2407800|NCT03519126|No Intervention|control|Group of volunteers who will not be treated
2407801|NCT03519113|Experimental|Test group 1|GC1102 80,000 IU
2407802|NCT03519113|Experimental|Test group 2|GC1102 100,000 IU
2407803|NCT03519113|Active Comparator|Control group|I.V HBIG
3185220|NCT00732719|Active Comparator|Profile D|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 10 mm Hg and upper cuff at 0mm Hg
3185221|NCT00732719|Active Comparator|Profile E|Foot at 30mm Hg, Gaiter at 40 mm Hg, mid-calf at 40 mm Hg and upper cuff at 40mm Hg
3185222|NCT00732719|Active Comparator|Profile F|Foot at 20mm Hg, Gaiter at 30 mm Hg, mid-calf at 30 mm Hg and upper cuff at 30mm Hg
3185223|NCT00732719|Active Comparator|Profile G|Foot at 10mm Hg, Gaiter at 20 mm Hg, mid-calf at 20 mm Hg and upper cuff at 20mm Hg
3185224|NCT00732732|Experimental|Green banana|Subjects receiving green banana powder.
2407809|NCT03519074|Experimental|TS-1 combined with cisplatin|Eligible patients will be stratified by degree of liver dysfunction into 4 cohorts, in accordance to the National Cancer Institute Organ Dysfunction Working Group (NCI-ODWG) criteria
2407810|NCT03519061|Experimental|Treatment|This is the group of enrollees who receive budesonide
2407811|NCT03519048|Active Comparator|Conventional follow-up|clinical examination with nasofibroscopy every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter. Low Dose Chest CTscan every year in patients with tobacco consumption history of > 20 pack-year. Panendoscopy plus CT-scan are performed in case of clinical symptoms or abnormal clinical exam.
2407812|NCT03519048|Experimental|Intensive follow-up strategy|adding to the conventional follow-up strategy , an annual head&neck and thoracic injected CT-scan and Lugol upper gastrointestinal endoscopy (the first performed 12 months after inclusion), annual whole body PET-CT (the first at 6 months after inclusion). These 3 exams are performed every year during 3 years after inclusion (i.e. 3 CT-scan, 3 digestive endoscopies and 3 PET-CT per patient). Clinical follow up will be conducted as in the conventional follow up group and panendoscopy or bronchoscopy will be performed if needed. After 3 years, patients will be followed by conventional follow-up.
2407813|NCT03519035||Borderline personality disorder Patient|"Patients will be recruited in the different services. They have to respect inclusion criteria which are : patient with BPD (clinical diagnosis), patients 18 years of age or older, patients who can give their consent.~In this study, patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations."
2407814|NCT03519022|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
2407815|NCT03519022|Active Comparator|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on duloxetine and methylphenidate during placebo maintenance. Cocaine will be administered acutely during duloxetine maintenance. Placebo will be administered acutely during duloxetine maintenance.
2407816|NCT03519009|Experimental|IPS Plus Abstinence-Contingent Wage Supplement|Abstinence-contingent wage supplements are provided for obtaining and maintaining competitive employment.
2407817|NCT03519009|No Intervention|Usual Care Control|Counseling and referrals to employment and treatment programs.
2407818|NCT03518996|Experimental|TMS/tACS|Subjects will receive 5 days of 3x daily rTMS (intermittent theta burst stimulation) or tACS (transcranial alternating current stimulation) targeted over the cerebellum.
2407819|NCT03518996|Sham Comparator|Sham TMS/tACS|Subjects will receive 5 days of 3x daily sham stimulation of the cerebellum.
2407820|NCT03518983|Sham Comparator|Sham Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) by the sham probe.
2407821|NCT03518983|Active Comparator|Active Group|The subjects of this group will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session), twice a week (total of 6 weeks) at energy level 7.
2407822|NCT03518970|Experimental|Nursing intervention|The experimental group will receive the Nursing intervention to reduce uncertainty in illness and increase quality of life in family caregivers of patients with cancer in palliative care
2407823|NCT03518970|No Intervention|Conventional care|The control group will receive the nursing care conventionally given in the health care institution
2407824|NCT03518957|Experimental|Exercise intervention|Patients who are randomised to this arm will be enrolled to the exercise programme.
3185225|NCT00732732|Placebo Comparator|Placebo|Microcrystalline cellulose given as placebo
3185226|NCT00732745|Experimental|Phase II arm I|Patients receive docetaxel IV over 1 hour on days 1 and 8, oxaliplatin IV over 2 hours on day 1, and oral vandetanib (at the maximum tolerated dose determined in phase I) once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
2407826|NCT03518944||occult premature ovarian insufficiency|Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion >4 weeks apart
2407827|NCT03518931|No Intervention|Control|This arm included individuals randomized to receiving fitness information only.
2407828|NCT03518931|Experimental|Intervention|This arm included individuals randomized to having fitness assessments performed.
2407829|NCT03518905|Sham Comparator|sham-treatment|Patients with symptomatic large heterotopic gastric mucosa receive an esophagoscopy without radiofrequency ablation under sedation
2407830|NCT03518905|Active Comparator|treatment arm|Patients with symptomatic large hetertotopic gastric mucosa receive an esophagoscopy with radiofrequency ablation (12J/cm2) using the Barrx channel RFA endoscopic catheter (Medtronic)
2407831|NCT03518892||Spinal Cord Injury Group|Body Composition, Resting Metabolic Rate, and dietary assessment
2407832|NCT03518892||Healthy Controls|Body Composition, Resting Metabolic Rate, and dietary assessment
2407833|NCT03518879|Experimental|ASTHMA-Educator arm|The ASTHMA-Educator mobile application for patient-centered asthma education. The application is administered via on-site iPad (tablet).
2407834|NCT03518853|Experimental|Short-course Radiation Therapy|Short-course Hypofractionated Once-weekly Radiation Therapy: 35Gy in 5 fractions delivered once a week.
2407836|NCT03518827||Athletes|For Asymmetry measurement, the group will consist of 200 athletes of different sports (the proportion not strictly predefined) - track and field, racket sports, ball sports, other team sports, swimming, running, cycling, dancing, ice skating, etc.
2407837|NCT03518814||Multimetastatic melanoma in remission|Questionnaires
2407838|NCT03518801|Experimental|Prolonged Exposure + Cannabidiol|Psychotherapy plus active medication
2407839|NCT03518801|Active Comparator|Prolonged Exposure + Placebo|Psychotherapy plus placebo medication
2407840|NCT03518788|Experimental|Pleur-X|Placement of a permanent drainage under local anesthesia
2407841|NCT03518788|Experimental|pleurodesis|Pleurodesis with talc in VATS
2407842|NCT03518775||Normal Eyes|Eyes with best-corrected visual acuity of 20/20 or better, and lens opacities of 1.0 or less in the study eye using the LOCS III system, and no prior Laser Vision Correction.
2407843|NCT03518775||Cataract Eyes|Cataract in the study eye greater than Grade 1 using the LOCS III system for one or more: nuclear opacity, nuclear color, cortical opacity, or PSC.
2407844|NCT03518775||Post LVC Eyes|History of Laser Vision Correction (LVC)
2407845|NCT03518762|Experimental|Sustained lung inflation|"Participants in this arm (n=80) received:~Sustained lung inflation (SLI) manoeuvre(s) was applied once or twice, based on the protocol algorithm.~Within the first 60 seconds of life, assessment for the need of advanced resuscitation (defined as the need for more than oxygen and tactile stimulation during resuscitation) was done;~Infants who needed advanced resuscitation were considered to receive SLI as a rescue approach.~Infants who needed only oxygen and tactile stimulation were considered to receive SLI as a prophylactic approach.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
2407846|NCT03518762|Other|Control|"Participants in this arm (n=80) received:~Resuscitation according to the American academy of pediatrics guidelines.~Then Continuous positive airway pressure (CPAP). Intermittent positive pressure ventilation (IPPV) was given through an ETT, if intubation was needed."
2407847|NCT03518749|Active Comparator|1mA anodal tDCS + cognitive control training|1 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
2407848|NCT03518749|Active Comparator|2mA tDCS + cognitive control training|2 mA anodal tDCS will be administered to the left dlPFC (F3) for 23 mins during the performance of a cognitive control training.
2407849|NCT03518749|Placebo Comparator|sham tDCS + cognitive control training|Sham tDCS (30 secs of tDCS) will be administered to the left dlPFC (F3) with 2mA at the beginning of a cognitive control training.
3144577|NCT00044291|Experimental|Atamestane + toremifene|
2407853|NCT03518723|Experimental|Non-linear Periodized Resistance Training|"The objective of the Non-linear Periodized Resistance Training (NLPRT) program is to increase muscle strength as well as muscle endurance. The NLPRT program will over the 8 week intervention period target several different aspects of limb muscle function, by alternating the intensity and volume of the exercises.~Progression of exercise is symptom dependent and will be based on Borg CR-10 ratings (dyspnea, muscle fatigue and exertion).~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
2407854|NCT03518723|Active Comparator|Resistance Training|"The primary objective of the Resistance training (RT) group is to increase muscular strength. The RT program will be performed in line with current guidelines that are recommended for increasing muscular strength in patients with COPD.~Progression of exercise is performance dependent and will be based on the previous 2 sessions.~All exercises will be performed using exercise equipment that are available at each included center.~All sessions are supervised and conducted by local professionals using a group format, with approximately 2-4 participants per group."
2407855|NCT03518710|Experimental|Children with NF1|"One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :~Neuropsychological evaluation~Evaluation of the reading assistance technique"
3144578|NCT00044291|Active Comparator|Letrozole + placebo|
3144581|NCT00044525|Experimental|Arm 1|
3144582|NCT00044538|Experimental|Arm 1|
3144583|NCT00044551|Experimental|Arm 1|
3144584|NCT00044564|Experimental|Arm 1|
3144585|NCT00044590||Cases|Patients with Parkinson's Disease
3144586|NCT00044590||Controls|Controls, subjects without Parkinson's Disease
3144587|NCT00044629|Experimental|Cognitive Behavioral Therapy and Ambien|Cognitive Behavioral Therapy and Ambien
2407856|NCT03518697|Experimental|Exercise Group|"First 6 months supervised exercise program with telephone contact every two weeks~Second 6 months exercise program without telephone contact~Patients should increase habitual daily physical activity for 10-20 minutes per day 5 times per week~Activities were chosen according to the preferences, interests, and severity of disease of the patients~Activites should improve endurance, strength, coordination and flexibility~Every three month regular vistit at the CF care center (medical examination, lung function, exercise testing, counselling and evaluation of activities by acceleometry and if appropirate adaption of exercise program)"
2407857|NCT03518697|No Intervention|Control-Group|"12 months usual routine care and habitual exercise in daily life.~At start and after 12 month assessment of habitual exercise with accelerometry (Actigraph GTX3)"
2407858|NCT03518684|No Intervention|Group 1|Group 1 in which they will receive the standard care during labor and delivery without the use of the obstetrical gel
2407859|NCT03518684|Experimental|Group 2|Group 2 in which they will have the standard care during labor and delivery with the vaginal application of the obstetrical gel according to the study protocol. Those 2 groups will be further divided into 4 subgroups where the parity will be accounted for (nulliparous [never delivered beyond 20 weeks of gestation in a previous pregnancy] or primiparous or more)
2407860|NCT03518671|Experimental|CBT (face to face)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, face-face~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT."
2407861|NCT03518671|Experimental|CBT (telemedicine)|"Self-limited cognitive behavioral therapy (CBT) delivered via 5 weekly sessions, via tablet-based telemedicine platform~Up to one year after completion of treatment, patients with body image disturbance (BID) as determined by a Body Image Scale (BIS) score > 5 will undergo time-limited CBT consisting of 5 weekly sessions. Each session will be guided by the HNC BID module that we develop but customized to each patient's specific concerns. Each session will last ~60 minutes and be conducted one-one with a psychologist. Patients will complete questionnaires prior to CBT and 1 and 3 months after CBT. To overcome the expected travel distance-related barrier to receipt of CBT, patients will receive the intervention via tablet-based telemedicine delivery platform"
2407864|NCT03518645|Experimental|OPN strategy|The OPN NC Super High Pressure PTCA Balloon will be used as the study device for lesion preparation for BVS Absorb implantation - OPN strategy of lesion preparation. This balloon has a twin layer balloon construction, which allows a very high pressure resistance of 35 bar. The balloon has a 0.016'' lesion entry profile and is available in sizes between 1.5 and 4.5 mm and lengths of 10, 15 and 20 mm.
2407865|NCT03518645|Active Comparator|standard strategy|Predilatation with standard coronary balloon will be performed for lesion preparation for BVS Absorb implantation - standard strategy of lesion preparation.
2407866|NCT03518632|Active Comparator|Control group|
2407867|NCT03518632|Experimental|Interval training 1|
2407868|NCT03518632|Experimental|Interval training 2|
2407869|NCT03518619|Experimental|PFIcope+EMI|This will include: 1) an in-person personalized feedback session to present normative information and feedback on problems associated with drinking to cope, to discuss the individual's use of alcohol to cope, and to generate relapse prevention coping skills messages to be used in the EMI text intervention; 2) EMA to monitor affect and intention to drink after discharge; 3) tailored text messages (EMI) based on EMA responses (i.e., individualized coping skills messages when individuals report negative affect and intention to drink); and 4) additional EMA to monitor coping skills usage, alcohol use, and drinking to cope.
2407870|NCT03518606|Experimental|Breast cancer cohort|Patients presenting advanced refractory breast cancer
2407871|NCT03518606|Experimental|Head and neck cohort|Patients presenting advanced refractory head and neck cancer
2407872|NCT03518606|Experimental|Cervix cohort|Patients presenting advanced refractory cervix cancer
2407873|NCT03518606|Experimental|Prostate cohort|Patients presenting advanced refractory prostate cancer
2407874|NCT03518606|Experimental|Miscellaneous cohort|Patients presenting advanced refractory solid tumour with high mutational load
2407875|NCT03518593|Experimental|Intervention|Additional cash transfer and nutritional counselling
2407876|NCT03518593|No Intervention|Control|Existing cash transfer only
2407877|NCT03518567|Experimental|High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
2407878|NCT03518554|Experimental|JAB-3068 (SHP2 inhibitor)|Daily oral administration of JAB-3068
2407879|NCT03518541|Active Comparator|Goniometer|FDO: classic procedure with goniometer controlled derotation
2407880|NCT03518541|Experimental|EMT|FDO: procedure with electromagnetic tracking (EMT) controlling derotation
2407881|NCT03518528||transdermal|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
2407882|NCT03518528||vaginal|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
2407883|NCT03518515|Experimental|White potato (French fries)|Participants will be asked to consume 1 serving of French fries each day for 30 days.
2407884|NCT03518515|Experimental|White potato (French fries), +seasoning|Participants will be asked to consume 1 serving of French fries with added seasoning each day for 30 days.
2407885|NCT03518515|Active Comparator|Almond|Participants will be asked to consume 1 serving of almonds (calorie-matched to other arms) day for 30 days.
2407886|NCT03518502|Active Comparator|Sorafenib monotherapy arm|The sorafenib monotherapy group receives sorafenib immediately after randomization.
2407887|NCT03518502|Experimental|TACE-sorafenib sequential therapy arm|TACE(transarterial chemoembolization )-sorafenib group receives 2~4 times of TACE before starting sorafenib.
3144588|NCT00044629|Placebo Comparator|Cognitive Behavioral Therapy and Placebo|Cognitive Behavioral Therapy and Placebo
2407888|NCT03518489|Experimental|Experimental|Lappaconitine Adhesive Patch Lappaconitine Adhesive Patch is administered every radiation day, until the end of radiotherapy.
2407889|NCT03518489|Active Comparator|Control|Patients will be given standard care when oral pain is reported
2407890|NCT03518476|Experimental|Intervention arm|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
2407891|NCT03518476|Active Comparator|Control arm|Non-tobacco related training or education sessions will delivered to pharmacists in the control group.
2407892|NCT03518463|Experimental|Intervention|"ERAS arm received;~Preoperative:1. Intravenous (IV) cefazoline 1g 2. IV metoclopromide 10mg, dexamethasone 8mg, ranitidine 150mg~Intraoperative: 1. Hyperbaric bupivacaine 10-15mg plus intrathecal morphine 100mcg 2. Adrenaline 100mcg in 500ml of ringers lactate 3. Individualized goal directed fluid therapy 4. Reinforced counseling and education 5. wound infiltration with isobaric bupivacaine 2mg/kg 6. Rectal diclofenac 100mg and misoprostol 400mcg stat~Postoperative:~Feeding within 1 hour~urethral catheter removal at 6-8 hours~Mobilization at 8-10 hours~A single fixed dose combination of ibuprofen 400 mg and paracetamol 500 mg 8 hourly~Tablets Amoxicillin-clavulunate 850mg 12 hourly"
2407893|NCT03518463|Active Comparator|Control|"Standard care arm received;~IV ceftriaxone 2g or ampiclox 2g~Anesthetists administered IV fluids, vasopressors, and managed hypothermia based on their clinical impressions.~Oral feeding and breastfeeding were allowed any time after transfer to postnatal ward.~Urethral catheters were removed between 12-24 hours after surgery.~Ward nurses and obstetricians made decisions regarding treatment without study staff input or oversight."
2407894|NCT03518450|Active Comparator|Femoral Nerve Block|Ultrasound guided femoral nerve block, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2407895|NCT03518450|Active Comparator|Adductor Canal Block|Ultrasound guided adductor canal block, at the proximal third of the canal, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2407896|NCT03518450|Experimental|Apex Femoral Triangle Block|Ultrasound guided femoral triangle block, at the distal third of the triangle, 30 ml of 0.25% bupivacaine and 4 mg of dexamethasone to be administered.
2407897|NCT03518411|Experimental|Medical Students|Cognitive Behavioral Therapy Protocol
2407898|NCT03518398|Experimental|IPL group|IPL 9-13 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
2407899|NCT03518398|Sham Comparator|sham-IPL group|IPL 0 J/cm2 according to Fitzpatrick's skin type on day 0, 15, 45
2407900|NCT03518385||Patients with intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, this group patients will have intracavitary fluid.
2407901|NCT03518385||Patients without intracavitary fluid|to evaluate the correlation between the presence of intracavitary fluid during hormonal stimulation for IVF depending on the position of C-section-scar and the presence of an isthmocele, in this group patients will not have intracavitary fluid.
3144589|NCT00044629|Active Comparator|Cognitive Behavioral Therapy alone (no drug)|Cognitive Behavioral Therapy alone (no drug)
3144590|NCT00044668|Experimental|AC2993|5 μg AC2993, twice daily, for 4 weeks followed by 10 μg AC2993, twice daily, during a maintenance period
2407904|NCT03518346|Experimental|Virtual Reality Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. For the VR group, we are using the Samsung VR Go (VR head set), Samsung S7 (phone) and programmed distraction (Spaceburgers, Pebbles the Penguin, and/or Happy Place). Spaceburgers and Pebbles the Penguin were designed by the Department of Anesthesiology at Lucile Packard Children's Hospital Stanford through the Stanford Chariot Program (Childhood Anxiety Reduction Through Innovation and Technology). Happy Place is a nongame immersive experience that will be offered to children uninterested in the previously mentioned game. Happy Place was designed by a Swedish Pharmacy Chain, Apotek Hjartat, aimed to distract patients from their pain with a peaceful, interactive environment. Each of the video games runs for the length of time needed to complete the venipuncture.
2407905|NCT03518346|Active Comparator|Standard of Care Group|Participants may be randomized to the virtual reality, VR, group or the standard of care group. The standard of care group will use various distractions. Distraction tools include books and movies using a wall mounted TV as standard practice.
2407906|NCT03518333|Experimental|ARM 1|Injection of adipose derived cells into penis followed six months later with sham control saline injection procedure
2407907|NCT03518333|Experimental|ARM 2|Sham control saline injection procedure followed six months later by injection of adipose derived cells into penis
2407908|NCT03518320|Experimental|TAR-200 and Nivolumab Combination|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200 is placed into the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed. In combination, subjects are dosed intravenously with a Nivolumab Injection [Opdivo] within 3 days of TAR-200 placement. Subjects will receive four consecutive 21-day dosing cycles of the combination of TAR-200 and Nivolumab prior to radical cystectomy.
2407909|NCT03518294|No Intervention|Standard of Care|Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional. They will be informed to maintain their current physical activity level. Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity). Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
2407910|NCT03518294|Experimental|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
2407911|NCT03518281|Placebo Comparator|Placebo|
2407912|NCT03518281|Experimental|Treatment|Whole Cell Euglena delivering βeta Glucan
3144591|NCT00044694|Placebo Comparator|Placebo 0.01 mL|2 week placebo lead-in followed by Placebo 0.01 mL
2407913|NCT03518268|Active Comparator|Dietary supplement Vivomixx|Vivomixx sachets contains a mixture of 450 billion viable lyophilized bacteria from 8 strains: Lactobacillus paracasei DSM 24733, Lactobacillus plantarum DSM 24730, Lactobacillus acidophilus DSM 24735, Lactobacillus delbrueckii subspecies bulgaricus DSM 24734, Bifidobacterium longum DSM 3 24736, Bifidobacterium infantis DSM 24737, Bifidobacterium breve DSM 24732, and Streptococcus thermophilus DSM 24731
2407914|NCT03518268|Placebo Comparator|Placebo|The placebo sachets contain the inactive ingredients maltose and silicon dioxides
2407915|NCT03518255|No Intervention|Control group|This control group will not receive an intervention.
2407916|NCT03518255|Experimental|Nature video|A pre-validated nature images video will be shown to the patient during their chemotherapy session. After thirty minutes of the start of the chemotherapy session, the patient you will receive a notebook (specific to the study and blocked for other functions) that he can watch a presentation of nature images. It will be four videos with fifteen minutes each one.
2407917|NCT03518242|Experimental|Treatment (Specimen collection, chemotherapy)|"SPECIMEN COLLECTION: Patients undergo collection of tumor tissue and peripheral blood samples for analysis via next generation sequencing to identify novel pathways in the pathogenesis of breast cancer.~TREATMENT: Patients are invited to participate in a treatment study. Patients receive cyclophosphamide PO daily on days 1-21, methotrexate PO QD on days 1, 8, and 15, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity."
2407918|NCT03518229|Experimental|Intervention|Microsoft Band 2 application with UV messaging activated
2407919|NCT03518229|Active Comparator|Control|Microsoft Band 2 application (UV messaging not active)
2407920|NCT03518216|Experimental|ADAPT|Participants randomized to ADAPT will complete Aim to Decrease Anxiety and Pain Treatment (ADAPT), a remotely delivered tailored intervention that integrates mindfulness meditation with cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions are interactive with a trained psychological provider and the following 4 sessions are web-based. Each web-based session is followed by therapist support.
2407921|NCT03518216|No Intervention|Waitlist Control|Participants randomized to waitlist control will receive medical treatment as usual. These participants will be given the opportunity to complete ADAPT upon completion of the post assessment.
2407923|NCT03518190|Experimental|Suspected pressure injury|Patients evaluated with high-risk for pressure injury
2407924|NCT03518177|Experimental|Hospital-based PR group|The patient will receive an 8-week supervised Pulmonary Rehabilitation Exercise Program at hospital
2407925|NCT03518177|Experimental|Home-based PR group|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program at home
2407926|NCT03518164|Other|Allograft|Bone graft
2407927|NCT03518164|Other|Autograft|Bone from iliac crest
2407928|NCT03518151|Experimental|Intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section at store entrance; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
2407929|NCT03518151|Sham Comparator|Control|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
2407930|NCT03518138|Experimental|Group 1, study drug|65 patients treated with Q-122, 100 mg BID
2407931|NCT03518138|Placebo Comparator|Group 2, placebo|65 patients treated with placebo
2407938|NCT03518112|Experimental|Treatment (blinatumomab, combination chemotherapy)|See detailed description.
2407939|NCT03518099|Experimental|Patient|Any patient admitted for acute abdomen condition with or without ischemic causes.
2407940|NCT03518099|Experimental|witness|
3144592|NCT00044694|Placebo Comparator|Placebo 0.02 mL|2 week placebo lead-in followed by Placebo 0.02 mL
3144593|NCT00044694|Placebo Comparator|Placebo 0.03 mL|2 week placebo lead-in followed by Placebo 0.03 mL
3144594|NCT00044694|Placebo Comparator|Placebo 0.04 mL|2 week placebo lead-in followed by Placebo 0.04 mL
3144595|NCT00044694|Experimental|AC2993 2.5 mcg|2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL
3144596|NCT00044694|Experimental|AC2993 5.0 mcg|2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL
2407946|NCT03518060||Subjects receiving Juluca|Approximately 250 virologically suppressed HIV positive subjects on a stable antiretroviral regimen as indicated in local SmPC of Juluca will be included in the study. The subjects will be followed for approximately 3 years during routine clinical practice.
2407947|NCT03518047|Placebo Comparator|Placebo|Placebo for risankizumab by subcutaneous (SC) injection.
2407948|NCT03518047|Experimental|Risankizumab|Risankizumab by subcutaneous (SC) injection.
3144597|NCT00044694|Experimental|AC2993 7.5 mcg|2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL
3144598|NCT00044694|Experimental|AC2993 10.0 mcg|2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL
2407951|NCT03518021|Experimental|Naloxone, intranasal|
2407952|NCT03518021|Active Comparator|Naloxone, intramuscular|
2407953|NCT03518021|Placebo Comparator|placebo, intranasal|
2407954|NCT03518021|Placebo Comparator|placebo, intramuscular|
2408551|NCT03514303||Dust Mite|Subjects will test positive or negative to the allergen Dust Mite.
3144599|NCT00044707|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide injection is 0.6 mg/mL
3144600|NCT00044707|Placebo Comparator|Placebo|Placebo solution is the same, sterile preserved formulation, except the active ingredient, pramlintide, is omitted
3144601|NCT00044798|Experimental|1|Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
3144602|NCT00044798|Active Comparator|2|Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
3144603|NCT00044863|Experimental|1|Patients with metastatic EGFR-positive colorectal carcinoma
3144604|NCT00044915|Active Comparator|Arm 1|
2407957|NCT03517995|Active Comparator|Sulforaphane Plus Surgery|Sulforaphane Administration prior to bladder cancer surgery.
2407958|NCT03517995|Placebo Comparator|Placebo Plus Surgery|Placebo Administration prior to bladder cancer surgery.
2407959|NCT03517969|Active Comparator|Arm A (docetaxel, carboplatin)|Patients receive docetaxel IV over 60 minutes and carboplatin IV over 30 minutes, or carboplatin alone on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who have PSA progression or radiographic progression may crossover to Arm B.
2407960|NCT03517969|Experimental|Arm B (carboplatin, berzosertib)|Patients receive carboplatin IV over 30 minutes on day 1 and berzosertib IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2407961|NCT03517956|Experimental|Patients with FGFR1-4 - positive solid tumors|"Dose escalation:~The starting dose of the combination will be escalated in a stepwise fashion, escalating one drug at a time.~Dose expansion (urothelial cancer):~Patients in the dose expansion will be treated with the combination identified in the dose escalation part of the study."
2407962|NCT03517943|Experimental|Test treatment|Healthy adult subjects under fed conditions
2407963|NCT03517943|Active Comparator|Reference treatment|Healthy adult subjects under fed conditions
2407964|NCT03517930|Experimental|Test treatment|Healthy adult subjects under fasted conditions
2407965|NCT03517930|Active Comparator|Reference treatment|Healthy adult subjects under fasted conditions
2407966|NCT03517917||Arm 1|Tumour tissue collection and blood collection to enable a manufacturing process for immunotherapies to be developed.
2407967|NCT03517904|Experimental|IVUS-guided group|Intravascular ultrasound-guided intervention group
2407968|NCT03517904|Active Comparator|Angiography-guided group|Angiography-guided intervention group
2407969|NCT03517891|Experimental|WIC +|"The intervention consist in the implementation of an enhanced nutritional education and services model through the use of a combination of modalities to disseminate messages and educational materials framed in the health empowerment model. Each component of the intervention has been developed to provide the information consistent with the theoretical framework of the modality being used.~The intervention targets the following behaviors: Infant activation, Healthy sleep patterns, Screen time, Healthy feeding practices."
2407970|NCT03517891|No Intervention|WIC Standard of care (Control)|Participants recruited in randomly assigned control clinics will receive the WIC program standard of care. This includes the projected implementation of a web page for the nutritional education contacts. We will update our definition of the PR WIC program standard of care upon recruitment initiation and throughout the study implementation phase. We will also document the utilization rate of the web base platform provided by WIC among the control participants to determine baseline use of distance learning platforms.
2407971|NCT03517878||Comprehensive CHW Cohort|Pregnant women who become mothers and their infants living in areas served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Control Cohort clinic areas.
2407972|NCT03517878||Control Cohort|Pregnant women who become mothers and their infants living in areas that are not served by the comprehensive CHW program. These are areas around two primary health care clinics and matched to the Comprehensive CHW Cohort clinic areas.
2407973|NCT03517852|Experimental|Arm 1|Determine the feasibility and clinical utility of performing Human Intravital Microscopy (HIVM) in patients with peritoneal carcinomatosis during standard course of treatment (cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, or CRS-HIPEC).
2407974|NCT03517839|Experimental|Training Group|
2407975|NCT03517839|Sham Comparator|Control Group|
2407978|NCT03517787|Experimental|FES+TE|Participants receiving Functional electrical stimulation (FES) combined with therapeutic exercise (TE)
2407979|NCT03517787|Active Comparator|TE|Participants receiving only therapeutic exercise
2407980|NCT03517787|Other|REF-FES+TE|Healthy adults (reference group REF) that participate only in 1 session and receive FES and therapeutic exercise
2407981|NCT03517787|Other|REF-TE|Healthy adults that participate only in 1 session and receive only therapeutic exercise
2407982|NCT03517774|Experimental|3D Printed Socket|All participants will received a 3D Printed Prosthetic
2407983|NCT03517761|Experimental|Bone Marrow Concentrate treatment|Bone marrow concentrate subjects will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow nucleated cell layer. Injectate will then be used to treat the ligaments in the CCJ and upper cervical injections to C0-C3 ligaments and facets.
2407984|NCT03517761|Sham Comparator|Sham Control|Control subjects will also undergo a bone marrow aspiration of 30-60 cc to maintain blinding. Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia as well as receive sham upper cervical injections to C0-C3 ligaments and facets.
2407985|NCT03517748|Experimental|the investigational device: DM05|DM05 eye drops, multidose sterile emulsion, will be administered in the DM05 Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
2407986|NCT03517748|Active Comparator|The comparative device : Optive™|Optive™ eye drops, multidose sterile solution, will be administered in the Optive Arm at one to two drops instilled in each eye from 4 to 6 times per day during 84 days
3144605|NCT00044915|Placebo Comparator|Arm 2|
2407989|NCT03517722|Experimental|Ustekinumab|Participants will receive ustekinumab approximately 6 milligram per kilogram (mg/kg) intravenously (IV) based on body weight-range at Week 0 followed by 90 mg ustekinumab subcutaneously (SC) at Week 8 and every 8 weeks (q8w) thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will continue to receive 90 mg ustekinumab SC q8w through Week 160.
2407990|NCT03517722|Experimental|Placebo|Participants will receive matching placebo to ustekinumab IV at Week 0, followed by matching placebo to ustekinumab SC at Week 8 and q8w thereafter through Week 48 during double-blind period. Eligible participants who will enter the extension period will cross-over to receive 90 mg ustekinumab SC q8w through Week 160.
2407991|NCT03517709|Other|Conventional|
2407992|NCT03517709|Other|Blood Pressure Monitor|
2407993|NCT03517696|Active Comparator|Membrane Sweeping|Membrane sweeping
2407994|NCT03517696|No Intervention|Control|Routine vaginal exam
2407995|NCT03517683|Experimental|Low speed|Patients will receive intrathecal injection of the anesthetic mixture in a slow speed (1ml in 15 seconds)
2407996|NCT03517683|Active Comparator|High speed|Patients will receive intrathecal injection of the anesthetic mixture in a high speed (1ml in 5 seconds)
2407997|NCT03517657|Experimental|Bilateral motor priming + Task specific training (BMP + TST)|A combination of bilateral motor priming (BMP) plus task specific training (TST) for 30 hours over 5 weeks.
2407998|NCT03517657|Active Comparator|Control Priming + TST (CP + TST)|The control priming is transcutaneous electric stimulation (TENS) set at a low threshold followed by the same task specific training protocol for 30 hours over 5 weeks.
2407999|NCT03517644|Experimental|Deceptive Placebo (DP)|After pretreatment heat pain assessment, participants are informed that they are about to receive an effective analgesic cream. In fact, they receive a placebo cream. Next, the posttreatment pain assessment is conducted.
2408000|NCT03517644|Experimental|OLP with Hope (OLP Hope)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect. Next, the posttreatment pain assessment is conducted.
2408001|NCT03517644|Experimental|OLP with Expectations (OLP Expectation)|After pretreatment heat pain assessment, participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, using verbal instructions, the investigator aims to raise expectations among the participants that the cream will have a positive effect. Next, the posttreatment pain assessment is conducted.
2408002|NCT03517644|Experimental|Control|After pretreatment heat pain assessment, this group does not receive an intervention targeting pain sensation prior to the posttreatment pain assessment.
2408003|NCT03517631|Experimental|No busulfan preconditioning|shRNA-modified CD34+ cells without busulfan preconditioning.
2408004|NCT03517631|Experimental|Low dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
2408005|NCT03517631|Experimental|High dose busulfan preconditioning|shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
2408006|NCT03517618|Experimental|S-1 + leucovorin|Single arm
2408007|NCT03517605|Experimental|Exercise for cardiac rehabilitation|Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided into heating, aerobic exercise and recovery.
2408008|NCT03517592|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
2408009|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
2408010|NCT03517579|Experimental|Pilot Project|It is a Pilot study of 10 persons
3185227|NCT00732745|Active Comparator|Phase II arm II|Patients receive docetaxel and oxaliplatin as in arm I. Patients also receive an oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue to receive vandetanib beyond 8 courses in the absence of disease progression or unacceptable toxicity.
3185228|NCT00732771|Experimental|LCI696 1mg bid|
3185229|NCT00732784|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and calcium supplement on day 15).
2408016|NCT03517553|Experimental|EMS users in ESRD|Subjects then initiate passive electrical muscle stimulation (EMS) delivered by a commercially available FDA approved neuromuscular stimulator (EMPI 300PV or its replacement, EMPI Continuum device obtained from EMPI, Inc., St Paul MN) 3 times a week to the quadriceps muscle groups (15 minutes on each side, 30 minutes total) while on hemodialysis. The duration of training will last for 4 months. Subjects will be monitored at regular intervals during the training to make sure they are doing the training correctly and they are not experiencing any problems.
2408021|NCT03517527|No Intervention|Control|
2408022|NCT03517527|Experimental|Intervention|
2408023|NCT03517501|Active Comparator|ART-123|
2408024|NCT03517501|Placebo Comparator|Placebo|
2408025|NCT03517488|Experimental|XmAb20717|XmAb20717 administered by intravenous dosing on Days 1 and 15 of each 28-day cycle for a total of two cycles
2408026|NCT03517475|Experimental|Supervising for Home Safety modified|We will train caregivers to provide adequate levels of supervision to the 3-4 year-old children.
2408027|NCT03517475|Placebo Comparator|Services as Usual|Clients will receive home visiting services from Head Start
2408028|NCT03517462|Experimental|Ivermectin|Single dose directly observed treatment with Ivermectin 3Mg Tab (150 ug/kg) delivered orally.
2408552|NCT03514303||Oak|Subjects will test positive or negative to the allergen Oak.
3185230|NCT00732784|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and calcium supplement on day 1, Gleevec® alone on day 15).
3185231|NCT00732797|No Intervention|Routine Care|Participants will receive routine care.
3185232|NCT00732797|Active Comparator|Booklet|Participants will receive self-treatment booklets, but no expert telephone support.
2408032|NCT03517410||Smart phone Use Experimental group|Patients with CLBP
2408033|NCT03517397|Experimental|Mobile Contingency Management|
2408034|NCT03517384|Experimental|I-CBT for Body Dysmorphic Disorder|All participants will receive our Internet-Cognitive Behavioral Therapy treatment for Body Dysmorphic Disorder.
2408035|NCT03517371|Experimental|mHealth delivered exercise program|"Participants in the mHealth delivered exercise program have up to 10 in-person visits with a physical therapist over 12 months. The mHealth exercise program, consisting of walking, strengthening and stretching exercises, is prescribed and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week. The exercise program is video-recorded and accessed on a smartphone or computer tablet via an application (app). Cognitive-behavioral elements are integrated emphasizing participant engagement in managing their health condition. Components of the mHealth program include goal setting, action planning, automated rewards, self-monitoring of progress and a remote connection to a physical therapist through a messaging feature."
2408036|NCT03517371|Active Comparator|Exercise only|Participants in the control group have up to 10 in-person visits with a physical therapist over 12-months - equivalent to the dose provided to the mHealth condition. Participants are instructed by the physical therapist to engage in walking and perform the same progressive resistance and stretching exercises (tailored to their needs and provided in written format) at the same frequency (5x/week) as participants in the mHealth condition. Participants in the control condition are instructed to gradually progress their exercise program and to increase the amount of walking over a 1-year period. No cognitive-behavioral approaches or mHealth technology will be provided.
2408037|NCT03517358|Active Comparator|Pharmacy|service of care: pharmacy
2408038|NCT03517358|Active Comparator|Case management|service of care: case management
2408039|NCT03517345|Experimental|Prebiotic group|Given a prebiotic product (inulin + oligofructose; 5 g) mixed with conventional yogurt (100 g) which given as snack, twice a day.
2408040|NCT03517345|Experimental|Control group|Given conventional yogurt (100 g) which given as snack, twice a day.
2408041|NCT03517332||Cohort 1|"Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma~Subjects of cohort 1 must not:~• Have been treated for above diagnosed malignancy"
2408042|NCT03517332||Cohort 2|"Negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).~Subjects of cohort 2 must:~• Meet the listed matching criteria~Subjects of cohort 2 must not:~• Have been diagnosed/treated for a malignancy previously"
2408043|NCT03517319|Placebo Comparator|Placebo|Normal Saline 0.9% 1.2 ml will be injected to finger flexor muscles
2408044|NCT03517319|Experimental|Treatment dose 15|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U will be injected to finger flexor muscles
2408045|NCT03517319|Experimental|Treatment dose 30|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U will be injected to finger flexor muscles
2408046|NCT03517319|Experimental|Treatment dose 50|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U will be injected to finger flexor muscles
2408047|NCT03517319|Experimental|Treatment dose 70|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U will be injected to finger flexor muscles
2408048|NCT03517306||Beijing|No interventions
2408049|NCT03517306||Ningxia|No interventions
2408050|NCT03517306||Wenzhou|No interventions
2408051|NCT03517306||Changzhou|No interventions
2408052|NCT03517293|Experimental|Aerobic Exercise Intervention|Aerobic Exercise training 50 minutes of moderate intensity exercise, 3 times per week from ~16-40 weeks of pregnancy
2408053|NCT03517293|No Intervention|Control|usual daily activities - not exercise, not elevating heart rate
2408054|NCT03517280||Children with Neuroblastoma|Children undergoing treatment for Neuroblastoma at ITACI in Sao Paolo in Brazil who are under the age of 18 years.
2408055|NCT03517254|Experimental|Glutamine and strength training program|Three times per week, standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks of follow up. At the beginning and at the end of the training session, the experimental group will receive by mouth 10 grams of glutamine dissolved in 120 milliliters of water, all participants and team of researchers will not be aware of the supplement.
2408056|NCT03517254|Placebo Comparator|Placebo and strength training program|Three times per week a standardized and supervised resistance training by physicians will be conducted at the National Institute of Rehabilitation for 6 weeks after discharge. At the beginning and at the end of the training session, the placebo group will receive by mouth10 grams of maltodextrin dissolved in 120 milliliters of water. All participants and team of researchers will not be aware of the supplement content.
2408057|NCT03517241||Geographic atrophy secondary to AMD|20 patients clinically diagnosed with geographic atrophy (GA) secondary to AMD.
2408058|NCT03517241||Stargards disease|20 patients clinically and genetically diagnosed with Stargards disease (STGD)
2408059|NCT03517241||Branch retinal artery occlusion|20 patients clinically diagnosed with branch retinal artery occlusion (BRAO)
2408060|NCT03517241||Full thickness macular hole|20 patients clinically diagnosed with acute full thickness macular hole (FTMH) before and after macular surgery
2408061|NCT03517241||Healthy controls|20 healthy control subjects. Visual acuity of 20/16- 20/32
2408553|NCT03514303||Dog Dander|Subjects will test positive or negative to the allergen Dog Dander.
3185233|NCT00732797|Active Comparator|Booklet &Therapist Support|Participants will receive self-treatment booklets, and up to an hour's expert telephone support.
3185234|NCT00732810|Experimental|Breast cancer randomized to SCH 727965|
3185235|NCT00732810|Active Comparator|Breast cancer randomized to capecitabine|
2408063|NCT03517215|Experimental|Enhanced CB-ASP|If a site is randomized to the enhanced CB-ASP, prescribers at that site will be required to attend an education session. In the four months following the initial session, prescribers will be asked to complete one on-line eModule for each target condition (acute sinusitis, sore throat, acute bronchitis and acute uncomplicated cystitis) each month. Each module will take approximately 15 minutes to complete. Two audit and feedback reports (every 3 months) of their clinic's prescriptions for these conditions will be provided where they will be asked to review and discuss with their colleagues and study staff.
2408064|NCT03517215|Active Comparator|Standard CB-ASP|If a site is randomized to the standard CB-ASP strategy arm, prescribers will be offered the opportunity to attend the 1 hour introductory seminar by a web-link, provided with access to the short e-learning modules each month by email, and sent their clinic's audit and feedback reports by email for review two times during the study.
2408065|NCT03517215|No Intervention|Control|If a site is randomized to the control arm, the site will not receive any active interventions. Prescribers at the site will be offered access to the eModules at the completion of the study and provided with one audit and feedback report of their clinic's antibiotic prescribing patterns for local quality improvement needs as desired.
2408066|NCT03517189|Experimental|Aorta no-touch|Aorta no-touch off-pump coronary artery bypass surgery.
2408067|NCT03517176|Experimental|Part A (Dose Escalation)|Safety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m^2) / gemcitabine (1000mg/m^2) combination given on Days 1, 8, 15.
2408068|NCT03517176|Experimental|Part B (Expansion)|Safety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m^2) and gemcitabine (1000mg/m^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.
2408069|NCT03517163||Prospective Group|Individuals enrolled or just finished kindergarten who were diagnosed with Autism Spectrum Disorder through the DSM-5 diagnostic criteria
2408070|NCT03517150|Experimental|Experimental group|This group will use an oral appliance for treatment of obstructive sleep apnea. The oral appliance is custom-made and its titration is attained by means of progressive mandibular advancement that incrementally moves the mandible forward. This group of patients will use the oral appliance for 45 days.
2408071|NCT03517150|Active Comparator|Control group|This group will use a single adjustable silicone appliance in maxillar for 45 days, in order to compare to the experimental group.
2408072|NCT03517137|Experimental|Treatment|
2408073|NCT03517124|Experimental|Zirconia restorations|Dental restorations in surface modified zirconia bonded to tooth substance by dual cure resin cement
2408074|NCT03517124|Active Comparator|e.max|Restorations in e.max bonded to tooth substance by dual cure resin cement
2408075|NCT03517111|Experimental|Nutrition/substance use prevention|Parenting and nutrition curriculum targeting substance use prevention and diet improvement.
2408076|NCT03517111|Active Comparator|Substance use prevention only|Parenting curriculum targeting substance use prevention only.
2408077|NCT03517111|Sham Comparator|Academic success program|Control program focused only on academic success.
2408078|NCT03517098|Experimental|The ERAS group|Patients will be treated with the ERAS pathway
2408079|NCT03517098|Other|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care.
3144606|NCT00044967||Group 1|"Patients undergo baseline colonoscopy before or within 6 months of initial curative resection and then surveillance colonoscopy at 1, 3, and 5 years (+/- 6 months) after resection. The number, size, location, histology, and method of removal of polyps are documented at the time of colonoscopy. Patients also undergo microsatellite instability (MSI) status testing and complete family history questionnaires at baseline.~The prognostic significance of family history and MSI status is evaluated. The individual histologic features of the tumors are compared with the MSI status to determine their predictive value. The histologic features are also correlated with outcome to determine their prognostic significance.~Patients may be referred for genetic counseling."
2408084|NCT03517059||PD patients|30 PD patients in ON and OFF levodopa conditions
2408085|NCT03517059||Healthy control subjects|30 age matched healthy control subjects
2408086|NCT03517059||Neurological control subjects|10 patients with defined supra nuclear palsy
2408087|NCT03517046|Experimental|CartiLife (low-dose group)|Total defect volume in low-dose group is less than 2 ㎤. Low- and high-dose group are sequentially processed.
2408088|NCT03517046|Experimental|CartiLife (high-dose group)|Total defect volume in High-dose group is 2 ~ 4 ㎤.
2408089|NCT03517033|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
2408090|NCT03517033|Active Comparator|Reference|Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg
2408091|NCT03517020|Experimental|Test|Torrent's Nebivolol Tablets 20 mg
2408092|NCT03517020|Active Comparator|Reference|Forest Pharmaceuticals Inc.'s Bystolic® Tablets 20 mg
2408093|NCT03517007|Experimental|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
2408094|NCT03517007|No Intervention|Standard of Care|Provider continues routine, standard of care on the patient.
2408095|NCT03516994|Experimental|Structured Advance Care Planning|In the structured advance care planning approach, patients will participate in a 60 to 90 minute facilitated advance care planning conversation with a trained person using Respecting Choices (First Steps) guide and will receive a state advance directive form. The advance care planning facilitator will follow-up as needed after the session to answer additional questions.
2408096|NCT03516994|Active Comparator|Patient Driven Advance Care Planning|In the patient-driven advance care planning approach, patients receive a Five Wishes Form (easy to understand advance directive written in plain language), a state advance directive form, and at least two follow-up phone calls with an advance care planning contact who will answer questions.
2408137|NCT03516825|Experimental|Musical Neglect Training (MNT)|A single-subject design was used. All participants took Musical Neglect Training.
3144607|NCT00045019||discharged cancer patients|patients discharged from a surgery or medical ward of oncology institutes in Belgium, France, Germany, Italy, Poland, Spain, Sweden, Taiwan and United Kingdom (as part of a larger psychometric validation study) were asked to rate there level of satisfaction, using the EORTC QLQ-SAT32.
3144608|NCT00045175|Experimental|UCN-01 in combination with topotecan|
3144609|NCT00045188|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily. Treatment continues for at least 8 weeks in the absence of disease progression or unacceptable toxicity.
3144610|NCT00045396|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3144611|NCT00045526|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3144612|NCT00045565|Experimental|Group A|Patients receive arsenic trioxide IV over 2 hours once weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
3144613|NCT00045565|Experimental|Group B|Patients receive arsenic trioxide at a lower dose IV over 2 hours twice weekly for 6 weeks. Patients in both groups also undergo radiotherapy once daily 5 days a week for 6 weeks.
3144614|NCT00045591|Experimental|Celecoxib 100 mg|
3144615|NCT00045591|Experimental|Celecoxib 400 mg|
3144616|NCT00045617|Experimental|cisplatin and etoposide followed by vaccine|standard chemotherapy with cisplatin and etoposide followed by cisplans and etoposide with an anti-idiotype monoclonal antibody vaccine
3144617|NCT00045669|Experimental|Imatinib Mesylate|Adult patients with unresectable or metastatic adenoid cystic carcinoma measurable by Response Evaluation Criteria in Solid Tumors Group criteria and expressing c-kit by immunohistochemistry were treated with imatinib 400 mg orally bid. Response was assessed every 8 weeks
2408109|NCT03516968|Experimental|Monthly bolus arm|
2408110|NCT03516968|Active Comparator|Daily arm|
2408111|NCT03516968|Other|Control group|Group of obese patients without vitamin D deficiency
2408112|NCT03516942||Observational (questionnaire)|Patients complete questionnaires over 20-60 minutes at baseline and at 3, 6, 12, and 24 months after cancer diagnosis.
2408113|NCT03516929|Active Comparator|high risk group|history of stroke or TIA, carotid bruit, left main stem disease, other peripheral vascular disease
2408114|NCT03516929|Sham Comparator|low risk group|No history or stroke,TIA. NO left main stem disease
2408115|NCT03516916||Australia|Patients with a permanent colostomy after curative surgery for rectal cancer
2408116|NCT03516916||Brazil|Patients with a permanent colostomy after curative surgery for rectal cancer
2408117|NCT03516916||China|Patients with a permanent colostomy after curative surgery for rectal cancer
2408118|NCT03516916||Denmark|Patients with a permanent colostomy after curative surgery for rectal cancer
2408119|NCT03516916||Egypt|Patients with a permanent colostomy after curative surgery for rectal cancer
2408120|NCT03516916||Israel|Patients with a permanent colostomy after curative surgery for rectal cancer
2408121|NCT03516916||Lithuania|Patients with a permanent colostomy after curative surgery for rectal cancer
2408122|NCT03516916||the Netherlands|Patients with a permanent colostomy after curative surgery for rectal cancer
2408123|NCT03516916||Portugal|Patients with a permanent colostomy after curative surgery for rectal cancer
2408124|NCT03516916||Russia|Patients with a permanent colostomy after curative surgery for rectal cancer
2408125|NCT03516916||South Africa|Patients with a permanent colostomy after curative surgery for rectal cancer
2408126|NCT03516916||Spain|Patients with a permanent colostomy after curative surgery for rectal cancer
2408127|NCT03516916||Sweden|Patients with a permanent colostomy after curative surgery for rectal cancer
2408128|NCT03516916||Turkey|Patients with a permanent colostomy after curative surgery for rectal cancer
2408129|NCT03516916||the United Kingdom|Patients with a permanent colostomy after curative surgery for rectal cancer
2408130|NCT03516903|Active Comparator|Methotrexate & Folic acid|ddMTX-LDE 40mg/m2 (100mL total volume) IV and Folic acid 5mg by mouth (the day after ddMTX-LDE) weekly for 6 weeks
2408131|NCT03516903|Placebo Comparator|Placebo & folic acid|Placebo-LDE IV 100mL and Folic acid 5mg by mouth (the day after Placedo-LDE) weekly for 6 weeks
3144618|NCT00045682|Experimental|Treatment (polyglutamate paclitaxel)|Patients receive polyglutamate paclitaxel (CT-2103) IV over 10-20 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2408133|NCT03516851|Active Comparator|Precision bypass group|Using ICG with Flow800 software and multimodal neuronavigation to choose the recipient vessel
2408134|NCT03516851|No Intervention|Empirical group|choosing the recipient vessel by the surgeon's own experience
3144619|NCT00045773||1|
3144620|NCT00045786|Experimental|400 mg CC-1088|
3144621|NCT00045786|Experimental|800 mg CC-1088|
3144622|NCT00045786|Experimental|1200 mg CC-1088|
3144623|NCT00045786|Experimental|1500 mg CC-1088|
3144624|NCT00045799|Experimental|Omeprazole sodium bicarbonate immediate release PWD/FS|
3144625|NCT00045799|Active Comparator|Cimetidine IV|
3144626|NCT00045903|Experimental|Exposure and Ritual Prevention|Exposure and Ritual Prevention Therapy
3144627|NCT00045903|Active Comparator|Stress Management|Stress Management Therapy
3144628|NCT00045916|Experimental|High dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3144629|NCT00045916|Experimental|High dosage ECT + venlafaxine|Participants will receive venlafaxine and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3144630|NCT00045916|Placebo Comparator|High dosage ECT + placebo|Participants will receive placebo and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
3144631|NCT00045916|Experimental|Low dosage ECT + nortriptyline|Participants will receive nortriptyline and high dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
2408138|NCT03516812|Experimental|Treatment (olaparib, testosterone enanthate or cypionate)|Patients receive olaparib PO BID on days 1-28 and testosterone enanthate or cypionate IM on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2408139|NCT03516799|Experimental|Acupuncture (ACU) Group|The group of participants who opt in to acupuncture
2408140|NCT03516799|No Intervention|Treatment-as-Usual (TAU) Group|The group of participants who enroll in the study but opt out of acupuncture (treatment-as-usual)
2408141|NCT03516773|Experimental|Treatment A|Intervention: EB612 (EBP05) 2.25 mg orally (PO) four times a day (QID) (approximately 5 hours apart) for 4 doses, for a total dose of 9 mg per day
2408142|NCT03516773|Experimental|Treatment B|Intervention: EB612 (EBP05) 2.25 mg PO twice a day (BID) (approximately 10 hours apart) for 2 doses, for a total dose of 4.5 mg per day
2408143|NCT03516773|Active Comparator|Treatment C|Intervention: NATPARA/NATPAR PTH(1-84) 100 μg subcutaneous injection once daily (single dose)
2408144|NCT03516773|Experimental|Treatment D|Intervention: EB612 (EBP05) 2.25 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 6.75 mg per day
2408145|NCT03516773|Experimental|Treatment E - EB612 (EBP05)|Intervention: EB612 (EBP05) 0.75 mg PO TID (dose 1 and dose 2 approximately 10 hours apart; dose 2 and dose 3 approximately 5 hours apart- TID schedule option 2), for a total dose of 2.25 mg per day
2408146|NCT03516760|Experimental|GEM333|application of GEM333, a CD33 targeted bispecific antibody engaging T-cells
2408147|NCT03516747|Experimental|investigation group|participants that suffer hypercalcemia due to primary hyperparathyroidism. include all participants in the trial
2408148|NCT03516734|Experimental|Iron fortified lentils|Lentils will be fortified with iron in the lab setting at the Crop Development Center (CDC) of The University of Saskatchewan, Canada. The study will fortify lentil by spraying iron fortificant NaFeEDTA solution. A small sprayer will be placed at the beginning of the lentil polishing machine at a commercial lentil mill located near Saskatoon, Canada. The iron solution will be applied as a fine mist which will be absorbed into the lentil as it travels through the polishing drum. As the fortified lentil leaves the drum it will be bagged in 20 kg food grade bags. The expected concentration of Fe in the final product will be approximately 21 mg/100 g of lentil (fortified with NaFeEDTA solution with 1600 ppm of Fe).
2408149|NCT03516734|Active Comparator|Non iron-fortified lentils|It will be the same Saskatchewan (province of Canada) grown small cotyledon color lentil (Iron content 75-90ppm) without the iron fortification.
2408150|NCT03516734|Placebo Comparator|Usual Intake (no intervention)|It will be the usual intake of lentil- no additional lentil will be provided. However, participants will be free to consume lentils from anywhere (homemade or restaurants) if they want to, except our fortified lentils.
2408151|NCT03516721|Other|Obese adolescents|
2408152|NCT03516721|Other|Lean adolescents|
3144632|NCT00045916|Experimental|Low dosage ECT + venlafaxine|Participants will receive venlafaxine and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment.
3144633|NCT00045916|Experimental|Low dosage ECT + placebo|Participants will receive placebo and low dosage ECT. If the ECT is effective participants will receive lithium after ECT treatment weeks.
2408155|NCT03516682|No Intervention|Usual Care|Parents will receive usual care for their child at Kaiser Permanente Colorado. This includes recommendations for well child visits at 2, 4, 6 and 12 months of age as well as automated reminders for age eligible children to receive the flu shot during flu season.
2408156|NCT03516682|Experimental|Reminders|Parents randomized to the reminder arm will receive automated reminders to complete a 6 month and 12 month vaccine visit for their child. They will receive 2 reminders before the child is 6 and 12 months of age and 2 reminders after their child is 6 and 12 months of age. Reminders will not occur if they have received vaccines within the eligible time frame to receive a vaccine or have a visit scheduled. After randomization, participants in the intervention arm will have an opportunity to provide their preference on how they receive reminders (text, phone and/or email). Participants not providing a preference will receive text reminders. If a child is randomized into the study after the child is 7 months of age, the parent will only be eligible for reminders for the 12 month vaccine visit.
2408157|NCT03516669|Other|Intraluminal Clarithromycin eradication|20 Patients receive intraluminal Clarithromycin eradication of H. pylori.
2408158|NCT03516669|Other|Oral standard triple therapy|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor and two antibiotics ( amoxicillin, and clarithromycin) for 14 days.
2408187|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408342|NCT03515590|Experimental|Emulsion with solid droplets|Emulsion with solid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
2408555|NCT03514290|Experimental|GLASER|treated with Low-lever laser + tooth bleaching with 35% hydrogen peroxide (HP).
3144634|NCT00045968|Active Comparator|treatment cohort|
3144635|NCT00045968|Placebo Comparator|Placebo Chohort|Autologous PBMC
3144637|NCT00046085|Active Comparator|Patient customary care|12 months of patient customary care
3144638|NCT00046085|Experimental|Online family education|12 months of patient customary care and relative access to online education and support program
3144639|NCT00046111|Experimental|Primary Group|40 subjects on medium doses of Topotecan and tested for bioequivalence for 4 weeks.
3144644|NCT00046631||Adolescent girls|Chosen from 6 schools in 6 cities
3144645|NCT00046735|Experimental|1|
3185236|NCT00732810|Experimental|SCH 727965 in breast cancer after progression on capecitabine|
3185237|NCT00732810|Experimental|NSCLC randomized to SCH 727965|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
2408159|NCT03516656|Active Comparator|Standard heparin dose|The investigators will identify surgical patients placed on fixed dose heparin infusions at their attending surgeon's discretion-the proposed research will not dictate the initiation of the heparin drip intraoperatively. However, the investigators will identify patients already on heparin, evaluate steady state heparin anti-Xa levels and adjust patient's dose if necessary based on steady state anti-Xa levels. Eligible patients will be started on heparin fixed-dose intraoperatively and transitioned to a weight-based dose by their surgeons. Steady state anti-Xa levels will be drawn at least 6 hours after initiation of heparin infusion. Goal anti-Xa levels will be 0.1-0.35 IU/mL.
2408160|NCT03516656|Active Comparator|Real time heparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time heparin dose adjustment and will receive follow-up steady state anti-Xa levels. Anti-Xa level monitoring will be discontinued when in range peak levels are obtained, when heparin infusions are discontinued at surgeon discretion, or when the patient is discharged
2408161|NCT03516643|Experimental|Shockwave|Extracorporeal Shockwave treatment on Ischemic Myocardium
2408162|NCT03516630|Experimental|TRZ 20|Product is administered as single dose in the morning, under fasting conditions. 10 drops for the dose of 20 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2408163|NCT03516630|Experimental|TRZ 60|Product is administered as single dose in the morning, under fasting conditions. 30 drops for the dose of 60 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2408164|NCT03516630|Experimental|TRZ 140|Product is administered as single dose in the morning, under fasting conditions. 70 drops for the dose of 140 mg is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2408165|NCT03516630|Placebo Comparator|Placebo|Product is administered as single dose in the morning, under fasting conditions. Trazodone-matching placebo corresponding to 70 drops is suspended in 120 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2408166|NCT03516630|Active Comparator|Moxifloxacin|Product is administered as single dose in the morning, under fasting conditions. One 400 mg tablet is swallowed (without chewing) with 240 mL of still mineral water. A wash-out interval of at least 7 days is required before the administration of the other doses foreseen in the study.
2408167|NCT03516617|Experimental|Arm A (acalabrutinib)|Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
2408168|NCT03516617|Experimental|Arm B (acalabrutinib, obinutuzumab)|Patients receive acalabrutinib PO BID on days 1-28 and obinutuzumab IV on days 1, 2, 8, and 15 of cycle 1 and days 1 of subsequent cycles. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
2408169|NCT03516617|Active Comparator|Arm C (observation)|Patients will be observed every 6 months for up to 2 years.
2408170|NCT03516604|Experimental|PF-04995274|"PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days~+ 1 placebo capsule, once daily for 7-9 days"
2408171|NCT03516604|Active Comparator|Citalopram|"Citalopram, one x 20mg capsule, once daily for 7-9 days~+ 3 placebo tablets, once daily for 7-9 days"
2408172|NCT03516604|Placebo Comparator|Placebo|3 placebo tablets and 1 placebo capsule, once daily for 7-9 days
3144646|NCT00046865|Experimental|Acupressure|Arm I: Patients receive active acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied to a specific site each morning and again whenever nausea is experienced for 3-6 minutes.
3185238|NCT00732810|Active Comparator|NSCLC randomized to erlotinib|Note: Enrollment of participants with NSCLC was completed per protocol as of 26 JAN 2010
2408175|NCT03516565||Pregnancy group|Pregnant group included women, who were in their second trimester (weeks 16-24) and third trimester (weeks 25-34)
2408176|NCT03516565||Postpartum group|Postpartum group included women, who were evaluated 6 months after giving birth
2408177|NCT03516565||Non-pregnant group|Women who were systemically healthy and non-pregnant.
2408178|NCT03516552||Hemoglobin content on blood loss|Hemoglobin content on blood loss, to assess ratio hemoglobin/volume.
2408179|NCT03516539|Experimental|Group ML|Mcgrath videolaryngoscopy
2408180|NCT03516539|Active Comparator|Group DL|direct Macintosh laryngoscope
2408181|NCT03516526|Other|All patients in this study|Patients treated with natalizumab with a minimum of 1 year, without signs of disease activity (relapses, new T2 lesions on MRI) for a minimum of 1 year.
2408182|NCT03516513|Active Comparator|Problem Solving Therapy as Usual|"Clinicians in this arm of care will have access to the Case Management Tracking System which is already in use.~Intervention: unguided PST"
2408183|NCT03516513|Experimental|Assisted Problem Solving Therapy|"This arm will be designed and finalized in Phase 1 and 2 of the project. We anticipate that the intervention will leverage clinical notes required to be completed by clinicians and will provide information to clinicians to help patients improve over time, as well as help clinicians implement PST to high quality.~Intervention: guided PST"
2408184|NCT03516500|Experimental|Iron Sucrose injection group|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) through a butterfly needle into the bronchus of the targeting segment.
2408185|NCT03516487|Experimental|SAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^10 colony-forming units [CFU]) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408186|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
3185239|NCT00732810|Experimental|SCH 727965 in NSCLC after progression on erlotinib|Note: Crossover to SCH 727965 after progression on erlotinib was completed per protocol as of 26 JAN 2010
2408188|NCT03516487|Experimental|SAD HV SB: SYNB1618 (1 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1). On Day 1, subjects in this cohort receive a solid breakfast (SB) that contains approximately the same amount of calories and protein as the meal supplement shake given to subjects in the other SAD cohorts.
2408189|NCT03516487|Experimental|SAD HV: SYNB1618 (2 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (2 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408190|NCT03516487|Experimental|SAD HV: SYNB1618 (5 x 10^11 CFU)|HV subjects receive a single oral dose of SYNB1618 (5 x 10^11 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408191|NCT03516487|Placebo Comparator|SAD HV: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408192|NCT03516487|Experimental|SAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive a single oral dose of SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408193|NCT03516487|Placebo Comparator|SAD PKU: Placebo|HV subjects receive a single oral dose of placebo in a chilled buffered solution on Day 1 in the SAD study (Part 1).
2408194|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^10 CFU)|HV subjects receive oral SYNB1618 (1 x 10^10 CFU) in a chilled buffered solution 3 times per day (TID) for 7 days in the MAD study (Part 2).
2408195|NCT03516487|Experimental|MAD HV: SYNB1618 (5 x 10^10 CFU)|HV subjects receive oral SYNB1618 (5 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408196|NCT03516487|Experimental|MAD HV: SYNB1618 (7 x 10^10 CFU)|HV subjects receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408197|NCT03516487|Experimental|MAD HV: SYNB1618 (1 x 10^11 CFU)|HV subjects receive oral SYNB1618 (1 x 10^11 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408198|NCT03516487|Placebo Comparator|MAD HV: Placebo|HV subjects receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408199|NCT03516487|Experimental|MAD PKU: SYNB1618 (7 x 10^10 CFU)|Subjects with PKU receive oral SYNB1618 (7 x 10^10 CFU) in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408200|NCT03516487|Placebo Comparator|MAD PKU: Placebo|Subjects with PKU receive oral placebo in a chilled buffered solution TID for 7 days in the MAD study (Part 2).
2408201|NCT03516474||St. Michael's Hospital|"St. Michael's Hospital is an Acute care centre for the diabetic lower extremity.~n=100"
2408202|NCT03516474||South Riverdale Community Health Centre|South Riverdale is a Community Health Centre focused on prevention. n=100
2408203|NCT03516474||Westpark|Westpark is a rehabilitation site focused on post-operative/amputation care and preservation of the opposite limb. n=100
2408204|NCT03516474||Women's College Hospital|Women's College Hospital is an outpatient wound clinic focused on the management of DFUs. n=100
2408205|NCT03516461|Experimental|Selective Microbiota Transplant (SMT)|Patients undergo once SMT a day for three consecutive days.
2408206|NCT03516461|Experimental|Fecal Microbiota Transplantation (FMT)|Patients undergo FMT on day 1. If they fail to benefit from single FMT, repeat FMTs (no more than 3 times) would be performed.
2408207|NCT03516448|Active Comparator|the Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid
2408208|NCT03516448|Placebo Comparator|the placebo group|the placebo Gan Fu Le Tablets，6 tablets,po,tid
2408209|NCT03516435|Experimental|Parasacral transcutaneous ES|20min./session, 2 sessions/week ,12 sessions of Parasacral transcutaneous electrical stimulation.
2408210|NCT03516435|Active Comparator|Intravaginal electrical stimulation|20min./session, 2 sessions/week ,12 sessions of Intravaginal electrical stimulation.
2408211|NCT03516422|Placebo Comparator|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
2408212|NCT03516422|Experimental|ULTRASOUND DEBRIDEMENT GROUP:|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
2408213|NCT03516409|Active Comparator|Bio-Kult Infantis|1 sachet once a day mixed with milk, water or food.
2408214|NCT03516409|Placebo Comparator|Placebo|1 sachet once a day mixed with milk, water or food.
2408215|NCT03516396|Experimental|Training Plus|"Intervention: Community Development~Training plus enhanced community development activities"
2408216|NCT03516396|Active Comparator|Control|No inputs
2408217|NCT03516396|Experimental|Training Only|"Intervention: Training~Training Only (livestock management and child nutrition)"
2408218|NCT03516383||Experimental|"ABI < 0.6, confirmed PAD~50 - 90 years of age~In-patients or out-patients~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
2408219|NCT03516383||Control|"ABI of 0.9 < ABI < 1.2~50 - 90 years of age~Participants who understand the study and are able to give consent~Participants who can be followed by the same investigating team for the whole period of their participation in the study"
2408343|NCT03515590|Experimental|Emulsion with liquid droplets|Emulsion with liquid droplets will be consumed by participants in one study visit along with 1500 mg of crushed and dissolved acetaminophen.
3185240|NCT00732823|Placebo Comparator|Profile A|No device worn
2408220|NCT03516370|Experimental|study group|Scaling and root planning was followed by placement of Lyophilized Saccharomyces Boulardii 250 MG in the pocket. S. boulardii was delivered subgingivally by by mixing 1gm of sachet containing 250mg of lyophilized yeast with 0.5ml of distilled water this prepared paste was injected in the perio pocket with luer lock syring and cannula.
2408221|NCT03516370|Placebo Comparator|control group|Control site received placebo i.e distilled water as a mixture after scaling and root planning.
2408222|NCT03516357||low myopia|-3.00D < spherical equivalent refractive error < -0.50D
2408223|NCT03516357||moderate myopia|-6.00D < spherical equivalent refractive error ≤ -3.0D
2408224|NCT03516357||high myopia|spherical equivalent refractive error ≤ -6.0D
2408225|NCT03516344|No Intervention|Control|Subjects will remain at rest in supine position for one minute.
2408226|NCT03516344|Experimental|Iliac psoas muscle|In supine position with a high-density foam cushion under the subject's feet, they will be asked to make a push in the caudal direction, against the cushion, alternating between both feet with their knees stretched out, for one minute
2408227|NCT03516344|Experimental|Diaphragmatic Breathing|Subjects perform five cycles of diaphragmatic breathing in the supine position.
2408228|NCT03516344|Experimental|Liver pumping|A technique of hepatic supine pumping is performed by simultaneous compression in the right hypochondrium and epigastrium, in the opposite direction, during the inspiratory phase, stopping during the expiratory phase and repeating the maneuver for five respiratory cycles.
2408229|NCT03516344|Experimental|Spinal manipulation|A semi-direct vertebral manipulation, type Dog Technique in extension, will be performed on level D8
2408230|NCT03516331|Experimental|Part 1:FDL176 & FDL169 coadministration|To receive a single dose of FDL176 on Day 1, followed up FDL169 TID starting Day 8; and another single dose of FDL176 on Day 22.
2408231|NCT03516331|Experimental|Part 2:FDL176 & FDL169 coadministration|To receive FDL176 QD starting Day 1, and FDL169 TID starting Day 8
2408232|NCT03516318|Experimental|SMART Connections|"The intervention components include:~Informational messages that reflect the content of the structured group counseling curriculum and are posted to the Facebook group wall on a regular basis for approximately 4 to 5 months~Moderated, closed group chats in a secret Facebook group where YLHIV can interact with their peers and with a trained support group facilitator~Access to a trained facilitator via Facebook Messenger for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
2408233|NCT03516318|No Intervention|Control|All study participants, in both study arms, will receive standard services currently available to YLHIV in these facilities and communities. The services currently include: routine clinical care for HIV treatment including laboratory testing (CD4, viral load tests); active case management by community volunteers with intensive adherence support during the first 4 weeks of ART; adherence support through phone calls and SMS (short messaging service) reminders; and enhanced adherence counseling for patients with unsuppressed viral loads.
2408234|NCT03516305|Experimental|Staccato Alprazolam 1 mg|a single inhaled dose
2408238|NCT03516253|Experimental|Intervention group|Dietary Supplement: Fish oil + EPO. Fish oil (2 gel capsules, each 1g fish oil with 500 mg EPA+DHA) and EPO (Evening primrose oil 3 gel capsules with 117 mg GLA), 3 months with lunch.
2408239|NCT03516253|No Intervention|Control group|Dietary Supplement: Mineral oil (5 gel capsules, each 1g mineral oil), 3 months with lunch.
2408240|NCT03516240|Experimental|Experimental|Participants receive the topical analgesic, Biofreeze.
2408241|NCT03516240|Placebo Comparator|Placebo|Participants receive a placebo cream.
3185241|NCT00732823|Active Comparator|Profile B|Foot 40 mmHg, ankle 40 mmHg, mid-calf 35 mmHg, upper calf 30 mmHg
2408244|NCT03516214|Experimental|EGF816 (nazartinib) and trametinib|Patients will receive oral EGF816 (nazartinib) and trametinib at escalating dose levels. Intra-patient dose-escalation will not be allowed.
2408245|NCT03516201||obese patients after bariatric surgery|obese adults (≥ 18 years) who underwent bariatric surgery
2408246|NCT03516201||obese adultes without bariatric surgery|obese adults (≥ 18 years) who did not underwent bariatric surgery at the time of the examination
2408247|NCT03516188|Experimental|Alginate-antacid group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus alginate-antacid.
2408248|NCT03516188|Experimental|Non antacid alginate group|Participants will take normal meals with late night supper (i.e.two chicken burgers and one cup or 250 ml of teh-tarik) plus antacid alone.
2408249|NCT03516175|Active Comparator|Tight fitting mask|Pre oxygenation with tight facemask with 100% oxygen
2408250|NCT03516175|Experimental|High flow nasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange is used for pre oxygenation
2408251|NCT03516162||Patients With Brain Tumors/AVMs|"Patients with a brain tumour/AVM scheduled for maximum safe resection via craniotomy.~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
2408778|NCT03512652|Other|Patello|
2408252|NCT03516162||Patients With Hydrocephalus|"Patients with hydrocephalus scheduled for VP-shunting~Participants fulfilling all of the following inclusion criteria are eligible for the study:~Consent of the patient~Age: ≥18~Fluent language skills in German~Patient is capable to use a smartphone (based on the Google Android system) and uses a smartphone since at least 3 months~Preoperative smartphone-assessed day-to-day behaviour can be recorded for at least 1 week (7 days)"
2408253|NCT03516149|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
2408254|NCT03516149|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
2408255|NCT03516123|Experimental|CS3006|Participants will receive CS3006 orally at specified dose on specified days
2408256|NCT03516110||Prostate cancer subjects 60-<70 years|
2408257|NCT03516110||Prostate cancer subjects 70-<75 years|
2408258|NCT03516110||Prostate cancer subjects ≥ 75 years|
2408259|NCT03516097|Experimental|Experimental Group A|Structured school based intervention + mobile app usage
2408260|NCT03516097|Experimental|Experimental Group B|mobile app usage
2408261|NCT03516097|Active Comparator|Control Group|Structured school based intervention
2408262|NCT03516084|Experimental|ZL-2306(nirapairb)|
2408263|NCT03516084|Placebo Comparator|Placebo|
2408264|NCT03516071|Experimental|Brivanib 800 mg, QD + BSC|
2408265|NCT03516071|Experimental|Brivanib 400 mg, BID + BSC|
2408266|NCT03516045|Experimental|18F-AlF-NOTA-neurotensin PET/CT|One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT
2408267|NCT03516032|Experimental|walking exercises|walking in the hospital corridor
2408268|NCT03516032|Experimental|balance exercises|heel rise exercises
2408269|NCT03516019|Experimental|Weekday am personalized notices|Participants in this arm receive personalized weekday am notices on Wednesday at 7am.
2408270|NCT03516019|Experimental|Weekday pm personalized notices|Participants in this arm receive a personalized weekday pm notices on Wednesday at 7pm.
2408271|NCT03516019|Experimental|Weekend am personalized notices|Participants in this arm receive a personalized weekend am notices on Saturday at 7am.
2408272|NCT03516019|Experimental|Weekend pm personalized notices|Participants in this arm receive personalized pm notices on Saturday at 7pm.
2408273|NCT03516019|Experimental|Weekday am standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7am.
2408274|NCT03516019|Experimental|Weekday pm standard notices|Participants in this arm receive standard weekday notices on Wednesday at 7pm
2408275|NCT03516019|Experimental|Weekend am standard notices|Participants in this arm receive standard weekend notices on Saturday at 7am
2408276|NCT03516019|Experimental|Weekend pm standard notices|Participants in this arm receive standard weekend notices on Saturday at 7pm
2408277|NCT03516006|Experimental|UCMSC|infusion of aUCMSC and Ursodeoxycholic acid therapy
2408278|NCT03516006|Active Comparator|UDCA|Ursodeoxycholic acid therapy 15mg/kg/d
2408279|NCT03515980|Experimental|Mild hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh A score 5 to 6 points
2408280|NCT03515980|Experimental|Moderate hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh B score 7 to 9 points
2408281|NCT03515980|Experimental|Severe hepatic impairment|Based on Hepatic Function Impairment - Child-Pugh C score 10 to 15 points
2408282|NCT03515980|Experimental|Normal hepatic function|Based on Hepatic Function Impairment as defined by the investigator
2408283|NCT03515967|Experimental|Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) after injury using the I-PAS goggles
2408284|NCT03515967|Active Comparator|Non-Injured Athletes|Athletes tested for mild traumatic brain injury (mTBI) with no injury using the I-PAS goggles
3185242|NCT00732823|Active Comparator|Profile C|Foot 50 mmHg, ankle 50 mmHg, mid-calf 45 mmHg, upper calf 40 mmHg
3185243|NCT00732823|Active Comparator|Profile D|Foot 60 mmHg, ankle 60 mmHg, mid-calf 55 mmHg, upper calf 50 mmHg
2408287|NCT03515928|Active Comparator|Noise Exposed Group|
2408288|NCT03515928|Placebo Comparator|Control Group|
2408289|NCT03515902|Experimental|mouthguard|Mouthguard arm is application of mouthguard while swimming
2408290|NCT03515902|Experimental|mouthguard with desensitizing toothpaste|Mouthguard with desensitizing toothpaste arm is application of mouthguard with desensitizing toothpaste containing 8% arginine and calcium carbonate while swimming
2408291|NCT03515889|Experimental|Ideal Protein Weight Loss Protocol|This arm will follow the Ideal Protein method as documented in the Ideal Protein Clinic Manual and in the Ideal Protein Coaches Manual.
2408292|NCT03515889|Active Comparator|Standard Weight Loss|This arm utilizes evidence-based, low fat, low calorie strategies that have been shown to be effective for long-term weight loss and weight loss maintenance.
2408293|NCT03515876||Control|Patients will receive intravenous propofol infusion.
2408294|NCT03515876||Dexmedetomidine 0.5 microgram/kg group|Patients will receive dexmedetomidine 0.5 microgram/kg and then intravenous propofol infusion.
2408295|NCT03515876||Dexmedetomidine 1 microgram/kg group|Patients will receive dexmedetomidine 1 microgram/kg and then intravenous propofol infusion.
2408296|NCT03515863||Grave's disease with TAO|Patients with Grave's disease and TAO
2408297|NCT03515863||Grave's disease without TAO|Patients with Grave's disease but without TAO
2408335|NCT03515642|Experimental|HIIT group|The HIIT modality consisted of 30-40 minutes (min) of steady-state, high-intensity training 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 85% to 95% of the individual's maximum oxygen consumption rate (VO2max). Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6-weeks.
3185244|NCT00732836|Experimental|HAI Abraxane MTD|Dose escalation beginning Day 1, Cycle 2 dose level 180 mg/m^2 for maximum tolerated dose (MTD) of Hepatic Arterial Infusion of Abraxane (HAI Abraxane) following same dose intravenous Abraxane in Cycle 1 of 21 day cycle.
3185245|NCT00732836|Experimental|HAI Abraxane Expansion|HAI Abraxane dose expansion at MTD or dose level 3 (260 mg/m^2) if MTD not defined.
3185246|NCT00732849|No Intervention|1|Standard Enteral Nutrition - Peptisorb, Nutricia Ltd.
2408298|NCT03515837|Experimental|Pembro+Pemetrexed+Chemo|Participants receive pembrolizumab (pembro) 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo) (either carboplatin Area Under the Curve [AUC] 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
2408299|NCT03515837|Active Comparator|Placebo+Pemetrexed+Chemo|Participants receive normal saline solution via IV infusion on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W with no restrictions on the number of cycles PLUS platinum chemotherapy (chemo)(either carboplatin AUC 5 via IV infusion Q3W for 4 cycles [Cycles 1-4] or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles [Cycles 1-4]).
3185247|NCT00732849|No Intervention|2|Standard Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes
3185248|NCT00732849|Experimental|3|Immunomodulating Enteral Nutrition: Reconvan, Fresenius Kabi Poland
3185249|NCT00732849|Experimental|4|Immunomodulating Parenteral Nutrition: Aminomel, Lipofundin, Glucose, Cernevit, Tracutil, electrolytes + Omegaven (Fresenius Kabi), Dipepitven (Fresenius Kabi)
3185250|NCT00732862|Experimental|1|Baseline clamp study before treatment phase.
2408304|NCT03515811||Abdominal|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Abdominal (approximately 53 subjects)."
2408305|NCT03515811||Thoracic|"Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri-Staple™ 2.0 Intelligent Reloads.~Thoracic (approximately 74 subjects)."
2408306|NCT03515798|Experimental|Pembrolizumab|EC Paclitaxel + Pembrolizumab Injection
2408307|NCT03515798|Active Comparator|Standard neoadjuvant chemotherapy|EC Paclitaxel alone
2408308|NCT03515785||Ph+ ALL Patients|Patients with Ph+ ALL being treated with Iclusig®.
2408309|NCT03515772||Amlodipine with Dolutegravir|"This is the control group regarding HIV drug interaction potential on amlodipine"
2408310|NCT03515772||Amlodipine with Darunavir|"This is the case group regarding HIV drug interaction potential on amlodipine"
2408311|NCT03515772||Atorvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on atorvastatin"
2408312|NCT03515772||Atorvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on atorvastatin"
2408313|NCT03515772||Rosuvastatin with Dolutegravir|"This is the control group regarding HIV drug interaction potential on rosuvastatin"
2408314|NCT03515772||Rosuvastatin with Darunavir|"This is the case group regarding HIV drug interaction potential on rosuvastatin"
2408315|NCT03515759||hypertensive patients|60 pregnant women with singleton living fetus between 34 -38 wks gestation known to have severe hypertension in the current pregnancy were included
2408316|NCT03515746|Active Comparator|Exergaming2D|The participants will practise grab and grasp through exergaming in virtual environment (VE) on a laptop computer. During the task, they will sit in a comfortable chair in front of the screen.
2408317|NCT03515746|Active Comparator|Exergaming3D|The participants will practise grab and grasp through exergaming in virtual environment (VE) in 3D VE using Oculus Rift CV1 3D goggles. During the task, they will sit in a comfortable chair with head-mounted 3D display.
2408318|NCT03515733|Experimental|PF-04995274|PF-04995274, three x 5mg tablet (15mg total), once daily for 7-9 days
2408319|NCT03515733|Placebo Comparator|Placebo|3 placebo tablets, once daily for 7-9 days
2408320|NCT03515720|Experimental|Study group|Painful points will be located in the path of the sensory nerves of the knee in which asepsis and antisepsis will be performed, and then 0.5-1 ml of 5% dextrose solution will be applied subcutaneously at a 45º angle along the way. of the nerve with a 27 gauge needle of ½ inch. The number of injections will vary according to the symptoms to be treated. The application will be made once a week for 6 weeks. After the first application of neuroprolotherapy, the patient will be trained to perform a rehabilitation therapy program based on thermotherapy, kinesitherapy and knee strengthening exercises. At the end of the 6 sessions, a new assessment will be made with the WOMAC, EVA and measurement of movement arcs to assess the evolution after treatment.
2408321|NCT03515720|No Intervention|Control group|Physical therapy consisting of 10 sessions based on thermotherapy, kinesitherapy and muscle strengthening exercises to the knee. Subsequently, the patient will perform this therapy home until completing 6 weeks. At the end a new assessment will be made with measurement of movement arcs, WOMAC scale and EVA to assess the evolution after treatment.
2408322|NCT03515707|Experimental|Treatment (busulfan, etoposide, ASCT)|Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.
2408323|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF1|
2408324|NCT03515694|Placebo Comparator|Dose of 0mg/kg TOF2|
2408325|NCT03515694|Experimental|Dose of 0 ,5mg/kg TOF1|
2408326|NCT03515694|Active Comparator|Dose of 0,5mg/kg TOF2|
2408327|NCT03515694|Experimental|Dose of 1mg/kg TOF1|
2408328|NCT03515694|Active Comparator|Dose of 1mg/kg TOF2|
2408329|NCT03515694|Experimental|Dose of 2mg/kg TOF1|
2408330|NCT03515694|Active Comparator|Dose of 2mg/kg TOF2|
3185251|NCT00732862|Active Comparator|2|Final clamp experiment after 6 months intensive therapy.
3185252|NCT00732888|Other|1|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 15; and Tasigna® once daily on days 1 and 15 (i.e., Tasigna® alone on day 1, and combination of Tasigna® and calcium supplement on day 15).
2408333|NCT03515668|Experimental|Ritalin|20 mg Ritalin, 90 min before testing
2408334|NCT03515668|Placebo Comparator|Control|Identical size/taste placebo pill, 90 min before testing
2408336|NCT03515642|Active Comparator|SIT group|The SIT modality consisted of 6 to 10 repetitions of a 30 s segment of all-out exercise interspersed with 2 min of recovery, 3 d/wk on a stationary bicycle at the target heart rate (HR) range equivalent to 90% to 95% of the individual's maximum oxygen consumption rate (VO2max).
3185253|NCT00732888|Other|2|On an 18-day schedule, calcium supplement (Tums Ultra 1000®) once daily on day 1; and Tasigna® once daily on days 1 and 15 (i.e., combination of Tasigna® and calcium supplement on day 1, Tasigna® alone on day 15).
3185254|NCT00732914|Active Comparator|1|Sunitinib (first-line) followed by Sorafenib (second-line)
3185255|NCT00732914|Experimental|2|Sorafenib (first-line) followed by Sunitinib (second-line)
2408344|NCT03515577|Experimental|Diagnostic ([68]Ga-PSMA-11 PET/CT, Axumin PET/CT)|Participants receive (68)Ga-PSMA-11 IV and 60-90 minutes later, undergo PET/CT imaging over 3 hours. Participants also undergo best standard of care Axumin PET/CT within 2 weeks before or after (68)Ga-PSMA-11 PET/CT.
2408345|NCT03515564|Experimental|Alternative therapy|"Dance/Movement Therapy, Art Therapy, Mindful Yoga~60 minutes once weekly for 8 weeks"
2408346|NCT03515564|No Intervention|No Intervention|No Intervention
2408347|NCT03515551|Experimental|IMCnyeso dose Escalation Phase with approximately 4-10 cohorts|Phase (Arm 1) n=approximately 27 patients to establish the MTD/RP2D
2408348|NCT03515551|Experimental|IMCnyeso expansion with 3 cohorts|n=9-24/cohort treated at the RP2D to make a preliminary assessment of the anti-tumor activity of IMCnyeso
2408349|NCT03515538|Experimental|RRx-001 Pre-Treatment plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC (four doses total). No additional RRx-001 will be given during the course of RT/cisplatin
2408350|NCT03515538|Experimental|RRx-001 Pre-Treatment, 2 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day in each of weeks 2 and 5 during RT/cisplatin administration
2408351|NCT03515538|Experimental|RRx-001 Pre-Treatment, 6 Concurrent Doses plus SOC|Two infusions of RRx-001 will be given each week during the two weeks prior to the start of RT/cisplatin SOC. In addition, one dose of RRx-001 will be given on the last radiation day of each of the first 6 weeks during RT/cisplatin administration
2408352|NCT03515538|Active Comparator|Standard of Care|No doses of RRx-001 will be administered. Patients assigned to this arm will receive only standard of care in the form of a 7-week course of fractionated radiation therapy concurrent with a high-dose cisplatin regimen (100 mg/m2 dose in each of RT weeks 1, 4, and 7).
2408353|NCT03515525||Hematoma side|Drain secretion volume prior to revision surgery on the breast side affected by hematoma.
2408354|NCT03515525||Non-hematoma side|Drain secretion volume prior to revision surgery on the breast side not affected by hematoma.
2408355|NCT03515512|Experimental|Enasidenib|Enasidenib will be administered orally once daily in 28-day cycles
2408356|NCT03515499|Active Comparator|Control|The control arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use.
2408357|NCT03515499|Experimental|Treatment arm|The treatment arm will have medication monitoring sensors placed on their asthma medications. They will have reminders to take their medicines and access to a mobile app that will show them trends in their medication use. Additionally, they will be paid up to $1 per day for perfect medication adherence.
2408358|NCT03515486|Experimental|Post-stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations.
2408359|NCT03515473||CI532|Patients with CI532 cochlear implant
2408360|NCT03515473||CI522|Patients with CI522 cochlear implant
2408361|NCT03515473||CI512|Patients with CI512 cochlear implant
2408362|NCT03515460|Experimental|sugar oral load|oral ingestion of a high carbohydrate meal
2408363|NCT03515460|Experimental|fat oral load|oral ingestion of a high fat meal
2408364|NCT03515460|Experimental|sugar and fat oral loads|oral ingestion of a high carbohydrate and fat meal
2408365|NCT03515447||Before period|During this period no patient received Romiplostim.
2408366|NCT03515447||After period|"Application of the transfusion saving strategy protocol through Romiplostim treatment.~The first subcutaneous injection of 1.5 to 2 µg/kg of romiplostim was administered in the post-operative periods. An algorithm based on patient weight and platelet count was established to determine romiplostim doses. One injection per week was performed. Romiplostim posology was adjusted between 2 and 5µg/kg every week according to platelet count with a maximum of 4 administrations in the ICU."
2408367|NCT03515434|Active Comparator|ESP Block|Ultrasound-guided Erector spinae plane (ESP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2408368|NCT03515434|Active Comparator|TAP Block|Ultrasound-guided Transversus abdominis plane (TAP) block will be performed at the finishing of the surgery with 30 ml of a bupivacaine/lidocaine mixture. The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2408369|NCT03515434|Sham Comparator|Control|The postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2408370|NCT03515421|Experimental|Blood Glucose monitoring System (BGMS)|"Intervention: Blood Glucose monitoring Systems (BGMSs): Frazier 3 Verio and Frazier 3 UltraPLus.~Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)"
2408371|NCT03515408|Experimental|Real rTMS (motor area)|Real rTMS targeting motor area for 30 min
2408372|NCT03515408|Experimental|Real rTMS (parietal gyrus)|Real rTMS targeting parietal gyrus for 30 min
2408373|NCT03515408|Experimental|Real rTMS (both brain area)|Real rTMS targeting motor area and parietal gyrus for 15 min, separately
2408374|NCT03515408|Sham Comparator|Sham rTMS|Sham rTMS targeting motor area and parietal gyrus for 15 min, separately
2408375|NCT03515382|Experimental|Treatment A|single dose GLPG1690.
2408376|NCT03515382|Experimental|Treatment B|Single dose itraconazole + single dose GLPG1690.
2408377|NCT03515382|Experimental|Treatment C|Single dose voriconazole + single dose GLPG1690.
2408378|NCT03515369|Experimental|Hepatectomy plus Babaodan|Surgical removal of all lesions and take Babaodan oral capsule after operation
2408379|NCT03515369|Placebo Comparator|Hepatectomy plus Placebo|Surgical removal of all lesions and take Placebo oral capsule after operation
2408554|NCT03514290|Placebo Comparator|GPLACEBO|the laser tip was positioned without the emission of light (placebo effect) + tooth bleaching with 35% hydrogen peroxide (HP).
2408380|NCT03515356|Experimental|MI-Walk Intervention|"Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.~In addition, subjects will receive 8-weeks of motivational enhancement therapy- and a home-based aerobic walking intervention. Motivational interviewing will be delivered with concurrent feedback and motivational techniques in 30-45-minute sessions at intervention orientation (T1), 2 weeks (T3), and 4 weeks (T4)."
2408381|NCT03515356|Active Comparator|PA Education Alone|Subjects who are already receiving oxaliplatin prescribed by their oncologist (as standard of care) will receive a physical activity education pamphlet.
2408382|NCT03515343||Optical diagnosis with Optivista|Participants for which the optical diagnosis of detected colorectal polyps will be done with the new technique Pentax Optivista.
2408383|NCT03515343||Optical diagnosis with iScan|Participants for which the optical diagnosis of detected colorectal polyps will be done with the oldest technique Pentax iScan.
2408384|NCT03515330|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressant medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth application.
2408385|NCT03515330|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to aid in immunosuppressant medication adherence post-transplant.
2408386|NCT03515317|Experimental|LoRETA Z-score NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both LoRETA Z-score NF. A total treatment dosage of 600 minutes is needed.
2408387|NCT03515317|Experimental|theta/beta NF group|BrainMaster Discovery 24E (BrainMaster Technologies, Inc.) combined with Neuroguide software (Applied Neuroscience, Inc.) to conduct both theta/beta NF. A total treatment dosage of 600 minutes is needed.
2408388|NCT03515317|No Intervention|control group|The control group involves no NF training. The control group will be designed to parallel the cognitive tasks to control for practice effects due to repeated testing (pre- and post- assessments) and the time effect on cognitive function recovery (spontaneous recovery of cognition).
2408389|NCT03515304|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
2408390|NCT03515304|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
2408391|NCT03515291|Experimental|iMP cell injection|iMP cells injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
2408392|NCT03515291|Placebo Comparator|Control injection|Control (cell suspension solution) injected in to the epicardial surface of the heart during coronary artery bypass graft surgery.
2408393|NCT03515278|Experimental|suprascapular nerve block (SCNB) group|"SCNB with physiotherapy. Suprascapular nerve block: Ultrasound-guided SCNB by 3 c.c. 1% lidocaine with 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
2408394|NCT03515278|Active Comparator|intra-articular corticosteroid injection (IACI) group|"IACI with physiotherapy. Intra-articular steroid Injections: Receive intra-articular corticosteroid injection.Ultrasound-guided IACI with 3c.c. 1% lidocaine and 20mg triamcinolone.~Physiotherapy: The physiotherapy program includes physical modalities (heat therapy and electric therapy) and therapeutic exercise. (stretching, mobilization and ROM exercise, and strengthening)"
2408395|NCT03515265|Experimental|Fiber resin composite|Fiber reinforced resin composite restoration used as dentin substitute covered by conventional resin composite
2408396|NCT03515265|Active Comparator|Microhybrid resin composite|Microhybrid resin composite restoration with lower strength compared to Fiber reinforced resin composite restoration
2408397|NCT03515252|Experimental|Late stage lung cancer and liver cancer|Immune Killer Cells (IKC)
3144647|NCT00046865|Placebo Comparator|Placebo Acupressure|Arm II: Patients receive placebo acupressure plus usual nausea care during the second or third course of chemotherapy. Acupressure is applied as in arm I except at a non-specific site.
3144648|NCT00046865|Sham Comparator|Usual Care|Arm III: Patients receive usual nausea care during the second or third course of chemotherapy.
2408400|NCT03515213|Active Comparator|Active|
2408401|NCT03515213|Placebo Comparator|Placebo|
2408402|NCT03515200|Experimental|Treatment|"This study will be done in two parts: Part 1: Dose escalation and Part 2: Dose expansion.~In Part 1 - Dose escalation: Patients that lack Ph+ or Ph-like ALL, palbociclib, initially at 50mg/m2/day, 40% of the adult MTD, will be administered on Days 1-5 and 11-15, and escalated based on tolerability. If our highest dosing of 100mg/m2/day is tolerated, we will have a final dose level that receives an additional 10 days of palbociclib (Days 1-5, 11-15, and 21-30).~For patients that are Ph+ or have Ph-like ALL that are also receiving dasatinib or ruxolitinib: palbociclib, initially at 75mg/m2/day, 60% of the adult MTD, will be administered on Days 1-5 and 11-15 and escalated based on tolerability.~In Part 2 - Dose expansion: After determination of dose in Part 1, an additional 10 patients will be enrolled to confirm tolerability."
2408403|NCT03515187|Experimental|A1 Medicine treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution, 28 days
2408404|NCT03515187|Experimental|A2 Combined treatment group|0.3%sodium hyaluronate ophthalmic solution + 0.1 sodium bromide solution，with meibomian gland massage , 28 days
2408405|NCT03515187|Placebo Comparator|B1 Control group|Placebo
2408406|NCT03515187|Experimental|B2 Experiment group|0.3%sodium hyaluronate ophthalmic solution, 12 months
2408407|NCT03515174|Experimental|Interventional Program|Patients will participate in a structured supportive care program.
2408408|NCT03515174|Active Comparator|Control Group|Patients in the control group will receive usual care.
2408409|NCT03515161|Experimental|Closed-loop|Study patients will receive a baseline crystalloid infusion of 3 cc/kg/hr and all additional fluid management will be performed manually using the assisted fluid management sofware from the EV1000 monitor. A closed-loop system will automatically administer vasopressor based on the predefined target MAP chosen by the anesthesiologist in charge of the patient
2408410|NCT03515148|Experimental|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
2408411|NCT03515148|Experimental|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
2408412|NCT03515135|Experimental|Intervention group|"Subjects in this group will receive the Metacognitive Executive Function Training (MEFP) program in aiming to reduce ADHD symptoms and improve the executive function."
2408413|NCT03515135|No Intervention|Waiting group|Subjects in this group will not receive the MEFP program during the study period.
2408414|NCT03515122||Persons with Spinal cord injury (SCI)|The total population of a specified group of persons with traumatic SCI will be invited to participate.
2408415|NCT03515122||Matched control group|A matched control group of the general population at a ratio of 3-4 to each person with SCI will be recruited from the Swedish Cardiopulmonary and Bioimage Study.
2408416|NCT03515109|Active Comparator|group A|Altis tape surgical placement
2408417|NCT03515109|Placebo Comparator|group B|TVT transobturator tape placement
2408418|NCT03515096|Experimental|Eltrombopag|Thrombopoietin- receptor (TPO-R) agonist
2408419|NCT03515096|Placebo Comparator|rhTPO|Recombinant human thrombopoietin (rhTPO)
3144649|NCT00046917|Experimental|Treatment (chemotherapy)|Patients are stratified according to the number of prior treatment regimens (0 or 1 vs more than 1). Patients receive irinotecan hydrochloride IV over 30 minutes followed immediately by cisplatin IV over 30 minutes followed 7 hours later by alvocidib IV over 1-4.5 hours weekly for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3144650|NCT00047034|Experimental|Treatment (eribulin mesylate)|Patients receive E7389 IV over 1-2 minutes on days 1, 8, and 15. Treatment repeats every 4 weeks for at least 4 courses in the absence of disease progression or unacceptable toxicity.
2408422|NCT03515057|Experimental|Atrial Fibrillation Spot-Check|For eligible patients from primary care clinics randomly selected for the Atrial Fibrillation Spot-Check arm, practice medical assistants will screen assenting patients for undiagnosed AF during regularly scheduled office visits using a single-lead handheld electrocardiogram (ECG). Single-lead handheld electrocardiogram readings detecting AF will be confirmed during the same office visit with a standard 12-lead ECG at the discretion of the primary care physician. If AF is detected, the patient's PCP will be able to address the condition with them during the clinic visit and initiate appropriate follow-up to manage the AF.
2408423|NCT03515057|No Intervention|Usual Care|For eligible patients from primary care clinics randomly selected for the Usual Care arm, they will receive standard care during outpatient visits without change.
2408424|NCT03515044|Experimental|Cohort 1 40 mg Rifaximin SSD once daily|40 mg Rifaximin immediate release (IR) rifaximin SSD once daily (QD) and lactulose
2408425|NCT03515044|Experimental|Cohort 2 40 mg Rifaximin SSD twice daily|40 mg Rifaximin immediate release (IR) rifaximin SSD twice daily (BID) and lactulose
2408426|NCT03515044|Experimental|Cohort 3 80 mg Rifaximin SSD once daily|80 mg Rifaximin sustained extended release (SER) rifaximin SSD once daily (QD) and lactulose
2408427|NCT03515044|Experimental|Cohort 4 80 mg Rifaximin SSD twice daiy|Cohort 4 80 mg Rifaximin SSD twice daily (BID) and lactulose
2408428|NCT03515044|Experimental|Cohort 5 Placebo twice daily|SSD placebo twice daily (BID) and lactulose
2408429|NCT03515031|Experimental|High Flow Nasal Cannula Oxygenation|High Flow Nasal Cannula Oxygenation with a minimum flow ≥ 60L / min, and an FiO2 such as to maintain a SpO2 ≥ 92% for at least 48 hours until clinical stability
2408430|NCT03515031|Active Comparator|Venturi Mask Oxygenation|Venturi Mask Oxygenation, with an FiO2 such as to maintain an SpO2 ≥ 92% for at least 48 hours until clinical stability
2408431|NCT03515018|Experimental|Hydroxyurea|Drug: hydroxyurea, pulse therapy
2408432|NCT03515018|Active Comparator|imatinib|Drug: imatinib, 400mg PO per day
2408433|NCT03515005|Experimental|Lay Health Advisors|Intervention patients will meet monthly in small groups with a trained Lay Health Advisor.
2408434|NCT03515005|No Intervention|Usual Care|Control patients will receive usual care from their doctors.
2408435|NCT03514979|Experimental|AAV patients treated with rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2408436|NCT03514979|Experimental|AAV patients - never received rituximab|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2408437|NCT03514979|Experimental|Healthy controls|Pneumococcal Polysaccharide Conjugate vaccination at Month 0 and then Pneumococcal Polysaccharide Vaccination at Month 6.
2408473|NCT03514680|No Intervention|Period I|-Consented patients will complete electronic versions of the PRO-CTCAE CIPN severity and interference items, 0 - 10 worst CIPN pain numerical rating scale, and QLQ-CIPN20 via tablet prior to their clinician visit at the outpatient oncology center at three consecutive clinic visits: baseline, visit 2, visit 3.
3144651|NCT00047047|Experimental|Treatment (tanespimycin, gemcitabine hydrochloride, cisplatin)|"Cohort A (closed to accrual as of 3/2/04)*: Patients receive escalating doses of gemcitabine hydrochloride intravenously (IV) over 30 minutes, tanespimycin IV over 1 hour, and cisplatin IV over 2 hours on days 1 and 8. NOTE: *The maximum tolerated dose (MTD) of this 3-drug combination has been determined as of 3/2/04.~Cohort B (closed to accrual as of 3/2/05): Patients receive gemcitabine hydrochloride** IV over 30 minutes, tanespimycin IV over 1 hour, and cisplatin** IV over 2 hours on days 1 and 8.~Cohort C: Patients receive gemcitabine hydrochloride** IV over 30 minutes and tanespimycin IV over 1-2 hours on days 2 and 9.~Cohort D: Patients receive cisplatin** IV over 2 hours and tanespimycin IV over 1-2 hours on days 1 and 8.~Cohort E: Patients receive gemcitabine hydrochloride***, tanespimycin***, and cisplatin*** as in cohort B.~Continued (see detailed description)"
3144652|NCT00047073|Experimental|Phase 1|See intervention description.
3144653|NCT00047073|Experimental|Phase 2|See intervention description.
3144654|NCT00047112|Experimental|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE|CHIMIORADIOTHERAPIE SUIVIE DE CHIRURGIE
3185256|NCT00732927|Experimental|1|parnaparin, low molecular weight heparin
2408440|NCT03514953|Experimental|Reduced Physical Activity|Participants will reduce their physical activity level by >5000 steps per day for two weeks.
2408441|NCT03514927|Experimental|Treatment (HIFU, radical prostatectomy)|"HIFU PHASE: Participants undergo mpMRI and CEUS pre-HIFU treatment and then CEUS post-HIFU treatment. Participants then undergo HIFU treatment over 2-2.5 hours.~PROSTATECTOMY PHASE: Within 2-4 weeks post-HIFU treatment, participants undergo mpMRI 1-2 days prior to radical prostatectomy. On the day of surgery, participants undergo CEUS prior to radical prostatectomy."
2408442|NCT03514914|Experimental|CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling for married couples. Two sessions for men delivered by male health providers and two sessions for women delivered by female providers.
2408443|NCT03514914|No Intervention|Control|Control clusters will receive standard of care.
3144655|NCT00047112|Active Comparator|CHIRURGIE SEULE|CHIRURGIE SEULE
3144656|NCT00047125|Experimental|Selective irradiation|Irradiation of the ipsilateral level I - V of the neck up to a dose of 60 Gy (30x2Gy in 6 weeks).
2408446|NCT03514888|Experimental|HIPEC after Radical Cystectomy|After completion of radical cystectomy, HIPEC will be administered using closed abdomen technique for a duration of 60 minutes.
2408447|NCT03514875|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ intake, and second day will be placebo intake. Testing will take place 40-minutes after MitoQ and placebo intake. There will be a 2-week washout between testing days.
2408448|NCT03514875|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and placebo intake, and second day will be MitoQ intake. Testing will take place 40-minutes after placebo and MitoQ intake. There will be a 2-week washout between testing days.
2408449|NCT03514862|Experimental|Intervention|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then will be invited to continue to participate in 4 additional Mindfulness Booster Training.
2408450|NCT03514862|Active Comparator|Control|Participants will participate in 4 weeks of the Mindfulness-Based Intervention (MBI) and then continue to Self-Practice for 4 weeks.
2408451|NCT03514849|Experimental|PCI group|
2408452|NCT03514849|Placebo Comparator|Control group|
2408453|NCT03514836|Experimental|DCVac and ONCOS-102|ONCOS-102 is given intra-tumor up to 4 times, cyclophosphamide is given prior to the first dose of ONCOS-102 and at the fifth week of treatment DCVac is given sc every 21-28 days for up to 10 doses
2408454|NCT03514823|Experimental|IMT Group|
2408455|NCT03514823|Sham Comparator|No IMT Group|
2408456|NCT03514810|Placebo Comparator|Sertralin & Ketoprofen in MDD|To compare the median of Beck Depression Inventory-II (BDI-II) score of MDD patients after treatment with sertralin (50mg) daily+placebo and after treatment with combination of (sertralin & ketoprofen) for two months.
2408457|NCT03514810|Experimental|Interleukins in MDD after treatment|Some Interleukines level were estimated before and after treatment with sertralin 50 mg in combination with either placebo or ketoprofen 100mg daily.
2408458|NCT03514797|Experimental|Combined technique|A single session of in-office tooth bleaching will be performed with 35% hydrogen peroxide for 45 minutes. Following, the teeth will be further bleached with customized trays filled with 10% carbamide peroxide and used for 1h per day.
2408459|NCT03514797|Active Comparator|At-home bleaching|The teeth will be bleached only with customized trays filled with 10% carbamide peroxide and used for 1h per day.
2408460|NCT03514784|Active Comparator|BB-12 with LGG (Lower Dose)|BB-12 with LGG (Multistrain probiotic; lower dose): 1 billion CFUs
2408461|NCT03514784|Placebo Comparator|Placebo|Maltodextrin
2408462|NCT03514784|Active Comparator|BB-12 with LGG (Higher Dose)|BB-12 with LGG (Multistrain probiotic: higher dose): 10 billion CFUs
2408463|NCT03514771|Other|All Subjects|All subjects will have one side of their face treated with the laser and one side not treated to serve as the control.
2408464|NCT03514758|Experimental|normal hearing participants|normal hearing participants with and without hearing aids
2408465|NCT03514745|Active Comparator|GlideScope group|After the induction of anesthesia, endobronchial intubation is performed using the GlideScope.
2408466|NCT03514745|Experimental|Lighted stylet group|After the induction of anesthesia, endobronchial intubation is performed using a lighted stylet.
2408467|NCT03514732|Experimental|Novanuit® Triple Action|2 capsules of Novanuit® Triple Action once daily for 2 weeks, 30 minutes to 1 hour before bedtime.
3144657|NCT00047125|Active Comparator|Extensive irradiation + ipsilaterals levels|Irradiation on the whole mucosa of the larynx, hypopharynx, oropharynx and nasopharynx, and on both sides of the neck (levels I -V) up to a prophylactic dose of 50 Gy (25 x 2 Gy in 5 week).Irradiation of the ipsilateral level I - V of the neck should continue with an additional 10 Gy boost for a total dose of 60 Gy (30 x 2 Gy in 6 weeks).
2408469|NCT03514706|Experimental|Volume controlled ventilation|Group V: Patients will receive volume controlled mechanical ventilation. (Vt 7ml/kg ideal body weight).
2408470|NCT03514706|Experimental|Pressure controlled ventilation|Group P: Patients will receive pressure controlled mechanical ventilation. (to achieve Vt 7 ml/kg ideal body weight, Pmax 30 cmH2O)
2408471|NCT03514693|Active Comparator|PVI alone|PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
2408472|NCT03514693|Placebo Comparator|PVI plus additional ablation|PVI, additional CFAE or linear ablation after PVI, and ablation for AF triggers from non-PV foci, the cavotricuspid isthmus, clinical coexisting tachyarrhythmia such as atrial flutter (AFL), atrial tachycardia (AT), and supraventricular tachycardia, if necessary
3144658|NCT00047190|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3185257|NCT00732927|Active Comparator|2|aspirin
3185258|NCT00732953|Active Comparator|1|Genous stent implantation with paclitaxel-eluting balloon therapy
2408474|NCT03514680|Experimental|Period II|"Consented patients will complete the same battery of assessments from the usual care period at the baseline, visit 2, and visit 3 time points.~Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm"
2408475|NCT03514667|Active Comparator|intervention group|80 mg nanomicielle curcumin capsules once a day for 12 weeks
2408476|NCT03514667|Placebo Comparator|control group|placebo capsules once a day for 12 weeks
2408477|NCT03514654|Active Comparator|Mastectomy +/- reconstruction|Either a simple mastectomy or skin sparing mastectomy technique will be used. Women in this arm will be offered either immediate or delayed breast reconstruction according to standard practice. Reconstructions will be followed by chemotherapy and/or endocrine therapy as determined by local clinicians . Chest wall and/or regional nodal radiotherapy will be prescribed according to local centre policy.
2408478|NCT03514654|Active Comparator|Therapeutic Mammoplasty|"Therapeutic Mammoplasty (TM) comprises well-established surgical techniques involving volume displacement using breast reduction techniques, or volume replacement to maximize the volume of tissue that can be excised resulting in effective local control whilst maximizing cosmetic outcomes. This group will either have one disease site lumpectomy in the case of multifocal tumours or distant disease site lumpectomies in multicentric cancers."
3185259|NCT00732953|Active Comparator|2|Genous stent implantation
2408483|NCT03514628|Experimental|Valsalva Assist Device (VAD)|Intervention is the use of Valsalva Assist Device (VAD) to deliver the Valsalva strain
2408484|NCT03514628|Active Comparator|Standard Care|Intervention is the use of Standard technique to deliver Valsalva strain eg blowing on empty syringe
2408485|NCT03514615|Placebo Comparator|Placebo Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
2408486|NCT03514615|Experimental|Active Gel|Each participant will be allocated to only one dosing group. The treatments will be paired anatomically so that for each pair of sites, one closed incision site will receive the active gel and the other placebo.
3144659|NCT00047203|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 1 hour on days 1-3. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. After 12 months, patients achieving at least a partial response may continue treatment in the absence of disease progression or unacceptable toxicity.
3144660|NCT00047229|Experimental|G3139 in combination with Doxorubicin|
2408489|NCT03514589|Active Comparator|Arm 1|250 mcg IV synacthen
2408490|NCT03514589|Experimental|Arm 2|Nasal Synacthen
2408491|NCT03514576|Experimental|Pasireotide75|75 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
2408492|NCT03514576|Experimental|Pasireotide150|150 micrograms Pasireotide 0.3 MG/ML s.c. before a meal tolerance test (MTT)
3144661|NCT00047255|Experimental|Herceptin plus docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
2408496|NCT03514550|Experimental|total intravenous anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and propofol for perioperative anesthesia
2408497|NCT03514550|Active Comparator|Volatile anesthesia|Patients, scheduled for nephrectomy for kidney cancer will receive neuraxial epidural block and sevoflurane for perioperative anesthesia
2408498|NCT03514537|Experimental|Lipoaspiration|Closed microcannula harvesting of small volume of subdermal adipose tissue, including the stromal cellular and stromal tissue using sterile, disposable, microcannula system
2408499|NCT03514537|Experimental|Isolation & Concentration of cSVF|Isolation and Concentration of cellular stromal vascular fraction (cSVF) using a Healeon Medical CentriCyte 1000 centrifuge, incubator and shaker plate with sterile Liberase enzyme (Roche Medical) per manufacturer protocols
2408500|NCT03514537|Experimental|Delivery cSVF via Intravenous|cSVF from Arm 2 is suspended in a 500cc of sterile Normal Saline and deployed through 150 micron in-line filtration and intravenous route over 30-60 minute time frame.
2408501|NCT03514524|Experimental|healthy ageing|
2408502|NCT03514524|Experimental|TBI|
2408503|NCT03514524|Experimental|CTE|
2408504|NCT03514524|Experimental|Ischemic stroke|
2408505|NCT03514524|Experimental|aMCI and MBI|
2408506|NCT03514511|Experimental|Cohort 1 in healthy subjects|LEO 138559 (dose regiment 1) or LEO 138559 placebo
2408507|NCT03514511|Experimental|Cohort 2 in healthy subjects|LEO 138559 (dose regiment 2) or LEO 138559 placebo
2408508|NCT03514511|Experimental|Cohort 3 in healthy subjects|LEO 138559 (dose regiment 3) or LEO 138559 placebo
2408509|NCT03514511|Experimental|Cohort 4 in healthy subjects|LEO 138559 (dose regiment 4) or LEO 138559 placebo
2408510|NCT03514511|Experimental|Cohort 5 in healthy subjects|LEO 138559 (dose regiment 5) or LEO 138559 placebo
2408511|NCT03514511|Experimental|Cohort 6 in healthy subjects|LEO 138559 (dose regiment 6) or LEO 138559 placebo
2408512|NCT03514511|Experimental|Cohort 7 in healthy subjects|LEO 138559 (dose regiment 7) or LEO 138559 placebo
2408513|NCT03514511|Experimental|Cohort 8 in subjects with atopic dermatitis|LEO 138559 (dose regiment 8) or LEO 138559 placebo
2408514|NCT03514511|Experimental|Cohort 9 in subjects with atopic dermatitis|LEO 138559 (dose regiment 9) or LEO 138559 placebo
2408549|NCT03514303||Cat Dander|Subjects will test positive or negative to the allergen Cat Dander.
2408517|NCT03514485|Active Comparator|P+S- (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
2408518|NCT03514485|Active Comparator|P-S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the school intervention Open Airways for Schools Plus.
2408519|NCT03514485|Active Comparator|P+S+ (Partner School)|This arm includes children who attend one of the partnering schools and who are randomized to receive the enhanced school intervention Open Airways for Schools Plus, School-Based Asthma Therapy and the primary care intervention Yes We Can Children's Asthma Program.
2408520|NCT03514485|No Intervention|P-S- (Partner School)|This arm includes children who attend one of the partnering schools, and are randomized to the control group (no primary care or school intervention).
2408521|NCT03514485|Active Comparator|P+ (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to receive the primary care intervention Yes We Can Children's Asthma Program.
2408522|NCT03514485|No Intervention|P- (Non-Partner School)|This arm includes children who do not attend one of the partnering schools and who are randomized to the control group (no primary care intervention and ineligible for the school intervention).
2408523|NCT03514472|Active Comparator|Group A (Below 18 years)|Dried Moringa oleifera leaves (15g/recipe)
2408524|NCT03514472|Active Comparator|Group B (Above 18)|Dried Moringa oleifera leaves (15g/recipe)
2408525|NCT03514459|No Intervention|Control|Control clinics: Clinics randomized to the control arm will continue usual procedures. Periodic evaluation of cervical cancer screening rates will be examined every 3 months using FP register data.
2408526|NCT03514459|Experimental|Intervention with SAIA|Clinics randomized to the intervention arm will be introduced to the five steps of SAIA by study staff. The cascade analysis will be performed within the FP clinic to identify drop-offs in cervical cancer screening and referrals, using an Excel-based tool adapted from previous SAIA trials. Flow mapping performed by clinic and study staff will describe the cervical cancer screening process including who the client interacts with, timing of these interactions, any cervical cancer screening performed, and any referrals made. Initial drafts will be reviewed together with clinic and study stuff to ensure adequate and complete representations of processes. Study staff will work with clinic staff to identify bottlenecks in the process and potential solutions to improve flow. Proposed solutions will be implemented, and the process will be examined again to determine the effect of the implemented changes. The cycle will be repeated approximately every 6-8 weeks during the RCT.
2408527|NCT03514446|Experimental|Antibiotic therapy duration for 7 days|
2408528|NCT03514446|No Intervention|Antibiotic therapy duration for 14 days|
2408529|NCT03514433|No Intervention|Historical Control|This study will be utilizing electronic health record data to identify patients that match the TRIP eligibility criteria and received patient navigation prior to study rollout in June 2018. These patients will receive standard patient navigation at their care site and will act as historical controls in comparison to the TRIP experimental group.
2408530|NCT03514433|Experimental|TRIP Patient Navigation Intervention|This study will be enhancing current patient navigation at the participating 6 hospitals with the 3 components of the TRIP intervention (a shared patient registry, a social determinants of health platform, and additional training and support for Patient Navigators). All patients that are identified as TRIP eligible will receive these intervention benefits and will be categorized into the experimental arm of the study.
3185260|NCT00732966|Experimental|1|Hypertensive patients will be treated with losartan for one months
2408532|NCT03514407|Experimental|INCB059872|INCB059872
2408533|NCT03514394|Active Comparator|Problem Solving Therapy (PST)|6 weekly sessions to teach patients seven steps of problem solving (problem orientation, problem definition, goal setting, brain storming, decision making, action planning, solution evaluation).
2408534|NCT03514394|Experimental|Modified PST|This intervention will be a modification of PST, based on clinician feedback. It will be developed in phase 1 and 2 of this study. It will include elements of cognitive processing therapy, behavioral activation and distress tolerance. Anticipated number of sessions is 6.
2408535|NCT03514381|Other|Patients starting a treatment with Doxorubicin and Ifosfamide|
2408537|NCT03514355|Experimental|Intervention|Mindfulness-Based Stress Reduction (MBSR) is a program intended to draw upon the group's shared experiences to facilitate the development of mindfulness. MBSR is offered in 2.5-h classes on a weekly basis for 8 consecutive weeks, with a retreat day in between classes 6 and 7. This day involves guided meditations, allowing for continuity in practice. Classes include specific exercises (e.g. identifying thoughts, emotions and body sensations associated with illness); these are then extended as homework and discussed in the subsequent class. The curriculum themes and content are arranged week by week to reflect these principles.
2408538|NCT03514355|No Intervention|Control|The control group will receive usual care, with no treatment restrictions. Treating physicians will be informed of CES-D results. Patients will be asked to fulfill the same clinical assessment and questionnaires, and to provide the same biosamples than those patients in the intervention.
2408539|NCT03514342||Interscalene brachial plexus block|Ultrasound-guided interscalene brachial plexus block with 25 ml to 30 ml of 0.75% ropivacaine
3185261|NCT00732966|Experimental|2|Hypertensive patients will be treated with valsartan
2408541|NCT03514316|Active Comparator|Scalpel Gingivectomy|Patients treated with Scalpel Gingivectomy on the labial side of the anterior maxillary teeth
2408542|NCT03514316|Active Comparator|Laser Gingivectomy|Patients treated with Laser Gingivectomy on the labial side of the anterior maxillary teeth
2408543|NCT03514316|Active Comparator|Nonsurgical periodontal treatment|Patients treated with a full-mouth periodontal debridement
2408544|NCT03514303||Ragweed|Subjects will test positive or negative to the allergen Ragweed.
2408545|NCT03514303||Timothy Grass|Subjects will test positive or negative to the allergen Timothy Grass.
2408546|NCT03514303||Johnson Grass|Subjects will test positive or negative to the allergen Johnson Grass.
2408547|NCT03514303||Bermuda Grass|Subjects will test positive or negative to the allergen Bermuda Grass.
2408548|NCT03514303||Cladosporium|Subjects will test positive or negative to the allergen Cladosporium.
2408559|NCT03514264|Experimental|GUTTA PERCHA and AHPLUS cement (group A)|43 patients will undergo endodontic treatment with obturation with AHPlus cement and Gutta-Percha cones. This treatment will be performed in 2 sessions. First intervention: endodontic instrumentation and introduction of intra-canal medication that will remain in the tooth for 4 weeks. Second intervention: removal of intracanal medication and filling with cement and gutta percha AHPlus.
2408560|NCT03514264|Experimental|PBS CIMMO cement (group B)|43 patients will undergo endodontic treatment with PBS CIMMO® cement (single material).This treatment will be performed in 1 session.Single intervention: endodontic instrumentation and cement filling PBS CIMMO.
2408561|NCT03514251|No Intervention|Control group|Routine thyroidectomy and central lymph node dissection
2408562|NCT03514251|Experimental|Parathyroid marker group|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker.
2408563|NCT03514238|Experimental|Adults (BMI: ≥30 kg/m2)|"Obese individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
2408564|NCT03514238|Experimental|Adults (BMI: 18.5-24.9 kg/m2)|"Normal weight individuals will participate to three conditions:~Control Sitting Condition (C), Sitting for 35 minutes Acute Bout of Continuous Moderate Aerobic Exercise (MOD) 50-55% of heart rate reserve Acute Bout of High Intensity Interval Aerobic Exercise (HIIT) 85-90% heart rate reserve"
2408565|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|Exact sessional content of the MCT intervention is likely to involve attention training and situational attentional refocussing techniques, verbal reattribution strategies aimed to facilitate a reduction of self-processing strategies and to challenge metacognitive beliefs, and between-session tasks for participants to practice at home.
2408566|NCT03514212|Experimental|ProActiveS|As this was a feasibility study, all participants received the intervention.
2408567|NCT03514199|Experimental|Mediterranean-type diet|Recommends high consumption of whole grains, vegetables, nuts, fruits, vegetables and olive oil as the main source of fat used for salads. Moderate to high fish consumption and low consumption of red and processed meats. Poultry and dairy products (such as yogurt or cheese) will be consumed in small quantities and moderate consumption of alcohol, usually in the form of red wine, will be recommended with meals for usual drinkers.
2408568|NCT03514199|Active Comparator|Low fat diet|It recommends reducing the intake of foods rich in fats, especially those saturated and hydrogenated.
2408569|NCT03514186|Experimental|Intensive Comprehensive Aphasia Program|60 hours of comprehensive speech and language therapy applied intensively, 4 hours per day, 5 days a week for three weeks.
2408570|NCT03514186|Active Comparator|Distributed Comprehensive Aphasia Tx|60 hours of comprehensive speech and language therapy distributed over 15 weeks (i.e. two 2-hour visits per week).
2408571|NCT03514160|Active Comparator|Group exercise|Group exercise training at a community site. Exercises included supervised upper and lower-body strength and balance exercises twice per week. Hand-made, weighted bars were used for resistance props and balance. The exercises included: chair squats; standing single leg hip abduction; hip extension; balance heal-to-toe walking; seated hip adduction and knee extension; wall push-ups; bent-over rows; shoulder press; elbow flexion and extension).
2408572|NCT03514160|No Intervention|Attention-Control group|Attendance to community site usual activities offered to older adults. Participants in this group were offered the exercise routine after completing the 12-week study.
2408573|NCT03514147|Experimental|Experimental|Pelvic Floor Muscle Training in group. Exercise Protocol: The exercise group was supervised and met for 1 hour, one time per week, for 12 weeks. Participants were instructed to perform their respective daily exercises.
2408574|NCT03514147|Active Comparator|Control|Pelvic Floor Muscle Training in home Exercise Protocol:The same exercise were performed at home for 12 weeks, without supervision. Participants were instructed to perform their respective daily exercises.
3185262|NCT00732979|Experimental|A|Infrahepatic inferior vena cava clamping The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
2408577|NCT03514121|Experimental|Phase 1a dose escalation/1b dose expansion|The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
2408578|NCT03514108|Active Comparator|Hydralazine Isosorbide Dinitrate|"Tablet BiDil (Hydralazine 37.5 mg/ isosorbide dinitrate (ISDN) 20 mg) 2 tablets x 3 daily.~Average treatment period 4 years."
2408579|NCT03514108|Placebo Comparator|Placebo (Hydralazine Isosorbide Dinitrate)|Tablet Placebo 2 tablets x 3 daily. Average treatment period 4 years.
2408580|NCT03514108|Active Comparator|Metformin|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
2408581|NCT03514108|Placebo Comparator|Placebo (Metformin)|Tablet Placebo 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily). Average treatment period 4 years.
2408582|NCT03514095|No Intervention|Control Group|The control group shall participate in the usual home-based care provided by their carer.
2408583|NCT03514095|Experimental|Individual Cognitive Stimulation Therapy|The experimental group shall participate in the Making a Difference 3 program (Yates et al., 2015) is aimed at elderly people with mild or major neurocognitive disorder, where informal caregiver (family, friend or neighbour) assume a partnering role in an one-to-one approach. The program is composed by a range of stimulating activities (sessions), each with two levels of difficulty. The carers are introduced to a set of key principles that guides them during individual cognitive stimulation sessions, tailoring the interventions to the needs and reality of the elderly participants.
2408584|NCT03514082||Adolescent Idiopathic Scoliosis|Subjects with AIS who are beginning to the conservative treatment.
2408585|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy for 6 weeks|Unmethylated O6-methylguanine DNA methyltransferase (MGMT) Glioblastoma and grade III glioma Every patient gets ruxolitinib + radiation x 60 Gy for 6 weeks over 6 weeks. The dose of radiation therapy is fixed at 60 Gy over 6 weeks
2408586|NCT03514069|Experimental|ruxolitinib + radiation x 60 Gy + temozolomide 75 mg/m|"Methylated MGMT Glioblastoma and grade III glioma. Arm 2 will start once the safe dose has been established for Arm 1 for every dose level.~Every patient gets ruxolitinib + radiation x 60 Gy + daily temozolomide at 75 mg/m2 for 6 weeks over 6 weeks.~The dose of radiation therapy is fixed at 60 Gy over 6 weeks (2 Gy x 30). The dose of temozolomide is 75 mg/m2 daily for 6 weeks"
2408587|NCT03514056||1|group Behcet
2408588|NCT03514056||2|group fibromyalgia
3144662|NCT00047255|Experimental|Docetaxel, Carboplatin, and Herceptin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
2408591|NCT03514030||positive|serum AQP4-antibody is positive
2408592|NCT03514030||negtive|serum AQP4-antibody is negtive
2408593|NCT03514017|Experimental|Pembrolizumab and Ibrutinib|"Treatment with pembrolizumab and ibrutinib and follow-up period of up to 24 months.~Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib is a small-molecule inhibitor of BTK."
2408594|NCT03514004|Experimental|Intervention|"The ICT-based intervention is known as Project Clan. Each participant randomized to the intervention group will have access to the web platform and mobile applications of Project Clan - a virtual community that seeks to promote adolescent mental health and wellbeing as students interact, express themselves, and resolve concerns, with the support of peers and mental health professionals. During the three-month intervention, participants will have complete anonymity, unless trained psychologists supervising the platform as community counselors identify behaviors associated with suicide risk and proceed to follow an established emergency protocol. The counselors will be available to answer community questions and provide support on an individual basis."
2408595|NCT03514004|No Intervention|Control|Participants in the control group will also be assigned a username and password to access the website, but they will be met with a user interface that only displays a space to answer the corresponding assessments. In addition to the introductory presentation, they will be given a brochure with information regarding adolescent suicide and wellbeing and tips with regard to seeking help and assisting others. This will include the contact information for a telephone hotline, to ensure they can receive professional help if needed.
2408596|NCT03513991|Experimental|IF-VLP (very low protein)|Participants were exclusively fed with an infant formula containing 1g of protein/dL, 26% alpha lactoalbumin, and 100% A2 casein for 4 months.
2408597|NCT03513991|Other|IF-LP (low protein)|Participants were exclusively fed with an infant formula containing 1.3 g of protein/dL, 26% alpha lactoalbumin, 100% A2 casein for 4 months.
2408598|NCT03513991|Other|IF-CSP (control standard protein)|Participants were exclusively fed with an infant formula containing 1.5 g of protein/dL, 50% A1 casein and 50% A2 casein for 4 months.
2408599|NCT03513991|No Intervention|HM (human milk)|Participants were exclusively breastfed
2408600|NCT03513978|Experimental|IAI Protocol|A progressive exercises with transference to sport protocol, oriented to improve the proprioception.
2408601|NCT03513978|Active Comparator|FIFA 11+ Protocol|A typical exercises protocol to soccer
2408602|NCT03513965|Experimental|Symptoms as Side Effects Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that these non-life-threatening symptoms are an unfortunate part of treatment that must be endured, similar to side effects from common medications.
2408603|NCT03513965|Experimental|Symptoms as Positive Signals Mindset|Both arms are given identical treatment instructions at their first clinic visit, including practical strategies for taking doses and managing symptoms. Families are given comprehensive instructions for recognizing life-threatening symptoms and administering epinephrine when appropriate. However, information about the implications of non-life-threatening symptoms differs between arms. At the first clinic visit, families are given verbal (e.g., provider explanations) and written information (e.g., brochures on symptom management) informing them about symptoms in different ways. In this arm, families are informed that symptoms are a sign that that their bodies are gradually increasing desensitization, similar to having sore muscles after a difficult workout.
2408606|NCT03513939|Experimental|T1DM Cell Pouch™ Recipients|Eligible Type 1 Diabetes Mellitus (T1DM) subjects with hypoglycemia unawareness and a history of severe hypoglycemic episodes undergoing Sernova Cell Pouch™ intervention
2408607|NCT03513926||Non-OSA group|Patients with out sleep apnea.
2408608|NCT03513926||OSA group|Patients with OSA, without cardiovascular comorbidities who could be treated with Continuous Positive Airway Pressure
2408609|NCT03513926||OSA with hypertension group|Patients with OSA, with hypertension who could be treated with Continuous Positive Airway Pressure
2408610|NCT03513926||OSA with CVE group|Patients with OSA, with a previous ictus or stroke who could be treated with Continuous Positive Airway Pressure
2408611|NCT03513913|Experimental|IVF|Oocytes fertilized by conventional in vitro fertilization (IVF) method
2408612|NCT03513913|Experimental|ICSI|Oocytes fertilized by intracytoplasmic sperm injection (ICSI) method
2408613|NCT03513900||cirrhosis|In this cross-sectional study , we will collect all patients with cirrhosis who meet the inclusion and exclusion criteria criteria coming to The Second Affiliated Hospital, Xi'an Jiaotong University since March 2018 to December 2018.
2408614|NCT03513887||Group/Cohorts|we will prospectively collect patients with liver cirrhosis who fulfill all inclusion criterias and will be treated in the Department of Gastroenterology of the Second Affiliated Hospital of Xi'an Jiaotong University.
2408615|NCT03513874|Experimental|Metformin + Insulin|
2408616|NCT03513874|Active Comparator|Insulin alone|
2408617|NCT03513861|Experimental|Aim 1: Parental FASTER tool training|The goal is to see whether the child's parent/ guardian can be trained in overall severity of illness assessment using the FASTER Tool, to match the performance of a professional.
2408618|NCT03513861|Active Comparator|Aim 2: Intervention group|The intervention group parents will be taught the FASTER assessment tool. Intervention group parents will each be asked to monitor their own hospitalized child hourly using the FASTER assessment tool, and put up color-coded flags indicating severity of illness to the healthcare team. Parents will record the frequency of healthcare provider assessments of their child over the 24 hour intervention period.
2408619|NCT03513861|No Intervention|Aim 2: Control Group|The control group parents will not be taught the FASTER assessment tool. Hence they will not be involved in monitoring their child, nor signaling severity of their child's illness per color-coded flag system. Control group parents will record the frequency of healthcare provider assessments of their child over the 24 hrs enrollment period.
3185263|NCT00732979|Active Comparator|B|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
3185264|NCT00733018|Active Comparator|A|Diet A - Western diet
2408622|NCT03513822|Active Comparator|Chronic neuropathic pain and bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
2408623|NCT03513822|Placebo Comparator|Chronic neuropathic pain and bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and ulcer pressure (inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
2408624|NCT03513822|Active Comparator|Chronic neuropathic pain without bedsore Ketamine group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. KETAMINE INFUSION IVSE 1mg/kg during 2 hours (0,5mg/kg/h). Preparation of 100mg in fifty cc, syringe with 2mg/ml. Rate of administration: Speed = Patient weight divided by four.~Maximum 100mg. One and only perfusion."
2408625|NCT03513822|Placebo Comparator|Chronic neuropathic pain without bedsore Placebo group|"Spinal cord injury population with central neuropathic pain at the lesional or sub-lesion level, chronically (for more than three months).~Patients medullary wounded with chronic pain and no ulcer pressure (no inflammation factor).~Midazolam 1mg before infusion. Sodium chloride infusion IVSE during 2 hours. Rate of administration : Speed = patient weight divided by four.~One and only perfusion."
2408626|NCT03513809||Acute hypoxemic respiratory failure|Patients with acute hypoxemic respiratory failure breathing spontaneously with no requirements of immediate intubation connected to thoracic electrical impedance tomography.
2408627|NCT03513770|Experimental|Ketorolac|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 ketorolac tromethamine + saline infusions into the occluded arm.
2408628|NCT03513770|Placebo Comparator|Control|The Wrist-to-Elbow occlusion procedure will be performed followed by 2 saline only infusions into the occluded arm.
3185265|NCT00733018|Active Comparator|B|Diet B - Balanced diet
3185266|NCT00733031|Experimental|gemcitabine|gemcitabine administered in combination with AZD6918
2408631|NCT03513744|Experimental|infant formula containing five HMOs|
2408632|NCT03513744|No Intervention|infant formula|
2408633|NCT03513744|No Intervention|breast milk group|
2408634|NCT03513731|Experimental|Adipose-derived stem cell injection|ADRC treatment group will receive ADRCs yielded from processing of lipoaspirate by a fluoroscopic-guided injection into the affected segment. The segment will consist of 2 joints per level and up to two levels (no more than 4 joints) injected during the procedure.
2408635|NCT03513731|Active Comparator|Corticosteroid injection|The control group will undergo standard fluoroscopy guided injection of glucocorticoids and local anesthetics.
2408636|NCT03513705|Experimental|Best practice|Enhanced implementation of best practices in pancreatic cancer care
2408637|NCT03513705|No Intervention|Current practice|Pancreatic cancer care according to current practice
2408638|NCT03513692|Active Comparator|Fill-Up composite resin|"In this arm of the study, participants will have the dental restoration completed with FillUp from Coltene, a composite resin a CE marked and licensed restorative material."
2408639|NCT03513692|Active Comparator|Conventional; composite|In this arm of the study, participants will have the dental restoration completed with a conventional composite resin using a CE marked and licensed restorative material.
2408640|NCT03513679|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2408641|NCT03513679|No Intervention|Control Group|Gait and balance testing to be administered once in healthy subjects
2408642|NCT03513666|Experimental|treatment arm|Toripalimab 240 mg or 360 mg Q3W in combination with chemotherapy
2408643|NCT03513653||Acute heart failure|Patients hospitalized for acute heart failure and underwent echocardiography with speckle-tracking imaging
3185267|NCT00733031|Experimental|pemetrexed|pemetrexed administered in combination with AZD6918
3185268|NCT00733031|Experimental|AZD6918|AZD6918 administered alone
3185269|NCT00733044|Experimental|Specialized Care|Stepped-care cognitive behavioural approach with elements from tinnitus retraining therapy
2408644|NCT03513627||Implant|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at a dental implant born crown in the front region of the jaw
2408645|NCT03513627||Tooth|Post-occlusive reactive hyperaemia test (PORH test) in the gingiva at the contralateral natural tooth
3185270|NCT00733044|Active Comparator|Usual Care|Audiological diagnostics and intervention and, if necessary, one or more consultations with a social worker with a maximum of ten one hour session
3185271|NCT00733057|Experimental|1|Minocycline treatment
2408648|NCT03513601|Experimental|(R)-CHOP regimen|(R)-CHOP regimen((rituximab)，cyclophosphamide，epirubicin，vincristine and prednisone)，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
2408649|NCT03513601|Experimental|(R)-CVP regimen|(R)-CVP regimen((rituximab)，cyclophosphamide，vincristine and prednisone) The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
3185272|NCT00733057|Placebo Comparator|2|Placebo
3185273|NCT00733083|Active Comparator|1|0,1 mg/kg of oxycodone
3185274|NCT00733083|Active Comparator|2|0,1 mg/kg of morphine
2408653|NCT03513575|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink."
2408654|NCT03513575|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2408655|NCT03513575|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml of 0.2% Chlorhexidine mouthrinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the gargle as an intervention."
2408656|NCT03513575|Experimental|Group 4: fluoridated tooth paste|"The subject collects unstimulated saliva in a sterile glass dish for measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Co., Mumbai, India) for 2 minutes using soft brush. Unstimulated saliva samples are collected thereafter to measure and record the pH of saliva at 15, 30 and 45 minutes after subject completes the brushing as an intervention."
2408657|NCT03513575|Experimental|Group 5: Polyol containing gum|"The subject collects unstimulated saliva in a sterile glass dish for the measurement of baseline pH of saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit. Unstimulated saliva samples are thereafter collected from to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2408658|NCT03513575|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test flavored milk drink, Amul Kool® milk, (Gujarat Cooperative Milk Marketing Federation Ltd.) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test flavored milk drink.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
3185275|NCT00733083|Active Comparator|3|0,5 mg/kg dexamethasone (max 24 mg
2408660|NCT03513549||Loxapine 10 MG|ADASUVE (loxapine) inhalation powder in a 10-milligram (mg) single-use oral inhaler. One dose in a 24-hour period.
2408661|NCT03513536|Experimental|Intervention 1|The women in this arm will receive the Citrus-Based Aromatherapy product to apply regularly for 6 days.
2408662|NCT03513536|Experimental|Intervention 2|The women in this arm will receive the Mint-Based Aromatherapy product to apply regularly for 6 days.
2408663|NCT03513536|Experimental|Intervention 3|The women in this arm will receive the Spice-Scented Aromatherapy product to apply regularly for 6 days.
3185276|NCT00733083|Placebo Comparator|4|NaCl 0,9%
3185277|NCT00733109|Active Comparator|excision of the lesion|
3185278|NCT00733109|No Intervention|espontaneous regression|
3185279|NCT00733122|Experimental|A|GARDASIL, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3185280|NCT00733148||1|Routine Care
2408664|NCT03513536|Placebo Comparator|Control|The women in this arm will receive a vegetable oil roll-on product to apply regularly for 6 days.
2408665|NCT03513523|Experimental|Group 1: 1X dose of NRPT|250 mg of NR and 50 mg of PT
2408666|NCT03513523|Experimental|Group 2: 2X dose of NRPT|500 mg of NR and 100 mg of PT
2408667|NCT03513523|Placebo Comparator|Group 3: Placebo|Placebo capsules contain microcrystalline cellulose, silicon dioxide and magnesium stearate
2408668|NCT03513510|Experimental|iChoose|6 biweekly family sessions, 6 biweekly telephone support calls to parents, 6 biweekly newsletters for children, and 3 supervised exercise sessions per week/3 months; delivers intervention to parents and children only
2408669|NCT03513497|Experimental|Periodontal Profile Class (PPC-A)|Periodontally healthy participants (PPC-A) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
2408670|NCT03513497|Experimental|Periodontal Profile Class (PPC-G)|Participants with severe periodontal disease (PPC-G) will wear customized acrylic mouthguard only during tooth brushing for 21 days.
2408671|NCT03513484|Experimental|Treatment (nintedanib, azacitidine)|Participants receive nintedanib PO BID on days 1-28 and azacitidine IV or SC on days 1-7. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 courses, participants may discontinue treatment, receive nintedanib every 4-8 weeks, or receive nintedanib and azacitidine every 4-8 weeks.
2408672|NCT03513471|Experimental|Anakinra then Placebo Treatment|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to the Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
2408673|NCT03513471|Experimental|Placebo then Anakinra Treatment|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
2408674|NCT03513458|Experimental|Anakinra then Placebo|Subjects randomized to this arm will receive the experimental treatment of Anakinra on their first exposure to Dermatophagoides Farinae (dust mite) allergen challenge, followed by the Anakinra matching placebo on their second exposure.
2408675|NCT03513458|Experimental|Placebo then Anakinra|Subjects randomized to this arm will receive the inactive placebo on their first exposure to the Dust Mite Allergen challenge, followed by the experimental treatment of Anakinra on their second exposure.
2408676|NCT03513445|Experimental|Lumbar Spine Surgery with Injection|Patients undergoing lumbar spine surgery will receive a peri-incisional injection of pain medications (morphine, epinephrine, and ropivacaine) during their surgery.
2408677|NCT03513445|No Intervention|Lumbar Spine Surgery without Injection|Patients undergoing lumbar spine surgery will NOT receive a peri-incisional injection of pain medications during their surgery.
2408678|NCT03513432|Experimental|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day
2408679|NCT03513432|Experimental|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day
2408680|NCT03513432|Experimental|Non-alcoholic beer with 0.00 % alcohol|330 ml non-alcoholic beer (0.00 % alcohol)/day
2408681|NCT03513419|Experimental|AMOR Method|The AMOR Method: The parent resilience training involves a series of eight weekly 90-minute group sessions, as well as three individual sessions. Group session content includes training in mindfulness, grief and loss processing, acceptance and committed actions, optimistic thinking, and resilience through the use of didactic training, group discussions, and homework assignments. Individual session content will center on additional and individualized training in grief and loss processing, optimistic thinking, and maintaining resilience over time.
2408682|NCT03513419|No Intervention|Wait List|Participants assigned to the waitlist will continue stable treatments and will be offered the opportunity to participate in the treatment after completion of the 8-week trial.
2408683|NCT03513406|Active Comparator|Sugammadex|Muscle relaxant reversal will be attained with sugammadex 2 mg/kgm IV.
2408684|NCT03513406|Active Comparator|Neostigmine|Muscle relaxant reversal will be attained with neostigmine 50 mcg/kgm plus glycopyrrolate10 mcg/kgm IV.
2408685|NCT03513393|Experimental|A: Epclusa + omeprazole + Coca Cola (test 1)|Day 1 - 6 40mg omeprazole QD; on Day 5 a single-dose of SOF/VEL with 250 mL of Coca Cola Classic is administered (test 1).
2408686|NCT03513393|Experimental|B: Epclusa + omeprazole + water (test 2)|Day 8 - 13: 40mg omeprazole QD; on Day 12 a single-dose of SOF/VEL is administered (test 2).
2408687|NCT03513393|Active Comparator|C: Epclusa + water (Reference)|Day 15 - 21: no treatment with omeprazole; on Day 19 a single-dose of SOF/VEL is administered (reference).
2408688|NCT03513380|Experimental|Exergaming|free access to the exergame PedalTanks
2408689|NCT03513380|No Intervention|Control|recommended to continue with their normal daily routine
2408690|NCT03513367||Boys with Muscular Duchenne Dystrophy|"105 boys with Muscular Duchenne Dystrophy (DMD) distributed as follows: 35 patients with Duchenne muscular dystrophy by age category, 8-12 years old and 13-18 years old.~Children will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of his parents"
2408691|NCT03513367||Parents of boys with Muscular Duchenne Dystrophy|105 parents of boys with Muscular Duchenne Dystrophy For the 5-7 age group, only parents answer the questionnaire but medical data are collected : 35 by age category (5-7; 8-12; 13-18) Parents will complete the questionnaire of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale regardless of their children
2408692|NCT03513354|No Intervention|Control group|The control group did not perform any of the interventions.
2408693|NCT03513354|Experimental|Soil group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
2408779|NCT03512639|Active Comparator|Study|Patients in the study group were given homeopathic medication (Arnica montana C30 and Bellis perennis C30) .
2409221|NCT03509922|Experimental|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
2408694|NCT03513354|Experimental|Pool group|(2) Stretching from the lateral flexors of the cervical spine, elbow flexors and extensors, trunk lateral flexors, flexors and extensors of hip with support of 30 seconds (1x30), (3) aerobic workout through front and lateral gait walking for 20 minutes, (4) resisted exercise for upper limbs (anterior, middle and posterior deltoid, biceps, triceps) and to the lower limbs (abductors, flexors and extensors of hip and flexors and extensors knee, calf), using dumbbells and shin guards for the resistance (20 minutes), (5) balance and proprioception training through front and backward walking on mattresses, march in a straight line with one foot in front of the other, one-feet support orthostatism, touching some points marked on the ground with the toe (15 minutes)
2408695|NCT03513341||Maastricht University First Year Students|Maastricht University 2017-2018 undergraduate first year students are invited to participate in the study. The participants are invited to complete a demographics questionnaire, wear an ActivPAL accelerometer for 7 days, and to complete daily diaries (modified International Physical Activity Questionnaire) for 7 days.
2408696|NCT03513328|Experimental|Group A--Thiotepa single dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2408697|NCT03513328|Experimental|Group A--Thiotepa escalated dose|Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2408698|NCT03513328|Active Comparator|Group B--Thiotepa single dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2408699|NCT03513328|Active Comparator|Group B--Thiotepa escalated dose|Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).
2408700|NCT03513315|Experimental|Intervention Community Clusters|For the community-based arm of the study, 16 clusters will be randomized into intervention and control groups. Those in the intervention group will receive implementation of community-based Home Heat Bundle. This Bundle includes education from community health workers on the signs and symptoms of heat-related illness, how to prevent the illness, and when to seek treatment. In addition, the intervention group will receive SMS messaging with information about heatwaves. The education and Short Message Service (SMS) messaging will occur in March and April via meetings in households and in public spaces. There will be a total of 40 activities, each lasting approximately two hours.
2408701|NCT03513315|Experimental|Control Community Clusters|Eight community clusters of 1000 population each where regular community-based healthcare services will be provided without focused interventions on identification and management of heat-related illnesses. These clusters will receive regular community healthcare provision.
2408702|NCT03513302|Placebo Comparator|placebo|
2408703|NCT03513302|Active Comparator|nitrate|
2408704|NCT03513289||Patient, Carer, and Clinician Interviews|This group/cohort consists of patients who experienced critical illness and were hospitalized in an ICU setting.
2408705|NCT03513276|Experimental|Multimodal analgesia + Local Infiltration Anesthesia|100cc of 2% ropivacaine + Adrenaline 10mcg/ml + 20cc saline solution
2408706|NCT03513276|Active Comparator|Multimodal analgesia + saline solution|120cc of saline solution
2408707|NCT03513263|Active Comparator|Scaling and polishing plus oral hygiene instruction|This arm will contain RA participants with PD who will continue with their treatment for RA and also receive the intervention of scaling and polishing plus oral hygiene instructions
2408708|NCT03513263|Sham Comparator|only oral hygiene instructions|This arm will contain rheumatoid arthritis (RA) participants with periodontitis who will continue with their treatment for (RA) and also receive only oral hygiene instructions
2408709|NCT03513250|Experimental|hyoscine-n-butylbromide group|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
2408710|NCT03513250|Placebo Comparator|control group|the same volume (1 ml) of normal saline intravenously immediately before the end of the cesarean section.
2408711|NCT03513237|Experimental|Cervical dilation group|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal after extraction of placenta and membranes and will remove the outer gloves after digital dilatation of the cervix.
2408712|NCT03513237|No Intervention|no cervical dilation group|No cervical dilation will be done.
2408713|NCT03513224|Experimental|eDosette|
2408714|NCT03513211|Experimental|Dose escalation arm|Suba-itraconazole in combination dose escalating hydroxychloroquine H
2408715|NCT03513211|Experimental|Phase II: Dose expansion arm|Suba-itraconazole with recommended phase II dose of hydroxychloroquine as determined by phase I arm.
2408716|NCT03513198||Non-resectable pancreatic cancer|"All patients with a suspicion of pancreatic masses will undergo EUS (including EUS-FNA for confirmation of diagnosis). A positive cytological diagnosis will be taken as a final proof of malignancy of the pancreas mass. The diagnoses obtained by EUS-FNA will be further verified during a clinical follow-up of at least 6 months.~Both pancreatic adenocarcinomas and pancreatic neuroendocrine tumors will be included.~Endoscopic ultrasound (including fine needle aspiration for confirmation of diagnosis) with sequential contrast-enhanced endoscopic ultrasound and elastography endoscopic ultrasound and contrast-enhanced computed tomography will be performed before and 2 months after the first course of treatment"
2408717|NCT03513185||Patients with SSD|Patients are diagnosed with SSD by physician according to DSM-5,and will be treated with Deanxit, SSRI or SRNI on the basis of severity assessment by physician.
2408718|NCT03513185||Patients with non-SSD|No SSD is diagnosed by physician according to DSM-5
2408719|NCT03513172|Active Comparator|Brimonidine Pre-Administration During First Visit|
2408720|NCT03513172|Active Comparator|Brimonidine Pre-Administration During Second Visit|
2408721|NCT03513159|Experimental|Pathfinder support|Pathfinder support with development of an individual care plan for the intervention patients and their informal caregivers, with the hospital physicians already inside the hospital setting. This will then be developed and improved further during up to twelve months after hospital release with the primary physician. The pathfinders will coordinate the ambulatory care team services and closely involve the primary physicians. The patients and their informal caregivers will be empowered and educated to achieve a stabilization or improvement in functionality, independence, quality of life, coping with disease, nutritional status and wound healing process. In the regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
2408722|NCT03513159|No Intervention|Control without pathfinder support|Control patients will not be supported by pathfinders. In regular assessments they will be tested for functionality and nutritional parameters, quality of life and stress scores.
2408723|NCT03513146|Experimental|OPAMM group|"During the pre-feeding period, infants will receive mother's colostrum (to the maximum of 0.2 ml) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 2 to 4 hours.~When an infant fits the criteria to start enteral feeding, 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
2408724|NCT03513146|No Intervention|Control Group|"During the pre-feeding period, preterm infants will remain NPO. When an infant fits the criteria to start enteral feeding, own mother's colostrum or milk will be given by the regular gavage feeding on intervals regulated by the feeding protocol.~This practice will be continued till the infants reach full oral feeding."
2408725|NCT03513133|Experimental|working memory training|Patients with severe TBI will receive a hierarchical training of working memory according to a previously described methodology. They will receive 3 sessions per week during three months (each session=1 h approximately)
2408726|NCT03513094|Experimental|Without and With Transversus Abdominis|"Without:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, without transversus abdominis contraction.~With:~Participants performed three trials of self-selected, comfortable paced walking in the motion lab to collect kinetic data, with 50% MVIC transversus abdominis contraction."
2408727|NCT03513081|Experimental|Educative Session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child tasted it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
2408728|NCT03513081|No Intervention|Control|Children in the control group don´t receive an educative session. Before the study starts children are asked to eat a salad. After 9 weeks, all children in the control group will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
2408729|NCT03513068|No Intervention|Standard Of Care (SOC)|Standard of care long-term oxygen therapy
2408730|NCT03513068|Experimental|SOC + POC (Portable Oxygen Concentrator)|Standard of care long-term oxygen therapy + POC
2408731|NCT03513055|Experimental|inject premixed insulin|patients inject premixed insulin themselves then nurse inject premixed insulin
2408732|NCT03513042||Cohort|"Intervention:~- Standard of care Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy.~Baseline measurements:~- All patients undergo baseline FDG PET-CT and FAZA PET-CT of the head-neck area.~Interim measurements conventional):~FDG PET-CT will be repeated at the end of the second week of IMPT.~FAZA PET will only be repeated at the end of the second week of IMPT if a hypoxic tumour volume was found at baseline scanning.~A subcohort will also undergo activation PET imaging three times during IMPT."
2408733|NCT03513029|Experimental|Study Device|VytronUS Ablation System
2408734|NCT03513016|Experimental|Part A: UBX0101|Part A: UBX0101, single intra-articular injection, ascending dose
2408735|NCT03513016|Placebo Comparator|Part A: Placebo|Part A: Placebo, single intra-articular injection, ascending dose
2408736|NCT03513016|Experimental|Part B: UBX0101|Part B: UBX0101, single intra-articular injection, fixed dose
2408737|NCT03513016|Placebo Comparator|Part B: Placebo|Part B: Placebo, single intra-articular injection, fixed dose
2408738|NCT03513003|Experimental|Functional pacifier|Swap from the habitual pacifier to a functional pacifier
2408739|NCT03513003|Active Comparator|Stop habit|Stop the use of the habitual pacifier and or baby bottle
2408740|NCT03512990|Experimental|Bupivacaine - Superior Trunk Block|"Patients scheduled for rotator cuff surgery received 6 mL of 0,5% bupivacaine in the superior Trunk.~6 mL of methylene blue will be injected into cadavers with the same technique."
2408741|NCT03512977|Experimental|Sphenopalatine Ganglion Block Group|patients will be performed transnasal sphenopalatine block and conservative treatment ( iv hydration, analgesic agents, caffeine or theophylline)
2408742|NCT03512977|Active Comparator|Standard Treatment Group|patients will receive standard supportive treatment ( Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline)
2408743|NCT03512964|Other|Rapid HIV Treatment Initiation|Initiation and reinitiation of antiretroviral therapy with dolutegravir 50 mg by mouth once daily and descovy 1 tablet by mouth once daily the same-day as HIV diagnosis and/or first clinic visit for people newly diagnosed with HIV and patients previously diagnosed with HIV but not on medications and not in care for over six months.
2408744|NCT03512951|Experimental|Normal hearing|A control group including ten normal-hearing participants. These participants are recruited because they can be considered as a reference when compared to hearing-impaired patients. They usually provide homogeneous results that are expected to be significantly different than those obtained with hearing-impaired patients. In this study, normal-hearing participants are expected to provide better and more consistent performance of auditory distance estimation.
2408780|NCT03512639|Placebo Comparator|control|Patients in the control group were given placebo medication. The placebos and the active medication were indistinguishable in appearance, taste and smell
2408745|NCT03512951|Experimental|10 experienced hearing impaired|A group of ten (expected sample size) severe-to-profound hearing-impaired patients who have a past and/or present experience of more than 6 months with remote microphone systems. These patients are expected to be aware of the drawbacks of the current remote microphone technology with respect to sound localization, auditory distance estimation, and audio-visual fusion.
2408746|NCT03512951|Experimental|10 naive hearing impaired|A group of ten severe-to-profound hearing-impaired patients with no past or current experience with remote microphone systems. They are referred to as naïve patients. These patients must have similar profiles to the patients in the experienced group as regards the degree of hearing loss, origin of hearing loss (congenital, pre- or post-lingual disability), age, gender, and hearing aid technology. They will be selected and recruited on the basis of the patients included in experienced group
2408747|NCT03512938|Active Comparator|Non-smoker Group|This group included non-smoker generalized aggressive periodontitis patients.
2408748|NCT03512938|Experimental|Smoker Group|This group included smoker generalized aggressive periodontitis patients.
2408749|NCT03512925|Experimental|Standardized post-coercion review|Intervention: Standardized post-coercion review session. Patients allocated to this arm receive a standardized post-coercion review of the coercive measure they experienced using the developed guidelines.
2408750|NCT03512925|No Intervention|Control group|Patients allocated to this arm are treated following usual standards and routine. This might include some form of post-coercion review that doesn't follow the developed standardized guidelines.
2408751|NCT03512899|Active Comparator|Internal jugular vein access|Internal jugular vein access preferably right, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
2408752|NCT03512899|Active Comparator|Axillary vein access|Axillary vein access with single incision, assisted by ultrasound and radioscopy. Catheter: districath®, 8.5 French.
2408753|NCT03512886|Active Comparator|Single task training|The exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
2408754|NCT03512886|Experimental|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
2408755|NCT03512886|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
2408756|NCT03512873|Experimental|Tranilast|
2408757|NCT03512860|Experimental|E4/DRSP (Treatment A) - E4/DRSP + VAL (Treatment B)|Sequence A-B: A single oral dose of E4 combined with DRSP (Treatment A) will be administered during the Period 1. After a washout, subjects will enter into the Period 2. They will receive the Treatment B which consists in multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration.
2408758|NCT03512860|Experimental|E4/DRSP + VAL (Treatment B) - E4/DRSP (Treatment A)|Sequence B-A: During Period 1, subjects will receive the Treatment B (multiple oral doses of VAL for 12 consecutive days and one single oral dose of E4/DRSP on Day 5 of the VAL administration) . After a washout, subjects will enter into the Period 2 and receive the Treatment A (a single oral dose of E4 combined with DRSP).
2408759|NCT03512834|Experimental|Paclitaxel+Avelumab|Paclitaxel combination with Avelumab for inoperable angiosarcoma
2408760|NCT03512821|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
2408761|NCT03512821|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
2408762|NCT03512808|Experimental|Ursodiol 500mg tablets|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
2408763|NCT03512808|Active Comparator|Urso Forte 500mg tablets|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
2408764|NCT03512782|No Intervention|CONTROL|
2408765|NCT03512782|Experimental|INTERVENTION|
2408766|NCT03512756|Experimental|Part 1 and Part 2 SM-88 Arm|"(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)~(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met."
2408767|NCT03512756|Experimental|Physician's Choice|Physician's Choice therapy will be administered for a total of 125 evaluable subjects until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
2408768|NCT03512730|Experimental|Titanium brush, H2O2 3%, plastic curettes|
2408769|NCT03512730|Active Comparator|H2O2 3%, plastic curettes|
2408770|NCT03512717|Experimental|Potenfill|
2408771|NCT03512717|Active Comparator|Powerfill|
2408772|NCT03512691|Experimental|Information on CVD risk|Respondents will receive information on the predicted probability of having a heart attack or stroke within 10 years. The predictions will be obtained from the Globorisk tool (www.globorisk.org). All information will be provided within a risk perceptions module of the baseline survey. Only this module will differ across the two treatment groups (information and lottery) and the control group. Information obtained from earlier modules will be retrieved automatically and used to make predictions of CVD risk consistent with the risk factor profile of the respondent.
2408773|NCT03512691|Experimental|Lottery Incentive|Respondents will be offered a ticket for a lottery with a money prize on condition that they visit a specific public health clinic for a checkup. There will be one prize per barangay giving each respondent a one in ten chance of winning P5000 (US$100). The prize is equivalent to approximately 14 days earnings at the regional minimum wage.
2408774|NCT03512691|No Intervention|Control|No intervention will be introduced to the participants in this arm.
2408775|NCT03512665|Experimental|Full dose supplement group|Patients assigned to this group will receive a daily dose of 7 mL of the study supplement (a mixture of pine, macadamia and pomegranate oils). The appearance and organoleptic properties will be similar to those of the interventions in the other two groups
2408776|NCT03512665|Experimental|Low dose Supplement group|Patients assigned to this group will receive a daily dose of 7 mL of a mixture containing 50% study supplement and 50% sunflower oil. The appearance and organoleptic properties will be similar to those of the interventions in the other two group
2408777|NCT03512665|Other|Control Oil Group|Patients assigned to this group will receive a daily 7 mL dose of an oil (sunflower oil) with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups
2408781|NCT03512626|Experimental|Multifocal IOL (OptiVis)|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a hybrid (refractive-diffractive) multifocal IOL (OptiVis, Aaren Scientific) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
2408782|NCT03512626|Active Comparator|Monofocal IOL|"Ambulatory surgery was performed by the same, experienced surgeon, under topical anesthesia, using as a technique phacoemulsification with small incision (2.75) in clear cornea in the most curved meridian.~The randomly assigned IOL (in this arm: a monofocal IOL (AR40e, AMO) was implanted in the capsular bag. The second eye with the same type of lens of the first eye was operated within 2-4 weeks."
2408783|NCT03512600|Experimental|Study group|"All patients will follow four different dietary interventions (with or without cacao) for 1 day prior to the taking of a urine sample.~After the sample is taken the patient will follow a washout period of 6 days before following a different diet and this process will be repeated for each patient until they have followed the four diets.~."
2408784|NCT03512587|Experimental|Personal quantum sonotherapy group|Patients who will listen through MP3 devices the personalized quantum sonotherapy previously created through a especialized software, before the application of regional anesthesia.
2408785|NCT03512587|Placebo Comparator|Control group|Patients will wear headphones but without playing the personalized quantum sonotherapy
2408786|NCT03512574|Experimental|Group PD|combination of pregabalin and dexmedetomidine
2408787|NCT03512574|Active Comparator|Group P|pregabalin +placebo
2408788|NCT03512574|Active Comparator|Group D|placebo + dexmedetomidine
2408789|NCT03512574|Placebo Comparator|Group C|placebo + placebo
2408790|NCT03512548|Experimental|Part 1 Period 1|Part 1 Period 1: Relacorilant 350mg will be given once on Day 1
2408791|NCT03512548|Experimental|Part 1 Period 2|Part 1 Period 2: Itraconazole 200mg will be given for three days
2408792|NCT03512548|Experimental|Part 1 Period 3|Part 1 Period 3: Relacorilant 350mg will be given once with concomitant itraconazole and itraconazole will continue for three additional days
2408793|NCT03512548|Experimental|Part 2 Period A|Part 2 Period A: Relacorilant 300mg will be given once daily for 10 days
2408794|NCT03512548|Experimental|Part 2 Period B|Part 2 Period B: Relacorilant 300mg will be given once daily in combination with itraconazole 200mg once daily for 10 days
2408795|NCT03512535||Stage 1|Samples from up to 20 participants will be used to finalise the analytical methods
2408796|NCT03512535||Stage 2|Samples from up to 200 participants will be used to then validate the normal ranges of these markers across different age ranges in both genders
2408797|NCT03512522|Experimental|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Online Group will receive access to the course on the computer (online). A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
2408798|NCT03512522|Experimental|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that have been experiencing pain for at least three months. Participants randomized to the Workbook Group will receive access to the course in a printed (workbook) format. A researcher will act as a guide who provides general support and encouragement, as opposed to a clinician who would offer comprehensive therapy. The guide will aim to contact participants weekly via telephone for approximately 5 to 10 minutes.
2408799|NCT03512522|No Intervention|Wait List Control Group|Participants who are randomly allocated to the wait list control group will be provided access to the course after the twelve-week period has passed.
2408800|NCT03512509|Experimental|A|Low glycaemic potato
2408801|NCT03512509|Experimental|B|High glycaemic potato
2408802|NCT03512496|Placebo Comparator|Acute energy drink - Control|Coloured Water was given 40 min prior to the OGTT test.
2408803|NCT03512496|Active Comparator|Acute energy drink - Caffeine|Sugar Free energy drink at 5mg/kg caffeine was given 40 min prior to OGTT test.
2408804|NCT03512496|Sham Comparator|Acute energy drink- Decaf|Sugar free decaf energy drink (vitamins only) was given 40 min prior to OGTT test. Amount of drink was same as that of Caffeine
2408805|NCT03512483|No Intervention|Usual Care|Control group participants will be notified of their assignment and will continue their usual care with the AF clinic receiving onsite care. Participants will be contacted at 3 time points (baseline, 3 months, and 6 months)
2408806|NCT03512483|Experimental|Virtual Atrial Fibrillation Clinic|Participants in the intervention group can expect to receive between 1 and 4 telehealth appointments over a 6 month period, as well as being contacted by the research team at 3 time points for data collection (baseline, 3 months, and 6 months). Telehealth appointments will consist of remote interactions with clinicians. Telehealth appointments will take place in participants' homes, using their personal computer/tablet/smartphone. Participants will also receive an orientation to the website and will be encouraged to visit often and utilize the resources. To promote and encourage website interaction, emails will be sent to participants once semi-monthly for the duration of the intervention with highlights and important messages from the website.
2408807|NCT03512470|Experimental|Sistema Prevena ™ (TVAC)|Negative topical pressure system (Sistema Prevena ™).
2408808|NCT03512470|Active Comparator|Standard medication|Standard medication with sterile gauzes and a TNT patch or medicated patch
3185281|NCT00733148||2|Insulin infusion based on model predictive algorithm (MPC)
3185282|NCT00733161|Active Comparator|1|Passive leg cycle exercise with stretching and resistance training
2408811|NCT03512444|Experimental|Negative pressure|"Negative pressure system is applied with negative pressure (Active)~at a participant's unilateral arm"
2408812|NCT03512444|No Intervention|No negative pressure|"Negative pressure system is applied without negative pressure (Inactive)~at a participant's contralateral arm"
2408813|NCT03512431||Study group|Only one arm in the present study
2408939|NCT03511677|Experimental|Intervention Group|Customized insole with metatarsal support
3185283|NCT00733161|Active Comparator|2|Stretching and resistance training
3185284|NCT00733174|Experimental|1|Rosiglitazone
3185285|NCT00733174|Placebo Comparator|2|Placebo
2408814|NCT03512418|Experimental|PrEPsteps|Participants receive the digital pills with Truvada, plus the PrEPsteps intervention that is programmed at the randomization study visit (Study Visit 2). Participants will use PrEPsteps and the digital pill to measure Truvada adherence for months 1-3.
2408815|NCT03512418|Active Comparator|Control|Participants receive digital pills with Truvada alone. Participants will use digital pills with Truvada for months 1-3.
2408816|NCT03512405|Experimental|Treatment (pembrolizumab, blinatumomab)|Participants receive pembrolizumab IV over 30 minutes on day 15 of course 1 and days 1 and 22 of courses 2 -4, and blinatumomab IV on days 1-28. Treatment repeats every 35-42 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2408817|NCT03512392|Experimental|Conservative fluid and deresuscitation|"Fluid restriction (avoidance of maintenance intravenous fluid and minimisation of drug diluent volumes)~Daily assessment of eligibility for deresuscitation for 3 days (eligible if oedema in more than 1 site and cumulative fluid balance > 2 litres)~Deresuscitation to target negative daily fluid balance of 1 to 3 litres:~5mg Indapamide daily (enteral) 100mg Spironolactone daily (enteral) 0.5mg/kg furosemide once (intravenous, max 40mg) 2.5-20mg/hr furosemide infusion titrated to effect OR continuous renal replacement therapy with fluid removal"
2408818|NCT03512392|Active Comparator|Usual care|Usual care at the discretion of the treating team
2408819|NCT03512379|Experimental|Robot assisted surgery group|Spinal surgery using TIANJI Robot system.
2408820|NCT03512379|Active Comparator|Free hand surgery group|Spinal surgery using fluoroscopy-based free hand technique
2408821|NCT03512379|Active Comparator|Navigation-assisted surgery group|Spinal surgery using Navigation-assisted technique
2408822|NCT03512366|Experimental|Desarsda's technique|"These patients wil be operated by the Desarda's technique without using any prosthetic mesh. A strip of external oblique aponeurosis will be used to strengthen the defect.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia~Intervention:~A strip will be separated from the upper leaf of the external oblique aponeurosis keeping its insertion and continuity with the muscle intact. This strip will be sutured with the inguinal ligament below and the muscle arch or conjoint tendon above behind the spermatic cord to form the new inguinal floor. Continuous non absorbable prolene 2-0 suture will be used to secure it to the inguinal ligament inferiorly , and will be secured superiorly to the internal oblique muscle using interrupted absorbable vicryl sutures."
2408823|NCT03512366|Active Comparator|Lichtenstein's technique|"These patients will be operated using prosthetic mesh described as Lichtenstein's tension free mesh hernioplasty.~Both field block and local infiltration with tumescent anaesthesia techniques will be used for anaesthesia.~Intervention :~A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring. Laterally, 2 cm silt will be made through the mesh to accommodate the cord. while the two tails will be sutured to create a new deep ring made of mesh."
3185286|NCT00733187|Experimental|1|
2408825|NCT03512340|Experimental|Part A|Part A will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of SRF231 as a monotherapy in patients with advanced solid tumors and lymphoma/Chronic lymphocytic leukemia.
2408826|NCT03512340|Experimental|Part B Cohort 1|Depending upon the results from Part A of the study and the decision from the Safety Review Committee, 1 or 2 doses or dosing frequencies of SRF231 in select advanced solid and hematologic malignancies.
2408827|NCT03512327|Experimental|Autoimmune protocol (AIP) diet|Adult patients with active Crohn's disease or ulcerative colitis, undergoing 11 week autoimmune protocol diet, to examine therapeutic efficacy
2408828|NCT03512314|Experimental|Tadekinig alfa|Active drug treatment during 26 weeks
2408829|NCT03512301|Experimental|CAMCI Baseline Only|Computerized and paper-pencil neuropsychological tests, baseline
2408830|NCT03512301|Experimental|CAMCI Baseline + Follow-Up|Computerized and paper-pencil neuropsychological tests, Baseline + Follow-Up
3185287|NCT00733200|No Intervention|Control group|
3185288|NCT00733239|Experimental|1|Receives 2-4 of the drugs listed under Intervention
2408833|NCT03512275|Experimental|400mg cohort, no prior treatment with anti-TNF agent(s)|N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
2408834|NCT03512275|Experimental|400 mg cohort, prior treatment with anti-TNF agent(s)|N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
3185289|NCT00733265|Experimental|AZD6140|
3185290|NCT00733317|Active Comparator|1-Budesonide nebulized suspension|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times and will not give after 3 doses
2408837|NCT03512249|Experimental|H56:IC31|"The H56 fusion protein is formulated with IC31 in a GMP-compliant environment in a ready to use final formulated vaccine.~H56:IC31 is administered twice with a 56 days (+/-10) interval, as 5 μg H56 adjuvanted with IC31 consisting of 500 nmol KLK and 20 nmol ODN1a, in a total volume of 0.5mL by the intramuscular route in the deltoid area using standard aseptic technique."
2408838|NCT03512249|Placebo Comparator|Placebo|Sterile saline for injection
2408839|NCT03512236|Experimental|BC Pram Ins|Single subcutaneous injection of BC Pram Ins + injection of placebo (0.9% NaCl) to ensure the double dummy
2408840|NCT03512236|Active Comparator|Symlin® and Humulin®|Simultaneous subcutaneous injections avec pramlintide and human insulin
2408841|NCT03512236|Active Comparator|Humalog®|Single subcutaneous injection of lispro + injection of placebo (0.9% NaCl) to ensure the double dummy
2408940|NCT03511677|Placebo Comparator|Control Group|Placebo flat insole
3185291|NCT00733317|Placebo Comparator|2- 0.9% saline|Children will receive 2 ml of saline every 20 minutes for 3 times and will not give after 3 doses
3185292|NCT00733382|Experimental|1|
3185293|NCT00733382|Active Comparator|2|
3185294|NCT00733395|Experimental|1|Tart cherry juice
3185295|NCT00733395|Placebo Comparator|2|Fruit juice
3185296|NCT00733434|Experimental|1|Patients receiving PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
3144663|NCT00047307|Experimental|Treatment (alvocidib, gemcitabine hydrochloride, 3DRT)|"Patients receive flavopiridol IV over 1 hour twice weekly (on days 1 and 4 or days 2 and 5) for 6 weeks. Concurrently, patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~Four weeks after the completion of radiotherapy, patients are re-evaluated*. Beginning within 4-7 weeks after the completion of chemotherapy and radiotherapy, patients receive gemcitabine hydrochloride alone or in combination with another cytotoxic agent or gemcitabine hydrochloride combined with a targeted drug (e.g., erlotinib or bevacizumab) at the discretion of the oncologist. NOTE: *Patients whose imaging studies suggest potential curative resection are referred for a surgical evaluation before initiating gemcitabine hydrochloride therapy. Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. Continued (see detailed description)"
3144664|NCT00047333|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144665|NCT00047346|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3144666|NCT00047411|Active Comparator|1|Intervention: Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines.
3144667|NCT00047411|Experimental|2|Use of the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
2408848|NCT03512184|Other|YMCA Class|This Arm's objective is to determine the effect of the YMCA's Diabetes Prevention Program on NAFLD as determined by comparison of liver enzymes pre- and post- program.
2408849|NCT03512171|Experimental|Amphetamine|One oral dose of dextroamphetamine (0.43 mg/kg) up to a maximum dose of 45mg. The dose is administered in 10mg and 2.5mg capsules prepared by the Vanderbilt Investigational Drug Services (IDS). Note: We are not testing the effect of dextro-amphetamine on a symptom. Rather it is part of the diagnostic intervention that is used to measure dopamine release assessed as the decline in [18F]fallypride binding relative to baseline.
2408850|NCT03512171|Placebo Comparator|Placebo|One oral placebo dose, with capsules prepared by the Vanderbilt Investigational Drug Services (IDS). This provides the baseline against which dopamine release is measured.
2408851|NCT03512171|Experimental|[18F]-FE-PE2I|[18F]-FE-PE2I is a radioligand for measuring dopamine transporters with positron emission tomography (PET). All participants complete this arm. The arm does not include administration of amphetamine or placebo.
2408852|NCT03512158|Experimental|High NCPAP|Administration of high NCPAP (> 8 cmH2O) following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
2408853|NCT03512158|Active Comparator|NIPPV|Administration of NIPPV following either failure of traditional NCPAP pressures (≤ 8 cmH2O) OR post-extubation from high endotracheal mechanical ventilation settings (defined as mean airway pressure ≥10 cmH2O)
2408854|NCT03512145|Experimental|VIPUN Balloon Catheter|Recording of gastric motility with the investigational medical device. Gastric emptying rate of a liquid meal is assessed with the 13C-octanoate breath test.
2408855|NCT03512132||control|
2408856|NCT03512132||T1D with normal albumin levels|
2408857|NCT03512132||T1D with macroalbuminuria|
2408858|NCT03512132||T1D with microalbuminuria|
2408859|NCT03512132||T1D with microalbuminuria and statins|
3144668|NCT00047437|Active Comparator|2|
2408861|NCT03512106|Experimental|Acupuncture group|Chinese traditional acupuncture
2408862|NCT03512106|Placebo Comparator|Sham group|Sham
2408863|NCT03512093||Retrospective chart review|
2408864|NCT03512093||Focus Group Discussion (FGD) of the medical staff|
2408865|NCT03512093||Interviews of mothers|
2408866|NCT03512080||Stable International Normalised Ratio|Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).
2408868|NCT03512054|Experimental|Experimental procedure|
2409222|NCT03509909|Experimental|Hatha yoga|12- week group-based yoga class
3144669|NCT00047437|No Intervention|1|
3144670|NCT00047450|Placebo Comparator|1|Participants will take placebo
3144671|NCT00047450|Active Comparator|2|Participants will take citalopram (Celexa)
3144672|NCT00047502|Experimental|Gleevec + SCH 66336|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day, and SCH66336 100 mg by mouth twice a day."
3144673|NCT00047554||TRAVATAN|Travoprost, 0.004% ophthalmic solution, 1 drop to the study eye once daily in the evening for up to 5 years
3144674|NCT00047671|Active Comparator|Citalopram|All subjects receive an FDA approved dose of Citalopram
3144675|NCT00047710|Experimental|Bevacizumab|Radiation, Bevacizumab, and Capecitabine
3144676|NCT00047827|Experimental|1|
3144677|NCT00047983|No Intervention|Control|Controls and will receive no dietary supplements
3144678|NCT00047983|Experimental|Arginine and Canola Oil|Daily nutritional supplements of arginine and canola oil
3144679|NCT00047983|Experimental|Arginine and Coromega|Daily nutritional supplements of arginine and Coromega
3144680|NCT00048087|Experimental|Iressa + Docetaxel|
3144681|NCT00048100|Experimental|Apheresis + Transplant|Skin biopsy & either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.
3144682|NCT00048126|Experimental|1|
3144683|NCT00048139|Experimental|1|
3144684|NCT00048152|Experimental|1|
3144685|NCT00048152|Experimental|2|
3144686|NCT00048152|Experimental|3|
3144687|NCT00048555|Experimental|1|
3144688|NCT00048633|Experimental|Tariquidar|
3144689|NCT00048646|Placebo Comparator|placebo|placebo
3144690|NCT00048646|Experimental|IV progesterone|IV progesterone
3185297|NCT00733434|Placebo Comparator|2|Patients receiving 500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
2408875|NCT03512015|Experimental|LuCApp + Standard Care|"LuCApp (Lung Cancer App) is an application developed by researchers and lung cancer clinicians to gather symptom data in real time and to share it with healthcare professionals.~LuCApp allows daily monitoring and grading of a list of symptoms which trigger alerts to the physicians in case predefined severity thresholds are met."
2408876|NCT03512015|Active Comparator|Standard Care|Usual care will consist of standard procedures currently available at participating centers for monitoring and documenting symptoms. These therapeutical procedures are based on the guidelines developed by the National Comprehensive Cancer Network (NCCN) and the Associazione Italiana di Oncologia Medica (AIOM). Symptoms for control arm patients will be discussed and registered during scheduled clinical visits with the oncologists. Standard-of-care patients will fill out their PROMs following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
3144691|NCT00048672|Experimental|Gleevec|Gleevec 400 mg orally daily. Dose adjustments made at discretion of treating physician within these guidelines: The highest dose acceptable is 800 mg daily. The lowest dose acceptable is 300 mg. No dose adjustment of more than 200 mg at one time is allowed. Dose adjustments to less than 300 mg may be approved after consultation with the principal investigator.
3144692|NCT00048750|Experimental|1|
2408879|NCT03511989|Active Comparator|Bone Borne distractor|The device being investigated, Boneborne distraction appliance
2408880|NCT03511989|Other|Tooth borne distractor|The control device Toothborne distraction appliance
2408881|NCT03511989|No Intervention|Segmental LF1 osteotomy group 1|Control Group, no stabilization of palatal vault
2408882|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 2|Testgroup, biodegradable plate at osteotomy site in palate
2408883|NCT03511989|Active Comparator|Segmental LF1 osteotomy group 3|Testgroup, autologous bonegraft at palatal osteotomy site
2408884|NCT03511976|No Intervention|Business as Usual (BAU)|One-third of participants will be assigned to this condition and will receive academic accommodations and interventions as deemed appropriate by their teachers, school personnel, and parents. This condition is intended to mirror current standard procedures for youth with ADHD. Thus, the specific accommodations and interventions are expected to vary across students. Some students' parents and physicians may choose to start stimulant medication with a goal of improving classroom performance.
2408885|NCT03511976|Experimental|Response to Intervention (RTI): Tier 1|Two-thirds of participants will be assigned to the RTI Tier 1 Arm. Teachers of students in this arm will receive consultation in RTI Tier 1 Classroom Management strategies.
2408886|NCT03511976|Experimental|RTI: Daily Report Card (DRC)|Students assigned to the RTI Tier 1 Arm, who do not respond to the initial RTI Tier 1 Classroom Management strategies, will move to the RTI DRC Arm of the study. Teachers of students in this arm of the study will receive consultation to implement a daily report card.
2408887|NCT03511976|Experimental|RTI: Enhanced|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the RTI: Enhanced Arm. Students in this arm will receive a more intensive classroom behavioral intervention directed at individual target behaviors through an enhanced DRC.
2408888|NCT03511976|Experimental|Medication|Half of students in the RTI DRC Arm who do not respond to the DRC intervention will be randomly assigned to the Medication arm and will receive stimulant medication as an additional intervention.
2408889|NCT03511963|Experimental|HLX04|
2408890|NCT03511963|Active Comparator|Bevacizumab|
3185298|NCT00733460|Experimental|BF-PET|
2408893|NCT03511924|Experimental|Intradialytic resistance training|During the 12-week intradialytic training plan subjects will be performed 3 to 5 sets of 3 different lower extremities exercises, each set will consist of 12 up to 18 repetitions of a single exercise. Subjects will take 1 to 2 minutes rest between each set. The resistance training will be realized 3 times per week and will be performed during haemodialysis therapy.
2408894|NCT03511924|No Intervention|Control programme|Control subjects will receive no intervention during the 12-weeks of the experiment. Through the 12-week control period, all participants will be instructed to maintain a standard treatment regimen and to maintain their customary dietary and physical activity patterns.
2408895|NCT03511911|Experimental|GROUP A1|In GROUP A1, participants are all healthy women.A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group A1 will be tested by inspector B twice in the same way as what they have done the first day.
2408896|NCT03511911|Experimental|GROUP A2|In GROUP A2,participants are all healthy women.A gynecological physician evaluates participant's pelvic floor muscle strength by vaginal palpation without telling the participant her result, and records it on a unique paper other than in the Case Report Form as what GROUP A1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group A2 will be tested by inspector A twice in the same way as what they have done the first day.
2408897|NCT03511911|Experimental|GROUP B1|In GROUP B1,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the patient her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,patients in group B1 will be tested by inspector B twice in the same way as what they have done the first day.
3144693|NCT00048750|Placebo Comparator|2|
3144694|NCT00048828|Active Comparator|1|
3144695|NCT00048828|Active Comparator|2|
3144696|NCT00048854|Active Comparator|1|Participants will receive treatment as usual
3144697|NCT00048854|Experimental|2|Participants will take sertraline
3144698|NCT00048958||No treatment|Samples as defined per the protocol for previously untreated patients with AML, ALL, MDS or MM will be submitted for analysis and within one month patients are required to register onto a CALGB treatment study.
2408898|NCT03511911|Experimental|GROUP B2|In GROUP B2,patients are all with pelvic floor disorders.A gynecological physician evaluates the patient's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP B1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,patients in group B2 will be tested by inspector A twice in the same way as what they have done the first day.
2408899|NCT03511911|Experimental|GROUP C1|In GROUP C1,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) without telling the participant her result, and records it on a unique paper other than in the Case Report Form.Then inspector A will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.After three days,participants in group C1 will be tested by inspector B twice in the same way as what they have done the first day.
2408900|NCT03511911|Experimental|GROUP C2|In GROUP C2,participants are all female who give birth to a child within a year(compliance and twice assessment are guaranteed,but PFMT are not allowed during the interval).A gynecological physician evaluates the participant's pelvic floor muscle strength by vaginal palpation without telling patient her result, and records it on a unique paper other than in the Case Report Form as what GROUP C1 do.Then it is inspector B who will test them twice using the PHENIX instrument with a 5 minutes' interval at the same day.Three days later,participants in group C2 will be tested by inspector A twice in the same way as what they have done the first day.
2408901|NCT03511898|Experimental|THR-149 dose level 1|
2408902|NCT03511898|Experimental|THR-149 dose level 2|
2408903|NCT03511898|Experimental|THR-149 dose level 3|
2408904|NCT03511885||high cardiovascular risk patients|"Coronary patients~Elective coronary artery bypass surgery (CABG).~Elective percutaneous coronary intervention (PCI) .~Acute coronary syndromes (acute myocardial infarction with ST elevation (STEMI) and Non ST elevation MI (Non- STEMI) including those treated with primary PCI and/or CABG, and unstable angina).~People at high risk of cardiovascular disease (CVD) who have been prescribed one or more of the following medications: (i) blood pressure and/or (ii) lipid and/or (iii) glucose lowering (diet and/or oral hypoglycaemic agents and/or insulin) treatments prescribed by a physician."
2408905|NCT03511872|Experimental|Peers' group|"36 Medical students are allocated randomly to Peers' group where they are trained on BLS skills by senior students.~Four students from the latest three years of study in medical schools in Syria (4th, 5th, and 6th) are randomly selected and enrolled to be instructors for basic life support training course to transfer the resuscitation skills to medical students from pre-clinical years."
2408906|NCT03511872|Experimental|Professionals' group|36 students are allocated randomly to professionals' group where they are trained on BLS skills by professional trainers in emergency. Four professionals (2 emergency doctors, cardiologist and anesthesiologist) are leading training to the control group to deliver the basic life support training course with the same duration and content as the intervention group.
2408907|NCT03511859||Control Group|Mammography/ultrasonography confirmed no findings.
2408908|NCT03511859||Cancer Group|The biopsy result is breast cancer.
2408909|NCT03511846|Experimental|Oral capsaicin|
2408910|NCT03511846|Sham Comparator|Oral capsaicin and Medical Air|
2408911|NCT03511846|Experimental|Oral Capsaicin and Low Flow Oxygen|
2408912|NCT03511846|Experimental|Oral capsaicin and High Flow Oxygen|
2408913|NCT03511846|Experimental|Topical capsaicin|
2408914|NCT03511846|Sham Comparator|Topical capsaicin and Medical Air|
2408915|NCT03511846|Experimental|Topical capsaicin and Low Flow Oxygen|
2408916|NCT03511846|Experimental|Topical capsaicin and High Flow Oxygen|
2408917|NCT03511846|Experimental|Intranasal capsaicin|
2408918|NCT03511846|Sham Comparator|Intranasal capsaicin and Medical Air|
2408919|NCT03511846|Experimental|Intranasal capsaicin and Low Flow Oxygen|
2408920|NCT03511846|Experimental|Intranasal capsaicin and High Flow Oxygen|
2408921|NCT03511846|Experimental|Cold water irrigation|
2408922|NCT03511846|Sham Comparator|Cold water irrigation and Medical Air|
2408923|NCT03511846|Experimental|Cold water irrigation and Low Flow Oxygen|
2408924|NCT03511846|Experimental|Cold water irrigation and High Flow Oxygen|
2408925|NCT03511833|Active Comparator|Morphine group|Morphine group will receive IV medication and IN saline.
2408926|NCT03511833|Experimental|Ketamine group|Ketamine group will receive IV saline and IN medication.
2408927|NCT03511807|Experimental|Electrical/ Acoustic stimulation|
2408930|NCT03511768|Experimental|18F-AlF-NOTA-octreotide PET/CT|One injection of the radioligand 18F-AlF-NOTA-octreotide
2408931|NCT03511755|Experimental|TEN 1-11 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-11 kHz)
2408932|NCT03511755|Active Comparator|TEN 1-3 kHz|Transdermal Electrical Neuromodulator (TEN) waveform pulsed biphasic current (1-3 kHz)
2408933|NCT03511729||A single exposure to general anesthesia|Participants who have surgery under general anesthesia (without anesthesia/surgery before)
2408934|NCT03511729||Multiple exposures to general anesthesia|Participants who have surgery under general anesthesia (had anesthesia/surgery before)
2408935|NCT03511703|Experimental|Apatinib|
2408936|NCT03511703|Other|TACE|
3144699|NCT00048971||Group 1|Patients undergo collection of blood specimens for polymerase chain reaction and restriction fragment length polymorphism analysis. Genotyping assays are performed to determine UGT1A1 promoter genotyping, UGT1A1 coding polymorphisms, TS promoter polymorphisms, and MTHFR polymorphisms.
2408943|NCT03511651|Other|FRC at clinical PEEP level|Measuring FRC at clinical PEEP level
2408944|NCT03511651|Experimental|FRC at clinical PEEP + 5cmH2O|Increasing PEEP to clinical PEEP + 5cmH2O
3144700|NCT00048984||Basic science (biomarker analysis)|Patients undergo various specimen collections, including bone marrow aspirate, paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens. These specimens are collected before, during, and after any chemotherapy regimens, during follow-up, and at time of recurrence. Translocation studies are performed on specimens to identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined. Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase chain reaction.
3144701|NCT00049010|Experimental|Group 1|"Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy.~Patients are followed every 4 months for 3.5 years."
2408947|NCT03511625|Experimental|Acthar|80 units of Acthar Injectable Product will be injected subcutaneously daily for three days, followed by twice weekly for four weeks.
2408948|NCT03511625|Active Comparator|Depo Medrol|40 milligrams of Depo Medrol will be injected intramuscularly one time
2408949|NCT03511612|Other|Pattern A|Intervention : Each subject has 3 measurements of ABI starting with oscillometric device and then using the Doppler method.
2408950|NCT03511612|Other|Pattern B|Intervention : Each subject has 3 measurements of ABI starting with Doppler method and then using oscillometric device.
2408951|NCT03511599|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2408952|NCT03511599|Active Comparator|Placebo|Participants will ingest a capsule identical to the study medication, however this capsule will contain a placebo.Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2408953|NCT03511560|Active Comparator|Tacrolimus, Immediate release|Tacrolimus (immediate-release) will be administered twice daily per clinical judgment of supervising physician (dosing and monitoring in accordance with center protocol) to a minimum whole blood tacrolimus concentration of at least 8 ng/mL.
2408954|NCT03511560|Experimental|Envarsus XR|Envarsus XR (Tacrolimus Extended Release Oral Tablet) will be administered once daily at initial weight-based dose of 0.12 mg/kg. Dosing and monitoring thereafter predicated on clinical judgment to a minimum whole blood tacrolimus concentration of at least 8 ng/mL. When possible, patients will receive their daily dose of Envarsus using the fewest number of pills possible.
2408955|NCT03511547|Active Comparator|Intervention group 1: Pitch-Patch|Reconstruction with patch augmentation using a synthetic patch
2408956|NCT03511547|Active Comparator|Intervention group 2: ArthroFlex|Reconstruction with patch augmentation using a biological human dermis patch
2408957|NCT03511547|No Intervention|Control|
2408958|NCT03511534|Active Comparator|Psychotherapy|Participants will receive evidenced based psychotherapy by a trained psychologist
2408959|NCT03511534|Active Comparator|Pharmacotherapy|Participants will receive pharmacotherapy by a psychiatrist
2408962|NCT03511508|Active Comparator|ChroPreg|The participants in the intervention Group receive the midwife-coordinated, individualized and specialized intervention plus standard care
2408963|NCT03511508|No Intervention|Standard care alone|"Participants in the control group receive the standard care for pregnant women with chronic disease.~The standard care is given to the participants in the control group. The standard care for pregnant women with chronic disease include five routine visits at a non-specialized midwife and an individually scheduled number of visits with an obstetrician, depending on the type and severity of the chronic Medical disease and possible pregnancy complications.~The women in the control Group have the same amount of ultrasound examinations as do the women in the intervention Group.~Women in the control Group can attend auditorium antenatal classes at the hospital."
2408964|NCT03511495||Keratoconic Patients|
2408965|NCT03511482|Experimental|MyAsthma Application and Lloyds Pharmacy Online Doctor|Web based applications to support people with Asthma management
2408966|NCT03511482|Experimental|MyAsthma Application and Usual care|Web based application to support people with Asthma Management
2408967|NCT03511482|No Intervention|Usual care only (control)|Usual care of asthma management
2408968|NCT03511469|Experimental|Control Group|Patients in this group will only received standardized rehabilitation protochol after Bankart surgery
2408969|NCT03511469|Experimental|Isokinetic Group|Patients in this group will receive concentric training for rotator cuff muscles with isokinetic device in addition the the standart rehabilitation protocol.
2408970|NCT03511456||FLLDH-PELD|Extraforaminal LDH patients received PELD operation
2408971|NCT03511443|Other|Diagnostic performance of hsRDT|Comparing diagnostic power of two diagnostics
2409071|NCT03510975|Sham Comparator|Verbal Behavioral Therapy|All children and their parents were instructed only a verbal behavioral therapy
2409072|NCT03510975|Experimental|Check-list|All participants were instructed a behavioral therapy with a written formed check-list for parents to complete
3144702|NCT00049023|Experimental|90Y-DOTA-tyr3-OCTREOTIDE|Dose escalation will proceed so that the single-cycle and three-cycle maximum tolerated doses of 90Y-DOTA-tyr3-Octreotide can be determined. The initial dose of 90Y-DOTA-tyr3-Octreotide to be administered is 30 mCi/m2 in each of three cycles. Dose escalation will proceed in 10 mCi/m2 intervals and will be permitted for the next cohort of subjects pending completion of Cycle 3 by 2 members of the previous cohort with no DLTs. A DLT is defined as a Grade 3 renal toxicity, Grade 4 bone marrow toxicity, or any other Grade 3 toxicity whether or not related to study drug and regardless of duration. Lymphopenia will not be used to define a DLT.
3185299|NCT00733473|Active Comparator|1 Budesonide|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 1 mg nebulized budesonide 2 times a day upto 5 days
2408973|NCT03511404|Experimental|Chronical LBP|Patients with chronic low back pain to be measured with Numeric Pain Rating Scale (NPRS).
2408974|NCT03511391|Experimental|Experimental arm|"Stereotactic body radiotherapy concurrent with checkpoint inhibitor treatment:~Nivolumab or Pembrolizumab or Atezolizumab + SBRT"
2408975|NCT03511391|Active Comparator|Control arm|"Checkpoint inhibitor treatment only:~Nivolumab or Pembrolizumab or Atezolizumab monotherapy"
3185300|NCT00733473|Placebo Comparator|2 Placebo saline|This arm consist 50 children with recurrent wheezing who are hospitalized for wheezing epizode. They received 2ml of nebulized saline 2 times a day upto 5 days
3185301|NCT00733486|Other|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
2408978|NCT03511365|Experimental|Probiotic administration|After baseline collection of serum and fecal microbiota, each subject will be administered the probiotic formulation VSL#3 450 Billion CFU Twice daily for 8 weeks. Serum and fecal microbiota will again be collected at the end of the intervention and compared with baseline with each subject serving as his or her own control.
2408979|NCT03511352|No Intervention|Control Condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
2408980|NCT03511352|Experimental|Frequent Sit-to-Stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period and a mid-point bathroom break.
2408981|NCT03511352|Experimental|Stand More (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 8-minute standing breaks, 1 per hour, and a mid-point bathroom break.
2408982|NCT03511339|No Intervention|Control|Brain rest
2408983|NCT03511339|Experimental|TecTraum Device|Treatment with study device
3185302|NCT00733525|Experimental|Stepped Care|Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
2408985|NCT03511313|Experimental|Renal denervation|Renal angiography and renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), and maintaining anti-hypertensive medications
2408986|NCT03511313|Sham Comparator|Renal angiography|Renal angiography and maintaining anti-hypertensive medications
2408987|NCT03511300|Placebo Comparator|Standard Instructions|Participants will receive standard instructions for cognitive tasks.
2408988|NCT03511300|Experimental|Goal Setting Instructions|Participants will receive goal-setting instructions for cognitive tasks.
2408989|NCT03511287|Experimental|IMT group|"Group intervention: home-based interval inspiratory muscle training:~during 8 weeks (two sessions per day, daily)~two times 30 breaths with one-minute rest between them in each session~training resistance set to the highest tolerable load according to scores pointed by the patient on the Borg score (between 4 and 6) aiming 50% of actual pimax or higher adjusted in the supervised weekly session"
2408990|NCT03511274|Experimental|Hygiene based educational film|Women randomised to receive the CMV educational intervention will fill in a questionnaire and view the film. The website will also contain interactive information about CMV and how to prevent it. After watching the film and reading the information, women will be asked to fill in a post-intervention questionnaire. The website will be accessible via the participants' own mobile device or computer or dedicated study tablets or computers on-site. Using a web-based intervention, we will be able to monitor use of the educational intervention and also collect data in real time.
2408991|NCT03511274|No Intervention|Treatment as usual (TAU)|Women who are randomised to the TAU group will also be asked to log-on the website. Instead of receiving specific information about prevention of CMV in pregnancy, they will receive information about routine antenatal immunisation. In the UK, the Department of Health recommends that all pregnant women should be offer immunisation against pertussis (whooping cough) and influenza (if pregnant during the influenza session). This will ensure that participants in the TAU arm of the study also derive benefit from the study.
2408992|NCT03511261|Active Comparator|10%Curcumin mucoadhesive gel|"Drug: Curcumin arm Curcumin10% mucoadhesive gel~Group 1 patients:~Drug : 10% curcumin mucoadhesive gel usage : Topical application Frequency : Twice daily Duration : 6 months"
2408993|NCT03511261|Active Comparator|Curcumin capsules 500mg|"Group 2 patients:~Drug : curcumin 500 mg capsules usage : oral intake Frequency : Twice daily Duration : 6 months"
2408994|NCT03511261|Active Comparator|5% Curcumin gel+Curcumin capsules 250mg|"Group 3 patients:~Drug: 5% Curcumin mucoadhesive gel & Curcumin capsules 250mg usage : Topical application and oral intake Frequency : Twice daily Duration : 6 months"
2408995|NCT03511261|Placebo Comparator|Placebo capsules|Group 4 patients Drug: Placebo capsules usage : oral intake Frequency : Twice daily Duration : 6 months
2408996|NCT03511248|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
2408997|NCT03511248|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
2408998|NCT03511222|Experimental|Dose Escalation: Vorolanib + Nivolumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level.~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2409223|NCT03509909|Active Comparator|Supportive physical activity|12-week group-based stretching and strengthening class
2408999|NCT03511222|Experimental|Dose Escalation: Vorolanib + Pembrolizumab|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at the assigned dose level~Patients receiving pembrolizumab will get it on an outpatient basis as a 30-minute (-5/+10 minutes) intravenous infusion at a dose of 200 mg on Day 1 of each 21-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2409000|NCT03511222|Experimental|Vorolanib + Nivolumab (Small Cell Lung Cancer)|"Vorolanib is an oral drug which will be administered daily on an outpatient basis at 300 mg daily~Patients receiving nivolumab will get it on an outpatient basis as a 30-minute intravenous infusion at a dose of 480 mg on Day 1 of each 28-day cycle~In light of immunotherapy approach, treatment beyond progression is allowed as long as patient has clinical stability. Patients can stay on the regimen unless excessive toxicity or clinical or radiographic disease progression per RECIST"
2409001|NCT03511209|Experimental|CBTI plus Taper method A|Participants in this arm will receive CBTI plus the novel hypnotic tapering method.
2409002|NCT03511209|Active Comparator|CBTI plus Taper method B|Participants in this arm will receive CBTI plus the usual tapering method used by the VA.
2409004|NCT03511183|Experimental|alternative regiment|"The first stage:XELOX + bevacizumab chemotherapy and XELIRI + bevacizumab chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage.~The second stage: continue to apply another plan until there is progress or intolerance."
2409005|NCT03511183|Placebo Comparator|classical regiment|Use the XELOX + bevacizumab chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI + bevacizumab chemotherapy until there is progress or intolerance.
2409006|NCT03511170|Experimental|alternative regiment|The first stage:XELOX chemotherapy and XELIRI chemotherapy (alternation of every two cycles) until one of the schemes appears imaging progress or intolerance.And then enter the second stage. The second stage: continue to apply another plan until there is progress or intolerance.
2409007|NCT03511170|Placebo Comparator|classical regiment|Use the XELOX chemotherapy until appears imaging progress or intolerance.And then change to the XELIRI chemotherapy until there is progress or intolerance.
3144703|NCT00049088|Experimental|Treatment (docetaxel, bevacizumab)|For course 1, patients receive docetaxel IV over 1 hour on days 1 and 8 and bortezomib IV over 3-5 seconds on days 9 and 12. Patients then receive 1 week of rest. For course 2 and all subsequent courses, patients receive docetaxel on days 1 and 8 and bortezomib on days 2, 5, 9, and 12. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 2-6 patients receive escalating doses of bortezomib and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose-limiting toxicity.
3144704|NCT00049114|Experimental|Treatment (doxorubicin, cyclophosphamide, tipifarnib, G-CSF)|"PHASE I (nonregional stage IV disease) (closed to accrual as of 1/19/04): Patients receive doxorubicin IV over 10-15 minutes and cyclophosphamide IV over 30 minutes on day 1, oral tipifarnib twice daily on days 2-7, and G-CSF subcutaneously on days 2-13. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~PHASE II (stage IIB, IIIA, IIIB, or IIIC): Patients receive tipifarnib at the MTD and doxorubicin, cyclophosphamide, and G-CSF as in phase I (phase I closed to accrual as of 1/19/04). After the fourth course, patients may undergo complete resection."
2409010|NCT03511144|Active Comparator|Measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
2409011|NCT03511144|Active Comparator|Ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
3144705|NCT00049140|Experimental|EF5|This is a non randomised single arm pilot study.
3144706|NCT00049166|Experimental|Regimen A (erlotinib hydrochloride, IMRT)|"Patients receive oral erlotinib once daily. Beginning on day 15, patients also undergo IMRT once daily 5 days a week for 7 weeks.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3144707|NCT00049166|Experimental|Regimen B (erlotinib hydrochloride, cisplatin, IMRT)|"Patients receive oral erlotinib and undergo IMRT as in regimen A. Patients also receive cisplatin IV over 20 minutes on each day of radiotherapy.~Patients in both regimens continue to receive erlotinib until the last day of IMRT (patients already in the maintenance phase of this study as of 5/11/04 continue to receive erlotinib once daily for up to 2 years) in the absence of disease progression or unacceptable toxicity.~In both regimens, cohorts of 3-6 patients receive escalating doses of erlotinib until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3185303|NCT00733525|Active Comparator|Cognitive Behavioral Therapy|Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.
3185304|NCT00733538|Active Comparator|1|patients receiving zometa treatment
3185305|NCT00733538|No Intervention|2|No treatment, just follow-up
3185306|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 1|Eligible subjects will receive repeat oral doses of GSK962040 given as 10 milligrams once daily tablet for 14 days.
3185307|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 2|Eligible subjects will receive repeat oral doses of GSK962040 given as 30 milligrams once daily tablet for 14 days.
2409224|NCT03509896||Participants newly diagnosed with CML-CP|
3144708|NCT00049192|Experimental|Treatment (oblimersen sodium, imatinib mesylate)|"Patients receive oblimersen IV continuously on days 1-10 and oral imatinib mesylate once or twice daily. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without a hematologic response after 2 courses go off study. Patients with complete or partial response after 4 courses may continue to receive oral imatinib mesylate daily.~Patients in cohort 2 receive an escalated dose of oblimersen; if well tolerated, subsequent cohorts receive oblimersen at the higher dose with the original dose of imatinib mesylate. If oblimersen is not well tolerated in cohort 2, subsequent cohorts receive the original dose of oblimersen with an escalated dose of imatinib mesylate. The first 6 patients accrued continue to receive the original dose (dose taken prior to study) of imatinib mesylate throughout the study."
3144709|NCT00049218|Experimental|Vaccine Administration|"• Phase I: Beginning 9 weeks after completion of chemotherapy, patients receive autologous dendritic cell-adenovirus p53 vaccine subcutaneously (SC) on days 1, 14, and 28. Patients without PD may undergo repeat leukapheresis on day 49. Patients receive vaccine SC again on days 56, 84, and 112 in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of autologous dendritic cell-adenovirus p53 vaccine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~• Phase II: Patients receive autologous dendritic cell-adenovirus p53 vaccine at the MTD determined in phase I."
3144710|NCT00049283|Experimental|Treatment (erlotinib hydrochloride, docetaxel, and radiation)|Patients receive oral erlotinib alone daily on weeks 1 and 2. Patients then receive oral erlotinib daily beginning on day 1 and docetaxel IV over 1 hour on day 3 of weeks 3-9. Patients also undergo radiotherapy once daily 5 days a week on weeks 3-9. Patients continue erlotinib for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who had N2 or greater cervical lymph node involvement at baseline or have residual neck adenopathy after chemoradiotherapy undergo neck dissection 6-8 weeks after completion of chemoradiotherapy. Erlotinib is held for 1 week before planned surgery and until healing is complete.
3144711|NCT00049309|No Intervention|Control|Usual diet
3144712|NCT00049309|Experimental|Flaxseed diet|30 gram flaxseed dietary modification
3144713|NCT00049309|Experimental|Low fat diet|Low fat dietary modification
3144714|NCT00049309|Experimental|Low fat + Flaxseed diet|Low fat and 30 gram flaxseed dietary modification
3144715|NCT00049335|Experimental|Capecitabine|Capecitabine 1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, Days 1-14 of 21 day cycle.
3144716|NCT00049387|Experimental|Treatment (tipifarnib, temozolomide, radiation therapy)|See Detailed Description
3144717|NCT00049400|Experimental|treatment|Single-arm, dose-escalation of BMS-247550
3144718|NCT00049569|Experimental|Arm I|See detailed description.
3144719|NCT00049569|Experimental|Arm II|See detailed description.
3144720|NCT00049582|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 3 hours twice daily OR IV over 1 hour once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3144721|NCT00049595|Active Comparator|ABVD|8 cycles of ABVD
3144722|NCT00049595|Experimental|BEACOPP|4 cycles of BEACOPP Escalated + 4 cycles of BEACOPP Baseline
3144723|NCT00049764|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3144724|NCT00049764|Placebo Comparator|2|0.9% sodium chloride
3144725|NCT00049816|No Intervention|1|Participants will receive no intervention and will act as the control group.
3144726|NCT00049816|Experimental|2|Participants will partake in a walking exercise program.
3144727|NCT00049816|Experimental|3|Participants will partake in a cycling exercise program.
3144728|NCT00050037|Experimental|CD-ROM based CBT|Group is given a copy of the CD-ROM program to complete at home over 10 weeks. At the end of each week, these patients upload and transmit their encrypted tracking data to the research coordinator. At the end of the treatment, participants who have not improved are offered a course of traditional manual-based group therapy, follow-up in an ongoing maintenance group in an eating disorders program, or an alternative treatment.
2409387|NCT03508895|Active Comparator|Casein protein|25 grams of protein powder, twice a day
3144729|NCT00050037|Active Comparator|Standard Group CBT|"Group undergoes standard group CBT. Therapy is administered over 10 weeks in five 90-minute sessions. The key topics are similar to those covered in the CD-ROM group: psychoeducation, developing a personal profile, standardizing meal times, recognizing emotional eating, increasing daily activity, learning the language of CBT, identifying automatic thoughts, restructuring thoughts, identifying cues and consequences, chaining, surfing the urge, and preventing relapses. Therapy sessions include a didactic section followed by group interaction and discussion. All group sessions are audiotaped and monitored."
3144730|NCT00050037|No Intervention|Waiting List|Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
3144731|NCT00050076|Experimental|MCC-135 50 mg BID|
3144732|NCT00050076|Experimental|MCC-135 100 mg QD|
3144733|NCT00050076|Experimental|MCC-135 200 mg QD|
3144734|NCT00050076|Placebo Comparator|Placebo|
3144735|NCT00050115||Hepatitis A + AA cohort|Subjects seen either at Clinical center or by outside physician
3144740|NCT00050349|Experimental|EPO906|
3144741|NCT00050414|Experimental|Trabectedin|Trabectedin 0.58 mg/m2 administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression. Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
3144742|NCT00050427|Experimental|001|ET743 580 mcg/m2 3-hour i.v. infusion on Days 1 8 and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
3144743|NCT00050427|Experimental|002|ET743 1 300 mcg/m2 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone 10 mg i.v will be administered 30 minutes prior to each trabectedin infusion.
3144744|NCT00050440|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.
3144745|NCT00050505|Experimental|Cohort C|N=100 to 110 subjects receives 1:10 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3144746|NCT00050505|Experimental|Cohort B|N=571 to 581 subjects receives 1:5 diluted dose of Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3144747|NCT00050505|Experimental|Cohort A|N=226 to 236 subjects receives undiluted dose Dryvax vaccine on Day 0 and 1:5 revaccination dose on Day 56
3144748|NCT00050531|Experimental|Gleevec|Gleevec 400 mg orally twice daily.
3144749|NCT00050531|Experimental|Gleevec + Peg-Intron + GM-CSF|Gleevec 400 mg orally twice daily. Peg-Intron 0.5 mcg/kg each week subcutaneously. GM-CSF 125 mcg/m^2 three times per week subcutaneously.
3144750|NCT00050557|Experimental|1|Participants will receive immediate Multi-Family Psychoeducation Group treatment and ongoing treatment as usual
3144751|NCT00050557|Active Comparator|2|Participants will receive treatment as usual and waitlist Multi-Family Psychoeducation Group treatment
2409053|NCT03511092|Experimental|HMB-FA|
2409054|NCT03511092|Experimental|HMB-Ca|
2409055|NCT03511092|Experimental|alfa-HICA|
2409056|NCT03511092|Placebo Comparator|Placebo|
3144752|NCT00050570|Experimental|Intervention|An 8-week, Internet- based, structured cognitive- behavioral program combined with an online, asynchronous, moderated discussion group.
3144753|NCT00050570|No Intervention|Control|The waitlist control group was only contacted at the time of assessments and was offered the intervention at the end of the study, after the 2-year follow-up assessment was completed.
2409059|NCT03511066|Experimental|CT-P27 Dose1|CT-P27 will be administrated once in IV infusion.
2409060|NCT03511066|Experimental|CT-P27 Dose2|CT-P27 will be administrated once in IV infusion.
2409061|NCT03511066|Placebo Comparator|Placebo|Placebo will be administrated once in IV infusion.
2409063|NCT03511040|Experimental|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
2409064|NCT03511027|Experimental|Intervention (SME + Karie Device)|Patients randomly assigned to receive SME+Karie will 1) undergo Screening for Self Medication Readiness to determine self-management capacity, 2) will receive self-medication education (SME) by a study Occupational Therapist, and 3) receive a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. In addition, this group will receive orientation to the Karie Automated Medication Delivery by the study Occupational Therapist. The participants in the intervention arm will use the Karie device for all applicable medications for the study duration.
2409065|NCT03511027|Active Comparator|Control (SME only)|"West Park has a Self-Medication Education Program policy in place which seeks to establish independent medication self-medication capacity during the inpatient stay. Eligibility criteria for SME include a need to manage medications independently at home; stabilized on medication (as per pharmacist/physician discretion); and mild-moderate cognitive/physical impairments (as per an OT assessment). During SME participants receive training by an Occupational Therapist, followed by a 5-day self-medication performance assessment by an Registered Nurse prior to discharge. Participants in the SME group will fill prescriptions as usual for the duration of study."
2409066|NCT03511014|Experimental|microcurrent|
2409067|NCT03511014|Sham Comparator|control|
3144754|NCT00050583|Experimental|1|10 Session modified CBT (including a relaxation component) administered by trained mental health clinicians at the primary care setting
3144755|NCT00050583|No Intervention|2|"Treatment as Usual, defined as the use of a consultation letter and traditional primary care management."
3144756|NCT00050609|Placebo Comparator|1|
3144757|NCT00050609|Active Comparator|2|5 mg tadalafil
3144758|NCT00050609|Active Comparator|3|20 mg tadalafil
3144759|NCT00050648|Active Comparator|cyclosporine|oral medication 2mg/kg/day orally from Day 0 until Day 90
3144760|NCT00050648|Active Comparator|anti-TAC|1mg/kg/dose medication every other week on the odd week (week 1-13)
3144761|NCT00050648|Experimental|Cyclosporine and anti-TAC|DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
3144762|NCT00050661|Active Comparator|Narrow Band Ultraviolet B|312nm
3144763|NCT00050661|Experimental|anti-TAC or placebo|
3144764|NCT00050674|Experimental|Filgrastim-SD/01|6 mg SC, Day 9, 24 hours after the end of the chemotherapy infusion
3144768|NCT00050791|Experimental|VLCD and leptin|Very low calorie diet formula providing 800 calories per day and leptin treatment.
3144769|NCT00050791|Active Comparator|placebo|Very low calorie diet and placebo treatment
3144770|NCT00051090|Experimental|A|All eligible study participants
3144771|NCT00051129|Experimental|Anecortave Acetate|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
3144772|NCT00051129|Placebo Comparator|Anecortave Acetate Vehicle|Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
3144773|NCT00051246|Active Comparator|1 M-ITG|Mother-infant group psychotherapy
3144774|NCT00051246|Active Comparator|2 - IPT|Individual interpersonal psychotherapy
3144775|NCT00051285|Experimental|Enoximone|
3144776|NCT00051285|Placebo Comparator|Placebo|
2409073|NCT03510975|Active Comparator|Desmopressin plus verbal therapy|All children in Group III received desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) plus verbal behavioral therapy.
2409074|NCT03510962|Active Comparator|Group 1: no intervention|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice."
2409075|NCT03510962|Experimental|Group 2: tap water gargle|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva.The subject is then given 100 ml of test mixed fruit juice,Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2409076|NCT03510962|Experimental|Group 3: 0.2% chlorhexidine|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2409077|NCT03510962|Experimental|Group 4: fluoridated tooth paste|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will Brush with fluoridated toothpaste (Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the brushing as an intervention."
2409078|NCT03510962|Experimental|Group 5: Polyol containing gum|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will chew polyol containing gum (Orbit®, Wrigley Company) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the chewing gum as an intervention."
2409079|NCT03510962|Experimental|Group 6: 1% sodium bicarbonate solution|"The subject collects the unstimulated saliva in a sterile glass dish for the measurement of baseline pH of the saliva. The subject is then given 100 ml of test mixed fruit juice, Tropicana® Mixed Fruit Juice, (PepsiCo, Inc) to drink. The subject will sip, swish and swallow the drink within 2 minutes.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva after 5 and 15 minutes of consumption of the test mixed fruit juice.~The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
2409080|NCT03510949|Other|Group N|Patients' nasal mucosa will be anaesthetized and vasoconstricted. K-Y gel will be applied to the tip of nasopharyngeal airway (NPA) of appropriate size. The NPA will then be advanced into the dominant nostril along the septum horizontally.
2409081|NCT03510949|Other|Group L|K-Y gel will be applied to the tip of the laryngeal mask (LMA) of appropriate size. The LMA will be introduced along the hard palate towards the hypopharynx until resistance is felt.
2409082|NCT03510936|No Intervention|blue light phototherapy|the patients in this arm will not receive probiotics.
2409083|NCT03510936|Experimental|probiotics concurrent with phototherapy|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks
2409084|NCT03510923||Patients who underwent an appendectomy|Patients of all ages who underwent an appendectomy in the elective or non-elective setting.
2409085|NCT03510923||Patients who underwent a cholecystectomy|Patients of all ages who underwent a cholecystectomy in the elective or non-elective setting.
3185308|NCT00733551|Experimental|Subjects receiving GSK962040 in cohort 3|Eligible subjects will receive repeat oral doses of GSK962040 given as 100 milligrams once daily tablet for 14 days.
2409088|NCT03510897|Active Comparator|QPI-1002|QPI-1002 Injection, Single dose
2409089|NCT03510897|Placebo Comparator|Placebo|isotonic saline
2409090|NCT03510884|Experimental|Alirocumab|Alirocumab (one of 4 doses, depending on body weight and Q2W or Q4W dose regimens) will be administered subcutaneously (SC). Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose.
2409091|NCT03510884|Placebo Comparator|Palcebo|Alirocumab Placebo will be administered SC. Patients treated with optimal dose of statin with or without other LMT or non-statin LMT if statin intolerant at stable dose
2409092|NCT03510871|Experimental|nivolumab plus ipilimumab|nivolumab plus ipilimumab
2409093|NCT03510858|Experimental|Intervention group|
2409094|NCT03510858|Other|Control group with crossover|Participants in the control group will receive the intervention after 12 months, cross-over design
2409129|NCT03510611|Experimental|Period 1: fed control → Period 2: fasted control|Period 1: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, without the breakfast
2409095|NCT03510845|Experimental|Repairable ACL tear|Patients whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle.
2409096|NCT03510845|Other|Irreparable ACL tear|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
2409097|NCT03510832||STEMI patients undergoing Emergent PCI|
2409098|NCT03510806|Placebo Comparator|Placebo|taste, color, and calorie-matched to supplement
2409099|NCT03510806|Experimental|Supplement|Proprietary protein and fruit extract blend
2409100|NCT03510793||Balanced anesthesia|Patients receiving balanced anesthesia (desflurane + remifentanil) according to the attending physician's decision
2409101|NCT03510793||Total intravenous anesthesia|Patients receiving total intravenous anesthesia (TIVA) using propofol + remifentanil with target-controlled infusion according to the attending physician's decision.
2409102|NCT03510780|Active Comparator|EMD treated patients|"Periodontal surgery with Enamel Matrix Derivative is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers EMD will be applied to the entire root surfaces ; then, ABG will be applied alternatively with EMD into the IBD according to the sandwich technique until the IBD will be completely filled. Finally the flap will be repositionated and sutures completed by interrupted sutures."
2409103|NCT03510780|Experimental|PRF treated patients|Periodontal surgery with Platelet Rich Fibrin is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous corticocancellous BG material will be collected using bone scrapers , the PRF membrane cut into small pieces and mixed with the ABG will be placed within the IBDs until they will be completely filled. Then the other two PRF membranes in each patient will be adapted over the grafted defect Finally horizontal mattress and interrupted sutures will be carried out.
2409104|NCT03510767|Experimental|TQ-B3525|
2409105|NCT03510741|Active Comparator|Sodium Benzoate|Sodium Benzoate added to TAU will be administered at 1000mg daily
2409106|NCT03510741|Active Comparator|N-Acetylcysteine|N-Acetylcysteine added to TAU 1000 mgs twice daily dose
2409107|NCT03510741|Active Comparator|Placebo|Placebo added to TAU
2409108|NCT03510741|Active Comparator|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
2409109|NCT03510728|No Intervention|No single-session intervention-EMA|Participants will be assessed both using a computer and using their phone. However, they will not receive an intervention at the start of the study and will only be using their phone for ecological assessment only data collection.
2409110|NCT03510728|Active Comparator|Standard single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will interact with their phone only for assessment purposes.
2409111|NCT03510728|Experimental|Augment single-session intervention-EMA|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will interact with their phone only for assessment purposes.
2409112|NCT03510728|Experimental|No single-session intervention-EMI|Participants in this group will not take a single-session intervention at baseline, but will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2409113|NCT03510728|Experimental|Standard single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will be followed up. Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2409114|NCT03510728|Experimental|Augment single-session intervention-EMI|Participants will take a computerized BMI with known efficacy, the college drinker's check up, and will also take a computerized intervention developed to increase the use of protective behavioral strategies during drinking (Protective Behavioral Strategies Intervention). Participants in this condition will be interacting with their phones during drinking occasions to promote protective behavioral strategy use (Ecological Momentary Intervention).
2409116|NCT03510702||Periodontal patients.|Taking gingival Crevicular fluid.
2409117|NCT03510702||Periodontally healthy patients.|Taking gingival Crevicular fluid.
3144777|NCT00051350|Placebo Comparator|CARB|Diet rich in carbohydrate
3144778|NCT00051350|Active Comparator|UNSAT|Diet rich in unsaturated fat
3144779|NCT00051350|Active Comparator|PROTEIN|Diet rich in protein
2409121|NCT03510676|Experimental|NiTiDES|Single arm
2409126|NCT03510650||Patients|50 patients with sepsis versus 50 patients with HLH [anticipated]
2409127|NCT03510624|Experimental|First rebaudioside A and then placebo|
2409128|NCT03510624|Experimental|First placebo and then rebaudioside A|
3144780|NCT00051714|Experimental|Early Primary Prevention|
3144781|NCT00051740|Active Comparator|Cognitive Adaptation Therapy|Subjects receive Cognitive adaptation therapy as part of treatment for schizophrenia
3144782|NCT00051740|Active Comparator|Minimal Environmental Support|Subjects receive minimal environmental support in schizophrenia treatment
3144783|NCT00051831|Experimental|1|
3144786|NCT00051922|Experimental|1|Participants will receive vaccine and will be followed for 1 year
3144787|NCT00051935|Experimental|1|
3144788|NCT00052013|Experimental|PTK787/ZK 222584|
3144789|NCT00052026|Placebo Comparator|1|Placebo
3144790|NCT00052026|Experimental|2|Low-dose carvedilol
3144791|NCT00052026|Experimental|3|high-dose carvedilol
3144792|NCT00052091|Experimental|1 Problem Solving Therapy|12 weekly sessions of problem solving therapy (PST)
3144793|NCT00052091|Experimental|2 Brief Supportive Therapy|12 weekly sessions of brief supportive therapy (BST)
3144794|NCT00052182|Experimental|1|Immunization on Day 0 and Weeks 4, 8, and 16
2409130|NCT03510611|Experimental|Period 1: fasted control → Period 2: fed control|Period 1: administration of Ensartinib 225mg at 7:30am, without the breakfast；Period 2: administration of Ensartinib 225mg at 7:30am, 30 minutes after the breakfast
2409133|NCT03510585|Experimental|saline and sniffing|This RRC is the combination of positioning (laying down), sniffing (only one side), throat vibration and saline instillation. And then the other side.
2409134|NCT03510585|Placebo Comparator|sniffing|Pacient will be in a lay down condition and will perform sniffing with throat vibration several times each side (but with no saline instillation)
2409135|NCT03510572|Experimental|Healthy volunteer|Cognitively healthy subjects will receive a single IV injection of [18F]PI-2620.
2409136|NCT03510572|Experimental|Alzheimer's Disease|Alzheimer's Disease Subjects will receive a single IV injection of [18F]PI-2620.
2409137|NCT03510572|Experimental|Frontotemporal dementia|frontotemporal dementia Subjects will receive a single IV injection of [18F]PI-2620.
2409138|NCT03510572|Experimental|Parkinson's disease|Parkinson's disease Subjects will receive a single IV injection of [18F]PI-2620.
2409139|NCT03510559|Active Comparator|Brachial Plexus Block|It will be at the discretion of the anesthesiologist performing the block to choose a supraclavicular, infraclavicular or axillary block to achieve adequate surgical anesthesia of the operative arm. After sterile skin preparation with chlorhexidine, a linear array transducer probe is placed on the skin and the appropriate nerve structures are identified. Local anesthetics (30 mL of 50:50 mix of 0.5% bupivacaine and 2% lidocaine) will then be injected in 5 mL aliquots after negative aspiration for blood to achieve circumferential spread around the brachial plexus. Patients who have a failed brachial plexus block may undergo a rescue forearm block, and will be recorded as requiring supplemental local anesthetic.
2409140|NCT03510559|Experimental|Forearm Nerve Block|Patients allocated to the forearm block will have it performed in the semi-setting position. After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a linear array transducer probe is placed at the distal forearm to visualize each peripheral nerve (radial, ulnar, median, and lateral antebrachial cutaneous). A 5 cm 22 G insulated needle is then used to target each nerve individually and infiltrate 7.5mL of the 50:50 mixture (similar to the brachial plexus block group) at each nerve to a total of 30mL.
2409141|NCT03510546|Experimental|Active|"De-novo: Each capsule contains 60 mg. pyridostigmine. 1 capsule is administered twice within 4 hours.~Chronic: Each capsule contains 60 mg. pyridostigmine. Number of administered capsules per dosage depend on the patient's usual dosage. Study drug is administered twice within 4 hours.~Patients are examined/rated before 1st dose, 1 hour after 1st dose, 1 hour after 2nd dose (Visit 1). After cross-over (Visit 2), patients will be rated open-label at 1 month (Visit 3) and 3 months (Visit 4)."
2409142|NCT03510546|Placebo Comparator|Placebo|"Same as Active, however capsules contain placebo."
2409143|NCT03510533|Experimental|Eating disorders patients|first clinical visit in nutrition department of CHU de Rouen for eating disorders (anorexia nervosa, hyperphagia or bulimia) according to the classification DSM-V
2409144|NCT03510533|Other|healthy volunteers|Volunteers with negative SCOFF test (No active or history of eating disorders)
2409145|NCT03510520|Experimental|Medium Cut-Off Haemodialysis (Theranova)|Participants will receive medium cut-off haemodialysis treatment for 6 months in total (3 times per week treatment).
2409146|NCT03510520|Active Comparator|On-Line Haemodiafiltration|Participant will remain on their usual on-line haemodiafiltration (HDF) treatment for the 6 month study duration (3 times per week treatment).
2409147|NCT03510494|Experimental|Intervention|Trebling of weekly curricular physical education (270 minutes per week)
2409148|NCT03510494|No Intervention|Control|Standard curriculum physical education (90 minutes per week)
3144795|NCT00052195|Placebo Comparator|B|
3144796|NCT00052195|Experimental|A|
2409220|NCT03509922|Experimental|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
3144797|NCT00052208|Experimental|Treatment (gefitinib, radiation therapy)|Patients receive gefitinib PO QD for 7 weeks. Beginning 1 week after initiation of gefitinib, patients undergo radiation therapy QD 5 days a week for 6 weeks. Treatment with gefitinib continues for up to 18 months in the absence of disease progression or unacceptable toxicity.
3144798|NCT00052221|Experimental|Arm I: Epoetin Alfa|Epoetin alfa subcutaneously (SC) once weekly for 6 weeks
3144799|NCT00052221|Placebo Comparator|Arm II: Placebo|Placebo subcutaneously (SC) once weekly for 6 weeks
3144800|NCT00052286|Experimental|drug dosage 1|- Arm I: Patients receive oral high-dose modafinil twice daily.
3144801|NCT00052286|Experimental|drug dosage 2|- Arm II: Patients receive oral low-dose modafinil twice daily.
3144802|NCT00052299|Experimental|ARM A|GO + MICE for remission induction followed by GO + mini-ICE for consolidation
3144803|NCT00052299|Active Comparator|ARM B|MICE for remission induction followed by mini-ICE for consolidation
3144804|NCT00052338|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, followed 1 hour later by bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with a clinical or radiographic response may continue receiving bortezomib beyond 6 courses.
3144805|NCT00052364|Experimental|Treatment (oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144806|NCT00052377|Experimental|Treatment (aldesleukin, recombinant interleukin-12)|"Patients receive IL-12 SC twice weekly for 24 weeks.~Disease is assessed at 13 weeks. Patients who do not have progressive disease also receive IL-2 SC 3 consecutive days a week during weeks 13-24. Patients with progressive disease at week 13 receive IL-2 SC at a fixed dose during weeks 13-24.~Patients with responding disease after week 24 may continue to receive IL-2 and IL-12 for another 12 weeks.~Cohorts of 3-6 patients receive escalating doses of IL-2 until the MTD is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RD is the dose preceding the MTD. Additional patients are treated at the RD."
3144807|NCT00052468|Experimental|TCG|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses
3144808|NCT00052468|Active Comparator|TC|Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses
3144809|NCT00052481||Quality of life questionnaire|"Patients are randomized to 1 of 2 arms on ACOSOG-Z0070 (radical prostatectomy vs brachytherapy).~Patients in both arms complete a quality of life questionnaire at baseline, 2 and 6 months after treatment, and then at 1, 2, 4, 7, and 10 years after treatment as part of ACOSOG-Z0071."
3144810|NCT00052494|Experimental|STI-571 with cisplatin and irinotecan|
2409160|NCT03510429|Active Comparator|Routine post-op care|Routine post-op care (N=20)
2409161|NCT03510429|Experimental|Routine post-op care with Nutritional supplement|Routine post-op care + Nutritional supplement by specific product (N=20)
2409162|NCT03510416|Experimental|apatinib combined with TACE|Apatinib is administered after TACE 4-7 days, and TACE treatment is performed after discontinuation of apatinib for 4 days.Every 28 days is a cycle.
2409163|NCT03510403|Experimental|Device : nasal airway stent|Patients with OSA or snoring use the nasal airway stent nastent™ each night for sleeping. The device is a tube-shaped medical device that is inserted from the nose and the tip of the tube reaches the soft palate. The inserted tube aids breathing by preventing the obstruction of the airway which causes poor sleep, frequent awakening during sleep and snoring.
3144811|NCT00052520|Experimental|Treatment|See Detailed Description
2409165|NCT03510377|Experimental|Aquatic physical intervention|Aquatic physical intervention: Ai-Chi
2409166|NCT03510377|Experimental|On-land physical intervention|On-land physical intervention: Tai-Chi
2409167|NCT03510377|Experimental|Non physical intervention|Non physical intervention: Guided imagery
2409168|NCT03510364|Experimental|Dietary intervention|All participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days.
2409169|NCT03510351||Treated subjects|All patients with Pseudomonas infections treated with ceftolozane-taezobactam who meet the inclusion criteria
2409170|NCT03510338|Experimental|Sublingual sildenafil (fasted)|Subjects receive a single dose of 100 mg sildenafil
2409171|NCT03510338|Active Comparator|Oral sildenafil (fed)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
2409172|NCT03510338|Experimental|Sublingual sildenafil (fed)|Subjects receive a single dose of 100 mg sildenafil
2409173|NCT03510338|Active Comparator|Oral comparator (fasted)|Subjects receive a single dose of 50 mg sildenafil (Viagra)
2409174|NCT03510325|Experimental|Olanzapine|dosage form:po dosage:5-20mg frequency:qn duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2409175|NCT03510325|Experimental|Risperidone|dosage form:po dosage:4-6mg frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2409176|NCT03510325|Experimental|Amisulpride|dosage form:po dosage:0.4-1.2g frequency:2 doses duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2409177|NCT03510325|Experimental|Aripiprazole|dosage form:po dosage:15-30mg frequency:qd duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2409178|NCT03510325|Experimental|Paliperidone long-acting injection|dosage form:im dosage:75-150mg frequency:once a month duration:If the drug is effective, it can be taken for a long time. If the drug is ineffective or the side effect is too difficult to tolerate, the drug should be changed according to the treatment stage.
2409179|NCT03510312||Long-term follow up, observational|This cohort does not involve interventions, just follow up of prognosis of ischemic stroke/transient ischemic attack patients.
2409180|NCT03510299|Placebo Comparator|Control group|
2409181|NCT03510299|Experimental|McGrath group|
2409182|NCT03510286||Pregnant women|Pregnant women attending ANC clinics in Techiman Holy Family Hospital and Kintampo North and South districts (all hospitals and clinics inclusive where ANC services are provided) are the primary participant group- primarily women of reproductive age. Pregnant women attending routine ANC will be enrolled. In addition to routine ANC, pregnant women will be tested with the Test-it™ PrCr Urinalysis Strips. Pregnant women are a potentially vulnerable population whose participation in this research is necessary given the target use case for this diagnostic tool: providing reliable and accurate point of care screening of proteinuria in ANC settings. The legal age of consent in Ghana is 18 years and women under the age of 18 will not be recruited for this study.
3185309|NCT00733551|Placebo Comparator|Subjects receiving placebo in cohort 1, 2 and 3|Eligible subjects will receive repeat oral doses of placebo tablets given once daily for 14 days in cohort 1, 2 and 3.
2409184|NCT03510260|Placebo Comparator|Control Group|Subject will undergo regular consenting only. At our unit consent for an elective cesarean delivery occurs in the same day of surgery, few hours before the procedure in a private room in labor and delivery while awaiting surgery. The COMRADE questionnaire (our primary outcome) will be obtained after the completion of the paper consent form.
2409185|NCT03510260|Experimental|Study Group I|Subject will receive an electronic invitation to complete the consent process electronically and will proceed through the Confirmed Consent system prior to arrival to labor and delivery on day of surgery, which is the routine patient flow at this time. The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group) before the completion of the paper consent form, in order to assess satisfaction and understanding of the e-confirmed consenting process completed before the procedure. After completion of the survey, the subject will sign the regular paper consent for the procedure as standard in our institution.
2409186|NCT03510260|Experimental|Study Group II|Subject will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent is obtained in order to assess whether both methods combined together improve the subjects' satisfaction of the consenting methods and better understanding of the surgical procedure.
3185310|NCT00733564|Active Comparator|1|Paracervical block will be performed
2409187|NCT03510221|Active Comparator|Antioxidants|Subjects received 3 antioxidant capsules (1 capsule of blueberry + 1 capsule of cranberry + 1 capsule pomegranate - a day) during 4 weeks.
2409188|NCT03510221|Placebo Comparator|Placebo|Subjects received 3 placebo capsules during 4 weeks.
2409189|NCT03510208|Experimental|Cohort 1 -50mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 50mg (Cohort 1) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
2409190|NCT03510208|Experimental|Cohort 2 -100mg panitumumab-IRDye800|A panitumumab-IRDye800 dose of 100mg (Cohort 2) with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery. Participants then undergo NIR imaging during standard of care surgery 1-5 days after receiving panitumumab-IRDye800.
2409191|NCT03510208|Experimental|Cohort 3 -100mg panitumumab-IRDye800|Cohort 3 dose will be determined based on Cohort 1 and Cohort 2, with or without a 100 mg loading dose of unlabeled panitumumab will be injected 1 to 5 days before the planed standard of care surgery
3185311|NCT00733564|Experimental|2|Propofol anesthesia will be performed
3185312|NCT00733564|Experimental|3|Sevoflurane anesthesia will be performed
2409194|NCT03510169|Experimental|NeoVest|Negative pressure ventilation using NeoVest
2409195|NCT03510156|Experimental|Treatment|
2409196|NCT03510156|No Intervention|Observation|
2409197|NCT03510143|No Intervention|Control|No use of Neoveil in the neck node dissection area
2409198|NCT03510143|Experimental|Neoveil|Use of Neoveil in the neck node dissection area
2409199|NCT03510130|Experimental|Routine leg movement|Intervention group- In the second stage of labor, attending physician or nurse will help the participant in routine leg movements every 20-30 minutes.
2409200|NCT03510130|No Intervention|Control group|Control group which includes women during the second stage of labor with no intervention (routine leg movement).
2409201|NCT03510117|Other|Mindfulness|Mindfulness
2409202|NCT03510104|Experimental|MRX-2843|MRX-2843: Dose Escalation Successive dose escalation cohorts to determine MTD
2409203|NCT03510091|Experimental|Video-Assisted Counseling|Patients receiving video-assisted counseling
2409204|NCT03510078|Experimental|Intensive glycemic control|With a target of blood glucose range of 130 mg/dL or less
2409205|NCT03510078|Experimental|Conventional glycemic control|With a target of blood glucose range of 130-180 mg/dL
2409206|NCT03510052|Other|Diet Modification Pilot Program|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
2409207|NCT03510039|Active Comparator|"Before Group"|35 Thirds benefiting from the usual care
2409208|NCT03510039|Experimental|"After Group"|"Recruit 35 Thirds for the phase phase After : Early device / Follow up by nurses"
2409209|NCT03510026|Other|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
2409210|NCT03510013|Experimental|1-1-8 wash-in|Wash-in using O2:N2O or O2:air 1:1 L/min with sevoflurane 8%
2409211|NCT03510000|Experimental|Main arm|Single arm open-label cross-over study with random order of SGLT-2 inhibitor intervention (Empagliflozin 25mg po qd), in which each cross-over phase includes different meal strategies (carbohydrate counting, meal announcement, no meal announcement) on separate days in the setting of single hormone artificial pancreas
2409212|NCT03509987|Other|hb analysis with Hemacue|Hb analysis with Hemacue and with arterial blood gas analyser in geriatric ill patients requiring intensive care
3185313|NCT00733577|Experimental|Cohort 1|15 mg SB756050 or placebo
2409214|NCT03509961|Other|Observational Arm|"Patients are enrolled to the observational arm to proceed with NGS-MRD testing pre-HCT. If NGS-MRD negative, eligible patients may be considered for the Treatment Arm to receive a myeloablative non-TBI conditioning regimen prior to HCT.~If NGS-MRD positive, patients may continue in the observational arm and receive HCT under the direction of their transplant physician and followed on the study for outcome."
2409215|NCT03509961|Other|Treatment Arm|Patients enrolled to the observational arm that are NGS-MRD pre-HCT are considered for the Treatment Arm. Patients will receive a myeloablative non-TBI conditioning regimen prior to the transplant consisting on busulfan, fludarabine and thiotepa. Patients will be followed for outcome for up to 5 years.
3185314|NCT00733577|Experimental|Cohort 2|Planned dose for Cohorts 2 50mg SB756050 or placebo
3185315|NCT00733577|Experimental|Cohort 3|Planned dose for Cohort 3 150mg SB756050 or placebo
2409218|NCT03509935|Experimental|Intervention Ultrasound Group|"Patients will be submitted to Ultrasound protocol, namely:~In the first 6 to 12 hours of admission to ICU~Second US after 12-24 hours of inclusion.~Third US after 24-48 hours of inclusion.~Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions.~US inferior vena cava, collapsability or distensibility index according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility between normal, reduced or severely reduced.~The US findings will be communicated to the attending physicians who will conduct the patient, according to the protocol, recommending the administration of volume or not, and the use of vasopressors and/or inotropic drugs."
2409219|NCT03509935|No Intervention|Control Group|Patients randomized to this group will receive care according to the indication of the attending physicians, composed mainly of intensive care physicians, without bedside US. Patients may be submitted to echocardiographic, abdominal and vascular examinations, among others, requested to ultrasound service, according to the indication.
3185316|NCT00733577|Experimental|Cohort 4|Planned dose for Cohort 4 600mg SB756050 or placebo
3185317|NCT00733603|Sham Comparator|Global Therapeutic Massage (GTM)|Non-specific somatic treatment with full-body Western massage.
3185318|NCT00733603|Active Comparator|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
3185319|NCT00733616|Experimental|1|
3185320|NCT00733642|Experimental|PF-04360365 1 mg/kg|
3185321|NCT00733642|Experimental|PF-04360365 3 mg/kg|
3185322|NCT00733642|Experimental|PF-04360365 5 mg/kg|
2409227|NCT03509870|Other|mesenchymal stromal cells|mesenchymal stromal cells in collagen scaffold
2409228|NCT03509857|Placebo Comparator|normal standard of care infusion of propofol without analgesia|normal standard of care infusion of propofol without analgesia
2409229|NCT03509857|Experimental|infusion of propofol with application of vibration analgesia|infusion of propofol with application of vibration analgesia
2409230|NCT03509844|Experimental|Prolonged Exposure|Psychotherapy: 10 weeks, Prolonged Exposure (individual sessions) according to the manual developed by Foa et al., adapted for a residential care setting
2409231|NCT03509844|Experimental|STAIR|Psychotherapy: 10 weeks, Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting
2409232|NCT03509844|Experimental|STAIR/NT|Psychotherapy: 16 weeks, 10 weeks Skills Training in Affect and Interpersonal Regulation (STAIR) (group sessions), followed by 6 weeks of Narrative Therapy (NT) (individual sessions), according to the manual developed by Cloitre et al., adapted for a residential care setting.
2409233|NCT03509831|Other|INT2150-A|
2409234|NCT03509831|Other|INT2150-B|
2409235|NCT03509818|Experimental|Plyometric|Effects of plyometric acute exercise
2409236|NCT03509818|Experimental|Aerobic|Effects of aerobic acute exercise
2409237|NCT03509805|Experimental|OSA in obese patient during pregnancy|OSA in polysomnography
2409238|NCT03509805|Experimental|no OSA in obese patient during pregnancy|no OSA in polysomnography
2409239|NCT03509792|Experimental|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
2409240|NCT03509792|Placebo Comparator|Attention placebo|Smartphone activity for same amount of time.
2409241|NCT03509779||NSCLC|NSCLC localized disease treated by surgery
3185323|NCT00733642|Experimental|PF-04360365 10 mg/kg|
2409243|NCT03509753|Experimental|High Fiber|Per 10 ounces of feed: 4 g oat-soy fiber with 45% short-chain fructooligosaccharides, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
2409244|NCT03509753|Active Comparator|Low Fiber|Per 10 ounces of feed: 0 g fiber, 296 kCal, 19 g protein, 8 g fat, and 39 g carbohydrates. Feed rate/duration individualized for each patient.
2409245|NCT03509740|Experimental|tramadol|Intravenous 100 mg tramadol in 100 ml saline with slow infusion over 10 minutes.
2409246|NCT03509740|Active Comparator|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion over 10 minutes.
2409247|NCT03509714|Active Comparator|Experimental: Part 1 Oxaloacetate Random|Participants take 2 capsules Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend per day during their entire menstrual cycle (approximately 28 days) or 2 capsules of 250 mg rice flour (Placebo). After one menstrual cycle, they cross-over to the other option.
2409248|NCT03509714|Active Comparator|Experimental: Part 2 Oxaloacetate Second|Participants take 2 capsules of 250 mg rice flour (Placebo) per day during their entire menstrual cycle (approximately 28 days). After one menstrual cycle, they cross-over to 2 capsules of Jubilance 100 mg Oxaloacetate/150 mg Ascorbic Acid blend.
2409249|NCT03509701||Subject (RCVS)|Patients who meet the definition of RCVS. (1) acute and severe headache with or without focal deficits or seizures, (2) uniphasic course without new symptoms more than 1 month after clinical onset, (3) segmental vasoconstriction of cerebral arteries shown by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or transfemoral cerebral angiography (TFCA),(4) normal or near normal cerebrospinal fluid analysis and (5) complete or substantial normalisation of arteries shown by follow-up angiography within 12 weeks.
2409250|NCT03509701||Control|Patients with thunderclap headache and intracranial stenosis, but not diagnosed as RCVS.
2409251|NCT03509688|Experimental|entecavir|drug:entecavir 0.5mg/day, one time/day,144weeks
2409252|NCT03509688|Experimental|entecavir+resveratrol|entecavir 0.5mg/day, 144weeks intervention:resveratrol 1000mg/day, 48weeks
2409253|NCT03509688|Experimental|entecavir+thymosin α1|entecavir 0.5mg/day, 144weeks thymosin α1 2 times/week, 24weeks
3185324|NCT00733681|Experimental|PFC Sigma RP TC3 Revision Knee System|Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).
3185325|NCT00733694|Other|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
2409256|NCT03509662|Placebo Comparator|Placebo group|Group 1 will be treated with placebos for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2409257|NCT03509662|Active Comparator|Vitamin C - 3 gr/day|Group 2 will be treated with 1.5 gr Vitamin C b.i.d. (3 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2409258|NCT03509662|Active Comparator|Vitamin C - 10 gr/day|Group 3 will be treated with 5 gr Vitamin C b.i.d. (10 gr/day) for 4 days. All patients will receive Thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate
2409259|NCT03509649|Experimental|Experienced - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from an experienced clinician
2409260|NCT03509649|Experimental|Experienced - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from an experienced clinician
2409261|NCT03509649|Active Comparator|Novice - Positive|Participants will receive cervical spine manipulation after being given a positive description of the technique from a novice clinician
2409262|NCT03509649|Active Comparator|Novice - Negative|Participants will receive cervical spine manipulation after being given a negative description of the technique from a novice clinician
3185326|NCT00733707|Experimental|1|Text messaging reminders
2409383|NCT03508908|No Intervention|Observation Period|HIV testing will only be done if ordered by the primary care clinician. Individuals diagnosed with HIV who have not yet notified partners will be offered assisted partner notification at a 6-week visit.
3185327|NCT00733707|No Intervention|2|No text messaging reminder
3185328|NCT00733720|Active Comparator|1|Each subject will receive all 3 doses of suboxone and placebo
2409264|NCT03509623|Experimental|Blood coagulation and aflibercept|Blood sampling through direct peripheral venous puncture will be collected from treatment naive patients commencing treatment with intravitreal injections of aflibercept for neovascular AMD before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection. Blood coagulation parameters will be evaluated at each timepoint.
2409265|NCT03509610|Active Comparator|CONTROL|Diet consisting of 50% carbohydrate (20% sugar), 15% protein, 35% fat
2409266|NCT03509610|Experimental|LOW SUG|Diet consisting of 50% carbohydrate (<5% sugar), 15% protein, 35% fat
2409267|NCT03509610|Experimental|LOW CHO|Diet consisting of <8% carbohydrate (<5% sugar), 15% protein, >77% fat
2409268|NCT03509597|Experimental|Aerobic Exercise|This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
2409269|NCT03509597|Experimental|Cognitive Training|The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
2409270|NCT03509597|Sham Comparator|Treatment as usual|The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
2409271|NCT03509584|Experimental|part #1a|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
2409272|NCT03509584|Experimental|part #1b|non-small cell lung cancer (NSCLC) patients with bone metatase(s) eligible for localized hypo-fractionated radiotherapy
2409273|NCT03509584|Experimental|part #2a|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
2409274|NCT03509584|Experimental|part #2b|NSCLC patients eligible for a localized radiotherapy of one target lesion (outside the brain)
3144812|NCT00052559|Experimental|Treatment (bevacizumab, fluorouracil, radiation therapy)|"Patients receive bevacizumab IV over 30-90 minutes on day 1 (courses 1-4). Beginning with course 2, patients also receive fluorouracil IV continuously on days 1-14 and undergo external beam radiotherapy on days 1-5 and 8-12. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo surgery 7 weeks after completion of chemoradiotherapy.~Cohorts of 6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 20 additional patients are treated at the MTD."
3144813|NCT00052585|Experimental|Treatment (irinotecan, gefitinib, leucovorin, fluorouracil)|Patients receive oral gefitinib daily beginning on day 1, irinotecan IV over 90 minutes on days 1 and 15, and leucovorin calcium IV over 2 hours and fluorouracil IV over 3-5 seconds followed by a 22-hour infusion on days 1, 2, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2409277|NCT03509558|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous electrical stimulation combined with physical therapy that targets rehabilitation of walking and standing functions
2409278|NCT03509558|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of walking and standing functions
2409279|NCT03509545|Experimental|CHF Patients: ER Torsemide 40 mg|CHF patients will be given 40 mg ER Torsemide
2409280|NCT03509545|Active Comparator|CHF Patients: Furosemide 40 mg|CHF patients are on 40 mg of Furosemide
2409281|NCT03509519|Experimental|NMES-Millicurrent Group|NMES-millicurrent group will receive the NMES experimental treatment. Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min on each leg.
2409282|NCT03509519|Sham Comparator|NMES-Microcurrent Group|The NMES-microcurrent group will receive the Sham Treatment. The Sham Treatment will consist of electrode pad application for 40 mins on each leg, but electrical current will not be delivered. Otherwise all procedures will be the same as the NMES-millicurrent experimental group. Participants will be informed they are receiving microcurrent stimulation which is typically not felt by patients. Microcurrent stimulation is an actual type of electrical stimulation that is used therapeutically and is typically not felt by patients, however, participants will not receive this treatment. Participants will be informed of the actual treatment received at the study conclusion. Those in the Sham Group will be given the opportunity to receive the treatment at the conclusion of the study.
2409283|NCT03509506|No Intervention|Non-App Group|"The participants will be instructed to continue their daily routine, track their daily steps with a pedometer, and record their daily steps on the Activity Log paper form."
2409284|NCT03509506|Experimental|App Group|The participants will be trained how to use the mobile application (Heart Failure Health Storyline (HFHS)) to track their health status, physical activity, manage their medications schedule, and explore the other features that the application has. Additionally, they will receive a pedometer to track their daily steps and record their data on the mobile application.
2409285|NCT03509493||Patients without structural heart disease|
2409286|NCT03509493||Patients with structural heart disease|
2409287|NCT03509493||Patients with high risk parameters for AF development|
2409288|NCT03509493||Patients post-cryptogenic stroke|
2409289|NCT03509493||Patients post-cardioversion therapy|
2409290|NCT03509493||Patients post-ablation therapy|
2409291|NCT03509480|Active Comparator|Curettage with Vitoss|ultraporous beta-tricalcium phosphate mixed with autologous bone marrow aspirate for patients undergoing surgical curettage for benign bone lesions
2409292|NCT03509480|Active Comparator|Curettage with Prodense|ultraporous beta-tricalcium phosphate mixed with calcium sulfate for patients undergoing surgical curettage for benign bone lesions
3144814|NCT00052598|Experimental|Treatment (adoptive immunotherapy)|Patients receive allogeneic CD8+ PR3-specific CTLs IV over 1-2 hours on days 0, 7, 14, 28, and 49 and aldesleukin SC twice daily on days 28-41 and 49-63 in the absence of unacceptable toxicity.
3144815|NCT00052611|Experimental|Celecoxib|Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
3144816|NCT00052689|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients with progressive disease crossover to arm II.
2409297|NCT03509454||Type 1 DM, Normo albuminuric|Type 1 diabetics with no history of albumnuria (UACR < 30 mg/g in 2 out of 3 consecutive samples)
2409298|NCT03509454||Type 1 DM, Micro albuminuric|Type 1 diabetics with history of micro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
2409299|NCT03509454||Type 1 DM, Macro albuminuric|Type 1 diabetics with history of macro albumnuria (UACR 30-299 mg/g in 2 out of 3 consecutive samples)
2409300|NCT03509454||Healthy subjects|Subjects with no history of diabetes, other diseases or intake of medicine which in the judgement of the investigator could affect the results, specifically renal, cardiovascular or inflammatory/infectious diseases should be considered for exclusion.
2409301|NCT03509441||South Asians with Insulin Resistance|125 patients (anticipated)
2409302|NCT03509441||South Asians without Insulin Resistance|125 patients (anticipated)
2409303|NCT03509428|No Intervention|Control|Usual care plus additional monitoring
2409304|NCT03509428|Experimental|SRETP|Structured Responsive Exercise Training Programme (SRETP) prior to surgery
2409305|NCT03509428|Experimental|Psychological support|Psychological support prior to surgery
2409306|NCT03509428|Experimental|SRETP and psychological support|Structured Responsive Exercise Training Programme (SRETP) and psychological support prior to surgery
2409307|NCT03509402|Experimental|Short implants|A full-arch screw-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6mm)
2409308|NCT03509402|Active Comparator|Long implants|A full-arch srew-retained mandibular prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
2409309|NCT03509376|Experimental|Suture repair|Diastasis recti is repaired using nylon suture for the plication
2409310|NCT03509376|Experimental|Rolled mesh repair|Diastasis recti is repaired with self gripping mesh to reinforce the suture line
2409311|NCT03509363|Experimental|Intervention|Participants allocated to the intervention group will be prescribed a set of exercise video with QR code provided in home exercise pamphlets and they have to perform the prescribed exercises under the guidance of video.The content of home exercise program in both groups is the same and is based on the recommendations from the National Stroke Foundation Clinical Guidelines, including mobilization exercise, strengthening exercise and balance training which is tailor-made for different mobility level of stroke patients. Suitability of participating home exercise program will be assessed by physiotherapists based on environmental risk, fall risk and competence of patients or carers in performing exercise with patients. The number of exercises prescribed, frequency and intensity of exercise varies from participants and will be determinated by physiotherapists
2409312|NCT03509363|No Intervention|Control|Participants in control group will be given instructions for their home exercise program in a traditional pamphlet includes photographs and instructions of exercise demonstration.
2409315|NCT03509324|Other|duration of disease|different duration of disease receive insulin LISPRO
2409316|NCT03509311||Asthma Group|"That group consists from patients who had diagnosed as asthma by doctors from Chest Diseases Department of Gazi University Hospital.~Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment, depression and anxiety level assesment and asthma management knowledge assesment apply to this group."
2409317|NCT03509311||Healthy Group|That group consists from participants who do not have any diagnosed disease. Physical activity level assesment, maximal and submaximal exercise capacity assesment, respiratory function assesment, respiratory muscle strength assesment, respiratory muscle endurance assesment, peripheral muscle strength assesment, quality of life assesment about disease specific, respiratory, sleep and cough associated, fatigue severity assesment and depression and anxiety level assesment apply to this group.
2409318|NCT03509298|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2409386|NCT03508895|Experimental|Whole hemp seed protein plus bioactive peptides|22.5 grams of hemp seed protein and 2.5 grams of hemp seed protein hydrolysate derived bioactive peptides, twice a day
3144817|NCT00052689|Experimental|Arm II|Patients receive bortezomib as in arm I and gemcitabine IV over 30 minutes on days 1 and 8.
3144818|NCT00052780|Experimental|Treatment (temozolomide, O6-benzylguanine)|See Detailed Description
3144819|NCT00052845|Experimental|Combined chemotherapy|combination of 3 chemotherapy agents for hormone refractory prostate cancer
3144820|NCT00052884|Experimental|Amifostine, Melphalan, and Stem Cell Reconstitution|Amifostine, Melphalan, and Stem Cell Reconstitution. Doses of Melphalan tested included 100 mg/m2 and 120 mg/m2
3144821|NCT00052897|Experimental|Arm I|"Patients receive SGN-00101 subcutaneously once on weeks 0, 4, and 8. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 5-6 patients receive escalating doses of SGN-00101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 1 of 6 patients experience dose-limiting toxicity."
3144822|NCT00052936|Experimental|S6|6x CHOP-14
3144823|NCT00052936|Experimental|R6|6x CHOP-14 + 8x Rituximab
3144824|NCT00052936|Experimental|S8|8x CHOP-14
3144825|NCT00052936|Experimental|R8|8x CHOP-14 + 8x Rituximab
3144826|NCT00052949|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate twice daily for 28 days. Courses continue in the absence of disease progression or unacceptable toxicity.
2409319|NCT03509298|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2409320|NCT03509298|No Intervention|Conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2409321|NCT03509285|Placebo Comparator|Qualification Y|Placebo; administered orally as a single dose of 2 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2409322|NCT03509285|Active Comparator|Qualification Z|Alprazolam 2.0 mg; administered orally as a single dose of 2 x 1.0 mg alprazolam tablets, over-encapsulated
2409323|NCT03509285|Placebo Comparator|Treatment A|Placebo; administered orally as a single dose of 4 x cenobamate-matched placebo tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2409324|NCT03509285|Active Comparator|Treatment B|Alprazolam 1.5 mg; administered orally as a single dose of 3 x 0.5 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
2409325|NCT03509285|Active Comparator|Treatment C|Alprazolam 3.0 mg; administered orally as a single dose of 3 x 1.0 mg alprazolam tablets, over-encapsulated and 4 x cenobamate-matched placebo tablets
2409326|NCT03509285|Experimental|Treatment D|Cenobamate, 200 mg; administered orally as a single dose of 2 x 100 mg cenobamate tablets, 2 x cenobamate-matched placebo tablets, and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2409327|NCT03509285|Experimental|Treatment E|Cenobamate, 400 mg; administered orally as a single dose of 4 x 100 mg cenobamate tablets and 3 x 100 mg lactose tablets, over-encapsulated (alprazolam placebo)
2409328|NCT03509272|No Intervention|Control Group|
2409329|NCT03509272|Experimental|remote monitoring group|
2409330|NCT03509259||Asthma|"If the doctor has been diagnosed with asthma and one or more of the following criteria is met;~FEV1 (Forced expiratory volume in 1 second) increased more than 12% & 200 mL after 10-20 minutes of inhalation of short-acting bronchodilator (200-400 mg salbutamol)~Positive bronchial provocation tests (methacholine, mannitol, exercise, aspirin, etc.)~FEV1 Increased more than 12% & 200 mL from baseline FEV1 after anti-inflammatory treatment for 4 weeks or longer.~They can have concomittent COPD or not"
2409331|NCT03509259||Healthy control|Subjects who performed coronary artery calcium scoring CT for health checkup purpose.(retrospective group = historical control group)
2409332|NCT03509246|Experimental|Pegylated liposomal doxorubicin plus Bortezomib combination|At BRCA wild-type platinum-resistant recurrent ovarian cancer patients, Pegylated liposomal doxorubicin and Bortezomib combination therapy for six cycles.
2409333|NCT03509233|Active Comparator|Q-SRP|Quadrant scaling and root planing
2409334|NCT03509233|Experimental|FMS|Full mouth scaling and root planing
2409335|NCT03509233|Experimental|FMD|Full mouth disinfection
2409336|NCT03509233|Experimental|FMDP|Full mouth disinfection with periopolishing
2409337|NCT03509220|Experimental|PBK-1701TC|2-Day Split-Dosing Regimen
2409338|NCT03509220|Active Comparator|Standard oral preparation|2-Day Split-Dosing Regimen
3185329|NCT00733733|Active Comparator|ATG|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
2409340|NCT03509194||Pediatric liver disease patients|Comparison of outcome of pediatric liver disease and prognostic functional liver test results and gene expression in liver biopsies.
2409341|NCT03509181|Experimental|CBM|Cognitive Bias Modification for Interpretation delivered via smartphone
2409342|NCT03509181|Active Comparator|Symptom Tracking|Weekly symptom monitoring smartphone app with anxiety and depression symptom scores
2409343|NCT03509168|Active Comparator|Misoprostol Pfizer Brand arm|participants receive a single dose of 400mcg vaginal misoprostol preoperatively (60minutes before) during open myomectomy
2409344|NCT03509168|Other|No misoprostol arm|standard of care
2409345|NCT03509155|No Intervention|Control group|The first arm as a control group obtaining only routine IYCF consultation by the posyandu (integrated health service post) cadres and without the provision of biscuits.
2409346|NCT03509155|Active Comparator|National portion & IYCF counseling|The second arm as the national portion & IYCF counseling group to get biscuit with standardized portion as recommended by Ministry of Health and also given the IYCF counseling by the cadres and nutritionist.In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
2409347|NCT03509155|Experimental|Adjusted portion & local food counseling|the third arm as the adjusted portion & local food counseling group receiving biscuit with adjustment in portion and IYCF Counseling that emphasize the optimization of local food. In the second and third arm, treatment was administered for 3 months according to the recommended duration of biscuit delivery by the Ministry of Health, but all respondents from three arms will continue to be followed in third, sixth, and ninth months from the beginning of treatment.
2409348|NCT03509142|Experimental|IBS implantation|Implantation of IBS in patients with coronary artery lesions. All the subjects will be assigned to cohort 1 (n=30) and cohort 2 (n=15).
2409349|NCT03509129|Active Comparator|TECH (Technology)|Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.
2409350|NCT03509129|Experimental|TECH+COMP (Technology + Competition)|Participants will receive the same intervention components as the TECH goup, as well as a study designed team competition.
2409384|NCT03508908|Active Comparator|Intervention Period|Combination intervention with HIV-1 RNA testing followed by rapid tests if positive for HIV diagnosis, immediate ART if diagnosed, assisted partner notification with HIV-1 RNA testing of partners, and PrEP for uninfected partners in discordant relationships.
2409385|NCT03508895|Experimental|Whole hemp seed protein|25 grams of hemp seed protein powder, twice a day
2409353|NCT03509103|Experimental|Electronic partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
2409354|NCT03509103|Active Comparator|Paper Partograph|An standard training on how to use and fill out partograph was conducted
2409355|NCT03509090|Active Comparator|ESP block group|Unilateral ESP block will be applied as postoperative regional analgesia technique in addition to the multimodal therapy. Then she is positioned in a right lateral position to perform ESP blocks. The skin will be disinfected and ESP block at one side will be performed in the lateral decubitus position and at T4 transverse process level by using 10-MHz linear ultrasound probe (Logic Ebook XP General Electrics, USA). The probe will be located 3 cm lateral to T4 spinous process in longitudinal parasagittal orientation. An 8 cm 21 gauge needle (BRAUN Stimuplex A®, Germany) will be inserted by using out of the plane technique. The ESP blocks proceed with 15 ml of 0,25% bupivacaine, 7,5 ml 1 % lidocaine, ,7,5 ml 0,9 % NaCl as total 30 ml . The injections will be applied after the confirmation of location by hidrodisection developed anterior to erector spinae muscle with 1-2 ml of local anesthetic solution.
2409356|NCT03509090|Active Comparator|Control group|In this group, patients will receive only multimodal analgesic treatment including patient-controlled analgesia prepared with tramadol. Patient-controlled analgesia (PCA) with tramadol at 3mg/cc concentration is programmed with no basal infusion, demand dose 10 mg and 20-minute lock-out interval. Also, patients received 1 gr paracetamol in every 6 hours.
2409357|NCT03509064||1: Patients with small fiber neuropathy|patients with Sjogren syndrome have a definite small fiber neuropathy
2409358|NCT03509064||2: Patients without peripheral neuropathy|patients with Sjogren syndrome without signs of peripheral neuropathy (small or large fiber)
2409359|NCT03509051|Experimental|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
2409360|NCT03509038|Experimental|Urinary incontinence before bariatric surgery|All patients with urinary incontinence before bariatric surgery will be addressed for a urodynamic exam
2409361|NCT03509025|Experimental|Long Term Follow-up after Jointstem Transplantation|
2409370|NCT03508999|Experimental|Metronidazole Gel|Group A subjects will be given standard oral hygiene instructions on the visit with a standard 0.8 % metronidazole gel instructed to apply topically on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2409371|NCT03508999|Other|SMS Text Reminder|Subjects will be provided biweekly reminder via SMS in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2409372|NCT03508999|Placebo Comparator|Placebo|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
2409373|NCT03508973|Experimental|Sculptra|Sculptra, an injectable implant containing microparticles of ply-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol and sterile water, will be injected into the decolletage.
2409374|NCT03508947|Experimental|WVE-210201 (Dose A) or placebo|
2409375|NCT03508947|Experimental|WVE-210201 (Dose B) or placebo|
2409376|NCT03508947|Experimental|WVE-210201 (Dose C) or placebo|
2409377|NCT03508947|Experimental|WVE-210201 (Dose D) or placebo|
2409378|NCT03508947|Experimental|WVE-210201 (Dose E) or placebo|
2409381|NCT03508921|Experimental|Periprocedural Antibiotics Only|Patients receive a one-time dose of antibiotics at the time of injection, prior to injection.
2409382|NCT03508921|Experimental|Extended Antibiotics|Patients receive a peri-procedural dose of antibiotics and an extended (3-day) course of antibiotics to be taken post-procedurally.
2409388|NCT03508882|Active Comparator|Preseptal-pretarsal|The Preseptal-pretarsal group will receive injections of Botulinum Toxin Type A 100Unit/Vial (Product) in the preseptal site (Injection pattern A) and Saline Solution for Injection (placebo control) in the pretarsal site for 2 cycles at 3 months apart. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
2409389|NCT03508882|Active Comparator|Pretarsal-preseptal|The Pretarsal-preseptal group will initially receive injections Botulinum Toxin Type A 100Unit/Vial (Product) in the reverse with the intervention at the pretarsal site (Injection pattern B) for 2 cycles at 3 months apart. Groups 1 and 2 will crossover and receive the alternative intervention. Both groups will crossover and receive the alternative intervention. Hence in the second half of the trial, the Preseptal-pretarsal group will be injected with BtA in Pattern B and Pretarsal-preseptal group will receive Pattern A.
2409390|NCT03508869|Active Comparator|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
2409391|NCT03508869|Active Comparator|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
2409392|NCT03508869|Active Comparator|Dysport® in conjunction with Mirvaso|Dysport® in conjunction with Mirvaso
2409393|NCT03508856|Experimental|Picato 0.015% gel|Picato 0.015% gel, is a topical treatment for actinic ketatoses.
3185330|NCT00733733|No Intervention|Control|Standard immunosuppressive treatment for renal transplantation including tacrolimus/MMF/prednisolone without ATG treatment.
3185331|NCT00733772|Experimental|A|healthy lifestyle counseling + 30 grams/day supplement of Flaxseed
3185332|NCT00733772|Sham Comparator|B|TLC diet
2409397|NCT03508817|Experimental|Atropine Sulfate 0.01% Eye Drops Group|Intervention group will receive atropine sulphate eye drops 0.01% once nightly for 2 years.
2409398|NCT03508817|No Intervention|Control group|Control group will not receive any medication.
2409399|NCT03508804|Experimental|Lidocaine-prilocaine cream|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the lidocaine-prilocaine cream vaginally using a syringe
2409400|NCT03508804|Placebo Comparator|Placebo cream (pain lucubrating gel)|5-10 minutes prior to the start of the procedure, the participant will self-administer 10ml of the placebo cream vaginally using a syringe
2409401|NCT03508791|Active Comparator|Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the Trendelenberg position
2409402|NCT03508791|Active Comparator|reverse Trendelenburg group|Arterial, end-tidal, and transcutaneous carbon dioxide partial pressure are monitored in the reverse Trendelenberg position
2409403|NCT03508778|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
2409404|NCT03508778|Active Comparator|PanOptix|Commercially available trifocal IOL implanted in the capsular bag of the eye during cataract surgery. Both eyes were implanted, with the second eye surgery occurring after the Week 1 follow up for the first eye surgery.
2409405|NCT03508765|Experimental|rsfMRI + Neurocognitive Tests|Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).
3185333|NCT00733785|Experimental|2mg tablet|2 mg tablet fasted
2409409|NCT03508726|Experimental|Phase I dose escalation/Phase II portion|"Phase 1 dose escalation:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation.~Phase II portion:~Patients will receive radiation therapy over 5 weeks, during which time they will be receiving intravenous (IV) ascorbate infusions three times a week. Ascorbate infusions will be continued until the end of radiation therapy. Surgery will be performed 4-6 weeks from the end of radiation."
2409472|NCT03508336||patients with disorders of consciousness|Patients with disorders of consciousness from several brain injury, assessed by Coma Recovery Scale-Revised (CRS-R), have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state.
3185334|NCT00733785|Experimental|4 mg tablet|4 mg tablet fasted
3185335|NCT00733785|Experimental|8mg tablet|8 mg tablet fasted
3185336|NCT00733785|Experimental|2 x 4 mg tablets|2 x 4mg tablets fasting
3185337|NCT00733785|Experimental|2 x 2mg tablets|2 x 2mg tablets fasting
3185338|NCT00733785|Experimental|8 mg tablet fed|8 mg tablet fed
3185339|NCT00733785|Experimental|Repeat dose|8 mg once a day for 6 days
3185340|NCT00733798|Experimental|1|
2409410|NCT03508713||early RA patients|patients must fulfill the 1987 ACR classification criteria for rheumatoid arthritis or 2010 Rheumatoid arthritis classification criteria of ACR/EULAR, and meet the condition that the course of disease was no more than 6 months. If enrolled, patients will be treated with disease modified antirheumatic drugs or biological agents.
2409411|NCT03508700|Experimental|TNX-102 SL 5.6 mg|2 tablets of TNX-102 SL 2.8 mg taken simultaneously and sublingually (under the tongue) each day at bedtime starting on Day 0 for 40 weeks
3185341|NCT00733811|Experimental|1|Sequential treatment including DFP at 75 mg/kg, divided into three oral daily doses, for four days per week and DFO by subcutaneous infusions (8-12h) at 50 mg/kg/day for the remaining three days per week
3185342|NCT00733811|Active Comparator|2|Deferiprone alone at 75 mg/kg divided into three oral daily doses
2409414|NCT03508674|Experimental|Intervention|Levita Magnetic Surgical System
3185343|NCT00733837|Experimental|A|This is a repeated measures study. All participants experience the same conditions.
2409416|NCT03508648|Placebo Comparator|Matching Placebo|Subjects previously enrolled in the placebo arm of study G201002.
2409417|NCT03508648|Active Comparator|1 mg GTx-024|Subjects previously enrolled in the 1 mg GTx-024 arm of study G201002.
2409418|NCT03508648|Active Comparator|3 mg GTx-024|Subjects previously enrolled in the 3 mg GTx-024 arm of study G201002.
2409419|NCT03508635|Experimental|SAD Cohorts 1 through 6|Participants will receive single doses of 5 mg up to 400 mg of CORT125134 (capsule) in a dose escalation format. The doses selected will be subject to amendment based on emerging data.
2409420|NCT03508635|Placebo Comparator|SAD Cohorts 1 through 6 Placebo|Participants will receive single doses of Matching Placebo of CORT125134 (capsule).
2409421|NCT03508635|Experimental|Food Effect Cohort 7|Participants will receive a single dose of CORT125134 (capsule) with a standard high fat breakfast. The dose will be chosen such that it has been previously administered in a prior SAD cohort.
2409422|NCT03508635|Experimental|Pharmacological Effect Cohort 8|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
2409423|NCT03508635|Experimental|Proof of Concept (POC) Cohort 9|Participants will receive a single dose of 25 mg of prednisone on Day -19; a single dose of 25 mg of prednisone and 600 mg of mifepristone on Day -12; and a single dose of 25 mg prednisone and a single dose of CORT125134 on Day 1. An oral glucose tolerance test will be administered on each study day. The dose of CORT125134 will be chosen such that it has been previously administered in a prior SAD cohort.
2409424|NCT03508635|Experimental|MAD Cohorts 10 and 11|Participants will receive the selected dose of CORT125134 (capsule) following receipt of data from Cohorts 1-9 up to a maximum frequency of twice a day for a total of 14 days.
2409425|NCT03508635|Placebo Comparator|MAD Cohorts 10 and 11 Placebo|Participants will receive Matching Placebo of CORT125134 (capsule) up to a maximum frequency of twice a day for a total of 14 days.
2409426|NCT03508635|Experimental|MAD of PoPE Cohorts 12 and 13|Proof of Pharmacological Effect (PoPE+POC). Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the selected dose of CORT125134 (capsule) for a total of 13 days. Participants may either receive a higher dose level than previously administered or a repeat of a dose level given in 1 of the previous 2 MAD Cohorts. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
2409427|NCT03508635|Placebo Comparator|MAD of PoPE Cohort 12 and 13 Placebo|Participants will receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day -5. Participants will then receive the Matching Placebo of CORT125134 (capsule) for a total of 13 days. Participants will then receive 25 mg of prednisone (both cohorts) and an oral glucose tolerance test (Cohort 13 only) on Day 14.
2409428|NCT03508622|Experimental|Telehealth|This group will receive weight management treatment via 12 online group sessions, over 6 months. They will have Bluetooth-enabled scales that will allow them to transmit their weight data to the PI in between research visits. They will answer questionnaires and have research visits at baseline, 3 months, and 6 months.
2409429|NCT03508622|Other|Empower|This retrospective control group received standard in-clinic individualized weight management with a multi-disciplinary group of providers, via 6 monthly clinic visits, over 6 months.
3185344|NCT00733850|Experimental|1|Kanglaite Injection plus Gemcitabine
2409431|NCT03508596|Experimental|Intervention|"Intervention group (IG)~An educational intervention for the supervisors"
2409432|NCT03508596|No Intervention|Control|control group (CG)
2409433|NCT03508596|No Intervention|Non-Intervention|group without intervention (GWI)
2409434|NCT03508583||Participation|"Parents will complete the The Measure of Processes of Care 56- 20 (MPOC 56-20) questionary~Service providers will complete The Measure of Processes of Care for Service Providers (MPOC-SP)"
2409435|NCT03508570|Experimental|Group I (nivolumab)|Patients receive nivolumab i.p. over 90 minutes on days 1, 15, and 29. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2409436|NCT03508570|Experimental|Group II (nivolumab and ipilimumab)|Patients receive nivolumab as in group I and ipilimumab i.p. on day 1. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2409438|NCT03508544|Active Comparator|Lumbar ESP block|Ultrasound-guided lumbar Erector spinae plane (ESP) block performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2409473|NCT03508323|Experimental|Teneligliptin|
2409474|NCT03508323|Placebo Comparator|Placebo|
2409616|NCT03507322||Ultrasound texturization|Application of ultrasound texturization (2D/3D ultrasound scanning)
3185345|NCT00733850|Active Comparator|2|Gemcitabine
3185346|NCT00733863|Experimental|1|
3185347|NCT00733863|Placebo Comparator|2|
3185348|NCT00733876|Experimental|A|
3185349|NCT00733889|Experimental|1|
2409439|NCT03508544|Active Comparator|QLB Block|Ultrasound-guided transmuscular quadratus lumborum block (QLB) performed at the begining of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed
2409440|NCT03508544|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2409441|NCT03508531|Active Comparator|ESP Block|Ultrasound-guided bilateral Erector spinae plane block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2409442|NCT03508531|Active Comparator|OSTAP Block|Ultrasound-guided bilateral OSTAP block performed at end of the surgery with 40 ml of a bupivacaine/lidocaine mixture. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2409443|NCT03508531|Sham Comparator|Control|Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed. No block will be performed in this group.
2409444|NCT03508518|Experimental|Shared care device in psychiatry (DSPP)|System focused on collaboration between general medicine (GP) and psychiatry, offering psychiatric assessment consultations and guidance for patient addressed by his/her GP. Referrals are made to the GP with support for care or the patient can be oriented to routine psychiatric care.
2409445|NCT03508518|Active Comparator|Care as usual|"Patient will have usual care :~Psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center"
2409446|NCT03508492|Active Comparator|Knee surgeons|Four knee surgeons
2409447|NCT03508492|Active Comparator|Hip surgeons|Six hip surgeons
2409448|NCT03508492|Active Comparator|Cardiac surgeons|6 cardiac surgeons
2409449|NCT03508492|Active Comparator|Colon surgeons|6 colon surgeons
2409450|NCT03508479|Experimental|RG-HRV16 Inoculation|While wearing a dental bib, subjects will be asked to blow the nose prior to inoculation. With the head tilted back, a total of 0.5 mL (0.25 mL/nostril) will be administered using the MAD Nasal™ Intranasal Mucosal Atomization Device. Subjects instructed not to blow nose for 30 minutes afterwards.
2409451|NCT03508466||Group 1|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to intravenous ferric carboxymaltose (Ferinject)
2409452|NCT03508466||Group 2|adult participants from 18-65 years of age previous intravenous ferric carboxymaltose (Ferinject) and no hypersensitivity reaction
2409453|NCT03508466||Group 3|adult participants from 18-65 years of age previous hypersensitivity reaction grades I-IV to iron sucrose (Venofer)
2409454|NCT03508466||Group 4|adult participants from 18-65 years of age previous intravenous iron sucrose (Venofer) and no hypersensitivity reaction
2409455|NCT03508453|Active Comparator|IC14 (monoclonal anti-CD14 antibody)|IC14 4 mg/kg intravenously twice weekly for 12 weeks
2409456|NCT03508453|Placebo Comparator|Placebo|Placebo intravenously twice weekly for 12 weeks
2409457|NCT03508440|Active Comparator|Standard of Care|Oral steroids (prednisone or prednisolone) 60mg per day for 10 days or 60mg/day for 5 days followed by a 5 day taper
2409458|NCT03508440|Experimental|SOC + injection|Oral steroids as described above + intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks.
2409459|NCT03508440|Other|Injection only|Only Intratympanic injection of dexamethasone (up to 1cc of 24mg/ml) - 3 injections over three weeks
2409460|NCT03508427|Experimental|Toi Même plus treatment as usual|"One-Arm study Intervention: Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.~Tool: Toi Même mobile app"
2409461|NCT03508414|Experimental|Ketogenic diet|
2409462|NCT03508414|Experimental|Intermittent therapeutical fasting|
2409463|NCT03508414|Active Comparator|Control group|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
2409464|NCT03508401|Experimental|ICU intubated patients|"After inclusion, Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). The left ventricular outflow tract velocity time index (LVOT TVI) will be measured with this device. Then, a passive leg raising (PLR) will be performed and finally LVOT VTI will be measured again after PLR~Patients will be classified in two groups according to the hemodynamic response to PLR :~Patients are responders if LVOT VTI increases of at least 10% after PLR~patients are non-responders if LVOT VTI does not increase or increase of less than 10% after PLR."
2409465|NCT03508375|Experimental|SSc without ILD|
2409466|NCT03508375|Experimental|SSc with ILD|
2409467|NCT03508375|Active Comparator|patients with idiopathic pulmonary fibrosis|
2409468|NCT03508362|Experimental|Drug user|Regular use of cocaine
2409469|NCT03508362|Active Comparator|Healthy volunteers|non-drug user
2409470|NCT03508349|Experimental|IST using RDT|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the intervention group (IST+ routine care) will be tested for malaria at the health center during their ANC visits with an RDT. If positive, they will be treated with artemisinin-based combination therapy (ACT) in second or third trimester or quinine in the first trimester.
2409471|NCT03508349|No Intervention|Routine Antenatal Care|Women presenting for their first ANC visit to facilities will be consecutively enrolled after providing informed consent. Women in the comparison group (routine care) will receive routine antenatal care services per the national guidelines. They will not be tested for malaria at each antenatal care visit unless they are symptomatic for malaria.
2409516|NCT03507972|Other|Ankle ultrasound & ankle MRI|Ankle ultrasound performed on the day of emergency consultation member MRI (without injection of contrast products) performed within 7 days following the trauma
2409475|NCT03508310|Experimental|Intervention|29-minute clinic waiting room video intervention that includes three vignettes and a 2-part animation sequence about main characters who model overcoming challenges to optimal HIV care. The video was played on continuous loop in recognition of typically short patient wait times. Waiting room posters used images from the video to direct patients' attention to the video and reinforce prevention messages.
2409476|NCT03508310|No Intervention|Comparison|Historical comparison condition. Patients were exposed to standard waiting room environment (absent of intervention video and posters).
2409477|NCT03508284||Patients with Multiple Sclerosis|MS patients (EDSS: 0-5,5)
2409478|NCT03508284||Healthy group|Healthy individuals without chronic disease
2409479|NCT03508271||Elderly individuals with NVAF and HF who are taking OAC's|
2409480|NCT03508258||Participants with NVAF starting Apixaban|
2409481|NCT03508258||Participants with NVAF starting Warfarin|
2409482|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength light therapy
3185350|NCT00733915|Experimental|Single arm|Cohort of total knee replacements with LCS Complete knee implants
3185351|NCT00733928|Other|1 - All Polyethylene Tibia|Total knee replacement with an all polyethylene tibial tray
2409485|NCT03508219|Experimental|BiOSS LIM C|The treatment strategy consists of contemporary PCI of the left-main bifurcation, using the BiOSS LIM C stent system, following diagnostic angiography demonstrating significant distal unprotected left main disease and local Heart Team discussion applying the anatomic SYNTAX Score.
2409486|NCT03508206|Experimental|SBRP arm|Food supplement in hard gelatin capsule form containing a Standardized botanical blend rich in polyphenols (SBRP)
2409487|NCT03508206|Placebo Comparator|Placebo arm|Hard gelatin capsule form containing maltodextrin, with the same appearance as SBRP capsules
2409488|NCT03508193|Experimental|Intervention|Whole-foods based smoothie as nutritional therapy
2409489|NCT03508180|Experimental|foot reflexology|patients WITH foot reflexology session during chemotherapy treatments
2409490|NCT03508180|Placebo Comparator|platinum-based treatment|Patients WITHOUT ANY foot reflexology session during chemotherapy treatments
2409491|NCT03508167|Experimental|Thermal Band plus Dorilax®|
2409492|NCT03508167|Other|Thermal Band plus Placebo|
2409493|NCT03508154|Active Comparator|Control Meal 1|Control carbohydrate solution
2409494|NCT03508154|Active Comparator|Control Meal 2|Control carbohydrate solution
2409495|NCT03508154|Experimental|Experimental Nutritional Product|Study nutritional formulation
2409496|NCT03508141|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 60mg/kg FC FIBTEM A5 1-4mm = 50mg/kg FC FIBTEM A5 5-6mm = 40mg/kg FC FIBTEM A5 7-8mm = 30mg/kg FC FIBTEM A5 9-10mm = 20mg/kg FC
2409497|NCT03508141|Active Comparator|Cryoprecipitate|Fibrinogen Replacement using Cryoprecipitate as per ROTEM (FIBTEM) FIBTEM A5 0mm = 6ml/kg Cryoprecipitate FIBTEM A5 1-4mm = 5ml/kg Cryoprecipitate FIBTEM A5 5-6mm = 4ml/kg Cryoprecipitate FIBTEM A5 7-8mm = 3ml/kg Cryoprecipitate FIBTEM A5 9-10mm = 2ml/kg Cryoprecipitate
2409498|NCT03508128||Micra subjects|Surgical procedure
2409499|NCT03508102|Experimental|Remifentanil 1 μg kg-1 (R1)|Received remifentanil 1μg/kg when induction of general anesthesia
2409500|NCT03508102|Experimental|Remifentanil 0.5 μg kg-1 (R0.5),|Received remifentanil 0.5μg/kg when induction of general anesthesia
2409501|NCT03508102|No Intervention|saline (control)|Injected the equal volume normal saline when induction of general anesthesia
2409502|NCT03508089|Other|Control Arm|
2409503|NCT03508089|Active Comparator|Multiple Sclerosis Arm|
2409504|NCT03508076|Sham Comparator|Sham Capsule|Patients swallowed 1 sham Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2409505|NCT03508076|Experimental|Vibration Capsule of low level|Patients swallowed 1 low level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2409506|NCT03508076|Experimental|Vibration Capsule of high level|Patients swallowed 1 high level vibration Capsule Vibrating capsule with water every three days，recorded his defecation time, defecation frequency and bristol score.The total capsule need to take 12.
2409507|NCT03508063||Healthy population|Healthy subjects receiving stimuli (thermal stimuli and stressogenic physical stimuli) at rest, and being monitored MCPM.
3185352|NCT00733928|Active Comparator|2 - Poly & Metal Tibia|Total knee replacement with a metal-backed tibial component
3185353|NCT00733941|Experimental|High frequency training|24 interval exercises performed 8 times per week
2409510|NCT03508037|Experimental|Experimental group|The subject receives the Functional Electrical Stimulation (FES) when he or she has the intention to move. It is obtained through electroencephalography.
2409511|NCT03508037|Active Comparator|Control group|The subject receives the Functional Electrical Stimulation (FES) after o before (0.5 seconds) when he or she has the intention to move. It is obtained through electroencephalography.
2409512|NCT03508011|Experimental|IMP4297|
2409513|NCT03507998|Experimental|CGX1321 Dosing|"Dose Escalation Phase: Ascending doses of CGX1321 will be administered by cohort to determine the maximum tolerated dose. Patients will receive CGX1321, once daily, orally, for 3 weeks (21 days) followed by a one week (7 day) washout period in each 28 day cycle, according to the cohort they are assigned.~Dose Expansion Phase: Patients will receive the recommended dose (identified in the Dose Expansion Phase) of CGX1321"
2409514|NCT03507985||The exposed group|The exposed group where patients receive morphine analgesia The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later.
2409515|NCT03507985||The unexposed group|"The unexposed group where patients receive 1 +/- 2-stage analgesia is non-opioid analgesics.~The patient will realise two tests evaluating memory and attention, for the first at the inclusion visit after giving his consent, and in a second time during the follow up visit 15 days or 1 month later."
2409614|NCT03507335||Atrial fibrillation|Patients with atrial fibrillation during measurements
3185354|NCT00733941|Experimental|Normal frequency training|24 interval exercises performed 3 times per week
3185355|NCT00733967|Placebo Comparator|Placebo|Matching oral placebo capsules as control.
2409517|NCT03507959|Experimental|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
2409518|NCT03507959|Experimental|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
2409519|NCT03507959|Experimental|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
2409520|NCT03507959|Experimental|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
2409521|NCT03507959|No Intervention|Control group|This group does not take the nasal spray.
2409522|NCT03507946|Experimental|Test|"Subject self control; Plaque 1: Dermawrap - combined 460nm, 633nm, and 830nm LED therapyDaily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.~Plaque 2: No Intervention"
2409523|NCT03507920|Experimental|Neck passive mobilizations|
2409524|NCT03507920|Placebo Comparator|Manual contact|
2409525|NCT03507907|Experimental|Study Group|Mulligan mobilization techniques were applied to the older adults.
2409526|NCT03507907|Other|Control Group|Conventional physiotherapy programs were applied to the older adults who included in control group.
2409527|NCT03507894||m-health stroke rehabilitation|8-week multimodal exercise rehabilitation program (MERP) based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
2409528|NCT03507881||Ennovate|Implantation of an Ennovate® internal fixation
2409529|NCT03507868||Group 1|Periodontally healthy individuals
2409530|NCT03507868||Group 2|Chronic periodontitis patients
2409531|NCT03507855|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
2409532|NCT03507855|Active Comparator|Control|Normal operating room environment.
2409533|NCT03507842|Experimental|High-dose cytarabine|High-dose cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
2409534|NCT03507842|Experimental|high-dose daunorubicin|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7) plus high-dose daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
2409535|NCT03507829|Active Comparator|Basal insulin|NPH Insulin Titration Regimen : Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
2409536|NCT03507829|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
2409537|NCT03507829|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
2409538|NCT03507803|Experimental|Gait Biofeedback|This group will receive audiovisual feedback about the position of their foot during walking. Feedback will be provided over 8 total sessions.
2409539|NCT03507803|No Intervention|Control|This arm will not receive any audiovisual feedback about the position of their foot during walking.
2409540|NCT03507790|Active Comparator|Active Treatment- CT1812 100 mg|CT1812 at a dose of 100 n=40 group
2409541|NCT03507790|Active Comparator|Active Treatment- CT1812 300 mg|CT1812 at a dose of 300mg, n=40 group
2409542|NCT03507790|Placebo Comparator|Placebo Comparator - Placebo|Placebo, n=40 group
2409543|NCT03507777|Active Comparator|Coronary PCI guided by OCT|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with OCT guidance according to the algorithm described in the protocol. OCT imaging is required pre and post stent implantation.~At the end of the procedure, a final OCT imaging run must be performed."
2409544|NCT03507777|Active Comparator|Coronary PCI guided by Angiography|"Intervention = Coronary stenting with planned drug eluting stent (DES).~Stenting will be performed with angiography guidance according to local standard practice.~At the end of the procedure, a blinded OCT shall be performed to document final stent dimensions and results."
2409545|NCT03507764|No Intervention|Control Group|"During the randomized study phase (6 months),subjects will perform their usual activity without access to the treadmill workstation in the dispatch center.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation at the workplace."
2409546|NCT03507764|Experimental|Experimental Group|"During the randomized study phase, subjects will have an open access to the treadmill workstation with the indication to use it for at least one hour (continuous or split) on working days.~After six months, all subjects will continue to be assessed with free access to the treadmill workstation."
2409547|NCT03507751||Meropenem|Patients who require meropenem and CRRT during ICU (intensive care unit) stay
2409548|NCT03507738|Experimental|Adult MT-5625 middle dose|Adult receiving intramuscular injection with either middle dose of MT-5625 or placebo
2409549|NCT03507738|Experimental|Adult MT-5625 high dose|Adult receiving intramuscular injection with either high dose of MT-5625 or placebo
2409550|NCT03507738|Experimental|Toddler MT-5625 middle dose|Toddler receiving intramuscular injection with either middle dose of MT-5625 or placebo
2409551|NCT03507738|Experimental|Toddler MT-5625 high dose|Toddler receiving intramuscular injection with either high dose of MT-5625 or placebo
2409552|NCT03507738|Experimental|Infant MT-5625 low dose|Infant receiving intramuscular injection with either low dose of MT-5625 or placebo
2409553|NCT03507738|Experimental|Infant MT-5625 middle dose|Infant receiving intramuscular injection with either middle dose of MT-5625 or placebo
2409554|NCT03507738|Experimental|Infant MT-5625 high dose|Infant receiving intramuscular injection with either high dose of MT-5625 or placebo
2409555|NCT03507738|Active Comparator|Rotarix|Infant receiving oral administration with Rotarix
2409615|NCT03507335||Sinus|Patients with sinus rhythm during measurements
2409617|NCT03507309||To be specified by Steering Committee.|
2409558|NCT03507712|Active Comparator|Symmetrical IO weakening.|Same surgery in both eyes
2409559|NCT03507712|Active Comparator|Asymmetrical IO weakening.|Different amounts or different surgery in each eye
2409560|NCT03507699|Experimental|Immunotherapy alone|Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg.
2409561|NCT03507699|Experimental|Combined radiotherapy and immunotherapy|"Liver radiation therapy: three treatments to one liver metastasis, administered on alternate days.~Nivolumab will be administered at a dose of 3mg/kg every 2 weeks. Ipilimumab will be administered at a dose of 1mg/kg every 6 weeks. CMP-001 will be administered both into the liver metastasis (once), and also injected subcutaneously (four times, over six weeks) at a dose of 5-10 mg."
2409562|NCT03507686|Experimental|BIIB111|Participants will receive a single dose of sub-retinal injection of BIIB111 in each eye at Day 0 separated by an interval of <6 months, 6-12 months, or >12 months.
2409567|NCT03507660|Experimental|verbal instruction|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles.~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~squeeze the anus~shorten the penis~elevate the scrotum"
3185356|NCT00733967|Active Comparator|Varenicline|See assigned interventions.
3185357|NCT00734045||1|Subjects with diagnosed congestive heart failure
2409570|NCT03507634|Active Comparator|Opioid Based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl and Sevoflurane.
2409571|NCT03507634|Active Comparator|Opioid Free Anesthesia|General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine and Sevoflurane.
2409572|NCT03507621||Propofol Group|1- Propofol Group: Propofol group will use 1 mg / kg propofol for the patient.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete .
2409573|NCT03507621||Sevoflurane Group|1- Sevofluran Group: sevoflurane was administered at one minimum alveolar concentration (MAC) to end-tidal concentrations of 3% to 5%.Preoperative blood will be taken from the patients and cortisol, acth, glucagon, aldosterone, adrenalin, noradrenalin, PGE2, CRH will be studied. During the operation, the patient's systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, oxygen saturation will be followed. Analgesia will be provided according to the body movements of the patient and VAS measurement will be performed. Remifentanyl will be used as a anelgesic 0.5 mcg/ kg during operation. The patient's pain will be assessed by the VAS (Visuel Analogue Scale) scoring system and during the first hour postoperatively after the patient's consciousness is complete.
2409574|NCT03507608|Experimental|flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
2409575|NCT03507608|Placebo Comparator|placebo|placebo prior to brachytherapy and prostatic biopsy
2409576|NCT03507595||Patients with initial diagnosis of PCa|"T2 stage: PSA>20ng/ml, Gleason Score >= 8;~T3 or T4 stage;~The imaging examination was negative or localized metastasis of the pelvic lymph node, but there was no distant metastasis of lymph nodes or bone and internal organs other than the pelvic cavity."
2409577|NCT03507595||Patients with biochemical recurrent PCa|"After the RRP surgery,the serum PSA was over 0.2 ng/ml in two consecutive sera;~After the radiotherapy: the lowest PSA is up to 2 ng/ml."
2409578|NCT03507595||Patients with CRPC|"The serum testosterone is in the castration level (< 50 ng/dL or < 1.7 nmol/L);~The PSA is elevated 3 times in a row, the base value is increased by more than 50%, and the PSA > 2ng/mL(the interval is one week);~The continuation of the anti-androgen drugs, flunamine was stopped for at least 4 weeks, and biglumide was suspended for at least 6 weeks;~Despite the continued standard androgen deprivation therapy, the PSA is still progressing."
2409579|NCT03507582|Active Comparator|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
2409580|NCT03507582|Active Comparator|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
3185358|NCT00734045||2|Subjects not diagnosed with congestive heart failure
3185359|NCT00734058|Experimental|Persistent AF|Treatment arm to be compared with historical control.
3185360|NCT00734084|Other|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
2409582|NCT03507556|Experimental|Triple paste and induced bleeding|The triple paste is a mixture of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol will be used and next visit intracanal bleeding will be induced
2409583|NCT03507543|Experimental|IMP4297|
2409584|NCT03507504||care pathway with SCU-B|250 patients with dementia and behavioural and psychological symptoms of dementia (BPSD) followed up by six clinical centres with a Special Care Unit for BPSD (SCU-B)
2409585|NCT03507504||care pathway without SCU-B|250 patients with dementia and BPSD followed up by six clinical centres without SCU-B
3144827|NCT00053027|Experimental|rituximab + cladribine|"Patients receive rituximab IV over 4-8 hours on day 1 and cladribine IV over 2 hours on days 4-8. If 2 or more patients experience unacceptable toxicity during the first course, the study is discontinued; otherwise, the study is opened for enrollment at all NCCTG sites.~Treatment repeats every 28 days for a total of 2-6 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually for 2 years."
2409587|NCT03507478|Experimental|BPI1000013|Subjects suffering from pain associated with plantar fasciitis or general heel pain
2409588|NCT03507465|Experimental|Letrozole Plus Low-Dose Metronomic Capecitabine|
2409589|NCT03507465|Active Comparator|EC-T|
3144828|NCT00053040|Experimental|Surgery for tumor resection + IL13-PE38QQR infusion|
3144829|NCT00053053|Experimental|Juven supplement|Juven nutritional supplement given twice a day for 8 weeks
3144830|NCT00053053|Active Comparator|Non-Juven supplement|Non-Juven nutritional supplement given twice a day for 8 weeks
3144831|NCT00053196|Experimental|Non myeloblative allogeneic transplant|Non myeloblative allogeneic hematopoietic cell transplantation after prior autologous transplantation
3144832|NCT00053209|Experimental|Pemetrexed Disodium and Gemcitabine|Pemetrexed disodium 500 mg/m2 followed by gemcitabine 1000 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on day 8 of a 21-day cycle for a maximum of 6 cycles
3144833|NCT00053222|Experimental|Arm A|Arsenic trioxide (0.3 mg/kg/day iv for 5 days every 28 days)
3144834|NCT00053235||Ancillary-Correlative|Genomic DNA is isolated from OCT-embedded tissue and analyzed using comparative genomic hybridization. The chromosomal changes identified by this method are compared to those identified using the Taqman method, a quantitative genomic polymerase chain reaction analysis. Chromosome 8q is of specific interest. Other chromosomal changes may be detected in chromosomes 3q, 7q, 16q, and/or 17pter-q21.
2409597|NCT03507439|Experimental|Heart failure patients|Patients with worsening heart failure (HF) and recent hospitalization for the treatment of HF or patients with chronic stable HF with either preserved (EF ≥ 45%) or reduced ejection fraction (EF ≤ 35%)
2409598|NCT03507426|Active Comparator|Retrobulbar group|Retrobulbar block
2409599|NCT03507426|Active Comparator|Ketamine group|Intravenous analgesia
2409600|NCT03507426|No Intervention|Control group|General anesthesia alone
2409601|NCT03507413|Active Comparator|INVESTIGATIONAL DRUG|oral metformin treatment with 2000Mg daily: Glucophage 500mg Tablet (2-0-2) daily for 1 year
2409602|NCT03507413|Placebo Comparator|COMPARATIVE DRUG|Placebo matching M90 Oral Tablet treatment twice daily (2-0-2) for 1 year
2409603|NCT03507400|Experimental|non-waiting list group|Intervention: Introvision: mental and emotional self-regulation
2409604|NCT03507400|Experimental|waiting list group|"Intervention: Introvision: mental and emotional self-regulation~Introvision is teached to participants of the waiting-list group at least 6 weaks or more after first group"
2409605|NCT03507387|Experimental|Intramuscular phenylephrine group|Patients in intramuscular phenylephrine group will receive spinal anesthesia with bupivacaine. 5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
2409606|NCT03507387|Active Comparator|Intravenous phenylephrine group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed.
2409607|NCT03507387|Placebo Comparator|Placebo group|Patients in intravenous phenylephrine group will receive spinal anesthesia with bupivacaine. 1ml of 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia. 1ml of 0.9% normal saline intravenous injection will be given after the subarachnoid injection is completed.
2409608|NCT03507374|Placebo Comparator|Placebo Comparator|After review of eligibility criteria, 20 patients will be randomized to the placebo arm of the study where patient will administer one subcutaneous injection of placebo every two weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg.
2409609|NCT03507374|Active Comparator|Active Comparator|After review of eligibility criteria, 20 patients will be randomized to receive the investigational treatment of alirocumab 150mg which will be administered subcutaneously with a single-dose pre-filled pen syringe every 2 weeks for a total of 52 weeks. Additionally, per standard-of-care, patient will also be treated with atorvastatin 40-80 mg
2409610|NCT03507361|Experimental|MUSIC|Music will be administered through a normal computer equipped with a technology (Sound-of-Soul) that translates the patient's heart rate variability (HRV) into sounds according to a digital computer music-library. Music will start 10 minutes before and will end at the completion of the interventional procedure
2409611|NCT03507361|No Intervention|DUMB EARPHONES|Dumb earphones will be placed over patient's ears starting 10 minutes before and ending at the completion of the interventional procedure.
2409612|NCT03507348|Other|Desensitization with Tocilizumab and rituximab (MFI >15000)|
2409613|NCT03507348|Other|Desensitization with Rituximab only (MFI<15000)|
3144835|NCT00053326|Experimental|Treatment (fenretinide)|Patients receive oral fenretinide 3 times daily (or 2 times daily if over 18 years of age) on days 1-7. Treatment repeats every 3 weeks for up to 30 courses in the absence of disease progression or unacceptable toxicity.
3144836|NCT00053339|Experimental|trastuzumab|"Patients receive trastuzumab (Herceptin) IV over 60-90 minutes on day 1.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
2409620|NCT03507270|Other|FABP group|Coronary angiography and PCI (according to indications).
2409621|NCT03507257||Early Onset Alzheimer's Disease (EOAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid positive status (florbetaben PET scan with evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
2409622|NCT03507257||Cognitively Normal (CN) Controls|"Meets criteria for cognitively normal, based on an absence of significant impairment in cognitive functions and activities of daily living~Mini-Mental State Exam score between 26-30~CDR score = 0~flortaucipir (18F-AV-1451) PET scanning"
2409623|NCT03507257||Early Onset non-Alzheimer's Disease (EOnonAD)|"Diagnosis of NIA-AA criteria of MCI due to AD or probable AD dementia~Amyloid negative status (florbetaben PET scan with no evidence of elevated amyloid as determined by a central read)~CDR score ≤ 1.0~flortaucipir (18F-AV-1451) PET scanning"
2409624|NCT03507244|Experimental|Group 1,Intra-pemetrexed, radiotherapy|The treatment regimen consisted of intrathecal chemotherapy (via lumbar puncture, pemetrexed 10 mg, plus dexamethasone 5 mg, once per week, 5-8 times, 4-7 weeks in total) and radiotherapy. Radiotherapy consisted of fractionated, conformal radiation given at a daily dose of 2 Gy. The planning volume consisted of sites of symptomatic disease, bulky disease observed on magnetic resonance imaging, including the whole brain and basis cranii received 40 Gy in 20 fractions, 4 weeks in total, and/or segment of spinal canal received 40-50 Gy.
2409625|NCT03507231|Active Comparator|Control|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination.
2409626|NCT03507231|Experimental|Direct Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for Vaccination ($5 Amazon Gift Card).
2409627|NCT03507231|Experimental|Indirect Incentive|Participants will receive an E-mail Message encouraging them to get vaccinated, and asking them to indicate if they intend to do so and to complete a brief questionnaire after vaccination. They are offered an Incentive for completing a short survey ($5 Amazon Gift Card).
2409628|NCT03507218||1|Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
2409629|NCT03507205||HOST-BIOLIMUS-Korea-3000|Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
2409630|NCT03507205||EXCELLENT-PRIME|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
2409631|NCT03507205||EXCELLENT Prospective cohort|Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
2409632|NCT03507205||HOST-RESOLINTE|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
2409633|NCT03507205||RESOLUTE-Korea|Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
2409634|NCT03507192|No Intervention|Arm 1|30 subjects In arm 1, no intervention is performed.
2409635|NCT03507192|Active Comparator|Arm 2|30 patients In arm 2 , active comparators, Muscle relaxation using full body massage machine is performed every morning and evening for 30 minutes.
2409636|NCT03507179|Placebo Comparator|conventional dentures|a complete denture made through conventional processing technique
2409637|NCT03507179|Active Comparator|3d printed dentures|a complete denture made through 3D printing
2409638|NCT03507166|Experimental|RC48-ADC|Participants will receive RC48-ADC every 2 weeks (Q2W) until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participant decision to withdraw from therapy, or death (whichever occurs first).
2409639|NCT03507153|Active Comparator|Bre-fllex group|Maxillary class III modification I edentulous patients that will recieve Bre-flex partial denture
2409640|NCT03507153|Experimental|PEEK group|Maxillary class III modification I edentulous patients that will recieve PEEK partial denture
2409641|NCT03507127|Active Comparator|Varenicline|
2409642|NCT03507127|Placebo Comparator|Placebo|
2409643|NCT03507114|Experimental|Rumination-Focused CBT (RFCBT)|RFCBT seeks to change the process of thinking as opposed to the content of thoughts as in standard CBT. The underlying idea is that shifting individuals repetitive negative thinking into the concrete mode will reduce unconstructive ruminations and worries.
2409644|NCT03507114|No Intervention|Wait List Control Group|This arm represents the wait-list comparison group.
2409646|NCT03507088|Experimental|fulvestrant|500mg fulvestrant on days 0, 14, 28 and every 28 days thereafter Fluoroestradiol-PET is performed at baseline and after 28 days
2409647|NCT03507075|Active Comparator|Contingent|The Contingent group will receive nearly immediate monetary payments over the internet each day they remotely provide negative breathalyzer samples, but will not receive the payments if they provide positive samples or fail to provide samples in a timely manner.
2409648|NCT03507075|Sham Comparator|Noncontingent|The Noncontingent group will receive payments each day they successfully provide samples independent of the alcohol content of those samples.
2409649|NCT03507062|Experimental|Chloride-rich solution|Patients will receive two boluses of 10 and 20 ml/kg of the 0.9% saline in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2409650|NCT03507062|Experimental|Low-chloride solution A|Patients will receive two boluses of 10 and 20 ml/kg of Ringer's lactate in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2409680|NCT03506880|Active Comparator|Surgeon General Materials|Information published by the Surgeon General about teens and drinking
2409681|NCT03506880|No Intervention|Control|TAU
2409651|NCT03507062|Experimental|Very low-chloride solution|Patients will receive two boluses of 10 and 20 ml/kg of a plasmalyte-like solution (namely soluzione elettrolitica reintegrante [SER]) in two different moments after at least 1 hour from each other. Plasma arterial blood gas (ABG) and electrolytes, along with plasmatic creatinine, albumin and phosphate will be measured immediately before and five minutes after fluid boluses. Urinary electrolytes (Na, K, Cl) will be measured immediately before fluid bolus and after one hour from fluid administration along with ABG and plasmatic electrolytes and creatinine, phosphate and albumin.
2409652|NCT03507049|Active Comparator|Intervention group|The intervention Group receives operation with SI-joint arthrodesis with the iFuse implant. The patient undergoes full anesthesia. The procedure starts with an approximately 5cm long skin incision over the posterolateral aspect of the pelvis. A guide-pin is inserted over the sacroiliac joint at the desired entry-point, verified by fluoroscopy. The surgeons drills and boraches over the pin and the ifuse implant is inserted. This is repeated for a total of three implants. The wound is closed with non-resorbable suture. An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure.
2409653|NCT03507049|Sham Comparator|Sham group|"The sham operation will consist of the surgeon making the same skin incision as for an iFuse procedure, although nothing more, and then closing the wound.~The patients undergoing a sham operation will be under general anesthesia for a random time of 20-40minutes in order to keep the two procedures as similar as possible.~An injection of the SIJ with local anesthetic is performed under guidance of fluoroscopy at the time of the procedure."
2409654|NCT03507049|Other|Functional MRI study|The Swedish patients will also undergo quantitative sensory testing at inclusion and at 6 month follow-up. At the same time they will undergo a cerebral MRI and a Functional MRI looking at activation of the CNS from pain in the sacroiliac joints induced by one leg lift. The purpose of this study is to look at contributing factors in treatment response. One hopes to map which CNS mechanisms are involved in causing the chronic pain these patients experience as well as how they respond to treatment.
3185361|NCT00734110|Experimental|P.F.C. Sigma Total Knee Replacement System|Primary total knee arthroplasty using the fixed bearing P.F.C. Sigma Total Knee Replacement System.
2409656|NCT03507023|Placebo Comparator|Placebo Control|2 capsules per day, each with 400 mg Cellulose microcrystalline, for 6 weeks.
2409657|NCT03507023|Experimental|Dietetic Supplement Group|2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 6 weeks.
3144837|NCT00053339|Experimental|trastuzumab + tamoxifen|"Patients receive trastuzumab V over 60-90 minutes on day 1 and oral tamoxifen once daily on days 1-21.~In both arms, treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years."
3144838|NCT00053430|Experimental|1|Participants will receive low dose thalidomide for 28 days
2409660|NCT03506997|Experimental|Pembrolizumab|Pembrolizumab will be given at a dose of 200mg IV every 3 weeks for a maximum of two years
2409661|NCT03506984|Experimental|Group A|the participant will do a program of inspiratory muscle training for 10-15 minutes once daily using Threshold Inspiration Muscle Training Device
2409662|NCT03506984|Experimental|Group B|the participant will start cycling slowly for five minutes without resistance at the beginning of the exercise as warming up, then the active phase will last 20-30 minutes, then decrease the speed with no resistance at the end of the exercise as cooling down using Electronic Bicycle Ergometer
3144839|NCT00053430|Placebo Comparator|2|Participants will receive low dose thalidomide placebo for 28 days
3144840|NCT00053508|Experimental|Group 1|ACAM1000
2409665|NCT03506958||General Practice|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the general practice Zorgplein Lemmer.
2409666|NCT03506958||Hospital|Hundred patients with an X-ray confirmed diagnosis of a non-complex fracture or dislocation and planned to be treated in the Antonius Hospital Sneek.
2409667|NCT03506945|Experimental|mPEP|Behavioral Activation Therapy - Increase engagement in pleasant activities
2409668|NCT03506945|Active Comparator|Bibliotherapy|Bibliotherapy - Develop improved coping and problem-solving skills
2409669|NCT03506932|Experimental|Untreated|Bread containing 20% yellow pea flour.
2409670|NCT03506932|Experimental|Heat treated with 0% moisture|Bread containing 20% yellow pea flour.
2409671|NCT03506932|Experimental|Heat treated with 10% moisture|Bread containing 20% yellow pea flour.
2409672|NCT03506932|Active Comparator|Wheat|Bread made with 100% wheat flour
2409673|NCT03506919|Experimental|Arthitec 1|
2409674|NCT03506919|Experimental|Arthitec 2|
2409675|NCT03506906|Active Comparator|Conventional-approach|The non-invasive ventilation therapy will be optimized according to routine tests (blood gas analysis, lung function, ventilator's built-in software analysis)
2409676|NCT03506906|Experimental|Sleep studies-based approach|Additionally to the routine tests, the results of a nocturnal polysomnography and transcutaneous capnometry under the non-invasive ventilation therapy will be considered for the therapy optimization.
2409677|NCT03506893|Experimental|Alphapump|Alfapump® device implantation under general anesthesia (30-45 minutes)
2409678|NCT03506893|Active Comparator|Ascites puncture|Iterative paracentesis compensated for by albumin infusions in ambulatory care.
2409679|NCT03506880|Experimental|MADD Materials|Handbook developed by MADD and the PI to guide parents in discussing underage drinking, behaviors, and consequences with their teens
3144841|NCT00053508|Experimental|Group 2|ACAM1000
3144842|NCT00053508|Experimental|Group 3|ACAM1000
3144843|NCT00053508|Active Comparator|Group 4|Dryvax
3144844|NCT00053573|Experimental|1|
3144845|NCT00053625|Active Comparator|SA #1 Arm 1: Unilateral DBS in GPi|
3144846|NCT00053625|Active Comparator|SA #1 Arm 2: Unilateral DBS in STN|
3144847|NCT00053625|Active Comparator|SA #2 Arm 1: Bilateral DBS in GPi|Patients with GPi bilateral DBS (previously had unilateral DBS in the GPi, now have bilateral DBS in GPi)
3144848|NCT00053625|Active Comparator|SA #2 Arm 2: Bilateral DBS in STN|Patients with STN bilateral DBS (previously had unilateral DBS in the STN, now have bilateral DBS in STN)
3144849|NCT00053768|Active Comparator|CHOEP-21|"CHOEP-21-Schema:~Cyclophosphamid (750 mg/m2 i.v. d1), Doxorubicin (50 mg/m2 i.v. d1), Vincristin (2 mg i.v. d1), Etoposid (100 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
2409682|NCT03506867|Active Comparator|Usual care arm|We will provide the participants in this arm with pamphlets and knowledge about available services in the city through partner agencies. The life skills, training, and work arm will be offered to the usual care arm participants after the first six months of study enrollment.
2409683|NCT03506867|Active Comparator|Life skills, training, and work arm|Participants will receive life-skills workshops, training, education resources and access to small-paid or volunteering positions.
2409684|NCT03506854|Experimental|Normal Renal Function|Subjects with normal renal function will be matched by age (±10 years), weight (± 20%), and gender to the pooled mean values of subjects with the moderate renal impairment. Subjects will receive 1 dose of ISIS 681257.
2409685|NCT03506854|Experimental|Moderate Renal Impairment|Presence of moderate renal impairment (eGFR 30-59 mL/min/1.73m2). Subjects will receive 1 dose of ISIS 681257.
2409686|NCT03506841|Active Comparator|Cerbrolysin|Preterm infants with gestational age less than 32 weeks at birth will receive once weekly Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections) starting at the corrected postnatal age of 5 months.
2409687|NCT03506841|No Intervention|Control|Preterm infants with gestational age less than 32 weeks at birth will receive routine care.
2409688|NCT03506828|Active Comparator|Surgical sympathectomy|All patients in this group will have standard surgical procedure
2409689|NCT03506828|Active Comparator|Radiofrequency ablation with phenol injection|patient will receive radiofrequency ablation of T2 and T3 sympathetic ganglia + phenol 6% (0.5ml) injection
2409690|NCT03506815|Experimental|Rivaroxaban Thromboprophylaxis|Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.
2409691|NCT03506815|No Intervention|Standard of care|No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.
2409692|NCT03506802|Experimental|Treatment (Genetically engineered PBMC and PBSC)|Refer to outline
2409693|NCT03506789|Active Comparator|Treatment A:|24 mg dexamethasone i.v. perioperatively and 24 mg dexamethasone i.v. on the first postoperative day
2409694|NCT03506789|Active Comparator|Treatment B:|24 mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
2409695|NCT03506789|Placebo Comparator|Placebo|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
2409696|NCT03506776|Active Comparator|Education Only Group|The education only group will receive foot self-management education.
2409697|NCT03506776|Experimental|Education and Thermometer Group|The intervention group will receive foot self-management education. Additionally, the intervention group will receive a Commercially Available Infrared Thermometer (CAIT). Education on use of the CAIT will be provided through demonstration using a foot model and CAIT.
2409698|NCT03506763|Placebo Comparator|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
2409699|NCT03506763|Active Comparator|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
2409700|NCT03506763|Active Comparator|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
2409701|NCT03506750|Experimental|IVC-1day|patients with proliferative diabetic retinopathy receiving IVC 1 days before surgery
2409702|NCT03506750|Experimental|IVC-2day|patients with proliferative diabetic retinopathy receiving IVC 2 days before surgery
2409703|NCT03506750|Experimental|IVC-3day|patients with proliferative diabetic retinopathy receiving IVC 3 days before surgery
2409704|NCT03506750|Experimental|IVC-4day|patients with proliferative diabetic retinopathy receiving IVC 4 days before surgery
2409705|NCT03506750|Experimental|IVC-5day|patients with proliferative diabetic retinopathy receiving IVC 5 days before surgery
2409706|NCT03506750|Experimental|IVC-6day|patients with proliferative diabetic retinopathy receiving IVC 6 days before surgery
2409707|NCT03506750|Experimental|IVC-7day|patients with proliferative diabetic retinopathy receiving IVC 7 days before surgery
2409708|NCT03506750|Sham Comparator|IVC-sham|patients with proliferative diabetic retinopathy receiving sham IVC
2409709|NCT03506750|Placebo Comparator|non-DR|patients with other retinopathy (idiopathic macular hole or epiretinal membrane)
2409710|NCT03506737|Experimental|Conventional exercise protocol|Conventional global exercise
2409711|NCT03506737|Experimental|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise
2409714|NCT03506711|Active Comparator|T1DM Children and adolescents|Children and adolescents with Type 1 Diabetes Mellitus
2409715|NCT03506711|Active Comparator|Healthy Children and adolescents|Healthy community-dwelling children on no medication
2409716|NCT03506685|No Intervention|control group Standard ACL protocol|This group will receive the standard ACL protocol rehab
2409717|NCT03506685|Experimental|Dry needling and STM group|This group will also receive the standard ACL protocol in addition to STM and DN
2409718|NCT03506672|Experimental|Experimental group|Approach based on the meanings of vocal behaviours
2409719|NCT03506672|Active Comparator|Control group|Usual practices of formal caregivers regarding vocal behaviours
2409720|NCT03506659|Active Comparator|Test|2000 patients healthy in anesthesiology consultation
2409721|NCT03506659|Experimental|Patients|2000 patients in pain clinic consultation
2409724|NCT03506633|Experimental|MitoQ-Placebo|Subjects will be tested on two different days, first day will be baseline and MitoQ and second day will be Placebo. Testing will take place forty-minutes after MitoQ/placebo intake. There will be a 2-week washout between testing days.
2409842|NCT03505684|Placebo Comparator|Control group|1,000 mg of placebo (starch) was orally administered per day for 12 weeks
2409725|NCT03506633|Experimental|Placebo-MitoQ|Subjects will be tested on two different days, first day will be baseline and Placebo and second day will be MitoQ. Testing will take place forty-minutes after placebo/MitoQ intake. There will be a 2-week washout between testing days.
2409726|NCT03506620|Placebo Comparator|Control|Subjects will be randomized to receive a single-injection QL block with normal saline (Saline Solution for Injection).
2409727|NCT03506620|Experimental|QL Block|Subjects will be randomized to receive a single-injection QL block with either local anesthetic (0.25% Ropivacaine injection).
2409728|NCT03506607|Experimental|Exercise in hypoxia 1500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%.
2409729|NCT03506607|Experimental|Exercise in hypoxia 2500m|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%.
2409730|NCT03506607|Placebo Comparator|Exercise in normoxia|During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
2409731|NCT03506594|Active Comparator|Radiofrequency ON and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the vagina, using a condom and gel to the emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41° C, which this parameter will be placed in the equipment, maintained for 2 minutes at the anterior wall and 2 others minutes at the posterior wall. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in supine position. The session will be quick, with an average duration of 20 minutes. Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
2409732|NCT03506594|Placebo Comparator|Radiofrequency OFF and Kinesiotherapy|"The patient will be in supine decubitus, the vaginal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radiofrequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given."
2409733|NCT03506568|No Intervention|Control - no reminder|For Group 1, there will be no changes to their instructions or smart phone, which is the most common clinical situation.
2409734|NCT03506568|Experimental|Integrated daily reminder using the D3 app|For Group 2, they will have their D3 app turned on to deliver both a push notification reminder to their smart phone and audio and visual reminders to their D3 device.
2409735|NCT03506555|Active Comparator|the arm A (Veress needle)|a standard reusable Veress needle technique was performed for laparoscopic entry
2409736|NCT03506555|Active Comparator|the arm B (Hasson)|the standard open Hasson technique was performed for laparoscopic entry
2409737|NCT03506542|Experimental|Ologen (OLO)|Ologen implant (model 830601) placed over scleral flap during phacotrabeculectomy
2409738|NCT03506542|Active Comparator|Mitomycin C (MMC)|Mitomycin C (MMC) 0.3 mg/ml for 3 minutes under the scleral flap during phacotrabeculectomy (standard procedure)
2409739|NCT03506516|Experimental|single type|Restricted to drinking only one type of alcohol
2409740|NCT03506516|Active Comparator|mixed type|Drinking and mixing different types of alcohols freely
2409741|NCT03506503|Experimental|processed Nanofat grafting|processed autologous Nanofat will be injected into the area of the scalp with androgenic alopecia.
2409742|NCT03506490|Experimental|Experimental|The participants of this study were 33 subjects of both genders (M = 68 years old; SD = 4.2 years old) and were divided in two groups: a control group (N = 15; M = 67, 6 years old; SD = 4.1 years old) and an experimental group (N = 18; M = 67, 4 years old; SD = 4.4 years old). The participants performed a Soda Pop test before the aerobic training session (Baseline). The training session lasted 45 minutes and was composed of running exercises. After the training session, the motor memory consolidation was held in three different stages: Training; 1 hour after training; 24 hours after training.
2409745|NCT03506464|Experimental|plantar fasciitis group|Myofascial release technique
2409746|NCT03506464|No Intervention|control group|None of the control group received the treatment
3144850|NCT00053768|Experimental|high CHOEP-21|"High-CHOEP-21-Schema:~Cyclophosphamid (1400 mg/m2 i.v. d1), Doxorubicin (32,5 mg/m2 i.v. d1+2), Vincristin (2 mg i.v. d1), Etoposid (175 mg/m² i.v. d1-3), Prednison (100 mg p.o. d1-5)"
2409748|NCT03506438|Experimental|Mobile app group|Clinicians and family members will receive access to versions of the needs-focused mobile app that differ in content.
2409749|NCT03506438|Placebo Comparator|Usual care|Usual ICU care
2409753|NCT03506412|Experimental|Entresto™|HFpEF patients will be given Entresto™
2409754|NCT03506399|Experimental|Oral Contraceptive (OC)|Ethinyl estradiol and levonorgestrel administered as a single dose, orally
2409755|NCT03506399|Experimental|Lanabecestat|Single oral dose of lanabecestat
2409756|NCT03506399|Experimental|Lanabecestat and OC|A single oral dose of oral contraceptive and single daily doses of lanabecestat
3144851|NCT00053833|Experimental|irinotecan|irinotecan
3144852|NCT00053885|Experimental|PTK787/ZK 222584|"Patients receive oral PTK787/ZK 222584 daily. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months for 1 year, every 4 months for 1 year, and then every 6 months for 1 year."
3144853|NCT00053950|Experimental|Cohort I|Groups of 3-6 patients receive escalating doses of PZA at a fixed infusion time until the MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
2409758|NCT03506373|Experimental|Treatment (ixazomib citrate, ibrutinib)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
2409759|NCT03506360|Experimental|Treatment (ixazomib citrate, pembrolizumab, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71 and pembrolizumab IV over 30 minutes on days 1, 22, 43, 64. Patients also receive dexamethasone PO on days 1, 8, 15, 29, 36, 43, 57, 64, and 71. Cycles with dexamethasone repeat every 84 days for up to 1 year and cycles with ixazomib citrate and pembrolizumab repeat every 84 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3185362|NCT00734123|Experimental|1|Participants assigned to the intensive arm (1) will be targeted to specified therapeutic aims (concerning lipids, blood pressure and antiplatelets)according to the results of carotid ultrasound and ankle-brachial index.
3185363|NCT00734123|Active Comparator|2|Participants assigned to control group (2) will be followed according to the clinical standard of care.
2409762|NCT03506334|Experimental|Pediatric Scoliosis Patients|Tether group
2409763|NCT03506334|Active Comparator|Pediatric Scoliosis Control Patients|Fusion (control) group
2409764|NCT03506321|Other|LANS|Lesions are assessed with chromoendoscopy, HD-WL & NBI
2409765|NCT03506308|Other|LUTONIX 035 Drug Coated Balloon PTA Catheter|This is a single-arm study. All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
3185364|NCT00734136|Other|1|50 surgical subjects undergoing either liver transplantation or hepatic resection
3185365|NCT00734136|Other|2|50 Subjects with Liver disease who are are not surgical candidates
2409768|NCT03506282|No Intervention|No music|The participants will be required to run on a treadmill at 3 different speeds (6-8-10 km/h) with no music.
2409769|NCT03506282|Active Comparator|Traffic audio track|In addition to running on the treadmill, participants will be listening to an audio track resembling normal outdoor noise (70 dB) through earphones connected to a mobile phone.
2409770|NCT03506282|Experimental|Music at moderate volume|In addition to running on the treadmill, participants will be listening to music at a moderate volume (80 dB) through earphones connected to a mobile phone.
2409771|NCT03506282|Experimental|Music at moderate-to-high volume|In addition to running on the treadmill, participants will be listening to music at a moderate-to-high volume (85 dB) through earphones connected to a mobile phone.
2409772|NCT03506256|Experimental|Norofloxacin|The recommended dosage of norfloxacin for urinary-tract infections in adults is 400 mg orally every 12 hours; the drug should be given for 7 to 10 days in uncomplicated infections and for 10 to 21 days in complicated ones. Adverse drug effects were mild and included disturbances of the gastrointestinal tract and the central nervous system. The study shall be completed in accordance with the ICH topic E6 (R1)(CPMP/ICH/one hundred thirty five/95) guiding principle for top medical practice and the ideas enunciated within the announcement of Helsinki and the approval by way of an Institutional Ethics Committee.
2409773|NCT03506243|Experimental|Test group|Follitrope PFS
2409774|NCT03506243|Active Comparator|Control group|Gonal-F pen
2409775|NCT03506230|Experimental|Incentives group|a bonus to buy their medications if they improve their HbA1c
2409776|NCT03506230|No Intervention|Standard group|Will buy their medications as usual
2409777|NCT03506217||mitral valve prolaps|Hemodynamic recovery and anesthesia revealed by invasive arterial cardiac output (CO) measurement (Vigileo Flo-trac device) in 13 cases who underwent mitral valve (MV) repair with the transapical off-pump minimally invasive method in our clinic.
2409778|NCT03506178|Experimental|Obstructive sleep apnea patients|
2409779|NCT03506178|Other|Healthy controls|
2409780|NCT03506165|Experimental|Rheumatoid Arthritis with Periodontitis|Rheumatoid Arthritis patients with Periodontitis diagnosed after oral examination then treated with Periodontal treatment
2409781|NCT03506165|No Intervention|Rheumatoid without Periodontitis|Rheumatoid Arthritis patients without Periodontitis diagnosed after oral examination with. No interventions
2409782|NCT03506152||Culture positive|
2409783|NCT03506152||Culture negative|
2409784|NCT03506139|Experimental|Radiation Therapy|External beam radiation therapy delivered to target volume.
2409785|NCT03506126|Experimental|Leucine Adults > 60|In this arm, all subjects will receive all 8 of the leucine test levels, assigned in random order.
2409786|NCT03506113|Active Comparator|Gram stain-guided therapy group|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
2409787|NCT03506113|Active Comparator|Guidelines-based therapy group|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs
2409788|NCT03506100|Other|water walking in spirometric values|Experimental: practice swimming complemented with water walking
2409789|NCT03506087|Experimental|Coaching|Receives printed advance care planning (ACP) materials. Receives advance care planning coaching session. May receive followup coaching session, typically by telephone.
2409790|NCT03506087|Active Comparator|Enhanced Control|Receives printed advance care planning materials only.
2409843|NCT03505671|Experimental|Group 1 (acupuncture)|Participants undergo 8 45-minute acupuncture treatments over 10 weeks.
3185366|NCT00734175|Experimental|1|Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
3185367|NCT00734201|Experimental|1|Randomised to a parallel group comparison of either one of four doses of study drug (1mg, 2mg, 5mg, 25mg) or placebo. Dosed once daily for 28 days
2409791|NCT03506074||General population|"Adult volunteers (≥18 years of age) selected as part of a project to investigate the role of lifestyle in preventing chronic diseases supported by the Campus Salute association (www.campussalute.it).~All volunteers performed the flavor test as described in Maione et al, Endocrine, 2016 (doi:10.1007/s12020-015-0690-y)."
2409792|NCT03506061|Experimental|Trikafta|Participants will receive Trikafta for 28 days
2409793|NCT03506048|Experimental|Treatment (lenvatinib)|Patients receive lenvatinib PO QD for 8 weeks and up to 12 weeks in the absence of disease progression or unaccepted toxicity. Patients also receive radioactive iodine (RAI) I-131 orally as standard of care.
2409794|NCT03506035||Rheumatoid arthritis|Patients who meet the criteria of the 1987 ACR
2409795|NCT03506035||Arthritis not Rheumatoid arthritis|Patients with psoriatic arthritis, peripheric spondyloarthropathies and connective tissue diseases.
2409796|NCT03506035||Healthy controls|From health blood donors
2409797|NCT03506022|Other|patients with type 1 mellitus diabetes|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters
2409798|NCT03506009|Experimental|Argatroban combined with rt-PA|
2409799|NCT03506009|Active Comparator|rt-PA|
2409800|NCT03505996|Experimental|CS1001|Participants will receive CS1001 1200 mg by intravenous infusion every three weeks
2409801|NCT03505983|Active Comparator|ESR Prosthetic Foot First|Subject will start with an energy storing and returning (ESR) prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot, and a powered prosthetic foot for 1 week. During the final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
2409802|NCT03505983|Active Comparator|Articulating ESR Prosthetic Foot First|Subjects will start with an Articulating ESR prosthetic foot first for 1 week, then will complete an additional week with the ESR prosthetic foot, and a powered prosthetic foot for 1 week.The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
2409803|NCT03505983|Active Comparator|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR prosthetic foot and an ESR prosthetic foot for 1 week. The final 4 weeks, all prosthetic feet will be available for use and subjects will self-select which foot to use for daily activities.
2409804|NCT03505970|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
2409805|NCT03505970|Placebo Comparator|Placebo|Individuals will ingest 0.3 g/kg maltodextrin before undergoing exercise
2409806|NCT03505957|Experimental|SafeBreak Vascular Intervention|Every study participant will have SafeBreak Vasculars installed in each of their IV lines.
2409808|NCT03505931||Eluvia|Patients treated with Eluvia stent
2409809|NCT03505918|No Intervention|Standard municipal rehabilitation|Standard care with postoperative rehabilitation at the municipal facility.
2409810|NCT03505918|Experimental|No referral for rehabilitation|No referral for supervised postoperative rehabilitation. Only standard information booklet and advice during hospitalization.
2409811|NCT03505905|Experimental|Pregnenlone (phase 1 and 2)|Participants will receive pregnenolone at phase 1 (baseline-WK 7) and 2 (WK 8-16). The titration schedule is as follows: at baseline a 50 mg (BID, 7 days). WK 1=150 mg (BID, 7 days); WK 2=250 mg (BID, 14 days) and WK 4=250 mg (BID, 14 days) (BID, 14 days). At phase 2 (WK 8) to maintain the double blind of rerandomization, treatment in all conditions recommence at a dosage frequency similar to phase 1. At WK 8=250 mg (BID, 7 days); at WK 9=250 mg (BID, 7 days); WK 10=250 mg (BID, 14 days) and WK 12=250 mg (BID, 14 days) . During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (BID, 4 days) and 50 mg (BID, 4 days), discontinue.
2409812|NCT03505905|Placebo Comparator|Placebo rerandom to placebo|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1= placebo (7 days); at WK 2=placebo (14 days) and WK 4=placebo (14 days). Placebo nonresponders rerandomized to placebo: At WK 8=placebo (7 days);WK 9=placebo (7 days);WK 10=placebo (14 days) and WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo (4 days) and placebo (4 days), discontinue.
2409813|NCT03505905|Experimental|Placebo rerandom to pregnenolone|Participants will receive placebo at phase 1 (baseline-WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Nonresponders are rerandomized to receive either treatment at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo nonresponders who are rerandomized to pregnenolone: At WK 8=250 mg (7 days);WK 9=250 mg (7 days);WK 10=250 mg (14 days) & WK 12=250 mg (14 days). During the participants' final WK (16), they will be instructed to titrate down the treatment according to the following schedule: 150 mg (4 days) and 50 mg (4 days), discontinue.
2409814|NCT03505905|Placebo Comparator|Placebo responsive cont placebo|Participants will placebo throughout phase 1 (baseline- WK 7) & treatment response assessed (MADRS score reduced <50% at WK8). Responders continue to receive placebo at phase 2 (WK8-16).The titration schedule is as follows (dosage throughout is BID): at baseline placebo (7 days). At WK 1=placebo (7 days); WK 2=placebo (14 days) & WK 4=placebo (14 days). Placebo responders remain on placebo: At WK 8, placebo (7 days); WK 9=placebo (7 days); WK 10=placebo (14 days) & WK 12=placebo (14 days). During the participants' final WK (16), they will be instructed to titrate down (done in order to maintain the double blind) the treatment according to the following schedule: placebo= 4 days) and placebo=4 days, discontinue.
2409816|NCT03505866|Other|Mutual support groups of HIV|HIV-positive people who did not enroll in a community home-based care intervention and receiving regular HIV services and support from mutual support groups of HIV
2409817|NCT03505853|Experimental|Givosiran with 5-probe cocktail|
2409818|NCT03505840||antiphospholipid group|pregnant ladies in the third trimester who have antiphospholipid syndrome
2409819|NCT03505840||control group|pregnant ladies in the third trimester who have no medical disorders with pregnancy
2409820|NCT03505827||TECNIS Monofocal|This group of patients has chosen to undergo implantation of a TECNIS monofocal ZCB00 lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 Humphrey visual field test prior to surgery, and a 24-2 SITA standard Humphrey visual field test after surgery at 1 month post-operatively.
2409821|NCT03505827||TECNIS Symfony|This group of patients has chosen to undergo implantation of a TECNIS Symfony extended depth of focus lens during cataract surgery. This decision was made prior to enrolment in the study. This group of patients will receive standard of care cataract surgery, as any other patient would. The sole intervention we will be undertaking is a 24-2 SITA standard Humphrey visual field test prior to surgery, and a 24-2 Humphrey visual field test after surgery at 1 month post-operatively.
2409822|NCT03505814|Experimental|Optiflow Group|high flow (6l/min), humidified oxygen administred into nasal cannula for post-extubation new born ventilated patients.
2409823|NCT03505814|Active Comparator|Control Group|Conventional oxygen therapy for post extubation care
2409824|NCT03505788|Placebo Comparator|high-dose loop diuretics+placebo|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of placebo.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of placebo. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
2409825|NCT03505788|Experimental|high-dose loop diuretics+acetazolamide|"At the moment of randomization (day 1), oral loop diuretics are stopped and the patient receives IV loop diuretics at a dose equal to the double of his oral daily maintenance dose + 500 mg IV bolus of acetazolamide.~If the patient still have signs of volume overload the next mornings (day 2 and day 3), the patient will receive IV loop diuretics at a dose equal to the oral daily maintenance dose + 500 mg IV bolus of acetazolamide. It the patient has no sign of volume overload at these time points, the study treatment will be stopped."
2409826|NCT03505775|Other|23Na-MRI|A 23Na magnetic resonance imaging of the calf (muscle and skin) was performed in every participating patient after clinical and laboratory examinations.
3144854|NCT00053950|Experimental|Cohort II|Groups of 3-6 patients receive PZA at the dose/hour established in cohort I at escalating infusion times until another MTD is determined. In both cohorts the MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients receive G-CSF IV or subcutaneously beginning on day 4 and continuing until blood counts recover. Patients also undergo reinfusion of stem cells over 15-30 minutes on day 4 as needed per protocol.
3144855|NCT00053963|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144856|NCT00053976|Experimental|Daclizumab|"Patients are randomized to 1 of 2 treatment arms.~Arm I:~Patients receive methylprednisolone or equivalent corticosteroid IV or orally~Daclizumab IV on days 0, 3, 7, 14, and then weekly as indicated until day 100.~Arm II: Patients receive methylprednisolone or equivalent corticosteroid as in arm I and placebo.~Patients are followed at 1 year and then annually thereafter."
3144857|NCT00053976|Placebo Comparator|Placebo|"Patients are randomized to 1 of 2 treatment arms.~Patients receive methylprednisolone or equivalent corticosteroid as in Daclizumab arm~Placebo IV on days 0, 3, 7, 14, and then weekly as indicated until day 100."
2409831|NCT03505736||Diagnostic (stress test)|Within 2 years of initiating anti-estrogen therapy or 2 years after completing chemotherapy, participants undergo a stress test which consists of receiving adenosine IV over 1-5 minutes or regadenoson IV over 2 minutes and then undergoing CMR imaging over 45-60 minutes at baseline, and again 3-6 months later.
2409832|NCT03505723|Active Comparator|Tranexamic Acid (TXA)|Patients will receive a 1g loading dose of intravenous TXA before surgery and a 1g loading dose of intravenous TXA at the end of surgery (wound closure).
2409833|NCT03505723|Placebo Comparator|Placebo (0.9% normal saline)|Patients will receive a 1g loading dose of placebo (0.9% normal saline) before surgery and a 1g loading dose of placebo (0.9% normal saline) at the end of surgery (wound closure).
2409834|NCT03505723|Active Comparator|Hypotension-avoidance strategy|Aims to avoid hypotension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
2409835|NCT03505723|Placebo Comparator|Perioperative hypertension-avoidance strategy|Aims to avoid hypertension before surgery (preoperative), during surgery (intraoperative) and for the first 2 days after the day of surgery (postoperative).
2409836|NCT03505710|Experimental|Cohort 1: HER2 Overexpressing|Cohort 1 will enroll participants with HER2-overexpressing(immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
2409837|NCT03505710|Experimental|Cohort 1a: HER2 Overexpressing|Cohort 1a will enroll participants with HER2-overexpressing (immunohistochemistry [IHC] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma to receive 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).
2409838|NCT03505710|Experimental|Cohort 2: HER2 Mutated|Cohort 2 will enroll participants with HER2-mutated, unresectable and/or metastatic NSCLC to receive 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).
2409839|NCT03505697|Experimental|IMT+PR Group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training. In addition standard pulmonary rehabilitation, patients received inspiratory muscle training.
2409840|NCT03505697|Experimental|PR group|Patients received a 3-month standard hospital-based Pulmonary Rehabilitation included aerobic and strength training.
2409841|NCT03505684|Experimental|CTP group|1,000 mg of collagen tripeptide (CTP) was orally administered per day for 12 weeks.
3144858|NCT00054041|Experimental|Arm I (HspE7)|Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
3144859|NCT00054041|Experimental|Arm II (control)|Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy.
3144860|NCT00054119|Experimental|Treatment|Patients receive karenitecin IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144861|NCT00054184|Experimental|Study drug|
2409844|NCT03505671|Active Comparator|Group 2 (usual care)|Participants receive usual care.
2409845|NCT03505658|Experimental|Intervention|The Intervention is educational with 6 workshops for 2 hrs a week. Data/ assessments are collected, pre and post the 6 weeks intervention and 6 months post follow-up.
2409846|NCT03505658|No Intervention|Control|One or two non-intervention related workshop talks are given; 1 hr each during the same 6 weeks as the intervention arm. Pre and post assessment/ data collection and 6 months follow-up are completed.
2409847|NCT03505645|Active Comparator|Treatment group 1: Periarticular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 1.
2409848|NCT03505645|Active Comparator|Treatment Group 2: Intra-articular infiltration|Patients undergoing total knee replacement who are randomised to Treatment Group 2.
2409849|NCT03505632|Experimental|Recruitment with low PEEP|Recruitment maneuver ( RM) will carried out during 2 minutes with increasing PEEP in stepwise manner.PEEP increase from 5 to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths), PEEP to 20 cmH2O (10 breaths).Then decrease by 5 cmH2O every 3 breaths till back to preset PEEP 5 cmH2O .Recruitment carried out at the following times: post intubation(T1) , after insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O .
2409850|NCT03505632|Active Comparator|High PEEP without RM|"Patients will receive from the start during anesthesia high PEEP (15 cmH2O) with maintaining the peak airway pressure below 40 cm H2O.~Monitoring times: after intubation(T1), post-insufflation(T2), after desuflation (T3) and before extubation(T4)."
2409851|NCT03505619|Experimental|ASSIST 1.0|A ten-week intervention program using a person-centred approach to support the older person to set up goals to perform daily activities that he/she wants or needs to do. The activity goals will target improvements in quality of life, physical health, mental well-being, and conditions for social community. The focus will be on supporting the older person's activities in everyday life that are considered meaningful for the individual. During the intervention, a specially designed application will send reminders and feedback related to the older adults' activity goals of doing their prioritized everyday activities both to the older adults and to the home care providers via mobile phones, tablet etc. The home care providers will participate in coaching sessions supporting the intervention held by the team of researchers.
2409852|NCT03505619|No Intervention|Ordinary home care services|The home care providers in the control group (CG) will provide services as usual to older adults participating in the control group. They will however, identify potential older persons to participate in the control group according to the same procedure and criteria as the intervention group.
2409853|NCT03505606|Active Comparator|Control|Visual acuity tests on control participants
2409854|NCT03505606|Experimental|Amblyopic|Visual acuity tests on amblyopic participants.
2409856|NCT03505567|Other|Random Sequenced Interventions|Participants from three condition groups (normal, glaucoma, retinal disease) assigned two interventions (Kowa OCT Bi-μ and the Optovue iVue 100) under random sequence assignments.
2409857|NCT03505554|Experimental|Lorlatinib|100 mg QD
2409858|NCT03505541||Control group|Healthy, term, non-obese (BMI < 30) pregnant women with a singleton gestation scheduled for CS delivery at 37-41 weeks of gestation.
2409859|NCT03505541||Study group 1|Term pregnant, non-obese (BMI <30), diagnosed with gestational diabetes, scheduled for CS delivery between 37-41 weeks of gestation.
2409860|NCT03505541||Study group 2|Term pregnant, obese (BMI >30), non-diabetic and scheduled for CS delivery between 37-41 weeks of gestation
2409861|NCT03505528|Experimental|Cohort Group|There are five patient cohort groups. Each will receive a progressively higher starting dose of phenelzine sulfate, consecutively. Cohort A will start at 15mg/day and will be increased to 30mg/d by week 2 and further increased to 45mg/d for week 3, which will be maintained throughout the study. Cohort B will start at 45mg/d and will be held constant throughout the Study. Similarly, Cohort C, D & E will start at 60, 75 and 90mg/d, respectively, and will also be held on this dose throughout the study. The decision to escalate the dose for the next cohort will be made on the basis of the number of dose limiting toxicity (DLT) events observed during the first 8 weeks in the preceding cohort group. In addition, all cohort groups will receive a constant dose of Abraxane at 100mg/m2.
2409862|NCT03505515||Lung Cancer Patricipants in China|Participants with advanced/metastatic lung cancer (advanced NSCLC (IIIB/IV) and extensive disease SCLC) in China
2409863|NCT03505502|Placebo Comparator|placebo arm|group receive i/v saline plus irrigation of the myoma bed with normal saline
2409864|NCT03505502|Experimental|IV tranexamic acid group|group received IV tranexamic 1gm in normal saline
2409865|NCT03505502|Active Comparator|topical tranexamic acid group|group received topical tranexamic 2gm in normal saline
2409866|NCT03505489|Experimental|Mannitol challenge|Mannitol challenge performed per standard mannitol challenge procedure with deep inhalation technique
2409867|NCT03505489|Experimental|Mannitol challenge w/ TBI|Mannitol challenge performed per standard mannitol challenge procedure except with tidal breathing technique
2409868|NCT03505489|Experimental|Methacholine challenge w/ DI|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure except with deep inhalation technique
2409869|NCT03505489|Experimental|Methacholine challenge|Methacholine challenge performed per standard 2-minute tidal breathing challenge procedure (tidal breathing technique)
2409870|NCT03505476|Experimental|Study Participants|Device: Entac Medical device application Other: Patient Daily Assessment Other: Patient Discharge Assessment
2409871|NCT03505463||Injured participants|
2409872|NCT03505463||Healthy participants|
2409873|NCT03505450||Population sample|
2409874|NCT03505450||Purposive Sample|
2409875|NCT03505437|Experimental|Stress + Exposure|Stress Condition: Cold water condition of the socially evaluated cold pressor test (SECPT; Schwabe et al, 2008).
2409876|NCT03505437|Active Comparator|Control + Exposure|Control condition: Warm water condition of the SECPT.
2409877|NCT03505424|Active Comparator|Group 1: Standard of Care|Parents of infants born from April -mid-August 2018 (Group 1)
2409878|NCT03505424|Active Comparator|Group 2: NICU2HOME app|Parents of infants born from mid-August 2018- January 2019 (Group 2)
2409879|NCT03505424|Active Comparator|Group 3: SMART NICU2HOME app|Parents of infants born from February- June 2019 (Group 3)
2409880|NCT03505411|Experimental|melatonin, submaximal effort|1 arm 5 mg melatonin 1 hr before bedtime for 30 days
2409881|NCT03505398|Experimental|central vision disorder|
2409882|NCT03505398|Experimental|peripheral vision disorder|
2409883|NCT03505398|Other|control|
2409884|NCT03505385|Experimental|Co-created intervention|"The Get Ready (GR) intervention was delivered one-to-one with the care home resident and a relevant family member during a 12-week period:~The familiarisation stage aimed to build a rapport with two long-term achievement goals to sit less and move more with the resident and the family member and consisted of two sessions, one in week 1 (50-60minutes) and the other in week 3 (30-40 minutes).~The ramping up stage aimed to review the rapport and reach an achievable consensus with the resident and the family member. It consisted of two sessions, one in week 5 and the other in week 7 (20-30 minutes each).~The maintenance stage aimed at integrating behaviours and included two sessions, one in week 9 and the other at week 12 (20-30 minutes each). Sessions 5 and 6 were used to understand how the resident was getting on with their short-term GR goals, facilitating some problem-solving discussions."
2409885|NCT03505385|No Intervention|Usual care|
2409887|NCT03505359|Experimental|Experimental group|Group treated by the new protocol with partial knee immobilization
2409888|NCT03505359|Active Comparator|Control group|Group treated by a standard protocol for ACL reconstruction.
2409889|NCT03505346|Experimental|percutanous coronary intervention(PCI)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention
2409890|NCT03505346|Experimental|Coronary artery bypass-graft(CABG)|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention
2409891|NCT03505333|Experimental|conventional suture ligature|use of conventional sutures for hysterectomy
2409892|NCT03505333|Active Comparator|Liga Sure|use of conventional sutures plus use of Liga-sure for hysterectomy
3144862|NCT00054236|Experimental|non-myeloablative conditioning regimen|
3144863|NCT00054405|Experimental|Treatment (IL-12, aldesleukin)|"Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.~Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.~Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.~Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD."
3144864|NCT00054418|Experimental|calcium carbonate, vitamin D and risedronate|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and risedronate 35 mg weekly.
3144865|NCT00054418|Placebo Comparator|calcium carbonate, vitamin D and placebo|Patients receive calcium carbonate 600 mg daily, vitamin D 400 U daily and placebo weekly.
2409897|NCT03505294|Experimental|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks will be applied."
2409898|NCT03505294|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform.
2409899|NCT03505268|Experimental|telemedicine intervention|The intervention group, in addition to usual care, will get 10 telemedicine interventions by a certified nurse and dietitian who both specialize in treatment of type 1 diabetes.
2409900|NCT03505268|No Intervention|usual care|Usual care consisted of visits to the diabetes center every three months and communication with their doctor by phone when needed.
2409901|NCT03505255|Active Comparator|Group A|Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
2409902|NCT03505255|Active Comparator|Group B|Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.
2409903|NCT03505255|Active Comparator|Group C|Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.
2409904|NCT03505255|Placebo Comparator|Group D|Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.
2409905|NCT03505242|Experimental|BB|
2409906|NCT03505242|Experimental|DLT|
3144866|NCT00054431|Experimental|Treatment (imatinib mesylate, decitabine)|Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks. Courses repeat every 4-6 weeks in the absence of disease progression or unacceptable toxicity.
3144867|NCT00054444|Experimental|Treatment (topotecan hydrochloride, radiation, cisplatin)|Patients undergo radiotherapy 5 days a week for 6 weeks. Patients receive cisplatin IV and topotecan IV over 30 minutes once weekly for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
3144868|NCT00054457|Experimental|docetaxel + capecitabine|"Patients receive docetaxel IV over 1 hour on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, at each tumor measurement, and at the end of treatment.~Patients are followed every 3 months until disease progression and then every 6 months until 3 years from registration."
3144869|NCT00054483|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144870|NCT00054548|Experimental|Treatment (oblimersen sodium, paclitaxel)|"Patients receive oblimersen IV continuously on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~An additional cohort of 12-15 patients receives treatment as above with oblimersen at the MTD."
3144871|NCT00054587|Active Comparator|6 FEC|Patients receive fluorouracil IV, or epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy 5 days a week for 5 weeks.
2409907|NCT03505229|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Prior to SBRT, fiducial markers will be placed to aid with image guidance during radiation delivery. Fiducials will be inserted endoscopically (preferable) or intraoperatively. After this procedure, patients will have radiotherapy planning. During treatment, the fiducials will be used for registration with the images acquired during treatment (including kV fluoroscopy, MV or optical). The acquired images may be processed to determine fiducial location using KIM or MATT software from University of Sydney. SBRT 30-45Gray in 5 fractions will be given over 2 weeks.~Four weeks after completion of SBRT participants will repeat a re-staging PET and CT scans. Those considered to be resectable will proceed to have surgery 6-10 weeks post SBRT."
2409908|NCT03505216||Patient population|Children referred to paediatric pulmonary outpatient clinics for respiratory symptoms such as wheeze, cough, dyspnea, exercise- and sleep-related breathing problems.
2409909|NCT03505203|Experimental|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
2409910|NCT03505203|Active Comparator|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe
2409916|NCT03505177|Experimental|Chitin-glucan|Supplementation during 3 weeks with 4.5g per day of chitin-glucan fiber
2409917|NCT03505151|Experimental|All subjects|
2409918|NCT03505138|Experimental|Group intervention|Conventional management for COPD will take place in our health care system more telematics intervention.
2409919|NCT03505138|Active Comparator|Group control|Is performed only conventional management of COPD in our health care system.
2409920|NCT03505125||PKU Patients|Adults with PKU will be interviewed about the symptoms and impacts of PKU.
2409921|NCT03505125||Observers|Close friends and family members of adults with PKU will be interviewed about the behaviors they have observed in adults with PKU
2409922|NCT03505125||Clinical Experts|Experienced, practicing clinicians currently treating adults with PKU will be interviewed about the symptoms and impacts of PKU on their patients.
2409923|NCT03505112|Experimental|Goal-directed therapy group|The patients in goal-directed therapy (GDT) group will be managed according to the goal-directed therapy protocol during the surgery.
2409924|NCT03505112|No Intervention|Control group|The patients in control group will be managed according to standard perioperative care.
2409925|NCT03505099|Experimental|onasemnogene abeparvovec-xioi|One-time intravenous infusion of onasemnogene abeparvovec-xioi at 1.1 X 10^14 vg/kg
2409926|NCT03505086||cohort|All patients fulfilling the eligibility criteria who can be asked for consent. Basic register of only patient diagnosis, treatment and bleeding yes or no (without identifiable information).
2409927|NCT03505086||cases|Patient with clinically relevant bleeding, defined as major and clinically relevant non-major bleeding that leads to substantial additional medical care: WHO score 3-4 and part of the WHO score 2 bleedings (depending on the need for additional care).
2409928|NCT03505086||controls|Patient without clinically relevant bleeding matched to a case patient based on diagnosis and therapy.
3144872|NCT00054587|Experimental|6 DE|Patients receive epirubicin IV over 10 minutes and docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 6 courses. Patients then undergo radiotherapy as in arm I
3144873|NCT00054821|Experimental|Group A|Group A participants will be treated with mechanical distraction with motion
2409931|NCT03505047|Experimental|Immediate group:|The Copper Intrauterine device will be inserted within 24 hours of the expulsion of the fetus and placenta or after surgical evacuation for placental remains, and prior to discharge from the facility.
2409932|NCT03505047|No Intervention|Delayed Group|The Copper Intrauterine device will be inserted at a local community health centre 14-28 days after discharge.
2409933|NCT03505034|Experimental|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
2409936|NCT03505008|Experimental|MTX-Monotherapy Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the maximum tolerated dose (MTD) of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and simple disease activity index (SDAI) remission is achieved at Week 24, the MTX therapy will continue until Week 48.
2409937|NCT03505008|Experimental|ADA/MTX-Maximum Tolerated Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to the MTX therapy until Week 48.
2409938|NCT03505008|Experimental|ADA/MTX-Reduced Dose Group|Participants will receive Methotrexate (MTX) at a starting dose of 6 to 8 mg/week, which will be promptly escalated to the MTD of ≤25 mg/week up to Week 12, and maintained until Week 24. If the dosage of MTX is maintained ≥ 10 mg/week and SDAI remission is not achieved at Week 24, Adalimumab (ADA) 40 mg will be administered subcutaneously every other week in addition to low-dose MTX (6 to 8 mg/week) treatment until Week 48.
2409939|NCT03504995|Experimental|IRE patients|patients who will underwent 'Focal irreversible electroporation of the prostate cancer'
2409940|NCT03504982|Experimental|Treatment 1|Treatment sequences: A*-B-C-D
2409941|NCT03504982|Experimental|Treatment 2|Treatment sequences: D-A-B-C*
2409972|NCT03504748|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
3144874|NCT00054821|Active Comparator|Group B|Group B participants will be treated with mechanical distraction without motion
3144875|NCT00054925|Active Comparator|Personal contact (PC)|The Personal Contact (PC) intervention offers one-on-one guidance and support in maintaining weight loss.
3144876|NCT00054925|Active Comparator|Interactive technology (IT)|Utilizes internet and automated phone technology to enhance the frequency and timeliness of feedback.
3144881|NCT00055302|Experimental|1|
2409942|NCT03504956|Other|Healthy Volunteers|"Approximately 100 healthy male/female adult normals or controls will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant."
2409943|NCT03504956|Other|Coronary Artery Disease (CAD) Patients|40 male/female adult outpatients who are suspected of having or have been diagnosed with coronary artery disease (CAD) will receive non-contrast or contrast-enhanced Cardiac MRI. Imaging may include administration of contrast and a beta blocker, based upon the focus of the study at the time of the scan, as well as the safety profile of the participant.
2409944|NCT03504943|Active Comparator|Early Intradialytic Exercise|Intradialytic cycling will occur in the first half of hemodialysis treatment
2409945|NCT03504943|Experimental|Late Intradialytic Exercise|Intradialytic cycling will occur in the second half of hemodialysis treatment
2409946|NCT03504930||Impact of biotherapy on postoperative morbidity|Impact of biotherapy on postoperative morbidity in ulcerative colitis
3144882|NCT00055315|Active Comparator|STEPPS|Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes
3185368|NCT00734227|Active Comparator|A|"Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months.~Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians.~Procedure: Emergency portacaval shunt."
2409949|NCT03504904|Experimental|Internet-delivered ACT and CFT|8 week, guided internet- delivered acceptance and commitment therapy (ACT) and compassion focused therapy (CFT)
2409950|NCT03504904|No Intervention|Wait list control group|Wait list control group, received treatment at later point.
2409951|NCT03504891|Experimental|MRI Prior to CRT for Upgrades|MRI will be performed prior to CRT upgrade.
2409952|NCT03504891|Active Comparator|MRI Prior to de novo CRT Implants|MRI will be performed prior to de novo CRT implants.
2409953|NCT03504878||Patients undergoing laparoscopic appendectomy|Appendix removal via scope.
2409954|NCT03504878||Patients undergoing open appendectomy|Open operation for removal of appendix
2409955|NCT03504865|Experimental|Liposomal bupivacaine|"If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a field-effect encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement."
2409956|NCT03504865|Active Comparator|Standard bupivacaine|Patients randomized to the SB arm will receive weight-based dosing of bupivacaine, administered in the same manner as the LB arm.
2409957|NCT03504865|Placebo Comparator|Placebo|Patients who are in the placebo arm will have a similar volume of saline injected into the operative site.
3185369|NCT00734227|Active Comparator|B|Procedure: Emergency TIPS.
3185370|NCT00734240|Experimental|A|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 355312 or placebo
3185371|NCT00734240|Experimental|B|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3185372|NCT00734240|Experimental|C|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2409963|NCT03504813|Experimental|Urinary Incontinence|"The involuntary loss of urine through the urethra, objectively demonstrable and constituting for the person who suffers it a social and hygienic problem.~In this arm, participants will receive the following interventions: physical activities program, training of the pelvic floor and counseling about occupational performance"
2409964|NCT03504813|Experimental|Insomnia|"A condition characterized by an unsatisfactory amount or quality of sleep which persists for a considerable period. This disorder includes difficulties for the falling and/or staying asleep and early awakening in the final phase of sleep.~In this arm, participants will receive the following interventions: physical activities program, relaxation training and counseling about occupational performance."
2409965|NCT03504813|Experimental|Risk of falls|"Involuntary events that cause people to lose balance and find themselves on the ground or other firm surfaces. The factor of falls can be intrinsic (related to the person) or extrinsic (derived from the activity or environment of the individual).~In this arm, participants will receive the following interventions: physical activities program, and counseling about occupational performance"
2409966|NCT03504800||Group A: Classification of Corneal Irregularities|This group will consist of participants >14 years old with various types of corneal irregularities. Their data will be compared against participants with healthy corneas. Data for this group will be gathered only once.
2409967|NCT03504800||Group B: Detection of Keratoconus Progression|Participants from Group A who are diagnosed with keratoconus will be selected for this longitudinal study to monitor keratoconus progression. They will be followed up to 4 years.
2409968|NCT03504800||Group C: OCT-and-Topography Guided PTK|Participants from Group A will be selected for this group if they have vision primarily limited by scars, dystrophy, or high astigmatism that could be treated by PTK. They will be followed up to 1 year.
3185373|NCT00734240|Experimental|AA|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving 353512 or placebo
2409970|NCT03504761|Experimental|ClariCore System|ClariCore System study designed to obtain prostate biopsies utilizing real-time tissue classification with the ClariCore Optical Biopsy System.
2409971|NCT03504748|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
2409973|NCT03504735|Placebo Comparator|Therapeutic Lifestyle Change+Placebo|Therapeutic Life-style change intervention with Placebo pills.
2409974|NCT03504735|Active Comparator|Therapeutic Lifestyle Change+Caduet|Therapeutic Lifestyle Change intervention with Caduet pills.
2409975|NCT03504722|Experimental|RESCUE+PE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area Society for the Prevention of Cruelty to Animals (SPCA) facilities.All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
2409976|NCT03504722|Active Comparator|PE+delayed RESCUE|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD.
2409977|NCT03504709||Patient (n=50)|Adults with acute severe traumatic brain injury who undergo advanced neuroimaging and electrophysiological studies while in the intensive care unit and are followed for 6 months post injury.
2409978|NCT03504709||Healthy (n=25)|Healthy adults with no neurological, psychiatric, or medical disease.
2409979|NCT03504696||Patients with Advanced Melanoma|RIC-Mel patients with advanced (unresectable or metastatic) melanoma treated with nivolumab in the context of nivolumab ATU program (occurred from 12-Sep-2014 to 31-Aug-2015)
2409980|NCT03504683|Experimental|Early Time-Restricted Feeding|
2409981|NCT03504683|Experimental|Mid-day Time-Restricted Feeding|
2409982|NCT03504683|Placebo Comparator|Control Schedule|
2409983|NCT03504670|Experimental|Early amniotomy|Women randomized to early amniotomy will have their membranes ruptured in usual fashion using an amniotomy hook when the cervix is less than 4cm dilated. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. Prior to amniotomy, the obstetric provider will assess whether or not the fetal head is engaged. If the fetal head is not engaged (applied to the cervix), amniotomy will be deferred. The patient will be examined every 2 hours until amniotomy can be safely performed (in keeping with our institutional standard of care to examine women every 2-4 hours in labor).
2409984|NCT03504670|Experimental|Late amniotomy|Women randomized to late amniotomy will have their membranes ruptured once the cervix reaches at least 4cm dilation. This will occur after cervical ripening has taken place, with 1) a cervical Foley balloon catheter with or without oxytocin and/or 2) misoprostol. If the cervix fails to reach 4cm dilation 12 hours following cervical ripening, amniotomy will be performed.
2409985|NCT03504657|Experimental|Drug-coated balloon angioplasty|
2409986|NCT03504657|Active Comparator|stenting angioplasty|
2409987|NCT03504644|Experimental|Treatment (venetoclax, vincristine liposomal)|Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
2409988|NCT03504631||Breast cancer patients on tamoxifen|Patients currently on treatment with tamoxifen for at least 4 months.
2409989|NCT03504618||Metastatic colon cancer patients|Colon cancer patients with metastase at the diagnostic time, impossibility of radical resection, adenocarcinoma, treated by at least 3 cycles of FOLFOXIRI in the first-line in the Oncology and Palliative Care Department
2409990|NCT03504605|Experimental|Self-compassion intervention|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. They will then receive the online self-compassion intervention as detailed in Sirois, Bögels and Emerson (in revision). This involves parents in the experimental condition being given a validated set of instructions asking them to reflect on the event and write self-compassionate responses (see intervention).
2409991|NCT03504605|No Intervention|Control|Participants will be asked to recall and write (in an online text-box) about a parenting event during which they felt shame. Those in the control condition will be asked to re-read the account of the event and make notes about factual information (e.g. time of day, who was there, etc.). It should be noted that if the SCI is found to reduce state shame and increase state self-compassion, it will be offered to participants in the control group.
2409992|NCT03504592|Experimental|Glooko App|Glooko application and meter compatibility device (if required)
2409993|NCT03504592|Active Comparator|Traditional Care|Traditional clinic reporting system: paper/MyChart/emailed glucose logs
3144883|NCT00055315|Placebo Comparator|Treatment as Usual|"Patients with Borderline Personality Disorder. Each subject met DSM-IV criteria for BPD, confirmed through a clinical interview and a review of the patient's case notes.~TAU for this BPD population includes medical management, group and individual therapy."
2409996|NCT03504566|Other|Intervention|All patients recieve, in randomomized order a four way treatment schedule. Due to the nature of the study, the individual patient will serve as his/hers own comparator.
2409999|NCT03504540||Case (with pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, with pseudo-drusen-like deposits"
2410000|NCT03504540||Control (without pseudo-drusen-like deposits)|"Patients with lupus, treated or not with antimalarial drugs, without pseudo-drusen-like deposits"
2410001|NCT03504527|Experimental|triple combinations|Budesonide/Fermotil inhalant 160ug/4.5ug bid; Tiotropium bromide inhalants 18ug qd
2410002|NCT03504527|Active Comparator|double combinations|Fermotil inhalants 4.5ug bid; Tiotropium bromide inhalants 18ug qd
2410003|NCT03504514|No Intervention|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
2410004|NCT03504514|Experimental|Adapted mechanical ventilation|Mechanical ventilation with parameters specifically modified to improve speech the effect is evaluated with speech trials during different ventilation conditions
2410005|NCT03504501|Experimental|Exp. I: Noonan Syndrome - Lovastatin|200 mg Lovastatin daily for four days / Lovastatin-placebo (cross-over) prior to transcranial magnetic stimulation and test of attentional performance
2410006|NCT03504501|Experimental|Exp. II: Noonan Syndrome - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
2410007|NCT03504501|Experimental|Exp. III: Neurofibromatosis Type 1 - Lamotrigine|300 mg Lamotrigine single dose / Lamotrigine-placebo prior to transcranial magnetic stimulation and test of attentional performance
2410008|NCT03504488|Experimental|Monotherapy - CAB-ROR2-ADC (BA3021) alone|BA3021 alone
2410009|NCT03504488|Experimental|Combination Therapy|CAB-ROR2-ADC (BA3021) with PD-1 inhibitor
2410010|NCT03504475|Experimental|Paroxetine Hydrochloride Tablet|During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.
2410011|NCT03504475|Active Comparator|Paxil®|During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.
2410012|NCT03504462|Experimental|Distal tibial nerve block|Patient receiving a specific block of medial and lateral plantar nerves in order to preserve the calcaneal nerve
2410013|NCT03504449|Experimental|surgery without neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery without neoadjuvant chemoradiotherapy.
2410014|NCT03504449|Experimental|surgery with neoadjuvant chemoradiotherapy|For T3N1-2M0 rectal cancer with negative circumferential resection margin based on MRI assessment, recieve surgery following neoadjuvant chemoradiotherapy.
3144884|NCT00055393|Active Comparator|Subjects receivng Bupropion|The active arm subjects in this study (n = 18) received flexibly dosed bupropion in this randomized 12-week double-blind trial.
3144885|NCT00055393|Placebo Comparator|Subjects receiving Placebo|The inactive arm subjects in this randomly controlled study (n = 21) received a placebo.
3144886|NCT00055419|Experimental|400 mg/m2|
3144887|NCT00055575|Experimental|Depressed Patients with Major Depression DIsorder|
3144888|NCT00055575|Experimental|Depressed Patients with Bipolar Disorder|
3144889|NCT00055575|Experimental|Healthy Control|
2410021|NCT03504371|Active Comparator|bilateral erector spinae block|The patient placed in a lateral position and ultrasound transducer placed 3 cm lateral to the T7 spinous process. Three muscles will be identified: trapezius, rhomboid major, and erector spinae. 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side in the same way without changing the position of the patient to achieve sensory block T5-T10 .
2410022|NCT03504371|Sham Comparator|Thoracic epidural anesthesia|an epidural catheter placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine will be injected followed by 5-6 ml of bupivacaine 0.25%
2410023|NCT03504358||Analysis before liver resection|Multivariate analysis of predictive factors associated with survival
2410024|NCT03504358||Different risk group|Low-risk group, moderate-risk group, high-risk group
2410025|NCT03504358||Model comparison|Comparison of models in predicting survival
2410026|NCT03504345|Active Comparator|Control Group|This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
2410027|NCT03504345|Experimental|Experimental Group|This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
2410028|NCT03504332|Experimental|Calcium Hydroxide in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Pure Calcium Hydroxide powder mixed with saline will be placed as intra-canal medication in the 1st visit of dental pulp revascularization.
2410100|NCT03503812|No Intervention|No intervention to DDS exposure - Atrial Fibrillation|
3144890|NCT00055679|Active Comparator|6 FEC|6 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
3144891|NCT00055679|Experimental|4 FEC|4 cycles of CYCLOPHOSPHAMIDE + EPIRUBICINE + 5-FLUOROURACILE
3144892|NCT00055731|Experimental|Chemotherapy|
3144893|NCT00055731|Active Comparator|Without Chemotherapy|
3144894|NCT00055757|Experimental|Treatment (tipifarnib, gemcitabine, cisplatin)|"Patients receive oral tipifarnib twice daily on days 1-14, gemcitabine IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients with at least stable disease may continue to receive oral tipifarnib alone twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3144895|NCT00055770|Experimental|Arm I|"PHASE I: Patients receive oral erlotinib once daily on days 1-28 and docetaxel IV over 1 hour on days 8, 15, and 22. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6 patients receives erlotinib at the MTD.~PHASE II: Patients receive erlotinib at the MTD and docetaxel as in phase I."
3144896|NCT00055809|Experimental|Arm I (bevacizumab)|Patients receive bevacizumab IV on day 1.
3144897|NCT00055809|Experimental|Arm II (PEG-interferon alfa-2b)|Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
3144898|NCT00055848||Group 1|"Patients donate blood samples for analysis of colorectal susceptibility genes. Patients also complete a questionnaire regarding family cancer history.~A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.~Participants do not receive the results of the genetic testing, and the results do not influence the type or duration of treatment."
3144899|NCT00055861|Experimental|Treatment (bevacizumab, docetaxel)|Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
3144900|NCT00055913|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2410029|NCT03504332|Active Comparator|Di-antibiotic paste in revascularization|Revascularization of necrotic anterior teeth: canals disinfection step. Mix 1:1 ciprofloxacin: metronidazole to a final concentration of 0.1 mg/ml, placed as intra-canal medication in the 1st visit of dental pulp revascularization.
2410030|NCT03504319||Lean Group|Pre-pregnancy BMI between 18.5 and 24.9 kg/m2
2410031|NCT03504319||Obese Group|Pre-pregnancy BMI ≥30 kg/m2
2410032|NCT03504280|Active Comparator|high dose IM|cholecalciferol 600,000 IU given intramuscularly
2410033|NCT03504280|Active Comparator|high dose oral|cholecalciferol 600,000 IU given orally
2410034|NCT03504280|Active Comparator|low dose oral|cholecalciferol 400,000 IU given orally in 2 divided doses given monthly for 2 consecutive months followed by daily maintenance dose of 1000 IU
2410035|NCT03504267|Experimental|Physical Activity Group|The PAG (physical activity) group will receive evidence-based educational information as well as a list of local resources for pursuing physical activity.
2410036|NCT03504267|No Intervention|Standard of Care Group|The SOC (standard of care) group will receive no additional information beyond standard-of-care brochures and information
2410037|NCT03504254||CSM|A total of 50 CM patients requiring surgical decompression will be recruited. The inclusion criteria are a clinical diagnosis of CM including the signs of corticospinal lesions together with the appropriate radiographic findings. Patients with acute spinal cord injuries, prior spinal intervention or claustrophobia will be excluded.
2410038|NCT03504241|Experimental|MSCs 10^4 cells/kg+anti-rejection drugs|The first dosing cohort of 2 participants will receive 12 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg every 4-weeks.
2410039|NCT03504241|Experimental|MSCs 10^5 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^4 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^5 cells/kg every 4-weeks.
2410040|NCT03504241|Experimental|MSCs 10^6 cells/kg+anti-rejection drugs|If the first 3 infusions of 10^5 donor-derived Mesenchymal Stromal Cells (MSCs) cells/kg are well tolerated, this cohort of 2 participants will receive 12 infusions of 10^6 cells/kg every 4-weeks.
2410041|NCT03504215|Experimental|young adults|Both young adults born preterm (n=60) and term (n=30) will undergo the exercise intervention.
2410042|NCT03504202|Experimental|Trimetazidine|
3185374|NCT00734240|Experimental|BB|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2410044|NCT03504176||Intervention|Patients will be ventilated according to the bundle; including ventilation targets, tidal volume, end expiratory pressure-fraction of inspired oxygen titration.
2410045|NCT03504176||Control|Standard of care prior to implementation of the ventilation bundle
2410046|NCT03504163|Experimental|Pembrolizumab (MK-3475)|Patients will receive Pembrolizumab (MK-3475) administered after TUR as single agent initial therapy. Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period, unless there is unacceptable toxicity or other reasons to discontinue treatment occur.
2410047|NCT03504150|Experimental|SPHERE|It is an online self-guided comprehensive cognitive-behavioural therapy program that offers a headache diary, learning modules that teach a variety of cognitive and behavioural skills to cope better with their headaches, and a discussion forum where users may interact.
2410048|NCT03504150|Experimental|PRISM|It is an online self-guided brief cognitive-behavioural therapy program that offers a headache diary and helps users discover their headache triggers and non-triggers. Then the program provides the users with a few personalized recommendations to help them to cope with their triggers.
2410049|NCT03504150|No Intervention|Usual care|
3144901|NCT00055913|Experimental|Arm II|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144902|NCT00055978|Experimental|Arm I|Patients receive oral placebo twice daily for 6 months.
2410052|NCT03504124|Experimental|Intervention group|Patients will receive a multicomponent intervention.
2410053|NCT03504124|No Intervention|Control group|Patients will receive the usual care.
2410054|NCT03504111|Active Comparator|Needle Tenotomy|1 group will be assigned to get the standard treatment for chronic tendinopathy, percutaneous needle tenotomy (PNT). It is currently considered a standard treatment option. Ultrasound guided PNT with approximately 25 passes through the tendon and enthesis with approximately an 18 gauge needle with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used
2410055|NCT03504111|Active Comparator|Platelet Rich Plasma|1 group will be assigned to the PRP arm. Investigators will have a trained provider draw the blood, and prepare the PRP according to manufacturer and departmental (KP) protocol. Ultrasound guided injection of this PRP using approximately an 18 gauge needle with a single pass through the tendon into affected area as demonstrated on ultrasound. Adequate amount of anesthetic will be given in a separate syringe with adequate amount of anesthetic (lidocaine) for effective anesthesia. Investigators will keep track of amount and type of anesthetic used. The amount of anesthesia will be the same in both arms of the study
2410056|NCT03504098||Lung cancer patients tumor|Using to analysis metabolomic markers, one carbon folate nutrition levels in lung cancer patients.
2410057|NCT03504098||Lung cancer patients blood|Using to analysis folate, B12, homocysteine levels in plasma and RBC. Using to analysis cDNA gene test in buffy coat.
2410058|NCT03504098||Lung cancer patients|Supply nutrition counseling
2410059|NCT03504085|Experimental|Hatha Yoga|This arm will receive the active Hatha yoga intervention. Instructors lead participants through various yoga poses for 60-minutes, 1-2x weekly for 12 weeks, and daily home practice is recommended.
2410060|NCT03504085|Active Comparator|Restorative Yoga|This arm will receive a restorative yoga intervention. Instructors guide participants through relaxation exercises, typically with eyes closed, laying down, and minimal movement 60-minutes, 1-2x weekly for 12 weeks.
3144903|NCT00055978|Experimental|Arm II|Patients receive oral celecoxib twice daily for 6 months.
3144904|NCT00055991|Experimental|Bexarotene|Bexarotene / Targretin
3144905|NCT00055991|Placebo Comparator|Sugar Pill|Sugar pill / placebo
3185375|NCT00734240|Experimental|CC|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2410061|NCT03504072|Active Comparator|Tofacitinib 5mg|tofacitinib 5 mg 12 hourly daily for 9 months. Evaluation schedule will be baseline, 1st month, 3rd months and 3 monthly for 9 months. relevant investigations will be done at each visit. occurrence of tuberculosis and infections will be recorded at follow up visits.
2410062|NCT03504072|Active Comparator|Etanercept 50 mg|Etanercept 50 mg subcutaneously every 7 days interval for 1st month then, Etanercept 50 mg in 15 days interval for 2nd month then 50 mg every 21 days interval for 9 months. Occurrence of tuberculosis and infections will be recorded at follow up visits.
2410063|NCT03504059|No Intervention|Control|The usual educational program is applied
2410064|NCT03504059|Active Comparator|Short Intervention|A two-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
2410065|NCT03504059|Active Comparator|Long Intervention|A four-year specially designed educational program is applied. This program aims to encourage a healthy lifestyle through gamification, including diet education, physical activity and self esteem.
2410066|NCT03504046|Experimental|Artificial Pancreas App|After completing a 1 week open-loop run in period, subjects will use the APS APP for a 48-hour period in an observed transitional environment.
2410067|NCT03504033|Experimental|Xenon|Xenon concentration of 50-60 % will be used for maintenance of general anesthesia and will be adjusted to maintain Bispectral index (BIS) value between 40 and 60.
2410068|NCT03504033|Active Comparator|Desflurane|Desflurane concentrations of 4-5%/0.8 minimum alveolar concentration (MAC) respectively will be used for maintenance of general anesthesia and will be adjusted to maintain BIS index value between 40 and 60.
3185376|NCT00734240|Experimental|G|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3185377|NCT00734240|Experimental|H|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2410071|NCT03503994|Other|Drug|"Patients receiving inhaled beclomethasone diproprionate in four escalating doses:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
2410072|NCT03503981||Anxiety unit|Patients have anxiety as a primary diagnose. Receive treatment for anxiety (CBT and MCT).
2410073|NCT03503981||Eating disorder unit|Patients have eating disorder as primary diagnose. Receive treatment for their eating disorder (CBT and compassion-focused therapy).
2410074|NCT03503981||Depression unit|Patients have depression as primary disorder. Receive treatment for their depression (Short-term dynamic therapy, existential therapy and relational psychodynamic therapy).
2410075|NCT03503981||Family unit|One of the members of the family has a psychological disorder. The treatment is focused towards the family and family dynamics.
2410076|NCT03503981||Trauma unit|Patients have PTSD and relational trauma as primary diagnosis. Receive stabilizing treatment and exposure therapy.
2410077|NCT03503968|Experimental|Phase I - 3 disease entities|MDG1011 administration of escalating doses
2410078|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 1|MDG1011 administration of Phase II recommended dose
2410079|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 1|Investigator Choice therapy
2410080|NCT03503968|Experimental|Phase II - HLA*02:01 - disease entity 2|MDG1011 administration of Phase II recommended dose
2410081|NCT03503968|Active Comparator|Phase II - HLA*other - disease entity 2|Investigator Choice therapy
2410082|NCT03503955|Experimental|study group|fine motor skills activities and Leap-Motion virtual reality games
2410083|NCT03503955|Experimental|control group|fine motor skills activities
2410084|NCT03503942|Experimental|Treatment arm|Participants in the treatment arm will receive structured group-based lifestyle interventions with stepwise addition of metformin for selected high-risk participants.
2410085|NCT03503942|No Intervention|Control|Participants in the control arm will receive the current standard of care for pre-diabetes which includes counseling on lifestyle modifications and follow up by primary care physicians.
2410086|NCT03503929|Other|LaparoGuard System|All patients receiving laparoscopic surgery, candidates for prolonged time under anesthesia, and are admitted for gynecological, urological or general surgery procedures who consent to use of the LaparoGuard System.
2410087|NCT03503903|Experimental|Wet Cupping|One armed self-controlled study. Individuals in this arm will receive three concecutive WCT application
2410088|NCT03503877|Other|SAGE Media|SAGE single-step MEDIA
2410089|NCT03503877|Other|GLOBAL Media|LIFE GLOBAL single-step MEDIA
2410090|NCT03503864|Experimental|ATO-combined chemotherapy|Patients receive combined induction chemotherapy with arsenic trioxide.
2410091|NCT03503851|Active Comparator|One CLIP|Implantation of single MitraClip
2410092|NCT03503851|Active Comparator|Two CLIPs|Implantation of second MitraClip (after successful Implantation of single MitraClip)
2410093|NCT03503838|Experimental|Online Yoga|The intervention will be 12 weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). Qualified Udaya yoga instructors who collectively have over 200 years of training and experience will expertly instruct the online yoga classes.
2410094|NCT03503838|No Intervention|Wait-List Control|The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group.
2410095|NCT03503825|Experimental|Healthy Volunteers|Healthy volunteers will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety, knee image evaluation, and radioactivity biodistribution and dosimetry.
2410096|NCT03503825|Experimental|Osteo Arthritis of the knee|Subjects with knee osteoarthritis will be administered [Tc-99m]-RPI-T-087 Injection, single IV dose of 555 MBq and will be monitored for safety and knee image evaluation.
2410097|NCT03503812|No Intervention|No intervention to DDS exposure - Asthma in Children|
2410098|NCT03503812|Experimental|Intervention 1 - Asthma in Children|
2410099|NCT03503812|Experimental|Intervention 2 - Asthma in Children|
2410103|NCT03503799||Observational Group|Patients with primary invasive breast cancer, Stage I/II; ER positive, HER2 (human epidermal growth factor receptor 2) negative, N0-N1, T1-T3, tested with EndoPredict®, age over 18 years, informed consent
2410104|NCT03503786|Active Comparator|Chemotherapy|Carboplatin AUC 5+Paclitaxel 175 mg/m2 q 21days for 6-8 cycles and Avelumab
2410105|NCT03503786|Experimental|Chemotherapy and avelumab|Carboplatin AUC 5+ Paclitaxel 175 mg/ m2+Avelumab 10 mg/kg q 21days for 6 -8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
2410106|NCT03503773|Experimental|Treatment Arm:|Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter
2410107|NCT03503773|Sham Comparator|Sham Control Arm|Only renal angiography performed
2410108|NCT03503760|Experimental|true-sham|"Patients first received the true LIMFA Therapy® treatment for 3 weeks followed by 3 weeks of washout and then six sham sessions for 3 weeks more."
2410109|NCT03503760|Experimental|sham-true|"Patients first received the sham treatment for 3 weeks followed by 3 weeks of washout and then six true LIMFA Therapy® sessions for 3 weeks more."
2410110|NCT03503734||Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
2410111|NCT03503721|Experimental|BipolEP|includes all patients undergoing BipolEP surgery
2410112|NCT03503721|Active Comparator|TURP|includes all patients undergoing TURP surgery
2410113|NCT03503708|Experimental|Intervention Group|All the eligible participants will receive Livitol-17 capsules. It consist of 390 mg of whole herbs and extract of Phyllanthus niruri (Bhumyamalaki), Boerhaavia diffusa (Punarnava) and Picroorrhiza kurroa (Katuki).
2410114|NCT03503695|Active Comparator|Auricular Acupuncture|Sterile acupuncture semi-permanent (ASP) gold needles will be administered in the following acupuncture points: Cingulate Gyrus, Thalamus point, Omega 2, Point Zero, and Shen Men starting in either ear and alternating left and right until 10 ASP needles are placed. The needles may remain in the AA points for 3-4 days.
2410115|NCT03503695|No Intervention|Comparison Group|There will be no intervention. The participants will be instructed to return on Day 8.
2410116|NCT03503682|Active Comparator|standard treatment|Patients in this group are treated with 3000 cGy in 10 daily fractions
2410117|NCT03503682|Experimental|short course treatment|Patients in this group are treated with 2000 cGy in 4 fractions administered twice a day (at least 6-8 hours interval)
2410118|NCT03503669|Active Comparator|Memory Training|Group memory training will be administered for amnestic mild cognitive impairment (MCI)
2410119|NCT03503669|Experimental|Kundalini yoga and meditation|Participants will engage in weekly yoga classes and daily 12 minute meditation
2410120|NCT03503656||CompuFlo|All the consecutive patients undergoing to an epidural catheter placement in Gynecological and Obstetric setting
2410121|NCT03503630|Experimental|Locally advanced rectal cancer patients|"Week 1: D1-5: radiotherapy 25 Gy in 5 fractions~mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)~Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision"
2410122|NCT03503617|Experimental|RehabTouch Exercise Program|Participants will perform targetted movement exercises by interacting with the RehabTouch pucks, as described and monitored on a computer. Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks.
2410123|NCT03503617|Active Comparator|Conventional tabletop exercise program|Conventional tabletop exercise program is a traditional exercise program described in a booklet similar to what is typical provided to stroke patients upon their discharge from the hospital. Participants will be asked to perform these exercises at least 3 hours per week for 3 consecutive weeks.
2410124|NCT03503604|Experimental|group 1|hPV19 mAb plus FOLFOX(5-Fluorouracil,Oxaliplatin,Leucovorin)
2410125|NCT03503604|Experimental|group 2|hPV19 mAb plus paclitaxel/carboplatin
2410126|NCT03503604|Experimental|group 3|hPV19 mAb plus gemcitabine/carboplatin
2410127|NCT03503604|Experimental|group 4|hPV19 mAb plus FOLFIRI(5-Fluorouracil,Irinotecan, Leucovorin)
3185378|NCT00734240|Experimental|I|single-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3185379|NCT00734240|Experimental|GG|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
3185380|NCT00734240|Experimental|HH|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2410131|NCT03503539|Experimental|Mini percutaneous nephrolithotomy|All operations were performed or supervised by the same surgeon. Right after the patients in mini-PNL group were placed a 5F ureteral catheter with general anesthesia, they were had a prone position and the access was performed by choosing the optimal calyx to reach the stone following the contrast agent was given. The guide wire was then placed and the stones were broken with a laser lithotripter using a 12F nephroscope (Modular minimally invasive PCNL system, Karl Storz, Tuttlingen, Germany) following the dilatation using an one step dilator with a 16.5F access sheath. When necessary, stones were removed using the stone removal forceps. Right after a 14-Fr nephrostomy tube was inserted and an antegrade pyelography was taken, the operation was terminated.
3185381|NCT00734240|Experimental|II|multiple-dose cohort (n=4, randomized 3 active : 1 placebo) receiving ISIS 353512 or placebo
2410132|NCT03503539|Active Comparator|Retrograde intrarenal surgery|Following the general anesthesia performed, a safety guide wire was placed and semirigid ureteroscopy (9.5 / 11.5F) was performed. Stones were fragmented using a 270 micron meter laser fiber with the help of 7.5-F fiber optic flexible ureterorenoscope after the placement of ureteral access sheat (9.5 / 11.5 F). Stone fragmentation was accomplished using a laser energy of 0.5-1.5 J and a rate of 5-15 Hz and adjusting this range according to stone hardness. 4.7F JJ stent was routinely placed at the end of the operation because of worries about possible edema etc. due to access sheath. In this group, access sheath could not be placed in 2 patients due to the small diameter of the ureter, and JJ stent was placed, and 2 weeks later, the procedure was performed as it was in the others.
2410133|NCT03503526|Experimental|Music therapy treatment|"An intervention consisting of 12 weekly sessions of trauma-focused treatment in form of group music and imagery therapy.~Receptive music therapy."
2410134|NCT03503526|No Intervention|Wait List Control|No treatment for approximately 12 weeks.
2410135|NCT03503513|Experimental|Gentamicin sulfate|
2410136|NCT03503500|Experimental|Laid-back breastfeeding|Women will breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves, without following particular procedure to breastfed.
2410137|NCT03503500|Active Comparator|Standard care|Staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast,
2410138|NCT03503487|No Intervention|Control|Patients receiving standard informed consent procedure before intervention
2410139|NCT03503487|Experimental|Planner 1|Patients receiving 3D informed consent procedure before intervention with Surgical Theater
2410140|NCT03503487|Experimental|Planner 2|Patients receiving 3D informed consent procedure before intervention with Vesalius
2410141|NCT03503474||CDI cases|
2410142|NCT03503474||CDI negative controls|
2410143|NCT03503461||Control group|Control group is a population of subjects admitted to day hospitalization for renal function tests or in conventional hospitalization, but without kidney transplant. Exosome analysis will be perform in urine sample.
2410144|NCT03503461||Kidney transplants group|Kidney transplants group is a kidney transplant subjects population 3 months ago. Exosome analysis will be perform in urine sample collected at 3 months.
2410145|NCT03503448|Other|space between 11/21|Osteotomy between the maxillary central incisors
2410146|NCT03503448|Other|space between 12/13 and 22/23|Osteotomy between the maxillary lateral incisors and canines
2410147|NCT03503435|Other|Art therapy intervention|Participants will then take part in six-weeks of group art therapy with a goal of increasing self-awareness and expression. During the intervention sessions, participants will have access to a wide range of materials conventionally used in art therapy excluding materials that may be abrasive or powdery and unsuitable around people wearing a stoma.
2410148|NCT03503422|Experimental|tDCS (anodal) + therapeutic exercises|"Real transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
2410149|NCT03503422|Sham Comparator|tDCS (sham) + therapeutic exercises|"Sham transcranial direct current stimulation associated with therapeutic exercises~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion)."
2410150|NCT03503409|Experimental|AG-120|Subjects enrolled will receive continuous 28-day cycles of AG-120 - 500 mg. AG-120 will be dispensed on Day 1 of each treatment cycle
2410151|NCT03503396|Experimental|BAC feedback|Participants will receive a warning when their BAC is above a set limit (cutpoint is not disclosed by well below legal limit). Warning will notify them that their results indicate it is not safe for them to drive.
2410152|NCT03503396|Active Comparator|No Feedback|Participants will not receive any information on their BAC from their device.
2410153|NCT03503383||Controlled group|pregnant women without any medical disorders during pregnancy
2410154|NCT03503383||Diseased group|Patients complaining of hypertension with pregnancy
2410155|NCT03503370|Experimental|chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
2410156|NCT03503370|Placebo Comparator|placebo|Participants randomized to the placebo will wash their feet using bath CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
2410161|NCT03503344|Experimental|Arm I (apalutamide, SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity. Beginning 60 days after first dose of apalutamide, participants also undergo stereotactic body radiation therapy for 1-5 fractions.
2410162|NCT03503344|Active Comparator|Arm II (SBRT)|Participants receive apalutamide PO QD on days 1-28. Courses repeat every 28 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
2410163|NCT03503331|Experimental|[C-11]PiB-PET/MRI|All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system. The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
2410242|NCT03502720||Case Patients|Prospective series of ten patients on which the external 3D guide system will be used.
2410167|NCT03503305|Experimental|Adipose Derived Regenerative Cell group|Subjects in the treated group will receive an Adipose derived regenerative cells (ADRCs) injection into the wrist using a fluoroscopic-guided injection .
2410168|NCT03503305|Active Comparator|Corticosteroid group|Subjects in the active control group will receive a corticosteroid injection into the wrist using a fluoroscopic-guided injection.
3185382|NCT00734240|Experimental|F (100 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
3185383|NCT00734240|Experimental|Dose-Titration 1|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
2410171|NCT03503279|No Intervention|Macintosh Laryngoscope|
2410172|NCT03503279|Active Comparator|McGrath MAC® Video Laryngoscope|
2410173|NCT03503266|Experimental|[14C] MT-7117|14-C MT-7117
2410174|NCT03503253|Other|Single-arm|LAA leak closure using detachable coils; Interlock-35 Fibered IDC Occlusion System, Concerto Helix Detachable Coil System
2410175|NCT03503227|Active Comparator|Aspirin|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)
2410176|NCT03503227|Active Comparator|Aspirin and prednisolone|Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).
2410177|NCT03503214||Septic patients|Patients with sepsis or septic shock according to the SEPSIS-III (Singer M Jama 2016) admitted to the general Intensive Care Unit
2410178|NCT03503214||Healthy volunteers|Subjects without known respiratory, cardiovascular, hepatic, renal or hematologic diseases.
2410179|NCT03503201|Active Comparator|treatment|patients receive chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) for 2 months before Intracytoplasmic sperm injection cycle
2410180|NCT03503201|No Intervention|No treatment|patients will not receive chromium supplementation before Intracytoplasmic sperm injection cycle
3185384|NCT00734240|Experimental|F (200 mg)|single-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
2410182|NCT03503175|Experimental|Novel urinary access system|Participants randomized to this arm will receive the novel urinary access system (CystoSureTM).
2410183|NCT03503175|Active Comparator|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and rigid cystoscopy.
3185385|NCT00734240|Experimental|Dose-Titration 7|multiple-dose cohort (n=4, randomized 3 active: 1 placebo) receiving ISIS 353512 or placebo
2410185|NCT03503136|Experimental|A (TPF+P-RT)|Induction docetaxel, cisplatin, and fluorouracil plus concurrent chemoradiotherapy with cisplatin
2410186|NCT03503136|Experimental|B (TNF+N-RT)|Induction docetaxel, nedaplatin, and fluorouracil plus concurrent chemoradiotherapy with nedaplatin
2410187|NCT03503136|Experimental|C (TPX+P-RT)|Induction docetaxel, cisplatin, and capecitabine plus concurrent chemoradiotherapy with cisplatin
2410188|NCT03503136|Experimental|D (TNX+N-RT)|Induction docetaxel, nedaplatin, and capecitabine plus concurrent chemoradiotherapy with nedaplatin
2410189|NCT03503123||COPD patients with deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV with severe symptoms of deventilation dyspnoea (Borg Dyspnoea Scale ≥ 5)
2410190|NCT03503123||COPD patients without deventilation dyspnoea|Ten severe COPD patients (age>18yr) using chronic NIV without symptoms of deventilation dyspnoea, matched with the first cohort/group with regard to the degree of static lung hyperinflation and NIV settings.
2410191|NCT03503110|Experimental|dMRI and electrocorticography|Direct measurements of cortical electrical properties of patients operated on awake surgery for a brain tumor, using electrocorticography (ECoG), based on the dMRI tractography data previously acquired for each patient.
2410192|NCT03503097||Ancillary-Correlative (questionnaires, Color kit, counseling)|Participants receive web-based or hard-copy questionnaires and saliva collection kits via mail or in person. Participants also provide saliva samples to be mailed back to Color Genomics for genetic testing once complete. Participants then receive phone-based genetic counseling if they are identified to have an inherited mutation in a DNA repair gene. All participants have access to phone-based genetic counseling whether or not they are not found to have a mutation.
2410193|NCT03503084|Experimental|TCC group|Classical Yang's TCC exercise
2410194|NCT03503058|Experimental|Group 1|N=140 will receive PfSPZ Vaccine; three doses of 9x10^5 PfSPZ of PfSPZ Vaccine administered by direct venous inoculation (DVI) given at 0, 7 and 28 day intervals.
2410195|NCT03503058|Placebo Comparator|Group 2|N=70 will receive normal saline; three doses of NS administered by DVI given at 0, 7 and 28 day intervals.
2410196|NCT03503058|Experimental|Group 3|"N=140 will receive PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis; three doses of 2x10^5 PfSPZ of PfSPZ Challenge administered by DVI at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.~CQ will first be given as a loading dose of 620 mg base two days before the first administration of PfSPZ Challenge, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of PfSPZ Challenge."
2410197|NCT03503058|Placebo Comparator|Group 4|"N=70 will receive normal; three doses of NS administered by DVI given at 0, 28 and 56 day intervals (or 0, 4 and 8 week intervals), with weekly CQ.~CQ will first be given as a loading dose of 620 mg base two days before the first administration of NS, followed by weekly 310 mg doses of CQ with the last dose 5 days after the last dose of NS."
2410198|NCT03503032||Fenestrated|Standard extracardiac fontan undergoing Fontan fenestration creation
2410199|NCT03503032||Non fenestrated|Standard extracardiac fontan without fenestration
2410200|NCT03503019||Diabetic|
2410201|NCT03503019||Non-diabetic|
3185386|NCT00734253|Experimental|1|Pyridorin 150 mg bid
3185387|NCT00734253|Experimental|2|Pyridorin 300 mg bid
3185388|NCT00734253|Placebo Comparator|3|Placebo bid
2410202|NCT03502993||MOFICHE|This is an observational study assessing the management and outcome of children presenting to Emergency Departments (ED) with fever across Europe. This study will use large departmental datasets to collect information on at least 50,000 febrile episodes . This study will use large-scale, pseudo-anonymized departmental data, and will not involve consented patient recruitment; nor will it use patient samples. Data included in MOFICHE will be based on that collected as part of routine clinical care. Antibiotic prescription, hospitalisation and number/type of investigations, re-attendance at ED within 5 days of the first hospital presentation will be recorded.
2410203|NCT03502993||BIVA studies|A minimum of 3,000 children will be recruited to the BIVA-ED study, in order to capture sufficient children with confirmed bacterial infection. Additional children with less common febrile illnesses will also be recruited: 500 critically ill (BIVA-PIC); 200 at high-risk of bacterial illness through primary or secondary immunodeficiency (BIVA-HR); 150 with an inflammatory diagnosis, whose initial presentation is difficult to discriminate from bacterial infection (BIVA-INF). Samples collected from recruits in the BIVA studies will be used for the validation of biomarkers (clinical, proteomic and transcriptomic biomarkers) for diagnosis of febrile illness, including markers of bacterial and viral infection (confirmed by culture and/or molecular microbiology) and inflammatory conditions.
2410204|NCT03502980|Active Comparator|Peripherally inserted central venous catheters|Bard PowerPICC
2410205|NCT03502980|Active Comparator|Midline|Bard PowerMidline catheter
2410206|NCT03502967|Experimental|Hyperpolarized [1-13C] Pyruvate|Injection with hyperpolarized [1-13C] Pyruvate during MRI.
2410207|NCT03502967|Experimental|Hyperpolarized [2-13C] Pyruvate|Injection with hyperpolarized [2-13C] Pyruvate during MRI.
2410208|NCT03502954|Experimental|ABY-039 IV|
2410209|NCT03502954|Experimental|ABY-039 SC|
2410210|NCT03502954|Placebo Comparator|Placebo IV|
2410211|NCT03502954|Placebo Comparator|Placebo SC|
3185389|NCT00734266||1 Control|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
3185390|NCT00734266||2 COPD|Patients with and without chronic obstructive pulmonary disease diagnosed before scheduling for cardiac surgery.
3185391|NCT00734279|Experimental|1|Girls with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
2410215|NCT03502928|Active Comparator|Conventional Treatment|Motor Control + Manual Therapy
2410216|NCT03502928|Experimental|Experimental Treatment|Motor Control + Manual Therapy + Dry Needling
3185392|NCT00734279|Experimental|2|Girls with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
3185393|NCT00734279|Experimental|3|Boys with Early Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
2410219|NCT03502902|Experimental|HEC68498|administered once on first day in each Treatment Period， HEC68498 VS placebo 3:1 ratio
2410220|NCT03502902|Placebo Comparator|placebo|administered once on first day in each Treatment Period
2410221|NCT03502889|Active Comparator|Adductor Canal Block Alone|Control arm to receive Adductor Canal Block without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance
2410222|NCT03502889|Experimental|SPANK Block Plus Adductor Canal Block|Experimental arm to receive Adductor Canal Block plus SPANK Block (Sensory Posterior Articular Nerves of the Knee) without additional interventions Intervention: ropivacaine 0.5% 15cc injected under ultrasound guidance into the adductor canal plus 20cc ropivacaine 0.5% injected into the posterior tissues of the knee
2410223|NCT03502863|Experimental|Digital refraction|Web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone
2410224|NCT03502863|Active Comparator|Manual Refraction|Manual manifest refraction is performed by an eyesore specialist using a phoropter.
2410225|NCT03502850|Experimental|ASK120067|patients take ASK120067 orally once per day at different dose
2410226|NCT03502837||Healthy controls|age-matched right-handed healthy volunteers
2410227|NCT03502837||the mininally conscious state|Patients present reproducible signs of awareness such as purposeful eye movements or response to verbal order
2410228|NCT03502837||the vegetative state|Patients preserved autonomous functioning (e.g., preserved sleep-wake cycles),but without awareness of oneself or of the environment
2410229|NCT03502824|Active Comparator|PuraPly® AM plus Standard of Care|
2410230|NCT03502824|Active Comparator|Standard of Care (SOC) for Pressure Ulcers|
2410231|NCT03502811||MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR and XTR system
2410233|NCT03502785|Experimental|Cohort A|Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 therapy. Cohort A participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
2410234|NCT03502785|Experimental|Cohort B|Participants with locally advanced unresectable or metastatic/recurrent UCa who are treatment naïve and ineligible for cisplatin-based chemotherapy. Cohort B participants will be treated with INO-5401 and INO-9012 in combination with atezolizumab.
2410235|NCT03502772|Experimental|Pilates exercises group|
2410236|NCT03502772|Active Comparator|Home exercise program group|
2410237|NCT03502759|No Intervention|Pre-intervention|Seizure patients receive usual care.
2410238|NCT03502759|Experimental|Post-intervention|Physicians provide care enhanced by computer based clinical decision support about SUDEP.
2410239|NCT03502746|Experimental|Nivolumab + Ramucirumab|Nivolumab 240mg IV + Ramucirumab 8mg/kg IV
2410240|NCT03502733|Experimental|Treatment (copanlisib, nivolumab, ipilimumab)|"DOUBLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15 and nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~TRIPLET TREATMENT PLAN: Patients receive copanlisib IV over 1 hour on days 1, 8, and 15, nivolumab IV over 30 minutes on day 1 or on days 1 and 15. Beginning cycle 2, patients also receive ipilimumab IV over 90 minutes on day 1 for a total of 4 doses. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2410241|NCT03502720||Control Patients|"Data obtained retrospectively from Scaphoid fixation surgeries performed at our center using the standard procedure (no device for guide wire positioning).~This control group should have registered al parameters and variables to be studied."
3144906|NCT00056030|Experimental|cetuximab + oxaliplatin + leucovorin + fluorouracil|"Patients receive cetuximab IV over 1 hour (over 2 hours on day 1 of course 1 only) on days 1 and 8. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously on days 1-2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity, for a minimum of 12 courses or until deemed to have resectable disease.~Quality of life is assessed at baseline and prior to each treatment course.~Patients are followed every 3 months for 1 year and then every 6 months for 3 years."
3144907|NCT00056056|Experimental|Bexarotene and PUVA|
3144908|NCT00056056|Active Comparator|PUVA|
3144909|NCT00056069|Experimental|Observational|Questionnaire Administration: Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
3144910|NCT00056082|Experimental|Celecoxib 400 mg bid|Celecoxib 400 mg bid
3144911|NCT00056095|Experimental|Allograft (compatible family member)|
3144912|NCT00056095|Other|Allograft (compatible non-family member)|
3144913|NCT00056277|Other|Arm 1|
3144914|NCT00056290|Active Comparator|1|VEGF
3144915|NCT00056290|Placebo Comparator|2|Placebo
3144916|NCT00056303|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up targets nurturance, synchrony, and non-frightening behavior, as well as providing caregivers with help calming toddlers.
3144917|NCT00056303|Active Comparator|Developmental Education for Families|Developmental Education for Families targets providing cognitive stimulation to their children.
3144918|NCT00056329|Experimental|1|vitamin E plus multivitamin
3144919|NCT00056329|Placebo Comparator|2|placebo with multivitamin
3144920|NCT00056394|Experimental|1|Participants will receive comprehensive pain coping skills.
3144921|NCT00056394|Active Comparator|2|Participants will receive arthritis education.
3144922|NCT00056394|Active Comparator|3|Participants will receive standard care.
3144923|NCT00056446|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
3144924|NCT00056446|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
3144925|NCT00056459|Experimental|1|Oxaliplatin/5-FU/LV and PTK787/ZK 222584
2410264|NCT03502694|Experimental|Regimen A (Low-Dose Lumicitabine)|Participants will receive a single 750 milligram (mg) loading dose (LD) (Dose 1) of lumicitabine and matching placebo followed by nine 250 mg tablets as maintenance doses (MDs) (Doses 2 to 10) of lumicitabine and matching placebo administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2410265|NCT03502694|Experimental|Regimen B (High-Dose Lumicitabine)|Participants will receive a single 1000 mg LD (Dose 1) of lumicitabine followed by nine 500 mg tablets as MDs (Doses 2 to 10) of lumicitabine and matching placebo tablet, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2410266|NCT03502694|Placebo Comparator|Regimen C (Placebo)|Participants will receive a placebo LD (Dose 1) followed by nine MDs (Doses 2 to 10) of matching placebo, administered twice daily during Day 1 to Day 5/6 (depending on the timing of the LD).
2410268|NCT03502668|Experimental|Phase 1 Stage A|3 cohorts of 6 subjects each in a schedule in 28-day cycles of ASTX727 LD
2410269|NCT03502668|Experimental|Phase 1 Stage B|3 cohorts of 10 subjects each in 28-day cycles of ASTX727 LD
2410270|NCT03502668|Experimental|Phase 2|80 additional subjects randomized in a 1:1 ratio studying two different doses
2410271|NCT03502655|Other|Intervention message (first phase)|Standardized message The intervention will consist in the delivery of a message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered through an audio record
3144926|NCT00056459|Placebo Comparator|2|Oxaliplatin/5-FU/LV and placebo
3144927|NCT00056537|Experimental|1|
3144928|NCT00056589|Experimental|rFXIII|
3144929|NCT00056654|Experimental|1|
3144930|NCT00056667|Experimental|CBT plus relaxation response|Participants will receive cognitive behavioral therapy plus relaxation response training
3144931|NCT00056667|Active Comparator|Relaxation Response|Participants will receive relaxation response training
3144932|NCT00056667|Placebo Comparator|Education|Participants will receive rheumatoid arthritis education
3144933|NCT00056693|Experimental|A|
3144934|NCT00056966|Experimental|1|recipients of HLA matched sibling transplants
3144935|NCT00056966|Experimental|2|recipients of unrelated or mismatched family donor transplants
3144936|NCT00056979|Experimental|Fludarabine, CAMPATH-1H , Anti-CD45, FK506|Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) infusion for three days. Anti-CD45 will be given as a daily 6-hour IV infusion over the next 4 days. To help prevent body from rejecting the transplant, the drug FK506 will be given, starting two days before the transplant and continuing for three months.
3144937|NCT00057005|Experimental|1|
3144938|NCT00057044|Other|Arm 1|
3144939|NCT00057057|Other|Arm 1|
3144940|NCT00057070|Other|Arm 1|
3144941|NCT00057083|Other|Arm 1|
3144942|NCT00057096|Other|Arm 1|
3144943|NCT00057109||Group 1|
3144944|NCT00057122|Active Comparator|1|
3144945|NCT00057122|Active Comparator|2|
3144946|NCT00057122|Active Comparator|3|
3144947|NCT00057122|Active Comparator|4|
3144948|NCT00057135|Other|Arm 1|
3144949|NCT00057148|Other|Arm 1|
3144950|NCT00057161|Other|Arm 1|
3144951|NCT00057174|Other|Arm 1|
3144952|NCT00057187|Other|Arm 1|
3144953|NCT00057200|Other|Arm 1|
3144954|NCT00057252||1|Patients with medical imaging records
3144955|NCT00057291|Experimental|caregiving intervention|One group received caregiving intervention, another received only training, and a third was business as usual. These were the interventions.
3144956|NCT00057356|Placebo Comparator|1|
3144957|NCT00057356|Experimental|2|Low dose
3144958|NCT00057356|Experimental|3|Middle dose
3144959|NCT00057356|Experimental|4|High dose
3144960|NCT00057408|Experimental|1|Treatment with olanzapine
3144961|NCT00057408|Placebo Comparator|2|Matching placebo treatment
2410272|NCT03502655|Active Comparator|Control message (first phase)|Standardized message The intervention will consist in the delivery of a control message, whose content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered through an audio record.
2410273|NCT03502655|Other|Intervention message (second phase)|Standardized message The intervention will consist in the delivery of message with a positive content regarding the insertion of the peripheral venous catheter. The message will be delivered by the health providers themselves before inserting the catheter.
2410274|NCT03502655|Active Comparator|Control message (second phase)|Standardized message In this arm, the patient will be delivered a control message, which content is based upon the usual caregiver-patient communication prior to the insertion of a peripheral venous catheter. The message will be delivered by the caregivers themselves before inserting the catheter.
2410275|NCT03502642|Placebo Comparator|Placebo (P)|Placebo group parturients will receive spinal anesthesia with intrathecal morphine and will have continuous normal saline wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
2410276|NCT03502642|Active Comparator|Ropivacaine (R)|Ropivacaine group parturients will receive spinal anesthesia without intrathecal morphine and will have continuous ropivacaine (Ropivacaina Molteni®) wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain).
2410277|NCT03502629|Experimental|GB226 3mg/kg every 2 weeks|Geptanolimab Injection, 3mg/kg every 2 weeks
3185394|NCT00734279|Experimental|4|Boys with Delayed Puberty receive ganirelix and leuprolide acetate to determine effect of ganirelix on gonadotropin secretion
2410280|NCT03502603|Active Comparator|Cerebral neurological illness (CNI) participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
2410281|NCT03502603|Active Comparator|Non-CNI participants|Identified from the department of Rehabilitation, Psychiatry, and Medicine and referred to the research staff via in-person communication, email or staff message
2410282|NCT03502590|Experimental|IGEL arm|
2410283|NCT03502577|Experimental|Treatment (Chemotherapy, BCMA-specific CAR T-cells, LY3039478)|Participants receive fludarabine and cyclophosphamide on days -4 to -2. Participants then receive BCMA-specific CAR T-cells IV over 20-30 minutes on day 0 and LY3039478 PO on days 2, 4, 7, 9, 11, 14, 16, and 18.
2410284|NCT03502564|Active Comparator|CBT for ED only|In this arm, participants will receive CBT for ED following intensive ED treatment (see intervention section for description).
2410285|NCT03502564|Experimental|Concurrent CBT for ED and PTSD|In this arm, participants will receive concurrent CBT for ED and PTSD following intensive treatment. (see intervention section for description).
2410286|NCT03502551|Experimental|Treatment with Ketamine|In this arm an IV infusion of 0.5 mg/kg of ketamine will be administered over 40 minutes.
2410287|NCT03502538|Experimental|Curaprox 5460 Ultra Soft|Brushing with a Curaprox Ultra Soft 5460 toothbrush for one minute timed without orientations about brushing techniques and without supervision
2410288|NCT03502538|Active Comparator|Oral-B Indicator Plus|Brushing with a Oral-B Indicator Plus toothbrush for one minute timed without orientations about brushing techniques and without supervision
2410289|NCT03502525|Experimental|Break the Cycle Intervention|All study participants are assigned to this experimental arm.
2410290|NCT03502512|Experimental|Arm I (REVOLVE technique)|Patients undergo reconstructive surgery with REVOLVE technique.
2410291|NCT03502512|Experimental|Arm II (PureGraft technique)|Patients undergo reconstructive surgery with PureGraft technique.
2410292|NCT03502499|Experimental|Half-normal saline|
2410293|NCT03502499|Active Comparator|Normal saline|
2410294|NCT03502486|Experimental|Moderate exercise|20 minutes of cycle ergometry at 50 - 60% of heart rate max.
2410295|NCT03502486|Experimental|Intense Exercise|20 minutes of cycle ergometry at 70 - 80% of heart rate max.
2410296|NCT03502486|Active Comparator|Rest|20 minutes of seated reading.
2410297|NCT03502473|Experimental|One pass/no treatment arm|One random flank will be treated with UltraShape Power device with one pass or remained as a control (no treatment)
2410298|NCT03502473|Experimental|Multiple passes treatment arm|Second flank will be treated with UltraShape Power device with multiple passes.
2410299|NCT03502460|Other|ORFALU|"Lung ultrasound consists of the application of a high-frequency ultrasound probe type Trans Thoracic Echography (ETT) on the anterior and lateral chest of the patient. Since air and bone do not pass through the US, it is the artefacts due to these structures that constitute ultrasound lung semiology.~Esophageal Doppler is a means of monitoring cardiac output measuring stroke volume (SV)."
2410300|NCT03502447|Experimental|TearCare|TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands.
2410301|NCT03502447|Active Comparator|Warm Compress & Lid Massage|Subjects will perform warm compress and lid massage at home daily.
2410302|NCT03502434|Experimental|90 mg/mL SM04755 in water|90 mg/mL SM04755 in water applied via patches
2410303|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle|90 mg/mL SM04755 in aqueous Vehicle applied via patches
2410304|NCT03502434|Experimental|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)|90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches
2410305|NCT03502434|Other|Vehicle|Aqueous Vehicle applied via patches
2410306|NCT03502434|Other|White petrolatum|White petrolatum (Negative control) applied via patches
2410307|NCT03502434|Other|Sodium lauryl sulfate|Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches
2410308|NCT03502421|Experimental|Ketamine|Continuous infusion of Ketamine 0.3 to 0.5 mg/kg per hour PCA Dilaudid 2.0-2.5 mg
2410309|NCT03502421|No Intervention|Opioid Only|Patient-controlled analgesia Dilaudid 2.0-2.5 mg
2410310|NCT03502408|Experimental|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
2410311|NCT03502395|Active Comparator|Group I|Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
2410312|NCT03502395|Placebo Comparator|Group II|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
2410313|NCT03502382|Other|radilogical|Radiological: standing antero-posterior full-length digital images of the lower extremities
2410314|NCT03502369|Experimental|QL group|Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.
2410315|NCT03502369|No Intervention|C group|Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.
2410316|NCT03502356|Active Comparator|Control Group|This group will include 200women undergoing elective cs. In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
2410317|NCT03502356|No Intervention|Study Group|This group will include 200women undergoing elective cs. In this group, patients will receive only standard prophylaxis antibiotic(CEFAZOLIN)
2410318|NCT03502343|Experimental|Modified Gemcitabine plus nab-Paclitaxel|The intervention group
2410319|NCT03502330|Experimental|Cohort 1 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
2410320|NCT03502330|Experimental|Cohort 2 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.03 mg/kg administered in 14 day cycles.
2410321|NCT03502330|Experimental|Cohort 3 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
2410322|NCT03502330|Experimental|Cohort 4 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.1 mg/kg administered in 14 day cycles.
2410323|NCT03502330|Experimental|Cohort 5 Advanced Solid Tumors|Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
2410324|NCT03502330|Experimental|Cohort 6 Advanced Solid Tumors|Nivolumab 240 mg plus Cabiralizumab 4mg/kg plus APX005M 0.3 mg/kg administered in 14 day cycles.
2410325|NCT03502330|Experimental|Cohort 7 Advanced Melanoma|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2410326|NCT03502330|Experimental|Cohort 8 NSCLC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2410327|NCT03502330|Experimental|Cohort 9 RCC|Patients will be treated at the estimated APX005M RP2D in combination with nivolumab 240 mg IV and cabiralizumab 4 mg/kg on day 1 of each 14-day cycle.
2410328|NCT03502317|Experimental|Prehabilitation Study Arm|Patients will participate in a two-pronged prehabilitation strategy - physical prehabilitation and psychological prehabilitation. Prehabilitation will last from a minimum of 21 days to a maximum of 42 days before a patient's clinically indicated surgery.
2410329|NCT03502317|No Intervention|Usual Care Study Arm|No specific exercises or stress reduction techniques are prescribed and the patient will be counseled to continue their current level of activity, and will be given the information on exercise as outlined in the Cancer Care Ontario guidelines. Patients in the Usual Care arm will also be given the same Fitbit activity tracker as patients in the Prehabilitation arm in order to eliminate the activity tracker as an intervention itself and to be able to track the activity (steps) for comparison. Patients in the Usual Care arm will be required to wear their Fitbit activity tracker from the day of randomization to 90 days post-surgery. Patients will record their steps in the diary provided.
2410330|NCT03502304|Active Comparator|Control group|No-exercise
2410331|NCT03502304|Experimental|Endurance training plus resistant training|To concurrent training (endurance training plus resistant training, RT) program will be use cycle ergometers adapted for obese adults (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Prior to the CT intervention, all subjects were familiarized (during 3 sessions) with the training protocols. The CT intervention included 3 weekly sessions of both ET and RT. The core part of each session included RT followed by ET exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
2410332|NCT03502291|Active Comparator|Study One: LAIV + Inoculation|LAIV Nasal Spray: Inoculation (FLUMIST or FLUENZ) plus intramuscular placebo then inoculation with pneumococci bacteria
2410333|NCT03502291|Placebo Comparator|Study One: Placebo + inoculation|Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo then inoculation with pneumococci bacterial
2410334|NCT03502291|Active Comparator|Study Two: Inoculation + LAIV|Inoculation with pneumococci bacteria then Live attenuated Influenza Vaccine Nasal Spray (FLUMIST or FLUENZ) plus intramuscular placebo
2410335|NCT03502291|Placebo Comparator|Study Two: Inoculation + placebo|Inoculation with pneumococci bacteria then Quadrivalent Inactivated Influenza Vaccine Intramuscular (Fluarix Tetra) plus nasal placebo
2410336|NCT03502278|Active Comparator|PTSD lay-led group treatment program|This group will go through the Islamic Trauma Healing Program
2410337|NCT03502278|No Intervention|Waitlist|Waitlist
3144962|NCT00057473|Experimental|Arm A|
2410339|NCT03502252|Experimental|Treatment Group|Semillas de Apego is a group-based psychosocial program for victimized caregivers with children 2 to 5 in Colombia, a country devastated by violence. The program's builds upon scientific evidence on (i) the way in which violence hinders early childhood development and erodes mothers' mental health and their capacity to form nurturing relationships with their children, and (ii) the effectiveness of promoting healthy child-parent attachments to mitigate the effects of toxic stress on toddlers (Lieberman and Van Horn, 2011).
2410340|NCT03502252|No Intervention|Control Group|Centers and participants assigned to the this group continue to have access to the regular early childhood programs offered through the centers to which children are affiliated.
2410341|NCT03502239|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
2410342|NCT03502239|No Intervention|Control- wait list group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
2410343|NCT03502226|Experimental|Intervention group|Received tailored feedback regarding sexual health risks
3144963|NCT00057473|Active Comparator|Arm B|
3144964|NCT00057499|Experimental|IBC-VS01 vaccine|IBC-VS01 vaccine is administered twice.
3144965|NCT00057499|Placebo Comparator|Control Group|IBC-VS01 placebo is administered twice
2410344|NCT03502226|No Intervention|Control group|Did not receive tailored feedback.
2410345|NCT03502187|Active Comparator|Primary Care Management (PCM)|Non-specific LBP, where the cause for the pain cannot be determined, accounts for ninety percent of LBP cases.(Koes, et al, 2006) Reducing pain and continuing daily activity to prevent deconditioning are the primary therapy goals of PCM. Traditional PCM treatment of LBP will include advice/information on self-care options, over-the-counter analgesics, heat application, and remaining active.(Chou, et al., 2007; Koes, et al, 2010) Despite evidence that physical activity is effective, limiting activity remains common; individuals cite pain or re-injury fear as a limiting factor.( Lethem, et al., 1983; Poirandeau, et al., 2006; Steenstra, et al., 2016)
2410346|NCT03502187|Experimental|NeuromuscularElectricalStimulation(NMES)|Rehabilitation requires activation of deep stabilizing muscle groups in the lumbopelvic region. Traditional exercises specific for these muscles are hard to teach with poor compliance. NMES is effective in stimulating these muscles, (Porcari, et al., 2005; Glaser, et al., 2001) resulting in enhanced activation, and improved performance. (Coghlan, et al., 2011) NMES devices are programmed to exercise core muscles through a series of stimulated muscle contractions. Concurrent muscle stimulation of the abdominal wall and lumbar paraspinal area has been shown to be most effective to maximally activate deep lumbar stabilizers in LBP patients. (Baek, et al., 2016) NMES provides as much pain relief as transcutaneous electric nerve stimulation (TENS) in LBP subjects. (Moore SR, Shurman J, 1997)
2410347|NCT03502187|Experimental|Progressive Exercise Plan (PEP)|The literature suggests that this intervention may be of benefit in military personnel with subacute LBP. (Chou, et al., 2007;Marshall PW, Murphy BA, 2006) Meta-analysis showed evidence that graded-activity exercise improved patient outcomes in subacute LBP; however, evidence for other exercise programs were inconsistent. (Hayden, et al., 2005) A strengthening program involving the trunk and abdomen muscles showed clinical reductions in low back pain and disability with high adherence. (Kendall, et al., 2015) Systematic reviews were unable to support any one type of exercise over another. The use of pain-relieving modalities combined with muscle strengthening, such as home-based electrotherapy or progressive exercise, could reduce pain and improve function more rapidly.
2410348|NCT03502161||All subjects|Those receiving a SOT and coming off either 3 months or 6 months of antiviral prophylaxis.
3144966|NCT00057512|Experimental|Intratumoral M4N|The initial dose was 5 mg/cm3 of tumor volume on Days 1, 8, and 15. Dose escalation in cohorts on this schedule took place up to 20 mg/cm3 tumor volume. The dose per lesion was based upon the volume of tumor, and the total dose did not exceed 1197 mg M4N/m2 body surface area.
2410350|NCT03502135|Experimental|Intranasal Anesthesia|Two intranasal sprays of tetracaine HCl and oxymetazoline HCl nasal spray anesthetic administered 4 minutes apart into the nostril corresponding to the side of the treated tooth. If inadequate anesthetic response obtained within 10 minutes, a third spray will be administered and assessed for effective anesthesia after 4 minutes.
2410351|NCT03502122|Experimental|VR rehabilitation|Virtual Reality based rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
2410352|NCT03502122|Active Comparator|control- conventional rehabilitation|conventional rehabilitation therapy for motor function, 1 hour a time at an intensity of three times per week over 8 weeks (total, 24 sessions).
2410353|NCT03502109|Experimental|Intervention group|Medication review with follow-up every 2 months, conducted by a trained pharmacist.
2410354|NCT03502109|No Intervention|Control group|Usual care by physicians, nurses and dietitians.
2410355|NCT03502096|Experimental|100% portion size|100% portion sizes of all foods served (baseline). To-go container and controls received this meal.
2410356|NCT03502096|Experimental|125% portion size|125% of baseline portions served. To-go container and controls received this meal.
2410357|NCT03502096|Experimental|150% portion size|150% of baseline portions served. To-go container and controls received this meal.
2410358|NCT03502096|Experimental|175% portion size|175% of baseline portions served. To-go container and controls received this meal.
2410360|NCT03502044|Active Comparator|Arm 1, active KOS treatment|Patients in arm 1 receive active KOS treatment throughout study, which means 16 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
2410361|NCT03502044|Placebo Comparator|Arm 2, 8 inactive KOS treatments then 8 active KOS treatments|Patients in arm 2 receive inactive KOS treatment during the first 8 KOS treatments of the study. Thereafter patients in arm 2 receive 8 active KOS treatments. Patients receive KOS treatments twice a week during 8 consecutive weeks.
2410362|NCT03502031|Experimental|Renin-Angioten (RAAombination with Spironolactone|Patients with overt Type II diabetic nephropathy and >5 mg/gm UP/Cr ratio that wi to maximal RAAS blockade (ACE/ARB-such as Lisinopril 2000mg, Losartan in combination with Spironolactone (25 m Qday) for 24 months. The determination of maximum tolerwill be left to the discretion anyone at the site
2410363|NCT03502018|Placebo Comparator|Saline|This arm will receive Saline along with Bupivacaine
2410364|NCT03502018|Experimental|Bupivacaine liposome|This arm will receive Exparel along with Bupivacaine
2410365|NCT03502005|Experimental|BIKTARVY®|initiation of single pill once daily bictegravir/emtricitabine/tenofovir alafenamide from prior efavirenz/emtricitabine/tenofovir DF
2410366|NCT03501992|Other|Practice A|Practice A will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice A will be assigned to receive the current care intervention. in the second step, Practice A will be assigned to receive the current care intervention. In the third step, Practice A will receive the reminder-recall intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
2410367|NCT03501992|Other|Practice B|Practice B will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice B will be assigned to receive the current care intervention. In the second step, Practice B will be assigned to receive the reminder-recall intervention. In the third step, Practice B will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice A will receive the combined reminder-recall and audit-and-feedback intervention.
2410393|NCT03501784|Active Comparator|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
3144967|NCT00057525|Experimental|Anthrax vaccine with or without PBS|Administor 1 dose 5 μg rPA with PBS (5 Volunteers)
2410368|NCT03501992|Other|Practice C|Practice C will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice C will be assigned to receive the current care intervention. In the second step, Practice C will be assigned to receive the audit-and-feedback intervention. In the third step, Practice C will receive the audit-and-feedback intervention. In the fourth step, Practice C will receive the combined reminder-recall and audit-and-feedback intervention.
2410369|NCT03501992|Other|Practice D|Practice D will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice D will be assigned to receive the current care intervention. In the second step, Practice D will be assigned to receive the current care intervention. In the third step, Practice D will receive the audit-and-feedback intervention. In the fourth step, Practice D will receive the combined reminder-recall and audit-and-feedback intervention.
2410370|NCT03501992|Other|Practice E|Practice E will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice E will be assigned to receive the current care intervention. In the second step, Practice E will be assigned to receive the reminder-recall intervention. In the third step, Practice E will receive the reminder-recall intervention. In the fourth step, Practice E will receive the combined reminder-recall and audit-and-feedback intervention.
2410371|NCT03501992|Other|Practice F|Practice F will consist of the eligible patients empaneled to one of the six participating practices. In the first step, Practice F will be assigned to receive the current care intervention. In the second step, Practice F will be assigned to receive the audit-and-feedback intervention. In the third step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention. In the fourth step, Practice F will receive the combined reminder-recall and audit-and-feedback intervention.
3144968|NCT00057525|Placebo Comparator|Placebo|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combinedwith phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
2410373|NCT03501966|Active Comparator|Acetazolamide including Diet|"Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet."
2410374|NCT03501966|Active Comparator|Optic Nerve Sheath Fenestration|"Acetazolamide including Diet plus Optic Nerve Sheath Fenestration (ONSF) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~ONSF performed by qualified, certified orbital surgeon using either a medial or supero-medial lid crease approach. ONSF will be performed in one or both eyes, depending on criteria."
2410375|NCT03501966|Active Comparator|Ventriculoperitoneal CSF Shunting|"Acetazolamide including Diet plus Ventriculoperitoneal CSF Shunting (VPS) Subjects will use 250 mg tablets of acetazolamide, divided into two doses, taken with meals. Initial dose will be 1,000 mg twice per day and increased per titration schedule (Table 6 in protocol).~Dietary consultation will include advising subjects to adopt a low sodium weight reduced diet.~VPS performed by qualified, certified neurosurgeon using a frameless image-guided stereotactic system and positioning a shunt catheter in the lateral ventricle of the cerebral hemisphere not associated with speech. The catheter will be connected to an adjustable valve, and a distal shunt system will be placed in the peritoneal cavity."
2410376|NCT03501953|Experimental|Nature Exposure|6-week physical activity course in a natural environment
2410377|NCT03501953|Active Comparator|Urban Exposure|6-week physical activity course in an urban environment
2410378|NCT03501927|Active Comparator|FOCUS (focused cardiac ultrasound)|Patients allocated to FOCUS will receive a preoperative FOCUS examination in conjunction with a standard anesthetic preoperative evaluation.
2410379|NCT03501927|No Intervention|Control|Patients allocated til control arm will receive a standard anesthetic preoperative evaluation according to hospitals' standards.
2410380|NCT03501914|Experimental|Mindfulness Based Intervention|Mindfulness principles based manualized intervention will be provided to the participants which is developed by colleagues in Manchester. This intervention will be adapted to be accessible for people having intellectual disability (ID) in Pakistan.Sessions will take place once-weekly for 12 weeks including an initial orientation session. It will include breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking
2410381|NCT03501888|Active Comparator|Cognitive Behavior Therapy (CBT)|CBT: individually, ca 18 weeks.
2410382|NCT03501888|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT: given in a group setting: ca 18 weeks.
2410383|NCT03501875|Experimental|CAC Score|CAC Score evaluated by the Agatston method
2410384|NCT03501862|Experimental|Mindfulness-based intervention|Intervention: a twelve 1.5 weekly program on mindfulness-based cognitive therapy (psychosis)
2410385|NCT03501862|Active Comparator|Psychoeducation|Intervention: a twelve 1.5 hours weekly program on psychoeducation (psychosis)
2410386|NCT03501849|Experimental|Polypectomy using a cold snare|Polypectomy by cold-snare technique
2410387|NCT03501836|Experimental|Rapid Rhythm Handheld 8-lead ECG Device|Participants will have measurements taken with the 8 lead ECG system, which will be compared to the conventional standard care 12 lead ECG.
2410388|NCT03501823||Peripheral vascular disease|"All adult patients (aged 18 years and above) proven or highly suspected to have peripheral arterial or venous disease.~Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
2410389|NCT03501823||Oncology|"All adult patients (ages 18 years and above) proven or highly suspected to have solid organ malignancy Ultrasound to be performed first in order to correct Photoacoustic tomography positioning.~Photoacoustic tomography to be performed after ultrasound"
2410390|NCT03501797|Experimental|Early singing intervention (AB)|Participants receive a 16 weeks of singing-based rehabilitation and standard care (SC) followed by 16 weeks of SC only.
2410391|NCT03501797|Experimental|Late singing intervention (BA)|Participants receive a 16 weeks of SC only followed by 16 weeks of singing intervention and SC.
2410392|NCT03501784|Experimental|Novidia Dental bonding and flow|Nobio particles incorporated within Novidia Dental Bonding and Flow.
3144969|NCT00057564|Experimental|A (Thalidomide & Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
3144970|NCT00057564|Placebo Comparator|B (Dexamethasone and placebo)|Dexamethasone and placebo
2410394|NCT03501771|Experimental|Acupuncture|Acupuncture needle will be administered.
2410395|NCT03501758||Remission with treatment|Patients randomized to continue medical treatment with biologics
2410396|NCT03501758||Remission without treatment|Patients randomized to stop medical treatment with biologics
2410397|NCT03501745|Other|Management Group|
2410398|NCT03501745|Other|control group|
2410399|NCT03501732|Experimental|Values Affirmation plus Risk Feedback|Values Affirmation with Risk Feedback in substance use and HIV domains of risk
2410400|NCT03501732|Active Comparator|Risk Feedback|Sham Values Affirmation with Risk Feedback in substance use and HIV domains of risk
2410401|NCT03501732|No Intervention|Sleep Control|Description of sleep habits in lieu of values affirmation/sham values affirmation. No risk feedback
2410402|NCT03501719||Triple ART|Patients who remain in triple ART during the follow-up.
2410403|NCT03501719||Dual ART|Patients switched to dual ART during the follow-up.
2410404|NCT03501719||Monotherapy|Patients switched to monotherapy during the follow-up.
2410405|NCT03501706|Experimental|Active Training (AT) Group|Participants will complete four computerized training programs to improve executive function (EF), including Sequenced Recall of Digits - Auditory, Sequenced Reverse Recall of Digits - Auditory, Sequenced Recall of Words - Visual, Verbal Memory - Visual.
2410406|NCT03501706|No Intervention|Control Training (CT) Group|Participants will complete the four computerized programs relating to executive function (EF), but without memory requirements for control.
3185395|NCT00734292|Placebo Comparator|I|"Period 1 Treatment Regimen A: FlutiForm 250/10 ug~Period 2 Treatment Regimen B: FlutiForm 100/10 ug~Period 3 Treatment Regimen C: placebo"
2410409|NCT03501680|Experimental|Group A: intensive insulin|Group A: intensive insulin (glycemic control 4.4-6.1mmol/L)
2410410|NCT03501680|Active Comparator|Group B: standard insulin|Group B: standard insulin (glycemic control 7.8-10.0 mmol/L),
2410411|NCT03501680|Active Comparator|Group C: plasmapheresis|Group C: plasmapheresis
2410412|NCT03501667|Active Comparator|Use of decision support tool|Trainee using decision support tool while assessing a clinical case. This intervention will affect the study participant fund of knowledge on the case.
2410413|NCT03501667|Active Comparator|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
2410414|NCT03501654|Experimental|TecnisSymfony intraocular lens insertion group|
2410415|NCT03501641|Experimental|image-based virtual reality learning|The participants will undergo 10-minute image-based virtual reality learning for history taking and physical examination of otolaryngology.
2410416|NCT03501641|Active Comparator|video-based learning|The participants will undergo 10-minute video-based learning for history taking and physical examination of otolaryngology.
2410417|NCT03501628|Placebo Comparator|Placebo|"2 servings daily~Serving information:~204 kcal~2.8 g fat~44.4 g carbohydrate~0.4 g protein (0 g L-leucine)"
2410418|NCT03501628|Experimental|L-leucine + maltodextrin|"2 servings daily~Serving information:~200 kcal~2.0 g fat~43.1 g carbohydrate~2.8 g protein (2.8 g L-leucine)"
2410419|NCT03501628|Experimental|Whey protein concentrate|"2 servings daily~Serving information:~184 kcal~3.5 g fat~12 g carbohydrate~26.3 g protein (2.8 g L-leucine)"
2410420|NCT03501628|Experimental|Hydrolyzed whey protein concentrate|"2 servings daily~Serving information:~192 kcal~4.6 g fat~12.2 g carbohydrate~25.4 g protein (2.9 g L-leucine)"
2410421|NCT03501628|Experimental|Soy protein concentrate|"2 servings daily~Serving information:~266 kcal~4.5 g fat~17.2 g carbohydrate~39.2 g protein (2.9 g L-leucine)"
2410422|NCT03501602|Active Comparator|LMA protector group|The LMA Protector is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts
2410423|NCT03501602|Active Comparator|I-gel LMA group|The I-gel is an alternative supraglottic device which provides the seal over the airway versus an inflatable cuff.
3144971|NCT00057603|Experimental|Deep Brain Stimulation|Participants receive deep brain stimulation treatment for 30 months.
2410425|NCT03501563||Case Group|"Participants with ASA 1-2, aged 18-60 years, undergoing hypotensive anesthesia in the operation of the septoplasty in Recep Tayyip Erdoğan University Medical Faculty Training and Research Hospital. Participants with uncontrolled hypertension, diabetes mellitus, cerebrovascular disease, cogulopathy, morbid obesity (BMI ≥35) and renal disease will not be taken.~Participants were first pre-medicated with an infusion of midazolam 0.05 mg/kg, fentanyl 1 µg/kg, lidocaine 1 mg/kg. Induction of anesthesia was achieved with an infusion of propofol 1-2 mg/kg and vecuronium bromide 0.6 mg/kg and after 2 to 3 minutes participants were intubated with the appropriate tube size. Anesthesia was maintained with an infusion of remi fentanyl (0.05 - 1 µg/Kg/min), with oxygen (O2) in air with desflurane."
2410427|NCT03501537|Experimental|Surgical treatment with free gingival graft|Free gingival graft harvested from the palate will be placed around the diseased implant
2410428|NCT03501524|Experimental|VATS evacuation|patients selected for VATS after failure of first thoracostomy tube drainage
2410429|NCT03501524|Experimental|thoracostomy tube|patients selected for thoracostomy tube reinsertion after failure of drainage with first thoracostomy tube
2410430|NCT03501511|Active Comparator|IDF modules|Diabetes educations using IDF Arabic translated modules
2410431|NCT03501511|Experimental|Conversational Maps|Diabetes Educations using Ramadan fasting conversational maps (Arabic maps)
2410432|NCT03501498|Experimental|loperamide|Slows intestinal transit time
2410433|NCT03501498|Experimental|senna|Speeds up intestinal transit time
2410434|NCT03501472|Experimental|Text-only PWL, immediate post|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2410435|NCT03501472|Experimental|Text-only PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2410436|NCT03501472|Experimental|Low-emot PWL, immed post|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2410437|NCT03501472|Experimental|Low-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit little emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2410438|NCT03501472|Experimental|High-emot PWL, immed posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2410439|NCT03501472|Experimental|High-emot PWL, delay posttest|"Exposure to 4 FDA-mandated warning labels paired with images that elicit high emotion and numeric risk information for 8 outcomes related to those warnings (2 outcomes for each PWL; half as percentage, half as frequency)~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks following last exposure to warning labels"
2410440|NCT03501459|Experimental|Rituximab|
2410441|NCT03501433|Experimental|Nicotinamide Riboside Chloride (Niagen)|7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
2410442|NCT03501433|Placebo Comparator|Placebo|7 days of placebo supplementation (2/day)
2410443|NCT03501420||Physicians|A sample of 230 to 325 rheumatologists actively involved in management and treatment decisions of pSS subjects in France, Italy, Spain, Germany and the United States will be included in the survey.
2410444|NCT03501420||Subjects with pSS|Subjects with a confirmed diagnosis of pSS under consultation of the rheumatologists enrolled in the study will be included.
2410445|NCT03501407||Erythema migrans|Patients for whom a diagnosis of acute phase of Lyme disease is done on the basis of the existence of an erythema migrans and a tick bite history in the days preceding the occurrence of erythema (before and after antibiotics treatment) will be recruited
2410446|NCT03501407||No-erythema migrans|"Patients with unspecific symptoms (the most common symptoms being:~headache, arthralgia, myalgia, febrile episode) appearing within 3 months after a tick bite will be recruited"
2410447|NCT03501394|Experimental|Single Arm|25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited. During the study, patients will receive the standard care and the current study will not alter the care plan offered to them. All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions. Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery. Health questionnaire will be completed by each patient.
2410448|NCT03501381|Active Comparator|High Dose Interleukin 2|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19
2410449|NCT03501381|Experimental|High Dose Interleukin 2 plus Entinostat|HD IL-2 600,000 IU/kg Every 8 hours on Days 1-5 and Days 15-19 plus Entinostat 5 mg orally every 2 weeks starting Day -14
2410450|NCT03501368|Experimental|Trametinib + Ceritinib Treatment|Study treatment will be given in cycles. Each cycle will be 4 weeks (28 days). Post-Treatment (follow-up) Period: Participants will return to the study site between 30-40 days after the last dose of trametinib + ceritinib for an end-of-treatment assessment. Additional follow-up will occur for related Adverse Events (AEs) that are not resolved by this time and related Serious Adverse Events (SAEs) that occur after the time of this visit. Participants will be followed for survival every 3 months for the first year following end of treatment, and then every 6 months for up to 5 years after end of treatment.
2410451|NCT03501355|Active Comparator|Strength training group|Intervention:Inspiratory muscle strength training group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device
2410452|NCT03501355|Active Comparator|Endurance training group|Intervention: Inspiratory muscle endurance training group received inspiratory muscle endurance training (IMT) using POWERbreathe Classic threshold loading device
2410453|NCT03501342|Experimental|Virtual reality group|In virtual reality group, 30 minutes of Pilates training, 10 minutes of rest and then 20 minutes of virtual reality will be applied.
2410454|NCT03501342|Active Comparator|Dynamic Balance Training|"In the Dynamic Balance Training group, 20 minutes of dynamic balance exercises will be applied after Pilates training."
2410455|NCT03501342|No Intervention|Control group|The control group will be taught relaxation exercises and will be asked to perform the exercises at home.
2410456|NCT03501329||Outpatients in Community Psychiatry|"Treatment with consultations, social support, psychological and psychopharmacological treatment. This is routine psychiatric care.~Treatment was not changed as a result of the investigation in itself."
2410457|NCT03501316|Active Comparator|Hand Instrumentation|Root surface debridement using hand instruments.
2410458|NCT03501316|Active Comparator|Ultrasonic Instrumentation|Root surface debridement using ultrasonic scaler.
2410459|NCT03501303|Experimental|No touch|No touch technique. Patients are randomized to no touch vein harvesting. The technique is used as routine in Medical care by some hospitals.
2410460|NCT03501303|Other|Control|Control technique. Patients are randomized to Control vein harvesting. The technique is used as routine in Medical care.
2410461|NCT03501290|Other|Oral Nutritional Supplement Group|All patients will be in one group, receiving the active product, Oral Nutritional Supplement with 'Fortimel® Protein supplementation'
3185396|NCT00734292|Placebo Comparator|II|"Period 1 Treatment Regimen B: FlutiForm 100/10 ug~Period 2 Treatment Regimen C: placebo~Period 3 Treatment Regimen A: FlutiForm 250/10 ug"
2410498|NCT03501134||Tumor treating fields|Patients diagnosed with WHO Grade IV malignant glioma who are approved and planned to use the NovoTTF device
2411550|NCT03493737||OH (Outpatient Hospital)|Bortezomib is always injected at Outpatient hospital
3185397|NCT00734292|Placebo Comparator|III|"Period 1 Treatment Regimen C: placebo~Period 2 Treatment Regimen A: FlutiForm 250/10 ug~Period 3 Treatment Regimen B: FlutiForm 100/10 ug"
3185398|NCT00734318|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 micrograms (2 puffs bd)
3185399|NCT00734318|Experimental|Flutiform 50/5 micrograms|Flutiform 50/5 micrograms (2 puffs bd)
2410468|NCT03501251|Experimental|Moxidectin 8 mg|A single tablet of 8 mg of moxidectin
2410469|NCT03501251|Experimental|Moxidectin 8 mg + Albendazole|A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
2410470|NCT03501251|Experimental|Moxidectin 16 mg|Two tablets of 8 mg of moxidectin ( = 16 mg)
2410471|NCT03501251|Experimental|Moxidectin 16 mg + Albendazole|Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
2410472|NCT03501251|Experimental|Moxidectin 24 mg|Three tablets of 8 mg of moxidectin ( = 24 mg)
2410473|NCT03501251|Experimental|Moxidectin 24 mg + Albendazole|Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
2410474|NCT03501251|Placebo Comparator|Placebo|A single tablet of placebo
2410475|NCT03501238|Experimental|BSG|Participant receives bovine milk, then milk substitute, then milk substitute treated with gelatin
2410476|NCT03501238|Experimental|BGS|Participant receives bovine milk, then milk substitute with gelatin, then milk substitute
2410477|NCT03501238|Experimental|SBG|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin.
2410478|NCT03501238|Experimental|SGB|Participant receives milk substitute, then bovine milk, then milk substitute with gelatin
2410479|NCT03501238|Experimental|GSB|Participant receives milk substitute with gelatin, then milk substitute, then bovine milk.
2410480|NCT03501238|Experimental|GBS|Participant receives milk substitute with gelatin, then bovine milk, then milk substitute.
2410481|NCT03501225|Experimental|ozone|tooth extraction under irrigation with ozonated water
2410482|NCT03501225|Experimental|water|tooth extraction under irrigation with ozonated water or doubly distilled water
2410483|NCT03501212|Active Comparator|Interventional|EMLA group layer of 2.5 gr EMLA cream (standard adult dose) was applied to both wrists
2410484|NCT03501212|Placebo Comparator|Placebo|Placebo cream was applied to both wrists
2410485|NCT03501199|Experimental|PRF Group|PRF is will be used in immediate dental implant placement.
2410486|NCT03501199|Experimental|Graft Group|The xenogenic graft is will be used in immediate dental implant placement.
2410487|NCT03501199|Experimental|Control Group|No extra material is will be used in immediate dental implant placement.
2410488|NCT03501186|Experimental|Group 1|forward walking on leveled surface
2410489|NCT03501186|Active Comparator|Group 2|forward walking on sand.
2410490|NCT03501186|Experimental|Group 3|Backward walking on leveled surface
2410491|NCT03501186|Active Comparator|Group 4|Backward walking on sand.
3144972|NCT00057629|Active Comparator|1 Prolonged Exposure|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
3144973|NCT00057629|Active Comparator|2 Individual and group therapy|"TUGT (Treatment as usual group therapy - used in Study 1), delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is no formal, structured format for these groups; counselors are sensitive to the participants' needs and follow their lead re content covered in discussions and exercises.~Supportive counseling (SC - study 2): individual therapy delivered in 10 weekly, 90 minute sessions. Therapist helps patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these."
3144974|NCT00057642|Other|Sertraline, venlafaxine, bupropion|This is an open trial so there is only one arm using standard antidepressant medications.
3144975|NCT00057759|Experimental|Sildenafil citrate|Sildenafil with dose escalation as needed from 50 mg to 100 mg/day prn for 12 weeks.
2410496|NCT03501147|Experimental|Intervention|15 minutes of resistance training at the work place every day
2410497|NCT03501147|No Intervention|Control|Usual work
2411551|NCT03493711||Breast Fed|Exclusively breastfed for first 3 months of life
3144976|NCT00057759|Placebo Comparator|Placebo|"Placebo with similar dose escalation opportunity for 12 weeks."
3144977|NCT00057850|Experimental|Arm I|"Phase I: Patients receive BMS-247550 IV over 3 hours and cisplatin IV over 30-60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of BMS-247550 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment as above at the recommended phase II dose of BMS-247550.~Phase II: Patients receive treatment as in Phase I at the recommended phase II dose of BMS-247550."
3144978|NCT00057915|Experimental|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
3144979|NCT00057967|Experimental|Treatment arm|alemtuzumab
3144980|NCT00058084|Experimental|Arm I|Patients receive ixabepilone (BMS-247550) IV over 3 hours on day 1.
3144981|NCT00058084|Experimental|Arm II|Patients receive mitoxantrone IV over 30 minutes on day 1 and oral prednisone twice daily on days 1-21. In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3144982|NCT00058097|Experimental|Treatment (tipifarnib)|"INDUCTION THERAPY: Patients receive oral tipifarnib twice daily for 3 weeks. Treatment repeats every 4 weeks for up to 3 courses.~RADIOTHERAPY: Within 14 days after the completion of induction therapy, patients undergo radiotherapy daily, 5 days a week, for 6 weeks.~MAINTENANCE THERAPY: Two weeks after the completion of radiotherapy, patients receive additional tipifarnib as in induction therapy.~Treatment continues in the absence of disease progression or unacceptable toxicity."
3144983|NCT00058201|Active Comparator|Arm I|Patients receive leucovorin calcium IV and fluorouracil IV on days 1-5.
3144984|NCT00058201|Experimental|Arm II|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15.
3144985|NCT00058201|No Intervention|Arm III|Patients undergo observation.
2410499|NCT03501108|No Intervention|Control|Patients in the control arm receive usual pharmaceutical care in hospital i.e. daily medication review by the attending physicians and ward-assigned pharmacist.
2410500|NCT03501108|Experimental|Intervention|Patients in the intervention arm receive usual pharmaceutical care as per the control group plus application of STOPPFrail deprescribing criteria advice points on their medication list at a single time point i.e. within 24 hours of randomization. The bespoke STOPPFrail advice report is presented to the patient's attending physician who then adjusts the patient's prescriptions according to the STOPPFrail advice points. The attending physician can implement as few or as many STOPPFrail advice points as he/she sees appropriate.
2410501|NCT03501095||patients|patients who must undergo general and/or urology surgery of an elective type
2410502|NCT03501082|Experimental|L. Reuteri PB-W1 Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2410503|NCT03501082|Experimental|L. Reuteri DSM20016T Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2410504|NCT03501082|Placebo Comparator|Placebo Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. 5 of the participants will be assigned to consume their usual diet for the first diet period. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
2410505|NCT03501082|Experimental|L. Reuteri PB-W1 Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri PB-W1 strain provided on day 4 of each diet period.The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri PB-W1 strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2410506|NCT03501082|Experimental|L. Reuteri DSM20016T Non-West Diet Start|5 participants will be assigned to this group and provided with a one time dose of L. Reuteri DSM20016T strain provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The L. Reuteri DSM20016T strain will be provided as a drinkable solution (approximately 2.25x10^10 viable cells will be provided in 50 ml of water).
2410507|NCT03501082|Placebo Comparator|Placebo Non-Western Diet Start|5 participants will be assigned to this group and provided with a one time dose of a placebo provided on day 4 of each diet period. The participants will be assigned to consume a non-western diet that will be prepared by the research team. The placebo will be provided as a drinkable solution (approximately 2 g maltodextrain dissolved in 50 ml of water).
3185400|NCT00734318|Active Comparator|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|Flixotide pMDI 250 mcg (2 puffs bd) + foradil pMDI 24 50/5 mcg (bd)
3185401|NCT00734318|Active Comparator|Flixotide pMDI 250 micrograms|Flixatide pMDI 250 micrograms (2 puffs bd)
3185402|NCT00734331||IBD|Inflammatory bowel disease patients
3185403|NCT00734331||Control|Average risk patients undergoing screening colonoscopy
3185404|NCT00734357|Experimental|Isovue Arm|Subjects with a clinically scheduled CT examination will be given the contrast Isovue. The investigators of this study will determine which contrast medication subjects will receive using randomization.
3185405|NCT00734357|Experimental|Omnipaque Arm|Subjects with a clinically scheduled CT examination will be given the contrast Omnipaque. The investigators of this study will determine which contrast medication subjects will receive using randomization
2410514|NCT03501056|Experimental|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2410515|NCT03501056|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2410516|NCT03501056|No Intervention|conventional therapy|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3185406|NCT00734370|Experimental|VRET|Virtual Reality Exposure Therapy for agoraphobic participants
2410518|NCT03501030|Experimental|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
2410519|NCT03501030|No Intervention|No activity restriction|Women in the control group will not receive any reccomandation regarding activity restriction. Bed rest and abstain from sexual intercourse will also not recommended.
2410520|NCT03501017|Experimental|Intervention group|The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).
2410665|NCT03500081||Cancer Patients|Cancer patients with any solid tumor type planning to undergo a course of radiation therapy.
3185407|NCT00734370|Active Comparator|Exposure in vivo|Standard exposure in vivo for panic disorder
3185408|NCT00734370|No Intervention|Wait-list control|Wait-list control group. Participants from this arm are randomized to the two active conditions after 10 weeks of waiting.
3185409|NCT00734383|Experimental|1|Propofol Cardioprotection
3185410|NCT00734383|Experimental|2|Volatile Anesthesia Preconditioning
3185411|NCT00734422|Experimental|VRET with yohimbine|Virtual Reality Exposure Therapy will be combined with the administration of yohimbine hydrochloride
3185412|NCT00734422|Placebo Comparator|VRET with placebo|Virtual Reality Exposure Therapy will be combined with an inactive placebo pill (Albochin).
3185413|NCT00734435|Active Comparator|1|Zonisamide SR 360 mg and olanzapine 10-20 mg daily
3185414|NCT00734435|Placebo Comparator|2|Placebo and olanzapine 10-20 mg daily
2410521|NCT03501017|Active Comparator|Control Group|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
2410522|NCT03501004|Experimental|The Acupuncture Group|Sterile acupuncture needles for single use will be used.The intervention is going to be executed using the acupuncture points GV14（Dazhui）and GB20 (Fengchi) for 20 minutes.The acupuncture needles will be inserted to a depth of 0.8 to 1 cm using GV14（Dazhui）and GB20 (Fengchi).
2410523|NCT03501004|Sham Comparator|The Sham Acupuncture Group|Sterile acupuncture needles for single use will be used.The sham acupuncture group's acupuncture needles will be inserted to a depth of 0.1 to 0.2 cm with nonacupuncture points located 0.5 cm in lateral to the real acupoint or to the right for midline points for 20 minutes.
2410524|NCT03500991|Experimental|ARM A (Tumor Cavity Infusion)|"patients with supratentorial tumors for which CAR T cells will be delivered into the tumor resection cavity~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
2410525|NCT03500991|Experimental|ARM B (Ventricular System Infusion)|"patients with either infratentorial tumors or leptomeningeal tumors for which the CAR T cells will be delivered into the fourth ventricle or lateral ventricle, respectively~Intervention: HER2-specific chimeric antigen receptor (CAR) T cell"
2410526|NCT03500978|Experimental|Peer CBT Intervention|Women allocated to the peer-specialist delivered CBT intervention group will be mailed an intervention workbook (CBT exercises) and have their first telephone-based intervention session scheduled. The CBT intervention group will receive 8 telephone-based CBT intervention sessions (over 9 weeks) delivered by peer specialists. Each session will last up to 30 minutes.
2410527|NCT03500978|No Intervention|Control|Women allocated to the observation-only control group will not receive any intervention.
2410528|NCT03500965|Experimental|Text-only PWL, absol risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2410529|NCT03500965|Experimental|text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2410530|NCT03500965|Experimental|graphic PWL, absol risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2410531|NCT03500965|Experimental|graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2410532|NCT03500952|Experimental|Patient Decision Aid|Birth Control After Pregnancy patient decision aid and supporting document
2410533|NCT03500952|Active Comparator|Patient Information Leaflet|Postpartum Birth Control patient information leaflet
2410534|NCT03500939|Experimental|Normobaric hyperoxygenation + standard of care|Normobaric hyperoxygenation (NBHO), i.e. inhalation of 100% oxygen at high flow (≥ 40 L/min) via a sealed non-rebreather face-mask with reservoir, or in case of intubation/ventilation for (study-independent) TBY, ventilation with an inspiratory oxygen fraction (FiO2) of 1.0. NBHO is started within 3 hours of stroke symptom onset (witnessed or last seen well) and within 20 minutes after end of baseline brain imaging and applied until the end of TBY procedure (defined by removal of guide catheter from sheath) or, in case TBY is not attempted, 4 hours after start of study treatment.
2410535|NCT03500939|Active Comparator|standard of care alone|standard of care alone; oxygen supplementation if SpO2 ≤ 94% at 2 to 4 L/min via nasal cannula according to guidelines of the European Stroke Organisation (ESO), or in case of TBY-related intubation/ventilation, ventilation with an initial FiO2 of 0.3 to be gradually increased if SpO2 ≤ 94%.
2410536|NCT03500926|Active Comparator|hype standard|total hip replacement with standard femoral stem
2410537|NCT03500926|Experimental|hype mini|total hip replacement with short uncemented femoral stem
2410538|NCT03500913||Adults with growth hormone deficiency|Subjects who present to the neuroendocrine unit at Columbia University Irving Medical Center (CUIMC) for therapy of GH deficiency or who are followed in the unit and have active GH deficiency and are planning to initiate a therapy.
2410539|NCT03500913||Control group|Healthy subjects matched to the GH deficiency subjects for age (+/- 5 years), gender and total fat mass (+/- 4%).
2410540|NCT03500900|Experimental|Vildagliptin|DPP-4 inhibitor, acute administration (50 mg.)
2410541|NCT03500900|Placebo Comparator|Placebo|Placebo treatment, acute administration
2410542|NCT03500887|Other|1. Bag inflated so that intrabagpressure increases with 2 mmHg|
2410543|NCT03500887|Other|2. Bag inflated to ¾ volume of 1|
2410544|NCT03500874|Experimental|Systematic Chemotherapy + HAI(FUDR)|"Patients will receive Systemic FOLFOX + HAI (FUDR) every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15.~floxuridine (FUDR) 0.12mg/Kg/d,d1-14 and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
2410545|NCT03500874|Active Comparator|Systematic Chemotherapy|"Patients will receive FOLFOX every every 28 days:~Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1,15; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1,15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1,15."
2410546|NCT03500861|Experimental|Dry Needling|While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.
2410547|NCT03500861|Sham Comparator|Sham Dry Needling|In the Sham Dry Needling (SDN) group, three times a week for 2 weeks, the SDN procedure was applied into the adipose tissue located at any area where an active TrPs was absent.
2410548|NCT03500848|Active Comparator|Tacrolimus-based group|Tacrolimus-based immunosuppression regimen: Tacrolimus+MMF and/or steroids
2410549|NCT03500848|Experimental|Sirolimus-based group|Sirolimus-based immunosuppression regimen: Tacrolimus (Tacrolimus elimination 30 (± 5) days post LT)+Sirolimus+MMF and/or steroids
2410550|NCT03500835|Experimental|App Plus Coaching (AC)|6 month addiction model based weight loss intervention in the form of an iPhone app coupled with personalized coaching.
2410551|NCT03500835|Experimental|App Alone (AA)|6 month addiction model based weight loss intervention in the form of an iPhone app.
2410552|NCT03500835|Experimental|Clinic|In-Clinic Multi-disciplinary monthly weight management program. Curriculum adapted from the KidsNFitness Program and administered by an MD, RD, Psychologist and Health Educator over 90 minute sessions
2410553|NCT03500822|Experimental|Metronome-paced tachypnea|Dynamic hyperinflation by the method of metronome-paced tachypnea.
2410554|NCT03500822|Experimental|Exspiratory-stenosis breathing|Dynamic hyperinflation by the method of expiratory-stenosis breathing.
2410555|NCT03500809|Experimental|Aqueous release (Burping) of the wound|"Following uneventful cataract surgery, wound burping will be performed in all eligible patients who gave their informed consent. The procedure will be offered whenever the intraocular pressure (IOP) is either higher than 30 mmHg or deemed inappropriate in view of the ocular condition (e.g. glaucoma).~After 'burping' the wound, patients will have their IOP measured using Goldmann application tonometry (GAT) immediately and at 2 hours. The 'burping' procedure will be repeated until satisfactory pressure is achieved and care will be taken to avoid shallowing of the anterior chamber while fluid is released. We will assess for the presence of leaks from the wound with a Seidel test with fluorescein 5% once the IOP is satisfactory. To prevent any infection after each procedure, we will prescribe post-op drops including chloramphenicol 0.5% four times a day for 2 weeks or minimum of 3 days and these will continue as per routine. All other complications will be recorded at follow-up."
2410556|NCT03500796|Other|Corneal perforation patients|"Patients who had/impeding corneal perforation due to melting of the cornea after infection with a corneal pathogen (bacterial or viral), with no previous surgical intervention.~Patients will undergo:~Platelet rich plasma clot implantation Wound closure with amniotic membrane"
2410557|NCT03500783|Experimental|Nitric Oxide|Patients of this group receive treatment with exogenous gaseous nitric oxide supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease.
2410558|NCT03500783|Placebo Comparator|Standard CPB|Patients of this group receive sham-treatment without supplying nitric oxide to the cardiopulmonary bypass circuit during coronary artery bypass grafting for coronary artery disease. Considering dilution of nitric oxide at a high ratio of 1 to 25,000 in the gas mixture of the cardiopulmonary bypass circuit (CPB), no addition of any inert gas to the CPB circuit is required in sham-treatment group.
2410559|NCT03500770|Experimental|Transcranial Direct Current Stimulator|The Transcranial Direct Current Stimulator device (tDCS) is a safe technique which poses a non-significant risk to study subjects. This technique uses weak current which is applied by using two electrodes. In the literature, no undesirable or long-lasting side effects due to device have been reported, nor have any participants reportedly abandoned a study due to discomfort.
2410561|NCT03500744|Experimental|Erector spinae plane block|"The ESPB will be performed with ultrasound guidance. After identifying a suitable location between 8th and 10th thoracic spine transverse process, the overlying skin will be infiltrated with local anesthetic. A 22 gauge 90-mm needle will be inserted to make contact with the transverse process and withdraw slightly. Ropivacaine 0.5% 20 mL will be injected at this location. The same procedure will be performed on the other side.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
2410562|NCT03500744|Sham Comparator|Shame block|"A sham block will be performed by performing ultrasound examination of the back looking for intended location for ESPB placement. Skin will be infiltrated with local anesthetics but ESPB will not be performed.~Additionally, patients will receive acetaminophen, gabapentin and intravenous patient-controlled analgesia opioids."
2410563|NCT03500731|Experimental|Lung and Bone Marrow Transplantation|"All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.~Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression.~Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved."
2410564|NCT03500718|Experimental|Pediatric patients with bilateral sensorineural hearing loss|One group will be studied: Patients undergoing cochlear implantation surgery between age 1 and 6 years who meet the above inclusion and exclusion criteria seen in JIPMER during the study period.
2410565|NCT03500705|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening) while observing the reflection of the exercising limb in the mirror (Mirror Therapy) which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2410566|NCT03500705|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric elbow extensions with their less-affected upper limb (Cross-Education of Strengthening). Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
3185415|NCT00734448|Experimental|A,1|Gestational diabetes patients who take myo-inositol
3185416|NCT00734461|Placebo Comparator|Placebo|Placebo, single dose
3185417|NCT00734461|Active Comparator|Oxycodone 20 mg|Oxycodone 20 mg single dose tablet
2411081|NCT03497000|Experimental|OCTA group|Patients in this group underwent OCTA-guided half-dose photodynamic therapy.
3185418|NCT00734461|Active Comparator|Oxycodone 40 mg|Oxycodone 40 mg single dose tablet
3185419|NCT00734461|Experimental|PTI-801 20/.001 mg|Oxycodone 20 mg / Naltrexone 0.001 mg
3185420|NCT00734461|Experimental|PTI-801 40/.001 mg|Oxycodone 40 mg / Naltrexone 0.001 mg
2410570|NCT03500666|Experimental|Robot lateral neck lymph node dissection|Robot neck lateral lymph node dissection was performed in patients with thyroid cancer and lateral cervical lymph node metastasis.
2410571|NCT03500666|Experimental|Total endoscopic lateral cervical lymph node dissection|Patients with thyroid cancer and lateral cervical lymph node metastases underwent total endoscopic neck dissection.
2410572|NCT03500653|Active Comparator|Active|4 gr Curcumin daily for 1 year in addition to vedolizumab 300 mg per infusion (standard of care)
2410573|NCT03500653|Placebo Comparator|Sham|4 gr placebo daily for 1 year in addition to vedolizumab300 mg per infusion (standard of care)
2410574|NCT03500640|Active Comparator|DPP Plus: 30-minute calls|Following the 6-month, 16-session, DPP core program, 30-minute group telephone calls will be implemented. Structured behavioral DPP maintenance sessions with a healthy aging focus occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
2410575|NCT03500640|Placebo Comparator|DPP Minimal: 15-minute calls|Following the 6-month, 16-session, DPP core program, 15-minute group telephone calls will be implemented. Social-support sessions occur once-per-month from months 7 to 12, and every-two-months from months 13 to 24.
2410576|NCT03500627|Experimental|Cohort 1|20 mg/kg OP-101 administered intravenously for over 1 hour.
2410577|NCT03500627|Experimental|Cohort 2|40 mg/kg OP-101 administered intravenously for over 1 hour.
2410578|NCT03500627|Experimental|Cohort 3 (optional)|80 mg/kg OP-101 administered intravenously for over 1 hour.
3144986|NCT00058227|Experimental|Treatment (alvocidib, fludarabine phosphate, rituximab)|Patients receive fludarabine phosphate IV over 15-30 minutes on days 1-5 and rituximab IV over 3-4 hours on day 1. Alvocidib is administered IV over 60 minutes on day 1 in cohort 1; on days 1 and 2 in cohort 2; and on days 1, 2, and 3 in cohort 3. In cohorts 4 and 5, patients receive fludarabine phosphate and rituximab as above and alvocidib IV over 30 minutes and then IV over 4 hours on day 1 of courses 2-6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3144987|NCT00058253|Experimental|Group I|Patients receive docetaxel IV over 1 hour and 17-AAG IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2410581|NCT03500601|Experimental|Active treatment|Nut components
2410582|NCT03500601|Placebo Comparator|Placebo|Placebo
2410583|NCT03500588||normotensive pregnant women more than 20 weeks gestation.|One hundred and forty-five pregnant women after 20 weeks with normal blood pressure were evaluated for VEGF gene mutation.
2410584|NCT03500588||Pregnant women after 20 weeks with preeclampsia.|One hundred and forty-five pregnant women after 20 weeks with preeclampsia were evaluated for VEGF gene mutation by using PCR and Pulsitality index of umbilical artery by doppler velocimetry.
2410585|NCT03500575|Experimental|photopheresis|
2410586|NCT03500575|No Intervention|control|
2410587|NCT03500562||HCV participant population in China|
2410588|NCT03500549|Experimental|1,080mg APL-2 administered subcutaneously|1,080mg APL-2 administered subcutaneously twice weekly or every three days.
2410589|NCT03500549|Active Comparator|Eculizumab|Complement (C5) Inhibitor
2410590|NCT03500536|No Intervention|Waitlist Control|8 weeks of treatment as usual followed by 8 weeks of IntelliCare treatment.
2410591|NCT03500536|Experimental|Experimental|8 weeks of IntelliCare treatment followed by 8 weeks of treatment as usual.
2410592|NCT03500523|Experimental|1-study group|study group: pregnant women
2410593|NCT03500523|Experimental|2-control group|control group: healthy non pregnant women
3144988|NCT00058253|Experimental|Group II|Patients receive docetaxel IV over 30 minutes and 17-AAG as in group 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3144989|NCT00058266|Experimental|Group A|Patients receive oral genistein once daily for 1-2 months, undergo radical prostatectomy, and then continue oral genistein once daily for 1-2 months afterward (for a total of 3 months of therapy).
3144990|NCT00058266|Experimental|Group B|Patients undergo radical prostatectomy. Beginning 1 month after surgery, patients receive genistein as in arm I for 3 months.
3144991|NCT00058292|Experimental|Treatment Arm|
3144992|NCT00058305|Experimental|Treatment (bryostatin 1, vincristine sulfate)|"Patients receive bryostatin 1 IV over 24 hours on days 1 and 15 and vincristine IV on days 2 and 16. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients without disease progression after 6 courses may continue therapy with bryostatin 1 IV over 24 hours on days 1 and 22 and vincristine IV on days 2 and 23. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity."
3144993|NCT00058318|Experimental|Treatment|Gemcitabine + Capecitabine
2410600|NCT03500445|Experimental|Treatment Arm (D-KRd)|
2410601|NCT03500432|Active Comparator|periprostatic group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periprostatic block
2410602|NCT03500432|Active Comparator|PAT group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+periapical triangle (PAT) block
2410603|NCT03500432|Experimental|TPA switch group|local anesthesia of trnasperineal prostate biopsy with subcutaneous local anesthesia+TPA switch (transperineal prostate biopsy local anesthesia switch) block
3144994|NCT00058331|Experimental|epoetin alfa - long term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Then patients receive EPO SC once weekly for 18 weeks. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
3144995|NCT00058331|Experimental|epoetin alfa - short term dosing|"Patients receive epoetin alfa (EPO) subcutaneously (SC) once weekly for 3 weeks. Patients receive EPO SC on day 1 of weeks 4, 7, 10, 13, 16, and 19. Quality of life is assessed at randomization at then monthly during study treatment.~Patients are followed every 6 months for 1 year."
3144996|NCT00058357|Active Comparator|Lidocaine patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
3185421|NCT00734461|Experimental|PTI-801 20/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
3185422|NCT00734461|Experimental|PTI-801 40/.0001 mg|Oxycodone 40 mg / Naltrexone 0.0001 mg
2411682|NCT03492736|Placebo Comparator|Placebo|30 days placebo taken nightly 1 hour before bed
2410609|NCT03500393|Active Comparator|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
2410610|NCT03500393|Experimental|Remotely Supervised Exercise (REM)|The REM program is designed to function as an Acceptance-based health coaching intervention and will utilize theory-based behavior change techniques (i.e., goal setting/action planning, self-monitoring, receiving feedback, and reviewing relevant goals in the light of feedback) to promote adoption and adherence to the exercise prescription.
2410611|NCT03500380|Experimental|RC48-ADC|Participants will receive RC48-ADC 2.0 mg/kg intravenous (IV) infusion each 14-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
2410612|NCT03500380|Active Comparator|Lapatinib + Capecitabine|Participants will receive lapatinib 1250 mg orally once daily during each 21-day cycle + capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination.
2410613|NCT03500367|Experimental|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
2410614|NCT03500354|Experimental|Nutrient|Nutrient drink
3144997|NCT00058357|Placebo Comparator|Placebo patch|Participants will be instructed to apply a patch or patches (up to 3 maximum simultaneously) directly to the affected area. The patch(es) should be applied during awake hours and then left on continuously for approximately 18 hours or until usual bedtime sleep.
3144998|NCT00058461|Experimental|Treatment (chemotherapy, rituximab)|Patients receive ifosfamide IV over 2 hours and etoposide IV over 1 hour on days 3-5, rituximab IV on days 1 and 3, and carboplatin IV over 1 hour on day 3. Patients receive filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Patients also receive intrathecal (IT) chemotherapy comprising methotrexate and cytarabine. Patients with B-cell large cell lymphoma and negative CSF cytology receive IT chemotherapy on day 3 of the first course only. Patients with small non-cleaved cell lymphoma or B-cell acute lymphoblastic leukemia and negative CSF cytology receive IT chemotherapy on day 3. All patients with positive CSF cytology receive IT chemotherapy on days 3, 10, and 17 of the first and second courses. Treatment repeats every 23 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2410618|NCT03500315|Experimental|HIV D+/R+|HIV-infected individuals that accept an organ from an HIV-infected deceased donor - enrollment 80
2410619|NCT03500315|No Intervention|HIV D-/R+|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor -enrollment 80
2410620|NCT03500315|No Intervention|HIV D-/R+ (observational)|HIV-infected individuals that accept an organ from an HIV-uninfected deceased donor and randomized to observational group - enrollment 200
2410624|NCT03500276|Experimental|Yoga program|"12 weeks of Yoga in daily life practice, 2x weekly for 90 minutes including physical exercises (asanas), breathing exercises (pranayama), relaxation and meditation exercises."
2410625|NCT03500276|Active Comparator|Arthritis-education control|12 weeks of arthritis - education classes, consisting of 1x weekly sessions for 120 minutes including lectures on arthritis and related issues followed by group discussion.
2410626|NCT03500263|Active Comparator|Cohorts 1 and 2: PTI-808 Active Co-admin with PTI-801 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2410627|NCT03500263|Placebo Comparator|Cohorts 1 and 2: PTI-808 Placebo Co-admin with PTI-801 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2410628|NCT03500263|Active Comparator|Cohort 3 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2410629|NCT03500263|Placebo Comparator|Cohort 3 PTI-808 placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for a total of 14 days. A follow up visit will occur on Day 21.
2410630|NCT03500263|Active Comparator|Cohort 4 PTI-808 Active + PTI-801 Active + PTI-428 Active|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
2410631|NCT03500263|Placebo Comparator|Cohort 4 PTI-808 Placebo + PTI-801 Placebo + PTI-428 Placebo|Subjects will be randomized to receive either PTI-808 co-administered with PTI-801 and PTI-428 or placebos once-a-day for 7 days immediately followed by PTI-808 co-administered with PTI-801 or placebos once-a-day for 7 days. A follow-up visit will occur on Day 21.
2410632|NCT03500250||Nurses|Nurses working on the neurological wards of three hospitals (one university hospital and two general hospitals)
2410666|NCT03500081||Healthy Volunteers|Faculty members in the Department of Radiation Oncology have volunteered to participate in this research project. They are investigators and are interested in the abilities of this new machine(MR-Linac) and the potential benefits to patients who will be treated in their department. These scans will be used to optimize scanning parameters for various body sites and to identify appropriate positioning methods for future patient treatments.
3144999|NCT00058474|Active Comparator|Arm 1: 5-FU + RT|Patients receive fluorouracil IV continuously and undergo radiation therapy (RT) once daily 5 days a week for 5-6 weeks.
3145000|NCT00058474|Experimental|Arm 2: 5-FU + RT + Oxaliplatin|Patients receive fluorouracil and undergo RT as in arm 1. Patients also receive oxaliplatin IV over 1 hour once weekly for 5 weeks.
3145001|NCT00058474|Experimental|Arm 3: Capecitabine + RT|Patients receive oral capecitabine twice daily and undergo RT once daily 5 days a week for 5-6 weeks.
3145002|NCT00058474|Experimental|Arm 4: Capecitabine + RT + Oxaliplatin|Patients receive capecitabine and undergo RT as in arm 3. Patients also receive oxaliplatin as in arm 2.
3145003|NCT00058526|Experimental|Cohort 1|Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
3145004|NCT00058526|Experimental|Cohort 2|Six doses of dHER2 (100 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
3145005|NCT00058526|Experimental|Cohort 3|Six doses of dHER2 (500 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
3145006|NCT00058526|Experimental|Cohort 4|Three doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 4, and 14. Patients in this cohort can receive two booster doses at Weeks 34 and 38, respectively.
2410640|NCT03500185|Experimental|PFMT in group|Participants randomized to this group will perform the PFMT protocol in a group, with physiotherapeutic supervision, lasting 1 hour, in the Outpatient Clinic of Gynecology of Hospital of Clinics of Porto Alegre (HCPA), for a period of 3 months. You will also be instructed to perform exercises at home. After this period, they will be reassessed and will follow the same protocol for another 3 months now at home. After this period, they will be evaluated again.
2410641|NCT03500185|Active Comparator|PFMT at home|Randomized participants for this group will receive guidance on the home PFMT protocol on the day of the initial evaluation. They will be instructed to perform the exercises daily for a period of 3 months. After 3 months they will be re-evaluated and will follow the same protocol for another 3 months at home. After this period they will be evaluated again.
2410642|NCT03500172|Active Comparator|DTP, Continue DTP if Responsive|
2410643|NCT03500172|Active Comparator|DTP, Standard of Care (SoC) if Responsive|
2410644|NCT03500172|Active Comparator|DTP, Continue DTP if Non-Responsive|
2410645|NCT03500172|Active Comparator|DTP, DTP+ICM if Non-Responsive|
2410646|NCT03500172|Active Comparator|ICM, Continue ICM if Responsive|
2410647|NCT03500172|Active Comparator|ICM, SoC if Responsive|
2410648|NCT03500172|Active Comparator|ICM, Continue ICM if Non-Responsive|
2410649|NCT03500172|Active Comparator|ICM, ICM+DTP if Non-Responsive|
2410652|NCT03500146||Normal sexual function|Patients with an overall FSFI score equal to or above 26.5 will be in the normal sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
2410653|NCT03500146||Low sexual function|Female sexual dysfunction is defined as an overall FSFI score below 26.5, patients meeting this criteria will be in the low sexual function group. Patients in both groups will be treated with an overactive bladder treatment, either anticholinergics, beta-agonists or PTNS.
2410654|NCT03500133|Experimental|Group A|"Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.~No radiotherapy if CR at the end of chemotherapy."
2410655|NCT03500133|Experimental|Group B|"Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy"
2410656|NCT03500133|Experimental|Group B2|"Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2410657|NCT03500133|Experimental|Group C|"Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.~No radiotherapy if CR at the end of chemotherapy."
2410658|NCT03500133|Experimental|Group D|"Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2410659|NCT03500133|Experimental|Group E|"High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy"
2410660|NCT03500133|Experimental|Group F|"High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.~No radiotherapy if CR at the end of chemotherapy. IN 30Gy RT in case of PR at the end of chemotherapy"
2410661|NCT03500120||Primary Aldosteronism|Aldosterone/renin concentration ratio(ARR)≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST≥6 ng/dl
2410662|NCT03500120||non Primary Aldosteronism|1. ARR≥1.0 (ng/dl)/(mIU/l) and 2. PAC post-FST<6 ng/dl
2410663|NCT03500107|Experimental|Blue LED 401 +/- 5 nm|The Blue LED 401 +/- 5 nm will be applied in the participant, in a closed room by a physiotherapist for 1 hour. The apparatus will be supported on a tripod, statically, externally, 5 cm away from the vulva abd vaginal region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol consists of only one session. This part of the study will see if there is bactericidal effect of the blue LED.
3145007|NCT00058591|Experimental|Treatment|Treatment dose levels 1, 2 and 3
3145008|NCT00058604|Experimental|Treatment|Each patient will receive a Biological/Vaccine Intravenous injection of EBV specific CTLs
3145009|NCT00058617|Experimental|Injection of EBV Specific CTLs|Subjects will receive autologous EBV Specific CTLs. Patients that agree will recieve CTLs that have been marked with the neomycin resistance gene.
3145010|NCT00058773|Experimental|CTL Administration|Infusion of EBV Specific Cytotoxic T-Lymphocytes
3145011|NCT00058799|Experimental|Dose Level 1|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
3145012|NCT00058799|Experimental|Dose Level 2|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
3145013|NCT00058799|Experimental|Dose Level 3|Patients are treated with up to six injections of their gene-modified CD40L and IL-2 skin fibroblasts and leukemic blasts, separated by one-two weeks in an immunological treatment window.
3145014|NCT00058812|Experimental|EBV specific T cells|EBV specific T cells
3145015|NCT00058890|Experimental|Gabapentin|
3145016|NCT00058890|Placebo Comparator|Placebo|
3145017|NCT00058955|Experimental|1|Sodium oxybate
3145018|NCT00058955|Active Comparator|2|triazolam
3145019|NCT00058955|Active Comparator|3|pentobarbital
3145020|NCT00058955|Placebo Comparator|4|Placebo
3145021|NCT00059254|Experimental|Oleic acid (OA)|
3145022|NCT00059254|Experimental|Palmitic acid (PA)|
3145023|NCT00059280|Experimental|1|
3145024|NCT00059306|Active Comparator|Antiplatelet|Participants receive aspirin + placebo OR aspirin + clopidogrel
2410667|NCT03500055|Experimental|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin.
2410668|NCT03500055|No Intervention|Control|Normal operative procedure. The abdominal closure bundle will not be used.
2410669|NCT03500042|Experimental|respiratory muscle weakness|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
2410670|NCT03500042|Experimental|normal respiratory muscle|Patients with respiratory muscle weakness are performing the inspiratory pressure threshold device, expiratory pressure threshold device and concurrent inspiratory and expiratory muscle device for one minute randomly.
2410671|NCT03500029|Experimental|TMS treatment group|In the Transcranial magnetic stimulation (TMS) treatment group patients with severe depression receive rTMS treatment without drug treatment.
2410672|NCT03500029|Active Comparator|medication group|In the medication group patients with severe depression are treated with anti-depressants.
2410673|NCT03500029|No Intervention|healthy control group|The control group don't accept intervention and treatment.
2410674|NCT03500016|Experimental|Acute exercise and exercise training|"Euglycemic-hyperinsulinemic clamp before and after 8 weeks supervised exercise training. Before exercise training the participants will also do an acute exercise on 1 hour with muscle biopsies taken before and after exercise and then again 4 hours into recovery."
2410675|NCT03500003|Experimental|Milk acute intake|14 adult and 14 elderly volunteers will consume 600mL of milk. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
2410676|NCT03500003|Experimental|Yogurt acute intake|14 adult and 14 elderly volunteers will consume 600mL of yogurt. Blood (11 sampling points) and urine samples (3 collection points) will be collected before the ingestion and during the postprandial period (6h).
2410677|NCT03499977|Experimental|Sitting|The participant will be asked to sit for 10 min (not increasing their heart rate) then do the anti-saccade task
2410678|NCT03499977|Experimental|Low-Intensity Cycling|Participant will be asked to cycle for 10 min (<40% VO2R) and then perform the anti-saccade task
2410679|NCT03499977|Experimental|Moderate-Intensity Cycling|The participant will be asked to do 10 min of cycling (40-59% VO2R) followed but the anti-saccade task
2410680|NCT03499977|Experimental|High-Intensity Cycling|The participant will be asked to do 10 min of cycling (60%-84% VO2R) followed but the anti-saccade task
2410681|NCT03499964|Experimental|Optilume Treatment|The treatment arm will be the Urotronic Optilume Drug Coated Balloon (DCB).
2410682|NCT03499964|Active Comparator|Control Treatment|The control arm will be treated by a urethral dilation method considered to be best standard of care for the study site and subject. A control treatment may be either a rod, uncoated balloon or DVIU.
2410683|NCT03499951|Other|Wheelchair Skills Trainers|Individuals will receive remotely delivered wheelchair skills training, after which they will be assessed on their ability to teach the Wheelchair Skills Trainees a series of wheelchair skills in a one-on-one environment. The intervention for this group is Wheelchair Skills Training - Remote.
2410684|NCT03499951|Other|Wheelchair Skills Trainees|Individuals will receive one-on-one wheelchair skills training from the Wheelchair Skills Trainers. The intervention for this group is Wheelchair Skills Training - In Person.
2410685|NCT03499925|Experimental|Test Group|Telephone consultation effectiveness and cognitive behaviors
2410686|NCT03499925|No Intervention|Comparison Group|Routine product inspection
3145025|NCT00059306|Active Comparator|Blood pressure|The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
3145026|NCT00059345|Experimental|Arm 1: Acupuncture|Participants will receive acupuncture
3145027|NCT00059345|Placebo Comparator|Arm 2: Shallow needling|Participants will receive shallow needling on non-mederian points
2410690|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/1mL|"In the intervention group, Ketamine Hydrochloride 50Mg/1mL was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds). Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention."
2410691|NCT03499886|Experimental|Ketamine Hydrochloride 50Mg/mL|in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds. Patient assessment was performed before and two minutes after ketamine injection, and then every 5 minutes after the reduction of the fracture, by an anesthetist blind to the type of intervention.
2410695|NCT03499847|Active Comparator|Active Intervention|subjects will be given a pamphlet about the advanced medical directive, and a standardized face-to-face counselling session will be conducted with their healthcare provider
2410696|NCT03499847|Active Comparator|Passive Intervention|subjects will be given a pamphlet about the advanced medical directive
2410697|NCT03499847|No Intervention|Control|
2410698|NCT03499834|Experimental|Study Group|26 patients who has successfully undergone the screening criteria will be enrolled for treatment. Immune Killer Cells (IKC) will be administered through Intravenous Injection (I.V.) Frequency: One injection per week, twenty-four injections on-treatment
2410699|NCT03499821|Experimental|Study population|EDOF ICL implanted into both eyes of eligible subjects.
3145028|NCT00059345|Other|Arm 3: No Acupuncture or Placebo Treatment|Participants will receive usual care, no acupuncture or placebo acupuncture treatment.
3145029|NCT00059358|Experimental|1|Participants will begin receive either Rebetron or PEG-Intron plus ribavirin therapy from Weeks 2 through 48
3145030|NCT00059371|Active Comparator|Circumcised immediately|
3145031|NCT00059371|Placebo Comparator|Delayed Circumcision|Men who were randomized to delayed circumcision were scheduled to be offered male circumcision 2 years after their randomization.
3145032|NCT00059423||1|Individuals of African descent with benign ethnic neutropenia (BEN) at baseline
3145033|NCT00059423||2|Individuals of African descent without benign ethnic neutropenia (BEN) at baseline
3145034|NCT00059462|Experimental|Arm 1|
3145035|NCT00059462|Active Comparator|Arm 2|
3145036|NCT00059592|Experimental|Valacyclovir|oral Valacyclovir three times a day for 5 to 10 days.
2410702|NCT03499769|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
2410703|NCT03499769|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
3145037|NCT00059605|Experimental|DOTAP:Chol-fus1|Infusion intravenous once every 3 weeks
3145038|NCT00059618|Experimental|Bortezomib|PS-341 (Bortezomib) 0.8-1.5 mg/m^2 IV push + Carboplatin (AUC 5) IV on Day 1 of each cycle, then Bortezomib alone on Days 4, 8 and 11 in each 28 day cycle.
2410706|NCT03499743|Experimental|group1 (hyoscine Butyl-bromide group)|group1 will receive hyoscine butyl bromide 10 mg (BUSCOPAN tablets, produced by Chemical Industries Development (CID), Giza - A.R.E. under licence of Boehringer Ingelheim International GmbH - Germany) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
2410707|NCT03499743|Placebo Comparator|group 3 (PLACEBO GROUP)|will receive a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib 2 hours before IUD insertion.
2410708|NCT03499743|Experimental|group 2(celecoxib group)|group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide 2 hours before IUD insertion.
2410709|NCT03499704|Experimental|Pioglitazone + Alogliptin + Metformin (PAM)|Pioglitazone 15 milligram (mg) and alogliptin 25 mg in fixed dose combination (FDC) tablet (SYR-322-4833), orally once daily and metformin greater than or equal to (>=) 500 mg, tablet, orally, twice a day for up to 52 weeks. At Week 12, if participants has HbA1c >=7.5%, pioglitazone dose will be titrated up to 30 mg based on investigator's opinion and up-titrated dose will be maintained up to Week 52.
2410710|NCT03499704|Active Comparator|Dapagliflozin + Alogliptin + Metformin (DAM)|Dapagliflozin 10 mg, tablet, orally, once daily with alogliptin 25 mg, tablet, orally, once daily, and metformin >=500 mg, tablet, orally, twice a day, for up to Week 52.
2410711|NCT03499691|Experimental|Expanded Hemodialysis (HDx) Therapy|Patients will undergo 3 dialysis sessions per week with Theranova 500 for up to 24 weeks.
2410712|NCT03499691|Active Comparator|Hemodiafiltration (HDF) Therapy|Patients will undergo 3 dialysis sessions per week with on-line HDF for up to 24 weeks.
2410713|NCT03499678||Lung Cancer|Small cell lung cancers (SCLC) and non-small cell lung cancers (NSCLC)
2410714|NCT03499678||Control|Age and sex matched control individuals
2410715|NCT03499665|Experimental|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|This group of patients received patients with bruxism. It was applied proprioceptive neuromuscular facilitation (PNF), myofascial releasing maneuvers and home exercises.
2410716|NCT03499665|Active Comparator|Myofascial Releasing Maneuvers and Home Exercises Group|This group of patients received patient with bruxism. It was applied myofascial releasing maneuvers and home exercises.
2410717|NCT03499665|Active Comparator|Control Group|This group of patients received patient with bruxism. It was applied conventional treatment and no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
2410718|NCT03499652||derivation cohort|The data of derivation cohort are used to derive the neonatal bacterial meningitis risk score
2410719|NCT03499652||validation cohort|The data of validation cohort are used to validate the neonatal bacterial meningitis risk score
2410720|NCT03499639|Other|patients with HCV and ESKD|Ombitasvir / Paritaprevir / Ritonavir/Ribavirin Oral Tablet
2410721|NCT03499626|Experimental|ASLAN001|A 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdrawal of consent.
2410722|NCT03499613||Chronic low back pain|Patients with chronic low back pain participating to a 3 weeks Multidisciplinary rehabilitation program
2410723|NCT03499600|Experimental|Clinical Assessment and CFI|CA and CFI families will receive the Cultural Formulation Interview prior to their standard Clinical Assessment during their intake.
2410724|NCT03499600|Active Comparator|Clinical Assessment Only|CA families will receive a standard Clinical Assessment during intake.
2410725|NCT03499587||Obese pregnant women|BMI >30 with early OB visit medical records accessible
2410726|NCT03499587||Normal weight pregnant women|BMI 18.5-25 with early OB visit medical records accessible.
2410727|NCT03499574|Experimental|Biofeedback group|Dysphagia therapy using surface EMG as biofeedback - 10 x 45 minute sessions of swallow strength and skill training using surface electromyography as biofeedback tool. This group will also receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education.
2410728|NCT03499574|Other|Control group|This group will receive usual care provided by Speech and Language Therapists, which may involve assessment, review, therapy, patient/family education
2410729|NCT03499561||pregnant women in first Trimester|A urine sample will be taken from pregnant women before 14 weeks of pregnancy
2410730|NCT03499561||pregnant women in second Trimester|A urine sample will be taken from pregnant women from 14 weeks +1 day till 28 weeks
2410731|NCT03499561||pregnant women in third Trimester|A urine sample will be taken from pregnant women from 28 weeks +1 day till 40 weeks
2410732|NCT03499548|Experimental|Intervention|10 hours of intensive CBT for suicide will be delivered to male prisoners who are having thoughts of ending their lives. This will be delivered in 2 hours sessions, 5 times across 2 weeks.
2410733|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/EPA|Participants viewed radon and smoking risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
2410734|NCT03499535|Active Comparator|Study 1: Radon&Smoking Synergistic/Idaho|Participants viewed radon and smoking risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
2410771|NCT03499262|Experimental|Group Social ABcs|Participants receiving Group Social ABCs intervention
2410735|NCT03499535|Experimental|Study 1: Radon Only / EPA|Participants viewed only radon risk information taken from the EPA's pamphlet on the dangers of radon gas exposure.
2410736|NCT03499535|Experimental|Study 1: Radon Only / Idaho|Participants viewed only radon risk information taken from Idaho's Department of Health and Human Welfare's pamphlet on the dangers of radon gas exposure.
2410737|NCT03499535|Experimental|Study 2: Radon Only|Participants viewed a radon-only message that focused only on the effect of radon on lung-cancer risk.
2410738|NCT03499535|Other|Study 2: Radon and Smoking Isolated|Participants viewed a radon-and-smoking-isolated message that covered the individual effects of radon and of smoking on lung cancer, but without mentioning their synergistic effect.
2410739|NCT03499535|Active Comparator|Study 2: Radon & Smoking Synergistic|Participants viewed a radon-and-smoking-synergistic message that covered the individual effects of radon and of smoking but that also included information about their synergistic effect.
2410740|NCT03499522||Observational group|"80 patients with congenital coagulopathies (hemophilia A and B, and von Willebrand's disease), of legal age, will be included in the study. Patients will be recruited in six centers, from different regions of Spain.~The inclusion criteria to participate in the present study are patients: with a medical diagnosis of congenital coagulopathies (hemophilia A and B, or von Willebrand's disease); adults; in a prophylactic or on demand regimen with FVIII / FIX concentrates; and that they have signed the informed consent document.~On the other hand, those patients with: neurological or cognitive alterations that impede the comprehension of the questionnaires will be excluded from the study; inability to walk autonomously or with an orthosis; and without access to digital media to complement the measuring instruments."
2410741|NCT03499509|Experimental|Low Glycemic Diet|
2410742|NCT03499509|Placebo Comparator|High Glycemic Diet|
2410743|NCT03499483|Experimental|Open Label Biktarvy|Single arm all participants receive open label study product intervention.
2410744|NCT03499470|Active Comparator|Intervention|"The intervention mainly consists of a developed protocol for education about the disease and medications AND an education of the equipment and how to use it to have the best benefit.~Actions in structured discharge and follow up protocol:~Patient education for disease severity and medications~Education of family/relatives about medications and types of equipment~Detailed education for LTOT and/or NIV (how to use, duration of use, solutions for possible common problems)~Preparation of home environment for patients needs~Regular telephone visits on day 7 and day 14 after discharge and telephone visits in emergency situations and early referral to the hospital when needed~Outpatient control for the first month"
2410745|NCT03499470|No Intervention|Control|Control patients will receive usual care
2410746|NCT03499457|Experimental|treatment|penicillin chalange test, as descibed.
2410747|NCT03499444|Experimental|Oral Rucaparib monotherapy|Part I: Dose Escalation, Part II: Dose Expansion (Additional patients will be enrolled at the recommended dose as defined in Part I of the study.)
2410748|NCT03499418||newborns with TTN|Group of late preterm and full-term newborns with TTN evaluated by modified Silverman scale
2410749|NCT03499418||newborns with PPHN|Group of late preterm and full-term newborns with respiratory failure with PPHN evaluated by echocardiography
2410750|NCT03499405|Experimental|Intervention group|Intervention group will receive a family navigator intervention from a culturally matched family navigator.
2410751|NCT03499405|No Intervention|Control group|Control group will not receive a family navigator intervention from a culturally matched family navigator.
2410752|NCT03499392|Other|psychological investigation|
2410753|NCT03499379||Women initiating use of an intrauterine device|"Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.~A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion."
3185423|NCT00734487||1. AREDS2 subjects|Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.
2410755|NCT03499340|Experimental|Text-only PWL, absolute risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2410756|NCT03499340|Experimental|Text-only PWL, relative risk|Exposure to FDA-mandated warning labels, without a graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2410757|NCT03499340|Experimental|Low arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2410758|NCT03499340|Experimental|Low arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a low arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2410759|NCT03499340|Experimental|High arousal graphic PWL, absolute risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk of a smoking-related disease
2410760|NCT03499340|Experimental|High arousal graphic PWL, relative risk|Exposure to FDA-mandated warning labels, paired with a high arousal graphic image, accompanied by risk information about smoker's risk and non-smoker's risk of a smoking-related disease
2410761|NCT03499327|Active Comparator|Wheat germ oil (UV treated)|Wheat germ oil (UV treated)
2410762|NCT03499327|Placebo Comparator|Wheat germ oil (untreated)|Wheat germ oil (untreated)
2410763|NCT03499327|No Intervention|Control|no study products
2410764|NCT03499314|Experimental|RS-tDCS Stimulation|20 times 20 minute stimulation session supervised by a study technician through a videoconferencing platform, VSee
2410765|NCT03499314|Placebo Comparator|Sham Stimulation|20 ×20-minute sessions sham tDCS
2410766|NCT03499301||Chronic pain|Patients with chronic pain when arrived to emergency room.
2410767|NCT03499301||No chronic pain|Patients without chronic pain when arrived to emergency room.
2410768|NCT03499288||Children and youth with cerebral palsy|Subjects between 1 month and 18 years of age with Cerebral Palsy who visited the coordinating HCP within the past 12 months.
2410769|NCT03499275|Sham Comparator|Sham NMES|Sham neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
2410770|NCT03499275|Experimental|Active NMES|Neuromuscular electrical stimulation plus home exercise programme and advice on breathlessness management
2410772|NCT03499249|Experimental|N-Acetylcysteine Treatment|Will receive continuous intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
3145039|NCT00059631|Experimental|Bortezomib + Mitoxantrone|"Bortezomib starting dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.~Mitoxantrone starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles."
3145040|NCT00059683|Experimental|Cervical Cerclage Group|Women randomized to receive cerclage should receive cervical cerclage
3145041|NCT00059683|No Intervention|Control Group|Women randomized to not receive cerclage represent the control arm
2410776|NCT03499223|Experimental|Ranibizumab + THR-317|Subjects will receive intravitreal ranibizumab in combination with THR-317
2410777|NCT03499223|Active Comparator|Sham + ranibizumab|Subjects will receive a sham injection in combination with intravitreal ranibizumab
2410778|NCT03499210|Experimental|Investigational group|All subjects will participate in study procedures involving use of the ReWalk ReStore device.
2410779|NCT03499184|Experimental|Local Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be delivered locally every 12 hours for 12 weeks
2410780|NCT03499184|Experimental|Systemic Probiotics|P Flor (Lactobacillus reuteri 1.2 billion CFU) will be administered every 12 hours for 12 weeks
2410781|NCT03499184|Active Comparator|Systemic Antibiotics|Amoxil 500 mg capsule and Flagyl 400 mg tablet by mouth, will be given every 8 hours for 5 days
2410782|NCT03499171|Experimental|Citalopram|20mg, once a day
2410783|NCT03499171|Placebo Comparator|Placebo|Once a day
2410784|NCT03499158||1|affected arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome
2410785|NCT03499158||2|healthy arms of patients who had gone to electrodiagnostic study and diagnosed as carpal tunnel syndrome in the other arms
2410786|NCT03499145||Eligible patients for AI test.|Device: ophthalmology diagnostic system. An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
2410787|NCT03499132||General anesthesia (with opioids)|orthopedic surgery plus general anesthesia
2410788|NCT03499132||Epidural anesthesia (without opioids)|orthopedic surgery plus epidural anesthesia (without opioids use)
2410789|NCT03499132||Subarachnoid anesthesia (with opioids)|orthopedic surgery plus subarachnoid anesthesia (plus intrathecal opioid)
2410790|NCT03499132||Regional anesthesia (without opioids)|orthopedic surgery plus regional anesthesia (peripheral nerve block, continous or single shot, without opioid use)
2410793|NCT03499106|Experimental|Healthy Volunteers|Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.
2410794|NCT03499093||Prosthetic patient with esthetic expectations|Prosthetic patients with esthetic expectations (PP-E, n=35), Patients seeking for restoration or replacement of anterior teeth, or expressing any esthetic expectation
2410795|NCT03499093||Prosthetic patients without esthetic expectations|Prosthetic patients without esthetic expectations (PP-NE, n=35) Patients pending restoration or replacement of posterior teeth (premolars and molars), expressing only functional expectation
2410796|NCT03499093||Dental patient with esthetic concern|Dental patient with esthetic concern(C-E, n=35) Patient consulting for follow up, having crowns or removable denture replacing anterior teeth
2410797|NCT03499093||Dental patient without any esthetic concern|Dental patient without any esthetic concern (C-NE, n=35) Patient consulting for follow up, having no crown or removable denture replacing anterior teeth.
2410798|NCT03499080||Patients in medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
2410799|NCT03499080||Patients in treatment as Usual Åråsen|Inpatient unit colocated with the medication free unit. Same level of care. Similar treatment program, shorter treatment duration (on average 3 weeks).
2410800|NCT03499080||Patients in treatment as Usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
2410803|NCT03499054|No Intervention|control group|Hemodialysis patients in the control group who receive only routine nursing care during hemodialysis
2410804|NCT03499054|Experimental|exercise group|The exercise group are asked to perform breathing exercises during hemodialysis for the study period of 3 months.
2410805|NCT03499041|Experimental|LY3314814 Control|LY3314814 administered orally to participants with normal hepatic function
2410806|NCT03499041|Experimental|LY3314814 Mild|LY3314814 administered orally to participants with mild hepatic impairment
2410807|NCT03499041|Experimental|LY3314814 Moderate|LY3314814 administered orally to participants with moderate hepatic impairment
2410808|NCT03499041|Experimental|LY3314814 Severe|LY3314814 administered orally to participants with severe hepatic impairment
2410848|NCT03498781|Experimental|Exercise-only intervention|Participants will receive information regarding the health benefits of regular aerobic and resistance training exercise and current physical activity guidelines for adults.
3145043|NCT00059761|Experimental|Sequence A: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
3145044|NCT00059761|Experimental|Sequence B: Level 1|Irinotecan 40 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3145045|NCT00059761|Experimental|Sequence A: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
3185424|NCT00734487||2. Controls|Age-matched subjects without retinal pathology
2410811|NCT03499015|No Intervention|Ear without BET|ear without BET treatment works as control
2410812|NCT03499015|Experimental|BET ear|ear with BET treatment works as intervention arm
2410813|NCT03499002|Experimental|Simulation Lab|
2410814|NCT03499002|Experimental|ER in situ Simulation|
2410815|NCT03498989|Experimental|preterm formula milk neoborn|will be given preterm formula milk
2410816|NCT03498989|Experimental|exclusive breast milk|will be given exclusive breast milk
2410817|NCT03498976|Other|Pulsed radiofrequency on SE nerve|Single technic
2410818|NCT03498976|Other|Pulsed radiofrequency on SE + CF nerves|Combinated technic
2410819|NCT03498963|Other|bronchoalveolar lavage|
2410820|NCT03498950|No Intervention|Placebo Group|submitted to the routine laser therapy protocol in addition to simulated laser irradiation on the taste papillae
2410821|NCT03498950|Experimental|Test Group|submitted to the same laser therapy protocol as that of the Placebo Group, however, laser irradiation on the taste papillae will be effective.
2410822|NCT03498937|Experimental|Group 1|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 active tDCS sessions, followed by 10 sham tDCS sessions
2410823|NCT03498937|Experimental|Group 2|Subjects suffering from Borderline Personality Disorder randomly assigned to start the trial by 10 sham tDCS sessions, followed by 10 active tDCS sessions
2410824|NCT03498924||CASES|Patients with endometrial cancer
2410825|NCT03498924||CONTROLS|Matched controls without neoplasm disease
2410826|NCT03498911|Active Comparator|envelope Coronally Advanced Flap (eCAF)|A mucogingival surgery where an envelope flap is coronally advanced and sutured to cover the mucosal recession
2410827|NCT03498911|Experimental|Modified Tunnel Technique (MTT)|A mucogingival surgery where the gingiva is released without reflecting a flap (as described for tunnel techniques) and then coronally advanced and sutured to cover the mucosal recession
2410828|NCT03498898|Active Comparator|Group A|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
2410829|NCT03498898|No Intervention|Group B|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total hip replacement
2410830|NCT03498898|Active Comparator|Group C|American Society of Anesthesiologists (ASA) Score 2-3 with chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement.
2410831|NCT03498898|No Intervention|Group D|American Society of Anesthesiologists (ASA) Score 2-3 with no chronic use of Beta adrenergic receptor blockers planned to undergo total knee replacement
2410832|NCT03498885|Experimental|Low ligation|Left colic artery (LCA) is identified, tie the sigmoid artery and superior rectal artery,Apical lymph node dissection with the left colic artery preservation is performed.
2410833|NCT03498885|Active Comparator|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apical lymph nodes dissection is performed.
2410834|NCT03498872|Active Comparator|Able-bodied individuals|
2410835|NCT03498872|Experimental|Transtibial amputee|
2410836|NCT03498872|Experimental|Transfemoral amputee|
2410837|NCT03498859|Other|Home-based training|10 weeks of home-based training with no supervision of a physiotherapist
2410838|NCT03498859|Other|Physiotherapist-supervised training|Physiotherapist-supervised training once per week during 10 weeks in addition to home-based training
2410839|NCT03498846|Experimental|Modified EA and AMLK|Modified corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe corneal burn.
2410840|NCT03498846|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe corneal burn.
2410841|NCT03498833|Other|Test-retest reliability testing|Minimum 50 IKOA will be evaluated with the scale on two occasions within two weeks to establish test retest reliability.
2410842|NCT03498820|Experimental|Analgesia Nociception Index|Intraoperative remifentanil administration guided by the Analgesia Nociception Index
2410843|NCT03498820|Active Comparator|Usual practice|Intraoperative remifentanil administration managed in standard practice
2410844|NCT03498807|Experimental|Control group_Use Ventilator P/V tool|Use the Pressure/Volume Loop
2410845|NCT03498807|Active Comparator|Study group_Use EIT|Use the Electrical Impedance Tomography
2410846|NCT03498794|Active Comparator|Ureteral stent|"Technique of ureteral stent insertion:~All patients will be in lithotomy position, and an endoscopy operating table with fluoroscopic imaging capability will be used. Before the procedures, all patients will have retrograde ureteropyelography. Then, a 0.035-inch hydrophilic guide wire will be placed into the renal pelvis under the guidance of flexible cystoscope.~The ureteral stent will be inserted retrograde by using flexible cystoscope, under mild sedation or local anesthesia by instilling 2% xylocain gel per urethra. Patients will be covered by specific antimicrobial therapy according to urine and/or blood culture. This treatment will be continued until there was no fever and any evidence of infection disappeared. A Foley's catheter will be left in the bladder for 2 hours in all patients. In each case the type of stent will be that of 5 or 6 F, with side-holes and remain in place until definitive treatment of stone."
2410847|NCT03498794|Active Comparator|Percutaneous nephrostomy tube|"Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively. The patients will be placed on the ultrasound table with fluoroscopic imaging capability in prone position and a pillow placed under the abdomen on the affected side to support the kidney. Then the initial puncture site will be chosen, cleaned and draped. Local anesthesia was injected and a stab incision was given at the puncture site. The 18-gauge Chiba needle will be inserted at the renal angle or at the posterior axillary line under ultrasound guidance into dilated pelvicalyceal system. Urine or pus drained out spontaneously or will be sucked with a disposable syringe and sample was sent to the laboratory for culture and sensitively."
3185425|NCT00734513|Experimental|1|Partner-assisted Emotional Disclosure
3185426|NCT00734513|Active Comparator|2|Cancer Education
2410849|NCT03498781|Sham Comparator|Control intervention|Participants will receive information regarding the health risks of chronic stress as well as suggested methods to reduce stress.
2410850|NCT03498768||Inpatients with lung nodules|All inpatients in our department are invited to finish the questionnaire at inpatient education on the first day of hospitalization as the baseline date, then they are followed up by phone call to reevaluate their psychosocial status at 6 months and 1 year after the surgery.
2410851|NCT03498755|Experimental|Multi-sectoral anemia behavior change|Address multiple behavioral determinants of anemia by promoting the identification, knowledge, valuation and practice of four behavioral domains: 1) consumption of micronutrient-rich animal-source foods; 2) malaria and soil-transmitted helminth infection control practices; 3) water, sanitation and hygiene (WASH) best practices; and 4) women's autonomy in decision-making and control of the use of earned income.
2410852|NCT03498755|Experimental|Strengthening market engagement of fish processors|Assist women in overcoming limited access to credit, inadequate storage facilities, and insufficient information about market prices, which constrain the timeliness and amount of market-ready product available for sale, through a three-pronged approach that includes: 1) a conditional cash transfer; 2) entrepreneurship training; and 3) enhanced access to market price information.
2410853|NCT03498755|Experimental|Improving fish smoking technology and practices|Introduce and promote a recently developed fish smoking oven known as the Ahotor, which was explicitly designed to reduce emission from biomass fuel combustion, decrease polycyclic aromatic hydrocarbon (PAH) levels of smoked fish, and increase fuel efficiency. Use of this oven will reduce workload, increase earnings, and reduce harmful occupational exposures. Introduction of this improved fish smoking oven will be combined with behavior change education focused on promoting optimal fish smoking and handling practices.
2410854|NCT03498742||No SABA users|Asthmatic subjects that did not use short acting beta2 agonists in the last 3 months and being using none agent or ICS, systemic corticosteroids of combined ICS/LABA as relief symptoms agent.
2410855|NCT03498742||SABA users|Most of the asthmatic subjects usually inhale SABA as rescue medication and many times SABA is the only one prescribed treatment for asthma.
2410856|NCT03498729||Persistent AF|
2410857|NCT03498729||Paroxysmal AF|
2410858|NCT03498729||Psoriasis|
2410859|NCT03498729||Healthy Controls|
3145046|NCT00059761|Experimental|Sequence B: Level 2|Irinotecan 50 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3145047|NCT00059761|Experimental|Sequence A: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent radiation therapy (RT) at 1.5 Gy BID
2410862|NCT03498703|Experimental|Azathioprine|
2410863|NCT03498703|Placebo Comparator|Control|
2410864|NCT03498690|Active Comparator|Integrative|
2410865|NCT03498690|Active Comparator|Role Specific|
2410866|NCT03498690|Active Comparator|Consecutive|
2410867|NCT03498677|Active Comparator|Method of presentation one|
2410868|NCT03498677|Active Comparator|Method of presentation two|
2410869|NCT03498664|Experimental|EMR-C group|"A plastic cap for mucosectomy (MH-597, Olympus Optical Co., Ltd, Tokyo, Japan) with an outer diameter of 17 mm and a length of 15 mm will be preloaded on the tip of the colonoscope. Inside the distal end of the cap there is a gutter which positions the opened polypectomy snare.~After submucosal injection, the cap will be applied against the lesion which will be aspirated by controlled suction, avoiding excessive protrusion of tissue in order not to trap the muscular layer.~The tissue will then be gripped with the snare and resection will be performed. A specific polypectomy snare which can be adapted into the gutter of the cap will be used (SD-221U-25, Olympus Optical Co., Ltd, Tokyo, Japan)."
2410870|NCT03498664|Active Comparator|EMR-S group|The resection will be performed using a standard polypectomy snare, which diameter will be chosen according to the size of the lesion, after lifting the lesion from the underlying layers with a submucosal injection of liquid.
2410871|NCT03498651|Experimental|CBM-I, low attrition|Computer- or phone-based Cognitive Bias Modification - Interpretation training
2410872|NCT03498651|Experimental|CBM-I, high attrition, coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training + Coaching
2410873|NCT03498651|Experimental|CBM-I, high attrition, no coach|Computer- or phone-based Cognitive Bias Modification - Interpretation training
2410874|NCT03498651|Active Comparator|Psychoeducation|Online psychoeducation about anxiety
3145048|NCT00059761|Experimental|Sequence B: Level 3|Irinotecan 60 mg/m2, cisplatin 60 mg/m2, concurrent RT at 2 Gy once daily
3145049|NCT00059813|Experimental|Treatment (recombinant interferon alfa, oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-7 and interferon alfa subcutaneously on days 4, 6, 8, 10, and 12 of course 1 and on days 1, 3, 5, 8, 10, and 12 of all subsequent courses. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive an additional 2 courses past CR.
2410877|NCT03498625|Other|Clinical remission CD|
2410878|NCT03498612|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
2410879|NCT03498599|Experimental|Novelty facilitated extinction|Behavioral intervention. After Pavlovian fear conditioning, the shock is omitted and replaced by a novel, surprising, and neutral auditory tone.
2410880|NCT03498599|Other|Standard extinction|The shock is omitted during standard extinction
2410881|NCT03498586|Experimental|Half-normal saline|
2410882|NCT03498586|Active Comparator|Normal saline|
2410883|NCT03498573|Experimental|tunneling surgical technique|
3185427|NCT00734526|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
2410885|NCT03498547|Active Comparator|Caudal Block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ultrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
2410886|NCT03498547|Active Comparator|Saddle Block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonography guidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
2410887|NCT03498534|Active Comparator|Patients with a -TST|In all patients with a negative TST test, Isoniazid 300 mg per day will be administered for 6 months
2410888|NCT03498534|Active Comparator|Patients with a +TST|In patients with a +TST test researchers will test for HIV, hepatic function and we will take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
2410889|NCT03498534|Active Comparator|HIV positive patients|The researchers will test hepatic function and take a chest x-ray. Isoniazid 300 mg per day will be administered for 6 months
3185428|NCT00734526|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
3185429|NCT00734526|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
2410892|NCT03498508||Healthcare professionals in Dalarna County Council|Healthcare professionals working in-hospital at the hospitals in Mora, Avesta and Falun, Sweden, n=1473.
2410893|NCT03498508||Healthcare professionals in Region Västmanland|Healthcare professionals working in-hospital at the hospital in Västerås, Region Västmanland, Sweden, n=1571.
2410894|NCT03498495|Experimental|SMART Intervention|
2410895|NCT03498495|No Intervention|Usual Care|
2410896|NCT03498482|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1.5 and 2 hours depending on the needs of the participant.
2410897|NCT03498469|Active Comparator|No Parenting program|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant. Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. At a minimum, each family will be visited on a monthly basis during the first 6 months post-placement and then every other month for the next 9 months. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
2410898|NCT03498469|Experimental|Parenting program|Those in the intervention arm will receive an enhanced reintegration package of services that consist of the standard package (case management and cash grant) plus a parenting program called 'Esanyu Mu Maka' or Happiness in the Home. The parenting curriculum used will be an adaptation of the evidence-based Sinovuyo Kids curriculum, tailored for caregivers of children age 1 to 13 years. It will have specifically designed components to address parenting challenges under reunification/reintegration conditions and to support the child and caregiver in building their relationship. It will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months.
2410899|NCT03498456|Experimental|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
2410900|NCT03498456|Active Comparator|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
2410901|NCT03498430|Experimental|Copanlisib (Aliqopa, BAY80-6946)|Planned at least 12 patients who meet the entry criteria will receive 60 mg copanlisib as single agent, with dosing on Days 1, 8 and 15 of each 28-day treatment cycle
2410902|NCT03498417||Graves' diseases|Patients with Graves' disease. No interventions foreseen
2410903|NCT03498417||Autoimmune thyroiditis|Patients with autoimmune thyroiditis. No interventions foreseen
2410904|NCT03498417||Healthy Subjects|Normal healthy subjects. No interventions foreseen
2410905|NCT03498404|Experimental|Photodynamic Therapy and SRP|"Procedure/Surgery: Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.~Treatment with TFDa in the Test Group maintained the protocol of applications in the periods of 2, 7 and 14 days post-surgical intervention."
2410906|NCT03498404|Sham Comparator|SRP and Sham Photodynamic Therapy|Procedure/Surgery: Sham Photodynamic Therapy After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
2410907|NCT03498391|Experimental|Propofol|Propofol sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
2410908|NCT03498391|Experimental|Ketamine|Ketamine sedation titrated to clinical effect as measured by Richmond Agitation-Sedation Scale.
2410909|NCT03498378|Experimental|Avelumab, Palbociclib, and Cetuximab|Identify the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) for the combination of palbociclib, avelumab, and cetuximab
2410910|NCT03498365|Experimental|Online MCDA|
2410911|NCT03498365|Active Comparator|Online Delphi|
2410912|NCT03498326|Experimental|gemcitabine|one group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection.
2410913|NCT03498326|Experimental|gemcitabine plus celecoxib|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection, and receive additional celecoxib every days during chemotherapy period.
2411016|NCT03497611||Patients with aortic stenosis|Patients receiving Edwards SAPIEN 3 Transcatheter aortic valve implantation
2410914|NCT03498313|Experimental|Transdermal Estradiol + Placebo|.1mg per 24 hours transdermal estradiol applied to the skin weekly, and sugar pill manufactured to mimic the progesterone pills taken twice daily by mouth, for 14 days.
2410915|NCT03498313|Experimental|Oral Micronized Progesterone + Placebo|100 mg oral micronized progesterone pill taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
2410916|NCT03498313|Placebo Comparator|Placebos|Sugar pill designed to mimic the P4 pills taken twice daily by mouth, and clear patch manufactured to mimic the E2 patch applied to the skin weekly, for 14 days.
3185430|NCT00734526|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
3185431|NCT00734552|Active Comparator|1|α-Keto Acid plus low protein diet
3185432|NCT00734552|Other|2|Normal protein diet
3185433|NCT00734565|Experimental|1|
2410921|NCT03498274|Experimental|Fitting System|a self-directed hearing screening based on a known algorithm from Audiology Inc. sold in an automated audiogram by Grason Stadler, GSI and a simplified version of the software. The flow of the new software is driven by the end user, but a trained professional should always assist with the fitting. The new software will first perform a hearing screening on the end user and then recommend a hearing aid and prescribe amplification to the hearing aid based on the hearing screening results.
2410922|NCT03498274|Active Comparator|Traditional Fitting System|A traditional fitting method will be used as a control. This system is controlled by a trained professional, who performs the entire fitting without much interaction from the end user. The hearing instruments will be fit with the same settings as the experimental arm.
2410923|NCT03498261|Active Comparator|Gabapentin|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
2410924|NCT03498261|Placebo Comparator|Placebo|The primary outcome of interest will be used to evaluate the efficacy of a single preoperative dose of gabapentin when compared to placebo on opioid consumption in patients undergoing rhinoplasty.
2410925|NCT03498248|Experimental|Neutropenia in chemotherapy|Neutropenia after cytotoxic chemotherapy
2410926|NCT03498235|Experimental|Team Sevoflurane|
2410927|NCT03498235|Experimental|Team Propofol|
2410928|NCT03498222|Experimental|Dose Level -1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 9mg/m2
2410929|NCT03498222|Experimental|Dose Level 1|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 18mg/m2
2410930|NCT03498222|Experimental|Dose Level 2|Atezolizumab 1200mg Pemetrexed 500mg/m2 Carboplatin AUC5 ADI PEG20 36mg/m2
3185434|NCT00734669||1|Type 2 diabetic patients on glibenclamide at individual dosage up to 7 mg/day for more than one year prone to hypoglycemic events
2410932|NCT03498183|Experimental|ARM experimental|All the patients will have MIBI-Tc99m/Iodine-123 . Following the injections they will have a scintigraphy.
2410933|NCT03498170|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - itraconazole 200mg on Day 1 to 14 and BCT197 14mg on Day 7"
2410934|NCT03498157|Experimental|Partly Supervised Prehabilitation|Will be offered an initial one week (5 days for 3 hours each) supervised exercise prehabilitation program including a two hour group-based prehabilitation class at Penn State Rehabilitation Hospital, Hummelstown. The following weeks till surgery the learned exercise program should be done home-based for 5 times a week. A weekly phone call during this period will help to support and adapt the exercise program.
2410935|NCT03498157|Active Comparator|Home-based Prehabilitation|Will be offered an individual one-on-one appointment for an exercise introduction session with an exercise and cancer specialist and weekly phone calls to support and adapt the exercise program. The exercises should be done home-based for 5 times a week until the time of surgery. Furthermore, a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute will be offered.
2410936|NCT03498157|Active Comparator|Control Group|Will be offered a two hour group-based prehabilitation class at the Penn State Hershey Cancer Institute.
2410937|NCT03498157|No Intervention|Comparison group- women too active|Added comparison group: Women who are ineligible on the basis of 'engaging in systematic intense exercise training (at least 1h twice a week) will be recruited to complete measures only, with no randomization
2410938|NCT03498144||Patients with acquired punctal stenosis|Patients with acquired punctal stenosis with epiphora
2410939|NCT03498144||Control subjects|normal subjects, without evidence of any punctal abnormalities.
2410940|NCT03498131|Experimental|3 mg Melatonin|Subjects will receive 3 mg melatonin once a day.
2410941|NCT03498131|Experimental|5 mg Melatonin|Subjects will receive 5 mg melatonin once a day.
2410942|NCT03498118|Experimental|Transversus Abdominis Plane Block group|after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side.
2410943|NCT03498118|Active Comparator|Wound Infiltration group|at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously into the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure
2410944|NCT03498105||Emergency Department (ED)|"450-500 participants who will;~self present to the Emergency Department (ED) will chest pain~be brought in by ambulance to ED with acute chest pain~be referred from Primary care or Urgent care centre with cardiac sounding chest pain"
2410945|NCT03498105||Community Cardiology Service (CCS)|This study group will consist of between 80-100 participants who self present to the Community Cardiology Service (CCS) in Milton Keynes primary care surgery
2410946|NCT03498105||Participants with stable angina|This study group will consist of 450-500 participants with stable angina who have been referred for Stress Echocardiography.
2410947|NCT03498105||Elective Coronary Angioplasty|This study group will consist of between 50-100 participants who will have been referred for elective coronary angioplasty
2410948|NCT03498105||Cardio-toxic Chemotherapy|Consecutive patients being initiated on any of the following medication deemed as cardio toxic and requiring cardiac function will be approached to be recruited into the study.
2411051|NCT03497325|Placebo Comparator|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
2410949|NCT03498092|Experimental|Bupivacaine-Dexmedetomidine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline and 1mcg/kg dexmedetomidine in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
2410950|NCT03498092|Active Comparator|Bupivacaine group|After general anesthesia, patients will receive a cocktail of isobaric bupivacaine 2.5 mg/ml plus 5 micrograms (mcg)/ml adrenaline in a volume of 0.5 ml/kg injected superficial to serratus muscle between and below latissimus dorsi muscle.
2410951|NCT03498092|Placebo Comparator|Saline group|This group will serve as a control and blinding group and will receive saline infiltration in the same manner.
2410952|NCT03498066|Experimental|Discontinuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will undergo withdrawal of their βB treatment..
2410953|NCT03498066|Active Comparator|Continuation of the Betablockers (βB)|1850 post-MI patients treated with chronic βB treatment will be continued under their usual βB treatment without modification.
2410954|NCT03498053|Other|Cigarette brands smoked by participant|"The 3 experimental days per participant are exactly the same, except the cigarette brand they smoke.~The content of an experimental day is described in the study design."
2410955|NCT03498040||Patients with or at risk of carcinoid heart disease|"Adult patients with well-differentiated metastatic ileum or bronchial neuroendocrine tumor~Adult patients with carcinoid syndrome or elevated urinary 5HIAA regardless of primary site"
2410956|NCT03498027||Data Collection|
2410957|NCT03498014|Active Comparator|Prescription as standard|
2410958|NCT03498014|Experimental|Pharmacogenetic-guided prescription|
2410959|NCT03498001|Experimental|Patients|
2410960|NCT03497988|Experimental|Syntocinon (=Oxytocin), then Placebo|"Single-Dose Intranasal Oxytocin~Single-Dose Placebo"
2410961|NCT03497988|Experimental|Placebo, then Syntocinon (=Oxytocin)|"Single-Dose Placebo~Single-Dose Intranasal Oxytocin"
2410962|NCT03497975|Active Comparator|Active|162 mg nalbuphine ER tablets, BID
2410963|NCT03497975|Placebo Comparator|Placebo|Matching placebo tablets
2410964|NCT03497962||ITU patients|25 patients will be recruited from the Intensive Care Unit/ High dependency unit Inclusion- Adults (>18years) with community acquired pneumonia (CAP).
2410965|NCT03497962||Healthy volunteer|24 healthy adult volunteers will be recruited to establish a comparison data set and to extend the laboratory observations to include other bacterial pathogens.
2410966|NCT03497936|Experimental|Women's Stories|Participants in this group will be randomly assigned to use the Women's Stories intervention.
2410967|NCT03497936|No Intervention|Programming as usual|Participants in this group will be randomly assigned participate in their usual programming.
2410968|NCT03497923|Active Comparator|Neostigmine|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive neostigmine 50 μg kg-1.
2410969|NCT03497923|Experimental|Sugammadex|Patients are anesthesized with Propofol and receive 0.6mg-1 of rocuronium for tracheal intubation. Neuromuscular monitoring will be done on the ulnar nerve by train-of-four (TOF) using a TOF-Watch-SX® acceleromyograph (Organon [Ireland] Ltd). After spontaneous recovery of 2 twitches at the train-of-four monitor (TOF), patients receive sugammadex (Bridion®) 2 mg kg-1.
3185435|NCT00734682|Experimental|Nanoliposomal CPT-11|All patients are treated with nanoliposomal CPT-11
3185436|NCT00734695|Experimental|1|Baruch Pade Medical Center
3185437|NCT00734695|Active Comparator|2|Rambam Medical Center
2410973|NCT03497884|Experimental|Real rTMS (low frequency)|Real rTMS (low frequency) is 1Hz.
2410974|NCT03497884|Sham Comparator|Sham rTMS|Sham rTMS session includes low frequency and high frequency stimulations.
2410975|NCT03497884|Experimental|Real rTMS (high frequency)|Real rTMS (high frequency) is 10Hz.
2410976|NCT03497871|Experimental|HeartMan intervention group|"80 patients are in the intervention group (40 in Belgium and 40 in Italy).~They use the HeartMan system in addition to receiving standard care."
2410977|NCT03497871|No Intervention|Standard care (control) group|"40 patients are in the no-intervention group (20 in Belgium and 20 in Italy).~They receive standard care, which consists of optimal medical treatment according to the international guidelines. In addition, written and oral education on heart failure disease and its management is provided by the heart failure nurse at the moment a patient has been diagnosed with heart failure or whenever he is rehospitalized for heart failure if necessary. Further support after discharge is possible by giving the patient the opportunity to call with the heart failure nurse in case he has questions about his treatment or health condition. Regular visits with the treating physician are scheduled several times per year."
2410978|NCT03497858|Experimental|coconut water|participants will complete the simulated basketball game with coconut water supplementation
2410979|NCT03497858|Placebo Comparator|Placebo - water|participants will complete the simulated basketball game with water supplementation
2410980|NCT03497858|Experimental|Sports drink|participants will complete the simulated basketball game with sports drink supplementation
3185438|NCT00734695|Active Comparator|3|Soroka Medical Center
3185439|NCT00734708|Experimental|A|positive drug (0.3% Trafermin contained)
3185440|NCT00734708|Placebo Comparator|P|control
3185441|NCT00734721|Active Comparator|A|Presentation of factual information video
3185442|NCT00734721|Active Comparator|B|Presentation of injection syringe/needle
2412307|NCT03488706||Gray Zone Group|The gray zone group PSA between 4.00 to 10.99 ng/ml.
3185443|NCT00734721|Active Comparator|C|Presentation of emotional information video
3185444|NCT00734721|Active Comparator|D|Stress relaxation music
3185445|NCT00734760|Experimental|A|a tailored, face-to-face education and counseling intervention with a nurse lasting approximately 45 minutes, followed by a telephonic reinforcement in 30 days
3185446|NCT00734760|No Intervention|B|care-as-usual with data collection at the same time points as the experimental group
3185447|NCT00734786|Placebo Comparator|2|Volunteers will be their own control by randomly receiving the active on one face side and the placebo on the opposite one.
3185448|NCT00734812|Active Comparator|1|Laparoscopic supracervical hysterectomy (LSH)
3185449|NCT00734812|Active Comparator|2|Total Laparoscopic Hysterectomy (TLH)
2410993|NCT03497819|Experimental|CARTmeso/19 treatment arm|Patients with pancreatic cancer receiving CARTmeso and CART19 autologous cells via artery infusion or i.v. with cyclophosphamide precondition
2410994|NCT03497806|Experimental|High Dose CP101|The active ingredient of CP101, Full-Spectrum Microbiota™, is derived from the stools of normal healthy donors who are highly screened, tested, and monitored in a clinically structured donation program.
2410995|NCT03497793|Experimental|Skin-to-skin care with SNUBY|Mothers providing skin-to-skin care with the use of SNUBY
2410996|NCT03497780||ACL Tear|Patients with ACL tears
2410997|NCT03497780||Healthy Subjects|Healthy subjects
2410998|NCT03497767|Experimental|Osimertinib|80mg Osimerinib taken once daily
2410999|NCT03497767|Experimental|Stereotactic Radiosurgery + Osimertinib|Upfront Stereotactic Radiosurgery (SRS) followed by 80mg Osimerinib taken once daily
2411000|NCT03497754|Experimental|Cardiac output measurements|Cardiac output will be measured using TTE with and without the use of Probefix so not 2 arms but 2 consecutive measurements in the same patient
2411001|NCT03497715|Experimental|Experimental 1|Treatment order: Ibuprofen liquid capsules, Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen (Wockhardt)
2411002|NCT03497715|Experimental|Experimental 2|Treatment order: Ibuprofen lysine, Ibuprofen (Wockhardt), Ibuprofen sodium, Ibuprofen (Nurofen), Ibuprofen liquid capsules
2411003|NCT03497715|Experimental|Experimental 3|Treatment order: Ibuprofen liquid capsules, Ibuprofen (Nurofen)1, Ibuprofen sodium, Ibuprofen (Wockhardt), Ibuprofen lysine
2411004|NCT03497715|Experimental|Experimental 4|Treatment order: Ibuprofen (Wockhardt), Ibuprofen (Nurofen), Ibuprofen lysine, Ibuprofen liquid capsules, Ibuprofen sodium
2411005|NCT03497702|Experimental|Experimental|Patients receive neoadjuvant chemotherapy (doxorubicin 60mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 every 3 weeks for 4 cycles followed by docetaxel 75mg/m2 IV on day 1 every 3 weeks for 4 cycles) plus letrozole with or without leuproelin depending on menopausal status
2411006|NCT03497689|Experimental|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Intravenous (IV) or subcutaneous (SC) treprostinil induction followed by transition to oral treprostinil
3145050|NCT00059826|Experimental|Interferon-based chemoradiation therapy|"Cycle 1: Chemoradiotherapy (CRT)~5-fluorouracil continuous infusion (CI) via an ambulatory infusion pump into a central venous catheter at 175 mg/m2/day for 38 consecutive days, unless toxicity occurs~cisplatin given on the first day only of each week of this cycle (days 1, 8, 15, 22, 29, 36)~IFN-alpha-2b 3 million units given subcutaneously on days 1, 3, and 5 of each week for 5½ weeks~XRT 5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday - Friday, for 5½ weeks~Cycles 2 and 3: Post-CRT Chemotherapy~Post-CRT chemotherapy starts 4 - 6 weeks after completion of Cycle 1, unless the study physician deems further delay is necessary. Patients will be given 2 cycles of chemotherapy (cycles 2 and 3).~-- 5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest"
3145051|NCT00059852|Experimental|gemcitabine + erlotinib|"Patients receive gemcitabine IV on days 1 and 8 and oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients achieving a complete response are followed every 6 weeks for up to 5 years or until disease progression (PD). Patients discontinuing study therapy for any other reason are followed every 3 months until PD and then every 6 months for up to 5 years."
3145052|NCT00059865|Experimental|pemetrexed + gemcitabine|"Phase II: Patients receive pemetrexed disodium as in phase I and gemcitabine at the recommended phase II dose.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
2411010|NCT03497663|Experimental|VIA Family intervention|VIA Family is a family based intervention. A multidisciplinary team of specialists from adult mental health services, child and adolescent mental health services and social services will be responsible for providing the basic treatment elements that are: case management and regular contact with the case manager, psychoeducation for the whole family, parental training (Triple P) and early intervention for mental problems of the child.
2411011|NCT03497663|Active Comparator|Treatment as Usual (TAU)|TAU is defined as any kind of help and support focusing on high risk children and parental mental illness. At present, the municipalities and the mental health services do not offer any kind of family focused intervention addressing parental mental illness that can be compared to the VIA Family program.
2411012|NCT03497650|Experimental|Mirror Therapy + Cross-Education.|Patients performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb while observing the reflection of the exercising limb in the mirror which was placed in the patient's mid-sagittal plane. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2411013|NCT03497650|Active Comparator|Cross-Education of Strengthening.|Patients trained without a mirror entirely. They performed 4 sets of 5 maximal isometric ankle dorsiflexions with their less-affected lower limb. Training sessions took place 3 days per week for four weeks in the participant's own home under the supervision of 2 exercise professionals.
2411014|NCT03497637|Active Comparator|Pd/Pa guided Therapy|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
2411015|NCT03497637|Active Comparator|FFR guided therapy|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
3145053|NCT00059891|Experimental|Anal Sphincter Prosthesis|All patients will follow a common treatment algorithm. Anorectal reconstruction with the ABS neosphincter device will be a staged surgical approach. Routine postoperative testing will then be performed at 6 months (+/- 8 weeks) and 12 months (+/- 8 weeks), following ileostomy reversal which we have designated as time zero. Postoperative testing will include completion of a series of questionnaires.
3145054|NCT00059930|Experimental|Adjuvant Hepatic Arterial Infusion & Combination Chemotherapy|This is a Phase I study with the primary objective of defining the maximum tolerated dose of hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump in combination with intravenous oxaliplatin plus systemic fluorouracil (5FU)/leucovorin (LV) in the adjuvant setting after resection of hepatic metastases from colorectal cancer. A total of eleven dose levels will be considered.
3145055|NCT00060086|Experimental|Pomegranate Juice|Subjects are given oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
2411017|NCT03497598|Experimental|mannose|"2g d-mannose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months.The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
2411018|NCT03497598|Placebo Comparator|placebo|"2g Hänseler lactose (white) powder (Hänseler AG, Herisau, Switzerland) daily (sachet) for 6 months. The powder is dispensed in neutral sticks and ready to be dissolved in 100ml of water for oral Ingestion.~rUTI diary"
3185450|NCT00734825|Active Comparator|1|IV contrast
2411020|NCT03497559|Experimental|Music|Patients will received 30 minutes of classical music 3 times per day . Music will be delivered with noise cancellation headphones.
2411021|NCT03497559|Sham Comparator|Noise cancellation|Patients will received 30 minutes of silent recording 3 times per day . Music will be delivered with noise cancellation headphones.
2411022|NCT03497559|No Intervention|Control|Patients will receive standard of care.
2411023|NCT03497546|Experimental|Exercise|Usual care PLUS concurrent (aerobic and strength) supervised exercise program of 16 weeks (3 sessions/week, 60 min/session, progressively increasing in volume and intensity). The program will be conducted by certified Exercise Science professionals.
2411024|NCT03497546|No Intervention|Control|Usual care routinely delivered after bariatric surgery, based on national (Spanish) and international recommendations, focused on nutritional status monitoring and diet/physical activity counseling.
2411025|NCT03497533|Experimental|TriCAR-T-CD19|Tri-functional anti-CD19 chimeric antigen receptor transduced autologous T cells will be administered intravenously
2411026|NCT03497520|Experimental|scoliosis patients|scoliosis patients who have cobb angle over 10 degree perform asymmetric spinal stabilization exercise
3145056|NCT00060112|Experimental|Treatment (oblimersen sodium and gemcitabine hydrochloride)|Patients receive oblimersen IV continuously on days 1-5 and gemcitabine IV over 2-3 hours on day 5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3145057|NCT00060125|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
2411029|NCT03497494|Active Comparator|Without hiatal suture|the different distance of pylorus without hiatal suture
2411030|NCT03497494|Active Comparator|With hiatal suture|the different distance of pylorus without hiatal suture
2411031|NCT03497481||Neopterin Dosage|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
2411032|NCT03497468|Active Comparator|Control group|Patients in this group will receive combined exercise training included aerobic and strengthening exercises, 3 times a week for 6 weeks. All exercise sessions will be performed under the supervision of a physiotherapist.
2411033|NCT03497468|Experimental|Training group|Patients in this group will receive task-oriented training additional to combined exercise training 3 times a week for 6 weeks. Task-oriented training included more functional daily life mobility activities like reaching, obstacle walking, stairs climbing. All exercise sessions will be performed under the supervision of a physiotherapist.
2411034|NCT03497442|Experimental|Treatment Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of brimonidine 0.33% gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
2411035|NCT03497442|Placebo Comparator|Placebo Arm|This is a randomized vehicle controlled, double blinded, interventional study. Patients of East Asian descent with a history of Asian Flushing Syndrome will be asked to apply a thin layer of vehicle gel to one half of their face thirty minutes before consuming alcohol (1.5 oz vodka for women, 3.0 oz vodka for men). The Photos will be taken 30 minutes, one hour, and 1.5 hours after consumption of alcohol. Erythema will be assessed at each time point by both the patient and study investigator using a 5- point erythema assesment score. Patient blood alcohol content (BAC) will be measured noninvasively at each time point.
3145058|NCT00060203|Experimental|Brostallicin|
3185451|NCT00734825|Active Comparator|2|IV contrast and oral contrast
2411038|NCT03497416||Anemic|
2411039|NCT03497416||Non-anemic|
2411040|NCT03497403|Active Comparator|Control|Socket preservation control. After tooth extraction, bone graft is applied to socket and a non-cross-linked membrane is used in primary intentional healing.
2411041|NCT03497403|Experimental|Experimental|Socket preservation experimental. After tooth extraction, bone graft is applied to socket and a cross-linked membrane is used in secondary intention healing.
2411042|NCT03497390|Active Comparator|EMERALD|Patients will have 1-year multicomponent program (EMERALD) intervention including a total of 3 interactive workshops focusing on empowerment skills, healthy eating and exercise. Please refer to the protocol for further details.
2411043|NCT03497390|Placebo Comparator|Usual care|Usual management without any workshop or program
2411044|NCT03497377|Experimental|18F-DCFPyL Injection & 18F-NaF|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL injected by slow IV push. A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose
2411045|NCT03497364|Experimental|Bupivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. The dose of bupivacaine depended on height of subjects.
2411046|NCT03497364|Experimental|Ropivacaine group|Pregnant women received combined spinal-epidural anesthesia by injecting ropivacaine. The dose of ropivacaine depended on height of subjects).
2411047|NCT03497364|No Intervention|Control group|Pregnant women received combined spinal-epidural anesthesia by injecting bupivacaine. 2ml bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection for all subjects.
2411048|NCT03497351|Experimental|Group N|the group treated with nicardipine
2411049|NCT03497351|Experimental|Group U|the group treated with Urapidil
2411050|NCT03497325|Experimental|PRP|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
2412346|NCT03488329|Experimental|Intervention|"Intervention group~Individual nutritional therapy"
2411052|NCT03497299|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
2411053|NCT03497299|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with tobacco dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) tobacco abstinence.
2411054|NCT03497286|Experimental|Treatment|Participants in the treatment condition will be enrolled in the text-based mentorship program and will be able to engage with their assigned mentor as much or as little as they choose.
2411055|NCT03497286|Active Comparator|Control|Participants in the control condition will receive periodic informational texts related to the growth and development of their new baby.
2411056|NCT03497273|Experimental|Itacitinib + corticosteroids|Itacitinib administered in combination with corticosteroids.
2411057|NCT03497260|Experimental|Fructose in water first, water only second|Intake of 20 g of fructose dissolved in 200 ml of tap water at first visit; intake of 200 ml of tap water at second visit
2411058|NCT03497260|Experimental|Water only first, Fructose in water second|Intake of 200 ml of tap water at first visit; intake of 200 ml of 20 g of fructose dissolved in 200 ml of tap water at second visit
2411059|NCT03497247|Experimental|Mindfulness-Based Cognitive-Behavioral Therapy|
2411060|NCT03497247|Active Comparator|Cognitive-Behavioral Therapy|
2411061|NCT03497234|Experimental|All women eligible to participate|All women presenting who sign the consent and found eligible will have a VF and AF sample taken and analyzed on the Perilynx Analyzer to measure AF and VF fluid. This does not affect their regular standard of care and diagnosis
2411062|NCT03497221|Other|Education intervention|The educational intervention is based on a hospital institutional protocol for patient using enteral tubes. A clinical simulation will be performed using a low fidelity manikin, where nursing technicians will identify and correct erros, such as: inconsistency between the patient's identification and the diet label, the administration of the diet with a low headboard, fixation of tube not detached and dirty, delay of the diet and others. The simulation will be described through a guide.
2411063|NCT03497221|Other|Visual identity campaign|"The visual identity will be given by a set of actions, called campaign. The campaign consists in the creation and implantation of different materials to be used at the bedside of the patients in use of diet by SNE, such as: (a) poster summarizing care, (b) colored adhesive label to identify devices (c) badge with safety care reminders."
2411064|NCT03497208|Experimental|Microneedling+cell susp+phototherapy|Experiment is about the use of abrasion technic with dermaroller, equipped with a 0,25mm needle, applied on a vitiligo lesion. After that, a transplant with non cultured cell suspension (melanocytes and keratinocytes) will be applied to pacient 's skin scalp.
2411065|NCT03497208|Active Comparator|Microneedling and phototherapy|Technique involves only the abrasion with dermaroller equipped with 0,25mm on the lesion of vitiligo.
2411066|NCT03497195|Active Comparator|Community level screening; Arm 1|use of chest X-ray plus Xpert Ultra for community level TB screening
2411067|NCT03497195|Active Comparator|Community level screening: Arm 2|use of C-reactive Protein and Xpert Ultra for community level TB screening
2411068|NCT03497182|Experimental|Breath sample collection|
3185452|NCT00734838|Experimental|Core needle biopsy|Patients needing a needle biopsy of a breast mass
3185453|NCT00734838|Placebo Comparator|Reduction mammoplasty|Any patients scheduled for a reduction mammoplasty who would like to participate in a study to better understand breast cancer
2411071|NCT03497117|Other|CF pulmonary exacerbation group|"Patients with cystic fibrosis being treated for a pulmonary exacerbation will undergo Lung Clearance Index (LCI) and an MRI with PFP.~LCI testing will take place before the MRI. Each test will take 5-20 minutes and up to three tests will be performed with at least 5-minute rest periods between each test.~PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet."
2411072|NCT03497091||Enteral Tube fed children|Enteral Formula
2411073|NCT03497078|Other|Refered patients for scintigraphy|
2411074|NCT03497052||Group 1|Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
2411075|NCT03497052||Group 2|Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
3185454|NCT00734864|Other|1|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
3185455|NCT00734864|Other|2|Subjects NOT taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs).
3185456|NCT00734877|Active Comparator|ARM A|The standard TT3 Regimen (S-TT3) will consist of 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
2411079|NCT03497013|Experimental|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
2411080|NCT03497013|Sham Comparator|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
3185457|NCT00734877|Experimental|ARM B|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD- PACE
3185458|NCT00734916|Active Comparator|1|Omegaven 10%
3185459|NCT00734916|Active Comparator|2|Intralipid 10%
3185460|NCT00734916|Placebo Comparator|3|Placebo
3185461|NCT00734942|Experimental|1|intervention group
3185462|NCT00734942|No Intervention|2|waiting group
3185463|NCT00734955|Experimental|Reduction Mammoplasty|Patients undergoing reduction mammoplasty
3185464|NCT00734955|Experimental|Mastectomy|Patients undergoing mastectomy
2411082|NCT03497000|Active Comparator|ICGA group|Patients in this group underwent normal ICGA-guided half dose photodynamic therapy.
3185465|NCT00734955|Experimental|Lumpectomy|Patients undergoing a lumpectomy
3185466|NCT00735020|Experimental|1|
3185467|NCT00735020|Active Comparator|2|
3185468|NCT00735046||1|Intervention
2411087|NCT03496961|Experimental|Yan Nian Jiu Zhuan Fa|The kneading process will be done under the therapist guidance for 30 minutes with an average pressure of 5 Newton each time for 3 times every day.
2411088|NCT03496961|Placebo Comparator|cognitive psychology education|Psychological counseling and behavioral cognition education are conducted once a week and the rest 6 times online or by phone.
2411089|NCT03496961|No Intervention|blank control|this group will have no therapeutic exercises or cognitive education when other two groups receive therapy.
2411090|NCT03496948|Experimental|TeGeCoach|Home-based exercise program consisting of telephone health coaching, remote walking exercise monitoring based on wearable monitors and intensified primary care.
2411091|NCT03496948|No Intervention|Usual care group (TAU)|Patients randomized to TAU receive written information about courses offered by their statutory health insurance. Health insurance companies offer a variety of courses to encourage regular exercise and to promote lifestyle changes, including SEPs (vascular and cardio exercise), physical therapy, nutritional assistance programs, smoking cessation programs, weight loss programs, and patient education programs for obesity and diabetes.
2411092|NCT03496935|Active Comparator|Tunneled dialysis catheter|In this arm, patients will be randomized to undergo tunneled dialysis catheter insertion.
2411093|NCT03496935|Active Comparator|Non-tunneled dialysis catheter|In this arm, patients will be randomized to undergo non-tunneled dialysis catheter insertion.
3145059|NCT00060307|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2411095|NCT03496909|Active Comparator|Standard OT|
2411096|NCT03496909|Experimental|PhysioTouch|
2411097|NCT03496896|Experimental|"TARGET intervention"|The intervention group will receive a standardized transition care intervention by a trained nurse composed of a pre-discharge component and 2 post-discharge follow-up phone calls 3 days and 14 days after discharge.
2411098|NCT03496896|No Intervention|Control|The group control will receive usual care without additional intervention.
3145060|NCT00060320|Experimental|black cohost|"Patients receive oral black cohosh twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
3185469|NCT00735046||2|control
2411101|NCT03496870|Experimental|Opicapone once daily with Carbidopa/Levodopa|Opicapone administered once daily for 14 days; carbidopa/levodopa administered at set frequency on Study Days 1, 2 & 15
2411102|NCT03496857|Experimental|Photobiomodulation analgesia|"LED therapy sessions will be held in the pre-labor room. The patient who will undergo analgesia and the professional responsible for placing the LED plate on the patient's back, between T10 and L2, will be present at the time of the intervention. The LED plate will be covered with clear disposable plastic (PVC) to avoid cross-contamination and ensure hygiene. During the interventions, the patient will be allowed to choose the position that is the most comfortable for her.~Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention."
2411103|NCT03496857|Active Comparator|bath therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
2411104|NCT03496844|No Intervention|Routine F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who have had an F-18 fluciclovine-PET/CT scan for routine standard of care for biochemical recurrence. These patients would be asked to participate in the study only if there is a need for a standard of care bone biopsy.
2411105|NCT03496844|Active Comparator|Research F-18 fluciclovine-PET/CT scan|This arm will consist of prostate cancer patients who would not ordinarily obtain an Axumin-PET scan for routine standard of care but have a need for bone biopsy. This will include patients with metastatic castrate resistant prostate cancer. For example, a patient with known lymph node recurrence of prostate cancer and suspicious finding on a bone scan would be asked to participate in the study and get a F-18 fluciclovine-PET/CT scan prior to the standard of care bone biopsy.
2411106|NCT03496831||Rheumatoid Arthritis|Registered in DANBIO with a diagnosis of M05.9, M06.0 or M06.9.
2411107|NCT03496831||Spondyloarthritis|Registered in DANBIO with a diagnosis of M45.9, M46.1, M46.8+M02.9, M46.8+M07.4, M46.8+M07.5 or M46.9.
2411108|NCT03496831||Psoriatic Arthritis|Registered in DANBIO with a diagnosis of M07.3 or M46.8+M07.2.
2411109|NCT03496818||Crohn's Disease|Participants age 18-80 years old, diagnosed with Crohn's disease with active disease based on MR enterography or CT enterography confirmed within the prior 90 days.
2411110|NCT03496818||Healthy controls|Participants age 18-80 years old, with no diagnosis of inflammatory bowel disease.
3185470|NCT00735059|Experimental|1|treatment with dialyzer ELISIO 170H
3185471|NCT00735059|Active Comparator|2|treatment with dialyzer PES-170DS
3185472|NCT00735085|Experimental|SLV334|
3185473|NCT00735085|Placebo Comparator|Placebo|
3185474|NCT00735098|Experimental|1|KBA exercise protocol
3185475|NCT00735098|Experimental|2|strength training exercise protocol
3185476|NCT00735098|Experimental|3|KBA and strength training protocol
3185477|NCT00735098|Sham Comparator|4|
3185478|NCT00735111|Experimental|Karnofsky Performance Status Score|
2411113|NCT03496792|Experimental|Tilt + external pressure|"Tilt + external pressure on legs performed in both BP elevated with standing and BP maintained with standing groups."
2411114|NCT03496792|Placebo Comparator|Tilt + no external pressure|"Tilt + no external pressure performed in both BP elevated with standing and BP maintained with standing groups."
2411115|NCT03496792|Experimental|Limb occlusion + negative pressure|"Limb occlusion + negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
2411116|NCT03496792|Placebo Comparator|Limb occlusion + no negative pressure|"Limb occlusion + no negative pressure performed in both BP elevated with standing and BP maintained with standing groups."
2411117|NCT03496779|Experimental|Experimental|"Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.~Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.~Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions."
2411118|NCT03496766|Experimental|Experimental Arm|Tipifarnib 600 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months
2411119|NCT03496753|Experimental|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
2411120|NCT03496753|No Intervention|Control|The control group will receive orientation regarding breast care and adequate breastfeeding techniques. The experimental group will receive the same orientation plus phototherapy sessions using a device developed especially for the treatment of nipple trauma. Both groups will be followed up for six consecutive weeks.
2411121|NCT03496740|Active Comparator|Penile Block|"Ultrasound guided dorsal penile nerve block will be administered after general anesthesia.~0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks"
2411122|NCT03496740|Active Comparator|Pudendal Block|Nerve stimulator-guided pudendal block. 0,25% Bupivacaine 0,5ml/kg (max. 20ml) will be used for the blocks
2411123|NCT03496727||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation, patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2411124|NCT03496727||Patient controlled analgesia|Anesthesia induction was performed on all patients.At the end of the operation, all patients were performed with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2411125|NCT03496714|Active Comparator|PSYED-T|In PSYED-T (psychoeducation on trauma symptoms), participants will receive a psychoeducation handout and watch a related video on common reactions to trauma. Participants in this condition will also receive a rationale stating that both learning about the nature of trauma reactions and monitoring symptoms are important for preventing development of PTSD.
2411126|NCT03496714|Experimental|PSYED-T+SB|Participants in PSYED-T+SB (Combined psychoeducation on trauma reactions and safety behaviors) will receive psychoeducation handouts and videos on the nature of trauma symptoms and the nature of safety behaviors and how to fade them. Participants in this condition will also receive a rationale stating that learning about the nature of trauma reactions and safety behaviors, learning to fade safety behaviors, and monitoring symptoms are important in the prevention of PTSD.
2411127|NCT03496714|No Intervention|Monitoring-only control|The third condition will be a monitoring-only control and thus will receive no psychoeducation information. Participants in the control condition will receive a rationale that monitoring symptoms is important in the prevention of PTSD development.
3185479|NCT00735124|Active Comparator|Single pre-op dose of Gabapentine|Active treatment with the study drug
2411129|NCT03496688|Active Comparator|bone substitute material MCBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using mineralized sol-vent-dehydrated bone allograft material.
2411130|NCT03496688|Active Comparator|bone substitute material FDBA|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using freeze-dried mineralized bone allograft material.
2411131|NCT03496688|Active Comparator|bone substitute material ABB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using anorganic bovine bone material.
2411132|NCT03496688|Active Comparator|bone substitute material EB|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using equine-derived bone material.
2411133|NCT03496688|Active Comparator|bone substitute material HA-β-TCP 30/70|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using synthetic micromacroporous bi-phasic calcium-phosphate block consisting of 70% beta-tricalcium phosphate and 30% hy-droxyapatite material.
2411134|NCT03496688|Active Comparator|bone substitute material BC|Sinus floor augmentation: a bony window was created along the lateral wall of the sinus, the sinus membrane was carefully elevated and the created space was augmented using bioapatite-collagen material.
2411135|NCT03496675|Other|Standard care|Participants receive standard care as locally available. The components of standard care are recorded.
2411136|NCT03496675|Experimental|Group Music Therapy (GMT)|"GMT is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~In line with usual practice, and as appropriate in local contexts, residents of a unit allocated to GMT may be divided into smaller groups (e.g. around 5 participants)."
2411194|NCT03496259|Experimental|On-Q Group|Patients in this group will have an On-Q pump placed at the end of the operation
3185480|NCT00735124|Placebo Comparator|Placebo|Placebo arm for blinding the medication
3185481|NCT00735137|No Intervention|A|Expectant management in twin pregnancy
2411137|NCT03496675|Experimental|Recreational Choir Singing (RCS)|"RCS is provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.~RCS may be conducted in larger groups (e.g. with all residents of the unit in one group)."
2411138|NCT03496675|Experimental|GMT + RCS|Group Music Therapy and Recreational Choir Singing are both provided twice weekly for the first three months, followed by weekly sessions for the next three months, with possible extension after that period as desired and feasible. Sessions are 45 minutes each.
3145061|NCT00060320|Placebo Comparator|placebo|"Patients receive oral placebo twice daily for 4 weeks. All patients then cross over to the other arm and receive treatment for 4 weeks.~After completion of the crossover treatment, all patients may opt to receive open-label black cohosh for an additional 8 weeks.~Patients complete a hot flash diary daily at baseline and during the 8-week double-blind study, and then daily for 8 weeks during optional open-label treatment.~Patients who opt to receive open-label black cohosh are followed at 6 months, 1 year, and 2 years."
3145062|NCT00060359|Experimental|Treatment (paclitaxel poliglumex, carboplatin)|"DOSE-ESCALATION PHASE: Patients receive CT-2103 IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of CT-2103 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of treatment.~FEASIBILITY PHASE: Once the MTD of CT-2103 is determined, an additional 20-40 patients receive treatment at that dose level combined with carboplatin as above."
3145063|NCT00060372|Experimental|Treatment (ipilmumab and donor lymphocyte infusion)|Patients receive ipilimumab IV over 90 minutes. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients with persistent or progressive disease at 60 days after ipilimumab administration and no evidence of graft-versus-host disease receive donor lymphocyte infusions every 60 days for a total of 3 infusions.
2411142|NCT03496649|Experimental|Dysport|"Dysport administration by intramuscular injection Each patient will receive one dose of Dysport at Visit 1.~At least 2 of the 4 muscles below will be injected, depending on which muscles are affected:~250 IU for the gracilis muscle 200 IU for the pectineus muscle 300 IU for the adductor longus muscle 200 IU for the adductor brevis muscle~These injections will be uni or bilateral, it will depend on clinical diagnosis.~If necessary, the 4 muscles will be injected with a maximum of 1500U Dysport. The total dose cannot exceed 1500 units."
2411143|NCT03496636|Experimental|Ovarian tissue transplant|Transplantation of ovarian tissue into the abdomen. Only for patients who have previously frozen ovarian tissue
3145064|NCT00060411|Experimental|Treatment (combination chemotherapy)|Patients receive oral elotinib alone once daily for 1 week before the beginning of course 1. Patients then receive oral erlotinib once daily on days 1-28; oxaliplatin IV over 2 hours on day 1; and leucovorin calcium IV over 2 hours and fluorouracil IV over 22 hours on days 1 and 2. Patients also receive bevacizumab IV over 30-90 minutes on day 15 of course 1 and on days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145065|NCT00060450|Experimental|1|Inhaled Nitric Oxide
2411146|NCT03496610|Active Comparator|Quadratus Lumborum (QL) Block|Patients will receive a bilateral ultrasound guided QL block by the anesthesia team.
2411147|NCT03496610|Active Comparator|Surgical wound infiltration|Patients will receive 166 mg of liposomal bupivacaine mixed with 50 mg non-liposomal bupivacaine infiltrated into the wound by the surgeon.
3145066|NCT00060450|Placebo Comparator|2|Placebo gas
3145068|NCT00060567|Other|1|Active combination of E7070 and irinotecan.
2411151|NCT03496584|Active Comparator|Pomegranate Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Pomegranate Juice , followed by 12 weeks of pomegranate juice consumption.
2411152|NCT03496584|Placebo Comparator|Placebo Juice|Postprandial high fat meal will be administered with pomegranate juice with the first dose of the intervention, Placebo Juice , followed by 12 weeks of pomegranate juice consumption.
2411153|NCT03496571|Placebo Comparator|Placebo|Subjects in this arm will receive 4 monthly doses of placebo.
2411154|NCT03496571|Experimental|1 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 1 mg/kg, and a fourth dose of 1 mg/kg
2411155|NCT03496571|Experimental|3 mg/kg of AK002|Subjects in this arm will receive 4 monthly doses of AK002: a first dose of 0.3 mg/kg, a second dose of 1 mg/kg, a third dose of 3 mg/kg, and a fourth dose of 3 mg/kg
2411156|NCT03496558|Experimental|150 pregnant women with a history of risk|
2411157|NCT03496558|No Intervention|150 healthy pregnant women|
2411160|NCT03496532|Experimental|Pulse generator change under sedation|"The efficacy of every set will be measured on induced changes in LFP recorded from the STN electrodes.LFP will be compared between before, during and right after each stimulation conditions. The stimulation order will be randomized. All other stimulation parameters will be the same (macrocontact with most beta-oscillations, 1 minute, 1.5mA) .~Hence 4 sets of 1 minutes of STN stimulation will be performed, for:~Symmetrical biphasic pulses versus standard pseudo monophasic pulses (study I; 2 sets).~Pseudorandom uniform distribution stimulation paradigms versus pseudorandom Poisson distribution stimulation paradigms (study II: 2 sets)."
2411161|NCT03496532|Experimental|First pulse generator implantation under general an|The depth of anesthesia will be documented, recording the BIS spectral analysis index. The difference in spectral amplitude density of LFP, in particular in beta band oscillations will be correlated with the depth of anesthesia as measured with the BIS index.
3145069|NCT00060567|Other|2|Active combination of E7070 and irinotecan.
3145070|NCT00060567|Other|3|Active combination of E7070 and irinotecan.
3145071|NCT00060632|Experimental|Cohort 1: Ridaforolimus 6.25 mg|
3145072|NCT00060632|Experimental|Cohort 2: Ridaforolimus 12.5 mg|
3145073|NCT00060632|Experimental|Cohort 3: Ridaforolimus 25 mg|
3145074|NCT00060632|Experimental|Cohort 4: Ridaforolimus 50 mg|
3145075|NCT00060632|Experimental|Cohort 5: Ridaforolimus 100 mg|
2411162|NCT03496519|Experimental|Dose Escalation|"Dose escalation will occur following a 3+3 design in all advanced tumor types meeting the inclusion and exclusion criteria.~Cohort -1 (if necessary): Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
2411163|NCT03496519|Experimental|Dose Expansion|Patients at this level will receive the safest dose of Durvalumab and Trabectedin that was determined during the Dose Escalation Phase. There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be fixed dosage of Trabectedin for each cohort, given through intravenous infusion as an outpatient, over a 24 hour period on Day 1 every 21 days.
2411164|NCT03496506|Experimental|Sequential treatment arm|Subjects receive 1 tablet of selexipag twice daily from Day 1 to Day 9 and 1 tablet in the morning of Day 10. In the morning of Day 4 and 1 hour before the administration of selexipag, they receive 4 tablets of clopidogrel. Then from Day 5 to Day 10, 1 hour before the morning administration of selexipag, they receive 1 tablet of clopidogrel .
2411165|NCT03496493||All patients|All patients enrolled in trial will have peripheral oxygen saturation simultaneously recorded with both study devices on non-adjacent (second and fourth) fingers of the same hand.
3145076|NCT00060632|Experimental|Cohort 6: Ridaforolimus 75 mg|
3145077|NCT00060645|Experimental|1|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
2411168|NCT03496454|Other|PfSPZ Challenge|this is a basic sciences protocol designed to study the effect of pre-exposure to Plasmodium falciparum (Pf) on malaria parasite kinetics, clinical symptoms and immunity after Controlled Human Malaria Infection by administration of an injection PfSPZ Challenge in Gambian adults. Based on a well-defined serological profile representing the extremes of current malaria exposure in The Gambia, two cohorts will be identified to study the impact of naturally acquired immunity on susceptibility for a Controlled Human Malaria Infection. The classification as a clinical trial results from the administration of the PfSPZ Challenge to the healthy volunteers
2411169|NCT03496441||Group 1|Colorectal cancer patients who will undergo a surgical resection with digestive anastomosis. Fecal sample collection for analysis before and after surgery (2 samples).
2411170|NCT03496441||Group 2|Patients having undergone surgical resection with digestive anastomosis for colorectal cancer or inflammatory bowel disease, complicated by anastomotic leakage. Fecal sample collection for analysis after surgery, once the leak is confirmed.
2411171|NCT03496441||Group 3|Patients with uncomplicated hernia pathology, without gastrointestinal comorbidity to undergo a surgery to heal this hernia without involving a gastrointestinal resection. Fecal sample collection for analysis before surgery (1 sample).
2411172|NCT03496441||Group 4|Inflammatory bowel disease patients waiting for elective surgery involving gastrointestinal resection. Fecal sample collection for analysis during surgery, directly from the bowel content (1 sample).
2411174|NCT03496415|Experimental|Remote ischemic conditioning|
2411175|NCT03496415|Sham Comparator|Sham remote ischemic conditioning|
2411176|NCT03496402|Experimental|High risk Cohorts|Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
2411177|NCT03496402|Experimental|Low risk Cohort|Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid
2411178|NCT03496389|Experimental|Gabapentin + panadol|
2411179|NCT03496389|Active Comparator|Tramadol + panadol|
2411180|NCT03496376|Experimental|Kinesio Taping Group|Kinesio Taping Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set plus thoracic kinesio taping application.
2411181|NCT03496376|Active Comparator|Control Group|Control Group received three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
2411182|NCT03496363||CHD with Hypothyroidism|
2411183|NCT03496350|Experimental|Internet CBT|Internet-based cognitive behavioural therapy in Arabic with therapeutic guidance through email.
2411184|NCT03496350|No Intervention|Wait-list|Wait-list control
2411189|NCT03496311||Pregnant Women|Pregnant women with gestational age > 35 weeks undergoing spinal anesthesia for elective cesarean section.
2411190|NCT03496311||Control Group|Fertile, non-pregnant women undergoing spinal anesthesia for elective surgery.
3145078|NCT00060723||Adenotonsillectomy group|Children ages 5-12 who are scheduled for adenotonsillectomy for obstructive sleep apnea
3145079|NCT00060723||Comparison group|Children ages 5-12, scheduled for hernia repairs, other procedures not involving the head, chest or neck, or no procedures. Additional exclusions include children with a history of recurrent throat infections, large tonsils, history of or plans for adenoidectomy and/or tonsillectomy or who have been previously diagnosed with sleep-disordered breathing.
3145080|NCT00060762|Experimental|Interpersonal Therapy|Interpersonal Therapy is a psychotherapy aimed at resolving interpersonal difficulties
3145081|NCT00060762|Active Comparator|Behavioral Weight Loss Treatment|Behavioral Weight Loss Treatment is aimed solely at weight loss, however it has been shown to decrease binge eating
3145082|NCT00060762|Active Comparator|Guided Self Help|Guided Self-Help is a brief psychotherapy based on cognitive-behavioral treatment
3145085|NCT00060814|Experimental|Combined Pharmacotherapy and Counseling|300 mg Bupropion/4mg Nicotine Gum/Motivational Interviewing
3145086|NCT00060892|Active Comparator|1|0.4 mg AMG0001 on days 0, 14, and 28
3145087|NCT00060892|Active Comparator|2|4.0 mg AMG0001 on days 0, 14, and 28
3145088|NCT00060892|Active Comparator|3|4.0 mg AMG0001 on days 0 and 28; placebo on day 14
3145089|NCT00060892|Placebo Comparator|4|Placebo (saline) on days 0, 14, and 28
2411195|NCT03496259|Active Comparator|Epidural Group|Patients in this group will have an epidural catheter placed at the end of the operation
2411196|NCT03496246|Active Comparator|Group A|patients with vitamin D deficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2411197|NCT03496246|Active Comparator|Group B|patients with vitamin D insufficiency are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2411198|NCT03496246|Active Comparator|Group C|patients with normal vitamin D level normal are investigated for serum total 25 hydroxycholecalciferol 25(OH) vitamin D,complete blood count (CBC),serum calcium level ,serum phosphurus level,erythrocyte sedimentation rate (ESR),C-reactive protein (CRP),serum creatinine ,serum albumin level,seum alanine aminotransferase and serum potassium level.
2411199|NCT03496233|Experimental|All patients included|All patients included will be treated with Elbasvir/grazoprevir for 8 weeks
3185482|NCT00735137|Experimental|B|Vaginal pessary treatment in twin pregnancy
2411202|NCT03496207|Placebo Comparator|Placebo|Placebo SC every 21 days plus SOC for 24 weeks
2411203|NCT03496207|Experimental|Sotatercept 0.3 mg/kg|Sotatercept, 0.3 mg/kg SC every 21 days plus SOC for 24 weeks
2411204|NCT03496207|Experimental|Sotatercept 0.7 mg/kg|Sotatercept, 0.7 mg/kg SC every 21 days plus SOC for 24 weeks
3145090|NCT00061087|Active Comparator|METHYLPHENIDATE|Methylphenidate
3145091|NCT00061087|Active Comparator|BUPROPION|Bupropion
3145092|NCT00061087|Placebo Comparator|PLACEBO|Placebo
2411208|NCT03496168|Experimental|mavacamten (MYK-461)|
2411209|NCT03496155|Experimental|Intervention Group (Arm 1- Main)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
2411210|NCT03496155|No Intervention|Control Group (Arm 1- Main)|Will receive usual care at well-child visit.
2411211|NCT03496155|Experimental|Intervention Group (Arm 1-asthma subgroup)|"Will receive the Build Your Teen's Strengths educational pamphlet, health coaching sessions, and provider endorsement."
2411212|NCT03496155|No Intervention|Control Group (Arm 1-asthma subgroup)|Will receive usual care at well-child visit.
2411213|NCT03496155|No Intervention|Control Group (Arm 2)|Convenience sample used for a post-hoc, exploratory analysis. Will receive usual care at well-child visit.
2411214|NCT03496142|Active Comparator|Transperineal prostate biopsy|Patient will have a transperineal prostate biopsy.
2411215|NCT03496142|Active Comparator|Transrectal prostate biopsy|Patient will have a transrectal prostate biopsy.
2411216|NCT03496129|Experimental|Personalized Feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
2411217|NCT03496129|Experimental|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
2411218|NCT03496129|Active Comparator|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
2411219|NCT03496116|Experimental|ECIG Session: 0.5 Ohms, 3 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 3 mg
2411220|NCT03496116|Experimental|ECIG Session 0.5 Ohms, 8 mg|Heating coil resistance 0.5 Ohms Liquid nicotine concentration 8 mg
2411221|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 3 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 3 mg
2411222|NCT03496116|Experimental|ECIG Session 1.5 Ohms, 8 mg|Heating coil resistance 1.5 Ohms Liquid nicotine concentration 8 mg
2411223|NCT03496103|Other|Allergic Subjects|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
2411224|NCT03496103|Other|Healthy|After recording baseline symptoms, subjects were exposed to ragweed pollen for three hours and symptoms were recorded
3145093|NCT00061100|Experimental|RISE intervention|Targeted RISE intervention- Behavior therapy Rise
3145094|NCT00061100|Active Comparator|Standard Education|Education intervention. Standard prevention education
3145095|NCT00061113|Active Comparator|1|fluoxetine + CBT
3145096|NCT00061113|Placebo Comparator|2|placebo + CBT
3145097|NCT00061243|Experimental|1|Participants will receive different doses of the vaccine to determine the optimal dose
3145098|NCT00061243|Experimental|2|Participants will receive different doses of the vaccine to determine the optimal dose
3145099|NCT00061243|Experimental|3|Participants will receive different doses of the vaccine to determine the optimal dose
3145100|NCT00061243|Experimental|4|Participants will receive the vaccine through either intradermal or intramuscular administration
3145101|NCT00061243|Experimental|5|Participants will receive the vaccine through either intradermal or intramuscular administration
3145102|NCT00061269|Experimental|VARD|Videoscopic-Assisted Retroperitoneal Debridement (VARD)
3145103|NCT00061282|Placebo Comparator|1|
3145104|NCT00061282|Active Comparator|2|Clotrimazole Therapy
3145105|NCT00061282|Active Comparator|3|Clotrimazole Therapy
3145106|NCT00061321|Active Comparator|1|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum
2411225|NCT03496090|Experimental|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
2411226|NCT03496090|Active Comparator|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
2411227|NCT03496077|Experimental|Flavored LCCs|Half of the group will start with a flavored little cigar/cigarillo (LCC) and cross over to unflavored LCC. The LCCs will be a popular brand already available for sale on the market.
2411228|NCT03496077|Experimental|Unflavored LCCs|Half of the group will start with an unflavored little cigar/cigarillo (LCC) and cross over to flavored LCC. The LCCs will be a popular brand already available for sale on the market.
2411229|NCT03496064||Anterior circulation LVO patients with ASPECTS <6|
2411230|NCT03496064||Anterior circulation LVO patients with NIHSS<8|
2411231|NCT03496064||Posterior versus anterior circulation LVO patients|
2411232|NCT03496064||LVO patients with isolated PCA or ACA occlusions|
2411233|NCT03496064||Tandem lesions versus non-tandem lesion|
2411234|NCT03496064||Bridging vs Direct MT|
3145107|NCT00061321|Experimental|2|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day)by mouth, from week 1 through week 6 post-partum Infants: Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
3145108|NCT00061347|Experimental|1|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
2411237|NCT03496025|Experimental|Electrical stimulation|
2411241|NCT03495999||Normouricemia|Serum uric of 7mg/dl or less in men or 6mg/dl or less in women
2411242|NCT03495999||Hyperuricemia|Serum uric of 7mg/dl or more in men or 6mg/dl or more in women
2411243|NCT03495986|Experimental|Home-Based Exercise & Diet Group|16-week home based functional electrical stimulation leg cycle ergometry exercise program and diet intervention
2411244|NCT03495986|Placebo Comparator|Home-Based Diet Alone Group|Diet intervention
2411245|NCT03495973||Participants with Crohn's Disease (CD)|Participants with CD will be assessed for the effectiveness of ustekinumab in accordance with national guidelines and routine standard of care. Data will be prospectively collected with the aid of the Swedish inflammatory bowel disease (IBD) registry, SWIBREG and medical records of each participant. Data will also be collected retrospectively from SWIBREG and other databases including national databases such as the participant registry in which cases the national databases will be considered source data.
3145109|NCT00061360|Experimental|ATG+CsA|ATG+CsA for 6 months followed by a slow CsA taper in the subsequent 18 months
3145110|NCT00061360|Experimental|ATG+CsA+RA|ATG+CsA+RAPA for 6 months
3145111|NCT00061490|Experimental|1|16 weekly educational meetings
2411249|NCT03495934|Experimental|single oral administration of 14C-pracinostat in the fas|
3145112|NCT00061490|No Intervention|2|Wait list control
3145113|NCT00061516|Experimental|Brinzolamide suspension, 1%|Dosed twice daily for 12 weeks
3145114|NCT00061516|Experimental|Levobetaxolol suspension, 0.5%|Dosed twice daily for 12 weeks
3145115|NCT00061542|Experimental|Betaxolol|Two doses daily for 12 weeks
3145116|NCT00061542|Experimental|TGFS 0.25%|Two doses daily for 12 weeks
3145117|NCT00061542|Experimental|TGFS 0.5%|Two doses daily for 12 weeks
3145118|NCT00061620|Experimental|Tezacitabine|Tezacitabine as a bolus infusion daily x 5
3145119|NCT00061698|Active Comparator|Cognitive Behavior Therapy Child Only|Participants completed 20 sessions of CBT
3145120|NCT00061698|Active Comparator|CBT plus Parent training|Child participants completed 20 sessions of CBT and parents completed 8 sessions of parent training
3145121|NCT00061698|No Intervention|Minimal Contact Control|Participants waited 12 weeks for treatment but their safety and well-being were monitored during this time
3145122|NCT00061750|Experimental|ICL670|
3145123|NCT00061750|Active Comparator|Deferoxamine|
3145124|NCT00061815|Experimental|Cetuximab+FOLFOX4|"Day 1 - cetuximab loading dose of 400 mg/m2 IV, infused over 2 hours; oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion~Day 8 - cetuximab maintenance dose of 250 mg/m2 IV infused over 60 minutes"
3145125|NCT00061815|Active Comparator|FOLFOX4.|"Day 1 - oxaliplatin (85 mg/m2) simultaneously with leucovorin (200 mg/m2), followed by 5-FU 400 mg/m2 IV bolus followed by 5-FU 600 mg/m2 as a 22-hour continuous infusion.~Day 2 - leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 IV bolus followed by another dose of 5-FU 600 mg/m2 as a 22-hour continuous infusion."
3145126|NCT00061828||Biliary Atresia|Infants presenting with cholestasis who are diagnosed with biliary atresia.
3145127|NCT00061828||Non-Biliary Atresia|Infants presenting with cholestasis without a diagnosis of biliary atresia.
3145128|NCT00061919|Experimental|Active arm (thalidomide)|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
3145129|NCT00061919|Placebo Comparator|Placebo arm|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
3145130|NCT00061958|Experimental|Treatment (arsenic trioxide)|Patients receive a loading dose of arsenic trioxide IV over 2 hours on days 1-5 on week 1. Beginning on week 2, patients receive a maintenance dose of arsenic trioxide IV twice weekly thereafter. Courses repeat every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients achieving a CR continue to receive therapy for at least 6 months beyond CR.
3145131|NCT00062023|Active Comparator|Arm I Sulindac|Oral sulindac twice daily.
3185483|NCT00735137|No Intervention|C|Expectant management in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
2411256|NCT03495882|Experimental|AGEN1884 + AGEN2034|AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical)
3185484|NCT00735137|Experimental|D|Vaginal pessary treatment in singleton pregnancy with short cervix; Women with cervix <15 mm will be commenced on vaginal progesterone
2411262|NCT03495830||Carotid endarterectomy|Patients that underwent intervention (CEA or CAS) are followed by clinical examination and carotid duplex on 12, 24 and 36 month If there is coexisting contralateral carotid stenosis with grade greater than 50% and not requiring interventional treatment (CEA or CAS), patient should cross in optimal medical therapy group.
2411263|NCT03495830||Optimal medical therapy group|Patients not subjected to intervention (or in whom one carotid has been treated with CAS or CEA and contralateral has stenosis is greater than 50%) will be followed with carotid duplex (at 12, 24 and 36 months) and MRI imaging of carotid tree from aortic arch up to the circle of Willis after 12 and 36 months.
2411265|NCT03495804|Active Comparator|mannitol|Participants are given a minimum of 1500 mL of a preparation of mannitol as oral contrast agent over an hour prior to the examination.
2411266|NCT03495804|Experimental|polyethylene glycol|Participants are given a minimum of 1500 mL of a preparation of polyethylene glycol as oral contrast agent over an hour prior to the examination.
2411267|NCT03495791|Experimental|EI development phase.|
2411268|NCT03495791|No Intervention|Pilot-testing phase.|
2411269|NCT03495778|Experimental|Test Granola|50.5 g Test Granola
2411270|NCT03495778|Placebo Comparator|Control Granola|54.3 Control Granola
2411271|NCT03495765|Active Comparator|Well controlled|Eligibile people with diabetic macular oedema and HBA1C < 7.5
2411272|NCT03495765|Active Comparator|Poorly controlled|eligible people with Diabetic macular oedema and HBAIC >10.0
2411273|NCT03495752|Experimental|Pre/Post Repeated Measures|Performance on the forward-step-down test (FSDT) before and at one, five, and ten minutes following the Bruce Fatigue Protocol
2411274|NCT03495739|Experimental|RDG-17012® capsule|RDG-17012 ® capsule(dabigatran etexilate tosylate)
2411275|NCT03495739|Active Comparator|Pradaxa® capsule|Pradaxa® capsule(dabigatran etexilate mesylate)
2411276|NCT03495726|Experimental|Headspace app|Participants randomized to use the mindfulness app for 6 weeks.
2411277|NCT03495726|No Intervention|Waitlist control group|This group will receive treatment as usual for 6 weeks. After the completing the 6-week surveys, the waitlist group will receive a subscription to the Headspace app.
2411278|NCT03495713|Experimental|Single Arm|Subjects will receive initial treatment with the immunomodulatory agent, nivolumab, followed by low-dose (4 Gy x 2) involved-site radiotherapy in subjects with less than an anatomic CR after the first restaging scan. Patients with anatomic CR will continue nivolumab alone without radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease, and must be eligible for treatment with nivolumab.
3145132|NCT00062023|Active Comparator|Arm II Aspirin|Oral aspirin once daily.
3145133|NCT00062023|Active Comparator|Arm III Ursodiol|Oral ursodiol three times daily.
2411281|NCT03495674|Experimental|Group I (FITBIT, cycling)|Starting on day 15, participants wear FITBIT and complete cycling classes over 45 minutes 3 times a week for a total of 12 classes a month for up to 1 year.
2411282|NCT03495674|Active Comparator|Group II (FITBIT, information)|Starting on day 15, participants receive information about exercise guidelines and wear FITBIT to track heart rate and activities for up to 1 year.
3145134|NCT00062023|Placebo Comparator|Arm IV: Sulindac Placebo|Oral sulindac placebo twice daily.
3145135|NCT00062062|Experimental|gefitinib|"Patients receive oral gefitinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
3145136|NCT00062062|Experimental|paclitaxel + carboplatin + gefitinib|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of chemotherapy and in the absence of disease progression, patients receive oral gefitinib as in group I.~Quality of life is assessed at baseline and after the completion of course 2.~Patients are followed every 3 months for 5 years."
3145137|NCT00062075|Experimental|Treatment|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3145138|NCT00062101|Experimental|Group I (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib once daily and oral celecoxib twice daily.
3145139|NCT00062101|Experimental|Group II (erlotinib hydrochloride)|Patients receive erlotinib as in group 1.
3145140|NCT00062114|Experimental|rituximab + yttrium Y 90 ibritumomab tiuxetan|"Patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV (for imaging) over 10 minutes on day 1. Patients undergo 1 (or 2 if needed) imaging scan between days 2-5. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.~Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
3145141|NCT00062127|Experimental|Arm I (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan IV over 90 minutes on days 1 and 22 and oral thalidomide once daily on days 15-28. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3185485|NCT00735150||1|25 female and 5 male BRCA carriers
3185486|NCT00735163|Experimental|A|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
2411287|NCT03495635|Experimental|BBBS Community-Based Mentoring|Big Brothers Big Sisters Community-Based Mentoring Program
2411288|NCT03495635|No Intervention|Control|Not eligible to participate in a Big Brothers Big Sisters mentoring program, but may participate in other mentoring programs.
2411289|NCT03495622|Experimental|Motivational Interviewing/Text messaging|Home visits by community health worker to deliver motivational interviewing and set up a structured text messaging strategy designed around a pre-determined quit date for smoking cessation.
2411290|NCT03495622|No Intervention|Control|All participants will receive brief verbal advice about the hazards of smoking and the benefits of smoking cessation.
2411291|NCT03495609|Experimental|Ovitrelle|
2411292|NCT03495596||Videolaryngoscopy patients|The patients who were attempted to be intubated with videolaryngoscopy
2411293|NCT03495583|Experimental|Early introduction|Six commonly allergenic foods introduced (in a randomly assigned order) into the diets of exclusively breastfed infants from about 3 months of age.
2411294|NCT03495583|No Intervention|Standard introduction|Infants followed UK DoH standard advice for weaning
2411295|NCT03495570||A|HIV-infected (chronic or acute infection) with a HIV viral load of >1000 copies/mL in the 6 months prior to study entry and not (yet) in receipt of combination antiretroviral therapy (cART) at study entry.
2411296|NCT03495570||B|HIV-infected on cART with HIV viral load <50 copies/mL within the 6 months prior to study entry, at least one measure of HCV (chronic or acute infection) showing a detectable HCV viral load and not in receipt of HCV treatment at study entry.
2411297|NCT03495570||C|HCV mono-infected (chronic or acute infection) with detectable HCV viral load (>lower limit of quantification) in the prior 6 months and not in receipt of HCV treatment at study entry.
2411298|NCT03495570||D|HBV mono-infected (chronic or acute infection) patients with detectable HBV viral load in the prior 6 months and not in receipt of HBV treatment at study entry.
2411299|NCT03495557|Sham Comparator|Control|Simple closure
2411300|NCT03495557|Experimental|Experimental|Simple closure + mesh
2411301|NCT03495544||Hereditary BC|Pathogenic germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
2411302|NCT03495544||Sporadic BC|Without germline mutations in DNA-repair genes (TP53 MLH1 MSH2 MSH6 PMS2 EPCAM APC MUTYH CDKN2A CDK4 ATM KIT PDGFRA CDH1 CTNNA1 PRSS1 SPINK1 BRCA1 BRCA2 FANCI FANCL PALB2 RAD51B RAD51C RAD54L RAD51D CHEK1 CHEK2 CDK12 BRIP1 PPP2R2A BARD1 PARP1 STK11 XRCC3)
2411303|NCT03495531|No Intervention|Standard of Care|Standard of Care
2411304|NCT03495531|Experimental|VR Use|Obstetrics patients who use virtual reality
2411305|NCT03495518|Active Comparator|Symptom feedback to Health Care Provider|"For those randomized to the intervention arm, symptom screening using SPARK will be completed once daily for 5 days on an iPad using the approach refined in aim 2. Daily SSPedi reports will be printed and provided in the patient chart. On days 1 and 3±1, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical care"
2411306|NCT03495518|Active Comparator|Standard of care|For those randomized to the control arm, a clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
2411307|NCT03495505|Experimental|WiSE-CRT eligible|Patients need to meet all the inclusion and none of the exclusion criteria in order to be eligible for the study. All these patients will receive the WiSE-CRT implant.
2411308|NCT03495492|Experimental|Participants|Group receiving dermal chelation and nutritional therapy
3185487|NCT00735176|Experimental|Artificial Cervical Disc|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
2411310|NCT03495466|Active Comparator|Local only Anesthesia|The patient will receive local only anesthesia during the first surgery and local with sedation anesthesia for their second surgery.
2411311|NCT03495466|Active Comparator|Local with sedation anesthesia|The patient will receive local with sedation anesthesia during the first surgery and local only anesthesia for their second surgery.
2411312|NCT03495453|Active Comparator|CSI's DIAMONDBACK 360® Peripheral Orbital Atherectomy (OAS)|OAS (using CSI device) followed by Inpact Admiral drug coated balloon (DCB)
2411313|NCT03495453|Active Comparator|Medtronic's Hawkone Directional Atherectomy system (DAS)|DAS (using the Hawkone device) followed by DCB
2411314|NCT03495440|Experimental|Center Sessions|Treatment condition in which participants receive psychoeducation and communication coaching.
2411315|NCT03495440|Active Comparator|At-home|Active, self-study control condition in which participants receive regular communication with study personnel and self-study materials to review on their own.
2411316|NCT03495427|Experimental|Radioactive Diagnostic Imaging|Participants will receive F-DCFPyL PSMA PET imaging annually for 4 years. An administered dose of 9 ± 1 mCi (333 ±37 MBq) F-DCFPyL Injection will be administered via an in-dwelling catheter placed in an antecubital vein or an equivalent venous access.
2411317|NCT03495414||Healthy Controls (HC)|Controls will be physically and psychologically healthy and will show no indication of clinical hypersexuality.
2411318|NCT03495414||Patients with hypersexual disorder (HD)|Patients will meet diagnostic criteria for HD as defined in the DSM-5 proposed criteria for hypersexual disorder (Kafka, 2010)
2411319|NCT03495401|Experimental|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
2411320|NCT03495401|Placebo Comparator|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
2411321|NCT03495388||Major Inpatient Surgeries|Children ages 8-17.9 undergoing pectus excavatum or idiopathic scoliosis spinal fusion at Riley Hospital for Children, who have consented to participate in an observational clinical study as approved by the IU IRB, protocol #1707525204.
3185488|NCT00735176|Active Comparator|ACDF|Anterior cervical discectomy and fusion (ACDF)
3185489|NCT00735189|Experimental|1|Patient continues to receive anticoagulation care from the Anticoagulation Management Service
2411322|NCT03495375|Experimental|Treatment with a probiotic|Synbiotic2000Forte (SF) it is composed of 3 LAB species known to have anti-inflammatory effects and restoring the intestinal barrier, and 4 fermentable fibers: Pediococcus pentosaceus 5-33:3, Lactobacillus paracasei subsp paracasei 19, and Lactobacillus plantarum 2362 in combination with the following four fermentable fibres: betaglucan, inulin, pectin and resistant starch, a formula that is currently produced by Synbiotic AB, Sweden.
2411323|NCT03495375|Placebo Comparator|Treatment with placebo powder|Placebo will be a non-digestable carbohydrate with similar texture and flavor to the SF also provided by Synbiotic AB, Sweden.
2411324|NCT03495362|Experimental|Intervention group|"Ingredients: yeast beta-glucan, and capsule shell Capsule, per capsule with 500mg insoluble beta-glucan, twice a day, 1 capsule each time.~The intervention period is about 3 months."
2411325|NCT03495362|Placebo Comparator|Placebo group|Ingredients: starch, and capsule shell Capsule, per capsule with 500mg starch, twice a day, 1 capsule each time. The intervention period is about 3 months.
2411326|NCT03495349||Diabetic foot infection|All of the patients followed for a diabetic foot infection in Hospices Civils of Lyon
2411327|NCT03495336|Experimental|Washout period|Coffee abstention phase for 2 weeks.
2411328|NCT03495336|Experimental|Light roast coffee (LR)|Participants will follow LR Coffee consumption procedure and consume at least 3 cups of Light (LR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
2411329|NCT03495336|Experimental|Second washout period|coffee abstention phase for 2 weeks
2411330|NCT03495336|Experimental|Dark roast coffee (DR)|Participants will follow DR Coffee consumption procedure and consume at least 3 cups of Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks.
2411331|NCT03495323|Experimental|Prexasertib + LY3300054|"Prexasertib is administered intravenously twice per cycle~LY3300054 is administered intravenously twice per cycle"
2411332|NCT03495310|Experimental|Mindfulness|"In this group, children and their parents will receive a mindfulness session once a week, with a duration of 90 minutes, during 8 weeks (sessions will be separated for children and parents). Mindfulness sessions will be coordinated by experts in mindfulness techniques in children and adults respectively from the collaborator Institution Spanish School of Transpersonal Development Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan if necessary. Also a 60-minute walk 3 times a week will be recommended"
2411333|NCT03495310|No Intervention|Control|In this group, children and their parents will receive information regarding what is a healthy diet and physical activity attached to the World Health Organization recommendations. The session will be coordinated by a pediatric endocrinologist. Previous to the session, a 24-hour food recall questionnaire will be applied to offer a meal plan restricted in 500 kcal. The 24-R will be repeated at each session in order to make adjustments to the meal plan when necessary. Also a 60-minute walk 3 times a week will be recommended
2411334|NCT03495297|No Intervention|S-ICD Implant with defibrillation test|Patients undergoing de novo S-ICD implantation including induction of VF and defibrillation testing post-implant
2411335|NCT03495297|Experimental|S-ICD Implant without defibrillation test|Patients undergoing de novo S-ICD implantation without induction of VF and defibrillation testing post-implant
2411336|NCT03495284|Experimental|Potato treatment|Participants will be provided with one potato-based side dish, equivalent to one medium sized potato, every day for 4 weeks for incorporation into their self-selected diet. The potato-based side dish will be prepared at the Penn State Metabolic Kitchen. The potato side dish will consist of commonly consumed potato-based sides in the U.S. and there will be limited inclusion of ingredients high in saturated fat, refined sugars or sodium. French fries will not be provided. The variety of potatoes will represent consumption patterns in the U.S. including white, russet, yellow and red potatoes.
2411337|NCT03495284|Active Comparator|Refined grain treatment|Participants will be provided with a calorie-matched refined grain-based side dish every day for 4 weeks for incorporation into their self-selected diet. The refined grain-based side dishes will be prepared at the Penn State Metabolic Kitchen and ingredients high in saturated fat, refined sugar or sodium will not be used. These will be sides commonly eaten in the U.S. (e.g. pasta made with white flour and white rice, white bread rolls). During this treatment, participants will be told not to consume potatoes.
2411338|NCT03495271||Hemodialysis Patients|"Inclusion Criteria:~Patient's undergoing hemodialysis.~Male and female of any race~18 years/ older.~Those with dysphagia were excluded.~In both participant groups, before each tasting protocol commences, sterile cotton dental rolls will be placed in the participant's mouth. This will be used to collect a saliva sample and determine salivary flow.~Tasting Protocol: The hemodialysis patients will taste each solutions twice, both before and after their dialysis session. An sensory questionnaire and an open ended comment box will be given for participants to type in other words to describe the sensations.~In dialysis patients only, blood will be drawn pre and post dialysis for serum ion concentrations."
2411339|NCT03495271||Healthy Controls|"Inclusion Criteria~No tongue, lip, or cheek piercings~Over 18 years of age~Normal taste and smell function~No known issues with salivation or dry mouth~Willing to comply with study protocol (taste samples and provide saliva)~The above protocol will be mimicked in the healthy control group. The only difference is that instead of a pre/post dialysis tastings, the control population will have a 2-4 hour gap in between tastings in order to follow the approximate time-frame of the dialysis patients. Finally they will not be required to provide blood samples."
2411340|NCT03495258|Experimental|Clarion Evolve Laser Vaporization System|Clarion Evolve Laser Vaporization System
2411341|NCT03495258|Experimental|Olympus TURis Plasma Vaporization|Olympus TURis Plasma Vaporization
2411342|NCT03495245||Opioid Usage|Patients that are currently diagnosed with fibromyalgia and taking opioids.
2411343|NCT03495245||No Opioid Usage|Patients that are currently diagnosed with fibromyalgia and are not taking opioids.
2411344|NCT03495219||Esophageal Manometry|Esophageal manometry is a test to assess motor function of the upper esophageal sphincter, esophageal body and lower esophageal sphincter
2411345|NCT03495206|Experimental|Y-2(Edaravone And Borneol) sublingual tablet|
2411346|NCT03495193|Active Comparator|Exercise Group|Subjects randomized to the exercise training group will complete 16 weeks of exercise training. Exercise training will be performed 3x/week.
2411378|NCT03494972|Active Comparator|drain|Tetracyclin drain
2411379|NCT03494972|Sham Comparator|No-drain|No drain
2411347|NCT03495193|Active Comparator|No Exercise Group|Subjects randomized to the no-Ex group will receive a handout with tips for improving sleep hygiene. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty.
2411348|NCT03495180|Experimental|Standard EEG or SSEP|the intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
2411349|NCT03495167|Experimental|SyB C-1101|
3185490|NCT00735189|Active Comparator|2|Patient receives anticoagulation care from their usual primary care physician
2411351|NCT03495141|Active Comparator|Supervised|Participants first take part in supervised/coached colonoscopy module session twice (case one and case two) and then transition to performing an unassisted colonoscopy module twice (case three and case four).
2411352|NCT03495141|Active Comparator|Unsupervised|Participants will either first partake in an unsupervised colonoscopy module twice (case one and case two) and then transition to a supervised/coached colonoscopy module session twice (case three and case four).
2411353|NCT03495128|Experimental|Bed rest|Three days of bed rest at -6 degrees of head-down tilt
2411354|NCT03495128|Experimental|Reconditioning|Three days of one-legged knee extension contractions to recondition one leg
2411355|NCT03495115|Active Comparator|SCREENING MRI|Standard MRI procedure will be used.
2411356|NCT03495115|Experimental|SCREENING MG BI-RADS 4/5|"RSI is a DWI sequence with a built in distortion-correction technique that can be applied to any diffusion technique using echo planar imaging acquisition.~RSI will be performed using pulsed-field gradient, spin-echo, echo planar imaging with multi-shell diffusion data .~The b0 images will be collected in both the forward and reverse phase encoding directions to allow for post-processing correction of spatial distortion from magnetic field."
3185491|NCT00735228|Active Comparator|1|Perioperative blood glucose was controlled within the normal levels (80-110 mg/dL) by artificial pancreas.
3185492|NCT00735228|Active Comparator|2|Perioperative blood glucose concentration was controlled within the range from 140 to 160 mg/dL by artificial pancreas.
3185493|NCT00735280|Experimental|Reduced dose of unfractionated heparin|
2411360|NCT03495089|Experimental|patients with type 2 DM|"Patients with type 2 DM over 40 years of age, with or without symptoms of neuropathy, attended in Primary Care.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance- DEC quantification using the Sudoscan® device."
2411361|NCT03495089|Experimental|prediabetes|"Patients with intermediate alterations of glucose metabolism defined as impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) determined by OGTT after 2-hour 75 g oral glucose administration.~Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device."
2411362|NCT03495089|Experimental|control group|Patients without glucose alterations (normal glucose tolerance). Intervention(s) to be administered:After verifying the inclusion criteria and receiving written informed consent to participate, during the first visit to the Primary Care centres the medical history of the patient will be obtained and a physical examination will be performed using the Monofilament testing -MFT and the Neuropathy Disability Score-NDS and Utah Early Neuropathy Scale-UENS questionnaires will be given to screen for polyneuropathy-PN. The patient will also undergo dermal electrochemical conductance-DEC quantification using the Sudoscan® device.
2411363|NCT03495076|Experimental|Saline injection|In the saline condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline solution.
2411364|NCT03495076|Sham Comparator|Sham injection|In the sham injection condition, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
2411365|NCT03495076|No Intervention|Control|Participants in the control condition will not receive any kind of pain or pinprick sensation.
2411366|NCT03495063|Experimental|Natural Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of natural caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
2411367|NCT03495063|Experimental|Synthetic Caffeine|Subjects will be their own control and will have repeated measures after the consumption of a drink with 400mg of synthetic caffeine. Blood pressure measurements will be taken at baseline, then hourly for four hours.
2411368|NCT03495037|Experimental|Real World Strategy Training|Group intervention including education and strategy training to manage everyday functional difficulties.
2411369|NCT03495037|Active Comparator|Psychosocial Education|Group sessions including education on brain health.
2411370|NCT03495024|Other|Smoking cessation with varenicline|FDA-approved indication of varenicline for smoking cessation
2411371|NCT03495011||Cohort A|Patient with recently identified calcifications on mammography requiring biopsy. Patients will undergo a quantitative, multiparametric breast MRI as part of their clinical care. MRI will not change need for biopsy, but could identify additional suspicious sites. Only patients diagnosed with pure DCIS at biopsy and eventual surgical excision will receive Oncotype DX DCIS score testing.
2411372|NCT03495011||Cohort B|Patient with recent diagnosis of biopsy-proven DCIS would complete a research quantitative, multiparametric breast MRI as part of their clinical care. Only patients diagnosed with pure DCIS at surgical resection will receive Oncotype DX DCIS score testing.
2411373|NCT03494998||Children and young people|Aged 0-16 years
3185494|NCT00735293|Other|Treatment|There is only one arm to this study. All patients will receive treatment with the VASER for their axillary hyperhidrosis/bromidrosis
2411380|NCT03494959|Experimental|Treatment with Pentaglobin|Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days.
2411381|NCT03494946|Experimental|Arm A|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group A, will undergo Liver transplantation
2411382|NCT03494946|Active Comparator|Arm B|Patients that suffer from Colorectal cancer and metastasis to liver that are randomized to Group B, will be given chemotherapy, TACE, SIRT or other available treatment options.
3185495|NCT00735319|No Intervention|A|In the 7 control Capital Health community health centers, babies will be followed up according to the current policy. Bilirubin determinations will be performed at the discretion of the visiting nurse if the infant is inappropriately jaundiced or at the request of the physician if risk factors are present. Transcutaneous Bilirubinometers will not be available in each of these 7 centers for all the duration of the study.
2411385|NCT03494920|Other|Direct endovascular clot retrieval|Endovascular clot retrieval (ECR) within 4.5 hours stroke
2411386|NCT03494920|Other|Bridging thrombolysis followed by ECR|Intravenous tPA (at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour) followed by ECR
2411387|NCT03494907|Experimental|Seltorexant (Low and high dose)|Participants will receive seltorexant tablets orally in 2 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2411388|NCT03494907|Experimental|Moxifloxacin|Participants will receive moxifloxacin tablets orally in 1 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2411389|NCT03494907|Experimental|Placebo Matched to Seltorexant|Participants will receive seltorexant placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2411390|NCT03494907|Experimental|Placebo Matched to Moxifloxacin|Participants will receive moxifloxacin placebo tablets orally in 3 of 4 treatment arms (A,B,C,D) in a cross-over design, with 7 days wash-out phase between each treatment period.
2411391|NCT03494894||patients with Cystic Fibrosis and Primary Ciliary Dyskinesia|
2411392|NCT03494881|Experimental|Treatment Arm|This is an open-label pilot investigation and all study participants are assigned to active treatment. There is no placebo arm in this study.
2411393|NCT03494868|No Intervention|Fasting|Fasting prior to elective cesarean section delivery (standard of care)
2411394|NCT03494868|Experimental|Carbohydrate Drink|Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
2411395|NCT03494855||Neonates|<1 month of age SyMRI software used for brain imaging and radiological interpretation
2411396|NCT03494855||Infants|1mth - 2 years of age SyMRI software used for brain imaging and radiological interpretation
2411397|NCT03494855||Adolescents|2 - 12 years of age SyMRI software used for brain imaging and radiological interpretation
2411398|NCT03494855||Teenagers|13-18 years of age SyMRI software used for brain imaging and radiological interpretation
2411399|NCT03494855||Healthy Adults|Preliminary Evaluation SyMRI software used for brain imaging and radiological interpretation
2411400|NCT03494842|Active Comparator|the active TENS group|Transcutaneous nerve stimulation (TENS)
2411401|NCT03494842|Placebo Comparator|the placebo TENS group|Placebo Transcutaneous nerve stimulation (TENS)
2411403|NCT03494803||Control|
2411404|NCT03494803||Prostate Cancer|
2411405|NCT03494777|Experimental|Adherence-based incentivization|"Participants will be eligible for prize drawings at every regular clinic visit based on high adherence as measured by MEMS-caps. In addition there will be an annual prize drawing that is conditional on showing high adherence over the course of the year.~This arm will receive the intervention 'Incentivization based on high adherence' and the intervention 'Annual adherence prize drawing' and (if eligible) the intervention 'Year 2 booster'.~Note: the 70 treatment initiating clients will all be assigned to this arm to receive preliminary data as to whether incentives may work for this group."
2411406|NCT03494777|Experimental|Viral suppression-based incentivization|"Participants will be able to participate in prize drawings at every clinic visit where eligibility will be based on timely drug refills (that coincide with the clinic visits). Participants will also have a chance to enter a prize drawing at the end of every year if they show viral suppression.~This arm will receive the intervention 'Incentivization based on timely clinic visit' and the intervention 'Annual viral suppression-based prize drawing', and (if eligible) the intervention 'Year 2 booster'."
2411407|NCT03494777|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices.
2411408|NCT03494764|Active Comparator|5 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
2411409|NCT03494764|Active Comparator|3 Days Hyperbaric Therapy|Patients will be enrolled and follow an identical medical treatment algorithm. At day 3 responders (based on partial Mayo score) will be re-randomized in a 1:1 fashion to complete 5 total days of HBOT (1 session per day) or to stop after 3 days of HBOT. Non-responders will be entered into an open label arm to complete 5 total days of HBOT.
2411410|NCT03494751|Experimental|Heart Monitor|We used the device (heart monitor) in the patients with myocardial infarction.
2411411|NCT03494751|Active Comparator|No Heart Monitor|No heart monitor device in the patients with myocardial infarction (control).
2411412|NCT03494738||Newborn infants|Neonates born from consented women at the study hospital
2411415|NCT03494712|Experimental|S 95010|Increasing single doses of S 95010 to 5 subjects.
2411416|NCT03494712|Placebo Comparator|Placebo|Increasing single doses of Placebo to 2 subjects.
2411417|NCT03494699|Experimental|Intervention group|
2411418|NCT03494699|No Intervention|Control group|
2411419|NCT03494686|Experimental|LLETZ under local anaesthesia|The LLETZ procedure will be performed under local anaesthesia
2411420|NCT03494686|Active Comparator|LLETZ under general anaesthesia|The LLETZ procedure will be performed under general anaesthesia
2411421|NCT03494673||Control|Normal controls without headaches will undergo BOLD MRI with prospective CO2 targeting
2411422|NCT03494673||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo BOLD MRI with prospective CO2 targeting
3145142|NCT00062127|Experimental|Arm II (irinotecan hydrochloride and thalidomide)|Patients receive irinotecan as in arm I and oral thalidomide once daily on days -6 to 7. All patients undergo disease re-evaluation at 6 weeks. Patients with stable or responsive disease may receive additional courses comprising irinotecan IV on day 1 and oral thalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2411425|NCT03494634|Experimental|Chidamide|
2411426|NCT03494621|No Intervention|Control group|Participants randomly assigned to the control group will have three prenatal contacts at the same gestational ages as the intervention participants. These contacts will include collection of covariate data, review of locally available educational materials on pregnancy/infant care led by trained study staff, and assessment of the overall session quality and acceptability. The educational materials provided during these sessions are drawn from materials currently available at local health care facilities
2411427|NCT03494621|Experimental|Protecting Babies While They Sleep|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. The protocol for the focus groups and interviews has been reviewed by the Tribal Institutional Review Board. The focus groups were conducted in Rapid City and a western Tribal reservation with pregnant adult women and pregnant, parenting, or other interested adolescent women; fathers (adult men); and elder women. Two focus groups were held for each category of individuals. Additional qualitative data was collected via key informant interviews with individuals vested and experienced in maternal and child health.
2411428|NCT03494595||Thrombosis|Patients who will develop thrombosis perioperatively
2411429|NCT03494595||No thrombosis|Patients who will not develop thrombosis perioperatively
2411430|NCT03494582|Experimental|Sacral Hysteropexy|Abdominal approach for uterine suspension
2411431|NCT03494582|Experimental|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
2411432|NCT03494569|Experimental|Treatment (TMLI, fludarabine, melphalan)|Participants undergo TMLI BID on days -8 to -5, and receive fludarabine IV on days -4 to -2 and melphalan on day -2. Participants then undergo alloHCT on day 0.
2411433|NCT03494556||No Intervention|Paramedic will use data collected during routine care to complete four risk stratification tools.
2411434|NCT03494530|Other|Early initiation of edoxaban|Participants will be initiated on edoxaban within ≤ 5 days following ischemic stroke
2411435|NCT03494530|Other|Delayed initiation of edoxaban|Participants will be initiated on edoxaban within 6-14 days following ischemic stroke
2411436|NCT03494517||Preeclampsia|"Women aged 18-45 years~Confirmed pregnancy > 30 weeks of gestation~Singleton or multiple pregnancies~Admission in maternity of the Women's hospital with clinically suspected signs of severe preeclampsia:~Systolic blood pressure >140 mmHg or diastolic pressure > 90 mmHg and~Proteinuria > 0.3 grams in a 24-hour urine or protein:creatinine ratio >0.3 or~Signs of end-organ dysfunction (platelet count < 100'000G/l, serum creatinine >110 mg/l, or doubling of the serum creatinine, elevated serum transaminases to twice normal concentration)"
2411437|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
2411438|NCT03494504|Experimental|Reproxalap Ophthalmic Solution (0.5%)|
2411439|NCT03494504|Placebo Comparator|Vehicle Ophthalmic Solution|
2411440|NCT03494478|Experimental|Cohort group|All participants will have evaluations at inclusion and 12 months. Neuropsychological testing Actimetry Selfquestionnaires on emotional topics
2411441|NCT03494465|Active Comparator|MEDICAL TREATMENT GROUP|"Medical treatment will be used in a staggered manner and may also associate laser trabeculoplasty. If necessary, then surgical treatment would be indicated: trabeculectomy. or another filtering surgery.~Inadequate IOP control will be determined by the local ophthalmologist, and additional treatment will be indicated to achieve an target IOP."
2411442|NCT03494465|Experimental|INTERVENTION GROUP|"In lens extraction arm, patients will undergo lens phacoemulsification with intraocular lens implant (IOL) within 60 days after randomization.~If additional treatment is required, the same stepped sequence of therapy described for medical treatment group will be used and will be considered a therapeutic failure."
2411443|NCT03494452||Low back pain - no intervention|Patients who perform sitting occupational activities for at least 4 hours/day and have had low back pain for at least the previous 6 months
2411444|NCT03494452||Healthy - no intervention|Healthy persons who perform sitting occupational activities for at least 4 hours/day
2411445|NCT03494426|Experimental|interventional group|patients will receive Radiofrequency thoracic sympathectomy then will receive pregabalin ,tramadol,and tricyclic antidepressants
2411446|NCT03494426|Active Comparator|control group|patients will receive pregabalin ,tramadol,and tricyclic antidepressants
2411447|NCT03494413|Experimental|20 patients (1-20) validation arm|Accuracy of cerebral flow measurement between TPS and CDS in 20 patients undergoing cardiovascular surgery with cardiopulmonary bypass
2411448|NCT03494413|Experimental|20 patients (21-40) HCA arm|Assessment and comparison of TPS and CDS in hypothermic circulatory arrest (HCA) during cardiovascular surgery
2411449|NCT03494400|Experimental|Presential Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform presential aerobic training.
2411450|NCT03494400|Active Comparator|Presential Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform presential aerobic training.
2411451|NCT03494400|Experimental|Home-based Aerobic Training with Hormone Therapy|A group of women with breast cancer who use Tamoxifen or Aromatase Inhibitor and will perform home-based aerobic training.
2411452|NCT03494400|Active Comparator|Home-based Aerobic Training without Breast Cancer|A group of women without breast cancer who use Aromatase Inhibitor and will perform aerobic training home-based.
2411453|NCT03494387|Experimental|1|
2411454|NCT03494387|Experimental|2|
2411456|NCT03494361||Young normal group|normal participants below 60 years
2411457|NCT03494361||Old normal group|normal participants above 60 years
2411458|NCT03494348|No Intervention|Cruciate Retaining Polyethylene (CR)|This is the standard Polyethylene articular surface
2411459|NCT03494348|Active Comparator|Medial Congruent Polyethylene (MC)|The intervention here will be the MC articular surface. This is the new Polyethylene articular surface with a more congruent medial side and a more flat lateral side which should better resemble natural anatomy.
2411461|NCT03494322|Experimental|Avelumab + cetuximab|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab + cetuximab combination therapy:~Cycle 1~Day 1: Cetuximab 500* mg/m2 given IV over approx 3 hrs~Day 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~All other cycles:~- Days 1 and 15: Cetuximab 500* mg/m2 given IV over approx 2 hrs + avelumab 10 mg/kg given IV over approx 1 hr~*Cetuximab dose will be dependent on outcome of safety run-in.~There must be a 60 minute break between the administration of cetuximab and avelumab."
2411462|NCT03494322|Other|Avelumab monotherapy|"Patients will receive treatment in 4-week cycles and treatment may continue for up to 1 year.~Avelumab monotherapy will be given as follows:~All cycles Avelumab 10 mg/kg on days 1 and 15 given IV over approximately 1 hour"
2411463|NCT03494309|Experimental|ORIF|Open Reduction & Internal Fixation
2411464|NCT03494309|Active Comparator|CREF|Closed Reduction & External Fixation
2411465|NCT03494296||Open, multi-center, prospective|All enrolled and relapsed patients received D-COP regimen chemotherapy
2411466|NCT03494283||CrossFit injuries|
2411467|NCT03494270|Experimental|Rosuvamibe Tab|Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
2411468|NCT03494270|Active Comparator|Monorova Tab|Rosuvastatin 20mg qd for 24 weeks
2411469|NCT03494257|Active Comparator|Brinzolamide-Brimonidine fixed combination|1 drop of the brinzolamide-brimonidine fixed combination instilled in the patients cul de sac immediately after surgery
2411470|NCT03494257|No Intervention|No topical IOP reducing medication|No IOP reducing drops instilled after surgery
2411471|NCT03494244||ADM|Patients having undergone direct-to-implant breast reconstruction using acellular dermal matrix.
2411472|NCT03494244||Non-ADM (Vicryl)|Patients having undergone direct-to-implant breast reconstruction using non-acellular dermal matrix mesh (Vicryl mesh).
2411473|NCT03494231|Experimental|HLX06, in patients with solid cancers|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX06 once per week. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 500, 750, 900, 1200, 1500 mg, starting from 500 mg/kg.
2411474|NCT03494218|Experimental|vegetative state|patients with vegetative state lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
2411475|NCT03494218|Experimental|minimally conscious state|Patients with minimally conscious state display inconsistent, but reproducible and discernible signs of awareness using CRS-R. The nailbed pressure was applied for 5 seconds and ended as soon as the behavioral response were captured. The raters recorded patients' behavioral responses using Nociception Coma Scale (NCS) during 10 seconds after each noxious stimulus.
2411476|NCT03494205|Experimental|Test group|"For the patients of the test-group Urtica comp gel is applied three times per day locally on the skin as soon as the patient senses itching, tingling and/or reddening. Otherwise the skincare is exactly as the control group in line with the departments general guidelines.~In case of marked worsening, e.g. epitheliolysis, the patient may receive Flammazine and Ialugen plus as rescue-care.~Rescue care: according to the departments therapeutic guidelines patients will receive Flammazine and/or Ialugen plus as clinically indicated at the discretion of the treating physician (usually in cases of marked worsening of the skin condition like e.g. epitheliolysis)."
2411477|NCT03494205|Active Comparator|Control group|"Control group receiving the institutional standard skin care Excipial-Hydrolotion - all other therapeutic interventions, assessments and rescue-care will be the same in both groups."
2411478|NCT03494192|Experimental|scapula based|"Cold pack~Stretching Exercises~Exercise training focus on scapulothoracic muscles will be applied two times per week total 12 week"
2411479|NCT03494192|Experimental|scapula&rotator cuff based|"Cold pack~Stretching Exercises~Exercise training focus on scapulothoracic muscles~Exercise training focus on rotator cuff muscles will be applied two times per week total 12 week"
2411480|NCT03494179|Experimental|High Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
2411481|NCT03494179|Experimental|Low Dose of ICP-022|Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
2411482|NCT03494166|No Intervention|Low Need Benchmark or Follow-up|In the low need benchmark or follow-up group, they will receive baseline and 13-week assessments (about 30-40 minutes) over the telephone. A brief assessment (about 5 minutes) at week 4 over the telephone will assess symptoms. Approximately 35% of all participants will be in this group.
2411483|NCT03494166|Experimental|High Need A-SMH or TIP-C|Participants will be mailed the printed Symptom Management and Survivorship Handbook (SMH). The Group A participant will be called every week for 4 weeks to ask about symptoms and suggest strategies from the SMH to relieve symptoms. Calls will last approximately 10 minutes. After 4 weeks, participants will be re-randomized to continue in SMH for 8 more weeks or to add Telephone Interpersonal Counseling (TIP-C) Intervention for the subsequent 8 weeks. If the TIP-C is added, the counselor will call the participant once per week for about 35-40 minutes to assess and discuss strategies for managing symptoms, provide survivorship education, and discuss interpersonal relationships, communication, and social support. At week 13, the participant will complete the second assessment.
2411525|NCT03493906|Experimental|Intervention|Patient Ambassador Support
2411526|NCT03493893||Affixus|To compare Affixus to PFNA and TFNA
2411527|NCT03493893||PFNA|To compare PFNA to Affixus and TFNA
2411528|NCT03493893||TFNA|To compare TFNA toPFNA and Affixus
2411484|NCT03494166|Experimental|High Need B-TIP-C+SMH|Participant will be called every week for the first 8 weeks using a combination of TIP-C and SMH. The counselor will assess and discuss interpersonal relationships, communication, social support, managing symptoms and survivorship. At the end of 8 weeks, the final 4 calls will focus be the SMH protocol. At week 13, the second assessment will be conducted.
3145143|NCT00062179|Experimental|paclitaxel/carboplatin/celecoxib|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy
3145144|NCT00062179|Placebo Comparator|paclitaxel/Carboplatin/Placebo|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy
2411487|NCT03494114|Experimental|COPD Patients|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ. In addition, PET imaging data will be compared with disease severity, based on pulmonary function testing.
2411488|NCT03494114|Experimental|Individuals without COPD|Folate imaging will be performed with 68Ga-EC2115 prior to scheduled bronchoscopy, which will be performed for clinical purposes to evaluate a suspicious lung nodule. The unused portion of the bronchoalveolar lavage (not necessary for clinical purposes), will be interrogated to compare PET imaging with parameters of inflammation in BAL, including the number/percentage of macrophages expressing FRβ.
2411489|NCT03494101||Non-typhoid Salmonella infection|Patients with a non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
2411490|NCT03494101||Acute, infectious diarrhea|Patients with acute, infectious diarrhea without non-typhoid Salmonella infection. Blood samples, stool samples and clinical information will be collected.
2411491|NCT03494101||Healthy individuals|Healthy individuals with no symptoms of acute or chronic diarrhea. Blood samples, stool samples and clinical information will be collected.
2411492|NCT03494088||Children with Autism with gastrointestinal (GI) symtpoms|
2411493|NCT03494088||Children with Autism without gastrointestinal (GI) symtpoms|
2411494|NCT03494088||Healthy Children|
2411495|NCT03494062|Experimental|Exercise|Home-based exercise intervention
2411496|NCT03494062|No Intervention|Control|Usual care
2411497|NCT03494049|Active Comparator|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O'clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
2411498|NCT03494049|Active Comparator|Standard HoLEP|Standard HoLEP TECHNIQUE as described by Elhilali et al 2010
2411499|NCT03494036|Experimental|Synbiotic|Synbiotic capsule containing 3x1.000.000.000 Colony Forming Units probiotics (Lactobacillus helveticus R0052 60%, Bifidobacterium infantis R0033 20%, dan Bifidobacterium bifidum R0071 20%) and fructooligosaccharide 80 mg. The dosage is once daily and it is given for 60 days
2411500|NCT03494036|Placebo Comparator|Placebo|Placebo capsule containing saccharum lactis. The dosage is once daily and it is given for 60 days
2411501|NCT03494010||prospective cohort|Patients will be followed to determine the impact of the hybrid closed-loop (HCL) system that was prescribed at part of clinical care.
2411502|NCT03494010||historical controls|Medical record data of these patients, who did not use the HCL system, will be compared with patients in the HCL cohort.
2411503|NCT03493997|Experimental|Radiotherapy+Ialuril®+Ialuril Soft Gels®|Radiotherapy+Ialuril®+Ialuril Soft Gels®
2411504|NCT03493997|Active Comparator|Radiotherapy only|Radiotherapy only
2411505|NCT03493984|Experimental|Ginger exosomes|
2411506|NCT03493984|Experimental|Aloe exosomes|
2411507|NCT03493984|Experimental|Ginger and aloe exosomes|
2411508|NCT03493984|Placebo Comparator|Placebo|
2411509|NCT03493971|Active Comparator|Carotid artery stenting (CAS)|Carotid revascularization performed using CAS
2411510|NCT03493971|Active Comparator|Carotid endarterectomy (CEA)|Carotid revascularization performed using CEA
3145145|NCT00062244|Experimental|Arm I|"Phase I: Patients receive oblimersen IV continuously on days 1-7. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 1-6 patients receive escalating doses of oblimersen until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment as in phase I at the MTD of oblimersen. Patients are followed every 3 months for 2 years."
3145146|NCT00062309|Active Comparator|CIMRT|76 Gy in 38 fractions
3145147|NCT00062309|Experimental|HIMRT|70.2 Gy in 26 fractions
3145148|NCT00062387|Experimental|Arm I|Patients receive oral perifosine 4 times daily on days 1 and 2 and once daily on days 3-28 during course 1. Patients receive oral perifosine once daily on days 1-28 for all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145149|NCT00062452||A-1,2,3|The cohort (A) comprised of high risk infants. There were 3 sub groups studied within this cohort: (1) premature infants, (2) Infants with congenital gut anomalies, and (3) perinatal asphyxia.
3145150|NCT00062478|Experimental|1|Karenitecin for intravenous use
3145151|NCT00062491|Experimental|1|Karenitecin (BNP1350)
3145152|NCT00062504|Experimental|1|Valproic: 10mg TID week 1, 25mg TID week 2, 35mg week 3
3145153|NCT00062504|Experimental|2|Non-enzyme-inducing anti-epileptic drugs: 25mg TID week 1, 35mg week 2, 50mg week 3
2411520|NCT03493932|Experimental|1|Recurrent Glioblastoma patients
3145154|NCT00062504|Experimental|3|Enzyme-inducing anti-epileptic drugs: 35mg TID week 1, 505mg week 2, 75mg week 3
3145155|NCT00062530|Experimental|1|All participants will receive oral vaccine at study entry, although dosage will vary
2411529|NCT03493880||naCT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemotherapy.
2411530|NCT03493880||naCRT|Advanced gastric cancer or esophagogastric cancer receiving neoadjuvant (preoperative) chemoradiotherapy.
2411531|NCT03493867|Other|Vitaliti|The subject's blood pressure will be simultaneously determined and recorded using the invasive arterial line blood pressure reading and the test Vitaliti device readings.
3185496|NCT00735319|Experimental|B|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained.Depending on the level of bilirubin obtained and whether risk factors (gestational age < 38 weeks, blood group incompatibility with DAT positive) are present or not, a different management plan will apply. The algorithm is based on curves established by Bhutani et al to predict the risk of significant hyperbilirubinemia based on predischarge bilirubin measurements.
3185497|NCT00735332|Experimental|Single-Arm|
2411534|NCT03493841|Experimental|Group A|Group A will receive racemic lipoic acid first and R-lipoic acid second
2411535|NCT03493841|Experimental|Group B|Group B will receive R- lipoic acid first and racemic lipoic acid second
3185498|NCT00735345|Experimental|Treatment Arm|Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy
3185499|NCT00735358|Active Comparator|A|Single dose cyanoacrylate in one shot
3185500|NCT00735358|Experimental|B|Double doses cyanoacrylate in one shot
3185501|NCT00735410|Experimental|1|
3185502|NCT00735423||No groups|IDE used for outcome measurement not intervention
2411541|NCT03493802||Patients with a previous diagnosis of ADPKD|Patients that have been diagnosed with ADPKD and meet the study's inclusion criteria
2411542|NCT03493802||Healthy individuals as controls|Age and gender-matched healthy controls
2411543|NCT03493789|Experimental|Diagnostic (FDG-PET, SBRT)|Participants receive fludeoxyglucose F-18 IV and after 60 minutes undergo positron emission tomography (PET) within 4 weeks of the first planned stereotactic body radiation therapy (SBRT) fraction, prior to the second planned fraction, and prior to the fifth planned fraction.
2411544|NCT03493776|Active Comparator|Pre-Transplant Group|VZV Subunit vaccine will be administered
2411545|NCT03493776|Experimental|Post-Transplant Group|VZV Subunit vaccine will be administered
2411546|NCT03493763||serum AFP negative HCC patients|"Patients who received liver resection within 3 months;~Hepatocellular carcinoma confirmed pathologically;~Serum alpha-fetoprotein level lower than 20ng/ml before hepatectomy."
2411547|NCT03493750|No Intervention|Healthplan guide alone|"Nurse applies the daily-practice questionnaire called Healthplan guide to screen and identify people with dental diseases, among those in vulnerable situation, and to sensitize them about the importance of oral hygiene and how to improve it.~After that, the nurse has to state if, from her/his point of view the patient needs dental care or not. Whatever the answer, the nurse makes an appointment to a dental practice, in the 30 following days, and gives it to the patient with a free bus ticket. Randomization is done at that time.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organized but outside this trial."
2411548|NCT03493750|Experimental|Oral and dental evaluation|"After application of the Healthplan guide, nurse statement of the need of dental care or not, making of an appointment to the dental practice and gift of a free bus ticket, if the patient is randomized in the experimental group, the nurse completes the evaluation with a mouth inspection in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface. At the end of this exam, the nurse has to state again if, from her/his point of view the patient needs dental care or not.~The dentist, blinded of the patient's group, makes a dental exam and says if the patient needs dental care or not.~If care are indicated, they will be organised but outside this trial."
2411549|NCT03493737||HaH (Hospital-at-Home)|Bortezomib is injected at Outpatient hospital at day 1 and at Home at further day of cycles
3185503|NCT00735488||A|Thalassemia Minor carriers
3185504|NCT00735488||B|Sickle cell carriers
3185505|NCT00735501||A|
3185506|NCT00735527|Experimental|1|Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
3185507|NCT00735527|Active Comparator|2|Intra-venous lorazepam 0.1 mg/kg (max 4 mg)
3185508|NCT00735540||A|Acute organic diseases
3185509|NCT00735540||B|Patients with chronic diseases
3185510|NCT00735540||C|Patients with psychiatric diagnosis
3185511|NCT00735579||Study group|Patients undergoing major abdominal surgery
3185512|NCT00735592||A|Children discharged with the recommendation of performing a follow up X rays after lobar pneumonia
3185513|NCT00735605|Active Comparator|1:BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
3185514|NCT00735605|Active Comparator|2 BTX A|Injected with BTX-A in the left lateral position; anesthesia was not required
3185515|NCT00735605|Active Comparator|3: PDPR|Inner half of puborectalis sling was divided on each side by using a scalpel NO
3185516|NCT00735631|Experimental|1|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
3185517|NCT00735683|Placebo Comparator|1|
3185518|NCT00735683|Experimental|2|
3185519|NCT00735683|Experimental|3|
3185520|NCT00735683|Experimental|4|
3185521|NCT00735683|Experimental|5|
3185522|NCT00735683|Experimental|6|
3185523|NCT00735722|Active Comparator|Concomitant HIFU ablation|HIFU AF Ablation
3185524|NCT00735722|No Intervention|Best medical treatment|Best medical treatment
3185525|NCT00735748|Experimental|1|Tramadol per os (Tradonal Odis® orodispersible tablets)
3185526|NCT00735748|Active Comparator|2|Tramadol IV (Tradonal® IV)
3185527|NCT00735761|Experimental|1|ME-609 (5% acyclovir and 1% hydrocortisone)
3185528|NCT00735761|Active Comparator|2|Acyclovir in ME-609 vehicle (5% acyclovir)
3185529|NCT00735774|Experimental|11C-ORM-13070|
3185530|NCT00735800|Active Comparator|Supportive Counseling|
3185531|NCT00735800|Experimental|Problem-Solving|
3185532|NCT00735813|Experimental|A|Tunneled central venous catheters locked with Taurolock
2411552|NCT03493711||Milk-based fomula fed|Exclusively on Similac Advance Formula for at least 1 month prior to visit
3185533|NCT00735813|Active Comparator|B|Tunneled central venous catheter locked with heparin
3185534|NCT00735865|Active Comparator|1|
3185535|NCT00735865|Active Comparator|2|
2411556|NCT03493685|Experimental|sparsentan for double-blind and open-label extension|Sparsentan will be administered as a single oral morning dose; an initial dose of 400 mg daily titrating up to a target dose of 800 mg, daily
2411557|NCT03493685|Active Comparator|Irbesartan|Irbesartan will be administered as a single oral morning dose; an initial dose of 150 mg daily titrating up to a target dose of 300 mg, daily
2411558|NCT03493659|No Intervention|Sit-Sit|The participants will sit during the tutorials, and sit during the concept tests given to measure their learning.
2411559|NCT03493659|Active Comparator|Sit-Stand|The participants will sit during the tutorials. Intervention: Behavioral: Standing during Concept Test will be administered
2411560|NCT03493659|Active Comparator|Stand-Stand|The participants will stand during the tutorials, and stand during the concept tests given to measure their learning. Intervention: Behavioral: Standing during Concept Test and regular tutorial session will be administered.
2411561|NCT03493659|Active Comparator|Stand-Sit|"The participants will stand during the tutorials. Intervention: Behavioral: Standing during regular tutorial session will be administered.~However, participants will sit during the concept tests given to measure their learning."
2411562|NCT03493646|Active Comparator|Azacitidine|6 cycles of azacitidine (28 day cycle)
2411563|NCT03493646|Experimental|CC 486|6 cycles CC 486 (28 day cycle)
2411564|NCT03493633||EzyGain at Home|Setting up a walking device at home for people aged 60 years with partial walking disability regardless of etiology and pathology leading to walking disability.
2411565|NCT03493620|Experimental|Device arm|Gastric endosuturing will be performed until the entire gastric body is sutured in the form of a tube.
2411566|NCT03493620|Sham Comparator|Sham arm|Group II is a control group (only the endoscopist will know which group each patient belongs to)
3185536|NCT00735865|Active Comparator|3|
2411568|NCT03493594|No Intervention|Control|"Control group will receive standard health care.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
2411569|NCT03493594|Experimental|Nutrition education program|"The intervention group will receive an early nutrition program for 12 months. Workshops format will be mainly in form of talks and experience sharing groups which run by lactation consultants, nutritionists / dietitians. All classes and workshops will be run for 4-6 times to cater for subjects recruited in different phases.~To improve the compliance of the subjects, both intervention group and control group can attend one vision development workshop at 2-month postpartum and two parenting workshops at 6- and 12-month postpartum."
2411570|NCT03493581|Experimental|NSCLC patients|
2411571|NCT03493568|Experimental|Genvoya 150Mg-150Mg-200Mg-10Mg Table|switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
2411572|NCT03493568|Active Comparator|Dolutegravir 50 mg plus one RTI (at label dose)|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
2411573|NCT03493555|Experimental|Intervention Development|Peer Health Navigator for PrEP
3185537|NCT00735865|Active Comparator|4|
3185538|NCT00735930|Experimental|Treatment (alvocidib, lenalidomide)|Patients receive alvocidib IV over 4.5 hours on days 1, 8, and 15 in course 1 followed by a week of rest. Beginning in course 2 and all subsequent courses, patients receive lenalidomide PO QD on days 1-21 and alvocidib IV over 4.5 hours on days 3, 10, and 17. Treatment repeats every 35 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
2411576|NCT03493529||Normal Weight|BMI: Between 18.50 and 29.99 kg/m2
2411577|NCT03493529||Obesity Clas I|BMI between 30 and 34.99 Kg/m2
2411578|NCT03493529||Obesity Clas II|BMI between 35 and 39.99 Kg/m2
2411579|NCT03493529||Obesity Clas III|BMI> 40 Kg/m2
2411580|NCT03493503|Experimental|Salbutamol loading dose|Salbutamol loading dose of 15 mcg/kg in 10 minutes, with a maximum of 750 mcg.
2411581|NCT03493503|Placebo Comparator|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes.
2411582|NCT03493490|Experimental|Neodolpasse|"In the Neodolpasse® arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine."
2411583|NCT03493490|Active Comparator|Diclofenac|"In the Diclofenac arm patients receive two infusions over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.~The Infusion solution contains 75 mg (250 mL) of the NSAID diclofenac."
2411584|NCT03493490|Placebo Comparator|Placebo|In the Placebo arm patients receive two physiologic saline infusion (250 mL) over 30 minutes after fixation of the graft replacement and with a time interval of 8 hours each during the first 24 hours.
2411585|NCT03493477||Skeletal Class II Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be higher than mean value, mean value 3 ±2), Witt's appraisal should be higher than mean value (mean value zero), and McNamara analysis (A-B diff NV should be higher than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class II relation
2411586|NCT03493477||Skeletal Class III Group|From the lateral cephalometric radiograph , Steiner analysis (ANB angle should be lower than mean value, mean value 3 ±2), Witt's appraisal should be lower than mean value (mean value zero), and McNamara analysis (A-B diff NV should be lower than mean value, mean value 4±2).At least two of the three mentioned analyses should verify skeletal class III relation
2411587|NCT03493464|Experimental|Treatment|Subjects will receive a single dose of BR55 at 0.03 mL/kg or 0.05 mL/kg.
3185539|NCT00735995|Experimental|A|Individual CBT
2411612|NCT03493282|Active Comparator|Active Treatment- CT1812 100 mg|7 subjects randomized to 100 mg CT1812
3185540|NCT00735995|Experimental|B|Group CBT
3185541|NCT00735995|No Intervention|C|Waiting-list control
3185542|NCT00736008||A|Patients with thromboembolic events
2411588|NCT03493451|Experimental|NK/T cell lymphoma and with other mature T-cell neoplasms|"In this cohort, participants will be treated with tislelizumab 200 mg intravenously (IV) on Day 1 of each cycle.BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.~Cohort 1: Participants with relapsed or refractory extranodal NK/T cell lymphoma (nasal or non-nasal type)~Cohort 2: other mature T-cell neoplasms (limited to the following histologies: peripheral T-cell lymphoma-not otherwise specified, angioimmunoblastic T-cell lymphoma, or anaplastic large-cell lymphoma)~Cohort 3: cutaneous T-cell lymphoma (limited to mycosis fungoides and Sèzary syndrome)"
2411589|NCT03493438|Experimental|Relaxation Group|Patients performed Jacobson relaxation technique in supine position. Respiration control and various visual imaging techniques were used during the technique. Relaxation exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2411590|NCT03493438|Experimental|Proprioceptive Neuromuscular Facilitation Group|Patients exercised with proprioceptive neuromuscular facilitation technique for trunk muscles using chopping and lifting patterns with ritmic initiation PNF exercises were made by the physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2411591|NCT03493438|Experimental|Core stabilization group|Patients had core stabilization exercises that involved spinal mobility. The patients performed the drawing-in maneuver within various visual imaging techniques during all exercises, especially with respiratory control. Exercises were made within the supervision of a physiotherapist. The application period was 20 minutes for one session, 3 days a week and totally six weeks.
2411592|NCT03493438|Other|control group|Patients in the control group were told the importance of a single session exercise
3145156|NCT00062543|Experimental|Hepatic Artery Infusion|Donor-derived CD34+ cells administered in a total volume of 100ml via hepatic artery over 10 minutes. Cells given as a dose escalation study. First cohort of 3 patients receive 1 * 106 CD34+ cells/kg. Next 3 patients receive 2.5 * 106 CD34+cells/kg. Next 3 patients receive 5 * 106 CD34+ cells/kg. Less than 1 * 105 T cells/kg administered.
3145157|NCT00062569|Experimental|1|
2411595|NCT03493412|Experimental|BH4-Placebo|Subjects will be tested on two different days, first day will be baseline and Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin) and second day will be Placebo. Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
2411596|NCT03493412|Experimental|Placebo-BH4|Subjects will be tested on two different days, first day will be baseline and placebo and second day will be Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin). Testing will take place one-hour after BH4/placebo intake. There will be a 2-week washout between testing days.
2411597|NCT03493399|Experimental|Problem Gamblers|Interference
2411602|NCT03493373|Experimental|Exercise and nervous system mobilization|This group will receive neural mobilization and therapeutic exercise: two sessions of 60 minutes during 8 weeks.
2411603|NCT03493373|Experimental|Exercise|This group will receive therapeutic exercise: two sessions of 60 minutes during 8 weeks.
2411604|NCT03493360|Experimental|Visual feedback|Participants will be asked to perform movements of the low back while looking at a mirror for visual feedback.
2411605|NCT03493360|Active Comparator|No visual feedback|Participants will be asked to perform movements of the low back while the mirrors are covered and no visual feedback is provided.
2411606|NCT03493347|Experimental|Equine-assisted Occupational Therapy|All children will receive the Equine-assisted Occupational Therapy (EAOT) intervention, which includes occupational therapy administered in an equine environment. Common intervention activities include grooming, tacking, mounting, and riding the horse.
2411607|NCT03493334|Experimental|Visual feedback|Participants in this group will receive visual feedback of their neck when performing 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation).
2411608|NCT03493334|Active Comparator|No visual feedback|Participants in this group will perform 10 repetitions of each of neck movements (flexion, extension, side-flexion and rotation) without feedback.
2411609|NCT03493321|Experimental|PRF with MTA|PRF with MTA with PRF with Theracal as intervention
2411610|NCT03493308|Experimental|Pain neuroscience and exercise|Participants will received an 8 week intervention consisting of pain neuroscience education and exercise. Pain neuroscience education will be conducted in line with international guidelines, covering the neurophysiology of pain, transition from from acute to chronic pain and the nervous system ability to modulate the pain experience. exercise will include general exercise and dance.
3145158|NCT00062569|Experimental|2|
3145159|NCT00062829|Other|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
3145160|NCT00062842|Experimental|Irinotecan weekly|Irinotecan was administered over 90 min weekly 4x, every 6 weeks.
3145161|NCT00062855|Experimental|Gene Modified Neuroblastoma Cells|Gene modified neuroblastoma cells given as 4 subcutaneous injections over 5 weeks
3145162|NCT00062985|No Intervention|Control|
3145163|NCT00062985|Experimental|Mail-based weight loss intervention|
3145164|NCT00062985|Experimental|Telephone-based weight loss intervention|
3145165|NCT00063076|Experimental|Targretin®|Targretin® (bexarotene) Gel 1%, treat half head
3145166|NCT00063076|No Intervention|Control|Half head untreated as control
3145167|NCT00063089|Experimental|altastaph|S. aureus Immune Globulin Intravenous (Human) 5%
3145168|NCT00063089|Placebo Comparator|Placebo|0.45% Normal Saline
3145169|NCT00063128|Experimental|A|
3145170|NCT00063128|Active Comparator|B|
3145171|NCT00063141|Experimental|Arm A|
3145172|NCT00063141|Active Comparator|Arm B|
3145173|NCT00063323|Active Comparator|Bupropion|Bupropion (brand name Zyban Sustained Release). Participants used bupropion SR 150 mg twice daily during the 16-week maintenance treatment.
3145174|NCT00063323|Active Comparator|Nicotine gum|Nicotine gum (brand name Nicorette) During the maintenance 16-week maintenance treatment phase, participants assigned to this arm received 2 mg. nicotine gum.
2411613|NCT03493282|Active Comparator|Active Treatment- CT1812 300 mg|7 subjects randomized to 300 mg CT1812
2411614|NCT03493282|Placebo Comparator|Placebo|7 subjects randomized to matching placebo
2411615|NCT03493269|Experimental|BAY1834845|"Part 1 in healthy male subjects:~Dose Groups 1-4 : orally administered multiple ascending doses. The treatment will last 10 consecutive days (treatment period1) and 1 day (treatment period 2) Dose Group 5: The treatment will last 1 day (treatment period 1) and 10 consecutive days (treatment period 2)"
2411616|NCT03493269|Placebo Comparator|Matching Placebo|Part 1: Matching placebo in healthy male subjects.
2411617|NCT03493269|Experimental|Chosen dose of BAY1834845|Part 2: This dose level will be adminstered in female and male patients with psoriasis
2411618|NCT03493269|Placebo Comparator|Placebo|Part 2: The placebo will be adminstered in female and male patients with psoriasis
2411619|NCT03493256||type 2 neurological complications present|The group of patients diagnosed with postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
2411620|NCT03493256||type 2 neurological complications absent|The group of patients without neurological complications.
2411621|NCT03493243||Adolescents exposed|Only clinical questionnaires
2411622|NCT03493230|Experimental|Patient with malignant melanoma|Patient with advanced or metastatic malignant melanoma (stage IIIB inoperable or IIIC or stage IV) will have a first blood test before any treatment, then at day 15 or 30 after initiation of therapy, and every two months until recurrence or progression for a maximum of 22 months.
2411623|NCT03493217|Experimental|ICP-022|Two regimens of ICP-022 (High and low dose QD) are designed for study Part I to determine RP2D. The RP2D determined will be used in Part II to further evaluate the preliminary efficacy of ICP-022 in Chinese subjects with R/R CLL/SLL.
2411624|NCT03493204|Experimental|Home-delivered, salt restricted|Meal description: salt-restricted (1500 mg to 2000 mg daily), > 2100 kilocalorie, high protein (>80 g daily) in addition to receiving standard pamphlet receipt
2411625|NCT03493204|Active Comparator|Dietary Advice|Standard of care, advice on salt-restriction using standard pamphlet receipt
2411626|NCT03493191|Experimental|0.5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 0.5μg/kg SHR0410 (n=6) or placebo (n=2)
2411627|NCT03493191|Experimental|1 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 1μg/kg SHR0410 (n=6) or placebo (n=2)
2411628|NCT03493191|Experimental|2 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 2μg/kg SHR0410 (n=6) or placebo (n=2)
2411629|NCT03493191|Experimental|5 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 5μg/kg SHR0410 (n=6) or placebo (n=2)
2411630|NCT03493191|Experimental|10 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
2411631|NCT03493191|Experimental|20 μg/kg SHR0410|8 subjects will be randomized in a 3:1 ratio to receive a single dose of either 10μg/kg SHR0410 (n=6) or placebo (n=2)
2411632|NCT03493178|Active Comparator|MCI-active|30 Subjects with MCI will receive N-acetylcysteine and glycine for 12-weeks. ll subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks.
2411633|NCT03493178|Placebo Comparator|MCI-placebo|30 subjects will received alanine for 12-weeks. All subjects will be studied at baseline prior to supplementation, after completing 12-weeks of supplementation, and 12-weeks after stopping supplementation (i.e. at 24-weeks). Supplements are only provided for first 12-weeks
2411634|NCT03493139|Experimental|PAAC-R|Physical Activity Across the Curriculum-Remote (PAAC-R) will include protocol specific activity breaks delivered remotely via a television in the classroom.
2411635|NCT03493139|Experimental|PAAC-T|Physical Activity Across the Curriculum-Teacher (PAAC-T) will include protocol specific activity breaks delivered by the classroom teacher.
2411638|NCT03493100|Experimental|oral nutritional supplementation|This group receives optimized nutritional support, by ONS for a period of four weeks.
2411639|NCT03493100|Other|Control|The control group will receive treatment according to usual care.
2411640|NCT03493087|Active Comparator|Menakinon-7|Menakinon-7 360 µg tablet by mouth, every day for 6 weeks
2411641|NCT03493087|Active Comparator|Diet with vitamin K|Diet rich in vitamin K for 6 weeks
2411642|NCT03493061|Experimental|Systemic CPT-11 + HAI (FUDR+L-OHP)|"Patients will receive Systemic CPT-11 + HAI (FUDR+L-OHP) every 28 days:~Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; followed by Oxaliplatin 85 mg/m2 over 3 hours through the HAI pump on Day 1 and 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~then Irinotecan 150 mg/m2 IV over 90 minutes on Day 15, followed by Oxaliplatin 85 mg/m2 IV over 3 hours on Day 15.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
2411643|NCT03493048|Experimental|Cetuximab Plus FOLFOXIRI|Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
2411644|NCT03493048|Active Comparator|Cetuximab Plus FOLFOX|Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
2411645|NCT03493035||MCA aneurysm group|All patients with unruptured MCA aneurysm diagnosed on three-dimensional computed tomography angiography (3D CTA) and transcranial color-coded sonography (TCCS) .
2411646|NCT03493035||non-MCA aneurysm group|All patients with no evidence of intracranial pathologies on 3D CTA and diagnosed on transcranial color-coded sonography (TCCS).
2411647|NCT03493022|Experimental|Test Granola|50.5 g Test Granola
2411648|NCT03493022|Placebo Comparator|Control Granola|54.3 Control Granola
2411649|NCT03493009|Experimental|10mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 10 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
2411650|NCT03493009|Experimental|15mg Magnesium citrate|subjects will be required to follow a specific bowel preparation instruction consisting of dietary restrictions (no dried fruit, seeds or nuts) starting 5 days prior to the colonoscopy, an low residue diet at the day before the procedure, followed by a split dose of 15 mg of Magnesium citrate, followed by colonoscopy procedure with Pure-Vu System
2411651|NCT03492996|Experimental|LCB01-0371 dose with a [14C]-LCB01-0371-tracer|A mass balance study to investigate the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose in healthy male subjects
2411652|NCT03492983|No Intervention|Control group|No intervention
2411653|NCT03492983|Experimental|Intervention group|Addition of 10 g/day of high cocoa content chocolate to the usual diet for six months
2411654|NCT03492970|Other|10 adult patients with SMS|Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
2411655|NCT03492957|Experimental|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change. There is no control group ion this feasibility study.
2411656|NCT03492944||Ultrasound Microbubble Contrast Agent|All subjects will receive intravenous Lumason microbubble contrast agent; there is no comparative ultrasound contrast agent. Contrast Enhanced Ultrasound findings/results will be correlated with comparable, clinically performed, CTE/MRE findings/results
2411657|NCT03492931|Experimental|Treatment arm|Single dose of ticagrelor based on age
2411658|NCT03492918|Experimental|pembrolizumab group|Drug:Pembrolizumab Dose/Potency:200 mg Dose Frequency:Q3W Route of Administration:IV infusion Regimen/Treatment Period:Day 1 of each 3 week cycle Use:Experimental
2411659|NCT03492905|Experimental|Internet-based CBT|Internet-based Cognitive Behaviour Therapy (iCBT)
2411660|NCT03492892|Experimental|Acupuncture|Use real acupuncture treatment for blood pressure management in patients with hypertension
2411661|NCT03492892|Sham Comparator|Sham Acupuncture|Use non-acupoint as the stimulating site in acupuncture for the treatment of hypertension
2411662|NCT03492879|Experimental|Biopsy: Routine tests & EIT Technology|The patients will undergo a routine liver biopsy and also routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
2411663|NCT03492879|Experimental|Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and Electrical Impedance Technology (EIT).
2411664|NCT03492879|Experimental|NASH : Routine tests & EIT Technology|The patients will undergo a routine liver Ultrasonography, Shear wave elastography and quantification of liver steatosis using the Electrical Impedance Technology (EIT).
2411665|NCT03492866|Active Comparator|Gentamicin Sulfate|All subjects will be treated with topical gentamycin applied twice daily (1 fingertip unit (FTU)) to the right half of the scalp. Total study period: 6 months.
2411666|NCT03492866|No Intervention|No treatment|The medication won't be applied to the left half of the scalp.
2411667|NCT03492853||patients with AMD|150 patients with age related macular degeneration more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
2411668|NCT03492853||control group|150 patients in control group without the clinical signs of the disease more than 50 years old who will have retina photodocumented and genotyped for AMD SNP's
2411669|NCT03492840|Experimental|RZL-012|"A single-time injection, multiple subcutaneous injections of RZL-012 administered into the subcutaneous fat.~Dercum's disease - dosing according to nodule size:~Nodule of 2-2.9cm - 2 injections (0.1 mL each); total of 10 mg RZL-012.~Nodules of 3-3.9cm - 3 injections (0.1 mL each); total of 15 mg RZL-012.~Nodules of 4-8cm - 4 injections (0.1 mL each); total of 20 mg RZL-012.~Lipedema -~2 subjects will receive 20mg RZL-012 in 4 injections in each leg adding up to 8 injections of 40mg RZL-012.~2 subjects will receive 30mg RZL-012 in 6 injections in each leg adding up to 12 injections of 60mg RZL-012.~2 subjects will receive 40mg RZL-012 in 8 injections in each leg adding up to 16 injections of 80mg RZL-012."
2411670|NCT03492827|Experimental|gargle group|drugs，chlorhexidine acetate gargle dosage，15ml，twice daily， duration，3days before ESD
2411671|NCT03492827|No Intervention|Control group|Control group will not be interventioned with gargle
2411672|NCT03492814|Experimental|Partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
2411673|NCT03492814|Active Comparator|Total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
2411675|NCT03492788|Active Comparator|ECGI-optimized VV-offset|
2411676|NCT03492788|Placebo Comparator|Zero VV-offset|
2411677|NCT03492775|Active Comparator|Arm A:Obinutuzumab single agent|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
2411678|NCT03492775|Active Comparator|Arm B:Obinutuzumab plus Bendamustine|"Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles~If at least 'stable disease':~Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45"
2411679|NCT03492749||Group Busulfan|Patients submitted a Bone marrow transplantation with the busulfan chemotherapy in the conditioning. Saliva monitoring
2411680|NCT03492749||Group no busulfan|Patients submitted a Bone marrow transplantation without busulfan chemotherapy in the conditioning.Saliva monitoring
2411681|NCT03492736|Experimental|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
2411683|NCT03492723|Experimental|garlic groupe|Concentrated Aged Garlic Extract Microcrystalline Cellulose 133 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
2411684|NCT03492723|Placebo Comparator|placebo groupe|Microcrystalline Cellulose 258.55 mg Carboxymethylcellulose Calcium 6 mg Agar Powder 35 mg Coloring Agent 0.45 mg Details: Gardenia Extractive 44.5%, Corn Syrup 55% Potassium pyrophosphate 0.5% Silicon Dioxide 3.5 mg Calcium Stearate 3.5 mg Total Weight 307 mg
2411685|NCT03492710|Experimental|IGIV-SN|Immunoglobulin, Supplied in 5g (100mL) and/or 10g (200mL)
2411686|NCT03492697|Experimental|PF-06882961|
2411687|NCT03492671|Experimental|Chemotherapy and SBRT|"Pre-Operative Chemotherapy: Within 28 days of study enrollment, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of four 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Post-Operative Chemotherapy: Within 5-10 weeks after surgery, subjects will receive a combination of Gemcitabine and Nab-paclitaxel for a maximum of two 28-day cycles. Gemcitabine 1000 mg/m2 IV on Days 1,8,15. Nab-paclitaxel 125 mg/m2 on Days 1,8,15.~Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy."
2411688|NCT03492658|Experimental|Combination therapy (MTX/abatacept)|Treatment with a combination of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) for another 6 months.
2411689|NCT03492658|Active Comparator|Methotrexate (MTX) monotherapy|Treatment with methotrexate monotherapy (10 - 25 mg once weekly) for 12 months.
2411690|NCT03492645|Active Comparator|Office Group|
2411691|NCT03492645|Experimental|Telephone Group|
2411692|NCT03492632||Women with Psoriasis|Reproductive age women newly diagnosed with psoriasis
2411693|NCT03492632||Women without Psoriasis|Reproductive age women without psoriasis to serve as control
2411694|NCT03492619|Active Comparator|Non-Intensive Intervention|Three short group sessions that promote healthy lifestyles
2411695|NCT03492619|Experimental|Intensive Intervention|a) Individual level: a six-month intervention comprised of 12 two-hour sessions, three follow-up monthly sessions, two workshops with the participants' household members and community members and one final session that will be graduation day; b) Household level: 2 workshops about co-responsibility in the household, and self-care and nutrition, including a theater performance. Six assignments with household members' participation; c) Community level: Distribution of 2 different educational materials (one about co-responsibility and another about self-care, including healthy nutrition) and carry out the 2 workshops mentioned above, both with household and community members.
2411696|NCT03492606||multiple sclerosis patients|
2411697|NCT03492593|Experimental|lycopene|A dose of lycopene (20 mg) is provided as part of an emulsified liquid meal (with or without 160 mg powdered ferrous sulfate). Samples from the upper digestive tract (gastric or duodenal) are aspirated over 4 hours, and blood collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 3 additional visits with 2 weeks between each visit. The same protocol is followed, with the subject receiving all combinations of meal (w/ and w/o iron) and upper digestive tract sampling (gastric or duodenal)
2411698|NCT03492593|Experimental|13C beta-carotene|A dose of 13C beta-carotene (20 mg) is provided as part of an emulsified liquid meal. Samples from the upper digestive tract (gastric or duodenal) are aspirated over 5 hours, blood collected over 7 hours, and urine collected over 7 hours. Blood plasma and chylomicron fractions isolated. The subject returns for 1 additional visit with a minimum of 4 weeks between each visit. The same protocol is followed, with sampling taken from the remaining upper digestive tract compartment (gastric or duodenal)
2411699|NCT03492593|Placebo Comparator|control|The same procedure is followed (as detailed in the experimental arms) but the subject receives an emulsified liquid meal without carotenoids or vitamin E.
2411700|NCT03492580||Cohort 1: Canagliflozin|A target cohort which includes new users of canagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. Truven Health MarketScan Commercial Claims and Encounters Database (CCAE) 2. Truven Health MarketScan Medicare Supplemental and Coordination of Benefits Database (MDCR) 3. Truven Health MarketScan Multi-state Medicaid Database (MDCD) 4. OptumInsight's de-identified Clinformatics Datamart, Extended-Date of Death (Optum).
2411701|NCT03492580||Cohort 2: Canagliflozin with Cardiovascular Disease (CVD)|A target cohort which includes new users of canagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411702|NCT03492580||Cohort 3: Empagliflozin|A comparator cohort which includes new users of empagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411703|NCT03492580||Cohort 4: Empagliflozin with CVD|A comparator cohort which includes new users of empagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411704|NCT03492580||Cohort 5: Dapagliflozin|A comparator cohort which includes new users of dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411705|NCT03492580||Cohort 6: Dapagliflozin with CVD|A comparator cohort which includes new users of dapagliflozin with established CVD for clinical characterization and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411706|NCT03492580||Cohort 7: Empagliflozin or Dapagliflozin|A target cohort which includes new users of empagliflozin or dapagliflozin for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411707|NCT03492580||Cohort 8: Empagliflozin or Dapagliflozin with CVD|A target cohort which includes new users of empagliflozin or dapagliflozin with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411708|NCT03492580||Cohort 9: DPP-4 inhibitor (i)/ GLP-1 agonist (a)/ other AHA|A comparator cohort which includes new users of any dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonist, or other select antihyperglycemic agents (AHA) for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411742|NCT03492385|Experimental|3: 1000 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2411709|NCT03492580||Cohort 10: DPP-4 (i)/ GLP-1 (a)/ other AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411710|NCT03492580||Cohort 11: DPP-4 (i),GLP-1 (a),TZD, SU, insulin, other AHA|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, thiazolidinediones (TZD), sulfonylureas (SU), insulin, or other select AHA for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411711|NCT03492580||Cohort 12: DPP-4(i), GLP-1(a), TZD, SU, insulin, AHA with CVD|A comparator cohort which includes new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established CVD for clinical characterization, and population-level effect estimation. It will use 4 databases: 1. CCAE 2. MDCR 3. MDCD 4. Optum.
2411712|NCT03492567|Experimental|Blood monocyte precursors/osteoclasts|Blood test
3185543|NCT00736021|Experimental|A|Single arm (open label study): Provide twelve weeks of treatment with high does (40 mg daily) of escitalopram to trauma survivors with chronic PTSD.
3185544|NCT00736047|Active Comparator|1|
2411715|NCT03492541|Experimental|SYSTANE Complete|Propylene glycol-based eye drops, 1 drop in each eye twice a day (BID) (morning and evening) for 28 days. Patients can administer additional doses in between the scheduled daily doses as needed
2411716|NCT03492528|Experimental|Cardiovascular patients treated for a cancer|
2411717|NCT03492515|Experimental|experimental group|Accepting the treatment of rhTPO according platelet and bleeding condition
2411718|NCT03492515|Active Comparator|non-administered group|No rhTPO will be used. If necessary, the patients will be given transfusion of platelets according to the their conditions.
2411719|NCT03492515|No Intervention|healthy control group|Healthy pregnant women and no use of any medicine。
2411720|NCT03492502|Experimental|Allo-SCT patients with GI related GVHD|"Allo-SCT patients above 18 years of age with acute steroid-resistant GI-related GVHD grade III-IV.~The diagnosis of GVHD will be made on clinical grounds (in line with the major associations' recommendations) - the appearance of characteristic mucoid diarrhea within 100 days after Allo-SCT, with or without associated skin/liver involvement. In cases of atypical presentation - we will recommend biopsy or endoscopy for diagnosis. Patients suspected to have Clostridium difficille associated diarrhea will be tested for toxin (CDT).~Steroid-resistant GI-related GVHD will be defined as lack of improvement (same stage) or worsening of GI symptoms after 7 days of steroid therapy (≥ 2 ml/kg of IV methylprednisolone)."
2411721|NCT03492476|Experimental|Circaid|Compression sleeve on the day associated with the night wearing of the system of contention circaid®
2411722|NCT03492476|Active Comparator|Reference treatment|Compression sleeve during the day associated with a possible treatment with it during the night, according to the recommendations of the HAS
2411723|NCT03492463|Active Comparator|Nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2411724|NCT03492463|Active Comparator|Non-nicotine e-cigs + Nicotine patches|Participants will receive e-cigarettes not containing nicotine and nicotine patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2411725|NCT03492463|Active Comparator|Nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2411726|NCT03492463|Placebo Comparator|Non-nicotine e-cigs + Placebo patches|Participants will receive e-cigarettes not containing nicotine and placebo patches (21mg/24hr) and will be asked to switch from cigarette use to use of the study e-cigarettes for eight weeks.
2411727|NCT03492450|No Intervention|Control Group|All subjects continue participating in their normal daily and physical activities.
2411728|NCT03492450|Experimental|Treadmill training Group|16 sessions (2 sessions/week for 8 weeks) of treadmill training as recommended in a review on this subject (Langeskov-Christensen, 2015) aimed at the reduction/stabilization of gait and balance disturbances.
2411729|NCT03492437|Experimental|Dabigatran, Then Tepotinib followed by Dabigatran+Tepotinib|Dabigatran etexilate in treatment period 1 followed by tepotinib alone for 7 days and then tepotinib co-administered with Dabigatran in treatment period 2. Two treatment periods will be separated by a 3-day wash-out period.
2411730|NCT03492424||Focal therapy for prostate cancer|"All men >18 years of age undergoing focal therapy for primary or salvage treatment of prostate cancer will be included. Men who had received prior focal therapy are also eligible for inclusion.~The purpose of this study is collect observational data regarding patterns of care and outcomes of focal therapies for prostate cancer, including but not limited to: high-intensity focused ultrasound (HIFU), cryotherapy, focal laser ablation, irreversible electroporation, photodynamic therapy, and brachytherapy."
2411731|NCT03492411|Experimental|eHealth Intervention|This group will receive information about an eHealth breastfeeding co-parenting resource. They will have a short demonstration of the site and will receive weekly emails for 6 weeks reminding them about the resource and their participation in the study.
2411732|NCT03492411|No Intervention|Usual Care|This group will not receive any intervention. They will receive emails for 6 weeks reminding them that they are in the study.
3185545|NCT00736047|Placebo Comparator|2|
3185546|NCT00736060||1|Sickle cell anemia
3185547|NCT00736060||2|Sickle cell thalassemia
3185548|NCT00736086||1|Subjects who are ambulated early post-percutaneous, cardiac or peripheral vascular, diagnostic catheterization procedures with the use of StarClose® Vascular Closure System in the femoral artery after diagnostic catheterization procedure.
3185549|NCT00736112|Experimental|BMT and food allergy|trial subjects will receive food allergy testing and management in conjunction with BMT (Bilateral Myringotomy with Tympanostomy Tubes). Food allergy management involves parental education on how to avoid the specific offending foods.
2411740|NCT03492385|Experimental|1: 100 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2411741|NCT03492385|Experimental|2: 300 mg PB2452 or Placebo (no Ticagrelor)|PB2452 Infusion or Placebo - Sodium Chloride
2411743|NCT03492385|Experimental|4: 1000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride With Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2411744|NCT03492385|Experimental|5: 3000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2411745|NCT03492385|Experimental|6: 9000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2411746|NCT03492385|Experimental|7: 18000 mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for a total of 5 doses
2411747|NCT03492385|Experimental|8: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
2411748|NCT03492385|Experimental|9: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre and Post-Trx)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses and 180 mg 24 hours post-dose
2411749|NCT03492385|Experimental|10: Dose TBD mg PB2452 or Placebo (Ticagrelor Pre-Txt)|PB2452 Infusion or Placebo - Sodium Chloride with Ticagrelor Oral Tablet: 180 mg+90 mg BID for 5 doses
2411750|NCT03492372||Spine patients|Patients undergoing spine surgery where spinal tissue is discarded/removed will be recruited. Tissue samples will be used to look at normal and pathologic molecular signatures.
2411751|NCT03492359|Active Comparator|Normal Control|Participants with no diagnosis of respiratory disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
2411752|NCT03492359|Active Comparator|COPD Patients|Participants with chronic obstructive pulmonary disease between the ages of 0 and 80 whose breathing will be measured using Thora-3Di structured light plethysmography, body plethysmography and spirometry.
2411753|NCT03492346||LGMD2E Subject Population|"Individuals:~Confirmed LGMD2E diagnosis by genetic testing or~Suspected of having LGMD type 2E due to symptoms and a diagnosed family member or a member of a community with a large population of one of these two types"
2411754|NCT03492333|Experimental|Gluten free diet|Single arm
2411755|NCT03492307|Active Comparator|Standard Flow Protocol|Patients randomized to this arm will receive HFNC according to our current protocol with a maximum of 8L/min.
2411756|NCT03492307|Experimental|Weight-Based Flow Protocol|Patients randomized to this arm will receive HFNC according to a weight-based algorithm at 2L/kg/min.
2411757|NCT03492294||patients with disorders of consciousness|patients with disorders of consciousness from several brain injury have been clinically classified into coma, unresponsive wakefulness syndrome and minimally conscious state. These patients were scaned by functional magnetic resonance imaging.
3185550|NCT00736112|Experimental|BMT and adenoidectomy|"involves BMT (Bilateral Myringotomy with Tympanostomy Tubes), adenoidectomy, and food allergy testing and management.~Food allergy management involves parental education on how to avoid the specific offending foods."
2411761|NCT03492268|Experimental|BCMA-CART|Autologous T cells transduced to express anti-BCMA chimeric antigen receptor (CAR)
2411762|NCT03492255|Active Comparator|Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC|The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
2411763|NCT03492255|Experimental|Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC|CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.
2411764|NCT03492242||Adverse drug reaction induced by immune checkpoint inhibitors|Case reported in the World Health Organization (WHO) and the Base Nationale de PharmacoVigilance of patient treated by ICI, with a chronology compatible with the drug toxicity
2411765|NCT03492229|Experimental|tDCS+AMT|TDCS in combination with movement training before treadmill training
2411766|NCT03492229|Active Comparator|tDCS|tDCS only before treadmill training
2411767|NCT03492229|Active Comparator|AMT|Movement training only before treadmill training
2411768|NCT03492229|Sham Comparator|Control|No priming before treadmill training
2411769|NCT03492216|No Intervention|Control|All participants will receive brief alcohol and adherence counseling according to Uganda Ministry of Health guidelines.
2411770|NCT03492216|Experimental|Escalating incentives (EtG tests)|Escalating incentives for EtG negative urine test (Intervention: Incentives for negative EtG test).
2411771|NCT03492216|Experimental|Escalating incentives (IsoScreen tests)|Escalating incentives for IsoScreen positive urine tests (Intervention: Incentives for positive IsoScreen test).
2411772|NCT03492216|Experimental|Escalating incentives (EtG + IsoScreen)|Escalating incentives for EtG negative tests and for IsoScreen positive urine tests with the incentives rewarded separately (Interventions: Incentives for negative EtG test and Incentives for positive IsoScreen test).
2411773|NCT03492203|Experimental|Active Cognitive Remediation -Long-term|Participants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
2411774|NCT03492203|Active Comparator|Active Cognitive Remediation -Short-term|Participants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
2411775|NCT03492203|Placebo Comparator|Cognitive Remediation Control|Participants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
2411807|NCT03491956|Other|DFPP group|self contrast (before and after DFPP)
2411776|NCT03492190||adults|"Select the individual:~Healthy, non-pregnant adults 18-65 years of age, not taking any medication, including NSAIDs, not taking antibiotics within 4 weeks of study, BMI within 18-35 range and stable weight.~Exclusion criteria: children and elderly (over 65), pregnancy, diagnosed with non-communicable or communicable disease, being under restrictive diet, antibiotics within 4 weeks of study, medications within 4 weeks of study. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, adults will be eat the bean enrichment of deuterium for availability protein, collected urine, saliva and blood."
2411777|NCT03492190||Children|"Fifty children will be recruited from ages varying from 1 to 3 years and of both sexes. Children who use medications, who do not habitually consume beans, will be excluded and when there is no explicit written authorization from the parents or guardians.~All the children with different status of nutrition will be eaten the beans. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, children will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult)."
2411778|NCT03492190||Elderly|Fifty individuals of both sexes will be recruited, previously evaluated by complete clinical / laboratory examination and medical history. The elderly will be excluded from antiinflammatory, chemotherapeutic, corticoid, allergy and bean aversion or antibiotic therapy. These drugs could interfere with protein bioavailability. They will eat beans for 5 days. The beans will be soaked for 3 h, water discarded and beans cooked for 20 min in pressure cook. And in the end for the week, elderly will be eat the bean enrichment of deuterium for availability protein, collected urine or saliva depend on the best biological samples of pilot study (adult).
3145175|NCT00063323|Active Comparator|Bupropion+Nicotine Gum|Combined active treatments: Bupropion (Zyban SR) and nicotine gum (Nicorette). Participants were instructed to use the 150 mg bupropion pill twice daily and the 2 mg. gum as needed during the 16-week maintenance treatment phase.
3145176|NCT00063323|Placebo Comparator|Double placebo|Placebo gum + placebo pill. Identical placebo pill was used twice daily and identical placebo gum was used as needed.
2411781|NCT03492138|Experimental|Participants with relapsed/refractory multiple myeloma|ONC201, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Run-in phase of ONC201 and dexamethasone weekly until progression at 4 weeks, lack of response at 8 weeks, or progression followed by the addition of weekly ixazomib.
2411782|NCT03492125|Experimental|low dose|MS-533
2411783|NCT03492125|Experimental|mid low dose|MS-533
2411784|NCT03492125|Experimental|mid high dose|MS-533
2411785|NCT03492125|Experimental|high dose|MS-533
2411786|NCT03492112|Experimental|People attending needle syringe programs in Australia|Participants will be screened for Hepatitis C using the Finger-stick whole blood HCV RNA Point of Care GeneXpert. Participants with hepatitis C will be offered treatment with a pan-genotypic DAA HCV therapy- either 12 weeks of sofosbuvir/velpatasvir or 8 weeks of glecaprevir/pibrentasvir.
2411788|NCT03492086|Experimental|Rosemary and alkylglycerol capsules|
2411789|NCT03492086|Placebo Comparator|Control capsules|
2411790|NCT03492073|Experimental|Emotional Supportive Mindfulness-based Program|"The program is based on 15/20 minutes sessions of meditative practices in which can participate only the patients, only his/her caregiver, or both.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
2411791|NCT03492073|Active Comparator|Emotional Supportive Program|"The program is based on 15/20 minutes sessions based on narrative therapy, in which the patient or his/her caregiver or both can talk about their emotions.~Number of sessions is an independent outcome, because it depends on the number of days of hospitalization."
3145177|NCT00063336|Experimental|1|Participants will receive cognitive remediation treatment.
2411793|NCT03492047|Active Comparator|control|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks only
2411794|NCT03492047|Experimental|high dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and high dose N-acetylcysteine (1200 mg twice daily) for the paclitaxel treatment period
2411795|NCT03492047|Experimental|low dose N-acetyl cysteine|they will receive paclitaxel 80 mg/m2 once per week for 12 weeks and low dose N-acetylcysteine (600mg twice daily) for the paclitaxel treatment period.
2411796|NCT03492034|Active Comparator|IUD during CS|
2411797|NCT03492034|Active Comparator|IUD after puerperium|
2411800|NCT03492008|Active Comparator|Conventional technique|Nasogastric tube
2411801|NCT03492008|Experimental|Contralateral cricothyroid pressure|Nasogastric tube
2411802|NCT03492008|Experimental|Ipsilateral head turning|Nasogastric tube
2411803|NCT03491995|Experimental|Quadruple therapy|Moxifloxacin, Nitazoxanide, Omeprazole sodium bicarbonate, Doxycyclin
2411804|NCT03491995|Active Comparator|Classic treatment|Omeprazole, clarithromycin, amoxicillin
2411805|NCT03491969|Experimental|Alpha-Lipoic Acid(α-LA)|Double blind treatment period consisted of treatment with CHF standard treatments, followed by α-LA 200 mg tid over a total duration of 24 months.
2411806|NCT03491969|Placebo Comparator|Placebo|Double blind treatment period consisted of treatment with CHF standard treatments, followed by Placebo 200 mg tid over a total duration of 24 months.
3145178|NCT00063336|Experimental|2|Participants will receive computer-skills training.
3145179|NCT00063388|Experimental|1|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
3145180|NCT00063401|Experimental|1|Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
3145181|NCT00063453|Experimental|Vitamin E and selenium placebo|Vitamin E alone
3145182|NCT00063453|Experimental|Selenium and vitamin E placebo|Selenium alone
3145183|NCT00063453|Experimental|Vitamin E and selenium|Vitamin E and selenium combined
2411808|NCT03491943|Experimental|Midline group|Preprocedural ultrasound-assisted midline approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2411809|NCT03491943|Active Comparator|Paramedian group|Preprocedural ultrasound-assisted paramedian approach of spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2411810|NCT03491930|Experimental|Interventional Cohort|"VA MOVE! Coach app: Weight loss using the VA MOVE! Coach weight loss app which presents positive feedback, education in nutrition and portion sizes, coping mechanisms, charts and graphs. App will be used for three months.~Telephone Coaching: Weekly phone coaching will provide further support and assist with problem solving and goal setting for a three month period.~Standard of care for weight loss (the 2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
2411811|NCT03491930|Active Comparator|Control Cohort|"Standard of care for weight loss (2013 AHA/ACC/TOS guidelines). Followed for three months.~Pre and post weight loss metabolic measurements will be obtained."
3185551|NCT00736112|Active Comparator|BMT alone|The standard protocol for children presenting with initial Chronic OME is to perform a BMT (Bilateral Myringotomy with Tympanostomy Tubes).
3185552|NCT00736138|Active Comparator|1|training and pellots
2411814|NCT03491904|Experimental|Auto-injector (AI)|
2411815|NCT03491904|Experimental|Prefilled syringe (PFS)|
3185553|NCT00736138|No Intervention|2|control
3185554|NCT00736151|Experimental|1|Ralfinamide administered orally at rising doses of 80 - 320 mg/day
2411818|NCT03491878|Experimental|3D approach|Three dimensional laparoscopic cholecystectomy including segments IVB and V
2411819|NCT03491878|Active Comparator|open approach|Open cholecystectomy including segments IVB and V
2411820|NCT03491865|Experimental|REAL media Plus|Participants in this group will be assigned to use the REAL media Plus curriculum.
2411821|NCT03491865|No Intervention|programming as usual|Participants in this group will participate in their usual school curriculum. They will have the opportunity to use the REAL media Plus curriculum at the conclusion of the study.
2411822|NCT03491852|Experimental|BOOST Intervention|"The BOOST intervention consists of 8 group-based, weekly one-hour sessions. While every BOOST session is different, in general they will focus on helping participants fight back against stigmatizing thoughts and develop a sense of self-worth and empowerment. BOOST sessions are group-based and facilitated by trained clinicians, with the aid of a peer support worker to provide unique insights on living with and overcoming self-stigma. Content of sessions involve group discussions, exercises conducted in session, and between-session missions (i.e., home practice activities)."
2411823|NCT03491852|Active Comparator|Waitlist Controls|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis. Frequency of contact largely depends on the individual needs of patients. Waitlist controls will be offered the BOOST intervention 3 months post-enrollment.
2411824|NCT03491826||ROM before 34 weeks (A)|premature rupture of membrane before 34 weeks
2411825|NCT03491826||ROM after 34 weeks (B)|premature rupture of membrane after 34 weeks
3185555|NCT00736151|Active Comparator|2|Placebo controlled with randomization of 2:1
2411827|NCT03491787||Ultrasound guidance|The ultrasound guidance was used to establish intraosseous access
2411828|NCT03491787||Not ultrasound guidance|The ultrasound guidance was not used to obtain intraosseous access
2411829|NCT03491774|Experimental|Montessori Intervention|Participants will receive Montessori intervention for three months,twice weekly sessions over the period of three months.
2411830|NCT03491761|Experimental|PRP Treatment|PRP is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. The PRP is obtained from a maximum 16 cc sample of the patients' blood drawn at the time of treatment. Using sterile technique, the venous blood is transferred to a centrifuge and prepared by the centrifugation process for 5 minutes. 4-7 mL of PRP is transferred from the large outer syringe into the small inner syringe and injected within 30 minutes of being spun to negate the need of anticoagulants. The procedure will take approximately 20-30 minutes.
2411831|NCT03491761|Active Comparator|HA Treatment|HA is injected using 22 gauge needles through the classic approach (lateral midpatellar) in a sterile setting. Euflexxa will be prepared according to the package insert.
2411832|NCT03491748|Experimental|Part A (SAD): Cohort 1, 100 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and pharmacokinetics (PK) of a single ascending dose (SAD) of oral ETX0282. Participants will be treated with a single oral dose of 100 milligrams (mg) ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411833|NCT03491748|Experimental|Part A (SAD): Cohort 2, 200 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411834|NCT03491748|Experimental|Part A (SAD): Cohort 3, 400 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 400 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411835|NCT03491748|Experimental|Part A (SAD): Cohort 4, 800 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 800 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411836|NCT03491748|Experimental|Part A (SAD): Cohort 5, 600 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411953|NCT03491007|No Intervention|Placebo|Subjects will receive a one-time oral dose of PBO prior to initial brain imaging followed by sustained administration of PBO for 6 weeks.
2411837|NCT03491748|Experimental|Part A (SAD): Cohort 6 (Elderly), 300 mg ETX0282/Placebo|Part A of the study will explore the safety, tolerability, and PK of a SAD of oral ETX0282. Elderly participants (aged 65 years or older) will be treated with a single oral dose of 300 mg ETX0282 or placebo in a fasted state. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour postdose assessments (Day 4).
2411838|NCT03491748|Experimental|Part B (Food Effect): Cohort 7, 100 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 100 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 100 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
2411839|NCT03491748|Experimental|Part C (MAD): Cohort 9, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed three times a day (TID) beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2411840|NCT03491748|Experimental|Part C (MAD): Cohort 10, 200 mg ETX0282/Placebo|Part C of the study will explore the safety, tolerability, and PK of MAD of oral ETX0282. Part C will be administered in a fed state. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 1, and will then be dosed TID beginning on the morning of Day 2 (i.e., 24 hours after the Day 1 dose) through Day 7. Participants will be treated with a single oral dose of 200 mg ETX0282 or placebo on the morning of Day 8. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 8 dose assessments (Day 11).
2411841|NCT03491748|Experimental|Part D: Cohort 12, ETX0282/Placebo plus Cefpodoxime Proxetil|Part D of the study will explore the safety, tolerability, and PK of oral ETX0282 when administered as a single oral dose in combination with cefpodoxime proxetil tablets to healthy participants in a fed state. Participants will be treated with a single oral dose of 600 mg ETX0282 or placebo in a fed state on Day 1, with a single oral dose of 400 mg cefpodoxime proxetil in a fed state on Day 4, and with a single oral dose of 600 mg ETX0282 or placebo plus a single oral dose of 400 mg cefpodoxime proxetil dosed at the same time in a fed state on Day 7. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post Day 7 dose assessments (Day 10).
2411842|NCT03491748|Experimental|Part B (Food Effect): Cohort 14, 300 mg ETX0282/Placebo|Part B of the study will explore the effect of food on oral ETX0282. Participants will be treated with a single oral dose of 300 mg ETX0282 or placebo (Day 1) while fasted and with a single oral dose of 300 mg ETX0282 or placebo (Day 4) with a high-fat meal. They will be confined to the Study Unit from Day -1 and discharged following collection of the 72-hour post fed state dose assessments (Day 7).
2411843|NCT03491748|Experimental|Part G: Cohort 17, 300 mg ETX0282/Placebo|Part G of the study will explore the tolerability and PK profile of oral ETX0282 when administered either as a single dose (i.e., 300 mg as a single dose) or in 4 equal, divided doses over a 6 hour period (i.e., 75 mg every 2 hours for 4 doses [a 300 mg total dose]) when administered in a fasted state. Participants will receive the 2 treatments in a cross-over design according to one of 2 randomized sequences: AB or BA. Treatment A: 0 hours, 4 × 75 mg ETX0282/placebo; 2, 4, and 6 hours, 1 × 75 mg placebo. Treatment B: 0 hours, 1 × 75 mg ETX0282/placebo and 3 × 75 mg placebo; 2, 4, and 6 hours, 1 × 75 mg ETX0282/placebo. Participants will be confined to the Study Unit from Day -1 and discharged following collection of the 24 hours post Day 4 dose assessments (Day 5).
2411844|NCT03491735||Group A|Patients referred to glaucoma sub-specialty clinics in Kasr Al-Aini Hospital, Cairo University, Egypt in the year 2018
2411845|NCT03491735||Group B|Patients referred to glaucoma sub-specialty clinics in Sadguru Netra Chikitsalaya Postgraduate Institute of Ophthalmology, Mumbai, India in the year 2018
2411846|NCT03491709|Experimental|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection 250mg/m2 single administration
2411847|NCT03491709|Active Comparator|Cetuximab injection|Cetuximab,Erbitux 250mg/m2 single administration
2411848|NCT03491696|Experimental|Patients|It is an open label study, designed with 14 patients, men and women, from 18 to 60 years old, hospitalized for a characterized depressive episode (as defined by International Classification of Diseases version 10 criteria). They have to be refractory to an antidepressant treatment prescribed in primary care medicine and have a Dexamethasone Suppression Test (DTS) non-suppression status. All patients included will take the association of SSRI/SNRI and METYRAPONE for 28 days.
3145184|NCT00063453|Placebo Comparator|vitamin E Placebo and Selenium placebo|Double placebo
3145185|NCT00063531||GeneSTAR participant meeting entry criteria|Healthy siblings of patients with early onset CAD (<60 years old) and the adult offspring of the siblings or probands
2411851|NCT03491657|Experimental|virtual reality distraction (Yes VR)|In addition to their standard pain medications, patients will play a virtual realty game named SnowWorld during some portions of their burn wound cleaning procedure, on each study day.
2411852|NCT03491657|Active Comparator|music distraction (No VR condition)|In addition to their standard pain medications, patients will listen to music during comparable portions of their burn wound cleaning procedure, on each study day.
2411853|NCT03491644|Active Comparator|Liberal oxygen|"Liberal oxygen administration (to mimic current practice) for the first 24 hours without interruption.~In the trauma bay and during intrahospital transportation this implies administration of a FiO2 of 1.0 for intubated patients and an oxygen flow on a non-rebreather with reservoir of 15 l/min for non-intubated patients. In the operating room, patients will receive a FiO2 of ≥ 0.8 to obtain a saturation of ≥ 98%. Patients admitted to the ICU/PACU/floor will receive and FiO2 of ≥ 0.8 or more to obtain a saturation of ≥ 98% when intubated and for non-intubated patients a non-rebreather with reservoir will be set to 15 l/min."
3145186|NCT00063583|Placebo Comparator|Placebo|Placebo
3145187|NCT00063583|Experimental|Pirfenidone 1200 mg/day|Pirfenidone will be administered at a dose of 1200 mg/day
3145188|NCT00063583|Experimental|Pirfenidone 2400 mg/day|Pirfenidone will be administered at 2400 mg/day
3145189|NCT00063778|Experimental|1 x 10^4 IU dose|Vaccine dose of 1 x 10^4 IU per injection
3145190|NCT00063778|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
2411854|NCT03491644|Experimental|Titrated oxygen|"Titrated oxygen administration for the first 24 hours without interruption. Lowest dosage of oxygen possible in order to achieve a saturation of at least 94%, either using mechanical ventilation (intubated patients), a nasal cannula, a non-rebreather or nothing.~A saturation above 94% shall not be aimed for using supplemental oxygen, and thus only patients without oxygen requirement shall have saturations above 94%.~The intervention will only be interrupted in case the saturation becomes unmeasurable - if this happens, the treating physician shall treat the patient as he/she judges best fit. As soon as the saturation is measurable again, the intervention will resume. The treating physician must document and explain the situation."
2411855|NCT03491631|Experimental|2 drugs combination group|
2411856|NCT03491631|Experimental|3 drugs combination group|
2411857|NCT03491618|Active Comparator|PARALLEL|Thick canulae (18 gauge) placed parallel to Medial Branch under fluoroscopy.
2411858|NCT03491618|Active Comparator|PERPENDICULAR|Thin canulae (22 gauge) placed perpendicular to Medial Branch under fluoroscopy.
2411859|NCT03491605||peripheral EBV-DNA load|subjects with high load (>1×103 copies/ml）of EBV-DNA copies in peripheral blood.
2411860|NCT03491592|Experimental|Enhanced Physical Activity Intervention|A data driven enhanced Pasos Hacia La Salud intervention based on results and participant feedback from the motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention in the parent study.
2411861|NCT03491592|Active Comparator|Original Physical Activity Intervention|The original Internet-based program is a computer expert system-driven, individually tailored Spanish language intervention, guided by Social Cognitive Theory (SCT) and the Transtheoretical Model (TTM).
2411862|NCT03491579|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with standard chemotherapy (Cladribine and Cytarabine)
2411863|NCT03491566|Experimental|Clinic Pilates Group|Initial assessments of participants were made and they were taught key components of the Clinical Pilates exercises. Exercises were administered for 4 weeks, 3 days/week, 40-50 minutes/session under the supervision of a physiotherapist. Groups of 9-10 people with similar physical characteristics and fitness level for session times were created. The sessions were started with level 1 exercises requiring more support and less control. Each exercise was repeated 8-10 times; as the physical level of the participants increased, exercises progressed towards level 3 exercises requiring more attention, concentration and control. Each session consisted of an average of 10 minutes warm-up, 20 to 30 minutes of matt and 10 minutes cooling of of Clinical Pilates exercises.
2411864|NCT03491566|Experimental|Aerobic Exercise Group|"Initial assessments of participants were made before the first session. Using an elliptical bicycle or bicycle, or treadmill under the supervision of a physiotherapist, a total of 150 minutes moderate intensity (50-70% of maximal heart rate (HRmax)) aerobic exercise in accordance with the World Health Organization's guideline was applied, 3 days/week (50 mins/session) or 5 days/week (30 mins /session) for 4 weeks. The instruments to be used for the exercises were chosen according to the preference of the individual. HRmax was calculated using the 220-years. For example; at the age of 20 years, the target heart rate was determined as 100-140 beats/min for moderate physical activity in a person with HRmax 200 beats/min."
3185556|NCT00736164|Experimental|Arm I|Patients receive oral selenomethionine once daily for 8-9 weeks.
3185557|NCT00736164|Placebo Comparator|Arm II|Patients receive oral placebo once daily for 8-9 weeks.
3185558|NCT00736177|Active Comparator|Control|Patients in the control group will undergo conventional IVF cycles with fresh blastocyst transfer.
3185559|NCT00736177|Experimental|Test group|Patients in the Test group will have their embryos cryopreserved for transfer in a second cycle.
3185560|NCT00736203||A|non-smokers
3185561|NCT00736268|Experimental|CST|Telephone-based Enhanced Coping Skills Training (CST)
2411871|NCT03491540|Experimental|"1)  MBP and oral antibiotics  group"|Sennosides colonic preparation Oral Gentamycin Oral Ornidazole
2411872|NCT03491540|Placebo Comparator|"2)  MBP alone  group"|Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole
2411873|NCT03491527|Active Comparator|Conventional Resin Cement|Resin cement without MTA
2411874|NCT03491527|Active Comparator|MTA Resin Cement|Resin cement with MTA
2411875|NCT03491514|Experimental|Test Granola|51 g of Test Granola
2411876|NCT03491514|Placebo Comparator|Control Granola|54.1 Control Granola
2411877|NCT03491501||Industrial employees|Ergonomic evaluation using questionnaires in different Industrial settings will be conducted and thus Industrial employees form the included subject group.
3185562|NCT00736268|Other|UMC|Usual Medical Care and COPD education and symptom monitoring (UMC)
3185563|NCT00736281|No Intervention|Placebo Food Drops|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
3185564|NCT00736281|Active Comparator|Food Drops|Group 2 (intervention group) will receive sublingual immunotherapy (escalation followed by maintenance) with vials containing glycerin and the previously diagnosed food allergens (peptides).
3185565|NCT00736294|Experimental|Ramipril|Inhibition Conversion Enzyme
3185566|NCT00736294|Placebo Comparator|Placebo|Placebo
3185567|NCT00736307|Experimental|1|Cultured limbal stem cells Transplantation
3185568|NCT00736320|Active Comparator|A|2 cycles ABVD followed by 20 Gy IF-RT irrespective of FDG-PET results after chemotherapy
3185569|NCT00736320|Experimental|B|2 cycles ABVD followed by 20 Gy IF-RT if FDG-PET is positive after chemotherapy; 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
3185570|NCT00736346|Active Comparator|1|
3185571|NCT00736346|Active Comparator|2|
3185572|NCT00736346|Active Comparator|3|
3185573|NCT00736346|No Intervention|4|
3185574|NCT00736372|Experimental|Investigational Drug|Dose Escalation
3185575|NCT00736398||Observation|Spinal fusion
2411878|NCT03491488|Experimental|Intervention Group|"300 children in the randomly selected crèche classrooms receiving the Brain Games intervention.~The Brain Games intervention we propose in this project is designed to complement and improve current government efforts. Given the importance of executive functioning skills and the high plasticity around age three, early programs like the ones proposed here may be the most effective tool to reduce socioeconomic and intergenerational disparities, and thus nicely complement current social protection policies."
2411879|NCT03491488|No Intervention|Control Group|300 children in the randomly selected creches classrooms receiving the regular Brazilian curriculum.
2411880|NCT03491475||Negative Ajmaline test|No appearance of a type 1 ECG during Ajmaline test
2411881|NCT03491475||Positive Ajmaline test|Appearance of a type 1 ECG during Ajmaline test
2411882|NCT03491462|Experimental|Arimoclomol|Arimoclomol, capsule
2411883|NCT03491462|Placebo Comparator|Placebo|Placebo oral capsule (matching to experimental Arm)
2411884|NCT03491449|Experimental|Group A: pressure ≥140 and ≤160mmHg|Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.
2411885|NCT03491449|Active Comparator|Group B: Keep systolic pressure <185mmHg|Intensive management of blood pressure, maintaining systolic blood pressure <185 mm Hg for 72 hours.
2411886|NCT03491436|Experimental|Remote monitoring group|Women (at risk of) GDM will be included in this study. They receive a iHealth Align (a glucose monitor) and associated glycemiestrips. The app of iHealth will be downloaded on the pregnant women's Smartphone to collect the data and to send them to the researcher in the hospital.
2411887|NCT03491423|Experimental|Patients|
2411888|NCT03491410|Placebo Comparator|1|Arm 1: standard Unit´s protocol + placebo
2411889|NCT03491410|Experimental|B|Arm 2: standard Unit´s protocol + aspirin
3145191|NCT00063778|Placebo Comparator|Placebo|
2411891|NCT03491371|Experimental|osteosarcoma|all patients had been given apatinib alone
2411892|NCT03491371|Experimental|Ewing sarcoma|Some of patients had been given apatinib alone while some of them had been given apatinib+everolimus
2411893|NCT03491371|Experimental|soft tissue sarcoma|Some of the patients had been given apatinib alone while some of the patients had been given apatinib together with GT chemotherapy, which was gemcitabine 1000 mg/m2 d1,8 and docetaxel 75 mg/m2 d8 once every 21 day.
2411894|NCT03491371|Experimental|Chondrosarcoma|Patients were given apatinib alone
2411895|NCT03491358|Active Comparator|Wright jet nebulizer|Will employ the Wright jet nebulizer for use in an allergen challenge triad
2411896|NCT03491358|Experimental|Solo vibrating mesh nebulizer|Will employ the Aerogen Solo vibrating mesh device for use in an allergen challenge triad
2411897|NCT03491345|Experimental|avelumab|
2411898|NCT03491332|Placebo Comparator|group C|general circuit group
2411899|NCT03491332|Active Comparator|group H|warm circuit group
2411900|NCT03491332|Experimental|group SH|new warm circuit group
2411901|NCT03491319|Placebo Comparator|Group C Control|spinal anaesthesia was given with table in neutral positon. Same position was maintained after spinal anaesthesia
2411902|NCT03491319|Active Comparator|Group X|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal
2411903|NCT03491319|Active Comparator|Group Y|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
2411904|NCT03491306|Active Comparator|Group 1|patients will receive partial denture constructed from breflex material
2411905|NCT03491306|Experimental|Group 2|patients will receive partial denture constructed from PEEK material
2411906|NCT03491293|Active Comparator|Behavioral Weight Loss + Text chat|Internet delivery of a behavioral weight control program via text in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will weigh themselves daily and report their weight privately (data will only be accessible by research personnel) on the study website.
2411907|NCT03491293|Experimental|Behavioral Weight Loss + Video chat|Internet delivery of a behavioral weight control program via video in a group format facilitated by an experienced registered dietitian. Participants will have access to study materials including behavioral weight loss lessons on the study's website. Participants will be given smart scales to weigh daily, and weight will be transmitted to a secure website accessible only by research personnel.
2411908|NCT03491280||Group 1|Subjects with unclear rare diseases, clinically characterized in the context of outpatient/ inpatient standard care at the University Hospital Tübingen (UKT) or cooperating location, genetic diagnostic (NGS diagnostic) must be performed.
2411909|NCT03491280||Group 2|Subjects with unclear rare diseases, genetic diagnostic (NGS diagnostic) is already performed.
2411910|NCT03491267|Experimental|Subjects with alopecia-- area treated|One area will be treated
2411911|NCT03491267|Experimental|Subjects with alopecia-- area un-treated|One area will be un-treated
2411912|NCT03491254||Group A/exposure group|Huaier Granule & biliary drainage
2411913|NCT03491254||Group B/non-exposure group|biliary drainage.
2411914|NCT03491241|Experimental|pre-diabetics obese patients|These pre-diabetic obese patients will be treated by hypocaloric diet therapy. these patients were under metformine therapy at enrollment.
2411915|NCT03491241|Placebo Comparator|pre-diabetics patients|These pre-diabetic patients will be treated by hypocaloric diet therapy alone.
2411916|NCT03491241|Active Comparator|obese patients|These obese patients will be treated by hypocaloric diet therapy.
2411917|NCT03491215|Experimental|Ruxolitinib|All patients will receive ruxolitinib in addition to corticosteroids +/-calcineurin inhibitor (CNI)
2411918|NCT03491202||atrial fibrillation|Patients with a diagnosis of atrial fibrillation will be eligible for enrollment
2411919|NCT03491189|Active Comparator|Lag screw fixation|Lag screw fixation
2411920|NCT03491189|Active Comparator|Helical Blade fixation|Helical Blade fixation
3145192|NCT00063804|Experimental|1|escalating single doses of AMD070 ranging from 1/4 to 1 times the maximum tolerated dose (MTD)
3145193|NCT00063804|Experimental|2|single dose of 200 mg AMD070 after eating a standardized meal
3145194|NCT00063804|Experimental|3|single dose of 200 mg AMD070 on Days 1, 3, and 17 and single dose of 100 mg ritonavir on Days 3 through 18
3145195|NCT00063817|Experimental|Conditioning Regimen|"Cyclophosphamide intravenously (IV) on days -5 and -4 with respect to transplantation; MEDI-507 on days -1, 0, and 1 (after a test dose of 0.1 mg per kg on day -2); and cyclosporine A IV and thymic irradiation on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered daily postoperatively, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months.~Amendment applicable to the 4th and 5th participant: rituximab on days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days."
2411922|NCT03491163||Patients|Syndecan-1 concentration evaluation
3185576|NCT00736411|Active Comparator|1|IVF
2411925|NCT03491124|Sham Comparator|Sham Treatment|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will also receive a sham intervention, pointing a laser pointer to the ear without turning the laser on.
2411926|NCT03491124|Experimental|Auricular Acupuncture|Participants will continue to receive usual care from their primary care provider, which can include medications, physical therapy, biofeedback, and education according to DoD/VA guidelines for LBP management. Participants randomized to this arm will receive up to five ASP needles per ear placed in the predetermined BFA pattern. Needles are placed until the participant states pain is reduced 1/10.
2411927|NCT03491111|Experimental|IMT & EMT|Interventions: Respiratory muscle training for EMT+IMT. Respiratory muscle training for IMT (Inspiratory muscle training)+EMT (Expiratory muscle training). Respiratory muscle breathing training for patients with inspiratory muscle weakness and swallowing disturbance (MIP less than 70% of normal range).
2411928|NCT03491111|Active Comparator|Control group|Intervention: Non-training group, receive regular rehabilitation. All participants will receive usual rehabilitation care including body positioning instruction, postural correction, breathing control, cough maneuver, respiratory muscle stretch, chest wall mobility exercise and ventilation, fatigue management.
2411929|NCT03491111|Experimental|EMT group|Intervention: Respiratory muscle training for EMT. Respiratory muscle breathing training for swallowing disturbance. EMT for patients with swallowing disturbance will commence from 15% to 75% of threshold load of an individual's MEP.
2411930|NCT03491098|Placebo Comparator|momestone furoate spray first group: will be given|Nasonex spray one puff in each nostril daily for 8 weeks
2411931|NCT03491098|Placebo Comparator|prednisolone sodium phosphate 15mg second group: will be given|Predsol fort tablet three times per day for 1 week then gradual withdrawal over 2 weeks
2411932|NCT03491098|Placebo Comparator|hypertonic sea water solution spray third group: will be given|Nasal spray one puff in each nostril daily for 8 weeks
2411933|NCT03491085|Active Comparator|tonsillictomy with antibiotics|
2411934|NCT03491085|No Intervention|tonsillictomy Without Antibiotics|
2411935|NCT03491072|Experimental|Transcutaneous electrical nerve stimulation (TENS)|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
2411936|NCT03491072|Active Comparator|Fentanyl|Patients will receive IV fentanyl 1µg /Kg. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
3145196|NCT00063895|Experimental|Treatment (erlotinib hydrochloride)|Patients receive oral erlotinib on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145197|NCT00063947|Experimental|Treatment (radiotherapy, gemcitabine, erlotinib hydrochloride)|Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
2411939|NCT03491046|Experimental|Patient population with ACL injury or reconstruction|
2411940|NCT03491046|Experimental|Patient population without ACL injury or reconstruction|
2411941|NCT03491033||advanced-stage ovarian cancer group|250 patients with pathologically confirmed epithelial ovarian cancer who received at least 1 cycle of NAC at Yonsei Cancer Hospital from 2006 to 2017.
3145198|NCT00063960|Experimental|floxuridine + irinotecan|"Within 4-8 weeks after prior resection or ablation, patients receive hepatic arterial infusion of floxuridine continuously on days 1-14 and irinotecan IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of unacceptable toxicity.~Patients are followed every 3 months for 2 years."
3145199|NCT00063973|Experimental|Treatment (cilengitide)|"Patients receive cilengitide (EMD 121974) IV over 1 hour twice weekly. Treatment repeats every 4 weeks for 13 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of cilengitide until the MTD is determined. The MTD is defined as the dose at which 25% of patients are expected to experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are accrued and treated at that dose level for a total of 12 patients at the MTD."
3145200|NCT00064012|Active Comparator|Velcade Alone|Velcade
3145201|NCT00064012|Experimental|Velcade plus Docetaxel|Velcade plus Docetaxel
3145202|NCT00064103|Experimental|Treatment (Ad5CMV-p53 gene)|"Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD."
2411954|NCT03491007|Placebo Comparator|DHEA|Subjects will receive a one-time oral dose of DHEA prior to initial brain imaging followed by sustained administration of DHEA for 6 weeks.
2411955|NCT03490994|Experimental|Rivaroxaban|Rivaroxaban
2411956|NCT03490994|Active Comparator|Warfarin|warfarin + enoxaparin
2411959|NCT03490968|Other|Healthy Subjects|
2411960|NCT03490968|Experimental|Peripheral Artery Disease (PAD) with Supervised Exercise|Subjects will be referred for supervised exercise therapy. Subjects will have 3 visits per week for 12 weeks. Each visit will include a minimum of 30 to 40 minutes of exercise to improve ambulation with a certified trainer.
2411961|NCT03490968|Active Comparator|PAD Subjects Who Undergo Revascularization of the Leg|This group of subjects are receiving leg revascularization as part of standard of care.
2411962|NCT03490955|Sham Comparator|Salad|Subjects will consume a vegetable salad without dressing one time in the morning.
2411963|NCT03490955|Active Comparator|Salad dressing (canola oil)|Subjects will consume a vegetable salad with dressing (canola oil) one time in the morning
2411964|NCT03490955|Active Comparator|black pepper|Subjects will consume a vegetable salad without dressing (canola oil) but with black pepper one time in the morning
2411965|NCT03490955|Active Comparator|Salad dressing (canola oil) and black pepper|Subjects will consume a vegetable salad with dressing (canola oil) and with black pepper one time in the morning
2411966|NCT03490955|Active Comparator|Salad dressing (olive oil) and black pepper|Subjects will consume a vegetable salad with dressing (olive oil) and with black pepper one time in the morning
2411967|NCT03490955|Active Comparator|Salad dressing (corn oil) and black pepper|Subjects will consume a vegetable salad with dressing (corn oil) and with black pepper one time in the morning
2411968|NCT03490955|Active Comparator|Salad dressing (sunflower oil) and black pepper|Subjects will consume a vegetable salad with dressing (sunflower oil) and with black pepper one time in the morning
2411969|NCT03490955|Active Comparator|Salad dressing (flaxseed oil) and black pepper|Subjects will consume a vegetable salad with dressing (flaxseed oil) and with black pepper one time in the morning
2411974|NCT03490929|Experimental|Contrast-enhanced ultrasound arm|contrast-enhanced ultrasound
3145203|NCT00064116|Active Comparator|Arm A: CHOP-21|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
3145204|NCT00064116|Active Comparator|Arm B: CHOP-21 + Rituximab|Rituximab 375 mg/m² i.v. day 1* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
2411979|NCT03490890|Experimental|Microwave ablation in the GGO|Patients with GGO were treated with microwave ablation.
2411984|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 1|2g β-glucan
2411985|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 2|4g β-glucan
2411986|NCT03490851|Experimental|Oatmeal + OatWell28XF Intervention 3|4g β-glucan plus β-glucanase
2411987|NCT03490851|Placebo Comparator|Cream of Rice|27 grams of cream of rice
3145205|NCT00064129|Experimental|Treatment (monoclonal antibody, colony-stimulating factors)|Patients receive ipilimumab IV over 90 minutes on day 1 and sargramostim (GM-CSF) SC on days 1-14. Treatment repeats every 28 days for 4-6 courses. GM-CSF continues beyond 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of ipilimumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Some patients undergo blood sample collection periodically for laboratory and pharmacokinetic studies. Samples are analyzed for human anti-human antibodies, IgG antibodies to ipilimumab semi-quantitative ELISA assay, and plasma concentrations of ipilimumab via quantitative ELISA assay.
3145206|NCT00064142|Experimental|Arm I (halofuginone hydrobromide)|Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.
3145207|NCT00064142|Placebo Comparator|Arm II (placebo)|Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.
3145208|NCT00064246|Experimental|Treatment (rituximab, yttrium Y 90 ibritumomab tiuxetan)|"Phase I: Patients receive rituximab IV and indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo 2 (or 3 if needed) imaging scans between days 1-6. In the absence of altered biodistribution, patients receive rituximab IV followed within 4 hours by IDEC-Y2B8 IV over 10 minutes on day 8.~Phase II: Patients receive treatment as in phase I at the MTD of IDEC-Y2B8. Patients are followed monthly for 3 months, every 3 months for 2 years, and then every 6 months for 2 years."
3145209|NCT00064272|Experimental|Arm I|Patients receive lower-dose oral ginger twice daily.
3145210|NCT00064272|Experimental|Arm II|Patients receive higher-dose oral ginger twice daily.
3145211|NCT00064272|Placebo Comparator|Arm III|Patients receive oral placebo twice daily.
3145212|NCT00064324|Experimental|Arm I|Patients receive a loading dose of oral perifosine every 6 hours for a total of 4 doses on day 1 and once daily on days 2-28 of course 1 only. For all subsequent courses, patients receive oral perifosine once daily on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2411995|NCT03490825|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
2411996|NCT03490825|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
2411997|NCT03490825|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
2411998|NCT03490825|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No EOF will be imposed. This arm will also include a melatonin placebo (Lactose/Starch) supplementation given daily during the intervention.
2411999|NCT03490812|Experimental|Prospective population|
2412000|NCT03490812|Experimental|Retrospective population|
2412001|NCT03490786|Experimental|Dose escalation|Single arm dose escalation.
2412002|NCT03490760|Experimental|Durvalumab plus Radiation Therapy|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks plus 24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
2412003|NCT03490747|Experimental|Co-developed referral scheme|A physical activity referral scheme co-developed by multidisciplinary stakeholders to incorporate behaviour change support and ensure pragmatic relevance and feasibility.
2412004|NCT03490747|Active Comparator|Usual care referral scheme|Comparative, usual care exercise referral scheme.
2412005|NCT03490747|No Intervention|No treatment control|Lifestyle advice leaflet only (provided to participants in all arms during baseline assessments).
2412006|NCT03490734|Active Comparator|Beverage A (Sweetened)|"One quarter of the group to receive black cherry and orange flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2412007|NCT03490734|Active Comparator|Beverage B (Sweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage with added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2412008|NCT03490734|Active Comparator|Beverage A (Unsweetened)|"One quarter of the group to receive black cherry and orange flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2412009|NCT03490734|Active Comparator|Beverage B (Unsweetened)|"One quarter of the group to receive strawberry kiwi & lemonade flavored beverage no added sugar for 3 weeks.~MRIs will be performed before starting and then after 3 weeks of daily beverage consumption wherein participants will be presented with visual stimuli of two beverage logos, one representing a tasteless beverage solution and another representing the assigned beverage. Each 1-second presentation signals impending delivery of 3 mL of the associated beverage via a plastic mouthpiece during MRI."
2412010|NCT03490721|Experimental|Intervention|Clustering care for 20 minutes.
2412011|NCT03490721|No Intervention|Control|Standard care non clustered.
2412012|NCT03490708|Experimental|Tranilast|Subjects who were treated with tranilast
2412013|NCT03490695|Experimental|Practice Facilitation Group A|After the first 12 months of usual care (No Practice Facilitation), group A will begin to receive the Practice Facilitation (PF) Strategy at the CHPS compounds in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package.
2412014|NCT03490695|Experimental|Practice Facilitation Group B|"Group B will receive Usual Care (no PF) between 12-24 months which includes Ghana's National Health Insurance, behavioral counseling and referral to care through the usual care system.~After 24 months into the trial, Group B will then receive Practice Facilitation strategy in addition to Ghana's National Health insurance and the World Health Organization (WHO) CVD Risk Assessment package for a duration of another 12 months, as this is a stepped wedge design.~During this 12 months period, practice facilitation will end in the Group A arm."
3145213|NCT00064389|Experimental|1|levalbuterol 90 mcg MDI QID
3145214|NCT00064389|Active Comparator|2|racemic albuterol HFA MDI 180 mcg QID
3145215|NCT00064402|Experimental|1|Arformoterol 50 mcg QD and placebo MDI
2412063|NCT03490344|Experimental|Participants with Multiple Myeloma|Participants with MM with very good partial response (VGPR) or better after induction therapy with/without consolidative HDT/ASCT and MRD positive by bone marrow flow cytometry and MM participants who were previously MRD negative after induction and consolidation and recently (within last 3 months) turned MRD positive by bone marrow flow cytometry will be enrolled.
3145216|NCT00064402|Experimental|2|Arformoterol 25 mcg BID and Placebo MDI
3145217|NCT00064402|Experimental|3|Arformoterol 15 mcg BID and placebo MDI
3145218|NCT00064402|Active Comparator|4|Salmeterol MDI 42 mcg BID and placebo inhalation solution
3145219|NCT00064402|Placebo Comparator|5|Placebo MDI and placebo inhalation solution
3145220|NCT00064415|Experimental|1|Arformoterol tartrate 50 mcg QD
3145221|NCT00064415|Active Comparator|2|Salmeterol 42 mcg BID
3145222|NCT00064428|Experimental|Fondaparinux - UFH not indicated|Subjects with no indication for UFH therapy: 2.5mg od, sc, (1st dose IV) x 8 days or discharge
3145223|NCT00064428|Placebo Comparator|Control - UFH not indicated|Subjects with no indication for UFH therapy: Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
3145224|NCT00064428|Experimental|Fondaparinux - UFH indicated|Subjects indicated for UFH: 2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus + 24-48 hr infusion
2412019|NCT03490669|Experimental|Dose Escalation|Multiple dose levels of MSC-1 treatment once every 3 weeks
2412020|NCT03490669|Experimental|Dose Expansion|MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
2412021|NCT03490656|Experimental|Healthy volunteer population|
2412022|NCT03490656|Experimental|Patient population|
2412023|NCT03490643|Other|TMD Group|people who has TMD
2412024|NCT03490643|Other|Control Group|individuals who dont have healthy temporomandibular joint
2412025|NCT03490630||All patients|Patients undergoing elective surgery with anesthesia
2412026|NCT03490617|Active Comparator|Vaginal Misoprostol Group|Vaginal misoprostol (400 μg) 4 hours prior to IUD insertion
2412027|NCT03490617|Placebo Comparator|Placebo group|Vaginal placebo tablets 4 hours prior to IUD insertion
2412028|NCT03490591|Experimental|Robotic-assisted intervention|In the Robotic-assisted intervention :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
2412029|NCT03490578|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
2412030|NCT03490578|Active Comparator|Intensive treadmill training|Intensive treadmill training using an usual treadmill
2412031|NCT03490565|Active Comparator|EX group|Exercise training
2412032|NCT03490565|No Intervention|CON-group|Usual Care
2412033|NCT03490552|Sham Comparator|group A|include clots which have been extracted by mechanical thrombectomy and with definite stroke etiology and submitted to the RNA analysis in blinded coded label .
2412034|NCT03490552|Experimental|group B|include all clots which have been extracted by mechanical thrombectomy and with unknown stroke etiology and submitted to RNA analysis in cryptogenic label.
2412035|NCT03490539||azathioprine (AZT)|Patients with MG who are receiving azathioprine as part of routine clinical care
2412036|NCT03490539||mycophenolate mofetil (MMF)|Patients with MG who are receiving mycophenolate mofetil as part of routine clinical care
2412037|NCT03490526|Experimental|Root canal disinfection with XP-endo Finisher|
2412038|NCT03490526|Active Comparator|Root canal disinfection with passive ultrasonic irrigation|
2412039|NCT03490513|Placebo Comparator|Weight loss plus placebo|Participants will take a placebo every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
2412040|NCT03490513|Experimental|Weight loss plus anastrozole|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and undergo supervised exercise training program.
2412041|NCT03490500||S100B protein dosage|Biological
2412042|NCT03490487|Active Comparator|A antiepileptic|will receive conventional antiepileptic drugs only
2412043|NCT03490487|Experimental|B steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs
2412044|NCT03490474|Experimental|Pain Inducing Massage|Participants will receive manual pressure applied to one myofascial trigger point.
2412045|NCT03490474|Active Comparator|Pain Free Massage|Participants will receive light touch applied to one myofascial trigger point.
2412046|NCT03490474|Placebo Comparator|Coldpressor|Participants will place hand into water cooled to 6 degrees Celsius (males) or 8 degrees Celsius (females).
2412047|NCT03490461||Statin group|Statin therapy was defined as the administration of statins for more than 30 days after liver transplantation
2412048|NCT03490461||Non-statin group|the administration of statins for less than 30 days after liver transplantation
2412049|NCT03490448|Other|intervention group|aerobic exercise and appropriate caloric control
2412050|NCT03490435||Study participants|Both healthy and ailing individuals, both sex, including adults and children.
2412051|NCT03490422|Experimental|Pulpotomy|Pulpotomy is performed in carious-exposed pulp in mature permanent teeth
2412052|NCT03490409|Experimental|compression stocking|The intervention group will receive a thigh compression stocking, which is to be used for 24 hours a day for 14 days after surgery.
2412053|NCT03490409|No Intervention|Conventional treatment|The control group will receive conventional treatment, a compression bandage placed at the end of surgery and removed on the night of the surgery.
2412054|NCT03490396|Experimental|Arm 1 (Gelclair at time of conditioning)|All subjects in study Arm 1 will receive GEL starting on the first day of conditioning.
2412055|NCT03490396|Active Comparator|Arm 2 (Gelclair when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive GEL.
2412056|NCT03490396|Active Comparator|Arm 3 (MMW when OM diagnosed)|Subjects in Arm 2 will be observed from initiation of conditioning to Day +14. If subjects develop G1 or G2 OM via WHO OM scale during this period, they will at that time be randomized to immediately receive MMW.
2412057|NCT03490383||patients without CBD calculi|patients without CBD calculi
2412058|NCT03490383||CBD calculi without ERCP history|patients with CBD calculi without ERCP history
2412059|NCT03490383||CBD calculi with ERCP history|patients with CBD calculi and ERCP history
2412060|NCT03490370|Experimental|Electronic Muscle Stimulation Activity|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4. All participants taking part will be allocated to the Electronic Muscle Stimulation Activity (EMS) intervention from baseline for the duration of 12 weeks. There will be 6 EMS sessions of 35mins/per session each week.
2412061|NCT03490357|Active Comparator|Control - Transversus Abdominus Plane Block|Standardized ERAS regional nerve block
2412062|NCT03490357|Experimental|Quadratus Lumborum Block|Quadratus lumborum nerve block
2412087|NCT03490162|Experimental|Food Effect|300 mg of DM1157 (2 capsules of 150 mg) orally with high fat diet, n=6, and matching placebo (2 capsules) orally with high fat diet, n=2
2412347|NCT03488329|No Intervention|Control|"Control group~Standard treatment"
3145225|NCT00064428|Active Comparator|Control - unfractionated heparin|Subjects indicated for UFH: UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
3185577|NCT00736411|Other|II|treatment
2412064|NCT03490331|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene17) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
2412065|NCT03490318||Patients with DMO and/or PDR|
2412066|NCT03490305||Combatants|Men 16-50 years old or combatants by own admission.
2412067|NCT03490305||Civilians|Children <16 years, all women and men ≥50 years.
2412068|NCT03490292|Experimental|Run-In Phase|"6 patients enrolled will receive weekly carboplatin (AUC2) and paclitaxel (50 mg/m2) [intravenous infusion on days 1, 8, 15, 22, & 29] while undergoing radiation therapy [23 fractions, M-F, estimated completion day 35].~Avelumab combined with Chemoradiation - Avelumab (10 mg/kg IV) every 2 weeks starting on the day of the last chemotherapy infusion (day 29). A total of 3 doses administered during the pre-operative period and an additional 6 doses of avelumab post-operatively.~Trial enrollment will resume after at least 5 patients do not have a DLT during the DLT evaluation period or until all 6 patients are seen for post-operative evaluation. If 2 or more patients experience dose limiting toxicities associated with the proposed treatments, further accrual of the subjects will be halted and trial will be suspended. Trial may be reopened in the future with appropriate schedule and dose modifications of the proposed treatment."
2412069|NCT03490292|Experimental|Expansion Cohort|Following a determination of safe and tolerable treatment outcome of the Run-In Phase, Part 2 of the trial will enroll 18 additional patients to evaluate activity of the proposed treatment and to obtain further safety information (carboplatin, paclitaxel, radiation & Avelumab combined with Chemoradiation).
2412070|NCT03490279|Experimental|A|Lactoferrin CRX 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
2412071|NCT03490279|Placebo Comparator|B|Placebo 100 mg, capsule formulation, 2 tablets taken together once daily, on an empty stomach (before breakfast)
2412072|NCT03490266|Active Comparator|Laparoscopic Repair|The abdomen will be entered and insufflated utilizing a 5 mm optical port. Only 5 mm ports will be utilized laterally to take down all anterior abdominal wall adhesions. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through a 11 or 12 mm port placed through the defect. Excision of hernia sac and preperitoneal fat and defect closure will be performed per current practice. The mesh will be secured in four points with 0-PDS sutures and/or tacked with a double crown of tacks per our current practice.
2412073|NCT03490266|Experimental|Robotic Repair|Three lateral ports will be placed including a 12 port for the camera. Adhesions will be taken down from the anterior abdominal wall. Hernia sac and preperitoneal fat will be excised per current practice and defect will be closed using a running locking barbed suture. A mid-density polypropylene mesh with a one-sided adhesion barrier that provides at least 5 cm of overlap in all directions will be inserted through the 12 mm port. The mesh will be secured circumferentially with a running barbed suture.
2412074|NCT03490253|Active Comparator|Static Messaging|We will send patients a total of seven messages per week (one per day) at 10.00 am. For the physical health management messages we use messages from established topics in the Diabetes Prevention Program(23) content with the emphasis on physical activity and stress management. The final message, on the seventh day will ask patients to rate their mood on a scale from 1 to 9. Physical activity (step-count/day) will be passively monitored via the app on their smartphone.
2412075|NCT03490253|Experimental|Adaptive Messaging|Patients in the adaptive messaging arm will receive the daily messages of the static arm, and additionally receive daily messages within different categories of feedback and motivational messages that are chosen using a reinforcement learning (RL) algorithm. Physical activity (step-count/day) will be actively monitored via the app on their smartphone.
2412076|NCT03490253|No Intervention|Control Condition|Control patients will only install the app on their phone and will not receive any feedback messages. They will receive one message a week, on a fixed day, asking them to assess their mood in the previous week on a scale of 1 to 9. The message will be sent daily at 10:00 am. Non-responders will receive reminders to submit their mood self-assessments in two hour intervals.
3185578|NCT00736424||1|Have received bilateral AN stimulation of the anterior nucleus (AN) of the thalamus for epilepsy or are receiving it at the time of enrollment
3185579|NCT00736437|Experimental|1|ME-609
2412079|NCT03490214|Experimental|Muscular Dystrophia|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
2412080|NCT03490214|Active Comparator|Healthy Volunteer|Multispectral Optoacoustic Tomography (MSOT) of muscles (left and right, total 8 sites) leg proximal: Musculus quadriceps, distal: Musculus triceps surae arm proximal: Musculus biceps, distal: Musculus brachioradialis
2412081|NCT03490201|Active Comparator|Randomized - Control|
2412082|NCT03490201|Active Comparator|Randomized - Treatment|
2412083|NCT03490201|Experimental|Non-randomized - Treatment|
2412084|NCT03490188|Experimental|Treatment Arm|Patients assigned to treatment arm will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center. In addition, they will be matched with a mentor who will conduct 5 meetings with the patients (which includes one video chat meeting, 4 30-minute phone calls) and discuss the following topics related to post-discharge: Medications, Lab Work, Fluid Intake and Adherence to doctor's appointment
2412085|NCT03490188|No Intervention|Control Arm|Control arm recipient will receive standard post-transplantation discharge care that includes weekly follow-up visits and 24-hour access to transplant triage call center
2412086|NCT03490175||All patients|Patients undergoing general anesthesia for elective surgery
3185580|NCT00736437|Placebo Comparator|2|Vehicle
3185581|NCT00736463|Active Comparator|1|Aimvastatin 80 mg
3185582|NCT00736463|Active Comparator|2|Atorvastatin 80 mg
2412088|NCT03490162|Experimental|MAD 1|150 mg of DM1157 (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (1 capsule) orally daily for three days with 240 ml of water after an overnight fast, n=2
2412089|NCT03490162|Experimental|MAD 2|300 mg of DM1157 (2 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (2 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2412090|NCT03490162|Experimental|MAD 3|600 mg of DM1157 (4 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (4 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2412091|NCT03490162|Experimental|MAD 4|900 mg of DM1157 (6 capsules of 150 mg) orally daily for three days with 240 ml of water after an overnight fast, n=8, and matching placebo (6 capsules) orally daily for three days with 240 ml of water after an overnight fast, n=2
2412092|NCT03490162|Experimental|SAD 1|9 mg of DM1157 (1 capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
2412093|NCT03490162|Experimental|SAD 2|27 mg of DM1157 (3 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (3 capsules) orally with 240 ml of water after an overnight fast, n=2
2412094|NCT03490162|Experimental|SAD 3|81 mg of DM1157 (9 capsules of 9 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (9 capsule) orally with 240 ml of water after an overnight fast, n=2
2412095|NCT03490162|Experimental|SAD 4|150 mg of DM1157 (1capsule) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (1 capsule) orally with 240 ml of water after an overnight fast, n=2
2412096|NCT03490162|Experimental|SAD 5|300 mg of DM1157 (2 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (2 capsules) orally with 240 ml of water after an overnight fast, n=2
2412097|NCT03490162|Experimental|SAD 6|600 mg of DM1157 (4 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (4 capsules) orally with 240 ml of water after an overnight fast, n=2
2412098|NCT03490162|Experimental|SAD 7|900 mg of DM1157 (6 capsules of 150 mg) orally with 240 ml of water after an overnight fast, n=6, and matching placebo (6 capsules) orally with 240 ml of water after an overnight fast (n=2)
2412099|NCT03490149||ECT|
2412100|NCT03490149||Medication - Treatment as usual|
2412101|NCT03490149||Healthy controls|
2412102|NCT03490123|Experimental|Intervention|"Repeated total community treatment, TCT with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single dose every 6 months, for 12 months (3 doses).~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin."
2412103|NCT03490123|Active Comparator|Control|"Single total community treatment, TCT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at month 0 (1 dose); followed by two total targeted treatment, TTT, with study drug: Azithromycin tablets, 30mg/Kg (maximum 2g), a single, at months 6 and 12.~Study interventions are:~R1-Total community treatment with azithromycin, R2-Total targeted treatment with azithromycin, R3-Total targeted treatment with azithromycin."
3185583|NCT00736515|Experimental|Combination therapy|The subjects allocated into this arm will receive the combination therapy of oral administration of 60~120mg Gliclazide MR (Diamicron MR) and subcutaneous injection of basal insulin (Insulin Glargine Injection, Lantus) once daily for 3 months
3185584|NCT00736515|Active Comparator|monotherapy|The patients allocated into this arm will receive the monotherapy of subcutaneous injection of premixed insulin (Biosynthetic Human Insulin Injection, Novolin 30R) twice daily for 3 months.
2412106|NCT03490097|Experimental|Group I|low dose of simvastatin10 mg plus sofosbuvir 400mg / daclatasvir 60 mg daily for 12 weeks.
2412107|NCT03490097|Active Comparator|Group II|sofosbuvir plus daclatasvir
2412108|NCT03490084||Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
2412109|NCT03490084||Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
2412111|NCT03490045|Experimental|Intervention Condition|Postpartum women and their infants will be randomly assigned to the treatment condition and receive a diaper incentive for their participation.
2412112|NCT03490045|Active Comparator|Comparison Condition|Postpartum women and their infants will be randomly assigned to the control condition and will receive a conditional cash transfer of equivalent value of the diapers provided to the intervention group.
3185585|NCT00736528|Experimental|PF-04447943 05 mg dose|
3185586|NCT00736528|Experimental|PF-04447943 15 mg dose|
3185587|NCT00736528|Experimental|PF-04447943 45 mg dose|
2412116|NCT03490019|Experimental|Metformin Therapy|Metformin therapy once daily for 24 weeks with a dose of 500, 850 or 1000 mg depending on body weight
2412117|NCT03490006|Active Comparator|Paravertebral Block|For this arm, the initial level will be at T3-4 and an out-of-plane technique to guide the needle tip to a point between the costotransverse ligament and the parietal pleura between the visualized transverse processes. Then, a few milliliters of 0.5% ropivacaine will be injected slowly to displace the pleura ventrally as the paravertebral space fills with local anesthetic. After negative aspiration, the rest of 0.5% ropivacaine (total 10 ml) will be injected in 5 ml increments to further fill the paravertebral space. The procedure will then be repeated in the same exact fashion at the T5-6 level. We will observe local anesthetic spread under real-time ultrasound imaging.
2412303|NCT03488732||Patients undergonig transcatheter valvular interventions|
3185588|NCT00736528|Placebo Comparator|Placebo|
3185589|NCT00736541|Experimental|2|
3185590|NCT00736593|Experimental|1|
3185591|NCT00736606|Experimental|Period 1|simvastatin
3185592|NCT00736606|Experimental|Period 2|simvastatin + AZD9056
3185593|NCT00736619|Experimental|1|"Cetuximab loading dose, 400 mg/m2 intravenously (IV) IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days~Cetuximab 250 mg/m2 weekly IV X 7 weeks~Albumin-bound paclitaxel (Abraxane®) weekly IV X 7 weeks, according to dose escalation scheme"
2412118|NCT03490006|Experimental|Erector Spinae Plane Block|For this arm, the needle tip will be directed under ultrasound guidance using an in-plane technique towards the T5 transverse process until the needle tip contacts os. Then, a few milliliters of ropivacaine will be injected slowly to separate the plane between the erector spinae muscle and the transverse process. After negative aspiration, the rest of the 0.5% ropivacaine will be injected (total 20ml)
2412119|NCT03489993||FGF23-Related Hypophosphatemic Diseases|The diagnostic tests Ang II, Ang-(1-7), FGF23, and klotho will be measured in the cohort. Patients in the cohort will have the diseases X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets type 1 (ARHR1), autosomal recessive hypophosphatemic rickets type 2 (ARHR2), osteoglophonic dysplasia, Jansen-type metaphyseal chondrodysplasia, Raine syndrome, McCune-Alright syndrome, and epidermal nevus syndrome (ENS).
2412120|NCT03489980||Ambulatory consultation waiting room|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form before a medial consultation with hospital practitioner.
2412121|NCT03489980||Hemodialysis service|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during hemodialysis.
2412122|NCT03489980||Day hospitalization service : psychiatry|Patient from ambulatory consultation waiting room Group, coloring-type artistic task of a complex form during day hospitalization.
2412123|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are below 3.0 mmol/L.
2412124|NCT03489967|Active Comparator|16g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 16g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
2412125|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels < 3.0 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are below 3.0 mmol/L
2412126|NCT03489967|Active Comparator|32g of carbohydrates - Glucose levels 3.0-3.5 mmol/L|Hypoglycemia treatment with 32g of carbohydrates will be given when glucose levels are between 3.0 and 3.5 mmol/L.
2412127|NCT03489954||Non-specific chronic neck pain group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
2412128|NCT03489954||Healthy group|In evaluation of participants, endurance of deep cervical flexor muscles will be measured using stabilizer pressure biofeedback unit with cranio-cervical flexion test. Neck position sense of 6-direction (flexion, extension, right-left lateral flexion and right-left rotation) will be measured by CROM device (cervical range of motion device). Body balace will be measured by Balance Master System.
3185594|NCT00736658|Experimental|AZD1386|4 groups receiving a specified volume of the active component AZD1386 at different points of time.
3185595|NCT00736658|Placebo Comparator|Placebo|Included in each dose group
3185596|NCT00736671||Observational Parkinson's Disease|Observational study of subjects with Parkinson disease
2412132|NCT03489928|Experimental|Oral Misoprostol|50ug po q4h orally, as needed
2412133|NCT03489928|Experimental|Low dose vaginal misoprostol|25-50ug q6h, vaginally, as needed
2412134|NCT03489928|Experimental|Usual vaginal dinoprostone|1-2mg q6h, vaginally as needed
2412135|NCT03489915||Patients with macular edema due to RVO|assessment of visual acuity using Landolt chart and follow up of macular edema using OCT
2412136|NCT03489902|Experimental|Transobturator arm|Transobturator Paravaginal Repair
2412137|NCT03489902|Experimental|Transvaginal arm|traditional transvaginal Paravaginal Repair
2412138|NCT03489889|Experimental|capsule|pharmaceutical form: capsule ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
2412139|NCT03489889|Experimental|tablet|pharmaceutical form: tablet ursodeoxycholic acid 300 mg 13-15mg/kg day 3 months
2412140|NCT03489876|Experimental|Synthetic Cartilage Implant|Participants receive the synthetic cartilage implant. The synthetic cartilage implant that will be used is the Cartiva implant.
2412141|NCT03489876|Active Comparator|Osteochondral Autograft Transfer|Participants receive the current standard osteochondral autograft transfer procedure.
3185597|NCT00736671||Observational Normal Control aubjects|Observational study of normal control subjects
3185598|NCT00736684|Active Comparator|1|Proximal Femoral Nail AntirotationTM (PFNA)
3185599|NCT00736684|Other|2|Gamma Nail 3TM (Gamma3)
3185600|NCT00736697|Experimental|1|
2412146|NCT03489837|Experimental|Levotuss CR tab|oral taken
2412147|NCT03489837|Active Comparator|Levotuss syrup|oral taken
2412148|NCT03489824|Experimental|modified-WIM colonoscopy in RLP|Modified-water immersion method colonoscopy is performed to patients with right-lateral starting position (RLP). Patients will lie in the right lateral position with both hips and knees flexed at the beginning and change the position into supine and at last left-lateral position when it is needed.
2412149|NCT03489824|Active Comparator|modified-WIM colonoscopy in LLP|Modified-water immersion method (WIM) colonoscopy is performed to patients with left-lateral starting position (LLP). Patients will lie in the left lateral position with right hip and knee flexed and left leg straight at the beginning and change the position into supine and at last right lateral position when it is needed.
3185601|NCT00736710|Experimental|1|
3185602|NCT00736710|Sham Comparator|2|
3185603|NCT00736736|Active Comparator|Leg Press|Leg Press exercise for 3 times/week and sustain for 8 weeks.
2412153|NCT03489798|Experimental|6 Misoprostol|Up to six doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
2412304|NCT03488719|Experimental|Cohort 1|Tesofensine 0.25mg
3185604|NCT00736736|Experimental|Hip Exercise|Additional hip abductor and hip external rotator strength training to leg press exercise for people in this group. All participants received exercise for 3 times per week for 8 weeks.
3185605|NCT00736736|No Intervention|Control|Education was given during 8 weeks of study period. After 8 weeks of study, exercise was given as compensation.
2412154|NCT03489798|Active Comparator|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
2412155|NCT03489785||Movement|If there is unexpected movement
2412156|NCT03489785||No movement|If there is no unexpected movement
2412157|NCT03489772|Experimental|1 mg ITI-214|Single dose
2412158|NCT03489772|Experimental|10 mg ITI-214|Single dose
2412159|NCT03489772|Placebo Comparator|Placebo|Single dose
2412160|NCT03489759|Experimental|ViE15-A|The patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using ViE15-A hemofilter
2412161|NCT03489759|Active Comparator|REXEED-15A|TThe patients were randomly allocated to two groups by using computer-generated numbers. The renal replacement therapy will be started using REXEED-15A
2412162|NCT03489746|Experimental|Inhaled corticosteroid withdrawal|Patients meeting the study criteria for withdrawal will have their ICS containing regime changed to a LABA/LAMA regime without ICS.
2412163|NCT03489746|Active Comparator|Standard care|Patients will continue on their current recommended regimen including ICS.
2412164|NCT03489733|Experimental|Intervention Group|Infant Formula with hydrolyzed protein and breast milk until at least 120 days of life
2412165|NCT03489733|Experimental|Control Group|Infant Formula with intact protein and breast milk until at least 120 days of life
2412166|NCT03489733|No Intervention|Breast Fed Group|Exclusively breast ilk until at least 120 days of life
3185606|NCT00736749||Observational (long-term follow-up)|Within 3 months of enrollment of ALTE05N1, patients receive a mailed packet introducing the LTFC. Patients are asked to complete a patient response form, verify information provided in packet, and update contact and health status information. The Health Status Update Form is a brief document including questions about current health status, disease status, and cancer therapy received since the last mailing. Patients may respond by use of postage prepaid envelopes, email, or 24-hour toll-free telephone number.
3185607|NCT00736762|Experimental|GPR|Global postural re-education intervention
3145226|NCT00064519||Families with MI|"In conjunction with collaborators in Germany, we have established one of the largest collections of families with MI, comprising 1,406 individuals in 513 Western-European families. Based on this collection, our total genome scan and linkage analysis has identified a region on chromosome 14 with a significant linkage signal for myocardial infarction (LOD = 3.9, pointwise P = 0.00015, genome-wide P < 0.05)5. Preliminary results from an association study in a subset of these families has identified a small set of single nucleotide polymorphisms (SNPs) within candidate genes in this region as being suggestively associated with MI.~No drugs are to be administre"
3145227|NCT00064649|Active Comparator|2|Transurethral Needle Ablation (TUNA)
2412171|NCT03489694||Subjects|Each subject will undergo skin test endpoint titrations with three different testers.
2412172|NCT03489681|Experimental|Acupuncture, low dosage|treat as six acupoints
2412173|NCT03489681|Experimental|Acupuncture, high dosage|treat as 18 acupoints
2412174|NCT03489681|No Intervention|Control group|no acupuncture treatment, healthy control
2412175|NCT03489668|Active Comparator|PCOS|Metformin administration 1500mg/day
2412176|NCT03489668|No Intervention|Control|
2412177|NCT03489655|Experimental|Maintenance Phase Intervention|Participants receive a phone-based Community Health Worker (CHW) intervention in addition to bi-monthly data collection calls with a research assistant.
2412178|NCT03489655|No Intervention|Maintenance Phase Control|Participants receive no further interventions, but have bi-monthly data collection calls with a research assistant.
2412179|NCT03489642|Experimental|COPD Telehealth Program|Participants will take part in a structured telehealth program for 12 weeks. Web-based educational tools will be made available to participants. Study participants will meet with a registered respiratory therapist two times per week.
2412180|NCT03489629|Experimental|Treatment|"Subjects are treated with one oral antibiotic, one topical antibiotic, an oral rinse, and instructed to use environmental decontamination techniques.~Trimethoprim Sulfamethoxazole (TMP/SMX) is the primary oral antibiotic to be used. Subjects with allergy or intolerance to TMP_SMX will use minocycline as an alternative antibiotic. Topical antibiotics are nasal Mupirocin, and the oral rinse/gurgle with 0.12% chlorhexidine gluconate."
2412181|NCT03489616|Experimental|Radiotherapy+chemotherapy+ rhGM-CSF|Patients with PR or SD after first-line chemotherapy will be treated with pemetrexed on d1 (500mg/m2) or other single agent on d1, d8. Local radiotherapy dose will be> 4Gy per time（or BED >45Gy） from day 2 to day 15 in a cycle of 21 days. Subcutaneous injection of rhGM-CSF (200ug/m² per day) will be executed 24 hours after chemotherapy. Repeat in the second metastatic lesions.
2412182|NCT03489616|Experimental|Single agent maintenance therapy|Maintenance treatment by single agent in a cycle of 21 days.
2412183|NCT03489590|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.
2412184|NCT03489564||Active|Physically active will be defined by self-report and confirmed by step counts >8,000 per day from activity monitoring.
2412185|NCT03489564||Sedentary|Sedentary lifestyle will be defined by self-report and confirmed by step counts <5,000 per day from activity monitoring.
2412187|NCT03489538||RYGB Patients|Laparoscopic long limb roux-en-Y gastric bypass group. All consecutive patients eligible for bariatric surgery.
3145228|NCT00064649|Active Comparator|3|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
2412190|NCT03489512|Experimental|A (Chloraprep)|2% chlorhexidine gluconate with 70% isopropyl alcohol with a sterile 3ml single dose applicator. Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
2412191|NCT03489512|Active Comparator|B (Clorhexidine 2%)|2% aqueous base chlorhexidine (10 ml single dose containers). Use for the preparation of the skin before insertion of the central venous catheters and at each dressing change.
2412192|NCT03489499||All patients|Patients undergoing elective surgery with anesthesia
2412193|NCT03489460|Active Comparator|Receive sleep health messages + GAD|Procedures will be delivered to users of the GAD, individuals who have opted in via their smartphone application, to receive messages about various areas of health.
2412305|NCT03488719|Experimental|Cohort 2|Tesofensine 0.50mg
2412194|NCT03489460|Active Comparator|Sleep message No GAD|For two weeks participants agree to receive sleep health messages and wear the GAD
2412195|NCT03489447||Sepsis group|All adult (>= 18 years) patients with a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
2412196|NCT03489447||Non-sepsis group|All adult (>=18 years) patients without a diagnosis of sepsis included in the Swedish ICU Registry between 2008-01-01 and 2016-10-18
3145229|NCT00064649|Active Comparator|1|Transurethral Microwave Thermotherapy (TUMT)
3145230|NCT00064714|Experimental|Group 1|Group 1 will receive immunosuppression and AC2993; then immunosuppression only
2412199|NCT03489421||HIV Infected|
2412200|NCT03489421||Un-infected controls|Controls without HIV from a historical pre-approved-IRB-protocol database
2412201|NCT03489395|Experimental|Edoxaban|Used for Treatment. All patients will receive edoxaban 60 mg once a day, with open-label design, for 4 weeks. Edoxaban daily dose will be reduced to 30 mg/day in case of: body weight ≤60 kg, or concomitant therapy with verapamil/quinidine/dronedarone.
3145231|NCT00064714|Experimental|Group 2|Group 2 will receive AC2993 only; then neither immunosuppression nor AC2993
3145232|NCT00064714|Experimental|Group 3|Group 3 will receive immunosuppression and AC2993; then immunosuppression and AC2993
2412205|NCT03489356|Experimental|Intervention|Addressing Behavior Change (ABC) intervention delivery method
2412206|NCT03489356|No Intervention|Control|Control
3145233|NCT00064714|Experimental|Group 4|Group 4 will receive AC2993 only; then AC2993 only
2412208|NCT03489330||Northwestern Memorial Hospital data|Inpatient intravenous vancomycin use
2412209|NCT03489330||Henry Ford Hospital data|Inpatient intravenous vancomycin use
2412210|NCT03489330||University of Michigan Hospital data|Inpatient intravenous vancomycin use
2412211|NCT03489317||No metabolic syndrome|Participants who do not fulfill any of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2412212|NCT03489317||Metabolic syndrome- partial|Participants who fulfill one or two of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2412213|NCT03489317||Metabolic syndrome- full|Participants who fulfill three or more of the five criteria for metabolic syndrome defined by the International Diabetes Federation.
2412215|NCT03489291|Experimental|Single infusion of AMT-061|Subjects will receive a single infusion of AAV5-hFIXco-Padua (AMT- 061) at baseline. After IMP administration (post IMP), subjects will be monitored for tolerance to the IMP and detection of potential immediate AEs at the clinical trial site for 24 hours (overnight stay).
3145234|NCT00064883||Patients|Pediatric cancer patients referred to the ROB who have received or require radiation therapy
2412217|NCT03489265|Other|Eluxadoline followed by Placebo|Following a 2-week run-in period, patients will receive Eluxadoline 100 mg twice daily for 4 weeks then placebo tablets taken twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
2412218|NCT03489265|Other|Placebo followed by Eluxadoline|Following a 2-week run-in period, patients will receive placebo twice daily for 4 weeks then Eluxadoline 100 mg twice daily for 4 weeks followed by a 2-week follow-up period during which placebo will be administered twice daily.
3145235|NCT00064974|Experimental|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
2412220|NCT03489239|Experimental|Single Arm|SingleArm: TAF 25 mg
2412221|NCT03489226|Active Comparator|Capsimax 2 mg|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2412222|NCT03489226|Placebo Comparator|Placebo|single dose with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2412223|NCT03489226|Active Comparator|Capsimax 4 mg plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2412224|NCT03489226|Placebo Comparator|Placebo plus 250 kcal meal|single dose with 250 kcal meal with satiety measures and metabolic rate measured before and after. Food intake measured 1 hour after dose.
2412225|NCT03489213|Active Comparator|Arm I (DGA/AICR)|Patients receive DGA/AICR-based dietary intervention for 6 months consisting of 12 education sessions (60 minutes each) every other week. Lectures will take place in an urban garden where fruit, vegetable, and herb harvesting 1-2 times per week is encouraged. All participants will be given a FitBit and regular physical activity will be encouraged. Finally, remote health coaching is offered to all study subjects for the duration of the intervention (12 weeks).
2412226|NCT03489213|Experimental|Arm II (DGA/AICR plus Beef)|Patients receive the same intervention as in Arm I with the addition of 18 ounces of lean beef provided by the study to each subject. Subjects will be encouraged to consume the lean beef and lectures will incorporate healthy beef consumption into each lesson and cooking demonstration.
2412227|NCT03489200|Experimental|EH301|
2412228|NCT03489200|Placebo Comparator|Placebo|
2412230|NCT03489174|Experimental|Monthly Pregnancy Screening|Patients at the Hamilton Clinic present to the clinic most often on a weekly basis to provide a urine sample for urine drug screening and to meet with their MRP. This same urine sample will be tested for pregnancy in the intervention group once per month. Resulting positive test results will be reported to the patient through their attending physician on the day of testing.
2412231|NCT03489174|Active Comparator|Usual Care|Participants in the control group will not receive study-initiated urine pregnancy testing but will receive usual care, which may include pregnancy testing based on patient request or clinical judgement.
2412232|NCT03489161|Experimental|Buprenorphine|Buprenorphine administered in the emergency room after patients presenting to the emergency department (ED) due to opioid OD who have been treated with opioid antagonist (naloxone) and are stable and alert.
2412306|NCT03488719|Experimental|Cohort 3|Tesofensine 0.75mg
3145236|NCT00065208|Experimental|Reiki|Energy therapy
3145237|NCT00065208|Sham Comparator|Pretend Reiki|
3145238|NCT00065208|Other|Rest / Guided Imagery|Rest for pre-surgery outcomes Guided Imagery for post-surgery outcomes
3145239|NCT00065325|Active Comparator|1|Exemestane
3145240|NCT00065325|Experimental|2|Fulvestrant
3145241|NCT00065351|Experimental|1|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
2412233|NCT03489148|Experimental|Tamarkoz®|A Sufi method to focus, called Tamarkoz®. Participants had met in class twice a week for two and a half hours total for three months. One day of the week, they met for theoretical teachings of Sufism, and for the second day in the week they met with a Tamarkoz® instructor to learn meditation techniques.
2412234|NCT03489148|Active Comparator|Stress Management Resources|The self-care stress management group used the campus resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, and online reading materials for stress management as needed for themselves.
2412235|NCT03489148|No Intervention|Waitlist|The waitlist control group did not receive Tamarkoz® and did not use the stress management resources on campus for the duration of the study.
2412236|NCT03489135|Experimental|Intervention using the ReVene Thrombectomy Catheter|Open label, prospective, non-randomised, multi-centre first-in-human evaluation of the Vetex ReVene Thrombectomy Catheter for treatment of acute iliofemoral deep vein thrombosis (DVT).
3145242|NCT00065546|Active Comparator|1|Post-menopausal women randomized to receive estrogen replacement therapy.
3145243|NCT00065546|Placebo Comparator|2|Post-menopausal women randomized to receive a placebo.
3145244|NCT00065546|Experimental|3|Pre-menopausal women with specific genetic variants.
3145245|NCT00065585|No Intervention|Usual care|
2412241|NCT03489096|Experimental|Cryoballoon Ablation|Cryoballoon Ablation: PVI + substrate modification. Left atrial fibrosis ablation in addition to standard pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation. Ablation will be performed utilizing the Medtronic Arctic Front Advance Cryoballoon catheter.
2412242|NCT03489083|Experimental|Trained Group|Subjects performing strength training three times per week for twelve weeks.
2412243|NCT03489083|Placebo Comparator|No Training Group|"Subjects performing placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks."
2412244|NCT03489070|Active Comparator|Traumastem®|Oxidized nonregenerated cellulose hemostatic agents.Traumastem® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
2412245|NCT03489070|Active Comparator|Surgicel®|Oxidized regenerated cellulose hemostatic agents.Surgicle® absorbable patches, applied topically, once, intraoperatively to stop bleeding.The patches are used on the wound surface of the liver.
2412246|NCT03489057|Experimental|PERC Program|Prostate Cancer Education and Resources for Couples (PERC) program. Participants assigned to experimental condition will receive access to the PERC website.
2412247|NCT03489057|Active Comparator|usual care plus NCI website|Participants in this usual care plus NCI website group will be automatically directed to the NCI prostate cancer website after logging in to the study website homepage.
2412248|NCT03489044|Experimental|Active treatment arm (Levetiracetam)|When in the active arm, after a baseline visit, participants will up-titrate Levetiracetam in 250mg steps at intervals of one week to Levetiracetam 500mg twice daily (two tablets twice daily). Participants will be maintained on Levetiracetam 500mg bd for four weeks and have a further full assessment at 8 weeks after being on Levetiracetam. Participants will then down-titrate Levetiracetam by 250mg every week until weaned to nil.
2412249|NCT03489044|Placebo Comparator|Control arm (placebo oral tablets)|When in the control arm, after a baseline visit, participants will up-titrate placebo (manufactured to look identical to Levetiracetam 250mg) in one tablet steps at intervals of one week to two tablets twice daily. Participants will be maintained on placebo for four weeks and have a further full assessment at 8 weeks after being on placebo. Participants will then down-titrate placebo by one tablet every week until weaned to nil.
2412250|NCT03489031||Diabetes Mellitus, Type 1|patients with type 1 diabetes
2412251|NCT03489031||Diabetes Mellitus, Type 2|patients with type 2 diabetes
2412252|NCT03489018|Active Comparator|Full dose PCV13 (2p+1 schedule)|Full dose PCV13 administration in 2p+1 schedule
2412253|NCT03489018|Experimental|40% dose PCV13 (2p+1 schedule)|Fractional (40%) dose PCV13 administration in 2p+1 schedule
2412254|NCT03489018|Experimental|20% dose PCV13 (2p+1 schedule)|Fractional (20%) dose PCV13 administration in 2p+1 schedule
2412255|NCT03489018|Active Comparator|Full dose PCV10 (2p+1 schedule)|Full dose PCV10 administration in 2p+1 schedule
2412256|NCT03489018|Experimental|40% dose PCV10 (2p+1 schedule)|Fractional (40%) dose PCV10 administration in 2p+1 schedule
2412257|NCT03489018|Experimental|20% dose PCV10 (2p+1 schedule)|Fractional (20%) dose PCV10 administration in 2p+1 schedule
2412258|NCT03489018|Active Comparator|Full dose PCV10 (3p+0 schedule)|The current vaccine (PCV10) and schedule (3p+0) in use in the Kenyan routine immunisation programme as an additional comparison arm.
2412259|NCT03489005|Other|Treatment Period 1|"Interventions to be administered:~Schema 1:~400 mg BIA 5-1058~1200 mg BIA 5-1058~Placebo~Moxifloxacin~Schema 2:~1200 mg BIA 5-1058~Placebo~400 mg BIA 5-1058~Moxifloxacin"
2412260|NCT03489005|Other|Treatment Period 2|"Interventions to be administered:~Schema 1~1200 mg BIA 5-1058~Moxifloxacin~400 mg BIA 5-1058~Placebo~Schema 2:~Placebo~Moxifloxacin~1200 mg BIA 5-1058~400 mg BIA 5-1058"
2412261|NCT03489005|Other|Treatment Period 3|"Interventions to be administered:~Schema 1~Placebo~400 mg BIA 5-1058~Moxifloxacin~1200 mg BIA 5-1058~Schema 2~400 mg BIA 5-1058~1200 mg BIA 5-1058~Moxifloxacin~Placebo"
2412262|NCT03489005|Other|Treatment Period 4|"Interventions to be administered:~Schema 1~Moxifloxacin~Placebo~1200 mg BIA 5-1058~400 mg BIA 5-1058 Schema 2~1. Moxifloxacin 2. 400 mg BIA 5-1058 3. Placebo 4. 1200 mg BIA 5-1058"
2412263|NCT03488992|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
2412264|NCT03488992|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
2412265|NCT03488979||Educational Interventional Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
2412266|NCT03488979||Attention Control Group|Primary outcome measure: Difference in MOSSAS-3HF score between intervention group and control group, administered 4 weeks after discharge.
3145246|NCT00065585|Placebo Comparator|non needle control|
3145247|NCT00065585|Sham Comparator|Acupuncture - Standardized Points|
3145248|NCT00065585|Experimental|Accupunture - Experimental Points|
3145249|NCT00065637|Experimental|1|Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks
2412267|NCT03488966|Experimental|MB-EAT|Behavioral: group psychotherapy. Eight weekly sessions, each session is 2 hours in duration.
2412268|NCT03488966|No Intervention|Waitlist Control|Wait list control.
2412269|NCT03488953|Other|Transplantation Arm|
2412270|NCT03488940|Active Comparator|24-hours group|"The septic patients randomized to 24-hours group will be received enteral nutrition preparation by 24 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
2412271|NCT03488940|Experimental|16-hours group|"The septic patients randomized to 16-hours group will be received enteral nutrition preparation by 16 hours of continuously pumping through stomach tube every day.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
2412272|NCT03488940|Experimental|intermittent group|"The septic patients randomized to intermittent group will be received enteral nutrition preparations by four meals every day(08:00,12:00 18:00,22:00), each meal are pumped within 60mins through stomach tube.~Feeding will be started within 24 hours in admission of ICU. The time of therapy is 7 days."
3185608|NCT00736788|Experimental|1|Four different oral dose levels of a suspension containing AZD1704
3185609|NCT00736788|Placebo Comparator|2|oral suspension
2412275|NCT03488914|Other|Intervention|
2412276|NCT03488914|Other|Enhanced Treatment as Usual|
2412277|NCT03488901||methotrexate sensitive|patients with gestational choriocarcinoma cured with methotrexate alone
2412278|NCT03488901||methotrexate resistant|patients with gestational choriocarcinoma not cured with methotrexate alone
2412279|NCT03488901||polychemotherapy sensitive|patients with gestational choriocarcinoma cured with polychemotherapy
2412280|NCT03488901||polychemotherapy resistant|patients with gestational choriocarcinoma not cured with polychemotherapy
2412281|NCT03488901||hydatidiform moles without malignant transformation|patients treated for hydatidiform moles but who did not turn into trophoblastic tumors (=controls)
2412282|NCT03488901||placental site trophoblastic tumors|patients with placental site trophoblastic tumors not cured with polychemotherapy
2412283|NCT03488888|Sham Comparator|Normal Saline|"General Anesthesia + Bilateral Pectoral injection of Normal Saline 0,9%~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL normal saline 0,9% between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis menor and Serratil Muscles~3- Injection of 20 mL of normal saline 0,9% between Pectoralis minor and serratil muscles 4-Visualize the hydrodissection performed by the solution"
2412284|NCT03488888|Experimental|Bupivacaine|"General Anesthesia + Bilateral Pectoral injection of 30 mL of 0.25% Bupivacaine~Ultrasound-guided visualization of Pectoralis major and pectoralis minor muscles~Injection of 10 mL of local anesthetic between muscles lateral to the thoracoacromial artery.~Visualization of Pectoralis minor and Serratil Muscles~3- Injection of 20 mL of local anesthestic between Pectoralis minor and Serratil muscles 4-Visualize the hydrodissection performed by the solution"
2412285|NCT03488875|Experimental|mMBRT|Individuals in the mMBRT group will receive an 8-week mindfulness-based intervention in groups of approximately 15 individuals in 8 weekly 2-hour classes (one of these classes, toward the end of the course, is approximately 4 hours and integrates many of the practices and teachings covered throughout the training program).
2412286|NCT03488875|No Intervention|Waitlist control group|Individuals in the waitlist control group will complete the same assessments as those in the active treatment group, but will not be offered any intervention until the conclusion of the trial. At this time, control group participants will be offered the intervention.
2412287|NCT03488836|Active Comparator|race|race rotation protocol
2412288|NCT03488836|Active Comparator|reciproc|reciprocal endodontic treatment group
2412289|NCT03488823|Experimental|Young with Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
2412290|NCT03488823|Placebo Comparator|Young without Flavanol|Young patients (< 45 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols .
2412291|NCT03488823|Experimental|Old with Flavanol|Old patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink with flavanols ( 2x400 mg Flavanols).
2412292|NCT03488823|Placebo Comparator|Old without Flavanol|Young patients (>60 years) will get twice daily from1 week vor catheterisation till one week after catheterisation drink without flavanols.
2412293|NCT03488810|Active Comparator|Arm A: ADT + radiation therapy|"Patient will receive 2 injections of a three-monthly LHRH agonist depot plus non-steroidal anti-androgen (rescue treatment) (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
2412294|NCT03488810|Experimental|Arm B: ADT + radiation therapy + Apalutamide|"Patients will receive 2 injections of a three-monthly LHRH agonist depot. Apalutamide treatment: 240 mg PO daily, started the same day as the first LHRHa injection, for 6 months.~All patients will receive standard fractionation radiation therapy (RT) between 0 and 12 weeks after first injection of LHRH agonist."
2412295|NCT03488797|Experimental|Experimental|Supervised web- and home-based exercise intervention
2412296|NCT03488797|No Intervention|No Intervention|"Control group - Standard of Care~Re-assessment 24 weeks (6 month) after enrolment.~Afterwards crossover into experimental group"
2412297|NCT03488771||Control|Kidney transplant recipients without clinical/laboratory/biopsy signs of infection or graft rejection
2412298|NCT03488771||Infection|Kidney transplant recipients presenting with clinical or laboratory signs of infection (bacterial or viral)
2412299|NCT03488771||Rejection|Kidney transplant recipients presenting with clinical, laboratory or biopsy signs of graft rejection.
2412302|NCT03488745|Experimental|IntelliCare + Phone Coaching|Participants will receive IntelliCare apps with phone coaching for 7 weeks. In this arm, participants will pick two IntelliCare apps to use every week. Participants will receive a phone coaching call before they use the apps, for approximately 30 minutes, as well as 3 weeks after initiating app use (10 minute call).
3145250|NCT00065637|Placebo Comparator|2|Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks
3145251|NCT00065715|No Intervention|A|No pills
2412310|NCT03488680|Experimental|Intervention group|Behavior change communication
2412311|NCT03488680|No Intervention|Control group|No Behavior change communication
2412312|NCT03488667|Experimental|mFOLFOX6 (Leucovorin-Fluorouracil-Oxaliplatin) + Pembrolizumab|"Drug: Pembrolizumab Dose: 200 mg Dose Frequency: Every three weeks (Q3W) Route: Intravenous (IV) infusion~Drug: Oxaliplatin Dose: 85 milligrams per meter squared (mg/m2) Dose Frequency: Every 2 weeks (Q2W) Route: IV infusion~Drug: Leucovorin Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV infusion~Drug: Fluorouracil Dose: 400 mg/m2 Dose Frequency: Q2W Route: IV bolus~Drug: Fluorouracil Dose: 2,400 mg/m2 Dose Frequency: Q2W Route: IV continuous 46-hour infusion~Pembrolizumab will be administered at a fixed dose of 200 mg IV over 30 minutes every 3 weeks. Participants will receive 3 doses of the drug on Days 1, 22, 43 during the neoadjuvant phase of the study, and 12 doses of the drug on Days 1, 22, 43 during the adjuvant phase of the study (total 15 doses). Participants will receive 4 doses of mFOLFOX6 regimen on Days 1, 15, 29, 43 during the neoadjuvant phase of the study, and 4 doses during the adjuvant phase of the study (total 8 doses)."
3145252|NCT00065715|Placebo Comparator|B|Blinded placebo
3145253|NCT00065715|Experimental|C|Echinacea - Blinded
2412315|NCT03488602|Experimental|F-SPS Intervention|This group will receive the F-SPS intervention.
2412316|NCT03488602|Active Comparator|Enhanced Usual Care (EUC)|This group will receive Enhanced Usual Care (EUC)
2412317|NCT03488576|Active Comparator|Complete Peeling|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with complete macular peeling of the internal limiting membrane.
2412318|NCT03488576|Experimental|Foveal Sparing|Patient underwent scheduled vitrectomy for epiretinal membrane or macular hole with partial peeling the internal limiting membrane (foveal sparing).
2412319|NCT03488563|Experimental|B244 Dose 1|B244 1X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2412320|NCT03488563|Experimental|B244 Dose 2|B244 4X suspension in 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2412321|NCT03488563|Placebo Comparator|Vehicle|Vehicle, 30ml/bottle Subjects will apply 1 pump per nostril twice-a-day
2412322|NCT03488550|Experimental|ANX007-GLA-01|
2412323|NCT03488537|Other|patients referred for colonoscopy|All patients referred for colonoscopy where invited to participate in our study.
2412324|NCT03488524|Experimental|AMX0035|AMX0035 twice daily--a combination therapeutic including 3 gram of Phenylbutyrate and 1g TUDCA
2412325|NCT03488511|Experimental|Intervention group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of six small protein and energy enriched meals and snacks that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
2412326|NCT03488511|No Intervention|Control group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
2412327|NCT03488498||Receiving NSAID medication|Receiving NSAID medication
2412328|NCT03488498||Receiving NSAID medication and weight bath therapy,|
2412329|NCT03488498||Receiving weight bath therapy,|
2412330|NCT03488485|Other|DAA arm|"Direct Acting Antivirals therapy An algorithm was developed using DAA (Sofosbuvir-based regimens to treat all patients (RKD).~Non Cirrhotics: Sofosbuvir (SOF)+ Daclatasvir (DCV) for 12-weeks~Cirrhotics:~Genotype 3 were treated with SOF+DCV+ ribavirin (RBV) for 24 weeks, Non-Genotype 3 patients were treated with SOF+LDV+RBV for 12-weeks or with SOF+LDV for 24-weeks (in RBV intolerant patients)."
2412331|NCT03488472|Experimental|NovoTTF-200A device + Stereotactic Radiosurgery (SRS)|Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.
2412332|NCT03488459|Other|Routine preoperative information from a nurse|
2412333|NCT03488459|Experimental|Additional information support from a psychologist|
2412334|NCT03488433|Active Comparator|Antirotation sling|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
2412335|NCT03488433|Active Comparator|abduction brace|Patients who undergo reverse shoulder arthroplasty or rotator cuff repair will be randomly assigned to this group.
2412336|NCT03488420||Atrial Fibrillation and/or Atrial Flutter|Subjects taking edoxaban 30mg or 60 mg will be followed for 2 years. Subjects will perform the Montreal Cognitive Assessment (MoCA) Test at baseline and 1-year follow up. They will also answer the Anti-Clot Treatment questionnaire (ACTS-Q) at 1-year.
2412337|NCT03488394|Experimental|Treatment|Gene therapy (autologous, CD34+ cell enriched cells fraction containing HSCs, transduced with the IDUA LV encoding for the human IDUA gene and cryopreserved in cryoformulation medium)
2412338|NCT03488381|Experimental|Soccer Heading|
2412339|NCT03488381|Sham Comparator|Kicking-Control|
2412340|NCT03488368||Supportive-care group|Observation of IgAN patients who received supportive care measures (without additional immunosuppression) during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
2412341|NCT03488368||Immunosuppression group|Observation of IgAN patients who received supportive care measures and additional immunosuppression during the first three years after randomization, i.e. trial phase of the original STOP-IgAN trial.
2412342|NCT03488355|Experimental|Modified Reporting|Modified laboratory report
2412343|NCT03488355|No Intervention|Standard Reporting|Standard laboratory report
2412344|NCT03488342|Other|Rives technique|Rives technique for primary inguinal hernia
2412345|NCT03488342|Other|Lichtenstein repair|Lichtenstein repair for primary inguinal hernia
3145254|NCT00065715|Experimental|D|Echinacea - Unblinded, Open Label
3145255|NCT00065728|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
3145256|NCT00065845|No Intervention|Abdominal Sacral Colpopexy with no Burch colposuspension|Abdominal sacral colpopexy is performed through a laparotomy approach.
2412348|NCT03488316|Active Comparator|Calcium Hydroxide temporary filling material|Temporary filling with Ca(OH)2
2412349|NCT03488316|Active Comparator|MTA temporary filling material|Temporary filling with MTA
2412350|NCT03488303||Main group|Study has only one group
2412351|NCT03488290|Experimental|LTP Plus TF CBT|LTP Plus TF CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
2412352|NCT03488290|Other|Treatment as Usual|TAU group will receive routine care consisting of routine follow ups
2412353|NCT03488277|Experimental|LE: leg elevation group|the patients of this group will be positionned in supine with 15° left tilt and will have a leg elevation with a 30 cm pillow positionned under the heels. this position will be hold immediately after spinal anesthesia until fetal extraction
2412354|NCT03488277|No Intervention|CG: Control group|The patients of this group will be positiooned in supine with 15° left tlit after spinal anesthesia. no leg elevation
2412355|NCT03488264||United States|50 participants will be recruited from the United States.
2412356|NCT03488264||Jamaica|50 participants will be recruited from Jamaica.
2412357|NCT03488251|Experimental|MT-3724 10mcg/kg-GEMOX|MT-3724 10 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 10 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
2412358|NCT03488251|Experimental|MT-3724 25mcg/kg-GEMOX|MT-3724 25 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 25 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
2412359|NCT03488251|Experimental|MT-3724 50mcg/kg- GEMOX|MT-3724 50 mcg/kg/dose IV for 10 doses over (Days 1,3, 5, 8, 10, 12, 15, 22, 29 and 36) of 42 days cycle for Cycle 1. Cycle 2 and beyond MT-3724 50 mcg/kg/dose IV will be administered weekly (on Days 1, 8, 15, and 22) of each 28-day cycle in combination with GEMOX .
3185610|NCT00736801|Experimental|A|Treatment with Salmeterol for 2 weeks, followed by a treatment with Salmeterol and Fluticasone for 2 weeks.
3185611|NCT00736814|Active Comparator|Arm I|Patients receive standard chemotherapy of docetaxel and carboplatin.
2412362|NCT03488212|Active Comparator|Basic Implementation Intervention|
2412363|NCT03488212|Experimental|Enhanced Implementation Intervention|
2412364|NCT03488212|Active Comparator|Online Treatment; Control Maintenance Intervention|
2412365|NCT03488212|Experimental|Online Treatment; Monthly Lessons & Feedback for Maintenance|
2412366|NCT03488212|Experimental|Online Treatment; Refresher Courses for Maintenance|
2412367|NCT03488199|Active Comparator|Stent Acculink™ (RX ACCULINK CAROTID STENT SYSTEM)|50 Carotid stenting (RX ACCULINK CAROTID STENT SYSTEM)
2412368|NCT03488199|Experimental|Stent CGuard™ (The CGuardTM Embolic Prevention System (EPS))|50 Carotid stenting (The CGuardTM Embolic Prevention System (EPS))
2412369|NCT03488186|Experimental|Lansoprazole Capsules|Lansoprazole Capsules of Beijing Sihuan Pharm, 30 mg
2412370|NCT03488186|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules of Takeda Pharmaceutical Company Limited, 30 mg
2412371|NCT03488173|Experimental|Lansoprazole Capsules|Lansoprazole Capsules 30 mg of Beijing Sihuan Pharm
2412372|NCT03488173|Active Comparator|Lansoprazole enteric-coated Capsules|Lansoprazole enteric-coated Capsules 30 mg of Takeda Pharmaceutical Company Limited
2412373|NCT03488160|Experimental|Single arm|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:the first day,the second day Duration:total two times
2412374|NCT03488147|Experimental|Esomeprazole Only|Subjects assigned to the treatment group 'A' will receive one 20 mg esomeprazole tablet daily starting 1 week prior to the cervical operation and will continue to receive the esomeprazole until the end of the study
2412375|NCT03488147|Active Comparator|Esomeprazole and Placebo Oral Tablet|Subjects belonging to the treatment group 'B' will receive one placebo tablet (physically resembling an esomeprazole tablet 20 mg ) daily starting one week prior to the cervical operation. Subjects will then receive one 20 mg esomeprazole daily starting immediately after the operation and will continue to receive the esomeprazole until the end of the study.
2412376|NCT03488147|Placebo Comparator|Placebo Oral Tablet Only|Subjects belonging to the treatment group 'C' will receive one placebo tablet (physically resembling a 20 mg esomeprazole tablet) daily starting one week prior to the cervical operation and will continue to receive the placebo tablet until the end of the study
2412377|NCT03488121|Experimental|Poster Only|This arm will only receive motivational posters.
2412378|NCT03488121|Experimental|Thank-you Letter Only|This arm will only receive thank-you letters.
2412379|NCT03488121|Experimental|Double Incentive|This arm will receive both motivational posters and thank-you letters.
2412380|NCT03488121|No Intervention|Control|This arm will not receive any intervention.
3185612|NCT00736814|Experimental|Arm II, Genotype A1|Patients receive docetaxel and vinorelbine ditartrate.
3185613|NCT00736814|Experimental|Arm II, Genotype A2|Patients receive gemcitabine hydrochloride and vinorelbine ditartrate.
2412383|NCT03488095|Other|Behavior changing intervention|Thirty minutes behavior counselling (PPT.) to experimental group. BCI for SLT and BQ Use in Adolescents: A CRT
2412384|NCT03488095|No Intervention|Control Cluster|No thirty minutes behavior counselling (PPT.) to control group
2412385|NCT03488082|Experimental|Measurement of the bold signal|
2412423|NCT03487770|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
2412424|NCT03487770|Placebo Comparator|Placebo Oral Solution|2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
3185614|NCT00736814|Experimental|Arm II, Genotype B1|Patients receive docetaxel and carboplatin.
3185615|NCT00736814|Experimental|Arm II, Genotype B2|Patients receive gemcitabine hydrochloride and carboplatin.
2412386|NCT03488056|Experimental|Test - ICCMS|"The dentists will perform clinical examination on children following the ICCMS sequence:~The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
2412387|NCT03488056|Active Comparator|Control - Standard care SESC|"The clinical sequence in this group will be:~Caries Diagnosis Operative and non-operative treatments Indication of recall interval according to the dentist However, dentists will do that without a schematic guide to follow. They will do as they usually do in their practices."
2412388|NCT03488043||Retrospective cohort|All patients having a CT-guided transthoracic biopsy from September 2012 and September 2017.
2412389|NCT03488043||Prospective cohort|All patients having a CT-guided transthoracic biopsy from April 2018.
3185616|NCT00736827||Patients with non-septic shock|Postoperative/posttraumatic surgical critically ill patients with non-septic shock with threatening acute renal failure
2412391|NCT03488017|Experimental|Placebo Ocular Coil (left eye)|Left eye
2412392|NCT03488017|Experimental|Placebo Ocular Coil (right eye)|Right eye
2412393|NCT03487991|Experimental|personalized behavioral recommendations|Will receive recommendations for altering sleep related behavior based on data from in-home monitoring.
2412394|NCT03487991|No Intervention|educational control|Will receive the data without recommendations. Will receive personalized recommendations after the follow up assessment.
2412395|NCT03487978||Migraineurs|Patients diagnosed with migraine based on the ICHD-3 beta will undergo 3-tesla resting-state functional MRI.
2412396|NCT03487978||Control|Normal controls without headaches will undergo 3-tesla resting-state functional MRI.
2412397|NCT03487965|Experimental|Low dose Polyphenol|130 mg of Aronia Extract with 120 mg of licorice root combination blend provided to subjects once per day for 16 weeks.
2412398|NCT03487965|Experimental|High dose Polyphenol|200 mg of Aronia extract provided to subjects once per day for 16 weeks
2412399|NCT03487965|Placebo Comparator|Placebo control|Inert tablet provided to subjects once per day for 16 weeks
2412400|NCT03487952||LDCT screening group|People receive questionnaire administration at baseline, then subsequent yearly chest LDCT scan and follow up.
2412401|NCT03487939|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
2412402|NCT03487926||Group 1 (IBD primary diagnosis)|Participants have active IBD
2412403|NCT03487926||Group 2( IBD + comorbid MDE)|1 [18F]FEPPA PET scan in those with IBD symptoms in the past 2 years as well present with MDE
2412404|NCT03487926||Group 3-Controls|"Matched for Level of Depressive Symptoms and Otherwise Healthy~-Subjects in an otherwise healthy state with major depressive episodes, obsessive compulsive disorder, or generalized anxiety disorder will provide psychiatric diagnosis matched controls to those with IBD. Data for group three will be largely obtained from previous recent studies (it is anticipated that 95% of this data is already available)."
2412405|NCT03487913|Experimental|High dose|Oral lixivaptan
2412406|NCT03487913|Experimental|Low dose|Oral lixivaptan
2412407|NCT03487900|Other|Clinical remission CD|
2412408|NCT03487874|Experimental|Interscalene block with C8 root block|The 5th to 8th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
2412409|NCT03487874|Active Comparator|Conventional interscalene block|The 5th to 7th cervical nerve root block under ultrasound guidance using 25 to 30 ml of 0.75% ropivacaine
3185617|NCT00736827||Patients with septic shock|Postoperative/posttraumatic surgical critically ill patients with septic shock with threatening acute renal failure
2412411|NCT03487835|Experimental|Kinesiotape group|
2412412|NCT03487835|Experimental|Control group|
2412413|NCT03487822|Experimental|Path Pain|Path Pain participants will be receiving 8 weekly therapy session by license clinicians trained in the Path Pain intervention. They will also receive 4, 15-minute phone booster sessions, on a monthly basis after their final therapy session. They will also be invited to monthly group educational sessions. Both intervention and usual care participants will be receiving a pain educational booklet.
2412414|NCT03487822|No Intervention|Usual Care with Education|Usual Care with Education (UCE) will receive a pain educational booklet. Following completion of their 24 weeks in the study, they will also be invited to attend the monthly group educational sessions.
2412415|NCT03487822|No Intervention|Provider Feedback|Providers of patients in the study will take part in a short interview on their impressions of the intervention.
2412416|NCT03487809||NTUH|National Taiwan University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
2412417|NCT03487809||FJUH|Fu Jen University Hospital, all participants receive Duasma (budesonide, 200mcg/puff)
2412418|NCT03487809||CGH|Cathay General Hospital, all participants receive Alvesco (Ciclesonide, 160mcg/puff)
2412421|NCT03487783|Experimental|Aripiprazole Oral Solution|1 mg/mL, 2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
2412422|NCT03487783|Placebo Comparator|Placebo Oral Solution|2-20 mg/day (2-20 mL/day), once daily for 8 weeks, administered at about the same time every day, either before or after meal
3185618|NCT00736866|Experimental|Acetylcysteine|
3185619|NCT00736866|Placebo Comparator|Control|
2412425|NCT03487757|Active Comparator|Control Group|After recording the demographic and clinical information at the beginning of the study and after 8 weeks, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They won't receive any intervention by this time. At the end of 8 weeks, they may be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training.
2412426|NCT03487757|Experimental|Training Group|After recording the demographic and clinical information at the beginning of the study, respiratory muscle strength, respiratory functions and postural control evaluations will be performed to the children. They will be included in the 8-week physiotherapy program, which will be once a week and 45-60 minutes by supervision of physiotherapist and 4 days a week home exercise program. The program will include core stabilization exercise training. After the eight week training program the evaluations will be repeated.
2412427|NCT03487744|Active Comparator|Promote without fiber|Lower osmolality enteral tube feed formulation
2412428|NCT03487744|Active Comparator|Osmolite 1.5|Higher osmolality enteral tube feed formulation
2412429|NCT03487731|Placebo Comparator|Group 1 - Placebo|Group 1 - Five (5) subjects will be treated with a single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection. These subjects will be part of the control (Standard care) group.
2412430|NCT03487731|Experimental|Group 2 - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group 2 - Five (5) subjects will be treated with a single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml. These subjects will be part of the experimental group.
2412431|NCT03487731|Experimental|Group A - Allogeneic Human Mesenchymal Stem Cells (hMSCs)|Group A will consist of 15 subjects that will receive 20 million Allogeneic hMSCs delivered via lumbar level injection based on pain originator.
2412432|NCT03487731|Placebo Comparator|Group B - Placebo|Group B will consist of 15 subjects who will receive 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution via lumbar level injection based on pain originator.
3185620|NCT00736892||A|All patients meeting the American European Consensus definition of acute lung injury will be included, regardless of etiology of respiratory failure. Specifically, all patients with rapid onset of acute lung injury not of cardiac origin (no indication of heart failure or a pulmonary capillary wedge pressure of greater than 18 mmHg, with pulmonary infiltrates in all four quadrants and a PaO2/FIO2 of > 200 to <300 mmHg or ≤ 200 mmHg.
3185621|NCT00736918|Experimental|Case management|Case management
3185622|NCT00736918|Active Comparator|Enhanced usual care|Enhanced usual care
2412436|NCT03487692|Experimental|2018 Training Cohort|10 health centers will be randomized to the 2018 Training Cohort. Teams from these health centers will be trained and will implement a 6 month diabetes group visit and text messaging intervention (Diabetes MESSAGES Program).
2412437|NCT03487692|Other|2020 Training Cohort|10 health centers will be randomized to the 2020 Training Cohort. Prior to beginning training, these health centers will collect data on randomly selected patients receiving usual care to serve as the control group. After this first parallel group trial period, teams from these health centers will be trained and will implement the 6 month diabetes group visit and text messaging intervention during a second single group trial period (Diabetes MESSAGES Program (second trial)).
2412438|NCT03487679|Experimental|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water only fasting and final day of habitual eating of the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
2412439|NCT03487666|Experimental|Arm A|Nivolumab 360 mg iv q3weeks for x 6 cycles
2412440|NCT03487666|Active Comparator|Arm B|Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
2412441|NCT03487666|Experimental|Arm C|Nivolumab 360mg iv q3weeks + Capecitabine 1250mg/m2 bid D1-D14 q3 weeks x 6 cycles
2412442|NCT03487640||Transanal rectal mucosa resection|TARMR: Transanal resection of rectal mucosa for at least 5cm in length.
2412443|NCT03487640||Laparoscopic rectal suspension and colectomy|LARSC: We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
2412444|NCT03487627|Experimental|Electronic and Care Support Manager Contact|Participants receive electronic content and contact with a Care Support Manager
2412445|NCT03487627|Active Comparator|Enhanced treatment-as-usual (TAU)|Participants receive enhanced treatment-as-usual
2412446|NCT03487614|Experimental|Behavior-based parental intervention|The study intervention included two primary components: 1) physician-family health behavior conversations during well-child visits, and 2) four monthly visits with a RDN to evaluate, educate, and implement improved feeding habits and nutritional choices. A third optional component of the intervention included counseling sessions with a social worker to help families overcome barriers to change, such as food security, family relationships, and general parenting strategies.
2412447|NCT03487614|No Intervention|Control|Control parents signed the informed consent document and then completed all baseline assessments during their child's medical visit. Control participants then received their usual medical care. Follow-up evaluations, including child anthropometry and completion of study surveys were assessed approximately 6 months later during a second office visit. For children <3 years of age at baseline, follow up visits coincided with their subsequent well-child visit (i.e. 30-month or 3-year appointment) as per AAP visit frequency recommendations. For patients ≥3 years of age, families attended a separate office visit 6 months after their baseline visit in order to complete follow-up study assessments.
2412448|NCT03487601|Active Comparator|Active tDCS|Active transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of active stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
2412449|NCT03487601|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation: Participants will undergo five consecutive days (Monday-Friday) of sham stimulation beginning the Monday after their on-study chemotherapy administration. Questionnaires and cognitive assessment will be completed on the first and last days of stimulation (i.e., Monday and Friday). On all 5 days, participants will engage in cognitive tasks while receiving stimulation (either active or sham) in order to maximize stimulation effects 43. In order to assess for duration of subjective effects, participants will complete self-report measures of subjective fatigue, cognitive function and QOL immediately prior to their next chemotherapy (approximately 10-14 days after completion of stimulation).
3145257|NCT00065845|Experimental|Abdominal Sacral Colpopexy with Burch Colposuspension|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
2412452|NCT03487562|Experimental|Sequence 1|Part I: A-B-D-C A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2412453|NCT03487562|Experimental|Sequence 2|Part I: B-C-A-D A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2412454|NCT03487562|Experimental|Sequence 3|Part I: C-D-B-A A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2412455|NCT03487562|Experimental|Sequence 4|Part I: D-A-C-B A: DWP14012 A mg bid B: DWP14012 A mg bid + Clarithromycin 500 mg bid C: DWP14012 A mg bid + Clarithromycin 500 mg bid + Amoxicillin 1 g bid D: Clarithromycin 500 mg bid + Amoxicillin 1 g bid
2412456|NCT03487562|Experimental|A|Part II: (DWP14012 B mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2412457|NCT03487562|Experimental|B|Part II: (DWP14012 A mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2412458|NCT03487562|Experimental|C|Part II: (Lansoprazole 30 mg + Clarithromycin 500 mg + Amoxicillin 1g) bid
2412460|NCT03487523|Active Comparator|Intervention 1|Text message (SMS Message)
2412461|NCT03487523|Active Comparator|Intervention 2|Text message (SMS Message)
2412462|NCT03487523|No Intervention|Intervention 3|no intervention
2412463|NCT03487510||NO groups|no groups apply.
2412464|NCT03487497||Patients|Patients who underwent lateral column lengthening osteotomy
2412465|NCT03487497||Healthy subjects|Healthy subjects without intervention
2412466|NCT03487484||With protective stoma|Patients in which intraoperatively the decision was made to add a protective stoma (following a risk algorithm) to total mesorectal excision. In patients quality of life, the Gastrointestinal Quality of Life Index (GIQLI) questionnaire, Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied.
2412467|NCT03487484||No stoma|"Patients in which intraoperatively the decision was made to refrain from adding a protective stoma (following a risk algorithm) to total mesorectal excision.~In patients quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index), Quality of Life Questionnaire for gastrointestinal tract and Faecal Incontinence Score will be applied."
2412468|NCT03487471|Active Comparator|Real-time elastography|98 patients with breast lesion will a receive breast ultrasound (real time elastography)
2412469|NCT03487471|Active Comparator|Shear Wave|98 patients with breast lesion will a receive breast ultrasound (shear wave elastography)
2412470|NCT03487458|No Intervention|Control|participants receive no surgical treatment
2412471|NCT03487458|Experimental|Rib Fixation Surgery|participants receive surgical treatment
3145258|NCT00066001|Placebo Comparator|1, 2, 3, 4|The 4 arms of the study are based on the treatment groups: 1. scaling and root planing alone (SRP); 2. SRP plus repeated professional supragingival plaque removal; 3. SRP + systemically administered metronidazole; 4. SRP + repeated professional supragingival plaque removal + systemically administered metronidazole.
3145259|NCT00066014|Active Comparator|treatment modalities changed for comparison|All subjects experienced all treatment modalities being studied.
2412474|NCT03487432|Experimental|OPN NC|Patients receiving a Super High-Pressure NC PTCA Balloon (OPN NC)
2412475|NCT03487432|Experimental|NSE Alpha|Patients receiving a Scoring PTCA Balloon (NSE Alpha)
2412476|NCT03487419||patients develop atrial fibrillation|patients post coronary artery bypass grafting who develop atrial fibrillation post operative
2412477|NCT03487419||patients who not develop atrial fibrillation|patients post coronary artery bypass grafting who don't develop atrial fibrillation post operative
2412478|NCT03487406|Placebo Comparator|Placebo Ticagrelor & placebo Aspirin|Placebo Ticagrelor 90 mg- one tablet, twice daily. Placebo Aspirin 75 mg- one tablet, once a day.
2412479|NCT03487406|Active Comparator|Aspirin & Placebo Ticagrelor|Aspirin 75mg - one tablet, once a day. Placebo Ticagrelor 90 mg- one tablet, twice daily.
2412480|NCT03487406|Active Comparator|Placebo Aspirin & Ticagrelor|Placebo Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
2412481|NCT03487406|Experimental|Aspirin & Ticagrelor|Aspirin 75 mg - one tablet, once a day. Ticagrelor 90 mg- one tablet, twice daily.
2412482|NCT03487393|Experimental|Vitalflow treatment|The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).
2412483|NCT03487380|Experimental|Alzheimer with rapid DCR|
2412484|NCT03487380|Experimental|Alzheimer without rapid DCR|
2412485|NCT03487380|Sham Comparator|Control|
2412486|NCT03487367||Early stage subjects|This cohort is defined by individuals with a total SARA score of less than or equal to 9.5
2412487|NCT03487367||Premanifest mutation carriers|This cohort is defined by the presence of positive genetic diagnosis but no signs of ataxia and total SARA score of less than or equal to 2.5
2412488|NCT03487367||50%-at-risk subjects|This cohort is defined by individuals who are at risk for SCA1 or SCA3 because they have a family member who tested positive for SCA1 or SCA3. Total SARA score is less than or equal to 2.5
3145260|NCT00066027|Experimental|low-dose doxycycline|low-dose doxycycline (20 mg doxycycline hyclate)
2412489|NCT03487367||Previously diagnosed early stage|This cohort is defined by individuals who were included in prior CRC-SCA, EUROSCA, ESMI or SPATAX studies who had a total SARA score of less than or equal to 10 in 2009-2012
2412490|NCT03487354|Active Comparator|Single daily dose|
2412491|NCT03487354|Active Comparator|Multiple daily doses|
2412492|NCT03487341|Active Comparator|Cord drainage|
2412493|NCT03487341|Active Comparator|Cord clamping|
2412494|NCT03487328|Active Comparator|Modified technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
2412495|NCT03487328|Active Comparator|Conventional technique for Sacrospinous-Sacrotuberous Fixation|Modified technique for Sacrospinous-Sacrotuberous Fixation
2412496|NCT03487315|Experimental|specific IgE|Different level of specific IgE and immunoblot
2412497|NCT03487302||cCHD|
2412498|NCT03487302||CONTROLS|
2412499|NCT03487289|Experimental|natural orifice|Patients who underwent laparoscopic surgery and removed the specimen from the natural orifice will be gathered. demographic data and perioperative results will be compiled
2412500|NCT03487289|No Intervention|conventional|patients who underwent laparoscopic surgery and removed specimen with conventional will be gathered. demographic data and perioperative results will be compiled. (conventional extraction is suprapubic or median incision)
2412506|NCT03487263|Experimental|IC14 dose level 1|For the initial 3 patients: intravenous IC14 at a dosage of 2 mg/kg on Study Day 1, then 1 mg/kg once daily on Study Days 3-5 for 4 total doses
2412507|NCT03487263|Experimental|IC14 dose level 2|For the subsequent 7 patients: intravenous IC14 at a dosage of 4 mg/kg/day on Day 1, followed by IC14 2 mg/kg/day on Days 2-4
2412508|NCT03487250||TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
2412509|NCT03487237|Experimental|All patient|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
2412510|NCT03487224||Hoarding Disorder|Adults diagnosed with Hoarding Disorder
2412511|NCT03487224||Healthy Controls|Adults without mental illness
2412512|NCT03487211|Active Comparator|Duloxetine Group|Duloxetine 30mg once daily to be started for 1 week. Dose will then be titrated to 60mg once daily and the patients followed for a total of 12 weeks.
2412513|NCT03487211|Experimental|Escitalopram Group|Escitalopram 10mg once daily to be started for 1 week. Dose will then be titrated to 20mg once daily and the patients followed for a total of 12 weeks.
2412514|NCT03487198|Experimental|Brexpiprazole|2-3 mg/day, once daily for 6 weeks, oral administration
2412515|NCT03487198|Placebo Comparator|Placebo|2-3 mg/day, once daily for 6 weeks, oral administration
2412516|NCT03487185|Experimental|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep advice counseling
2412517|NCT03487185|Other|Sleep Advice Control|Initial sleep advice counseling alone
2412518|NCT03487172|Other|Right Side Treated|Subjects will be randomized to have their right side treated with PLLA and their left side treated with normal saline.
2412519|NCT03487172|Other|Left Side Treated|Subjects will be randomized to have their left side treated with PLLA and their right side treated with normal saline.
2412520|NCT03487159|Other|Liver biopsy ,Elastography and MRE|Performance of routine Liver biopsy,Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
2412521|NCT03487159|Other|Elastography and MRE|Performance of routine Shear Wave Elastography and investigational MRE (Magnetic Resonance Elastography) in order to evaluate liver fibrosis stage.
2412522|NCT03487146|No Intervention|HD(hemodialysis) group|HD group as conventional control arm
2412523|NCT03487146|Active Comparator|HD+HP(hemodialysis+hemoperfusion) group|HD+HP as active interventional group.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.
2412524|NCT03487133|Experimental|bortezomib/dexamethasone|Subjects who have been diagnosed with stable lesions more than 4 cycles of induction therapy (Induction Therapy Part I) will receive additional induction therapy 4 cycles (Induction Therapy Part II) Patients who have been diagnosed with a stable disease response after a total of eight cycles of induction therapy receive up to one year of maintenance therapy.
2412525|NCT03487120|No Intervention|lumbar laminectomy|
2412526|NCT03487120|Active Comparator|lumbar laminectomy with denervation of the facet joint|
2412527|NCT03487107|Experimental|SOF 400 mg+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.
2412528|NCT03487094|Active Comparator|Growth, Tolerance of Infants-Exp|Infant Formula
2412529|NCT03487094|Active Comparator|Growth,Tolerance of Infants-Com|Infant Formula
2412530|NCT03487081|Experimental|Social regulation|Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.
2412531|NCT03487081|Active Comparator|Self regulation|Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.
2412532|NCT03487068|Other|Patients with NAFLD|
2412533|NCT03487055|Experimental|treatment group|The subjects would receive 120 mg TK006 every 4-week over a period of 84 days.
3145261|NCT00066027|Placebo Comparator|Placebo|Placebo
2412670|NCT03486210||Phase 1 Group 1|Healthy volunteers
3145262|NCT00066053|Experimental|Periodontal Treatment: SRP|Comprehensive scaling & root planing and subgingival tissue removal; fluorides applied as appropriate; oral hygiene instructions.
3145263|NCT00066053|Active Comparator|Community Comparator|Referral to community dentist with copy of x-rays and letter with diagnosis and recomendations for treatment.
3145264|NCT00066092|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
2412534|NCT03487042|Experimental|Generalized vitiligo patients|"Each patient with generalized vitiligo will be subjected to the following:~One side will be treated by narrow band ultraviolet rays sessions twice weekly for 3 months + topical bimatoprost 0.03% ophthalmic solution solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% ophthalmic solution twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months."
2412535|NCT03487029|Experimental|short duration group|30sn %100 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
2412536|NCT03487029|Experimental|long duration group|4dk %85 Wmax 120sn %25 Wmax 3 sessions/week total 8 weeks
2412537|NCT03487016|Active Comparator|A: Gemcitabine/nab-Paclitaxel (Standard)|"Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2412538|NCT03487016|Experimental|B: NAPOLI regimen|"On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2412539|NCT03487016|Experimental|C: seq-NAPOLI-FOLFOX|"The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.~NAPOLI:~On Day 1 of a 14-day cycle:~Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~mFOLFOX6:~On Day 1 of a 14-day cycle:~Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)~Treatment is given until disease progression or the occurrence of unacceptable toxicity."
2412540|NCT03487003|Active Comparator|MR group|When the patients asleep, 0.3 mg/kg rocuronium is administered.
2412541|NCT03487003|Experimental|NMR group|When the patients asleep, 0.3 mg/kg saline is administered.
2412551|NCT03486977||Establishments with telemedicine system|Establishments equipped for telemedicine (teleconsultation, casualty) as part of the regional project of the Aquitaine regional program telemedicine device deployment.
2412552|NCT03486977||Establishments without telemedicine system|"Defined and equipped for telemedicine EHPAD after mating on the number of residents, the GMP (average weighted GIR), the PMP (weighted average PATHOS), the distance to a hospital with an emergency shelter service.~The rate of unscheduled hospitalizations will be collected during follow-up visits in clinical departments of the healthcare of the Gironde by a research staff"
2412553|NCT03486964||DPP-4 plus other therapies|Patients in therapy with DPP-4 inhibitors in addition to sulfonylureas and/or biguanides and/or thiazolidinediones and/or insulin
2412554|NCT03486964||Other therapies|Patients in therapy with other hypoglycemic classes, such as sulphonylureas and/or biguanides and/or thiazolidinediones and/or insulin.
2412555|NCT03486938|Placebo Comparator|Placebo Oral Tablet|Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
2412556|NCT03486938|Experimental|AGB101 220 mg tablet|Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
2412557|NCT03486925|Experimental|oxytocin group|
2412558|NCT03486925|Placebo Comparator|placebo group|
2412559|NCT03486912|Experimental|BMS-986036 Dose Level 1|
2412560|NCT03486912|Experimental|BMS-986036 Dose Level 2|
2412561|NCT03486912|Experimental|BMS-986036 Dose Level 3|
2412562|NCT03486912|Placebo Comparator|Placebo|
2412563|NCT03486899|Experimental|BMS-986036 Dose Level 1|Administered by subcutaneous injection.
2412564|NCT03486899|Experimental|BMS-986036 Dose Level 2|Administered by subcutaneous injection.
2412565|NCT03486899|Experimental|BMS-986036 Dose Level 3|Administered by subcutaneous injection.
2412566|NCT03486899|Placebo Comparator|Placebo|Administered by subcutaneous injection.
2412567|NCT03486886|Experimental|PSMA -PET/CT scanning|
3145265|NCT00066092|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
3145266|NCT00066092|Active Comparator|filgrastim|Filgrastim given daily for PBPC mobilization
3145267|NCT00066131|Active Comparator|Scaling and root planing|Scaling and root planing delivered prior to 21 weeks of gestation.
2412671|NCT03486210||Phase 1 Group 2|Health professionals
2412672|NCT03486210||Phase 2 Group 1|Control group : patients obese without surgery
3145268|NCT00066131|No Intervention|Placebo|Delayed treatment group. Controls monitored clinically from baseline to 29-32 weeks of gestation. Scaling and root planing provided after delivery.
3145269|NCT00066157|Experimental|1|estradiol patch and medroxyprogesterone
3145270|NCT00066157|Active Comparator|2|estradiol patch and placebo pill
3145271|NCT00066157|Active Comparator|3|placebo patch and medroxyprogesterone
3145272|NCT00066157|Placebo Comparator|4|placebo patch and placebo pill
3145273|NCT00066196|Other|2|Integrin + Dacarbazine
3145274|NCT00066196|Active Comparator|1|MEDI-522
3145275|NCT00066248|Experimental|Subjects that respond to Periactin|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
3145276|NCT00066248|Experimental|Non-responders to Periactin- Megace Arm|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
3145277|NCT00066378|Experimental|Arimidex + Iressa® 250 mg|Arimidex + Iressa® 250 mg Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
3145278|NCT00066378|Active Comparator|Arimidex + Placebo|Treatment should be administered until documented disease progression, unacceptable toxicity as judged by the responsible physician or patient refusal
3145279|NCT00066430|Experimental|Infrared coagulator|
3145280|NCT00066443|Experimental|Pegfilgrastim, docetaxel and epirubicin|
3145281|NCT00066456|Experimental|Treatment (chemosensitization, radiation, docetaxel)|Patients receive docetaxel IV over 30 minutes once daily on days 1, 8, 15, 22, 29, and 35. Within 3 hours after beginning docetaxel, patients also receive low-dose abdominal radiotherapy twice daily (at least 4 hours apart) on days 1, 2, 8, 9, 15, 16, 22, 24, 29, 30, 35, and 36. Treatment continues in the absence of unacceptable toxicity.
2412573|NCT03486860|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
2412574|NCT03486860|Other|Waitlist Control|Untreated comparison group during the study, received parent psychoeducation intervention after the active treatment group.
2412575|NCT03486847|Experimental|Repetitive recruitment with PEEP|One alveolar recruitment at before surgery and repetitive alveolar recruitment (once an hour) during surgery
2412576|NCT03486847|Active Comparator|One recruitment with PEEP|One alveolar recruitment at before surgery
3185623|NCT00736931|Experimental|1|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3185624|NCT00736931|Active Comparator|2|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3185625|NCT00736931|Active Comparator|3|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
2412580|NCT03486821|Experimental|Hypofrac Radiation Therapy|"All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.~Radiation treatment will start approximately 1-2 weeks after the simulation scan. Prior to each treatment, you will be asked to have a full bladder and empty rectum. You will be asked to take a liquid diet starting the afternoon prior to each treatment, and a laxative (such as Miralax) in the evening prior to each treatment. You will also be asked to take a Fleet's enema about 1 hours prior to the treatment time to ensure that the rectum is empty. To ensure full bladder, you will be asked to drink about 32 oz of water after the enema. This is the same procedure as above for the prep before the simulation scan.~Each treatment should take about 10-20 minutes."
2412581|NCT03486808|Experimental|Dual stimulation|i) anodal stimulation of left inferior frontal cortex ii) anodal stimulation on left dorsolateral prefrontal cortex
2412582|NCT03486808|Active Comparator|IFG stimulation|anodal stimulation of left inferior frontal cortex
2412583|NCT03486808|Active Comparator|DLPFC stimulation|anodal stimulation on left dorsolateral prefrontal cortex
2412584|NCT03486808|Sham Comparator|Sham stimulation|sham stimulation
2412585|NCT03486795|Experimental|Dual stimulation|"anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex~anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area"
2412586|NCT03486795|Experimental|M1 stimulation|anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
2412587|NCT03486795|Experimental|PMC stimulation|anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
2412588|NCT03486795|Sham Comparator|Sham stimulation|Sham stimulation
2412589|NCT03486782|Active Comparator|Dual stimulation|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area ii) anodal stimulation on ipsilesional dorsolateral prefrontal cortex and cathodal stimulation of contralesional supraorbital area
2412590|NCT03486782|Active Comparator|Single stimulation 1|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional inferior frontal cortex
2412591|NCT03486782|Active Comparator|Single stimulation 2|i) anodal stimulation of ipsilesional inferior frontal cortex and cathodal stimulation of contralesional supraorbital area
2412592|NCT03486769|Experimental|Dual Stimulation 1|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional premotor cortex and cathodal stimulation on contralesional supraorbital area.
2412593|NCT03486769|Experimental|Dual Stimulation 2|i) anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex, ii) anodal stimulation on ipsilesional anterior intraparietal sulcus and cathodal stimulation on contralesional supraorbital area.
2412594|NCT03486769|Experimental|Single stimulation|anodal stimulation on ipsilesional primary motor cortex and cathodal stimulation on contralesional primary motor cortex
2412595|NCT03486756|Experimental|Internet-CBT|Internet-CBT for anxiety-related asthma 8 weekly modules of CBT delivered over the internet and targeting enhanced function and decreased symptoms of anxiety. Participants work independently from home with the treatment and receive support from experienced Internet-CBT Psychologists through written messages in the secure platform.
2412596|NCT03486743|Experimental|Intervention arm|Participants in the intervention arm will be asked to watch a short educational video on LARC (Long acting reversible contraceptive) and to complete a survey before and after watching the video.
2412597|NCT03486743|No Intervention|Control arm|Participants in the intervention arm will only be asked to complete a survey.
2412598|NCT03486730|Experimental|Dose escalation phase|Groups of patients will receive increasing doses of BT1718 to find a safe dose that best targets the cancer cells. In this phase it is expected that approximately 50-60 patients with advanced solid tumours will be entered in the study.
2412599|NCT03486730|Experimental|Dose expansion phase|Larger groups of patients will receive the selected dose of BT1718 to allow us to find out more about how the drug is working. In this phase it is proposed that up to 70 patients with tumour types known to commonly overexpress MT1-MMP and where MT1-MMP overexpression is confirmed during prospective selection at enrolment (i.e. squamous non-small cell lung cancer) will be entered in the study.
2412600|NCT03486717|Experimental|Control|Study group that does not wear the virtual reality goggles. This group will serve as a control.
3185626|NCT00736931|Placebo Comparator|4|4 arms (in cross-over): brivaracetam, levetiracetam, lorazepam and placebo.
3185627|NCT00736970|Experimental|1|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus
3185628|NCT00736983|Active Comparator|1|Adalimumab
2412601|NCT03486704|Experimental|Face to Face VRRS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
2412602|NCT03486704|Active Comparator|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
2412603|NCT03486704|Active Comparator|FTF VRRS plus unstructured CS|Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week.
2412604|NCT03486704|Experimental|Face to Face VRRS plus active tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
2412605|NCT03486704|Active Comparator|Face to Face VRRS plus placebo tDCS and telerehabilitation|Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS combined with placebo tDCS applied to the dorsolateral prefrontal cortex of the left hemisphere over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.
2412606|NCT03486691|Experimental|preoperative left lobe measurement|routine preoperative left lobe measurement
2412607|NCT03486691|Active Comparator|Control group|Control group without routine measurement of left lobe
3185629|NCT00736983|Placebo Comparator|2|ciprofloxacin
2412609|NCT03486665||Diagnosed with Multiple Sclerosis|Patients previously diagnosed with Multiple Sclerosis
2412610|NCT03486665||Newly Diagnosed with Multiple Sclerosis|Patients diagnosed for the first time with Multiple Sclerosis and hospitalized
2412611|NCT03486665||Healthy Volunteers|Health volunteers who do not have an autoimmune diseases, including Multiple Sclerosis
2412612|NCT03486639||Patients undergoing urodynamic|All patients older than 18 who are refered for Urodynamics examination
2412613|NCT03486626|Experimental|Patients|
2412614|NCT03486613|Other|Group AT|PROM registration via the DANBIO App on a smartphone and thereafter the touch screen solution
2412615|NCT03486613|Other|Group TA|PROM registration via the touch screen solution and thereafter the DANBIO App
2412616|NCT03486600|Other|fluid resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
2412617|NCT03486587|Experimental|Changfukang® group|Patients in Changfukang group will receive Changfukang® (Bacillus Cereus tablets).
2412618|NCT03486574||Gastric cancer|Pathologically proven diseases after upper gastroendoscopy and biopsy. Previous pathological reports and endoscopic image can be used.
2412619|NCT03486574||non-gastric cnacer|Rull out gastric cancer by upper gastroendoscopy. The results 3 moths before enrollment is available.
2412620|NCT03486561|Other|Ranolazine|Ranolazine was approved by the U.S. Food and Drug Administration in 2006 in 500 mg and 1000 mg extended-release doses, advising 500 mg BID as a starting dose and 1000 mg BID as maximum dose
2412621|NCT03486548|Sham Comparator|control group|adductor canal block with sham block
2412622|NCT03486548|Experimental|sciatic group|adductor canal block with popliteal sciatic nerve block
2412623|NCT03486535||Diabetic patients|Diabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
2412624|NCT03486535||Non-diabetic patients|Nondiabetic patients will receive ultrasound-guided infraclavicular brachial plexus blocks (ICBs) with the mixture of 15 mL lidocaine 2% and 15 mL bupivacaine 0.5%.
2412625|NCT03486509|Experimental|afatinib 40mg bid plus chemotherapy|afatinib 40mg bid po plus chemotherapy
2412626|NCT03486496|Experimental|Gefitinib and Berberine|Experimental: Gefitinib and Berberine Patients will be treated with Gefitinib and Berberine. Gefitinib: 250 mg p.o., daily. Berberine: 50 mg p.o., tid.
2412627|NCT03486483|Experimental|Supervised Slackline Training|Supervised Slackline training in children and teenagers with spastic cerebral palsy (grade I and II of the Gross Motor Function Classification System). Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
2412628|NCT03486483|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine.
2412629|NCT03486457|Experimental|Treatment Sequence A|Tofacitinib 5 mg BID for 6 months
2412630|NCT03486457|Placebo Comparator|Treatment Sequence B|Placebo for 3 months then tofacitinib 5 mg BID for 3 months
2412631|NCT03486444|Experimental|Patient population|When a patient receives an ultrasound examination as part of standard of care or within another clinical research trial, such an examination may serve for an intra-individual comparator examination between conventional and new, ultra-portable ultrasound imaging. Patients will be identified in the clinical setting when appropriate and will be appropriately approached for consent for a combination of ultrasound with the physical exam, for medical student education, IV access, and novel application. Patients will be enrolled and accounted for in the appropriate sub-population.
2412632|NCT03486444|Experimental|Healthy volunteer population|The volunteer population will allow us to practice the use of this equipment and understand the limitations and applicability. The results will be the images acquired as well as surveys from the volunteers and those performing the scans, who will be enrolled in the staff population of this study.
2412633|NCT03486444|Experimental|Student and staff population|To understand the impact of ultraportable ultrasound, survey tools will be used to understand the workflow and clinical care applications and integration of these devices. All staff and student members will be appropriately consented; however, we anticipate that this portion of the study will be minimal risk.
2412634|NCT03486431|Experimental|Level I|5 x 7 Gy SABR
2412635|NCT03486431|Experimental|Level II|3 x 10 Gy SABR
2412636|NCT03486431|Experimental|Level III|1 x 20 Gy SABR
2412673|NCT03486210||Phase 2 Group 2|Patients who have underwent a sleeve gastrectomy
2412674|NCT03486210||Phase 2 Group 3|Patients who have underwent a gastric bypass
2412637|NCT03486405|Experimental|Intervention group|The experimental group will have no in person education by researchers. All education and running modification will be performed via video. Education on running form, a home exercise program, and a 4 week return to run program will be provided to the subjects through e-mail. They will also receive the same in person video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
2412638|NCT03486405|Active Comparator|Control group|This group will have the same 4 week return to run program, home exercise program, and video analysis performed at weeks 0 (initial), 10 and 6 months to assess running kinematics.
2412644|NCT03486366|Other|Workpackage1 WP1|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach 1998), aged up to 4 years, diagnosis of epilepsy established on the basis of clinical seizures or epileptiform changes on EEG within 1-7 days prior to baseline. We plan to enroll 60 TSC patients into WP1 to Epimarker in 12 months.
2412645|NCT03486366|Other|Workpackage2 WP2|Non interventional trial: male or female children with a definite diagnosis of TSC (Roach criteria: Roach 1998) and epilepsy, aged up to 16 years, seizure free, in whom a decision to withdraw antiepileptic drugs was made. We plan to enroll 60 TSC patients into WP2 to Epimarker in 12 months. The data obtained in children seizure free at the end of follow-up and patients with recurrent seizures will be compare.
2412646|NCT03486353|Experimental|Run-In Phase, Regimen 1|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 twice daily (BID) for 14 days plus azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days. One treatment cycle will be 28 days in duration.
2412647|NCT03486353|Experimental|Run-In Phase, Regimen 2|Patients will be treated with FF-10501-01 at a dose of 400 mg/m2 BID for 21 days plus azacitidine at a dose of 75 mg/m2 either SC or IV x 7 days every 28 days.
2412648|NCT03486340|Experimental|Cardiological assessment|a sub-acute cardiologic assessment and aggressive management of risk factors before oncologic treatment
2412649|NCT03486340|No Intervention|Standard treatment|Standard chemotherapeutic treatment
2412650|NCT03486327|Experimental|0.03mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.03mL/kg.
2412651|NCT03486327|Experimental|0.05mL/kg Dose Group|A group of up to 8 subjects to receive a single dose of BR55 at 0.05mL/kg.
2412652|NCT03486327|Experimental|0.08mL/kg Dose Group|A group of 8 subjects to receive a single dose of BR55 at 0.08mL/kg.
2412653|NCT03486314|Experimental|Part A: Pevonedistat 50 mg/m^2 + Rifampin 600 mg|Pevonedistat 50 milligram per square meter (mg/m^2), intravenous infusion, once on Day 1 and 10 along with rifampin 600 milligram (mg), capsule, orally, once daily from Day 3 up to Day 11 in Part A. After completion of Part A, participants had opportunity to continue into optional Part B.
2412654|NCT03486314|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 intravenously in combination with docetaxel 75 mg/m^2 or at 20 mg/m^2 in combination with carboplatin +paclitaxel 175 mg/m^2; pevonedistat was given in combination on Day 1 and as a single agent on Days 3 and 5 of each 21-day cycle. Participants were treated for up to 12 cycles or symptomatic deterioration or PD, treatment was discontinued for another reason, or until the study is stopped in Part B. The choice of combination partner (docetaxel or carboplatin + paclitaxel) was based on investigator discretion. If the sponsor and investigator determine that a participant would derive clinical benefit from continued treatment, the participant may remain on the current combination therapy or receive pevonedistat as a single agent beyond 12 cycles.
3145282|NCT00066482|Experimental|combination chemotherapy|"Induction therapy: bleomycin sulfate IV over 10-20 minutes on day 1, etoposide IV over 1 hour and cisplatin IV over 4 hours on days 1-5, and cyclophosphamide IV over 1 hour on day 1. MESNA & Filgrastim (G-CSF) subcutaneously once daily beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. 6 patients receive escalating doses of cyclophosphamide until the maximum tolerated dose (MTD) is determined.~Evaluated after 4 courses of therapy. Partial response or stable disease undergo second-look conventional surgery & receive 2 more courses of induction therapy then re-evaluated. Those who do not achieve complete response (CR) after a total of 6 courses may undergo a third conventional surgery. Tumor that cannot be removed are removed from study therapy. Achievement of a CR at anytime are followed monthly for 1 year, every 6 months for 1 year, and then annually for 3 years."
3145283|NCT00066586|Active Comparator|Exemestane|
2412657|NCT03486288||Delirium|
2412658|NCT03486288||No Delirium|
2412659|NCT03486275|Active Comparator|Hygie game|Prototype video game called Hygie on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
2412660|NCT03486275|Active Comparator|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva)
2412661|NCT03486262||Lung carcinoma on IPF|Lung carcinoma on IPF
2412662|NCT03486249|Experimental|Patient difficult to wean|Repetition of medical examinations performed as part of the care. All patients will have a cardiac echo examination and diaphragm function assessment before the spontaneous breathing trial.
2412663|NCT03486236|Experimental|Cohort C1|
2412664|NCT03486236|Placebo Comparator|Cohort C1: Triple Placebo|
2412665|NCT03486236|Experimental|Cohort C2|
2412666|NCT03486236|Placebo Comparator|Cohort C2: Triple Placebo|
3145284|NCT00066586|Placebo Comparator|Placebo|
3145285|NCT00066612|Experimental|Treatment|Irinotecan
3145286|NCT00066625|Experimental|Treatment (oxaliplatin, bortezomib)|"Patients receive oxaliplatin IV over 2 hours on days 1 and 15 and bortezomib IV over 3-5 seconds on days 1, 4, 15, and 18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of oxaliplatin and bortezomib until the MTDs are determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3145287|NCT00066638|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a stable plateau (stable paraprotein levels or urine protein excretion over 3 consecutive determinations at least 4 weeks apart) may receive maintenance therapy comprising FR901228 IV on days 1 and 15, with courses repeating every 28 days.
2412676|NCT03486158|Experimental|CalproSmart application|In addition to regular outpatient clinic visits and a routine CalproSmart test every 3 months, patients are instructed to obtain fecal samples if they experience symptoms suspect of recurrent IBD and to perform home analysis with CalproSmart™ system test kit
2412677|NCT03486158|No Intervention|Standard follow-up|In addition to regular outpatient clinic visits and a routine calprotectin test in the same week as the visit date, patients bring home an Fecal-calprotectin tube and envelope and are instructed to obtain fecal samples and send these to local lab if they experience symptoms suspect of recurrent IBD
2412678|NCT03486145|Experimental|FVS (fruit and vegetable juice supplement)|The supplement contained ≈ 260-280 mg or 4 mmoles nitrate per two-ounce serving along with ≈ 51 mg total polyphenols. The FVS contains 7880 mg of a proprietary blend of beet root extract (Beta vulgaris), celery stem and leaf extract (Apium graveolens), red spinach leaf extract (Amaranthus dubius), stevia leaf extract (Stevia rebaudiana), and a fruit and vegetable extract blend (green tea leaf, red grape, white grape, bilberry, carrot, grapefruit, papaya, pineapple, strawberry, apple, apricot, cherry, orange, broccoli, green cabbage leaf, onion, garlic, black current, asparagus, tomato, olive and cucumber). Virtually all of the nitrates in FVS derive from the beet, celery, and red spinach extracts.
2412679|NCT03486145|Placebo Comparator|PRU (prune juice)|The placebo supplement was prune juice (Sunsweet brand 100% prune juice) (PRU). Prune juice was selected based on its very similar caloric and sugar content, its high antioxidant and phenolic profile, but low nitrate content. The prune juice contained <0.6 mg nitrates and 133 mg total polyphenols per two-ounce serving.
2412680|NCT03486132|Other|interrupted repair of mediolateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut"
2412681|NCT03486132|Other|continous repair of mediolateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants Mediolateral episiotomy:it is defined as an incision beginning in the midline and directed laterally and downwards away from the rectum .The incision is usually about four centimeters long. In addition to the skin and subcutaneous tissues the bulbocavernosus, transverse perineal, and puborectalis muscles will be cut The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
2412682|NCT03486132|Other|interrupted repair of lateral episiotomy|"using the interrupted suture (IT) which involves placing three layers of sutures: a continuous non-locking stitch to close the vaginal epithelium. commencing above the apex of the wound and finishing at the level of the fourchette; three or four interrupted sutures to reapproximate the deep and superficial perineal muscles; and interrupted transcutaneous technique to close the skin.~The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0 And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity"
2412683|NCT03486132|Other|continuous repair of lateral episiotomy|continuous knotless suturing technique (CKT) which involves placing the first stitch above the apex of vaginal trauma to secure any bleeding points that might not be visible. Vaginal wound, perineal muscles (deep and superficial), and skin are reapproximated with a loose, continuous, non-locking technique. The skin sutures will be placed closely fairly deeply in the subcutaneous tissue, reversing back and finishing with a terminal knot placed in the vagina beyond the hymeneal remnants And Lateral episiotomy; It begins in the vaginal introitus 1 or 2 cm lateral to the midline and is directe downwards towards the ischial tuberosity The standard suture material in the study will be EGYSORB (sterile coated synthetic polyglycolic acid absorbable braided suture) No 2/0
2412684|NCT03486106|Placebo Comparator|Headphones without music|Participants in the control group will receive noise-cancelling wireless headphones that will not play any noise throughout the procedure. They will also receive propofol for sedation as needed.
2412685|NCT03486106|Experimental|Headphones with music|Participants in the experimental group will receive the same noise-cancelling wireless headphones but will be permitted to listen to the music of their choice while in the operating room. They will also receive propofol for sedation as needed.
2412686|NCT03486093|Experimental|CVC managed by healthcare workers|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations.
2412687|NCT03486093|Experimental|CVC managed by healthcare workers plus port protector|Patients with CVC managed by healthcare workers trained/retrained to GAVECELT recommendations with the aid of port protector devices.
2412688|NCT03486080|Active Comparator|Dutogliptin/filgrastim combination|Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days
2412689|NCT03486080|Placebo Comparator|Placebo control|Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days
3145288|NCT00066768|Experimental|Arm I|Patients receive low-dose suramin IV over 30 minutes and docetaxel IV over 1 hour on day 1.
2412691|NCT03486054|Experimental|Experimental Arm A|Whole blood treated with amustaline and glutathione, a pathogen reduction technology (PRT), ordered and administered to study patients by their treating physicians
2412692|NCT03486054|Active Comparator|Control Arm B|Standard of Care (either red blood cells or whole blood)
2412693|NCT03486041|Experimental|immediate ComB|12 weekly sessions of ComB treatment in individual therapy, following a detailed manual.
2412694|NCT03486041|Placebo Comparator|Minimal Attention Control|Weekly brief phone call from therapist to check on participant safety, medication changes if any, and recent stressors. After week 12, participants in this arm received delayed ComB [as in the Experimental condition -- 12 weekly sessions of individual therapy for TTM based on ComB model].
2412695|NCT03486028||ASAM Counties/non-computerized|Pre- and 1115-waived counties that are implementing the ASAM. Intervention is adherence to ASAM protocols.
2412696|NCT03486028||ASAM Counties/computerized|Counties using a computerized system to assist in intervention determination according to ASAM protocols. Intervention is adherence to ASAM protocols.
2412697|NCT03486028||Non-ASAM Counties|"Pre- and non-waived control counties that are not implementing the ASAM. Intervention is non-adherence to ASAM protocols."
2412698|NCT03486015|Experimental|30% glucose|This group will be given 2 ml of 30% glucose in the mouth before the physical examination of the infant.
2412699|NCT03486015|Placebo Comparator|Sterile water|This group will be given 2 ml of sterile water in the mouth before the physical examination of the infant.
2412700|NCT03486002|Other|Cleansweep closed suction system|
2412701|NCT03486002|Other|Halyard closed suction system|
2412702|NCT03485989|Experimental|Hazelnuts|Participants given 2 ounces (~57 grams) of dry roasted hazelnuts to consume each day.
3185630|NCT00737035|Experimental|1-Intervention|For 16 weeks, participants will have access to an interactive healthcare communication application (IHCA).
2412704|NCT03485963|Experimental|Fixed dose HIV-1 specific T-cells (HST-NEETs)|Patients will be screened for eligibility in Step 1 and undergo a blood draw of 100-120mL to allow production of autologous HST-NEETS. patients will receive a fixed dose of 2x10e7/m2. For the first 3 recipients, the infusions will occur 4 weeks apart. If no adverse reactions occur that are attributable to the HST-NEETs, the recipients thereafter will receive the two infusions separated by 2 weeks.
3185631|NCT00737035|Active Comparator|2- Control|For 16 weeks, participants will have access to generally available Internet-based information about parenting, trauma, and child development.
3185632|NCT00737087|Other|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
2412707|NCT03485937|Experimental|Pre-Operative Videos + verbal/written instructions|This video contains the same instructions that the patient receives when they arrive at the clinic, as well as a video walk through of the clinic/patient room. Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions.
2412708|NCT03485937|Active Comparator|verbal/written instructions|This arm will receive the standard-of-care verbal/written instructions and the pre-operative video explanation. These instructions contain the same content as in the pre-operative videos
3185633|NCT00737126|Placebo Comparator|1|Administration of an oral placebo pill
3185634|NCT00737126|Experimental|2|Administration of oral folic acid
3185635|NCT00737139|Active Comparator|1|Intra-articular Injection of Marcaine/Epinephrine
2412714|NCT03485885||Maqui Berry Extract (MBE)|To be tested for the extracts bioavailability
2412715|NCT03485872|Experimental|Self-Screening and Referral Information|The intervention will include a combination of self-screening and UI specific information and resources. Older adults in the intervention group will complete a gender specific UI Self-Screening tool. Men will complete the International Consultation on Incontinence Modular Questionnaire (ICIQ) for Males and women will complete the ICIQ for Females. In addition, the intervention group will receive a fact sheet with UI specific information, contact information to the local incontinence clinic and a link to a website with patient incontinence resources and education.
2412716|NCT03485872|Active Comparator|Control Group|Older adults assigned to the control group will receive standard care from their physicians. Standard care may differ from general practitioner to general practitioner. Usual care for urinary incontinence (UI) from general practitioners is generally minimal. Most patients do not tell their physicians about UI, and most physicians do not ask about UI. If this topic does come up during a GP appointment, a patient may be offered no treatment, lifestyle advice (e.g., do not drink before bed), told to do Kegels (but likely not instructed how to do these properly) or in some cases, offered pharmacological therapies (which will be captured in our questionnaire with the participants). But standard of care is unfortunately very often no care.
2412717|NCT03485859|Experimental|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
3185636|NCT00737139|Active Comparator|2|Intra-articular Injection of Marcaine alone
3185637|NCT00737152|Experimental|1|All subjects will take RAS 130 administered orally in tablet form at a starting dose of 4 mg once a day or 2 mg tablets twice a day.
3185638|NCT00737165|Experimental|Multimodal community intervention|Multimodal suicide prevention program
2412718|NCT03485859|Placebo Comparator|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
2412719|NCT03485846|Experimental|Narlaprevir + Ritonavir + Daclatasvir|All of enrolled patients receive equal study therapy with Narlaprevir/Ritonavir/Daclatasvir daily for 12 weeks
2412720|NCT03485833|Experimental|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography during end expiratory and end inspiratory occlusion test to predict volume responsiveness.Responders are defined by an increase in velocity time integral over 15% after infusion of 5ml/kg of crystalloid solution.
2412721|NCT03485820|Experimental|COMPASS|COMPASS is a complex intervention that combines 2 evidence-based treatment strategies at a new point of care (transition from inpatient rehabilitation). The objective of home visits by an occupational therapy (OT) practitioner is to remediate barriers in the home and community that influence daily activities and community participation. The treatment will include a set of 1 predischarge and four 75-minute postdischarge visits. The intervention is followed by 2 booster sessions.
2412722|NCT03485820|Sham Comparator|Education program|"An OT practitioner will deliver the program in accordance with Evidence-Based Educational Guidelines for Stroke Survivors after Discharge Home. Topic order is determined by participants. Four 75-minute sessions will be provided. Topics may include stroke symptoms, risk factors and preventing stroke recurrence, nutrition, managing emotions, sleep, pain. Written materials from the National Stroke Association and the American Stroke Association are provided."
2412723|NCT03485807|Experimental|Mindfulness Training (MT)|
2412724|NCT03485807|Experimental|Active Coping Training (CT)|
3185639|NCT00737165|Active Comparator|Community intervention as usual|Suicide prevention program as usual
2412726|NCT03485768|Experimental|percutaneous disc decompression with coblation nucleoplasty|PDCN will be performed in patients who are allocated to this group by using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA)
2412727|NCT03485768|Active Comparator|Manual Therapy|Participants who are allocated to this group will undergo manual therapy treatments containing two kinds: sustained natural apophyseal glides (SNAGs) plus passive joint mobilisations (PJMs)
2412728|NCT03485755||Children|Children 8-10 years of age
2412729|NCT03485755||Biological Mothers|Biological mothers of children now ages 8-10 years of age
2412730|NCT03485729|Experimental|Biopsy-mandated|
2412731|NCT03485729|Experimental|Biopsy-optional|
2412732|NCT03485729|Experimental|Dosing twice per week on two consecutive days|
2412733|NCT03485716|Experimental|running under hypoxia - first|running under hypoxia (first day) and normoxia (second day)
2412734|NCT03485716|Active Comparator|running under normoxia - first|running under normoxia (first day) and hypoxia (second day)
2412735|NCT03485703|Experimental|azithromycin group|A control group composed of 40 newborns receiving azithromycin
2412736|NCT03485703|Placebo Comparator|placebo group|comparative group composed of 40 newborns who would receive saline 0.9%
2412737|NCT03485690||COPD|COPD patients with no restrictions. The study protocol does not consider ad-hoc different patient groups. Prospective follow-up will be equally done in all recruited patients
2412738|NCT03485677|Experimental|Cohort 1: Eliglustat monotherapy|"Eliglustat for at least two years. Cohort 1 patients that experience significant clinical decline will receive rescue treatment.~Rescue Treatment Step 1: Switch from eliglustat to imiglucerase monotherapy.~Rescue Treatment Step 2: Patients who after 6 months of rescue therapy with imiglucerase monotherapy do not show improvement in the parameter(s) that led to the switch from eliglustat to imiglucerase, will then receive combination therapy with eliglustat + imiglucerase."
2412739|NCT03485677|Experimental|Cohort 2: Eliglustat plus imiglucerase|Eliglustat plus imiglucerase for two years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
2412740|NCT03485664||Study Group|Severe pain on percussion of the relevant tooth was considered as basic criteria when deciding on acute infection phase. The acutely infected teeth were labelled as the study group
2412741|NCT03485664||Control Group|The asymptomatic teeth were labelled as the control group
2412742|NCT03485638||Cetuximab administration|
2412743|NCT03485625|Experimental|Lidocaine|Patients in group C will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
2412744|NCT03485625|Experimental|Lidocaine+ Ketorolac|Patients in group K receive 3 mg/kg of lidocaine 2% + 20 mg ketorolac diluted with saline to a total volume of 40 ml.
2412745|NCT03485625|Experimental|Lidocaine+Paracetamol|Patients in group P will receive 3 mg/kg of lidocaine 2% + 300 mg paracetamol diluted with saline to a total volume of 40 ml.
2412746|NCT03485612||change of the optic nerve sheath diameter|The test group will be male and female patients, aged over 18 and below 90 years of age. Each patient will be operated for urological reasons in the position for lithotomy.
2412747|NCT03485599||HIV infected people|Blood samples will be taken and rapid HIV test by ELIZA will be done ,for positive cases Westron blot done
2412748|NCT03485586||Group:Traditional ultrasonic biological|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use traditional ultrasonic biological combined with cornea curvimeter to measure the ocular parameter.
2412749|NCT03485586||Group:Lenstar|The measurement of axial length was performed in 60 eyes (30 eyes for each group) with senile cataract of vitrectomised eye of diabetic retinopathy using lenstar and traditional ultrasonic biological combined with cornea curvimeter.In this group,we use lenstar to measure the ocular parameter.
2412750|NCT03485560|Experimental|internvention of Chrinic skin conditions|All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
2412751|NCT03485547|Experimental|Venetoclax|"Venetoclax is administered on a daily basis orally.~The investigators will use a modified 3+3 with a de-escalation dose level design to establish the appropriate and tolerable dose of venetoclax."
2412752|NCT03485534|Experimental|Tenofovir Disoproxil|Tenofovir Disoproxil 245mg, a daily dose for 48 weeks
2412753|NCT03485534|Placebo Comparator|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300mg, a daily dose for 48 weeks
2412754|NCT03485521|Active Comparator|Practical Work|15 students who participate in a practical work lasting two hours about the procedures of the tracheobronchial aspiration
2412755|NCT03485521|Experimental|Stimulation Group|Group with competences and reasoning clinic 15 students Simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence after reading the procedures of the tracheobronchial aspiration
3185640|NCT00737191|Active Comparator|Arm I|Patients receive oral opioid and oral placebo once daily for 4 weeks.
3185641|NCT00737191|Experimental|Arm II|Patients receive oral opioid and 2.5 mg oral olanzapine once daily for 4 weeks.
2412758|NCT03485482|Experimental|Group Ivabradine|six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
2412759|NCT03485482|Experimental|Group Bisoprolol|six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
2412760|NCT03485482|Experimental|Group combination|six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
2412761|NCT03485469|Other|Usual Care|The control group will benefit from a standard care dietary consultation in the service and 9 dietary consultations by phone every 15 days.
2412762|NCT03485469|Other|Hypnosis|The experimental group will benefit from a dietary consultation in the service, 9 dietary consultations by telephone every 15 days to which will be associated 7 individual sessions of hypnosis and 3 individual sessions of learning to autohypnosis. A recording containing the induction of a self-hypnosis session will be given to the subject at the end of the 10 sessions, in order to promote the continuation of home-made autohypnosis.
2412763|NCT03485456|Experimental|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
2412764|NCT03485443|Active Comparator|Group I (%0.9 NaCl 10ml/kg)|"The group (Group 1) received 10 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
2412765|NCT03485443|Active Comparator|Group II (%0.9 NaCl 20ml/kg)|"The group (Group 2) received 30 ml kg-1 throughout the entire surgical procedure.~Four point scale using scored vomiting. m CHEOPS Scale using scored between 0-10."
2412766|NCT03485430|Active Comparator|Intervention|Receives tapering of opioid dose at baseline
2412767|NCT03485430|No Intervention|Control|Waiting-list. Receives tapering after 4 months.
2412768|NCT03485417|Active Comparator|Aripiprazole Arm|Aripiprazole (oral or depot) Oral: 10-30mg daily Depot: 300-400mg every four week; Intramuscularly
2412769|NCT03485417|Active Comparator|Paliperidone Arm|Paliperidone (oral or depot) Oral: 3-12mg Depot: Intramuscularly; a) sustenna 50-150mg every four weekly, or b) trinza 273-819mg every 12 weekly
2412770|NCT03485417|Other|Treatment as Usual Arm|Treatment as Usual arm
2412771|NCT03485404|Experimental|VB12+FA|Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
2412772|NCT03485404|Placebo Comparator|Placebo|Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
2412773|NCT03485404|Other|Non-surgical controls|Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.
2412774|NCT03485391|Experimental|PE+Exposure Workout Buddy|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to meet patients at exposure sites in the community to offer support during exposure.
2412775|NCT03485391|Active Comparator|PE+Peer General Support|Prolonged Exposure with assistance of Veteran who has successfully completed treatment to call and talk to patients once per week, informally meet at patient appointments, encourage session attendance and check in about progress.
3145289|NCT00066768|Experimental|Arm II|Patients receive low-dose suramin IV over 30 minutes and gemcitabine IV over 30 minutes on days 1 and 8.
3145290|NCT00066859|Active Comparator|Arm 1: Sertraline (Zoloft) 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
3145291|NCT00066859|Active Comparator|Arm 2 - St. John's Wort 600mg|St. John's wort 600 mg daily for 1 week. If tolerated dose may be increased to 900 mg daily for four months.
3145292|NCT00066950|No Intervention|Counseling Only|Oral Health Counseling Only
3145293|NCT00066950|Experimental|CHX+Counseling (caregiver) + FV (child)|Oral Health Counseling plus Chlorhexidine for caregiver plus fluoride varnish every 6 months from 12mo to 30mo of age for child
3145294|NCT00067015|Experimental|IMRT alone to 86.4 Gy|External radiotherapy is given for 10 weeks, Monday through Friday for a total of 48 sessions. The total dose of radiotherapy delivered during these 10 weeks is 86.4 Gy. The radiation treatments are delivered with a high precision technique called intensity modulated radiotherapy or IMRT. For this treatment, no hormonal therapy is required.
3185642|NCT00737191|Experimental|Arm III|Patients receive oral opioid and 5 mg oral olanzapine once daily for 4 weeks.
3185643|NCT00737217||Parkinson's disease|
3185644|NCT00737217||Normal Controls|
3185645|NCT00737256|Experimental|1|
2412786|NCT03485352||Bariatric Surgery patients|Patients attending a private clinic specialized in the treatment of obesity and bariatric surgery. Patients to be analyzed should have a medical indication for bariatric surgery.
2412787|NCT03485339||Case|Ketamine user with psychotic disorders
2412788|NCT03485339||Control Group 1|Ketamine user without psychotic disorders
2412789|NCT03485339||Control Group 2|Non-ketamine-using drug user with psychotic disorders
2412790|NCT03485339||Control Group 3|Non-ketamine-using drug user without psychotic disorders ( identified from register-based medical record system)
3185646|NCT00737256|Active Comparator|2|
2412792|NCT03485300||Patients with chronic liver or kidney diseases|"Patients with chronic liver diseases may affect warfarin therapeutic outcome as liver is the site of metabolism of the drug by cytochrome p 450 enzymes so it decrease warfarin absorption~Kidney diseases also affect the clearance of the drug these patients will undergo liver function tests and kidney function tests"
2413087|NCT03483285|Active Comparator|heart rate|Effects of İntubation with Airtraq or Storz to heart rate
3185647|NCT00737295|Experimental|US|There will be no experimental or control group, rather each individual will act as his/her own control.
3185648|NCT00737308|Experimental|A|crown for clasp
2412793|NCT03485300||Non compliance of the patient|Missed dose of the warfarin or intermittent drug intake may affect drug therapeutic outcome as well as changing time of drug administration during the day
2412794|NCT03485300||Drugs or food interactions|Administration of other drugs beside warfarin may affect its therapeutic outcome either by inhibition or synergism certain food may also interfere with warfarin especially vitamin k and c rich food so patients will be followed up for drug or food interactions
3185649|NCT00737334|Active Comparator|1|All patients will have continuous EEGo, BIS and FORE-SIGHT monitoring, which will be correlated with arterial to jugular venous lactate differences.
2412796|NCT03485274|Active Comparator|Vortioxetine Arm|Oral: 5-20mg daily
2412797|NCT03485274|Active Comparator|Treatment as Usual|Any medication or Rx other than vortixoetine
2412798|NCT03485261||Group A|patient group include 50 female patients with chronic renal failure (eGFR <15ml/min/1.7m2 )
2412799|NCT03485261||Group B|the control group including 50 healthy females age matched with the patient group
2412800|NCT03485248|Active Comparator|Beetroot juice|Beetroot Juice cotaining on average 9mmol of nitrate per dose
2412801|NCT03485248|Placebo Comparator|Placebo beet juice (Nitrate depleted)|Beetroot juice nitrate depleted
2412802|NCT03485235|Experimental|D&C|
2412803|NCT03485235|Other|No D&C|
3185650|NCT00737347|No Intervention|1|usual care. Subjects had one 90 minute visit with registered dietitian
3185651|NCT00737347|Active Comparator|2.|Standard care. Subjects had 4 sessions with registered dietitian
3185652|NCT00737347|Active Comparator|3|Intensive care. subjects had 10 visits with registered dietitian
3185653|NCT00737373|Experimental|1|FLOT
3185654|NCT00737373|Active Comparator|2|FLO
2412809|NCT03485196||MSI-H group|We use the immunohistochemical expression of mismatch repair proteins (MutS protein homolog 2( MSH2),MutS protein homolog 6( MSH6) and PMS2（postmeiotic segregation increased 2 ）) to Determine the MSI status . When two antibodies or more show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite instability high (MSI-H).
2412810|NCT03485196||MSI-L group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status. When one antibodies show negative nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite unstable low (MSI-L).
2412811|NCT03485196||MSS group|We use the immunohistochemical expression of mismatch repair proteins (MLH1, MSH2, MSH6 and PMS2) to Determine the MSI status . when all the four antibodies show positive nuclear staining of the tumor cells, the MSI state can be defined as Microsatellite stable (MSS).
2412812|NCT03485183|Experimental|Intervention Group|The PI will set up the PicTek white/pink noise machine on the bedside table, and it will automatically turn on at 2200 and off at 0700 to the patient's preferred sound. The staff nurses will chart Nu-DESC scores every shift and as needed for change in mental status as is the current policy. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid.
2412813|NCT03485183|Other|Control Group|The PI will perform a chart review of patients who were admitted the month prior to the intervention being implemented. The PI will collect Nu-DESC scores for the duration of the participants' hospital stays, age, race, gender, presence of a dementia diagnosis, and use of a pharmacological sleep aid. These patients will receive the standard of care for delirium prevention.
2412814|NCT03485170|Other|PET|Hemophilia patients receive PET evaluation
2412815|NCT03485157|Experimental|Micronized dHACM|Injection of micronized dHACM
2412816|NCT03485157|Placebo Comparator|Saline|Injection of 0.9% Sodium Chloride Injection, USP
2412817|NCT03485144|Experimental|TV003|Live Attenuated Virus Vaccine-TetraVax-DV
2412818|NCT03485144|Placebo Comparator|Placebo for TV003|Placebo
2412819|NCT03485131|Experimental|Transcranial direct-current stimulation|Intervention of 2 mAmp Transcranial direct-current stimulation treatments given twice daily for 20 min each per day for 4 weeks on consecutive weekdays. Twice-daily sessions were separated by at least 3 hours (one in the AM and the other one in the PM)
2412820|NCT03485131|Sham Comparator|Sham tDCS|Intervention of placebo stimulation with ranscranial direct-current stimulation(sham tDCS), the stimulation parameters were displayed, but after 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse was delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
2412821|NCT03485118|Experimental|HS006+Chemotherapy|"Participants received six 21-day cycles of HS006(375 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone/prednisolone(CHOP) chemotherapy(21-day cycles).~Participants received six 21-day cycles of HS006(500 mg per square meter) combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles)."
2412822|NCT03485118|Active Comparator|Rituxan+Chemotherapy|Participants received six 21-day cycles of Rituxan combined with six cycles of standard cyclophosphamide,doxorubicin,vincristine,and prednisone(CHOP) chemotherapy(21-day cycles).
2412823|NCT03485105||CTX-benefit group|CTX-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will be beneficial from adjuvant chemotherapy
2412824|NCT03485105||no-benefit group|no-benefit group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, this group will not be beneficial from adjuvant chemotherapy
2412825|NCT03485105||high-risk group|high-risk group: based on the result of nProfiler Stomach cancer assay kit which was decided by expression level of mRNA, the prognosis of this group will be worse compared to others regardless of the response to adjuvant chemotherapy
2412826|NCT03485092|Active Comparator|Empagliflozin|Empagliflozin 10mg tablets for oral self-administration once daily
2412827|NCT03485092|Placebo Comparator|Placebo Oral Tablet|placebo tablets for oral self-administration once daily
2412828|NCT03485066|Experimental|Training|20 healthy participants, 4 week training of a challenging cognitive task (Tetris) between PET/MR measurements
2412829|NCT03485066|No Intervention|Control|20 healthy participants, no training between PET/MR measurements
3185655|NCT00737399|Experimental|1|Lifestyle Counseling with Emotional Freedom Techniques (EFT)
3185656|NCT00737412|Active Comparator|1|The probiotic Bio-K+ CL1285 RX®
3185657|NCT00737412|Placebo Comparator|2|Placebo
2412831|NCT03485027|Experimental|XELOX regimen|oxaliplatin 130mg/m2，intravenous，on Day1 capecitabine 1000mg/m2，oral，bid，on Day1-14 every three weeks
2412832|NCT03485027|Experimental|FOLFOX regimen|oxaliplatin 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
2412833|NCT03485027|Experimental|FOLFIRI regimen|irinotecan 85mg/m2，intravenous，on Day1 leucovorin 400mg/m2，intravenous，on Day1 5-FU 400mg/m2，intravenous，on Day1 5-FU 2.4g/m2，CIV 46h every two weeks
2412834|NCT03485027|Experimental|IRI regimen|irinotecan single agent 180mg/m2，intravenous，on Day1 every two weeks
2412835|NCT03485014|Experimental|Experimental: EXPAREL 4 mg/kg|Single dose of EXPAREL 4 mg/kg
2412836|NCT03485001|Sham Comparator|Sham of Argon Laser Treatment|Slit lamp light exposure
2412837|NCT03485001|Experimental|Argon Laser Treatment|Argon Laser Treatment
2412838|NCT03484988|Placebo Comparator|Placebo oil|Ingredients: Corn oil, 500mg per capsule
2412839|NCT03484988|Experimental|Echium oil|Ingredients: Echium oil,500mg per capsule
2412840|NCT03484988|Experimental|Mixed oil|Ingredients:Mixed oil(Echium oil,camelina oil,safflower oil) 500mg per capsule
2412841|NCT03484975|Other|Observation group|Patients undergoing coronary angiography and intravascular imaging for either diagnostic purposes or for PCI following a presentation with either stable angina or an acute coronary syndrome.
2412842|NCT03484962|Experimental|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
2412843|NCT03484962|Active Comparator|Cryotherapy & Activated CIK and bispecific antibody|the maximum tumor length≥2cm, use cryotherapy. the maximum tumor length<2 cm,Biological/Vaccine:Activated CIK and bispecific antibody CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
2412844|NCT03484962|No Intervention|No intervention|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2412845|NCT03484949|Experimental|pre-endoscopic screening risk assessment|
2412846|NCT03484949|No Intervention|routine screening|
2412847|NCT03484936|Active Comparator|RIC+Standard medical treatment|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days. Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
2412848|NCT03484936|Placebo Comparator|Sham RIC+Standard medical treatment|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.Additionally,the patients will be treated with standard medical treatment according to 2014 chinese guideline for the diagnosis and treatment of intracerebral hemorrhage.
2412854|NCT03484910|Experimental|BFB group|Exercise therapy - Six-week training program of stationary cycling with a real-time visual EMG biofeedback
2412855|NCT03484910|Active Comparator|CON group|Exercise therapy - Six-week training program of stationary cycling without EMG biofeedback
2412856|NCT03484897|Experimental|P927 - LICHTENA DermAD CREMA CORPO|Application of the product under study mono-laterally at level of the forearm, including the antecubital fold, on the right or left side according to a randomization list defined by the investigator.
2412857|NCT03484884||Thyroid cancer/nodal metastasis|Participants will have thyroid cancer and nodal metastasis in the neck, supraclavicular, axillary and/or inguinal area.
2412858|NCT03484858|Other|High glycaemic index meal and exercise|
2412859|NCT03484858|Other|High glycaemic index meal and rest|
2412860|NCT03484858|Other|Low glycaemic index meal and exercise|
2412861|NCT03484858|Other|Low glycaemic index meal and rest|
2412862|NCT03484845|Active Comparator|Oral lactoferrin|women who take oral lactoferrin sachets 100 mg twice daily for one month.
2412863|NCT03484845|Active Comparator|Oral ferrous fumarate|women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month.
2412864|NCT03484845|Active Comparator|Combined lactoferrin & ferrous fumarate|women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month.
2412865|NCT03484832|Experimental|Spray group|Using Walter Ritter Ethyl Chloride Spray and placebo cream
2412866|NCT03484832|Experimental|EMLA group|Using EMLA cream and placebo spray
2412867|NCT03484832|Placebo Comparator|Placebo group|Using placebo cream and placebo spray
2412869|NCT03484793|Experimental|AESOP integrated to CPOE for reducing medication errors|18 were assigned to the experimental group
2412870|NCT03484793|No Intervention|Non AESOP|19 were assigned to the traditional CPOE system
2412871|NCT03484780|Experimental|VisONE ADS|Patients implanted with a VisONE stimulator and leads for receiving continual Synchronized Diaphragmatic Stimulation
2412872|NCT03484767||Methylmalonic Acidemia Participants|Individuals with isolated MMA (mut0 and mut-)
2412873|NCT03484767||Propionic Acidemia Participants|Individuals with isolated PA
2412874|NCT03484754|Experimental|corrugator|single injection of 10 Units of botulinum toxina in the corrugator and procerus
2412875|NCT03484754|Active Comparator|orbicularis oculi|single injection of 10 Units of botulinum toxina in the lateral muscle orbicularis oculi (involved in crow's feet wrinkles)
2412876|NCT03484741|Experimental|MSC and PRP|15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.
2412877|NCT03484728|Placebo Comparator|High-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
2412878|NCT03484728|Other|Low-expectation placebo manipulation|application of nonactive body cream on forearm for 10 minutes
2412879|NCT03484715|Experimental|Physical Activity Intervention|Each participant in this arm will outline a small number of activity-related goals and will receive a 4 month personalised physical programme where additional physical activity will be incorporated into their daily routines. Nursing home staff will receive two educational sessions, which will provide them with the necessary skills to monitor participants physical activity programmes within the nursing home.
2412880|NCT03484715|No Intervention|Usual Care Control|The participants in the control arm will receive usual care, which will be guided by current nursing and medical care plans.
2412881|NCT03484702|Experimental|Administration of JCAR017|JCAR017 will be infused at a dose of 100 x 10^6 JCAR017-positive transfected viable T cells (50 × 10^6 CD8+ CAR+ T cells and 50 × 10^6 CD4+ CAR+ T cells), on Day 1 (2 to 7 days after completion of lymphodepleting chemotherapy (LD) chemotherapy)
2412882|NCT03484689|Other|MBCT arm|8-week MBCT program
2412883|NCT03484676|Other|Unilateral Non comminuted zygomatic complex fracture|Patient undergo treatment no control group
2412884|NCT03484663|Experimental|Small catheter with chest tube after uniport vats|Insertion of small catheter drainage in the same opening with chest tube after uniport vats
2412885|NCT03484663|No Intervention|Chest tube only after uniport vats|After uniport vats we put chest tube only
2412886|NCT03484650|Placebo Comparator|Control|Patients will receive standard care plus infusion of placebo
2412887|NCT03484650|Experimental|Lidocaine|Patients will receive lidocaine infusions peri-operatively
2412888|NCT03484637||Lifestyle-medicine intervention|Photographic follow-up every 4 weeks
2412889|NCT03484624|Experimental|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
2412890|NCT03484611|Active Comparator|AMH < 0.3 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH < 0,3 ng/ml
2412891|NCT03484611|Active Comparator|AMH 0.3 to 0.7 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.3 to 0.7 ng/ml
2412892|NCT03484611|Active Comparator|AMH > 0.7 to 1 ng/ml|Poor ovarian responders according to ESHRE consensus with serum AMH 0.7 to 1 ng/ml
2412893|NCT03484598|Experimental|SPEAC Treatment Arm|All study participants will be provided with a SPEAC System to use in their home environment.
2412894|NCT03484585|Experimental|Rogaratinib (BAY1163877)|Healthy male subjects
2412895|NCT03484559||1|
2412896|NCT03484546||folicular|Women who will undergo endometrioma cystectomy in her follicular phase of menstrual period.
2412897|NCT03484546||ovulatory|Women who will undergo endometrioma cystectomy in her ovulatory phase (12-14th day of mestrual period cycle for women regular period) of menstrual cycle.
2412898|NCT03484546||luteal|Women who will undergo endometrioma cystectomy in her luteal phase of menstrual period.
2412899|NCT03484533|Active Comparator|HIV Self-test kit|
2412900|NCT03484533|Active Comparator|Invitation letter-standard of care|
2412901|NCT03484520|Experimental|Venetoclax + Dinaciclib|Venetoclax and dinaciclib will be administered in combination. Different combinations of dose levels for venetoclax and dinaciclib will be explored.
2412902|NCT03484507|Active Comparator|Chlorhexidine monotherapy|Topical chlorhexidine 0.04%
2412903|NCT03484507|Experimental|Chlorhexidine plus povidone iodine|Topical chlorhexidine 0.04% plus povidone iodine 2.5%
2412904|NCT03484507|Experimental|Early corticosteroids|Topical prednisolone sodium phosophate 1% for weeks 4-11
2412905|NCT03484507|Experimental|Late corticosteroids|Artificial tears for weeks 4-5, then topical prednisolone sodium phosophate 1% for weeks 6-11
2412906|NCT03484507|Placebo Comparator|Placebo|Artificial tears for weeks 4-11
2412907|NCT03484494|Other|Active first|Subjects receive active Low Field Magnetic Stimulation in the first imaging visit and sham in the second.
2412908|NCT03484494|Other|Sham first|Subjects receive sham Low Field Magnetic Stimulation in the first imaging visit and active in the second.
2412909|NCT03484481||1;Oral nutritional support (ONS)|patients ongoing hemodialysis who received only oral nutritional support (Nutrena) and refused intradialytic parenteral nutrition; n: 14
2412910|NCT03484481||2; Intradialytic Parenteral Nutrition|patients ongoing hemodialysis who received only Intradialytic Parenteral Nutrition (Kabiven central) and refused parenteral nutrition; n: 14
2412911|NCT03484481||group 3; combination group|patients ongoing hemodialysis received both ONS and Intradialytic Parenteral Nutrition NS; n: 10
2412912|NCT03484481||group 4; dietetic support group;|patients ongoing hemodialysis who refused all types of nutritional support and only followed by counselling, n: 18
2412913|NCT03484468||femtosecond_laser|participants had there lasik corneal flap creation using femtosecond laser
2412914|NCT03484468||moria_microkeratome|participants had there lasik corneal flap creation using moria microkeratome
3185658|NCT00737425|Active Comparator|1|
3185659|NCT00737425|Sham Comparator|2|
3185660|NCT00737451||skin itching|
3185661|NCT00737490|Active Comparator|1|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm"
2412919|NCT03484416|Active Comparator|Routine calcium|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium (by calcium carbonate) and 1,000 IU/day cholecalciferol for 2 weeks, beginning on the first postoperative day
2412920|NCT03484416|No Intervention|control|Patients in the control group did not receive calcium or cholecalciferol for 2 weeks
3185662|NCT00737490|Active Comparator|2|"Simultaneous BiV pacing. Simultaneous Arm"
3185663|NCT00737503|Experimental|1|All eligible children in the experimental arm will be vaccinated with the Rotavirus vaccine
2412921|NCT03484403|Active Comparator|Control Group|Study participants will not receive a back brace but will receive back school education and the same physical therapy exercise instruction as the treatment group.
2412922|NCT03484403|Experimental|Treatment Group|Study participants in this group will receive a lumbar support back brace and will receive back school education and the same physical therapy exercise instruction as the control group.
2412923|NCT03484390|Experimental|Mindfulness-based stress reduction|The MBSR program is a manualized course that includes meditation, relaxing movement, and breathing. A certified MBSR instructor will teach the courses in a group-based format for 120 minute sessions, once per week for eight weeks.
2412924|NCT03484390|Active Comparator|Wellness Group|The Wellness control group uses a health education manual that provides information on various aspects of health, including diet, physical activity, sleep, stress management, and communication. The manual is used during weekly check-in phone calls for an 8-week period.
2412925|NCT03484377|Experimental|Anodal tDCS|The anodal tDCS electrode will be placed over the area corresponding to the right DLPFC (F4 of the EEG10-20 international system). The anodal tDCS condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
2412926|NCT03484377|Sham Comparator|Sham tDCS|The sham (cathodal) electrode will be placed over the left supraorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session.
2412927|NCT03484364|Experimental|Intervention Group|The ENACTS intervention is eight weeks of peer-facilitated educational classes about hypertension self-management and autonomous support from family or friend enrolled as support person.
2412928|NCT03484364|No Intervention|Waitlist Group|Usual care and $30 in groceries each week for 8 weeks.
2412929|NCT03484351|Experimental|Fall Monty Activity Programme (FallMAP)|A multifactorial falls prevention activity programme
2412930|NCT03484338|Experimental|Intervention|
2412931|NCT03484338|Active Comparator|Wait list controlled|
2412932|NCT03484299|Other|Treatment|Irreversible electroporation and treatment with either FOLFIRINOX or Gemcitabine (based upon which chemotherapy regimen received prior to IRE)
2412933|NCT03484286|Other|Control group|Subject to standard care. No interventions above and beyond what is deemed standard care for heart failure patients in the region where the study takes place.
2412934|NCT03484286|Experimental|Intervention group|Device: OPTILOGG
3145295|NCT00067015|Experimental|IMRT TO 75.6 Gy plus Adjuvant Androgen Deprivation|Prior to a planned course of radiotherapy, which will last for eight and a half weeks, 10 weeks of hormonal therapy are given. The hormonal therapy will start with a daily pill called Casodex. Three to seven days after starting this pill, a Zoladex injection will be administered in addition to the Casodex pill. Zoladex hormonal therapy is given in the form of a monthly injection. After 10 weeks from the initiation of hormone therapy, you will begin external radiotherapy. For these treatments only 42 treatment sessions are given. The total dose of radiotherapy delivered during these 8.5 weeks is 75.6 Gy. The hormone injections continue during the radiation treatments and for 2 years after the radiation treatments. The pills are only taken for the 10 weeks before and also during the radiation treatments, however afterwards the pills are discontinued.
3145297|NCT00067080|Experimental|ICL670 + deferoxamine|
3185664|NCT00737503|No Intervention|2|Children will not be vaccinated with rotavirus vaccine.
2412939|NCT03484260||Case group: Testosterone Product|Male subjects prescribed testosterone in UK
2412940|NCT03484260||Control group|Matched male subjects not prescribed testosterone in the UK
2412941|NCT03484247|Active Comparator|Group Infraclavicular|Infraclavicular Brachial Plexus Block: The inferolateral of the subclavian artery will be targeted with a 85 mm peripheral nerve stimulator needle with ultrasound guidance. When the needle tip was seen near the posterior cord of brachial plexus local anesthetic will be administered with single injection after aspiration.
2412942|NCT03484247|Active Comparator|Group Axillary|Axillary Brachial Plexus Block: The procedure will be performed with a 50 mm peripheral nerve stimulator needle with ultrasound guidance. Local anesthetic will be administered with multiple injection (radial, ulnar, median and musculocutaneous nerves) after aspiration.
2412943|NCT03484234|Experimental|Ultimaster stent|
2412944|NCT03484234|Active Comparator|Xience alpine stent|
2412945|NCT03484221|Experimental|FOLFOXIRI+short-course radiation+XELOX|Firstly, 4 cycles of neoadjuvant FOLFOXIRI chemotherapy were administered. Subsequently, a short-course radiation therapy (5Gy*5) will be performed. After that, 4 cycles of XELOX chemotherapy will be administered followed by surgery.
2412946|NCT03484195|Experimental|FOLFOXIRI|Patients received 4 cycles of neoadjuvant FOLFOXIRI chemotherapy before surgical resection.
3185665|NCT00737516|Experimental|single arm|HPC, Cord Blood
3185666|NCT00737542|Placebo Comparator|A|
2412949|NCT03484169|No Intervention|Control group|No intervention
2412950|NCT03484169|Experimental|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
2412951|NCT03484156|Experimental|Volunteers|"The Installation of 3PEGASE Sensor in elders volunteers to monitor clinical indicators at home.The instrument is for monitoring functional and cognitive autonomy in frail or disable elderly persons living alone at home.~The volunteers will have 70 years old or more, living alone at home, frail of disable (ADL> or =3) and able to walk by themselves."
3185667|NCT00737542|Experimental|B|
2412955|NCT03484117|No Intervention|Treatment as Usual|Participants in this arm will receive bilingual written materials on healthy living with HIV at the baseline visit. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants.
2414071|NCT03476304|Active Comparator|Post retained direct composite restoration|
2412956|NCT03484117|Experimental|Community Health Worker|Participants in the intervention arm will receive 5 one-on-one sessions over 24 weeks with a Spanish-speaking CHW. At baseline and exit, all participants will be assessed using instruments to measure demographics and self-perceived barriers to care for Hispanic immigrants
2412957|NCT03484104||Hypothermic circulatory arrest|Patients undergoing cardiac surgery with hypothermic circulatory arrest and selective antegrade cerebral perfusion
2412958|NCT03484091|Experimental|H group|Single dose of Hyruan-One 3 mL intra-articular knee injection.
2412959|NCT03484091|Active Comparator|S group|Single dose of Hylan G-F 20 (Synvisc) 6 mL intra-articular knee injection.
2412960|NCT03484091|Placebo Comparator|N group|Single dose of normal saline 6 mL intra-articular knee injection.
2412961|NCT03484078|Experimental|Vibration Platform|The vibration group will stand on a platform that emits a mild vibration 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
2412962|NCT03484078|Placebo Comparator|Placebo Platform|The placebo group will stand on a placebo platform 10 minutes per day for 6 months. There will also be a 6 month no-treatment period.
2412963|NCT03484065||Afibrinogenemia|
2412964|NCT03484052|Other|Jugular ultrasound|
2412965|NCT03484039|Experimental|Epilepsy Patients|The group will receive the module (a 1-2 hour course on either medication adherence, seizure documentation, memory improvement or stress management) right after a baseline assessment. A post assessment and delayed post assessment will be conducted after the module is administered.
2412966|NCT03484026|Experimental|BioFe Medical Food|Consumption of BioFe Medical Food in a single cohort of up to 8 female subjects with iron deficiency.
2412967|NCT03484000|Experimental|Immediate MBCR group|The Online Mindfulness Based Cancer Recovery (MBCR) program intervention is delivered in 12 weekly real-time interactive 55-minute sessions offered over consecutive weeks.
2412968|NCT03484000|Other|Waitlist control group|Treatment as usual, followed by a delayed (wait-list) intervention of the same Online Mindfulness Based Cancer Recovery (MBCR) program after the post-CT assessment.
2412969|NCT03483987|Experimental|Sof+Ledi+R arm|"Participants with HCV genotype 1,4, 5 or 6 and relapsed with following regimens will be treated with sofosbuvir, ledipasvir and ribavirin combination~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
2412970|NCT03483987|Experimental|Sof+Ledi+R+Peg-IFN arm|Participants with HCV genotype 1,4, 5 or 6, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
2412971|NCT03483987|Experimental|Sof+Dacla+R arm|"Participants with HCV genotype 2 or 3 and relapsed with following regimens will be treated with a combination of sofosbuvir, daclatasvir and ribavirin~Sofosbuvir plus velpatasvir with or without ribavirin for 12 weeks~Sofosbuvir plus ribavirin with or without pegylated interferon for 12 or 24 weeks~Sofosbuvir plus velpatasvir with or without ribavirin for 24 weeks and are not eligible for pegylated interferon"
2412972|NCT03483987|Experimental|Sof+Dacla+R+Peg-IFN arm|Participants with HCV genotype 2 or 3, who have relapsed after a 24 weeks treatment regimen of sofosbuvir plus velpatasvir with or without ribavirin combination and are eligible for pegylated interferon, will be treated with a combination of sofosbuvir, ledipasvir, ribavirin plus pegylated interferon
2412973|NCT03483987|Experimental|Sof+Velpa+R arm|"Following group of participants will be treated with sofosbuvir, velpatasvir and ribavirin combination~who were treated earlier with 12 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin or~who were earlier treated with a 24 treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are not eligible for pegylated interferon"
2412974|NCT03483987|Experimental|Sof+Velpa+R+Peg-IFN arm|Participants, who have relapsed after a 24 week treatment regimen of either sofosbuvir plus daclatasvir or sofosbuvir plus ledipasvir with or without ribavirin and are eligible for pegylated interferon will be treated with sofosbuvir, velpatasvir, ribavirin and pegylated interferon combination
2412975|NCT03483974||neoplasm|neoplasm found in follow up
2412976|NCT03483974||non-neoplasm|non-neoplasm patients in follow up
3145298|NCT00067106||1: Women failing therapy|Participants will have study visits at study entry, 2 weeks after changing medications, then every 4 weeks until the amount of HIV in the blood and genital tract are undetectable. Drug levels in the blood and genital tract will also be measured at the first visit and after changing medications. Once the level of HIV is undetectable, women will be seen every 3 months for 36 months. Participants in Group 1 will be followed no more than 42 months.
3145299|NCT00067106||2: Women suppressed on therapy|Participants will have study visits for blood and genital tract collections at study entry and then every 4 weeks for 12 months
3145300|NCT00067119|Experimental|Aggrenox|
3145301|NCT00067119|Placebo Comparator|Placebo|
3145302|NCT00067340|Experimental|Intervention group|Subjects received chlorhexidine mouthwash and xylitol gum , in addition to the usual care specified under the control group
3145303|NCT00067340|Placebo Comparator|Control|Subjects received enhanced dental care, health information, toothbrushes and toothpaste. They also received placebo gum and placebo mouth rinse
3145304|NCT00067366|Experimental|Coping Skills Training|manualized coping skills training delivered along with conservative care
3145305|NCT00067366|Active Comparator|Standard Care|Attention and life counseling added to Standard conservative care
3145306|NCT00067379|Active Comparator|1|Medicaid patients with medically necessary malocclusions treated during the mixed dentition with limited goals followed by observation
3145307|NCT00067587||HIV Negative|HIV negative subjects
2412987|NCT03483948|Experimental|HMPL-523 & Azacitidine|HMPL-523 will be taken orally once daily continuously through a 28-days Cycle of study treatment. Azacitidine will be administered subcutaneously, beginning on Day 1 through Day 7 of each Cycle.
2413088|NCT03483285|Active Comparator|mean arterial pressure|Effect of intubation with Airtraq or Storz to mean arterial pressure
2413611|NCT03479619|Experimental|C/33/1|Lancing device C with personal lancet of size 33 G and minimum puncture depth.
3145308|NCT00067587||HIV Positive - NEVER had ARV therapy.|HIV Positive - NEVER had ARV therapy.
3185668|NCT00737555|Experimental|1|Once daily oral administration of CHR-2797 ( escalating dose groups) in solid tumour patients receiving paclitaxel infusion every three weeks
3185669|NCT00737620|Active Comparator|propaten graft|
2412990|NCT03483922||chronic hepatitis B|This group will include 50 with hepatitis B subjects and the diagnoses will be based on AASLD practice guideline.
2412991|NCT03483922||HCC Cases|"This group will include 350 in stage 0, stage A, stage B, Stage C+D of hepatocellular carcinoma.~HCC staging will be diagnosed according to EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma"
2412992|NCT03483922||Healthy|This group will include 50 healthy sex and age matched controls.
2412993|NCT03483909|Experimental|left IFG iTBS|intermittent theta burst stimulation over the left inferior frontal gyrus
2412994|NCT03483909|Active Comparator|right IPL cTBS|continuous theta burst stimulation over the right inferior parietal cortex
2412995|NCT03483909|Placebo Comparator|placebo|Placebo TMS stimulation over the left inferior parietal cortex
3185670|NCT00737620|Active Comparator|Standard graft|
3185671|NCT00737646|Other|1|Usual care
2412998|NCT03483883|Experimental|Single Arm|
2412999|NCT03483870|Placebo Comparator|Morphine sulphate & Placebo|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of normal saline 0.9% (placebo) IV injection preoperative.
2413000|NCT03483870|Active Comparator|Morphine sulphate & Granisetron|20 parturients under intrathecal anesthesia will receive 200 ug morphine sulphate intrathecally and 2 mL of 2 mg granisetron IV injection preoperative.
2413001|NCT03483857|Experimental|Peer Navigation|Individuals assigned to the PN condition will be assigned to one of 10 PN case managers who will follow an SOP described for initial intake and follow up visits with each participant. Participants will be asked to provide contact information for themselves and up to 3 individuals whom study staff can contact in case they cannot make direct contact with the study participant assigned to PN. PN will meet with their clients at least once monthly to discuss treatment related issues including medication access, side effects, adherence, stigma or discrimination related to HIV or their taking ART medication, etc. Participants will have contact information for their assigned PN and may contact them for reasons related to their treatment between scheduled monthly visits if they choose. All visits with PN will be recorded by the PN. and participants who fail to attend up to 3 scheduled PN appointments will be considered LTFU for the intervention.
2413002|NCT03483857|No Intervention|Standard of Care|Individuals assigned to SOC will be referred directly to the NCHC/RLS staff for treatment initiation or continuation. At intake they will receive standard treatment information per MPDOH guidelines, as well as information about Anova's RLS and Health4Men clinical and psychosocial services available at the NCHC. They will receive monthly text message reminders from study staff to refill ART prescriptions, and a separate reminder in month 6 to schedule complete their 6-month clinical visit. Study staff will verify that participants have picked up medications and attended all scheduled clinical visits by means of chart review and data extraction. Per MPDOH guidelines, individuals who fail to collect medications 3 months in a row, or who fail to attend their 6-month HIV clinical follow-up appointment, will be considered non-engaged and lost to follow up (LTFU).
2413003|NCT03483831|Experimental|Intervention group|Students of 5 secondary school classes aged 12-14
2413004|NCT03483831|No Intervention|Control group|Students of 5 secondary school classes aged 12-14
2413005|NCT03483818|Active Comparator|Pharmacist-Led Pathway|Assessment & Treatment of HCV infection with oral antivirals in a community pharmacy pathway
2413006|NCT03483818|Active Comparator|Conventional Care Pathway|Assessment & Treatment of HCV infection with oral antivirals in a conventional care pathway
2413007|NCT03483805|Experimental|Treatment|Protalsafe product, daily, 12 weeks
2413008|NCT03483805|Placebo Comparator|Placebo|Placebo product, daily, 12 weeks
2413009|NCT03483792||PCOS group|
2413010|NCT03483792||Control group|
2413011|NCT03483779|Experimental|Experimental group:Ginkgo biloba pills|Five Ginkgo biloba pills a time and three times a day. One treatment period including 8 weeks.
2413012|NCT03483779|Placebo Comparator|Control group:placebo pills|Five placebo pills a time and three times a day. One treatment period including 8 weeks.
2413013|NCT03483766|No Intervention|Baseline before robotic functional rehabilitation|Baseline spinal cord MRI scan
2413014|NCT03483766|Experimental|post rehabilitation|Those patients will receive 3 months muscle strength enhancement as pre-rehabilitation. Then, we will design robotic hand rehabilitation programme for each individuals. All participants will receive robotic rehabilitation for 1 year. After then, a follow-up spinal cord MRI scan and clinical assessment will evaluate the results of this project.
2413015|NCT03483753|Experimental|Vasopressin group|Blinded vasopressin
2413016|NCT03483753|Active Comparator|Norepinephrine group|Blinded norepinephrine
2413017|NCT03483740|Experimental|Cognitive remediation group therapy|8 weekly 3-hour sessions of CRGT
2413018|NCT03483740|Active Comparator|Mutual aid support group|8 weekly 3-hour sessions of HIV group therapy
2413019|NCT03483727|Experimental|Digital cognitive aid|The digital cognitive aid is designed as a smartphone app.
2413020|NCT03483727|Experimental|no digital cognitive aid|No cognitive aid in the hand of the leader during crises management.
2413021|NCT03483714||Healthy Participants|Spinal manipulation
2413022|NCT03483714||Acute Low back pain participants|Spinal Manipulation
2413023|NCT03483714||Chronic low back pain participants|Spinal Manipulation
2413612|NCT03479619|Experimental|C/33/5|Lancing device C with personal lancet of size 33 G and maximum puncture depth.
3185672|NCT00737646|Experimental|2|Clinic-focused intervention: The clinicians and clinical staff in each of the clinics will be scheduled for training sessions. The provider trainings will be designed for clinicians and clinical staff and will be conducted in at least two separate sessions of approximately 3 hours total duration. The sessions will be scheduled to accommodate the clinic schedule, but will be held with no more than 1 month between them. Participants in clinic training sessions will receive continuing education credit.
2413024|NCT03483701|Experimental|Cognitive Remediation Therapy|Participants in the experimental group will continue to receive IPS services, which is part of their standard care. In addition, they will be required to complete up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer, on their own schedule. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
2413025|NCT03483701|No Intervention|Treatment as Usual|Participants in the control condition will continue to receive IPS services as usual.
2413026|NCT03483688|Experimental|CD19-directed CAR-T cells|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
3185673|NCT00737646|Experimental|3|"Clinic-focused and patient focused intervention: The clinic focused-intervention as described in Arm 2 will be combined with a patient-focused intervention.~Patient focused intervention: CRC education packets, based upon previously developed CDC CRC patient education materials, have been adapted for each study site. These CRC educational packets will be mailed to average-risk patients aged 50-80 years who are due for CRC screening (based on electronic records) and who schedule a non-acute ambulatory care visit in clinics assigned to the patient-focused intervention. A cover letter signed by the patient's physician will be included with each packet. The packets will be mailed approximately 1 week before the medical appointment."
3185674|NCT00737659|Experimental|1|Concentration Controlled (CC)group will receive an individually adjusted MMF dosing regimen based on the plasma concentrations of mycophenolic acid (MPA,the active metabolite of mycophenolate mofetil).
2413029|NCT03483662|Experimental|Multicomponent Intervention|Protocol-based treatment using the SPRINT stepped-care intensive BP management algorithm, dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification
2413030|NCT03483662|Active Comparator|Enhanced Usual Care|Webinar education session for providers on the new ACC/AHA hypertensive clinical guideline and the SPRINT study findings
2413031|NCT03483649|Experimental|HLX04|
2413032|NCT03483649|Active Comparator|United States (US) Avastin®|
2413033|NCT03483649|Active Comparator|European Union (EU) Avastin®|
2413034|NCT03483649|Active Comparator|China (CN) Avastin®|
2413035|NCT03483636|Experimental|Lemborexant|Participants will be randomized to receive a 10 milligram (mg) lemborexant tablet administered with 50 milliliter (mL) water followed by a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2413036|NCT03483636|Experimental|Lemborexant Plus Alcohol|Participants will be randomized to receive a 10 mg lemborexant tablet administered with 50 mL water followed by alcohol (0.6 grams per kilogram [g/kg] of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2413037|NCT03483636|Experimental|Alcohol|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol (0.6 g/kg of alcohol for females or 0.7 g/kg of alcohol for males) for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
2413038|NCT03483636|Placebo Comparator|Placebo|Participants will be randomized to receive a 10 mg lemborexant-matched placebo tablet administered with 50 mL water followed by alcohol for a total volume of 300 mL (approximately 150 mL per aliquot) of a low-calorie beverage (e.g., cranberry beverage) after an overnight fast of at least 8 hours and a sleep period of at least 8 hours. Treatment will be administered after a light breakfast (ie, not high fat), at approximately 120 minutes after wake time in the morning.
3185675|NCT00737659|Active Comparator|2|Fixed dose (FD) group will receive an a priori set dose of 2mg\day MMF, the recommended dose, with a possible secondary adaptation by the clinician based on criteria of clinical efficacy, toxicity or interactions with other medications.
3185676|NCT00737685|Experimental|Fludarabine|
2413043|NCT03483610|Active Comparator|screening and referral|
2413044|NCT03483610|Active Comparator|behavioral intervention|
2413045|NCT03483597||rheumatologists|Inclusion criteria: Registered rheumatoid specialist physicians subordinated to the 12 designated hospitals The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in rheumatologists.
2413046|NCT03483597||patients|Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
2413047|NCT03483558|Experimental|Control|Participants were fed a standardized diet (without any vegetables) in this experiment.
2413048|NCT03483558|Experimental|Spinach|Participants were fed a standardized diet with 200g spinach in this experiment.
2413049|NCT03483558|Experimental|Celery|Participants were fed a standardized diet with 200g celery in this experiment.
2413050|NCT03483558|Experimental|Onion|Participants were fed a standardized diet with 200g onion in this experiment.
2413051|NCT03483558|Experimental|Mixed Vegetables|Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
2413052|NCT03483545|Experimental|Follitropin delta and HP-hMG|Follitropin delta combined with highly purified human menopausal gonadotrophin
2413053|NCT03483532||Lit Control pH Up without cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract without cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
2413208|NCT03482401|No Intervention|Control group|Participating patients did not consume the supplement but provided biological samples to the trial
2413054|NCT03483532||Lit Control pH Up with dry cocoa extract|The nutritional exposure will consist in the intake of 1 capsule of the food supplement based on citrate and plant extract with cocoa extract dosed at the rate of one during breakfast and another during dinner, during a period of 14 days to a group of 30 patients.
2413055|NCT03483519|Experimental|Prehabilitation|Patients in the Prehabilitation Group and are randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
2413056|NCT03483519|Active Comparator|Standard of Care|Patients in the Standard of Care will not receive an additional an exercise program, patients will receive the usual care received by all orthopaedic patients.
2413058|NCT03483493|Experimental|Exposure Response Prevention for tics|10-weeks, online delivered, therapist supported exposure response prevention (ERP) therapy for tics
2413059|NCT03483493|Active Comparator|Active Control (Psychoeducation)|10-weeks, online delivered, therapist supported psychoeducation for tics
2413060|NCT03483480|Experimental|Non powered-NPWT|
2413061|NCT03483480|Active Comparator|Open Technique|
2413062|NCT03483467|Experimental|1|Application of Omnigen
2413063|NCT03483467|Placebo Comparator|2|Dummy Omnigen Packaging
2413064|NCT03483454|Experimental|Exercise classes|This group of children and their parents will participate in an exercise class for 8 weeks.
2413065|NCT03483454|Experimental|Home exercise|"This group of children and their parents will participate in exercise at home for 8 weeks. This is currently the standard of care in the weight management clinic (advise to continue increasing activity at home). This group is considered the control group."
2413066|NCT03483428|Experimental|Parent Coaches|"Parent coaches will complete interventionist training and supervision in the Family Check-Up, an evidence-based behavioral parent training (BPT) program, including in the adaptations for families with DHH children. Each parent coach will deliver the intervention to 5 parent-child dyads."
2413067|NCT03483428|Experimental|Parent-Child Dyads|"Parents and children will receive the adapted Family Check-Up behavioral parent training (BPT) intervention delivered by parent coaches."
2413068|NCT03483415|Experimental|Grup L|"IV patient-controlled analgesia (PCA) morphine~+ Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine"
2413069|NCT03483415|Active Comparator|Group P|IV patient-controlled analgesia (PCA) morphine
2413070|NCT03483402|Experimental|PEXG treated with MLT|Patients with pseudoexfoliation glaucoma (PEXG) under prostaglandine analogue monotherapy with inadequate IOP control treated with 360-degrees 532nm micropulse laser trabeculoplasty (MLT)
2413071|NCT03483389|Experimental|Alcohol, placebo|Alcohol, ethyl - Placebo
2413072|NCT03483389|Experimental|Alcohol, low dose|Alcohol, ethyl - Low dose
2413073|NCT03483389|Experimental|Alcohol, moderate dose|Alcohol, ethyl - Moderate dose
2413074|NCT03483376|Active Comparator|Dental prophylaxis|Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste.
2413075|NCT03483376|Experimental|Dental prophylaxis + aPDT|"Study volunteers with black plaque stained teeth will receive standard dental prophylactic cleaning, followed by antimicrobial photodynamic therapy (aPDT) to remove the stain. The prophylaxis will be carried out using an ultrasonic scaler, prophylaxis brush and abrasive paste. The aPDT protocol is as follows:~Patient will rinse the oral cavity with 20 ml of an aqueous solution of curcumin (photosensitizer; 1.5 g/L) for 30 seconds.~Blue light from a Bluephase 20i curing lamp will be applied perpendicularly for 1 min per tooth (30 seconds on the vestibular side and 30 seconds on the palatal side).~Remaining photosensitizer will be removed using the prophylaxis brush. The aPDT protocol is repeated following a rest period of 10 days."
2413076|NCT03483363|Experimental|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure. All groups with receive standard parenteral intravenous (IV) prophylactic antibiotic.
2413077|NCT03483363|Active Comparator|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
2413078|NCT03483350|Experimental|1- 1st group|1- 1st group will include 30 patients will receive intravenous granisetron 10 μg/kg after induction of anesthesia and before start of surgery
2413079|NCT03483350|Experimental|2- 2nd|2- 2nd group will include 30 patients will receive intravenous midazolam 50 μg/kg after induction of anesthesia and before start of surgery
2413080|NCT03483350|Experimental|3- 3rd group|3- 3rd group will include 30 patients will receive combination intravenous granisetron 5 μg/kg with midazolam 25 μg/kg after induction of anesthesia and before start of surgery
3145309|NCT00067587||HIV positive, on a NNRTI, non-PI regimen|HIV positive, currently on a NNRTI, non-PI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI-containing regimen and at least ONE year must have passed since receipt of last PI-containing regimen.
3145310|NCT00067587||HIV positive, on a PI, non-NNRTI regimen|HIV positive, currently on a PI, non-NNRTI regimen for at least 3 months. Must NEVER have received a total of more than SIX months of NNRTI-containing regimen and at least ONE year must have passed since receipt of last NNRTIcontaining regimen.
2413084|NCT03483311|Experimental|psoriasis patients|Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
2413085|NCT03483311|Experimental|controls|Tissue levels of resolvin D1 in controls
2413086|NCT03483298||elevated sperm DNA fragmentation|Couples with male partners who will be undergoing a TESA procedure secondary to elevated DNA fragmentation (>25% DFI) as part of their routine IVF treatment will have half of the women's eggs inseminated with ejaculated sperm and the other half with surgically obtained sperm via the ICSI procedure
3145311|NCT00067587||HIV positive, on a non-PI, non-NNRTI|HIV positive, currently on a non-PI, non-NNRTI containing regimen for at least 3 months. Must NEVER have received a total of more than SIX months of PI- and/or NNRTI- containing regimen and at least ONE year must have passed since receipt of last PI- and/or NNRTI-containing regimen.
3145312|NCT00067613|Active Comparator|Intervention|Clinical sites randomized to intervention will receive training in the benchmarking BPD management methods identified at the Benchmark sites.
2413089|NCT03483259|Experimental|Arm A-Sulfatinib T capsule|The subjects in this arm will receive sulfatinib T capsules from Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd.
2413090|NCT03483259|Experimental|Arm B-Sulfatinib R capsule|The subjects in this arm will receive sulfatinib R capsules from Beijing Yiling Bioengineering Technology Co., Ltd.
3145313|NCT00067613|Placebo Comparator|Control|Clinical sites randomized to Control will continue with their normal management practices for BPD.
3145314|NCT00067626|Experimental|1|500/1000 mcg oral chromium taken daily or placebo (crossover)
2413093|NCT03483233|Experimental|fMRI and EEG study|
2413094|NCT03483220||cases|patients with substance use disorder
2413095|NCT03483207|Experimental|MVT with anticoagulation therapy(heparin &warfarin)|patients with confirmed diagnosis of acute MVT on CT scan but having no signs of peritonitis or established CT signs of gangrene will be treated conservatively with anticoagulation(heparin &warfarin) while other cases will be for surgical management and not included in the study.
2413096|NCT03483207|Experimental|MVT with failure of anticoagulation therapy(heparin &warfarin)|patients who underwent conservative therapy with anticoagulation (heparin &warfarin) but showed no improvement .
2413097|NCT03483194|Active Comparator|Kalinox®|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen (Kalinox®)
2413098|NCT03483194|Experimental|Virtual Reality|The included patients in this group will have, during the intervention, a local anesthesia by xylocaine® 10 mg / mL (1 bottle of 20 mL) in complement of a virtual reality (VR) session.
2413099|NCT03483181||Orthopedic surgery patient records|Medical records from patients aged 18 years or older with orthopedic surgeries during the hospitalization
2413100|NCT03483168|Experimental|Culturally sensitive pain education|
2413101|NCT03483168|Active Comparator|Standard pain education|
2413102|NCT03483142|Experimental|misoprostol group|misoprostol group ( study group ) ( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
2413103|NCT03483142|Placebo Comparator|placebo group|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol.
2413104|NCT03483129|Experimental|Consultation|The consultation will provide the participant with one to one information regarding the benefits of physical activity and healthy eating. Emphasis will placed on the importance of achieving at least 150 minutes of moderate physical activity each week as well as adhering to healthy dietary habits, based on the NHS Eatwell Guide (Eatwell Guide, 2016). Furthermore, participants will have the opportunity to discuss pre-diabetes with a trained practice nurse and ask any questions they may have.
2413105|NCT03483129|No Intervention|Control|All participants will receive an information leaflet detailing pre-diabetes, the associated risks and steps that can be taken to avoid developing diabetes.
2413106|NCT03483116|Experimental|High dose RV3-BB neonatal schedule|High dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2413107|NCT03483116|Experimental|Mid dose RV3-BB neonatal schedule|Mid dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2413108|NCT03483116|Experimental|Low dose RV3-BB neonatal schedule|Low dose neonatal RV3-BB vaccine schedule. RV3-BB Vaccine for Investigational product doses 1 (0-5 days), 2 (week 6) and 3 (week 10) and placebo for Investigational product dose 4 (week 14)
2413109|NCT03483116|Experimental|High dose RV3-BB infant schedule|High dose infant RV3-BB vaccine schedule. Placebo for Investigational product dose 1 (0-5 days) and RV3-BB Vaccine for Investigational product doses 2 (week 6) 3 (week 10) and dose 4 (week 14)
2413110|NCT03483103|Experimental|Treatment|Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).
2413111|NCT03483090|Experimental|Treatment A|4000mg Swisse High Strength Deep Sea Krill Oil (Superba BOOST) (4 capsules containing 1000mg each)
2413112|NCT03483090|Placebo Comparator|Treatment B|4 capsules of matching Placebo orally daily (1000mg each of mixed vegetable Oil)
2413113|NCT03483077|Experimental|BI 730460|
2413114|NCT03483077|Placebo Comparator|Placebo|
2413115|NCT03483064|No Intervention|Control group|Subjects without low back pain to whom the electric current is put but it is not activated.
2413116|NCT03483064|Experimental|Healthy group|Subjects without low back pain to whom the electric current is put but it is activated.
2413120|NCT03483025|Other|Hair Cleansing product 1|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413121|NCT03483025|Other|Hair cleansing product 2|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413122|NCT03483025|Other|Hair cleansing product 3|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413123|NCT03483025|Other|Hair cleansing product 4|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413124|NCT03483025|Other|Hair cleansing product 5|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413125|NCT03483025|Other|Hair cleansing product 6|Skin Testing of Hair cleansing products all pts will test 6 hair cleansing products, but site of testing will be randomized and blinded
2413231|NCT03482245|Experimental|Appendicitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
3145315|NCT00067626|Experimental|2|500/1000 mcg oral chromium taken daily or placebo (crossover)
3145316|NCT00067639|Experimental|Pegfilgrastim + Apheresis|12 mg Pegfilgrastim as subcutaneous injection on day 1 + Apheresis daily till target stem cell dose reached.
3145317|NCT00067665|No Intervention|1|Control group of 50 patients where dry weight is not changed.
2413127|NCT03482999||Control|Standard Wound Closure with drains
2413128|NCT03482999||TissuGlu Surgical Adhesive|TissuGlu was used for approximation and adhesion of the flaps in conjunction with drains
2413129|NCT03482986|Experimental|Group A|Subject will be advised to follow dietary habits plan A. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
2413130|NCT03482986|Experimental|Group B|Subject will be advised to follow dietary habits plan B. Since this is a single blind study, the details of the dietary interventions cannot be released during recruitment stage, but will be made public once enrollment closes.
2413133|NCT03482960|Experimental|129Xe MRI|Participants will self-administer hyperpolarized xenon gas via inhalation prior to the investigators acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant will return to the MRI scanner, where the second phase of the study will occur. PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath.
2413134|NCT03482960|Experimental|19F MRI with PFP|PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. After the MRI is complete, participant performs spirometry maneuvers in a room outside the magnet. Once a minimum of 15 minutes has elapsed since leaving the MRI scanner, the participant returns to the MRI scanner, where he/she will self-administer hyperpolarized xenon gas prior to acquiring MRI images. MRI imaging will be taken during approximately 15-second breath-holds.
2413135|NCT03482947|Experimental|TAP|ultrasonography-guided transversus abdominis plane block administration of (1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
2413136|NCT03482947|Experimental|Caudal|Caudal epidural block administration of (1 mL/kg of bupivacaine 0.25% &1 μ/kg dexmedetomidine
2413137|NCT03482934||hypertensive patients|
2413138|NCT03482908|Experimental|Responsive parenting treatment|Early Healthy Lifestyles (EHL) screening tool reported by participants to identify potentially obesogenic parenting practices and child behaviors; data sharing/coordination into electronic health records to inform counseling by trained providers; responsive parenting curriculum delivered by trained WIC nutritionists.
2413139|NCT03482908|No Intervention|Standard Care Control|Standard of pediatric and WIC care
2413140|NCT03482895||Patient: Blood sampling & Feces sampling|"Blood samplings at different times after a meal test: 0, 15, 30, 60, 90 and 120 minutes.~Feces sampling: collection during 24 hours"
2413142|NCT03482869|Experimental|Diabetic patients|Patients referred for the equilibrium or diagnosis of diabetes mellitus will be proposed to participate and estimate their walking ability with the WELSH (Walking estimated limitation stated by History) based solely on images
2413143|NCT03482856|Experimental|Modern Neuroscience Approach (MNA) plus CBT-I|MNA (i.e. modern pain neuroscience approach) combined with CBT-I (i.e. cognitive-behavioural therapy for insomnia)
2413144|NCT03482856|Active Comparator|MNA alone|The MNA (i.e. modern pain neuroscience approach) alone
2413145|NCT03482843||Vitamin D Deficiency|25-Vitamin D level <25 ng/ml
2413146|NCT03482843||Sufficient Vitamin D Level|25-Vitamin D Level >=25-70 ng/ml
2413147|NCT03482817|Experimental|Probe drug cocktail / Ze 117|One-sequence, Probe drug cocktail alone and in combination with Ze 117.
3145318|NCT00067665|Experimental|2|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
3145319|NCT00067704|Experimental|Trauma writing|Four sessions of writing about traumatic experiences.
3145320|NCT00067704|Sham Comparator|Writing about daily events|Four sessions of writing about their daily experiences.
3145321|NCT00067717|Experimental|Distant Healing|This group received distant healing but was blinded to the condition.
3145322|NCT00067717|Placebo Comparator|Non-blinded Distant Healing|This group received the distant healing intervention and was called every day they were receiving to be told they were receiving it, therefore enhancing expectancy.
2413153|NCT03482765|Experimental|Probiotic 1|Probiotic 1: A dietary probiotic supplement which contains Bifidobacterium lactis. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
2414072|NCT03476304|Active Comparator|Post retained ceramic restoration|
3145323|NCT00067717|No Intervention|Blinded Control|This group was blinded to the intervention condition and did not receive any distant healing.
3145324|NCT00067730|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3145325|NCT00067743|Other|1|Open Label trial
3145326|NCT00067756|Experimental|4-PBA|The study will involve a 4-PBA dose escalation and pharmacokinetics component The study group will be comprised of a total of at least 10 AAT-deficient,(phenotype ZZ referred to as PiZZ) patients. These patients will be divided into two groups: with and without clinical evidence of mild to moderate hepatocellular injury.
3145327|NCT00067769|Active Comparator|TAU|Patients received treatment as usual (TAU) as defined as continued clinical care.
3145328|NCT00067769|Experimental|TAU+UCanPoopToo|Patients received treatment as usual (TAU) plus the Internet intervention (UCanPoopToo.)
3145329|NCT00067782|Active Comparator|1|
3145330|NCT00067782|Active Comparator|2|
3145332|NCT00067873|Active Comparator|Diet only|
3145333|NCT00067873|Experimental|Diet plus aerobic exercise|
3145334|NCT00067873|Experimental|Diet plus resistance exercise|
3145335|NCT00067938|Other|Arm 1|Open label single arm study
2413154|NCT03482765|Experimental|Probiotic 2|Probiotic 2: A dietary probiotic supplement which contains Lactobacillus acidophilus. Dose: > 10 billion CFU, Frequency: 1 capsule/day, duration: 6 weeks.
2413155|NCT03482765|Placebo Comparator|Placebo|The Placebo contains MCC.
2413156|NCT03482726|Other|Cycling Cadence Modulation|3 initial visits to collect baseline information; 6-week HIIT indoor cycling program at the individual prescribed cadence; final study visit for post-intervention measures.
3185677|NCT00737724|Experimental|Group 1|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
2413159|NCT03482700|Other|Intervention|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
2413160|NCT03482700|Other|Control|Usual standard of care
2413161|NCT03482687|Experimental|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid.
2413162|NCT03482687|No Intervention|Comparison Group|No intervention was provided, only usual care.
2413163|NCT03482674|No Intervention|Control Group|The control group will receive standard care as provided by the German statutory health insurance.
2413164|NCT03482674|Experimental|Intervention group|The intervention group receives the DIMINI lifestyle intervention for a period of three months.
2413165|NCT03482661|No Intervention|Control|The patients swallowed the capsule with water in the supine position. When the capsule reached the stomach, the capsule was lifted away from the posterior wall, rotated and advanced to the fundus and cardiac regions, and then to the gastric body, angulus, antrum and pylorus. After completing the stomach examination, the capsule moved automatically without magnetic control and entered the duodenum under physiological conditions. The position of the capsule was verified through real-time viewer.
2413166|NCT03482661|Experimental|Magnetic steering|After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis.
2413167|NCT03482648|Experimental|Single Ascending Doses|
2413168|NCT03482648|Experimental|Multiple Ascending Doses|
2413173|NCT03482622||Patients undergoing Mohs surgery|Skin samples excised during Mohs surgery will be measured by the Fast Raman device. The Fast Raman measurements will be compared to gold standard histopathology to determine measurement accuracy.
2413174|NCT03482596|Experimental|Intervention|All participants will follow the personalised multifaceted intervention to reducing/breaking prolonged sitting.
3145336|NCT00068055|Experimental|1|60 subjects to receive Omr-IgG-am.
2413179|NCT03482544|Active Comparator|Pregabalin Group|We will give 150 mg pregabalin capsule orally 1 day before surgery and 1 hour before surgery (totally two times) to the pregabalin group patients.
2413180|NCT03482544|Active Comparator|Control Group|In control group, we will empty the drug material from capsules and give only empty capsules to the control group patients at the same times.
2413181|NCT03482531||before group|"In the before group, the investigators retrospectively included 405 patients who had a dinoprostone vaginal insert for cervical ripening before induction of labor, between January 2015 and September 2016.~Multivariate and regression analysis showed that the factors significantly increasing the time to delivery were: Nulliparity, obesity, a closed cervix on initial examination, and intact membranes at the time of insertion. The investigators also described a regression equation that allows to calculate the mean time from insert placement to delivery for each patient."
2414073|NCT03476291||Normal|normal macular structure of horizontal OCT B-scans
3145337|NCT00068055|Active Comparator|2|20 subjects to receive Polygam® S/D (IVIG).
3145338|NCT00068055|Placebo Comparator|3|20 subjects to receive normal saline.
3145339|NCT00068224||Ciliopathy|Children and adults who carry a clinical diagnosis of a known ciliopathy and those patients who have typical features suggestive of a cliopathy but not fulfilling the diagnostic criteria.
3145340|NCT00068302|Experimental|Sirolimus|This is a dose escalation study including 4-dose levels. Subjects will receive a one-time loading dose of sirolimus on day 0, time 0. Subsequent dosing at the assigned dose level will start 24 hours following the initial loading dose
3145341|NCT00068315|Experimental|Treatment (bortezomib, fludarabine, rituximab)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and fludarabine IV over 30 minutes on days 1-3 or 1-5. Patients may also receive rituximab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3145342|NCT00068328||Group 1|"Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.~Patients are followed annually for at least 5 years."
3145343|NCT00068432|Experimental|Gemcitabine + Celecoxib|Oral celecoxib twice daily on days 1-28. Gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
3145344|NCT00068458|Active Comparator|Arm 1: calcium diet|Calcium-Rich Diet (dietary counseling + materials promoting an intake of 1,200 - 2,500 mg/day).
3145345|NCT00068458|Active Comparator|Arm 2: Exercise + Calcium-Rich Diet|Exercise + Calcium Rich Diet (dietary counseling + materials promoting strength training and aerobic activity + a calcium intake of 1,200 - 2,500 mg/day).
3145346|NCT00068458|Active Comparator|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|Dietary counseling + materials promoting strength training and aerobic activity + a diet that has < 20% of energy coming from fat and intakes of fruits and vegetables of > 5 servings/day + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
3145347|NCT00068484|Experimental|Treatment (topotecan hydrochloride, bortezomib)|Patients receive topotecan IV over 30 minutes on days 1-5. Beginning with course 2, patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2413182|NCT03482531||after group|"The investigators will prospectively include all eligible patients with a vaginal dinoprostone insert for cervical ripening during the next two years, starting on April 1st, 2018. At Angers hospital, there are around 600 cases of dinoprostone vaginal inserts per year, so the investigators will be able to include 400 to 500 patients during the study's duration.~The equation will be incorporated when scheduling patients for cervical ripening with vaginal dinoprostone insert. The main objective of this study is to analyze to evaluate our mathematical model. One of the secondary objectives is to analyze whether the use of the personalized scheduling based on the mathematical model would decrease the rate of nocturnal deliveries (between midnight and 6 a.m.)."
2413183|NCT03482518|Experimental|Intervention Group|The intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover with elements in insoles. They will be advised to wear the slipper for 4 hours in the first week and up to 8 hours after that period. Should any part of you feel uncomfortable, the participant should return immediately so that the appropriate adjustments are made in the slipper
2413184|NCT03482518|Sham Comparator|Control group|"The control (sham) group volunteers will receive a pair of custom slippers with perforated synthetic leather cover as those used by GI.~The difference will be that these slippers will not have the elements in the insoles."
3145348|NCT00068497|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib on day 1 and then daily beginning on day 8. Treatment continues in the absence of disease progression or unacceptable toxicity.
2413186|NCT03482492|Active Comparator|Tramadol|Group Tramadol patients received tramadol 1 mg kg-1 iv
2413187|NCT03482492|Active Comparator|Tramadol-Paracetamol|Group Tramadol-Paracetamol patients received paracetamol 1 gr iv in addition to tramadol 1 mg kg-1 iv 30 minutes before the end of the operation and after the operation at 6 hour intervals for 24 hours
2413188|NCT03482479|Experimental|Naltrexone Hydrochloride|Naltrexone hydrochloride for oral use, 4.5 mg per capsule, taken once a day for 6 weeks.
2413189|NCT03482479|Placebo Comparator|Placebo Comparator|Placebo to match naltrexone for oral use to be taken once a day for 6 weeks.
2413190|NCT03482466|Experimental|PTSD patients|12 PTSD patients will be recruited to undergo neurofeedback training .
2413200|NCT03482440|Placebo Comparator|Placebo|
2413201|NCT03482440|Experimental|Salsalate|
2413202|NCT03482427|Experimental|Intervention|After completion of the Healthy Hear Score assessment, participants will receive a lifestyle intervention based on the Healthy Heart Score results for 12-weeks by trained dietetic interns on-site. Participants will receive a check-in email or phone 6 weeks after the initial visit. A Registered Dietitian is also available to speak with patients. The intervention will consist on educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors
2413203|NCT03482427|No Intervention|Control|Participants in the control group will follow their usual care protocol after taking the Healthy Heart Score assessment. Researchers will provide the Healthy Heart Score survey results, but will not discuss or interpret the results with them. Participants can discuss any concern they have with their usual physician if they choose. After the follow-up visit and upon completion of the study, all participants in the control group may also receive the educational handouts and will be granted access to the Healthy Heart Score application if they wish.
2413204|NCT03482414|Active Comparator|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
2413205|NCT03482414|Experimental|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
2413206|NCT03482414|Experimental|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
2413207|NCT03482401|Experimental|Polyphenol group|Patients consumed a polyphenol-rich dietary supplement (commercial lemon, orange, pomegranate, olive, grape, cocoa, curcuma and broccoli extracts), mainly rich in simple phenolics such as hydroxytyrosol and the polyphenols procyanidins, hesperidin, eriocitrin, curcumin, resveratrol, punicalagin and ellagic acid. Cocoa extract also contains the methylxanthines theobromine and caffeine.
3145349|NCT00068510|Experimental|autologous tumor lysate-pulsed DC|
3145350|NCT00068549|Experimental|Treatment|Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 in the absence of disease progression or unacceptable toxicity. Patients also undergo external whole pelvis radiotherapy once daily on days 1-5, 8-13, 15-20, 22-27, and 29-34. After completion of external beam radiotherapy, patients undergo intracavitary radiotherapy and parametrial radiotherapy. The total elapsed time for completion of all radiotherapy is not more than 8 weeks.
3145351|NCT00068653|Experimental|Celecoxib & ZD1839|"Celecoxib: 400mg orally two times a day, taken with meals.~ZD1839: 250 mg po every day, taken with or without food."
3145352|NCT00068666|Experimental|radiation + temozolomide|"Patients receive concurrent chemoradiotherapy comprising whole brain radiotherapy daily on days 1-5, 8-13, and 16-21 and oral temozolomide daily on days 1-5. Subsequent treatment with temozolomide repeats every 4 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months."
3145353|NCT00068731|Experimental|lycopene|"Patients receive oral lycopene twice daily on days 1-28. Courses repeat every 28 days for at least 4 months in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months until disease progression and then every 6 months for up to 5 years."
3145354|NCT00068783|Experimental|Treatment|Patients receive oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression, unacceptable toxicity, or symptomatic deterioration.
3145355|NCT00068809|Experimental|Short-cycle therapy (SCT)|At entry, subjects will switch from continuous HAART to SCT. All subjects will then be followed to assess viral load breakthrough over 48 weeks on SCT.
3145356|NCT00068874|Active Comparator|1|Educational comparison group
3145357|NCT00068874|Experimental|2|Group receiving coping intervention designed to enhance coping and psychological adjustment
3145358|NCT00068874|No Intervention|3|Comparison control group with no active intervention
3145359|NCT00068991|Experimental|1|Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session. After training, participants complete a post-training evaluation of the training sessions. Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
2413209|NCT03482388|Experimental|Crowdsourced intervention|A multimedia component will deliver two videos and two images promoting HBV and HCV testing developed through a crowdsourcing contest in China. A participatory component will invite men to submit suggestions for how to improve crowdsourced videos and images.
2413210|NCT03482388|Other|Control|No images or videos will be viewed, and suggestions for improving hepatitis testing materials will not be collected.
2413211|NCT03482375||No Stones on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
2413212|NCT03482375||Stones seen on POC after ERCP|This is a cohort in which there are no stones seen on Cholangioscopy after ERCP and cholangiogram to treat gall stones.
2413213|NCT03482362|Experimental|Cohort A; KRASmt, BRAFwt, BRAF-like CC|Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
2413214|NCT03482362|Experimental|Cohort B; KRASwt, BRAFmt, BRAF-like CC|Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
2413215|NCT03482349|Experimental|Total Knee Robotically-Assisted|The intervention is then performed with a new device and surgical procedure. At first the femur and the tibia are fixed to the operating table with a special clamp and the knee bones are exposed with the standard technique; then the surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
2413216|NCT03482349|No Intervention|Total Knee Manual-Executed by Surgeon|Your orthopaedic surgeon will remove the damaged cartilage and bone, and then position the new metal and plastic implants to restore the alignment and function of your knee.
2413217|NCT03482336|Other|Uninstructed Group|"For the first block of participants recruited (39, one of which withdrew from boredom), no overt reference was made regarding the FOP labels that were present on the images that participants viewed during the course of the video game. Participants comprising this block were referred to as uninstructed."
2413218|NCT03482336|Other|Minimally trained|"Realizing that subjects might not use the FOP during decision making when not informed that it contained nutrition information, we conducted a second experiment (N= 41) which provided minimal information about the FOP. These subjects (the minimally instructed group) were provided with further instruction. At the beginning of the experiment, in addition to being shown the basic premise of the game and told that Munchy preferred to eat healthy options, the researcher pointed to one of the FOPs and told children this information might be helpful when you decide what's healthy."
2413219|NCT03482323|Experimental|Exercise intervention|Exercise class will run twice a week for 12 weeks. Participants will be encouraged to maintain their exercise beyond the intervention. An exercise trainer will lead the classes. The main activity of the classes includes aerobic exercises of walking on treadmill, or out-doors depending on group preference and weather, at a set pace individually tailored for moderate intensity of exercise, determined by baseline physical functioning assessment and modified based on Rated Perceived Exertion (RPE), or cycling on a stationary bike, using a set resistance to the physical functioning assessment and RPE. A set of four strengthening exercises are included in one of the exercise classes each week. These exercises are chosen to increase strength in the leg, arm, abdomen and improve trunk stability. Weights for the strengthening exercise will be set to give participants a moderate level of intensity of exercise.
2413220|NCT03482323|Experimental|Tai-chi intervention|The classes will run twice a week for 12 weeks with each session lasting approximately 60 minutes. Classes will be taught by an experienced tai-chi master, who will explain the theory behind tai-chi and the principles of the techniques. The supervised session includes a warm up, self-massage and a guided run through of the movements, breathing techniques, and relaxation in tai-chi. The tai-chi master will guide participants to practice the tai-chi they learn in the classes at home each day. Upon completion of the 12 weeks course, participants will be encouraged to continue their tai-chi practice, given guidance on local services and programmes they may join if they wish to.
2413221|NCT03482323|No Intervention|Control group|Participants randomised to the control group shall receive written information on health levels of physical activity, which they can participate in at home (self-management) and continue to receive their usual care, participants will be followed up with an assessment at 12 weeks, 6 months and one year. At the end of the evaluation stage of the study, survivors in the control group will be invited to take part in an intervention of their choice.
2413222|NCT03482310|Experimental|Cortical Control of Grasp Patterns|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
3145360|NCT00068991|Experimental|2|Participants will be villagers considered influential members of their community. In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Participants will also attend additional support meetings monthly, from Months 2 to 15. They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
3145361|NCT00068991|Experimental|3|Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
2413225|NCT03482284|Experimental|Monosaccharide 1|Participants receive standardized meals with a defined amount of monosaccharide 1.
2413226|NCT03482284|Experimental|Monosaccharide 2|Participants receive standardized meals with a defined amount of monosaccharide 2.
2413227|NCT03482258|Experimental|Treatment Prebiotic|3 week daily dose of Vivinal-GOS (galacto-oligosaccharide)
2413228|NCT03482258|Placebo Comparator|Placebo|3 week daily dose of Maltodextrin
2413229|NCT03482245|Experimental|Pneumonia: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
2413230|NCT03482245|Experimental|Diverticulitis: Blue Light|High illuminance (1000lux), blue spectrum (peak 441 nm) light for an initial 24 hour photoperiod after surgery for diverticulitis
3145362|NCT00069017|Active Comparator|1|MEDI-522 - 4 mg/kg of MEDI-522 (N=200)
3145363|NCT00069017|Placebo Comparator|2|Placebo (N=100)
2413232|NCT03482245|No Intervention|Pneumonia: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod and then a 12 hour photoperiod for days 2 and 3 after randomization.
2413233|NCT03482245|No Intervention|Diverticulitis: Ambient Light|Standard ambient hospital lighting (~300 lux)for an initial 24 hour photoperiod after surgery for diverticulitis.
2413234|NCT03482245|No Intervention|Appendicitis: Ambient Light|Standard ambient hospital lighting (~300 lux) for an initial 24 hour photoperiod after surgery for diverticulitis.
2413235|NCT03482232||Patients visiting GP|All patients visiting GP. The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
2413236|NCT03482232||Patient visiting pediatricians|All patients visiting pediatricians (0 to 14 years old). The frequency of some drugs and diagnosis tests include in the Do-Not-Do recommendations will be analyzed.
2413237|NCT03482219|Experimental|Intensive treatment|"Participants will undergo 8 sessions with an occupational therapist. Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises. The occupational therapy consists of the following which will be provided as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
2413238|NCT03482219|Active Comparator|Home app intervention|Participants will meet with the occupational therapist to establish the home exercise program and set up the home exercise app. The app has videos depicting each exercise and ability to track adherence to exercises.
2413239|NCT03482206|Experimental|Healthy subjects|Healthy adult volunteers (age 18 or greater) that are not claustrophobic, do not have hyperventilation or panic disorders, not pregnant, have no metal implants and can pass the MRI screening questions.
2413240|NCT03482193||Adolescents|Adolescents in 2nd or 4th year in secondary school, from 9 different schools in Liège, Belgium.
2413241|NCT03482180|Experimental|Investigational Group- KI1106|KI1106 tablet - daily administration
2413242|NCT03482180|Active Comparator|Control Group - Atorvastatin|Atorvastatin Calcium 20mg - daily administration
2413243|NCT03482167|Placebo Comparator|Placebo|placebo
2413244|NCT03482167|Experimental|Nicotinamide Riboside|Niagen® (ChromaDex, Inc.) 500 mg, twice daily
2413245|NCT03482154||With Malglycemia|
2413246|NCT03482154||Without Malglycemia|
2413247|NCT03482141|Other|WES|Whole exome sequencing (WES) will take place.
2413248|NCT03482128||preAlgorithm|Standard coagulation management of patients undergoing cardiac surgery
2413249|NCT03482128||postAlgorithm|Coagulation management guided by SONOCLOT of patients undergoing cardiac surgery
2413250|NCT03482115|Experimental|Comatose patient|Subject with coma of traumatic or anoxic aetiology : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
2413251|NCT03482115|Other|control volunteers|subject control : PET examination with radiopharmaceutical drug [18F] DPA-714, MRI examination and Blood samples.
2413252|NCT03482102|Experimental|Tremelimumab + Durvalumab + Radiation|"Durvalumab via IV infusion every 28 days for up to 4 doses/cycles~Tremelimumab via IV infusion every 28 days for up to 4 doses/cycles, and then continue durvalumab monotherapy every 4 weeks starting on Week 16 for up to 8 months.~Radiation therapy will only be given during cycle 2"
3145364|NCT00069069|Experimental|1|single center, Phase 1, open label, dose escalation trial assessing safety profile of four doses of intranasal recombinant human E-selectin
3145365|NCT00069082|Active Comparator|Civamide|Nasal Solution 0.01%
2413255|NCT03482076|Other|transferrin receptor concentration|Prevelance of iron deficiency in this patients
2413256|NCT03482063|Experimental|Swisse Ultiboost Memory + Focus|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
2413257|NCT03482063|Placebo Comparator|Placebo|two tablets daily, one tablet during or immediately after breakfast, and one tablet during or immediately after lunch, for the duration of the trial period
2413258|NCT03482050|Experimental|AstroRx|
2413259|NCT03482037|Experimental|Rec 0/0438|Rec 0/0438 1 mg (first cohort), 2 mg (second cohort) to be administered by intravesical instillation once daily for four weeks
2413260|NCT03482037|Placebo Comparator|Placebo|Placebo, to be administered by intravesical instillation once daily for four weeks
2413261|NCT03482024|Experimental|Tirzepatide - Healthy|Group 1 - Tirzepatide administered subcutaneously (SC) to healthy participants with normal renal function.
2413262|NCT03482024|Experimental|Tirzepatide - Mild Renal Impairment|Group 2 - Tirzepatide administered SC to participants with mild renal impairment.
2413263|NCT03482024|Experimental|Tirzepatide - Moderate Renal Impairment|Group 3 - Tirzepatide administered SC to participants with moderate renal impairment.
2413264|NCT03482024|Experimental|Tirzepatide - Severe Renal Impairment|Group 4 - Tirzepatide administered SC to participants with severe renal impairment.
2413265|NCT03482024|Experimental|Tirzepatide - End Stage Renal Disease (ESRD)|Group 5 - Tirzepatide administered SC to participants with ESRD.
2413268|NCT03481998|Experimental|Cohort 1 (Part 1)|Participants receive SHR6390 (at protocol defined dose levels) in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
2413644|NCT03479359||Group 1|In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.
3145366|NCT00069082|Placebo Comparator|Placebo|Placebo nasal solution with sodium chloride 10%
3145367|NCT00069134|Experimental|Sulfur Amino Acids|12 children with edematous severe malnutrition will be assigned to receive 0.65 mmol/kg/d of sulfur amino acids. Supplements will be added to the children's daily diets.
3145368|NCT00069134|Placebo Comparator|Alanine|12 children with edematous severe malnutrition are assigned to receive 0.65 mmol/kg/d of alanine as placebo. Supplements will be added to the children's daily diets.
3145369|NCT00069381|Experimental|study arm|
3145370|NCT00069407|Active Comparator|RUL|Right unilateral electroconvulsive therapy
3145371|NCT00069407|Active Comparator|BL|Bilateral electroconvulsive therapy
3145372|NCT00069407|Active Comparator|BF|Bifrontal electroconvulsive therapy
3145373|NCT00069459|Other|Extended-release Bupropion Hydrochloride|Extended-release Bupropion Hydrochloride
2413269|NCT03481998|Experimental|Cohort 2 (Part 1)|SHR6390 (TBD), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
2413270|NCT03481998|Experimental|SHR6390 + Letrozole or anastrozole (Part 2)|SHR6390 (RP2D, recommended Phase 2 dose), in combination with letrozole 2.5 mg or anastrozole 1mg, orally once daily (continuously).
2413271|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 3 (Part 1)|SHR6390 (at protocol defined dose levels), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
2413272|NCT03481998|Experimental|SHR6390 + Fulvestrant Cohort 4 (Part 1)|SHR6390 (TBD), in combination with Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle once daily
2413273|NCT03481972|Experimental|Doxy/TUDCA|"doxycicline (100 mg / BID)~tauroursodeoxycholic acid (250 mg / TID)"
2413274|NCT03481972|Active Comparator|Standard of care|Standard of care therapies.
2413275|NCT03481959|Experimental|Methylphenidate|Methylphenidate delay shape, 10 and 30 mg capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).
2413276|NCT03481959|Placebo Comparator|Matching Placebo|
2413277|NCT03481946|Experimental|BAY1093884 in subjects with Hemophilia|Single dose of BAY1093884 over 30 minutes administered in subjects with severe congenital Hemophilia A or B, with inhibitors or without inhibitors
2413278|NCT03481933|Experimental|1:left-excitatory tDCS|20 SD patients who receive left-excitatory trans cranial stimulation
2413279|NCT03481933|Active Comparator|2:right-inhibitory tDCS|20 SD patients who receive right-inhibotory trans cranial stimulation
2413280|NCT03481933|Sham Comparator|3:sham tDCS|20 SD patients who receive sham stimulation
2413281|NCT03481920|Experimental|PEGPH20 + Avelumab|PEGPH20, a multi-site PEGylated enzyme generated by conjugating N-hydroxysuccinimidyl ester of methoxypoly(ethylene glycol)-butanoic acid (MSBA30K/B or PEG) and recombinant human hyaluronidase (rHuPH20). PEGPH20 has a half-life of approximately 2 days, thereby enabling systemic activity and sustained duration of action to degrade HA. In many different tumor types tested in murine xenograft models, response to PEGPH20 has been shown to be more robust for tumors characterized by higher HA expression.
2413282|NCT03481907|Other|Internalized Control|Subjects will receive 2 punch biopsy created wounds, one on each thigh, which will be addressed with primary closure with sutures or will be treated with Nuvagen collagen powder at time of wounding and daily thereafter. Suture(s) will be removed in 2 weeks. At week four, the wounded site will be biopsied again for tissue collection/evaluation, and treated with primary closure again. Suture(s) will be removed within to weeks. For those using collagen powder, the biopsy site will be biopsied again at week 4, and wound care will again be with NuvagenTM collagen powder until closure.
2413283|NCT03481894|Experimental|Kabiven®|Kabiven is a sterile, hypertonic emulsion in a three chamber container. The separate chambers contain either amino acids with electrolytes, dextrose, or lipid injectable emulsion.
2413284|NCT03481894|Active Comparator|Compounded standard parenteral nutrition|"The control drug will be compounded for each individual patient as prescribed by the physician. Compounding will be performed according to normal hospital procedure which meets the requirements of the United States Pharmacopeial Convention (USP) <797> Pharmaceutical Compounding-Sterile Preparations."
2413285|NCT03481868||Chronic Myeloid Leukemia|Patients newly diagnosed for Chronic Myeloid Leukemia, according to inclusion and exclusion criteria
2413286|NCT03481855||Progressive bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with progressive increase of negative pressure by a step-wise approach (-15mmHg, -30mmHg, -45mmHg).
2413287|NCT03481855||Prolonged bleeding simulation|The study intervention by a lower-body-low-pressure chamber is performed in this group of healthy volunteers with prolonged exposure to a negative pressure of -15mmHg.
3145374|NCT00069706|Experimental|AL-12182 0.003%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3145375|NCT00069706|Placebo Comparator|AL-12182 Solution Vehicle|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3145376|NCT00069706|Active Comparator|Latanoprost|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
2413293|NCT03481790|Experimental|Lactoferrin|100mg of bovine lactoferrin (Pravotin sachets, Hygint, Egypt) twice a day.
2413294|NCT03481790|Experimental|ferrous sulphate + folic acid (vitamin B9)|150mg of dried ferrous sulphate + folic acid (vitamin B9) 0.50mg (Ferrofol, E.I.P.I.C.O, Egypt) three capsules per day.
2413295|NCT03481777|Active Comparator|Remote Ischemic Conditioning|"Remote ischemic conditioning (RIC) is applied in the hyperacute prehospital phase using an automated RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be 200 mmHg; but if initial systolic blood pressure is above 175 mmHg, the cuff is automatically inflated to 35 mmHg above the systolic blood pressure.~Initial remote ischemic conditioning: prehospital phase, all included patients~Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy"
2413325|NCT03481582|Active Comparator|Group without nitroglycerin|They will be subjected to TV ultrasound for folliculometry till maturation of the follicle ≥18mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
2413369|NCT03481218||Individuals without chronic diseases|Young adults (male and female) between the ages of 18 and 35, without chronic diseases.
3145377|NCT00069706|Experimental|AL-12182 0.01%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3145378|NCT00069706|Experimental|AL-12182 0.03%|One drop in the study eye(s) once daily at approximately 8 a.m. for 14 days
3145379|NCT00069836|Experimental|Arm 1|
3145380|NCT00069927|Experimental|Arm 1- Adderall- XR®|Adderall-XR® 1 10 mg/day for 3-12 weeks depending on subject's response
2413296|NCT03481777|Sham Comparator|Sham - Remote Ischemic Conditioning|"Sham remote ischemic conditioning (Sham-RIC) is applied in the hyperacute prehospital phase using an automated Sham-RIC device.~Treatment characteristics: Five cycles (50 minutes), each consisting of five minutes of cuff inflation followed by five minutes with a deflated cuff. The cuff pressure will be always be 20 mmHg.~Initial Sham remote ischemic conditioning: prehospital phase, all included patients~Sham Remote ischemic conditioning at +6 hours: In-hospital, only patients with AIS and ICH, all centres~Sham Remote Ischemic Postconditioning (twice daily for 7 days): In-hospital/rehabilitation, Only patients with AIS and ICH and only at Aarhus University Hospital~Usual care with or without acute reperfusion therapy."
2413297|NCT03481764||FS: Febrile Seizures|Involved patient with diagnosed Febrile Seizures which were hospitalized or recieved ambulatory treatment in University Children´s Hospital in Belgrade. Ages 5-14 years
2413298|NCT03481764||CN: Control group|The control group was made of healthy children older than 5 years of age, which have never had any neurological disorders in their anamnesis and who were patients in preschool or school dispensaries in the city of Belgrade
2413299|NCT03481764||SFS : group of individuals with simple FS|Simplex febrile seizures (SFS) last shorter than 15 minutes and their type is tonic-clonic. Also, they did not show signs of recidivism during the first 24 hours and were diagnosed at the patients aged from 6th months to 5th year
2413300|NCT03481764||CFS : group of individuals with complex FS|Complex febrile seizures (CFS) were diagnosed at those patients that had focal seizure or epileptic status or seizure having the body temperature lower than 38 degree, which occurred outside of the typical age group and finally which repeated in the first 24 hours again
2413301|NCT03481764||WFS: group of individuals with FS and without epilepsia|group of children with Febrile Seizure and not developed epilepsia
2413302|NCT03481764||EFS: group of individuals with epilepsia and Febrile Seizures|Group of children with Febrile Seizures, who have developed Epilepsy
2413303|NCT03481751||Patients with Crohn Disease|Patients with Crohn's disease scheduled for ileocolonoscopy
2413304|NCT03481738||PKD Diagnosed|Participants diagnosed with PK deficiency by the presence of 2 or more PKLR gene mutations as well as clinical features.
2413307|NCT03481699|Experimental|Incremental theory of personality|1 hour behavioral intervention (based on ITP) consisting on several tasks to be completed on paper individually.
2413308|NCT03481699|Other|Educational intervention|1 hour educational intervention (about the human brain) consisting on several tasks to be completed on paper individually.
2413309|NCT03481686|Experimental|Patients with injections of ESA|Patients with injections of ESA
2413310|NCT03481673|Experimental|Intervention|This pre-experimental pilot project is a single group, pretest-posttest design with a 6-week post-intervention follow-up. A single group design was chosen for this feasibility pilot study because the COPE for Asthma intervention is newly adapted for 8 to 12-year-old children with asthma in an urban setting. The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression. Surveys with children and their parents/caregivers (CGs) will occur at baseline, immediately post-intervention and 6 weeks' post-intervention.
2413313|NCT03481647|Active Comparator|Intervention|The intervention consists of professional oral care and swabbing of the mucosal membranes with a saline and bicarbonate solution, five daily rinses with a saline and bicarbonate solution, a diary to register oral care measures and rinses
2413314|NCT03481647|No Intervention|Control|Professional oral care once a week according to existing routine
3145381|NCT00069927|Experimental|Arm II Concerta®|Concerta ® 18 mg/day for 3-12 weeks depending on subject's response
3145382|NCT00069992|Experimental|Submyeloablative Allogeneic Stem Cell Transplant|Total Body Irradiation Fludarabine Campath 1H
3145383|NCT00070057|Experimental|Arm I (celecoxib)|Patients receive oral celecoxib twice daily for 1-3 weeks (according to the duration between biopsy and surgery) in the absence of unacceptable toxicity.
2413318|NCT03481621|Active Comparator|Group1a, Acupuncture on Vulvodynia|Focus on using the local points in pudendal nerve distribution area
2413319|NCT03481621|Active Comparator|Group1b, Acupuncture on Vulvodynia|Focus on traditional acupuncture using common meridian or distal points
2413320|NCT03481621|Active Comparator|Group2, Standard care or waiting lists|Standard care without acupuncture
2413321|NCT03481608|Active Comparator|Olive Oil Shake|"Intervention: No Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil."
2413322|NCT03481608|Experimental|Coconut Oil Shake|"Intervention: Lauric Acid~A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil."
3145384|NCT00070057|Experimental|Arm II (high-dose celecoxib)|Patients receive a higher dose of oral celecoxib as in arm I.
3145385|NCT00070057|Active Comparator|Arm III (surgery)|Patients do not receive treatment. All patients undergo surgery.
2413368|NCT03481218||Patients with type 1 diabetes|Young adults (male and female) between the ages of 18 and 35, who have type 1 diabetes for at least one year.
3145386|NCT00070122|Experimental|Arm I (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
3145387|NCT00070122|Experimental|Arm II (oxaliplatin, capecitabine)|Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.
3145388|NCT00070148|Active Comparator|Arm 1 Oxandrolone 20 mg daily|Oxandrolone 20 mg (10 mg BID) for 12 weeks. 4 additional weeks of follow-up.
2413326|NCT03481582|Experimental|Group with nitroglycerin|They will receive (nitrodermal®) 5 mg (patch) from 2nd day of cycle till maturation of the follicles ≥ 18 mm then Three dimensional power Doppler will be used to assess the uterine and sub-endometrial blood flow.
2413327|NCT03481569|Experimental|Pharmacokinetic sample|Plasma and cerebrospinal fluid samples performed at different timepoint during administration of antibiotic prescribed in routine use
3145389|NCT00070148|Active Comparator|Megace 800 mg|Megestrol acetate 800 mg daily for 12 weeks. 4 additional weeks of follow-up.
3145390|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover.~IMMUNOTHERAPY: Cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of recombinant interferon gamma and interleukin-2. When sufficiently recovered, Aldesleukin once daily for 18 days."
2413330|NCT03481543|Experimental|In-line nebulization through NIV mask|Bronchodilator nebulization is given through NIV circuit.
2413331|NCT03481543|Active Comparator|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished.
2413332|NCT03481530||Blinded|Continuing Glucose Monitoring System will be blinded
2413333|NCT03481530||Unblinded|Continuing Glucose Monitoring System will be open. Participant can review results if they choose.
2413334|NCT03481517|Experimental|Wound with local anesthesia|5 mL Bupivacaine is injected into subcutaneous area near surgical wound
2413335|NCT03481517|No Intervention|Wound without local anesthesia|Nothing is injected into subcutaneous area near surgical wound
2413336|NCT03481504|Experimental|ACT-ETP|Cognitive behavioral treatment
2413337|NCT03481504|No Intervention|Usual care|no intervention
2413338|NCT03481491|Sham Comparator|Sham cerebellar stimulation|Participants will receive a Sham stimulation (inefficient probe) applied over the cerebellum.
2413339|NCT03481491|Active Comparator|Real cerebellar stimulation|Participants will receive a real continuous theta burst stimulation (cTBS) applied over the cerebellum.
2413340|NCT03481478||Patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
2413341|NCT03481478||Dislocation patients with greater tuberosity fractures|If humeral surgical neck fractures can be detected through CT or MRI in such groups.
2413342|NCT03481452|Experimental|psychotherapy intervention group|NBO behavioral intervention would be used to improve mother-infant dyad interaction and infants' disorders of regulation of states.
2413343|NCT03481452|No Intervention|control group|No behavioral intervention would be used.
2413344|NCT03481439||Primary cohort|Primary cohort : Cohort of patient between January and February 2017
2413345|NCT03481439||Secondary cohort|Secondary cohort : Cohort of patient between February and March 2018
2413346|NCT03481426|Experimental|Workplace intervention group|Workers with back problems receive both information/advice and participatory workplace intervention organized by Occupational Health Physioterapist.
2413347|NCT03481426|No Intervention|Information and advice group|Workers with back problems receive only information / advice by Occupational Health Physiotherapist, not the workplace intervention.
2413348|NCT03481400|Experimental|Calcitonin gene-related peptide|Calcitonin gene-related peptide infusion (1.5 micrograms/min for 20 mins)
2413349|NCT03481400|Experimental|Placebo|Infusion with placebo (isotonic saline)
2413350|NCT03481387|Other|PERCEVAL S valve|patients to be treated with PERCEVAL S valve
2413351|NCT03481374|Active Comparator|subjects with Type 1 Diabetes mellitus|Type 1 diabetes patients without cardiovascular disease undergo autonomic function testing
2413352|NCT03481374|Placebo Comparator|Healthy controls|healthy people without known disease undergo autonomic function testing
2413353|NCT03481348|Experimental|Pharyngeal Electrical Stimulation|PES for 10 minutes per day on 3 consecutive days in addition to standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
2413354|NCT03481348|No Intervention|Control|Standard therapy (logopedic counselling, advice for nutrition, learning of swallowing techniques)
2413355|NCT03481335|Experimental|Intervention Community|Intervention communities (barangays) will receive the intervention (CHAP-P sessions).
2413356|NCT03481335|No Intervention|Control Community|Control communities (barangays) will receive care as usual.
2413357|NCT03481322|Active Comparator|Cooked diet with controlled amount of salt|Patients will receive intervention diet (cooked with controlled amount of salt)
2413358|NCT03481322|Placebo Comparator|Cooked without salt|Patients will receive the standard diet (cooked without salt and 2 grams of salt separated will be added by the patient)
3185678|NCT00737724|Experimental|Group 2|Receives only antituberculosis therapy, and 2 months afterwards antiretroviral therapy
3185679|NCT00737750|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
3185680|NCT00737750|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
2413362|NCT03481296|Active Comparator|Advanced Control|The advanced control group receives a set of standard materials regarding colorectal cancer screening.
2413363|NCT03481296|Experimental|Culturally Adapted Decision Support Navigation Intervention|The culturally adapted decision support navigation intervention group receives everything advanced group receives as well as decision support and navigation contacts.
3185681|NCT00737750|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
2413366|NCT03481257||Ticagrelor|ACS patients treated with aspirin (100mg/d) and ticagrelor (90mg bid)
2413367|NCT03481257||Clopidogrel + very low dose rivaroxaban|ACS patients treated with aspirin (100mg/d), clopidogrel(75mg/d) and very low dose rivaroxaban (2.5mg bid)
2413370|NCT03481205|Experimental|Ischemic Conditioning|Doctormate device used en route to the comprehensive stroke center
2413371|NCT03481192|Experimental|A group using amnesic substances|"A group of patients admitted for IMV exclusively using amnesic substances. Benzodiazepines, benzodiazepines, tricyclic antidepressants, neuroleptics, antihistamines, other atropine substances, anti-epileptics and opiates.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
2413372|NCT03481192|Active Comparator|A control group|"A control group that ingested exclusively non-amnesic substances among them most frequently ingested in this context, ie the following classes: level 1 analgesics, antibiotics, serotonergic and noradrenergic antidepressants, oral antidiabetic, thyroid hormones, anti oral coagulant.~Two visits for evaluation, the first one for the first evaluation of cognitive functions directly following the psychiatric interview, and the second one at 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place."
2413373|NCT03481179|Experimental|Experimental: hf rTMS and Physical therapy|High frequency TMS will be applied with an eight shaped coil angled at 45 degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1) injured. Forty stimulus trains will be provide at 10Hz over the injured hemisphere, at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 2000 pulses for approximately 20 minutes, with 120% of resting motor threshold (RMT). After TMS, patients will be submitted to 50 minutes of physical therapy protocol.
2413374|NCT03481179|Sham Comparator|Control: Sham hf rTMS and Physical theraphy|In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
2413375|NCT03481166|Experimental|Education on breastfeeding pain|Both the experimental and control groups will receive usual prenatal education offered through our regional public health program. In addition to usual prenatal education, the experimental group will also receive a one-hour, nurse led (a Registered Nurse specially trained in perinatal care), small group-based education session with specific focus on breastfeeding pain. The goals of this educational intervention are to provide pregnant women with anticipatory guidance around pain which is commonly experienced while breastfeeding in the first two weeks postpartum. Education will include the prevalence, etiology and management of various types of breastfeeding-related pain experienced postpartum.
2413376|NCT03481166|No Intervention|Usual prenatal education|Women allocated to the usual prenatal education group will receive prenatal classes through their local public health unit. Women enrolled in classes will receive approximately 12 hours of combined in-class and online prenatal content. Topics include: discomforts of pregnancy, labor and birth, medical interventions, adjustment to parenting, breastfeeding, and caring for the newborn. Breastfeeding-related material includes basic mechanisms of milk production, benefits of breastfeeding, benefits of skin-to-skin, correct breastfeeding latch, breastfeeding positions, timing of feeds, responding to infant cues, and caring for nipples. Women in the usual prenatal education group will not receive education on the prevalence and etiology of nipple pain, nor specific pain management strategies.
2413377|NCT03481153|Placebo Comparator|Sham tDCS|Participants will be participate in a 20-minute sham tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex. Sham stimulation will be applied.
2413378|NCT03481153|Active Comparator|tDCS|Participants will participate in a 20-minute tDCS session. tDCS electrodes will be placed on the left (anodal positive polarity) and right (cathodal;negative polarity) dorsolateral prefrontal cortex.
2413379|NCT03481140||Control|donor site DIEP flap breast reconstruction procedure with standard wound closure with drains
2413380|NCT03481140||TissuGlu Surgical Adhesive|donor site DIEP flap breast reconstruction procedure with standard wound closure with TissuGlu Surgical Adhesive and no drains
2413381|NCT03481127|Active Comparator|Arm 1: Usual Care|-No psychosocial care in clinic
2413382|NCT03481127|Experimental|Arm 2: Integrated Care|-Those who receive integrated care will receive a one-page care plan completed by Dr. Vanderlan including their scores from screening questionnaires , recommendations for coping strategies and available supportive resources.
3185682|NCT00737763|Experimental|A|This group will receive weekly efalizumab injections for 6 months
3185683|NCT00737763|Placebo Comparator|B|This group will receive placebo injections for 6 months
2413385|NCT03481101|Other|All patients|Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
2413386|NCT03481088|Other|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
2413387|NCT03481075|Experimental|Rigid and Elastic registration softwares|
2413388|NCT03481062||Neutral|
2413389|NCT03481062||abduction|
2413390|NCT03481062||pad|
2413391|NCT03481062||combination|
2413392|NCT03481049|Experimental|Usual CM|Participants will earn at least 3 prize draws each time they submit an alcohol negative urine samples during weeks 5-20, plus treatment as usual
2413393|NCT03481049|Experimental|High-Magnitude CM|Participants will earn twice as many prize draws than those in the Usual CM for alcohol abstinence during weeks 5-20, plus treatment as usual.
2413394|NCT03481049|Experimental|Shaping CM|Participants will earn prize draws for light drinking during weeks 5-8 instead of alcohol abstinence and will then earn prize draws for abstinence during weeks 9-20, plus treatment as usual.
2413434|NCT03480789|Experimental|eye patch + DEX|given dexmedetomidine to meet RASS -1 and wearing the eye patch from 22:00 to 6:00 of the next day
3185684|NCT00737776||A|
2413395|NCT03481036|Active Comparator|Non cirrhotic|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg), LDV (90 mg) and DCV (60 mg) per day
2413396|NCT03481036|Active Comparator|Genotype 1,4,5 and 6 with cirrhosis|Sofosbuvir (SOF)+ Ledipasvir (LDV) for 12-weeks + weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and LDV (90 mg) per day
2413397|NCT03481036|Active Comparator|Genotype 2 and 3 with Cirrhosis|Sofosbuvir (SOF)+Daclatasvir (DCV) for 12 weeks+ weight based Ribavirin Patients < 35 kg will be given half doses of medications and patients ≥35 kg will be given adult dosages of SOF (400 mg) and DCV (60 mg) per day
2413398|NCT03481023|Experimental|Esophageal thermal regulation device|
2413399|NCT03481023|Active Comparator|LET monitoring|
2413400|NCT03481010|Experimental|PAO with hip arthroscopy|"Patient's in the Scope PAO group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the Scope-PAO group have been randomized to receive a periacetabular osteotomy with a hip arthroscopy."
2413401|NCT03481010|Active Comparator|PAO without hip arthroscopy|"Patient's in the PAO-only group have been diagnosed with hip dysplasia and a decision has been made between the patient and the surgeon that the best way to treat the hip problems is with surgery. Patient's in the PAO-only group have been randomized to receive a periacetabular osteotomy only."
2413402|NCT03480997|Experimental|albuterol sulfate 100 mcg|albuterol sulfate 100 mcg Test MDI
2413403|NCT03480997|Active Comparator|albuterol sulfate 200 mcg|albuterol sulfate 200 mcg Reference MDI
2413404|NCT03480997|Experimental|albuterol sulfate and ipratropium bromide|albuterol sulfate 100 mcg and ipratropium bromide 20 mcg Test MDI
2413405|NCT03480984|Active Comparator|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
2413406|NCT03480984|Active Comparator|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
2413407|NCT03480971|Active Comparator|Active 1000 mg Tempol Solution|Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
2413408|NCT03480971|Placebo Comparator|Placebo Solution|Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)
2413409|NCT03480958|Active Comparator|ESP group|Erector Spinae Plane Block administered group
2413410|NCT03480958|Active Comparator|TPVB group|Thoracic Paravertebral Block administered group
2413411|NCT03480958|Other|Control Group|No regional anesthesia technique will be applied to control group; but will be provided with iv PCA
3185685|NCT00737789|Experimental|Mesalazine once/day|Participants received 4g oral Mesalazine once a day (2 sachets of prolonged release granules) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral mesalazine 2g once daily (1 sachet/day) for an additional 4 weeks (maintenance period).
3185686|NCT00737789|Active Comparator|Mesalazine twice/day|Participants received oral mesalazine 4 g per day in two divided doses (1 sachet prolonged release granules twice a day) for 8 weeks during the induction period. In addition, participants received a liquid enema of 1g Mesalazine once a day at bedtime for the first 4 weeks. Participants who were in remission at Week 8 received oral Mesalazine 2g (one sachet) once a day for an additional 4 weeks (maintenance period).
3185687|NCT00737802||Normal Control|Normal control subjects are the participants with no history of GERD, no signs and symptoms of GERD
3185688|NCT00737802||GERD Patients|GERD patients are those with history of GERD, signs and symptoms of GERD and selected signs and symptoms of GERD in the questionnaire.
3185689|NCT00737802||Barrett's patients|Barrett's patients are those participants who in addition to all the qualities of GERD patients have long standing history of GERD and mucosal changes in the esophagus.
3185690|NCT00737815|Active Comparator|A|Magnesium citrate: a total of 500 mg of elemental magnesium
2413418|NCT03480906|Experimental|Microdose administration|Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD
2413419|NCT03480906|Active Comparator|Eyedrop administration|Latanoprost ophthalmic solution administered as an eyedrop
2413420|NCT03480893|Experimental|Small size interarcuair decompression|Patients will undergo small size interarcuair decompression
2413421|NCT03480893|Active Comparator|Laminectomy|Patients will undergo laminectomy
2413422|NCT03480880|Experimental|Group BIS|Thiopentone dosing during induction of anaesthesia based on guidance of Bispectral Index values.
2413423|NCT03480880|No Intervention|Group Clinical|Thiopentone dosing during induction of anaesthesia based on clinical guidance targeted to loss of eyelash reflex or loss of response to noxious stimulus.
2413424|NCT03480867|Experimental|Pre-operative RT and TMZ|Single Arm: Pre-operative Radiation +Temozolomide followed by Surgery plus six cycles of Temozolomide
2413425|NCT03480854|No Intervention|Baseline Analysis|To conduct studies of variation in performance across microsystems and to utilize benchmarking analyses to identify top performers.
2413426|NCT03480854|Experimental|The effect of continuous quality improvements (CQI)|To study the comparative improvement of selected primary process performance indicators (DMT and MRI process measures) over a 3 year period (Years 2-3) in microsystems receiving CQI interventions versus those not receiving CQI intervention, and between two different CQI intervention types (IHI Breakthrough Series and Patient Centered Medical Home).
3185691|NCT00737815|Placebo Comparator|B|Placebo pills
2413428|NCT03480815|Active Comparator|TLA device|These patients will be withdrawal of omalizumab treatment and receive nocturnal temperature controlled laminar flow device at nighttime for 12 months.
2413429|NCT03480815|Placebo Comparator|None device|These patients will be withdrawal of omalizumab treatment and do not receive TLA device for 12 months.
3185692|NCT00737828|Active Comparator|A|Control - Standard Perioperative Pathway, clinician decides post-operative care environment (usual care)
2413432|NCT03480789|Experimental|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
2413433|NCT03480789|Experimental|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
2413435|NCT03480789|No Intervention|usual treatment|treatment as usual
3185693|NCT00737828|Experimental|B|Intervention - Perioperative care pathway guided by CPX Results i.e.anaerobic threshold & ventilatory equivalents
3185694|NCT00737841|Experimental|A|Bifidobacterium breve
3185695|NCT00737841|Placebo Comparator|B|Placebo
2413441|NCT03480737|Experimental|10 Hz rTMS|
2413442|NCT03480737|Sham Comparator|Sham rTMS|
2413443|NCT03480737|Experimental|iTBS rTMS|
2413444|NCT03480724|Active Comparator|Google Cardboard VRA|This group of subjects will receive VRA intervention using Google Cardboard Virtual reality head- mounted display powered by a iPod touch.
2413445|NCT03480724|Active Comparator|Oculus Rift VRA|This group of subjects will receive VRA with Oculus Rift
2413446|NCT03480724|No Intervention|Control|This group of subjects will receive no intervention beyond standard sedation, anesthetic, and/or restraint-this group will serve as the control group
2413447|NCT03480711|Experimental|Group (A)|20 eyes of 20 patients of uncontrolled POAG administrated intervention will be subscleral trabeculectomy (SST) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
2413448|NCT03480711|Experimental|group (B)|20 eyes of 20 patients of uncontrolled POAG d Administrated intervention will be ESST another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
2413449|NCT03480698||Cerebrolysin and standard stroke care|
2413450|NCT03480698||Standard stroke care|
3185696|NCT00737854|Experimental|1 ARM|Otherwise healthy patients with oral lichen planus (precancerous/erosive OLP)
2413452|NCT03480672|Experimental|Pembrolizumab + aRCH|Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)
2413453|NCT03480672|Active Comparator|aRCH|adjuvant radio-chemotherapy (aRCH)
2413454|NCT03480659||Breast Cancer|Early stage luminal A and triple negative breast cancer [TNBC] (estrogen receptor-negative (ER-), progesterone receptor-negative (PR-) and HER2-negative (HER2-)
2413455|NCT03480659||Control|Age matched control females
2413456|NCT03480646|Experimental|CPI-1205 Combination with Enzalutamide|
2413457|NCT03480646|Experimental|CPI-1205 Combination with Abiraterone/Prednisone|
2413458|NCT03480633||Control|Defined as patients without a history of heart failure
2413459|NCT03480633||Heart Failure w/NormalEjectionFraction|Heart Failure with Normal Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of greater than or equal to 50%.
2413460|NCT03480633||HeartFailure w/ReducedEjectionFraction|Heart Failure with Reduced Ejection Fraction is defined as having a Left Ventricle Ejection Fraction of less than 50%.
2413461|NCT03480620|Experimental|Telerehabilitation|Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
2413462|NCT03480620|Active Comparator|Usual care|Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
2413463|NCT03480607|Active Comparator|Dexmedetomidine group|Dexmedetomidine in conjunction with bupivacaine for infra-orbital nerve block
2413464|NCT03480607|Active Comparator|Dexamethasone group|Dexamethasone in conjunction with bupivacaine f
2413465|NCT03480594|Experimental|Fatty Liver Patients|Hyperpolarized [13C] Pyruvate Injection in Fatty Liver patients
2413466|NCT03480594|Experimental|Healthy Control Subjects|Hyperpolarized [13C] Pyruvate Injection in Healthy Control Subjects
2413467|NCT03480581|Experimental|Reverse First ICARE Training|Participants will engage in 12-sessions in the reverse direction followed by 12-sessions in the forward direction.
2413468|NCT03480581|Experimental|Forward First ICARE Training|Participants will engage in 12-sessions in the forward direction followed by 12-sessions in the reverse direction.
2413469|NCT03480568|Experimental|alirocumab|Alirocumab 150 mg q 2 weeks for 12 weeks
2413470|NCT03480555|Active Comparator|Replenish Protein group|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
2413471|NCT03480555|Other|Standard Protein group|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
2413472|NCT03480529||Arthritis or lupus or CLS induced by a drug|Case reported in the World Health Organization (WHO) of arthritis or lupus, or Hepatitis, or capillary leak syndrome of patient treated by a drug, with a chronology compatible with the drug toxicity
2413473|NCT03480516|Experimental|SDF arm|SDF arm is application of 38% silver diamine fluoride solution (SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained.
3185697|NCT00737867|Experimental|A|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2 Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Gemcitabine infusion 1000 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
3185698|NCT00737867|Active Comparator|B|"Day 1: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2 + Carboplatin infusion AUC = 5 (Calvert's formula) Day 8: Vinorelbine (Navelbine® Oral) capsules 60 mg/m2~All patients will receive a maximum of 3 courses with an interval of 3 weeks"
2413474|NCT03480516|Experimental|Fluoride varnish arm|Fluoride varnish arm is application of 5% sodium fluoride varnish on all surface of every tooth.
2413475|NCT03480516|Experimental|Combination arm|Combination arm is application of 38% silver diamine fluoride solution(SDF) on cavitated caries in primary molar, , cavities in anterior teeth will be applied only on additional consent obtained and then apply of 5% sodium fluoride varnish on all surface of every tooth.
2413476|NCT03480503||study group|Patients with acne vulgaris , measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
2413477|NCT03480503||Control group|Healthy control volunteers, measurement of serum apelin12 by using ELISA technique ,complete lipid profile and fasting blood glucose.
2413478|NCT03480477||Pelvic Floor Disorders Group|Will collect patient information from new patients who present to the Urogynecology Clinic
2413479|NCT03480477||Control Group|Will collect patient information from patients who present to Gynecologic Clinic for their annual examination
2413480|NCT03480477||Chronic Pelvic Pain Group|Will collect patient information from patients who present to their Chronic Pelvic Pain Clinic appointment
2413481|NCT03480464|Experimental|App-technology group|"App-technology to increase physical activity Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which the participants are able to register their daily physical activity in bouts of 10 min and their intake if supplementary vitamins. They will also be able to set personal goals every week for the level (minutes) of physical activity and get feedback every week in whether they fulfilled the goal or not. They will also get feedback on the intake of supplementary vitamin intake."
2413482|NCT03480464|No Intervention|Control group|The control group will receive standard information about the benefit of physical activity after surgery.
2413483|NCT03480451|Other|Single Arm|"This project is being withdrawn. No revisions to ARM is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
2413484|NCT03480438|Experimental|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 μg/day as continuous intravenous infusion at constant flow rate for four weeks defined as one treatment cycle. Up to four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9 μg/day."
3185699|NCT00737880|Active Comparator|1|In situ organ perfusion using HTK solution during pancreas procurement
2413486|NCT03480412||Follicular Phase|
2413487|NCT03480412||Luteal Phase|
2413488|NCT03480386|Experimental|Intervention|Patients randomized in this arm will start with the home based pulmonary rehabilitation program.
2413489|NCT03480386|Active Comparator|Control|Patients randomized in this arm will start the intervention after 12 weeks of usual care.
2413490|NCT03480360|Other|Johns Hopkins' conditioning regimen|Cyclophosphamide, fludarabine, total body irradiation, immune suppression including tacrolimus and cellcept, Granulocyte colony-stimulating factor (G-CSF), and peripheral blood transplant
2413491|NCT03480334|Experimental|Arm A|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
2413492|NCT03480321|Active Comparator|Cilostazol 100 mg|
2413493|NCT03480321|Experimental|PMR 150 mg|
2413494|NCT03480321|Experimental|PMR 200 mg|
2413495|NCT03480308|Active Comparator|Bupivacaine fentanyl group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
2413496|NCT03480308|Active Comparator|Bupivacaine dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , dexamethasone 4 mg in paravertebral block
2413497|NCT03480308|Active Comparator|Bupivacaine fentanyl dexamethasone group|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg , dexamethasone 4 mg in paravertebral block
2413498|NCT03480295|Experimental|HA0.4%+TAU0.5%|Patients had to administer 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.4% and taurine 0.5% in addition to the ongoing glaucoma treatment
2413499|NCT03480295|Active Comparator|HA0.2%|Patients took 4 drops/day of an ophthalmic solution containing hyaluronic acid 0.2%
2413500|NCT03480282|Experimental|Prognosis Information and Provider Scripts|Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
2413501|NCT03480256|Experimental|SHR6390 combined with pyrotinib|Group A:pyrotinib 400mg qd combined with SHR 6390 100mg qd Group B: pyrotinib 400mg qd combined with SHR 6390 125mg qd Group C: pyrotinib 400mg qd combined with SHR 6390 150mg qd Group D: pyrotinib 400mg qd combined with SHR 6390 175mg qd Group E: pyrotinib 320mg qd combined with SHR 6390 100mg qd
3185700|NCT00737880|Active Comparator|2|In situ perfusion using UW solution during pancreas procurement
2413645|NCT03479359||Group 2|In this group, internship are not given the pathology outcome of each prostate biopsy.
3185701|NCT00737906|Experimental|I|Surgical turbinate reduction procedure
3185702|NCT00737919|Active Comparator|1|A group of subjects consuming daily 2 grams of plant stanols 4-6 weeks before the operation
3185703|NCT00737919|Active Comparator|2|A group of patients consuming daily 2 grams of plant sterols 4-6 weeks before the operation
3185704|NCT00737932|Experimental|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day (sequential cohorts)
3185705|NCT00737932|Placebo Comparator|Placebo|Matching placebo
3185706|NCT00737945||2|
3185707|NCT00737958||1|Patients with documented stable coronary artery disease, symptoms of stable angina pectoris, and a positive standard BRUCE exercise stress test at 3 - 13 minutes.
2413503|NCT03480230|Experimental|Treatment arm|"Non-squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses.~Compound 565994 500 mg/m2 administered over 10 minutes, and~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour.~Compound 565994 and platinum are to be given on day 1 of every 3-week cycle for 3 cycles.~Squamous histology:~Compound 121564 10 mg/Kg administered over 60 minutes every 2 weeks for 4 doses.~Compound 232673 AUC=5 mg/mL/min administered over 15-60 minutes or Compound 454893 at 75 mg/m2 over 1 hour on day 1 of every cycle.~Compound 343782 1,000 mg/m2 administered over 30 minutes on days 1 and 8 of each cycle.~Platinum and Compound 343782 will be given for 3 cycles."
2413504|NCT03480217|Experimental|Multifaceted Implementation Strategy|Patients will be screened for hypertension by primary care providers, registered nurses, medical assistants, and front desk staff from clinics randomized to receive the intervention, Multifaceted Implementation Strategy.
2413505|NCT03480217|No Intervention|Usual Care|Patients will be screened for hypertension by primary care providers, nurses, medical assistants, and front desk staff of clinics randomized to the usual care group that do not intentionally receive any parts of the multifaceted implementation strategy.
2413506|NCT03480191|Experimental|Patients|
2413507|NCT03480165|Experimental|20 mg Parecoxib + 0.75% Ropivacaine|1 ml of 20 mg Parecoxib is given concurrently with 19 mls of 0.75% ropivacaine
2413508|NCT03480165|Active Comparator|0.75% Ropivacaine only|19 ml of Ropivacaine at a concentration of 0.75% is given concurrently with 1 ml of 0.9% saline
3185708|NCT00737971|Active Comparator|A|Avastin intravitreal injection D0, Week 4, Week 8
3185709|NCT00737971|Active Comparator|B|Triamcinolone intravitreal injection
2413512|NCT03480126|Placebo Comparator|Herbal Tea 1|Placebo Tea should will be ingested 3 times per day for 3 months
2413513|NCT03480126|Experimental|Herbal Tea 2|Experimental Herbal Tea A will be ingested 3 times per day for 3 months
2413514|NCT03480126|Experimental|Herbal Tea 3|Experimental Herbal Tea B will be ingested 3 times per day for 3 months
2413515|NCT03480126|Experimental|Herbal Tea 4|Experimental Herbal Tea C will be ingested 3 times per day for 3 months
2413516|NCT03480113|Experimental|Mindfulness-based Intervention|1 session of health education regrading the harms from smoking and 6 sessions of Mindfulness-based intervention, 1 hour each session.
2413517|NCT03480113|Active Comparator|Physical Fitness intervention|1 session of health education regrading the harms from smoking and 6 sessions of physical fitness and stretch exercise, 1 hour each session.
2413518|NCT03480100||Xylometazoline Nasal spray|1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
2413519|NCT03480100||Xylometazoline + Ectoin Nasal Douche|Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
2413520|NCT03480087||Chemotherapy alone|Patient treated with anthracycline containing chemotherapy
2413521|NCT03480087||Chemotherapy plus radiotherapy|Patient treated with anthracycline containing chemotherapy followed by mediastinal radiotherapy
2413522|NCT03480074|Active Comparator|Staple Ligation|Arm 1: Staple Ligation
2413523|NCT03480074|Active Comparator|Selective Suture Ligation|Arm 2: Selective Suture Ligation
2413524|NCT03480074|Active Comparator|Single Suture Ligation|Arm 3: Single Suture Ligation
2413525|NCT03480061|Active Comparator|Dexmedetomidine Hydrochloride Group|Patients will receive a loading dose of 1 μg/kg dexmedetomidine prior to transfer to CVICU over 20 min immediately postoperative, followed by continuous infusion of 0.1- 1.0 μg/kg/h for up to 24 hours or until patient is ready for discharge from CVICU (whichever is earlier).
2413526|NCT03480061|No Intervention|Standard of Care Group|Standard sedation protocols will be followed at the discretion of the attending physician.
3185710|NCT00737971|Active Comparator|C|Avastin + Triamcinolone intravitreal injection simultaneously
3185711|NCT00737984|No Intervention|1|Group 1 patients will receive standard superovulation-IUI treatment without endometrial sampling
3185712|NCT00737984|Active Comparator|2|Group 2 patients will receive standard superovulation-IUI treatment with endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
3185713|NCT00737997|Placebo Comparator|1|
3185714|NCT00737997|Experimental|2|
3185715|NCT00738010|Experimental|KH|Kneehab is a garment integrated NMES device with multipath technology.
3185716|NCT00738010|Active Comparator|PS|Poli-Stim, a standard NMES device, used for 3 times per day, five days per week for 12 weeks.
3185717|NCT00738010|Active Comparator|CO|Control group performed voluntary muscle contractions for 20 minutes 3 times per day, 5 days per week for 12 weeks.
2413535|NCT03479996|Experimental|Anesthetic|
2413536|NCT03479996|No Intervention|Control|
2413537|NCT03479983|Experimental|AMX160|500 mg (one capsule) x 2 times daily for 90 days
2413538|NCT03479983|Placebo Comparator|Placebo|500mg (one capsule) x 2 times daily for 90 days.
2413539|NCT03479970|Experimental|GNPT + Social Cognition|"Experimental Group: will undertake a rehabilitation treatment integrated by a set of tasks aimed at working attention, memory and executive functions together with a computerized treatment for the rehabilitation of the Social Cognition. The treatment will be carried out through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT).~The treatment will consist of the carrying out of 24 treatment sessions"
2413540|NCT03479970|Active Comparator|GNPT (only N-SC measures)|Control Group: will only conduct a cognitive rehabilitation treatment through the cognitive telerehabilitation platform Guttmann, NeuroPersonalTrainer® (GNPT) focused on attention, memory and executive functions.
3185718|NCT00738036||Group P|Exposed to an acute painful phenomenon requiring an analgesic management
3185719|NCT00738036||Group C|Control, not exposed to acute pain
3185720|NCT00738075||PD+FOG|Patients with Parkinson's disease prone to freezing
3185721|NCT00738088|Experimental|1|Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c
3185722|NCT00738114||1|group without hyperglycemia (fasting blood glucose below 126mg/dl) approximately 1000 patients
3185723|NCT00738114||2|group with hyperglycemia (fasting blood glucose above 125 mg/dl) or history of diabetes approximately 500 patients
3185724|NCT00738127|Experimental|1|Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
2413547|NCT03479918|Active Comparator|R-DA-EPOCH-21|The protocol involves 4-6 cycles. Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid.
2413548|NCT03479918|Active Comparator|R-BL-M-04|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 50 mg/m2/day IV day 3, Vincristine 2 mg IV 1 day, Cytarabine 150 mg/m2/day IV 1 h 4, 5 days.~Course C:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1500 mg/m2 12 h IV 1 day, Vinblastine 5 mg/m2 IV day 1, Cytarabine 2000 mg/m2/day IV 3 h 2, 3 days, Etoposide 150 mg/m2/day IV 3-5 days.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2413549|NCT03479918|Active Comparator|R-DA-EPOCH-21 + auto-SCT|"The protocol involves 4-6 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2413550|NCT03479918|Active Comparator|R-BL-M-04 + auto-SCT|"The protocol involves 4 cycles. Patients with complete remission after 4 cycles undergo auto-SCT.~Intrathecal administration of dexamethasone 4 mg, methotrexate 15 mg and cytarabine 30 mg is required once during chemotherapy. In case of CNS involvement intrathecal administration is repeated 3 times a week till the normal cell count in cerebrospinal liquid."
2413551|NCT03479905|Sham Comparator|Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 36%
2413552|NCT03479905|Sham Comparator|Face mask group|A standard face mask will be used at 8L/minute during the colonoscopy. The FiO2 delivered to the patient at this rate has been shown to be equal to 60%.
2413553|NCT03479905|Experimental|High Floow Oxygen delivery|Oxygen will be delivered by using high flow nasal cannula
2413554|NCT03479892|Experimental|NNC0194-0499|Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
2413555|NCT03479892|Placebo Comparator|Placebo|Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
2413556|NCT03479879|Experimental|Estradiol + Misoprostol|
2413557|NCT03479879|Placebo Comparator|Placebo + Misoprostol|
2413558|NCT03479866|Experimental|Dietary intervention|2 week dietary intervention using standardized test meals
2413559|NCT03479853||Cases : suffering from ocular or oculo-cutaneous rosacea|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
2413560|NCT03479853||Witnesses|"Without any present or past palpebral meibomian Gland Dysfunction~Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device."
2413561|NCT03479840||Patients undergoing PCI|all-comer population undergoing PCI
2413562|NCT03479827|Experimental|Experimental|Subjects will undergo three Wavefront measurements, once with no contact lens, once with a monofocal contact lens and once with a bifocal contact lens.
2413563|NCT03479814|Experimental|IMRT-SIB plus sequential IG-RT boost|45 Gy plus 5 Gy concomitant boost are delivered to rectum and locoregional lymphnodes (25 fractions); sequential IG-RT (imaging guided-radiotherapy) boost of 5 Gy in 2 fractions is planned with 18-FDG-PET
2413564|NCT03479801||Conventional Open|Conventional open thyroidectomy group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2413565|NCT03479801||Transoral Endoscopic Surgery|Transoral endoscopic thyroidectomy via vestibular approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2413566|NCT03479801||Endoscopic Thyroidectomy via Breast|Endoscopic thyroidectomy via breast approach or bilateral areola approach group (thyroid neoplasms patients who underwent conventional thyroidectomy procedure with or without postoperative central node dissection)
2413567|NCT03479788||DM|Observational study. NO intervention
2413568|NCT03479788||non-DM|Observational study. NO intervention
2413569|NCT03479775||Youth female athletes with poor muscle function|Youth female athletes (floorball, football and handball) with assessed poor muscle function at baseline.
2413570|NCT03479775||Youth female athletes with good muscle function|Youth female athletes (floorball, football and handball) with assessed good muscle function at baseline.
2413571|NCT03479762||Liraglutide|Patients in the CPRD primary care database who have been prescribed liraglutide after the UK launch of Saxenda® (and have no liraglutide prescriptions in the previous 12 months)
2413572|NCT03479749|Experimental|RegenoGel-OSP - RegenoGel-OSP|First injection- the patients will receive RegenoGel-OSP; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP also
2413573|NCT03479749|Experimental|RegenoGel - RegenoGel|First injection- the patients will receive RegenoGel; Second injection (after 3 months interval)- the patients will receive RegenoGel also
2413574|NCT03479749|Placebo Comparator|Placebo - RegenoGel-OSP|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel-OSP
2413575|NCT03479749|Placebo Comparator|Placebo - RegenoGel|First injection- the patients will receive Placebo; Second injection (after 3 months interval)- the patients will receive RegenoGel
2413576|NCT03479736||Cohort 1: Participants with Achilles Tendon Rupture (ATR)|Participants will be defined as having ATR if they receive a diagnosis for ATR as well as one of the following procedures: tenotomy or primary ruptured Achilles Tendon (AT) repair (with or without graft) within 7 days of diagnosis. Index will be based on the earlier date of diagnosis or procedure. Participants with ATR, and exposures to Fluoroquinolone (FQ) or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2413577|NCT03479736||Cohort 2: Participants with Retinal Detachment (RD)|Participants will be defined as having a RD if they received a diagnosis of RD and a procedure for RD, e.g.: sclera buckle, vitrectomy, retinopexy, retinal cryotherapy, silicone oil fill, air gas fluid exchange or pneumatic retinopexy, within 14 days of index. Index will be defined as the earlier date of diagnosis or procedure. Participants with RD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2413578|NCT03479736||Cohort 3: Participants with Aortic Aneurysm & Dissection (AAD)|Participants will be defined as having AAD if they received a primary diagnosis for aortic aneurysm, aortic rupture or dissection and have also received an aortic repair surgical procedure concurrently to the AAD diagnosis, in an inpatient or emergency department (ED) setting. Index will be defined as the earlier date of diagnosis or procedure. Participants with AAD, and exposures to FQ or any of the other antibiotics or febrile illness not treated with antibiotic, within a defined study period and at least 1 year of continuous enrollment prior to the event will be included. It will use data from 3 databases, which are Truven CCAE and Medicare (Supplemental) and Optum ClinFormatics (Optum).
2413579|NCT03479710|Experimental|FMT infusion|FMT will be performed using frozen donor stool samples obtained from the stool bank of CUHK. 100-200ml of FMT solution or sterile saline will be infused over 2-3 minutes into the distal duodenum or jejunum via OGD.
2413580|NCT03479710|No Intervention|Control|No FMT infusion.
2413583|NCT03479684|Experimental|Gene-directed group|the first day given model prediction dose * 1.5 times（<6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
2413584|NCT03479684|Active Comparator|Standard care group|the first day given 4.5mg; adjusted dose based on INR from the second day
2413585|NCT03479671|No Intervention|Saline|Insulin sensitivity (rate of glucose disposal)
2413586|NCT03479671|Experimental|Low Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 30 ml/hr fatty acid infusion
2413587|NCT03479671|Experimental|Medium Dose Fatty Acids|Insulin sensitivity (rate of glucose disposal) in response to 60 ml/hr fatty acid infusion
2413588|NCT03479658|Experimental|HIIT two sessions|Two sessions per week of HIIT + nutritional education (1 session/week)
2413589|NCT03479658|Experimental|HIIT one session|One session per week of HIIT + nutritional education (1 session/week)
2413590|NCT03479658|Active Comparator|Nutritional education|Nutritional education (1 session/week)
2413591|NCT03479645|No Intervention|Control|Control arm - usual practice. Simple SMS reminder that informs patients they are overdue for CRC screening and requests they contact the clinic.
2413592|NCT03479645|Experimental|Intervention|Serial text messages and mailed FIT kit
2413593|NCT03479632|Experimental|Intervention Group|The intervention group will undergo an aerobic walking program using a treadmill, a body-weight support system, and an assistive device.
2413594|NCT03479632|Active Comparator|Control Group|The control group will receive standard physical therapy (PT).
2413595|NCT03479619|Experimental|A/28/1|Lancing device A with personal lancet of size 28 G and minimum puncture depth.
2413596|NCT03479619|Experimental|A/28/5|Lancing device A with personal lancet of size 28 G and maximum puncture depth.
2413597|NCT03479619|Experimental|A/30/1|Lancing device A with personal lancet of size 30 G and minimum puncture depth.
2413598|NCT03479619|Experimental|A/30/5|Lancing device A with personal lancet of size 30 G and maximum puncture depth.
2413599|NCT03479619|Experimental|A/33/1|Lancing device A with personal lancet of size 33 G and minimum puncture depth.
2413600|NCT03479619|Experimental|A/33/5|Lancing device A with personal lancet of size 33 G and maximum puncture depth.
2413601|NCT03479619|Experimental|B/28/1|Lancing device B with personal lancet of size 28 G and minimum puncture depth.
2413602|NCT03479619|Experimental|B/28/5|Lancing device B with personal lancet of size 28 G and maximum puncture depth.
2413603|NCT03479619|Experimental|B/30/1|Lancing device B with personal lancet of size 30 G and minimum puncture depth.
2413604|NCT03479619|Experimental|B/30/5|Lancing device B with personal lancet of size 30 G and maximum puncture depth.
2413605|NCT03479619|Experimental|B/33/1|Lancing device B with personal lancet of size 33 G and minimum puncture depth.
2413606|NCT03479619|Experimental|B/33/5|Lancing device B with personal lancet of size 33 G and maximum puncture depth.
2413607|NCT03479619|Experimental|C/28/1|Lancing device C with personal lancet of size 28 G and minimum puncture depth.
2413608|NCT03479619|Experimental|C/28/5|Lancing device C with personal lancet of size 28 G and maximum puncture depth.
2413609|NCT03479619|Experimental|C/30/1|Lancing device C with personal lancet of size 30 G and minimum puncture depth.
2413610|NCT03479619|Experimental|C/30/5|Lancing device C with personal lancet of size 30 G and maximum puncture depth.
2413613|NCT03479606|Experimental|Immediate Intervention|Participants will receive 24 online emotional regulation skills-training sessions twice weekly and will complete online questionnaires sent every four weeks throughout baseline, the 12-week intervention, and 12-week follow-up.
2413614|NCT03479606|Active Comparator|Waitlist Intervention|After a 12-week wait-period without any intervention, participants will receive 24 online emotion regulation skills-training sessions. Every four weeks, participants will complete online questionnaires every throughout baseline, 12-week wait-period, 12-week intervention, and 12-week follow-up.
2413615|NCT03479593||CMR and OCT in NSTEMI patients with MVD|NSTEMI patients with multi vessel disease
2413616|NCT03479567|Other|HC|Healthy controls, i.e. older adults without cognitive impairment
2413617|NCT03479567|Other|MiD|older adults with mild dementia
2413618|NCT03479567|Other|MoD|older adults with moderate dementia
2413619|NCT03479554|Experimental|Early antihypertensive treatment group|BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group.
2413620|NCT03479554|Active Comparator|Delayed antihypertensive treatment group|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization.
2413621|NCT03479541|Experimental|Physical Therapy (Early)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
2413622|NCT03479541|Experimental|Physical Therapy (Standard of Care)|"Two sub-arms include Vestibular Rehabilitation  n=40, and Vestibular Rehabilitation with Home Monitoring n=40"
2413623|NCT03479528||Dyspepsia|All patients who were satisfied with the inclusion criteria and exclusion criteria in the department of the second affiliated hospital of Xi'an jiaotong university,Xijing Hospital, Tangdu Hospital, Xi'an No.3 Hospital, and received investigation.
2413624|NCT03479515||Formerly-Premature Toddlers|Data will be used to create and evaluate predictive equation
2413625|NCT03479502|Active Comparator|Methylprednisolone|Patients meeting the inclusion criteria will be randomized into either the control group of intra-articular injection of 40mg Methylprednisolone once every 2 two weeks for 4 weeks (day 1, week 2, week 4) with 20 patients in each group. Injections will be administered by the treating physician.
2413626|NCT03479502|Active Comparator|Doxycycline|Patients meeting the inclusion criteria will be randomized or the experimental group of intraarticular injection of 50 mg doxycycline once every 2 two weeks for 4 weeks (day 1, week 2, week 4), with 20 patients in each group. Injections will be administered by the treating physician.
2413627|NCT03479489|Experimental|Human dehydrated amnion/chorion allofraft|Closed hemorrhoidectomy patched with human dehydrated amnion chorion allograft
2413628|NCT03479476|Placebo Comparator|Placebo Medication|The placebo will be dosed in a weight-dependent manner. Liquid placebo will be provided to any participants unable to swallow the placebo capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
2413629|NCT03479476|Active Comparator|Active Metformin Medication|The active metformin medication will be dosed in a weight-dependent manner. Liquid metformin (100mg/cc) will be provided to any participants unable to swallow the metformin capsules. For participants under 50kg at baseline, the initial dose will be 250mg once per day, and if this dose is well tolerated, they will increase each week by 250mg until a maximum dose of 1000mg daily is reached. For participants at and above 50kg at baseline, the initial dose will be 500mg once per day, and if this dose is well tolerated, they will increase each week by 500mg until a maximum dose of 2000mg daily is reached. After the 4-week titration period, each participant will continue dosing at his or her maximum tolerated dose daily for the remaining 12 weeks of the study.
2413630|NCT03479463||Treatment with Dehydrated Human Amnion Chorion Allograft|
2413631|NCT03479463||Standard of Care|
2413632|NCT03479424||Training Set|n = 333
2413633|NCT03479424||Validation Set|n = 167
2413634|NCT03479411|Experimental|Part 1 single ascending dose|Intervention: drug Itraconzaole powder: single dose of 5mg, 10mg or 25 mg Other name: PUR1900
2413635|NCT03479411|Experimental|Part 2 multiple ascending dose|Intervention: drug Itraconzaole powder: 10 mg or 20 mg daily for 14 days Other name: PUR1900
2413636|NCT03479411|Active Comparator|Part 3 2-period crossover single dose|Intervention: drug Itraconzaole powder: 20 mg single dose and Itraconzaole oral solution 200 mg single dose Other names: PUR1900, Sporanox
2413637|NCT03479398||App Condition|Although we will be mostly observing routine practice, we will randomize patients into either an App condition or paper condition. The App condition refers to patients completing routine Cognitive Behavioral Therapy (CBT) worksheets on a mobile application during session. Everything else that occurs in treatment sessions will be consistent with routine care practices.
2413638|NCT03479398||Paper Condition|Although we will be mostly observing routine practice, we do randomize patients into either an App condition or paper condition. The paper condition refers to patients completing routine CBT worksheets on paper (the current standard) during session.
2413639|NCT03479385|Experimental|Integrative Medicine Intervention|Study participants randomized to the Integrative Medicine intervention will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months potentially followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
2413640|NCT03479385|Experimental|Health Education Intervention|Study participants randomized to the Health Education intervention will attend 14 sessions with a Health Educator over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
2413641|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 1|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2413642|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 2|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2413643|NCT03479372|Experimental|PAN-90806 Eye Drops, dose 3|PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks
2413646|NCT03479346|Experimental|GGT group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2413647|NCT03479346|Placebo Comparator|Placebo group|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2413648|NCT03479333|Experimental|Short implant|
2413649|NCT03479333|Active Comparator|standard implant with sinus lift|
2413650|NCT03479320|Experimental|Lidocaine group|Lidocaine group will receive intravenous bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the completion of surgery
2413651|NCT03479320|Placebo Comparator|Placebo|They will receive the same volume of 0.9% of normal saline as calculated for the experimental group
2413655|NCT03479294||Exposure group|Exposure group patients are those who voluntarily choose to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy. Jiangzhong Group will donate the first 30 bottles of medicine, and afterwards, patients may purchase if they still need to take it. The length of time and dose of Shenlingcao Oral Liquid are unlimited and other adjunctive treatments may be used at the same time.
2413656|NCT03479294||Control group|Control group patients are those who voluntarily choose not to use Shenlingcao Oral Liquid recommended by the doctor in NSCLC patients receiving adjuvant chemotherapy.
2413657|NCT03479268|Experimental|Treatment (pevonedistat, ibrutinib)|Participants receive pevonedistat IV over 1 hour on days 1, 3, and 5, and ibrutinib PO daily on days 2-21 of course 1 and days 1-21 of subsequent courses. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Participants then receive only ibrutinib PO daily on days 1-21. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable toxicity.
2413658|NCT03479255|Experimental|Smartphone-enabled structured exercise therapy (SE-SET)|"This arm involves a smartphone app Movn - rehabilitation platform based on MULTIFIT, a case-management system for secondary prevention and patient surveillance after acute MI.~The key features of the smartphone app include daily reminders to exercise, virtual diary for patients to enter data on exercise sessions, two-way secure messaging with the health coach, and educational videos on heart and vascular health."
2413659|NCT03479255|Active Comparator|Standard exercise therapy|Self-directed, unsupervised exercise as prescribed by the patient's physician.
2413660|NCT03479229|Experimental|Geneveve Treatment|Active Treatment
2413661|NCT03479229|Placebo Comparator|Sham Treatment|Sham Treatment
3185725|NCT00738127|Experimental|2|Group II (treatment with Inoue et al.'s technique) Fifteen patients (15 wrists) were evaluated at an average of 51 months. Nine patients were men and 6 were women. The mean age of the group at the time of surgery was 37.5 years (range, 24 to 58 years). The dominant hand was involved in 10 and nondominant hand, in seven.
3185726|NCT00738140|Experimental|A|Intensive lifestyle intervention based on the Diabetes Prevention Program
3185727|NCT00738140|No Intervention|B|Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program
2413665|NCT03479190|Active Comparator|Platelet rich plasma|ultrasound guided injection of Platelet rich plasma
2413666|NCT03479190|Placebo Comparator|Normal saline|ultrasound guided injection of Normal saline
2413667|NCT03479177|Experimental|High Intensity Interval Training|The exercise group will participate in a home and telephone-based program consisting of a 12-week high intensity interval training workout (HIIT). The home-based exercise sessions will be prescribed by the program exercise counselor, with a goal to exercise three times per week. The program will be tailored to meet specific fitness and strength needs of the participant. The participant will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. At 12 weeks, participants in both the exercise and wait-list control group will complete online questionnaires. The ActiGraph will be returned to the University of Minnesota research staff via a pre-paid postage envelope.
2413668|NCT03479177|No Intervention|Wait-List Control Group|Participants in the wait-list control condition will have the option of receiving the exercise intervention program after completion of the final assessment.
2413669|NCT03479164|Experimental|Ultra Low-Dose CT|One non-contrast gated aortic (NCGA) computer tomography scan, a low radiation, non-contrast, low cost CT based study
2413670|NCT03479151|Experimental|MR-HIFU of painful bone metastases|Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases
2413671|NCT03479138||Neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with long acting beta agonists (LABA) + high doses inhaled corticosteroids (ICS) with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
2413672|NCT03479138||Non neutrophilic asthma|Patients 18 to 80 years old diagnosed of severe asthma, requiring treatment at least with LABA+ high doses ICS, with eosinophil count in blood<300/mm3. They must be ex-smokers with less than 10 packs-year and no other relevant pulmonary disease.
2413673|NCT03479125||Historical emricasan or placebo subjects|Subjects with liver fibrosis or cirrhosis who have received at least one dose of emricasan or placebo in a prior IDN-6556 study including IDN-6556-07, IDN-6556-12, IDN-6556-14 or IDN-6556-17.
2413674|NCT03479112|Experimental|Flashcards|Study participants in this arm of the trial received bleeding control flashcards that contain diagrams and figures to correctly identify the severity of the injury and visual instructions on the appropriate application of pressure dressing, hemostatic packing, and tourniquet.
2413675|NCT03479112|Experimental|Audio-kit|Study subjects in this arm received a commercially available audio bleeding control kit. The kit included a diagram and visual aids to identify the correct severity of the injury and determine the appropriate method of bleeding control. The kit also had buttons on it to play stepwise audio instructions on the application of compression dressing, hemostatic packing and tourniquet application in two languages (English and Spanish). The audio kits were bought at the market price and the name of the manufacturer was not mentioned in the manuscript to avoid conflict of interest.
3185728|NCT00738153||A|
2414357|NCT03474458|Experimental|Experimental intervention|doxycycline (100 mg bid)
2413676|NCT03479112|Experimental|Bleeding Control (B-Con) training|Study subjects in this arm were given the American College of Surgeons Bleeding Control Basic (B-Con) in-person training course by qualified instructors. This curriculum was developed by a collaboration between American College of Surgeons and the Hartford Consensus. The session included a multimedia presentation in a class format that included some background information about extremity hemorrhage and potential benefits of immediate first-response and hemorrhage control, steps to take in a mass casualty scenario and instructional videos on hemorrhage control modalities and their appropriate use. This was followed by hands-on training in hemorrhage control, with 1:4, instructor to trainee ratio.
2413677|NCT03479112|No Intervention|Control|Study subjects in this arm of the trial received no intervention (no training or access to point-of-care prompts) to assess baseline competence in hemorrhage control.
2413678|NCT03479112|Experimental|Retention of B-Con course|Control, Audio-kit, and flashcard arms undergo B-Con training at the completion of the initial evaluation, and the B-Con arm completed training prior to testing in order that all participants obtain training and then can be evaluated at retention testing. a. 3-9 months after the trial, investigators planned to test all study subjects with a simulated mass causality scenario for retention of knowledge and skills. This test will be the same as the initial test for competence at tourniquet placement in the trial and the same evaluation form will be used to evaluate the study subjects.
2413679|NCT03479086|Experimental|Topiramate|Topiramate 200mg/day
2413680|NCT03479086|Experimental|Naltrexone|Naltrexone 50mg/day
2413681|NCT03479073||Stroke group|Patients who experienced stroke or systemic embolic event following catheter ablation for AF.
2413682|NCT03479073||Control group|Patients who did not experienced stroke or systemic embolic event following catheter ablation for AF.
2413683|NCT03479060|Active Comparator|Continue WCT Application|From the 3rd month to the 12th month Wet cupping applied as an intervention MIDAS was applied at the end of the 6th and 12th months.
2413684|NCT03479060|No Intervention|Discontinue WCT Application|No intervention in this arm.Only MIDAS applied
2413685|NCT03479047|Experimental|Ventilated patients|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
2413686|NCT03479034||Group 1|"Ages 18-85~Cognitively able to understand instructions and care for themselves~Lives in the community (not institutionalised)~Owner of a smartphone and able to use Apps~On 3 or more chronic prescription medications~Has had experience with prescriptions in Australia for at least 1 year~Current patient attending Holdsworth House Medical Practice~Willing to use the ScalaMed ePrescription application"
2413687|NCT03479008||Phase I|This phase will recruit healthy volunteers who will be vibrated with the prototype device using various vibration frequencies to determine which frequency produces the optimal physiologic response. Physiologic responses will be determined with a number of devices capable of measuring such things as tissue oxygenation, oxygen consumption, and muscle activity. Blood samples will also be taken to measure certain chemical markers associated with activity and increase blood flow. Volunteers will be randomized to receive alternating 5 minute episode of various vibration frequencies.
2413688|NCT03479008||Phase 2|Based on data collected from Phase I used to determine optimal vibration strategies, the investigators will recruit critically ill patients from the Intensive Care unit who are expected to be immobilized for a prolonged period of time due to the nature of their illness. these patient subjects will undergo up to three 5-10 minute vibration sessions a day for 5 days. Similar physiologic responses will be measured in these patients. Baseline blood values will be taken at prior to the first day of vibration and then additional samples taken at the end of each day of vibration. No randomization will take place in this phase.
2413689|NCT03478995|Experimental|GX-I7|Determined dose of GX-I7 on Day1 of each cycle
3185729|NCT00738166|Experimental|II|organic animal manure
3185730|NCT00738166|Active Comparator|III|conventional
3185731|NCT00738166|Experimental|I|organic green manure
3185732|NCT00738179|Experimental|1|CPAP plus standard care of cardiovascular risk factors
3185733|NCT00738179|Active Comparator|2|Standard care alone
3185734|NCT00738192|Active Comparator|1|Fentanyl delivered for controlling awaking pain
3185735|NCT00738192|Active Comparator|2|Sufentanil delivered for controlling awaking pain
3185736|NCT00738192|Active Comparator|3|Butorphanol delivered for controlling awaking pain
3185737|NCT00738205||1|
3185738|NCT00738205||2|
3185739|NCT00738218|Other|MDCT|Single Arm study. All patients underwent MDCT.
3185740|NCT00738231|Active Comparator|I|"Group I's training material consisted of a brochure with the information we wanted the public to know about heart disease. The brochure had such titles as Cardiovascular Diseases, let us protect our hearts, the importance of cholesterol in preventing heart diseases, watch out for blood pressure, quit smoking for your health, weight watching, nutrition, food to avoid in cardiovascular disease, an easy method: exercise and exercise control, and an appropriate body weight vs. height chart for adults"
3185741|NCT00738231|Active Comparator|II|The Group II training material document was a letter in the form of a prescription in which the individual was addressed by name, the risk factors established at the first stage were explained, and the suggested measures for protection from such risk factors were indicated.
3185742|NCT00738244||1|Normal hearing listeners
3185743|NCT00738244||2|Listeners with mild-to-moderate sensorineural hearing loss
3185744|NCT00738257|Experimental|Parmidronate|
3185745|NCT00738296|Active Comparator|A|Group A: Comparator
3185746|NCT00738296|Active Comparator|B|Group B: Comparator
3185747|NCT00738296|Experimental|C|Group C: Drug
3185748|NCT00738309||Operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment is recommended to prevent progression of the curvature or to correct trunk deformity (unacceptable cosmesis).
3185749|NCT00738309||Non-operative|Diagnosis of classical Scheuermann's Kyphosis (3 successive vertebrae wedged 5 degrees or more, +/- end plate deformities) or idiopathic structural Kyphosis (rigid structural kyphosis without classic Scheuermann's Kyphosis findings) for which surgical treatment was not undertaken.
3185750|NCT00738322|Experimental|1|
3185751|NCT00738322|Placebo Comparator|2|
3185752|NCT00738348|Active Comparator|2|250mL of 5% glucose plus 300mg of sivelstat was infected through the vein at 10mL per an hour
3185753|NCT00738348|Placebo Comparator|1|250mL of 5% glucose was injected though the vein at 10mL per an hour
3185754|NCT00738387|Experimental|ASA404 + docetaxel|"1800 mg/m2 of ASA404 intravenous (IV) on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
3185755|NCT00738387|Placebo Comparator|Placebo + docetaxel|"Placebo i.v. on day 1 of each 21 day cycle~75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days"
3185756|NCT00738413|Active Comparator|Arm 1|Subjects will be treated for 6 days with deferoxamine.
3185757|NCT00738413|Active Comparator|Arm 2|Subjects will be treated for 6 days with deferasirox.
3185758|NCT00738413|Experimental|Arm 3|Subjects will be treated for 6 days with a combination of deferoxamine and deferasirox.
3185759|NCT00738439||Operative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees requiring surgery.
3185760|NCT00738439||Nonoperative|Diagnosis of adult degenerative or idiopathic scoliosis with a curvature of the spine measuring greater than or equal to 20 degrees not requiring surgery.
2413710|NCT03478852||Single Arm|Single arm open enrollment of patients with standard of care treatment and evaluation
3185761|NCT00738452|Experimental|Treatment (chemo, monoclonal antibody therapy, radiation)|CHEMORADIOTHERAPY: Patients undergo external beam radiation therapy 5 days a week for 45 days. Beginning within 24 hours of the start of radiation therapy, patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36 OR cisplatin IV over 60 minutes on days 1, 8, 29, and 36 and etoposide IV over 60 minutes on days 1-5 and 29-33. CONSOLIDATION RADIOIMMUNOTHERAPY: Beginning 6-10 weeks after completion of chemoradiotherapy, patients with stable disease, partial response, or complete response receive a therapeutic dose of yttrium Y 90 anti-CEA monoclonal antibody cT84.66 IV. Treatment continues in the absence of disease progression or unacceptable toxicity.
2413712|NCT03478826||ILD|250 patients (male and females >18 years of age) with the diagnosis of fibrotic DILD (IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis.
2413713|NCT03478826||Healthy|100 healthy participants as a control group.
2413714|NCT03478826||Pneumonia|25 patients with pneumonia as a control group.
2413715|NCT03478813|Experimental|Intervention group|Voiding school (VS) is based on urotherapy guidelines for educating children with incontinence highlighting regular voiding habits and life-style advice. Learning by doing, understanding the body function by concrete example videos and pictures, and discussing are the main teaching methods.The intervention is delivered face-to-face in groups of 4-6 children. The VS includes three sessions one months apart. Duration of each VS session is three hours. The intervention is delivered with detailed manual. The intervention is provided by an urotherapist and a public-health nurse.
2413716|NCT03478813|No Intervention|Usual care group|The control group receives treatment according to the new 2016 guidelines of incontinence care in child welfare clinics in the city concerning. Treatment is carried out by public health nurse individually in consulting hours or by telephone.
2413717|NCT03478800|Experimental|High school football players and acupuncture|50 healthy high school football players without active musculoskeletal injury
3185762|NCT00738478|Experimental|A|Arm A: with nasogastric tube
3185763|NCT00738478|Active Comparator|B|Arm B: without nasogastric tube
2413720|NCT03478774|Active Comparator|Control|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, continuous videolaryngoscopy will be performed.
2413721|NCT03478774|Experimental|High flow|These patients will receive HFNCT with oxygen 70l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
2413722|NCT03478774|Experimental|medium flow|These patients will receive oxygen 10l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
2413723|NCT03478774|Experimental|low flow|These patients will receive oxygen 2l/min after induction of general anesthesia. Throughout the entire measurement period of 15 or 30 minutes, jaw thrust will be performed.
2413724|NCT03478774|Experimental|minimal flow|These patients will receive a standard tracheal tubes after induction of general anesthesia, with 100% Oxygen and Minimum-flow 0.25l/min. The measurement period is 15 or 30 minutes.
2413725|NCT03478748|Active Comparator|one-to-one dental health education|Conventional oral health education programme that mainly focuses at child level, which has been the normal practice at the Ministry of Health, were provided to the control participants.
2413726|NCT03478748|Experimental|anticipatory guidance technique|Anticipatory guidance technique were applied where appropriate dental health education (according to the children's milestones) were provided to mothers and their children.
2413727|NCT03478735|Experimental|Ultrasound Guided GON Block at C2|Ultrasound Guided Greater Occipital Nerve Block at C2
2413728|NCT03478735|Active Comparator|Landmark based GON Block|Landmark-Based Greater Occipital Nerve Block
2413729|NCT03478722||Maintenance Hemodialysis Patients|Protein meal, stable isotope amino acid infusion
2413730|NCT03478722||Control Subjects|Protein meal, stable isotope amino acid infusion
2413731|NCT03478709||Volume expansion|
2413732|NCT03478709||norepinephrine|
3185764|NCT00738491||1|Patients with stable angina pectoris and documented coronary heart disease recruited in Edinburgh
3185765|NCT00738491||2|Patients with stable angina pectoris and documented coronary heart disease recruited in London
3185766|NCT00738504||1|
3185767|NCT00738504||2|
3185768|NCT00738504||Group 1|Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
3185769|NCT00738504||Group 2|Group 2 (Intensive Insulin Therapy). Continuous intravenous insulin infusion was adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 to 120 mg/dl. Patients were submitted to capillary glycemic measurements every 2 hours. The insulin dose was adjusted according to an algorithm run by nurses and overseen by physicians. These patients received glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids (Diason, Nutricia Clinical Care Ltd).
3185770|NCT00738517|Active Comparator|1|Immunoadsorption with subsequent immunoglobulin substitution
2413737|NCT03478670||ADA-SCID subjects treated with Strimvelis|Subjects with ADA-SCID who have received Strimvelis (previously GSK2696273) gene therapy
3185771|NCT00738517|No Intervention|2|
3185772|NCT00738556|Active Comparator|1|Full cover stenting of coronary lesions
3185773|NCT00738556|Active Comparator|2|Spot-stenting of significantly stenotic parts of a coronary lesion
2413741|NCT03478631|Experimental|High Nitrate Dehydrated Vegetables|Participants are given high-nitrate dehydrated vegetable powders contained in opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
2413742|NCT03478631|Active Comparator|Low-Nitrate Dehydrated Vegetables|Participants are given low-nitrate dehydrated vegetable powders contained in three opaque sachets. Participants are advised to consume three sachets per day, over the course of three meals, for 16 weeks.
2413743|NCT03478618|Active Comparator|Group R|30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative.
2413744|NCT03478618|Active Comparator|Group L|30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative.
2413745|NCT03478605|Experimental|Olanzapine|Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;
2413746|NCT03478605|Active Comparator|Aprepitant|Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;
3185774|NCT00738569|Experimental|Raltegravir|
3185775|NCT00738582|Experimental|Open Label|Pemetrexed, Cisplatin and MORAb-009 (Amatuximab)
2413749|NCT03478579||Emergency physicians|The observational group will be composed of emergency physicians working in the French Midi-Pyrenees region. Physicians must work since 2 years in emergency service
2413750|NCT03478566|Experimental|Transcutaneous CO2 monitoring|
2413751|NCT03478553||People with IPF|
2413752|NCT03478553||Family members without IPF|
2413753|NCT03478527|Experimental|verum condition probiotics|The verum condition probiotics in the present study is a freely available product, Vivomixx® powder (dietary supplement). Each dose (4.4g) contains 450 billion bacteria, composed of eight bacterial strains: Lactobacilli (L. paracasei, L. plantarum, L. acidophilus, L.delbrueckii subsp. bulgaricus), Bifidobacteria (B. longum, B. infantis, B. breve), and Streptococcus thermophiles. 30 Participants will be randomly assigned to this condition. The intake period is 28 days, daily dose = 4.4g.
2413754|NCT03478527|Placebo Comparator|placebo condition|In the placebo condition participants will receive a placebo powder (comparable in taste and consistency to Vivomixx® = verum condition probiotics) that contains no probiotic bacteria. 30 Participants will be randomly assigned to that condition. The intake period is 28 days, daily dose = 4.4g.
2413755|NCT03478514|Experimental|Single Arm|"All patients will receive palbociclib at 100 mg oral once a day for 21 days, followed by 7 days off.~Ibrutinib will be administered at 560 mg oral continuously."
2413756|NCT03478501|Experimental|Decision Aid Group|Participants randomized to this arm will view the decision aid on a tablet in the emergency department.
2413757|NCT03478501|No Intervention|Control Group|Participants randomized to this arm will be asked to review general suicide prevention information on a tablet in the emergency department.
2413758|NCT03478488|Experimental|KN035|"KN035 plus Gemcitabine & oxaliplatin KN035 2.5 mg/Kg, administered as subcutaneous injection, weekly of each 21-day cycle.~Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles."
2413759|NCT03478488|Active Comparator|Gemcitabine & oxaliplatin|Gemcitabine 1000 mg/m^2, IV infusion on Day 1 and Day 8, and oxaliplatin 85 mg/m^2, IV infusion on Day 1 of each 21-day cycle for no more than 6 cycles.
2413760|NCT03478475|Experimental|Vitamin D group|The vitamin D group received three times per week a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada)
2413761|NCT03478475|Placebo Comparator|Placebo group|The placebo group received three times per week a tablet containing microcrystalline cellulose (66.3%), starch (33.2%), and magnesium stearate (0.5%), per serving.
3185776|NCT00738595|Experimental|1|EVT 302, 5 mg once Daily
2413763|NCT03478449|Experimental|Fine sorting lymph node group|
2413764|NCT03478449|No Intervention|Regional sorting lymph node group|
2413765|NCT03478436|Other|fed group|14 once daily oral doses of doxycycline 40 mg, preceded by a standardized high-fat, high-calorie breakfast
2413766|NCT03478436|Other|fasting group|14 once daily oral doses of doxycycline 40 mg in fasting conditions (no food allowed 8 hours prior to dosing)
2413803|NCT03478241|Active Comparator|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system.
2413804|NCT03478228|Experimental|Multi-Sensory Training (MST)|Multi-Sensory Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
3185777|NCT00738595|Placebo Comparator|2|Placebo once daily
3185778|NCT00738595|Experimental|3|EVT 302 plus open label Nicotine replacement
3185779|NCT00738595|Active Comparator|4|Placebo plus nicotine replacement therapy
3185780|NCT00738608||1|33 pat. with verum
3185781|NCT00738608||2|33 Pat. with placebo
3185782|NCT00738621|Active Comparator|1|Oral aprepitant 40 mg - given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction ondansetron (4mg (2ml) intravenous) administered at cessation of anesthesia
3185783|NCT00738621|Placebo Comparator|A,2|Oral aprepitant 40 mg- given within 3 hours prior to induction dexamethasone (4mg intravenous) administered immediately after induction Placebo ( intravenous saline 2ml) administered at cessation of anesthesia
2413767|NCT03478423|Experimental|Codeine|"Patients will be provided with 30mg tablets of codeine, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2413768|NCT03478423|Experimental|Oxycodone|"Patients will be provided with 5mg tablets of oxycodone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2413769|NCT03478423|Experimental|Hydromorphone|"Patients will be provided with 1mg tablets of hydromorphone, instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.~Patients will also receive 500mg tablets of acetaminophen with instructions to take 1-2 tablets by mouth every 8 hours as needed for pain.~Patients will also receive 17g sachets of PEG, Dissolve in 120 to 240 mL (4 to 8 ounces) of beverage and drink. Use one sachet daily as needed to prevent constipation if you are taking the opioid study drug."
2413770|NCT03478410|Other|Atrial fibrillation|An epicardial fat biopsy will be taken from patients with chronic atrial fibrillation or paroxysmal atrial fibrillation who undergo any cardiac surgery
2413771|NCT03478410|Other|Control|An epicardial fat biopsy will be taken from patients without any history of atrial fibrillation who undergo any cardiac surgery
2413772|NCT03478397|Active Comparator|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
2413773|NCT03478397|No Intervention|Usual Care|Women with HPV self-collected tests receive usual care. Upon opting for the HPV self-collected test, women will be instructed to go to the health care center in 30 days to pick up the results.
2413774|NCT03478384|Experimental|Coaching group|Patient coaching
2413775|NCT03478384|No Intervention|Control group|Control group - no additional coaching provided
3185784|NCT00738634|Experimental|Physical activity mediated|"Self-motivated physical activity intervention~Materials mailed to participants"
3185785|NCT00738634|Active Comparator|Nutrition control|"Nutrition attention-control arm.~Delivered by researcher."
3185786|NCT00738634|Experimental|Physical activity researcher contact|"Self-motivated physical activity intervention~Delivered by researcher."
3185787|NCT00738647|Active Comparator|Ceram X|Fillings made with a traditional composite material (Ceram X)
2413780|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2413781|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2413782|NCT03478358|Experimental|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2413783|NCT03478358|Experimental|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7 GBq (100 mCi) of 177LuDOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
2413784|NCT03478345|Experimental|THRIVE Study|
2413785|NCT03478332|Active Comparator|Treatment group|The aim of the arm is to test if the addition of Yangxinshi pills to the conventional coronary heart disease medicine will improve the exercise tolerance of the coronary heart disease
2413786|NCT03478332|Placebo Comparator|Control group|The patients of the control group are treated with conventional coronary heart disease medicine plus the placebos-Yangxinshi simulant
2413787|NCT03478319|Experimental|Cohort 1|ACE-2494 or placebo 0.06 mg/kg SC Day 1
2413788|NCT03478319|Experimental|Cohort 2|ACE-2494 or placebo 0.2 mg/kg SC Day 1
2413789|NCT03478319|Experimental|Cohort 3|ACE-2494 or placebo 0.6 mg/kg SC Day 1
2413790|NCT03478319|Experimental|Cohort 4|ACE-2494 or placebo 1.0 mg/kg SC Day 1
2413791|NCT03478319|Experimental|Cohort 5|ACE-2494 or placebo 2.0 mg/kg SC Day 1
2413792|NCT03478319|Experimental|Cohort 6|ACE-2494 or placebo TBD (not to exceed 3.0 mg/kg SC) Day 1
2413793|NCT03478306|Active Comparator|Arm 1|Melatonin, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
2413794|NCT03478306|Placebo Comparator|Arm 2|Place, 1 tablet (4 mg), every evening 2 hours before bed in 21 days.
2413795|NCT03478293|Experimental|iStent inject surgery|Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
2413796|NCT03478280|Active Comparator|Brodalumab|Subjects will receive 210 mg of Kyntheum administered by subcutaneous injection at Weeks 0, 1 and 2 followed by 210 mg every other week (EOW) thereafter.
2413797|NCT03478280|Placebo Comparator|Placebo|Subjects will receive placebo doses administered by subcutaneous injection at Weeks 0, 1 and 2 followed by placebo EOW thereafter.
2413798|NCT03478267||Fetal heart rate 110-130 bpm|Pregnancies in which the fetal baseline heart rate is between 110 beats per minute and 130 beats per minute.
2413799|NCT03478267||Fetal heart rate 140-160 bpm|Pregnancies in which the fetal baseline heart rate is between 140 beats per minute and 160 beats per minute.
3185788|NCT00738647|Experimental|Filtek Silorane|Fillings made with a new composite material (Filtek silorane)
2413801|NCT03478241|Active Comparator|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system.
2413802|NCT03478241|Active Comparator|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system.
2414155|NCT03475810|Active Comparator|midazolam|Patients do not watch virtual reality videos but will be administered iv sedative drugs before spinal attempt.
2413805|NCT03478228|Active Comparator|Wrist Stabilisation Training (WT)|Wrist Stabilisation Training. 6 treatment sessions, supervised by a physiotherapist, during a 3 months training period, and a written exercise program that is to be performed daily at home. The participants keep a home exercise diary during the training period.
2413806|NCT03478215|Experimental|Mesenchymal Stromal Stem Cells Infusion|"Intervention: Mesenchymal stromal stem cells infusion. This is the active investigational intervention, administered intravenously at surgery and day 4 post-transplant in a dose-escalation fashion beginning as 1x10^6 cells for the first dose group, 2x10^6 cells for the second dose group, or 3x10^6 cells for the last dose group. The infusion set-up will be covered to mask the group assignment.~Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care."
2413807|NCT03478215|Placebo Comparator|Placebo Infusion|Placebo: A normal saline infusion. This is the placebo intervention to occur at surgery and day 4 post-transplant. The infusion set-up will be covered to mask the group assignment. Participants will also receive BASILIXIMAB (Simulect, for all subjects at a standard dose, 20mg reconstituted with normal saline or 5% dextrose) on the day of surgery and day 3 or 4 post-transplant administered by a member of the anesthesia team; TACROLIMUS (Prograf for maintenance therapy), MYCOPHENOLATE MOFETIL (Cellcept for maintenance therapy), and CORTICOSTEROIDS as routine care.
2413808|NCT03478202|Experimental|Open Label RELEASE Supplement|
2413809|NCT03478176||Patients|
3185789|NCT00738660|Experimental|A|single experimental arm cross over of patients, addition of Ramipril onto Telmisartan.
3185790|NCT00738686|Experimental|1|Single-arm study, no placebo or control group
2413812|NCT03478150|Experimental|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol and applied in the cavity, where the ethanol evaporates, while the zinc oxide nano-particles infiltrate into the carious floor of the cavity.
2413813|NCT03478150|Experimental|laser diode|Each cavity will be irradiated in contact mode with continuous wave of radiation. The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. The fiber optic will be disinfected for each use by 70% ethyl alcohol and inserted inside the cavity to 1mm with a spiral continuous movement clockwise from the top to the floor and anti-clockwise in the reverse direction. This procedure improves the distribution of the laser light inside the cavity and to avoid excessive heat generation in the internal cavity surface. Irradiation time will be 15 seconds and repeated 5 times with 15 second intervals with contact, according to manufacture instructions. During this study the output power will be adjusted at 1.5W.
2413814|NCT03478137|Experimental|CPAP intervention|Over the course of 4-7 months, participants will have to wear the CPAP every night, at least 4 hours per night.
2413815|NCT03478137|No Intervention|Control 1|Eligible participants who declined to participate in the study. Their main study visit data will be used to compare with the intervention group.
2413816|NCT03478137|No Intervention|Control 2|Eligible participants who were not approached, hence not given the opportunity to accept or decline. Their main study visit data will be used to compare with the intervention group.
2413817|NCT03478124||PSP patients|Patients suffering from Progressive Supranuclear Palsy (PSP)
2413818|NCT03478124||PD Patients|Patients suffering from Parkinson's disease (PD)
2413819|NCT03478111|Experimental|CMAB008+MTX|"Drug: CMAB008 (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
2413820|NCT03478111|Active Comparator|Remicade+MTX|"Drug: Remicade (recombinant chimeric anti-TNF-α monoclonal antibody injection) infusion of 3mg/kg in Week 0, 2, 6, 14, 22, 30.~Drug: MIX (methotrexate) will be oral administered at a dose of 7.5mg~15mg weekly from Week 0 to 38."
2413821|NCT03478098|Experimental|10 Roux-en-Y Gastric Bypass patients|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
2413822|NCT03478098|Experimental|10 control subjects|4 study days in randomized order are conducted with interventions: Low GI mealtest, High GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest and subsequent exercise
2413823|NCT03478085|Active Comparator|Traditional exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking.
2413824|NCT03478085|Experimental|Oxygen guided exercise therapy|Training will be performed three times a week for 12 weeks. Each session will take place on a GaitKeeper treadmill (Sammons Preston, IL) treadmill and will last 45 minutes with a 5 minute warm up and cool down of either cycling or walking. All patients will be outfitted during exercise with the PortaMon NIRS device on the most affected calf (including subjects in the symptom-driven exercise cohort). The intensity of training will be adjusted to either pain (claudication) rating or oxygen tension. In preliminary studies, a 50% reduction in the tissue saturation index is typically not associated with severe claudication and will be used as the lower level threshold to gauge physical effort (i.e., if subjects do not desaturate by >50% then the intensity of training - the walking pace - will be increased). The training duration, intensity, pain rating, and oxygen tension will be recorded.
2413825|NCT03478085|Placebo Comparator|Control|Patients will be advised to walk independently.
2413826|NCT03478059|Experimental|Mild Traumatic Brain Injury|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~Subjects with mTBI residuals will be gently progressed through exercise stations in an individually tailored fashion."
2413945|NCT03477227|Active Comparator|Usual stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear usual compression socks for four weeks (usual care)
3185791|NCT00738712|Experimental|New MRI techniques|New hardware or software technologies designed to improve MRI (Magnetic Resonance Imaging) exams.
3185792|NCT00738725||1|Survey only
3185793|NCT00738725||2|Imaging group
3185794|NCT00738725||3|Non-imaging group
2413827|NCT03478059|Other|Healthy Control|"60 minute, 3 times per week, 6 week long Cognitive and Motor Dual-task Intervention program. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI.~In addition to providing comparison data, the healthy control, athletic 18-34 year old subjects will be used to identify levels and intensity of progressions of dual-task training stations appropriate for highly trained athletes and military personnel recovering from concussion."
2413828|NCT03478046|Experimental|Obese individuals|Apparently healthy, weight-stable, obese and physically inactive male volunteers will be recruited. Intervention is an 8 to 10% weight loss induced by chronic exercise training and dietary modification
2413829|NCT03478033|Active Comparator|Rifampicin group|"Rifampicin group: Intensive treatment（4 types of anti-TB medicines）for 2 months, then isoniazid and rifampicin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifampicin: 10-20mg/kg pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
2413830|NCT03478033|Experimental|Rifabutin group|"Rifabutin group: Intensive treatment（4 types anti-TB medicines）for 2 months,then isoniazid and rifabutin for 4 months of consolidation therapy.~isoniazid: 10-15mg/kg rifabutin: 0.45g/d(W<50kg); 0.6g/d( W≥50kg） pyrazinamide: 30-40mg/kg thambutol: 0.75(W<50kg)；1.0 g/d（W≥50kg）"
2413831|NCT03478020|Experimental|Pre-Treatment, Treatment Cycles A & B|"Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days.~Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days"
2413835|NCT03477994|Active Comparator|dexmedetomidine group|"Upon arrival to ICU, in the dexmedetomidine group, patients will receive an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4~+4 Combative ,+3 Very agitated ,+2 Agitated,+1 Restless, 0 Alert and calm, -1 Drowsy , -2 Light sedation, -3 Moderate sedation, -4 Deep sedation, -5 Unarrousable Taking into consideration if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h. Once the patient will be extubated, wean the infusion by 0.1μg/kg/h till reaching 0.2μg/kg/h. Slow the weaning rate if evidence of withdrawal reactions as agitation or hypertension occur."
2413836|NCT03477994|Sham Comparator|clonidine group|In clonidine group, the patients will receive 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4 Five ampoules of clonidine(750 μg) will be drawn up and diluted in 45ml of normal saline.
2413837|NCT03477981|Other|Study cohort|Participants will receive standard white bread for two weeks and then alginate bread for two weeks. All participants will receive the bread in the same order.
2413838|NCT03477968||PE|"Patients presenting with PE suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment completed for this group : 13th February 2020"
2413839|NCT03477968||DVT|"Patients presenting with DVT suspicion. Diagnosis will be performed according to Standard of Care. Plasma samples will be collected if PTP score is Low or Moderate. If diagnosis is negative, patients will be followed for 3 months to evaluate potential VTE development.~Enrolment on going"
2413840|NCT03477955|Active Comparator|Peek Group|Patients that received PEEK interspinous spacer
2413841|NCT03477955|Active Comparator|Silicon Group|Patients that received Silicon interspinous spacer and did not receive PEEK interspinous spacer
2413842|NCT03477955|Active Comparator|Control Group|Patients that did not receive PEEK interspinous spacer nor Silicon interspinous spacer
2413843|NCT03477942|Experimental|Osteoarthritis|The OA subgroup will be patients aged 18-60 years who have chronic knee pain due to early OA that have not responded to conservative, non-invasive measures such as physical therapy, medications, and activity modification.
2413844|NCT03477942|Experimental|Cartilage|The focal chondral defect subgroup will be patients aged 18-60 years who participate in recreational or professional sports and are symptomatic from a focal chondral defect shown on MRI.
2413845|NCT03477929|Experimental|ganirelix|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
2413846|NCT03477929|Experimental|cetrorelix|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
2413847|NCT03477916|Other|Control (Placebo FMT and cellulose)|
2413848|NCT03477916|Experimental|FMT only (FMT followed by cellulose)|
2413849|NCT03477916|Other|Prebiotic only (Placebo FMT and prebiotic fiber)|
2413850|NCT03477916|Experimental|FMT + prebiotic fiber|
3185795|NCT00738751|Experimental|Dose Escalation Followed by Expansion|Eligible participants were enrolled in a 3+3 dose-escalation design to determine the maximum tolerated dose (MTD) of twice weekly panobinostat plus daily erlotinib at 4 planned dose levels (DLs).
3185796|NCT00738764|Experimental|Cohort 1|PDL192 Dose Level 1
3185797|NCT00738764|Experimental|Cohort 2|PDL192 Dose Level 2
3185798|NCT00738764|Experimental|Cohort 3|PDL192 Dose Level 3
2413879|NCT03477747|Experimental|Endurance Training Microcurrent|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
3185799|NCT00738764|Experimental|Cohort 4|PDL192 Dose Level 4
3185800|NCT00738764|Experimental|Cohort 5|PDL192 Dose Level 5
3185801|NCT00738764|Experimental|Cohort 6|PDL192 Dose Level 6
3185802|NCT00738777|Active Comparator|1|Anastrozole
3185803|NCT00738777|Experimental|2|Anastrozole + Fulvestrant
3185804|NCT00738777|Active Comparator|3|Tamoxifen
3185805|NCT00738777|Other|4|Tamoxifen (pre-menopausal and male patients)
2413857|NCT03477877|Experimental|Indashyikirwa|Sectors which receive the full Indashyikirwa programme, including (1) couples training and activist training and support by RWAMREC, and (2) opinion leader training and establishment of women's spaces by the Rwanda Women's Network.
2413858|NCT03477877|Active Comparator|VSLA Only|Sectors that continue to receive only the village savings and loan association (VSLA) programmes offered by CARE Rwanda
2413859|NCT03477864|Experimental|Arm A (REGN2810, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 IV over 30 minutes on day 1 of week 1 and in week 4, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
2413860|NCT03477864|Experimental|Arm B (ipilimumab, SBRT, surgery)|Participants receive ipilimumab via intraprostatic injection on day 1 of week 1, and undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
2413861|NCT03477864|Experimental|Arm C (REGN2810, ipilimumab, SBRT, surgery)|Participants receive anti-PD-1 monoclonal antibody REGN2810 as in Arm A and ipilimumab as in Arm B. Participants also undergo SBRT for 4 fractions on days 2-5 of week 3. Within 14-21 days, participants undergo radical prostatectomy.
3185806|NCT00738790|Experimental|1|Preoperative radiotherapy with five fractions of 5 Gy during one week and boost 4 Gy after 1 week interval, total dose 29 Gy; after 6 weeks full-thickness local excision
3185807|NCT00738790|Active Comparator|2|"Radiochemotherapy with 28 fractions of 1,8 Gy plus boost 5,4 Gy in 3 fractions~+ simultaneous bolus 5-Fluorouracil and leucovorin; after 6 weeks full-thickness local excision"
3185808|NCT00738803|Experimental|1|Leg Length and offset measurement arm
2413865|NCT03477825|Placebo Comparator|Placebo|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
2413866|NCT03477825|Experimental|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
2413867|NCT03477825|Experimental|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
2413868|NCT03477812||Healthy children|Healthy children 7-14 years of age.
2413869|NCT03477812||Nocturnal enuresis with polyuria|Children with nocturnal enuresis and polyuria aged 7-14 years.
2413870|NCT03477812||Nocturnal enuresis without polyuria|Children without nocturnal enuresis and polyuria aged 7-14 years.
2413871|NCT03477799|Active Comparator|Active|anodal stimulation over the right dlPFC
2413872|NCT03477799|Placebo Comparator|Sham|sham stimulation over the right dlPFC
2413873|NCT03477786|Active Comparator|tight BP|"Interventions: anti-hypertension drug prescription by physician and case management by health educator.~Blood pressure is targeted at 120/80 mmHg in the tight BP control group."
2413874|NCT03477786|Placebo Comparator|usual BP|"Interventions: The physicians follow their usual care patterns to prescribe anti-HT drugs.~Blood pressure is targeted at < 140/90 mmHg in the usual BP control group."
2413875|NCT03477773|Experimental|Intervention|Perform three session of high-intensity, interval training sessions per week over the 6-week intervention
2413876|NCT03477773|No Intervention|Control|Continue with their normal habitual lifestyle over the 6-week intervention
2413877|NCT03477747|Experimental|Resistance Training Microcurrent|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2413878|NCT03477747|Sham Comparator|Resistance Training Shadow|"Participants will combine a 10-week periodized and controlled resistance programme with 3 h of sham comparator after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2413944|NCT03477227|Experimental|Short stocking|After radiofrequency ablation of the GSF and phlebectomy varicose tributaries, patients will wear compression socks without foot for four weeks
2413946|NCT03477214||Normal|No UI, no OAB conditions. Transvaginal biomechanical and electromyography mapping will be completed.
3185809|NCT00738816|Other|Intervention|Systematic medication review
2413880|NCT03477747|Sham Comparator|Endurance Training Shadow|"Participants will combine a 10-week periodized and controlled endurance programme with 3 h of microcurrent after training.~Measurements pre and post-intervention will be body composition via DEXA, endurance performance (1 RM bench press and Squat) endurance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes, IL6, IL1, Myoglobin, salivary cortisol and testosterone. Elbow flexors, vastus medialis and vbastus lateralis muscle thickness"
2413881|NCT03477734|Experimental|CS1 & heart monitor - AF patients|Males and females diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
2413882|NCT03477734|Active Comparator|CS1 & heart monitor -Healthy volunteers|Males and females not diagnosed with atrial fibrillation will be fitted with the CardiacSense1 and Holter heart monitor for 24-48 hours while going about daily activities, results shall be compared and analysed
2413883|NCT03477721||Group with cancer cachexia (CTB)|For diagnosis of cachexia it will be used the following criteria (Evans et al., 2008)
2413884|NCT03477721||Group without cancer cachexia (TB)|
2413885|NCT03477708||Study group|TCCO2 monitoring
2413886|NCT03477708||Control group|Routine monitoring
2413887|NCT03477695|Experimental|Upright device|Ambulatory use of the Upright device
2413888|NCT03477682|Experimental|Early Ambulation Group|The patient will remain on bed rest for one day following surgery and will be encouraged to be out of bed and ambulating on the second day following surgery.
2413889|NCT03477682|No Intervention|Standard Group|The patient will remain on bed rest for five days following surgery and will be encouraged to be out of bed and ambulating on the sixth day following surgery.
2413890|NCT03477669|Experimental|chamomile/probiotic arm|Infant will receive 5 drops of the study product once per day with a feeding at midday.
2413891|NCT03477669|Placebo Comparator|Placebo of chamomile/probiotic arm|Infant will receive 5 drops of a placebo product once a day at midday.
2413892|NCT03477656|Experimental|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption according to the initial isoagglutinin titer.
2413893|NCT03477656|Experimental|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis according to the initial isoagglutinin titer.
2413894|NCT03477643||Refractory Multiple Myeloma|Patients with relapsed and refractory multiple myeloma who have received treatment with pomalidomide, cyclophosphamide, and dexamethasone following the GEM-PETHEMA clinical practice guidelines between 01/01/2015 to 01/04/2018
2413895|NCT03477630|Experimental|Platelet Rich Plasma|Infiltration injected 8 cc per session, 4 sessions, 1 session every 15 days.
2413896|NCT03477630|Active Comparator|Hyaluronic Acid|Infiltration, injected 6 cc per session, 1 sessions.
2413897|NCT03477617|Experimental|Intraoperative Hemodynamic Algorithm|In the experimental group, the anesthesiologist will have complete access to data from the minimal invasive cardiac output monitor. During the intraoperative period, the anesthesiologist will be instructed to use a hemodynamic management algorithm to manage episodes of significant hypotension
2413898|NCT03477617|Active Comparator|Usual Hemodynamic Management|In the control arm, the participant will be monitored by the cardiac output monitor, but the anesthesiologists in the operating room will be blinded to hemodynamic data from the monitor. Data from the monitor will be stored electronically and used to compare hemodynamic parameters between study arms.
2413899|NCT03477604|Experimental|MicroStent and Standard PTA|Implant of the MicroStent peripheral vascular stent system for treatment of arterial lesions below the knee.
2413900|NCT03477604|Active Comparator|Standard PTA|
2413901|NCT03477591|Experimental|Evidence + PDA|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources), plus a blog post on PDAs and the relevant decision aid from the Portal database
2413902|NCT03477591|Experimental|Evidence only|The same evidence-based information as group 1 (Evidence + PDA), but without the PDA to quantify the effect of accessing evidence through the Portal alone
2413903|NCT03477591|Sham Comparator|Attention control|Information on how to distinguish high from low-quality health information, not specific to cancer screening or PDAs
2413904|NCT03477578||FoG+|Parkinsonian patients with Freezing of Gait
2413905|NCT03477578||FoG-|Parkinsonian patients withou Freezing of Gait
2413906|NCT03477565|Experimental|Sperimental group|"Patients who belong to the sperimental group (SPER) will receive the standard treatment and Kinesio tape lymphatic drainage technique application.~The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and physiotherapy counseling."
2413907|NCT03477565|No Intervention|Control group|"Patients who belong to the control group (CONTR) will receive only the standard treatment. Standard treatment consists in physiotherapy evaluation and counseling. The educational part, the demonstration of the exercises and the prosthesis mobilization are included in this treatment."
2413908|NCT03477552|Experimental|Accuvein V400 device|In the Accuvein group, the nurse uses the Accuvein device to identify the veins before any puncture to infuse the patient and then proceeds as usual, under illumination of the device.
2413909|NCT03477552|Active Comparator|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
2413910|NCT03477539|Experimental|Treatment (daratumumab, ASCT, lenalidomide)|"CONSOLIDATION I: Patients receive daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2, and on days 1 and 15 of cycles 3-4. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION II: Beginning 8 weeks after completion of daratumumab cycle 2 or 4, patients undergo ASCT.~MAINTENANCE: Within 14 days after completion of day 100 visit post-SCT, patients receive daratumumab IV on day 1 and lenalidomide PO daily on days 1-21. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients who are still maintaining response continue to receive daratumumab IV every 3 months in the absence of disease progression or unacceptable toxicity."
2413911|NCT03477526|Experimental|COPD patients (GOLD stage III-IV)|
2413912|NCT03477526|Active Comparator|IPF patients|
2413913|NCT03477513|Experimental|Single Arm|Dose-escalated radiation therapy
2414358|NCT03474458|Active Comparator|Control intervention|Standard of care therapy
2413914|NCT03477500|Experimental|HSCT (Cyclophosphamide and ATG)|"Day 1: Cyclophosphamide 2.0 g/m2 body surface area Days 5-10: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight/day sc.~Day 11 and until apheresis is discontinued: Granulocyte colony stimulating factor (filgrastim) 5 mcg/kg body weight x 2 sc/day.~HSCT days -5 to -2: Cyclophosphamide 50 mg/kg/day. HSCT days -5 to -1: Anti-thymocyte globulin (ATG-rabbit, Thymoglobuline®) 0.5 mg/kg body weight iv on day -5, 1.0 mg ATG-rabbit/kg will be given iv on day -4, and 1.5 mg ATG-rabbit /kg will be given iv on days -3,-2 and -1 over 10 hours.~HSCT day 0: Reinfusion of a minimum of 3,0 x 106 CD 34+ cells/kg body weight."
2413915|NCT03477500|Active Comparator|Alemtuzumab|Alemtuzumab 12 mg iv daily on 5 consecutive days at first alemtuzumab treatment cycle, followed by 3 consecutive days at the second alemtuzumab treatment cycle 12 months later.
2413916|NCT03477487|Experimental|Lowest dose|The lowest dose of XT-150 in the escalation schedule
2413917|NCT03477487|Experimental|Second dose|The 2nd dose of XT-150 in the escalation sequence
2413918|NCT03477487|Experimental|Third dose|The 3rd dose of XT-150 in the escalation sequence
2413919|NCT03477487|Experimental|Highest dose|The highest dose of XT-150 in the escalation sequence
2413920|NCT03477461||terlipressin group|patients presented with oliguria or high levels creatinine
2413921|NCT03477448|Active Comparator|PPD group|"This group will include 20 patients who will be treated with IL injection of PPD at a dose of 10 IU (0.1 ml) supplied an insulin syringe in the largest wart.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions"
2413922|NCT03477448|Active Comparator|Bleomycin group|"This group will include 20 patients who will be treated with IL injection of bleomycin.~Injections will be repeated for all patients into the same lesion (largest wart) every 2 weeks for three treatment sessions, if needed."
2413923|NCT03477435|Experimental|Opt-in clinical reminder|As the investigators have done previously, the reminder will be self-explanatory, and will walk staff through each step of referral. The reminder will include the following domains: normative advice, referral to treatment, handout
2413924|NCT03477435|Experimental|Opt-out tobacco treatment|The investigators will directly change the treatment status quo by implementing a clinical reminder that automatically initiates tobacco treatment referral at the time the reminder is activated.
2413925|NCT03477422|Experimental|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|"CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was an Experimental drug in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. It was administered twelve hourly through intravenous route as infusion over 30 minutes. The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the Principal Investigator (PI).~Interventions:~Drug: CSE-1034 (Ceftriaxone + Sulbactam + EDTA)~Drug: Matching Placebo"
2413926|NCT03477422|Active Comparator|Meropenem|"Meropenem was the active comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg. It was administered eight hourly through intravenous route as infusion over 30 minutes.The duration of the active treatment was for 5-14 days depending upon the severity of the disease, which was determined by the PI.~Interventions:~Drug: Meropenem~Drug: Matching Placebo"
2413927|NCT03477409||Neonatal intensive care patients|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
2413928|NCT03477396|Experimental|Treatment (ribociclib, aromatase inhibitor)|Participants receive ribociclib orally PO QD on days 1-21 and aromatase inhibitor per treating investigator's discretion. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3185810|NCT00738829|Experimental|Treatment Arm|Lenalidomide Dose Escalation combined with Fludarabine/Rituximab followed by maximum tolerated lenalidomide dose/Rituximab maintenance therapy
3185811|NCT00738842|Experimental|1|
2413931|NCT03477344|Active Comparator|Dexmédétomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
2413932|NCT03477344|Placebo Comparator|Sodium Chloride 0,9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
2413933|NCT03477318||Patients undergoing screening colonoscopy|Patients undergoing first-time colonoscopy using white light with at least 1 polyp resected.
2413934|NCT03477305|Experimental|BerryCare Participants|Subjects will be recruited to participate in a community gardening program where they will learn the benefits of both physical active gardening and consuming homegrown foods through blackberry consumption.
2413935|NCT03477292|Experimental|Long duration of antibiotics|14 days of Colistin
2413936|NCT03477292|Active Comparator|Short duration of antibiotics|7 days of Colistin
3185812|NCT00738842|Placebo Comparator|2|
3185813|NCT00738855|Active Comparator|1|Gastrografin group
3185814|NCT00738855|Placebo Comparator|2|Control group
2413940|NCT03477266|Experimental|Mouth dissolving mosapride|Fluxopride 5mg of Macryrl egypt 2 tablets one day before and immediately after elective cesarean section every 8hour for maximum of 5 days
2413941|NCT03477266|Placebo Comparator|Placebo mouth dissolving tablets|Dummy identical tablets taken in the same way
2413942|NCT03477253|Active Comparator|LC within 72 hours of disease onset|Immediate laparoscopic cholecystectomy within 72 hours of the onset of symptoms was performed in these patients
2413943|NCT03477253|Active Comparator|LC after 72 hours of disease onset|Late laparoscopic cholecystectomy after 72 hours of the onset of symptoms was performed in these patients
2413947|NCT03477214||Urinary incontinence|Urinary incontinence conditions. Transvaginal biomechanical and electromyography mapping will be completed.
3185815|NCT00738920|Active Comparator|MC-CBT|Self Administered Cognitive Behavior Therapy
3185816|NCT00738920|Active Comparator|Standard-CBT|Therapist Administered Cognitive Behavior Therapy
3185817|NCT00738920|Active Comparator|Education/Support|Behavioral Patient Education/Counseling
3185818|NCT00738933|Active Comparator|A|A group of patients consuming 2 grams plant stanols 4-8 weeks before the operation
2413949|NCT03477201|Experimental|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Intervention: 30 patients will undergo a robotic assisted laparoscopic inguinal hernia repair. This will be done using the DaVinci Robotic Platform by Intuitive Surgical. This an accepted safe method of repairing inguinal hernia. This platform uses special robotic ports produced and supplied by Intuitive Surgical required to dock the machine to the patient. Monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
2413950|NCT03477201|Active Comparator|Standard Laparoscopic inguinal hernia repair|Intervention: 30 patients will undergo a laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia. This platform uses standard laparoscopic ports. In our institution we use plastic ports made by Covidien, Boulder, CO. The operation will require two 5mm VersaPort (Covidien) and a Hassan Port. As in the robotic arm, monopolar energy will be provided by a ForceTriad system (Covidien, Boulder, CO), standard an common system used in most ORs. This will be used for dissection. The investigators will obtain small biopsies from port site to assess stray energy transfer injury, a model described by earlier studies.
2413951|NCT03477188|Experimental|Somatosensorial and Vestibular Exercises Group|This group of patients received patients with acute stroke. It will be applied somatosensorial and vestibular rehabilitation additional conventional therapy
2413952|NCT03477188|Active Comparator|Conventional Group|This Group patients received patient with acute stroke. It will be applied classical physiotherapy and conventional exercises.
2413953|NCT03477175|Experimental|Cohort A : Lenvatinib|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
2413954|NCT03477175|Experimental|Cohort B: Lenvatinib plus Comparator drug|The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
2413955|NCT03477175|Experimental|Cohort C: Comparator drug|"The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo.~For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo."
2413956|NCT03477162|Experimental|Metformin|Patients enrolled will be treated with metformin (administered orally; 750 mg QD for 4 days, then 750 mg BID for 3-6 days; or clinically indicated metformin) for a total of 7-10 days prior to surgery, up until the night before surgery.
2413957|NCT03477149|Experimental|Embolization with Easyx|Patients requiring embolization of varicocele, portal vein before ablation, type 2 endoleak, angiomyolipoma or active bleeding will be treated with the liquid embolic agent Easyx during index procedure.
2413958|NCT03477136||First group: semen parameter showing normospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2413959|NCT03477136||second group: semen parameter asthenozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2413960|NCT03477136||Third group: semen parameter oligozoospermic|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2413961|NCT03477136||Forth groupsemen parameter: astheno-teratozoospermic,|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2413962|NCT03477136||Fifth group semen parameter: oligo asthenoteratozoospermia|"group will include 30 male~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)~blood and semen sample will be collected from all males to evaluate vitamin D level by ELISA ."
2413963|NCT03477123|Experimental|Intervention|Walking therapy with Exo-H2 exoskeleton
2413964|NCT03477123|No Intervention|Control|Group receiving conventional walking therapy without robotic exoskeleton
2413965|NCT03477110|Experimental|Treatment (temozolomide, radiation, NovoTTF-200A device)|Participants receive temozolomide PO QD starting day 1 to the end of radiation therapy and undergo 30 fractions of radiation therapy over 15-20 minutes each, 5 days a week (Monday-Friday) for 6 weeks. Beginning day 1 of radiation therapy, participants undergo tumor treatment fields therapy using NovoTTF-200A device over 18 hours or more daily in the absence of disease progression or unacceptable toxicity. Beginning 28 days after the last dose of radiation therapy, participants receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2413966|NCT03477097|No Intervention|Control group w/o social network intervention|Subjects did not receive any intervention of nutrition, physical activity and social network.
2413967|NCT03477097|Experimental|Control group w/ social network intervention|Subjects only received the intervention of social network.
2413968|NCT03477097|Experimental|Nutrition group 1 w/o social network intervention|Subjects only received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder).
2413969|NCT03477097|Experimental|Nutrition group 1 w/ social network intervention|Subjects received the nutrition I intervention (e.g., food plate and multiple vitamin/ minerals powder) and social network intervention as well.
2413970|NCT03477097|Experimental|Nutrition group 2 w/o social network intervention|Subjects only received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil).
2414359|NCT03474445|Active Comparator|Control group|Volar Plate Osteosynthesis Aptus 2.5
2413971|NCT03477097|Experimental|Nutrition group 2 w/ social network intervention|Subjects received the nutrition II intervention (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and social network intervention as well.
2413972|NCT03477097|Experimental|Physical activity group w/o social network intervention|Subjects only received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training.
2413973|NCT03477097|Experimental|Physical activity group w/ social network intervention|Subjects received the personalized homed-based exercise prescription, which consisted of a combination of strength, flexibility, balance and endurance training, and social network intervention as well.
2413974|NCT03477097|Experimental|Nutrition 1 + physical activity group w/o social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder) and exercise (e.g., personalized homed-based exercise plan) intervention.
2413975|NCT03477097|Experimental|Nutrition 1 + physical activity group w/ social network|Subjects received the nutrition I (e.g., food plate and multiple vitamin/ minerals powder), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
2413976|NCT03477097|Experimental|Nutrition 2 + physical activity group w/o social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil) and exercise (e.g., personalized homed-based exercise plan) intervention.
2413977|NCT03477097|Experimental|Nutrition 2 + physical activity group w/ social network|Subjects only received the nutrition II (e.g., food plate, multiple vitamin/ minerals powder, fruit/vegetable concentrate capsule, and fish oil), exercise (e.g., personalized homed-based exercise plan), and social network intervention.
2413978|NCT03477084||Long Term Care Facilities|Spread of ESBL-producing E. coli and K. pneumoniae among the residents of Long Term Care Facilities.
2413979|NCT03477084||Households|Household transmission of ESBL-producing bacteria after hospital discharge of a patient carrying ESBL-producing E. coli or K. pneumoniae.
2413980|NCT03477058|Experimental|WO 3308 cosmetic product for topical use|WO 3308 is used to treat acute or chronic pruritus
2413981|NCT03477045|Active Comparator|Fish oil|Fish oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
2413982|NCT03477045|Experimental|Camelina seed oil|Camelina seed oil providing 450 mg of eicosapentaenoic acid plus docosahexaenoic acid per dose
2413983|NCT03477019|Experimental|Breast cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for breast cancer.
2413984|NCT03477019|Other|Breast cancer control lesion|This arm will only receive treatment with conventional chemotherapy for breastcancer and microbubbles intravenously.
2413985|NCT03477019|Experimental|Colorectal cancer target lesion|This arm will receive experimental treatment of focused ultrasound. In addition this arm will receive treatment with microbubbles intravenously and conventional chemotherapy for colorectal cancer.
2413986|NCT03477019|Other|Colorectal cancer control lesion|This arm will only receive treatment with conventional chemotherapy for colorectal cancer and microbubbles intravenously.
3185819|NCT00738933|Active Comparator|E|A group of patients consuming daily 2 grams plant sterols 4-8 weeks before the operation.
3185820|NCT00738933|Placebo Comparator|C|
2413989|NCT03476993|Experimental|BCD-085|All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day
3185821|NCT00738946|Experimental|2|Amodiaquine+pyrimethamine versus placebo
3185822|NCT00738959|Experimental|1|
2413992|NCT03476967||Pretreatment x Posttreatment|The group was evaluated through non-invasive complementary examinations before laser therapy and at the 1-year follow-up visit to analyze possible optical disc alterations that may occur after retinal panretinal photocoagulation in patients with proliferative diabetic retinopathy.
2413993|NCT03476941|Experimental|Antibiotic Irrigation|The drain will be irrigated twice/day with the above antibiotic solution for 7 days maximum
2413994|NCT03476941|Placebo Comparator|Normal Saline Irrigation|The drain will be irrigated twice/day with normal saline
2413995|NCT03476928|Experimental|Treatment Group A1|4 treatment periods of 12 weeks, each separated by 1 bleeding episode
2413996|NCT03476928|Experimental|Treatment Group A2|2 treatment periods of 24 weeks, separated by 2 bleeding episodes
2413997|NCT03476915||screened infants|Asymptomatic infants under age of 6 months, presenting to the pediatric orthopaedic outpatient clinic at Assiut university hospital for other problems will be subjected to ultrasound examination of the hip joint.
2413998|NCT03476902|Experimental|Integrated Mobile Treatment|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
2413999|NCT03476889|Experimental|Intervention|Cows milk based infant formula containing fermented infant formula and prebiotic oligosaccharides
2414000|NCT03476889|Active Comparator|Control|Cows milk based infant formula containing prebiotic oligosaccharides (commercially available Aptamil ProNutra)
2414001|NCT03476889|No Intervention|Breastfed reference|Exclusively breastfed from birth to study completion
2414002|NCT03476876|Experimental|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
2414003|NCT03476876|Active Comparator|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
2414004|NCT03476863|Experimental|Alveolar Recruitment Maneuver|
2414005|NCT03476863|Active Comparator|Conventional mechanical ventilation|
2414074|NCT03476291||Abnormal|abnormal macular structure of horizontal OCT B-scans, including many sub-categories of pathological features, like epiretinal membrane, pigment epithelium detachment, ect.
3185823|NCT00738985|Placebo Comparator|ezetimibe/simvastatin 10/20 mg + placebo|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe (+) simvastatin 10/20 mg + placebo for 12 weeks. Safety and efficacy parameters are measured at baseline and 12 weeks later
3185824|NCT00738985|Active Comparator|ezetimibe/simvastatin 10/20 mg + MK0524A|The intervention consisted of an isocaloric diet, an exercise program (30 min/day of aerobic activity) and ezetimibe/simvastatin 10/20 mg + MK0524A 1 gr for 6 weeks, if efficacy achieved will continue with ezetimibe (+) simvastatin 10/20 mg + MK0524A 1 gr + placebo; if not achieved, will receive ezetimibe (+) simvastatin 10/20 mg + MK0524A 2 gr for 6 weeks.
3185825|NCT00738998|Experimental|Questionnaire and Telephone Assessments|Breast cancer patients assigned to one or two groups: Group 1) enrolled at beginning of anastrozole treatment; or Group 2) if beginning third year of anastrozole treatment.
2414008|NCT03476837|Experimental|Behavioral Treatment|Following baseline, the CHWs will deliver three doses of the intervention to the treatment (intervention) group over a 6-month period with follow-up at 12 months for all WCGs. At 1, 3, and 6 months, WCGs will receive motivational interviewing, educational materials and biofeedback based on the child's saliva sample and WCG's carbon monoxide.
2414009|NCT03476837|Active Comparator|Control|WCGs will receive educational materials in the mail at 1, 3, and 6 months.
2414010|NCT03476811|No Intervention|Control Group|Normal treatment paradigm (no anesthetic pump) with pain medications, only.
2414011|NCT03476811|Active Comparator|Marciano Group|Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.
2414012|NCT03476811|Placebo Comparator|Placebo Group|OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.
3185826|NCT00739011|Experimental|1|
2414014|NCT03476785|Experimental|High Intensity Exercise|Subjects randomized to receive high intensity aerobic exercise will undergo exercise training for 1 year. A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
2414015|NCT03476785|Placebo Comparator|Yoga|Subjects randomized to yoga will receive instructions on strength and flexibility exercises.
2414016|NCT03476772|No Intervention|A|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % via caudal route to achieve post operative analgesia
2414017|NCT03476772|Active Comparator|B|children undergoing hypospadius repair given 1 ml/kg of bupivicaine 0.25 % plus 0.1 mg nalbuphine via caudal route to achieve post operative analgesia
3185827|NCT00739037|Placebo Comparator|A|
3185828|NCT00739037|Experimental|B|
2414020|NCT03476746|Experimental|LEO 90100 foam|"LEO 90100 foam (containing calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g).~Pilot part: 6 single applications of LEO 90100 foam on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
2414021|NCT03476746|Active Comparator|Dovobet® ointment|"Pilot part: 6 single applications of Dovobet® ointment on Day 1 (for 12 sites in total).~Pivotal part: To be decided based on the result of the pilot part"
2414022|NCT03476733||patient with drug related problem|patient with drug related problem
2414023|NCT03476733||patient without drug related problem|patient without drug related problem
2414024|NCT03476707||Anemic|People with a preoperative hematocrit less than 0.39
2414025|NCT03476707||Non-anemic|People with a preoperative hematocrit greater than or equal to 0.39
2414026|NCT03476694|Experimental|20ml of 0.75% Ropivacine|
2414027|NCT03476694|Experimental|25ml of 0.75% Ropivacine|
3185829|NCT00739076|Experimental|1|Virtual Reality Hypnosis
2414029|NCT03476668|Active Comparator|RPD PD patients|Right-side affected PD patients. Intervention: MIRT
2414030|NCT03476668|Active Comparator|LPD PD patients|Left-side affected (LPD) PD patients. Intervention: MIRT
2414031|NCT03476655||Participants with Chronic Lymphocytic Leukemia (CLL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of CLL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
2414032|NCT03476655||Participants with Mantle Cell Lymphoma (MCL)|This study will collect retrospective data on effectiveness and outcome parameters for participants of MCL being managed with ibrutinib in the clinical practice. The primary data source for this observational study will be the medical records of each enrolled participant.
2414033|NCT03476642|Active Comparator|Ropivacaine with Epinephrine|Group RE will have 20mL of 0.5% Ropivacaine with epinephrine injected at the left or right T5 transverse process.
2414034|NCT03476642|Active Comparator|Ropivacaine without Epinephrine|Group R will have 20mL of 0.5% Ropivacaine without epinephrine injected at the left or right T5 transverse process.
2414035|NCT03476629|Experimental|Combined Training|Combined Training with 2 types of physical activity
2414036|NCT03476629|Experimental|Standard Training|Physical activity with aerobic exercise
2414037|NCT03476629|Experimental|Respiratory Muscle Training|Respiratory muscle performance
2414038|NCT03476616|Active Comparator|Eplerenone (-based therapy) arm|"Obese pts with hypertension, starting treatment with eplerenone 25mg twice daily (BD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with eplerenone, or dual therapy with eplerenone and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
2414039|NCT03476616|Active Comparator|Valsartan (-based therapy) arm|"Obese pts with hypertension, starting treatment with valsartan 160mg once daily (OD). ABPM wil be scheduled at wks 8, 16 and 24.~At wk 8 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan. If not controlled (mean ABPM > 130/80mm Hg) at wk8, amlodipine 5mg OD will be added.~At wk 16 if mean ABPM < 130/80mm Hg will continue to monotherapy with valsartan, or dual therapy with valsartan and amlodipine. If not controlled (mean ABPM > 130/80mm Hg) at wk16, indapamide 1,5mg OD will be added. All patients will be followed up for 24 weeks."
2414040|NCT03476590|No Intervention|standard care|In standard care group the patients will be recommended to visit physician/cardiologists in standard healthcare system. Two non-interventional visits will be performed: recruitment visit (day of enrolment) and summary visit (12th month after the enrolment)
3185830|NCT00739076|Experimental|2|Virtual Reality Distraction
3185831|NCT00739076|Experimental|3|Standard treatment.
2414041|NCT03476590|Experimental|intervention group|"In intervention group patients will be referred to ambulatory care point (ACP) and the physicians will perform remote teleconsultations. The visits will be realized by nurses supported with vital sign assessment based on bioimpedance diagnostic methods (impedance cardiography, bioimpedance scale). The ambulatory visits will be performed according to the schedule: (1') recruitment visit (1st day of enrolment) performed by physician -> 7 ambulatory visits: (1) 1st day of enrolment (performed by nurse and physician), (2) 7th-10th day (performed by nurse and physician), (3) 1st month, (4) 3th month, (5) 6th month, (6) 9th month, (7) 12th month after the enrolment (visits no 3-7 performed by nurse with tele-supervision by physician) and -> (7') summary visit (12th month after the enrolment) performed by physician.~The plan of visits may be modified if required by the clinical status change, i.e. deterioration of clinical parameters and interim hospitalizations for worsening heart failure."
2414042|NCT03476564|Experimental|intervention group|intervention group will receive pentoxifylline (Trental S.R.) 400 mg/BD plus vit E (PHARCO) 400 mg/BD 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled.
2414043|NCT03476564|No Intervention|comparison group|. The comparison group will not receive the above drugs. The main outcome measure will be clinical pregnancy rate.
2414044|NCT03476499|Experimental|Planned skin flap procedure|"Inclusion Criteria: i. Planned skin flap procedure, ii. SpO2 above 96% and iii: Written informed consent.~Exclusion criteria: Use of epinephrine, patent blue V or methelyne blue during procedure.~The near infrared imaging NIR device is experimental. Experimental means that the NIR imaging is not used routinely in patients' care.~The research will require no extra study visits. Images will be taken at 3 - 4 time points and a separate photo consent will be obtained prior to imaging.~One set of pre-procedure images, NIR images will be taken prior to the start of the breast surgery.~One set of intra-operative Images that will be taken intra-operatively following the mastectomy.~One to two follow-up sets of NIR images will be taken at the standard post-op follow-up visits at 1 to 2 weeks post-op for up to 30 days post-op. Follow-up visits will be scheduled as per the standard of care."
2414045|NCT03476486|Experimental|Treatment|The hand that was subject to thread carpal tunnel release surgery
2414046|NCT03476486|No Intervention|Control|The hand that was not treated
2414047|NCT03476460|Experimental|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, patients will take 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
2414048|NCT03476460|Active Comparator|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
2414049|NCT03476447|Active Comparator|High dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a high dose per daily oral feeding
2414050|NCT03476447|Active Comparator|Medium dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a medium dose per daily oral feeding
2414051|NCT03476447|Active Comparator|Low dose B. infantis EVC001|10 participants will receive powdered B. infantis EVC001 at a low dose per daily oral feeding
2414052|NCT03476447|Placebo Comparator|Lactose Placebo|10 participants will receive powdered lactose per daily oral feeding
2414053|NCT03476434|No Intervention|group A (HR-WLE)|Two tandem colonoscopies: first inspection was on high-resolution white-light endoscopy from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection also on HR-WLE.
2414054|NCT03476434|Experimental|group B (HR_CE)|two tandem colonoscopies: first inspection was on HR-WLE from the cecum/ileo-colonic anastomosis to the rectum, followed by a second inspection with panchromoendoscopy on indigo carmine.
2414055|NCT03476421||R0 hepatectomy|Those HCC patients operated with standard R0 hepatectomy
2414056|NCT03476421||R1par hepatectomy|Those HCC patients operated with R1par hepatectomy
2414057|NCT03476421||R1vasc hepatectomy|Those HCC patients operated with R1vasc hepatectomy
2414058|NCT03476421||R1par+R1vasc hepatectomy|Those HCC patients operated with both R1par and R1vasc hepatectomy
2414059|NCT03476408|Experimental|Single Group Correlation|Correlation between these topics.
2414060|NCT03476382|Experimental|Experimental Group|Participants use active Ultrasound Bone Growth Stimulator device according to Investigational Protocol.
2414063|NCT03476356|Experimental|Group L|This group will receive oral clomiphene citrate (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle plus oral carnitine supplementation (Carnivita Forte, Eva Pharma, Egypt) (1g tablet, three times per day) from the third day of the cycle until the day of the pregnancy test.
2414064|NCT03476356|Active Comparator|Group C|This group will receive oral clomiphene citrate only (Clomid, Global Napi Pharmaceuticals (GNP), Egypt) (50 mg tablet, two times per day) from the third day of the cycle until the seventh day of the cycle.
2414065|NCT03476343|Experimental|MRI for Neonates|MRI
3185832|NCT00739115|Experimental|1|Heliox gas added to nasal CPAP for the first 72 hours of life
2414067|NCT03476317|Experimental|Group 1-Fluconazole|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus fluconazole orally once daily (Day 1-14).
2414068|NCT03476317|Placebo Comparator|Group 1-Placebo|Vancomycin oral suspension four times daily (Day 1-14), plus neomycin orally three times daily (Days 1-3), plus ciprofloxacin orally twice daily (Day 4-14), plus Polyethylene Glycol 3350 (Miralax) dissolved in Gatorade on day 2, plus placebo.
2414069|NCT03476317|No Intervention|Group 2|Collect stool samples for calprotectin in patients undergoing colonoscopy for clinical care to evaluate effect of bowel lavage alone on calprotectin.
2414070|NCT03476304|Experimental|Semi-direct composite endocrown restorations|
2414076|NCT03476265|Experimental|Ineffective Esophageal Motility and GERD|Patients with gastroesophageal reflux disease (GERD) refractory to proton pump inhibitors (PPI) and ineffective esophageal motility (IEM) according to the Chicago classification v3.0.
2414077|NCT03476252|Experimental|patients|ST elevation myocardial infarction
3185833|NCT00739115|No Intervention|2|Conventional nasal CPAP for the first 72 hours of life
2414079|NCT03476226|Experimental|Group 1|"The research team will provide the intervention to subjects. Intervention: The nursing-driven Cognitive Dysfunction Coping Strategy Teaching Sheet and provide education as to its use.~QOL survey administered"
2414080|NCT03476226|No Intervention|Group 2|Provide current standard of education for cognitive dysfunction. QOL survey administered
2414081|NCT03476213|Experimental|Group TCI|induction and anesthesia will be held by using target-controll infusion
2414082|NCT03476213|Active Comparator|Group TIVA|induction and anesthesia will be held by manual dosing of propofol and sufentanil
2414083|NCT03476200|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy consisting of fourteen weekly group sessions, one hour and a half each, directed by two clinical psychologist.
2414084|NCT03476200|No Intervention|Control Group|Control Group with no intervention.
2414085|NCT03476187|Experimental|µCor wearers|Wear the µCor device
2414086|NCT03476174|Experimental|Pembrolizumab and HD Interleukin 2|Pembrolizumab 200 mg IV over 30 minutes; Day 1 of each cycle 3 weeks (21 days) for 2 cycles. IL-2 600,000 IU/kg2 IV over 15 minutes every 8 hours for up to 14 doses over 5 days; Days 1-5 = Cycle 1; 9 days of rest in between; Days 15-19 = Cycle 2
2414087|NCT03476161|Other|Group 1|"upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
2414088|NCT03476161|Other|Group 2|"upper right and lower left 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive~upper left and lower right 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive"
2414089|NCT03476148|Experimental|Interactive Device Rehabilitation|
2414090|NCT03476148|Active Comparator|Inpatient Rehabilitation|
3185834|NCT00739128|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intramuscular route
3185835|NCT00739128|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive repeat hep B vaccine via intradermal route
2414093|NCT03476122||Disease Group|The disease group is diagnosed with colorectal cancer 0-4 and has not been treated.
2414094|NCT03476122||Control Group|The control group will receive Colonoscopy
2414095|NCT03476109|Active Comparator|Omalizumab|"Patients randomized to omalizumab and then prolonged or not (based on their response at 4 months) until the end of the study (22mo).~Non responders will be switched to mepolizumab arm."
2414096|NCT03476109|Active Comparator|Mepolizumab|"Patients randomized to mepolizumab and then prolonged or not (based on their response at 6 months) until the end of the study (22mo).~Non responders will be switched to omalizumab arm."
2414097|NCT03476096||Control|healthy pregnant women
2414098|NCT03476096||Pre-eclampsia|high-risk pregnant women
2414099|NCT03476083|Experimental|Group A|This is the experimental group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 14-16 and continue until delivery. The mothers will be followed together with their infants until postpartum week 28. Infants will receive hepatitis B vaccine at birth and additional hepatitis B (HBV) vaccine at the age of week 4 and week 24. HBIg will be omitted for the infants in this group.
2414100|NCT03476083|Active Comparator|Group B|This is the comparative group. Participating mothers will receive Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily, starting at gestational weeks 28 and continue until delivery. Patients in group B will have similar follow-up schedules as those in the experimental group. Infants will receive hepatitis B vaccine plus HBIg at birth and additional hepatitis B vaccine at the age of week 4 and week 24.
2414101|NCT03476070||AYA cancer patients|Patients (aged between 15-39) diagnosed with breast cancer, lymphoma or germ cell tumor
2414102|NCT03476070||Healthy controls|Healthy controls
2414103|NCT03476057||Advanced gastrointestinal tumor|200 patients with pathologically confirmed Advanced gastrointestinal tumor who never treated with chemotherapy at Fujian Cancer Hospital
2414104|NCT03476044|Active Comparator|Group Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
2414105|NCT03476044|Active Comparator|Group Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
2414106|NCT03476031||study group|patients with hepatitis c nephropathy detected by lab and renal biopsy
2414107|NCT03476018|Placebo Comparator|Placebo|
2414108|NCT03476018|Experimental|0.2 microgram Z-100|
2414109|NCT03476018|Experimental|2 microgram Z-100|
2414110|NCT03476018|Experimental|20 microgram Z-100|
2414111|NCT03476005|Active Comparator|Proficiently Trained interns -|Provided with proficiency based progression training supported by technology enhanced learning
2414112|NCT03476005|No Intervention|Historical controls|no extra training provided
3185836|NCT00739141|Experimental|1|There are three chemotherapy drugs involved. They are called fludarabine (5 doses), cyclophosphamide (1 dose), and thiotepa (2 doses). Also two days of radiation therapy. This is called Total Body Irradiation or TBI. The TBI if given for two days before, the transplant. On transplant day, the cord blood cells will be given through a catheter. The immune suppressing drugs given are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through the catheter. Later they can be given as tablets.
3185837|NCT00739154||1|glaucoma patients who also suffer from epileptic disorder and receiving chronic oral Phenytoin treatment
3185838|NCT00739154||2|glaucoma patients who also suffer from epileptic disorder receiving anti-convulsant treatment other then Phenytoin
3185839|NCT00739154||3|glaucoma patients with no epileptic disorder and not receiving anti-convulsant treatment
3185840|NCT00739167||Y90 Group|Patients receiving treatment with radioembolization.
2414116|NCT03475966|Experimental|Prehabilitation|Exercise, nutrition and relaxation techniques all beginning four weeks prior to surgery date.
2414117|NCT03475966|Active Comparator|Rehabilitation|Exercise, nutrition and relaxation techniques all beginning immediately after surgery.
2414129|NCT03475914||Psoriasis vulgaris|Pathological conditions stable for at least 1 month before collection. One punch biopsy from each patient, was taken from a big reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
2414130|NCT03475914||Psoriasis guttate|One punch biopsy from each patient, was taken from a small reddish and scaly plaque and another punch biopsy from the perilesional healthy skin.
2414131|NCT03475914||Healthy skin of psoriasis vulgaris|Healthy skin area of 2mm2 belonging to the left gluteus from patients affected by psoriasis vulgaris
2414132|NCT03475914||Healthy skin of psoriasis guttate|Healthy skin area of 2mm2 belonging to the left gluteus rom patients affected by psoriasis guttate
2414133|NCT03475901|Experimental|Virtualy Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
2414134|NCT03475888|Active Comparator|Group A|Patients who have undergone a successful percutaneous CTO recanalization
2414135|NCT03475888|Active Comparator|Group B|Patients who have undergone a failed percutaneous CTO recanalization
2414136|NCT03475888|Active Comparator|Group C|Patients with an untreated CTO
3185841|NCT00739167||TACE Group|Patients receiving treatment with transcatheter arterial embolization
3185842|NCT00739167||RFA Group|Patients receiving treatment with radiofrequency ablation.
2414139|NCT03475862|Experimental|PTI-821 Manipulated|oxycodone 40 mg capsule
2414140|NCT03475862|Active Comparator|Oxycodone|Oxycodone 40 mg IR tablet crushed
2414141|NCT03475862|Active Comparator|OxyContin|Oxycodone ER 40 mg tablet crushed
2414142|NCT03475862|Placebo Comparator|Placebo|Matching placebos for experimental and active comparator arms
2414143|NCT03475862|Experimental|PTI-821 Non-manipulated|Oxycodone 40 mg non-manipulated
2414144|NCT03475849||RYGB subjects|Morbidly obese patients who has undergone an uncomplicated gastric bypass surgery more than 12 months before study start.
2414145|NCT03475849||Control subjects|Age, sex and BMI-matched healthy controls
2414146|NCT03475849||SG subjects|Morbidly obese patients who has undergone an uncomplicated sleeve gastrectomy surgery more than 12 months before study start.
2414147|NCT03475836|Placebo Comparator|Placebo|Vegetable oil
2414148|NCT03475836|Active Comparator|High-dose mint essential oil|100 μL Mentha piperita essential oil (in vegetable oil)
2414149|NCT03475836|Active Comparator|Low-dose mint essential oil|50 μL Mentha piperita essential oil (in vegetable oil)
2414150|NCT03475823|Placebo Comparator|Placebo control|Inert comparator indistinguishable from active interventions
2414151|NCT03475823|Active Comparator|Active control|240 mg ginkgo biloba
2414152|NCT03475823|Experimental|Low dose sideritis scardica|475 mg sideritis scardica
2414153|NCT03475823|Experimental|High dose sideritis scardica|950 mg sideritis scardica
2414154|NCT03475810|Experimental|VR GROUP|Patients watches 3D documentary videos on virtual reality glasses
3185843|NCT00739180|Other|Control|Standard care control
3185844|NCT00739180|Active Comparator|Aerobic Exercise|
3185845|NCT00739180|Active Comparator|Resistance Exercise|
3185846|NCT00739193|Placebo Comparator|Placebo|Placebo Control
3185847|NCT00739193|Experimental|PM101|PM101
3185848|NCT00739193|Active Comparator|Amiodarone IV|Amiodarone IV
2414156|NCT03475797|Experimental|Occipital Nerve Stimulation (ONS)|Occipital nerve stimulation with percutaneous or surgical lead plus optimal medical management
2414157|NCT03475797|Active Comparator|Optimal Medical Management (OMM)|Optimal Medical Management according to what is done in routine clinical practice
2414158|NCT03475784|Experimental|Restricted fluid therapy group|Restrictive fluid therapy: this group will not receive fluid pre-load, and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2mL/Kg/hour.
2414159|NCT03475784|Active Comparator|Liberal fluid therapy group|Liberal fluid therapy: this group will receive fluid pre-load (5 mL/Kg), and will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
2414160|NCT03475758|No Intervention|chemotherapy without goserelin|these patients will receive their chemotherapy without addition of Goserelin
2414161|NCT03475758|Experimental|chemotherapy with goserelin|these patients will receive their chemotherapy with addition of Goserelin
2414162|NCT03475745||Aphasia|Post stroke aphasia patients without any additional interventions for research purposes.
2414163|NCT03475745||Control|Healthy controls
2414164|NCT03475732|Experimental|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
2414165|NCT03475719|Active Comparator|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
2414166|NCT03475719|Experimental|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
2414167|NCT03475706|Experimental|Solabegron immediate release tablets low dose|
2414168|NCT03475706|Experimental|Solabegron immediate release tablets high dose|
2414169|NCT03475706|Placebo Comparator|Placebo Comparator|
2414170|NCT03475693|Experimental|Treatment arm|Patients will receive PO magnesium 400 mg, Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID and 400 mg MagOx tablets BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
2414171|NCT03475693|Placebo Comparator|Placebo arm|Patients will receive PO Zofran 4 mgODT, and Tylenol 500 mg in the emergency department. They will then continue with 500 mg Tylenol BID for the next 5 days. Symptom severity scores will be obtained and compared throughout this time as mentioned in the study design.
2414172|NCT03475680|Experimental|"1)  MBP and oral antibiotics  group"|"Sennosides colonic preparation Oral Gentamycin Oral Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
2414173|NCT03475680|Placebo Comparator|"2)  MBP alone  group"|"Sennosides colonic preparation Oral placebo Gentamycin Oral placebo Ornidazole~Sennosides colonic preparation (X-PREP) :~1 per day, on day -2 and day -1.~Placebo for oral gentamycin:~Same presentation as oral gentamycin x4 per day on day -2 and day -1. - Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1."
2414174|NCT03475680|Experimental|"3)  Oral antibiotics alone  group"|"Oral Gentamycin Oral Ornidazole~Gentamycin :~80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials.~Ornidazole :~g per day (2 tablet per day), on day -2 and day -1; In tablets."
2414175|NCT03475680|Placebo Comparator|"4)  No preparation  group"|"Oral placebo Gentamycin Oral placebo Ornidazole~- Placebo for oral gentamycin : Same presentation as oral gentamycin x4 per day on day -2 and day -1~- Placebo for oral ornidazole : Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
2414176|NCT03475654|Experimental|technology-assisted rehabilitation|The experimental group will receive treatment as usual, in addition to training with the Jintronix platform. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
2414177|NCT03475654|Active Comparator|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge. Participants will undergo their prescribed therapy regimen for 3 months, with outcomes follow-up to 12 months post-discharge.
2414178|NCT03475641|Active Comparator|The current standard anesthesia|Standard treatment during procedure
2414179|NCT03475641|Experimental|Femoral nerve blockade|Femoral nerve blockade added to the standard treatment.
2414180|NCT03475628|Experimental|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.
2414181|NCT03475615|Experimental|SOXP|
2414182|NCT03475615|Active Comparator|SOX|
2414183|NCT03475602||Cyclophosphamide|Drug: Cyclophosphamide，CTX Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
2414184|NCT03475602||Cyclosporin|Drug: Cyclosporin Determination of serum concentration of anti PLA2R antibody and anti TSHD7A antibody
2414185|NCT03475589|Other|single group|
2414186|NCT03475576|Other|all participants|The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian.
2414187|NCT03475563||Patients with coronary artery disease|(coronary artery disease)
2414188|NCT03475550|Active Comparator|Standard of care 1|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 1 includes more details than Standard of Care 2."
2414189|NCT03475550|Active Comparator|Standard of care 2|"Patients will receive one of 2 different descriptions of the medication's risks and benefits. Both descriptions meet ethical standards of transparency and respect for person and are commonly used but have never been compared. Standard of Care 2 includes fewer details than Standard of Care 1."
2414219|NCT03475355|Experimental|EG3|Each patient will be instructed to carefully observe the finalized movement performed by an experimenter standing in front of him (the examiner's left leg will be in front of the patient's right leg).
2414190|NCT03475537|Experimental|the treatment of transcranial direct current stimulation|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7×5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
2414191|NCT03475524|Experimental|study Metformin 1000 mg|
2414192|NCT03475524|Experimental|study Metformin 500 mg|
2414193|NCT03475524|Placebo Comparator|control group|
2414194|NCT03475485|Experimental|ID-Capsules- Active|"Randomly-assigned ingestions of ID-Capsules containing ingestible sensors (ID-Capsule- Active) while wearing the ID-Cap Reader (Wearable Sensor) under direct observation~• Subjects will ingest ID-Capsules containing the ingestible sensor which emits a signal from within the subject's stomach. This signal is detected by the wearable Reader, and the ingestion event is recorded."
2414195|NCT03475485|Placebo Comparator|ID-Capsules- Inactive|"Randomly-assigned ingestions of ID-Capsules containing no ingestible sensors while wearing the ID-Cap Reader under direct observation~• Subjects will also ingest empty placebo capsules that do not contain ingestible sensors. In the absence of an ingested sensor, no signal is received by the Reader after the capsule is ingested, and the ingestion event is not recorded."
2414196|NCT03475459|Experimental|study drug|Study drug (NPC-15 and/or Placebo ) will be orally administered once with 200 ml of water at 20:00 on the first days of Period I, Period II and Period III.
2414197|NCT03475446|Placebo Comparator|sham tES healthy elderly|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2414198|NCT03475446|Placebo Comparator|sham tES MCI|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2414199|NCT03475446|Placebo Comparator|sham tES AD|30 s of sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the left DLPFC and supraorbital region. Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for 20 minutes.
2414200|NCT03475446|Experimental|real anodal tDCS healthy elderly|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414201|NCT03475446|Experimental|real anodal tDCS MCI|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414202|NCT03475446|Experimental|real anodal tDCS AD|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414203|NCT03475446|Experimental|real tACS healthy elderly|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414204|NCT03475446|Experimental|real tACS MCI|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414205|NCT03475446|Experimental|real tACS AD|20 min of 1 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm rubber electrode over the left DLPFC and cathodal 10x10 rubber electrode over supraorbital region. Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2414206|NCT03475433||Beast cancer patients|All participants that suffer from breast cancer.
2414207|NCT03475433||Prostate cancer patients|All participants that suffer from prostate cancer.
2414208|NCT03475420||National Cancer Database|Use existing data to define surveillance strategy in use for patients in this cohort. We will use 10 randomly selected lung cancer resection patients from each accredited institution with stage I-III NSCLC (potentially curative resection) diagnosed in 2006-2007 and with 5 years of complete follow up or reported as deceased before 2012.
2414209|NCT03475407|Experimental|Treatment Group|Ozurdex intravitreal injection
2414210|NCT03475394|Active Comparator|Group 1 (Chlorhexidine gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 1% chlorhexidine gel administered in subsequent visits.
2414211|NCT03475394|Experimental|Group 2 (Morus alba gel)|Non surgical periodontal treatment at baseline and 0.1 ml of 16% Morus alba gel administered in subsequent visits.
2414212|NCT03475394|Placebo Comparator|Group 3 (Placebo)|Non surgical periodontal treatment at baseline and no gel is applied.
2414214|NCT03475368|Experimental|Vegetarian diet|People randomized to interventional groups will take a vegetarian diet (i.e. without animal products, except milk and eggs)
2414215|NCT03475368|Experimental|Low carbs|People randomized to interventional groups will take a low carbs diet (i.e. with a limited amount of carbohydrates).
2414216|NCT03475368|Active Comparator|Mediterranean diet|People randomized to interventional groups will take a mediterranean diet (i.e. with low glycemic index carbohydrates and vegetables).
2414217|NCT03475355|Experimental|EG1|Each patient will be instructed to carefully observe the finalized movement of the upper limb of an experimenter seated in front (the experimenter's left hand is right in front of the patient's right hand), without moving or imagining the movement.
2414218|NCT03475355|Experimental|EG2|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
2414220|NCT03475355|Experimental|EG4|Each patient will be instructed to look at a computer screen that is in front of him that will show a daily routine task (actions).
2414221|NCT03475355|Active Comparator|CG1|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of upper limbs and simulates that performed by the experimental groups."
2414222|NCT03475355|Active Comparator|CG2|"Participants will be shown for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. For each CGail patient condition a sequence of images will be presented for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, will be displayed together with an intrusive image (intruder) that the patient will be asked to identify so that his attention span can be controlled in real time. Participants will then be invited to perform movements of the limbs as far as possible for 2 minutes according to a standard sequence that involves articular mobilizations of lower limbs and simulates that performed by the experimental groups."
2414223|NCT03475342|Active Comparator|Tranexamic acid|One intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
2414224|NCT03475342|Placebo Comparator|Placebo|One Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
2414225|NCT03475329||adenoidectomy with bilateral partial tonsillectomy|
2414226|NCT03475329||adenoidectomy with complete unilateral tonsillectomy|
3185849|NCT00739206|Experimental|Cohort 1|Adult patients with uncomplicated malaria
3185850|NCT00739206|Experimental|Cohort 2|Pediatric patients with uncomplicated malaria
2414229|NCT03475303|Experimental|early hospital discharge|women will be discharged early from hospital 12 hours postoperatively after elective cesarean sections.
2414230|NCT03475290|Experimental|Self-Efficacy and Perceived Social Support|
2414231|NCT03475290|Experimental|Perceived Social Support and Self-Efficacy|
2414232|NCT03475290|Active Comparator|Self-Efficacy|
2414233|NCT03475290|Active Comparator|Perceived Social Support|
2414235|NCT03475264||Healthy|Healthy Participants
2414236|NCT03475264||BPD cohort|Participants born prematurely with a diagnosis of BPD
2414237|NCT03475264||Non-BPD cohort|Participants born prematurely without a diagnosis of BPD
2414238|NCT03475251|Experimental|CS1003|
2414239|NCT03475251|Experimental|CS1003 + regorafenib|
2414240|NCT03475238||Cohort for nursing care|Patients in ICU under oxygen and/or mechanical ventilation and/or vasoactive drugs and/or non-invasive ventilation
2414241|NCT03475225|Experimental|Experimental Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months
2414242|NCT03475225|Placebo Comparator|Control Arm|Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.
2414243|NCT03475212|Experimental|Virus specific T cell lines (VSTs) against three viruses|The study will evaluate whether partially-HLA matched allogeneic multivirus-specific VSTs, activated using overlapping peptide libraries spanning immunogenic antigens from CMV, adenovirus and EBV, will be safe and produce anti-viral effects in immunodeficient recipients infected with one of more of the targeted viruses that are persistent despite conventional anti-viral therapy.
2414244|NCT03475199|Experimental|FabLife group|Fablife personnalised support and telephone follow-up with a dietician.
2414245|NCT03475199|No Intervention|Control group|General dietary recommendations.
2414246|NCT03475186|Experimental|Ramipril|Ramipril will be taken once daily by mouth. It will be titrated during the first 3 weeks of chemoradiation to the highest tolerable dose (2.5-5 mg). This dose will be taken each day until 4 months post-chemoradiation treatment (22 weeks).
2414247|NCT03475173|Experimental|Laser Speckle Blood Flow Group|
2414248|NCT03475160|Active Comparator|Sildenafil Citrate|Sildenafil Citrate vaginal suppositories: 25 mg every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
2414249|NCT03475160|Placebo Comparator|Placebo|Placebo vaginal suppositories: every 6 hours. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
2414250|NCT03475147|Active Comparator|eyeFusion Control Subjects|Healthy normal controls with no known eye disorders age 18-80.
2414251|NCT03475147|Experimental|eyeFusion Patients|Scotoma subjects aged 18-80.
3185851|NCT00739206|Experimental|Cohort 3|Pediatric patients with severe malaria
2414253|NCT03475121|Experimental|Low Risk Patients|Patients with IRSS stage I, pT1, pT2 and pT3 stage will not receive adjuvant therapy
2414254|NCT03475121|Experimental|Higher Risk Patients|Patients with IRSS stage I, pT3b, pT3c, pT3d will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan
2414255|NCT03475121|Experimental|Stage II Patients|Patients with Stage II (pT4) will receive 6 cycles of adjuvant chemotherapy plus 6 doses of intrathecal topotecan and orbital radiotherapy
3185852|NCT00739219|Active Comparator|eNO group|eNO measurement is used to inform asthma management decisions
3185853|NCT00739219|No Intervention|control group|Asthma is managed according to existing standard of care
3185854|NCT00739232|Active Comparator|Active|Active
2414256|NCT03475121|Experimental|Patients with buphthalmus|Patients with buphthalmus (cT3c, cT3e) will receive 2 cycles of neo-adjuvant chemotherapy plus 6 doses of intrathecal topotecan followed by secondary enucleation and 6 cycles of adjuvant chemotherapy.
2414257|NCT03475108|Experimental|Community Health Worker Group|Patients are assigned a community health worker for one year, in addition to standard diabetes care. They do not receive a community health worker for the second year of the study.
2414258|NCT03475108|Other|Standard Diabetes Care Group|Patients receive standard diabetes care for one year. They receive a community health worker for the second year (as part of a crossover trial).
2414259|NCT03475095|Experimental|LDH patients|"ribs and bones Tuina therapy According to the diagnostic criteria ofvertebral dislocation,determine the position,degree and direction of the dislocation,assess the activity of the affected vertebrae.Treated with combining Tuina of muscle-loosing and bone-setting such as reinforcing ribs，kneading and plucking method,20 min every treatment,twice a week for a total time of 4 weeks."
2414260|NCT03475082|Placebo Comparator|Placebo TENS|30 minute TENS treatment where the stimulation ramps slowly to zero after 45 seconds. The lights/display on the unit are identical to the Active unit.
2414261|NCT03475082|Active Comparator|High Frequency TENS|30 minute TENS treatment at 100 Hertz (HZ). Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2414262|NCT03475082|Active Comparator|Alternating frequency TENS|30 minute TENS treatment with a pre programed mode alternating from 4 Hz and 100 HZ. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2414263|NCT03475082|Active Comparator|Modulated frequency TENS|30 minute TENS treatment at a pre programmed mode that ramps between 4 and 125 HZ over 12 seconds. Intensity set at a strong but comfortable setting and subject asked to increase intensity as tolerated every 5 minutes. Final stimulation intensity at end of Day 1 treatment used for the remainder of the treatment sessions for all 5 days.
2414264|NCT03475082|Active Comparator|High frequency TENS - increasing intensity|30 minute TENS treatment at 100 HZ. Intensity set at initial strong but comfortable setting on day one as above, then subjects asked for possible increases in intensity every 5 minutes on all five days.
2414265|NCT03475069|Experimental|Individual intervention|This exercise program was prepared specific to each patient in this group according to his/her physiotherapy assessment, functional performance tests and body analysis results. This exercise type focuses on patients' physical demands. Exercises were applied by a researcher physiotherapist.
2414266|NCT03475069|Experimental|Plates intervention|Plates exercises were applied as a group treatment. This exercise type contains non-impact exercises to develop strength, flexibility, balance, and inner awareness.Plates exercises were applied as a group treatment. Exercises were applied by a researcher physiotherapist.
2414267|NCT03475069|Experimental|Chalistenics intervention|These exercises included range of motion exercises of neck (flexion, extension, lateral flexion and rotation), shoulder (flexion, extension, abduction, adduction, internal and external rotation), elbow (flexion and extension), forearm (pronation and supination), wrist (flexion and extension), hip (flexion, extension, abduction and adduction, internal and external rotation), knee (flexion and extension), foot (dorsi and plantar flexion, pronation and supination) and trunk (flexion, extension, lateral flexion and rotation). Exercises were applied by a researcher physiotherapist.
3185855|NCT00739232|Placebo Comparator|Placebo|Placebo
3185856|NCT00739258||HIDU|intravenous drug user (IDU) with HIV infected
2414270|NCT03475043|Experimental|Auditory training: temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in a temporal (timing/duration) cue for 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear sentences that vary in speech rate for 6, 1-hour training sessions and will receive correct-answer feedback."
2414271|NCT03475043|Active Comparator|Auditory training: non-temporal cues|"Aim 1: Listeners will hear target acoustic stimuli that vary in either stimulus intensity or stimulus frequency during 9, 1-hour training sessions and will receive correct-answer feedback.~Aim 2: Listeners will hear speech in varying levels of noise during 6, 1-hour training sessions and will receive correct-answer feedback."
2414272|NCT03475043|No Intervention|Passive control group (Aims 1 and 2)|Listeners will be evaluated on pre-training and post-training tests, but will receive no training at all.
2414273|NCT03475030|No Intervention|Usual Care|Patients receive usual care and can continue using their existing pharmacy.
2414274|NCT03475030|Experimental|Smart Pillbox|Patients receive pre-filled medication trays from Curant Health Pharmacy or the Brigham and Women's Hospital Outpatient Pharmacy. The smart pillbox in which pre-filled medication trays are housed provide automated medication reminders.
2414275|NCT03475017|Active Comparator|Supplement A|Administration of 3 capsules with 500mg of curcumin and piperine per day, for 12 weeks
2414276|NCT03475017|Placebo Comparator|Supplement B|Administration of 3 capsules with 500mg of placebo (maize starch) per day, for 12 weeks
2414277|NCT03475004|Experimental|Combination Therapy|"Cohort A: Patients will start with 7-day run-in of binimetinib on day -7 of cycle 1 only. Pembrolizumab and bevacizumab will then be added to binimetinib on cycle 1 day +1. Cycle 1 will end on day 21. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles.~Cohort B: Patients will be treated with pembrolizumab, bevacizumab, and binimetinib together on day 1 of all cycles including cycle 1. Patients will start treatment with pembrolizumab, binimetinib, and bevacizumab on day 1 of all subsequent cycles."
2414278|NCT03474991|Active Comparator|Celestamine® N 0.5|oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
2414279|NCT03474991|Placebo Comparator|Placebo|oral placebo matched to the product described above
2414280|NCT03474978|Experimental|Upper Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in upper extremity
2414281|NCT03474978|Experimental|Lower Extremity Insertion|Peripherally Inserted Central Venous Cather (PICC) inserted in lower extremity
3185857|NCT00739258||IDU|intravenous drug user (IDU) without HIV
3185858|NCT00739258||MH|persons receiving methadone maintenance treatment
3185859|NCT00739271|Active Comparator|Study arm|Early enteral feed 48 hours after abdominal surgery
2414283|NCT03474952|Experimental|Remote ischemic preconditioning (RIPC)|Intervention is remote ischemic preconditioning (RIPC) consists of 4 cycles of 5-min ischemia (using pneumatic cuff pressure of 200 mmHg) and subsequent 5-min reperfusion applied to upper arm.
2414284|NCT03474952|Sham Comparator|Control (Sham-RIPC)|Intervention is Sham-RIPC (ischemia pressure < 10 mmHg) applied to upper arm.
2414285|NCT03474939|Active Comparator|MIDAZOLAM|Patients receive midazolam 7,5mg night before and 60 minutes prior to surgery as part of preanesthetic medication
2414286|NCT03474939|Placebo Comparator|PLACEBO|Patients receive 1000mg Glucose tablets night before and 60 minutes prior to surgery during premedication
2414287|NCT03474926|Experimental|Routine lymph node dissection (LND) during nephroureterectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
2414288|NCT03474926|Active Comparator|LND for lymph nodes enlargement found before or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery.
2414289|NCT03474913||Standard MRI first|Patients will have a standard of care MRI, then consent to study participation and have an upright MRI.
2414290|NCT03474913||MRIs in random order|Patients will consent to participate in the study, then do two MRIs in random order.
2414291|NCT03474900|Experimental|PLGA implant, Bioretec ltd. Finland|Treatment with biodegradable elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
2414292|NCT03474900|Active Comparator|Titanium elastic stable nail|Treatment with titanium elastic stable intramedullary nail in unstable forearm shaft fracture in paediatric population
2414293|NCT03474887||DIGI-Throat|Patients choosing to seek primary care through an online consultation with chief complaint sore throat.
2414294|NCT03474887||DIGI-Resp|Patients choosing to seek primary care through an online consultation with chief complaint cough/common cold/influenza.
2414295|NCT03474887||DIGI-Dysuria|Patients choosing to seek primary care through an online consultation with chief complaint dysuria.
2414296|NCT03474887||PHYSI-Throat+CONTROL-Throat|"Patients choosing to seek primary care through physical consultation with chief complaint sore throat.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of sore throat."
2414297|NCT03474887||PHYSI-Resp+CONTROL-Resp|"Patients choosing to seek primary care through physical consultation with chief complaint cough/common cold/influenza.~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of cough/common cold/influenza."
2414298|NCT03474887||PHYSI-Dysuria+CONTROL-Dysuria|"Patients choosing to seek primary care through physical consultation with chief complaint dysuria~+ Patients seeking primary care prior to implementation of online consultations, with a chief complaint of dysuria."
2414300|NCT03474861|Experimental|Combination therapy|The subjects will be given combination therapy which consists of an anticancer medication (A01) and immune cells (IC01).
2414301|NCT03474848|Experimental|HABIT|Protocol of 90-hour of Hand-Arm Bimanual Intensive Training - 6 hours/day; 5 days/week, for 3 weeks
2414302|NCT03474848|Active Comparator|Conventional Occupational Therapy (OT)|Provision of 2 sessions/week (45 minutes), for 3 weeks
2414303|NCT03474835|Other|ISCHEMIC HEART DISEASE and PROSTATE ADENOCARCINOMA|
2414304|NCT03474835|No Intervention|ISCHEMIC HEART DISEASE and PROSTATE hyperplasia|
2414305|NCT03474822|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 30 patients in each type cancer and each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites. The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
2414306|NCT03474796|Experimental|Novice|
2414307|NCT03474796|Experimental|Expert|
2414308|NCT03474783|Experimental|multidisciplinary intervention|
2414309|NCT03474770|Experimental|BIS-001ER|Dose administration for each participant will begin at 0.25mg b.i.d. escalating sequentially every 4 days to a maximum tolerated dose or target dose of 1.75mg b.i.d. Upon reaching the target dose or maximum tolerated dose, participants will maintain that dose for the balance of the 1 month out-patient titration period, after which they will begin a 96-hour in-patient video EEG monitoring treatment period.
2414310|NCT03474757||SPAF patients in Colombia_Rivaroxaban|First time users of rivaroxaban in the Audifarma database
2414311|NCT03474757||SPAF patients in Colombia_Dabigatran|First time users of dabigatran in the Audifarma database
2414312|NCT03474757||SPAF patients in Colombia_Apixaban|First time users of apixaban in the Audifarma database
2414313|NCT03474744|Experimental|Experimental Arm|Copanlisib 60 mg i.v. fixed dose days 1,8,15 Rituximab 375 mg/m2 day 1 i.v.
3145391|NCT00070187|Experimental|Hyperfractionated Involved-Field Radiotion-no immunotherapy|"Completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.~HIGH-DOSE PREPARATIVE REGIMEN: Beginning within 7 days after radiotherapy, carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.~ASCT: Autologous bone marrow or peripheral blood stem cell transplantation on day 0. Filgrastim (oral or IV) beginning on day 1 and continuing until blood counts recover."
3145392|NCT00070200|Experimental|All patients|Induction Cycles 1 and 2 (CT) (21 days each), Cyclophosphamide (Days 1 thru 5) weight based dosage (> 12 kg 400 mg/m2/day, < 12 kg 13.3 mg/kg/day, < 2 years old N/A. Topotecan (Days 1 thru 5) weight based dosage (> 12 kg 1.2 mg/m2/day, < 12 kg 0.04 mg/kg/day, < 2 years old 0.04 mg/kg/day). Filgrastim (Days 6 →) weight based dosage (> 12 kg 5 micrograms/kg, < 12 kg 5 micrograms /kg, < 2 years old 5 micrograms /kg.
3145393|NCT00070213|Active Comparator|MdG (modified de Gramont)|2 weekly 5FU/FA schedule
2414319|NCT03474705|Experimental|Eccentric Training Group|Eccentric training of the upper trapezius muscles. The intervention will consist of ten sessions of 25-30 minutes (twice a week over 5 consecutive weeks) of eccentric exercises of the shoulder muscles, as neural activation increases after 4 weeks of eccentric training. The total duration of the intervention will be 2 hours and a half.
3145394|NCT00070213|Experimental|OxMdG (80%) for 12 weeks|MdG + oxaliplatin
2414321|NCT03474666|Active Comparator|Strict Glycemic Control Group|Intravenous insulin as described by Keegan and Cols. 2010.
2414322|NCT03474666|Active Comparator|Standard Glycemic Control Group|Subcutaneous insulin as instititional protocol.
2414323|NCT03474653||Latitude 1 (Bulking)|Women with first line stress incontinence who choose to have Bulkamid as a treatment
2414324|NCT03474653||Latitude 2 (Choice)|Women with first line stress incontinence who choose to have any treatment including Bulking.
2414329|NCT03474627|Active Comparator|Non-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
2414330|NCT03474627|Experimental|PLGA-coated HA/TCP particles|Biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
2414331|NCT03474614|Experimental|treatment group|A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications.
2414332|NCT03474614|Other|Control Group|A control group of 10 (n=10) patients will receive only their routine medications (no propranolol) during the (-7 to -10 days) preoperative period. A control group (n=10) is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
2414333|NCT03474601||Acromegaly|Patients diagnosed with acromegaly
2414334|NCT03474601||Cushing's disease|Patients diagnosed with Cushing's disease
2414335|NCT03474601||Hyperprolactinemia/prolactinomas|Patients diagnosed with hyperprolactinemia/prolactinoma
2414336|NCT03474601||Pituitary stalk lesions|Patients diagnosed with pituitary stalk lesions
2414337|NCT03474601||Nonfunctioning pituitary adenomas|Patients diagnosed with nonfunctioning pituitary adenomas
2414338|NCT03474601||Central diabetes insipidus|Patients diagnosed with central diabetes insipidus
2414339|NCT03474601||Craniopharyngioma|Patients diagnosed with craniopharyngiomas
2414340|NCT03474601||Others|Patients diagnosed with other suprasellar/parasellar lesions
2414341|NCT03474588|Active Comparator|Standard Treatment (ST)|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant"
2414342|NCT03474588|Experimental|2. Standard treatment (ST) PLUS web-based CBT4CBT|"This is the same as the treatment normally received at this clinic. This will be tailored to participants' needs, but generally includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as:~Teaching about the treatment program~Teaching important ideas about recovery~Increasing knowledge about specific problems about addiction~Demonstrating new ways of coping with skills designed to fit each participant PLUS~Participants will have access the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on."
2414343|NCT03474575|Other|COPD patient|Prevention of re-hospitalization rate for Early supported discharge and enhanced homecare to patient admited for COPD exacerbation
2414344|NCT03474562|Experimental|Duowell Tab|Telmisartan 40mg/Rosuvastatin 20mg qd for 24 weeks
2414345|NCT03474562|Active Comparator|Monorova Tab + Amlopin Tab|Rosuvastatin 20mg + Amlodipine 5mg qd for 24 weeks
2414346|NCT03474549|Experimental|Tigertriever revascularization device|Mechanical thrombectomy with Tigertriever
2414347|NCT03474523|Experimental|Experimental or Diathermy-Radiofrecuency|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Diathermy-Radiofrecuency (manual 70% intensity of about 40-43º resistive modality for about 30 minutes and authomatic capacitive modality for about 10 minutes) and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
2414348|NCT03474523|Active Comparator|Control or Cavitation|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Cavitation (plane electrode for about 30 minutes and focal electrode for about 10 minutes) at 70% intensity and application of Presotherapy (intensity 35%, compression 35seg, pause 15 seg, speed 9, for about 30 minutes). Non-invasive treatment
2414349|NCT03474510|Experimental|EXPAREL|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
2414350|NCT03474510|Active Comparator|interscalene nerve block|Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer.
3145395|NCT00070213|Experimental|Capcitabine|
2414352|NCT03474484||np-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) and pulmonary infiltrate on chest X -ray at admission
2414353|NCT03474484||p-AECOPD|Patients with evidence of acute exacerbation of chronic obstructive pulmonary disorder (AECOPD) without pulmonary infiltrate on chest X -ray at admission
3145396|NCT00070213|Experimental|OxCap|
3185860|NCT00739271|Active Comparator|Control arm|Traditional treatment where patient is kept on a nasogastric drainage for a few days after abdominal surgery, wait for bowel sounds to appear and then start enteral feeds.
2414360|NCT03474445|Active Comparator|Study Group|Volar Plate Osteosynthesis Inteos 2.5
2414361|NCT03474432|Other|Optical Coherence Tomography|Patients who have undergone clinically-indicated PCI of LM where OCT was performed as part of the routine index procedure will be approached for the study and enrolled if eligible.
2414362|NCT03474393|No Intervention|Normal diabetes care|Continue with their normal diabetes care. Come in for control visits
2414363|NCT03474393|Experimental|Systematic intensive therapy|Intensive Internet and telephone contact for 4 months and Control visits
2414364|NCT03474380|Experimental|Intervention|"Implementation of iHI-FIVES program~Intervention: Behavioral: iHI-FIVES"
2414365|NCT03474380|No Intervention|Usual Care|Pre-implementation before iHI-FIVES program
2414366|NCT03474367||Unplanned Peritoneal Dialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate peritoneal dialysis (PD) in less than 48 hours after implantation of the peritoneal catheter, without family training or adequacy of the home. The patient must not have any absolute contraindications to initiate PD, which include: presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in ECG; and acute pulmonary edema. These patients will be treated with HD.
2414367|NCT03474367||Unplanned Hemodialysis|CKD patients stage 5 (eGFR < 15 ml/min/1,73m²) or stages 4 with abrupt worsening renal function requiring dialysis treatment immediately, followed or not by nephrologists prior to renal replacement therapy (RRT) indication, that agree to initiate HD without a functional arteriovenous fistula, ie, with a central venous catheter (nontunneled or tunneled).
2414368|NCT03474341||Resectable esophageal squamous cell- or adenocarcinoma|"Patients (>18 years) with potentially resectable locally advanced squamous cell- or adenocarcinoma of the esophagus or gastroesophageal junction, receiving nCRT according to the CROSS regimen prior to surgery.~CROSS regimen: weekly carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, delivered 5 days per week on workdays with intensity modulated radiotherapy, including photon and proton therapy)"
2414369|NCT03474328|Experimental|Treatment arm|
2414370|NCT03474315||CHF and CIED patients|600 CHF patients with ICD or CRT admitted to regulatory ambulatory visit.
2414371|NCT03474302|Experimental|Physical Activity|The intervention will be a 12-week community-based physical activity promotion program
2414372|NCT03474302|Active Comparator|Successful Aging|Those randomized to the successful aging group will receive health information pertinent to African Americans over the 12 weeks
2414373|NCT03474289|Experimental|Escalation|SHR-1316 administrated intravenously(IV) at protocol defined dose levels
2414374|NCT03474289|Experimental|Expansion|SHR-1316 administrated IV in advanced solid tumors and selected tumor type
2414375|NCT03474276|Active Comparator|Control group|"Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months).~200 grams / day for children between 6 and 11 months. 300 grams / day for children aged from 12 to 24 months old."
2414376|NCT03474276|Active Comparator|Azythromycin|Fortified Blended Flour (in association with a single dose of Albendazole at inclusion for children older than 12 months) associated to Azythromycin, 20mg/kgs/days during the three first days of the study.
2414377|NCT03474276|Active Comparator|Prebiotic|Fortified Blended Flour mixed with Inuline and fructo-oligosaccharides (Synergy1) 2g/day, given to the child through the whole intervention (in association with a single dose of Albendazole at inclusion for children older than 12 months)
2414378|NCT03474263|Experimental|IC14 (monoclonal anti-CD14 antibody)|Biologic: IC14 (monoclonal anti-CD14 antibody) 4 mg/kg intravenously followed by IC14 2 mg/kg intravenously on Days 2-4. This four-day cycle will be repeated on Days 8-11.
2414379|NCT03474237||Non-functioning adrenal incidentaloma|patients who were diagnosed with non-functioning adrenal incidentaloma on computed tomography or magnetic resonance imaging
2414380|NCT03474237||Pheochromocytoma|patients who were diagnosed with pheochromocytoma biochemically or histologically
2414381|NCT03474237||Primary aldosteronism|patients who were diagnosed with primary aldosteronism by saline loading test
2414382|NCT03474237||Adrenal cushing syndrome|patients who were diagnosed with adrenal cushing syndrome by dexamethasone suppression test and 24 urine free cortisol test.
2414383|NCT03474237||Adrenocortical carcinoma|patients who were diagnosed with adrenocortical carcinoma by imaging study or histologic exam
2414384|NCT03474224||FloTrac patients|patients belong to this group will be managed with a stroke volume target hemodynamic protocol
2414385|NCT03474211||vaccinated|
2414386|NCT03474211||non vaccinated|
2414387|NCT03474198|Active Comparator|Standard TB Management Strategy|Standard combination treatment for pulmonary TB of 8 weeks rifampicin, isoniazid, pyrazinamide, ethambutol, then 16 weeks rifampicin, isoniazid only
2414388|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen B|"TRUNCATE-TB Management Strategy: 8 weeks* of initial treatment using Regimen B; close monitoring after treatment completion; treatment of relapse with 24 weeks of standard treatment.~*If persistent symptoms and positive smear at week 8, extend to 12 weeks of treatment using Regimen B; if persistent symptoms and positive smear at week 12, switch to standard treatment regimen and extend to 24 weeks of treatment.~Regimen B: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, linezolid"
2414389|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen C|"TRUNCATE-TB Management Strategy as described above, using Regimen C in place of B.~Regimen C: Rifampicin (35mg/kg), isoniazid, pyrazinamide, ethambutol, clofazimine"
2414390|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen D|"TRUNCATE-TB Management Strategy as described above, using Regimen D in place of B.~Regimen D: Rifapentine, isoniazid, pyrazinamide, linezolid, levofloxacin"
2414391|NCT03474198|Experimental|TRUNCATE-TB Management Strategy using Regimen E|"TRUNCATE-TB Management Strategy as described above, using Regimen E in place of B.~Regimen E: Isoniazid, pyrazinamide, ethambutol, linezolid, bedaquiline"
3185861|NCT00739349|Experimental|1|Cyclosporine 0.05%
2414392|NCT03474185||Single Cohort|"The intervention for the entire cohort will be Taking Charge of your Heart Health Cardiac Education Classes, delivered via four 2.5-hour group-based classes at TotalCardiology Rehabilitation in Calgary, Canada. Classes review physiology, risk factors, medications, nutrition, exercise, and stress management. Patients are required to complete these classes prior to starting CR exercise sessions."
2414395|NCT03474159|Other|patients|patients with Bicuspid aortic valve (defined using the Sievers classification) and confirmed with either Transthoracic Echocardiography, computed tomography, or Magnetic Resonance Imaging Carotid pulse rate measured on carotid arteries by UF
2414396|NCT03474146|Experimental|Ocimum sanctum extract as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2414397|NCT03474146|Active Comparator|Chlorhexidine Gluconate as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2414398|NCT03474146|Placebo Comparator|Propylene Glycol as mouthrinse|10ml mouthrinse was rinsed for 60sec twice a daily for 03 weeks.
2414399|NCT03474133|Experimental|Brentuximab|Brentuximab vedotin 1,8 mg/kg, every 21 days, up to 16 cycles
2414400|NCT03474120||IVF treatment group|Patients treated with IVF. IVF promotion process, ovulation, fertilization, embryo quality, transplantation and final outcome were collected after the treatment cycle was completed.
2414401|NCT03474120||No IVF treatment group|the patients who did not have received IVF treatment .Patients were followed up to collect hormone levels, ultrasound results.
3145397|NCT00070239|Experimental|Treatment|"PART 1 (closed to accrual as of 8/2005): Patients receive alvocidib IV over 1 hour on days 1, 8, and 15.~Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD* is determined.~PART 2: Patients receive alvocidib IV over 1 hour at or below the MTD determined in part 1 and then receive a maintenance dose of alvocidib IV over 1-6 hours on days 1, 8, and 15. Cohorts of 3-6 patients receive escalating durations of the maintenance dose of alvocidib until the MTD* is determined. An additional cohort of 10-20 patients receives alvocidib over 1 hour on days 1 and 15 at the MTD.~NOTE: *The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both parts, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3145398|NCT00070252|Experimental|Treatment (tipifarnib, capecitabine, docetaxel)|"Phase Ib: Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14 and docetaxel IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Phase II: Patients receive oral tipifarnib twice daily for 6 days. Beginning at least 48 hours after completion of the initial dose of tipifarnib, patients receive treatment as in phase Ib for up to 6 courses at the MTD of capecitabine."
2414404|NCT03474094|Experimental|pre-operative radiotherapy and atezolizumab|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery
2414405|NCT03474094|Experimental|pre-operative atezolizumab and post-operative radiotherapy|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy
2414406|NCT03474094|Active Comparator|pre-operative radiotherapy and post-operative atezolizumab|Pre-operative radiotherapy then surgery followed by 2 cycles of atezolizumab
2414409|NCT03474055|Experimental|LBRV-PV Lot A|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).
2414410|NCT03474055|Experimental|LBRV-PV Lot B|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).
2414411|NCT03474055|Experimental|LBRV-PV Lot C|The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).
2414412|NCT03474055|Active Comparator|ROTASIIL|The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.
2414413|NCT03474042|Experimental|GLPG2737|GLPG2737 will be provided as capsules for oral use.
2414414|NCT03474042|Placebo Comparator|Placebo|Placebo will be provided as capsules for oral use.
2414417|NCT03474016||Patients with early breast cancer(30)|
2414418|NCT03474016||Patients with advanced breast cancer(30)|
2414419|NCT03474016||Patients with benign breast diseases(20)|
2414420|NCT03474016||Apparently healthy females as a control group(36)|
2414421|NCT03473990|Active Comparator|Laboratory HIT|Supervised (Laboratory HIT) exercise in the lab up to 4 times per week for 4 weeks
2414422|NCT03473990|Active Comparator|Home HIT|Unsupervised (Home HIT) exercise at home up to 4 times per week for 4 weeks
2414423|NCT03473990|No Intervention|Control Group|No intervention
3145399|NCT00070265|Experimental|Treatment (oxaliplatin, capecitabine, and surgery)|"Neoadjuvant chemotherapy: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Surgery: Four to six weeks after the completion of chemotherapy, patients undergo surgical resection of the tumor.~Adjuvant chemotherapy: Patients with satisfactory response to therapy receive 4 additional courses of oxaliplatin and capecitabine after surgery."
3145400|NCT00070304|Experimental|Treatment|Patients receive vinorelbine tartrate IV over 6-10 minutes and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Patients also receive filgrastim (G-CSF) subcutaneously daily beginning on day 9 and continuing for at least 7 days and until blood counts recover. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease after 2 courses may proceed directly to stem cell transplantation off study OR receive 2 additional courses. Patients with stable disease after 2 courses receive at least 2 additional courses. Patients with continued stable or responding disease (with no disease progression) after 4 courses may continue to receive study treatment for up to 1 year or discontinue study for alternative therapy at the discretion of the treating physician.
3145401|NCT00070382|Experimental|Darbepoetin alfa|darbepoetin alfa administered once every two weeks at a dose of 200 ug over a 16 week treatment period.
3145402|NCT00070382|Active Comparator|Epoetin alfa|epoetin alfa administered at 40,000 unites, once per week over a 16-week treatment period.
2414426|NCT03473964||Treatment|The study intervention is the observation of study subjects who have received H.P. Acthar® Gel (adrenocorticotrophic hormone), 40 units twice weekly injections in patients who have sarcoid uveitis and to assess it's effectiveness by measuring changes the degree of aqueous and vitreous inflammatory cells present, the degree of aqueous flare, and changes in visual acuity, macular thickness, intraocular pressure and quality of life measures assessed by using the National Eye Institute Visual Function Questionnaires (VFQ-25)
2414427|NCT03473951||Hyperuricemia|Hyperuricemia is defined as a serum uric acid level of 7 mg/dl or more in men or 6 mg/dl or more in women
2414428|NCT03473938||Spatz3 AIGB|Patients with implanted Spatz3 AIGB balloon.
2414429|NCT03473925|Experimental|Navarixin Dose A + Pembrolizumab|Participants receive navarixin Dose A via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2414430|NCT03473925|Experimental|Navarixin Dose B + Pembrolizumab|Participants receive navarixin Dose B via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
2414431|NCT03473912||RA patients|before or after medication
2414432|NCT03473912||Systemic sclerosis patients|before or after medication
2414433|NCT03473912||IgG4 RD patients|before or after medication
2414434|NCT03473912||Lupus patients|before or after medication
2414435|NCT03473899|Active Comparator|rESWT + RP|Device: rESWT
2414436|NCT03473899|Placebo Comparator|sham-rESWT + RP|Device: sham-rESWT
3185862|NCT00739349|Experimental|2|Cyclosporine 0.1%
2414439|NCT03473847|Experimental|Repeatability and Reproducibility - Normal eyes|"This arm will include 20 eyes of 20 patients with no previous ocular surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
2414440|NCT03473847|Experimental|Repeatability and Reproducibility - Post-op eyes|"This arm will include 20 eyes of 20 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned a number of times using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). The scan sequence will be undertaken on a single day as follows:~5 consecutive repeated scans of the cornea will be performed by the first operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set).~There will be a break of about 30 minutes.~5 consecutive repeated scans of the cornea will be performed by the second operator using each of the four devices (expected total time approximately 5 minutes for each OCT scan set and 15 minutes for the Insight 100 scan set)."
2414441|NCT03473847|Experimental|Comparison between devices - Normal eyes|"This arm will include 101 eyes of 101 patients with no previous ocular surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
2414442|NCT03473847|Experimental|Comparison between devices - Post-op eyes|"This arm will include 101 eyes of 101 patients between 3 and 9 months after corneal laser refractive surgery.~The research participant will be scanned once using each of the four devices (the Insight 100 VHF digital ultrasound scanner, the Cirrus HD OCT 5000, the RTVue OCT, and the MS-39 OCT). Expected total time approximately 20 minutes to complete all four scans."
2414443|NCT03473834|Experimental|Modified exercise programme|Modified exercise program is the intervention for the exercise group that they will be received this programm over 1 month.
2414444|NCT03473834|Active Comparator|Parkinson's disease Medication|Medication is the standard treatment for individuals with Parkinson's disease. Therefore, the control group will be received the medication only.
2414445|NCT03473821|No Intervention|Neuromuscular Training|Participants in this group will undergo rehabilitation for ACL injury consisting of neuromuscular training according to care-as-usual treatment common to physical therapy professionals.
2414446|NCT03473821|Experimental|MOTIFS|Participants in this group will receive an intervention that has been developed according to our new training model, known as MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS). In this intervention, patients will receive a neuromuscular training rehabilitation program with integrated dynamic motor imagery.
3185863|NCT00739349|Placebo Comparator|3|vehicle/placebo
3145403|NCT00070434|Experimental|Irinotecan + 5-FU + Leucovorin|Irinotecan 180mg/m2, IV for 90min on Day 1, q 2 wk x 4 cycles; 5-FU 400 mg/m2, IV bolus on Day 1, q 2 wk x 4 cycles; 5-FU 2.4 g/m2 IV for 46 hours on Day 1, q 2 wk x 4 cycles; Leucovorin 200 mg/m2 IV for 2 hours on Day 1, q 2 wk x4 cycles.
2414449|NCT03473782||Voiding Diary|
2414450|NCT03473782||Urodynamics Correlation Study|
2414451|NCT03473769|Experimental|Vital Signs at 2 Hours + CAM-ICU|enhanced vital sign and delirium monitoring in patients for who the per-sepsis algorithm reaches alert threshold.
2414452|NCT03473769|No Intervention|No Intervention|No intervention. Patient treated per standard of care.
3145404|NCT00070434|Experimental|Irinotecan + Oxaliplatin|Irinotecan 175mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; Oxaliplatin 85mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles
3185864|NCT00739388|Experimental|Arm: 5-azacytidine|5-azacytidine 100 mg/m2/day s.c. on days 1-5 of a 28-day cycle.
3185866|NCT00739414|Experimental|LBH589 (Panobinostat)|
3185867|NCT00739440|Experimental|I|Patients 15 to 60 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
3185868|NCT00739440|Experimental|II|Patients 15 to 60 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
3145405|NCT00070434|Experimental|Oxaliplatin + 5-FU + Leucovorin|Oxaliplatin 85mg/m2 IV for 90 minutes on Day 1, q 2wk x4 cycles; 5-FU 400mg/m2 IV bolus on Day 1, q 2wk x4 cycles; 5-FU 2.4g/m2 IV for 46 hours on Day 1, q 2wk x4 cycles; Leucovorin 200mg/m2 IV for 2 hours on Day 1, q 2wk x4 cycles.
3145406|NCT00070486|Experimental|Gem + Carboplatin + Zileuton|
3145407|NCT00070486|Experimental|Gem + Carboplatin + celecoxib|
3145408|NCT00070486|Experimental|Gem + carboplatin + zilueton + celecoxib|
3145409|NCT00070525|Experimental|Arm I|Patients receive oral tipifarnib twice daily on days 1-21. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2414458|NCT03473730|Experimental|Cohort 1 Renal (daratumumab, biopsy, surgery)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter during weeks 1-8. Treatment repeats every week for up to 8 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo biopsy, nephrectomy, or metastasectomy during weeks 10-12. Patients may then restart treatment with daratumumab beginning 2 weeks after biopsy or 4-6 weeks after nephrectomy or metastasectomy. Cycles repeat every 2 weeks for 4 months and then monthly for 1 year in the absence of disease progression or unacceptable toxicity.
2414459|NCT03473730|Experimental|Cohort 2 Bladder (daratumumab)|Patients receive daratumumab IV over 8 hours for the first dose and then over 4 hours for all doses thereafter beginning at week 1. Cycles repeat every week for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
2414460|NCT03473717|Active Comparator|classic method group|IUD/IUS insertion will be done using the conventional method
2414461|NCT03473717|Active Comparator|direct method group|IUD/IUS insertion will be done using the direct method
2414462|NCT03473704|Experimental|Treatment group (TG)|The treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
2414463|NCT03473704|Placebo Comparator|Control group (CG)|The control group (CG) will be evaluated in the same phases as the TG.
2414464|NCT03473691|Experimental|Glembatumumab vedotin (GV)|
2414465|NCT03473678|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 10 days
2414466|NCT03473678|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 10 days
2414471|NCT03473652|Other|Adapted walking platform|
2414472|NCT03473639|Experimental|Entinostat and Capecitabine|"Dose escalation of the combination of entinostat and capecitabine in MBC patients. This dose will be given to MBC patients and to BC patients with residual invasive disease after neoadjuvant chemotherapy and surgery.~The dose combinations include:~Combination 1: 3 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 2: 5 mg/week entinostat, 800 mg/m2 twice a day for 14 days of capecitabine Combination 3: 3 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine Combination 4: 5 mg/week entinostat, 1000 mg/m2 twice a day for 14 days of capecitabine~If a participant experiences unacceptable side effects, he or she will receive the next lowest dose combination. If he or she is on Combination 1, he or she will stop study treatment."
2414473|NCT03473626|Experimental|Alicaforsen tablets|Regimen A - Alicaforsen tablets with food
2414474|NCT03473626|Experimental|alicaforsen tablets|Regimen B - Alicaforsen tablets without food
2414475|NCT03473613|Active Comparator|Calcium infusion|10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days
2414476|NCT03473613|Active Comparator|Oral Cabergoline|Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily
2414477|NCT03473600|Experimental|study group|•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
2414478|NCT03473600|Active Comparator|control group|•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
2414479|NCT03473587|Experimental|Motivational Interview|Subjects will engage in a brief motivational interview to establish an action plan and discuss follow-up interviews a 3 and 6 months post ED visit
2414480|NCT03473587|Active Comparator|Standard of Care|Subjects will be provided a standard of care colorectal cancer screening brochure at the time of ED visit
3145410|NCT00070551|Experimental|Stratum I (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 2 hours twice daily on days 2, 4, and 6.
3145411|NCT00070551|Experimental|Stratum II (GTI-2040, cytarabine)|Patients receive GTI-2040 IV continuously on days 1-6 and high-dose cytarabine IV over 4 hours once daily on days 2-6. In both strata, treatment continues in the absence of unacceptable toxicity.
3145412|NCT00070616|Experimental|Palifermin 6 x 60 μg/kg/day|The first 3 consecutive daily doses were administered before the initiation of conditioning therapy (study days -11, -10, and -9); 3 additional consecutive daily doses were administered after administration of radiotherapy, chemotherapy and PBPC transplantation (study days 0, 1, and 2).
3145413|NCT00070616|Experimental|Palifermin 2 x 180 μg/kg/day|The first dose was administered on study day -11, 3 days before the initiation of conditioning therapy, and the second dose was given on day 0 after administration of radiotherapy, chemotherapy and the PBPC infusion
3145414|NCT00070629|Experimental|1|Chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection
2414487|NCT03473548|Experimental|Portable Sleep Monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
3145415|NCT00070629|Active Comparator|2|Chemotherapy (a taxane and a platinum compound)
3145416|NCT00070642|Experimental|CPG 7909 Injection plus chemotherapy|CPG 7909 Injection plus DTIC
3145417|NCT00070642|Active Comparator|Chemotherapy alone|dacarbazine
3145418|NCT00070642|Experimental|CPG 7909 Injection 10 mg|
3145419|NCT00070642|Experimental|CPG 7909 Injection 40 mg|
3145420|NCT00070811||Revision|Patients with repaired cleft lip who receive lip revision surgery
3145421|NCT00070811||Non-Revision|Patients with repaired cleft lip who do not have lip revision surgery
2414488|NCT03473535|Active Comparator|PST Alone|Participants will receive six sessions of face-to-face PST.
2414489|NCT03473535|Experimental|Blended-Therapy|Participants with receive six sessions of face-to-face PST supplemented by the BEACON platform.
2414490|NCT03473522|Experimental|anodal tDCS +Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes) over the motor cortex representation of trunk and lower limbs. Immediately after tDCS application all the patients will participate in an exercise therapy protocol involving balance control, strength,
2414491|NCT03473522|Sham Comparator|Sham tDCS+ Exercise Therapy|Anodal tDCS (2mA of intensity, for twenty minutes but thirdy seconds ON) over the motor cortex representation of trunk and lower limbs.
2414492|NCT03473509|Experimental|Chronic Kidney Disease (CKD) Registry|The CKD registry provided primary care practice teams with point-of-care data about patient-specific CKD status, recent ambulatory clinic blood pressure (BP) readings, status of Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) prescription, and quantification of albuminuria (UACR). It also provided data about diabetes care, immunization status, and data pertinent to age appropriate cancer screening, to align with usual care. Point-of-care decision support reminded primary care providers (PCPs) about guideline concordant care for individuals with CKD. Quarterly feedback to practice teams and individual PCPs identified patients with CKD and BP >140/90 mmHg, those not prescribed an ACEi/ARB, and those with albuminuria.
2414493|NCT03473509|No Intervention|Usual Care Registry|Usual care consisted of an electronic registry that was in use before trial implementation. It provided practice teams with point-of-care data about diabetes care, age-appropriate cancer screening and immunizations, but no CKD-related data. Medical assistants were encouraged to use the usual care registry to identify patients who were due for cancer screening or immunizations. Quarterly feedback was not provided for practice teams randomized to receive usual care.
2414494|NCT03473496|Experimental|CART therapy in multiple myeloma|In order to assess the safety and validity of using CAR-T therapy refractory/rela-psed multiple myeloma patients with one kind of BCMA-CART,CD138-CART,CD56-CART or CD38-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
2414495|NCT03473483|Experimental|SREC only or cigarette only use|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; pharmacokinetic (PK) blood draws; ad libitum use of product; cardiovascular (CV) monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
2414496|NCT03473483|Experimental|Alternate product from Arm 1|Four days of SREC/Usual cigarette/product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes a standardized session of product use; 4-hr abstinence; PK blood draws; ad libitum use of product; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
2414497|NCT03473483|Experimental|Standardized Dual Use|Four days of SREC and/or usual product use as regular with daily diary. Admitted to hospital research ward on Day 5 and 6 for 2 hospital day visits that includes ad libitum SREC use and less than usual amount of cigarette use; CV monitoring, 12-hr urine collections, and 12-hr circadian blood draws.
2414498|NCT03473470|No Intervention|not warmed|Not warming system
2414499|NCT03473470|Active Comparator|warmed group 1|forced air warming and warmed intravenous fluids
2414500|NCT03473470|Active Comparator|warmed group 2|warmed intravenous fluids
2414501|NCT03473457|Experimental|CART therapy in Acute myeloid leukemia|In order to assess the safety and validity of using CAR-T therapy refractory/relapsed acute myeloid leukemia（AML）patients with one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART,subjects will receive 10^6-10^7/Kg transduced CAR T cells at one time.
2414502|NCT03473431|Experimental|ketamine|single infusion of 0.5 mg / kg ketamine
2414503|NCT03473431|Sham Comparator|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
2414504|NCT03473418|Experimental|Ketoconazole gel|use of Ketoconazole in situ gel for treatment of vaginal candidiasis
2414505|NCT03473418|Active Comparator|terconazole cream|use of terconazole 0.8 cream for treatment of vaginal candidiasis
2414506|NCT03473405|Sham Comparator|Control|In the control arm, the ABS device will be placed as usual on the patient, but the airflow will NOT be activated. Only the technician in the room will be aware whether the device is turned on or not.
2414507|NCT03473405|Experimental|Air Barrier System|In the experimental (intervention) arm, the ABS device will be placed as usual on the patient, and the airflow will be activated. Only the technician in the room will be aware whether the device is turned on or not.
2414508|NCT03473379||Phase 1: concept elicitation and coding|The aim of this phase is to elicit concepts from patients, caregivers, and oncology clinicians through focus groups of patients and caregivers, qualitative interviews and surveys. Approximately 55 patients or caregivers will participate in this phase.
2414509|NCT03473379||Phase 2: Item generation and analysis|The aim of this phase is produce a draft version of the questionnaire. Approximately 90 patients or caregivers will be recruited in this phase for item ranking and analysis through questionnaire evaluation and cognitive interviews.
2414510|NCT03473379||Phase 3: Instrument refinement and internal validation|The aim of this phase is generate the final version of the instrument. Approximately 101 patients or caregivers will participate in this phase by completing the questionnaire
2414511|NCT03473379||Phase 4: External validation|In this phase the questionnaire will undergo further psychometric testing for validation and approximately 220 patients or caregivers will be asked to complete the PROFTC-I questionnaire along with quality of life instruments
3145422|NCT00070811||Non-cleft|Non-cleft 'control' subjects.
3145423|NCT00070824|Experimental|B|Patients with osteoarthritis pain at rest
2414645|NCT03472508|Sham Comparator|0 mg folic acid|Enalapril Maleate (10mg) with 0 mg folic acid
2414646|NCT03472508|Active Comparator|0.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg)
3145424|NCT00070824|Experimental|A|Normal Subjects without pain
3145425|NCT00070954|Placebo Comparator|2|look-alike placebo
3145426|NCT00070954|Active Comparator|Ginkgo Biloba|Compared to placebo
3145427|NCT00071071|Experimental|280 mg and 560 mg|
3145428|NCT00071084|Experimental|280 mg and 980 mg|
3145429|NCT00071097|Experimental|001|TMC114/rtv 400mg TMC114/100mg rtv once daily
3145430|NCT00071097|No Intervention|005|Control Group Control Group, no intervention
2414514|NCT03473353|Other|Pediatric Clinicians|Survey data will be gathered from pediatric clinicians and also parents of pediatric patients at two time periods. At baseline, no Medical Scribes will be working with the clinicians, and then several months later, data will be gathered when Medical scribes ARE working with clinicians.
2414515|NCT03473340|Experimental|Pirfenidone Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
2414516|NCT03473340|Placebo Comparator|Placebo Capsule|"Method of Administration: Oral (capsule)~Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily"
2414517|NCT03473314|Experimental|Nitric Oxide gas at 160ppm|Nitric Oxide 160ppm for 50-80 minutes two -three times a day for 365 days
3185869|NCT00739453|Experimental|Schedule 1|OSI-906 is administered on Days 1-3 every 7 days. Erlotinib will be administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
3185870|NCT00739453|Experimental|Schedule 2|OSI-906 is administered daily starting on Day 1 and erlotinib is administered daily starting on Day 2 of the initial treatment period and on Day 1-21 for all remaining treatment periods.
3185871|NCT00739453|Experimental|Schedule 3|OSI-906 is administered continuously twice daily starting on Day 1 and erlotinib is administered daily starting on Day 2. The NSCLC expansion cohort will follow Schedule 3 with the exception that erlotinib is administered daily starting on Day 8.
2414521|NCT03473288|Active Comparator|Moderate Intensity Treadmill Exercise|Moderate intensity treadmill exercise three times per week for 10-12 weeks
2414522|NCT03473288|Placebo Comparator|Sedentary Controls|Serve as a sedentary (little exercise) control for 10-12 weeks
2414523|NCT03473275||1: control|"Healthy normotensive participants. Cold pressor test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.~PinPrick test on feet 3 times for 40 seconds during brain BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
2414524|NCT03473275||2: untreated hypertensive|"Untreated (or off antihypertensive drugs) hypertensive patients (ABPM proven essential hypertension).~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
2414525|NCT03473275||3. resistant hypertensive|"Patients with proven resistant hypertension and not renal denervated or for whom a renal denervation is planned according to the criteria of the CHUV.~Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound."
2414526|NCT03473275||4. renal denervation|Patients with a renal denervation. Cold pressor test on feet 3 times for 40 seconds during BOLD fMRI (2 runs), renal ultrasound and contrast-enhanced ultrasound.
2414527|NCT03473262||EMPA|Empagliflozin 25 mg/day
2414528|NCT03473262||INS|Insulin Glargine dose-titrated
2414529|NCT03473249|No Intervention|Retrospective Review|Comparison of CT and CEUS results from retrospective chart review of children who have had a CEUS for trauma at the Children's Hospital of Philadelphia (CHOP).
2414530|NCT03473249|No Intervention|Prospective Observation|Prospective observation of comparison of CT and CEUS results among children who are undergoing a CEUS and abdominal CT as part of clinical care.
2414531|NCT03473249|Other|Contrast-Enhanced Ultrasound using Lumason|Prospective intervention using contrast enhanced ultrasound with IV contrast Lumason.
3185872|NCT00739466|Experimental|low dose|Liposomal Alendronate dose of 0.001 mg
3185873|NCT00739466|Experimental|high dose|Liposomal Alendronate dose of 0.01 mg
3185874|NCT00739466|Placebo Comparator|placebo|IV saline infusion
3185875|NCT00739479|Active Comparator|1|Patients will be randomized to receive PHWP. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
3185876|NCT00739479|Placebo Comparator|2|Patients will be randomized to receive PHG. Since sex and baseline weight can influence the response, randomization will be stratified according to these variables.
3185877|NCT00739492|Active Comparator|1|deposit based incentive
3185878|NCT00739492|Active Comparator|2|"deposit based incentive framed with maintenance period"
3185879|NCT00739492|No Intervention|3|Control arm, no financial incentive
3145431|NCT00071097|Experimental|004|TMC114/rtv 600mg TMC114/100mg rtv twice daily
3145432|NCT00071097|Experimental|003|TMC114/rtv 400mg TMC114/100mg rtv both twice daily
2414542|NCT03473210|Active Comparator|Amniopatch group|in which women were subjected to active treatment included prophylactic antibiotics and antenatal corticosteroids with an effort to seal the ruptured membranes using the amniopatch technique.
2414543|NCT03473210|Active Comparator|control group|in which women were subjected to conservative management with prophylactic antibiotics and antenatal corticosteroids
3185880|NCT00739505|Experimental|Cohort 1|3 HPP patients are to be enrolled in Cohort 1 and receive a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 1 is at 8 weeks.
3185881|NCT00739505|Experimental|Cohort 2|Cohort 2 will begin when the safety and PK data for Cohort 1 weeks 1-4 has been reviewed by the DSMB. Cohort 2 will enroll 3 HPP patients and will receive a higher dose level than Cohort 1. Cohort 2 patients will have a single IV dose and three weekly SC doses of Asfotase Alfa . End of Study for patients in Cohort 2 is at 8 weeks.
3185882|NCT00739518|Experimental|MRI scan - new technology|The patient's clinical MRI scan will also utilize some new technology, such as a change in software or additional MRI sequences
2414547|NCT03473158|Active Comparator|Mechanical|fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle
2414548|NCT03473158|Active Comparator|Chemical|fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle
2414549|NCT03473145|Active Comparator|Health Living Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention. This group will receive one in-person health coaching sessions and 6 phone counseling sessions.
2416050|NCT03463187|Experimental|40mg SHR-1314 (Part B)|SHR-1314 40mg, subcutaneously
3185883|NCT00739531||Asthmatics|Subjects with asthma
2414550|NCT03473145|Experimental|Reduce Sitting|Participants in the Reduce Sitting condition will receive an intervention aimed at reducing daily sitting time. This group will receive five in-person health coaching sessions and two phone counseling sessions.
2414551|NCT03473145|Experimental|Sit-to-Stand Transition|Participants in the Sit-to-Stand Transition condition will receive an intervention aimed at increasing the daily number of brief sit-to-stand transitions. This group will receive five in-person health coaching sessions and two phone counseling sessions.
2414552|NCT03473132|Experimental|Treatment|Based on starting international normalized ratio (INR) and target INR, the dose of four factor prothrombin complex concentrate will be calculated and infused. Coagulation factor levels will be assessed over 48-72 hours.
2414553|NCT03473119||Control|Healthy individuals
2414554|NCT03473119||Asthma|Asthma acute exacerbations
2414555|NCT03473119||Asthma with CAP|Asthma acute exacerbations with community-acquired pneumonia
2414556|NCT03473119||COPD|Acute exacerbations of chronic obstructive pulmonary disease
2414557|NCT03473119||COPD with CAP|Acute exacerbations of chronic obstructive pulmonary disease with community-acquired pneumonia
2414558|NCT03473119||CAP|Community-acquired pneumonia
2414559|NCT03473106|Experimental|Surgical Side|Surgical side requiring the use of a pneumatic tourniquet.
2414560|NCT03473106|No Intervention|Non Surgical Side|Contralateral side (Control Thigh).
2414561|NCT03473093|Active Comparator|morphine|This group will receive only morphine infusion (20microgram/kg/h)
2414562|NCT03473093|Active Comparator|pregabalin|This group will receive only morphine infusion (20microgram/kg/h) and oral pregabalin (150 mg)
2414563|NCT03473080|Other|Internet CBT|Participants and their parents receive 16 weeks of internet-delivered cognitive behavior therapy (CBT) with psychologist support.
2414564|NCT03473067|Experimental|Social Norms Marketing|This arm includes a social norms marketing campaign tailored to the school.
2414565|NCT03473067|Active Comparator|Capacity Building|This arm includes a series of teacher training, and parent engagement meetings, with the goal of building capacity to address violence in the school.
2414566|NCT03473054||Web-based Mindfulness Course|Participants will complete a 2 week baseline phase, followed by the four week web-based mindfulness course intervention phase, and a four week follow-up period.
2414567|NCT03473041|Active Comparator|Hybrid sling|70 patients with stress urinary incontinence treated with surgeon tailored hybrid sling
2414568|NCT03473041|Active Comparator|TVT-O|70 patients with stress urinary incontinence treated with conventional TVT-O
2414569|NCT03473028|Active Comparator|transabdominal ultrasound|400 obese female undergo transabdominal ultrasound guided embryo transfer
2414570|NCT03473028|Active Comparator|transvaginal group|400 obese female undergo transvaginal ultrasound guided embryo transfer
2414571|NCT03473015|Experimental|PICSO arm|STEMI patients with elevated pre-stenting index of microcirculatory resistance (IMR) greater than 40 units treated with pressure-controlled intermittent coronary sinus occlusion (PICSO)
2414572|NCT03473015|No Intervention|Control|Matched historical cohort of STEMI patients with elevated IMR greater than 40, not treated with PICSO
2414573|NCT03473002|Placebo Comparator|Placebo|One dose of placebo (0.9% Sodium Chloride) intranasally, n=4
2414574|NCT03473002|Experimental|SeVRSV|1 x 10^7 EID50 (one dose) of SeVRSV vaccine intranasally, n=16
2414575|NCT03472989|Active Comparator|Radial extracorporeal shock wave|Active shock wave treatment. All patients will get standardized information and custom made foot orthosis.
2414576|NCT03472989|Sham Comparator|Sham-radial extracorporeal shock wave|Sham- shock wave treatment. All patients will get standardized information and custom made foot orthosis.
2414577|NCT03472989|Active Comparator|Standardized high-load exercise program|High-load exercise treatment. All patients will get standardized information and custom made foot orthosis.
2414578|NCT03472989|Active Comparator|Usual care|Only standardized information and custom made foot orthosis
2414579|NCT03472976|Experimental|Group 1|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Imiquimod (Aldara) cream topically (deltoid) on Day 1 and Day 22. N=25
2414580|NCT03472976|Experimental|Group 2|0.1 ml of influenza A/H5N1 IIV vaccine (9 mcg HA) intradermally 15 minutes after the application of approximately 250 mg of Aqueous Cream B.P. (Control Cream) topically (deltoid) on Day 1 and Day 22. N=25
2414581|NCT03472963|No Intervention|Pre- drug|Participants will not receive any drug. They will be asked to return 1-6 weeks after the screening visit for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, rectal swabs, urine sample, and rectal biopsy via rigid sigmoidoscopy.
2414582|NCT03472963|Experimental|Group A.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 2 hours after dosing.
2414583|NCT03472963|Experimental|Group A.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 24 hours after dosing.
2414584|NCT03472963|Experimental|Group A.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 2 hours, 24 hours (+/- 1 hour), and 72 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 72 hours after dosing.
2414585|NCT03472963|Experimental|Group B.1|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 4 hours after dosing.
2414647|NCT03472508|Active Comparator|0.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.4mg) with 0.2 mg folic acid
2414648|NCT03472508|Active Comparator|0.8mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg)
2414586|NCT03472963|Experimental|Group B.2|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 48 hours after dosing.
2414587|NCT03472963|Experimental|Group B.3|Men will be dosed with Genvoya and Darunavir® on site (time of dose will be recorded) and asked to return in 4 hours, 48 hours (+/- 1 hour), and 96 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 96 hours after dosing.
2414588|NCT03472963|Experimental|Group C|Participants will be given a one- day supply of with Genvoya and Darunavir®. Participants return 8 hours (+/- 30min window), 24 hours (+/- 1 hr), and 48 hours (+/- 1 hour) after taking dose for study procedures (blood collection, oral cheek swab, penile swabs, urethral swab, and a urine sample). Participant will undergo rectal swabs and rectal biopsy via rigid sigmoidoscopy in 8 hours after taking the medication.
2414589|NCT03472950|Experimental|Ranolazine 500mg|Participants will take Ranolazine 500mg twice daily for up to 4 weeks.
2414590|NCT03472950|Experimental|Ranolazine 1000mg|Participants will take Ranolazine 1000mg twice daily for up to 4 weeks.
2414591|NCT03472937|Active Comparator|Inpatient cervical ripening group|Subjects in this arm will be seen in the outpatient setting, and if they qualify and are randomized to the inpatient (control) group, they will be admitted to labor and delivery the next day for cervical ripening with a transcervical Foley catheter.
2414592|NCT03472937|Active Comparator|Outpatient cervical ripening group|Subjects in this arm will undergo cervical ripening with a transcervical Foley catheter in the outpatient setting (intervention arm). The transcervical catheter will be placed in the office after confirmation of fetal well-being. They will then return the next day to be admitted to labor and delivery for induction of labor with oxytocin.
2414593|NCT03472924|Experimental|Kinesio Tape|Kinesiotaping of the peroneus longus according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016) followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs.
2414594|NCT03472924|No Intervention|Control|Baseline measures followed by standardized set of therapeutic exercises that are commonly implemented in ankle rehabilitation programs, but no use of kinesiotape.
3185884|NCT00739544|Other|1|Quantitative sensory testing (QST) of healthy women to create reference values for QST evaluation of women treated for breast cancer
3185885|NCT00739570|No Intervention|1|
3185886|NCT00739570|Active Comparator|2|Activator chiropractic technique basic scan protocol
3185887|NCT00739609|Experimental|1|
2414599|NCT03472872|Experimental|Ketorolac Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 15mg ketorolac in 100mL 0.9% normal saline IVPB
2414600|NCT03472872|Experimental|Acetaminophen Arm|The patient will receive a 0.9% normal saline bolus of 1,000ml at 500ml/hr, 25mg diphenhydramine IV, 10mg prochlorperazine IV, 1,000mg acetaminophen in a 100ml IVPB
2414601|NCT03472859|Experimental|Split-face group 1|In group 1 the left side of the face will be treated with KTP and right side with PHOTOLASE.
2414602|NCT03472859|Experimental|Split-face group 2|In group 2 the right side of the face will be treated with KTP and left side with PHOTOLASE.
2414603|NCT03472846|Active Comparator|Group 1 - DMAB|postmenopausal women without type 2 diabetes mellitus treated with denosumab
2414604|NCT03472846|Active Comparator|Group 2 - TPTD|postmenopausal women with type 2 Diabetes mellitus treated with teriparatide
2414605|NCT03472846|Active Comparator|Group 3 - DMAB|postmenopausal women with type 2 diabetes mellitus treated with denosumab
2414606|NCT03472846|Active Comparator|Group 4 - TPTD|postmenopausal women without type 2 diabetes mellitus treated with teriparatid
2414607|NCT03472833|Experimental|High-dose|"Intervention with high dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 180.000 I.U. on day 1, and then 4000 I.U. per day for 60 days."
2414608|NCT03472833|Active Comparator|Standard-dose|"Intervention with standard dose oral vitamin D3 supplementation.~1 drop equals 400 I.U. This group will get 800 I.U. per day for 60 days."
2414609|NCT03472820|Experimental|Intervention Group|The intervention will be diet, lifestyle, exercise and stress management recommendations combined with taking two different supplements twice daily, in divided doses.
2414610|NCT03472820|No Intervention|Control Group|The control group will undergo the same testing measures as the intervention group, but will not have access to the education information or be instructed to change diet or lifestyle factors. They will have access to the information after the study is complete.
2414611|NCT03472807|Other|Cancer patient|"Collection of blood sample or saliva~Collection of a tumor sample taken before the participation of the patient in study~Collection of blood sample if tumor sample is not available"
2414612|NCT03472807|Other|Parent of cancer patient|-Collection of blood sample or saliva
2414613|NCT03472781||Children with intraocular inflammation|All children diagnosed with intraocular inflammation at Singapore National Eye center from from January 1989 to January 2017.
2414614|NCT03472768||ECMO-supported group|Thirty critically-ill children (age newborn to 18 years) who are intubated and supported by ECMO. Normal adult-level haptoglobin concentrations are achieved by 6-12 months of age. We will target enrollment of 15 subjects less than 12 months of age and 15 subjects over 12 months of age
2414615|NCT03472768||Age-matched group with respiratory failure|Sixty critically-ill children (age newborn to 18 years) who are intubated with acute respiratory failure due to any cause and not supported by ECMO. Two control subjects will be enrolled for every 1 experimental ECMO subject.
2414616|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
3185888|NCT00739635|Experimental|1|
3185889|NCT00739635|Placebo Comparator|2|
3185890|NCT00739687|Experimental|ALT-711|Alagebrium 200 mg BID
3185891|NCT00739687|Experimental|Placebo|Placebo
2414617|NCT03472755|Other|Direct anterior techniques.|. In the direct anterior technique, patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached.
2414618|NCT03472729|Experimental|AGE-ON Workshop|Intervention participants will take part in a 6-week workshop to learn 1) basic features of the iPad; 2) how to use the internet; 3) how to take and view photos; 4) how to send and receive emails; and 5) other 'fun' functions.
2414619|NCT03472729|No Intervention|Wait-list control|Wait-list control group to be offered workshops after the study is complete
3145433|NCT00071097|Experimental|002|TMC114/rtv 800mg TMC114/100mg rtv once daily
2414621|NCT03472703|Other|Hungry|Her subjects will first have a break, then undergo all measurement and at the end of the study-day they will receive their lunch
2414622|NCT03472703|Other|Satiated|Her subjects will first receive their lunch, then perform all the tasks and last will have a break
2414623|NCT03472690|Experimental|Active|0.1 mL, self-administered subcutaneous injection, every second day
2414624|NCT03472690|Placebo Comparator|Placebo|0.1 mL, self-administered subcutaneous injection, every second day
2414625|NCT03472677|Experimental|Cohort 1|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
2414626|NCT03472677|Experimental|Cohort 2|Controlled cooling wrap versus ice pack cooling.
2414627|NCT03472677|Experimental|Cohort 3|Controlled cooling parameters will be determined after evaluation of data from prior cohorts.
2414628|NCT03472677|Experimental|Cohort 4|Controlled cooling with knee device versus no cooling (determined after evaluation of data from previous cohorts).
2414629|NCT03472664|Experimental|Modified Mediterranean Ketogenic Diet|"The MMKD is a low carbohydrate/high fat diet aimed at inducing ketosis, as the experimental diet in the proposed study. Participants on the MMKD will keep their daily carbohydrate consumption below 20 grams per day throughout the 4 month intervention.The MMKD group will be supplied with extra virgin olive oil during their in person visits to use as a source of fat in their diet, and will be encouraged to eat plentiful fish, lean meats, and nutrient rich foods that meet the requirement of <20 grams total carbohydrates per day.~Participants will receive a daily multivitamin (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet."
2414630|NCT03472664|Experimental|American Heart Association Diet|The American Heart Association Diet (AHAD), is a low fat/high carbohydrate diet (<40 grams/day) will be used as the control diet. Participants on the AHAD will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Participants will receive the same daily multivitamin supplement (Centrum Silver) over the course of the study and instructed to take 1 tablet each day while on the diet.
2414631|NCT03472651|Experimental|Cohort A1 Fasted condition|Subjects in cohort A1 will be administered the Investigational Medicinal Product in a fasted state, 30 subjects per cohort
2414632|NCT03472651|Experimental|Cohort A2 Fed condition|Subjects in cohort A2 will be administered the Investigational Medicinal Product in a fed state, 30 subjects per cohort
2414633|NCT03472638|Experimental|Active -> Sham|15 days of active, followed by 15 days of sham rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
2414634|NCT03472638|Experimental|Sham -> Active|15 days of sham, followed by 15 days of active rTMS, targeting dorsomedial prefrontal cortex bilaterally, two sessions per day (1 hour apart), 20 Hz stimulation, at 120% resting motor threshold
2414635|NCT03472625||Acute stroke patients|All acute stroke patients will be screened for aphasia, dysarthria or dysphagia. When one of the symptoms is present, standardized assessments will follow to evaluate the severity. Recovery in time will be measured +/- 1 week following stroke.
2414636|NCT03472612|Experimental|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA (intervention)
3145434|NCT00071240|Experimental|Growth Hormone Arm|Growth hormone receipt in the first year, post-growth hormone follow-up in the second year
3145435|NCT00071240|Active Comparator|2|Observation only in the 1st year, GH receipt in the second year
2414639|NCT03472573|Experimental|Treatment (palbociclib, dexamethasone)|"INDUCTION: Participants receive palbociclib PO daily and dexamethasone PO daily for 28 days in the absence of disease progression or unacceptable toxicity. Participants with disease response (M0, M1, or M2) continue to Maintenance. Patients without a disease response discontinue treatment.~MAINTENANCE: Participants receive dexamethasone with a taper PO daily on days 1-7. Participants also receive palbociclib daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2414640|NCT03472560|Experimental|Avelumab in combination with axitinib|Avelumab administered at 800 mg IV every two weeks in combination with axitinib, 5 mg PO BID.
3145436|NCT00071409|Placebo Comparator|placebo|1.5 mL SC injection
3145437|NCT00071409|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3145438|NCT00071409|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3145439|NCT00071422|Placebo Comparator|placebo|1.5 mL SC injection, once daily for 90 days
3145440|NCT00071422|Experimental|300 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3145441|NCT00071422|Experimental|600 mg INGAP Peptide|1.5 mL SC injection, once daily for 90 days
3145442|NCT00071461|Experimental|1|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
3145443|NCT00071461|Placebo Comparator|2|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
3145444|NCT00071500|Experimental|1|Participants will use MedSignals with all of its features
3145445|NCT00071500|Experimental|2|Participants will use MedSignals with only alarm features
3145446|NCT00071500|No Intervention|3|Participants will not use any device
3145447|NCT00071526||Diabetes Type I|Subjects with Type I diabetes mellitus
3145448|NCT00071526||Diabetes Type II|Subjects with Type II diabetes mellitus
2414649|NCT03472508|Active Comparator|1.2mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.4 mg folic acid
2414650|NCT03472508|Active Comparator|1.6mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 0.8 mg folic acid
2414651|NCT03472508|Active Comparator|2.0mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.2 mg folic acid
2414652|NCT03472508|Active Comparator|2.4mg Folic acid|Enalapril Maleate and Folic Acid Tablets (Yiye) (10mg:0.8mg) with 1.6 mg folic acid
2414653|NCT03472495|Active Comparator|Oral Immediate Release Diltiazem|Diltiazem immediate release 60mg orally once (Diltiazem oral product)
2414654|NCT03472495|Active Comparator|Continuous Infusion IV Diltiazem|Diltiazem 2.5-5 mg/hour intravenous Titrate by 1.25 mg every 15-60 minutes. Maximum titration dose 15 mg/hour. Titration Goal of HR <110 (Diltiazem Injectable Product)
2414655|NCT03472482||Ab+ cognitively intact volunteers|"amyloid-positive cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2414656|NCT03472482||Ab- cognitively intact volunteers|"amyloid-negative cognitively intact controls (55-80 years)~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2414657|NCT03472482||amyloid-positive MCI patients|"amyloid-positive patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2414658|NCT03472482||amyloid-negative MCI patients|"amyloid-negative patients with Mild Cognitive Impairment~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2414659|NCT03472482||AD patients|"patients in the dementia stage of Alzheimer's Disease~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
2414660|NCT03472482||LBD patients|"patients with Lewy Body Dementia~interventions: non-invasive retinal imaging with Optical Coherence Tomography (OCT), OCT-angiography (OCT-A), Autofluorescence, Fundus Photography, Hyperspectral Imaging"
3185892|NCT00739700||A|There is only one cohort of subjects, the critically ill. The NIBP will be correlated with the IABP in each subject.
3185893|NCT00739713|Experimental|SB|Sea buckthorn oil group
2414663|NCT03472456||Articaïne|
2414664|NCT03472456||Eugénol|
2414665|NCT03472443|Experimental|Sinew Acupuncture|
2414666|NCT03472443|No Intervention|Waitlist|
2414667|NCT03472430|Active Comparator|Treatment group|Transcutaneous electrical nerve stimulation machine, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
2414668|NCT03472430|Sham Comparator|Placebo group|TENS machine with electrodes not emitting any impulses, start 5 minutes before start of oocyte retrieval and stop 5 minutes after removal of oocyte retrieval needle
2414669|NCT03472417|Active Comparator|Active partial rebreathing device|
2414670|NCT03472417|Sham Comparator|Dummy partial rebreathing device|
2414671|NCT03472404|Experimental|Intervention Group|Internal Brace augmented ankle Ligament reconstruction
2414672|NCT03472404|Active Comparator|Control Group|Brostrom-Gould ankle Ligament reconstruction
2414673|NCT03472391|Active Comparator|Intervention|Supervised exercise therapy by physical therapist: patients allocated to physical therapy will participate in a 4-week (2 sessions a week of 40 minutes) supervised and tailored exercise program mainly consisting of light strength training. The exercise program is an add-on treatment to the primary treatment of re-nutrition and somatic stabilization.
2414674|NCT03472391|No Intervention|Control|The control group follows ordinary treatment in consisting of re-nutrition and somatic stabilization
2414675|NCT03472378|Experimental|Active Treatment Group|DFN-15
2414676|NCT03472378|Placebo Comparator|Placebo Group|
2414677|NCT03472365|Experimental|Cohort 1|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus capecitabine 1000 mg/m^2 twice daily (BID) by continous oral adminstration for 14 days, followed by a recovery period of 7 days, plus oxaliplatin 130 mg/m^2, IV q3w; for 4-6 cycles followed by SHR-1210 plus apatinib 375 mg PO qd.
2414678|NCT03472365|Experimental|Cohort 2|Participants receive SHR-1210 200 mg, intravenously (IV) every 3 weeks(Q3W) plus apatinib 375 mg daily (QD) continous oral. Study treatment will be started on Day 1 of each 3-week cycle.
2414679|NCT03472352|Experimental|Single Arm|The subjects will be given an anticancer medication (A01) and immune cells (IC01).
2414680|NCT03472339|Experimental|Group A|diclofenac sodium75 mg, intravenously, once
2414681|NCT03472339|Active Comparator|Group B|diclofenac sodium 100 mg, orally, once
3185894|NCT00739713|Placebo Comparator|PL|Placebo group
3185895|NCT00739739|Experimental|PD 0299685 15mg|
3185896|NCT00739739|Experimental|PD 0299685 30mg|
3185897|NCT00739739|Placebo Comparator|Placebo|
3185898|NCT00739830|Experimental|1|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
3185899|NCT00739830|Active Comparator|2|Investigator's choice of: oral medroxyprogesterone acetate tablets 200 mg daily or oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily) OR Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
3185900|NCT00739869||1|Participants will include women who participated in the Women's Health Initiative Memory Study.
3185901|NCT00739895||Athletes|high performing athletes
3185902|NCT00739921|Experimental|1|"Patients with sinusitis compared to patients without.~To find out if any specific type of fungus or mold is correlated with chronic sinus disease. The study will add new information about the different types of fungus and mold found in the human nose."
3185903|NCT00739947||1|Standard of Care
3185904|NCT00739986|Experimental|1|Semapimod 60 mg IV x 1 day, placebo IV x 2 days
3185905|NCT00739986|Experimental|2|Semapimod 60 mg IV x 3 days
3185906|NCT00739986|Placebo Comparator|3|Placebo comparator IV x 3 days
3185907|NCT00740012|Active Comparator|Even, low numbers|They start with a alarm- clock night. No venous blood drawing.
3185908|NCT00740012|Active Comparator|Even, high numbers|They start with a nurse performing blood glucose determination. No venous blood drawing.
3185909|NCT00740012|Active Comparator|Uneven, low numbers|They start with an alarm- clock night and have venous blood drawing.
2414687|NCT03472313|Experimental|Experimental: [18F]MNI-958|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-958.
2414688|NCT03472300||Frederiksberg Citizens|All citizen in the Frederiksberg Community aged 60-69
3185910|NCT00740012|Active Comparator|Uneven, high numbers|They start with a nurse performing blood glucose determination and have venous blood drawing.
3185911|NCT00740025||QD|Women who received their meds as QD administration
2414691|NCT03472274|Active Comparator|Cisplatin-based neoadjuvant chemotherapy|"Patients allocated to the control arm will receive any of the following cisplatin based neoadjuvant treatment:~Regimen 1: Gemcitabine + Cisplatin Regimen 2: Methotrexate + Vinblastine + Doxorubicin + Cisplatin Regimen 3: Gemcitabine + Paclitaxel + Cisplatin"
2414692|NCT03472274|Experimental|Durvalumab plus Tremelimumab|Patients randomized to experimental arma will receive 28-day treatment cycle x 3 cycles of Durvalumab + Tremelimumab 75 mg every 4 weeks
2414693|NCT03472261|Experimental|Experimental Group|Patients treated by Botulinum toxin A and twister and specific home exercise program
2414694|NCT03472261|Active Comparator|Conventional Therapy Group|Patients treated by Botulinum toxin A and specific home exercise program
2414695|NCT03472248|Experimental|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
2414696|NCT03472235|Active Comparator|A|include 20 patients will be treated with TCA25% +microneedle 8 sessions for TCA 25 peel and 4 sessions for microneedle (derma pen).
2414697|NCT03472235|Active Comparator|B|include 20 patient will be treated with TCA 25% only ( 8 sessions)
2414698|NCT03472222|Experimental|Arsha Vidya Program|Arsha Vidya outreach community program was conducted with children. An unique well-planned teaching program developed to educate Indian cultural values & heritage to young children and adults with yoga, chants, religious and spiritual practices through stories, group activities and plays.
2414699|NCT03472209||Group A|ETCO2=26-35 mmHg
2414700|NCT03472209||Group B|ETCO2=36-45 mmHg
2414701|NCT03472196|Experimental|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
2414702|NCT03472183|Other|Patients with Alzheimer's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2414703|NCT03472183|Other|Patients with Parkinson's disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2414704|NCT03472183|Other|Patients without neurodegenerative disease|During the course of the colonoscopy that the patients should have in the context of their usual medical care, additional biopsies of colon will be removed to perform in vitro analysis for this study.
2414705|NCT03472170|Experimental|Experimental Arm|"The nutritional supplement used will be bovine lactoferrin, a product marketed according to the regulations of the European Union, and approved by the European Food Safety Agency (EFSA) in 2012, and by the American Agency for Food and Drug Administration ( FDA) in 2013. It will be acquired after purchase from Dicofarm® (Rome, Italy).~The Hospital Pharmacy Service will provide the established dose of lactoferrin, according to the administration schedule of 150 mg / kg / day (maximum 300 mg / day).~The treatments will be administered in liquid form, in the least amount possible. The administration of lactoferrin will be carried out enterally, orally or by nasogastric tube.~The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
2414706|NCT03472170|Placebo Comparator|Control Arm|"Placebo with similar visual and taste characteristics to the nutritional supplement of bovine lactoferrin.~It will be administered in liquid form, in the least amount possible. The administration of placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the NB with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before."
2414707|NCT03472157|Experimental|Bariatric surgery|"Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy.~Decision of the surgery type will be made according to surgical expertise, habits of investigation centers and the patient's desire. All patients receive nutritional support and therapeutic education adapted to recommendations bariatric surgery care."
2414708|NCT03472157|Active Comparator|Lifestyle therapy|The group will received the medical standard treatment defined as lifestyle therapy combining diet with increased physical activity (standard treatment, control) (figure 1, design of study).
2414812|NCT03471429||Dog|Patient sees therapy dog for 15 minutes, which is standard of care at this hospital.
3185912|NCT00740025||BID|Women who received their gonadotropins as a BID dose
3185913|NCT00740038|Active Comparator|1|Active Control: Usual Care
3185914|NCT00740038|Experimental|2|Stress Management Intervention
3185915|NCT00740038|Experimental|3|Exercise Intervention
3185916|NCT00740038|Experimental|4|Combined Stress Management and Exercise Intervention
3185917|NCT00740103|Experimental|1|Semapimod 60 mg IV x 3 days q 6 - 8 weeks
3185918|NCT00740116|Active Comparator|1|Tranexamic acid
3185919|NCT00740116|Placebo Comparator|2|0.9% NaCl solution
3185920|NCT00740142|Active Comparator|1|Interventional arm: oral L-ornithine-L-aspartate and oral lactulose
3185921|NCT00740142|Placebo Comparator|2|Oral lactulose
3185922|NCT00740155|Experimental|Group 1|
3185923|NCT00740155|Experimental|Group 2|
3185924|NCT00740155|Experimental|Group 3|
3185925|NCT00740155|Experimental|Group 4|
2414709|NCT03472144|Experimental|CRSwNP - Subgrp 1(Momentasone - Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
2414710|NCT03472144|Experimental|CRSwNP-Subgrp 2(Levofloxacin - Right)|Patients undergoing balloon sinuplasty with receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
2414711|NCT03472144|Experimental|CRSwNP-Subgrp 3(Steroid/Antibotic Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
2414712|NCT03472144|Experimental|CRSsNP - Subgrp 1 (Momentasone Right)|Patients undergoing ballon sinuplasty will receive a gel loaded with steroids (Momentasone) only on right side and placebo on left side
2414713|NCT03472144|Experimental|CRSsNP - Subgrp 2 (Levofloxacin Right)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only on right side and placebo on left side
2414714|NCT03472144|Experimental|CRSsNP-Subgrp 3(Steroid/Antibiotic Right|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on right side and placebo on left side
2414715|NCT03472144|Active Comparator|CRSwNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only on left side and placebo on right side
2414716|NCT03472144|Active Comparator|CRSwNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
2414717|NCT03472144|Active Comparator|CRSwNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
2414718|NCT03472144|Active Comparator|CRSsNP - Subgrp 1 (Momentasone Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with steroids (Momentasone) only left side and placebo on right side
2414719|NCT03472144|Active Comparator|CRSsNP - Subgrp 2 (Levofloxacin Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with antibiotic (Levofloxacin) only left side and placebo on right side
2414720|NCT03472144|Active Comparator|CRSsNP-Subgrp 3(Steroid/Antibiotic Left)|Patients undergoing balloon sinuplasty will receive a gel loaded with both steroids and antibiotic on left side and placebo on right side
2414721|NCT03472131|Experimental|Septic spondylodiscitis|A unilateral posterolateral approach and debridement with titanium cage insertion supplemented by screw fixation for severe sick patients suffering from septic spondylodiscitis
2414722|NCT03472118|Experimental|High Flow Apneic Oxygenation|Apneic oxygenation using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE)
2414723|NCT03472105|Other|Habitual diet|18 participants were on a habitual diet for 7 days
2414724|NCT03472105|Active Comparator|New Nordic Renal Diet|18 participants were given a New Nordic Renal Diet for 7 days
2414725|NCT03472092|Experimental|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT) is a mind and body based intervention using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem solving, and using calming self-statements.
2414726|NCT03472092|Placebo Comparator|Placebo|The placebo pill will be administered once a day at home, to be taken by mouth.
2414727|NCT03472092|Active Comparator|Amitriptyline|Amitriptyline will be administered once a day at home, to be taken by mouth. Dosage will be weight-based.
2414728|NCT03472092|Active Comparator|Biofeedback-Assisted Relaxation Training (BART)|Biofeedback-Assisted Relaxation Training (BART) is a mind and body based intervention that focuses specifically on mind and body techniques such as deep breathing, muscle relaxation, and guided imagery skills to manage pain.
2414729|NCT03472092|Active Comparator|Cognitive Retraining (CR)|Cognitive Retraining (CR) is a mind and body based intervention that focuses on the use of tests of evidence and other cognitive strategies such as positive coping statements and pleasant activities and mindfulness to manage pain.
2414730|NCT03472066||a group of women who have been conized|Previous conization
2414731|NCT03472066||control group with asymptomatic patients|on routine second trim no previous conization
2414732|NCT03472053|Experimental|BIO-11006 plus standard of care|Aerosolized BIO-11006 (125mg BID) plus standard of care (Pemetrexed plus Carboplatin) is administered for three months.
2414733|NCT03472053|Experimental|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's Formula) is administered every three weeks for three months.
2414734|NCT03472040|Experimental|BCX7353 150 mg once daily|
2414735|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 1|
2414736|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 2|
2414737|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 3|
2414738|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 4|
2414739|NCT03472027|Experimental|BCD-145 Monotherapy Dose Level 5|
3185926|NCT00740155|Active Comparator|Group 5|
2414741|NCT03472001|Experimental|Training group|2-hour training based on reflection and feedback
2414742|NCT03472001|Active Comparator|Lecture group|1-hour lecture
2414743|NCT03472001|No Intervention|Control group|The remaining students only attending dermatology electives
2414744|NCT03471988|Experimental|AK1820|Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
2414745|NCT03471988|Active Comparator|Voriconazole|Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.
3185927|NCT00740168||TG|Bevacizumab treatment group with metastasized cancer
3185928|NCT00740194|Experimental|1|Aromatase inhibition
2414813|NCT03471429||No Dog|Patient receives standard of care
3185929|NCT00740194|Active Comparator|2|Estradiol
3185930|NCT00740272|Experimental|1|AF ablation + pacemaker
3185931|NCT00740272|Active Comparator|2|Pacemaker
3185932|NCT00740285|Experimental|1|
2414748|NCT03471949|Experimental|CGM in a population with normal OGTT|A non-randomized, days 1-7 blinded, and days 8-14 non-blinded Dexcom G4 (CGM) trial. Each subject will sample capillary blood with the HemoCue meter and measure the concentration of glucose, minimum 3 times per day for 14 days.
2414749|NCT03471936|Other|Acquisition of pressure-volume loops|
2414750|NCT03471923||CD Patients|Subjects must have a prior diagnosis of cervical dystonia and be capable of participating in all study procedures. Subjects will undergo assessment of non-motor features.
2414751|NCT03471923||Family Members|Subjects must be a first order relation of a Vanderbilt patient diagnosed with cervical dystonia. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
2414752|NCT03471923||Healthy volunteers|Subjects must be healthy volunteers who are neurologically normal. The subject must pass a short neurological examination to ensure the subject does not have cervical dystonia or any sensory deficits. Subjects will undergo assessment of non-motor features.
2414753|NCT03471910|Experimental|Diosmin|Diosmin 600mg, one tablet once daily
2414754|NCT03471910|Active Comparator|Diosmin + Hesperidin|Diosmin 900mg + Hesperidin 100mg, one tablet once daily
2414755|NCT03471897||RCC|Patients with pathologically confirmed diagnosis of RCC
2414756|NCT03471897||Controls|Subjects self-reported as healthy
2414757|NCT03471884|Experimental|Nonintubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
2414758|NCT03471884|Active Comparator|Intubated thoracoscopic lobectomy|Lung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
3185933|NCT00740285|Placebo Comparator|2|
2414764|NCT03471858|Active Comparator|Cervical Balloon|Transcervical 2-way 18 French (18F) single balloon Foley catheter, applied using a sponge-holding forceps into the cervical canal with the balloon inflated to a minimum of 30ml and maximum of 60ml with sterile water or saline [1]. This will be administered once during the study and will be retained for a maximum of 12 hours within the 24 hour study period.
2414765|NCT03471858|Active Comparator|Prostaglandin|Prostaglandin E2 (Prostin®) 3mg tablet, placed high in the vaginal fornix. This will be administered per vaginum once in the first 6 hours; a second dose is administered at the discretion of the clinician / clinical team 6 hours after the first pessary, for a cumulative total of 6mg within the 24 hour study period.
3145449|NCT00071526||Healthy Volunteers|Healthy Volunteers
2414769|NCT03471819||Patients withf Atopic Dermatitis|Diagnosis is based upon American Academy of Dermatology recommendations for Diagnostic Criteria 2014.
2414770|NCT03471819||healthy volunteers|Normal individuals not complaining of any dermatological diseases
2414771|NCT03471806|Experimental|Bulimia Nervosa patients|Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
2414772|NCT03471806|Experimental|Healthy controls|Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
2414773|NCT03471793||Colonic polyp|Patients referred for EMR of a colonic polyp >20mm
2414774|NCT03471767|Experimental|AXS-05|Participants will receive AXS-05 (Dextromethorphan Immediate Release + Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
2414775|NCT03471767|Active Comparator|Bupropion SR|Participants will receive Bupropion SR (Bupropion Sustained Release) for 4 weeks and will be instructed to take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
2414776|NCT03471754|Experimental|Treatment Arm A|TESA-HB Device, Mode 3 (15mA). Treatment arm involves two 5-day treatment cycles over a 2-week period, with 2 days off between each of the 5-day cycles. The treatment period will as for two full weeks.
2414811|NCT03471442|Experimental|Erector spinae plane|Ultrasound-guided erector spinae plane block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
3145450|NCT00071539|Experimental|TP38 50 ng/mL|
3145451|NCT00071539|Experimental|TP38 100 ng/mL|
3145452|NCT00071565||1|475 families with multiple affected family members (phase I) 200 families with multiple affected family members (phase II) 1800 subjects with sporadic intracranial aneurysms
3145453|NCT00071578|Experimental|1|Group therapy Negative Emotion Focus
3145454|NCT00071578|Placebo Comparator|2|Group Psychotherapy- Self Esteem Focus
3145455|NCT00071617|Experimental|Youth-Nominated Support Team|Adolescents nominate up to 4 caring adults from family, school, community settings. These adults participate in psychoeducation sessions regarding adolescent's treatment plan and support needs. They maintain regular, supportive contact with the adolescent for 3 months -- with ongoing consultation and support check-ins from study clinical staff.
3145456|NCT00071617|No Intervention|Enhanced Treatment as Usual|Adolescents in this condition receive study assessments and risk management services (at time of assessments) only
3145457|NCT00071643|Experimental|1 Problem Solving Therapy|Participants will receive problem solving therapy.
3145458|NCT00071643|Experimental|2. Escitalopram|Participants will receive escitalopram.
3145459|NCT00071643|Placebo Comparator|3 Placebo|Participants will receive placebo.
3145460|NCT00071773|Active Comparator|Modified Early Treatment Diabetic Retinopathy Study (ETDRS)|modified-ETDRS
3145461|NCT00071773|Active Comparator|Mild Macular Grid (MMG)|MMG technique
3145463|NCT00071916||African American|Adult African American participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
3145464|NCT00071916||Caucasian|Caucasian participants with compensated chronic hepatitis C who have not been previously been treated with interferon and/or ribavirin.
3145465|NCT00071942|Experimental|Treatment (vaccine therapy)|Patients receive vaccination comprising recombinant vaccinia-MUC-1 and recombinant vaccinia-TRICOM vaccine intradermally on days 1 and 29 (for a total of 2 doses) in the absence of disease progression or unacceptable toxicity.
3145466|NCT00071994|Experimental|Treatment (gefitinib)|Patients receive oral gefitinib daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2414777|NCT03471741||MARA-2: IMRT with concomitant boost|A forward planned IMRT technique was used and the prescribed dose to the whole breast was 50 Gy plus a concomitant boost of 10 Gy to the tumor bed
2414778|NCT03471741||CG: 3D-RT with sequential boost|The whole breast received 50.4 Gy in 28 fractions delivered with 3D-RT, followed by a sequential boost on the tumor bed of 10 Gy in 4 fractions delivered with electrons
3145467|NCT00072033|Active Comparator|Arm A|Docetaxel and Cisplatin chemo- and radiochemotherapy followed by surgery
3145468|NCT00072046|Experimental|Interferon|Treatment with interferon alfa 2b
2414781|NCT03471702|Experimental|Single Arm Study|All subjects enrolled on study will utilize Aqueduct's Smart External Drain (SED) from the time of external drain implementation until end of study upon discharge of SED or switch to standard of care external drain.
2414782|NCT03471689|Experimental|Mindfulness|
2414783|NCT03471689|Active Comparator|Positive reappraisal|
2414785|NCT03471663|Experimental|D-0502|D-0502
2414786|NCT03471663|Experimental|D-0502 in combination with palbociclib|D-0502 in combination with palbociclib
2414787|NCT03471650|Experimental|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
2414788|NCT03471637|Experimental|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
3145469|NCT00072046|Experimental|Interferon + bevacizumab|Addition of bevacizumab to interferon alfa 2b treatment
2414790|NCT03471611|Experimental|Subjects with Endothelial Dysfunction|Subjects will be treated with Granulocyte Colony-Stimulating Factor (G-CSF) for 5 days at a dose of 5 mg/kg twice daily. When count of CD34+ cells is sufficient, the CD34+ cells will be collected by apheresis. Autologous CD34+ cells will be injected into the subjects at a rate of 10 ml/min.
2414791|NCT03471585|Placebo Comparator|Placebo oral capsule|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the THC arm.
2414792|NCT03471585|Experimental|THC|Participants came in for the first session that involved encoding emotional pictures and lists of semantically related words (Deese-Roediger-McDermott or DRM task; a false memory task). Forty-eight hours later, participants received a placebo capsule (dextrose) and waited 2 hours Participants were monitored for the next 2 hours including physiological and subjective measures every 30 minutes. After 2 hours, participants' memory for the emotional stimuli and DRM stimuli was tested. Participants then encoded object stimuli overlaid onto scenes followed by a working memory test with simple color squares. After the memory tests and 3.5 hours post-capsule, if participants' physiological and subjective measures had returned to baseline, they were allowed to leave. Forty-eight hours later, memory for the object-scene stimuli was tested. Other than the capsule, this arm was identical to the placebo arm.
2414793|NCT03471572||1|Ovarian Cancer
2414794|NCT03471559|Active Comparator|Reference formulation|Cannabidiol capsule, 200 mg
2414795|NCT03471559|Experimental|New formulation|Cannabidiol, intranasal gel (XX mg, dose need to be determined during the study)
2414796|NCT03471546|Experimental|Palliative care|Newly diagnosed patients will be referred to a palliative care provider in the clinic for initial consultation and follow-up during their initial treatment for WHO Grade IV malignant glioma. Patients will be asked to complete a number of questionnaires and assessment forms at different time intervals during the course of their initial treatment. In addition, we will ask patients' neuro-oncology providers for feedback regarding their satisfaction with the Palliative Care services provided to the patient.
2414797|NCT03471533|Experimental|Ëxperimental|"Consumption during 84 days of Lippia citriodora 325 mg + Hibiscus sabdariffa 175 mg.~Two capsules a day will be consumed thirty minutes before breakfast for 84 days."
2414798|NCT03471533|Placebo Comparator|Placebo|Consumption during 84 days of saccharose. Two capsules a day will be consumed thirty minutes before breakfast for 84 days.
3145470|NCT00072098|Experimental|Experimental Group|Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene
2414800|NCT03471507|Experimental|Bonipar|
2414801|NCT03471507|Active Comparator|Diclofenac topical solution 1.5%|
2414802|NCT03471494||Breast cancer|
2414803|NCT03471494||Gastric cancer|
2414804|NCT03471494||Colon cancer|
2414805|NCT03471468|Experimental|kinetics of microparticles under chemotherapy|kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.
2414806|NCT03471455|Active Comparator|Terbinafine alone|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks.
2414807|NCT03471455|Active Comparator|Terbinafine plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral terbinafine 250 mg once a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
2414808|NCT03471455|Active Comparator|Itraconazole only|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks.
2414809|NCT03471455|Active Comparator|Itraconazole plus isotretinoin|Patients of recurrent dermatophytosis (recurrent episodes for more than 6 months) will receive oral itraconazole 200 mg twice a day for 4 weeks and oral isotretinoin 20 mg/ day for 6 months.
2414810|NCT03471442|Active Comparator|Paravertebral|Ultrasound-guided paravertebral block performed pre-operatively with 20ml of a ropivacaine / bupivacaine mixture.
3185934|NCT00740298|Active Comparator|1|Sweet Taste
2414814|NCT03471416||Children with ALL|Children undergoing ALL treatment at UNOP Guatemala who are under the age of 18 years.
2414815|NCT03471403||FAP|FAP patients with duodenal adenomas
2414816|NCT03471390|Experimental|ProQuaS 2- Intervention|
2414817|NCT03471377||standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long.
2414818|NCT03471377||assigned a planned case duration value from predictive model|Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.
2414821|NCT03471351|Experimental|Tenalisib+Pembrolizumab|Participants receive Tenalisib in escalating doses Orally BID and pembrolizumab as a fixed dose intravenously (IV) in Escalation and Expansion.
2414822|NCT03471338|Experimental|Experimental Group|Patients benefit cognitive rehabilitation
2414823|NCT03471338|Sham Comparator|Standard Psychological care|Patients do not benefit cognitive rehabilitation
2414824|NCT03471325|Experimental|Plaque Disclosed with Air Flow (PDAF)|Plaque will be disclosed prior to polishing with the air flow system.
2414825|NCT03471325|Experimental|Plaque Disclosed with Rubber Cup (PD-RC)|Plaque will be disclosed prior to polishing with the rubber cup and fine grit prophylaxis paste.
2414826|NCT03471325|Experimental|Non Plaque Disclosed Air Flow (NPD-AF)|Air polishing system will be used to remove the plaque
2414827|NCT03471325|Placebo Comparator|Non Plaque Disclosed Rubber Cup (NPD-RC)|Rubber Cup polishing to remove plaque.
2414828|NCT03471312||treated with magnesium therapy|will receive magnesium sulphate 10 mg \kg \day as a single oral dose for one month duration
2414829|NCT03471312||treated with placebo drug|will receive placebo drug
2414830|NCT03471286|Experimental|Sub-Protocol A|Epacadostat
2414831|NCT03471273|Other|endoscopic management|
2414832|NCT03471273|Other|follow up|
2414833|NCT03471273|Other|surgery|
2414834|NCT03471260|Experimental|Treatment (venetoclax, ivosidenib, azacitidine)|Patients receive venetoclax PO daily on days 1-14. Patients also receive ivosidenib PO daily on days 15-28 of cycle 1 and days 1-28 of subsequent cycles. Patients may also receive azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145471|NCT00072137|Experimental|Arm A (rf-GM-CSF, closed to accrual 10/2004)|Patients receive recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3185935|NCT00740298|Active Comparator|2|warmth
2414837|NCT03471221|Experimental|Therapy Dog Visits|"Participants randomized to Therapy Dog Visits will receive a visit from a therapy dog and handler team up to one time per week for up to four weeks, depending on length of hospitalization and therapy dog team capacity.~Therapy dog visits will last up to about 20 minutes and activities may include: petting the dog, watching the dog perform a trick, and talking with the dog handler.~All activities will follow the current procedures and regulations in place at Seattle Children's Hospital."
2414838|NCT03471221|No Intervention|Control Group|Participants randomized to the Control Group will receive usual medical care.
2414839|NCT03471208|Experimental|Dynamic Navigation|Dental implant surgery via dynamic navigation assistance
2414840|NCT03471208|Active Comparator|Freehand|Dental implant surgery via conventional freehand
2414841|NCT03471195||CP|A total of 20 children with cerebral palsy and dental decay will undergothe following Collection of Saliva Total Salivary Cytokine Profile
2414842|NCT03471195||Control|A total of 20 verbal children without cerebral palsy matched for age and extent of dental decay will undergo the following Collection of Saliva Total Salivary Cytokine Profile
2414843|NCT03471182|Active Comparator|Psychiatric and Cognitive Testing|All participants will complete psychiatric assessment and cognitive testing.
2414844|NCT03471182|Active Comparator|Cocaine Self-adminstration|This arm plans to assess the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug in a human laboratory study of self-regulated cocaine administration.
2414845|NCT03471182|Active Comparator|Positron Emission Tomography|All participants will complete a PET scan to assess mGluR5 receptors using [18-F]FPEB
2414846|NCT03471182|Active Comparator|Magnetic Resonance Imaging|All participants will complete one MRI scan to assess brain structure and function.
2414847|NCT03471169|Experimental|Desirable TEG|Patients receiving antiplatelet medication and desirable thrombelastogram(TEG) test results.
2414848|NCT03471169|Sham Comparator|Undesirable TEG|Patients receiving antiplatelet medication and undesirable thrombelastogram(TEG) test results.
2414849|NCT03471156||Post EMR|Patients are observed post EMR procedure for pain. Standard of care data is collected
2414850|NCT03471143|Experimental|IV VTS-270 for NPC1 infants|"Phase 1: Dosing frequency will be twice a week administered via a peripherally inserted central catheter (PICC) for six weeks for a total of 12 administrations. Doses 3-12 will occur as an outpatient.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6 will receive 500 mg/kg Cohort 2: Subjects 7-12 will receive 1000 mg/kg Subjects who demonstrate significant reduction either in the glycine-conjugated trihydroxycholanic acid biomarker or serum bilirubin (direct bilirubin or direct bilirubin:total bilirubin ratio) will be allowed to crossover into the second phase of the study, an open-label phase of six months duration. In the this phase of the study, dosing frequency will be monthly with IV VTS-270 administered via peripheral IV access for six months for a total of six administrations."
2414851|NCT03471130|Experimental|Low dose MT-8554 or placebo to match|Low dose MT-8554
2414852|NCT03471130|Experimental|High dose MT-8554 or placebo to match|High dose MT-8554
2414886|NCT03470896|Other|Bis traditional consultation|"If a patient, in the group  preanesthesia teleconsultation  cannot realized his teleconsultation because of technical problem, he will be assigned on the sub group  bis traditional preanesthesia consultation ."
3185936|NCT00740311|Experimental|Filling|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
2414853|NCT03471117|Active Comparator|Pioglitazone|The subjects will be given 1 month supply of Pioglitazone pills. Pioglitazone is a class of anti-diabetic drugs called thiazolidinediones that are primarily used in the treatment of type 2 diabetes. The aim of the study is to determine if Pioglitazone also reduces ADMA and sympathetic nerve activity in CKD patients. This drug will be taken orally as a pill or capsule for one month. The dosage is 15 mg/day. This is on the lower dosage side for pioglitazone with the maximum dosage being 45mg/day. The research subjects are not responsible for the cost of the drug or for drug administration costs. The subjects will be verbally instructed to take 1 pill everyday by mouth, for 1 month. In addition, the pill bottle will be labeled with the same instructions.
2414854|NCT03471117|Placebo Comparator|Placebo|Placebo pills are made of avicel microcrystalline cellulose and magnesium stearate, which are inactive ingredients in the Pioglitazone pills. The placebo pills will be of similar color and appearance as the Pioglitazone pills
2414855|NCT03471104|Experimental|PAID in clinical diabetes consultations|Participants randomised to the intervention arm. Participants complete the Problem Area in Diabetes scale (PAID) and evaluation PROMs. Participants with specified PAID scores will be offered an empowerment-based follow-up by diabetes specialist nurses.
2414856|NCT03471104|No Intervention|Control group|Participants randomised to the control group. Participants complete PROMs but the results/answers will not be available in the electronic patient records until the trial is finished. The participants will receive standard care.
2414857|NCT03471091|Experimental|Intervention group|"Intervention group subjects will use NIV with the integrated tele-monitoring management program as home therapy and accomplish the following tasks via mobile COPD Butler APP: 1) upload daily NIV usage data， blood pressure, oxygen saturation, and heart rate measurement; 2) daily medication taken recording; 3) regular self-reported health questionnaire and symptom recording; 4) read health education materials.~Information collected from the intervention group by the APP will be monitored by physician team from the leading hospital through physician web portal. The physician team will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly."
2414858|NCT03471091|No Intervention|Control group|Control group subjects will only use NIV according to their treatment plan at home. NIV usage data will be read from the NIV secure digital memory card for the control group.
3145472|NCT00072137|Experimental|Arm B (rf-TRICOM, closed to accrual 10/2004)|Patients receive recombinant fowlpox-TRICOM vaccine intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3145473|NCT00072137|Experimental|Arm C (rfTRICOM and rf-GM-CSF)|Patients receive recombinant fowlpox-TRICOM vaccine combined with recombinant fowlpox GM-CSF vaccine adjuvant intravesically over 2 hours for 4 weekly doses (on days 1, 8, 15, and 22) with the last dose given 4-6 days prior to cystectomy.
3185937|NCT00740311|No Intervention|Without filling|
2414862|NCT03471052|Experimental|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)
2414863|NCT03471052|No Intervention|Sham procedure|Endoscopy will be performed under conscious sedation and all BarrX RFA equipment will be set up in room. A sound recording of the BarrxTM RFA device will be played (a distinct bell sound that is emitted from the generator) during the procedure.
2414864|NCT03471039|Active Comparator|Active|PACAP-27
2414865|NCT03471039|Placebo Comparator|Placebo|Saline
2414866|NCT03471026||pCMS+|Children undergoing infratentorial craniotomy for brain tumour resection whom develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
2414867|NCT03471026||pCMS-|Children undergoing infratentorial craniotomy for brain tumour resection whom do not develop pCMS will undergo pre-, post-operative and delayed follow-up advanced MRI sequences
2414868|NCT03471026||Controls|Healthy control children whom have never undergone intracranial surgery have had advanced MRI sequences acquired
2414869|NCT03471013||Patients and caregivers|Patients suffering from schizophrenia accompanied by their caregiver
2414870|NCT03471000|Experimental|Short implants Treatment|Group 2 (G2; n=15 patients) had short implants (OsseoSpeed ™ L6mm Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed without sinus lift and augmentation procedure.
2414871|NCT03471000|Active Comparator|Regular Implants Treatment|Group 1 (G1; n=15 patients) had conventional dental implants (OsseoSpeed ™ L11 Ø4 mm and L13 Ø4 mm) [DENTSPLY Implants, Waltham, MA, USA] placed, preceded by the sinus lift procedure from a lateral window approach with the application of the xenogeneic bone graft Geistlich Bio-Oss® [Geistlich AG, Wolhusen, Switzerland]. The lateral window approach sinus lift surgery was performed 6 weeks prior to the implant placement by the same surgeon.
2414872|NCT03470987||Group 1:nO-Ctrl|Non-obese patients without generalized chronic periodontitis who were undergone Phase I periodontal therapy
2414873|NCT03470987||Group 2:nO-CP|Non-obese patients with generalized chronic periodontitis who were undergone Phase I periodontal therapy
2414874|NCT03470987||Group 3: O-Ctrl|Obese patients without generalized chronic periodontitis who were undergone metabolic control and Phase I periodontal therapy
2414875|NCT03470987||Group 4: O-CP|Obese patients with generalized chronic periodontitis who were undergone metbolic control and Phase I periodontal therapy
2414876|NCT03470974|Experimental|Intervention Group|The intervention group receives self-titration strategy training and lifestyle education.
2414877|NCT03470974|No Intervention|Control Group|The control group receives usual care and lifestyle education.
2414878|NCT03470961|Experimental|Anti-Tlymphocyte Globulins|intravenous，2mg/kg/d，for 5 days
2414879|NCT03470961|Active Comparator|Anti-thymocyte Globulins|intravenous，1.5mg/kg/d，for 4 days
2414880|NCT03470922|Experimental|Arm A: Relatlimab + Nivolumab|Combination
2414881|NCT03470922|Experimental|Arm B: Nivolumab|Monotherapy
2414882|NCT03470909|Other|Skin-Sparing Mastectomy (SSM)|
2414883|NCT03470909|Other|Nipple-Sparing Mastectomy (NSM)|
2414884|NCT03470896|Active Comparator|Preanesthesia teleconsultation|Preanesthesia teleconsultation through video-conference, between an anesthesiologist of the surgical center Emile Galle, in a medical consulting room in the surgical center Emile Galle, and a patient at home or at work. The patient must be in a quiet area, which allows the confidential medical contact.
2414885|NCT03470896|Active Comparator|Preanesthesia traditional consultation|Preanesthesia traditional consultation between an anesthesiologist of the surgical center Emile Galle, and a patient, in a medical consulting room in the surgical center Emile Galle.
2414887|NCT03470883||endoscopic resection of a colorectal lesion|Patient having undergone endoscopic resection of a colorectal lesion stage 4 or 5 of the modified Vienna classification during the last 5 years at the institute.
2414888|NCT03470870||Patients discharged before 2 days after surgery|patients discharged before 2 days of hospitalization following surgery
2414889|NCT03470870||Patients discharged after 2 days after surgery|patients discharging after 2 days of hospitalization following surgery
2414890|NCT03470857||Patients|Oncological patients: lymphomas (Hodgkin's, DLBCL), breast and ovarian cancers, brain gliomas.
2414891|NCT03470857||Control|The number at most half as large as the patients' group, composed of healthy people at similar age and the same sex as patients.
2414892|NCT03470844||5-10 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2414893|NCT03470844||2-5 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2414894|NCT03470844||1-2 years post severe burn injury|"Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2414895|NCT03470844||Control|"Healthy age, gender, socioeconomic and educational level matched control.~Interventions:~Face-to-face neurocognitive tests examining attention, processing speed, working memory and executive function.~Psychological screening for the symptoms of depression, anxiety and post-traumatic stress disorder using the patient health questionnaire (PHQ9), generalised anxiety (GAD7) scoring systems and the trauma screening questionnaire.~fMRI studies including resting state fMRI, T1w-mpr, T2w-FLAIR, Diffusion Tensor Imaging (DTI) with 30 directions, Spectroscopy CSI chemical shift imaging, Spectroscopy SVS single voxel, susceptibility weighted imaging (SWI), double inversion recovery (DIR) and Perfusion ASL.~Quality of Life Self-Assessment data."
2414896|NCT03470818|Experimental|Intervention group|"Preparatory instructional videos (flipped classroom model)~32 participants~Application of a flipped classroom model~Prior to the simulation session, the intervention group will have received the study intervention. This consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
2414897|NCT03470818|Sham Comparator|Control group|"Sham videos~Participants in the control group will also be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility.~This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
2414898|NCT03470805|Experimental|Olaparib|Olaparib orally twice daily at 150 mgs bid continually
2414899|NCT03470792|Experimental|Microcirculation-assisted|ECMO blood flow will be adjusted by conventional clinical conditions, hemodynamic parameters and microcirculation parameters
2414900|NCT03470792|Active Comparator|Control|ECMO blood flow will be adjusted by clinical conditions and conventional hemodynamic parameters
2414901|NCT03470779|Experimental|Treatment group|Participants randomly assigned to the treatment group will participate in an interdisciplinary treatment program in which local Kurdish psychotherapists and physiotherapists provide a 10-week intervention program. Treatment will consist of group physiotherapy and group psychotherapy
2414902|NCT03470779|No Intervention|Wait-list group|Participants randomly assigned to the wait-list group will not receive treatment but will participate in outcome data collection for comparison purposes.
2414903|NCT03470766|Active Comparator|Active Lead (AL)|One octad lead placed where contacts 4 and 5 span the T9-T10 disc space.
2414904|NCT03470766|Sham Comparator|Sham Lead (SL)|One octad lead implanted subcutaneously behind the IPG and will serve to dissipate the current from the battery
2414905|NCT03470753|Active Comparator|Exercise Amount|Phase 1: 2 or 4 exercises.
2414906|NCT03470753|Active Comparator|Type of instruction|Phase 1: Handout on paper versus handout and visual demonstration/performance.
2414907|NCT03470753|Active Comparator|Delivery Type|Phase 2: Handout vs electronic delivery
2414908|NCT03470753|Experimental|Reminder Type|Phase 2: Mobile reminders vs no mobile reminders
3185938|NCT00740324|Active Comparator|N|
3185939|NCT00740324|Active Comparator|B|
2416051|NCT03463187|Experimental|80mg SHR-1314 (Part B)|SHR-1314 80mg, subcutaneously
3185940|NCT00740324|Active Comparator|G|
3185941|NCT00740337||COPD|Participants in this group will be people who have COPD and plan to undergo lung resection surgery at Barnes-Jewish Hospital (BJH).
3185942|NCT00740337||Control|Participants in this group will be people who do not have COPD and plan to undergo lung resection surgery at BJH.
2414911|NCT03470727|Experimental|Citrate arm|Citrate dialysate Phase 1 : Reduce heparin to 50% Phase 2: Reduce heparin to 25% Phase 3: Heparin free
2414912|NCT03470714|Experimental|Kinesiotaping Group|The group in which kinesiotaping is applied to non-dominant biceps brachii muscle of participants before 24 hours the force irradiation experiment.
2414913|NCT03470714|Active Comparator|Control group|The group in which the participants only perform the the force irradiation experiment.
2414914|NCT03470701|No Intervention|Control - usual care|This arm will receive usual care.
2414915|NCT03470701|Experimental|Mailed Urinalysis Smartphone Kit|This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
2414916|NCT03470688||Originator|Originator anti-TNF agents. Dosage as per physician's decision based on approved indication.
2414917|NCT03470688||Biosimilar|Biosimilar anti-TNF agents. Dosage as per physician's decision based on approved indication.
2414918|NCT03470675|Placebo Comparator|Epidural saline + IV saline|Sterile saline via the epidural catheter. Sterile saline via intravenous catheter.
2414919|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV saline|3 milligrams morphine via the epidural catheter. Sterile saline via intravenous catheter.
2414920|NCT03470675|Active Comparator|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|3 milligrams morphine via the epidural catheter. Ketamine 0.3 milligrams per kilogram via intravenous catheter.
2414921|NCT03470662|Experimental|experimental group|Care bundle
2414922|NCT03470662|No Intervention|control group|routine care
2414923|NCT03470649|Experimental|Treatment|Patients in this group would receive Iron Isomaltoside 1000 (Monofer®) after main procedure of total knee arthroplasty. The dose of iron isomaltoside would be determined based on the patient's body weight.
2414924|NCT03470649|No Intervention|Control|Patients in this group would receive 100ml of normal saline after main procedure of total knee arthroplasty.
2414925|NCT03470636|Experimental|HeartLight X3|Pulmonary vein isolation using HeartLight X3
2414926|NCT03470623|Experimental|bioabsorbable screws|hallux valgus treated with chevron osteotomy using bioabsorbable screws
2414927|NCT03470623|Experimental|steel screws|hallux valgus treated with chevron osteotomy using steel screws
2414928|NCT03470597||Pregnant women with pre-gestational HSG history|All enrolled pregnant women with pre-gestational ethiodized-oil HSG will be followed up without grouping and be kept track for maternal and offspring's health outcomes in this case registry study.
2414929|NCT03470584||Tzu Chi Vegetarian Study|12062 Tzu Chi volunteers of the Buddhist Tzu Chi Foundation recruited throughout communities in Taiwan in the year 2005. All participants filled out a self-administered questionnaire on basic information, medical history, lifestyle, and diet. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
2414930|NCT03470584||Tzu Chi Health Study|6002 participants who came for health examination at the Dalin Tzu Chi Hospital between the years 2007 to 2009. 77% were Tzu Chi volunteers. All participants were interviewed on a structured questionnaire including basic information, medical history, lifestyle, and diet, and received a comprehensive health examination. Diet exposure: 1/3 vegetarians, 2/3 nonvegetarians.
2414931|NCT03470558||Sleeve gastrectomy patients|Patients electing to undergo sleeve gastrectomy will monitor their dietary habits.
3185943|NCT00740350|Experimental|Experimental|Logan Basic chiropractic adjustments during pregnancy.
3185944|NCT00740363|Experimental|A|Patients will receive 4 weeks of treatment with sitagliptin once daily
2414934|NCT03470532|Experimental|Group A|buccal infiltration of 4% Articaine with epinephrine
2414935|NCT03470532|Active Comparator|Group B|buccal infiltration of 2% Mepivacaine with epinephrine
2414936|NCT03470506||Ischemic stroke|Diagnosed with an ischemic stroke by a Neurologist
2414938|NCT03470480|Experimental|Treatment rTMS + meth pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving real rTMS treatments. This group will be referred to as real METH (RM).
2414939|NCT03470480|Active Comparator|Treatment rTMS + neutral pictures|Participants in this group will receive real repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving real rTMS treatments. This group will be referred to as real neutral (RN).
2414940|NCT03470480|Sham Comparator|Sham rTMS + meth pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of methamphetamine-related pictures to evaluate response to methamphetamine visual cues while receiving sham rTMS treatments. This group will be referred to as sham METH (SM).
2414941|NCT03470480|Sham Comparator|Sham rTMS + neutral pictures|Participants in this group will receive sham repetitive transcranial magnetic stimulation treatments. Before each rTMS session they will be exposed to a series of neutral pictures to evaluate response to neutral visual cues while receiving sham rTMS treatments. This group will be referred to as sham neutral (SN).
2414942|NCT03470454||diabetics on linagelptin|Diabetic patients were given linagelptin for blood glucose control
2414943|NCT03470454||diabetics on other DPP4 inhibitors|Diabetic pateints were given other DPP4 inhibitors eg: vlidagliptin for blood glucose control
2414948|NCT03470428||Pediatric Fontan Patients|Participants ages 10 to 18 who have had Lateral Tunnel or Extracardiac Fontan procedures.
2414949|NCT03470428||Adult Fontan Patients|Participants ages 18 to 60 who have had Lateral Tunnel or Extracardiac Fontan procedures.
2414950|NCT03470415||Group A|Patients with type 2 diabetes milletus with normoalbuminuria.
2414951|NCT03470415||Group B|Patients with type 2 diabetes milletus with microalbuminuria.
2414952|NCT03470415||Group C|Patients with type 2 diabetes milletus with macroalbuminuria.
2415105|NCT03469284|Experimental|Group 2 (medium dose methylene blue, standard of care)|Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
2414953|NCT03470402|Experimental|Intervention group|"Women who screen as eligible for BRCA genetic counseling will receive the education and decision support tool, RealRisks, along with standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).~The enrolled health care providers of these women will be given access to BNAV, which summarizes their enrolled patients' breast cancer risk profiles and provides educational resources on genetic testing and prevention options. Before their clinical encounter with an enrolled patient, these providers will also be sent the personalized breast cancer risk summary that is created by data the patient entered into RealRisks."
2414954|NCT03470402|Active Comparator|Control group|Women who screen as eligible for BRCA genetic counseling will receive standard educational material and a high-risk message. The high-risk status of the women will also be flagged in the online tool used by the hospital to visualize electronic health record data (iNYP).
2414955|NCT03470389|Experimental|HVPG|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
2414956|NCT03470376|Experimental|Nutraceutical combination (NC)|Patients on standardized diet regimen taking a NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day for 3 months
2414957|NCT03470376|Active Comparator|No nutraceutical combination (noNC)|Patients on standardized diet regimen without taking any NC
2414958|NCT03470363|Active Comparator|Group Spinal anesthesia|"Knee surgery under spinal anesthesia~Intervention involves spinal administration of 12,5 mg bupivacaine and 2,5 microgram sufentanil."
2414959|NCT03470363|Active Comparator|Group Sevoflurane anesthesia|"Knee surgery under sevoflurane anesthesia~Intervention involves administration of inhaled sevoflurane for maintenance of general anesthesia"
2414960|NCT03470350|Experimental|TGF-beta activated colorectal cancer|TGF-beta activated advanced colorectal cancer treated with galunisertib and capecitabine
2414961|NCT03470337|Experimental|Phlogenzym|Treatment with German licensed drug Phlogenzym (6 tablets/day)
2414962|NCT03470337|Placebo Comparator|Placebo|Placebo equates Phlogenzym but without active ingredients
2414963|NCT03470324|Active Comparator|[standard STN] + swallowing therapy|standard stimulation on subthalamic (STN) contacts plus swallowing therapy
2414964|NCT03470324|Experimental|[STN+SNr] + swallowing therapy|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) plus swallowing therapy
2414965|NCT03470311|Active Comparator|Benralizumab|Benralizumab 30mg in 1mL subcutaneously
2414966|NCT03470311|Placebo Comparator|Placebo|Matched placebo (1mL) to active Benralizumab subcutaneously
2414967|NCT03470298|Active Comparator|Mid luteal Endometrial Scratching (MLES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 . At this arm scratching done at mid luteal phase (day21) of the cycle before induction for ICSI
2414968|NCT03470298|Active Comparator|Retrieval Endometrial Scratching (RES)|Making injury to endometrium by using Manual Vacuum Aspiration cannula size 5 .Here scratching done at same day of ovum pick up of ICSI cycle the difference only between arm of MLES and RES only in the timing of scratching .
2414969|NCT03470285|Other|Patients with small solid renal tumor|In addition to the actual workflow for a patient presenting a renal tumor, patients will undergo an additional Multiparametric MR imaging (mpMRI).
2414970|NCT03470272|Experimental|Active Device|"Active Device: The FB Professional LED red light therapy system~FB Professional is a treatment regime using the FB Professional device for fat removal using red light therapy.~Intervention device: FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs."
2414971|NCT03470259|Experimental|EMI-137 0.09mg/kg administration|"Three patients will be once administered with EMI-137 0.09 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2414972|NCT03470259|Experimental|EMI-137 0.13mg/kg administration|"Three patients will be once administered with EMI-137 0.13 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2414973|NCT03470259|Experimental|EMI-137 0.18mg/kg administration|"Three patients will be once administered with EMI-137 0.18 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2414974|NCT03470259|Experimental|EMI-137 0.045mg/kg administration|"If we have a excellent tumor to background ratio ((tumor fluorescence)/(surrounding tissue fluorescence)) in the 0.09 mg/kg group, we will de-escalate back to a 0.045 mg/kg group to evaluate TBR and reduce possible tracer toxicity in a thyroid cancer population with 90% 20 year survival.~Three patients will be once administered with EMI-137 0.045 mg/kg. Thereafter the patient will be observed for an hour. Two hours after injection surgery will be performed and only ex-vivo imaging and spectroscopy will be performed of thyroid glands and lymph nodes with a multispectral Near Infrared Fluorescence (NIRF) camera system and spectroscopy system.~After interim analysis will be decided if this dosage group has an adequate tumor-to-background ratio and dose extension will be performed."
2414975|NCT03470246|No Intervention|CABG control group|The group of coronary artery disease patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2415106|NCT03469284|Experimental|Group 3 (higher dose methylene blue, standard of care)|Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
2414976|NCT03470246|Experimental|PACO intervention for CABG patients|The group of coronary artery disease patients receiving the PACO intervention for CABG patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after coronary artery bypass grafting. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2414977|NCT03470246|No Intervention|AVR control group|The group of aortic valve stenosis patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2414978|NCT03470246|Experimental|PACO intervention for AVR patients|The group of aortic valve stenosis patients receiving the PACO intervention for AVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after aortic valve replacement. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2414979|NCT03470246|No Intervention|MVR control group|The group of mitral valve insufficiency patients receiving the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The post-operative rehabilitation includes written and oral physical activity guidance from a physiotherapist.
2414980|NCT03470246|Experimental|PACO intervention for MVR patients|The group of mitral valve insufficiency patients receiving the PACO intervention for MVR patients besides the standard postoperative rehabilitation of Kuopio and Turku university hospitals after mitral valve repair. The PACO intervention includes activity guidance (i.e. goals to improve daily steps and physical activity levels, and reduce prolonged sitting) provided to the patients with the novel combination of ExSed application, MoveSense accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be included to the intervention.
2414981|NCT03470220||Ultrasound|All included patients will be examined with ultrasound
2414982|NCT03470207|No Intervention|Post-Intervention Cohort (Aim 1)|This arm will not have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
2414983|NCT03470207|Experimental|Pre-Intervention Cohort (Aim 3)|This arm will have the intervention of the implementation of the structured post-pulmonary embolism follow up protocol that is outlined in Aim 1.
3185945|NCT00740363|Placebo Comparator|B|No treatment for 4 weeks
2414986|NCT03470181||Participants with Diagnosed CVS|This cohort will consist of 15 current patients previously diagnosed with Cyclic Vomiting Syndrome.
2414987|NCT03470181||Healthy Volunteers|This cohort will consist of 15 healthy volunteers, with no history of Cyclic Vomiting.
2414988|NCT03470168|Experimental|Hyperbaric Oxygen Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
2414989|NCT03470168|Placebo Comparator|Placebo group|were also taken inside the Hyperbaric Chamber, but received only normobaric oxygen therapy for the same period of time at 1 ATA
2414991|NCT03470142|Active Comparator|traditional laparoscopy-assisted surgery|The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
2414992|NCT03470142|Experimental|total laparoscopic surgery with no incision (NOSES)|The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice such as anal.
2414993|NCT03470129|Active Comparator|Helioseal F|fissure sealing with the conventional product
2414994|NCT03470129|Experimental|Helioseal F Plus|fissure sealing with the new product
2414995|NCT03470116|Experimental|MacGrath MAC video laryngoscopy|Patients will benefit MacGrath MAC video laryngoscopy for intubation after curarization
2414996|NCT03470116|Active Comparator|direct laryngoscopy|Patients will benefit direct laryngoscopy for intubation after curarization
2414997|NCT03470103||Treatment naïve wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2414998|NCT03470103||Treatment naïve DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2414999|NCT03470103||Previously treated wAMD|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2415000|NCT03470103||Previously treated DME|The decision regarding treatment is made at the discretion of the attending physician, according to his/her medical practice
2415001|NCT03470090|Experimental|Neuromuscular Exercises Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and neuromuscular exercises training
2415002|NCT03470090|Active Comparator|Conventional Group|This group of patients received patient with knee osteoarthritis. It will be applied classical physiotherapy and conventional exercises.
2415003|NCT03470077|Experimental|Group A|40 randomly allocated Patients undergoing repair of rupture globe will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.
2415004|NCT03470077|Experimental|Group B|40 randomly allocated Patients undergoing repair of rupture globe.will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
2415107|NCT03469284|Active Comparator|Group 4 (standard of care)|Patients receive standard of care therapy.
2415341|NCT03467828|No Intervention|Control Group|Infants born in similar gestational week and birth weight but not diagnosed with BPD.
2415005|NCT03470064||RV Dysfunction|All pediatric patients who present to pediatric cardiothoracic unit, Assiut University Hospital and who meet the listed inclusion and exclusion criteria will be eligible for the study. Patients' charts will be retrieved based on their surgical procedures. The charts will be reviewed and eligible patients will be filtered. The needed variables will be entered into our data base for later data analysis
2415006|NCT03470051||(2) QT Ultrasound scans prior to breast biopsy|Subjects will undergo a baseline QT scan, and a follow-up QT scan performed between 90 days and 180 days from their baseline QT Scan accompanied by a HHUS and ultrasound-guided breast biopsy following the first follow-up QT scan. BI-RADS will be confirmed by the radiologist at the time of the first HHUS. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for an additional follow-up QT Scan 12 months from the time of their baseline QT Scan.
2415007|NCT03470051||(0-1) QT Ultrasound scans prior to breast biopsy|"Subjects that have not had (2) two QT Scans before their breast biopsy and who haven't yet had a breast biopsy will undergo an optional baseline QT scan accompanied by a HHUS and ultrasound-guided breast biopsy. BI-RADS will be confirmed by the radiologist. Subjects will receive a telephone follow-up contact approximately 2-3 business days after their ultrasound-guided breast biopsy to assess if any adverse events have occurred. Subjects will be asked to come back for a follow-up QT Scan between 90 and 180 days from the time of their study biopsy.~Subjects that have had a breast biopsy on their identified breast mass(es) prior to study enrollment and have not already had two (2) QT Scans will undergo an optional baseline QT scan if between 0 and 30 days from their breast biopsy.~Subjects will be asked to come back for a follow-up QT Scan 12 months from the time of their study biopsy."
2415008|NCT03470038|Experimental|NGF condition + Control condition|"All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
2415009|NCT03470038|Experimental|Control condition + NGF condition|"All participants will receive five injections with isotonic saline (9%/0.5ml) into the tibialis anterior muscle in their non-dominant leg~After 4 weeks:~All participants will receive five injections with NGF (1ug/0.5ml) into the tibialis anterior muscle in their non-dominant leg"
2415010|NCT03470025|Experimental|Psychological Intervention|A weekly combined face to face & telephone-based PI (F-TPI); Psychological Intervention and medical therapy
2415011|NCT03470025|Experimental|A telephone-based PI (TPI)|Psychological Intervention - A telephone-based PI (TPI); Psychological Intervention and medical therapy
2415012|NCT03470025|No Intervention|Optimal medical therapy|Patients will receive optimal medical therapy
3185946|NCT00740415|Experimental|ARM RiBVD|"RiBVD 6 cycles every 28 days day 1 :~Rituximab /Mabthera®, 375 mg/m2 en IV~Bendamustine, 90 mg/m2 en IVD~Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 2 : - Bendamustine, 90 mg/m2 en IVD~Dexamethasone, 40 mg IV day 4 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 8 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD day 11 : - Bortezomib/Velcade®, 1,3 mg/m2 en IVD"
2415015|NCT03469986||Autism Spectrum Disorder|Children who meet criteria based on expert clinical diagnosis for autism spectrum disorder will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
2415016|NCT03469986||Non-autism Spectrum Disorder|Children who do not meet criteria for autism spectrum disorder based on expert clinical diagnosis will be tested with the Marcus Autism Center Investigational Device and expert clinical assessment.
2415017|NCT03469960|Active Comparator|Arm A : standard treatment|6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
2415018|NCT03469960|Experimental|Arm B : experimental arm|6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended
2415019|NCT03469947|Experimental|Prehospital Tranexamic Acid|1 gram of Tranexamic Acid will be given during medical transport
2415020|NCT03469947|No Intervention|Matched Controls|Retrospective matched controls
2415021|NCT03469934|Experimental|ANB020|ANB020, administration of ANB020
2415022|NCT03469934|Placebo Comparator|Placebo|Placebo, administration of Placebo
2415023|NCT03469921||15-17 years old|15-17 years old
2415024|NCT03469921||18-25 years old|18-25 years old
2415025|NCT03469921||26-30 years old|26-30 years old
2415026|NCT03469921||acute leukemia|acute leukemia
2415027|NCT03469921||non-Hodgkin's lymphoma|non-Hodgkin's lymphoma
2415028|NCT03469921||Hodgkin lymphoma|Hodgkin lymphoma
2415029|NCT03469921||pediatric therapeutic regimen administered|pediatric therapeutic regimen administered
2415030|NCT03469921||adult therapeutic regimen administered|adult therapeutic regimen administered
2415031|NCT03469921||patients included in clinical trials|patients included in clinical trials
2415032|NCT03469921||patients not included in clinical trials|patients not included in clinical trials
2415033|NCT03469895||active CLL treated with ibrutinib or idelalisib for CAI|"Patient with CLL Active autoimmune cytopenia Initiation of a treatment with ibrutinib or idelalisib for autoimmune cytopenia.~The progressive nature of contemporary CAI LLC is not a criterion of exclusion."
2415034|NCT03469882|Experimental|High protein and exercise (HPE) group|Begining within 48 hours of ICU admission participants will receive nutrition support with energy expenditure measured by indirect calorimetry, 2.0 to 2.2 g/kg/day of protein and in-bed cycle ergometry exercise.
2415035|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise
2415036|NCT03469869|Experimental|balanced and sustainable diet|The intervention group will receive menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the control group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
2415037|NCT03469869|Active Comparator|balanced diet|the intervention group receive get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will receive menu recommendation of balanced diet for 8 weeks. these menus are given in the apps
2415108|NCT03469271|Other|Training and Placebo|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo for eight weeks
2415038|NCT03469856|Other|single arm|The ASET Pilot study is a multicenter, single arm, open-label trial of single antiplatelet therapy with prasugrel for patients undergoing successful and optimal PCI for chronic stable angina with normal cardiac biomarkers values. angiographic and/or findings from intracoronary imaging, only then patients will be enrolled in the study and loaded with prasugrel 60 mg and continued with prasugrel only (10 mg once a day) for three months. Aspirin and clopidogrel will be discontinued. At the 3-months follow-up visit, prasugrel (only) will be replaced by aspirin (only) or dual-antiplatelet therapy according to local standard of care.
2415039|NCT03469843||Patients|patients with transposition of the great arteries long after repair with the arterial switch operation
2415040|NCT03469830|Experimental|SSCP & SPMS|"The smart scar care pad (SCCP):~The SCCP is a newly invented insert material that can maximise treatment outcomes via enhanced compression and occlusion. The wearing regime for SCCP is 4 hours a day for the first day, with 2-hour increments added every other day until the total wearing time reached 23 hours. SSCP was cleaned twice a day for hygienic reasons.~The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
2415041|NCT03469830|Active Comparator|SPMS|"The smart pressure monitored suit(SPMS):~The SPMS is a type of custom-made pressure garment. SPMS was used 23 hours a day and only removed when showering."
2415042|NCT03469817|No Intervention|Patients who have undergone THR with Trident Cup|Patients who have had THR with Trident Cups and have previously had an MRI taken at the Hospital for Special Surgery at 1 year post-op.
2415043|NCT03469817|Other|Patients who have undergone THR with Trident II Cup|Patients who have had THR with Trident II Cups and will have an MRI taken at their one year post-operative visit.
2415044|NCT03469804|Experimental|Pembrolizumab|Pembrolizumab Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
2415045|NCT03469791|Active Comparator|Micro-decompression alone|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-precerving decompression without fusion
2415046|NCT03469791|Active Comparator|Decompression and instrumented fusion|In Surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional Cage
2415047|NCT03469778|Experimental|Robotic Therapy|After consent, 10 participants will be included in a training program, as described below: 1º session will be robotic calibration and assessment; the following 18 sessions will be conducted the robotic therapy for upper limbs, three times a week. Each session will have a total duration of 55 minutes, including initial patient positioning and adjusting and after a sequence of game tasks.
2415048|NCT03469765||Group of patients after aortic surgery|with subanalysis of patients with/without supra-/infrarenal surgery
2415049|NCT03469752|Experimental|Intervention group|8 weekly education sessions 2.5 hours
2415050|NCT03469752|No Intervention|Wait-list control group|No education sessions
2415051|NCT03469726|Other|Patients with (suspected) PDAC|"Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.~Suspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months."
2415052|NCT03469713|Experimental|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
2415053|NCT03469700|Experimental|GA+PVB|Patients will receive general anesthesia with paravertebral block
2415054|NCT03469700|Active Comparator|GA+placebo PVB|Patients will receive general anesthesia with placebo block
2415055|NCT03469687|Other|Symax uncemented hip stem|The Symax hip stem is an uncemented design forged from Ti6Al4V alloy (Stryker EMEA). Primary mechanical stability is provided by anatomical metaphyseal geometry. The hip stem features a size dependent anteversion, neck length and offset, with a CCD angle of 128°. Secondary biological stability is accomplished by fast osseous integration due to the BONIT-HA coating on the metaphyseal part of the stem.
2415056|NCT03469674|Experimental|Molecular profile based treatment|Determination of the integrated clinicopathological and molecular profile to determine adjuvant treatment: observation for favourable profile; vaginal brachytherapy for intermediate profile; external beam radiotherapy for unfavourable profile
2415057|NCT03469674|Active Comparator|Vaginal brachytherapy|Adjuvant vaginal brachytherapy (standard treatment)
2415058|NCT03469661||Immune Thrombocytopenia Diagnosis|
2415059|NCT03469661||Myelodysplastic Syndrome Diagnosis|
2415060|NCT03469622|Active Comparator|EndoRings|Colonoscopy is performed with the EndoRings attached
2415061|NCT03469622|Active Comparator|Standard Colonoscopy|Standard colonoscopy without any additional devices
2415062|NCT03469609|Experimental|Perioperative mucous fistula refeeding|Perioperative mucous fistula refeeding between enterostomy creation and enterostomy closure
2415063|NCT03469609|No Intervention|No mucous fistula refeeding|No perioperative mucous fistula refeeding
2415064|NCT03469583|Experimental|EYP001 dose1|EYP001 capsules by mouth
2415065|NCT03469583|Active Comparator|Entecavir 1mg|2 tablets of 0.5mg, by mouth
2415066|NCT03469583|Experimental|EYP001 dose 1 + Entecavir 1mg|EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
2415067|NCT03469570|Experimental|Assisted Fluid Management|
2415068|NCT03469557|Experimental|Esophageal Squamous Cell Carcinoma (ESCC)|
2415069|NCT03469557|Experimental|Gastric (GC) and Gastroesophageal Junction (GEJ) Carcinoma|
2415070|NCT03469544||Group 1 (30)|"Patient with cancer thyroid proved by cytological analysis Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood ,Enzyme linked Immunosorbent Assay for serum midkine level"
2415071|NCT03469544||Group 2 (30)|"Patient with benign thyroid nodule Interventions;complete blood picture ,serum urea and creatinine,liver function test ,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
2415072|NCT03469544||Group 3 (30)|"Normal healthy subjects as control group Interventions;complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
2415073|NCT03469531|Experimental|experimental group|Patients receive nimotuzumab combined with cisplatin and undergo external-beam radiation and brachytherapy as the patients in experimental group.
2415074|NCT03469531|Active Comparator|control group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group.
2415075|NCT03469518|Sham Comparator|β-Cx plus PS|Fruit and milk based beverage enriched with beta-cryptoxanthin and plant sterols
2415076|NCT03469518|Active Comparator|β-Cx plus PS plus GOS|Fruit and milk bases beverage enriched with beta-criptoxanthin, plant sterols and galactooligosaccharides
2415077|NCT03469505|Active Comparator|data from veterans using COPES|Data from veterans using COPES for chronic pain
2415078|NCT03469505|Active Comparator|data from veterans using CBT-CP|Data from veterans using CBT-CP for chronic pain
2415079|NCT03469492|Active Comparator|type 2 diabetes mellitus|Subjects with type 2 diabetes on insulin.
2415080|NCT03469492|Active Comparator|type 1 diabetes mellitus|Subjects with type 1 diabetes on insulin.
2415081|NCT03469479|Experimental|Resection plus HAIC with FOLFOX|Patients receive 4 times of neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX and hepatic resection
2415082|NCT03469479|Active Comparator|Resection|Patients receive hepatic resection without neoadjuvant hepatic arterial infusion chemotherapy
2415083|NCT03469466||untrained|Volunteers untrained in bedside ultrasound technique
2415084|NCT03469466||trained|Volunteers previously trained and experienced in bedside ultrasound technique
2415085|NCT03469466||healthy volunteer|Standardized patient who will undergo ultrasound study
2415086|NCT03469453|Experimental|Internet-delivered CBT|Internet-delivered Cognitive Behavioral Therapy (ICBT) for GAD, 10 weeks. Patients and their parents work with separate programs via the Internet. Both have contact with a therapist. Participants practice awareness of worry through daily worry monitoring. They identify their own behaviors that reinforce worry, i.e. control and avoidance behaviors. The program gives a rationale for behavior change, which is then implemented. Participants practice problem solving and exposure to uncertainty inducing situations and thoughts. Parents receive support and psycho education about worry. They practice alternative parental behaviors, which decrease focus on worry while validating the child's feelings. Treatment contains planning for maintenance of treatment gains for both patients and parents.
2415087|NCT03469440|Active Comparator|Goal-directed therapy|Patients randomized to this group will be monitoring by continuous central venous oxygen saturation. Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.
2415088|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy.
2415089|NCT03469414||Wheelchair Mobility and Speed|This group will participate in activity-based measures employed in routine occupational and physical therapy practice to assess participants' wheelchair speed, maneuverability, and endurance. These measures include: the Life Space Assessment Scale, 6-Minute Push Test, Forward Push Test, Wheelchair Slalom Test, Craig Handicap Assessment and Reporting Technique, and PART-O.
2415090|NCT03469414||GPS Tracking|A GPS tracker will be placed on the wheelchairs of 25 individuals who consent to participate in this arm of the project. Using a GPS tracker will provide a direct measure of the community locations these participants go. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
2415091|NCT03469401||intervention|Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage
2415092|NCT03469388|Experimental|elective EVAR patients|Elective EVAR patients will be included in one arm only
2415093|NCT03469375||LAPC patients with mFOFLRINOX-based neoadjuvant therapy|LAPC patients were enrolled prospectively and diagnosed by MDT group in our hospital. These patients further received the neoadjuvant therapy with mFOLFIRINOX, the Overall survival, Progression survival, response to mFOLFIRINOX, chemo-related Toxicities, Postoperative complications and Histopathologic staging were measured.
2415094|NCT03469362|Experimental|Extracorporeal Urinary Diversion (ECD)|Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
2415095|NCT03469362|Experimental|Intracorporal Urinary Diversion (ICD)|Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
3185947|NCT00740428|Experimental|G1|pregnants for the first time who will receive the physical therapy guide
3185948|NCT00740441|Experimental|A|AS1411 treatment
3185949|NCT00740454||A|Pregnant or post-partum women with a clinically suspected DVT and a negative distal and proximal leg veins compression ultrasonography
2415099|NCT03469323|Experimental|Nonintubated VATS succinylcholine|Nonintubated VATS using mini-dose succinylcholine in the beginning of open pneumothorax
2415100|NCT03469323|Placebo Comparator|Nonintubated VATS placebo|Nonintubated VATS not using succinylcholine in the beginning of open pneumothorax
2415101|NCT03469310|Experimental|Acetaminophen|Tylenol (also known as acetaminophen) 1000mg every 6 hours for 3 days and tramadol 50 mg every 6 hours as needed for moderate to severe pain
2415102|NCT03469310|Active Comparator|Codeine Acetaminophen|Tylenol #3 (codeine-acetaminophen) 1 tab every 4 hours or 2 tabs every 6 hours as needed for pain
2415103|NCT03469297|Experimental|Brown Glaucoma Implant|
2415104|NCT03469284|Experimental|Group 1 (lower dose methylene blue, standard of care)|Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
3185950|NCT00740493|Active Comparator|1|18 months of active warfarin therapy
3185951|NCT00740493|Placebo Comparator|2|18 months of placebo of warfarin
3185952|NCT00740519||A|
2415109|NCT03469271|Other|Sham Training and Vitamin D3 Metabolite|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25 (OH)2 D3 orally for eight weeks
2415110|NCT03469271|Other|Training and Vitamin D3 Metabolite|Inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus 1,25(OH)2 D3 orally for eight weeks
2415111|NCT03469271|Other|Sham Training and Placebo|Sham inspiratory isometric resistance training with the Threshold Inspiratory Muscle Trainer (IMT) plus oral placebo orally for eight weeks
3185953|NCT00740532||Observation|Breast cancer patients treated with Herceptin-based therapy
2415113|NCT03469245||abdominal aortic aneurysms treated by fenestrated endovascular|Patients have an abdominal aortic aneurysms treated by fenestrated endovascular anacondaTM of society Vascutek will be included. Predisurge society will perform numerical simulation.
2415114|NCT03469232|Experimental|Huanglian-Jiedu Decoction in acute pericoronitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2415115|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent aphthous stomatitis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2415116|NCT03469232|Experimental|Huanglian-Jiedu Decoction in recurrent herpes simplex labialis|All eligible patients entering this group will receive Huanglian-Jiedu Decoction(prepared as granule). 1 bag per time and twice a day for 5 days.
2415117|NCT03469219||Study group|patients with psoriasis vulgaris. measuring serum granulysin level for all patients and tissue granulysin level in lesional and perilesional skin for a number of patients using Enzyme Linked Immunosorbent Assay.
2415118|NCT03469219||Control group|Healthy volunteers. measuring serum granulysin level for all healthy volunteers and tissue granulysin level for a number of them using Enzyme Linked Immunosorbent Assay.
2415119|NCT03469206|Sham Comparator|Direct MT|Direct mechanical thrombectomy (MT) with no intravenous thrombolysis
2415120|NCT03469206|Active Comparator|IVT combine with MT|Intravenous thrombolysis before mechanical thrombectomy
2415121|NCT03469193|Active Comparator|internal PUC implanted with mechanical ancillary|
2415122|NCT03469193|Experimental|Internal PUC implanted with robotic assistance|
2415123|NCT03469180|Active Comparator|Control Group|Childrens in this group will receive treadmill training, three times a week for 8 weeks. Each season will be supervised and last 45 minutes.
2415124|NCT03469180|Experimental|Training Group|İn addition to treadmill training, childrens in this group (after a rest for 5 minutes) will also receive whole body vibration training for 15 minutes.
2415125|NCT03469167|Experimental|CEGP003|
2415126|NCT03469167|Active Comparator|Injection Tx|
2415127|NCT03469154|Experimental|Dyad training|The participants in this arm will train in teams of two. Participants will be instructed in paediatric basic life support by instructional videos in a computer programme and train on children resuscitation manikins. Training involves recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management. The training involves series of short video clips and following exercises. Each participant performs the exercise and the other gives feedback. Afterwards roles are changed. The procedure is done for all exercises after a video clip. The duration of the training is maximum 50 minutes
2415128|NCT03469154|Active Comparator|Instructor led training|"Participants train in courses of up to 6 participants with an instructor. Training content is identical to dyad training content involving: recognition of cardiac arrest, cardio-pulmonary resuscitation and foreign body airway obstruction management.~Skills are instructed by an instructor using af 4 step approach (1. show skills, 2. show with explanation, 3. participants instruct instructor, 4. participants performs the skills on resuscitation manikins). Training is maximum two hours but course duration is adjusted to number of participants two allow for similar hands-on time per participant as in the experimental arm."
2415129|NCT03469141|No Intervention|Control Group|The control group will continue to have the WC sensor system for measurement only and will not receive biofeedback after receiving instructions on the importance of pressure relief (PR) maneuvers for skin care, as well as training regarding the three pressure relief maneuvers. Materials (including fact sheets, etc.) will be incorporated in the educational content of the project.
2415130|NCT03469141|Experimental|Intervention Group|The intervention group will receive biofeedback via the smartphone app.
2415131|NCT03469128|Active Comparator|Cognitive processing therapy|Cognitive Processing Therapy (CPT) in which participants completed 12 sessions of CPT
2415132|NCT03469128|Active Comparator|Sertraline|Patients with co-occurrence PTSD & SUD disorders were treated by Sertraline.
2415133|NCT03469128|Placebo Comparator|Control group|Placebo Control group
2415134|NCT03469115|Active Comparator|BMI above 95%|Serum blood will be taken from obese youths with suspected metabolic syndrome
2415135|NCT03469115|Active Comparator|BMI below 3%|Serum blood will be taken from slim youths
2415136|NCT03469089|Placebo Comparator|Placebo/placebo|Placebo for ketamine (0.9% NaCl) + Placebo for modafinil (microcrystalline cellulose capsule)
2415137|NCT03469089|Experimental|Ketamine 0.58/placebo|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Placebo for modafinil
2415138|NCT03469089|Experimental|Ketamine 0.58/modafinil|Ketamine (0.23 mg/kg + 0.58 mg/kg/h) + Modafinil (200 mg)
2415139|NCT03469089|Experimental|Ketamine 0.31/placebo|Ketamine (0.12 mg/kg + 0.31 mg/kg/h) + Placebo for modafinil
2415140|NCT03469076|Experimental|ACN Cream|Patients with mild to moderate acne using ACN Cream
2415141|NCT03469063|Experimental|AferBio|Daily oral AferBio (20 g/day, in sachets)
2415142|NCT03469063|Placebo Comparator|Placebo|Daily oral placebo (20 g/day, in sachets)
3145474|NCT00072150|Experimental|Treatment (bortezomib)|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Patients with a solitary site of disease (i.e., lung or nodal metastases) and who have a partial response (PR) may be considered for surgical resection. Patients with a PR with residual disease after salvage surgery are eligible to continue study therapy. Patients who achieve a complete response, either through resection or bortezomib therapy, receive 2 additional courses of study therapy."
3185954|NCT00740545|Placebo Comparator|2|
3185955|NCT00740545|Experimental|1|
2415146|NCT03469037|Experimental|Oxygen first|Optiflow with an inspired fraction of oxygen of 100% in the first seance Optiflow with an inspired fraction of oxygen of 21 % in the second seance
2415147|NCT03469037|Experimental|Air first|Optiflow with an inspired fraction of oxygen of 21 % in the first seance Optiflow with an inspired fraction of oxygen of 100 % in the second seance
2415148|NCT03469024|Experimental|Home rehabilitation program|It consists in a home rehabilitation program. Patients will recieve electroanalgesia with TENS and an exercise program following the McKenzie method. At first and second sessions, patients will be instructed on how to use electroanalgesia and how to perform the exercises. Then, patients will perform the therapy at home. Patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
2415149|NCT03469024|Active Comparator|e-Health program|It consists in a support system for the treatment of chronic low back pain based on web technologies. The system can register a subject and provide a treatment of electroanalgesia and exercise through the Mckenzie method. Video applications of electroanalgesia and exercises will be shown to patients who use their computer or mobile device to access the platform through the Internet. The treatments will be recommended by the system based on the database that is configured to accommodate the application of electroanalgesia and McKenzie exercises based on the diagnosis according to the McKenzie method.patients will perform the treatment 3 times per week, for 4 weeks, with a total of 24 sessions
2415150|NCT03469011|Experimental|Imatinib oral100mg tablets|"A standard 3+3 trial design will be utilized for the imatinib dosing. In general, patients will be treated in cohorts of 3-6 with escalating doses of imatinib using oral 100mg tablets.~Dose Level -1=100mg, +1=200mg (starting dose for cohort 1), +2=300mg, +3=400mg, +4=600mg (if needed)."
2415151|NCT03468998|Active Comparator|Ridge Preservation with Small Particle Allograft|
2415152|NCT03468998|Active Comparator|Ridge Preservation with Large Particle Allograft|
2415153|NCT03468998|Active Comparator|Ridge Augmentation with Small Particle Allograft|
2415154|NCT03468998|Active Comparator|Ridge Augmentation with Large Particle Allograft|
2415155|NCT03468985|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 60 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2415156|NCT03468985|Experimental|Arm B (nivolumab, cabozantinib s-malate)|Patients receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2415157|NCT03468985|Experimental|Arm C (nivolumab, cabozantinib s-malate, ipilimumab)|Patients receive nivolumab IV over 60 minutes on day 1, cabozantinib s-malate PO daily on days 1-28, and ipilimumab IV over 90 minutes every 8 weeks. Cycles for nivolumab and cabozantinib s-malate repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2415158|NCT03468985|Experimental|Arm T (nivolumab, cabozantinib s-malate, ipilimumab)|Patients with ROS1 gene rearrangement, MET exon 14 splice mutations, MET high amplification, or RET gene rearrangement receive nivolumab IV over 60 minutes on day 1 and cabozantinib s-malate PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2415159|NCT03468972|Experimental|Immunosuppression|corticosteroids or cyclophosphamide added on corticosteroids
2415160|NCT03468972|Active Comparator|Intensive supportive care|intensive supportive care with RAS blockers, blood pressure control, and protein restriction diet
2415161|NCT03468959||Mother-child pairs|Families were recruited from lists of children receiving autism services obtained via the California Department of Developmental Services (DDS), from other studies at the Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, or by self-referrals. The inclusion criteria were: a) mother or father had a biological child with ASD, and the mother was b) at least 18 years old; c) pregnant or planning a pregnancy, and biologically able to become pregnant; d) living within 2 hours of the MIND Institute; e) sufficiently fluent in English.
2415162|NCT03468946|Other|high caries risk|children with high caries -identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
2415163|NCT03468946|Other|medium caries risk|children with medium caries- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
2415164|NCT03468946|Other|low risk|no caries or low risk- identified by cariogram to evaluate sweet taste perception, salty taste perception, sour taste perception and bitter taste perception of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors.
3185956|NCT00740558|Active Comparator|1|Two groups received a traditional chiropractic adjustment of the lumbar 5 and the other group received a manually assisted mechanical force adjustment of the lumbar 5.
3185957|NCT00740558|Sham Comparator|2|The investigators had two groups, one for each chiropractic technique used in the research project and we had a control group
3185958|NCT00740571|Active Comparator|1|Strategy in which patient starts with amitriptyline
3185959|NCT00740571|Active Comparator|2|Strategy in which patient starts with pregabalin
2415169|NCT03468907|Experimental|Early cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. Antiviral therapy was discontinued in intrapartum.
2415170|NCT03468907|Experimental|Late cessation|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg or TDF 300 mg (as per patients' wishes) daily between gestational weeks 24 and 28. After delivery, mothers ceased antiviral treatment at postpartum 6 weeks.
2415171|NCT03468907|No Intervention|Control|Eligible patients who refused antiviral therapy but consented to the study were assigned to the control arm.
2415172|NCT03468894|No Intervention|Control|The control group will continue to work as usual at their regular workstations.
2415195|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DFE)|Participants will receive Treatment D on Day 1 period 1 then Treatment F on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
3185960|NCT00740610|Experimental|Cohort 1|22 subjects to receive 1 mg GS-9450 for 4 weeks
3185961|NCT00740610|Experimental|Cohort 2|22 subjects to receive 5 mg GS-9450 for 4 weeks
2415173|NCT03468894|Experimental|Intervention|A shared treadmill workstation will be installed in participating offices, or in a nearby location in case there is no space to fit the workstation in the office, enrolled to this group. Within the intervention group there will be a maximum allocation of two participants per treadmill desk. The participants in the intervention group will be asked to interrupt their sitting with 20 minutes of self-selected light-intensity walking at a speed of 1-4 km/h each hour for a minimum of 6 hours per shift to accumulate a total of 2 hours of light-intensity activity per work day.
2415174|NCT03468881||Breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy.
3185962|NCT00740610|Experimental|Cohort 3|22 subjects to receive 10 mg GS-9450 for 4 weeks
2415178|NCT03468842|Placebo Comparator|Placebo|Composition: excipients without probiotic: 2%w/v Guam guar and 6% w/v hydroxyethilcellulose Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
2415179|NCT03468842|Active Comparator|Probiotic|Composition: Streptococcus dentisani: 2,5E+09CFUs, 2% (p/v) Guam Guar and 6% (p/v) Hidroxietilcelulosa. Dose of 2.5E+09 cfu/vial considering one administration every 48 hours, it will be equivalent to a dose of 1.0E+10 cfu/week Application in mouth of a bucoadhesive gel. Applied by the profesional at days 0, 15 and 30 and by the participants the rest of the days Frequency: each 48 h by the participants Duration: during 30 days
2415180|NCT03468829|Experimental|ALX-0171 Dose 1|
2415181|NCT03468829|Experimental|ALX-0171 Dose 2|
2415182|NCT03468829|Placebo Comparator|Placebo|
3185963|NCT00740610|Experimental|Cohort 4|22 subjects to receive 40 mg GS-9450 for 4 weeks
3185964|NCT00740610|Placebo Comparator|Cohort 5|22 subjects to receive placebo to match GS-9450 for 4 weeks
2415185|NCT03468803|Experimental|Beta D Glucan (BDG) in surgery|Serial Beta D Glucan measurements in each patients before, during, and after surgery
2415186|NCT03468790|Experimental|CMAB007 + Seretide/Symbicort + Ventolin|CMAB007(recombinant humanized anti-IgE monoclonal antibody for injection ) will be at a fixed dose determined by the subjects' total IgE and weight at V0. All the subjects will be treated subcutaneously for 24 weeks. The 4-week total dose is 0.016mg/kg/IgE(IU/ml), administered every 2 or 4 weeks, for the subjects with total IgE level 60-700IU/ml. If the total IgE level is 700-1500IU/ml, they will be administered 375mg every 2 weeks. Symbicort(Budesonide and formoterol fumarate powder for inhalation) or Seretide (salmeterol xinafoate and fluticasone propionate powder for inhalation) will be used 1/2 inhalations bid as asthma-controlled drug during the whole study. Ventolin (Salbutamol sulphate aerosol) will be used as asthma rescue drug.
2415187|NCT03468790|Placebo Comparator|Placebo + Seretide/Symbicort + Ventolin|Placebo is without active components of the study drug and used as same as the study drug.
2415188|NCT03468777|Experimental|Part 1: Treatment Sequence (ABC)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 1 then Treatment B as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment C (optional Part 2) as a single dose of 150 mg ranitidine administered after 2 hours of single dose of 1000 mg lumicitabine (4*250 mg tablets) under fasted condition on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415189|NCT03468777|Experimental|Part 1: Treatment Sequence (BAC)|Participants will receive Treatment B on Days 1 to 5 of period 1 then Treatment A on Day 1 of period 2 followed by Treatment C (optional Part 2) on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415190|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (DEF)|Participants will receive Treatment D as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 1 then Treatment E as a single oral dose of 30 mg lansoprazole under fasted condition on Days 1 to 4 and on Day 5 (administered 2 hours before a single oral dose of 1,000 mg lumicitabine) in period 2 followed by Treatment F as a single oral dose of 150 mg ranitidine administered after 2 hours after a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) after standardized breakfast on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415191|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EFD)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment F on Day 1 of period 2 followed by Treatment D on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415192|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FDE)|Participants will receive Treatment F on Days 1 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment E on Days 1 to 5 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415193|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (FED)|Participants will receive Treatment F on Day 1 of period 1 then Treatment E on Days 1 to 5 of period 2 followed by Treatment D on Days 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415194|NCT03468777|Experimental|Optional Part 3: Treatment Sequence (EDF)|Participants will receive Treatment E on Days 1 to 5 of period 1 then Treatment D on Day 1 of period 2 followed by Treatment F on Day 1 of period 3. A washout period of at least 21 days will be maintained between each treatment period.
2415309|NCT03467997|Active Comparator|Diesel Exhaust and stress|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed and are subject to a mental stress test (TSST) which involves a public speaking and math task.
3185965|NCT00740623|Experimental|001|Carisbamate 800 mg/day for 14 weeks
3185966|NCT00740623|Experimental|002|Carisbamate 1,200 mg/day for 14 weeks
3185967|NCT00740623|Placebo Comparator|003|placebo for 14 weeks
3185968|NCT00740649|Experimental|1|HSD-016
3185969|NCT00740649|Other|2|placebo
3185970|NCT00740662||1|Distal gastric bypass
2415196|NCT03468751|Experimental|HLX10, Dose Finding Cohort|Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive an infusion of assigned dose of HLX10 once every two weeks. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 0.3, 1.0, 3.0, and 10 mg/kg, starting from 0.3 mg/kg.
2415197|NCT03468751|Experimental|HLX10, Dose Expansion Cohort (200 mg )|Each cycle of treatment consists of 4 weeks. Patients who enroll into this expansion cohort will receive an infusion of assigned dose of HLX10 at 200 mg once every two weeks.
2415198|NCT03468725|Experimental|XPF-008|Single oral dose
2415199|NCT03468725|Active Comparator|Placebo|Single oral dose
2415200|NCT03468712|Experimental|Experimental group|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
2415201|NCT03468699|Experimental|Autologous BMMC transplantation|Stem cell transplantations include 2 administrations of autologous bone marrow mononuclear cells via the hepatic artery at baseline and 6 months afterward
2415202|NCT03468686|Active Comparator|bilateral rTMS|sequential bilateral repetitive Transcranial Magnetic Stimulation (rTMS)
2415203|NCT03468686|Sham Comparator|Sham rTMS|Sham Transcranial Magnetic Stimulation (rTMS)
2415204|NCT03468686|Active Comparator|Unilateral rTMS|Unilateral (High frequency) repetitive Transcranial Magnetic Stimulation (rTMS)
2415205|NCT03468660|Experimental|Experimental group|Auditory training with feedback
2415206|NCT03468660|No Intervention|Passive control group|Pre-post testing only; no training
2415207|NCT03468660|Active Comparator|Active Control group|Listening task with no feeback
2415208|NCT03468647|Experimental|FRAGIL-IT testing group|FRAGIL-IT tools : connected soles, connected weighting machine and measure of gripping force
2415209|NCT03468634|Experimental|Adenocarcinoma|patients diagnosed with adenocarcinoma
2415210|NCT03468634|Experimental|Squamous cell cancer|patients diagnosed with squamous cell cancer
2415211|NCT03468634|Experimental|Other|patients diagnosed with another condition
2415212|NCT03468634|Experimental|Barrett's oesophagus|patients diagnosed with Barrett's oesophagus
2415213|NCT03468634|Experimental|Low-grade dysplasia|patients diagnosed with low-grade dysplasia
2415214|NCT03468634|Experimental|High-grade dysplasia|patients diagnosed with high-grade dysplasia
2415215|NCT03468634|Experimental|Indefinite for dysplasia|patients where the diagnosis is unclear
2415216|NCT03468634|Experimental|no dysplasia|patients not diagnosed with any cancer
2415217|NCT03468621|Other|Intradermal wound closure|Intradermal wound closure of the groin wound
2415218|NCT03468621|Other|Transdermal wound closure|Wound closure of the groin wound with metal staples
2415223|NCT03468595|Experimental|test 1|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with CHX (Drogsan, Istanbul, Turkey, 0.2%) was performed at one session for once.
2415224|NCT03468595|Experimental|test 2|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with Listerine (Johnson & Johnson, Istanbul, Turkey, containing, 21.6% ethanol, 0.092% eucalyptol, 0.064% thymol, 0.042% menthol and 0.06% methyl salicylate) was performed at one session for once.
2415225|NCT03468595|Active Comparator|control|The treatment of periodontitis was performed with ultrasonic instrumentation (Piezonmaster 700; Electro Medical Systems, Nyon, Switzerland) with distilled water was performed at one session for once.
2415226|NCT03468582|Experimental|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
2415227|NCT03468569|Experimental|Functional Movement Screen|Movement Analysis for injury risk
2415228|NCT03468569|Experimental|Vertical Jump Test|Jump test Height Measurement, Functional Movement Screen
2415229|NCT03468569|Experimental|Y Balance Test|Functional lower extremity reach with balance, Functional Movement Screen
2415230|NCT03468569|Experimental|Illinois Agility Test|Agility measurement, Functional Movement Screen
2415231|NCT03468569|No Intervention|Injury History|Athletes injury history for last year was recorded as injury count.
2415232|NCT03468556|Experimental|test drug|2 tabs of SNP-610
2415233|NCT03468556|Placebo Comparator|placebo|2 tabs of placebo
3185971|NCT00740675|Experimental|1|"At post-discharge follow-up visit with PCP, PCP views:~Discharge medication reconciliation screen.~Prompts to perform post-discharge reconciliation at the first post-discharge visit."
3185972|NCT00740675|No Intervention|Uusual care|PCPs manage the patient's medications after hospital discharge as they normally would.
3185973|NCT00740688|Experimental|Experimental Group|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
2415237|NCT03468517|No Intervention|Control group|Standard preoperative evaluation process will continue without any intervention.
2415238|NCT03468517|Active Comparator|Bathe Group|In the comparator group of patients, Bathe method will be applied at preoperative evaluation process.
2415239|NCT03468504|Experimental|Mirror Therapy & Treadmill Training|"Mirror Therapy: Participants view a mirror reflection of their non-affected limb which is placed in their mid-sagittal plane for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
2415310|NCT03467984|Experimental|LBVE|Infants will receive a 0.5mL intramuscular injection of LBVE at 6,10 and 14 weeks of age
2415240|NCT03468504|Placebo Comparator|Placebo Mirror & Treadmill Training|"Placebo Mirror Therapy: Participants view a mirror which is placed forward/ahead of them in their mid-sagittal plane, and cannot see a reflection of any lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
2415241|NCT03468491|Experimental|Combined training group|Biomechanical taping will first being applied to the participants of the combined training group. They will be asked to perform following exercises in this session afterwards. As the treatment session goes on, a set of foot intrinsic muscle strengthening exercise and lower extremity neuromuscular exercise will be provided.
2415242|NCT03468491|Active Comparator|Proximal training group|For participants of the proximal training group, only a set of lower extremity neuromuscular exercise will be provided. This set of exercises is designed to be the same as for participants of combined training group.
2415243|NCT03468478|Experimental|sirolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID oftacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of sirolimus of 3mg once a day to reach blood trough concentration between 4-8 ng/mL.
2415244|NCT03468478|Experimental|everolimus +tacrolimus|Patients will receive initial dose of 0,05 mg/kg BID de tacrolimus to reach blood trough concentration between 3-5 ng/mL. Initial dose of 1.5 mg BID of everolimus to reach blood trough concentration between 4-8 ng/mL.
2415245|NCT03468478|Active Comparator|mycophenolate +tacrolimus|Patients will receive initial dose of 0,1 mg/kg BID de tacrolimusto reach blood trough concentration between Fixed dose of mycophenolate (mycophenolate mofetil, 1 g BID or sodium mycophenolate, 720 mg BID).
2415246|NCT03468465|Experimental|Medical device: Transcutaneous electrical neurostimulation|Medical device 4 weeks with daily sessions of 30 minutes
2415247|NCT03468465|Active Comparator|Solifenacin|10 mg tablet daily during 75 days maximum
2415248|NCT03468452||Early extubation|The endotracheal tube is removed in the operation room, and no suction support is required after surgery.
2415249|NCT03468452||late extubation|"Take the tracheal tube back to the ward for respiratory support or removal of air.~The catheter is inserted again within 48h."
2415250|NCT03468439|Other|femoral nerve block|
2415252|NCT03468413|Experimental|Single ascending dose, CP1050 or Placebo|
2415253|NCT03468413|Experimental|Multiple ascending dose, CP1050 or Placebo|
2415254|NCT03468387|Active Comparator|Primary realignment|
2415255|NCT03468387|Active Comparator|Suprapubic cystostomy|
2415256|NCT03468374|Active Comparator|Lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
2415257|NCT03468374|Active Comparator|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
2415258|NCT03468361|Placebo Comparator|Control Group|Patients in control group will be allowed to continue their conventional medications and with a placebo.
2415259|NCT03468361|Experimental|Intervention Group|Patients in intervention group who would be taking their usual medications along with parsley in a convenient dosage form.
2415260|NCT03468348|Placebo Comparator|placebo group|
2415261|NCT03468348|Active Comparator|duloxetine 30|
2415262|NCT03468348|Active Comparator|duloxetine 60|
2415263|NCT03468348|Active Comparator|duloxetine 90|
2415264|NCT03468335|Other|Single Arm|"Cancer treatment for PDAC:~Nal-IRI (4.3 mg/ml) 70 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
2415265|NCT03468322|Experimental|AC-203 1% ointment|AC-203 1% ointment, QD
2415266|NCT03468322|Placebo Comparator|Vehicle ointment|Vehicle ointment, QD
2415267|NCT03468309||Genecept Assay and G-DIG decision tool|Veterans who have been prescribed 5 or more medications, with at least two being for a mental health diagnosis. Also allowable would be one medication for a mental health diagnosis and another medication for side effects related to a medication prescribed for the mental health diagnosis.
2415268|NCT03468296|Experimental|Continued Q2 Week Treatment|Will receive intravitreal aflibercept (2.0mg) injections for an additional four consecutive 2 week intervals at weeks 18, 20, 22, and 24
2415269|NCT03468296|Active Comparator|Treat-And-Extend Treatment|Will receive intravitreal aflibercept (2.0mg) injections on a treat-and-extend basis through week 24 with a minimum inter-treatment interval of q4 weeks.
2415270|NCT03468283|Experimental|Intervention|"Intervention was the addition of mobile healthcare-based diabetes self-management education, which consisted of mobile application for diabetes and individualized regular message feedback sent by healthcare professionals, to current diabetes management."
2415271|NCT03468283|No Intervention|control|Participants of control group maintained previous diabetes management in Kangbuk Samsung Hospital throughout this study. Providers were not involved with patient prescriptions.
2415272|NCT03468257|Active Comparator|Progressive Muscle Relaxation only|Condition 1: 7-dose control - Progressive Muscle Relaxation only
2415273|NCT03468257|Experimental|Pairs Progressive Muscle Relaxation with fruit|Condition 2: 5-dose - Pairs Progressive Muscle Relaxation with fruit 5 consecutive days; Condition 3: 7-dose - Pairs Progressive Muscle Relaxation with fruit 7 consecutive days; Condition 4: 9-dose - Pairs Progressive Muscle Relaxation with fruit 9 consecutive days
2415274|NCT03468244|Experimental|Personalized mRNA Tumor Vaccine|Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients with Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma
2415275|NCT03468231|Active Comparator|Sorafenib plus HAIC of FOLFOX|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin, Fluorouracil and Leucovorin
2415276|NCT03468231|Experimental|Sorafenbi plus HAIC of OXA|Sorafenib combined with Hepatic arterial infusion chemotherapy with Oxaliplatin
2415277|NCT03468218|Experimental|Treatment (pembrolizumab, cabozantinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and cabozantinib PO QD on days 1-21. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2415278|NCT03468205||Main Cohort|Main cohort of patients meeting all of the eligibility criteria enrolled through newspaper adds, flyers and via non personal recruitment.
2415279|NCT03468205||Subgroup|Smaller group of patients, meeting eligibility criteria for the main study, enrolled through clinical visits. These patients will be followed more closely and also be recorded in a logbook in order for later review. Some of the participants in this group will be interviewed in a semi-qualitative interview about their experiences of breathlessness.
2415280|NCT03468192|Experimental|non-precaution group|Study Group: Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed.
2415281|NCT03468192|No Intervention|precaution group|Control Group: the precaution group (PG) had standard postoperative hip precautions included limited flexion of the hip to 90° (avoid reaching down to toes or bringing knee up beyond 90°) and limited adduction of the hip (avoid sleeping on side and avoid crossing legs at knees or ankles). The mandatory assistive equipment to use for at least 3 months were reacher and stocking application aid. The patients were instructed only to use elevated chair, bed and toilet in order not to flex more than 90° in the hip. For the same reason a brace over the knee was prescribed for 6 weeks, particularly in patients with cognitive limitations.
3185974|NCT00740688|Sham Comparator|Sham Group|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
2415283|NCT03468166||Chronic stroke|The data for motor function and gait pattern analysis was obtained.
2415284|NCT03468153|Experimental|CAR-T cell therapy|Patient-derived dual specificity CD19 and CD22 CAR-T
2415285|NCT03468140|Experimental|Current end stage liver disease patients|Eculizumab
2415286|NCT03468140|Other|Historical controls|The Ochsner database will be used to obtain 5 historical matches for each study participant. Matching criteria for each patient will include: 1) gender; 2) (MELD) Score ± 5; 3) age ± 5 years; 4) body mass index (BMI) ± 5 kg/m2; 5) donor macrosteatosis ± 5%; and 6) CIT± 3 hours.
2415287|NCT03468114|Experimental|Intervention|Participant households will receive 4 visits by health extension workers delivering intervention
2415288|NCT03468114|Active Comparator|Control|Participant households will receive 4 visits by health extension workers delivering standard care
2415289|NCT03468101||Dairy farmers COPD|
2415290|NCT03468101||Non farmers COPD|
2415291|NCT03468088|Experimental|Hand grip strengthening|This group will receive handgrip strengthening exercises.
2415292|NCT03468088|Active Comparator|Conventional treatment|This group will receive conventional exercises.
3185975|NCT00740701|Sham Comparator|Sham TMS|A Sham TMS coil, designed to elicit sham cerebellar transcranial magnetic stimulation, is used to administer sham TMS pulses after letters are presented.
2415294|NCT03468062|Experimental|Dexmedetomidine|0.5 mg/kg of dexmedetomidine (Precedex; Hospira, Lake Forest, IL) is mixed in normal saline 100mL and administered for 5 minutes after anesthetic induction.
2415295|NCT03468062|Placebo Comparator|Placebo|Only normal saline 100mL is administered for 5 minutes after anesthetic induction.
2415296|NCT03468049|Experimental|Topical App. of Allium Cepa Extract|Intervention: 5mg of Allium Cepa Extract (Allium Cepa oil) will be applied on the shoulder joint of the participant, followed by kneading massage until the Allium Cepa oil deeply penetrate into the shoulder joint in addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
2415297|NCT03468049|Experimental|Phonophoresis of Allium Cepa extract|Intervention: 5mg of Allium Cepa extract (Allium Cepa oil) would be applied on the shoulder joint of the participant, followed by phonophoresis using ultrasound set at at treatment parameter of pulse mode (50%), 1mHz transducer frequency and stroking technique of 1.5w/cm square for 5mins to allow deeper penetration of the Allium Cepa oilinto the joint in addition to standard physiotherapy management of shoulder pain post stroke.Three times in a week for four weeks
2415298|NCT03468049|Experimental|Raw mashed Allium Cepa Application|Intervention: 5g or a small size Raw Allium Cepa (onion)bulb will be cut into pieces and then mashed inside pestle and mortar, thereafter the Raw mashed Allium Cepa will then be applied on the surface of the shoulder joint of the participant and then secured with a gauze bandage for 2 hours to allow deeper penetrationin addition to standard physiotherapy management of shoulder pain post stroke. Three times in a week for four weeks
2415299|NCT03468049|Active Comparator|Standard physiotherapy group (SPG)|Participant in this group will be receiving standard physiotherapy management of shoulder pain post stroke. The standard physiotherapy management will divided into two forms of activities, the first approach is soft tissue manipulation using common massage medium in particular powder would be used in this study. The second approach is the use of therapeutic exercises and this therapeutic exercises will be categorized into three (basic level, intermediate level and advance level of shoulder joint exercises) depending on the stage of recovery of the participants. Three times in a week for four weeks
2415300|NCT03468036||Extubation with 100% O2|for further information please refer to study protocol
2415301|NCT03468036||Extubation with 35% O2|for further information please refer to study protocol
2415302|NCT03468023|Experimental|Short arm cast|Patient treated with below-elbow cast
2415303|NCT03468023|Active Comparator|Long arm cast|Patients treated with above-elbow cast
2415304|NCT03468010|Active Comparator|The control group (Group A)|In Group A, observation is given after chemoradiation
2415305|NCT03468010|Experimental|The experiment group (Group B)|in Group B, three cycles of Paclitaxel, Cisplatin are administered after radiation with concurrent cisplatin. The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel 135mg/m2 plus Cisplatin 60mg/m2 once 3 weeks.
2415306|NCT03467997|No Intervention|Filtered Air|Subjects sit in a room for two hours breathing in filtered air which resembles levels of air pollution found in the ambient environment
2415307|NCT03467997|Active Comparator|Diesel Exhaust|Subjects sit in a room for two hours breathing in diesel exhaust at 200 micrograms of meter cubed.
2415308|NCT03467997|Active Comparator|TSST/Stress only|Subjects undergo a mental stress test, known as the Trier Social Stress Test (TSST), which involves a public speaking and math task.
2415311|NCT03467984|Active Comparator|Prevnar13|Infants will receive a 0.5mL intramuscular injection of Prevnar13 at 6,10 and 14 weeks of age
3185976|NCT00740701|Experimental|TMS|A genuine TMS coil is used to administer cerebellar transcranial magnetic stimulation pulses after letter presentation.
3185977|NCT00740740||1|Patients scheduled for elective conventional aneurysm repair
3185978|NCT00740740||2|Patients scheduled for emergent conventional aneurysm repair
3185979|NCT00740740||3|Patients scheduled for aortic bypass surgery
3185980|NCT00740753|Other|Treatment|yttrium 90 (TheraSphere) administration
3185981|NCT00740766|Experimental|Monitored|
3185982|NCT00740766|No Intervention|Unmonitored|
3185983|NCT00740805|Experimental|Treatment (veliparib, cyclophosphamide, doxorubicin)|"GROUP I: Patients receive veliparib PO every 12 hours on days 1-4 and cyclophosphamide IV over 60 minutes on day 3.~GROUP II: Patients receive veliparib PO every 12 hours on days 1-4, cyclophosphamide IV over 60 minutes on day 3, and doxorubicin hydrochloride IV over 15 minutes on day 3.~GROUP III: Patients receive veliparib PO every 12 hours on days 1-7, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1.~GROUP IV: Patients receive veliparib PO every 12 hours on days 1-14, cyclophosphamide IV over 60 minutes on day 1, and doxorubicin hydrochloride over 15 minutes on day 1.~In all groups, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3185984|NCT00740818|No Intervention|A|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
3185985|NCT00740818|Sham Comparator|B|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
2415319|NCT03467932|Active Comparator|Cohort A: ORMD-0801 once daily - QHS|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
2415320|NCT03467932|Active Comparator|Cohort A: ORMD-0801 twice daily - BID|Dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
2415321|NCT03467932|Active Comparator|Cohort A: ORMD-0801 three times daily - TID|ORMD-0801 three times daily - TID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
2415322|NCT03467932|Placebo Comparator|Cohort A: Matched Placebo Oral Capsule|Placebo matched to one of the three active comparator arms. (either QHS, BID, or TID)
2415323|NCT03467932|Placebo Comparator|Cohort A: Excipient-Matched Placebo three times daily-TID|Excipient matched placebo in a non-randomized single-blind fashion, TID, dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast and lunch.
2415324|NCT03467932|Active Comparator|Cohort B:ORMD-0801, 8 mg once daily - QHS:|ORMD-0801 8 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
2415325|NCT03467932|Active Comparator|Cohort B: ORMD-0801 8 mg twice daily - BID|ORMD-0801 8 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
2415326|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg once daily - QHS:|ORMD-0801 16 mg once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
2415327|NCT03467932|Active Comparator|Cohort B: ORMD-0801 16 mg twice daily - BID|ORMD-0801 16 mg twice daily - BID: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes) and 30-45 minutes prior to breakfast.
2415328|NCT03467932|Placebo Comparator|Excipient matched placebo once daily - QHS|Excipient matched placebo once daily - QHS: dosed in the evening prior to bedtime (@ 10 PM ± 90 minutes)
2415329|NCT03467919|Experimental|MFAT(Micro Fragmented Adipose Tissue)|Intra-articular knee injection of autologous Micro Fragmented Adipose Tissue harvested from the thigh using tumescent lipoaspiration and processing with minimal manipulation. This harvested tissue will then be injected into the patient's knee.
2415330|NCT03467919|Active Comparator|Conventional therapy|Intra-articular injection of corticosteroid (Triamcinolone 40mg).
2415331|NCT03467906||Weight loss < median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
2415332|NCT03467906||Weight loss > median of group|Sleeve gastrectomy surgery patients will take part in in-laboratory assessment. Based on 1-year post-surgical weight loss, a median split will be done to allocate subjects to one of two groups.
2415333|NCT03467880||Healthy subjects|Healthy subjects.
2415334|NCT03467880||Chronic obstructive pulmonary disease|Patience with chronic obstructive pulmonary disease.
2415335|NCT03467880||Asthma|Patience with asthma.
2415336|NCT03467880||Interstitial lung disease|Patience with interstitial lung disease.
2415337|NCT03467880||Upper airway obstruction|Patience with upper airway obstruction.
2415338|NCT03467867|Experimental|Venetoclax + Rituximab|Participants will be initially placed in a venetoclax 5 weeks ramp-up period, and will be administered an initial 20 mg oral tablet dose once daily (QD), incrementing weekly up to a maximum dose of 400 mg. Participants will then continue taking venetoclax 400 mg QD from Week 5 onwards, as directed by the investigator in combination with rituximab 375 mg/m^2 IV on Day 1 of Cycle 1 followed by 13.4 mL of rituximab SC 1,600 mg/26,800 Units vial (1,600 mg rituximab and 26,800 Units hyaluronidase human) on Day 1 of Cycle 2-6.
2415339|NCT03467854||VV ECMO|Patients 18 years of age or older, initiated on veno-venous (VV) ECMO for acute respiratory distress syndrome, and receiving piperacillin/tazobactam.Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An additional four blood samples will be drawn on day 2 at the same time points.
3185986|NCT00740818|Experimental|C|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
3185987|NCT00740844|No Intervention|1|No intermittent pneumatic compression of the lower limbs during patient hospitalisation in réanimation unit
3185988|NCT00740844|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
3185989|NCT00740883|Active Comparator|1|18 months of active warfarin therapy
3185990|NCT00740883|Placebo Comparator|2|18 months of placebo of warfarin
3185991|NCT00740896|Active Comparator|1|Participants smoke 8 cigarettes in 4 hours.
3185992|NCT00740896|Sham Comparator|2|Participants are not allowed to smoke for 4 hours.
3185993|NCT00740909|No Intervention|MAC|Minimal Attention Control
3185994|NCT00740909|Experimental|CBT|Cognitive Behavioral Therapy
3185995|NCT00740922||1|
3185996|NCT00740935|Other|1|Cohort of vaccinated infants against rotavirus
3185997|NCT00740948|Experimental|1|Rituximab
3185998|NCT00740948|Placebo Comparator|2|Placebo
2415344|NCT03467776||healthy|healthy control, 5 months to 3 years
2415345|NCT03467776||wheezing with atopy|suspected asthma with wheezing (>3 episodes per year) and atopy
2415346|NCT03467776||wheezing without atopy|wheezing without atopy
3185999|NCT00740961||Patients with cancer|Patients ≥ 65 years with new stage I-III breast or colon cancer seeking care. Patients will be matched on baseline scores, age and sex. Patients will be age and sex matched due to the known relation between inflammatory markers and demographic characteristics39,40, and will be matched on baseline VES scores to ensure similar baseline VES-13 scores between groups and which will then allow us to then assess effect of cancer treatment on outcomes.
3186000|NCT00740961||Patients without cancer|non-cancer patients, seeking care at out-patient clinics
2415349|NCT03467750|Experimental|Ketorolac|Participants randomized to the ketorolac group will receive 0.5mg/kg IV at the end of the adenotonsillectomy procedure, once hemostasis has been achieved
2415350|NCT03467750|Active Comparator|Standard of Care|Participants randomized to this group will receive the pain management standard of care for the adenotonsillectomy procedure.
2415351|NCT03467737|Experimental|Normal sorghum porridge, algal starch|Sorghum porridge with 13C-algal starch
2415352|NCT03467737|Experimental|Normal sorghum porridge, algal dextrins|Sorghum porridge with 13C-algal starch limit dextrins
2415353|NCT03467737|Experimental|Normal sorghum porridge, labeled flour|Sorghum porridge with 13C-labeled sorghum flour
2415354|NCT03467737|Experimental|Modified sorghum porridge, labeled flour|Modified sorghum porridge with 13C-labeled sorghum flour
2415355|NCT03467737|Experimental|Thinned sorghum porridge, labeled flour|Modified thinned sorghum porridge with 13C-labeled sorghum flour
2415356|NCT03467737|Experimental|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with 13C-labeled octanoic acid
2415357|NCT03467724|Active Comparator|Fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
2415358|NCT03467724|No Intervention|No fractional radiofrequency|Each surgical scar will be divided equally into two sections. One section of the scar will receive the study treatment while the other section will receive no study treatment for the duration of the study.
2415359|NCT03467698|Experimental|Active tDCS|active HD-tDCS will be administered
2415360|NCT03467698|Sham Comparator|Sham tDCS|sham HD-tDCS will be administered
3186001|NCT00740987|No Intervention|1|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
3186002|NCT00740987|Experimental|2|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
2415363|NCT03467672||Infected patients|
2415364|NCT03467672||Control group|
2415365|NCT03467659|Experimental|Cracked whole wheat porridge|Large particle whole wheat porridge
2415366|NCT03467659|Experimental|Semolina wheat porridge|Large particle refined wheat porridge
2415367|NCT03467659|Experimental|Whole wheat flour porridge|Small particle whole wheat porridge
2415368|NCT03467659|Experimental|Refined wheat flour porridge|Small particle refined wheat porridge
2415369|NCT03467659|Experimental|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran
2415370|NCT03467659|Experimental|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran
2415371|NCT03467646|Active Comparator|Sleeve Gastrectomy|Patients undergo a laparoscopic sleeve gastrectomy as bariatric procedure
2415372|NCT03467646|Active Comparator|Roux-en-Y gastric bypass|Patients undergo a laparoscopic Roux-en-Y gastric bypass as bariatric procedure
2415373|NCT03467646|Experimental|One-Anastomosis gastric bypass|Patients undergo a laparoscopic One-Anastomosis gastric bypass as bariatric procedure
2415374|NCT03467633|Experimental|High-intensity interval training (HIIT)|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the University of Ottawa Heart Institute prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
2415375|NCT03467633|No Intervention|Usual Care Control|Participants assigned to the control group will have usual care, which involves no behavioural interventions leading up to their electro-cardioversion.
2415376|NCT03467620|Experimental|Cannabidiol oral capsule|25-mg capsule of Cannabidiol (CBD) per day taken daily for a duration of 12 weeks.
2415377|NCT03467620|Placebo Comparator|Placebo oral capsule|One placebo capsule per day for a duration of 12 weeks
2415378|NCT03467607|Active Comparator|3ml/kg|15 patients ventilated with 3ml/kg ideal body weight while on one lung ventilation
2415379|NCT03467607|Active Comparator|4ml/kg|15 patients ventilated with 4ml/kg ideal body weight while on one lung ventilation
2415380|NCT03467607|Active Comparator|control|15 patients ventilated using the anaesthetists usual ventilation strategy
2415508|NCT03466593|Active Comparator|Retrospective cohort|Routine care before the prehabilitation program was introduced
2415509|NCT03466593|Experimental|Extra early mobilization|Mobilization the day of surgery
2415510|NCT03466593|Active Comparator|Traditional mobilization|Routine care with mobilization the day after surgery
3186003|NCT00741000|Experimental|Experimental|Cervical low force mobilization procedure.
2415381|NCT03467594|Experimental|Intervention arm|"8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.~Outcome measures assessed at baseline and follow-up (8 weeks)"
2415382|NCT03467594|No Intervention|Control|Outcome measures only at baseline at follow-up (8 weeks)
2415383|NCT03467568|Active Comparator|Sodium chloride / Water|The sodium chloride / water arm involves 300mg sodium chloride being consumed in a capsule and on two occasions 150ml of water being drunk
2415384|NCT03467568|Active Comparator|Sodium chloride / no water|A capsule containing 300mg of sodium chloride will be consumed but no water will be drunk over the morning
2415385|NCT03467568|Active Comparator|Placebo / water|A capsule containing a placebo will be consumed and on two occasions 150ml of water will be drunk
2415386|NCT03467568|Placebo Comparator|Placebo / no water|A capsule containing a placebo will be consumed but no water will be drunk over the morning
2415387|NCT03467555|Experimental|distalization group|Class II correction using zygomatic miniplates
2415388|NCT03467542|Experimental|dAVF treatment|PHIL® Liquid Embolic System
2415389|NCT03467516|Experimental|Tumor Infiltrating Lymphocytes (TIL)|Patients with uveal melanoma will receive the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide followed by infusion of up to 2x10^11 TIL infused intravenously through a central vein catheter and Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
2415390|NCT03467503|No Intervention|Prenatal Care/Nutrition Education|Participants were given nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
2415391|NCT03467503|Experimental|Dietary Intervention|Participants were given dietary blueberries (2 cups) and soluble fiber (12g). They also received nutrition educational counseling on healthy dietary habits and gestational weight gain as part of standard prenatal care.
2415392|NCT03467490|Experimental|Treatment|65 participants will be invited to receive a one-day educational intervention (first study visit) at the Ivey Eye Institute. The educational intervention includes watching a short video series and receiving educational handouts which summarize the content of the videos. Participants will have access to the educational handbook for reference. At two months post-intervention, participants will be invited back to St. Joseph's Hospital to complete the second administration of the heiQ and OSDI. Participants will have an opportunity to ask the ophthalmologist any question during the question and answer period. Participants will then be asked to provide feedback on the video series using a participation satisfaction survey and will be given an educational handbook which may be used to as a reference/guide on how to self-manage
2415393|NCT03467490|No Intervention|Control|Patients will continue with treatment as usual without any educational intervention. They will complete the heiQ and OSDI at baseline and 2 months later during a routine office visit. At the 2-month visit, participants will be asked to complete the second administration of the heiQ and OSDI before being offered the opportunity to view the videos series, receive the educational handbook, and provide feedback on the educational material.
3186004|NCT00741052|Experimental|1|Ciprofloxacin
2415395|NCT03467464|Experimental|Intervention|EMDR treatment
2415396|NCT03467438|Experimental|A|Zinc-l-carnosine, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
2415397|NCT03467438|Placebo Comparator|B|Placebo, liquid oral formulation, 75mg twice daily (20mL, using the measuring cup, twice daily), to be swallowed on an empty stomach (waiting at least one hour from the last meal).
3186005|NCT00741052|Active Comparator|2|Azithromycin
2415405|NCT03467399|Experimental|Cochlear implant users|This is a within-subject, repeated measures study. There was one arm in this study, each subject served as their own control. All subjects received all interventions.
3145475|NCT00072163|Experimental|Treatment (temozolomide, thalidomide)|Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
2415511|NCT03466580|Experimental|Intervention|('Standard' specialized palliative care +) The Carer Support Needs Assessment Tool (CSNAT) intervention.
2415512|NCT03466580|No Intervention|Control|('Standard' specialized palliative care). No intervention offered.
2416052|NCT03463187|Experimental|160mg SHR-1314 (Part B)|SHR-1314 160mg, subcutaneously
3145476|NCT00072215|Experimental|Regimen A: TIP|
3145477|NCT00072215|Experimental|Regimen B: VeIP|
3145478|NCT00072358|Experimental|patients have refractory bone marrow disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
3145479|NCT00072358|Experimental|patients have no evidence of disease|This phase II trial of the anti-GD2 murine IgG3 monoclonal antibody 3F8 combined with granulocyte-macrophage colony stimulating factor (GM-CSF) will assess response of minimal residual disease (MRD) in patients with high-risk neuroblastoma (NB) and help establish the optimal way to use GM-CSF.
3145480|NCT00072436|Experimental|Treatment|"Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose."
3145481|NCT00072462|Active Comparator|Anastrozole|
3145482|NCT00072462|Active Comparator|Tamoxifen|
3145483|NCT00072527|Experimental|Induction and consolidation chemotherapy|"Induction chemotherapy (Cycles 1 and 2): Patients receive cisplatin 30 mg/m^2 on days 1, 8, 22 and 29 and irinotecan 65 mg/m^2 on days 1, 8, 22 and 29 for cycles 1 and 2.~Consolidation chemotherapy (Cycles 3, 4 and 5 beginning on day 43, week 7): Patients receive carboplatin on days 43, 64 and 85, etoposide 100 mg/m^2 IV on days 43-45, 64-66 and 85-87 and XRT 5 fractions/week starting on day 43"
3145484|NCT00072631|Experimental|1 erlotinib|
3145485|NCT00072657|Experimental|1|Participants will partake in cognitive behavioral therapy for 12 weeks.
3145486|NCT00072657|Experimental|2|Participants will partake in tai chi chih for 12 weeks.
2415411|NCT03467360|Experimental|One experimental arm|non randomized, open-label extension cohort, evaluating the safety of acetazolamide in combination with platinum and etoposide-based radiochemotherapy in patients with Localized small lung cancer
2415412|NCT03467347|Experimental|VR used continuously for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used continuously for approximately 90 days.
2415413|NCT03467347|Experimental|VR used cyclically for approximately 90 days|One silicone elastomer vaginal ring (VR) containing the active 200 mg dapivirine (DPV) and 320 mg levonorgestrel (LNG), used cyclically for approximately 90 days. Use the VR for 28 days, remove for 2 days.
2415414|NCT03467334|Experimental|B. breve|Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.
2415415|NCT03467334|Experimental|B. breve plus L. fermentum|Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.
2415416|NCT03467334|Active Comparator|Simethicone 20 mg|Control group that will receive simethicone 4 times (10 drops) a day.
2415417|NCT03467321||Pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
2415418|NCT03467321||Non-pregnant group|Balance with the one leg balance test with the eyes open and closed, pulmonary functions with a spirometer, and LBP with the Visual Analogue Scale (VAS) were assessed.
2415419|NCT03467308||Colorectal cancer patients|50 Patients confirmed histopathologically to have early stages of colorectal cancer.
2415420|NCT03467308||Risky group|20 risky patients (those with ulcerative colitis, chron's disease, familial adenomatous polyposis).
2415421|NCT03467295||Surgically treated group|Surgical removal of intracerebral CMs by craniotomy with or without following stereotactic radiosurgery.
2415422|NCT03467295||Conservatively treated group|Observation with the best medicine administration and supportive treatment are performed.
2415423|NCT03467282|Experimental|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
2415424|NCT03467282|Placebo Comparator|Placebo|1g polydextrose/maltodextrin - twice day
2415425|NCT03467256|Experimental|experimental|Patients will receive fludarabine 120 mg/m2 (totally) intravenously (IV) over 30 minutes on days -5 to -2 and cyclophosphamide 750 mg/m2 IV over 60 minutes on day -2. One hour prior to infusion of CAR T-cells patients will receive tocilizumab IV 8 mg/kg (max 800 mg) over 1 hour. Patients then receive CD19-CAR T cells IV over 20-30 minutes on day 0.
2415426|NCT03467243|Experimental|CBSST|Veterans participate in 20 weekly group sessions using Cognitive Behavioral Social Skills Training model
2415427|NCT03467243|Experimental|SST|Veterans participate in 20 weekly group sessions using Social Skills Training model
2415428|NCT03467243|Other|Treatment as usual|Veterans receive treatment as usual
2415429|NCT03467230||NoL Index|All patients will be monitored by PMD-200 device
3145487|NCT00072657|Active Comparator|3|Participants will act as a control and attend educational sessions for 12 weeks.
3145488|NCT00072670|Experimental|Trabectedin 0.58 milligram per square meter (mg/m^2)|Trabectedin will be administered as 3-hour intravenous infusion at dose of 0.58 mg/m^2 weekly on Day 1, 8 and 15 in 28-day cycle and will be continued until disease progression or unacceptable toxicity.
2415432|NCT03467191|Experimental|Alcohol Beverage|Moderate dose of alcohol (target BAC .08%)
2415433|NCT03467191|Placebo Comparator|Placebo Beverage|
2415434|NCT03467178|Experimental|Decitabine plus Carboplatin|Carboplatin AUC 5 d 8 q 28 plus Decitabine 10 mg/mq iv d1-5 q 28
2415435|NCT03467178|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 or Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28
2415436|NCT03467165|Experimental|Hand ExAblate|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
2415437|NCT03467165|Experimental|Hip ExAblate|MRgFUS treatment of pain caused by hip OA
2415438|NCT03467152|Experimental|E2027|Participants will be randomized to receive a 50 milligram (mg) once daily oral dose of E2027 for 12 weeks.
2415439|NCT03467152|Placebo Comparator|Placebo|Participants will be randomized to receive a 50 mg once daily oral dose of E2027-matched placebo for 12 weeks.
2415513|NCT03466567|Experimental|Oral semaglutide, ciclosporin, probenecid|Participants will receive oral semaglutide in treatment period 1, ciclosporin in treatment period 2, and probenecid in treatment period 3.
3145489|NCT00072670|Experimental|Trabectedin 1.5 mg/m^2|Trabectedin will be administered at dose of 1.5 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
3145490|NCT00072670|Experimental|Trabectedin 1.2 mg/m^2|Trabectedin will be administered at dose of 1.2 mg/m^2 as 24-hour infusion every three weeks, and will be continued until disease progression or unacceptable toxicity.
3145491|NCT00072839|Placebo Comparator|Placebo|placebo solution injected subcutaneously daily into either thigh or abdomen.
3145492|NCT00072839|Experimental|teduglutide 0.05|teduglutide 0.05 mg/kg/d injected subcutaneously daily.
3145493|NCT00072839|Experimental|teduglutide 0.1|0.1 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
3145494|NCT00072839|Experimental|teduglutide|0.2 mg/kg/d teduglutide injected subcutaneously into thigh or abdomen
3145495|NCT00072904|Placebo Comparator|III|Placebo take half tab with meals tid
3145496|NCT00072930|Active Comparator|1|MEDI-522 + Docetaxel + Prednisone + Zoledronic Acid (N=55)
3145497|NCT00072930|Other|2|Docetaxel + Prednisone + Zoledronic Acid (N=55)
2415440|NCT03467139|Experimental|Study Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion by physiotherapist. Then, abdominal breathing exercise training was given 3 times a week as 30 sets of 3 sets a week and the patients were treated for 8 weeks
2415441|NCT03467139|No Intervention|Control Group|Hotpack was applied for 15 min and TENS was applied for 15 min and ultrasonics for 5 min. Then scapular mobilization and passive stretching exercises were applied for 8 weeks in 10 sets of 3 sets (flexion, abduction, internal and external rotation) to increase joint range of motion.
2415442|NCT03467113|Experimental|ZX008 0.2 to 0.8 mg/kg/day|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive open-label ZX008 (flexible dosing 0.2 mg/kg/day to 0.8 mg/kg/day)
2415443|NCT03467100|Experimental|XEN901|Single ascending dose: Single oral dose for each cohort; Multiple ascending dose: 7 days of single oral dose twice daily for each cohort
2415444|NCT03467100|Placebo Comparator|Placebo|Single Ascending Dose: Single oral dose for each cohort; Multiple Ascending Dose: 7 days of single oral dose twice daily for each cohort
2415445|NCT03467087|Experimental|Electrical muscle stimulation|Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.
2415446|NCT03467061|Active Comparator|Nitrate-rich beetroot juice|2 x 70mL concentrated juice per day for 14 days
2415447|NCT03467061|Placebo Comparator|Nitrate-depleted beetroot juice|2 x 70mL concentrated juice per day for 14 days
2415448|NCT03467061|Other|Antibacterial mouthwash|2 x 10mL antibacterial mouthwash per day for 14 days
3186006|NCT00741078|Experimental|atorvastatin, amlodipine|
2415451|NCT03467035||desaturation|"ΔSpO2 >10% or lowest SpO2<90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
2415452|NCT03467035||non-desaturation|"ΔSpO2 <10% and lowest SpO2>90 during baseline six minute walk test~Check serum level of inflammasone, such as IL-1beta, TGF-beta TRT-PCR for PBMC"
2415453|NCT03467009|Experimental|iPACT Intervention|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention.~Eight-week longitudinal tailored CBT-based text-message program."
2415454|NCT03467009|Active Comparator|Control: Enhanced Usual Care (EUC)|The investigators will provide participants with a standard resource sheet with information on bullying and mental health resources.
2415455|NCT03467009|Experimental|iPACT Intervention- App|"In-clinic brief session, introducing basic principles of cognitive behavioral theory and the structure of the message portion of the intervention delivered via app.~Eight-week longitudinal tailored CBT-based message program delivered via app."
3145498|NCT00072982|Active Comparator|1|Fish Oil
3145499|NCT00072982|Active Comparator|2|Borage Oil
2415458|NCT03466983|Experimental|Iron Isomaltoside|Iron Isomaltoside (Monofer) administered IV
2415459|NCT03466983|Active Comparator|Ferric Carboxymaltose|Ferric Carboxymaltose (Injectafer) administered IV
2415460|NCT03466970||IgG4 patient|20 samples of IgG4 patients
2415461|NCT03466970||healthy donors|20 healthy donors
2415462|NCT03466957|Experimental|3D printed applicator|individually designed applicator for BT
2415463|NCT03466944||5-24 year old paediatric patients with childhood Leukaemia|Cooperative paediatric individuals and young adults (5-24-years-old) with proven Acute Lymphoblastic Leukaemia (ALL) or Acute Myeloblastic Leukaemia (AML) planned for bone marrow transplantation.
2415464|NCT03466931|Experimental|Dietary intervention|Meals containing Milk and Milk
2415465|NCT03466931|No Intervention|Historical cohort|Standard care
2415467|NCT03466905|Active Comparator|Intervention|Assessment of Ambulance Medical Service
2415468|NCT03466905|No Intervention|Control|Local treatment guidelines
2415469|NCT03466879||Active device users|Users will use an active SYNUS Pain Relief device
2415470|NCT03466879||Sham device users|Users will use a sham SYNUS Pain Relief device that is not providing treatment
2415471|NCT03466866|Experimental|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
2415472|NCT03466866|Active Comparator|Intensive Diabetes Education|In-home diabetes education
2415473|NCT03466840|Experimental|The Coronally Advanced Lingual Flap|"On the lingual side of mandible, a full-thickness muco-periosteal flap is elevated until reaching mylohyoid line. Using a blunt instrument, a connective tissue band is localized continuing with the epimysium of the mylohyoid muscle and is inserted into the inner part of the lingual flap . The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe the amount of advancement is measured."
2415572|NCT03466307||Group B|Thirty patients without nocturnal shoulder pain
3145500|NCT00072982|Active Comparator|3|Fish Oil and Borage Oil
3145504|NCT00073242|Experimental|leptin repletion|Repletion of leptin following weight loss induced by dietary modification.
3145505|NCT00073242|Experimental|T3 repletion|Repletion of T3 following weight loss induced by dietary modification.
3145506|NCT00073346|Experimental|cognitive behavior therapy for hoarding disorder|Cognitive behavior therapy included 26 sessions of motivational enhancements; skills training for sorting, organizing and problem solving; direct practice not acquiring new items and discarding possessions to remove clutter and organize possessions; cognitive therapy to evaluate beliefs about possessions; and relapse prevention skills.
2415474|NCT03466840|Active Comparator|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured"
2415475|NCT03466814||JIA participants|
2415476|NCT03466801|Experimental|Group prednisone|Prednisone was taken 1mg/kg/d(maximum 60mg/d)for 8 weeks to start.Then decreased 5mg every 2 weeks; When reduced to 40mg,reduced 5mg every 4 weeks. When reduced to 20mg, reduced 2.5mg every 8 weeks until the end.
2415477|NCT03466801|Active Comparator|Group MP and CTX|The first month,Methylprednisolone(MP) was injected for 3 days(weight >60kg,500mg/d;<60 kg,300mg/d),and 0.4mg/kg/d for 27 day.The second month,Cyclophosphamide(CTX) orally was 100mg/d for 1 month.And this regimen is repeated for six months.
2415478|NCT03466788|Other|Patients treated with chemotherapy|
2415479|NCT03466788|Other|Patients not treated with chemotherapy|
2415480|NCT03466749|Experimental|Intervention group|Paclitaxel Eluting Balloon Catheter treatment
2415481|NCT03466736||cognitively intact older adults|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2415482|NCT03466736||Mild Cognitive Impairment|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2415483|NCT03466736||Alzheimer's disease|Each subject will receive an amyloid PET scan with [18F]flutemetamol
2415484|NCT03466710|Active Comparator|Colposcopy arm|Patients received colposcopy as per standard of care
2415485|NCT03466710|Experimental|Pap arm|Patients received a Pap test only
2415486|NCT03466710|Experimental|HPV arm|Patients received an HPV test only
2415487|NCT03466697|Other|Healthy subjects|All subjects will be injected twice for each visit (normal saline or glucose)
2415488|NCT03466684|Experimental|BIA-directed fluid resuscitation|After the achievement of CVP, MAP and ScvO2 goals, if hyperhydration (HL > 74.3%) was found, then the following fluid management was applied with each passing 6h. If HL was above 87% (severe level), fluid infusion was restricted, a furosemide drip was used, and CRRT was initiated with an ultrafiltration rate when patients were failure or inadequate response to above diuretic therapy that gave a net negative fluid balance of at least 1500 ml during the next 6h. If HL was 81%-87% (moderate level), above methods were used to trigger a net negative fluid balance (about 1000 ml) for the next 6h. Similarly, If HL was 74.3%-81% (mild level), a net negative fluid balance of about 500 ml would be achieved during the next 6h of ICU hospitalization. If HL was blow 71%, a state of dehydration, CVP, MAP, and ScvO2 was maintained as above during ICU resuscitation.
2415489|NCT03466684|Active Comparator|Traditional fluid resuscitation|A timely restricted intravenous fluid regimen or dehydration therapy was implemented by two senior clinicians according to cumulative fluid balance recording and hemodynamic condition such as heart rate, blood pressure, central venous pressure, mean arterial pressure, urine output and body weight change.
2415490|NCT03466671|Other|Low dose once per day and placebo|"Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
2415491|NCT03466671|Other|Low dose twice per day and placebo|Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
2415492|NCT03466671|Other|High dose once per day and placebo|"Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.~After four weeks washout, four weeks administrations of placebo twice per day in morning and evening."
2415493|NCT03466671|Other|High dose twice per day and placebo|Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
2415494|NCT03466671|Other|Placebo and low dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
2415495|NCT03466671|Other|Placebo and low dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
2415496|NCT03466671|Other|Placebo and high dose once per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
2415497|NCT03466671|Other|Placebo and high dose twice per day|Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.
3186007|NCT00741117|Active Comparator|Low Bilirubin Group|Low Bilirubin Group: subjects with a bilirubin level less than or equal to 10 mg/dl
3186008|NCT00741117|Active Comparator|Medium Bilirubin Group|Medium Bilirubin Group: subjects with a bilirubin level from 11mg/dl to 30 mg/dl
2415500|NCT03466645|Active Comparator|1st group, receiving vancomycin|The 1st group receives vancomycin an hour before craniotomy
2415501|NCT03466645|Active Comparator|2nd group, receiving cefazolin|The 2nd group receives cefazolin an hour before craniotomy
2415502|NCT03466632|Active Comparator|• Propofol Group|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..
2415503|NCT03466632|Active Comparator|• Dexmedetomidine Group|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
2415504|NCT03466619|Experimental|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
2415505|NCT03466606|Experimental|Prehabilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
2415506|NCT03466606|No Intervention|Control|Conventional treatment
2415507|NCT03466593|Experimental|Prospective cohort-prehabilitation|A prehabilitation program including advice about diet, increased physical activity and cessation of smoking and drinking alcohol.
2415573|NCT03466307||Group C|Healthy controls
2415514|NCT03466567|Experimental|Probenecid, oral semaglutide, ciclosporin|Participants will receive probenecid in treatment period 1, oral semaglutide in treatment period 2, and ciclosporin in treatment period 3.
2415515|NCT03466567|Experimental|Ciclosporin, probenecid, oral semaglutide|Participants will receive ciclosporin in treatment period 1, probenecid in treatment period 2, and oral semaglutide in treatment period 3.
2415516|NCT03466554|Experimental|hyperbaric oxygen therapy (HBOT) active treatment|60 daily HBOT sessions will be administrated 5 days per week. Comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
2415517|NCT03466554|No Intervention|Control-follow up|"The standard of care of psychological and mediational support .~After 3 months of follow up, participants will be re-evaluated. The individuals in the control group will then be offered to receive the treatment and to be re-reevaluated after the treatment is over (3 months)."
2415518|NCT03466541|Experimental|Riskbruk|The employees randomised to the Riskbruk group will be offered two consultations a ∼15 min with the OHS. The subjects will receive individual feedback on the screening results. During these sessions, Motivational Interviewing will be used.
2415519|NCT03466541|Experimental|Balance|The group allocated to the Balance intervention will follow a comprehensive multi-session eHealth intervention with personalised feedback on the screening results.
2415520|NCT03466541|No Intervention|Control group/usual care|The control group will receive the usual follow-up provided by the OHS for persons with risky alcohol behaviour. In order to provide something that appears as a plausible follow-up to the control participants, they will be given a booklet that covers general information about alcohol and potential risks and harms of drinking. The booklet contains no advise on how to achieve a change in drinking behaviour.
2415521|NCT03466528|Active Comparator|Standard treatment - Pabrinex alone|Pabrinex alone
2415522|NCT03466528|Active Comparator|Pabrinex + magnesium sulphate|standard treatment and magnesium sulphate
2415523|NCT03466528|Experimental|Magnesium sulphate alone|This group receives the study intervention and delayed Pabrinex
2415524|NCT03466515|Experimental|intervention|Patients enrolled in the study will be treated for their anal fistula by surgical closure of the internal opening, debridement of the fistula and injection of patients own stem cells enriched fatty tissue around the fistula.
2415525|NCT03466502|No Intervention|No oral vancomycin|
2415526|NCT03466502|Experimental|Oral vancomycin 125 mg twice daily|
2415527|NCT03466502|Experimental|Oral vancomycin 125 mg daily|
2415528|NCT03466489|Experimental|Floraseal|The surgical site will first be cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. Once dry, the FloraSeal surgical preparatory solution will be applied per the manufacturers recommendations. The extremity will be draped in sterile fashion however adhesive drapes over the surgical site itself will not be applied.
2415529|NCT03466489|No Intervention|Control|The operative site is first cleaned with isopropyl alcohol. Once the site is dry, alcohol based chlorhexidine gluconate preparatory solution will be applied to the surgical site. The operative site will then be draped in sterile fashion. An iodine impregnated adhesive drape will then be applied to the surgical site.
2415530|NCT03466476|Experimental|Wearable Technology|Patients in this arm will be provided with their own Consensus TracPatch wearable device as well as instructions on its use.
2415531|NCT03466476|No Intervention|Current Standard|Patients in this arm will not be provided with any wearable device.
2415532|NCT03466463|Experimental|GNT0003|2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study
2415533|NCT03466450|Experimental|Glasdegib and Temozolomide Oral Capsule|"During Phase Ib, Four to six weeks after surgical diagnosis, concurrent with radiotherapy (STUPP) + temozolomide (75mg/m2/day for 42 days) + PF-04449913 (Glasdegib) (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered.~During Phase II, Radiation therapy, temozolomide and glasdegib will be administered. This last, as the dose that have been selected previously, based on the Phase Ib results. Glasdegib ( PF-04449913) recommended dose until progresion of disease, unacceptable toxicity, non-compliance, consent withdrawal up to 2 years."
2415534|NCT03466437|Experimental|Glass-fiber post + composite resin restoration|
2415535|NCT03466437|Experimental|Glass-fiber post + metalceramic crown|
2415536|NCT03466437|Active Comparator|Cast-metal post + metalceramic crown|
2415537|NCT03466424||Group 1|preoperative short-course radiotherapy(5×6Gy) followed by 4×mFOLFOX6 chemotherapy
2415538|NCT03466424||Group 2|preoperative short-course radiotherapy(5×7Gy) followed by 4×mFOLFOX6 chemotherapy
2415539|NCT03466424||Group 3|preoperative short-course radiotherapy(5×8Gy) followed by 4×mFOLFOX6 chemotherapy
2415540|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 1 (Guselkumab)|Participants will receive guselkumab (Dose 1) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-Term Extension (LTE) phase and continue to receive guselkumab.
2415541|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 2 (Guselkumab)|Participants will receive guselkumab (Dose 3) by intravenous (IV) infusion, followed by guselkumab (Dose 2) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2415542|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 3 (Guselkumab)|Participants will receive guselkumab (Dose 4) by intravenous (IV) infusion, followed by guselkumab (Dose 5) by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2415543|NCT03466411|Active Comparator|Phase 2 (GALAXI 1): Group 4 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE and continue to receive ustekinumab.
2415544|NCT03466411|Experimental|Phase 2 (GALAXI 1): Group 5 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (Ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
2415644|NCT03465839|Experimental|Bedside handover|Education for improving handovers quality + Education for improving bedside handovers
2415545|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 1 and Group 2 (Guselkumab)|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the LTE phase and continue to receive guselkumab.
2415546|NCT03466411|Active Comparator|Phase 3 (GALAXI 2 and 3): Group 3 (Ustekinumab)|Participants will receive ustekinumab by intravenous (IV) infusion, followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue ustekinumab may enter the LTE phase and continue to receive ustekinumab.
2415547|NCT03466411|Experimental|Phase 3 (GALAXI 2 and 3): Group 4 (Placebo/Ustekinumab)|Participants will receive placebo administered by intravenous (IV) infusion. At Week 12, non-responders will receive active treatment (ustekinumab) administered by intravenous (IV) infusion followed by subcutaneous (SC) injection. Participants who are eligible and willing to continue placebo/ustekinumab may enter the LTE and continue to receive placebo/ustekinumab.
2415548|NCT03466398|Experimental|Intervention Arm|Patients will use the Vivify Health RPM protocol as part of their diabetes management. They required to complete the Care Plan questions on a daily basis, and will upload blood glucose readings directly to the tablet twice a day. They will also have scheduled video conferences with study team physicians or advanced practice nurses on a weekly basis, to discuss ongoing diabetes management and educational objectives.
2415549|NCT03466398|No Intervention|Control Arm|Patients in this arm will manage their diabetes at home per normal standard of care, without any extra intervention from the study investigators.
2415550|NCT03466385|Experimental|Nasal High Flow|Patients randomized to NHF device with initial settings of flow=50-60 L·min-1, temperature=37ο Celsius and FiO2 adjusted to maintain SpO2 between 88%-92%.
2415551|NCT03466385|Active Comparator|Non-Invasive Ventilation|Patients randomized to NIV with initial settings EPAP=3cmH2O, IPAP=15cmH2O, I:E=1:2 to 1:3, inspiratory time=0.8-1.2sec and FiO2 adjusted to maintain SpO2 between 88%-92%.
2415552|NCT03466372|Experimental|biofeedback 1|biofeedback training with progression of targets
2415553|NCT03466372|Active Comparator|biofeedback 2|biofeedback training with progression of targets and speeds
2415554|NCT03466359|Experimental|DEF-EI|these adolescents will follow a dietary restriction of 10% of their daily energy intake.
2415555|NCT03466359|Experimental|DEF-EX|these adolescents will increase their physical activity-induced energy expenditure by 10% per day.
3145507|NCT00073346|No Intervention|Wait list control|Participants waited to receive treatment for 12 weeks
3145508|NCT00073398|Experimental|1|Ph II Arm 1
3145509|NCT00073593|Experimental|bivalirudin|250mg vial given as 0.75mg/kg intravenous (IV) bolus and 1.75 mg/kg/hr IV infusion for the duration of the procedure with the option to increase or decrease the infusion in 0.25 mg/kg/hr increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an ACT>300 seconds.
3145510|NCT00073593|Active Comparator|heparin/protamine|1.5-3.5 mg/kg (200-400 U/kg) intravenous (IV) bolus to target an ACT >300 seconds followed by weight-adjusted boluses as needed during the procedure to achieve/maintain the target ACT. Protamine as needed
3145511|NCT00073619|Experimental|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
2415561|NCT03466333|Experimental|Investigational medicinal product|Oral enalapril maleate once daily: 5mg for 1 week, then 10mg for 2 weeks, then 20mg maintenance (for total of 6 months postpartum)
2415562|NCT03466333|Placebo Comparator|Placebo|Oral placebo once daily for 6 months postpartum
2415563|NCT03466333|No Intervention|Observational arm|For participants who decline to be take part in the interventional part of the study (decline randomisation to IMP/placebo) however they consent to the observational components of the study (serial echocardiography and biomarkers postpartum).
2415564|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T7-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -9, -8 and -7.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 7 days (T7) after the end of the preconditioning regimen"
2415565|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL1|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 1: 1x108 NKR-2 (adjusted at 1.5x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
2415566|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL2|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 2: 3x108 NKR-2 (adjusted at 4.6x106 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
2415567|NCT03466320|Experimental|Phase I Dose Escalation Segment 1 - T3-DL3|"Preconditioning (consisting in cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² daily {CYFLU}) at days -5, -4 and -3.~Dose 3: 1x109 NKR-2 (adjusted at 1.5x107 NKR-2/kg for patients with body weight ≤ 65 kg) administered at 3 days (T3) after the end of the preconditioning regimen"
2415568|NCT03466320|Experimental|Phase I Dose Escalation - extension|This extension segment will enroll more patients (to reach 9 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
2415569|NCT03466320|Experimental|Phase II Segment 1|This extension segment will enroll more patients (to reach 13 evaluable patients in total) to further evaluate the selected treatment regimen, i.e., the recommended NKR-2 dose (1x108 or 3x108 or 1x109NKR-2/injection) with the CYFLU preconditioning treatment administered at the recommended interval (T3 or T7) prior to NKR-2 administration.
2415570|NCT03466320|Experimental|Phase II Segment 2|Enrollment in the Phase II part of the study will be divided in 2 consecutive segments, with 13 patients in total in the segment 1 and 30 new patients in segment 2 (43 patients in total) if the study is not terminated due to futility, according a Simon's two-stage optimal design
2415571|NCT03466307||Group A|Thirty patients with nocturnal shoulder pain
3186009|NCT00741117|Active Comparator|High Bilirubin Group|High Bilirubin Group: subjects with a bilirubin level greater than or equal to 30 mg/dl
3186010|NCT00741130||C|normal volunteers
3145512|NCT00073619|No Intervention|Non-intervention Comparison|Provide no active intervention to the comparison group, although assess the children at the same assessment points as the experimental group. Participants in the control arm were told they were FRIENDS Program participants.They received rewards for participating in the assessments.
2415575|NCT03466281|Active Comparator|IBS School|Patient education provided in a group setting
2415576|NCT03466281|Active Comparator|Internet patient education|Patient education provided via the internet
2415577|NCT03466268|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
2415578|NCT03466255||Cardiac outpatients|Subjects referred for outpatient coronary angiography.
2415579|NCT03466242|Experimental|Intranasal Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine (1-2ug/kg)
2415580|NCT03466242|Active Comparator|IV Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine (1mg/kg)
2415581|NCT03466229|Active Comparator|Antioxidant|Androferti - 1 twice per day
2415582|NCT03466229|Placebo Comparator|Placebo|Placebo - 1 twice per day
2415583|NCT03466216|Experimental|AlphaMedix|There is only a single treatment arm.
3145513|NCT00073645|Experimental|1|Family/Parents CBT (FCBT) for 14 to 16 weekly sessions
3145514|NCT00073645|Active Comparator|2|Peer/Group CBT (GCBT) for 14 to 16 weekly sessions
2415586|NCT03466190|Experimental|Custom made PEEK plate fixation|Open Reduction Internal Fixation using Custom made PEEK plates.
2415587|NCT03466190|Active Comparator|Titanium plate fixation|Open Reduction Internal Fixation using conventional titanium plating system.
2415588|NCT03466177||Ab+ AD patients|"amyloid positive Alzheimer's Disease patients~Venous blood sampling Hematology and chemistry~Genotyping: apolipoprotein E (apoE) polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2415589|NCT03466177||Ab+ Mild Cognitive Impairment (MCI) patients|"amyloid positive Mild Cognitive Impairment patients~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2415590|NCT03466177||Ab+ cognitively intact volunteers|"amyloid positive cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2415591|NCT03466177||Ab- cognitively intact volunteers|"amyloid negative cognitively intact volunteers~Venous blood sampling Hematology and chemistry~Genotyping: apoE polymorphism Cerebral imaging~Brain MRI MPRAGE volumetric MRI, en FLAIR and Gradient Echo sequence~18F-Flutemetamol PET CT~Neuropsychiatric testing Auditory Verbal Learning Test (AVLT) Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Raven's Progressive Matrices (RPM) Mini Mental State Examination (MMSE) Neuropsychiatric Inventory (NPI) Cornell Scale for Depression in Dementia (CSDD)~Ocular examination Visual acuity, biomicroscopy, funduscopy Fundus pictures, including hyperspectral imaging OCT + angio-OCT (Non-invasive, multimodal retinal imaging)"
2415592|NCT03466164|Experimental|Behavioral: Mindfulness Based Stress Reduction Program|Mindfulness-Based Stress Reduction MZ: identical (monozygotic; MZ) twins are tested in a pre-post manner, with only one twin randomly assigned to MT in between the two testing sessions
2415593|NCT03466164|No Intervention|Control MZ|Control MZ twin will complete 2 testing sessions without intervention.
3145515|NCT00073671|Experimental|1|Participants receive a group cognitive-behavioral prevention program, which involved 8 weekly sessions and 6 monthly sessions of CBT skills such as cognitive restructuring, problem-solving, assertivenss, and behavioral activation. Participants in this arm also were able to seek the same kinds of nonstudy treatments as described in the usual care arm.
3145516|NCT00073671|Active Comparator|2|Participants receive usual care, which involves any type of treatment (e.g., psychotherapy, counseling, pharmacotherapy).
2415596|NCT03466138||General Anesthesia|subjects requiring a surgical procedure under general anesthesia. monitored by PMD-200
2415597|NCT03466125||Adult patients who underwent cardiac surgery in Massachusetts|No interventions. A retrospective cohort study of patients who underwent cardiac surgery in Massachusetts in calendar years 2012 - 2016.
3145517|NCT00073684|Experimental|1|Participants will receive 8 sessions of TF-CBT with narrative.
3145518|NCT00073684|Experimental|2|Participants will receive 8 sessions of TF-CBT without narrative.
3145519|NCT00073684|Experimental|3|Participants will receive 16 sessions of TF-CBT with narrative.
3145520|NCT00073684|Experimental|4|Participants will receive 16 sessions of TF-CBT without narrative.
3145521|NCT00073697|Experimental|1|Interpersonal Psychotherapy
3145522|NCT00073697|Experimental|2|Escitalopram
3145523|NCT00073697|Experimental|3|Escitalopram plus IPT
3145524|NCT00073736|Experimental|MB07133 Dose Level 1|7-day continuous infusion in 28-day cycles
3145525|NCT00073736|Experimental|MB07133 Dose Level 2|7-day continuous infusion in 28-day cycles
3145526|NCT00073736|Experimental|MB07133 Dose Level 3|7-day continuous infusion in 28-day cycles
3145527|NCT00073736|Experimental|MB07133 Dose Level 4|7-day continuous infusion in 28-day cycles
3145528|NCT00073736|Experimental|MB07133 Dose Level 5|7-day continuous infusion in 28-day cycles
3186011|NCT00741130||G|glaucoma patients
3186012|NCT00741143|Experimental|1|Group that receives NaFeEDTA fortified wheat flour
2415618|NCT03466034||Endometriod|Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
2415619|NCT03466034||Serous|Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
2415620|NCT03466021|Active Comparator|Liraglutide|Liraglutide injection 3.0 mg daily
2415621|NCT03466021|Placebo Comparator|Placebo|Placebo, matching injection pen
2415622|NCT03466008|Experimental|Whole body cryotherapy arm|intervention consisted of 10 sessions of WBC (three minutes for each session) which were performed in addition to usual care in a standard cryotherapy room over a duration of 8 days.
2415623|NCT03466008|No Intervention|Usual treatment arm|usual care
2415624|NCT03465995||NKI iPAS Diagnostic Protocol|Research participants who qualify for this study will put on EKG leads, and then a non-invasive device called iPAS, which will record heart rate and eye tracking data while participants perform a task on the screen of the device. The testing session will not exceed 30 minutes. Participants will take a total of 3 recordings over a period of roughly 5 weeks.
3145529|NCT00073788||Subjects with PTSD|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Study group subjects will be PTSD positive. Overt CVD is exclusionary.
3145530|NCT00073788||Control Group|Subjects will be American Indian, between the ages of 18-68. Approximately 66% will be female, 33% male, which conforms to the distribution of PTSD in this population. Control subjects will be PTSD negative. For both groups: overt CVD is exclusionary.
2415627|NCT03465969|Other|Liver or kidney transplant participants of Advagraf|Transplant participants will provide 1 whole blood venepuncture sample and 1 whole blood finger prick MITRA sample at pre-dose of participant's usual oral dose of commercial Advagraf and at approximately 1 and 3 hours post-dose.
2415628|NCT03465956|Other|Laparoscopic Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy for patients with morbid obesity using the gastro-intestinal anastomosis stapler.
2415629|NCT03465943|Active Comparator|Ringer|This group will receive 1 L of Ringer's solution as a preload
2415630|NCT03465943|Active Comparator|Voluven|This group will receive 500 ml of 6% hydroxyethyl starch ( Voluven ) and 500 ml Ringer's solution as a preload
2415631|NCT03465930||Patients with lymphedema|Patients affected by primary or secondary lymphedema. The intervention will consist in supermicrosurgical lymphatico-venous anastomoses (sLVA) to allow drainage of the lymph in the venous stream distal to the obstruction. sLVA is a minimally invasive procedure performed under local anesthesia. It requires an accurate visualization of the lymphatic vessels that are still functional.
2415632|NCT03465917|Experimental|Renal Denervation|Renal denervation using the Peregrine Catheter for extravascular administration of ethanol
2415641|NCT03465865||ILM-flap|Patients after surgical repair of macular holes with ILM-flap transposition are invitied to a follow-up for optical coherence tomography and visual acuity testing one year after surgery
2415642|NCT03465852|Experimental|Intervention arm|"Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, and will receive the Spanish language ChiCAS intervention shortly after being randomized and will complete a follow-up assessment 6 months after completing the intervention.~."
2415643|NCT03465852|Other|Wait list comparison (control) arm|Persons randomized to this arm will have completed the study consent process (including being tested with the INSTI rapid HIV test to verify their self-reported HIV negative status and their eligibility to participate in the study) and the baseline survey, but will not receive the Spanish language ChiCAS intervention until they complete a follow-up assessment 6 months after completing the baseline assessment.
2415645|NCT03465839|Active Comparator|Control|Education for improving handovers quality
3145534|NCT00073814|Experimental|1|levalbuterol MDI 90 mcg QID
3145535|NCT00073814|Active Comparator|2|racemic albuterol MDI 190 mcg QID
3145536|NCT00073814|Placebo Comparator|3|Placebo MDI QID
3145537|NCT00073827|Experimental|1|levalbuterol MDI 90 mcg QID
3145538|NCT00073827|Active Comparator|2|racemic albuterol MDI 180 mcg QID
3145539|NCT00073827|Placebo Comparator|3|Placebo MDI QID
3145540|NCT00073840|Active Comparator|I|Levalbuterol 90 ųg QID (manufacturing site A or B)
3145541|NCT00073840|Active Comparator|II|Racemic Albuterol 180 ųg QID
3145542|NCT00073840|Placebo Comparator|III|Placebo QID
3145543|NCT00073892|Experimental|PI-88|Patients receive four consecutive days treatment each week in a 4-week cycle.
3145544|NCT00073905|Active Comparator|Arm A|Capecitabine plus Gemcitabine
3145545|NCT00074022|Experimental|Treatment (GTI-2040, docetaxel)|"Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.~Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I."
3145546|NCT00074048|Experimental|1|BL22 immunotoxin
3145547|NCT00074087|Experimental|Caelyx|doxorubicin HCl liposome IV over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 6 courses.
3145548|NCT00074204|Experimental|Immediate Docetaxel|Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
3145549|NCT00074204|Active Comparator|Delayed Docetaxel|Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
3145550|NCT00074295|Experimental|treatment|GVAX lung cancer vaccine
2415646|NCT03465826|Experimental|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
2415647|NCT03465826|Active Comparator|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
2415648|NCT03465813|Experimental|CaringGuidance Intervention|Three months of web-based CaringGuidance psychoeducational program use, independently on home computer in addition to usual care.
2415649|NCT03465813|No Intervention|Usual Care|Three months of care as usual from subjects' clinics and community as the subject chooses.
2415650|NCT03465800|Active Comparator|Self-Monitoring|Participants self-monitor their physical activity
2415651|NCT03465800|Experimental|Daily Incentives|daily payments for physical activity
2415652|NCT03465800|Experimental|Delayed Lump Sum Incentives|lump sum payments for physical activity
2415653|NCT03465787|Experimental|Lurasidone HCL 160 mg|Lurasidone HCL 160 mg/day
2415654|NCT03465787|Active Comparator|Quetiapine XR 600 mg|Quetiapine XR 600 mg/day
2415655|NCT03465774||Group 2 (IPC alone)|Patients undergo IPC placement.
2415656|NCT03465774||Group I (IPC, doxycycline)|Patients undergo IPC placement and receive doxycycline via IPC 5 days later.
2415657|NCT03465761|Experimental|ExAblate 4000 System|ExAblate treatment of Bilateral Essential Tremor
2415658|NCT03465748|Experimental|Experimental-OrthoK|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles or soft contact lenses (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
2415659|NCT03465748|No Intervention|Control|The study will be a randomized control study using a single-masked design to investigate axial elongation and myopic progression in children wearing ortho-k lenses (study group) versus single-vision spectacles (control group) for a period of 24 months. A minimum of 40 and a maximum of 60 subjects will be recruited from patients at Illinois Eye Institute. Once eligibility has been determined by an unmasked observer, patients will be randomly assigned to either the orthokeratology group or the single-vision contact lens /spectacle group
3186013|NCT00741143|Placebo Comparator|2|Unfortified wheat flour
3145551|NCT00074321|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3145552|NCT00074373||human beings|human beings of all sexes, ages, and health statuses
2415668|NCT03465670|Active Comparator|CHX|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse (10 ml for 1 minute, t.i.d. for 21 days)
2415669|NCT03465670|Experimental|CHX+HA+ADS|Post-surgery use of a 0.2% chlorhexidine (CHX) mouthrinse containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) (10 ml for 1 minute, t.i.d. for 21 days)
2415670|NCT03465644|Experimental|Tailored arm|early (<6-month post-PCI) intensified (low-dose ticagrelor [120 mg loading, then 60 mg bid maintenance] and aspirin) and late (>6-month post-PCI) deescalated (clopidogrel alone) strategy
2415671|NCT03465644|Active Comparator|Conventional arm|clopidogrel + aspirin for 12months
2415672|NCT03465631|Experimental|SMART Glove system with dual-tDCS|VR-based SMART Glove system with dual-tDCS
2415673|NCT03465631|Sham Comparator|SMART Glove system with sham-tDCS|VR-based SMART Glove system with sham-tDCS
3145553|NCT00074399|Experimental|1|Participants will receive nevirapine for 6 weeks
3145554|NCT00074399|Placebo Comparator|2|Participants will receive nevirapine placebo for 6 weeks
3145555|NCT00074438|Experimental|1|
3145556|NCT00074438|Experimental|2|
3145557|NCT00074438|Experimental|3|
3145558|NCT00074438|Experimental|4|
3145559|NCT00074438|Experimental|5|
3145560|NCT00074438|Experimental|6|
3145561|NCT00074438|Placebo Comparator|7|
3145562|NCT00074438|Placebo Comparator|8|
3145563|NCT00074438|Placebo Comparator|9|
3145564|NCT00074568||1|Patients with scleroderma and their family members (parents, brothers, and sisters)
2415676|NCT03465592|Experimental|Nivolumab|"Adults: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks. Children and Adolescents weighing 40 kg or more: 240 mg IV over 30 minutes every 2 weeks OR 480 mg IV over 30 minutes every 4 weeks.~Children and Adolescents weighing less than 40 kg: 3 mg/kg IV over 30 minutes every 2 weeks.A maximum of 24 cycles will be given on study."
2415677|NCT03465579|Other|Cohort 1|Men with suspected clinically-significant PCa (CS-PCa) who are candidates for prostate biopsy or after first-round negative transrectal ultrasonography (TRUS) biopsy
2415678|NCT03465579|Other|Cohort 2|Men framed in Active Surveillance (PRIAS study), scheduled for PRIAS repeat biopsy.
2415679|NCT03465579|Other|Cohort 3a|Men with high-risk PCa (HR-PCa) prior to radical surgery.
2415680|NCT03465579|Other|Cohort 3b|Men diagnosed with CS-PCa prior to nerve-sparing prostate surgery (NSS).
2415681|NCT03465566||Children with BECTS|"Children with active BECTS according to state-of-the-art diagnostic criteria of ILAE (International League Against Epilepsy). Eligible subjects will be recruited at their first clinical observation in the epilepsy centers involved in the study.~All subjects will perform five diagnostic evaluations named:~IDS (Intelligence and Development Scale) MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
2415682|NCT03465566||Healthy children|"Healthy controls matched for sex, age range, and education with no family history for epilepsy or other neuropsychiatric disorders.~All subjects will perform the following tests:~MMSPE (Mini Mental State Pediatric Examination) CDI 2 (Children Depression Inventory 2) CBCL (Child Behavior Check List) Tests of facial expression evaluation"
2415683|NCT03465553|Experimental|Short course radiotherapy|The radiotherapy is delivered over 2 days with accelerated hypo-fractionation.
2415692|NCT03465527|Experimental|Prednisolone|"Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days~Hydration, antibiotics, allopurinol, nutritional supplements, and so on."
2415693|NCT03465501||Low Dose Rate|Patients treated with brachytherapy at low dose rate of the anal canal with aim of boost
2415694|NCT03465501||High Dose Rate|Patients treated by brachytherapy with a high dose rate of the anal canal aiming for boost
2415695|NCT03465488|Experimental|Subjects|All participants that meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study and receive a subject identifier (SubjectID). At baseline, all participants will receive a single treatment of albendazole 400mg and their stool will be examined for helminth eggs. Two to three weeks after treatment a follow-up examination of their stool is performed.
2415696|NCT03465475||Group 1|The patient who receive 300 mL fresh gas flow with AGC mode during the general anesthesia
2415697|NCT03465475||Group 2|The patient who receive 600 mL fresh gas flow with AGC mode during the general anesthesia
2415698|NCT03465475||Group 3|The patient who receive 600 mL fresh gas flow with manuelly during the general anesthesia
2415699|NCT03465462|Active Comparator|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
2415700|NCT03465462|Active Comparator|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
2415701|NCT03465462|Active Comparator|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
2415702|NCT03465449|Active Comparator|usual care|
2415703|NCT03465449|Experimental|CKD-EDU arm|
3186014|NCT00741169|Experimental|Treatment Sequence ABC|Participants will be randomized to each of the 6 different treatment sequences. Each treatment sequence will consist of Treatment A (TMC435350 200 mg once daily for 7 days), Treatment B (rifampin 600 mg once daily for 7 days), and Treatment C (TMC435350 200 mg once daily+rifampin 600 mg once daily for 7 days). Participants will receive 1 treatment (A, B, or C) during each treatment session. There will be 3 treatment sessions, each treatment session will be separated by 10 days.
3186015|NCT00741169|Experimental|Treatment Sequence BCA|
3186016|NCT00741169|Experimental|Treatment Sequence CAB|
3186017|NCT00741169|Experimental|Treatment sequence CBA|
2415708|NCT03465423||patients with nonfunctioning pituitary tumor|patients with nonfunctioning pituitary tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
2415709|NCT03465423||patients with pituitary somatotroph tumor|patients with pituitary somatotroph tumor undergoing transsphenoidal pituitary surgery under total intravenous anesthesia
2415710|NCT03465410|Active Comparator|GROUP I Standard adjustment|Standard dosage of Tacrolimus
2415711|NCT03465410|Experimental|GROUP II Bayesian prediction adjustment|Bayesian prediction Tacrolimus dosage
2415712|NCT03465397|Experimental|experimental|Biomarkers driven immunosuppressive therapy: the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
2415713|NCT03465397|No Intervention|control|All patients receive the usual triple immunosuppressive treatment, without depending on the results of any biomarker.
3145565|NCT00074568||2|Healthy volunteers with no autoimmune disease and without a first-degree relative with a systemic autoimmune disease
3186018|NCT00741169|Experimental|Treatment Sequence BAC|
2415714|NCT03465384|Active Comparator|Comet in group format|The standard format of the intervention that is well established in primary and specialized care in Sweden. Parents receive the education/training in small groups led by two group leaders.
2415715|NCT03465384|Experimental|Internet-based Comet|The same content as the group format of Comet, but delivered mainly as online self-help.
2415716|NCT03465371|Experimental|OnDemand Training Intervention|Participants receiving the OnDemand Training Intervention
2415717|NCT03465371|Active Comparator|InPerson Intervention|Participants receiving the InPerson Intervention
2415718|NCT03465345|Experimental|Metformin + OPC dose escalation|
2415719|NCT03465332||Lung specialist|Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
2415720|NCT03465332||Subjects with COPD|Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.
2415721|NCT03465319||Sevoflurane|10 patients receiving an anesthesia with sevoflurane
2415722|NCT03465319||Desflurane|10 patients receiving an anesthesia with desflurane
2415723|NCT03465306|Experimental|Intensive digital CBT|
2415724|NCT03465306|Active Comparator|Standard digital CBT|
2415725|NCT03465293||SUDD post-menopausal female|Post-menopausal women with non-specific left side pain and altered bowel habit who are having mechanical bowel preparation for a colonoscopy
2415726|NCT03465267|Experimental|Armeo power|Armeo power robot for upper extremity
2415727|NCT03465267|Experimental|Armeo spring|Armeo spring robot for upper extremity
2415728|NCT03465254||Cohort|Recruited members of the cohort are children aged 9-14 years old and eligible to receive the dengue vaccine at the time of the initiation of community-based dengue immunization program of the Department of Health.
2415729|NCT03465241||Monitoring by NGS group|This group will accept the ctDNA dynamic monitoring on the following phase:the day before surgery,the 3rd to 7th day after surgery,3 to 4 weeks after adjuvant chemotherapy finished, then every 6 months in the following 2 years.
2415730|NCT03465228|Experimental|Training group|This group will do the Deep Water Running, with intervals and continuous training twice a week, and before each session, will be applied the LED equipment. The training will be thirty minutes and will be controlled by heart rate, 70% to 80% maximum heart rate in continuous training, and maximum heart rate in intervals training.
2415731|NCT03465228|Experimental|Training and LED group|This group will receive the photobiomodulation treatment and the same training model of training group.
2415732|NCT03465228|Experimental|LED group|This group will receive only the photobiomodulation treatment with 30 seconds of light emitting in four points of lumbar region.
2415733|NCT03465215|Experimental|Assessment of inflammation grade|Tissue obtained by CD patients will be analyzed using digital holographic microscopy and comparing histological analysis.
2415734|NCT03465202|Experimental|Capecitabine|
2415735|NCT03465176|Experimental|Intervention|The women in this arm will receive an essential oil blend to inhale each afternoon for two weeks.
2415736|NCT03465176|Placebo Comparator|Control|The women in this arm will receive an odorless vegetable based oil to inhale each afternoon for two weeks as a control/placebo.
2415737|NCT03465163|No Intervention|Recovery|Two months recovery (no stimulation) following bilateral implantation of Medtronic PC+S devices into the anterior nucleus of the thalamus and the hippocampus. Thirty second EEG snapshots will be recorded every 15 minutes
2415738|NCT03465163|No Intervention|Baseline|No stimulation, 30 second EEG snapshots recorded every 15 minutes We require a minimum of 5 seizures to occur during this phase.
2415739|NCT03465163|Experimental|Probing|"Deep Brain Stimulation Electrically stimulate the thalamus continuously at a low frequency (2Hz). Thirty second EEG snapshots recorded every 15 minutes.~We require a minimum of 5 seizures to occur during this phase."
2415740|NCT03465163|Experimental|Probe Calibrated Deep Brain Stimulation|Deep Brain Stimulation In this phase we explore 18 deep brain stimulation parameter configurations (three stimulus intensities; 3,4,5 Volts, six different frequencies; 125 130, 135, 140,145, 150 Hz) during two of the clinic visits. Each deep brain stimulation parameter configuration will be tested for 1 minute with 4 minutes between each configuration test. The probing responses will be used to optimise the deep brain stimulation parameters for each participant. This phase of the study continues for 2 months.
2415741|NCT03465163|Experimental|Open Deep Brain Stimulation|Deep Brain Stimulation During this phase the deep brain stimulation parameters may be altered from the probing optimised parameters according to patient needs.
2415742|NCT03465137|Experimental|Immediate therapy|Participants randomized to the immediate therapy arm will receive a weekly individual psychotherapy intervention called Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
2415743|NCT03465137|No Intervention|Waitlist|Participants randomized to the waitlist arm will receive no intervention for 12 weeks. After this 12 week period they will receive a the same weekly individual psychotherapy intervention as the immediate therapy group: Coordinated Anxiety Learning and Management (CALM). The CALM program is an evidence based, exposure-focused therapy (http://calmtoolsforliving.org). Its computer-assisted format guides the therapist through psychoeducation, an introduction to cognitive restructuring, in-session and at-home exposures, and relapse prevention. Therapy will be delivered in 10 weekly 50-minute sessions within a 12 week period.
2415744|NCT03465124|Active Comparator|Femtosecond Laser assisted Cataract Surgery|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order.
2415745|NCT03465124|Active Comparator|Manual Cataract Surgery|Manual Cataract Surgery will be performed in contralateral (to LCS) eye of patient with bilateral age-related cataract.
2415788|NCT03464864|Experimental|Treprostinil Inhalation Powder 300 mcg|
2415748|NCT03465098|Experimental|enrolled patients|All enrolled patients will be received a strict low carbohydrate (< 3gr/day of carbohydrate) and 12h fasting before 18F-FDG PET/CT exam and 24h after a 18F-FDG PET/CT preceded by a low carbohydrate diet with 12h fasting
2415749|NCT03465085|Experimental|Group I: Heparin nebulized group|Group (I): 20 patients received inhaled Unfractionated Heparin at a dose of 10000 IU/4h by nebulizer, with the total daily dose of nebulized Unfractionated Heparin 60,000 IU
2415750|NCT03465085|Experimental|Group II: Streptokinase group|Group (II): 20 patients received inhaled Streptokinase at a dose of 250,000 IU/4h by nebulizer, with the total daily dose of nebulized Streptokinase 1,500,000 IU.
2415751|NCT03465085|No Intervention|Group III: Control group|Twenty patients whom guardian declined to participate actively in the study but accepted to participate passively by consenting for using their data were assigned as Group III or the control group and received conservative management
2415752|NCT03465072|Experimental|Exercise training|8 Weeks exercise training 3x per week 30-40 minutes per session
2415753|NCT03465059|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of Zanubrutinib (80 mg).
2415754|NCT03465059|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2415755|NCT03465059|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2415756|NCT03465059|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of Zanubrutinib (80 mg).
2415757|NCT03465046|Experimental|low performance group 1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
2415758|NCT03465046|Experimental|low performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
2415759|NCT03465046|Experimental|moderate-high performance group1|Protocol 1 will be the intervention administered with 80 h modified constraint induced movement therapy and 20 h bimanual intensive therapy
2415760|NCT03465046|Experimental|moderate-high performance group 2|Protocol 2 will be the intervention administered with 80h bimanual intensive therapy and 20h modified constraint induced movement therapy
2415761|NCT03465033|No Intervention|Usual Care|Patients will receive basic indications of rehabilitation consisting of daily mobilization of the jaw (perform several movements a day opening movements, laterotrusion and mouth protrusion).
2415762|NCT03465033|Experimental|Early Physiotherapy|
2415763|NCT03465020||ITP patients|On active treatment
2415764|NCT03465007|Active Comparator|Hydrocortisone|100mg Hydrocortisone will be administered prior to hemodialysis
2415765|NCT03465007|Placebo Comparator|Placebo|100mg normal saline will be administered prior to hemodialysis
2415766|NCT03464994|Other|ichthyosis patients|patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.
2415767|NCT03464994|Other|control population|patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination
2415768|NCT03464981||Advanced HF patients scheduled to undergo LVAD implantation|
2415769|NCT03464968|Experimental|mFOLFOX|D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
2415770|NCT03464968|Experimental|mFOLFIRI|D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks
2415771|NCT03464955|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
2415772|NCT03464955|Experimental|Intervention Group with Passive Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
2415773|NCT03464955|Experimental|Intervention Group with Active Content|Interventional arm will use technology based distractions (VR headsets, AR headset, tablets, or BERT projector) to prevent high anxiety before non-invasive surgical subspecialty procedures.
2415774|NCT03464942|Active Comparator|Single Dose|SABR 20Gy given as a single dose (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
2415775|NCT03464942|Active Comparator|Fractionated Dose|SABR 24Gy given as 3 fractions (to 1 -4 metastases with at least 1 untreated metastasis) followed by atezolizumab (1200 mg) every 3 weeks for 24 months.
2415776|NCT03464929||Airtraq indirect laryngoscopy|Intubation attempts using Airtraq device.
2415777|NCT03464929||King Vision indirect laryngoscopy|Intubation attempts using King Vision device
2415778|NCT03464916|Experimental|CAR2 Anti-CD38 A2 CAR-T Cells|Relapsed or Refractory Multiple Myeloma
2415779|NCT03464890|Experimental|LICHTENA DermAD|"Comparison within subjects of P926 - LICHTENA DermAD CREMA VISO and P927 - LICHTENA DermAD CREMA CORPO versus placebo and versus untreated control area. Study products were applied once, on experimentally induced erythema by repeated tape stripping on 4 different adjacent skin areas of the forearms (volar surface - 2 areas on each side)"
2415780|NCT03464877|Experimental|Intervention group|Standardized six-week duration multi-station full-body supervised exercise program. The frequency was 2-3 sessions per week. The duration of each session was 60 minutes.
2415781|NCT03464864|Experimental|Treprostinil Inhalation Powder 30 mcg|
2415782|NCT03464864|Experimental|Treprostinil Inhalation Powder 60 mcg|
2415783|NCT03464864|Experimental|Treprostinil Inhalation Powder 90 mcg|
2415784|NCT03464864|Experimental|Treprostinil Inhalation Powder 120 mcg|
2415785|NCT03464864|Experimental|Treprostinil Inhalation Powder 150 mcg|
2415786|NCT03464864|Experimental|Treprostinil Inhalation Powder 180 mcg|
2415787|NCT03464864|Experimental|Treprostinil Inhalation Powder 240 mcg|
2415789|NCT03464851||Unknown/Normal/Mild Disease|No prior carotid duplex study or known normal or mild disease in the ICAs (PSV <= 125 cm/sec)
2415790|NCT03464851||Known moderate or severe ICA Stenosis (PSV>125 cm/sec)|
2415791|NCT03464851||Known ICA Fibromuscular Dysplasia|
2415792|NCT03464838|Experimental|Real Stimulation tDCS with CBT|16 participants will attend to one weekly tDCS stimulation session with intensity 1.8 milliamps for 8 consecutive weeks. Following the tDCS session, participants will attend to a cognitive behavioural therapy (CBT) session. One tDCS + CBT session per week (Total: 8 sessions).
2415793|NCT03464838|Sham Comparator|Sham tDCS with CBT|16 participants will attend to one weekly Sham tDCS session with intensity 0 milliamps for 8 consecutive weeks. Following the Sham tDCS session, participants will attend to a CBT session. One Sham tDCS + CBT session per week (Total: 8 sessions).
2415794|NCT03464825|Other|Intervention|Participants in the intervention group receive balance training during 3 months 3 times per week
2415795|NCT03464825|No Intervention|Control|Care as usual
2415796|NCT03464812|Other|DSMES Group|Patients with type 2 diabetes will undergo a diabetes education program (DSMES) and evaluated for outcomes before and after completing the program.
2415797|NCT03464786|Experimental|absorbable collagen membrane|Subjects randomized in this arm will receive Lando® absorbable collagen membrane after tooth extraction.
2415798|NCT03464786|Active Comparator|Bio-Gide resorbable bilayer membrane|Subjects randomized in this arm will receive Bio-Gide resorbable bilayer membrane after tooth extraction.
2415799|NCT03464773|Other|Pathway|The PIUO Pathway is implemented by clinicians (MD and RN) with expertise in treating pain in children. Each participant proceeds through the PIUO Pathway as long as their pain persists, but will exit the PIUO Pathway at any stage in case their pain is resolved. The Pathway has two steps: Step 1 is a thorough history and patient evaluation, including directed testing. Step 2 is a series of screening tests to further explore any potential underlying disease or injury not apparent based on history and physical examination.
2415800|NCT03464773|No Intervention|Waitlist|Participants randomized to the Waitlist will cross over to the Pathway after 8 weeks.
2415801|NCT03464760|Placebo Comparator|Placebo|
2415802|NCT03464760|Experimental|Spirulina-Silicon supplementation|
2415803|NCT03464734|Experimental|Pembrolizumab + nab-paclitaxel|pembrolizumab 200 mg + nab-paclitaxel 125 mg/m2, intravenously
2415804|NCT03464721||Surgery Outpatients|
2415805|NCT03464708|Experimental|HMB|HMB 3 g/day until hospital discharge or 28-days (whichever comes first). HMB to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
2415806|NCT03464708|Placebo Comparator|Placebo|Placebo (lactose) 3 g/day until hospital discharge or 28-days (whichever comes first). Placebo to be provided in powder form and administered via enteral feeding tube whilst in the ICU and orally once able to eat and drink.
2415807|NCT03464695|Active Comparator|O2matic|Oxygen administered by O2matic. Automatic adjustment based on continuous measurement of SpO2.
2415808|NCT03464695|No Intervention|Manual|Oxygen administered by manual control based on nurse's intermittent measurement of SpO2.
2415809|NCT03464682|Experimental|HS-25 10mg|HS-25 10mg, Placebo of HS-25 1 tablet, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
2415810|NCT03464682|Experimental|HS-25 20mg|HS-25 10mg 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12weeks
2415811|NCT03464682|Experimental|HS-25 10mg combination with Atorvastatin|HS-25 10mg, Aorvastatin 10mg, Placebo of HS-25 1 tablet, oral once daily, 12 weeks
2415812|NCT03464682|Experimental|HS-25 20mg combination with Atorvastatin|HS-25 20mg, Aorvastatin 10mg, oral once daily, 12 weeks
2415813|NCT03464682|Active Comparator|Aorvastatin 10mg|Aorvastatin 10mg, Placebo of HS-25 2 tablets, oral once daily, 12 weeks
2415814|NCT03464682|Placebo Comparator|Placebo of HS-25 and Aorvastatin|Placebo of HS-25 2 tablets, Placebo of Aorvastatin 1 tablet, oral once daily, 12 weeks
2415815|NCT03464669||Group prenatal education|Prenatal education delivered in-person by health and social services centers
2415816|NCT03464669||Online prenatal education|Online prenatal education provided or recommended by health and social services centers
2415817|NCT03464669||Control group|Absence of prenatal education
2415818|NCT03464656|Experimental|Patients|"Patients presenting with male infertility, who are found to have abnormal semen analysis shall be recruited to this study.~Interventions:~Patients will be given Fairhaven Pro for Men as antioxidant in a dose of 3 tablets twice daily for 3 months.~Full assessment of fertility will be done."
2415819|NCT03464643|Other|Single embryo culture|Embryo is cultured individually in 25 ul media
2415820|NCT03464643|Other|Group embryo culture|2-3 Embryos are group cultured in 50 ul media
2415821|NCT03464630|Experimental|Mom & Baby Net|Skills based maternal depression treatment and targeted infant social-communication promotion
2415822|NCT03464630|Active Comparator|Developmental Awareness System|Depression and infant develop awareness
2415823|NCT03464604||Group 1 Control group|Patients randomized into this group will follow normal standard of care in Nova Scotia
2415824|NCT03464604||Group 2 Active group|"Patients randomized into this group will be part of the active arm of the study. They will be pre-screened and asked the following questions:~Sign an Information and Authorization form~Demographic data: gender, date of birth, ethnicity~Health history (duration of lesion, changes in lesion, specific changes, who identified the lesion, measurement in two greatest dimensions radially and color."
2415825|NCT03464565||Patients with acute ischemic stroke secondary to LVO|
2415826|NCT03464552|Active Comparator|Celecoxib group|will receive oral Celecoxib 200 mg capsule (Celebrex®200, Pfizer, USA) once 3 hours before the colposcopic guided biopsy
2415827|NCT03464552|Placebo Comparator|Placebo group|will receive oral placebo capsule once 3 hours before the colposcopic guided biopsy
2415828|NCT03464539|Other|CD patients|PG low molecular weight chitosan 3 times per day
2415829|NCT03464526|Active Comparator|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
2415830|NCT03464526|Active Comparator|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
2415831|NCT03464526|Active Comparator|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
2415832|NCT03464526|Placebo Comparator|Placebo|Placebo tablet, once daily for 12 weeks
2415833|NCT03464513|Other|Patients with GIT bleeding|Patients with active lower Gastrointestinal bleeding
2415837|NCT03464487|Active Comparator|Daily LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy diet everyday along with the antiepileptic drugs.
2415838|NCT03464487|Active Comparator|Intermittent LGIT|The children with drug resistant epilepsy in this arm will receive Low Glycemic Index Therapy Diet on five days of each week along with antiepileptic drugs. Rest of the two days, they will receive a liberal diet.
2415839|NCT03464474|Experimental|Assessment of inflammation grade|Colonic biopsies will be acquired. Biopsies from all patients will be examined using digital holographic microscopy as well as performing a histopathological analysis using the Nancy-score (Goldstandard).
2415840|NCT03464461|Placebo Comparator|0 mg|0 mg ketorolac - placebo
2415841|NCT03464461|Active Comparator|10 mg|10 mg ketorolac - low dose ketorolac
2415842|NCT03464461|Active Comparator|30 mg|30 mg ketorolac - usual dose ketorolac
2415843|NCT03464448||1|Patients with RRMS who have been newly prescribed Teriflunomide.
2415844|NCT03464448||2|Healthy Controls
2415845|NCT03464435|Experimental|tacrolimus and loteprednol etabonate/tobramycin|topical eye drops
3186019|NCT00741169|Experimental|Treatment Sequence ACB|
3145566|NCT00074607|Experimental|Intrathecal gemcitabine administration|"Intrathecal gemcitabine will be given on a weekly schedule for the first cohort of patients at the 5 mg dose level and then a twice-weekly (i.e., every 3 to 4 days) schedule. Drug administration will be by the intraventricular (Ommaya reservoir injection) route.~Patients will be hospitalized overnight following their first dose of gemcitabine. If the first dose is well tolerated, subsequent induction doses may be administered in the outpatient setting with close observation for a minimum of 2 hours after administration.~Dose Levels and Dose Escalation:~Dose Level 1a: 5 mg~Dose Level 1b: 5 mg~Dose Level 2: 10 mg~Dose Level 3: 20 mg~Dose Level 4: 30 mg~Dose Level 5: 40 mg~Dose Level 6: 50 mg"
3145567|NCT00074737|Active Comparator|cenersen, idarubicin|cenersen, idarubicin, no cytarabine
3145568|NCT00074737|Active Comparator|cenersen, idarubicin, cytarabine|cenersen, idarubicin, standard dose cytarabine
2415850|NCT03464396||Preterm infant study visits|"Preterm infants Study Visits~Bedside Physiology Study at 28, 32, 36, 40, and 52 weeks GA.~Respiratory tests:~Carotid Body Function Test will be completed at 32, 36, 40 and 52 weeks GA~Room Air Challenge (RAC) or Hypoxia Challenge Test (HCT) will be completed at 36 weeks GA~Effects of nasal cannula flow be completed at 28, 32, 36, 40 and 52 weeks GA~Magnetic Resonance Imaging (MRI): Completed on a subset of infants between 37-40 weeks GA or before discharge, whichever comes first.~Echocardiogram (Echo): Completed at 32, 36 and 52 weeks GA~Blood sample: Obtained at 32, 36 and 52 weeks GA"
2415854|NCT03464370|Experimental|TLE-AE Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2415855|NCT03464370|Active Comparator|Non AE epileptic Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2415856|NCT03464370|Active Comparator|Extra-temporal epilepsy Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors and then evaluate the traumatic events and to date them with respect to the beginning of epilepsy in different populations of epileptics.
2415857|NCT03464370|Active Comparator|Healthy volunteers Group|30 subjects Age between 18 and 65 case-control with 2 witnesses per sex and age matched cases (within 5 years) for the evaluation of the primary endpoint. For the secondary endpoints, 3 controls will be matched for each case on gender and age (within 5 years) Measure of emotional stressors
2415994|NCT03463525|Experimental|[11C]osimertinib + oral osimertinib|IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.
3145569|NCT00074737|Active Comparator|cenersen, idarubicin, HDAC|cenersen, idarubicin, HDAC (high dose cytarabine)
3145570|NCT00074750|Experimental|DTGM|Starting dose of DTGM fusion protein 2 mcg/kg/day as a short (30 min) intravenous infusion, three times /week (M,W,F) for two consecutive weeks. In absence of defined grade 3/4 nonhematological toxicities in the first 0/3 or 1/6 patients, the dose will be escalated by 1 mcg/kg/day for the next patient cohort.
3145571|NCT00074763|Experimental|Platelet Transfusion|ThromboSol-preserved autologous platelet transfusion or Standard platelet transfusion. All patients receive both platelets frozen with Thrombosol and fresh random platelets. The order in which patients receive these two types of platelets randomized in a crossover design. Patients randomly assigned to receive either the sequence FRP then Thrombosol or Thrombosol then FRP. The randomization will occur after second cycle of chemotherapy, since all patients will receive FRP with the first cycle.
3145572|NCT00074776|Experimental|1 Lithium|
3145573|NCT00074776|Experimental|2 Lamotrigine|
3145574|NCT00074789|Experimental|1|Participants will receive home-based interpersonal depression treatment for 26 weeks
3145575|NCT00074789|Active Comparator|2|Participants will receive attention control/usual care for 26 weeks
3145576|NCT00074828|Experimental|A|
3145577|NCT00074828|Active Comparator|B|
3145578|NCT00074932|Other|1|
3145579|NCT00074997|Experimental|001|OZ1 Single intravenous infusion of 2-20 x 10 to the power of 7 OZ1 transduced autologous CD34+ cells per kilogram of body weight
3145580|NCT00074997|Placebo Comparator|002|Placebo Single intravenous infusion of placebo transduced autologous CD34+ cells per kilogram of body weight
3145581|NCT00075010|Experimental|Decitabine + Valproic acid|Decitabine 15 mg/m^2 by vein over 1 hour times 10 days
3145582|NCT00075101|Experimental|Study Cycle|
3145583|NCT00075114|Other|1 Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
3145584|NCT00075114|No Intervention|2 Control Group|Participants randomized to this arm did not receive any interventions.
2415858|NCT03464357|Active Comparator|Symptomatic patients with dry eye|8 symptomatic patients with dry eye (mild to severe) assessed using a validated questionnaire (OSDI score, Appendix 1) associated with a disabling photophobia (need to wear sunglasses permanently outside, restriction of the outputs in case of significant brightness, restriction of the use of the screens because of the visual embarrassment ...). The fMRI will be carried out following the inclusion visit after all the necessary checks
2415859|NCT03464357|Active Comparator|Asymptomatic patient|"8 asymptomatic patients presenting neither photophobia (even minimal) or dry eye.~The fMRI will be carried out following the inclusion visit after all the necessary checks"
2415860|NCT03464344|Other|Patients with cortical superficial siderosis.|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
2415861|NCT03464344|Other|Patients without cortical superficial siderosis|During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
2415862|NCT03464331|Experimental|EXP group|Participants in EXP group (EXP) will be asked to practise Zero-time exercises (ZTE) at least 20-30 minutes per day, and on most and preferably all days of the week.
2415863|NCT03464331|Placebo Comparator|CON group|Participants in CON group (CON) will be asked to practise relaxation exercises (RE) and deep-breathing exercises (DBE) at least 30 mins every day.
2415864|NCT03464305|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
2415865|NCT03464305|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
2415866|NCT03464292|Placebo Comparator|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin. The patch will applied to the hand for 30 - 60 min. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
2415867|NCT03464292|Active Comparator|Capsaicin Patch 8% or 0.1% Capsaicin Cream|8% capsaicin topical patch or 0.1% capsaicin cream. The patch will applied to the hand for 30 - 60 min. The cream will be applied similarly on a 3 cm2 area of the arm. Patients will be instructed to not touch or wash their hands during the course of the study to minimize spreading of the patch to other areas of the body. Subsequently, the patch will be immediately removed.
2415868|NCT03464279|Experimental|Intervention Site|"The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral nudge, urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic."
2415869|NCT03464279|Active Comparator|Control Site|The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.
2415870|NCT03464266|Active Comparator|DMPA and PrEP|
2415871|NCT03464266|Active Comparator|DMPA and no PrEP|
2415872|NCT03464266|Active Comparator|Condoms only and PrEP|
2415873|NCT03464266|Active Comparator|Condoms only and no PrEP|
2415874|NCT03464240|Active Comparator|Glucose|50 grams glucose in 50 ml water
2415875|NCT03464240|Placebo Comparator|Water|50 ml water
2415876|NCT03464227|Experimental|UCB0107|Subjects randomized to this arm will receive UCB0107. This arm will consist of a maximum of 7 cohorts. The dose for cohort 1 will be fixed, proposed doses for cohorts 2,3,4,5,6 and 7 may be adapted based upon recommendation by the Safety Review Group.
2415877|NCT03464227|Placebo Comparator|Placebo|Subjects randomized to this arm will receive matching Placebo to UCB0107. This arm will consist of a maximum of 7 cohorts.
2415878|NCT03464214|Active Comparator|Vibration Group|Local vibration on neck muscles
2415879|NCT03464214|Active Comparator|Stabilization Group|Cervical stabilization exercises on cervical region
2415880|NCT03464214|No Intervention|Control Group|Individuals performed only daily living activities
2415881|NCT03464201|Experimental|Enzalutamide|Enzalutamide 160 mg daily p.o. (4 capsules 40mg per day)
2415882|NCT03464188|No Intervention|Usual Care|Usual care family caregiver participants will be informed of the UAB Comprehensive Cancer Center Patient and Family Resources webpage.
2415883|NCT03464188|Experimental|Project Cornerstone|The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician. Regular caregiver distress thermometer screening and problem support and self-care coaching. Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions.
2415884|NCT03464175|Active Comparator|Heated-humidifier left on during nebulization|
2415885|NCT03464175|Active Comparator|Heated-humidifier turned off 30 minutes before nebulization|
2415886|NCT03464175|Active Comparator|Use of a heat and moisture exchanger (HME) filter|
2415887|NCT03464175|Active Comparator|Use of a dry ventilator circuit specific for aerosol therapy|
2415888|NCT03464162|Experimental|Social Network Meetings Group|"This arm will receive Social Network Meetings for a 6 month period. Meetings may occur as often as 3 times a week when there is a crisis or more commonly would occur once every other week. These meetings will last between 60 and 90 minutes and will take place for however long the clients and their social networks would like within the project period. Ideally, each client and his/her Social Network would participate in 4 meetings during the 6 month period. This group would continue to receive care as usual with the addition of these meetings.~*Final sample in this arm was N=3."
2415889|NCT03464162|No Intervention|No Social Network Meetings Group|"This arm will not receive the Social Network Meetings intervention. Clients in this arm will participate in the study for 6 months and receive care as usual during this time.~*Final sample in this arm was N=1."
2415890|NCT03464162|Other|Social Network Members|"This arm is comprised of individuals who are social network members of clients who are receiving the Social Network Meetings intervention.~*Final sample in this arm was N=3 (social network members of arm 1)."
2415891|NCT03464149||Study Arm|"One armed study, blood from each patient is analysed by the following assays:~Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)"
2415892|NCT03464136|Experimental|Group 1 (Ustekinumab)|Participants will receive intravenous (IV) infusion of ustekinumab (approximately 6 milligram/kilogram [mg/kg]) and 4 subcutaneous (SC) injections of placebo for adalimumab at Week 0, followed by 2 SC injections of placebo at Week 2. From Week 4 to Week 56, participants will self-administer one SC injection of ustekinumab 90 milligram (mg) every 8 weeks (q8w) starting at Week 8 and placebo adalimumab at the other designated every 2 weeks (q2w) dosing intervals.
2415893|NCT03464136|Active Comparator|Group 2 (Adalimumab)|Participants will receive IV infusion of placebo for ustekinumab and 4 SC injections of adalimumab (each 40 mg, total dose 160 mg) at Week 0, followed by 2 SC injections of adalimumab (each 40 mg, total dose 80 mg) at Week 2. From Week 4 to Week 56, participants will self-administer 1 SC injection of adalimumab 40 mg q2w.
3145585|NCT00075140||1|All Participants hav a family member with Huntington Disease
3145586|NCT00075179|Experimental|Nesiritide|Nesiritide 0.01 mcg/kg/min by vein over 30 minutes during right heart catheterization procedure.
3145587|NCT00075374|Experimental|Docetaxel|
2415899|NCT03464084|Other|bright light placebo|
2415900|NCT03464084|Other|bright light melatonin|
2415901|NCT03464084|Other|dim light|
2415902|NCT03464071|Experimental|Group HVM|When randomized to the Hyperinflation with mechanical ventilator (HVM) group, there will be an increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
2415903|NCT03464071|Experimental|Group HM|When randomized to the Manual hyperinflation (HM) group, the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
2415904|NCT03464058|Experimental|Part 1: Regimen A|Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.
2415905|NCT03464058|Experimental|Part 1: Regimen B|Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.
2415906|NCT03464058|Experimental|Part 1: Regimen C|Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.
2415907|NCT03464058|Experimental|Part 1: Regimen D|Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.
2415908|NCT03464058|Experimental|Part 1: Regimen E|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.
2415909|NCT03464058|Experimental|Part 1: Regimen F|Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.
2415910|NCT03464058|Experimental|Part 2: Regimen G|Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2415911|NCT03464058|Experimental|Part 2: Regimen H|Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2415912|NCT03464058|Experimental|Part 2: Regimen I|Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.
2415913|NCT03464058|Experimental|Part 2: Regimen J|Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.
2415914|NCT03464058|Experimental|Part 3: Regimen K|Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).
2415915|NCT03464058|Experimental|Part 3: Regimen L|Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
2415916|NCT03464058|Experimental|Part 3: Regimen M|Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).
3145588|NCT00075387|Experimental|Arm I (combination chemotherapy)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA over 10 minutes.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
2415918|NCT03464032|Experimental|BCD-135|Dose-escalation Arm (0.4, 1, 3, 10, 20 mg/kg)
2415919|NCT03464019|Experimental|Etripamil 70 mg Single Dose|Self- administration of a single dose of 70 mg of etripamil.
2415920|NCT03464019|Placebo Comparator|Placebo Single Dose|Self- administration of a single dose of placebo.
2415921|NCT03464019|Experimental|Etripamil 70 mg with Optional Second Dose|Dosing regimen that permits a second dose of etripamil 70 mg
2415922|NCT03464019|Placebo Comparator|Placebo with Optional Second Dose|Dosing regimen that permits a second dose of placebo.
2415923|NCT03464006|Experimental|Online Support Module|Patients in the online support module group will receive a tablet which has the developed peripheral arterial disease platform installed on it. The platform helps the patient to monitor factors related to their peripheral arterial disease such as exercise, smoking, and diet and helps them to track and modify these behaviours.
2415924|NCT03464006|Active Comparator|Standard of Care|Patients in this arm will receive the standard of care as provided by the institution.
2415925|NCT03463993|Experimental|Group A|Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.
2415926|NCT03463993|Active Comparator|Group B|Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby
2415927|NCT03463980|Experimental|Compassion meditation (CM)|The CM participants will attend six weekly sessions (each 120 minute), and will be video and/or audiotaped. Each weekly CM session will entail a 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants will be encouraged to meditate at least 30 minutes a day and will be asked to track their daily meditation time and bring in their tracking sheet to each session.
2415928|NCT03463980|Active Comparator|Support group (SG)|SG participants will attend six weekly sessions, 90 minutes in length. It will be unstructured. Participants will use this time to talk about current concerns and to receive support and guidance from other group members and the leaders.
2415929|NCT03463967|Active Comparator|Lycopene supplemented|Energy-restricted diet supplemented with lycopene-enriched tomato juice
2415930|NCT03463967|Sham Comparator|Calories Restricted|Energy-restricted diet
2415931|NCT03463954|Experimental|Novilase Laser Ablation and excision|Eligible subject will receive image-guided laser ablation of a targeted malignant breast tumor. At 4-6 weeks following the ablation, she will receive a MRI and excision. Pathology and MRI will determine rate of complete ablation. Subject is expected to proceed with radiation and/or adjuvant therapy per standard of care.
3186020|NCT00741182|Experimental|Femur PTH(1-34)|24 participants with trochanteric fractures will be assigned to Forsteo (PTH(1-34)) treatment
3186021|NCT00741182|No Intervention|Femur Control|"24 participants with trochanteric fractures will be assigned to no treatment"
3186022|NCT00741182|Experimental|Humerus PTH(1-34)|24 participants with collum chirurgicum fracture will be assigned to Forsteo (PTH(1-34)) treatment
2415935|NCT03463902|Experimental|left IFG anodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2415936|NCT03463902|Active Comparator|left IFG cathodal|2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2415937|NCT03463902|Active Comparator|left IPL anodal|2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
2415938|NCT03463902|Active Comparator|left IPL cathodal|2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
2415939|NCT03463902|Placebo Comparator|Placebo|anodal electrode over left IFG, cathodal electrode over right IFG, stimulation only during 30 sec ramp at beginning and end of 10 min
3186023|NCT00741182|No Intervention|Humerus Control|"24 participants with collum chirurgicum fracture will be assigned to no treatment."
2415941|NCT03463876|Experimental|SHR-1210+Apatinib|Patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.
3186024|NCT00741195|Experimental|1|Docetaxel/Bevacizumab
3186025|NCT00741208|Other|1|Patients randomized to receive soy isoflavone twice daily for 2 weeks. Patients will cross-over and receive placebo medication for 2 weeks later in the study
2415944|NCT03463837|Experimental|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%,Virginia Tobacco [5 days] in confinement.
2415945|NCT03463837|Experimental|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, Cool Mint [5 days] in confinement.
2415946|NCT03463837|Experimental|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, Mango [5 days] in confinement.
2415947|NCT03463837|Experimental|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, Creme Bruele [5 days] in confinement.
2415948|NCT03463837|Active Comparator|Combustible cigarette|Exclusive use of combustible cigarette [5 days] in confinement.
2415949|NCT03463837|Sham Comparator|Smoking cessation (no smoking)|Smoking cessation (no smoking).
2415950|NCT03463824|Experimental|Experimental Group 1|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
2415951|NCT03463824|Experimental|Experimental Group 2|Participants will produce progressively larger lumbar flexion excursions at each game level and across treatment sessions.
2415952|NCT03463798||Patients|Patients with a suspicion of diaphragmatic dysfunction
2415953|NCT03463798||Healthy volunteers|Subjects without any medical condition
2415954|NCT03463785||Chinese|Chinese mild or moderate OSA patients
2415955|NCT03463785||Dutch|Dutch mild or moderate OSA patients
2415956|NCT03463772|Active Comparator|standard IVF|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group A will receive standard IVF procedure. Other standard assisted reproductive treatments are similar and parallel between two groups.
2415957|NCT03463772|Active Comparator|In vitro maturation|On the Day2/3 of the menstrual cycle, qualified participants will be randomized into either of two groups. Participants in group B will receive IVM procedure.Other standard assisted reproductive treatments are similar and parallel between two groups.
2415958|NCT03463759||Recurrent Low Back Pain Patients|Participants experiencing a current episode of their recurrent non-specific low back pain at the time of recruitment.
2415959|NCT03463759||Healthy Volunteers|Participants matched in age and gender to one of the recurrent low back pain patients, with no significant past low back pain, chronic pain or other relevant medical disorders.
2415960|NCT03463746|Experimental|Experimental group (EG)|Subacute stroke patients will get standard individual physical therapy 2x/week, 45min and electromechanical-assisted gait training on LYRA® gait trainer 3x/week, 45min.
2415961|NCT03463746|Active Comparator|Comparator group (CG)|The CG will get standard individual physical therapy 5x/week, 45min without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
3186026|NCT00741208|Other|2|Patients randomized to receive placebo medication twice daily for 2 weeks. Patients will cross-over and receive soy isoflavone for 2 weeks later in the study
2416053|NCT03463187|Experimental|240mg SHR-1314 (Part B)|SHR-1314 240mg, subcutaneously
3186027|NCT00741221|Experimental|1|Pemetrexed/Bevacizumab
3186028|NCT00741234|Experimental|A|Advanced solid tumors
3186029|NCT00741234|Experimental|B|Advanced hematologic malignancies
3186030|NCT00741234|Experimental|C|Myelodysplastic Syndrome
3186031|NCT00741312|Experimental|I|
3186032|NCT00741312|Active Comparator|II|
2415962|NCT03463733|Experimental|Daily hydroxyurea and temozolomide|"Hydroxyurea and temozolomide will be administered every 4 weeks, with 28 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis. Oral hydroxyurea (dose specified by the Dose Cohort below) and oral temozolomide (50 mg/m2/day) will be administered daily in 28-day cycles for 12 cycles or until unacceptable toxicity, intolerance, progressive disease, or withdrawal of consent. Patients will be treated in dose cohorts of 3 with each cohort receiving a specific daily dose assignment of hydroxyurea.~All patients in the study will receive temozolomide at 50 mg/m2/day (dose-intense schedule). The starting dose level for hydroxyurea will be 200 mg daily (QD) up to a maximum of 2000mg hydroxyurea a day."
2415963|NCT03463720||Extremity wound|Patients with extremity wounds. Infected and not infected patients will be compared.
2415964|NCT03463707|Experimental|Treatment with BP101|
2415965|NCT03463707|Placebo Comparator|Treatment with placebo|
2415966|NCT03463694|Experimental|Hypertonic Saline ~2.6% NaCl|3 drops each nostril of Hypertonic Saline (HS) at least 4 times a day until asymptomatic or maximum of 28 days
2415967|NCT03463694|No Intervention|Standard Care|Control arm of standard symptomatic care only
2415968|NCT03463681|Experimental|Cabozantinib|all subjects will recieve open label Cabozantinib 60 mg orally once daily
2415969|NCT03463668||symptomatic non-covered duodenal prosthesis|Any symptomatic duodenal stenosis with symptomatic duodenal duodenal prosthesis between 2010 and 2017.
2415970|NCT03463655||solid cancer in a palliative situation with ascites|Patient over the age of 18, followed for a solid cancer in a palliative metastatic situation, having had a puncture of ascites.
2415971|NCT03463642|Experimental|Vitamin D3 pill|100 pills = 100,000IU + Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
2415972|NCT03463642|Placebo Comparator|Pill placebo|100 pills = Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
2415973|NCT03463642|Experimental|Vitamin D3 oral liquid|100 drops = 100,000IU in orange syrup
2415974|NCT03463642|Placebo Comparator|Oral liquid placebo|100 drops orange syrup
2415975|NCT03463642|Experimental|Skin oil + Vitamin D3 + penetrator|100,000IU + mineral oil+ Tangerine essential oil (10ml)
2415976|NCT03463642|Experimental|Skin oil + Vitamin D3|100,000IU + mineral oil
2415977|NCT03463642|Placebo Comparator|Skin oil placebo|Skin application: 100ml of mineral oil coloured with food colourant to match active oil sample
2415978|NCT03463629|Experimental|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
2415979|NCT03463629|Active Comparator|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services. Data for this arm will be collected through retrospective chart review.
2415980|NCT03463616||CT abdomen|Patients who had a CT abdomen as primary work-up before treatment planning for rectal cancer.
2415981|NCT03463616||MRI Abdomen|Patients who had a MRI abdomen as primary work-up before treatment planning for rectal cancer.
2415982|NCT03463603||Asian racial identity|"Those who self-report Asian or related terms as their racial identity."
2415983|NCT03463603||South Asian racial identity|"Those who self-report South Asian or related terms as their racial identity."
2415984|NCT03463603||Other racial identity|"All others, who self-report neither Asian, South Asian or their related terms as their racial identity."
2415985|NCT03463590|Experimental|DBS|All subjects will undergo bilateral surgical implantation of DBS system to habenula. The DBS system will be active at one week after surgery.
2415986|NCT03463577||Exposed Group|Pregnant women vaccinated with Boostrix on or after the 1st day of the 27th week of pregnancy; who were not vaccinated with any other Tdap vaccine at any other time during the pregnancy are in scope of this study.
2415987|NCT03463577||Unexposed Group|Women matched to the exposed cohort and pregnant sometime during the approximate estimated period between 1/1/2012-12/31/2013 who did not receive any Tdap vaccine during the pregnancy are in scope of this study.
2415988|NCT03463564|Active Comparator|Insulin pump|Insulin Pump with rapid acting insulin analog lispro
2415989|NCT03463564|Active Comparator|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection at bed-time of basal insulin glargine or degludec
2415990|NCT03463551|Experimental|ABL-101 IV as per dosing cohort + Supplementary O2 for 24h|"Patients will receive either ABL-101 or placebo (equivalent volume of 0.9% Sodium Chloride) within ascending dose groups of 6 patients each (4 to ABL-101, 2 to placebo).The starting cohort will be Cohort 1: 0.5mL/kg.~In the event that the start dose of Cohort 1 is considered intolerable in the opinion of the iDMC based on incidence of patients experiencing dose-limiting toxicities (DLTs), the iDMC will have the option of recommending a lower dose cohort (Cohort -1) of 0.25ml/kg (to a maximum of 25ml) be undertaken.~Cohort 1: 0.5 mL/kg to a maximum of 50ml; Cohort 2: 1.5mL/kg to a maximum of 150ml; Cohort 3: 3.0mL/kg to a maximum of 300ml.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
2415991|NCT03463551|Placebo Comparator|IV 0.9% NaCl as per dosing cohort + supplementary O2 for 24h|"Cohort 1: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 2: Volume matched to the calculation used for ABL-101 using patient weight; Cohort 3: Volume matched to the calculation used for ABL-101 using patient weight.~All patients will receive Oxygen 60% by face mask (8l/min) for approximately 24h after ABL-101 or placebo administration."
2415992|NCT03463538|Active Comparator|Arthroscopic capsular release|Surgical release performed under general anesthetic
2415993|NCT03463538|Active Comparator|Hydro-dilatation|injection of water under local anesthetic in to shoulder joint
2415997|NCT03463499|Experimental|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
2415998|NCT03463473|Experimental|MSB2311 Injection|MSB2311 will be administered as an IV infusion once every 3 weeks (Q3W). The planned doses starts at 0.3 mg/kg and may be escalted to 20 mg/kg, but dose levels or the dosing interval may be adjusted during the study based on emerging data.
2415999|NCT03463460|Experimental|Treatment (pembrolizumab, sunitinib malate)|Participants receive pembrolizumab IV over 30 minutes on day 1 and sunitinib malate PO daily on days 1-14. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2416000|NCT03463447|Experimental|Hand strength|We selected volunteers without motor abnormalities with aged 6 to 17 years divided in groups (n = 30) according to an age group. The tests were performed in a single session lasting 20 minutes, when volunteers used a hydraulic dynamometer and an electronic dynamometer, in order to quantify the hand strength.
2416001|NCT03463434|Experimental|Air Fluidized Therapy|Patients will be placed on the Envella AFT bed
2416002|NCT03463434|Active Comparator|Continuous Low Pressure-LAL|Patients will receive a Continuous low pressure mattress with low air loss
3145589|NCT00075387|Experimental|Arm II (combination chemotherapy, sodium thiosulfate)|"Patients receive cyclophosphamide IV, etoposide phosphate IV, and carboplatin IA as in Arm I. Patients also receive sodium thiosulfate IV over 15 minutes 4 and 8 hours later.~Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3145590|NCT00075439|Experimental|Arm I|Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2416005|NCT03463395|No Intervention|Standard of Care|Group A will receive standard of care
2416006|NCT03463395|Experimental|Reza band use|Group B will receive standard care plus the Reza band (worn as recommended by the manufacturer)
2416007|NCT03463382|Active Comparator|ESP Group|"Erector Spinae Plane Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
2416008|NCT03463382|Active Comparator|QLB Group|"Quadratus Lumborum Block Group~Block Drug: 0,25% bupivacaine 0,5ml/kg (max.20ml) were used for blocks"
2416009|NCT03463369|Experimental|Placebo + Nucleos(t)ide Analogs (NA)|Participants will receive placebo intramuscular (IM) injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
2416010|NCT03463369|Experimental|JNJ-64300535 + NA|Participants will receive JNJ-64300535 IM injection on Day 1, Week 4, and Week 12, along with standard of care NA treatment.
2416011|NCT03463356|Experimental|Shame Intervention|Participants will complete a two shame intervention sessions approximately one week apart.
2416012|NCT03463343|Experimental|Manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
2416013|NCT03463343|Active Comparator|Mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
2416014|NCT03463343|Placebo Comparator|Placebo|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
2416015|NCT03463343|No Intervention|Control|The subjects stayed in supine position and no intervention occurred.
2416016|NCT03463330|Experimental|Intervention Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice the Qigong exercise during the study.
2416017|NCT03463330|Sham Comparator|Control Group|Participation in the intervention group will involve a total of 14 visits over about 14 weeks to the study site, and then a 6-month follow-up evaluation. Participants will learn and practice a mild body exercise during the study.
2416018|NCT03463317|Experimental|LAA closure group|Left atrial appendage closure by use of CE-mark approved LAA closure devices followed by post procedure treatment (antiplatelet therapy e.g. acetylsalicylic acid, clopidogrel)
2416019|NCT03463317|Active Comparator|Best medical care group|No left atrial appendage closure. Treatment with best medical care (NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or VKA (phenprocoumon, warfarin)
2416020|NCT03463291||Study group|All patients with bony lesions
2416021|NCT03463278||0-4 blastocysts|group A: cumulative pregnancy rate of 0-4 blastocysts vitrified
2416022|NCT03463278||5-7 blastocysts|group B: cumulative pregnancy rate of 5-7 blastocysts vitrified
2416023|NCT03463278||>7 blastocysts|group C: cumulative pregnancy rate of >7 blastocysts vitrified
2416024|NCT03463265|Experimental|ABI-009|
2416025|NCT03463265|Experimental|ABI-009 + bevacizumab|
2416026|NCT03463265|Experimental|ABI-009 + temozolomide|
2416027|NCT03463265|Experimental|ABI-009 + lomustine|
2416028|NCT03463265|Experimental|ABI-009 + temozolomide + radiotherapy|
2416029|NCT03463265|Experimental|ABI-009 + marizomib|
2416030|NCT03463252|Active Comparator|MPA for EC without progesterone contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2416048|NCT03463187|Experimental|160mg SHR-1314-Part A|SHR-1314 160mg, subcutaneously
2416049|NCT03463187|Experimental|240mg SHR-1314-Part A|SHR-1314 240mg, subcutaneously
3145591|NCT00075491|Experimental|Arm I (fenretinide, surgery)|Patients receive neoadjuvant oral fenretinide twice daily for 1 week and then undergo surgical resection.
3145592|NCT00075491|Active Comparator|Arm II (surgery)|Patients undergo surgical resection.
2416031|NCT03463252|Experimental|MPA+Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2416032|NCT03463252|Experimental|Mirena® for EC without contraindication|The enrolled patient (endometrial cancer without contraindication of oral high dose progesterone) is allocated to one of three groups, MPA only, MPA+LNG-IUS, LNG-IUS only, by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2416033|NCT03463252|Active Comparator|GnRH agonist+Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2416034|NCT03463252|Experimental|Mirena® for EC with contraindication|The enrolled patient (endometrial cancer with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if endometrial cancer is still present after 3 cycles.
2416035|NCT03463252|Active Comparator|Mirena® for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2416036|NCT03463252|Experimental|MPA for EAH without progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia without contraindication of oral high dose progesterone) is allocated to either MPA or LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2416037|NCT03463252|Active Comparator|Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2416038|NCT03463252|Experimental|GnRH-a+Mirena® for EAH with progesterone contraindication|The enrolled patient (atypical endometrial hyperplasia with contraindication of oral high dose progesterone) is allocated to either GnRH-a+ LNG-IUS or only LNG-IUS by randomization. Continuous treatment for 3 months is one cycle. Hysteroscopic evaluation and biopsy will procedure every cycle. Patients with partial response or in stable condition, after 2 cycles, will receive continuous treatment for one more cycle again. Patients with complete response after 2 or 3 cycles are encouraged to pregnancy. The consideration of giving up fertility-sparing treatment is recommended: 1) if patient have documented progression on the biopsies; 2) if EAH is still present after 3 cycles.
2416040|NCT03463226||Low testosterone|"Patients with HF and testosterone deficiency.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
2416041|NCT03463226||Normal testosterone|"Patients with HF and normal plasma levels of testosterone.~Cardiopulmonary exercise test~Muscle Sympathetic Nerve Activity~Dual-energy X-ray absorptiometry~Venous occlusion plethysmography~Blood sample collection~Dynamometers for Handgrip Strength"
2416042|NCT03463213|Experimental|SHE Tribe|SHE Tribe is a social network-based peer-facilitated intervention to promote adoption of health behaviors
2416043|NCT03463200|No Intervention|Control group|It will not apply any tape.
2416044|NCT03463200|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
2416045|NCT03463200|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
2416046|NCT03463200|Experimental|Experimental group 3|Apply Micropore tape in the erector spine muscles.
2416047|NCT03463187|Experimental|80mg SHR-1314-Part A|SHR-1314 80mg, subcutaneously
2416054|NCT03463187|Experimental|SHR-1314 Placebo (Part B)|SHR-1314 Placebo, subcutaneously
2416055|NCT03463174|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have a dental implant placed in the mandibular midline followed by the immediately insertion of a ball attachment and the incorporation of a retention matrix to the mandibular denture.
2416056|NCT03463174|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment besides the new set of conventional complete dentures. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
3186033|NCT00741325||G-CSF plus plerixafor|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received plerixafor, prior to undergoing apheresis.
3186034|NCT00741325||G-CSF plus placebo|Participants in Study AMD3100-3101 (NCT00103610)underwent mobilization with granulocyte colony-stimulating factor (G-CSF)and received placebo, prior to undergoing apheresis.
2416059|NCT03463148||1|Men/Women who meet the inclusion/exclusion criteria of this protocol.
2416060|NCT03463135|Experimental|SAR439794 [PE SLIT + GLA)]|GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
2416061|NCT03463135|Experimental|Placebo for GLA + SLIT PE|Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks
2416062|NCT03463135|Placebo Comparator|Placebo for GLA + Placebo for SLIT PE|Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks
2416063|NCT03463122|Other|Training first|This group completed 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy followed by four weeks of conventional therapy
2416064|NCT03463122|Other|Waiting first|This group completed four weeks of conventional therapy followed by 20 sessions of a field of regard-focused visual exploration therapy program using an head mount display (five daily sessions per week over a period of four weeks) in addition to conventional therapy.
2416065|NCT03463109|Other|Healthy Volunteers|Electrocutaneous stimulation. A standardized grid will be drawn over the participants' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid selected at random. Participants will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet the location on which they will perceive each painful stimulation.
2416066|NCT03463109|Other|Chronic Low Back Pain|"Assessment + Electrocutaneous stimulation. Patients with chronic low back pain will be asked to provide information about their lifestyle, level of disability, current pain, general pain and to undergo an assessment of kinesiophobia and health status.~After the assessment, a standardized grid will be drawn over the patients' lumbar region. Circular electrodes, connected to a constant current stimulator, will be applied at points on the grid. Patients will be blinded to the electrode locations. Sets of painful electrocutaneous stimuli will be randomly delivered for each electrode. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
2416067|NCT03463096|Experimental|Centrifuge study|High G acceleration on a long-arm human centrifuge
2416068|NCT03463083|Active Comparator|Bupivacaine dexmedetomidine group|Group 1 (bupivacaine + dexmedetomidine (BD) group); will Receive an epidural study solution of 18 ml of 0.25% of bupivacaine hydrochloride plus 1 ml of dexmedetomidine (1 mcg/kg) plus 1 ml normal saline keeping the total volume of 20 ml in a syringe pump .
2416069|NCT03463083|Active Comparator|Bupivacaine fentanyl group|Group 2 (bupivacaine + fentanyl (BF) group) ; will Receive an epidural study solution of 18 ml of 0.25% bupivacaine plus 2 ml fentanyl (1 mcg/kg) keeping the total volume of 20 ml in a syringe pump .
2416070|NCT03463070|Active Comparator|preoperative misoprostol group|70 women who received 600 mg misoprostol rectally preoperatively before cesarean section
2416071|NCT03463070|Active Comparator|postoperative misoprostol group|70 women who received 600 mg misoprostol postoperatively at operating theatre after cesarean section
2416072|NCT03463057|Other|Atezolizumab|18 cycles atezolizumab followed by 12 months of observation
2416073|NCT03463044|Placebo Comparator|Placebo|
2416074|NCT03463044|Experimental|MOTREM 1|
2416075|NCT03463044|Experimental|MOTREM 2|
2416076|NCT03463044|Experimental|MOTREM 3|
2416077|NCT03463044|Experimental|MOTREM 4|
2416078|NCT03463044|Experimental|MOTREM 5|
2416079|NCT03463044|Experimental|MOTREM 6|
2416080|NCT03463044|Experimental|MOTREM 7|
2416081|NCT03463044|Experimental|MOTREM 8|
3186035|NCT00741351|Experimental|IF|Sevoflurane (Inhalation)+Fentanyl
3186036|NCT00741351|Experimental|IR|Sevoflurane (Inhalation)+Remifentanyl
2416084|NCT03463018|Experimental|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
2416085|NCT03463018|Placebo Comparator|Placebo|Identical excipients as in the experimental arm, without the active ingredient
2416086|NCT03463005|Experimental|Royal jelly|The study subjects included healthy women who had husbands with male-factor infertility problems.
2416087|NCT03463005|Active Comparator|IUI group|The study subjects included in IUI group were healthy women who had husbands with male-factor infertility problems.
2416088|NCT03462992||FIT-positive individuals|Patients being positive to an FIT test performed in the context of the Flemish (Northern Belgium) colorectal cancer screening campaign. These patients are male and female between 56 and 74 years old.
2416162|NCT03462485|No Intervention|Control|Control participants will continue their normal activities.
2416163|NCT03462472|Experimental|15 minute lower leg heating|
2416164|NCT03462472|Experimental|45 minute lower leg heating|
2416165|NCT03462472|No Intervention|Control|
3186037|NCT00741351|Experimental|ER|Propofol (Endovenous)+ Remifentanyl
3186038|NCT00741364|Active Comparator|1|vitamin D3 (400 IU/d)
3186039|NCT00741364|Active Comparator|2|vitamin D3 (10,000 IU/d)
2416089|NCT03462979|Experimental|Open Results with home testing|Participants in the open results arm will be provided with Gluten Detective home testing kits (immunochromatographic lateral flow tests) at week 8 of the study for immediate qualitative (yes/no) feedback about the presence of biomarkers of gluten in their stool and/or urine. During the period from week 8 to week 30, participants will be contacted a total of 6 times at random intervals to collect and test urine samples and complete a questionnaire.Additionally, participants will be given 4 stool test kits, with instructions that they may use these at times of their choosing and will report results and reasons for test use, if any. During this time participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit.
2416090|NCT03462979|No Intervention|Blinded (sample collection only)|Participants in the blinded arms will not be given a test kit but will be given sample collection materials. During the period from week 8 to week 30 of the study, participants will be contacted a total of 6 times at random intervals, instructed to collect urine samples, and complete a questionnaire. Participants will also keep a diary of suspected gluten exposures. All samples collected will be returned during the week 30 study visit. After completion of sample collection, all participants will be unblinded and notified of the results once the samples have been processed.
3145593|NCT00075569|Active Comparator|1 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 1 month; followed by LEEP or cone biopsy
2416092|NCT03462953|Placebo Comparator|individuals with healthy gingiva|Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls.
2416093|NCT03462953|Placebo Comparator|periodontally diseased individuals|Gingival tissue samples will be harvested during periodontal surgery and extraction of the periodontally hopeless tooth for the periodontitis patients.
2416094|NCT03462940|Experimental|TUDCA Group|All subjects will receive 500 mg/day in a one week run-in period and then 1750 mg/day in one week treatment period of of the nutritional supplement Tauroursodeoxycholic acid (TUDCA).
2416097|NCT03462901|Experimental|Elastic rod fixation|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures
2416098|NCT03462875||Crohn's Disease Patients|Subjects having confirmed diagnosis of Crohn's disease which is defined by endoscopy, radiology and histology; and having documented ileocaecal or right-sided colonic disease
2416099|NCT03462875||Non-household Controls|Non-affected subjects who will under colonoscopy for polyp or colorectal cancer screening, or investigations of gastrointestinal symptoms other than Inflammatory Bowel Disease
2416100|NCT03462875||First Degree Relatives|Non-affected first degree relatives of cases
2416101|NCT03462875||Household/co-habitant Controls|Non-affected subjects living in the same household with the cases in the recent 6 months
2416102|NCT03462862|Experimental|Group 1|patients will receive partial denture constructed from PEEK material
2416103|NCT03462862|Active Comparator|Group 2|patients will receive partial denture constructed from breflex material
2416104|NCT03462849|Other|Patients with EFL at PEP 5|Patients with EFL at PEP 5 at the time of inclusion either in supine or semi-recumbent position
2416105|NCT03462849|Other|Patients with no EFL at PEP 5|Patients with no EFL at PEP 5 at the time of inclusion in both supine and semi-recumbent positions
2416106|NCT03462836|Experimental|IV ketamine/lidocaine/IV PCA (MA) group|In addition to basic anesthetic methods, multimodal analgesia with IV ketamine, lidocaine and IV PCA apply
2416107|NCT03462836|Active Comparator|IV PCA only (CA) group|In addition to basic anesthetic methods, only IC PCA apply for pain control
2416108|NCT03462823|Active Comparator|Control treatment|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
2416109|NCT03462823|Experimental|Experimental treatment|ACL-reconstruction using hamstring autograft with hybrid fixation combined with the osteoconductive device under study.
2416110|NCT03462784||Cases|
2416111|NCT03462771|Experimental|Group exercise fish oil|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive omega-3 fatty acid supplements to be ingested 2g in the main meals, totaling 4g daily.
2416112|NCT03462771|Placebo Comparator|Group exercise placebo|Using the Randomizer Research program, 15 elderly women will participate in a resistance exercise protocol and receive sunflower oil to be ingested 2g in the main meals, totaling 4g daily.
2416113|NCT03462758|Other|Control Group|IUD placed 6-8 weeks postpartum (standard of care, interval placement)
2416114|NCT03462758|Experimental|Intervention Group|IUD placed 2-4 weeks postpartum (early postpartum placement, EPP)
2416117|NCT03462732|Active Comparator|Group I|Endotracheal tube plus Nelaton catheter
2416118|NCT03462732|Active Comparator|Group II|Endotracheal tube
3145594|NCT00075569|Active Comparator|2 month follow-up|3 monthly subcutaneous vaccinations with 500 microg of HspE7 followed by monthly colposcopic follow-up for 2 months; followed by LEEP or cone biopsy
2416166|NCT03462472|Experimental|15 minute lower leg TENS|
2416167|NCT03462472|Experimental|45 minute lower leg TENS|
3145595|NCT00075621|Other|tandem transplant|"Drug: filgrastim 16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection~Drug: melphalan 200 mg/kg over 2 days~Procedure/Surgery: autologous peripheral blood stem cell transplantation~autologous peripheral blood stem cell transplantation"
3145596|NCT00075634|Experimental|Arm I|"PART A (solid tumor patients): Patients receive decitabine IV over 1 hour on days 0-6 and doxorubicin IV over 15 minutes and cyclophosphamide IV over 1 hour on day 7. Patients then receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 8 and continuing until blood counts recover OR pegfilgrastim SC once on day 8 or 9*. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~PART B (neuroblastoma patients): Once the MTD is determined for part A, patients are treated as in part A at the MTD."
3145597|NCT00075647|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3145598|NCT00075686|Experimental|gemcitabine hydrochloride + IMC-C225|Loading dose: gemcitabine hydrochloride 1000mg/m2, IV on Day 1; Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only) Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles; gemcitabine hydrochloride 1000mg/m2, IV on Days 8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
3145599|NCT00075686|Experimental|gemcitabine hydrochloride alone|gemcitabine hydrochloride 1000mg/m2, IV on Days 1,8,15,22 of cycle 1 and Days 1,8,15 of all subsequent cycles.
2416121|NCT03462706|Experimental|Cold Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold snare techniques.
2416122|NCT03462706|Experimental|Hot Snare|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot snare techniques.
2416123|NCT03462706|Experimental|Cold EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using cold EMR techniques.
2416124|NCT03462706|Experimental|Hot EMR|Polyps sized 6mm to 15mm found during colonoscopy will be removed using hot EMR techniques.
2416125|NCT03462693||Group 1|Dry needling plus standard physiotherapy treatment
2416126|NCT03462693||Group 2|Standard physiotherapy treatment
3145600|NCT00075751|Experimental|Treatment (gemcitabine hydrochloride, carboplatin, bortezomib)|Patients receive gemcitabine IV over 30 minutes on days 1 and 8, carboplatin IV over 15-30 minutes on day 1, and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone on the above schedule for up to 1 year at the discretion of the treating physician.
3145601|NCT00075842|Experimental|Arm I|Patients receive oral Valeriana officinalis (Valerian) once daily for 8 weeks.
2416129|NCT03462667|Experimental|Stoma Boot Camp|Participants will attend the Stoma Boot Camp session prior to surgery.
2416130|NCT03462667|Active Comparator|Regular Care|Participants will receive normal standard of care prior to surgery.
2416131|NCT03462654|Active Comparator|individual LiFE (iLiFE)|In iLiFE, LiFE activities to increase strength, improve balance, and promote physical activity as well as habitualization strategies are introduced and taught in 7 highly individualized, one-to-one home visits.
2416132|NCT03462654|Experimental|group LiFE (gLiFE)|In gLiFE, the same LiFE activities as performed in iLiFE are introduced and taught in 7 group sessions with 8 to 12 participants. Implementation and habitualization strategies will be addressed within the group setting, making use of group dynamics and processes.
2416133|NCT03462641|Active Comparator|Flumazenil|Flumazenil 1mg in 10cc normal saline will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
2416134|NCT03462641|Placebo Comparator|Placebo|10 cc of normal saline placebo will be given intravenously (iv) over 5-10 minutes and a detailed clinical assessment will follow for the next 90 minutes.
2416135|NCT03462628|Experimental|Study Group|PVI with additional low-voltage substrate modification
2416136|NCT03462628|Active Comparator|Control Group|PVI
2416137|NCT03462602|Experimental|NGT group|NGT group
2416138|NCT03462602|Experimental|non-NGT group|non-NGT group
2416139|NCT03462589|Experimental|SY-008 dose 1|A single dose of SY-008 (2~30mg) taken orally.
2416140|NCT03462589|Experimental|SY-008 dose 2|A single dose of SY-008 (2~30mg) taken orally.
2416141|NCT03462589|Experimental|SY-008 dose 3|A single dose of SY-008 (2~30mg) taken orally.
2416142|NCT03462589|Experimental|SY-008 dose 4|A single dose of SY-008 (2~30mg) taken orally.
2416143|NCT03462589|Experimental|SY-008 dose 5|A single dose of SY-008 (2~30mg) taken orally.
2416144|NCT03462589|Placebo Comparator|SY-008 matching placebo|from 6mg to 30mg
3186040|NCT00741364|Active Comparator|3|vitamin D3 (40,000 IU/d)
3145602|NCT00075842|Placebo Comparator|Arm II|Patients receive an oral placebo once daily for 8 weeks.
3145603|NCT00075855|Experimental|testosterone|"Patients receive topical testosterone once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
2416150|NCT03462550|Active Comparator|LMA Supreme|
2416151|NCT03462550|Experimental|LMA Protector|
2416152|NCT03462537|Experimental|Experimental group 1|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line.
2416153|NCT03462537|Experimental|Experimental group 2|This group performed aerobic exercise just after low level laser therapy in the abdominal region with eight electrodes distributed in line, but low level laser therapy device was switched off.
2416154|NCT03462537|Placebo Comparator|Placebo group|Low level laser therapy without power. This group performed the low level laser therapy protocol, but low level laser therapy device was switched off.
2416155|NCT03462524||Neoadjuvant chemotherapy|
2416156|NCT03462524||Neoadjuvant chemoradiation|
2416157|NCT03462511|No Intervention|Control Group|Dyads randomized to the control group will receive standard care and education handouts.
2416158|NCT03462511|Experimental|Intervention Group|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
2416159|NCT03462498|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists and clopidogrel monotherapy for 59 months
2416160|NCT03462498|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists; 11-month DAPT composed of aspirin and clopidogrel and aspirin monotherapy for 48 months
2416161|NCT03462485|Experimental|Golf intervention|The golf intervention will be an eight-week golf programme in which participants will be taught to play golf in two 150-min sessions each week. Each session will begin with 30 minutes of socialising, then 90 minutes playing golf, followed by another 30 minutes socialising. The golf sessions will progress from putting, to chipping, and then a full swing, with sessions taking place on a nine-hole golf course.
3145604|NCT00075855|Other|placebo|"Patients receive a topical placebo once daily for 4 weeks. After 4 weeks, patients cross over to the other treatment arm.~Changes in sexual functioning, mood states, and medical outcome vitality are assessed at baseline and then at the end of weeks 4 and 8.~Patients who continue or restart testosterone cream after the 8-week study period are followed at 6 months."
3145605|NCT00075868|Experimental|Sandostatin LAR® Depot|Sandostatin LAR® Depot Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
2416170|NCT03462446||Treatment group with Rivaroxaban|Patients treated with Rivaroxaban
2416171|NCT03462446||Control group with VKAs|Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).
2416172|NCT03462420|Experimental|PT+ walking|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. In addition, participants will be asked to perform free walking at their own pace for 30-45 min, 5 days per week for 6 consecutive weeks and to record their walking date/time on a diary form provided by the research team before commencing the study. Participants in PT+ group will also be provided with accelerometer to accurately estimate their physical activity level.
2416173|NCT03462420|Active Comparator|Regular PT|Participants in this group will be referred to a physical therapy facility according to their preferences and the intervention will be chosen by the treating physical therapist. Participants in this group will not be notified about the walking program.
2416174|NCT03462407|Experimental|DAID|Trained assistants will help participants train their dog to engage in imitation based dog training, using positive reinforcement training (operant conditioning) focused on physical activities.
2416175|NCT03462407|Active Comparator|Dog walking|Trained assistants will help children train their dog to walk on a loose leash (eliminate pulling behavior) during this period using positive training techniques. The focus of this group will be on appropriate walking behavior to facilitate enjoyable independent dog-walking at home.
2416176|NCT03462407|No Intervention|Control|This group will all own family dogs but will not participate in either intervention during year 1. All participants assigned to the waitlist will be offered the DAID intervention the subsequent summer.
2416177|NCT03462394||Current Script Version|This arm will receive the version of the call script currently used as part of regular care at NYU Langone Health.
2416178|NCT03462394||Script Iterations|This arm will receive an iterated version of the script that might contain changes in wording or structure that are different from the current version of the script.
2416179|NCT03462381|Experimental|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
2416180|NCT03462381|Placebo Comparator|Carbohydrate|Three endurance training sessions weekly with carbohydrate supplementation post-exercise and before sleep.
2416181|NCT03462368|Active Comparator|Control|Root surface treatment by scaling and root planing
2416182|NCT03462368|Experimental|antimicrobial photodynamic therapy|Root surface treatment by antimicrobial photodynamic therapy
2416183|NCT03462368|Active Comparator|Photobiomodulation|Treatment of the whole surgical site with laser
2416184|NCT03462342|Experimental|A. Olaparib Pill + AZD6738.|"Cohort A: Recurrent platinum-sensitive ovarian cancer (progression greater than 6 months from last receipt of platinum-based chemotherapy), approximately 37 patients could be treated with an interim analysis after 17 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
2416185|NCT03462342|Experimental|B. Olaparib Pill + AZD6738.|"Cohort B: Recurrent platinum-resistant ovarian cancer (progression less than or equal to 6 months of the last receipt), approximately 37 patients could be treated with an interim analysis after 12 subjects.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
2416186|NCT03462342|Experimental|C. Olaparib Pill + AZD6738.|"Cohort C: PARP inhibitor (PARPi) resistant (subjects who have progressed on a PARPi), patients must be platinum-sensitive, and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 subjects could be treated.~All patients will receive the combination of AZD6738 and olaparib. Patients will be administered olaparib orally twice daily at 300 mg BD. Patients will be administered AZD6738 orally once daily at 160 mg on days 1 to 7.~For ease of administration, the AZD6738 should be administered at the same time as one of the olaparib doses and thus with one glass of water."
2416187|NCT03462342|Experimental|D-1. Olaparib Pill + AZD6738.|"Cohort D Part I: Patients will be platinum sensitive/platinum resistant ovarian cancer. Patient may or may not have received prior PARPi and will be enrolled irrespective of their BRCA status. The number of subjects treated will depend on the number of dose levels explored with a minimum of 12 subjects up to 30 subjects.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
2416188|NCT03462342|Experimental|D-2 Olaparib Pill + AZD6738.|"Cohort D Part II: Patients with ovarian cancer who are PARP inhibitor (PARPi) resistant (patients who have progressed on a PARPi). Patients must be platinum-sensitive and have a germline or somatic BRCA mutation or an HRD mutation. Approximately 12 patients will be treated.~All patients will receive the combination of AZD6738 and olaparib. Cohort D will take a lower dose of olaparib (100-200 mg daily for a 28-day cycle) and a higher dose of AZD6738 (160-320 mg daily for about 14 days). Three to five dosing schedules will be evaluated."
2416189|NCT03462329|Active Comparator|patients with erythema migrans|Patients will be treated with antibiotics for Lyme disease.
2416190|NCT03462329|No Intervention|controls|Control subjects will not be given antibiotics.
2416242|NCT03462069|Experimental|Treatment A (Test)|Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day
2416243|NCT03462069|Active Comparator|Treatment B (Reference)|Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day
2416399|NCT03461003|Active Comparator|Usual Care|No protocol will be introduced to standardize BP management in the control arm.
3145606|NCT00075868|Placebo Comparator|Placebo|Placebo Pre-RT (between day -7 and day -4 of RT) and Day 22 (± 3 days)
2416192|NCT03462303|Placebo Comparator|tDCS sham + balanced drink|
2416193|NCT03462303|Experimental|tDCS sham + tyrosine depleted drink|
2416194|NCT03462303|Experimental|tDCS anodal + balanced drink|
2416195|NCT03462303|Experimental|tDCS anodal +tyrosine depleted drink|
2416198|NCT03462277||Control group|Control group was defined as people with negative findings in coronary angiograms.
2416199|NCT03462277||Coronary Heart Disease group|CHD patients was defined as at least one lesion in a coronary artery or branches in coronary angiograms.
2416200|NCT03462264|No Intervention|Control Group / Group 1|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic.
2416201|NCT03462264|Experimental|Group 2|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a pre-formatted diary for them to fill out.
2416202|NCT03462264|Experimental|Group 3|This group will receive their personalised exercise schedule after treatment as per routine treatment at the clinic as well as a link to download the free ScolioGold App on to their mobile from the clinic.
3145607|NCT00076063|Experimental|A|Participants in Groups A will receive four injections over 6 months of either LIPO-5 or a placebo.
3145608|NCT00076063|Experimental|B|Participants in Group B will receive four injections over 6 months of either the ALVAC-HIV (vCP1452) or a placebo.
2416205|NCT03462238|Other|Kidney transplant patients|Group of renal transplant patients for 24 months
2416206|NCT03462238|Other|Dialysis patients|Group of dialysis patients for 24 months
2416207|NCT03462212|Other|Standard treatment|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d 1 q 21 for 6 cycles + Bevacizumab 15 mg/kg d 1 q 21 days for 22 cycles (in combination and maintenance)
2416208|NCT03462212|Experimental|Carboplatin + Paclitaxel + Bevacizumab + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Bevacizumab 15 mg/kg d1 q 21 for 22 cycles (in combination and maintenance) + Rucaparib at the dose defined by the Phase I study continuously for 2 years (Rucaparib only in maintenance)
2416209|NCT03462212|Experimental|Carboplatin + Paclitaxel + Rucaparib|Carboplatin AUC 5 + Paclitaxel 175 mg/mq d1 q 21 days for 6 cycles + Rucaparib 600 mg BID continuously for 2 years (Rucaparib only as maintenance).
2416210|NCT03462199|Placebo Comparator|Placebo|
2416211|NCT03462199|Experimental|Actazin High Dose|
2416212|NCT03462199|Experimental|Actazin Low Dose|
2416213|NCT03462199|Active Comparator|Control Formula|
2416214|NCT03462199|Experimental|Livaux High Dose|
2416215|NCT03462199|Experimental|Livaux Low Dose|
2416216|NCT03462186|Experimental|Intervention|Invitation to use healthfinder website
2416217|NCT03462186|No Intervention|Control|No intervention
2416218|NCT03462173|Experimental|30 mg single dose|Healthy subjects, receiving a single dose of 30 mg yimitasvir(N=6) or placebo(N=2)
2416219|NCT03462173|Experimental|100 mg single dose|Healthy subjects, receiving a single dose of 100 mg yimitasvir (N=6) or placebo(N=2)
2416220|NCT03462173|Experimental|200 mg single dose|Healthy subjects, receiving a single dose of 200 mg yimitasvir (N=6) or placebo(N=2)
2416221|NCT03462173|Experimental|400 mg single dose|Healthy subjects, receiving a single dose of 400 mg yimitasvir (N=6) or placebo(N=2)
2416222|NCT03462173|Experimental|600 mg single dose|Healthy subjects, receiving a single dose of 600 mg yimitasvir (N=6) or placebo(N=2)
2416223|NCT03462173|Experimental|800 mg single dose|Healthy subjects, receiving a single dose of 800 mg yimitasvir (N=6) or placebo(N=2)
2416224|NCT03462173|Experimental|1000 mg single dose|Healthy subjects, receiving a single dose of 1000 mg yimitasvir (N=6) or placebo(N=2)
2416225|NCT03462160|Placebo Comparator|Placebo supply for 90 days|Patients will receive placebo (in blinded sachets)
2416226|NCT03462160|Experimental|Probiotic supply for 90 days|Patients will receive probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 (in blinded sachets).
2416227|NCT03462147|Sham Comparator|SHAM|No stimulation will be given
2416228|NCT03462147|Experimental|High Density Stimulation|New way of spinal cord stimulation
2416229|NCT03462147|Active Comparator|Conventional stimulation|the most used stimulation of the spinal cord
2416230|NCT03462134||Survey amongst orthopaedic surgeons|Selected of 20 patients from the Escape trial (NCT01850719)
2416231|NCT03462121|Experimental|RPh201|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the IMP (20 mg RPh201).
2416232|NCT03462121|Placebo Comparator|Placebo|A 26-week schedule consisting of twice-weekly subcutaneous administration of 400 μL of the vehicle control.
2416233|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Adult|1 doses of 1 ml of Rotavirus vaccine per oral
2416234|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Children|1 doses of 1 ml of Rotavirus vaccine per oral
2416235|NCT03462108|Experimental|Rotavirus (Bio Farma) Vaccine-Neonates|3 doses of 1 ml of Rotavirus vaccine per oral
2416236|NCT03462108|Placebo Comparator|Placebo-Neonates|3 doses of 1 ml of Placebo (contains 30% sucrose in DMEM) per oral
2416237|NCT03462095|No Intervention|no Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will continue with 2 years maintenance
2416238|NCT03462095|Experimental|Auto-HSCT|After completing prolonged consolidation T-cell ALL patients will get autologous HSCT followed by 2 years maintenance
3186041|NCT00741377|Experimental|BHQ880 + zoledronic acid|BHQ880 3-40 mg/kg in combination with zoledronic acid 4 mg on day 1 of a 28-day cycle.
3186042|NCT00741403|Experimental|A|IV Infusion of CPI-613 on Days 1,4,8,11,15,18 of 28 day cycle in patients with advanced malignancies
3145609|NCT00076063|Experimental|C|Participants in Groups C will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
3186043|NCT00741416||Case|Those with a diagnosis of Coronary Artery Disease
2416244|NCT03462056|Experimental|CF Ready to Use Supplemental Food.|Participants will receive Cystic Fibrosis Ready to Use Supplemental Food sufficient to provide approximately 20% of estimated daily caloric needs up to 500kcal of total calories, 18.5 grams of protein and 28g of fat. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition
2416245|NCT03462043|Active Comparator|Sequence A|
2416246|NCT03462043|Active Comparator|Sequence B|
2416247|NCT03462043|Active Comparator|Sequence C|
2416248|NCT03462043|Active Comparator|Sequence D|
2416251|NCT03462017|Experimental|SAR247799|SAR247799 repeated doses once daily in the morning under fasted condition for 28 days according to a sequential dose design
2416252|NCT03462017|Placebo Comparator|Placebo|Identical matching placebo for SAR247799 and for sildenafil once daily in the morning under fasted condition for 28 days
2416253|NCT03462017|Active Comparator|Sildenafil|Sildenafil once daily in the morning under fasted condition for 28 days
2416254|NCT03462004|Experimental|Cohort 1: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^6.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
2416255|NCT03462004|Placebo Comparator|Cohort 1: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
2416256|NCT03462004|Experimental|Cohort 2: HPIV3/ΔHNF/EbovZ GP vaccine|Participants will receive two doses of 10^7.0 PFU/mL of HPIV3/ΔHNF/EbovZ GP vaccine on Days 0 and 28 (+28).
2416257|NCT03462004|Placebo Comparator|Cohort 2: Placebo|Participants will receive two doses of placebo on Days 0 and 28 (+28).
2416258|NCT03461991|Other|Patients scheduled for corneal transplantation|
2416259|NCT03461978|Other|10 patients with meibomian gland dysfunction|
2416260|NCT03461978|Other|10 patients with cataract|
2416261|NCT03461978|Other|10 patients after minimally invasive glaucoma surgery (MIGS)|
2416262|NCT03461978|Other|10 patients after partial corneal transplantation|
2416263|NCT03461978|Other|5 patients with demodicosis|
2416264|NCT03461978|Other|5 patients with conjunctival pathologies|
2416265|NCT03461978|Other|5 patients with Acanthamoeba keratitis|
2416266|NCT03461978|Other|5 patients with aniridia|
3186044|NCT00741416||Control|Those who do not have Coronary Artery Disease (are healthy) but are matched to a Case participant by age, gender, and ethnicity.
3186045|NCT00741429||Ex-TI|Ex-Technosphere® Insulin Inhalation Powder (subjects previously received TI Inhalation Powder)
3186046|NCT00741429||Non Ex-TI|Non Ex-Technosphere® Insulin Inhalation Powder (subjects previously received another anti-diabetic medication)
3186047|NCT00741442|Experimental|1|RDEA806 400 mg qd
2416271|NCT03461939||ePRIME|"Participants in the study will receive training in using the ePRIME system to report their symptoms and side effects on a weekly basis from home via the internet for 12 weeks while receiving early phase trial treatment. Patients will be sent email/text reminders to enter their symptoms on the system once a week. Patients will be reminded that the data they enter via the online system will not be reviewed promptly by their hospital team and therefore they should continue to contact their treatment team via the contact numbers they have been given.~As part of the research project, we will monitor the number of notifications for severe AE generated by the system to address concerns from the interviews conducted in the first phase of this research project that ePROs will lead to increased workload for clinicians."
2416272|NCT03461926|Experimental|HAPA-treatment|(SB-related planning + daily text messages)
2416273|NCT03461926|No Intervention|Control|(No Treatment) Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaires.
2416274|NCT03461913|Active Comparator|normal pregnancy|women at full term healthy pregnancy who underwent elective Cesarean section
2416275|NCT03461913|Active Comparator|pregnancy hypertension|women at full term pregnancy associated with hypertension who underwent elective Cesarean section
2416276|NCT03461900|Experimental|Minifluid challenge|100 ml of 4% Albumin will be deliver to assess fluid responsiveness
2416277|NCT03461900|Experimental|Control|Patient will be treated as defined by most recent surviving sepsis campaign guidelines
2416280|NCT03461874|Active Comparator|Treatment as usual|Education of patients followed by Pharmacological Prophylaxis, prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Calcium channel blockers
2416281|NCT03461874|Experimental|Treatment as usual + ACT|"Education of patients, Pharmacological Prophylaxis prescribed based on patients' profile, and eight group sessions of 90 minutes of ACT.~The ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program."
3186048|NCT00741442|Experimental|3|RDEA806 400 mg bid
3186049|NCT00741442|Placebo Comparator|2|Placebo QD
2416284|NCT03461848|Experimental|CYPHP Evelina London Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
2416285|NCT03461848|Active Comparator|Enhanced Usual Care Model|Practice clusters across Lambeth and Southwark have been randomised to introduce either the CYPHP Evelina London model of care, or Enhanced Usual Care.
2416286|NCT03461835|Active Comparator|M4|High risk classification if the chance of the PUL being an EP ≥5 %; a calculation based on the average value of the two hCG and the ratio of these two hCG (0 h/48 h). Otherwise a low risk classification is made and a predicted outcome of either an IUP or failed PUL is presented.
2416287|NCT03461835|Active Comparator|NICE|High risk classification if the change in rising hCG levels ≤ 63 % or the change in declining hCG ≤ 50 %. If these cut-offs are exceeded the PUL is classified as low risk and predicted to be either an IUP or failed PUL depending on rising or declining hCG levels.
2416288|NCT03461822||SRT in primary-inoperable solid tumors|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in primary-inoperable solid tumors
2416289|NCT03461822||Classic radiotherapy in primary-inoperable solid tumors|Classic radiotherapy in 1.8-2.0 Gy per fraction in primary-inoperable solid tumors
2416290|NCT03461822||SRT in oligometastatic cancer|stereotactic radiotherapy in hypofractionated regimes in 1-5 fractions in oligometastatic cancer
2416291|NCT03461822||Classic radiotherapy in oligometastatic cancer|Classic radiotherapy in 1.8-2.0 Gy per fraction in oligometastatic cancer
2416292|NCT03461809||Ocular motor nerve palsy treated by ocular acupuncture|Ocular motor nerve palsy patients who received ocular acupuncture treatment
2416293|NCT03461783|Experimental|Zorflex Activated Carbon Dressing|Patients randomized into the experimental group will only be treated using an activated carbon dressing (Zorflex® Activated Carbon Cloth Dressing; Chemviron Carbon Cloth Carbon, West Midlands, United Kingdom; a division of Calgon Carbon Corporation, Pittsburgh, PA) for wet wounds or with saline and Zorflex® Activated Carbon Cloth Dressing for dry wounds.
2416294|NCT03461783|Active Comparator|Standard of Care for Wound Care|Patients with wet wounds randomized into the control group will be treated using foam, calcium alginate or compressive dressings, whereas those with dry wounds will be treated with hydrogel and compressive dressings.
2416295|NCT03461770|No Intervention|Control group|Patients will receive anesthesia induction with Sevoflurane using a circular circuit without CPAP. Protective ventilation with 5 cmH20 of positive end-expiratory pressure (PEEP) will be initiated after induction. At the end of surgery, mechanical ventilation will stop allowing spontaneous ventilation. Patients will be extubated without CPAP. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
2416296|NCT03461770|Experimental|CPAP group|Patients will receive anesthesia induction using 5 cmH20 of CPAP until the moment of intubation. After induction patients will receive the same protective ventilation than the control group. A lung recruitment maneuver will be applied if these patients present atelectasis during surgery. At the end of surgery, patients will be extubated under the modality of CPAP with 5 cmH20. Lung ultrasound examinations will be performed at different times-points: before anesthesia induction, during surgery, at the end of surgery and before extubation, and after extubation.
3186050|NCT00741442|Placebo Comparator|4|Placebo BID
3186051|NCT00741481||1|all study population
2416299|NCT03461731|Sham Comparator|Control|Participant will receive a sham treatment that consists of just the 660-nm aiming beam
2416300|NCT03461731|Experimental|800 nm laser|800 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
2416301|NCT03461731|Experimental|combination laser|905 nm and 800 nm will be applied at 4.4 joules per square cm with a total of 8.8 Joules per square cm during 40 repetitive handgrips.
2416302|NCT03461731|Experimental|905 nm laser|905 nm laser will be applied at 4.4 Joules per square cm on the forearm during 40 repetitive hand grips
2416303|NCT03461718|Experimental|Ketamine|Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
2416304|NCT03461718|Active Comparator|Control|This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.
3186052|NCT00741494|No Intervention|1|HBA score over 65% control
2416306|NCT03461679|Experimental|Intervention|Adductor canal block Femoral triangle block
2416307|NCT03461679|Active Comparator|Standard|Femoral triangle block
2416308|NCT03461666|Active Comparator|Cognitive Behavior Therapy-Insomnia|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2416309|NCT03461666|Active Comparator|Focus Of Attention|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2416310|NCT03461666|Active Comparator|Combined-CBT-I and FOA Group|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2416311|NCT03461666|Active Comparator|Sleep Hygiene|Participants receive 6 one hour in person behavioral psycho-intervention sessions from a treatment provider.
2416312|NCT03461653|Other|Telemedicine counselling|intervention group Women who will receive telemedicine counselling
2416313|NCT03461653|No Intervention|Standard care|Women who will receive standard face-to-face counselling
2416355|NCT03461341||Patients post curative intent surgery for esophageal cancer|Patients post potentially curative surgery for cTxNxM0 esophageal or esophagogastric junction (Siewert type I, II and III) cancer.
2416471|NCT03460470|Active Comparator|Sildenafil 40mgx3 daily|Sildenafil 40mgx3 daily for 6 months
3186053|NCT00741494|No Intervention|2|HBA score over 65%, non-participant (to even out the participation between patients with low HBA scores and those with high HBA scores)
3186054|NCT00741494|Active Comparator|3|HBA score over 65%. PICSI dish is used to select the sperm for ICSI.
3186055|NCT00741494|Experimental|4|HBA score less than 65%. PICSI dish used to select sperm for ICSI.
3186056|NCT00741494|No Intervention|5|HBA Score less than 65%. Control
3186057|NCT00741507|Active Comparator|1|No alcohol drinking
3186058|NCT00741507|Active Comparator|2|Mild alcohol drinking
3186059|NCT00741507|Active Comparator|3|Moderate alcohol drinking
2416314|NCT03461640|Experimental|Community-based doula support for labour|"Women will receive support from a Community-based doula (CBD) plus standard labour support. Women will meet twice with the CBD prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. The CBD will then stay with her throughout her labour and birth and support her with interpretation/Communication with the staff and emotional and instrumental support. The CBD-support will be in addition to any other support people she may have, such as her partner.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation.~CBDs will be recruited, trained and employed by non-profit organization MIRA, using well-tested processes."
2416315|NCT03461640|Active Comparator|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
2416316|NCT03461627|Experimental|Salmeterol Xinafoate and Fluticasone Propinate Powder|Salmeterol Xinafoate and Fluticasone Propinate Powder for inhalation (50ug/250ug) 50ug/250ug 1 puff twice a day for 4 weeks
2416317|NCT03461627|Active Comparator|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
2416318|NCT03461614|Experimental|Exercise Group|In addition to the service routine rehabilitation program, in this group all participant receive as group training with instructor supervising 5-6 participants. The specific days of the week and time of day in which the participants trained remained constant throughout each training protocol. Training programs lasted 6 weeks and comprised 2 training sessions per week with a total of 12 training sessions. A 45-60 min training sessions per week with a 2 day gap between each session.
2416319|NCT03461614|Other|Control Group|In addition to the service routine rehabilitation program, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
2416320|NCT03461601|Active Comparator|HCG uterine flushing group|Uterine flushing was done one day before Intrauterine insemination (IUI) with HCG (500 IU) in 10 ml of saline followed by Intrauterine insemination (IUI).
2416321|NCT03461601|Placebo Comparator|IUI alone group|Intrauterine insemination alone plus vaginal flushing with 10 ml normal saline
2416322|NCT03461588|Active Comparator|Free-breathing|standard treatment
2416323|NCT03461588|Experimental|Deep inspiratory breath-holding|new technique
2416324|NCT03461575|Experimental|HU007|"Cyclosporine 0.02%, trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
2416325|NCT03461575|Active Comparator|Restasis|"Cyclosporine 0.05%~1 drop b.i.d at 12hr interval for 12 weeks"
2416326|NCT03461575|Active Comparator|Moisview|"trehalose 3%~1 drop b.i.d at 12hr interval for 12 weeks"
2416327|NCT03461562|Experimental|Experimental|
2416328|NCT03461562|Active Comparator|Control|
2416329|NCT03461549||Healthy adults|Evaluate sensor performance on both lower limbs of healthy adult subjects for pressure sensing and skin temperature sensing.
2416330|NCT03461549||Venous Leg Ulcer Adults|Evaluate sensor performance on both lower limbs of adult subjects with an active venous leg ulcer or history of a venous leg ulcer for pressure sensing and skin temperature sensing.
2416331|NCT03461536|Active Comparator|Clinical Decision Support|Participants in this arm will receive the study intervention, the clinical decision support.
2416332|NCT03461536|No Intervention|Usual care|Participants in this arm will not receive the the clinical decision support tool.
2416333|NCT03461510|Experimental|Type 2 Diabetes|Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2416334|NCT03461510|No Intervention|Lean Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2416335|NCT03461510|No Intervention|Obese Control|Controls do not undergo Hyperglycemic clamp and Hyperinsulinemic Euglycemic clamp
2416336|NCT03461497||Patients Cohort|Patients undergoing abdominal surgery
2416337|NCT03461471|Experimental|Intervention Group|Exercise intervention
2416338|NCT03461458|Experimental|5×10^6 AD-MSCs|Subjects will receive one injection of 5 million Autologous Adipose-Derived Mesenchymal Stromal Cells
2416339|NCT03461458|Experimental|20×10^6 AD-MSCs|Subjects will receive one injection of 20 million Autologous Adipose-Derived Mesenchymal Stromal Cells
2416340|NCT03461445|Active Comparator|Immediate Release Tacrolimus|Patients will receive immediate release tacrolimus
2416341|NCT03461445|Experimental|Envarsus|Patients will be converted to Envarsus formulation of tacrolimus
2416342|NCT03461432|Experimental|Personalised Cognitive Remediation Therapy (pCRT)|A case-control study design with pre- and post-therapy assessment, comparing a group of participants with schizophrenia who received standard CRT, with a similar group of participants receiving pCRT.
2416343|NCT03461419|Experimental|Microcannula Harvest Adipose Stroma|Acquisition of AD-tSVF via closed syringe microcannula
2416344|NCT03461419|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration closed system to create cellular stromal vascular fraction (cSVF)
2416345|NCT03461419|Experimental|Sterile Normal Saline IV|Re-suspension of cSVF pellet in Sterile Normal Saline Intravenous Delivery
3186060|NCT00741507|Active Comparator|4|Severe over alcohol drinking
3186061|NCT00741507|Active Comparator|5|Alcohol-dependent
2416348|NCT03461393||Intervention Group|Repetitive Training with Medical-Eye-Trainer (MET)
2416349|NCT03461380|Experimental|Menopause Relief EP-40|Fixed combination of black cohosh EP-40 and Rhodiola rosea EPR-7 206.5 mg orally twice daily; daily dose 413 mg of active ingredients
2416350|NCT03461380|Active Comparator|High Dose Black Cohosh|Black cohosh 500 mg orally twice daily; daily dose 1000 mg of active ingredient
2416351|NCT03461380|Placebo Comparator|Placebo|Placebo capsule 600 mg excipients orally twice daily
2416352|NCT03461380|Active Comparator|Low Dose Black Cohosh|Black cohosh 6.5 mg orally twice daily; daily dose 13 mg of active ingredient
3186062|NCT00741520|Placebo Comparator|1|Control group
3186063|NCT00741520|Active Comparator|2|CPAP
2416356|NCT03461328|Experimental|Mg-group|10% MgSO4 solution will be used, a loading dose of 30mg/kg over 20 min (equivalent to infusion rate of 0.9 ml/kg/hr for 20 min) will be given followed by continuous infusion of 10mg/kg/hr (equivalent to infusion rate of 0.1ml/kg/hr).
2416357|NCT03461328|No Intervention|Control group|In control group, same rates of infusion for loading and maintenance will be applied using 0.9 normal saline.
2416358|NCT03461315|No Intervention|Traditional Mode|Traditional Model: Team That Cares for the Rest of the Community
2416359|NCT03461315|Experimental|Study Model|Study Model:Team Dedicated Exclusively to the Home Patient
2416360|NCT03461302|Experimental|Topical Coal Tar treatment|
2416361|NCT03461302|Active Comparator|Topical Corticosteroids treatment|
3186064|NCT00741546||A|Patients referred for cardiac surgery intervention
2416363|NCT03461276|Experimental|ABvac40|Six administrations of ABvac40; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of ABvac40.
2416364|NCT03461276|Placebo Comparator|Placebo|Six administrations of Placebo; the first five administered once every 4 weeks and the sixth at week 42. Each administration consists of 1mL subcutaneous injection of the vaccine's vehicle buffer without the active component.
2416365|NCT03461263|Active Comparator|Group A|phonophoresis treatment using pumpkin seeds oil
2416366|NCT03461263|No Intervention|Group B|Low intensity Ultrasound
2416367|NCT03461263|No Intervention|Group C|Placebo Low intensity Ultrasound
2416368|NCT03461250||HCV serology negative in HD|Risk factors
2416369|NCT03461250||HCV serology positive in HD|Risk factors HCV viral load HCV genotype Liver elastography by Fibroscan
2416370|NCT03461224||MARA-1: accelerated hypofractionated RT|A forward planned IMRT technique was used and the prescribed dose to the breast was 40 Gy in 16 fx with a concomitant boost of 4 Gy.
2416371|NCT03461224||CG: conventional fractionated RT|In the CG, the whole breast received 50.4 Gy in 28 fractions (fx) delivered with 3D-RT, followed by a sequential boost on the tumour bed of 10 Gy in 4 fx delivered with electrons
3186065|NCT00741559|Experimental|1|
2416373|NCT03461198|Experimental|Treatment|Restylane® Silk to a defined area of mid to low cheeks.
2416374|NCT03461185|Experimental|EGFR-TKI plus anti-angiogenesis|EGFR-TKI(erlotinib or gefitinib) plus anti-angiogenesis(endostatin or apatinib or anlotinib)
2416375|NCT03461185|Active Comparator|EGFR-TKI|EGFR-TKI(erlotinib or gefitinib)
2416376|NCT03461172||patients operated for breast cancer|patients operated for histologically proven breast cancer
2416377|NCT03461159|Experimental|H-reflex conditioning - Healthy|Operant conditioning of H-reflexes in healthy volunteers
2416378|NCT03461159|Experimental|H-reflex conditioning - Stroke|Operant conditioning of H-reflexes in people post-stroke
2416379|NCT03461159|Experimental|MEP conditioning - Healthy|Operant conditioning of motor evoked potentials in healthy volunteers
2416380|NCT03461159|Experimental|MEP conditioning - Stroke|Operant conditioning of motor evoked potentials in people post-stroke
3186066|NCT00741572||1|
2416382|NCT03461133||Reference|All patients admitted to the participating surgical wards from 2015-01-01 to 2015-12-31
2416383|NCT03461133||Intervention|All patients admitted to the participating surgical wards from 2016-07-01 to 2017-06-30
3186067|NCT00741572||2|
3186068|NCT00741585|Active Comparator|1|Treatment with all prescribed hypertension medications on awakening
2416386|NCT03461107||patients with heart failure|
2416387|NCT03461081|Experimental|Group I|Period I: administration of telmisartan/Amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days Period II: atorvastatin for 4 days
2416388|NCT03461081|Experimental|Group II|Period I: administration of atorvastatin for 4 days Period II: administration of telmisartan/amlodipine for 10 days then administration of telmisartan/amlodipine and atorvastatin for 4 days
2416389|NCT03461068|Experimental|Ketone monoester|Acute morning dose of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (0.45 ml/kg body weight)
2416390|NCT03461068|Placebo Comparator|Placebo|Acute morning dose of flavour-matched placebo.
2416391|NCT03461055|Experimental|Lavender|Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
2416392|NCT03461055|Placebo Comparator|Water|1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination.
2416393|NCT03461042|Experimental|Arm R|Co-administer following medication for 12 weeks since informed consent; R group: taking capsule of Ramelteon 8mg once daily before sleeping.
2416394|NCT03461042|Placebo Comparator|Arm PL|Co-administer following medication for 12 weeks since informed consent; Placebo group: taking capsule of Placebo once daily before bedtime.
2416395|NCT03461029||BIS|Group of 196 patients in whom sedation monitoring is performed using the Bispectral Index Monitoring (BIS) system.
2416396|NCT03461016|Experimental|Smartphone-Based Exposure Therapy|Participants assigned to the Smartphone-Based Exposure Therapy group will receive two weeks of exposure therapy via their smartphone. Participants will have the opportunity to receive up to 50 minutes of exposure video intervention daily for the two weeks.
2416397|NCT03461016|No Intervention|Waitlist Control|Participants who have been randomly assigned to participate in the Waitlist Control group will not receive treatment; however, after the two weeks of no intervention, participants in this condition will be offered the same treatment as the treatment condition.
2416398|NCT03461003|Experimental|NICHE method|In the NICHE method, antihypertensive therapy will be chosen using an n-of-trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.
3186069|NCT00741585|Active Comparator|2|Treatment with at least one prescribed hypertension medication at bedtime
3186070|NCT00741624|Experimental|1|bilateral post refractive surgery subject
3186071|NCT00741637|Experimental|Vaccine|Live attenuated oral CholeraGarde® (5x107 to 1x109 CFU) vaccine
3186072|NCT00741637|Placebo Comparator|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
3186073|NCT00741650|Experimental|1|Information and peer advisor
3186074|NCT00741650|Experimental|2|Information, peer advisor and referral to further treatment
3186075|NCT00741650|No Intervention|3|Treatment as usual
2416402|NCT03460977|Experimental|Dose Escalation (Part 1A)|Participants with SCLC, CRPC and FL will receive PF-06821497 at escalating dose levels
2416403|NCT03460977|Experimental|Dose Escalation (Part 1B)|Participants with FL will receive PF-06821497 at escalating dose levels
2416404|NCT03460977|Experimental|Dose Escalation (Part 1C)|Participants with CRPC will receive PF-06821497 at escalating dose levels.
2416405|NCT03460977|Experimental|Dose Escalation (Part 2A)|Participants with CRPC and SCLC will receive PF-06821497 at escalating dose levels in combination with SOC.
2416406|NCT03460977|Experimental|Dose Expansion (Part 2B)|Participants with CRPC will receive PF-06821497 in combination with SOC or SOC alone.
2416407|NCT03460964|Experimental|Patients with Diabetes|All participants will receive a minimum of 2 doses of pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat. Glucose will be measured with both an adhesive (needle-free) glucose sensor and a glucometer, at fasting, and time points ranging from 15 to 200 minutes after consuming a standardized meal. There are no other interventions.
2416408|NCT03460951||CIDP patients|15 patients with CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy ) who satisfy the definite CIDP criteria of the Joint Task Force of the EFNS and PNS 1 (situations A and B according to the French CIDP work group2), and who agree to undergo cervical MRI.
2416409|NCT03460951||Normal volunteers|15 healthy subjects matched for age and gender to CIDP patients
2416410|NCT03460951||Charcot-Marie-Tooth disease type 1A patients (CMT-1A)|15 CMT-1A patients (proven by genetic testing), will be included as Charcot-Marie-Tooth disease type 1A patients (CMT-1A) is one of the main differential diagnoses of CIDP characterized by the diffuse demyelination of peripheral nerves.
2416411|NCT03460938|Experimental|RIPC|
2416412|NCT03460938|No Intervention|Control|
2416413|NCT03460925|Experimental|SBRT plus chemotherapy|"Patients with unresectable or borderline resectable locally advanced pancreatic carcinoma at time of diagnosis"
2416414|NCT03460912||All participants|
3186076|NCT00741663|Active Comparator|A|
2416416|NCT03460886|Experimental|Bihemispheric stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2416417|NCT03460886|Experimental|Ipsilesional stimulation|"Anodal stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2416418|NCT03460886|Experimental|Contralesional stimulation|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Anodal stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2416419|NCT03460886|Active Comparator|Sham|"Sham stimulation on ipsilesional leg motor primary cortex and supplementary motor area~Sham stimulation on contralesional leg motor primary cortex and supplementary motor area Subject walks on treadmill for 10 minute during stimulation."
2416420|NCT03460860|Experimental|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|
2416421|NCT03460860|Placebo Comparator|Placebo|
2416422|NCT03460834||Obese asthmatic patients|Observational Cohort
2416423|NCT03460821||Employees|Male and female employees (≥ 18 years of age) of the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK), Charité Universitätsmedizin Berlin experienced in the field of neurocognitive testing: residents, specialist physician for anesthesiology, senior physicians, medical students engaged in research projects
2416424|NCT03460808|Experimental|atorvastatin, acetylcysteine & danazol|atorvastatin 20mg qd po plus acetylcysteine 400mg tid po plus danazol 200mg bid po for 12 weeks
2416425|NCT03460795|Experimental|Conventional plus MSC and Tregs treatment|
2416426|NCT03460769||Pancreatic Cancer|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2416427|NCT03460769||Chronic Pancreatitis|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2416428|NCT03460769||Type 3c Diabetes Mellitus|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer will be responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT).
2416429|NCT03460756|Experimental|Ganaxolone|Oral
2416430|NCT03460756|Placebo Comparator|Placebo|Oral
2416431|NCT03460743|Experimental|Study group|single or two doses of quadrivalent recombinant 180 ugm hemagglutinin influenza vaccine
2416432|NCT03460743|Active Comparator|Control group|single or two doses of quadrivalent inactivated influenza vaccine.
2416433|NCT03460730|Experimental|Immunised children|Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)
2416472|NCT03460470|Placebo Comparator|Placebo tablet x3 daily|Placebo for Sildenafil 40mgx3 daily for 6 months
2416473|NCT03460457|Experimental|TQB2450|
3186077|NCT00741663|Experimental|B|
3186078|NCT00741676|Active Comparator|2|
3186079|NCT00741676|Experimental|1|
3186080|NCT00741689|Experimental|1|AZD1656 in 6 increasing oral single doses given to 6 groups (5 on active and 1 on placebo in each group)
3186081|NCT00741702|Experimental|Intervention group|A home care nurse followed a predefined treatment algorithm of pharmacologic antihypertensive therapy.
3186082|NCT00741702|No Intervention|Control group|Treatment decisions were made by each subject's primary care physician. Participants in this group received usual care.
3186083|NCT00741715|Placebo Comparator|1|
3186084|NCT00741715|Experimental|2|AVE5530 25mg
3186085|NCT00741715|Experimental|3|AVE5530 50mg
3186086|NCT00741715|Active Comparator|4|atorvastatin 10mg
2416434|NCT03460717|Experimental|Intervention group: PNFS-TMC|Procedure- The patients in the intervention group were examined and the most painful points over the knee with the avoidance of the proposed site for skin incision for a future knee replacement operation were marked. The marked points received an intervention in the form of application of Peripheral Nerve Field Stimulation by Thermal Micro-Cautery (PNFS-TMC), an intense heat by metal rod was applied to the painful points for 0.3 to 0.5 seconds. The patients to receive 4 sessions over a period of 8 weeks with 2 weeks rest after every session.
2416435|NCT03460717|No Intervention|Control group: Stepladder analgesics|Patients with painful knee osteoarthritis and on the waiting list for a total knee replacement surgery and declined to have PNFS-TMC were included in the control group. The control group received the stepladder analgesic protocol for pain management. The analgesic protocol was managed by the orthopaedic team without any interference by the investigators.
2416436|NCT03460704|Experimental|Drug: Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45% Other Name: Promixin
2416437|NCT03460704|Placebo Comparator|Drug: Saline Solution|1 ml saline solution 0.45%
2416438|NCT03460691||Group 1|Group 1:patients who will undergo the bariatric surgery
2416439|NCT03460678|Other|Pemetrexed Arm|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
2416440|NCT03460678|Other|Erlotinib Arm|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)
2416441|NCT03460665|Experimental|Microparticles|arteriography and an injection of inert microparticles of 75 µm in neovessels
2416442|NCT03460665|Placebo Comparator|Placebo|knee arteriography and injection of saline solution in neovessels
3186087|NCT00741715|Experimental|5|atorvastatin 10mg + AVE5530 25mg
2416444|NCT03460639|Active Comparator|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
2416445|NCT03460639|Sham Comparator|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
2416446|NCT03460639|Other|Control group|In this group, no treatment will be done, we will only induce fatigue, for evaluation.
2416447|NCT03460626|Placebo Comparator|Group-I (Control group)|This group will be administered a placebo that is an odorless oil without any therapeutic effect)
2416448|NCT03460626|Experimental|Group-II (Treated group)|This group will be administered lavender oil.
2416449|NCT03460626|No Intervention|Group-III (Untreated group)|No intervention will be provided in this group.
2416450|NCT03460613|Other|FGID Patients|
2416451|NCT03460613|No Intervention|Hepatology Control Group|
2416452|NCT03460613|No Intervention|Healthy Volunteers|
3186088|NCT00741715|Experimental|6|atorvastatin 10mg + AVE5530 50mg
2416454|NCT03460574|Experimental|INFORMATION|"Participants in this condition receive a manipulation suggesting that the performance test TEMINT, they previously worked on, has been shown to be highly relevant for daily life and professional success. We anticipated that after receiving this fake information about the TEMINT, it would be difficult for participants to engage in cognitive immunization processes because the validity and utility of the expectation-disconfirming experience is explicitly highlighted."
2416455|NCT03460574|Experimental|SALIENCE|Participants in this condition are asked to think about how well they performed on this really difficult performance test. We anticipated that this manipulation would enhance expectation change, as the salience of the expectation-disconfirming experience was explicitly increased.
2416456|NCT03460574|Experimental|ATTENTION|Before working on the performance test, participants in this conditions receive the instruction to attentionally focus on their personal result in the performance test. Further, they are asked to specify what would be personally good result for them. We anticipated that after receiving this instruction, the expectation-disconfirming performance feedback should be salient for the participants, hence making it difficult for them to engage in cognitive immunization strategies.
2416457|NCT03460574|Experimental|CONTROL|Participants in this condition receive no further information. Therefore, they are passing through the standard procedure of the previously developed experimental paradigm.
2416458|NCT03460561|Active Comparator|TEA group|peri operative thoracic epidural block (TEA) via fentanyl-levo bupivacaine infusion.
2416459|NCT03460561|Active Comparator|RSB group|peri operative rectus sheath block (RSB) via fentanyl-levo bupivacaine infusion.
2416460|NCT03460548|Experimental|Remogen|
2416461|NCT03460548|Active Comparator|Cationorm|
2416462|NCT03460522|Experimental|Induction Therapy with Inotuzumab Ozogamicin|Patients will receive up to 3 cycles Inotuzumab with applications on day 1, 8 and 15 in each cycle. First dose will be 0.8 mg/m² on Day 1. All subsequent doses will be 0,5 mg/m².
2416463|NCT03460509|Placebo Comparator|Sugammadex 0 mg/kg|Placebo NaCl 0,9%
2416464|NCT03460509|Active Comparator|Sugammadex 0,25 mg/kg|Sugammadex 0.25 mg/kg IBW
2416465|NCT03460509|Active Comparator|Sugammadex 0,5 mg/kg|Sugammadex 0.50 mg/kg IBW
2416466|NCT03460509|Active Comparator|Sugammadex 1mg/kg|Sugammadex 1.0 mg/kg IBW
2416467|NCT03460509|Active Comparator|Sugammadex 2mg/kg|Sugammadex 2 mg/kg IBW
2416468|NCT03460496|Experimental|APN-led Intervention|"Intervention group being provided with the interventions described below.~Advanced practice nurses' interventions~Neonatologists: neonatal outpatient consultation~psychological support~lactation consultant~physiotherapeutic interventions~collaboration with social workers~music therapy~close collaboration with other health care professionals~interprofessional roundtable meetings"
2416469|NCT03460496|No Intervention|Control, Standard Care|Control group receiving standard care
2416470|NCT03460483|Experimental|Comprehensive LS genetic testing|Testing for inherited forms of cancer and tumor sequencing
3186089|NCT00741715|Active Comparator|7|atorvastatin 20mg
3186090|NCT00741715|Experimental|8|atorvastatin 20mg + AVE5530 25mg
3186091|NCT00741715|Experimental|9|atorvastatin 20mg + AVE5530 50mg
3186092|NCT00741715|Active Comparator|10|atorvastatin 40mg
2416474|NCT03460444|Experimental|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days while consuming a diet similar to the recommended health guidelines (40-50% carbohydrate; 30-40% fat; 20-25% protein).
2416475|NCT03460431|Experimental|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm one session every month for 4 months
2416476|NCT03460431|Experimental|Nd YAG laser 1064nm|Nd YAG laser 1064nm
2416477|NCT03460431|Experimental|combined two laser types|combined fractional CO2 laser 10,600nm and Nd YAG laser 1064nm lasers treatment to keloid
2416478|NCT03460418||Multiloc nail|Fracture treated with a Multiloc nail (patients treated between 2012 and 2017)
2416479|NCT03460418||Philos plate|Fracture treated with a Philos plate (patients treated between 2012 and 2017)
2416480|NCT03460418||arthroplasty|Fracture treated by arthroplasty (patients treated between 2012 and 2017)
2416481|NCT03460405|Experimental|VI-DT vaccine (adults,adolescent)|1 dose of 0.5 ml Vi-DT vaccine
2416482|NCT03460405|Active Comparator|Vi polysaccharide (adults,adolescent)|1 dose of 0.5 ml Vi polysaccharide vaccine
2416483|NCT03460405|Experimental|VI-DT vaccine (children)|1 dose of 0.5 ml Vi-DT vaccine
2416484|NCT03460405|Active Comparator|Vi polysaccharide vaccine (children)|1 dose of 0.5 ml Vi polysaccharide vaccine
2416485|NCT03460405|Experimental|VI-DT vaccine (infants)|1 dose of 0.5 ml Vi-DT vaccine
2416486|NCT03460405|Active Comparator|IPV Vaccine (infants)|1 dose of 0.5 ml IPV vaccine
2416487|NCT03460392||Neurological and behavioral disorders|Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
2416488|NCT03460392||Subjects affected by bone diseases|Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
2416489|NCT03460392||Dysmetabolic and/or endocrine disorders|Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
2416490|NCT03460392||Subjects performing agonistic activity|Subjects performing physical activity at agonistic level are enrolled.
2416491|NCT03460392||Gastroenteric disorders|Subjects affected by gastric and/or enteric disorders are enrolled.
2416492|NCT03460392||Prolonged antibiotic therapy|Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
2416493|NCT03460392||Healthy subjects|Subjects without any known ongoing disease are enrolled.
2416494|NCT03460340|Experimental|FM group|patients diagnosed with Fibromyalgia receiving dTMS treatment.
2416495|NCT03460340|Sham Comparator|placebo group|patients diagnosed with Fibromyalgia receiving sham- treatment.
2416496|NCT03460288|Experimental|Intervention Group|The training-program includes ten pictures related to slot-machine gambling and 10 neutral pictures that need to be either pushed (i.e., avoidance) or pulled (i.e., approach) with the computer mouse or finger (when a tablet is used) according to a non-affective dimension (color of the frame). Pictures are presented in random order.
2416497|NCT03460288|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive the retraining intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including pharmacological treatment. Participants in the wait-list control condition receive full access to the training program after completion of the post-assessment.
2416498|NCT03460275|Other|single group|Osimertinib Mesylate Tablets 80 mg, one time a day until disease progression
2416499|NCT03460262|Active Comparator|Standard dressing-Cutiplast®|
2416500|NCT03460262|Experimental|Negative pressure wound therapy-PICO®|
2416501|NCT03460249|Active Comparator|BP table or chair, systolic or diastolic|record the BP obtained in each patient position
2416502|NCT03460249|Active Comparator|as above|as above
3186093|NCT00741715|Experimental|11|atorvastatin 40mg + AVE5530 25mg
2416504|NCT03460223|Experimental|Conventional plus MSC treatment|
2416505|NCT03460184||G.A Group A|Group A: n= 30 Parturiant patients will receive general anesthesia. General anesthesia will be conducted After pre-oxygenation for 3-5 minutes. 5% thiopental (5 mg/kg) will be administered intravenously over 30s, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium as needed. After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by intravenous infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake, the anesthesia is adequately reversed, and the patient is following commands
2416506|NCT03460184||Spinal A Group B|"Group B: n= 30 Parturiant patients will receive spinal anesthesia. In the sitting position and after complete aseptic precaution are taken, 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, either via midline or paramedian approaches using 22 guage Quinke needle with the bevel directed laterally. 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl (0.5 ml) will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage.~The patient will be put flat in the supine position with left uterine displacement using wedge under the right loin and the surgeon will be allowed to sterilize and wrap the field after confirmation of the solidity of the block its level.~All patiens will be observed for cardiac complications in the form of non-fatal MI, arrhythmias and sudden cardiac death until discharged after at least 72h."
3186094|NCT00741715|Experimental|12|atorvastatin 40mg + AVE5530 50mg
2416508|NCT03460145|Experimental|Strip with Lavender Oil (Lx)|"Application of Nasal Strip with essential oil (Lavender), 20minutes before induction.~VAS- Anxiety scores pre and post inhalation."
2416509|NCT03460145|Placebo Comparator|Strip without Lavender Oil (Px)|Application of Nasal strip without essential oil, acting as placebo. VAS- Anxiety scores pre and post placebo.
2416510|NCT03460132|Experimental|Extraction cases|patients receive Tomas orthodontic miniscrew implant as a mean of anchorage augmentation
2416511|NCT03460093||case (SHPB+)|Superior hypogastric plexus block present
2416512|NCT03460093||control (SHPB-)|Superior hypogastric plexus block not present
2416513|NCT03460080||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
2416514|NCT03460080||Hepatic hemangioma patients|
3186095|NCT00741715|Active Comparator|13|atorvastatin 80mg
2416515|NCT03460067|Experimental|Arm A|Patient is required to have lumpectomy with sentinel lymph node biopsy shows pCR and will complete 1 year of trastuzumab +/- pertuzumab treatment. No radiation, or an omission of radiation, will be given on this arm, including external beam, brachytherapy or intraoperative radiation. Patients will be required to follow up with a medical, surgical, or radiation oncologist every 3 months for 5 years. At these follow up visits, a physical exam will be performed to assess for any disease recurrence. Screening mammogram or MRI is recommended every 6 months for patients on this arm.
2416516|NCT03460067|No Intervention|Arm B|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. Patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens such as blood and urine, for correlative studies.
2416517|NCT03460067|No Intervention|Arm C|Patient is required to have her-2 positive breast cancer, clinically node negative from exam. patient will complete neoadjuvant chemotherapy per Medical Oncologist. This arm will not undergo lumpectomy with sentinel lymph node biopsy shows pCR. The patient will proceed with radiation as standard of care. This arm includes a review of outcomes in the patient's medical chart as well as a collection of biospecimens, such as blood and urine, for correlative studies.
2416518|NCT03460054||IgA Nephropathy (IgAN)|Biopsy-Proven IgAN
2416519|NCT03460054||Focal Segmental Glomerulosclerosis (FSGS)|Biopsy-Proven FSGS
2416520|NCT03460054||Membranous Nephropathy (MGN)|Biopsy-Proven MGN
2416521|NCT03460054||Mesangioproliferative Glomerulonephritis (MPGN)|Biopsy-Proven MPGN
2416522|NCT03460054||Minimal Change Disease (MCD)|Biopsy-Proven MCD
2416523|NCT03460041|Placebo Comparator|Control|
2416524|NCT03460041|Active Comparator|Magnesium|
2416525|NCT03460041|Active Comparator|Dexmetedomedine|
2416526|NCT03460028|Experimental|Yoga Condition|Participants randomized to the Yoga Condition will participate in a specialized yoga intervention.
2416527|NCT03460028|No Intervention|Wait-List Control Condition|Participants randomized to the Wait-List Control Condition will participate in a specialized yoga intervention once the Yoga Condition has completed their assigned intervention.
2416530|NCT03460002|Experimental|Measles vaccine|In intervention villages children will be weighed and receive standard measles vaccine in one dose if they are between 9-59 months old.
2416531|NCT03460002|Experimental|Oral polio vaccine|In intervention villages children will be weighed and receive standard oral polio vaccine in one or two doses if they are between 0-8 months old.
2416532|NCT03460002|No Intervention|Weighing-MV|In control villages children aged 9-59 months acting as controls to the MV-intervention arm will be weighed only.
2416533|NCT03460002|No Intervention|Weighing-OPV|In control villages children aged 0-8 months acting as controls to the OPV-intervention arm will be weighed only.
2416534|NCT03459989||pregnant women|we will measure expected fetal weight by ultrasound by hadlock's formula and thigh soft tissue for each pregnant woman
2416535|NCT03459976||2 groups|control group case group
2416536|NCT03459963|Experimental|group C|indwelling urinary catheter
2416537|NCT03459963|No Intervention|group N|Non cathetrized patients
2416538|NCT03459950||Chronic Insomnia group|60 patients with chronic insomnia are included in the Chronic Insomnia group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
2416539|NCT03459950||Normal control group|60 normal people are included in the normal control group. Men and women half, the age of 18-60 years old, signature to the Information for Patient.
2416540|NCT03459937|Experimental|Hatha Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Hatha Yoga.
2416541|NCT03459937|Experimental|Vinyasa Yoga Intervention|This intervention will be a behavioral weight loss intervention that includes group intervention session, prescribed dietary recommendations, and inclusion of Vinyasa Yoga.
2416542|NCT03459911|Experimental|Losartan potassium 100 mg Tablets|Losartan potassium is the test product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Losartan potassium.
2416543|NCT03459911|Active Comparator|Cozaar® (Losartan potassium)100 mg Tablets|Cozaar® (Losartan potassium) is the reference product. In period 1 and period 2, 33 of 66 subjects will be given single oral dose (1 x 100 mg) of Cozaar®.
2416544|NCT03459898|Other|Active Breathing Control|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
2416545|NCT03459898|Other|Deep Inspiration Breath Hold|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
2416546|NCT03459885|Experimental|PAS|The intervention is given to peripheral nerve - motor cortex pairs selected by the investigator.
2416547|NCT03459872||Acupuncture Intervention group|RU-Fit gathers measurements of fine motor control were gathered from this group before and after acupuncture treatments.
2416548|NCT03459872||Control/ Non-Intervention|This group received no intervention but still had measurements of fine motor control gathered from RU-Fit medical device.
3186096|NCT00741715|Experimental|14|atorvastatin 80mg + AVE5530 25mg
3186097|NCT00741715|Experimental|15|atorvastatin 80mg + AVE5530 50mg
2416555|NCT03459833|Experimental|group 1|15 patients They will receive a topical anesthetic agent for 30 minutes (Emla cream; lidocaine 25 mg, prilocaine 25 mg, Astra Xeneca, Mississauga, Canada) followed by injection of two prefilled 1 ml syringes with 30 G needle of hyaluronic acid (HA; Teosyal® PureSense Global Action, Teoxane Laboratories, Geneva, Switzerland). After 18 months from the HA injection, cross-over to placebo arm will be done.
2416556|NCT03459833|Placebo Comparator|group 2|They receive by the same method 2 ml saline as a placebo. After one month of the injection, cross-over to HA arm will be done.
2416557|NCT03459820|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
2416558|NCT03459807|Experimental|Home systolic blood pressure (SBP) <140 mmHg|"Participants will be asked to take morning and evening blood pressures every two weeks on a non-dialysis day.~Participants will be asked to transmit these measures to the study team at minimum every 2 weeks either via Bluetooth technology, a manual log, telephone call, text message, e-mail, or verbal communication.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
2416559|NCT03459807|Active Comparator|Pre-dialysis SBP <140 mmHg|"Blood pressures taken in the clinical setting at prior to start of dialysis treatment will be recorded.~Assigned intervention will be dry weight adjustment and/or adjustment of standard anti-hypertensive medications."
3186098|NCT00741728||general population|Observational study of 10000 adult men and women from the general population who benefited from a free extensive health check up in Paris, France
3186099|NCT00741754|Experimental|I, II|compare the amount of salivary flow of the same patient at different times.
2416562|NCT03459781|Experimental|Cognitively-Based Compassion Training|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CBCT®.
2416563|NCT03459781|Active Comparator|CHE (Cancer Health Education)|Cancer survivors and their informal caregivers (family and close friends), one of whom has at least mild depression and/or anxiety features (determined by PROMIS Depression 4a and PROMIS Anxiety 4a, respectively) who are randomized to CHE.
2416564|NCT03459755|Experimental|Lifestyle Intervention|Patients assigned to the Physical Activity arm will undergo exercise testing protocol and have supervised physical activity interventions while on study. Patients will also complete questionnaires and have research blood drawn.
2416565|NCT03459755|No Intervention|Usual care|Patients will complete questionnaires and have research blood drawn.
2416566|NCT03459742|Experimental|Intervention|Gamification strategy. In 2018, the intervention group are 15 schools from Municipality of Santiago. In 2019, the intervention will cover all eligible schools in the Municipality of Santiago.
2416567|NCT03459742|No Intervention|Control|In 2018, the control group will be 5 randomly selected schools from Municipality of Santiago and 4 schools from Municipality of Estación Central. In 2019, the control group will be 4000 participants chosen from neighboring municipalities
2416568|NCT03459729|Experimental|Antitumor B|ATB will be administered on an outpatient basis.
2416569|NCT03459716||Systemic sclerosis patients w/ PH|Pulmonary hypertension will be defined as a mean pulmonary artery pressure≥25mmHg on right heart catheterization
2416570|NCT03459716||Systemic sclerosis patients w/o PH|Pulmonary hypertension will be excluded based on all of the following echocardiogram features: estimated systolic pulmonary artery pressure<35mmHg and absence of right atrial or right ventricular (RV) enlargement and lack of qualitative RV dysfunction. If a subject has any of these echo features, they will be referred for right heart catheterization (RHC) and included in the appropriate group based on their RHC results.
2416571|NCT03459703|Experimental|Early Time-Restricted Feeding|
2416572|NCT03459703|Active Comparator|Control Schedule|
2416573|NCT03459690|Experimental|Experienced meditators|Meditation ≥ 30 min per day for at least 5 days per week over the past 1 year
2416574|NCT03459690|Experimental|Novice meditators|No meditation practice in the previous year and < 20 entire lifetime hours
2416575|NCT03459677|Experimental|Back2School Condition|"The Back2School condition is a Modular Trans-Diagnostic Cognitive Behavioral Therapy (MTCBT) treating school absenteeism in youths.~The MTCBT intervention consist of 10 sessions and 4 school meetings, conducted over a period of 4 months."
2416576|NCT03459677|Active Comparator|Treatment As Usual Condition|"The Treatment As Usual condition (TAU) consist of an array of interventions that the municipality is required to give youths presenting school absenteeism.~The TAU condition will last for 4 months."
2416577|NCT03459664|Experimental|RECOVER|The intervention in the RECOVER stepped-care model includes specific evidence-based treatment options for severity grade 1 to 4.
2416578|NCT03459664|Active Comparator|Treatment As Usual|The active comparator is treatment as usual (TAU) and provides all common care options within the German health care system, depending on the severity grade 1 to 4.
2416579|NCT03459651|Experimental|ANS training|
2416580|NCT03459638||Periodontitis|Screening for DM, ASCVD, MetS and OSAS in patients with periodontitis
2416581|NCT03459638||No periodontitis|'Screening for DM, ASCVD, MetS and OSAS in patients without periodontitis
2416582|NCT03459625|Experimental|Mindfulness-Based Stress Reduction (MSBR)|MSBR (Kabat-Zinn, 1990), 8-week group-based intervention where participants learn mindfulness skills to help alleviate parenting stress among parents of young children with Autism Spectrum Disorder.
2416583|NCT03459625|Active Comparator|Psychoeducational Support Group (PE)|PE is a 8-week group-based intervention to provide psychosocial support and resources for parents of young children with Autism Spectrum Disorder.
3186100|NCT00741767|Other|Salmeterol-fluticasone|Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks. Patients will cross-over and receive placebo medication for 4 weeks later in the study.
3186101|NCT00741767|Other|Placebo|Patients randomized to receive placebo medication twice daily for 4 weeks. Patients will cross-over and receive study medication later in the study.
2416588|NCT03459599|Active Comparator|Prophylaxis|Current protocol of administering antibiotics maintained
2416589|NCT03459599|Active Comparator|No prophylaxis|Antibiotics withheld, with appropriate observation and follow up
2416626|NCT03459339|Experimental|Experimental OFDI capsule imaging|"Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.~Intervention: 'Tethered Capsule Endomicroscopy (TCE) Imaging of Barrett's esophagus using OFDI capsule"
2416590|NCT03459586|Experimental|9zest app facilitated exercise|App to facilitate exercises for 3 times a week for 12 weeks. The app includes physical therapist-designed exercises that are modified using an algorithm to the participants physical capabilities and PD status. Exercises include strengthening, balance, range of motion, and endurance type exercise.
2416591|NCT03459573|Active Comparator|T2D: One Drop with Fitbit Ionic|
2416592|NCT03459573|Active Comparator|T2D: One Drop without Fitbit Ionic|
2416593|NCT03459573|No Intervention|T2D: Waitlist Control|
2416594|NCT03459573|Active Comparator|T1D: One Drop with Fitbit Ionic|
2416595|NCT03459573|Active Comparator|T1D: One Drop without Fitbit Ionic|
2416596|NCT03459573|Active Comparator|PD: One Drop with Fitbit Charge 2|
2416597|NCT03459573|Active Comparator|PD: One Drop without Fitbit Charge 2|
2416598|NCT03459560|Experimental|PolyPill|Single daily dose of PolyPill and minimal care.
2416599|NCT03459560|No Intervention|Control|Only minimal care
2416600|NCT03459547|Experimental|dental implant + PEEK (test)|Dental implant insertion, material polyetheretherketone
2416601|NCT03459547|Active Comparator|dental implant + Ti-5 (control)|Dental implant insertion, material titanium group 5
2416602|NCT03459547|Active Comparator|dental implant + zirconia (control)|dental implant insertion, material zirconia
2416603|NCT03459547|Active Comparator|dental implant + Ti-4 (control)|dental implant insertion, material titanium group 4
2416605|NCT03459521|Experimental|Fendrix HBV vaccine|Drug: Fendrix Fendrix suspension for injection GlaxoSmithKline Route of administration, dose regimen: Intra-muscular Dose: 0.5 ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline, 1, 2 and 6 months.
2416606|NCT03459508||Primary antiphospholipid syndrome women|"Informed consent~Detailed history emphasizing on~a. obstetric complications related to antiphospholipid syndrome: i. Recurrent miscarriage ii. Fetal demise iii. Fetal growth restriction iv. Severe pre-eclampsia or eclampsia v. Placental insufficiency vi. Placental abruption b. Systemic vascular complications related to antiphospholipid syndrome: i. Arterial thrombosis ii. Venous thrombosis iii. Small-vessel thrombosis~Revision of diagnosis of primary antiphospholipid syndrome:~Exclusion of antiphospholipid syndrome secondary to SLE and other autoimmune diseases by: antinuclear (ANA), anti-Smith (Sm) and anti-double stranded DNA (dsDNA) antibodies.~Ophthalmological examination:"
2416607|NCT03459495|Active Comparator|Group A|Group A: ultrasound group
2416608|NCT03459495|Placebo Comparator|Group P|Group P: placebo ultrasound group
3145610|NCT00076063|Experimental|D|Participants in Group D will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
3145611|NCT00076063|Experimental|E|Participants in Group E will receive six injections over 6 months. Participants in this group will receive either ALVAC-HIV (vCP1452) and LIPO-5 or a placebo. Participants who receive the vaccine combination will receive four injections of the same dose of ALVAC-HIV (vCP1452) and two injections of LIPO-5. The dose of LIPO-5 will be different for participants in Groups C, D, and E.
2416611|NCT03459469|Experimental|Investigational drug|An open-label, non-randomized study to evaluate safety of Tegavivint administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
2416612|NCT03459456||OCD subjects|"Subjects meeting inclusion/exclusion criteria with OCD will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
2416613|NCT03459456||Control subjects|"Subjects meeting inclusion/exclusion criteria without OCD (age and gender matched with OCD subjects) will be exposed to the following:~Provocation OC task (Provoc)~Trier Social Stress Test (TSST)~Exposure provocation task"
2416614|NCT03459430|Experimental|Low Intensity training group|Low Intensity training group will complete a 6 week core stability training program with low intensity/oscillation exercises
2416615|NCT03459430|Experimental|High Intensity training group|High Intensity training group will complete a 6 week core stability training program with high intensity/oscillation exercises
2416616|NCT03459430|No Intervention|Control group|Control group will have 6 weeks with no intervention before post-test
2416617|NCT03459417|Active Comparator|intrathecal morphine+LA|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
2416618|NCT03459417|Active Comparator|intrathecal morphine+LA+Mg sulp. 50|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
2416619|NCT03459417|Active Comparator|intrathecal morphine+LA+ Mg sulp.100|patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
2416620|NCT03459404||Sufentanil NanoTab PCA System/15 mcg|"Drug: Sufentanil 15 mcg~Unless contraindicated patients also received around the clock regimen of NSAIDS (ketoprofen 200 mg/day) and acetaminophen (1000 mg every 8 hours)."
2416621|NCT03459391|Experimental|XC221 60 mg|Cohort 1:16 subjects were randomized in a 3:1 ratio to be treated either with 60 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
2416622|NCT03459391|Experimental|XC221 200 mg|Cohort 2: 16 subjects were randomized in a 3:1 ratio to be treated either with 200 mg XC221 (12 subjects) or placebo (4 subjects, see placebo arm).
2416623|NCT03459391|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (4 subjects from each cohort).
3145612|NCT00076141||Older, Racially Diverse Males|Racially Divers Males over 50, expected to live more than 5 years
2416625|NCT03459352|Experimental|ePRO|There is no therapeutic intervention. Patients will use ePRO system to report systems. We will describe use in patients to determine compliance in reporting symptoms.
3145613|NCT00076154||Group 1|
2416628|NCT03459326||FIV group|men whose couple taken care of fecundation in vitro
2416629|NCT03459326||ICSI group|men whose couple taken care of intracytoplasmic injection
2416630|NCT03459326||IUI group|men whose couple taken care of intrauterine insemination
2416631|NCT03459313|Experimental|Active group|The active group will be provided the intervention program, i.e. access to a website.
2416632|NCT03459313|No Intervention|Control group|The control group will continue to train according to their routines and will get access to the website after 4 months.
2416633|NCT03459287|Experimental|INTERCEPT (test)|The INTERCEPT treatment process uses amustaline and glutathione together with a processing solution in a single-use disposable set and results in pathogen and leukocyte inactivated RBCs suspended in SAG-M additive solution (INTERCEPT RBCs). The INTERCEPT treatment will be performed on leukocyte reduced RBC components prepared from whole blood collections and suspended in AS-5 additive solution within 24 hours of collection. The test component is allogeneic INTERCEPT RBCs suspended in SAG-M and stored at 1°C to 6 for up to 35 days post-donation and administered intravenously. Dose and schedule of RBC transfusions will be determined by the treating physician.
2416634|NCT03459287|Active Comparator|Conventional (Control)|The control transfusion component is a conventional leukocyte-reduced RBC component in an FDA approved additive solution (AS-1, AS-3 or AS-5) stored at 1°C to 6°C for up to 35 days post-donation and administered intravenously. The Control RBC components will be handled and labeled in a manner so as to maintain blinding. Dose and schedule of RBC transfusions will be determined by the treating physician.
2416635|NCT03459274||VR-Biofeedback Feedback Sharers|These participants would express either interest or a lack of interest in trying biofeedback/virtual reality therapy. They will be instructed on how to use the virtual reality equipment and program. Then, they will have the option to participate in the biofeedback/virtual reality experience, if they choose to do so, before sharing their feedback.
2416636|NCT03459261||POM|post-traumatic osteomyelitis group (POM), the participants who developed post-traumatic osteomyelitis after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4). Patients were included in POM group after additional assessment of meeting the CDC/NHSN surveillance definition criteria for osteomyelitis: positive intraoperative withdrawal bone and soft tissue sample, types of cultured bacteria, histopathologic proof of osteomyelitis and clinical signs of surgical site infection.
2416637|NCT03459261||NO POM|No POM group, the participants who did not develop postraumatic osteomyelitis to tibia after primary surgical treatment and were taken blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4) in follow up interval of 6 months /control group/. Patients were included in No POM group after assessment of not meeting the CDC/NHSN surveillance definition criteria for osteomyelitis.
2416638|NCT03459248|Experimental|Dual therapy|Patients will receive 10 mg metoclopramide with 4mg ondansetron before induction of general anesthesia
2416639|NCT03459248|Active Comparator|Monotherapy|Patients will receive 10 mg metoclopramide before induction of general anesthesia.
2416640|NCT03459235|Experimental|population from registry data|the intervention involves completing several quality of life questionnaires validated in the medical literature (LARS score, FSFI, USP, IIEF, IPPS, QLQ C-30, QLQ-CR29)
3145614|NCT00076180|Experimental|1|One dose of Hu-MiK Beta-1
3145615|NCT00076206|Experimental|A|CCI-779 1 mg dose to be taken orally daily up to 12 weeks.
2416644|NCT03459183|Experimental|Infrasound - verum|In this condition, participants are exposed with non-audible infrasound from the Infrasound (85dB; 6Hz) source, for 8 constant hours during their night sleep. The source is placed close to the participant's bed (approximately 1-2 meters).
2416645|NCT03459183|Placebo Comparator|Infrasound - placebo|In this condition, participants are not exposed to any sound. The infrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Infrasound dummy source looks exactly like the active infrasound source but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
2416646|NCT03459183|Experimental|Ultrasound - verum|In this condition, participants are exposed to non-audible ultrasound, emitted by the Ultrasound (10dB below hearing threshold; 22.4 kHz) source for 8 constant hours during their night sleep. The source is placed close to the participant's bed (1-2 meters), at the level of the participant's head (for instance on a nightstand).
2416647|NCT03459183|Placebo Comparator|Ultrasound - placebo|In this condition, participants are not exposed to any sound. The Ultrasound dummy source is placed close to the participant's bed, exactly like in the Infrasound - verum condition (1-2 meters). The Ultrasound dummy source looks exactly like the active ultrasound source, but produces no sound at all. Participants are told that this source emits sound for 8 constant hours during their night sleep.
2416648|NCT03459170|Experimental|BPX-501 T cells and rimiducid|"All subjects will receive 3 courses of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of AP1903 ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
2416649|NCT03459157|Other|HIV prevention package including PrEP|
2416650|NCT03459144|Experimental|photodynamic therapy|Participants will be given the standard verteporfin photodynamic therapy at baseline followed by additional standard verteporfin PDT as needed (every three months)(namely 1+PRN regimen).
2416651|NCT03459144|Experimental|intravitreal ranibizumab|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab will be given to the participants when necessary (every month) (namely 1+PRN regimen).
2416652|NCT03459144|Experimental|combination therapy of PDT and IVR|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the standard verteporfin PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary (every month)(namely 1+PRN regimen).
3145616|NCT00076206|Experimental|B|CCI-779 2 mg dose to be taken orally daily up to 12 weeks.
3145617|NCT00076206|Experimental|C|CCI-779 4 mg dose to be taken orally daily up to 12 weeks.
3145618|NCT00076206|Placebo Comparator|D|Placebo dose to be taken orally daily up to 12 weeks.
3145619|NCT00076232|Experimental|1|Participants will receive acyclovir for the duration of the study
2416655|NCT03459118|Experimental|Function Focused Care|FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the champion and stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
2416656|NCT03459118|Placebo Comparator|Education Only|Education only sites are exposed to Step II of the Four step approach described under the treatment arm. They receive baseline education of staff.
2416657|NCT03459105|Experimental|Ultrasound-assisted|Preprocedural ultrasound-assisted paramedian spinal anesthesia will be performed. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2416658|NCT03459105|Active Comparator|Landmark-guided|Landmark-guided spinal anesthesia will be performed, via either midline or paramedian approach. 0.5% heavy bupivacaine will be injected to intrathecal space for spinal anesthesia.
2416659|NCT03459092|Experimental|Botox-based treatment regimen|First intervention is a Botulinum toxin type A injection. If further treatment is necessary, strabismus surgery can be performed.
2416660|NCT03459092|Active Comparator|Surgery-based treatment regimen|First intervention is strabismus surgery. If further treatment is necessary, strabismus surgery can be repeated.
2416661|NCT03459079|Active Comparator|lanifibranor arm|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving lanifibranor 800 mg/day.
2416662|NCT03459079|Placebo Comparator|Placebo|Two arm, randomized (1:1), double-blind, placebo-controlled, 24-week treatment study receiving placebo.
2416663|NCT03459066||Institution-Group 8 district|Group of patients belonging to institutions of district 8. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2416664|NCT03459066||Institution-Group 9 district|Group of patients belonging to institutions of district 9. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2416665|NCT03459066||Institution-Group 10 district|Group of patients belonging to institutions of district 10. Patients will be evaluated in 3 different times with different assessment instruments for tone, functionality and quality of life.
2416666|NCT03459053|Experimental|CBART|6 weeks participation in CBART protocol before beginning IVF treatment
2416667|NCT03459053|No Intervention|Wait control|Participants will receive treatment as usual and will be able to receive the intervention after the study is complete.
2416669|NCT03459027|Active Comparator|Nitrate Rich Beetroot Powder (nitrate)|Dietary nitrate in the form of beetroot powder (10g) mixed in water will be administered acutely
2416670|NCT03459027|Placebo Comparator|Placebo Beetroot Powder|Beetroot powder devoid of nitrate (10g) will be mixed in water and administered acutely
2416671|NCT03459014|Experimental|Stimulus rich VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the experimental group will walk in a stimulus rich VE such as walking in a park.
2416672|NCT03459014|Active Comparator|Stimulus poor VE|Participants will be tested during 1 RAG session in the Lokomat. Participants in the control group will walk in a stimulus poor VE, such as walking through an endless hallway.
2416673|NCT03459001||Tube Fed Malnourished Outpatients|Outpatients that are malnourished or at risk of malnutrition and have been placed on a nutritional care plan, which includes a complete tube feeding formula as sole source nutrition
3145620|NCT00076232|Placebo Comparator|2|Participants will receive acyclovir placebo for the duration of the trial
2416675|NCT03458975|Active Comparator|Selected liver metastases of the patient|Liver metastases randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy
2416676|NCT03458975|Placebo Comparator|Not-selected liver metastases of the patient|Liver metatstases not randomized to receive sonoporation (US waves + gaseous microbubbles). The patient continue to receive the usual systemic chemotherapy like the active comparator arm
2416677|NCT03458962||Genetic Enrollees|Enrollment of patients for whom WGS may be beneficial. Patients who are ill and for whom a genetic diagnosis is suspected but not yet established.
2416678|NCT03458923|Active Comparator|Group A|15 eyes will receive 0.1 ml containing 500µg of diclofenac intravitreally, repeated monthly for 3 months.
2416679|NCT03458923|Active Comparator|Group B|15 eyes will receive 0.5 mg Ranibizumab intravitreally, repeated monthly for 3 months.
2416680|NCT03458910|Experimental|HRV-increase group|Half of the participants will be randomly assigned to this group who will undergo daily practice to increase their heart rate variability (HRV).
2416681|NCT03458910|Experimental|HRV-decrease group|Half of the participants will be randomly assigned to this group who will undergo daily practice to decrease their HRV and heart rate.
2416682|NCT03458897|Experimental|MRI arm|Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
2416683|NCT03458884|Experimental|Cardiorespiratory interval training|Cardiorespiratory interval training program on ergometer cycle, 30-40 minutes, 3 days a week for 8 weeks.
2416684|NCT03458884|No Intervention|Usual care|Usual ESD care including information about post-stroke fatigue, support and practical advice about how to identify and manage fatigue symptoms in daily tasks, such as the adaptation and prioritization of activities, physical activity and rest.
3145621|NCT00076310|Experimental|Cisplatin + Docetaxel + OSI-774|"Cisplatin 75 mg/m^2 IV every 21 days.~Docetaxel 60 mg/m^2 IV repeated every 21 days.~OSI-774 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached."
2416686|NCT03458858|Other|Mixed Berry Diet|Participants will receive between 400 to 800 grams of mixed berries daily, as a proportion of their daily caloric intake added to their base diet. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2416687|NCT03458858|Other|Carbohydrate Control Jello|Participants will receive between 400 to 800 grams of strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
3145622|NCT00076349|Experimental|1|open-label, single arm, clinical trial of bendamustine (SDX-105) plus rituximab
2416688|NCT03458858|Other|Fiber Enriched Jello|Participants will receive between 400 to 800 grams of fiber enriched strawberry jello daily, as a proportion of their daily caloric intake added to their base diet. The jello will be matched to the mixed berries in both total carbohydrate level and fiber content, and in the same gram quantity. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2416689|NCT03458858|Other|Low Fiber Mixed Berry Juice|Participants will receive 1 liter per day of low fiber mixed berry juice added to their base diet. The juice will be squeezed from the mixed berries, then filtered. The sugar level of the juice will match that of the mixed berries. The base diet will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2416690|NCT03458845||Group 1|This group consists of cirrhotic patients with any abdominal hernia
2416691|NCT03458845||Group 2|This group consists of cirrhotic patients without any hernias
2416692|NCT03458832||FSHD-COM|All participants will be asked to undergo FSHD-specific functional rating scale tests and procedures and Electrical Impedance Myography.
2416693|NCT03458819||Control|Patients on neither active Vitamin D or a statin
2416694|NCT03458819||Vit D|Patients on active Vitamin D but not a statin
2416695|NCT03458819||Statin|Patients on a statin but not active Vitamin D
2416696|NCT03458819||D + Statin|Patients on both active Vitamin D and a statin
2416697|NCT03458806||Control|Subjects with echocardiographically confirmed valvular disease of less than moderate-to-severe grading with regards to aortic stenosis (AS) and mitral regurgitation (MR). Note that within this cohort will be a sub cohort consisting of subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
2416698|NCT03458806||AS Case|Subjects with echocardiographically confirmed aortic stenosis (AS) of moderate-to-severe or greater grading.
2416699|NCT03458806||MR Case|Subjects with echocardiographically confirmed mitral regurgitation (MR) of moderate-to-severe or greater grading.
2416700|NCT03458806||Control Subgroup|Subjects with structurally normal hearts, with no greater than mild valvular disease of any valve, no prior valvular intervention, and no evidence of congenital heart disease.
2416701|NCT03458793|Experimental|The experimental group|The experimental group will take part in the 12 week intervention after randomisation consisting of group walking and educational workshops performed once weekly for up to 90 minutes in total for each session.
2416702|NCT03458793|No Intervention|The control group|The control group will be a wait-listed arm that will be offered an intervention at 12 weeks after the randomisation (the delayed intervention).
2416703|NCT03458780||Yellow Fever Vaccine Participant|Healthy participants who receive the Yellow fever vaccine for travel and/or occupational risk will have peripheral blood samples collected longitudinally at time points selected for different immune events post-vaccination according to published studies (Day 0 baseline; Days: 3, 7, 14, and 42).
2416704|NCT03458767|Experimental|Intervention group|Eight weekly 90-minute group educational sessions attended via a computer, tablet, or smart phone using a web-based video conference platform.
2416705|NCT03458767|No Intervention|Control group|Enhanced usual care control group will receive an illustrated instructional booklet on Physical Activity for persons with MS developed by the National Center on Health, Physical Activity and Disability (NCHPAD).
2416706|NCT03458754||Patients|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
2416707|NCT03458754||Healthy controls|Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
3145623|NCT00076453|Experimental|1|Participants will wear lateral wedge orthotic inserts.
3145624|NCT00076453|Active Comparator|2|Participants will wear standard orthotic inserts.
3145625|NCT00076791|Active Comparator|1|Each participant in Cohort 1 received a single 600 mg oral dose of TDF at the start of active labor or 4 hours prior to C-section, with concurrent administration of standard intravenous zidovudine (ZDV) prophylaxis and/or other antiretrovirals prescribed by her physician. The infants from Cohort 1 received only the standard 6 weeks of oral ZDV prophylaxis postpartum.
3145626|NCT00076791|Active Comparator|2|Mothers in Cohort 2 will receive a single dose of 900 mg of TDF combined with 600 mg emtricitabine, along with standard ZDV prophylaxis and/or other antiretrovirals prescribed by her physician. Infants will receive a single dose of TDF at 4 mg/kg combined with 3 mg/kg emtricitabine as soon as possible after delivery and within 6 hours of age as well as the standard 6 weeks of oral ZDV prophylaxis after birth.
3145627|NCT00076817|Experimental|1|Participants will receive vaccine injections in the groin area or the upper arm
2416713|NCT03458715|Experimental|SGLT2 inhibitor (Empagliflozin 25 MG)|We add SGLT2 inhibitor (Empagliflozin 25 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy for 6 months.
2416714|NCT03458715|Active Comparator|DPP4 inhibitor (Linagliptin 5 MG)|We add DPP4 inhibitor (Linagliptin 5 MG, oral, once daily) to type 2 diabetes patient poorly controlled with premix insulin therapy.for 6 months.
2416717|NCT03458689|Other|Left hemicolectomy without nerve blocks|Left hemicolectomy, laparoscopic technique Enteral and parenteral analgesics such as paracetamol and oksykodon
2416718|NCT03458689|Active Comparator|Left hemicolectomy with TAP block|Left hemicolectomy, laparoscopic technique TAP block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
3145628|NCT00076817|Placebo Comparator|2|Participants will receive vaccine placebo injections in the groin area or the upper arm
2416719|NCT03458689|Active Comparator|Left hemicolectomy with QL block|Left hemicolectomy, laparoscopic technique QL block bilateral with Naropin 3,75 mg/ml, 2 x 20 ml
2416720|NCT03458676|Experimental|Advanced MR Imaging (AMRI) Scan|"AMRI scan performed within 2 weeks before standard of care brain surgery.~During the surgery, neurosurgeon(s) use the information collected from the AMRI to decide what area of the brain tumor will be biopsied."
2416721|NCT03458663|Experimental|Prevena|Patients randomized to application of Prevena ™ and ACTIV.A.C ™ Therapy System 4-7 days post-operatively. Patients will return to the surgical day clinic to have the system removed either at day 7 or when/ if function ceases. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing
2416722|NCT03458663|No Intervention|Conentional postoperative care|patients randomized to convetional postoperative regime with a penrose drain (passive) and a dry draping for 24 hours and after usage of sanitary pads. Patients receive 3 days oral antibiotics postoperatively (Ciproxin 250 mg x 2 and Metronidazole 500 mg x 3). Drain is removed after 24 hours and Sutures are removed at clinical control after 14 days and patients are seen again by BCL surgeon after 3 months and are discharged when completely healeddrainage and conventional wound dressing.
2416723|NCT03458650|Experimental|LXI-15028 50 mg|For 50 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
2416724|NCT03458650|Experimental|LXI-15028 100 mg|100 mg dose group plans to enroll 14 healthy subjects (investigational drug:placebo=10:4), half males and half females. Five subjects of each gender will receive LXI-15028, while 2 subjects of each gender will receive placebo. Intra-group randomization will be implemented in each dose group; each subject will receive either LXI-15028 or placebo.
2416725|NCT03458650|Experimental|LXI-15028 200 mg|200 mg dose groups, each is planned to enroll 12 healthy subjects (investigational drug :placebo=10:2), half males and half females. Five subjects of each gender will receive LXI-15028, while 1 subject of each gender will receive placebo
2416726|NCT03458637|Experimental|LITE Program with usual care.|LITE Program with usual care. LITE program involves four x 180 min weekly sessions, followed by three x 90 min monthly sessions, for adolescents and parents. The key aspects covered in the LITE program are in keeping with Health Promotion Board guidelines for the management of overweight and obesity and include healthy food choices and eating patterns, increasing physical activity and reducing sedentary behavior. The parenting aspects aim to support and increase parental capacity to implement and maintain the lifestyle changes.
2416727|NCT03458637|Active Comparator|Usual Care|Usual care consisting of Weight management clinic consultation at baseline randomization, 3 and 6 months post randomization in a tertiary setting in KK Hospital. Duration of treatment is 6 months. Qualified pediatrician, trained in screening for causes and medical complications of obesity in children, runs the weight management clinic and review the participant at each visit. Optional physical activity, dietary consultation at each weight management clinic visit.
2416728|NCT03458624||Not applicable-observational study|Not applicable-observational study
2416729|NCT03458611|Experimental|Group A|In period 1 group A will receive the active intervention and in period 2 they will receive the placebo intervention.
2416730|NCT03458611|Experimental|Group B|In period 1 group B will receive the placebo intervention and in period 2 they will receive the active intervention.
2416731|NCT03458598|Experimental|Single shot rectus sheath block|The treatment group will have pre-operative ultrasound-guided single shot bilateral rectus sheath blocks with 20 ml of a ropivacaine / bupivacaine mixture per side.
2416732|NCT03458598|Sham Comparator|Placebo Control|The control group will have a pre-operative sham ultrasound-guided subcutaneous injection of 1ml saline per side.
2416733|NCT03458585||Group 1: patients attending for a 99mTc-MDP bone scan.|Group 1: Patients will be approached after they had their injection for the bone scan procedure. Completion of questionnaire will take place during the three hour uptake period, before they have the scan.
2416734|NCT03458585||Group 2: patients attending for a 18F- FDG PET/CT scan.|Group 2: Patients will be approached and consented after they had their injection and scan for 18F- FDG PET/CT. Completion of questionnaire will take place immediately after patients have changed and wait to leave the department, while they wait for their scan to be checked .
2416735|NCT03458572|Experimental|Intervention|1.5mm Seirin Pyonex needle at LI11 point
2416736|NCT03458572|Sham Comparator|Control|0.3mm Seirin Pyonex needle at TB10 point
2416737|NCT03458559|Active Comparator|Radium-223-chloride|Radium-223-chloride 50kBg/kg, every 4 weeks intravenously, for a total of 6 administrations.
2416738|NCT03458559|Experimental|Rhenium-188-HEDP|Rhenium-188-HEDP 40MBq/kg, every 8 weeks intravenously, for a total of 3 administrations.
2416739|NCT03458546|Experimental|Roflumilast and R-CHOP|
2416740|NCT03458533||Group 1|Obese patients with indication to bariatric surgery
2416741|NCT03458533||Group 2|Overweight or obese patients without indication to bariatric surgery, able to obtain weight loss trough diet and lifestyle changes
2416742|NCT03458533||Group 3|Overweight or obese patients without indication to bariatric surgery, not able to obtain weight loss trough diet and lifestyle changes
2416743|NCT03458520||Image Registry|patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor will receive MR imaging, PET/MR imaging (and if available, PET/CT imaging)
2416744|NCT03458507|Active Comparator|Usual interface|"Patients which begin with their usual interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for alternative interface, seven days familiarisation, second polygraphy and side effect assessment at the end of the second week."
2416745|NCT03458507|Active Comparator|Alternative interface|"Patients which begin with the alternative interface for one week, home polygraphy and side effect assessment at the end of the first week.~Switch for usual interface, seven days with usual device, second polygraphy and side effect assessment at the end of the second week."
2416746|NCT03458494|Experimental|Mediterranean Diet|during one week participants will receive food products common in the diet of Mediterranean populations
2416747|NCT03458494|Experimental|Low-fat diet|during one week participants will receive food products low in fat content
2417847|NCT03450720|Experimental|GLPG2737 single dose.|Single dose of GLPG2737 oral suspension.
2416748|NCT03458481|Experimental|SOF+DAG181 100 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 100 mg for 12 weeks.
2416749|NCT03458481|Experimental|SOF+DAG181 200 mg|Patients with genotype 1 HCV infection without cirrhosis will receive SOF+DAG181 200 mg for 12 weeks.
2416750|NCT03458468|Experimental|Group A|Tranexamic Acid 1g IV
2416751|NCT03458468|Placebo Comparator|Group B|Saline injection
2416752|NCT03458455||A|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions
2416753|NCT03458455||B|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions
2416754|NCT03458455||C|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + nivolumab or pembrolizumab
2416755|NCT03458455||D|Patients with brain metastases from malignant melanoma receiving stereotactic radiosurgery to selected lesions + ipilimumab, nivolumab or pembrolizumab
2416756|NCT03458455||E|Patients with brain metastases from non-small cell lung cancer receiving stereotactic radiosurgery to selected lesions + epidermal growth factor receptor (EGFR) inhibitors
2416757|NCT03458442|Experimental|Intervention Arm|Standard surgical training + simulation-based surgical training
2416758|NCT03458442|Active Comparator|Control Arm|Standard surgical training
2416759|NCT03458429|Experimental|Frail, older subjects|Treated subjects are the frail, older subjects who will be treated with Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma (GMFFP) in this protocol.
2416760|NCT03458416|Experimental|Cannabidiol Oral Solution: 20-40 mg/kg/day|Participants will receive total daily doses between 20 milligrams per kilograms per day (mg/kg/day), 30 mg/kg/day, and 40 mg/kg/day. The two equivalent doses will be administered twice a day with a standard meal approximately every 12 hours.
2416761|NCT03458403|Experimental|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for.
2416762|NCT03458390|Experimental|HyGIeaCare and PillCam COLON|Patient will receive the HyGIeaCare colon irrigation prior to their PillCam COLON procedure
2416763|NCT03458377|Experimental|Telephone call group|The patient receives the colonoscopy information from the primary care center on the day of the request for the test and a 20 minute educational telephone call 7 days before de procedure.
2416764|NCT03458377|No Intervention|Non-telephone call group|The patient only receives the colonoscopy information from the primary care center on the day of the request for the test.
2416765|NCT03458364|Experimental|High flow nasal cannula|High flow nasal cannula (HFNC) is a type of oxygen device, which provides high concentration oxygen in a high flow, which exceeds patient's inspiratory flow demand, to improve oxygenation.
2416766|NCT03458364|Active Comparator|Noninvasive ventilation|Non-invasive ventilation (NIV) refers to the provision of ventilatory support through the patient's upper airway using a mask. This technique is distinguished from those which bypass the upper airway with a tracheal tube, laryngeal mask, or tracheostomy and are therefore considered invasive.
2416767|NCT03458351|Active Comparator|Remote ischemic preconditioning|"Remote ischemic conditioning after anesthesia induction~- four cycles of 5 min of ischemia followed by 5 min of reperfusion by inflation to 200 mm Hg and deflation of a blood pressure cuff on the upper arm"
2416768|NCT03458351|Sham Comparator|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10mm Hg.
2416769|NCT03458325|Experimental|Furoscix Infusor Prospective Treatment|Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.
2416770|NCT03458325|No Intervention|Propensity-Matched Historical Control|The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.
2416771|NCT03458312|No Intervention|Family and Network support measurements|"The perceived 'Family support' and 'Caregiver burden' (FNC) will be measured among 30 families.~Test time points:~Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52)"
2416772|NCT03458312|Experimental|Family and network consultations|Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns.
2416773|NCT03458299|Experimental|Motivational Interviewing|The MI intervention will incorporate open-ended questions, personalized feedback, and discussion about participants' alcohol use and drug, associated risk behaviors (e.g., drinking and driving), and the consequences of these behaviors. Individual MI procedures will incorporate the core principles of MI described by Miller and Rollnick, including expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. Therapist interventions will be tailored to the participants' readiness to change/current stage of change (pre-contemplation, contemplation, preparation, action, maintenance, and relapse).
2416774|NCT03458299|Experimental|Psychoeducation|The Psychoeducation session will consist of therapist assisted viewing and discussion of four educational DVDs about adolescent alcohol use, drug use, and driving under the influence provided by Human Relations Media, Mount Kisco, NY (hrmvideo.com).
2416775|NCT03458286|No Intervention|Control group|The control group will be required to attend the diabetic foot clinic for their usual care for their diabetic foot ulcer with weekly review for a maximum of eight weeks. They will also have a follow up appointment 4 weeks after completion of treatment.
2416776|NCT03458286|Experimental|Experimental Arm|A device- BRH-A2 wound healing device will provide Combined ultrasound and electric current stimulation (CUSECS) treatment which is the intervention for this arm. Participants in this group will receive an adjunctive combined ultrasound and electric current stimulation (CUSECS) treatment along their usual treatment for their diabetic ulcer twice weekly for 8 weeks using the BRH-A2 wound healing device. They will also have a follow up appointment 4 weeks after completion of treatment.
2416777|NCT03458273||Zero fluoro|Patients in whom Zero fluoroscopy ablation was performed under the guidance of Ensite for mapping and ablation and fluoroscopy will not be used during the procedure.
2416778|NCT03458273||Conventional ablation without 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic guidance only.~Additional use of Ensite/Carto/Localisa for mapping was not allowed."
2416779|NCT03458273||Conventional ablation with 3D|"Patients in whom Conventional fluoroscopy ablation was performed under fluoroscopic and Ensite/Carto guidance and ablation during the procedure.~Use of fluoroscopy and additional Ensite/Carto for mapping and ablation was mandatory."
2416780|NCT03458260|Experimental|Experimental|Pixantrone plus rituximab, ifosfamide and etoposide.
2416781|NCT03458247|Active Comparator|Abiraterone acetate standard dose|1000 mg/day
2416782|NCT03458247|Experimental|Abiraterone acetate escalated dose|2000 mg/day
2416783|NCT03458234|Experimental|Focal SBRT with intra-urethral radiotransponder|This study will enroll patients that have a confirmed histology of prostate cancer. They will undergo a 3T MRI scan as well as a CT simulation with 16 French Foley Catheter containing dummy beacons for treatment planning purposes. The patient will then receive focal stereotactic body radiotherapy (SBRT) at a dose of 40 gy in 5 total fractions. Patients will be followed for 24 total months with specific follow-ups at 3, 6, 9, 12, 18, and 24 months.
2416784|NCT03458221|Experimental|itraconazole / tamoxifen|In case of HedgeHog pathway positivity itraconazole will be administered in case of ER pathway positivity tamoxifen will be adminisered
2416785|NCT03458208|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
2416786|NCT03458208|Active Comparator|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 1 000 mg tablet immediate release) in a fed condition"
2416788|NCT03458182|Experimental|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
2416789|NCT03458182|No Intervention|No intervention|No added exercise period (normal exercise test).
2416790|NCT03458169|Experimental|LEAP usability|"Therapist LEAP session feedback~Participant LEAP session feedback~LEAP risk control validation"
2416791|NCT03458156|Experimental|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
2416792|NCT03458156|Experimental|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
2416793|NCT03458156|Experimental|the control group|The patients will be assigned to the control group.
2416794|NCT03458143||ketamine 150 ng/ml|The first group will receive the classical premedication with 2 mg of Midazolam. A bolus dose of Ketamine will be given, then to be titrated in TCI mode with a target concentration of 150 ng/ml. Right after, the Remifentanil TCI will be started at a concentration of 1 ng/ml and the procedure can begin.
2416795|NCT03458143||ketamine 200 ng/ml|The second group will be treated in the exact way as the first, with the exception that the target effect site concentration is aimed at 200 ng/ml.
2416796|NCT03458130|Active Comparator|AG10 Low Dose|Low dose group
2416797|NCT03458130|Active Comparator|AG10 High Dose|High dose group
2416798|NCT03458130|Placebo Comparator|Placebo|
2416799|NCT03458117|Experimental|Talimogene Laherparepvec (T-VEC)|Intralesional injections of T-VEC up to 4.0 mL of 10 to the 6 plaque-forming Units/mL (PFU/mL)
2416800|NCT03458104|Experimental|Vocal Cord Atrophy|Quantify changes in aerodynamic and aeroacoustics patterns in patients with vocal cord atrophy (VCA) before and after voice therapy. To evaluate changes, subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx before and after voice therapy.
2416801|NCT03458104|Active Comparator|Healthy Volunteer|Develop a validated computational model for assessing normative laryngeal aerodynamic and aeroacoustic patterns in healthy elderly individuals. To assess normal laryngeal aerodynamic and aeroacoustic patterns in this cohort, subjects will subjects will have Laryngovideostroboscopy, Acoustic/Auerodynamic testing, and Cone Beam CT scans of the larynx.
2416802|NCT03458091|Active Comparator|Intubation|The patients will be intubated and ventilated
2416803|NCT03458091|Experimental|THRIVE|The patients will be oxygenated during apnea using THRIVE
2416804|NCT03458078|Placebo Comparator|Group C|Control group
2416805|NCT03458078|Active Comparator|Group Mg|Magnesium sulfate group
2416806|NCT03458078|Active Comparator|Group MDZ|Midazolam group
2416807|NCT03458065||S-ICD|
2416808|NCT03458065||T-ICD|
2416809|NCT03458039|Experimental|In-person CETA|This is the in-person delivery method of the Common Elements Treatment Approach (CETA).
2416810|NCT03458039|Experimental|Telephone CETA (T-CETA)|This is the technology-based delivery method for the Common Elements Treatment Approach (CETA).
2416811|NCT03458039|Active Comparator|Treatment As Usual|This is the treatment as usual control condition who will engage with their usual care in the community and will receive CETA, if desired, following completion of the study.
2416812|NCT03458026|Experimental|connected object + SMS of physical activity reminders|"The patients will be included during their visit of follow-up and will receive a watch connected. They will have an information meeting for their to explain how step shows it. They will also receive advice to practise an adapted physical activity. During 12 weeks of SMS (text messages) every week to motivate them to realize these exercises.~At the end of 12 weeks the connected watch will be deprived of them as well as SMS (text messages). They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will get back their watch. They will have in more 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, they return the watch and finish the study."
2416813|NCT03458026|Other|Without connected object|"The patients will be included during their visit of follow-up.They will have an information to practice suitable activity during 12 weeks At the end of 12 weeks, they realised follow-up. They will have to realize an activity in autonomy during 12 weeks.~At the end of the twenty-fourth week, they will have 1 session with a coach and 2 sessions to be made in autonomy during 12 weeks.~In 36 week, the study will be finished."
2416958|NCT03456947|No Intervention|control group|the patients receive routine preoperative preparation without having Pregabalin
3145630|NCT00076934|Experimental|1|Participants receive Regimen 1 for 4 months
3145631|NCT00076934|Experimental|2|Participants receive Regimen 2 for 4 months
2416814|NCT03458013|Experimental|Mindfulness Meditation plus Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
2416815|NCT03458013|No Intervention|Standard Care in Hand Therapy|Participants will be recruited from patients suffering from a traumatic injury who are entering hand therapy at a community based clinic in the Los Angeles area.
2416816|NCT03458000|Active Comparator|Active Control|Video Capsule Endoscopy will be administered during ED, but video will not be read until after inpatient EGD. Subject will have hospital admission with an EGD conducted during hospital stay.
2416817|NCT03458000|Experimental|Experimental|Subject will have Video Capsule Endoscopy read during ED length of stay, disposition will be determined using Capsule Endoscopy Risk Assessment.
2416818|NCT03457974|Experimental|congenital heart disease|42 patients
2416819|NCT03457974|Other|helathy children|42 children
2416820|NCT03457961||Adjunctive Perampanel|A group of patients who aged 12 years or above and have a diagnosis of epilepsy with simple partial seizure and/or complex partial seizures
3145632|NCT00076934|Experimental|3|Participants receive Regimen 3 for 4 months
3145633|NCT00076934|Experimental|4|Participants receive Regimen 4 for 4 months
3145634|NCT00077025|Active Comparator|Anastrozole-placebo|Anastrozole (ZD1033, Arimidex)-Placebo
2416827|NCT03457922||Group Therapy|Patients in the Stanford Department of Psychiatry and Behavioral Sciences who are enrolling in a trans-diagnostic anxiety therapy group will be invited to participate in research on group processes and outcomes.
2416829|NCT03457896|Experimental|Arm 1|"Guardant360 test on blood from select patients with known HER2 status.~Prior to assignment to Arm 1, HER2 test on blood obtained from Quadruple Wild-Type patients who received anti-EGFR therapy. Patients with HER2 amplified, HER2 Wild-Type or HER2 mutated will recieve:~• Neratinib daily + Trastuzumab weekly until disease progression"
2416830|NCT03457896|Experimental|Arm 2|"Patients with HER2 Wild Type or HER2 amplified with no prior anti-EGFR therapy will receive:~• Neratinib daily + Cetuximab weekly until disease progression"
2416831|NCT03457883|Experimental|group A|accepted herniamesh mesh
2416832|NCT03457883|Experimental|group B|accepted biological graft of cook
2416833|NCT03457870|Experimental|Intermittent Energy Restriction|Dietary intervention: Intermittent energy restriction
2416834|NCT03457870|Experimental|Chewing|Mastication intervention: chewing
2416835|NCT03457870|Experimental|Chewing + Intermittent Energy Restriction|Dietary and mastication intervention: Intermittent energy restriction and chewing
2416836|NCT03457870|No Intervention|Control|No intervention: Control
2416837|NCT03457857|Other|Group 1 - Cleanser|Regimen with Baby Cleanser Only
2416838|NCT03457857|Other|Group 2 - Cleanser and Lotion|Regimen containing Baby Cleanser/Shampoo and Baby Lotion
2416839|NCT03457844|Experimental|Anlotinib|
2416840|NCT03457831||Status Epilepticus|Convulsive and Non-Convulsive Status Epilepticus ; and Pseudo Status Epilepticus
2416843|NCT03457805|Other|Prostatic Artery Embolization (PAE)|PAE performed under local anesthesia using officially approved microspheres.
2416844|NCT03457792||Abatacept for Rheumatoid Arthritis (RA)|Participants diagnosed with moderate to severe active RA within the last 24 months and initiated treatment with Abatacept
2416845|NCT03457779|Experimental|Non Glucose Arm|4 patients without glucose infusion
2416846|NCT03457779|Experimental|Glucose Arm|12 Patients with glucose infusion
2416847|NCT03457766|Experimental|Patients with skin lesions|Using HIFU in identification of safety margins of lesions clinically apparent locally malignant, or malignant
2416848|NCT03457753|Experimental|Subjects with ALS|Riluzole Oral Soluble Film (ROSF) 50 mg will be administered in subjects with ALS twice daily. It is intended that at least five (5) of the twenty-five (25) subjects enrolled will be subjects scoring greater than 20 on the Eating Assessment Tool (EAT-10) (representative of ALS patients reporting moderate swallowing impairments in a patient report validated scale).
2416849|NCT03457740|Experimental|Formula 1|Formula 1 with nutrients and herbs, 4 capsules daily, 6 weeks
2416850|NCT03457740|Experimental|Formula 2|Formula 2 with nutrients and herbs, 4 capsules daily, 6 weeks
2416851|NCT03457740|Placebo Comparator|Placebo|Placebo, 4 capsules daily, 6 weeks
2416959|NCT03456947|Experimental|Pregabalin150mg group|the patients receive 150mg pregabalin 60 minutes prior to the surgery
2418384|NCT03446976|Experimental|CT-P13 SC Auto-injector|CT-P13 SC Auto-injector
3145635|NCT00077025|Active Comparator|Anastrozole-ZD1839|Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
3145636|NCT00077051|Experimental|Single Arm|
3145637|NCT00077142|Experimental|TAC-101|Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.
3145638|NCT00077155|Experimental|Treatment (cilengitide)|Patients receive cilengitide (EMD 121974) IV continuously on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of EMD 121974 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
2416855|NCT03457714||Guided I-CBT for persons with SCI|Persons with spinal cord injury
3145639|NCT00077181|Experimental|Treatment (cytarabine and triapine)|Patients receive high-dose cytarabine IV over 2 hours on days 1-5 and triapine IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3145640|NCT00077194|Experimental|Arm I|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3145641|NCT00077233|Active Comparator|Arm A: FOLFIRI|Patients receive irinotecan 180 mg/m^2 over 90 minutes on day 1, then leucovorin 400 mg/m^2 over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. One cycle of therapy is 8 weeks.
3145642|NCT00077233|Experimental|Arm B: FOLFIRI + C225|Patients receive irinotecan 180 mg/m^2 over 90 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5FU 400 mg/m^2 IV bolus injection then 5FU 2400 mg/m^2 continuous IV infusion over 46-48 hours repeated every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
2416860|NCT03457688|Active Comparator|prebiotic inulin-type fructans|
2416861|NCT03457688|Placebo Comparator|placebo maltodextrin|
2416862|NCT03457675|Experimental|Activa PC+S DBS implant for OCD|all subjects will receive surgical implantation of DBS system
2416863|NCT03457675|Experimental|One Month Blinded Discontinuation Period|all subjects will enter a one-month blinded discontinuation period to confirm clinical benefit at the end of Month 8.
2416864|NCT03457662|Active Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
2416865|NCT03457662|Experimental|OMC and SDT|OMC and SDT are administrated in this arm.
2416866|NCT03457649|Active Comparator|ARGX-113|SAD and MAD with test product at different increasing doses
2416867|NCT03457649|Placebo Comparator|Placebo|SAD and MAD with placebo at different increasing doses
2416869|NCT03457623|Experimental|Innovative supported|In addition to usual care, patients benefit from connected tools (overpoise, sphygmomanometer...), physical activity, a strong accompaniment with a referent person
2416870|NCT03457623|No Intervention|conventional supported|Patients benefit from usual care
2416871|NCT03457610|Experimental|Speech and language intervention|
2416872|NCT03457597|Experimental|Period 1|Period 1 (Study Days 1 to 4): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 1. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 2
2416873|NCT03457597|Experimental|Period 2|Period 2 (Study Days 5 to 13): Relacorilant will be given daily from Day 5 to Day 13.
2416874|NCT03457597|Experimental|Period 3|Period 3 (Study Days 14 to 17): Midazolam hydrochloride and metoprolol tartrate will be given once on Day 14. Pioglitazone hydrochloride, tolbutamide and omeprazole will be given once on Day 15. Relacorilant will be given daily from Day 14 to Day 17.
2416875|NCT03457584|Active Comparator|BSS arm|BSS is given at the end of surgery
2416876|NCT03457584|Experimental|air arm|air-tamponade is given at the end of surgery
2416877|NCT03457545|Experimental|Intervention|Eligible participants will take part in the home-based pulmonary rehabilitation using the Aidcube platform in-person assessment and training with a research coordinator (i.e. physical exercise capacity assessment, SPPB, disability survey, exercise prescription determination, exercise training, dyspnea control techniques) and complete an follow-up assessment at the 8th week.
2416878|NCT03457545|No Intervention|No Intervention|Ineligible participants will receive standard of care
2416879|NCT03457532|Experimental|Dose escalation study of Glumetinib|To determine the maximum tolerated dose (MTD) of Glumetinib
3145643|NCT00077233|Active Comparator|Arm C: FOLFOX|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 IV over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks.
3145644|NCT00077233|Experimental|Arm D: FOLFOX + C225|Patients receive oxaliplatin 85 mg/m^2 IV infused over 120 minutes, then leucovorin 400 mg/m^2 over 2 hours followed by 5 FU 400 mg/m^2 IV bolus injection then 5 FU 2400 mg/m^2 continuous IV infusion over 46-48 hours every 2 weeks. Patients also receive cetuximab 400 mg/m^2 IV over 120 minutes day 1, then 250 mg/m^2 IV over 60 minutes weekly. All patients must be premedicated with diphenhydramine hydrochloride 50 mg (or a similar agent) IV prior to the first dose of cetuximab in an effort to prevent a hypersensitivity reaction. Premedication is recommended prior to subsequent doses, but at the Investigator's discretion the dose of diphenhydramine (or a similar agent) may be reduced.
3145645|NCT00077298|Experimental|Arm A (cetuximab, bevacizumab, irinotecan)I|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, and 36; bevacizumab IV over 30-90 minutes on days 1*, 15, and 29 OR on days 1 and 22; and irinotecan IV over 30-90 minutes (at the same dose and schedule that the patient previously received) beginning on day 1.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
3145646|NCT00077298|Experimental|Arm B (cetuximab and bevacizumab)|"Patients receive cetuximab as in Arm A and bevacizumab IV over 30-90 minutes on days 1*, 15, and 29.~NOTE: *Bevacizumab is given on day 2 (instead of day 1) of course 1, and is given on day 1 of subsequent courses."
3145647|NCT00077311|Experimental|Chemotherapy without BNP7787|Chemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
3145648|NCT00077311|Experimental|Chemotherapy + BNP7787|Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
3145649|NCT00077324||Surgery + blood and serum collection|"Patients undergo lung resection. Patients also undergo preoperative and postoperative collection of whole blood and serum for proteomic profiling using surface-enhanced laser desorption/ionization-time of flight mass spectrometry. A lung tissue biopsy taken at surgery is also analyzed.~Patients are followed at 60-90 days and then annually for 2-5 years."
2416880|NCT03457519|Active Comparator|Intervention Group A|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 8 months while counting respiratory rate of children under 5 visually using a timer.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
2416881|NCT03457519|Active Comparator|Intervention Group B|"CHWs trained in ChARM and using ChARM as a self-monitoring tool for 4 months while counting respiratory rate of children under 5 visually using a time; then discontinue using ChARM and continue to monitor the respiratory rate visually using a timer only for the remaining 4 months.~Intervention: The Children's Respiration Monitor (also known as ChARM) device is routinely used to diagnose Pneumonia cases but in this study it will be used as a self-monitoring and teaching aide for strengthening CHWs skills."
2416882|NCT03457519|No Intervention|Control Group C|CHWs who did not receive the ChARM training and will be monitoring the respiratory rate of children under 5 visually using a timer only, as per the MoH traditional training.
2416883|NCT03457506|Other|Patients undergo a digital PET/CT|Single arm prospective study of paired PET scans. Patients who are referred to the nuclear medicine department to undergo a PET scan, will undergo a PET/CT scan on the conventional scanner as well as the digital PET/CT scanner.
2416884|NCT03457493|Experimental|Healthy Controls, DPA-714-PET/MRI|
2416885|NCT03457493|Experimental|Early Parkinson's Disease, DPA-714-PET/MRI|
2416886|NCT03457480|Experimental|Prevention (text messages, computer messages)|"PHASE I: Participants attend focus group over 2 hours.~PHASE II: Participants receive 2 text messages per day for 30 days at baseline and after 3 months.~PHASE III: Participants read 64 computer messages with or without images over 30 minutes and have their facial expressions assessed."
2416887|NCT03457467|Experimental|SBRT+apatinib group|Apatinib mesylate tablets: 500mg / day, 28 days / cycle, follow-up to the progress of the disease, toxicity intolerable or patients require withdrawal; SBRT: according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment.
2416888|NCT03457454||Primary Care Provider/Staff Participants Interviews|"Up to two primary care providers and at least one staff person at each of the 16 clinics, with approximately 5 interviewees per clinic. Eligible providers and staff include physicians, nurse practitioners, nurses, case managers, medical assistants, administrative staff, or other employees of the clinic involved in the cancer screening and follow-up process.~If the participant verbally consents, the research team member will conduct an interview with the provider to learn about the current processes used to support and monitor colorectal cancer screening (CRC) from screening initiation through follow-up; assess capacity and interest in implementing Evidence Based Practices for supporting and monitoring CRC screening, including any ideas interviewees have or find appealing; and engage the organizations as partners to build interest, capacity, and infrastructure for future intervention trial and other future studies."
2416889|NCT03457454||Patient Participants Interviews|"10 patients across 5 clinics will be recruited for interviews, which will address the patient experience with screening and follow-up.~If the participant verbally consents, the research team member will conduct an interview with the patient participant to gain a deeper understanding of the CRC screening process from the patient's perspective; the gaps, challenges, or road blocks/speed bumps to completing CRC screening steps; and what organizations can do better or differently to help people complete the CRC screening process."
2416890|NCT03457454||Patient Participants Anonymous Survey|-Patient participants will be recruited to take an anonymous mailed survey, which will address patient level barriers to screening and follow-up focusing on out of pocket costs.
2416891|NCT03457454||Colonoscopy Provider/Staff Participants Interviews|"Colonoscopy providers and a staff or mid-level provider in each office will be recruited for interviews.~If the participant consents, the research team member will conduct an interview to learn about current processes used to support and monitor colorectal cancer screening from the perspective of gastroenterology/colonoscopy sites and to learn about how gastroenterology/colonoscopy sites communicate and coordinate care with other healthcare organizations and patients to support and monitor colorectal cancer screening."
2416892|NCT03457441|Other|Near visual acuity +1.0 and +0.7 logMAR|Subjects with near visual acuity between +1.0 and +0.7 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2416893|NCT03457441|Other|Near visual acuity +0.6 and +0.3 logMAR|Subjects with near visual acuity between +0.6 and +0.3 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2416894|NCT03457441|Other|Near visual acuity +0.2 and +0.0 logMAR|Subjects with near visual acuity between +0.2 and +0.0 logMAR , when eligible and providing informed consent, assigned to evaluation with OdySight mobile medical application
2416895|NCT03457415||Healthy Cohort|Healthy Cohort: current non-smoker who has smoked less than 5 pack-years in his or her lifetime, and if smoked, quit more than 15 years ago, and has no known lung disease.
2416896|NCT03457415||High-risk Cohort|High-risk Cohort: individual aged ≥55-74 who is a current smoker with a smoking history of at least 30 pack-years or current non-smoker who has a smoking history of at least 30 pack-years and quit smoking within the past 15 years.
2416897|NCT03457415||Cancer Cohort|Cancer Cohort: individual who has been diagnosed by a physician as highly suspect for having lung cancer, but has not yet undergone a biopsy nor received therapy, and after providing a sputum sample is confirmed to have lung cancer by biopsy.
2416898|NCT03457402|Experimental|Treatment|Participants in the Experimental arm will begin the Shaping Delay Tolerance behavioral intervention immediately after baseline, and this training will last for about 6 weeks.
2416899|NCT03457402|Active Comparator|Wait-list Control|After baseline, participants in the Wait-list Control arm will wait for about 6-weeks before entering the pre-treatment phase, which is a repeat of effortful control assessments and behavior questionnaires, and then they will begin training for with the Shaping Delay Tolerance behavioral intervention.
2416900|NCT03457389|Experimental|Experimental group|Serum prolactin level is adjusted to less than 5 ng/mL during cabergoline administration.
2416901|NCT03457389|Active Comparator|Control group|Serum prolactin level is adjusted to normal range during cabergoline administration.
2416902|NCT03457363|Experimental|Double Trunk Mask|DTM will be add above nasal cannula
2416903|NCT03457363|Active Comparator|Nasal Cannula Alone|Patients receive oxygen only thought nasal Cannula
2416904|NCT03457350|Experimental|office hysteroscopy|Office hysteroscopy 30 degrees 2.6 mm telescope with an outer sheath of 3.2 mm (Storz Co., Tutlingen, Germany). Hysteroscopy is performed as usual by proper examination of the vagina and the ectocervix for any abnormality followed by introduction of the hysteroscope into the cervical canal. At this step, the hysteroscopist waits for a while until the distending fluid forms a micro-cavity. At this point, the telescope is advanced with necessary rotatory movements of the 30 degrees telescope guided by the vision of the dark spot which is the internal os. If it is reached, again waiting for some time to allow fluid distension of the internal os area.
2416905|NCT03457350|Experimental|blind cervical probing|Cervical probing is started with a 2 mm probe after grasping the cervix with a multi-tooth tenaculum put anteriorly or posteriorly according to prior transabdominal or transvaginal sonographic examination of the cervical canal. If the probe succeedes to bypass the internal os, a higher caliber probe is used. Thereafter, a uterine sound (4mm = 1.33 Fr) is introduced into the endometrial cavity. Lastly, gentle cervical dilatation up to Hegar's 8 is performed as usual with classic leaving each dilator for 30 seconds inside the internal os. If probes couldn't bypass the internal os, the procedure is considered failed. If the probe enters a cavity other than endometrial cavity, a false passage is considered.
2416906|NCT03457337|Experimental|S-1 plus Gefitinib|"S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally, continuous administration of 14 days, rest for 7 days. BSA <1.25 m2, 80 mg / day; BSA 1.25 m2 to <1.5 m2, 100 mg / day; BSA 1.5 m2 or more, 120 mg / day. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject.~Gefitinib: 250mg, 1 day, orally, fasting or with the same service. Until disease progression, intolerance of toxicity or withdrawal of informed consent from the subject."
2416907|NCT03457337|Active Comparator|Gefitinib|Gefitinib 250 mg/day oral daily
2416908|NCT03457324|Experimental|JCM-16021 Group|JCM-16021 granules 8g/sachet, three times daily for 8 weeks.
2416909|NCT03457324|Placebo Comparator|Placebo Group|Placebo granules 8g/sachet, three times daily for 8 weeks
2416910|NCT03457311|Other|OGSP measurement|For the OGSP measurement, subjects will be orally administered with 1.25 ml/kg G.S.P. oral solution (400 mg/ml of galactose). At least 20 ml water will be given to subjects after drinking G.S.P. oral solution within 3 to 5 minutes. Sixty minutes after oral G.S.P. solution, a sample of 0.5 ml of whole blood will be taken from subject's finger for the determination of OGSP value.
2416911|NCT03457298|Experimental|Ossix Volumax|lateral bone augmentation using volume maintaining collagen scaffold (Ossix Volumax)
2416912|NCT03457298|Active Comparator|FDBA with collagen membrane|lateral bone augmentation using the current gold standard FDBA plus resorbable collagen membrane
2416913|NCT03457285|Experimental|Physiotherapy via the Salaso Apllication Intervention|"All participants' physiotherapy- prescribed exercise programmes will be monitored via the Salaso application. Telehealth appointments will occur monthly and modifications to exercises will be made as required.~This will continue for the 6-month duration of the intervention."
2416914|NCT03457272|Experimental|New risk assessment|New risk assesment
2416915|NCT03457272|No Intervention|Standard|Standard risk assessment
2416916|NCT03457259|Active Comparator|Midline|Pt. will receive midline catheters. The outcomes will be registered and some patients will be examined once weekly for thrombosis with ultrasound.
2416917|NCT03457259|Active Comparator|Conventional|Pt. will receive the conventional treatment (PVC and/or PICCline/CVC). The outcomes will be registered.
2416918|NCT03457246|Experimental|D-Pigment rich texture|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by test product ( D-pigment rich texture).
2416919|NCT03457246|Placebo Comparator|Hydrance optimale riche|Hand with 5 to 10 lentigos (graded 6 or more on the severity grading scale) treated by reference product (Hydrance optimale riche)
2416920|NCT03457233|Active Comparator|Normal weight|18.5- 24.9 kg/m2
2416921|NCT03457233|Active Comparator|Overweight|BMI 25-29.9 kg/m2
2416922|NCT03457233|Active Comparator|Obese|BMI ≥ 30 kg/m2
2416923|NCT03457207|Experimental|combined minilaparotomy- laparoscopy approach|women undergo the new technique of surgical treatment of endometriomas of the ovary
2416924|NCT03457194||Pregnant women|"150 participants (pregnant women at least 18 years of age and meeting eligibility criteria) will be enrolled and administered the FluQuadri, the quadrivalent influenza vaccine which will be administered by single-dose intramuscular injection.~Single-dose intramuscular injection of Adacel - DTP vaccine (multiple actives) will also be administered to all enrolled pregnant women who are at gestation 28 weeks or greater at the time of enrolment.~Where the vaccines are to be co-administered, FluQuadri will be administered into the dominant arm and Adacel into the non-dominant arm.~Pregnant women will be at a gestation of 20 weeks or greater at the time of enrolment. The vaccines administered are currently licensed and recommended in Australia to be given during pregnancy."
2416925|NCT03457181|Active Comparator|music group|in music group, patient was asked to choose one music genres from 5 different music genres according to his/her preference. Patient selected music was delivered by an iPhone 6 and Music app (Apple Inc., USA) through the iPhone's headphones.
2416926|NCT03457181|Active Comparator|operating room noise group|in operating room noise group, operating room noise was delivered by an iPhone and Microphone App (Free version, Von Bruno). This application allows the iPhone to be used as a live microphone.
2416929|NCT03457142|Experimental|Treatment (abatacept, ixazomib citrate, dexamethasone)|Patients receive abatacept IV over 30 minutes on day 1 of course 1, then SC on days 2, 8, 15, and 22 of course 1, and then on days 1, 8, 15, and 22 of subsequent courses. Patients also receive ixazomib citrate PO QD on days 1, 8, and 15 and dexamethasone on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2416960|NCT03456947|Experimental|Pregabalin300mg group|the patients receive 300mg pregabalin 60 minutes prior to the surgery
3186102|NCT00741780||G-CSF plus plerixafor|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received plerixafor prior to undergoing apheresis.
3186103|NCT00741780||G-CSF plus placebo|Participants in AMD3100-3102 (NCT00103662) who underwent mobilization with granulocyte colony-stimulating factor (G-CSF) and received placebo prior to undergoing apheresis.
3186104|NCT00741806|Experimental|GHB04L1|Single dose, dose escalation
3186105|NCT00741806|Placebo Comparator|SPGN buffer|
2416936|NCT03457090|Experimental|Patient treated with ECMO|Patient treated with ECMO will have Examination : a TCD and Trans-Thoracic Echocardiography (TTE)
2416937|NCT03457077|Experimental|Brief Intervention|Participants will receive a brief intervention at week 0
2416938|NCT03457077|Other|Delayed Intervention|Participants will receive a brief intervention at 6 months
2416939|NCT03457064|No Intervention|Physical Activity (PA)|Physical activity (PA) involved a program of physical exercise alone.
2416940|NCT03457064|Active Comparator|PA+Social Adherence Intervention(PASAI)|PA+Social Adherence Intervention(PASAI) involved a program of physical exercise combined with a social adherence intervention.
2416941|NCT03457051|Active Comparator|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint that is made of plastic or metal.
2416942|NCT03457051|Experimental|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced
2416943|NCT03457038|Experimental|Patient with Septic Shock|Patient Hospitalized in Intensive Care Unit for sepsis of any etiology. The number of follow-up visits will not be changed compared to usual patient follow-up hospitalized in the intensive care unit but there will be blood testing more frequently
2416944|NCT03457025|Active Comparator|Standard of Care Therapy|Reference Therapy
2416945|NCT03457025|Experimental|Standard of Care + HOTB|Reference therapy in addition to Hyperbaric Oxygen Therapy
2416946|NCT03457012||Semaglutide|Participants will receive semaglutide at the treating physician's discretion as part of the usual clinical practice. The prescription and use of semaglutide is completely independent of this study. Total study duration for the individual patient will be approximately 30 weeks
2416947|NCT03456999|Active Comparator|MAU868|BKV-specific, pan-serotype neutralizing antibody
2416948|NCT03456999|Placebo Comparator|Placebo|Matching placebo
2416949|NCT03456986|Experimental|PATH neurotraining (treatment)|Subject looks at computer screen to determine whether bars in fish-shaped window move left or right relative to background bars. The subject reports which way center pattern moves by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
2416950|NCT03456986|Active Comparator|Orientation Discrimination (control)|Subject looks at computer screen to determine whether bars in center circular window are tilted left or right relative to vertically oriented background bars. The subject reports which way center pattern is tilted by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes orientation of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern colored or black and white, and by increasing pattern's complexity level. This Intervention will be trained for one training cycle, between 10-20 minutes, 3 times each week for 12 weeks.
2416951|NCT03456973|Experimental|Nurse AMIE|
3186106|NCT00741832|Experimental|I|Patients breath while a conical positive expiratory pressure device during exercises
3186107|NCT00741832|Active Comparator|C|Patients (normal) breath during exercise
3186108|NCT00741845|Active Comparator|1|intravaginal metronidazole 750mg + 200mg miconazole
3186109|NCT00741845|Active Comparator|2|intravaginal metronidazole 750mg
3186110|NCT00741845|Active Comparator|3|intravaginal metronidazole 37.5mg
3186111|NCT00741884|Experimental|Arm 1|
2418385|NCT03446976|Experimental|CT-P13 SC Pre-filled Syringe|CT-P13 SC Pre-filled Syringe
3186112|NCT00741884|Experimental|Arm 2|
3186113|NCT00741884|Experimental|Arm 3|
3186114|NCT00741884|Active Comparator|Arm 4|
3186115|NCT00741884|Placebo Comparator|Arm 5|
3186116|NCT00741897|Experimental|1|Fexofenadine
3186117|NCT00741910|Experimental|1|Semapimod 60 mg IV q 6 - 10 weeks
3186118|NCT00741923|Experimental|Bean group|A group consuming 5 cups/week of navy beans for a month
3186119|NCT00741949|Experimental|1|
3186120|NCT00741949|Placebo Comparator|2|
3186121|NCT00741962|Experimental|1|
3186122|NCT00741962|Placebo Comparator|2|
3186123|NCT00741975|Experimental|1|Affect Management
3186124|NCT00741975|Active Comparator|2|General Health Promotion
3186125|NCT00742014|Experimental|1|
3186126|NCT00742040|Experimental|1|
3186127|NCT00742040|Active Comparator|2|
3186128|NCT00742066|Experimental|I|Irbesartan
3186129|NCT00742066|Active Comparator|II|Felodipine
3186130|NCT00742066|Placebo Comparator|III|Placebo
3186131|NCT00742092|Experimental|1|miglustat
3186132|NCT00742092|Placebo Comparator|2|placebo
3186133|NCT00742105|Experimental|BGT226|
3186134|NCT00742118|Experimental|2|patient with chronic inflammatory intestinal disease
3186135|NCT00742118|Other|3|patient having no symptoms
3186136|NCT00742118|Experimental|1|patient with irritable bowel syndrome
3145650|NCT00077350|Experimental|Treatment (triapine and gemcitabine hydrochloride)|Patients receive 3-AP (Triapine^®) IV over 2 hours and gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3145651|NCT00077363|Experimental|Treatment (tipifarnib, capecitabine)|Patients receive oral tipifarnib twice daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 4 additional courses beyond documentation of CR.
3145652|NCT00077428|Experimental|Treatment (bortezomib, doxorubicin hydrochloride)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression continue to receive bortezomib as above and doxorubicin IV over 2-5 minutes on days 1 and 8. Treatment repeats every 21 days for up to 14 courses in the absence of further disease progression or unacceptable toxicity.
2416964|NCT03456921|Experimental|Game participants|"All participants will engage in playing the end-of-life conversation game called Hello, which involves answering open-ended questions about medical decision making and end-of-life issues."
2416965|NCT03456908|Experimental|myeloma before MV-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with myeloma before MV-NIS treatment, and at Day 8-9 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 8 scan. Patients will be selected from subjects electing to participate in IRB 06-005263 at Mayo Clinic: Phase I/II Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma,"
2416966|NCT03456908|Experimental|endometrial cancer before VSV-hINF-NIS treatment|"Perform [18F]BF4-PET and [99mTc]pertechnetate-SPECT imaging in 10 patients with endometrial cancer before VSV-hINF-NIS treatment, and at Day 3-5 to monitor NIS activity in the tumors. To show the correlation of positive regional uptake with tissue histopathology for NIS, biopsies will be taken, when accessible, after the day 3-5 scan. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Metastatic and/or Incurable Endometrial and Epithelial Ovarian Cancer, IRB 15-007000"
2416967|NCT03456895|Experimental|Healthy volunteer population|"Healthy volunteer participants will have one of two options for participation:~completion of an electronic survey tool to assess the perception and preference of environmental factors (virtual participation)~completion of the above survey and participation in environmental experiences and providing feedback about their experience (physical participation)"
2416968|NCT03456895|Experimental|Patient population|Patient participants will complete a survey tool and either participate in specific environmental experience testing or may be exposed to an environmental experience during the imaging examination. The imaging exam will be assessed in regard to quality factors such as motion artifacts as an indicator of being relaxed during the examination.
2416969|NCT03456895|Experimental|Staff population|Staff participants who work in imaging-related healthcare environments will complete survey tools regarding their perception and preference of environmental factors and/or will participate in environmental experiences and provide feedback.
3145653|NCT00077441|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3145654|NCT00077454|Experimental|Treatment (erlotinib hydrochloride, temozolomide)|Patients receive oral erlotinib once daily on days 1-28. Beginning with course 2, patients also receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 23 courses in the absence of disease progression or unacceptable toxicity.
2416972|NCT03456869|Experimental|PSI group|The patient specific implant (PSI) is used to completed the genioplasty.
3145655|NCT00077467|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2416976|NCT03456830|Experimental|ALLN-177|ALLN-177 3,750 units per capsule
2416977|NCT03456830|Placebo Comparator|Placebo|Placebo capsule
3145656|NCT00077493|Active Comparator|1|BL22 immunotoxin
3145657|NCT00077493|Active Comparator|2|antibody therapy
2416980|NCT03456804|Experimental|Treatment ESK981|Patients receive pan-VEGFR/TIE2 (Vascular Endothelial Growth Factor Receptor/angopoeitin receptor2) tyrosine kinase inhibitor CEP-11981 PO QD for 5 days (Monday-Friday). Treatment repeats for up to 8 weeks in the absence of disease progression or unacceptable toxicity. If treatment is successful after 8 weeks, patients may receive up to 6 months of pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981.
2416981|NCT03456791||endometrial carcinoma( cases)|42 patients with abnormal uterine bleeding and diagnosed endometrial cancer at prior endometrial biopsy, underwent staging laparotomy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
2416982|NCT03456791||benign diseases(control)|42 patients with abnormal uterine bleeding and diagnosed benign endometrial pathology by endometrial biopsy will be subjected to withdrawal of blood sample for measurement of human epididymis protein 4
3145658|NCT00077493|Active Comparator|3|immunotoxin therapy
3145659|NCT00077493|Active Comparator|4|monoclonal antibody therapy
3145660|NCT00077545|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3145661|NCT00077584|Experimental|Bosentan|The patients received bosentan 62.5 mg twice daily (b.i.d.) for 4 weeks and then 125 mg b.i.d. for 20 weeks
3145662|NCT00077584|Placebo Comparator|Placebo|The patients received the matching placebo for 24 weeks
3145663|NCT00077597|Experimental|1|
3145664|NCT00077597|Active Comparator|2|
2416984|NCT03456752|Experimental|Dexamethasone|Dexamethasone 8mg intravenously prior to anesthesia induction
2416985|NCT03456752|Placebo Comparator|Control|Normal Saline 1.6ml intravenously prior to anesthesia induction
2416986|NCT03456739||suppurative otitis media with effusion|
2416987|NCT03456739||non suppurative otitis media with effusion|
2416988|NCT03456726|Experimental|FL with EZH2 gene mutation|Participants with follicular lymphoma (FL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 milligrams (mg) twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
2416989|NCT03456726|Experimental|DLBCL with EZH2 gene mutation|Participants with diffuse large B-cell lymphoma (DLBCL) with the EZH2 gene mutation will receive oral tazemetostat at a starting dose of 800 mg twice daily (1600 mg total daily dose) by continuous regimen, no less than 8 hours between doses.
2416990|NCT03456713|Experimental|LY3074828 Formulation A|LY3074828 solution formulation in two prefilled syringes, administered as subcutaneous (SC) injection
2416991|NCT03456713|Experimental|LY3074828 Formulation B|LY3074828 solution formulation in a prefilled syringe, administered as a SC injection
2416992|NCT03456713|Experimental|LY3074828 Formulation C|LY3074828 solution formulation in an auto-injector
2416993|NCT03456713|Experimental|LY3074828 Formulation D|LY3074828 solution formulation in an auto-injector
2416995|NCT03456687|Experimental|Exenatide|This group will receive a weekly Exenatide 2mg injection for one year.
2416996|NCT03456674|Experimental|LaseMD System|Subjects will receive LaseMD System treatment(s) for treatment of melasma.
2416997|NCT03456661|Active Comparator|Levobupivacaine|Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
2416998|NCT03456661|Active Comparator|Levobupivacaine + Dexmedetomidine|Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al[1]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
2416999|NCT03456648|Experimental|Part A : postdialysis low dose|Interdialytic kinetics of low dose (2.5 mg apixaban) post-dialysis
2417000|NCT03456648|Experimental|Part A: ipostdialysis high dose|Interdialytic kinetics of high dose (5 mg apixaban) post-dialysis
2417001|NCT03456648|Experimental|Part B : predialysis low dose|Intra- and interrdialytic kinetics of low (2.5 mg) apixaban pre-dialysis
2417002|NCT03456648|Experimental|Part B : predialysis high dose|Intra- and interrdialytic kinetics of high (5 mg) apixaban pre-dialysis
2417003|NCT03456635|No Intervention|usual antimicrobial prophylaxys|standard of care: perioperative antimicrobial prophylaxis without computerized decision support system
2417004|NCT03456635|Experimental|guided antimicrobial prophylaxis|perioperative antimicrobial prophylaxis guided by a computerized decision support system
2417005|NCT03456609|Experimental|shenqifuzheng|
2417006|NCT03456609|Placebo Comparator|0.9%sodium chloride|
2417007|NCT03456596||Institution|Community cancer centers implementing ENABLE
2417008|NCT03456583||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
2417009|NCT03456570|Active Comparator|progesterone|these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
2417010|NCT03456570|Placebo Comparator|placebo|those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment
2417011|NCT03456557|Experimental|Computed tomography.|
2417012|NCT03456544||VAN-AKI|Patients who had vancomycin associated acute kidney injury.
2417013|NCT03456544||None VAN-AKI|Patients who didn't have vancomycin associated acute kidney injury.
2417014|NCT03456531|Active Comparator|group 1|20 patients will receive pulsed radiofrequency for 6 minutes to suprascapular nerve
2417015|NCT03456531|Placebo Comparator|group 2|"20 patients will receive their medical treatment in the form of NSAIDs ibubrofen,Aspirin"
2417016|NCT03456505|Experimental|Mindfulness|Participants randomly assigned to the mindfulness meditation condition will meet for five, 15-minute sessions, in which they will receive training in basic mindfulness skills (Wallace, 2006).
2417017|NCT03456505|Active Comparator|Active Listening|Participants randomly assigned to the active listening condition will meet for five, 15-minute sessions, in which they will listen to Gilbert White's The Natural History of Selborne.
2417018|NCT03456492||case|Hyponatremic elderly patients (>70 years) with hip fractures
2417019|NCT03456492||control|Normonatremic elderly patients(>70 years) undergoing joint replacement
2417020|NCT03456466|Experimental|TQB2303|
2417021|NCT03456466|Active Comparator|Rituximab|
2417024|NCT03456440||hepatitis C child pugh's class A|patients are examined with MRI
2417025|NCT03456440||normal individuals|controls cases are examined with MRI
2417971|NCT03449784||patients with dyslipidemia non achieving LDL-C target|patients with dyslipidemia non achieving LDL-C target
3145667|NCT00077948|Experimental|active enoximone plus active ER metoprolol|
3145668|NCT00077948|Active Comparator|placebo enoximone plus active ER metoprolol|
3145669|NCT00077948|Placebo Comparator|placebo enoximone plus placebo ER metoprolol|
2417027|NCT03456414|Experimental|Virtual reality during hemodialysis|During 12 weeks subjects will exercise during hemodialysis. The intervention will be virtual reality exercise during hemodialysis.
2417028|NCT03456414|No Intervention|Control period - no exercise|During 12 weeks subjects will not exercise during hemodialysis
2417029|NCT03456401|Other|Sorafenib or Sunitinib|Sorafenib will be administered at 400 mg bid daily Sunitinib will be administered at 50 mg die orally (4 week on/2 weeks off)
2417030|NCT03456388|Experimental|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts . Each cohort will be administered in different dose once for 7 days.
2417031|NCT03456388|Active Comparator|Placebo Enteric-coated Tablets|There will be 7 ascending cohorts. placebo enteric-coate tablets to mimic Ammoxetine Hydrochloride Enteric-coated tablets.
2417032|NCT03456362|Active Comparator|Cerebellar iTBS|Intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
2417033|NCT03456362|Sham Comparator|Sham iTBS|Sham intermittent theta burst stimulation applied immediately before the daily physical therapy session for a period of three weeks.
2417034|NCT03456349|Experimental|Low dose|HTL0018318
2417035|NCT03456349|Experimental|Medium dose|HTL0018318
2417036|NCT03456349|Experimental|High dose|HTL0018318
2417037|NCT03456349|Placebo Comparator|Placebo|Placebo
3145671|NCT00078195|Experimental|Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT|Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
3145672|NCT00078195|Experimental|Omalizumab pre-treatment, omalizumab|Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
2417040|NCT03456323|Experimental|Palliative Care Consultation|After enrollment the palliative care consultation team will meet with the patient-surrogate pair one or more times to (1) assess symptoms, (2) provide supportive counseling, (3) make symptom treatment recommendations to the primary team of physicians, and (4) will address goals of care.
2417041|NCT03456323|Placebo Comparator|Usual Care|Patient-surrogate pairs randomized to usual care will continue to receive care by their primary physicians without having a palliative care consultation intervention offered.
2417042|NCT03456310|Experimental|Trans-perineal ultrasound|Transperineal ultrasonography is done by 2D ultrasound machine, curved probe is placed in the perineum, mid sagittal and axial views are obtained Then it's accuracy is assessed according to findings on dynamic pelvic MRI .
2417043|NCT03456297|Experimental|Experimental cluster|The Web-based clinical pedagogy program (WCP) will be provided to the participants in the experimental cluster.
2417044|NCT03456297|No Intervention|Control cluster|The participants in the control cluster will receive the current face-to-face preceptorship course.
2417045|NCT03456284|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device
2417046|NCT03456271||fracture group|
2417047|NCT03456271||non-fracture group|
2417048|NCT03456258|Experimental|Lactoferrin|To measure hemoglobin difference and serum ferritin
2417049|NCT03456258|Experimental|Ferrous sulphate|To measure hemoglobin difference and serum ferritin
2417051|NCT03456232|Experimental|High-flux hemodialysis|High-flux hemodialysis lasting for 4 hours
2417052|NCT03456232|Active Comparator|Hemodiafiltration|Hemodiafiltration lasting for 4 hours
2417053|NCT03456219|Experimental|Shift workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the normal protein diet.
2417054|NCT03456219|Experimental|Night workers|Night workers of the Hospital of Clinics of Uberlândia, Federal University of Uberlândia, received the high-protein diet.
2417055|NCT03456206||"Diet, Cancer and Health cohort"|"Participants from the Diet, Cancer and Health (DCH) cohort with no CID diagnosis at entry to the DCH study. The number of persons developing a CID (defined as at least one of the mentioned CIDs) during follow up (1993/1997 - 2018) and the number of persons not developing a CID will be investigated.~Based on the participants reporting of dietary habits in the Food Frequency Questionnaire (FFQ) from the DCH study, the exposure intake of red and processed meat and fibres will be investigated in both CID cases and non-cases.~Other exposure variables are Lifestyle factors independently or combined and are also obtained from the data in the DCH cohort."
2417057|NCT03456180||Haemoadsorption with Cytosorb cartridge|patients with septic shock and acute renal failure requiring renal replacement therapy with the haemoadsorption cartridge Cytosorb
2417058|NCT03456167|Experimental|Mobile app for follow-up care|Participants will use an app to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores daily for 2 weeks post-op & weekly for another 4 weeks. Surgeons will use a wireless interface to access that data and monitor the patient's condition. Participants will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, followup-related financial costs, and telemedicine satisfaction at 2 & 6 weeks post-op. They will attend prescribed follow-up appointments with their surgeon with the option to skip 1 or more follow-up appointments dependent on their recovery trajectory & surgeon.
2417059|NCT03456167|No Intervention|Conventional inperson followup care|The conventional follow-up care group will keep to conventional follow-up schedules of all surgeons involved. They will complete questionnaires and keep diaries related to satisfaction, medical system encounters, surgical complications, and followup-related financial costs at 2 & 6 weeks post-op and attend all scheduled follow up appointments.
2417060|NCT03456154|Experimental|Botox|In this group patients will receive 3 injections of botox on each masseter (left and right), after randomization. This injection will be performed once, and the patient will be evaluated after 3 and 6 months after this day.
2417061|NCT03456154|Active Comparator|Occlusal splint|In this group patients will receive an occlusal splint, which will be manufactured after taking their full mouth impression. This appliance has to be worn everyday, for 6 months, at night.
2417062|NCT03456128|Experimental|Intervention|The experimental group will receive CAPABLE services. These include ≤10 sessions: ≤ 6 with an Occupational Therapist (OT) and ≤ 4 sessions with a Registered Nurse (RN) and up to ≤ $1,500 of home safety and home modifications from a licensed handyman who is guided by the OT. The OT and RN sessions will target participants' self-identified functional goals (e.g., getting safely into the tub, getting upstairs to sleep in own bed).
2417063|NCT03456128|No Intervention|Usual Care|Participants in the usual care group will not receive visit from study clinicians and will continue to receive their usual VNSNY CHOICE benefits and healthcare.
2417064|NCT03456115|Experimental|Mechanical Nasal Dilator|All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
2417065|NCT03456102|Other|Pravastatin 80 mg|Pravastatin 80 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 2 will only be recruited if pravastatin 80 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
2417066|NCT03456102|Other|Pravastatin 120 mg|Pravastatin 120 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 3 will only be recruited if pravastatin 120 mg is well tolerated and safe, yet drug exposures are significantly reduced due to the known interaction with rifampin.
2417067|NCT03456102|Other|Pravastatin 160 mg|Pravastatin 160 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days
2417068|NCT03456102|Other|Pravastatin 40 mg|Pravastatin 40 mg, isoniazid 300 mg, rifampin 450 mg (weight <50 kg) or 600 mg (weight >50 kg), pyrazinamide 20-25 mg/kg, and ethambutol 15-20 mg/kg daily for 14 days Arm 4 will only be recruited if pravastatin 80 mg is not tolerated as specified in protocol.
2417069|NCT03456089|Other|Neurogenic Bladder Patients|Patients with neurogenic bladder undergoing urodynamics testing
3145673|NCT00078195|Active Comparator|Ragweed RIT, ragweed IT|Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
3145674|NCT00078195|Placebo Comparator|Placebo|Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
3145675|NCT00078247|Experimental|1|Participants will receive 6 months of ARV therapy and treatment for TB
3145676|NCT00078247|Experimental|2|Participants will not receive ARV therapy until CD4 counts drop below 250 cells/mm3. All participants will receive treatment for TB.
2417074|NCT03456050|Experimental|FRC group|This group will receive FRC exercise.
2417075|NCT03456050|Experimental|Conventional treatment|This group will receive conventional exercise.
2417076|NCT03456011|Other|BFA with Eufflexa injections|"BFA treatment before Sodium Hyaluronate injections.~Intervention: BFA"
2417077|NCT03456011|No Intervention|Anesthetic with Eufflexa injections|"Receiving Standard of care determined by their provider~No interventions"
2417078|NCT03455998||post surgery|Patienst consultation Questionnaires
2417079|NCT03455998||pre and post surgery|Patient consultation Questionnaires
2417080|NCT03455985|Experimental|Discharge Order Set (DOS)|Patients in the DOS group will receive instructions for self-titration of basal insulin as part of the discharge order. The DOS contains a comprehensive checklist for basic diet, hospital follow-up, glucose targets and instructions for monitoring, insulin pens and pen needles, glucose testing supplies, and ancillary orders. Phone calls will assess adherence with instructions for self-titration. Glucose lowering medication management following discharge will otherwise be conducted by the patient's usual or designated standard of care provider.
2417081|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
2417082|NCT03455972|Experimental|anti-CD19 and anti-BCMA CAR|Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (on d0) and anti-BCMA CAR T cells as split-dose (40% on d1 and 60% on d2)
2417083|NCT03455959|Experimental|Allergic Asthmatic or Healthy Control Adults|Allergic Asthmatic or Healthy Control Adults will undergo Bronchoscopy/BAL and airway brushing
2417084|NCT03455946|Experimental|Interventional|DASH Cloud with Alexa
2417085|NCT03455933|Experimental|Shockwave Light Pain Group|Sham Comparator. It will received a light intensity shockwave in the lateral epicondyle regulated until reach a 3/10 in the Visual Analog Scale (VAS) scale.
2417086|NCT03455933|Experimental|Shockwave Moderate Pain Group|Experimental Intervention. It will received a moderate intensity shockwave in the lateral epicondyle regulated until reach a 6/10 in the Visual Analog Scale (VAS) scale.
2417087|NCT03455933|Other|Cold Pressure Group|Control Group. The cold pressure test will be apply to this group. The investigators will use a container with an outer part filled with ice and an inner part filled with water, both separated by a screen that prevents direct contact between the ice and the hand. The water will be regularly stirred to maintain the temperature near to 0.7ºC.
2417088|NCT03455920|Experimental|Multidisciplinary arm|Patients randomized in this group will have their first sleep clinic evaluation with the clinical nurse. She will then discuss each case with the pulmonologist and validate the diagnostic and therapeutic avenue.
2417089|NCT03455920|Active Comparator|Pulmonologist arm|Patients randomized in this group will have their first sleep clinic evaluation with the pulmonologist.
2417090|NCT03455907||Patients|patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
2417091|NCT03455894|Experimental|Smart carpet|
3145677|NCT00078260|Experimental|A|
3145678|NCT00078260|Experimental|B|
2417092|NCT03455881||NICU TED Genetic Cohort|This study involves one inpatient biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
2417093|NCT03455881||NICU TED MRI Cohort|This study involves up to three inpatient NICU MRI encounters. The first MRI may be done before surgical repair if the clinical team feels the infant is clinically stable. The second MRI may be completed post-surgical repair of TED. An additional 3rd MRI may be done prior to the time of discharge from the NICU. The pre repair, post-surgical, and pre discharge MRIs will provide valuable data for the understanding of tracheal esophageal malformation disorders and may provide clinical guidance for the participant's care.
2417094|NCT03455881||TED Genetic Cohort|This study involves one biofluid collection encounter from the subject, one biofluid collection encounter from each biological parent, and an optional biofluid collection encounter from other biological family members.
2417095|NCT03455881||NICU Control MRI Cohort|This study involves two inpatient NICU MRI encounters. The first MRI will occur within the first month of life, and the second MRI will occur prior to discharge.
2417096|NCT03455868||Sleeve gastrectomy diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Sleeve gastrectomy
2417097|NCT03455868||Roux-in-Y gastric bypass diabetes|35 Men and women with type 2 diabetes and obesity undergoing bariatric surgery : Roux-in-Y gastric bypass
2417098|NCT03455868||Sleeve gastrectomy no diabetes|35 Men and women without type 2 diabetes and with obesity undergoing bariatric surgery : Sleeve gastrectomy
2417099|NCT03455868||Control|30 Men and women with a normal BMI and normoglycemia matched for age and sex with bariatric groups
2417100|NCT03455855|Experimental|treated with the Jetstream System|It is intended that all patients with qualifying lesions would be considered for enrollment and treated with the Jetstream System.
3145679|NCT00078273|No Intervention|Assessment Only Control|Completed Baseline and 6 month follow-up surveys only.
3145680|NCT00078273|Experimental|Personalized Feedback Intervention|See Intervention Description
2417104|NCT03455829|Experimental|Part 1: G1T38 + Osimertinib|Patients will receive a single oral dose of G1T38 on Cycle 1 Day -16 and on Cycle 1 Day -2. Patients will receive oral osimertinib 80 mg beginning Cycle 1 Days -14. Patients will begin G1T38 once-daily dosing on Cycle 1 Day 1 (in combination with osimertinib 80 mg).
2417105|NCT03455829|Experimental|Part 2: G1T38 + Osimertinib|Patients will be randomized to receive G1T38 at the dose determined in Part 1 in combination with osimertinib 80 mg, each administered once-daily.
2417106|NCT03455829|Active Comparator|Part 2: Osimertinib|"Patients will be randomized to receive osimertinib 80 mg once-daily.~At the time of disease progression per RECIST v1.1, patients who were initially randomized to receive osimertinib alone may crossover to receive G1T38 + osimertinib."
2417107|NCT03455816|Experimental|Group that uses the Social Diabetes App (research group)|This group use the App Social diabetes with the glucometer Glucomen Areo to monitoring the glucemia during 6 month
2417108|NCT03455816|Active Comparator|Usual clinical monitoring group (control group)|This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
2417109|NCT03455790|Experimental|Wheelchair Basketball|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
2417110|NCT03455790|Experimental|20 Meters Sprint Test|It will be done to evaluate the speed of sportsmen's wheelchair use. The sportsman will be prompted to take the chair as fast as possible after the wheelchair has been positioned so that the front bar is on the field edge. The 2 meter slow-down distance will also be counted in seconds and the completion time of the 20 meter track will be measured.
2417111|NCT03455790|Other|Slalom test|It will be done to measure the ability of sportsmen to use wheelchairs. Five cones will be placed starting 1.5 meters from the starting line of the Sahara, with a distance of 1.5 meters between them. Sportsmen will be required to complete the course by making a slalom between these topics and making a slalom in the same way by turning back and passing through the starting line. Track completion times will be recorded in seconds.
2417112|NCT03455790|Other|Zone Shot Test|Zone Shot test will be applied to evaluate the shooting skills of the athletes. In the starting position the athlete will be asked to shoot the pot from the athlete with the warning given while on the foul shooting line and then to take their own rebounds. They will have to shoot again from the point where they have taken the rebound and rebound and go back to the foul line. The test will continue for 2 minutes in this manner. At the end of the 2-minute training period, the athletes will score the correct shot 2, the missed shot 1 point and the total score will be recorded.
2417113|NCT03455790|Other|Aerobic Capacity|To measure aerobic capacity values, it shall be measured with Cosmed K5® device and Cosmos-Saturn branded treadmill using TS which is used in routine workout with customized ramp protocol. Before starting the test, the athlete's TS walking belt at a speed of 1 mph (1.7 km / h) at 0% incline for 3 min. and it will be checked whether or not the gas measuring equipment is disturbing the participant. If the athlete is unable to continue, the time at which the test will end will be determined. Time min. . The air that the individual exposes during the test will be collected using a breath by breath method.
2417114|NCT03455790|Other|Anaerobic Capacity|Using the Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement, TS basketball athletes will be subjected to a Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions.
2417115|NCT03455790|Other|Isokinetic shoulder muscle strength|Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer.
2417116|NCT03455777|Experimental|AKCEA-ANGPTL3-LRX Dose 1|
2417972|NCT03449784||patients with dyslipidemia achieving LDL-C target|patients with dyslipidemia achieving LDL-C target
2417119|NCT03455751|No Intervention|Control|The control arm will receive no intervention and will follow standard of care for post-operative pain management.
2417120|NCT03455751|Experimental|PGx-guided|The PGx-guided arm will received altered post-operative pain management based on the results of pharmacogenomic testing.
2417121|NCT03455725|Active Comparator|CardiAMP cell therapy system|"Roll-in phase:~Up to 10 subjects with refractory chronic myocardial ischemia CCS class III-IV will be treated in an unblinded, uncontrolled roll-in phase.~In the subsequent randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 222 Subjects will be randomized to treatment with the CardiAMP cell therapy system."
2417122|NCT03455725|Sham Comparator|Sham procedure control|"Randomized phase:~Up to 333 subjects with refractory chronic myocardial ischemia CCS class III-IV will be randomized. Up to 111 subjects will be treated with a Sham Treatment (no introduction of trans endocardial delivery catheter and no administration of autologous cells)"
2417123|NCT03455712|Experimental|Intervention|Subjects to receive the Gestational Weight Gain Card at enrollment in addition to standard prenatal care.
2417124|NCT03455712|No Intervention|Standard-of-Care|No intervention to be delivered. Subjects to receive standard prenatal care.
2417125|NCT03455699||Experimental: VenaSeal SCS|Endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
2417126|NCT03455699||Active Comparator: RFA|Endovenous insertion of the ClosureFast radiofrequency ablation (RFA) catheter into a target site in diseased great saphenous veins (GSV). Heat is applied to the target vein using radiofrequency energy to ablate the target vein. Subjects were randomized in a 1:1 ratio to either VenaSeal SCS or to RFA at the time of enrollment into the VeClose study (NCT01807585).
2417127|NCT03455699||Experimental: Roll-in (VenaSeal SCS)|Prior to initiation of the randomized cohort at each site for the VeClose study (NCT01807585), a non-randomized cohort of 2 subjects per site (roll-in phase) were enrolled and treated with VenaSeal SCS with endovenous delivery of VenaSeal Adhesive (VA) to a target site in diseased great saphenous veins (GSV). The VA is dispensed in small amounts with each pull of the trigger equaling 0.10 cc.
2417128|NCT03455686|Experimental|Patients with and without lung disease|All enrolled patients will undergo pulmonary function testing, questionnaires, 1H MRI, static ventilation and/or diffusion-weighted hyperpolarized 129Xe MRI and sputum induction at one or more timepoints over five years.
2417129|NCT03455673||Atrial fibrillation|ATE score will be determined for patients hospitalized for ablation of atrial fibrillation or symptomatic left atrial tachycardia
2417130|NCT03455660||Pre-January 2015|Patients who underwent cesarean delivery between February 2013 and December 2014.
2417131|NCT03455660||Post-January 2016|Patients who underwent cesarean delivery between February 2016 and December 2017.
2417132|NCT03455647|Experimental|ASF Promotion plus Girinka|Participants have received a cow from the government of Rwanda through the Girinka program and will receive an animal source food promotion intervention from the study.
2417133|NCT03455647|No Intervention|Girinka only|Participants have received a cow from the government of Rwanda through the Girinka program and will not receive any intervention from the study.
2417134|NCT03455647|No Intervention|Girinka eligible|Participants are eligible to receive a cow through the government of Rwanda Girinka program, but have not yet received a cow. They will not receive any intervention from the study.
2417135|NCT03455634|Active Comparator|Twin Block|Twin Block functional appliance
2417136|NCT03455634|Active Comparator|Sander|Sander bite jumping appliance
2417137|NCT03455634|No Intervention|Control|no intervention
2417138|NCT03455621|Placebo Comparator|Pea-size amount of non-F dentifrice|Non-fluoride dentifrice (0 ppm F); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
2417139|NCT03455621|Experimental|0.025 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.025 g
2417140|NCT03455621|Experimental|0.05 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.05 g
2417141|NCT03455621|Experimental|0.1 g of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.1 g
2417142|NCT03455621|Active Comparator|Pea-size amount of 1,100 ppm F dentifrice|Fluoride dentifrice (1,100 ppm F, as NaF); to be used twice/day. Amount to be used: 0.3 g (pea-size amount)
2417143|NCT03455608|Active Comparator|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified (RE-ACTIVE)
2417144|NCT03455608|Active Comparator|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
2417145|NCT03455608|Active Comparator|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
2417146|NCT03455582|Experimental|patient|PPMS diagnosis according to McDonald 2010 criteria (Polman et al, 2011)
2417147|NCT03455582|Active Comparator|Control|40 Healthy controls
2417148|NCT03455569|Experimental|Behavioral sleep education|manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
2417149|NCT03455569|Experimental|Education only|education on sleep, aging, and dementia but without specific or individualized recommendations
3186137|NCT00742131|Experimental|Subjects receiving GSK1363089|Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.
3186138|NCT00742144|Experimental|ofatumumab|Japanese patients with CD20 positive follicular lymphoma or chronic lymphocytic leukemia
3186139|NCT00742157|No Intervention|UNMC Group|Compare the low and high dose effects of Growth Hormone from previously pooled patients (high dose) and UNMC patients (low dose).
2417153|NCT03455530|Experimental|Intervention Group|The intervention group will receive the IH-enhanced CHW intervention before (~3 months) the other arm (Delayed Intervention Group).
2417154|NCT03455530|Other|Delayed Intervention Group|The delayed intervention group will receive the IH-enhanced CHW intervention after (~3 months) the other arm (Intervention Group).
3186140|NCT00742196||1|No parapapillary atrophy
2417156|NCT03455504|Experimental|Cohort 1|FLAI + V400 mg
2417157|NCT03455504|Experimental|Cohort 2|FLAI + V600 mg
3186141|NCT00742196||2|Parapapillary atrophy
2417161|NCT03455478|Experimental|corrected refractive error|
2417162|NCT03455478|No Intervention|uncorrected refractive error|
2417163|NCT03455465||No intervention|Patients in this arm will not be approached by community health workers during their visit to the Emergency Department.
2417164|NCT03455465||Community Health Worker Program|Participants in this group will be approached by a community health worker during their visit to the Emergency Department with the goal of enrolling them in a comprehensive post-discharge program.
2417165|NCT03455452||Cohort 1: Nivolumab|Participants diagnosed with advanced renal cell carcinoma (RCC) and whose physician has decided to initiate a treatment with Nivolumab for the first time for the treatment of RCC
2417166|NCT03455452||Cohort 2: Nivolumab + Ipilimumab|Participants diagnosed with advanced RCC and whose physician has decided to start a new systemic therapy with nivolumab + ipilimumab for the first time for the treatment of RCC
3145681|NCT00078273|Experimental|Cognitive Behavioral Intervention|See Intervention Description
2417168|NCT03455426|Experimental|letrozole group|letrozole 5mg/day starting from day 3 of menstrual cycle for 5 days
2417169|NCT03455426|No Intervention|natural cycle group|
2417170|NCT03455387||sampling of serum marker Flt1 and PIGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
2417171|NCT03455374|Experimental|Treatment with CSI atherectomy device|removal of the plaque from vessel wall by optical coherence tomography
2417172|NCT03455361||Stark Implant with low primary stability|Patient who had received bone level V-Blast implants with low primary stability.
2417173|NCT03455361||Stark Implant with primary stability|Patient who had received bone level V-Blast implants and achieved primary stability.
2417174|NCT03455348|No Intervention|cathete to less than 4 four centimeters to the wrist joint|
2417175|NCT03455348|Active Comparator|catheter to more than four centimeters to the wrist joint|
2417176|NCT03455335|Experimental|low dose cohort|20 million hMSCs .
2417177|NCT03455335|Experimental|mid dose cohort|40 million hMSCs
2417178|NCT03455335|Experimental|high dose cohort|80 million hMSCs .
2417179|NCT03455322|Active Comparator|norepinephrine|norepinephrine continuous intravenous infusion in a dose of 0.05-0.3ug/Kg/min. average7-10 days to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days.
2417180|NCT03455322|Active Comparator|midodrine & octreotide|midodrine 5mg three times/day orally & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6hS.C. for 7-10 days
2417181|NCT03455309|Active Comparator|NDV-3A|0.5 mL dose containing 300 micrograms of recombinant Als3 protein in phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
2417182|NCT03455309|Placebo Comparator|Placebo|0.5 mL dose containing phosphate-buffered saline and 0.5 mg aluminum as aluminum hydroxide
2417183|NCT03455296|Active Comparator|central venous oxygen saturation ScVO2 normalization|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids (Ringer, Ringer acetate or saline 0.9%) 500ml / 30 min. guided by ScVO2with target value ≥ 70%
2417184|NCT03455296|Active Comparator|Lactate clearance|Fluid therapy is initiated with maintenance fluid (Ringer or Ringer acetate) plus replacement with crystalloids 500ml / 30 min. guided by lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study
2417185|NCT03455283||Clariscan 0.5 mmol/ml|Participants will receive Clariscan 0.5 mmol/ml injection as apart of clinical practice at the medical discretion of the prescribing physician.
2417186|NCT03455283||All Gadolinium-Based Contrast Agents (GBCAs)|Participants will receive GBCA as part of clinical practice at the medical discretion of the prescribing physician.
2417187|NCT03455270|Experimental|Part 1: Dose Escalation (G1T48)|"Patients in Part 1 will receive a single oral dose of G1T48 on Cycle 1 Day -3 and will begin once-daily dosing on Cycle 1 Day 1.~The initial dose cohort shall receive an identified starting dose and subsequent cohorts shall receive higher doses based on the safety and PK data obtained from the previous dose levels."
2417188|NCT03455270|Experimental|Part 1: Food Effect Cohort (G1T48)|"In Part 1, additional G1T48 cohort(s) of 8 patients may be enrolled to assess the effect of different fat content meals (eg, high fat, moderate fat, or low-fat) on the rate and extent of the absorption of G1T48.~Patients will receive a single oral dose of G1T48 on Cycle 1 Day -10 and on Cycle 1 Day -3. Patients will begin G1T48 once-daily dosing on Cycle 1 Day 1."
2417189|NCT03455270|Experimental|Part 2: Monotherapy Dose Expansion (G1T48)|Patients in Part 2 will receive G1T48 once-daily at the dose determined in Part 1.
2417190|NCT03455270|Experimental|Part 3: Combination Dose Expansion (G1T48+palbociclib)|Patients in Part 3 will receive G1T48 once-daily at the dose determined in Part 2 in combination with palbociclib once-daily on Days 1 to 21 of each 28-day cycle.
2417191|NCT03455257|No Intervention|Control|Families assigned to this arm will be assessment only controls that do not receive the cash transfer.
2417192|NCT03455257|Experimental|Intervention|Families assigned to this arm will recieve a cash transfer following an in-depth conversation with the head of household and the signing of a contract stating they understand the purpose of the study.
2417193|NCT03455231|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation
3145682|NCT00078390|Experimental|S-3304 plus chemo-irradiation|The tolerable dose of S-3304 determined in the Phase 1 part of the study will be dosed BID along with a standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy
3145683|NCT00078390|Active Comparator|Chemo-irradiation|The standard of care regimen of radiation and paclitaxel/carboplatin chemotherapy will be administered
2417196|NCT03455205|Experimental|shenqifuzheng injection|"Shenqifuzheng injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens:~Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio All test drugs should be covered with dark bags before infusion, and use a dark infusion to guarantee the implementation of the blind method."
2417197|NCT03455205|Placebo Comparator|0.9% sodium chloride injection|0.9% sodium chloride injection of 500 ml,intravenous drip, 1 times a day, 7 days post, rest is 14 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment,The programme provides for chemotherapy regimens: Colorectal cancer: CapeOX scheme - oxaliplatin + capecitabine Esophageal cancer: DP/TP programme - docetaxel/paclitaxel + cisplatin/carboplatin Gastric cancer: SOX scheme - oxaliplatin + tigio No interventions have been included in Arm Description for '0.9% sodium chloride injection'
2417198|NCT03455192|Experimental|Synbiotic supplements|One synbiotic tablet, per day, during 30 days
2417199|NCT03455192|Placebo Comparator|Placebo Oral Tablet|One placebo tablet , per day, during 30 days
2417200|NCT03455179|Experimental|Slow-speed traditional resistance training|Resistance training with variable resistances (elastic band) at high intensity and slow-speed (2s of concentric contraction and 2s of eccentric contraction) twice a week over 20 weeks.
2417201|NCT03455179|Experimental|High-speed resistance training|Resistance training with variable resistances (elastic band) at low intensity and high-speed (''as fast as possible´´ for the concentric contraction, pause for 1 second and 2-3 seconds for the eccentric contraction) twice a week over 20 weeks.
2417202|NCT03455179|Experimental|Multicomponent training|Training sessions with balance, resistance, aerobic, flexibility and coordination components twice a week over 20 weeks.
2417203|NCT03455179|No Intervention|Control|Participants randomized into the CONTROL group will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
2417204|NCT03455166|Other|Psoriasis|
2417205|NCT03455166|Other|Psoriatic arthropathy|
2417206|NCT03455153||Most active|COPD patients with higher physical activity levels as defined by daily step counts.
2417207|NCT03455153||Least active|COPD patients with lower physical activity levels as defined by daily step counts.
2417208|NCT03455140|Experimental|Group 1 - Leukaemia|PEG- BCT-100 in patients with Leukaemia Starting dose 1600U/Kg IV infusion weekly
2417209|NCT03455140|Experimental|Group 2 - Neuroblastoma|PEG- BCT-100 in patients with Neuroblastoma Starting dose 1600U/Kg IV infusion weekly
2417210|NCT03455140|Experimental|Group 3 - Sarcomas|PEG- BCT-100 in patients with Sarcomas Starting dose 1600U/Kg IV infusion weekly
2417211|NCT03455140|Experimental|Group 4 - High Grade Glioma|PEG- BCT-100 in patients with High Grade Gliomas Starting dose 1600U/Kg IV infusion weekly
2417212|NCT03455127|No Intervention|Classic Public Works as Usual|Half of the sample will be eligible to receive or be receiving the Government of Rwanda's (GOR) flagship social protection programming, Vision 2020 Program (VUP). One component of this program is to provide cash for work opportunities for labor endowed vulnerable households, i.e. one able bodied adult. Vulnerable households are those in Poverty Level 1 category, the GOR's poverty classification system. Furthermore, this study will require households in the control group receiving classic public works as usual to have at least one child between the ages of 6 months to 36 months.
2417213|NCT03455127|Experimental|Classic Public Works + FSI ECD|Half of the sample will receive the FSI ECD home visiting parenting program alongside the GOR's classic public works programming. These households will be in Poverty Level 1 with an able-bodied adult, thus eligible to receive or be received the GORs public works programming. They will have a child between 6 and 36 months at enrollment. Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
2417214|NCT03455114|Experimental|capsular fixation surgery|patients required capsule centration safely undergo capsular fixation surgery with AssiAnchor under local anesthesia .
2417215|NCT03455101||Patients with diabetes mellitus|Patients with type 1 or type 2 diabetes who were under follow-up in the same center for at least a year.
2417216|NCT03455088|Experimental|DBT group|DBT group has 55 patients, maybe will be divided them into 6 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time.
2417217|NCT03455088|Active Comparator|Drug therapy group|Drug therapy group has 55 patients, and the investigator may use fluoxetine as treatment drug.
2417218|NCT03455088|Experimental|DBT and drug therapy group|DBT and drug therapy group has 55 patients, maybe the investigator can divide them into 7 groups. Every group has 8-10 patients. Every group receive 12 times DBT group therapy and 1 times a week for 120 minutes each time. At the same time, the investigator use fluoxetine as treatment drug.
2417219|NCT03455075|Experimental|Lower DMAU + LNG|DMAU 100 mg + LNG 30 mcg administered orally in capsules.
2417220|NCT03455075|Experimental|Middle DMAU + LNG|DMAU 200 mg + LNG 30 mcg administered orally in capsules.
2417221|NCT03455075|Experimental|Middle DMAU + Placebo|DMAU 200 mg + placebo administered orally in capsules.
2417222|NCT03455075|Experimental|Higher DMAU + Placebo|DMAU 400 mg + placebo administered orally in capsules.
2417223|NCT03455075|Placebo Comparator|Placebo|Placebo administered orally capsules.
2417224|NCT03455049|Experimental|Normal subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
2417225|NCT03455049|Placebo Comparator|Normal subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
2417226|NCT03455049|Experimental|Prediabetes subject experimental|Participants get Andrographis Paniculata Extract 550 mg, two capsules, twice a day, for 14 days.
2418122|NCT03448770|Experimental|Polyethlene Glycol|PEG (Polyethlene Glycol)- 17 gm sachet 3-4 times per day
2417227|NCT03455049|Placebo Comparator|Prediabetes subject placebo|Participants get placebo consist of Lactose 98%, Mg 2%, two capsules, twice a day, for 14 days.
2417228|NCT03455036|Experimental|Whole body vibration training|Healthy female subjects complete whole body vibration training (10 x 1 min exposure)
2417229|NCT03455023|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care.
2417230|NCT03455023|No Intervention|control group|Patients will receive usual medical care.
2417231|NCT03455010|No Intervention|Normal load|Healthy subjects walking for 30 minutes on a treadmill with normal body weight
2417232|NCT03455010|Experimental|Increased load|Healthy subjects walking for 30 minutes on a treadmill with 20% additional body weight
2417233|NCT03455010|Experimental|Reduced load|Healthy subjects walking for 30 minutes on a treadmill with 20% lower body weight
2417234|NCT03454997|Active Comparator|Standard Implementation Intervention|The standard version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings.
2417235|NCT03454997|Active Comparator|Enhanced Implementation Intervention|The enhanced version will train community mental health program staff to become ACHIEVE-D coaches and peers to become ACHIEVE-D peer-leaders, will include in-person and online training and avatar-assisted motivational interviewing practice as well as organizational strategy meetings. The enhanced version will also include performance coaching.
2417236|NCT03454984|Experimental|SGI-110|"SGI 110 (Guadecitabine) will start on day 40, In case the patient is not eligible yet, he should be assessed again each 30 days until day 130, after what, he is not considered eligible for a preventive treatment by SGI.~Initial dose will be 30/m2/day SQ for 5 days~total 10 cycles of SGI-110"
2417237|NCT03454971|Experimental|MinOS arm|Patients are followed according to MinOS protocol:
2417238|NCT03454958||Data collection|Data will be collected at four time points over the course of approximately one year and nine months. Participating couples (women and men) will be recruited during the first trimester of their first pregnancy. First measurement will take place in the week of the first routine ultrasound scan (week 12 of pregnancy) (=T0). First follow-up measures will take place six weeks postpartum (=T1). The second and third follow-up measurements will take place at six months postpartum (=T2) and twelve months postpartum (=T3).
2417239|NCT03454945|Experimental|Doxycyline|Oral Vibramycin antibiotic100 mg capsule every 12 hours for 3 months
2417240|NCT03454945|Active Comparator|Phototherapy|UVA+ psoralen 3 sessions per week for 3 months
2417241|NCT03454932||Rheumatoid Arthritis|Patients with Rheumatoid Arthritis
2417242|NCT03454932||Psoriatic Arthritis|Patients with Psoriatic Arthritis
2417243|NCT03454932||Spondylarthritis|Patients with Spondylarthritis
2417244|NCT03454919|Other|Palbociclib|single arm
2417245|NCT03454906||L Hemoglobin|L Hemoglobin: consistently low all 6 months with low hemoglobin levels
2417246|NCT03454906||T Hemoglobin|T Hemoglobin; consistently within the target range all 6 months with target-range hemoglobin levels
2417247|NCT03454906||H Hemoglobin|H Hemoglobin: consistently high all 6 months with high hemoglobin levels
2417248|NCT03454906||LAL Hemoglobin|LAL Hemoglobin: low amplitude fluctuation with low hemoglobin; all 6 months with low or target range hemoglobin levels
2417249|NCT03454906||LAH Hemoglobin|LAH Hemoglobin: low-amplitude fluctuation with high hemoglobin levels 6 months with target-range or high hemoglobin levels)
2417250|NCT03454906||HA Hemoglobin|HA Hemoglobin ; high-amplitude fluctuation low, target-range, and high hemoglobin levels within the 6 month period
2417251|NCT03454893|Experimental|Single Assignment AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
2417252|NCT03454867|Experimental|Hemofiltration (treatment)|Standard acute ischemic stroke treatment + hemofiltration Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
2417253|NCT03454867|Active Comparator|Control|Standard acute ischemic stroke treatment Standard treatment included thrombolytic therapy for eligible candidates (tPA 0,9 mg/kg, max dose 90 mg)
2417254|NCT03454854|Experimental|APP-assisted anti-thrombotic therapy|Intelligent response system:real-time receiving data or events that doctor or patient terminal upload,then spontaneously evaluate the thrombosis and bleeding risk based on code of point built-in,respectively send messages to doctor and patient after this, then doctors direct the patients to adjust treatment schedule.Develop an exemplary anti-thrombotic therapy network data platform and a intelligent terminal APP, establish an new pattern used in long-time anti-thrombotic management based on dynamic risk evaluation, and promoted and verified by 10 thousands large sample's cohort study.
2417255|NCT03454841||Prasugrel|Patients with myocardial infarction will receive prasugrel as a part of dual antiplatelet therapy with aspirin.
2417256|NCT03454841||Ticagrelor|Patients with myocardial infarction will receive ticagrelor as a part of dual antiplatelet therapy with aspirin.
2417257|NCT03454828|Experimental|obese carbohydrate diet|Obese adolescents with a body mass index (BMI) >95th percentile.
2417258|NCT03454828|Active Comparator|lean carbohydrate diet|Lean adolescents with a body mass index (BMI) <85th percentile.
2417259|NCT03454815|Experimental|Patency Group|apical patency was maintained during chemomechanical preparation
2417260|NCT03454815|No Intervention|Non Patency Group|Apical patency was not maintained during chemomechanical preparation
2417261|NCT03454802|Active Comparator|Normal subjects|Normal subjects 'Passive Leg Raising'
2417262|NCT03454802|Active Comparator|ICU patients|ICU patients 'Passive Leg Raising'
2417263|NCT03454802|Active Comparator|Cardiac Outpatients|Cardiac Outpatients 'Passive Leg Raising'
2417264|NCT03454789|Active Comparator|LB Group|Ultrasound-guided brachial plexus block for LB Group (15 ml lidocaine 1% + 15 ml bupivacaine 0.5%)
2417265|NCT03454789|Active Comparator|BS Group|Ultrasound-guided brachial plexus block for BS Group (20 ml bupivacaine 0.5% + 10 ml normal saline)
2417266|NCT03454789|Active Comparator|LS Group|Ultrasound-guided brachial plexus block for LS Group (20 ml lidocaine 1% + 10 ml normal saline)
2417267|NCT03454789|Active Comparator|BL Group|and Ultrasound-guided brachial plexus block for BL Group (20 ml bupivacaine 0.5% + 10 ml lidocaine 1%)
2417268|NCT03454776|Active Comparator|Unloader One brace|Patients receiving an active brace, Unloader One with active straps facilitating unloading of affected knee compartment
2417269|NCT03454776|Placebo Comparator|Placebo brace|Patients receiving a dummy, lookalike or placebo brace without active straps that facilitate unloading of the affected knee compartment
2417270|NCT03454763|Experimental|Arm A, Intensive|Arm A, Intensive every 5 weeks
2417271|NCT03454763|Experimental|Arm B, Non Intensive|Arm B, Non Intensive every 8-10 weeks
2417272|NCT03454750|Experimental|177Lu-PSMA|177Lu PSMA
2417273|NCT03454737|Experimental|mesenchymal stem cells|
2417274|NCT03454737|Active Comparator|Pure platelet-rich plasma|
2417275|NCT03454724|Experimental|MeRes100 BRS|MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
2417276|NCT03454724|Active Comparator|Xience EES|Xience EES is a Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
2417277|NCT03454711|Experimental|Patient with food addcitions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
2417278|NCT03454711|Experimental|Patients without food addictions|"Patients (20) will be selected from the Yale Food Addiction Scale (YFAS): a validated screening of FA questionnaire.~Three clinical visits will be realized in less than two months"
2417279|NCT03454698|Other|Contol|"Usual care for patients in the CG is defined as follows: Visits to the outpatient wound-care centre as directed by a physician. Wound care performed by the wound expert according to the hospital's own standards. This standard corresponds to the one from the EWMA."
2417280|NCT03454685||NCSLC group|NSCLC patients,including stage I to stage IV.
2417281|NCT03454685||Healthy subjects|healthy subjects
2417282|NCT03454672|Experimental|Tixel|Tixel Treatment.
2417283|NCT03454672|Active Comparator|Laser|Laser Treatment.
2417284|NCT03454659||high (0.8 )|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients are undergoing supratentorial craniotomy surgeons.
2417285|NCT03454659||low (0,4) fiO2|The purpose of this study is to compare the effect of high 0.8 and low 0.4 FiO2 ventilation primarily on surgical field infection and secondarily on postoperative pulmonary complications in patients undergoing supratentorial craniotomy surgeons.
2417286|NCT03454646|Experimental|Group randomized for continuing treatment|"Group who continues the cholinesterase inhibitors (CI). The treatment is one of the CI (donepezil, galantamine or rivastigmine) with market authorization and commercialized for more than 15 years in France. The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual.~All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
2417287|NCT03454646|No Intervention|Group randomized for stopping treatment|Group who stops the CI. No placebo will be given, over 2 years All randomised patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
2417288|NCT03454633|Experimental|Mild hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 28.1 - 34 degrees Celsius
2417289|NCT03454633|Active Comparator|Moderate hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass at temperature 20.1 - 28 degrees Celsius
2417290|NCT03454620|Experimental|GC1118 combination with irinotecan|GC1118 weekly(3mg or 4mg) + irinotecan 180mg/m2 biweekly dosing
2417291|NCT03454620|Experimental|GC1118 combination with FOLFIRI|GC1118 weekly(3mg or 4mg) + FOLFIRI biweekly dosing
2417292|NCT03454607|Experimental|FREE robot|Patients undergoing sinus surgery with the FREE robot
2417293|NCT03454594|Experimental|low level laser hemotherapy|Watch laser acupuncture and nasal irradiation
2417294|NCT03454594|No Intervention|control|all the participants in this group did not receive low level laser irradiation during the study period
3186142|NCT00742222|Other|single arm, treatment with FDA cleared technology|Patients who have early stage breast cancer, and are candidate for intracavitary accelerated partial breast irradiation may be considered for this study.
3186143|NCT00742248|Active Comparator|A|Formoterol pMDI
3186144|NCT00742248|Active Comparator|B|Formoterol dry powder
2417298|NCT03454555|Active Comparator|Arm 1|Arm 1 patients will receive guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Shared Decision-Making (SDM) intervention.
2417299|NCT03454555|Active Comparator|Arm 2|Arm 2 patients will receive the guideline-concordant pharmacotherapy based on clinical guidelines for opioid therapy for chronic noncancer pain plus the Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT+CP) Intervention.
2417300|NCT03454542|Experimental|Menicon DSRB Redesign|Menicon DSRB Modified Lens Design is a single use contact lens with revised thickness specifications worn for 6 hours or more.
2417301|NCT03454542|Active Comparator|Menicon DSRB Original Design|Menicon DSRB Initial Lens Design is a single use contact lens with the original thickness specifications worn for 6 hours or more.
2417302|NCT03454529|Experimental|Treatment (simvastatin)|Patients receive simvastatin PO daily for 2-4 weeks in the absence of disease progression or unacceptable toxicity.
2417303|NCT03454516|No Intervention|Standard Care|This group is the usual standard treatment group
2417304|NCT03454516|Other|Telemonitoring group|This group will followed up with telemonitoring
2417305|NCT03454503||First cohort|Newly diagnosed patients
2417306|NCT03454503||Second cohort|Patients switched from reference product (Glivec® )
2418152|NCT03448510|Experimental|Irreversible electroporation treatment|Subjects will receive irreversible electroporation of the prostate
3186145|NCT00742248|Placebo Comparator|C|Placebo pMDI DPI
3186146|NCT00742261|Experimental|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
3186147|NCT00742287|Placebo Comparator|1|placebo
2417307|NCT03454477|Experimental|conventional open surgery|Patients who met the inclusion criteria were selected for a conventional open surgery procedure for a conventional neck incision for thyroid surgery.
2417308|NCT03454477|Experimental|endoscopic thyroidectomy|Patients who met the inclusion criteria were selected to undergo thyroid surgery via endoscopic thyroidectomy
2417309|NCT03454477|Experimental|robotic thyroidectomy|Patients who met the inclusion criteria chose the Da Vinci robot for thyroid surgery.
2417310|NCT03454464|Sham Comparator|Conventional operation group|Conventional operation group,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure.
2417311|NCT03454464|Experimental|central neck dissection first group|central neck dissection first group,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
2417312|NCT03454451|Experimental|Cohort 1a|CPI-006
2417313|NCT03454451|Experimental|Cohort1b|CPI-006 + ciforadenant
2417314|NCT03454451|Experimental|Cohort 1c|CPI-006 + pembrolizumab
2417315|NCT03454451|Experimental|Cohort 2a|CPI-006
2417316|NCT03454451|Experimental|Cohort 2b|CPI-006 + ciforadenant
2417317|NCT03454451|Experimental|Cohort 2c|CPI-006 + pembrolizumab
2417318|NCT03454438|Experimental|Algorithm|Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
2417319|NCT03454438|Experimental|Triage|Triage by rheumatologist in a primary care setting.
2417320|NCT03454438|No Intervention|Usual care|Control group consisting of usual care.
2417321|NCT03454425|Experimental|Exablate Subthalamotomy|Exablate treatment for Parkinson's Disease Motor Features
2417322|NCT03454425|Sham Comparator|Sham ExAblate Subthalamotomy|
2417323|NCT03454399|No Intervention|TEE image before suction|Suction orogastric tube which is attached to TEE probe
2417324|NCT03454399|Experimental|TEE image after suction|Suction orogastric tube which is attached to TEE probe
2417325|NCT03454386|Active Comparator|Active Treatment|"Stress Management and Resilience Training Program~This group will be initially enrolled in the program."
2417326|NCT03454386|Other|Control|"Self-Management Stress Reduction Program~This group will be placed in a self-management stress reduction program. During this time these participants will be given a popular stress reduction book to read over 12 weeks. They will complete questionnaires at weeks 4 and 12. After the 12 weeks, this group will be enrolled in the online SMART program and complete assessments at week 24 (upon completion of the program."
2417327|NCT03454373|Experimental|Incentive for return to care|"Standard of care HIV primary care services, including counseling to return to care, plus a one-time re-start incentive of 22,500 TZS to return to care."
2417328|NCT03454373|No Intervention|Comparator|Standard of care HIV primary care services, including counseling to return to care.
2417329|NCT03454347|Experimental|Protein Supplementation Group|Participants in this group will complete two weeks of lower limb suspension and receive 75g/day of supplemental protein in addition to education aimed at increasing protein intake through their diet.
2417330|NCT03454347|Active Comparator|Non-Supplemental Group|Participants in this group will complete two weeks of lower limb suspension and will receive no supplementation or nutritional education.
2417331|NCT03454334|Active Comparator|AMO Tecnis Symfony|"Multifocal with extended range of vision, Diffractive, No Preloaded, Aspheric, +3.25 D near add and +2.17 D intermediate 6.0mm Hydrophilic~-0.20~Has nine diffractive steps, The proprietary achromatic technology corrects chromatic aberration. This creates improved contrast sensitivity."
2417332|NCT03454334|Active Comparator|AcrySof ReSTOR (Alcon Laboratories)|"Multifocal ,Diffractive, +3.00D and for Near, Aspheric, Has 9 steps (rings), Light: 41% for far; 41% for near: 18% reflected (lost).~6.0mm Silicone~-0.10 Bifocal ,One piece,Blue filter ,Central diffractive region of 3.6_mm for near and distance vision ,Apodised ,peripheral refractive region is dedicated to distance vision"
2417333|NCT03454334|Active Comparator|AT Lisa tri (CarlZeiss Meditec AG)|Trifocal, diffractive, +3.33 D near add and +1.66 D intermediate add at the IOL plane, aspheric (aberration correcting) Optic Diameter 6.0 mm Total Diameter 11.0 mm Haptic Angulation 0° Lens Design Single-piece, MICS Incision Size 1.8 mm Company Labeled A-Constant1 118.6 Diopter Range 0.0 to +32.0 D, 0.5 D increments ACD 5.32
2417334|NCT03454334|Active Comparator|PanOptix(Alcon Laboratories)|"Trifocal,Difractive,+3.25D Near,+2.17 D intermediate 6.0mm hydrophobic~-0.27 One piece ,aspheric , Focal 4.5 mm (15 diffractive zones)"
3145684|NCT00078442|Experimental|1|Participants will receive weekly injections of 180 mcg PEG-IFN alfa-2a at the clinic for 12 weeks. After Week 12, participants will be followed off-treatment until Week 18.
3186148|NCT00742287|Active Comparator|2|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)
2417339|NCT03454282|Experimental|FMD Arm|The intervention consists in 5-day FMD (Fasting Mimicking Diet) to be followed for one cycle (Cohorts A and B) or for 4 consecutive every-four week cycles postoperatively.
2417340|NCT03454269|Active Comparator|PD patients with visual hallucinations (PD-VH)|PD patients without hallucinations or illusions
2417341|NCT03454269|Active Comparator|Patients with illusions (PD-I)|PD patients with Illusions and without hallucinations
2417342|NCT03454269|Active Comparator|Patients without visual hallucinations or illusions (PD-nVHI))|PD patients without Illusions and with hallucinations
2418953|NCT03443050|Active Comparator|Control|Balance training on stable surface
2417343|NCT03454256|Experimental|Virtual Reality Group (VRG)|The Virtual Reality Group (VRG) will perform the rehabilitation trough the Virtual Reality Rehabilitation system (VRRS, Khymeia,Italy). The patient standing upright on a balance board will practice exercises of vertical position control with a visual biofeedback received from the VRRS and interacting with the serious video-games. The difficulty level of the exercises will increase gradually session by session. Every session will last 45 minutes with a frequency of at least 5 times a week.
2417344|NCT03454256|No Intervention|Control Group (CG)|The Control Group (CG) will perform the traditional treatment consisting of the exercises of rehabilitation of gait and postural passages, exercises for postural control, and proprioceptive exercises in a vertical position according to the method chosen by the physiotherapist. Every session will last 45 minutes with a frequency of at least 5 times a week.
2417345|NCT03454243|Experimental|RXDX-106|
2417346|NCT03454230|Experimental|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
2417347|NCT03454230|No Intervention|Common repositioning practice|pressure ulcer prevention cares are provided according to usual practice. Frequency and modality of positioning applied to the patients are collected.
2417348|NCT03454217|Active Comparator|Oxycodone|Postoperative pain treatment with oxycodone
2417349|NCT03454217|Active Comparator|Tramadol|Postoperative pain treatment with tramadol
2417350|NCT03454204||Pharmacokinetic|Establish a pharmacokinetic relationship between plasma concentration and the effect of norepinephrine in patients under concentration-target intravenous anesthesia by identifying significant covariates during general anesthesia.
2417351|NCT03454191|Experimental|Erector spinae plane block|
2417352|NCT03454191|Placebo Comparator|Placebo|
2417353|NCT03454178||Hypertensive patients|150 Chinese patients with a diagnosis of essential hypertension from a primary care clinic
2417354|NCT03454165|Experimental|Single Arm|Evaluate the MTD of BNC105P in combination with ibrutinib in patients with relapsed/refractory CLL. Treatment will be administered on an outpatient basis but will also be permitted inpatient. BNC105P will be administered as a single agent prior to initiation of ibrutinib. Beginning with cycle 2, ibrutinib will be administered concomitantly with BNC105P at a starting dose of 420 mg PO daily. Each cycle will last for 21 days. Provided no toxicities occur, each patient will be treated for 6 cycles.
2417355|NCT03454152||patients|pediatric patients with diabetic ketoacidosis come to Assuit University Children Hospital within one year. Electrocardiogram and echocardiography will be done to all patient with diabetic ketoacidosis
2417356|NCT03454139|Active Comparator|Subcostal TAP group|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,25 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia. After that, the patient is positioned to lithotomy position and the open-end catheter is inserted. After that the patient is turned to prone position and the percutaneous nephrolithotomy is performed. Tramadol 100 mg iv is administrated 20 minutes before the end of the surgery. Morphine patient controlled analgesia is planned for postoperative pain management.
2417357|NCT03454139|No Intervention|Non- TAP group|Percutaneous nephrolithotomy is performed under general anesthesia. No regional analgesia is administered to this patients. Paracetamol 1000 mg/100ml; iv and Tramadol 100mg iv is administered 20 minutes before the end of the surgery for postoperative analgesia. Morphine patient controlled analgesia is planned for postoperative pain management.
2417358|NCT03454126|Experimental|Cohort 1: BIIB095 5 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 5 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417359|NCT03454126|Experimental|Cohort 2: BIIB095 25 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 25 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417360|NCT03454126|Experimental|Cohort 3: BIIB095 100 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 100 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417361|NCT03454126|Experimental|Cohort 4 (Fasted): BIIB095 200 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 200 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417362|NCT03454126|Experimental|Cohort 4 (Fed): BIIB095 200 mg|After a minimum 2 week washout period, followed by an overnight fast of at least 8 hours, participants will consume a high fat breakfast. Participants will then receive a single dose of either BIIB095 200 mg or placebo orally within 30 minutes after starting the breakfast, followed by a fast from food for at least 4 hours post dose.
2417363|NCT03454126|Experimental|Cohort 5: BIIB095 400 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 400 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417364|NCT03454126|Experimental|Cohort 6: BIIB095 600 mg|Following an overnight fast from food of at least 8 hours, participants will receive a single dose of either BIIB095 600 mg or placebo orally, followed by a fast of at least 4 hours post dose.
2417365|NCT03454126|Experimental|Cohort 7: BIIB095 50 mg BID|Participants will receive a single dose of either BIIB095 50 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2417366|NCT03454126|Experimental|Cohort 8: BIIB095 100 mg BID|Participants will receive a single dose of either BIIB095 100 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2417367|NCT03454126|Experimental|Cohort 9: BIIB095 200 mg BID|Participants will receive a single dose of either BIIB095 200 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2417368|NCT03454126|Experimental|Cohort 10: BIIB095 300 mg BID|Participants will receive a single dose of either BIIB095 300 mg or placebo orally BID approximately 12 hours apart from Days 1 to 13, and once in the morning on Day 14. Morning doses will be preceded by an overnight fast from food of at least 8 hours and will be followed by a fast of at least 2 hours post dose. Evening doses will be preceded by a fast from food of at least 2 hours and will be followed by a fast of at least 2 hours post dose.
2417369|NCT03454100|Experimental|multi-sectoral package of activities|Villages in the experimental arm received the full multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
2417370|NCT03454100|No Intervention|Control|Villages in the control arm did not receive teh multi-sectoral package of village level activities.
2417371|NCT03454087|Experimental|Enteral Dextrose Infusion|Critically-ill participants with sepsis enrolled in the interventional arm will receive a 24-hour infusion of dextrose solution by the enteral route to be initiated via an existing nasogastric or orogastric tube within the first 48 hours of meeting sepsis criteria.
2417372|NCT03454087|Placebo Comparator|Placebo|Critically-ill participants with sepsis in the placebo arm will receive a 24-hour enteral free water infusion via an existing orogastric or nasogastric tube within 48 hours of meeting sepsis criteria.
2417373|NCT03454074|Experimental|B-Fit intervention|Combines group education about brain health with individualized goal-setting and group problem-solving to help participants effectively integrate healthy behavioral changes into their everyday lives.
2417374|NCT03454074|Active Comparator|Education Only|Provide group education about healthy behavior changes without problem-solving component.
2417375|NCT03454074|No Intervention|Wait-list|No intervention administered. Will be offered intervention following a delay.
2417376|NCT03454061|Experimental|Intervention|Physical activity intervention
2417377|NCT03454061|No Intervention|Control|Keep usual activities in kindergarten
3186149|NCT00742300|Experimental|A|Treatment Group
3186150|NCT00742339|Active Comparator|1|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 1.
3186151|NCT00742339|Experimental|2|Fifty patients with cirrhosis and HRS will be randomly assigned to arm 2.
3186152|NCT00742352||Breast cancer patients|
2417382|NCT03454035|Experimental|Open-label, single arm Phase I|Ulixertinib added to palbociclib
2417383|NCT03454022|Active Comparator|Usual care|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure."
2417384|NCT03454022|Experimental|DART|"Participants receive an educational pamphlet from the National Kidney Foundation, Choosing a Treatment for Kidney Failure. They also receive a link to access the web-based decision-aid program, Decision-Aid for Renal Therapy (DART). Participants may access this program using a computer at home throughout the duration of the trial. Those who do not have a computer with web access at home are assisted in watching the program in the clinic."
2417385|NCT03454009|Experimental|Multimodal hygiene intervention|"Employees will receive hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer. Training materials discuss the importance of performing hygiene behaviors to prevent the spread of pathogens, such as, cleaning hands, using tissues to cover one's mouth and nose when coughing or sneezing, and keeping office surfaces clean.~In addition, hygiene materials will be placed in common areas frequented by employees in the intervention group that include, educational hygiene posters, free standing hand sanitizer delivery stands, and bottles of hand sanitizer ."
2417386|NCT03454009|No Intervention|Control|Employees will complete all surveys but will not have access to additional hygiene products. Will follow usual hygiene behaviors.
2418153|NCT03448510|Active Comparator|standard medication group|Subjects will receive either α-blocker or 5α reductase monotherapy or combination therapy.
3186153|NCT00742352||Lung cancer patients|
3186154|NCT00742365||A|Participants will be given a 1-hour lab test of bright light treatment, then the bright light treatment for 6 weeks.
3186155|NCT00742365||B|Participants will be given a 1-hour treatment of the red light placebo, then the bright light treatment for 6 weeks.
3186156|NCT00742378||C|Normal controls
3186157|NCT00742378||G|Glaucoma
3186158|NCT00742430||Resistant|patients who are resistant to standard antithrombotic drugs
3186159|NCT00742430||Nonresistant|patients who are not resistant to standard dual antithrombotic drugs
3186160|NCT00742443|Other|1|Active versus Placebo within patient
3186161|NCT00742443|Other|2|Active vs. Placebo within patient
3186162|NCT00742443|Other|3|Active vs. Active within patient
3186163|NCT00742456|Experimental|I|Glucose
3186164|NCT00742456|Placebo Comparator|II|Placebo
3186165|NCT00742521|Active Comparator|1|Euglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
3186166|NCT00742521|Active Comparator|2|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
3186167|NCT00742521|Active Comparator|3|Euglycemic glucose clamp procedure x 2 with cortisol infusion of 2ug/kg on Day 1 and hypoglycemic glucose clamp procedure on Day 2.
2417387|NCT03453996|Experimental|Intervention|Cardiologists will receive computerized clinical decision support information for CI-AKI prevention for patients identified above the median (> 5%) risk of AKI based on the NCDR risk prediction model for CI-AKI.
2417388|NCT03453996|Other|Control|Usual care.
2417389|NCT03453983|Experimental|Anodal tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
2417390|NCT03453983|Sham Comparator|Sham tDCS Intervention Group|Transcrainial Direct Current Stimulation (tDCS): The right primary motor cortex will be localized and a saline soaked sponge electrode will be placed onto M1 with a second saline soaked sponge electrode placed on the contralateral supraorbital region.
2417391|NCT03453970|Experimental|Therapeutic Education Program|"The program is based on adapted interventions and will consist of the following phases:~Phase I: Identification of self-care needs in Diabetes Mellitus through the EBADE questionnaire. This instrument will identify the needs grouped by constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention).~Phase II: Application of interventions adapted according to the behavioral mediator who encounters barriers. The interventions will be applied both in the face-to-face and telephone modality, using the Nursing Intervention Classification and their respective activities.~Phase III: measurement of the clinical variables and reported by the patients described in the objectives."
2417392|NCT03453970|No Intervention|Usual Care|The conventional intervention consists of the usual care that is followed in the nursing consultations in primary care to patients with type 2 DM, based on the recommendations of the Clinical Practice Guide of the National Health System
2417393|NCT03453957|Experimental|Professional Development Program|Therapists who participate in workshops and consultation sessions with study trainers during study-related therapy sessions and their participating patients/clients.
2417394|NCT03453957|No Intervention|Control|Therapists who did not participate in workshops and consultations sessions while engaging in study-related therapy sessions and their participating patients/clients.
2417395|NCT03453944|Experimental|VF03-K active stimulation|NMES applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
2417396|NCT03453944|Sham Comparator|VF03-K sham stimulation|Sham stimulation applied to the abdominal wall muscles using the VentFree prototype (VF03-K). Sham stimulation is applied twice daily for 30 minutes, 5 days per week, for 6 weeks or until the patient is weaned from mechanical ventilation, whichever occurs sooner.
2417397|NCT03453918|Experimental|Polyphenols|patients will receive during the meal, 2 capsules of Oligopin® containing 50 mg of polyphenols each. They will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of Oligopin® contains two excipients: 150 mg of maltodextrin and 30 mg of magnesium stearate.
2417398|NCT03453918|Experimental|Placebo|patients will receive during the meal, 2 capsules of placebo, visually identical to Oligopin®. The patient will take the two capsules simultaneously with a glass of water, after the starter. Each capsule of placebo contains two excipients: 218.9 mg of maltodextrin and 1.1 mg of magnesium stearate.
2417399|NCT03453905|Experimental|CTFEA|Decision on preventive surgery vs follow-up will be based on expert judgement, Mirels' score and CTFEA
2417400|NCT03453905|Other|Mirels|Decision on preventive surgery vs follow-up will be based on expert judgement and Mirels' score
2417401|NCT03453892||anti CTLA-4|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti CTLA-4) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
2417402|NCT03453892||anti PD-1/PD-L1|The study cohort consist of patients suffering from metastatic cancer of several entities which will be treated with palliative RT and/or ICI (anti PD-1/PD-L1) at Department of Radiation Oncology of Universitätsklinikum Erlangen.
2417403|NCT03453879||1: Study population|Participants in this study are working staff (junior and senior doctors, midwifes and other health personal) in the maternity wards of two hospitals in Central Region Denmark: Horsens Regional Hospital and Aarhus University Hospital, Skejby.
3145685|NCT00078507|Active Comparator|Opening Exercises Only|Standard of care opening exercises following BSSO surgery to regain mouth opening
3145686|NCT00078507|Experimental|Sensory Retraining Exercises|3 sets of facial exercises performed with soft cosmetic brush 1 wk - 4 wks after surgery; 4wks to 3 mos after surgery; 3 mos to 6 mos after surgery.
2417406|NCT03453853|Experimental|Mitral Loop Cerclage|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
2417407|NCT03453840|Active Comparator|HIV-infected 3-day AL|Standard 3-day twice daily (BID) regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-infected and stabilized on EFV-based ART.
2417408|NCT03453840|Experimental|HIV-infected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-infected and stabilized on EFV-based ART.
2417409|NCT03453840|Active Comparator|HIV-uninfected 3-day AL|Standard 3-day BID regimen of artemether-lumefantrine for uncomplicated malaria, given over 4 days (Study Days 0, 1, 2 and 3) so that sampling will begin in the morning of day 3. These participants are HIV-uninfected.
2417410|NCT03453840|Experimental|HIV-uninfected 5-day AL|Extended 5-day BID regimen of artemether-lumefantrine, given over 6 days (Study Days 0, 1, 2, 3, 4, and 5) so that sampling will begin in the morning of day 5. These participants are HIV-uninfected.
2417411|NCT03453827||PEX|Patients after Cataract surgery with PES
2417412|NCT03453827||Control|Patients after Cataract surgery without PES
2417413|NCT03453814|Experimental|Interventional|Music therapy.
2417414|NCT03453814|No Intervention|Comparison|No music therapy.
2417469|NCT03453398|Experimental|Group 2|Shifts over 24-hours, shift cycle of 10 days (morning, morning, afternoon, afternoon, rest, night, night, night off, rest, rest).
2417470|NCT03453398|Active Comparator|Group 3|Only diurnal shifts, shift cycle of 5 days (morning, afternoon, morning, afternoon, morning, rest, rest).
2417415|NCT03453801|Experimental|MZ twins 2-5 yo|Monozygotic twins, 2-5 yo (annual return): In 2014-2015, individual twin participants will be given FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0, 7 and 60 post-immunization. Vaccine naive children will receive two immunizations in the first year, 28 days apart then return annually for flu immunization. Blood samples will be obtained on Days 0, 7 and 60 post second-immunization. Beginning in 2015-2016, participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an intramuscular (IM) injection annually following Advisory Committee on Immunization Practices (ACIP) recommendation against LAIV4.
2417416|NCT03453801|Experimental|Non-twins 6 mo-10 yo|Non-twins 6 mo-10 years (annual return): In 2014-2015, participants between 6-23 mo will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) IM then switch to FluMist® a live, attenuated influenza vaccine quadrivalent (LAIV4) intranasally starting at age 24 months in annual follow-up. Participants aged 24 mo-8 yo will be given LAIV4 at enrollment and for annual follow-up. However, if LAIV4 is contraindicated, the child will continue with IIV4. Participants 9-10 yo will be given IIV4 annually. Vaccine non-naive participants will return annually for flu immunization and for blood samples on Days 0 and 60 post immunization. Vaccine naive children will get two doses of vaccine the first year then return annually for flu immunization and blood samples on Day 0 and 60 post second immunization. Beginning in 2015-2016, all participants in this arm will receive Fluzone® inactivated influenza vaccine quadrivalent (IIV4) annually following ACIP recommendation against LAIV4.
2417417|NCT03453801|Experimental|Non-twins 6-12 mo Flu/MMRV Naïve|Non-twins 6-12 mo Flu/MMRV Naïve (annual return): In 2014-2015, participants 6-12 mo who are flu and MMRV naïve will be given Fluzone® inactivated influenza vaccine quadrivalent (IIV4) as an IM injection. In Year 1, participants will return for a second flu immunization at least 28 days later and for blood samples on Days 0 and 60 post-second immunization and on Day 60 post MMRV (to be given by primary care physician). In Years 2-5, participants will return annually for Fluzone® IIV4 flu immunization and for blood samples on Days 0 and 60 post-immunization.
2417418|NCT03453788|Experimental|Intervention group|Alternating follow-up visits by nurse and doctor. In the nurse-led consultations, the patients will be introduced to the smartphone LETSGOapp with access to information on cancer treatment and side effects, physical activity advice. Two-monthly assessment of 12 symptoms that may represent relapse through the app.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
2417419|NCT03453788|No Intervention|Reference group|Regular hospital follow-up.The patients will fill in an electronic questionnaire package at baseline, 3, and 6 months after treatment.
2417420|NCT03453775|Active Comparator|Ultrasound guided infiltration|"Ultrasound guided periradicular lumbar infiltration. Prone position. Lumbar spine level located in a median sagittal plane (spinous processes). High resolution curved 5MHz ultrasound probe. Probe is then rotated 90° for a median transverse image. Transverse plane translation towards desired side to have in the same plane: spinous process, vertebral blade, zygapophysial articulation, lateral facet, transverse process. Needle passes skin at 45° angle, directed in plane to the foramen. Fluoroscopy then performed to check needle's correct position. Poorly positioned needles will be replaced to obtain an intra-foraminal/epidural periradicular diffusion of the contrast medium. Once position is confirmed, Depomedrol 40mg + lidocaine 2% (1ml) is injected."
2417421|NCT03453775|Active Comparator|Fluoroscopy guided infiltration|"Fluoroscopy guided periradicular lumbar infiltration. Prone position. Anatomical identification by radioscopy: antero-posterior and sagittal planes. Needle placement in an anteroposterior view, needle is then advanced in an inclined plane of 20° with respect to the initial axis, tunnel vision type image. Foramen is then reached in a sagittal view (not to progress too far in the intra-foraminal level). Needle progression is secured by neurostimulation (territory concerned by the root, intensity 0.2 milliampere to be at a distance of 1mm from the nerve root). Once needle is in place, fluoroscopy is performed to verify correct positioning (Omnipaque 300mg/ml of Iohexol, 0.2 to 0.5ml). Once position confirmed, mixture Depomedrol 40mg + lidocaine 2% (1ml) is injected."
2417422|NCT03453762|Active Comparator|Recruitment maneuver group|After anesthetic induction, recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
2417423|NCT03453762|Experimental|Lung ultrasonography group|After anesthetic induction, recruitment maneuver is performed, being guided by ultrasonography.
2417424|NCT03453749|Other|Salovum|Patients will be given Salovum 1g/kg body weight/24 hours, divided into 6 dosages and given during 5 consecutive days.
2417425|NCT03453736||Robotic procedures|Experiences and practices in Robotic theatres will be studied via semi-structured interviews with staff as well as team observations during real time robotic surgery. As the study is a qualitative one, data collection will continue till we reach saturation of theoretical categories. We expect 20 interviews and 10 observations to suffice.
2417426|NCT03453736||Non-Robotic procedures|"Staff involved in robotic surgery will have almost definitely worked in non-robotic theatres ie major abdominal and laparoscopic. Staff interviews will explore differences in experiences and practices between these different theatre setups.~In addition, we aim to observe further 5 non-robotic procedures to evaluate staff teamwork and communication within the more regular theatre setup."
2417427|NCT03453723|Experimental|magic glove hypnosis|Magic glove hypnosis technique use before propofol infusion
2417428|NCT03453723|Active Comparator|lidocaine|extemporaneous mixture with lidocaine for propofol infusion
3145687|NCT00078520|Experimental|Dose Level 1|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
2417466|NCT03453424|Active Comparator|TEA group|"Intraoperative,thoracic epidural injection of bupivacaine (0.125%+fentanyl 5 mic/ml ) ,initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till start of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
2417431|NCT03453697|Experimental|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.Through adjusting the inhaled nitrogen concentration in patients, the patients could be simulated as the OSA patients who had intermittent hypoxic state due to upper airway collapse at night. This process is equivalent to acute intermittent hypoxia 25-30 times/h, which is clinically intermediate to severe OSA.
2417432|NCT03453684|Experimental|Administration of Vancomycin|Administration of Vancomycin 15 mg/kg over 1 hour prior to surgical incision
2417433|NCT03453671|Experimental|Mindfulness|Participants will use the strategy of mindfulness, i.e., present moment awareness with nonjudgment and acceptance, while exercising.
2417434|NCT03453671|Experimental|Distraction|Participants will use the strategy of distraction, i.e., directing their attention to something other than exercise (specifically a podcast) while exercising.
2417435|NCT03453671|Active Comparator|Self-Monitoring|Participants will monitor their internal experience while exercising, without distraction and without being taught mindfulness skills of nonjudgment and acceptance.
2417436|NCT03453658|Active Comparator|Manual instrumentation|Manual instrumentation: Endodontic treatment will be performed with the use of conventional endodontic manual files.
2417437|NCT03453658|Experimental|Reciprocating instrumentation|Mechanized instrumentation: Endodontic treatment will be performed with the use of reciprocating mechanized files. The files are activated by an engine that produces reciprocating movements.
2417438|NCT03453632|Experimental|Botulinic toxin|Injections of botulinic toxin (Dysport®, Allergan) 200 UI
2417439|NCT03453632|Placebo Comparator|Placebo|Injections of physiological serum
2417440|NCT03453619|Experimental|APL-2|Open Label, Study Drug, APL-2
2417441|NCT03453606|Active Comparator|home group|
2417442|NCT03453606|Active Comparator|center group|
2417443|NCT03453567||TAVR|Transcatheter Aortic Valve Replacement
2417444|NCT03453567||Sutureless AVR|Sutureless Aortic Valve Replacement
2417445|NCT03453567||Conventional AVR|Conventional Aortic Valve Replacement
2417446|NCT03453554|Experimental|DMN/Smart Home Partnership|Participants will learn how to use a digital memory notebook partnered with smart environment prompting technology to support everyday activities of daily living and reduce problems associated with memory deficits.
2417447|NCT03453554|Active Comparator|Digital Memory Notebook app|Participants will learn how to use a Digital Memory Notebook app to support everyday activities of daily living and reduce problems associated with memory deficits.
2417448|NCT03453541|Experimental|Ketorolac Tromethamine|This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
2417449|NCT03453541|Placebo Comparator|0.9% Normal Saline|This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.
2417450|NCT03453528|Experimental|68Ga-PSMA|68Ga-PSMA
3186168|NCT00742521|Active Comparator|4|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
3186169|NCT00742547|No Intervention|Control group|No telephone counseling + usual care
3145688|NCT00078520|Experimental|Dose Level 2|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
3186170|NCT00742547|Experimental|Telephone Counseling|Telephone counseling + usual care
3186171|NCT00742599|Active Comparator|N|
2417456|NCT03453489|Experimental|Treatment (AMT-PET, telotristat etiprate)|Participants undergo AMT-PET within 7 days prior to, and 9-14 days after start of telotristat etiprate treatment. Participants receive telotristat etiprate PO TID for 9-14 days.
2417457|NCT03453476|Experimental|SRP and Fotosan 630|Scaling and root planing, photodynamic therapy using Fotosan 630
2417458|NCT03453476|No Intervention|Control|Scaling and root planing only
2417459|NCT03453463|Experimental|exercise and protein supplementation|Predominately resistance exercise training 2-3x week for 18 months; 1.5-1.7 g/kg/d total protein supplementation, Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
2417460|NCT03453463|No Intervention|control|Calcium and Vitamin-D-supplementation (i.e. 800 mg/800 IE/d)
2417461|NCT03453450||Health TAPESTRY volunteers|Volunteers in a primary care setting connecting with Health TAPESTRY clients
2417462|NCT03453450||Health TAPESTRY Volunteer Coordinators|The coordinators of volunteers
2417463|NCT03453437|No Intervention|Control group|Receiving no intervention (control groups will be offered the intervention after the experimental group has completed the course)
2417464|NCT03453437|Experimental|Active group|Receiving Mindful Self-Compassion intervention
2417465|NCT03453424|Active Comparator|TEA+DEX group|"Intra operative thoracic epidural injection of (bupivacaine 0.125% +fentanyl 2 mic/ ml) , initial bolus dose of 8 ml before skin incision followed by fixed rate infusion of 6 ml/h till end of abdominal layer closure.~Postoperative, thoracic epidural injection of (bupivacaine 0.0625%+fentanyl 2 mic /ml + dexmedetomidine 0.5 mic/ ml) at infusion rate 6 ml /h and bolus dose of 3 ml with lockout time 10 min"
2417467|NCT03453411||Non interventional study|
2417468|NCT03453398|Experimental|Group 1|Shifts over 24-hours, shift cycle of 5 days (morning, afternoon, night, night off, rest).
2419309|NCT03440762|Other|AF awareness education|AF awareness education face to face
3186172|NCT00742599|Placebo Comparator|P|
3186173|NCT00742612|Active Comparator|1|ARC1779 Injection
3186174|NCT00742612|Placebo Comparator|2|Placebo (normal saline)
3145689|NCT00078520|Experimental|Dose Level- Fixed Dose|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
3145690|NCT00078533|Experimental|CMV CTL infusion|Subjects are assigned a dose level at the time of enrollment.
2417473|NCT03453372|Experimental|Active|MRgFUS treatment of pain caused by knee osteoarthritis
2417474|NCT03453372|Placebo Comparator|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
2417475|NCT03453359|Experimental|BIS|Group of patients (90) in whom sedation is adjusted using as main parameters the information obtained by the BIS sedation monitor (BIS VISTA, Aspect Medical Systems, USA).
2417476|NCT03453359|Active Comparator|Ramsay|Group of patients (90) in whom sedation is based on subjective monitoring of the level of sedation, using the Ramsay scale as a reference.
2417477|NCT03453346|Experimental|Noncirrhotic and cirrhotic GT-2|Generic sofosbuvir tablet 400 mg once daily plus weight-adjusted ribavirin tablet (1000 mg for <75 kg, and 1200 mg for >=75 kg) twice daily with meal, orally given, for 12 successive weeks
2417478|NCT03453333|Experimental|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
2417479|NCT03453333|Experimental|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
2417480|NCT03453320|Experimental|Rapid - Slow|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (30 minutes), second time slow (120 minutes). Albumin solution"
2417481|NCT03453320|Experimental|Slow - Rapid|"Two infusions of 3 ml/kg bodyweight of hyperoncotic albumin 20%, with an interval of 3 to 20 weeks between.~First time rapid (120 minutes), second time slow (30 minutes). Albumin solution"
2417482|NCT03453307||Group-1|NSCLC patients receiving chemotherapy or target therapy treatment.
2417483|NCT03453294|Experimental|Apnoeic oxygenation using THRIVE|Oxygenation by apnoea oxygenation using THRIVE
2417484|NCT03453294|Active Comparator|Endotracheal intubation and mechanical ventilation|Ventilation and oxygenation by an endotracheal tub and mechanical ventilation
2417485|NCT03453281|Experimental|Aflibercept Injection [Eylea]|Intravitreal injection of 2 mg in 0.05 ml Aflibercept. Frequency: once Duration: 10-15 minutes
2417488|NCT03453255|Experimental|t(8;21)AML|chemotherapy 5-Aza-2'-deoxycytidine IV 20mg/m2 d8-12 homoharringtonine IV 2mg d1-5 chidamide P.O. 30mg twice/W cytarabine IV 1000mg/m2(<60 year old) 500mg/m2(>60 year old) IV q12h d1,3,5
2417489|NCT03453216|Experimental|Behavioral test and fMRI|Neuropsychological tests and training in behavioral tasks and a Functional Magnetic Resonance Imaging (fMRI) exam
2417490|NCT03453203|Placebo Comparator|Control|"Both arms with be diagnosed using tenderpoints In the control arm the tenderpoint will Be palpated for 90 secs with no counterstrain treatment applied.~Both treatment and control groups will remain on their current migraine medication regiment."
2417491|NCT03453203|Other|Treatment (conterstrain)|Both arms with be diagnosed using tenderpoints. Treatment arm will be treated with counterstrain technique. Counterstrain is a passive manipulative technique which the tissue being treated is positioned at a point of balance, or ease, AWAY from the restrictive barrier (The most thought of form of manipulative technique is high velocity low amplitude which is typically performed by chiropractors in spinal manipulation which goes TOWARD the restrictive barrier and actually pass through the restrictive barrier). Once a tenderpoint is found in the muscles the area of treatment is placed in a (three dimensional) position that will eliminate the sensation (tenderness).The treatment position is held for 90 seconds or until a release is felt (a decrease in muscle tension). Both treatment and control groups will remain on their current migraine medication regiment.
2417492|NCT03453190|Other|Psoriasis Patients on Comb. Treatment|Patients will be given Apremilast 30 mg bid and Clobetasol Spray 0.05 % bid on a tapering schedule over 16 weeks.
2417493|NCT03453177|No Intervention|Standard of Care|ampicillin 50mg/kg twice daily and gentamicin [3mg/kg for babies <2kg or 5mg/kg for babies >2kg] once daily for 7 days, as per Kenyan guidelines).
2417494|NCT03453177|Experimental|Standard of Care plus Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
2417495|NCT03453164|Experimental|Radiotherapy + Nivolumab|Localized short-term radiotherapy (22.5 Gy/5 fractions/5 days, Day 1-5) + nivolumab (starting on Day 15-22, a dose of 3 mg/kg (body weight), every 2 weeks to a total of 6 courses)
2417497|NCT03453138|Experimental|LMA Protector Group|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
2417498|NCT03453138|Experimental|Tracheal Intubation Group|Patients will be intubated after standart anesthesia induction and we will record heamodynamic variables. including mean blood pressure and heart rate
2417499|NCT03453125|Experimental|Spanish mSMT Experimental Treatment|Administered by computer and paper and pencil.
2417500|NCT03453125|Active Comparator|Spanish mSMT Control Treatment|Administered by computer and paper and pencil.
2417501|NCT03453112|Experimental|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)
2417502|NCT03453112|Active Comparator|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.
2417503|NCT03453099||Study Cohort|Any ASA I or II patients scheduled for elective day case general anaesthesia at Chelsea & Westminster Hospital, involving a standard propofol-fentanyl induction regimen, aged between 18-65 years . See specific exclusion criteria below.
2417683|NCT03451877|Other|Control group|Emmetropic children TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
2417504|NCT03453086|Active Comparator|Group I:|These patients will receive single ipsilateral Ultrasound TPVB which performed with the patient in the sitting position at the level of the T4 with the probe in a vertical position 2.5-3 cm lateral to the midline. The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes which visualized with the superior costo-transverse ligament and the pleura visible in between . After this, 15-20 cc of bupivacaine 0.25% will be injected
2417505|NCT03453086|Active Comparator|Group II :|These patients will receive serratus anterior plane block. The block will be performed while the patient is in the supine position by using a linear Ultrasound probe of high frequency (6-13 MHz) after sheathing. The probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted inferiorly and laterally, until the 5th rib is identified in the midaxillary line. The latissimus dorsi (superficial and posterior) , teres major (superior) and serratus muscles (deep and inferior) will be then easily identifiable by U/S overlying the fifth rib.
2417506|NCT03453073||chocolate consumption level referent|women who ate 1 oz. (28.35 g) of chocolate <1 time/month
2417507|NCT03453073||chocolate consumption level 2|women who ate 1 oz. (28.35 g) of chocolate between 1 and <1.5 times/month
2417508|NCT03453073||chocolate consumption level 3|women who ate 1 oz. (28.35 g) of chocolate between 1.5 and <3.5 times/month,
2417509|NCT03453073||chocolate consumption level 4|women who ate 1 oz. (28.35 g) of chocolate between 3.5 times/month and <3 times/week
2417510|NCT03453073||chocolate consumption level 5|women who ate 1 oz. (28.35 g) of chocolate >3 times/week
2417511|NCT03453073||No physician diagnosis|No incidence of serious chronic disease prior to visit 3
2417512|NCT03453073||Physician diagnosis|Incidence of serious chronic disease prior to visit 3
2417513|NCT03453073||Younger|Age<65 years at follow-up baseline
2417514|NCT03453073||Older|Age>=65 years at follow-up baseline
3186175|NCT00742638|Experimental|The arm 1|Quetiapine fumarate tablet:25mg and 200mg
3186176|NCT00742638|Active Comparator|The arm 2|Sodium valproate tablet 200mg
3186177|NCT00742664|Experimental|1|Will receive 12 sessions of twice weekly psychotherapy targeting obsessive-compulsive symptoms.
3186178|NCT00742664|Placebo Comparator|2|
3186179|NCT00742677|Experimental|Group 1 (early feeding)|Patients are offered a liquid diet on day 1 for 24 hours following surgery. Beginning on day 2, patients who tolerate a liquid diet are offered a light regular diet until hospital discharge.
2417520|NCT03453047||1|Healthy volunteers. Liver donor groups; Course of the research: Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
2417521|NCT03453047||2|Liver transplant groups;Course of the research Blood samples from all groups shall be taken for S100β and NSE in preoperative period, in the operating room and after 1 and 6 months in postoperative period. Mortality and morbidity of the patients shall be recorded. Neurological damage and its effect on prognosis shall be examined within the patients who were transplanted liver with S100β and NSE. Demographic data of the patients, accompanying diseases, American Society of Anesthesia classification, etiology, Model For End-Stage Liver Disease score, Child classification, sodium, potassium, total bilirubin, alanine aminotransferase, aspartate aminotransferase, Alkaline phosphatase, International Normalized Ratio, creatinine and urea shall be recorded. Intraoperative medicine administration and fluid balance, duration of operation, graft hot ischemia and graft cold ischemia durations, initial pulmonary artery pressure, blood component transplantations shall be recorded.
2417522|NCT03453034|Experimental|TQ-B3233 capsule|QD or BID; patients are given the doses according to the protocal, and a cycle is 28 days.
2417523|NCT03453021||mepolizumab|Patients will receive a subcutaneous injection of mepolizumab 100 mg every 4 weeks for one year, for a total of 12 injections
2417524|NCT03452995|Active Comparator|Physiotherapy: LYMPHO DRAINAGE|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day by means of Manual lymphodrainage consisting in special massage technique that allows lymphatic drainage, or removal of interstitial fluid stagnation according to Vodder, in association to the standard rehabilitation protocol for TKA (Kinetec, functional rehabilitation and walking training
2417525|NCT03452995|Active Comparator|Physiotherapy: KINESIOTAPING|Patients will be treated on the second postoperative day, on the 4th postoperative day and on the 6th post-operative day through the use of patches acting through the sensory system giving stimuli to receptors on the skin, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training .
2417526|NCT03452995|Experimental|Physiotherapy:LYMPHO+KINESIO|Patients will ne treated with both kinesiotaping and lymphodreinage on the second post-operative day, on 4 days post-operative and on the 6th post-operative day, in association to the standard rehabilitation protocol for TKA (kinetec, functional rehabilitation and walking training
2417527|NCT03452982|Experimental|Patients with ovarian cancer|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection
2417528|NCT03452956||FTD Cohort|No intervention-observation only
3145691|NCT00078572|Active Comparator|capecitabine alone|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2. Randomization is 1:1.
2417531|NCT03452930|Experimental|Stage 1A (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2417532|NCT03452930|Experimental|Stage 1B (tinostamustine)|Patients receive tinostamustine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2417533|NCT03452930|Experimental|Stage 2 (RT, tinostamustine)|Patients undergo RT 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive tinostamustine IV on day 1 or days 1 and 15 (to be determined following stage 1). Treatment repeats every 21 days (day 1) or 28 days (days 1 and 15) for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2417534|NCT03452917|Placebo Comparator|Placebo|2 ml of normal saline (n=500)
2417535|NCT03452917|Experimental|sodium nitrite|45 mg IV of sodium nitrite (n=500) or 60 mg IV sodium nitrite (n=500) given during active resuscitation from out of hospital cardiac arrest.
2417536|NCT03452904|Experimental|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
2417537|NCT03452904|Active Comparator|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting stent
2417538|NCT03452891|Experimental|SIM-MCL|
2417539|NCT03452891|Placebo Comparator|MCL|
2417540|NCT03452878||Aggressive refractory patient|A pre defined group of individuals will be included in the study. This group is considered aggressive refractory patient and will be submitted to the bilateral amygdalotomy surgery.
2417543|NCT03452852|Other|NPWT (PICO device)|In this arm, investigators will use the PICO system (Smith and Nephew) for compression therapy after split thickness skin graft of leg ulcers.
2417544|NCT03452852|Other|Compression bandaging (Coban 2 lite)|In this arm, investigators will use the Coban 2 lite compression bandaging for compression therapy after split thickness skin graft of leg ulcers.
3145692|NCT00078572|Experimental|Combination|Lapatinib 1250 mg once daily plus capecitbine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the combination arm was 2000 mg/m2.
3145693|NCT00078624|Experimental|1|Traditional exercise program supplemented with knee stability training activities
3145694|NCT00078624|Active Comparator|2|Traditional exercise program
2417550|NCT03452787||Boston Puerto Rican Health Study (NCT01231958)|40 with CC and 40 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
2417551|NCT03452787||GOLDN (NCT00083369)|107 participants with CC genotype and 272 with TT genotype for APOA2 rs5082.
2417552|NCT03452787||Framingham Heart Study (NCT00005121)|73 with CC and 170 with TT genotypes at APOA2 rs5082. Participants of each genotype will be further divided into two subgroups based on SFA intake: low, <22 grams/day, high, ≥22 grams/day.
2417553|NCT03452774||Study Group|Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP).
2417554|NCT03452748|Experimental|FTIR arm|all excised membranes are examined with FTIR spectroscopy
2417555|NCT03452735||patients diagnosed before age 40|Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
2417556|NCT03452735||Control Group|Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility
2417557|NCT03452722||Study group|Applied rtPA
2417558|NCT03452722||Control study|rtPA not applied
2417559|NCT03452709|No Intervention|Control group: no intervention|Only the normal practise
2417560|NCT03452709|Experimental|therapeutic exercise|In this group the intervention is the prescription of physical activity. The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week.
2417561|NCT03452709|Experimental|ABPM|In this group the arterial pressure is evaluated with ABPM.
2417562|NCT03452709|Experimental|therapeutic exercise + ABPM|
2417563|NCT03452696|Experimental|Calcium supplement 10/90|Microencapsulated calcium, 1389 mg orally (10% protein and 90% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 doses of 1389 mg each orally, to make a total contribution of 1,000 mg. of calcium element.
2417564|NCT03452696|Experimental|Calcium supplement 5/95|Microencapsulated calcium1316 mg orally (5% protein and 95% calcium carbonate, corresponding to 500 mg of calcium element per tablet). There will be 2 shots of 1,316 mg each orally, to make a total contribution of 1,000 mg. calcium element
2417565|NCT03452696|Active Comparator|Calcium carbonate supplement|1,250 mg orally (500 mg of calcium element). There will be 2 doses of 1,250 mg. each orally, to make a total contribution of 1,000 mg. of calcium element.
2417684|NCT03451864||Deficient Vit D|Mothers with serum 25(OH) D levels less than 20 ng/dl
3145695|NCT00078793||Methotrexate group|Includes subjects being treated with methotrexate alone or in combination with other DMARDs with the exception of etanercept.
2417566|NCT03452696|Active Comparator|Calcium citrate supplement|1,500 mg orally (315 mg of calcium element). There will be 2 taken orally, to make a total contribution of 945 mg. calcium element
2417567|NCT03452683|No Intervention|Usual Care|Participants randomized to the Usual Care arm will receive educational handouts.
2417568|NCT03452683|Experimental|Movn Mobile App|Participants randomized to the Movn Mobile App arm will have the Movn app downloaded to their cell phone. Participants will enter in their weight and symptoms into the app every day.
2417569|NCT03452670|Experimental|Active Group|Participants in this group will use a contemplative wellness application for 8 weeks.
2417570|NCT03452670|Other|Waitlist Group|The waitlist group will receive no intervention during the study but will be able to use the wellness application after completion of the study.
2417571|NCT03452657|Experimental|Ranibizumab|Participants received 0.5mg intravitreal ranibizumab injection
2417572|NCT03452657|Sham Comparator|Sham-injection|No drug involved in the sham procedure; patient's eye is anesthetized and a syringe without needle gently pressed on the conjunctival surface to simulate the force of an actual injection
2417573|NCT03452618|Experimental|patients with a NIV equipment|Determination of diagnosis variables in a group of patient who benefit of the Non Invasive ventilation equipment one year after the diagnostic
2417574|NCT03452618|Active Comparator|patients without a NIV equipment|Determination of diagnosis variables in a group of patient who not benefit of the Non Invasive ventilation equipment one year after the diagnostic
2417575|NCT03452605|Experimental|high cocoa flavanol drink|high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI
2417576|NCT03452605|Placebo Comparator|low cocoa flavanol drink|low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI
2417577|NCT03452592|Experimental|The way patients take Alflutinib|patients take Alflutinib orally once per day at dose of 80mg or160mg
2417578|NCT03452579|Active Comparator|Nivolumab + Standard Dose Bevacizumab|"nivolumab 240 mg IV and standard dose bevacizumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
2417579|NCT03452579|Experimental|Nivolumab + Low Dose Bevacizumab|"nivolumab 240 mg IV and low dose bevacizumab 3mg/kg every 2 weeks until disease progression or unacceptable toxicity~Nivolumab is to be administered first. The second infusion will be bevacizumab, and will start no sooner than 10 minutes after completion of the nivolumab infusion"
2417580|NCT03452566|Experimental|ingenol mebutate gel|Phase 1/2, always 3 consecutive days, with 24 hours interval, dosage from 5 mg/cm2 to 18 mg/cm2 in a 3+3 design.
2417581|NCT03452553|Experimental|Open Label Treatment|Chemoembolization using LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
2417582|NCT03452540|Experimental|DS102|Participants in this group will receive 2000mg DS102 capsules daily.
2417583|NCT03452540|Placebo Comparator|Placebo|Participants in this group will receive placebo capsules daily.
2417586|NCT03452514||Cohort 1 - Low Dose CT (LDCT) Scan|Individuals undergoing their first or subsequent annual LDCT screening study
2417587|NCT03452514||Cohort 2 - Diagnostic CT Scan|Individuals referred for a follow-up diagnostic chest CT scan due to a lung-RADS category 3 or 4 result on a previous LDCT scan
2417588|NCT03452501||Naïve group|Newly diagnosed patients
2417589|NCT03452501||Switched group|Patients who received at least one dose of Infliximab reference medicinal product (RMP) before the first infusion of Remsima®
2417590|NCT03452488|Placebo Comparator|Arm 1 - Placebo oral capsule|"4 capsules taken twice a day: in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Component : Microcrystalline cellulose, Colloidal anhydrous silica"
2417591|NCT03452488|Experimental|Arm 2 - BIO101 - Half daily dose 350 mg|"4 capsules taken twice a day (2 placebo and 2 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20-hydroxyecdysone (20E) containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
2417592|NCT03452488|Experimental|Arm 3 - BIO101 - Full daily dose 700 mg|"4 capsules taken twice a day (4 experimental study drug) in the morning and in the evening with the meal approximately at 12-hour distance for 26 weeks.~Study Drug Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate."
2417593|NCT03452475|Active Comparator|Arterolane-piperaquine|Arterolane-piperaquine for 3 days
2417594|NCT03452475|Active Comparator|Arterolane-piperaquine+mefloquine|Arterolane-piperaquine + mefloquine for 3 days
2417595|NCT03452475|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine for 3 days
2417596|NCT03452462|Experimental|Direct His Bundle Pacing|Pacing from the His bundle lead
2417597|NCT03452462|Active Comparator|Biventricular Pacing|Pacing from the right ventricular and coronary sinus leads
2417598|NCT03452449||Lumbar spine surgery|Patients undergoing planned lumbar spine surgery
2417599|NCT03452436||Testicular cancer patients|Forty testicular cancer patients included after orchiectomy but prior to any further treatment.
2417600|NCT03452436||Prostate cancer patients|Forty prostate cancer patients included prior to medical castration and radiotherapy.
2417601|NCT03452436||Healthy controls|Forty age- and education-matched healthy controls (20 matched to testicular cancer patients, 20 matched to prostate cancer patients).
2417602|NCT03452423|Experimental|ACRFP|Patient suffering from osteoarthritis of knee joints, and planning to receive ACRFP, are enrolled into this study. Gait pattern is obtained preoperatively, 3 months, and 6 months postoperatively.
2419339|NCT03440554|Experimental|Whole Body Non-Contrast MRI|
2417607|NCT03452384|Experimental|acupucture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface.
2417608|NCT03452384|Sham Comparator|control|For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998). The needles will be affixed with plastic O-rings and adhesive tapes. The needles with blunt tips will be quickly put onto the same acupoints used in real acupuncture without inserting into the skin.
3186180|NCT00742677|Active Comparator|Group 2 (traditional feeding)|Patients are offered nothing by mouth on days 1 and 2 following surgery. Beginning on day 3, patients are offered a liquid diet for 24 hours. Beginning on day 4, patients who tolerate a liquid diet (absence of nausea and vomiting) are offered a semi-solid diet for 24 hours. Beginning on day 5, patients who tolerate a semi-solid diet are offered a light regular diet until hospital discharge.
3186181|NCT00742690|Active Comparator|1|35 patients with cirrhosis and type 1 HRS
2417611|NCT03452345|Experimental|MEDITOXIN|
2417612|NCT03452345|Placebo Comparator|Placebo|
2417613|NCT03452332|Experimental|Treatment (tremelimumab, durvalumab, SABR)|Participants receive tremelimumab IV over 1 hour followed by durvalumab IV over 1 hour on day 1 of each cycle. Participants also undergo SABR over 30-45 minutes on days 8, 10, and 12 of cycle 1. Treatment with tremelimumab repeats every 4 weeks for up to 4 cycles, and treatment with durvalumab repeats every 4 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
2417614|NCT03452319|Experimental|Pretraining|Increased physical activity daily Daily strength training Daily inspiratory and expiratory muscle training Standard care during hospital stay and continued training after discharge.
2417615|NCT03452319|Active Comparator|Usual care treatment|Standard care including preoperative information and postoperative breathing exercises and mobilization during hospital stay.
2417616|NCT03452306|Experimental|Metformin|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release in a fasting condition~Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
2417617|NCT03452306|Active Comparator|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fasting condition~Fourth Intervention Period:~Single administered dose of Glucophage® ( 750 mg tablet extended-release) in a fed condition"
2417618|NCT03452267|Experimental|Metformin|
2417619|NCT03452267|Experimental|Pioglitazone|
2417620|NCT03452267|Placebo Comparator|Placebo|
2417621|NCT03452254|Active Comparator|Experimental Group|Active bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
2417622|NCT03452254|Sham Comparator|Control Group|Sham bi-hemispheric transcranial Direct Current Stimulation combined with modified Constraint Induced Movement Therapy.
2417623|NCT03452241|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
2417624|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use
2417625|NCT03452241|Experimental|Intervention Group 1|The medical staffs who received the training will use the manual of brief intervention twice to deliver it and other materials about the harm of substance use.
2417626|NCT03452228|Experimental|evinacumab|
2417627|NCT03452228|Experimental|Placebo|
2417628|NCT03452215|Experimental|Study|
2417629|NCT03452215|Sham Comparator|Control|
3145696|NCT00078806|Experimental|Part 1: Etanercept|"Participants received 0.4 mg/kg etanercept administered subcutaneously twice a week for up to 6 months in Part 1A.~Participants who had a partial response entered Part 1B and received 0.8 mg/kg etanercept twice weekly for up to 4 months."
3145697|NCT00078806|Placebo Comparator|Part 2: Placebo|Participants who met response criteria in Part 1 were randomized to receive placebo twice a week for up to 3 months.
3186182|NCT00742690|Experimental|2|35 patients with cirrhosis and type 1 HRS
3186183|NCT00742703|Experimental|1|
3186184|NCT00742703|Active Comparator|2|
3186185|NCT00742716|Experimental|CTA018 Injection low dose|Low dose IV 3 times a week for 4 weeks
2417636|NCT03452163|Experimental|Anesthesia, General|Subjects under anesthesia that are expected to stay for at least 24 hours in the ICU/NICU will be monitored by the PMD-200 device. An EEG monitor device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
2417637|NCT03452150|Experimental|Daily oral dose of D-0316|
3145698|NCT00078806|Experimental|Part 2: Etanercept|Participants who met response criteria in Part 1 were randomized to continue receiving etanercept twice a week at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to 3 months.
3186186|NCT00742716|Experimental|CTA018 Injection low to mid dose|low to mid dose IV 3 times a week for 4 weeks
2417640|NCT03452124|Active Comparator|IQOS|I quit ordinary smoking (IQOS) assistes cessation program
2417641|NCT03452124|Active Comparator|Smoker control|Conventional cigarette smoking continuation
2417643|NCT03452085|Active Comparator|artificial saliva spray (AS)|"The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment."
2417685|NCT03451864||Normal vit D|Mothers with serum 25(OH) D levels more than 20 ng/dl
2419399|NCT03440138||Complutense University of Madrid, Spain|
3186187|NCT00742716|Experimental|CTA018 Injection mid to high dose|mid to high dose IV 3 times a week for 4 weeks
3186188|NCT00742716|Experimental|CTA018 Injection high dose|high dose IV 3 times a week for 4 weeks
2417644|NCT03452085|Placebo Comparator|maritime throat spray (TT)|"The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days.~After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment."
2417645|NCT03452072|Experimental|0.25% Timolol gel under the paraffin gauzes|"Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
2417646|NCT03452072|Active Comparator|Standard of Care dressings|"Vaseline will be applied to wound bed immediately after surgery before dressing is applied~Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing~This daily routine continues for 12 weeks' post-surgery (even if the surgical defect has completely healed in the interim)"
2417647|NCT03452059|Experimental|AiLegs/AiWalker|use of lower extremity rehabilitation training robot assisted walking (including AiLegs, AiWalker)
2417648|NCT03452059|Active Comparator|HKAFO/RGO|use hip and knee ankle foot orthosis (HKAFO) assisted walking
2417649|NCT03452046||PS 10 mmHg, PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2417650|NCT03452046||PS 10 mmHg PEEP 0 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2417651|NCT03452046||PS 0 mmHg PEEP 5 mmHg|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2417652|NCT03452046||t tube (PS 0 mmHg PEEP 0mmHg)|IVC diametres, CI-IVC, distensibility and delta index measurements using by ultrasound. Central venous pressure correlation with IVC index
2417657|NCT03452020|Other|Tyto Thermometer, SoC Thermometer, Predicate IR Th|"All the study participants undergo temperature measurements with:~Tyto Thermometer~Standard of Care thermometer~Predicate IR thermometer"
2417658|NCT03452007|Experimental|Bladder Mapping and Training|Individuals already implanted with a spinal cord epidural stimulator will receive epidural stimulation targeted at enhancing both the storage and voiding phase of micturition cycle.
2417659|NCT03451994||Body odor|individuals self-reporting idiopathic body odor with or without bad breath
2417660|NCT03451994||Breath odor|individuals self-reporting idiopathic bad breath but no body odor
2417661|NCT03451981|Sham Comparator|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine.
2417662|NCT03451981|Experimental|Er:YAG laser|Er:YAG laser treatment will be provided on the implant surface.
2417663|NCT03451981|Active Comparator|Air Powder|an Air-Powder treatment will be provided on the implant surface.
2417664|NCT03451968|Experimental|critically ill|"amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive).~it is a single bolus, no other elements or drug will be administered."
2417665|NCT03451968|Active Comparator|control|amino acid tracer injection for metabolism analysis The dose needed to be injected from the tracer element in the beginning of the study is a bolus of 16ml Amino acid tracer (non-radioactive) it is a single bolus, no other elements or drug will be administered.
2417666|NCT03451955|Experimental|Intervention group|Patients in the intervention group follow a gluten-free diet for six months.
2417667|NCT03451955|No Intervention|Control group|Patients in the control group follow their usual diet for six months
2417668|NCT03451942|Experimental|surgery group after FLOT regimen chemotherapy|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
2417669|NCT03451942|Placebo Comparator|FLOT regimen chemotherapy|Continue 4 cycles of the FLOT regimen chemotherapy and evaluate the efficacy every 8 weeks.
3145699|NCT00078806|Experimental|Part 3:|Participants who experienced a flare or completed 3 months of treatment in Part 2 entered Part 3 and received open-label treatment with etanercept at the same dose as in Part 1 (0.4 or 0.8 mg/kg) for up to a maximum of 12 months, including treatment in Part 2.
3145700|NCT00078832|Experimental|anastrozole|anastrozole 1mg
2417672|NCT03451903||Mechanical thrombectomy group|Patients with acute stroke treated by mechanical thrombectomy.
2417673|NCT03451903||Combined procedure group|Patients with acute stroke treated by intravenous thrombolysis (with actilyse) and mechanical thrombectomy.
2417674|NCT03451890|Experimental|Cohort 1: E2730 40 mg|Participants will receive a single oral dose of E2730 40 milligrams (mg) under fasted conditions.
2417675|NCT03451890|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2417676|NCT03451890|Experimental|Cohort 2: E2730 80 mg|Participants will receive a single oral dose of E2730 80 mg under fasted conditions.
2417677|NCT03451890|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2417678|NCT03451890|Experimental|Cohort 3: E2730 120 mg|Participants will receive a single oral dose of E2730 120 mg under fasted conditions.
2417679|NCT03451890|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2417680|NCT03451890|Experimental|Cohort 4: E2730 160 mg|Participants will receive a single oral dose of E2730 160 mg under fasted conditions.
2417681|NCT03451890|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of matching placebo under fasted conditions.
2417682|NCT03451877|Active Comparator|Study group|Children with cycloplegia refractive error more than -6 D TGFB1 AND LAMA1 GENE POLYMORPHISMS were examined
3145701|NCT00078832|Placebo Comparator|placebo|anastrozole 1mg PLACEBO
3145702|NCT00078845|Experimental|Amifostine|500 mg subcutaneous three times a week on Monday, Wednesday and Friday for 4 weeks.
3145703|NCT00078858|Experimental|Treatment (prolonged MMF and truncated CSP)|"CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, and undergo TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic PBMC transplant on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 150 and mycophenolate mofetil PO or IV TID on days 0-30, BID on days 31-150, and then taper to day 180. Treatment continues in the absence of unacceptable toxicity."
3145704|NCT00078923|Experimental|Placebo|Arm I (control group): Patients receive 4 placebo capsules by mouth daily for three weeks.
3145705|NCT00078923|Experimental|Soy isoflavones and placebo|Arm II: Patients receive oral soy isoflavones (PTI G-2535) 150 mg genistein capsules + 3 placebo capsules by mouth daily for 3 weeks.
3145706|NCT00078923|Experimental|Soy Isoflavones/Placebo|Arm III: Patients receive oral soy isoflavones (PTI G-2535) 300 mg genistein capsules + 2 placebo capsules by mouth daily for 3 weeks.
2417690|NCT03451838||Diabetes mellitus|Pregnant women with diabetes mellitus will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
2417691|NCT03451838||control group|Pregnant women with no medical disorders will be examined by us to measures placental volume and thickness ,IV thickness and HbA1c
2417695|NCT03451812||prostate cancer|The newly diagnostic number for the high-risk PCa patients in our hospital annually is ~70, it is clinically feasible to recruit 40 patients a year since the study begins. The study could be completed in 3 years with 120 cases.
2417697|NCT03451786|Experimental|Treatment group|
3186189|NCT00742729|Experimental|Arm 1|Educational small group session with free FOBT kit
3186190|NCT00742729|Experimental|Arm 2|Educational small group session with no FOBT kit
2417700|NCT03451760|Experimental|Feru-guard|Over a 12 week period participants will take two 280 mg hard gel capsules of Feru-guard 100M per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal. Each capsule contains 180.32 mg ferulic acid and 20.02 mg of Angelica archangelica. Total daily dose will be 560mg of Feru-guard 100M, with 360.64 mg of ferulic acid and 40.04 mg of Angelica archangelica.
2417701|NCT03451760|Placebo Comparator|Placebo|Over a 12 week period participants will take two 280 mg hard gel capsules of a placebo per day (1 capsule am, 1 capsule pm). One capsule will be taken in the morning with a meal and one capsule will be taken in the afternoon with a meal.Total daily dosage will be 560mg of a maltodextrin, calcium stearate, and vanilla food flavor mixture.
2417702|NCT03451747||postmenopausal hypertensive women|
2417703|NCT03451747||mached hypertensive men|
2417704|NCT03451734||treatment cohort|in sub-project 1, participants are randomized into olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups, we give them evaluation, and adjust dose of medication and deal with side effect if necessary.
2417705|NCT03451734||adjunctive group|Patients who do not have an ideal response to antipsychotics treatment (reduction rate of Positive and Negative Symptom Scale (PANSS) score less than 25%) in sub-project 2 are recruited in this trial. They are randomly assigned to antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups, and the antipsychotic drugs used at this stage are still consistent with the first trial of sub-project 2. At baseline, 4 weeks and 8 weeks after treatment, all participants receive evaluations.
2417706|NCT03451734||metformin and lifestyle intervention for MetS|Participants who develop MetS at the last visit in sub-project 1 and sub-project 2 are recruited in this trial. Patients are randomized into low-dose metformin (1000 mg/d), high-dose metformin (1500 mg/d), low dose metformin plus lifestyle intervention group (1000 mg/d), high dose metformin plus lifestyle intervention (1500 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
2417707|NCT03451734||metformin and lifestyle prevention for high risk of MetS|Participants who are at a high risk of MetS are recruited in this trial. Participants are randomized into low dose metformin (750 mg/d), high dose metformin (1000 mg/d), lifestyle intervention, and placebo groups. The timepoints of the visits are at baseline, the 4th week, the 8th week, and the 12th week.
2417774|NCT03451266|Placebo Comparator|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (placebo arm).
3145707|NCT00078923|Experimental|Soy Isoflavones|Arm IV: Arm III: Patients receive oral soy isoflavones (PTI G-2535) 600 mg genistein capsules by mouth daily for 3 weeks.
3145708|NCT00078962|Experimental|Treatment (GTI-2040, gemcitabine hydrochloride)|"Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
3145709|NCT00078975|Experimental|Triapine in combination with Gemcitabine|
3145710|NCT00078988|Experimental|Arm I (high-dose chemotherapy and ASCR)|Patients receive high-dose chemotherapy comprising carboplatin IV over 4 hours on days -8 to -6; thiotepa IV over 3 hours and etoposide IV over 3 hours on days -5 to -3; and filgrastim (G-CSF) IV or SC once daily beginning on day 1 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 0.
3145711|NCT00078988|Experimental|Arm II (intermediate-dose chemotherapy and ASCR)|Patients receive intermediate-dose chemotherapy comprising carboplatin IV over 4 hours and thiotepa IV over 3 hours on days 1-2 and G-CSF IV or SC once daily beginning on day 4 and continuing until blood counts recover. Autologous PBSC or bone marrow are reinfused on day 3. Treatment repeats every 28 days for a total of 3 courses.
3186191|NCT00742729|Sham Comparator|Arm 3|Control
3186192|NCT00742742|Experimental|A|Nutrition advice (accroding to AHA recommendation) + 30 grams/day supplement of walnuts,walnuts were incorpatated into bread that provided to the participants
2417708|NCT03451734||validation cohort|in sub-project 2, there are1,800 first-episode schizophrenia patients recruited from 19 hospitals, and six groups as with sub-project 1. The assessments (timepoint and content) are conducted as in sub-project 1.
3145712|NCT00078988|Experimental|Arm III (isotretinoin)|Patients receive oral isotretinoin twice daily on days 1-14. Treatment repeats every 28 days for a total of 6 courses.
2417710|NCT03451708|Experimental|Optimization of OKS|Crossover study examining various OKS protocols on improving symptoms of hemispatial neglect
2417711|NCT03451708|Experimental|Safety and efficacy study|Randomized study assessing the safety and efficacy of OKS in treating hemispatial neglect
2417712|NCT03451708|Experimental|Effect of repetitive stimulation|Benefits of daily, repetitive OKS in treating hemispatial neglect
2417713|NCT03451708|Experimental|OKS and gait|Effect of OKS on gait and balance
2417714|NCT03451695|Experimental|Morphine group|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
2417715|NCT03451695|Placebo Comparator|Placebo group|Placebo group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1 ml).
2417716|NCT03451682|Experimental|procyanidine group|
2417717|NCT03451682|No Intervention|Control group|
2417718|NCT03451669||Shunt suspected to be functioning|
2417719|NCT03451669||Shunt suspected to not be functioning|
2417720|NCT03451643|Experimental|Endoscopic Expandable Stent|Procedure/Surgery. Endeosocpically a self-expandable metal stent will be placed in the colon rectum. Chemotherapy will be added
2417721|NCT03451643|Active Comparator|Colorectal Resection|Procedure/Surgery. A standard open or laparoscopic surgery will be performed to remove the colorectal cancer. Chemotherapy will be added
2417722|NCT03451630|Active Comparator|High-Touch|Delivered primarily via face-to-face interactions, with telephonic interactions and information sharing that does not require access to mobile devices or the Internet. In-person support and/or telephonic interactions to occur at least four times over at least a four-month period.
2417723|NCT03451630|Active Comparator|High-Tech|Delivered via a remote care management platform and digital health tools. Remote care support interactions to occur for at least a four-month period.
2417724|NCT03451630|Active Comparator|Usual Care|Delivered via Health Plan support and resources within 14 days of an initial home or telephonic visit.
2417725|NCT03451617|Other|Xpedition stent delivery system|
2417726|NCT03451617|Other|Alpine stent delivery system|
2417727|NCT03451591|Active Comparator|Isosorbide Mononitrate XL (ISMN)|Oral Isotard® 25mg XL (Isosorbide Mononitrate) tablets. Oral Isotard® 25mg XL: Day 1-5 / 25mg daily morning dose. Day 6 to week 52 / 50mg daily morning dose. Week 53 / 25mg daily morning dose. Week 54 / NIL dose. Or Oral Isosorbide mononitrate (ISMN) non-XL 20mg tablets: Day 1-5 / 20mg daily evening dose. Day 6 to week 52 / 20mg twice daily morning & evening. Week 53 / 20mg daily morning dose. Week 54 / NIL dose.
2417728|NCT03451591|Active Comparator|Cilostazol|Oral Cilostazol 100mg tablets. Day 1-5 / 50mg daily evening dose. Day 6-10 / 50mg twice daily morning & evening. Day 11-15 / 50mg daily morning dose & 100mg daily evening dose. Day 16 to week 52 / 100mg twice daily morning & evening. Week 53 / 50mg twice daily morning & evening. Week 54 / NIL dose.
2417729|NCT03451591|Active Comparator|ISMN XL and Cilostazol|Oral Isotard® 25 mg XL (ISMN) and oral Cilostazol 100mg tablets. Day 1-5 / ISMN - 25mg daily evening dose / Cilostazol - NIL. Day 6-10 / ISMN - 50mg daily morning dose and Cilostazol - NIL. Day 11-15 / ISMN - 50mg daily morning dose / Cilostazol - 50mg daily evening dose. Day 16-20 / ISMN - 50mg daily morning dose and Cilostazol - 50mg twice daily morning & evening. Day 21-25 / ISMN - 50mg daily morning dose and Cilostazol - twice daily, 50mg morning & 100mg evening dose. Day 26-30 ISMN - 50mg daily morning dose and Cilostazol 100mg - twice daily morning & evening. Day 30 to week 52 / ISMN 50mg morning dose and Cilostazol 100mg - twice daily morning & evening. Week 53 / ISMN 25mg daily morning dose and Cilostazol 50mg twice daily morning & evening. Week 54 / NIL dose
2417730|NCT03451591|Placebo Comparator|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol is administered for the entire duration of the study.
3145713|NCT00078988|No Intervention|Arm IV (no isotretinoin)|Patients do not receive maintenance therapy.
2417732|NCT03451552|No Intervention|Control (211 services)|Patients allocated to the control arm will be directed to the Ontario 211 navigation service, which is already available to the general public free of charge. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use existing navigation services provided by Ontario 211 to help them access the CR referred to them by their PHCP. The research assistant will instruct patients to dial 2-1-1 to obtain additional information on the nature of this service.
2417733|NCT03451552|Experimental|Intervention (Patient Navigator)|Patients allocated to the intervention arm will be offered the services of the ARC Patient Navigator. After consenting to participate in the study and completing the telephone survey, the research assistant will inform these patients that they can use the services offered by the ARC patient navigator to help them access the CR referred to them by their PHCP. Following a brief description of the services provided by the navigator (e.g., arrange transportation, make appointments, fill out forms, etc.), patients will be offered to be contacted by the navigator by telephone or to meet with the navigator in person on a day and time that is most convenient for them.
2417734|NCT03451526||Surgeries+adjuvant chemotherapies|Patients who received radical resection of lung cancer + adjuvant chemotherapies
2417735|NCT03451526||Perioperative chemotherapies|Patients who received perioperative chemotherapies
2417736|NCT03451513|Experimental|Pride Body Project (PBP)|Participants assigned to this condition take part in a two-session intervention based on dissonance theory which encourages them to challenge the body ideal.
2417737|NCT03451513|Active Comparator|Media Advocacy (MA)|Participants assigned to this condition take place in a time and attention-matched active control where they discuss the role of media in promoting the body ideal.
2417738|NCT03451500|Experimental|Carbidopa-levodopa 2 tablets daily|carbidopa-levodopa 25-100 mg 2 tablets daily hs
2417739|NCT03451500|Experimental|carbidopa-levodopa 6 tablets daily|carbidopa-levodopa 25-100 mg, 2 tablets, 3 times daily, with breakfast, with supper and hs
2417740|NCT03451500|Placebo Comparator|Placebo|Placebo, 2 tablets, 3 times daily, with breakfast, with supper and hs
2417741|NCT03451487|Placebo Comparator|Reference drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2417742|NCT03451487|Experimental|Test drug (1000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period I and II. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*2 tablets = 1000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2417743|NCT03451487|Placebo Comparator|Reference drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~Panadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study period."
2417744|NCT03451487|Experimental|Test drug (4000mg)|"Eligible subjects were randomly assigned to either of the two treatment sequence.The evaluable subjects were those who had completed both period III and IV. The study was completed when there were at least 12 evaluable subjects.~SafeTynadol® oral dosage form (500 mg*8 tablets = 4000 mg) was orally administered with 240 ml of water once daily in the morning in each of the single-dose study"
3145714|NCT00079014|Experimental|Treatment (triapine, doxorubicin hydrochloride)|"Patients receive doxorubicin IV over 15 minutes on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-4. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients are treated at that dose level."
2417746|NCT03451448||Healthy volunteers|Healthy volunteers to undergo MRI using USPIO contrast
2417747|NCT03451448||Stable coronary artery disease|Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation
2417748|NCT03451448||Recent acute coronary syndrome|Patients with recent (3 months) type 1 myocardial infarction
2417749|NCT03451435|No Intervention|Control|No intervention will be administered in this group as it serves as a control group.
2417750|NCT03451435|Experimental|NAC Treatment|N-Acetyl Cysteine treatment during root canal revascularization
3145715|NCT00079105|Active Comparator|Treatment|Treatment with VEPEMB - Vinblastine sulfate, Cyclophosphamide, Procarbazine hydrochloride, Prednisolone, Etoposide, Mitoxantrone hydrochloride, and Bleomycin sulfate
3145716|NCT00079105|No Intervention|Registration|Registration, without treatment
2417753|NCT03451409|Active Comparator|OCD Proband|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2417754|NCT03451409|Active Comparator|OCD Siblings|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2417755|NCT03451409|Active Comparator|Healthy Controls|Healthy controls (HC, n=50) without a family history of OCD will be matched to SIB.
2417756|NCT03451396|Active Comparator|Mild Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >308 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
2417757|NCT03451396|Active Comparator|Moderate to Severe Dry Eye Cohort|Prospective 3 month study of subjects with Tear Osmolarity >320 and VAS eye dryness ≥ 40 using 5% Lifitegrast ophthalmic solution BID.
2417758|NCT03451383||Breast Cancer Case|Women age 60+ with a newly diagnosed breast adenocarcinoma staged 0-3.
2417759|NCT03451383||Non-Cancer Controls|Women age 60+ with no diagnosis of breast cancer.
2417760|NCT03451357||patients with Dependence degree|Dependence degree already certificated by Dependence Law: It is calculated by accepting an expected proportion of 40% patients with dependence, with a precision 6.5% and confidence level of 95%, obtaining a N= 200 patients. Assuming a 15% of loses, we estimate we will need N=230 to be followed. This sample size would enable us to construct logistic regression models including simultaneously up to 5 predictive factors to assess the relationship between each of the independent variables and the occurrence of dependency.
2417761|NCT03451344|Experimental|Integrated rehabilitation group|Participants will receive the standardized community-based rehabilitation and simultaneously receive a 6-month integrated rehabilitation based on the Community-based Addiction Rehabilitation Electronic System.
2417762|NCT03451344|Active Comparator|Community-based rehabilitation group|Participants will receive the standardized community-based rehabilitation.
2417763|NCT03451331|Experimental|Arm A|Gemcitabine plus carboplatin plus nivolumab
2417764|NCT03451331|Experimental|Arm B|Gemcitabine plus oxaliplatin plus nivolumab
2417765|NCT03451318|Active Comparator|drug therapy|Nasonex(mometasone furoate),1 spray,QD (Quaque Die in Latin),for 3 months.
2417766|NCT03451318|Active Comparator|tonsillar adenoidectomy|tonsillar adenoidectomy
2417767|NCT03451318|Active Comparator|orthodontic treatment|Apply Twin-block appliance combined with maxillary expander
2417768|NCT03451318|Active Comparator|tonsillar adenoidectomy plus orthodontic treatment|Apply Twin-block appliance combined with maxillary expander one month after tonsillar adenoidectomy .
2417769|NCT03451305|Experimental|Pillow group|Before surgery, with the patient lying in the supine position, a soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position. 12 hours duration suggested from 11:00 pm 1 night before the surgery till next day.
2417770|NCT03451305|No Intervention|No pillow group|No intervention was given in this group before surgery.
2417771|NCT03451292|Experimental|Standard Medical Treatment + Albutein 20%|Standard Medical Treatment plus Albutein 20% administrations
2417772|NCT03451292|Active Comparator|Standard Medical Treatment|The sites will follow the Standard Medical Treatment as per their Standard of Care.
2417773|NCT03451266|Experimental|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum (vitamin C arm).
3186193|NCT00742742|Sham Comparator|B|Registed dietians give the advice for health lyfestyle
3186194|NCT00742755|Experimental|Prospective Intervention|Peer navigator intervention
2417775|NCT03451253|Experimental|amino acid mixture beverage|amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
2417776|NCT03451253|Active Comparator|glucose based sports drink|glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.
2417777|NCT03451240|Experimental|Intervention|
2417778|NCT03451227|Experimental|Dexmedetomidine Group|The study drug dexmedetomidine (PrecedexTM) is supplied as dexmedetomidine HCL 200mcg/vial (100mcg/ml). This will be added to 98 ml 0.9% NaCl to achieve a concentration of 2mcg/ml and infused at 0.2-1mcg/kg/hour from the start of the case. The infusion rate will be commenced at 1mcg/kg/hour in those less than or equal to 65 years of age, and at 0.7mcg/kg/hr in those greater than 65 years of age, and then titrated based on the intraoperative sedation scores (to achieve a Sedation and Agitation scale (SAS) score of less than or equal to 4) and cardiovascular parameters (within 30% of baseline).
2417779|NCT03451227|Active Comparator|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline)
2417780|NCT03451214|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 11 mg/d and 25 mg supplemental zinc/d
2417781|NCT03451201|Experimental|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer 3 times a week for 8 weeks
2417782|NCT03451201|Active Comparator|Moderate Continuous Exercise Training|Moderate Continuous Interval Training
2417783|NCT03451201|Other|Non-exercise|Sedentary Type 1 Diabetes Controls.
3145717|NCT00079118|Experimental|docetaxel + irinotecan|"Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.~Patients are followed every 2 months until disease progression and then every 6 months thereafter."
3145718|NCT00079131|Experimental|Treatment (oblimersen sodium)|Patients receive oblimersen IV continuously on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2417786|NCT03451149|Experimental|Intervention|Undergo transjugular intrahepatic portosystemic shunt creation using a radiofrequency wire (Powerwire) in lieu of a trocar needle to cut through liver parenchyma
2417787|NCT03451123|Experimental|FET-PET/MRI|O-(2-[F-18]FET)-L-tyrosine (FET) for brain PET/MRI
2417788|NCT03451110|Experimental|Part 1: Lemborexant plus Loestrin|Healthy female participants will receive a single oral dose of Loestrin 1.5/30 (containing ethinyl estradiol [EE] 0.030 milligrams [mg] and norethindrone [NE] 1.5 mg) in the evening of Day 1 after a fast of at least 3 hours. After a washout period of at least 4 days, participants will receive 10 mg lemborexant orally for 10 days. Lemborexant will continue to be administered in the evening on Days 15 through 18, followed by a single oral dose of Loestrin on Day 15 when administered with lemborexant after fasting in the evening for at least 3 hours.
2417789|NCT03451110|Experimental|Part 2: Lemborexant plus Famotidine|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. On Day 15, participants will receive a single oral dose of 40 mg famotidine, followed at least 2 hours later by a single dose of 10 mg lemborexant. After a washout period of up to 14 days participants will receive 10 mg lemborexant orally for 10 days.
2417790|NCT03451110|Experimental|Part 3: Lemborexant plus Fluconazole|Healthy participants will receive a single oral dose of 10 mg lemborexant in the morning of Day 1 after an overnight fast of at least 10 hours. After a washout interval of approximately 10 days, on Day 11, participants will be administered 400 mg fluconazole followed by 200 mg fluconazole once daily from Days 12 to 26. During this time a single dose of 10 mg lemborexant will be administered following an overnight fast of at least 10 hours along with fluconazole on Day 15 only.
3186195|NCT00742768|Active Comparator|1|softgel capsules
3186196|NCT00742768|Active Comparator|2|Gelpell capsules
3186197|NCT00742794||1|Hymenoptera sting allergic patients under immunotherapy
2417798|NCT03451058||Mild TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2417799|NCT03451058||Moderate to Severe TBI Group|History of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2417800|NCT03451058||Healthy Controls|No history of head injury, Active Duty Service Member or Veteran, age 18-55, fluent in English
2417801|NCT03451045|Experimental|Lenabasum 20 mg BID|
2417802|NCT03451045|Experimental|Lenabasum 5 mg BID|
2417803|NCT03451045|Placebo Comparator|Placebo BID|
2417804|NCT03451019|Active Comparator|sevelamer hydrochloride|the subject receive a single dose of 2,4 g
2417805|NCT03451019|Active Comparator|lanthanum carbonate|the subject receive a single dose of 1.0 g
3145719|NCT00079235|Experimental|Arm I|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.
3145720|NCT00079352|Experimental|Treatment (gemcitabine, irinotecan, alvocidib)|Patients receive gemcitabine IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 15. Patients also receive flavopiridol IV over 60 minutes on days 2 and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2417808|NCT03450993|Experimental|Immediate SMART Program Intervention|Subjects will receive the SMART-3RP intervention following study enrollment.
2417809|NCT03450993|Other|Delayed SMART Program Intervention|Subjects will record symptoms following enrollment and receive the SMART-3RP intervention approximately 3 months following study enrollment.
2417810|NCT03450980|Other|EyeTurn App|All participants will have their eye alignment measured with both the experimental device (EyeTurn app) and the clinical gold standard tests or ground truth (simulated strabismus gaze angles).
2417811|NCT03450967|Experimental|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
2417812|NCT03450954||Case(AMT patients)|patients who have undergone amniotic membrane transplant in our unit up till 2016.
2417813|NCT03450954||Control(Patients without AMT)|bullous keratopathy patients awaiting endothelial keratoplasty
2417814|NCT03450928|Active Comparator|Short POEM|Patients in the Short POEM-group will undergo a Peroral Endoscopic Myotomy (POEM) extended for a total of 7 cm (including 4 cm above the esophago-gastric junction and 3cm on the stomach).
2417815|NCT03450928|Active Comparator|Long POEM|Patients in the Long POEM-group will receive a 12cm-long Peroral Endoscopic Myotomy (POEM), including 9 cm on the esophagus and 3cm on the gastric wall
3186198|NCT00742807|Experimental|1|Administration of low dose of alfentanil hydrochloride before paracervical block
3186199|NCT00742807|Active Comparator|2|Administration of alfentanil hydrochloride dose after paracervical block
2417818|NCT03450902|Experimental|Chinese herb & acupuncture|Participants will take Yiqi Suoquan granule and receive acupuncture.
2417819|NCT03450902|Active Comparator|Chinese herb & sham acupuncture|Participants will take Yiqi Suoquan granule and receive sham acupuncture.
2417820|NCT03450902|Active Comparator|Placebo & acupuncture|Participants will take placebo granule and receive acupuncture.
2417821|NCT03450902|Placebo Comparator|Placebo & sham acupuncture|Participants will take placebo granule and receive sham acupuncture.
2417822|NCT03450889||Intervention arm|This study uses only one arm. All patients in this intervention arm will be surveyed using the aforementioned study protocol, which means patients will undergo a colonoscopy (or sigmoidoscopy in patients with previous subtotal colectomy) with surveillance intervals of either 1 or 2 years, depending on the amount and type of polyps resected during previous surveillance.
2417823|NCT03450876||Healthy Control|Individuals without melanoma (stage III or IV) diagnosis that have been included in the PROFILES cohort
2417824|NCT03450876||24 to < 36 months post-ipilimumab treatment|24 to 36 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2014 in one of the 14 melanoma centers in the Netherlands
2417825|NCT03450876||≥ 36 to < 48 months post-ipilimumab treatment|36 to 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab in 2013 in one of the 14 melanoma centers in the Netherlands
2417826|NCT03450876||≥ 48 months post-ipilimumab treatment|Greater than 48 month post-ipilimumab treatment advanced melanoma patients that were treated with ipilimumab between 2011 and 2012 in one of the 14 melanoma centers in the Netherlands
2417827|NCT03450863||Fast-acting insulin aspart|Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice. The prescription and use of fast-acting insulin aspart is completely independent of this study. Total study duration for the individual patient will be approximately 24 weeks.
2417828|NCT03450850|Other|NOVOTTF-200A|NOVOTTF-200A treatment in Bevacizumab-Naïve Subjects with Recurrent WHO Grade III Malignant Astrocytoma
2417829|NCT03450837||Anabolic androgenic steroids users|"This group had been involved in strength training for at least 2 years, self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year. All participants were on a cycle over the course of the study.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2417830|NCT03450837||Anabolic androgenic steroids nonusers|"This group had been involved in strength training for at least 2 years and they have never took anabolic androgenic steroids.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2417831|NCT03450837||Sedentary control|"This group were sedentary men without cardiovascular disease.~Coronary Computed Tomography Angiography and Macrophage cholesterol efflux mediated by HDL"
2417832|NCT03450824||The study group|The participants with patellofemoral pain.
2417833|NCT03450824||The control group|The participants without patellofemoral pain.
2417834|NCT03450811|Active Comparator|Study group|The patients underwent elective open or laparoscopic inguinal hernia repair at a general surgery clinic.
2417835|NCT03450811|No Intervention|Control group|patients who were admitted to the outpatient clinics with various diseases or healthy persons
2417836|NCT03450798|Active Comparator|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
2417837|NCT03450798|Sham Comparator|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
3186200|NCT00742820|Experimental|1|Calcium Acetate Oral Solution 667 mg per 5 mL
3186201|NCT00742820|Active Comparator|2|Calcium Acetate 667 mg Gelcaps
2417840|NCT03450759|Experimental|Treatment sequence 1|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate)"
2417841|NCT03450759|Experimental|Treatment sequence 2|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 capsule AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 oral suspension (reference)"
2417842|NCT03450759|Experimental|Treatment sequence 3|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (fast rate) AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule"
2417843|NCT03450759|Experimental|Treatment sequence 4|"In Part A, randomized subjects will receive orally single dose of all treatments in fasted condition in the following sequence:~AZD9977 ER capsule (Int. rate) AZD9977 Oral suspension (reference) AZD9977 capsule AZD9977 ER capsule (fast rate)"
2417844|NCT03450746||Healthy patients for orthopaedic surgery|Standard general anaesthesia and ventilation with FiO2 0.50 for at least 45 minutes following the standard settings in our department.
2417845|NCT03450733||Previously Implanted (Group 1)|Subjects previously implanted with components of the Wright Medical Technology (WMT) Metal-on-Metal (MoM) Total Hip Arthroplasty (THA) System
2417850|NCT03450681|Placebo Comparator|No pulsed radiofrequency|Procedure consists of a mock incision at the pulsed radiofrequency needle insertion site and standard perioperative pain management by the pain clinic (femoral catheter and PCA)
2417851|NCT03450681|Experimental|Pulsed Radiofrequency|Procedure consists in pre-operative pulsed radiofrequency under ultrasound guidance of the saphenous nerve and standard postoperative pain management by the pain clinic (femoral catheter and PCA)
3186202|NCT00742820|Other|3|Calcium Citrate 950 mg Caplets
3186203|NCT00742833|Experimental|3|
2417854|NCT03450655|Experimental|Intervention Group|Weeks 1-10: exercise program in group. Weeks 11-20: no intervention. Weeks 21-31: no intervention.
2417855|NCT03450655|Experimental|Control group|Weeks 1-10: no intervention. Weeks 11-20: no intervention. Weeks 21-31: exercise program at home.
2417856|NCT03450642||Observation|Patients presenting with right Iliac Fosse pain
2417857|NCT03450629|Experimental|Brimonidine Tartrate Ophthalmic Suspension|
2417858|NCT03450629|Active Comparator|Brimonidine Tartrate Ophthalmic Solution|
2417859|NCT03450616|Experimental|Negative Pressure Wound Therapy|Subjects will have one venous stasis ulcer treated with the PICO Negative Pressure Wound Therapy Device
2417860|NCT03450616|Active Comparator|Compression Dressing- Standard of Care|Subjects will have one venous stasis ulcer treated with the standard of care compression dressing.
2417861|NCT03450603||stable COPD|Chronic obstructive pulmonary disease (COPD) was confirmed if the patient had a baseline post-bronchodilator FEV1 less than 80% of the reference value and forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) quotient of less than 70%.Select patients with COPD without acute attack within three months．
2417862|NCT03450603||exacerbation of COPD|Exacerbation was defined as an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough, and/or sputum that was beyond normal day to day variations and may have warranted a change in regular medication in a patient with underlying COPD.
2417863|NCT03450577||PCI of bifurcation lesions|Patients who have undergone bifurcation coronary artery stenting.
2417864|NCT03450564|Experimental|Women Education|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
2417865|NCT03450564|Experimental|Male Involvement|In the married women arm there was an intervention with health education provision based on the baseline finding so as to fill the gap.Faema leader and video from (role model women who start to use FP, model who allows his wife to use FP, religious leader, FP experts was used.Health extension workers were responsible in assisting the faema leader. Twice a month there was a provision of health education message about family planning for a total of 9 months.
2417866|NCT03450564|Other|Control group|The third arm in this community-based intervention was following the community without provision of male and married women education. In this arm, there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
2417867|NCT03450551|Experimental|Twin Block|61 patients will receive the Twin Block appliance (one of the three appliances being studied)
2417868|NCT03450551|Active Comparator|Herbst|61 patients will receive the Herbst appliance (one of the three appliances being studied)
2417869|NCT03450551|Active Comparator|Frog distalising appliance|61 patients will receive the Frog distalising appliance (one of the three appliances being studied)
2417870|NCT03450499|Experimental|analgesic effects of ketamine|the experimental group will receive ketamine intravenously at 0.25 mg per kg before skin incision.
2417871|NCT03450499|Placebo Comparator|placebo|they will receive same volume of 0.9% normal saline as calculated for experimental group before skin incision.
2417872|NCT03450486|Experimental|affected limb|measurements of balance from the affected side of individuals with unilateral knee osteoarthritis following an exercise session
2417873|NCT03450486|Active Comparator|unaffected limb|measurements of balance from the unaffected side of individuals with unilateral knee osteoarthritis following an exercise session
3186204|NCT00742833|Placebo Comparator|1|
2417875|NCT03450460|Experimental|1/week peer support|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support program once per week.
2417876|NCT03450460|No Intervention|wait list control group|These individuals with acquired brain injury will receive the Ontario Brain Injury Association Peer Support once the trial period is complete.
2417877|NCT03450434|Experimental|XC8 2 mg|XC8 2mg orally
2417878|NCT03450434|Experimental|XC8 10 mg|XC8 10 mg orally
2417879|NCT03450434|Experimental|XC8 100 mg|XC8 100 mg orally
2417880|NCT03450434|Placebo Comparator|Placebo|Placebo 2 mg, 10 mg or 100 mg orally
2417919|NCT03450174|Experimental|Fortified product plus|this group will receive fortified product along with daily messages on diet diversity and healthy nutrition practices
3186205|NCT00742846|Active Comparator|Group 1|The patient receives intra-articular steroid and local anesthetic injection under fluoroscopy.
2417881|NCT03450421|Experimental|Actamax™Adhesion Barrier|Following Myomectomy, subjects randomized to the Actamax™Adhesion Barrier Arm will have up to 30mL of product applied to all sites of surgery (area of treatment/trauma).
2417882|NCT03450421|No Intervention|Surgical Control|Myomectomy will be performed with no adhesion barrier application.
2417883|NCT03450408|Active Comparator|Placement with gloved hand|The Foley bulb transcervical dilator will be placed blindly with a gloved hand.
2417884|NCT03450408|Active Comparator|Placement with sterile speculum|The cervix will be directly visualized using a sterile speculum, and an instrument will be used to advance the Foley bulb transcervical dilator into the cervical os.
2417885|NCT03450395|Placebo Comparator|Cereal - Cream of Rice|40 g cream of rice
2417886|NCT03450395|Experimental|Cereal - Oats containing beta-glucan|40 g oats
2417887|NCT03450382|Experimental|Hans Kai Participant|Participants receiving Hans Kai intervention
2417888|NCT03450382|No Intervention|Control|Participants not enrolled in Hans Kai
3186206|NCT00742846|Active Comparator|Group 2|The patient receives subacromial steroid and local anesthetic injection under fluoroscopy.
3186207|NCT00742846|Active Comparator|Group 3|The patient receives intra-articular local anesthetic injection under fluoroscopy.
2417891|NCT03450330|Experimental|daily dose of AZD4205|daily dose of AZD4205
2417892|NCT03450317|Experimental|Aspirin|Aspirin 80mg once daily
2417893|NCT03450317|No Intervention|Non-treatment group|No intervention
2417894|NCT03450291|Experimental|Recovered from anorexia nervosa|Those who have a past diagnosis of AN (defined by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria) but are currently recovered, as shown by BMI over 18.5 throughout the last 12 months (self-report and current weight measured). Defined as either 'fully recovered'and: score must be within the 'normal range' of the Eating Disorders Examination Questionnaire (EDE-Q) global mean scores for young women, below 20 on the EAT-26 and below 16 on the Clinical Impairment Assessment for Eating Disorders (CIA); or partially recovered where one or more of these scores may be above the above-mentioned cutoffs.
2417895|NCT03450291|Experimental|High scoring on the EAT-26|Those who score above 20 on the EAT-26, but who do not declare a former diagnosis of an eating disorder (though they may meet criteria for a current diagnosis during the Structured Clinical Interview for the DSM-5).
2417896|NCT03450291|Experimental|Healthy controls|No history of or current diagnosis of any psychiatric disorder (especially eating disorders) which could impact study results.
2417897|NCT03450278|No Intervention|control|canine retraction without any means of acceleration.
2417898|NCT03450278|Experimental|micro-osteoperforation|canine retraction accelerated with micro-osteoperforation
2417899|NCT03450265|Experimental|Hemopatch|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
2417900|NCT03450265|Active Comparator|TachoSil|Patients undergo elective pulmonary resection. Following resection, primary stapling and suturing will be done and air leakage will be assessed. If a specific grade-level of air leakage is present, patients will be randomized and either Hemopatch or TachoSil applied.
3186208|NCT00742846|Active Comparator|Group 4|The patient receives subacromial local anesthetic injection under fluoroscopy.
3186209|NCT00742898|Experimental|1|Non-targeted opt-out rapid HIV screening fully integrated into an urban, inner-city ED.
2417903|NCT03450239|Experimental|Recovered from anorexia nervosa|Women who have recovered from Anorexia Nervosa for over a year. BMI over 18.5, aged 18-40, scores on Eating Disorder Examination (EDE) within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
2417904|NCT03450239|Experimental|Healthy controls|Healthy control women. BMI over 18.5, aged 18-40, scores on EDE within 1 standard deviation of the global mean. All these participants undergo an MRI scan.
2417905|NCT03450226|Experimental|treatment|patients will receive a stellate ganglion block with 10 ml of 0.25 % bupivacaine
2417906|NCT03450226|No Intervention|control|patients will be controlled
2417907|NCT03450213|Active Comparator|Patients with keratoconus|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
2417908|NCT03450213|Placebo Comparator|Normal people at the same age and sex|Pentacam will be used for comparison between astigmatism in patients with keratoconus and normal people at the same age and sex.
2417909|NCT03450200|Experimental|Exercises Group|three times daily exercises of hands and fingers exercises and foot exercises which last for 10 minutes in eight weeks, and health education about diabetic foot care
2417910|NCT03450200|Other|Control Group|health education about diabetic foot care
2417916|NCT03450174|Placebo Comparator|Control|this group, only placebo product will be given
2417917|NCT03450174|Experimental|Formative messages|this group will be received only daily formative messages on diet diversity, healthy and best nutrition practices
2417918|NCT03450174|Experimental|Fortified product|this group will be received only fortified product on alternate day up to 6 months
3186210|NCT00742898|Active Comparator|2|Diagnostic rapid HIV testing fully integrated into an urban, inner-city ED.
3186211|NCT00742911|Experimental|1|
3186212|NCT00742937|Placebo Comparator|A|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of vitamin E will be administer.
2417920|NCT03450161|Experimental|High-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 20 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2417921|NCT03450161|Experimental|Low-Dose Bolus of Fentanyl|"5 minutes prior to sternotomy, patients will receive a fentanyl bolus of 3 mcg/kg BW (verum) and a perfusion pump with sodium chloride (NaCl 0.9%; placebo) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2417922|NCT03450161|Experimental|Continuous Dose of Fentanyl|"5 minutes prior to sternotomy, patients will receive a NaCl 0.9% bolus (placebo) and a perfusion pump with fentanyl (verum) will be begun according to the Shibutani dosing scheme.~As in the other arms, patients will be induced with 3mcg/kg BW fentanyl and the treating physician may administer boli on an as needed basis."
2417923|NCT03450148|Experimental|Pavlok wristband with electric stimulus|Participants in intervention group will wear wristband and will get a slight electric stimulus when they press the device
2417924|NCT03450148|Placebo Comparator|Pavlok wristband without electric stimulus|Participants in control group will wear wristband and will not get a slight electric stimulus when they press the device
2417925|NCT03450135||Mid-pubertal girls|Adolescent girls (ages 11-14) who are undergoing a healthy pubertal transition (Tanner developmental stage 3 or 4) will perform Trier Social Stress Test and Emotional go/no-go task.
2417926|NCT03450122|Experimental|Cohort 0 (cyclophosphamide, T cells, aldesleukin)|Participants receive cyclophosphamide IV over 30-60 minutes on day -2 and autologous NY-ESO-1-specific CD8-positive T lymphocytes IV over 60 minutes on day 0. Then, 6 hours later and twice a day for 14 days, receive aldesleukin SC in the absence of disease progression or unacceptable toxicity.
2417927|NCT03450122|Experimental|Cohort 1 (cyclophosphamide, T cells, aldesleukin, LV305)|Participants receive cyclophosphamide, autologous NY-ESO-1-specific CD8-positive T lymphocytes, and aldesleukin as in Cohort 0. Participants also receive dendritic cell-targeting lentiviral vector ID-LV305 ID on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
2417928|NCT03450109|Experimental|LY01005|One LY01005 3.6 mg gluteal IM injection.
2417929|NCT03450109|Active Comparator|Zoladex|One Zoladex 3.6 mg subcutaneous injection into the anterior abdominal wall
3186213|NCT00742937|Experimental|B|After birth the women will receive one capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E and eight days after delivery the second capsule of 200,000 UI of retinol palmitate (vitamin A)plus vitamin E will be administer.
3186214|NCT00742950|Active Comparator|I|Nasal 2.8-mm corneal incision
3186215|NCT00742950|Active Comparator|II|Temporal 2.8-mm corneal incision
3186216|NCT00742950|Active Comparator|III|Superior 2.8-mm corneal incision
3186217|NCT00742976|Active Comparator|1|8 weeks of insulin Detemir, then cross over to 8 Weeks of Insulatard, then cross over to 1 week of Detemir
2417935|NCT03450057|Experimental|Daratumumab + Dexamethasone|"Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter.~Dexamethasone 40 mg (20 mg for patients>75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
2417936|NCT03450044|Experimental|Vaccinated|Transfer of autologous dendritic cells interspersed with chemotherapy doses
2417937|NCT03450044|No Intervention|Control|Control patients who follow their basic treatment with chemotherapy with the A/C scheme
2417938|NCT03450031|Experimental|NAC (no drug/no device) and NFP|NAC with mixed grass pollen will be conducted. Nasal mucosal inflammatory mediators will be collected via nasal filter paper (NFP)
2417939|NCT03450031|Experimental|NAC (no drug/no device) and NFP AND NLF|NAC with mixed grass pollen will be conducted. Nasal filter paper (NFP)sampling will be conducted from one nostril per time point. Subjects in Cohort B will also undergo nasal lavage (NLF) pre-NAC and at serial time points thereafter up to 8 hours
2417940|NCT03450018|Experimental|SLC-0111 + Gemcitabine|"Dose Level 1 - SLC-0111 (500 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 2 - SLC-0111 (750 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)~Dose Level 3 - SLC-0111 (1000 mg/day PO daily for 28 days) and Gemcitabine (1000 mg/m^2 IV on day 1, 8, and 15)"
2417941|NCT03450005||emerging Candida isolates|Web-based registry of invasive infections by Candida species
2417942|NCT03449992|Experimental|Intervention group|Participants in this group ingested nitrate-rich beetroot juice for 15 days
2417943|NCT03449992|Placebo Comparator|Placebo group|Participants in this group ingested a placebo drink for 15 days
3186218|NCT00742976|Active Comparator|2|8 weeks of Insulin Insulatard, then cross over to 8 weeks of insulin Detemir, then crossover to 1 week of Insulin Insulatard
3186219|NCT00742989|Experimental|A|OLT administration
3186220|NCT00742989|Sham Comparator|B|placebo-OLT
3186221|NCT00743002|Experimental|TT223 with Metformin and/or TZD|TT223 as a treatment for Type 2 diabetes is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
2417948|NCT03449966|Experimental|Target biopsy under pCLE|(Cellvisio® with confocal minoprobe™, Mauna Kea Technologies, France)
2417949|NCT03449966|Active Comparator|Random biopsy at cancer lesion under WLE|WLE (GIF-HQ290, Olympus, Japan) group
2419400|NCT03440138||Musgrove Park Hospital, Taunton, UK|
3186222|NCT00743002|Placebo Comparator|Placebo with Metformin and/or TZD|Placebo as a comparator is administered by injection once daily at 1 mg, 2 mg and 3 mg patients currently treated with Metformin and/or Thiazolidinedione (TZD).
3186223|NCT00743028|Experimental|1|
3186224|NCT00743028|Experimental|2|
3186225|NCT00743028|Experimental|3|
3186226|NCT00743028|Experimental|4|
3186227|NCT00743028|Experimental|5|
3186228|NCT00743028|Experimental|6|
3186229|NCT00743041|Experimental|1|Standard of Care plus EFT (Emotional Freedom Techniques)
3186230|NCT00743041|No Intervention|2|Standard of Care (SOC)
2417950|NCT03449940|Active Comparator|Immediate repair (group 1)|"Penile explorations were done within 24 hours of presentation, under general or spinal anaesthesia.~1g Ceftriaxone IV was given.~Incision-- Subcoronal, circumferential & degloving.~Repair-- Continuous technique with inverted knots using 3-0 polyglactin suture.~All patients were discharged from hospital within 24 hours."
2417951|NCT03449940|Active Comparator|Delayed repair (group 2)|"Patients were not admitted; instead they were discharged from hospital and given an elective surgery date. Oral Diclofenac Sodium 50mg was prescribed to be taken as needed and instructions to abstain from any sexual activity.~In an ambulatory setting, surgery was done 7 - 10 days later.~1g Ceftriaxone IV was given.~Local anaesthesia (dorsal penile nerve block): 1% Lidocaine 10cc was given.~Incision--- 2 - 3cm localized incision over the site of the rolling sign.~Repair--- Continuous technique with inverted knots using 3-0 polyglactin suture."
2417952|NCT03449927|Active Comparator|Control Arm: Regular menu|"Calorie count initiated on day +1 of transplant and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for control group: standard of care, verbal or printed handouts, standard educations created by Barnes Jewish Hospital (BJH) oncology dietitians"
2417953|NCT03449927|Experimental|Intervention Arm: Specialized Menu|"Calorie count and tool provided on day +1 and ending upon count recovery~Symptom worksheet initiated on day +1 of transplant and ending upon count recovery (absolute neutrophil count of 1000)~Goals to monitor: calorie and protein intake, self-reported diarrhea and nausea~Interventions provided for intervention group: standard of care provided by BJH oncology dietitians, tools including nausea and diarrhea menus and follow up by registered dietitian (RD) to provide additional counseling on menus as symptoms arise"
2417954|NCT03449901|Experimental|Cohort 1: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~Treatment may continue for up to 34 cycles (103 weeks)"
2417955|NCT03449901|Experimental|Cohort 2: ADI-PEG 20 + Gemcitabine + Docetaxel|"ADI-PEG 20 will be given on Day -7 of Cycle 1 and then on Days 1, 8, and 15 of each subsequent cycle. Cycles are 21 days. ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m2 via intramuscular injection into either the deltoid or gluteal muscle.~Gemcitabine will be given intravenously at a dose of 600 mg/m2 over 90 minutes on Days 1 and 8 of each cycle. Docetaxel will be given intravenously at a dose of 60 mg/m2 over 60 minutes on Day 8 of each cycle. Patients started on gemcitabine at a dose of 900 mg/m2 or 750 mg/m2 or docetaxel at a dose of 75 mg/m2 per previous protocol version will be allowed to continue at that dose level~After Cycle 8, patients may continue on ADI-PEG 20 alone (without gemcitabine and docetaxel) upon request.~Treatment may continue for up to 34 cycles (103 weeks)"
2417956|NCT03449888||St. Louis VA Healthcare System stress testing referrals|St. Louis VA Healthcare System cardiac stress testing laboratory referrals who are eligible and willing to complete an arm exercise ECG stress test, a treadmill ECG stress test if able, a regadenoson myocardial perfusion imaging stress test, and a coronary artery calcium score and cardiac computed tomographic angiography evaluation within 60 days if not referred for invasive coronary arteriography.
2417957|NCT03449862|Experimental|LEGAL-COST|Clinicians were first presented malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan) then patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test)
2417958|NCT03449862|Active Comparator|COST-LEGAL|Clinicians were first presented with patient out-of-pocket cost information for brain CT image (which provides them insight into what the patient is likely to pay for the test) then malpractice case law summary information (which suggests clinician not likely to be sued for not ordering CT scan)
2417959|NCT03449849|Other|Base diet|Subjects will consume a base diet prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
2417960|NCT03449849|Other|Kale Treatment|Subjects will consume 500 g of kale per 2000 kcal of food, split between breakfast and dinner, as a supplement to the base diet.
2417961|NCT03449836|Experimental|Streptococcus salivarius 24SMBc + Strept.oralis 89a|spray with Streptococcus salivarius 24SMBc + Strept. oralis 89a
2417962|NCT03449836|Active Comparator|fluticasone + mometasone|spray with fluticasone and mometasone
2417963|NCT03449836|Placebo Comparator|placebo|spray with isotonic solution
2417964|NCT03449823||TTTS Cases|Cases of monochorionic / diamniotic twin pregnancies diagnosed with twin-twin transfusion syndrome.
2417965|NCT03449823||MCDA Controls|Controls of monochorionic / diamniotic twin pregnancies without a diagnosis of twin-twin transfusion syndrome.
2417966|NCT03449810|Experimental|DSE plus MET (group A)|"The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.~The MET procedure will involve a total of 5-10 contralateral isometric voluntary contractions that will be resisted by force equal to the participant's for 30 seconds with 5 seconds rest between contractions (corresponding to 20-30%)."
2417967|NCT03449810|Active Comparator|DSE only (group B)|The DSE will consist of seven exercise activities that will be administered at random viz; 1. Bridging 2. Supine twist stretch 3. Double leg knee to chest stretch 4. Plank heel raise 5. Ball squat 6. Leg press on ball 7. Hip Lifts.
2417968|NCT03449810|Active Comparator|Standard Physiotherapy Treatment (group C)|This group will involve classical massage, therapeutic exercises (strengthening spinal and abdominal muscles) and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region. The participants will be asked to perform the therapeutic exercises once a day at home.
2417969|NCT03449797|Sham Comparator|Group A|AAVS performed with no intraprocedural rapid cortisol assay
2417970|NCT03449797|Experimental|Group B|AVS performed plus intraprocedural rapid cortisol assay
2419401|NCT03440138||University of Gothenburg, Sweden|
3186231|NCT00743067|Experimental|Cohort 1|Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
2417975|NCT03449732|Experimental|PDR measurement group A|Two measurements of PDR perioperatively before and after opioid administration in toddlers (28 days until 23 months)
2417976|NCT03449732|Experimental|PDR measurement group B|Two measurements of PDR perioperatively before and after opioid administration in children (2 until 11 years)
2417977|NCT03449732|Experimental|PDR measurement group C|Two measurements of PDR perioperatively before and after opioid administration in adolescents (12 until 18 years)
2417978|NCT03449719|Active Comparator|Abiraterone|The treatment phase consists of systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist (control arm).
2417979|NCT03449719|Experimental|Abiraterone associated withAblative Radiation|"the patients in the experimental arm will receive SBRT to all metastatic lesions, concomitantly with abiraterone acetate.~SBRT will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations.~Considering an Alfa/beta of 3, a BED3 > 100 Gy is recommended"
2417980|NCT03449693|Experimental|Magnesium Oxide Supplement|Magnesium Oxide 250 mg tablet, daily for 30 days.
2417981|NCT03449693|No Intervention|No Supplement|No Intervention
3145721|NCT00079378|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days.~Cohorts of 6 patients receive escalating doses of decitabine until the MEPD is determined. The MEPD is defined as the dose at which at least 5 of 6 patients meet gene methylation criteria and no more than 1 of 6 patients experiences DLT.~Once the MEPD is determined, patients receive decitabine at that dose level administered as above and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days.~Cohorts of 3-6 patients receive escalating doses of valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. The MEPD of valproic acid is then determined using established gene methylation and toxicity criteria. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity."
3145722|NCT00079404|Experimental|Arm I|Patients with solid tumors receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-120 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2417984|NCT03449667|Active Comparator|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
2417985|NCT03449667|Sham Comparator|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
2417986|NCT03449654|Other|Liraglutide|
2417987|NCT03449654|Other|placebo|
2417988|NCT03449641|Other|Positive airway pressure (PAP) treatment|Positive airway pressure (PAP),which reverses upper airway obstruction, is effective in the majority of patients with stable obesity hypoventilation syndrome (OHS).
2417989|NCT03449628|Experimental|L. casei DG®|"Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
2417990|NCT03449628|Placebo Comparator|Placebo|"Interventions : capsules for oral use, indistinguishable from active product.~1 capsule, b.i.d. for 12 weeks"
2417991|NCT03449602|Experimental|Mini-thoraoscopy|The mini-thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 5.5 mm and a working channel diameter of 3.5 mm.
2417992|NCT03449602|Active Comparator|Conventional rigid thoracoscopy|The rigid thoracoscope manufactured by Richard Wolf GmbH, Knettligen, Germany will be used for performing thoracoscopic pleural biopsies. It has an outer diameter of 10 mm and channel internal diameter of 5 mm.
2417993|NCT03449589||Smokers|RA patients currently smoking
2417994|NCT03449589||Former smokers|RA patients who previously smoked
2417995|NCT03449589||Non smokers|Non smoking RA patients
3145723|NCT00079430|Experimental|Treatment (adjuvant, paclitaxel, carboplatin, bevacizumab)|Patients receive paclitaxel IV over 3 hours followed by intraperitoneal carboplatin over 15 minutes on day 1 in course 1. Beginning in course 2, patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2417998|NCT03449563|Placebo Comparator|Placebo group (group G)|
2417999|NCT03449563|Active Comparator|Ultrasound-guided TPVB group (group U)|
2418000|NCT03449563|Experimental|open TPVB group(group E)|
2418001|NCT03449550|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
2418002|NCT03449550|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP) or Standard Polysomnography (PSG)
2418003|NCT03449537|Experimental|EHCF+LGG|extensively hydrolyzed casein formula supplemented with the probiotic Lactobacillus rhamnosus GG
2418004|NCT03449537|Active Comparator|AAF|hypoallergenic formula based on amino acid-based formula
2418005|NCT03449524|Active Comparator|75mg CXA-10|Once daily dosing of 75mg CXA-10 in the morning
2418006|NCT03449524|Active Comparator|150mg CXA-10|Once daily dosing of 150mg CXA-10 in the morning
2418007|NCT03449524|Placebo Comparator|Placebo|Once daily dosing in the morning
2418155|NCT03448484|Experimental|Intervention|Intervention (agriculture-focused package + nutrition-sensitive and nutrition-specific interventions=integrated package)
3145724|NCT00079443|Experimental|Treatment|"PHASE II: Patients receive FR901228 IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~Patients who achieve a complete or partial remission receive 2 additional courses (for a total of 6 courses). Patients with stable disease after 4 courses or progressive disease at any time after 2 courses proceed to the phase I portion of the study.~PHASE I: Patients receive rituximab IV over approximately 4-8 hours on day 1; fludarabine IV over 10-30 minutes on days 2-4; and FR901228 IV over 4 hours on days 2, 9, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3145725|NCT00079456|Experimental|Treatment (temsirolimus)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2418012|NCT03449498|Experimental|study group|Intensive qualitative functional therapy
2418013|NCT03449498|Experimental|control group|Intensive functional therapy
2418014|NCT03449459|Experimental|oral probiotics|
2418015|NCT03449459|Experimental|aerosol inhaled amikacin|
2418016|NCT03449459|Experimental|combined vaccination|
2418017|NCT03449459|No Intervention|conventional therapy (blank control)|According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.
2418030|NCT03449420||Post Partum Hemorrhage|Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge
2418031|NCT03449394|Active Comparator|Delusions (Tx)|
2418032|NCT03449394|No Intervention|Delusions (TAU)|
2418033|NCT03449394|Active Comparator|Depression (Tx)|
2418034|NCT03449394|No Intervention|Depression (TAU)|
3145726|NCT00079482|Active Comparator|1|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of 1 to 6 months, the induction regimen will be MEC.
3145727|NCT00079482|Active Comparator|2|Induction chemotherapy with or without sequential treatment with oral CEP-701 at 80 mg bid. For patients with duration of first CR of more than 6 months to 24 months, the induction regimen will be HiDAC.
2418037|NCT03449368||Cohort 1|Includes age group 5-10 with a cap at 50 subjects. This is a retrospective, observational study.
2418038|NCT03449368||Cohort 2|Includes age group 11-15 with a cap of 50 subjects. This is a retrospective, observational study.
2418039|NCT03449368||Cohort 3|Includes age group 16-20 with a cap of 40 subjects. This is a retrospective, observational study.
2418040|NCT03449368||Cohort 4|Includes age group 21-30 with a cap of 40 subjects. This is a retrospective, observational study.
2418041|NCT03449368||Cohort 5|Includes age group 31-40 with a cap at 40 subjects. This is a retrospective, observational study.
2418042|NCT03449368||Cohort 6|Includes age group 41-50 with a cap at 40 subjects. This is a retrospective, observational study.
2418043|NCT03449368||Cohort 7|Includes age group 51-70 with a cap at 40 subjects. This is a retrospective, observational study.
2418044|NCT03449355||vaginal group|
2418045|NCT03449355||cesarean section group|
2418047|NCT03449329|Placebo Comparator|placebo SIP block|This group will receive a placebo SIP block injection with 60mL NaCl 0.9%
2418048|NCT03449329|Active Comparator|Locoregional SIP block|"This group will receive a SIP block using:~3mg/kg Ropivacain 1%~1mcg/kg dexmedetomidine (Dexdor®) 100mcg/ml Addition of NaCl 0.9% up to 60ml"
2418049|NCT03449316|Experimental|Inhaler technique education|This group will receive a structured and regular follow-up plan, with education on inhaler technique. Patients will be trained by a Family Doctor (the primary investigator) in terms of the inhaler technique using placebo devices similar to their own devices. A teach-to-goal approach will be used, repeating all correct steps as many times as needed in order for patients to perform them correctly at each evaluation. There will be visits at baseline and after 3, 6 and 12 months to assess outcomes. In each visit, and prior to the main intervention with the primary investigator, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator.
2418050|NCT03449316|No Intervention|Usual Care|"This group will receive usual care from their own Family doctors, with no specific intervention. Each doctor will perform the necessary consultations according to his real life judgment. Besides this, this group will perform visits at baseline and after 3, 6 and 12 months to assess secondary outcomes. At each visit, assessment of the inhaler technique and application of all questionnaires (clinical control, treatment adhesion and quality of life) will be performed by a secondary blinded investigator. At any appointment, if the patient asks for or if the clinician decides to teach inhaler technique, that will be recorded.~If any adjustments are made in drug classes or device types in every participants, this information will be recorded."
3145728|NCT00079547|Active Comparator|1|Low-calorie diet
3145729|NCT00079547|Experimental|2|Low-carbohydrate diet
3145730|NCT00079586|Active Comparator|Heparin|unfractionated heparin will be administered as per institutional practice
3145731|NCT00079586|Experimental|Angiomax|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
3145732|NCT00079599|Experimental|1|
3145733|NCT00079599|Placebo Comparator|2|
3145734|NCT00079612|Experimental|Arm 1|
3145735|NCT00079612|Placebo Comparator|Arm 2|
3145736|NCT00079716|Experimental|1|
3145737|NCT00079820|Experimental|A|MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112
3145738|NCT00079820|Experimental|B|MVA3000 Smallpox vaccine (1x10-8) with no Challenge
3145739|NCT00079820|Placebo Comparator|C|Placebo
3145740|NCT00079820|Experimental|D|MVA3000 Smallpox vaccine (1x10-7) with Dryvax challenge at Day 112
3145741|NCT00079820|Experimental|E|MVA3000 Smallpox vaccine (1x10-6) with Dryvax challenge at Day 112
3145742|NCT00079911|Experimental|Suppressive + Episodic Therapy|Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.
2418051|NCT03449303|Active Comparator|EOI|10% dilution of Curcuma longa, Piper nigrum, Pelargonium asperum, Zingiber officinale, Mentha x piperita, and Rosmarinus officinalis ct. cineole in Simmondsia chinensis
2418052|NCT03449303|Placebo Comparator|Placebo|Simmondsia chinensis
2418053|NCT03449290|Experimental|Kinesio taping group|Kinesio taping was applied on trunk muscles
2418054|NCT03449290|Sham Comparator|Control group|Sham Kinesio taping was applied on trunk muscles
2418055|NCT03449277|Active Comparator|take oral nifedipine tablets|Women who take the oral tablets of nifedipine till discharge of hospital
2418056|NCT03449277|Active Comparator|take oral labetalol tablets|Women who take the oral tablets of labetalol till discharge of hospital
3145743|NCT00079911|Placebo Comparator|Episodic Therapy|Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.
2418058|NCT03449251|Experimental|Substudy 1A - Apelin|In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range
2418059|NCT03449251|Experimental|Substudy 1B - Apelin/Normal Saline|In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline
2418060|NCT03449251|Experimental|Substudy 2A - Relaxin/Normal Saline|In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin
2418061|NCT03449251|Experimental|Substudy 2B - Relaxin|In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)
2418062|NCT03449251|Experimental|Substudy 3A - Relaxin with Apelin/Saline|In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)
2418063|NCT03449251|Experimental|Substudy 3B - Apelin with Relaxin/Saline|In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)
2418064|NCT03449251|Experimental|Substudy 4 - Apelin and Relaxin|In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin
2418065|NCT03449238|Other|pembrolizumab and SRS|Pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
2418066|NCT03449225|No Intervention|Control Arm|The participant will be given a digital device (IPad or Kindle Fire) to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once the survey is complete, the participant will proceed with standard education, provided by a resident/physician in the clinic, about prenatal screening and testing for chromosome conditions and for carrier status. Once the standard education has been completed, the participant will be approached to complete a post-education survey which includes questions about knowledge, intent to have or decline screening or testing, and demographic variables.
2418067|NCT03449225|Experimental|Test Arm|• The participant she will be given a digital device on which to access the computer aided genetics educational module. Prior to accessing the module, the patient will be asked to complete a pre-education survey (web-based pre-intervention survey housed on the Qualtrics platform). Once she has completed the survey, she will interact with the Computer-Aided Genetic Education Module which is tailored for her clinical situation. Once the participant has completed reviewing the module, she will be asked to complete the web-based post-module survey which includes questions about knowledge, intent to have or decline screening or testing, acceptability of the module, and demographic variables.
2418068|NCT03449212||SOD1 ALS|
2418069|NCT03449212||Sporadic ALS|
2418070|NCT03449212||Asymptomatic SOD1 gene carriers|
2418071|NCT03449199|Experimental|TMX-049 dose 1|
2418072|NCT03449199|Experimental|TMX-049 dose 2|
2418073|NCT03449199|Placebo Comparator|TMX-049 Placebo|
2418074|NCT03449186||Pregnancy group|Women, who were in their second trimester (weeks 16-24) or third trimester (weeks 25-34)selected for the study. Saliva and GCF samples were collected and clinical periodontal measurements were made gently
2418075|NCT03449186||Postpartum group|Postpartum women 6 months after giving birth recalled. Saliva and GCF samples were collected and clinical periodontal measurements were made.
2418076|NCT03449173|Experimental|Sunitinib|Sunitinib orally administered at 50 mg once daily for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks
2418077|NCT03449160|Active Comparator|Physical Therapy|Receive standard physical therapy
2418078|NCT03449160|Experimental|posture training device|Receive a posture training device in addition to standard physical therapy
2418085|NCT03449121|Experimental|Slow breathing|Slow breathing techniques with exhale greater than inhale
2418154|NCT03448497||Advanced Melanoma patients who intiated first-line therapy|patients who initiated any first-line therapy for advanced melanoma and had not previously received treatment for their advanced disease
2418156|NCT03448484|Other|Control|Control (agriculture-focused package)
3145744|NCT00079963|Experimental|X|Vitamin C
3145745|NCT00079963|Experimental|Y|Vitamin E
3145746|NCT00079963|Placebo Comparator|Z|Placebo
3145747|NCT00080093|Experimental|1|Participants will receive individual feedback and specially-tailored manuals at study entry and at Months 2 and 4
3145748|NCT00080093|Experimental|2|Participants will receive general HIV information feedback and the best-available informational manual at study entry and at Months 2 and 4
3145749|NCT00080145|Active Comparator|risperidone plus parent management training|
3145750|NCT00080145|Active Comparator|risperidone only|
3145751|NCT00080236|Placebo Comparator|Donor organ placebo and Recipient placebo|
3145752|NCT00080236|Active Comparator|Donor organ: IDN-6556 (15μg/ml), Recipient: Placebo|
3145753|NCT00080236|Active Comparator|Donor organ: IDN-6556 (5 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
3145754|NCT00080236|Active Comparator|Donor organ: IDN-6556(15 μg/ml), Recipient: IDN-6556 0.5 mg/kg|
3145755|NCT00080262|Experimental|1|
3145756|NCT00080314|Active Comparator|A1|
3145757|NCT00080314|Placebo Comparator|A2|
3145758|NCT00080327|Active Comparator|1|
3145759|NCT00080327|Active Comparator|2|
3145760|NCT00080327|Active Comparator|3|
3145761|NCT00080327|Placebo Comparator|4|
3145762|NCT00080444|Experimental|Part 1: Aprepitant|Day 1: aprepitant 125 mg orally (PO), ondansetron 0.15 mg/kg x 3 doses intravenously (IV), dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For 1 cycle and up to 9 subsequent optional cycles.
2418089|NCT03449095|Experimental|Alcohol Administration|A moderate dose of alcohol (Target BAC .08%)
2418090|NCT03449095|No Intervention|Control Beverage Administration|Participants consume a non-alcoholic beverage
2418091|NCT03449082|Experimental|High concentration of Allo-ASC group|High concentration of Allo-ASC 0.5cc (Total: 10 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2418092|NCT03449082|Experimental|Low concentration of Allo-ASC group|Low concentration of Allo-ASC 0.5cc (Total: 1 million cells) & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2418093|NCT03449082|Placebo Comparator|Placebo Comparator (Fibrin) group|Normal saline 0.5cc & Fibrin glue 0.5cc by ultrasonographic guided intra-tendon injection
2418094|NCT03449069|Experimental|MSC-AFP|This is a single treatment group study. All patients will receive treatment of a stem cell coated fistula plug.
2418095|NCT03449056|Experimental|TREATMENT|salbutamol nebulization
2418099|NCT03449017|Experimental|E-cig use condition|Participants self-administer their own electronic cigarette device
2418100|NCT03448978|Experimental|Descartes-08 plus fludarabine/cyclophosphamide pretreat|Autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
2418103|NCT03448926||DCIS|Patients must have histologically confirmed ductal carcinoma in situ (DCIS) in a single breast without evidence of invasive cancer (presence of lobular carcinoma in situ (LCIS) or other benign breast disease in addition to DCIS is acceptable)
2418104|NCT03448913||PECS block+ General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received PECS block AND general anesthesia for the surgery.
2418105|NCT03448913||General anesthesia|Patients undergoing mastectomy, partial mastectomy and/or axillary clearance who received general anesthesia only for the surgery.
2418106|NCT03448900|Experimental|Multicomponent intervention|The intervention group consisted in face-to-face 50-minute meeting [motivational interviewing (MI)]; online self-help material focused on: (1) decisions; (2) moods; (3) social life; (4) smoking health effects; and (5) quitting; e-mail 15 days before the MI, group therapy 2 months after the MI (60 minutes), a second follow-up visit 4 months after the MI (20 minutes).
2418107|NCT03448900|Active Comparator|Brief advice|The control group received a brief advice (5-10minutes) and a self-help pamphlet called 'Stop smoking'. Before giving brief advice, the nurse assessed smokers' habits and their willingness to quit. As is usually in this type of studies there were no follow-up sessions for this group.
2418108|NCT03448887|Experimental|Study group|Extended HD with MCO dialyzer
2418109|NCT03448887|Active Comparator|Control group|Online hemodiafiltration
2418110|NCT03448874|Experimental|Seal-G MIST System|Seal-G MIST System is a surgical sealant that will be applied adjunctively to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
2418111|NCT03448874|No Intervention|Standard of care|Patients in the control arm will receive the standard of care [SOC] for colorectal resection surgery with primary anastomosis (no additional intervention)
2418112|NCT03448861|Experimental|Polso Wearable watch|Polso Wearable watch for the purpose of NEWS measurement
2418113|NCT03448848|Experimental|study|
2418114|NCT03448848|Placebo Comparator|control|
2418115|NCT03448835|Experimental|atezolizumab and chemotherapy|1 cycle of atezolizumab followed by 4 cycles atezolizumab, capecitabine, oxaliplatin and docetaxel
2418116|NCT03448822||sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure.
2418117|NCT03448809|Experimental|MMM (Mind My Mind training)|Mind My Mind training
2418118|NCT03448809|Active Comparator|TAU (Treatment as Usual)|Treatment as Usual
2418119|NCT03448796|Active Comparator|HTO-group|Group receives opening wedge high tibial osteotomy with Tomofix -plate. Operative intervention is followed by supervised physiotherapeutic rehabilitation.
2418120|NCT03448796|Active Comparator|FT -group|Group receives only supervised physiotherapeutic rehabilitation.
2418121|NCT03448770|Active Comparator|Lactulsoe|Lactulose : 20-30gm 2-3 doses per day
2419402|NCT03440138||AZ Sint-Jan Hospital in Bruges, Belgium|
3145763|NCT00080444|Active Comparator|Part 1: Standard Therapy|Day 1: placebo to aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 16 mg PO. Day 2: placebo to aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 3: placebo for aprepitant 80 mg PO, dexamethasone 8 mg PO. Day 4: dexamethasone 8 mg PO. For 1 cycle; participants may receive open-label aprepitant for up to 9 subsequent optional cycles.
3145764|NCT00080444|Active Comparator|Part 2: Aprepitant|Day 1: aprepitant 125 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 8 mg PO. Day 2: aprepitant 80 mg PO, ondansetron 0.15 mg/kg x 3 doses IV, dexamethasone 4 mg PO. Day 3: aprepitant 80 mg PO, dexamethasone 4 mg PO. Day 4: dexamethasone 4 mg PO. For up to 10 cycles.
3145765|NCT00080626|Experimental|Docetaxel|Neoadjuvant therapy with docetaxel (IV, 100 mg/m2, every 14 days with growth factor support with pegfilgrastim) for a total of 4 cycles prior to conventional surgery for breast cancer.
3145766|NCT00080665|Experimental|Imatinib mesylate and docetaxel|Imatinib mesylate (400-600 mg, oral, once daily) and docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
3145767|NCT00080678|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel 30 mg/m^2 intravenous over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral 600 mg imatinib mesylate.
3145768|NCT00080678|Placebo Comparator|Docetaxel + Placebo|Docetaxel 30 mg/m^2 intravenous (IV) over 60 minutes on days 1, 8, 15, and 22 in 42-day cycles, with daily oral placebo.
3145769|NCT00080743|Active Comparator|Tamoxifen|Tamoxifen 20 mg po once daily
3145770|NCT00080743|Placebo Comparator|Placebo|Placebo comparator one tablet po once daily
2418123|NCT03448757|Experimental|Autonomic response|"Group for determination of biofeedback response - 40 individuals. For the formation of this study group of subjects, 20 healthy volunteers and 20 patients with advanced hepatocellular carcinoma will be selected and studied.~Group for determination of ideal frequency - 20 patients. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma participants in the group will be selected and studied to determine biofeedback response.~Group for determination of new specific frequencies - 20 individuals. For the formation of this study group of subjects, 20 patients with advanced hepatocellular carcinoma not exposed to any specific frequency will be selected."
2418124|NCT03448744|Experimental|combiantion therapy group|thymosin alpha 1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
2418125|NCT03448744|Placebo Comparator|entecavir group|ETV (0.5 mg orally, daily) at least for 72 weeks
2418126|NCT03448731|Experimental|Doxycycline|Doxycycline 50 mg p.o. daily during 6 weeks
2418127|NCT03448718|Experimental|Olaparib Monotherapy|The starting dose of olaparib tablets will be dependent on the subject's calculated creatinine clearance (CrCl). Subjects with a CrCl of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
2418128|NCT03448705|Experimental|Group 1 - Study drug 1 (i.e. 4Fluart ID 1 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 1 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
2418129|NCT03448705|Experimental|Group 2 - Study drug 2 (i.e. 4Fluart ID 2 µg/0.1 ml QIV)|Vaccination of 12 subjects will be performed with the intradermal quadrivalent influenza vaccine containing 2 µg haemagglutinin per virus strain in 0.1 ml as a single dose.
2418130|NCT03448705|Active Comparator|Group 3 - Comparator drug (i.e. 3Fluart IM 6 µg/0.5 ml TIV)|Vaccination of 12 subjects will be performed with the intramuscular trivalent influenza vaccine containing 6 µg haemagglutinin per virus strain in 0.5 ml as a single dose.
2418131|NCT03448692|Experimental|PF-06730512 Cohort 1|Subjects in cohort 1 will receive dose 1 Intravenous (IV) infusion.
2418132|NCT03448692|Experimental|PF-06730512 Cohort 2|Subjects in cohort 2 will receive dose 2 IV infusion.
3186232|NCT00743067|Experimental|Cohort 2|Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
2418134|NCT03448653|Experimental|Colonoscopy with NBI|
2418135|NCT03448627||Group 1: HSCT recipients|Pulmonary functions [spirometry], maximal exercise capacity [Modified-Incremental Shuttle Walk Test (ISWT)], inspiratory and expiratory muscle strength (MIP and MEP, respectively) [mouth pressure device] and peripheral muscle strength [hand-held dynamometer] were evaluated in allogeneic HSCT recipients (n=66).Vital signs, dyspnea and fatigue perception [Modified Borg Scale] were recorded as pre-post measurements of Modified-ISWT.
2418136|NCT03448627||Group 2: healthy individuals|Healthy individuals (n=50) were selected from individuals without known and diagnosed any chronic diseases. Similar measurements were applicated in healthy individuals.
2418137|NCT03448601|No Intervention|Non-tailored control group|Participates will read the standard Alzheimer's disease and Precision Medicine brochure with standard text-based content NOT specifically tailored for AI/ANs.
2418138|NCT03448601|Experimental|Culturally tailored video intervention group|Participants will view a short 5-minute culturally-tailored video.
2418139|NCT03448601|Experimental|Culturally tailored brochure intervention group|Participants will read a culturally-tailored educational brochure on Alzheimer's disease and Precision Medicine.
2418140|NCT03448588||group with normal T4 level or T4/T3|participants with T4 within 4.3-12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) ≤7.52, which are considered to be normal T4 level and T4/T3.
2418141|NCT03448588||group with elevated T4 level or T4/T3|participants with T4 more than 12.5ug/dl and ratio of T4/T3(T4(ug/dl)/T3 (ng/ml)) > 7.52, which are considered to be elevated T4 level and T4/T3.
2418142|NCT03448575|Sham Comparator|Control - Medication Alert Only|The control arm medication alert is a simple text pop-up in the EMR that will inform the prescriber of Choosing Wisely® recommendations developed the American Psychiatric Association regarding antipsychotic medication use in children and adolescents.
2418143|NCT03448575|Experimental|Intervention - Alert + CAP Review AND Enhanced BH Access|"The intervention alert prompts the prescriber to keep/remove the antipsychotic order, and/or order any study services: behavioral health navigation, expedited psychotherapy access, virtual consult with a child and adolescent psychiatrist (CAP). Passive case review by the study CAP will occur for all intervention arm cases. A virtual consult will be scheduled if the prescriber ordered it or the CAP needs to discuss the case. The CAP will provide the prescriber with a written summary of his/her review.~Following review by the CAP, a navigator reaches out to the eligible intervention arm patient/family to offer extra support. The navigator's role is to (a) provide extra support to facilitate access and engagement in appropriate psychosocial therapies; (b) coordinate short-duration bridging therapy sessions for teens/families not engaged in psychotherapy, when appropriate; and (c) keep the prescriber informed of any clinically relevant updates."
2418144|NCT03448562|Experimental|Study Group|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm (STABLE-SR)
2418145|NCT03448562|Active Comparator|Control Group|CPVI alone
2418146|NCT03448549|Experimental|Group A (TGOP-OX)|Colorectal cancer patients p-staged III are randomized and assigned with TGOP-OX (Tegafur，gimeracil and oteracil potassium+Oxaliplatin) as adjuvant chemotherapy.
2418147|NCT03448549|Active Comparator|Group B (XELOX)|Colorectal cancer patients p-staged III are randomized and assigned with XELOX (Xeloda+Oxaliplatin) as adjuvant chemotherapy.
3186233|NCT00743067|Experimental|Cohort 3|Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
2418150|NCT03448523|Experimental|Right To Play's Positive Child and Youth Development program|Behavioural intervention
2418151|NCT03448523|No Intervention|Control|No intervention; intervention to be offered after end line assessment
2419403|NCT03440138||Bristol|
2419404|NCT03440138||Cleveland Clinic, Weston, Florida, USA|
2418157|NCT03448471||Group 1: severe-fatigued recipients|These recipients had Fatigue Severity Scale score ≥36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
2418158|NCT03448471||Group 2: non-severe-fatigued recipients|These recipients had Fatigue Severity Scale score <36. All recipients evaluated with similar methods. Meaurements were Pulmonary function tests, Respiratory muscle strength, Peripheral muscle strength, Functional exercise capacity, Dyspnea, Fatigue, Depression and Quality of life.
2418159|NCT03448458|Experimental|Gallium Ga 68-DOTATATE PET/CT|Patients receive gallium Ga 68-DOTATATE IV. Within 55-70 minutes, patients undergo PET (positron emission tomography)/CT (computed tomography).
2418160|NCT03448445||High-risk MCI|This cohort will include participants with high-risk mild cognitive impairment (MCI).
2418161|NCT03448445||Low-risk MCI|This cohort will include participants with low-risk MCI.
3145771|NCT00080756|Experimental|Group 1 (planned risk reduction mastectomy)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 6 months. Patients then undergo planned risk reduction mastectomy.
3145772|NCT00080756|Active Comparator|Group 2 (continued survaillance)|Patients receive deslorelin, estradiol, and testosterone intranasally QD for 10 months. Patients then undergo continued surveillance through 10 months.
2418168|NCT03448380||SMBG and FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
2418169|NCT03448367||SMBG/FreeStyle Libre|During the intervention phase, subjects will use FreeStyle Libre Flash Glucose Monitoring System for 6 months to managed their diabetes.
2418170|NCT03448354|Experimental|NAC-IDS-HIPEC|Under the clinicians' decision, HIPEC procedures will be performed at the time of IDS.
2418171|NCT03448354|No Intervention|NAC-IDS|Under the clinicians' decision, HIPEC procedures will not be performed at the time of IDS.
2418172|NCT03448328|Experimental|Pea Protein|NUTRALYS pea protein supplement
2418173|NCT03448328|Experimental|Whey Protein|Whey protein supplement
2418174|NCT03448328|Active Comparator|Apple juice|Apple juice
2418175|NCT03448315|Active Comparator|real tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
2418176|NCT03448315|Sham Comparator|sham tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions) but stimulation device is turned off without the participant knowledge
2418177|NCT03448302||Patients with colorectal adenocarcinoma|The patients will undergo computed tomography perfusion
2418178|NCT03448289|No Intervention|Control|This group will not receive the RLPT.
2418179|NCT03448289|Experimental|Intervention|This group will receive the RLPT.
2418180|NCT03448276|Experimental|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
2418181|NCT03448276|Active Comparator|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
2418182|NCT03448263|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
2418183|NCT03448263|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
2418184|NCT03448263|Experimental|Reciproc instruments|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
2418185|NCT03448250|Experimental|Optimune|Optimune is an web-based psychological intervention for women with breast cancer. Beyond established CBT techniques targeting depression, anxiety, and fatigue, this intervention specifically includes elements that have shown effects on markers of immune status and inflammation, including sleep, stress management (e.g., mindfulness-based techniques) and lifestyle optimization (dietary and physical activity advice). Content is continuously adapted to users' concerns and needs. It contains interactive dialogues that can be accessed via computer or smart-phone, illustrations, audio files and motivating text messages. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
2418186|NCT03448250|Active Comparator|Care-as-Usual|As in the experimental arm, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Optimune six months post-baseline (i.e., wait list with respect to Optimune access).
2418187|NCT03448237|Active Comparator|Speech therapy|Speech therapy adapted to the child,
2418188|NCT03448237|Experimental|Combined Treatment|Association of speech therapy and proprioceptive treatment, adapted to the child.
2418191|NCT03448211|Experimental|Para-toluenesulfonamide Injection (PTS)|Investigational product
2418192|NCT03448198|Other|Knee arthritis|Total knee replacement
2418193|NCT03448185|Placebo Comparator|Control|Subjects randomized to control group will receive olive oil placebo capsules and yoga intervention for 1 year.
2418194|NCT03448185|Experimental|Exercise and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as aerobic exercise intervention for 1 year.
2418195|NCT03448185|Active Comparator|Yoga and omega-3 fatty acids|Subjects will receive high dose omega-3 fatty acids as well as yoga intervention for 1 year.
2418196|NCT03448185|Active Comparator|Exercise control|Subjects will receive olive oil placebo as well as aerobic exercise intervention for 1 year.
2418197|NCT03448172|Experimental|Investigational Product|[14C]PF-05221304
2418198|NCT03448159|Experimental|Fluoxetine Hydrochloride|Fluoxetine (Prozac) will be administered to this group. A ramp up period of 3-5 weeks will take place where the patient takes 10mg of Prozac per day. After that, the participant will take the regular dose of 20mg for the duration of the exercise intervention (12 weeks).
3145773|NCT00080782|Experimental|Arm I: Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1, and oral celecoxib twice daily in absence of disease progression.
3145774|NCT00080782|Experimental|Arm II: No Celecoxib|Doxorubicin IV over 30 minutes on days 1, 8, 15, and 22 + Strontium chloride Sr 89 IV on day 1.
3145775|NCT00080808|Active Comparator|Arm I|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
2418199|NCT03448159|Placebo Comparator|Placebo|"An over-encapsulated placebo, or sugar pill (so it appears identical to the trial drug) will be administered to this group. During the 3-5 week ramp up period for the experimental group, these participants will take a placebo identical to the 10mg Prozac capsule. After that, the participant will take a placebo identical to the 20mg Prozac capsule for the duration of the exercise intervention (12 weeks)."
2418200|NCT03448146|Experimental|Para-Toluenesulfonamide|".The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~. In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient."
2418201|NCT03448133|Experimental|rTMS treatment group|The participants will be devided into rTMS treatment and sham treatment by means of randomized methods.The protocol of treatment is to use rTMS with high frequency 10/20Hz 120%RMT 20 times for one month. The device is Magtism rTMS made in London, UK
2418202|NCT03448133|Sham Comparator|sham treatment group|The control group is to receive sham treatment. The device is the same as the one used in the real treatment group.
2418203|NCT03448120|No Intervention|Control Group|The volunteers who will remain in prolonged rest (10 minutes for homeostasis plus 30 minutes of no intervention).
2418204|NCT03448120|Experimental|Acupuncture Group|The volunteers will receive six needles in six acupoints in the non-dominant upper limb for 30 minutes.
2418205|NCT03448120|Experimental|Dry needling Group|The volunteers will receive application of six needles arranged in the non-dominant biceps brachialis for 30 minutes.
2418206|NCT03448107|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2418207|NCT03448107|Active Comparator|Complex Prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
2418208|NCT03448094|Experimental|Resveratrol|500mg of Veri-te Resveratrol (consumed as two 250mg tablets, at two timepoints each day).
2418209|NCT03448094|Placebo Comparator|Placebo|Matched placebo capsules (1 capsule consumed at two timepoints each day).
2418210|NCT03448081|Active Comparator|SNA-120 + Calcipotriene|
2418211|NCT03448081|Placebo Comparator|Placebo + Calcipotriene|
3186234|NCT00743067|Experimental|Cohort 4|Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
2418214|NCT03448055|Other|Interventional|Immunocal 20gm daily
3145776|NCT00080808|Active Comparator|Arm II (No sural nerve grafting)|Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.
3145777|NCT00080847|Experimental|Arm I (closed to accrual as of 9/21/04)|Patients receive rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 1 and oral prednisone on days 1-5.
2418217|NCT03448029||Endovascular Patients|Patients undergoing endovascular interventions for symptomatic PAD
2418218|NCT03448016|Experimental|Alcohol use disorders|[C-11]NOP-1A PET Scan
2418219|NCT03448016|Experimental|Controls|[C-11]NOP-1A PET Scan
2418220|NCT03448003|Experimental|Group I (IO prevention program)|Patients attend IO prevention program consisting of 1-2 physical activity, nutrition and diet, and mind-body practice sessions over 60 minutes weekly for 12 weeks. Patients also attend a behavioral counseling session once weekly for up to 26 weeks. Patients complete exercises over 30-60 minutes 3-5 times weekly for 12 weeks.
2418221|NCT03448003|Active Comparator|Group II (no intervention)|Patients receive no intervention. After 26 weeks, patients may crossover to Group I.
2418222|NCT03447990|Other|Part 1/SAD and Part 2/MAD - drug|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
2418223|NCT03447990|Other|Part 1/SAD and Part 2/MAD - placebo|"Part 1/SAD: Crossover, Single ascending dose of MYK-491/placebo~Part 2/MAD: Parallel, multiple ascending dose of MYK-491/placebo"
2418224|NCT03447977|Experimental|cervical group|cervical spinal mobilizations, exercises, 2 session for 6 weeks
2418225|NCT03447977|Experimental|thoracic group|cervical and thoracic spinal mobilizations, exercises, 2 session for 6 weeks
2418226|NCT03447977|Experimental|exercise group|exercises, 2 session for 6 weeks
2418227|NCT03447964||Type 1 diabetes|dosing of sphingolipids
2418228|NCT03447964||Type 2 diabetes|Dosing of sphingolipids
2418229|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 20%TTV|Group 1: total dose = 20% total tumor volume
2418230|NCT03447951|Experimental|PTS100 (Para-Toluenesulfonamide): 30%TTV|Group 2: total dose = 30% total tumor volume
2418231|NCT03447938|Active Comparator|CABG with sternotomy|Patients in this group will undergo coronary artery bypass grafting (CABG) in the usual way, through an incision in the middle of the chest, through the breastbone or sternum (conventional CABG).
2419405|NCT03440138||Oswaldo Cruz German Hospital, Sao Paolo, Brazil|
3145778|NCT00080847|Experimental|Arm II|Patients receive oblimersen IV continuously on days 1-7; rituximab IV over 6 hours, cyclophosphamide IV over 15-45 minutes, doxorubicin IV over 5-20 minutes, and vincristine IV over 5-15 minutes on day 5; and oral prednisone on days 5-10.
3145779|NCT00080873|Experimental|Receive Traumeel S|
3145780|NCT00080873|Placebo Comparator|Receive placebo|
3145781|NCT00080886|Other|Arm 1|
2418232|NCT03447938|Experimental|Minimally-invasive CABG|Patients in this group will undergo coronary artery bypass grafting (CABG) using a minimally-invasive approach (MICS CABG), through smaller incisions between the ribs.
2418233|NCT03447925|Experimental|Medicinal Plant X Salicylate|Treatment Group (TG) will receive topical treatment with medicinal plant and Salicylate Group (SG) will receive topical treatment with salicylate 10%, both once a day, for 30 consecutive days.
2418234|NCT03447925|Experimental|Medicinal Plant X Vaseline|Treatment Group (TG) will receive topical treatment with medicinal plant and Control Group (CG) will receive topical treatment with vaseline cream, both once a day, for 30 consecutive days.
2418235|NCT03447912|Experimental|Intervention Condition|Fourteen communities will be assigned to the intervention.
2418236|NCT03447912|No Intervention|Control Condition|The 14 communities assigned as controls will participate in the population-level survey and will be provided with a site-specific summary of findings but will not participate in any aspects of the intervention. To examine potential contamination in the control communities, a follow-up interview will be conducted with public health center leaders to assess any local coalition or grassroots actions regarding tobacco control that may have naturally occurred or be influenced by coalition activity in other communities.
2418237|NCT03447899|Experimental|ABC Intervention|"The investigators will deliver the Attachment and Biobehavioral Catch-up (ABC) in the home weekly using live, in-room coaching, to give caregivers feedback as they use targeted skills during interactions with the child. The intervention will last 10 sessions. Study participants in both groups will complete study measures at baseline, 1 month, 3 months, post-intervention, 6 months, and 12 months."
2418238|NCT03447899|No Intervention|Standard of Care|"Subjects will receive normal standard of care without the Attachment and Biobehavioral Catch-up (ABC)."
2418239|NCT03447886||Quality Of Life|"This study uses qualitative research methods, specifically semi-structured interviews.~This will include moderator guide development,~Phone interviews with breast cancer survivors will be conducted~Qualitative data analysis of the phone interviews will be conducted"
2418240|NCT03447873|Active Comparator|Triple therapy|To Continue with triple therapy with Elvitegravir/cobicistat + tenofovir alafenamide + emtricitabine or Dolutegravir + abacavir + lamivudine once daily.
2418241|NCT03447873|Experimental|Switch to dual therapy A|Switch to dual therapy with Darunavir/cobicistat (800150 mg) + lamivudine (300 mg) once daily once daily.
2418242|NCT03447873|Experimental|Switch to dual therapy B|Switch to dual therapy with Dolutegravir (50 mg) + lamivudine (300 mg) once daily
2418243|NCT03447860|Active Comparator|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress.
2418244|NCT03447860|Experimental|PAACC|A mindfulness-based multi-component caregiver intervention to reduce caregiver stress.
2418245|NCT03447847|Experimental|Phase 1|A=oligomineral water, B=oligomineral water
2418246|NCT03447847|Experimental|Phase 2|A=oligomineral water, B=bicarbonate-rich water
2418247|NCT03447847|Experimental|Phase 3|A=bicarbonate-rich water, B=oligomineral water
2418248|NCT03447847|Experimental|Phase 4|A=bicarbonate-rich water, B=bicarbonate-rich water
2418249|NCT03447834|Experimental|Selective intracoronary hypothermia + PPCI|Patients will be eligible for this study if they are admitted for acute anterior wall ST-elevation myocardial infarction with total ST-segment deviation of at least 5 mm. If the patient has TIMI grade flow 0 or 1, the experimental arm will be treated by selective intracoronary hypothermia just before and after reperfusion, in addition to routine PPCI.
2418250|NCT03447834|Other|Standard PPCI|The control group will receive routine PPCI.
3186235|NCT00743067|Experimental|Cohort 5|Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.
3186236|NCT00743080|Experimental|1|Laparoscopic myomectomy and supracervical hysterectomy using GYNECARE MORCELLEX
3186237|NCT00743080|Active Comparator|2|Laparoscopic myomectomy and supracervical hysterectomy using ROTOCUT G1
2418254|NCT03447808|Experimental|Treatment (daratumumab, ibrutinib)|Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of subsequent courses. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Beginning course 2, patients also receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2418255|NCT03447795|Experimental|autogenous tooth grafted sites|
2418256|NCT03447795|Active Comparator|autogenous demineralised dentin grafted sites|
2418257|NCT03447782|Experimental|NDPH Persistent|"Patients will be evaluated in clinic 1 month after the phone call evaluation. At this time, patients will begin a 3 month trial of low-dose naltrexone (Naltrexone HCL powder compounded to provide 4.5mg once per day orally).~Patients will be evaluated in clinic 3 months after beginning treatment with naltrexone."
3186238|NCT00743132||1|Postoperative no renal dysfunction
3186239|NCT00743132||2|Postoperative renal dysfunction
2418260|NCT03447756|Experimental|ABX-1431|One or more oral capsules containing 2 mg or 10 mg or 50 mg of ABX-1431 HCl or matching placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of ABX-1431 HCl with the daily dose between 8 mg and 24 mg of ABX-1431. Each patients dose will be determined by the Investigator based on assessment of adverse events.
2418261|NCT03447756|Placebo Comparator|Placebo oral capsule|One or more oral capsules containing placebo are administered daily to enrolled patients. Patients will undergo a blinded dose escalation. All patients will receive placebo on some days to assess safety and neuropathic pain. Patients will undergo an optimized titration of placebo. Each patients dose will be determined by the Investigator based on assessment of adverse events.
3186240|NCT00743171||1|Good adherent patient: patient performed ≥ 80% of predicted HS within 24 months
3186241|NCT00743171||2|Moderate adherent patient: patient performed ≥ 50% of predicted HS within 24 months
3186242|NCT00743171||3|Non-adherent patient: patient performed < 50% of predicted HS within 24 months.
3186243|NCT00743210|Experimental|1|Oral L-citrulline, 3 grams once per day for 3 weeks.
3186244|NCT00743210|Placebo Comparator|2|Placebo, 3 grams once per day for 3 weeks.
3186245|NCT00743223||1|Study-group: The volunteers were selected on a randomized form among the individuals who went to the clinic of orofacial pain and temporomandibular disorders of São Paulo Hospital.
3186246|NCT00743223||2|Control-group: The volunteers were selected on a randomized form among the individuals who went to the dental offices of the researchers.
3186247|NCT00743236|Experimental|Arm I|Patients undergo warm ischemia followed by partial nephrectomy.
2418266|NCT03447717|Experimental|ActiGait|Patients who get the ActiGait implant
2418267|NCT03447704|Experimental|BCD-085 (netakimab)|
2418268|NCT03447704|Placebo Comparator|Placebo|
2418269|NCT03447691|Experimental|DES Group|"Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min~DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
2418270|NCT03447691|Active Comparator|TIVA Group|"Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion.~TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate)."
2418271|NCT03447678|Experimental|Pembrolizumab|subjects with PD-L1 low (PD-L1Lo), EGFR wt, EML4/ALK fusion negative NSCLC
2418272|NCT03447665|No Intervention|Control|Infant sleep monitoring and parental surveys only
2418273|NCT03447665|Experimental|Intervention (Bedtime only)|Infant behavioral sleep intervention implemented at bedtime only. Parents are instructed to soothe/help their infant back to sleep after night wakings. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
2418274|NCT03447665|Experimental|Intervention (All night)|Infant behavioral sleep intervention implemented at bedtime and after each subsequent infant night waking. Includes a tailored sleep schedule and bedtime routine, as well as support from a sleep interventionist.
2418275|NCT03447652|No Intervention|Control Group|Each patient in the control group did not perform any rehabilitation exercises. Over the intervention time frame, the patient was required to check in with a member of the research team each week to discuss any changes in their ankle or report any injury incidence.
2418276|NCT03447652|Experimental|Resistance Band Group|Each session, patients completed resistance training using a resistance band in 4 directions of ankle motion (plantarflexion, dorsiflexion, inversion and eversion). Patients would complete 3 sets of 10 repetitions during each session. Every 3 sessions, the band resistance would increase.
2418277|NCT03447652|Experimental|Biomechanical Ankle Platform System|The Biomechanical Ankle Platform System board is an oval shaped board that utilizes a half-sphere on the bottom of the board to allow the patient to train on an unstable surface. A one legged stance on their involved limb was performed on the Biomechanical Ankle Platform System board while clockwise and counterclockwise circles were completed. The initial rotation of direction was selected by the patient and changed every 10 seconds of the 40-second trial. Five 40-second trials were completed with 1-minute rest intervals in between the trials. Progression was determined by the supervising clinician and was based on the patient's ability to make smooth transitions between direction changes and completion of smooth circular rotations in both directions.
2418278|NCT03447652|Experimental|Combination Group|Patients completing the combination protocol completed both the resistance band and Biomechanical Ankle Platform System board protocols during each session. The order of exercise completion was counterbalanced for each session.
3186248|NCT00743236|Experimental|Arm II|Patients undergo cold ischemia followed by partial nephrectomy.
3186249|NCT00743301|Active Comparator|Olive oil|
2418281|NCT03447626||Prospective Group- Robotic UKA Arm|Robotic UKA with the MAKO machine.
2418282|NCT03447626||Control- Fixed and Mobile UKA Arm|Patients who have received fixed or mobile bearing UKA
2418283|NCT03447626||Control-Total Knee Arthroplasty|Patients who have had cemented or cementless total knee arthroplasty
2418284|NCT03447613||elderly participants with surgery|The studied cohort were participants 50 years old or older, without a diagnosis of dementia, and scheduled to have orthopedic or urological surgery under spinal anesthesia at Shanghai 10th People's Hospital.
2418285|NCT03447600|Experimental|Alternate day fasting|Participants randomised to Alternate Day Fasting weight loss intervention. One day fasting of 25% total energy requirements alternated with one day ad libitum intake until study completion at >/=5% weight loss which is an average of 12 weeks.
2418286|NCT03447600|Active Comparator|Continuous caloric restriction|Participants randomised to continuous caloric restriction weight loss intervention. Every day intake of 75% total energy requirements until study completion at >/=5% weight loss which is an average of 12 weeks.
2418287|NCT03447587|Experimental|Electroacupuncture|Subjects will receive 4 weeks of acupuncture following with a semi-standardized protocol.
2418288|NCT03447587|Placebo Comparator|Sham acupuncture group|Subjects will receive sham acupuncture with the same sterilization procedure as traditional acupuncture group.
3186250|NCT00743301|Experimental|Palm olein|
2418321|NCT03447340|Experimental|Cafeteria and behavior|Receives cafeteria intervention and behavior intervention
2418322|NCT03447340|Active Comparator|Cafeteria only|Receives only cafeteria intervention
2419406|NCT03440138||Clínica Las Condes, Santiago, Chile|
3186251|NCT00743301|Active Comparator|Lard|
3186252|NCT00743327||1|Participants receiving ADT and pioglitazone
3186253|NCT00743327||2|Participants receiving ADT only
3186254|NCT00743327||3|Participants not receiving ADT and in remission from prostate cancer
2418291|NCT03447561|Experimental|Anticipatory + consummatory food reward|PET-MR scan session with a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (viewing neutral images and drinking sips of water) and the fourth block the 'food reward condition' (viewing high-calorie food images and drinking sips of chocolate milkshake).
2418292|NCT03447561|Experimental|Consummatory food reward|PET-MR scan session with purely consummatory food reward (drinking sips of chocolate milkshake). This scan session will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' (drinking sips of water) and the fourth block the 'food reward condition' (drinking sips of chocolate milkshake).
2418293|NCT03447548|Experimental|Processing speed training|Neurofeedback processing speed training
2418294|NCT03447548|Active Comparator|Active control|Computer games
2418295|NCT03447535||classic oppositional defiant disorder|"CODD Group:  classic  oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group CODD ( classic  oppositional defiant disorder): teacher report SDQ total difficulties score (≥ 12), parents report SDQ total difficulties score (≥14)"
2418296|NCT03447535||intrafamilial oppositional defiant disorder|"IODD group: intrafamilial oppositional defiant disorder~SDQ total difficulties score and the parents report SDQ total difficulties score:~Group IODD (Intrafamilial Oppositional Defiant Disorder): teacher report SDQ total difficulties score normal (<12), parents report SDQ total difficulties score abnormal (>16)"
2418297|NCT03447509|Active Comparator|Experiment 1a|Examine physiological mechanisms contributing to the control of precision and power grip behaviors. To accomplish this aim the investigators propose to complete one main experiment. The investigators will test the hypotheses that there are two fundamentally distinct modes of hand operation after SCI. One involves brainstem pathways, and permits whole-hand 'power grip', while the other involves corticospinal and motor cortical connections, and allows a wide range of fractionated finger movements (precision grip) after SCI. Measurements of corticospinal, reticulospinal, and motoneuron excitability will be tested during index finger abduction, precision and power grip.
2418298|NCT03447509|Active Comparator|Experiment 1b|To accomplish this aim the investigators propose to complete one main experiment. The investigators will use iTMS and/or an acoustic startle stimuli to test the hypothesis that induced-plasticity protocols (iTMS and startle stimuli) will enhance EMG and force output in hand muscles during grasping. In a randomized sham crossover design, SCI and controls will be assigned to two groups: (1) iTMS applied during precision and power grip (two randomized sessions), and (2) startle applied during precision and power grip (two randomized sessions).
2418299|NCT03447509|Active Comparator|Experiment 2|To accomplish this aim the investigators propose to complete one main experiment. The investigators will combine iTMS and/or acoustic startle with precision and power grip training to test the hypothesis that 'precision and power grip training outcomes will be enhanced by iTMS and startle induced plasticity'. In a randomized sham controlled design, SCI and control subjects will be assigned to: training+iTMS and training+sham iTMS and training+startle and training+sham startle.
2418300|NCT03447496||Closed reduction|The children were treated with closed reduction.
2418301|NCT03447496||Open reduction|The children were treated with open reduction.
2418302|NCT03447483|Other|Cohort of patients starting a treatment by ICI|
2418303|NCT03447470|Other|Monotherapy RXC004 - Module 1|Patients will be given RXC004 at a specified dose level and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD
2418304|NCT03447470|Other|Combination RXC004 plus Nivolumab - Module 2|Patients will be given RXC004 at specific doses in combination with a standard dose of Nivolumab and reviewed for Dose Limiting Toxicities Once the DLT period is complete RXC004 will be given at a higher dose until MTD
2418305|NCT03447457|Other|standard oxygen group|Patients are treated with standard oxygen delivered through nasal cannula, face mask or non-rebreathing reservoir
2418306|NCT03447457|Other|High-flow oxygen group|Patients are treated with high-flow nasal cannula oxygen continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min
2418307|NCT03447444|Other|music and physical activity|An intervention consisting of physical activity, music and walking, was systematically implemented for eight weeks
2418308|NCT03447431||MSI colon tumours|MSI colon tumours (as compared to MSS CRCs and matching normal colonic mucosa) Identification of exon/intron sites affected by aberrant splicing events due to MSI in CRC
2418309|NCT03447418|Other|no treatment, open label|
2418310|NCT03447405|Experimental|Dino Egg Safety and useability|Test the usability of the device (safety for the NICU was confirmed), not the effectiveness of the parents' voice delivery for the infant. Parent and nursing questionnaires about the importance of the device availability and its usability will be collected from parents and RN staff that choose to provide the feedback.
2418311|NCT03447405|No Intervention|Standard of Care|
2418312|NCT03447392|Experimental|patient education and Chinese medicine|1-hour, one-on-one teaching session with a educator to the standard discharge education of Integrated Traditional and Western Medicine
2418313|NCT03447392|No Intervention|patient education|no discharge education
2418314|NCT03447379|Active Comparator|P2Y12 monotherapy after 3 months of DAPT|P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)
2418315|NCT03447379|Active Comparator|Dual-antiplatelet therapy for a year|DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year
2418316|NCT03447366|Experimental|Mitral doppler|Mitral doppler before and after vascular filling
2418323|NCT03447327|Other|operated group|patients undergoing surgery for chronic subdural hematoma by single burr hole under local anaesthesia
3186255|NCT00743353|Experimental|A|16 subjects to be enrolled; Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
3186256|NCT00743379|Experimental|A|TH-302 in combination with Gemcitabine. 1,000 mg/m2 of Gemcitabine is administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
3186257|NCT00743379|Experimental|B|TH-302 in combination with Docetaxel. 75 mg/m2 of Docetaxel is administered IV over 60 minutes on Day 1 of a 21-day cycle.
3186258|NCT00743379|Experimental|C|TH-302 in combination with Pemetrexed. 500 mg/m2 of Pemetrexed is administered IV over 10 minutes on Day 1 of a 21-day cycle.
3186259|NCT00743405|Other|Cohort 1|Subjects will be receive GSK1034702 0.5 milligram (mg) following the dose escalation plan
3186260|NCT00743405|Other|Cohort 2|Subjects will be receive GSK1034702 5 mg following the dose escalation plan
3186261|NCT00743418|Other|1|Healthy controls Mini Mental State evaluation score >28/30
3186262|NCT00743418|Other|2|Mild Cognitive Impairment: Mini Mental State Evaluation Score (MMSE)=26-28/30
3186263|NCT00743418|Other|3|Mild Dementia: Mini Mental State Evaluation Score (MMSE)=21-25/30
3186264|NCT00743457||VPS Patients|Children 6 months-18 years with VPS and symptoms of possible shunt failure
3186265|NCT00743470|Experimental|A, B|Group 1 receives regimen A and B. A: Healthy volunteers, receiving one 150 mg rifabutin QD alone. B: Healthy volunteers, receiving 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
3186266|NCT00743470|Experimental|C|Group 2 receives regimen C. C: 150 mg rifabutin QD+ two lopinavir/ritonavir 200/50 mg tablets BID.
3186267|NCT00743496|Experimental|Group 1|Participants who consent to the study will receive Anti-GD2 antibody.
3186268|NCT00743522||Control|PROVE Trial settings
3186269|NCT00743522||Experimental|Pre-selected settings
3186270|NCT00743535|Experimental|1|Transobturatory correction of anterior defect plus TOT
3186271|NCT00743535|Active Comparator|2|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
3186272|NCT00743548|Active Comparator|1|Interdental brush (IB), the intervention is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
2418342|NCT03447301|Experimental|Extra virgin olive oil|Extra virgin olive oil (30mL) daily
2418343|NCT03447301|No Intervention|Control|No consumption of extra virgin olive oil
2418344|NCT03447275||Controls|Apparently healthy subjects without type 2 diabetes
2418345|NCT03447275||Patients with type 2 diabetes|type 2 Diabetes since 5 years or longer
3186273|NCT00743548|Placebo Comparator|2|Dental floss (DF), the positive control, is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
3186274|NCT00743561|Other|1|
3186275|NCT00743587|Placebo Comparator|A|
3186276|NCT00743587|Active Comparator|B|
3186277|NCT00743587|Active Comparator|C|
3186278|NCT00743587|Active Comparator|D|
3186279|NCT00743600|Experimental|1|Patients with shoulder pain who were clinically referred to Ultrasound for evaluation
3186280|NCT00743600|Active Comparator|2|healthy volunteers who do not have shoulder pain
3186281|NCT00743626|Other|1|Healthy patients screened for cervical cancer
3186282|NCT00743639|Other|1|Interventional
3186283|NCT00743678|Experimental|NEO|NEO : Neoadjuvant therapy with FOLFOX6 plus cetuximab
3186284|NCT00743691|No Intervention|Arm1|Make a diagnosis of Neonatal infections and refer patients according to IMNCI guideline
3186285|NCT00743691|Active Comparator|2|Health extension Workers will Make a diagnosis of Neonatal infections and treat with antibiotics when referal is not possible
3186286|NCT00743743|Experimental|1|receive 1 Longevinex brand capsule daily containing 215 mg of resveratrol active ingredient
3186287|NCT00743743|Placebo Comparator|2|Receive 1 capsule daily for 52 weeks containing placebo for comparison to experimental arm
3186288|NCT00743756|Experimental|1|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for twelve consecutive months. In addition, the subjects received diabetes education at every visit (8 clinic visits and 8 phone calls)
3186289|NCT00743756|Experimental|2|A total of 20 African-American patients with type 2 diabetes will be randomized to receive home-delivered meals for six consecutive months. In addition, the subjects received diabetes education for up to twelve months(8 clinic visits and 8 phone calls)
3186290|NCT00743756|Other|3|20 subjects received 12 months of diabetes education (8 clinic visits and 8 phone calls)
3186291|NCT00743769|Active Comparator|2|"Thymosin Beta 4~A single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD (once a day)"
3186292|NCT00743769|Placebo Comparator|1|Placebo A single bolus injection of 0.0 mg QD of thymosin beta 4
3186293|NCT00743795|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 48 weeks + 24 weeks treatment-free follow-up (n = 50)
3186294|NCT00743795|Experimental|2|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up (n = 100)
3186295|NCT00743795|Experimental|3|Peginterferon and ribavirin + GS 9190 40 mg BID for 48 weeks + 24 weeks treatment-free follow-up. However, subjects who achieve RVR (HCV RNA undetectable at Week 4) and maintain that response through Week 24 will stop all study drugs at Week 24 and be followed for an additional 48 weeks (n = 50).
3186296|NCT00743821||TBI Patients|Individuals who have suffered a mild traumatic brain injury and have persistent post-concussive symptoms (PCS)
3186297|NCT00743821||Normals|Individuals of comparable age and education who have not suffered a traumatic brain injury
3186298|NCT00743834|Other|A|Effectiveness of Luvox CR plus Web-based CBT for OCD
3186299|NCT00743847|Placebo Comparator|placebo|
3186300|NCT00743847|Active Comparator|varenicline 0.5 mg BID|
3186301|NCT00743847|Active Comparator|varenicline 1mg BID|
2418346|NCT03447262|Experimental|Open-label triple combination|"Subjects will receive 240 mg VX-659 / 100 mg TEZ / 150 mg IVA as FDC tablets in the morning and 150 mg IVA as mono tablet in the evening.~Parent studies are Phase 3 Vertex studies investigating VX-659 in combination with TEZ and IVA. This includes Studies VX17-659-102 and VX17-659-103."
3186302|NCT00743860|Experimental|Single dose|single oral dose
3186303|NCT00743860|Experimental|Repeat Dose|28 day repeat dose
2418349|NCT03447236|Experimental|Feuerstein Program|All subjects participating in the Feuerstein Program will be evaluated by anatomical and functional MRI as well as computerized cognitive assessment prior to and following intervention as outlined in the protocol.
2418350|NCT03447223||ADHD-patients|The children and adolescent 6-15 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
2418351|NCT03447223||Controls-healthy children|Age- and gender- matched healthy 6-15 years old children and adolescent.
2418352|NCT03447210|Experimental|Assisted Partner Services|All participants in this arm will be offered assisted partner services (APS) which involves outreach to sexual partners and to individuals with whom they use injection drugs. When partners are contacted they are offered HIV and HCV testing. There is no comparison arm.
2418353|NCT03447197|Active Comparator|On-Pump|Use of extracorporeal circulation
2418354|NCT03447197|No Intervention|Off-Pump|
2418355|NCT03447184||Androgen priming|Eight weeks prior to stimulation for IVF - at the onset of menses, patients will start treatment with a low dose of rhCG (Ovitrelle). At the same time daily treatment with the aromatase inhibitor will commence, concomitantly with GnRHa down-regulation with a depot GnRHa (28days). After 8 weeks, a standard rFSH stimulation with either 300 IU rFSH or 300 IU rFSH+rLH will start. The androgen priming (hCG and aromatase inhibitor) will stop on the first day of stimulation.
2418356|NCT03447171||Refractive Error|
2418357|NCT03447158|Experimental|15% Dextrose group|4.5cc 15% dextrose and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
2418358|NCT03447158|Placebo Comparator|control group|4.5cc normal saline and 0.5cc 1% xylocaine was injected into inflamed subacromial bursa under sonographically guidance
2418359|NCT03447145|Experimental|TQ-B3203|
2418360|NCT03447132|Active Comparator|Fulvestrant 500mg + Palbociclib 125mg|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
2418361|NCT03447132|Placebo Comparator|Fulvestrant 500mg + Placebos|+ Goserelin 3.6 mg if pre or peri menopausal patient - duration 4 months
2418362|NCT03447119|Experimental|Living Well with a Disability|The parents will work together with the project directors to deliver the adapted curriculum to participating families. With bi-weekly meetings for 10 weeks between parent facilitators and family participants in the home or another desired location. The project directors have already participated in the facilitator training and will serve as mentors to newly trained facilitators. At the end of the online training session, the parent facilitators will be equipped to successfully implement the Living Well curriculum.
2418363|NCT03447106|Experimental|Open|
2418364|NCT03447106|Experimental|Laparoscopic|
2418365|NCT03447106|Experimental|Robotic|
2418366|NCT03447093||Control group|30 healthy volunteers were included in the healthy control group
2418367|NCT03447093||Drug treatment group|30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill
2418368|NCT03447093||Incipient group|30 untreated GD patients
2418369|NCT03447093||Hashimoto's thyroiditis group|30 HT patients
2418370|NCT03447080|Other|Control 1|White bread
2418371|NCT03447080|Other|Control 2|White bread
2418372|NCT03447080|Experimental|Rice bran soybean milk|White Bread with 195ml of rice bran soybean mil
2418373|NCT03447080|Experimental|Soybean milk|White Bread with 195ml of soybean milk
2418374|NCT03447067|Experimental|Conventional surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar by regular manor.~(Based on :Panorama and CBCT ) technique : 1- flap design 2- bone removal 3- tooth division 4- closure flap (suture)"
2418375|NCT03447067|Experimental|computer guided surgery|"comprised 9 patient undergoing surgical removal of deeply impacted mandibular third molar using computer guided surgical cutting stent.~Based on (panorama , CBCT and fabricating computer guided stent technique: 1- flap design 2- accurate setting stent in a predesign site 3- bony window removing according to the stent design 4- surgical separation of the teeth with extraction the remaning part . 5- identify the nerve 6- replace the bony window in to original place with stability 7- closure and depridment"
2418376|NCT03447054|Experimental|Combined TDCS active and ICT active|Five consecutive days: Twenty minutes of TDCS on the right dorsolateral prefrontal cortex while performing an alcohol-cue inhibitory control training consisting to systematically paired go responses with non-alcohol pictures and no-go responses with alcohol-related pictures.
2418377|NCT03447054|Active Comparator|Combined TDCS sham and ICT active|Five consecutive days: Twenty minutes of sham TDCS on the right dorsolateral prefrontal cortex, while performing a no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
2418378|NCT03447054|Active Comparator|Combined TDCS active and ICT inactive|Five consecutive days: Twenty minutes of active TDCS in association with no-cue go/no-go training consisting to carry out a go/no-go paradigm with no alcohol-related content.
2418379|NCT03447054|Sham Comparator|Combined Sham TDCS and inactive ICT|Five consecutive days: Twenty minutes of Inactive TDCS combined with an non alcohol-cue inhibitory control training consisting to carry out a go/no-go paradigm with no alcohol-related content.
3186304|NCT00743873|Placebo Comparator|2|saline
3186305|NCT00743873|Experimental|1|Plasma Rich in Growth Factors (PRGF)
3186306|NCT00743886|Placebo Comparator|2|saline
3186307|NCT00743886|Experimental|1|Plasma Rich in Growth Factors (PRGF)
3186308|NCT00743899|Experimental|1|The aggressive group
3186309|NCT00743899|Experimental|2|The conservative group
3186310|NCT00743912|Experimental|1|open-label rifaximin 550 mg TID
3186311|NCT00743925|Active Comparator|1|A-002 (500 mg QD) plus Atorvastatin (80 mg QD)
2418386|NCT03446963|Experimental|Single arm: Groups 4 Health|Social group intervention. The aim is to practice participating in a social group within a safe environment; to identify groups and social networks which are meaningful for the person; and to understand any barriers people may have to engaging with these groups/networks.
2418387|NCT03446950|Active Comparator|Candy Cane|Participants in this arm will be positioned with their legs in candy cane stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
2418388|NCT03446950|Active Comparator|Boot Stirrups|Participants in this arm will have their feet placed in boot stirrups. Patients will then undergo scheduled vaginal surgery and be asked to complete PROMIS questionnaires before and after surgery.
2418389|NCT03446937|Experimental|Dexamethasone sodium phosphate injection|Intervention: Drug: Dexamethasone sodium phosphate injection Two doses Intramuscular Dexamethasone sodium phosphate 12mg given12 hours apart. (produced by Taizhou Overseas International Ltd. 126-128 Qingnian Road Jiaojiang, Taizhou, Zhejiang, China)
2418390|NCT03446937|Experimental|Betamethasone sodium phosphate injection|Intervention: Drug: Betamethasone sodium phosphate injection Two doses of intramuscular betamethasone sodium phosphate 12mg given 12 hours apart. (obtained from Twinbrook pkwy, Rockville, MD Singapore. CAT No 1068004, Lot: R004e0)
2418391|NCT03446937|Placebo Comparator|Water for injection|Intervention. Drug: Water for injection. Two doses of intramuscular water for injection given 12 hours apart.
2418392|NCT03446924|Placebo Comparator|Control|The control group will be given a single dose of 1.5 g rice flour in capsule form (250 mg / capsule). The gelatine capsules (MyProtein, Northwich, UK) used are identical to those used in the treatment group. Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).
2418393|NCT03446924|Active Comparator|Treatment|"The treatment group will be given a single dose of 1.5g phosphatidic acid in capsule form (250 mg / capsule). Capsules are prepared by the investigatory team using good hygiene practice in the research kitchen of the School of Sport, Exercise and Rehabilitation (University of Birmingham).~PA is considered a dietary supplement ingredient according to the US FDA. The source of PA will be a commercial available soy-derived PA (Mediator®, Chemi Nutra, White Bear Lake, MN). The safety of Mediator® Soy-PA has been thoroughly demonstrated in humans. Mediator® Soy-PA does not contain any compounds with narcotic, psychotropic or pharmaceutical effects and is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Mediator® Soy-PA is not a medicinal product."
2418394|NCT03446911|Active Comparator|SABR|Patients receive prior to surgery (lobectomy) SABR.
2418395|NCT03446911|Active Comparator|SABR + pembrolizumab|Patients receive prior to surgery (lobectomy) SABR + 2 rounds of pembrolizumab
2418396|NCT03446898||Adults Living at Qinghai-Tibet Plateau for Work Purpose|Qinghai-Tibet Plateau is a high altitude area in which human would be exposed in chronic hypoxia environment.
3186312|NCT00743925|Placebo Comparator|2|Matching Placebo tablets plus Atorvastatin (80 mg QD)
3186313|NCT00743938|Experimental|A1|
2418399|NCT03446872||All Study Participants|Patients in South Korea with a diagnosis of metastatic pancreatic cancer who have been prescribed ONIVYDE
2418400|NCT03446859|Experimental|TENS|It consists of 25 subjects with primary dysmenorrhea which were put on TENS for 30 minutes, three for 3 days. The subject were placed in supine lying in a comfortable position as possible. The abdomen to the inguinal region were decently exposed and cleaned, after inspection of the area for cuts, skin infections or any abnormalities. A pair of electrodes ( inactive electrodes) will be placed a little below the umbilicus ( Right and Left) and the other pair(active electrode) along the inguinal region at the level of pubic symphysis ( Right and Left) according to (Akinbo et al 2000). A quadripolar method will be used for electrode placement.
2418401|NCT03446859|No Intervention|Control|These are 25 subjects which were not in any intervention. These were subjects that were not placed on TENS and were not used to drug taken for the amelioration of the dysmenorrhea. They were educated on the purpose of research and their inform consent was obtained. Their pain intensity was measured firs, third and 5th days
3186314|NCT00743938|Active Comparator|B2|
3186315|NCT00743951|Experimental|1 Patient decision aid|Patient decision aid about treatment options for osteoarthritis
3186316|NCT00743951|Active Comparator|2 Usual care|Usual patient educational materials
2418405|NCT03446833|Experimental|All Subjects|Subjects who meet the intraoperative criteria will receive The LFP Beta aDBS System.
2418406|NCT03446820|Other|Sleep participants|Crossover from standard sheets to hygro cotton sheets
2418407|NCT03446807|Experimental|Droxidopa|The Droxidopa starting dose for all eligible patients in the Titration Periods are 100mg three times daily (TID). Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved or the subject doesn't notice an improvement in their subjective fatigue on a higher dose compared to the most recent dose. Half of the subjects will be on Droxidopa for 3 months during the double-blind phase. All subjects will be on Droxidopa for 3 months during the open-label phase.
2418408|NCT03446807|Placebo Comparator|Placebo Oral Tablet|The placebo starting dose for all eligible patients in the Titration Period is 100mg TID. Doses will be titrated by 100mg TID; increments will be made weekly until the optimal dose is achieved. Half of the subjects will be on placebo for 3 months during the double-blind phase.
2418409|NCT03446794||patients with NVAF and ESCKD on HD|
3186317|NCT00743964|Experimental|ECX|Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
3186318|NCT00743964|Active Comparator|CX|Cisplatin and capecitabine combination chemotherapy will be administered.
3186319|NCT00743977|Active Comparator|A|
2418564|NCT03445676|No Intervention|Usual Care|Study personnel silently observe and record what the healthcare worker does at each hand hygiene opportunity without direction to the healthcare worker
3186320|NCT00743977|Experimental|B|
3186321|NCT00743990|Active Comparator|A|
3186322|NCT00743990|Placebo Comparator|B|
3186323|NCT00743990|No Intervention|3|no intervention
3186324|NCT00744016|Placebo Comparator|2|Placebo
2418414|NCT03446755|Experimental|Intrauterine balloon (Cook medical)|Insertion of a hearth shaped intrauterine balloon immediately after hysteroscopic adhesiolysis and left in place for 7 days under antibiotic prophylaxis.
2418415|NCT03446742||Cardiovascular rehabilitation group|Initially all patients will have their charts analyzed, from which data will be extracted for characterization of the population, and anthropometric data will be measured for calculation of body mass index. Afterwards, patients will have their clinical, physical and biochemical parameters. They will be followed up for a period of 2 months during the routines of the cardiovascular rehabilitation sessions for assessment of signs and symptoms. In the second stage the patients will perform the normal routines of their cardiovascular rehabilitation program for a period of 6 months. In the third stage, patients will have their clinical, physical and biochemical parameters and then followed up for another 2 months during the routines of the sessions of the cardiovascular rehabilitation program to evaluate signs and symptoms, which will allow to evaluate if gains/losses in the physical parameters can exert influences in the appearance of signs and symptoms during the sessions.
2418416|NCT03446729|Experimental|Memory Self Monitoring (MSM)|"Intervention: Guided self-help Behavioral Weight Loss. The MSM group is assigned to self-monitor in habit books what they consume in their previous meal immediately prior to each meal, similar to other studies exploring the effect of episodic meal memory on food intake."
2418417|NCT03446729|Active Comparator|Caloric Self Monitoring (CSM)|"Intervention: Guided self-help Behavioral Weight Loss. The CSM group is assigned to self-monitor what food they consume, and the associated caloric content after each meal in their habit books in line with traditional BWL self-monitoring."
2418418|NCT03446716|Experimental|EXTENSION|During the extension condition, caregivers were instructed to put their child to bed 90 minutes earlier than their habitual bedtime for five consecutive nights. Caregivers were provided a list of tips to aid in implementing the earlier bedtime.
2418419|NCT03446716|No Intervention|CONTROL|Children followed their normal bedtime routine for five consecutive nights.
2418420|NCT03446703|Experimental|SCIT Social cognition interactive|Psychosocial intervention based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs & Penn; Lahera & Benito, in press).
2418421|NCT03446703|Active Comparator|TAR Training in affect recognition|Training in Affect Recognition it is a 12-session training on facial affect recognition over a period of 6 weeks.
3186325|NCT00744016|Active Comparator|1|Granulated mesalamine
3186326|NCT00744029|Active Comparator|Intervention group|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
2418424|NCT03446677|Experimental|Asymptomatic persons with HIV|
2418425|NCT03446664|Experimental|Microburst Stimulation|Microburst stimulation to tolerability and effectiveness
2418426|NCT03446651|Experimental|Lysine Chloride|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Lysine Chloride group will receive the active intervention.
2418427|NCT03446651|Placebo Comparator|Placebo|Participants will be randomized to 7 days of therapy with either 115 mmol/day of lysine chloride or placebo. People in the Placebo group will receive placebo.
2418428|NCT03446638|Experimental|Computational Biology-Informed Treatment|Patients randomized to this arm will receive an FDA-approved drug or combination of drugs predicted to have a therapeutic effect based on their individual MDS disease genetic profile by a computational biology simulation software program. The specific drug or combination of drugs that a patient on this arm will receive will be decided jointly by a molecular oncology board comprised of physicians, pharmacists, and nurse coordinators and the treating physician. Patients will receive a minimum of 2 months and a maximum of 4 months of treatment with the selected drug or combination of drugs.
2418429|NCT03446638|Active Comparator|Standard of Care Treatment|Patients randomized to this arm will receive either one of three standard of care treatment regimens of the treating physician's choice (low-dose cytarabine, 7 + 3 induction, or FLAG induction) or supportive care alone. Patients will receive a minimum of 2 months and a maximum of 4 months of the selected treatment regimen or of supportive care alone.
2418430|NCT03446625|Experimental|Resveratrol|Resveratrol will be administered orally at the dose of 2 g/day for 9 days, starting on the day of ovulation triggering.
2418431|NCT03446625|Placebo Comparator|Control|Placebo treatment will be administered for 9 days, starting on the day of ovulation triggering.
3186327|NCT00744029|No Intervention|Control group|No intervention was performed
3186328|NCT00744068|Experimental|1|Structured Directive Telephone Support Calls
2418434|NCT03446599|Experimental|Hydroxocobalamin|Participants in this arm will receive one intravenous 5-gram dose of hydroxocobalamin reconstituted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2418435|NCT03446599|Experimental|Methyelene blue|Participants in this arm will receive one intravenous 2mg/kg dose of methylene blue diluted in 200ml of normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2418436|NCT03446599|Placebo Comparator|Normal saline|Participants in this arm will receive an intravenous administration of 200ml normal saline over 10-15minutes at the time of initiation of cardiopulmonary bypass.
2418771|NCT03444272|No Intervention|Supportive treatment|supportive liver therapy
2418772|NCT03444259||Atrial fibrillation|Patients with atrial fibrillation
3186329|NCT00744068|Experimental|2|Structured Non-Directive Telephone Continuing Care Support
3186330|NCT00744068|Experimental|3|Unstructured Directive Telephone Support
3186331|NCT00744068|Experimental|4|Unstructured Non-Directive Telephone Support
3186332|NCT00744068|No Intervention|5|
3186333|NCT00744094|Placebo Comparator|1|placebo drink
3186334|NCT00744094|Experimental|2|protein drink
3145782|NCT00080951|Experimental|irinotecan + oxaliplatin + leucovorin + fluorouracil|"Patients receive irinotecan IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV and fluorouracil IV over 90 minutes on days 2-5. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, before each chemotherapy course, and at the end of treatment.~Patients are followed every 3 months until 5 years after registration."
2418439|NCT03446560|Active Comparator|CPAP, conventional follow up|Follow up of patients after initiation of treatment according to clinical routine at the study site.
2418440|NCT03446560|Active Comparator|CPAP, telemedicine based follow up|Follow up of patients after initiation of treatment according to a telemedicine based routine.
2418441|NCT03446547|No Intervention|Arm A|SBRT and follow-up
2418442|NCT03446547|Experimental|Arm B|SBRT followed by Durvalumab
2418443|NCT03446534|Experimental|Amoxicillin|Amoxicillin 100mg/ml mixture (Imacillin), 0.25ml/kg every 8 hours for 7 days.
2418444|NCT03446534|Placebo Comparator|Placebo|Placebo mixture 0.25ml/kg every 8 hours for 7 days
2418447|NCT03446508|Experimental|Active frontal|Active HD-tDCS
2418448|NCT03446508|Experimental|Active parietal|Active HD-tDCS
2418449|NCT03446508|Sham Comparator|Sham control|Sham HD-tDCS
2418450|NCT03446495||Trabectedin + PLD|Trabectedin + PLD according to SmPC
2418451|NCT03446469|Experimental|Individuals with Chronic Ankle instability|Individuals with history of ankle sprains will be screened using the inclusion criteria before being included in the study
2418452|NCT03446456|Placebo Comparator|Saline|"Under direction of a research team member, participants will self-administer intranasal normal saline shortly before beginning the fMRI experiment.~Investigators, staff, and participants were blinded to the treatment options. Each of the agents will be administrated by means of a nasal spray. Participants will be instructed by a nurse/PI to self-administer the nasal spray as follows: one spray in each nostril alternating sides, 30 seconds apart for a total of two sprays per nostril."
2418453|NCT03446456|Experimental|Arginine vasopressin|"Under direction of a research team member, participants will self-administer intranasal vasopressin shortly before beginning the fMRI experiment. The of AVP will be 40IU. The quantity per unit (1 mL) of Arg8-vasopressin synthetic, manufactured by Polypeptide Group Inc. (http://www.polypeptide.com) was 0.323 mg. This amount was diluted in 0.9% sodium chloride (B. Broun Medical Inc.).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment. Participants will be first stratified for sex and then randomized to saline (0.4 mL) or vasopressin (40 IU) group, respectively."
2418454|NCT03446443|Experimental|Honghe Fujie lotion group|
2418455|NCT03446443|Active Comparator|Metronidazole Suppositories group|
2418456|NCT03446430|Experimental|Hypertensives|PWV measurement by LDV
2418457|NCT03446417|Experimental|Phase 1|Up to 9 sequential dose escalation cohorts to determine maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is identified.
2418458|NCT03446417|Experimental|Phase 2|"MTD/RP2D in subjects:~Cohort 1: with T790M mutation in epidermal growth factor receptor (EGFR) gene, and are osimertinib naïve.~Cohort 2: EGFRm amenable to EGFR inhibitor therapy (eg, exon 19 del, L858R) and who have never been treated with EGFRis."
2418459|NCT03446404||MOST Cohort|"One portion of the cohort will be age 62-92 years, average age approximately 71 years, at the start of this study. This cohort will consist of participants who already have symptomatic knee OA, in many cases advanced disease, or who had risk factors at the start of the Multicenter Osteoarthritis Study but have not developed symptomatic knee OA. All of the existing cohort who have 1 or 2 native knees will be approached providing native knees are not considered to be Kellgren-Lawrence grade 4 (bone on bone). The other portion of the cohort will consist of subjects with knee pain, aching or stiffness at baseline and participants without any knee symptoms in the previous 30 days. Both knees with Kellgren-Lawrence grades of radiographic OA of 0, 1, or 2 in the tibiofemoral (TF) and patellofemoral (PF) compartments."
2418460|NCT03446391||Kinematic alignment with GMK Sphere®|Patients enrolled prospectively with surgeries planned to get kinematic alignment
2418461|NCT03446391||Mechanical alignment with GMK Sphere®|Historical group who had mechanical alignment, match-paired with the prospective group
2418462|NCT03446378|Experimental|Anodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2418463|NCT03446378|Experimental|Cathodal tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where cathodal electrode will be on the affected hemisphere and the anodal electrode, on the contralateral supraorbital region. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2418464|NCT03446378|Sham Comparator|Sham tDCS + physical therapy|tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the contralateral supraorbital region. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions
2418465|NCT03446365|Experimental|ASMAS|ASMAS is an asthma self-management program based on NHLBI clinical guidelines for optimal school-based asthma management. It involves 4, 1½ hour sessions delivered in group format in the urban, middle school setting by a Latino High School Peer who has asthma. ASMAS focuses on asthma pathophysiology, symptom management, asthma medications, and trigger control.
2418466|NCT03446365|Active Comparator|Asthma education plus child health|"Asthma Education plus Child Health control condition will be delivered by an adult Health Educator , and includes 4 sessions (1 1/2 hrs long) of our existing asthma education (Asthma's Magic Number) with added general health topics (nutrition, physical activity, safety)."
2418467|NCT03446365|No Intervention|No Treatment Control|Students randomly assigned to this arm , will receive standard of care, which is no treatment, and will not participate in any group intervention sessions.
2418773|NCT03444259||Coronary bypass|Patients undergoing coronary bypass
2419407|NCT03440138||Brown University, Providence Rhode Island|
2418471|NCT03446326|Experimental|Stroke volume and cardiac output|"Pacing runs will occur at the following rates:~50 beats per minute (bpm)~60 bpm~70 bpm~80 bpm~90 bpm~100 bpm~110 bpm~120 bpm~130 bpm~The finger blood pressure cuff will be calibrated between pacing runs.~Following the final pacing run while supine, the patient will be given 10 minutes to rest prior to the upright portion of the study. They will then be strapped into the table (so they will not fall) and then they will be tilted up to >70 degrees (almost standing up). They will stand for ~10 minutes prior to commencing the next pacing trains."
2418472|NCT03446313|Experimental|MVN Group|Participants assigned to the MVN Group will be using the Movn Rehab mobile app after they are discharged from cardiac rehab.
2418473|NCT03446313|No Intervention|Usual Care|Participants assigned to the Usual Care group will receive standard instructions and educational handouts after they are discharged from cardiac rehab.
2418474|NCT03446300||college student population|
2418475|NCT03446300||working population|
2418476|NCT03446300||aged more than 50 years old population|
2418477|NCT03446261|Experimental|Rosuvamibe® Tab|Rosuvamibe® Tab (rosuvastatin 5mg/ezetimibe 10mg) qd for 8 weeks
2418478|NCT03446261|Active Comparator|Monorova® Tab|Monorova® Tab (rosuvastatin 10mg) qd for 8 weeks
2418479|NCT03446248|Active Comparator|Fetal Acoustic Stimulator|Participants in this group will receive fetal vibroacoustic stimulation with the Corometrics-146 device first, followed by the mobile phone application second.
2418480|NCT03446248|Experimental|Mobile Phone Application|Participants in this group will receive fetal vibroacoustic stimulation with the mobile phone application first, followed by the Corometrics-146 device second.
2418481|NCT03446235|Experimental|Connected Health|This group will get 2 interviews about physical exercise (exercise instruction with motivational interview) and 6 communications with individualized instruction and counseling of their physical exercise (investigators can access activity data and exercise log) including the usage of the monitoring device.
2418482|NCT03446235|Active Comparator|Self-Monitoring|This group will do physical exercise following the initial instruction and self-monitor them. Investigators can access activity data and exercise log but will not discuss with the subjects about the data.
2418483|NCT03446222|Active Comparator|Catheter Ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
2418484|NCT03446222|Active Comparator|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
2418485|NCT03446209|Experimental|Tocilizumab|Tocilizumab Infusion RoAcemtra (EU) or Actemra (Rest of the world)
2418486|NCT03446209|Placebo Comparator|Placebo|0,9% physiological Saline
2418487|NCT03446196|Experimental|MOSTCARE UP|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
2418488|NCT03446196|No Intervention|CLINICIAN EXPERIENCE|Fluid replacement will be made based on clinician experience
2418489|NCT03446183||Smoking cessation prospective|Smoking cessation workshops
2418490|NCT03446183||Smoking cessation retrospective|File review of former workshop participants
2418496|NCT03446157|Experimental|Open-label, single arm, Phase II|Cetuximab and palbociclib
2418497|NCT03446144|Experimental|IONIS-FB-Lrx|
2418498|NCT03446144|Placebo Comparator|Placebo (sterile saline 0.9%)|
2418499|NCT03446118|Experimental|MRI to detect inflammation and fibrosis in EoE patients|To assess through MRI the existence of an inflammatory and fibrotic component in strictures of eosinophilic esophagitis patients and to determine if this component is responsive to a therapeutic course of budesonide.
2418500|NCT03446105|Experimental|App-based behavioral intervention|Participants randomized to this study arm will take part in the Achieving Wellness After Kancer in Early life (AWAKE) behavioral intervention for 8 weeks.
2418501|NCT03446105|Active Comparator|Attention control group|Participants randomized to this study arm will take part in a behavioral intervention and coaching for 8 weeks.
2418502|NCT03446092|Experimental|Mindfulness group|Group will receive mindfulness intervention
2418503|NCT03446079|Experimental|Primary Subjects|Male or female subjects 21 or older that meet the specified inclusion/exclusion criteria taking genetic test and applying topical anti aging cream per the protocol.
2418504|NCT03446066||case group|20 cases suffering from excessive daytime sleepiness (4 females and 16 males) with their age range 32-58yrs and BMI range is 24.97-39.06 kg/m2
2418505|NCT03446066||control group|20 healthy subjects (5 females and 15 males) with their age range 31-55yrs and BMI range is 23.40-43.0 kg/m2
2419408|NCT03440138||Fresno Bariatric, CA, USA|
3145783|NCT00080990|Experimental|Treatment (alvocidib with oxaliplatin, 5-FU, leucovorin)|"Patients receive alvocidib IV over 1 hour, oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 48 hours on days 1, 15, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of flavopiridol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, the cohort is expanded and an additional 10 patients are treated at that dose."
2418508|NCT03446040|Experimental|Part A Dose Escalation: BMS-986258|
2418509|NCT03446040|Experimental|Part A1: BMS-986258 + Recombinant human hyaluronidase PH20 (rHuPH20)|
2418510|NCT03446040|Experimental|Part B Dose Escalation: BMS-986258 + nivolumab|
2418511|NCT03446040|Experimental|Part C Cohort Expansion: BMS-986258 + nivolumab|
2418512|NCT03446027|No Intervention|Control|There will be no change to the local site standard of care for patients with IC attributed to participation in this trial. Those sites with Supervised Exercise Therapy (SET) will continue to provide this intervention as per their normal standard of care and locally agreed protocol.
2418513|NCT03446027|Experimental|Device|Local therapy + Neuromuscular Electrical Stimulation (NMES)
2418514|NCT03446014||Control Group for Fitbit Sub-Study|Patient will be given Fitbit device, but will have no access to Fitbit website or interface. The coordinator will set up the patient's Fitbit on the office computer and will have access to the fitbit's associated username and password (this will be generated by the coordinator). The patient will be instructed to walk as much as they can each day, and to check the Fitbit wrist band periodically throughout the day to view their walking progress. At the end of the three month intervention, the patient will complete questionnaires and undergo a repeat 6 minute walk test.
2418515|NCT03446014||Intervention Group for Fitbit Sub-Study|Patient will be given the Fitbit device and instructed on how to use it. They will be given their username and password to the Fitbit device, and instructed on how to interact with other patients in the study as well as the coordinator on the Fitbit website. The coordinator will also show the patient how to install the application on a smart phone device and use the device via smartphone. The patient will then be instructed to walk as far as they can each day for a period of 12 weeks. Patients will check their steps daily and interact with other patients who participate in the study. Patients will return for a 3 month follow-up appointment where they will undergo a redo 6 minute walk test and questionnaires.
2418516|NCT03446001|Experimental|TRx0237 16 mg/day|
2418517|NCT03446001|Placebo Comparator|Placebo|
2418518|NCT03446001|Experimental|TRx0237 8 mg/day|
2418519|NCT03445988|Active Comparator|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
2418520|NCT03445988|Active Comparator|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Peers are people with chronic pain who live in the communities in which they teach. For this project, at least one peer facilitator per workshop will have had experience with prescription opioid use. Intervention fidelity is determined by having a trained observer with a checklist attend random workshop sessions. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session.
2418521|NCT03445988|Placebo Comparator|Taper Only (Usual Care)|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
2418522|NCT03445988|No Intervention|Observational Arm|Participants that do not wish to reduce their opioid medications but are otherwise eligible and interested in the research study will be offered participation in the observational arm. The observational arm of the study will not include interventions of any kind and will only collect survey data for the year following consent.
2418523|NCT03445975|Experimental|Experimental|The 3-in-1 perineal care washcloth procedure has been adopted to deliver hygiene care (total or perineal) or baths
2418524|NCT03445975|No Intervention|standard|The deliver of hygiene care (total or perineal) or baths has been performed using water and pH neutral soap
2418525|NCT03445962||Down Syndrome (DS)|Assessment of OSAS predictive factors in Down Syndrome without or without OSAS
2418526|NCT03445949|Other|30 days DAPT|short postimplantation dual antiplatelet therapy
2418527|NCT03445949|Other|6 months DAPT|extended postimplantation dual antiplatelet therapy
2418528|NCT03445936|Active Comparator|Parietene Macro|Parietene Macro is a macroporous synthetic mesh used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
2418529|NCT03445936|Active Comparator|Permacol|Permacol is a acellular porcine dermal implant used in retro muscular sublay position to prevent incisional hernia after loop-ileostomy closure.
2418532|NCT03445910|Experimental|Human chorionic gonadotrophin|The hCG Group included 50 patients who had an intrauterine injected of 500 IU of hCG on the day of ovum pick-up
2418533|NCT03445910|No Intervention|control|The Control Group included 50 patients who went through the ICSI conventional protocol without intrauterine injection.
2418534|NCT03445897|Experimental|Intervention|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
2418535|NCT03445884|Experimental|Acute myocardial infarctions group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. three times. 1-3 days after intervention, 7-10 days after intervention and 30-35 days after intervention.
2418536|NCT03445884|Active Comparator|Control group|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV. one time.
2418537|NCT03445871|Active Comparator|Patients with active rheumatoid arthritis|Patients with active rheumatoid arthritis will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
2419409|NCT03440138||Rijnstate Hospital, Arnhem, The Netherlands|
2418538|NCT03445871|Active Comparator|Patients with rheumatoid arthritis into remission|Patients with rheumatoid arthritis into remission will be included. They will have a blood sample and Compliance Rheumatology Questionnaire (CRQ).
2418539|NCT03445858|Experimental|Pembrolizumab, Decitabine, Radiation|Patients will receive pembrolizumab and decitabine every 28 days, and a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions.
2418540|NCT03445845|Experimental|targeting IL-23/17 axis|"The experimental group (targeting IL-23/17 axis) receiving secukinumab in compliance with the marketing authorization regimen: 150 mg per week for 5 weeks, and then every month by subcutaneous injection.~Blood specimen at each visits"
2418541|NCT03445845|Active Comparator|TNF blocker|"• The control group receiving a second TNF blocker in compliance with the marketing authorization regimen:~The TNF blocker (originator or biosimilar) will be different to the TNF used before the inclusion and will be chose by the investigator:~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow.~Blood specimen at each visits"
2418542|NCT03445819|Other|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon. The trial is designed in a pragmatic fashion to allow participating surgeons from the multiple participating sites to perform fixation as per the standard of care at their institution. Post-operative care will include standard-of-care antibiotics and deep vein thrombosis (DVT) prophylaxis, both prescribed at the discretion of the attending surgeon.
2418543|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery. Patients will be weight bearing as tolerated immediately in a removable knee immobilizer, with progressive range-of-motion exercises begun at two weeks following randomization
2418544|NCT03445780|Experimental|First Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection
2418545|NCT03445780|Experimental|Second Group|The skin between the distal palmar crease and the palmo-digital crease and the palmo-digital crease will be pinched for 5 seconds prior to injection
2418546|NCT03445780|Experimental|Third Group|Skin cooling with ethyl chloride spray will be used for 5 seconds prior to injection as well as a second pinch to the skin between the distal palmar crease and the palmo digital crease
2418547|NCT03445780|Experimental|Fourth Group|Subjects will sit behind a screen with a small opening large enough to introduce the injection hand. They will not see any of the procedure.
2418548|NCT03445767|No Intervention|Standard Care|All patients will receive perioperative care per the standards of TOH. Standard care relevant to our study consists of a history by a nurse or physician; a best possible medication history performed by a pharmacy technician; and standardized perioperative-specific medication recommendations (e.g., anticoagulant, diabetes agent, and ACE-inhibitor management) based on medical directives. Medication recommendations beyond these medical directives do not occur as standard care in our clinics. Participants will be informed that their medical care will proceed as usual and that they are being recruited for a study to evaluate medication recommendations before surgery
2418549|NCT03445767|Experimental|Intervention|In addition to standard care, the intervention will include a structured preoperative polypharmacy management strategy that consists of: a) input of best possible medication history and comorbidities into our polypharmacy management tool (MedSafer); b) communication of the prioritized deprescribing plan (if indicated) to the patient's active treating physicians (automatically via fax), to the perioperative team (surgeon, anesthesiologist), and to the electronic medical record. During the pre-operative visit, the patient will receive a generalized information flyer about deprescribing. As in the usual care phase, patients will continue to receive usual recommendations from the perioperative team based on medical directives relevant to the perioperative period.
2418552|NCT03445741|Active Comparator|Supervised treadmill group (%70 VO2 max)|Supervised treadmill group (%70 VO2 max) (group 1): The participants were instructed walking exercise at their target heart rate, (% 70 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2418553|NCT03445741|Experimental|Supervised treadmill group (%50 VO2 max)|Supervised treadmill group (%50 VO2 max) (group 2): The participants were instructed walking exercise at their target heart rate, (% 50 of maximum oxygen consumption) on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2418554|NCT03445741|Experimental|ECE PEDO pedometer group (%50 VO2 max)|ECE PEDO pedometer group (%50 VO2 max) (group 3): The participants were instructed walking with ECE PEDO which the number of steps taken in a minute corresponding to target HR at % 50 of maximum oxygen consumption were provided.
3145784|NCT00081094|Other|PET scan (FDG-PET & 11C-acetate-PET)|Patients will undergo routine clinical FDG-PET and research 11C-acetate-PET prior to planned surgical resection of the lesion(s) or explantation of the liver.
3186335|NCT00744133|Experimental|Group 1: 1, 3, or 5 bites|Part A: 18 subjects receive 1, 3, or 5 bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
2418557|NCT03445715|Experimental|Cohort I|Single intra-articular injection ART-I02: 2.4x10E12 vg / wrist joint
2418558|NCT03445715|Experimental|Cohort II|Single intra-articular injection of ART-I02: 2.4x10E13 vg / wrist joint
2418559|NCT03445715|Experimental|Cohort III|Single intra-articular injection in the wrist joint of ART-I02 Maximum Tolerated Dose (MTD) as assessed in cohorts I and II:
2418560|NCT03445702|Experimental|Metformin intolerant & metformin|Metformin 1000mg once
2418561|NCT03445702|Placebo Comparator|Metformin intolerant & placebo|Placebo 1000mg once
2418562|NCT03445702|Active Comparator|Metformin tolerant & metformin|Metformin 1000mg once
2418563|NCT03445702|Placebo Comparator|Metformin tolerant and placebo|Placebo 1000mg once
2418565|NCT03445676|Experimental|ABHR directly on gloves|Healthcare worker will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
2418566|NCT03445676|Placebo Comparator|Ideal Standard|Healthcare worker will be directed by study personnel to remove gloves, perform hand hygiene and replace gloves at each hand hygiene opportunity
2418567|NCT03445663|Experimental|AMG 424|Comparison of different dosages of AMG 424
2418568|NCT03445650|Experimental|ADX-102 1% Topical Dermal Cream (reproxalap)|
2418569|NCT03445650|Placebo Comparator|Vehicle of ADX-102 Topical Dermal Cream|
2418570|NCT03445624||patient on traditional therapy|Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)
2418571|NCT03445624||patient on infliximab|drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months
2418572|NCT03445611|Experimental|Group 1|These patients will receive a corticosteroid solution with lidocaine containing parabens.
2418573|NCT03445611|Active Comparator|Group 2|These patients will receive corticosteroid solution with paraben free lidocaine.
2418574|NCT03445598|Experimental|Interactive CCBT group|This group receives Interactive and Personalized CCBT
2418575|NCT03445598|Active Comparator|Limited CCBT control group|This group receives Feature-limited CCBT
2418576|NCT03445598|Other|Waitlist control group|This group receives waitlist control
2418577|NCT03445585||Primary Sclerosing Cholangitis|Patients with a diagnosis of primary sclerosing cholangitis (PSC).
2418578|NCT03445585||Primary Biliary Cirrhosis/Cholangitis|Patients with a diagnosis of primary biliary cirrhosis (PBC).
2418579|NCT03445585||Control group 1|Patients who do not have PBC or PSC but do have another form of chronic liver disease.
2418580|NCT03445585||Control group 2|Patients without liver disease.
2418581|NCT03445572|Experimental|Group I (MSB)|Participants are instructed on the MSB technique and then perform MSB over 15 minutes BID for 28 days.
2418582|NCT03445572|Experimental|Group II (IK meditation)|Participants are instructed on the 3 steps of IK meditation and then perform IK meditation over 15 minutes BID for 28 days.
2418583|NCT03445572|Active Comparator|Group III (waitlist)|Participants are placed on a waitlist and receive standard supportive care for 28 days. After 28 days, participants may crossover to Group II.
2418584|NCT03445559|No Intervention|Control|No intervention
2418585|NCT03445559|Experimental|Intervention|The intervention is comprised of three components: 1) Clinical Order Check, 2) Academic Detailing, and 3) Audit and Feedback.
2418586|NCT03445546||oral P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with oral P2Y12 Inhibitor (from the historic cohort of NCT02914795)
2418587|NCT03445546||intravenous P2Y12 inhibition|Patients with cardiac arrest and myocardial infarction treated with intravenous P2Y12 Inhibitor (cangrelor)
2418588|NCT03445533|Experimental|Arm A: ipilimumab|ipilimumab 3 mg/kg intravenous
2418589|NCT03445533|Experimental|Arm B: IMO-2125 plus ipilimumab|IMO-2125 by intratumoral injection plus ipilimumab 3 mg/kg intravenous
2418590|NCT03445520|No Intervention|Transition Passport Comparison Group|This group will only receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide.
2418591|NCT03445520|Experimental|Intervention Coaching Group|This group will also receive the Transition Passport, which includes the Transition Checklist, Student Snapshot, Parent/Caregiver Guide, and Student Guide. This group will also receive coaching support to implement these resources. The coach will be a member of the research team who will introduce the resources to the family, briefly teach them fundamental information about the transition process, provide brief coaching phone calls, and help parents identify an appropriate person at the school or district who can work with them to complete the Student Snapshot. This group will also use ParentSquare to enhance and encourage communication between parent and members of the child's school team.
2418592|NCT03445507|Experimental|Intervention|Use of an evidence-based chat bot for smoking cessation
2418593|NCT03445507|Active Comparator|Control|Usual care (Madrid Health System Portfolio).
2418594|NCT03445494|Experimental|Brace|After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night
2418595|NCT03445494|Experimental|Normal sling|After surgery the patient must wear the normal sling for two weeks
2418596|NCT03445481|Experimental|Femoral prosthesis|newly developed prosthesis for trans-femoral amputation
2418597|NCT03445468|Experimental|IL-YANG Quadrivalent Influenza Vaccine|The vaccine contains both B strain (Yamagata, Victoria)
2418598|NCT03445468|Active Comparator|IL-YANG Flu Vaccine Pre-filled Syringe|The vaccine contains the B/Yamagata strain and it was approved for commercial sale by Ministry of Food and Drug Safety.
2418599|NCT03445455||De novo AHRF|"Acute hypoxemic non hypercapnic respiratory failure with a PaO2/FiO2 ratio < 200.~The following oxygenation devices are used and assessed during routine care:~High concentration mask, High flow nasal canula, NIV using buco-nasal mask or Helmet.~Electro impedence tomography signal will be recorded throughout this assessement for tidal volume measurement"
2418600|NCT03445442||Group 1|Sacrocolpopexy (SCP)
2418601|NCT03445442||Group 2|Native tissue repair surgery (NTR)
2418602|NCT03445442||Group 3|Vaginal mesh repair surgery (VMR)
2418603|NCT03445429|Experimental|3D-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 3D-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 4 K-display system. After that again a NASA Task load index questionnaire is performed.
2418604|NCT03445429|Experimental|4K-display system|Subjects in this arm will perform the tasks on the minimal-invasive training set-up first with the 4K-display system. Then they will do the NASA task load index questionnaire. After that they will perform the tasks with the 3D-display system. After that again a NASA Task load index questionnaire is performed.
2418605|NCT03445416|Experimental|Intervention: POL arm|POL intervention. Enrolled POLs will be randomized at their intake visit; those randomized to the intervention arm will attend the popular opinion leader training (developed in Aim 1) and will be asked to diffuse the intervention messages to their network recruits.
2419410|NCT03440138||CHU Nice, France|
2418606|NCT03445416|Active Comparator|Comparison group|POLs who are randomized to the comparison arm will receive an abbreviated version of the POL training that includes general health messaging, but does not incorporate medical mistrust, stigma or specific vaccination messaging.
2418607|NCT03445403|Experimental|Chronic pain disorders|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
2418608|NCT03445403|Active Comparator|Healthy controls|Administration of offset analgesia and control and constant paradigms using moderate heat pain as determined by the individual subject reporting of 50 mm on a visual analog pain scale of 0-100 mm.
3186336|NCT00744133|Experimental|Group 2: N bites|Part B: 20 subjects receive N bites of Anopheles stephensi mosquitoes infected with the NF54 strain of Plasmodium falciparum.
3186337|NCT00744146|Experimental|1|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 50 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
2418611|NCT03445377|Active Comparator|Real-time continuous glucose monitoring|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. Training on the use of DEXCOM G5 or similar will be provided by the research team. Competency on the use of the system will be evaluated. Participants will be advised to use real-time CGM continuously for the next 8 weeks. At the end of the first intervention, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
2418612|NCT03445377|Placebo Comparator|Self-monitoring of blood glucose|Subjects will be reviewed and a blood sample will be taken for the measurement of HbA1c. During the Control Period, masked CGM will be applied for one week, during Week 1, 4 and 8. At the end of this, a blood sample for the measurement of HbA1c will be taken. Validated questionnaires evaluating diabetes-related distress, management and user acceptance will be completed.
2418613|NCT03445364|Active Comparator|Low coronary injection-pressure, 200 psi|"Patients with STEMI who undergo Primary PCI with the use of low intracoronary dye injection pressure (of 200 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
2418614|NCT03445364|Active Comparator|High coronary injection-pressure,550 psi|"Patients with STEMI who undergo Primary PCI with the use of higher intracoronary dye injection pressure (of 500 psi), by using ACIST automated injector. Patients will recieve bare-metal stents at the courtasy of the interventional cardiologist, only in infarct-related artery.~Use of different injection pressure during primary PCI"
2418615|NCT03445351|Experimental|Aerobic, resistance and concorrent|The group underwent exercise program with protocols of resistance training, aerobic training and concurrent training, with frequency of three times per week.
2418616|NCT03445338|Experimental|Cohort 1|
2418617|NCT03445338|Experimental|Cohort 2|
2418618|NCT03445338|Experimental|Cohort 3|
2418619|NCT03445325|Experimental|LiGHT v2.1|Participants will be assigned the intervention (use of the parent or teen app for 4.5 months) and asked to use throughout the intervention period (all participants are assigned to the intervention arm and results will be analyzed pre- and post-intervention).
2418620|NCT03445312||study cohort|All non-ICU medicine and surgery patients at Sinai Health System who have a mid-stream urine culture ordered
2418621|NCT03445299|Experimental|Music|Daily music listening for 30 minutes at bedtime
2418622|NCT03445286|Experimental|Silver Diamine Fluordie Application|This group will receive Silver Diamine Fluoride (SDF) application once every week within three weeks period
2418623|NCT03445286|Placebo Comparator|Normal Saline|This control group will receive normal saline application once a week within a a three-week period
2418624|NCT03445260|Placebo Comparator|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
2418625|NCT03445260|Experimental|Nutritional Supplements|carbohydrate loading, immunonutrition (formulated liquid diet), protein supplement
2418626|NCT03445247|Sham Comparator|Control|No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points
2418627|NCT03445247|Experimental|Extracorporeal low-intensity shockwave group|with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.
2418628|NCT03445234|Experimental|Blueberry|Freeze-dried blueberry powder
2418629|NCT03445234|Placebo Comparator|Placebo|Placebo powder
2418630|NCT03445234|Experimental|Banana|Acute banana ingestion
2418631|NCT03445234|Experimental|No banana|No banana ingestion
2418632|NCT03445221|Active Comparator|Group I|patients will receive preoperative immunonutrition in the form of glutamine) Dipeptiven-Fresenius Kabi) given by intravenous infusion 0.4g/kg/day for 5 days before surgery.
2418633|NCT03445221|Active Comparator|Group II|patients will continue preoperative oral conventional diet.
2418634|NCT03445208|Experimental|Cohort 1|BMI 18.0 to ≤ 25.0
2418635|NCT03445208|Experimental|Cohort 2|BMI >25.0 to ≤ 30.0
2418636|NCT03445208|Experimental|Cohort 3|BMI >30.0 ≤ 40.0
3186338|NCT00744146|Experimental|2|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 100 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3186339|NCT00744146|Experimental|3|"Eight volunteers total.~Randomized such that six volunteers will receive Protexia as a single 250 mg dose and two volunteers will receive saline placebo of the same volume on Study Days 1 and 72.~Volunteers to be followed for approximately 142 days total."
2418639|NCT03445182|Active Comparator|Control group|Local anaesthesia with conventional syringe
2418640|NCT03445182|Active Comparator|DentalVibe group|Local anaesthesia with conventional syringe + DentalVibe
2418641|NCT03445169|Experimental|Fasting|Belzutifan tablets taken after fasting
2418642|NCT03445169|Experimental|Non-Fasting|Belzutifan taken after eating a high calorie meal
2418774|NCT03444259||Aortic valve replacement|Patients undergoing aortic valve replacement
2418775|NCT03444259||Mitral valve repair|Patients undergoing mitral valve repair
2419411|NCT03440138||Claraspital Basel, Switzerland|
3186340|NCT00744146|Experimental|4|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 500 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
2418645|NCT03445130|Active Comparator|Lavandula Angustifolia oil (LO)|2 Drops in Oxygen Mask
2418646|NCT03445130|Active Comparator|Michelia Alba Leaf oil (MA)|2 Drops in Oxygen Mask
2418647|NCT03445130|Active Comparator|Almond oil (AO)|2 Drops in Oxygen Mask
2418648|NCT03445130|Active Comparator|Water|2 Drops in Oxygen Mask
2418649|NCT03445117|Experimental|Intervention|Clinics assigned to the intervention arm will receive an educational intervention. This comprises posters on vaccination to be put up in the clinic, as well as a flyer which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies.
2418650|NCT03445117|No Intervention|Control|Clinics assigned to control arm will run as per their normal operations and not have the interventions implemented.
2418651|NCT03445104|Experimental|Huperzine A|Huperzine A will be provided in the form of a single capsule for oral ingestion.
2418652|NCT03445104|Placebo Comparator|Rice Flour|Placebo will be provided in the form of a single capsule for oral ingestion.
2418653|NCT03445091|Experimental|Patients using investigational product|Open-label use of SANKOM Patent Socks
2418654|NCT03445078|Active Comparator|A|Participants will be administered firstly selenium-rich corn powder 20g/d for 1 month and ordinary corn powder 20g/d for another month subsequently with a month washout period.
2418655|NCT03445078|Placebo Comparator|B|Participants will be administered firstly ordinary corn powder 20g/d for 1 month and selenium-rich corn powder 20g/d for another month subsequently with a month washout period.
3186341|NCT00744146|Experimental|5|"Six volunteers total.~Randomized such that four volunteers will receive Protexia as a single 750 mg dose and two volunteers will receive saline placebo of the same volume on Study Day 1.~Volunteers to be followed for approximately 71 days total."
3186342|NCT00744159||OC|Open colorectal resection
3186343|NCT00744159||LC|Laparoscopic colorectal resection
3186344|NCT00744172|Active Comparator|I|laparoscopy
2418660|NCT03445052|Experimental|2018 XPAND Intervention Arm|This group will receive the personalised adherence intervention in 2018 in addition to routine clinical care.
2418661|NCT03445052|No Intervention|2018 XPAND Control Arm|This group will receive routine clinical care and act as the control group for the primary objective: To compare the mean daily dose of UVR (SEDs) reaching the face between the intervention group and control group over a 3 week period in June to July (follow-up 1). This group will receive the intervention in 2019, to allow within group change to be assessed.
2418662|NCT03445039|Experimental|TSFE using osteotomes with bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute is placed in this group.The interventions in the arm are bone grafting and the TSFE will be performed by osteotomes.
2418663|NCT03445039|Experimental|TSFE using osteotomes without bone grafting|The patients in this group will receive transalveolar sinus floor elevation with osteotomes and mallet. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by osteotomes.
2418664|NCT03445039|Experimental|modified TSFE with bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute is placed before the implant placement.Interventions in the arm are bone grafting and the TSFE will be performed by dask drills.
2418665|NCT03445039|Experimental|modified TSFE without bone grafting|The patients in this group will receive modified transalveolar sinus floor elevation with the Dask drills. The cortical plate of the sinus floor is grinded or removed by the dome like drills. And the membrane is elevated by the surgical instruments. The bone substitute will not be placed in this group.The intervention in the arm is the TSFE will be performed by dask drills.
2418666|NCT03445013|Experimental|SB414 6%|SB414 6% topically twice daily
2418667|NCT03445013|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
2418776|NCT03444259||Other|Patients undergoing cardiac surgery for indication other than above
2418852|NCT03443778|Active Comparator|Nacl 0,9% (Control) group|Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
3186345|NCT00744172|Active Comparator|2|vaginal
3186346|NCT00744172|Active Comparator|3|abdominal
3186347|NCT00744185|Placebo Comparator|2|30-days placebo treatment
3186348|NCT00744185|Experimental|1|30-days propranolol treatment
3186349|NCT00744198|Active Comparator|1|Autologous sling
3186350|NCT00744198|Active Comparator|2|Synthetic sling
3186351|NCT00744198|Active Comparator|3|Biological sling
3186352|NCT00744224|Placebo Comparator|1|
3186353|NCT00744224|Active Comparator|2|
3186354|NCT00744224|Active Comparator|3|
3186355|NCT00744250|Other|1|"Pre-treatment vs. post-treatment-~In the first phase, before administration of the capsules and liquid diet, baseline gastric and duodenal secretions will be aspirated via the oro-enteric tube. Subjects will get 5 placebo capsules at Time=0 given orally with the liquid Lundh diet. Pancreato-biliary and duodenal secretions in the duodenal region will be aspirated continuously over the first 20 min. Gastric and duodenal fluids will be aspirated from 20-180 min at specified time points. Following a rest of 1 hour, the same process will be repeated with the drug capsules. At the end of the study the catheter will be removed and patient will be offered a meal."
3186356|NCT00744276|Active Comparator|1|
3186357|NCT00744276|Active Comparator|2|
3186358|NCT00744276|Active Comparator|3|
3186359|NCT00744276|Placebo Comparator|4|
3186360|NCT00744276|Placebo Comparator|5|
3186361|NCT00744276|Placebo Comparator|6|
3186362|NCT00744289|No Intervention|Arm 1|Participants in Arm 1 will not receive any financial incentive after the second and third dose of hepatitis B vaccine have been administered.
3186363|NCT00744289|Other|Arm 2|Participants in Arm 2 will receive a small financial incentive after the second and third dose of the hepatitis B vaccine
2418668|NCT03445000|Experimental|Trial treatment|"Alectinib is administered orally, 600 mg, twice per day (1200 mg per day) until progression, refusal or unacceptable toxicity.~Trial treatment may also continue beyond progression, with physician and patient agreement, for as long as the patient may still derive clinical benefit as per investigator decision."
2418669|NCT03444987||patients group|"include 35 pre-menopausal women (age ˂ 50 years) enrolled to undergo hysterectomy for symptomatic UF at the women health hospitals, Assiut University.~The protein expression of the followings markers will be estimated in tumor tissue samples:~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT ) by ELISA (protein level). analysis.~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method~."
2418670|NCT03444987||Control group|"include 35 normal myometrial tissue samples obtained 1 cm away from the fibroid capsule from the same patients.~The protein expression followings markers will be estimated in normal myometrial tissue samples~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis.~Phosphorylated protein kinase B (pAKT) by ELISA (protein level).~Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method.~Reduced glutathione, an antioxidant marker by a colorimetric method~."
2418671|NCT03444974|Active Comparator|Patient therapy group|"Adolescents with substance use disorders~Receiving an adapted treatment according to the MATRIX-A therapy"
2418672|NCT03444974|Active Comparator|Parental therapy group|"Parents of adolescents with substance use disorders~Receiving an adapted treatment according to the MATRIX-A therapy"
2418673|NCT03444974|No Intervention|Patient waiting list group|"Adolescents with substance use disorders~On the waiting list for receiving a MATRIX-A therapy"
2418674|NCT03444974|No Intervention|Parental waiting list group|"Parents of adolescents with substance use disorders~On the waiting list for receiving a MATRIX-A therapy"
2418675|NCT03444974|No Intervention|control group|"Adolescents with no history of substance use disorders~no other intake of psychotropic substances such as psychotropic medication"
3186364|NCT00744302|Experimental|PCD|Physiological calcium (1.25 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
2418677|NCT03444948|Experimental|3 radiofrequency ablation procedures|Subject will undergo 3 radiofrequency ablation procedures at 1 month intervals (EUS-RFA using Habib Tm as a probe)
2418678|NCT03444948|Active Comparator|standard medical care|Subject will receive standard medical care, including pain relief drugs
2418679|NCT03444935|Experimental|Intervention|Participants randomized to the intervention group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the control group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
2418680|NCT03444935|Other|Control|Participants randomized to the control group will receive a predetermined amount of follow-up phone calls after discharge from the Crisis Centre. They can expect a minimum of one call and a maximum of five calls over the five week period immediately following discharge to the community. The number and nature of phone calls they receive will be different from participants in the intervention group. Participants will be informed upon discharge of the dates they should anticipate phone calls, but it will not be revealed to them which group they were randomized to.
2418681|NCT03444922|Placebo Comparator|Placebo|Participants consume Vanilla Wafer cookie
2418682|NCT03444922|Experimental|BPA 4 ug/kg BW|Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie
2418683|NCT03444922|Experimental|BPA 50 ug/kg BW|Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie
3145785|NCT00081211|Experimental|Treatment (PV701)|Patients receive intratumoral PV701 once weekly for 3 weeks. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of PV701 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 evaluable patients are treated at that dose.
3186365|NCT00744302|Active Comparator|NCD|Normal calcium (1.5 mmol/L) dialysate therapy All subjects in the study phase will continue to take calcium carbonate and/or active vitamin D agents.
2418687|NCT03444896|Experimental|Acupuncture group|
2418688|NCT03444896|Placebo Comparator|Sham acupuncture group|
2418689|NCT03444883|Active Comparator|Treatment Group|10mg Ilaprazole x 2 tablets
2418690|NCT03444883|Placebo Comparator|Control Group|10mg placebo of Ilaprazole x 2 tablets
2418693|NCT03444857|Experimental|CPAP treatment|Continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) plus standard care (according to current STEMI guidelines) for 3 months after pPCI
2418694|NCT03444857|No Intervention|Control|Standard care (according to current STEMI guidelines) for 3 months after PPCI with no intervention for OSA
2418695|NCT03444844|Experimental|Biochemical recurrent prostate cancer|"IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by whole body PET/CT scanning (pelvis to shoulders) for ~ 60 min (~150 min for first 10 patients/dosimetry) starting immediately after injection.~A contrast CT scan follows PET scan."
2418696|NCT03444844|Experimental|Intermediate/High Risk primary prostate cancer|IV injection of 2 - 6 mCi of Ga-68 P16-093 followed by list mode PET/CT scanning using a fixed FOV including the pelvis area for ~ 50 min.
2418697|NCT03444831|Experimental|Buspirone plus Omeprazole|
2418698|NCT03444831|Placebo Comparator|Placebo plus Omeprazole|
2418699|NCT03444818|Experimental|[14C]-E6007|Participants will receive a single oral dose of 60 milligrams (mg) of [14C]-E6007.
2418700|NCT03444805||NISSC-2|SSC patients treated with AHSCT
2418777|NCT03444246|Experimental|Iodine free diet group|The arm with non iodized salt，the subject in the non iodized salt group used the iodized salt for the first three months, and the iodized salt was changed after three months.
2418701|NCT03444792|Experimental|Group I (dilation group)|the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure. - If failed we will use artery forceps to dilate cervix
2418702|NCT03444792|No Intervention|Group II (non dilatation group)|the surgeon will perform cesarian section without attempting cervical dilatation
3145786|NCT00081224|Experimental|celecoxib + capecitabine + radiation + surgery|"Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.~Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.~Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3145787|NCT00081250|Experimental|Arm I|Patients receive oral creatine daily.
3186366|NCT00744315|Other|1|Controlled
3145788|NCT00081250|Placebo Comparator|Arm II|Patients receive oral placebo daily.
3145789|NCT00081276|Experimental|Treatment (triapine and cisplatin)|Patients receive 3-AP IV over 2 hours on days 1-4 and cisplatin IV over 1 hour on days 2 and 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2418708|NCT03444727|Experimental|Ice Pre-treatment|Participants will hold an exam glove filled with ice to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
2418709|NCT03444727|Placebo Comparator|Room Temperature Water Pre-Treatment|Participants will hold an exam glove filled with room temperature water to intended biopsy area for 30 seconds prior to preparation and local anesthetic injection.
2418710|NCT03444714|Experimental|RiMO-301+Radiotherapy|3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
3145790|NCT00081354||Barrett's esophagus|Barrett's esophagus
3145791|NCT00081354||Controls negative for Barrett's esophagus|Controls negative for Barrett's esophagus
2418713|NCT03444688|Active Comparator|CT, Control Group|Conventional Gait Training
2418714|NCT03444688|Experimental|WT, Experimental Group|Gait rehabilitation with walker
2418715|NCT03444662|Placebo Comparator|Placebo|Intervention: Dietary Supplement: Placebo supplement
2418716|NCT03444662|Experimental|Cognizin and Omega-3|Intervention: Dietary Supplement: Citicoline and Omega-3 supplement
2418717|NCT03444662|Experimental|Omega-3|Intervention: Dietary Supplement: Omega-3 supplement
2418718|NCT03444649|Experimental|Dosis finding|Epacadostat is given for 2 cycles of 28 days at a dose according to the titration design together with Standard chemotherapy (Idarubicin and Cytarabine)
2418719|NCT03444636|Experimental|Ropivacaine/Fentanyl|
2418720|NCT03444636|Active Comparator|Bupivacaine/Fentanyl|
2418721|NCT03444610|Other|Arm (blood transfusion escalation rate)|The intervention for the arm (blood transfusion escalation rate) will be about giving blood transfusion with escalating rate as described in intervention part to Any condition that expected to receive more than one blood transfusion, like thalassemia major or intermedia, sickle cell anemia, aplastic anemia, malignant diseases.
3186367|NCT00744341|Experimental|1|
3186368|NCT00744341|Experimental|2|
2418724|NCT03444571|No Intervention|Control|
2418725|NCT03444571|Experimental|DNA based diagnosis|
2418726|NCT03444558|Experimental|Dietary Supplement|50 subjects with the metabolic syndrome receiving natural supplement containing chlorogenic acid and luteolin (450 mg/die)
2418727|NCT03444558|Placebo Comparator|Placebo|50 subjects with the metabolic syndrome receiving placebo (without any active ingredients)
2418728|NCT03444532|Experimental|12-week aerobic exercise and cognitive-behavioral therapy|12-week aerobic exercise, two times per week, and cognitive-behavioral therapy for insomnia in total four sessions
2418729|NCT03444532|No Intervention|Control group|Patients assigned to the control group will receive usual care
2418730|NCT03444519|Experimental|Mannitol A|in this group, Mannitol (1.0g/kg) is given just after the induction of general anesthesia
2418731|NCT03444519|Active Comparator|Mannitol B|in this group, Mannitol (1.0g/kg) is given at the time of skin incision
2418732|NCT03444506|Placebo Comparator|Placebo nasal spray|Placebo nasal spray - 2 sprays per nostril, BID
2418733|NCT03444506|Experimental|Molo 1 (also referred as GSP 301-2 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID
2418734|NCT03444506|Experimental|Molo 2 (also referred as GSP 301-1 NS)|Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD
2418735|NCT03444506|Active Comparator|DYMISTA nasal spray|Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID
2418736|NCT03444506|Active Comparator|PATANASE nasal spray|Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID
3145792|NCT00081367|Experimental|Cognitive behavioral therapy (CBT) + standard care|Participants will receive ten weekly sessions of treatment plus standard care for suicide prevention.
3145793|NCT00081367|Active Comparator|Standard care alone|Participants will receive standard care for suicide prevention.
3145794|NCT00081471|Experimental|1|
3145795|NCT00081471|Active Comparator|2|
3145796|NCT00081484|Experimental|1|
3145797|NCT00081484|Active Comparator|2|
3145798|NCT00081510|Experimental|Lonafarnib plus Anastrozole|Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib
3145799|NCT00081510|Active Comparator|Placebo plus Anastrozole|Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo
3145800|NCT00081588|Experimental|001|TMC114600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
2418737|NCT03444493|Experimental|Exercise|The exercise group performed specific localized exercises aimed at restoring the stabilizing protective function of the transversus abdominis (TrA). The exercises were designed specifically to activate and train the isometric holding function of the TrA muscle at the affected vertebral segment. Additionally, the exercise group was informed about protecting for biomechanics of lumbar spine.
2418738|NCT03444493|No Intervention|Control|Control group was informed about protecting for biomechanics of lumbar spine.
2418739|NCT03444480|Experimental|Remimazolam Tosylate 1|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start， 0.5 mg Flumazenil is administered
2418740|NCT03444480|Experimental|Remimazolam Tosylate 2|IV bolus of Remimazolam Tosylate with a loading dose of 0.4mg/kg body weight over 1 minute followed by a maintenance dose of 1.5mg/kg/h over 2 hours.1 h 55 min after dosing start time,0.5ml placebo is administered
2418741|NCT03444467|Experimental|NNC9204-1513|Participants will receive increasing doses of NNC9204-1513.
2418742|NCT03444467|Active Comparator|Glucagon|Participants will receive a single fixed dose of glucagon.
2418743|NCT03444454|Experimental|VRRS Khymeia|"The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program).~The exercise program will be remotely charged by therapist on the patient's computer.~Each patient's performed session will be reviewed remotely by the therapist."
2418744|NCT03444454|Active Comparator|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
2418745|NCT03444454|Experimental|VRRS Khymeia plus active tDCS|The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
2418746|NCT03444454|Active Comparator|VRRS Khymeia plus placebo tDCS|The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
2418747|NCT03444428||Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
2418748|NCT03444428||Without Non Invasive Ventilation|"Age, height, weight~History and Physical Examination~Evaluation of dyspnoea: mMRC, Borg scale (Seated-Supine)~Amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)~Sleep-Disordered Breathing in Neuromuscular Disease Questionnaire (SiNQ-5)~24h Blood Pressure monitor~Spirometry - FEV1 and FVC~Respiratory muscle strength - MIP, MEP, and SNIP~Arterial Blood Gases~Carotid-femoral pulse wave velocity~Breath CO exhale"
2418749|NCT03444415|Experimental|Motivational interviewing in groups|The Intervention is performed at Primary Care Centers by health professionals (General Practitioners, Nurses, Pediatricians and Midwives), during pregnancy and the first 2 years of the child. Researchers will be trained in motivational interviewing and group dynamics. Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children. They intend to encourage the shift towards healthy lifestyles to parents on issues related to diet, physical activity and smoking habit, encourage breastfeeding and increase their knowledge and self-efficacy to promote healthy habits regarding diet, physical activity and sleep habits of their children.
2418750|NCT03444415|Other|Control Group|"Control Group: Usual Care as established in the Programa Integral de Atención a la Mujer (Comprehensive Program of Woman Assistance) and the Programa de Atención al Niño Sano (Well Child Program) in the Servicio Murciano de Salud.~Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits."
2418751|NCT03444402|Experimental|Group A|Period 1: Test drug(CKD-381 formulation I), Period 2: Test drug(CKD-381 formulation II), Period 3: Reference drug(D026)
2418752|NCT03444402|Experimental|Group B|Period 1: Test drug(CKD-381 formulation II), Period 2: Reference drug(D026), Period 3: Test drug(CKD-381 formulation I)
2418753|NCT03444402|Experimental|Group C|Period 1: Reference drug(D026), Period 2: Test drug(CKD-381 formulation I), Period 3: Test drug(CKD-381 formulation II)
2418754|NCT03444389||Study group|Patients with hemorrhoids
2418755|NCT03444389||Control group|Healthy participants without hemorrhoids
2418756|NCT03444376|Experimental|GX-188E, Keytruda|GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg
2418757|NCT03444363|Experimental|Study group|SRP plus diode laser (810 nm wavelength, 1 W power)
2418758|NCT03444363|Active Comparator|Control group|SRP plus placebo
2418759|NCT03444350|Active Comparator|Control group|SRP plus placebo
2418760|NCT03444350|Experimental|Gaseous ozone group|SRP plus gaseous ozone [1 W (100 mJ, 10 Hz)]
2418761|NCT03444337||Catheter Ablation Group|Patients undergoing FIRM guided ablation of paroxysmal or persistent atrial fibrillation with pre-procedure high resolution cardiac MRI
2418762|NCT03444324|Experimental|BT524|Investigational Human Fibrinogen Concentrate
2418763|NCT03444324|Active Comparator|Fresh Frozen Plasma (FFP)|Standard of Care
2418764|NCT03444311|Active Comparator|A: 1 dosis|1 dosis (3E+09 cfu/day + 6 g of fiber/day)
2418765|NCT03444311|Active Comparator|B: 2 dosis|2 dosis (3E+09 cfu/day + 12 g of fiber/day)
2418766|NCT03444298|Placebo Comparator|Placebo first, then Gamma Tocopherol|Participants that are randomized to placebo treatment will take a short treatment course of Safflower Oil followed by chamber exposure with wood smoke particulate. After a 4-week washout period, participants will cross over to the gamma Tocopherol (active) treatment group.
2418767|NCT03444298|Active Comparator|GammaTocopherol first, then Placebo|Participants that are randomized γT treatment will take a short treatment course of gamma Tocopherol followed by chamber exposure with WSP. After a 4-week washout period, participants will cross over to the placebo treatment group.
2418768|NCT03444285|Active Comparator|Warm Up|
2418769|NCT03444285|Active Comparator|Hot Pack|
2418770|NCT03444272|Experimental|Hepatitis C Treatment|HCV Treatment (Sofosbuvir and Daklatasuvir)
2419412|NCT03440138||Gastro-Obeso-Center Advanced Med Inst, Brazil|
2418778|NCT03444246|Active Comparator|Normal iodine diet group|The arm with iodized salt，the subject in the control group were consumed with iodized salt within six months.
2418779|NCT03444233|Experimental|low f1 diet|low fructose diet week 1
2418780|NCT03444233|Experimental|fruit rich diet|fruit rich diet week 2
2418781|NCT03444233|Experimental|low f2 diet|low fructose diet week 3
2418782|NCT03444233|Experimental|HFCS rich diet|HFCS rich diet week 4
2418783|NCT03444220|Active Comparator|ACHIM|Anaerobically Cultivated Human Intestinal Microbiota
2418784|NCT03444220|Placebo Comparator|Placebo|Anaerobically Cultivated medium
2418785|NCT03444207|Experimental|Group A|Endurance training
2418786|NCT03444207|Experimental|Group B|Endurance-strength training
2418787|NCT03444194|Experimental|Biopsi arm|
3145801|NCT00081822|Other|Clofarabine + Ara-C|An initial dose escalation of clofarabine with a fixed standard dose of Ara-C in phase I will be used to determine an optimal phase II dose.
3145802|NCT00081874|Experimental|RAD001|"Phase I: Participants initially treated with 5 mg RAD001 by mouth daily for 28 days.~Phase II: The MTD (either 5mg or 10mg) administered daily until intolerance or failure or lack of response after 4 cycles of therapy. For assessment purposes, each cycle will comprise a 28-day period."
3145803|NCT00081887|Experimental|Weekly Clofarabine|
2418791|NCT03444168||Candidate for Lumbar Spine Surgery|Participants have been designated to be a candidate for lumbar spine surgery to treat chronic low back and/or leg pain and you have agreed to proceed with the surgery.
2418792|NCT03444168||Lumbar Failed Back Surgery Syndrome|Participants have been diagnosed with having lumbar failed back surgery syndrome and have persistent and moderate-to-severe low back and/or leg pain for more than 6 months after a lumbar spine surgery.
2418793|NCT03444168||Healthy Volunteer|Participants are a healthy volunteer wishing to participate in a research study.
2418796|NCT03444142|Active Comparator|Drug: Exenatide LAR|Exenatide LAR 2 mg, once weekly subcutaneously before breakfast during 4 weeks.
2418797|NCT03444142|Active Comparator|Drug: Dulaglutide|Dulaglutide .75 mg, once weekly subcutaneously Before breakfast during 4 weeks.
2418798|NCT03444129|Active Comparator|Control|This group will participate in a health education workshop with weekly sessions (control group)
2418799|NCT03444129|Experimental|Game|This group will participate in the health education workshop plus the interactive health game (intervention group).
2418800|NCT03444116||Cases (+FDO)|Patients who underwent an FDO
2418801|NCT03444116||Controls (-FDO)|Same as cases but did not undergo an FDO
2418802|NCT03444103|Active Comparator|Clazakizumab / Clazakizumab|Monthly subcutaneous injections of 25mg clazakizumab for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
2418803|NCT03444103|Placebo Comparator|Placebo / Clazakizumab|Monthly subcutaneous injections of placebo (saline) for three months (after completion of part A, monthly injection of 25mg clazakizumab for nine months).
2418806|NCT03444077|Active Comparator|Control group|The patients allocated in the control group will be managed as recommended in the local guidelines and protocols. As the trial involves participating centers with different prehospital and hospital realities and local practices, the control group will reflect a wide panel of levels of care and will not be limited to a unique approach.
2418807|NCT03444077|Experimental|Intervention group|"Patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.~TICCS < 10 This subgroup will be considered without a need for DCR and without coagulopathy. There will not be any activation of the DCR components (no phone contact to the blood bank, to the surgical team, no prehospital transfusion). There will be any prehospital treatment/prevention of the hyperfibrinolysis using Tranexamic acid (TXA). Crystalloids infusion will be allowed.~TICCS ≥ 10 This subgroup will be considered with a need for DCR and with coagulopathy. They will be treated using the STTTOPPP the bleeding protocol."
2418808|NCT03444064|No Intervention|Control|Participants in this arm receive islet transplant only, and no PolyTregs.
2418809|NCT03444064|Experimental|Treatment|Participants in this arm receive PolyTregs infusion at week 6 post islet transplant.
2418810|NCT03444051||20-gauge Procore®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 20-gauge Procore® during the period study"
2418811|NCT03444051||22-gauge Acquire®|"Between March and December 2017, 68 EUS-FNB were consecutively performed in our unit for a pancreatic or peripancreatic mass. The choice of the needle depended upon the availability at the time of admission:~34 punctures were performed with a 22-gauge Acquire® during the period study"
2418812|NCT03444038|Experimental|NBI-98854|NBI-98854 administered once daily for up to 24 weeks
3145804|NCT00081900|Experimental|DENSPM|
3145805|NCT00082043|Experimental|1|Dutasteride 2.5 mg by mouth daily for one month
3145806|NCT00082043|Placebo Comparator|2|Placebo oral capsule for two months
3145807|NCT00082095|Experimental|Group 1 (doxorubicin)|Pegylated liposomal doxorubicin 40 mg/m2 administered intravenously on Day 1 of each cycle. Cycle is repeated every 28 days, up to one year.
3145808|NCT00082095|Active Comparator|Group 2 (capecitabine )|Capecitabine administered orally at a dosage of 2000 mg/m2/day (1000 mg/m2 BID) for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
3145809|NCT00082147|Experimental|Biopsy|Biopsy
3145810|NCT00082186|Experimental|1|Oral bosentan tablets
3145811|NCT00082199|Active Comparator|A1|
3145812|NCT00082199|Placebo Comparator|A2|
3145813|NCT00082212|Experimental|1|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
3145814|NCT00082225|Experimental|EBV specific T cells|"Patients receiving CTLs as therapy for relapsed Lymphoma or who are at high risk for relapse or patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.~A fixed dose of CD45 MAb (400ug/kg over 4 hours daily times 4 given over 2 daily IV infusions) will be used."
3145815|NCT00082238|Experimental|Cystic fibrosis (CF)|
3145816|NCT00082238|Active Comparator|Healthy volunteers|
3145817|NCT00082277|Experimental|1|High-Risk Fragility Fracture-Open-Label, Non-Comparative Stratum
2418813|NCT03444025|Experimental|Group A|Goserelin 3.6 mg depot injection will be administered subcutaneously every month along with standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
2418814|NCT03444025|No Intervention|Group B|Standard chemotherapy regimen: AC-P: Doxorubicin 60 mg/m2 IV plus cyclophosphamide 600 mg/m2 every 3 weeks for four cycles, followed by paclitaxel 80 mg/m2 by 1 hour infusion every week for 12 weeks. Each cycle is 21 days.
2418815|NCT03443986|Experimental|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes.
2418816|NCT03443986|Sham Comparator|Resistance training associated with sham|"The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown. The vibration sham; will be held with the disconnected platform. A device will be connected producing a noise similar to the sound of the connected platform for a time equivalent to the treatment protocol, since it will not be possible to distinguishing noticeably stimulate vibrator. Participants that will undergo false vibration will not have contact with those who carry out the real treatment."
2418817|NCT03443986|No Intervention|Control group|Will not be submitted to any physical intervention. It continues in your daily life with only monitoring via phone callings. Guidelines about foot care.
3145818|NCT00082277|Experimental|2|Moderate-Risk of Fragility Fracture-Randomised, Double-Blind Stratum
3145819|NCT00082277|Experimental|3|Low-Risk of Fragility Fracture - Open-Label, Non-Comparative Stratum
2418820|NCT03443960|Experimental|Treatment A (TNX-102 SL)|2 x TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg once daily for 20 consecutive days
2418821|NCT03443960|Active Comparator|Treatment B (AMRIX)|1 x AMRIX ER capsule 30 mg once daily for 20 consecutive days
2418822|NCT03443947|Experimental|D group|
2418823|NCT03443921|Experimental|Surgery Group|In Surgery Group, an artery divestment combined pancreatectomy will be performed if no pre-operative contra-indication or intra-operative metastasis were revealed. Post-operative adjuvant chemotherapies were prescribed according to performance status.
2418824|NCT03443921|Active Comparator|NeoChemo Group|In NeoChemo (Neoadjuvant Chemotherapy) Group, neoadjuvant chemotherapy will be utilized. After 2 circles of neoadjuvant chemotherapies, patients will be reevaluated and curative operation would be attempted if without disease progression.
2418826|NCT03443895|Active Comparator|Experimental: AEF0117|Subjects in cohorts 1 through 3 receive active treatments. Subjects in Cohorts 1 through 3 will receive a single dose of 0.6, 2 and 6mg respectively of AEF0117 on Day 1 to Day 7.
2418827|NCT03443895|Placebo Comparator|Placebo|Subjects in Cohorts1 through 3 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
2418828|NCT03443882|Active Comparator|Astaxanthin formulation #1|capsules
2418829|NCT03443882|Active Comparator|Astaxanthin formulation #2|tablets
2418830|NCT03443882|Active Comparator|Astaxanthin formulation #3|powder
2418831|NCT03443882|Experimental|Astaxanthin formulations|fast condition
2418832|NCT03443869|Experimental|Letermovir|Letermovir (LET) 480mg (or 240 mg when co-administered with cyclosporin A) tablet orally; placebo to VGCV tablet orally once daily; and 400 mg capsule of acyclovir (ACV) orally every 12 hours for 28 weeks
2418833|NCT03443869|Active Comparator|Valganciclovir|900 mg Valganciclovir (VGCV) tablet orally, once daily; placebo to LET tablet orally once daily; and placebo to ACV orally every 12 hours for 28 weeks
2418834|NCT03443856|Other|chemotherapy arm|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
2418835|NCT03443856|Experimental|immunotherapy arm|Treatment: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year. No chemotherapy.
2418836|NCT03443843|Experimental|Sequence 1|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
2418837|NCT03443843|Experimental|Sequence 2|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
2418838|NCT03443843|Experimental|Sequence 3|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
2418839|NCT03443843|Experimental|Sequence 4|Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
2418840|NCT03443830|Experimental|0.2 mg/kg|Subject will be administered with 0.2 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418841|NCT03443830|Experimental|0.5 mg/kg|Subject will be administered with 0.5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418842|NCT03443830|Experimental|1 mg/kg|Subject will be administered with 1 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418843|NCT03443830|Experimental|5 mg/kg|Subject will be administered with 5 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418844|NCT03443830|Experimental|10 mg/kg|Subject will be administered with 10 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418845|NCT03443830|Experimental|20 mg/kg|Subject will be administered with 20 mg/kg of Tyzivumab via IV infusion over a period of 30 minutes.
2418846|NCT03443817|No Intervention|Control group|There is no conventional rehabilitation follow up program, but all patients are encouraged to continue training
2418847|NCT03443817|Experimental|Intervention group|The intervention group will obtain telerehabilitation
2418848|NCT03443804|Experimental|Test(DW1401)|tid PO, DW1401+Placebo of Stillen tab.
2418849|NCT03443804|Active Comparator|Reference(Stillen tab.)|tid PO, Stillen tab.+Placebo of DW1401
2418850|NCT03443791|Experimental|women enrolled|pregnant women enrolled in trial
2418851|NCT03443791|Other|newborns of female study participants|newborns will be tested to determine if virus is present.
2419413|NCT03440138||Hospital Dipreca Santiago Región Metropolitana , Chile|
2418853|NCT03443778|Active Comparator|Bupivacaine 0,5%|Bupivacaine 0.5% 1 mg/kg with in Nacl 0,9% 3-5 ml separately two part for each tonsil before surgery
2418854|NCT03443778|Active Comparator|Bupivacaine 0,5% , Dexamethasone|Bupivacaine 0,5% 1 mg/kg,dexamethasone 0.5 mg/kg (max dosage 8mg) 3-5 ml separately two part for each tonsil before surgery
2418855|NCT03443765||Patients with Pityriasis alba|
2418856|NCT03443765||Healthy participants (control group)|
2418857|NCT03443752|Experimental|Shotokan-Karate|The protocol for Shotokan-karate training will involve a one hour training session which will be broken down into 3 major components. The training program will consist of warm-up exercises, katas (choreographed karate movements), and cool-down exercise.
2418858|NCT03443752|Experimental|Tai-Chi|The protocol for Tai Chi will involve a one-hour training session which will be conducted by an instructor at the Sun Life Financial Movement Disorders and Rehabilitation Centre.The following program will be held three times per week.
2418859|NCT03443726|Experimental|Infiltrative technique|Patients in this arm will have buccal and lingual infiltrative anesthesia with 4% articaine 1:100.000 epinephrine for third molar extraction.
2418860|NCT03443726|Active Comparator|Nerve block technique|Patients in this arm will have inferior alveolar nerve and buccal nerve block with 4% articaine 1:100.000 epinephrine for third molar extraction.
2418866|NCT03443687|Active Comparator|Pelvic Floor Physical Therapy|If randomized to this arm, women will complete demographic forms and questionnaires. They will then undergo the intervention of 4 pelvic floor physical therapy visits over 3 months. At that time they will return for a follow up visit and complete questionnaires.
2418867|NCT03443687|Experimental|Home Biofeedback|If randomized to this arm, women will complete demographic forms and questionnaires. They will then be given a pelvic floor exercise device that is bluetooth linked to a smartphone application. They will be instructed on how to use the device daily for 3 months and their intervention will be to perform daily exercises with the device in place. At 3 months they will return for a follow up visit and complete questionnaires.
3145820|NCT00082290|Experimental|a massage|About 45 minute massage
2418869|NCT03443661|Experimental|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
2418870|NCT03443635|Experimental|Treatment|Subjects receiving hands-on cooking and nutrition education classes
2418871|NCT03443635|No Intervention|Control|Subjects not receiving any additional nutrition education aside from that contained in their curricula (for trainees) or medical care (for patients)
2418872|NCT03443622|Experimental|SC-43 100 mg/day|SC-43 Oral Solution (100 mg/ml), 1 ml by mouth, q.d. for 28 days
2418873|NCT03443622|Experimental|SC-43 200 mg/day|SC-43 Oral Solution (100 mg/ml), 2 ml by mouth, q.d. for 28 days
2418874|NCT03443622|Experimental|SC-43 400 mg/day|SC-43 Oral Solution (100 mg/ml), 4 ml by mouth, q.d. for 28 days
2418875|NCT03443622|Experimental|SC-43 600 mg/day|SC-43 Oral Solution (100 mg/ml), 6 ml by mouth, q.d. for 28 days
2418876|NCT03443622|Experimental|SC-43 900 mg/day|SC-43 Oral Solution (100 mg/ml), 9 ml by mouth, q.d. for 28 days
2418877|NCT03443622|Experimental|SC-43 1200 mg/day|SC-43 Oral Solution (100 mg/ml), 12 ml by mouth, q.d. for 28 days
2418878|NCT03443609|Other|68Ga-HBED-CC-PSMA PET / CT|"Patients will receive 68Ga-HBED-CC-PSMA PET / CT imaging for the detection of prostate cancer recurrence sites. This determination will be made at the patient and lesion level by reference to the gold standard (or truth standard) that will be obtained from the histology data and / or from an imaging and evolution follow-up. PSA over a period of at least 6 months (RECIST 1.1 criteria)."
2418879|NCT03443596|Active Comparator|Early intensive BP control|BP in participants in this arm is treated aggressively, lowered and maintained at systolic blood pressure between 140-160mmHg, within 6 hours of stroke onset and maintained in this range for first 72 hours.
2418880|NCT03443596|No Intervention|Guidelined based BP control|Participants are treated according to the current international guidelines in thrombolysed acute ischemic stroke patients, i.e., less than 180/105mmHg
2418881|NCT03443570|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rituximab in combination with bortezomib at the indicated dose
2418882|NCT03443570|Active Comparator|control group|100 enrolled patients are randomly picked up to take rituximabalone at the indicated dose
2418883|NCT03443557||oral nutrition supplement group|hospitalized malnourished patients who were received oral nutrition supplement during hospital course
2418884|NCT03443557||control group|hospitalized malnourished patients who were received only hospital food during hospital course
2418885|NCT03443544||Intestinal origin|Either perianal abcess or rectal carcinoma
2418886|NCT03443544||Testicular Origin|Complicated epididymitis with fascitis,
2418887|NCT03443544||Urinary Origin|From urinary tract infection or fistulae from urethral trauma
2418888|NCT03443544||Cutaneous Origin|mostly folliculitis, and skin infections
2418889|NCT03443531|Experimental|TCM|Patients in this group will receive two types of TCM treatment, which are Bufei Huatan granule, Yifei Qinghua granule. The herbal extract twice daily for 24 weeks for lower dosage. The two granules are corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
2419018|NCT03442621|Experimental|Relacorilant with a high fat breakfast|Relacorilant with a high fat breakfast
3145821|NCT00082290|Experimental|visit with a volunteer|45 minute visit
3145822|NCT00082290|Experimental|period of quiet time|45 minutes of quiet time
3145823|NCT00082446|Experimental|E|Subject will receive an SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of placebo by scarification.
3145824|NCT00082446|Active Comparator|D|Subject will receive a SC dose of placebo on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3145825|NCT00082446|Experimental|C|Subject will receive a SC dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
2418890|NCT03443531|Placebo Comparator|placebo TCM|Patients in this group will be given two placebo TCM treatment, which are which are placebo Bufei Huatan granule, placebo Yifei Qinghua granule, corresponding to the two traditional Chinese syndromes in sequence, which are syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung, Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung.
2418891|NCT03443518|Experimental|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical land mark for psoas plexus, also normal saline 0.9% IV infusion will be in the same rate of the Remifentanil infusion for the other group.
2418892|NCT03443518|Experimental|L.A infiltration /Remifentanil infusion|L.A infiltration (lidocaine) 5 ml of 2% will be injected subcutaneous as L.A infiltration then Remifentanil infusion with rate 0.03-0.1 μg / kg / min to achieve Visual Analog Scale 3 or less.
2418893|NCT03443492|Experimental|SLOG|800 mg/m2 gemcitabine at a fixed rate of 10 mg/m2/min followed by a 2-hour intravenous infusion of oxaliplatin on day 1 plus twice daily oral S-1 80-120 mg/day (based on BSA) and oral leucovorin 30 mg twice a day on day 1 to day 7, every 14 days as a cycle
2418894|NCT03443492|Experimental|mFOLFIRINOX|oxaliplatin at a dose of 85 mg/m2, given as a 2-hour infusion, with the addition, after 30 minutes, of irinotecan at a dose of 150 mg/m2, given as a 90-minute infusion. The treatment was immediately followed by a continuous intravenous infusion via central venous catheter of leucovorin 400 mg/m2 given as a 2-hour infusion and 5-FU 2400 mg/m2 over a 46-hour period on day 1 every 14 days/cycle.
2418895|NCT03443479||Patients with type II ARF|All patients with type II respiratory failure that were deemed by the treating physician to require ventilatory support either with non-invasive ventilation (NIV) or High-Flow Nasal Cannula (HFNC).
2418896|NCT03443466|Experimental|Epidural electrical stimulation (EES)|n=20
2418897|NCT03443466|Active Comparator|Loss of resistance (LOR)|n=20
2418898|NCT03443453|Experimental|MIV-711 ABCD|Subjects will first receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B). Thereafter they will receive the capsule formulation under fasted conditions (C) followed by the capsule formulation administered under fed conditions (D).
2418899|NCT03443453|Experimental|MIV-711 CDAB|Subjects will first receive the capsule formulation under fasted conditions (C)followed by the capsule formulation administered under fed conditions (D). Thereafter they will receive the tablet formulation under fasted conditions (A) followed by the tablet formulation administered under fed conditions (B).
3186369|NCT00744341|Experimental|3|
3186370|NCT00744341|Experimental|4|
3186371|NCT00744341|Placebo Comparator|5|
3186372|NCT00744354|Experimental|Non-Randomized Open Label Single Arm|Phase 1 dose escalation trial of vorinostat in combination with bortezomib and pegylated liposomal doxorubicin hydrochloride.
3186373|NCT00744367|Placebo Comparator|Placebo|Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.
3186374|NCT00744367|Experimental|Taspoglutide 10mg|Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment
3186375|NCT00744367|Experimental|Taspoglutide 10mg/20mg|Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.
2418907|NCT03443401||patient participants|patients with chronic low back pain receiving standard physical therapy care
2418908|NCT03443401||Physical Therapy clinician participants|Licensed physical therapist that is providing standard physical therapy care for a patient participant
2418909|NCT03443388|Active Comparator|Part 2: Helmet|"After a screening period, 10 patients with drug resistant epilepsy will first be assigned to wear one Hövding inflatable helmet in their daily lives. Subjects will fill out questionnaires about their seizures, injuries, and the circumstances of inflation when it occurs. After experiencing a seizure resulting in a fall or any helmet deployment, patients will crossover to the no helmet group. If no seizure resulting in fall occurs in 3 months, participation will end."
2418910|NCT03443388|No Intervention|Part 2: No Helmet|"After a screening period, 10 subjects with drug resistant epilepsy will first be assigned to not wear an inflatable helmet. Subjects will fill out questionnaires about their seizures and injuries. After approximately 3 months, patients will crossover to the helmet group."
2418911|NCT03443375|Experimental|Nonperiodized resistance training|The Nonperiodized group performed was an intervention based on resistance exercise program with a constant intensity.
2418912|NCT03443375|Experimental|Daily undulating periodized|The Daily undulating periodized program was an intervention based on daily alterations on exercise load. .
2418913|NCT03443375|No Intervention|Control group|The control group remained their regular habits of life during all study period, without engaging in physical exercise programs.
2418914|NCT03443362||Chronic urticaria|50 consecutive chronic urticaria patients receiving medical care within the CHU Brugmann Hospital. Diagnose according to the European Academy of Allergy and Clinical Immunology (EAACI) guidelines.
2418915|NCT03443362||Control|20 healthy control patients, without chronic urticaria. Patients coming to the CHU Brugmann hospital for the excision of atypical naevi.
2418916|NCT03443349|Other|Use of the medical Device: Vibwife One|"The medical device will be used according to its market authorization.~Because it will be used for the first time in pregnant women, the following three step application procedure has been determined:~First five pregnant women use the device for 10 minutes. Each of them in a position and module proposed by the midwife with the agreement of the woman.~Next 10 pregnant women use the device for 20 minutes. Again, position and module according to the decision of the midwife with the agreement of the woman.~All the remaining pregnant women (35) use the device for 30 minutes. Position and module according to the decision of the midwife with the agreement of the woman.~During the intervention period, position and module might be changed once if required."
2418917|NCT03443323|Experimental|OST-S Intervention group|
2418918|NCT03443323|No Intervention|Treatment as usual control group|
2418919|NCT03443310|Other|Ultrasound assessment of DVT|DVT ultrasound vs Clinical assessment in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
3186376|NCT00744393|Active Comparator|A|Active drug
3186377|NCT00744393|Placebo Comparator|P|Placebo drug
3186378|NCT00744406|Experimental|1|
3186379|NCT00744406|Experimental|2|
2418920|NCT03443297|Experimental|Early Feeding group|Active ingredient: maternal expressed breast milk Time of initiation of first feeding: 24 to 48 hours of age. Doses: Initially 4 hourly feeding will be started with 0.5 ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. On the following day 3 hourly, thereafter 2 hourly feeding will be provided in both groups. Gradually amount of feeding will be increased after reaching 2 hourly feeding at the rate of 10 ml/kg/day for initial 10 days then 20ml/kg/day in 2 aliquots till full feeding(150ml/kg/day).For babies with birth weight <1200 gram, rate of feeding advancement 10 ml/kg/day till full feeds. Time of starting first feeding and time to reach full feeding, both will be documented in a questionnaire for each patient.
2418921|NCT03443297|No Intervention|Late Feeding group|Feeding with maternal breast milk will be given in conventional way
2418922|NCT03443284|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of an iPhone or iPod Touch Operating System (iOS) mobile application (app) and a health care provider (HCP) portal.
2418923|NCT03443284|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
2418924|NCT03443271|Experimental|Group T (TAP Block with Bupivicaine)|Ultrasound guided TAP block will be performed in this group. Bupivicaine 0.25 % 20 ml will be administered in the block on either side.
2418925|NCT03443271|Placebo Comparator|Group C (TAP Block with Placebo drug)|Ultrasound guided TAP block will be performed in this group. 0.9 % Saline 20 ml will be administered in the block on either side.
2418926|NCT03443258|Experimental|Intervention Group (IG)|Patients receive needs assessment tool integrated in nursing consultation in accordance with requirements by Danish Health and Medicine Board follow-up program for HNC patients. The consultation consists of 6 steps 1. Welcoming patient; 2. Introducing patient to assessment tool; 3. Discuss symptoms and concerns patient wishes to discuss; 4. Follow up on patients symptoms, concerns and emotional reactions/problems; 5. Accompany/support patient during appointment with surgeon and in cooperation with patient and surgeon ensure that problems arising from the tool needing medical attention are focused on; 6. Continue the consultation after appointment with surgeon; refer patient to multi-disciplinary team members when needed
2418927|NCT03443258|No Intervention|Control Group (CG)|CG will receive standard care according to the Danish Health and Medicine Board's follow-up program for HNC patients. At present this is done by a staff nurse interviewing the patient, who is a member of the rehabilitation team who perform nursing consultations. The interview takes place after the appointment with the surgeon. The nurse refers the patient to physical rehabilitation if needed
2418928|NCT03443245||Stroke patients|Patient will have thrombolysis treatment as part of their standard care.
2418929|NCT03443245||Healthy Volunteers|Healthy volunteers to act as control group for stroke patients.
2418930|NCT03443232|Experimental|Cryoballoon ablation group|Persistens atrial fibrillation in Cryoballoon ablation group will apply cryoablation
2418931|NCT03443232|Other|Radiofrequency ablation group|Persistens atrial fibrillation in Radiofrequency ablation group will apply Radiofrequency ablation
2418932|NCT03443219|Experimental|Spritztube®|The patients were randomly allocated to two groups by using computer-generated numbers.In Spritztube® group, Spritztube® was inserted into each patient after anesthesia induction.
2418933|NCT03443219|Active Comparator|LMA Supreme™|The patients were randomly allocated to two groups by using computer-generated numbers.In vgroup, LMA Supreme™was inserted into each patient after anesthesia induction.
2418934|NCT03443206|Experimental|Intervention|This condition will include access to a website that includes a social component, in addition to psychoeducation and access to resources.
2418935|NCT03443206|Active Comparator|Control|This condition will include access to a website that includes psychoeducation and access to resources.
2418936|NCT03443193|Experimental|Linear training|Linear training consists to a progressive improvement of the training load during the 3 month-program.
2418937|NCT03443193|Experimental|Non-linear training|Non-linear training consists to an undulating progressive improvement of the training load during the 3 month-program.
2418938|NCT03443180|Other|Dietary intervention|Participants will be asked to remove food containing gluten and ATI from their diets for 4 weeks.
2418939|NCT03443167|Active Comparator|Intervention group|Training on emergency telephone numbers and mnemonics
2418940|NCT03443167|Sham Comparator|Control group|Sham generic formation on the cardiopulmonary arrest.
2418941|NCT03443141|Experimental|Vitamin E dressing|Patients will receive a Vitamin E-containing dressing over the wound
2418942|NCT03443141|Sham Comparator|Standard dressing|Patients will receive a standard dressing over the wound
2418943|NCT03443128|Experimental|Vinorelbine monotherapy treatment|Patients will be treated with Vinorelbine. Four weeks as a course. There are 20 courses in total.
2418944|NCT03443102||SARS survivors|First-line HCWs infected during the SRAS-CoV pandemic in Peking University People's Hospital, China. Diagnose was further confirmed by SARS-CoV seropositive results.
2418945|NCT03443102||Controls|"Coworkers of the infected HCWs, who also exposed to SARS patients or specimens. Infection was further excluded by SARS-CoV seronegative results.~Healthy controls matched for age, sex and disease condition, but without exposures to SARS virus."
2418946|NCT03443089|Experimental|Test formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
2418947|NCT03443089|Active Comparator|Reference formulation|Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
2418948|NCT03443076|Experimental|EPA + DHA in SMEDS Formulation|Subject will receive a single 500 mg oral dose of EPA + DHA in a SMEDS formulation
2418949|NCT03443076|Active Comparator|EPA + DHA (Lovaza)|Subject will receive a single 840 mg oral dose of EPA + DHA as Lovaza
3186380|NCT00744406|Experimental|3|
2418952|NCT03443050|Experimental|Experimental|Balance training on unstable surfaces
3186381|NCT00744419|Experimental|3 age groups|Assigned to the arm based on age.
3186382|NCT00744445|Active Comparator|0800|r-HuEPO administered at 0800 hrs
3186383|NCT00744445|Active Comparator|1500|r-HuEPO administered at 1500 hrs
2418954|NCT03443037||Amantadine group|Patients admitted to the critical care with diagnosis of coma state who have received amantadin 200 mg / day for fourteen days according to İCU protocols decided by primary physician
2418955|NCT03443037||Control group|Patients admitted to the critical care with diagnosis of coma state who haven't received amantadin
3186384|NCT00744445|Active Comparator|2200|r-HuEPO administered at 2200 hrs
3186385|NCT00744458|Active Comparator|1|
3186386|NCT00744458|Active Comparator|2|
3186387|NCT00744458|Active Comparator|3|
2418960|NCT03443011|Experimental|participants|All participants will be examined with both CT techniques. First a low dose CT without intravenous contrast followed by the standard method, a full dose CT with intravenous contrast
2418961|NCT03442998|Other|Suburban|Study participants will wall on a suburban sidewalk setting for 50 minutes.
2418962|NCT03442998|Other|Nature|Study participants will wall on a nature path setting for 50 minutes.
2418963|NCT03442985|Experimental|Palovarotene 2.5 mg daily regimen|
2418964|NCT03442985|Experimental|Palovarotene 5.0 mg daily regimen|
2418965|NCT03442985|Placebo Comparator|Placebo regimen|
2418966|NCT03442972|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
2418967|NCT03442972|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
2418968|NCT03442959||patient with primary resection of the Small Intestinal TNE|
2418969|NCT03442959||patient without primary resection of the Small Intestinal TNE|
2418970|NCT03442946||INS|Patients in need of a cardiovascular surgery will be included in this observational study. The focus is on the nutrition therapies provided to these critically ill patients according to institutional or international nutrition guidelines, what ever applies for the participating sites.
3186388|NCT00744484|Experimental|B1|B1 - training in water
3186389|NCT00744484|Experimental|S1|S1 - training on land
2418973|NCT03442920|Experimental|Obese women|Obese women who participated exercise programme.
2418974|NCT03442920|No Intervention|Normal weighted|Normal weighted women with non-periodontitis
2418975|NCT03442907|Experimental|Study group|"The intraoperative blood pressure target for all patients in the study group is the mean arterial pressure (+ 10mmHg maximum) derived from the prior 24-hour blood pressure measurement.~To achieve the blood pressure target, fluid or vasoactive substances will be used."
2418976|NCT03442907|Active Comparator|Control group|Study patients of the control group are treated according to the standard operating procedures (SOP) of the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf.
2418977|NCT03442894|Active Comparator|Standard PT Treatment|"This group will receive manual therapy and exercise interventions provided by their physical therapist. The treatment will occur for 10 sessions over 6 weeks.~Interventions: Manual therapy interventions including mobilization and manipulation of the shoulder girdle spine and ribcage. Exercise interventions will include strengthening and flexibility exercises for rotator cuff and shoulder girdle musculature."
2418978|NCT03442894|Experimental|Standard PT Treatment plus DN|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits.
2418979|NCT03442894|Sham Comparator|Standard PT Treatment plus Sham DN|In addition to the standard PT treatment, patients in the sham DN group will receive 6 sessions of sham DN intervention.
2418980|NCT03442881||benign adnexal mass|pathological examination of the specimen after excision reveals benign criteria
2418981|NCT03442881||Malignant adnexal mass|pathological examination of the specimen after excision reveals malignant criteria
3186390|NCT00744510|Experimental|1|Reflexology
3186391|NCT00744510|No Intervention|2|
3186392|NCT00744536|Experimental|Lenalidomide and Melphalan|Lenalidomide + Melphalan both given metronomically
2418985|NCT03442816|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
2418986|NCT03442803|Experimental|Propofol TCI|Delivery of Propofol via a Target-controlled infusion pump for procedural sedation.
2418987|NCT03442790|Experimental|Agitated Saline Method|The proper placement of the central venous line will be confirmed using agitated saline under ultrasound vision
2418988|NCT03442790|Active Comparator|Chest X-Ray Confirmation|The proper placement of the central venous line will be compared with chest x-ray obtained in supine position after central line placement
2419019|NCT03442621|Experimental|Relacorilant with a moderate breakfast|Relacorilant with a moderate breakfast
2419020|NCT03442608|Experimental|mild hypothermia|Device: Zoll 2000 and/or CureWrap 3500 cooling system,lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
2419021|NCT03442608|Placebo Comparator|northermia|normal physical cooling methods,like ice bag, conditionally required.
3186393|NCT00744549|Experimental|A|This group of men will be on active treatment (antioxidants) for one year and placebo for the second year.
3186394|NCT00744549|Experimental|B|This group of men will be on placebo for one year and active treatment (antioxidants) for the second year.
3186395|NCT00744562|Experimental|Open-label OMP-21M18|
3186396|NCT00744575||1|Chronic Back Pain
3186397|NCT00744575||2|Healthy Sex & Age Matched Controls
3186398|NCT00744588||alcohol dependence|Alcohol-dependent subjects currently being treated in an inpatient treatment facility.
3186399|NCT00744601||1|Patients with Cocaine Addiction
3186400|NCT00744601||2|Healthy Control Volunteers
3186401|NCT00744614||1|Medical Intensive care unit patients with asthma, COPD, ILD or coronary disease who are at risk of intubation
3186402|NCT00744640|Experimental|single|single arm study with triple combination chemotherapy
3186403|NCT00744666|Experimental|1|Patients receive Prednisolone 1% 1gtt qid x 4 weeks. If the intraocular pressure (IOP) after the 4 weeks is > or equal to 21 mmHg, then IVTA will be withheld. If the IOP < 21mmHg, then patients will receive an injection of IVTA.
3186404|NCT00744666|No Intervention|2|Patients will receive an injection of IVTA (no trial of Prednisolone gtts is given).
3186405|NCT00744679|Experimental|Natalizumab 300 mg|Natalizumab infused at 300 mg every 28 days during the screening and assessment periods of the study which continues the therapy of the previous 12 months and maintains steady-state pharmacokinetics.
3186406|NCT00744705||1|Normal subjects who received routine health check-up in a comprehensive medical testing center
3186407|NCT00744731|Experimental|001|placebo placebo for 1 week
3186408|NCT00744731|Experimental|002|carisbamate 400 mg/day to 1,200 mg per day
3186409|NCT00744744||Survey|
2418992|NCT03442764|Experimental|Group 1|Active Treatment for participants with base target trough concentration
2418993|NCT03442764|Experimental|Group 2|Active Treatment for participants with higher target trough concentration
2418994|NCT03442764|Placebo Comparator|Placebo|Placebo Group
2418995|NCT03442751|Active Comparator|Epithelium-on CXL Treatment Group|Study eye receives Paracel 1, Paracel 2 R0185 and irradiated using KXL High Power System (10 J)
2418996|NCT03442751|Sham Comparator|Sham Treatment/Control Group|Sham eye receives Paracel Placebo and irradiated using KXL High Power System (2 J)
2418997|NCT03442738||Group I Endocuff group|Group I Endocuff cap use
2418998|NCT03442738||Group II standard colonoscope|Group II standard colonoscope, no further device used
3186410|NCT00744835|Experimental|1|Ablation Management
3186411|NCT00744900|Experimental|A|
3186412|NCT00744913|Experimental|1|
3186413|NCT00744913|Active Comparator|2|
2419003|NCT03442712|Active Comparator|Treatment arm 1|"Auricular acupressure (AA) plus smartphone App:~Semen Vaccaria laccaria will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear. Subjects will be requested to apply pressure on the acupoints thrice per day. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. The total treatment period will be 8 weeks."
2419004|NCT03442712|Active Comparator|Treatment arm 2|The participants will only receive AA treatment and are required to perform daily self-administered seeds pressing.
2419005|NCT03442712|No Intervention|Treatment arm 3|The participants in the waitlist control group will maintain their usual dietary and exercising patterns.
3186414|NCT00744926|Placebo Comparator|placebo|
2419007|NCT03442686|Experimental|Spring 2018 Compass Course Group|Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018. All participants will complete study questionnaires before and after the Spring sessions.
2419008|NCT03442686|No Intervention|Spring 2018 Comparison Group|Two groups of up to 15 participants will receive the study intervention in Fall 2018. All participants will complete study questionnaires before and after the Spring sessions. Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
2419009|NCT03442673|Active Comparator|CG (Chemotherapy/G-CSF) - Regime|Vinorelbine 35 mg/m2 at day 1 as an i.v. infusion over 10 minutes or gemcitabine 1250 mg/m2 as a 30 minutes infusion at day 1. G-CSF will be started at day 4 at 10mcg/kg b.w. split in two daily doses, until the end of the stem cell collection procedure, with the first collection attempt on day 8.
2419010|NCT03442673|Experimental|G (G-CSF) - Regime|G-CSF at 10mcg/kg b.w. split in two daily doses starting from day 1 until the end of the stem cell collection procedure, with the first collection attempt on day 5.
2419011|NCT03442660|Other|Data collection|An electronic data capture (EDC) system will be used to collect data in electronic format. Data will be collected at the enrolment visit, at the follow-up visit (8 weeks +/-2 weeks) and 1 to 4 days after the follow-up visit.
2419012|NCT03442647|Active Comparator|Living donors|sinistrin clearance dynamic measurement
2419013|NCT03442647|Active Comparator|ADPKD patients|sinistrin clearance dynamic measurement
2419014|NCT03442647|Active Comparator|Patients with primary renal tumor|sinistrin clearance dynamic measurement
2419015|NCT03442634|Experimental|Early Hydration Group|this study group will get 200 ml of sugar free water within 1 hour after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Early Oral Hydration
2419016|NCT03442634|Active Comparator|Traditional Hydration Group|this study group will get 200 ml of sugar free water after 6 hours after cesarean section followed by oral hydration as per patients' desire then starting semisolid and solid foods when patients are open bowel Intervention: Traditional Oral Hydration
2419017|NCT03442621|Experimental|Relacorilant Fasted|Relacorilant Fasted
2419148|NCT03441802|Active Comparator|Cases|
3186415|NCT00744926|Experimental|taspoglutide 10mg sc|
3186416|NCT00744926|Experimental|taspoglutide 10mg/20mg sc|
3186417|NCT00745004|Experimental|1|Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days.
3186418|NCT00745004|Placebo Comparator|2|Placebo 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days.
3186419|NCT00745017|Experimental|1|
3186420|NCT00745017|Experimental|2|
3186421|NCT00745017|Experimental|3|
3186422|NCT00745043|Placebo Comparator|R302|Daily placebo capsules
3186423|NCT00745043|Active Comparator|R303|Daily metoprolol 95mg capsules
3186424|NCT00745043|Active Comparator|R304|Daily propranolol 80mg capsules
3186425|NCT00745043|Active Comparator|Open Label|Daily Metoprolol 190mg capsules
3186426|NCT00745108|Experimental|Tibolone 1.25 mg|
3186427|NCT00745108|Experimental|Tibolone 2.5 mg|
3186428|NCT00745108|Active Comparator|CE/MPA|
3186429|NCT00745134|Experimental|Arm I (curcumin)|Patients undergo radiation therapy 5 days a week for a total of 28 fractions. Patients also receive capecitabine PO BID on the days of radiation therapy and curcumin PO BID in weeks 1-11.5.
3186430|NCT00745134|Active Comparator|Arm II (placebo)|Patients undergo radiation therapy and receive capecitabine as in Arm I. Patients also receive placebo PO BID in weeks 1-11.5.
3186431|NCT00745147|Experimental|A|Chinese herbal formula + Placebo of duphalac
3186432|NCT00745147|Active Comparator|B|Duphalac + Placebo of Chinese herbal formula
3186433|NCT00745160||1|Never-smokers with lung cancer
3186434|NCT00745173|Other|1|
3186435|NCT00745186|Active Comparator|1|Glucagen
3186436|NCT00745186|Experimental|2|Mayne Glucagon
3186437|NCT00745199|Experimental|1|Patients on hemodialysis with pruritus, receiving cromolyn sodium
3186438|NCT00745199|Experimental|2|patients on hemodialysis with pruritus, receiving placebo
3186439|NCT00745199|No Intervention|3|Patients on hemodialysis but without pruritus who do not receive any treatment.
2419024|NCT03442582||Afluria|Afluria exposure in pregnancy
3145826|NCT00082446|Experimental|B|Subjects will receive a SC dose of MVA 5x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3145827|NCT00082446|Experimental|A|Subjects will receive a SC dose of MVA 2x10^7 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
2419027|NCT03442543|Experimental|charcoal|
2419028|NCT03442543|Experimental|silver wire|
2419029|NCT03442530|Active Comparator|Tobacco Treatment As Usual (TTAU)|Eligible women assigned to the control group will be informed of the risks of tobacco use and benefits of quitting using the ACOG 5A's approach by their healthcare provider.5 This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The study coordinator will invite participants to complete the tobacco use questionnaires (TUQ),urine cotinine validation, and Expired Air Carbon Monoxide (EACO) analysis to assess ongoing tobacco use at the designated time points.
2419030|NCT03442530|Experimental|ToPIC|Eligible women assigned to the intervention will receive TTAU plus ToPIC administered by the CTTS. At least once monthly, at routinely scheduled prenatal visits or through telephone, the CTTS will provide cessation counseling. The CTTS will invite participants to complete TUQs,urine cotinine validation and EACO analysis to assess ongoing tobacco use at the designated time points.
2419031|NCT03442517|Experimental|Group-based phone counseling (GBPC)|Participants will take part in weekly group-based phone counseling sessions for 6 weeks starting between 16-30 weeks of pregnancy.
2419032|NCT03442517|Active Comparator|Usual prenatal care|Participants will continue their usual prenatal care.
2419033|NCT03442504|Other|FES PET/CT|"The images will be made immediately after the injection of the FES in a dynamic acquisition, of 30 minutes, centered on a positive FDG lesion. The imaging will then be completed 1 hour after the injection, after obtaining a urination, by an acquisition whole body (from the top of the skull to the root of the thighs or more if element on FDG or conventional imaging) which will be performed in the supine position with arms around the body. During the PET / CT scan, patients will breathe spontaneously. The acquisition will last 30 minutes."
2419034|NCT03442491||Hayman's Haemostatic Suture|Women that had major Post-partum Haemorrhage, defined as postpartum blood loss in excess of 2000 ml, resistant to pharmacologic treatment and that underwent Hayman's Haemostatic Suture.
2419035|NCT03442478|Experimental|2D/3D Tomosynthesis|2D/3D Tomosynthesis images will be obtained in addition to standard mammographic images.
2419036|NCT03442465||Regenerative Osseous Surgery|Participants undergoing osseous reconstructive surgery (RegOS) for bone sarcoma
2419037|NCT03442465||Other Reconstructive Surgery|Participants undergoing other reconstructive surgery for bone sarcoma
2419038|NCT03442452|Other|Electronic Decision Aid|For this study, we will be testing a novel electronic decision aid to improve Acute Myeloid Leukemia patients' understanding of their illness, prognosis, and treatment options.
2419039|NCT03442439|Active Comparator|Nutrition and Play Intervention (NPI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
2419040|NCT03442439|Experimental|Family Nurture Intervention (FNI)|Half of the mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
2419041|NCT03442426|Experimental|Intervention Cohort|Integrated model of primary care
2419042|NCT03442413|Experimental|2-[18F]-FA PET/CT|Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following two overnights of abstinence. To achieve and confirm two overnights of abstinence, participants will present to the inpatient CHPS the day prior to the scheduled scan and stay overnight
2419043|NCT03442400|Experimental|FFR/iFR arm|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire
2419044|NCT03442387|Experimental|Positive frame|The numerical expressions were presented in a positive way: e.g. treatment was successful for 4 out of 10 persons.
2419045|NCT03442387|Experimental|Negative frame|The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
2419046|NCT03442374|Experimental|Exercise|A single bout of moderate intensity lumbar extensor muscle exercise.
2419047|NCT03442374|No Intervention|Non-exercise|No exercise intervention.
2419048|NCT03442361||Intralipid|Standard soybean oil-based therapy
2419049|NCT03442361||Clinoleic|Olive oil based therapy
2419050|NCT03442348|Experimental|Omega 3 fatty acid supplements|Participants in this arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
2419051|NCT03442348|Active Comparator|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (inulin fibre) per day for a period of 6 weeks.
2419052|NCT03442335||Recurrent miscarriage: 2+ miscarriages|Women who suffered 2 or more unexplained recurrent miscarriages.
2419053|NCT03442335||Extreme recurrent miscarriage: 5+ miscarriages|Women who suffered 5 or more unexplained recurrent miscarriages.
3145828|NCT00082446|Experimental|F|Subject will receive an IM dose of MVA 1x10^8 on day 0 and day 28. On day 112 subjects will receive a dose of Dryvax® by scarification.
3145829|NCT00082485|Active Comparator|1|
2419056|NCT03442309|Experimental|Simple Prevention|"One drop (0.05 ml) of silver diamine fluoride (Advantage ArrestTM) solution at 38% concentration (2.24 F-ion mg/dose) will be dispensed per child. Posterior tooth surfaces to be treated will be dried, after which the SDF will be applied with a micro-brush to all asymptomatic carious lesions and to all pits and fissures on bicuspids and molar teeth for thirty seconds. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
3145830|NCT00082485|Placebo Comparator|2|
3145831|NCT00082498|Placebo Comparator|1|Group 1 will receive placebo
3145832|NCT00082498|Experimental|2|Group 2 will receive 5 mg vicriviroc daily
3145833|NCT00082498|Experimental|3|Group 3 will receive 10 mg vicriviroc daily
3145834|NCT00082498|Experimental|4|Group 4 will receive 15 mg vicriviroc daily
3145835|NCT00082706|Experimental|5-FU, Leucovorin, Gemcitabine + Cisplatin|5-FU continuous infusion over Days 1 - 5; Leucovorin once a day as a short infusion on Days 1 - 5; Cisplatin infusion over a few hours (usually 2-4 hours) once a day on Days 1 - 5; Gemcitabine infusion over 30 minutes on Days 1 & 5 only.
2419057|NCT03442309|Active Comparator|Complex prevention|"Pits and fissures on all bicuspids and molar teeth will be sealed with glass ionomer sealants (GC Fuji IX). Glass ionomer sealants (interim therapeutic restorations) will also be placed on all frank asymptomatic carious lesions. Fluoride varnishes (5% NaF) will then be applied to all teeth.~Dosage frequency will be twice-yearly."
3145836|NCT00082719|Experimental|Arm I|Low-dose interferon alfa subcutaneously (SC) twice daily.
3145837|NCT00082719|Experimental|Arm II|Interferon alfa as in arm I at a higher dose.
2419060|NCT03442283||Supplementation|
2419061|NCT03442283||No Supplementation|
2419062|NCT03442257|Experimental|SMS group|Participants in the intervention group will receive four semi-personalized messages per week in addition to their usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
2419063|NCT03442257|No Intervention|Control|The control group will receive usual care according to the National Board of Health and Welfare guidelines for hypertension treatment.
2419064|NCT03442244|Experimental|LEO 90100 foam|Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner LEO 90100 foam contains Calcipotriol hydrate 52.2 μg/g (equivalent to 50.0 μg/g calcipotriol) plus Betamethasone dipropionate 0.643 mg/g
2419065|NCT03442244|Placebo Comparator|Vehicle foam|"Each subject has each of the 2 investigational products applied at the same time on 2 sites on the back. The location on which the treatments are applied is randomised in a double-blinded manner.~Foam vehicle does not contain active ingredients"
2419066|NCT03442231||Journey™ UNI Unicompartmental Knee System|Subjects previously received knee replacement
2419067|NCT03442218|Experimental|Clorhexidine|Vaginal wash with clorhexidine solution
2419068|NCT03442218|Placebo Comparator|Saline solution|Vaginal wash with saline solution
2419069|NCT03442205|Experimental|Group A|
2419070|NCT03442205|Experimental|Group B|
2419071|NCT03442205|Experimental|Group C|
2419073|NCT03442179|Active Comparator|Treatment Group|Anesthesiologists in the treatment group use the unprocessed EEG waveforms and EEG spectrogram to maintain appropriate levels of unconsciousness for general anesthesia while avoiding burst suppression.
2419074|NCT03442179|No Intervention|Control Group|Anesthesiologists managing patients assigned to the control group will manage each anesthetic based on their clinical judgment, using standard monitoring required by American Society of Anesthesiologists (ASA), which include cardiac and respiratory monitoring, but not EEG monitoring.
2419075|NCT03442166|Active Comparator|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
2419076|NCT03442166|Sham Comparator|Sham group|Patients (n=17) will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
2419077|NCT03442153|Experimental|Solgar No7|Aflapin 100 mg and Collagen UC2 40 mg by mouth every 24 hours for 90 days
2419078|NCT03442153|Placebo Comparator|Placebo for Solgar No7|Placebo 1 Capsule by mouth, every 24 hours for 90 days
2419079|NCT03442140|Experimental|Experimental|Patients who completed the Baylor Martha Foster Lung Center Pulmonary Rehabilitation Program at least six months ago will participate in the 12-week harmonica program
2419080|NCT03442127|Other|Patient Group|Program users
2419081|NCT03442114|Experimental|Hydroxyurea SDM Toolkit (H-SDM)|During the H-SDM toolkit condition, sites will develop methods for identifying Eligible Patients & Monitoring Progress, have the opportunity to use Implementation Tools, and will use the Visit Decision Aids. The H-SDM toolkit has four visit decision aids to support parents in their decision about hydroxyurea: pre-visit brochure, in-visit issue card, after-visit booklet and video narratives {videos of parents telling their story about how they made a decision about hydroxyurea).
2419082|NCT03442114|Active Comparator|Clinician Pocket Guide|In this condition, sites will provide current guidelines for offering hydroxyurea and use the American Society of Hematology (ASH) pocket guide as a reference. ASH developed 'The Hydroxyurea and Transfusion Therapy for the Treatment of Sickle Cell Disease' clinician pocket guide based on the National Heart, Lung, and Blood Institute's Evidence Based Management of Sickle Cell Disease: Expert Panel Report, 2014.'
2419083|NCT03442101||Treatment group|These participants are newly diagnosed with psychosis.
3145838|NCT00082719|Experimental|Arm III|Interferon alfa SC once daily.
3145839|NCT00082719|Experimental|Arm IV|Interferon alfa as in arm III at a higher dose.
2419086|NCT03442075||Group 1|Group 1 an analgesic suppository was applied
2419087|NCT03442075||Group 2|Group 2 was administered analgesic orally
2419088|NCT03442075||Group 3|Group 3 was given trans rectal gel
2419089|NCT03442075||Group 4|Group was performed peri prostatic infiltration.
2419090|NCT03442075||Group 5|Group was performed by placebo oral
2419149|NCT03441802|Other|Controls|
3145840|NCT00082732|Experimental|Arm I: Dietary Intervention|Nutritional counseling on a low-fat, high-fiber, soy supplemented diet and behavior-based activities, such as goal-setting, contracting, and stimulus control, once weekly for 6 weeks, every 3 weeks for 33 weeks, and then at weeks 44, 48, and 52.
2419091|NCT03442062|Experimental|AFIX|Clinics randomly assigned to this arm will receive an Assessment Feedback Incentives and eXchange (AFIX) consultation delivered in-person by a state health department immunization specialist.This arm includes ~ 90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2419092|NCT03442062|Experimental|Physician-to-physician engagement|Clinics randomly assigned to this arm will receive physician-to-physician (P2P) consultations delivered remotely to providers by physician educators. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2419093|NCT03442062|Experimental|AFIX + P2P|Clinics randomly assigned to this arm will receive both an Assessment Feedback Incentives and eXchange (AFIX) consultation and a physician-to-physician (P2P) consultation.This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2419094|NCT03442062|Other|Active Intervention Control|Clinics randomly assigned to this arm will receive a brief non-HPV vaccine related quality improvement consultation. This arm includes ~90 high-volume primary care clinics in three states (New York, Wisconsin, Arizona).
2419095|NCT03442049|Experimental|Study group|Spinal stabilization exercises in addition to home exercise program
2419096|NCT03442049|Active Comparator|Control Group|Home exercise program
3186440|NCT00745225|Experimental|Active intervention arm|Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
3186441|NCT00745225|Placebo Comparator|placebo pill|placebo comparator
2419099|NCT03442023|Experimental|Chlorhexidine 2%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 2% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 2%
2419100|NCT03442023|Active Comparator|Chlorhexidine 0.12%|Subjects in this arm will receive standard care plus mouth rinse every 12 hours via spray with 0.12% chlorhexidine concentration, one week intervention, Drug: Chlorhexidine gluconate at 0.12%
2419101|NCT03442010||People with adverse drug event|People with adverse drug event
2419102|NCT03442010||People without adverse drug event|People without adverse drug event
2419103|NCT03441997|Experimental|Full mind-body exercises|Participants will be trained to perform a type of mind-body exercise that involves low intensity exercise and body movements similar to Tai Chi. Participants will be asked to exercise 2 times per day for 8 weeks.
2419104|NCT03441997|Active Comparator|Light mobility exercises: Control Group|The Light mobility exercises group will perform a similar exercise as the experimental group. However without a few components. Participants will be asked to exercise two times per day for 8 weeks.
2419105|NCT03441997|No Intervention|Healthy Controls|Healthy females will be asked to make one visit to complete aerobic exercise test, questionnaires, and provide blood samples.
3186442|NCT00745238|Experimental|Myotonic Dystrophy 1|
3186443|NCT00745264|Experimental|2|400 mg Ketoprofen from Diractin to 4 joints
3186444|NCT00745264|Experimental|3|100 and 400 mg Ketoprofen used concomittant with heat
3186445|NCT00745264|Experimental|4|100 and 400 mg Ketoprofen concomittant with moderate exercise
3186446|NCT00745264|Experimental|1|100 mg ketoprofen to 2 joints
3186447|NCT00745303||1|Subjects in this group received TCC training for 3 months
3186448|NCT00745303||2|Subjects in this group received no TCC training within 3 months
3186449|NCT00745316|Experimental|1|oral Dose 1
3186450|NCT00745316|Experimental|2|oral Dose 2
3186451|NCT00745316|Experimental|3|oral Dose 3
3186452|NCT00745316|Experimental|4|oral Dose 4
3186453|NCT00745316|Experimental|5|oral Dose 5
3186454|NCT00745316|Placebo Comparator|6|Placebo - 2 capsules bid
3186455|NCT00745329||2|"patients~healthy volunteers"
3186456|NCT00745342|Experimental|Teamwork Group|Families randomized to the Teamwork Group received the behavioral family teamwork intervention.
3186457|NCT00745342|No Intervention|Standard Care|Families in the Standard Care group received standard diabetes care and equal attention from study staff between visits to schedule appointments and encourage regular diabetes follow-up care.
3186458|NCT00745355||1|new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion
3186459|NCT00745381||1|This registry will be open to all patients with GEPNET or NET of unknown primary.
3186460|NCT00745407|Experimental|fenofibrate 160 mg, placebo|
3186461|NCT00745433||A|Repaglinide add-on to metformin.
3186462|NCT00745446|Experimental|1|1 hour exposure to filtered air
3186463|NCT00745446|Experimental|2|1 hour exposure to diesel exhaust (300mcg/m3)
3186464|NCT00745446|Experimental|3|1 hour exposure to filtered diesel exhaust
3186465|NCT00745459|Experimental|N|20 mL NPO-11
3186466|NCT00745472||1|
3186467|NCT00745472||2|
3186468|NCT00745485|Experimental|Zoldronic|
3186469|NCT00745511|Active Comparator|1|
3186470|NCT00745511|Active Comparator|2|
3186471|NCT00745511|Placebo Comparator|3|
3186472|NCT00745537|Experimental|Adolescent Mother|aged less than 17 years old and recently gave birth
3186473|NCT00745563|Experimental|A|
3186474|NCT00745576|Experimental|1|
3186475|NCT00745589|Active Comparator|higher dose sevelamer|first-line higher dose sevelamer hydrochloride
3186476|NCT00745589|Active Comparator|low dose sevelamer|second-line fixed low-dose sevelamer hydrochloride added to calcium carbonate
3186477|NCT00745602|Experimental|1|Patients referred for elective direct current cardioversion (DCCV) of atrial fibrillation.
3186478|NCT00745641||1|Sixty patients with abdominal illness and scheduled abdominal X-ray computed tomography examination will be included.
3186479|NCT00745667|Active Comparator|1|laparoscopic
3186480|NCT00745667|Active Comparator|2|open correction
3186481|NCT00745680||A|A: AMI patient
3186482|NCT00745693|Experimental|1|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
3186483|NCT00745693|Experimental|2|1 hour exposure to filtered air, followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
3186484|NCT00745693|Experimental|3|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin-1 (5pmol/min)
2419118|NCT03441971|Experimental|Single Arm|Participants will receive the device on Day 1.
2419119|NCT03441958|Experimental|ECT-001 (UM171) expanded cord blood|"Patients will receive a reduced intensity conditioning regimen containing Cyclophosphamide 50 mg/kg, Fludarabine 40 mg/m2 x 5 days and total body irradiation 200 cGy.~The cord to be expanded is thawed 7 days prior to transplant and undergoes CD34+ selection. The CD34+ product will be placed in the fed-batch culture with UM171 for a 7-day expansion and is infused fresh on Day 0. The CD34- product is cryopreserved and will be thawed and infused on Day +1.~Patients will receive standard supportive care and GVHD prophylaxis with Mycophenolate mofetil and Tacrolimus."
2419120|NCT03441945|No Intervention|control|"The patients swallowed the capsule with water in the lying position.After finishing the stomach examination, the operation of the capsule is adjusted to small bowel mode without magnetic control. Capsule entered the duodenum under physiological peristalsis. The position of the capsule was established using a real-time viewer. If the capsule failed to enter the duodenum after one hour, domperidone (10 mg) was orally administered."
2419121|NCT03441945|Experimental|magnetic steering|"After finishing the stomach examination as the control protocol, the capsule was lifted with the magnetic control, then rotating the capsule until the camera end oriented toward the pylorus . Next, the endoscopist could drag the capsule close to the pylorus with the guidance magnet robot, waiting for the open of pylorus. Once the pylorus opened, the capsule could enter the duodenum with gastric peristalsis. After reaching the duodenal bulb, capsule was held to the maximum position of Z, then the capsule would scan the duodenal bulb automatically with the mode 360° automatic scanning."
2419122|NCT03441932|Active Comparator|Dysphagia screening failed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
2419123|NCT03441932|Active Comparator|Dysphagia screening passed arm|"Subjets within the this arm will have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree. An ENT resident blinded to the result of the screening test will do this intervention"
2419124|NCT03441919||Patients with type 1 diabetes, poor glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c >64 mmol/mol"
2419125|NCT03441919||Patients with type 1 diabetes, good glycemic control|"Diagnosis based on clinical criteria~Duration of diabetes ≥10 years~Age ≥20 years, ≤ 60 years~HbA1c <64 mmol/mol"
2419126|NCT03441919||Healthy subjects|"Absence of disease, no use of medication~Matched for age, gender and BMI~HbA1c <42 mmol/mol"
2419127|NCT03441893|Experimental|Patients with ulcerative colitis|
2419128|NCT03441893|Experimental|Participants (control group)|
2419129|NCT03441893|Active Comparator|UC patients (cohort 1)|
2419130|NCT03441893|Active Comparator|UC patients (cohort 2)|
2419131|NCT03441893|Active Comparator|UC patients (cohort 3)|
2419132|NCT03441867|Experimental|(CBT-Sz) - PNES|Participants with history of a head injury and confirmed Psychogenic Non-Epileptic Seizures will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
2419133|NCT03441867|Experimental|(CBT-Sz) - PTE|Participants with history of a head injury and confirmed Post-Traumatic Epilepsy (PTE) will complete 2 brain fMRI scans along with 12 weeks of one hour CBT-Sz sessions by a trained therapist.
2419134|NCT03441867|Active Comparator|TBI Control|Participants with TBI will complete 2 brain fMRI scans.
2419135|NCT03441867|Active Comparator|Healthy Volunteer|Healthy control volunteers will complete 2 brain fMRI scans.
2419136|NCT03441854||HFNC group|The investigators will prospectively include 30 patients admitted to 13- bed PICU after liver transplantation and treated with HFNC oxygen delivery after extubation.
2419137|NCT03441854||Control Group|For each study group patient, a match control subject (matching criteria: age ± 10%, PaO2/FiO2 ± 30, diagnosis, Model for End-Stage Liver Disease (MELD) ± 10%) will be chosen from a group of 70 patients treated with conventional oxygen delivery (Venturi Mask) during the previous 2 years.
2419138|NCT03441841|Experimental|Lidocaine + prilocaine|Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2419139|NCT03441841|Active Comparator|Lidocaine|Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2419140|NCT03441841|Active Comparator|Prilocaine|Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
2419141|NCT03441828|Experimental|Group DNMB|"Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
2419142|NCT03441828|Active Comparator|Group MNMB|"Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)"
2419143|NCT03441815|Experimental|XC8 2 mg|Cohort 1: 6 subjects were randomized in a 2:1 ratio to be treated either with 2 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2419144|NCT03441815|Experimental|XC8 10 mg|Cohort 2: 6 subjects were randomized in a 2:1 ratio to be treated either with 10 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2419145|NCT03441815|Experimental|XC8 50 mg|Cohort 3: 6 subjects were randomized in a 2:1 ratio to be treated either with 50 mg XC8 (4 subjects) or placebo (2 subjects, see placebo arm).
2419146|NCT03441815|Experimental|XC8 200 mg|Cohort 4: 10 subjects were randomized in a 4:1 ratio to be treated either with 200 mg XC8 (8 subjects) or placebo (2 subjects, see placebo arm).
2419147|NCT03441815|Placebo Comparator|Placebo|Placebo comparator arm consists of 8 subjects (2 subjects in each cohort).
3186485|NCT00745693|Experimental|4|1 hour exposure to dilute diesel exhaust (300mcg/m3), followed by forearm venous occlusion plethysmography at 2 hours after the exposure and infusion of endothelin receptor antagonists BQ-123 and BQ-788
2419152|NCT03441776|Other|Randomized GVRT|Randomized Generalized Vestibular Rehabilitation Treatment (8 treatments) as part of standard of care (not research visits)
2419153|NCT03441776|Other|Randomized IVRT|Randomized Individualized Vestibular Rehabilitation Treatment (3 treatments) as part of standard of care (not research visits)
2419154|NCT03441763|Experimental|Normal participants|Emed foot device 3 times/measure to determine foot pressure in normal participants. .
2419155|NCT03441763|Experimental|Over weight participants|Emed foot device 3 times/measure to determine foot pressure in over weight participants.
2419156|NCT03441763|Experimental|Obese participants|Emed foot device 3 times/measure foot pressure in obese participants.
3145841|NCT00082732|No Intervention|Arm II: Observation|Observation every 6 weeks for 36 weeks and then every 8 weeks for 18 weeks.
3145842|NCT00082745||Observational (genetic analysis)|DNA from peripheral blood or saliva sample of patients is analyzed for the presence of polymorphisms in genes associated with an increased risk of late-occurring complications.
2419159|NCT03441737|Experimental|Exercise|Aerobic exercise intervention
2419160|NCT03441737|Active Comparator|Non-Exercise|Non-aerobic exercise intervention
2419161|NCT03441724||STEMI before PCI|ST-segment elevation, recording acquired before coronary intervention
2419162|NCT03441724||STEMI after PCI|ST-segment elevation, recording acquired from the same patients after coronary intervention
2419163|NCT03441711||Group 1|elevated sFlt-1/PlGF ratio
2419164|NCT03441711||Group 2|normal sFlt-1/PlGF ratio
2419165|NCT03441698|Experimental|Genuine acupuncture (A)|Genuine acupuncture (A) with neutral communication (A1) or positive communication (A2)
2419166|NCT03441698|Placebo Comparator|Sham Acupuncture (B)|Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
2419167|NCT03441698|Active Comparator|Rest (C)|Rest (C) with neutral communication (C1) or positive communication (C2)
2419168|NCT03441685|Experimental|Verb strategies|"The examiner labels each target word and performs the corresponding action six times in each condition. She elicits the target word from the participant two times per word per condition and provides feedback on accuracy each time. In the semantic cues condition, the examiner prompts the child to perform the target action twice. In the syntactic cues condition, instead of only saying the target word with the present progressive verb marker, the examiner uses two forms of complete sentences while performing the action (i.e., I am X-ing, and See. I X.). In the combined condition, the examiner prompts the child to perform the target action and consistently uses complete sentences."
2419169|NCT03441672|Experimental|Intervention|Participants in the intervention group interact with the game technology to learn about prenatal screening, in addition to usual care provided in the clinic.
2419170|NCT03441672|No Intervention|Control|Participants in the control group learn about prenatal screening through usual care in the clinic.
3186486|NCT00745706|Other|A|Implantable Loop Recorder (ILR) implant
3186487|NCT00745719|Experimental|1|surgical total parathyroidectomy with forearm autografting
2419175|NCT03441620|Placebo Comparator|Control|Calorie and fiber-matched control powder
2419176|NCT03441620|Experimental|Strawberry one serving|Freeze-dried powder equivalent to one serving fresh strawberries per day.
2419177|NCT03441620|Experimental|Strawberry two-half servings|Freeze-dried powder equivalent to 2.5 serving fresh strawberries per day.
2419178|NCT03441607|Active Comparator|Drug|Intervention: 40 mg of micronized human amnion chorion membrane biologic (mHACMb); administered 1(x) on second visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2419179|NCT03441607|Placebo Comparator|Placebo|Intervention: 1cc of saline will be administered as a one time injection on visit 2, administered 1(x) on first visit; followed by 2 follow-up visits for assessment over a duration of 3 months.
2419182|NCT03441568|Experimental|BAY987534|Infants and children with quiescent atopic dermatitis
2419183|NCT03441555|Experimental|Venetoclax + Alvocidib|Venetoclax administered orally once daily (QD) and Alvocidib administered as an intravenous infusion on Days 1, 2, and 3 for all 28-day treatment cycles. Different combinations of dose levels for venetoclax and alvocidib may be explored.
2419184|NCT03441542|Experimental|Data-assisted Case Navigation|Patients are recruited and consented into the study by the patient navigator after which the navigator provides assistance with scheduling, reminders, and transportation. The navigator is also charged with responding to patient questions, and monitoring and documenting if and when patients achieve HCV care milestones. Each month, the project will update the Grady Liver Clinic HCV patient registry, to generate information about the patient's HCV care progress and use this information to develop instructions sheets regarding the expected care milestones to be achieved that month for each patient. During the month, the navigator will participate in project meetings and report on milestone achievement and barriers for patients assigned to the experimental arm of the study.
2419213|NCT03441373|Placebo Comparator|Placebo (Group D)|Placebo orally.
3145843|NCT00082784|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds followed by flavopiridol IV over 1 hour on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3145844|NCT00082875|Experimental|Arm I|"Patients receive cilengitide IV over 1 hour on days 1, 4, 8, 11*, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *For the first course only, treatment is omitted on day 11"
3145845|NCT00082875|Experimental|Arm II|Patients receive cilengitide as in arm I at a higher dose.
3145846|NCT00082966|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of rapid disease progression or unacceptable toxicity.
3145847|NCT00083031|Experimental|Arm A-Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose~Bevacizumab- Via IV on predetermined days per cycle"
3145848|NCT00083031|Experimental|Arm B- Without Bevacizumab|"Methotrexate- twice daily on predetermined days per each week per cycle~Cyclophosphamide- oral, daily, predetermined dose"
3145849|NCT00083070|Experimental|Temozolomide Therapy|
2419185|NCT03441542|Active Comparator|Standard of Care|Patients are recruited and consented into the study by the patient navigator at which time they will be reminded of their infection, consequences of untreated disease, and the availability of study sponsored antiviral treatment should they seek it. Patients will not be subsequently contacted by the study. Patients who seek treatment without patient navigation services will receive the same study provided HCV pre-treatment care and study provided treatment drugs when indicated. Self-referral to care and antiviral therapy when indicated are known to be effective in curing HCV among some patients, this arm is classified as an active comparator.
2419186|NCT03441529|Experimental|Treatment Sequence 1 (AB)|Participants will receive Treatment A as a single oral dose of 1000 milligram (mg) lumicitabine (4*250 mg tablets) on Day 1 of period 1 followed by Treatment B as a single oral dose of 1000 mg lumicitabine (4*250 mg tablets) together with piperacillin/tazobactam administered as three 30-minute Intravenous (IV) infusions of 4.5 gram (g) piperacillin/tazobactam (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
2419187|NCT03441529|Experimental|Treatment Sequence 2 (BA)|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. A washout period of at least 21 days will be maintained between each treatment period.
2419188|NCT03441516|Experimental|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400mg bid + Donepezil 10mg qd for 24 weeks
2419189|NCT03441516|Active Comparator|Aripezil® Tab.|Donepezil 10mg qd for 24 weeks
2419190|NCT03441503|Experimental|Child HCAHPS: Automated Administration|"Child HCAHPS: Automated day-of-discharge survey~On the day of discharge at the hospital, parents will be contacted to solicit survey responses using patient televisions (GetWell) as follows:~Day 0 (Day of likely discharge): Respondent will be promoted to complete Child HCAHPS on their television as part of the routine discharge process. Respondent will also be asked for their email address to complete post-discharge items and their appropriate contact information will be collected.~Days 2-42: Standard hospital protocol (i.e., mail, email, or IVR) with the post-discharge questions."
2419191|NCT03441503|No Intervention|Standard Administration of Child HCAHPS|Parents will be contacted to complete Child HCAHPS using the standard protocol for mail, email, or IVR survey administration. The surveys will be administered by the survey vendor contracted by the participating site to administer Child HCAHPS.
2419192|NCT03441490|Active Comparator|ICBT standard|Internet-based cognitive behavioural therapy with therapeutic guidance through mail
2419193|NCT03441490|Experimental|ICBT chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat
2419194|NCT03441490|Experimental|ICBT learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail
2419195|NCT03441490|Experimental|ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat
2419196|NCT03441464|Experimental|1st Tier Dose Level|3 patients administered single dose of LUM015 at 0.5 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
2419197|NCT03441464|Experimental|2nd Tier Dose Leel|3 patients administered single dose of LUM015 at 1.0 mg/kg. Imaging with the LUM imaging device will be performed ex vivo on resected tissue.
2419198|NCT03441464|Experimental|3rd Tier Dose Level|After evaluation of the fluorescence signal observed with the LUM imaging device in the three other cohorts,the subsequent 3 patients will receive a dose of 0.5-1.5 mg/kg.
2419199|NCT03441464|No Intervention|Auto-fluorescence|No LUM015 injection will be given to three (3) patients to measure baseline tissue fluorescence. The tissue will still be imaged ex-vivo using the LUM Imaging Device
2419200|NCT03441438|Active Comparator|Control|Patients without asthma or aspirin intolerance who may or may not react to alcoholic beverages
2419201|NCT03441438|Active Comparator|Aspirin Tolerant Asthma|Patients with asthma who are tolerant to aspirin and/or other NSAIDs and note sensitivity to alcoholic beverages
2419202|NCT03441438|Active Comparator|Aspirin Intolerant Asthma / AERD|Patients with AERD who note sensitivity to alcoholic beverages
2419203|NCT03441425|No Intervention|Control|The control group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin returns to spontaneous circulation at the end of the scenario. They will then complete a retention simulation session three months later.
2419204|NCT03441425|Experimental|Unexpected death|The experimental group participants will complete a cardiac arrest simulation scenario on the first day in which the mannequin unexpectedly dies at the end of the scenario. They will then complete a retention simulation session three months later.
2419205|NCT03441412|Experimental|Ticagrelor/Epinephrine/Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg-1 min-1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
2419206|NCT03441399|Experimental|Escalating Incentives|Participants assigned to the escalating financial incentives will receive an increasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
2419207|NCT03441399|Experimental|De-escalating Incentives|Participants assigned to the de-escalating financial incentives will receive a decreasing financial incentive for taking their antidepressant medication for the initial 6 weeks of treatment.
2419208|NCT03441399|No Intervention|Control|Participants in this condition will receive usual care.
2419209|NCT03441386|Experimental|Cognitive Study|Cognitive Responses was analyzed after different intensities physical exercise sessions.
2419210|NCT03441373|Experimental|XC8 20 mg and Placebo (Group A)|XC8 20 mg orally. 2 tablets of XC8 10 mg +2 tablets of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period
2419211|NCT03441373|Experimental|XC8 100 mg and Placebo (Group B)|"XC8 100 mg orally.~1 tablet of XC8 100 mg +2 tablets of Placebo 10 mg + 1 tablet of Placebo 100 mg (in total 4 tablets) once daily during 5 days of treatment period"
2419212|NCT03441373|Experimental|XC8 200 mg and Placebo (Group C)|XC8 200 mg orally. 2 tablets of XC8 100 mg +2 tablets of Placebo 10 mg (in total 4 tablets) once daily during 5 days of treatment period.
3145850|NCT00083109|Experimental|Treatment (suramin and fluorouracil)|"PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.~PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.~In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
3145851|NCT00083161|Experimental|Oral cyclophosphamide plus standard cisplatin with etoposide|"Etoposide 120 mg/m2 IV Days 1-3 or Etoposide 120 mg/ m2 IV Day1 followed by Etoposide 120 mg/ m2 PO BID Days 2-3~Cisplatin 60 mg/m2 IV Day 1 Every 21 days x 4 cycles~Cyclophosphamide 25 mg PO BID Days 8-19 of each cycle"
3145852|NCT00083304|Experimental|Efaproxiral + WBRT + Supplemental Oxygen|
2419217|NCT03441347|Experimental|Specific rehabilitation program|Specific, personalized, multidisciplinary rehabilitation program consisting of physical- and occupational therapy.
2419218|NCT03441347|Other|Usual Care|Usual care for people with neuralgic amyotrophy, may vary per individual
2419219|NCT03441334|Experimental|High Frequency rTMS|The High Frequency rTMS group will receive real repetitive transcranial magnetic stimulation (rTMS) in 5Hz at 90% of resting motor threshold delivered to the bilateral motor areas via a figure of 8 air-filmed coil. The stimulation is structured as 24 10-second trains with a inter-train interval of 30 second.
2419220|NCT03441334|Sham Comparator|Sham rTMS|The Sham rTMS group will receive the same protocol but delivered via a sham coil which generates the same auditory and cutaneous feedback as the real stimulation. However, there will be no active stimulation.
3145853|NCT00083304|Active Comparator|WBRT + Supplemental Oxygen|
3145854|NCT00083460|Active Comparator|1|
2419223|NCT03441308|Active Comparator|Educational method of group treatment|Educational method of group treatment based on regular meals and food based on Nordic nutrition recommendations. The method has been developed by a district nurse at Ljungby. Ten meetings in groups of 6-8 participants over 6 months. Group meeting number 5 includes short individual consultations. In addition, individual consultation after group meeting 1 and 10.
2419224|NCT03441308|Placebo Comparator|Dietary advice|The control group is offered dietary advice according to the Swedish National Food Agency's guidelines for overweight and obesity (including brochures) at one occasion.
2419225|NCT03441295|Experimental|Study 1 Ligamys|Repair Surgery.
2419226|NCT03441295|Experimental|Study 1 Internal Bracing|Repair Surgery.
2419227|NCT03441295|Experimental|Study 2 Internal Bracing|Repair Surgery.
2419228|NCT03441295|Active Comparator|Study 2 Reconstruction|Reconstructive Surgery.
2419229|NCT03441282||ASA Patients I|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A normal healthy patient Healthy, non-smoking, no or minimal alcohol use"
2419230|NCT03441282||ASA Patients III|"Age 18-80 years old, English-speaking, not on current Fentanyl/opioid therapy, no use of opioid medications in the 3 months prior to surgery, scheduled for elective surgery at UAB main.~A patient with severe systemic disease Substantive functional limitations; One or more moderate to severe diseases. Examples include (but not limited to): poorly controlled DM or HTN, COPD, morbid obesity (BMI ≥40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA < 60 weeks, history (>3 months) of MI, CVA, TIA, or CAD/stents."
3186488|NCT00745732|Experimental|Radiation Therapy + ZD6474|"Radiation Therapy - Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day.~ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth."
3186489|NCT00745745|Active Comparator|1|Apical ICD lead placement
3186490|NCT00745745|Experimental|2|Mid-Septal ICD lead placement
2419234|NCT03441256|Experimental|Intervention|All participant in the intervention group will undergo the LION procedure and subsequent neurostimulation.
2419235|NCT03441256|Active Comparator|Control|All participants in the control group will be issued with a device for neuromuscular electrical stimulation.
2419236|NCT03441243||Case group:Cesarean section urgently|- 43 patients had an emergency caesarean section between 01/01/2015 and 31/12/2016.
2419237|NCT03441243||Case group:Hemorrhage of deliverance|- 85 patients had haemorrhage of the delivery with need for a transfusion between 01/01/2015 and 31/12/2017.
2419238|NCT03441243||Control group: delivery physiological low path|- A control group will consist of 128 patients who had a physiological low birth delivery over the same period.
2419239|NCT03441230|Active Comparator|Circumference of 13 cm, sphere form (diameter of 4 cm)|
2419240|NCT03441230|Active Comparator|Circumference of 13 cm, cylinder form, length 11 cm|
2419241|NCT03441230|Active Comparator|Circumference of 16 cm, sphere form (diameter of 5 cm)|
2419242|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 11 cm|
2419243|NCT03441230|Active Comparator|Circumference of 16 cm, cylinder form, length 18 cm|
2419244|NCT03441230|Active Comparator|Circumference of 19 cm, sphere form (diameter of 6 cm)|
2419245|NCT03441230|Active Comparator|Circumference of 19 cm, cylinder form, length 11 cm|
2419246|NCT03441230|Active Comparator|Circumference of 22 cm, sphere form (diameter of 7 cm)|
2419247|NCT03441230|Active Comparator|Circumference of 25 cm, sphere form (diameter of 8 cm)|
2419248|NCT03441230|Active Comparator|Circumference of 28 cm, sphere form (diameter of 9 cm)|
3145855|NCT00083460|Active Comparator|2|
3145856|NCT00083499||Group 1|Index cases
3145857|NCT00083499||Group 2|Relatives of Index Cases
3145858|NCT00083499||Group 3|Fetal tissue
3145860|NCT00083603|Experimental|1|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
3145861|NCT00083603|Placebo Comparator|2|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
3186491|NCT00745771|Active Comparator|1|200 mg Ketoprofen
2419249|NCT03441217|Experimental|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide IV upon arrival in the Labor and Delivery Unit (4-5 cms).
2419250|NCT03441217|Placebo Comparator|Saline solution|Nulliparous women with gestations at term receive Saline Solution IV upon arrival in the Labor and Delivery Unit (4-5 cms).
2419251|NCT03441204|Active Comparator|LTOT 24 h/day (intervention)|Long-term oxygen therapy (LTOT) prescribed 24 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
2419252|NCT03441204|Active Comparator|LTOT 15 h/day (control)|Long-term oxygen therapy (LTOT) prescribed 15 h/day. The LTOT is provided according to standard clinical practice using oxygen concentrator, cylinders or liquid oxygen and administered mainly through nasal prongs. The oxygen dose (l/min) is titrated aiming at a PaO2 on oxygen > 8 kPa in accordance with current routine practice and management guidelines.
2419253|NCT03441191|Experimental|Active AVS|Active AVS consists of a 30-minute pulsing lights (red, green, blue) and sounds that gradually descend from alpha (10 Hz) to delta (2 Hz).
2419254|NCT03441191|Placebo Comparator|Placebo Control AVS|The placebo control AVS program consists of 30 minutes of constant dim light that slowly changes in color, and a steady monotone at ultra-low (<1 Hz) frequency (outside of the entrainment range).
3186492|NCT00745771|Active Comparator|2|100 mg Ketoprofen
2419256|NCT03441152|Experimental|tDCS+CT|application of tDCS in combination with CT
2419257|NCT03441152|Sham Comparator|Sham tDCS|application of sham tDCS in combination with CT
2419258|NCT03441152|Active Comparator|CT|application of CT
3145862|NCT00083603|Experimental|3|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3145863|NCT00083603|Placebo Comparator|4|Empty TBC-MVA vector administered in each deltoid on Days 0, 28; empty TBC-FPV vector administered in each deltoid on Days 84, 140, and 196
2419261|NCT03441126||Multicenter Quality Improvement program|Locally developed and reliably implemented ICU Quality Improvement program to reduce blood culture use.
3145864|NCT00083603|Experimental|5|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3145865|NCT00083603|Placebo Comparator|6|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3186493|NCT00745784||1|Young spouses/domestic partners (20-49 years old) of cancer patients who have died from cancer.
3186494|NCT00745797|Experimental|Prophylactic WBRT|Take the whole brain radiotherapy radiotherapy
2419266|NCT03441100|Experimental|Experimental: IMA202 Product|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~One dose of IMA202 product will be infused intravenously. Four dose levels will be evaluated. At least two patients per cohort will be treated.~Post-infusion of IMA202 product, administration of low dose recombinant human interleukin-2"
2419267|NCT03441087|Other|Transvaginal ultrasound|Transvaginal ultrasound was applied 216 women with abnormal uterine bleeding.The transvaginal ultrasound diagnoses were compared with the received endometrial samples.
2419268|NCT03441087|Other|Hysteroscopy|Hysteroscopy was also performed under general anesthesia.Hysteroscopy was performed by a single operator (NNY).The operator and two supervising endoscopists were blinded to the ultrasound results.After the hysteroscopy, endometrial sampling was also done. The diagnoses were compared with the received endometrial samples.
2419269|NCT03441074|Experimental|Intervention Group|Patients randomly assigned to intervention group will get enhanced olfactory stimuli during the perioperative period
2419270|NCT03441074|No Intervention|Non-intervention Group|Patients randomly assigned to non-intervention group will not get any olfactory stimuli during the perioperative period
2419271|NCT03441061|Experimental|Treatment (inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV over 1 hour on days 1 and 8. Treatment repeats every 21-28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
2419272|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 1 - 0.25 μCi/kg Ac-225 with 1.6 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
2419273|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 2 - 0.50 μCi/kg Ac-225 with 3.2 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
2419274|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 3 - 0.75 μCi/kg Ac-225 with 4.7μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
2419306|NCT03440801|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
2419307|NCT03440775|Experimental|Experimental|
2419308|NCT03440775|Sham Comparator|Comparator|
2419275|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 4 - 1.00 μCi/kg Ac-225 with 6.4 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
2419276|NCT03441048|Experimental|Lintuzumab Ac225 (Dose 5 - 1.25 μCi/kg Ac-225 with 8.0 μg/kg lintuzumab)|Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m^2/day IV over two hours on days 2-6; cytarabine 2 gm/m^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
2419277|NCT03441035||Adults, uncomplicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
2419278|NCT03441035||Adults, complicated|Adults undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in plasma and in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until hospital discharge or postoperative day 21. B-Hb is taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points. A infusion of deuterium labeled phenylalanine will be given in the ICU at 1-3 occasions to determine the synthesis rate of albumin.
2419279|NCT03441035||Children|Children undergoing liver transplantation. Mass balance of albumin will be undertaken by sampling of albumin in in all fluids that is infused or lost from the body to keep track of albumin and hemoglobin changes until postoperative day 7. P-albumin and B-Hb is only taken routinely and not study specific samples. Plasma for ELISAs is taken at 2-3 time points.
2419280|NCT03441022|Experimental|Cardioversion|Amiigo watch during atrial fibrillation cardioversion. Optional sub-study: additional 30 days wearing Amiigo watch as well as BodyGuardian device.
2419281|NCT03440996|Experimental|Clinpro™ 5000|Participants will use Clinpro™ 5000 to brush their teeth for two minutes twice daily for 4 months.
2419282|NCT03440996|Experimental|Clinpro™ Tooth Crème|Participants will use Clinpro™ Tooth Crème to brush their teeth for two minutes twice daily for 4 months.
2419283|NCT03440996|Active Comparator|MI-Paste Plus|Participants will use MI-Paste Plus to brush their teeth for two minutes twice daily for 4 months.
2419284|NCT03440983|Experimental|MRI data acquiring in healthy volunteers|MRI data acquiring in healthy volonteers
2419285|NCT03440970|Experimental|Lysine Chloride|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
2419286|NCT03440970|Placebo Comparator|Placebo|Patients will be randomized to receive either lysine chloride or placebo. Patients will receive the study drug twice a day for 5 days of randomized therapy, starting after the completion of a blood volume assessment.
2419287|NCT03440957|Other|Osteopathy treatment|
3186495|NCT00745797|No Intervention|Observer Group|The first 14 days after randomization and patient follow-up after 1 month to complete the FACT-L questionnaire and the MMSE scale.
3186496|NCT00745810||1|sequential changes before and after cardiopulmonary bypass including ROS, antioxidant status, leukocyte elastase, complements, inflammatory cytokines
3186497|NCT00745836|Experimental|atorvastatin 10 mg, 80 mg|
3186498|NCT00745862||1|female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment
2419292|NCT03440892||1|
2419293|NCT03440879|Experimental|ADT group|Prostate cancer patients currently receiving androgen deprivation therapy (Zoladex)
2419294|NCT03440879|No Intervention|No-ADT group|Prostate cancer patients without any history of receiving any form of androgen deprivation therapy
2419295|NCT03440866|Experimental|Intervention|Administration of drugs concomitantly.
2419296|NCT03440866|No Intervention|Control|Administration of oral Mifepristone 600 mg and after interval of 48 hours administration of oral Misoprostol 400 mcg.
2419299|NCT03440840|Experimental|Computer Training with active tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with active transcranial direct current stimulation (tDCS).
2419300|NCT03440840|Active Comparator|Computer Training with sham tDCS|Participants randomized to this arm will receive computer-based cognitive training using a car racing game with sham transcranial direct current stimulation (tDCS).
2419301|NCT03440840|Placebo Comparator|Computer Training with or without tDCS|Participants in this arm will watch educational videos as a comparator to computer training with the car racing game (watching educational videos).
2419302|NCT03440827|Other|Child with slow-flow malformation|"Phase 1: Collect of experiences, perceptions, difficulties, needs and expectations of patients with slow-flow vascular malformation (for the age group of 11 to 15 years-old) using the focus group method.~Phase 2 : Administration of the scale of life's quality for validation."
2419303|NCT03440814|Experimental|DCCR|75 - 450 mg DCCR
2419304|NCT03440814|Placebo Comparator|Placebo|75 - 450 mg placebo for DCCR
2419305|NCT03440801|Experimental|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
3186499|NCT00745888||1|age > 18 y/o Patients admitted to surgical ICU
3186500|NCT00745914|Experimental|1|Pioglitazone drug 15mg daily for 3 months then 30mg for 9 months (Peroxisome Proliferator-Activated Receptor-gamma agonist)
3186501|NCT00745914|Placebo Comparator|2|placebo comparator drug 15mg daily for 3months, then 30mg for 9 months
2419310|NCT03440749|Experimental|Children with Cerebral Palsy (PC)|Serial reaction time task: repeating a sequence of movements according to the luminous stimuli
2419311|NCT03440749|Active Comparator|Control Group|Serial reaction time task: of movements according to the luminous stimuli
3186502|NCT00745927|No Intervention|Room air insufflations|Room air will be used for insufflations during colonoscopy
3186503|NCT00745927|Active Comparator|CO2 insufflations|CO2 will be used for insufflations during colonoscopy
2419316|NCT03440710|Experimental|with BET|with BET and Tympanoplast
2419317|NCT03440710|Other|without BET|with Tympanoplast only
2419318|NCT03440697||Aortopathy- Closed to external enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography)
2419319|NCT03440697||Syndromic- Open to external enrollment|"Subjects with a genetic diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS), Vascular Ehlers-Danlos Syndrome (EDS)~•positive genetic testing and/or a previous cardiac study required to be eligible"
2419320|NCT03440697||Aortopathy with Positive Genetic Results- Open to Enrollment|Subjects with aortic disease including TAA or dissection, aortic tortuosity, or aortic hypoplasia/stenosis (based on any cardiac imaging modality including echocardiography, CT, MRI, or angiography) who also have positive genetic testing results related to aortopathy.
2419321|NCT03440697||Aortic Valve Disease- Closed to enrollment|Subjects with aortic valve disease (bicuspid, unicuspid, or tricuspid disease)
2419322|NCT03440697||Family Members- Open to external enrollment|"Family members of eligible subjects~•Only family members of subjects with syndromic diagnoses are eligible for external enrollment at this time"
2419323|NCT03440697||Controls- Closed to external enrollment|Control subjects having tissue removed during a surgical procedure (e.g. coronary artery bypass graft surgery (CABG), cardiac transplant, etc.)
2419324|NCT03440684|Experimental|Healthy individuals|Forty-one healthy individuals were volunteer to participate in the study and 39 of them had no neurological disease, were from 18 to 65 years old, and had no upper extremity injuries. And they have joined to exercise training during 6 weeks.
2419325|NCT03440671|Experimental|Hutox Inj|Hutox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2419326|NCT03440671|Active Comparator|Botox Inj|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2419327|NCT03440645|Experimental|Family or Household Members|
2419328|NCT03440632|Other|FES start|"Start: 4 weeks 'adaptation phase' and 8 weeks 'FES phase'. Adaption phase: the stimulus (in Volt) will gradually be increased up to an effective level and the wear time has to be increased from 30 minutes to 6 hours a day. FES phase: the participants have to wear the FES device for minimal 6 hours a day during walking. Usual physiotherapy can be continued during the FES phase.~Second: after the FES phase, this group will enter the 'wash-out' period of 6 weeks for fading of the therapeutic effects, in which they return to their conventional therapy. Afterwards, 12 weeks of conventional therapy (orthoses/shoes and usual physiotherapy) with measurements at start and end will follow."
2419329|NCT03440632|Other|Conventional start|"Start: wearing usual orthoses/shoes on a daily basis for the first 12 weeks of the study. Usual physiotherapy can be continued.~Second: after 12 weeks this group will enter a 6 week watch out phase, and next be switched to FES treatment for 12 weeks, consisting of: 4 weeks 'adaptation phase' with gradual increase of the treatment and 8 weeks 'FES phase'."
2419331|NCT03440606|Experimental|MCAT Supervision Group|The 6-week 3-hour Mindful-Compassion Art Therapy (MCAT) supervision will include intervention elements of brief psycho-education, weekly mindfulness mediation that serve as a foundation to foster creative art making, reflective writing, group sharing and discussion.
2419332|NCT03440606|Experimental|Waitlist Control Group|Those assigned to the waitlist control group will not receive Mindful-Compassion Art Therapy (MCAT) supervision until approximately 1.5 month later; equivalent intervention and assessment procedures will be administered.
2419333|NCT03440593|Experimental|Measured Arm|Patients allocated to the measured energy expenditure (group M) will receive the intervention. Caloric delivery will target results of IC measurement.
2419334|NCT03440593|No Intervention|Estimated Arm|Patients allocated to the estimated energy expenditure (group E) will receive nutrition with caloric intake calculated based on the Penn State equation.
2419335|NCT03440580|Active Comparator|Intervention|The intervention school will receive the BOOSTH intervention: Boosth activity tracker, Boosth sync app, Boosht game app
2419336|NCT03440580|No Intervention|control group|The control school will receive the standard curriculum. After the study is finished the children of the control school will receive the Boosth product
2419337|NCT03440567|Experimental|Cohort I (avelumab, utomilumab, RICE)|Patients receive rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2 or rituximab IV on day 1, etoposide phosphate IV on days 1-3, avelumab IV over 60 minutes on days 2, utomilumab IV over 60 minutes on day 2, ifosfamide IV over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may then undergo autologous hematopoietic stem cell transplantation.
2419338|NCT03440567|Experimental|Cohort II (avelumab, utomilumab, rituximab, ibrutinib)|Patients receive rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, and ibrutinib PO QD or rituximab IV on day 1, avelumab IV over 60 minutes on days 2 and 16, utomilumab IV on day 2, and ibrutinib PO QD. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. (Closed as of 12/12/2019)
2419340|NCT03440541|Experimental|treated|Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
2419341|NCT03440515|Experimental|prednisone|prednisone 30mg/day 3weeks oral, if on rash or pruritus prednisolone 20mg/day 3weeks -> 10mg/day->7.5mg/day->5mg/day->stop
2419342|NCT03440502||control group.|Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
2419343|NCT03440502||study group|The same as control group but with DM or gestational diabetes Parturients aged 18 or older (American Society of Anesthesiologist physical status II-III parturients ASA II-III) undergoing cesarean delivery under spinal anaesthesia, singleton pregnancy, full term, elective
2419344|NCT03440489|Other|six-minute walking test|physical performance of the muscle: measured by Gait speed test, Timed up and go test, six-minute walking test , 30 seconds chair stand test
2419345|NCT03440476|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
2419346|NCT03440476|Active Comparator|Intervention plus feedback booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-only booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The content is clearly automatically generated.
2419347|NCT03440476|Active Comparator|Intervention plus feedback and personal contact booster|Participants navigate through e-checkup to go, the well-established alcohol intervention, then receives the Feedback-plus-personal-contact booster. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, their own use, and harm reduction strategies. The email is sent from a member of the research staff.
2419348|NCT03440463|Placebo Comparator|Intervention-only Control|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains only a reminder to participate in follow-up surveys.
2419349|NCT03440463|Experimental|Intervention plus Norms-only booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use.
2419350|NCT03440463|Experimental|Intervention plus Norms-plus-Strategies booster|Participants navigate through e-checkup to go, the well-established alcohol intervention. Their email 2 weeks later contains a reminder to participate in follow-up surveys, plus personalized feedback based on participant reported perceived alcohol norms, actual alcohol norms, and their own use. It also includes reported harm reduction strategies, and other strategies they might consider.
3145866|NCT00083603|Experimental|7|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3186504|NCT00745953|Active Comparator|Valsartan|This arm will determine if blockade of the renin-angiotensin system reduces myocardial fat levels and improves insulin sensitivity. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
3186505|NCT00745953|Active Comparator|Hydrochlorothiazide|This arm will determine if thiazide diuretics elevate myocardial triglyceride levels. It consists of 6 visits: visit1 (baseline); visit2 (2 weeks); visit3 (1 month); visit4 (3 month); visit5 (6 month); visit6 (8 month). Visits 1 & 6 will consist of blood tests, glucose tolerance test by FSivGTT, MRS, & 24 hr ambulatory blood pressure monitoring. During visit 1, patients receive automatic blood pressure monitor, OMRON, to record blood pressure between visits. Visits 2 & 3 are needed for the adjustment of medication to the final dose level. During visits 4 & 5, Dr. Price will check subject's status as they continue the medication. In case of uncontrolled blood pressure, Dr. Price will prescribe amlodipine for the additional BP control.
3186506|NCT00745992||Fungal infections|"Patients with invasive fungal infections; and~Patients who receive PO or IV voriconazole for more than 3 days"
3186507|NCT00746005|Experimental|1|3 g EPA-DHA
3186508|NCT00746005|Placebo Comparator|2|Placebo: sunflower oil
3186509|NCT00746031|Active Comparator|1|GnRH analogue-Zoladex
3186510|NCT00746031|Active Comparator|2|GnRH antagonist plus GnRH analogue
2419363|NCT03440398|Active Comparator|Open NSM|Conventional Nipple Sparing Mastectomy
2419364|NCT03440398|Experimental|Robotic NSM|Robotic Nipple-Sparing Mastectomy
3145867|NCT00083603|Placebo Comparator|8|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3186511|NCT00746031|No Intervention|3|
2419414|NCT03440138||Medical University Wien, Austria|
3186512|NCT00746044||1|Healthy volunteers >18y, 20 male, 20 female
3186513|NCT00746057|Other|1|Patients aged 18 to 65 years old receiving a first cadaveric renal graft.
3145868|NCT00083603|Experimental|9|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
3145869|NCT00083603|Placebo Comparator|10|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
2419369|NCT03440359|Other|# 1- no progesterone therapy|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7.Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination. No supplemental progesterone therapy in luteal phase
2419370|NCT03440359|Active Comparator|# 2 - Progesterone Vaginal Gel 8%|Letrrozole 2.5 to 5 mg oral tablet cycle day 3-7. Pelvic ultrasound at cycle day 11 or 12 and repeat if needed until leading follicle is >17 mm. Ovidrel 250 mcg injected sq. Timed intercourse or intrauterine insemination.Crinone 8% (progesterone) vaginal therapy was provided in luteal phase for 14 days .Administration was started the second day after intrauterine insemination or timed intercourse.
2419371|NCT03440346|Experimental|Few-foods diet intervention|
3186514|NCT00746070||A, primary aldosteronism|patients approved to be aldosteronism
3186515|NCT00746070||B, essential hypertension|patients approved to be essential hypertension
2419374|NCT03440307|Placebo Comparator|Email Only|Participants received weekly email about health and fitness education. No face-to-face intervention, and not provided any other information about bisphenol exposure.
2419375|NCT03440307|Experimental|Face-to-Face Meetings|Participants met with a counselor once per week for 3-weeks to reduce bisphenol exposure. Intervention included same weekly email about health and fitness education as Email only group, and a weekly face-to-face meetings to reduce bisphenol exposures from food, cosmetics, and packaged products. Women provided with bisphenol-free cosmetics, hygiene, and glass food/water containers.
2419376|NCT03440294|Other|with neoprene suit and life jacket|"Realization of the following examinations WITH neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
2419377|NCT03440294|Other|without neoprene suit and life jacket|"Realization of the following examinations WITHOUT neoprene suit and life jacket :~resting standard spirometry~maximum exercise testing. No drug and no placebo will be used in this arm."
2419378|NCT03440281||Preterm group|included pregnant females delivered prior to completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
2419379|NCT03440281||Term group|Included pregnant females delivered after completed 37 weeks of gestation. All participants underwent assessment of uterine artery Doppler indices and maternal serum homocysteine estimation
2419380|NCT03440268|Experimental|N Acetyl Cysteine|NAC in pre operatory 150mg/kg infusion in 2 hours. NAC during the surgery 50mg/kg in 6 hours. The influence of NAC will be assess in post operatory moment with routine exams
2419381|NCT03440268|Placebo Comparator|Placebos|Saline solution in pre operatory. Saline Solution duing the surgery. The post operatory datas of both groups will be compare
2419382|NCT03440255|Experimental|Transcutaneous Vagus Nerve Stimulation|TaVNS 8 sessions, 30 min, 4 weeks GAD: 20 Hertz (Hz) - 80 microseconds (µs) CP: 5Hz-200µs IBS: 3Hz-250µs
2419383|NCT03440242||JJVC Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
2419384|NCT03440242||JJVC Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the JJVC Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
2419385|NCT03440242||Marketed Contact Lens (Asymptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to an Asymptomatic group based on wear time responses during the baseline assessment.
2419386|NCT03440242||Marketed Contact Lens (Symptomatic)|Subjects between the ages of 18 and 45 years of age will be enrolled to the Marketed Contact Lens arm based on their habitual lenses and then stratified to a Symptomatic group based on wear time responses during the baseline assessment.
3145870|NCT00083603|Experimental|11|rFPV-HIV vaccine administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, and 196
3186516|NCT00746083|Experimental|Intervention group|
2419389|NCT03440216|Experimental|Sampling if GFR = or > 30 mL/min|"Note: GFR = Glomerular Filtration Rate~Patients with a normal of moderately decreased renal function~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content when possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration when possible"
2419390|NCT03440216|Experimental|Sampling if GFR < 30 mL/min|"Patients with severe renal insufficiency or hemodialysis:~Temocillin: 6 g in continuous infusion over 24 h;~Ceftriaxone: bolus 2 g (in 30 min) every 12h~Meropenem: prolonged infusion (3 h) of 2 g every 8h~Blood sampling for antibiotic (temocillin, ceftriaxone or meropenem) pharmacokinetic analysis / Tissue sampling (lung) for determination of antibiotic content if possible / Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic concentration if possible"
2419391|NCT03440203||no Diabetic neuropathy|
2419392|NCT03440203||Diabetic peripheral neuropathy|
2419393|NCT03440203||Diabetic peripheral neuropathic pain|
2419394|NCT03440151|Experimental|contralateral submental flap for tongue cancer defect|
2419395|NCT03440151|Active Comparator|primary closure for tongue cancer defect|
2419396|NCT03440138||University Hospital Zurich|
2419397|NCT03440138||St Pierre University Hospital, Brussels, Belgium|
2419398|NCT03440138||Sana Klinikum, Offenbach, Germany|
3186517|NCT00746083|No Intervention|Control group|
3186518|NCT00746109|Placebo Comparator|NOPACKING|The comparison group will undergo a routine incision and drainage procedure but will not have packing placed inside the abscess cavity.
3186519|NCT00746109|Experimental|PACKING|This group will receive wound packing as per usual protocol
2419415|NCT03440125|Experimental|Healthy|Healthy participants with no low back pain. 20 min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical) on the back will be administered.
2419416|NCT03440125|Experimental|LBP patients - CPC Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical).
2419417|NCT03440125|Experimental|LBP patients - CPC and ES/M Group|Participants suffering from low back pain (LBP) receiving 10 times (within 3 weeks) 20min application of Cayenne Pepper Cataplasm (Cayenne Pepper topical), and half of the subject also receiving 10 min electrical Stimulation and 10 min massage Treatment on the back.
2419418|NCT03440112|Active Comparator|Clarithromycin (Not used anymore as of 4/2020)|Clarithromycin 250mg (1 capsule) will be taken orally twice a day for 3 days and if tolerated will be increased to 500mg (2 capsules) orally twice a day for 4-6 days.
2419419|NCT03440112|Placebo Comparator|Placebo (Not used anymore as of 4/2020)|Placebo will be taken exactly as the clarithromycin arm: 1 capsule orally twice a day for 3 days and if tolerated will be increased to 2 capsules orally twice a day for 4-6 days.
2419420|NCT03440112|Active Comparator|Transdermal flumazenil (added 4/2020)|Added in April 2020. Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
2419421|NCT03440112|Placebo Comparator|Placebo cream (added 4/2020)|Added in April 2020. Placebo will be taken exactly as the transdermal flumazenil arm: Subjects will take 18mg transdermal application every 3-4 hrs dispensed as 3 dispenser bottle clicks of 0.25 ml each, while awake for 3 days then if no side-effects subjects will increase to 36mg transdermal application every 3-4 hrs dispensed as 6 dispenser bottle clicks of 0.25 ml each, while awake.
2419422|NCT03440099|Other|Training|All participants will participate in the 16-week resistance exercise training program.
2419423|NCT03440086|Experimental|Abdominal Jackson-Pratt drain|Patients in this arm will undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
2419424|NCT03440086|No Intervention|Controls|Patients in this arm will not undergo one-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
2419425|NCT03440073|Experimental|Mulligan Concept Intervention|Mulligan Concept Intervention, including Mobilizations with Movement intervention is administered. Up to 30 minutes total treatment time.
2419426|NCT03440073|Sham Comparator|Sham Mulligan Concept Treatment|Assessment procedures of the Mulligan Concept are followed, but no manual pressure is applied to the participant during treatment to provide a sham Mulligan Concept Treatment.
2419427|NCT03440060|No Intervention|standard group|participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy
2419428|NCT03440060|Active Comparator|Procalcitonin group|participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml
3145871|NCT00083603|Placebo Comparator|12|Empty TBC-FPV vector administered as two separate 1-mL intramuscular injections, one into each deltoid at Days 0, 28, 84, 140, and 196
2419430|NCT03440034|Experimental|Pioglitazone|All subjects will be provided Pioglitazone 15mg tablets, total dose of 45mg (3 tablets) for oral administration once daily. 32-week treatment period.
2419431|NCT03440021|Experimental|High-dosage (60mg) ORM-12741|6 x 10 mg ORM-12741 immediate release capsules in a single dose
2419432|NCT03440021|Experimental|Low-dosage (10mg) ORM-12741|1 x 10 mg ORM-12741 immediate release capsules and 5 x placebo capsules in a single dose
2419433|NCT03440021|Placebo Comparator|Placebo|6 x placebo capsules in a single dose
2419434|NCT03440008||Control|Able-bodied, age matched subjects with no foot and ankle pathology
2419435|NCT03440008||OA|Subjects with ankle OA, with all classifications of ankle misalignment (varus, neutral, valgus)
2419436|NCT03439995|Experimental|Open Lung Protective Ventilation|Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
2419437|NCT03439995|Active Comparator|Conventional Ventilation|Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect
2419438|NCT03439982|Experimental|FMT|Open label FMT administered at week 0 by colonoscopy and weeks 1-4 by enema
2419439|NCT03439969|No Intervention|Control|Dental appointment, one hour and included activities that are normally part of a SPT (Suportive Periodontal Treatment) consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon and Text Messages were not used.
2419440|NCT03439969|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
2419441|NCT03439969|Experimental|Mobile Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
3145872|NCT00083603|Experimental|13|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28; rFPV-HIV env/gag and rFPV-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid at Days 84, 140, and 196
3186520|NCT00746135|Active Comparator|A|Conventional Biventricular Stimulation: RV Apex and LV Lead Tip
2419442|NCT03439969|Experimental|Intra Oral Camera and Text Messages|Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback. Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.Participants also received SMS a total of 16 messages (SMS). One per week.
2419443|NCT03439956||Transvaginal specimen extraction (cases)|Pregnant women that underwent previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
2419444|NCT03439956||Controls|Pregnant women that did not undergo previous laparoscopic myomectomy or ovarian cystectomy with transvaginal specimen extraction.
2419445|NCT03439943|Experimental|Lixisenatide|Lixisenatide (10μg/d for 14 days and then 20μg/d): once daily subcutaneous
2419446|NCT03439943|Placebo Comparator|Placebo|Placebo: once daily subcutaneous injection
3145873|NCT00083603|Placebo Comparator|14|Empty TBC-MVA vector administered in each deltoid Days 0, 28; empty TBC-FPV vector administered in each deltoid Days 84, 140, and 196
3145874|NCT00083603|Experimental|15|rMVA-HIV env/gag and rMVA-HIV tat/rev/nef-RT administered as two separate 1-mL intramuscular injections, with rMVA-HIV env/gag into the left deltoid, rMVA-HIV tat/rev/nef-RT into the right deltoid at Days 0, 28, 84, 140, 196
3145875|NCT00083603|Placebo Comparator|16|Empty TBC-MVA vector administered in each deltoid Days 0, 28, 84, 140, 196
3145876|NCT00083772|Experimental|1|Nesiritide
2419451|NCT03439904|Experimental|pharmaceutical care intervention group|Patients will receive individualized pharmaceutical care in addition to usual medical care
2419452|NCT03439904|No Intervention|control group|Patients will receive usual medical care
2419453|NCT03439891|Experimental|Lead-in Arm I (Part 2: nivolumab, sorafenib)|After determination of MTD [Part 1] participants receive nivolumab IV over 30 minutes on days 1 and 15, and sorafenib PO beginning on day 15 of course 1, then on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2419454|NCT03439891|Experimental|Lead-in Arm II (Part 2: sorafenib, nivolumab)|After determination of MTD [Part 1] participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2419455|NCT03439891|Experimental|Part 1: Dose Escalation (CLOSED TO ENROLLMENT)|Participants receive sorafenib PO on days 1-28, and nivolumab IV over 30 minutes beginning on day 15 of course 1, then on days 1 and 15 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course will continue until 1 dose-limiting toxicity occurs to establish maximum tolerated dose.
2419456|NCT03439878|Experimental|Galactose|Ingestion of 0.75 g/kg body mass of d-galactose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
2419457|NCT03439878|Active Comparator|Glucose|Ingestion of 0.75 g/kg body mass of dextrose monohydrate co-ingested with cream to provide 1 g/kg body mass of fat.
2419458|NCT03439865|Experimental|standard of care treatment + ivacaftor|topical nasal steroid spray and culture-directed antibiotics + ivacaftor 150 mg tablet
2419459|NCT03439865|Placebo Comparator|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics
2419460|NCT03439852|Experimental|Light to Moderate Physical Activity/Sedentary Time|The telephone counseling plus group cohesion intervention is designed to increase Light-to-Moderate intensity physical activity (LMPA) and reduce Sedentary time (ST). The 12-wk intervention includes group discussions during 3 regular monthly club meetings when clubs' accumulated milestones for LMPA/ST min/wk will be identified and future cumulative club goals for PA/ST set. In addition, each member will receive 12 weekly personalized phone calls from health coaches who will use motivational interviewing to set individualized LMPA/ST goals setting, reduce barriers, and facilitate social support for LMPA/ST change.
2419461|NCT03439852|No Intervention|Delayed Treatment/Healthy Aging|Delayed Treatment (DT) / Healthy Aging materials Condition is for 12 weeks and participants receive 12 phone calls using a previously developed contact-matched protocol that uses mailed healthy aging information and telephone calls to assess symptom ratings. After the initial 12 weeks they then receive the LMPA/ST intervention
2419462|NCT03439839|Experimental|Arm 1|10 patients receiving LNP023 high dose daily over up to approximately 3 years
2419463|NCT03439839|Experimental|Arm 2|5 patients receiving LNP023 low dose daily over up to approximately 3 years
2419464|NCT03439813|Experimental|TASK-CBT|Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
2419465|NCT03439813|Active Comparator|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
2419466|NCT03439800|Experimental|Mental and Physical Practice|"Action observation: is defined as the observation of the motor action, in this study, through a video.~Mental Practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical Practice: is the execution of the motor action."
2419467|NCT03439800|Active Comparator|Physical Practice|Physical Practice: is the execution of the motor action.
2419468|NCT03439787|Active Comparator|Active Popliteal Plexus Block|10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
2419469|NCT03439787|Placebo Comparator|Placebo Popliteal Plexus Block|10 ml Sodium Chloride 0.9 %
3145877|NCT00083824|Placebo Comparator|Sugar Pill|Placebo
2419471|NCT03439761|Experimental|PT-112 Injection|PT-112 Injection alone
3145878|NCT00083824|Experimental|Estrogens, Conjugated (USP)|Conjugated Equine Estrogen 0.625 mg/day for 3 years, drug
2419474|NCT03439735|Experimental|Cohort A: Participants with untreated metastatic disease receiving ET and a CDK 4/6|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
2419475|NCT03439735|Experimental|Cohort B: Participants initiating a CDK 4/6 i after progression on ET.|Participants will undergo blood collection (intervention) at time of initiating treatment with endocrine therapy and palbociclib, at 4 weeks after initiating this treatment, and every 3-4 months while on treatment. If a participant progresses on this treatment, they will have a blood collection at that time.
2419476|NCT03439722||Patients|Episodic cluster headache patients will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
2419477|NCT03439722||Controls|Controls will be admitted for 1 night where a polysomnography will be performed by the Danish Center of Sleep Medicine.
2419478|NCT03439709|Experimental|intervention|Gamma knife radiosurgery (Leksell Gamma Knife, Elekta AB, Stockholm, Sweden) is used for intervention. Administration of standard medical therapy using Lanreotide 60 mg concurrently starts with radiosurgery
2419479|NCT03439709|Active Comparator|control|Without radiosurgery, standard medical therapy (Lanreotide 60Mg Solution for Injection) same with interventional group is applied
2419480|NCT03439696|Experimental|Needlescopic-assisted|Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
2419481|NCT03439696|Active Comparator|Uniportal|Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
2419482|NCT03439683||Physicians|"Definition: Physicians working in the ICU for at least 50% of their time in the hospital~Intervention: Survey about patient-ventilator asynchrony"
2419483|NCT03439683||Nurses|"Definition: Nurses working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
2419484|NCT03439683||Respiratory Therapists|"Definition: Respiratory Therapists working in the ICU for at least 20 hours/week~Intervention: Survey about patient-ventilator asynchrony"
2419485|NCT03439670|Experimental|Treatment Group 1|Patients enrolled in Treatment Group 1 (experimental group) will receive vamorolone 2.0 mg/kg/day for the duration of the study.
2419486|NCT03439670|Experimental|Treatment Group 2|Patients enrolled in Treatment Group 2 (experimental group) will receive vamorolone at 6.0 mg/kg/day for the duration of the study.
2419487|NCT03439670|Active Comparator|Treatment Group 3|Patients enrolled in Treatment Group 3 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks of treatment with 2.0 mg/kg/day vamorolone.
2419488|NCT03439670|Active Comparator|Treatment Group 4|Patients enrolled in Treatment Group 4 (active comparator group) will receive prednisone 0.75 mg/kg/day for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
2419489|NCT03439670|Placebo Comparator|Treatment Group 5|Patients enrolled in Treatment Group 5 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 2.0 mg/kg/day vamorolone.
2419490|NCT03439670|Placebo Comparator|Treatment Group 6|Patients enrolled in Treatment Group 6 (placebo comparator group) will receive placebo daily for 24 weeks followed by 20 weeks treatment with 6.0 mg/kg/day vamorolone.
2419493|NCT03439631|Active Comparator|Tiered OR Satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
2419494|NCT03439631|Other|Status Qou OR satisfaction|Patient satisfaction questionnaire with surgical experience in Tiered OR
2419495|NCT03439618|Other|continuous feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h
2419496|NCT03439618|Other|time-restricted feeding|The total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 6h (7:00-9:00,11:00-13:00,17:00-19:00).
2419497|NCT03439592||hyperglycemic patients|diabetic patients admitted for STEMI and with hyperglycemia at hospital admission.
2419498|NCT03439592||normoglycemic patients|diabetic patients admitted for STEMI and with normoglycemia at hospital admission.
2419499|NCT03439579|Experimental|Home weight loss program|Participants will be instructed to daily monitor their body weight, minutes of activity, number of steps, and calories consumed for the duration of the pilot study, and they will receive recorded individualized feedback on this self-monitored data from Weight Management Center clinicians (registered dietitians, exercise psychologists, and behavioral specialists).
2419500|NCT03439566||Total hip arthroplasty|No intervention will take place. Only registration and data collection of patient´s care and treatment will take place. There will be no changes in patient´s treatment.
2419501|NCT03439553|Experimental|Intervention|People shown ads with referral to target websites.
2419502|NCT03439553|Active Comparator|Intervention with control websites|People shown ads with referral to control websites.
2419503|NCT03439553|No Intervention|Control|People who make target queries, but are not shown the ads.
2419504|NCT03439540|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 12 weeks.
2419505|NCT03439540|Experimental|Plantago major|Individuals receive Plantago major daily, for 12 weeks.
3145879|NCT00083824|Experimental|Medroxyprogesterone 17-acetate|Conjugated Equine Estrogen 0.625 mg/day plus Medroxyprogesterone Acetate 2.5 mg/day
3145880|NCT00083863||Framingham Heart Study Offspring|
3145881|NCT00083863||FHS Gen 3|
3145882|NCT00083941|Experimental|TroVax and IL-2|TroVax: Intramuscular into the deltoid muscle of the upper arm, 10x dose (6.83 x 108 pfu/ml). IL 2: High dose IL 2, 600,000 IU/kg intravenously every 8 hours up to a maximum of 15 injections.
3145883|NCT00083980|Active Comparator|active antidepressant drug comparator|Venlafaxine ER
3145884|NCT00083980|Placebo Comparator|Sugar pill|Inert placebo pills as duble dummy - up to 4 per day for kava and 3 per day for venlafaxine
3145885|NCT00083980|Experimental|Herbal treatment kava|Kava
3145886|NCT00084032|Experimental|1|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will continue taking ARV therapy for 16 weeks and then stop ARVs for 64 weeks.
3145887|NCT00084032|Experimental|2|In Step 1, participants will receive ARV therapy for 24 weeks. Upon entering Step 2, participants will stop ARVs for 4 weeks, take ARVs for 8 weeks, stop ARVs for 4 weeks, take ARVs for 8 weeks, and then stop ARVs for 56 weeks.
2419510|NCT03439501|Other|avelumab|"1 Cycle: 10mg/kg Avelumab administered via IV every 2 weeks (1st, 15th)~Interval of 1 cycle: 28 days ③ Administration schedule: Repeated until disease progression or unacceptable toxicity and dose adjustments may be permitted based on the toxicity that occurs every cycle."
2419511|NCT03439488|Experimental|Part 1 (Healthy Participants): Single Ascending Dose (SAD)|Participants in Cohorts 1 to 5 and 3 optional cohorts (Cohorts 6, 7 and 10) will receive a single dose of JNJ-440/placebo on Day 1. Two cohorts will receive a second dose of JNJ-440/placebo in a fed state (participants from Cohort 3 will also participate in Cohort 8) or as an alternative JNJ-440 formulation (participants from Cohort 2 will also participate in optional Cohort 9) after a washout window of at least 10 days. In Cohorts 1 to 4, study drug will be administered under fasted conditions; in the remaining cohorts, study drug will be administered under fasted/fed conditions depending on the results of the food effect evaluation.
2419512|NCT03439488|Experimental|Part 2 (Healthy Participants): Multiple Ascending Dose (MAD)|Participants in Cohorts 1 and 2 will receive a once daily dose of JNJ-440/placebo for the duration of 7 days under fasted or fed conditions. Participants in an optional cohort (Cohort 3) may receive a once daily or twice daily dose of JNJ-440/placebo for the duration of 7 or 14 days under fasted or fed conditions. The starting dose for Cohort 1 in Part 2 will be determined by the Sponsor in consultation with the Principal Investigator based on the data from Part 1. Dose escalation will be performed only after review of safety and pharmacokinetic (PK) data after a minimum of 7 days of study drug administration.
2419513|NCT03439488|Experimental|Part 3 (Chronic Hepatitis B [CHB] Participants): MAD|Participants in Cohorts 1 and 2 and 3 optional cohorts (Cohorts 3, 4, and 5) will receive multiple ascending doses of JNJ-440/placebo once daily or twice daily for 28 days under fed or fasted conditions. The starting dose and formulation for Cohort 1 will be determined based on the review of available data in healthy participants from Part 1 (SAD) and Part 2 (MAD). Dose escalation will be performed only after review of safety, tolerability, and PK data after a minimum of 14 days of study drug administration from at least 8 CHB participants.
2419514|NCT03439436|Experimental|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
2419515|NCT03439436|Active Comparator|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
2419516|NCT03439423||Patients who underwent EVAR|
2419517|NCT03439410||Internal Medicine ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
2419518|NCT03439410||Subacute ward|The Clinical Complexity Index (CCI) will be administered to all patients admitted to the ward.
2419519|NCT03439397|Experimental|Ballon Technique group|Intervention：Ballon Technique
2419520|NCT03439397|Active Comparator|SOAI group|Intervention：Selective Ophthalmic Artery Infusion
2419521|NCT03439384|Experimental|Experimental: Home Telemonitoring|Patients will receive home telemonitoring equipment and monitor their health for 60 days post-enrollment. A monitoring nurse will receive and review the patients health data on a daily basis for the 60 day duration and provide remote care, counseling and education.
2419522|NCT03439384|No Intervention|Control: No Home Telemonitoring|The patient will not receive any home telemonitoring once enrolled and will continue to receive the usual care he/she can expect as part of his/her care plan.
2419523|NCT03439371|Experimental|HLA-mismatched micro-transplantation|HLA-mismatched micro-transplantation
2419524|NCT03439358|Experimental|Magnesium sulfate|Magnesium sulfate (MgSO4) infusion will be commenced prior to epidural top-up.
2419525|NCT03439358|Placebo Comparator|Normal saline|Normal saline infusion will be commenced prior to epidural top-up.
2419526|NCT03439345|Experimental|Fenofibrate 145 mg|Name: fenofibrate; Form: tablet; Dosage: 145 mg; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
2419527|NCT03439345|Placebo Comparator|Placebo Oral Tablet|Name: placebo; Form: tablet; Dosage: not applicable; Frequency: one tablet daily with normal renal function, one tablet every 2nd day with chronic kidney disease
2419528|NCT03439319|Active Comparator|MyndMove® therapy|Non-invasive Functional Electrical Stimulation (FES) technique with surface electrodes to stimulate from 3 to 8 muscles to create purposeful movements in one or both hands/arms
2419529|NCT03439319|Active Comparator|Intensive Conventional therapy|Using Conventional therapy which focuses exclusively on the purposeful movements in one or both hands/arms
2419530|NCT03439306||healthy adult volunteer|"Subject is 18 to 50 years of age.~Subject is a non-smoker or who has not smoked within 2 days prior to the study."
2419531|NCT03439293|Experimental|Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg|Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 milligram per kilogram (mg/kg), intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), have an unacceptable toxicity, or withdraw consent, or when the study has completed or until the sponsor terminates the study.
2419532|NCT03439280|Experimental|Phase 1 Dose Escalation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. Dose escalation of TAK-079 will range from 45 milligram (mg) to 1800 mg and may be done using a 3 + 3 dose escalation design to determine a MTD and/or RP2D.
2419533|NCT03439280|Experimental|Phase 1 Dose Confirmation Cohort: TAK-079|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the previous cohort of Phase 1.
2419534|NCT03439280|Experimental|Phase 1 Combination Cohort: TAK-079 + PomDex|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, orally, once daily on Days 1 to 21 and dexamethasone, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD. TAK-079 dose will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1.
2420544|NCT03432299|Experimental|RFA for PTMC|Group who will undergo RFA after diagnosis of PTC
2419535|NCT03439280|Experimental|Phase 2a: TAK-079 TBD|TAK-079, subcutaneously, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons. TAK-079 dose for this phase will be determined based on review of the available safety, efficacy, pharmacokinetic, and pharmacodynamic data obtained from the Phase 1 portion of the study.
2419536|NCT03439267|Active Comparator|Proactive Current National Guidelines Group|Standard Interventional Control Group. Will receive treatment recommendation according to the current National guidelines for statin initiation and follow-up.
2419537|NCT03439267|Experimental|Proactive CAC Group|Investigational Interventional Group. Will undergo coronary artery calcium screening and will receive statin recommendation based on the cardiovascular risk algorithm.
2419538|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg|10 mg OCA for up to 18 months
2419539|NCT03439254|Experimental|Obeticholic Acid (OCA) 10 mg to 25 mg|10 mg OCA for the first 3 months and then may titrate up to 25 mg OCA for the remaining 15 months of the study
2419540|NCT03439254|Placebo Comparator|Placebo|Placebo for up to 18 months
2419541|NCT03439241|Experimental|Silent arm|The participants test the new Coloplast ostomy device use the product as they usually would.
2419542|NCT03439241|Experimental|Active arm|The participants test the tnew Coloplast ostomy device and are guided by the measuring device
2419543|NCT03439228|Experimental|Brace|Lumbar brace wear prescribed for 3 months post-operation
2419544|NCT03439228|No Intervention|No brace|No lumbar brace prescribed
2419545|NCT03439215|Experimental|Lorlatinb Arm|Eligible patients will be treated with Lorlatinib at the dose of 100 mg QD p.o.
2419546|NCT03439202|Other|No arm used|No drug use for this study. No arm used in this study. Subjects are exposed to hypoxic conditions (clinical study).
3186521|NCT00746135|Active Comparator|B|"Anodal-Cathodal Biventricular Stimulation: cathodal LV Stimulation und anodal RVHis Stimulation = Anodal-cathodal Bi-V."
3186522|NCT00746135|Active Comparator|C|Anodal-Cathodal Tri-V Stimulation: RV-apex and LV and RV-His
3186523|NCT00746148|Experimental|1|Reflexology
3186524|NCT00746148|No Intervention|2|No intervention
2419551|NCT03439176|Experimental|Test of new adhesive strips|"The subjects will test adhesives strips made of 4 different adhesives:~Standard adhesive 1 Standard adhesive 2 PL4 PL16-L"
2419552|NCT03439163||PD patients|the entire group underwent MRI scan
2419553|NCT03439150|Other|Study arm|The study arm will undergo absolute flow and resistance measurements immediately after PPCI of the culprit artery
3186525|NCT00746161|Active Comparator|1|Roux-en-Y
3186526|NCT00746161|Experimental|2|double tract reconstruction
3186527|NCT00746174|Active Comparator|Rosiglitazone|Subjects in this arm will be randomly assigned to treatment with Rosiglitazone 4mg daily. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The dose will then be increased to Rosiglitazone 8mg daily (if indicated). The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
3186528|NCT00746174|Placebo Comparator|Placebo|Subjects in this arm will be randomly assigned to treatment with placebo. After 4 weeks, we will assess changes in glucose levels and liver enzymes. The patients will be reevaluated every 4 weeks, and at the end of 16 weeks, the participants will all be admitted to the research center at UTSW to measure changes in the following: 1) insulin sensitivity; 2) lipid content of heart, liver, & skeletal muscle; and 3) lipid oxidation using respiratory gas exchange. The patients will then switch to the alternative therapy for 16 additional weeks before the studies are repeated.
2419558|NCT03439111|Placebo Comparator|Placebo|Intervention : Placebo + Standardized Lycium chinense Fruit Extract (LCF) capsules Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment 3 week wash-out Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment
2419559|NCT03439111|Experimental|Experimental|Intervention : Standardized Lycium chinense Fruit Extract (LCF) capsules + Placebo Experimental : Oral administration, 600 mg two capsules (146 mg of the Standardized Lycium chinense Fruit Extract (LCF)/capsule) three times a day for 4 week treatment 3 week wash-out Placebo Comparator : Oral administration, 600 mg two capsules (600 mg of Starch/capsule) three times a day for 4 week treatment
2419560|NCT03439098|Experimental|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg/day
2419561|NCT03439098|Experimental|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg/day
2419562|NCT03439098|Placebo Comparator|Placebo|Placebo
2419563|NCT03439085|Experimental|Treatment (INO-3112, durvalumab)|Patients receive DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 IM and via electroporation at 1, 3, 7, and 12 weeks and durvalumab IV at 4, 8, and 12 weeks. Starting week 12, cycles repeat every 8 weeks for DNA plasmid-encoding interleukin-12/HPV DNA plasmids therapeutic vaccine INO-3112 and every 4 weeks for up to 13 doses of durvalumab in the absence of disease progression or unacceptable toxicity.
3186529|NCT00746200|Experimental|A|
3186530|NCT00746200|Sham Comparator|S|
2419566|NCT03439059|Experimental|intervention- reducing SB|prompted to do 10min of light physical activity 3x/day
2419567|NCT03439059|No Intervention|Control|go about their normal daily living
3186531|NCT00746226|Active Comparator|A|Numbers 509-513, 700-709 and 900-909 Probiotic combination of L. acidophilus and B. lactis
3186532|NCT00746226|Placebo Comparator|B|"Numbers 612-624 and 800-811~Microcrystalline cellulose"
3186533|NCT00746265|Active Comparator|SBT|Standard behavioral treatment based on the LEARN manual.
3186534|NCT00746265|Active Comparator|ABT|Acceptance-based group that is based on the behavioral interventions contained in LEARN manual
3186535|NCT00746278|Experimental|1|Laparoscopic ovarian cystectomy using bipolar
3186536|NCT00746278|Experimental|2|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
3186537|NCT00746278|Active Comparator|3|Laparoscopic ovarian cystectomy using suture
2419570|NCT03439033|Experimental|PET/MRI|PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
2419571|NCT03439033|Experimental|Multiple PET/MRI|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC: Subjects will be invited to participate in two visits within two years, the second being an optional visit. During each visit, subjects will undergo a PET/MRI after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC. This arm will be restricted to subjects who plan to undergo focal therapy.
2419572|NCT03439033|Experimental|PET/CT|PET/CT with Gallium-68 labeled PSMA-HBED-CC: Subjects will have one visit during which they will undergo a PET/CT after being injected with the study drug, Gallium-68 labeled PSMA-HBED-CC.
2419573|NCT03439020|Experimental|FCSEMS + Plastic|"Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture and insert an additional plastic stent to anchor the metal stent.~(Plastic stent anchoring)"
2419574|NCT03439020|Active Comparator|FCSEMS|Insert only a fully covered self expandable metal stent (FCSEMS) without a plastic stent for malignant biliary stricture.
2419575|NCT03439007||Hypotensive|A group of pediatric patients who showed hypotension during induction of anesthesia
2419576|NCT03439007||Normotensive|A group of pediatric patients who did not show hypotension during induction of anesthesia
2419577|NCT03438994|Active Comparator|Participants diagnosed with ASD|
2419578|NCT03438994|Experimental|Participants diagnosed with OND|
2419579|NCT03438994|Active Comparator|Typically developing participants|
2419580|NCT03438968|Experimental|High-Intensity aerobic training|Individuals will exercise using a high-intensity interval exercise training protocol
2419581|NCT03438968|Active Comparator|Standard Moderate continuous training|Individuals will exercise using a standard moderate intensity continuous exercise training protocol
2419582|NCT03438955|Experimental|Cohort A|Administration of omacor soft capsule 4000mg for 16 days, and followed by omacor soft capsule 4000mg and Pritor tablet 40mg in combination for 7 days.
2419583|NCT03438955|Experimental|Cohort B|Administration of Pritor tablet 40mg for 7 days, and followed by Pritor tablet 40mg and Omacor soft capsule 4000mg in combination for 16 days.
2419584|NCT03438942|Experimental|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
2419585|NCT03438942|Active Comparator|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
2419586|NCT03438903||Normal group|Healthy subjects without any ocular problems Repeat exams of OCT device (SD and SS-OCT)
2419587|NCT03438903||Retinal diseases group|Patients with various macular diseases Repeat exams of OCT device (SD and SS-OCT)
2419588|NCT03438890|Experimental|Warm saline group|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
2419589|NCT03438890|Experimental|anti-fog agent group|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
2419590|NCT03438890|Experimental|chlorhexidine group|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
2419591|NCT03438890|No Intervention|control group|In the control group, the lens was not wiped gauze or applied any solution before use of the laparoscope. When occurred the event of each laparoscopic lens fogging (LLF) that splatter of irrigation fluid, blood, and body fluids affected visual clearance, the laparoscopic lens was manually rubbed with clean gauze by a scrub nurse.
2419594|NCT03438864|Experimental|10 Hz|Interferential current, entry frequency 4000 Hz and 4010 Hz, beat frequency 10 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
2419595|NCT03438864|Experimental|100 Hz|Interferential current, entry frequency 4000 Hz and 4100 Hz, beat frequency 100 Hz, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
2419596|NCT03438864|Sham Comparator|Placebo-Sham Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
2419597|NCT03438851|Experimental|Full-time Cognitive Rehabilitation Program|Participants in full-time program will be asked to complete 4 experimental sessions with the NeuroCatch Platform™ over the course of 3 months (i.e. one session/ month).
2419598|NCT03438851|Experimental|Part-time Cognitive Rehabilitation Program|Participants in the part-time program will be asked to complete 3 experimental sessions with the NeuroCatch Platform™ over 3 months (i.e. one session/1.5 months).
2419599|NCT03438838|Active Comparator|Laparoscopic Heller's Myotomy (LHM)alone|A minimum 10 patients undergo Laparoscopic Heller's myotomy alone
2419600|NCT03438838|Active Comparator|LHM with Anterior Fundoplication|A Minimum 10 patients undergo Laparoscopic Heller's myotomy along with fundoplication
2419601|NCT03438812|Experimental|Poor ovarian responders with DHEA|Women who meet the Bologna criteria receive dehydroepiandrosterone (DHEA, 90 mg daily for two months at least) supplementation prior to the IVF cycle.
2419602|NCT03438812|No Intervention|Poor ovarian responders|Women who meet the Bologna criteria undergo the IVF cycle without pretreatment with DHEA
2419603|NCT03438812|No Intervention|Normal ovarian responders|Women who do not meet the Bologna criteria and have normal ovarian response to ovarian stimulation.
2419604|NCT03438799||Cordio|Cordio R&D database to develop the Cordio System
2419605|NCT03438786|Experimental|group A|Patients undergoing trans-inguinal pre-peritoneal (TIPP) hernioplasty
2419606|NCT03438786|Experimental|group B|Patients undergoing lichtnestein's hernioplasty
2419607|NCT03438773|Other|Envarsus|Study group - Envarsus once daily in addition to standard of care.
2419608|NCT03438773|Other|Tacrolimus|Control group - Tacrolimus twice daily in addition to standard of care.
2419609|NCT03438760|Placebo Comparator|Science + Phonological Awareness|In all conditions, science is taught via the Full Option Science System Next Generation Edition (FOSS, 2015, https://www.fossweb.com/) curriculum that involves 1) Prediction, 2) Experiment, 3) Journal/Reflection, and 4) dialogic reading centered around a given theme such as plant life. In the control condition, a minimum of six phoneme identifications and five rhymes will be incorporated into each lesson of this curriculum. While these activities are likely to improve the children's awareness of the sounds of the language (a foundational skill for learning to read), they are not likely to improve their access to the science being taught. Therefore, this intervention constitutes a placebo.
2419610|NCT03438760|Experimental|Science + Grammar Intervention|In the science + grammar condition, focused stimulation, an intervention commonly used to target expressive language, will be used to treat complement clauses during the FOSS activities. The approach is incidental, rather than explicit. The active ingredients are models and recasts of the target structure. Recasts occur when an examiner responds to a child's naturally occurring utterance by expanding or extending the child's utterance to include a target grammatical structure. Recasts and/or models will be provided at an average rate of one per minute, an accepted therapeutic dose.
2419611|NCT03438760|Experimental|Science + Vocabulary Intervention|This arm involves Robust Vocabulary Instruction, an explicit approach that emphasizes multiple and rich encounters in authentic contexts to promote depth of semantic knowledge of 20 words that pertain to scientific practices applicable to the FOSS lessons. The children receive a cumulative exposure of at least 20 times per word (a minimum of 5 times per each of four lessons) and at least 4 chances to produce the word (a minimum of 1 chance per each of four lessons).
2419612|NCT03438747|Experimental|P-15L Bone Graft|The investigational group will be treated with P-15L Bone Graft in an instrumented TLIF
2419613|NCT03438747|Active Comparator|Local autologous bone|The active control group will be treated with local autologous bone in an instrumented TLIF
2419614|NCT03438734|Active Comparator|Low flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 0.75 L/min. Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
2419615|NCT03438734|Sham Comparator|Normal flow|"Anesthesia was maintained with desflurane inhalation with a flow of 2 L/min in 0.5 O2 oxygen-air mixture in both groups. While target minimum alveolar concentration (MAC) was 1-1.5 and the flow rate was adjusted to 1.5 L/min.Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.~The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of Bispectral Index (BIS, Bispectral Index, Monitoring System) decreases with the deepening of anesthesia."
3145888|NCT00084123|Experimental|Healing Touch|Healing Touch Therapy
3145889|NCT00084123|Active Comparator|Relaxation Therapy|Relaxation Therapy
2419618|NCT03438708|Experimental|Axitinib Oral Tablet [Inlyta]|Axitinib 5 mg PO BID for 8-10 weeks
2419619|NCT03438695|Experimental|Motorized Spiral Enteroscopy|Patients with indication for total enteroscopy. day1: anterograde motorized spiral enteroscopy, day 2: retrograde motorized spiral enteroscopy
3145890|NCT00084123|Placebo Comparator|Standard Care|Standard Care
3145891|NCT00084253|Active Comparator|1|
3145892|NCT00084253|Active Comparator|2|
2419623|NCT03438656|Experimental|Behavioral Activation Arm|See treatment description for information on Behavioral Activation. Participants will receive 12 weekly sessions of Behavioral Activation.
2419624|NCT03438643||Patient|Patients treated with ECP and corticosteroid as first-line treatment for cGVHD
2419627|NCT03438617|Experimental|First Cohort|The first cohort of 3 CHCs will receive the peer support intervention for the full duration of the study period (12 months).
2419628|NCT03438617|Other|Second Cohort|The second cohort of 3 CHCs will serve as a control group for the first 3 months of the study. After 3 months, the second cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 9 months.
3145896|NCT00084370|Experimental|Group 1|Group I: Patients receive oral celecoxib twice daily for 3 months and then undergo prophylactic oophorectomy.
3145897|NCT00084370|Experimental|Group II|Group II: Patients undergo immediate prophylactic oophorectomy.
3145898|NCT00084396|Experimental|Letrozole/Surgery|
3145899|NCT00084435|Experimental|chemoRT after surgery|chemoRT with cisplatin and docetaxel after surgery
3145900|NCT00084461|Experimental|Treatment (romidepsin)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses beyond CR.
3186538|NCT00746291|Experimental|A|Traumatic brain injury
3186539|NCT00746291|Experimental|B|Cerebral palsy
2419629|NCT03438617|Other|Third Cohort|The third cohort of 4 CHCs will serve as a control group for the first 6 months of the study. After 6 months, the third cohort will implement the peer support intervention according to the protocols established in the first cohort. The participants in this cohort will receive the intervention for 6 months.
2419630|NCT03438604|Other|Donepezil TDS with Heat Applied|Corplex Donepezil TDS 5 mg/day with heat applied
2419631|NCT03438604|Other|Donepezil TDS without Heat|Corplex Donepezil TDS 5 mg/day with no heat applied
2419632|NCT03438604|Other|Donepezil TDS Extension Study with Heat|Corplex Donepezil TDS 5 mg/day with heat. Two skin sensors will be placed underneath the TDS and adjacent to the TDS.
2419633|NCT03438591|Experimental|Cerclage-CRT (medtronic 4196 lead)|trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing'
3186540|NCT00746291|Experimental|C|Controls
3186541|NCT00746304||1|infantile esotropia
2419636|NCT03438565||Participants with intracranial large vessel occlusive stroke|50 patients who have been treated with the Asahi Chikai Black 18 neurovascular guidewire.
2419637|NCT03438565||Historical Control Group|The historical control will include 50 retrospective consecutive patients (who fulfill inclusion and exclusion criteria) treated for acute anterior circulation large vessel occlusive stroke prior to the initiation of the Sure -18 registry.
2419638|NCT03438552|Experimental|SBRT at a total dose of 30 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30 Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
2419639|NCT03438552|Experimental|SBRT at a total dose of 25 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
2419640|NCT03438552|Experimental|SBRT at a total dose of 36 Gy|Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
3186542|NCT00746304||2|acquired esotropia
3186543|NCT00746317|Experimental|1|
3186544|NCT00746343|Experimental|IRRI|"The integrated risk reduction intervention (IRRI) consists of three components:~psychiatric treatment by a study psychiatrist~assessment, referral, monitoring, and coordination by a certified registered nurse practitioner (CRNP) of medical treatment provided by the subject's own primary care physician~a healthy lifestyle behaviors program delivered by a lifestyle coach. The treating psychiatrist will work in collaboration with a CRNP and a lifestyle coach. The CRNP will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care and will follow-up on adherence to the medical treatment recommendations. The CRNP will be responsible for coordinating the psychopharmacological care provided by the psychiatrist, the healthy lifestyle behaviors program that will be delivered by the lifestyle coach, and the medical care provided by the subject's PCP."
3186545|NCT00746343|Experimental|PCCM|"Psychiatric Care with Medical Monitoring (PCMM)~The psychiatric care with medical monitoring condition (PCMM) consists of two components:~psychiatric treatment by a study psychiatrist~assessment and referral by a psychiatric research nurse for medical treatment provided by the subject's own primary care physician.~The treating psychiatrist will be assisted by a psychiatric nurse clinician who will assess and monitor the subject's medical needs and refer the subject to their primary care physician for care."
3186546|NCT00746369|No Intervention|2|
3186547|NCT00746369|Experimental|Intervention|IMARA HIV Prevention Intervention. Three individual sessions for incarcerated female teens.
2419647|NCT03438526|Experimental|Melatonin (Circadin ®)|
2419648|NCT03438526|Placebo Comparator|Placebo|
2419649|NCT03438513||Problem Solving Therapy|This program is intended for caregivers to acquire techniques to manage stressful situations encountered in everyday life.
2419650|NCT03438513||Speaking group|The group will be led by a psychologist.
2419651|NCT03438513||Standard medical care|Occupational Therapy Assessment Psychological assessment
2419652|NCT03438500|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
2419653|NCT03438487||Flucelvax Trivalent or Quadrivalent Influenza Vaccine|Flucelvax Trivalent or Quadrivalent exposure in pregnancy
2419654|NCT03438474|Active Comparator|Arm A standard surgical procedure|"Standard surgical procedure for endometrial cancer:~total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)"
2419655|NCT03438474|Experimental|Arm B systematic lymphadenectomy (LNE)|"In addition to standard procedures as defined for Arm A:~systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels"
2419821|NCT03437317|Experimental|Active - 1 Behavior/MEG|Participants completed 1 session of 6 Perceptual Retraining blocks following an instructional presentation.
3186548|NCT00746382|Active Comparator|1|Roflumilast cream 0.5%
3186549|NCT00746382|Placebo Comparator|2|Placebo cream
3186550|NCT00746408||Main 1|Insurants of the health insurance company BARMER using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
3186551|NCT00746408||Main 2|Insurants of the health insurance company BARMER using search engines and portals to gather internet information about the type of headache they suffer from.
3186552|NCT00746408||Online 1|Internet users using the prototype to receive expert system guided tailored internet information about the type of headache they suffer from.
3186553|NCT00746408||Online 2|Internet users using search engines and portals to gather internet information about the type of headache they suffer from.
3186554|NCT00746434|Active Comparator|1|Roflumilast cream 0.5%
3186555|NCT00746434|Placebo Comparator|2|Placebo cream
3186556|NCT00746447|Experimental|3.0g OD|
3186557|NCT00746447|Experimental|1.5g OD|
3186558|NCT00746447|Active Comparator|0.5g TID|
3186559|NCT00746460|Experimental|A|Behavioral
2419656|NCT03438461|Experimental|Part 1|In Part 1, all participants will receive a single oral dose of seltorexant (40 milligram [mg]) in all the 6 treatments as Treatment A (Formulation 1 in fasted state), B (Formulation 1 in semi-fasted state), C (Formulation 2 in fasted state), D (Formulation 2 in semi-fasted state), E (Formulation 3 in fasted state) and F (Formulation 3 in semi-fasted state) and the participants will be assigned to one of the 8 sequences (that is, ADBCEF, ADBCFE, BACDEF, BACDFE, CBDAEF, CBDAFE, DCABEF, DCABFE). A washout period of at least 7 days between subsequent study drug administrations on Day 1 of each treatment period will be maintained.
2419657|NCT03438461|Experimental|Part 2 (Optional)|Optional Part 2 will only be performed if considered to be warranted by the sponsor based on the preliminary pharmacokinetic (PK) analysis of the results from Part 1. Participants will receive a single oral dose of seltorexant (20 mg) as 3 different formulations assigned to one of the either 6 or 4 treatment sequences under fasted or semi-fasted conditions. The treatment will be assigned in 1 of the 6 or 4 assigned sequences per treatment period that is either Period 1 to 6 or Period 1 to 4).
2419658|NCT03438435|Experimental|QRH-882260 Heptapeptide|Five mL of reconstituted (with sterile 0.9% NaCl) QRH-882260 Cy-5-labeled heptapeptide
2419659|NCT03438422|Experimental|GROUP A|1 tablet a day of pollen A extract containing (140 mg aqueous extract and 8mg lipid purified pollen, aqueous extract pumpkin seed 300mg, 10mg Vitamin E)
2419660|NCT03438422|Active Comparator|GROUP B|1 tablet a day of pollen B extract containing (140 mg aqueous extract and lipid 8 mg of purified pollen)
2419661|NCT03438422|Active Comparator|GROUP C|1 tablet a day of pollen extract C containing (Pollen extract 160 mg, pumpkin seed extract, 300 mg and Vitamin E 10 mg)
2419662|NCT03438422|Placebo Comparator|PLACEBO|1 tablet a day of placebo
2419663|NCT03438409|Experimental|Single Arm Study|This study has a single arm with repeated baseline measures. This arm will complete the robotic gait training.
3186560|NCT00746473||1|15 HIV-1 infected individuals, with or without AIDS, who had never received ARV. These patients had not yet been indicated for ARV, or had had HIV-1 infection diagnosed a few days before inclusion in this study.
3186561|NCT00746473||2|"27 HIV-1 infected individuals, sick or not, on ARV treatment, five with two nucleoside/nucleotide reverse transcriptase inhibitors (NRTI) and one nonnucleoside reverse transcriptase inhibitor (NNRTI), and 22 on HAART with two NRTI, or one NRTI and one NNRTI, and one protease inhibitor (PI), and VL equal to or greater than 50 copies of plasma RNA/mL.~Treatment duration in this group varied between three and 145 months (mean 53.62 months; median 42 months)."
3186562|NCT00746473||3|31 HIV-1 infected individuals on ARV treatment, 16 on HAART with two NRTI, or one NRTI and one NNRTI, and one PI, and 15 with two NRTI and one NNRTI. All G3 patients had undetectable VL for at least the past 6 months. Treatment in this group varied between five to 108 months (mean 48.13 months; median 42 months).
2419667|NCT03438370|No Intervention|Three monthly ART supply at facilities|Sites at which patients will be provided three monthly ART supply at health facilities.
2419668|NCT03438370|Experimental|Three monthly ART supply at CAGs|Sites at which patients will be provided three monthly ART supply at Community ART Groups (CAGs).
2419669|NCT03438370|Experimental|Six monthly ART supply at outreaches|Sites at which patients will be provided six monthly ART supply at Community distribution points or outreaches.
2419671|NCT03438344|Experimental|Arm I (CMV-MVA triplex vaccine)|Patients receive multi-antigen CMV-modified vaccinia Ankara vaccine via injection on days 28 and 56 post-HCT.
2419672|NCT03438344|Placebo Comparator|Arm II (placebo)|Patients receive placebo via injection on days 28 and 56 post-HCT.
2419673|NCT03438331|Experimental|CBT-I|
2419674|NCT03438331|Active Comparator|CBT-D|
2419675|NCT03438331|No Intervention|Waiting-list control|
2419676|NCT03438318|Experimental|Part A (CMP-001, Atezolizumab and Optional Radiation Therapy)|Participants will receive CMP-001 5 milligrams (mg) SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by every 3 weeks thereafter until discontinuation of treatment in combination with atezolizumab SC every 3 weeks starting at Week 2. Route of administration (IT/SC) for CMP-001 beyond Week 5 will be determined by Investigator. Participants enrolled in Part A who progressed per RECIST v1.1 on combination of CMP-001 and atezolizumab have opportunity to enroll in Part A optional radiation therapy add-on after documented disease progression per CT/MRI or PET scan. After CMP-001 washout period of 10 days, participants will be treated with radiation consisting of 20 grays in 5 fractions for 5 days then resume CMP-001 treatment.
2419677|NCT03438318|Experimental|Part B (Radiation Therapy, CMP-001 and Atezolizumab)|Participants will be treated with radiation therapy consisting of 20 grays in 5 fractions for 5 days, then participants will receive CMP-001 5 mg SC once weekly for 2 weeks, then 10 mg IT once weekly for 3 weeks, followed by dosing every 3 weeks thereafter until discontinuation of treatment. The route of administration (that is, IT or SC) for CMP-001 beyond Week 5 will be determined by the Investigator. First dose of CMP-001 will be administered within 2 days of radiation therapy. Atezolizumab will be administered SC in combination with CMP-001 every 3 weeks starting at Week 2.
2419678|NCT03438305||Group D|
2419679|NCT03438305||Group N|
2419680|NCT03438292|Experimental|Group A - TPGS emulsified with berberine|After an 8-10 hour overnight fast, Group A will receive two soft capsules of TPGS (400mg) emulsified berberine. Following a 7 day wash out period, Group A participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Following another 7 day wash out period, Group A participants will then receive two hard shell capsules of the berberine reference powder 400mg. Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
2419681|NCT03438292|Experimental|Group B - Quillaja extract emulsified with Berberine|After an 8-10 hour overnight fast, Group B will receive four soft capsules of Quillaja extract emulsified berberine (400mg). Following a 7 day wash out period, Group B participants will then receive two hard shell capsules of the berberine reference powder (400mg). Following another 7 day wash out period, Group B participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
2419745|NCT03437785|Experimental|Experimental Group 1|Patients assigned to this group are treated with CKD-495 75mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 150mg, ,Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2419682|NCT03438292|Experimental|Group C - Berberine reference powder|After an 8-10 hour overnight fast, Group C will receive two hard shell capsules of the berberine reference powder (400mg). Following a 7 day wash out period, Group C participants will then receive two soft gel capsules of TPGS emulsified berberine (400mg). Following another 7 day wash out period, Group C participants will then receive four capsules of the Quillaja extract emulsified berberine (200mg). Each TPGS and berberine reference powder capsules contains 400 mg berberine. Each Quillaja extract capsule contains 200mg berberine. The total amount of berberine throughout is 800 mg.
2419683|NCT03438279||First-Line Ipilimumab|patients who received ipilimumab as their first-line treatment
2419686|NCT03438240|Active Comparator|Group BF|Bupivacaine plus Fentanyl
2419687|NCT03438240|Active Comparator|Group BD|Bupivacaine plus Dexmedetomidine
2419688|NCT03438227|Experimental|Intravenous iron dextran infusion|Women randomized to receive intravenous iron infusion will receive a single infusion of dextran 1000mg IV as an inpatient on the antepartum or Labor & Delivery Unit. They will receive continuous fetal monitoring for 30 minutes before and after the infusion as well for the duration of the infusion
2419689|NCT03438227|Active Comparator|Oral ferrous sulfate supplementation|Women randomized to continue oral iron will continue to take ferrous sulfate 325mg one to three tablets daily, with the final dose at the discretion of the patient's obstetric provider.
2419690|NCT03438214|Active Comparator|Vancomycin continuous infusion|Continuous infusion of vancomycin
2419691|NCT03438214|Active Comparator|Vancomycin intermittent infusion|Intermittent infusion of vancomycin
2419692|NCT03438201|Active Comparator|High-protein diet|High Protein Diet (2,0 - 2,5g/Kg body weight/day) Physical Activity protocol
2419693|NCT03438201|Active Comparator|Normoproteic diet|Standard Protein Diet (1,0 - 1,2g/Kg body weight/day) Physical Activity protocol
2419694|NCT03438188|Experimental|Smoker Group|The smokers group will be scanned on 2 occasions: (1) after a 4 day monitored practice quit attempt (biochemically verified), and (2) after 4 days of smoking as usual (order counterbalanced).
2419695|NCT03438188|No Intervention|Non-Smoking Comparison Group|Healthy non-smokers will complete one period (comparable to abstinence arm) of the study to serve as a baseline comparison group.
2419696|NCT03438175|No Intervention|Control|Families of Critically Ill will be informed about patients'clinical status only by oral communication during daily family meeting
2419697|NCT03438175|Experimental|Intervention|Families of critically ill patients will receive during the first ICU day of their loved one a brochure presenting the ICU and inviting them to visit a website specifically created for this project: www.intensiva.it Moreover, in the waiting room of the ICU will be placed 8 posters to improve comprehension and to legitimize emotions.
2419698|NCT03438162|No Intervention|Control group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications.
2419699|NCT03438162|Experimental|Intervention group|Patients in both groups received diabetes education during the hospital stay. Standardized diabetes education includes education regarding the disease, diet, physical activity, alcohol intake, smoking, education regarding diabetes medication, self monitoring of glucose, and education regarding acute and chronic complications. Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
2419700|NCT03438136|Experimental|Intervention arm|This arm will be enrolled in the intervention.
2419701|NCT03438136|No Intervention|No intervention arm|This arm will be enrolled in a no contact control group.
2419702|NCT03438123|Experimental|CZT SPECT|CZT SPECT imaging with/without the addition of CT on the Spectrum Dynamics camera
2419703|NCT03438084|Experimental|Interesterified|Commercially available interesterifed fat spread. 50g fat.
2419704|NCT03438084|Active Comparator|Non- interesterified|Commercially available non-interesterified fat. 50g fat.
2419705|NCT03438084|Active Comparator|Control|Rapeseed oil. 50 g fat.
2419706|NCT03438084|Active Comparator|Saturated fat control|Butter. 50g fat
2419707|NCT03438071||Control group|
2419708|NCT03438071||Videoconference group|
2419709|NCT03438058||With complement-activating anti-HLA DSAs|Patients with complement-activating anti-HLA DSAs either C1q, C3d, C4d and IgG subclass
2419710|NCT03438058||Without complement-activating anti-HLA DSAs|Patients with anti-HLA DSAs but without the ability to activate the complement (either C1q, C3d, C4d and IgG subclass)
2419711|NCT03438058||Without DSAs and without complement-activating DSAs|Matching group of patients without DSAs and without complement-activating DSAs
3145901|NCT00084539|Experimental|Radiation therapy|"Radiation Therapy~Daily 5 days per week for 4 weeks~45 Gy in 20 fractions whole breast~56 Gy in 20 fractions to boost volume"
3145902|NCT00084604|Experimental|Treatment (bevacizumab, cisplatin, irinotecan)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive cisplatin IV over 30 minutes followed by irinotecan IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2419818|NCT03437317|Experimental|Active - MEG|Participants completed 1 session of 8 Perceptual Retraining blocks following an instructional presentation.
3145903|NCT00084630|Experimental|Treatment (imatinib mesylate)|Patients receive oral imatinib mesylate once daily on days 1-56. Treatment repeats every 56 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with documented tumor progression and no serious side effects may continue therapy at a higher dose for another 6 courses.
3145904|NCT00084643|Experimental|Treatment (GTI-2040, capecitabine, oxaliplatin)|Patients receive GTI-2040 IV continuously on days 1-14, oral capecitabine twice daily on days 2-15, and oxaliplatin IV over 2 hours on day 2 of the first course. In all subsequent courses, capecitabine is administered on days 1-14, oxaliplatin is administered on day 1, and GTI-2040 is administered as in course 1. Courses repeat every 21 days in the absence of disease progression and unacceptable toxicity.
3145905|NCT00084656|Experimental|Arm 1|
3145906|NCT00084695|Experimental|Regimen A|Patients undergo total body irradiation (TBI) two times daily on days -7 to -4. Patients receive cyclophosphamide IV over 30-60 minutes on days -3 and -2 and anti-thymocyte globulin (ATG) IV over at least 6 hours on days -3 to -1.
2419715|NCT03438019|Experimental|TIRE IMT|The TIRE IMT group will receive a tablet with the TIRE software installed and a PrO2® device through which they will train. Training consists of six levels (A-F) with six inspirations at each level for a total of 36 breaths. Recovery times between breaths range from 40 to 5 seconds as the subject advances each level. TIRE data will be stored in the tablet for subsequent interrogation and data retrieval.
2419716|NCT03438019|Experimental|Standard IMT group|The Standard IMT group will receive a Threshold® Inspiratory Muscle Trainer. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject. Subjects will be instructed to perform up to 36 breaths daily. To compare with TIRE training, we will ask participants to perform this within a 30-minute session.
2419717|NCT03438019|Sham Comparator|Sham IMT group|The Sham IMT group will also receive a Threshold® device and undergo the exact protocol of group 2 but with minimal resistance applied (7 cm H2O, the lowest in the device).
2419719|NCT03437993|Experimental|Recollect|Recollect is a video game which incorporates scientifically supported renditions of N-Back, Item Span, and Multiple-Identity tracking tasks. These tasks are independently shown to improve working memory in a manner that transfers to untrained tasks.
2419720|NCT03437993|Sham Comparator|Tetris|Tetris is a video game which has not been shown to have any benefits in the improvement of executive functioning.
2419721|NCT03437980|Experimental|propofol spinal acceptance|"The surgeon and the anesthetist will discuss the exclusion criteria. Then they will discuss the information's about spinal and general anesthesia with the illegible patients, also reply the patient's questions in a preoperative visit. The primary decision for the patient; either spinal or general anesthesia will be recorded.~The patients refusing spinal anesthesia will be discussed again to detect the rate of acceptance of spinal anesthesia if propofol sedation is ensured during the procedure to provide a painless spinal injection. The final decision will be applied; either spinal with procedural sedation, or general anesthesia."
2419722|NCT03437967|Other|ABAB|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~ABAB initial period is active treatment - LASER.~Active Treatment:~LASER light is delivered to the skin and deeper tissues affected by pain using either a wand or glass roller ball. Ten to 25 Watts of LASER energy is delivered to the painful regions for 8 to 16 minutes depending on the size of the area treated and other factors such as skin pigmentation."
2419723|NCT03437967|Other|BABA|"Treatment, either LASER (arm A) or LOW LEVEL LASER (arm B) will be provided 3 (not less than 2) days a week for three weeks at which time crossover into the alternate arm occurs (BABA to ABAB or ABAB to BABA).~BABA initial period is sham treatment - LOW LEVEL LASER.~LOW LEVEL LASER treatment:~Low level LASER is provided in a similar fashion using LASER power levels (1 Watt) that produce warmth only at superficial skin levels."
2419724|NCT03437954|Other|Standard soft diet|
2419725|NCT03437954|Other|Non-restricted diet|
3145907|NCT00084695|Experimental|Regimen B (patients who do not receive TBI)|Patients receive oral busulfan 4 times daily on days -8 to -5, and ATG IV over at least 6 hours and melphalan IV over 15-20 minutes on days -4 to -2.
3145908|NCT00084695|Experimental|Regimen C (patients with Fanconi's anemia/related disorders)|Patients undergo TBI on day -6. Patients receive ATG IV over at least 6 hours and methylprednisolone IV on days -5 to -1 and fludarabine IV over 30 minutes and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
3145909|NCT00084695|Experimental|Regimen D|Patients receive oral or IV busulfan 4 times daily on days -9 to -5, ATG IV over at least 6 hours on days -5 to -3, and cyclophosphamide IV over 30-60 minutes on days -5 to -2.
3145910|NCT00084773|Experimental|Cetuximab, Fluorouracil, and Pelvic Irradiation|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64 and fluorouracil IV continuously on days 1-42. Patients undergo whole-pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-40. Treatment continues in the absence of disease progression or unacceptable toxicity.~Approximately 1-3 weeks after completion of study treatment, patients undergo surgical resection followed by adjuvant chemotherapy off-study.~Patients are followed for up to 5 years."
3145911|NCT00084812|Experimental|Safingol and Cisplatin|"Patients receive safingol IV over 1 hour and cisplatin IV over 1 hour on day 1. Courses repeat every 21 days* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive safingol on days 1 and 8 and cisplatin on day 8 for course 1 only; course 1 is 28 days in duration.~Cohorts of 3-6 patients receive escalating doses of safingol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose level."
3145912|NCT00084825|Experimental|Docetaxel + Imatinib Mesylate|Docetaxel intravenous (IV) over 1 hour on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-42. Courses repeat every 42 days.
2419733|NCT03437915|Experimental|Treatment Arm|28.5 Gy delivered in 5 daily fractions then 4-12 weeks post NIBB, surgery via partial mastectomy
2419734|NCT03437902|Experimental|Rutin C group|patients will receive Rutin 60 mg in combination with vitamin C 160 mg three times daily in addition to usual antidiabetic treatment for 8 weeks..
2419735|NCT03437902|Experimental|Vitamin C group|patients will receive vitamin C 500 mg once daily in addition to usual antidiabetic treatment for 8 weeks.
2419736|NCT03437902|No Intervention|Control group|patients will receive their usual antidiabetic treatment only for 8 weeks.
2419738|NCT03437876|Experimental|patients with HBV induced cirrhosis|patients with HBV induced cirrhosis will be recruited for study, which involved a 4 times intestinal microbiota transplant and the time interval is generally 2 weeks.
2419740|NCT03437850||South African cohort|
2419741|NCT03437850||Swedish Cohort|
2419742|NCT03437824|Experimental|Cyanocobalamin|Vitamin B12, 1,000 mg, Once
2419743|NCT03437824|Placebo Comparator|Placebo|Normal Saline Solution (0.9% Sodium Chloride), Once
2419744|NCT03437811||Active Treatment|Active arm, Electro Flo Percussor, Model 5000 airway clearance system for daily basis as needed (pro re nata).
2420591|NCT03431961|Placebo Comparator|Placebo|0.9% normal saline administered twice daily for 14 days
2419746|NCT03437785|Experimental|Experimental Group 2|Patients assigned to this group are treated with CKD-495 150mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2419747|NCT03437785|Placebo Comparator|Placebo Group|Patients assigned to this group are treated with 4 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab., Placebo of the Rebamipide 100mg Tab.)
2419748|NCT03437785|Active Comparator|Active comparator Group 1|Patients assigned to this group are treated with Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab, and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of the Rebamipide 100mg Tab.)
2419749|NCT03437785|Active Comparator|Active comparator Group 2|Patients assigned to this group are treated with Rebamipide 100mg Tab.,and other 3 Placebo Tab.(Placebo of the CKD-495 75mg, Placebo of the CKD-495 150mg, Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.)
2419750|NCT03437772||CBT with mindfulness|
2419751|NCT03437772||Treatment as Usual: Barkley therapy|
2419752|NCT03437759|Experimental|Experimental group|Our intervention is to add treatment of exosomes derived from mesenchymal stem cells (MSC-Exo) after pars plana vitrectomy(PPV) and ILM peeling.
2419753|NCT03437759|No Intervention|Control group|Control group that receives treatment of only pars plana vitrectomy(PPV) and ILM peeling.
3186563|NCT00746473||4|20 blood donors without clinical complaints and negative for anti-HIV-1/2 antibodies. None of them showed any sign of disease.
2419755|NCT03437720|Experimental|SAR425899 (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2419756|NCT03437720|Experimental|SAR425899 (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2419757|NCT03437720|Placebo Comparator|Placebo (Low Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2419758|NCT03437720|Placebo Comparator|Placebo (High Dose)|Once daily dose with weekly dose escalations, if tolerated, until target dose is reached. From week 14 (Day 99) until week 52, no further dose adjustments are planned.
2419759|NCT03437707|Placebo Comparator|placebo|250 ml saline will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2419760|NCT03437707|Active Comparator|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2419761|NCT03437707|Active Comparator|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received Morphine Sulfate with intravenous patient controlled analgesia (IV PCA) pump during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
2419762|NCT03437694|Experimental|Medication Optimization Intervention|This group will represent those participants whose medical records have been provided to the pharmacist.
2419763|NCT03437694|Active Comparator|Medication Optimization Control|This group will represent those participants whose medical records have not been provided to the pharmacist.
2419764|NCT03437681|Experimental|Insufficient sleep|Each participant will receive 4 nights of insufficient sleep.
2419765|NCT03437668|Experimental|Withania Somnifera Extract (WSE)|WSE 500 mg bid for 12 weeks
2419766|NCT03437668|Placebo Comparator|Placebo tablets|Placebo oral tablet bid for 12 weeks
2419767|NCT03437655|Active Comparator|Zinc oxide and eugenol|Temporary direct restoration with zinc oxide and eugenol.
2419768|NCT03437655|Active Comparator|Mineral trioxide aggregate|Temporary direct restoration with Mineral trioxide aggregate.
2419769|NCT03437642||Tako-Tsubo - STP|Short term psychotherapy + Classic cardiological therapy
2419770|NCT03437642||Tako-Tsubo - Control|Classic cardiological therapy only
2419771|NCT03437642||Oncologic - STP|Short term psychotherapy + Classic oncological therapy
2419772|NCT03437642||Oncologic - Control|Classic oncological therapy only
2419773|NCT03437642||AMI - STP|Short term psychotherapy + Classic cardiological therapy
2419774|NCT03437642||AMI - Control|Classic cardiological therapy only
2419775|NCT03437642||Healthy Subjects|No therapy
2419776|NCT03437629|Active Comparator|Calcium Hydroxide temporary cement|Cementation of a temporary crown with cement based on calcium hydroxide.
2419777|NCT03437629|Active Comparator|MTA temporary cement|Cementation of a temporary crown with cement based on Mineral trioxide aggregate .
3186564|NCT00746486|Experimental|A|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
2419780|NCT03437603|Experimental|Eltrombopag group|Starting dose is 25mg daily for the first 3 days, then increasing to 50mg for another week. Maintenance dosage is 50mg or 75 mg per day dependent on patients' status and doctors' opinion.Planned duration of treatment with eltrombopag is 8 weeks.When patients achieve persistent complete response for 2 weeks,they may stop medicine.
2419819|NCT03437317|Sham Comparator|Control - MEG|Participants completed 1 session of 8 blocks of Gender Discrimination Task.
2419820|NCT03437317|Experimental|Active - 3 Behavior/EEG|Participants completed 3 sessions of Perceptual Retraining following an instructional presentation. The first session included 6 blocks of perceptual training, and the second session included 12 blocks of perceptual training. No perceptual training was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
2419781|NCT03437590|Experimental|Part 1: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline positron emission tomography (PET)/ magnetic resonance (MR) scan with [18F]-JNJ-64413739 on Day 1. In Period 1 (on Day 2) and Period 2 (on Day 1), participants will receive oral dose of JNJ-55308942 (maximum dose 120 milligram [mg]). After approximately 4 hours of JNJ-55308942 dosing, participants will receive an intravenous (IV) injection of [18F]-JNJ-64413739, followed by a PET/MR scan. Doses will be selected based on the principal investigator's discretion. A wash-out period of at least 7 days will be maintained between the 2 doses of JNJ-55308942.
2419782|NCT03437590|Experimental|Part 2: JNJ-55308942 and [18F]-JNJ-64413739|Participants will first undergo a baseline PET/MR scan with [18F]-JNJ-64413739 on Day 1. Participants will receive oral dose of JNJ-55308942 (maximum dose 120 mg) on Day 2, followed by two post-treatment scans, one obtained at Tmax (4 hours postdose) and one at 24 hours postdose. Doses will be selected based on the principal investigator's discretion.
3186565|NCT00746486|Active Comparator|B|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d
3186566|NCT00746499|Experimental|1|No control group, only one active arm with subjects taking Raltegravir.
3186567|NCT00746525|Experimental|Brain Computer Interface Training Stroke Experimental Group|Individuals in the stroke experimental group received treatment with BCI, FES, and motor learning targeted at their upper extremity motor deficits following stroke.
3186568|NCT00746538|Experimental|1|metallic stent group
2419787|NCT03437551||no intervention|Cross-sectional Observation study
2419788|NCT03437538|Active Comparator|First MCO-HD, then High-flux-HDF|Participants with ongoing HDF-treatments will have measurements during an intervention with a 4h dialysis with MCO-HD, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during a 4h dialysis with High-flux-HDF
2419789|NCT03437538|Active Comparator|First High-flux-HDF, then MCO-HD|Participants with ongoing HDF-treatments will have measurements during a 4h dialysis with High-flux-HDF, followed by 2 weeks of washout with ordinary HDF, thereafter measurements during an intervention with a 4h dialysis with MCO-HD
2419790|NCT03437525|Experimental|Peer Support Intervention|The experimental group will receive the peer support intervention for 12 months.
2419791|NCT03437525|No Intervention|Control|Usual care
3186569|NCT00746538|Active Comparator|2|plastic stent group
3186570|NCT00746616|Experimental|1|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
2419794|NCT03437499|Active Comparator|Positive Pressure Ventilation|Positive Pressure Ventilation ( peak pressure set at 25 cmH20 and PEEP set at 5 cmH2O, with 40 inflations per minute)
2419795|NCT03437499|Experimental|Sustained Inflation|Prolonged inflation ( 25 cmH20 for 15 seconds) followed by PEEP set at 5 cmH2O
2419796|NCT03437486||Familial Pulmonary Fibrosis|Subjects asked to participate in this study will be unaffected family members of patients previously diagnosed with familial interstitial pneumonia (FIP) which is the familial form of idiopathic pulmonary fibrosis (IPF).
2419797|NCT03437473|Active Comparator|Active stimulation QD|
2419798|NCT03437473|Active Comparator|Active stimulation QID|
2419799|NCT03437473|Sham Comparator|No stimulation|
2419800|NCT03437460|Active Comparator|Ibuprofen 600mg|Treatment group participants receive a single 600 mg of over-the-counter ibuprofen.
2419801|NCT03437460|Placebo Comparator|Prenatal vitamins|The placebo group participants receive a single dose of a pre-natal multivitamin.
2419802|NCT03437460|No Intervention|Control group|Control-group participants are not provided with any treatment and they are fully informed regarding their treatment status.
3186571|NCT00746629|Active Comparator|Prescribed Skills|Behavioral skills are all prescribed and considered necessary tools expected to be used consistently, completely, and uniformly by all participants throughout treatment
3186572|NCT00746629|Experimental|Self-Directed Skills|Behavioral skills are considered a tool box from which families are encouraged to select skills that best apply to that family's situation in attempts to help their child make eating and activity change.
3186573|NCT00746642|Experimental|A|"Glucose measurements using Mellitor device."
2419806|NCT03437434||BunnyLens and Gore-Tex suture|All patients Underwent 4 point PC-IOL scleral fixation with Gore-Tex sutures
2419807|NCT03437421|Experimental|Type II diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
2419808|NCT03437421|Experimental|Type I diabetic patients|3 month Vitamin D3 (cholecalciferol) supplementation in patients with vitamin D deficiency, based on 25-OH-D3 dosage.
2419809|NCT03437408|Experimental|Mapping and ablation|Automated Substrate maps with different pacing modes. Validation of collected substrate. Data collection during ablation
2419810|NCT03437395|Other|Partial Breast Irradiation|All participants will be treated with partial breast irradiation by utilizing 3D conformal external beam irradiation or balloon brachytherapy. This is not a randomized study.
2419811|NCT03437382|Other|RFA + radioembolization|Quirem Medical Holmium-166 radioembolization microspheres
2419812|NCT03437369|Experimental|Ivabradine|Drug: Ivabradine Oral tablets 2.5 mg Dose: 10-15 mg/day Duration: 30 days
2419813|NCT03437369|Other|Standard of Care|The study drug will be compared with standard of Care treatment
2419814|NCT03437356|Active Comparator|ADT ON Group|'CLOSE'-guided PVI with continuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation.
2419815|NCT03437356|Active Comparator|ADT OFF Group|'CLOSE' guided PVI with discontinuation of antiarrhythmic drug therapy (ADT) at the end of the 3-months blanking period after ablation
3186574|NCT00746642|Active Comparator|B|"Glucose measurements conducted by using gold standard, Yellow Springs glucose analyzer"
3186575|NCT00746655|Other|SBRT / TACE|
3186576|NCT00746681|Experimental|A|Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily
3186577|NCT00746681|Active Comparator|B|Tolterodine SR 4 mg once daily
3186578|NCT00746681|Placebo Comparator|C|Placebo
3186579|NCT00746681|Experimental|D|Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily
3186580|NCT00746681|Experimental|E|Pregabalin 150 mg twice daily
3186581|NCT00746707|Experimental|1|use of octyl-2-cyanoacrylate adhesive glue for perineal tear grade 1 in 80 women
3186582|NCT00746707|Active Comparator|3|use of traditional suturing for perineal tear grade 1 in 50 women
2419822|NCT03437317|Sham Comparator|Control - 3 Behavior/MEG|Participants completed 3 sessions of a Gender Discrimination Task. The first session included 6 blocks of gender discrimination task, and the second session included 12 blocks of the gender discrimination task. No gender discrimination task was performed in session 3. Sessions were spaced approximately 7 days apart, with a minimum of 3 days and a maximum of 14 days apart.
2419823|NCT03437304|Experimental|Immunose™ FLU 1%|Immunose™ FLU 1%. QIV, 30 μg HA/strain and 1% Endocine™ 200 μl for intranasal administration, 2 dosing occasions.
2419824|NCT03437304|Experimental|Immunose™ FLU 2%, 200 μl|Immunose™ FLU 2%. QIV, 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration, 2 dosing occasions.
2419825|NCT03437304|Experimental|Immunose™ FLU 2%, 300 μl|Immunose™ FLU 2%, 300 μl. QIV, 30 μg HA/strain and 2% Endocine™, 300 μl for intranasal administration, 2 dosing occasions.
2419826|NCT03437304|Experimental|Influenza antigen|Influenza antigen. QIV, 30 μg HA/strain, 200 μl for intranasal administrations, 2 dosing occasions.
2419827|NCT03437304|Placebo Comparator|Placebo|Placebo. Saline (NaCl), 200 μl for intranasal administration, 2 dosing occasions.
2419828|NCT03437304|Experimental|i.m comparator and Immunose™ FLU 2%|i.m comparator: QIV 15 μg HA/strain, 500 µl for a single intramuscular administration, and Immunose FLU 2%: QIV 30 μg HA/strain and 2% Endocine™, 200 μl for intranasal administration. A second dose of Immunose FLU 2% will be administered 3 weeks later.
2419829|NCT03437304|Active Comparator|i.m comparator|i.m comparator. QIV 15 μg HA/strain, 500 µl for a single intramuscular administration.
2419830|NCT03437291||Abnormal placental invasion|patients had placenta previa with histopathologically confirmed abnormal invasion with all three grades i.e. accreta, increta and percreta,
2419831|NCT03437291||Normal placenta|patients had placenta previa with no abnormal invasion
3186583|NCT00746720|Experimental|A, 1|Study part 1 (n = 8)
3186584|NCT00746720|Placebo Comparator|A, 2|Study part 1 (n = 4)
3145913|NCT00084877|Experimental|Treatment (triapine, irinotecan hydrochloride)|"Patients receive irinotecan IV over 1 hour on day 1 and 3-AP (Triapine®) IV over 2 hours on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of irinotecan and 3-AP (Triapine®) until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional patients are treated at that dose."
2419836|NCT03437239|Experimental|Occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy to include occlusion training.
2419837|NCT03437239|No Intervention|Non-occlusion Training|Patients undergoing a biceps tenodesis that are expected to begin a rehabilitation protocol with strength training by 6 weeks postoperatively for a continued 12 weeks course of 2-3 times per week of occupational therapy without occlusion training (standard of care).
2419838|NCT03437226|Experimental|Levosimendan Arm|Patients receive 6 or 24 hours infusion depending on the site. Levosimendan 2.5 MG/M 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Levosimendan 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Levosimendan
2419839|NCT03437226|Placebo Comparator|Placebo Arm|Patients receive 6 or 24 hours infusion depending on the site. 6h infusion group: 0,2 μg/kg/min 7 times (day 0, 14, 28, 42, 56, 70, 84) Placebo 24h infusion group: 0,1 μg/kg/min 5 times (day 0, 21,42,63,84) Placebo
2419840|NCT03437213|Experimental|Total intravenous anesthesia group|propofol, and fentanyl-based regimen.
2419841|NCT03437213|Active Comparator|Total intravenous plus block group|ultrasound guided paravertebral block before induction then propofol and fentanyl maintenance.
2419842|NCT03437200|Experimental|Arm A: Chemoradiation + Nivolumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT.~Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year."
2419843|NCT03437200|Experimental|Arm B: Chemoradiation + Nivolumab + Ipilimumab|Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year
2419844|NCT03437187|Other|Cholecystectomy without nerve blocks|Cholecystectomy, enteral and parenteral analgesics
2419845|NCT03437187|Placebo Comparator|Cholecystectomy with placebo nerve block|Cholecystectomy, NaCl as a placebo Quadratus lumborum block
2419846|NCT03437187|Active Comparator|Cholecystectomy with naropin nerve block|Cholecystectomy, Quadratus lumborum block with naropin
2419847|NCT03437161|Experimental|Radiation Therapy (RT)|Patients attend a simulation visit and undergo two CT scans, one in the prone position and one in the supine position with DIBH. Within 1 week after the simulation visit, patients undergo radiation therapy either in the supine position with DIBH or in the prone position daily for 15-30 consecutive days as per physician's prescription.
2419848|NCT03437148|Experimental|patients with Atrial septal defect type Ostium Secundum|patients with Atrial septal defect type Ostium Secundum, eligible for an interventional closure
2419849|NCT03437135||Witness patients|Healthy Volunteers
2419850|NCT03437135||Type 1 diabetic patients|patients with type 1 diabetes
2419851|NCT03437135||Type 2 diabetic patients|patients with type 2 diabetes
2419852|NCT03437122|Experimental|All|
2419853|NCT03437096|Other|venipuncture pain|pain during venipuncture
3145914|NCT00084903|Experimental|Fluorescence Spectroscopy|
3145915|NCT00084916|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145916|NCT00084981|Experimental|Treatment (decitabine, valproic acid)|"Patients receive decitabine IV over 1 hour on days 1-10 and oral valproic acid three times daily on days 5-21. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of decitabine and valproic acid until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. After the MTD is determined, an additional 6 patients are treated at that dose."
2419854|NCT03437083||Eribulin|Eribulin was administered at a dose of 1.4 milligrams per meters squared (mg/m^2) (as eribulin 1.23 mg/m^2) by a 2- to 5-minute intravenous infusion or as a diluted solution on Day 1 and Day 8 every 21 days.
2419855|NCT03437070|Experimental|TDO Dose Level|Trabectedin [T], Doxorubicin [D], and Olaratumab [O]
2419856|NCT03437057|Experimental|Patients treated with acethylsalicylic acid 250 mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with acetylsalicylic acid not suspended.
3145917|NCT00085111|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3145918|NCT00085124|Experimental|Arm I|"Remission induction therapy: Patients receive oblimersen IV continuously on days 1-10, cytarabine IV continuously on days 4-10, and daunorubicin IV on days 4-6.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive oblimersen IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive oblimersen IV continuously on days 1-8 and high-dose cytarabine IV over 3 hours on days 4-8. Patients with a continuing CR receive a second course of consolidation therapy."
3186585|NCT00746720|Experimental|B, 1|Study part 2 (n = 20)
2419863|NCT03437005|Experimental|Desonide 0.05%|Low potency steroid topical medication applied to specific locations on the face and extremities, twice daily for two weeks
2419864|NCT03437005|Experimental|Ketoconazole 2%|Antifungal topical medication applied to specific locations on the face and extremities, twice daily for two weeks
2419865|NCT03436992|Experimental|Women with type 1 diabetes|Women with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (Antioxidant cocktail, Resveratrol, or placebo)
2419866|NCT03436992|No Intervention|Healthy control women|Healthy women who participate will receive no intervention and serve as controls.
2419867|NCT03436992|Experimental|Men with type 1 diabetes|Men with type 1 diabetes will be randomly assigned to 1 of the 3 interventions (AOX cocktail, Resveratrol, or placebo)
2419868|NCT03436979||Subjects|Subjects who are undergoing surgical treatment for uterine prolapse will be included in the study and will be treated using the NeuGuide™ System.
2419869|NCT03436953|Experimental|CX-8998 T-type calcium channel blocker|
2419870|NCT03436953|Placebo Comparator|Comparator|
2419871|NCT03436940|Active Comparator|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
2419872|NCT03436940|Experimental|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
2419873|NCT03436927|Experimental|Nintendo Wii Fit|Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
2419874|NCT03436927|Experimental|Balance Trainer|Participants in the Balance Trainer group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
2419875|NCT03436927|No Intervention|Control|Patients in the 'Group III-control group' were included in the waiting list until the end of the study.
2419876|NCT03436914|Experimental|PPI|Esomezol®
2419878|NCT03436875||FH+|FH+ = having at least 1 parent with type 2 diabetes
2419879|NCT03436875||FH-|FH- = having no history of type 2 diabetes for two generations (parents and grandparents)
2419881|NCT03436849|Experimental|ESN364 dose-1 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
2419882|NCT03436849|Experimental|ESN364 dose-2 group in Part 1|Healthy male subjects will receive a single dose of ESN364.
2419883|NCT03436849|Placebo Comparator|Placebo group in Part 1|Healthy male subjects will receive a single dose of Placebo.
2419884|NCT03436849|Experimental|Male ESN364 group in Part 2|Healthy male subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2419885|NCT03436849|Experimental|Pre-menopausal female ESN364 group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2419886|NCT03436849|Experimental|Post-menopausal female ESN364 group in Part 2|Healthy post-menopausal female subjects will receive a single dose of ESN364 followed by washout period, then receive once daily dosing of ESN364 for 10 consecutive days at the same dose level.
2419887|NCT03436849|Placebo Comparator|Male placebo group in Part 2|Healthy male subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2419888|NCT03436849|Placebo Comparator|Pre-menopausal female placebo group in Part 2|Healthy pre-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2419889|NCT03436849|Placebo Comparator|Post-menopausal female placebo group in Part 2|Healthy post-menopausal female subjects will receive a single dose of Placebo followed by washout period, then receive once daily dosing of Placebo for 10 consecutive days.
2419890|NCT03436836|Experimental|Group N|"group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline.~Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study"
2419891|NCT03436836|Active Comparator|Group C|Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline
2419892|NCT03436823|Experimental|R.TMS + nurse semi-structured interview|Repeated Transcranial Magnetic Stimulation sessions associated with nurse semi-structured interview
2419893|NCT03436823|Sham Comparator|R.TMS + Music & Relaxation|Repeated Transcranial Magnetic Stimulation sessions associated with music listening & relaxation with eyes closed
3186586|NCT00746720|Placebo Comparator|B, 2|Study part 2 (n = 20)
3186587|NCT00746759||Standard of Care|
2419896|NCT03436784|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
2419897|NCT03436784|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
2419898|NCT03436771||JCAR017-treated|Patients who received previous treatment with JCAR017
2419899|NCT03436771||JCARH125-treated|Patients who received previous treatment with JCARH125
3186588|NCT00746772|Active Comparator|1|Patients with oral lichen planus
3186589|NCT00746772|Placebo Comparator|2|Patients with oral lichen planus
3186590|NCT00746811|Other|1|P-OM3 for the first six weeks of treatment. Placebo for the second six weeks of treatment.
3186591|NCT00746811|Other|2|Placebo for the first six weeks of treatment. P-OM3 for the second six weeks of treatment.
2419904|NCT03436719|Experimental|Oral with Intravenous|Oral metronidazole and erythromycine administration on the day before surgery with intravenous cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
2419905|NCT03436719|Active Comparator|Intravenous|Intravenous dose cefoperazone before surgery (30-90 min) and additional doses every third hour during surgery
2419906|NCT03436706||Participants|The cohort will consist of male and female children ages 11-12 accompanied by a participating parent over the age of 18 years. The family income of participants in this cohort cannot exceed 200% of the federal poverty level established in 2018.
2419907|NCT03436693|Experimental|Canagliflozin 100mg|
2419908|NCT03436693|Placebo Comparator|Placebo|
2419909|NCT03436680|Experimental|Group I (neurofeedback)|Participants complete at least neurofeedback training sessions over 30 minutes 2 times a week for up to 5 weeks.
2419910|NCT03436680|Active Comparator|Group II (standard of care)|Participants receive standard of care.
2419911|NCT03436667||Orthopedic surgery|Pediatric patients presenting for ambulatory orthopedic procedures
3186592|NCT00746824|Experimental|1|"AM dose: 0.85 mg~PM dose: placebo"
3186593|NCT00746824|Experimental|2|"AM dose: 0.85 mg~PM dose: 0.85 mg"
2419914|NCT03436628|Experimental|App Use|Kids (10-15 years old) with type 1 diabetes and one of their parents will receive the MyT1DHero app to use for a 3-month period. Participants are urged to use the app four times each day.
2419915|NCT03436615|Experimental|SB206 4%|SB206 4% topically twice daily
2419916|NCT03436615|Experimental|SB206 8%|SB206 8% topically twice daily
2419917|NCT03436615|Experimental|SB206 12%|SB206 12% topically once or twice daily
2419918|NCT03436615|Placebo Comparator|Placebo (vehicle gel)|Vehicle Gel topically once or twice daily
2419919|NCT03436602||Training cohort|Cohort of follicular lymphoma patients for the development of the multilayer risk stratification model
2419920|NCT03436602||Validation cohort|Cohort of follicular lymphoma patients for the validation of the developed multilayer risk stratification model
2419921|NCT03436589|No Intervention|Control Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group. The control group participants received no lessons. Control group participants received the same study assessments at the same timepoints as the intervention group. The control group participants may have had limited contact with the nutrition educators only to update contact information, to set or remind of appointments to complete study assessments, or to receive non-nutrition or non-resource management resources.
2419922|NCT03436589|Experimental|Intervention Group|Participants who met eligibility requirements and agreed to be randomly allocated to a treatment group.The Intervention group participants received lessons from the nutrition educators, completed the same study assessments at the same timepoints as the control group, and may have had additional interaction with the nutrition educators in accordance with normal Indiana SNAP-Ed protocol.
2419923|NCT03436576|Active Comparator|Autologous Serum 20%|Treatment with Autologous Serum 20% for 2 months
2419924|NCT03436576|Active Comparator|Autologous Serum 50%|Treatment with Autologous Serum 50% for 2 months
2419925|NCT03436563|Experimental|Treatment (M7824)|Patients receive M7824 IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity (Cohorts A,B, and C) or for six doses in patients with detectable circulating tumor DNA (ctDNA) following resection of all known liver metastases (Cohort D).
2419928|NCT03436537||Gingival recession (GR) group|GR group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
2419929|NCT03436537||Gingival enlargement (GE) group|GE group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
2419930|NCT03436537||periodontal healthy (H) group|H group answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale.
3186594|NCT00746824|Experimental|3|"AM dose: 2.55 mg~PM dose: placebo"
3186595|NCT00746824|Experimental|4|"AM dose: placebo~PM dose: 2.55 mg"
3186596|NCT00746824|Experimental|5|"AM dose: 2.55 mg~PM dose: 2.55 mg"
3186597|NCT00746824|Experimental|6|"AM dose: placebo~PM dose: placebo"
3186598|NCT00746837|Experimental|1|Single ascending IV dose, 3 treatment periods separated by a minimum 14 day washout between doses
3186599|NCT00746837|Experimental|2|2 cohorts single IV dose + multiple oral dose period separated by a minimum of 14 days washout between IV and oral dose
2419931|NCT03436524||Training cohort|Cohort of chronic lymphocytic leukemia patients at Binet A stage for the development of the risk stratification model
2419932|NCT03436524||Validation cohorts|Cohorts of chronic lymphocytic leukemia patients at Binet A stage for the validation of the risk stratification model
2419933|NCT03436511||Subjects with COPD|Subjects with a COPD diagnosis confirmed with a post-bronchodilator Forced Expiratory Volume in 1 second/Forced Vital capacity <70% recorded at any time in the medical record who have a qualifying peripheral blood eosinophil test recorded in the 3 months prior to the inclusion visit attend to a routine follow-up visit during the inclusion period, fulfill the inclusion/exclusion criteria and provide informed consent to participate, will be included in this study.
2419934|NCT03436498|Experimental|SAR341402/NovoLog|SAR341402 will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of SAR341402 as treatment, patient will switch with NovoLog® as treatment.
2419935|NCT03436498|Experimental|NovoLog/SAR341402|Novolog will be self-administered via continuous subcutaneous insulin infusion via an insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion. After 4 weeks of NovoLog® as treatment, patient will switch with SAR341402 as treatment.
3186600|NCT00746850|Experimental|H|early LC within 72 hours after the diagnosis with H (Harmonic)
3186601|NCT00746850|Active Comparator|MD|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)
2419938|NCT03436472|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
2419939|NCT03436472|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
2419940|NCT03436459|Active Comparator|Extracorporeal shock wave therapy group|Patients in the shock wave therapy group received total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute by using BTL-6000 SWT Topline Power® 3 times with a week's interval between the treatments.
2419941|NCT03436459|Active Comparator|Low Level Laser Therapy group|Patients in the laser therapy group received LLLT once a day for three weeks (altogether 15 working days) to the trigger points and around them in the upper trapezius. The type of laser used: PR999 4 Watt (W) scanning laser; Medical Italia®, around trigger points with 3 Joule /centimeter² (J/cm²), power 800 milliwatt (mW), frequency 2000 Hertz (Hz), on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot.
2419942|NCT03436446||Orthopedic Patients|Orthopedic patients will undergo an interview with the research team regarding the framing of various social incentives to promote increased response rates for patient reported outcome measures post-operatively.
2419947|NCT03436407||PrEP Group|Subject offered to start PrEP treatment in routine clinical practice
2419948|NCT03436407||Control Group|"Enrolled patients will be regarded as their own control when it comes to their sexual health and quality of life reported for period prior to inclusion in the study.~Subjects diagnosed with HIV within last 12 months in general clinical practice and referred to the outpatient clinic at the Dept. of Infectious Diseases, OUS. (details in protocol 3.3.2)~Frequency of STI reported to the National Institute of Public Health (MSIS) will be compared with the frequency of STIs in the study cohort."
2419949|NCT03436394|Experimental|Evobrutinib: Normal Renal Function|Subjects with estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter per minute per 1.73 meter square (mL/min/1.73 m^2) will receive a single oral dose of evobrutinib under fasting conditions.
2419950|NCT03436394|Experimental|Evobrutinib: Severe Renal Impairment|Subjects with eGFR less than (<) 30 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2419951|NCT03436394|Experimental|Evobrutinib: Moderate Renal Impairment|Subjects with eGFR >= to 30 mL/min/1.73 m^2 and < 60 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2419952|NCT03436394|Experimental|Evobrutinib: Mild Renal Impairment|Subjects with eGFR >= to 60 mL/min/1.73 m^2 and < 90 mL/min/1.73 m^2 will receive a single oral dose of evobrutinib under fasting conditions.
2419953|NCT03436381||Overweight and obese patients|Patient undergoing elective upper endoscopy or colonoscopy, body mass index equal or greater than 25 kg/m2.
2419954|NCT03436368|Active Comparator|CSA group|Continuous Spinal Anesthesia
2419955|NCT03436368|Active Comparator|GA group|General Anesthesia
2419956|NCT03436355|Experimental|Physical activity|60 minutes of daily physical activity (see intervention)
2419957|NCT03436342|Experimental|68Ga-Pentixafor, PET/CT|Inject 68Ga-Pentixafor and then perform PET/CT scan.
2419958|NCT03436329|Experimental|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
2419959|NCT03436329|Active Comparator|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
2419960|NCT03436316|Experimental|SAD Cohort 1 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 1) and 2 participants will receive placebo.
2419961|NCT03436316|Experimental|SAD Cohort 2 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 2) and 2 participants will receive placebo.
2419962|NCT03436316|Experimental|SAD Cohort 3 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 3) and 2 participants will receive placebo.
2419963|NCT03436316|Experimental|SAD Cohort 4 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 4) and 2 participants will receive placebo.
2420011|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 1|Intervention: One dose pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2419964|NCT03436316|Experimental|SAD Cohort 5 (Part 1)|"6 Participants will receive AZD8154 (single inhaled small particle dose 5) and 2 participants will receive placebo.~Participants in this Cohort will return for a second Treatment Period after a minimum washout period of 7 to 14 days. All 6 subjects will receive an inhaled dose of AZD8154 (large particle size)."
2419965|NCT03436316|Experimental|SAD Cohort 6 (Part 1)|6 Participants will receive AZD8154 (single inhaled small particle dose 6) and 2 participants will receive placebo.
2419966|NCT03436316|Experimental|Cohort 1 (Part 2)|All participants in this cohort will receive single IV dose of AZD8154 in Treatment Period 1 and then after washout period, will receive inhaled AZD8154 (small particle size) in Treatment Period 2.
2419967|NCT03436316|Experimental|MAD Cohort 1 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 8) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 8) or placebo once daily from Day 4 to Day 12.
2419968|NCT03436316|Experimental|MAD Cohort 2 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 9) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (Inhaled dose 9) or placebo once daily from Day 4 to Day 12.
2419969|NCT03436316|Experimental|MAD Cohort 3 (Part 3)|6 Participants will receive AZD8154 (single inhaled dose 10) and 2 participants will receive placebo on Day 1. Participants will then receive multiple dosing of AZD8154 (inhaled dose 10) or placebo once daily from Day 4 to Day 12.
2419970|NCT03436303|Experimental|CEE 0.625 mg/MP 100mg|CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
2419971|NCT03436303|Experimental|CEE 0.3 mg/MP 100mg|CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years
2419972|NCT03436303|Experimental|CEE 0.625 mg/dydrogesterone 10mg|CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years
3186602|NCT00746876|Active Comparator|Unipolar|15 patients randomized for treatment with a unipolar hip hemiarthroplasty
3186603|NCT00746876|Active Comparator|Bipolar|15 patients randomized for treatment with a bipolar hip hemiarthroplasty
2419975|NCT03436277|Placebo Comparator|Placebo|Sucralose 1,5 g
2419976|NCT03436277|Experimental|L-Carnitine|L- Carnitine 1,5 g
2419977|NCT03436264||high sensitivity to pain|
2419978|NCT03436264||low sensitivity to pain|
2419979|NCT03436251|Experimental|Local Hyperthermia at 44℃ for HPV+/CIN-1|Local hyperthermia at 44℃ for 30 mins on cervical region, at days of 1,2,3 and 17, 18. HPV+ and normal cytology or HPV+/CIN-1
2419980|NCT03436251|Sham Comparator|local hyperthermia at 37℃ for 30 mins|HPV+/CIN-1
2419981|NCT03436251|Active Comparator|coniztion of the cervix treatment|coniztion of cervix for HPV+/CIN2, including LEEP or cold knife coniztion
2419982|NCT03436251|Experimental|Local Hyperthermia at 44℃ for CIN2/HPV+|Local hyperthermia at 44℃ for 30 mins at days of 1,2,3 and 17, 18. HPV+ and CIN2.
3186604|NCT00746902|Active Comparator|1|Arm 1: Active CPAP, a nasal continuous positive airway pressure
2419984|NCT03436225|Other|Group one|Group one will receive dexamethasone orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
2419985|NCT03436225|Other|Group two|Group two will receive dexamethasone parenteral (0.15mg /kg /dose) twice daily for 3 to 5 days.
2419986|NCT03436225|Other|Group three|Group three will receive inhaled nebulized budesonide (1 mg/2ml) twice daily for 3 to 5 days.
2419987|NCT03436225|Other|Group four|Group four will receive symptomatic treatment in form of inhaled nebulized salbutamol(0.15mg/kg/ dose) daily every 6-8 hours.
2419988|NCT03436212|Other|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device for 14 days
2419992|NCT03436186||no arm|no arm
2419993|NCT03436173|Experimental|Fluoxetine|Fluoxetine 10 mg/2.5 ml
2419994|NCT03436173|Placebo Comparator|Placebo|Peppermint syrup measured to equivalent volume
2419995|NCT03436160|Experimental|WR826647|100 mcg Carbon-14 radio labeled WR826647 administered via IV
2419996|NCT03436160|Experimental|WR909388|100 mcg Carbon-14 radio labeled WR909388 administered via IV
2419997|NCT03436160|Experimental|WR909390|100 mcg Carbon-14 radio labeled WR909390 administered via IV
3186605|NCT00746902|Sham Comparator|2|Arm 2 : Sham CPAP :Placebo/CPAP
3186606|NCT00746967|Other|Arm 1|
2420000|NCT03436134|Active Comparator|Plasma Exchange Group|Patients receiving Exchange plasma as a treatment of chronic antibody mediated rejection.
2420001|NCT03436134|Experimental|Double filtration PlasmaPheresis Group|Patients receiving double filtration plasmapheresis as a treatment of chronic antibody mediated rejection.
2420002|NCT03436121|Experimental|Experimental Arm|Participants will be assigned to receive a single dose of IV ketamine (0.3 mg.kg) + midazolam
2420003|NCT03436121|Active Comparator|Active Placebo Arm|Participants will be assigned to receive a single dose of IV placebo + midazolam
2420004|NCT03436108||PCOS group|patients who have PCOS
2420005|NCT03436108||control group|patients who donnot have PCOS
2420006|NCT03436095||research group|bundle measures to help patient to weaning ventilator
2420007|NCT03436095||historical control group|retrospect the patients who were difficult to wean from ventilator and collect some materials to compare.
2420008|NCT03436095||External control group|contrast other same level hospitals measures to patients who are difficult to wean ventilator.
3186607|NCT00746980|Experimental|Treatment|Subjects receiving drug
3186608|NCT00746993|Experimental|1|Structured contraceptive counseling and routine care.
2420053|NCT03435809|Active Comparator|Pozzi for intrauterine insemination|Treatment done with a pozzi tenaculum forceps
3186609|NCT00746993|No Intervention|2|Routine care.
3186610|NCT00747019|Experimental|PBPA|
3186611|NCT00747019|Active Comparator|PE|
3186612|NCT00747032|Active Comparator|1|NYC 0462 Ointment
3186613|NCT00747032|Placebo Comparator|2|Placebo
3186614|NCT00747045|Experimental|Low tidal volume|Tidal volume of 6 mL/Kg ideal body weight
3186615|NCT00747045|Active Comparator|Usual care|Tidal volume of 10 mL/Kg ideal body weight
2420012|NCT03436056|Other|Dose escalation cohort - DOSE LEVEL 2|Intervention: One dose of pembrolizumab 200 mg (week 1) followed by lung Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#) in week 3. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2420013|NCT03436056|Other|Part B - Expansion cohort|Intervention: One dose of pembrolizumab 200 mg (week 1) followed in by lung Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose determined in Part A in week 3, dosed at the maximum tolerated dose determined in Part A. Treatment with pembrolizumab 200 mg will be continued given every 3 weeks.
2420014|NCT03436043|Experimental|Transmural stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks followed by transmural plastic stenting in the residual cavity.
2420015|NCT03436043|No Intervention|No stenting|In patients of walled off necrosis with disconnected pancreatic duct syndrome, metal stent will be removed at 3-4 weeks without any further intervention.
2420016|NCT03436030|Experimental|Single arm, breathing manuevers|All subjects perform/undergo Valsalva, Muller, CPAP, hand grip, and passive leg raise, with ultrasound examination of heart recorded before and during the manoeuvre.
2420017|NCT03436017||ADHD|Patient with ADHD diagnosis criterion. The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach
2420018|NCT03436017||non ADHD|"Patient with symptom of hyperactivity and/or attention deficiency but without ADHD diagnosis criterion.~The aim is the identification of Biomarkers of ADHD by a Metabolomic Approach."
2420019|NCT03436004|Experimental|Experimental|Colonoscopy with specific device with CE marking (Endocuff Vision)
2420020|NCT03436004|Active Comparator|Active Comparator|Colonoscopy with standard device of the center
2420021|NCT03435991||OAB patients|
2420022|NCT03435991||Healthy volunteers|
2420023|NCT03435978||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
2420024|NCT03435978||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
2420025|NCT03435965||PPROM from 20- less than 28 weeks|pregnant ladies with PROM from 20 - 28 weeks
2420026|NCT03435965||PROM from more than 28 weeks - less than 37 weeks|pregnant ladies with PROM from more than 28- less than37 weeks
2420027|NCT03435965||control group pregnant ladies in labour after 37 weeks|control group pregnant ladies in labour after 37 weeks with rupture of membrane in labour or in cs
2420028|NCT03435952|Experimental|Pembrolizumab + Clostridium novyi-NT|"Participants receive Pembrolizumab by vein over about 30 minutes on Day 0 and then every 3 weeks for up to 12 months.~Clostridium novyi-NT injected into the tumor on Day 8.~Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT"
3186616|NCT00747058|Experimental|healthy volunteers|
2420030|NCT03435913|Experimental|Standard PEEP ventilation|During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and 5 cmH20 of PEEP at every intra-abdominal pressure (IAP) step (8, 12 and 15 mmHg).
2420031|NCT03435913|Experimental|Matched PEEP Ventilation|"During pneumoeperitoneum insufflation the patient is ventilated with 7 ml/kg per ideal body weight, inspiration:expiration (I:E) ratio 1:2, and respiration rate (RR) to maintain EtCO2 at 35-38 mmHg and a level of PEEP matched to every IAP step (8, 12 and 15 mmHg).~1 mmHg = 1,36 cmH20.~Between the standard and matched PEEP intervention there is a washout period that with a recruitment maneuver to re-establish baseline lung condition."
2420032|NCT03435900|Experimental|Intervention group|
2420033|NCT03435900|Active Comparator|Control group|
2420034|NCT03435887|Active Comparator|Alere q HIV-1/2 Detect for point of care infant testing|POC testing with Alere q HIV-1/2 Detect at birth and 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
2420035|NCT03435887|Active Comparator|GeneXpert HIV-1 Qual for point of care infant testing|POC testing with GeneXpert HIV-1 Qual at-birth and at 6-weeks postnatal in parallel with standard of care HIV DNA PCR testing
2420036|NCT03435874|Experimental|Group 1 Active|n=6. Age 18-35 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 at D56.
2420037|NCT03435874|Placebo Comparator|Group 1 Comparator|n=3. Age 18-35 years. Rabies vaccine at D0 and D56.
2420038|NCT03435874|Experimental|Group 2a Active|n=6. Age 1-6 years. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
2420039|NCT03435874|Placebo Comparator|Group 2a Comparator|n=3. Age 1-6 years. Rabies vaccine at D0 and D56.
2420040|NCT03435874|Experimental|Group 2b Active|n=12. Age 1-6 years. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
2420041|NCT03435874|Placebo Comparator|Group 2b Comparator|n=6. Age 1-6 years. Rabies vaccine at D0 and D56.
2420042|NCT03435874|Experimental|Group 3a Active|n=6. Age 6-11 months. 1x10 10 vp ChAd63 RH5 at D0 and 1x10 8 pfu MVA RH5 D56.
2420043|NCT03435874|Placebo Comparator|Group 3a Comparator|n=3. Age 6-11 months. Rabies vaccine at D0 and D56.
2420044|NCT03435874|Experimental|Group 3b Active|n=12. Age 6-11 months. 5x10 10 vp ChAd63 RH5 at D0 and 2x10 8 pfu MVA RH5 D56.
2420045|NCT03435874|Placebo Comparator|Group 3b Comparator|n=6. Age 6-11 months. Rabies vaccine at D0 and D56.
2420046|NCT03435861|Experimental|VX-745|In the present study, VX-745 will be given at the dosage of 40 mg twice a day (1 tab. of 40 mg, twice), orally for 12 weeks
2420047|NCT03435861|Placebo Comparator|placebo|In the present study, placebo will be given twice a day (1 tab. , twice), orally for 12 weeks
2420048|NCT03435848|Experimental|BST-236|BST-236 Intravenous, 4.5 g/m2/d or 2.5 g/m2/d, for 6 days
2420049|NCT03435835|Sham Comparator|Thermoneutral|Participants will be dressed in water-circulating trousers that are connected to a pump. Water at 33ºC will be circulated through the pants for 80 minutes.
2420050|NCT03435835|Active Comparator|Heat Therapy|Participants will be dressed in water circulating trousers that are connected to. Warm water (42-43ºC) will be circulated through the pants for 80 minutes.
2420051|NCT03435822|Other|asthma action plan management group|Patients in this group will be provided both written asthma action plan and mobile-based APP to remind them take medicine regularly and direct them what to do when asthma get worse.
2420052|NCT03435822|Other|conventional management group|Patients in this group will be provided conventional management method with prescriptions and asthma diaries.
3186617|NCT00747058|Placebo Comparator|Placebo|
2420054|NCT03435809|Active Comparator|No Pozzi for intrauterine insemination|Treatment done without a tenaculum forceps
2420055|NCT03435796|Other|Subjects exposed to Gene-modified (GM) T cell therapy|Subjects will be followed for 15 years from the last GM T cells infusion until withdrawal of consent, lost to follow-up, or death, whichever occurs first. Annual safety assessments will be conducted every 6 months during the first 5 years from the date of last GM T cell infusion. Laboratory evaluations and safety assessments will be conducted during this period. After 5 years, subjects will continue to be followed yearly. During the trial, pediatric subjects will be monitored for growth, development and sexual maturity. Stage 5 per Tanner Staging Criteria must be reached prior to study discontinuation.
2420058|NCT03435770|Experimental|EUSRA RFA needle|This procedure is very similar to the standard technique of EUS-guided fine needle aspiration. All patients would undergo EUS with a linear array or therapeutic echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the EUSRA RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue.
2420059|NCT03435757|Experimental|Test Group OFD+IMP+CPS|OFD+IMP+CPS; open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty (CPS)
2420060|NCT03435757|Active Comparator|Control group (OFD+IMP)|OFD+IMP;open flap debridement (OFD) and intramarrow penetration (IMP)
2420061|NCT03435744|Experimental|Simvastatin with TAU|Participants will receive Simvastatin 20 mg added to TAU for 3 months
2420062|NCT03435744|Placebo Comparator|Placebo Oral Tablet with TAU|Participants will receive placebo added to TAU for 3 months
2420063|NCT03435731|Experimental|Treatment Group|This group will undergo 1 month Dual Therapy.
2420064|NCT03435718|Experimental|OXF6|Patients receive a single 6 mg/kg dose of oxfendazole administered orally.
2420065|NCT03435718|Experimental|OXF15|Patients receive a single 15 mg/kg dose of oxfendazole administered orally.
2420066|NCT03435718|Experimental|OXF30|Patients receive a single 30 mg/kg dose of oxfendazole administered orally.
2420067|NCT03435718|Experimental|OXF15x3|Patients receive a 15 mg/kg dose of oxfendazole administered orally once a day for each of three consecutive days.
2420068|NCT03435718|Active Comparator|ALB400|Patients receive a single 400 mg/kg dose of albendazole administered orally.
2420069|NCT03435705|Experimental|intervention arm|maintaining of occupational therapy for a 4 months period
2420070|NCT03435705|No Intervention|control arm|usual care after the end of the recommended initial program
3145919|NCT00085124|Experimental|Arm II|"Remission induction therapy: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on days 1-3.~Patients who achieve CR proceed to consolidation therapy. Patients who do not achieve CR receive a second course of induction therapy.~Second remission induction therapy: Patients receive cytarabine IV continuously on days 1-5 and daunorubicin IV on days 1 and 2.~Patients who achieve CR proceed to consolidation therapy.~Consolidation therapy: Patients receive high-dose cytarabine IV over 3 hours on days 1-5. Patients with a continuing CR receive a second course of consolidation therapy."
3145920|NCT00085189|Experimental|Cohort I (melanoma peptide vaccine, Montanide ISA-51)|Patients receive multi-epitope peptide melanoma peptide vaccine with incomplete Freund's adjuvant and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
3145921|NCT00085189|Experimental|Cohort II (melanoma peptide vaccine, Montanide ISA 51 VG)|Patients receive multi-epitope peptide melanoma peptide vaccine with Montanide ISA 51 VG and agatolimod sodium SC at 0, 2, 4, 6, 8, 10, 14, 18, 22, 26, 38, and 50 weeks and then every six months for two years for up to 16 vaccinations in the absence of disease progression or unacceptable toxicity.
2420074|NCT03435679|Experimental|one-stage|one-stage surgical treatment of the infected knee arthroplasty
2420075|NCT03435679|Active Comparator|two-stage|two-stage surgical treatment of the infected knee arthroplasty with a interim period of 8-10 weeks between stages
2420076|NCT03435666|Experimental|Capecitabine|Capecitabine is the test product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) Capecitabine.
2420077|NCT03435666|Active Comparator|XELODA|XELODA is the reference product.In period 1, period 2 and period 3, 13 of 39 Subjects were given Single oral dose (1250 mg/m2) XELODA.
2420078|NCT03435653|Active Comparator|Control group|Control group OFD with DFDBA
2420079|NCT03435653|Experimental|Test group|Test group OFD with decortication and DFDBA
3145922|NCT00085280|Experimental|Treatment (erlotinib hydrochloride)|"Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Patients complete the Smoking Status Survey, a questionnaire regarding smoking habits, at baseline, and then every 3 months during study treatment."
3145923|NCT00085306|Experimental|Recombinant interferon beta|
2420082|NCT03435627||Norditropin® (naïve participants)|The treatment period of Norditropin® for naïve participants will be up to 208 weeks.
2420083|NCT03435627||Norditropin® (non-naïve participants)|The treatment period of Norditropin® for non-naïve participants will be up to 442 weeks.
3145924|NCT00085358|Experimental|Treatment (carboplatin, paclitaxel, docetaxel, bevacizumab)|"Patients receive IP carboplatin on day 1, and paclitaxel IV over 3 hour (part A) or docetaxel IV over 1 hour (Part B) on day 1, and IP paclitaxel on day 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients receive IP carboplatin on day 1, paclitaxel IV on day 1, and IP paclitaxel on day 8 in course 1 as in part A dose-escalation phase. Beginning in course 2 and all subsequent courses, patients receive IP carboplatin on day 1, IV paclitaxel on day 1, and IP paclitaxel on day 8 as in the dose-escalation phase, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3145925|NCT00085371|Experimental|Treatment (triapene)|Patients receive triapene IV over 2 hours on days 1-4 and 15-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3145926|NCT00085384|Experimental|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
3145927|NCT00085384|Experimental|Arm II|Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
3186618|NCT00747071|Experimental|1|Hospitalized patients with Clostridium difficile associated diarrhea.
2420085|NCT03435601|Experimental|Anifrolumab|Anifrolumab 300 mg IV administration Q4W, a total of 6 doses
2420086|NCT03435601|Placebo Comparator|Placebo|Placebo IV administration Q4W, a total of 6 doses
2420087|NCT03435588|Active Comparator|EUS-FNA with ROSE|EUS-FNA with ROSE is performed with a 22 or 25 gauge FNA needle. The sampled specimen is expressed into a glass slide with a stylet; then using another glass slide the sample is spread out to make smears on two slides. Each pair of slides is then numbered according to their respective needle passes. One slide is air dried and stained with modified Giemsa stain for ROSE, while the other slide is fixed in 95% ethanol and later coated with with Papanicolaou stain.
2420088|NCT03435588|Experimental|EUS-FNB alone|EUS-FNB is performed with a 22 or 25 gauge Core-needle. Tissue sampling technique is standardized between the endoscopists. Two passes are performed using the core needle. The biopsied samples are then expressed using a stylet into a jar filled with 10% formalin. A third pass is allowed if, on macroscopic inspection of the acquired sample, the specimen is deemed insufficient by the endoscopist.
2420089|NCT03435575|Active Comparator|Intervention group|Children in the intervention group will receive Boosth: Boosth activity tracker, Boosth syncc app and Boosth game app
2420090|NCT03435575|No Intervention|Control group|Standard care
3186619|NCT00747071|Experimental|2|Close hospital contacts of each index case
2420092|NCT03435549|No Intervention|Arm 1: Control Arm (Usual care)|If Patient is randomized to Arm 1, no contact will occur, patient will receive standard and routine clinical care
2420093|NCT03435549|Experimental|Arm 2a: Remote monitoring|If Patient is randomized to Arm 2a they will remote monitoring for 6 weeks post-surgery
2420094|NCT03435549|Experimental|Arm 2b: Remote monitoring plus goal setting and social support|If Patient is randomized to Arm 2b, they will receive a remote monitoring plus social support and nudge messaging for 6 weeks post-surgery
2420095|NCT03435536|Experimental|Circulating tumor DNA|circulating tumor DNA rate at various times of pancreatic cancer resection
2420096|NCT03435523|Experimental|Open lung approach|Recruitment maneuver during OLV in thoracic surgery
3186620|NCT00747084|Experimental|Arm 1: Study Treatment|Study Treatment: warm water loading of the sigmoid colon and warm water irrigation for dealing with colonic spasms.
3186621|NCT00747084|No Intervention|Arm 2: Control Treatment|Control Treatment: no water loading and waiting for spasms to subside.
2420100|NCT03435484|Active Comparator|Arm A|Participants in this group will receive one version (out of two) of instructions for completing the Health Assessment Questionnaire.
2420101|NCT03435484|Active Comparator|Arm B|Participants in this group will receive another version (out of two) of instructions for completing the Health Assessment Questionnaire.
2420102|NCT03435471|Experimental|G1 - Clinician-Directed Therapy|"Clinician-Directed Weekly Swallowing Therapy: Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises and review the home swallowing exercise program. Each session will last 30 minutes +/- ten minutes. Other assessments include:~Clinician-Directed Prophylactic Swallowing Exercises~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~DIGEST Safety Grade"
2420103|NCT03435471|Active Comparator|G2 - Patient-Directed Home Therapy|"Patient-Directed Home Swallowing Therapy: One face-to-face meeting with a study speech pathologist prior to initiation of treatment. During that session, they will be encouraged to practice the given exercises independently on a specific daily schedule regime throughout their treatment. Other assessments include:~Prophylactic Swallowing Home Exercise Program~Penetration/Aspiration Scale (PAS)~Functional Oral Intake Scale (FOIS)~Eating Assessment Tool-10 (EAT-10)~University of Washington Quality of Life (UW-QOL)~Performance Status Scale for Head and Neck Cancer Patients (PSS-HN)~DIGEST Safety Grade"
2420104|NCT03435458|Experimental|Balloon catheter + oral misoprostol|
2420105|NCT03435458|Active Comparator|Oral misoprostol alone|
2420106|NCT03435445|Experimental|Online platform group|Online platform with diet, physical activity and behavior change recommendations for 24 weeks
2420107|NCT03435445|Experimental|Online dietitian coaching|Diet, physical activity and behavior change recommendations for 24 weeks and online sessions with a dietitian specialist for 12 weeks
2420108|NCT03435445|Active Comparator|Control group|Videos with diet, physical activity and behavior change recommendations for 24 weeks
2420109|NCT03435432|Active Comparator|Glucose|50 grams of glucose in 50 ml water
2420110|NCT03435432|Placebo Comparator|Water|50 ml water
2420229|NCT03434483||Chronic coronary atherosclerosis|Patients with chronic atherosclerosis. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
3186622|NCT00747097|Experimental|1|gemcitabine+cetuximab
3186623|NCT00747110|Experimental|A|9mg budesonide OD
3186624|NCT00747110|Active Comparator|B|3g mesalazine OD
3186625|NCT00747123|Placebo Comparator|Placebo|Subcutaneous injection on days 1, 29, 57 and 85.
3186626|NCT00747123|Experimental|ACE-011 0.1 mg/kg|Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3186627|NCT00747123|Experimental|ACE-011 0.3 mg/kg|Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3186628|NCT00747123|Experimental|ACE-011 0.5 mg/kg|Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).
3186629|NCT00747162|Experimental|1|We will use The INVOS cerebral oximeter to determine oxygen content in the healthy muscle. In addition, we will use a the DermaSpectrometer to determine if there are differences in our readings according to skin color.
2420111|NCT03435419||CL suspects|"Individuals with suggestive signs of cutaneous leishmaniasis presenting themselves at the National Malaria & Leishmaniasis Control Program (NMLCP) Leishmaniasis clinic in Kabul, Afghanistan.~These will be tested by diagnostic tests under evaluation:~i) LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection ii) CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection And their performance compared against a reference combining microscopy and PCR."
2420112|NCT03435406||cirrhosis with HPS|Diagnosed as HPS
2420113|NCT03435406||cirrhosis without HPS|Not Diagnosed as HPS
2420114|NCT03435380|Experimental|Control (C)|Targeted mailed educational materials (C).
2420115|NCT03435380|Experimental|Patient activation (PA)|C + patient activation (PA) consisting of (1) smartphone app with HIPAA compliant survivorship care plan that can be viewed, printed, or emailed to their primary care provider; and (2) two-way (interactive) tailored text messages with links to video vignettes discussing the primary barriers to breast MRI and mammography.
2420116|NCT03435380|Active Comparator|Patient activation + primary care provider activation (PA+PCP)|C + PA + PCP activation (PA+PCP) with physician materials about breast cancer risk in this population along with national and international guidelines for breast cancer surveillance.
2420117|NCT03435367|Experimental|Intervention Group (VR)|The patient will be allowed to 'try-out' the VR system (including all auditory and visual features) for ~5 minutes prior to the start of the procedure. In addition to usual care, consisting of child-life presence and topical analgesics if ordered by the treating medical team, children in the experimental condition will wear the VR HMD plus headphones and hold the VR controller.
2420118|NCT03435367|Active Comparator|Control Group (Standard Care - Video)|The patient will be allowed to watch an age-appropriate video on a tablet device. The patient will be offered to wear the same headphones as in the experimental condition. The patient will have the tablet and headphones for ~5 minutes prior to the start of the procedure. In addition, the patient will receive standard care consisting of a child life specialist and topical analgesics (if ordered by the treating medical team).
2420119|NCT03435354|Experimental|Intervention|Physical activity counselling during cardiac clinic visit with additional supports for community physical activity and access to a kinesiologist.
2420120|NCT03435354|No Intervention|Usual Care|Cardiac clinic visit with usual care but no physical activity counselling
2420121|NCT03435341||Patients diagnosed with AML|The study population will consist of approximately 150 patients over 60 with AML diagnosis according to WHO 2016 criteria.
2420122|NCT03435328|Experimental|TENS intervention|"one group receiving TENS:~- The electrode of TENS unit will be placed vertically, externally on skin overlying the parotid gland, in the preauricular area bilaterally, 1 cm in front of the tragus area."
2420123|NCT03435315|Active Comparator|Treadmill exercise|
2420124|NCT03435315|Experimental|Treadmill exercise with behavioral techniques|
2420125|NCT03435302|Experimental|Temozolomide Plus Cisplatin|per os 200 mg/m^2/d temozolomide on days 1 to 5 plus i.v. 75 mg/m^2 cisplatin divided into 3 days,which was repeated every 3 weeks for six cycles
2420126|NCT03435302|Active Comparator|High-Dose IFN-a2b|Participants will be treated with i.v. 15×10^6U/m^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10^6U IFN- a2b three times per week for 48 weeks.
2420127|NCT03435289|Other|CPI-613, Gemcitabine and Nab-paclitaxel|CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
2420128|NCT03435276|Experimental|Cohort 1|Randomized subjects will receive AZD9977 50 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose Day 2 to Day 7
2420129|NCT03435276|Experimental|Cohort 2|Randomized subjects will receive AZD9977 150 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
2420130|NCT03435276|Experimental|Cohort 3|Randomized subjects will receive AZD9977 300 mg or placebo oral suspension single dose on Day 1 and Day 8; twice daily dose on Day 2 to Day 7
2420131|NCT03435263||hospital admission group B|Women presented with premature rupture of membranes will be admitted at hospital.
2420132|NCT03435263||home management group A|home management
2420133|NCT03435250|Experimental|AG-270|AG-270 will be administered on Days 1 to 28 of each 28-day cycle. Treatment will continue until disease progression or unacceptable toxicity.
2420134|NCT03435250|Experimental|AG-270/docetaxel|AG-270 will be administered daily, starting 1 week prior to docetaxel infusion. Starting on Cycle 1 Day 1, docetaxel (by intravenous infusion [IV]) will be administered once during each 21-day cycle. Treatment with AG-270 and docetaxel will continue until disease progression or unacceptable toxicity.
2420135|NCT03435250|Experimental|AG-270/nab-paclitaxel/gemcitabine|AG-270 will be administered daily, starting 1 week prior to nab-paclitaxel and gemcitabine infusion. Starting on Cycle 1 Day 1, nab-paclitaxel and gemcitabine IV will be administered on Days 1,8, and 15 during each 28-day cycle. Treatment with AG-270, nab-paclitaxel, and gemcitabine will continue until disease progression or unacceptable toxicity.
3186630|NCT00747175|Experimental|1|3 (alt.4) gradually increasing repeated oral doses of AZD1656 given to 3 (alt.4) groups (6 on active and 2 on placebo in each group)
3186631|NCT00747175|Experimental|2|Oral dose of AZD1656 titrated during 3 days to a tolerable dose (15 on active and 5 on placebo)
3186632|NCT00747188|Experimental|2|
3186633|NCT00747188|No Intervention|A, 2, III|
2420140|NCT03435172|Experimental|Treatment Group|Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.
2420141|NCT03435172|No Intervention|Usual Care|Standard care of split thickness meshed skin graft (STSG) will be used.
2420231|NCT03434444|Active Comparator|Low Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M)
2420232|NCT03434444|Active Comparator|Propranolol|The myometrial samples are bathed in a propranol solution at 10 -6M
3186634|NCT00747201|Active Comparator|2 Packaged intervention only|Patients will be seen by providers who receive the intervention package only.
3186635|NCT00747201|Experimental|1 Packaged intervention, training, and technical assistance|Patients will be seen by providers who receive the packaged intervention, along with provider training and ongoing technical assistance.
3186636|NCT00747253|Experimental|Single Active Arm|Only Arm. Patients treated using AutoLITT System.
2420142|NCT03435159|Experimental|Manual Chiropractic Spinal Manipulation|Demographic informations, pain, previous trauma, diseases, current medicine, past surgical operations, pregnancy, smoking use and cervical artery dissection history in family are questioned. Cervical flexion, extension, right and left rotations, right and left lateral flexions are measured by physiotherapist, in sitting position and with goniometer.Upper extremity muscle strength was measured with manual muscle testing in sitting position by physical therapist. The muscles innervated by C4, C5, C6, C7, C8 and T1 cervical nerves were examined bilaterally. Cervical foraminal compression test was used to eliminate cervical root compression.Vertebrobasilar artery was assessed by premanipulative vertebrobasilar insufficiency test.Neck Disability Index was used to evaluate the functional neck status of the participants. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after manual manipulative intervention.
2420143|NCT03435159|Experimental|Instrumental Chiropractic Spinal Manipulation|The same assessments were applied to determine the eligibility of participants for this study. After all assessments, participants who were eligible for this study were undertaken Doppler Ultrasonography before and after instrumental manipulative intervention.
2420144|NCT03435146|Experimental|Groups 1,2,3 and 4|"Group 1: The first 12 participants (Group 1A) will undergo semi-intensive PK sampling and will be key to determining whether an increased dosing of dolutegravir is required in groups 1B. Group 1B will receive dolutegravir at the new dose (if applicable) and will also undergo semi-intensive PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 2: The next 30 (Group 2) will receive dolutegravir at the new dose and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs~Group 3: The next 25 (Group 3) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~IPT plus DTG +2NRTIs~Group 4: The next 50 (Group 4) will receive dolutegravir at the same dose as Group 2 and will only have sparse PK sampling. All will undergo safety and HIV VL assessments.~3HP plus DTG +2NRTIs"
2420145|NCT03435133|Active Comparator|Prasugrel|
2420146|NCT03435133|Active Comparator|Ticagrelor|
2420147|NCT03435120||Breakthrough Cancer Pain|No intervention (Non Interventional Study)
2420148|NCT03435107|Experimental|Durvalumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were refractory to fluoropyrimidines, irinotecan and oxaliplatin with or without targeted agents will be accrued.~After checking the eligibility for the study entry, patients will be entered into the study treatment with durvalumab monotherapy."
2420149|NCT03435094||Fosamax®|1 group will be treated with alendronate 70 mg tablets (Fosamax®)
2420150|NCT03435094||Binosto®|1 group will be treated with alendronate 70 mg effervescent tablets for buffered solution (Binosto®)
3186637|NCT00747279|Experimental|1|Carbohydrate restrictive strategy
2420154|NCT03435068|Experimental|Ceramic rotary bur|For the ceramic bur group(Meisenger gingivectomies, ceramic rotary burs were used with 400-rpm rotary systems and with no serum irrigation, per the manufacturer's recommendation.
2420155|NCT03435068|Experimental|Diode laser|In the laser group (LG), a diode laser was applied to the operation sites in accordance with the manufacturer's guidelines (2.8 W continuous wave mode, wavelength 980 nm). The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power. The laser never made contact with the gingival tissue. The practice distance did not affect the laser spot size, which was 0.5 cm-1 cm. Smoke associated with the laser application was aspirated from the surgical site.
2420156|NCT03435068|Active Comparator|Scalpel|In the scalpel group following the local anesthetic administration, the gingivectomy was performed with a #15 scalpel. Subsequent to the operation, the borderline of gingiva was determined via the use of a pointer dental tweezers, and excessive gingival tissue was then removed with Gracey curettes
3145928|NCT00085384|Experimental|Arm III|Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
2420158|NCT03435042|Experimental|Children with cancer + their siblings|
2420159|NCT03435042|Experimental|Parents of children with cancer|
2420160|NCT03435029|Experimental|Cognitive Remediation Program (REHACOP)|The cognitive rehabilitation program (REHACOP) is a 5 month intervention that allows both individual and group intervention. For the purpose of this study, we included intervention in several domains: attention, language, memory, processing speed, and executive functioning for 3 months, 3 times per week, in 60 minute per session.
2420161|NCT03435029|Active Comparator|Occupational Therapy|The control group performed of occupational group activities (memory tasks, reading the newspaper, drawing, singing or doing crafts). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
2420162|NCT03435016|Other|Diagnosis|
2420163|NCT03435003|Experimental|Intervention Arm|"A) Pre-operatively: aprepitant 80 mg oral capsule and scopolamine transdermal patch.~B) Intra-operatively: total intravenous anesthesia (TIVA) will be maintained with IV infusions of propofol, and dexmedetomidine infusion or intermittent bolus dosing of fentanyl after induction. Sugammadex (2-4 mg/Kg IV) will be used for reversal of neuromuscular blockade in both groups. A single dose of dexamethasone 8 mg IV will be administered after induction, and a single dose of ondansetron 4 mg IV will be administered approximately 20 minutes prior to the end of operation.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
2420164|NCT03435003|Active Comparator|Control Arm|"A) Pre-operatively: No intervention~B) Intra-operatively: inhalation anesthetics (sevoflurane or desflurane) and intermittent opioid boluses will be used for maintenance of anesthesia, as standard practice in the institution of the investigators and across the country. PONV prevention measures in the control group will be limited to dexamethasone 8 mg and ondansetron 4 mg.~C) Post-operatively: Scheduled ondansetron and Raglan every 6 hours, using Compazine as a rescue medication."
2420298|NCT03434054|Experimental|Losartan|single dose of 50mg losartan, tablet, over-encapsulated, to be taken orally
3145929|NCT00085397|Experimental|Arm I|Patients undergo surgical harvesting of tumor cells for subsequent fusion. Patients receive vaccination comprising dendritic cells (DC) fused with autologous tumor cells subcutaneously on day 1. Treatment repeats every 21 days for 3 courses. Patients who achieve a partial (PR) or complete response (CR) may receive an additional 3 courses.
3145930|NCT00085397|Experimental|Arm II|Patients receive vaccination comprising DC pulsed with gp100 antigen IV on day 1. Treatment repeats every 21 days for 6 courses. Patients who achieve a PR or CR may receive an additional 6 courses.
2420165|NCT03434990|Experimental|Spinal manipulation/myofascial release|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. Myofascial release will be done on paravertebral muscle (Erector spinae, quadratus lumborum) and on gluteus maximus and piriform muscles, the pressure will depend of pain tolerance of each subject. After this procedure, the spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
2420166|NCT03434990|Active Comparator|Spinal manipulation|2x/week, for 3 weeks, performed by a chiropractor. Sessions will last 20 minutes, with 1 individual per session. The spinal manipulation will be performed on the sacroiliac join and on the lumbar vertebrae with less mobility.
3186638|NCT00747279|Active Comparator|2|Intensive insulin therapy
3186639|NCT00747292|Active Comparator|Epidural|Epidural
2420169|NCT03434951|Experimental|Intrathecal morphine and bupivacaine|0,2mg intrathecal morphine and 12,5mg bupivacaine administered
2420170|NCT03434951|Active Comparator|Placebo|12,5mg bupivacaine and NaCl 0,9% to match the same volume administered
2420171|NCT03434938|Experimental|MI Intervention|Standard geriatric rehabilitation combined with 4 MI sessions (within 72 hours from admission, within 6 days, at 1 week from the second session and pre-discharge, respectively). MI will be delivered by nurses trained through a certified MI course and additional group coaching sessions will be offered them throughout the study. Quality control of the MI sessions will be carried out using Motivational Interviewing Treatment Integrity (MITI) Code 3.1.1 through random video recording.
2420172|NCT03434938|No Intervention|Standard rehabilitation|Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
2420173|NCT03434899|Experimental|Intervention group|Health care plan including physical exercise and online support during the entire study
2420174|NCT03434899|Active Comparator|Control Group|Health care plan including physical exercise
2420175|NCT03434886|Experimental|CF View|
2420176|NCT03434886|Active Comparator|CF Educational videos|
2420177|NCT03434886|Active Comparator|CF View and videos|
2420178|NCT03434886|No Intervention|Usual standard of care|
2420179|NCT03434873|Active Comparator|Sacral magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots
2420180|NCT03434873|Active Comparator|Cortical magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex
2420181|NCT03434860|Active Comparator|probiotic|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
2420182|NCT03434860|Placebo Comparator|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) per day.
2420183|NCT03434847|No Intervention|Control|Standard preoperative assessment
2420184|NCT03434847|Active Comparator|Education|Pre-operative education regarding post-operative pain expectations
3186640|NCT00747292|Active Comparator|2|Spinal
2420186|NCT03434782|Experimental|G1- Negative Control|Group with no desensitizing treatment. Prior to bleaching therapy, a water-soluble placebo gel, with non-active agent will be applied to dental vestibular surfaces. After bleaching therapy, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
2420187|NCT03434782|Experimental|G2- LASER (Positive Control)|Group treated with placebo gel before bleaching and with LLLT after in-office bleaching.
2420188|NCT03434782|Experimental|G3- KNO3 (Positive Control)|Group treated with desensitizing gel before bleaching and after in-office bleaching, the LASER tip will be positioned in two points (apical and cervical), without light emission (placebo).
2420189|NCT03434782|Experimental|G4- KNO3 + LASER|Group treated with desensitizing gel before bleaching and with LLLT after in-office bleaching.
2420190|NCT03434769|Experimental|Cyclophosphamide + Fludarabine + Infusion of CAR-T Cells|Lymphodepletive regimen, consisting of Cyclophosphamide 60mg/kg IV on day -6 and Fludarabine 25mg/m2 IV on days -5 to -3. Followed by infusion of Chimeric antigen receptor T-cells (CAR-T) on day 0
2420191|NCT03434756|Experimental|Propioceptive Training|
2420192|NCT03434743|Experimental|Rehabilitative Intervention|Experimental rehabilitative intervention consists of non-nutritive sucking on emptied breast, one time per day for 10 minutes.
2420193|NCT03434743|Active Comparator|Control Intervention|Control active comparator intervention consists of non-nutritive sucking on a pacifier, one time per day for 10 minutes.
2420194|NCT03434730|Experimental|Adult Participants With High Risk Hematologic Malignancies|
2420195|NCT03434717|Experimental|Control (high distress)|Control group receiving care as usual
2420196|NCT03434717|Experimental|Individualised rehabilitation|"Patients with high distress receive the intervention individualized rehabilitation including evaluation of individual needs and based on that physical, psychological or social interventions to promote rehabilitation."
2420197|NCT03434717|Experimental|Control group (low distress)|Control group receiving care as usual
2420198|NCT03434704|Experimental|Single Arm Treatment|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine; PBSC graft; GvHD prophylaxis; Primary antifungal prophylaxis."
2420233|NCT03434444|Active Comparator|Propranolol + low dose oxytocin|The myometrial samples are bathed in an oxytocin solution at increasing concentrations (from 10 -12M to 10 -9M) plus propranol (10 -6M)
2420234|NCT03434444|Active Comparator|High Dose Oxytocin|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
3186641|NCT00747292|Active Comparator|3|Patients in this limb receive a PCA
3186642|NCT00747305|Experimental|Sunitinib|Sunitinib will be administered for 8 weeks prior to sugery
3186643|NCT00747318|Experimental|1|
3186644|NCT00747331|Experimental|A|
3186645|NCT00747331|Placebo Comparator|B|
3186646|NCT00747357|Experimental|1|Balloon first
3186647|NCT00747357|Experimental|2|Stent First
2420199|NCT03434691|Experimental|DEX group|continuous infusion of Dexmedetomidine at 0.4 μg/kg per hour and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
2420200|NCT03434691|Active Comparator|MDZ group|continuous infusion of a Midazolam at 0,1 mg/kg/h and remifentanyl A microdialysis probe was placed into the femoral quadriceps. An initial set of measurements will be obtained during the sedation with Midazolam and remifentanyl (before randomization). This set of measurements will be considered as baseline. Then samples were collected every 6 hours for 3 days. The changes in the energy-related metabolites lactate, the lactate/pyruvate ratio, glucose and glycerol were analyzed. Concomitantly with dialysate sampling, the effects on global haemodynamics, were assessed. Lactate and L/P clearances were also calculated.
2420201|NCT03434678|Experimental|Epidural-General Anesthesia|
2420202|NCT03434678|Active Comparator|General Anesthesia|
2420203|NCT03434665|Other|Recruited patients|Transradial celiac artery angiography
2420204|NCT03434652|Active Comparator|Active percutaneous neurostimulation|Subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
2420205|NCT03434652|Sham Comparator|Sham percutaneous neurostimulation|Each subject randomized to 5 days of active vs sham neurostimulation therapy during an illness cycle. With next illness cycle, each subject will cross over to the other one (active vs sham).
2420206|NCT03434639||1 - Ophthalmology patients|Ophthalmology patients who are receiving an intravenous dose of either fluorescein or indocyanine green (ICG) as part of their routine ophthalmic care (e.g. as part of a fluorescence angiography examination) will be recruited to the first stage of this study. These patients will take part in preliminary studies aimed at determining whether it is possible to detect fluorescein and ICG in the blood using transcutaneous fluorescence measurements.
2420207|NCT03434639||2a - Healthy subjects|Healthy subjects with no known issues of increased gut permeability. These subjects will act as negative controls in all gut permeability studies.
2420208|NCT03434639||2b - Healthy subjects (gastric emptying)|A subset of healthy volunteers will be recruited to take part in experiments to help in understanding the impact of gastric emptying rate as a confounding factor in measurements of gut permeability.
2420209|NCT03434639||3 - Increased permeability|Gastro-intestinal (GI) and non-GI patients who are expected to exhibit increased gut permeability (e.g. patients with celiac disease, inflammatory bowel disease (IBD), liver disease, HIV or another condition in which increased intestinal permeability is common). The more extreme cases in this group will act as positive controls.
2420210|NCT03434626|Experimental|ACP Education|Eligible patients in the experimental group will receive an educational intervention from an advance care planning navigator consisting of a 4-item values tool, a Goals of Care Designation form and, if applicable, watch a cardiopulmonary resuscitation video.
2420211|NCT03434626|Active Comparator|Usual care|Patients in the usual care group will complete a Goals of Care Designation form with the family physician.
2420212|NCT03434613|Active Comparator|Rosuvastatin monotherapy|Rosuvastatin 5mg 1T daily for 6 months
2420213|NCT03434613|Experimental|Rosuvastatin + ezetimibe combination therapy|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
2420214|NCT03434600|Active Comparator|Oxford|Patients receiving an Oxford UKA, which is the standard treatment for patients with medial osteoarthritis of the knee at our department.
2420215|NCT03434600|Experimental|Sigma|Patients receiving a Sigma UKA, which is the experimental treatment.
2420216|NCT03434587|Experimental|Syndactyly|Syndactyly
2420217|NCT03434587|Active Comparator|Reduction and inmobilization|Closed reduction and splint inmobilization
2420218|NCT03434574|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
2420219|NCT03434574|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
2420220|NCT03434548||Cohort 1|Healthy Controls
2420221|NCT03434548||Cohort 2|Huntington's Disease Gene Expansion Carriers (HDGECs: premanifest near-onset, peri-manifest, and manifest), and Healthy Controls
2420222|NCT03434535|Experimental|Intervention|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months. They will also receive an activity sensor and weight scale. Health state data from this group will be generated over a 3-6 month period and remotely monitored. These data will be used to provide personalized feedback regarding the participant's progress towards established goals.
2420223|NCT03434535|No Intervention|Control|The participants will complete a digital health-related quality of life survey on a programmed tablet at baseline and each month for the following 3-6 months.
2420225|NCT03434496|Experimental|Experimental group|The investigators will enroll 30 patients with PD, randomly divided into two groups: (A) gait training with Music; (B) conventional treadmill gait training. The 15 patients in the experimental group will perform training by means of the device Gait Trainer 3 (Biodex), where they will train on a tredmill equipped with music. They will walk following specific musical beets and rhythms so to entrain their own internal rhythm. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
2420226|NCT03434496|Active Comparator|Control Group|The control group will perform only conventional gait treadmill training, besides physical exercises to improve muscle force and tone. Subjects will attend 3 sessions a week for at least 4 weeks. Each session will last 45-min.
2420227|NCT03434483||Acute Coronary Syndrome|Patients with an episode of acute coronary syndrome. Clinical evaluation 1 year. Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis.
2420228|NCT03434483||ACS-Angiographic substudy|"Patients included in the Acute Coronary Syndrome group with clinical indication for revascularization.~Clinical evaluation. Assessment of the atherosclerotic plaque in a moderate lession at baseline and 1-year .~Gene variants in atherosclerosis. Microbiota analysis. Immunological analysis"
2420235|NCT03434444|Active Comparator|High Dose Oxytocin, Propranolol-pretreated|The myometrial samples are bathed in an oxytocin solution (10 -5M) plus propranolol (10 -6M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M)
2420236|NCT03434444|Active Comparator|High dose oxytocin + propranolol|The myometrial samples are bathed in an oxytocin solution (10 -5M), followed by increasing concentrations of oxytocin (from 10 -8M to 10 -5M) plus propranolol (10 -6M)
3186648|NCT00747370|Other|1|16 healthy volunteers with no complaints of urinary symptoms and without urogenital prolapse of more than first degree.
2420238|NCT03434405|Experimental|SocialMind|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
2420239|NCT03434392|Active Comparator|Healthy Controls|"Subjects with no pancreatic disease and no abdominal pain.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
2420240|NCT03434392|Active Comparator|Suspected CP|"Suspected Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
2420241|NCT03434392|Active Comparator|Definite CP|"Definite Chronic Pancreatitis patients.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires.~A subset of these patients who undergo endotherapy as per clinical recommendation from clinical provider independent of this study will be followed for 6 months after their clinical intervention for repeat Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3 and questionnaires."
2420242|NCT03434392|Active Comparator|Sphincter of Oddi Dysfunction or Functional Dyspepsia|"Patients with Sphincter of Oddi Dysfunction Type 1 or Type 2, or who have a prior diagnosis of Functional Dyspepsia.~Subjects will undergo the following Interventions:~Quantitative Sensory Test 1, Quantitative Sensory Test 2, and Quantitative Sensory Test 3, They will also fill out validated questionnaires."
3186649|NCT00747370|Other|2|Forty two stress urinary incontinence patients without prior urogenital prolapse or incontinence operation and without genital prolapse more than first degree
3186650|NCT00747370|Other|3|16 genital prolapse women without prior prolapse operations or any symptoms of incontinence
2420245|NCT03434366|Experimental|ketamine and dexmedetomidine group|intranasal ketamine and dexmedetomidine was treated in the children
2420246|NCT03434366|Experimental|ketamine group|intranasal ketamine was treated in the children
2420247|NCT03434366|Placebo Comparator|control group|intranasal insaline was used in the children
2420248|NCT03434353|Experimental|Group 1 (Inarigivir Soproxil 50 mg + TAF)|Inarigivir Soproxil 50 mg (2 x 25 mg capsule) plus TAF for 12 weeks, followed by TAF for 36 weeks
2420249|NCT03434353|Experimental|Group 2 (TAF)|TAF for 48 weeks
2420250|NCT03434353|Experimental|Group 3 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 200 mg (2 x 100 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks
2420251|NCT03434353|Experimental|Group 4 (Inarigivir Soproxil 100 mg)|Inarigivir Soproxil 100 mg tablet for 12 weeks in virally suppressed participants currently being treated with a commercially available NUC
2420252|NCT03434353|Experimental|Group 5 (Inarigivir Soproxil 200 mg + TAF)|Inarigivir Soproxil 400 mg (2 x 200 mg tablet) plus TAF for 12 weeks, followed by TAF for 36 weeks (Group 5 applies to Hong Kong only)
2420253|NCT03434340|Experimental|Granisetron & Dexamethasone & Peppermint essential oil|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn followed by Peppermint essential oil 2 drops on nasal strip applied for 6 hours
2420254|NCT03434340|Active Comparator|Granisetron & Dexamethasone|Granisetron 1mg and Dexamethasone 4mg administer as intravenous injection once right after delivery of newborn
2420255|NCT03434327|Experimental|Strength Training|Strength training will use 75-80% of the subject's maximum for the specific exercise and contractions will occur at 2s concentric and 3s eccentric. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
2420256|NCT03434327|Experimental|Power Training|For power training the subjects will perform the concentric phase at high speed, while eccentric portion will last approximately 2 sec. Loads will vary from 30-80% of the subject's maximum depending on the biomechanical nature of the joints involved in the exercise. All training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 24 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
2420257|NCT03434314|Experimental|MISACE arm|"Minimally-Invasive Segmental Artery Coil-Embolization~MISACE procedure prior to aneurysm repair~segmental arteries are occluded with coils or plugs in one to three MISACE sessions (staged procedure)"
2420258|NCT03434314|No Intervention|control arm|receives treatment of aneurysm as usual: open surgical repair or endovascular repair without MISACE
2420261|NCT03434288||Diabetic patients with foot osteomyelitis|Biological and MRI signs of foot osteomyelitis
2420262|NCT03434275|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
2420263|NCT03434275|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
2420264|NCT03434262|Experimental|A: ribociclib + gemcitabine|Stratum A participants with a diagnosis of refractory or recurrent medulloblastoma (Group 3/4) or refractory or recurrent ependymoma. (including: ependymoma, not otherwise specified (NOS), WHO Grade III; ependymoma, RELA fusion positive; anaplastic ependymoma; ependymoma, NOS, WHO grade II). They receive combination treatment with ribociclib and gemcitabine. They may also receive growth therapy support with filgrastim.
2420265|NCT03434262|Experimental|B: ribociclib + trametinib|Stratum B participants with a diagnosis of one of the following refractory or recurrent CNS diseases: medulloblastoma, [sonic hedgehog (SHH)- or WNT-activated];; high grade glioma (including: high grade glioma, (NOS), WHO Grade III or IV; anaplastic astrocytoma, IDH mutant; glioblastoma, IDH-wildtype; glioblastoma, IDH-mutant; diffuse midline glioma, H3K27-mutant; anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted; anaplastic pleomorphic xanthoastrocytoma); select CNS embryonal tumors (including: embryonal tumors with multilayered rosettes, C19MC-altered; embryonal tumors with multilayered rosettes, NOS; medulloepithelioma; CNS neuroblastoma; CNS ganglioneuroblastoma; CNS embryonal tumor, NOS; atypical teratoid/rhabdoid tumor; CNS embryonal tumor with rhabdoid features). They receive combination treatment with ribociclib and trametinib.
2420266|NCT03434262|Experimental|C: ribociclib + sonidegib|Stratum C participants with refractory or recurrent medulloblastoma (SHH-activated) >6 months off smoothened inhibitor, presence of 9q loss or PTCH1 mutant, skeletally mature. They received combination treatment with ribociclib and sonidegib.
3186651|NCT00747383|Active Comparator|1|
3186652|NCT00747383|Active Comparator|2|
2420269|NCT03434236|Placebo Comparator|Placebo|Patients will be taking placebo twice daily for 5 days prior to surgery. The placebo has a similar taste and smell as the active supplement.
2420270|NCT03434236|Experimental|low dose Lipinova (30mL)|Patients will take 15 mL Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
2420271|NCT03434236|Experimental|high dose Lipinova (60mL)|Patients will take 30mL of Lipinova (a dietary supplement containing omega-3 PUFA's) twice daily for 5 days prior to surgery.
2420272|NCT03434223||Single Cohort|
2420273|NCT03434210|Experimental|LAT-treated Community Model|The subjects in experimental group are on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
2420274|NCT03434210|Other|Care as usual|"The subjects in control group are on  cared as usual Which means Patients will be managed follow the request of National Continuing Management and Intervention Program for Psychoses. Patients will managed by community mental health professionals, get education information and rehablitation guidence from them."
2420275|NCT03434197|Experimental|SFPP (Esflurbiprofen plaster)|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
2420276|NCT03434197|Active Comparator|Diclofenac gel|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
2420277|NCT03434171|Active Comparator|Aerobic excercise|women who practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
2420278|NCT03434171|Active Comparator|Dietary modfications|women who received diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
2420279|NCT03434158|Experimental|Olaparib|600 mg/day
2420280|NCT03434145||patients with chronic kidney diseases|patients with end stage retinal disease undergoing hemodialysis underwent various ophthalmologic exams before and after hemodialysis.
2420281|NCT03434132|Active Comparator|Open Radical Cystectomy|Open Radical Cystectomy, pelvic lymph node dissection, urinary diversion (neobladder or ileal conduit)
2420282|NCT03434132|Experimental|Robot assisted radical cystectomy|Robot assisted radical cystectomy, pelvic lymph node dissection, intracorporeal urinary diversion (neobladder or ileal conduit)
3186653|NCT00747396|Experimental|Foster Care Placement Group|Children randomized to this group were placed in high quality foster care developed for the study.
3186654|NCT00747396|No Intervention|Care As Usual Group|Children randomized to this group remained in institutional care.
2420285|NCT03434106|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
2420286|NCT03434106|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
2420287|NCT03434106|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
2420288|NCT03434106|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
2420289|NCT03434093|Active Comparator|PPC-DLPFC|In this arm, the TMS paired-pulses will be first delivered over the posterior parietal cortex (PPC) and then over the dorsolateral prefrontal cortex (DLPFC)
2420290|NCT03434093|Active Comparator|DLPFC-PPC|Arm Description: In this arm, the TMS paired-pulses will be first delivered over the over the dorsolateral prefrontal cortex (DLPFC) and then posterior parietal cortex (PPC)
3186655|NCT00747409|Active Comparator|Hum|use of human regular insulin and NPH insulin
3186656|NCT00747409|Active Comparator|Ana|use of insulin aspart and insulin detemir
3186657|NCT00747422|Experimental|I|
2420294|NCT03434067||Primary hyperthyroidism|Patients diagnosed with primary hyperparathyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
2420295|NCT03434067||Secondary hyperthyroidism|Patients diagnosed with Secondary hyperthyroidism are prepared for parathyroid surgery. PTH test paper is used addtional at the time point according to Miami principle
2420296|NCT03434067||Unilateral thyroidectomy|Patients diagnosed with unilateral thyroid benign tumor were prepared for unilateral thyroidectomy. PTH test paper is used addtional at postoperation
2420297|NCT03434067||thyroidectomy and bilateral CCD|Patients diagnosed with bilateral thyroid carcinoma were prepared to undergo total thyroidectomy and bilateral central clearing.PTH test paper is used addtional at postoperation
2420902|NCT03429881|Active Comparator|Laser CO2 treatment ovarian endometriomas|
3186658|NCT00747487|Experimental|1|Idebenone
3186659|NCT00747487|Placebo Comparator|2|Placebo
3186660|NCT00747513|Experimental|I|intervention group
3186661|NCT00747526|Experimental|Rabeprazole sodium 5 mg|
3186662|NCT00747526|Experimental|Rabeprazole sodium 10 mg|
3186663|NCT00747539||1|This group will be composed of 165 HCV-infected people who are not also HIV infected.
2420299|NCT03434054|Placebo Comparator|Placebo|single dose of placebo (main ingredient microcrystalline cellulose), tablet, over-encapsulated, to be taken orally
2420300|NCT03434041|Experimental|Intranasal Esketamine plus Oral Antidepressant|Eligible participants will self-administer esketamine (56 mg or 84 mg) intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Treatment Phase. All participants will start at a dose of 56 milligram (mg) on Day 1. The dose may be increased to 84 mg or maintained at 56 mg per investigator's discretion. In addition, participants will simultaneously initiate a new, open-label 1 of 4 oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine extended release [XR]) on Day 1 that will be continued for the duration of the 4-week Double-Blind Treatment Phase.
2420301|NCT03434041|Active Comparator|Oral Antidepressant plus Intranasal Placebo|Eligible Participants will self-administer matching placebo intranasally twice per week for 4 weeks in Double-Blind Treatment Phase. In addition, participants will simultaneously initiate a new, open-label oral antidepressant medications (duloxetine, escitalopram, sertraline, or venlafaxine XR) on Day 1 that will be continued for the duration of Double-Blind Treatment Phase.
2420302|NCT03434028|Other|Restrictive Fluids|The general approach will be to use vasopressors to treat hypotension as opposed to intravenous fluids. Maintenance fluids should not be used.
2420303|NCT03434028|Other|Liberal Fluids|The general approach is to use fluid boluses to treat hypotension.
2420304|NCT03434015||Left atrial appendage closure|"All patient referred to a department of interventional cardiology for percutaneous left atrial appendage closure may be included.~All centers practicing this procedure in France will participate to the present study, whatever the technique used. The patients included in the protocol will be followed as part of the care by centers that will have carried out the procedure."
2420305|NCT03434002|Experimental|Arm-A|Randomized 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation
2420306|NCT03434002|Experimental|Arm-B|Randomized other 15 residents out of 30 Post Graduate Year 1 or 2 anesthesia residents (not involved in initial Virtual Reality testing) will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation
2420307|NCT03433989|Experimental|Diagnosis and follow up arm|
2420308|NCT03433976|Other|Hyperbaric Bupivacaine|spinal anesthesia for planned cesarean sections control group
2420309|NCT03433976|Active Comparator|Hyperbaric Prilocaïne|spinal anesthesia for planned cesarean sections
2420310|NCT03433963|Experimental|L-Arg supplement group|Study participants in the group will take L-Arg supplement during the trial.
2420311|NCT03433963|Placebo Comparator|Control group|Study participants in the group will take placebo during the trial.
3186664|NCT00747539||2|This group will be composed of 165 HCV-infected people who are also HIV infected.
2420313|NCT03433937|Experimental|Negative pressure wound therapy|
2420314|NCT03433937|Active Comparator|Control|Micropore tape
3186665|NCT00747578||1|"AS patients who fit the modified New York criteria (1984)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
2420320|NCT03433885||Progressors|Progressors are those individuals with early or intermediate AMD at baseline who progress to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who progress to advanced AMD in both eyes.
2420321|NCT03433885||Nonprogressor|Nonprogressors are those individuals with early or intermediate AMD at baseline who do not progressed to advanced AMD during follow-up, and individuals with advanced AMD in one eye at baseline who do not progress to advanced AMD in fellow eye.
2420322|NCT03433872|Other|Caregivers|"Caregiver refers to teachers and child care providers in infant and toddler classrooms in center-based or FCC settings. All caregivers in the study will be assigned to the intervention. The PD providers supporting these caregivers will be trained in the We Grow Together: The Q-CCIIT Professional Development System."
2420323|NCT03433859|Experimental|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb
2420324|NCT03433859|Active Comparator|Topical Aluminium Chloride|Topical Aluminium Chloride (cosmetic product) on the lower limb
2420325|NCT03433846||Preterm Infants|Blood samples will be obtained from preterm and former preterm infants at birth and then monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
2420326|NCT03433846||Term Infants|Blood samples will be obtained from term control infants admitted to the NICU monthly until hospital discharge. The sample would consist of either up to 0.5ml of blood obtained during a requested clinical blood draw, discarded blood, or a dried blood spot specimen. If no discard samples are available and study blood samples need to be obtained instead, this will occur for a maximum period of 6 months and no more than 3ml of blood will be collected over the entire study period.
2420327|NCT03433833|Experimental|Intervention|Patients will be given digoxin orally daily for 24 weeks. The initial dose will be selected with the goal of achieving a serum digoxin concentration of 0.5-0.9 ng/ml, a dose range recommended for heart failure patients. A dose of 0.0625, 0.125 or 0.25 mg daily will be selected based on a normogram.
2420328|NCT03433820|Experimental|randomized repeated biopsy|"The study will entail 1 cohort with a randomized repeated biopsy collection time. Three skin punch biopsies (3 mm) of the lower back will be taken from each volunteer on day 0. One biopsy sample taken on day 0 will serve as a baseline measurement for the repeated samples regarding the histology, immunohistochemistry, and RNA sequencing (RNA-seq) or real-time reverse transcription polymerase chain reaction (qRT-PCR) assessments.~Repeated biopsies of the same location as on day 0 will be taken on day 7, 14 or 21 (biopsy lesion and day randomized), and day 28, 42 or 56 (biopsy lesion and day randomized) for all subjects. The observation biopsy (biopsy lesion randomized) will serve as primary biopsy and followed for all measurements."
2420355|NCT03433625|No Intervention|Waiting list|6 week wait (with assessments) before being transferred to the experimental condition.
3186666|NCT00747578||2|"RA patients who fit the American College of Rheumatology (ACR) criteria (1987)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
3186667|NCT00747578||3|"SLE patients who fit the ACR revised criteria for the classification of SLE (1997)~Exclusion criteria :~Patients who have cognitive impairment.~Patients who have overlapping syndrome of any 2 of the 3 rheumatic disease (eg. RA overlapping with SLE).~Patients who are less than 18 years old or older than 65 years old.~Patients who visited rheumatologists in the outpatient clinics of the Division of Rheumatology at Taichung Veterans General Hospital for less than 4 times in 2008."
3186668|NCT00747604||Increlex patients|Eligible patients will be patients beginning therapy with Increlex® or those previously treated with Increlex.
2420332|NCT03433781|Experimental|Absorbic Acid|All patients will receive at least 1 cycle of treatment (4 weeks). Patients with clinical benefit (CR,PR, or SD) then will undergo a second 4-week cycle of treatment.
2420333|NCT03433768||poor responders|
2420334|NCT03433768||normal responders|
3186669|NCT00747630|Experimental|Intervention|The group selected to watch the video.
3186670|NCT00747656||1|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and not eligible for bypass based on transport time
3186671|NCT00747656||2|3 lead ECG subjects with chest pain and suspected ischemia transported to the nearest receiving ED and eligible for bypass based on transport time, if 12 lead PHECG was possible
3186672|NCT00747656||3|12 lead ECG subjects with prehospital notification transported to nearest receiving ED adn not eligible for bypass to PCI center based on transport time
2420339|NCT03433742|Other|Preoperative Group|This is a group of 30 patients who will be undergoing a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at a preoperative visit.
2420340|NCT03433742|Other|1 year Postoperative Group|This is the same group of 30 patients who are now one year post op after having a total hip replacement with a Trident II shell. This group of patients will have their bloods drawn and tested for metal ion levels at their one year visit.
2420341|NCT03433729|Experimental|Patient Agenda Form|Patient Agenda form: Patients receive an agenda form to use before their consultation.
2420342|NCT03433729|No Intervention|Usual care|Patients' appointment continues as usual.
2420343|NCT03433716|Experimental|PNM group|Subjects were treated for 3 weeks, once a week. Specifically, this consisted in the application of a square wave biphasic electrical current, with 10Hz frequency, a 250µs pulse width, and the maximal tolerable intensity to cause an exacerbated muscle contraction for a total of 1.5 mins, according to the protocol by Valera and Minaya. The subjects were seated while their arms were supported by an arm rest, forearms pronated and elbows moderately flexed. The radial nerve was located at 4cm proximal to the tip of the lateral epicondyle of humerus using an ultrasound machine (cross-section), subsequently, an acupuncture needle (0.30mm x 30mm) was inserted in a short axis approach, perpendicular to the surface of the skin, until the perineurium of the radial nerve (in close proximity).
2420344|NCT03433716|No Intervention|Control group|the subects of the control group received no any treatment
3186673|NCT00747656||4|12 lead PHECG subjects with prehospital notification bypassed past the nearest receiving ED to the PCI center.
2420346|NCT03433690|Experimental|High Intensity Interval Training|Twelve weeks of High Intensity Interval Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
2420347|NCT03433690|Active Comparator|Moderate training|Twelve weeks of Moderate Training, twice a week, in combination with multidisciplinary treatment at outpatient obesity clinic.
3186674|NCT00747708|Experimental|Peripheral|Patients are randomised in a 1:1 ratio to receive granulocyte-colony stimulating factor (G-CSF) or placebo injection
3186675|NCT00747708|Experimental|Percutaneous intracoronary injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
2420350|NCT03433664|Experimental|Treatment|Each treatment half of the scar received three standardised CO2 laser treatments using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping. Post-operatively all laser treatment and control zones had emollient applied and silicone dressings which were removed at 48 hours. Further emollient was applied twice daily for 2 weeks to all areas of the scar. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
2420351|NCT03433664|No Intervention|Control|Each control half of the scar received emollient applied twice daily for 2 weeks to all areas of the scar after each treatment. Standard care scar management (including silicone, massage and pressure garments) was directed by burn occupational therapists and was continued for all areas of scar.
2420352|NCT03433651|Experimental|creatine monohydrate|Experimental will take by mouth 5 grams a day of creatine monohydrate powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
2420353|NCT03433651|Placebo Comparator|Placebo|Placebo will take by mouth 5 grams a day of placebo powder. Subjects will be given a 30 day supply of the study powder. They will be reminded to take the powder as instructed.
2420354|NCT03433625|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
3186676|NCT00747708|Experimental|Percutaneous intramyocardial injection|All patients will receive granulocyte-colony stimulating factor injections followed by a bone marrow aspiration. Patients will be randomised in a 1:1 ratio to receive intramyocardial injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
3186677|NCT00747721|Experimental|1|Dexmedetomidine
3186678|NCT00747760||1|Extended family members
3186679|NCT00747760||2|Control- subjects from the same town without known thyroid diseases
2420356|NCT03433612|Other|All Patients|"Estimates of the location of the L4-L5 intervertebral space will be done by the classic intercristal line technique and novel SAIL technique. Each technique will be performed by different randomly assigned investigators.~* Both techiques will be assessed on all patients"
2420357|NCT03433599|Active Comparator|rAIH + training by research staff|Participants will receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by research staff.
2420358|NCT03433599|Sham Comparator|sham rAIH + training|Participants will sham receive repeated exposure to acute Intermittent Hypoxia (rAIH) and training by the research staff.
2420359|NCT03433586|Placebo Comparator|Placebo|Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
2420360|NCT03433586|Active Comparator|Aspirin|Aspirin (81mg) will be taken orally daily for 10-14 days.
2420361|NCT03433573|Experimental|Intervention|Abbott Sensor Based Glucose Monitoring System
2420362|NCT03433560||Korean female breast cancer patients|
2420363|NCT03433547|Experimental|Buckle|Macular buckling, Limbal paracentesis, and intraocular gas injection.
2420364|NCT03433547|Active Comparator|Vitrectomy|Vitrectomy, peeling internal limiting membrane, and gas tamponade.
2420365|NCT03433534||Pharmacokinetic of Nivolumab|Patients under nivolumab (Opdivo 10 MG/ML) for the treatment of non small cell lung carcinoma or renal cell carcinoma. Measure of nivolumab residual concentration 14 days after administration of nivolumab and just before the new perfusion.
2420366|NCT03433508|Experimental|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
2420367|NCT03433508|Active Comparator|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
2420368|NCT03433495|Active Comparator|Melodic Intonation Therapy|The duration of therapy was 12 sessions performed over a 6-week period. Each session lasted 30 minutes. They were performed individually by a speech-experienced therapist previously trained in Melodic Intonation Therapy.
2420369|NCT03433495|No Intervention|Waiting list|No intervention
3186680|NCT00747799|Experimental|1|Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
3186681|NCT00747877|Experimental|Arm I|Patients receive high-dose melphalan IV on day -1 followed by autologous stem cell transplantation (ASCT) on day 0.
3186682|NCT00747877|Experimental|Arm II|Patients receive low-dose cyclophosphamide IV or orally once a week for 12-20 weeks for a total of 12 courses.
3186683|NCT00747890|Active Comparator|I|
2420374|NCT03433469|Experimental|Treatment (osimertinib)|Participants receive 80mg osimertinib orally, once a day (PO QD) on days 1-28. Treatment repeats every 28 days for a minimum of 1 cycle prior to surgery in the absence of disease progression or unacceptable toxicity. Investigators will have the option to give a second cycle of study drug prior to surgery if clinically indicated. Depending on the timing of the final scans, patients may ultimately receive up to two weeks additional therapy with study drug beyond end of cycle 1 (or cycle 2) while awaiting surgery. Patients then undergo surgical resection of their cancer. No treatment with the study drug will be given after surgery.
3186684|NCT00747890|Other|II|
3186685|NCT00747929|Placebo Comparator|S-2367 Placebo|Placebo + reduced calorie diet
2420377|NCT03433443|Active Comparator|Control group|Usual physical rehabilitation group
2420378|NCT03433443|Experimental|Intervention group|Case manager assisted rehabilitation
2420379|NCT03433430|Other|truSculpt|truSculpt treatment
2420380|NCT03433417|Other|Cutera truSculpt|One truSculpt treatment
2420384|NCT03433391|Other|Surgery Plus Oxiplex|Oxiplex will be applied after hemostasis is achieved and prior to closure, in adult patients undergoing single level partial discectomy.
2420385|NCT03433391|Other|Surgery Only|Standard of care procedures for adult patients undergoing single level partial discectomy will be followed.
2420386|NCT03433378|Active Comparator|Tretinoin cream, 0.05%|Apply once a day application, under at-home use conditions.
2420387|NCT03433378|Active Comparator|RETIN-A® (tretinoin) cream, 0.05%|Apply once a day application, under at-home use conditions.
2420388|NCT03433378|Placebo Comparator|Vehicle of the test product|Apply once a day application, under at-home use conditions.
2420389|NCT03433365||1|Potential study subjects will sign an informed consent prior undergoing any study related procedure. Patients enrolled in this study will receive Lenalidomide-based regimen as maintenance therapy according to their previous decided therapeutic schedule. All consecutive patients treated with Lenalidomide-based regimen as maintenance therapy and with inclusion criteria will be asked to participate to this study.
2420390|NCT03433352||Control group|30 healthy volunteers were included in the healthy control group
2420391|NCT03433352||Recrudescence group|30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
2420392|NCT03433352||No recrudescence group|30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
2420435|NCT03433092||N Malila et. al,2002|
3186686|NCT00747929|Experimental|S-2367 800 mg|S-2367 800 mg q.d. + reduced calorie diet
3186687|NCT00747929|Experimental|S-2367 1600 mg|S-2367 1600 mg q.d. + reduced calorie diet
3186688|NCT00747942|No Intervention|A|exercise referral to lifestyle activities at the level of moderate intensity without support
3186689|NCT00747942|Active Comparator|B|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
3186690|NCT00747968|Active Comparator|glp-1-analogue|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be heart OR CNS-PET scanned
2420395|NCT03433313|Experimental|EG12014|Epirubicin and cyclophosphamide followed by EG12014 plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
2420396|NCT03433313|Active Comparator|Herceptin|Epirubicin and cyclophosphamide followed by Herceptin plus paclitaxel. All patients will be scheduled for surgery (breast and axillary lymph nodes) at 3 to 6 weeks after completion of neoadjuvant chemotherapy.
2420397|NCT03433300|Experimental|Microprocessor Knee|Ottobock Kenevo/Ottobock C-Leg
2420398|NCT03433300|Active Comparator|Nonmicroprocessor knee|Ottobock 3R60 for K3 participants, Ottobock 3R62 for K2 participants.
2420399|NCT03433287|Experimental|18F-NaF-PET/MRI|Eligible patients who give informed consent will be offered a NaF -PET/MRI scan
2420400|NCT03433274|Experimental|Randomized Cohort - Treatment Group|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
2420401|NCT03433274|Active Comparator|Randomized Cohort - Control Group|Treatment of mitral regurgitation within commercially approved MitraClip system indications
2420402|NCT03433274|Experimental|Non-Randomized Cohort|Treatment of mitral regurgitation with the Tendyne Mitral Valve System
2420403|NCT03433274|Experimental|Mitral Annular Calcification (MAC) Cohort|Treatment of mitral regurgitation and mitral annular calcification with the Tendyne Mitral Valve System
2420406|NCT03433248|Experimental|EMPA/LINA 10/5 mg QD (n=22)|8w EMPA followed by 8w EMPA/LINA 10/5 mg QD (n=22)
2420407|NCT03433248|Experimental|LINA/EMPA 5/10 mg QD (N=22)|8w LINA followed by LINA/EMPA 5/10 mg QD (N=22)
2420408|NCT03433248|Active Comparator|Gliclazide 30 mg QD/BID (N=22)|8w Gliclazide 30 mg QD, followed by 8w Gliclazide BID (N=22)
2420409|NCT03433235|Experimental|Early edoxaban initiation group|Low dose of edoxaban (15 or 30 mg) once daily from Day 2, then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
2420410|NCT03433235|Active Comparator|Conventional edoxaban initiation group|No antithrombotic treatment† -- then standard dose of edoxaban (30 or 60 mg) according to '3-6' rule.
2420411|NCT03433222|Experimental|HF-LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2420412|NCT03433222|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to HF-LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established or the study endpoint of 640 J/cm2 has been achieved, an additional 24 or 27 HF-LED-RL phototherapy subjects (for a total of 30) and 16 or 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2420413|NCT03433209|Active Comparator|Ligasure device|This group of women undergoing hysterectomy were randomized to the Ligasure energy device
2420414|NCT03433209|Active Comparator|Articulating Enseal|This group of women undergoing hysterectomy were randomized to the articulating Enseal energy device
2420415|NCT03433196|Experimental|HS-25 and Atorvastatin|HS-25 20mg, Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet
2420416|NCT03433196|Active Comparator|Atorvastatin|Atorvastatin 20mg, Placebo of HS-25 2 tablets
2420417|NCT03433183|Experimental|Selumetinib and Sirolimus|A Simon's two-stage phase 2 trial of MEK inhibitor selumetinib in combination with the mTOR inhibitor sirolimus to determine the safety and clinical benefit in patients with unresectable or metastatic MPNSTs. Both agents will be given orally on an empty stomach. Selumetinib will be given orally at a dose of 50mg twice daily continuously. Sirolimus will be given orally at a dose of 4mg once daily with a cycle 1 day 1 loading dose of 12mg. Each cycle will be considered 28 days.
2420418|NCT03433170|Experimental|Quadrupled semitendinosus graft|Autologous quadrupled semitendinosus graft is used to reconstruct the ACL injury
2420419|NCT03433170|Active Comparator|ST-Gracilis graft|Both gracilis and semitendinosus autologous graft are used to reconstruct the ACL injury
2420420|NCT03433157|Experimental|Hall technique|SSCs placed on primary teeth using Hall technique
2420421|NCT03433157|Active Comparator|Traditional technique|SSCs placed on primary teeth using Traditional technique
2420422|NCT03433144|Experimental|Intervention TXA|patients receiving TXA10mg/kg IV pre-operatively
2420423|NCT03433144|Placebo Comparator|Placebo|patients will receive an equivalent amount of normal saline 0.9% IV pre-operatively
2420424|NCT03433118|Experimental|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers to patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
2420425|NCT03433118|No Intervention|Standard care|Standard care for patients attending the UCH radiotherapy department for radiotherapy intended to be curative of their cancer
2420426|NCT03433105||1/patients with tracheostomy tubes and prolonged MV use|Patients who have tracheostomy tubes and with prolonged mechanical ventilation
2420427|NCT03433092||Jing Huang et. al, 2017|
2420428|NCT03433092||Max Leenders et. al,2014|
2420429|NCT03433092||Yusuke Okuyama et. al,2014|
2420430|NCT03433092||GC Kabat et. al,2012|
2420431|NCT03433092||Christina Persson et. al,2008|
2420432|NCT03433092||M Jenab et. al,2006|
2420433|NCT03433092||Kenji Wakai et. al,2005|
2420434|NCT03433092||Christian C. Abnet et. al,2003|
2420437|NCT03433079||Acute Kidney Injury|Patients > 18 years of age with acute kidney injury were enroled into the study. Arterial levels of neutrophil gelatinase-associated lipocalin (NGAL), arterial lactate, interleukin-6 (IL-6), procalcitonin (PCT) and myoglobin were investigated in all patients.
2420438|NCT03433066|Experimental|group I (Test)|Advanced platelet-rich fibrin mixed with biphasic alloplast
2420439|NCT03433066|Active Comparator|Group II (control)|Biphasic alloplast mixed with saline
2420440|NCT03433053|Placebo Comparator|Control|Participants will be exposed to a generic HIV testing message.
2420441|NCT03433053|Experimental|Experiment|Participants will be exposed to a targeted HIV testing message, developed specifically for African American women.
2420442|NCT03433040|Other|non obese|250mg 17 OHP-C
2420443|NCT03433040|Other|obese - control|250mg 17 OHP-C
2420444|NCT03433040|Experimental|obese|500mg 17 OHP-C
2420445|NCT03433027|Experimental|BB-401|BB-401 Intratumoral injection
2420446|NCT03433014|Active Comparator|0.5% Levobupivacaine|The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision.
2420447|NCT03433014|Other|Control|The control group will not receive any local infiltrative agent.
2420448|NCT03433001||Ixazomib + Lenalidomide + Dexamethasone|Participants will take ixazomib, lenalidomide, and dexamethasone under conditions of standard medical care in this study. The dosage and administration of ixazomib, lenalidomide, and dexamethasone will not be defined by the protocol but according to the package insert of each drug.
2420449|NCT03432988|Experimental|nurses in the hemodialysis service|Nursing Solution-Focused: Two two-hour training modules were designed by two recognized solution-focused therapy experts. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays.
2420450|NCT03432975|Experimental|Povidone Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine.
2420451|NCT03432975|Placebo Comparator|Sterile saline solution|The other side of the mouth will be irrigated with a sterile saline solution.
2420452|NCT03432962||Food code group|The participants freely selected foods from the online dietary assessment tool to record what they had eaten over the last 24h. They then provided information on brand details. The recalls were recoded to take into account all branded items and then recoded again to take represent all generic (ie. no brands) foods.
2420453|NCT03432949|No Intervention|Standard of Care Radium-223|Radium-223 treatment will be administered as per standard of care.
2420454|NCT03432949|Experimental|Radium-223 with oral Dexamethasone 0.5 mg|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
2420455|NCT03432936|Experimental|MRI guided procedure software evaluation|Evaluate the workflow and effectiveness of the Philips Interventional iSuite software during biopsies and/or ablations versus standard MR imaging in aiding needle placement.
2420456|NCT03432923|Experimental|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
2420457|NCT03432923|Placebo Comparator|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
2420458|NCT03432910|Other|treatment group|Participants of the study undergo the standard stages of the clinical routine within a PAP therapy setting: a diagnostic night followed by one or two treatment nights.
2420459|NCT03432897|Experimental|Treatment|"Olaparib 300 mg BID q 4 weeks for up to 3 cycles. The 3rd cycle will not be given if patient is found to progress post cycle 2.~Between 22-42 days post Olaparib, patients will undergo a prostatectomy."
2420460|NCT03432884|Experimental|Part A: BGB-3111|
2420461|NCT03432884|Placebo Comparator|Part A: Placebo|
2420462|NCT03432884|Experimental|Part B: BGB-3111, Placebo, and Moxifloxicin|
2420463|NCT03432871|Experimental|Nicotinamide Riboside|"This is an open-label experimental medicine study.~All subjects will receive the same dosage of the supplement Nicotinamide Riboside."
3186691|NCT00747968|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1-analogue versus placebo infusion 15 patients will be CNS OR heart-PET scanned.
3186692|NCT00747981|Experimental|A|Thoracic CT Scan
3186693|NCT00747994||1|
2420467|NCT03432845||Sugammadex reversal group|Surgical patients will have their muscle relaxant reversed with sugammadex
2420468|NCT03432845||Glycopyrrolate / Neostigmine reversal group|Surgical patients will have their muscle relaxant reversed with glycopyrrolate and neostigmine
2420469|NCT03432832|Experimental|Emotion Awareness/Skills Enhancement|"EASE Therapy includes 16 weekly sessions focused on mindfulness exercise, review of prior content, practicing prior skills, outline of current session, discussion of the new skill, handouts, practice and plan for out of session practice held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The investigators will apply a multimodal teaching approach, where individual therapy is buttressed by parent involvement and practice sessions in the youth's community. A secure website developed for this project (emotion-Coach or e-Coach) will augment the intervention by providing online supports to increase treatment intensity or dosage. There will be specific information on how to reinforce the skills at home and in the community."
2420470|NCT03432832|Active Comparator|Supportive Therapy|Supportive Therapy will involve attending 16 weekly therapy sessions held in Webster Hall in Pittsburgh, at the Center for the Prevention of Youth Behavior Problems in Tuscaloosa or via telehealth conferencing software. The intervention will not involve mindfulness or other emotion regulation strategies used in EASE. The therapy will be tailored to the individual's needs and will include aspects common in supportive therapy such as reflective listening, antecedent management, and problem-solving. This program does not have an online component.
3186694|NCT00748007|Experimental|A|
3186695|NCT00748007|Placebo Comparator|Placebo|Placebo
3186696|NCT00748020|Active Comparator|group 1|Erythematogenic irradiation scheme
3186697|NCT00748020|Active Comparator|group 2|Suberythematogenic irradiation scheme
3186698|NCT00748046|Experimental|Radium-223 chloride (Xofigo, BAY88-8223)|The patients will receive Radium-223 chloride as an escalating dose of either 50, 100 or 200 kBq/kg b.w. (0.0014, 0.0027 or 0.0054 mCi/kg).
2420473|NCT03432806||presumptive Stage II or III colon cancer|
2420474|NCT03432806||Stage IV colon cancer with resectable hepatic metastases|
2420475|NCT03432806||Stage IV colon cancer with unresectable hepatic metastases|
2420476|NCT03432806||Stage I colon cancer, pre-neoplastic or benign colon lesions|
2420477|NCT03432793|Experimental|TD-9855 + Fluvoxamine + Caffeine|Male smokers will receive TD-9855, fluvoxamine, and caffeine
2420478|NCT03432793|Experimental|TD-9855 + Itraconazole + Caffeine|Male non-smokers will receive TD-9855, itraconazole, and caffeine
2420479|NCT03432780|Experimental|Docetaxel, hormone and radiation therapy|Radiation therapy combined with weekly docetaxel (20 mg/m2) and hormone therapy.
2420480|NCT03432780|Active Comparator|Hormone and radiation therapy|Radiation therapy and hormone therapy
2420481|NCT03432767||Women having a vaginal delivery|A non-invasive hemoglobin monitor will be attached to the patient's finger and kept on for 2 hours after she delivers. Heart rate and blood pressure will be measured every 10 minutes.
2420482|NCT03432754|Experimental|Mindfulness-Based Attention Training|Four weekly group mindfulness attention training sessions of a 1.5-hour duration. Participants provided with audio recordings, readings, and homework assignments consisting of various mindfulness practices.
2420483|NCT03432754|Active Comparator|Lifestyle Education Group|Four weekly group lifestyle education sessions of a 1.5-hour duration. Homework consisting of reading, diet monitoring, stretching/toning exercises, and brainstorming new healthy living techniques/ideas.
2420485|NCT03432728||S-ECC|Children in their fifth year of life with severe early childhood caries Children selected will require complete dental rehabilitation under general anesthesia All enrolled children will receive treatment of all dental carious lesions under general anesthesia
2420486|NCT03432728||Control|Children age and sex matched with the S-ECC group who are free of dental caries
2420487|NCT03432715|Experimental|Wellness Champions for Change + Students|Schools randomized to the WCC+S arm will receive both the Teacher Intervention and the Student Wellness Champion Intervention.
2420488|NCT03432715|Experimental|Wellness Champions for Change|Schools randomized to the WCC+S arm will receive only the Teacher Intervention.
2420489|NCT03432715|No Intervention|Control|The control group will not receive either intervention. Schools will be given a modified SWC curriculum as well as the teacher training at the end of the data collection period.
2420490|NCT03432702|Active Comparator|Alveolar ridge augmentation without ABG|Horizontal ridge augmentation using guided bone regeneration without autogenous block graft (ABG)
2420491|NCT03432702|Experimental|Alveolar ridge augmentation with ABG|Horizontal ridge augmentation using guided bone regeneration with autogenous block graft (ABG).
2420492|NCT03432689|Experimental|D-Cycloserine|Participants will ingest a capsule containing 100mg of the antibiotic d-cycloserine. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2420493|NCT03432689|Placebo Comparator|Placebo|Participants will ingest a capsule identical to that containing the study medication, however this capsule will contain a placebo. Their baseline motor evoked potentials (MEP) will be recorded for 30 minutes prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the motor cortex and change in MEP amplitude will be measured following stimulation up to 90 minutes later and then once again the following morning (16 hours later).
2420494|NCT03432676|Experimental|Treatment (pembrolizumab, epacadostat)|Participants receive pembrolizumab IV over 30 minutes on day 1 and epacadostat PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unaccepted toxicity.
2420495|NCT03432663|Experimental|24h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached Intravenous amiodarone (1)
2420496|NCT03432663|Experimental|72h infusion|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached Intravenous amiodarone (2)
2420497|NCT03432650|Experimental|QLB Block + Standard of Care|"Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.~Patients will receive a single shot anterior QLB (30cc 0.5% Bupivacaine with 2mg preservative free dexamethasone)."
2420498|NCT03432650|No Intervention|Standard of Care|Patients will receive either a spinal (4cc Mepivacaine) or combined spinal epidural anesthetic (dose up 50 5 cc 2% lidocaine) with IV sedation. Intraoperative anti-emetics will consist of IV ondansetron and IV dexamethasone. Intra-operative analgesics will be IV fentanyl, IV acetaminophen, IV ketorolac, and IV ketamine. No Block will be given.
2420499|NCT03432637|Experimental|SV|undergoing thoracoscopic lobectomy under spontaneous ventilation (SV)
2420500|NCT03432637|Active Comparator|SLV|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation(SLV)
2420501|NCT03432624||Experiment Subgroup, Group One|Experiment Subgroup, Group One consists of pancreatic cancer patients, in which 120 are operable, and 120 are not operable.
2420502|NCT03432624||Control Subgroup, Group One|Control Subgroup, Group One consists of 150 patients, in which 30 are of gallbladder carcinoma, 60 are of biliary tract lower segment carcinoma, 60 are of gastrointestinal carcinoma.
2420903|NCT03429868|Experimental|integrated PET/MRI|The enrolled subjects receive an integrated 18F-FDG PET/MRI during tumor staging.
3186699|NCT00748059|Experimental|A|Patients with Orthostatic Hypotension
2420503|NCT03432624||Interference Subgroup, Group One|Interference Subgroup, Group One consists of 150 patients, in which 60 are of chronic pancreatitis, 90 are of other types of pancreatic tumor, in which 30 are of IPMN (intraductal papillary mucinous neoplasm), 30 are of SPT (solid pseudopapillary tumor of pancreas), and 30 pancreatic cystic adenoma.
2420504|NCT03432624||Experiment Subgroup, Group Two|Group Two consists of 210 patients selected from Group One, of which the Experiment Subgroup, Group Two consists of the 120 operable pancreatic cancer patients who have had successful surgery.
2420505|NCT03432624||Control Subgroup, Group Two|Control Subgroup, Group Two consists of 90 patients of other cancers who have had successful surgery, in which 30 are of gallbladder carcinoma, and 60 are of biliary tract lower segment carcinoma.
2420506|NCT03432611|Experimental|Complete app|198 women with primary dysmenorrhea who receive an app which includes a self-care information feature and a self-acupressure feature.
2420507|NCT03432611|Active Comparator|Control intervention I|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-care information feature, but not the self-acupressure feature.
2420508|NCT03432611|Active Comparator|Control intervention II|198 women with primary dysmenorrhea who receive an app for menstrual pain which includes the self-acupressure feature, but not the self-care information feature.
2420509|NCT03432598|Experimental|Non-squamous NSCLC|"Day 1 of each 21-day (3 weeks) cycle: Tislelizumab + pemetrexed + cisplatin 75 mg/m²/day IV (or carboplatin AUC 5).~Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted."
2420510|NCT03432598|Experimental|Squamous NSCLC Cohort A|"Tislelizumab every 3 weeks (Q3W) + paclitaxel + cisplatin (or carboplatin), Q3W.~Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
2420511|NCT03432598|Experimental|Squamous NSCLC Cohort B|"Tislelizumab Q3W on Day 1 + gemcitabine on Day 1 and Day 8 + cisplatin IV (or carboplatin) on Day 1.~Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
2420512|NCT03432598|Experimental|SCLC|"Tislelizumab Q3W on Day 1, etoposide on Days 1, 2, and 3 + cisplatin (or carboplatin) on Day 1.~Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles.~Following either completion of or discontinuation from chemotherapy, tislelizumab will be continued as scheduled, if clinically appropriate."
2420513|NCT03432585||Family Support Grant applicants|Participants include applicants for the Family Support Grants that will be provided for the American Society for Nutrition annual meeting who are willing to complete the applicant survey.
2420514|NCT03432572|Experimental|pyridium|Group A will take 200 mg of oral Pyridium 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2420515|NCT03432572|Active Comparator|riboflavin|Group B will take 400 mg of riboflavin 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2420516|NCT03432572|Placebo Comparator|thiamine|Group C will take the placebo (50 mg of thiamine) 1 hour before surgery and then the urine jets will be evaluated on cystoscopy in the operating room during a gynecological procedure.
2420517|NCT03432559|Other|endoscopy|endoscopy of the upper GI tract
2420518|NCT03432546||ICU patients|Over 18-year old intensive care patients, non-interventional prospective observational study
3186700|NCT00748111|Experimental|1|Sudden cardiac death hospitalized
3186701|NCT00748111|Experimental|2|Acute myocardial infarction
2420521|NCT03432507||disc herniation|patients suffering from disc herniation
2420522|NCT03432507||spinal stenosis|patients suffering from spinal stenosis
2420523|NCT03432494|Experimental|Study Arm 1|Subjects undergoing transcaval access for TAVR
2420524|NCT03432481|Experimental|Knee Arthroplasty using BUKS|Unicompartmental Knee Arthroplasty Surgery
2420525|NCT03432468|Active Comparator|postmenopausal hypertensive women|
2420526|NCT03432468|Placebo Comparator|age-matched hypertensive male patients|
2420527|NCT03432442|Experimental|Group 1 (6 dengue patients)|Volunteers weighed > 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
2420528|NCT03432442|Experimental|Group 2 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 400 µg of ivermectin per 1 kg of body weight
2420529|NCT03432442|Experimental|Group 3 (6 dengue patients)|Volunteers weighed > 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
2420530|NCT03432442|Experimental|Group 4 (6 dengue patients)|Volunteers weighed 15 to 30 kg receiving 600 µg of ivermectin per 1 kg of body weight
2420531|NCT03432416|Experimental|Regimen 1: Continuous Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.
2420532|NCT03432416|Experimental|Regimen 2: Cyclical Usage|Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).
2420533|NCT03432403||New LMA or Old LMA|newly designed LMA or older designed LMA
3186702|NCT00748111|Experimental|3|Angioplasty procedures programmed
3186703|NCT00748111|Experimental|4|Sudden cardiac death hospitalized without coronary syndrome
2420537|NCT03432351||Children: 0-36mo|EEG sensor will be placed on the subject's forehead to observe and record EEG activity. No other applicable intervention.
2420538|NCT03432338||idiopathic parkinson|Classical Parkinson´s disease, idiopathic
2420539|NCT03432338||secondary parkinsonism|parkinsonism due to other reasons than idiopathic
2420540|NCT03432338||controls|persona matched by age and gender, non parkinsonism
2420541|NCT03432325|Experimental|Neural Enabled Prosthesis|Neural Enabled Prosthesis Treatment Group
3186704|NCT00748124|Experimental|PleuraSeal Sealant Device|
3186705|NCT00748124|Other|Control|
3186706|NCT00748137|Active Comparator|Fixed dose|Fixed meal size and fixed aspart insulin dose except for minor changes based on measured blood glucose. Detemir basal insulin.
3186707|NCT00748137|Experimental|ezy-BICC dose calculation card|variable meal size with variable aspart insulin dose determined with use of individualised dose calculation card. Detemir basal insulin.
2420547|NCT03432273|Experimental|Nicotine 2 mg mint lozenges|
2420548|NCT03432273|Active Comparator|NiQuitin 2 mg mint lozenges|
2420549|NCT03432260|Experimental|DUR-928 30 mg|Lowest dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
2420550|NCT03432260|Experimental|DUR-928 90 mg|Middle dose of 3 dose escalation arms: 30mg, 90 mg and 150 mg
2420551|NCT03432260|Experimental|DUR-928 150 mg|Highest dose of dose escalation arms: 30mg, 90 mg and 150 mg
2420552|NCT03432247|Experimental|Interactive Music Therapy|Six 45-minute individual interactive music therapy sessions.
2420553|NCT03432247|Active Comparator|Verbal-based support|Six 45-minute individual verbal support sessions
2420554|NCT03432234||COPD and frequent exacerbation|Patient with COPD diagnosis and at least two exacerbations by year (FE)
2420555|NCT03432234||COPD no frequent exacerbation|Patient with COPD diagnosis with no frequent exacerbation, less than 2 by year (NE).
2420556|NCT03432234||Healthy (control)|Healthy volunteers patients (H)
2420557|NCT03432221||MDD|Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
2420558|NCT03432221||Healthy Controls|Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited
2420559|NCT03432208|Active Comparator|ESOPHAGO-GASTRO-DUODENOSCOPY (EGD)|GI consult Procedure performed is EGD
2420560|NCT03432208|Experimental|ENDOSCOPIC ULTRASOUND (EUS)|GI consult Procedure performed is EUS
2420561|NCT03432195|Experimental|Donepezil TDS Back|Corplex Donepezil TDS 10 mg/day applied to the Back for 1 week (7 days)
2420562|NCT03432195|Experimental|Donepezil TDS Buttock|Corplex Donepezil TDS 10 mg/day applied to the Buttock for 1 week (7 days)
2420563|NCT03432195|Experimental|Donepezil TDS Leg|Corplex Donepezil TDS 10 mg/day applied to the Leg for 1 week (7 days)
2420564|NCT03432182|Other|very premature infants|Electroencephalography allowing sleep observation
2420565|NCT03432169|Active Comparator|Yoga|Stretching with mindfulness
2420566|NCT03432169|Active Comparator|Stretching|Stretching exercises without mindfulness
2420567|NCT03432156|Experimental|Experimental group|subjects who are treated with autologous Tcm cells immunotherapy
2420568|NCT03432156|No Intervention|No intervention group|subjects who are treated without autologous Tcm cells immunotherapy
2420569|NCT03432143|Experimental|Community Reviewers|24 community members will receive training and mentoring in reviewing manuscripts. Approximately 284 manuscripts will be randomized into the intervention group over the duration of the study. Manuscripts will be reviewed by both a community member and scientific reviewers.
2420570|NCT03432143|No Intervention|Scientific Reviewers Only|Approximately 284 manuscripts will be randomized into the control group over the duration of the study. Manuscripts will be reviewed by multiple scientific reviewers. Community reviewers will not be involved in reviewing these manuscripts.
2420571|NCT03432130|Experimental|Experimental group|Performing a structural training program twice a week, 30 minutes each.
2420572|NCT03432130|No Intervention|Control group|
2420573|NCT03432117|Experimental|Fixed respiratory rehabilitation program(A)|respiratory rehabilitation program for 12 weeks
2420574|NCT03432117|Experimental|Mixed respiratory rehabilitation program(B)|Fixed respiratory rehabilitation for 6 weeks, and then responsive respiratory rehabilitation for 6 weeks
2420575|NCT03432117|No Intervention|Control(C)|Ordinary rehabilitation service of the site for 12 weeks
2420576|NCT03432104|Experimental|Verum|This arm receives 1 x 450 mg-capsule of Oxxynea®, a blend of polyphenol-rich fruit and vegetable extracts
2420577|NCT03432104|Placebo Comparator|Placebo|This arms receives 1 x 450 mg-capsule of Placebo, containing maltodextrin only
2420578|NCT03432078|Active Comparator|Individual hypnotherapy|Treatment given on a individual basis, face to face.
2420579|NCT03432078|Active Comparator|Group hypnotherapy|Treatment given in a group setting, face to face.
2420580|NCT03432065|Experimental|Buspirone|Buspirone tablets will be administered twice daily, and will be titrated to a maximum daily dose of 60mg for 8 weeks.
2420581|NCT03432039|Placebo Comparator|Psychoeducation arm|This arm will provide information about admission procedures, story telling and a follow-up phone call
2420582|NCT03432039|Experimental|Behavioral intervention|This arm will provide information about what invasive procedures maybe given to the child, the emotional and behavioral reactions of the child while on the ward, games and stories that the child can engage with the mother and a follow-up phone call
2420583|NCT03432026||Non-smoker COPD patients|stable non-smoker COPD patients diagnosed by a previous spiromtery to have FEV1/FVC less than 70
2420584|NCT03432013|Active Comparator|SUD-CBT|Standard cognitive behavioral therapy for substance use disorder
2420585|NCT03432013|Experimental|CUD-AMT|Experimental affective management training for cannabis use disorder specifically
2420586|NCT03432000|Experimental|subjects with schizophrenia|Performances on temporal task Subjective alterations of time perception in patients with an adapted scale (EAWE) Global symptomatology with PANSS (positive and negative symptom scale)
2420587|NCT03432000|Sham Comparator|healthy subjects|Evaluate the links (correlation) between perception of temporal sequencing and perception of causality using an adapted experimental paradigm (Michotte paradigm) and to compare performance between healthy subjects and controls Investigate the existence of a correlation between these alterations and the peculiarities of the subjective experience of time (EAWE scale) in the group of subjects with schizophrenia
2420588|NCT03431987||Marijuana Users|
2420589|NCT03431974|Experimental|Aminopterin oral capsule|LD-Aminopterin tablets (0.5 mg tablet) over-encapsulated, 3.0 mg (6 tablets) once orally each week for 14 weeks (14 doses).
2420590|NCT03431974|Placebo Comparator|Placebo oral capsule|Placebo capsules containing microcrystalline once orally each week for 14 weeks (14 doses).
3186708|NCT00748150|Experimental|1|
2420592|NCT03431961|Experimental|Intranasal Corticosteroid|Triamcinolone acetonide aqueous nasal spray at a dose of 220 mcg administered twice daily (for a total daily dose of 440 mcg) for 14 days
2420593|NCT03431948|Experimental|SBRT with Nivolumab and Urelumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and urelumab.
2420594|NCT03431948|Experimental|SBRT with Nivolumab and Cabiralizumab|Patients will receive stereotactic body radiation therapy (SBRT) in combination with nivolumab and cabiralizumab .
2420595|NCT03431922|Experimental|endovascular denervation|endovascular denervation
2420596|NCT03431909|Experimental|Kallikrein group|Subjects receive kailikang treatment according to real clinical practice (suggest above 14 days treatment),0.15 peptide nucleic acids(PNA), once a day.
2420597|NCT03431909|Sham Comparator|Control group|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
2420598|NCT03431896||Primary|"1.) To evaluate the relative amount of misfolded ATTR oligomers in asymptomatic ATTR amyloid genetic carriers and correlate their levels with clinical symptoms and outcomes.~Determine if misfolded ATTR oligomers are elevated compared to healthy control data obtained by Scripps during probe development~Describe the levels longitudinally~Determine if treatment with ATTR-specific medications (examples: diflunisal, doxycycline, ursodiol, tauroursodeoxycholic acid (TUDCA), green tea extract, curcumin, tafamidis, inotersen, patisiran) lead to reduction in the probe levels in those with elevated levels at baseline"
2420599|NCT03431870|Other|Aorta dilated|Patients with aorta of 40mm or more who undergo a cardiac surgery. The intervention include: Trans-Esophageal Echocardiography
3186709|NCT00748163|Experimental|Stage IV Non-Small Cell Lung Cancer Patients|Patients with stage IV non-small cell lung cancer treated with paclitaxel albumin-stabilized nanoparticle formulation and sunitinib malate as first-line therapy.
3186710|NCT00748176||A|
2420602|NCT03431831|Active Comparator|Intervention Control|All participants will receive diet/physical intervention. One arm will receive diet/physical activity intervention alone as a Intervention/usual care condition.
2420603|NCT03431831|Experimental|Counselling|These participants will receive usual care and counseling in the form of motivational interviewing weekly with goal setting for the first 5 weeks and monthly intervention for the final 5 months.
2420604|NCT03431831|Experimental|Contrave|These participants will receive usual care and prescription of Contrave for weight loss. They will be seen weekly for the first 5 weeks and monthly for the final 5 months.
2420605|NCT03431831|Experimental|Contrave and counseling|These participants will receive usual care of diet and physical activity recommendations and Contrave prescription and counseling (motivational interviewing interventions weekly for the first 5 weeks and then monthly for 5 months.
2420606|NCT03431805|Experimental|Tranexamic acid|intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)
2420607|NCT03431805|Placebo Comparator|Chloride solution|sodium intravenous administration of 10-mL of chloride solution (0.9% -10mL).
2420608|NCT03431792|Experimental|Long-Tail-FETO|"Fetus with severe CDH and o/e TFLV Ratio of < 25% or < 35% with liver herniation. The Long tail FETO will performed between 26 and 30 weeks of gestation.~The MRI control will be perfirmed ar 32-34 weeks of gestation. Long Tail FETO: fetal i.m. application of 0.1 mg/kg Pancuronium, 1 µg/kg Fentanyl® and 0.01 mg/kg atropine. (Long-Tail Goldbal 5, 2,5 ml, BALT Extrusion, Montmorency, France). The fetoscope (Karl Storz, Tuttlingen, Germany) with a diameter of 1.3 mm, will be percutaneously inserted through a sheath into the uterus and then into the fetal trachea. The fetoscope will be removed and the balloon will be inserted under 4-D ultrasound guidance into the fetal trachea. The position of the balloon and suture will be visualized using the fetoscopy.~The Long tail ballon will be removed by a second FETO after 34 weeks' gestation or bei the fetus itself with or without of the long tail balloon puncture with 22 gauge needle. The EXIT procedure is also possible."
2420609|NCT03431779|Experimental|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
2420610|NCT03431779|Active Comparator|Surgical excision|Excision of painful areas
2420611|NCT03431766|Placebo Comparator|control group A|on this group a placebo gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment.
2420612|NCT03431766|Experimental|test group B|on this group a 0.20% chlorhexidine gel will be applied on the internal surface of the implant during all the surgical and prosthetic phases of the treatment described on the study protocol.
2420613|NCT03431753|Experimental|PSA, STHLM3 and mpMRI for PC detection|mpMRI, and if suspect MR-targeted prostate biopsy, in men with increased PC risk as judged from the STHLM3 test and/or an elevated prostate specific antigen test.
2420614|NCT03431714|Experimental|single arm|Artesunate amodiaquine tablets containing 25/67.5 mg, 50/135mg and 100/270 mg base of artesunate-amodiaquine were administered according to body weight Dihrdroartemisinin piperaquine tablets containing 160/20mg and 320/40mg base of piperaquine dihydroartemisinin were administered according to body weight
2420615|NCT03431701|Experimental|Group chlorhexidine|Patients will receive chlorhexidine abdominal and vaginal scrubbing
2420616|NCT03431701|Active Comparator|Group iodine|Patients will receive iodine abdominal and vaginal scrubbing
2420617|NCT03431688|Active Comparator|PAM|treatment with PPI, metonidazole, amoxicillin
2420618|NCT03431688|Active Comparator|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
2420619|NCT03431675|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
2420620|NCT03431675|Active Comparator|Household prophylaxis arm|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
2420678|NCT03431298|Experimental|Aerobic exercise & movement control|"The duration of intervention is 8 weeks.~Individualized functional movement control training is 60 min/week~Aerobic exercise is 60 min/week"
2420904|NCT03429855|Experimental|study group|Bobath based trunk exercises
2420621|NCT03431675|Active Comparator|Community prophylaxis arm|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension)
2420622|NCT03431662|Experimental|Ellipse IM HTO Nail|In this arm, the subjects varus malalignment is corrected with Ellipse Intramedullary High Tibial Osteotomy Intramedullary Nail, which is a CE device. The device achieves the correction via progressive distraction osteogenesis.
2420623|NCT03431662|Active Comparator|TomoFix|In this arm, the subjects varus malalignment is corrected with Synthes TomoFix system, which is a CE device. The device achieves the correction via fixating an accute intraoperative correction of the varus malalignment.
2420624|NCT03431649|Experimental|Beraprost Sodium|"Beraprost 1mcg/kg/day, divided in 3 doses orally patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~22 patients"
2420625|NCT03431649|Active Comparator|Sildenafil citrate|"Sildenafil 0.4 mg/kg/time, 4 times daily per oral patient was followed up for 12 weeks, then echocardiography evaluation was performed in patient completed the study.~20 patients"
2420626|NCT03431636|Experimental|Immersion in cold water|"The athlete will remain submerged in a Cryo Control - Ice Bath Systems® bathtub, which allows filtration and maintenance of constant water temperature, and shoulder blade water (Getto and Golden, 2013) for 15 minutes in the 15 degrees Celsius (Machado et al, 2016)."
2420627|NCT03431636|Active Comparator|Ice pack|The athlete will remain for 20 minutes with plastic packets of 500 grams of ice each, in the region of the evaluated muscles.
2420628|NCT03431636|Sham Comparator|Control|Group in which the athlete will be instructed to remain seated in a comfortable position, at rest, for 20 minutes.
2420629|NCT03431623|Experimental|CKD-11101(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2420630|NCT03431623|Active Comparator|NESP(Darbepoetin alfa)|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2420631|NCT03431610|Experimental|SB414 2%|SB414 2% topically twice daily
2420632|NCT03431610|Experimental|SB414 6%|SB414 6% topically twice daily
2420633|NCT03431610|Placebo Comparator|Vehicle Cream|Vehicle Cream topically twice daily
2420634|NCT03431597|Experimental|oral nutritional supplementation|Daily novel micronutrient supplement: 800 μg folic acid, 5.2 μg cyanocobalamin (B12), 2.8 mg Riboflavin-5'- phosphate (B2), 4g trimethylglycine (betaine) in drink powder form. The drink will be dissolved in 200ml of water and taken daily for 12 weeks
2420635|NCT03431597|Active Comparator|oral nutritional supplementation, UNIMMAP|The United Nations Multiple Micronutrient Preparation (UNIMMAP) supplement is a capsule containing 15 micronutrients (vitamins A, D, E, B1, B2, B6, B12, C, Niacin, Folic Acid, Fe, Zn, Cu, I, Se) at the Recommended Daily Allowance level. UNIMMAP will be provided in capsule form and taken daily with water for 12 weeks.
2420636|NCT03431597|No Intervention|control|no treatment will be given to this group observation only (no placebo)
2420637|NCT03431584|Active Comparator|Infiltration of corticosteroids|
2420638|NCT03431584|Experimental|Infiltration of corticosteroids and hyaluronic acid|
2420639|NCT03431571|Other|Single arm|ReLEx SMILE treatment can be done binocular or monocular, no masking and randomization used, no control group
2420640|NCT03431558|Experimental|Group 1|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2420641|NCT03431558|Experimental|Group 2|"bLF (Bovine Lactoferrin plus Glucan D 99.4%) Dose: 300mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2420642|NCT03431558|Placebo Comparator|Group 3|"Placebo: Only Glucan-D (99.4% glucoseDose: 150 mg Frequency: a single daily dose mixed with milk (preferentially breast milk otherwise formula milk).~Duration: 1 month"
2420643|NCT03431545|Experimental|PALS and BEECH|Play and Learning Strategies (PALS) and Beginning Education: Early Childcare at Home (BEECH) include web-based parent and teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.
2420644|NCT03431545|Active Comparator|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
2420645|NCT03431532||neuraxial anesthesia|Patients with total knee replacement surgery having neuraxial anesthesia along with the procedure.
2420646|NCT03431532||general anesthesia|Patients with total knee replacement surgery having General anesthesia along with the procedure.
2420647|NCT03431519||Group A|The subjects received VP with PEEK and Sr-HA
2420648|NCT03431519||Group B|The subjects received VP with PEEK and PMMA
2420649|NCT03431506|Active Comparator|non-training group|
2420650|NCT03431506|Experimental|training group|
2420651|NCT03431493|Experimental|Behavioral Activation - Rehabilitation|Behavioral Activation - Rehabilitation
2420652|NCT03431493|No Intervention|Usual Care Control|Usual Care Control
2420654|NCT03431467|No Intervention|Control|VA-ECMO alone per standard clinical protocol.
2420655|NCT03431467|Experimental|Experimental|VA-ECMO with early institution of Impella CP LV venting
2420656|NCT03431454|Active Comparator|home-based vision orthoptic therapy (HBVOT) group|In the home-based vision orthoptic therapy (HBVOT) group, patients were trained to do the pencil push-ups procedure 15 minutes per day, five days a week
2420657|NCT03431454|Active Comparator|office-based vision orthoptic therapy (OBVOT) group|In the office-based vision orthoptic therapy (OBVOT) group, 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed
2420658|NCT03431454|Active Comparator|augmented office-based vision orthoptic therapy (AOBVOT) group|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
2420660|NCT03431428|Experimental|transanal surgery|"To ensure the complete cutting edge with no residual tumor, the tumor with corresponding mesorectal excision was removed by the distance edge of 1cm.~The intestinal wall was sutured to ensure the integrity of the bowel."
2420661|NCT03431428|Placebo Comparator|Miles surgery|According to the total mesorectal excision(TME) principle, complete mesorectum, lymph node and the anus was excised. A sigmoid colostomy was finally performed.
2420662|NCT03431415|Active Comparator|Surgery|Patients that will undergo surgery (anatomical segmentectomy, lobectomy or bilobectomy) as primary lung cancer treatment
2420663|NCT03431415|Active Comparator|SBRT (Stereotactic Body Radiation Therapy)|Patients that will undergo SBRT as primary lung cancer treatment
2420664|NCT03431402|Other|Acute stroke receive hyperbaric oxygen|
2420665|NCT03431402|No Intervention|Acute stroke receive only conventional treatment|
2420666|NCT03431389|Active Comparator|Decannulated group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Trial of decannulation was considered successful, if there was no need to reapply tracheostomy within 6 months of decannulation.
2420667|NCT03431389|Active Comparator|Failure of decannulation group|Decannulation was considered when the patients were no longer in need for tracheostomy tube and fulfilled the criteria of decannulation: No need for mechanical ventilation, no chocking with oral intake, no chest infection, effective cough reflex, laryngeal examination show bilateral mobile vocal cords with sufficient gap. Decannulation trail was considered failed if there was a need to reapplication of tracheostomy at the time of decannulation or within six months of decannulation the duration of follow up.
2420668|NCT03431363||Observational group|Patient dosing options will be stratified into three groups defined as standard, frail/elderly (age > 65 or ECOG 2), and cannabis-experienced (> weekly use of cannabis in the past year outside of NYC Medical Marijuana program). NYC specified cannabis formulation options are defined by THC:CBD ratio as 1:1, low THC:high CBD, high THC:low CBD, and high THC:high CBD.
3145931|NCT00085449|Experimental|Regimen A + B|"Conditioning regimen A: Patients receive alemtuzumab IV over 2 hours on days -14 to -12; fludarabine IV over 30 minutes on days -7 to -3; and melphalan IV over 20-30 minutes on day -2.~Conditioning regimen B: Patients receive oral or IV cyclosporine twice daily and oral or IV mycophenolate mofetil twice daily on days -15 to 0. Patients also receive alemtuzumab, fludarabine, and melphalan as in conditioning regimen A. Patients undergo low-dose total body irradiation twice daily on days -2 and -1.~All patients undergo allogeneic, T-cell-depleted, CD34-positive peripheral blood stem cell transplantation on day 0. Patients receive sargramostim (GM-CSF) subcutaneously beginning on day 1 and continuing until blood counts recover.~Patients are followed every 3 months for 1 year and then every 6 months for 5 years."
3145932|NCT00085501|Active Comparator|1|
3145933|NCT00085501|Active Comparator|2|
3145934|NCT00085527|Experimental|depsipeptide|Depsipeptide administered on Days 1, 8, and15 of a 28-day cycle.
2420675|NCT03431324|Experimental|Mating-EFT Intervention Effectiveness|"Study 1: 90 participants will attend an initial session, at which point they will provide demographic information as well as their relationship status. They will then be randomly assigned to complete either the Episodic Future Thinking about Mating Opportunities intervention, a general-EFT intervention, or an unrelated questionnaire (yoked control condition).~All participants will submit daily reports of the number of cigarettes smoked for a period of one week. Participants will then complete a series of questionnaires measuring individual differences in fundamental social motives (including mate-seeking motives), self-efficacy, and nicotine dependence."
2420676|NCT03431324|Experimental|Message Tailoring for Smoking Cessation|Study 2: A quasi-experimental design will be employed in order to determine whether targeting individuals who are single and highly motivated to seek a mate with a Targeted Mating-EFT Intervention is a more effective means of reducing cigarette consumption than presenting all individuals with a general-EFT intervention. A total of 180 smokers who intend to quit or reduce smoking will be recruited as participants. These individuals will be selected from a larger pool of participants based upon responses to screening questions. The screening questions will measure relationship status and mate seeking motivation.
2420677|NCT03431311|Experimental|Adoptive Cell Therapy (ACT)|"The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.~Escalating dose per week, from 1 x108 cells (week 1) to 2x109 cells (week 4 onwards) using a central venous catheter. The doses listed indicate the maximum number of T cells per injection at any given time point."
2420679|NCT03431298|Active Comparator|Aerobic exercise|"The duration of intervention is 8 weeks.~Frequency: 2 times/ week~Duration: 60min/ time"
3145935|NCT00085553|Experimental|Treatment (erlotinib hydrochloride, tipifarnib)|Patients receive erlotinib hydrochloride PO QD on days 1-28 (days 8-28 of course 1 as of 11/4/2013) and tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. (Closed to accrual as of 2/2/06)
3145936|NCT00085670||Group 1|Bone marrow failure subjects
3145937|NCT00085722|Experimental|Dextrose|Subjects in Group 1 receive PrT with 15% and 25% dextrose solution, as it is generally practiced in the US today.
3145938|NCT00085722|Placebo Comparator|Normal saline|Subjects in Group 2 will receive the same treatment as Group 1, except that a 0.9% 'normal' saline solution with no known benefit will be used instead of dextrose.
3145939|NCT00085722|Other|Exercise|At-home physical therapy exercises as a non-injection control
3145940|NCT00085787|Experimental|ARRY-142886|
3145941|NCT00085852|Experimental|Single|Treatment with BLVR
3145942|NCT00085969|Placebo Comparator|A1 - Placebo 0.04 mL twice daily|
3145943|NCT00085969|Placebo Comparator|A2 - Placebo 0.04 mL once daily|
3145944|NCT00085969|Placebo Comparator|A3 - Placebo 0.08 mL once daily|
3145945|NCT00085969|Experimental|B - Exenatide 10 mcg twice daily|
3145946|NCT00085969|Experimental|C - Exenatide 10 mcg once daily|
3145947|NCT00085969|Experimental|D - Exenatide 20 mcg once daily|
2420680|NCT03431285|Active Comparator|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration.
2420681|NCT03431285|Active Comparator|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml normal saline (NS) infused over 30 minutes in addition to standard IV hydration
2420682|NCT03431272|Experimental|Treatment|lifitegrast ophthalmic solution 5.0%, to be instilled 1 drop in each eye, twice a day
2420683|NCT03431259|Experimental|Enrollment group|
2420684|NCT03431259|No Intervention|Information group|
2420685|NCT03431246|Experimental|Gardasil and Gardasil-9|
2420686|NCT03431233|Experimental|Group 1|protein enriched bar->commercial cereal bar->water
2420687|NCT03431233|Experimental|Group 2|protein enriched bar->water->commercial cereal bar
2420688|NCT03431233|Experimental|Group 3|commercial cereal bar->protein enriched bar->water
2420689|NCT03431233|Experimental|Group 4|commercial cereal bar->water->protein enriched bar
2420690|NCT03431233|Experimental|Group 5|water->protein enriched bar->commercial cereal bar
2420691|NCT03431233|Experimental|Group 6|water->commercial cereal bar->protein enriched bar
2420692|NCT03431220|Experimental|RENASYS TOUCH NPWT System|Negative Pressure Wound Therapy (NPWT)
2420693|NCT03431207||healthy group|"For the healthy group, the visual acuity of both eyes was in the 95% referenced range with no structural abnormalities.~The referenced range could be found in the following publication:~Mayer, DL., et al. Monocular acuity norms for the Teller Acuity Cards between ages one month and four years. Investigative Ophthalmology & Visual Science. 36(3):671 (1995)"
2420694|NCT03431207||mildly impaired group|"The mildly impaired group was defined as a VA out of the 95% reference range in at least 1 eye, but the VA of both eyes was in the 99% referenced range with structural abnormalities."
2420695|NCT03431207||severely impaired group|"For the severely impaired group, the VA of both eyes was out of the 99% referenced range or worse than light perception with structural abnormalities."
2420696|NCT03431194|Active Comparator|midodrine group|Patients will receive midodrine tablets
2420697|NCT03431194|Placebo Comparator|placebo group|Patients receive sugary oral tablets therapy
2420698|NCT03431181|Experimental|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
2420699|NCT03431181|Active Comparator|Usual Care|Patients in the control arm will receive usual care (as per local practices).
2420700|NCT03431168|Active Comparator|Azithromycin/TMPS|"Azithromycin 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
2420701|NCT03431168|Placebo Comparator|Placebo/TMPS|"Azithromycin placebo 1 gm po daily x 3 days at enrollment and at each 4 week follow up visit.~TMPS double strength 1 tablet po daily."
2420702|NCT03431155|Experimental|Experimental group|Nursing intervention
2420703|NCT03431155|No Intervention|Control Group|- Receive routine nursing care
2420704|NCT03431142|Experimental|Clopidogrel monotherapy|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.
2420705|NCT03431142|Active Comparator|Clopidogrel plus aspirin|On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.
2420706|NCT03431116||Low implanted placenta group|
2420707|NCT03431103|Other|After home exercise program|"Patients will be instructed to use the Wii Fit for 20 minutes at least twice a week for 12 weeks using specific Wii Fit exercises while on the Wii pressure sensor floor mat. The Wii Fit exercises will be as follows: 1. Basic Run (warm-up exercise by walking in place); 2.Bird's Eye, Bull's-Eye (mostly arms, requires arm flipping); 3.Free Step (lower extremity exercise); 4.Hula Hoop (gyration exercise)"
2420708|NCT03431090|Experimental|CliniMACS Isolation|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
2420709|NCT03431077|Experimental|LJPC-501|Angiotensin II administered via continuous infusion (1.25 - 40 ng/kg/min) for 24 hours up to 168 hours.
2420710|NCT03431064||Surgical patients less than 18 years old|Patients less than 18 years old having surgery with general anesthesia at Boston Children's Hospital
2420711|NCT03431051|Active Comparator|Healthy Beverage Initiative|A Healthy Beverage Initiative and health education will be implemented at two hospital campuses.
2420712|NCT03431051|No Intervention|Control Arm|No change in beverages or education at two hospital campuses.
2420713|NCT03431025|No Intervention|Control|Participants in the Control Arm will wear sensors to monitor their upper limb movement but will not receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
2420714|NCT03431025|Experimental|Intervention|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
3186711|NCT00748202|Active Comparator|1|intravenous administration of C1-Inhibitor, after the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far
3186712|NCT00748202|Active Comparator|2|subcutaneous administration of C1-Inhibitor. After the end of the first observation period (at least after 7 days), each arm switches cross-over to the alternative administration mode not investigated so far.
3186713|NCT00748228|Experimental|A|10 mEq/day dietary sodium
3186714|NCT00748228|Experimental|B|150 mEq/day dietary sodium
3186715|NCT00748228|Experimental|C|300 mEq/day dietary sodium
3186716|NCT00748254||Rheumatoid Arthritis|Patients who have active disease affecting the joints in the hand will have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound
3186717|NCT00748254||Normal controls|Healthy volunteers who do not have arthritis will also have Laser Based Photoacoustic Tomography (PAT), MRI, Ultrasound on the joints of their hand
3186718|NCT00748280|Experimental|1|ORCT
3186719|NCT00748280|Experimental|2|PCEM/PMTA
3186720|NCT00748293|No Intervention|A|PEG-ELS 2000 ml ingestion in the morning of colonoscopy
3186721|NCT00748293|Other|B|Low-reside diet on previous day (breakfast, lunch and dinner), PEG-ELS 1500 mL in the morning of colonoscopy
3186722|NCT00748306|Experimental|GSK2190915|Intervention
2420719|NCT03430999|Experimental|Group 1 (Japanese) Calmangafodipir|
2420720|NCT03430999|Placebo Comparator|Group 1 (Japanese) Placebo|
2420721|NCT03430999|Experimental|Group 2 (Caucasian) Calmangafodipir|
2420722|NCT03430999|Placebo Comparator|Group 2 (Caucasian) Placebo|
3186723|NCT00748306|Placebo Comparator|Placebo|
3186724|NCT00748319|Other|1|Detection of KIR receptor
2420725|NCT03430973|Experimental|Experiment 1|The purpose of Experiment 1 is to develop a standardized measure of aggressive driving for driver simulation experiments. After giving their consent, participants (N=200) will complete several personal variables (i.e., gender, age, driving experience, driving frequency, trait anger, self-reported aggressive and prosocial driving). Next, participants will watch several short videos of aggressive driving (e.g., speeding, tailgating, driving on shoulder), and road rage (e.g., hitting another vehicle or pedestrian). Participants will indicate whether the driver's behavior was aggressive (yes, no), and will rate how aggressive it was on an 11-point scale (0=not at all aggressive to 10=extremely aggressive). A debriefing will follow.
2420726|NCT03430973|Experimental|Experiment 2|Experiment 2 tests whether participants actually drive more aggressively after a playing a violent or nonviolent racing video game. After giving their consent, participants (N=60, n=30 each group) will complete the same personal variables as in Experiment 1, and will report the video games they play. Next, participants will be randomly assigned to play one of two types of video games for 20 minutes: (1) violent racing video game, (2) nonviolent racing game, or (3) a neutral game. After participants complete the driving scenario, participants will complete measures of state and hostile appraisals. A debriefing will follow.
2420727|NCT03430973|Experimental|Experiment 3|"Experiment 3 tests the effects of racial bumper stickers on black and white participants. After giving their consent, participants (N=120; n=60 black, n=60 white) will complete the personal variables (see Experiment 1), the race IAT, and report their political party. Some cars in the driving scenario will contain bumper stickers. Experiment 3 contains four conditions: (1) white participants / All Lives Matter stickers, (2) black participants / All Lives Matter stickers, (3) white participants / Black Lives Matter stickers, (4) black participants / Black Lives Matter stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward the #BLM and #ALM movements. A debriefing will follow."
2420728|NCT03430973|Experimental|Experiment 4|"Experiment 4 tests the effects of political bumper stickers on aggressive driving in Republicans versus Democrats. After giving their consent, participants (N=120; n=60 Republicans, n=60 Democrats) will complete the personal variables (see Experiment 1). Some cars in the driving scenario will contain bumper stickers. Experiment 4 has four conditions: (1) Republicans / Donald Trump for President 2016 stickers, (2) Republicans / Hillary Clinton for President 2016 stickers, (3) Democrats / Donald Trump for President 2016 stickers, (4) Democrats / Hillary Clinton for President 2016 stickers. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will report their attitudes toward Trump and Clinton. A debriefing will follow."
2420729|NCT03430973|Experimental|Experiment 5|Experiment 5 tests whether alcohol-related cues can increase aggressive driving. After giving their consent, participants (N=60) will complete the personal variables (see Experiment 1). Next, participants will be randomly assigned to one of two conditions: (1) case of beer on passenger seat, or (2) case of water on passenger seat. Participants will be told that the object on the seat is part of a different experiment that the other experimenter forgot to clean up, which they should ignore it. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
2420730|NCT03430973|Experimental|Experiment 6|Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
2420731|NCT03430973|Experimental|Experiment 7|"Experiment 7 tests whether roadside vegetation can reduce aggression in frustrated drivers. After giving their consent, participants (N=90, n=30 per group) will complete the personality variables (see Experiment 1). Next, they will complete the Enjoyment of Nature Scale (Cheng & Moore, 2012), which contains 7 items (e.g., I like to see wild flowers in nature and Being in the natural environment makes me feel peaceful; 1=strongly disagree to 5= strongly disagree; Cronbach =.87). Next, participants will be randomly assigned to one of three driving scenarios: (1) roadside vegetation, (2) trash, or (3) control (no roadside vegetation / no trash). After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed."
2420732|NCT03430960|Other|Group A - Standard of Care|
2420733|NCT03430960|Experimental|Group B - mCare group|
2420734|NCT03430947|Experimental|Treatment|all patients will be treated with Vemurafenib + Cobimetinib
2420736|NCT03430921|Other|Enlighten™ Laser and a MLA Attachment|Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment
2420905|NCT03429855|Other|control group|conventional physiotherapy approaches
3186725|NCT00748332|Active Comparator|1|Standard oral nutritional supplement
3186726|NCT00748332|Experimental|2|Omega-3-enriched oral nutritional supplement
3186727|NCT00748345|Experimental|1|Caspofungin (drug)
3186728|NCT00748358|Experimental|drug|drug
3186729|NCT00748371|Experimental|1|ASA 40mg daily for 8 weeks followed by 3 weeks of observation
3186730|NCT00748371|Experimental|2|ASA 1300mg daily for 8 weeks followed by 3 weeks of observation
3186731|NCT00748371|Placebo Comparator|3|Placebo: one Avicel (cellulose) capsule by mouth twice daily
3186732|NCT00748384||1|Self trained subjects
3186733|NCT00748384||2|supervised trained subjects
3186734|NCT00748397|Experimental|A|
3186735|NCT00748423|Experimental|1|Nitric Oxide in nitrogen
3186736|NCT00748423|Placebo Comparator|2|Nitrogen
2420737|NCT03430908||Participants with an endotracheal tube|Participants undergoing general anesthesia with an endotracheal tube will have a gastric tube blindly inserted by an anesthesia provider.
2420739|NCT03430882|Experimental|Treatment (sapanisertib, paclitaxel, carboplatin)|Patients receive sapanisertib PO QD on days 2-4, 9-11, and 16-18, paclitaxel IV over 3 hours on days 1, 8, and 15, and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2420740|NCT03430869|Experimental|F-18 AV-45|F-18 AV-45 imaging
2420741|NCT03430869|Experimental|F-18-THK-5351|F-18-THK-5351 imaging
3186737|NCT00748436|Placebo Comparator|A|Matching placebo twice a day
3186738|NCT00748436|Experimental|B|Betahistine 24 mg twice a day (48 mg/day total)
3186739|NCT00748436|Experimental|C|Betahistine 48 mg twice a day (96 mg/day total)
3145949|NCT00086060|Experimental|1 - Relaxation Training|Participants will receive relaxation training and standard care for FM
3145950|NCT00086060|Experimental|2 Exercise Regimen|Participants will receive an exercise regimen and standard care for FM
2420747|NCT03430830|Experimental|GROUP 1|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 19th to 25th day： Ravidasvir 200mg administered orally once daily.
2420748|NCT03430830|Experimental|GROUP 2|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily ; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2420749|NCT03430830|Experimental|GROUP 3|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2420750|NCT03430830|Experimental|GROUP 4|1st day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: Ravidasvir 200mg administered orally once daily; 3rd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2420751|NCT03430830|Experimental|GROUP 5|1st day: Ravidasvir 200mg administered orally once daily; 2nd day: 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2420752|NCT03430830|Experimental|GROUP 6|1st day: 2 tablets of Ravidasvir 50mg administered orally once daily; 2nd day: 1 tablet of Ravidasvir 200mg and 2 tablets of Ravidasvir 50mg administered orally once daily; 3rd day: Ravidasvir 200mg administered orally once daily; 19th to 25th day：Ravidasvir 200mg administered orally once daily.
2420753|NCT03430817|Experimental|Group C|Citicholine Drug
2420754|NCT03430817|Experimental|Group A|Amantadine Drug
2420755|NCT03430817|Experimental|Group D|Both Citocholine and Amantadine
2420756|NCT03430804||Single gruop320 parturients|Measurement of cervical length and digital examination of Bishop score in 320 women undergoing induction of labour will be carried out in ain shams university maternity hospital.
3145951|NCT00086060|Active Comparator|3 Standard Care|Participants will receive standard of care for FM
3145952|NCT00086060|No Intervention|4 Health Controls|Health participants will act as a control
2420759|NCT03430778|Experimental|High CO2 group|end tidal CO2 : 40-45 mmHg
2420760|NCT03430778|Placebo Comparator|Low CO2 group|end tidal CO2 : 30-35 mmHg
2420761|NCT03430765|Experimental|Acceptance and Commitment Therapy|Standard breast cancer treatment plus a single 2 hour individual Acceptance and Commitment Therapy coping skills session.
2420762|NCT03430765|No Intervention|Treatment as Usual|Standard breast cancer treatment.
2420763|NCT03430752||Survivors of Childhood Solid Tumors|Survivors of Childhood Solid Tumors were invited to fill in a set of questionnaires.
2420764|NCT03430752||Survivors of Childhood Leukemia|Survivors of Childhood Leukemia were invited to fill in a set of questionnaires.
2420765|NCT03430739||Babies; Usage time of Helmet between 15-18 hours a day|Babies who worn the helmet for 15-18 hours a day
2420766|NCT03430739||Babies; Usage time of Helmet between 19-23 hours a day|Babies who worn the helmet for 19-23 hours a day
2420767|NCT03430726|Experimental|Healthy Kids Probiotic Yogurt Drink Group|Healthy children will be given a commercially available yogurt drink containing a multi-strain probiotic, Bio-Kidz® (12.5 billion CFU/98g; Lactobacillus acidophilus CL1285®, Lactobacillus casei LBC80R® and Lactobacillus rhamnosus CLR2®), daily for 14 days.
2420768|NCT03430713|Experimental|Dental colour measurement|Comparison of dental colour measurement between two shade guides VITA Classical and VITA Toothguide 3D-Master and two spectrophotometers VITA Easyshade and Spectroshade Micro
2420769|NCT03430700|Experimental|Treatment|All patient will receive Pembrolizumab (100 mg/ 4mL) every 3 weeks for a maximum of 2 years. Pembrolizumab 200mg will be administered as a 30 minute IV infusion every 3 weeks.
2420770|NCT03430687|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec intravesically (10ml of 10^6 PFU/mL) on days 1, 8, 15, 22, 29, and 36 or days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
2420771|NCT03430674|Experimental|Exercise Intervention|Clinic and at home exercise sessions.
2420772|NCT03430661|Experimental|Part A: Group 1|Clopidogrel will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
2420773|NCT03430661|Experimental|Part A: Group 2|Clopidogrel will be administered 12 h after ACT-246475 or placebo
3145953|NCT00086099|Experimental|1|Idarubicin plus amifostine
3145954|NCT00086099|Experimental|2|Idarubincin
3145955|NCT00086125|Experimental|1|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
3145956|NCT00086177|Active Comparator|1|Progesterone 8% vaginal gel
3145957|NCT00086177|Placebo Comparator|2|Placebo Vaginal Gel
3186740|NCT00748449|Active Comparator|1|CT Colonography
2420774|NCT03430661|Experimental|Part A: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and clopidogrel may be studied
2420775|NCT03430661|Experimental|Part B: Group 1|Prasugrel will be administered 12 h after ACT-246475 or placebo
2420776|NCT03430661|Experimental|Part B: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
2420777|NCT03430661|Experimental|Part B: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and prasugrel may be studied
2420778|NCT03430661|Experimental|Part C: Group 1|Ticagrelor will be administered 0.5 h after ACT-246475 or placebo, i.e., at the time of tmax
2420779|NCT03430661|Experimental|Part C: Group 2|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
2420780|NCT03430661|Experimental|Part C: Group 3|Any time interval up to 24 h between the administration of ACT-246475 or placebo and ticagrelor may be studied
2420785|NCT03430622|Experimental|LTP Plus|LTP Plus group participants will receive intervention over the telephone for 3 months one session per week for 2 months and rest of the sessions fortnightly by trained graduates, expert in delivering LTP plus intervention.
2420786|NCT03430622|Active Comparator|Treatment as Usual (TAU)|TAU group will receive routine care and their follow up will be done after completion of the intervention and then at 6-month post randomization.
2420787|NCT03430609|Active Comparator|Bipolar tweezers Astus Medical©|Laparoscopic treatment for endometrioma Astus© will use Bipolar coagulation (bipolar tweezers, Astus Medical ©, Copyright 2015, Tampa FL, USA) with 30 W power and a Valleylab generator (Medronic ©, Copyright 2017, Medtronic Parkway, Minneapolis, USA); the number of coagulated points will be counted, and the time for coagulation will be measured in seconds. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2420788|NCT03430609|Active Comparator|2-0 Vicryl® Suture|Laparoscopic treatment for endometrioma Vicryl® will use suturing with simple suture (2-0/Vicryl polyglactin absorbable synthetic suture; Ethicon Inc., New Jersey, USA); the number of sutures will be recorded. Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2420789|NCT03430609|Active Comparator|Surgicel®|Laparoscopic treatment for endometrioma Surgicel® will use Hemostatic matrix (Surgicel® Original Absorbable Hemostat, Ethicon, USA). Transvaginal ultrasound for antral follicle count and blood collection will be performed in this group of patients before surgery, 1, 3 and 6 months after the procedure to dose AMH level, FSH level and to count the number of antral follicle.
2420790|NCT03430596|Experimental|pramipexole|pramipexole ,flexible dose (0.375mg/d-0.75mg/d)
2420791|NCT03430596|Active Comparator|Antan|Antan,flexible dose (2-4mg/d)
2420792|NCT03430583||MZ101|Dosing per treatment regimen
2420793|NCT03430570|Experimental|Tablet TRAC Emotion Regulation Intervention|
2420794|NCT03430570|No Intervention|Waitlist Control|Control participants are assessed on the same schedule as the treatment condition and offered the intervention after the 3-month follow-up
2420795|NCT03430557|Experimental|Periapical surgery with PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and PRP will be filled in the lesion before closure of flap
2420796|NCT03430557|Active Comparator|Periapical surgery without PRP|MTA Retrograde filling will be performed after apicectomy for involved teeth and flap will be closed without placement of PRP
2420797|NCT03430544|Placebo Comparator|Placebo|
2420798|NCT03430544|Experimental|1.5 mg/d cariprazine|
2420799|NCT03430544|Experimental|3.0 mg/d cariprazine|
2420800|NCT03430531|Experimental|Sphenopalatine ganglion block|Sphenopalatine ganglion block: this block will be performed by inserting swabs, with lidocaine squirted on them, into each nostril and reaching the nasopharyngeal wall.
2420801|NCT03430518|Experimental|Her2-negative Metastatic Breast Ca and Recurrent Ovarian Ca|Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian cancer
2420802|NCT03430505|Active Comparator|Bilevel|Bilevel 10 minutes after bronchoprovocation with saline solution 4.5%. IPAP 12 and EPAP 8
2420803|NCT03430505|Active Comparator|Albuterol|400micrograms after bronchoprovocation with saline solution 4.5%.
2420804|NCT03430479|Experimental|Cohort A|
2420805|NCT03430479|Experimental|Cohort B|
2420806|NCT03430466|Experimental|Durvalmab&Tremelimumab&Fulvestrant|Durvalmab&Tremelimumab&Fulvestrant
2420807|NCT03430453|Experimental|Patient with ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed.
2420808|NCT03430440|Experimental|CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button.
2420809|NCT03430440|Active Comparator|Conventional mode|The conventional mode in which only the basal infusion rate is set to be fixed.
2420810|NCT03430427||Community-Dwelling Older Adults|The group will consist of 240 community-dwelling older adults with a range of mobility function based on the short physical performance battery (SPPB).
2420811|NCT03430414||Therapy Responders|
2420812|NCT03430414||Non-Responders|
2420834|NCT03430258|Placebo Comparator|conventional oxygen therapy|oxygen was delivered by a nasal cannula or nonrebreather mask
2420835|NCT03430258|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
3186741|NCT00748449|Active Comparator|2|Colonoscopy
3186742|NCT00748462|Experimental|1|Fractional CO2 laser resurfacing
3186743|NCT00748475|Experimental|Neurofeedback|
2420813|NCT03430401|Experimental|Perceptual-based memory encoding|It will involve the use of visual imagery and the method of loci. To achieve this, each of the 15 daily tasks will be filmed and a short video created. In addition, each task will be broken down into 5-6 photographed steps based on activity analysis and task breakdown. The program will prompt the user to indicate in which room of the house the task would usually be completed. Once correct location is identified, the program will prompt the user to watch a chosen daily task video and then visualise themselves completing the task in their home environment.
2420814|NCT03430401|Experimental|Semantic-based memory encoding|It will incorporate association-based strategies to assist with recalling the steps of daily tasks. The steps of a given daily task will be provided and the user will be prompted to link the steps using a honeycomb concept, which makes use of the chunking method to encode the sequenced steps. Following this, the program will prompt the user to categorise the steps according to their association with given words cues. The word cues will represent time, places, objects, and people. The program will then take the user response and form a verbal and visual story according to the responses given. The program will help identify any problems in the sequencing and prompt the user to re-categorise if required.
2420815|NCT03430401|Active Comparator|Cognitive stimulation|Participants will complete an online cognitive exercise program, Lumosity (Sarkar, Scanlon, & Drescher, 2007). A study conducted by Hardy, Drescher, Sarkar, Kellett, and Scanlon (2011) indicated that participants who engaged in Lumosity showed greater improvements in memory in comparison to a non-intervention control group.
2420816|NCT03430388|Active Comparator|Rheumatic diseases patients|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
2420817|NCT03430388|Active Comparator|Healthy controls|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
2420818|NCT03430375|Active Comparator|Alternating air then static air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the alternating air wheelchair cushion for 32 minutes and then the static air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes.
2420819|NCT03430375|Active Comparator|Static air then alternating air cushion|The participants in all three populations or groups (healthy adults, adults with stroke, and adults with spinal cord injury) will first sit on the static air wheelchair cushion for 32 minutes and then the alternating air cushion for 32 minutes under two conditions (static: sitting without intentional moving) and (active: reaching with their upper extremity) while pressure mapping and skin responses are recorded. The Roho static air cushion is a common wheelchair cushion currently used for pressure relief purposes. The Ease alternating air wheelchair cushion inflates/deflates which shifts the points of pressure [every 3 minutes] and allows fresh blood to flow where the pressure has been lifted.
2420820|NCT03430362|Active Comparator|Hyoscine group|7. Group A will receive injection Hyoscine butyl bromide 40 mg single intravenous dose
2420821|NCT03430362|Placebo Comparator|Control group|Group B, will receive 2 ml of normal saline single intravenous dose
3186744|NCT00748488|Experimental|A|Physical Therapy aimed to promote the level of physical activity
3186745|NCT00748488|Active Comparator|B|Physical Therapy aimed to move safely
2420824|NCT03430336|Experimental|Computer-assisted medication management|"Family physician adds, modifies and optimizes medication in patient's with polypharmacy assisted by an user-initiated computerized decision support system (CDSS) which provides drug-therapy relevant information about patients (e.g. diagnoses and treatments) and alerts in case of drug-drug, drug-disease, drug-age interactions to systematically assess the appropriateness of medication:~CDSS provides drug-therapy relevant information~modification of medication~assessment of medication appropriateness~medication plan~Guidance in medication process"
2420825|NCT03430336|No Intervention|Control arm|Patients will receive the usual clinical care based on current clinical practice guidelines during intervention period. After completion of trial, the patients in the control group will be invited to participate after written informed consent to receive the intervention.
2420826|NCT03430310|Experimental|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. Participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
2420827|NCT03430310|Placebo Comparator|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
2420828|NCT03430297|Experimental|JS001 240mg Q2W|
2420829|NCT03430297|Active Comparator|Dacarbazine 1000mg/m2 Q3W|
2420830|NCT03430284|Experimental|Integrated Treatment|
2420831|NCT03430284|Other|General Treatment|
2420832|NCT03430271|Active Comparator|Physical Activity (PA) Intervention|
2420833|NCT03430271|Placebo Comparator|Health Education (HE) Intervention|
3186746|NCT00748501|Active Comparator|Cohort 1|SB-509 drug administration via IM injection of neck, arms, and legs
3186747|NCT00748501|Active Comparator|Cohort 2|SB-509 drug administration via IM injection of legs
2420837|NCT03430232|Experimental|Part I (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level 1, 3, 5, 7 or placebo as a short infusion according to randomization.
2420838|NCT03430232|Experimental|Part I (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level 2, 4, 6, 8 or placebo as a short infusion according to randomization.
2420839|NCT03430232|Experimental|Part II (Panel 1): STR-324 or placebo|Subjects will receive STR-324 dose level A or placebo as a long infusion according to randomization.
2420840|NCT03430232|Experimental|Part II (Panel 2): STR-324 or placebo|Subjects will receive STR-324 dose level B or placebo as a long infusion according to randomization.
2420841|NCT03430232|Experimental|Part II (Panel 3): STR-324 or placebo|Subjects will receive STR-324 dose level C or placebo as a long infusion according to randomization.
2420842|NCT03430219||Subchondroplasty Procedure|The SCP Procedure targets and fills bone defects with AccuFill bone substitute material utilizing an arthroscopic / percutaneous approach
3186748|NCT00748527|Active Comparator|Arm I|Patients receive carboplatin IV over 30-60 minutes on day 1.
3186749|NCT00748527|Experimental|Arm II|Patients receive decitabine IV over 6 hours on day 1 and carboplatin IV over 30-60 minutes on day 8.
2420845|NCT03430193|Experimental|FIRM group|FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward. PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided.
2420846|NCT03430193|Active Comparator|Conventional group|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
2420847|NCT03430193|No Intervention|No-rehabilitation group|Discharged patients not transferred to rehabilitation unit after surgery for hip fracture.
2420848|NCT03430180|Placebo Comparator|placebo nasal spray|Drug: placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
2420849|NCT03430180|Active Comparator|Naloxone hydrochloride 40mg/ml nasal spray|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
2420850|NCT03430167|Other|Group I - Formal Therapy|Supervised physical therapy will be ordered 2 times/week initially for 6 weeks and then tailored to a minimum of 1 visit/week based upon the individual progress of each patient. Home exercises will be provided to the patient by the therapist to be performed daily. Supervised physical therapy will be discontinued once the patient demonstrates independence with the final phase of rehabilitation, which represents the graduated strengthening program.
2420851|NCT03430167|Other|Group II - Home Therapy|In the study group all patients will be instructed in a standardized fashion regarding a home exercise program. This program will involve a standardized a set of five exercises. These exercises will be reviewed with patients in clinic in a standardized fashion and patients will be provided with an instructive hand-out.
2420852|NCT03430154||Adults with hemophilia and obesity/overweight|Adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
2420853|NCT03430154||Caregivers identified with obesity/overweight|Caregivers of children (any gender) currently aged <18 years with hemophilia (any severity, with or without inhibitors) caregiver-identified with obesity or overweight
2420854|NCT03430154||Spouses or partners self-identified with obesity/overweight|Spouses or partners of adults (any gender) aged ≥18 years with hemophilia (any severity, with or without inhibitors) self-identified with obesity or overweight
2420855|NCT03430154||Healthcare profs. managing hemophilia and obesity/overweight|Healthcare professional (pediatric or adult hematologist, nurse, nurse practitioner, physician assistant, physical therapist, social worker) actively working in a federally designated hemophilia-treatment center for at least 3 years and with experience managing patients with hemophilia and obesity or overweight.
2420856|NCT03430141|Experimental|Intervention for all participants|Nutritarian Diet-style: Intervention for all participants: All participants are exposed to the same nutrition treatment/intervention protocol.
2420857|NCT03430128|Experimental|Oral IMPACT|"Perioperative immunonutrition will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.~The recommended dose for IMPACT immunotherapy is one packet, to be taken three times a day."
2420858|NCT03430128|Active Comparator|Standard Nutrition (ENSURE)|Standard nutritional supplementation will commence 5-7 days prior to surgery, and will continue for 5-7 days post-surgery, as soon as the patient is able to consume full feeds as instructed by his/her primary physician.
3186750|NCT00748592|Placebo Comparator|Placebo|
3186751|NCT00748592|Experimental|PD 0200390, 5 mg|
3186752|NCT00748592|Experimental|PD 0200390, 15 mg|
3186753|NCT00748592|Experimental|PD 0200390, 30 mg|
2420863|NCT03430102||LeftHeartCath|Patients scheduled for LV catheterization for direct measurement of LVEDP
3186754|NCT00748605|Placebo Comparator|Placebo|S-2367 placebo + LCD (Low Calorie Diet) +RCD (Reduced Calorie Diet)
3186755|NCT00748605|Experimental|S-2367 1600 mg q.d. 54 weeks|S-2367 placebo + LCD for 6 weeks and 1600 mg S-2367 + RCD for 54 weeks
3186756|NCT00748605|Experimental|S-2367 1600 mg q.d. 60 weeks|S-23671600 mg q.d. + LCD for 6 weeks and S-2367 1600 mg q.d + RCD for 54 weeks
3186757|NCT00748618|Other|1|Standard vitamin treatment
3186758|NCT00748618|Active Comparator|2|50,000 I.U. of vitamin D3
3186759|NCT00748631|Experimental|1|balloon Kyphoplasty
3186760|NCT00748644|Experimental|1|Experimental drug = rituximab for maintenance
3186761|NCT00748644|Active Comparator|2|Comparator drug = azathioprine for maintenance
3186762|NCT00748670|Experimental|A|
2420869|NCT03430076|Experimental|Revascularization by (Propaten)®|Revascularization by PTFE with heparin bonded luminal surface (Propaten)®
2420870|NCT03430076|Active Comparator|Revascularization by Crude PTFE|
3145958|NCT00086242|Experimental|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
3145959|NCT00086242|No Intervention|Usual Care|Eligible patients are randomized to receive either psychosocial telephone counseling (PTC) or usual care. The usual care are were only contacted by the study team to collect data in an identical frame to subjects receiving PTC.
3145960|NCT00086268|Experimental|Zometa®|4mg monthly for 12 months from date of first chemotherapy dose
3186763|NCT00748696|No Intervention|1|No intervention
2420876|NCT03430037|Experimental|Treatment|Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.
2420877|NCT03430037|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days, for 2 consecutive months.
2420878|NCT03430024||Cases|"We will enrol 100 women who have been newly diagnosed with T2 (>2cm) palpable invasive breast cancer having primary surgical treatment at Maidstone Hospital. We will exclude all patients with a metabolic disorder, significant co-morbidities and locally advanced or metastatic disease as well as those with a previous history of cancer treatment. We will collect data on tumour size, grade and phenotype as well as ER, progesterone receptor (PR) and Her-2 expression status and patient demographic information.~We will investigate the Association of Myosin VI with oestrogen receptor."
2420879|NCT03430024||Controls|A cohort of control breast tissue will be obtained from 20 patients undergoing benign surgical breast procedures. For those control patients having reduction mammoplasties the excised tissue will be core biopsied but patients having other types of benign surgery will have an extra core biopsy taken from breast tissue surrounding the lesion being excised.
2420880|NCT03430011|Experimental|JCARH125|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by a single dose of JCARH125
2420881|NCT03430011|Experimental|JCARH125 + anakinra|Subjects will receive a course of lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by prophylactic treatment with anakinra and a single dose of JCARH125
2420882|NCT03429998|Placebo Comparator|LDL apheresis|LDL apheresis during at least one year
2420883|NCT03429998|Active Comparator|Evolocumab|140 mg evolocumab biweekly
2420884|NCT03429998|Active Comparator|LDL apheresis and evolocumab|LDL-apheresis monthly evolocumab 140 mg biweekly
3145961|NCT00086268|No Intervention|no further treatment|Control arm; no further treatment. Follow-up monthly for 12 months from date of first chemotherapy dose
3145962|NCT00086359|Experimental|A|One pill of abacavir/lamivudine/zidovudine twice daily
2420887|NCT03429972|Experimental|Paclitaxel and Elasto-Gel™ Cryotherapy|Cryotherapy will be applied using Elasto-Gel™ hypothermia mitts and slippers for 15 minutes before, during and 15 minutes after each paclitaxel infusion.
2420888|NCT03429972|Other|Paclitaxel alone|Paclitaxel will be administered without cryotherapy.
2420889|NCT03429959|Experimental|SOCKNLEG|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
2420890|NCT03429959|Active Comparator|SIGVARIS Cotton|Donning and doffing success of the study stocking compared with both stockings, wearing of the study stocking for a day, standardized non invasive measurement to calculate leg volume of the study leg
2420891|NCT03429946|Active Comparator|Hypoglycemia and Spironolactone|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of 100 mg of spironolactone - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2420892|NCT03429946|Active Comparator|Hypoglycemia and Placebo|Participants undergo two 120-minute hypoglycemic hyperinsulinemic clamp procedures (50 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2420893|NCT03429946|Placebo Comparator|Euglycemia and Placebo|Participants undergo two 120-minute euglycemic hyperinsulinemic clamp procedures (90 mg/dL) - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Participants receive two doses of placebo - one dose 12 hours and one dose 3 hours before the first clamp starts. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
2420894|NCT03429933|Experimental|Single Ascending Dose|BMS-986278 or placebo
2420895|NCT03429933|Experimental|Multiple Ascending Dose|BMS-986278 or placebo
2420896|NCT03429920|Experimental|Q CAN PLUS POWDER|QCAN PLUS POWDER:2 pouches per day, each pouch contains(12-15gms of fermented soy powder)
2420897|NCT03429920|Placebo Comparator|placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research Inc.)
2420900|NCT03429894|Experimental|Treatment|All patients will undergo imaging (angiography and IVUS) follow-up with approximately one-half of the patients returning for follow up at 9 months and approximately one-half returning for follow up at 12 months.
2420901|NCT03429881|Active Comparator|Laparoscopic stripping ovarian endometriomas|
2420906|NCT03429829|Experimental|Flairesse varnish|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as fluoridated toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. In addition, fluoride varnish (22.600 ppm, DMG, Hamburg, Germany) was applied in 3-monthly intervals by the local non-professional assistants who had been trained beforehand and supervised at the first application.
2420907|NCT03429829|No Intervention|Control|Children were part of the LiveSmart tooth brushing program. They all received a new toothbrush at baseline and at every follow-up visit as well as toothpaste. Their daily toothbrushing was supervised by the local trained non-professional assistant. Beyond that, the children in this arm were left untreated.
2420908|NCT03429816|Experimental|Interventional Arm|"Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.~Organoid cultures of pre-treatment tumor biopsies will be established and exposed to the same chemotherapy as the corresponding patient; in vitro response to treatment will be correlated with the in vivo response of patients.~Whole genome, methylome and RNA sequencing of tumors biopsies and organoids will be performed prior to as well as after systemic treatment."
2420911|NCT03429790|Experimental|group intra-operative cell salvage|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether the experimental group or the no intervention group."
2420912|NCT03429790|Active Comparator|group allogeneic blood transfusion|"The theoretical amount of blood transfusion should be based on the following formula:~The amount of blood transfusion needed (ML) * Hb= (Hb2-Hb1) * blood volume of blood transfusion Hb1: actual measured hemoglobin; Hb2: target hemoglobin (100 g / L) Blood volume = 100ml/kg * body weight The difference between the actual blood transfusion and the theoretical blood transfusion should be controlled within ± 15% of the theoretical blood transfusion (in terms of hemoglobin), whether group intra-operative cell salvage or group allogeneic blood transfusion."
2420913|NCT03429777|Experimental|Hearing Loss Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in patients with hearing loss.
2420914|NCT03429777|Active Comparator|Control Group|The investigators will characterize hearing-in-noise thresholds (also referred to as a speech-reception threshold) as measured by the HearMe app in control subjects without any prior or current hearing loss.
2420915|NCT03429764|Active Comparator|Control group (CG),CISS|continuous independent sling sutures (CISS) will be placed with minimum two intact contact points at the surgical site,
2420916|NCT03429764|Experimental|Test group (TG),VIMS|internal mattress suture (VIMS) will be placed with minimum two intact contact points at the surgical site,
2420917|NCT03429751|Experimental|Liberal fluid group|received 30 ml/Kg/h crystalloid for maximum 3 hours.
2420918|NCT03429751|Active Comparator|Restrictive fluid group|received 10 ml /Kg/h crystalloids for maximum 3 hours.
2420919|NCT03429738|Experimental|Experimental Drug|Drug: Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets Temmler Werke GmbH/ Part of Aenova Group, Germany, Intervention: one tablet administered after an overnight fast of at least 10 hours
2420920|NCT03429738|Active Comparator|Active Comparator|Active Comparator: RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets Wyeth Santé Familiale, France, Intervention: one tablet administered after an overnight fast of at least 10 hours
2420921|NCT03429725|Experimental|Individualism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For individualism condition, participant is tasked to write statements relating to his/her differences from the his/her immediate community, circle pronouns that relate to the self, and read passages related to individualism.
2420922|NCT03429725|Experimental|Collectivism|Participant will be randomly allocated to either the individualism condition or the collectivism condition. For collectivism condition, participant is tasked to write statements relating to his/her similarities to the his/her immediate community, circle collective pronouns, and read passages related to collectivism.
2420924|NCT03429699|Experimental|Intervention group|
2420925|NCT03429699|Other|Control group|
2420926|NCT03429686|Experimental|DRT Intervention|Intervention: Individual digital reminiscence therapy programme.
2420927|NCT03429673||Patients with surgeries|Pathologically diagnosed elderly early Chinese patients with non-small cell lung cancer who received lobectomy or segment/wedge dissection
2420928|NCT03429660||Cohort|"Data to be collected are :~- Medical information on Immune Thrombocytopenia treatment"
2420929|NCT03429647|Other|Sigmoid perfusion|Measured by visible light spectroscopy
2420930|NCT03429634|Experimental|Balloon-Stent Kissing technique|randomly, patients with bifurcation lesion treated by Balloon-Stent Kissing intervention technique in this group.For procedure,stent in main vessel and balloon protect of side branch,final kiss-balloon was performed.
2420931|NCT03429634|Sham Comparator|Jailed Wire technique|randomly,patients with bifurcation lesion treated by Jailed Wire intervention technique in this group.For procedure,stent in main vessel and only wire protect of side branch.If need,post-stent rewire of branch,and balloon dilation of side branch was performed.
2421105|NCT03428529|Active Comparator|5-Flourouracil|Neoadjuvant 5-Fluorouracil plus RT
2420932|NCT03429621|Experimental|Simethicone|Each woman in the intervention group will be given Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery.
2420933|NCT03429621|No Intervention|No simethicone|The women will not be given Simethicone.
2420934|NCT03429608||patients with low thrombus burden|patients with the lower volume of aspirated thrombi, as measured using micro-CT
2420935|NCT03429608||patients with high thrombus burden|patients with the higher volume of aspirated thrombi, as measured using micro-CT
2420936|NCT03429595|Experimental|Group 1: ATx201 GEL 2%|
2420937|NCT03429595|Experimental|Group 2: ATx201 GEL 4%|
2420938|NCT03429595|Experimental|Group 3: ATx201 GEL 4% plus vehicle|
2420939|NCT03429595|Experimental|Group 4: ATx201 GEL 4% plus vehicle|
2420940|NCT03429595|Placebo Comparator|Group 5: Vehicle|
2420941|NCT03429582|Active Comparator|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
2420942|NCT03429582|Experimental|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
2420943|NCT03429582|Experimental|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
2420944|NCT03429569|Sham Comparator|accelerated conventional technique|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
2420945|NCT03429569|Sham Comparator|iontophoresis|"Pachymetry greater than 400μm~Topographic criteria for keratoconus evolution:~Variation over a 6-month period of the following changes:~An increase equal to or greater than 1D of maximum keratometry (Kmax) And / or an increase in mean keratometry (Kmean) greater than or equal to 0.75D And / or an increase in the difference between the meridian and the most arched and the least arched (Kmax-Kmin) greater than or equal to 0.75D And / or a decrease in the central thickness greater than or equal to 2% Criteria of non-inclusion Age under 18 Ectasies post LASIK Pregnant women breastfeeding Major corneal opacities Absence of consent to participation in the study No affiliation to Social Security or State Medical Aid (AME) or Universal Medical Coverage (CMU)"
3145963|NCT00086359|Experimental|B|One pill of zidovudine/lamivudine and four pills of lopinavir/ritonavir twice daily.
3145964|NCT00086489|Experimental|10 mg/kg|pts treated at 10 mg/kg dose level on a monthly regimen
3145965|NCT00086489|Experimental|15 mg/kg|pts treated at 15 mg/kg dose level on a quarterly regimen
2420953|NCT03429530||Group1|20 patients with chronic HCV
2420954|NCT03429530||GroupII|20 patient with chronic HCV related liver cirrhosis
2420955|NCT03429530||GroupIII|40 patients with chronic HCV related liver cirrhosis complicated by hepatocellular cacinoma
2420956|NCT03429530||group IV|20 healthy blood donors will also be included as a control group
2420957|NCT03429517||Patients|ACS Lipogram
2420958|NCT03429517||Controls|Normal LDL-C level Lipogram
2420959|NCT03429504||Obese breast cancer patients|Response to treatment and progression free survival in obese breast cancer patients
2420960|NCT03429504||non obese breast cancer patients|Response to treatment and progression free survival in non obese breast cancer patients
2420961|NCT03429491|Placebo Comparator|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
2420962|NCT03429491|Experimental|Leucine-enriched protein|Juice based supplement containing leucine-enriched protein
2420963|NCT03429491|Experimental|Leucine-enriched protein + LC n-3 PUFA|Juice based supplement containing leucine-enriched protein and LC n-3 PUFA
2420964|NCT03429478|Experimental|Music|Preoperative application of a Bluetooth enabled headphones with standard music played for atleast 2 hours preoperatively.
2420965|NCT03429478|Active Comparator|No Music|Preoperative application of a Bluetooth enabled headphones with no music played and headphones will just mask the surrounding noise.
2420966|NCT03429465|Experimental|EVO|All children receive 4 weeks of EVO 5 days/week for 20 minutes per day in a stepped wedge design.
2420967|NCT03429439|Experimental|IMT Combined with Antiviral Therapy|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved a 6 times intestinal microbiota transplant and the time interval is generally 2 weeks.~Interventions:~Procedure: Intestinal Microbiota Transplantation Procedure: antiviral therapy"
2420968|NCT03429439|Other|Antiviral Agents|"60 chronic hepatitis B patients ongoing antiviral therapy will be recruited for the study, which involved 12 months antiviral therapy.~Interventions:~Procedure: antiviral therapy"
2420969|NCT03429426||Rheumatoid arthritis|"Patients with Rheumatoid arthritis ≥5 years according to the ACR/EULAR 2010 classification criteria or the American Rheumatism Association 1987 revised criteria.~ICD-10: M059 Seropositive rheumatoid arthritis UNS, M060 Seronegative rheumatoid arthritis, M069 Rheumatoid arthritis UNS."
2420970|NCT03429426||Pre-Rheumatoid arthritis|Patients with joint pain, but no swelling and Anti-CCP 3 times above the upper limit.
2420971|NCT03429426||Healthy Subjects|Healthy age- and sex-matched Individuals are recruited, as a control group.
2421106|NCT03428516|Experimental|Fixed CPAP|CPAP always deliver air with the same pressure
3145966|NCT00086645|Experimental|citalopram hydrobromide|citalopram hydrobromide, up to 20 mg daily
3145967|NCT00086645|Placebo Comparator|placebo|placebo, up to equivalent of 20 mg of active comparator daily
3145968|NCT00086671|Experimental|ABT-874 200 mg weekly|
3145969|NCT00086671|Placebo Comparator|Placebo|
3145970|NCT00086671|Experimental|ABT 874 QOW|
3145971|NCT00086736|Experimental|Arm I|Patients receive oral eflornithine and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3145972|NCT00086736|Experimental|Arm II|Patients receive oral eflornithine and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
2420972|NCT03429413|Active Comparator|Parents|Parents of 11-12 year old children who visit participating interventional clinics during study period.
2420973|NCT03429413|Active Comparator|Health Care Provider|Health care providers and clinic staff for 11-12 year old patients at 4 participating pediatric clinics.
2420974|NCT03429413|No Intervention|Adolescents at Intervention clinics|Adolescents between 11-12 years of age. Adolescent vaccination data is used in the study, adolescents will assent to participate. The parents, however, use the HIT system.
2420975|NCT03429413|No Intervention|Adolescents at Control Clinic|Parents of 11-12 year old children who visit participating control clinics during study period.
2420976|NCT03429413|No Intervention|Health Care Provider at Control Clinic|Health care providers and clinic staff for 11-12 year old patients at 3 participating pediatric control clinics.
2420977|NCT03429400|Other|Morphine Sulfate|oral morphine sulfate tablets oral morphine sulfate oral solution
2420978|NCT03429387|Experimental|FDG-PET/CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have an FDG-PET/CT performed to look for source of fever.
2420979|NCT03429387|Active Comparator|Conventional CT arm|Participants with persistent febrile neutropenia after 72 hours of onset who are randomized to this arm will have a conventional CT (HRCT chest and sinuses +/- other regions as per clinician's discretion) performed to look for source of fever.
2420980|NCT03429374|Active Comparator|Liquiband Fix8 glue mesh fixation|
2420981|NCT03429374|Active Comparator|Mesh fixation with absorbable tacks|
3186764|NCT00748696|Experimental|2|patient receiving oral nutrition supplement
3186765|NCT00748696|Experimental|3|resistance training
2420984|NCT03429335|Experimental|Teaching session & Just TRAC It|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will also explain Just TRAC It! and help the youth to enter their health information into their phone."
2420985|NCT03429335|Active Comparator|Teaching session & MyHealth Passport|"Youth will attend a single one-on-one teaching session with a cardiology nurse (RN) the same day as their pediatric cardiology clinic visit. The RN will help youth complete and print out a MyHealth Passport to track their medical information."
2420986|NCT03429322|Experimental|Medical Care and Resource Facilitation|All intervention components will be delivered remotely: there will be no face-to-face interaction with the participants. The intervention is comprised of the clinical, educational, and supportive services of Mayo's Brain Rehabilitation Clinic integrated with the MN BIA RF program.
2420987|NCT03429322|Active Comparator|Usual care|Individuals with TBI, their family members and PCPs assigned to the usual care group will receive care and provide services as usual in their communities. Individuals with TBI assigned to the usual care group will receive RF as routinely provided by MN BIA.
2420988|NCT03429309|Other|Anesthesia-induction with propofol|
2420989|NCT03429296|Experimental|Autohypnosis learning|In this arm, patients are taught autohypnosis during sessions in groups of 3 to 6 with a qualified hypnotherapist. Sessions are set every two weeks, for a total of 6 sessions. Individual sessions are possible for patients who missed a session.
2420990|NCT03429296|No Intervention|Standard of care|In this arm, patients are not taught autohypnosis and are treated according to standard of care.
3186766|NCT00748696|Experimental|4|patients receiving resistance training and oral nutritional supplement
2420992|NCT03429257||Pregnant Women in Mukono Uganda|Single-group study
2420993|NCT03429244|Experimental|Low and intermediate risk prostate cancer|
2420994|NCT03429231||Active Group|Women who are taking coenzyme Q and who will continue taking it for 3 months
2420995|NCT03429231||Control Group|Women who are not taking coenzyme Q and who will not take it in the next 3 months
3186767|NCT00748722||1|Female patients, age 18-60 years, suitable for breast reconstruction using the lower abdominal tissue.
2420997|NCT03429205|Experimental|No heating - Study group|Patient will undergo bariatric surgery without utilization of external heating device.
2420998|NCT03429205|Other|Heating - Control group|Patient will undergo bariatric surgery with utilization of external heating device.
2420999|NCT03429192||N2 non-small cell lung cancer|Chinese patients with N2 non-small cell lung cancer
2421000|NCT03429179|Experimental|High anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were >10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
2421001|NCT03429179|Placebo Comparator|High anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were >10, and received an infusion of the same volume of 0.9% saline
2421002|NCT03429179|Experimental|Low anxiety butorphanol group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
2421003|NCT03429179|Placebo Comparator|Low anxiety 0.9% saline group|preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline
2421004|NCT03429166|Experimental|STAIR|STAIR stands for Skills Training in Affective and Interpersonal Regulation a non-trauma-focused treatment
2421005|NCT03429166|Active Comparator|PCT|PCT stands for Present Centered Therapy, a non-trauma-focused treatment
2421006|NCT03429140|Experimental|Group 1 - Gel-One|Gel-One (3ml/30 mg Hyaluronan) one time injection at visit 3
2421007|NCT03429140|Placebo Comparator|Group 1 - Saline Placebo|3 ml saline placebo one time injection at visit 3
2421008|NCT03429127||Normal saline fluid group|The patients in this group will receive up to 2000 ml of normal saline during neurosurgical operation.
2421009|NCT03429127||Balanced fluid group|The patients in this group will receive up to 2000 ml of balanced fluids during neurosurgical operation.
2421010|NCT03429114||Binge eating/purging|Adolescents engaging in recurrent binge eating and/or purging behavior.
2421011|NCT03429114||Healthy comparison|Adolescents who do not have a history of eating disorders
2421012|NCT03429101|Experimental|Poziotinib|"Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD."
2421013|NCT03429088|Experimental|Telephone counseling|Participants were provided with approximately 7 telephone-based motivational interviewing over a 24-week period to increase their physical activity.
2421014|NCT03429088|No Intervention|Usual care|Participants in the usual care arm received a packet of places near their home in which they could engage in physical activity if they chose.
2421015|NCT03429075|Experimental|Psilocybin|Patients receive Psilocybin
2421016|NCT03429075|Active Comparator|Escitalopram|Patients receive Escitalopram
2421017|NCT03429062||personal training|Individuals with a diagnosis of MS and any level of function will be recruited to participate in exercise two times per week with trained personal trainers. Exercise consists of strengthening, stretching, balance, endurance and gait when able. Equipment to be used include treadmill, stationary bike, weight equipment.
2421018|NCT03429062||Whole Body Platform|Individuals with a diagnosis of MS and able to walk with or without an assistive device will be recruited to participate in whole body platform training two times per week with a physical therapist. The exercise on the whole body platform includes strengthening, balance, stretching, and endurance for 30 second bouts. The whole body platform is on for 30 seconds then off. Each exercise will use the 30 seconds to complete.
2421019|NCT03429049|Placebo Comparator|Placebo|Single intra-articular 1.0 mg Placebo Injection
2421020|NCT03429049|Experimental|CNTX-4975-05|Single intra-articular 1.0 mg CNTX-4975-05 (trans-capsaicin) injection
3186768|NCT00748735||A1|heart failure patients undergoing CRT implantation
2421022|NCT03429010|Experimental|"New guideline"|"New guideline anesthesia strategy team (Group A)"
2421023|NCT03429010|No Intervention|Current strategy|Current anesthesia strategy team (Group B)
3186769|NCT00748748|Experimental|1|Lactobacillus rhamnosus GG capsule three times per day while taking their antibiotic(s) and for 7 days following completion of the antibiotic.
2421026|NCT03428984|Experimental|EXPAREL 20 + 20|20 mL EXPAREL with 20 mL normal saline
2421027|NCT03428984|Experimental|EXPAREL 20 + 10|20 mL EXPAREL with 10 mL normal saline
2421028|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) fortnightly|Arm 1a: NUC-3373 administered IV followed by a 2-week washout period. The next dose of NUC-3373 administered in combination with LV at 400 mg/m2. All subsequent doses of NUC-3373 administered in combination with LV every 2 weeks in 28-day cycles.
2421029|NCT03428958|Experimental|NUC-3373 fortnightly|Arm 1b: LV 400 mg/m2 administered IV over 2 hours prior to NUC-3373 infusion followed by a 2-week washout period. Then, NUC-3373 administered IV every 2 weeks without LV in 28-day cycles.
2421030|NCT03428958|Experimental|NUC-3373 + leucovorin (LV) weekly|Arm 1c: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV weekly on Days 1, 8, 15 and 22 of 28-day cycles.
2421031|NCT03428958|Experimental|NUC-3373 + leucovorin (LV); combination chemotherapy ineligible|Arm 1d: LV 400 mg/m2 administered IV over 2 hours followed by NUC-3373 administered IV on Days 1, 8, 15 and 22 of 28-day cycles.
2421032|NCT03428958|Experimental|NUC-3373 + oxaliplatin weekly|Arm 2a: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
2421033|NCT03428958|Experimental|NUC-3373 + irinotecan weekly|Arm 2b: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
2421034|NCT03428958|Experimental|NUC-3373 + oxaliplatin (NUFOX) expansion|Arm 2c: At the completion of Arm 2a, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with oxaliplatin (85 mg/m2) administered on Days 1 and 15.
2421035|NCT03428958|Experimental|NUC-3373 + irinotecan (NUFIRI) expansion|Arm 2d: At the completion of Arm 2b, the recommended dose of NUC-3373 (+LV 400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with irinotecan (180 mg/m2) on Days 1 and 15.
2421036|NCT03428958|Experimental|NUFOX + bevacizumab weekly|Arm 3a: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV will be administered weekly, oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
2421037|NCT03428958|Experimental|NUFOX + bevacizumab fortnightly|Arm 3b: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c will be combined with bevacizumab. NUC-3373+LV+oxaliplatin will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
2421038|NCT03428958|Experimental|NUFIRI + bevacizumab weekly|Arm 3c: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV will be administered weekly, irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
2421039|NCT03428958|Experimental|NUFIRI + bevacizumab fortnightly|Arm 3d: NUC-3373, LV and irinotecan at dose levels used in Arm 2d will be combined with bevacizumab. NUC-3373+LV+irinotecan will be administered fortnightly and bevacizumab will be administered in accordance with standard local practice.
2421040|NCT03428958|Experimental|NUC-3373 + LV + bevacizumab; maintenance patients|Arm 3e: NUC-3373+LV (400 mg/m2) administered weekly on Days 1, 8, 15 and 22 of 28-day cycles in combination with bevacizumab and bevacizumab will be administered in accordance with standard local practice.
2421041|NCT03428958|Experimental|NUFOX + cetuximab|Arm 3f: NUC-3373, LV and oxaliplatin at dose levels used in Arm 2c may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, oxaliplatin will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
2421042|NCT03428958|Experimental|NUFIRI + cetuximab|Arm 3g: NUC-3373, LV and irinotecan at dose levels used in Arm 2d may be administered in subsequent cetuximab cohorts. NUC-3373+LV may be administered weekly or fortnightly, irinotecan will be administered fortnightly and cetuximab will be administered in accordance with standard local practice.
2421045|NCT03428932|Active Comparator|Standard Care|Subjects will continue on their current treatment (insulin pump or injections), with follow up every 3 months. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
2421046|NCT03428932|Active Comparator|Closed-Loop|Subjects will transition from their current treatment (insulin pump or injections) onto the Medtronic 670G insulin pump (intervention arm as a comparator) and will have close contact with the study team. Neurocognitive testing and brain MRI/fMRI will be done at enrollment and 6 months.
2421047|NCT03428919|Active Comparator|Intracytoplasmic Sperm Injection (ICSI)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3 under ultrasound guidance. A maximum of 2 embryos will be transferred into the uterus. The remaining grade 1 and 2 embryos will be frozen."
2421048|NCT03428919|Active Comparator|In Vitro Fertilization (IVF)|"All patients will be treated with a GnRH antagonist protocol. hCG (Ovitrelle 250 mg) will be used in the presence of at least three leading follicles of 17 mm. In women with ≥15 follicles ≥12 mm, 0,2 mg Triptorelin (Diphereline) will be used when there is at least two leading follicles of 17 mm. Oocyte retrieval will be performed 36 hours after triggering.~Insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours (100,000 motile sperm/ml). Inseminated OCCs will be cultured overnight in culture medium.~Fertilization check will be performed at period of 16-18 hours after insemination. Embryo transfer will be performed on day 3. A maximum of 2 embryos will be transferred. The remaining grade 1-2 embryos will be frozen."
2421049|NCT03428906|Experimental|Oxytocin|Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment, stress and anxiety. Subjects receiving an intranasal spray of OXT (8 IU or 13.44 mg; Syntocinon-spray; Novartis, Switzerland) .
2421050|NCT03428906|Placebo Comparator|Placebo|Placebo contains all ingredients except for the peptide in three puffs of 1.33 IU per 2.24mg nostril.
2421051|NCT03428893|Experimental|Mobile Application Group|The mobile app group will receive physical therapy as determined by the physical therapist and agree to receive the home exercise prescription using a mobile app on their phone or personal tablet
2421052|NCT03428893|No Intervention|Control|The control group will receive physical therapy as determined by the physical therapist based on clinical practice guidelines and will receive the home exercise program in the traditional way through paper exercise handouts
2421053|NCT03428880|Active Comparator|spinal morphine|intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
2421054|NCT03428880|Active Comparator|quadratus lumborum block|"intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline.~Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side."
2421055|NCT03428841||Patients with dural puncture at epidural|Patients who sustained an accidental dural puncture during the epidural procedure.
2421056|NCT03428841||Patients with no dural puncture|Patients with no dural puncture during epidural procedure, to serve as a control group.
2421057|NCT03428828|Experimental|Amygdala Neurofeedback|attempt to up regulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Five sessions will be performed within a 2 month period.
2421058|NCT03428828|Active Comparator|Parietal Neurofeedback|attempt to upregulate the left horizontal segment of the intraparietal sulcus, a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback. Five sessions will be performed within a 2 month period.
3186770|NCT00748761|Experimental|OCD Active CBT|Children with obsessive-compulsive disorder (OCD) will be treated with cognitive behavioral therapy (CBT) from the time of enrollment.
3186771|NCT00748761|Active Comparator|OCD Waitlist|Children with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
2421061|NCT03428802|Experimental|Treatment (pembrolizumab)|Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants with disease progression may continue pembrolizumab for up to 1 year.
2421062|NCT03428789||Innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction with additional sensory nerve coaptation.
2421063|NCT03428789||Non-innervated DIEP flaps|Patients in this group underwent immediate or delayed, unilateral or bilateral deep inferior epigastric artery perforator (DIEP) flap breast reconstruction without sensory nerve coaptation.
2421064|NCT03428776|Sham Comparator|Controls|Self returns
2421065|NCT03428776|Active Comparator|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives
2421066|NCT03428776|Active Comparator|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives
2421067|NCT03428763|Experimental|Homebased disease monitoring (eHealth)|Participants allocated to the intervention group will be trained in self-monitoring of their RA
2421068|NCT03428763|Active Comparator|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
2421071|NCT03428737|Other|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
2421072|NCT03428737|Other|Nocturnal pressure support ventilation|Use of a pressure support level identical during the night to the pressure support level at the end of the day.
2421073|NCT03428724|Active Comparator|standard group|standard polyethylene glycol preparation for colonoscopy
2421074|NCT03428724|Experimental|individualized group|either a low or a high volume bowel preparation according to patient characteristics
2421075|NCT03428711|Placebo Comparator|Placebo Oral Tablet|Placebo comparator twice-a-day, for 12 months
2421076|NCT03428711|Experimental|Mesoglycan Oral Tablet|"a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~50 mg, twice-a-day, for 12 months"
2421077|NCT03428698|Experimental|experimental device|The extraction was completed, the socket was filled with a topical amino acid + sodium hyaluronate gel (Aminogam®, sterile syringe 2 ml).
2421078|NCT03428698|Placebo Comparator|control no device|The extraction was completed, socket was flushed, using a 2ml sterile syringe similar to one utilized to apply the gel, with sterile physiological solution.
2421079|NCT03428685|Active Comparator|Intervention group|
2421080|NCT03428685|Placebo Comparator|Placebo group|
2421081|NCT03428672|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2421082|NCT03428672|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2421083|NCT03428659||Sub-acute stroke|More than 1 week post-stroke Ischemic or hemorrhagic stroke
2421084|NCT03428633|Active Comparator|Group A|Thoracic paravertebral block using ropivacaine
2421085|NCT03428633|Active Comparator|Group B|Morphine IV
2421086|NCT03428620|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints that will be manipulated include proximal tibiofibular, the distal tibiofibular, and talocrural joints and will be mobilized the first three sessions prior to the participants performing the exercise protocol.
2421087|NCT03428620|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
2421088|NCT03428607|Experimental|AZD6738+Olaparib|AZD6738 160mg QD per os administered for 7 days and olaparib 300mg BID per os administered daily. One cycle is considered of 28 days.
2421089|NCT03428594|Experimental|CKD-11101|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2421090|NCT03428594|Active Comparator|NESP|The dose of investigational product (Darbepoetin alfa) is adjusted according to the principles reflecting the MFDS (Ministry of Food and Drug Safety) approval for NESP, but is determined by the investigator's judgment considering various factors of the subjects that may affect the treatment of anemia.
2421091|NCT03428581|Experimental|ALND with ARM +/- LVB|Axillary Lymph Node Dissection (ALND) using Axillary Reverse Mapping (ARM) with Lympho-venous bypass (LVB) will be performed.
2421092|NCT03428581|Active Comparator|ALND without ARM +/- LVB|Axillary Lymph Node Dissection (ALND)
2421093|NCT03428568|Experimental|Herbal Melanin|Herbal melanin 1800 milligram(mg) orally thrice a day with meals (300mgx2 capsules)
2421094|NCT03428568|Active Comparator|Nexium|omeprazole 40 mg once per day for one month.
2421095|NCT03428568|Experimental|H-Pylori infected : Herbal Melanin|Herbal melanin 1800 mg orally thrice a day(TID) with meals (300 mg x2 capsules)
2421096|NCT03428568|Active Comparator|nexium+ amoxil+clarithromycin|"omeprazole40 mg P.O. Twice per Day(BID) for one month + Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks.~Omeprazole+Amoxil+clarithromycin is the standard triple therapy given"
2421097|NCT03428568|Experimental|nexium +Herbal melanin|omeprazole 40 mg P.O. BID for one month +1800 mg Herbal melanin PO TID (300mg x2 capsules) Omeprazole + Herbal melanin will be tested
2421098|NCT03428568|Experimental|Herbal melanin+amoxil+ clarithromycin|Amoxil 1000mg P.O. BID for 2 weeks+ Clarithromycin500 mg PO BID for two weeks +1800 mg Herbal melanin PO TID(300 mg X 2 capsules) Herbal melanin+Amoxil+Clarithromycin will be tested
2421099|NCT03428555|Experimental|Integrate Care Pathway|"The intervention is an Integrated Care Pathway with 3 key components.~Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People.~Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol.~Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD)."
2421100|NCT03428555|Active Comparator|Treatment As Usual|Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
2421101|NCT03428542|No Intervention|Control arm|Instructed not to practice any yoga or mindfulness during the five-week study period.
2421102|NCT03428542|Active Comparator|Yin yoga intervention arm|"The Yin yoga intervention arm will receive Yin yoga, a calm-paced practice that uses seated and lying down positions.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
2421103|NCT03428542|Active Comparator|YOMI program intervention arm|"The YOMI intervention arm will receive stress education + yoga, and bring together education about stress, mindfulness and yoga practice. It will involve weekly group meetings, homework, and yoga postures. Stress education and mindfulness will make up one portion of the intervention. This will take place in a group lecture format and shall be conducted by a mental health professional(s). Yoga practice in a group format will make up the second portion of the intervention.~Participants were also provided a CD which contained a 10-minute voice recording called conscious breathing. The guided instructions encouraged participants to keep awareness on their breath and to use calm, slow, nostril breathing."
2421104|NCT03428529|Experimental|Capecitabine|Neoadjuvant capecitabine plus RT
2421177|NCT03427996||Coronary disease|
2421107|NCT03428516|Active Comparator|Auto-adjusting CPAP|Auto-CPAP changes the pressure delivered depending on events detected at any time (apnea, hypopnea …) and applies the lowest pressure required to eliminate events.
2421108|NCT03428503|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
2421109|NCT03428503|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
2421110|NCT03428490|Experimental|Fully Integrated Treatment|Evidence-based substance use treatment combined with Cognitive Behavioral Therapy (CBT) for Social Anxiety Disorder Intervention name: Fully integrated treatment
2421111|NCT03428490|Active Comparator|Usual Intensive Outpatient Care|Evidence-based substance use disorder treatment Intervention name: Stand-alone Intensive Outpatient Program
2421112|NCT03428477|Experimental|Icosapent Ethyl (EPA-EE)|Soft gelatin capsules containing 1g pure EPA-EE equivalent to 914mg EPA-FFA. Administered as 4g per day to be taken as 2 capsules in the morning and 2 capsules in the evening.
2421113|NCT03428477|Placebo Comparator|Placebo|Soft gelatin capsules containing light mineral oil. 4 capsules to be taken per day (2 in the morning and 2 in the evening).
2421114|NCT03428464|Experimental|Sodium bicarbonate|During the treatment period, participants will receive 0.5 mEq/kg-lean body weight (LBW)/day of oral sodium bicarbonate for 8 weeks.
2421115|NCT03428464|Placebo Comparator|Placebo|During the control period, participants will take the same number of placebo capsules as if they were assigned 0.5 mEq/kg-LBW/day of sodium bicarbonate.
2421116|NCT03428451|Active Comparator|Group A (Hypertonic saline )|patients will receive NaCl 3% HS at a dose of 4 ml/kg/hr.
2421117|NCT03428451|Active Comparator|Group B (Hypertonic saline)|patients will receive NaCl 3% HS at a dose of 2 ml/kg/hr.
2421118|NCT03428451|Active Comparator|Group C (Normal saline)|patients will receive NaCl 0.9% NS at a dose of 6 ml/kg/hr.
2421119|NCT03428438|Other|Study group SMS to home phone|A physical reminder by a physiotherapist, and a daily reminder of physical exercise by SMS on weekdays A through E.
2421120|NCT03428438|Other|Controlled group hospital based|Physical rehabilitation in the ward physiotherapist
2421121|NCT03428425|Experimental|apatinib paclitaxel S-1|
2421122|NCT03428412|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
2421123|NCT03428412|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM in addition conventional drug according to 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.
2421124|NCT03428399||Breast reconstruction patients|Self-reported psychosocial variables and a clinical interview assessing mental health history will be administered prior to participants' scheduled mastectomy and breast reconstruction surgery (which is part of their routine medical care for cancer treatment or prevention). Follow up self-report measures will be collected after the surgery as well.
2421125|NCT03428386|Experimental|Gastric plication ileal bypass|single-anastomosis plication ileal bypass
2421126|NCT03428373|Experimental|Len-Dex+Rivaroxaban|Patients with MM will receive Len-Dex combination and Rivaroxaban (10 mg) daily
2421127|NCT03428373|Active Comparator|Len-Dex+ASA|Patients MM will receive Len-Dex combination and ASA 81 mg daily
3186772|NCT00748761|No Intervention|Healthy Controls|Healthy control children will be given no intervention.
2421129|NCT03428347|Experimental|Group 1|1.4 mg/kg body weight
2421130|NCT03428347|Experimental|Group 2|7 mg/kg body weight
2421131|NCT03428347|Experimental|Group 3|14 mg/kg body weight
2421132|NCT03428334|Experimental|Oral roflumilast|oral roflumilast 500 microgram daily for 4 weeks
2421133|NCT03428308|Experimental|Individualized treatment of detected somatic disease(s)|
2421134|NCT03428295|Experimental|Experimental: Single Cohort in CRC|This study is a single-arm, single-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
2421135|NCT03428282|Experimental|VR Box|Inferior alveolar nerve block will be performed with the aid of VR box as a means of distracting patients' attention.
2421136|NCT03428282|Experimental|Tablet device|Inferior alveolar nerve block will be performed with the aid of a tablet device as a means of distracting patients' attention.
2421137|NCT03428282|Active Comparator|Anesthesia|Inferior alveolar nerve block will be performed in the normal manner without any specific intervention to distract patients' attention. Classic anesthesia will be applied.
2421138|NCT03428269|Experimental|simulation by gaming group|In the simulation by gaming group, the students will individually play with two cases of the LabforGames Warning game (postoperative hemorrhage case and brain trauma in elderly case). After each case, a debriefing to which with all players will participate will be conducted by an instructor.
2421139|NCT03428269|Active Comparator|traditional education group|In traditional education group, the students will individually work on the two same cases but the two vignettes and adjoining questions will be presented and answered by the student on a paper sheet. Then a global review of the two cases and the major messages to be retained will be presented by a teacher.
2421140|NCT03428256|Active Comparator|Pre-oxygenation with a standard anaesthetic face mask|Pre-oxygenation delivered in the standard way; 3 minutes, Fraction of inspired oxygen (FiO2) 1.0, 8 vital capacity breaths in the last minute
2421141|NCT03428256|Experimental|Pre-oxygenation using Optiflow and THRIVE technique|Pre-oxygenation delivered via nasal high flow humidified oxygen (Optiflow) and THRIVE technique. Gradually increased to 70 litres/minute, mouth closed, 8 vital capacity breaths in the last minute
2421142|NCT03428243||truSculpt|truSculpt effectiveness after 18 months
3186773|NCT00748774||MDASI-BT|MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) questionnaire given to patients with a primary brain tumor and their caregivers.
2421216|NCT03427736||Drug of Interest|Individuals receiving anesthetics or analgesics per standard of care
3186774|NCT00748787|Experimental|1|
3186775|NCT00748787|Placebo Comparator|2|
3186776|NCT00748800|Experimental|1|
3186777|NCT00748800|Active Comparator|2|
3186778|NCT00748813|Other|1|
3186779|NCT00748852|Experimental|1|JTT-302, 400 mg
3186780|NCT00748891|Experimental|1|Open label 30mg Cediranib administered once daily during scanning phase and if tolerated by patient, until disease progression
3186781|NCT00748904|Experimental|A|35 patients receiving rifaximin
3186782|NCT00748904|Experimental|B|35 patients receiving lactulose
2421147|NCT03428217|Experimental|CB-Cabo|CB-839 orally twice daily + cabozantinib orally once daily
2421148|NCT03428217|Placebo Comparator|Pbo-Cabo|Placebo orally twice daily + cabozantinib orally once daily
2421149|NCT03428204|Other|180 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 180 seconds for percutaneous treatment of femoropopliteal artery stenosis
2421150|NCT03428204|Other|300 seconds balloon dilation|Percutaneous angioplasty with balloon dilation during 300 seconds for percutaneous treatment of femoropopliteal artery stenosis
2421151|NCT03428178|Experimental|rAAV2-ND4|A Single IVT of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
2421152|NCT03428165|Other|human chorionic gonadotropin (HCG)|Ovulation triggered using HCG: choriogonadotropin alpha (Ovitrelle, Merck Serono), 250 μg/0.5ml
2421153|NCT03428165|No Intervention|spontaneous|
3186783|NCT00748930||Cohort 1|Subjects previously enrolled in the ATTRACT trial from three Canadian sites.
3186784|NCT00748995||Neurocognition Deployment Health Study (NDHS) participants|Surviving NDHS participants who returned from their initial deployment to Iraq or Afghanistan.
2421156|NCT03428139|Active Comparator|Group I|Each patient in this group was treated with pulsed radiofrequency on the affected dorsal root ganglion at 42°C for 120 seconds
2421157|NCT03428139|Active Comparator|Group II|Each patient in this group was treated with pulsed radiofrequency as in group I plus oral alpha lipoic acid (ALA) 600 mg.
2421158|NCT03428126|Experimental|Durvalumab + Trametinib|"Participants take Trametinib tablets by mouth every day. Trametinib taken alone for the first 7 days of the study then participants begin receiving it in combination with Durvalumab.~Participants receive Durvalumab by vein every 4 weeks.~Each cycle is 28 days."
2421159|NCT03428113||ICU patient unable to void for 6 hours|ICU patients unable to void after 6 hours after a indwelling urinary catheter is removed or since time of admission
2421160|NCT03428113||renal failure with low urine volume|ICU patients with renal failure, acute kidney injury or acute on chronic with minimal urine output without an indwelling urinary catheter
3186785|NCT00749008||Term Infants|High risk infants with history of respiratory insufficiency requiring NICU care.
3186786|NCT00749008||Preterm Infants|Infants less than 37 weeks gestational age.
3186787|NCT00749021|Active Comparator|Regimen 1|Intravitreal injection of Ranibizumab monthly for 12 months.
3186788|NCT00749021|Active Comparator|Regimen 2|Intravitreal injection of ranibizumab for 4 months (at Day 0, Month 1, Month 2, and Month 3) followed by by treatments on predefined re-treatment criteria.
2421165|NCT03428087||patients undergoing prostatic biopsy|Patients who are candidates for prostate biopsy as suffering from urinary symptoms accompanied by clinical suspicions such as high total PSA value and / or presence of prostate nodule and / or evidence of obvious lesion to available imaging methods.
2421166|NCT03428074||Patients with the surgery of Ivor-Lewis|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Ivor-Lewis
2421167|NCT03428074||Patients with the surgery of Mckeown|Pathologically diagnosed IA-IIIB patients with esophageal cancer who received minimally invasive surgery of Mckeown
2421168|NCT03428061||Intervention group|The intervention under study will be the integrated care for cardiovascular risk management (CVRM), based on the Dutch CVRM guideline. Patients with a history of cardiovascular disease (CVD), a high cardiovascular risk (CVR) (>10%) or use of antihypertensives or lipid lowering drugs are included in the program. Patients will be invited for an intake consultation, including a blood test, an interview, physical examination and estimation of the 10-years cardiovascular risk. If indicated, treatment with medication will be started and general lifestyle advises will be given. Patients can be referred to smoking cessation therapy, dietician and exercise programs or a physiotherapist. Patients will be controlled on a regular base to evaluate and adjust their personal goals.
2421169|NCT03428061||Control group|Usual care will be based on the Dutch CVRM guideline, describing how to calculate the CVR and advices to lower this risk by lifestyle intervention and/or medication. However systematic identification of patients eligible for CVRM, actively inviting patients for a visit, regular follow-up and standardized collaboration with other disciplines in the health care chain are not necessarily part of usual care.
2421170|NCT03428048||Adults diagnosed with paroxysmal and persistent Afib|Adults diagnosed with paroxysmal and persistent Afib who are identified as candidates for an intervention either surgical (epicardial) known as the hybrid approach or an endocardial ablation with either laser, radio frequency or cryoablation energy source.
2421171|NCT03428035|Experimental|Modified Package Insert|Simplified and focused on neutral risk perception. The representations and formulations are based on the findings from research on evidence-based patient information and risk communication. The package insert contains the same information as the statutory package insert to ensure that it complies with the legal requirements.
2421172|NCT03428035|No Intervention|Verbal Information|The patient is informed verbally about side effects and does not receive any package insert.
2421173|NCT03428035|Active Comparator|Control|Package insert according to EU Directive 2001/83 / EC (usual package insert)
2421174|NCT03428022|Experimental|Apatinib combined with EGFR-TKI|Apatinib（Tablet（Tab. ）500millgram（mg）/day（d）） combined with EGFR-TKI（as previously）
3186789|NCT00749021|Active Comparator|Regimen 3|Intravitreal injection of Ranibizumab 2.0mg monthly for 12 months
3186790|NCT00749021|Active Comparator|Regimen 4|Intravitreal injection 2.0mg ranibizumab for 4 months (at Day 0, Month 1 and Month 2, and Month 3) followed by PRN treatments on pre-defined re-treatment criteria
3186791|NCT00749034|Experimental|1|VPM1002 in three dosages
2421178|NCT03427983|Other|US-guided regular injection|US in-plane injection with corticosteroid and 1cc of lidocaine. Total of 2cc.
2421179|NCT03427983|Other|US-guided hydrodissection|US in-plane injection with corticosteroid and 1cc of lidocaine, and 3cc of saline. Total of 5cc.
2421180|NCT03427970|Active Comparator|control group|Control subjects will receive observation for 6 months.
2421181|NCT03427970|Experimental|experimental group|Experimental group will perform three-dimensionally integrated exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 20-min period per day under the supervision of the parents at home.The treatment regimens lasted for 6 months.
2421182|NCT03427957|Experimental|New hysteroscopic grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.
2421183|NCT03427957|Active Comparator|Classic spoon grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic spoon grasper.
2421184|NCT03427957|Active Comparator|Classic alligator grasper|Patients allocated in this group will undergo hysteroscopic endometrial biopsy through the classic alligator grasper.
2421185|NCT03427944|Active Comparator|Calcium Dobesilate group|Calcium dobesilate group was treated with calcium dobesilate (500mg, tid , po), its conservative treatment was the same as that of the conventional treatment group
2421186|NCT03427944|Placebo Comparator|Conventional Treatment group|conventional treatment group was treated with conventional conservative treatment of renal failure (low protein, low salt, low fat, low phosphorus diet, balance the internal environment; control blood pressure ; remove intestinal toxins etc.)
3186792|NCT00749034|Active Comparator|2|BCG
2421188|NCT03427918|Experimental|patient-partner|patients and their partners will receive a weekly Mindfulness-Based Sex Therapy program. The treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
2421189|NCT03427918|Experimental|patient-partner and health care providers|patients and their partners as well as health care providers will receive a weekly Mindfulness-Based Sex Therapy program. Th treatments will deliver by a group of facilitators to groups of women consisting of 4-7 women.
2421190|NCT03427918|No Intervention|Control group|The control group will receive a routine counseling
2421191|NCT03427905|Active Comparator|GROUP I|lipoaspiration and transplantation of ADSVCs (for adipose-derived stromal vascular cells/primary fresh cells without culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
2421192|NCT03427905|Active Comparator|GROUP II|lipoaspiration and transplantation of ADSCs (for adipose-derived mesynchymal stem cells/after culture) Interventions: - Procedure: Lipoaspiration; - Procedure: Transplantation
3186793|NCT00749047|Experimental|1|Open label arm
2421194|NCT03427879|Placebo Comparator|Low flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, low flavonoid, sports nutrition recovery beverage 14 days.
2421195|NCT03427879|Active Comparator|High flavonoid beverage|Subjects will consume 310 milliliters per day of a dairy-based, high flavonoid, sports nutrition recovery beverage 14 days.
2421196|NCT03427866|Experimental|Ruxolitinib Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
2421197|NCT03427866|Experimental|Ruxolitinib Not Eligible pre-HSCT|"Ruxolitinib will be taken orally at a fixed dose twice every day after transplant~Dosing will be continuous, with a new cycle scheduled to start every 28 days.~There will be no break in dosing between cycles~Ruxolitinib can be administered with or without food."
2421198|NCT03427853|Experimental|LY06006|LY06006 18mg, 60mg 120mg subcutaneous injection
2421199|NCT03427853|Placebo Comparator|Placebo|Placebo subcutaneous injection
2421200|NCT03427840||Hypo|The participants with a superior hypogastric block
2421201|NCT03427840||NoHypo|The participants without a superior hypogastric block; the patients with an epidural catheter, who receive a different block technique (ie: TAP block), or who are unsuitable for SHP block (ie: if retroperitone is opened intraoperatively by the surgeon)
2421202|NCT03427827|Experimental|Adjuvant PD-1 antibody arm|Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation
2421203|NCT03427827|No Intervention|Best supportive care|Patients randomized to this arm will receive best supportive care after chemoradiation
2421204|NCT03427814|Experimental|Pamiparib|Approximately 64 participants to receive pamiparib orally.
2421205|NCT03427814|Placebo Comparator|Placebo|Approximately 64 participants to receive placebo orally.
2421206|NCT03427801||Treatment Group|Chronic kidney disease patient receiving palliative care and erythropoiesis-stimulating agent
2421207|NCT03427801||Control Group|Chronic kidney disease patient receiving palliative care without erythropoiesis-stimulating agent
2421208|NCT03427788|Experimental|Verum|Study group 1-11 of BAY2328065 (increasing dose levels for study group 2-11)
2421209|NCT03427788|Placebo Comparator|Placebo|Study group 1-11 of Placebo
2421210|NCT03427775||pre-MP3|before implementation of the multimodal analgesia protocol
2421211|NCT03427775||post-MP3|after implementation of the multimodal analgesia protocol
2421212|NCT03427762|Experimental|Healthy cycling group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then there is a bicycle every 1 hour.
2421213|NCT03427762|Experimental|Healthy xbox group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Then they will train 1 hour every day on an xbox program.
2421214|NCT03427762|No Intervention|Healthy controll group|During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
2421215|NCT03427762|Experimental|PD groupe|"Patients with PD have already been evaluated and compared to the results of a healthy group within a separate experiment.~The study and the results have been completed. Clinical trial number:NCT03193268"
3186794|NCT00749060|Other|1|conventional treatment
3186795|NCT00749060|Other|2|kyphoplasty by balloons
3186796|NCT00749060|Other|3|vertebroplasty
3186797|NCT00749086|Experimental|2|balloon kyphoplasty
3186798|NCT00749086|Active Comparator|1|vertebroplasty
2421217|NCT03427723|Active Comparator|Standard care|visualization and palpation
2421218|NCT03427723|Experimental|Accuvein|system uses an infrared laser beam to project the image of superficial veins to the skin
2421219|NCT03427710|Experimental|Cohort A1|CiVi007 dose 1
2421220|NCT03427710|Experimental|Cohort A2|CiVi007 dose 2
2421221|NCT03427710|Experimental|Cohort A3|CiVi007 dose 3
2421222|NCT03427710|Experimental|Cohort A4|CiVi007 dose 4
2421223|NCT03427710|Experimental|Cohort A5|CiVi007 dose 5
2421224|NCT03427710|Placebo Comparator|Combined placebo group|group response from placebo subsets of dosing cohorts
2421225|NCT03427697|Experimental|Intervention group|Head-mounted video display which shows video with virtual reality and accommodation relax technique in combination,40 minutes per day
2421226|NCT03427697|No Intervention|Control group|No intervention will be performed in the control group
2421227|NCT03427684|Experimental|Hypo-fractionated radiotherapy|Hypo-fractionated neoadjuvant radiotherapy concurrent with S1 chemotherapy for local advanced gastric cancer
2421228|NCT03427671|Experimental|Occlusin 500 microspheres|Uterine fibroid embolization
2421229|NCT03427658|Experimental|Increase sweet food consumption|Participants are asked to increase their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and additional sweet food consumption recommended.
2421230|NCT03427658|Active Comparator|Decrease sweet food consumption|Participants are asked to decrease their consumption of sweet foods throughout their diet. Participants will be supported through an individual dietary interview where sweet foods will be highlighted and substitutions for sweet food consumption will be recommended.
2421231|NCT03427645|No Intervention|Control Surrogate Arm|Usual care control group will complete baseline and follow-up questionnaires with standard decision making techniques. This group will not be asked to use the decision making tool.
2421232|NCT03427645|Experimental|Surrogate Decision Tool Arm|This group will complete a baseline questionnaire, then use the tool and complete follow up questionnaires.
2421233|NCT03427632||percutaneous Vertebroplasty|patients meet the inclusion and exclusion criteria will be subjected to percutaneous vertebroplasty receiving bone cement (Polymethyl methacrylate)
3186799|NCT00749099|Placebo Comparator|Phase I|All subject participate in Phase I
2421235|NCT03427606|Experimental|Continuous Suture|
2421236|NCT03427606|Active Comparator|Single 5-points Suture|
2421237|NCT03427593|Experimental|Patients|Patients with the phenotype (PID and Neutropenia and lymphoproliferation)
2421238|NCT03427593|Other|relatives (parents)|
2421239|NCT03427593|Sham Comparator|Controls|
2421240|NCT03427580|Experimental|treatment group|
2421241|NCT03427580|Experimental|delayed treatment control group|
2421242|NCT03427567||Sublobar dissection|Chinese NSCLC patients who received sublobar dissection
2421243|NCT03427554|Experimental|Tretinoin cream 0.1%|Once daily at home, to apply the entire affected areas of the face.
2421244|NCT03427554|Active Comparator|RETIN-A® Cream|Once daily at home, to apply the entire affected areas of the face.
2421245|NCT03427554|Placebo Comparator|Vehicle of the test product|Once daily at home, to apply the entire affected areas of the face.
2421246|NCT03427541||Patients with surgeries|NSCLC patients with surgeries
2421247|NCT03427528|Experimental|FAB Pilot Study (Male Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.~Male partners will receive Fathers and Babies (FAB Intervention) while his female partner will receive MB 1-on-1 plus MB-TXT."
2421248|NCT03427528|Experimental|MB 1-on-1 Plus TEXT (Female Participants)|"Dyads including a female client and her male partner will receive separate interventions. The inventions are complimentary and will be implemented in parallel.~Female clients will receive the Mothers and Babies with -Text Messages intervention (i.e., MB 1-on-1 plus MB-TXT) while her male partner will receive FAB."
2421249|NCT03427515|Experimental|Lactobacillus|Lactobacillus rhamnosus GG (ATCC 53103) - encapsulated
2421250|NCT03427515|Placebo Comparator|Placebo|Placebo - encapsulated mixture of maltodextrins
2421251|NCT03427515|Experimental|Saccharomyces|Saccharomyces boulardii (CNCM I-1079) - encapsulated
2421252|NCT03427502|Experimental|Study Group|"Experimental: Study Group At the end of surgery before nasal packing, scrub nurse will prepare 10 ml solution 0.5% bupivacaine with 1:2,00,000 adrenaline in a syringe and pass it over to the operating surgeon. The surgeon will block anterior ethmoidal nerve.~Injection technique: External nasal nerve will be blocked through an inter-cartilaginous injection into the dorsum of the nose.~Internal nasal nerve will be blocked in septum and lateral wall of nose. Septal block is done in upper anterior part of nasal septum. Three injections will be given on lateral nasal wall. First injection will be given just antero-superior to the attachment of middle turbinate (axilla). Second injection will be given at the anterior end of middle turbinate and third injection at the medial surface of middle turbinate. Withdrawal of injection will be done prior to deposition of solution every time to ensure that the solution is not deposited directly into a blood vessel."
2421253|NCT03427502|Placebo Comparator|Control Group|"At the end of surgery before nasal packing, scrub nurse will pass 10 ml of normal saline in a syringe to the surgeron.~Injection technique remains the same as in Study group."
2421254|NCT03427489||Coronary heart disease|Qatari individuals presenting with or have a history of an acute coronary syndrome (myocardial infarction or unstable angina) are being recruited as study subjects.
2421255|NCT03427489||Controls|Ethnicity-matched individuals without history of CHD such as myocardial infarction or prior PCI are being recruited as controls.
2421256|NCT03427476|Experimental|Metastatic RCC (> 3 lesions)|Patients with metastatic renal cell carcinoma and planned biopsy of a metastatic lesion (N = 5)
2421257|NCT03427476|Experimental|RCC patients with primary lesions > 7 mm in diameter|Cohort B: Patients with evidence of primary renal cell carcinoma and lesions > 7 cm (may also have metastatic disease) (N = 5)
2421258|NCT03427463|Active Comparator|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
2421259|NCT03427463|Experimental|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
3186800|NCT00749099|Active Comparator|Phase II|All subject participate in Phase II
3186801|NCT00749112|Experimental|A|
2421260|NCT03427450||Healthy Volunteers (Controls)|A control population of healthy volunteers (HVs) consisting of women with no prior/current history of cancer and no known history of breast disease (the information obtained from the HVs may be 'self-reports', as complete medical records may not be available at the enrolling site for these control subjects), and with a broadly similar age range to the cancer patient study population. All eligible and consenting subjects will have blood draw.
2421261|NCT03427450||MBC Patients (Cancers)|Women with either newly diagnosed metastatic breast cancer who are about to start a new line of therapy of any type for the treatment and/or management of their disease or those with currently progressive or recurrent disease (as determined by any means) will be eligible for enrollment into the cancer population. All eligible and consenting subjects will have blood draw.
2421262|NCT03427437|Active Comparator|Conventional Group|Caudal block was performed by conventional method with %0,25 bupivacaine plus 1/200.000 adrenalin
2421263|NCT03427437|Active Comparator|Ultrasound Group|Caudal block was performed by ultrasound method with %0,25 bupivacaine plus 1/200.000 adrenalin
3186802|NCT00749138|Experimental|tamoxifen|open label giving of tamoxifen
2421273|NCT03427385|Experimental|Minimum Effective dose|Local anesthetic Ropivacaine 0.5% injection for adductor canal block
2421274|NCT03427372||group 1: patients with headache|the patients who have post spinal puncture headache after spinal anesthesia
2421275|NCT03427372||group 2: patients without headache|the patients who do not have post spinal puncture headache after spinal anesthesia
2421276|NCT03427372||group 3: patients with backache|the patients who have post spinal puncture backache after spinal anesthesia
2421277|NCT03427372||group 4: patients without backache|the patients who do not have post spinal puncture backache after spinal anesthesia
2421278|NCT03427359|Experimental|experimental arm|Induction chemotherapy: capecitabine tablet 1000mg/m2 po bid from day1 to 14,cisplatin injection 80mg/m2 iv day1,every 3 weeks for a total of 3 cycles. Then followed by concurrent chemoradiotherapy with cisplatin injection 100mg/m2 iv every 3 weeks for a total of 2 cycles.
2421279|NCT03427346|Active Comparator|EMR|Endoscopic mucosal resection
2421280|NCT03427346|Active Comparator|ESD|Endoscopic submucosal dissection
2421281|NCT03427333|Experimental|The Rook® Epicardial Access Kit|The Rook® Epicardial Access Kit will be used to gain access the epicardial surface of the heart via a subxiphoid approach in adult patients with a normal, non-distended pericardial space.
2421282|NCT03427320|Experimental|[131]I-IAZA whole body and SPECT imaging|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
2421283|NCT03427294||Care providers involved in lumbar arthrodesis|surgeons, physiotherapists, behavioral therapists, researchers, occupational therapists
2421284|NCT03427281|Experimental|Cohort: Belgian orthopaedic surgeons & neurosurgeon|
3186803|NCT00749151|No Intervention|Literature|
2421286|NCT03427255|Active Comparator|CBT group treatment|CBT group treatment-plus involving partners: 10 group sessions and 3 couple sessions
2421287|NCT03427255|Other|Waiting list|Six months waiting-list control condition.
2421288|NCT03427242|Experimental|treatment arm|oral apatinib
2421289|NCT03427229|Experimental|Multiple-infusion FMT|Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
2421290|NCT03427229|Active Comparator|Single-infusion FMT|Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days
2421291|NCT03427216|Active Comparator|Vaginal Baclofen/diazepam supp|Insert vaginal suppository once daily
2421292|NCT03427216|Placebo Comparator|Vaginal Placebo supp|Insert vaginal suppository once daily
2421293|NCT03427203|Experimental|Arm 1|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 2 Coloplast Ostomy device 3"
2421294|NCT03427203|Experimental|Arm 2|"The subjects test the products in the following order~SenSura Mio (comparator) Coloplast Ostomy device 1 Coloplast Ostomy device 3 Coloplast Ostomy device2"
2421295|NCT03427190|Active Comparator|Control|Phone contact with patient will be made by a professional psychologist within 21 days of hospital discharge. If contact cannot be made after 9 attempts, post-cards will be sent monthly at M2, M3, M4 and M5, asking the participant to establish contact with the designated psychologist. The phone call will determine whether or not the participant is in a state of suicidal crisis. If yes, steps will be taken to attend the crisis within 24 hours.
2421296|NCT03427190|Other|APSOM|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
3186804|NCT00749151|Experimental|Lit + Counseling|
3186805|NCT00749177|Active Comparator|2|Traditional Healing arm Provides Traditional Healing options only
2421299|NCT03427164|Experimental|TIPS|Participants will have measurements taken of spleen stiffness before and after TIPS. Participation will last about 12 months, with visits at 1-2 weeks post-TIPS, 3 months, 6 months, and 12 months.
2421300|NCT03427151|Experimental|IPP-201101|every 4 weeks
2421301|NCT03427138|Experimental|Jasper|JASPER (Joint Attention Symbolic Play Engagement Regulation) is a targeted intervention that focusses on early communication skills.
2421302|NCT03427138|Experimental|Parent Education|Parent education intervention focusses on parenting a child with autism.
2421303|NCT03427125|Experimental|Tenapanor 10 mg, 20 mg, 30 mg BID|During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
2421304|NCT03427125|Placebo Comparator|Placebo|Placebo
2421305|NCT03427125|Active Comparator|Sevelamer Carbonate|Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)
2421306|NCT03427099|Active Comparator|Control group|usual care
2421307|NCT03427099|Experimental|Intervention group|Rehabilitation with a biopsychosocial focus
2421308|NCT03427086|Active Comparator|Interventional|Patient will received high dose of biotin (300 mg/day)
2421309|NCT03427086|Placebo Comparator|Placebo|Patients will receive placebo
2421312|NCT03427060|Experimental|Coversin treatment|Coversin - 22.5mg followed by 45mg for 6 months.
3145973|NCT00086736|Experimental|Arm III|Patients receive oral eflornithine placebo and oral bicalutamide once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
3145974|NCT00086736|Experimental|Arm IV|Patients receive oral eflornithine placebo and oral bicalutamide placebo once daily for 28 days in the absence of unacceptable toxicity. Patients then undergo either prostatectomy or brachytherapy, as determined by the patient, on day 29.
2421315|NCT03427034|Experimental|Cystoscopic surveillance|Patients with previous history of bladder cancer undergoing flexible cystoscopy will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
2421316|NCT03427034|Experimental|Haematuria group|Patients referred with haematuria to exclude bladder cancer will privide a urine sample to see if BladderLight system can exclude presence of bladder cancer
2421317|NCT03427034|No Intervention|Longitudinal group|Patient with Negative cystoscopy with a positive BladderLight® test will be followed for 12 months to see if they subsequently develop bladder cancer.
2421318|NCT03427021|Experimental|Arm A|will be treated with consistent exposure to oral ice
2421319|NCT03427021|Active Comparator|Arm B|Will not be treated with consistent exposure to oral ice.
2421320|NCT03427008|No Intervention|Standard of Care|Participants in the control arm will be instructed to take their immunosuppressive medications as prescribed and attend required follow-up as is standard of care, and will not receive the mHealth app.
2421321|NCT03427008|Experimental|mHealth Intervention|Participants in the intervention arm will receive the mHealth app either while they are an inpatient post-transplant, or at their first post-transplant clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the mHealth app and explain its functioning. Participants will then use the application to aid in immunosuppressive medication adherence post-transplant.
2421345|NCT03426852||Study group|Individuals with lumbar back pain plus sacroiliac disc herniation
2421346|NCT03426852||Control Group|Individuals with lumbar back pain
2421347|NCT03426839|Active Comparator|Conventional group|In the conventional group (group 1) haemostasis strategy guided by conventional coagulation tests will be carried out.
2421348|NCT03426839|Active Comparator|Point of care group|In the point of care group (group 2) transfusion algorithms guided by point-of-care (POC) tests will be applied. We will use viscoelastic thromboelastometry and impedance aggregometry.
2421349|NCT03426826|Placebo Comparator|Arm 1|Placebo Comparator placebo into the jejunum through upper endoscopy.
3145975|NCT00086749||Tamoxifen group|
3145976|NCT00086762|Experimental|MR Therapy|Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. A CD with the mindfulness relaxation technique recorded on it will be given to participant. Participant to listen to the recording for about 30 minutes before receiving chemotherapy and during the time they are receiving chemotherapy. In addition to the mindfulness relaxation technique, they will also receive general information about how to manage symptoms that develop due to the chemotherapy they are receiving.
3145977|NCT00086762|Experimental|Relaxing Music (RM) Therapy|Arm II: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment.
3145978|NCT00086762|Active Comparator|Standard Symptom Management|Arm III: Participants receive standard symptom management education.
3145979|NCT00086801|Experimental|doxorubicin + vinblastine + gemcitabine|"Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and gemcitabine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo fludeoxyglucose F 18 positron-emission tomography (PET) scanning and CT scan before treatment and after courses 2 and 6 of therapy to assess response. Patients with a positive PET scan after completion of study therapy may undergo biopsy. A PET scan is performed 3 months later if biopsy is negative or biopsy is unable to be performed.~Patients are followed every 3 months for 1 year, every 4 months for 2 years, every 6 months for 2 years, and then annually for 5 years."
3145980|NCT00086827|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have continuing tumor response or stable disease after 6 courses receive 2 additional courses beyond best response.
3145981|NCT00086840|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving an objective response may receive 3 consolidation courses of therapy.
3145982|NCT00086944|Experimental|Treatment (genase, combination chemotherapy)|See detailed description.
2421330|NCT03426982|Experimental|Anti-Xa group|- Heparin was monitored by Anti-Xa activity, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 0.30 and 0.70 IU/mL
2421331|NCT03426982|Experimental|APTT group|- Heparin was monitored by APTT, and clinicians adjusted dose of heparin to maintain it within the therapeutic range between 1.5 and 2.5 time the basiline.
2421332|NCT03426969|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on days -5, fludarabine phosphate IV over 1 hour on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously for approximately 2 weeks, then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 100, and filgrastim SC daily from day 7 until continued until ANC > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
2421333|NCT03426956|Experimental|Glucose|
2421334|NCT03426956|Experimental|Glucose + Canagliflozin|
2421335|NCT03426943|Experimental|CVVH using oXiris™ filter|"Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
2421336|NCT03426943|Active Comparator|CVVH using PrismafleX HF1400 filter|"Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).~They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH."
2421337|NCT03426930|Active Comparator|The reference treatment of dysmorphophobia used|
2421338|NCT03426930|Experimental|The reference treatment with the virtual reality|
2421339|NCT03426904|Experimental|Neoadjuvant FOLFOX|4 cycles of FOLFOX (Folinic acid, fluorouracil and oxaliplatin) neoadjuvant followed by surgery and 8 cycles of FOLFOX
2421340|NCT03426904|Active Comparator|Conventional adjuvant FOLFOX|surgery followed by 12 cycles of FOLFOX
3145983|NCT00086970|Experimental|Arm I (ifosfamide)|Patients receive high-dose ifosfamide IV continuously over 72 hours on days 1-3.
2421342|NCT03426878|Active Comparator|Traditional genetic counseling|This will be typical genetic counseling that a patient would receive in a traditional genetic counseling setting.
2421343|NCT03426878|Experimental|Modified genetic counseling|This will be genetic counseling that is modified for a lower literacy patient and will include fewer technical terms and less complicated genetic information.
3145984|NCT00086970|Experimental|Arm II (O6-benzylguanine, ifosfamide)|Patients receive a bolus dose of O6-benzylguanine (BG) IV over 1 hour on day 1 followed by BG IV continuously and high-dose ifosfamide IV continuously over 72 hours on days 1-3.
3145985|NCT00086983|Experimental|Treatment (becatacarin, oxaliplatin)|"Patients receive rebeccamycin analogue IV over 1 hour on days 1-5 and oxaliplatin IV over 2 hours on day 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue and oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
3145986|NCT00087009|Experimental|Group I|Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
3145987|NCT00087009|Experimental|Group II|Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.
3145988|NCT00087035|Experimental|Taxotere plus Tarceva|"Patients receive Tarceva 150 mg daily for 21 consecutive days (one treatment cycle). In addition, all patients will receive single agent Taxotere 60 mg/m2 IV over 1 hour infusion every 21 ± 2 days and have it administered on day 1.~Taxotere + Tarceva to be taken for three cycles past maximal response or until one of the following occurs: 1) a drug-related toxicity requiring discontinuation, 2) disease progression, or 3) for a maximum of 9 cycles.~Upon completion of 9 cycles of Taxotere plus Tarceva, patients showing evidence of objective response (CR, PR or stable disease) may continue in the extension phase of the study and receive treatment with Tarceva alone. Treatment response evaluated after four cycles of Tarceva treatment(immediately prior to cycle 14). Patients with progression of disease will be taken off study. Responding and stable disease patients will remain on study for up to 8 extension-phase cycles for a total of 17 cycles."
3145989|NCT00087074|Experimental|Treatment (temsirolimus)|Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses beyond CR.
3145990|NCT00087178|Active Comparator|Arm 1: adriamycin + cyclophosphamide|Patients receive adriamycin IV over 15 minutes followed by cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
3145991|NCT00087178|Experimental|Arm 2: fluorouracil + epirubicin + cyclophosphamide|Patients receive fluorouracil IV, epirubicin IV over 15 minutes, and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.
3145992|NCT00087191|Experimental|Diagnostic (EF5, motexafin lutetium)|Patients receive EF5 IV over 1-2.5 hours on day 1 and motexafin lutetium IV over 10-15 minutes on day 2. Patients undergo definitive surgical resection approximately 3 hours after motexafin lutetium administration. Hypoxia and motexafin lutetium levels in the resected tumors are evaluated. Tumor to normal tissue ratios are also determined.
3145993|NCT00087204|Experimental|Treatment (becatecarin)|Patients receive rebeccamycin analogue (XL119) IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 1 additional course beyond CR. Patients achieving a PR or HI receive 2 additional courses beyond PR or HI. Cohorts of 3-6 patients receive escalating doses of XL119 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
3145994|NCT00087217|Experimental|Treatment (tanespimycin, paclitaxel)|Patients receive 17-AAG IV over 1 hour on days 1*, 4, 8, 11, 15 and 18 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3145995|NCT00087256|Placebo Comparator|Arm 1: placebo|one placebo capsule taken orally twice a day for 3 years
2421350|NCT03426826|Active Comparator|Arm 2|Active Comparator: Donor Stool Transplant Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool into the jejunum through upper endoscopy.
2421351|NCT03426813|Other|Early mobilization|Historical control group for early mobilization
2421352|NCT03426800|Experimental|Migraine_acupuncture and training|Migraine acupuncture and training
2421353|NCT03426800|Experimental|Migraine training|Migraine training
2421354|NCT03426800|Experimental|Tension_acupuncture and training|Tension headache acupuncture and training
2421355|NCT03426800|Experimental|Tension headache training|Tension headache training
3186806|NCT00749177|Active Comparator|3|Traditional Healing and usual standard of care arm Subjects will access both treatment options
2421357|NCT03426774|Experimental|YG ( 25-59yrs) -GJogger|Gentle Jogger applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421358|NCT03426774|Experimental|OG (Greater than 60 yrs)-GJogger|Gentle Jogger applied to each individual in (1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421359|NCT03426774|Experimental|YG ( 25-59yrs) -GJumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421360|NCT03426774|Experimental|OG (Greater than 60 yrs)-Gjumper|Gentle Jumper applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421361|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJogger Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421362|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)- GJogger-Sham|A Sham Gentle Jogger is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421363|NCT03426774|Sham Comparator|YG ( 25-59yrs) -GJumper- Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421364|NCT03426774|Sham Comparator|OG (Greater than 60 yrs)-GJumper Sham|A Sham Gentle Jumper is applied to each individual in 1) supine, 2) semi-recumbent, 3) sitting, 4) Trendelenburg and 5) reverse Trendelenburg Each Subject serves as his/her own control.
2421365|NCT03426761|Experimental|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
2421366|NCT03426761|Active Comparator|Standard of Care|Standard of care intravenous antibiotic based on microbiology susceptibility testing. Infusions may be one to three times daily for three to eight weeks. Examples of standard of care include vancomycin, daptomycin, nafcillin, cefazolin.
2421367|NCT03426748|Active Comparator|Low dose rate brachytherapy|Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
2421368|NCT03426748|Experimental|High dose rate brachytherapy|"Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
2421369|NCT03426735|Experimental|Dry heat|Dry heat application with a termal bag
2421370|NCT03426735|Active Comparator|Dry cold|Dry cold application with a termal bag
2421371|NCT03426722|Active Comparator|L-carnitine|L-carnitine 500mg three times daily (per oral)
2421372|NCT03426722|Placebo Comparator|Placebo|Placebo 500mg three times daily (per oral)
2421373|NCT03426709|Experimental|Low intensity Internet-delivered psychotherapy|improved Treatment-as-usual (TAU) + face to face (2 sessions of 90 minutes/session) + low intensity psychological intervention (6 sessions of 60 minutes/session) applied by ICTs (Information and communication technologies) in groups of 8-12 people.
2421374|NCT03426709|No Intervention|Improved Treatment-as-usual (TAU)|In this group, the general practitioner (GP) will apply the usual but improved treatment. The GP will have a training meeting and will be provided with the recommendations of one of the Guidelines for the Treatment of Adult Depression in AP most used in our country.
2421375|NCT03426696||Thyroid Related Eye Disease|Survey about the psychological condition would done with the patients of Thyroid Related Eye Disease
2421376|NCT03426683|Experimental|Standardized IMT|The patients will receive Standardized Intestinal Microbiota Transplantation(Standardized IMT). The IMT was given to mid-gut by nose-jejunum nutrition tube or capsules. It was given three times a week.
2421377|NCT03426683|No Intervention|traditional drugs|The patients will receive traditional medicine treatment as usual.
2421378|NCT03426670|Active Comparator|OraQuick HIV Self-Test|Sex workers in the intervention arm will be instructed to self-test before starting each monthly course of PrEP. HIV Self-testing will be performed during the months between scheduled quarterly visits.
2421379|NCT03426670|No Intervention|In-clinic testing|All study participants will receive quarterly in-clinic HIV testing as standard-of-care.
2421380|NCT03426657|Experimental|Durvalumab + Tremelimumab + RT|Durvalumab (1500 mg,q4W) + Tremelimumab (75 mg, q4W / since Amendment 3: 300 mg absolute dose d5) for up to a maximum of 4 doses/cycles combined with radiotherapy (35 x 2.0/1.8/1.6 Gy) followed by durvalumab monotherapy 1500mg via IV infusion q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 8 additional durvalumab doses.
2421381|NCT03426644|Active Comparator|Group A|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.
2421382|NCT03426644|Experimental|Group B|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
2421383|NCT03426644|Experimental|Group C|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target.In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
3186807|NCT00749177|Active Comparator|1|Treatment as usual
2421384|NCT03426644|Experimental|Group D|A time in bed target will be assigned to participants and parents will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group D.
3186808|NCT00749216|Experimental|QW|IV infusion of 400mg once each week for 2 months
3186809|NCT00749216|Experimental|Q4W|IV infusion of 400mg once every four weeks for 2 months
2421387|NCT03426618||Pediatric participants with Hepatitis B Virus (HBV)|All participants who received at least 1 dose of Baraclude.
2421389|NCT03426592|Active Comparator|Vitamin D3, 10000 Intl Units Oral Capsule|Vitamin D3, 10000 Intl Units Oral Capsule, daily for 6 months
2421390|NCT03426592|Placebo Comparator|Placebo oral capsule|Oleic acid capsule by mouth, daily for 6 months
2421391|NCT03426579||Reliability of NeuroSENSE ®in children|Children scheduled for direct laryngoscopy with surgical intervention the reliability of NeuroSENSE ®monitoring will be evaluated
3186810|NCT00749216|Experimental|Q8W|IV infusion of 400mg once every eight weeks for 2 months
2421393|NCT03426553|Experimental|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
2421394|NCT03426553|Active Comparator|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
2421395|NCT03426540|Experimental|Conbercept|intravitreal conbercept (10 mg/mL, 0.5 mg) immediately after surgery
2421396|NCT03426540|No Intervention|control group|Pars plana vitrectomy alone
2421397|NCT03426527|Placebo Comparator|Levobupivacaine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine General anesthesia
2421398|NCT03426527|Active Comparator|Levobupivacaine-Dexmedetomidine|Patients will receive bilateral superficial cervical plexus block using levobupivacaine-dexmedetomidine General anesthesia
2421399|NCT03426514|Experimental|Three-port Laparoscopic Surgery|Patients with colorectal cancer undergo three-port laparoscopic surgery.
2421400|NCT03426514|Experimental|Conventional Laparoscopic Surgery|Patients with colorectal cancer undergo conventional laparoscopic surgery（4 or more ports）.
2421401|NCT03426488||Västerbotten Intervention Programme|"The cohort is population-based and consists of blood and data from primarily 40, 50 and 60 year olds, taken every year in this age group in connection with the Västerbotten health surveys from 1985 - present.~The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.~The database NSDD (Northern Sweden Diet Database) consists of survey data from VIP concerning nutritional factors.~A large part is fasting samples.~Individuals: 105,700 Individuals with repeated samples: 40,700 Sampling occasions: 156,300"
2421402|NCT03426488||Mammography Screening Project|"Samples and data are collected in connection with mammography screenings 1995-2006. The blood samples consist primarily of EDTA and heparin blood samples divided into plasma, erythrocyte concentrate and buffy coat, and for a certain percentage, the DNA is also extracted. The cohort consists of women, 18-82 years old (95% between 48 and 70 years old).~Survey data can be linked to the blood samples.~Individuals: 28,800 Individuals with repeated samples: 14,600 Sampling occasions: 54,000"
2421403|NCT03426488||The Northern Swedish MONICA Project|"The MONICA study is a longitudinal population-based database for research in cardiovascular disease and diabetes. Since 1985, seven screenings has been performed (1986, 1990, 1994, 1999, 2004, 2009 and 2014) of a randomized selection of the population in the counties of Västerbotten and Norrbotten in Northern Sweden.~Individuals: 11,800 Individuals with repeated samples: 3,500 Sampling occasions: 15,300 (March 2015)"
2421404|NCT03426475|No Intervention|Control Group|Care of nursing home residents as usual.
2421405|NCT03426475|Experimental|Interventional Group|Implementation of interprof ACT measures to improve collaboration and communication between general practitioners and nursing staff. Measures are selected and adapted by nursing home management / nurses, GPs and residents' relatives or representatives.
2421406|NCT03426462|Experimental|Age 1-6 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
2421407|NCT03426462|Experimental|Age 8-13 years|"Induction of anesthesia with propofol using infusion pumps that are programmed with a pharmacokinetic model to achieve a calculated plasma concentration of the drug; this is followed by two anesthetic deepening episodes.~The target plasma concentrations achieved, as calculated by the programmed pump, is exactly the same in both age groups."
2421408|NCT03426449|Active Comparator|Posterolateral sphincterotomy|Division of internal anal sphincter at 5 o'clock position
2421409|NCT03426449|Active Comparator|Lateral sphincterotomy|Division of internal anal sphincter at 3 o'clock position
3186811|NCT00749229|Other|1|Balloon kyphoplasty
2421411|NCT03426423|Experimental|Intervention|12 weeks smoking cessation intervention tailored to diabetic and gender specificities, delivered by a study nurse.
2421412|NCT03426423|Active Comparator|Control|Usual care comprising a unique intervention of 5-10 minutes, non tailored smoking cessation intervention, delivered by a study nurse.
2421413|NCT03426397||Study population|
2421414|NCT03426384|Active Comparator|Intervention Group|"The Intervention Group will enter daily tasks into the Mymee app. After the first intake session, the subject will participate in weekly 20-30-minute coaching sessions with the Health Coach. At the second session, the Health Coach will review the symptoms and the free text entered by the subject to determine which dietary and environmental factors will be monitored in the Mymee app.~Each subsequent week, the Health Coach will review and discuss with the subject the food diary and the data entered into the Mymee app during the previous week. Based on this discussion and the subject's medical records, the Health Coach will determine or revise which symptoms will continue to be monitored using the Mymee App."
3186812|NCT00749242|Other|1|conventional orthopedic brace with antalgic treatment
3186813|NCT00749242|Other|2|balloon kyphoplasty introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
2421415|NCT03426384|No Intervention|Control Group|The Control Group subjects will receive no training, coaching, or other intervention services from Mymee. The Control Group subjects will complete the same battery of assessments at the same intervals as the Intervention Group subjects.
2421416|NCT03426371|Experimental|Experimental|All eligible subjects will receive KL-140 in combination with mFOLFOX-6 chemotherapy regimen.
2421417|NCT03426371|Placebo Comparator|Placebo Comparator|All eligible subjects will receive Placebo in combination with mFOLFOX-6 chemotherapy regimen.
2421418|NCT03426358|Experimental|Patients undergoing HSCT|LSM assessed by Elastographic Techniques
3186814|NCT00749255||FFDM|a sum of at least 200 cancer cases, mammographically visible, on at least one image view (including masses and calcifications)
3186815|NCT00749281||1|Patients with angiographically confirmed significant CAD
2421421|NCT03426319||Primary adrenal insufficiency|Patients with primary adrenal insufficiency on hormone replacement therapy with hydrocortisone.
2421422|NCT03426306|Experimental|4DCT-ventilation|The patient will undergo 4DCT imaging. The 4DCT imaging data along with image processing techniques will be used to generate a 4DCT-ventilation map. All surgical decisions will be based on the current standard of care imaging (VQ scans) and not on the 4DCT imaging results.
2421423|NCT03426293||Arterial procedure and ACT measurement|All patients undergoing an open or endovascular arterial procedure in which heparin is used peri-procedurally and the ACT is measured to determine effect of heparin
2421424|NCT03426280|Experimental|Apple Watch|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
2421425|NCT03426280|No Intervention|Usual Care|Usual care.
3186816|NCT00749281||2|Patients without significant CAD
3145996|NCT00087256|Experimental|Arm 2: celecoxib|one 400 mg capsule taken orally twice a day for 3 years
3145997|NCT00087269|Experimental|Treatment (erlotinib)|Patients receive oral erlotinib once daily on days 1-14 or days 1-21 in the absence of unacceptable toxicity. Patients then undergo surgical resection on the last day of study drug administration (day 14 or day 21). Patients may receive chemotherapy and/or radiotherapy after surgical resection at the discretion of the primary physician.
2421430|NCT03426241||smoking chronic periodontitis|
2421431|NCT03426241||non-smoking periodontitis|
2421432|NCT03426241||smoking healthy|
2421433|NCT03426241||non-smoking healthy|
2421434|NCT03426215||Ten year follow-up group|No interventions will be administered (Magnetic Resonance Imaging (MRI) will be administered as an outcome measurement).
2421435|NCT03426202|Experimental|modafinil group|a single dose of p.o. modafinil (200mg)
2421436|NCT03426202|Experimental|placebo group|a single dose of p.o. placebo (200mg)
2421437|NCT03426189||HIV infected individuals on long term ART|"Leukapheresis~Lymph node biopsy"
2421438|NCT03426176|Experimental|male oxytocin and ATD group|male subjects receiving oxytocin and ATD treatment
2421439|NCT03426176|Experimental|male oxytocin and placebo group|male subjects receiving oxytocin and ATD-placebo treatment
2421440|NCT03426176|Experimental|male placebo and ATD group|male subjects receiving oxytocin placebo and ATD treatment
2421441|NCT03426176|Placebo Comparator|male placebo group|male subjects receiving oxytocin placebo and ATD placebo treatment
2421442|NCT03426163|Experimental|VR group|Application of virtual reality 12 hours before arthroscopic surgery
2421443|NCT03426163|No Intervention|Non-VR group|Application of knee MRI 12 hours before arthroscopic surgery
2421444|NCT03426150|Experimental|CPP-ACP|Tooth mousse (GC, Japan) application on the specimen surface for 3 min.
2421445|NCT03426150|Placebo Comparator|Deionized water|Deionized water application on the specimen surface for 3 min
2421449|NCT03426124||Retrospective|Individuals with intermediate-high or high risk pulmonary embolism who were consecutively treated with the Ekosonic Endovascular System (EKOS) and thrombolytic drug between January 2014 and one year prior to site activation.
2421450|NCT03426124||Prospective|Individuals who are experiencing intermediate-high or high risk pulmonary embolism where the treating investigator has selected the EKOS device and thrombolytic drug. The duration of ultrasound and volume of thrombolytic drug are selected per physician discretion.
2421451|NCT03426111|Placebo Comparator|Placebo|Diagnostic upper endoscopy plus lifestyle modification.
2421452|NCT03426111|Active Comparator|Treatment|Endoscopic gastric tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) plus lifestyle modification.
2421453|NCT03426098|Experimental|Treatment|After baseline evaluation, all subjects will undergo a series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
2421454|NCT03426085|Placebo Comparator|Placebo|Same formulation as active medication minus the active ingredient. Patients will start with 0.1 mL of liraglutide placebo and will escalate the dose every week in 0.1 ml increments until the 0.3 ml dose is reached. Escalation will be done according to patients' tolerance and glucose control
2421455|NCT03426085|Experimental|Liraglutide 6 mg Solution for Injection|After randomization, patients will undergo a treatment dose escalation phase. Liraglutide will be started at 0.6 mg SQ QD for 1 week, increased to 1.2 mg subcutaneous, per day (SQ, QD) for 1 week, and then increased and maintained on 1.8 mg SQ QD or maximally tolerated dose if self monitored blood glucose (SMBG) is at goal. Escalation will be done according to patients' tolerance and glucose control
2421520|NCT03425669|Sham Comparator|Active stimulation|Patients are randomly chosen to the group who will get acitive stimulation without taking medicine.
3145998|NCT00087295|Experimental|Treatment|Depsipeptide
3145999|NCT00087373|Experimental|Treatment (recombinant fowlpox-TRICOM vaccine)|Patients receive fowlpox-TRICOM intratumorally on day 1 of weeks 1, 4, and 7 (maximum of 3 injections for a single lesion) (course 1). After 3 injections (course 1), patients with stable or responding disease receive additional injections into new lesions following the same schedule as above. Treatment repeats every 9 weeks for a maximum total of 9 injections (3 injections total into a maximum of 3 different tumors) (total of 3 courses) in the absence of disease progression or unacceptable toxicity
3146000|NCT00087386|Experimental|Treatment (tanespimycin)|Patients receive tanespimycin IV over 1-6 hours once weekly for 6 weeks. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
2421456|NCT03426072|Experimental|modified IHI breakthrough series|"The SCOPE intervention is a complex, high facilitation, multi-component intervention operating at the microsystem (resident care unit) level of the organization and is designed to engage, develop, and equip Health Care Aides to implement improvement initiatives."
2421457|NCT03426072|No Intervention|Control|The control units (propensity matched) have no intervention and form a naturalistic control
2421458|NCT03426059||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
2421459|NCT03426046|Experimental|Biodentine|Partial pulpotomy treatment with Biodentine
2421460|NCT03426046|Active Comparator|Calcium Hydroxide|Partial pulpotomy treatment with Calcium Hydroxide
2421461|NCT03426046|Experimental|Mineral Trioxide Aggregate|Partial pulpotomy treatment with Mineral Trioxide Aggregate
2421462|NCT03426033|Experimental|Single dose of warfarin|Single dose of warfarin administered to obtain pharmacokinetic information.
2421463|NCT03426033|Experimental|Warfarin in combination with ISIS 681257|ISIS 681257 administered and pharmacokinetic assessments are taken. Then ISIS 681257 is administered with warfarin and additional pharmacokinetic information is obtained.
2421464|NCT03426020|Active Comparator|Oral midazolam (Demizolam®)|To prevent emergence agitation patient premedicated by 0.5 mg oral midazolam At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
2421465|NCT03426020|Active Comparator|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|To prevent emergence agitation patient premedicated by watching a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) At the end of sugery patients postoperatif emergence agitation evaluated by PAED(pediatric anesthesia emergence delirium scale).
2421466|NCT03426020|Active Comparator|Play game (PC fishing game)|To prevent emergence agitation patient premedicated by playing a simple PC game (fishing game) At the end of sugery patients postoperatif emergence agitation evaluated PAED(pediatric anesthesia emergence delirium scale).
2421467|NCT03426007|Experimental|Uterine Lavage|Embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
2421468|NCT03425994||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) tablet by mouth, once daily for 48 weeks
2421469|NCT03425981|Experimental|WB-EMS-SRT|Training with basic global electrostimulation
2421470|NCT03425981|Experimental|WB-EMS-WT|Training with specific global electrostimulation for runners
2421471|NCT03425981|Placebo Comparator|CG|The participants in the control group will maintain the volume and intensity of the training prior to the intervention study and the subjects of the WB-EMS and WB-EMS-AC groups will substitute one conventional training day for one with global electrostimulation for six weeks; the training of the first group will be non-specific and that of the second specific for runners and the duration of both will be 20 minutes.
2421472|NCT03425968||Knee hyperextension group|athletes who has knee hyperextension
2421473|NCT03425968||Control group|athletes who doesn't have knee hyperextension
2421474|NCT03425955|Experimental|GROUP 1|Normotypic or overweight subjects with rounded, oval or squared face (aged 35-50 years)
2421475|NCT03425955|Experimental|GROUP 2|"Thin subjects with oval or triangular face and sagging skin (aged 45-60 years)"
2421476|NCT03425942|Experimental|Internet CBT for insomnia|The intervention consists of Internet-based Cognitive Behavioral Therapy for insomnia (ICBT-i) (the main components are sleep restriction and stimulus control) for five consecutive weeks.
2421477|NCT03425942|Active Comparator|Internet ART for insomnia|The intervention consists of internet-based applied relaxation exercises/techniques (ART) (different and commonly used) for five consecutive weeks.The acronyme for this intervention is (IART-i).
2421478|NCT03425929|Active Comparator|Oxytocin (6 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure and three days after the second trauma movie exposure (24 IU per day)
2421479|NCT03425929|Active Comparator|Oxytocin (3 days)|Intranasal administration, 24 international units (IU) oxytocin for three days after the first trauma movie exposure (24 IU per day) and placebo nasal spray for three days after the second trauma movie exposure
2421480|NCT03425929|Placebo Comparator|Placebo|Placebo nasal spray for six days
2421481|NCT03425916||Primiparous women|Women after normal, not operative, vaginal one-child delivery
2421482|NCT03425916||Nulliparous women|Women without any child or pregnancy, age-matched
2421483|NCT03425903|Active Comparator|Whole Body Cryotherapy sessions|10 Whole Body Cryotherapy sessions administered on alternate days. Patient fills the questionaires and then comes into the cabin wearing only underwear. The door is closed and the session begins, with the release of nitrogen gas to the cabin indoors, which will be in contact with the patient's body surface for 3 minutes. The intervention is performed on alternate days, so 3 sessions per week are administered. Afterwards will be compared when intervening as an control group without sessions, and with 3 visits per week and fills in the questionnaires
2421484|NCT03425903|No Intervention|Control group|Without sessions. Patient attends a control visit weekly, for 3 consecutive weeks and fills in the questionnaires to control the variables while treatment is not applied. Afterwards will be compared when intervening as an intervention group receiving 3 sessions per week and fills in the questionnaires.
2421485|NCT03425890|Experimental|SURE Program Group|The intervention group will receive a SURE program booklet and will perform individualized daily self-exercise and functional use of the arm and hand on their own outside of therapy for 60 minutes/day, 6 days/week for 4 weeks. These self-exercises and upper limb functional use will be performed in addition to usual care. Three SURE program booklets have been developed which relate to the affected upper limb motor capability using individual Fugl Meyer (ULFM) score. Each SURE program booklet consists of warm-up exercises, strengthening exercises and motor tasks. The SURE program booklet also includes selected functional motor tasks to be performed by the participants using their affected upper limb. The performance of the exercises and functional motor tasks will be reviewed three times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.
2421521|NCT03425669|Active Comparator|Controls with sham stimulation|Controls without ADHD are randomly chosen to the group who will get sham stimulation.
2421522|NCT03425669|Sham Comparator|Controls with active stimulation|Controls without ADHD are randomly chosen to the group who will get active stimulation.
2421486|NCT03425890|Experimental|Education Group|The control group will receive an education booklet with 10 modules. The education booklet will contain information on stroke, recovery and management strategies after stroke. Participants are to complete 2-3 modules per week and answer 1-2 simple questions after each module. Each module including answering questions takes approximately 5-10 minutes to complete. CPI will review the information with the participants 3 times per week for the first 2 weeks, two times for the third week and one time for the fourth week of intervention period.The participants in the control group will continue with their usual care in the hospital.
2421487|NCT03425877|Experimental|Parkinson's disease Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2421488|NCT03425877|Experimental|Stroke Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2421489|NCT03425877|Experimental|Healthy Subjects Group|"The study envisages the recruitment of 45 subjects (see Sample Size on page 11), to be divided into 15 subjects per group. The groups will be formed by subjects diagnosed with Parkinson's and Stroke disease, for 50% men and 50% for women. The control subjects, on the other hand, will be neurologically healthy volunteers of equal age and scholarship and gender.~All the groups will attend the same procedure and interventions: MS Band 2 , Rest, Emotion Assessment, Single Task, Dual Task ."
2421490|NCT03425864|Other|immediate implant|patient will receive immediate implant alone.
2421491|NCT03425864|Active Comparator|immediate implant with connective tissue graft|patient will receive immediate implant and connective tissue gaft
2421492|NCT03425851|Experimental|Intervention Group|Receive 600 diapers.
2421493|NCT03425851|Active Comparator|Control Group|Receive resources of diaper banks as requested.
2421494|NCT03425838|Active Comparator|Strategy A CDK4/6 inhibitor in 1st line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) plus CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference) in first line followed by fulvestrant in second line.
2421495|NCT03425838|Active Comparator|Strategy B CDK4/6 inhibitor in 2nd line|Non-steroidal aromatase inhibitor (letrozole or anastrozole, at the discretion of the treating physician) in first line followed by fulvestrant plus CDK4/6 inhibitor in second line (palbociclib, ribociclib or abemaciclib, depending on availability and physician's preference).
2421496|NCT03425825||LD-SCLC receiving 1st line treatment|patients with LD-SCLC receiving first-line treatment, including potential maintenance treatment
2421497|NCT03425825||ED-SCLC receiving 1st line treatment|patients with ED-SCLC receiving first-line treatment, including potential maintenance treatment
2421498|NCT03425825||relapsed/refractory receiving 2nd or later-line treatment|relapsed/refractory patients receiving second- or later-line treatment
2421499|NCT03425812|Experimental|Non- NSAIDS group|To withdraw NSAIDS therapy
2421500|NCT03425812|Active Comparator|NSAIDS group|To continue NSAIDS therapy
3186817|NCT00749294||Observation|
3186818|NCT00749307|Experimental|1|
2421505|NCT03425773|Experimental|BVAC-B|BVAC-B IV injection at 0, 4, 8, 12nd weeks.
2421506|NCT03425747|Active Comparator|Calcium Carbonate|Calcium Carbonate
2421507|NCT03425747|Active Comparator|calcium Citrate|Calcium Citrate
2421508|NCT03425734|Experimental|D group|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
2421509|NCT03425734|Experimental|S group|50 ml saline
2421510|NCT03425721||All Participants|
2421511|NCT03425708|Active Comparator|Treatment group1|Febuxostat pill 20mg was used to treat CKD patients with hyperuricaemia.
2421512|NCT03425708|Active Comparator|Treatment group2|Febuxostat pill 40mg was used to treat CKD patients with hyperuricaemia.
2421513|NCT03425708|No Intervention|Control group|Treatment of CKD patients with hyperuricaemia with conventional methods.
2421514|NCT03425695|Experimental|Test group|"Free Gingival Graft (FGG) + Low Level Laser Therapy (LLLT) + Clinical Examination~The test group received LLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) at the FGG sites with a wavelength of 810 nm and output power of 0.1 W, for 60 s, with an energy density of 6 J/cm2 in the continuous wave mode (spot size:0.5 cm). The laser beam was directed perpendicularly toward the tissue in the noncontact mode. The laser was irradiated at the recipient sites immediately after surgery and 1, 3, 7, and 14 days later."
2421515|NCT03425695|Placebo Comparator|Control group|"Free Gingival Graft (FGG)+Placebo Low Level Laser Therapy (PLLLT) + Clinical Examination~The control group received PLLLT with a diode laser (CheseeTM Diode Laser, Wuhan, China ) same as test group without pushing the start button"
2421516|NCT03425682||Cervical Fusion - ACDF|Up to 50 patients undergoing anterior cervical discectomy and fusion (ACDF) using ViBone will be enrolled.
2421517|NCT03425682||Lumbar Interbody Fusion|Up to 50 patients undergoing lumbar interbody fusion (TLIF, PLIF, ALIF, or LLIF) using ViBone will also be enrolled.
2421518|NCT03425669|Active Comparator|Placebo medication and sham stimulation|Patients will be randomly chosen to the group who will get a combination of placebo and sham stimulation.
2421519|NCT03425669|Active Comparator|Active medication|Patients are randomly chosen to the group who will get active medication without stimulation.
3186819|NCT00749307|Placebo Comparator|2|
3186820|NCT00749320|Other|ASL MRI|ASL MRI performed at different time intervals on participants receiving sunitnib or pazopanib for treating RCC
3186821|NCT00749333|Experimental|1|
3186822|NCT00749333|Placebo Comparator|2|
2421523|NCT03425656|Experimental|Trastuzumab (AryoTrust)|Trastuzumab (AryoTrust) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
2421524|NCT03425656|Active Comparator|Trastuzumab (Herceptin)|Trastuzumab (Herceptin) is given concomitantly with docetaxel (for four 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide
3146001|NCT00087399|Experimental|gabapentin + antidepressant|"Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment."
3146002|NCT00087399|Experimental|gabapentin|"Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment."
2421527|NCT03425630|Experimental|Argicolina (cross-over vs Normolip)|Argicolina is a dietary supplement containing monacolin (sachets)
2421528|NCT03425630|Active Comparator|Normolip (cross-over vs Argicolina)|Normolip is a dietary supplement containing monacolin (tablets)
2421529|NCT03425617|Experimental|Tiotropium + Olodaterol first|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 3 followed by PLACEBO via Respimat® single dose in Visit 4
2421530|NCT03425617|Experimental|PLACEBO FIRST|Placebo via Respimat® single dose in Visit 3 followed bytiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose in Visit 4
2421531|NCT03425604||Endometriosis I y II, according to ASRM classification|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
2421532|NCT03425604||patients without endometriosis|Cycles were chosen for analysis only when all the following selection criteria were satisfied: < 38 years old women, antral follicle count > 6, basal FSH < 10mUI/ml, BMI<30, Infertility time <4 years, absence of uterine malformations, endometrial polyps or myomas, absence of known thrombofilia, normal kayotype, < 3 previous IUI cycles, no male severe factor associated
3146003|NCT00087412|Experimental|Treatment|Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3146004|NCT00087581|Experimental|Group A: Monitored MMF + Reduced CNI|Group A will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or intravenous (IV) form. The initial dose will be at least 1 gram twice a day (BID) in adults and 600 milligrams per meter-squared (mg/m^2) in pediatrics. Subsequent doses will be adjusted to maintain blood mycophenolic acid (MPA) levels greater than or equal to (≥) 1.3 micrograms per milliliter (μg/mL) with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain reduced blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 nanograms per milliliter (ng/mL); Days 30-90, 125-165 ng/mL; Days 90 through end of study, 95-145 ng/mL. Tacrolimus target concentrations areas follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL; Days 90 through end of study, 3-5 ng/mL.
2421535|NCT03425578|Experimental|MSG + CHO|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by 75 g dextrose.
2421536|NCT03425578|Active Comparator|MSG + placebo B|Participants will ingest 150 mg/kg body mass monosodium glutamate followed by a non-caloric, flavoured placebo.
2421537|NCT03425578|Active Comparator|Placebo A + CHO|Participants will ingest placebo capsules followed by 75 g dextrose.
3186823|NCT00749346|Experimental|A|Treatment with concomitant Alimta and NovoTTF-100L
2421539|NCT03425552|Experimental|Test treatment|Paliperidone palmitate extended-release injectable suspension for intramuscular use 156 mg (100 mg of Paliperiodne)
2421540|NCT03425552|Active Comparator|Reference treatment|Paliperidone palmitate 156 mg (equivalent to Paliperidone 100 mg) extended release injectable suspension
3186824|NCT00749359|Experimental|open label treatment|On each treatment period, subjects will receive controlled release paroxetine 37.5 milligram (mg) on Day 1.
2421543|NCT03425526|Experimental|Treatment (allogeneic adenovirus-specific CTLs)|Within two weeks of enrollment, patients receive allogeneic adenovirus-specific CTLs IV over 30 minutes. Patients may receive additional allogeneic adenovirus-specific CTL infusions at the discretion of the investigator in the absence of disease progression or unacceptable toxicity.
2421544|NCT03425513||Hepatitis B group|
2421545|NCT03425500|Experimental|Bridging Rotator Cuff Group|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using GRAFTJACKET™ allograft.
2421546|NCT03425500|Active Comparator|Superior Capsular Group|Superior Capsular Reconstruction of massive rotator cuff tear
2421547|NCT03425487|Experimental|MBSR+TAU|Mindfulness based Intervention (MBSR) + Usual specialized treatment in mental health. MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
2421548|NCT03425487|Experimental|ABCT+TAU|Compassion based Intervention (ABCT) + Usual specialized treatment in mental health. ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
2421549|NCT03425487|Active Comparator|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
2421550|NCT03425474|Experimental|Remimazolam Tosilate|Remimazolam Tosilate at 5mg for initial dose
2421551|NCT03425474|Active Comparator|Propofol|Propofol at 1.5mg/kg for initial dose
2421552|NCT03425461|Experimental|Arm A (anti-SEMA4D VX15/2503, nivolumab)|ARM A: Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 30 minutes every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
2421620|NCT03424941|Active Comparator|CABG and SAVR|CABG and SAVR
2421621|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
2421622|NCT03424928|Experimental|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
2421553|NCT03425461|Experimental|Arm B (anti-SEMA4D VX15/2503, ipilimumab)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 30 minutes every 21 days for courses 1-4, then receive anti-SEMA4D monoclonal antibody VX15/2503 every 28 days for subsequent courses for up to 12 months in the absence of disease progression or unacceptable toxicity.
2421554|NCT03425448|Active Comparator|Heparin group|
2421555|NCT03425448|Experimental|Neotrolin Group|
2421556|NCT03425422|Experimental|Therapy|VITARIA system implantation on the right cervical vagus nerve in addition to stable guideline-directed medical therapy
2421557|NCT03425422|No Intervention|Control|Stable guideline-directed medical therapy
2421558|NCT03425409|Other|Continuous Flow|Oxygen delivery at 4 liters per minute is the standard method
2421559|NCT03425409|Other|Pneumatic Pulsed Flow|Oxygen delivery using test method
3186825|NCT00749372|Other|1|Patients who meet eligibility will be sent for radiographic imaging to include T2* cardiac and liver MRI to ascertain quantification of organ-specific iron concentrations as well as cardiac left ventricular ejection fraction.
3186826|NCT00749385|Experimental|1|PN 400
3186827|NCT00749385|Active Comparator|2|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)
3186828|NCT00749385|Active Comparator|3|Enteric-coated naproxen tablet (500mg)
3186829|NCT00749385|Active Comparator|4|EC esomeprazole capsule (20mg)
2421565|NCT03425383||Test group|Subjects having periapical disease diagnosed clinically and radiographically and free from any other systemic illness. FMD and c-IMT will be determined by ultrasound
2421566|NCT03425383||Control group|Healthy subject. FMD and c-IMT will be determined by ultrasound
2421567|NCT03425370|Experimental|Wound Side A: buried sutures, Wound Side B: tissue adhesive|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
2421568|NCT03425370|Experimental|Wound Side A: tissue adhesive, Wound Side B: buried sutures|Wounds halves will be labeled as A (left/superior) or B (right/inferior), the halves will be randomized to receive either tissue glue or deep sutures.
2421569|NCT03425357|Experimental|Low Load Exercises|An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction.
2421570|NCT03425344|Other|Diagnostic|All participants will be exposed to shoulder- MRI, ultrasound and sonoelastography.
3186830|NCT00749424|Experimental|1|crushing technique
2421572|NCT03425318|Experimental|Single arm|Patients with ARDS will be placed inside of a Continuous Negative Abdominal Pressure Device. Negative pressure will be applied to the abdomen as an adjunct to positive pressure ventilation
2421573|NCT03425292|Active Comparator|1 SOC (closed to enrollment)|Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide
2421574|NCT03425292|Experimental|2 Nivo|Nivolumab
2421575|NCT03425292|Experimental|3 Nivo-Ipi (closed to enrollment)|Nivolumab plus Ipilimumab
2421576|NCT03425292|Experimental|4 Nivo-Ipi-CCNU-TMZ|Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide
2421577|NCT03425292|Experimental|5 Nivo-Ipi-TMZ|Nivolumab plus Ipilimumab plus metronomic Temozolomide
2421578|NCT03425292|Experimental|6 Nivo-Ipi-Bev-TMZ|Nivolumab plus Ipilimumab plus Bevacizumab plus metronomic Temozolomide
2421579|NCT03425279|Experimental|BA3011|Phase 1: All patients will receive BA3011, CAB-AXL-ADC. Phase 2: All patients will receive either BA3011 alone or in combination with PD-1 inhibitor.
2421580|NCT03425279|Experimental|Combination Therapy|Phase 2: BA3011 in combination with PD-1 inhibitor.
2421581|NCT03425266|Experimental|Interactive decision support tool|Online interactive multimedia decision support tool that the patient interacts with before seeing their provider that helps them learn more about chronic pain, identify treatment goals and preferences, and communicate more effectively with their provider. The tool takes between 20-45 minutes to use. It generates and transmits a preference summary for the patient and a summary of relevant shared decision making elements and medical history elements intended for sharing with providers if the patient chooses.
2421582|NCT03425266|No Intervention|Control|Our control arm is a leading consumer-facing website designed for people with chronic pain (the ACPA). Subjects randomly assigned to this arm will be directed to the page focusing on communication tools, which also includes links to other parts of the website. The specific page is: https://theacpa.org/Communication-Tools
3186831|NCT00749424|Active Comparator|2|provisional T stenting technique
2421584|NCT03425240|Experimental|Nerve Stimulation|Acute placement of electrodes and electrostimulation of the pelvic plexus nerves during open radical prostatectomy.
3186832|NCT00749450|Experimental|Arm I|Patients receive OxMdG or XELOX combination chemotherapy for a total of 12 courses for treatment lasting a total of 24 weeks.
3186833|NCT00749450|Experimental|Arm II|Patients receive OxMdG or XELOX combination chemotherapy for a total of 6 courses for treatment lasting a total of 12 weeks.
3186834|NCT00749489|Experimental|Femoral Nerve Block|Intervention patients will have a continuous fascia iliaca blocks placed by a regional anesthesiologist 24 hours after the initial single injection femoral nerve block or at the time of surgery.
3186835|NCT00749489|No Intervention|No Intervention|No intervention
3186836|NCT00749502|Experimental|Part A-Dose escalation and confirmation|
3186837|NCT00749502|Experimental|Part B - Prostate/Ovarian Cancer Cohort|
3186838|NCT00749502|Experimental|Part C - T-PLL/CLL cohort|
3186839|NCT00749502|Experimental|Part D - CRC, endometrial, breast, and ovarian cancer cohort|
3186840|NCT00749528||1|Children vith recurrent wheezing
3186841|NCT00749528||2|Healthy children
3186842|NCT00749541||1normal catheter.|
3186843|NCT00749541||abnormal catheter.|
3186844|NCT00749554|Active Comparator|Disc biacuplasty|
3186845|NCT00749554|Placebo Comparator|Sham treatment.|
3186846|NCT00749567|Experimental|1|Erlotinib/Bevacizumab
3186847|NCT00749593||CaHASE 1|Adults with CAH
3186848|NCT00749619|Experimental|A|
3186849|NCT00749619|Experimental|B|
3186850|NCT00749619|No Intervention|C|
3186851|NCT00749632|Active Comparator|1|
2421585|NCT03425227|Experimental|study group / control group|"The subjects belonging to the study group carried out three sessions per week over a 6-week period. Each session involved 20 minutes of activity divided into three parts.~The subjects belonging to the control group continued to lead their daily lives in the course of which they had no physical activity scheduled."
2421586|NCT03425214|Experimental|NC with RBD|fMRI and video polysmnography
2421587|NCT03425214|Experimental|NC without RBD|fMRI and video polysomnography
2421588|NCT03425214|Experimental|control group (healthy subjects)|fMRI
3146005|NCT00087581|Experimental|Group B: Monitored MMF + Full CNI|Group B will receive concentration-controlled/monitored MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
3186852|NCT00749632|Active Comparator|2|
2421591|NCT03425175|No Intervention|Control group|Standard care with recording of video but no audio-recording
2421592|NCT03425175|Experimental|Intervention group|Standard care with the addition of simultaneous audio-recording during the operation.
2421593|NCT03425162|Active Comparator|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+PCA (morphine)
2421594|NCT03425162|Sham Comparator|Group P|Group P:PCA (morphine)
2421595|NCT03425149|Experimental|Treatment Group I|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.5 ml Placebo on Day 7
2421596|NCT03425149|Experimental|Treatment Group II|0.5 ml (6 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.5 ml Placebo on Day 28
2421597|NCT03425149|Experimental|Treatment Group III|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 28, 0.25 ml Placebo on Day 7
2421598|NCT03425149|Experimental|Treatment Group IV|0.25 ml (3 antigen units (AU)) of VLA1601 on Day 0 and 7, 0.25 ml Placebo on Day 28
2421599|NCT03425149|Placebo Comparator|Treatment Group V|0.5 ml Placebo on Day 0, 7 and 28
2421600|NCT03425136|Experimental|SAIA (Systems Analysis & Improvement)|Intervention is a five-step package of industrial engineering methods known as SAIA (the systems analysis and improvement approach) delivered by district maternal and child health managers to subordinate health facilities that provide prevention of mother-to-child HIV services.
2421601|NCT03425136|No Intervention|Control|Routine provision of prevention of mother-to-child HIV transmission services and routine support from district maternal and child health managers to subordinate facilities.
2421602|NCT03425123|Experimental|REP Group|All participants in this single arm study will receive Regenerative Endodontic Procedure (REP). It regenerates the root tip on recently erupted permanent teeth that did not complete root development due to pulp infection and necrosis by allowing cells to migrate from the surrounding periapical tissue and enter the pulp space. Cells contained within the intentional bleeding create at the root tip help in root completion as well as increasing the thickness of the canal walls over up to two years following the procedure.
3186853|NCT00749632|Active Comparator|3|
3186854|NCT00749645|Active Comparator|1 - FANG(30)|1 - Active comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the active product, in addition to base medication (Mtx + Pdn)
2421605|NCT03425084|Experimental|Morphine|Intravenous morphine (0,15 mg/kg) will be given as a single dosis at the end of the surgery followed by morphine administrated by patient-controlled analgesia (PCA) as single boluses (0,04mg/kg)
2421606|NCT03425071||Healthy volunteers|"Healthy volunteers - subjects without exposure to tacrolimus. Blood samples from these subjects will be used in in vitro experiments."
2421607|NCT03425071||kidney transplant (KTx) months 1-2|"Kidney transplant recipients recruited during the months 1 to 2 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to high blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
2421608|NCT03425071||KTx months 4-5|"Kidney transplant recipients recruited during the months 4 to 5 of follow up after kidney transplantation surgery. These are subjects expected to be exposed to standard blood levels of tacrolimus. Blood samples from these subjects will be used in ex vivo experiments."
2421609|NCT03425045|Experimental|Repetitive Transcranial Magnetic Stimulation|Patients in this study arm will undergo the rTMS stimulation as described above.
2421610|NCT03425045|Sham Comparator|Sham stimulation|Patients in this study arm will undergo the sham stimulation as described above.
2421611|NCT03425045|Active Comparator|Ginkgo Biloba Extract|Patients in this study arm will receive medication therapy as described above, without any rTMS or sham procedure.
3186855|NCT00749645|Placebo Comparator|2 - Placebo|2 - Placebo comparator, consisted of 30 adult patients with active Rheumatoid Arthritis, randomly assigned, taking the placebo formulation, in addition to base medication (Mtx + Pdn)
3186856|NCT00749710|Active Comparator|1|immediate operation - ORIF - of hip fracture in patient treated with clopidogrel
2421614|NCT03424993|Experimental|Dietary Sodium Restriction|Daily habitual dietary sodium intake < 2000mg
2421615|NCT03424993|Sham Comparator|Control|Routine habitual dietary sodium intake >3400mg
2421616|NCT03424980||Tyrosine kinase inhibitors|Diagnosed patients with advanced non-small cell lung cancer (NSCLC) with brain metastases who were administered with tyrosine kinase inhibitors only or combination therapies of tyrosine kinase inhibitors
2421617|NCT03424967|Experimental|ABM therapy|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
2421618|NCT03424954|Experimental|EpxOstomy|Post-operative ileostomy patients will receive the study intervention for 30 days following discharge from the hospital.
2421619|NCT03424941|Experimental|FFR-guided PCI and TAVI|FFR-guided PCI and subsequently TAVI treatment with the Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO
3186857|NCT00749710|Active Comparator|2|ORIF - surgical treatment patients not on antiaggregant therapy
3186858|NCT00749723|Experimental|1: P-HIT-REZ 2005|"intravenous chemotherapy with carboplatin/etoposide,followed by~high dose chemotherapy with thiotepa, carboplatin, etoposide and autologous stem cell transplantation if patient have achieved a complete remission or~maintenance therapy with oral trofosfamide, etoposide"
3186859|NCT00749723|Experimental|2: P-HIT-REZ 2005|"oral chemotherapy with temozolomide, followed by~high dose chemotherapy with temozolomide, thiotepa and autologous stem cell transplantation if patient have achieved a complete remission~maintenance therapy with oral temozolomide or in case of progression with oral trofosfamide, etoposide"
2421625|NCT03424902||group1|patients with no or mild paravalular leakage
2421626|NCT03424902||group 2|patients with moderate or or severe paravalvular leakage
2421627|NCT03424889|Experimental|Xylometazoline|Patients receiving topical xylometazoline nasally during bronchoscopy
2421628|NCT03424889|Placebo Comparator|Saline placebo|Patients receiving topical saline nasally during bronchoscopy
2421629|NCT03424876||Arm A|Imatinib 400 mg/day or 600mg/day, and within 6 weeks after surgery, continuous treatment was not tolerated until tumor progression, recurrence or adverse reactions were not tolerated.
2421630|NCT03424876||Arm B|Sunitinib 37.5 mg/day, continuous taking, or 50 mg/day (4/2), began within 6 weeks after surgery, and was continuously administered until tumor progression, recurrence or adverse reactions were not tolerated
2421631|NCT03424863|Experimental|Aortic stent graft patients|Patients who have received an aortic stent graft who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
2421632|NCT03424863|Experimental|Healthy volunteers|Healthy volunteers in general good health with no history of heart disease who will perform one session of moderate intensity muscle strengthening during which blood pressure will be measured.
2421633|NCT03424850|Experimental|HDR brachytherapy - 21 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.
2421634|NCT03424850|Experimental|HDR brachytherapy - 23 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.
2421635|NCT03424850|Experimental|HDR brachytherapy - 25 Gy|-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.
2421636|NCT03424837|Experimental|Intervention Arm: SoC (standard of care) and ASCENT|Health care per institutional standard plus ASCENT via the TrueNTH website.
2421637|NCT03424837|No Intervention|Control Arm: SoC and TrueNRH|Health care per institutional standard, plus access to the public information on the TrueNTH website; such as the symptom tracker, exercise & diet, and lived experiences modules.
2421638|NCT03424824|Experimental|BP1.3656 low dose|
2421639|NCT03424824|Experimental|BP1.3656 intermediate dose|
2421640|NCT03424824|Placebo Comparator|Placebo|
2421641|NCT03424811|Experimental|Intervention Group|Includes core behavior change strategies and behavioral skills training designed to promote healthy eating behaviors.
2421642|NCT03424811|No Intervention|Control Group|Information provided will mimic what families may receive during a routine well-child visit.
2421643|NCT03424772||Patients with unexplained DD/ID|Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.
2421644|NCT03424759|Experimental|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
2421645|NCT03424746|Experimental|Open label EDTA chelation|EDTA-based chelation therapy plus vitamins in diabetic patients with severe peripheral artery disease presenting with impending amputation and determine if there is an improvement in outcomes and a delay or reduction of amputations.
2421646|NCT03424733|Active Comparator|Current Plegridy Users|Members in this group have been previously titrated and are currently taking the pegylated interferon beta-1 (Plegridy) injection once every two weeks. These patients will complete a total of six study injections of Plegridy (125 micrograms) totaling a 12 week study duration. Subjects must take two 325mg tablets of Tylenol 1 hour prior to each study injection, and one 20mg Prednisone tablet 4-5 hours prior to injections two through six only.
2421647|NCT03424733|Experimental|New Plegridy Users|Members in this group have never taken the pegylated interferon beta-1a (Plegridy) injection, and so they must first by titrated by injecting with a 63 and 94 microgram Plegridy dose. Titrations, along with full dose injections (125 micrograms) occur every two weeks. Patients must take two 325mg tablets of Tylenol prior to each titration injection. The third study dosage involves subjects taking the full 125 microgram Plegridy dosage with two 325mg Tylenol tablets prior to injection. The final five study injections (four through eight) require patients to take two 325mg Tylenol tablets 1 hour prior to injection, and one 20mg Prednisone tablet 4-5 hours prior to injection.
2421648|NCT03424720|Experimental|Comparison of PLE and BIS|Investigators assess PLE and BIS values as indicators of the depth of anesthesia during induction and emergence of anesthesia and facial nerve integrity monitoring
2421649|NCT03424707|Experimental|combination|
2421650|NCT03424707|Active Comparator|single|
2421651|NCT03424707|Placebo Comparator|placebo|
2421652|NCT03424694|Experimental|2 fractions of 14.5 Gy HDR Brachytherapy|"High Dose Rate (HDR) Brachytherapy as monotherapy at a dose of 29 Gy is delivered in 2 fractions of 14.5 Gy, minimum 6 hours a part, delivered on a single implant procedure with 2 MRI assisted plannings and dosimetries.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
2421653|NCT03424694|Experimental|1 fraction of 19.5 Gy HDR brachytherapy|"HDR Brachytherapy as monotherapy at a dose 19.5 Gy is delivered in 1 fraction. Treatment is done on a single ultrasound guided implant, post implant MRI assisted planning and dosimetry.~HDR brachytherapy implant is done under anesthesia with ultrasound guidance as an out-patient procedure."
2421656|NCT03424655|Experimental|Group TFA|Twisted files were used serially with a single controlled motion according to the manufacturer's instructions.
2421691|NCT03424447|No Intervention|Non stimulated|Prospective data obtained from non stimulated patients
2421657|NCT03424655|Experimental|Group BF|The root canals were cleaned and shaped using a #40 instrument for thin or curved canals and a #55 file for widespread canals.
2421658|NCT03424655|Experimental|Group WON|WaveOne files was used to prepare narrow, straight and curved canals, and a file (40.08) was used for large and wide canals.
2421659|NCT03424655|Experimental|Group REC|Reciproc instrument was used in thin and curved RC, and R40 files (40.06) were used in wide canals.
2421660|NCT03424642|Experimental|Interactive 4D-ultrasound examination|Pregnant women who are randomized to 4D-ultrasound intervention group will receive additional 4D-ultrasound examinations 2-3 times between gestational weeks 25-32. Patients in this group will also receive psychologist's interview twice and fill out questionaries.
2421661|NCT03424642|No Intervention|Control group|Pregnant women who are randomized to control group will receive psychologist's interview twice twice and fill out questionaires.
2421662|NCT03424629|Experimental|Low-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 1 x 10^6 cells/kg in normal saline injection
2421663|NCT03424629|Experimental|High-Dose UC-MSCs|Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) 3 x 10^6 cells/kg in normal saline injection
2421664|NCT03424629|Active Comparator|Methotrexate|5-25mg Methotrexate orally
2421665|NCT03424616|Experimental|Postoperative immediate Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was turned on 1-2 weeks postoperatively.
2421666|NCT03424616|Sham Comparator|Postoperative delayed Deep brain stimulation|The addicts undergone the deep brain stimulation while the stimulation (Suzhou Sceneray® DBS System) was off until 25 months postoperatively, during which the following up was kept, then the the stimulation was turned on 25 months postoperatively.
2421667|NCT03424603|Experimental|STRO-001|intravenous
2421668|NCT03424590|Active Comparator|COTS|Volunteers will be provided with Clearblue connected Ovulation test system to use during the study period, accortding to the instructions for use.
2421669|NCT03424590|No Intervention|Control|Volunteers will not be provided with Clearblue Connected Ovulation Test System and will be instructed not to use any other ovulation predictions tests during the study period.
2421670|NCT03424577|Experimental|H3B-6527|Healthy male participants will be randomly assigned to 1 of 2 possible treatment sequences: either H3B-6527 capsule with food on Day 1 and H3B-6527 capsule without food on Day 5 (treatment sequence fed/fasted), or H3B-6527 capsule without food on Day 1 and H3B-6527 capsule with food on Day 5 (treatment sequence fasted/fed).
2421671|NCT03424564|Experimental|Perampanel single-dose Part: 2 mg group|Participants will receive a single 2 milligrams (mg) dose of perampanel orally under fasted conditions.
2421672|NCT03424564|Experimental|Perampanel single-dose Part: 4 mg group|Participants will receive a single 4 mg dose of perampanel orally under fasted conditions.
2421673|NCT03424564|Experimental|Perampanel single-dose Part: 8 mg group|Participants will receive a single 8 mg dose of perampanel orally under fasted conditions.
2421674|NCT03424564|Experimental|Perampanel multiple-dose Part|Participants will receive multiple oral dose of perampanel (2 milligrams per day [mg/day] from Day 1 to Day 7 and 4 mg/day from Day 8 to Day 21). Fasted condition is required for Days 1 and 21.
2421675|NCT03424551|Experimental|Vibrator|Local or Whole body vibration was applied at six different frequencies to Healthy control and spastic spinal cord injury. For local vibration, vibration frequencies were 50, 85, 140, 185, 235 and 265 Hz . For whole body vibration, vibration frequencies were 35, 37, 39, 41, 43 and 45 Hz
2421676|NCT03424538|Experimental|MSt|The MSt group that received 5 weeks of intensive therapy.
2421677|NCT03424538|No Intervention|MSc|The MS controll group that did not receive treatment.
2421678|NCT03424538|Experimental|MStp|The MStp Group performs a traditional physiotherapy for 5 weeks.
2421679|NCT03424525|Experimental|Biodistribution|The Biodistribution cohort referred from orthopedics who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [11C]trimethoprim PET/CT scans over a period of approximately 2 ½ hours.
2421680|NCT03424525|Experimental|Dynamic|The Dynamic cohort will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans imaging post injection of [11C]trimethoprim. Some subjects who may be selected clinically to undergo surgical or antibiotic treatment may undergo a second therapy may also undergo an optional second [11C]trimethoprim PET/CT after the initiation of therapy to collect pilot data on the changes in [11C]trimethoprim biodistribution and uptake with therapy, the timing of this scan may vary depending on the type of treatment the patient is receiving.
2421681|NCT03424512|Experimental|Group Metacognitive Therapy|Group metacognitive therapy (MCT) is a brief psychological intervention designed to be delivered in small groups of 4-8 patients over a course of six, 90 minute sessions conducted on a weekly basis
2421682|NCT03424499|Active Comparator|Single-use catheter|"Participants will use a sterile single-use catheter of polyvinyl chloride (PVC) for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique, each PVC catheter will be sterile and used only once for each catheterization.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
2421683|NCT03424499|Experimental|Reused catheter|"Participants will use a clean reused catheter of polyvinyl chloride for intermittent urethral catheterization.~Intermittent Bladder Catheterization will be done using clean technique. The PVC catheter will be used for 1 week, cleaning the catheter with water and soup after each catheterization and stored in a container with 0.5% benzalkonium chloride.~A Urine culture will be performed at day 0, 7, 14, 28, 49 and 56 (a total of 8 cultures)"
2421684|NCT03424486||Adolescents (14 to 17 years old)|Patients with CF
2421685|NCT03424486||Parents|Parents of adolescents (14 to 17 years old with CF (father, mother and other)
3146006|NCT00087581|Experimental|Group C: Fixed MMF + Full CNI|Group C will receive fixed-dose MMF with an oral CNI, either cyclosporine or tacrolimus. Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. Subsequent doses are not to be adjusted, except in the case of unacceptable toxicity. The selected CNI will be dosed to maintain standard/full blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 250-270 ng/mL; Days 90 through end of study, 190-220 ng/mL. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 8-10 ng/mL; Days 90 through end of study, 6-8 ng/mL.
2421692|NCT03424447|Experimental|Stimulated|Prospective data obtaied from stimulated patients
2421693|NCT03424434||Medical staff of an UHC, practitioners and residents|The target population is practitioners and residents who works at hospital in an UHC, they are also specialists, surgeons, dental surgeons.
2421694|NCT03424421|Experimental|subscapular sling|semitendinosus subscapular sling procedure
2421695|NCT03424408|Other|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
2421696|NCT03424395|Other|Personalized dietary and wellness program|An integrated personalized nutrition program which includes a combination of dietary and wellness advice/counseling on wellness and meals, or dietary and wellness advice/counseling alone, each for 10 weeks.
2421697|NCT03424382||Phase I|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
2421698|NCT03424382||Phase II|Participants will complete an intake form and assessment tool survey on an electronic device provided by research staff in their hospital room. If an individual is unable to complete the instrument, he or she may have another individual enter his or her answers on the electronic device.
2421699|NCT03424369||Eustachian tube unobstructed|
2421700|NCT03424369||Eustachian tube dysfunction|
2421701|NCT03424356|Experimental|lma with rocuronium bromide|In study group, 2-3 mg/kg propofol, 1mcg/kg fentanyl and 0.15 mg/kg rocuronium bromide will be administered during lma insertion in cystoscopy procedure.
2421702|NCT03424356|Active Comparator|lma with saline solution|In control group, 2-3 mg/kg propofol, 1 mcg/kg fentanyl and saline(no rocuronium) will be administered during lma insertion in cystoscopy procedure.
2421703|NCT03424343||cancer survivor, parents, sibling|
2421704|NCT03424330|Experimental|Arm1 - ReX first|Subjects begin with the ReX-C Intervention stage followed by Standard of Care stage.
2421705|NCT03424330|Experimental|Arm 2- Standard of Care first|Subjects start with Standard of Care stage followed by ReX-C Intervention.
2421706|NCT03424317|Active Comparator|Sodium intake reduction and exercise|education of sodium intake reduction and regular exercise
2421707|NCT03424317|Placebo Comparator|Exercise|education of regular exercise only
2421708|NCT03424304|Other|Excel V™ Laser With Green Genesis|Treatment with Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment for skin quality in desired area
2421709|NCT03424291|Experimental|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
2421710|NCT03424278|Active Comparator|Motor Control|
2421711|NCT03424278|Experimental|Resistance Training|
3186860|NCT00749723|Experimental|3: E-HIT-REZ 2005|Phase II: oral chemotherapy with temozolomide after progression oral trofosfamide, etoposide
3186861|NCT00749723|Experimental|Intraventricular Etoposide|Phase II, intraventricular chemotherapy with etoposide
2421714|NCT03424252|Experimental|FDL169 Dose Level 1,sublingual to oral|Dose level 1 sublingual first and oral second.
2421715|NCT03424252|Experimental|FDL169 Dose Level 1 dosing,oral to sublingual|Dose level 1 oral first and sublingual second.
2421716|NCT03424252|Experimental|FDL169 Dose Level 2 sublingual to oral,Optional|Dose level 2 sublingual first and oral second.
2421717|NCT03424252|Experimental|FDL169 Dose Level 2 oral to sublingual,Optional|Dose level 2 oral first and sublingual second.
3186862|NCT00749736|Active Comparator|1|4000 IU of cholecalciferol per day
2421719|NCT03424226|Experimental|day of acetazolamide|acetazolamide 125mg twice a day, started morning of ascent
2421720|NCT03424226|Active Comparator|night before acetazolamide|acetazolamide 125mg twice a day, started evening before ascent
2421721|NCT03424213||white low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
2421722|NCT03424213||white high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
2421723|NCT03424213||white intermediate aggressive|intermediate aggressive = all other cases
2421724|NCT03424213||AA low aggressive|low aggressive = Gleason score < 7 and stage cT1-cT2 and PSA < 10 ng/ml
2421725|NCT03424213||AA high aggressive|high aggressive = Gleason score ≥ 8 or PSA > 20 ng/ml or Gleason score = 7 and stage cT3-cT4
2421726|NCT03424213||AA intermediate aggressive|intermediate aggressive = all other cases
2421727|NCT03424200|Other|Coaching plus Routine Care|Participants will receive coaching plus routine care
2421728|NCT03424200|Other|Routine Care|Participants will receive the routine care
2421732|NCT03424174|Experimental|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
2421733|NCT03424174|Active Comparator|Standard Total Knee Arthroplasty|Implantation Standard Total Knee Arthroplasty
2421734|NCT03424161|Other|Secret RF|Treatment with Secret RF for skin quality
2421735|NCT03424148|Other|Excel V™ Laser & Micro-Lens Array Attach|Treatment with Excel V™ Laser and a Micro-Lens Array Attachment for skin quality
2421736|NCT03424135|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
2421799|NCT03423758||Pseudoexfoliation Glaucoma|Already diagnosed Pseudoexfoliation glaucoma patients with age more than 50 years
3146007|NCT00087711|Experimental|A|
3146008|NCT00087711|Active Comparator|B|
3146009|NCT00087802|Active Comparator|Stratum 1|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease). Randomization schedules will be produced for each stratum, and treatment allocation will be carried out centrally
2421737|NCT03424135|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods (Dosing Periods 1 and 2) with each period consisting of 4 days starting with an overnight fast of at least 10 hours. Subjects will consume a standardized high calorie, high fat breakfast approximately 30 minutes prior to dosing followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two study drug administrations are separated by a 7 calendar days washout phase.
2421741|NCT03424109||Beneficiaries with a one-year mortality of at least 30%|The patient cohort will be extracted via the Centers for Medicare and Medicaid Services (CMS) Research Data Assistance Center (ResDAC) using a two-step process to maximize diversity, and minimize intentional or unintentional exclusions based on risk, age, health literacy, demographics, or expected adherence.
2421742|NCT03424083||1 cohort|adult patients of both sexes (>18 and <80 years) with no previous diagnosis or follow up by a pulmonologist, send by a general practitioner to the lung function lab
2421743|NCT03424070|Active Comparator|Laryngoscopy view with a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy with and then without the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
2421744|NCT03424070|Placebo Comparator|Laryngoscopy without a shoulder roll|The primary outcome is the difference in the height of the lateral canthus of the eyelid of the laryngoscopist above the OR table during laryngoscopy without and then with the shoulder roll. These two positions will be compared using photos of the best glottic view taken during laryngoscopy with a shoulder roll in place. Then a photo of the best glottic view will be taken during laryngoscopy without the shoulder roll in place. These two views will be compared by a blinded anesthesiologist using the POGO scale.
2421745|NCT03424057|Experimental|Group 1|"Group 1 were treated with the new technique (Asymmetric Primary Closure and Additional Skin Excision).~In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume."
2421746|NCT03424057|Active Comparator|Group 2|Group 2 were treated with the standard Karydakis technique.
3186863|NCT00749736|Active Comparator|2|1 mcg of doxercalciferol per day.
3186864|NCT00749736|Placebo Comparator|3|placebo for six months
3186865|NCT00749788|Experimental|1|JTT-302, 200 mg
2421750|NCT03424031|Experimental|Verticalization|the patient will be placed in the most vertical position possible.
2421751|NCT03424031|No Intervention|Passive mobilization|Passive mobilization of the lower limb deficit
2421752|NCT03424018|Experimental|BMN 111|
3146010|NCT00087802|Active Comparator|Stratum 2|Subjects will be randomized in a 1:1 allocation to either GEMOX or CP after signed consents and baseline evaluations are completed, allowing for safe entry into the study. In order to avoid an unbalanced distribution by baseline characteristics, randomization will be stratified by one factor: disease stage (in a 1:4 proportion for Stage IIIb vs. Stage IV or relapsed disease).
3146011|NCT00087867|Experimental|001|SCIO-469 two 30-mg capsules three times daily
3146012|NCT00087867|Other|002|SCIO-469 and bortezomib In addition to SCIO-469 patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1 4 8 and 11 of a 21-day cycle followed by a 10-day rest period
3146013|NCT00087880|Active Comparator|Brief Treatment|Participants will start with a 21 mg nicotine patch, tapering to 14 mg patch and finally tapering to 7 mg patch. The nicotine patch will be administered on Week 3 of the program. Participants will meet with medical staff during Weeks 1, 2, 5, and 11. Five group counseling sessions must be attended by the participants. Assessments will be conducted on Weeks 12, 24, 36, 52, 64, and 104.
3146014|NCT00087880|Active Comparator|Extended Bupropion/Low Contact|Participants will receive the Brief Treatment followed by ongoing Bupropion treatment through Week 52. Participants will meet with medical staff once a month.
3146015|NCT00087880|Placebo Comparator|Extended Placebo/Low Contact|Participants will receive the Brief Treatment followed by placebo medication (sugar-pill) through Week 52 and meet with medical staff once a month.
3146016|NCT00087880|Active Comparator|Extended Bupropion/High Contact|Participants will receive Brief Treatment followed by ongoing bupropion treatment through Week 52. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
2421800|NCT03423758||Angle closure Glaucoma|Already diagnosed Angle closure Glaucoma patients with age more than 21 years
2421801|NCT03423758||Primary open-angle Glaucoma|Already diagnosed primary open-angle glaucoma with age more than 30 years
3186866|NCT00749788|Experimental|2|JTT-302, 400 mg
3186867|NCT00749788|Placebo Comparator|3|Matching placebo tablets
3186868|NCT00749801|Active Comparator|A|nattokinase-mono formula (3500FU)
3186869|NCT00749801|Experimental|B|Nattokinase compound-multiple formulae
3186870|NCT00749801|Placebo Comparator|C|Placebo
3186871|NCT00749814|Experimental|A|Study group will receive melatonin.
3186872|NCT00749814|Placebo Comparator|B|Placebo
3186873|NCT00749814|No Intervention|C|No intervention control group.
3186874|NCT00749827|Active Comparator|1|Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours
3186875|NCT00749827|Active Comparator|2|Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
3186876|NCT00749840||HIV Care Questionnaire|Patients with a new diagnosis of HIV infection.
2421761|NCT03423992|Experimental|Biological: Chimeric antigen receptor T cells|
2421762|NCT03423979|Experimental|Optilume™ BPH Prostatic DCB Dilation Catheter|Optilume™ BPH Prostatic DCB treatment procedure
2421763|NCT03423966|Experimental|Self Objective Mobility Evaluation|Usual Care Plus a Smartphone pedometer App
2421764|NCT03423966|No Intervention|Usual Care (UC)|Usual Care of obesity
2421765|NCT03423953||Anatomic|Patients receiving the Anatomic or Hemi verison of the Comprehensive Nano.
2421766|NCT03423953||Reverse|Patients who have received the Reverse version of the Comprehensive Nano.
2421767|NCT03423940|Experimental|Evaluation of Treatment Dosage|The goal of intervention for arm 1 is to examine the optimal duration of treatment with functional communication training (FCT). Investigators will treat each subject's behavior using FCT in three distinct contexts which will be associated with either short, moderate, or extended treatment durations. The investigators will counterbalance the order of treatment durations (short, moderate, and extended) across subjects, but each subject will receive treatment at each duration. Resurgence will be tested following each treatment duration.
2421768|NCT03423940|Active Comparator|Empirically Derived Schedule Thinning|The goal of the intervention for arm 2 is to develop the optimal progression for reinforcement schedule thinning during functional communication training. The investigators will use measurements of destructive behavior, appropriate behavior, and reinforcer deliveries during each treatment session to inform the frequency of reinforcers that will be available during upcoming treatment sessions. The investigators will develop the schedule thinning progression by plugging these measurements into the quantitative model to describe the proper steps to schedule thinning to decrease the probability of a relapse of destructive behavior. The investigators will compare these results to those in the extant literature.
2421769|NCT03423927|Experimental|Intervention group : hypnosis + self-care|Groupal intervention combining self-care techniques and self-hypnosis exercises
2421770|NCT03423927|No Intervention|Control group : no intervention|Control group receiving usual care but not the intervention
2421771|NCT03423914|Experimental|Writing Intervention Group|Expressive writing The participant will write four days about her deepest thoughts and feelings in relation to the experience of hospitalization of the premature newborn and how this experience is related to your current life and to your future.
2421772|NCT03423914|Active Comparator|Control Group|Only Writing The participants will write about situations not related to the subjective human experience of their preterm birth, but about general aspects.
2421773|NCT03423901|Experimental|ABO/HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 12 ABO and HLA incompatible kidney transplantation (KT)
2421774|NCT03423901|Experimental|ABO incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 28 ABO incompatible kidney transplantation
2421775|NCT03423901|Experimental|HLA incompatible KT|Blood sampling for descriptive analysis of clinical, biological and histological of 20 HLA incompatible kidney transplantation
2421776|NCT03423888|Experimental|High-flow nasal oxygen|
2421777|NCT03423875|No Intervention|Control|Patients assigned to the control condition will be treated using the current standard of care, clinical assessments, to identify delirium.
2421778|NCT03423875|Experimental|Intervention|PrEDICTgame score (subject's relative risk of delirium) will be shared with ED physicians in the intervention arm. After viewing the tests results, ED physicians will be asked to reassess delirium risk, and indicate if they would change their management based on the PrEDICT app scores.
2421779|NCT03423849|Experimental|The original program (NG/NP)|Vinorelbine injection 25mg/m2 on day 1 and day 8, Gemcitabine injection 1250mg/m2 on day1 and day 8,every 3 weeks for 3 cycles（for the patients who used the NG salvage therapy） or Vinorelbine injection 25mg/m2 on day 1 and day 8,Cisplatin injection 25mg/m2 on day1,every 3 weeks for 3 cycles（for the patients who used the NP salvage therapy ）
2421780|NCT03423849|Experimental|One of the original program (N)|Vinorelbine injection,25mg/m2 on day 1 and day 8,every 3 weeks for 6 cycles. or, Vinorelbine oral 60mg/m2 on day 1,every week for 6 cycles.
2421781|NCT03423849|Experimental|Capecitabine monotherapy|Capecitabine oral 1250mg/m2,bid,for 6 cycles
2421782|NCT03423836||High Risk Infants|Motor infants born prior to 35 weeks gestational age, or, infants small (<10th percentile) for gestational age.
2421783|NCT03423836||Low Risk Infants|Motor infants born after the completion of the 37th week of gestation and appropriate for gestational age.
2421784|NCT03423823|Experimental|Study Drug Arm|Receiving 1.25mg of 0.05mL of Ziv-aflibercept intravitreal injection every month
2421785|NCT03423823|Other|Control Arm|Receiving bevacizumab, ranibizumab, or aflibercept intravitreal injection every 5 to 12 weeks (varied intervals based on individual need for treatment)
2421786|NCT03423810|Experimental|Group 1: Hydralazine|Participants will take hydralazine twice daily for total of 6 weeks. The dose of hydralazine will be increased every 2 weeks.
2421787|NCT03423797|Active Comparator|NaF without fTCP|25% AgNO3 solution followed by 5% NaF.
2421788|NCT03423797|Experimental|NaF with fTCP|25% AgNO3 solution followed by 5% NaF with fTCP.
2421789|NCT03423784|Experimental|HA BPX V3.3|A HMWHA gel available in a formulation specificaly designed for use in infants
2421790|NCT03423784|Active Comparator|Dentinox-Gel N|Gold standard for teething symptoms
2421791|NCT03423771|Experimental|NPF-08 Low dose （1-day treatment）|
2421792|NCT03423771|Experimental|NPF-08 Medium dose （2-day split dose）|
2421793|NCT03423771|Experimental|NPF-08 High dose （2-day split dose）|
2421794|NCT03423771|Experimental|NPF-08 Medium dose （1-day treatment）|
2421795|NCT03423771|Experimental|NPF-08 High dose （1-day treatment）|
2421796|NCT03423771|Experimental|NPF-08 Low～High dose （1-day treatment）|
2421797|NCT03423771|Experimental|NPF-08 Medium～High dose （2-day split dose）|
2421798|NCT03423758||Healthy controls|Healthy subjects with age more than 60 years
2421802|NCT03423732|Active Comparator|Active Group|Patients randomized to the active treatment group will receive CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin); 15 000 000 via common femoral artery injection and 15 000 000 via intramuscular injections above the knee (ATK, 6 injection sites) and below the knee (BTK, 6 injection sites).
2421803|NCT03423732|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) injections in the same manner.
2421804|NCT03423719|Experimental|Verum|This arm receives 2 x 450 mg capsules of Fiit-ns®, a blend of polyphenol-rich fruit and vegetables extracts, daily for 16 weeks.
2421805|NCT03423719|Placebo Comparator|Placebo|This arm receives 2 x 450 mg capsules of Placebo, containing maltodextrin only, daily for 16 weeks.
2421806|NCT03423706|Experimental|new model of haplo-HSCT|use the new model of haplo-HSCT to treat the r/r B-ALL patients matching the inclusion criterion
2421807|NCT03423693||Asthma with SAO+|Asthmatic patients with RV/TLC > or = 40
2421808|NCT03423693||Asthma with SAO-|Asthmatic patients with RV/TLC < 40
2421809|NCT03423693||ACO|Asthmatic patients with smoking > or = 10 pack years who have persistent airway obstruction (post-BD FEV1/FVC < 0.7) or COPD patients who have bronchodilator (BD) reversibility (absolute increase in FEV1 > or = 200 ml and FEV1% > or =12% after BD)
2421810|NCT03423693||COPD|Patients with history of smoking > or = 10 pack year with post-BD FEV1/FVC < 0.7 and negative BD reversibility (absolute increase in FEV1 < 200 ml and FEV1% <12% after BD)
3146017|NCT00087880|Placebo Comparator|Extended Placebo/High Contact|Participants receive the Brief Treatment followed by a placebo medication through Week 52 and meet with medical staff once per month. Participants will attending counseling session 20-40 minutes in duration and will be scheduled at weeks 12, 14, 16, 18, 20, 24, 28, 32, 36, 44, and 52. The contents of these sessions will introduce additional information focusing on motivation, social support, mood management, weight gain, and dependence/withdrawal. Subjects will be contact by phone between counseling sessions (at Weeks 13, 15, 18, 22, 26, 30, 34, 36, 40, 48) for a brief check-in.
3146018|NCT00087984|Experimental|MB-002-003|
2421813|NCT03423667|Experimental|N-acetylcysteine|
2421814|NCT03423667|Placebo Comparator|Lactose powder|
3146019|NCT00088010|Experimental|1|
2421820|NCT03423615|Experimental|CHHIP Arm|"All enrolled students in schools in the CHHIP Arm were eligible to receive the CHHIP intervention. The CHHIP intervention was delivered by lay fieldworkers (SHAs). Intervention activities included:~Health Education: activity-based curriculum with lessons delivered once per week. Units include hygiene, nutrition, safety, disease prevention& management, and social, emotional, and behavior development.~Basic Primary Health Services: school-based treatment including deworming and iron supplementation; screening and referral programs including growth monitoring, well-child exam, vision screening, epilepsy screening, and oral health; psychosocial and counseling support for students with atypical behaviors.~Health School Environment: improvements to physical infrastructure including latrines and water systems; modeling of positive behavior reinforcement, inclusive learning environment, and avoidance of corporal punishment."
2421821|NCT03423615|No Intervention|Comparison Arm|All enrolled students in schools in the Comparison Arm received school health activities as were routinely available in their school, through their curriculum, or through special events.
2421822|NCT03423602|Experimental|Investigational device|PerQseal® closure system
3146020|NCT00088010|Placebo Comparator|2|
2421824|NCT03423576|Experimental|Intervention|comprehensive patient-centered outpatient health service with multiple components. These components included the addition of a case-manager, structured interventions to improve patient education and adherence to therapy, psychological counselling, social services, and exercise advice. For each Patient, relevant components were identified and a written Intervention plan was negotiated and signed.
2421825|NCT03423576|No Intervention|Control|Standard care
2421826|NCT03423563|Experimental|Flexible fiberoptic bronchoscopy|Fiberoptic intubation has been considered for a long time the gold standard technique for intubation when there is anticipated or known difficult airway or as a rescue device in can't intubate but can ventilate scenarios
2421827|NCT03423563|Experimental|Fexible intubation video endoscopy|Video-assisted techniques allow to indirectly visualize the laryngeal structures with fiber optical or camera chip technique and to show the video picture on an external or built-in monitor
3146021|NCT00088140|Placebo Comparator|Placebo|
2421829|NCT03423537|Experimental|Group 1 [HCG (+) group]|"Group 1 will indicate the application of the protocol by adding hCG with the initiation of standard GnRH agonist protocol for IVF / ICSI with rFSH"
2421830|NCT03423537|Placebo Comparator|Group 2 [placebo]|"Group 2 will indicate the application of the standard GnRH agonist protocol without the addition of hCG, but placebo, instead"
2421832|NCT03423511|Experimental|MiStent II Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
2421833|NCT03423511|Active Comparator|Xience or Promus Coronary Artery Stents|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
2421854|NCT03423381|Placebo Comparator|Control product|A cereal based product with low concentrations of df. The control portion is consumed as a single evening meal prior to determinations of test variables in the morning.
3146022|NCT00088140|Active Comparator|IDN-6556 5 mg twice a day (BID)|
3146023|NCT00088140|Active Comparator|IDN-6556 25mg twice a day (BID)|
3146024|NCT00088140|Active Comparator|IDN-6556 50 mg twice a day (BID)|
2421834|NCT03423498|Experimental|groups with toe-spread-out exercise|This arm included individuals with hallux valgus (research group A) and without deformation (research group B), who were patients of Department of Rehabilitation, Poznan University of Medical Sciences. They performed the toe-spread-out exercises for 14 days and were examined twice: before and after exercises. The examination of participants included a surface electromyography, electroneurography and goniometer tests to measure the range of motion in the hallux joints.
2421835|NCT03423498|No Intervention|control group|This arm included individuals with hallux valgus deformity from the control group which did not undergo any therapy of hallux. They were patients of Department of Rehabilitation as well. These participants were examined twice at an interval of 14 days in the same way as the patients from experimental arm.
2421836|NCT03423485|Experimental|Study arm|Anastomosis is performed according to Standard of Care with the addition of the CG-100 Intraluminal Bypass Device
2421837|NCT03423472|Experimental|Full intervention|Healthy Baby Toolkit (HBT) in addition to Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
2421838|NCT03423472|Active Comparator|Partial intervention|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and education on family nutrition, with special emphasis on women and children < 2y; especially diet diversity and vitamin A intake
2421839|NCT03423472|Other|Control|Government standard of care for nutrition education through the Health Development Army
2421842|NCT03423446|Experimental|Severe Hepatic Impairment|Up to 8 subjects with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15 points)
2421843|NCT03423446|Experimental|Healthy Control|Up to 8 healthy control subjects with normal hepatic function
2421844|NCT03423433|No Intervention|Control condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography.~During the second two visits, participants will have either undergo a 180 minute seated protocol or a 180 minute heel raising protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes in both protocols, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout the 180 minutes. EMG will record muscle activation during heel raises after each 30 minutes.~Ten weeks after these sessions have been completed, participants will return to the laboratory for follow-up a session assessing resting measures in an identical protocol to the first visit."
2421845|NCT03423433|Experimental|Experimental (heel raise) condition|"This condition will recruit fifteen chronic stroke sufferers. In the first visit, participants will undertake five Stroop familiarisation tests alongside baseline pulse wave analysis (PWA) and pulse wave velocity (PWV). Participants will practice this movement before maximum voluntary contractions (MVC) will be measured using electromyography. During the second two visits, participants will have undergo a 180 minute seated or a 180 minute heel raise protocol (10 heel raises per 10 minutes) After 10, 30, 90, 120, 150 and 180 minutes, PWA, PWV and Stroop task results will be recorded. NIRS will measure peripheral and cerebral oxygen perfusion throughout. EMG will record muscle activation during heel raises after each 30 minutes.~Participants in this arm will be prescribed a ten-week heel-raise programme involving hourly heel raises. Ten weeks later, participants will return to the laboratory for follow-up sessions assessing resting measures in an identical protocol to the first visit."
2421847|NCT03423394|Experimental|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment.
2421848|NCT03423394|Active Comparator|Treatment as Usual|The treatment as usual (TAU) condition was selected to mirror the existing process in the military for identifying and encouraging treatment for personnel who screen positive for PTSD.
2421849|NCT03423381|Experimental|Cereal product 1|Cereal based müsli no. 1, made from typical Swedish cereals. All experimental products have different types and amounts of dietary fibre (df). The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2421850|NCT03423381|Experimental|Cereal product 2|Cereal based muesli no. 2 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2421851|NCT03423381|Experimental|Cereal product 3|Cereal based muesli no.3 made from typical Swedish cereals. All experimental products have different types and amounts of df.The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2421852|NCT03423381|Experimental|Cereal product 4|Cereal based muesli no. 4 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2421853|NCT03423381|Experimental|Cereal product 5|Cereal based muesli no. 5 made from typical Swedish cereals. All experimental products have different types and amounts of df. The test portion is consumed as a single evening meal prior to determinations of test variables in the morning.
2421855|NCT03423368|Experimental|Libramed|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of Libramed for 30 days
2421856|NCT03423368|Placebo Comparator|Placebo|Each patient will be admistered 6 tablets/day (3 tablets before lunch, 3 tablets before dinner) of placebo for 30 days
2421860|NCT03423342|Experimental|Nicotinamide Riboside|Nicotinamide riboside will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
2421861|NCT03423342|Placebo Comparator|Placebo|Matching placebo will be supplied as 250mg capsules, to be administered orally. The initial dose will be 1 capsule twice daily, followed by weekly up-titration by 1 capsule/dose to a final dose of 4 capsules (1000mg) twice daily at the end of Week 4. Participants will be continued on the final dose up to the final follow up visit (week 12). If, at any step, a dose increase is not tolerated, the maximum previously-tolerated dose will be continued through to week 12.
2421862|NCT03423329|Experimental|Group A|"Intervention:Drug: Brufen & Placebo~Brufen syrup 10 ml, once, 1 hour before local anesthesia"
2421863|NCT03423329|Experimental|Group B|"Intervention: Drug: Cital and Placebo~Cital Syrup 10 ml, once 1 hour before Local anesthesia"
2421864|NCT03423329|Placebo Comparator|Group C|"Intervention: Drug: Placebo~Other names:~(Placebo for Brufen) (Placebo for Cital)~Sansovit Iron Multivitamin syrup, an orange-coloured, orange-flavoured"
2421865|NCT03423316|No Intervention|Healthy Controls|
2421866|NCT03423316|No Intervention|Age-Matched Controls|Subjects without PAD who have the same average age as the PAD patients
2421867|NCT03423316|Experimental|PAD Patients|Patients with PAD. Approximately 75% of PAD patients will be enrolled in the 12-week exercise therapy program.
2421868|NCT03423303|Experimental|Screening arm|Invitation to prostate cancer screening and questionnaires.
2421869|NCT03423303|No Intervention|Control arm|Registry-based follow-up and a questionnaire.
2421870|NCT03423277|Experimental|Easy Stretch Toolkit|All participants will be using one or more of devices for 60 minutes 2 times per day for the duration of the 8 week trial. Prescriptive instructions for specific intraoral placements will be given based on the participant's deficit areas.
3146025|NCT00088231|Experimental|PTK 787 + Imatinib|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. On Day 8, PTK 787 250 mg by mouth every day and imatinib 600 mg by mouth every day (for Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia- blastic phase (CML-BP) and imatinib 400 mg by mouth every day (for Agnogenic Myeloid Metaplasia (AMM). Length of therapy is four courses; each course equals 28 days. Patients assessed for response after each course.
3146026|NCT00088231|Experimental|PTK 787 (vatalanib) Alone|For 1 week prior to receipt of study combination regimen, all patients will receive single agent PTK 787 at dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels. Patients should not have a grade 3 or 4 PTK 787-related adverse events in order to begin study combination therapy with a imatinib on day 8. PTK 787 250 mg by mouth for Days 1 - 7.
3146027|NCT00088257||Mother-child pairs|Subset of mother-child pairs enrolled in Project Viva, a cohort study of pregnant women and their offspring. 411 mother-child pairs with measures of lymphocyte proliferation in their cord blood samples make up the subset for this study.
3146028|NCT00088426||Control|Control group of Williams-Beuren (also known as Williams) syndrome
2421875|NCT03423225|Experimental|ADVAGRAF®|One arm: Treatment conversion will take placefrom twice daily tacrolimus to once daily tacrolimus (ADVAGRAF) 3 months after transplant in new liver transplant recipients.
2421876|NCT03423212|Experimental|Experimental Condition|Participants assigned to the experimental arm will be enrolled in the 2-session Just Do You intervention described elsewhere.
2421877|NCT03423212|No Intervention|Treatment as Usual Condition|Participants assigned to treatment as usual will receive the PROS program that is standard in the agencies without any additional intervention.
2421878|NCT03423212|Active Comparator|Active Control Condition|Participants assigned to the active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
2421879|NCT03423199|Experimental|Palbociclib + Tamoxifen ± Goserelin|Palbociclib 125 mg/day, orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
2421880|NCT03423199|Active Comparator|Placebo + Tamoxifen ± Goserelin|Placebo orally once daily on Day 1 to Day 21 followed by 7 days off treatment for each 28 day cycle, plus tamoxifen 20 mg orally once daily (continuously)
3146029|NCT00088426||Family|Direct blood relatives (typically parents, and occasionally siblings of affected individuals) ofpatients with HPE are also eligible to participate.
3146030|NCT00088426||HPE|Patients with HPE
2421889|NCT03423147|Experimental|Chlorhexidine gluconate vaginal scrub and cloth|Patients will have a 2% chlorhexidine gluconate cloth applied to their abdomen as well as 4% chlorhexidine gluconate vaginal scrub applied as a vaginal cleanse in the operating room prior to cesarean section
2421890|NCT03423147|Active Comparator|Standard Treatment|Patients who are not in the intervention arm will receive the standard of care prior to a cesarean section. In the operating room the patient will receive an abdominal cleanse with 2% Chloraprep solution (2% chlorhexidine gluconate) in addition to routine IV antibiotics.
2421891|NCT03423134|Experimental|Test of new adhesive strip|A new adhesive strip will be tested in this investigation
2421894|NCT03423108|No Intervention|Control|Participants randomized to this group will perform monthly cohabitation meetings.
2421895|NCT03423108|Experimental|G150|Participants randomized to this group will be enrolled to a 150 min/week structured and supervised exercise training. The program consists of 3 sessions in a week, each of these lasting 50 minutes. The session will be composed of aerobic training (25 minutes at 60-75% of HRmax) and strength training (25 minutes, 8 whole-body exercises at up to 8-12 maximal repetitions).
2421896|NCT03423108|Experimental|G300|Participants randomized to this group will be enrolled to the same structural settings of G150 group (type of exercise, exercise intensity and weekly frequency). They will receive twice the G150 group dose's. To do so, each session will last 100 minutes (50 minutes of aerobic exercise training and 50 minutes of strength training).
2421897|NCT03423095|Placebo Comparator|Active Jaw Exercise with Relaxation|Participants randomized to this arm will complete active jaw exercises and visualization relaxation exercise (control group).
2421898|NCT03423095|Active Comparator|Active Tongue Exercise|Participants randomized to this arm will complete active tongue exercises only.
2421899|NCT03423095|Experimental|Active Tongue Exercise + Mental Practice|Participants randomized to this arm will complete active tongue exercises and mental practice of tongue exercise via motor imagery.
2421900|NCT03423095|Experimental|Mental Practice Tongue Exercise|Participants randomized to this arm will complete mental practice of tongue exercise via motor imagery only.
2421902|NCT03423069|Experimental|Diet low in FODMAPs|Diet low in FODMAPs (diet A) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
2421903|NCT03423069|Active Comparator|Specific dietary advice for IBS|Dietary advice for IBS (diet B) during 12 weeks (with intermediate nutritional checks every 4 weeks) before returning to the final study visit.
2421904|NCT03423056|Experimental|Preoperative exercise program|"The individualized aerobic training program will be developed according to Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks.~Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed as follows:~Week 1: heart rate target: 50% of maximum heart rate Week 2: heart rate target: 60% of maximum heart rate Week 3: heart rate target: 70% of maximum heart rate Week 4: heart rate target: 60% of maximum heart rate The aerobic exercise will be carried on a treadmill or in a stationary bicycle, according to the patient's preferences and will be supervised by a physical therapist."
2421905|NCT03423043||Distal Radius Fracture Patients|Adult patients who have sustained a Distal Radius Fracture.
2421906|NCT03423030|Experimental|Panel A - Active|N = 6, 10 mg then 40 mg of PBTZ169 Formulation
2421907|NCT03423030|Placebo Comparator|Panel A - Placebo|N = 2, 10 mg then 40 mg of matching placebo
2421908|NCT03423030|Experimental|Panel B - Active|N = 6, 20 mg then 80 mg of PBTZ169 Formulation
2421909|NCT03423030|Placebo Comparator|Panel B - Placebo|N = 2, 20 mg then 80 mg of matching placebo
2421910|NCT03423030|Experimental|Panel C - Active|N = 6, First dosing of Panel C with 160 mg PBTZ169 Formulation then Second dosing of Panel C with 160 mg PBTZ169 Native Crystalline Powder (NCP)
2421911|NCT03423030|Active Comparator|Panel C - Placebo|N = 2, 160 mg of matching placebo for the two interventions
2421912|NCT03423030|Experimental|Panel D - Active|N = 6, First dosing of Panel D with 320 mg PBTZ169 Formulation then Second dosing of Panel D with 320 mg PBTZ169 Native Crystalline Powder (NCP)
2421913|NCT03423030|Active Comparator|Panel D - Placebo|N = 2, 320 mg of matching placebo for the two interventions
2421914|NCT03423017|Other|Pierre Robin sequence|"Infants with PRS : retrognathism, glossoptosis, cleft palate~Group 1a : isolated PRS Group 1b : PRS with bone disease or collagen disease (Stickler) Group 1c : syndromic PRS or associated PRS without bone disease or collagen disease"
2421915|NCT03423017|Other|Superior airway obstruction, AWO|Infants with AWO : laryngomalacia, tracheal stenosis, laryngeal stenosis, others etiology
2421916|NCT03423017|Other|Healthy infants|Healthy infants : siblings of sudden unexpected death of the infant
2421917|NCT03423004|Experimental|Patient with lesional skin|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
2421918|NCT03423004|No Intervention|Patients with healthy skin|the skin will be recovered during a surgical procedure (surgical waste) for patients who will not be opposed
3146031|NCT00088543|Experimental|1 Low dose|total dose 4.5 mg/kg Thymoglobulin
3146032|NCT00088543|Experimental|2 High dose|total dose 8.5 mg/kg Thymoglobulin
3146033|NCT00088556|Experimental|Triplet Combination of TLK286 Carboplatin & Paclitaxel|Experimental
3146034|NCT00088582|Experimental|Sandostatin s.c. (Octreotide)|
3146035|NCT00088582|Experimental|Pasireotide (SOM230)|
3146036|NCT00088764|Experimental|1|Education: Either coping skills training or arthritis education interventions
3146037|NCT00088764|Experimental|2|Writing: Either emotional disclosure writing or health behavior writing
3146038|NCT00088777|Experimental|MET|
3146039|NCT00088777|Experimental|CSE|
2421919|NCT03422991|Other|Congestive Heart Failure patients Cohort|Cluster of patients with congestive heart failure NYHA ≥2, with at least one cardiac decompensation, NT-proBNP (N-terminal pro-brain natriuretic peptide) > 500 ng/l. Will be followed during 18 months.
2421920|NCT03422978|Sham Comparator|Saline bolus|10mL normal saline solution administered intravenously over 60 seconds starting after intubation.
2421921|NCT03422978|Experimental|Dexmedetomidine 0.25 mcg/kg|0.25 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2421922|NCT03422978|Experimental|Dexmedetomidine 0.50 mcg/kg|0.50 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2421923|NCT03422978|Experimental|Dexmedetomidine 1.00 mcg/kg|1.00 mcg/kg dexmedetomidine diluted with normal saline to a 10mL volume, administered intravenously over 60 seconds starting after intubation.
2421924|NCT03422965|Active Comparator|Type 1 Diabetes Mellitus|Cohort of Type 1 DM patients
2421925|NCT03422965|Sham Comparator|Healthy controls|Cohort of Healthy controls
2421926|NCT03422939||Less experienced dietitians|There was no intervention, but we conducted separate analyses to identify differences according to the level of experience of the dietician. We used the median number of years of professional experience (median=8) to split the sample and create two subgroups: 1) less experienced dieticians (less than 9 years of experience; n= 225)
2421927|NCT03422939||More experienced dietitians|and 2) more experienced dieticians (9 years of experience or more; n=215).
2421928|NCT03422926|Experimental|Intervention|Social marketing messaging campaign
2421929|NCT03422926|No Intervention|Control|No messaging campaign
2421930|NCT03422913|Experimental|CLCVP Group|Controlled low central venous pressure(CLCVP) will be performed combined with intraoperative combined hilar intermittent (Pringle method)
2421931|NCT03422913|No Intervention|Control Group|Only intraoperative combined hilar intermittent (Pringle method) will be performed
2421932|NCT03422900|Experimental|Specific Diabetes Formula|"Diabetes-Specific Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 10,1 g/100 ml;~Fat: 4,5 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 345 mOsm/l~Fiber: 1,78 g/100 ml (80% soluble; 20% insoluble)."
2421933|NCT03422900|Active Comparator|Standard Formula|"Standard Enteral Formula:~Caloric density: 1,0 kcal/ml~Energy: 100 kcal~Carbohydrates: 13,8 g/100 ml;~Fat: 3,4 g/100 ml~Prot: 3,8 g/100 ml~Osmolarity: 220 mOsm/l~Fiber: 0 g/100 ml"
2421934|NCT03422887|Active Comparator|flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg
2421935|NCT03422887|Experimental|nalbuphine|nalbuphine intraoperative administration 0.1mg/kg
2421936|NCT03422887|Experimental|nalbuphine and flurbiprofen axetil|flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg
2421937|NCT03422874|Experimental|Nelfinavir plus MLN9708|"Both Nelfinavir and MLN9708 will be given orally (by mouth). MLN9708 will be given as 3 mg orally twice weekly. Study drugs will be administered on 21-day treatment cycles. All cycles are 21 days.~During the first cycle of MLN9708 only will initially be administered orally at a fixed dose of 3mg twice weekly for 2 weeks, on Mondays and Thursdays during this treatment cycle. During the third week there will be no study combination drug therapy(for Cycle 1 only). During Cycles 2 and 3, MLN9708 administered twice weekly on Mondays and Thursdays for the first 2 weeks of Cycles 2 and 3. Nelfinavir (escalating cohorts [1250mg, 1875mg, 2500mg, 3125mg]) will be administered orally twice daily in the dose cohorts listed."
2421938|NCT03422861|Active Comparator|Nabilone Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and nabilone as per protocol
2421939|NCT03422861|Placebo Comparator|Placebo Treatment|Patients who are chronic opioid users for chronic pain and have been exposed to cannabis or cannabinoid products, treated with IV PCA and placebo
2421940|NCT03422848|Active Comparator|Water intervention arm|The water intervention group will increase their habitual daily water intake with 1.5 L of tap water. Furthermore they will receive general life style advice (general oral and written advice on diet and physical activity).
2421941|NCT03422848|Other|Control arm|Control group that will receive general life style advice (general oral and written advice on diet and physical activity).
2421942|NCT03422835|Active Comparator|R-TME|Robotic total mesentery excision surgery for rectal cancer.
2421943|NCT03422835|Experimental|R-TaTME|Robotic transanal total mesentery excision surgery for rectal cancer.
2421946|NCT03422796|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 6mg/ml sumatriptan
2421947|NCT03422796|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placeb
2421948|NCT03422783|Experimental|Included patients|There is only one arm in this study. Intervention will be electrical forearm stimulus under general anesthesia and the response of NOL index following this stimulus and its correlation with postoperative parameters such as pain and opioid consumption in post anesthesia care unit.
2421949|NCT03422770|Other|Mild aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2421950|NCT03422770|Other|Moderate aortic stenosis|25 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2421951|NCT03422770|Other|Severe aortic stenosis|50 patients, all undergoing echocardiography, MRI, blood test, questionnaires, 6 min walking test, ECG and Holter-ECG.
2421952|NCT03422770|Other|Controls|100 subjects, all undergoing echocardiography and blood test, 30 undergoing MRI.
2421953|NCT03422757|Experimental|adaptive DBS|adaptive Deep Brain Stimulation, by AlphaDBSvext.
2421954|NCT03422757|Active Comparator|conventional DBS|conventional Deep Brain Stimulation, by AlphaDBSvext.
2421955|NCT03422744|Experimental|patient with peripheral lung lesion|"Patient presenting a peripheral lung lesion seen at Ct-scan but invisible at simple endoscopy.~Intervention : trans bronchial biopsy guided by echo-endoscopic miniprobes.~Intervention: If first intervention doesn't give a diagnosis we get cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control"
2424816|NCT03402776|No Intervention|good resp. after 3 vacc. inject.|no randomization for a 4th dose.
3146040|NCT00088855|Experimental|Treatment (bortezomib and pegylated liposomal doxorubicin)|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 4. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3146041|NCT00088894|Experimental|Arm I (gemcitabine hydrochloride, bevacizumab)|Patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30-90 minutes on days 1 and 15.
2421958|NCT03422718|Experimental|Arm 1|No healthy behavior texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
2421959|NCT03422718|Experimental|Arm 2|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging No physician appointment and transportation scheduling
2421960|NCT03422718|Experimental|Arm 3|No healthy behavior texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
2421961|NCT03422718|Experimental|Arm 4|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging No physician appointment and transportation scheduling
2421962|NCT03422718|Experimental|Arm 5|No healthy behavior texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
2421963|NCT03422718|Experimental|Arm 6|Healthy Behavior Texts BP Monitoring Weekly Via Text Messaging Physician appointment and transportation scheduling
2421964|NCT03422718|Experimental|Arm 7|No healthy behavior texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
2421965|NCT03422718|Experimental|Arm 8|Healthy Behavior Texts BP Monitoring Daily Via Text Messaging Physician appointment and transportation scheduling
2421966|NCT03422705|Sham Comparator|Standard of care|No intervention - no programming, no medical intervention.
2421967|NCT03422705|Experimental|Optimised programming|Optimised pacemaker programming to avoid right ventricular pacing.
2421968|NCT03422705|Experimental|Medical therapy|Lisinopril uptitrated to optimally tolerated dose.
2421969|NCT03422692|Experimental|BioXlude memebrane|Subjects in this arm will receive demineralized freeze dried bone allograft covered with BioXclude amnion-chorion membrane following tooth extraction
2421970|NCT03422692|Active Comparator|Mem-Lok|subjects in this arm will receive demineralized freeze dried bone allograft covered with Mem-Lok collagenous membrane following tooth extraction
2421971|NCT03422679|Experimental|CB-103|CB-103 capsules will be administered orally as a continuous once daily (QD) dosing during the treatment period of Part A (escalation) and Part B (expansion).
2421972|NCT03422666|Experimental|Teduglutide|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose
2421973|NCT03422666|Placebo Comparator|Placebo|Placebo, subcutaneous, single dose
2421974|NCT03422653|Active Comparator|CR845 0.5mcg/kg|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
2421975|NCT03422653|Placebo Comparator|Placebo|IV Placebo administered after each dialysis session (3 times/week)
2421976|NCT03422640|Experimental|Treatment arm with apremilast|Open label arm treating frontal fibrosing alopecia with apremilast
3146042|NCT00088894|Active Comparator|Arm II (gemcitabine hydrochloride, placebo)|Patients receive gemcitabine IV as in arm I and placebo IV over 30-90 minutes on days 1 and 15.
3146043|NCT00088933|Experimental|Arm I|Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.
2421979|NCT03422614||Patient|Patients with Primary Immunodeficiency
2421980|NCT03422614||Control|Healthy Controls
2421981|NCT03422601||3 months treatment|FOLFOX or CAPOX
2421982|NCT03422601||6 months treatment|FOLFOX or CAPOX
2421983|NCT03422588|Experimental|Intracorporeal|Totally laparoscopic right colectomy with intracorporeal anastomosis
2421984|NCT03422588|Active Comparator|Extracorporeal|Laparoscopic assisted right colectomy with extracorporeal anastomosis
2421985|NCT03422575|Experimental|Test|Etoricoxib 120Mg film-coated Tablet at single dose was given to subjects in this arm.
2421986|NCT03422575|Active Comparator|Reference|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk) was given to subjects in this arm.
2421987|NCT03422562|Active Comparator|Probiotic|Florababy probiotic (0.5g per day) will be started at or after 72 hours of life and will be administered in 1ml sterile water prior to feed.
2421988|NCT03422562|No Intervention|Control|Standard of care arm
2421989|NCT03422549|Active Comparator|CPAP|"Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.~Intervention: Device: Drager VN500 Ventilator"
2421990|NCT03422549|Active Comparator|NHFOV|"Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality has not been well studied to date.~Intervention: Device: Drager VN500 Ventilator"
2421991|NCT03422536|Experimental|Arm I (ficlatuzumab)|Patients receive ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2421992|NCT03422536|Experimental|Arm II (ficlatuzumab, cetuximab)|Patients receive cetuximab IV over 60 -120 minutes and ficlatuzumab IV over 30-60 minutes every 2 weeks in the absence of disease progression or unaccepted toxicity. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2421993|NCT03422523|Active Comparator|Arm A Control|6 Cycles of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) every 14 days.
3146044|NCT00088933|Experimental|Arm II|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.
3146045|NCT00088933|Experimental|Arm III|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.
3146046|NCT00088933|Experimental|Arm IV|Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.
3146047|NCT00088933|Experimental|Arm V|Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.
2421994|NCT03422523|Experimental|Arm B Experimental|"1 Cycle of R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) followed by 5 cycles of R-GemOx with Atezolizumab every 14 days.~Followed by 8 maintenance cycles of Atezolizumab every 21 days."
2421995|NCT03422510|Experimental|Regimen 1 - CXA-10 75 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm stays at 75 mg.
2421996|NCT03422510|Experimental|Regimen 1 - CXA-10 150 mg|Subjects in regimen 1 will start at 75 mg and may stay at 75 mg or increase to 150 mg. This treatment arm increases to 150 mg.
2421997|NCT03422510|Experimental|Regimen 2 - CXA-10 150 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm stays at 150 mg.
2421998|NCT03422510|Experimental|Regimen 2 - CXA-10 300 mg|Subjects in regimen 2 will start at 150 mg and may stay at 150 mg or increase to 300 mg. This treatment arm increases to 300 mg.
2421999|NCT03422497||Male hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have male sex listed in their discharge abstract
2422000|NCT03422497||Female hip fracture surgery patients|Individuals 65 years or older admitted non-electively to hospital with a diagnosis of hip fracture who have surgery for their hip fracture and have female sex listed in their discharge abstract
2422001|NCT03422484||People with at least one medication error|People with at least one medication error at hospital admission
2422002|NCT03422484||People without medication error at hospital admission|People without medication error at hospital admission
2422003|NCT03422471|Experimental|Hypoglycemia|Participants are exposed to two 90 minute episodes of hypoglycemia (50 mg/dl) through a hyperinsulinemic hypoglycemic clamp. Baroreflex sensitivity will be assessed before, during, and 16 hours after the hypoglycemia.
2422004|NCT03422458|No Intervention|natural healing|no treatment and the coagulum within the socket is left open for spontaneous healing
2422005|NCT03422458|Experimental|Alveolar Ridge Preservation|A bone substitute material (BioOss Collagen) is placed within the bony envelope at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mucograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
2422006|NCT03422458|Experimental|Immediate Implant + Alveolar Ridge Preservation|An immediate implant (Winsix) placement is performed. After implant insertion, a bone substitute material (BioOss Collagen) is placed in the gap occurred between the implant surface and the hard tissue walls of the extraction socket at least to the level of the palatal/ lingual bone plate. Subsequently, the soft tissue borders of the alveole is de-epithelialized using a diamond drill under copious irrigation with water. A collagen matrix (Mugograft Seal) is adapted to the soft tissue borders again using single interrupted sutures.
2422007|NCT03422445|Experimental|Apatinib plus Temozolomide|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,apatinib+temozolomide.
2422008|NCT03422432|Experimental|Group 1|Patients are identified pre-operatively on radiological imaging. Prophylactic HIPEC will be delivered intra-operatively, immediately after the resection of the primary tumour, and only if the patient is deemed well enough to receive the HIPEC.
2422009|NCT03422432|Experimental|Group 2|Patients are identified post-operative based on histological findings. They will be counselled to receive prophylactic HIPEC only. If peritoneal nodules are found during surgery, these patients will be excluded from the study.
2422010|NCT03422419|Experimental|TIPS+Anticoagulation|
2422011|NCT03422419|Active Comparator|Anticoagulation|
2422012|NCT03422406||HH group|Group (participants) with pre-gestational history of undergoing hysterosalpingography (HSG) using an oil-soluble iodinated contrast medium
2422013|NCT03422406||Non-HH group|Group (participants) without pre-gestational history of undergoing hysterosalpingography (HSG)
2422014|NCT03422393|Experimental|venetoclax with high-dose ibrutinib|venetoclax with high-dose ibrutinib for the treatment of patients with chronic lymphocytic leukemia with progressive disease on single agent ibrutinib.
2422015|NCT03422380||Weight Loss Maintainers (WLM)|Individuals maintaining ≥13.6 kg (30 lb) weight loss for ≥1 year
2422016|NCT03422380||Normal Weight Controls (NC)|Individuals with normal weight whose BMI was matched to the current BMI of the WLM. NC had to be weight stable and not maintaining a weight loss of ≥13.6kg
2422017|NCT03422380||Controls with Overweight/Obesity (OC)|Individuals with overweight/obesity whose BMI was matched to the pre-weight loss maximum BMI of WLM. OC had to be weight stable and not maintaining a weight loss of ≥13.6kg
2422018|NCT03422367|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
2422019|NCT03422367|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
2422020|NCT03422367|No Intervention|Control|Participants who are unable to complete JASPER due to age or time/distance commitment can enroll for single-time point participation
2422021|NCT03422354|Active Comparator|Paravertebral block Group|Patients will receive single shot L1-L2 PVB before undergoing GA Full monitoring with ECG , NIBP , puls oximetry will be applied. The level between L1 and L2 will be identified using U/S as well as transverse processes depth. Insertion points will be marked 2.5 cm lateral to the superior aspect of corresponding spinous processes, A 22-gauge Tuohy needle will be advanced until it made contact with the transverse process. The needle will be withdrawn slightly and walked off caudally to an additional depth of 1 cm. Once this is reached, 20cc of bupivacaine 0.25% will be injected slowly To control intraoperative blood pressure, fentanyl will be used as well as hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.
2422022|NCT03422354|Active Comparator|General anesthesia Group|"Patients will receive only GA All patients in the study will receive GA in the form of propofol 2mg/kg , atracurium 0.5ml/kg ,fentanyl 100 microgram in induction with ETT and mechanical ventilation , full monitoring with ECG , NIBP and puls oximetry will be applied.~To control intraoperative BP,fentanyl will be used as well as,hypotensive drugs ( propranolol and nitroglycerine and the total dose will be recorded.~To achieve post operative analgesia, intravenous paracetamol( 1gram ) and pethidine IV (50 mg ) will be added when needed"
2422023|NCT03422341|Experimental|GenePOC testing|"The swab will be used for the testing on the revogene using the GenePOC Strep A, C/G assay.~Intervention will be the Comparison between GenePOC CR and Reference Method."
2422024|NCT03422341|Active Comparator|Reference Method|"The swab will be used to detect the presence or absence of Strep A, C/G using standard microbiology method.~Intervention will be the Comparison between GenePOC CR and Reference Method."
3146048|NCT00088933|Experimental|Arm VI|Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.
2422026|NCT03422315|Experimental|External control|propofol;injection;2mg/kg;single-dose
2422027|NCT03422302|Experimental|Treatment (CT simulation, CPAP, DIBH, SBRT, BiPAP)|Patients undergo free-breathing, DIBH, and CPAP CT simulation scans. If patient has difficulty exhaling on CPAP, then patient undergo BiPAP CT simulation. The attending physician then compares all 3 simulation treatment plans (free-breathing, DIBH, and CPAP/BiPAP) and determines which method to use during SBRT. If CPAP/BiPAP is chosen as preferred method, patients wear CPAP/BiPAP over 1 hour prior to SBRT, then again during SBRT over 30-60 minutes. All other patients complete free-breathing or DIBH during SBRT over 30-60 minutes.
2422028|NCT03422289|Experimental|Myo-inositol + folic acid|2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation.
2422029|NCT03422289|Experimental|Myo-inositol + folic a. + α-lactalbumin|2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation
2422030|NCT03422276|Active Comparator|Rehabilitation Discharge Plan|Commission on Accreditation of Rehabilitation Facilities (CARF) standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury, including patient and family education, written discharge care instructions, and telephone follow up from a clinical provider.
2422031|NCT03422276|Active Comparator|Rehabilitation Transition Plan|Approximately 12 scheduled contacts from a TBI care manager 6 months following discharge in addition to the CARF standards for discharge.
2422032|NCT03422263||Patients with T2DM under new therapy with SGLT-2-Inhibitors|Patients with T2DM under new therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
2422033|NCT03422263||Patients with T2DM without SGLT-2-Inhibitors.|Patients with T2DM without therapy with SGLT-2-Inhibitors (Empagliflozin 10 mg per day, Dapagliflozin 10 mg per day, Canagliflozin 100 mg per day) at baseline.
2422034|NCT03422263||Patients without T2DM manifesting similar comorbidities|Patients without T2DM manifesting similar comorbidities (Haemoglobin value, renal function, similar body mass index, cardiovascular disease profile)
2422039|NCT03422237|Experimental|RSV ΔNS2/Δ1313/I1314L vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
2422040|NCT03422237|Experimental|RSV 276 vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
2422041|NCT03422237|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2422042|NCT03422224||Good transplant function|Kidney transplant recipients without histological signs of rejection.
2422043|NCT03422224||Transplant Rejection|Kidney transplant recipinets experiencing a T cell mediated rejection episode.
2422044|NCT03422211||Sports orthopaedic surgery|Patients that recently underwent orthopaedic sports surgery performed by two separate surgeons
3146049|NCT00088946|Experimental|Arm 1|Polyphenon E plus erlotinib placebo daily for 12 months.
3146050|NCT00088946|Experimental|Arm 2|Erlotinib and Polyphenon E placebo daily for 12 months.
2422050|NCT03422146|Experimental|Cliradex® eyelid hygiene|Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.
2422051|NCT03422146|Other|I-Lid 'n Lash® Hygiene|Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,
2422052|NCT03422133||Pre-Implementation Phase|"Participants in this group (before the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.~Patients will be recruited using standardized procedures, and process and outcome measures will be recorded using the same tools and methods in both study phases to decrease the risk of measurement and selection bias."
3146051|NCT00088946|Placebo Comparator|Arm 3|Erlotinib placebo and Polyphenon E placebo daily for 12 months.
3146052|NCT00088959|Experimental|Treatment (erlotinib hydrochloride, celecoxib)|Patients receive oral erlotinib hydrochloride once daily and oral celecoxib twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
3146053|NCT00088998|Experimental|docetaxel + bevacizumab + capecitabine|"Patients receive docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive at least 2 additional courses beyond CR.~Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years."
3146054|NCT00089063|Experimental|Arm I (vaccine therapy)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG SC on day 1 of weeks 0, 26, 52, 78, and 104 (total of 5 vaccinations).
3146055|NCT00089063|Experimental|Arm II (vaccine therapy, sargramostim)|Patients receive vaccination comprising tyrosinase peptide, gp100 antigen, and MART-1 antigen emulsified with Montanide ISA-51 and ISA-51 VG as in arm I. Patients also receive sargramostim (GM-CSF) SC on days 1-5 of weeks 0, 26, 52, 78, and 104.
3146056|NCT00089089|Experimental|Treatment (decitabine)|"Patients receive decitabine IV over 1 hour on days 1-5 or on days 1-5 and 8-12. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3146057|NCT00089154|Experimental|Treatment (apolizumab)|Patients receive apolizumab IV over 2-4 hours on days 1, 2, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity.
2422053|NCT03422133||Post-Implementation Phase|Participants in this group (after the eHealth app is implemented in the PAU) will be English or French speaking patients, aged 18 and older, scheduled for major non-cardiac elective surgery.
2422054|NCT03422120||Healthy Donors|Healthy patients, without a diagnosis of cancer and age>40. The Natural Killer Cell Activity Assay (NKA) will be measured with a blood test.
2422055|NCT03422120||Colorectal Cancer Surgery Patients|Patients >40 years of age with a histologically confirmed diagnosis of primary colorectal cancer and a planned surgical resection of the primary tumour. The Natural Killer Cell Activity Assay (NKA) will be measured at various perioperative time points with a blood test.
2422056|NCT03422107||TAVI|Transcatheter Aortic Valve Implantation
2422057|NCT03422107||cAVR|Conventional Valve Replacement
2422058|NCT03422107||rCABG|minimally invasive coronary artery bypass graft
2422059|NCT03422107||cCABG|Conventional Coronary Artery Bypass Graft
3146058|NCT00089180|Experimental|Arm I (liposomal T4N5 lotion)|Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
3146059|NCT00089180|Placebo Comparator|Arm II (placebo)|Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.
3146060|NCT00089219|Experimental|Arm A. 6MHP vaccine 200 mcg|vaccine containing 6 melanoma helper peptides, at 200 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
3146061|NCT00089219|Experimental|Arm B. 6MHP vaccine 400 mcg|vaccine containing 6 melanoma helper peptides, at 400 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
3146062|NCT00089219|Experimental|Arm C. 6MHP vaccine 800 mcg|vaccine containing 6 melanoma helper peptides, at 800 mcg per peptide, with GM-CSF and IFA (Montanide ISA-51)
2422065|NCT03422081||growth hormone deficiency|
2422066|NCT03422081||small for gestational age|
2422067|NCT03422081||matched controls|
2422068|NCT03422068|Experimental|BI 1015550|
2422069|NCT03422068|Placebo Comparator|Placebo|
2422070|NCT03422055|Experimental|99mTc-Fucoidan SPECT|
2422071|NCT03422042|Active Comparator|Short duration of antibiotic|group A: will received intravenous antibiotic until the temperature is less than 37.8 c for 72 hours, then antibiotic is discontinued
2422072|NCT03422042|Active Comparator|Standard treatment of antibiotic|group B: will received intravenous antibiotic for 7 days, and followed by oral antibiotic for 7 days, regardless of body temperature
2422073|NCT03422029|Experimental|177Lu-Dotatate PRRT|177Lu-Dotatate A maximum of 8 cycles of 1000mCi 177Lu-Dotatate, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 8 cycles, every 8 weeks
2422074|NCT03422016||autistic spectrum disorder|intelligence quotient IQ>85 age 4-25yrs
2422075|NCT03422016||control|age 4-25yrs no eye disorder
2422078|NCT03421990||Group A|General anesthesia technique
2422079|NCT03421990||Group B|Regional anesthesia technique
2422080|NCT03421964|Active Comparator|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after traumatic brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, virtual sessions.
2422081|NCT03421964|Experimental|Resilience/Adjustment Counseling with Booster Sessions|Intervention to promote resilience and adjustment (RAI) is implemented in seven, 60-minute, virtual sessions; however individuals within this study arm will receive three additional 60-minute, virtual sessions three months after completing the seven initial sessions. The three booster sessions provide an opportunity for individuals to review course content, consolidate gains, and discuss challenges.
2422082|NCT03421938|Experimental|Group 1 (Downhill Exercise Group)|This group will have downhill walking exercises with %10 slope.
2422083|NCT03421938|Experimental|Group 2 ( Uphill Exercise Group)|This group will have uphill walking exercises on the treadmill with %10 slope.
2422084|NCT03421925|Other|Divided mesh group|In this group, surgeon will use a mesh divided in to two legs in laparoscopic totally extraperitoneal repair
2422085|NCT03421925|Other|Non divided mesh group|In this group, surgeon will use a non divided mesh in laparoscopic totally extraperitoneal repair
2422086|NCT03421912|Experimental|Arm A : Cicaplast balm B5|Use of Cicaplast balm B5, 2 to 3 applications per day, since the first day of iEGFR treatment initiation for 30 days to avoid or limit appearance of cutaneous toxicities related to iEGFR treatment.
2422087|NCT03421912|Active Comparator|Arm B : Dexeryl|Use of Dexeryl, 2 to 3 applications per day, since de first day of iEGFR treatment initiation for 30 days to avoid or limit appearence of cutaneous toxicities related to iEGFR treatment.
2422088|NCT03421899||Genetic Parkinson's group|Those participants with Parkinson's disease and a genetic mutation known to cause or increase risk of Parkinson's disease (e.g. Parkin, PINK1, GBA or LRRK2)
2422089|NCT03421899||Idiopathic Parkinson's group|Those participants with Parkinson's disease but without a known genetic mutation known to cause or increase risk of Parkinson's disease
2422090|NCT03421899||Healthy control group|Those participants unaffected by Parkinson's disease
3146063|NCT00089245|Experimental|Radiolabeled Monoclonal Antibody Therapy|This is a Phase I trial designed to evaluate the Maximally Tolerated Dose (MTD) of intrathecal 131I-8H9. In order to find the MTD, a dose escalation scheme will be employed with patients entering in cohorts of 3 at each dose level from 10 mCi to 60 mCi and a cohort of 6 at each dose level from 70 mCi to 100 mCi.
3146064|NCT00089271|Experimental|Treatment (alvespimycin hydrochloride)|Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1-6 hours on days 1-3 or 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3146065|NCT00089310|Experimental|Sentinal node mapping|
3146066|NCT00089323|Other|1: Bone Marrow Aspiration|
2422093|NCT03421873||Intervention (Implementation) group|Chest pain patients enrolled during a 10 month period after a change in routine care, i.e. the implementation of a 0h/1h hs-cTnT protocol
2422094|NCT03421873||Control group|Chest pain patients managed at the 3 intervention EDs during the corresponding 10 months of the previous year (intervention hospitals acting as their own controls) as well as chest pain patients managed during the corresponding before-and-after period at EDs not implementing the protocol (concurrent controls).
2422095|NCT03421860|Active Comparator|ephedrine|will receive ephedrine :a bolus of 9 mg after SA once intervention: will receive complementary doses of ephedrine 6 mgto maintain systolic blood pressure above 80 % of baseline
2422096|NCT03421860|Active Comparator|phenylephrine|will receive Phenylephrine : a bolus of 100 mcg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2422097|NCT03421860|Active Comparator|ondansetron|will receive ondansetron: a bolus of 8 mg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2422098|NCT03421860|Active Comparator|norepinephrine|will receive noradrenaline (norepinephrine) a bolus of 0,25 mcg/kg once intervention: will receive complementary doses of ephedrine 6 mg to maintain systolic blood pressure above 80 % of baseline
2422099|NCT03421847||Major Depression Group|We will measure the vestibular activity of Major depression patients with Rotatory Test and electronystagmography
2422100|NCT03421847||Healthy Control Group|We will measure the vestibular activity of Healthy subjects with Rotatory Test and electronystagmography.
2422101|NCT03421834|Experimental|Prophylactic VT ablation prior to ICD implantation|
2422102|NCT03421834|Active Comparator|ICD implantation and optimal medical treatment|ICD implantation and optimal medical care until at least 2 appropriate ICD shock occurs or an arrhythmic storm and catheter ablation thereafter.
2422103|NCT03421821|Experimental|Subfascial Injection Group|30 ml of 0.33% ropivacaine was injected to subfascial.
2422104|NCT03421821|Active Comparator|Extrafascial Injection Group|30 ml of 0.33% ropivacaine was injected to extrafascial.
2422105|NCT03421808|Experimental|SYNC TMS|Patients will receive daily left prefrontal transcranial magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm.
2422106|NCT03421808|Active Comparator|Non-Sync TMS|Patients will receive daily left prefrontal transcranial Magnetic stimulation (TMS), 120% MT, 3000 pulses/session, for 30 sessions. They will have EEG and the TMS will be delivered at their individual alpha frequency (IAF) (8-12 Hz) and the first TMS pulse in each train of 40 pulses will NOT be synchronized with the EEG so that the TMS pulse fires during the rising phase of the alpha rhythm. This is the way conventional TMS is delivered now and is FDA approved.
2422107|NCT03421795|Experimental|Let's Talk About Pain Training|Participants complete pre-, post- and follow-up measures, and receive a pain training program. The pain assessment and management training will be based on a training previously developed and piloted by Genik et al. (2017). The training will be facilitated by the same researcher (L.G.) throughout the study.
2422108|NCT03421795|Sham Comparator|Family Centered Care Training|Participants complete all of the same measures as those in the intervention, but receive a training about family centered care. This training will be facilitated by Andrea Cross (PhD Candidate) from CanChild and will be related to the F-words of childhood disability (function, family, fitness, fun, friends, future; Rosenbaum & Gorter, 2012) .
2422109|NCT03421782|Experimental|Exercise - Arm I|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks.
2422110|NCT03421782|Experimental|Exercise plus PROSPECT Cognitive Behavior Therapy (CBT)|Patients undergo POWER exercise intervention consisting of supervised exercise training sessions over 50 minutes every 7 days for a total of 12 sessions and 150 minutes of moderate-intensity exercise weekly for 12 weeks. Patients also undergo PROSPECT internet-based CBT intervention over 12 weeks.
2422111|NCT03421769|Experimental|EA and AMLK|Corneal epithelial autograft (EA) combined with allogeneic middle lamellar keratoplasty (AMLK) is used for the treatment of patients with severe ocular burns.
2422112|NCT03421769|Active Comparator|LA and AMLK|Limbal autograft (LA) combined with AMLK is used for the treatment of patients with severe ocular burns.
2422113|NCT03421756|Experimental|Non Myeloablative regimen (Alemtuzumab)|Sickle cell patient receives sibling donor peripheral blood stem cell transplant with non-myeloablative pre-transplant conditioning.
2422114|NCT03421743|Experimental|Inhaled molgramostim/antimycobacterials|Inhaled molgramostim administered in subjects who remain sputum culture positive while currently on a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen, which has been ongoing for at least 6 months prior to the Baseline Visit
2422115|NCT03421743|Experimental|Inhaled molgramostim|Inhaled molgramostim administered in subjects who remain sputum culture positive but have stopped a multidrug Nontuberculous Mycobacterial (NTM) guideline based antimycobacterial regimen at least 28 days prior to Screening due to lack of response or intolerance, or who never started such treatment
3186877|NCT00749853|Experimental|1|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
3186878|NCT00749853|Active Comparator|2|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
3186879|NCT00749866|Active Comparator|1|Nebulised Gentamicin
2422151|NCT03421535|Experimental|Opposite SI joint Stretch|A certified athletic trainer supervised and observed the athlete as he performed the SI joint stretch opposite his dominant shoulder.
3186880|NCT00749866|Placebo Comparator|2|Nebulised 0.9% Saline
3186881|NCT00749905|Experimental|1|Low fiber diet for 5 days prior to procedure
3186882|NCT00749905|Active Comparator|2|regular diet
3186883|NCT00749918|Experimental|1|Each subject was evaluated and data was collected before and after the intervention
3186884|NCT00749983|Experimental|1|creatine intake
3186885|NCT00749983|Placebo Comparator|2|placebo (dextrose) intake
3186886|NCT00750009|Experimental|Arm I (PRE-ACT)|Patients receive tailored feedback and video content to address clinical trial barriers following baseline assessment.
3186887|NCT00750009|Active Comparator|Arm II (control)|Patients receive generic clinical trials educational feedback taken from NCI publications following baseline assessment.
2422128|NCT03421717|Experimental|Test|Treatment/maintenance of implants postsurgically performed by the use of chitosan brushes
2422129|NCT03421717|Active Comparator|Control|Treatment/maintenance of implants postsurgically performed by the use of titanium curettes
2422130|NCT03421691|Other|Excel V laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
2422131|NCT03421678||Japanese American|Two parents of Japanese descent
2422132|NCT03421678||Non-Hispanic Whites|Two parents of non-Hispanic white descent
2422133|NCT03421678||Native Hawaiians|At least one parent of Hawaiian descent
2422134|NCT03421665||Titan 3-D Wedge System|Subjects who receive one or more Titan 3D wedge(s).
2422135|NCT03421652|Experimental|Treatment (nivolumab, radiation therapy)|Given IV
2422136|NCT03421639|Active Comparator|Ulipristal acetate|control group treated with Ulipristal acetate as control
2422137|NCT03421639|Experimental|Aromatase inhibitor plus GnRH analog|experimental group treated with aromatase inhibitor plus GnRH analog
2422138|NCT03421626||Primary Enrollment|Initial enrollment of patients with history of CML
2422139|NCT03421613|Experimental|3VM1001 cream|Patients will be randomized to self treat with 2 g of VM1001 cream times daily for ten days, have a five day wash out period and then 10 days of self treatment with the comparator.
2422140|NCT03421613|Placebo Comparator|Placebo|Patients will be randomized to self treat with either active product or placebo comparator thrice daily for 10 days followed by a 5 day wash out period then 10 days of experimental treatment thrice daily for 20 days.
2422141|NCT03421600|Active Comparator|Blue laser imaging|Blue laser imaging
2422142|NCT03421600|Experimental|White light imaging|White light imaging
2422143|NCT03421587||Individuals exposed to an intentional/non-intentional trauma|
2422144|NCT03421587||Healthy controls without trauma-exposure|
2422145|NCT03421574|Experimental|MR-Guided Focused Ultrasound|
2422146|NCT03421561|Experimental|DCB Subjects|"The Stellarex DCB is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater than or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm The nominal dose density of paclitaxel on the Stellarex DCB is 2.0 μg/mm2. Indications The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
2422147|NCT03421561|Placebo Comparator|PTA Subjects|"The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).~Basic Catheter Specifications~Guidewire: 0.035~Balloon Length: 40/80/120 mm~Sheath Compatibility: greater to or equal to 6 French~Balloon Diameter: 4/5/6 mm~Shaft length: 135 cm Indications The EverCross Balloon Catheter is intended to dilate stenosis in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for stent post-dilation in the peripheral vasculature. For additional information refer to the EverCross Instructions for Use."
2422148|NCT03421548|Experimental|BKpro I with EyeMate|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
2422149|NCT03421548|No Intervention|BKpro I|Keratoprosthesis surgery indicated, defined as having a severely opaque and vascularised cornea AND either a verifiable history of two or more prior failed corneal transplant procedures, limbal stem cells deficiency or a medical condition such as alkali burns or autoimmune disease that makes the success of a traditional corneal transplant procedure unlikely. Potential study subjects will be solicited for participation in the clinical trial only after they have consented to the keratoprosthesis operation.
2422150|NCT03421535|Active Comparator|Sleeper stretch group|A certified athletic trainer supervised and observed the athlete as he performed the sleeper stretch on his dominant shoulder.
2422219|NCT03421093||Surgeries and adjuvant therapies|Surgeries or surgeries plus adjuvant therapies
3186888|NCT00750022|Experimental|E1|
3186889|NCT00750022|Active Comparator|A1|
3186890|NCT00750035|Experimental|1|total abdominal hysterectomy and
3186891|NCT00750035|Experimental|2|Subtotal hysterectomy
3186892|NCT00750074||1|"During volume assist-control ventilation, a 0.4 second end-inspiratory pause will be set and the following pressures measured: peak pressure; plateau pressure; and PEEP. The following ventilator settings will be recorded: inspiratory flow; expired tidal volume; and rate. The presence or absence of autoPEEP will be noted.~During pressure-control ventilation, the flow versus time waveform will be printed from the ventilator using a conventional computer printer for later analysis. The following ventilator settings will be recorded: inspiratory pressure; PEEP; and expired tidal volume."
3186893|NCT00750087||1|Schizophrenia patients stabilized on Seroquel XR
3186894|NCT00750100|Active Comparator|A|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.
2422152|NCT03421522|Experimental|Intervention - ICBN preservation|For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved.
2422153|NCT03421522|No Intervention|Control - Usual Care|For participants allocated to the usual surgical care arm, attending surgeons will perform a standard Level 1 and 2 axillary node dissection (sacrifice of the ICBN), either alone or with mastectomy or breast conserving surgery.
2422154|NCT03421496|Experimental|Cannabidiol Oral Solution (CBD)|"Cannabidiol Oral Solution, up to 40 milligrams per kilogram per day (mg/kg/day), participants will be dosed approximately every 12 hours with food.~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
2422155|NCT03421496|Placebo Comparator|Placebo|"Matching CBD placebo, up to 40 mg/kg/day, participants will be dosed approximately every 12 hours with food.~Participants will also be taking vigabatrin, up to 150 mg/kg/day, divided twice daily with food."
2422156|NCT03421483|Active Comparator|Folic Acid supplementation|Participants receive an adult multivitamin supplement along with a folic acid supplement
2422157|NCT03421483|Placebo Comparator|No supplementation|Participants only receive an adult multivitamin supplement
2422158|NCT03421457|Experimental|Lateral suspension|"Uterus-preserving Laparoscopic lateral suspension with mesh technique will be performed in this arm."
2422159|NCT03421457|Experimental|Sacrocervicopexy|"Uterus-preserving Laparoscopic sacrocervicopexy with mesh technique will be performed in this arm."
2422163|NCT03421405|Experimental|Intervention Arm|All participants will be asked to attend 4 separate experimental sessions over the course of approximately 4 weeks (i.e. one session/week). During each session, participants will listen to three different auditory stimulus sequences including sounds and words while EEG activity is recorded using the NeuroCatch Platform™ device.
2422164|NCT03421392||Idiopathic thrombocytopenic purpura|
2422165|NCT03421392||non immunological thrombocytopenia|patient with constitutive thrombocytopenia, myelodysplastic syndrome, or chemotherapy-induced thrombocytopenia
2422166|NCT03421392||without thrombocytopenia|
2422169|NCT03421366||Cystic Fibrosis on Posaconazole|"Able to provide written informed consent~Greater than 18 years of age or older~Have a diagnosis of cystic fibrosis~No known azole hypersensitivity~To commence as part of their standard of care the newer modified release oral formulation of posaconazole to treat Aspergillus~Able to provide a pre-treatment sputum collected for fungal culture as part of standard of care~Have been prescribed a loading dose of 300mg bd for 1 day of the modified release posaconazole tablet followed by 300mg daily."
3146067|NCT00089349|Experimental|Arm I|"Course 1: Patients receive alemtuzumab IV over 2 hours on days 1-5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 in the absence of disease progression or unacceptable toxicity. Patients achieving complete remission (CR), partial remission (PR), or cytolytic PR at day 29, or patients with CNS disease that achieve a CNS 1 or CNS 2 status, proceed to course 2.~Courses 2 and 3: Patients receive alemtuzumab IV over 2 hours on days 1, 8, 15, and 22; methotrexate IV continuously over 24 hours on day 1 and then orally once daily on days 8, 15, and 22; and oral mercaptopurine once daily on days 1-28. Patients with a CR or PR at day 29 proceed to course 3. In course 3, patients receive alemtuzumab, methotrexate, and mercaptopurine as in course 2.~CNS prophylaxis*: Patients receive methotrexate intrathecally on day 1 of courses 2 and 3 on day 1 of courses 2 and 3.~NOTE: * CNS-negative patients receive methotrexate intrathecally on day 15 of course 1 and day 1 of courses 2 and 3."
3146068|NCT00089362|Experimental|Treatment (alvespimycin hydrochloride)|"Patients receive alvespimycin hydrochloride IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-2 patients receive accelerated escalating doses of alvespimycin hydrochloride until at least 1 of 2 patients experience DLT. Cohorts are then expanded to 3-6 patients who receive escalating doses (in a standard manner) of alvespimycin hydrochloride until MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience DLT. Once the MTD is determined, 10 additional patients are treated at that dose."
3146069|NCT00089388|Experimental|Arm I (low dose cilengitide)|Patients receive cilengitide IV at a lower dose over 1 hour twice weekly for 4 weeks.
3146070|NCT00089388|Experimental|Arm II (higher dose cilengitide)|Patients receive cilengitide IV at a higher dose over 1 hour twice weekly for 4 weeks.
3146071|NCT00089492|Experimental|1|
3146072|NCT00089492|Active Comparator|2|
3146073|NCT00089570|Experimental|Terlipressin|Terlipressin
3146074|NCT00089570|Placebo Comparator|Placebo|Placebo
3146075|NCT00089804|Active Comparator|1|300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
2422179|NCT03421327||Families at-risk for HD|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2422180|NCT03421327||Families at-risk for hereditary cancer|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2422320|NCT03420443|Other|No oral supplementation|No oral supplementation.
3146076|NCT00089804|Active Comparator|2|900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
3146077|NCT00089804|Placebo Comparator|3|A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly
3146078|NCT00089856|Other|2|Standard of care - chemotherapy
3146079|NCT00089856|Experimental|1|Immunotherapy
3146080|NCT00089908|Experimental|1|One subcutaneous vaccination with rDEN1delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
3146081|NCT00089908|Experimental|2|One subcutaneous vaccination with rDEN1delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
3146082|NCT00089908|Placebo Comparator|3|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3146083|NCT00089921|Experimental|001|SCIO-469 30 mg capsule three times daily for 12 weeks
2422181|NCT03421327||Genetic Counselors|No interventions will be administered. Participation involves one semi-structured interview that will last up to one hour. The interview will be scheduled at a time and place that is convenient for the participant. The participant will be given the option to conduct the interview via phone, Skype, or in-person at Johns Hopkins.
2422182|NCT03421314|Experimental|Zinc|Participants in this arm will take a daily 30 mg dose of zinc gluconate during 6 months
2422183|NCT03421314|Experimental|Selenium|Participants in this arm will take a daily 200 mcg of selenium yeast during 6 months
2422184|NCT03421314|Experimental|Zinc + Selenium|Participants in this arm will take a daily 30 mg dose of zinc gluconate + 200 mcg of selenium yeast during 6 months
2422185|NCT03421314|No Intervention|Control|Participants in this arm will not take supplementation as a control.
2422186|NCT03421301|Experimental|1. Dietary portfolio (DP)|the dietary portfolio was given daily in the breakfast and dinner for 2.5 months
2422187|NCT03421301|Placebo Comparator|2. placebo (P)|the placebo (P) was based was given daily in the breakfast and dinner for 2.5 months
2422188|NCT03421288|Experimental|Arm A: FLOT with Atezolizumab|Patients randomized to treatment Arm A will receive atezolizumab (840 mg IV over 1 hour) + FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of atezolizumab + FLOT followed by 8 additional 3-week treatment cycles with atezolizumab alone (maintenance setting: 1,200 mg q3w). FLOT can be deescalated to FLO, FLT or FL in case of chemorelated toxicity at any time and at the discretion of investigator.
2422189|NCT03421288|Active Comparator|Arm B: FLOT alone|Patients randomized to Arm B will receive FLOT alone for four 2-week treatment cycles prior to surgery. Following surgery, patients will receive four further 2-week cycles of chemotherapy alone. FLOT can be deescalated to FLO, FLT or FL in case of chemo-related toxicity at any time and at the discretion of investigator. Docetaxel 50 mg/m², d1 Oxaliplatin 85 mg/m², d1 Calciumfolinat 200 mg/m², d1 5-Fluorouracil 2600 mg/m², d1
2422190|NCT03421275|Experimental|Esketamine|intravenous anaesthetic and analgetic
2422191|NCT03421275|Active Comparator|Fentanyl Citrate|intravenous opioid analgetic
2422192|NCT03421275|Placebo Comparator|Saline Nasal|"intravenous Natriumklorid b. Braun 9 mg/ml"
2422193|NCT03421262|Experimental|One-step:IADPSG Criteria|Gestational diabetes screening with fasting 2 hour 75g. Receive a fasting 2 hour 75 gr oral glucose tolerance test and diagnosed based on the IADPSG which is if one or more values exceed the following diagnostic threshold: Fasting 92, 1-hour 180, or 2-hour 153 mg/dL.
2422194|NCT03421262|Active Comparator|Two-step:NDDG Criteria|"Step 1: Perform a 1h 50-g glucose load test (nonfasting. If the plasma glucose level measured 1 h after the load is 140 mg/dL, proceed to a 100-g OGTT.~Step 2: 100-g OGTT. The diagnosis of GDM is made if at least two of the following four plasma glucose levels(measured fasting and 1 h, 2 h, 3 h after the OGTT) are met or exceeded: 105mg/dl, 190mg/dl, 165mg/dl and 145mg/dl respectively"
2422195|NCT03421249|Active Comparator|Group A - Intervention|Submitted to knee and hip muscle strengthening exercises and electromagnetic field therapy with Magnetron ® (Meditea - ARG) using the coplanar technique
2422196|NCT03421249|Active Comparator|Group B - exercises|Performed exercises to strengthen the hip and knee muscles
2422197|NCT03421249|Placebo Comparator|Group C - Placebo|Performed hip and knee strengthening exercises and electromagnetic field therapy with the coplanar Magnetron® technique, but with the device switched off
2422198|NCT03421249|Active Comparator|Group D - Apparatus|Only use electromagnetic field therapy with the coplanar Magnetron® technique
2422199|NCT03421236|Experimental|non muscle invasive bladder cancer patient|intravesical instillation of Ty21a in patients not requiring BCG
2422200|NCT03421223||Case|Individuals diagnosed with chronic pain
2422201|NCT03421223||Control|Individuals without chronic pain
3186895|NCT00750100|Experimental|B|Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.
3186896|NCT00750113|Experimental|Arm 1|
3186897|NCT00750113|Experimental|Arm 2|
3186898|NCT00750113|Experimental|Arm 3|
3186899|NCT00750178|Experimental|A|MK0683
2422210|NCT03421158|No Intervention|Control|Newborns received no pain interventions during the procedure
2422211|NCT03421158|Experimental|Breastfeeding|Newborns were breastfed during the procedure
2422212|NCT03421158|Experimental|Oral Sucrose|Newborns were given oral sucrose during the procedure
2422213|NCT03421158|Experimental|Skin to skin contact|Newborns were placed in direct contact with their mothers during the procedure
2422214|NCT03421158|Experimental|Non-nutritive sucking|Newborns were given a pacifier to suck on during the procedure
2422215|NCT03421119|Experimental|CinnaGen-liraglutide|CinnaGen-liraglutide (Liraglutide 6 MG/ML Pen Injector by CinnaGen Company) will be administered 1.8 mg/day subcutaneously. Doses of CinnaGen-liraglutide will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
2422216|NCT03421119|Active Comparator|Victoza®|Victoza® (Liraglutide 6 MG/ML Pen Injector by Novo Nordisk Company) will be administered 1.8 mg/day subcutaneously. Doses of Victoza® will be up-titrated from 0.6 mg/day in the first week to 1.2 mg/day in the second, third and fourth weeks, up to 1.8 mg/day from the start of the fifth week to the end of 26th week. Patients in this group will continue to receive metformin along with a Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose.
2422217|NCT03421106|Experimental|Intervention Food Pantries|Food pantries will transform to offer healthier and more appealing food ; the effect on clients will be measured.
2422218|NCT03421106|Active Comparator|Control Food Pantries|Food pantries will make no changes during the evaluation period; the effect on clients will be measured.
2422220|NCT03421080|Active Comparator|MoodGYM Only|The MoodGYM only Internet intervention will consist of a popular, automated, self-help cognitive behavioral therapy program for depression comprising five modules to be completed over five weeks and an online workbook incorporating 29 exercises. A series of published research trials has shown MoodGYM to be effective in reducing depressive symptoms in users in a range of settings (e.g., schools, universities, Lifeline suicide prevention, U.K. NHS Choices online), for different aspects of the mental health service spectrum (e.g., prevention vs treatment), and different age groups (adults, adolescents).
2422221|NCT03421080|Experimental|MoodGYM + CYD|The MoodGYM + CYD intervention condition will consist of the MoodGYM only intervention and an online intervention providing feedback on quantity and frequency of drinking, severity of hazardous drinking, and provides recommendations for safe levels of alcohol consumption (Check Your Drinking - CYD). The CYD Final Report will be provided as part of the participant's MoodDYM dashboard.
2422222|NCT03421054|Other|nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
2422223|NCT03421041|Experimental|Dexamethasone group|
2422224|NCT03421041|No Intervention|control group|
2422225|NCT03421028|Active Comparator|Control group|Patients with masticatory muscle pain treated with occlusal splint, physiotherapy and counseling
2422226|NCT03421028|Experimental|Experimental group 1|Patients diagnosed with masticatory muscle pain treated with 4 meetings of EMG-biofeedback assisted training
2422227|NCT03421028|Experimental|Experimental group 2|Patients diagnosed with masticatory muscle pain treated with 8 meetings of EMG-biofeedback
2422228|NCT03421015||case group|patients with biochemical recurrence and positive imaging (case group)
2422229|NCT03421015||Control Group|patients without biochemical recurrence (control group)
2422230|NCT03421002|Experimental|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour. Micafungin will be administered for a minimum of 14 days until 1 of the following conditions applied: •Negative results (absence of Candida growth) from at least 2 consecutive blood cultures and/or resolution of clinical and laboratory symptoms and reduction of mannan antigen blood level (< 125 pg/mL) are obtained. •In case of meningitis, hydrocephalus and external ventricular derivation, negative results (absence of Candida growth) from at least 2 consecutive cerebral spinal fluid (CSF) cultures associated with resolution of clinical and laboratory symptoms. •Interruption (including addition or switch to another antifungal agent or dosage change of micafungin) due to demonstration of therapy failure.
2422231|NCT03420989|Active Comparator|Active snack food|snack food with carob and seaweeds 50 gr per day
2422232|NCT03420989|Placebo Comparator|Control snack food|snack food without carob and seaweeds 50 gr per day
2422233|NCT03420976|Experimental|Novel Supplement-based Therapy|"Low FODMAP diet + supplements outlined below:~Product Name: Liver-G.I. Detox Active Ingredients: Alpha lipoic acid, n-acetyl-l-cystine, turmeric root extract, milk thistle seed extract, broccoli sprout concentrate, artichoke leaf extract, taurine, glycine, l-glutamine, l-methionine, and chlorella.~Product Name: l-Glutamine Active Ingredients: l-glutamine~Product Name: MicroDefense Active Ingredients: berberine sulfate, olive leaf extract, sweet wormwood, clove bud powder, and grapefruit seed and fruit extract.~Product Name: A.C. Formulla II Active Ingredients: calcium and magnesium undecylenate, calcium and magnesium caprylate, bromelain, grapefruit seed and fruit extract, and berberine sulfate~Product Name: Probiotic-5 (Pure Encapsulations) Active Ingredients: Probiotic blend~Product Name: Digestive Enzymes Ultra with Betaine HCl Active Ingredients: Digestive enzyme blend and betaine HCl"
2422234|NCT03420963|Experimental|Treatment (cyclophosphamide, etoposide, NK cells)|Patients receive cyclophosphamide IV QD over 30 minutes and etoposide IV QD over 60 minutes on days 1-5 in the absence of unacceptable toxicity. Patients then receive cord blood derived allogeneic NK cells IV on day 8.
2422235|NCT03420950|Other|Sedative first|Rapid sequence intubation: sedative first
2422236|NCT03420950|Other|Paralytic agent first|Rapid sequence intubation: paralytic first
2422237|NCT03420937|Experimental|Deep Neuromuscular Block|"Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min.~Intervention: Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
2422238|NCT03420937|Experimental|Moderate Neuromuscular Block|Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Intervention: Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9.
2422239|NCT03420924|Experimental|Thermal suit|
2422240|NCT03420924|Active Comparator|Conventional hospital clothes|
2422241|NCT03420911|Active Comparator|dexketoprofen trometamol group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg
2422242|NCT03420911|Active Comparator|dexketoprofen trometamol plus midazolam group|Received the study drugs in 100 mL of normal saline within 5 minutes. The dexketoprofen trometamol dose was 50 mg and the midazolam dose was 1 mg.
2422243|NCT03420898||1|General Medicine in Hospital Unit 70 Bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422244|NCT03420898||2|General Medicine in Hospital 38 Bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422245|NCT03420898||3|Cardiovascular Surgery in Hospital Unit 36 bed. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422385|NCT03420001||controls|women after one vaginal delivery
2422246|NCT03420898||4|General Surgery in Hospital 24 bed Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422247|NCT03420898||5|Cardiac 36-bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422248|NCT03420898||6|General Medicine 26 Bed in Hospital Unit. Quality Improvement Intervention, prescription reduction The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
2422249|NCT03420885|Experimental|Ba Duan Jin Group|Ba Duan Jin plus health education. Participants take part in 16-week program. The health education is conducted as the Health Education Group. Besides, the participants attended two 90-minute sessions of group-based Ba Duan Jin training per week and practiced at least three 30-minute Ba Duan Jin sessions at home per day.
2422250|NCT03420885|Active Comparator|Health Education Group|Health education. Participants take part in 16-week program. The health education includes work, rest, diet and other basic programs according to the different conditions of participants.
2422251|NCT03420872||Subset from PROGRESS cohort|Participants included children 4-6 years of age from mother-child pairs in the Programming Research in Obesity, Growth Environment and Social Stress (PROGRESS) prospective birth cohort in Mexico City
2422252|NCT03420846|Experimental|OCT Mapped arm|OCT is used to map the tumour margins as the first stage MMS estimate
2422253|NCT03420846|No Intervention|Control arm|Standard MMS is performed
2422254|NCT03420833|Experimental|CRT-On first, then CRT-Off|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed on in the first intervention period, and after six months the CRT function will be turned off in the second intervention period.
2422255|NCT03420833|Experimental|CRT-Off first, then CRT-On|Subjects will be randomized to have the cardiac resynchronization therapy pacemaker (CRT-P) programmed off in the first intervention period, and after six months the CRT function will be turned on in the second intervention period.
2422256|NCT03420820|Experimental|5% Betadine, Ocular Surface only|Use of 5% P-I from bottle dropper to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
2422257|NCT03420820|Experimental|10% Betadine, Ocular Surface only|Use of 10% P-I swabstick to sterilize the ocular surface only, prior to injection. Intervention: bacterial culture swab.
2422258|NCT03420820|Experimental|10% Betadine, Ocular Surface and Adnexa|Use of 10% P-I swabstick to sterilize the ocular surface and surrounding lids and eyelashes only, prior to injection. Intervention: bacterial culture swab.
2422259|NCT03420807|Experimental|MHRC camera|Subjects will undergo a retina imaging session with the MHRC camera.
2422260|NCT03420794|Active Comparator|Control Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once just prior to surgery.
2422261|NCT03420794|Experimental|Study Group|Patients undergoing total laparoscopic hysterectomy for benign disease who will receive celecoxib 200mg, acetaminophen 1000mg, and gabapentin 600mg by mouth once 3-4 hours prior to surgery.
2422265|NCT03420768|Experimental|Part 1 BMS-986263 45mg weekly|
2422266|NCT03420768|Experimental|Part 1 BMS-986263 90mg weekly|
2422267|NCT03420768|Placebo Comparator|Part 1 Placebo weekly|
2422268|NCT03420768|Experimental|Part 2 BMS-986263 45mg every 2 weeks|
2422269|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 2 weeks|
2422270|NCT03420768|Experimental|Part 2 BMS-986263 90mg every 4 weeks|
2422271|NCT03420768|Placebo Comparator|Part 2 Placebo every 2 weeks|
2422272|NCT03420755|Experimental|MB 1-on-1 Only|Mothers and Babies 1-on-1. MB 1-on-1 -12-session intervention Each MB session lasts 15-20 minutes and is delivered as part of a regularly scheduled home visit (English or Spanish).
2422273|NCT03420755|Experimental|MB 1-on-1 Plus TEXT|Mothers and Babies Plus Text. MB 1-on-1 along with text enhancements both in English and Spanish.
2422274|NCT03420742|Experimental|Midazolam 3 mg + Brigatinib 90 mg|Midazolam 3 mg, orally, once on Day 1, followed by brigatinib 90 mg, orally, once daily on Days 2 to 8, further followed by brigatinib 180 mg, orally, once daily on Days 9 to 28 in Part A Cycle 1 (28 days treatment cycle). Participants escalating to brigatinib 180 mg once daily will also receive midazolam 3 mg, orally, once on Day 21 of Part A Cycle 1. After completion of Part A, participants will continue into Part B. Participants in Part B will receive brigatinib up to 180 mg (or at the highest tolerated dose in Part A), orally, once daily in a 28 day treatment cycle, up to a maximum of 23 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
2422275|NCT03420729|Experimental|magnetic assisted capsule endoscopy|All participants will undergo magnetic assisted capsule endoscopy at the sloan medical centre
2422276|NCT03420729|Active Comparator|gastroscopy|All participants will undergo gastroscopy as standard of care at sheffield teaching hospitals
2422277|NCT03420716|Experimental|functional yogurt|Participants are given the symbiotic yogurt daily (180 ml)
2422278|NCT03420716|Experimental|control yogurt|Participants are given the control yogurt daily (180 ml)
2422279|NCT03420703|Active Comparator|Block group|Erector espine plane block will be administrated to this group. An intravenous patient controlled analgesia device will be given to the patients postoperatively
2422280|NCT03420703|Sham Comparator|control group|An intravenous patient controlled analgesia device will be given to the patients postoperatively
2422281|NCT03420690||Family of patient|
2422282|NCT03420677|Active Comparator|Application of tones|During non-rapid eye movement (NREM) sleep short tones will be played
2422283|NCT03420677|Sham Comparator|No application of tones|During NREM sleep no short tones will be played
2422284|NCT03420664|Experimental|Cast immobilisation|A below knee cast is applied in order to achieve ankle immobilisation for one hour
2422285|NCT03420664|Experimental|Orthosis (VACOped) immobilisation|A below knee orthosis which allows for ankle movement is applied for one hour.
2422286|NCT03420651|Experimental|PEFR Guided Management|Peak Expiratory Flow Rate (PEFR) Patients in this group will perform PEFR testing every 30 minutes and this data along with the National Asthma Prevention and Education Program guidelines will be considered by primary ED medical providers in the management of this group.
2422287|NCT03420651|Experimental|Non-PEFR Guided Management|Standard Clinical Judgement Patients in this group will receive management based on primary medical provider's clinical judgement.
2422288|NCT03420638|Experimental|Adjunct Exparel|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL], i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension on each side.
2422289|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication-bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.-into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
3186900|NCT00750230|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 30 days.
3186901|NCT00750243|Experimental|A|
3186902|NCT00750243|Active Comparator|B|
3186903|NCT00750256|Experimental|Cohorts|This study will be a single-blind, randomized, placebo-controlled, dose-rising, single dose, parallel group study with 6 proposed Cohorts from 2mg to 450mg.
2422294|NCT03420612||training|The training cohort was used to determine the influencing factors of the pain during the colonoscopy and establish the intubation discomfort score (IDS)
2422295|NCT03420612||validation|The validation cohort was used to verify the IDS
2422296|NCT03420599||health control|healthy controls are all from normal volunteers
2422297|NCT03420599||splenectomy|Traumatic patients after total splenectomy
2422298|NCT03420586|Active Comparator|Nitrous oxide Group|The nitrous oxide group (GN2O) will receive air in 30% O2 during general anesthesia until the last 30 min of surgery, when 70% N2O in 30% O2 will be administered.
2422299|NCT03420586|No Intervention|Oxygen Group|The Oxygen group will receive gas carrier mixture consisting of air in 30% O2 during general anesthesia.
2422300|NCT03420560|Experimental|warmer temperature|To compare the incidence and intensity of pain on injection that is caused by propofol in warm temperature（27℃） versus normal temperature(23℃).
2422301|NCT03420560|Placebo Comparator|normal temperature|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol in different room temperature(27 VS 23).
2422302|NCT03420547|Experimental|Intervention group|Group of participants receiving the RISE intervention
2422303|NCT03420547|No Intervention|Standard Care (waitlist)|Group receiving no intervention in first 6 weeks.They will have the option of participating in the RISE program after their second assessment at week 6.
2422304|NCT03420534|Experimental|iloperidone in fasting|iloperidone 1mg by mouth once for 6 days in the first cycle or the second cycle
2422305|NCT03420534|Active Comparator|placebo tablets in fasting|placebo mimic iloperidone 1mg by mouth once for 6 days in the second cycle or the first cycle
2422306|NCT03420534|Active Comparator|placebo tablets in postprandial|placebo mimic iloperidone 1mg by mouth once for 6 days
2422307|NCT03420534|Experimental|iloperidone in postprandial|iloperidone 1mg by mouth once for 6 days
2422308|NCT03420521|Other|Nivolumab plus Ipilimumab|Nivolumab-240 mg IV over 60 minutes Q2W Ipilimumab 1mg/kg IV over 30 minutes Q6W
2422309|NCT03420508|Experimental|ensartinib|The screening portion of the trial will test archival tumor material for the presence of ALKATI using a Nanostring-based RNA assay for any patients deemed to be current or future candidates for this trial. This will require approximately 5 formalin-fixed paraffin- embedded (FFPE) slides of 5-8 micron thickness. For the treatment portion of the study, all patients will receive ensartinib orally at a dose of 225mg daily.
2422310|NCT03420495|Experimental|OCD Group|Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for principal OCD. These participants will complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
2422311|NCT03420495|Experimental|Non-psychiatric Control Group|No current DSM-5 diagnosis. These participants will also complete clinician interviews, self-report questionnaires, and receive the Decision-Making Tasks Intervention.
2422312|NCT03420482|Experimental|Fecal Microbiota Transplant (FMT) oral capsules|Subjects will receive 15 oral capsules of FMT on days 1, 2, 7, 14, and 21.
2422313|NCT03420482|Placebo Comparator|Placebo capsules|Subjects will receive placebo capsules on the same schedule as the experimental arm (days 1, 2, 7, 14, and 21).
2422314|NCT03420469|Experimental|Baseline CYP2D6 activity|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
2422315|NCT03420469|Experimental|CYP2D6 activity with single dose of bupropion|The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
2422316|NCT03420469|Experimental|CYP2D6 activity after treatment with bupropion to steady sate|CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
2422317|NCT03420456|Experimental|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy and the light energy may activate under-stimulated brain regions.
2422318|NCT03420443|Experimental|Oat bran|45 g oat bran
2422319|NCT03420443|Experimental|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bran + probiotic bacteria.
3186904|NCT00750295|Experimental|1|
3186905|NCT00750295|Experimental|2|
3186906|NCT00750295|Experimental|3|
3186907|NCT00750295|Experimental|4|
2422321|NCT03420417|Experimental|Assessement of respiratory mechanics|Measurement of respiratory mechanics characteristics
2422322|NCT03420404|Experimental|Collaborative care with TCM physicians|TCM physician involved collaborative care model (TCMCMC): The intervention arm will involve the TCM physician in the management of patients with AxSpA in addition to the usual rheumatological care.
2422323|NCT03420404|No Intervention|Usual care only|The attending rheumatologist will prescribe a variety of treatment inclusive of medications such as non-steroidal anti-inflammatory drugs and physiotherapy.
2422324|NCT03420391|Placebo Comparator|Placebo PBMT|Participants will be treated with placebo PBMT in different time-points before the eccentric exercise protocol (5 minutes, 3 hours, 6 hours or 24 hours). Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
2422325|NCT03420391|Active Comparator|5 Minutes|"Participants will be performed the eccentric exercise protocol 5 minutes after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
2422326|NCT03420391|Active Comparator|3 Hours|"3 hours: Participants will be performed the eccentric exercise protocol 3 hours after PBMT.~Assessments will be performed before at baseline, 1 minute, 1 hour and 24, 48 hours after the end of exercise protocol."
2422327|NCT03420391|Active Comparator|6 Hours|"6 hours: Participants will be performed the eccentric exercise protocol 6 hours after PBMT.~Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol."
2422328|NCT03420391|Active Comparator|24 hours|24 hours: Participants will be performed the eccentric exercise protocol 24 hours after PBMT. Assessments will be performed before at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
2422329|NCT03420391|No Intervention|Control|Participants will not receive intervention. Assessments will be performed at baseline, 1 minute, 1 hour, 24 and 48 hours after the end of exercise protocol.
2422330|NCT03420378|Experimental|Interventional Arm|Patients with vitamin D deficiency will receive vitamin D replacement therapy. Before and after therapy, cutaneous silent period will be measured from each upper extremity and latencies will be recorded. Their LANSS scores and Notthingham Health Profile will be recorded before and after treatment.
2422331|NCT03420365|Experimental|Type of intervention|A single bout of aerobic exercise, or a single bout of balance and coordination exercise, or reading a magazine
2422332|NCT03420352|Other|butterfly needle with valve|thromboelastography
2422333|NCT03420352|Other|Standard hypodermic needle|thromboelastography
2422334|NCT03420339|Experimental|Subjects on stimulant medication|All participants: Children and adolescents diagnosed with AD/HD, displaying disruptive behavior, and taking stimulant medication.
2422335|NCT03420326||Atria fibrillation (AF) group|"Detection of AF during 30 seconds ECG assessment~Once diagnosed with atrial fibrillation before~Undergo the frailty status assessment"
2422336|NCT03420326||Non-AF group|"No detection of AF during 30 seconds ECG assessment~Undergo the frailty status assessment"
2422337|NCT03420313|Experimental|Interim Buprenorphine Treatment|"Interim Buprenorphine Treatment includes (a) Maintenance treatment with Buprenorphine/ naloxone sublingual tablets with bi-monthly clinic visits for observed dosing and the remaining doses dispensed at home via a secure computerized portable device (Med-O-Wheel, Addoz, Finland).~(b) nightly calls from an automated Interactive Voice Response (IVR) phone system to assess any drug use, withdrawal and craving, (c) IVR-generated random call-backs for urinalysis and pill counts, and (d) HIV+Hepatitis education delivered via iPad. (e) monthly follow-up assessments"
2422338|NCT03420313|No Intervention|Waitlist Control|Waitlist Control participants will remain on the waitlist for their treatment of choice but complete the same monthly assessments.
3186908|NCT00750295|Experimental|5|
2422340|NCT03420287|Experimental|MPM prepared from allogenic bone graft|All patients in this group will receive MPM prepared from allogenic bone graft
2422341|NCT03420287|Active Comparator|Autogenous bone graft group|All patients in this group will receive autogenous bone graft only
2422342|NCT03420274|Experimental|Intervention|This arm will utilize a point-of-care shared decision-making tool (NEST).
2422343|NCT03420274|Placebo Comparator|Control|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
2422344|NCT03420261|Active Comparator|Crystalloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of 0.9% saline (up to a maximum of 30 ml/kg)
2422345|NCT03420261|Experimental|Colloid group|individualized goal-directed fluid optimization (cardiac preload) by 250 ml boluses of HES 130/0.4 (up to a maximum of 30 ml/kg, VOLUVEN ®, Fresenius Kabi)
2422346|NCT03420248|Experimental|Non-spherical polyvinyl alcohol particle|For embolic material, non-spherical polyvinyl alcohol particle is used.
2422347|NCT03420248|Experimental|Tris-acryl gelatin microsphere|For embolic material, Tris-acryl gelatin microsphere is used.
2422348|NCT03420235|No Intervention|Control group|Control group will receive standard care alone.
2422349|NCT03420235|Experimental|Home monitoring group|Intervention will consist of a home monitoring program added to standard care.
2422350|NCT03420222|Experimental|AVP-786|Dose 1 capsules administered twice a day over a 12-week period
2422351|NCT03420222|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
2422352|NCT03420209|Experimental|Group applying PNF technique|The experimental goup who are applying PNF technique with elastic bands for the upper extremities. Before the group will perform stretching and resisted exercises at the warming up period, after they will do PNF exercises with elastic bands on two PNF pattern for the upper extremities and finally they will do some stretching exercises for the cool down period. The programme will continue for 30-45 minutes, three times a week, for 12 weeks. They will work one by one with a physical therapist.
2422353|NCT03420209|No Intervention|Home Programme|This group will perform only breathing exercises daily at home during 12 weeks.
2422354|NCT03420196|Experimental|Supervised Rehabilitation program|It will be consist in a supervised exercise program by physical therapist, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility
2422386|NCT03419988|Experimental|Exercise Intervention|8-weeks exercise intervention: 3-days per week for 45-55 minutes per session
3186909|NCT00750295|Experimental|6|
3186910|NCT00750295|Experimental|7|
3186911|NCT00750334|Experimental|Part A|clofarabine Dose Escalation
2422355|NCT03420196|Active Comparator|Nonsupervised rehabilitation program|It will consist in an exercise program for home, nonsupervised, including the following structures: diaphragm, tranverse abdominis muscle, pelvic, gluteus, CORE and spinal mobility. The patients will perform an exercise program at home.
2422356|NCT03420170|Experimental|Graded Exercise Integrated Education|"The graded exercise (8 weeks)~Strengthening exercise~Aerobic Exercise~Educational session to increase exercise self-efficacy and physical activity level (16 weeks)"
2422357|NCT03420170|Active Comparator|Conventional physical therapy|Normal routine of physical therapy (8 weeks)
2422358|NCT03420157||Focus Group 1 & 2|Each Focus Group of 10 women will be led by a psychologist according to a semi-directive interview pattern. This interview guideline specifies in details the ideal proceedings of Focus Group, as well as the various predetermined topics to be addressed in the form of questions and / or relaunches. The interview guideline is divided into 2 parts: the accompanying letter and the leaflet explaining how to perform the vaginal self-sampling.
2422359|NCT03420144|Active Comparator|Standard Medical Therapy|Standard medical therapy: diuretics, lactulose, rifaximin, diuretics, albumin infusion, nutritional support (as required)
2422360|NCT03420144|Active Comparator|Growth hormone|Growth Hormone: GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (based on IGF-1 levels) subcutaneously for 1 year.
2422361|NCT03420131||FFR-iFR-QFR group|
2422363|NCT03420105|Other|Group A|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2422364|NCT03420105|Other|Group B|Patients perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2422365|NCT03420105|Other|Healthy volunteers|Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
2422366|NCT03420092|Experimental|Treatment A|The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
2422367|NCT03420092|Experimental|Treatment B|The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
2422368|NCT03420092|Experimental|Treatment C|The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
2422369|NCT03420092|Experimental|Treatment D|The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
2422370|NCT03420092|Experimental|Treatment E|The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
2422371|NCT03420092|Experimental|Treatment F|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
2422372|NCT03420079|Experimental|Dose escalation cohort of FCN-411|"FCN-411 will be orally administrated at five sequential dose levels, which are 4 mg, 8 mg, 16 mg, 24 mg, and 32 mg.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
2422373|NCT03420079|Experimental|Dose expansion cohort of FCN-411|"FCN-411 will be orally administrated at MTD.~Patients must be diagnosed with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).~Participants will receive FCN-411 monotherapy once daily (QD) for sequential 21-day cycles."
2422374|NCT03420066||Retrospective data collection|Group includes subjects that were implanted with the Nexus device as part of compassionate use procedure before joining the CIP008 study. Only intervention foreseen by CIP008 study is retrospective collection of data previously recorded as standard of care in medical charts (refer to Intervention/treatment section)
2422375|NCT03420053|Experimental|Group 1 HIV- vaccine recipients|"Group 1: n=6, HIV negative vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either normal saline placebo (NS) or PfSPZ Vaccine.~Efficacy will be assessed by controlled human malaria infection (CHMI) at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2422376|NCT03420053|Placebo Comparator|Group 1 HIV- NS controls|"Group 1: n=3, HIV negative NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 1, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2422377|NCT03420053|Experimental|Group 2a HIV+ vaccine sentinels|Group 2a: n=3, HIV positive vaccine recipients will receive 4.5x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days.
2422378|NCT03420053|Experimental|Group 2b HIV+ vaccine recipients|"Group 2b: n=6, HIV positive vaccine recipients will receive 9.0x10^5 PfSPZ Vaccine at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of PfSPZ Vaccine. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2422379|NCT03420053|Placebo Comparator|Group 2b HIV+ placebo controls|"Group 2b: n=3, HIV positive NS placebo recipients will receive NS at 0, +2, +4, +6 and +28 days. Total no. of volunteers in Group 2b, n=9, where volunteers will be randomized in a 1:2 ratio to receive either NS placebo or PfSPZ Vaccine.~Efficacy will be assessed by CHMI at +3 weeks (+2 to +10 weeks) after the last dose of NS. CHMI will be by DVI of 3,200 PfSPZ Challenge."
2422380|NCT03420040|Experimental|QS-M Needle Free Injector group|To observe the use of insulin in glycemia under good blood glucose control in the QS-M Needle Free Injector group.
2422381|NCT03420040|Active Comparator|Glargine pen group|To observe the amount of insulin used by the Glargine pen group under good blood glucose control.
2422382|NCT03420014|Active Comparator|Arm 1: Doxorubicin|Patients will receive a fixed dose doxorubicin, administered as a 15 ± 5 minutes i.v. infusion.
2422383|NCT03420014|Experimental|Arm 2: L19TNF plus doxorubicin|"Patients will receive a fixed dose of L19TNF in combination with a fixed dose doxorubicin.~Doxorubicin will be administered as a 15 ± 5 minutes i.v. infusion on day 1 of each 21-day cycle followed by at least 30 minutes pause before starting infusion of L19TNF."
2422384|NCT03420001||VBAC|secundiparous women after one vaginal birth after caesarean section
2422387|NCT03419988|No Intervention|Control|8-weeks control: asked not to change anything or start exercising.
2422388|NCT03419975|Experimental|TJO-002|
2422389|NCT03419975|Active Comparator|latanoprost|
2422391|NCT03419936||Helicobacter pylori(HP) positive|Participants who are diagnosed with gastric cancer and Helicobacter Pylori infection will be treated with subtotal gastrectomy.
2422392|NCT03419923|Placebo Comparator|saline flushes|saline flushes with 250 mL were carried out every 30 min.
2422393|NCT03419923|Active Comparator|one stage regional citrate|one stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
2422394|NCT03419923|Experimental|two stage regional citrate|two stage regional citrate:4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
2422395|NCT03419910|Experimental|BMS-986165 and cyclosporine|BMS-986165 and cyclosporine administered orally
3146084|NCT00089921|Experimental|002|SCIO-469 60 mg capsule three times daily for 12 weeks
2422398|NCT03419858|Experimental|Mindfulness Meditation Group|"Subjects participated in four sessions (20 min/session) of mindfulness training. Participants were taught that perceived sensory events are momentary and fleeting and require no further evaluation. They were asked to close their eyes, relax and to focus on the flow of their breathing and simply let go of discursive thoughts."
2422399|NCT03419858|Active Comparator|Placebo Meditation Group|The purpose of this intervention was to lead subjects to attend to one's breathing in a non-evaluative manner. Subjects were instructed to sit with a straight posture, closed eyes, and to take a deep, slow breaths every 2-3 minutes.
2422400|NCT03419858|Active Comparator|Slow-Breathing Group|A validated (Chalaye et al., 2009) slow breathing training regimen was employed, using fluctuating light, to teach individuals to independently lower their respective respiration rate. Subjects practiced lowering their respiration rates across four, 20 minute sessions.
2422401|NCT03419845|Experimental|Step Right Buddy arm|To use modified walking frame using the Step Right Buddy
2422402|NCT03419832|Experimental|NEAT Form|Study participants will be randomized to the NEAT form and the materials that accompany it (also detailing the ARIC study).
2422403|NCT03419832|Active Comparator|Standard Form|Study participants will be randomized to the traditional standard consent form (detailing the ARIC study).
2422404|NCT03419819|Experimental|PKU Sphere|"Phase 1: 1 week To evaluate the acceptability of PKU Sphere during a short-term (1 week) period. Individuals with PKU will aim to consume a minimum of 30% of the medical food component of the diet as PKU Sphere. The amount will be assessed and advised on an individual basis.~Phase 2: 4 weeks To evaluate longer-term acceptability and metabolic control in individuals with PKU consuming an agreed target of 50 - 100% of their medical food component of the diet as PKU Sphere for 4 weeks. Some individuals, particularly young children between the ages of 3 - 6 years, may require a 1 - 3 week build up period to reach target volume which will be assessed on an individual basis."
2422405|NCT03419806|Experimental|Infudopa i.v.|"Infudopa i.v. in 75% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion.~From patient 6 and onwards:~Infudopa i.v. in 81% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion."
2422406|NCT03419806|Experimental|Infudopa s.c.|"Infudopa s.c. in the same dosage as the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion.~From patient 6 and onwards:~Infudopa s.c. in 86% of the subject's individual pre-study dosing of Duodopa will be delivered over a 16-h period, administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion."
2422407|NCT03419806|Active Comparator|LCIG (Duodopa)|Individually optimized dosing of LCIG (Duodopa) (delivered directly to the proximal small intestine via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube connected to a portable infusion pump) will be delivered over a 16-h period, administered as a morning rapid constant rate administration followed by continuous infusion.
2422408|NCT03419793|Experimental|physical therapy intervention and segmental muscle vibration|physiotherapy intervention and segmental muscle vibration device
2422409|NCT03419793|Sham Comparator|physical therapy intervention|physical therapy intervention alone
2422412|NCT03419767|Active Comparator|surgery with melatonin|Patients under carotid revascularization surgery with melatonin taken during perioperative period.
2422413|NCT03419767|Sham Comparator|surgery with blank control|Patients under carotid revascularization surgery with nothing unnecessary taken during perioperative period
2422414|NCT03419754|Experimental|Glucose and Fidgetting|75 g of glucose will be given at the beginning of the study day (days one with glucose+fidgeting )
2422415|NCT03419754|Placebo Comparator|Fidgetting|Subjects will fidget their legs in an up and down motion for 2.5 min on and then 2.5 min off for the duration of the study.
2422416|NCT03419741|Active Comparator|Active rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System will be used for the active rTMS treatment. Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% resting motor threshold, Total 60 trains, 15 minutes, Total pulses 3000 per day, 3000 x 5 = 15000 pulses for 5 sessions.
2422455|NCT03419468|Experimental|1|iPad administration of Self Geriatric Assessment Measure (SGAM)
2422456|NCT03419468|Active Comparator|2|Paper survey administration of Self Geriatric Assessment Measure (SGAM)
3146085|NCT00089921|Experimental|003|SCIO-469 100 mg tablet once daily for 12 weeks
3146086|NCT00089921|Placebo Comparator|004|Placebo 2 capsules three times daily and one tablet daily
3146087|NCT00089960|Other|Arm|AMG 125 mg daily continuously
3146088|NCT00090025|Experimental|becatecarin|becatecarin
3146089|NCT00090025|Active Comparator|5-FU Plus Leucovorin (LV)|5-Fluorouracil (5-FU) Plus Leucovorin (LV)
3146090|NCT00090038|Experimental|1|Rituximab
2422417|NCT03419741|Sham Comparator|Sham rTMS treatment|Transcranial Magnetic Stimulation Clinical Research System -sham TMS will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
2422418|NCT03419728|Experimental|Healthy Families, Healthy Futures|Family coaches meet with participating pregnant and parenting females, the woman's partner, and the child. Visit frequency varies from once per week to once per month, depending on the length of time in the program, the client's needs, and the accomplishment of program milestones. In the short term, the program seeks to increase the use of Long-Acting Reversible Contraception (LARC), enhance family functioning including improving father involvement, and to meet the baby's child development needs. In the long term, the program aims to delay subsequent pregnancies, ensure positive child development, and increase parents' self-sufficiency.
2422419|NCT03419728|No Intervention|Control group|"No active treatment for control group. Control group has access to business as usual services in community."
2422420|NCT03419715|Experimental|Bimatoprost Topical Solution|0.03% bimatoprost topical solution applied daily to the nail bed of fingers on one hand for 12 weeks
2422421|NCT03419715|Placebo Comparator|Control|Saline placebo topically applied daily to the nail be of fingers on one hand for 12 weeks
2422422|NCT03419702|No Intervention|Control|No almonds
2422423|NCT03419702|Experimental|Experimental|Almonds
2422425|NCT03419676|No Intervention|Control|No reinforcement.
2422426|NCT03419676|Experimental|Hemopatch|Reinforcement with Hemopatch.
2422427|NCT03419663||gastric cancer|
2422428|NCT03419650|Other|Treatment arm|treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.
2422429|NCT03419637|No Intervention|Control - Standard of Care|The standard of care consists of in-clinic counseling, informational handouts, and access to patient medical records
2422430|NCT03419637|Experimental|Intervention - Mobile app|The mobile app, or app, is used to document before and after photos of the excised skin areas and to document related diagnoses. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
2422431|NCT03419624|Experimental|Dapagliflozin plus Exenatide|Dapagliflozin (10mg orally once daily) plus Exenatide (2mg subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
2422432|NCT03419624|Placebo Comparator|Placebo plus Placebo|Placebo (film-coated tablet once daily) plus Placebo (subcutaneous once-weekly injection) as add-on to high-dose intensive insulin therapy
2422433|NCT03419624|Active Comparator|Placebo plus Exenatide|Placebo (film-coated tablet once daily) plus Exenatide (2mg subcutaneous once- weekly injection) as add-on to high dose intensive insulin therapy
2422434|NCT03419611|Experimental|Multi-Modal|3 Times Per Week for 4 weeks - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component followed by more treatment for 12 weeks
2422435|NCT03419611|Experimental|Multi-Modal + High Intensity Multi-Modal|3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 4 weeks, increasing to 5 times per week for 12 weeks
2422436|NCT03419611|Placebo Comparator|Treatment as Usual|Teacher provided with word list for 4 weeks followed by more treatment as usual for 12 weeks
2422437|NCT03419611|Experimental|Treatment as Usual + Multi-Modal|Teacher provided with word list for 4 weeks followed by 3 Times Per Week - Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 12 weeks
2422438|NCT03419611|Experimental|Treatment as Usual + High Intensity Multi-Modal|Teacher provided with word list for 4 weeks followed by Speech sound practice, Joint book reading, AAC activity, Computerized instruction component for 5 times per week for 12 weeks
2422440|NCT03419585|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
2422441|NCT03419585|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for the course of radiation therapy (approximately 8 weeks).
3146091|NCT00090038|No Intervention|2|No drug
3146092|NCT00090129|Experimental|Onercept|
2422444|NCT03419559|Experimental|LN-145 in combination with durvalumab|After nonmyeloablative (NMA) lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
2422445|NCT03419546||Bronchoscopic procedures|Bronchoscopies performed in different sites to evaluate the level of satisfaction of the operators with the device Ambu® aScope™ 4
3146093|NCT00090129|Placebo Comparator|Placebo|
3146094|NCT00090194|Experimental|Low Dose|0.5 gm/kg at 5 days pre-transplant and 7 days post-transplant
2422448|NCT03419520|Experimental|Intervention group|Schools receive healthy actions aimed to reduce the risk of developing obesity, along the study
2422449|NCT03419520|No Intervention|Control group|Schools monitored along the study but won't receive any healthy action.
2422450|NCT03419507|Active Comparator|Macintosh group|After separating participants into two groups, doctors that drawed envelop number 1 will be asked to intubate with laryngoscope by using No. 3 Macintosh laryngoscope
2422451|NCT03419507|Active Comparator|Endotracheal tube introducer group|After separating participants into two groups, doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by using the adult size endotracheal tube introducer with using No. 3 Macintosh laryngoscope.
2422452|NCT03419494||VDCLD regimen containing PLD|PLD 36mg/㎡.d d1、d15，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
2422453|NCT03419494||VDCLD regimen containing DNR|DNR 45mg/㎡.d d1～3，ivdrip，1h，VCR 1.4mg/㎡.d d1，d8，d15，d22 iv，CTX 800mg/㎡.d d1 ivdrip，L-asp 6000u/㎡.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
3146095|NCT00090194|Experimental|Middle Dose|1.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
3146096|NCT00090194|Experimental|High Dose|2.0 gm/kg at 5 days pre-transplant and 7 days post-transplant
2422457|NCT03419442||Ra-223 therapy before chemotherapy|Treatment sequence 1 will include all mCRPC patients who received Ra-223 alone or in combination with abiraterone or enzalutamide and subsequently received chemotherapy
2422458|NCT03419442||Ra-223 after chemotherapy|Treatment sequence 2 includes all mCRPC patients who received chemotherapy before Radium 223 therapy
2422459|NCT03419429|Experimental|Simvastatin/Occlusive membrane|open flap procedure, 1.2%simvastatin gel applied and covering the defect with resorbable collagen occlusive membrane .
2422460|NCT03419429|Experimental|Simvastatin/perforated membrane|open flap procedure, 1.2% simvastatin gel and covering the defect with resorbable collagen modified perforated membrane.
2422461|NCT03419429|Experimental|EDTA/Simvastatin/Occlusive membrane|open flap procedure, 24% EDTA root surface etching,1.2% simvastatin gel and then coverage of the defect with occlusive membrane.
2422462|NCT03419429|Experimental|EDTA/Simvastatin/perforated membrane|open flap procedure, 24% EDTA root surface etching, 1.2% simvastatin gel and then coverage of the defect with modified perforated membrane.
3186912|NCT00750334|Experimental|Part B|Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.
3186913|NCT00750386|Experimental|1|Paclitaxel/Carboplatin
3186914|NCT00750399|Experimental|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab on a monthly basis depending on response to treatment
2422466|NCT03419390|Other|Healthy subjects|One eye of each participant will be scanned with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
2422467|NCT03419390|Other|Diseased groups|lf one eye is affected, this will be chosen. lf both eyes are be affected, the eye with the severest symptoms will be chosen. Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)
2422468|NCT03419390|Other|Diseased subgroups|"Every second subject will be allocated to the subgroup.~Scanning with the investigational device (= combined Coaxial Optical Coherence Tomography (OCT) System)~Thickness measurement with reference medical device."
2422469|NCT03419377|Experimental|Standard care and sexological counseling|Standard care including gynecological examination and 6-8 sexological consultations.
2422470|NCT03419377|No Intervention|Standard care|Standard care including gynecological examination.
2422471|NCT03419364|Experimental|Nicotinamide|All participants will receive study agent
2422472|NCT03419351|Other|Main group|Main study group including all individuals that underwent the study procedures
2422473|NCT03419338|Experimental|Test group|Surgical alveolus + maxillary sinus lift with inorganic bovine bone + newly forming bone + collagen membrane
2422474|NCT03419338|Active Comparator|Control group|Maxillary sinus lift with inorganic bovine bone + collagen membrane
2422475|NCT03419325|Experimental|HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of both high on-treatment platelet reactivity (HTPR) and CYP2C19 loss-of-function (LOF) alleles:~An alternative therapy with either prasugrel or ticagrelor (in line with specific contraindications and precautions for each agent) will be strongly recommended for HPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2422476|NCT03419325|Experimental|HTPR/no-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of HTPR, but no CYP2C19 LOF allele found:~An alternative therapy should be considered for HTPR/no-LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2422477|NCT03419325|Experimental|no-HTPR/LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Presence of a CYP2C19 LOF allele, but no HTPR:~An alternative therapy should be considered for no-HTPR/LOF patients, within next 5-7 days. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2422478|NCT03419325|Experimental|No-HTPR/No-LOF|"Intervention: Genotyping (CYP2C19 assay) and P2RY12 testing to make decision on therapy.~Absence of both HTPR and CYP2C19 LOF alleles:~Maintaining clopidogrel for no-HPR/no-LOF patients. Changes in DAPT will be at the discretion of the clinician. Treatment strategies and clinical outcomes will be evaluated up to 6-months."
2422479|NCT03419312|Experimental|Study sequence A|"Proclaim™ Elite 5: Burst - Washout - Sham~14 days of burst stimulation.~7 days washout.~14 days of sham stimulation."
2422480|NCT03419312|Experimental|Study sequence B|"Proclaim™ Elite 5: Sham - Washout - Burst~14 days of sham stimulation.~7 days washout.~14 days of burst stimulation."
2422481|NCT03419299||Pre- Application|Patients admitted prior to use of tube feeding application
2422482|NCT03419299||Post- Application|Patients admitted when tube feeding application was being used.
2422483|NCT03419286||EGFR MUTATED|patient with lung cancer with EGFR mutation before transformation into small cell lung cancer
2424944|NCT03401775|No Intervention|Group2|No intervention will be administered
3186915|NCT00750412|Experimental|TeenScreen|
3186916|NCT00750412|No Intervention|Treatment As Usual|
3186917|NCT00750425|Experimental|1|Cediranib alone, followed by cediranib plus ketoconazole, followed by cediranib alone
3186918|NCT00750451|Experimental|LMWH|Women in the LMWH arm are administered 1 mg/kg/day subcutaneously low molecular weight heparin after oocyte collection in addition to routine luteal phase support with vaginal progesterone
3186919|NCT00750451|Active Comparator|Control|Women in the control arm are administered routine luteal phase support without the addition of LMWH
3186920|NCT00750477|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 8 weeks
3186921|NCT00750477|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 8 weeks
3186922|NCT00750516||Lacid|Hypotensive, non pregnant by history, non comfort care Emergency Department patients.
3186923|NCT00750529|Experimental|Galantamine|
3186924|NCT00750568||Group 1|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages 2 years to 6 years"
3186925|NCT00750568||Group 2|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 6 years to 12 years"
2422484|NCT03419286||EGFR NON MUTATED|patient with lung cancer without driver oncogenic before transformation into small cell lung cancer
2422485|NCT03419260||Cohort|Critically ill child undergoing clinically indicated EEG monitoring and electrographic seizure management.
2422486|NCT03419247|Experimental|Tumor tissue and blood sample collection|
2422491|NCT03419208|Experimental|SPIN-HAND Program|Offered the SPIN-HAND program
2422492|NCT03419208|No Intervention|Treatment as usual|Not offered SPIN-HAND program, treatment as usual
2422493|NCT03419195|Experimental|Type 2 diabetes|Men and women between the ages of 30-55 with well controlled type 2 diabetes (A1C <9%).
2422494|NCT03419195|Experimental|Healthy overweight controls|Men and women between the ages of 30-55 with BMI 25-40 and limited immediate family history of type 2 diabetes.
2422495|NCT03419182|Active Comparator|RCT - ORIF|A patient in this study arm consents to randomization and receives RCT - ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation.
2422496|NCT03419182|Active Comparator|RCT - (THA) + ORIF|A patient in this study arm consents to randomization and receives RCT - (THA) + ORIF as his/her treatment assignment. He/she will have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
2422497|NCT03419182|No Intervention|OBS - ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation.
2422498|NCT03419182|No Intervention|OBS (THA) + ORIF|A patient in this study arm does not consent to randomization, but does agree to be involved in the observational study. He/she decides, with input from his/her surgeon, to have his/her acetabular fracture treated by open reduction internal fixation with primary total hip arthroplasty.
2422499|NCT03419169|Experimental|Light load BFR resistance training|This arm of the clinical trial will involve eight weeks of twice weekly light load resistance training with BFR. Patients in this arm will complete four sets (30, 15, 15 and 15 repetitions, respectively) of unilateral leg press exercise at 30% of predicted one repetition maximum. BFR will be applied at 80% of total limb arterial occlusive pressure. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum. Both legs will be trained with BFR.
2422500|NCT03419169|Active Comparator|Heavy load resistance training|This arm of the clinical trial will involve eight weeks of twice weekly heavy load resistance training. Patients in this arm will complete three sets of ten repetitions of unilateral leg press exercise at 70% of predicted one repetition maximum. Both legs will be trained, with the affected limb trained first and the unaffected limb matched for volume at a relative percentage of one repetition maximum.
2422501|NCT03419156|Experimental|Text Message Arm|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
2422502|NCT03419143||Cohort 1|naïve of abatacept, other biologic agents and Targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs)
2422503|NCT03419143||Cohort 2|"naïve of abatacept, who previously failed one tumor necrosis factor inhibitor (TNFi), but are naïve of any other biologic agent and tsDMARDs"
2422504|NCT03419143||Cohort 3|naïve of abatacept, who previously failed treatment with tsDMARDs and/or biologic agents** other than a single TNFi
2422505|NCT03419130|Experimental|Cohort I (pembrolizumab, hypofractionated RT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity. Patients also receive hypofractionated RT over 5 fractions for 14 days.
2422506|NCT03419130|Experimental|Cohort II (pembrolizumab, conventionally fractionated RT)|Patients receive pembrolizumab as in Cohort I. Patients also receive conventionally fractionated RT over 30 fractions for 52 weeks.
2422507|NCT03419117|Experimental|Treatment|Patients in the experimental arm will receive an ESP block prior to induction of general anesthetic for their thoracoscopic wedge resection
2422508|NCT03419117|Placebo Comparator|Placebo|Patients allocated to the placebo-control arm will receive a placebo injection of normal saline in a fashion almost identical to that of the ESP block.
2422509|NCT03419104|Experimental|Preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
2422510|NCT03419091|Active Comparator|Reusable Ureteroscope|Standard ureteroscope.
2422511|NCT03419091|Experimental|single-use flexible digital ureteroscope (LithoVue)|Disposable ureteroscope being tested.
2422512|NCT03419065|Other|Relaxation Intervention|Women hospitalized on bed-rest for high risk pregnancy participated in Relaxation Interventions.
2422513|NCT03419052|Experimental|MINDSpeed Intervention|Consumption of foods high in polyphenols (i.e., MIND foods) AND speed of processing training
2422514|NCT03419052|Active Comparator|MIND food and training control|Consumption of foods high in polyphenols (i.e., MIND foods) AND online (inert) games
2422515|NCT03419052|Active Comparator|Control foods and speed of processing training|Consumption of low polyphenol foods AND speed of processing training
2422516|NCT03419052|Sham Comparator|Double Control|Consumption of low polyphenol foods AND online (inert) games
2422517|NCT03419039|Experimental|Anthocyanins|Medox. 2 capsules x 2 daily, 320 mg daily.
2422518|NCT03419039|Placebo Comparator|Placebo|2 identically appearing placebo capsules daily
2422519|NCT03419026||breast cancer|
2422520|NCT03419026||control|
2422521|NCT03419013|Experimental|Test of new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation
2422522|NCT03419000|Experimental|Patient|Patients suffering from drug-resistant focal epilepsy or from drug-resistant generalized epilepsy according to ILAE classification and undergoing long-term video-EEG monitoring in Epilepsy unit of Lyon to record and characterize her/his seizure
2422523|NCT03419000|Active Comparator|healthy volunteers|Adult (≥ 18 years) Without history of neurological disorders and/or psychiatric disorders, and/or general medical disorders
2422524|NCT03418987||Deformities of the spinal column|Patients with adolescent idiopathic scoliosis or adult degenerative scoliosis, treated or untreated.
2422525|NCT03418974|Experimental|Pitavastatin treatment|The drug pitavastatin is given to the patient according to the doctor's order and restricted to BangZhi produced by Jiangsu Wanbang Medicine Marketing Co., Ltd..
2422526|NCT03418974|Experimental|Atorvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
2422527|NCT03418974|Experimental|Rosuvastatin treatment|The drug atorvastatin is given to the patient according to the doctor's order and the drug band is unspecified.
3146097|NCT00090337|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks.
3146098|NCT00090337|Active Comparator|Arm II|Patients undergo standard of care for 4 weeks.
3146099|NCT00090415|Experimental|1|Child participants with autism will undergo intensive behavioral therapy.
2422531|NCT03418948|Active Comparator|2 x CC|2 x conventional colonoscopy (CC), back-to-back design
2422532|NCT03418948|Active Comparator|CC followed by EC|Conventional colonoscopy followed by Endocuff Vision- assisted colonoscopy, back-to-back design
2422533|NCT03418948|Active Comparator|EC followed by CC|Endocuff Vision-assisted colonoscopy followed by conventional colonoscopy, back-to-back design
2422534|NCT03418948|Active Comparator|2 x EC|2 x Endocuff Vision-assisted colonoscopy
2422535|NCT03418935|Experimental|Remaxol 400 ml|Group I: treatment with Remaxol 400 ml IV + Ringer solution 400 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2422536|NCT03418935|Experimental|Remaxol 800 ml|Group II: treatment with Remaxol 800 ml IV for 7 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2422537|NCT03418935|Placebo Comparator|Control|Group III: Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
2422538|NCT03418922|Experimental|Part 1: Lenvatinib Plus Nivolumab|Participants will receive specified doses of lenvatinib (oral) and nivolumab (intravenous) on specified days.
2422539|NCT03418922|Experimental|Part 2: Lenvatinib Plus Nivolumab|If tolerable in Part 1, participants will receive specified doses of lenvatinib and nivolumab on specified days until criteria for discontinuation are met.
2422540|NCT03418909||Oropharyngeal carcinoma (excluding M+ stage)|"Eligible patients with histologically verified early stage squamous cell carcinoma of the oropharynx.~Patients will be treated in accordance with current hospital protocols with transoral robotic surgery (T1-2, N1, M0) or radio(chemo)therapy (any T-stage, any N-stage, M0)."
2422541|NCT03418896|Experimental|human chorion gonadotropin|Pregnyl, hCG, 5000 IU times one im.
2422542|NCT03418883|Experimental|Mirror therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A mirror (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The reflective surface is oriented so that the participant could easily see the mirror image of his/her sound arm. Patient practises his/her sound arm with exercises, ranging from the simple elbow flexion-extension to complex tasks.
2422543|NCT03418883|Sham Comparator|Sham therapy|Patient is sitting on a conventional chair and placed her/his forearms on a table. A box (45 cm × 40 cm) is positioned between the two arms, at right angle with the patient's trunk. The opaque surface replaces the mirror reflecting surface. Patient practises his/her sound arm with exercises,ranging from the simple elbow flexion-extension to complex tasks.
2422544|NCT03418870|Experimental|Family Integrated Care (mFI-Care)|Parents of infants assigned to the Family Integrated Care (mFI-Care) intervention will be treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches. Parent training on the Canadian FI-Care Parent Curriculum will be provided during small group sessions facilitated by the study team. Parents will receive peer support from mFI-Care-trained alumni parents and can interact with other mFI-Care parents through the We3Health App secure online parent forum. mFI-Care parents will be expected to track time spent with their infant; record infant activity, feeds and output; track learning and skills acquisition; and keep a journal of the NICU experience using the We3Health app.
2422545|NCT03418870|No Intervention|Family-Centered Care (FCC)|Infants assigned to usual FCC will have NICU nurses as primary caregivers per standard NICU protocol. FCC provides parents with orientation to the NICU; individualized teaching and support; and encouragement to participate in infant care under nursing supervision. Individualized support from social workers, lactation consultants and other specialists will be offered. As part of the study, parents will be asked to use the We3Health mobile app track their time in the NICU, time learning and time spent in infant caregiving activities and to keep of a journal of their NICU experience.
2425247|NCT03399825||Retinopathy of prematurity (ROP)|Previously preterm children with a history of ROP
3146100|NCT00090415|No Intervention|2|Child participants without autism will receive no treatment and will undergo assessments to determine brain functioning only.
2422548|NCT03418844|Other|Interest group (patients treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
2422549|NCT03418844|Other|Patient control group (patients not treated with chemotherapy)|Patients will complete several self-questionnaires on living conditions and quality of life. They will also perform a cardiac, pulmonary, auditory and biological assessment
2422550|NCT03418844|Other|Healthy volunteers|Healthy volunteers will complete several self-questionnaires on living conditions and quality of life.
2422551|NCT03418831|Active Comparator|Raloxifene|Raloxifene Hydrochloride
2422552|NCT03418831|Placebo Comparator|Placebo|placebo tablet
2422553|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fasting|One tablet of IBUCR 600 mg under fasting condition
2422554|NCT03418805|Experimental|Ibuprofen CR Tablet 600 mg-fed|One tablet of IBUCR 600 mg under fed condition
2422555|NCT03418805|Active Comparator|Advil Ibuprofen table 200 mg-fasting|IBUAdv with a 4-hour dosing interval for 3 tablets (3×200 mg, q4h) under fasting condition
2422556|NCT03418805|Active Comparator|Motrin IB Ibuprofen Tablets 200 mg-fasting|IBUMot with a 4-hour doing interval for 3 tablets (3×200 mg, q4h) under fasting condition
3146101|NCT00090428|Experimental|1|Participants will follow a gluten-free and casein-free diet for 18 weeks. The compliance with the diet was monitored with 24 hour dietary recall and nutritional sufficiency with diet diary analysis.
2422558|NCT03418779|Experimental|Control Group|Optimized supportive care, YQF placebo (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
2422559|NCT03418779|Experimental|YQF Group|Optimized supportive care, YQF (oral granule), immunosuppression therapy comprises oral prednisolone plus intravenous cyclophosphamide.
2422560|NCT03418766||Normal|Normal healthy individual without migraine.
2422561|NCT03418766||Magraine|Clinical history of migraine diagnosed by a neurologist according to the International Classification of Headache Disorders.
2422562|NCT03418753||single|subjects with abnormal intracranial pressure
2422563|NCT03418740||FA Children|Children between the ages of 2 and 18 with genetically confirmed Friedreich's Ataxia
2422564|NCT03418727|Experimental|Study Drug Arm #1|Combination Therapy: brimonidine (0.2%) administered as eye drops, followed by corticosteroid eye drops, two times a day (BID) for 12 weeks
2422565|NCT03418727|Experimental|Study Drug Arm #2|Monotherapy: brimonidine (0.2%) administered as eye drops followed by placebo, two times a day (BID) for 12 weeks
2422566|NCT03418727|Placebo Comparator|Control Arm|Placebo: sodium carboxymethylcellulose (0.25%) administered as eye drops followed by a second application, two time a day (BID) for 12 weeks
2422570|NCT03418688|Active Comparator|COR388|Increasing doses of COR388 will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
2422571|NCT03418688|Placebo Comparator|Placebo|Matching placebo capsules will be administered for 10 days in cohorts 1-3 and for 28 days in cohort 4.
2422572|NCT03418675|Placebo Comparator|Placebo|1 milligram per day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
2422573|NCT03418675|Experimental|Rexulti|1 milligram per day day for the first week and 1 milligram per day for the final taper week 2 milligrams per day for 10 weeks between taper periods.
3146102|NCT00090428|Active Comparator|2|After established on a gluten free and casein free diet for at least 6 weeks, participants received double blind, placebo controlled challenges containing gluten, casein, gluten+casein, or placebo in a random order. Data was collected on behavioral and physiologic responses relative to the challenges. Children remained on the gluten free and casein free diet throughout this period.
3146103|NCT00090480|Experimental|Vaccine group|
2422578|NCT03418636|Experimental|Staying Safe (Ssafe)|"Ssafe is delivered in a small group format (consisting of approximately 10-12 participants) by a trained facilitator over 4 2.5-hour sessions (10 hours total). To help promote the maintenance of risk reduction over the trial's 12-month follow-up period, Ssafe participants will be provided with a novel interactive, smartphone-delivered booster application based on core Ssafe principles and risk reduction strategies."
2422579|NCT03418636|Active Comparator|Healthy Living|Healthy Living is a time- and attention-matched control intervention of equivalent session structure and duration as Ssafe (4 2.5-hour sessions; 10 hours total), also delivered in a small group format (10-12 participants). Healthy Living participants will be provided with a publicly available, sleep hygiene-focused smartphone app to promote healthy sleep habits over the trial's follow-up period.
2425248|NCT03399825||Diabetic retinopathy|Children with diabetes
3146104|NCT00090571||Sib Pairs|Two or more biological siblings affected with JIA.
2422580|NCT03418623|Experimental|GET73|GET73 is administered at the dose of 300 mg t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of GET73: 3 capsules of GET73 on the first day of the related phase, according to randomization, and 2 capsules on the second day of each phase.
2422581|NCT03418623|Placebo Comparator|Placebo|Placebo is administered t.i.d. per day, with a minimum gap of 4 hours between administrations and a maximum gap of 9 hours. Each subject ingests a total of 5 capsules of Placebo: 3 capsules of Placebo on the first day of the related phase, according to randomization, and 2 capsules on the second day.
2422582|NCT03418610|Other|Open Label Single Arm|Azelaic Acid Foam 15% applied twice daily
2422583|NCT03418597|Experimental|Deep local anesthesia + Virtual reality|Pre-medication procedures and lidocaïne injection are the same as in the current practice. During the intervention delay, the patient will also experience hypnosis through a virtual reality procedure .
2422584|NCT03418597|Active Comparator|Deep local anesthesia alone|The musculoskeletal biopsy is performed according to the standard practice using a deep local anesthesia with premedication and lidocaïne.
2422585|NCT03418584|Experimental|HybridAPC|The patient with Barrett's esophagus is treatment by HybridAPC.
3186926|NCT00750568||Group 3|"In-patient in the Pediatric Intensive Care Unit~Diagnosis of Status asthmaticus~Receiving a continuous infusion of terbutaline as part of their standard of care~Ages greater than 12 years to 18 years"
3186927|NCT00750581|Placebo Comparator|Standard dose group|The infants randomized to the standard dose group will receive indomethacin (0.1 mg/kg) at 24 hr intervals for 5 days. These infants will also receive 5 extra doses of normal saline infusion of similar volume at 12 hrly intervals between the indomethacin schedules to match the Escalating dose Indomethacin Schedule
2422588|NCT03418558|Experimental|HERACLES RESCUE|Patients will receive trastuzumab-emtansine, iv 3,6 mg/kg every 21 days. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first
2422589|NCT03418532|Experimental|single arm|MP0250 DARPin® drug candidate (6 mg/kg or 8 mg/kg or 12 mg/kg, infusion) on day 1 of each 21 day cycle. Osimertinib according to label
2422590|NCT03418519|Experimental|CIMT group|"Two-hour mCIMT per day for 15 days (dosage = 30 hours)~24-hour restraint for 3 weeks"
2422591|NCT03418519|No Intervention|Control group|no CIMT
2422592|NCT03418506|Experimental|Intervention|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
2422593|NCT03418506|No Intervention|Control|No specific education will be given to the control group.
2422594|NCT03418493|Experimental|LY3316531 (Part A)|LY3316531 administered IV and/or SC.
2422595|NCT03418493|Placebo Comparator|Placebo (Part A)|Placebo matching LY3316531 administered IV.
2422596|NCT03418493|Experimental|LY3316531 (Part B)|LY3316531 administered IV and/or SC.
2422597|NCT03418493|Placebo Comparator|Placebo (Part B)|Placebo matching LY3316531 administered IV and/or SC.
2422598|NCT03418493|Experimental|LY3316531 (Part C)|LY3316531 administered IV and/or SC.
2422599|NCT03418480|Experimental|RNA Vaccine A|Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.
2422600|NCT03418480|Experimental|RAN Vaccine B|Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.
2422601|NCT03418467||tachycardiomyopathy|Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.
2422602|NCT03418467||dilated cardiomyopathy|Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.
2422603|NCT03418454||Oral Squamous Cell Carcinoma|Buccal mucosa samples for Extraction of BACTERIAL DNA
2422604|NCT03418454||Oral Epithelial Dysplasia|Buccal mucosa samples for Extraction of BACTERIAL DNA
2422605|NCT03418454||Control: Healthy age matched patients|Buccal mucosa samples for Extraction of BACTERIAL DNA
2422606|NCT03418454||Osteonecrosis of the Jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
2422607|NCT03418454||Underlying disease, no necrosis of the jaw|Buccal mucosa samples for Extraction of BACTERIAL DNA
2422608|NCT03418428||Test group|Patients who underwent total or subtotal gastrectomy for the treatment of gastric cancer
2422609|NCT03418428||Control group 1|Patients who underwent endoscopic mucosal resection/submucosal dissection for the treatment of gastric cancer
2422610|NCT03418428||Control group 2|In-house relatives of Test group and Control group 1 participants
2422611|NCT03418428||Control group 3|Patients with long-term history of proton pump inhibitor usage
2422612|NCT03418415|Experimental|Renal denervation|Procedure: Renal denervation
2422613|NCT03418402|Experimental|Airseal®|Low pression laparoscopy with a 8 to 10 mmHg pneumoperitoneum.
2422614|NCT03418402|Active Comparator|Standard insufflator|laparoscopy realised with our usual insufflation system and a 12 to 15 mmHg pneumoperitoneum.
2422615|NCT03418389||Pediatric-onset Hypophosphatasia|
2422620|NCT03418363|Active Comparator|DHEA Oral Capsule|Subjects will take 100mg DHEA (dehydroepiandrosterone) daily
2422621|NCT03418363|Placebo Comparator|Placebo Oral Capsule|
2422652|NCT03418129|Experimental|Mobile App Neurofeedback|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2422776|NCT03417310|Experimental|"H joystick"|"Patients are treated with the H joystick on a traction table"
2422622|NCT03418337|Experimental|dexilansoprazole group (Dexilant 60 mg)|After randomization, 60 subjects will receive oral dexlansoprazole (Dexilant 60 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
2422623|NCT03418337|Active Comparator|lansoprazole group (Takepron OD 30 mg)|After randomization, 60 subjects will receive oral lansoprazole (Takepron OD 30 mg, Takeda Co. Ltd, Tokyo, Japan) once daily before breakfast for 8 weeks. Subjects will record their symptoms (cough, globus, NCCP, heart burn, and acid regurgitation) at daytime and nighttime everyday for 8 weeks. Symptoms suspecting drug adverse effect including nausea, diarrhea, constipation, headache, dizziness, fatigue, flatulence, etc will be recorded for 8 weeks.
3186928|NCT00750581|Active Comparator|Escalating dose group|The infants randomized to the Escalating dose group will receive indomethacin started at 0.2 mg/kg/dose every 12 hours for 2 doses with stepwise increment in indomethacin dose by 0.1 mg/kg/dose every 24 hours upto maximum dose of 0.6 mg/kg/dose
3186929|NCT00750594||1|
2422626|NCT03418311|No Intervention|Control-Group|Control-group-women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications.
2422627|NCT03418311|Experimental|Cervical Pessary-Group|placement of the cervical pessary (non-invasive) at enrollment; removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37.
2422628|NCT03418298|Experimental|Prehabilitation group|Subjects will carry out a preoperative internet-based program including aerobic and resistance training three sessions per week
2422629|NCT03418272||Ventilated Pediatric Intensive Care Unit patient Group|This will be a prospective descriptive case series where tracheal cultures and PCR results will be analyzed at initial intubation and again several days into the ICU stay.
2422630|NCT03418272||Intubated OR patient Control Group|For the healthy operating room children, also a case series where a single set of studies will be obtained. tracheal cultures and PCR results will be analyzed after intubation These two groups will be compared, non-randomized.
2422631|NCT03418259|Experimental|Active KCS Medical Device|
2422632|NCT03418259|Placebo Comparator|Inactive KCS Medical Device|
2422633|NCT03418246|Sham Comparator|GIC filling|"Intervention/treatment One group will be treated with a tooth colored filling that will be placed near the gum line (Glass Ionomer).~Placebo Comparator: GIC~Participants will have a restoration placed with GIC in the lesion near the gum line. Device: GIC Application of a tooth colored filling in the cavitated dental lesion. Other Name: Resin modified glass ionomer"
2422634|NCT03418246|Experimental|Biodentine filling|"Intervention/treatment The second group will be treated with Biodentine that will be placed near the gum line.Experimental: Biodentine~Participants will have a restoration placed with Biodentine in the lesion near the gum line. Device: Biodentine Application of a white colored filling in dental lesion."
2422635|NCT03418233|Active Comparator|Active Group|"Patients randomized to the active treatment group: Transcoronary or trans-bypass graft administration of CardioCell consist 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin) will be performed using a dedicated cell delivery catheter.~The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
2422636|NCT03418233|Placebo Comparator|Control Group|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
2422637|NCT03418220|Other|AMD early / intermediate|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD early / intermediate
2422638|NCT03418220|Other|AMD exudative|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD exudative
2422639|NCT03418220|Other|AMD atrophic|A blood and aqueous humor sample will be taken during cataract surgery in patients with AMD atrophic
2422640|NCT03418220|Other|control group|A blood and aqueous humor sample will be taken during cataract surgery in patients with cataract (control group)
2422641|NCT03418207|Other|TTMB for patients|give trans-perineal template-guided mapping biopsy for participants suspected prostate cancer
2422642|NCT03418194|Experimental|TAES group|Patients in group TAES group received transcutaneous acupoint electrical stimulation (disperse-dense waves, frequency 4/20Hz) at the points of PC6 (Neiguan) and PC4 (Ximen) from 30 min before anesthesia induction to the end of surgery,
2422643|NCT03418194|Placebo Comparator|control group|Patients in group C received electrode plate atthe points of PC6 (Neiguan) and PC4 (Ximen) without any electrical stimulation.
2422644|NCT03418181|Other|Standard Haemodialysis|Thrice weekly dialysis (control arm) - dialysis dose will not be adjusted according to Residual Kidney Function and subjects will be dialysed initially for 3.5-4 hours thrice weekly to ensure a target minimum eKt/V of 1.2.
2422645|NCT03418181|Experimental|Incremental dialysis|"Twice weekly dialysis - dialysis dose will be adjusted according to Residual Kidney Function.~Patients will commence dialysis for 3.5-4 hours twice weekly and have residual renal urea clearance formally measured by interdialytic urine collection at the end of the week following dialysis initiation. Subsequent to this, dialysis dose will be adjusted."
2422646|NCT03418168|Experimental|Molidustat (BAY85-3934)|Molidustat group
2422647|NCT03418155|Experimental|Treatment of TongBi Capsule|
2422648|NCT03418155|Placebo Comparator|Treatment of TongBi Placebo|
2422649|NCT03418142|Experimental|Priovi|Priovi is an Internet-administered intervention for people with BPD.
2422650|NCT03418142|Active Comparator|Care-as-Usual (CAU) / wait list|Additionaly, they will be informed about helpful and free available online self-help-proposals for BPD patients immediately after randomization.
2422651|NCT03418129|Experimental|Mobile App Mindfulness|Participants engage in the use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2422774|NCT03417323|Experimental|Compressive garment|Groups wear compression garment after WB-EMS induced muscle soreness
3186930|NCT00750594||2|
2422653|NCT03418129|Experimental|Mobile App Relaxation|Participants engage in use of a mobile application on an iPod Touch for a minimum of 10 minutes a day, 4 days a week for a total of 12 weeks.
2422654|NCT03418116|Experimental|Argus II|"Implantation of the Argus II Retinal Prosthesis in patients with advanced Retinitis Pigmentosa who have a measurable central residual visual field smaller than or equal to 5 degrees radius. The array will be placed parafoveally, adjacent to the preserved central visual field (i.e., tunnel vision) in these subjects."
2422655|NCT03418090|Active Comparator|Arm 1|Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy
2422656|NCT03418090|Active Comparator|Arm 2|Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI
2422657|NCT03418077|Experimental|energy drink|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
2422658|NCT03418077|Placebo Comparator|Placebo-control|Participants will serve as their own controls and have repeated measures obtained to determine if there is a difference between the placebo-control and energy drink arms
3186931|NCT00750620|Experimental|1. Severe renal impairment|severe renal impairment
3186932|NCT00750620|Experimental|2. Moderate renal impairment|moderate renal impairment
3186933|NCT00750620|Experimental|3. Mild renal impairment|mild renal impairment
3186934|NCT00750620|Experimental|4. Normal renal function|normal renal function
3186935|NCT00750633|Experimental|Moxidex|Moxidex otic solution
2422664|NCT03418038|Experimental|Arm A (ascorbic acid, combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2422665|NCT03418038|Active Comparator|Arm B (placebo, combination chemotherapy)|Patients receive placebo (normal saline) IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19, and rituximab intravenously IV, ifosfamide IV, carboplatin IV and etoposide IV on days 1-3. Patients who achieve MR or SD after 2 cycles may receive rituximab IV or PO, cisplatin IV or PO, cytarabine IV or PO, and dexamethasone IV or PO. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2422666|NCT03418038|Experimental|Arm C (ascorbic acid and combination chemotherapy)|Patients receive ascorbic acid IV on days 1, 3, 5, 8, 10, 12, 15, 17, and 19. Patients also receive ifosfamide, carboplatin, and etoposide IV or PO, or cisplatin, cytarabine, and dexamethasone IV or PO, or gemcitabine hydrochloride, dexamethasone, and cisplatin IV or PO, or gemcitabine hydrochloride and oxaliplatin IV or PO, or oxaliplatin, cytarabine, and dexamethasone IV or PO according standard regimen schedule. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve MR or SD after 2 cycles may switch to an alternative chemotherapy regimen.
2422667|NCT03418038|Experimental|Arm D (ascobic acid)|Patients receive ascorbic acid IV TIW. Treatments repeat every 28 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
2422668|NCT03418025|Experimental|Group I (Exercising Together program)|"Exercise Intervention. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.~EXERCISING TOGETHER PROGRAM: Participants complete three exercise sessions (approximately 1 hour per session) per week over 5-8 weeks during radiation treatment. Participants also receive a DVD of a partnered strength training exercise program to continue on their own after radiation is completed."
2422669|NCT03418025|Active Comparator|Group II (pre and post testing)|Questionnaire Administration & Survey Administration. All participants complete questionnaires about their health status, physical activity habits and relationship with their spouse/partner and undergo four physical tests at baseline and at the end of the 5-8 week radiation treatment. The questionnaires are then completed one final time 8 weeks following the completion of radiation treatment.
2422670|NCT03418012|Experimental|Cervical Pessary-Group|Cervical Pessary Group: placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at WoG 37
2422671|NCT03418012|Other|Control-Group|Control-Group women receive management as usual; i.e. expectant management with interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
2422672|NCT03417999|Experimental|Cohort 1|"Cohort 1A:~Dexmedetomidine 2 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo~Cohort 1B:~Dexmedetomidine 2 μg/kg~Under sedation with a natural airway~7 subjects age >2 yo and ≤ 6 yo~7 subjects age ≥1 mo and ≤2 yo"
2422673|NCT03417999|Experimental|Cohort 2|"Dexmedetomidine 4 μg/kg~Under general oral endotracheal anesthesia~7 subjects age >2 yo and ≤ 6 yo"
2422674|NCT03417999|Experimental|Cohort 3|Currently analyzing data. May perform a 3 μg/kg pending review.
2422675|NCT03417986|Experimental|Group 1a: TEP 26 mg daily for 4d|
2422676|NCT03417986|Experimental|Group 1b: TEP 52 mg daily for 4d|
2422677|NCT03417986|Experimental|Group 2: TEP 26 mg daily for 54d|
2422678|NCT03417973||complex regional pain syndrome|Chronic regional pain of lower limb(s) patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
2425249|NCT03399812|Experimental|Whey protein isolate|
3186936|NCT00750633|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3186937|NCT00750633|Active Comparator|Dexamethasone|Dexamethasone phosphate otic solution
3186938|NCT00750646||A|Subject's adherence to prescribed therapy will be monitored with an electronic compliance device.
3186939|NCT00750659|Experimental|1|Nilotinib treatment
2422679|NCT03417973||Chronic pelvic pain|Chronic pelvic or urological pain patients medically indicated to have dorsal root ganglion (DRG) stimulation for control of pain. DRG stimulator will be implanted for trial of 3-4 days and then permanently, if patient find acceptable levels of pain control with trial.
2422680|NCT03417960|Experimental|iTBS|accelerated iTBS to Left DLPFC
2422681|NCT03417947|Placebo Comparator|Placebo|Placebo identical to the vitamin D bolus in taste and appearance. The placebo will be administered once, at the beginning of the study. The oral liquid placebo will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.
2422682|NCT03417947|Experimental|Vitamin D bolus|The vitamin D bolus is an oral liquid supplement that will be administered once, at the beginning of the study. The oral liquid vitamin D bolus will be prepared at the Pharmacy in coded syringes and will be administered to the participants by a nurse at the sickle cell disease Clinic.The dose of vitamin D3 contained in the bolus is 300 000 IU.
2422683|NCT03417921|Experimental|ARM A|ABTL0812 (starting 1,300 mg tid orally) in combination with gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer
2422684|NCT03417921|Active Comparator|ARM B|Gemcitabine and nab-paclitaxel will be administered to patients with pancreatic cancer as standard pattern
2422685|NCT03417908|Active Comparator|COPD - PNF|COPD - PNF
2422686|NCT03417908|Sham Comparator|COPD - sham|COPD - sham
2422687|NCT03417908|Active Comparator|Individuals Without COPD - PNF|Individuals Without COPD - PNF
2422688|NCT03417908|Sham Comparator|Individuals Without COPD - sham|Individuals Without COPD - sham
2422689|NCT03417895|Experimental|A(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
2422690|NCT03417895|Experimental|B(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（5 Days on, 2 Days off）
2422691|NCT03417895|Experimental|C(SHR-1210+Apatinib)|• SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD（7 Days on, 7 Days off）
2422692|NCT03417882|Experimental|Cohort 1|All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
2422693|NCT03417856||Control|Healthy subjects with no history of ichthyosis from 1 year to 60 years of age.
2422694|NCT03417856||Ichthyosis|Subjects with a diagnosis of Netherton syndrome or ichthyosis from 1 year to 60 years of age.
2422695|NCT03417843|Experimental|EUSRA RF electrode|new ablation catheter RFA (RADIOFREQUENCY under EUS), developed by TAEWOONG company for the treatment of pancreatic premalignant and early malignant cystic lesion.
2422698|NCT03417817|Other|Healthy subjects|Bravo wireless pH monitoring over 96 hours
2422699|NCT03417791||kidney function recovery|the registry and follow up of consecutive patients with increased serum creatinine during hospital in 2007
2422703|NCT03417765|Experimental|Cohort A: 5 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
2422704|NCT03417765|Experimental|Cohort B: 10 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
2422705|NCT03417765|Experimental|Cohort C: 25 mg (FE 203799/Placebo)|Drug: FE 203799 Drug: BEAM Procedure: myeloablative chemotherapy Procedure: autologous stem cell transplantation
3146106|NCT00090740||Asthmatics|People who have asthma
2422711|NCT03417700|Experimental|Training NW|exercise and supplementation
2422712|NCT03417700|Experimental|Training HICT and vitamin D|Training HICT plus vitamin D
2422713|NCT03417700|Experimental|Placebo|placebo Vitamin D
2422714|NCT03417687|Active Comparator|Arm 1|Subjects will undergo hyperpolarized 129Xe MRI first, followed by 133Xe scintigraphy
2422715|NCT03417687|Active Comparator|Arm 2|Subjects will undergo 133Xe scintigraphy first, followed by hyperpolarized 129Xe MRI
3146107|NCT00090740||Controls|People who do not have asthma
3146108|NCT00090896|Experimental|CTLA4-Blocking Monoclonal Antibody|
2422718|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2422775|NCT03417323|No Intervention|No compression garment|Groups wear no compression garment after WB-EMS induced muscle soreness
2425250|NCT03399812|Active Comparator|Pea protein isolate|
3146109|NCT00090961|Experimental|12-week exercise program + education|A 12-week supervised exercise program consisting of 3 days a week on a stationary bike or treadmill. In addition, at the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
3146110|NCT00090961|Other|Education|At the time of enrollment patients are provided educational materials focusing on breathing and energy conservation.
3146111|NCT00091078|Experimental|Treatment (oblimersen sodium and imatinib mesylate)|Patients receive oblimersen IV continuously on days 1-14. Patients also receive oral imatinib mesylate on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146112|NCT00091091||All patients|Self report/Medical record review/ clinical eval
3146113|NCT00091117|Experimental|Treatment|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3146114|NCT00091130|Experimental|Arm I (SGN-00101)|Patients receive SGN-00101 vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
3146115|NCT00091130|Placebo Comparator|Arm II (placebo)|Patients receive placebo vaccine SC on day 1 of weeks 1, 4, and 8 for a maximum of 3 injections in the absence of unacceptable toxicity or the development of an invasive malignancy or serious illness.
3146116|NCT00091182|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3146117|NCT00091195|Experimental|Treatment (single-agent depsipeptide)|Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2422719|NCT03417661|Experimental|HEXI-PREP By Clinell Wipes vs Chloraprep|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2422720|NCT03417661|Experimental|Chloraprep vs Placebo|Both trial products will be applied bilaterally to between one and four predetermined anatomical sites on each participant, depending on whether the inclusion criteria for bioburden has been met for each sampling site. Each site will be sampled for bacterial load at four predetermined time points.
2422721|NCT03417648|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2422722|NCT03417648|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
2422723|NCT03417635|Experimental|Guided focused attention|"Participants will take part in a guided focused attention practice led by the researcher. This will include strategies used in meditations where participants focus on their breathing. More specifically, they will be instructed to close their eyes and focus on the sensation of breathing in one area of the body for the entire session. They will be given reminders throughout the session to remain on task (focusing on the breath) and not to let their thoughts wander.~Participants will be asked to either sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much that they might fall asleep."
2422724|NCT03417635|Active Comparator|Acoustic music|"Participants will be instructed to listen to a prepared soothing acoustic music track. The sessions will be led by a researcher. Participants will be asked to close their eyes and relax while listening to the music.~Participants will be asked to sit on a chair or cushion on floor to ensure they are comfortable to sit still for the session, but not so much they might fall asleep This group is used as active control group to control for socialization in group settings and any effects of consciously relaxing for the meetings."
2422725|NCT03417622|Experimental|Post-treatment volume-resection margin|Lumpectomy is performed with resection margin of the clinically / radiologically identifiable post-treatment tumor.
2422726|NCT03417622|Active Comparator|Pre-treatment volume-resection margin|Lumpectomy is performed with resection margin of the bracketed tissue.
2422727|NCT03417609||Sarcopenia|Elderly patients with sarcopenia
2422728|NCT03417609||Control|Elderly patients without sarcopenia
2422729|NCT03417596|Experimental|Vestibular Rehabilitation|"Adaptation Exercises The exercises were performed in horizontal and vertical planes, for a period of one minute each, three times a day.~Substitution Exercises Standing dynamic balance exercises: The patient stands and moves without walking. The patient might march in place, step forward or backward, step to the side, step up or down, or turn around.~Habituation exercises: These exercises that cause mild to moderate difficulty in daily life was given as an exercise to the patient. These exercises involved movements and positions sufficient to cause mild-to-moderate symptoms during the patient's daily activities Ambulation exercises: Exercises that include walking with head moving towards different sides.~The exercise program consisted of one session per week for a period of eight weeks. Each session lasted approximately 30-45 minutes and was conducted in the rehabilitation unit."
2422730|NCT03417596|Experimental|Vestibular Rehabilitation+Pharmacological Therapy|"Same exercises that were applied in first group were also applied to this group.~For pharmacological therapy, patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated."
2422731|NCT03417596|Other|Pharmacological Therapy only|Patients were assessed by a neurologist and appropriate drug options were applied based on patients' needs and features. Propranolol was selected primarily and other prophylactic drugs were used in the case of its' being contraindicated.
2422732|NCT03417583|No Intervention|Clinical Standard Care Group|These patients will continue to be seen by their regular neurology provider for Huntington's disease. They will not be treated explicitly according to the protocol, though they may be prescribed some of the same medications.
2422733|NCT03417583|Experimental|Protocol Intervention Group|These participants will transfer their clinical care to the study provider for the duration of the study, and their symptom treatment will be guided by the study protocol.
2422734|NCT03417570|Experimental|Arm 1: EGD with cap first, followed by EGD without cap|-Participants in the first arm will undergo EGD with cap first, followed by EGD without cap.
2422735|NCT03417570|Experimental|Arm 2: EGD without cap first, followed by EGD with cap|-Participants in the second arm will undergo EGD without cap first, followed by EGD with cap
2422739|NCT03417531|Active Comparator|Protein Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a simple home exercise strength program (3x30 minutes/week)
2422740|NCT03417531|Active Comparator|Protein-free Supplement plus Active Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a simple home exercise strength program (3x30 minutes/week)
2422741|NCT03417531|Active Comparator|Protein Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of L-leucine-enriched whey protein isolate powder (equivalent to 20 g of Protein) and perform a joint flexibility home exercise program (3x30 minutes/week)
2422742|NCT03417531|Sham Comparator|Protein-free Supplement plus Control Exercise|Participants will ingest twice daily 23.7 g of a protein-free, isocaloric powder blend and perform a joint flexibility home exercise program (3x30 minutes/week)
2422743|NCT03417518|Active Comparator|Desflurane Inhalant Product Group|general anesthesia with desflurane
2422744|NCT03417518|Experimental|Propofol Group|general anesthesia with propofol
3186940|NCT00750685|Other|Reconstruction|"The study population will consist of women aged 18 or over who are undergoing primary breast reconstruction.~The Reconstruction cohort will include subjects with loss of breast tissue due to mastectomy, contralateral breast for post-reconstruction symmetry or subjects with deformities secondary to disease, malignancy, trauma, and congenital deformity. Subjects in this cohort cannot have been implanted with breast implants, but may have tissue expanders. A Becker implant is considered a tissue expander until the port and fill tube have been removed. Women who undergo surgery primarily for a mastopexy will not be part of the reconstruction cohort."
3186941|NCT00750698|Experimental|1|"Erlotinib-responsive patients are those who progressed following either a complete or partial response to erlotinib or a period of stable disease lasting at least 3 months."
2422747|NCT03417492|Experimental|Sildenafil Citrate|Open label treatment with forced titration of sildenafil citrate.
2422750|NCT03417453|Active Comparator|Eye Drop Dispenser TYPE Opticare|subject will assess TYPE 1 dispenser
2422751|NCT03417453|Active Comparator|Eye Drop Dispenser Autodrop|subject will assess Autodrop dispenser
2422752|NCT03417440|Other|PA App+ On Your Feet+ CoachMe+ Proof Pos|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 3 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (3) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2422753|NCT03417440|Other|PA App + On Your Feet + Coach Me|"Participants in this arm will use a basic physical activity (PA) app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
2422754|NCT03417440|Other|PA App + On Your Feet + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2422755|NCT03417440|Other|PA App + On Your Feet|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) On Your Feet (sedentary activity monitoring with motivational messaging and peer suggestions)."
2422756|NCT03417440|Other|PA App + Coach Me + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following 2 features: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers); and (2) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2422757|NCT03417440|Other|PA App + Coach Me|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Coach Me (tailored messaging to increase the intensity level of everyday activities and overcome barriers)."
2422758|NCT03417440|Other|PA App + Proof Positive|"Participants in this arm will use a basic physical activity (PA) tracker app in conjunction with the following feature: (1) Proof Positive (explicit and implicit messaging to promote positive aging views)."
2422759|NCT03417440|Other|PA App|Participants in this arm will use a basic physical activity (PA) tracker app without any additional features.
2422760|NCT03417427|Active Comparator|Decitabine and Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive decitabine (15mg/m2 d1-5) combined with high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
2422761|NCT03417427|Placebo Comparator|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
2422762|NCT03417414||B-CLL|Patients with B-Cell CLL
2422763|NCT03417414||B-NHL|Patients with B-Cell NHL
2422764|NCT03417401|Experimental|RVC with tPA for CRVO|Single arm phase I open label study were CRVO patients will have a vitrectomy with retinal vein cannulation and a single infusion of tPA (0.25mg/ml) intravenously with a maximum dose of 1mg.
2422765|NCT03417388|Experimental|Intensive Medical Treatment (IMT)|"The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
2422766|NCT03417388|Active Comparator|Usual Care (UC)|"The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and face-time with site staff to reduce bias."
2422767|NCT03417375|Experimental|Osteocel Plus|Experimental product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
2422768|NCT03417375|Active Comparator|alloOss|The control product will be placed in one sinus while the control product will be placed in the contralateral sinus. (Randomized)
2422769|NCT03417362|Other|Animation|Animation describing process of early medical abortion, what to expect, how to take medicines. This is prior to consultation.
2422770|NCT03417362|No Intervention|Standard|Standard of Care - no animation ,standard consultation only.
2422771|NCT03417349||Aspiration thrombectomy|Patients with acute ischemic stroke of the anterior circulation whom the treating physician deemed eligible to be treated with SOFIA™/ SOFIA™ as a first line treatment technique
2422772|NCT03417336|Experimental|brachytherapy + External radiotherapy|Prostate booster, HDR brachytherapy with 15Gy in 1 fraction + external radiotherapy 25Gy in 5 fractions
2422773|NCT03417336|Active Comparator|External radiotherapy|Exclusive external radiotherapy. 25Gy in 5 fractions + a 40Gy prostate boost in stereotaxic conditions.
2422777|NCT03417310|Active Comparator|Common reduction methods|Patients are treated with common reduction methods on a traction table
2422778|NCT03417297|Experimental|high intensity focused ultrasound|Initially, 3 patients will be enrolled and followed for 3 months to assess the safety of study intervention which is unilateral MR guides focused ultrasound thalamotomy (anterior nucleus). These data will be reviewed by the Data and Safety Monitoring Committee (DSMC) and the FDA. If approval is granted by the DSMC and FDA, then up to an additional 7 participants will be enrolled.
2422779|NCT03417284|Experimental|Group 1 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
2422780|NCT03417284|Experimental|Group 2 (melphalan hydrochloride, HSCT, filgrastim)|"PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.~TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.~POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L."
2422781|NCT03417271|Active Comparator|30us stimulation then 60us stimulation|All patients will receive both types of stimulation in a randomised crossover design. This arm will receive 30us stimulation for 4 weeks then will be switched to 60us stimulation for 4 weeks.
2422782|NCT03417271|Active Comparator|60us stimulation then 30us stimulation|All patients will receive both types of stimulation in a randomised crossover design.This arm will receive 60us stimulation for 4 weeks then will be switched to 30us stimulation for 4 weeks.
2422783|NCT03417258||Patients with polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
2422784|NCT03417258||Patients without polyps|urinary phytoestrogen excretion and intestinal microbiota evaluation
2422785|NCT03417245|Experimental|fitusiran|Fitusiran administered subcutaneously (SC) as prophylaxis once monthly, with use of on-demand factor concentrates for treatment of breakthrough bleeding episodes. All patients will be treated for a total of 9 months
2422786|NCT03417245|Experimental|On demand factor concentrates|On-demand factor concentrates for treatment of breakthrough bleeding episodes. On-demand use of factor concentrates is defined as the use of these agents, as needed, for episodic bleeding, and not on a regular regimen intended to prevent spontaneous bleeding. All patients will be treated for a total of 9 months.
2422787|NCT03417232|Experimental|Split Full Split Elevation of CAF|The central portion of the flap apical to the recession was elevated full thickness by the use of a small periostium elevator inserted into the probable sulcus
2422788|NCT03417232|Sham Comparator|Split Elevation of CAF|The flap was fully elevated with a split thickness approach: the blade of the knife was inserted into the sulcus
3186942|NCT00750698|Experimental|2|"Erlotinib-nonresponsive patients are those who either progressed immediately during treatment with erlotinib (i.e. after at least 1 full cycle of erlotinib treatment) or had an objective response or period of stable disease lasting less than 3 months."
3186943|NCT00750711|Experimental|KT,2|There are two arms in this study: KT2 arm and KT4 arm. Patients in KT2 arm will be ablated with the 2 mm irrigated catheter and patients in KT4 mm will be ablated with the 4 mm irrigated catheter.
2422791|NCT03417206|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE between 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2422792|NCT03417206|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2422793|NCT03417206|Experimental|TIVA USING PROPOROL|Infusion of propofol will be adjusted at target of SE 40,remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, intraoperatively PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50% every 5 minutes until PRD decreases below 5%
2422794|NCT03417193|Active Comparator|Opioid based Anesthesia|General anesthesia will be induced using Propofol , fentanyl , and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with Remi-fentanyl , sevoflurane and nitrous oxide.
2422795|NCT03417193|Active Comparator|Opioid Free Anesthesia|-General anesthesia will be induced using dexmedetomidine and lidocaine started 10 minutes before induction, Propofol and Rocuronium . Ketamine will be administered on induction of anesthesia with the same dose to be repeated every hour. Anesthesia will be maintained with IV infusion of dexmedetomidine , lidocaine , sevoflurane and nitrous oxide.
2422796|NCT03417180|Experimental|SEVOFLURANE INHALATIONAL ANAESTHESIA|concentration of sevoflurane in the exhalation gas will be maintained to ensure target SE 40, remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2422797|NCT03417180|Experimental|DESFLURANE INHALATIONAL ANAESTHESIA|concentration of desflurane in the exhalation gas will be maintained to ensure target SE 40,remifentanil will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2422798|NCT03417180|Experimental|TIVA USING PROPOROL|infusion of propofol will be adjusted at target of SE 40, remifentanyl infusion will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50% every 5 minutes until SPI value decreases back to baseline value
2422799|NCT03417154|Experimental|Stage 1 Arms 1&2: Nivolumab and Cyclophosphamide|
2422800|NCT03417154|Experimental|Stage 2: Nivolumab and Cyclophosphamide|
3186944|NCT00750724|Placebo Comparator|B|2 ml of Normal saline intraarticular injection to the knee joint weekly for 5 weeks
2422802|NCT03417128|No Intervention|Control|Participants in the control group will receive a one-time personalised nutrition and lifestyle advised based from the Malaysian Dietary Guideline 2010. They will be assured to be followed up twice for the next six month.
2422803|NCT03417128|Experimental|Peer support|This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering.
2422804|NCT03417115||Advanced breast cancer - Her2 positive|Patients with HER2-positive advanced breast cancer
2422805|NCT03417115||Advanced breast cancer - triple negative|Patients with triple negative advanced breast cancer
2422806|NCT03417115||Advanced breast cancer - HR positive, Her2 negative|Patients with HR positive, Her2 negative advanced breast cancer
2422807|NCT03417115||Early breast cancer - HER2 positive|Patients with HER2 positive early breast cancer
2422808|NCT03417115||Early breast cancer - triple negative|Patients with triple negative early breast cancer
2422809|NCT03417115||Early breast cancer - HR positive, HER2 negative|Patients with HR positive, HER2 negative early breast cancer
2422812|NCT03417089|Experimental|falciform ligament suspension|routine suspension of falciform ligament during mini gastric bypass,
2422813|NCT03417089|Active Comparator|No suspension|working without suspension of the falciform ligament
2422814|NCT03417076|Experimental|Bexagliflozin|Each subject will receive a single oral dose of bexagliflozin tablets, 20 mg, followed by a single IV dosing of < 30 ug 14C-bexagliflozin in 0.9% saline solution).
2422815|NCT03417050||Randomized CABG patients|Patients which were randomized to undergo CABG.
2422816|NCT03417050||Randomized PCI patients|Patients which were randomized to undergo PCI.
2422817|NCT03417050||Registry CABG|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
2422818|NCT03417050||Registry PCI|Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
2422819|NCT03417037|Experimental|Arm A|BMS-986205 and Nivolumab administered in combination
2422820|NCT03417037|Experimental|Arm B|BMS-986205 and Nivolumab administered in combination with chemotherapy
2422821|NCT03417037|Active Comparator|Arm C|Chemotherapy administered alone
3186945|NCT00750724|Experimental|A|2 ml of 25 mg sodium hyaluronate intraarticular injection to the knee joint weekly for 5 weeks
2422823|NCT03416998|Active Comparator|Phototherapy Active|Phototherapy active group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.
2422824|NCT03416998|Placebo Comparator|Placebo Phototherapy|"Phototherapy placebo group will be administered 30 minutes prior to the soccer match as well as 48 h after the match in direct contact with the skin with light pressure at predetermined sites: nine on the knee extensor muscles, six on the knee flexor muscles and two on the gastrocnemius muscle on both lower limbs.~For placebo treatment, the same procedures and treatment times will be employed, but the equipment will be set in placebo mode. Only the researcher in charge of programming the device will have knowledge regarding which treatment is being used. However, the programmer will not participate in the execution of the treatment, evaluations or data analysis"
3186946|NCT00750750|Active Comparator|1|MFNS once daily
3186947|NCT00750750|Experimental|2|MFNS twice daily
3186948|NCT00750750|Active Comparator|3|Amoxicillin
2422828|NCT03416972||Stage I-III NSCLC patients|Stage I/II NSCLC patients receiving standard stereotactic body radiation therapy and Stage III patients receiving Standard platinum-based chemoradiotherapy will receive PET/MRI, DCE-CT, ECG/EKG, and bloodwork before and six weeks post treatment.
3186949|NCT00750750|Placebo Comparator|4|Placebo
3186950|NCT00750763|Active Comparator|1|PEG (Colonlytely) - 4 litres
2422831|NCT03416933|Experimental|Biological|
2422832|NCT03416920|Experimental|Wellframe|Subjects in this arm will use the Wellframe application for 90 days
2422833|NCT03416907|Active Comparator|Original|Participants will review the full-length, original consent form for the clinical trial.
2422834|NCT03416907|Experimental|Shortened|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
2422835|NCT03416907|Experimental|Reordered|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
2422836|NCT03416907|Experimental|Highlighted|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
2422837|NCT03416907|Experimental|Interactive|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
2422838|NCT03416894|Experimental|Deep Brain Stimulation|
2422859|NCT03416738|Active Comparator|Semantically focused treatment|This treatment will focus on improving word finding and comprehension of information.
2422860|NCT03416738|Active Comparator|Phonologically focused treatment|This treatment will focus on training speech sound production, targeting overall production abilities.
3186951|NCT00750763|Active Comparator|2|Picosulphate (Picolax/Picoprep) - 2 sachets
3186952|NCT00750763|Active Comparator|3|Sodium Phosphate (Fleet) - 2 bottles
3186953|NCT00750802|Experimental|1|
3186954|NCT00750802|Experimental|2|
3186955|NCT00750802|Active Comparator|3|
2422839|NCT03416868|Experimental|Week 3 start|"For the first two weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In the following 3 weeks of voice therapy (weeks 3 through 5), patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
2422840|NCT03416868|Experimental|Week 4 start|"For the first three weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy weeks 4 and 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
2422841|NCT03416868|Experimental|Week 5 start|"For the first four weeks of voice therapy, patients will receive ambulatory voice monitoring (no biofeedback) during their voice therapy sessions and throughout the week. In voice therapy week 5, patients in this arm will be provided ambulatory voice biofeedback. Week 6 involves monitoring without feedback in all subjects to evaluate washout and any effect of feedback dose. Monitoring per week: 20 minutes of phonation time after the therapy session (Day 1), 40 minutes of phonation time for each of the next consecutive two days (Days 2 and 3), and 40 minutes of phonation time for the day before the patient's subsequent voice therapy session (Day 4). During biofeedback weeks, feedback will be enabled only on Days 1 and 2."
3186956|NCT00750802|Placebo Comparator|4|
2422843|NCT03416842|Experimental|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
2422844|NCT03416829|Experimental|100% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (100% frequency - vibrotactile cueing every time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2422845|NCT03416829|Experimental|25% frequency|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (25% frequency - vibrotactile cueing every 4th time the participant exceeds a vocal intensity threshold). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2422846|NCT03416829|Experimental|Summary feedback|Some patients will be assigned (via block randomization) to receive ambulatory voice biofeedback (summary - no cueing, statistics shown every 2 minutes of voicing). Voice monitoring will be conducted for 3 days (device automatically turns off after 42 minutes of voicing): Day 1: biofeedback will be active all day , Day 2: the day after Day 1, no biofeedback, just monitoring to test short-term retention. Day 3: 7 days post-Day 1, no biofeedback, just monitoring to test longer-term retention.
2422847|NCT03416816|Experimental|DSP-0337|In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
2422848|NCT03416803|Experimental|Radiotherapy|Patients in the experimental group, who were at high risk for lymph node metastasis, underwent radiotherapy in the lymphatic drainage area. Radiotherapy was started in lymphatic drainage areas about 1 month after HCC surgery. The range of radiotherapy was hepatic portal area, pancreas circumference, celiac trunk and abdomen Around the aortic lymph drainage area, the dose of radiation 45Gy, conventional segmentation.
2422849|NCT03416803|No Intervention|Blank control|Patients in the control group , who were at high risk for lymph node metastasis，were followed up.
2422850|NCT03416777|Active Comparator|Meat-based diet (MBD)|Behavioral intervention with diet including 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat.
2422851|NCT03416777|Experimental|Meat-based alpha-tocopherol (MBD-T)|Behavioral intervention including diet with 4 servings per week of red meat, 3 servings per week of processed meat, and 1 servings per week of poultry, for a total amount of 900 g per week of meat with a dietary supplement of 100 mg/day of alpha-tocopherol in the form of tablet
2422852|NCT03416777|Experimental|Pesco-vegetarian (PVD)|Behavioral intervention with diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish
2422853|NCT03416764|Experimental|EFP-NF (participants without steady menstrual cycle).|EFP-NF training, twice a week for a total of 10 sessions .
2422854|NCT03416764|No Intervention|TAU|Participant will receive no EFP-NF training, and continue their treatment as usual (TAU).
2422855|NCT03416764|Experimental|EFP-NF during HIGH estrogen phase|EFP-NF training, twice a week, during high-estrogen phases only (days 7-21 of a 28-day cycle), for a total of 10 sessions.
2422856|NCT03416764|Experimental|EFP-NF during LOW estrogen phase|EFP-NF training, twice a week, during low-estrogen phases only (days 21-28 of a cycle and days 1-7 of the following cycle,based on a 28-day cycle), for a total of 10 sessions.
2422857|NCT03416751|Experimental|Fecal Microbial transplantation|Patients will get one-dose of 90ml of FMT enema on day 1 that has been received from OpenBiome using a rational donor
2422858|NCT03416751|Placebo Comparator|Placebo|Patients will get one-dose of 90ml of saline enema on day 1
2422861|NCT03416725||Patients with chronic suppurative otitis media.|patients of the age group 18-60 years with Chronic suppurative otitis media (CSOM) planned for tympanoplasty.
2422862|NCT03416712|No Intervention|Control|"To obtain baseline socioeconomic data on all children (intervention and control), study participants will utilize the Children's HealthWatch Survey (www.childrenshealthwatch.org), which is a standardized, validated survey designed to collect demographics and information on child health and development, parental health, and socioeconomic factors income, education level, financial literacy, childcare, and government assistance).~The control group will not complete the WE CARE HOUSTON survey and will not receive any referrals to community resources from the study team at the time of enrollment (they may be referred to resources by their medical/clinical team as per standard of care during their hospitalization at Texas Children's Hospital). The study investigators will offer control participants information on community resources at the end of the study. Study participants will be called for a 6 month follow up structure telephone survey."
2422863|NCT03416712|Experimental|Intervention|The intervention group will complete a short survey called the WE CARE HOUSTON survey. The WE CARE HOUSTON survey has been designed to quickly assess patient need for local services that address the social determinants of health. The WE CARE HOUSTON survey will be administered on paper or verbally if family is not able to read. Based on the parent's responses to the screening survey, the study investigators will use an algorithm to direct families to appropriate services and community resources. Families who screen positive for social needs will receive a handout on resources. For the families that screen positive for depression/ mental health needs, domestic violence, or alcohol and drug abuse, the study investigators will notify the medical/clinical team and recommend an inpatient social work prior to discharge. Intervention participants will be called 1 week-2 months after enrollment to follow up on resources and will be called for a 6 month follow up structured telephone survey.
2422864|NCT03416686|Experimental|Radiofrequency|
2422865|NCT03416673|Active Comparator|CTG+CAF|The surgical procedure will include a connective tissue graft harvested from the palate and used under a coronally advanced flap
2422866|NCT03416673|Experimental|peCTG+CAF|A papillary extended connective tissue graft reshaped after harvested from the palate will be used under a coronally advanced flap
2422867|NCT03416660|Active Comparator|Low density|Fractional carbon dioxide laser: Lesion A or part A parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 900µm spacing (7.4% density).
2422868|NCT03416660|Active Comparator|Medium density|Fractional carbon dioxide laser : Lesion B or part B parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 600µm spacing (12.6% density).
2422869|NCT03416660|Active Comparator|High density|Fractional carbon dioxide laser : Lesion C or part C parameters: 20 W, 800-1000μs dwell time, 2 to 3 stacks according to scar thickness, 300 µm spacing (25.6% density).
2422870|NCT03416647|Experimental|SMAS patients|
2422871|NCT03416634|Active Comparator|App Alone|Participants randomized to use the Microsoft Band app to track daily activity
2422872|NCT03416634|Experimental|App Plus Automated Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive automated, motivational text messages
2422873|NCT03416634|Experimental|App Plus Personalized Motivational Message|Participants randomized to use the Microsoft Band app to track daily activity, and to receive personalized, motivational text messages
2422874|NCT03416634|Active Comparator|Wearable Device Alone|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity
2422875|NCT03416634|Experimental|Wearable Device Plus Automated Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive automated, motivational text messages
2422876|NCT03416634|Experimental|Wearable Device Plus Personalized Motivational Message|Participants randomized to use the Garmin vivofit 3 wearable device to track daily activity, and to receive personalized, motivational text messages
3186958|NCT00750854|Experimental|NEM Treatment 1|NEM Formulation X (#0802), 500 mg, once daily, orally
3186959|NCT00750854|Experimental|NEM Treatment 2|NEM Formulation Y (#0505), 500 mg, once daily, orally
3186960|NCT00750932||T|Control
2422880|NCT03416595|Active Comparator|N1115 Probiotic Supplement|A probiotic supplement containing Lactobacillus paracasei N1115 [Junlebao Lp. N1115] Participators, who met inclusion criteria, will receive following product during 8 weeks: N1115 Probiotic Supplement in the form of powder packaged in sachet (one sachet containing 10^9 CFU Lp. N1115).
2422881|NCT03416595|Placebo Comparator|Placebo control|Dietary Supplement: Placebo Participators, who met inclusion criteria, will receive an identical N1115 Probiotic Supplement looking and tasting placebo.
2422882|NCT03416582|Experimental|SMENC Group|"The Symptom Management Education and Nurse Coaching (SMENC) intervention is a one hour in-person face-to-face education session followed by twice weekly telephone calls conducted all throughout the patient's chemoradiation treatment regimen.~During the telephone call, the patient will report the use of the Drinks Diary."
2422883|NCT03416569|Experimental|Nicotine-Prazosin Interaction Study|Over four test days, each participant will be tested with placebo, nicotine alone, prazosin alone, and nicotine + prazosin, in a double-blind sequence.
2422884|NCT03416556|Experimental|Mobilization to the glenohumeral joint|This condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder
2422885|NCT03416556|Sham Comparator|The manual contact condition|In this condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition.
2422886|NCT03416556|No Intervention|No-contact condition|There was no manual contact between the therapist and the participant
2422956|NCT03416088|Experimental|Liquid volume|Drink 300ml wine (alcohol concentration:13%) or 300ml coffee (caffeine concentration 1.2%).
3186961|NCT00750932||M|Minor with cystic fibrosis
3186962|NCT00750932||A|Adult with cystic fibrosis
3186963|NCT00750945|Experimental|A|Treadmill with Music cueing group
3186964|NCT00750945|Active Comparator|B|Treadmill group
3186965|NCT00750945|Placebo Comparator|C|Home walking group
2422888|NCT03416530|Experimental|ONC201 in relapsed/refractory H3 K27M glioma|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. Evidence of progression is not required so that ONC201 may be administered to patients in the maintenance setting or to patients with recurrent/refractory disease.
2422889|NCT03416530|Experimental|ONC201 in newly diagnosed DIPG|Pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. If H3 K27M status of tumor is unknown or archival tumor tissue is not available, then patients must agree to submit a post-mortem biopsy specimen.
2422890|NCT03416530|Experimental|Midline Glioma Biopsy|Pediatric patients midline gliomas are eligible with or without histologic confirmation and must be eligible for tumor biopsy as deemed by the site Investigator.
2422891|NCT03416530|Experimental|H3 K27M CSF Biopsy|Pediatric patients with recurrent glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory), have completed at least one line of prior therapy, must be willing to undergo serial lumbar puncture to obtain cerebrospinal fluid (CSF), and must be scheduled to undergo sedated MRIs.
2422892|NCT03416530|Experimental|Liquid ONC201 in relapsed/refractory H3 K27M glioma|Patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) or have diagnosed diffuse intrinsic pontine glioma (DIPG), defined as tumors with a pontine epicenter and diffuse involvement of the pons, are eligible with or without histologic confirmation. Patients must be 2-12 weeks from completion of first-line radiation.
2422893|NCT03416530|Experimental|Dose Expansion Cohort in relapsed/refractory H3 K27M glioma|Pediatric patients with previously-treated, histologically confirmed high-grade glioma with a known H3 K27M mutation, evidence of progressive disease contrast-enhanced brain MRI as defined by RANO-HGG criteria. Prior therapy with at least radiotherapy is required.
2422894|NCT03416530|Experimental|ONC201 given on two consecutive days of each week|Pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy will be enrolled to define the RP2D for single agent ONC201 given on two consecutive days of each week.
2422895|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 1b)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15mg/m^2/d over 60 minutes on days 1-5 and 8-12 q3w. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2422896|NCT03416517|Experimental|Anlotinib and Irinotecan(phase 2)|Anlotinib 12 or 8 mg/d PO on days 1-14 q3w. Irinotecan 20 or 15 mg/m^2/d IV over 60 minutes on days 1-5 and 8-12 q3w. The final dose of anlotinib and irinotecan depends on the result from previous phase Ib study. Vincristine 1.4mg/m^2/d IV on days 1,8 q3w. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
2422897|NCT03416504|Experimental|Gradual Exposure Group|The gradual exposure group received the Gradual Exposure (EXP-G) Intervention.
2422898|NCT03416504|Experimental|Variable Exposure Group|The variable exposure group received the Variable Exposure (EXP-V) Intervention.
2422899|NCT03416491|Experimental|NC_30|Non-cirrhotic subjects were medicated with KW-136 capsules 30 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2422900|NCT03416491|Experimental|NC_60|Non-cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2422901|NCT03416491|Experimental|LC_60|Cirrhotic subjects were medicated with KW-136 capsules 60 mg once daily and fixed-dose (400 mg once daily) sofosbuvir tablets for 12 successive weeks.
2422902|NCT03416478||ctDNA test group|
2422903|NCT03416452|Experimental|PD patients no|PD patients without freezing of gait
2422904|NCT03416452|Placebo Comparator|Healthy|HV using Mobile Gait Trainer
2422905|NCT03416452|Experimental|PD patients|pd patients using vibratory cueing device
2422906|NCT03416452|Experimental|PD patients 1|PD patients with freezing of gait
2422907|NCT03416452|Experimental|Healthy Volunteers|Age and gender matched healthy volunteers.
2422908|NCT03416439|Experimental|intervention arm|lifestyle intervention program carried out by trained professionals
2422909|NCT03416439|No Intervention|control arm|standard, unstructured information given by the family physicians
2422910|NCT03416426||patients undergone PFO closure|patients with ischemic stroke and PFO documented by bubble contrast TEE with no other identifiable cause of the ischemic event who undergone PFO closure using Amplatzer® PFO occluder or Gore® Septal Occluder
2422911|NCT03416413|Active Comparator|Ambulatory Phlebectomy|Ambulatory phlebectomy of varicose vein tributaries
2422912|NCT03416413|Active Comparator|Foam Sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
2422913|NCT03416400||Immature oocytes vitrified before In Vitro Maturation|Immature oocytes were vitrified using closed system vitrification. After warming, they were cultured during 36 hours in IVM medium and fixed for cellular analysis
2422914|NCT03416400||Immature oocytes cultured in vitro before vitrification|Immature oocytes were cultured in vitro in IVM medium during 36 hours. After IVM, they were vitrified. After warming, they were fixed for cellular analysis.
2422915|NCT03416400||Fresh oocytes|Immature oocytes were cultured in vitro in IVM medium during 36 hours and subsequently, fixed for cellular analysis.
2422916|NCT03416387|Other|OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION|
2422917|NCT03416374|Experimental|Combination Therapy + Ixazomib Therapy|Bortezomib + Lenalidomide + Dexamethasone, or Carfilzomib + Lenalidomide + Dexamethasone, standard recommended dose according to the package insert of each drug (Treatment Period I), followed by Ixazomib (4.0 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 to 21, and Dexamethasone (40 mg) on Days 1, 8, 15 and 22, of a 28-day cycle (Treatment Period II)
2422918|NCT03416361|Experimental|Vitamin D|4000IU Vitamin D3 as two 50mcg tablets per day
2422919|NCT03416361|Placebo Comparator|Control|Placebo - two chewable blackcurrant flavoured tablets per day
2422920|NCT03416348|Placebo Comparator|Placebo Comparator AIM 1|Aim 1: Demonstration of a strong association of the Sweating Intensity Visual Scale (SIVS) score with the HDSS would provide validation for use of the SIVS in interpreting the iodine-starch test and would establish the value of the iodine-starch test in clinical practice guidelines for diagnosing hyperhidrosis in amputees, just as it is in dermatology practice.
2422921|NCT03416348|Active Comparator|Aluminum Chloride vs Placebo in Amputees|Aim 2: The investigators will have completed the first clinical trial of Aluminum Chloride for residual limb hyperhidrosis. The investigators will then have a solid foundation of data that demonstrates the rates of adverse effects such as skin irritation, and rates and magnitudes of improvement in subjective and objective measures of sweating.
3146118|NCT00091247|Experimental|tetracycline|"Patients receive oral tetracycline twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
3146119|NCT00091247|Placebo Comparator|placebo|"Patients receive oral placebo twice daily. Treatment continues for 4 weeks in the absence of unacceptable toxicity.~Quality of life is assessed at baseline and then weekly for 8 weeks.~Patients are followed at weeks 4 and 8."
3146120|NCT00091286|Experimental|Peptide Vaccine + Montanide + GM-CSF|Colon peptide mixture (100 mcg each of the 4 peptides) plus 190 mcg of tetanus toxoid peptide, plus GM-CSF (110 mcg) in Montanide ISA-51 adjuvant
2422925|NCT03416322|No Intervention|Second Examination of the right colon|Second forward view examination of the right colon once the right colon (cecum to hepatic flexure) has been examined
2422926|NCT03416322|Experimental|Water exchange|"Water infusion during colonoscope insertion in the right colon (from hepatic flexure to cecum) and remove water during withdrawn (Exchange method)."
2422927|NCT03416296||normal placenta|TA , TV ,TP us
2422928|NCT03416296||placenta previa and MAP|TA,TV.TP us
2422932|NCT03416270|Experimental|Ertuglifozin Treatment Arm|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks
2422933|NCT03416270|Placebo Comparator|Placebo Arm|Placebo Matching Ertugliflozin Tablet for 12 weeks
2422934|NCT03416257||WIHS|Women's Interagency HIV Study
2422935|NCT03416257||MACS|Multicenter AIDS Cohort Study
3146121|NCT00091299|Experimental|warfarin|
3146122|NCT00091351|Experimental|surgery|"Patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
2422938|NCT03416231|Experimental|apatinib plus docetaxel|apatinib combine with docetaxel， 4~6 cycles
2422939|NCT03416218|Experimental|Intervention|All participants enrolled in the study will play Prognosis, the intervention being assessed in this study.
2422940|NCT03416205|Experimental|EST|EST is an operation using the Erbao electric knife and Three-cavity incision knife to make a large incision to the duodenal nipples，and the incision scope is the nipple mouth uplift length of 4/5. It has been used since 1974. The technique is intuitive and intact. However, EST cut too small to achieve the purpose of treatment and will affect the next step, and if the incision is too large it may be easier to occur gastrointestinal perforation and bleeding.The EST will also damage the anatomy of the Oddi sphincter structure,which causes bacterial reflux to the bile duct, the recurrence of CBD.Some surgeons prefer it because it's postoperative pancreatitis rate is lower and it may be easier to find the lesion position if bleeding or perforation occurs.
2422941|NCT03416205|Experimental|EPBD|EPBD is an operation using the Columnar expansion balloon to expand duodenal to achieve the purpose of using the basket and other instruments to take stone out. Balloon expansion may retain part of the sphincter not destroyed, and basically retain the normal physiological function of the nipple sphincter.Thus it may reduce the risk of recurrence of stones and bacterial reflux. However,the postoperative pancreatitis rate is high(4.8% -19.5% ), and nipple sphincter tear is uncontrollable in EPBD.If the digestive tract perforation or bleeding occur after EPBD,it is hard to accurately find the lesion position.Some surgeons prefer it for it's lower bleeding and perforation rate.
2422942|NCT03416205|Experimental|sEST+EPBD|sEST+EPBD is an operation combining EST and EPBD. Investigators use the Erbao electric knife and Three-cavity incision knife to make a small incision to the duodenal nipples, and the incision length is less than 5mm while the incision scope is less than the nipple mouth uplift length of 1/2. Then, Investigators match the appropriate Columnar expansion balloon according to the diameter of the common bile duct and gradually expand the duodenal nipples.This method allows the nipple sphincter to be cut in a small range, then the balloon can guide the direction of the nipple sphincter tearing after the expansion , so that the digestive tract bleeding, perforation may be smaller and more controllable. Besides,it may reduce postoperative pancreatitis rate and the recurrence rate of stones.
2422943|NCT03416192|Experimental|MCO-HD|Hemodialysis with Medium Cut-Off filter
2422944|NCT03416192|Active Comparator|High-flux HDF|Hemodiafiltration with standard high-flux filter
3146123|NCT00091351|Experimental|radiation + surgery|"Patients undergo preoperative radiotherapy once daily, 5 days a week, for 5.5 weeks. Within 28-63 days after the completion of radiotherapy, patients undergo surgery.~Treatment continues in the absence of disease progression or unacceptable toxicity.~Patients are followed at 28 days, 4 months, every 6 months for 5 years, and then annually for 5 years."
2422949|NCT03416153|Active Comparator|Standard Treatment|Patients will receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy)
2422950|NCT03416153|Experimental|De-escalation Treatment|Patients will initially receive a single prescription of 70 Gy in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). If certain parameters are met radiation therapy will be reduced to 54Gy to high risk Planned Target Volume (PTV) and 43.2Gy to low risk PTV all in 27 fractions.
2422951|NCT03416140|Experimental|Therapeutic exercise|
2422952|NCT03416140|No Intervention|Control|
2423054|NCT03415438||Group 2|Assessments will be done for 30 healthy volunteers
2422957|NCT03416062|Experimental|Remaxol® 400 ml + Placebo 400 ml|Treatment with Remaxol® 400 ml IV + Ringer solution 400 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2422958|NCT03416062|Experimental|Remaxol® 800 ml|Treatment with Remaxol® 800 ml IV for 10 days. Drug: Remaxol (succinate + methionine + inosine + nicotinamide)
2422959|NCT03416062|Placebo Comparator|Control|Treatment with Ringer's solution 800 ml IV for 7 days. Drug: Ringer's solution
2422960|NCT03416049||High-power PEMF device|20 participants with VSLU will receive PEMF therapy with a high-power PEMF device for 10 minutes twice a day for each VSLU area.
2422961|NCT03416049||Medium-power PEMF device|20 participants with VSLU will receive PEMF therapy with a medium-power PEMF device for 15 minutes twice a day per VSLU area.
2422962|NCT03416049||Low-power PEMF device|20 participants with VSLU will receive PEMF therapy with a low-power PEMF device for 30 minutes twice a day per VSLU area..
2422963|NCT03416049||Sham PEMF device|20 participants with VSLU will receive PEMF therapy with a sham PEMF device identical to the low-power PEMF device and will treat each VSLU area for 15 minutes twice a day.
2422964|NCT03416036|Experimental|Arm 1: TV003 + rDEN2Δ30-7169|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
2422965|NCT03416036|Experimental|Arm 2: TV003 + rDEN3Δ30|Participants will receive a single dose of TV003 at study entry (Day 0) and rDEN3Δ30 on Day 28.
2422966|NCT03416036|Placebo Comparator|Arm 3: Placebo + rDEN2Δ30-7169|Participants will receive placebo at study entry (Day 0) and rDEN2Δ30-7169 on Day 28.
2422967|NCT03416036|Placebo Comparator|Arm 4: Placebo + rDEN3Δ30|Participants will receive placebo at study entry (Day 0) and rDEN3Δ30 on Day 28.
2422968|NCT03416023|Experimental|Single|
2422969|NCT03416010|No Intervention|Control|In addition to standard prenatal care the PregnancyPlus attention control group for 6 weeks will receive 1.5 hours of ACOG-designed patient education pamphlets. Material will include prenatal and post-partum education.. Dr. Gennaro will conduct the training of the attention control group midwives. The same protocol for assessing fidelity for COPE-P also will be used for assessing fidelity to the attention control intervention
2422970|NCT03416010|Active Comparator|Intervention|In addition to standard prenatal care the COPE-P intervention group will also receive 1.5 hours each week for 6 weeks the cognitive-behavior skills building program driven by CBT as the theoretical framework by health care providers trained in COPE-P by Dr. Melnyk. The content of the COPE program is driven by the literature review, the theoretical framework, previous studies of COPE interventions with mothers of preterm infants and prior work with pregnant minority women by our team.
2422971|NCT03415997|Active Comparator|Total Body Weight|
2422972|NCT03415997|Active Comparator|Lean Body Weight|
2422973|NCT03415984||Exposed patients|Patients with Parkinson's disease treated with L-DOPA
2422974|NCT03415984||Non exposed patients|Patients with Parkinson's disease not treated with L-DOPA
2422975|NCT03415971|Active Comparator|ASTRA TECH implants|implant restoration(replace of a missing tooth) - 35 patients
2422976|NCT03415971|Active Comparator|CROWN|to fixed denture restorations in own teeth - 32 patients
2422977|NCT03415971|Placebo Comparator|non-edontulos|control group will consist 38 non-edotulos patients
2422978|NCT03415958||Open reduction internal fixation|Patients with displaced midshaft clavicle fractures will be offered operative treatment which involves open reduction and internal fixation.
2422979|NCT03415958||Conservative care|Patients will be treated in a sling for the acute phase of two weeks with progressive physiotherapy.
2422980|NCT03415945|Experimental|CRT implantation|In cardiac resynchronization therapy (CRT), biventricular pacing is performed by pacing the right ventricle (RV) and epicardium of the left ventricular (LV) posterolateral wall.
2422981|NCT03415932|Experimental|Health education|Assessment of healt care Contacts Before and after intervention
2422982|NCT03415919||IBD patients|Patients suffering from IBD scheduled to have a biopsy by colonoscopy.
2422983|NCT03415919||CRC patients|Patients suffering from CRC scheduled to have a biopsy by colonoscopy, or surgical resection of colon.
2422984|NCT03415919||Control patients|Patients who are scheduled to have a colonoscopy for routine screening to serve as a control population.
2422985|NCT03415906|Experimental|sacubitril+valsartan|Combined angiotensin receptor and neprilysin inhibition
2422986|NCT03415906|Active Comparator|valsartan|Angiotensin receptor inhibition alone
2422987|NCT03415880|Other|Control group|Participants attend 4 workshops and undergo all measurements at t=0, t=3, t=6, and t=12 months.
2422988|NCT03415880|Experimental|Intervention group|Participants attend 4 workshops, receive a wrist-worn feedback physical activity monitor, a smartphone app, and telephone coaching. All participants undergo all measurements at t=0, t=3, t=6, and t=12 months.
2422989|NCT03415867|Experimental|Dose escalation sequential cohorts|Glasdegib will be self-administered orally once daily in the morning as monotherapy in continuous 28-day treatment cycles for a maximum of 24 cycles. Those patients enrolled in the trial that obtain objective clinical benefit under treatment with glasdegib (defined as the achievement of at least a partial response at one or more target organs), will be allowed to proceed to a slow dose withdrawal phase over a period of 6 months after the end of Cycle 24. The dose reduction scheme is fully detailed in the protocol.
2422990|NCT03415854|Experimental|Paricalcitol (Zemplar)|Participants will be treated with the regimen according to the study protocol. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization and undergo imaging to determine response, if any.
2422991|NCT03415841|Experimental|mHealth|"50 patients who are randomized to the intervention group (mHealth remote monitoring devices) will be enabled with remote monitoring devices (Blood Pressure and wearable vital signs monitor, Biovotion) and Kardia mobile application, for home-based rehabilitation program followed by review in the outpatient Cardiology clinics."
2422992|NCT03415841|No Intervention|Control|The control group (50 patients) will just be monitored at fixed intervals in the outpatient Cardiology clinics
2422993|NCT03415828|Experimental|Ethanol gel|CE-marked medical device used according to its instructions for use: GELSCOM® Single injection in the selected disc(s) of 0.6 to 2.2 ml
2422994|NCT03415828|Active Comparator|Steroid infiltration|Authorized drug used according to its summary product characteristics: HYDROCORTANCYL 2,5 POUR CENT Single injection in the selected disc(s) of 0.2 to 2.0 ml
2422995|NCT03415815||T1-T3 esophageal cancer|Pathologically diagnosed patients with T1-T3 esophageal cancer who received surgeries
2422996|NCT03415802|Experimental|Nab-paclitaxel Plus S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) S-1 (40mg BID for body surface area<1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for body surface area>1.5 m2; D1-14, q3w)
2422997|NCT03415789||80 patients non ischemic DCM|"A cohort of 80 patients with nonischemic dilated cardiomyopathy in sinus rhythm with left ventricle ejection fraction (EF) less than 45%.~In the first 24 hours after enrollment a coagulation blood test, an electrocardiogram, a Doppler echocardiogram exam and a clinical examination (including neuropsiquiatric evaluation) will be performed.~A cardiac magnetic resonance and a brain magnetic resonance will be performed within 10 days after the enrollment."
2422998|NCT03415776|Experimental|Twice weekly|Two sessions of hemodialysis per week
2422999|NCT03415776|Experimental|Thrice weekly|Three sessions of hemodialysis per week
2423000|NCT03415763|No Intervention|Observation|Observation for patients with pathological complete response or yp stage I(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil)
2423001|NCT03415763|Experimental|5-fluorouracil|Capecitabine for patients with pathological complete response or yp stage I Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil )
2423002|NCT03415763|Experimental|5-fluorouracil alone|5-fluorouracil alone for patients with yp stage II or III Capecitabine 1250 mg/m2 twice daily for 14 days in a 3-week cycle to be administered orally after food, three cycles(According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
2423003|NCT03415763|Experimental|mFOLFOX6 or CAPOX|Oxaliplatin combined with 5-fluorouracil for patients with yp stage II or III mFOLFOX6 (leucovorin 400 mg/m2 as a 2-hour infusion, and the concurrent administration of oxaliplatin 85 mg/m2 as a 2-hour infusion, followed by a bolus of 5-FU 400 mg/m2 within 15 min and 46-hour infusion of 5-FU 2400 mg/m2 on day 1 every 2 weeks), three cycles or CAPOX (oxaliplatin 130 mg/m2 as a 2-hour infusion on day 1, followed by capecitabine 1000 mg/m2 twice daily for 14 days every 3 weeks), three cycles( According to the postoperative pathological stage, the present study was designed as a superiority trail for patients with yp stage II or III to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone)
2423004|NCT03415750|Experimental|Everolimus arm|Patients will be converted from Tacrolimus + Mycophenolate mofetil to Everolimus + Tacrolimus 'Conversion from Mycophenolate mofetil to Everolimus'
2423005|NCT03415750|Active Comparator|Mycophenolate arm|Patients will remain in Tacrolimus + Mycophenolate mofetil combination
2423006|NCT03415724|Active Comparator|1.8 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.
2423007|NCT03415724|Active Comparator|3.6 ml Lignocaine plus adrenaline|The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.
2423008|NCT03415724|Active Comparator|1.8 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
2423009|NCT03415724|Active Comparator|3.6 ml Lignocaine plus dexmedetomidine|conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.
2423010|NCT03415711|Experimental|Mesalamine plus high-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets per day (900 billion of bacteria per day) for 12 months.
2423011|NCT03415711|Experimental|Mesalamine plus low-probiotic preparation VSL#3®|Mesalamine 2.4 g/day in once daily administration plus VSL#3® 450 billion sachets, two sachets twice a day (1800 billion of bacteria per day) for 12 months.
2423012|NCT03415711|Active Comparator|Mesalamine plus Placebo|Mesalamine 2.4 g/day in once daily administration plus placebo for 12 months.
2423013|NCT03415698|Active Comparator|Standard Medical Therapy|Standard medical therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins, antibiotics. fresh frozen plasma and packed red-cell transfusions (as required)
2423014|NCT03415698|Active Comparator|G-CSF + Standard Medical Therapy|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
2423015|NCT03415685|Active Comparator|Group A: PicoPlus for unwanted tattoos.|Subjects receiving PicoPlus laser system treatment for unwanted tattoos.
2423016|NCT03415685|Active Comparator|Group B: PicoPlus for other dermatological conditions|Subjects receiving PicoPlus laser system treatment for unwanted benign pigmented lesions, melasma or other dermatological conditions such as skin rejuvenation.
2423017|NCT03415672|Active Comparator|Group 1|Subjects included in Group 1 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine. They will receive three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
2423018|NCT03415672|Experimental|Group 2|"Subjects included in Group 2 are adults who are non-responders (did not achieve seroprotection after 3 or more vaccinations with a Hepatitis B vaccine). They will receive three doses of HBAI20 at 0, 1, and 2 months.~The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly."
2423019|NCT03415659|Experimental|HWH340 monotherapy|HWH340 tablet, oral administration
2423020|NCT03415646|Active Comparator|Block Group|Erector Spinae Plane Block administered group
2423021|NCT03415646|Sham Comparator|Control Group|Control group
2423022|NCT03415633|Active Comparator|Diagnostic Randomizing|Randomizing to start with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
2423023|NCT03415633|Active Comparator|Therapeutic Randomizing|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA) or Standard Polysomnography (PSG)
2423024|NCT03415620|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlist of different music genres. Patient will choose the desired playlist and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
2423025|NCT03415594|Experimental|FE203799 5 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
2423026|NCT03415594|Placebo Comparator|Placebo|Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration
2423027|NCT03415594|Other|FE203799 10 mg|FE203799 GLP-2 analogue, once weekly, subcutaneous administration
3186966|NCT00750958|No Intervention|1|ED patients that are not monitored with conventional therapy.
3186967|NCT00750971|Experimental|1|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
2423030|NCT03415568|Placebo Comparator|LCT consumption|Muffin that contains 15g of long-chain triglyceride (LCT) oils were provided to conduct 6-h meal tolerance test.
2423031|NCT03415568|Experimental|MCDG consumption|Muffin that contains 15g of the mixture of medium-chain triglyceride and diacylglycerol (MCDG) oils were provided to conduct 6-h meal tolerance test.
2423032|NCT03415555|Experimental|ESP|Before the induction of general anesthesia, Erector Spinae Plane (ESP) blockade will be done. Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose.
2423033|NCT03415555|Experimental|PCA|Postoperative analgesia is provided with intravenous oxycodone. Patient-controlled analgesia pump (PCA) will be used for this purpose. ESP will not be done in this arm.
2423034|NCT03415542|Other|Exercise Intervention|Participants receive a print-based exercise promotion program across 12 weeks and are asked to monitor their exercise behavior using an app on their cell phone.
2423035|NCT03415529||4500 patients with ARDS|This is a secondary analysis of data from the LUNG SAFE database to determine the impact of alterations in arterial carbon dioxide tensions in patients with ARDS.
2423036|NCT03415516|Experimental|Gluma Universal, self-etch mode (GSE)|
2423037|NCT03415516|Experimental|Gluma Universal, selective etching (GSL)|
2423038|NCT03415516|Experimental|Gluma Universal, etch&rinse (GER)|
2423039|NCT03415516|Experimental|All Bond Universal, self-etch (ASE)|
2423040|NCT03415516|Experimental|All Bond Universal, selective etching (ASL)|
2423041|NCT03415516|Experimental|All Bond Universal, etch&rinse (AER)|
2423042|NCT03415516|Experimental|Single Bond2, etch&rinse (SBU)|
2423043|NCT03415503|Placebo Comparator|placebo|The placebo capsules only contained pullulan and maltodextrin.During the trial period, the participants were instructed to consume 2 Medox® placebo capsules twice daily (30 min after breakfast or supper).
2423044|NCT03415503|Experimental|40mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum). To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (40 mg anthocyanins per capsule) will provid a total daily intake of 40 mg anthocyanins.
2423045|NCT03415503|Experimental|80mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume one Medox® anthocyanin capsules and one Medox® placebo capsules 30 min after breakfast and consume two Medox® placebo capsules 30 min after supper.The anthocyanin capsules (80 mg anthocyanins per capsule) will provid a total daily intake of 80 mg anthocyanins.
2423046|NCT03415503|Experimental|320mg/d anthocyanins|Medox® Anthocyanin capsules is consisted of 17 different natural purified anthocyanins.from bilberry (Vaccinium myrtillus) and black currant (Ribesnigrum).To achieve the double-blind,every group are instructed to consume the same amount of capsule. During the trial period, the participants will be instructed to consume two Medox® anthocyanin capsules 30 min after breakfast and after supper.The anthocyanin capsules (80 mg anthocyanins per capsule,4 per day) will provid a total daily intake of 320 mg anthocyanins.
2423047|NCT03415490|Active Comparator|Classic technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~classic technique of self-adherent wrap after surgery"
2423048|NCT03415490|Experimental|Folded technique of self-adherent wrap|"over 16 years old~free of any symptoms in the eyes~folded technique of self-adherent wrap after surgery"
2423049|NCT03415477|Experimental|denosumab (Xgeva) treatment|Patients with aneurismal bone cysts received perioperative denosumab(Xgeva).
2423050|NCT03415464|Experimental|Functional training|15 weeks of structured exercise intervention in the form of functional training. We have divided 15 weeks into 5 cycles each cycle lasting 3 weeks. Intervention will be administered twice per week, and each session will last 45 minutes.Each 45 minutes will be further divided into 10 minutes of functional warm-up, 30 minutes of neuromuscular training (strength, agility, balance, coordination) and 5 minutes of cool down. During the 3 week period the intensity of exercise will be increased with different form of same exercise, different number of repetitions and exercise duration.
2423051|NCT03415464|No Intervention|Regular army training|Regular military training.
2423052|NCT03415451|Experimental|Fiberscope-Guided Nasogastric tube|Fiberscope-Guided Nasogastric tube insertion
2423053|NCT03415438||Group 1|Assessments will be done for 30 patients diagnosed as subacromial impingement syndrome in physical medicine and rehabilitation department of Baskent University.
3186968|NCT00750971|Active Comparator|2|Best currently available immunosuppressive/immunomodulatory therapy
3186969|NCT00750984|Experimental|1|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
3186970|NCT00750984|Active Comparator|2|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
3186971|NCT00750997||Hypertonic saline|Hypertonic resuscitation
2423055|NCT03415425|Active Comparator|Usual Care|The current version of the alert will fire for this arm of the study.
2423056|NCT03415425|Active Comparator|Alert Iteration|A modified version of the alert will fire for this arm of the study.
2423057|NCT03415412|Experimental|Group CU (Clearfil Universal)|Clearfil Univesal Bond (Kuraray Dental, New York, United States of America), adhesive system
2423058|NCT03415412|Experimental|Group IU (Ibond Universal)|IBond Universal (Heraeus Kulzer GmbH, Hanau, Germany), adhesive system
2423059|NCT03415412|Experimental|Group GP (G-Premio)|G-Premio Bond (GC Coorporation, Tokyo, Japan), adhesive system
2423060|NCT03415399|Experimental|i.v. arm|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
2423061|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2)|
2423062|NCT03415386|Experimental|aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid|
2423063|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.2)|
2423064|NCT03415386|Experimental|aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid|
2423065|NCT03415373|Experimental|Intervention arm|Each subject will undergo ID administration by Microneedle Adapter (Model UAR-2S) and hypodermic needle + syringe of 100 μL injectable saline into 3 different regions: the inner forearm, the deltoid and the thigh, at three (3) study visits. A total of 4 injections (2 x 50 μL saline and 2 x 100 μL saline) will be administered to each study participant in the injection sites (2 injections per inner forearm/deltoid/thigh and 2 injection per device).
2423066|NCT03415360|Other|cryoablation|peripheral nerve cryoablation
2423067|NCT03415347|Active Comparator|Abscess de-roofing and curettage|Abscess de-roofing and curettage. The patient will be placed in the lateral position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. A spindle-shaped (elliptical) excision will be performed to the lateral aspect of the abscess formation with a scalpel staying away from the midline. Once the pus has been drained through this lateral incision the wound cavity will then be curetted and washed out with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
2423068|NCT03415347|Active Comparator|Abscess wide local excision|Wide local excision. Patients will be placed in the prone position with the buttocks spread apart using tape. The cleft of the buttocks will be shaved prior to cleaning and preparation of the skin. Diluted methylene blue will be injected in all visible pits and a wide spindle-shaped (elliptical) midline excision of the skin and the underlying subcutaneous tissue down to the coccygeal (pre-sacral) fascia including all sinuses will be performed with electrocautery. The specimen will be sent for histology as per routine surgical practice. The wound will be washed with hydrogen peroxide. The wound size will be measured by the operating surgeon who will record the maximal length and width of the wound. Once haemostasis (cessation of any bleeding) is achieved the wound will be packed with Kaltostat ribbon and the wound dressed with blue gauze and mefix tape. The wound is therefore left open.
2423069|NCT03415334|Other|behavioral change|two approaches for behavior changes : social marketing and behavioral development
2423070|NCT03415321|Experimental|Intervention group|Postpartum Mobile Support Application
2423071|NCT03415321|No Intervention|Control Group|Routine care
2423072|NCT03415308||Patient Focus Groups|Identify patient preferences for constructs, and related outcomes, that reflect the expression of implicit bias in clinical encounters. I
2423073|NCT03415308||Stakeholders Cognitive Interviews|Investigators will conduct a series of semi-structured interviews.
2423074|NCT03415308||Pilot Testing of Implicit Bias Training|Refined intervention emerging from Aim 2. T
2423075|NCT03415295||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
2423076|NCT03415295||Healthy pregnant control|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls.
2423077|NCT03415282|Experimental|Open-label treatment arm|Open-label treatment arm - patients will receive RVT-501 0.5% twice daily (BID) for 4 weeks.
2423078|NCT03415269|Experimental|20 mg ambroxol|20 mg ambroxol lozenge delivered once on one day
2423079|NCT03415256|Experimental|passive vibration group|The passive vibration group patients will receive passive vibration (50 Hz, one cycle= 60 seconds working time with 2 seconds rest time) on their calf in supine position for ten minutes. The total number of sessions will be nine. Passive vibration will be given to the treatment group twice a week for four weeks (eight sessions) and the ninth session will be the follow up. At every session, the skin blood flow will be measured before, immediately, and 15 minutes after passive vibration.
2423080|NCT03415256|Active Comparator|no passive vibration group|The control group will not receive any treatment and continue their usual lifestyle. Balance, sensory measurement and skin blood flow will be taken at the beginning of the study, prior to the 5th treatment, and 1 week after the last intervention .
3186972|NCT00750997||Control: normal saline|Normal saline resuscitation
3186973|NCT00751010||1|In a mailed survey (Part 1 of this study), 127 women with a documented diagnosis of IC agreed to be contacted for an in-office examination.
2423083|NCT03415230|Experimental|Therapeutic massage|Women will undertake sessions of therapeutic massage
2423084|NCT03415230|Sham Comparator|Sham massage|Women will undertake sessions of sham massage
2423085|NCT03415217|Other|Neighbourhood Team Development|Neighbourhood Team Development consisted of a 30-month standardised training and implementation plan to promote inter-professional team collaboration and enhanced resident centeredness.
2423086|NCT03415204|Experimental|acupuncture|
2423087|NCT03415204|No Intervention|no acupuncture|
3186974|NCT00751049|Experimental|PhXA41|
3186975|NCT00751049|Active Comparator|timolol|
2423088|NCT03415191|Experimental|Ketamine Group|Five minutes before thoracotomy incision, Ketamine Group received a bolus dose of ketamine 1 mg/kg intravenously
2423089|NCT03415191|Placebo Comparator|Placebo Group|Five minutes before thoracotomy incision, Placebo Group received a bolus dose of normal saline 1 mg/kg intravenously
2423092|NCT03415165|Active Comparator|green tea buccal tablet|buccal tablet 3 times aday
2423093|NCT03415165|Sham Comparator|corticosteroids topical|topical steroids 3 times aday
2423095|NCT03415139||Arm 1 for MRD HCT Recipients|Patients undergo an Oral Glucose Tolerance Test (OGTT) and 1 hyperglycemic clamp will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
2423096|NCT03415139||Arm 2 for MRD HCT Recipients|Patients undergo 2 Oral Glucose Tolerance Test (OGTTs) (with and without GLP-1 infusion) will be performed on separate days prior to transplant and then each procedure will be repeated once between day+80 to day+100 (+/- 10 days) after transplant.
2423097|NCT03415126|Experimental|ASN007 ascending doses|Patients will receive escalating doses of ASN007 to identify the best dose.
2423098|NCT03415126|Experimental|ASN007 RD: KRAS mutant Melanoma|Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
2423099|NCT03415126|Experimental|ASN007 RD: NRAS mutant Melanoma|Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
2423100|NCT03415126|Experimental|ASN007 RD: KRAS mutant metastatic CRC|Patients with KRAS mutant CRC will receive the recommended dose from Part A
2423101|NCT03415126|Experimental|ASN007 RD: KRAS mutant NSCLC|Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
2423102|NCT03415126|Experimental|ASN007 RD: Metastatic Pancreatic Cancer|Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
2423103|NCT03415126|Experimental|ASN007 RD: MEK, All BRAF, BRAF-fusion cancers|Patients with solid tumors will receive the recommended dose from Part A
2423104|NCT03415100|Experimental|CAR-NK cells targeting NKG2D ligands|
2423105|NCT03415087|Active Comparator|sequential intrathecal injection of fentanyl and bupivacaine|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV,once drug: hyperbaric bupivacaine 0.5%10 mg IV,once both syringes were injected slowly sequentially
2423106|NCT03415087|Experimental|rapid sequential intrathecal injection of fentanyl and bupiva|intrathecal injection drug: fentanyl 25 μg (0.5 ml), IV, injected rapidly and mixed by CSF, once drug: hyperbaric bupivacaine 0.5%10 mg IV injected slowly once.
2423107|NCT03415074|Active Comparator|Supplemented low protein diet (sLPD)|Protein restriction to a low level (0.6 g/kg-day, mainly vegetarian) + ketoanalogues of essential amino-acids supplementation (Ketosteril 1 tb/10 kg dry bw)
2423108|NCT03415074|Active Comparator|Mild protein restriction diet (MPD)|Mild restriction in dietary protein intake (0.8 g/kg-day)
3146124|NCT00091377|Experimental|Arm A|Phenoxodiol IV 3 mg/kg combined with cisplatin 40 mg/m2 on Day 2 6 week cycles
3146125|NCT00091377|Experimental|Arm B|Phenoxodiol IV 3 mg/kg combined with paclitaxel 80 mg/m2 on Day 2 6 week cycles
2423111|NCT03415035||Patients with Chronic Lymphocytic Leukemia (CLL)|Patients with diagnosed CLL and eligible to venetoclax as per label
2423114|NCT03415009||HCV genotype 1 and genotype 2/3|DNA extracted from whole blood sample will be used as template for real-time PCR amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for rs12979860 and TT/GT/GG for rs8099917).
2423115|NCT03414996|Experimental|High-intensity interval training|Following 5 min warm-up at 30 % of maximal aerobic power (MAP) obtained at the cardiopulmonary exercise test, patients performed 2 sets of 10 minutes of repeated phases of 15 seconds at 100 % MAP alternating with 15 seconds of passive recovery. The 2 sets were separated by 4 min of passive recovery (no pedalling). Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
2423116|NCT03414996|Active Comparator|Moderate-intensity continuous exercise training|Duration was adjusted to match total energy expenditure of the high-intensity interval training session. Following 5 min warm-up at 30 % of maximal aerobic power (MAP), patients performed continuous exercise at 60 % MAP during 24 minutes. Patients performed 5-minutes of recovery period at 30 % MAP after the second set. Total time duration was 34 minutes.
3146126|NCT00091468|Placebo Comparator|Placebo Group|Placebo for first six months of study; moved to open-label active nicotine for second six months
3146127|NCT00091468|Experimental|Active Nicotine Group|Blinded active nicotine for first six months of study; open-label active nicotine for second six months
2423119|NCT03414970|Active Comparator|Group I (radiation therapy)|Patients undergo radiation therapy daily on Monday-Friday for 5-6 weeks.
2423120|NCT03414970|Experimental|Group II (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy daily on Monday-Friday for 3-4 weeks.
2423188|NCT03414463|Experimental|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
3146128|NCT00091637|Placebo Comparator|1|Placebo infusion
3146129|NCT00091637|Experimental|2|Pexelizumab infusion
3146130|NCT00091676|Experimental|ID-KLH + GM-CSF|
3146131|NCT00091676|Active Comparator|KLH + GM-CSF|
3146132|NCT00091715|Experimental|1|62.5 mg table twice a day for 4 weeks followed by 125 mg tablet twice a day for 6 months followed by an open label period until end of study.
3146133|NCT00091715|Placebo Comparator|2|placebo for 6 months followed by an open label period
3146134|NCT00091806|Experimental|Cohort 1|6mg/kg of panitumumab administered once every 2 weeks until subjects develop disease progression or are unable to tolerate the study drug
3146135|NCT00091806|Experimental|Cohort 2|Panitumumab 9 mg/kg administered once every 3 weeks until subjects develop disease progression or are unable to tolerate the study drug.
3146136|NCT00091858|Experimental|Darbepoetin alfa 6.75 mcg/kg Q4W|
3146137|NCT00091858|Placebo Comparator|Placebo Q4W|
3146138|NCT00091897|Experimental|Rituximab or placebo|Rituximab or placebo is administered through intravenous access on day 1 and again on day 15 (+/- 2 days)
3146139|NCT00091988|Experimental|Lifestyle & Behavioral Change Program|
3146140|NCT00091988|Active Comparator|Structured Education Program|
3146141|NCT00092001|Experimental|1|
2423121|NCT03414957||Malay PCOS women|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who fulfilled these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria
2423122|NCT03414957||Malay women without PCOS|Malay women underwent clinical assessment, followed by pelvic ultrasound scan, biochemical and hormonal blood tests. Using the Rotterdam criteria for the diagnosis of PCOS, Malay women who did not fulfill these criteria were inducted into this group. These women were then identified whether they had Metabolic Syndrome or not based on the WHO criteria.
2423123|NCT03414944|Experimental|SMART-Brain|selective brain radiotherapy based on SIB and hippocampus, inner ear avoidance.
2423124|NCT03414931|Experimental|NMDAE|An NMDA enhancer
2423125|NCT03414931|Active Comparator|SSRI|Sertraline
2423126|NCT03414931|Placebo Comparator|Placebo|Placebo
2423127|NCT03414918|Experimental|Clarithromycin|250 mg clarithromycin diluted in 250 ml saline will be administered as a slow infusion (45 min) in a peripheral vein during AVS. This dose of clarithromycin should yield peak plasma concentrations of 2.78 mcg/mL (on average)13, which are higher than the IC50 measured in vitro (0.53-1.29 mcg/mL).
2423128|NCT03414905|Experimental|Aspira Catheter & Drainage System|"Participants will have standard of care ultrasound and placement of the Aspira Catheter and Drainage System on Day 1~The removal of the Aspira Catheter and Drainage System will be dependent upon future ultrasound assessment and fluid output"
2423129|NCT03414892|Experimental|Globalagliatin Hydrochloride (SY-004)|If subjects tolerate 20mg of Globalagliatin Hydrochloride (SY-004) for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
2423130|NCT03414892|Placebo Comparator|Placebo|If subjects tolerate 20mg of Placebo for 7 days, dose escalation will occur in the following order of 40mg, 80mg and 120mg at weekly intervals until patients get intolerant or blood glucose controlled well or reach the maximal dose 120mg.
2423131|NCT03414879|Active Comparator|Ketamine group|Nebulization with ketamine
2423132|NCT03414879|Active Comparator|Lidocaine group|Nebulization with with lidocaine
2423133|NCT03414866||Acute thoracic aortic syndrome|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2423134|NCT03414866||Subacute/chronic dissection of the aorta|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2423135|NCT03414866||Aortic aneurysm|60 patients, standard of care (non-interventional) EQ-5D-5L QOL Questionnaire
2423136|NCT03414853||With algorithm use|
2423137|NCT03414853||No algorithm use|
2423138|NCT03414814|Experimental|Osimertinib|Osimertinib at 80mg dose will be administered orally once daily.
2423139|NCT03414801|Active Comparator|Cohort 1|Cat Allergic Subjects
2423140|NCT03414801|Active Comparator|Cohort 2|Non-Allergic Subjects will
2423141|NCT03414788|Experimental|Treatment Arm - PF 06687234 and [124I]IB PF 06687234|PF 06687234 and [124I]IB PF 06687234
2423142|NCT03414775|Active Comparator|Pediasure|Patients assigned to this arm will receive Pediasure
2423143|NCT03414775|Active Comparator|Nourish|Patients assigned to this arm will receive Nourish
2423144|NCT03414762|Experimental|PICO Dressing|PICO Negative Pressure Wound Therapy (Smith and Nephew Healthcare, Hull, United Kingdom) is a non-significant-risk, FDA Class II, medical device commercially available in the USA. The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.
2423145|NCT03414762|Active Comparator|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing.
2423146|NCT03414749|Experimental|Lower Extremity First (LEF)|The treatment was a non-specific long-axis distraction to the ankle, knee, and hip provided was at the discretion of the clinic doctor (over 25 years experience).
2423147|NCT03414749|Experimental|Upper Extremity First (UEF)|The treatment was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
2423148|NCT03414736|Experimental|Cohort 1|Daily dose escalation (click-by-click): Starting at dose 1 in the morning with daily increments to dose 2. During the escalation phase, the dose will only be increased if the patient is feeling fine.
2423149|NCT03414736|Experimental|Cohort 2|Weekly dose escalation in 6 escalation steps (7 dose levels): Starting at dose 1 injected in the morning with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
2423150|NCT03414736|Experimental|Cohort 3|Weekly dose escalation in 4 escalation steps (5 dose levels): Starting at dose 3 with weekly increments to dose 2. In case a dose level is not well tolerated by a patient, the treatment should continue at the same dose level for another 7 days before the next dose escalation.
2423151|NCT03414723|Experimental|SAR439954 with or without ramipril|"On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing.~On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing."
2423152|NCT03414710|Experimental|Intervention group|"Health education booklet plus video plus brief counseling~In addition to the educational booklet received by the control group, the intervention group will receive the following health promotion:~Watch a 10-minute video promoting VMMC~Receive a brief counseling promoting VMMC If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
2423229|NCT03414203|Active Comparator|active tDCS|Active tDCS for 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
2423153|NCT03414710|Active Comparator|Control group|"Health education booklet only After randomization took place, the control group will receive an education booklet introducing voluntary medical male circumcision.~If the participants are willing to take up VMMC, the counselors will facilitate them to make an appointment for check-up and surgery."
2423154|NCT03414697|Other|Control group|Routine rehabilitation treatments
2423155|NCT03414697|Experimental|Intravenous UC-MSCs group|Injection of UC-MSCs via the peripheral vein.
2423156|NCT03414697|Experimental|Intrathecal UC-MSCs group|Injection of UC-MSCs via the intrathecal route.
2423157|NCT03414697|Experimental|Intranasal UC-MSCs group|Injection of UC-MSCs via the nasal route.
3146142|NCT00092014|Experimental|Alendronate 70 mg|Alendronate sodium, 70 mg, orally once weekly for up to 24 months
3146143|NCT00092014|Active Comparator|Risendronate 35 mg|Risendronate, 35 mg, orally once weekly for up to 24 months
2423160|NCT03414671||historical control|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 11/30/2015-11/30/2017 (historical control, pre-standardized defined CSCPE
2423161|NCT03414671||Standardized|All infants born < 30 weeks gestation admitted to the Swedish Hospital NICU from 6/1/2018 - 12/31/20 (the group following implementation of the standardized defined CSCPE)
2423162|NCT03414658|Experimental|Trastuzumab + Vinorelbine|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle"
2423163|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab"
2423164|NCT03414658|Experimental|Trastuzumab + Vinorelbine + Avelumab + Utomilumab|"Trastuzumab is administered intravenously twice per cycle~Vinorelbine is administered intravenously 3 times per cycle~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle"
2423165|NCT03414658|Experimental|Trastuzumab + Avelumab + Utomilumab|"This is a crossover arm~Avelumab is administered intravenously twice per cycle~Antihistamine and with acetaminophen is mandatory 30 to 60 minutes prior to each dose of avelumab~Utomilumab is administered intravenously once per cycle~Trastuzumab is administered intravenously twice per cycle"
2423166|NCT03414645|Experimental|CAM-101 10%|FD hPL 10 vol/vol %
2423167|NCT03414645|Experimental|CAM-101 30%|FD hPL 30 vol/vol %
2423168|NCT03414645|Placebo Comparator|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
2423169|NCT03414632|Other|SPECT/CT|99mTc-PYP single-photon positive emission computed tomography with computed tomography
2423170|NCT03414619|Experimental|Intrusive Thoughts Group|Clinically significant intrusive thought in the domain of obsessions, worries, or depressive ruminations with a score above the clinical mean (≥ 37) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
2423171|NCT03414619|Experimental|Non-psychiatric Control Group|A score 1 SD below the community mean (≤ 15) on the trait repetitive negative thinking measure (Perseverative Thinking Questionnaire, PTQ). These participants will also receive the Cognitive Control Tasks and Script Driven Imagery Intervention.
2423172|NCT03414593|Experimental|preoperative blocked leg: group preB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml Before surgical incision
2423173|NCT03414593|Active Comparator|postoperative blocked leg: group postB|ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml After surgical incision
2423174|NCT03414580||Ulcerative colitis|Patients with ulcerative colitis whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2423175|NCT03414580||Crohn's disease|Patients with crohn's disease whose diagnosis had established on clinical, endoscopic, histologic, and/or radiological criteria. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2423176|NCT03414580||Healthy control|Subject with no intestinal symptoms or no known gastrointestinal disorders. Breath sampling for volatile organic compounds will be analysed by gas chromatography-mass spectrometry.
2423177|NCT03414567||Control Group|Non-smoker
2423178|NCT03414567||Study Group|Smoker
2423179|NCT03414554||HCV patients receiving DAAs|Patients with HCV-related liver cirrhosis (eligible for treatment) who will recieve DAAs therapy with one year follow up.markers: miR121, miR122, miR124will be assessed in both groups before and after DAAs
2423180|NCT03414541|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
2423181|NCT03414541|Experimental|500mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
2423182|NCT03414541|Experimental|1000mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
2423183|NCT03414528||Patients with PID|
3146144|NCT00092053|Placebo Comparator|Placebo|Participants will receive 3 placebo tablets once a month, for 3 months, on the first day of each treatment cycle.
2423186|NCT03414476|Experimental|ET group|Sampling : Hair follicles sampling on the scalp in women with Telogene Effluvium
2423187|NCT03414476|Experimental|Control group|Sampling: Hair follicles sampling on the scalp in women without Telogene Effluvium
2423277|NCT03413956||NSCLC patients with lymph metastases|Pathologically diagnosed patients with T1 non-small cell lung cancer complicated with lymph metastases after surgeries
3146145|NCT00092053|Experimental|ibandronate 100 mg|Participants will receive 2 ibandronate 50 mg tablets and 1 placebo tablet once a month, for 3 months, on the first day of each treatment cycle.
3146146|NCT00092053|Experimental|ibandronate 150 mg|Participants will receive 3 ibandronate 50 mg tablets once a month, for 3 months, on the first day of each treatment cycle.
3186976|NCT00751062|Active Comparator|Timolol|
3186977|NCT00751062|Experimental|PhXA41|
2423189|NCT03414463|Experimental|Waitlist Control|After Time 1 testing in Week 1, participants randomized to WLC will not receive any treatment during Weeks 2-5. The only staff interaction during this no treatment time period will be to schedule Time 2 testing appointment for week 6. After Time 2 testing, WLC will receive TREAT (weeks 14-17), followed up with testing.
2423190|NCT03414450|Experimental|Dose Escalation (Phase 1A)|An adaptive design using the ordinal Continual Reassessment Method (oCRM) will be used to determine the MTD and RD of ETC-1907206 in combination with dasatinib.
2423191|NCT03414450|Experimental|Dose Expansion (Phase 1B)|Once the MTD and/or RD has been determined in Phase 1A, an expansion cohort will be enrolled in order to characterize the safety, PK and preliminary clinical activity of ETC-1907206 in combination with dasatinib. Subjects may continue treatment in the study until disease progression, unacceptable toxicity, withdrawal of consent or it is judged not to be in the patient's interest to continue on the study.
2423192|NCT03414424|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
2423193|NCT03414398||Experimental|Qualitative interview
2423194|NCT03414385|Experimental|Exercise group|Research volunteers will be asked to undergo an acute bout of aerobic exercise at moderate intensity for ~120 minutes. Before and after the exercise the volunteer will undergo leg biopsy.
2423195|NCT03414372|Experimental|Tough Talks Online|Participants will use Tough Talks Online
2423196|NCT03414372|Experimental|Tough Talks Clinic|Participants will use receive Tough Talks in a clinic
2423197|NCT03414372|Placebo Comparator|Standard of Care|Participants will receive the standard of care (SOC).
3186978|NCT00751075|Active Comparator|1|MFNS once daily
3186979|NCT00751075|Experimental|2|MFNS twice daily
2423200|NCT03414346|Experimental|Exclusively ice pack:|Ice pack application: 500 grams of crushed ice.
2423201|NCT03414346|Experimental|Ice pack added 10% of water:|Wetted ice pack application: 500 grams of crushed ice added to 50 mL of water at room temperature.
2423202|NCT03414346|Experimental|Ice pack added 100% of water:|Wetted ice pack application: 500 grams of crushed ice added to 500 mL of water at room temperature.
2423203|NCT03414333|Experimental|Roux-en- Y gastric bypass (RYGB)|Roux-en- Y gastric bypass (RYGB) is the most popular bariatric procedure and it has been associated with improvements in glycemic control and cognitive function. It works by decreasing the amount of food you can eat at one sitting and by changing the hormones released at the bottom of the stomach and duodenum.we propose that RYGB is a model of chronic elevation of GLP-1 providing an opportunity to explore relationship between changes in the circulating hormone and brain glucose metabolism, cognitive function and neuroplasticity.
2423204|NCT03414333|Active Comparator|GLP-1|GLP-1 is an intestinal hormone secreted in response to nutrients.
2423205|NCT03414320|Experimental|Study Arm|We will gather data from this group of patients.
2423206|NCT03414307|Experimental|Intracerebral hemorrhage|Patients with ICH meeting inclusion/exclusion criteria undergo ROSA stereotactic robot-assisted intracerebral catheter placement to evacuate intracerebral or intracranial hemorrhage
2423207|NCT03414294|Experimental|K-755 Part A (SAD)|
2423208|NCT03414294|Placebo Comparator|Placebo Part A (SAD)|
2423209|NCT03414294|Experimental|K-755 Part B (MAD)|
2423210|NCT03414294|Placebo Comparator|Placebo Part B (MAD)|
2423211|NCT03414294|Experimental|K-755 Part C (FE)|
2423212|NCT03414294|Experimental|K-755 Part D (FE)|
2423213|NCT03414294|Experimental|K-755 Part E (MAD)|
2423214|NCT03414294|Placebo Comparator|Placebo Part E (MAD)|
2423215|NCT03414281|Experimental|TMQLB group 1|0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
2423216|NCT03414281|Experimental|TMQLB group 2|0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
2423217|NCT03414281|Active Comparator|TPVB group|0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.
2423218|NCT03414268|Experimental|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
2423219|NCT03414268|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
2423220|NCT03414255|Experimental|Micronized DHACM|1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)
2423221|NCT03414255|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
3186980|NCT00751075|Active Comparator|3|Amoxicillin
2423223|NCT03414229|Experimental|UPS, Liposarcoma or pleomorphic liposarcoma|Undifferentiated Pleomorphic Sarcoma (UPS) or Liposarcoma (dedifferentiated or pleomorphic liposarcoma) Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2423224|NCT03414229|Experimental|Leiomyosarcoma|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2423225|NCT03414229|Experimental|Vascular Sarcoma Subtypes|Including angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2423226|NCT03414229|Experimental|Other|Epacadostat 100mg Twice daily Continuously days 1-21 of each 3 week cycle Oral Pembrolizumab 200mg Every 3 weeks Day 1 of each 3 week cycle IV infusion
2423227|NCT03414216|Experimental|Group1 - early off-loading surgery|"Within 1 week of randomization, offloading surgery:~Tip of toe ulcers will be treated by percutaneous tenotomy. Ulcers under metatarsal heads will be offloaded with minimally invasive floating metatarsal osteotomy.~Ulcers plantar to the interphalangeal joint of the hallux will be treated by a modified Keller resection arthroplasty."
2423228|NCT03414216|Active Comparator|Group 2 - off-loading in fiberglass cast|"Tip of toe ulcers and ulcers plantar to the interphalangeal joint of the big toe will be casted in a fiberglass cast with a heel, ending under the metatarsal heads, leaving the toes in the air.~Ulcers under metatarsal heads will be casted in a full foot fiberglass cast with a heel with a window below the ulcer designed to relieve pressure under the metatarsal heads."
3186981|NCT00751075|Placebo Comparator|4|Placebo
3186982|NCT00751088|Active Comparator|1|Patients treated with Ajust positioning
3186983|NCT00751088|Active Comparator|2|Patients treated with MiniArc positioning
2423230|NCT03414203|Experimental|active tDCS with interval|Active tDCS for 15 minutes, interval of 20 minutes and more 15 minutes for 10 days over 2 weeks. Intensity: 2 milliampere. Placement: anode - left DLPFC; cathode - right supraorbital region
2423231|NCT03414203|Sham Comparator|sham tDCS|Sham tDCS for 15 minutes for 10 days over 2 weeks. The stimulation is non-active. Placement: anode - left DLPFC; cathode - right supraorbital region
2423232|NCT03414190|Experimental|Experimental|Automated semi-personalized mobile phone text message-based intervention for secondary prevention plus usual care.
2423233|NCT03414190|No Intervention|No Intervention|Usual Care
2423234|NCT03414177|Active Comparator|Telemedicine Group|Telemedicine participants will have asthma subspecialty follow-up visits conducted via real-time audio and video conferencing in conjunction with electronic examination peripherals and remote pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
2423235|NCT03414177|Active Comparator|In-Person Group|In-Person participants will have asthma subspecialty follow-up visits at a subspecialty clinic. They will receive pulmonary function testing (PFT). Participants will receive a survey link to complete an electronic survey to assess Asthma Control Test (ACT) score, healthcare utilization, and satisfaction.
2423236|NCT03414164|Experimental|procyanidine group|
2423237|NCT03414164|No Intervention|control group|
2423238|NCT03414151||Observational - Case Arm|All participants will be placed in this arm or group if they have an eligible psychiatric diagnosis as a case (there is no randomization procedure)
2423239|NCT03414151||Observational - Healthy Control Arm|All participants will be placed in this arm if they are healthy controls (there is no randomization procedure)
2423240|NCT03414138|Experimental|Mindfulness Meditation Group|"Research volunteers will participate in four sessions (20 min/session) of mindfulness training. Participants are taught that perceived sensory events are momentary and fleeting, requiring no further evaluation. They will be asked to close their eyes, relax and focus on the flow of their breathing by simply letting go of discursive thoughts."
2423241|NCT03414138|Active Comparator|Book Listening Control|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
2423242|NCT03414125|Active Comparator|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
2423243|NCT03414125|Experimental|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences.~Choice Strategy outreach invitation includes: 1) invitation letter, 2) option grid comparing FIT and colonoscopy 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
2423244|NCT03414112|Placebo Comparator|Intranasal Oxytocin Placebo|Intranasal placebo
2423245|NCT03414112|Experimental|Intranasal Oxytocin|Intranasal oxytocin
2423246|NCT03414099|Experimental|Ketum|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
2423247|NCT03414099|Placebo Comparator|Placebo|Each participant will consume a sequence of active ketum or placebo drinks. Pain tolerance will be measured using the cold pressor task after consuming each drink.
2423248|NCT03414086||Myositis in Remission|Subjects who are in remission with their myositis diagnosis.
2423249|NCT03414086||Healthy Controls|Subjects who do not have a myositis diagnosis.
2423250|NCT03414073|Sham Comparator|Group A Phase 1|"Conventional flossing technique using commercially available Reach® Floss One third of sample are randomly assigned to Group A and are to utilise conventional finger flossing technique in the first phase of 4-weeks. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2423251|NCT03414073|Active Comparator|Group B Phase 1|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss One third of sample are randomly assigned to Group B and are to utilise knotted floss technique in the first phase of 4-weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2423252|NCT03414073|Sham Comparator|Group C Phase 1|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes One third of sample are randomly assigned to Group C and are to utilise conventional interdental brushing technique in the first phase of 4-weeks twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2423276|NCT03413969|Experimental|Behavioral Intervention|The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.
2423766|NCT03410082|Active Comparator|BIS|The patients in the control group will receive MAC titrated according to bispectral index(BIS).
2423253|NCT03414073|Active Comparator|Group A Phase 2|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group A will use the knotted floss technique in the second phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2423254|NCT03414073|Sham Comparator|Group B Phase 2|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group B will use the conventional interdental brushing technique in the second phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2423255|NCT03414073|Sham Comparator|Group C Phase 2|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the conventional finger flossing technique in the second phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2423256|NCT03414073|Sham Comparator|Group A Phase 3|Conventional interdental brushing technique using Thermoseal® Proxa ns interdental brushes After a washout period of 2 weeks, those from Group A will use the conventional interdental brushing technique in the third phase for a period of 4 weeks, twice daily. The subjects will gently insert the brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
2423257|NCT03414073|Sham Comparator|Group B Phase 3|"Conventional flossing technique using commercially available Reach® Floss After a washout period of 2 weeks, those from Group B will use the conventional finger flossing technique in the third phase for a period of 4 weeks, twice daily. For the conventional flossing technique the subjects will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
2423258|NCT03414073|Active Comparator|Group C Phase 3|Knotted floss technique using an improvised flossing technique by putting a knot in commercially available Reach® Floss After a washout period of 2 weeks, those from Group C will use the knotted floss technique in the third phase for a period of 4 weeks, twice daily. The subjects will use the supplied floss lengths having a simple knot in the middle and will perform the same way as the conventional finger flossing technique, except that the insertion of floss will have to be in the non-knotted area and during the to and fro movements the knotted area of the floss will have to be engaged in the interdental area.
2423259|NCT03414060|Experimental|Intervention (Menstrual Cup)|The menstrual cup is a 100% silicone, flexible reservoir cup that, when inserted correctly in the vagina, is sanitary and efficacious in preventing leakage of menstrual blood and in eliminating odor.
3146147|NCT00092092|Experimental|Montelukast→Placebo|Participants receive one montelukast 5 mg chewable tablet once daily (QD) for 3 weeks. After a 2-week washout period, participants receive one placebo chewable tablet QD for 3 weeks.
3146148|NCT00092092|Experimental|Placebo→Montelukast|Participants receive one placebo chewable tablet QD for 3 weeks. After a 2-week washout period, participants receive one montelukast 5 mg chewable tablet QD for 3 weeks.
3146149|NCT00092092|Active Comparator|Budesonide→Placebo|Participants receive budesonide 200 mcg inhalation powder twice daily (BID) for 3 weeks. After a 2-week washout period, participants receive placebo inhalation powder BID for 3 weeks.
3146150|NCT00092092|Active Comparator|Placebo→Budesonide|Participants receive placebo inhalation powder BID for 3 weeks. After a 2-week washout period, participants receive budesonide 200 mcg inhalation powder BID for 3 weeks.
2423264|NCT03414034|Experimental|Arm A: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone. This arm was discontinued.
2423265|NCT03414034|Experimental|Arm B: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 24 mg/m^2 for 5 days (Day 1 through Day 5) out of a 14-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
2423266|NCT03414034|Experimental|Arm C: onvansertib + abiraterone and prednisone|On Day 1 of each cycle, onvansertib will be administered orally (PO) once daily (QD) at a dose of 12 mg/m^2 for 14 days (Day 1 through Day 14) out of a 21-day cycle. Beginning on Day 1 and continuing uninterrupted throughout each cycle, participants will also receive abiraterone and prednisone.
2423267|NCT03414021||Thyroid Diseases|SPECT-CT Scan
2423268|NCT03414021||Heart Diseases|SPECT-CT Scan
2423269|NCT03414021||Bone Diseases|SPECT-CT Scan
2423270|NCT03414021||Brain Diseases|SPECT-CT Scan
2423271|NCT03414021||Kidney Diseases|SPECT-CT Scan
2423272|NCT03414008|Experimental|Active Drug Group|Single dose
2423273|NCT03414008|Placebo Comparator|Placebo Group|
2423274|NCT03413995|Experimental|Rucaparib 600 mg BID, continuous dosing|Rucaparib 600mg by mouth twice daily, continuous dosing
2423275|NCT03413982||BC Patients|Patients with bladder cancer. This registry involves no intervention. Blood, urine, and tissue samples will be collected to be used for research.
2423767|NCT03410069|Experimental|IKORUS UP|
3186984|NCT00751088|Active Comparator|3|Patients treated with TVT secur system
2423278|NCT03413943|Experimental|explicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2423279|NCT03413943|Experimental|implicit gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2423280|NCT03413943|Sham Comparator|sham gaze training|This is an arm of the second phase of the study utilizing gaze training in two different teaching techniques (explicit vs implicit).
2423281|NCT03413930|Experimental|TaTME|Patients with mid or low rectal cancer undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
2423282|NCT03413930|Active Comparator|LaTME|Patients with mid or low rectal cancer undergo laparoscopic total mesorectal excision.
2423283|NCT03413917||Control group|patients who are admitted for repeat cesarean delivery with bilateral tubal ligation who do not develop uterine atony
2423284|NCT03413917||Study group|Patients who develop uterine atony either during cesarean delivery or who require surgical management of atony after delivery
2423285|NCT03413904|Experimental|transanal TME|Study procedure will consist in 2-team (combined) LAR with transanal TME using laparoscopic abdominal assistance.Transanal TME is performed either at the same time or following the above steps. Transanal endoscopic TME dissection will proceed circumferentially until the peritoneal cavity is entered anteriorly. Following complete mobilization of the rectosigmoid, the specimen is extracted transanally or using a Pfannenstiel incision followed by colorectal anastomosis, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
2423286|NCT03413904|Active Comparator|laparoscopic TME|Procedure will consist in 1 team performing laparoscopic TME. Following stapled closure of the rectum below the tumor, and complete mobilization of the rectosigmoid, the specimen is extracted using a Pfannenstiel incision . A stapled (knight-Griffen) colorectal anastomosis or coloanal anastomosis will be created and a temporary diverting stoma will be fashioned which is standard of care following surgery for this type of cancer.
2423287|NCT03413891|Placebo Comparator|Control Group|10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
2423288|NCT03413891|Experimental|Tranexamic Acid Group|10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
2423289|NCT03413878|Experimental|Wet snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a small air pocket
2423290|NCT03413878|Experimental|Dry snow/Small air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a small air pocket
2423291|NCT03413878|Experimental|Wet snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of wet avalanche snow with a large air pocket
2423292|NCT03413878|Experimental|Dry snow/Large air pocket|Breathing in the simulated avalanche snow. Breathing into model of dry avalanche snow with a large air pocket
2423293|NCT03413865|Experimental|OTN virtual clinic|Pharmacist and nurse led OTN based remote teleconference based clinic (OTN) The OTN clinic will be conducted by providing the patient with a link via email which will allow the patient to access OTN teleconferencing and meet virtually with a pharmacist and nurse during a previously scheduled appointment. Virtual clinic appointments will be 30 minutes long and will consist of a patient assessment and open ended questions about the patient health status using a modified version of the validated MOATT (MASCC Oral Agent Teaching Tool) created by the Multidisciplinary Association of Supportive Care in Cancer.
2423294|NCT03413865|No Intervention|In person Visits|Patients are followed in person at the cancer clinic based on standard of care guidelines
2423295|NCT03413839|Experimental|PSSE Group|Individuals will receive at least 6 sessions of physiotherapeutic scoliosis specific exercises (PSSE) (Schroth) physical therapy. Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
2423296|NCT03413839|Other|Conventional PT Group|Individuals will receive at least 6 sessions of conventional physical therapy (PT). Patients will also be required to perform exercises 5x/wk for 15 minutes at home. Compliance will be monitored by written log and weekly phone check-in after 8 weeks.
2423297|NCT03413826|Experimental|6 Days per week|This group will exercise 6 days per week and expend 3,000 kcal per week for 12 weeks
2423298|NCT03413826|Experimental|2 Days per week|This group will exercise 2 days per week and expend 3,000 kcal per week for 12 weeks
2423299|NCT03413826|No Intervention|control|This group will remain sedentary for 12 weeks
2423300|NCT03413800|Experimental|Lenalidomide-Dexamethasone-DLI|"Patients will receive Len (10 mg in the presence of ≤ grade I acute GVHD or absence of chronic GVHD; 5 mg in presence of controlled mild or moderate chronic GVHD) daily x 21 days with Dex 40 mg once weekly for a total of 6 cycles of 28 days each~For grade ≥III non hematologic or grade IV hematologic toxicity, Len can be reduced to 5 mg~In absence of these toxicities, acute GVHD (using Glucksberg modified criteria) or severe chronic GVHD (using NIH criteria), Len dose can be increased by 5 mg per cycle to a maximum of 25 mg~If eligibility is confirmed, sibling and unrelated donor transplant recipients will both receive 3 donor lymphocyte infusions (DLIs) at the following doses: 5 x 106 CD3+/kg; 1 x 107 CD3+/kg; 5 x 107 CD3+/kg~Patient will be followed for 5 years post relapse."
2423301|NCT03413774||Abortion group|910 women attended Fayoum University hospital outpatient gynecology clinic with recent first trimesteric spontaneous miscarriage
2423302|NCT03413774||Control group|940 women attended Fayoum University hospitalpresented for any other gynecological complaint
2423303|NCT03413748|Active Comparator|Peritoneal irrigation|Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
2423304|NCT03413748|Active Comparator|Non peritoneal irrigation|No Irrigation with 500 - 1000 ml of warm normal saline will be done after closure of visceral peritoneum
2423532|NCT03411889|Experimental|functional lacrimal delay|Participants shown to have functional delay on DSG will be included. The intervention will be an MRI scan during tear drainage
2425413|NCT03398720|Experimental|Cohort 3|Participants will receive HTI-1066 at dose level 3.
2423307|NCT03413722||Conversion Group|Kidney transplant recipients at the University of Kansas Medical Center (KUMC) who are currently on tacrolimus (CNI), and will be undergoing conversion to Everolimus + low dose CNI. Potential participants will be asked to participate in the study after the decision to convert CNI to Everolimus + low dose CNI has been made.
2423308|NCT03413722||Control Group|Kidney transplant recipients at KUMC on tacrolimus (CNI). These will be patients not planning to undergo any change in immunosuppression.
2423309|NCT03413709|Active Comparator|Treatment Group (n=350)|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour Family Formation Program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships,and economic stability and mobility. In addition, participants will receive case management and a variety of employment, legal and support services for up to one year following the completion of the curriculum.
2423310|NCT03413709|No Intervention|Comparison Group (n=350)|The sample comparison group will receive only the abbreviated 80 hour program. Which consist of economic stability and mobility only. These participants will receive employment case management and legal services for up to one year following the completion of the curriculum.
2423311|NCT03413696||Not referred for HCV therapy|
2423312|NCT03413696||Referred for HCV therapy,did not show up|
2423313|NCT03413696||Referred,attended HCV therapy evaluation|
2423314|NCT03413657|Other|Fluid responders|Patient's identified to have a significant increase in their cardiac output following a fluid bolus.
2423315|NCT03413657|Other|Fluid non-responders|Patient's identified to NOT have a significant increase in their cardiac output following a fluid bolus.
2423316|NCT03413631|Experimental|Prenatal mentalization intervention|The intervention group participants were offered three mentalization-focused 4D interactive ultrasounds at 24, 30 and 34 gestational weeks and a mentalization-focused week-by-week pregnancy diary combined with three prenatal sessions and option for one session after delivery in addition to obstetric care as usual (see Prenatal obstetric treatment as usual).
2423317|NCT03413631|Active Comparator|Prenatal obstetric treatment as usual|The control group received obstetric care as usual in a tertiary setting. The comprehensive treatment as usual was conducted at the hospital antenatal outpatient clinic, including regular obstetric ultrasounds. The multidisciplinary treatment team, consisting of an obstetrician, a midwife, a social worker and a psychiatric nurse, assess and support health and psychosocial situation of the pregnant woman. The pregnant woman was referred to addiction and psychiatric treatment when needed.
3186985|NCT00751088|Active Comparator|4|Patients treated with tension free vaginal tape
3186986|NCT00751127|Active Comparator|Timolol|
2423320|NCT03413605|Experimental|a multilevel CBPR intervention|The intervention will be delivered in group-based education workshop format. The education session is a curriculum-based group education; each group will be having about 15-20 participants. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics.(a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion. This session is to increase knowledge, change cultural beliefs and attitudes on risks of CRC and benefits of screening by using interactive discussion approaches, visual aids, motivation video and print materials.
2423321|NCT03413605|No Intervention|control group|the standard CDC's Clinical Preventive Services Guidelines for adults 50+ (CPS) will be provided to control groups.
2423322|NCT03413592|Other|Driving test|
2423323|NCT03413579|Experimental|Nimotuzumab|"Injection of 200 mg of Nimotuzumab (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~The objective of the present study is to assess the overall survival of patients after administration of Nimotuzumab hR3 monoclonal antibodies (combined with a chemotherapy) in the treatment of patients with cervix epithelial tumors as first-line treatment.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
2423324|NCT03413579|Placebo Comparator|Placebo|"Injection of the Placebo in the same procedures (weekly during 18 weeks), in combination with chemotherapy (6 cycles, every 21 days: 70 mg / m2 Cisplatin and Vinorelbine 60 mg / m2 (Per Os) at day 1 and day 8.~After the first line , a 200mg dose of hR3 monoclonal antibodies will be given every 14 days until progress.~A second -line chemotherapy is proposed, this is based on Carboplatin (CBP) at AUC of 6, and Paclitaxel (Txl) 175 mg / m2 / SC as 3 hour infusion, every 3 weeks, concomitant with the administration of hR3, every 14 days, until a toxicity limit or an ECOG status greater than 3 appears."
2423325|NCT03413566||Children with clinical diagnosis of CP|All children residing in Norway with a validated diagnosis of cerebral palsy.
2423326|NCT03413566||Children without CP|All children residing in Norway without a diagnosis of cerebral palsy.
2423327|NCT03413553|Active Comparator|control group|patient will receive immediate implant alone.
2423328|NCT03413553|Other|intervention group|"immediate implant combined with connective tissue graft and platelet rich fibrin .~."
2423329|NCT03413540|Experimental|Group 1|10-cm step, 10 reps
2423330|NCT03413540|Experimental|Group 2|10-cm step, 50 reps
2423331|NCT03413540|Experimental|Group 3|10-cm step, 100 reps
2423332|NCT03413540|Experimental|Group 4|20-cm step, 10 reps
2423333|NCT03413540|Experimental|Group 5|20-cm step, 50 reps
2423334|NCT03413540|Experimental|Group 6|20-cm step, 100 reps
2423335|NCT03413540|Experimental|Group 7|30-cm step, 10 reps
2423336|NCT03413540|Experimental|Group 8|30-cm step, 50 reps
2423337|NCT03413540|Experimental|Group 9|30-cm step, 100 reps
2423338|NCT03413540|No Intervention|Group 10|Control
2423339|NCT03413527|Experimental|rTMS Treatment|
2425414|NCT03398720|Experimental|Cohort 4|Participants will receive HTI-1066 at dose level 4.
3186987|NCT00751127|Experimental|PhXA41|
3186988|NCT00751166|Experimental|1|Desloratadine
3186989|NCT00751166|Active Comparator|2|Cetirizine
2423340|NCT03413514|Experimental|experiment group|Neoadjuvant chemotherapy(NACT) are performed for locally advanced gastric cancer. The clinical response is evaluated by MRI and enhanced CT. The cycle of neoadjuvant chemotherapy is decided by the doctor and the patents together with shared decision making(SDM). Radical gastrectomy with D2 lymph node dissection are performed after neoadjuvant chemotherapy. Adjuvant chemotherapy(ACT) are preformed after surgery. Questionnaires are preformed to evaluate the involvement emotion and reason for the decision of stopping neoadjuvant chemotherapy.
2423341|NCT03413501|No Intervention|Treatment as usual|Receives treatment as usual at the clinic
2423342|NCT03413501|Experimental|MUD-PI|Receives multi-disciplinary pain intervention, agroup-based, multi-disciplinary treatment
2423343|NCT03413488|Experimental|Kinesio taping|subject with shoulder impingement syndrome
2423344|NCT03413488|Active Comparator|Exercise|subject with shoulder impingement syndrome
2423345|NCT03413462|Active Comparator|HS-25|20mg, QD, 12 weeks
2423346|NCT03413462|Placebo Comparator|Placebo of HS-25|20mg, QD, 12 weeks
2423347|NCT03413449||Resections|Frailty model for patients undergoing esophagectomy and pneumonectomy/lobectomy for cancer
2423348|NCT03413436|Experimental|Lobaplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Lobaplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
2423349|NCT03413436|Active Comparator|Cisplatin group|i) thoracic ESCC stage II to III; ii) without any preoperation treatment for ESCC; iii) underwent R0 resection; iv) received at least one cycle ajuvant chemotherapy of Cisplatin plus Docetaxel; v) without ajuvant radiotherapy/chemoradiotherapy; vi) without history of other type of cancer. Completed clinical, pathological and follow up data.
2423350|NCT03413423|Experimental|BAT-CS|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
2423351|NCT03413423|Active Comparator|Smoking Cessation and Health & Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
2423352|NCT03413410|Experimental|Metoprolol interventional group|"This is a multi-center, prospective, open label, single-arm interventional study.~Patients hospitalized for ACS, fulfilling all of the inclusion criteria and none of the exclusion criteria can be enrolled in this study."
2423353|NCT03413384|Experimental|Ceftriaxone|"Name: Ceftriaxone~Dosage form: crystalline powder for intramuscular injection~Dose(s): 1 g~Dosing schedule: 1 g ceftriaxone with around 2.0 ml of lidocaine solvent per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle"
2423354|NCT03413384|Placebo Comparator|Placebo|same amount volume of placebo will be given on Day 1, Day 3, and Day 5 per cycle on a 2 weekly cycle
2423355|NCT03413371|Experimental|0,5 % bupivacaine with of 2% lidocaine|in group BL patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
2423356|NCT03413371|Experimental|0,5 % bupivacaine|in group B patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
2423357|NCT03413371|Experimental|1 % ropivacaine with of 2% lidocaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
2423358|NCT03413371|Experimental|1 % ropivacaine|in group RL patients in group BF will receive regional peribulbar block using a solution of 1% ropivacaine (5 ml)
2423359|NCT03413371|Experimental|paracetamol|in P group patients will receive preemptive analgesia using 1 gram of paracetamol before induction of general anaesthesia
2423360|NCT03413358|Experimental|Treatment group|Platinum-based two medicine (carboplatin / cisplatin) plus Sheng Bai oral liquid.
2423361|NCT03413358|Experimental|Control group|Blank control and Platinum-based two medicine (carboplatin / cisplatin) .
2423362|NCT03413345||subjects without a history of cardiac disease|
2423363|NCT03413345||subjects with a history of cardiac disease|
2423364|NCT03413332|Experimental|E-Talkcare Group|use the web-based patient education tool
2423365|NCT03413332|Placebo Comparator|Usual Care Group|receive usual care
2423366|NCT03413319|Experimental|ABBV-8E12|ABBV-8E12 administered by intravenous (IV) infusion.
2423367|NCT03413306|Experimental|Eltrombopag + IST (ATG + CsA)|
2423368|NCT03413306|Active Comparator|IST (ATG + CsA)|
2423369|NCT03413293||Nosocomial infected cirrhotic patients|
2423370|NCT03413280|Experimental|preoperative Rectus sheath block: group Pre|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml Before surgical incision
2423371|NCT03413280|Active Comparator|postoperative Rectus sheath block: group Post|ultrasound guided Rectus sheath block block with 0.25% ropivacaine 40ml After surgical incision
2423372|NCT03413267|Experimental|Custard|The food matrix ingested (once by each volunteer) is a custard containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2423373|NCT03413267|Experimental|Flan|The food matrix ingested (once by each volunteer) is a flan containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2423374|NCT03413267|Experimental|Sponge cake|The food matrix ingested (once by each volunteer) is a sponge cake containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2423375|NCT03413267|Experimental|Biscuit|The food matrix ingested (once by each volunteer) is biscuits containing 1250µg vitamin D (=50 000 UI), 12µg vitamin B12, 1000µg vitamin B9 and 20 mg lutein
2423376|NCT03413254|Active Comparator|2nd look DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up according to the Dutch colorectal cancer guideline until 5 years.
2423377|NCT03413254|Experimental|2nd and 3rd DLS + routine FU|Follow-up after curatively resected pT4 colon cancer, consisting of second look DLS after negative CT abdomen at 6-9 months and normal CEA, with subsequent routine follow-up and third look DLS after negative CT abdomen at 18 months and normal CEA. Third look DLS is not performed in patients with evidence of disease that is not curable, or in those already diagnosed with PM in the preceding period.
2423378|NCT03413228||Influenza-like illness group|
3186990|NCT00751166|Placebo Comparator|3|placebo
3186991|NCT00751192|Experimental|A|
2423379|NCT03413215|No Intervention|Standard Care|Patients randomized to the standard care group will receive usual care, which consists of clinic visits 4 monthly for review of BP, HbA1c and other investigations, and titration of medications;counseling with the diabetes nurse educator (DNE), and provision of educational materials on diabetes.
2423380|NCT03413215|Experimental|Intensive|Patient randomized to the intensive group will receive additional counselling and education by the DNE, medical social worker (MSW) on self-care and coping strategies for diabetes, and see the renal pharmacist for more intensive titration of antihypertensive medication between doctor visits. They will also be loaned blood pressure monitors and glucometers with test strips to perform self-monitoring at home in between outpatient visits. Smartphone and online technologies will be utilized to improve remote monitoring, education and self-care.
2423381|NCT03413202|Experimental|butylphthalide(NBP)|Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
2423382|NCT03413202|Placebo Comparator|placebo|Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo
2423383|NCT03413189||PREDICT participants|This cohort is obtained from the PREDICT study enrolment (approx. 500) and a review of their medical records will be conducted
2423384|NCT03413189||PREDITCABLE participants|This is a nested cohort of patients recruited into PREDICT (approx. 40) that consent for a physiotherapist home visit to assess their physical and cognitive function and perform and interview to obtain themes regarding recovery
2423385|NCT03413163|Sham Comparator|control|"Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.~Intervention: Other: Standard Pain Followup and Monitorization"
2423386|NCT03413163|Experimental|ESP block|"In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.~Interventions:~Procedure: Ultrasound guided erector spinae plane block Other: Standard Pain Followup and Monitorization"
2423387|NCT03413150||severely ill patients receiving amiodarone for ATs|cohort study was conducted from January 2007 to April 2012 in the 18-bed medical ICU of a tertiary teaching hospital.Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent atrial tachycardia during their hospitalization in the ICU.
2423388|NCT03413137|Active Comparator|Arm A|A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy
2423389|NCT03413137|Active Comparator|Arm B|A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy
2423390|NCT03413124|Active Comparator|Capsule then Tablet|MGL-3196 Capsule on Day 1 followed by MGL-3196 Tablet on Day 5
2423391|NCT03413124|Active Comparator|Tablet then Capsule|MGL-3196 Tablet on Day 1 followed by MGL-3196 Capsule on Day 5
2423392|NCT03413111|Experimental|Modified double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, a tiny cut of opening, with the length of 5mm, was performed with the sphincterotome. Then the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, needle knife (NK) precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
2423393|NCT03413111|No Intervention|Standard double wire technique|A sphincterotome was used for standard wire-guided cannulation. If the difficult biliary cannulation occurred and guidewire inadvertently entered PD, the guidewire was left in PD and the sphincterotome withdrew. The same sphincterotome was re-inserted in the working channel alongside the first guidewire, another wire is used for wire-guided selective cannulation of CBD. If the cannulation of CBD was not successful within 5 attempts, other cannulation techniques (e.g. transpancreatic precut, NK precut or over-the stent precut) would be tried at the discretion of endoscopists. A 5Fr, unflanged PD stent was placed before the ending of ERCP.
2423394|NCT03413098|Experimental|Trial nasal Continuous Positive Airway Pressure (CPAP) mask|Trial nasal CPAP mask
2423395|NCT03413085|Other|Group A|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: multifocal soft contact lens Right eye: single vision soft contact lens"
2423396|NCT03413085|Other|Group B|"Intervention name: multifocal soft contact lens/single vision soft contact lens~Left eye: single vision soft contact lens Right eye: multifocal soft contact lens"
2423397|NCT03413059|Active Comparator|morphine sulfate group|patients in this arm will receive : morphine dose 0.1mg /kg with 9 ml of 0.25 % bupivacaine with through epidural catheter on admission Then continuous epidural infusion of bupivacaine (0.1 mg.kg-1.h) 1st 72 hours
2423398|NCT03413059|Active Comparator|triamcinolone acetonide group|patients in this arm will receive will receive a mixture of 9 ml of 0.125 % bupivacaine with 80mg of triamcinolone ( 10 ml total volume) through epidural catheter on admission
2423399|NCT03413046||ALL|30 children with a recent diagnosis of PreB ALL
2423400|NCT03413046||Control|30 healthy children
2423401|NCT03413033||Group 1|43 participants will produce the vowel /a:/ three times as baseline during 5 seconds in habitual, comfortable speaking pitch and loudness. Thereafter, participants will produce series of a semi-occluded vocal tract exercises (resonance tube or lip trill). Afterwards, subjects will produce the vowel /a:/ three times once again. Electroglottographic signals will be captured before and after each exercise. A 15 minutes voice rest will be taken between exercises by all subjects.
2423402|NCT03413020|Experimental|Tailored Therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole, amoxicillin and one sensitive of clarithromycin, metronidazole and levofloxacin.If isolates were resistant to all three tested antibiotics, give esomeprazole, bismuth potassium citrate, metronidazole and amoxicillin for 14 days.
2423533|NCT03411876|Experimental|First ESWT with Oxymizer, second ESWT with CNC|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the Oxymizer and the second ESWT with a conventional nasal cannula (CNC).
2426787|NCT03388892|Experimental|Drug-Eluting Balloon|PTA with DEB at venous anastomotic stenosis of AVG
2423403|NCT03412994|Experimental|Apatinib group|"Apatinib combined with second-line chemotherapy (5-Fu combined with irinotecan or oxaliplatin standard regimen ) Apatinib tablets: 500 mg po qd . Continuous medication, the cycle is consistent with the chemotherapy cycle.~Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）"
2423404|NCT03412994|Placebo Comparator|Control group|Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.（Take CAPEOX for example）
2423405|NCT03412968|Experimental|Polysulfone Filter Group|The purpose of the research is to determine whether, by controlling the patient's hemodilution level and, therefore, the acute anaemia caused by the Cardiopulmonary Bypass (CPB) priming fluid, continuous conventional ultrafiltration (CUF) can decrease serum lactate levels during normothermic CPB by increasing the haematocrit and, consequently, the supply of oxygen to the tissues, and whether the haemofiltration membrane can remove lactate molecules in situations of hyperlactataemia in CPB.
2423406|NCT03412968|Active Comparator|Control Group|The purpose of the research is to determine serum lactate levels during normothermic cardiopulmonary bypass procedure (CPB) without continuous hemofiltration of the patient during the CPB.
2423407|NCT03412955|Experimental|Eribulin|Patients enrolled into the study will receive Eribulin 1.4mg/m2 on days 1 and 8 of a 21-day treatment cycle till disease progression or non-tolerable toxicity.
2423408|NCT03412942|Other|Treatment with FISH device|Vascular closure to be performed with FISH device.
3186992|NCT00751192|Active Comparator|B|
2423410|NCT03412916|Experimental|GetActive|The GetActive program uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions, and weekly practice assignments (homework). The GetActive sessions reflect a purposeful integration of the three treatment approaches (relaxation methods, stress appraisal & coping, and growth enhancement). The format is a 10-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions.
2423411|NCT03412916|Experimental|GetActive with Fitbit|The GetActive with Fitbit is identical to that of the p3RP with the addition of a digital monitoring device (i.e., Fitbit) for recording of physical activity.
2423412|NCT03412903||Control group|First observational period: Standard care without an advising pharmacist, 140 patients
2423413|NCT03412903||Implementation group|Second observational period: Standard care with an advising pharmacist, 140 patients
2423414|NCT03412903||Learning success group|Second observational period: Standard care without an advising pharmacist, 30 patients
2423415|NCT03412890|Experimental|Relugolix plus E2/NETA|Relugolix co-administered with E2/NETA for 28 weeks.
2423416|NCT03412877|Experimental|1/iTCR|Non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCR-Transduced PBL + high or low-dose aldesleukin
2423417|NCT03412877|Experimental|2/iTCR + Pembro|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Individual Patient TCRTransduced PBL + high- or low-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeksfollowing cell infusion
2423418|NCT03412851||A Direct Aspiration First Pass Technique|
2423419|NCT03412851||Stentriever Thrombectomy|
2423420|NCT03412838|Active Comparator|Cortico-Cancellous|Graft surgery with cortico-cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
2423421|NCT03412838|Active Comparator|Cancellous|Graft surgery with cancellous block, freeze dried bone allograft (FDBA) for treatment the atrophic maxilla prior implant placement
2423422|NCT03412825|Experimental|Nutrition Supplementation|
2423423|NCT03412825|No Intervention|Control|
2423424|NCT03412812|Experimental|Dose Escalated 5 Fraction Stereotactic Radiosurgery|Patients will undergo dose escalated five fraction stereotactic radiosurgery for diagnosed brain metastases. Tumors must fall into one of two categories: 2.1-4.0cm diameter or 4.1-6.0 cm diameter. Only single largest tumor will be treated with dose escalation. All other tumors (if present) will be treated with standard of care five fraction stereotactic radiosurgery.
2423425|NCT03412786|Experimental|Arm A: IM followed by IP|Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
2423426|NCT03412786|Experimental|Arm B: IP followed by IM|Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.
2423427|NCT03412773|Experimental|Arm A: Tislelizumab & Safety Run-In Substudy [Japan Only]|
2423428|NCT03412773|Active Comparator|Arm B: Sorafenib|
2423429|NCT03412760|Experimental|Exome sequencing|There is only one arm of this study. All enrolled participants with unexplained NIHF or other birth defect will be offered exome sequencing for the affected fetus or neonate. Please refer to the Study Design section for further details.
2423430|NCT03412747|Experimental|Bimekizumab Arm 1|Subjects will receive bimekizumab dose regimen 1 for 56 weeks. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
2423431|NCT03412747|Experimental|Bimekizumab Arm 2|Subjects will receive bimekizumab dose regimen 1 for 16 weeks and will proceed with bimekizumab dose regimen 2 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
2423432|NCT03412747|Active Comparator|Adalimumab Arm|Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
3186993|NCT00751205|Experimental|Arm 1|
3186994|NCT00751205|Placebo Comparator|Arm 2|
2423435|NCT03412721|Experimental|Laser analgesia|Procedure: Laser analgesic procedure Performing protocol for pre-emptive laser analgesia with Er:YAG laser (Litetouch, Syneron) switched on.
2423436|NCT03412721|Placebo Comparator|Placebo analgesia|Procedure: Placebo analgesic procedure Performing imitation of laser analgesic protocol with Er:YAG laser (Litetouch, Syneron) switched off - no pulse energy applied.
2423534|NCT03411876|Experimental|First ESWT with CNC, second ESWT with Oxymizer|Patients in this study arm first perform the first endurance shuttle walk test (ESWT) with the CNC and the second ESWT with the Oxymizer.
2423535|NCT03411863|Experimental|All subjects|All subjects undergo same full protocol, including CES at rest and CES plus active hand or wrist movements.
3186995|NCT00751218|Active Comparator|Arm 1|desloratadine
2423437|NCT03412708|Active Comparator|Vestibular Rehabilitation|"Vestibular Rehabilitation Program Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
2423438|NCT03412708|Experimental|Vestibular Rehabilitation supported with Virtual Reality|"Patients will perform the exercises in a virtual reality environment using a virtual reality goggle and a smartphone.The virtual environments consist of 2 media provided by the videos taken with a 360 camera . 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full. Exercises conducted while sitting and standing on a soft ground will happen in the 1st environment, and the ones on the treadmill will happen in the 2nd environment.~Exercises for Eye Movements: Smooth- Pursuit Eye Movements and Saccadic eye movements Exercises for Gaze Stability : Training of Vestibulo-ocular reflex and Cervico-ocular reflex Exercises for Postural Stability: In sitting or standing up position and walking~Duration of treatment: 3 weeks. Number of sessions: 15 Session frequency: 5 times a week. Session duration: 2 sets of 15 minutes, with a 5 minute break between sets, for a total of 35 minutes."
2423439|NCT03412695|Experimental|Arm A|Use of the MyFood tool among patients and nurses (intervention group)
2423440|NCT03412695|No Intervention|Arm B|No intervention. Regular hospital routines
2423441|NCT03412682|Experimental|Budesonide (6 mg)|
2423442|NCT03412682|Experimental|Budesonide (9 mg)|
2423443|NCT03412682|Active Comparator|Mesalazine (3,600 mg)|
2423444|NCT03412669|Experimental|Counselling|Supporting Addiction Affected Families Effectively is a contextually adapted version of the 5-Step Method, a psychosocial intervention based on the principles of the Stress-Strain-Coping-Support model. The intervention is manualised, and is delivered by lay counsellors over 5 sessions at a weekly basis. The 5 steps (covered in the 5 steps) include: 1) Exploring stresses and strains, 2) Providing relevant information, 3) Exploring and discussing coping behaviours, 4) Exploring and enhancing social support, and 5) Exploring additional needs, and further sources of help. The intervention is delivered in settings based on convenience of the participant: which might be a place outside the home (e.g. field office, neighbour's home), or the participant's home.
2423445|NCT03412669|Active Comparator|Enhanced Usual Care|In the study setting, usual care for affected family members is no care at all, as detection rates of stress/strain in affected family members are extremely low. Hence, Enhanced Usual Care for the control group consists of a minimal intervention, namely a leaflet. The leaflet focuses on the burden that affected family members experience in relation to a relative who drinks alcohol, and on various informal and formal sources of support that are available in the local community.
2423446|NCT03412656|Experimental|Patient|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing the subjects' own prosthetic sockets. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
2423447|NCT03412656|Other|Control|Testing will include assessments of activities of daily living (ADLs) by a physical therapist, biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks, and surveys assessing user preference regarding the force feedback feature, all while using the SoftHand Pro myoelectric lower arm prosthetic and the CUFF force feedback devices in tandem, utilizing an adapter simulating a prosthetic socket. Grip force will be recorded using sensors attached to the CUFF device. During each session, videos will be obtained of the subjects performing tasks for kinematics analysis. The experimental sessions are organized into one to two sessions, comprising up to 16 hours, as determined by subject availability.
2423449|NCT03412630|Experimental|Diagnostic (computed tomography perfusion imaging)|Patients undergo computed tomography perfusion imaging at baseline and on day 15 after initiation of standard of care bevacizumab treatment and before the second dose.
3186996|NCT00751218|Placebo Comparator|Arm 2|Placebo
2423451|NCT03412591|Other|Open label trial of suvorexant in SUDs|It is an open label trial to study the efficacy of suvorexant in a group of opioid use and alcohol use disorder subjects.
2423452|NCT03412578|No Intervention|Control|Infants in this group will receive ordinary supportive care and will not receive Massage Therapy
2423453|NCT03412578|Active Comparator|Massage group|"Infants in this group will receive Massage Therapy Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).~During massage therapy, infant's behavioural reaction was observed for signs of distress (e.g., yawning, finger splaying, crying)."
2423536|NCT03411850|Active Comparator|Orencia (Abatacept)|Orencia (Abatacept) Intravenous (IV) or Subcutaneous (SQ) injection
2423537|NCT03411850|Placebo Comparator|Placebo|Placebo (saline solution) given Intravenous (IV) or Subcutaneous (SQ)
3186997|NCT00751218|Active Comparator|Arm 3|cetirizine
3186998|NCT00751231|Active Comparator|Arm 1|300mg or 600mg loading dose of Clopidogrel followed by once daily dosing of 75 mg Clopidogrel for up to 120 days.
3186999|NCT00751231|Experimental|Arm 2|IV bolus of PRT060128 prior to PCI and twice daily administration of 50 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3146157|NCT00092391|Active Comparator|Control Group|M-M-R(TM) II at current release potency
2423458|NCT03412552||severe preeclampsia without HELLP syndrome|severe preeclampsia if they met one or more of the following criteria of The American College of Obstetricians and Gynecologists (10): systolic blood pressure >160 mm/ Hg or diastolic blood pressure >110 mm/Hg, headache, epigastric or right-upper-quadrant pain, visual disturbances,pulmonary edema, and proteinuria (urinary protein level >5 g/24 h).Women with severe preeclampsia selected for analysis also met all of the following laboratory criteria: platelet count ≥150,000/ mm3, serum lactate dehydrogenase <600 IU /dL, serum total bilirubin <1.2 mg/dL and serum aspartate aminotransferase <70IU/L
2423459|NCT03412552||eclampsia without HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded
2423460|NCT03412552||eclampsia with HELLP syndrome|Eclampsia was defined as tonic-clonic seizures occurring in patient diagnosed by preeclampsia patient. Any causes for convulsion other than eclampsia were excluded.HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
2423461|NCT03412552||HELLP syndrome without eclampsia|HELLP syndrome was defined by the clinical presentation of PET in association with thrombocytopenia (<150.000 cells/ul), hemolysis and elevated liver enzmes (elevated transaminases and lactic dyhydrogenases activities)
2423462|NCT03412526|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day~Preparation and administration of unselected or 4-1BB enriched TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
2423463|NCT03412513|Active Comparator|Mirabegron|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
2423464|NCT03412513|Placebo Comparator|Placebo|1:1 randomization to receive Mirabegron 50mg daily or placebo at visit 2. At visit 4 all subjects will receive Mirabegron 50mg.
2423465|NCT03412500|Active Comparator|Vancomycin trough concentration method|vancomycin dosage will be adjusted by the trough concentration method
2423466|NCT03412500|Experimental|Vancomycin equation-based method|vancomycin dosage will be adjusted by the equation-based method
2423467|NCT03412487|Active Comparator|premature ovarian failure|women under 40 years old with History of oligomenorrhea or amenorrhea for 1 year or more FSH level >20 IU/L at least 2 occasions 4-6 weeks apart (FSH level 20-40 IU/L indicates ovarian insufficiency, while level above 40 IU/L indicates complete failure).
2423468|NCT03412487|Active Comparator|Control group|A group of female patients presented with infertility but with regular menses and normal ovarian function (according to history, general examination, gynecological examination and FSH level).
2423469|NCT03412474|Active Comparator|Bupivacaine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%).
2423470|NCT03412474|Active Comparator|Dexmedetomidine|Patients will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
2423471|NCT03412461|Experimental|Thought Spot Application|Participants randomly assigned to the experimental arm will have access to the Thought Spot application. The Thought Spot application is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area. This group will continue to have access to usual care.
2423472|NCT03412461|Active Comparator|Resource pamphlet|Participants randomly assigned to the active comparator will receive a pamphlet that outlines mental health services and wellness services across the Greater Toronto Area. This group will continue to have access to usual care.
2423473|NCT03412435||Myocardial infarction|diagnosed as acute myocardial infarction and treated with medical treatment, coronary artery bypass surgery and percutaneous coronary intervention.
2423474|NCT03412422||Acute circulatory failure|Mechanically ventilated patients with acute circulatory failure, monitored with PiCCO method, who need fluid responsiveness assessment.
2423539|NCT03411811|Active Comparator|Usual Care|
2423540|NCT03411811|Experimental|Dextrose|
2426788|NCT03388892|Active Comparator|Plain Balloon|PTA with PCB at venous anastomotic stenosis of AVG
3146158|NCT00092391|Experimental|Mumps Expiry Group 1|M-M-R(TM) II at intermediate expiry potency
3146159|NCT00092391|Experimental|Mumps Expiry Group 2|M-M-R(TM) II at expiry potency
3146160|NCT00092729|Experimental|1|etoricoxib
3146161|NCT00092729|Placebo Comparator|2|Placebo to match etoricoxib
3146162|NCT00092729|Active Comparator|3|naproxen sodium
3146163|NCT00092833|Experimental|1|Ezetimibe
3146164|NCT00092989|Experimental|Montelukast 7 mg|Participants receive montelukast 7 mg intravenously (IV) until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
3187000|NCT00751231|Experimental|Arm 3|IV bolus of PRT060128 prior to PCI and twice daily administration of 100 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3187001|NCT00751231|Experimental|Arm 4|IV bolus of PRT060128 prior to PCI and twice daily administration of 150 mg oral PRT060128 for up to 120 days, with the first oral dose administered concurrently with the IV bolus.
3187002|NCT00751244|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
3187003|NCT00751244|Active Comparator|2|12 weekly sessions of one-to-one PCT (psychotherapy)
2423475|NCT03412409|Experimental|RIC regimen|"Old patients or those have high comorbidity burden without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
2423476|NCT03412396|Experimental|Treatment (apalutamide, radical prostatectomy)|Patients receive apalutamide PO daily for 24 weeks in the absence of disease progression or unacceptable toxicity. Within 2 weeks of completing apalutamide, patients undergo radical prostatectomy.
2423477|NCT03412370||Observational (questionnaires, cognitive assessment)|Patients complete questionnaires and cognitive assessments over 45-60 minutes within 3 weeks following mammography and at about 3 months in patients for whom biopsy is not required, before biopsy and at about 3 months in patients for whom biopsy is required, and at 4-6 weeks after first chemotherapy infusion in patients receiving chemotherapy.
2423478|NCT03412357|Experimental|pleurectomy/decortication|
2423479|NCT03412357|Experimental|indwelling pleural catheter|
2423480|NCT03412331|Active Comparator|Control Group|NPT including scaling and root planing was applied to 12 subjects with ultrasonic and hand instruments until the operator feels that root surface is clean, hard and smooth.
2423481|NCT03412331|Experimental|Test Group|Following NPT, toluidine blue O mediated PDT was performed with a LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark) to 12 subjects. The dye (0.1 mg/ml) was applied with a canula into the periodontal pockets. After 3 minutes, the subjects rinsed their mouths with sterile saline solution for removal of excessive dye. Then, the applicator of photosensitizer was inserted until the bottom of the periodontal pocket and photoinactivation was performed in 6 sites per tooth for 10 seconds of each sites with a total of 60 seconds per tooth.
2423482|NCT03412318|Experimental|Twisted file|Use of twisted file during cleaning and shaping of root canals
2423483|NCT03412318|Active Comparator|Mpro|Use of Mpro file during cleaning and shaping of root canals
2423484|NCT03412305|Active Comparator|Amoxicillin oral tablets|2 g amoxicillin tablets orally 1 hour before implant placement
2423485|NCT03412305|Placebo Comparator|Placebo|Placebo tablets orally 1 hour before implant placement
2423486|NCT03412292|Experimental|MAX-40279|"MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle).~After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts."
2423487|NCT03412266|Other|RIC regimen|"Low- and intermediate MDS patients without identical sibling donor or unrelated donor would receive RIC haplo-HSCT.~RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days -10 to -9), busulfan (3.2 mg/kg/day on days -8 to -6), cyclophosphamide (1.0 g/m2/day, days -5 to -4), fludarabine (30 mg/m-2/day, days -6 to -2), semustine (250 mg/m-2, day -3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days -5 to -2; Sanofi, France)."
2423488|NCT03412240|Experimental|Anti tachycardia pacing|
2423489|NCT03412227|Other|Principal Anxiety Disorder|Youth with a principal anxiety disorder
2423490|NCT03412227|Other|Principal Depressive Disorder|Youth with a principal unipolar depressive disorder
2423491|NCT03412201|Active Comparator|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
2423492|NCT03412201|Experimental|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
3146165|NCT00092989|Placebo Comparator|Placebo|Participants receive placebo IV until until a decision is made for one of the following: (1) discontinuation from the study, (2) discharge from the study site, or (3) admission to the hospital. All randomized participants will receive systemic corticosteroids (60 mg prednisone OR 50 mg prednisolone) orally immediately after the completion of the study drug administration. In addition, all participants will continue to receive standardized treatment in addition to study drug. Standardized treatment may consist of: (1) β-agonist administration beginning 20 minutes after study drug infusion, and every 20 minutes thereafter, as needed; (2) oxygen therapy; and (3) inhaled ipratropium every 60 minutes as needed.
3146166|NCT00093002|Experimental|1|250 mg fulvestrant
2423495|NCT03412175|Experimental|Behavioral Intervention|Participants in the lifestyle intervention arm will receive 6 individual visits with a CREATION Health Specialist over a 3 month period, and one follow up visit at 6 months. The visits include one 2 hour-long initial assessment, four 60-minute motivational interview sessions, and two 60-minute reassessments. Visits will focus on tailoring the intervention care plan to each individual, goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, self-regulatory techniques, and provision of psychosocial support using motivational interviewing techniques.
2423496|NCT03412175|No Intervention|Control Group|Participants in the control group will receive usual care as provided by their primary care physician. Participants in the control group will complete biometrics, surveys, and assessments at Visits 0, 5 and 6.
3146167|NCT00093002|Experimental|2|500 mg fulvestrant
2423541|NCT03411798|Experimental|Experimental|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI<4) maintenance.
2423542|NCT03411785|Experimental|CPC+ practices|This is the intervention group, and includes the practices that were selected and agreed to participate in the CPC+ model.
3146168|NCT00093054|Active Comparator|1|Cranberry juice
3146169|NCT00093054|Placebo Comparator|2|Placebo juice
3146170|NCT00093080|Experimental|Ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
3146171|NCT00093132|Experimental|Satraplatin|Satraplatin
3146172|NCT00093197|Experimental|A1: KAI-9803|
3146173|NCT00093197|Experimental|A2: KAI-9803|
3146174|NCT00093197|Experimental|A3: KAI-9803|
2423499|NCT03412149|Active Comparator|Mini Gastric Bypass|Mini Gastric Bypass: The gastric pouch will be performed starting below the incisura angularis (transverse resection 4 cm) on the lesser curvature (18).Then the stomach will be transected against a 36 Fr bougie up to the gastro-esophageal junction Then 1/3 of the small bowel will be excluded (approximately 200cms) and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler.
2423500|NCT03412149|Active Comparator|Roux en Y Gastric Bypass|Roux en Y Gastric Bypass: The steps of the standard double loop RYGB technique will be followed (17). The gastric pouch will be created 7 cm from the gastro-esophageal junction to obtain a volume of 30-40 ml, and the length of the alimentary limb will be 150 cm and 3.5-4 cm gastro-jejunostomy will be performed by linear stapler. The length of the biliopancreatic limb will be from 65 to 75 cm beyond the ligament of Treitz. The lengths of both limbs should carefully measured with a graduated instrument. The mesenteric defects will be closed.
2423501|NCT03412136|Experimental|Control|
2423502|NCT03412136|Experimental|Glucose|
2423503|NCT03412136|Experimental|Protein|
2423504|NCT03412123|Experimental|gLiFE pilot group|
3187004|NCT00751244|Other|3|90-day wait-list group
3187005|NCT00751257|Experimental|1|2400mg N-acetylcysteine (1200mg b.i.d.) for 4 consecutive weeks
2423507|NCT03412071|No Intervention|Control group|25 HIV-uninfected, uncircumcised men will be immediately circumcised following enrollment. This group will serve as the comparison to the four intervention groups.
2423508|NCT03412071|Active Comparator|Oral tinidazole group|25 HIV-uninfected, uncircumcised men will be randomized to receive oral tinidazole 2g once a day for two days.
2423509|NCT03412071|Active Comparator|Topical metronidazole (0.75%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 0.75% metronidazole cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2423510|NCT03412071|Active Comparator|Topical clindamycin (2%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply topical 2% clindamycin cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2423511|NCT03412071|Active Comparator|Topical hydrogen peroxide (1%) group|25 HIV-uninfected, uncircumcised men will be randomized to apply 1% hydrogen peroxide cream to the foreskin twice a day for one week, and then twice a week for three weeks.
2423512|NCT03412058|Experimental|Melanoma|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2423513|NCT03412058|Experimental|NSCLC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2423514|NCT03412058|Experimental|HNSCC|Biopsy and blood samples will be collected from patients treated with an antiPD-1 or antiPD-L1 antibody with marketing authorization for the indication, during the course of their treatment
2423515|NCT03412045|Experimental|treatment|this preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen in an effort to ameliorate pain and shorten the length of stay. In this sense, hyperbaric oxygen will be used as a treatment drug. Results will be compared with historical controls
2423516|NCT03412032|Other|ERC|Assessment as used by the European Resuscitation Council
2423517|NCT03412032|Other|AHA|Assessment as used by the American Heart Association
3187006|NCT00751257|Placebo Comparator|2|"Identically appearing placebo pills, packaged in an N-acetylcysteine slurry so that placebo will retain smell similar to active NAC capsules"
2423520|NCT03412006|Experimental|Fulacimstat (BAY1142524)|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
2423521|NCT03412006|Placebo Comparator|Placebo|Patients have to have a clinical diagnosis of diabetic kidney disease and have to be treated with standard of care for this condition
2423522|NCT03411980|Experimental|Subjects with moderately decreased renal function|Subjects with moderate renal impairment with an estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m*2 according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
2423523|NCT03411980|Experimental|Subjects with severely decreased renal function|Subjects with severe renal impairment not on dialysis with an eGFR <30 mL/min/1.73 m*2 (CKD-EPI formula).
2423524|NCT03411980|Experimental|Control subjects with normal renal function|Subjects with an eGFR ≥90 mL/min/1.73 m*2 (CKD-EPI formula) who are matched based on sex, age, race and weight.
2423525|NCT03411967|Experimental|apatinib combine with docetaxel|Docetaxel, 60 mg / m2, d1, iv + apatinib 500mg, po, qd
2423526|NCT03411954||HP-RT|Hippocampus avoidance: decrease the dose to hippocampus as low as possible without affecting the target volumes and other normal tissues
2423527|NCT03411941||Treatment-naïve nAMD patients|Patient data for whom treatment with IVT aflibercept injection was initiated as first-line treatment according to the SmPC and the SERV Guideline, in treatment-naive patients with newly diagnosed of nAMD in routine clinical practice.
2423528|NCT03411928|Experimental|Tracheolator|Tracheal dilatation using the study device as per the protocol.
3146175|NCT00093197|Experimental|A4: KAI-9803|
3146176|NCT00093197|Placebo Comparator|A5: Placebo|
3146177|NCT00093223|Experimental|1|35mg/m^2 infusion time is 3.5 minutes
3146178|NCT00093223|Experimental|2|2 doses of 35mg.m^2 with the second dose given 2 months later
3146179|NCT00093236|Experimental|Early Periodontal Treatment|Subjects will receive scaling, root planing and if needed periodontal surgery
3146180|NCT00093236|Active Comparator|Usual Dental Hygiene|Subjects will receive routine oral hygiene
3146181|NCT00093249|Experimental|clevidipine|Clevidipine was administered in a blinded fashion by intravenous (IV) infusion, starting at a rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr) and titrating upward, as tolerated, in doubling increments approximately every 90 seconds to achieve the desired blood pressure-lowering effect. Up-titration to 3.2 μg/kg/min (16 mg/hr) was allowed. Infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing in serial increments of 1.5 μg/kg/min up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
2423543|NCT03411785|No Intervention|Comparison practices|Comparison practices are the control group. This group includes practices not participating in the model that were matched to the CPC+ practices and whose outcomes will be compared to those of the CPC+ practices.
2423544|NCT03411772|Active Comparator|TAP block|Patients undergoing bariatric surgery having TAP block upon completion of the procedure
2423545|NCT03411772|Sham Comparator|Non TAP block|Patients undergoing bariatric surgery without having TAP block
2423546|NCT03411733||acne vlugaris group|Included recruited patients with acne vulgaris Intervention: Blood and stool samples collection
2423547|NCT03411733||Control group|Included healthy participants Intervention: Blood and stool samples collection
2423548|NCT03411720|Experimental|FES-row-training|Subjects will perform 4 months of FES-row-raining
2423549|NCT03411720|Other|Wait-list time control|Subjects will wait 4 months before performing being allowed to engage in 4 months of FES-row-training
2423550|NCT03411720|Active Comparator|Arms-only-row-training|Subjects will perform 4 months of arms-only row training before being allowed to engage in 4 months of FES-row-training
2423551|NCT03411707||Mutiple screening test group|
2423552|NCT03411681|Active Comparator|Normal Weight|
2423553|NCT03411681|Experimental|Obese|
2423554|NCT03411668|Experimental|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
2423555|NCT03411668|No Intervention|Usual Educational Programme|Without intervention. The participants in this group will be maintain usual educational programme.
2423556|NCT03411655|Active Comparator|Ambu® Aura-ITM|
2423557|NCT03411655|Active Comparator|Ambu Aura GainTM|
2423558|NCT03411603||INCA2 2006-07|"French National Dietary Intake Survey, conducted in 2006-2007 by the French Agency for Food, Environmental and Occupational Health Safety.~Adults aged 18y and over, n=1918 included in the analyses."
2423559|NCT03411603||NHANES 2011-12|Wave 2011-12 of the National Health and Nutrition Examination Survey, the US national dietary intake Survey, conducted by the Centers for Disease Control and Prevention (CDC) Adults aged 18y and over, n=5073 included in the analyses.
2423560|NCT03411590|Other|200ml|Toddlers will be allocated to the 200 ml group
2423561|NCT03411590|Other|400ml|Toddlers will be allocated to the 400 ml group
2423562|NCT03411590|Other|600ml|Toddlers will be allocated to the 600 ml
2423563|NCT03411577|Experimental|Behavioral Intervention|The adolescent HIV/STI risk-reduction intervention aims to: (a) increase knowledge of HIV risk and prevention; (b) strengthen behavioral beliefs regarding abstinence and safer sex; (c) increase self-efficacy and intentions to avoid unsafe sex; and (d) increase sexual communication and refusal skills. The mother component includes much of the same prevention knowledge and addresses parent-teen sexual risk communication, monitoring, and sexual role modeling. Interventions are held on two consecutive Saturdays for 6 hours each day. Mothers' groups meet separately from daughters' groups, although the groups will come together for the last module of each day.
2423564|NCT03411577|No Intervention|Control Group|"The control / comparison group is essentially a no intervention / wait-list control group. However, during pilot testing, participants expressed a strong desire to engage in some type of health activity. As a result, the control group members, both mothers and daughters, participated in a brief educational activity on reducing risk for cardiovascular disease. The educational activity was limited to a few hours on one Saturday. Participants returned the following week to complete post-test questionnaires along with the participants in the experimental group."
2423565|NCT03411564|Experimental|Group 1|Students enrolled in one or two targeted secondary schools in each city who are going to receive the intervention (workshop)
2423566|NCT03411564|No Intervention|Grup 0|Students from other centers with similar socioeconomic characteristics (relating to social characteristics and school location) to the centers.
2423567|NCT03411551|Active Comparator|Forearm Bier's block|Forearm intravenous regional anesthesia (Bier's block)
2423568|NCT03411551|Experimental|Peripheral Nerve Block|Ultrasound-guided peripheral nerve block (regional anesthesia)
2423569|NCT03411538||Hospital-acquired bacterial infection|
2423570|NCT03411525|Experimental|Commitment invitation at time 1|In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 1 month, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 8 months.
2423571|NCT03411525|Experimental|Commitment invitation at time 2|In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 2 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 7 months.
2423572|NCT03411525|Experimental|Commitment invitation at time 3|In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 3 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 6 months.
2423573|NCT03411525|Experimental|Commitment invitation at time 4|In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 4 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 5 months.
2423574|NCT03411525|Experimental|Commitment invitation at time 5|In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 5 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 4 months.
2423575|NCT03411525|Experimental|Commitment invitation at time 6|In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 6 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 3 months.
2423576|NCT03411525|Experimental|Commitment invitation at time 7|In the stepped wedge cluster randomized design, the seventh clinic will remain in the control period (no intervention) for 7 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 2 months.
2423765|NCT03410082|Active Comparator|OAA/S|The patients in the control group will receive MAC titrated according to observer's assessment of anesthesia/sedation(OAA/S) score.
2423577|NCT03411525|Experimental|Commitment invitation at time 8|In the stepped wedge cluster randomized design, the eighth clinic will remain in the control period (no intervention) for 8 months, followed by a 1 month transition period (where data will not be collected), before crossing over to the intervention period for 1 month.
2423578|NCT03411512||CHD|Newborns with structural congenital heart defects. The exclusion criteria were pulmonary or neurological disease, perinatal asphyxia, acute illness, prematurity and congenital abnormality other than CHD.
2423579|NCT03411512||Healthy controls|The control group comprised of healthy matched newborns without a diagnosed CHD.
2423580|NCT03411499|Experimental|Early surgery|Surgery within 72 hours from endocarditis diagnosis
2423581|NCT03411499|Active Comparator|Conventional therapy|Medical treatment and a possible delayed surgical intervention according to the current guidelines
2423582|NCT03411473|Experimental|AGEN1884 with pembrolizumab|AGEN1884 in combination with pembrolizumab
2423583|NCT03411460|Experimental|Interstitial glucose|Glucose level tested by continuous monitoring device
2423584|NCT03411460|Active Comparator|Blood glucose|Glucose level tested on glucose monitor using standard finger prick
2423585|NCT03411447|Active Comparator|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
2423586|NCT03411447|Active Comparator|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
2423587|NCT03411434|Experimental|ADHD patients|90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
2423588|NCT03411421|Experimental|Part 1 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio in Cohorts 1 to 3. AL-794 will be administered at a 100 milligram (mg) loading dose (LD) on the morning of Day 1, followed by a 50 mg maintenance dose (MD) on the evening of Day 1 and twice-daily (BID) on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days), at the discretion of the Sponsor and Principal Investigator (PI).
2423589|NCT03411421|Experimental|Part 2 (AL-794 or Placebo)|Participants will receive AL-794 or placebo in 2:1 ratio. AL-794 will be administered as 100 mg LD on the morning of Day 1, followed by a 50 mg MD on the evening of Day 1 and BID on Day 2 through Day 5. The duration of dosing may be extended (maximum duration 10 days). Based on the results of Part 1, the duration of dosing may be modified.
2423590|NCT03411408|Experimental|HBO and RT|Hyperbaric oxygenation therapy and Accelerated Hypofractionated intensity - modulated radiotherapy
2423591|NCT03411395|Placebo Comparator|Placebo drink|A standardized breakfast meal will be provided together with carbonated water containing aroma
2423592|NCT03411395|Experimental|5AA+CrPic Water Dose 1|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA and CrPic
2423593|NCT03411395|Experimental|5AA+CrPic Water Dose 2|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/2 of Dose 1) and CrPic
2423594|NCT03411395|Experimental|5AA+CrPic Water Dose 3|A standardized breakfast meal will be provided together with carbonated water containing aroma and active components 5AA (1/4 of Dose 1) and CrPic
2423595|NCT03411382|Experimental|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
2423596|NCT03411382|Experimental|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
2423597|NCT03411382|Experimental|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
2423598|NCT03411382|Placebo Comparator|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
2423599|NCT03411369|Experimental|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|Water-soluble powder in sachets of 4 grams. Each sachet contains 1 gram of Creatine, 2.5 grams of D-Ribose, 0.33 mg of B1 vitamin and 0.42 mg of B6 vitamin.
2423600|NCT03411369|Placebo Comparator|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
2423601|NCT03411356|Active Comparator|Daily Caloric Restriction (DCR)|Participants in this group will focus on daily calorie restriction as their dietary weight loss strategy.
2423602|NCT03411356|Experimental|Intermittent Fasting (IMF)|Participants in this group will focus on modified intermittent fasting as their dietary weight loss strategy.
2423603|NCT03411343|Active Comparator|Interscalene Block|Patients randomized to receive an intesrcalene block.
2423604|NCT03411343|Experimental|Costoclavicular Infraclavicular Block|Patients randomized to receive a costoclavicular infraclavicular block.
2423605|NCT03411330|Active Comparator|Group H (Hyaluronidase added to local anaesthetics)|"group H scalp block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg , Hyaluronidase will be added in in a dose of 1500 IU . The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block and not just a ring block. At the end of the scalp block further local anesthetic can be infiltrated locally to the pin sites and 7 nernes supraorbital nerve, a branch of the trigeminal nerve,supratrochlear nerve, a branch of the trigeminal nerve.~zygomaticotemporal nerve,auriculotemporal nerve, lesser occipital nerve, greater occipital nerve and greater auricular nerve"
2423606|NCT03411330|Active Comparator|Group A (local anaesthetics alone)|"Group A :scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum dose of 175 mg The scalp block technique includes infiltrating local anaesthetic to 7 nerves on either side. This is an anatomical block, and not just a ring block. At the end of the scalp block; further local anesthetic can be infiltrated locally to the pin sites and 7 nernes Supraorbital nerve, a branch of the trigeminal nerve.~supratrochlear nerve, a branch of the trigeminal nerve. zygomaticotemporal nerve, auriculotemporal nerve, lesser occipital nerve, greater occipital nerve, greater auricular nerve"
2423607|NCT03411291||Diet: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.
2423608|NCT03411291||Statin: MRI/MR Spectroscopy/MR Perfusion|Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.
2423609|NCT03411278|Experimental|Deep Oscillation (DO) self treatment|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2). The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
2423610|NCT03411278|No Intervention|No intervention, control|No intervention
2423611|NCT03411265|Experimental|RETAIN|Participants who meet criteria will receive the RETAIN self-administered, e-health application intervention.
2423612|NCT03411252|Experimental|Mirabegron|Patients will receive 50 mg of oral Mirabegron daily for 4 weeks and then switch to placebo by mouth daily for an additional 4 weeks.
2423613|NCT03411252|Placebo Comparator|Placebo|Patients will receive placebo by mouth daily for 4 weeks and then switch to oral Mirabegron 50 mg daily for an additional 4 weeks.
3146182|NCT00093249|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
2423615|NCT03411226||re-TREPP|Patients who presented with a recurrent inguinal hernia after previous TREPP repair.
2423616|NCT03411213|Experimental|Vascular function|Diffuse optical tomography detection of differences in vascular function between healthy volunteers and patients with proven heart disease or diabetes.
2423617|NCT03411213|Experimental|Coronary artery disease|Diffuse optical tomography prediction of presence or severity of coronary artery disease on angiography.
2423618|NCT03411200|Experimental|Intervention group (n=50)|Participants in the intervention group will receive usual care and the multimodal and exercise-based intervention.
2423619|NCT03411200|No Intervention|Control group (n=50)|Participants in the control group will receive usual care.
2423620|NCT03411187|Active Comparator|foot-control exhaust group|The foot-control exhaust group used of the Pressure adjustable foot-control method by the way of adjustable Pressure to intermittent exhaust
2423621|NCT03411187|Placebo Comparator|direct exhaust group|direct exhaust group exhaust through the Trocar hole.and without use of the Pressure adjustable foot-control method
2423622|NCT03411174|Experimental|HF-PBI|Hypofractionated partial breast irradiation was delivered to the tumor bed areas for low recurrence risk breast cancer patients, with prescription dose 40Gy in 15 fractions in 3 weeks.
2423623|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase I|Phase I: Single arm, non-randomized study in metastatic breast cancer patients. S81694 given intravenously every two weeks at different doses on D1 and D15 last for 28 days. The participants will also receive paclitaxel intravenously on D1, D8 and D15 last for 28 days.
2423624|NCT03411161|Active Comparator|paclitaxel phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~Paclitaxel given intravenously on D1, D8, and D15 at 80 mg/m² during a 28-day cycle."
2423625|NCT03411161|Experimental|Combination therapy (S81694 + paclitaxel) phase II|"Phase II: Randomised phase II part , two-arm, in untreated metastatic triple negative breast cancer patients.~S 81694 given intravenously on D1 and D15 at recommended phase 2 dose (RP2D). Paclitaxel given intravenously on D1, D8, and D15 during a 28-day cycle."
2423626|NCT03411148|Experimental|Exercise Group A|Weekly exercise sessions with physical therapist and psychologist
2423627|NCT03411148|Placebo Comparator|Exercise Group B|Home-based exercises
2423628|NCT03411122|Experimental|Single-sequence 3-period|Period 1: napabucasin 240 mg BID on days 1-2 Period 2: cytochrome P450 probe drugs during days 1-4 Period 3: napabucasin 240 mg BID on days 1-11, cytochrome P450 probe drugs during days 6-9
2423629|NCT03411109||Opioid Only Intrathecal|
2423630|NCT03411109||Opioid + Local Anesthetic Intrathecal|
2423631|NCT03411096|Experimental|Quadratus lumborum block|Quadratus lumborum block with 0.75% ropivacaine
2423632|NCT03411096|Placebo Comparator|Placebo|Quadratus lumborum block with normal saline
2423633|NCT03411083||Knee replacement|Patients assigned for total or unicompartmental knee replacement surgery
2423634|NCT03411070|Experimental|Treatment (SCOUT reflector surgery)|Patients undergo image-guided placement of the SCOUT reflector prior to course 2 of standard of care neoadjuvant chemotherapy. Patients undergo standard of care surgery approximately 4-8 weeks after chemotherapy completion.
2423635|NCT03411057||Mindfulness Based Stress Reduction (MBSR)|Inflammatory Arthritis (Rheumatoid Arthritis, Psoriatic Arthritis) and scleroderma participants in this group will attend an 8 week MBSR course. The MBSR course meets once per week for 2.5 hours with a 4-hour retreat on week 8.
2423636|NCT03411057||Control|Rheumatoid Arthritis, Psoriatic Arthritis, and scleroderma participants in this group will watch an educational stress reduction video (10 minutes).
2423637|NCT03411044||Subjects with a Fitmore Hip Stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and who received the Fitmore Hip Stem
2423663|NCT03410836|Experimental|intravenous lidocaine (IVL)|Will receive during the colorectal surgery under General Anesthesia intravenous lidocaine bolus 1.5mg/kg at the beginning of anesthesia (induction) and 1.5mg/kg/h until the end of anesthesia.
3187007|NCT00751270|Experimental|A|Arm A for unresectable malignant glioma was closed due to poor accrual.
2423640|NCT03411018||Conventional respiratory managed group.|Preterm infants born with less than 32 weeks gestational age (wGA) that entered in the neonatal Intensive care unit (NICU) from January 1 2012 to December 31 2013. These preterm infants were managed according to prior ventilatory protocol: Prophylactic Continuous positive airway pressure (CPAP) in delivery room, early surfactant administration by INSURE technique and volume target mechanical ventilation with rescue high frequency ventilation when needed. Mechanical ventilation exposure will be analyzed
2423641|NCT03411018||Less invasive managed group|Preterm Infants born with less than 32wGA that entered the NICU from January 1 2014 to December 31 2017. This infants are managed according to the actual ventilatory protocol. Prophylactic CPAP in delivery room, early surfactant administration by less invasive technique, nasal Synchronized positive pressure ventilation for CPAP failure and early rescue high frequency ventilation with minimally target volume.Mechanical ventilation exposure will be analyzed
2423642|NCT03411005|Experimental|Metabolic availability of lysine in Sorghum|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked sorghum with or without lentils, which will all be provided by the investigators."
2423643|NCT03410992|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 16 Weeks. Subjects who achieve certain predefined response criteria will be re-randomized to either receive bimekizumab or placebo until Week 56. Subjects who do not achieve predefined response criteria will enter the bimekizumab escape arm.
2423644|NCT03410992|Placebo Comparator|Placebo|Subjects will receive placebo for 16 Weeks. Subjects who achieve certain predefined response criteria will proceed with placebo until Week 56. Subjects who do not achieve certain predefined response criteria will enter the bimekizumab escape arm.
2423645|NCT03410992|Experimental|Bimekizumab Escape arm|Subjects who do not achieve certain predefined response criteria at Week 16 or later will enter the bimekizumab escape arm and will receive open-label bimekizumab for 12 weeks.
2423646|NCT03410979|Experimental|GLPG2737 single dose|Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
2423647|NCT03410979|Placebo Comparator|Placebo single dose|Single doses of Placebo oral suspension
2423648|NCT03410979|Experimental|GLP2737 multiple dose|Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
2423649|NCT03410979|Placebo Comparator|GLPG2737 multiple dose|Multiple doses of Placebo oral suspension
2423650|NCT03410966|Experimental|Intervention group|All patients affected by paroxysmal symptomatic atrial fibrillation, and anti-arrhythmic drug refractory atrial fibrillation will receive a trans catheter ablation therapy (intervention).
3187008|NCT00751270|Experimental|B|Arm B for resectable malignant glioma completed the Phase I accrual and long term follow up continues. A follow on study at dose level 3 was opened as a Phase 2a study (see BrTK02).
2423652|NCT03410940||Subjects who received a CLS Brevius Kinectiv stem|Subjects in need of a total hip arthroplasty who met the inclusion/exclusion criteria and received the CLS Brevius Kinectiv stem.
3187009|NCT00751283|Experimental|1|GRST Peripheral Catheter System
2423655|NCT03410901|Experimental|Treatment (radiation therapy, SD-101, BMS-986178)|Patients receive radiation therapy on days 1-2, TLR9 agonist SD-101 and anti-OX40 antibody BMS-986178 intratumorally on days 2, 9, 16, 23, and 30, and anti-OX40 antibody BMS-986178 IV on days 2, 30, 58, 86, 114, and 142 in the absence of disease progression or unacceptable toxicity.
2423656|NCT03410888|Experimental|popliteal approach|Blockade of the sciatic nerve at the level of the popliteal fossa.
2423657|NCT03410888|Active Comparator|infragluteal approach|Blocking the sciatic nerve at the subgluteal level.
2423658|NCT03410875|Experimental|Untreated Hairy Cell Leukemia|Participants with HCL with no prior treatment for the disease
3187010|NCT00751309||1|Lung and heart-lung transplanted subjects.
3187011|NCT00751322|Active Comparator|1|RBC transfusion of 5 days or less storage age
2423661|NCT03410849|Active Comparator|Gastric Bypass|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic gastric bypass
2423662|NCT03410849|Active Comparator|Sleeve Gastrectomy|A gastroscopy will be carried out to document the presence of inflammation and metaplasia in patients after an average of 5 years after laparoscopic sleeve gastrectomy
2423664|NCT03410836|Placebo Comparator|Placebo|Will receive the same volume of normal saline for the entire duration of anesthesia.
3187012|NCT00751322|Active Comparator|2|RBC transfusion of conventional storage age
3187013|NCT00751361|Active Comparator|1|Treatment group: Patients receive 10 Rheopheresis treatments within 17 weeks
3187014|NCT00751361|No Intervention|2|No treatment control group
3187015|NCT00751374|Other|group A|Topical gentamicin cream
3187016|NCT00751374|Active Comparator|Group B|topical gentamicin cream alternates with mupirocin cream at monthly basis
3187017|NCT00751387||1|
3187018|NCT00751413|Experimental|1|MK0633
3187019|NCT00751452||1|
3187020|NCT00751452||2|
3187021|NCT00751465|Active Comparator|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997)
3187022|NCT00751465|Active Comparator|Standard CBT|standard Cognitive Behavior Therapy, standard CBT following the model of Clark and Wells (1995).
3187023|NCT00751465|No Intervention|Wait list control|Wait list control group
2423665|NCT03410823|Experimental|PUSH Plus Protein and Nutrition|Participants will be given a whey-based protein supplement containing 27.6g of protein daily for 16 weeks and receive the PUSH intervention. PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive two visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
2423666|NCT03410810||Infant Control Group|The control arm (term born Infants) will receive an MRI at neonatal age and neurodevelopmental follow-up assessments, investigators will then compare significant morphological and diffusion properties within the brain to those of a Preterm brain.
2423667|NCT03410810||Infant Preterm Group|The experimental group will consist of preterm infants, who will receive an MRI at neonatal age and neurodevelopmental assessments. This groups scans will then be compared to those of the control arm. Significant biomarkers will then be identified.
2423668|NCT03410810||Childhood Control Group|The experimental group will consist of preterm born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children control arm. Significant biomarkers will then be identified.
2423669|NCT03410810||Childhood Preterm Group|The experimental group will consist of term born children aged 6-8 years, who received an MRI at neonatal age and will be called back for a neuropsychological assessment. This groups scans will then be compared to those of the children preterm group. Significant biomarkers will then be identified.
3187024|NCT00751478|Experimental|A|2 Placebo capsules (whole) + ALO-01 2 x 60 mg capsules (crushed) in apple juice + apple juice (MSIR placebo)
2423671|NCT03410784|Other|First-line chemotherapy with pembrolizumab|"Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
2423672|NCT03410771||ICU patients on amoxicillin/clavulanic acid|
2423673|NCT03410771||ICU patients on piperacillin/tazobactam|
2423674|NCT03410771||ICU patients on meropenem|
2423675|NCT03410771||ICU patients on vancomycin|
2423676|NCT03410745|Experimental|Exercise group|
2423677|NCT03410745|No Intervention|Control group|
2423678|NCT03410732|Experimental|Radical surgery plus activated DCs|In 21 days after a radical surgery, activated DCs are iv infused
2423679|NCT03410732|Active Comparator|Radical surgery only|Radical surgery only group as a control group
2423680|NCT03410719|Experimental|<55 (Low-GI group)|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals:Low-GI - pasta, barley, parboiled rice, legumes.
2423681|NCT03410719|Experimental|>70 (Hi-GI group).|intervention weeks 1-12 the subjects in each group will be counseled to follow their weight maintaining assigned diet using a combination of prescribed menus (breakfast, lunch, and snack eating occasions) and an item specific version of the Pasta Recipe Builder (dinner). The two group-specific diet plans will mostly contain the same foods and beverages typically included in Mediterranean-style diets, except for substitutions of major sources of carbohydrate in their meals: Hi-GI - rice, potato,
3187025|NCT00751478|Experimental|B|2 x 60 mg ALO-01 (whole) + 2 x placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
2423685|NCT03410680|No Intervention|Control arm|Patients will receive the standard of care at the clinic. Questionnaires will be applied 4 times in a period of 10 months
2423686|NCT03410680|Experimental|Intervention arm|"Each participant will receive FUERTES for a period of 4 months. It consists of receiving a habit-formation kit, which include an information and habit-formation tool that can be accessed through a web platform, a mobile app and a booklet; b) pill cases; c) a fidget cube; and f) a notebook. Patients will have the option of contacting a MD though WhatsApp regarding questions related to their treatment.~After completing baseline a questionnaire, patients with a score of 2 for barriers that might affect their ART adherence will be assigned a coach. The coach will have 7 one-on-one sessions with the patient in a period of 4 months in order to catalyze ART adherence. MSM living with HIV who have been taking ART for >3 years will provide a one-time one-on-one peer support session"
2423687|NCT03410667|Other|Standard Care|Standard of care arm
2423688|NCT03410667|Experimental|Intervention Arm|Intervention arm
2423689|NCT03410654|Experimental|adult kidney transplant recipients|Adult kidney transplant recipients on tacrolimus immediate release for at least six months who are being converted to tacrolimus extended release Envarsus XR® (TAC XR) for any reason by a transplant nephrologist and are willing to participate in cognitive assessment will be offered the opportunity to participate in the study. An assessment is also made at the 3 month point as baseline.
2423690|NCT03410641||Diet and antismoking advice|Dietary and antismoking advice, aiming to reduce participant's risk of cardiovascular diseases
2423691|NCT03410641||Control|No intervention
2426854|NCT03388424||quantification of microbiota in GI|Patients of both sex with gastrointestinal diseases
3146183|NCT00093262|Experimental|clevidipine|Clevidipine was administered in a blinded fashion intravenously, starting with an infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/hr), titrating upward, as tolerated by the patient, in doubling increments approximately every 90 seconds up to an infusion rate of 3.2 μg/kg/min (16 mg/hr) to achieve the desired blood pressure-lowering effect. Up-titration to infusion rates above 3.2 μg/kg/min could be used, guided by the patient's response, by increasing the infusion rate in serial increments of 1.5 μg/kg/min, up to the maximum recommended clevidipine infusion rate of 8.0 μg/kg/min. Clevidipine was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
2423696|NCT03410602|Placebo Comparator|Supragingival and subgingival scaling|Supragingival and subgingival scaling group comprised of 15 orthodontic patients treated with routine full-mouth supragingival scaling and subgingival scaling only around all banded first molars. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
2423697|NCT03410602|Active Comparator|Subgingival irrigation|Subgingival irrigation group comprised of 15 orthodontic patients treated with full-mouth supragingival scaling and subgingival scaling only around all banded first molars followed by irrigation with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent. Parameters such as radiographic evidence of alveolar crestal bone level, gingival index, probing pocket depth and clinical attachment level around the banded first molars and full-mouth plaque index were recorded as a change from baseline to 12th month.
2423698|NCT03410589||Single arm|
2423699|NCT03410576||Carotid artery stenting|Patients undergo carotid artery stenting.
2423700|NCT03410576||Carotid endarterectomy|Patients receive elective carotid endarterectomy.
2423701|NCT03410563||Healthy participants|
2423702|NCT03410550|Experimental|Exoskeleton Training|Twenty men with complete and incomplete SCI will be enrolled in the trial.
2423703|NCT03410537|Experimental|Taurine Supplementation|Taurine 2.4mg/d for 12 weeks
2423704|NCT03410537|Placebo Comparator|Placebo|Placebo 2.4mg/d for 12 weeks
2423705|NCT03410524|Active Comparator|Simethicone with PEG-3350 bisacodyl preparation|"Treatment arm:~200 mg Simethicone in 3 mL of liquid formulation mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
2423706|NCT03410524|Placebo Comparator|Placebo with PEG-3350 bisacodyl preparation|"Placebo arm:~3 mL of water mixed with low volume PEG-3350 bisacodyl combination preparation. Bowel preparation taken as per directions including the evening before and the day of the procedure."
2423707|NCT03410511|Experimental|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
2423708|NCT03410511|Experimental|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol/nicotine (mix 50:50) intake.
2423709|NCT03410511|Experimental|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
2423710|NCT03410498|Other|MS group|This group will perform walking trials in various conditions, i.e. normal walking, walking whilst performing an attention demanding task and walking while being physically tired.
2423711|NCT03410485|Active Comparator|Control (C Group )|Intervention for intraoperative analgesic administration will be based on heart rate and blood pressure variations. Intervention for intraoperative hypnotice/desflurane administration will based on keeping the MAC at 0.8.
2423712|NCT03410485|Experimental|Monitoring (M Group )|Intervention for intraoperative analgesic administration will be based on the NOL index (to keep it below 25). Intervention for the desflurane administration will be based on the BIS index (to keep it between 40-60).
2423713|NCT03410472|Experimental|Web based diet application|This arm entails the subject to record their diet into an online web program to monitor calories. The calorie goal will be given to the subjects in this group prior to the study based on dual x-ray absorptiometry test that will test resting metabolic rate.
2423714|NCT03410472|No Intervention|Control|This group will have body composition tested at week 1 and then repeat this test at 8 weeks having no intervention.
2423715|NCT03410459|Active Comparator|Gastric Bypass|Patients ≥ 5 years after laparoscopic gastric bypass receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
2423716|NCT03410459|Active Comparator|Sleeve gastrectomy|Patients ≥ 5 years after laparoscopic sleeve gastrectomy receive DEXA (= Dual-energy x-ray absorptiometry) in order to measure bone mass density
2423717|NCT03410446|Experimental|Ketamine|"Three doses of ketamine will be given intranasal:~Dose 1 will be 50 mg on Day 1~Dose 2 will be between 50-100 mg on Day 4~Dose 3 will be between 50-150 mg on Day 7"
2423718|NCT03410433|Active Comparator|Silk 4.0|Silk suture
2423719|NCT03410433|Active Comparator|PG910 4.0|Vicryl Rapid suture
2423720|NCT03410433|Experimental|PP 4.0|Non-absorbable polypropylene monofilament
2423721|NCT03410433|Active Comparator|Silk 5.0|Silk suture
2423722|NCT03410433|Active Comparator|PG910 5.0|Vicryl suture
2423723|NCT03410433|Experimental|PP 5.0|Non-absorbable polypropylene monofilament
2423724|NCT03410433|Experimental|APG 5.0|Antibacterial Vicryl suture
2423725|NCT03410433|Experimental|ePTFE 5.0|expanded polytetrafluoroethylene
2423726|NCT03410420|Active Comparator|Non aneurysmal|Intervention: four non-aneurysmal patients undergoing coronary artery bypass graft or aortic valve replacement will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
2423727|NCT03410420|Experimental|Aneurysmal|Intervention: four patients who are candidates for aortic replacement due to aneurysm will be administered pimonidazole-HCl orally in a single dose (0.5g/m2) 24 hours prior to scheduled surgical time.
2423764|NCT03410095||Sleep apnea patients|80 patients recently diagnosed with severe sleep apnea will participate in the Brain Changes in Sleep Apnea Study.
2423729|NCT03410394||registry of endocrine tumors|"Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22.~Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23~Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24~Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26"
2423730|NCT03410381|Experimental|Group using the application EMMA|Patients with personal history of suicide attempt or with suicidal ideation, will use the application during 6 months. Assessment of the predictive value of the algorithm for suicidal risk, acceptbability and satisfaction
2423731|NCT03410368|Experimental|autologous natural killer cells|Infusion of 1-2×10^9 NK cells every 14 days in the absence of progression or unacceptable toxicity until the 6 courses of treatment.
2423732|NCT03410368|No Intervention|routine follow-up|According to present guideline, no special treatment is advised for patients with SCLC after first-line therapy.They will be followed-up regularly.
2423733|NCT03410355|Experimental|BMAC/PRP Injection Group|This group will receive an injection of BMAC/PRP for treatment of OA
2423734|NCT03410355|Active Comparator|Cortisone Injection Group|This group will receive an injection of cortisone for treatment of OA
3146184|NCT00093262|Placebo Comparator|placebo|Placebo consisted of 20% lipid emulsion (the same lipid vehicle used for clevidipine) administered in a blinded fashion intravenously following the same study drug administration guidelines as with clevidipine study drug administration guidelines. As with clevidipine, placebo was to be administered for a minimum of 30 minutes, unless bailout occurred, and up to a maximum of one hour.
3187026|NCT00751478|Active Comparator|C|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + 120 mg MSIR in apple juice
3187027|NCT00751478|Placebo Comparator|D|2 x placebo capsules (whole) + 2 X placebo capsules (crushed) in apple juice + apple juice (MSIR placebo)
2423738|NCT03410329|Experimental|High weekly training frequency|three sessions a week of resistance training
2423739|NCT03410329|Experimental|Low weekly training frequency|one workouts per week
2423740|NCT03410316||Participants of the NEO study|Men and women aged 45 oy 65 years, with an oversampling of individuals with a BMI of 27 kg/m2 or higher
2423741|NCT03410303|Other|Intraoperative ultrasound|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
2423742|NCT03410290||Group 1|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
2423743|NCT03410277|Experimental|All Subjects|Experimental hypoglycemia
2423744|NCT03410264|Experimental|CR-EXP|Cognitive restructuring before exposure with response prevention (45 minute intervention).
2423745|NCT03410264|Experimental|EXP-CR|Exposure with response prevention before cognitive restructuring (45 minute intervention).
2423746|NCT03410264|Active Comparator|Stress Management|Stress management skills.
2423747|NCT03410238|Experimental|Treatment|Participants receive Saferteens Brief Intervention and a brochure containing psycho-education and resources.
2423748|NCT03410238|No Intervention|Control|Participants receive a brochure containing psycho-education and resources only.
2423749|NCT03410225|Experimental|CAMI-TPP|Young men, ages 15 to 24 years, will be receiving a modified CAMI aimed at Teen Pregnancy Prevention (CAMI-TPP).
2423750|NCT03410225|Active Comparator|CAMI-Fitness|Young men, ages 15 to 24 years, will be receiving CAMI aimed at healthy diet, physical activity and tobacco avoidance (CAMI-Fitness).
2423751|NCT03410212|Active Comparator|Ketorolac Tromethanine|In the experimental group, 30mg/mL, ketorolac tromethamine will be injected as same as the first IANB and 5 minutes following it.
2423752|NCT03410212|Sham Comparator|No injection|In the control group, 5 minutes following the IANB, the sham injection will be provided at the same place of the first injection.
2423753|NCT03410173|Experimental|Taurine|2.4mg/d for 12 weeks
2423754|NCT03410173|Placebo Comparator|Placebo|2.4mg/d for 12 weeks
2423755|NCT03410160||High frequency of adrenal crisis|Patients with a high frequency of adrenal crisis in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
2423756|NCT03410160||Low frequency of adrenal crisis|Patients with no adrenal crisis or a low frequency of AC in the past. Intervention: Clinical and biochemical examination (physical examination and blood-sampling before and after oral ingestion of glucocorticoids).
2423757|NCT03410147|Other|Concentration A|Concentration of 13C-sodium octanoate in enteral nutrition is 0.3 mg/ml
2423758|NCT03410147|Other|Concentration B|Concentration of 13C-sodium octanoate in enteral nutrition is 1.0 mg/ml
2423759|NCT03410147|Other|Concentration C|Concentration of 13C-sodium octanoate in enteral nutrition is 3.0 mg/ml
2423760|NCT03410134|Experimental|NeoMTA|Vital pulp therapy with NeoMTA
2423761|NCT03410121|Other|Standard 1 : Thoracic location|The intervention is characterized by the randomization into thoracic arm which means that patients will have an implantable Venous Access Device implanted into thoracic location
2423762|NCT03410121|Other|Standard 2 : Humeral location|The intervention is characterized by the randomization into humeral arm which means that patients will have an implantable Venous Access Device implanted into humeral location
3187028|NCT00751491|Active Comparator|III|
3187029|NCT00751491|Active Comparator|A|
3187030|NCT00751491|Placebo Comparator|placebo|
3187031|NCT00751517|Active Comparator|A|Cyclophosphamide
3187032|NCT00751517|Experimental|B|Methotrexate
3187033|NCT00751556|Experimental|Arm 1|
3187034|NCT00751556|Active Comparator|Arm 2|
3187035|NCT00751569||A1|A group of 3 to 5 pregnant women as donors for umbilical cord blood
2423775|NCT03410043|Experimental|Group I (LCT)|Patients receive osimertinib PO QD for 6-12 weeks. Patients then undergo surgery and/or radiation therapy daily for 5 consecutive days every week for up to 8 weeks. Patients continue osimertinib during and after radiation therapy. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2423776|NCT03410043|Experimental|Group II (no LCT)|Patients receive osimertinib PO QD. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2423777|NCT03410030|Experimental|Ascorbic Acid|Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials
3146185|NCT00093418|Experimental|Arm I|Arm I: Patients receive oral tipifarnib twice daily on days 1-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
2423779|NCT03410004|Experimental|Experimental|Drug: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
3187036|NCT00751582|Experimental|2|Food supplementation and nutrition education
3187037|NCT00751582|Experimental|1|Nutrition Education only
2423782|NCT03409978||In-Motion app for movement analysis|Participants will be recruited from infants referred to the high-risk follow-up clinic at the hospital. These at-risk children are included in the regular clinical follow-up program comprising a standard examination at 3 months corrected age (fidgety general movements period). Infant/families from St. Olavs Hospital (n= 15), in Norway, Lurie Children's Hospital (n=15), Chicago, USA, Christian Medical College (n=15), Vellore, India, University of Ghent (n=15), Belgium, and Hillerød Hospital (n=30), Copenhagen, Denmark will be invited to participate.
2423783|NCT03409965|Experimental|Lutronic Systems Combination Treatment|Combination treatment of the face and/or neck using the Lutronic Infini System and Lutronic LaseMD System.
2423784|NCT03409952|Active Comparator|Group A: LaseMD and DUAL 1927nm Laser|Group A subjects will receive split-side study treatments comparing two devices: LaseMD compared to the DUAL 1927nm laser.
2423785|NCT03409952|Active Comparator|Group B: LaseMD Optimized|Group B subjects will receive LaseMD Optimized Treatments based on Group A treatment data.
2423786|NCT03409939|Experimental|Aromatic Amino Acid Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
2423787|NCT03409926|Active Comparator|Microcrystalline Cellulose (MCC) 10 grams/day|non-fermentable active control
2423788|NCT03409926|Experimental|Acacia Gum 5 grams/day|fermentable dietary fiber
2423789|NCT03409926|Experimental|Acacia Gum 10 grams/day|fermentable dietary fiber
2423790|NCT03409913||GCA cases|In a cohort of patients suspected of GCA based on the following inclusion criteria were 1) age ≥50 years, 2) CRP>15mg/l or ESR>40mm/h, 3) either a) cranial symptoms, b) new-onset extremity claudication or c) weight loss >5 kilograms or fever>38oC for >3 weeks, patients with a clinical diagnosis of GCA is identified.
2423791|NCT03409913||controls|Age-(+/- 3 years) and sex-matched malignant melanoma (MM) patients who had a follow-up metastatic-disease-free FDG PET/CT ≥6 months after MM resection
2423792|NCT03409900|Experimental|LPB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
2423793|NCT03409900|Experimental|QLB Unilateral DAA THA|Patients will be randomized to receive either a LPB or QLB for post-operative analgesia. Randomization to either LPB or QLB will occur via block randomization using sealed sequentially numbered opaque envelopes that will correspond to the order with which patients are enrolled. Patients and research assistants will be blinded to their randomization by administration of intravenous sedation (titrated to patient comfort), utilization of ultrasonography to visualize pertinent structures for both blocks, and by the nature of the block technique themselves both being in close proximity on the posterior lower back.
2423794|NCT03409887|Experimental|Intraorifice Group|Intraorifice barrier of GIC.
2423795|NCT03409887|Experimental|Base Group|Base of GIC
2423796|NCT03409887|Active Comparator|Control Group|Direct composite restoration
2423797|NCT03409874|Experimental|Dry Needling and Spinal Manipulation|
2423798|NCT03409874|Active Comparator|Interocclusal Appliance, NSAIDs and TMJ Mobs|
3187038|NCT00751595|Experimental|ARM A (Tat Protein 7.5 or 30 microg 5X)|Group I: Subjects receiving 5 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 5 intradermal immunization with Tat (30 microg).
3187039|NCT00751595|Experimental|ARM B (Tat Protein 7.5 or 30 microg, 3X)|Group I: Subjects receiving 3 intradermal immunization with Tat (7.5 microg); Group II: Subjects receiving 3 intradermal immunization with Tat (30 microg)
3187040|NCT00751608|Experimental|1|
3187041|NCT00751608|Active Comparator|2|
3187042|NCT00751608|Placebo Comparator|3|
3187043|NCT00751647|Other|A1|Population receiving the CF specific outpatient PT services.
3187044|NCT00751673||TESS prosthesis|Consecutive series of patients with a TESS prosthesis.
3187045|NCT00751686||RV GE Group|
3187046|NCT00751699|Experimental|1|Asacol 6x400 mg Q24h at 7 am for 7 days
3187047|NCT00751699|Experimental|2|Asacol 2x400 mg Q8h at 7 am, 3 pm, and 11 pm for 7 days
3187048|NCT00751699|Experimental|3|Lialda 2x1.2g Q24h at 7 am for 7 days
2423799|NCT03409848|Experimental|A: Chemo-free immunotherapy|Week 1-12 Trastuzumab 6mg/kg d1 every 3 weeks (loading dose 8mg/kg) Nivolumab 1mg/kg i.v. d1 every 3 weeks Ipilimumab 3mg/kg i.v. d1 every 3 weeks Week 13 till EOT (max treatment period 12 months) Trastuzumab 4mg/kg d1 every 2 weeks Nivolumab 240mg i.v. d1 every 2 weeks
2423800|NCT03409848|Experimental|B: Chemo- / immunotherapy|"Trastuzumab 4mg/kg d1 every 2 weeks (loading dose 6mg/kg) Nivolumab 240mg i.v. d1 every 2 weeks mFOLFOX6 every 2 weeks Oxaliplatin at a dose of 85 mg/m2 IV over two hours (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv over two hours (day 1) 5-FU at a dose of 2400 mg/m2 IV over 46 hours (day 1-3)~Max Treatment period 12 months"
2423801|NCT03409835|Experimental|Ramosetron|
2423802|NCT03409835|Placebo Comparator|Control|
2423803|NCT03409822|Other|Placenta previa|
3146186|NCT00093418|Experimental|Arm II|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3146187|NCT00093418|Experimental|Arm III|Patients receive tipifarnib as in arm I, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
3146188|NCT00093418|Experimental|Arm IV|Patients receive tipifarnib as in arm II, but at a lower dose. In all arms, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients who achieve a complete remission (CR) receive up to 3 additional courses beyond CR. Patients in CR who develop recurrent disease after the completion of therapy are eligible to receive tipifarnib again.
2423809|NCT03409783|Active Comparator|Active or ENSO Group|Active ENSO device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2423810|NCT03409783|Sham Comparator|Sham Group|Sham device use for two weeks, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2423811|NCT03409770|No Intervention|Usual care|Usual care (normothermia) arm
2423812|NCT03409770|Experimental|Therapeutic hypothermia - 48 h|Whole body cooling (33 to 34 C) for 48 hours
2423813|NCT03409770|Experimental|Therapeutic hypothermia - 72 h|Whole body cooling (33 to 34 C) for 72 hours
2423814|NCT03409757||hemodialysis patients with hyperphosphatemia|"dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool~Velphoro® medication"
2423815|NCT03409757||control group|- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool
2423816|NCT03409744|Experimental|evinacumab|
3146189|NCT00093509|Experimental|Magnetic Resonance Based Thermometry|"Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90. Interstitial temperature measurements will be taken by placing a single (less than or equal to) 15 gauge thermometry catheter into the tumor.~In addition to hyperthermia treatment and radiation therapy all patients will receive conventional surgery for the removal of their tumors. Some patients will also receive chemotherapy if their treating physician thinks it is the their best interested (including the possibility of doxorubicin hydrochloride or ifosfamide and mesna)."
2423819|NCT03409705|Experimental|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
2423820|NCT03409705|Placebo Comparator|Control group|2,000 mg of placebo was orally administered per day for 12 weeks.
2423821|NCT03409679|Experimental|Murepavadin|Murepavadin IV + one anti-pseudomonal antibiotic
2423822|NCT03409679|Active Comparator|Two anti-pseudomonal antibiotics|Association of 2 anti-pseudomonal antibiotics
2423823|NCT03409666|Experimental|Taperloc Complete Microplasty stem|Subjects in need of a total hip artthroplasty who received the Taperloc Complete Microplasty stem.
2423824|NCT03409666|Active Comparator|Taperloc Complete Reduced Distal stem|Subjects in need of a total hip arthroplasty who received the Taperloc Complete Reduced Distal stem.
2423825|NCT03409627|Experimental|Group 1|Single infusion of INXN-4001, Dose 1
2423826|NCT03409627|Experimental|Group 2|Single infusion of INXN-4001, Dose 2
2423827|NCT03409614|Other|Chemo|Part 1: Chemotherapy
2423828|NCT03409614|Experimental|REGN2810+Chemo Part 1|Part 1: REGN2810+chemo
2423829|NCT03409614|Experimental|REGN2810+AbbrevChemo+ipi|Part 1: REGN2810+abbrev chemo+ipi
2423830|NCT03409614|Experimental|Placebo+Chemo|Part 2: Placebo plus chemo
2423831|NCT03409614|Experimental|REGN2810+Chemo Part 2|Part 2: REGN2810+chemo
2423832|NCT03409601|Experimental|100% Portion Size|Test meal consists of baseline (100%) portion size of meal.
2423833|NCT03409601|Experimental|125% Portion Size|Test meal consists of food portion size that is 125% the size of baseline portion.
2423834|NCT03409601|Experimental|150% Portion Size|Test meal consists of food portion size that is 150% the size of baseline portion.
2423835|NCT03409601|Experimental|175% Portion Size|Test meal consists of food portion size that is 175% the size of baseline portion.
2423836|NCT03409588|Experimental|Study Drug|Riociguat (Adempas) 0.5mg to 2.5 mg three time daily - oral medication
2423837|NCT03409575|Other|5 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes.
2423838|NCT03409575|Other|10 minutes stimulation|The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes.
2423839|NCT03409562|Experimental|Pain Neurophysiology Education and motor control training|This group will undergo two pain neurophysiology education sessions prior to motor control training.
2423840|NCT03409562|Active Comparator|motor control training alone|This group will only perform motor control training.
2423841|NCT03409536||SSEP Monitoring|participants will receive a brachial plexus block for their surgery and will be monitored for brachial plexus injury using the automated SSEP monitor.
2424187|NCT03407079|Experimental|Study Arm 1|Participants will receive sucralose capsules (approximately 4mg/kg/day) by mouth for 28 days.
2423842|NCT03409510|Experimental|Long-term UVB radiation|All participants received repeated UVB radiation for nine weeks. The treatment was identical for all participants.
2423843|NCT03409497|Active Comparator|Concord Grape Juice|Concord Grape Juice
2423844|NCT03409497|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
2423845|NCT03409497|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
2423846|NCT03409484|Active Comparator|Concord Grape Juice|100% Concord Grape Juice
2423847|NCT03409484|Sham Comparator|Low flavonoid low essence beverage|Low flavonoid low essence beverage
2423848|NCT03409484|Sham Comparator|Low flavonoid beverage|Low flavonoid beverage
3146190|NCT00093600|Experimental|PKC412 administered sequentially|twice daily oral dosing of PKC412 administered sequentially
2423850|NCT03409432|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on day 1-21. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3146191|NCT00093600|Experimental|PKC412 administered concomitantly|PKC412 administered concomitantly with standard induction daunorubicin and cytarabine therapy followed by high-dose consolidation therapy with cytarabine
3146192|NCT00093613|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib twice daily on days 1-28 (once daily on day 1 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients per stratum receive escalating doses of sorafenib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity."
2423853|NCT03409406|Experimental|Caregiver Intervention + ST Intervention|Parents/caregivers receive web-based tablet protocol containing sequenced communication information for working with their child at home in addition to the Standard of Care Intervention.
2423854|NCT03409406|Active Comparator|ST Intervention|This intervention is the once monthly standard of care intervention 30-minutes speech therapy (ST) session that the child receives at the hospital.
2423855|NCT03409393|Experimental|Intervention Group|The COPUS intervention plus usual care (OPUS treatment).
2423856|NCT03409393|Other|Control Group|Usual care (OPUS treatment).
2423857|NCT03409380|Experimental|Arginine|Arginine drink provided 1 time. There is about 10 g of arginine in the product.
2423858|NCT03409380|Placebo Comparator|Placebo|Placebo drink provided 1 time.
2423859|NCT03409367|Experimental|Daily Emollient|Parents assigned to the intervention arm will receive a lipid-rich emollient and educational materials promoting once daily full-body emollient use until their infant is 24 months old. Parents will select one of five emollients to be mailed to the dyad's home at enrollment and approximately every six months for the duration of the study. These emollients include (1) CeraVe Healing Ointment, (2) Vaseline, (3) Cetaphil cream, (4) CeraVe cream, and (5) Vanicream.
2423860|NCT03409367|No Intervention|Natural Skin|Parents assigned to the control arm will receive educational materials promoting general infant skin care guidelines only and will be asked to refrain from emollient use unless dry skin develops (current standard of care guidelines).
2423861|NCT03409354|Experimental|Tele-rehabilitation|Tele-rehabilitation via iPad.
2423862|NCT03409354|Active Comparator|Usual care|Usual rehabilitation care, prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
2423865|NCT03409315||Moxifloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of moxifloxacin.
2423866|NCT03409315||Levofloxacin, prospective|Prospective included patients (n=60) receiving centralized therapeutic drug monitoring of levofloxacin
2423867|NCT03409315||Moxifloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of moxifloxacin.
2423868|NCT03409315||Levofloxacin, historical controls|Historical controls (n=120) matched to prospective patients, did not receive centralized therapeutic drug monitoring of levofloxacin.
2423869|NCT03409302|Experimental|The ALGEapp (Brief i-ACT intervention)|The intervention builds on a previously unpublished face-to-face protocol for greek-speaking chronic pain sufferers (developed by Karekla & Vasiliou, 2013) and has been simplified and modified to produce a self-help digital internet-based modality, namely the ALGEApp. ALGEApp consists of a total of 4 approximately one-hour sessions, which are structured to be completed by the users in sequence within a time frame of 2-8 weeks (depending on the rate of completion by each user). The intervention is guided, which implies that an animated character (an Avatar) guides the user throughout the whole duration of the intervention. ALGEApp contains experiential and audiovisual psycho-educational material based on ACT, adopted for the Greek-Cypriot culture.
2423870|NCT03409302|Active Comparator|Active Control group|The Active control group will have access only to limited component of the ALGEApp intervention, namely the Bonus section, which contains limited psycho-educational information regarding pain management.
3146193|NCT00093626|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2423872|NCT03409276|Experimental|Group 1 (Treatment): Protein Vaccine/GLA-SE|Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Month 2.
2423873|NCT03409276|Placebo Comparator|Group 1 (Control)|Participants will receive placebo at Day 0 and Month 2.
2423874|NCT03409276|Experimental|Group 2 (Treatment) DNA Vaccine+Placebo+Protein Vaccine/GLA-SE|Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
2423875|NCT03409276|Placebo Comparator|Group 2 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
2424188|NCT03407079|Placebo Comparator|Study Arm 2|Participants will receive placebo capsules by mouth for 28 days.
2423876|NCT03409276|Experimental|Group 3 (Treatment): DNA Vaccine+Protein Vaccine/GLA-SE|Participants will receive 2 mg of the env (A,B,C,A/E)/gag (C) DNA vaccine and 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant at Day 0 and Months 1, 3, 6, and 8.
2423877|NCT03409276|Placebo Comparator|Group 3 (Control)|Participants will receive placebo at Day 0 and Months 1, 3, 6, and 8.
2423878|NCT03409250|Other|1-Arm study|prospective, 1-arm, monocenter, investigator initiated study Intravitreal injection with Lucentis (Ranibizumab)
2423879|NCT03409237||Group 1|Mannitol 0.2-0.3 g/kg 4 times/day.
2423880|NCT03409237||Group 2|Hypertonic saline solution 3%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2423881|NCT03409237||Group 3|Hypertonic solution saline 4%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2423882|NCT03409237||Group 4|Hypertonic saline solution 7%. Continous infusion of 0,5 ml/kg/h. If necessary a loading dose of 2,5 ml/kg is administered.
2423883|NCT03409224||Adults 18-99|Adults who are undergoing cryoablation
2423884|NCT03409211|Active Comparator|Pso|with or without PsA
2423885|NCT03409211|Active Comparator|Healthy Subjects|Without PsA
2423886|NCT03409198|Active Comparator|Arm A|Chemo only (pegylated liposomal doxorubicin + cyclophosphamide)
2423887|NCT03409198|Experimental|Arm B|Chemo + ipilimumab + nivolumab
2423888|NCT03409185|Experimental|Alcon lens group|Alcon 1 piece SA60AT lens
2423889|NCT03409185|Active Comparator|AMO lens group|AMO 1 piece Sensar AABOO lens
2423890|NCT03409172|Experimental|Control group (CTr)|No counseling or nutritional therapy and no exercise
2423891|NCT03409172|Experimental|Moderate intensity continuous training (MICT)|"Follow-up during a period of 8 weeks of supervised ergometer-based moderate-intensity continuous training based on HRmax (MICT).~MICT:~3 sessions per week~intensity at 65-75% HRmax~time-effort per session: 50 min"
2423892|NCT03409172|Experimental|High Intensity Interval Training (HIIT)|"Procedures: Follow-up during a period of 8 weeks of supervised ergometer-based high intensity interval training based on HRmax (HIIT).~HIIT:~3 sessions per week~10 bouts of one minute at 90% HRmax interspersed by one minute at 40% HRmax~time-effort per session: 25 min"
2423893|NCT03409146||Term Patients|"Approximately 80 pregnant women monitored in labor between 37 and 42 weeks' gestation will be necessary to complete the study. Subjects will have a singleton >37 week pregnancy.~Subjects will be recruited for the study in the following groups :~At least 10 patients with Body Mass Index (BMI) < 30 kg/m2 At least 10 patients with BMI 30-34.9 kg/m2 At least 10 patients with BMI ≥ 35 kg/m2"
2423894|NCT03409133|Experimental|Multi contact electrode implant|"Ten subjects with lower limb amputation will receive implanted multicontact stimulating nerve cuff electrodes connected to temporary percutaneous leads.~During experimental testing, a small amount of stimulation will be applied to the nerves through the contacts of the multichannel cuff electrode."
2423895|NCT03409120|Experimental|Dystonia Severity Assessment|We will measure the effects of DBS on dystonia by assessing changes in the Burke-Fahn-Marsden Dystonia Rating Scale at 2, 4, 6, and 12 months after surgery to implant the Boston Scientific Vercise PC IPG with directional DBS lead versus preoperative baseline.
3146194|NCT00093704|Experimental|Bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
3146195|NCT00093730|Experimental|BMS-59926|
2423898|NCT03409068|Experimental|C2-C4 compartment block|Experimental: the C2-C4 compartment anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenous muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
2423899|NCT03409068|Active Comparator|Costagliola block|Active Comparator: the Costagliola anesthetic block is performed by injecting Levobupivacaine 0.375% 20 mL injected in the posterior margin of the sternocleidomastoid muscle and along the anterior border of the same muscle.
2423900|NCT03409055||Group 0|patients without pleural effusion
2423901|NCT03409055||Group 1|patients with pleural effusion
2423902|NCT03409055||Group 2|patients with pleural Effusion and need of drainage
2423903|NCT03409029|Experimental|MRI Scan|As part of the study patients will undergo 4 MRI scans during radiotherapy treatment. These will take place during the 1st, 2nd, 3rd and 4th week of treatment
3187049|NCT00751712||Back of skull cerebral oximeter sensor|All patients enrolled will receive non-invasive oxygen perfusion monitoring on the back of the skull during their standard of care congenital heart surgery
3187050|NCT00751738|Experimental|1|125 mg azimilide
2423906|NCT03408990||Sleep study for clinical reasons|Children referred to sleep study for clinical reasons
2423907|NCT03408990||Healthy|Healthy children, no relevant pathologies
2423908|NCT03408977|Experimental|Men|
2423909|NCT03408977|Experimental|Women|
2423910|NCT03408964||Group 0 (set-up)|Patients with known diagnosis of CSPC (Group 0a) and CRPC (Group 0b) irrespective of the PC treatment (not first diagnosis)
2423911|NCT03408964||Group 1a (control)|Patients who underwent biopsies for suspected Prostate Cancer (PC), with a negative result for invasive cancer
2423912|NCT03408964||Group 1|Patients with a first diagnosis of localized biopsy-proven PC, untreated, planned to undergo radical surgery and / or radical radiotherapy
2423913|NCT03408964||Group 2|Patients with a diagnosis of locally advanced unresectable, recurrent or metastatic PC planned to receive first-line hormono therapy
2423914|NCT03408964||Group 3|Patients with recurrent/progressive/metastatic CRPC planned to receive chemotherapy
2423915|NCT03408951||Interventions (recording)|Patients requiring Intracardiac defibrillator (ICD) implantation or Defibrillation Test (DFT) or Electrophysiology (EP) study with high probability of supra ventricular tachyarrhythmia.
2423950|NCT03408743|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
2423951|NCT03408743|Experimental|Descriptive and injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
3187051|NCT00751751|Experimental|1|oral olmesartan medoxomil tablets 20 or 40 mg taken once daily for 52 weeks + hydrochlorothiazide tablets 12.5 or 25 mg , if needed to control BP after 12 weeks
2423916|NCT03408938||Continuous Hb monitoring with Masimo Radical|"Plethysmography Variability Index (PVI) is a measure of the dynamic changes in the perfusion index (PI) that occur during the respiratory cycle . PVI = ﴾PI Max - PI Min﴿ ÷ PI Maxx 100 %.~PVI has the potential to provide useful information concerning changes in the balance between intrathoracic airway pressure and intravascular fluid volume. Trending of PVI may be useful in monitoring surgical patients, both intraoperatively and postoperatively, for appropriate hydration states. For example, a rising PVI may indicate developing hypovolemia and gives an alarm for the need of appropriate fluid and or blood products transfusion supported by the patient hemoglobin level"
2423917|NCT03408925|Experimental|Intervention|The intervention consists of an exercise program developed by the medical team of the National Federation of Orienteering. Specifically, it consists of four exercises targeting strength, flexibility and coordination of the lower extremity. The orienteerers are asked to perform the exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function (online supplement). Each second week the exercises' difficulty level is increased.
2423918|NCT03408925|No Intervention|Control|Normal training, no intervention
2423919|NCT03408912|Other|CMR and angiography FFR|Patients will undergo both CMR and angiography to acquired FFR.
2423920|NCT03408899|Experimental|PC-1005|All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
2423923|NCT03408873|Experimental|Patient Noncompliance|Subjects enrolled in the study will receive both Abilify Miantena and the Customized Adherence Enhancement (CAE) intervention
2423924|NCT03408860|Other|2-week baseline|Patients complete assessment only for a duration of 2-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
2423925|NCT03408860|Other|4-week baseline|Patient complete assessment only for a duration of 4-weeks prior to starting the intervention: Countering Emotional Behaviors Module from the Unified Protocol.
2423926|NCT03408847|Active Comparator|MC-EVOO in addition to steroid therapy|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
2423927|NCT03408847|Placebo Comparator|Refined olive oil and steroid therapy|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
2423928|NCT03408834|Active Comparator|pulse variability index|fluid management performed by pulse variability index
2423929|NCT03408834|Placebo Comparator|conventional fluid management|fluid management performed by conventional fluid management
2423930|NCT03408821|Experimental|Problem Solving Therapy|All participants will attend 8 weekly sessions of Case Manager delivered Problem Solving Therapy.
3187052|NCT00751751|Active Comparator|2|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tables, after 12 weeks, if needed to control BP.
3187053|NCT00751764|Experimental|1|
2423933|NCT03408795|Other|JORS-LDG Group|Participants in JORS-LDG Group score the performance of procedure after LDG.
2423934|NCT03408782||No drainage|Those patients that underwent surgery and no drain was inserted at the end of the procedure
2423935|NCT03408782||Drainage|Those patients that underwent surgery and one or several drains were inserted at the end of the procedure.
2423936|NCT03408756|Active Comparator|Oral Methotrexate|Participants will receive methotrexate through oral route of administration
2423937|NCT03408756|Active Comparator|Subcutaneous Methotrexate|Participants will receive methotrexate through subcutaneous route of administration
2423938|NCT03408743|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
2423939|NCT03408743|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
2423940|NCT03408743|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks. *Also referred to as 'benefits' in other arm descriptions**
2423941|NCT03408743|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus perceived benefits and self-efficacy modules for a period up to 3 weeks.
2423942|NCT03408743|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
2423943|NCT03408743|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus injunctive norms and self-efficacy modules for a period up to 3 weeks.
2423944|NCT03408743|Experimental|Injunctive norms and benefits|Participants will have access to the knowledge module plus injunctive norms and perceived benefits modules for a period up to 3 weeks.
2423945|NCT03408743|Experimental|Injunctive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2423946|NCT03408743|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms modules for a period up to 3 weeks.
2423947|NCT03408743|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
2423948|NCT03408743|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
2423949|NCT03408743|Experimental|Descriptive norms, benefits, self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
3187054|NCT00751803|Experimental|BI 44370 TA Low Dose|
3187055|NCT00751803|Experimental|BI 44370 TA Medium Dose|
3187056|NCT00751803|Experimental|BI 44370 TA High Dose|
2423952|NCT03408743|Experimental|Descriptive and injunctive norms, and benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2423953|NCT03408743|Experimental|Descriptive & injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2423954|NCT03408743|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
2423955|NCT03408743|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
2423956|NCT03408743|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
2423957|NCT03408743|Experimental|Expectancies, benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2423958|NCT03408743|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
2423959|NCT03408743|Experimental|Expectancies, injunctive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2423960|NCT03408743|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2423961|NCT03408743|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2423962|NCT03408743|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
2423963|NCT03408743|Experimental|Expectancies, descriptive norms, self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
2423964|NCT03408743|Experimental|Expectancies, descriptive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
2423965|NCT03408743|Experimental|Expectancies, descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2423966|NCT03408743|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies , descriptive norms, and injunctive norms modules for a period up to 3 weeks.
2423967|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, efficacy|Participants will have access to the knowledge module plus the expectancies , descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2423968|NCT03408743|Experimental|Expectancies, descriptive & injunctive norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2423969|NCT03408743|Experimental|Expectancies, descriptive & injunctive, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
3187057|NCT00751803|Placebo Comparator|Placebo|
3187058|NCT00751803|Active Comparator|Eletriptan|
2423974|NCT03408717||Persistent post surgical pain (PPSP)|Questionnaires, Mechanical Temporal Summation assessment and pain threshold assessment will be assigned to patient. Within this cohort, some patients will have high pain score recorded (persistent pain) during the follow-up evaluations at 4 and 6 months.
3146196|NCT00093743|Experimental|Treatment (allogeneic bone marrow or PBSC transplantation)|"NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2, cyclosporine IV every 8-12 hours on days -3 to 0, and undergo low-dose TBI on day 0.~TRANSPLANTATION: Patients undergo allogeneic bone marrow or PBSC transplantation on day 0.~IMMUNOSUPPRESSION: Patients receive cyclosporine PO or IV every 8-12 hours on days 1-100 with taper to day 177, and mycophenolate mofetil PO or IV every 8 hours on days 0-40 with taper to day 96."
3146197|NCT00093769|Experimental|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
2423977|NCT03408691|Active Comparator|Test product|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks
2423978|NCT03408691|Placebo Comparator|Control product|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks
2423979|NCT03408691|No Intervention|No product|no product
3146198|NCT00093821|Experimental|Treatment (tanespimycin)|"Patients receive tanespimycin IV over 2-6 hours on days 1, 4, 8, and 11 (for patients with solid tumors) OR days 1, 4, 8, 11, 15, and 18 (for patients with leukemia). Courses for all patients repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 15 patients are treated at the MTD."
3146199|NCT00093873|Experimental|AMG 706|AMG 706 QD
2423985|NCT03408626|Experimental|papain chemomechenical caries removal agent (brix 3000)|papain chemomechenical caries removal agent (Birx 3000) and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action
2423986|NCT03408626|Placebo Comparator|conventional|conventional 330 bur
2423987|NCT03408613|Experimental|Positive Airway Pressure (PAP)|A registered polysomnographic technologist will perform a titration starting at 4 cm water (H2O) and adjust this value as needed to identify the optimal pressure to achieve an Apnea Hypopnea Index (AHI) <5 (including rapid eye movement sleep in the supine position). After PAP titration, subjects will be instructed to use the machine at the optimal pressure every night for 3 months. Compliance will be defined as: ≥4 hours use on 70% of nights and average use ≥6 hours per night.
2423988|NCT03408613|Experimental|Supplemental Oxygen (O2)|Subjects randomized to night-time supplemental oxygen will complete an overnight oxygen titration protocol in the clinical research unit. Initially, subjects will receive 0.5 liters oxygen (O2)/min; the delivery rate will then be increased by 0.5 l/min until oxygen saturation (SaO2) is ≥88%. The optimal O2 delivery rate determined during this study will be used for the intervention. The oxygen concentrators used at home will record cumulative hours of use to provide an objective measure of adherence (monitored weekly). Compliance will be defined as ≥6 h average use per night..
2423989|NCT03408613|Sham Comparator|Sham|Subjects in the sham treatment group will complete the oxygen titration protocol described for the night-time supplemental oxygen group, except that their oxygen concentrator will have been covertly modified to deliver room air at a rate of 0.5 l/min.
2423990|NCT03408613|No Intervention|Controls|Subjects without OSA will be recruited and complete all testing for primary outcome measures, but will not undergo any intervention.
2423991|NCT03408587|Experimental|CVA21 / Ipilimumab|Subjects will receive up to 8 cycles (Day 155) of intravenous CVA21 and 4 doses of ipilimumab (Days 8, 29, 50 and 71).
2423992|NCT03408574|Experimental|Older Adults|Healthy adults aged 65-75 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, placebo and perform a working memory task during the fMRI. BOLD signal is the outcome measure.
2423993|NCT03408574|Experimental|Younger Adults|Healthy adults aged 18-30 will participate in three study days where they are randomly assigned to receive either nicotine patch, oral mecamylamine, or placebo and perform a working memory task during the fMRI.BOLD signal is the outcome measure.
2423994|NCT03408561|Experimental|Health Services Research (message via Twitter)|Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
2423995|NCT03408548|Placebo Comparator|Placebo|Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.
2423996|NCT03408548|Experimental|Probiotic|Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.
2423997|NCT03408535|Other|Eriksholm Guide to Better Hearing|The Eriksholm Guide to Better Hearing is an online rehabilitation program. The program is made up of 5-weekly modules that cover different topics. Each module includes self-studies, training, and professional video coaching in hearing loss, hearing aids, and communication strategies.
2423998|NCT03408509|Experimental|Cognitive training|
2423999|NCT03408496|Experimental|Myofascial release|"Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through traces executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue."
2424000|NCT03408496|Experimental|Muscle Stretching|The muscle stretching protocol described by Bressan (2008) will be followed, which consists of 8 consecutive weekly sessions, lasting 40-45 minutes. In dorsal decubitus or sitting, the triceps surae, hamstring, gluteal, paravertebral, latissimocondyloideus, pectoral, trapezius and respiratory muscles will be stretched. The exercises will be performed in a series of five repetitions for 30 seconds.
2424001|NCT03408496|Active Comparator|Control|It will perform only the treatment prescribed by the responsable doctor, wich can be the use of drug and/or psychological treatment, and will be followed clinically by a rheumatologist during four medical appointments to monitor medication and follow in the analgesic's diary, according the standard procedure of attending the hospital where the patients will be recruited.
3187059|NCT00751816||Supportive Care|head and neck cancer survivors who are undergoing chemotherapy and radiation therapy
3187060|NCT00751829|Experimental|1|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to controll BP
2424004|NCT03408470|Experimental|TD-1473 Oral Capsule & [14C]-TD-1473 IV bolus|Cohort 1 - One oral dose and IV bolus administered 1 hr after oral dose of TD-1473
2424005|NCT03408470|Experimental|[14C]-TD-1473 Oral Capsule|Cohort 2 - One oral dose
2424006|NCT03408431|Experimental|Group E|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neck extension positioning.
2424007|NCT03408431|Active Comparator|Group C|After the placement of Ambu® AuraGain™, blind intubation will be performed in patients assigned group E with neutral head and neck position.
2424008|NCT03408418|Experimental|L-PRF group|The use of autologous leucocyte- and platelet-rich fibrin in alveolar sockets after dental extraction.
2424009|NCT03408418|No Intervention|Control|Conventional tooth extraction without any bone substitute.
2424010|NCT03408405|Experimental|Acthar Gel treatment group|Participants will be treated with 'Acthar Gel 80 UNT/ML Injectable Solution'. Initial dose for week 1 will be 50% of 80 units, injected twice per week. Week 2 is 75% of 80 units, week 3 and throughout treatment period (6 months in total) will be 80 units/ml twice per week.
3187061|NCT00751829|Active Comparator|2|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
3187062|NCT00751842|Active Comparator|A|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with Diamyd 20 µg on days 90 and 270.
3187063|NCT00751842|Active Comparator|B|This arm will receive 2 subcutaneous injections with 20 µg Diamyd on days 1 and 30, i.e., 1 prime and 1 booster dose, followed by 2 additional single doses with placebo on days 90 and 270.
3187064|NCT00751842|Placebo Comparator|C|This arm will receive 4 injections of placebo, 1 each on days 1, 30, 90 and 270.
3187065|NCT00751855|Active Comparator|1|Prolonged Exposure therapy with Hydrocortisone
3187066|NCT00751855|Placebo Comparator|2|Prolonged Exposure therapy with placebo
2424013|NCT03408366|Experimental|Women having a Laparotomy|The first 10 patients enrolled will undergo skin closure with staples. The next 10 patients enrolled will undergo skin closure with a running subcuticular suture.to evaluate skin perfusion using the Spectrum NIR imaging system following intravenous injection of ICG in all patients. Patients will be assigned skin closure with either running subcuticular suture or skin staples in a sequential, nonrandomized fashion before the procedure. After the planned surgical procedure is complete, ICG will be injected intravenously. Video of the incision will be recorded. After skin closure is complete, a second intravenous bolus of ICG (same dose as previously injected) will be given. Video of the incision will again be recorded. Measurement of perfusion will subsequently be performed by video analysis at the previously described three predefined points along the incision after surgery is complete and again after skin closure.
2424014|NCT03408353||Observational (mammography, questionnaires, blood collection)|Participants complete questionnaires over 15-25 minutes about personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity, and undergo collection of blood samples at baseline and then annually for 5 years. Participants also undergo standard of care mammography at baseline and then annually for 5 years.
2424015|NCT03408340|Experimental|Paravertebral Nerve Block|Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
2424016|NCT03408340|Active Comparator|Standard of Care Anesthesia|Participants in the control arm will undergo an anesthetic consistent with the standard of care.
2424017|NCT03408327|Experimental|Experimental group|"Wearable technology (fitness wristband & App)~4 times group activities (2 hr / each times)~LINE group interaction~Reminder and feedback form researcher"
2424018|NCT03408327|Active Comparator|Control group|"Wearable technology (fitness wristband + App)~Health promotion manual"
2424019|NCT03408314|Experimental|PediQUEST Response|"Weekly PediQUEST surveys are automatically assigned to parents and children (if 5 years old or older) and sent 48 hours prior to participant's usual clinic day~Once a PediQUEST survey is assigned, automated email reminders/app notifications are sent daily for two days~After 48 hours, unanswered or incomplete surveys are auto-submitted~PQ-feedback report generated automatically after a PQ Survey is answered~A pdf of the report is automatically emailed/available on mobile App to designated recipients~Will also receive oncology-PC integrated care through the Response team~Duration of follow-up: 18 weeks (2-week run-in period, followed by a 16-week post-randomization follow-up)"
2424020|NCT03408314|Other|Usual Cancer Care|"Will receive the usual cancer care provided at the participating sites~Will complete weekly PQ-Surveys (no feedback reports will be generated)~Can receive regular palliative care consultations following the site's usual referral procedures~Same follow-up (18 weeks)"
2424021|NCT03408301||Tourniquet deflation|Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia
2424022|NCT03408288||Nurses|
2424023|NCT03408288||Urologists|
2424024|NCT03408275||Pregnant women|Pregnant women enrolled in ALSPAC
2424025|NCT03408262|Active Comparator|Group A|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2424026|NCT03408262|Experimental|Group B|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2424027|NCT03408262|Experimental|Group C|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo
2424028|NCT03408262|Experimental|Group D|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo
2424029|NCT03408262|Active Comparator|Group E|Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2424030|NCT03408262|Experimental|Group F|Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2424031|NCT03408262|Experimental|Group G|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2424032|NCT03408262|Experimental|Group H|Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54
2424033|NCT03408249|Experimental|IBD patients|IBD patients performing IBDoc calprotectin test and ease-of-use questionnaires
2424034|NCT03408236|Experimental|Botulax|Single dose
2424035|NCT03408236|Active Comparator|Botox|Single dose
2424036|NCT03408223|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2424037|NCT03408223|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12-20 Gy on Days -8 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2424038|NCT03408210|Active Comparator|total body irradiation|Patient receives preparative therapy including cyclophosphamide and total body irradiation (TBI) of 10 Gy on Days -4 through -1, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2424147|NCT03407391||Somewhat picky eater|Identified as a somewhat picky eater from parental questionnaire
3187067|NCT00751868|Experimental|ARM 1|FEC e Ixabepilone. A goal of 48 patients will be enrolled in this study by 16 Italian centres of the GIM (Gruppo Italiano Mammella) Group. Subjects must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled in the study
3187068|NCT00751907|Experimental|Atorvastatin|40mg Atorvastatin nightly for 4 months
3187069|NCT00751907|Placebo Comparator|Placebo|matching placebo nightly for 4 months
3187070|NCT00751920|Experimental|1|
2424039|NCT03408210|Experimental|total marrow and lymphoid irradiation|Patient receives preparative therapy including cyclophosphamide and total marrow and lymphoid irradiation of 12 Gy on Days -6 through -2, and starts immunosuppressive therapy using cyclosporine or tacrolimus, methotrexate-based prophylaxes, followed by peripheral blood stem cell transplantation and granulocyte colony-stimulating factor administration.
2424040|NCT03408197|Experimental|EasyWarm|
2424041|NCT03408197|Active Comparator|BairHugger|
2424042|NCT03408184|Active Comparator|Lumbar paravertebral group|After general anesthesia, the patient is placed prone. To establish the level of the block, we used US-counting of vertebrae. After determining the lumbar one level, the block performed at a parallel line 2 cm lateral to the spinous process, the transducer is moved until the corresponding transverse process is identified. Utilizing an in-plane approach from lateral to medial, a spinal needle is advanced until contact with the transverse process. The needle is withdrawn and redirected caudally under the transverse process helped by the loss of resistance technique. the solution is slowly injected after negative aspiration for blood.
2424043|NCT03408184|Active Comparator|The field block group|The ilioinguinal nerve block was done at one fingerbreadth from the anterior superior iliac spine in a line with the pubic tubercle, The injection was done after the bob of the needle after passing the external oblique aponeurosis and muscle and 5ml of the solution is injected. The rest of the solution is injected in the incision line.
3187071|NCT00751946|Active Comparator|1|12 weekly sessions of one-to-one TARGET (psychotherapy)
3187072|NCT00751946|Active Comparator|2|12 weekly sessions of one-to-one ETAU (psychotherapy)
2424046|NCT03408158|No Intervention|HPA antigen and antibodies|Investigate the positive rate of HPA antibodies, the distribution and the specificity of HPA antigen and antibodies in Chinese blood disease patients.
2424047|NCT03408158|No Intervention|necessity of HPA antibodies screening|Investigate the connection between times of platelet transplantation and HPA antibody titer, which providing statistical data for evaluating the necessity and setting screening time and standards of HPA antibodies screening.
2424048|NCT03408158|Experimental|matched platlet infusion|Enable platelet donors'common HPA antigen to be typed and blood disease patients to be same type infusion of main HPA antigen as possible as early.The investigators compare the differences of platelet count between patients with same type infusion of main HPA antigen and not.
2424049|NCT03408145|Placebo Comparator|Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml and 1ml of Saline) comprising a total volume of 8.5ml fluid during one procedure.
2424050|NCT03408145|Active Comparator|Hyaluronic Acid & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Saline) comprising a total of 8.5mL fluid during one procedure.
2424051|NCT03408145|Active Comparator|Amniotic Tissue & Saline|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Saline and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
2424052|NCT03408145|Experimental|Amniotic Tissue & Hyaluronic Acid|The investigators aspirate 1-2ml of Synovial Fluid from the knee joint prior to administering a series of four injections (2.5ml, 2.5ml, 2.5ml of Hyaluronic Acid and 1ml Amniotic Tissue Allograft) comprising a total of 8.5mL fluid during one procedure.
2424053|NCT03408132|Experimental|FE203799 5 mg|FE203799 5 mg subcutaneous injection
2424054|NCT03408119|Experimental|Group A|100g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
2424055|NCT03408119|Experimental|Group B|50g daily dried plum consumption, plus 800 IU vitamin D and 450 mg elemental calcium
2424056|NCT03408119|Placebo Comparator|Group C|800 IU vitamin D and 450 mg elemental calcium
2424057|NCT03408093||Interferon beta-1b|Patients with CIS, RRMS or SPMS who had more than 6 months in treatment
2424058|NCT03408080|Experimental|Open Arm|All subjects will receive the same dosage throughout the study.
2424059|NCT03408054|No Intervention|Control group|No oxytocin desensitization (pretreatment), no nitroglycerin
2424060|NCT03408054|Active Comparator|Oxytocin desensitized - no nitroglycerin|Pretreated with oxytocin, no nitroglycerin exposure
2424061|NCT03408054|Active Comparator|Oxytocin desensitized - plus nitroglycerin|Pretreated with oxytocin followed by nitroglycerin exposure
2424062|NCT03408054|Active Comparator|Non oxytocin desensitized - plus nitroglycerin|No oxytocin pretreatment, followed by nitroglycerin exposure
2424063|NCT03408041||Alzheimer Disease|Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria
2424064|NCT03408028||Cognitive impairment|Geriatric patients with a cognitive impairment
2424065|NCT03408015|Experimental|Normal, asymptomatic non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2424066|NCT03408015|Experimental|Dry eye subjects, non-lens wearers|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2424067|NCT03408015|Experimental|Contact lens wearers with discomfort|Lifitegrast ophthalmic solution, 5.0%. Dosage: 1 drop in each eye, twice daily: once in the morning and once before bed.
2424068|NCT03408002|No Intervention|control group|no intervention
2424069|NCT03408002|Experimental|Psychological intervention|"Psychological intervention using the Four elements technique elaborated by Shapiro and reported in M. Luber (2009) during a psychological consultation conducted the day before surgery."
2424070|NCT03407976|Experimental|Apatinib and Pembrolizumab, all patients|
2424071|NCT03407963|Experimental|Prostate cancer patients|
2424072|NCT03407950|Other|Group IPT+|2 sessions of IPT+ by week during 6 months
2424073|NCT03407950|Other|Control Group|group without specific therapy (Treatment as usual) but same number and duration of each sessions than IPT+
3187073|NCT00751959|Active Comparator|2|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
3187074|NCT00751959|Experimental|1|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
2424074|NCT03407937|Other|Intervention|Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
2424075|NCT03407924|Experimental|Intervention aerobic exercise (AER)|Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
2424076|NCT03407924|Active Comparator|rehabilitation (R)|Participants with traumatic brain injury that are enrolled in a comprehensive rehabilitation program. These participants will receive standard rehabilitation. Given that the duration of the rehabilitative program is variable the duration of participation will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
2424077|NCT03407924|No Intervention|control (C)|Healthy volunteers' responsiveness to exercise and activity levels will be determined to detect TBI effects.
2424078|NCT03407911||Peri-implant microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2424079|NCT03407911||Periodontal pocket microbiota|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2424080|NCT03407911||healthy teeth|Bacterial population in Gingival Intracrevicular fluid harvested with adsorbent paper point
2424081|NCT03407898||C-mac D blade used for intubation|
2424082|NCT03407898||mcgrath X blade used for intubation|
2424083|NCT03407885|Experimental|Experimental|Bundled payments for knee and hip replacement
2424084|NCT03407885|No Intervention|Control|No intervention
2424085|NCT03407872|Experimental|PART A|6 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
2424086|NCT03407872|Experimental|PART B|4 cohorts will receive single dose of Esketamine DPI administered with dose escalation between cohorts.
2424087|NCT03407872|Experimental|PART C|4 cohorts will receive multiple dose of Esketamine DPI in two weeks' time administered with dose escalation between cohorts.
2424088|NCT03407872|Placebo Comparator|PART C placebo|4 cohorts will receive multiple dose of matching placebo in two weeks' time.
2424089|NCT03407859|Experimental|Sequential therapy with different CART|Sequential therapy With different CART including one kind of CD20/CD22/CD10-CART After CD19-CART therapy in CD19-negative relapse ALL patients, subjects will receive 1-5 x 10^6/Kg transduced CAR T cells at one time.
2424090|NCT03407846|Active Comparator|Total laparscopic hystrectomy|
2424091|NCT03407846|Experimental|Total abdominal hystrectomy|
3146200|NCT00093886|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
2424096|NCT03407820|Active Comparator|1st random 50% of cohort|Absorbable Chromic gut sutures
2424097|NCT03407820|Active Comparator|2nd random 50% of cohort|Non-absorbable Nylon sutures
2424098|NCT03407794|No Intervention|Control|Participants randomized into the control group will be asked to follow their usual diet during the 6 weeks of the intervention.
2424099|NCT03407794|Experimental|Fermented vegetable|Participants randomized into the fermented vegetable group will receive 1/2 cup per day of fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
2424100|NCT03407794|Active Comparator|Non-fermented vegetable|Participants randomized into the non-fermented vegetable group will receive 1/2 cup per day of non-fermented vegetables, including cabbage, carrots or pickles, for 6 weeks.
2424101|NCT03407781|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
2424102|NCT03407768|Other|Individualized interventions|Exercise, Yoga, massage therapy, acupuncture, and others
2424103|NCT03407755|Active Comparator|Air|Intraocular 100% atmospheric air (anterior chamber).
2424104|NCT03407755|Experimental|SF6|Intraocular 20% sulphur hexaflouride (anterior chamber).
2424105|NCT03407742|Experimental|Intervention|CAPAS Youth Parenting Intervention
2424106|NCT03407742|No Intervention|Wait-list control|Participants allocated to this condition were offered the parenting intervention until all T2 assessments of the intervention arm were completed
2424109|NCT03407716|Experimental|Group I (North American ginseng extract AFX-2)|Patients receive North American ginseng extract AFX-2 PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2424110|NCT03407716|Placebo Comparator|GROUP II (placebo)|Patients receive placebo PO BID on days 1-28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. At the end of course 2, patients may optionally crossover to Group I to receive ginseng for an additional 28 days.
2424111|NCT03407690||PIN2 study participants|All those giving swabs for the study
2424112|NCT03407677|Other|ROTO Track|The individual patient will serve as his/her own control before intervention with ROTO Track
2424113|NCT03407664||Men Screened for AAA in England|Men invited into the NHS AAA Screening programme in England in the years 2013-2017.
3187075|NCT00751985|Experimental|1|Personalized normative feedback (PFI). The PFI was a single-session intervention; it was displayed in a single screenshot and addressed the participant by name. It consisted of a summary of the participant's weekly consumption, a comparison with maximum drinking limits and a graphical comparison of the participant's consumption to the average level in the municipality (gender-specific), followed by information about health and social risks of heavy drinking as well as links for further self-help material and a local alcohol treatment facility.
3187076|NCT00751985|Experimental|2|Self-help material (SHM). The SHM was a single-session intervention and was displayed in a single screenshot. It consisted of information about maximum drinking limits, followed by information about health and social risks of heavy drinking as well as links for further standardized self-help material and a local alcohol treatment facility.
3187077|NCT00751985|Placebo Comparator|3|Control
2424117|NCT03407638|Active Comparator|PROUD Intervention|Primary care clinics randomized to the PROUD Intervention will implement the Massachusetts (MA) Model of collaborative care for opioids use disorders (OUDs). The PROUD trial provides financial support to cover the nurse case manager (NCM) salary and technical assistance for the duration of the study, but the health systems-not investigators-implement the MA Model as part of quality improvement, and the health system and its clinicians provide all clinical care.
2424118|NCT03407638|No Intervention|Usual Primary Care|Clinics randomized to usual primary care do not receive any resources or support from the study but are free to improve opioid use disorder (OUD) care in any way they choose.
3187078|NCT00752011|Experimental|Carboplatin + TAS-106|Carboplatin starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle. TAS-106 starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
3187079|NCT00752024|Experimental|1|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
3187080|NCT00752024|Active Comparator|2|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
3187081|NCT00752037|Other|1|open label single arm
2424123|NCT03407599|Experimental|Faster aspart followed by insulin aspart (NovoRapid®)|Participants will receive single dose of fast-acting insulin aspart followed by single dose of NovoRapid® on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
2424124|NCT03407599|Experimental|Insulin aspart (NovoRapid®) followed by faster aspart|Participants will receive single dose of NovoRapid® followed by single dose of fast-acting insulin aspart on two separate dosing visits. The dosing visits will be separated by a wash-out period of 3-22 days.
2424125|NCT03407586|Other|Diagnostic STI care|All participants underwent point-of-care STI testing, and if diagnosed with a STI were offered immediate therapy, and expedited therapy if indicated.
2424126|NCT03407573|Active Comparator|Restrictive|Restrictive transfused when Hb at or below 70
2424127|NCT03407573|Active Comparator|Liberal|Will receive blood transfusion when Hb drops below or equal to 90
2424128|NCT03407560|Experimental|SintLife|Use of SintLife putty as bone substitute for spinal fusion in lumbar spine surgery for degenerative diseases.
2424129|NCT03407521|Active Comparator|study group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with isosorbide mononitrate 20mg once
2424130|NCT03407521|Placebo Comparator|control group|misoprostol tab 200mcg 2 tab at first then one every 4 hours with placebo
2424131|NCT03407508|Placebo Comparator|Baseline|No dietary changes.
2424132|NCT03407508|Placebo Comparator|Comparison of Diets|Okinawan-based Nordic Diet or Control Diet.
3187082|NCT00752050|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
3187083|NCT00752050|Placebo Comparator|2|Preservative-free Saline - Part II ONLY. (Part I is Single Group and all participants receive active drug and are not randomized)
2424135|NCT03407469||Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE).
2424136|NCT03407443|Experimental|Exposure to Make the Connection messages|
2424137|NCT03407443|Active Comparator|Active Control group|
2424138|NCT03407443|No Intervention|No exposure control group|
3187084|NCT00752063|Experimental|A|All subjects will receive Sorafenib with Capecitabine and Oxaliplatin
3187085|NCT00752076|Experimental|1|We collected malignant pleural effusion for NSCLC cell lines with different EGFR mutations development and then we can compare the difference responses and signal pathways in these cell lines. We can also explore the detailed mechanism of TKI responsive cancer cell and try to develop other agent to enhance the pathways.
2424141|NCT03407417|Experimental|Fit Testing|Patients who self selected to receive FIT screening after interaction with the Application
2424142|NCT03407417|Active Comparator|Non-FIT testing|Patients who elected not to have FIT testing after interaction with the application
2424143|NCT03407404|Experimental|Ketamine-midazolam|Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
2424144|NCT03407404|Active Comparator|Morphine-Midazolam|Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.
2424145|NCT03407391||Picky eater|Identified as a very picky eater from parental questionnaire
2424146|NCT03407391||Not a picky eater|Identified as not a picky eater from parental questionnaire
2424148|NCT03407378|Experimental|Assessments ON regular PD treatment|IPT803 Questionnaires Motor assessments on regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
2424149|NCT03407378|Experimental|Assessments OFF regular PD treatment|IPT803 Questionnaires Motor assessments before taking regular PD treatment Optional pharmacogenetic assessments Optional Blood-Oxygen-level Dependent Functional-MRI
2424150|NCT03407365|Experimental|Home Exercises|Patients will be given a set of home exercises to perform as part of their rehabilitation home exercise program. They will be initially trained by a research team member and will be given a DVD home exercise video with instructions on how to perform the exercises.
2424151|NCT03407365|Active Comparator|DVD Program|Weeks 1-10, subjects will not be prescribed exercise at home. If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
2424152|NCT03407352|Active Comparator|Passive Video Game Play|Participants will play video games in a seated position for 60 minutes.
2424153|NCT03407352|Experimental|Active Video Game Play|Participants will play dance dance revolution (video game that requires lower body movement) for 60 minutes.
2424154|NCT03407339|Active Comparator|Shared Oral Care Intervention|
2424155|NCT03407339|No Intervention|Control|
2424156|NCT03407326|Experimental|Alternative|Participants will receive approximately 190 kcal/kg/day of alternative RUTF till recovery or up to 12 weeks of treatment.
2424157|NCT03407326|Active Comparator|Standard|Participants will receive approximately 190 kcal/kg/day of standard RUTF till recovery or up to 12 weeks of treatment.
3187086|NCT00752115|Active Comparator|A|Sildenafil plus carboplatin and weekly paclitaxel
2424159|NCT03407300|Active Comparator|Docetaxel|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel alone.
2424160|NCT03407300|Active Comparator|Docetaxel plus XH1|Stage III-IV NSCLC patients who failed first-line chemotherapy will be treated with Docetaxel plus Chinese traditional medicine XH1.
2424161|NCT03407287||Cardiac Catheterization|
2424162|NCT03407287||Distributive shock|
2424163|NCT03407287||Vasoactive and inotropic agents|
2424164|NCT03407287||Congestive heart failure|
2424165|NCT03407287||Atrial fibrillation|Patients with atrial fibrillation undergoing elective direct current cardioversion
2424166|NCT03407287||Patients undergoing surgery|Patients undergoing surgery requiring positive pressure ventilation and arterial line placement
2424167|NCT03407261|Experimental|Micro-osteoperforations|Minimally invasive micro-osteoperforations procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice
2424168|NCT03407261|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (sliding mechanics)
2424169|NCT03407235|Other|Laparoscopic Novices|"Four laparoscopic task will be undertaken on a computerized laparoscopic trainer and box trainer with eye patch.~Time to completion is recorded."
2424170|NCT03407222|Active Comparator|Intervention group|Intervention group receives weekly text messages which encourage the increment of daily step count
2424171|NCT03407222|No Intervention|Control group|Control group does not receive text message
2424172|NCT03407209|Sham Comparator|PEIB - Use of local levobupivacaine anesthetics: 0.625 mg / ml|"automatic hourly bolus: 8ml (5mg) on 3 min~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
2424173|NCT03407209|Experimental|FREE programming - levobupivacaine anesthetics: 0.625 mg / ml|"Epidural analgesia totally controlled by the patient~automatic hourly bolus: 0~patient controlled bolus: 8ml (5mg) on 3 min~refractory period: 8min~continuous infusion: 0~maximum dose: 65mg/4h"
2424174|NCT03407183||spastic neurogenic bladder|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) in patients with spastic neurogenic bladder is 200 U of onabotulinumtoxinA once, then follow up after three months.
3187087|NCT00752115|Placebo Comparator|P|carboplatin and weekly paclitaxel
2424176|NCT03407157|Experimental|Intervention|Probiotic supplementation
2424177|NCT03407157|Placebo Comparator|Control|Placebo
3146201|NCT00093886|Active Comparator|nitroglycerin|Nitroglycerin (NTG) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3146202|NCT00093912|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
2424180|NCT03407131|Experimental|Joint replacement|Intertrochanteric fracture patients were treated with joint replacement surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
2424181|NCT03407131|Active Comparator|Intramedullary nail fixation|Intertrochanteric fracture patients were treated with intramedullary nail fixation surgery.The postoperative drainage volume, blood transfusion volume, intraoperative blood loss, operative time, early weight bearing time will be recorded, and postoperative pulmonary infection, urinary tract infection, bedsore incidence and postoperative functional rehabilitation will be observed.
3187088|NCT00752141|Experimental|1|oral oxybutynin
3187089|NCT00752141|Experimental|2|oxybutynin topical gel
3187090|NCT00752141|Placebo Comparator|3|placebo tablets plus placebo gel
3187091|NCT00752167||Case|all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
3187092|NCT00752167||Control|control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
3187093|NCT00752180|Experimental|Wosulin R|Wosulin R,Regular insulin for injection(Recombinant Human Insulin)(600 nmol/ml, 100IU/ml)in vials 10.0 ml given subcutaneously.
3187094|NCT00752180|Active Comparator|Actrapid|Actrapid, Regular insulin for injection (Recombinant Human Insulin) (600nmol/ml,100IU/ml)in vials 10.0 ml given subcutaneously.
2424194|NCT03407027|Experimental|Quadratus triamcinolone|Quadratus lumborum muscle and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
2424195|NCT03407027|Experimental|Gluteus triamcinolone|Gluteus maximus and fascia infiltration with 40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
2424196|NCT03407027|Active Comparator|Quadratus without triamcinolone|Quadratus lumborum muscle and fascia infiltration with 10ml of levobupivacaine 0,25%.
2424197|NCT03407001|Experimental|Screening (US, CEUS, Lumason)|Within 30 days of routine MRI, participants undergo non-contrast ultrasound of the abdomen. Participants then receive Lumason IV and undergo contrast-enhanced ultrasound of the abdomen over 1 hour in the absence of disease progression or unacceptable toxicity.
2424198|NCT03406988|Experimental|Autologous fat grafting|Implantation of 0.5-1 ml of autologous AT at the base of the finger with DU.
2424199|NCT03406988|Placebo Comparator|Sham procedure|False liposuction followed by the injection of 0.5-1 ml of 0.9% saline solution at the base of the affected finger.
2424200|NCT03406975|Placebo Comparator|Control Group|Participants randomized to the control group (lifestyle intervention only) in Year 1 will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. Control group participants who were compliant with at least 75% of visits in Year 1, have not achieved ≥25% EWL or have a BMI >30 measured at the week 52 visit, and have no new psychosocial contraindications as deemed by the treatment team to the procedure will cross over to receive the Overstitch ESG in Year 2, in addition to the standard moderate intensity lifestyle intervention program for 12 months.
2424201|NCT03406975|Active Comparator|Treatment Group|Participants randomized to the treatment group will proceed to have the Overstitch ESG at the start of Year 1 and will undergo a standard moderate intensity life-style intervention during the first 12 months of participation. All patients undergoing ESG will go on a 6 weeks transitional diet.ESG patients will undergo a standard moderate intensity life-style intervention administered over 15 12 visits in the first year after ESG. ESG patients who have not achieved >25% EWL at the end of Year 1 will undergo a repeat upper endoscopy at 52 to 60 weeks to assess the durability of the plications. Patients will continue follow-up with a modified lifestyle intervention program administered over 6 visits in the second year
3187095|NCT00752245|Experimental|1|Dialysis during 4 hours
2424203|NCT03406949|Experimental|MGD009 + MGA012|B7-H3 x CD3 DART protein + anti-PD-1 antibody
2424204|NCT03406936|Active Comparator|Daily interruption of sedation|Daily interruption of sedation will be done at 7 am daily by stoppage of midazolam infusion
2424205|NCT03406936|No Intervention|No Sedation|No sedation will be given after initiation of mechanical ventilation
2424206|NCT03406923|No Intervention|Usual care|Receive usual care only.
2424207|NCT03406923|Experimental|Health literacy-psychosocial support|Receive 6-week sessions of individual health literacy-psychosocial support in addition to usual care. The health literacy-psychosocial support intervention includes 45-minute face-to-face counseling at week 1 and week 6 as well as weekly phone calls (week 2 to week 5.)
2424208|NCT03406910||Seventh day Adventist adults|Seventh day Adventist adults recruited from the USA and Canada. Approximately 65% female and 35% male. Composed of participants with different dietary patterns and a wide variation in egg and meat intake ranging from non-consumptive to daily consumption.
2424211|NCT03406884|Experimental|Open label C-kit+ cells Group A|Group A is an open-label treatment group determining safety and feasibility. Participants enrolled in this group will be receiving previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
2424212|NCT03406884|Active Comparator|C-kit+ cells Group B|Participants randomized to Group B Treatment Group will receive previously harvested c-kit+ cells during their Stage II BDCPA operation. Harvested c-kit+ cells will be injected into the right ventricle directly intramyocardially.
2424213|NCT03406884|No Intervention|No Intervention Group|Participants randomized to Group B Control Group will receive only their standard of care (SOC) Stage II BDCPA operation without the injection of harvested c-kit+ cells.
2424214|NCT03406871|Experimental|Nivolumab + Regorafenib|Nivolumab and Regorafenib
2424215|NCT03406858|Experimental|Treatment (pembrolizumab, HER2Bi-armed activated T cells)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks. Treatment repeats every 3 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning at least 1 week after pembrolizumab, patients receive HER2Bi-armed activated T cells IV over 5-15 minutes 2 times a week for 4 weeks in the absence of disease progression or unacceptable toxicity.
2424216|NCT03406845|Experimental|Chair-side mindfulness intervention|Consists of individually conducted meditative practices, lasting 20 minutes/session, 3 times per week for 8 weeks. The interventions will be conducted during their dialysis sessions. The mindfulness meditation sessions include well-described meditations such as the body scan (being aware of bodily sensation), gentle arm movements, guided and silent breath meditations.
2424217|NCT03406845|Active Comparator|Health Enhancement Plan (HEP)|Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
2424363|NCT03405857|Experimental|Group 1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
3187096|NCT00752245|Active Comparator|2|Dialysis during 6 hours
2424218|NCT03406832|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
2424219|NCT03406832|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
2424220|NCT03406832|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
2424221|NCT03406819|Experimental|Nitroprusside group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Nitroprusside Sodium via guide-catheter was performed. Then repeated administration of Nitroprusside Sodium was done prior to coronary stent implantation or post dilatation.
2424222|NCT03406819|Experimental|Tirofiban group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of Tirofiban Hydrochloride via guide-catheter was performed.
2424223|NCT03406819|Placebo Comparator|Control group|After coronary target vessel blood flow recovery by thrombus aspiration or/and balloon angioplasty (diameter ≤ 2.0mm), intracoronary infusion of heparinized saline via guide-catheter was performed.
2424224|NCT03406806|Experimental|GaitBox|
2424225|NCT03406806|Active Comparator|Sprint System device|
2424226|NCT03406806|Active Comparator|NIH Toolbox 4 meter test|
2424227|NCT03406793|Experimental|1. Standard MNP|
2424228|NCT03406793|Experimental|2. High zinc, low iron MNP|
2424229|NCT03406793|Experimental|3. High zinc, low/no iron|
2424230|NCT03406793|Active Comparator|4. Dispersible zinc supplement|
2424231|NCT03406793|Experimental|5. Intermittent zinc supplement|
2424232|NCT03406793|Placebo Comparator|6. Placebo powder|
2424233|NCT03406780|Experimental|CAP-1002|Patients will receive 150 million cardiosphere-derived cells (CDCs) via intravenous infusion every 3 months for a total of 4 doses.
2424234|NCT03406780|Placebo Comparator|Placebo|Patients will receive a placebo solution via intravenous infusion every 3 months for a total of 4 doses.
2424235|NCT03406767|Experimental|GLA:D Canada Program|GROUP 1: GLA:DTM CANADA GROUP (STANDARDIZED EXERCISE PROGRAM)
2424236|NCT03406767|Experimental|JointEffort Program|GROUP 2: JOINTEFFORT GROUP (INDIVIDUALIZED EXERCISE PROGRAM)
2424237|NCT03406754||Ezera LaMarpeh rehabilitation programs|Participation in a rehabilitation program for 8 weeks
2424238|NCT03406741|Experimental|Child with Hirschsprung's disease|Neuropsychological assessment at elementary school
2424239|NCT03406728|Active Comparator|PDSAFEX GROUP|Parkinson's Disease Sensory Attention Focused Exercise (PDSAFEX) is an exercise intervention developed in light of research which focuses on utilizing sensory integration and proprioception to improve balance. This intervention will be administered to one group of my participants. The protocol will be followed and led by trained volunteers.
2424240|NCT03406728|Active Comparator|CONTROL GROUP|The control group in this study will be asked to maintain their daily lifestyle as closely as possible for the 12-week duration of the study.
2424241|NCT03406728|Experimental|VIRTUAL REALITY GROUP|Virtual reality intervention will be assigned to this group. They will complete activities aimed at improving their dynamic balance. These activities are specifically developed based on previous literature and geared towards mirroring day to day activities/scenarios that individuals with PD may come into contact with.
2424243|NCT03406702|Experimental|CX-8998|T-type calcium channel blocker
2424244|NCT03406689|Active Comparator|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be administered 45' prior to the injection
2424245|NCT03406689|Active Comparator|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be administered 45' prior to the injection
2424246|NCT03406689|Placebo Comparator|Artificial tears|One drop of Artificial Tears will be administered 45' prior to the injection
2424247|NCT03406676|Experimental|Methylene blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
2424248|NCT03406676|No Intervention|saline|50ml of saline is administrated I.V before anesthesia induction.
2424249|NCT03406663|Experimental|Group 1|"In group 1, the dose of Gla-300 will be titrated by the patients by 1 unit per day until achieving a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (INSIGHT algorithm).~Titration algorithms:~Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~< 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
2424250|NCT03406663|Active Comparator|Group 2|"In group 2, the dose of Gla-300 will be titrated by the patients based on the SMPG values of the last 3 days at least weekly, but no more often than every 3 days to achieve a fasting SMPG in the target range of 4.4 to 5.6 mmol/L (EDITION algorithm).~Fasting SMPG (median of the last 3 days including current day) in the range of~≥ 7.8 mmol/L, increase 6 units of Gla-300 dose~> 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose~> 4.4 and ≤ 5.6 mmol/L, no change~≥ 3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose~< 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
2424251|NCT03406650|Experimental|Durvalumab in combination with standard therapy|Combination of standard therapy consisting (4 cycles cisplatin/ gemcitabin followed by surgery) with 4 cycles of neoadjuvant durvalumab and 10 cycles of adjuvant durvalumab
2424252|NCT03406624||Spinal fusion with modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, and with modic changes seen on MRI at the actual level for surgery
2424253|NCT03406624||Spinal fusion without modic changes|Patients scheduled for surgery with lumbar spinal fusion with procedures involving moderate to extensive removal of the disc, but with no modic changes seen on MRI at the actual level for surgery
2424254|NCT03406624||Disc herniation surgery with modic changes|Patients scheduled for disc herniation surgery, and with modic changes seen on MRI at the actual level for surgery
2424255|NCT03406624||Disc herniation surgery without modic changes|Patients scheduled for disc herniation surgery, but with no modic changes seen on MRI at the actual level for surgery
2424256|NCT03406611|Active Comparator|Pegtibatinase|
2424257|NCT03406611|Placebo Comparator|Placebo|
2424258|NCT03406598||Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
2424259|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 1)|
2424260|NCT03406585|Experimental|Allogeneic transplantation with WJMSCs (batch 2)|
2424261|NCT03406585|Placebo Comparator|Sham transplantation (placebo)|
2424262|NCT03406572|Experimental|HFHO Group|Patients will receive a first NIV session (for 2 hours) with predefined parameters, and ABG will be performed between one and two hours of starting NIV. NIV will be extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require predefined criteria. In-between each NIV session, oxygen will be delivered using a high flow nasal cannula, with a flow of 50-60L/min and a FiO2 set to reach a targeted SpO2: 88%≤SpO2 ≤ 92%. Predefined criteria will be used to resume NIV.
2424263|NCT03406572|Active Comparator|Standard O2 Group|NIV will be initiated based on the same criteria and with the same parameters as the HFHO group. ABG will also be performed between one and two hours and NIV extended according to ABG result (i.e. extended if pH < 7.30). Switch from NIV to oxygen will require the same predefined criteria as the HFHO group. In-between each NIV session, oxygen will be delivered using standard low flow O2 to reach the same targeted SpO2: 88% ≤SpO2 ≤ 92%. Similar criteria will be used to resume NIV
2424264|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion.
2424265|NCT03406546|Experimental|Group DR|Patients sedated with dexmedetomidine and remifentanil.
2424266|NCT03406546|Experimental|Group LMA|General anesthesia was applied using laryngeal mask.
2424267|NCT03406533|Experimental|Group F|Sedated with midazolam and fentanyl
2424268|NCT03406533|Experimental|Group DR|Sedated with midazolam, dexmedetomidine and remifentanil
2424269|NCT03406533|Experimental|Group DF|Sedated with midazolam, dexmedetomidine and fentanyl
2424270|NCT03406533|Experimental|Group PR|Sedated with midazolam, propofol and remifentanil
2424271|NCT03406520|Experimental|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated disk, will be applied to the peritoneal dialysis catheter exit-site and the disk will be changed once a week
2424272|NCT03406507|Experimental|ALXN1210|
2424273|NCT03406494|Experimental|intervention group|Early multicomponent physical therapy program plus sepsis standard therapy
2424274|NCT03406494|No Intervention|control group|Sepsis standard therapy, including early initiation of intravenous antibiotics, infection source debriding, appropriate fluid therapy, minimum sedation, protocolized weaning procedure, blood glucose control and early enteral feeding, etc.
2424275|NCT03406468|Experimental|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
2424276|NCT03406455||Primary TKA|A cohort of 25 patients undergoing primary TKA for osteoarthritis at our hospital will be enrolled into the study, which will receive IRB approval and be registered on ClinicalTrials.gov and RedCap. Patients will download the mobile application onto their personal smartphones (iOS) to record baseline activity and PROMs in the 2-4 weeks leading up to surgery. During the hospital admission, the knee sleeve will be fitted to the patient. The patient cohort will be followed for three months and four data points (both passive and active) will be extracted from the dashboard: PROMs, mean daily steps, ROM (particular attention to 2 weeks postoperatively), and home exercise plan (HEP) compliance.
2424277|NCT03406442|Other|patients|The patient who have lesions affecting pterygopalatine fossa, lateral recess of the sphenoid sinus, petrous apex, Meckel's cave, cavernous sinus, infratemporal fossa and lateral nasopharynx and can be treated by endonasal endoscopic transptergoid approaches
2424278|NCT03406429|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic or the non-fluent variant. All participants will receive the same study interventions in a within-subject crossover design.
2424279|NCT03406416|Experimental|Suprachoroidal retinal prosthesis|Prototype wide view suprachoroidal retinal prosthesis
2424280|NCT03406403|Active Comparator|Laryngeal mask airway group|20 slips of papers will be taken and labeled as group L (LMA) These slips will be placed in an envelope and one slip will be raised for each patient.
2424281|NCT03406403|Active Comparator|Magensium sulphate group|20 slips of papers will be taken and labeled as group M (Mgso4) These slips will be placed in an envelope and one slip will be raised for each patient
2424282|NCT03406403|Active Comparator|Control group (closure of anesthetics)|20 slips of papers will be taken and labeled as group C (Control) These slips will be placed in an envelope and one slip will be raised for each patient.
2424283|NCT03406390||primary pterygium|Observe the contrast sensitivity of primary pterygium patients and healthy control by quick CSF methods, and the pterygium group would achieve the pterygium surgery by the same surgeon (Jin Yuan) and then be performed the contrast sensitivity test on the 1st, 3rd and 6th month postoperatively.
3187097|NCT00752245|Active Comparator|3|Dialysis during 8 hours
3187098|NCT00752258|Experimental|1|Mentor Purified Toxin Botulinum Toxin Type A
2424364|NCT03405857|No Intervention|Group 2|No intervention will be administered
2424365|NCT03405831|Active Comparator|Ivabradine|Study participants in this arm will receive ivabradin 5 mg bid for a period of 12 weeks.
3187099|NCT00752271||1|24 adults with meniscal damage for which arthroscopy is clinically indicated
2424286|NCT03406364|Experimental|MG005|Cohort 1 :3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 2 :6 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours)] Cohort 3 :3 × 250 mgMG005+1 × 200 mgSorafenib; 3 × 250 mgMG005+1 × 200 mgSorafenib[8:00 AM (±2 hours); 8:00 PM (±2 hours)]
2424287|NCT03406351||Asthma|
2424288|NCT03406351||Healthy|Matched controls
3146203|NCT00093912|Active Comparator|sodium nitroprusside|Sodium nitroprusside (SNP) was initiated after insertion of an arterial line upon the occurrence of perioperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3146204|NCT00093925|Experimental|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously (IV) at an initial infusion rate of 0.4 μg/kg/min (non weight-based equivalent is 2 mg/h). Clevidipine was titrated to blood pressure lowering effect by doubling increments approximately every 90 seconds up to a maximum infusion rate of 3.2 μg/kg/min (16 mg/h). Infusion rates above 3.2 μg/kg/min were permitted up to the maximum infusion rate of 8.0 μg/kg/min. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU. Infusion rates between 4.4 and 8.0 μg/kg/min were to be administered for no more than 2 hours.
3146205|NCT00093925|Active Comparator|nicardipine|Nicardipine (NIC) was initiated after insertion of an arterial line upon the occurrence of postoperative hypertension, as determined by the investigator, and was administered intravenously as per institutional practice. Treatment was maintained as long as was deemed clinically necessary or until discharge from the ICU.
3146206|NCT00093977|Experimental|darbepoetin alfa SF|
2424300|NCT03406299|Experimental|SLOG regimen|Arm 1 interventions : SLOG regimen: treatment for every 14 days as one cycle Tegafur (S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day) Leucovorin 30 mg/b.i.d., day 1-7; Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1; Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (FDR, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin
2424301|NCT03406299|Active Comparator|GC regimen|Arm 2 interventions : GC regimen: treatment for every 21 days as one cycle Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
2424302|NCT03406273|Experimental|≥ 5 years of age|Cerebral Spinal (CS) radiation
2424303|NCT03406273|Experimental|< 5 yo and ≥ 3 yo and CSF +|Cerebral Spinal (CS) radiation
2424304|NCT03406273|Experimental|All < 3 yo & < 5 yo/≥ 3 yo CSF neg|Focal radiotherapy (SRS)
2424308|NCT03406247|Experimental|Nivolumab|Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months
2424309|NCT03406247|Experimental|Nivolumab + Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~nivolumab 240 mg every 2 weeks during 6 months~ipilimumab 1mg/kg IV every 6 weeks during 6 months"
2424310|NCT03406234||A group of participants|
2424311|NCT03406221|Experimental|Intervention arm|
2424312|NCT03406221|Active Comparator|Control Arm|
2424313|NCT03406208|Experimental|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
2424314|NCT03406208|Experimental|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
2424315|NCT03406195|Experimental|healthy older adults|Healthy older adults who will receive TMS
2424316|NCT03406169|Active Comparator|Sildenafil 25mg Oral Tablet|25mg sildenafil citrate twice daily
2424317|NCT03406169|Active Comparator|Pentoxifylline|400mg pentoxifylline twice daily
2424318|NCT03406169|Placebo Comparator|Placebo|placebo twice daily
2424319|NCT03406156|Experimental|Obinutuzumab +/- bendamustine then obinutuzumab + venetoclax|"Debulking Period: Obinutuzumab with or without bendamustine (bendamustine administered in participants with high tumor load as described in the protocol) during the debulking period (up to 6 cycles).~Treatment Period: Venetoclax + obinutuzumab regimen initiated when participant achieves low tumor burden during debulking period, or if the participant has not achieved low tumor burden status after 6 cycles of debulking, the participant may proceed to venetoclax per the discretion of the treating provider after discussion with the study physician. During this regimen period, participants to receive obinutuzumab in combination with venetoclax for 5 months then venetoclax therapy alone to continue for a total duration of up to 53 weeks."
2424320|NCT03406143|Experimental|CGF injection group|Concentrate Growth Factors(CGF) will be harvested through centrifugation afte intravenous blood collection. Venous blood was collected in tube and then centrifuged in Medifuge system（Thermo Scientific）. About 2ml liquid CGF can be harvested from 9ml venous blood. Patients will receive autologous CGF injection subdermally to expanded skin at the density of 0.02 ml/cm2.
2424321|NCT03406143|Sham Comparator|Control group|0.9% saline will be injected into expanded skin for control study. Patients will receive saline injection subdermally to expanded skin at the density of 0.02 ml/cm2.
2424322|NCT03406130|Active Comparator|Insignia orthodontic treatment|
2424323|NCT03406130|Experimental|Piezocision-assisted Insignia orthodontic treatment|
2424366|NCT03405831|Placebo Comparator|Placebo|Study participants in this arm will receive placebo bid for a period of 12 weeks.
3146207|NCT00094185||General|No intervention
3146208|NCT00094276|Experimental|1|Breathmobile intervention combined with a Facilitated Asthma Communication intervention (FACI)
3146209|NCT00094276|Active Comparator|2|FACI intervention
3146210|NCT00094276|Active Comparator|3|Breathmobile intervention
3146211|NCT00094276|No Intervention|4|Control group
3146212|NCT00094354||1|HIV-infected FPDs
3146213|NCT00094354||2|Family members of HIV-infected FPDs
3146214|NCT00094354||3|Local healthcare workers
2424324|NCT03406117|Experimental|HAT1-EPBF2|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
2424325|NCT03406117|Experimental|HAT1-HMF3|"CIT was conducted over a period of approximately 15 days for each subject to determine the irritation and/or sensitization potential of a test material(s) under occlusion by 14 repeated closed occlusive patch application every 24 hrs. A final grade was taken 24 hours following the last patch application.~PT was conducted over a period of approximately 6 days for each subject to determine the phototoxicity of the test product.~HRIPT was conducted over a period of approximately 6-8 weeks for each subject to confirm that the test substances will not produce evidence of delayed contact sensitization following external contact with the skin by means of a repeated patch application procedure."
2424326|NCT03406117|Active Comparator|Saline Solution: Sodium Chloride|Saline, Sodium Chlorine (NaCl; 0.9%), was used as the negative irritant control in the CIT portion of the study
2424327|NCT03406104|Experimental|GS010|Lenadogene nolparvovec Intravitreal occular unilateral Injection
2424328|NCT03406104|Sham Comparator|Sham|Sham Intravitreal occular unilateral Injection
2424329|NCT03406091||Poor Mobilizer (PM) in Multiple Myeloma (MM) patients|
2424332|NCT03406065|Experimental|Sodium bicarbonate supplementation|Group taking oral NaHCO3 supplementation in a progressive-dose regimen.
2424333|NCT03406065|Placebo Comparator|Placebo treatment|Group taking oral supplementation with placebo (maltodextrin with NaCl) in a similar tablet form prepared by the same producer as NaHCO3 tablets.
2424334|NCT03406052|Experimental|Smartphone-Assisted MB-CBT|Online intervention accessed through smartphone or online accessed computer comprised of Mindfulness-Based Cognitive Behaviour content
2424335|NCT03406052|No Intervention|Control|Standard psychiatric care
2424336|NCT03406039|Experimental|Integrated Online CBT and MI|Participants in this arm will be given access to the online integrated treatment.
2424337|NCT03406039|No Intervention|Psychoeducation (Control)|The control group will be provided with psychoeducational resources about alcohol and mental illness.
2424338|NCT03406026|Experimental|Balance System Protocol Stroke|Balance System Protocol Stroke differentiates 2 levels of difficulty in relation to the patient's condition and progressively according to their evolution. If the patient maintains stability in standing for at least 30 s, he starts in Level 2 and otherwise he will remain in Level 1 until he acquires it. In level 1 the progression of exercises is: 1.Pressure stimulation of the foot support points; 2.Proprioceptive ankle work; 3.Sit-to-stand work and vice versa; 4.Sit-to-stand work with delayed affection. In level 2, the progression of exercises is: 1.Standing unbalances; 2.Standing on Balance-pad; 3.Work to get monopodal support; 4.Balance pad in monopodal support; 5.Monopodal support work with closed eyes.
2424339|NCT03406026|Active Comparator|Control Stroke|The program of Control Stroke arm is based on an integral and rehabilitative approach in which the patient follows a personalized plan of exercises and therapies according to the deficits of each patient, the previous situation, the personal concerns with In order to perform a person-centered approach.
2424340|NCT03406013|Active Comparator|Group I|Written Information
2424341|NCT03406013|Experimental|Group II|Written Information Prescription
2424342|NCT03406013|Experimental|Group III|Written Information Prescription Technology
2424343|NCT03406013|Experimental|Group IV|Written Information Prescription Technology Coaching
2424344|NCT03406000|Experimental|Insulin glargine (U300)|Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.
2424345|NCT03405987||ECV < median|
2424346|NCT03405987||ECV ≥ median|
2424347|NCT03405974|Experimental|Aspirin|"Aspirin 100 mg~1 tablet/ day for 2 years"
2424348|NCT03405974|Placebo Comparator|Placebo|"Placebo~1 tablet/ day for 2 years"
2424349|NCT03405961||Manual PAR score|Patient will receive upper and lower impressions, which will be cast to produce plaster models. A calibrated individual will PAR score the casts in the traditional manner (regular care pathway)
2424350|NCT03405961||Direct digital PAR score|Patient will receive upper and lower intra-oral scans which will be PAR scored directly by the computer
2424351|NCT03405961||Indirect digital PAR score|Patient will receive upper and lower impressions which will be cast to produce plater models (regular care pathway). The casts will be scanned with Carestream 3600 intra oral scanner and scored digitally by the computer.
2424352|NCT03405948|Experimental|botulinum toxin|injection of Botulinum toxin
2424353|NCT03405948|Placebo Comparator|placebo|Injection of saline serum (placebo)
2424355|NCT03405922|Placebo Comparator|Placebo|Placebo 40 mL Saline 0.9%
2424356|NCT03405922|Active Comparator|Ropivacain|40 mL Ropivacain 0.5%
2424357|NCT03405909||Patients at risk for HCC|"Patients with any of the following conditions:~liver cirrhosis of any origin chronic hepatitis B infection chronic hepatitis C infection with advanced fibrosis non-alcoholic steatohepatitis (NASH) hemochromatosis~Interventions: B-mode ultrasound, contrast enhanced ultrasound (CEUS); MRI / histology"
2424358|NCT03405896|Experimental|Normal subjects|
2424359|NCT03405883||RIF (women with repeated implantation failure)|Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy
2424360|NCT03405883||NF (normal fertile women)|Spontaneous conception or conception after max 9 IUI cycles
2424361|NCT03405870|Experimental|Lipid|Infusion of drug (Smoflipid) will occur over a 16.5 hour period given once per day for the first two days of study enrollment.
2424362|NCT03405870|No Intervention|Control|Control patients will receive no experimental drug (ie, usual care)
2424368|NCT03405805||3+1|Healthy infants will receive 4 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4,6 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
2424369|NCT03405805||3+0|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 6 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
2424370|NCT03405805||2+1|Healthy infants will receive 3 doses of the 13-valent pneumococcal conjugate vaccine (PCV13) at 2,4 and 12 months of age and blood and serum collection pre- dose, 7 days post- (only blood) and 28 days post- last dose.
3146215|NCT00094354||4|Villagers not related to an HIV-infected individual
3146216|NCT00094380|Experimental|Dose-escalation portion: Low dose CTLA4-IgG4m (RG2077)|Three patients will receive a single intravenous infusion of 0.2 mg/kg CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities (CTC grade 3 or higher adverse event in the first 28 days after CTLA4-IgG4m administration that is possibly, probably, or definitely related to CTLA4-IgG4m (RG2077)). are observed, enrollment in the trial will be suspended pending DSMB review. If no dose-limiting toxicity is observed in the 0.2mg/kg dose, three patients will receive a single intravenous infusion of 2 mg/kg of CTLA4-IgG4m following the scheduled cyclophosphamide infusion on the same day. If one or more dose-limiting toxicities are observed, enrollment will be suspended pending review by the Data Safety and Monitoring Board (DSMB).If no dose-limiting toxicity is observed in the 2 mg/kg dose, treatment of patients with 10 mg/kg of CTLA4-IgG4m in combination with cyclophosphamide will proceed.
2424373|NCT03405753|Active Comparator|Aroia|
2424374|NCT03405753|Placebo Comparator|Placebo|
2424375|NCT03405740|Active Comparator|Remote Patient Management|Patients will be followed by remote monitoring only.
2424376|NCT03405740|Placebo Comparator|Standard of Care|Remote monitoring at 6 month intervals, alternating with yearly in-clinic visits at their usual site.
2424377|NCT03405727|No Intervention|Standard treatment|
2424378|NCT03405727|Experimental|Oral dietary supplements|
3146217|NCT00094380|Experimental|Part IIA: CTLA4-IgG4m|Participants randomized to the CTLA4-IgG4m Arm will receive a single intravenous infusion of 10 mg/kg CTLA4-IgG4m (RG2077) following the scheduled cyclophosphamide infusion on the same day
2424380|NCT03405701|Active Comparator|IVM (in vitro maturation)|Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred
2424381|NCT03405701|Active Comparator|IVF (in vitro fertilization)|Undergoing controlled ovarian hyperstimulation for in vitro Fertilization (IVF) with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist triggering will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
2424382|NCT03405688|Experimental|Acute transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2424383|NCT03405688|Other|Control - Acute transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2424384|NCT03405688|Experimental|Chronic transfusion|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2424385|NCT03405688|Other|Control - Chronic transfusion|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2424386|NCT03405688|Experimental|Transfusion prior to surgery|Blood donor heterozygous for the sickle cell disease allele (HbAS genotype)
2424387|NCT03405688|Other|Control - Transfusion prior to surgery|Blood donor not bearer of the sickle cell disease allele (HbAA genotype)
2424388|NCT03405675||SLAS 1|The subjects (N=2800) are recruited from all residents aged 55 years and above in Singapore in the areas covered by the South-East Community Development Council: Geylang, Aljunied, MacPherson, Marine Parade and Bedok (SLAS-I).
2424389|NCT03405675||SLAS 2|An additional 3200 subjects are recruited from residents in the Bukit Merah and Jurong (SLAS-II).
2424390|NCT03405662|Active Comparator|Acitve PBM|This arm will receive active photobiomodulation (PBM), delivered with the Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
2424391|NCT03405662|Sham Comparator|Sham PBM|This arm will not receive active photobiomodulation (PBM). Instead, they will use a sham Vielight Neuro Gamma device, once every other day (e.g., Mon, Wed, Fri) for 20 minutes for 16 weeks.
2424392|NCT03405649|Experimental|Group A|Participants train 60 min per session for 10 weeks on non-consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and weights, elastic bands and balls will be used. Babies less than 20 weeks of age will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
2424393|NCT03405649|Experimental|Group B|Participants train 60 min per session for 10 weeks on non consecutive days. All training sessions will be supervised by a qualified exercise instructor. Each training session will include a warm up phase of 5 minutes of dynamic and static stretching and a cool down phase consisting of 5 minutes of static stretching. Whole-body exercises and different equipment such as weights, elastic bands and balls will be used. Babies older than 20 weeks will be included in the exercise routine. Participants will perform 1-3 sets per exercise, 8-12 repetitions per set and a 90-s rest interval between sets.
2424394|NCT03405636|Experimental|Xeltis Pulmonary Valved Conduit|PV Conduit for RVOT reconstruction
2424458|NCT03405220|Experimental|Self-affirm, 10-item, Imagine ex, Study2|Behavioral: Self affirmation, 10 items, imagined examples
2424459|NCT03405220|Experimental|Self-affirm, 5-item, Imagine ex, Study 2|Behavioral: Self affirmation, 5 items, imagined examples
3146218|NCT00094380|Experimental|Part IIA: Control Group|Participants randomized to the control group will not receive treatment with CTLA4-IgG4m (RG2077); these participants will undergo all study evaluations with the exception of the CTLA4-IgG4m (RG2077) pharmacokinetic evaluations and immunogenicity evaluations.
3146219|NCT00094432|Active Comparator|A1|
2424395|NCT03405623|Active Comparator|Dynamic needle tip positioning|In DNTP, SAX is used, and additionally, when the needle tip is imaged in the screen as an hyper-echoic point, the practitioner (a) moves the US probe proximally a bit, and (b) the needle is advanced until the needle tip reappears in the screen. In this manner, the practitioner repeats (a) and (b) until the needle is inserted 1 cm into the lumen of vessel, and then the catheter is inserted to finish the procedure.
2424396|NCT03405623|Active Comparator|Conventional long-axis|
2424397|NCT03405610|Experimental|Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a mind body skills based program delivered individually via secure live video. The format is a 4-week program with weekly meetings and a focus on teaching skills to optimize recovery and prevent chronic pain and disability.
2424398|NCT03405610|No Intervention|Usual Care|The Usual Care (UC) group will continue with their current medical care.
2424399|NCT03405597|Experimental|Healthy control|Commercial Hepatitis B vaccine
2424400|NCT03405597|Experimental|Chronic hepatitis B with vaccination|Commercial Hepatitis B vaccine
2424401|NCT03405597|Active Comparator|Chronic hepatitis B without vaccination|Standard treatment
2424402|NCT03405584|Experimental|Bismuth Plus Dual Therapy|Esomeprazole 40mg bid, Amoxicillin 1.0g tid and Bismuth Potassium Citrate 600mg bid for 14 days.
2424403|NCT03405584|Active Comparator|Dual Therapy|Esomeprazole 40mg bid and Amoxicillin 1.0g tid for 14 days.
2424404|NCT03405545|Experimental|HIIT|This group of subjects will perform High Intensity Interval training 3x/week for 12 weeks
2424405|NCT03405519|Other|Radiotherapy planning|Radiotherapy planning using both CT and MRI scans
2424406|NCT03405493|Experimental|Wake and Light Therapy|This consists of (a) Total Sleep Deprivation with group support on days one and two; (b) Phase Advance of Sleep over 5 days and daily Light Therapy. (c) Light Therapy is given daily
2424407|NCT03405493|Active Comparator|Sleep and Light Therapy|Participants will be given information on sleep hygiene and getting a good night's sleep. They are then given Light Therapy daily for 1 week.
2424408|NCT03405480|Experimental|Rehabilitation|Physiotherapist-supervised outpatient rehabilitation program 2 times a week for a total of 8 weeks.
2424409|NCT03405480|No Intervention|No rehabilitation|Patients will receive usual care, including information pamphlets with information on the disease and the general importance of exercise.
2424410|NCT03405467||lightning accident|patients suffered injuries due to lightning strike
2424411|NCT03405467||frostbite|patients suffered injuries due to local hypothermia leading to frostbite injuries
2424412|NCT03405467||cpr and aed|patients suffered cardiac arrest in alpine region treated with or without automated external defibrillatior
2424413|NCT03405467||flight accident|patients suffered injuries due to use of a flying vehicle in mountainous regions.
2424414|NCT03405454|Active Comparator|standard chemotherapy|Patients on physician's choice of chemotherapy are allowed to receive any systemic chemotherapy either as a single agent or in combination. However, biologics( including bevacizumab) and oral tyrosine kinase inhibitors will not be allowed for patients on this arm
2424415|NCT03405454|Experimental|durvalumab|Patients on durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months
2424416|NCT03405441|Experimental|Part 1 (Panel 1): JNJ-55375515 and placebo|Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
2424417|NCT03405441|Experimental|Part 1 (Panel 2): JNJ-55375515 and placebo|Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations.
2424418|NCT03405441|Experimental|Part 2: JNJ-55375515 and placebo|Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3.
2424419|NCT03405428|Other|All patients|
2424420|NCT03405402|Experimental|Experimental group|Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)
2424421|NCT03405402|Other|Control group|Allo-immunization not detected
2424422|NCT03405389||Patients|Patients diagnosis of a mandibular fracture requiring Open Reduction and Internal Fixation (ORIF) and use of Mandibulo-Maxillary fixation (MMF) during or subsequent to surgical intervention for a minimum of two weeks
2424423|NCT03405376|Experimental|Branch retinal vein occlusion|Aflibercept 2mg is injected into the vitreous cavity. Center-involved macular edema secondary to branch retinal vein occlusion for no longer than 3 months (at the screening visit it should be ensured that the subjects will comply with the criterion of ≤ 3 months since onset of macular edema at their scheduled baseline visit)
3187100|NCT00752271||2|8 adults who have already undergone meniscal resection to serve as positive controls
3187101|NCT00752284|Experimental|A|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
2424426|NCT03405350|Active Comparator|Study Group|The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
2424427|NCT03405350|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
2424428|NCT03405337||FVIII products (prospective)|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) having initiated a FVIII products with improved half-life"
2424429|NCT03405337||Conventional FVIII replacement therapies|"Qualitative patient/caregiver study:~Hemophilia A patients/caregivers (N=30) receiving conventional FVIII replacement therapy for at least 6 months who are considering switching to a FVIII product with improved half-life within the next 1 year"
2424430|NCT03405337||FVIII products (retrospective)|"Quantitative physician interview/ chart review study:~Hemophilia A patients (N=100) who have switched from conventional FVIII replacement therapy to FVIII products with improved half-life."
2424431|NCT03405324|Active Comparator|active tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy .
2424432|NCT03405324|Sham Comparator|sham tDCS|a single session over the primary motor cortex with constant current of 2mA intensity was applied for 20 minutes with a 5-second ramp phase at the beginning applied to the participant patient before chemotherapy switched off after 30 second without the patient knowledge .
2424435|NCT03405298|Active Comparator|Educational Material with Collaborative Care available|In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.
2424436|NCT03405298|Active Comparator|Educational Material Only|Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.
2424437|NCT03405285|Experimental|Connected Catheter Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction
2424438|NCT03405272|Experimental|recombinant anti-EGFR monoclonal antibody（SCT200）|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
3187102|NCT00752284|Active Comparator|B|"Control Group:~total excision of lower wisdom tooth"
3187103|NCT00752297|Active Comparator|1|Mentor Purified Toxin Botulinum Toxin Type A
2424441|NCT03405246|Active Comparator|KIDFIT SAFE|The Control Group will be provided 12 web-based monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms. KIDFIT Safe web site targets environmentally safe childcare related topics such as use of sun screen, avoidance of choking hazards, pet safety, protection from electrical appliances, etc. KIDFIT Safe participants will attend both baseline and 12 month clinical visits.
2424442|NCT03405246|Experimental|KIDFIT HEALTHY|The KIDFIT intervention group combines traditional in-person and electronic participant contacts, including two scheduled individual visits with a nutrition coach, coaching calls throughout the year, and monthly group videoconferencing-type sessions. KIDFIT Healthy participants will attend both baseline and 12 month clinical visits.
2424443|NCT03405233|Experimental|Group A|Double vein cuff PTFE graft both at the inflow and outflow ends
2424444|NCT03405233|Active Comparator|Group B|Single vein cuffed PTFE graft at the outflow end
2424445|NCT03405233|Active Comparator|Group C|PTFE graft without vein cuff will be used
2424446|NCT03405220|Experimental|Self-affirm, No examples, Study 1|Behavioral: Self affirmation, 10 items, no examples
2424447|NCT03405220|Active Comparator|Self-affirm, Write examples, Study 1|Behavioral: Self affirmation, 10 items, written examples
2424448|NCT03405220|Experimental|Self-affirm, Imagine examples, Study 1|Behavioral: Self affirmation, 10 items, imagined examples
2424449|NCT03405220|No Intervention|Opinion survey, No examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will not be asked to provide examples for any items they respond yes to."
2424450|NCT03405220|No Intervention|Opinion survey, Write examples, Study 1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to provide written examples for each item they respond yes to."
2424451|NCT03405220|No Intervention|Opinion survey, Imagine examples, Study1|"No intervention: control. Participants will complete the 10 item personal opinion survey and will be asked to imagine examples for each item they respond yes to."
2424452|NCT03405220|Experimental|Self-affirm, 10-item, No ex, Study 2|Behavioral: Self affirmation, 10 items, no examples
2424453|NCT03405220|Experimental|Self-affirm, 5-item, No ex, Study 2|Behavioral: Self affirmation, 5 items, no examples
2424454|NCT03405220|Experimental|Self-affirm, 3-item, No ex, Study 2|Behavioral: Self affirmation, 3 items, no examples
2424455|NCT03405220|Active Comparator|Self-affirm, 10-item, Write ex, Study 2|Behavioral: Self affirmation, 10 items, written examples
2424456|NCT03405220|Experimental|Self-affirm, 5-item, Write ex, Study 2|Behavioral: Self affirmation, 5 items, written examples
2424457|NCT03405220|Experimental|Self-affirm, 3-item, Write ex, Study 2|Behavioral: Self affirmation, 3 items, written examples
3187104|NCT00752297|Placebo Comparator|2|Preservative-free Saline
2424460|NCT03405220|Experimental|Self-affirm, 3-item, Imagine ex, Study 2|Behavioral: Self affirmation, 3 items, imagined examples
2424461|NCT03405207|Active Comparator|active drug receiving group|the drug is vitamin D3 50000 UNT oral capsule prescribing under Holick's protocol, which is every week for 8 weeks then every month for long life
2424462|NCT03405207|Placebo Comparator|placebo receiving group|the same as active comparator unless the drug is the identical placebo oral capsule
2424463|NCT03405194|Experimental|Elvitegravir-Cobicistat-TAF-FTC|Elvitegravir 150mg po QD Cobicistat 150 mg po QD TAF 10 mg po QD FTC 200 mg QD
2424464|NCT03405194|Active Comparator|EFV-TDF-3TC|EFV 600 mg po QD TDF 300 mg po QD 3TC 300 mg po QD
2424465|NCT03405181|Experimental|Training with additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet with an additional weight characterized by 20% of the total mass of the upper limb placed on both wrists. This training will be adopted for the adequate weight intervention group and low weight intervention group.
2424466|NCT03405181|Placebo Comparator|Training without additional weight|The infants will be submitted to a reaching behavior training program of 4 weeks, two times per week (totaling 8 sessions). During this training program, infants will use a bracelet without additional weight, placed on both wrists. This training will be adopted for the adequate weight placebo group and low weight placebo group.
2424467|NCT03405168|Experimental|routine therapy plus moxifloxacin|Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.
2424468|NCT03405155|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over at least 30 minutes on day 1. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2424469|NCT03405142|Experimental|T1 or T2 stage and node negative|T1 or T2 stage primary tumor and node negative (i.e., cN0)
2424470|NCT03405142|Experimental|Any T stage and node positive|Any T stage tumor and node positive (i.e., cN+)
2424471|NCT03405129|Active Comparator|Factoid Group|The Factoid group will receive a smartphone app that delivers 2 factual messages per day
2424472|NCT03405129|Experimental|Phoenix Group|The Phoenix group will receive a smartphone app that includes multiple components that vary based upon the participant's smoking cessation stage
2424473|NCT03405129|Experimental|Phoenix + NRT Group|"The Phoenix + (Nicotine Replacement Therapy) NRT group will receive a smartphone app that is identical to the Phoenix group, with one additional feature. Participants will be able to click an Order Nicotine Patches and Gum button to order NRT."
2424474|NCT03405103|Experimental|Striving|Striving vs Boning-up & Personal Choice
2424475|NCT03405103|Active Comparator|Boning-up Standard Education|Boning-up vs Striving and Personal Choice
2424476|NCT03405103|Sham Comparator|Personal Choice|Personal Choice vs Striving & Boning-up
2424477|NCT03405090|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
2424478|NCT03405090|Active Comparator|Combivent Bronchodilator|Single dose, nebulized Combivent bronchodilator (0.5 mg ipratropium bromide + 2.5 mg salbutamol). This is a randomized, double-blind, two-treatment crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate with a constant fraction of 30% inhaled oxygen to that of a nebulized bronchodilator (Combivent). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and combivent at the second treatment visit, patients in the other arm will receive Combivent first and fentanyl second.
2424479|NCT03405077|Experimental|IPT Online Training|"Therapists in this study will be trained in IPT using an online platform. The program is self-paced but will have a deadline; the suggested pace is at least 12 hours spaced over 2 months. The guided online training program was developed in collaboration with 3C institute, an award-winning research and development company that creates web- and evidence-based programs. Content will be adapted from gold-standard training."
2424480|NCT03405064|Experimental|levonadifloxacin|oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
2424481|NCT03405064|Active Comparator|linezolid|oral linezolid (600 mg BID) or IV linezolid (600 mg BID)
2424482|NCT03405025|Other|Safety and Feasibility|All patients will undergo endoscopic US guided radiofrequency ablation, to assess safety and feasibility.
2424483|NCT03404999|Experimental|clinical decision support activated|"TWO MED ASSIST ALERTS~Enter height (when missing)~Repeat BP (when high)~ONE PROVIDER ALERT~BP high & prior BP/BP%s~Defines elev. BP, HTN stage 1-2 with button to enter diagnosis~Link to tailored ordersets~TAILORED ORDERSETS~Elevated BP~Button to schedule f-up <6 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 1~Buttons to order labs/studies pre-checked for stage 1 recs~Button for nephrology referral~Button to schedule f-up in 1-2 wk/<1 m~Button for diet/lifestyle counseling/check-out instructions~HTN stage 2~Buttons to order labs/studies for stage 2~Button for nephrology referral (pre-checked)~Button to f-up 1 wk~Button for diet/lifestyle counseling/check-out instruction"
2424484|NCT03404986|Other|Standardized ureteroscopy group|
2424485|NCT03404986|Other|Ultrasonography ureteroscopy group|
2424486|NCT03404960|Experimental|Arm A|Niraparib + Nivolumab
2424487|NCT03404960|Experimental|Arm B|Niraparib + Ipilimumab
2424488|NCT03404947|Experimental|Ethanol|Participants will ingest ethanol (in the form of 40% ethanol) at an ingestion rate of 0.1 grams/kg lean body mass/hour in a solution with water.
2424489|NCT03404947|No Intervention|No Ethanol|Participants will ingest a volume matched beverage of water only.
2424490|NCT03404934|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
2424491|NCT03404921|Experimental|ESTD group|Use tunnelling method during ESD operation
2424492|NCT03404921|Other|ESD group|Use traditional method during ESD operation
2424493|NCT03404908|Experimental|TAP|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
3146220|NCT00094432|Placebo Comparator|A2|
2424494|NCT03404908|Experimental|QLB|Ultrasound-guided quadratus lumborum block at the end of cesarean section
2424495|NCT03404895|Sham Comparator|Conventional Therapy|Conventional therapy of DFU comprises of four components: local wound care, antibiotic therapy, debridement and amputation, and pressure offloading.
2424496|NCT03404895|Active Comparator|Conventional Therapy + venous stent(s)|Patients will receive a venous stent in addition to conventional therapy
2424497|NCT03404882|Experimental|text messaging plus peer support arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. In addition to peer support, participants in this arm of the study will receive daily supportive text messages from an automated online application and reminder text messages for their community clinic/program appointments.
2424498|NCT03404882|Active Comparator|supportive/reminder text message only arm|Patients in the supportive/reminder text message only arm of the study will receive daily supportive text messages from the automated online application and reminder text messages for their community clinic/program appointments.
2424499|NCT03404882|No Intervention|Control arm|Patients in the control arm of the study will receive the usual follow-up appointment offered to all patients who are discharged from acute care. However, they will not receive peer support or supportive/reminder text messages.
2424500|NCT03404882|Active Comparator|peer support only arm|Patients will be assigned a peer support worker who will visit them during the last week of their inpatient stay to introduce themselves and build rapport before patients are discharged into the community. The peer support workers will visit the participants up to eight times over a six month period. The peer support workers will offer the opportunity for interactive text message support for six months. Patients will not receive daily supportive/reminder text messages
2424501|NCT03404869|Other|Treatment with ORL-1M - D-mannose|
2424502|NCT03404856|Other|Treatment with ORL-1G - D-galactose|
2424505|NCT03404830|Experimental|HIIT group|This group receives physical training based on HIIT
2424506|NCT03404830|Experimental|MICT group|This group receives physical training based on MICT
2424507|NCT03404830|No Intervention|No intervention group|This group does not receive any treatment.
2424508|NCT03404817|Active Comparator|Sequence 1|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fed condition Period 2: EMB-001 new formulation under fasted conditions Period 3: EMB-001 original formulation under fed conditions"
2424509|NCT03404817|Active Comparator|Sequence 2|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 original formulation under fed conditions Period 2: EMB-001 new formulation under fed conditions Period 3: EMB-001 new formulation under fasted conditions"
2424510|NCT03404817|Active Comparator|Sequence 3|"Subjects will receive investigational product (IP) once each Period as a single dose under fasted or fed conditions as follows:~Period 1: EMB-001 new formulation under fasted conditions Period 2: EMB-001 original formulation under fed conditions Period 3: EMB-001 new formulation under fed conditions"
2424511|NCT03404804|Experimental|Oral Challenge|Patients getting amoxicillin
3146221|NCT00094523|Experimental|Treatment Arm A|Subjects switched their baseline PI for fosamprenavir (± ritonavir) while maintaining their baseline regimen of two nucleoside or nucleotide reverse transcriptase inhibitors for 48 weeks.
3146222|NCT00094523|Experimental|Treatment Arm B|Subjects continued baseline regimen for first 24 weeks with the option of switching their initial PI for fosamprenavir (± ritonavir) while maintaining their baseline nucleoside or nucleotide reverse transcriptase inhibitor regimen for another 24 weeks
2424514|NCT03404765|Experimental|Tai Chi group|The Tai Chi group (i.e. the intervention group) received a 16-week Tai Chi program, of 32 sessions (2 sessions per week), each being one hour long.
2424515|NCT03404765|No Intervention|Ususal care group|The control group received the usual care offered by the respective centers. No intervention had been arranged for the control group during the study period. Participants in the control group were advised to attend different kinds of recreational activities provided by their community centers and to continue with their daily activities, including their usual general physical mobility and social activities.
2424516|NCT03404752|Experimental|Peg-Neutropine®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
2424517|NCT03404752|Active Comparator|Neulastim®|Study drug will be administered more than 24 hours after completion of chemotherapy and every 3 weeks with chemotherapy. Eligible patients scheduled to receive four or six cycles of chemotherapy in every three weeks will be screened in the preceding 28± 3 days and will be randomized (1:1) to one of two treatment arms (Peg-Filgrastim of GEMABIOTECH, or Peg-Filgrastim of Roche).
2424518|NCT03404739|Experimental|Single-dose group|Ceftazidime 2g at the start of POEM
2424519|NCT03404739|Active Comparator|Multiple-dose group|Ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure
2424520|NCT03404726|Experimental|Dose Escalation|Dose escalation with sequential cohorts enrolling patients with AML, MDS, or CMML. Patients will be treated in 28-day cycles with once daily oral administration of BAY2402234
2424669|NCT03403686||Diabetic no retinopathy|Patients with diabetes but with no evidence of diabetic retinopathy
2426855|NCT03388424||quantification of microbiota in Lung|Patients of both sex with Respiratory diseases
3146223|NCT00094679|Active Comparator|2hrs daily patching|2 hours patching per day to cover the sound eye
3146224|NCT00094679|Active Comparator|6hrs daily patching|6 hours per day patching to cover the sound eye
3146225|NCT00094705|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
3146226|NCT00094705|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of rDEN2/4delta30(ME) vaccine given in the deltoid region of either arm.
2424521|NCT03404726|Experimental|Dose Expansion: AML|After completion of dose escalation, an expansion cohort comprised of patients with AML will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
2424522|NCT03404726|Experimental|Dose Expansion: MDS|After completion of dose escalation, an expansion cohort comprised of patients with MDS will start. These patients will be treated in 28 day cycles with once daily oral administration of BAY2402234 at the maximum tolerated dose or pharmacologically active dose.
2424523|NCT03404713|Active Comparator|Standard Behavioral Weight Loss (BWL) Treatment|All participants will participate in 4 weeks of group based behavioral weight lost treatment in the intervention called Pathways to Health. Based on early treatment response (improvement in binge eating), participants will be assigned to either continue in this arm for the remaining 12 weeks of treatment (early strong responders) or be assigned to the 2nd arm of this study.
2424524|NCT03404713|Experimental|Acceptance-Based Binge Eating Treatment|After 4 weeks of standard BWL treatment, early weak responders will be assigned to individual acceptance-based treatment for the remaining 12 weeks of treatment.
2424525|NCT03404700|Experimental|Group 1:Test breakfast A and B|"*Please note: Part I of the study does not have separate groups. All subjects will undergo RFPM. The description of groups presented below is for part II of the study.~Subjects will have egg breakfast(test breakfast A) and egg breakfast with high saturated fat (test breakfast B) in any order."
2424526|NCT03404700|Experimental|Group 2:Test breakfast A and C|Subjects will have egg breakfast and (test breakfast A) and cereal breakfast (test breakfast C) in any order.
2424527|NCT03404700|Experimental|Group 3:Test breakfast A and D|Subjects will have egg breakfast (test breakfast A) and cereal breakfast (test breakfast C) in any order.
2424528|NCT03404700|Experimental|Group 4:Test breakfast B and C|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast (test breakfast C) in any order.
2424529|NCT03404700|Experimental|Group 5:Test breakfast B and D|Subjects will have egg breakfast with high saturated fat (test breakfast B) and cereal breakfast with high saturated fat (test breakfast D) in any order.
2424530|NCT03404700|Experimental|Group 6:Test breakfast C and D|Subjects will have cereal breakfast (test breakfast C) and cereal breakfast with high saturated fat (test breakfast D) in any order
2424531|NCT03404687||Patients with adnexal masses|
3187105|NCT00752323|Experimental|Arm I: Newly diagnosed GBM 10mg/kg|Arm I: Newly diagnosed GBM patients receive oral aminolevulinic acid(10mg/kg)at 6 hours before the midpoint of surgery.
3187106|NCT00752323|Experimental|Arm II: Newly diagnosed GBM 20mg/kg|Arm II: Newly diagnosed GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
3187107|NCT00752323|Experimental|Arm III: Recurrent GBM 10mg/kg|Arm III: Recurrent GBM patients receive oral aminolevulinic acid (10mg/kg)at 6 hours before the midpoint of surgery.
3187108|NCT00752323|Experimental|Arm IV: Recurrent GBM 20mg/kg|Arm IV: Recurrent GBM patients receive oral aminolevulinic acid (20mg/kg)at 6 hours before the midpoint of surgery.
3187109|NCT00752362|Active Comparator|1|Percutaneous coronary intervention with bare metal stent
3187110|NCT00752362|Experimental|2|Percutaneous coronary intervention with paclitaxel-eluting stent
2424538|NCT03404661||Pancreas Cancer Subjects|Patients with pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
2424539|NCT03404661||Control Subjects|Controls will receive Synthetic Human Secretin during an endoscopy procedure. Controls are at an elevated risk of pancreas cancer, including pancreatic cystic neoplasms.
2424540|NCT03404661||Familial Pancreatic Cancer Subjects|Subjects who have a family history of pancreas cancer will receive Synthetic Human Secretin during an endoscopy procedure.
3187111|NCT00752362|Experimental|3|Percutaneous coronary intervention with sirolimus-eluting stent
2424542|NCT03404635||Apixaban for VTE|
2424543|NCT03404635||Rivaroxaban for VTE|
2424544|NCT03404622|Active Comparator|Postplacental IUCD Insertion during Cesarean section|IUCD inserted postplacental removal
2424545|NCT03404622|Active Comparator|6 Week Post-Cesarean Insertion of IUCD|IUCD inserted after six weeks post Cesarean section delivery
3187112|NCT00752375|Active Comparator|A|Eligible children will be randomized to antibiotic prophylaxis. Children under 3 months will receive amoxicillin 10mg/kg once per day. Children >3months will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component). Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day.
2424547|NCT03404596|Experimental|Smoking Cessation Therapy|Participants will receive 6 weeks of the nicotine patch therapy and brief counseling sessions. Participants will also receive mindfulness strategies for 10 days during both the pre- and post-quit periods via smartphone to aid in their cessation attempt. AutoSense will be worn to detect stress and lapse throughout the 10 day period.
2424548|NCT03404583|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform
2424549|NCT03404583|No Intervention|Usual Care|Evidence-based care
2424550|NCT03404570|Experimental|High Dose (4 mg)|Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2424551|NCT03404570|Experimental|Low Dose (2 mg)|Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2424552|NCT03404570|Placebo Comparator|Placebo|Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth once daily (in the morning).
2424553|NCT03404557||Crohn's Disease patients group|44 patients
2424554|NCT03404557||Ulcerative Colitis patients group|22 patients
2424555|NCT03404557||Healthy volunteers group|22 patients
2424556|NCT03404544|Active Comparator|Carbetocin bolus|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 3 ml syringe over 2 sec and the 10 ml syringe will contain only normal saline given as infusion over 10 min.
3187113|NCT00752375|Placebo Comparator|B|Eligible children will then be randomized to placebo.
3187114|NCT00752401|Active Comparator|1|6800 IU/day of Cholecalciferol (Vitamin D3) orally for one year
3187115|NCT00752401|Placebo Comparator|2|Oral placebo solution daily for one year
3187116|NCT00752414|Experimental|1|MP-376 Inhalation Solution
3187117|NCT00752414|Placebo Comparator|2|Placebo
2424557|NCT03404544|Experimental|Carbetocin infusion|Patients in this arm will receive both syringes : the 3 ml and the 10 ml. The carbetocin 100 mcg will be in the 10 ml syringe as an infusion over 10min and the 3 ml syringe will contain only normal saline given iv over 2 sec as a bolus.
2424558|NCT03404531|Experimental|Social Media Messages Intervention Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website and theoretically-grounded social media messages.
2424559|NCT03404531|Active Comparator|Website Only Group|Participants randomized to this condition will have access to a newly developed, culturally-tailored interactive website only.
2424560|NCT03404518|Experimental|Norco and Ibuprofen|"This group will take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Ibuprofen 600mg every 6 hours as needed for additional pain control."
2424561|NCT03404518|Active Comparator|Ibuprofen and Norco|"This group will take Ibuprofen 600mg every 6 hours as needed for pain control as first line intervention.~If pain is not controlled after 60 minutes then can take Hydrocodone/acetaminophen 5mg/325mg every 6 hours as needed for additional pain control."
2424562|NCT03404505|Experimental|Infant Achievements|Families randomized to the IA condition will receive 17 in-home sessions. These include a one-time start up session followed by twice-weekly visits in which they will be coached on how to implement the IA strategies. Families will receive a set of developmentally appropriate toys.
2424563|NCT03404505|Experimental|Caregiver Education|In this condition, parents will receive 17 sessions with a trained study team member focused on promoting child development and well-being. Sessions include a one-time start-up visit followed by one in-home visit and one phone contact per week. Families will receive a set of developmentally appropriate toys.
2424564|NCT03404492|Other|Patients with pulmonary hypertension|
2424565|NCT03404479|Experimental|Co-administration group|Co-administration of Diacerein 50mg, Celecoxib 100mg.
2424566|NCT03404479|Active Comparator|Single administration group 1|Single administration of Diacerein 50mg and placebo.
2424567|NCT03404479|Active Comparator|Single administration group 2|Single administration of Celecoxib 100mg and placebo.
2424568|NCT03404466|Experimental|experimental group one|10 mg of Hypidone Hydrochloride tablets
2424569|NCT03404466|Experimental|experimental group two|20 mg of Hypidone Hydrochloride tablets
2424570|NCT03404453||Paediatric patients at preanaesthetic visi|Difficult airway incidence and prediction:Paediatric patients at preanaesthetic visit scheduled for surgery under general anaesthesia
2424571|NCT03404440|Active Comparator|L.Reuteri|Lactobacillus reuteri DSM 17938 + Lactobacillus reuteri ATCC PTA 6475 one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
2424572|NCT03404440|Placebo Comparator|Placebo|Placebo one tablet by mouth 7 times per day + Pantoprazole 20 mg twice a day for 28 days
2424573|NCT03404427|Sham Comparator|Normal sleep night|The first endurance test is the endurance motor control test after a normal sleep night.
2424574|NCT03404427|Experimental|Sleepless night|The first endurance test is the endurance motor test after a sleepless night.
2424575|NCT03404414|Experimental|18F-FDG PET/MRI and 18F-FDG PET/CT|The patients were injected with 370 MBq of 18F-FDG in one dose intravenously and underwent PET/MRI or PET/CT scan 1 hour later
2424578|NCT03404388|Experimental|Experimental|Balance Training
3146227|NCT00094705|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm.
3146228|NCT00094718|Experimental|1|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^3 PFU dose) into the deltoid region of either arm.
2424582|NCT03404349|Experimental|Mindfulness for Adolescence Course|Participants will attend mindfulness classes to include deep breathing, yoga, listening to music and meditation.
2424583|NCT03404336|Experimental|Well-being therapy|WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.
2424584|NCT03404336|Placebo Comparator|Control condition|The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.
2424585|NCT03404310|Experimental|Treatment|Zinc Sulfate 220mg twice daily for three months.
2424586|NCT03404310|Placebo Comparator|Placebo|Gelatin Placebo tablet twice daily for three months.
2424587|NCT03404297|Experimental|Immediate Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy while concurrently receiving chemotherapy
2424588|NCT03404297|Placebo Comparator|Delayed Compression Therapy Arm|Patients in this arm will receive a locally sourced version of compression therapy after completing ~ 14 weeks of chemotherapy.
2424589|NCT03404284||Intervention facilities|Includes 43 health facilities and their associated outreach sites
2424670|NCT03403686||Diabetic with mild retinopathy|Diabetics with mild non proliferative diabetic retinopathy (NPDR).
3146229|NCT00094718|Experimental|2|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^4 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 1 are analyzed.
3146230|NCT00094718|Experimental|3|One subcutaneous vaccination with WN/DEN4-3'delta30 vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after the results from Arm 2 are analyzed.
3146231|NCT00094718|Placebo Comparator|4|One subcutaneous vaccination with placebo vaccine into the deltoid region of either arm.
3146232|NCT00094744|Active Comparator|6hrs daily patching|6 hours per day of patching in the sound eye
3146233|NCT00094744|Active Comparator|Full-time daily patching|Patching of the sound eye all but one waking hour
3146234|NCT00094822||Pegfilgrastim|
2424590|NCT03404271|Placebo Comparator|Normal Diet|Participants in the normal diet (ND) group will follow a traditional dietary pattern, consisting of eating breakfast and continuing to eat throughout the day until the evening. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2424591|NCT03404271|Experimental|Time-Restricted Feeding|Participants in the time-restricted feeding (TRF) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive placebo capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2424592|NCT03404271|Experimental|Time-Restricted Feeding plus HMB|Participants in the time-restricted feeding plus HMB (TRF+HMB) group will consume all calories within an 8-hour period of time each day. Participants in this group will receive HMB capsules. Participants in all groups will follow an identical resistance training program and be provided with whey protein supplements.
2424593|NCT03404258||Study Patients|Infants between 1 month and 2 years of age undergoing evaluation for SCPA candidacy.
2424594|NCT03404258||Control Patients|Infants between 3 months and 12 months of age with no known cardio-pulmonary disease, no active infection, and no known genetic abnormality undergoing elective surgery for a non-cardiac indication.
2424595|NCT03404245|Active Comparator|Immediate Intervention Group|Education, Fitbit/self-management web app, physiotherapist counselling. These 3 components will be delivered to the participants in Months 1 and 2. The session will include a short presentation about physical activity in everyday life, an individual goal-setting session with a registered PT, and an orientation to the Fitbit device and the web app. Participants will be provided access to a Fitbit and an app account. The PT will review physical activity goals with participants via bi-weekly phone calls and progressively modify their activities. In Month 3-6, participants will continue using Fitbit and the app and have access to a PT via email as needed, but no phone call. In Months 7-12, participants may keep their Fitbit and app account, but will not have access to a PT.
2424596|NCT03404245|Placebo Comparator|Delayed Intervention Group|Same intervention with a 6 month delay: The full intervention will be initiated in Month 7 and 8 with a brief education session, use of a Fitbit paired with the self-management web app, and counseling by a PT. In Month 9-12, participants will continue the intervention without the PT phone calls, but will have email access to PT, if needed.
2424597|NCT03404232|Active Comparator|Group 1|patients with their first surgical intervention at the lumbar spine receive the Dynesys DTO device (Zimmer Spine, Inc.).
2424598|NCT03404232|Active Comparator|Group 2|patients with a previous surgical decompression but non-fusion procedure after lumbar spinal stenosis surgery receive the Dynesys DTO device (Zimmer Spine, Inc.).
2424599|NCT03404232|Active Comparator|Group 3|patients with the medical history of PLIF-/TLIF-technique and later onset of symptomatic ASD within the superior adjacent segment receive the Dynesys DTO device (Zimmer Spine, Inc.).
2424604|NCT03404193|Experimental|Treatment (decitabine, venetoclax)|Participants receive decitabine IV over 1 hour on days 1-10 and may also receive decitabine on days 1-5 after achieving complete remission/complete remission with incomplete count recovery during consolidation/maintenance. Participants also receive venetoclax PO daily on days 1-28 of cycle 1 and on days 1-21 of subsequent cycles. Treatment repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3146235|NCT00094822||PLACEBO|
2424607|NCT03404141|Experimental|Experimental group|"The intervention administered to the experimental group will be a cognitive-behavior therapy applied by two specifically trained psychologists.~Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions)."
2424608|NCT03404141|Active Comparator|Control group|The intervention administered to the control group will consist on a regular parent craft classes offered by the community midwife Due to COVID-19 pandemic, this group will be implemented online using a videocall online platform (from April 2019 to the end of mobility restrictions).
2424609|NCT03404128||Questionnaires|Questionnaire for patient Questionnaire for neurologist
2424610|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.25%)|
2424611|NCT03404115|Experimental|Reproxalap Ophthalmic Solution (0.1%)|
2424612|NCT03404115|Placebo Comparator|Vehicle Ophthalmic Solution|
2424613|NCT03404102||university clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
2424671|NCT03403686||Diabetic with moderate retinopathy|Diabetics with moderate NPDR
2424672|NCT03403686||Diabetics with severe retinopathy|Diabetic with severe NPDR.
2424673|NCT03403686||Diabetics with proliferative diabetic retinopathy (PDR)|Diabetics with proliferative diabetic retinopathy (PDR)
2424674|NCT03403660|Experimental|non white coat rounding|The postpartum physician rounding in this group will be performed wearing white coat.
3146236|NCT00094926|Experimental|001|
3146237|NCT00094926|Placebo Comparator|002|
3146238|NCT00094965|Experimental|1|
3146239|NCT00095251|Active Comparator|Dexmedetomidine group|Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
3146240|NCT00095251|Active Comparator|Lorazepam group|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
3146241|NCT00095290|Experimental|A1|
3146242|NCT00095290|Placebo Comparator|A2|
3146243|NCT00095316|Placebo Comparator|Placebo|Subjects receive placebo intravenously daily for 28 days
3146244|NCT00095316|Experimental|Caspofungin|Subjects receive 50mg/day caspofungin intravenously (IV) for 28 days
2424614|NCT03404102||primary healthcare unit clinic|"Enrollment: 200 Subjects will be enrolled from women attending family planning clinic for Cu- IUD insertion~Informed Consent: All participants will give their informed consent prior to enrollment.~Data collection & recording: Data of each patient will be recorded in a Case Record Form (CRF).~Follow up visits /questionnaire: will be conducted from each subject at 6 months and 12 months after Cu-IUD insertion. User satisfaction score and haemoglobin serum level will be included in the questionnaire."
2424615|NCT03404089|Experimental|pharmacokinetic device|MON4STRAT system
2424616|NCT03404076||GIST patients under TKI treatment|GIST patients under TKI treatment are subjected to Dual Energy CT
2424617|NCT03404063|Experimental|Active Group|Patients randomized to the active treatment group will receive 30 000 000 WJMSCs suspended in 20mL 0.9% NaCl and 5% albumin administered via the IRA.
2424618|NCT03404063|Placebo Comparator|Control Group|Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.
2424619|NCT03404050|Experimental|Music and dance movement therapy group|Music and dance movement therapy group
2424620|NCT03404037||Group I|Fifty-five coronary artery disease patients without type 2 DM
2424621|NCT03404037||Group II|Fifty-five coronary artery disease patients with type 2 DM
2424622|NCT03404024|Experimental|Stage 1-Low dose VM202RY|Patients in this group will receive total 1mg of VM202RY. (4 sites of 0.25mg/0.5 mL VM202RY)
2424623|NCT03404024|Experimental|Stage 1-Middle dose VM202RY|Patients in this group will receive total 2mg of VM202RY. (8 sites of 0.25mg/0.5 mL VM202RY)
2424624|NCT03404024|Experimental|Stage 1-High dose VM202RY|Patients in this group will receive total 3mg of VM202RY. (12 sites of 0.25mg/0.5 mL VM202RY)
2424625|NCT03404024|Placebo Comparator|Stage 2-Placebo|Patients in this group will receive 6mL of VM202RY vehicle. (12 sites of 0.5mL 0.9% NaCl, 1.1% sucrose)
2424626|NCT03404024|Experimental|Stage 2-Low dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-0.5mg VM202RY/1mg VM202RY/1.5mg VM202RY based on the tolerated dose result from Stage 1.)
2424627|NCT03404024|Experimental|Stage 2-High dose VM202RY|Patients in this group will receive total 6mL of VM202RY and VM202RY vehicle. (The dose of VM202RY can be one of the three candidate-1mg VM202RY/2mg VM202RY/3mg VM202RY based on the tolerated dose result from Stage 1.)
2424628|NCT03404011|Experimental|Propylene glycol and Glycerol intake|One gram intake of a Propylene glycol/Glycerol mix (50:50)
2424629|NCT03404011|Placebo Comparator|Mimicking intake|Mimicking Propylene glycol/Glycerol intake with the device turns off
2424630|NCT03403998|Experimental|Exercises|Neck flexors Training: Each patient will initially perform cranio-cervical flexion to sequentially reach 5 pressure targets in 2 mmHg increments from a baseline of 20 mmHg to the final level of 30 mmHg. For each target level, the contraction duration will be increased to 10 s, and the participant trained to perform 10 repetitions with brief rest periods between each contraction. Once one set of 10 repetitions of 10 s is achieved at one target level, the exercise will be progressed to train at the next target level up to the final target. Neck extensors training: Patients will perform cranio-cervical extension and upper cervical rotation in a prone on elbows position while maintaining the cervical spine in a neutral position, progressing to a 4-pt kneeling position.
2424631|NCT03403998|Placebo Comparator|Placebo|"The placebo group will receive placebo TENS (switched-off TENS apparatus with no perceptible stimulation). Four electrodes, 50 x 35 mm, will be placed on the neck muscles. The participant will be informed that this therapy is called a subthreshold current and they might not be able to feel any sensation underneath the electrodes during the treatment. The placebo treatment will be for 30 min twice a week for 8 weeks, as for the intervention group."
2424632|NCT03403985|Experimental|calcium hydroxide direct pulp capping|calcium hydroxide (Ca(OH)2 direct pulp capping will be performed in this group
2424633|NCT03403985|Experimental|MTA direct pulp capping|Mineral Trioxide Aggregate (MTA) direct pulp capping will be performed in this group
2424634|NCT03403972|Experimental|Group|Intervention: vancomycin 500 mg tid for 7 days (Vancozin 250 mg capsule)
2424635|NCT03403959|Experimental|SAD|Persons with visual impairment and SAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry during symptomatic winter phase and asymptomatic summer phase. Winter assessment is followed by a 6 week light therapy protocol ending with assessment of depression severity and repeated pupillometry.
2424636|NCT03403959|No Intervention|non-SAD|Control participants with similar visual impairment but without SAD/sSAD are assessed by clinical interview, depression rating, diurnal saliva melatonin and cortisol and chromatic pupillometry in winter and summer.
2424637|NCT03403946|Experimental|Intervention|"All patients received the same treatment.~Laryngscopy with C-MAC PM + Macintosh blade~Laryngscopy with C-MAC PM + D-Blade~Intubation with C-MAC PM + D-Blade"
2424638|NCT03403933|Experimental|cardiopathic patients in hypovitaminosis|Didrogyl 10 ml: 10 drops a day to obtain levels of vitamin D > 30 ng /ml. Once these values are obtained lower the dose to 4-5 drops a day, with the aim, however, of keeping the plasma values between 30 and 60 ng/ml during 6 months of the study
2424639|NCT03403907|Experimental|Probiotic|Probiotic administration
2424640|NCT03403881|Active Comparator|Physical activity promotion + TAU|"Physical activity promotion based on:~Pedometers use;~Weekly contact (telephone or face-to-face);~Contact based on a self-determination theory.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
2424641|NCT03403881|Placebo Comparator|Control|"Weekly calls with general health content.~TAU:~Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation."
2424642|NCT03403868|Other|Conductance catheter|Contractility-measurement with conductance catheter (pressure-volume-catheter)
2424675|NCT03403660|Placebo Comparator|White coat rounding|The postpartum physician rounding in this group will be performed not wearing white coat.
2424676|NCT03403647|Experimental|Vitamin D deficient|Vitamin D supplementation and close everolimus trough levels monitoring with oral dose adjustments
2424677|NCT03403647|No Intervention|No vitamin D deficiency|Regular and routine monitoring
2424786|NCT03402971||non healthy pregnant|non healthy women with suspected healthy or unhealthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2424643|NCT03403855|Experimental|Rocket® IPC- Long External Length|"Intervention Rocket® IPC- Long External Length: a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate their product."
2424644|NCT03403855|Experimental|Rocket® IPC- Short External Length|"Intervention Rocket® IPC- Short External Length : a regular full length (long catheter) Rocket catheter inserted at baseline, with an external length of 16cm. Catheter length will be modified at 2 weeks in clinic, shortened to an external length of 5cm (short catheter). Patient satisfaction will be collected at 2 weeks prior to the modification, and at 4 weeks when the patient has a shorter catheter.~The modification is easily done without any use of anesthesia as it is external to the patient using the tool kit that comes along with the catheter.~Patients will be referred to palliative home care services for assistance with drainage. The drainage catheters to be used in this study will be samples supplied by Rocket Medical Inc., for Dr. Amjadi to evaluate Rocket's product."
2424645|NCT03403842|Active Comparator|PERIDURAL|Peridural catheter positioning with a continuous infusion of ropivacaine 0,2% 99 ml+ sufentanil 50 mcg at an infusion rate of 4-6 ml/h
2424646|NCT03403842|Active Comparator|PCA MORPHINE|Patient controlled analgesia of endovenous morphine, injection dose 1 mg, lock-out time 10 minutes, maximum dosage for hour 4 mg
2424647|NCT03403842|Experimental|SSTS|Patients controlled analgesia of sublingual sufentanil tablet system, 15 mcg sufentanil tablets, lock out time 20 minutes
2424648|NCT03403829|Experimental|maintenance arm|Gemcitabine maintenance treatment
2424649|NCT03403829|Sham Comparator|control arm|observe and follow-up
2424650|NCT03403816|Active Comparator|Intervention|"Students in grades K-6 at 7 schools in two communities participating in a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions.~."
2424651|NCT03403816|No Intervention|Comparison|Students in grades K-6 at the same 7 schools in two communities as the intervention participants, but who did not participate in the before school physical activity program.
2424652|NCT03403803||Control Group|
2424653|NCT03403803||Optune Only|
2424654|NCT03403803||Optune and TMZ|
2424655|NCT03403790||Patients with depression in bipolar disorder|Patients with depression in bipolar disorder who are treated with quetiapine extended-release tablets for the first time
2424656|NCT03403777|Experimental|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks. Courses will be repeated every 14 days until progression or unacceptable toxicity. AVELUMAB will be administered as a 1-hour (-10 minutes / +20 minutes, i.e., 50-80 minutes) intravenous (i.v.) infusion. The dose of AVELUMAB will be calculated based on the weight of the subject determined on the day prior to or the day of each drug administration.
2424657|NCT03403764|Experimental|Wellness Intention Transmission Groups|"Aim of this part of the study is to examine whether intention broadcasted from an Intention Host Device (a device which stores and transmits an intention) will affect self-compassion, general wellness, and awakening. 300 trial participants will be randomly allocated to 1/3 in control and 2/3 in the experimental IHD group, respectively. Differences in outcomes between control and experimental groups are expected.~To address potential bias, those who enter the study but drop out are compared to those who complete the study to gauge potential differences between the two groups, and will report on this potential bias in the published manuscript."
2424658|NCT03403764|No Intervention|Independent Control Group|"Due to the global, emergent entanglement phenomenon, the investigators are curious if the investigators can test this idea within the context of the proposed study. The investigators added an additional but smaller control group which will complete the same three questionnaires for the first 6 months only and will be unaware of the larger study being conducted. These 50 subjects will be told they are completing the questionnaires in the context of a distinct, separate study and will be unaware of the Consciousness Field Project."
3146245|NCT00095329|Experimental|sirolimus|
3146246|NCT00095394|Experimental|A1|
2424661|NCT03403738|Active Comparator|Enhanced usual Care|usual care plus comprehensive resource list
2424662|NCT03403738|Experimental|BBN|Bounce Back Now intervention
2424666|NCT03403699||nondiabetics|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) the subject must be a healthy control and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
2424667|NCT03403699||Diabetic|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require: a) carry the diagnosis of diabetes and b) the subject be willing and have the ability to cooperate with the eye exam and blood draw.
2424668|NCT03403686||Controls|Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
3146247|NCT00095394|Active Comparator|A2|
3146248|NCT00095420|Experimental|1|Participants with autism will receive social skills training targeting children with autism
3146249|NCT00095420|Experimental|2|Participants without autism will receive social skills training to increase acceptance of peers with autism
3146250|NCT00095420|Experimental|3|Participants with and without autism will receive a combination treatment of social skills/education about autism
3146251|NCT00095420|Active Comparator|4|Participants with and without autism will receive usual training provided by their school district
3146252|NCT00095537|Experimental|Phase 1 MTD Study|
3146253|NCT00095550|Experimental|A1|
3146254|NCT00095550|Active Comparator|A2|
3146255|NCT00095550|Active Comparator|A3|
3146256|NCT00095667|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
3146257|NCT00095680|Experimental|001|SCIO-469 two 30-mg capsules three times daily
3146258|NCT00095680|Active Comparator|002|SCIO-469 and bortezomib The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
3146259|NCT00095693|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.
2424681|NCT03403595|Experimental|177Lu-EB-PSMA-617 dosimetry calculation|All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
2424682|NCT03403582|No Intervention|Control arm|A high-fat break fast meal with no raspberries.
2424683|NCT03403582|Experimental|Raspberry arm|A high-fat break fast meal with raspberries (250g frozen)
2424684|NCT03403569|Experimental|Triptolide Wilfordii Group|150 patients will be enrolled and be administrated with Triptolide Wilfordii 20mg three times a day(TID) per os combined with appropriate ART for 12 months.
2424685|NCT03403569|Placebo Comparator|Placebo Oral Tablet Group|150 patients will be enrolled and be administrated with placebo per os combined with appropriate ART for 12 months.
2424686|NCT03403556|Experimental|Rosuvamibe ® Tab.|Rosuvastatin 10mg/Ezetimibe10mg
2424687|NCT03403556|Active Comparator|Monorova ® Tab.|Rosuvastatin 20mg
2424688|NCT03403543||1|This cohort study only set up a group. We will follow up and observe the pregnant women's lifestyle during pregnancy in order to find the risk factors of adverse pregnancy outcomes. We will divide the participants into more than one group according to the variables（e.g. age, smoking status, drinking status, sleep pattern .etc.）
2424689|NCT03403530|Active Comparator|case group|'IgM rich immunoglobulin' intravenous infusion in the dose of 5 ml/ kg/ dose over 3 hours once a day for 3 days.
2424690|NCT03403530|Placebo Comparator|control group|antibiotics only
3187118|NCT00752453|Experimental|1|Dialysis during 4 hours
3187119|NCT00752453|Experimental|2|Dialysis during 6 hours
3187120|NCT00752453|Experimental|3|Dialysis during 8 hours
3187121|NCT00752479|Experimental|1|
2424697|NCT03403478|No Intervention|Control group|The volunteers will be instructed to remain in an orthostatic position immersed in water up to the imaginary line of the xiphoid process for 45 minutes without performing jerky body movements.
2424698|NCT03403478|Experimental|LICE|The light-intensity continuou exercise (LICE) session comprises a 45-minute of guide walking into the pool at 55-60% of maximum heart rate (HRmax). The HR will be checked every 2 minutes during the whole session.
2424699|NCT03403478|Experimental|MICE|The moderate-intensity continuous exercise (MICE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (30 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 30 minutes and will be performed by 3 sets of 5 exercises lasting 2 minutes each one at 70-75% HRmax. For all phases, HR will be measured every 2 minutes during the whole session.
2424700|NCT03403478|Experimental|HIIE|The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
2424701|NCT03403478|Experimental|Aquatic exercise training|The participants will be submitted to a 12-weeks of aquatic exercise program, twice a week, for 1 hour each day.
3146260|NCT00095719|Active Comparator|A1|
2424703|NCT03403452|Experimental|arm for Apatinib|500 mg,p.o.,qd
2424704|NCT03403439|Experimental|All Subjects|Reference Treatment - BI 1015550 alone followed by Test Treatment (itraconazole + BI 1015550)
2424710|NCT03403387|Experimental|GlutenShield|3 capsules of GlutenShield supplement/day for 28 days
2424711|NCT03403387|Placebo Comparator|Placebo|3 capsules of the placebo (Avicel and bentonite powder (for color))/ day for 28 days
2424787|NCT03402971||non healthy fetus|healthy or non healthy pregnant women with suspected non healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2424817|NCT03402776|Experimental|bad resp. after 3 vacc. inj., 4th inj|After randomization, these patients will receive a 4th dose one month after the 3rd dose.
3146261|NCT00095719|Placebo Comparator|B1|
3146262|NCT00095732|Experimental|Low Liprotamase Dose|Liprotamase in a fixed combination of lipase (5,000 units), protease (5,000 units) and amylase (750 units) administered orally (one Size 5 capsule of liprotamase and five Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
3146263|NCT00095732|Experimental|Mid Liprotamase Dose|Liprotamase in a fixed combination of lipase (25,000 units), protease (25,000 units) and amylase (3,750 units) administered orally (one Size 5 capsule of liprotamase, one Size 2 capsule of liprotamase, and four Size 2 capsules of placebo) with each of three meals and two snacks daily for 28 days
3146264|NCT00095732|Experimental|High Liprotamase Dose|Liprotamase in a fixed combination of lipase (100,000 units), protease (100,000 units) and amylase (15,000 units) administered orally (one Size 5 capsule of placebo and five Size 2 capsules of liprotamase) with each of three meals and two snacks daily for 28 days
3146265|NCT00095745|No Intervention|Antidepressant + Aripiprazole|
3146266|NCT00095758|Placebo Comparator|A1|
3146267|NCT00095758|Active Comparator|A2|
3146268|NCT00095797|Experimental|Treatment (XK469R)|Patients receive XK469R IV over 30-60 minutes on days 1, 3, and 5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3146269|NCT00095810|Experimental|A|
3146270|NCT00095823|Placebo Comparator|A1|
3146271|NCT00095823|Active Comparator|A2|
3146272|NCT00095823|No Intervention|A3|
3146273|NCT00095888|Experimental|Treatment (triapine, gemcitabine hydrochloride)|Patients receive 3-AP (Triapine®) IV over 2 hours followed by gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2424713|NCT03403361|Active Comparator|Arm A: Conventional SECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine single-energy computed tomography (SECT) or DECT scans~In Arm A, patients are treated with treatment plans optimized and calculated on the SECT data. Plan dose is re-calculated for every patient with the clinical plan in a Monte Carlo dose calculation engine for better accuracy. The investigators will use TOPAS, an extension of Geant4 simulation toolkit, as the dose calculation engine.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2424714|NCT03403361|Experimental|Arm B1: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B1, DECT data is used to estimate the actual dose delivered using the clinical plan based on SECT data.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2424715|NCT03403361|Experimental|Arm B2: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B2, the plan is re-optimized on DECT data with the conventional uncertainty margin of 3.5% of proton range.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2424716|NCT03403361|Experimental|Arm B3: DECT|"Patients enrolling in this study will undergo additional sequential DECT scans in addition to their routine SECT or DECT scans~In Arm B3, the plan is re-optimized on DECT data with the SPR uncertainties derived from the patient-specific uncertainty model developed.~An additional 2 sequential scans of the thorax or head-and-neck/brain scan settings will be acquired ranging from 70-140 kVp (with or without additional filter) prior to initiating radiation therapy.~Scans can be performed on the Phillips or Siemens scanners"
2424717|NCT03403348|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will be enrolled in 7 cohorts and receive one of the 7 corresponding SADs of JNJ-64417184, starting from 40 milligram (mg), or placebo in a fasted state. Dose escalation in the subsequent cohorts will depend on the human maximum observed plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) in previous cohorts.
2424718|NCT03403348|Experimental|Part 2A: Food Effect|Participants enrolled in cohort 4 of part 1 will roll-over in Part 2A and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo with a high-fat meal.
2424719|NCT03403348|Experimental|Part 2B: Relative Bioavailability (Optional)|Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
2424720|NCT03403348|Experimental|Part 3: Multiple Ascending Dose (MAD)|Participants will be enrolled in 3 cohorts and will receive one of the 3 corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 days. There will be 3 optional cohorts and participants in these cohorts will follow 7- to 14-day dosing schedule. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (SAD) cohorts. Additional cohorts may be evaluated at the discretion of the Sponsor and the Principal Investigator (PI).
2424721|NCT03403348|Experimental|Part 4: Human RSV Challenge (Proof-of-Concept Study Part)|Based on emerging PK and safety data from Part 3 (MAD), the participants inoculated with respiratory syncytial virus (RSV) -A Memphis 37b and confirmed positive by polymerase chain reaction (PCR) will either receive JNJ-64417184 or placebo once daily OR receive JNJ-64417184 (low dose), JNJ-64417184 (high dose) or placebo once daily.
2424722|NCT03403348|Experimental|Part 5: SAD/Japanese|Participants of Japanese descent will be enrolled in 3 cohorts and will receive one of the corresponding SADs of JNJ-64417184 or placebo in a fasted state. Dosing may be changed from fasted to a fed state, depending on emerging PK data from Part 2A. The starting dose and formulation will be selected based on the outcome of Parts 1 and 2. Dose escalation in the subsequent cohorts will depend on the observed human Cmax and AUC in previous cohorts.
2424723|NCT03403348|Experimental|Part 6: MAD/Japanese (Optional)|Participants of Japanese descent may be enrolled in 3 cohorts and will receive one of the corresponding MADs of JNJ-64417184 or placebo, dosed once daily for 7 to 14 days. Dosing will either occur in the fasted or the fed state, depending on the outcome of Part 2A. Dose selection and dose escalation in the MAD cohorts will depend on the observed human Cmax and AUC in previous (Parts 1, 2, 3, and 5) cohorts.
2424724|NCT03403335|Experimental|Mindfulness Based Practices for Health Care Professionals|
2424725|NCT03403335|No Intervention|Control Group|
2424726|NCT03403322|Other|First test|All measures were evaluated
2424727|NCT03403322|Other|Second test|All measures were evaluated
2424728|NCT03403309|Experimental|Inosine 5'-monophosphate arm|Subjects are treated with inosine 5'-monophosphate to increase serum uric acid level.
2424729|NCT03403309|Placebo Comparator|Placebo arm|Subjects are treated with placebo not to increase serum uric acid level.
2424730|NCT03403296||CLASSIC cohort|Patients with stage II-III GC who underwent D2 resection were randomized (1:1) after surgery to receive adjuvant capecitabine and oxaliplatin (eight three-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or observation alone. Assessment whether patients were disease free were done by abdominal CT or MRI and chest radiograph at regular intervals as planned by protocol.
2424731|NCT03403283||Group 1|Diabetic
2424732|NCT03403283||Group 2|Healthy Controls
2424761|NCT03403179|Experimental|Receiving Psychosocial Intervention|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
2424733|NCT03403270|Experimental|ENCOURAGE App Intervention|Users will download the ENCOURAGE mobile app. The App uses a time management technique (i.e. Pomodoro technique) as a strategy to provide prompts for users to engage in an activity. The App can be customized by the users to set prompts at intervals that fit into their schedule. For example, these activities can range from a stretching activity (e.g., a neck stretch), a standing activity (e.g., stand and read), or a physical activity (e.g., fill up the printer with paper, do a squat). Additionally, the App will use Behaviour Change Techniques as a strategy to support participants as they reduce their sedentary behaviour and improve their physical activity levels. The App uses a series of Behavior Change Techniques shown to be effective in promoting a more active lifestyle.
2424734|NCT03403257||Subjects with cognitive impairment|Subjects with MoCA <26
2424735|NCT03403257||Caregivers|Primary caregivers of subjects
2424736|NCT03403244|Experimental|US-MR image fusion-guided PTED|US-MR image fusion-guided PTED: the puncture procedure during PTED was performed under the guidance of ultrasound-MR fusion technique.
2424737|NCT03403244|Active Comparator|fluoroscopy-guided PTED|fluoroscopy-guided PTED: the puncture procedure during PTED was performed under the guidance of fluoroscopy.
3187122|NCT00752479|Active Comparator|2|
3187123|NCT00752492|Active Comparator|Study intervention|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. Ventilation will be assisted to maintain tidal volume of 8-10 mL/kg and respiratory rate of 20-25 breaths per minute to achieve minute ventilation of 15-20 L/min. Isocapnia manifold will maintain end-tidal PCO2 in range of 40-50 mm Hg.
3187124|NCT00752505|Experimental|A|
3187125|NCT00752505|Experimental|B|
3187126|NCT00752531|Experimental|HAT|
3187127|NCT00752531|No Intervention|Control|
3187128|NCT00752570|Placebo Comparator|2|AMG 386 placebo QW, FOLFIRI Q2W
3187129|NCT00752570|Active Comparator|1|Arm 1 : AMG 386 10 mg/kg QW, FOLFIRI Q2W
3187130|NCT00752583|Experimental|1|Peritoneal dialysis
3187131|NCT00752583|Active Comparator|2|Haemodialysis
3187132|NCT00752596|Experimental|1|1 tablet of 125 mg/day of azimilide 2HCl, oral
3187133|NCT00752674|Experimental|1|Neuromuscular balance
3187134|NCT00752687|Other|1|Single dose of ABT-072, dose escalation ranging from 10 mg to 320 mg or placebo in healthy volunteers
3187135|NCT00752687|Other|2|HCV positive subjects administered 160mg ABT-072 or placebo, multi-dose, QD
3187136|NCT00752700|No Intervention|1|Control group
3187137|NCT00752700|Active Comparator|2|Conventional resistance training program (CRT)
2424754|NCT03403218|Experimental|case group|BESTest, mini-BESTest, Berg scale and FES (falls efficacy scale) (in Spanish version is administrated in case group.
2424755|NCT03403205|Experimental|ALXN1840|"ALXN1840 was administered orally for 48 weeks at doses ranging from 15 milligrams (mg) every other day (QOD) up to a titrated dose of 60 mg daily.~Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period."
2424756|NCT03403205|Active Comparator|Standard of Care (SoC) Medication|SoC medication was administered for 48 weeks. Participants who completed the Primary Evaluation Period had the option to participate in the up to 60-month Extension Period.
3187138|NCT00752700|Experimental|3|Whole body vibration resistance training (WBV) on the FITVIBE-platform
3187139|NCT00752713||1|Patients presenting to hospital with AMI
3187140|NCT00752713||2|healthy volunteers as control group
3187141|NCT00752739|Placebo Comparator|Arm I|Patients receive oral placebo once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3187142|NCT00752739|Experimental|Arm II|Patients receive low-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3187143|NCT00752739|Experimental|Arm III|Patients receive high-dose oral selenium once daily for 48 months in the absence of disease progression or unacceptable toxicity.
3187144|NCT00752804|Experimental|1|Dialysis during 4 hours
3187145|NCT00752804|Active Comparator|2|Dialysis during 6 hours
3187146|NCT00752804|Active Comparator|3|Dialysis during 8 hours
3187147|NCT00752817|Experimental|SC|Subjects (surgical trainees) randomised to train under a proficiency-based progression virtual reality simulation curriculum
3187148|NCT00752817|Active Comparator|CC|Subjects (surgical trainees) randomised to the current surgical training curriculum
3187149|NCT00752830|Experimental|1|AZD0328 administration during fasting condition
3187150|NCT00752830|Experimental|2|AZD0328 administration after food intake
3187151|NCT00752843|Experimental|1|
3187152|NCT00752869|Placebo Comparator|B|This group will meet the same inclusion and exclusion criteria as the group receiving the study drug
3187153|NCT00752869|Active Comparator|A|This arm will receive the active medication dutasteride
3187154|NCT00752921|Active Comparator|A|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
3187155|NCT00752921|Placebo Comparator|B|Healthy Patients, age 18-65, who typically suffer from a Headache while fasting
3187156|NCT00752934|Experimental|group a|Baclofen followed by Placebo
3187157|NCT00752934|Experimental|group b|Placebo followed by Baclofen
3187158|NCT00752947|Experimental|A|
3187159|NCT00752947|Active Comparator|B|
3187160|NCT00752960||A|Patients receiving olanzapine
3187161|NCT00752960||B|patients receiving risperidone
3187162|NCT00752960||C|Patients receiving quetiapine
3187163|NCT00752960||D|Patients receiving aripiprazole
3187164|NCT00752960||E|patients receiving ziprasidone
3187165|NCT00752999|Experimental|A|150 mg tablet, oral, twice-a-day
3187166|NCT00752999|Placebo Comparator|B|Placebo tablet, oral, twice-a-day
3187167|NCT00753025|Experimental|CD133|
3187168|NCT00753025|Experimental|TNC|
3187169|NCT00753025|Placebo Comparator|Placebo|
3187170|NCT00753051|Active Comparator|1.|clozapine as the main agent and it will be adjuncted by haloperidol
3187171|NCT00753051|Active Comparator|2.|clozapine as the main agent and it will be adjuncted by electroconvulsive therapy
2424762|NCT03403166||DASH diet|The DASH diet consisted of a high intake of fruits, vegetables, and low-fat dairy products. It included a wide range of sources of protein, such as meat, fish, poultry, nuts, and beans. Sugar-sweetened beverages, desserts, and red meat were restricted. In terms of nutrients, the DASH diet had a high amount of fiber and protein; low amounts of saturated fat, total fat, and cholesterol; and intake of potassium, magnesium, and calcium at levels close to the 75th percentile of U.S. consumption.
2424763|NCT03403166||Fruits and vegetables diet|Potassium and magnesium intake was similar to the 75th percentile of U.S. consumption. Fiber intake was high. The fruits and vegetables diet consisted of more fruits and vegetables and fewer snacks and desserts than the control diet, but otherwise was similar to the control diet.
2424764|NCT03403166||Control diet|For the control diet, macronutrient intake was similar to average U.S. consumption and intake of potassium, magnesium, and calcium were similar to the 25th percentile of U.S. consumption. Sodium intake was approximately 3 g/day in each diet.
2424765|NCT03403153|Other|Pilot and Open Trial|All Participants will complete the 8-week parenting support intervention and will provide satisfaction and acceptability ratings of the intervention. In the pilot trial, participants will make these ratings after each session, in the open trial the ratings will be made pre and post intervention.
2424766|NCT03403140|Experimental|Single arm|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
2424767|NCT03403101|Experimental|SIRIOX regimen|5-FU and leucovorin in the FOLFIRINOX regimen were replaced with oral S-1, forming the SIRIOX regimen(S1 plus irinotecan and oxaliplatin)
2424768|NCT03403088|Experimental|Group LA|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
2424769|NCT03403088|Placebo Comparator|Group LA-P|INTERVENTION: to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
2424770|NCT03403088|Experimental|Group DE|INTERVENTION: to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
2424771|NCT03403088|Placebo Comparator|Group DE-P|INTERVENTION: to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
2424772|NCT03403088|Experimental|Group RGI|INTERVENTION: to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
2424773|NCT03403088|Experimental|Group RX|INTERVENTION: to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity
2424774|NCT03403075|Active Comparator|Usual Care|"Control Group will be offered usual care (UC), plus two sessions of therapeutic education delivered in small groups. In these educational sessions, patients are provided with useful information on communication strategies, problem solving strategies, recognition and management of symptoms and the management of any aids/orthoses provided in everyday life, etc. In the meetings, it will be emphasized the importance of maintaining an active lifestyle as much as possible by encouraging involvement in physical activity even during the cancer treatment period.~Written information material that summarizes the concepts addressed during group meetings will be provided."
2424775|NCT03403075|Experimental|ETAF: Therapeutic Education Physical Activity|"Intervention group will perform UC, and the two sessions of therapeutic education delivered in small group, as for the Control Group. The Intervention group will also provided for 6 individual sessions of therapeutic education and physical activity held by physiotherapists dedicated to the study, according to the patients' needs and objectives.~In these sessions, the topics discussed in group will be deepened, personalizing them according to the patient's characteristics. Furthermore, personalized physical activity is planned, taking into account the context of execution, the clinical condition and the patient's preferences. The patient will be trained to build an action plan aimed at self-plan physical activities and a diary will be provided to monitor the physical activity carried out autonomously.~Written information material that summarizes the concepts addressed during group and individual sessions will be provided."
2424776|NCT03403049|Experimental|Arm 1|Dose-escalation phase I clinical study. In the initial dose levels, 'dose-escalation' refers to an increase in the radiotherapy dose delivered using carbon ion radiotherapy along with a corresponding decrease in the dose delivered using photons.
2424778|NCT03403023|Experimental|DES treated patients|This single group of patients is imaged by the Tear Film Imager (TFI) device before and after treatment with Restasis, the treatment indicated for their condition.
2424779|NCT03403010|No Intervention|Control period|In this group conventional physiotherapy of the child will be continued and the therapist will be asked not to use any gaming activities. Also during the control period, the frequency and duration of the therapy sessions will not be influenced by the researchers.
2424780|NCT03403010|Active Comparator|Intervention period|In this group the usual individual physiotherapy program of the child will be continued as performed before the study and will be executed by the child's usual, familiar physiotherapist. The therapist will be asked to use the rehabilitation-specific gaming software every therapy session, for at least 15 to 20 minutes. The therapist will receive an extensive introduction and demonstration of the software and the researchers will participate in at least one therapy session.
2424781|NCT03403010|No Intervention|Wash-out period|The wash-out period is considered after each intervention period. As during the control period, therapy will be continued as usual during the washout-period but no gaming is allowed during therapy.
2424782|NCT03402997||Resistivity measurements|The resistivity measurements will be done by introducing the needle-probe into fresh healthy, peritumoral, and tumoral ex vivo tissues
2424783|NCT03402984|Experimental|Acotiamide|Acotiamide 100 mg t.i.d. for 3 weeks. Intake of medication 10 minutes before meal.
2424784|NCT03402984|Placebo Comparator|Placebo|Placebo tablets, t.i.d. for 3 weeks. Intake of placebo 10 minutes before meal.
2424785|NCT03402971||healthy pregnant+healthy fetus|healthy pregnant women with suspected healthy fetus will get one echocardiography examination each trimester of pregnancy and one after delivery
2424815|NCT03402789|Placebo Comparator|Placebo arm|Participants will receive a placebo pill daily in addition to 2 hours of daily eye patching of the affected eye.
2424788|NCT03402945|Active Comparator|Arm 1|"cefazolin prophylaxis plus Prevena negative-pressure wound management system . Cefazolin 2g (or 3g if greater than 120kg body weight) will be given within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 day"
2424789|NCT03402945|Active Comparator|Arm 2|"cefazolin and vancomycin prophylaxis plus Prevena negative-pressure wound management system. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hrs after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Prevena will be applied to all diabetic and/or obese patients (BMI >30kg/m2) at the end of surgery on the sternal as well as the vein harvest site (if open saphenous vein harvest) in the OR and left in place for 7 days."
2424790|NCT03402945|Active Comparator|Arm 3|"cefazolin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
2424791|NCT03402945|Active Comparator|Arm 4|"cefazolin and vancomycin prophylaxis plus standard wound dressing. Cefazolin 2g (or 3g if greater than 120kg body weight) within an hour of surgery, followed by one intra-operative dose of cefazolin at 4 hours after the first dose or upon wound closure (whatever comes first), and finally two post-operative doses q8h. Vancomycin at roughly 15mg/kg body weight intravenously, i.e. 1g, or 1.5g if greater than 85kg body weight. No intra-operative dose of vancomycin will be given, and a single second dose will be given 12 hours after the first dose.~Standard wound dressing: non-negative wound dressing as standard of care at the study site."
3187172|NCT00753064|Active Comparator|AScVS|a clinical scoring system for dose requirement for AScVS is evolved based on sweating, pulse rate, respiratory rate, blood pressure, CNS effects and presence of priapism. Computed doses were given according to clinical grading as intravenous bolus slowly.
3187173|NCT00753064|Active Comparator|Prazosin.|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
3187174|NCT00753064|Active Comparator|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin (500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
3187175|NCT00753090|Experimental|VG DDRP|This arm utilizes the Vanguard™ Deep Dish Rotating Platform Knee.
2424796|NCT03402919||Normal healthy elderly|participants with no subjective or objective cognitive deficits or decline.
2424797|NCT03402919||Subjective Cognitive Decline|Participants with a complaint of subjective cognitive impairment, but no objective evidence of such.
2424798|NCT03402919||Mild Cognitive Impairment (MCI)|Participants with objective evidence of cognitive impairment, but it does not impact on daily function.
2424799|NCT03402919||Vascular MCI|Participants meeting criteria of MCI who also show signs of cerebrovascular disease on imaging but have no history of stroke.
2424800|NCT03402919||Alzheimer's Disease|Participants with dementia of the Alzheimer's type according to the National Institute of Aging-Alzheimer's Association criteria
2424801|NCT03402919||Dementia of Mixed Etiology|Participants with dementia and evidence of more than one etiology.
2424802|NCT03402919||Lewy Body/Parkinson's spectrum|Participants with Parkinson's disease who show mild or moderate cognitive impairment and/or dementia.
2424803|NCT03402919||Frontotemporal dementia (FTD) spectrum|Participants with behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, or corticobasal syndrome
2424804|NCT03402906|Experimental|Family-Clinician Collaboration|"Experimental group which will be performing the Family-Clinician Collaboration Program. Family members will work closely with the Clinician to understand the status and goals of the stroke survivor, and family members will integrate Family-Mediated Treatment Procedures into their time spent with the patient.~Intervention: Behavioral - Family-Clinician Collaboration Program; Behavioral - Standard Care at KIR"
2424805|NCT03402906|Sham Comparator|Control|"Control group in which patient will receive the standard treatment provided at Kessler Institute for Rehabilitation (KIR).~Intervention: Behavioral - Standard Care at KIR"
2424807|NCT03402880|Experimental|Treatment (pembrolizumab, epacadostat)|Patients receive pembrolizumab IV on day 1 and epacadostat PO BID on days 1-21. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. Patients benefiting from treatment may continue for an additional 17 courses.
2424808|NCT03402867|Experimental|Intervention|Deep dry needling applied on active myofascial trigger points in the shoulder and neck regions
2424809|NCT03402854|Experimental|Active tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will receive active tDCS via sponges over the scalp.
2424810|NCT03402854|Experimental|Sham tDCS + bimanual training|In this arm, participants will engage in 120 min of bimanual training. Bimanual training involves using both hands to play with toys and games during the study. During the first 20 min of bimanual training, participants will wear the tDCS device that is worn by the active tDCS group, but in the sham group, participants will not receive stimulation during this 20 min period.
2424812|NCT03402815|Experimental|A|Patients received Maraviroc 300 mg/day in addition to current ART for 24 weeks. At the end of the first 24-week period patients were switched to ART with no additional treatment.
2424813|NCT03402815|Experimental|B|Patients received ART with no additional treatment for 24 weeks. At the end of the first 24-week period patients were switched to Maraviroc 300 mg/day in addition to current ART.
2424814|NCT03402789|Experimental|Docosahexaenoic acid (DHA) arm|Participants will receive a pill of docosahexaenoic acid 1,200mg daily in addition to 2 hours of daily eye patching of the affected eye.
2424818|NCT03402776|No Intervention|bad resp. after 3 vacc. inj., no 4th inj|After randomization, these patients will not receive a 4th dose one month after the 3rd dose.
2424819|NCT03402763|No Intervention|Control Arm|Participants receive a short informational handout on the process and choices involved in advance care planning.
2424820|NCT03402763|Experimental|Intervention|Participants are shown a 6-minute video that describe CPR, breathing tube placement, and mechanical breathing support in addition to the general process of advance care planning.
3187176|NCT00753090|Active Comparator|VG CR|This arm utilizes the Vanguard™ Cruciate Retaining Knee.
3187177|NCT00753103|Experimental|1|Patients with active vasculitis who receive infliximab in addition to standard immunosuppressive therapy
2424823|NCT03402737|Experimental|Stereotactic body radiotherapy + IM|Single arm phase I trial with 3 Stereotactic Body Radiation Therapy dose-escalation arms.
2424824|NCT03402711||Bleeding Risk in Chinese ACS II|1.This is an observational study，there is no intervention to be administered. 2.5500 ACS patients who meet the inclusion criteria for PCI treatment will be consecutively enrolled according to random number sampling.
2424825|NCT03402698|Experimental|cholecalciferol|cholecalciferol at a dose 1000 IU /day for 3 months
2424826|NCT03402685|No Intervention|NIBP-Group|NIBP will be shown, ClearSight will be covered.
2424827|NCT03402685|Experimental|ClearSight-Group|ClearSight will be shown, NIBP will be covered.
2424828|NCT03402672|Experimental|AWAITS|Participants who meet criteria will receive the AWAITS self-administered, e-health application intervention.
3187178|NCT00753103|Active Comparator|2|Patients with active ANCA associated vasculitis who receive standard immunosuppression but no infliximab
2424831|NCT03402646|Experimental|Reminder module (SMS and Phone call)|"Intervention will consist of a Reminder module delivered via SMS and telephone calls by an automated, customized software application. This will include standardized SMS reminder 3 days prior to scheduled immunization clinic appointments, telephone call reminders a day prior to scheduled clinic appointment (4 to 6pm) (in addition to standard care - routine paper-based appointment scheduling and counselling by care providers) for routine immunization. Reminders will be provided consistently for all immunization clinic appointments until the child turns 12 months of age."
2424832|NCT03402646|Experimental|Photovoice|In two small groups of 15 participants each per state, purposively selected pregnant women in their third trimester and parents of infants aged 0-12 months in the community, as well as community leaders, service providers and policy makers will be exposed to photographs (taken from other sources) of debilitating consequences of non-immunization, which will form the basis of the group discussions, knowledge sharing and consensus-building sessions, each lasting about 45 minutes to 1 hour. Each community cluster will be linked to a PHC.
2424833|NCT03402646|No Intervention|Control|Respondents in control clusters will receive standard care only - comprising routine paper-based appointment scheduling
2424834|NCT03402620|Active Comparator|four ampoules group|gonadotropin starting dose is 4 ampoules daily
2424835|NCT03402620|Active Comparator|six ampoules group|gonadotropin starting dose is 6 ampoules daily
2424838|NCT03402594|No Intervention|No oxygen|No oxygen supplementation given
2424839|NCT03402594|Active Comparator|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
2424840|NCT03402594|Experimental|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
2424841|NCT03402581||c-mac used for intubation|obese patients intubated with c-mac videolaryngoscope
2424842|NCT03402581||mc-grath used for intubation|obese patients intubated with mc-grath videolaryngoscope
2424843|NCT03402542||Cholecystectomy|Patients with a symptomatic vesicular lithiasis, having undergone cholecystectomy during a scheduled hospitalization in the CHU Brugmann Hospital between May 2016 and November 2017.
2424844|NCT03402529|Other|CESM|
2424845|NCT03402516|Experimental|18.5Fr resector|Used of a 18.5Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 7 and then a classic hysteroscopic resection will be performed with a 18.5Fr bipolar resector.
2424846|NCT03402516|Active Comparator|26Fr resector|Used of a 26Fr bipolar resector for hysteroscopic myomectomy. Cervical dilatation would be performed until Hegar bougie number 10 and then a classic hysteroscopic resection will be performed with a 24Fr bipolar resector.
2424847|NCT03402503|Experimental|Group A|Montelukast buccal film, administered 10-mg once or 30-mg twice daily (once in the morning and once in the evening) for 26 weeks.
2424848|NCT03402503|Placebo Comparator|Group B|Placebo buccal film, administered once or twice daily (once in the morning and once in the evening) for 26 weeks.
2424849|NCT03402490|Experimental|Motivational interviewing|Over a time span of 6 months, participants in the intervention group received up to 7 sessions of motivational counseling, lasting 15-30 minutes each, to enhance physical activity.
2424850|NCT03402490|No Intervention|Usual care|Participants who served as controls received usual care.
2424851|NCT03402464|Experimental|Icotinib combined dihydroaremisinin|
2424852|NCT03402438|Experimental|Normal (healthy subjects)|Healthy subjects matched for age, body weight and gender to the groups with renal impairment
2424853|NCT03402438|Experimental|Mildly renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 60 and below 90 ml/min/1.75 m*2
2424854|NCT03402438|Experimental|Moderately renal impaired|Subjects with renal impairment and an estimated glomerular function rate between equal or above 30 and below 60 ml/min/1.75 m*2
2424855|NCT03402438|Experimental|Severely renal impaired|Subjects with renal impairment and an estimated glomerular function rate between below 30 ml/min/1.75 m*2
2424856|NCT03402425|Experimental|All included patients|A 18F-FET PET scan is performed
2424857|NCT03402412|Experimental|Study Arm|Narrow-band UVB will be given to a small part of the patients skin with eczema. The rest of the skin surface serves as control.
2424858|NCT03402399|Other|Primary Myelofibrosis|Blood test
2424859|NCT03402399|Other|Secondary Myelofibrosis|Blood test
2424861|NCT03402373|Experimental|Lycoderm|soft gel contains nutritional supplement
2424862|NCT03402373|Placebo Comparator|Placebo|Soft gel without active ingredients
2424863|NCT03402360|Experimental|Virtual Reality rehabilitation group|The Virtual Reality group will perform upper extremity motor rehabilitation and neurocognitive rehabilitation based on virtual reality training.
2424864|NCT03402360|Active Comparator|Control group|The Control group will perform the same motor and neurocognitive rehabilitation but with the virtual reality turned off.
2424865|NCT03402347|Experimental|Laser irradiation regimes|Non-ionising radiation intervention will be applied to skin explants
2424866|NCT03402334|Experimental|CVD risk factor counseling|"This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling.~Cardiovascular risk factor counseling will include:~Increased risk for atherosclerosis with chronic HCV infection~Increased risk of heart attack and stroke~Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack"
2424867|NCT03402334|No Intervention|Standard of care counseling|"This arm will receive standard of care Hepatitis C counseling:~HCV infection poses an increased risk for hepatocellular carcinoma~Hepatitis C is a curable disease~Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles~HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV)~HCV+ individuals should reduce alcohol intake and shellfish consumption"
2424868|NCT03402321|Active Comparator|control group|Gelatin Sponge Sheet is a heamostatic agent act as a mechanical barrier to protect the palatal donor site
2424869|NCT03402321|Experimental|intervention group|alvogyl in a paste form with analgesic action to protect the palatal donor site and help to relief pain
2424870|NCT03402308|Experimental|Schisandra chinensis extract group|This group takes Schisandra chinensis extract for 12 weeks
2424871|NCT03402308|Placebo Comparator|Placebo group|This group takes placebo for 12 weeks
2424872|NCT03402295|Active Comparator|Vcd- (Bortezomibe, cyclophosphamide and dexamethasone)|"Intervention - Bortezomib 1.3mg/m2 Intra venous or Subcutaneous once a week (D1-8-15-22) 35days cycle Intervention- Dexamethasone 40mg once a week for four weeks orally or Intravenously- total dose per cycle was 160mg.~Intervention- Cyclophosphamide 900-2000mg- intravenously or orally- total dose monthly Total of four cycles"
2424873|NCT03402295|Active Comparator|Ctd- Cyclophosphamide, thalidomide and dexamethasone|"Intervention- Cyclophosphamide 900-2000mg intravenously or orally total dose monthly Intervention- Thalidomide 100-200mg orally- daily dose Intervention -Dexamethasone 40mg once a week for four weeks each month- total dose per cycle was 160mg Total of four cycles (cycles of 28 each one)~28 days each cycles- total of four cycles"
3146274|NCT00095901|Experimental|Capecitabine|Capecitabine (Xeloda 4:14. ) 150 mg and 500 mg tablets. Capecitabine will be administered at a dose of 1000 mg/m2 twice daily, for a total daily dose of 2000 mg/m 2. Capecitabine will administered P.O. or per G-tube B.I.D. for 14 days, followed by a one-week rest period in 3-week cycles.
3146275|NCT00095927|Active Comparator|Arm A Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN received;~4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system).~Subcutaneous daily amifostine at a dose of 500 mg"
3146276|NCT00095927|Experimental|Arm B No-Amifostine|"Patients with newly diagnosed, locally advanced stage ill or IV SCCHN~- 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m 2) concurrently with concomitant boost radiation consisting of 72 grays in 42 fractions over 6 weeks (every day for 18 days, twice a day for 12 days) (grading determined according to the TNM staging system)."
2424877|NCT03402256|Experimental|Text Message (TM)|"Participants will receive daily text messages and all elements of standard care. They received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Key domains of message topics were chosen based on the content of evidence-based, relapse prevention treatment. Daily messages determined current level of functioning and provide intervention messages in response. Text messages will be sent via Google Voice on a research computer. Participants will respond to the text messages either with a specified response (e.g. YES/NO) or a generic response (e.g. 1). Some messages will ask for a specific reply in response to a question. Based on the participant's response (e.g. high, med, low), the research assistant will respond with a text message tailored to the participant's message. All text messages will be sent to the HIC in an amendment to this protocol for approval."
2424878|NCT03402256|No Intervention|Standard Care (SC)|"Participants will receive only standard care provided by the liver transplantation team. No additional behavioral or psychosocial interventions will be provided. All aspects of care received by SC participants will also provided to the TM condition participants. Medical care will be managed by medical specialty providers. SC condition participants will receive behavioral treatment within the liver transplantation clinic by psychology fellows and/or psychologists/psychiatrists. Treatment schedules and session topics will be determined by individual providers, per usual practice.~These participants will receive only study-specific assessments. Participants in this condition will complete assessments at baseline, 4-weeks and 8-weeks that measure self- reported substance use, stress, and coping skills. At each in-person assessment, participants will provide urine for EtG analysis and will be compensated."
3146277|NCT00095966|Experimental|Treatment (sorafenib tosylate and gemcitabine hydrochloride)|Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3187179|NCT00753129|Active Comparator|1|Start with turning to prone position without head elevation, after 2 hours 30° head elevation, after 2 hours back to PP without head elevation.
2424884|NCT03402204|Experimental|Simvastatin 10 mg|Simvastatin 10 mg
2424885|NCT03402204|Experimental|Simvastatin 40 mg|Simvastatin 40 mg
2424886|NCT03402191|Active Comparator|L-arginine|l-arginine for pulmonary hypertension in patients with thalassemia.
2424887|NCT03402191|Active Comparator|Sildenafil|Sildenafil for pulmonary hypertension in patients with thalassemia.
2424888|NCT03402191|No Intervention|Control|No pulmonary hypertension
2424889|NCT03402178|Experimental|E2082|E2082 will be administered as a solution (0.2 milligram [mg]), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg E2082 solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg E2082 tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg E2082 under fasted conditions, and then they will receive 5 mg E2082 under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) E2082 tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg tablets once daily for 10 days. E2082 will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
2424890|NCT03402178|Placebo Comparator|E2082-matched placebo|Matched placebo will be administered as a solution (0.2 mg), a 0.5 mg tablet, and a 5 mg tablet. Part A: Cohort 1 participants will receive a single dose of a 0.2 mg matched placebo solution, and participants in Cohorts 2 to 4, respectively, will receive a single dose of 0.5 mg, 1 mg, or 2.5 mg matched placebo tablets under fasted conditions. Cohort 5 participants will receive a single dose of 5 mg matched placebo under fasted conditions, and then they will receive 5 mg matched placebo under fed conditions after washout. Participants in Cohorts 6 to 10, respectively, will receive 10 mg (adult participants), 15 mg, 25 mg, 40 mg, or 10 mg (elderly participants) matched placebo tablets under fasted conditions. Part B: Participants in Cohorts 1 to 4, respectively, will receive 2.5 mg, 5 mg, 10, or 15 mg matched placebo tablets once daily for 10 days. Matched placebo will be administered under fasted conditions on Day 1 and Day 10 and under fed conditions during Day 2 to Day 9.
2424891|NCT03402165|Experimental|Normal Alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2424892|NCT03402165|Experimental|Mild elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2424893|NCT03402165|Experimental|High elevation of alfafetoprotein|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir
2424894|NCT03402152|Experimental|NRX-101 vs. Placebo|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral placebo and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
2424895|NCT03402152|Experimental|NRX-101 vs. lurasidone HCl|Following study enrollment and randomization, subjects will undergo two treatment sessions, 3 days apart. Each treatment session will be conducted while the subject is undergoing Magnetic Resonance Spectroscopy to measure Glx in the ACC. In one treatment session the subject will receive oral lurasidone and in the other treatment session the subject will receive oral NRX-101. Following the second treatment session, the subject will participate in a four week open study of NRX-101, at the end of which a third session of Magnetic Resonance Spectroscopy will be conducted.
2424896|NCT03402139||IUGR infants|Intrauterine growth restricted infants will be enrolled. There are no interventions.
2424897|NCT03402139||AGA infants|Appropriate for gestational age infants will be enrolled. There are no interventions.
3187180|NCT00753129|Active Comparator|2|Start with turning to prone position with 30° head elevation, after 2 hours PP without head elevation, after 2 hours back to 0° PP.
2424899|NCT03402113|Experimental|Dexmedetomidine group|Dexmedetomidine consistent infusion as sedative.
2424900|NCT03402113|Active Comparator|Midazolam group|Midazolam consistent infusion as sedative.
2424901|NCT03402100|Experimental|0.01% atropine|children who received 0.01% atropine for myopia
2424902|NCT03402100|Experimental|0.005% atropine|children who received 0.005% atropine for myopia
2424903|NCT03402100|Experimental|0.25% Ketorolac|children who received 0.25% Ketorolac for myopia
2424904|NCT03402100|Experimental|0.01% atropine plus 0.25% Ketorolac|children who received 0.01% atropine plus 0.25% Ketorolac for myopia
2424905|NCT03402100|Experimental|0.005% atropine plus 0.25% Ketorolac|children who received 0.005% atropine plus 0.25% Ketorolac for myopia
2424906|NCT03402087|Experimental|BMS-986165+Methotrexate+Leucovorin|Three treatments administered
2424907|NCT03402074|Experimental|Group Hypnosis|5 sessions of group hypnosis, each 90 minutes; plus CDs/MP3 recordings to train at home
2424908|NCT03402061||Community living seniors|Approximately 50 seniors will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2424909|NCT03402061||LTC cognitively well|Approximately 15 seniors living in long term care who do not have cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2424910|NCT03402061||LTC persons living with dementia|Approximately 15 seniors living in long term care with cognitive impairment will taste test each nutrient enhanced recipe and determine acceptability and palatability.
2424941|NCT03401801|Active Comparator|8 ml of 1% lidocaine|Procedure: 8 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
2424942|NCT03401788|Experimental|Open Label Belzutifan|Participants receive 120 mg belzutifan orally once daily. Participants may continue to receive belzutifan in the absence of unacceptable treatment related toxicity or unequivocal disease progression.
3187181|NCT00753168|Experimental|1|OT-730 ophthalmic solution
3187182|NCT00753168|Active Comparator|2|timolol maleate ophthalmic solution
2424911|NCT03402048|Active Comparator|control arm|"At discretion of the treating phisician. Common chemotherapic regimens include:~Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle.~Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
2424912|NCT03402048|Experimental|experimental arm|"Treatment prescriptions will be based on gene analysis:~Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.~Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.~Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.~Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.~Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle.~Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity."
3187183|NCT00753168|Placebo Comparator|3|placebo eye drops
3187184|NCT00753181|Experimental|A1|Diabetes Meal Plan with Experimental Diabetes-Specific nutritional shake
2424915|NCT03402009|Experimental|Experimental|independent meditation using web-based tools, apps, and EEG neurofeedback
2424916|NCT03402009|Active Comparator|Active Control|independent meditation using web-based tools and apps
2424917|NCT03401996|Experimental|Real tDCS|
2424918|NCT03401996|Sham Comparator|Sham tDCS|
2424919|NCT03401983|Experimental|PFMT + AT|Pelvic Floor Muscle Training and Abdominal Training
2424920|NCT03401983|Active Comparator|PFMT|Pelvic Floor Muscle Training
2424921|NCT03401970|Active Comparator|Acellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from acellular sources, e.g., refined flour/bakery products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population.
2424922|NCT03401970|Experimental|Cellular carbohydrate diet|Prescribed dietary pattern. Carbohydrates from cellular sources, e.g., root vegetables, fruits, whole-grain rice, non-flour grain products, at least 500 grams of fruits/vegetables per day, and a macronutrient composition within typical nutritional recommendations for the general population similar to the acellular carbohydrate diet.
2424923|NCT03401970|Experimental|Low-carbohydrate high-fat diet|Prescribed dietary pattern. Energy largely from fat, cellular carbohydrate sources, and otherwise similar food types as in the acellular/cellular carbohydrate diets including at least 500 grams of fruits/vegetables per day.
2424924|NCT03401957||RAS wild-type colorectal cancer|RAS mutation of patients who are pathologically diagnosed as metastatic colorectal cancer with RAS wild type genotyping will be evaluated using liquid biopsy during cetuximab treatment.
2424925|NCT03401944|Active Comparator|Total Parenteral Nutrition (TPN)|Overnight infusion of Parenteral Nutrition supplied in all-in one bag -format. Infusion-rate of 0.16 gram Nitrogen/kg/day.
2424926|NCT03401944|Placebo Comparator|Control (saline infusion)|Overnight infusion of physiological saline at the same infusion-rate; ml/kg as intervention (TPN).
2424929|NCT03401905|Experimental|Low frequency|Percutaneous electrical nerve stimulation with frequency of 2 Hz and 120 microseconds of pulse width will be applied.
2424930|NCT03401905|Active Comparator|High frequency|Percutaneous electrical nerve stimulation with frequency of 120 Hz and 200 microseconds of pulse width will be applied.
2424931|NCT03401892|Experimental|Patients with a history of NAION|patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION) in one eye
2424932|NCT03401892|Experimental|Healthy control subjects|healthy age-and sex- matched control subjects
2424933|NCT03401879|Experimental|Patients with MS|Patients with Multiple Sclerosis
2424934|NCT03401879|Experimental|Healthy control subjects|Healthy age- and sex- matched control subjects
2424935|NCT03401866|Other|DSC-MRI scan|All subjects will receive a double dose injection protocol that will be split into multiple doses for sequential DSC-MRI scans.
2424936|NCT03401853|Experimental|Treatment (pembrolizumab, rituximab, obinutuzumab)|"INDUCTION: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive rituximab or obinutuzumab IV on days 1, 8, and 15 of cycle 1 and on day 1 of cycle 2. Cycles repeat every 3 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.~EXTENDED THERAPY: Patients with at least a partial response receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (35 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab Iv on day 1 of cycles 5, 9, 13, 17, 21, and 25 only."
2424937|NCT03401840|Experimental|postoperative SBRT|SBRT consists of a total dose of 36 Gy in 6 fractions over 11-13 days
2424938|NCT03401827|Experimental|Gemcitabine + nab-paclitaxel|Case with chemotherapy (Gemcitabine + nab-paclitaxel)
2424939|NCT03401801|Active Comparator|4 ml of 1% lidocaine|Procedure: 4 ml of 1% lidocaine is injected for stellate ganglion block using the Ultrasound(US)-guided lateral approach at the sixth cervical vertebral level.
2424940|NCT03401801|Active Comparator|6 ml of 1% lidocaine|Procedure: 6 ml of 1% lidocaine is injected for stellate ganglion block using the US-guided lateral approach at the sixth cervical vertebral level.
2424943|NCT03401775|Experimental|Group1|Cognitive rehabilitation program will be administered for 4 weeks, three times a week, 30 minutes a day
3187185|NCT00753181|Active Comparator|A2|Usual diet
2424951|NCT03401749|No Intervention|Control Group|Usual preadmission surgery instructions (shower the night before).
2424952|NCT03401749|Experimental|Theraworx Group|Usual preadmission surgery instructions (shower the night before) plus theraworx skin wipe system use the night before surgery and 1 hour before surgery.
2424953|NCT03401749|Experimental|CHG Group|Usual preadmission surgery instructions (shower the night before) plus chlorhexidine gluconate (CHG) skin wipe system use the night before surgery and 1 hour before surgery.
2424954|NCT03401736|Experimental|Group M：received midazolam|Patients who requires the mechanical ventilation allocated to the midazolam group (group M) were treated with an infusion bolus of 0.05 mg/kg and continuous infusion of 0.04 to 0.20 mg/kg/hour, with the dosage adjusted to achieve the desired level of sedation.
2424955|NCT03401736|Active Comparator|Group D: received dexmedetomidine|Patients who requires the mechanical ventilation allocated to the dexmedetomidine group (group D) received an infusion bolus of 1 ug/kg within 10 minutes and continuous infusion of 0.25 to 0.75 ug/kg/hour, with the dosage adjusted to achieve the desired level of sedation.All patients maintained BIS between 65~85 and the Ramsay score was 3 to 4.
2424956|NCT03401723|Other|Novices|"Any physician who has no experience of endoscopies or has done no more than 50 colonoscopies.~Each subject included are to perform on the Endoscopy Training System (ETS) during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
2424957|NCT03401723|Other|Experienced|"Includes any physician who have succeeded more than 140 colonoscopies. Professional backgrounds include surgeons and gastroenterologists.~Each subject included are to perform on the ETS during which data for 3D-Colonoscopy Progression Score and 3D-Colonoscopy Retraction Score is gathered."
2424960|NCT03401697||HIV/HCV Co-infected|Patients with HIV/HCV co-infection
2424961|NCT03401697||Type 2 Diabetes|Patients with Type 2 Diabetes
2424962|NCT03401684|Experimental|Resilient Minds|Four comprehensive, skill-building learning modules in the areas of psychological trauma, mental health problems, resiliency and workplace stress.
3187186|NCT00753181|Experimental|A3|Diabetes Meal Plan with Experimental Diabetes-Specific Nutritional Shake, diabetes specific Cereal, and diabetes specific snack bars.
3187187|NCT00753194||1|"Newborns that show a Pass On the newborn hearing screening program before hospital discharge"
2424965|NCT03401645|Experimental|Treatment (Alarm Active)|"Participants will be wearing the wrist device with an alarm timer that sends out signals every 5 minutes. The alarm is a buzzing noise and a vibration. Participants must turn off the alarm then perform a series of visuomotor tasks. This will be done for one hour, twice a day for two weeks.~Intervention: Device - Wrist Alarm; Behavioral - Home-based Arm and Hand Exercise"
2424966|NCT03401645|Sham Comparator|Control (Sham Control)|"Participants will perform the same tasks as the Alarm/Treatment group, but without the alarm timer. This is a series of visuomotor tasks for one hour, twice per day for two weeks.~Intervention: Behavioral - Home-based Arm and Hand Exercise"
2424967|NCT03401619||Osteoporosis With Cognitive impairment|
2424968|NCT03401619||Osteoporosis With Arterial stiffness|
2424969|NCT03401619||Osteoporosis|
2424970|NCT03401619||Normal|
2424971|NCT03401606|Active Comparator|Remifentanil|remifentanil and dexmedetomidine, 0.25 ng/mL, given intravenous, infusion, until surgery finished.
2424972|NCT03401606|Active Comparator|Dexmedetomidine|dexmedetomidine and remifentanil, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
2424973|NCT03401593|Active Comparator|ablation|Patients in this group are treated with radio-frequency catheter ablation.
2424974|NCT03401593|No Intervention|non-ablation|Patients in this group are treated with rate control medications (e.g., beta blocker, calcium channel blocker, and digitalis) and anti-arrhythmic drugs. They also can be treated with DC cardio-version.
2424975|NCT03401580|Experimental|Viena II - 160/10|Fixed-dose, 160mg +10 mg, orally, once daily.
2424976|NCT03401580|Experimental|Viena II - 190/10|Fixed-dose, 190mg + 10 mg, orally, once daily.
2424977|NCT03401580|Experimental|Viena II - 160/12|Fixed-dose, 160mg + 12 mg, orally, once daily.
2424978|NCT03401580|Experimental|Viena II - 190/12|Fixed-dose, 190mg + 12 mg, orally, once daily.
2424979|NCT03401567|Experimental|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group.
2424980|NCT03401567|No Intervention|Control group|Control group will continue daily activities and a brochure on strengthening exercises and protection from injuries.
2424981|NCT03401554|Active Comparator|collagen membrane group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with collagen membrane
2424982|NCT03401554|Experimental|titanium mesh group|Sinus floor elevation with simultaneous implant placement and closure of the osteotomy with titanium mesh
2424983|NCT03401541|Experimental|Fat-Mal, calcifediol then calciferol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and then receive one capsule of calciferol for the second round.
2424984|NCT03401541|Experimental|Fat-Mal, calciferol then calcifediol|Participants with diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
2424985|NCT03401541|Experimental|Non Fat-Mal, calcifediol then calciferol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calcifediol for the first round of blood draws and thenreceive one capsule of calciferol for the second round.
2425027|NCT03401281|Active Comparator|Butter|50g Butter to be consumed daily for four weeks
2425028|NCT03401281|Active Comparator|Olive oil|50g extra virgin olive oil to be consumed daily for four weeks
3187188|NCT00753194||2|"Newborns that show a fail and will be retested in 15 days."
2424986|NCT03401541|Experimental|Non Fat-Mal, calciferol then calcifediol|Participants that do not have a diagnosed fat malabsorption syndrome will initially receive one capsule of calciferol for the first round of blood draws and then receive one capsule of calcifediol for the second round.
2424987|NCT03401528|Experimental|Single Ascending Dose - AVB-S6-500|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
2424988|NCT03401528|Placebo Comparator|Single Ascending Dose - placebo|Four sequential dose escalation cohorts - patients are randomized either to investigational drug or matching placebo
2424989|NCT03401528|Experimental|Repeat Dose - AVB-S6-500|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
2424990|NCT03401528|Placebo Comparator|Repeat Dose - placebo|Four single doses of the investigational drug or matching placebo - patients are randomized either to investigational drug or matching placebo
2424991|NCT03401515|Active Comparator|Intervention|Adminstration of propranolol hydrochloride ( 1 MG /ml) 1 mg every 6 hrs .
2424992|NCT03401515|Placebo Comparator|Control|Adminstration of normal saline 1 mg every 6 hrs
2424993|NCT03401502|Experimental|Treatment groups|Ranolazine 1000 mg
2424994|NCT03401502|Placebo Comparator|Control group|Placebos
2424995|NCT03401489|Experimental|PACESETTER|
2424996|NCT03401489|No Intervention|Healthy Lifestyle Intervention Group|
2424997|NCT03401476|Active Comparator|Morphine sulfate - Visit 1|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 1.
2424998|NCT03401476|Active Comparator|Morphine sulfate - Visit 2|Patients who are randomized to this group will be administered a fixed 5mg dose of oral morphine sulfate prior to performing their 6MWT at Visit 2.
2424999|NCT03401463|Active Comparator|once a day|Cuff pressure checks once a day.
2425000|NCT03401463|Active Comparator|three times a day|Cuff pressure checks three times a day
3146278|NCT00096005|Experimental|Treatment (chemotherapy and enzyme inhibitor therapy)|"Patients receive tanespimycin IV over 1-2 hours and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of tanespimycin and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 12 additional patients are treated as above* at the MTD.~NOTE: *Bortezomib is not administered on day 1 of course 1 only. Patients are followed at 3 months."
3146279|NCT00096070|Experimental|Arm I|Patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29 and fluorouracil IV continuously for 5.5 weeks. Beginning 4-6 weeks after the completion of chemoradiotherapy, patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment with gemcitabine repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
2425003|NCT03401437||Retrospective cohorte|Patients seen in consultation between January 2017 and August 2017, who have already completed the SF-36 questionnaire (pre-operative, M1 and M3), the HAD and ANSM questionnaires (pre-operative and M3)
2425004|NCT03401437||Prospective cohorte|Patients seen in consultation between August 2017
2425005|NCT03401424|Experimental|improved Warren-type style|Minimally invasive treatment improved Warren-type cholangiocarcinoma reconstruction is easy
2425006|NCT03401424|Active Comparator|Roux-en-Y style|Early open cholecystectomy reconstruction surgery using Roux-en-Y style
2425007|NCT03401411|Experimental|Standard SCCMP|Health care provider completes triage survey of 15 fictional patient case scenarios using the standard SCCMP to prioritize each for admission.
2425008|NCT03401411|Experimental|SCCMP + Algorithm-based Triage Tool|Health care provider completes triage survey of 15 fictional patient case scenarios using SCCMP in addition to a newly designed flowchart-based triage guide to prioritize each for admission.
3146280|NCT00096083|Active Comparator|Melphalan Administration PHP|
3146281|NCT00096148|Experimental|Arm I (idarubicin, cytarabine)|"Arm I: Patients receive idarubicin IV over 1 hour on days 1-3 and cytarabine IV continuously over 24 hours on days 1-4.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
3146282|NCT00096148|Experimental|Arm II (idarubicin, cytarabine, bevacizumab)|"Patients receive idarubicin and cytarabine as in arm I. Patients also receive bevacizumab* IV over 30-90 minutes on day 1. Patients who do not achieve complete remission (CR) after the first induction course may receive a second induction course approximately 28 days* later. Patients who do not achieve CR after 2 courses are removed from the study.~NOTE: *Patients in arm II receive bevacizumab, independently of chemotherapy administration schedule, once every 21 days for 1 year from CR date.~Post-CR therapy: All patients receive 4 post-CR chemotherapy courses approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Course 1: Patients receive cytarabine IV continuously over 24 hours on days 1-5.~Course 2 and 4: Patients receive idarubicin IV over 1 hour and cytarabine IV continuously over 24 hours on days 1-4."
3146283|NCT00096213|Other|surgery|intralesional resection
2425013|NCT03401372|Experimental|Doxycycline/BCD chemotherapy|Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy
2425014|NCT03401372|Active Comparator|BCD chemotherapy|Bortezomib-cyclophosphamide-dexamethasone chemotherapy
2425015|NCT03401346|Experimental|INP104|Single dose 1.45 mg Dihydroergotamine Mesylate (DHE), administered by I123 Precision Olfactory Delivery (POD) device nasal spray (INP104)
2425016|NCT03401346|Active Comparator|D.H.E. 45 Injection (IV)|Single dose 1 mg Dihydroergotamine Mesylate (DHE) for intravenous injection
2425017|NCT03401346|Active Comparator|Migranal Nasal Spray|Single dose 2 mg Migranal Nasal Spray Dihydroergotamine Mesylate (DHE)
2425018|NCT03401333|Experimental|Text messaging and brief intervention|Brief motivational interview and 4-weeks of text messaging.
2425025|NCT03401294|Other|Single arm|FOLFOXIRI and Bevacizumab
2425026|NCT03401281|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
2425029|NCT03401268|Experimental|Patient cohort|The study population will include 24 patients, that are either already on IVIG or are eligible for ScIG as initial Ig replacement, that will undergo Ig replacement with subcutaneous immunoglobulin (ScIG) for a total of 6 months.
3146284|NCT00096291|Active Comparator|Sequence Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
3146285|NCT00096291|Other|Sequence of neoadjuvant CT: Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
2425032|NCT03401216|Experimental|SYNERGY 48 PCI + 3 month OCT follow-up|Synergy 48 mm stent implantation followed by 3 month OCT imaging
2425033|NCT03401216|Experimental|SYNERGY 48 PCI + 6 month OCT follow-up|Synergy 48 mm stent implantation followed by 6 month OCT imaging
2425040|NCT03401177|Experimental|Naproxen & Heavy resistance training|Naproxen: 500 mg x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
2425041|NCT03401177|Placebo Comparator|Placebo & Heavy resistance training|Placebo oral tablet: pill manufactured to mimic naproxen tablet x 2 daily for 7 days, HRT: 3 months physiotherapy guided training.
2425042|NCT03401125||Sickle cell disease patients (SS genotype)|Sickle cell disease patients with a SS genotype having an history of blood transfusions within the CHU Brugmann and the Queen Fabiola Children's Hospitals.
2425043|NCT03401112|Placebo Comparator|Placebo|
2425044|NCT03401112|Experimental|Dose 1|IMR-687
2425045|NCT03401112|Experimental|Dose 2|IMR-687
2425048|NCT03401086|Active Comparator|Study group|Kinesio Taping
2425049|NCT03401086|No Intervention|Control group|No intervention
2425050|NCT03401073|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 2 days. Followed by 0.9% Sodium Chloride over 1 day every 3 weeks for a total of 6 treatments. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
2425051|NCT03401073|Experimental|Intravenous Immunoglobulin|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. Treatment will consist of IVIG administered at an initial dose of 2 grams/kg over 2 days followed by 1 gram/kg over 1 day every 3 weeks for a total of 6 treatments
2425052|NCT03401060|Experimental|Experimental medication 1|Denosumab 60 mg subcutaneously injection with prefilled syringe
2425053|NCT03401060|Placebo Comparator|Experimental medication 2|NaCl 0.9%, 20ml phial, solution for injection
2425054|NCT03401047|Experimental|Transdermal Estradiol|Subjects will undergo estradiol administration for up to 9 days. Transdermal estradiol patches will be applied each day by study staff during study days two through nine (patches deliver 0.1 mg/day for a total dose of up to 0.6 mg/day).
2425055|NCT03401021||Crrent Male smokers|"Male smokers met the inclusion criteria below will be invited to fill in the questionnaires set, part of them will be invited to attend a semi-structured interview(optional).~be aged 18 or above,~have a history of smoking at least one cigarette per day before their partners became pregnant,~be involved with partners whose pregnancies could be confirmed,~able to read Chinese and communicate in the Mandarin dialect."
2425056|NCT03401008||Acromegalic patients|patients with a proven diagnosis of acromegaly achieved by an IGFA assay and a GH measure.
2425057|NCT03400995|Experimental|Intervention Arm|Each subject will receive a single oral administration of a solution containing 300 mg radiolabeled AK0529 in the fasted state.
2425058|NCT03400982|Experimental|Bone Mineral Density|Bone densitometry measurement: measurement of bone mineral densitometry with bone densitometry
2425059|NCT03400969|Active Comparator|Glycerol 17 %|Oral moisturizer
2425060|NCT03400969|Active Comparator|Aequasyal (OGT)|Oral moisturizer
2425061|NCT03400969|Active Comparator|Salient (new product)|Oral moisturizer
3146286|NCT00096343|Experimental|Paclitaxel IV followed by Carboplatin IV|paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3146287|NCT00096395|Experimental|Treatment (sorafenib tosylate, gemcitabine hydrochloride)|"Course 1 (56 days): Patients receive oral sorafenib twice daily on days 1-56 and gemcitabine IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43.~Course 2 and all subsequent courses (28 days): Patients receive oral sorafenib twice daily on days 1-28 and gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2426856|NCT03388424||quantification of microbiota Metabolic|Patients of both sex with Metabolic Diseases
3146288|NCT00096408|Active Comparator|1|Total Abdominal Hysterectomy
2425069|NCT03400930||OptiDiag-Cohort, Liberia|A respresentative population of 275 Liberian children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2425070|NCT03400930||OptiDiag/MANGO-Cohort, Burkina Faso|A respresentative population of 275 Burkinabé children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2425071|NCT03400930||OptiDiag-cohort, Bangladesh|A respresentative population of 275 Bangladeshi children with SAM and admitted to a CMAM/IMAM program supported by Action Against Hunger (75 of which have a MUAC < 115, 75 of which have a WHZ < -3 and 75 of which have both a MUAC < 115 mm and a WHZ < -3).
2425073|NCT03400891|Experimental|Intervention|This group received 14 sessions (one every 15 days) of one hour in the classroom, to work TPB constructs: attitude; subjective norms; perceived behavioural control and intention.
2425074|NCT03400891|No Intervention|Control|2 session of 1 hour each to give general information about fruit and vegetables intake and health.
2425075|NCT03400878|Active Comparator|BCG-JAPAN|Infants randomised to receive BCG-JAPAN at discharge from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated BCG-JAPAN vaccine (Japan BCG Laboratory, Tokyo, Japan) by intradermal injection in the left deltoid region.
2425076|NCT03400878|Active Comparator|BCG-RUSSIA|BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-RUSSIA (Serum Institute of India, Pune, India) by intradermal injection in the left deltoid region.
2425077|NCT03400865|Experimental|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.
3187189|NCT00753207|Experimental|Lapatinib and Epirubicin|Fixed dose of lapatinib in combination with escalating dose of epirubicin.
2425081|NCT03400839||Patients with ILD|"Patients with a medical diagnosis of interstitial lung disease.~Patients will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SGRQ-I;~HRQoL - SF36;~Anxiety and depression;~Symptoms - mMRC~Symptoms - UCSD/SOBQ;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
2425082|NCT03400839||Control Group|"Age-matched peers without lung diseases.~Participants will be submitted to the assessment of:~Daily physical activity levels;~6-minute walk test;~Cardiopulmonary exercise testing;~Muscle Function;~Lung Function;~Body composition;~HRQoL - SF36;~Anxiety and depression;~Sleep quality;~Sleepiness;~Inflammatory markers and oxidative stress.~Functional performance tests"
2425083|NCT03400826|Experimental|Treatment Group|The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
2425084|NCT03400826|Placebo Comparator|Placebo Group|The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
2425085|NCT03400813|No Intervention|Control|Patients in this group continue their usual care without intervention.
2425086|NCT03400813|Experimental|R-TEP EMDR|Patients in R-TEP EMDR group will receive the intervention.
2425091|NCT03400774|Other|Control|Oral glucose tolerance test with no stair-climbing
2425092|NCT03400774|Experimental|1 minute|Oral glucose tolerance test with 1 minute of stair-climbing
2425093|NCT03400774|Experimental|3 minutes|Oral glucose tolerance test with 3 minutes stair-climbing
2425094|NCT03400774|Active Comparator|10 minutes|Oral glucose tolerance test with 10 minutes stair-climbing
2425096|NCT03400735|Experimental|Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets|
2425097|NCT03400735|Active Comparator|Cefdinir 300 mg Capsules|
3146289|NCT00096408|Experimental|2|Total Laparoscopic Hysterectomy
2425135|NCT03400488|Experimental|AZD5718|Randomized subjects will receive orally once daily dose of AZD5718 oral suspension on Day 1 (SAD) and MAD from Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
3146290|NCT00096434|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146291|NCT00096499|Experimental|Treatment (ispinesib)|Patients receive SB-715992 IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3146292|NCT00096512|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146293|NCT00096629|Experimental|human PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
3146294|NCT00096629|Experimental|mouse PSMA|Patients will receive a total of 6 vaccinations via the intramuscular route. Sites of injection should have intact lymphatic drainage. Groups of six patients will be randomized at each dose level, 3 for each arm, to receive either three immunizations with mouse PSMA followed by three immunizations with human PSMA or three immunizations with human PSMA followed by three immunizations with mouse PSMA.
3146295|NCT00096668|Experimental|TOCOSOL Paclitaxel|TOCOSOL Paclitaxel administered weekly at 120mg/mm2
3146296|NCT00096733||Donors|Living liver donors. This label may also refer to those evaluated for liver donation who did not go on to donate, i.e., potential living liver donors.
2425098|NCT03400722|Experimental|DUOSTIM group|Pergoveris 150 -300 IU start from day 2 of the cycle up to the day of trigger, GnRH antagonist 0,25 mg start from day 7-8 of the cycle up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, stop period for 5 days, after stop period start Pergoveris 150 - 300 IU start up to the day of trigger, GnRH antagonist 0,25 mg start from day 6 of ovarian stimulation up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
2425099|NCT03400722|Experimental|Modified Shanghai Protocol group|Clomiphene 50 mg start from day 2-3 of the cycle up to the day of trigger, Pergoveris 150 - 300 IU - 6,8, 10 days of the cycle, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger, after stop period for 2-3 days start Pergoveris 150 - 300 IU up to the day of trigger, final trigger of ovarian stimulation - GnRH-a 0,2 mg, oocyte retrieval 35 hours after trigger. After oocyte retrieval fertilization will be carried out by IVI or ICSI, the development of embryos will be carried out up to blastocyst stage, then blastocyst vitrification will be performed.
2425100|NCT03400709|Experimental|N-acetylcisteine group|
2425101|NCT03400709|Placebo Comparator|Control group|
2425102|NCT03400696|Experimental|Randomized- Lower carbohydrate diet|
2425103|NCT03400696|Experimental|Randomized- Higher fiber diet|
2425104|NCT03400696|Experimental|Randomized- Exercise focused|
2425105|NCT03400696|Experimental|Participant chooses- Lower carbohydrate diet|
2425106|NCT03400696|Experimental|Participant chooses- Higher fiber diet|
2425107|NCT03400696|Experimental|Participant chooses- Exercise focused|
2425108|NCT03400683|Active Comparator|misoprostol only group|given 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), in sublingual every four hours for a maximum of five doses
2425109|NCT03400683|Active Comparator|misoprostol with letrozole group|group received 15mg( letrozole2.5mg) on three successive day patient take doses of letrozole for daily oral three successive day at home by herself and forth day admitted to our hospital followed by sublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
2425110|NCT03400683|Active Comparator|misoprotol with Foley's catheter group|the transcervical 16F Foley's catheter with 30 ml balloon capacity (Euromed for Medical Industries, Cairo, Egypt, under license of Kanglite, USA), inserted under aseptic conditions withsublingual misoprostol 200 microgram misoprostol (Misotac 200 microgram tablet, Sigma Pharmaceuticals, Egypt), every four hours for a maximum of five doses
2425111|NCT03400670|Active Comparator|Ventilator NCPAP|neonatal ventilator (SLE; Specialised Laboratory Equipment, UK) PEEP: 5 cmH2O
2425112|NCT03400670|Active Comparator|Infant Flow-driver NCPAP|infant flow-driver device (Infant Flow System, Viasys Corp., USA) PEEP:5-8 cmH2O, This group receive variable flow
2425113|NCT03400657||fully implemented to the MDT decision|group of patients fully implemented to the MDT decision
2425114|NCT03400657||not completly implemented to the MDT-decision|group of patients not completly implemented to the MDT decision
2425115|NCT03400657||not implemented to the MDT decision|group of patients not implemented to the MDT decision
2425116|NCT03400644|Active Comparator|With Collar|Subjects are prescribed with custom-made rigid cervical collar which are to be worn for 3 weeks postoperatively
2425117|NCT03400644|No Intervention|Without Collar|Subjects do not need to wear any cervical collar postoperatively
2425118|NCT03400631|Experimental|Dextrose 0. Aspiration 1 week.|Dextrose injection given at time 0, at 1 week aspiration only, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
2425119|NCT03400631|Experimental|Aspiration 0. Dextrose 1 week.|Aspiration only at time 0. Dextrose injection given at 1 week, and then open label injection of dextrose at 0, 1, 2, 3, 4, 5, and 6 months.
3146297|NCT00096733||Recipients|Liver transplant recipients (either living or deceased donor). This label may also refer to those who were evaluated for liver transplantation, but never received a transplant, i.e., potential recipients.
3146298|NCT00096746||A1|HIV infected individuals on first line ATV based HAART with presence of I50L mutation.
2425122|NCT03400605||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
2425123|NCT03400592|Experimental|irinotecan and nimotuzumab|Administration of irinotecan 180 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
3187190|NCT00753246|Placebo Comparator|Arm B|adults with TMZ, RT
2425125|NCT03400566|Experimental|Narrative (target)|Children will receive the story featuring the target vegetable and NO sensory experience.
2425126|NCT03400566|Experimental|Narrative+ experiential (target)|Children will receive the story featuring the target vegetable and experiential learning with the target vegetable.
2425127|NCT03400566|Active Comparator|Narrative (control)|Children will receive the story featuring the control vegetable and NO sensory experience.
2425128|NCT03400566|Active Comparator|Narrative+ experiential (control)|Children will receive the story featuring the control vegetable and experiential learning with the control vegetable.
2425129|NCT03400553|Experimental|non-traumatic thoracic pain|Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.
2425130|NCT03400540|Experimental|Group A|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze and lift the pelvic floor muscles as if stopping the flow of urine~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
2425131|NCT03400540|Experimental|Group B|"The participants will be verbal instructed to contract the pelvic floor muscle with the following sentences:~squeeze the pelvic floor muscles~squeeze the anus~Take a moderate breath in, let the breath out, draw in and lift your pelvic floor.~contract all of the above together"
2425132|NCT03400527|Experimental|Exercise|Participant will be pedaling a stationary exercise bicycle
3146299|NCT00096746||A2|HIV infected PI naïve on failed NNRTI based regimen.
3187191|NCT00753246|Experimental|Arm A|adults with TMZ, RT, nimotuzumab
3187192|NCT00753259|Experimental|AF Clinic|
2425136|NCT03400488|Placebo Comparator|Placebo|Randomized subjects will receive orally once daily dose of placebo matching AZD5718 oral suspension on Day 1 (SAD) and MAD form Days 3 to 10. On Day 2, no dose will be given. These procedures will be repeated in all cohorts.
3187193|NCT00753259|Active Comparator|Care as Usual|
3187194|NCT00753285|Experimental|Renal Denervation|
2425139|NCT03400462|Experimental|dry needling + oral appliance|Three visits are needed in this therapy method. Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd) Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, solution for skin disinfection, sterile gauze. Exposition time : 30 minutes once a week
2425140|NCT03400462|Experimental|antiinflammatory drugs + splint therapy|"Patient's instruction for NSAID use:~Nimesulide 2*100 mg/ 24 h- twice a day one pill of the 100 mg Nimesulide during 14 days"
2425141|NCT03400462|Active Comparator|splint therapy|"Splint therapy is an useful treatment method for several group of patients e.g TMD patients, patients with retrodiscitis, patients with muscle pain disorders like local muscle soreness or chronic myalgia.~The patients have been instructed to use the appliance during nighttime. After 7 days the patient had to came back for a control visit."
3187195|NCT00753311|Active Comparator|Rizatriptan|Patients with migraine with and without aura will be enrolled and randomly provided with study drug (rizatriptan 10 mg MLT or placebo, ratio 1:1). Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
2425144|NCT03400423|Experimental|Non-caffeine exercise|Exercise cognition score
2425145|NCT03400423|Active Comparator|Non-caffeine cognition|Caffeine cognition score
2425146|NCT03400423|Experimental|Caffeine consumption exercise|Exercise cognition score
2425147|NCT03400423|Active Comparator|Caffeine consumption cognition|Caffeine cognition score
2425148|NCT03400423|Experimental|Deprived Caffeine consumers exercise|Exercise cognition score
2425149|NCT03400423|Active Comparator|Deprived caffeine consumers cognition|Caffeine administration cognition score
2425150|NCT03400410|Experimental|Education Arm|"This group will take a survey and be asked some sexual history questions including their contraceptive practices with their sexual partner(s). They will then watch the educational video on hormonal contraception and then be asked a few questions about the video. Then they will be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
2425151|NCT03400410|No Intervention|No Education Arm|"This group will take a survey and be asked some sexual history questions including contraceptive practices with their sexual partner(s). They will then be asked for an email and phone number for follow up.~They will then be followed up 3 months from their visit through their contact option of choice (email, text, or call) to take an additional survey with similar sexual history questions and current contraceptive practices including if they have discussed hormonal contraception with their female partners, if their female partners are now using hormonal contraception, and impregnation rates of female partners."
2425152|NCT03400397||Intervention|Treatment with the Cool Kids programme. The Cool Kids programme is a manualised cognitive behavioural treatment programme for children with anxiety disorders.
2425153|NCT03400384|Experimental|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
2425154|NCT03400384|No Intervention|Control wait list|This arm will receive the intervention at the completion of the six-month follow-up period for the intervention group.
2425155|NCT03400371||Patients diagnosed with JME|People who meet the eligibility requirements and have been diagnosed with juvenile myoclonic epilepsy.
2425156|NCT03400371||Controls|People without a lifetime history of seizures.
2425157|NCT03400358||Medical abortion|150 singleton multiparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were multiparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2425158|NCT03400332|Experimental|Part 1A: BMS-986253 + nivolumab|
2425159|NCT03400332|Experimental|Part 1B: BMS-986253 + nivolumab|
2425160|NCT03400332|Experimental|Part 1C: BMS-986253 + nivolumab + ipilimumab|
2425161|NCT03400332|Experimental|Part 2A: BMS-986253 + nivolumab + ipilimumab|
2425162|NCT03400332|Placebo Comparator|Part 2B: Placebo + nivolumab + ipilimumab|
2425163|NCT03400319||Thoracic Aortic Aneurysm|Patients with Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva ≥39mm, or ascending aorta ≥42mm. Men: at the level of the sinus of valsalva ≥44mm, or ascending aorta ≥46mm.
2425164|NCT03400319||No Thoracic Aortic Aneurysm|Patients without Thoracic Aortic Aneurysm: Women: at the level of the sinus of valsalva <39mm, or ascending aorta <42mm. Men: at the level of the sinus of valsalva <44mm, or ascending aorta <46mm.
2425243|NCT03399851|Active Comparator|Watchman/FLX|Left atrial appendage closure (LAAC) with Watchman/FLX implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
2425168|NCT03400293||Subjects living with HIV|Subjects living with HIV will be recruited via digital advertising. These subjects will participate in completing various PRO instruments and targeted questions.
2425169|NCT03400280|Experimental|Best practice|Postoperative care according to a best practice algorithm for postoperative care focussing on early detection and minimally invasive management of postoperative pancreatic fistula.
2425170|NCT03400280|No Intervention|Current practice|Postoperative care according to current usual practice.
2425171|NCT03400267|Active Comparator|paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
2425172|NCT03400267|Active Comparator|fentanyl|
2425173|NCT03400254|Experimental|Phase II: Arm A|Patients will receive HCQ, 600 mg BID, for 24 weeks.
2425174|NCT03400254|Experimental|Phase II: Arm B|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 2 weeks administered weekly, as an intravenous dose of 150 mg.
2425175|NCT03400254|Experimental|Phase II: Arm C|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 6 weeks administered weekly, as an intravenous dose of 150 mg.
2425176|NCT03400254|Experimental|Phase II: Arm D|Patients will receive HCQ, 600 mg BID, for 24 weeks and GED x 12 weeks administered weekly, as an intravenous dose of 150 mg.
2425177|NCT03400254|Experimental|Phase Ib Arm|Patients will receive HCQ, 600 mg BID, and GED, administered weekly as an intravenous dose of 150 mg, for 6 weeks.
2425178|NCT03400241|Experimental|Tiotropium Easyhaler Product A|tiotropium bromide monohydrate 2 inhalations as a single dose
2425179|NCT03400241|Experimental|Tiotropium Easyhaler Product B|tiotropium bromide monohydrate 2 inhalations as a single dose
2425180|NCT03400241|Experimental|Tiotropium Easyhaler Product C|tiotropium bromide monohydrate 2 inhalations as a single dose
2425181|NCT03400241|Active Comparator|Spiriva HandiHaler|tiotropium bromide monohydrate 2 Spiriva capsules inhaled via HandiHaler
2425182|NCT03400228|Experimental|Protics|Patients in the intervention group were to drink 2 sachets of 1g of probiotic daily for 24 weeks
2425183|NCT03400228|Placebo Comparator|Placebo|Patients in the intervention group were to drink 2 sachets of 1g of maltodextrin daily for 24 weeks
3146300|NCT00096824||1|Participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of ACTG A5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue ACTG A5175. Physicians will make targeted diagnoses at each study visit.
3146301|NCT00096850|Experimental|1|From Days 1 to 8, participants will receive 600 mg RIF every 24 hours. From Days 9 to 19, participants will receive 300 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours. From Days 20 to 27, participants will receive 400 mg ATV and 100 mg RTV every 12 hours and 600 mg RIF every 24 hours.
2425186|NCT03400202||Group A: Dark Circles None|Group A includes participants with Dark Circle Severity Scale score 0 (None). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2425187|NCT03400202||Group B: Dark Circles Mild|Group B includes participants with Dark Circle Severity Scale score 1 to 3 (Mild). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2425188|NCT03400202||Group C: Dark Circles Moderate|Group C includes participants with Dark Circle Severity Scale score 4 to 6 (Moderate). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2425189|NCT03400202||Group D: Dark Circles Severe|Group D includes participants with Dark Circle Severity Scale score 7 to 9 (Severe). Assessments of the participant's eye dark circles will be made after facial cleansing, utilizing in vivo skin imaging and quality of life questionnaires.
2425190|NCT03400189|Other|Single arm|"Single oral dose of sulthiame (Ospolot® tablets)~Period I: 50 mg~Period II: 100 mg~Period III: 200 mg given 3 weeks apart"
3146302|NCT00096863|Placebo Comparator|A - placebo|per oral pill
3146303|NCT00096863|Active Comparator|B|Ziprasidone
2425195|NCT03400150|Experimental|ProSpace group|Marking + ProSpace implantation + IMRT
2425196|NCT03400150|Sham Comparator|Control group|Marking + IMRT
2425197|NCT03400137|Active Comparator|Healthy Volunteers|No family history (first degree relative) of glaucoma.
2425198|NCT03400137|Active Comparator|Glaucoma suspects|oEither IOP between 25 to 30 mmHg with central corneal thickness < 550µm, or a difference ≥ 0.2 in cup to disc ratio between eyes.
2425199|NCT03400137|Active Comparator|Glaucoma|Rim thinning, notching, undermining (excavation) or diffuse or localized RNFL defects that are characteristic of glaucoma.
2425200|NCT03400124|Active Comparator|ISBCS|The intervention group will undergo cataract surgery of both eyes on the same day (ISBCS)
2425201|NCT03400124|Active Comparator|DSBCS|The usual care / control group will undergo cataract surgery of both eyes on separate days, with a time period of at least two weeks between surgeries (DSBCS).
2425202|NCT03400111|Experimental|Low-level laser therapy|Patients upper and lower jaws will be irradiated with low-level laser therapy at specific points on the alveolus around the teeth from the vestibular and lingual sides. This group of patients will be followed up till the end of treatment.
2425203|NCT03400111|Experimental|Panadol-extra|Patients will be given Panadol-extra (565 mg: 500 mg paracetamol and 65 mg caffeine) at specific time points to control pain and discomfort during orthodontic treatment. This group of patients will be followed up till the end of treatment.
2425204|NCT03400111|No Intervention|Traditional Treatment|Patients will not undergo any actual irradiation therapy or take any active tablets during orthodontic treatment.
2425205|NCT03400085|No Intervention|Standard of Care|The control participants will be instructed to attend required follow-up as is standard of care, and will not receive the mHealth application.
2425244|NCT03399838|Experimental|Dexmedetomidine|Application of single dose of 4mcg/kg dexmedetomidine intranasally for pediatric procedural sedation at the emergency department
2426857|NCT03388424||quantification of microbiota in UG|Patients of both sex with Uro-genital Diseases
2425206|NCT03400085|Experimental|mHealth application|Participants in the intervention arm will receive the mHealth application at their first post-donation clinic visit. Study personnel will assist participants assigned to the mHealth intervention arm with downloading the application and explain its functioning. Participants will then use the application to complete their required 6-month, 1-year, and 2-year follow-up.
2425207|NCT03400072|Experimental|Unsupervised APA program|usual care plus a 6-month unsupervised APA program
2425208|NCT03400072|Experimental|Supervised APA program|usual care plus a 6-month supervised APA program
2425209|NCT03400072|No Intervention|Usual care|Usual care
2425210|NCT03400059|Experimental|Active Treatment|
2425211|NCT03400059|Sham Comparator|Sham Treatment|
2425214|NCT03400020|Experimental|Ascorbic acid|Ascorbic acid 1000 mg in normal saline IV 2 hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
2425215|NCT03400020|Placebo Comparator|Normal saline|Normal saline IV infusion 2 hours before the operation and for three days after operation.
2425216|NCT03400007||Prolapse surgery|
2425217|NCT03399994|Experimental|ABLUMINUS DES+|device implantation during coronary angioplasty
2425218|NCT03399994|Active Comparator|Everolimus-eluting DES|device implantation during coronary angioplasty
2425219|NCT03399981||Tysabri (TOUCH Cohort)|Patients from the Tysabri TOUCH prescribing programme who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
2425220|NCT03399981||Tysabri (EU MS Cohort)|Patients from the EU MS registry who have switched to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate).
2425221|NCT03399968|Experimental|ESWT|Application of shockwaves non-invasively at the level of injury
2425222|NCT03399968|Placebo Comparator|Placebo ESWT|Positioning of the therapy head at the injury level without application of shockwaves
2425223|NCT03399955|Experimental|Arm 1: Paromomycin + Miltefosine|Paromomycin 20 mg/kg/d IM for 14 days combined with Miltefosine allometric BID PO dosing for 42 days
2425224|NCT03399955|Experimental|Arm 2: Ambisome + Miltefosine|AmBisome® 5mg/kg/d IV infusion at D1, D3, D5 and D7 (20 mg/kg total dose) combined with Miltefosine allometric BID PO dosing for 28 days
2425225|NCT03399942|Experimental|DBS-ACC ON|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is ON and the second period, between M7 and M10 is OFF
2425226|NCT03399942|Experimental|DBS-ACC OFF|Start of stimulation of the DBS-ACC: On the first period, between M4 and M7, the DBS-ACC is OFF and the second period, between M7 and M10 is ON
2425227|NCT03399929||TBI + Rehabilitation|Traumatic Brain Injury patients that received post acute rehabilitation
2425228|NCT03399929||TBI + No Rehabilitation|Traumatic Brain Injury patients that did not receive post acute rehabilitation
2425229|NCT03399929||CVA + Rehabilitation|Stroke patients that received post acute rehabilitation
2425230|NCT03399929||CVA + No Rehabilitation|Stroke patients that did not received post acute rehabilitation
2425231|NCT03399916|Experimental|Prompt|"An email based prompt was sent- containing either a stand or move message. Exploratory variations of the prompt were designed to include the addition of a goal e.g., stand for the next 5-minutes, and/or employer support e.g., PTS says stand for the next 5 minutes."
2425232|NCT03399916|No Intervention|No Prompt|Prompt delivery was sequentially randomized to be sent (ST) or not sent (NST) to all participants (probability of 0.5), at eight decision points per day (between 9am and 5pm), to achieve a total of 3200 randomizations across participants (160 per participant). Therefore 50% of the time, no prompt was sent.
2425233|NCT03399903|Experimental|Pentasa|40 participants will be randomized to take 1 gram of Pentasa, twice daily for 8 weeks
2425234|NCT03399903|Active Comparator|Align|40 participants will be randomized to take Align tablets, once daily for 8 weeks
2425235|NCT03399890||Group S|Group S: Group sugammadex Patients in this group received sugammadex at the end of the surgery, as neuromuscular reversal agent. Neurological physical exam time was recorded.
2425236|NCT03399890||Group N|"Group N: Group Neostigmine~Patients in this group received neostigmine at the end of the surgeryas neuromuscular reversal agent. Neurological physical exam time was recorded."
2425237|NCT03399877|Active Comparator|Combining electromygraphy with uroflowmetry|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography
2425238|NCT03399877|Active Comparator|Uroflowmetry|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform uroflowmetry solely.
2425239|NCT03399877|Experimental|Uroflowmetry-Combining electromygraphy with uroflowmetry|Children who assigned Group C firstly perform uroflowmetry solely. and subsequently perform uroflowmetry-electromyography.
2425240|NCT03399864|Experimental|Experimental group|Apart from receiving scheduled medical follow-up, the subjects in the experimental group will receive a weekly 45-minute lesson on musical training for 52 weeks. The musical training will be conducted by the Music Children Foundation and be implemented in a ratio of one subject to one qualified orchestral performer at the subjects' homes. A musical instrument will be assigned to each subject based on their interests and the results of the prior assessment of subjects' expiratory function and fine motor skills. The musical training will start at the lowest level, such as hitting simple notes and end at the highest level, such as playing an entire song.
2425241|NCT03399864|Other|Control group|The subjects will receive usual care, such as medical follow-up according to the schedule of the oncology units.
2425242|NCT03399851|Active Comparator|Amplatzer Amulet|Left atrial appendage closure (LAAC) with Amplatzer Amulet implantation will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
2425245|NCT03399838|Active Comparator|Midazolam|0.5mg po/pr midazolam for pediatric sedation at the emergency department
3146304|NCT00096863|Active Comparator|C|Haloperidol
3146305|NCT00096915|Experimental|darbepoetin alfa|
3146306|NCT00097058||1|Continue current hormone therapy
3146307|NCT00097058||2|Taper off hormone therapy
2425257|NCT03399760|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2425258|NCT03399760|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2425259|NCT03399747|Experimental|Abb-R-CHOP|
2425260|NCT03399734|Experimental|Treatment A|4 milligrams (mg) perampanel tablet
2425261|NCT03399734|Experimental|Treatment B|4 mg perampanel fine granules
2425262|NCT03399721|Active Comparator|Chordate S101 Active|Active treatment With Device Chordate S101
2425263|NCT03399721|Placebo Comparator|Chordate S101 Placebo|Placebo treatment With Device Chordate S101
2425264|NCT03399695|Active Comparator|control|spontaneous breathing through a face mask connected to the anaesthesia machine delivering 100% oxygen gas flow (15l/min)
2425265|NCT03399695|Experimental|ohd|spontaneous breathing through a nasal cannula connected to an humidifier device delivering warm (37°C) high flow oxygen(60l/min)
2425266|NCT03399682||Incidence of Post Cystography Urinary Tract Infections|all children less than 16 years having cystography
2425267|NCT03399669|Experimental|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
2425268|NCT03399656|Placebo Comparator|Placebo|4 placebo tablets
2425269|NCT03399656|Active Comparator|Low Dose Avmacol|2 tablets Avmacol and 2 placebo tablets
2425270|NCT03399656|Active Comparator|High Dose Avmacol|4 Avmacol tablets
2425271|NCT03399630|Active Comparator|Injection of Autologous Adipose Tissue|Treatment knee receives injection of 1.5 cc's of adipose tissue mixed with 1.5 cc's of Lactated Ringers
2425272|NCT03399630|Placebo Comparator|Injection of Lactated Ringers|Placebo control group receives injection of 3 cc's of Lactated Ringers with no adipose tissue
2425273|NCT03399617|Active Comparator|Standard Care+MNPs|Participants will receive standard health care services provided by the Ministry of Health, including micronutrient powders (MNPs). Children 6 months old will receive 1 gram of powdered micronutrients for 60 days every 6 months until 24 months of age.
2425274|NCT03399617|Experimental|SPOON behavioral change strategy+SQ-LNS|Participants will receive Small Quantity Lipid-based Supplements (SQ-LNS) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of SQ-LNS will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities. SQ-LNS consists of a 20g nutrient supplement package to be consumed daily from 6-24 of age. SQ-LNS formulation does not include sugar.
2425275|NCT03399617|Experimental|SPOON behavioral change strategy+MNPs|Participants will receive micronutrient powders (MNPs) from 6-24 months and a behavioral change to promote adequate infant and young child feeding practices and the use of MNPs will be delivered to mothers or caregivers. The behavioral change strategy includes individual home-visits, group sessions, and community mobilization activities.
2425276|NCT03399604|Experimental|LIQ861 Inhaled Treprostinil|"LIQ861 inhaled treprostinil at capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg.~LIQ861 will be administered using the RS00 Model 8 dry powder inhalation (DPI) device (Plastiape S.p.A.; Osnago, Italy) at dose levels of 25 μg to 150 μg treprostinil QID in individual patients."
3146308|NCT00097214|Experimental|1|"Cetuximab 400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8. Carboplatin AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.~Therapy will continue for four cycles (12 weeks)for combination therapy"
3146309|NCT00097227|Active Comparator|Arm A (3-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks."
3146310|NCT00097227|Active Comparator|Arm B (4-week cycle)|"Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.~Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks."
3146311|NCT00097266|Placebo Comparator|A|
3146312|NCT00097266|Experimental|B|
2425282|NCT03399552|Experimental|Avelumab|The treatment will consist of one dose of avelumab every other week as well as a short course of SBRT after the first two doses of avelumab.
3146313|NCT00097266|Active Comparator|C|
3146314|NCT00097292||Annual Re-Testing/Annual Metabolic Monitoring|Participants will be monitored annually for risk of type 1 diabetes.
3146315|NCT00097292||Semi-Annual Metabolic Monitoring|Participants will be monitored every six months for risk of type 1 diabetes
3146316|NCT00097357|Experimental|A1|"Apixaban: 2.5 mg, BID~PLUS~Enoxaparin Placebo"
3146317|NCT00097357|Experimental|A2|"Apixaban: 5 mg, BID~PLUS~Enoxaparin Placebo"
3146318|NCT00097357|Experimental|A3|"Apixaban: 10 mg, BID~PLUS~Enoxaparin Placebo"
3146319|NCT00097357|Experimental|A4|"Apixaban: 5 mg, QD~PLUS~Enoxaparin Placebo"
3146320|NCT00097357|Experimental|A5|"Apixaban: 10 mg, QD~PLUS~Enoxaparin Placebo"
3146321|NCT00097357|Experimental|A6|"Apixaban: 20 mg, QD~PLUS~Enoxaparin Placebo"
3146322|NCT00097357|Active Comparator|E1|"Enoxaparin: 30 mg~PLUS~Apixaban Placebo"
2425284|NCT03399526|Experimental|Mapracorat|10 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of mapracorat was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2425285|NCT03399526|Active Comparator|Prednicarbate|10 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of prednicarbate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2425286|NCT03399526|Active Comparator|Clobetasol|10 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of clobetasol was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2425287|NCT03399526|Active Comparator|Calcipotriene|10 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
2425288|NCT03399526|Active Comparator|Calcipotriene/Betamethasone dipropionate|10 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the corresponding test fields (3 cm2) of the affected skin plaques (15 cm2 were treated in total [diameter 2 cm, distance to next test field at least 2 cm]). 200 µL of calcipotriene/betamethasone dipropionate was applied on 6 days a week for up to 4 weeks onto the defined test fields (12.5 cm2 were treated in total [diameter 1.8 cm, distance to next test field at least 1.5 cm]) occluded with Finn chambers of the non-lesional skin areas of 2.5 cm2
3146323|NCT00097357|Active Comparator|W1|Warfarin: 5 mg tablets dose titrated to a targeted INR of 1.8 to 3.0
2425290|NCT03399500|Active Comparator|Usual Case Management (UCM)|Group receives standard case management at the shelter
2425291|NCT03399500|Experimental|UCM + Smartphone|Group receives standard case management and an unlimited smartphone
2425292|NCT03399500|Experimental|Smartphone Based Case Management (SPCM)|Group receives standard case management and an unlimited smartphone with the SPCM app
2425293|NCT03399487|Experimental|Arm 1|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.~Patients will be continued to receive study drug until the end of study unless the patients in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's judgment."
2425294|NCT03399474|Active Comparator|Lidocaine only|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline for intravenous regional anesthesia.
2425295|NCT03399474|Experimental|0.5 ug/kg dexmedetomidine|Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.5 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min for intravenous regional anesthesia.
2425296|NCT03399474|Experimental|0.25 ug/kg dexmedetomidine|1 Lidocaine intravenous in a dose of 3 mg/kg lidocaine 0.5% diluted in 40 ml isotonic saline (maximum dose200 mg)+ Dexmedetomidine intravenous in a dose of 0.25 ug/kg, with the total volume diluted to 40 ml with normal saline 0.9%. The solution will be injected at a rate of 20 ml/min. for intravenous regional anesthesia.
2425297|NCT03399461||Group 1|Approximately 8 subjects with WAS between ages of 12 to 30 years will be included in Group 1.
2425298|NCT03399461||Group 2|Approximately 8 primary caregivers of subjects with WAS between ages 8 to 30 years will be included in Group 2.
2425299|NCT03399461||Group 3|Approximately 5 primary caregivers of subjects with WAS under the age of 8 years will be included in Group 3.
2425300|NCT03399448|Experimental|Multiple Myeloma (MM)|
2425301|NCT03399448|Experimental|Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL)|
2425302|NCT03399448|Experimental|Melanoma|Not Recruiting at the UPenn Site
2425303|NCT03399435|Experimental|Part A|8 cohorts are planned to be treated.
2425304|NCT03399435|Experimental|Part B|Part B will start at the earliest after 4 cohorts of Part A have been treated. Up to 8 cohorts are planned to be treated.
2425305|NCT03399435|Experimental|Part C|Part C will comprise 4 treatment groups. The neosaxitoxin dose will be the same in all 4 treatment groups.
2425306|NCT03399422|Experimental|i-PRF assisted upper canine retraction|I-PRF assisted upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2425307|NCT03399422|Experimental|conventional upper canine retraction|Conventional upper canine retraction will be performed in the other side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
2425308|NCT03399409|Experimental|Motivational Interviewing|
2425309|NCT03399409|Active Comparator|Anti-inflammatory information program|
2425310|NCT03399396|Experimental|Web-Based Coaching|Web-based delivery of practice facilitation for HPV vaccine
2425311|NCT03399396|Experimental|In-Person Coaching|In-person delivery of practice facilitation for HPV vaccine
2426858|NCT03388411||Obese children|Children ≥95 ‰ between age 7 and 12 years
2425312|NCT03399383|Other|Patient education (longitudinal analysis)|Patients with adrenal insufficiency complete a questionnaire before and 6 months after participation in a standardised patient education.
2425315|NCT03399357||≥ 65 Years old|Healthy community-dwelling elderly (men and women) age 65 and above who are eligible for influenza vaccine and fulfil inclusion and exclusion criteria
2425316|NCT03399344|Other|DW-MRI|Patients with undergo an additional diffusion-weighted MRI in addition to the standard diagnostic work-up
2425317|NCT03399331|Experimental|group 1|Efficacy of Manuka honey on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
2425318|NCT03399331|Experimental|Group 2|Efficacy of olive oil on severity and pain of OM compared to placebo (standard care) and to assess which of the two interventions is more beneficial.
2425319|NCT03399331|Placebo Comparator|Group 3|The control group at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine
2425320|NCT03399318|Experimental|Aggressive Antipyretics|regardless of temperature, children allocated to this arm will receive acetaminophen (30mg/kg load then 15mg/kg Q6 hours) and ibuprofen (10mg/kg Q 6 hours) for 72 hours. Pediatric syrup formulations of both agents will be administered orally or via nasogastric tube. For temperatures over 38.5 degrees Celsius, placebo will be added and if the fever persists, a cooling fan will be added.
2425321|NCT03399318|Placebo Comparator|Usual Care|will receive placebo for acetaminophen and placebo for ibuprofen. If they have a temperature over 38.5 degrees Celsius, they will receive acetaminophen (15mg/kg, Q6 hours), as needed. If the fever persists, a cooling fan will be added.
2425322|NCT03399292||Group 1|10 male and female healthy subjects receive Cationorm MD sine eye drops once
2425323|NCT03399292||Group 2|10 male and female volunteers with dry eye disease receive Cationorm MD sine eye drops once
2425324|NCT03399292||Group 3|10 male and female volunteers with Maibomian gland disease receive Cationorm MD sine eye drops once
2425325|NCT03399292||Group 4|10 male and female volunteers with receive Cationorm MD sine eye drops once
2425326|NCT03399279|Experimental|Open flap debridement & perforated&Nano|Perforated collagen membrane and nano-hydroxyapatite and open flap debridement
2425327|NCT03399279|Active Comparator|Open flap debridment &Occlusive&Nano|Occlusive membrane and nano-hydroxyapatite and open flap debridement
2425328|NCT03399266|Experimental|Double balloon catheter for induction of labor|in this group a trans-cervical double balloon catheter will be inserted. Following device insertion, 20 minutes of external monitoring is performed. The patient will be transferred to the Ob/Gyn ward for hospitalization. 12 hours after insertion of the device the balloons are deflated and the device removed. At this stage the patient is assessed for a second Bishop score and expectant management is resuming.
2425329|NCT03399266|No Intervention|Expectant management|Women in the expectant management group will be transferred to the Ob/Gyn ward for hospitalization and conservative management until spontaneous labor ensues.
2425330|NCT03399253|Active Comparator|Chemotherapy|chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2425331|NCT03399253|Experimental|Surgery+Chemotherapy|D2 Gastrectomy and Metastasectomy + chemotherapy with capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2425332|NCT03399240|Experimental|Vitastiq device|Vitastiq device is used for about 2 months to perform Vitastiq readings every day, preferably in the morning.
2425333|NCT03399227||Liver transplantation recipients|Venipuncture (6x) Bone mineral density measurement: lumbar spine, hip region (3x) high resolution peripheral quantitative CT: radius, tibia (3x)
2425334|NCT03399227||Control group|Venipuncture (1x) Bone mineral density measurement: lumbar spine, hip region (1x) high resolution peripheral quantitative CT: radius, tibia (1x)
2425335|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 1|IV injection, 0.27 mg/kg
2425336|NCT03399214|Experimental|IOP Injection, Phase 1b, Cohort 2|IV injection, 0.54 mg/kg
2425337|NCT03399201|Active Comparator|General Anesthesia|Standard General Anesthesia will be applied.The change of the pulmonary functions will be evaluated via spirometer.
2425338|NCT03399201|Active Comparator|Neuraxial Anesthesia|Neuraxial anesthesia will be applied. The change of the pulmonary functions will be evaluated via spirometer.
2425339|NCT03399188|Experimental|FMT group|Group who received fecal microbiome transplantation
2425340|NCT03399175|Other|Treatment group|Early high-dose corticosteroid and immunosuppressive therapy
2425341|NCT03399162|Experimental|PREHAB Group|"Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.~Patients in this group will also complete an 8-week PREHAB exercise program, with weekly exercise classes and a list of exercises to complete at home."
2425342|NCT03399162|Active Comparator|Standard of care group|Patients in this arm will receive the usual standard of care prior to surgery, which includes a PREHAB workshop; consultations with a surgeon, anaesthesiologist, and nurse; referrals to diabetes counselling and/or smoking cessation, as appropriate; and the usual diagnostic work-up.
2425343|NCT03399149||"Before phase"|Retrospective study of ICU admissions of hematology patients for respiratory and hemodynamic reasons Time period: January 2012 to March 2017
2425344|NCT03399149||"After Phase: Systematic evaluation by an intensivist"|"Corresponding to the period after the implementation of a systematic intensivist evaluation Daily screening of systolic blood pressure, oxygen saturation and oxygen requirements of all patients hospitalized in hematology wards. Systematic evaluation of any patient presenting the inclusion criteria by an intensivist and collegial care planning.~Time period: From March 2017 to end of study"
2425345|NCT03399136|Experimental|Moderate-intensity aerobic exercise|In the moderate-intensity aerobic exercise group, participants performed a self-paced 1-mile walk (3-5 METs) on an indoor track in the same exercise center as the high-intensity exercise group. Initial sessions lasted 20-30 minutes and were increased weekly to 45 minutes in parallel to the duration of the high-intensity exercise group.
2425346|NCT03399136|Experimental|High-intensity aerobic exercise|In the high-intensity aerobic exercise group, exercise training was performed on a motorized treadmill with occasional substitution with the elliptical machine as needed for joint pain. Target heart rate was based on the baseline treadmill test and was calculated as percentage of the heart rate reserve (HRR=maximal HR-resting HR). Initially, participants trained for 20-30 minutes at 50-60% of HRR. Duration and intensity was increased by 10% weekly so that within 5-7 weeks the aerobic exercise sessions lasted 30-45 minutes at 70-85% of HRR and at the end of the 16 weeks lasted 40-45 minutes at 75-90% of HRR.
2425347|NCT03399123|Experimental|Low tidal volume group|Use a low tidal volume(6'8ml/kg) ventilation mode during liver segmentation。
2425348|NCT03399123|Active Comparator|Standard tidal volume group|Use a standard tidal volume(10'12ml/kg) ventilation mode during operation.
2425349|NCT03399110|Experimental|XELOX for 4 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery (five 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 4 months or progress of disease
2425350|NCT03399110|Active Comparator|XELOX for 6 months|Adjuvant chemotherapy with capecitabine and oxaliplatin after surgery(eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
2425351|NCT03399097||non-obese|non-obese
2425352|NCT03399097||obese|obese
2425353|NCT03399097||previously obese|previously obese
2425354|NCT03399084|Experimental|Ferric carboxymaltose (test)|Patients will receive a single dose of Ferric carboxymaltose
2425355|NCT03399084|Active Comparator|Ferric carboxymaltose (reference)|Patients will receive a single dose of Ferric carboxymaltose
2425356|NCT03399071|Experimental|FLOT plus Avelumab (FLOT-A)|"Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour.~Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv"
2425357|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
2425358|NCT03399058|Other|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2). The Hearth messages are contextualized messages on child feeding practices that women in the community have found helpful to successfully prevent child malnutrition. This program will be delivered through in person community meetings.
2425359|NCT03399058|Other|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a similar program as group 2 with contextualized child feeding messages (PDH lite program) and receive follow-up through mobile support phone calls (Group 3).
2425360|NCT03399045|Experimental|9-minute withdrawal group|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy will not be included in the 9 minutes.
2425361|NCT03399045|Active Comparator|6-minute withdrawal group|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw. A stop watch will be utilized to remind endoscopists the withdrawal time. The time to perform polyp biopsy willwill not be included in the 9 minutes.
2425362|NCT03399032||Caspofungin|Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day
2425363|NCT03399019|Experimental|Dexmedetomidine|"Dexmedetomidine~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2425364|NCT03399019|Active Comparator|Propofol|"Propofol~: 0.75-3 mg/kr/hr continous infusion Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2425365|NCT03399019|Active Comparator|Midazolam|"Midazolam~: initial loading 0.5- 1 mng/kg for 10 minutes and maintenance 0.2-0.7mng/kg/hr~Check BIS (bispectral index) score and OAA/S (Observer assessment of alertness/sedation score) by time"
2425366|NCT03399006||preeclampsia|women who developed preeclampsia. Preeclampsia was defined as a blood pressure 140/90 mmHg and proteinuria of 300 mg in 24 hours, or two readings of at least 2+ on dipstick analysis of midstream urine specimens if no 24-hour urine collection was available in absence of urinary tract infection
2425367|NCT03399006||Normal pregnancy|women with normal blood presure
2425368|NCT03398993|Active Comparator|Scratch group|"Induction of ovulation will be done by clomophine citrate from 3rd day of cycle till 7th day of cycle and HMG 75IU (MerionaL) given from 6th day of cycle till 8th of cycle once daily. folliculometry done regularly during induction of ovulation till dominant follicle reached 18_20mm in size.~Then endometrial injury performed in pre ovulatory day by a thin pipelle (a fine, flexible, sterile, plastic tube) The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle"
2425369|NCT03398993|Active Comparator|Non scratch group|They will receive the same induction of ovulation as first group but without performing endometrial injury in preovulatory day
2425370|NCT03398980||survivors treated with CRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with convention radiotherapy (CRT).
2425371|NCT03398980||survivors treated with IMRT|Childhood and Adolescent Nasopharyngeal Carcinoma survivors who were treated with intensity-modulated radiotherapy (IMRT).
2425372|NCT03398941|Experimental|Combined group|
2425415|NCT03398694|Experimental|Arm 1|This is a single arm study so this arm will include all eligible subjects. All subjects will have radiosurgery 1-4 days prior to surgical resection.
2425375|NCT03398915||Robot-Guided Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of a robotic guidance system (SpineAssist or Renaissance, Mazor Robotics, Ltd., Caesarea, Israel or ROSA Spine, Medtech, Montpellier, France).
2425376|NCT03398915||Navigated Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of navigation (computer assistance using CT, O-arm or 3D-fluoroscopic imaging).
2425377|NCT03398915||Freehand Transpedicular Instrumentation|This arm will comprise all patients that receive transpedicular instrumentation by use of the conventional freehand technique.
2425378|NCT03398902|Experimental|Sleep extension|Participants in the sleep extension group will keep daily sleep diaries. Sleep diaries will be reviewed with the participant and an instructor trained in Cognitive Behavioral Therapy for Insomnia (CBTI) on a weekly basis. These weekly sessions will take place by telephone or videoconferencing.
2425379|NCT03398902|Active Comparator|Habitual sleep|Participants in the habitual sleep group will be instructed to keep their habitual bedtimes and wake times. Participants will keep daily sleep diaries that will we reviewed by a study team member each week. These weekly sessions will take place by telephone or videoconferencing.
2425380|NCT03398889||Unexplained Atherosclerosis phenotype|Residual score in linear regression >2
2425381|NCT03398889||Explained Atherosclerosis phenotype|Residual score in linear regression <-2, <2
2425382|NCT03398889||Protected Atherosclerosis phenotype|Residual score <-2
2425383|NCT03398876|Experimental|Part 1; Treatment Sequence ABDC|Participants will receive Treatment A (one spray of oromucosal nicotine spray [ONS]) at Visit 1, then Treatment B (2 consecutive sprays of ONS at Visit 2, then Treatment D (1 cigarette [10 puffs]) at Visit 3, followed by Treatment C (nicotine gum) at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2425384|NCT03398876|Experimental|Part 1; Treatment Sequence BCAD|Participants will receive Treatment B at Visit 1, then Treatment C at Visit 2, then Treatment A at Visit 3 followed by Treatment D at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2425385|NCT03398876|Experimental|Part 1; Treatment Sequence CDBA|Participants will receive Treatment C at Visit 1, then Treatment D at Visit 2, then Treatment B at Visit 3 followed by Treatment A at Visit 4. The visits will be separated by a period of at least 7 calendar days. The visits will be separated by a period of at least 7 calendar days.
2425386|NCT03398876|Experimental|Part 1; Treatment Sequence DACB|Participants will receive Treatment D at Visit 1, then Treatment A at Visit 2, then Treatment C at Visit 3 followed by Treatment B at Visit 4. The visits will be separated by a period of at least 7 calendar days.
2425387|NCT03398876|Experimental|Part 2; Treatment Sequence EF|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment E (two consecutive sprays of ONS once every 30 minutes until 11.5 hours) at Visit 5, followed by Treatment F (two consecutive sprays of ONS once every 1 hour until 11 hours) at Visit 6. The visits will be separated by a period of at least 7 calendar days.
2425388|NCT03398876|Experimental|Part 2; Treatment Sequence FE|Participants who complete Part 1 will be selected for Part 2 based on the results of genetic polymorphism test and other examinations. Selected participants will receive Treatment F at Visit 5 followed by Treatment E at Visit 6. The visits will be separated by a period of at least 7 calendar days.
2425389|NCT03398863|Active Comparator|Cleaning of uterine cavity|Cleaning of uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
2425390|NCT03398863|No Intervention|Not cleaning of uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
2425391|NCT03398837|Experimental|Cohort 1|Lenabasum 5 mg BID
2425392|NCT03398837|Experimental|Cohort 2|Lenabasum 20 mg BID
2425393|NCT03398837|Placebo Comparator|Cohort 3|Placebo BID
2425394|NCT03398824|Experimental|Treatment arm|Receive metformin HCl
2425395|NCT03398811||"Group I the depot medroxy-progesterone acetate group"|where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,
2425396|NCT03398811||"Group II Implanon group"|where they will have Implanon (etonogestrel implant) 68 mg implant
2425397|NCT03398811||group III (cerazette group)|where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.
3187196|NCT00753311|Placebo Comparator|placebo|Patients who met all the study entry criteria were enrolled and randomly allocated to receive either rizatriptan 10 mg wafer or placebo (ratio 1:1).Patients were encouraged to take migraine medication as soon as their migraine headache became moderate or severe. If the moderate or severe migraine headache persisted 2 h after dosing, or recurred within 24 h, patients had the option of taking their own rescue medication but triptans and ergot derivatives were prohibited for 24 h after study medication intake.
3187197|NCT00753324|Experimental|Routine three-drug antiretroviral prophyalxis|Cohort of 160 HIV-infected women, approached at > 28 weeks gestation and initiated on routine HAART for the purposes of PMTCT.
2425402|NCT03398785|Experimental|Intevention|Adrenal Artery Ablation
2425403|NCT03398785|No Intervention|Control|No intervention, but treated with standard anti-hypertensive drigs
2425404|NCT03398772|Experimental|Experiment|Comprehensive Health Coaching Program
2425405|NCT03398772|No Intervention|Control|Guideline-based usual care
2425406|NCT03398759|Experimental|Butorphanol|Butorphanol 20ug/kg , anesthesia induction，Intravenous injection
2425407|NCT03398759|Placebo Comparator|Placebo|Normal saline 5ml ， anesthesia induction，Intravenous injection
2425408|NCT03398746|Experimental|LOOP Technique|Placement of subcutaneous loop drain
2425409|NCT03398746|Active Comparator|Incision and Drainage|Standard Incision and Drainage Technique
2425410|NCT03398733|Other|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively.
2425411|NCT03398720|Experimental|Cohort 1|One participant will receive HTI-1066 at the starting dose.
2425412|NCT03398720|Experimental|Cohort 2|Participants will receive HTI-1066 at dose level 2.
2425416|NCT03398681|Active Comparator|Intravenous ferric carboxymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)] will be given as a perfusion of 20 mL (which is the amount of FCM that is equivalent to 1000 mg of iron) diluted in a sterile saline solution (0.9% weight/volume (w/v) NaCl) administered over at least 15 min.
2425417|NCT03398681|Placebo Comparator|Normal saline|Normal saline (0.9% weight/volume (w/v) NaCl) administered as per the instructions for active therapy.
2425418|NCT03398668|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
2425419|NCT03398668|Sham Comparator|Sham Comparator: Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
2425422|NCT03398642|Experimental|French Lifestyle Redesign|16 older adults, 10 without and 6 with disabilities, participated to weekly 2-hour group sessions, including outings, and monthly 1-hour individual sessions led by a occupational therapist over 6-month period and promoting healthy lifestyle and involvement in meaningful activities.
2425423|NCT03398629||IUGR group|Estimated fetal weight below10th percentile for gestational age associated with Abnormal Doppler flow in the umbilical cord (umbilical artery pulsatility index (PI)>95th percentile).
2425424|NCT03398629||Structural anomaly group|Fetus/neonates/infants who are diagnosed as congenital malformations, deformations, disruptions, dysplasias by ultrasound.
2425425|NCT03398629||Chromosomal anomaly group|Fetus/neonates/infants diagnosed by genetic amniocentesis or chorionic villus sampling for increased risk for fetal aneuploidy or fluorescence in situ hybridization.
2425426|NCT03398603||Group 1|25 women with age of 18-25 years
2425427|NCT03398603||Group 2|25 women with age of 26-40 years
2425428|NCT03398590|Experimental|mHealth Intervention for Older Adults|"Pilot study to test the feasibility and acceptability of a self-regulation theory-based mHealth behavior intervention for overweight or obese older adults with T2DM.~This is a one Group Pretest-Posttest Designed study. Ten participants will be recruited from Joslin Diabetes Center, Boston, MA. They will receive a 2-month, self-regulation theory-based weight loss intervention (five 60-minute, biweekly group sessions) and will be provided with a technology toolkit for self-monitoring including an (1) iPhone Plus, (2) the Lose It! app for self-monitoring of dietary intake, (3) Fitbit for self-monitoring of physical activity, (4) Bluetooth-enabled scale for daily weight, and (5) Bluetooth-enabled blood glucose monitor for testing blood glucose levels."
2425429|NCT03398577|Experimental|Intervention group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Intervention group will receive Dapagliflozin 10 mg in addition to oral anti-diabetic medication administered prior to study enrollment.
2425430|NCT03398577|Placebo Comparator|Control group|Eligible patients (HbA1C ≥ 7% and ≤ 9%) , who were allocated to the Control group will receive placebo in addition to oral anti-diabetic medication administered prior to study enrollment.
2425431|NCT03398564|Placebo Comparator|Group I (Control)|ultrasound guided Bilateral Erector Spinae Plan Block using isotonic saline
2425432|NCT03398564|Active Comparator|Group II (ESP)|ultrasound guided Bilateral Erector Spinae Plan Block with bupivacaine 0.25%
2425433|NCT03398564|Active Comparator|Group III(OSTAP)|Ultrasound-guided bilateral oblique subcostal TAP block
2425434|NCT03398538|Experimental|Mirragen Wound Matrix Dressing|MIRRAGEN™ Advanced Wound Matrix is intended for the use in the management of wounds including diabetic ulcers. Wound matrix dressing to be used per manufacturer instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing
2425435|NCT03398538|Active Comparator|Fibracol Wound Dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
2425436|NCT03398525|Active Comparator|Usual care|After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.
2425437|NCT03398525|Experimental|Musical intervention|"After patient information, appropriate skin antisepsis according to local procedures, surgical hand antisepsis by the operator, use of sterile drapes, gowns and gloves, insertion of a central venous catheter after after local anesthesia with 2% lidocaine, using ultrasound guidance.~In addition, a U-shaped music program (MUSIC CARE, trade mark) will be delivered to the patient through headphones throughout the catheter insertion procedure beginning with the operator's hand washing and ending once the dressing is put on the catheter insertion site."
2425438|NCT03398512|Experimental|Experimental|HIPEC with Raltitrexed at the time of fist surgery and twice repeat within one week after the surgery, following 3 cycles of 3-week Oxaliplatin/Capecitabine chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
2425439|NCT03398499|Experimental|Magnetoledotherapy|Active ELF EMF Participants will receive active transcranial low frequency elec-tromagnetic field and magnetic induction (ELF EMF) and high energy LED light were used stimulation,Using the Viofor JPS device (Med & Live)
2425440|NCT03398486|Experimental|Kinesiotaping|Original kinesiotaping active tapes Duration: 2 times Application maintenance 5 days with a break for the weekend Muscle application on the masseter muscle area, using a tape (5 cm wide) dissected into 2 parts called tails, which included the treatment site without their tension.
2425441|NCT03398486|Experimental|inactivation of trigger points (TrP)|Duration: 10-20 minutes of surgery; 2 inactivation treatments Between the treatments 5 days break
2425442|NCT03398473|Experimental|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial (SDV)
2425443|NCT03398473|Experimental|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial (MDV)
2425444|NCT03398460|Other|Health Care Providers|Bellevue hospital Medical Intensive Care Unit; 30 Nurses and 50 physcians
2425445|NCT03398434|Experimental|MAA868 low dose regimen|patients receive dose monthly.
2425446|NCT03398434|Experimental|MAA868 middle dose regimen|patients receive dose monthly.
2425447|NCT03398434|Experimental|MAA868 high dose regimen|patients receive dose monthly.
2425448|NCT03398434|Active Comparator|Apixaban|Apixaban 5 mg b.i.d
2425450|NCT03398408|Experimental|Intervention|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Participants in the intervention group will then be provided with the Lumosity cognitive flexibility training module and complete daily training for a total of five weeks. 1-3 days after completion of their training, all patients will be invited to complete the computerized versions of the TMT A and B, Color Match, and NCPT tests again on their personal computers."
2425451|NCT03398408|No Intervention|Control|"Patients in both groups will complete paper-pencil TMT A and B and the CWMST, the computer-based TMT A and B and Color Match, and NCPT tests upon enrollment into the study.~Patients in the control group will complete all tests upon enrollment and approximately five weeks after their initial testing, but will not participate in training."
2425452|NCT03398395|Active Comparator|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
2425453|NCT03398395|Active Comparator|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
2425454|NCT03398382|Placebo Comparator|Magnesium citrate tablet group|In this group patients will take magnesium citrate tablets 3 days postoperatively, so 400 mg magnesium citrate tbl (Solgar) /per day will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.
2425455|NCT03398382|Placebo Comparator|Placebo tablet group|"In this group patients will take placebo tablets 3 days postoperatively, so 400 mg /per day placebo tbl will be taken at the same time that will correspond to the time the first tablets were taken, 2 hours preoperatively.~Placebo tablets will be identical to the right drug (Magnesium citrate tbl.Solgar)"
2425456|NCT03398382|Placebo Comparator|Magnesium citrate lozenge group|In this group patients will take 100 mg. magnesium citrate lozenge (Diasporal) 30 min. before the procedure and continue to take up to 4 lozenges per day over the next 3 days in the same time intervals as it was on the day of surgery.
2425457|NCT03398382|Placebo Comparator|Placebo lozenge group|"In this group patients will take 100 mg. placebo lozenge 30 min. before the procedure and continue to take up to 4 pastilles per day over the next 3 days in the same time intervals as it was on the day of surgery.~Placebo lozenges will be identical to the right drug (Magnesium citrate tbl.(Diasporal)"
2425458|NCT03398369|Experimental|Intervention|CMR-Guided CRT
2425459|NCT03398369|No Intervention|Control|Standard CRT
2425465|NCT03398317|Experimental|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection
2425466|NCT03398317|Active Comparator|MACS|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with annexin V microbeads followed by separation on MACS Column, the eluted fraction contains non apoptotic sperm suitable for Oocyte injection.
3146328|NCT00097604|Experimental|Valerian|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
3146329|NCT00097604|Placebo Comparator|Placebo|This study used a cross-over design with valerian compared to placebo. Group 1 received valerian first followed by placebo after washout and cross-over; group 2 received placebo first followed by placebo after wash-out and cross-over.
2425469|NCT03398291|Active Comparator|Standard treatment|Patients continue to receive standard chemotherapy.
2425470|NCT03398291|Experimental|Surgical exploration|Patients receive surgical exploration and synchronous resection of primary pancreatic cancer and liver oligometastasis will be performed.
2425475|NCT03398252|Experimental|Doxazosin XL|Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
2425476|NCT03398252|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
2425477|NCT03398239|Active Comparator|BPAP ST/T|Non-invasive Ventilation with BPAP ST/T mode
2425478|NCT03398239|Experimental|AVAPS|Non-invasive Ventilation with AVAPS mode
2425479|NCT03398226||Control group|
2425480|NCT03398226||Distal Gastrectomy (DG) group|38 patients planing distal gastrectomy due to gastric cancer
2425481|NCT03398226||Total Gastrectomy (TG) group|38 patients planing total gastrectomy due to gastric cancer
3146330|NCT00097656|Experimental|Periodontal Treatment|maternal periodontal therapy
3146331|NCT00097747|Placebo Comparator|Placebo|Single injection administered intravenously
3146332|NCT00097747|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
3146333|NCT00097747|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
3146334|NCT00097747|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
3146335|NCT00097760|Experimental|Group 1|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
3146336|NCT00097760|Placebo Comparator|Group 2|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
3146337|NCT00097838|Experimental|1 x 10^5 IU dose|Vaccine dose of 1 x 10^5 IU per injection
3146338|NCT00097838|Experimental|1 x 10^6 IU dose|Vaccine dose of 1 x 10^6 IU per injection
3146339|NCT00097838|Experimental|1 x 10^7 IU dose|Vaccine dose of 1 x 10^7 IU per injection
3146340|NCT00097838|Experimental|1 x 10^8 IU dose|Vaccine dose of 1 x 10^8 IU per injection
3146341|NCT00097838|Placebo Comparator|Placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
3146342|NCT00097903|Experimental|1|Karenitecin IV/ Karenitecin tablet
3146344|NCT00098111|Active Comparator|Azathioprine 0.5 mg/kg body weight|
3146345|NCT00098111|Active Comparator|Azathioprine 2.5 mg/kg body weight|
3146346|NCT00098111|Active Comparator|Azathioprine 3.5 mg/kg body weight|
3146347|NCT00098137|Experimental|Olmesartan|Olmesartan tablet, 1 in the morning
2425487|NCT03398174|Experimental|Motor Control Exercise Plus Patient Education|"Participants will receive a total of 12 sessions (2 sessions per week) of exercise program consisting of motor control training and group patient education session once a week (6 sessions) all over 6-weeks.~The motor control training will be aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~The patient education program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2425488|NCT03398174|Experimental|Motor Control Exercise|"Participants will receive the same motor control exercise program described in the patient education and motor control exercise group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2425489|NCT03398174|Experimental|Patient Education|"Participants will receive the same patient education program described in the motor control exercise plus patient education group.~In addition, participants will also perform stretching exercises and instructed to perform continuous overground walk."
2425490|NCT03398161|Experimental|Treatment (ultra low dose radiation therapy)|Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.
3146348|NCT00098137|Placebo Comparator|Placebo|Placebo tablets, 1 in the morning
3146349|NCT00098163|Experimental|1|
3146350|NCT00098163|Placebo Comparator|2|
3146351|NCT00098397|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146352|NCT00098423|Experimental|Treatment (chemotherapy)|"Patients receive induction therapy comprising cytarabine IV continuously on days 1-5 and tanespimycin IV over 1 hour on days 3 and 6.~Patients achieving a morphologic complete response with CRi or partial response may be eligible to receive a second induction course of therapy after day 21 at the discretion of the principal investigator. Patients achieving a CR receive up to 4 courses of consolidation therapy with cytarabine and tanespimycin. Consolidation therapy repeats approximately every 60 days in the absence of disease progression or unacceptable toxicity. Patients who achieve CR and remain in remission for â¥ 6 months may be retreated with cytarabine and tanespimycin (at the current dose level or the MTD) at the time of relapse. Cohorts of 3-6 patients receive escalating doses of tanespimycin until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months."
3146353|NCT00098488|Experimental|Treatment (17-AGG and rituximab)|Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15 and 18 (course 1). Patients achieving ≥ 25% reduction in measurable disease after course 1 receive an additional course of single-agent 17-AAG approximately 10 days later in the absence of disease progression or unacceptable toxicity and provided absolute lymphocyte count continues to decrease. Patients failing to achieve a 25% reduction in measurable disease after course 1 OR with disease progression after courses 1 or 2 of single-agent 17-AAG proceed to combination therapy comprising 17-AAG IV over 2 hours on days 1, 4, 8, 11, 15, 18, and 22; and rituximab IV over 4 hours on days 1 and 2 and over 1 hour on days 4, 8, 15, and 22 in the absence of disease progression or unacceptable toxicity.
3146354|NCT00098501|Experimental|Arm I|Patients receive oral EKB-569 on days 1-28 and oral CCI-779 on days 1-7 and 15-21.
3146355|NCT00098514|Experimental|Dose Level 1a|10 mg/m2 dose of PT523 administered day 1 of a 28-day cycle as a 5 minute IV infusion (IV bolus)
3146356|NCT00098514|Experimental|Dose Level 1b|5 mg/m2 dose of PT523 administered days 1 and 8 of a 28-day cycle as a 5 minute IV infusion
3146357|NCT00098514|Experimental|Dose Level 1c|3.33 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3146358|NCT00098514|Experimental|Dose Level 2|5 mg/m2 dose of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3146359|NCT00098514|Experimental|Dose Level 3|7.5 mg/m2 dose (or 6.7 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3146360|NCT00098514|Experimental|Dose Level 4|11.25 mg/m2 dose (or 9 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
3146361|NCT00098514|Experimental|Dose Level 5|17 mg/m2 dose (or 12 mg/m2 depending on observed toxicity) of PT523 administered days 1, 8 and 15 of a 28-day cycle as a 5 minute IV infusion
2425506|NCT03398135|Placebo Comparator|Substudy 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by subcutaneous (SC) injection.
2425507|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
2425508|NCT03398135|Experimental|Substudy 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection.
2425509|NCT03398135|Experimental|Substudy 2: Open-label (OL) Clinical Assessment Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
2425510|NCT03398135|Experimental|Substudy 2: OL Therapeutic Drug Monitoring Risankizumab|Participants randomized to receive risankizumab dose 1 administered by subcutaneous (SC) injection.
2425511|NCT03398135|Experimental|Substudy 3: OL Extension Risankizumab|Participants who completed Sub-study 1 or 2 receive open-label risankizumab in Sub-study 3.
2425512|NCT03398122|Experimental|Apatinib combined with TACE|patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
2425513|NCT03398122|Placebo Comparator|chemoemtranscatherer arterial bolization|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
2425514|NCT03398109|Experimental|Customized toric IOL|Customized toric IOL for post-Dalk atigmatism in cataract patients
2425515|NCT03398096|Experimental|Cardiac shock wave therapy (CSWT) group|The CWST group were performed with a CSWT equipment (Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan with respect to the shockwave output and the number of shots implemented to each spot and the protocol developed by the University of Essen, Germany.
2425516|NCT03398096|No Intervention|Control group|No CWST treatment.
2425517|NCT03398083|Active Comparator|CBD (500 mg)|CBD (500 mg) capsule by mouth one time during the 18 day treatment period
2425518|NCT03398083|Active Comparator|CBD (1000 mg)|CBD (1000 mg) capsule by mouth one time during the 18 day treatment period
2425519|NCT03398083|Active Comparator|THC (2.5 mg)|THC 2.5 mg capsule by mouth one time during the 18 day treatment period
2425520|NCT03398083|Active Comparator|THC (30 mg)|THC 30 mg capsule by mouth one time during the 18 day treatment period
2425521|NCT03398083|Active Comparator|Alprazolam|Alpraxolam 1.5 mg capsule by mouth one time during the 18 day treatment period
2425522|NCT03398083|Placebo Comparator|Placebo Oral Capsule|Placebo capsule by mouth one time during the 18 day treatment period
2425523|NCT03398070||Motor Functional Neurological Disorder.|"The cohort will consist of patients with clinically established motor functional neurological disorder, which includes individuals with functional movement disorders, psychogenic nonepileptic seizures and functional limb weakness.~Patients will be receiving the standard of care within the Massachusetts General Hospital (MGH) Functional Neurological Disorders Clinic.~The updated standard of care that patient's receive in the MGH Functional Neurological Disorders Clinic includes the following:~Delivery of a positive rule-in diagnosis of functional neurological disorder~Individuals are provided with educational materials on functional neurological disorders~Referred to physical therapy and/or occupational therapy as clinically indicated~FND related cognitive behavioral therapy (CBT) referral when appropriate~Psychotropic medication management based on standard psychiatric care"
2425524|NCT03398057|Experimental|Health education group(intervention group)|Standardized heath education Program(SHEP) applied to this group participants .
2425525|NCT03398057|Placebo Comparator|Control group|Placebo health education.
2425526|NCT03398044|Experimental|Dexamethasone|Patients randomised into the Dexamethasone arm will be administered active studied drug during anaesthesia induction.
2425527|NCT03398044|Placebo Comparator|Placebo|Patients randomised into the control Placeboarm will be administered placebo during anaesthesia induction.
2425528|NCT03398031|Active Comparator|Magnesium supplement|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive 500 mg magnesium supplement
2425529|NCT03398031|Placebo Comparator|placebo|90 female pregnant after ICSI after biochemical diagnosis of pregnancy will receive placebo oral tablet
2425530|NCT03398018|Experimental|Treatment|Treated with repository corticotropin injection
2425531|NCT03398005|Experimental|CaPre|
2425532|NCT03398005|Placebo Comparator|Placebo|
2425533|NCT03397992|Active Comparator|Group A|Treatment with high dialysate temperature first followed by low dialysate temperature and alternating thereafter.
2425534|NCT03397992|Active Comparator|Group B|Treatment with low dialysate temperature first followed by high dialysate temperature and alternating thereafter
2425535|NCT03397979|Active Comparator|Infrequent soaking baths|Infrequent soaking baths, in this study, is defined as twice a week soaking baths for 10 minutes or less, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined above, and 2) Frequent soaking baths (defined as twice daily soaking baths for 15-20 minutes, over 2 weeks). All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
2425536|NCT03397979|Active Comparator|Frequent soaking baths|Frequent soaking baths, in this study, is defined as twice daily soaking baths for 15-20 minutes, over 2 weeks. However, this is a crossover study design with two interventions: 1) Infrequent soaking baths, as defined in the first arm description above, and 2) Frequent soaking baths, as defined above in this arm description. All subjects in the study will undergo both interventions, but in different order. Thus, this is a study comparing Infrequent Versus Frequent Soaking Baths. Each subject serves as their own control.
2425537|NCT03397966|Experimental|BNP infusion|Subjects will receive an IV infusion of recombinant human b-type natriuretic peptide (BNP (1-32)) for 240 minutes.
2425538|NCT03397966|Placebo Comparator|saline infusion (control)|Subjects will receive an IV infusion of normal saline for 240 minutes. The volume of saline delivered will be equivalent to the volume of saline that the subject receives during the BNP infusion visit.
2425539|NCT03397953|Experimental|Vinorelbine monotherapy treatment|Patients will be treated by Vinorelbine. Four weeks as a course. There are 20 courses in total.
2425540|NCT03397940||Year Round School|Children attending year round school
2425541|NCT03397940||Traditional School|Children attending a traditional school with a traditional calendar school year
2425542|NCT03397927|Experimental|orthosis|
2425543|NCT03397914|Experimental|Group A Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 2.5 mg/kg of colistimethate sodium intravenous as loading dose followed by 1.25 mg/kg every 12 hours as maintenance dose
2425544|NCT03397914|Experimental|Group B Regimen|Randomized 30 pediatric subjects suffering from febrile neutropenia with proven or suspected gram negative infection will receive 5 mg/kg of colistimethate sodium intravenous as loading dose followed by 2.5 mg/kg every 12 hours as maintenance dose
2425545|NCT03397901|Experimental|transverse colostomy|Diverting transverse colostomy were conducted under general or epidural anesthesia in the operating room. The transverse colon was pulled out through one 2*2cm incision. The omentum was dissected from transverse colon, and a double-cavity stoma of transverse colon was then created.
2425546|NCT03397888|Experimental|Cohort 1|Mild Impairment, Child-Pugh Category A
2425547|NCT03397888|Experimental|Cohort 2|Moderate Impairment, Child-Pugh Category B
2425548|NCT03397888|Experimental|Cohort 3|Essentially Healthy man or woman without liver disease matched to Cohorts 1 & 2 for age, sex and weight.
2425549|NCT03397875|Active Comparator|Zinc oxide based sealer|After root canal treatment obturation with gutta percha will be done using zinc oxide based sealer.
2425550|NCT03397875|Experimental|Epoxy resin based sealer|After root canal treatment obturation with gutta percha will be done using epoxy resin based sealer.
2425551|NCT03397875|Experimental|Bioactive silicone based sealer|After root canal treatment obturation with gutta percha will be done using bioactive silicone based sealer.
2425552|NCT03397862|Experimental|Corplex Donepezil TDS 5 mg/day|Subjects will receive Corplex Donepezil TDS 5 mg/day during Induction, Challenge, and Re-Challenge phase.
2425553|NCT03397862|Placebo Comparator|Vehicle TDS|Subjects will receive Vehicle TDS during Induction, Challenge, and Re-Challenge phase.
2425554|NCT03397849|Active Comparator|intervention using mobile technology (IMT) plus usual care|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan).
2425555|NCT03397849|No Intervention|Only usual care|Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
2425556|NCT03397836|Experimental|Health TAPESTRY Intervention|This patient group will begin receiving the TAPESTRY interventions from time zero
2425557|NCT03397836|Active Comparator|Usual Care|This patient group will receive the intervention after a 6 month waiting period. In the first 6 months they will receive usual care and they will be used as a comparison group.
2425558|NCT03397823||head and neck cancer pre RT|head and neck cancer patients before and after RT
2425559|NCT03397823||head and neck cancer treated|head and neck cancer patients treated with radiotherapy
2425560|NCT03397823||control group|age gender matched subjects
2425561|NCT03397810|Experimental|Singe arm|Subjects will receive a low dose radiotherapy focused to the heart
2425562|NCT03397797||Group with muscle relaxant|Rocuronium is used during the operation to maintain moderate relaxation.
2425563|NCT03397797||Group without muscle relaxant|Rocuronium is not used during the operation for the eletrophysiological monitoring.
2425564|NCT03397784||fluid responders|Patients whose stroke volume index increase by ≥15% in response to a 500-ml fluid bolus was defined as fluid responders.
2425565|NCT03397784||fluid non-responders|Patients whose stroke volume index increase by <15% in response to a 500-ml fluid bolus was defined as fluid non-responders.
2425568|NCT03397758|Experimental|Study population|They were treated with AGNES micro-insulated needles with RF applicators in two separate sessions, at intervals of four weeks.
2425569|NCT03397745|Other|BIS group|Patients who received the esophageal surgery
2425570|NCT03397732||Aorto-bifemoral bypass|Patients scheduled for elective aorto-bifemoral bypass surgery by vascular surgeons and consented to participate in the study.
2425571|NCT03397732||Aorta stentgraft|Patients scheduled for elective aorta stentgraft implantation by vascular surgeons and consented to participate in the study.
3146362|NCT00098527|Experimental|Treatment (romidepsin)|Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146363|NCT00098540|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2425574|NCT03397706|Experimental|Phase 1b Dose Escalation|"VRx-3996 (cohort 1) and valganciclovir~VRx-3996 (cohort 2) and valganciclovir~VRx-3996 (cohort 3) and valganciclovir~VRx-3996 (cohort 4) and valganciclovir~VRx-3996 (cohort 5) and valganciclovir"
2425575|NCT03397706|Experimental|Phase 2 Dose Expansion|VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
2425576|NCT03397706|Experimental|PK Cohort|Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
2425577|NCT03397693||1|Women with unexplained infertiltiy with no treatment given
2425578|NCT03397693||2|Women with Poly Cystic Ovary Syndrome (PCOS) who are not being treated with drugs of ovulation induction.
2425579|NCT03397693||3|Control fertile women with no treatment given.
2425580|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for 7 days|Participant will received 7-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal.
2425581|NCT03397680|Active Comparator|Rabeprazole-levofloxacin based quadruple therapy for14 days|Pparticipant will received 14-day once daily dose regimen of 1-tablet 750-mg Levofloxacin after meal, 2-tablet 500-mg Clarithromycin MR after meal, 3-tablet 20-mg Rabeprazole before meal and 1-tablet 1,048-mg Gastro bismol after meal
2425582|NCT03397667|Other|Control|Primary Care
2425583|NCT03397667|Experimental|Intervention|Primary Care plus ABC ANSWERS intervention
2425584|NCT03397654|Experimental|TACE followed by pembrolizumab|Trans-arterial chemoembolization (TACE) using doxorubicin solution (60 mg dose) and gelatin sponge particles; followed, at least 30 or 45 days later, by pembrolizumab solution (200 mg dose) every 3 weeks for a maximum of 1 year
2425585|NCT03397641|Active Comparator|Active|x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion. Doses of HBI-3000 (Cohorts A to G) may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 µg.h/mL and Cmax of 20 µg/mL (based on the NOAEL) in both 14-day repeat-dose toxicology species rat and minipig) and the expected therapeutic dose.
2425586|NCT03397641|Placebo Comparator|Placebo|Matching placebo for x mg HBI-3000 as x mL of a 50 mg/mL solution for intravenous infusion.
2425587|NCT03397628|No Intervention|Control|
2425588|NCT03397628|Experimental|Intervention|
2425589|NCT03397615|Active Comparator|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
2425590|NCT03397615|No Intervention|Non betadine douches|subjects didnot received a vaginal preparation prior to caesarean delivery
2425596|NCT03397576|Experimental|ATHENA|Subjects in the experimental arm will participate in monthly group medication adherence counseling sessions within prison led by a nurse and peer educator. After prison release, subjects in the experimental group will participate in four home visits during which intervention staff (nurses and peer educators working in teams) will deliver individualized medication adherence counseling based on the Freirian educational model.
2425597|NCT03397576|No Intervention|Control|Subjects in the control group will receive standard care, which includes a referral for HIV care and ART if prescribed ART within prison.
2425598|NCT03397563|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)
2425599|NCT03397563|Sham Comparator|Sham-CPAP treatment|sham Continuous Positive Airway Pressure (sham-CPAP)
2425600|NCT03397537|Other|the postmenopausal|2.5 mg letrozole every day for six months
2425601|NCT03397537|Experimental|the premenopausal|2.5 mg letrozole daily along with a GnRH analogue for ovarian suppression, which was administered as an intramuscular injection of 3.75 mg triptorelin every 28 days for 6 months.
2425602|NCT03397524|Experimental|optima4BP|optima4BP will receive several types of data to personalize the participant's medication treatment. The data include: remotely measured blood pressure (BP), and information on current medication treatment as well as health updates posted in Epic Electronic Record.
2425603|NCT03397524|No Intervention|Standard of Care|The participants randomized to the Standard of Care will follow usual care, as currently followed at the University of California San Francisco.
2425604|NCT03397511|Experimental|Usual Care+Financial Incentive|Smoking cessation counseling couples with financial incentives
2425605|NCT03397498|Experimental|Computerized cognitive training|Received the Computerized cognitive training program, CogniFit™
2425606|NCT03397498|Active Comparator|Control-games|Received the Computerized games program
2425607|NCT03397485|Experimental|Growing Milk|"Experimental Fortified milk has energy from fatty acids, protein and carbohydrates. This milk has probiotics and essential micronutrients such as Zn, Fe, vitamins ( A, D, E, K, C and B complex), selenium and Copper among others.~Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend."
2425608|NCT03397485|Active Comparator|Fortified Milk|Fortified milk has no energy from fatty acids nor micronutrients such as vitamin B12, Selenium and Copper. This milk was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Bottles were used to facilitate measuring in milliliters and were weighted before and after preparing milk in a diet measuring scale. Mothers were given the amount of milk necessary to prepare 480 ml per day during the weekend.
2425609|NCT03397472|Experimental|treatment group|use the sleep pillow with the magnetic field modulation treatment
2425610|NCT03397472|Placebo Comparator|placebo group|use the sleep pillow without magnetic field modulation treatment
2425611|NCT03397446|Experimental|Lisdexamfetamine dimesylate|A central nervous system stimulant, specifically, a prodrug of dextro-amphetamine
2425612|NCT03397433|Experimental|Intervention|"In this arm, an Information Technology physician assist tool will be used to predict best available therapy for patients coming to the hospital with either pneumonia, cellulitis, intraabdominal infection, or complicated urinary tract infection.~Intervention: After review of the information technology recommendation by a board certified Infectious Disease physician, the recommendation will be discussed with the primary care physician and treatment implemented."
2425613|NCT03397433|No Intervention|Control|In the two control hospitals there will be no use of the information technology tool for implementation of initial treatment (No intervention). No notes will be placed in the electronic health record and no contact as a result of this research will be made with the medical care team.
2425614|NCT03397420|Experimental|FAM-CARE|"Two facility clusters (one hospital and one health center, with their filter clinics) will be randomized to initiate the FAM-CARE program (where all HIV-positive family members are seen together as a unit and receive care together) with viral load monitoring"
2425615|NCT03397420|Active Comparator|Control Standard of Care|"Two clusters (one hospital and one health center, with their filter clinics) will be control standard-of care (usual practice) sites. Standard HIV care and treatment services, (drug resupply, clinical assessments etc.), including viral load monitoring, will be provided to adults and children in separate adult and pediatric clinics, even though they many be from the same family."
2425617|NCT03397342|No Intervention|standard breath hold|"Breath-hold CT and 4D-CT without CPAP~Breath-hold MRI and 4D-MRI without CPAP a) T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
2425618|NCT03397342|Experimental|CPAP intervention|"Breath-hold CT without CPAP~4D-CT with and without CPAP~4D-MRI with CPAP~T1-weighted, T2-weighted, Dixon fat/water, and ultra-short TE images"
2425619|NCT03397329|Active Comparator|Sequence A|
2425620|NCT03397329|Active Comparator|Sequence B|
2425621|NCT03397316|No Intervention|Marginal bone loss without grafting.|immediate implant placement in upper esthetic zone.
2425622|NCT03397316|Active Comparator|marginal bone loss with xenograft.|xenograft placement (Geistlich Bio-Oss) in immediate implant placement in upper esthetic zone between the residual labial bone and implant surface.
2426859|NCT03388411||Non-obese children|5‰< BMI <85 ‰ for children between the ages of 7 and 12 years
2425623|NCT03397303|Experimental|patients with peripheral neuropathies|This project aims to understand how nerve mechanical properties are altered in patients with rare peripheral neuropathies . Stiffness of various peripheral nerves will be measured using ultrasound shear wave elastography. Patients will be compared with age-matched controls.
2425624|NCT03397303|Other|controls|
2425625|NCT03397290|Experimental|Ultrasound Imaging|A Single Ultrasound Imaging to diagnose of pneumothorax post transthoracic lung biopsy.
2425626|NCT03397277|Experimental|Screened positive intervention video|Safety behaviour promoting video
2425627|NCT03397277|Sham Comparator|Screened positive control video|Pregnant women who screen positive for IPV using the AAS who are randomized into viewing the control video
2425628|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 0.3 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 0.3 mg OPT-302 intravitreal injection (0.05 mL)
2425629|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 1.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 1.0 mg OPT-302 intravitreal injection (0.05 mL)
2425630|NCT03397264|Experimental|Ph 1b: 2.0 mg aflibercept with 2.0 mg OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by 2.0 mg OPT-302 intravitreal injection (0.05 mL)
2425631|NCT03397264|Experimental|Ph 2a: 2.0 mg aflibercept with highest tested or maximum tolerated dose OPT-302|2.0 mg aflibercept intravitreal injection (0.05 mL) followed highest tested or maximum tolerated dose from Phase 1b OPT-302 intravitreal injection (0.05 mL)
2425632|NCT03397264|Sham Comparator|Ph 2a: 2.0 mg aflibercept with sham|2.0 mg aflibercept intravitreal injection (0.05 mL) followed by sham intravitreal injection
2425633|NCT03397251|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
2425634|NCT03397238||Non-metastatic TC|
2425635|NCT03397238||Metastatic TC|
2425636|NCT03397238||MNG surgery|
2425637|NCT03397238||MNG RAI treatment|
2425638|NCT03397238||Healthy volunteers|
2425639|NCT03397225|Experimental|Intervention group|The lifestyle intervention, including educational sessions were given to the intervention group of diabetes patients. The educational sessions were scheduled every two weeks and a total of four sessions was provided to the intervention group, the session held in the lecture room at the polyclinic. Also, they were received two individual sessions including dietary and physical activity advice during the consultation session in the diabetic clinic at the beginning and at the end of the study.
2425640|NCT03397225|Active Comparator|Control group|Lifestyle intervention, including individual lifestyle consultation, including dietary and physical activity consultation at the beginning and the end of the study, two sessions. This is done after the screening of the participants in the diabetic clinic at the beginning and at the end of the study.
2425641|NCT03397225|No Intervention|Anonymous data|The patients, n = 60, were recruited randomly and anonymously from the same diabetes clinic, and the HbA1c data was taken from the anonymous patients at two points over the 12-month study duration.
2425642|NCT03397212|Experimental|NADA and Clonidine|NADA acupuncture and treatment with tbl Clonidine
2425643|NCT03397212|Sham Comparator|Sham acupuncture and Clonidine|Sham ear acupuncture and treatment with tbl Clonidine
2425644|NCT03397199|Experimental|Apatinib + S-1|Apatinib + S-1
2425645|NCT03397186|Other|Basic science (trabectedin, biopsy)|Patients undergo a biopsy at baseline and then receive trabectedin for up to 4 cycles. Beginning 1 week after completion of cycle 2 and prior to cycle 3, patients undergo a second biopsy. Patients who achieve clinical benefit (CR, PR, SD) after the first post-treatment scan and who continue trabectedin for 4 cycles undergo a third biopsy after cycle 4.
2425646|NCT03397173|Experimental|Azacitidine + Ascorbic acid|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, (allowing for weekends, and holidays) of each 28-day cycle. Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle.
2425647|NCT03397160|No Intervention|Usual care|Participants assigned to the control arm will receive usual care, including whatever information materials are provided to them by their urologist.
2425648|NCT03397160|Active Comparator|Decision Support Intervention (DSI)|"Participants assigned to the intervention will receive Decision Support Intervention in the form of a decision aid plus health coaching. The decision aid (delivered by internet and as a Portable Document Format (PDF) document) provides participants with a report on options and outcomes as described in the literature; along with more tailored risk information. The tailored risk information will include their estimated risk of harboring more aggressive prostate cancer based on their clinical/pathologic features (i.e., My Clinical Risk). The DSI was developed and piloted at UCSF according to the International Patient Decision Aid Standards (see http://ipdas.ohri.ca/) (IRS# 14-13332), and incorporates tailored risk models developed and validated."
2425649|NCT03397147|No Intervention|Usual Care|Usual Care
2425650|NCT03397147|Experimental|Sleep Coach Jr.|Parents randomized to the intervention condition will receive a binder with the treatment manual, and the intervention will be administered in person (first session) and via telephone (second session) on an individual basis. The first session will focus on parent education and developing a positive bedtime routines, and the second session will be used to address barriers specific to the individual child.
2425651|NCT03397134|Experimental|Roluperidone 64 mg|Roluperidone 64 mg for entire study
2425652|NCT03397134|Experimental|Roluperidone 32 mg|Roluperidone mg for entire study
2425653|NCT03397134|Placebo Comparator|Placebo-1|Placebo for 12 weeks followed by Roluperidone 64 mg during open-label extension
2425654|NCT03397134|Placebo Comparator|Placebo-2|Placebo for 12 weeks followed by Roluperidone 32 mg during open-label extension
3187198|NCT00753324|No Intervention|Control arm|A cohort of 160 women will be enrolled from the control clinics, from 28 weeks gestation onward. At these sites, the antenatal zidovudine will be offered, with provision of single-dose nevirapine for self-administration in labor. This practice is in accordance with the current standard of care recommended by the Zambian National Guidelines for PMTCT.
3146364|NCT00098553|Experimental|everolimus|"Patients receive oral everolimus once daily for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.~Patients are followed every 2 months until disease progression and then every 4 months for up to 5 years after registration."
2425659|NCT03397095|Experimental|CSWT+BMMSCs|Patients in CSWT+BMMSCs group will receive a 3-month cardiac shock wave therapy and then a total of 1 million/kg BMMSCs will be infused using the stop-flow technique through an over-the-wire balloon catheter positioned in a coronary artery or bypass graft supplying the targeting viable myocardium.
2425660|NCT03397095|Sham Comparator|CSWT+Sham operation|Placebo group will receive a 3-month CSWT and a sham procedure.
2425661|NCT03397082|Experimental|Lidocaine + Paracervical blockade|5 minutes previous to endouterine manual aspiration, 5mL of lidocaine gel was applied plus standard paracervical blockade.
2425662|NCT03397082|Placebo Comparator|Placebo + paracervical blockade|5 minutes previous to endouterine manual aspiration, standard paracervical blockade was applied plus placebo gel (KY).
2425663|NCT03397069|Placebo Comparator|Group C(control)|Peribulbar block without midazolam (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml)
2425664|NCT03397069|Experimental|Group M1|Peribulbar block with midazolam 50 µg (peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml)
2425665|NCT03397069|Experimental|Group M2|Peribulbar block with midazolam 100 µg(peribulbar block using a mixture of lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml
2425666|NCT03397056||The study population|"The target population corresponds to patients with a respiratory disease already included in a biomedical research protocol.~Intervention: Questionnaire"
2425667|NCT03397043|Experimental|Healthy females|All participants receive the intervention: Protein intake (dose). This consists of varying levels of dietary protein intakes, in the form of crystalline amino acids, ranging from 0.2-3.0 g/kg/d
2425668|NCT03397030|Experimental|Home-Based Exercise Program|Participants will complete a prescribed home-based exercise program and will follow up with research staff at the UT Health San Antonio School of Nursing.
2425669|NCT03397030|No Intervention|Waitlist-Control Group|Participants assigned to this group will be asked to maintain normal activity and visit the UT Health San Antonio School of Nursing for research appointments.
3187199|NCT00753350|Experimental|1|Sensate™ anti-Obesity device
3187200|NCT00753389||1|
2425672|NCT03396991||Study Group|In the study Group the investigators enrolled 26 patients scheduled for hallux valgus surgery and treated with a new analgesici approach. After sub-gluteal sciatic nerve block with short acting local anesthetic (mepivacaine 2%, 15 ml), each patient received an ultrasound-guided Posterior Tibial Nerve Block (PTNB) with levobupivacaine 0,5% (7-8 ml). The investigators measured: the intensity of pain at the baseline (before the surgery) and at 3, 6, 12 and 24 hours (h) using a Visual Analogue Scale (VAS); the consumption of oxycodone in the first 24 hours after surgical treatment and the motor recovery using modified Bromage score.
2425673|NCT03396991||Control group|The investigators compared the study group with a control group of 26 patients previously scheduled for the same surgery and treated with another post-operative analgesia technique more frequently used in our hospital: local infiltration (Local Infiltration Anesthesia, LIA) with levobupivacaine 0, 5% (15 ml) performed by the surgeon directly on the operative site.
2425674|NCT03396978|Experimental|GnRHag|Participants will undergo 6 months of gonadotropin releasing hormone agonist (GnRHag) therapy (intramuscular injection of leuprolide acetate 3.75 mg for depot suspension; Lupron; TAP Pharmaceutical Products, Inc.; Lake Forest, IL) to chronically suppress ovarian hormones. A single injection of leuprolide acetate produces an initial stimulation (for up to 3 wk) followed by a prolonged suppression of pituitary gonadotropins and ovarian hormones. Repeated monthly dosing suppresses ovarian hormone secretion.
2425675|NCT03396965|Experimental|Mini-c-arm|Fluoroscopically aided reductions
2425676|NCT03396965|No Intervention|Standard|
3187201|NCT00753402|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
2425678|NCT03396939|Experimental|Orthosis|The intervention will be performed individually and will run for 12 weeks both at the community rehabilitation unit (3 times a week for 3 weeks) and at home (9 weeks). The group will receive an orthotic device for use during the study-specific exercises.
2425679|NCT03396939|No Intervention|Control|The group will receive the same amount of a study-specific training program without the orthotic device.
2425680|NCT03396926|Experimental|Treatment (pembrolizumab, bevacizumab, capecitabine)|Patients receive pembrolizumab IV over 30 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3187202|NCT00753402|Active Comparator|B|IV Endotoxin plus IV epinephrine
3187203|NCT00753428||Baseline evaluation|Prior to the implementation of the pilot project of giving routine HAART as a method of PMTCT, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households for the first round.
2425683|NCT03396900|Active Comparator|RhBMP-2 Protein, Recombinant|15 subjects treated with corticotomy with rhBMP-2 (C+BMP)
2425684|NCT03396900|Experimental|Conventional Corticotomy|15 subjects treated with conventional corticotomy (C) as in the PAOO protocol
2425685|NCT03396887|Experimental|Smartphone Application Users|"The experimental group will receive the smartphone intervention along with treatment as usual for 3-months. The smartphone application (UControlDrink) includes twice daily text message recovery support, relapse prevention cognitive behavioural therapy, 12 sessions in total, drinking and recovery activity logs where participants detail their abstinence, drinking and recovery activity engagement on a daily basis. Craving intervention in the form of a calm button to deal with cravings and prevent relapse and gamification, a system of encouraging positive behaviour with the awarding of points to achieve various status levels, is used to increase adherence and compliance with treatment recommendations."
3187204|NCT00753428||Following implementation|Two years after full implementation of the pilot project of giving routine HAART for PMTCT across all sites, a minimum of 387 households with children under the age of two will be sampled within each community, for a total of 1,548 households. [Note: At time of implementation, we used the same sampling frame for each community. Because of the population increased observed in parts of Kafue, the final number of households significantly exceeded the minimum threshold.]
3187205|NCT00753441|Experimental|A|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
3187206|NCT00753441|Active Comparator|B|Endoscopic biliary stenting using metal stent (completed by duodenal stent, if necessary)
2425686|NCT03396887|Active Comparator|Control Group|The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
2425687|NCT03396874|Experimental|68Ga-PSMA|PET/CT imaging
2425688|NCT03396861|Experimental|Subconjunctival aflibercept|Subconjunctival aflibercept 2 milligrams (mg) /0.05 milliliters (mL) administered at baseline visit and possibly again at Month 1 visit depending on initial response.
2425689|NCT03396848|Experimental|SHAReClinic|All participants will have access to the online clinic
3187207|NCT00753467|Experimental|1|IFN-γ 1b monotherapy: 200 micro-grams daily for 30 days
2425691|NCT03396809|Experimental|Punctal Plugs|This arm of the study receives punctal plug intervention.
2425692|NCT03396796|Experimental|Vagus nerve-preserving group|Every patient of vagus nerve-preserving group will receive the modified vagus nerve-preserving laparoscopic azygoportal disconnection procedure.
2425693|NCT03396796|No Intervention|Conventional group|Every patient of conventional group will receive the conventional laparoscopic azygoportal disconnection procedure.
2425694|NCT03396783|Experimental|SPP|during the visit, nurse will make a blood test for biological and immunological analysis, electromyogram and walk test
2425695|NCT03396783|Other|Control|during the visit, nurse will make a blood test for biological and immunological analysis
3187208|NCT00753467|Experimental|2|IFN-γ 1b 200 micro-grams daily) combination therapy with Adefovir dipivoxil (10 mg daily) for 30 days
3187209|NCT00753467|Active Comparator|3|Adefovir dipivoxil monotherapy (10 mg QD) 30 days
2425698|NCT03396757|Active Comparator|Standard strategy|RRT will be initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours (identical to the delayed strategy in AKIKI).
2425699|NCT03396757|Experimental|Delayed strategy|RRT will be considered only if one potentially severe following situation occurs (noticeable hyperkalemia, or acidosis or pulmonary edema due to fluid overload resulting in severe hypoxemia which do not respond rapidly to medical treatment) or if serum urea concentration reaches 50 mmol/L.
2425700|NCT03396744|Active Comparator|Morning group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention
2425701|NCT03396744|Active Comparator|Mid-day group|Exposition at 8 a.m +/- 30 min, during 10 active weeks, and assessed 6 months after this intervention.
2425702|NCT03396731|No Intervention|Standard care alone (control)|Multilayer/multi component compression bandaging treatment
2425703|NCT03396731|Active Comparator|6 hours geko™ (no longer recruiting)|geko™ device 6 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
2425704|NCT03396731|Active Comparator|12 hours geko™|geko™ device 12 hours daily for 4 weeks treatment phase, to be used in conjunction with Standard of care.
2425705|NCT03396718|Experimental|Interventional Arm A - HPV(+)|De-escalation Radio(chemo)therapy - Level 1
2425706|NCT03396718|Experimental|Interventional Arm B - HPV(+)|De-escalation Radio(chemo)therapy - Level 2
2425707|NCT03396718|Active Comparator|Observational Arm A - HPV(-)|Standard Radio(chemo)therapy
2425708|NCT03396718|Active Comparator|Observational Arm B - HPV(+)|Standard Radio(chemo)therapy
2425709|NCT03396692|Active Comparator|Control Arm|Pain management use intravenous morphine patient-controlled analgesia (PCA)
2425710|NCT03396692|Experimental|Posterior exo-thoracic fascia block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of the posterior exo-thoracic fascia with Ropivacaine
2425711|NCT03396692|Experimental|Paravertebral block arm|Pain management use intravenous morphine patient-controlled analgesia (PCA) and a block of paravertebral space with Ropivacaine
2425712|NCT03396679||CASPAR criteria agreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in agreement compare to Ultrasound examination
2425713|NCT03396679||CASPAR criteria disagreement|PsA patients fulfilling CASPAR criteria in remission as determined by physician with patient and physician's global assessment of disease activity in disagreement compare to Ultrasound examination
2425716|NCT03396653|Active Comparator|Peer-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
2425717|NCT03396653|Active Comparator|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
2425718|NCT03396640|Experimental|Unicondylar Knee Arhtroplasty|Operation with insertion of a knee arthroplasty using a unicompartmental device (Oxford phase 3, mobile bearing, uncemented)
2425719|NCT03396640|Active Comparator|Total Knee Arthroplasty|Operation with insertion of a knee arthroplasty using a total condylar device (PCR, nexgen with resurfacing, cemented)
2425720|NCT03396627||muller muscle|muller muscle and conjunctiva excised during muller muscle conjunctival resection
3187210|NCT00753493|Experimental|1|This is a one arm pharmacokinetic and safety study.
2425722|NCT03396601|Experimental|NRX-100 infusion|Infusion of IV NRX-100 (ketamine)
2425723|NCT03396601|Experimental|Saline (placebo) infusion|Infusion of IV Saline
2425724|NCT03396588|Active Comparator|Clonidine|Babies randomized to clonidine will receive 1mcg/kg/dose (with a dosing interval of 3 or 4 hours).
2425725|NCT03396588|Active Comparator|Morphine|Babies randomized to morphine will receive 0.06 mg/kg/dose (with a dosing interval of 3 or 4 hours).
3146365|NCT00098579|Experimental|Treatment (chemotherapy)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and alvocidib IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients reaching a cumulative doxorubicin dose of 600 mg/m^2 or experiencing cardiotoxicity may receive alvocidib alone at the discretion of the investigator. Cohorts of 3-6 patients receive escalating doses of alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Ten additional patients receive treatment at the MTD. Patients are followed every 3 months for 1 year.
2425728|NCT03396562||SCT Conditions|"Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.~Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years."
2425729|NCT03396549|Experimental|real tDCS|20 min of 2 mA tDCS over the right and left dorsolateral prefrontal cortex
2425730|NCT03396549|Sham Comparator|new sham tDCS|20 min 2 mA tDCS over the left and right sensorimotor cortex
2425731|NCT03396536||Group 1|Group 1 will be implants with keratinized mucosa (KM).
2425732|NCT03396536||Group 2|Group 2 implants without keratinized mucosa (KM). Alveolar mucosa (AM) directly present around the implant.
2425733|NCT03396523|Experimental|Losartan group|
2425734|NCT03396523|Placebo Comparator|Placebo group|
2425735|NCT03396510|Experimental|IMPROVED intervention|Patients randomized to the IMPROVED intervention will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the study team will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the study team will not provide guidance about what actions to take in response to patients' symptoms.
2425736|NCT03396510|No Intervention|Usual Care|Usual Care per hospital standard will be administered. Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports.
2425737|NCT03396497|Experimental|LYC-55716 + pembrolizumab|Subjects will receive combination treatment until disease progression or unacceptable toxicity, or up to a maximum of 24 months.
2425738|NCT03396484|Experimental|Methyldopa|"Adults: methyldopa 500mg twice daily for one week and then increased to 500mg three times a day~Children: methyldopa dose based on weight twice daily for one week then increased to three times a day"
2425739|NCT03396484|Placebo Comparator|Placebo|Inactive agent to match active drug in appearance and dose frequency.
2425740|NCT03396471|Experimental|Single Arm Assignment|Pembrolizumab + External Beam Radiation Therapy
2425741|NCT03396458||Hepatitis B group|Hepatitis B serology and questionnaire
3146366|NCT00098605|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146367|NCT00098618|Experimental|Treatment (sorafenib tosylate and recombinant interferon alfa)|Patients receive oral sorafenib twice daily and interferon alfa subcutaneously three times a week for 8 weeks. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity
3146368|NCT00098631|Experimental|Treatment (lapatinib ditosylate)|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3187211|NCT00753532|Placebo Comparator|MRI(+ve),|121 volunteers in MRI(+ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 62 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 59 received placebo. They were followed up every 3 months for a period of 2 years for their blood biochemistry profile and MRI of the brain was conducted at baseline, 12 months and 24 months..
2425748|NCT03396419||Acute Isch. Stk pts treat. w/SPG stimul.|"Following implantation (according to the ImpACT-24B protocol), subjects will be transferred to the angio suite. A baseline brain digital subtraction angiography (DSA) will then be performed by a trained physician prior to initiation of SPG stimulation according to the ImpACT-24B protocol.~Following the first SPG stimulation cycle of 4 minutes, a post-stimulation DSA will be performed.~Based on the results of the post-stimulation DSA, the physician may perform an additional DSA following the second SPG stimulation cycle.~The subject will then be transferred to the stroke department and will continue treatment according the ImpACT-24B protocol."
2425749|NCT03396406|Experimental|PCRF group|received Pulsed radiofrequency (PRF) at 42°C for 8 minutes followed by CRF at 60°C for 270s
2425750|NCT03396406|Experimental|CRF group|received sole thermocoagulation at 70°C for 270 s
2425751|NCT03396393|Experimental|Dihydroartemisinin 40mg|Randomized 30 patients will be received Dihydroartemisinin tablets 40mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2425752|NCT03396393|Experimental|Dihydroartemisinin 80mg|Randomized 30 patients will be received Dihydroartemisinin tablets 80mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2425753|NCT03396393|Experimental|Dihydroartemisinin 120mg|Randomized 30 patients will be received Dihydroartemisinin tablets 120mg in oral continuously from Week 0 to Week 24 in addition to SOC.
2425754|NCT03396393|Placebo Comparator|placebo|Randomized 30 patients will be received placebo tablets in oral continuously from Week 0 to Week 24 in addition to SOC.
2425755|NCT03396380|Active Comparator|vitamin D|93 women who will receive clomiphene citrate for induction of ovulation with vitamin D and calcium supplement
2425756|NCT03396380|Placebo Comparator|placebo|93 women who will receive clomiphene citrate for induction of ovulation with placebo and calcium supplement
2425757|NCT03396367|Experimental|PARTNER Intervention|This intervention is a four-session intervention designed to increase PrEP uptake, increase PrEP adherence, and reduce drug use and HIV transmission risk behaviors of individuals in relationships.
2425758|NCT03396367|Active Comparator|Education Intervention|This intervention is a four-session intervention that discussed drug use and its effect on physiological social functioning.
2425759|NCT03396354|Experimental|Integrated robotic surgery|
2425760|NCT03396354|Active Comparator|Conventional laparoscopic surgery|
2425861|NCT03395626|Experimental|ID-JPL934|probiotics 20%, corn starch 80%
3187212|NCT00753532|Placebo Comparator|MRI(-ve)|120 volunteers in MRI(-ve) cohort were randomized into two groups to receive either 200mg palm vitamin E (tocotrienols) softgel capsules or a identical looking placebo twice daily. 63 volunteers received 200mg palm vitamin E (tocotrienols) and the remaining 57 received placebo. They were followed up every 3 months for a period of 1 year for their blood biochemistry profile and MRI of the brain was conducted at baseline and 12 months.
2425762|NCT03396328|Active Comparator|Conventional education|
2425763|NCT03396328|Experimental|Low salt dietary education by smartphone application|
2425764|NCT03396315|Active Comparator|alendronate|Subjects will receive oral alendronate
2425765|NCT03396315|Active Comparator|zoledronic acid|Subjects will receive zoledronic acid
2425766|NCT03396302|Experimental|Experimental|The experimental group will receive access to the web-based lifestyle intervention (exercise and nutritional education).
2425767|NCT03396302|No Intervention|Control|The control group will receive Hospital treatment as usual.
2425768|NCT03396289|Active Comparator|Control Group|Patients in this group will receive conventional physiotherapy programme including balance exercises, 3 times a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other 2 sessions will be performed at home.
2425769|NCT03396289|Experimental|Training Group|In addition to conventional physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be performed under the supervision of a physiotherapist, other sessions will be performed at home.
2425770|NCT03396276|Experimental|Suboxone induction into MAT in the ED|Suboxone induction into medication-assisted treatment (MAT) in the emergency department (ED)
2425771|NCT03396263|Experimental|Online personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
2425772|NCT03396263|Experimental|Face-to-face personalised advice|Face-to-face delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive nutritional advice face-to-face (in person or via video chat).
2425773|NCT03396263|Placebo Comparator|Control|Non-personalised advice Control group. Online (web-based) delivery of non- personalised dietary, weight and physical activity advice based on the UK general health guidelines. This arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non- personalised).
2425774|NCT03396250|Experimental|Test product + Reference product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK (Pharmacokinetic) blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
2425775|NCT03396250|Experimental|Reference product + Test product|Each treatment sequence consists of two treatment periods with each period consisting of 4 days starting with an overnight fast of at least 10 hours followed by a single dose of study drug administration the morning of Day 1, then a 72-hour PK blood sampling period. The two drug administrations are separated by a 7 calendar days washout phase.
2425776|NCT03396237||Group A|Case group contain cases of unexplained infertility women
2425777|NCT03396237||Group B|Control group contain fertile pregnant women
2425778|NCT03396224||Patients who received the Avenir® Cemented Hip Stem|Patients suffering from severe hip pain and disability requiring total hip arthroplasty and who meet the inclusion/exclusion criteria
2425779|NCT03396211|Experimental|Apatinib (also known as rivoceranib) with Nivolumab|Oral daily doses of apatinib (as its mesylate salt) with a fixed dose of nivolumab given intravenously every 2 weeks
2425780|NCT03396185|Experimental|Icotinib|Patients with EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
2425781|NCT03396172|Other|Control|The intervention is an hospitalization with usual care. The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
2425782|NCT03396172|Active Comparator|FreeDom|"FreeDom strategy (early discharge, automated weaning at home, telemedicine, telereadaptation):~-initial conventional hospitalization before discharge home, O2 flow rate automatically titrated by FreeO2 (based on a SpO2 target). The hospital discharge will be possible if the definite criteria are met.~After hospital discharge, patient will have home hospitalisation. Automated oxygen flow titration, patient education will be conducted for using the telemedicine system, for questionnaires and for the tele-rehabilitation program will be initiated for home hospitalization,"
2425783|NCT03396159|Experimental|mini fluid challenge|mini fluid will be given and stroke volume will be assessed before and after
2425784|NCT03396146|Experimental|Type1diabetes with exocrine pancreatic function insufficiency|12 ml total blood tubes volume Fecal sample
2425785|NCT03396146|Experimental|Type1diabetes without exocrine pancreatic function insuficienc|12 ml total blood tubes volume Fecal sample
2425786|NCT03396146|Active Comparator|Type 3c diabetes|12 ml total blood tubes volume Fecal sample
2425787|NCT03396133|Experimental|Snap group|individuals in this arm used Snap according to the instruction on time and screened at the symptomatic
2425788|NCT03396133|No Intervention|RC group|patients in the RC arm accepted normal methods
2425789|NCT03396107|Active Comparator|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
2425790|NCT03396107|Placebo Comparator|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
2425791|NCT03396094|Experimental|Intervention|High-flow nasal cannula oxygenation at 60L/min for pre-oxygenation and apnoeic oxygenation
2425792|NCT03396094|Active Comparator|Control|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
2425862|NCT03395626|Placebo Comparator|placebo|corn starch 100%
2425795|NCT03396068|Experimental|NRX-101|Subjects will be treated with oral NRX-101 (fixed dose combination of D-Cycloserine/lurasidone) that will be titrated to a combined dose of 950mg/66mg per day.
2425796|NCT03396068|Active Comparator|Lurasidone comparator|Subjects will be treated with oral lurasidone in a matched placebo capsule that will be titrated to a dose of 66 mg per day
2425797|NCT03396055|Experimental|Treatment group|Specific rehabilitation exercise
2425798|NCT03396055|No Intervention|Control|No intervention
2425799|NCT03396042||Group 1|5 Patient target, ages 3 to 5 yr, with visual acuity Light Perception (LP) to <=20/200
2425800|NCT03396042||Group 2|5 Patient target, ages 3 to 5 yr, with visual acuity >20/200 to <=20/50
2425801|NCT03396042||Group 3|5 Patient target, ages 6 to 11 yr, with visual acuity LP to <=20/200
2425802|NCT03396042||Group 4|5 Patient target, ages 6 to 11 yr, with visual acuity >20/200 to <=20/50
2425803|NCT03396042||Group 5|5 Patient target, ages 12 to 17 yr, with visual acuity LP to <=20/200
2425804|NCT03396042||Group 6|5 Patient target, ages 12 to 17 yr, with visual acuity >20/200 to <=20/50
2425805|NCT03396042||Group 7|5 Patient target, ages 18yr and older, with visual acuity LP to <=20/200
2425806|NCT03396042||Group 8|5 Patient target, ages 18yr and older, with visual acuity >20/200 to <=20/50
2425807|NCT03396029|Experimental|Individually tailored lifestyle feedback|Written, standardized individually tailored lifestyle feedback based on participants responses to a lifestyle questionnaire, and a leaflet on healthy lifestyle mailed to the participant.
2425808|NCT03396029|Experimental|Standard leaflet|A leaflet on healthy lifestyle mailed to the participant.
2425809|NCT03396029|No Intervention|Control|No contact with the participant.
2425810|NCT03396016||Factor V|liver transplant patients having Factor V levels measured during their first postoperative week.
2425811|NCT03396003|Experimental|GALILEI G6 Lens Professional|The GALILEI G6 Lens Professional will measure anterior segment geometry and axial intra-ocular distances of the eye.
2425812|NCT03396003|Active Comparator|Oculus Pentacam AXL|The Oculus Pentacam AXL will measure anterior segment geometry and axial intra-ocular distances of the eye.
3187213|NCT00753558|Placebo Comparator|2|Oral solution of 0.45% saline and oral solution of H2O & saccharine. Oral gel composed of mineral oil, gelatine powder, pectin, sodium carboxymethylcellulose, polyethylene
3187214|NCT00753558|Active Comparator|1|Oral solution and buccal gel of gentamicin and polymyxin E
2425815|NCT03395977|Placebo Comparator|Placebos PO and IV|PO : per os IV : intraveinously
2425816|NCT03395977|Experimental|Febuxostat PO and Placebo IV|240 mg a day for 3 days
2425817|NCT03395977|Experimental|Febuxostat PO And Rasburicase IV|Febuxostat : 240 mg a day for 3 days. Uricase : 3 mg once.
2425818|NCT03395977|Experimental|Placebo PO And Rasburicase IV|Placebo : for 3 days. Uricase : 3 mg once.
2425819|NCT03395964|Active Comparator|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo-GIA-II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
2425820|NCT03395964|Experimental|Hybrid Dyna-CT guided localization|Patients will be brought into the Hybrid OR, and placed in the lateral decubitus position. A C-arm CT scan of the pre-determined ﬁeld of view that included the nodule position will be acquired during an end-inspiratory hold maneuver using a 5 sec scan protocol with 0.36mGy/projection and 248 projections acquired over 200°. The radiologist reviewed the C-arm CT scan to localize the nodule and plan trajectories for percutaneous hook-wire placement using Syngo iGuide needle guidance software. The planned needle pathways will be integrated into the C-arm fluoroscopic imaging system, which provided laser crossbar and guidance markers on fluoroscopy images to direct the needle pathway for hook wire placement.
2425821|NCT03395938|Placebo Comparator|Current practice|"Intervention A depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation."
2425822|NCT03395938|Active Comparator|Proactive engagement|"Intervention B involves a series of proactive engagements in hope to spur patients into contacting their siblings and improve their receptiveness towards colorectal cancer screening."
2425823|NCT03395925|Experimental|Celon Pro Surge|Ablation of thyroid tissue
2425824|NCT03395912|Experimental|Intervention|Infiltration of the subcutaneous layer with local anesthetic and combined with adrenaline.
2425825|NCT03395912|No Intervention|control|Abdominal layers will be closed without Infiltration .
2425826|NCT03395899|Active Comparator|Atezolizumab alone|1200mg of Atezolizumab D1 C1
2425827|NCT03395899|Experimental|Atezolizumab + Cobimetinib|Atezolizumab (1200mg IV D1 C1) + Cobimetinib (60mg PO D1 - 21 of C1)
2425828|NCT03395899|Experimental|Atezolizumab + Ipatasertib|Atezolizumab (1200mg IV D1 C1)+ Ipatasertib (400mg OD D1 - 21 of C1)
2425829|NCT03395899|Experimental|Atezolizumab + Ipatasertib + Bevacizumab|Atezolizumab (1200mg IV D1 C1)+ Cobimetinib (60mg PO D1 - 21 of C1) + Bevacizumab (10mg/kg IV D1 C1)
3187215|NCT00753571|Active Comparator|1|1,CTG,po
3187216|NCT00753571|Placebo Comparator|2|
2425832|NCT03395873|Experimental|Single arm|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
2425833|NCT03395860|Experimental|group A|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
2425834|NCT03395860|Experimental|group B|low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
3187217|NCT00753597|Experimental|1|Receiving active treatment
3187218|NCT00753662|Active Comparator|1|15 patients in group 1 will be treated with 1Hz frequency
3187219|NCT00753662|Active Comparator|2|15 patients in group 2 will be treated with 1Hz frequency 10Hz
2425835|NCT03395847|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
2425836|NCT03395834|Experimental|O3 monitor|tissue oxygenation comparison of O3 & INVOS
2425837|NCT03395821|Active Comparator|Conventional training|Residents will receive the traditional training for laparoscopic surgery according to their residency program.
2425838|NCT03395821|Experimental|Virtual Reality+conventional training|Residents will receive 12 weeks of virtual training for laparoscopy and their traditional training for laparoscopic surgery according to their residency program.
3187220|NCT00753662|Sham Comparator|3|15 patients in group 3 will be treated with SHAM (1Hz/10Hz)
2425840|NCT03395795|Other|Single arm|Single arm trial, every patient enroll in this study will follow the same protocol with classic and NAVA mode non-invasive ventilation.
2425841|NCT03395782||Age group 40-49|30 patients will be stratified to this age group.
2425842|NCT03395782||Age group 50-59|30 patients will be stratified to this age group.
2425843|NCT03395782||Age group 60-69|30 patients will be stratified to this age group.
2425844|NCT03395782||Age group 70-79|30 patients will be stratified to this age group.
2425845|NCT03395756|Active Comparator|12-14 mm follicle size group|Once the participant's leading follicle reaches 12-14mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2425846|NCT03395756|Active Comparator|15-17 mm follicle size group|Once the participant's leading follicle reaches 15-17mm, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2425847|NCT03395756|Active Comparator|18 mm or greater follicle size group|Once the participant's leading follicle reaches 18mm or greater, she will receive an IM administration of 150 mg Depot-Medroxyprogesterone Acetate. Prior to administration, she will have blood drawn for baseline progesterone, estradiol, and LH levels. One hour after receiving the injection, she will have blood drawn for medroxyprogesterone acetate levels. The next day, she will undergo a transvaginal ultrasound to assess the leading follicle and will have blood drawn for progesterone, estradiol, LH, and medroxyprogesterone acetate levels. For the next 4 consecutive days, she will have daily transvaginal ultrasounds to assess for signs of follicular rupture, and blood draws for hormonal assays. After, she will return twice weekly for two weeks for blood draw for progesterone levels.
2425848|NCT03395730|Experimental|"• Group (A) Study Group 1:"|"In the labor room women in Group A (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate intraumbilical vein injection of Oxytocin (Syntocinon®) 20 units diluted in 20 ml of 0.9% saline solution"
2425849|NCT03395730|Experimental|"• Group (B) Study Group 2:"|"In the labor room women in Group B (n = 50):~Clamping and cutting the placental cord after delivery of the baby.~Immediate unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes."
2425850|NCT03395730|Active Comparator|"• Group (C) Control Group:"|"In the labor room women in Group C (n = 50):~Clamping and cutting the placental cord after 2 minutes of delivery of the baby.~Placenta will be delivered spontaneously after appearance of clinical signs of placental separation"
2425851|NCT03395717|Experimental|Exoskeleton-Assisted Gait Training|Patients conduct sessions of gait training, each lasting 60 minutes, using the powered wearable exoskeleton (Ekso) in addition to conventional therapy. Before the treatment's beginning, a PT checks the correct alignment of the subject's joints with Ekso and the areas of greater pressure between body's skin and device, to set a proper Ekso fit as to customize the padding as well. The best individualized exoskeleton settings should be verified to plan a tailored robotic treatment. During treatment, subjects are trained to interface with the Ekso, with optimal postural arrangement and weight shifting strategies. No strength is required from the patient; only an appropriate balance and weight shifts are necessary to achieve walking, since steps are triggered by the user's lateral weight shift.
2425852|NCT03395717|No Intervention|Traditional Over ground Gait Training|"The Control Group (CG) performs 60 minutes. lasting sessions of Traditional Over ground Gait Training with a senior PT. In the starting phase, the gait task facilitation is allowed by the Pt's assistance or by using aids, such as walkers, tripods etc.~Traditional Over ground Gait Trainings include:~Sit-to-Stand tasks~Exercises for upright position control (right/left load shift): these tasks will allow to include people who are unable to walk in the CG.~CG patients will not use any other robots or treadmill for gait training."
2425853|NCT03395704|Active Comparator|LJPC-401|LJPC-401 solution for subcutaneous injection only, 5mg/1 mL (5mg/mL) or 10mg/1mL (10mg/mL) single use vial
2425854|NCT03395704|Placebo Comparator|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
2425855|NCT03395691|Active Comparator|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach.
2425856|NCT03395691|Active Comparator|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
2425857|NCT03395678|Experimental|Microneedling|Participants in this arm will receive 5 treatments of microneedling.
2425858|NCT03395678|Active Comparator|Fractional non-ablative 1,540nm laser|Participants in this arm will receive 5 treatments of fractional non-ablative1,540nm laser.
3187221|NCT00753740|Experimental|12mg/m2/dose|12mg per meter squared per dose
2425863|NCT03395613|No Intervention|Standard management|Standard sterile gauze dressing on surgical groin wound.
2425864|NCT03395613|Experimental|NPWT management|Negative Pressure Wound Therapy dressing on surgical groin wound.
2425865|NCT03395600|Active Comparator|0.1%bupivacaine+10µg sufentanyl|Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
2425866|NCT03395600|Active Comparator|0.125%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
2425867|NCT03395600|Active Comparator|0.1%bupivacaine+5µg sufentanyl|Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
2425868|NCT03395587|Experimental|Experimental intervention|Fluorescence-guided surgery (day 0) Leukapheresis (wk4) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) vaccination with autologous, tumor lysate-loaded, mature dendritic cells (DC) (7x, 2 - 10 x 106 DC each, intradermal injection, weekly wk11-14, wk17, 21, 25)Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)
2425869|NCT03395587|Other|Control intervention|"Standard therapy:~Fluorescence-guided surgery (day 0) Fractionated radiotherapy (60 Gy: 2 Gy/d, 5/7 d, 6 wks; wk5 10) and concomitant TMZ chemotherapy (75 mg/m2/d; 6 wks; wk5-10) Adjuvant TMZ chemotherapy (150-200 mg/m2/d, 6x, days 1 5 of 28 d cycle: wk15, 19, 23, 27, 31, 35)"
2425870|NCT03395574|Experimental|terlipressin group|group will receive terlipressin infusion one mg in 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of 160 μg per hour (8 ml/h).
2425871|NCT03395574|Placebo Comparator|saline (control) group|group will receive normal saline infusion 50 ml normal saline will be given over 30 minute as loading dose then will be maintained as infusion of (8 ml/h).
2425872|NCT03395561|Active Comparator|green coffe|2 capsuls of green coffe
2425873|NCT03395561|Placebo Comparator|control|2 capsuls
2425874|NCT03395548|Active Comparator|Inflammatory bowel disease|"The aim is to recruit 20 persons suffering from Crohn's disease or ulcerative colitis with stable medication and stable control of the disease.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2425875|NCT03395548|Active Comparator|Irritable bowel syndrome|"The aim is to recruit 20 persons suffering from irritable bowel syndrome (IBS) fulfilling rome criteria.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2425876|NCT03395548|Active Comparator|Healthy|"The aim is to recruit 20 persons without known illnesses with a comparable age to the other two groups.~As in each group the intervention will be the colon lavage with macrogol in combination with the colonoscopy."
2425877|NCT03395535|Experimental|'Laser-1st'|"Initial Selective Laser Trabeculoplasty (SLT) [PROCEDURE] followed by conventional medical therapy (eye-drops) as required.~All participants in this arm start their treatment pathway with SLT. If this does not reach the predefined, patient-specific target IOP then repeat laser (once only) is given. If the IOP target is then not reached additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed."
2425878|NCT03395535|Active Comparator|Medicine-1st|"Conventional medical therapy [DRUG] without laser. All participants in this arm start their treatment pathway medical treatment. If the IOP target is then not reached, additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy with mitomycin C) as needed.~During this pathway of treatment all commercially available medical treatments (eye-drops) are permitted according to a pre-specified step-wise intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
2425879|NCT03395522|Experimental|Device|ITind device implant
2425880|NCT03395496|Experimental|Biodentine|Dental materials
2425881|NCT03395496|Experimental|ProRoot MTA|Dental Materials
2425882|NCT03395483||Elective, adult colorectal surgical patients|All patients will be monitored by the non-invasive Masimo Radical7 pulseoximeter (Masimo, Irvine, CA, USA) measuring PPI and the MoorVMS-LDF (Moor Instruments Ldt., Axminster, UK) measuring mesenteric tissue blood flow using doppler flowmetry. Patients will be subjected to a haemodynamic challenge using anti-trendelenburg position.
2425883|NCT03395470|Experimental|Group A1|Dose 1 or placebo
2425884|NCT03395470|Experimental|Group A2|Dose 2 or placebo
2425885|NCT03395470|Experimental|Group A3|Dose 3 or placebo
2425886|NCT03395470|Experimental|Group A4|Dose 4 or placebo
2425887|NCT03395470|Experimental|Group A5|Dose 5 or placebo
2425888|NCT03395470|Experimental|Group B|Dose + Rosuvastatin
2425889|NCT03395457|Active Comparator|Care as usual|This is the care provided by the neurologist for chronic migraine.
2425890|NCT03395457|Experimental|Care as usual plus manual therapy|Other
2425891|NCT03395444|Active Comparator|Study Group|Pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
2425892|NCT03395444|Sham Comparator|Control Group|Sham pulsed shortwave therapy device used as an adjunct therapy immediately on the completion of the operation
2425893|NCT03395431|Active Comparator|FAB group|Arm A - Finger prick autologous blood (FAB) plus conventional treatment The patients will use FAB alongside conventional therapy as recommended by their treating ophthalmologist. A fingertip of the hand will be wiped with an alcohol steret and self-pricked using a standard diabetic lancet. The drop of blood is produced as normal and applied to the lower fornix of the affected eye(s) with the lower lid pulled down slightly by the patient. The blood will be applied 4 times a day. A fresh finger should be used for each eye. FAB should be applied at least 15 minutes after any artificial tears and no other drops applied for at least half an hour afterwards
2425894|NCT03395431|No Intervention|Control group|Arm B - Conventional treatment only The patients will use conventional therapy (artificial tears, cyclosporin drops and punctal plugs/cautery) as recommended by their treating ophthalmologist
2425895|NCT03395405|Experimental|Nitazoxanide Arm|500 mg (one tablet) nitazoxanide by mouth twice daily with food for 56 consecutive doses. N=80
2425896|NCT03395405|Placebo Comparator|Placebo Arm|Placebo (one tablet) by mouth twice daily with food for 56 consecutive doses. N=80
2425897|NCT03395392|Experimental|NRX-101|Following study enrollment and randomization, subjects will receive twice daily NRX-101
2425898|NCT03395392|Active Comparator|Lurasidone|Following study enrollment, subjects will receive twice daily lurasidone
2425899|NCT03395379||Group 1|RFA without air dissection protection
2425900|NCT03395379||Group 2|RFA with air dissection protection
2425901|NCT03395366|Active Comparator|Group 1|Multifaceted Educational / Cognitive Behavioral Intervention
2425902|NCT03395366|No Intervention|Group 2|Standard of Care + Dialysis Education without the Cognitive Behavioral component
3146369|NCT00098826|Experimental|Treatment (ispinesib)|"Induction chemotherapy: Patients receive SB-715992 IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Consolidation chemotherapy: Patients achieving CR, PR, or SD after induction chemotherapy receive up to 4 additional courses of SB-715992 beyond CR, PR, or SD.~Cohorts of 3-6 patients receive SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 9 patients are treated at the MTD."
3146370|NCT00098891|Experimental|Treatment (entinostat, isotretinoin)|Patients receive oral MS-275 once on days 1, 8, and 15 and oral isotretinoin twice daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.
2425908|NCT03395301|Experimental|tubal occlusion|Fiber coils were inserted into the interstitial part of fallopian tubes, and IVF-ET was taken out in the following.
2425909|NCT03395288|Experimental|RCT treatment arm|Participants in this arm will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days.
2425910|NCT03395288|No Intervention|RCT control arm|Participants in this arm will not use any additional intervention.
2425911|NCT03395288|Experimental|Observational arm|Participants in this arm will either take a total of 1000 mg D-mannose in capsule form every 12 hours OR they will dissolve one (1) level teaspoon of the nutraceutical powder (D-mannose) in at least 200 ml of water one time a day, approximately every 24 hours. (200 ml of water = 6.7 fluid ounces). Duration of study drug is 90 days. Participants in this arm of the study have different home medications prior to study enrollment than participants in the RCT treatment arm.
2425912|NCT03395275|Experimental|Intrathecal Pump Therapy Participants|Patients eligible for intrathecal pump therapy will undergo quantitative sensory tests and surveys during various stages of the treatment process.
2425913|NCT03395262|Experimental|Active with caffeine|Novel formula with caffeine
2425914|NCT03395262|Active Comparator|Active without caffeine|Novel formula without caffeine
2425915|NCT03395262|Placebo Comparator|Placebo|Dextrose
2425916|NCT03395249|Experimental|SPR994, FI, F2, F3, F4 Oral Tablets|"SPR994 is active against multidrug-resistant Gram-negative and Gram-positive pathogens that cause serious and life-threatening infections, including extended spectrum beta-lactamase (ESBL) producers as well as strains resistant to levofloxacin and trimethoprim/sulfamethoxazole. SPR994 is administered in tablet form orally. Up to five different time released formulations of SPR994 will be studied in this protocol at 100 mg, 300 mg, 600 mg and 900 mg dosages.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered twice daily (BID) over a period of 14 days or forty doses administered three times daily (TID) over period of 14 days"
2425917|NCT03395249|Placebo Comparator|Placebo Oral Tablet|"Placebo tablets (100, 300, and 600 mg) are pressed from a single placebo blend consisting of the same inactive ingredients; the active pharmaceutical ingredient (API) is replaced by Mannitol 200SD.~SAD Cohorts: One dose (two for food effect cohort) MAD Cohorts: Twenty-seven (27) doses administered BID over a period of 14 days or forty doses administered TID over a period of 14 days"
2425918|NCT03395249|Other|Optional Orapenem Open-Label Control|"A single, optional, open-label, control cohort that may enroll, in which all 8 subjects receive Orapenem.~SAD Cohort: One dose under fasted conditions and one dose under fed conditions."
2425920|NCT03395223|Experimental|ProvayBlue (Methylene Blue) arm|"Methylene Blue 0.5% will be administered.~1 mg/kg will be administered intravenously over 5-30 minutes. If methemoglobin level remains above 30% or if clinical symptoms persist, give a repeat dose of up to 1 mg/kg one hour after the first dose."
2425921|NCT03395210|Experimental|PRN1008 Daily|"Part A approximately 60 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension.~Part B approximately 25 patients: Up to 24 weeks open-label treatment with PRN1008 400mg BID; safety and dose evaluation. Patients who respond to PRN1008 per protocol may enter a long-term extension"
2425926|NCT03395171|Experimental|Treatment: Cholecalciferol (Vitamin D3)|Athletes with Vitamin D levels lower than 30ng/mL will be treated with the supplement for eight weeks.
2425927|NCT03395171|No Intervention|Prospective Control Group|Athletes with Vitamin D levels higher than 30ng/mL were enrolled and compared but not treated.
2425928|NCT03395158||Prior alert criteria|Patients who activated full, limited or no alert criteria according to the prior alert criteria
2425929|NCT03395158||Present alert criteria|Patients who activated full, limited or no alert criteria according to the present alert criteria
2425930|NCT03395145|Experimental|Bio-Oss Collagen and Mucograft Seal|Bone volume Changes after socket preservation using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal
2425931|NCT03395145|No Intervention|Natural healing|Evaluation of Bone volume Changes after tooth extraction (natural healing)
2425932|NCT03395132|Experimental|Fucicort® Lipid cream|Fucicort® Lipid cream is a combination of the antibiotic fusidic acid (20 mg/g) and the corticosteroid betamethasone (1 mg/g (as 17-valerate)). Twice daily for two weeks.
2425933|NCT03395132|Active Comparator|Fucidin cream +betamethasone cream|The combination treatment with Fucidin® cream followed by betamethasone (Lianbang Beisong®) cream. Twice daily for two weeks.
2425934|NCT03395132|Placebo Comparator|Vehicle cream|The vehicle cream, also named as Fucicort® Lipid cream vehicle, is the identical cream of Fucicort Lipid cream but without the active ingredient. Twice daily for two weeks.
2425935|NCT03395119|Sham Comparator|No Supplements|The control group includes 20 healthy volunteers who will receive no supplements in the study. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2425936|NCT03395119|Experimental|Fish oil|Twenty healthy young adults will receive fish oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2425937|NCT03395119|Experimental|Olive oil|Twenty healthy young adults will receive olive oil supplements for 4 weeks. After 4 weeks, subjects will be exposed to clean air for 2 hours on the first day, then ozone for 2 hours on the second day
2425938|NCT03395106|Experimental|Parent source + intuitive story content|
2425939|NCT03395106|Experimental|Doctor source + intuitive story content|
2425940|NCT03395106|Experimental|Parent source + deliberative content|
2425941|NCT03395106|Experimental|Doctor source + deliberative content|
2425942|NCT03395093|Experimental|FB with fentanyl|In the Bispectral Index monitoring,our study will use midazolam, propofol and fentanyl in the conscious sedation of FB
2425943|NCT03395093|Active Comparator|FB without fentanyl|In the Bispectral Index monitoring, our study will use midazolam, propofol in the conscious sedation of FB
2425944|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EEC|300mg DKN-01 monotherapy in recurrent EEC
2425945|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EEC|300mg DKN-01+paclitaxel in recurrent EEC
2425946|NCT03395080|Experimental|DKN-01 monotherapy in recurrent EOC|300mg DKN-01 monotherapy in recurrent EOC
2425947|NCT03395080|Experimental|DKN-01+paclitaxel in recurrent EOC|300mg DKN-01+paclitaxel in recurrent EOC
2425948|NCT03395080|Experimental|DKN-01 monotherapy in carcinosarcoma|600mg DKN-01 monotherapy in carcinosarcoma
2425949|NCT03395080|Experimental|DKN-01 +paclitaxel in carcinosarcoma|600mg DKN-01 +paclitaxel in carcinosarcoma
2425950|NCT03395067|Active Comparator|Lifestyle counseling|
2425951|NCT03395067|No Intervention|Control group|
2425952|NCT03395054|Other|the stabilization group|the stabilization group performed cervical stabilization exercises in lying, sitting, standing and on a swisball 3times a week during 8 weeks.
2425953|NCT03395054|Other|the control group|the control group performed conventional exercises including neck isometric, isotonic and posture exercises 3 times a week during 8 weeks.
2425954|NCT03395041||ATD - SG 01|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event revealed the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
2425955|NCT03395041||ATD - SG 02|"Patients with acute coronary syndrome in whom dental examination performed in the first 7 days after the index event did not reveal the presence of periodontal disease.~They will undergo complex cardiac imaging tests to assess plaque vulnerability and severity of coronary artery disease."
2425956|NCT03395015||Full-face 3-D images|3-D images acquisition of CLP patients' faces at rest is set at different timepoints: 1 week preoperative, 1- and 6-months postoperative. Therefore, laypeople's assessment of the facial appearance of CLP patients is based on full facial views.
2425957|NCT03395015||Nasolabial 3-D images|The control group is composed of cropped 3-D images of CLP patients' faces at rest, which show isolated nasolabial regions of CLP patients. The judgement of these pictures warrants an assessment based solely on the nasolabial appearance.
2425958|NCT03395002|Experimental|Tiotropium/Salmeterol/Fluticasone|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Discair®
2425959|NCT03395002|Active Comparator|Tiotropium + Salmeterol/Fluticasone|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® + Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus®
2425960|NCT03394989|Experimental|Test|Fluticasone propionate/salmeterol 100/50 µg
2425961|NCT03394989|Active Comparator|Comparator|Fluticasone propionate/salmeterol 100/50 µg
2425962|NCT03394989|Other|Placebo|Test Placebo
2425963|NCT03394976||Study population|Participants will be enrolled passively at health centres. Passive enrolment will include patients referred to or presenting directly at the health facilities.
2425964|NCT03394950|Experimental|rtPA combined with Butyphthalide|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
2425965|NCT03394950|Active Comparator|rtPA compared with placebo|Intravenous treatment with placebo injection, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with placebo injection 2 times/day for 14 days, followed by oral placebo capsule (3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
2425966|NCT03394937|Experimental|Cohort 1 600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 600 µg ECI-006
2425967|NCT03394937|Experimental|Cohort 1 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 5 doses of 1800 µg ECI-006
2425968|NCT03394937|Experimental|Cohort 2 1800 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 1800 µg ECI-006
2425969|NCT03394937|Experimental|Cohort 2 3600 µg ECI-006|Patients with melanoma are planned to be dosed intranodal with up to 9 doses of 3600 µg ECI-006
3187222|NCT00753740|Experimental|15mg/m2/dose|15mg per meter squared per dose
3187223|NCT00753740|Placebo Comparator|Placebo|5% dextrose infusion (placebo)
3187224|NCT00753779|Experimental|1|colesevelam HCl Tablets and simvastatin tablets
2425973|NCT03394911|Experimental|Experimental Group|250mg p.o. of healthy adult male facial skin surface lipid liquid pheromone on fresh, new, just-purchased, un-chewed Wrigley's Rain #5 sugarless chewing gum vehicle. 15 pieces or divided as tolerated.
2426004|NCT03394664|Experimental|Very-Low Carbohydrate Diet|Feeding study. Dietary composition (approximately): 75% fat
2426005|NCT03394664|Experimental|High-Carbohydrate Low-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
2427264|NCT03385668|Experimental|Pirfenidone|All patients will receive Pirfenidone
3187225|NCT00753779|Placebo Comparator|2|simvastatin and Welchol placebo
2425974|NCT03394911|Placebo Comparator|Placebo Group|Placebo identical to Experimental dose with randomly assigned identification numbers on unopened, unsealed key. Placebo and Experimental doses kept together and undifferentiable without the key being opened. Key available for opening 24/7 w/pharmaceuticals tech onsite. Keep pheromone/placebo doses under a fume hood. Wear 3M Versaflo activated charcoal filter supplied air respirator or equivalent to access.
3187226|NCT00753792|Active Comparator|1|methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered
2425976|NCT03394872||Drainage group|Patients under mechanical ventilator support due to acute respiratory failure who had significant pleural effusion and drainage plan according to the intensive Care Unit (ICU) protocols decided by primary physician
2425977|NCT03394846|Experimental|Pilot Test of MI Prototype|We will pilot test a Movement Integration product prototype with 60 elementary classroom teachers.
2425978|NCT03394833|Experimental|Preoperative fluids|40 individuals receiving preoperative colloid fluid bolus at 6 ml/kg LBW, (Gelofusine™, Fresenius Kabi AB, Sweden) before anesthesia induction by TCI (n = 20) or RSI (n =20).
2425979|NCT03394833|No Intervention|No preoperative fluids|40 individuals anesthetized by TCI (n = 20) or RSI (n =20) without preoperative fluids.
2425980|NCT03394820|Active Comparator|dexamethasone 1 hour prior to block|The patient will receive dexamethasone through IV one hour prior to receiving their block. During the patient's block, 1 hour after and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
2425981|NCT03394820|Experimental|dexamethasone during the block|The patient will receive dexamethasone through IV at the same time the patient has the SCB done. One hour prior to the block, one hour after the block and 2 hours after the block the patient will receive infusions of normal saline to maintain the blind.
2425982|NCT03394820|Active Comparator|dexamethasone 1 hour after block|The patient will receive dexamethasone through IV one hour after the block has been administered. One hour prior to block, during the block and two hours after the block the patient will receive normal saline to maintain the blind.
2425983|NCT03394820|Active Comparator|dexamethasone 2 hours after block|The patient will receive dexamethasone 2 hours after the block has been administered. One hour prior to the block, during the block and one hour after the block the patient will receive normal saline to maintain the blind.
2425984|NCT03394807|Experimental|LaGRA|regional anaesthesia of the right upper quadrant by injection of levobupivacaine 0.25% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
2425985|NCT03394807|Placebo Comparator|Placebo|Sham regional anaesthesia of the right upper quadrant by injection of Saline 0.9% to the transversus abdominis plane and the rectus sheath under laparoscopic guidance immediately following specimen removal
2425986|NCT03394794|Active Comparator|Kegel exercises|Pelvic floor exercises designed in the 1950s' by Arnold Kegel.
2425987|NCT03394794|Experimental|biofeedback|Biofeeback therapy to improve neuromuscular coordination and strengthen sphincter contractility.
2425988|NCT03394794|Experimental|electrostimulation|Administration of electric current with a specific device (stimulator) and through a vaginal prove, in order to improve pelvic floor contractility.
2425989|NCT03394794|Experimental|transcutaneous neuromodulation|Stimulation of tibial nerve with a specific electric current through a stimulator and surface electrodes
2425990|NCT03394781|Experimental|DUR-928 10 mg|10 mg oral suspension
2425991|NCT03394781|Experimental|DUR-928 50 mg|50 mg oral suspension
3187227|NCT00753792|Experimental|2|methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered
3187228|NCT00753818|Experimental|1|
2425994|NCT03394755|Experimental|Thrombosomes|
2425995|NCT03394742|Experimental|Intervention group|Peer support group received, in addition to usual care, peer support via telephone 1-5 times according to their own preference. Peer support was started at the time between diagnosis and the beginning of treatments.
2425996|NCT03394742|No Intervention|Control group|The control group received usual care only. For ethical reasons, participants in the control group were not discouraged from seeking peer support by themselves if they felt a need for it.
2425997|NCT03394729|Experimental|Propolis tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with propolis and xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
2425998|NCT03394729|Active Comparator|Xilytol tablet to limit dental biofilm|Individuals will be instructed to consume the tablet with xilytol to control dental biofilm, twice a day (at 10am and 5pm) for 7 days, giving a 30 day interval between the test and the control tablet.
2425999|NCT03394716||Patient brain tumor treated with fractionated radiotherapy|
2426000|NCT03394690|Active Comparator|green coffe|green coffe 2 capsuls of green coffe
2426001|NCT03394690|Placebo Comparator|control|2 capsuls of placebo
2426002|NCT03394677|Experimental|RVT-501 0.5% ointment|Subjects will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
2426003|NCT03394677|Placebo Comparator|RVT-501 vehicle ointment|Subjects will receive RVT-501 vehicle ointment twice daily (BID) for 4 weeks.
3187229|NCT00753818|Experimental|2|
3187230|NCT00753818|Experimental|3|
3187231|NCT00753818|Other|4|Control
3187232|NCT00753831|Experimental|1|Aurosling
3187233|NCT00753857|Experimental|1|Participants received 2 ads for drugs to reduce cardiovascular risk with drug facts boxes second pages.
3187234|NCT00753857|Active Comparator|2|Participants receive the same 2 advertisements for drugs to reduce cardiovascular risk with the standard second page (i.e., brief summary)
3187235|NCT00753870|Experimental|A|Otherwise healthy smokers
3187236|NCT00753883|Active Comparator|1|simvastatin 20 mg/qd for 8 weeks, and then add on ezetrol 10mg (if ldl-c . 160mg/dl) for another 8 weeks.
3187237|NCT00753883|Active Comparator|2|ezetrol 10 mg/qd for 8 weeks, and then add on simvastatin 20 mg qd (if ldl-c . 160mg/dl) for another 8 weeks
3187238|NCT00753909|Experimental|1|Paclitaxel/Carboplatin/Bevacizumab
3187239|NCT00753961|Active Comparator|1|fermented dairy product
3187240|NCT00753961|Placebo Comparator|2|non fermented acidified dairy product.
3187241|NCT00753974||biological specimen|Biological specimen is taken from cardiovascular procedures that would have been discarded
2426006|NCT03394664|Experimental|High-Carbohydrate High-Sugar Diet|Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
2426007|NCT03394651||Oral medication group|Patients in this group will receive oral medications to treat lower urinary tract symptoms
2426008|NCT03394651||Surgical treatment group|Patients in this group receive minimal invasive transurethral prostate procedures.
2426009|NCT03394638|Active Comparator|Conventional group|"Treatment includes:~10 individual and 3 group consultations at the outpatient department by several disciplines in the first postoperative year.~Additional visits if necessary~No further access to the BePATIENT website"
2426010|NCT03394638|Experimental|Online group|"Treatment includes:~Added to conventional group: Continuation of access to the BePATIENT website with:~eLearning programs~Informative videos~Patient network~Video consulting"
2426011|NCT03394638|Experimental|Device group|"Added to Online group:Four wireless devices, which are~Weight Scale~Blood Pressure~Oximeter~Activity Tracker"
2426012|NCT03394625|Experimental|immediate implant placement using socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
2426013|NCT03394625|Active Comparator|immediate implant placement using xenograft material|placing xenograft material in gap between implant and buccal bone
2426014|NCT03394612|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
2426015|NCT03394599|Active Comparator|TheraTrainer Only|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer only for the duration of their participation at the Geriatric program. Their carers will also be recruited.
2426016|NCT03394599|Experimental|TheraTrainer + Motiview|The 30 clients (15 per site) will have the opportunity to engage in cycling on the TheraTrainer with the addition of Motiview (engaging videos to watching while cycling). Their carers will also be recruited.
2426017|NCT03394586||UC patients with golimumab|We will retrospectively analyze all ulcerative colitis patients from the Swiss IBD cohort study treated with golimumab.
2426018|NCT03394573||OCT guided treatment arm|OCT guided aflibercept injection
2426019|NCT03394573||VA guided treatment arm|VA guided aflibercept injection
2426020|NCT03394560|Experimental|high-frequency rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
2426021|NCT03394560|Sham Comparator|sham rTMS + BWSTT|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with the combination between body weight-support treadmill training combined and high-frequency rTMS in improving the sensory-motor function of adult patients with chronic incomplete thoracolumbar spinal cord injury. The sessions will be performed three times a week for a month.
2426022|NCT03394547|Active Comparator|Active Treatment|Treatment for 2 menstrual cycles using the pulsed shortwave therapy Allay® device (BioElectronics Corp, Frederick USA)
2426023|NCT03394547|Placebo Comparator|Placebo|Treatment for 2 menstrual cycles using a placebo device which is identical in appearance to the active device but does not emit any pulsed shortwave therapy.
2426024|NCT03394547|No Intervention|No treatment|No intervention is given and a menstrual diary is completed for 2 cycles.
2426025|NCT03394534|Experimental|CGA group|
2426026|NCT03394534|No Intervention|Treatment as Usual|
3187242|NCT00753987|Experimental|1|
3187243|NCT00754000||Cohort 1|All patients in study
2426029|NCT03394495|Experimental|BCE Combination group|"16-week BCE programme with exercise training.~Six 1-hour sessions of BCE programme and a weekly 45-60 minute centre-based exercise programme from week 4 to week 16."
2426030|NCT03394495|No Intervention|Exercise group|"16-week programme with health talks and exercise training.~Six 1-hour sessions of health talks and a weekly 45-60 minutes centre-based exercise programme from week 4 to week 16."
2426031|NCT03394495|No Intervention|Control group|Six sessions of centre-based health talks on the management of different health issues with the exception of fatigue.
2426032|NCT03394482|Experimental|Lu AF35700 5 mg clinical formulation|
2426033|NCT03394482|Experimental|Lu AF35700 5 mg commercial formulation|
2426034|NCT03394482|Experimental|Lu AF35700 10 mg clinical formulation|
2426035|NCT03394482|Experimental|Lu AF35700 10 mg commercial formulation|
2426036|NCT03394482|Experimental|Lu AF35700 20 mg clinical formulation|
2426037|NCT03394482|Experimental|Lu AF35700 20 mg commercial formulation|
2426038|NCT03394469|Other|cohort|Collection of clinical and paraclinical data (biological and anthropometric) for evaluation of sarcopenic obesity in obese patients.
3146371|NCT00099008|Experimental|Arm I|Genistein
3146372|NCT00099008|Placebo Comparator|Arm II|Placebo
2426041|NCT03394430|Placebo Comparator|Group A|
2426042|NCT03394430|Experimental|Group B|
2426043|NCT03394430|Experimental|Group C|
2426044|NCT03394417|No Intervention|standard clinical practice (control)|aqueous cream
2426045|NCT03394417|Active Comparator|StrataXRT (intervention)|silicon-based gel
2426046|NCT03394404|Experimental|ECG-I mapping and PVI|ECG-I mapping and PVI
3146373|NCT00099086|Experimental|Experimental Arm|
3146374|NCT00099125|Experimental|RT with chemotherapy + post-radiation chemotherapy|Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy
3146375|NCT00099177|Experimental|1|
2427265|NCT03385655|Experimental|WEE-1 inhibitor|
2427266|NCT03385655|Experimental|cMET inhibitor|
3146376|NCT00099177|Active Comparator|2|
3146377|NCT00099203|Experimental|1|
3146378|NCT00099203|Active Comparator|2|
3146379|NCT00099320|Experimental|Exenatide|After a 2-week placebo lead-in period, exenatide will be given in an esclating dose along with the subject's current therapy regimen
3146380|NCT00099320|Placebo Comparator|Placebo|After a 2-week placebo lead-in period, subjects will be given placebo (in equivalent amounts to exenatide) in addition to their current therapy regimen.
2426052|NCT03394352|Experimental|Activity on Board|Blinded CGM data will be collected prior to the Experimental Admission to determine the insulin bolus that will be determined by the activity on board calculator. Subjects will wear a continuous glucose monitor during the study admission.
2426053|NCT03394352|Placebo Comparator|Usual Diabetes Care|Subjects will use their usual diabetes care, including basal rate, correction factor and carbohydrate-insulin ratio. Subjects will determine their own insulin usage during the Control Admission. Subjects will wear a continuous glucose monitor during the study admission.
2426054|NCT03394326|Experimental|LOW-ED|In the LOW-ED condition each participant will consume at least 10 low-ED foods/day (ED ≤1.0 kcal/g) and no more than 2 high ED foods/day (ED ≥3.0 kcal/g). Foods with an ED >1.0 kcal/g and <3.0 kcal/g will be unlimited; however, lowering the overall ED of the diet will be encouraged.
2426055|NCT03394326|Active Comparator|STANDARD|In the STANDARD condition participants will consume the recommendations for calories, fruits, vegetables and whole grains based on age and sex corresponding with MyPlate. The daily caloric recommendations from MyPlate are for weight maintenance.
2426056|NCT03394287|Experimental|SHR-1210 +Apatinib daily dosing|SHR-1210 200mg(3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, daily dosing (d1-d14)
2426057|NCT03394287|Experimental|SHR-1210+Apatinib intermittent dosing|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) iv Q2W combination With Apatinib 250mg, po, intermittent dosing(Continuous administration for 7 days every 14 days, d1-d7)
2426058|NCT03394274||Transfusion|Patients (n:892) were enrolled who underwent elective major surgery between the 01/01/2016-31/12/2016, and over the age of 18 years. They separated subgroups as restrictive and liberal blood transfusion groups
2426059|NCT03394261|Experimental|Patient Decision Aid|Patients in this arm will receive Patient Decision Aid for Medication Assisted Treatment for opioid use disorder.
2426060|NCT03394261|No Intervention|Record-only control group|Treatment records of patients receiving treatment in the same clinic in the prior 3 months will be abstracted for comparison purposes.
2426061|NCT03394235|Experimental|Long-pulsed, 1064nm Nd-YAG laser|All participants will receive long-pulsed, 1064nm Nd-YAG laser treatments with three different parameters at the occipital area.
2426062|NCT03394222|Experimental|Budesonide inhalation group|This group of participants were to receive 2mg/4ml of preoperative budesonide inhalation (Khartoum Road NORTH RYDE NSW 2113 Australia. AstraZeneca Pty Ltd) for 10 to 15min.
2426063|NCT03394222|Placebo Comparator|Normal saline inhalation group|This group of participants were to receive4ml of preoperative normal saline inhalation for 10 to 15min.
2426064|NCT03394209|Experimental|Favipiravir+oseltamivir|Favipiravir+oseltamivir will be given twice daily for a 10-day period.
2426065|NCT03394196|Experimental|No HIV-2 resistance|
2426066|NCT03394196|Experimental|HIV-2 NRTI resistance only|
2426067|NCT03394196|Experimental|HIV-2 NRTI and PI resistance|
2426068|NCT03394183|Experimental|Peripheral Artery Disease Participants|Patients diagnosed with peripheral artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre.
2426069|NCT03394183|Active Comparator|Coronary Artery Disease Participants|Patients diagnosed with coronary artery disease will undergo a 6 month cardiac rehabilitation program that is standard of care at the Toronto Rehabilitation Institute Rumsey Centre. The responses to cardiac rehabilitation for participants with coronary artery disease will be compared to participants with peripheral artery disease.
2426070|NCT03394170||Osteoarthritis|Participants who are undergoing unicompartmental knee replacement will be considered OA status
2426071|NCT03394170||Non-Osteoarthritis|"Participants with an acute injury (occurring no more than 90 days prior to surgery) with no history of knee injury or surgery, will be considered Non-OA status"
2426072|NCT03394157|Other|Diabetes Mellitus Type 2 in Obese patients|obese patients had metabolic surgery for the treatment for DMT2 .Preoperative data , which including SASI bypass , MGB and Sleeve gastrectomy
2426073|NCT03394144|Experimental|C1:AZD9150, C2:AZD9150+Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open
2426074|NCT03394131|Experimental|Hyalase|injection and hydro-dissection of median nerve using hyaluronidase followed by 10 cc normal saline ultrasonic guided
2426075|NCT03394131|Placebo Comparator|Placebo|injection and hydro-dissection of median nerve hydro-dissection using 10 cc saline injection ultrasonic guided
2426076|NCT03394131|Active Comparator|Insilin|injection and hydro-dissection of median nerve hydro-dissection using 10 IU insuline followed by 10 cc normal saline ultrasonic guided
2426077|NCT03394118|Experimental|Group_TAGRISSO|Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period.
2426078|NCT03394105|Experimental|intrapleural docetaxel administration|Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
2426079|NCT03394092||STEMI|The study population consists of 50 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
2426080|NCT03394092||Control|50 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as control group.Quantitative changes of IgG glycosylation be measured only once on admission.
3187244|NCT00754026|Active Comparator|1|
3187245|NCT00754026|Active Comparator|2|
2426087|NCT03394040||1|The study seeks individuals of all ages experiencing diarrhea from the Washington Metropolitan area
2426088|NCT03394027|Experimental|Arm 1|Single arm divided in three cohorts, each cohort with a different type of metastatic disease: ER + breast cancer, triple negative breast cancer, and endometrial cancer
2426089|NCT03394014|Active Comparator|popliteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) once circumferentially around the sciatic nerve at the popliteal fossa using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA)
2426090|NCT03394014|Active Comparator|subgluteal sciatic nerve block|injecting 25 ml of bupivacaine 0.5 % (Sunnypivacaine, 20 ml vial contains Bupivacaine HCL Monohydrate 105.5 mg eq. to 100 mg Bupivacaine HCL, Sunny Pharmaceutical, Badr city- Cairo- Egypt) circumferentially around the sciatic nerve at the subgluteal region using ultrasound device (S-Nerve ultrasound system, Fujifilm Sonosite Inc., Bothell, WA).
2426091|NCT03394001|Active Comparator|Lidocaine Hydrochloride|Wound infiltration with Lidocaine
2426092|NCT03394001|Active Comparator|Ketorolac tromethamine|Wound infiltration with Ketorolac
2426093|NCT03393988|Active Comparator|Group F|Fentanyl infusion (0.5 µg/kg/hr)
2426094|NCT03393988|Active Comparator|Group (TAP-Dex)|"Ultrasound guided TAP block and Dexmedetomidine~Ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine~Dexmedetomidine infusion(200 µg in 2 ml diluted in 48 ml of saline)~Fentanyl infusion (0.5 µg/kg/hr)."
2426095|NCT03393975|Experimental|Prophylaxis Cohort I|Participants randomized to SOC arm in prophylactic treatment cohort will receive a single dose intravenous (IV) infusions of 40 international units per kilogram (IU/kg) BAX-930 ORT product followed by a PK dose of their current SoC at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive SOC for 6 months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) in period 2 for the next six months. After period 2, participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose of IV infusions of 40 IU/kg for another 6 months.
2426096|NCT03393975|Experimental|Prophylaxis Cohort II|Participants randomized to BAX-930 arm in prophylactic cohort will receive a PK dose of their current SoC product followed by a single dose IV infusions of 40 IU/kg BAX-930 ORT at 14 days later in PK I with a washout period of 14 days (+ or - 2 days). In period 1 participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT once Q2W for the next six months followed by SOC for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
2426097|NCT03393975|Experimental|On Demand Cohort I|Participants randomized to SOC arm in On-demand cohort will receive the investigator-recommended SOC and dosing regimen during the acute event. In period 1 participants will receive IV infusions of 40 IU/kg dose of BAX-930 ORT once every 2 weeks (Q2W) for 6 months followed by SOC in period 2 for the next six months. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 ORT followed by IV infusions of 40 IU/kg BAX-930 SIN in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
2426098|NCT03393975|Experimental|On Demand Cohort II|Participants randomized to BAX-930 arm in On-demand cohort will receive initial dose of IV infusions 40 IU/kg [+/- 4 IU/kg] BAX-930 ORT or BAX-930 SIN infusion then a subsequent dose IV infusions of 20 IU/kg [+/- 2 IU/kg] BAX-930 ORT or BAX-930 SIN infusion on Day 2 and an additional daily dose IV infusions of 15 IU/kg [+/- 1.5 IU/kg] BAX 930 until 2 days after the acute event is resolved. In period 1 participants will receive SOC for the next six months followed by IV infusions of 40 IU/kg dose of BAX-930 ORT once Q2W for 6 months in period 2. Thereafter participants will receive a single dose IV infusions of 40 IU/kg BAX-930 SIN followed by IV infusions of 40 IU/kg BAX-930 ORT in PK II with a washout period of 14 days (+ or - 2 days). All the participants in period 3 will receive BAX-930 SIN prophylactic dose IV infusions of 40 IU/kg for another 6 months.
2426099|NCT03393962|Experimental|OC-EIEs|Autologous ovarian cancer antigen-specific cytotoxic lymphocytes
2426100|NCT03393949|Experimental|Group M|Patients in Group M received methylprednisolone 1mg•kg-1
2426101|NCT03393949|Experimental|Group C|Patients in Group C received isotonic saline 1mg•kg-1
3146381|NCT00099333|Experimental|Exenatide|The subjects will discontinue their insulin and substitute it with exenatide. Subjects will remain on their existing oral diabetic therapy.
3146382|NCT00099333|Active Comparator|Insulin|The subjects will remain on their current insulin therapy. Subjects will also remain on their existing oral diabetic therapy.
2426104|NCT03393923|No Intervention|Control Group|Patient will undergo gait analysis
2426105|NCT03393923|Experimental|Experimental group|Patient will undergo gait analysis with use of anterior wedge
2426106|NCT03393910|No Intervention|Observational|Normal pelvic exam exposures: External exam followed by speculum exam, followed by bimanual exam
2426107|NCT03393910|Active Comparator|Experimental Pelvic Exam|Changing the order of the pelvic exam Intervention: External exam, bimanual exam,speculum exam
2426108|NCT03393897||Hemodynamic instability with hypotension|
2426109|NCT03393884|Experimental|NACT + GEN-1|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles. GEN-1 100 mg/m2 IP will be administered on Days 8 and 15 of the first NACT cycle and then on Days 1, 8, and 15 of the subsequent 21 day NACT cycles for a total of 17 treatments.
2426110|NCT03393884|Active Comparator|NACT Alone|The NACT regimen will be paclitaxel 175 mg/m2 IV over 3 hours followed by carboplatin AUC 6 IV over 1 hour on Day 1. This will be repeated every 3 weeks for 6 cycles.
2426111|NCT03393858|Experimental|Immunotherapy plus Hyperthermia|
2427267|NCT03385655|Experimental|novel non-steroidal androgen receptor (AR) antagonist|
3146383|NCT00099502|Experimental|Arm 1|
3146384|NCT00099502|Experimental|Arm 2|
3146385|NCT00099502|Active Comparator|Arm 3|
3146386|NCT00099515|Experimental|A|
3146387|NCT00099515|Experimental|B|
3146388|NCT00099580|Experimental|1|
3146389|NCT00099580|Placebo Comparator|2|
2426115|NCT03393819|Experimental|Duraprep Surgical Solution|Surgical site (hip) is prepared with Duraprep (iodine-alcohol) prior to surgery according to package instructions.
2426116|NCT03393819|Experimental|Chloraprep Surgical Solution|Surgical site (hip) is prepared with Chloraprep (chlorhexidine-alcohol) prior to surgery according to package instructions.
2426119|NCT03393767|Other|prospective 1- Arm|OCT-guided high frequency intravitreal ranibizumab 0.5mg
2426127|NCT03393728|Experimental|Intervention|72-hour propanolol before specific treatment of hyperthyroidism
2426128|NCT03393715|Experimental|Perindopril morning|10 mg of perindopril oral tablet once daily in the morning for 56 days
2426129|NCT03393715|Active Comparator|Perindopril evening|10 mg of perindopril oral tablet once daily in the evening for 56 days
2426130|NCT03393702|Experimental|Gabapentin|"Single dose preoperative gabapentin.~After surgery gabapentin 2 times per day for 3 days."
2426131|NCT03393702|Placebo Comparator|Placebo Control|"Single dose preoperative placebo control.~After surgery placebo 2 times per day for 3 days."
2426132|NCT03393689|Experimental|Angiogenesis PET/MR|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/MR
2426133|NCT03393650|Active Comparator|Exercise + Placebo group|50 subjects will receive a placebo supplementation with an exercise intervention (EX group)
2426134|NCT03393650|Active Comparator|Exercise + Protein group|50 subjects will receive a protein supplementation combined with an exercise intervention (PROTEX group)
2426135|NCT03393637|Experimental|M-O-M-S Intervention|M-O-M-S intervention is 10, 1 hour prenatal mentored support groups
2427268|NCT03385655|Experimental|CFI400945 PLK4 inhibitor|
3146390|NCT00099606|Experimental|A1|
3146391|NCT00099619|Experimental|exenatide/insulin glargine|Arm that first receives exenatide, then crosses over to insulin glargine
3146392|NCT00099619|Experimental|Insulin glargine/exenatide|Arm that first receives insulin glargine, then crosses over to exenatide
3146393|NCT00099658|Experimental|1|HIV-uninfected infants born to HIV-uninfected mothers
3146394|NCT00099658|Experimental|2|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the delayed therapy arm (Arm 1) of CIPRA SA-Project 2
3146395|NCT00099658|Experimental|3|HIV-infected infants in CDC Disease Category 1 who were randomly assigned to the first early therapy arm (Arm 2) of CIPRA SA-Project 2
3146396|NCT00099658|Experimental|4|HIV-infected infants in CDC Disease Category 2 or 3 who were randomly assigned to the second early therapy arm (Arm 3) of CIPRA SA-Project 2
3146397|NCT00099658|Experimental|5|HIV-uninfected infants born to HIV infected mothers
2426136|NCT03393637|No Intervention|Routine Prenatal Care|Routine prenatal care in accordance with the Department of Defense Pregnancy Guidelines
2426137|NCT03393624||Cases: patients with dark circles|Patients who believe they have periorbicular hyperchromia and have a confirmatory physical examination performed by a dermatologist.
2426138|NCT03393624||Controls: patients without dark circles|Patients who believe that they do not have periorbicular hyperchromia under their eyes and have physical examination that excludes dark circles carried out by a dermatologist.
2426139|NCT03393611|Experimental|CPX-351 Salvage Therapy and Transplant|Subjects will receive CPX-351 salvage chemotherapy on Day -21, -19, and -17 as a bridge to allogeneic stem cell transplantation using a Fludarabine/Melphalan/rATG conditioning regimen and a haplo-cord graft.
2426140|NCT03393598|Experimental|pre-expansion using Kiwi® VAC-6000M|Expansion will be performed using a complete vacuum delivery system called Kiwi® VAC-6000M with the PalmPumpTM (Clinical Innovations, South Murray, Utah, USA).
2426141|NCT03393598|Experimental|pre-heating using Hilotherm Calido®.|Pre-Heating will be preformed using a Hiloterm Calido® System.
2426142|NCT03393598|Experimental|pre-expansion-heating|Both preconditioning methods Hilotherm Calido® plus Kiwi® VAC-6000M- will be applied.
2426143|NCT03393598|No Intervention|Control|No preconditioning methods will be applied.
2426144|NCT03393572|Active Comparator|Group BM|bupivacaine 0.25% plus magnesium sulphate.
2426145|NCT03393572|Active Comparator|Group BN|bupivacaine 0.25% plus nalbuphine
2426146|NCT03393559|Experimental|Group L|leg elevation during the beach chair position
2426147|NCT03393559|No Intervention|Group C|Patients' leg will be straightened without any intervention.
2426148|NCT03393546|Experimental|Auricular Point Acupressure - Interventionist|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day). The treatment will be administered by the research team's trained acupressure interventionist.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
2426149|NCT03393546|Experimental|Auricular Point Acupressure - Caregiver Training|"Auricular Point Acupressure includes 4 weekly treatments (the tape and seeds will remain on ear points for 5 days. Participants will be instructed to remove both at the end of the 5th day).~If participants live more than 15 miles away from the research team's office, the caregiver will receive in-person training by the interventionist on how to administer the treatment to their patient for the 4 weeks of treatment.~If participants live within 15 miles of the research team's office, they will be placed in the Interventionist or Caregiver Training arm."
2426150|NCT03393533|Other|Group I|Extraction third molar with pre and postoperative evaluation of edema, pain and trismus
2426151|NCT03393533|Active Comparator|Group II|Extraction third molar with therapeutic bandage pre and postoperative evaluation of edema, pain and trismus
3146398|NCT00099736|Experimental|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids,|
3146399|NCT00099736|Experimental|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|
3146400|NCT00099736|Experimental|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|
2426155|NCT03393507|Experimental|apatinib combine with chemotherapy|
2426156|NCT03393507|Active Comparator|chemotherapy|
3146401|NCT00099788|Experimental|1|Ranolazine
3146402|NCT00099788|Placebo Comparator|2|Placebo
3146403|NCT00099853|Experimental|Vildagliptin 50 mg qd + pioglitazone 45 mg qd|Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
2426160|NCT03393481|Experimental|MAA868 dose 1|MAA868 dose 1, single administration, subcutaneous
2426161|NCT03393481|Experimental|MAA868 dose 2|MAA868 dose 2, single administration, subcutaneous
2426162|NCT03393481|Active Comparator|Enoxaparin|Enoxaparin 40mg, once daily (o.d.) for 10 days
3146404|NCT00099853|Experimental|Vildagliptin 50 mg bid + pioglitazone 45 mg qd|Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
3146405|NCT00099853|Placebo Comparator|Vildagliptin placebo + pioglitazone 45 mg qd|Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks
2426165|NCT03393442|Experimental|1. Gd-exposed subjects|Diagnostic Test: Brain MRI scan Female subjects at high risk for breast cancer that previously underwent more than 6 Gd-based contrast enhanced MRI exams of the breast.
2426166|NCT03393442|Active Comparator|2. Healthy subjects|Diagnostic Test: Brain MRI scan Age-matched female control subjects that never received Gd-based contrast agents.
2426167|NCT03393429|Active Comparator|DAVID assisted training|Group I: Training assisted by DAVID devices
2426168|NCT03393429|Placebo Comparator|training recommendation|"Group II: Training based on stay active recommendations"
2426169|NCT03393416|Experimental|MASCT-I or MASCT-I +PD1 antibody|"This study is divided into three stages:~The first, second stage is the stage of the dose climbing, and the third stage is the dose expansion stage. The first stage is MASCT-I, using 3+3 design. The second stage is divided into two groups: MASCT-I+PD1 antibody in low dose group and MASCT-I+PD1 antibody in high dose group, using 3+3 design. The third stage is the dose expansion stage , 10 patients in the low or high dose group were treated with the corresponding dose group."
2426170|NCT03393403|Experimental|Dexmedetomidine_iv group|Dexmedetomidine 0.5mcg/kg (diluted in normal saline) intravenously infusion for 30min
2426171|NCT03393403|Experimental|Dexmedetomidine_adj group|Dexmedetomidine 0.5mcg/kg (adding to local anesthetic) perineural single bolus for subcostal TAP block 0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min
2426172|NCT03393403|Active Comparator|Control group|0.9% sodium chloride 0.125ml/kg intravenously infusion for 30min No dexmedetomidine use
2426173|NCT03393390||Healthy Controls|Subjects in this group will be defined as healthy controls after meeting with a clinician and determining that they do not meet the diagnostic criteria for any externalizing disorders or other psychiatric disorders.
2426262|NCT03392766|Experimental|Single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and brochial blocker
3146406|NCT00099866|Experimental|Vildagliptin|
3146407|NCT00099866|Active Comparator|Metformin|
3146408|NCT00099944|Experimental|LAF237 50 mg qd + glimepiride 4 mg qd|LAF237 50 mg qd + glimepiride 4 mg qd
3146409|NCT00099944|Experimental|LAF237 50 mg bid + glimepiride 4 mg qd|LAF237 50 mg bid + glimepiride 4 mg qd
3146410|NCT00099944|Placebo Comparator|LAF237 placebo + glimepiride 4 mg qd|LAF237 placebo + glimepiride 4 mg qd
2426174|NCT03393390||Externalizing|Subjects in this group will be defined as externalizing if the clinician determines that they meet the diagnostic criteria for one or more externalizing disorders, such as ADHD, ODD, or CD.
2426175|NCT03393377|Experimental|intervention group|received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days
2426176|NCT03393377|Placebo Comparator|control group|received placebo for 30 days
2426177|NCT03393364|Experimental|Opioid arm|Patients receive opioid medication, oxycodone, after outpatient urologic surgery.
2426178|NCT03393364|Experimental|Non-opioid arm|Patients receive a non-opioid medication, ketorolac, after outpatient urologic surgery.
2426179|NCT03393351|Experimental|Shared decision-making program|
2426180|NCT03393351|Active Comparator|Usual care|
2426181|NCT03393338|Experimental|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
2426182|NCT03393338|No Intervention|Usual Medical Care|Usual medical care
2426183|NCT03393312|Experimental|Bifrontal tDCS|"20 minutes of 2 mA transcranial direct current stimulation (tDCS), with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively).~The stimulation will be applied before or during task performance, depending on the condition assignment."
2426184|NCT03393312|Sham Comparator|Sham tDCS|"Participants receive 20 minutes of sham tDCS, with the anode placed over the left dorsolateral prefrontal cortex and the cathode placed over the right dorsolateral prefrontal cortex (F3 and F4 according to the 10/20 international EEG system, respectively). In sham tDCS, stimulation starts with 8s fade in followed by 30s direct current followed by 5s fade out followed by 870s without any stimulation.~The stimulation will be applied before or during task performance, depending on the condition assignment."
2426185|NCT03393299|Experimental|STOPP/START|Use of STOPP/START criteria during medication reconciliation
2426186|NCT03393299|No Intervention|CONTROL|Medication reconciliation done as usual, without the consideration of the STOPP/START criteria
2426187|NCT03393273|Experimental|Elotuzumab|This is a single arm phase II trial to assess the Very Good Partial Response rate of a strategy involving autologous hematopoietic stem cell transplantation, after intensive treatment and followed by consolidation phase, with elotuzumab, dexamethasone, velcade, and thalidomide in elderly patients.
2426188|NCT03393247|Active Comparator|infliximab and azathioprine at week 0|infliximab and azathioprine combination at week 0
2426189|NCT03393247|Active Comparator|infliximab and azathioprine at week 14|infliximab and azathioprine combination at week 14
2426190|NCT03393234|Experimental|A group|Patients who receive interphincteric resection (ISR) in this group will be given extra intraoperative radiation by INTRBEAM using low energy X-ray.
2426191|NCT03393234|No Intervention|B group|Patients who only receive interphincteric resection (ISR) in this group without intraoperative radiation.
2426192|NCT03393221|Experimental|SBWC+ER|Participants randomized to the Standard Behavioral Weight Control and Emotional Regulation (SBWC+ER) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. They receive the same information as the Standard Behavioral Weight Control group, but weekly sessions also include elements of TRAC, and it is designed to help teach emotion regulation skills to decrease overeating and sedentary behaviors and increase the likelihood of maintaining diet and exercise behaviors that are taught as part of SBWC interventions.
2426193|NCT03393221|Active Comparator|SBWC|Participants randomized to the Standard Behavioral Weight Control (SBWC) condition receive a 14-session intervention that is comprised of 12 consecutive weekly sessions and 2 booster sessions delivered at weeks 14 and 16. The intervention includes a dietary plan, a fitness plan, behavioral weight control management that includes self-monitoring, goal-setting, stimulus control strategies, and planning, as well as parental involvement.
3187246|NCT00754039|Experimental|1|Welchol + TriCor
3187247|NCT00754039|Placebo Comparator|2|Welchol + placebo
3187248|NCT00754078|Other|1|anal cancer patients treated with tomotherapy and chemotherapy
3187249|NCT00754091|Experimental|1|
2426198|NCT03393195|Experimental|Time-restricted eating plan|Participants in this group will be instructed to fast every day from 8pm until 12pm the following day. From 12pm until 8pm, participants can eat and drink whatever they want. During fasting hours, participants can drink water and black coffee.
2426199|NCT03393195|Active Comparator|Consistent Meal Timing Plan|Participants in this group will be instructed to eat three daily meals during specified eating times. Their first meal will be between 7am-11am. Second meal between 11am and 3pm, and third meal between 4pm-10pm. Participants will be encouraged to eat small snacks if needed so that they can eat their next meal during the specified window.
2426200|NCT03393182|Experimental|TLDG arm|"TLDG arm(Totally laparoscopic distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy."
3187250|NCT00754104|Experimental|A|
3187251|NCT00754117||All patients|All patients
3187252|NCT00754143|Placebo Comparator|A|Placebo
3187253|NCT00754143|Experimental|B|FG-3019 5 mg/kg
3187254|NCT00754143|Experimental|C|FG-3019 10 mg/kg
3187255|NCT00754182|Experimental|A|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with synthetic glue
3187256|NCT00754182|Active Comparator|B|Patients underwent thyroidectomy, emithyroidectomy, parathyroidectomy sutured with subcuticular suture
3187257|NCT00754195|Active Comparator|1|Insertion distance of thoracic epidural catheter: 3 cm
3187258|NCT00754195|Active Comparator|2|Insertion distance of thoracic epidural catheter: 5 cm
3187259|NCT00754195|Active Comparator|3|Insertion distance of thoracic epidural catheter: 7 cm
3187260|NCT00754221|Experimental|1|
3187261|NCT00754260|Experimental|Caffiene reduction group|Caffeine reduction group Intervention is to counseling to reduce caffeine intake
2426201|NCT03393182|Experimental|LADG arm|"LADG arm(Laparoscopy-assisted distal gastrectomy)~: After lymphadenectomy, gastrectomy and reconstruction procedure are performed through mini-laparotomy"
2426202|NCT03393156|Experimental|Internet-based metracognitive therapy|"The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book Metacognitive therapy for depression and anxiety by Adrian Wells (2011)."
2426203|NCT03393156|No Intervention|Wait-list|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.
2426204|NCT03393143||Oregon patients|Adult Medicaid patients with back pain who get their care in community health clinics in Oregon
2426205|NCT03393143||California patients|Adult Medicaid patients with back pain who get their care in community health clinics in California
2426206|NCT03393130||Participants possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who possess at least one copy of the APOE-ε4 allele.
2426207|NCT03393130||Participants not possessing APOE-ε4|Young adults who have suffered a severe burn injury necessitating intensive care admission 5 to 10 years previously, who do not possess a copy of the APOE-ε4 allele.
2426208|NCT03393117|Experimental|Liposomal Bupivacaine + Bupivacaine|This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
2426209|NCT03393117|Active Comparator|Bupivacaine|This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.
2426210|NCT03393104|Experimental|Motor Control Exercise and Patient Education|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise and 4 sessions (1 session per week) of patient education program as described in respective protocol.~In addition, they will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2426211|NCT03393104|Experimental|Motor Control Exercise|"Participants will receive a total of 16 sessions (2 sessions per week) of motor control exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2426212|NCT03393104|Experimental|Patient Education|"Participants will receive patient education session once a week at interval of 1-week over 8-weeks (4 sessions). The program will be aiming to provide non-threatening information to enable patients to better understand their pain, change any unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.~They will also perform segmental stretching exercises and instructed to perform continuous overground walk as indicated in the control group."
2426213|NCT03393091||Incidence of possible anaphylaxis|Data will be collected on 1000 consecutive general anaesthetic procedures in Assiut University Hospitals. After each elective operating list the anaesthetist will be asked to complete a form in which they will document the number of patients receiving general anaesthesia on the list and the number of those patients who developed any of the following features: unexpected, unexplained hypotension; unexpected bronchospasm resistant to treatment; angioedema; urticaria; severe itching; widespread erythema
2426216|NCT03393065|Experimental|intervention group pulmonary congestion|in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.
2426217|NCT03393065|No Intervention|Control group|control group the fluid management will not be LUS guided
2426218|NCT03393052|Active Comparator|Left Radial access|Left Radial approach for coronary angiography in patients with prior history of CABG surgery
2426219|NCT03393052|Active Comparator|Femoral access|Femoral approach for coronary angiography in patients with prior history of CABG surgery
2426220|NCT03393039|Experimental|Behavioral|Negative Affect Task
2426221|NCT03393026|Experimental|Lurasidone 40-160 mg|Lurasidone 40-160 mg
2426222|NCT03393013|Experimental|KZR-616 60 mg + standard therapy (Phase 2)|60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.
2426223|NCT03393013|Experimental|KZR-616 45 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
2426224|NCT03393013|Experimental|KZR-616 60 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
2426225|NCT03393013|Experimental|KZR-616 75 mg + standard of care therapy (Phase 1b)|Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.
3187262|NCT00754260|No Intervention|No caffeine reduction group|No Caffeine reduction group Intervention is to not counsel regarding caffeine intake
3187263|NCT00754273||1|PAL samples collected for pneumonia evaluation
3187264|NCT00754286|Experimental|Aromatherapy|Participants will be given aromatherapy wand at the onset of their chemotherapy treatment.
2426228|NCT03392987|Experimental|OTL-200 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-200 gene therapy. Subjects will also receive conditioning regimen with busulfan.
3187265|NCT00754286|Placebo Comparator|Placebo|Participants will be given the placebo wand at the onset of their chemotherapy treatment. Placebo wands will look identical to the scented wands but will not contain a scent.
2426230|NCT03392961|Experimental|IN-105 (Insulin Tregopil)|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
2426231|NCT03392961|Placebo Comparator|Placebo tablet|"Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.~Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.~Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F)."
3187266|NCT00754312|Experimental|1|ER positive
2426233|NCT03392922|Experimental|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery
2426234|NCT03392922|Experimental|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
2426235|NCT03392909|Experimental|Intravenous Gentamicin|Intravenous gentamicin (7.5 mgs/kg) daily for for either 14 days and then stopped or twice weekly for three months and then stopped.
2426236|NCT03392896|Experimental|Group A Active (DCR-PHXC)|HVs, single ascending doses of DCR-PHXC.
2426237|NCT03392896|Placebo Comparator|Group A Placebo|HVs, normal saline 0.9% injection to match active doses.
2426238|NCT03392896|Experimental|Group B Active (DCR-PHXC)|PH1 and PH2 patients, open label, single ascending doses of DCR-PHXC.
2426239|NCT03392883|Experimental|Digital Health Assisted Mental Healthcare|This Digital Health Assisted Mental Healthcare intervention will be based on the novel mobile-based platform (Laddr® from Square2 Systems).
2426240|NCT03392870|Experimental|TAVA-ACTIVE|Integrative interventional programme. It involves high-frequency multidisciplinary intervention: nursing, psychology, psychiatry and social services. A psychotherapeutic group would be offered to those patients with an intelligence quotient>70, verbal communication and no behavioural alterations.
2426241|NCT03392870|Active Comparator|CONTROL|As usual
2426242|NCT03392844|Experimental|Intervention: Bed after 7 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 7 days after initiating daily diary/actigraph procedures.
2426243|NCT03392844|Experimental|Wait-list: Bed after 14 days|Caregiver-child dyads in this condition will receive a bed, bedding, and sleep education from the Beds for Kids program 14 days after initiating daily diary/actigraph procedures.
2426244|NCT03392831|Experimental|Peripherally inserted central catheter|The peripherally inserted central catheter (PICC) with 3 to 6 French calibers, with one, two or three lumens Groshong and PowerPICC models. These calibers are dependent on the amount of lumens, which are used for single or concomitant infusions.
2426245|NCT03392831|Active Comparator|Central venous catheter|The central venous catheter (CVC), with a short stay of 3 to 7 French gauges with one or more lumens.
2426246|NCT03392818|Experimental|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
2426247|NCT03392818|Experimental|Fiberoptic bronchoscope|intubation of Uniblocker under the Under the guidance of Fiberoptic bronchoscope
2426248|NCT03392818|Experimental|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of FOB.
2426249|NCT03392805|Experimental|sedentary life style|
2426250|NCT03392805|No Intervention|physically active life style|
2426251|NCT03392792|Active Comparator|tissue plasmnogen activator|
2426252|NCT03392792|Active Comparator|thrombectoy|
2426253|NCT03392779|Experimental|ZSP1601(single dose)-25 mg while fasted(Cohort 1)|ZSP1601 25 mg /Placebo
2426254|NCT03392779|Experimental|ZSP1601(single dose)-50 mg while fasted(Cohort 2)|"ZSP1601 50 mg/Placebo~Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1."
2426255|NCT03392779|Experimental|ZSP1601(single dose)-100 mg while fasted(Cohort 3)|"ZSP1601 100 mg/Placebo~Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2."
2426256|NCT03392779|Experimental|ZSP1601(single dose)-175 mg while fasted(Cohort 4)|"ZSP1601 175 mg/Placebo~Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3."
2426257|NCT03392779|Experimental|ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)|"ZSP1601 275 mg/Placebo~Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4."
2426258|NCT03392779|Experimental|ZSP1601(single dose)-350 mg while fasted(Cohort 6)|"ZSP1601 350 mg/Placebo~Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5."
2426259|NCT03392779|Experimental|ZSP1601(food effect)-100 mg (Cohort FE)|"Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1.~Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8."
2426260|NCT03392779|Experimental|ZSP1601(multiple doses)-50 mg (Cohort 7)|"50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE~ZSP1601 50 mg/Placebo for 14 Days."
2426261|NCT03392779|Experimental|ZSP1601(multiple doses)-100 mg (Cohort 8)|"Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7.~ZSP1601 100 mg/Placebo for 14 Days."
3187267|NCT00754312|Experimental|2|ER negative and/or PR negative histology
3187268|NCT00754312|Experimental|3|triple negative histology (for ER, PR, HER-2)
2426263|NCT03392766|Experimental|Double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube
2426266|NCT03392740|Experimental|Lisinopril treatment|These patients will be initiated at 5mg lisinopril daily by the research nurse at the time of enrollment. The drug will then be titrated up by the research nurse in a stepwise fashion from 5mg, to 10mg, and then to 20mg once a day every 1 to 3 weeks according to their regular/scheduled next office visits. Blood pressure will be monitored at every visit by the research nurse if it is less than or equal to 90 mmHg
2426267|NCT03392740|Placebo Comparator|Placebo Oral Tablet|These patients will be started on the placebo medication at the time of enrollment. According to their regular scheduled visits every 1 to 3 weeks, they will meet with the research nurse and be given a new placebo medication to take once a day.
2426268|NCT03392727|Experimental|Study Box & Education Session|Parents are provided a baby box and infant health and safety products and participate in a face to face educational session
2426269|NCT03392727|Active Comparator|Community Box & Online Education|Parents are informed how to receive a free box from a community site and are provided a guide to online resources for prenatal and infant health promotion
2426270|NCT03392714|Experimental|R-B(O)AD|Intravenous R-B(O)AD every 4 weeks for up to 4 cycles
2426271|NCT03392701|Experimental|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
2426272|NCT03392701|Placebo Comparator|Placebo|NaCl
2426273|NCT03392688|Experimental|Patellofemoral pain group|"Diagnosis of PFP was established based on symptoms, physical examination performed by an orthopedic surgeon. Patients were also screened through physical examination to rule out ligamentous or meniscal injuries, patellar tendinitis and knee joint effusion by an orthopedic surgeon. All patients also underwent a radiologic examination consisting of AP, lateral and tangential radiograms.~Surface EMG, Kujala patellofemoral pain scale, Q angle measurement were administered to the PFP group."
2426274|NCT03392688|Active Comparator|Control Group|"Control group had similar demographic characteristics with PFP group, and neither one of the controls had any knee pathology or current knee pain or effusion that would effect the gait.~Surface EMG, Q angle measurement were administered to the control group."
2426275|NCT03392675|Experimental|Self-monitoring of BF and intervention|Self-monitoring and regulation skills will be provided to mothers at discharge. Aside from daily diaries outlining, infant feeding behaviors and pain, mothers will be instructed to watch several 5-minute video modules to assist with self-management of breast and nipple pain. These videos include: pain neurophysiology; non-pharmacological strategies; common BF issues and intervention; catastrophizing; stress reactivity; deep breathing; guided imagery and support (informational and instrumental). These mothers will also be asked to complete study questionnaires and measures at specified time points.
2426276|NCT03392675|No Intervention|Control|Usual care and asked to complete measures at follow-up time points.
2426277|NCT03392662||Hemopatch Sealant Use with Hepatobiliary Surgery|
2426278|NCT03392662||Hemopatch Sealant Use with General Surgery|
2426279|NCT03392662||Hemopatch Sealant Use with Lung Surgery|
2426280|NCT03392662||Hemopatch Sealant Use with Cardiovascular Surgery|
2426281|NCT03392662||Hemopatch Sealant Use with Neurological/Spinal Surgery|
2426282|NCT03392662||Hemopatch Sealant Use with Urologic Surgery|
2426283|NCT03392649|No Intervention|Sham Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, but the Parasym will not be turned on and the subject will not receive any stimulation. The clip will be switched to the other ear every 4 hours for a total of 48 hours.
2426284|NCT03392649|Experimental|Stimulation Group|At the end of cardiac surgery, the Parasym alligator clip will be placed on the subject's tragus, and the subject will receive continuous stimulation for 48 hours. The clip will be switched to the other ear every 4 hours.
2426285|NCT03392636|Experimental|Group A|Mitchell Banks Herniotomy
2426286|NCT03392636|Experimental|Group B|Fergusson Gross Herniotomy
2426287|NCT03392623|Other|Control group|Macules of melasma without any treatment
2426288|NCT03392623|Experimental|Niacinamide group|Macules of melasma treated with topical Niacinamide cream 4% for 8 weeks
2426289|NCT03392623|Experimental|Retinoic acid group|Macules of melasma treated with topical retinoic acid 0.05% for 8 weeks
2426290|NCT03392623|Placebo Comparator|Sunscreen group|Macules of melasma treated with sunscreen cream with a 50 sun protection factor for 8 weeks
2426291|NCT03392610||Bronchial endoscopy|Compare quality procedures performed with reusable versus disposable bronchoscopes in respiratory endoscopy unit
2426292|NCT03392610||Critical care unit|Compare quality procedures performed with reusable versus disposable bronchoscopes in critical care unit
2426293|NCT03392610||Anesthesia department|Compare quality procedures performed with reusable versus disposable bronchoscopes in anesthesia department
2426294|NCT03392597|Experimental|Brothers as Allie|Brothers as Allies is a strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years by addressing rigid beliefs and norms about masculinity that are harmful to the health, safety, relationships and opportunities of boys and young men. Groups of six to ten boys of similar age and development meet weekly with one or two facilitators for 1.5 to 2 hours for ten or more weeks. Meetings include warm up activities, an opportunity for check-in, experiential activities that address gender relevant topics (e.g., group challenges, games, skits, role plays), and a reflection and group dialogue component.
2426295|NCT03392597|Active Comparator|Programming-as-Usual|Usual programming implemented in afterschool programs.
3146411|NCT00100061|Active Comparator|Cranberry Juice|Cranberry Juice provided by Ocean Spray
3146412|NCT00100061|Placebo Comparator|Placebo cranberry juice|Taken orally
2426334|NCT03392272|Experimental|Tisseel|Müller's Muscle-Conjunctival Resection (MMCR) using glue instead of sutures
2427269|NCT03385655|Experimental|Ipatasertib AKT inhibitor|
3146413|NCT00100256|Experimental|Arm 1|
3146414|NCT00100295|Experimental|A|Herbal treatment
3146415|NCT00100295|Placebo Comparator|B|
3146416|NCT00100308|Experimental|1|Standard treatment plus unfractioned heparin low-dose continuous infusion
2426298|NCT03392571|Experimental|Resectable and borderline restable|"Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed.~Patients receive 3 cycles of preoperative chemotherapy (NGC-triple regimen). The regimen consists of gemcitabine 800 mg/m2, Nab-paclitaxel 100 mg/m2and Cisplatin 25 mg/m2 given IV weekly x 2, every 3 weeks (one cycle).~Patients will be evaluated for adjuvant therapy within 12 weeks of surgery which will consist of Nab-paclitaxel, gemcitabine, and Cisplatin IV weekly x 2, every 3 weeks (one cycle) x 3 cycles."
2426299|NCT03392558|Experimental|Nature-Based Sensitive Skin Regimen|"Burt's Bees Skin Care Regimen (Nature Based Sensitive Skin Regimen, NBSSR):~Burt's Bees Sensitive Facial Cleanser (to be used day and night)~Burt's Bees Sensitive Daily Moisturizing Cream (to be used in the day)~Burt's Bees Sensitive Night Cream (to be used at night)"
2426300|NCT03392558|Active Comparator|Control Regimen|"Control Skin Care Regimen (Control Regimen, CR):~Cetaphil Gentle Skin Cleanser (to be used day and night)~Cetaphil Moisturizing Lotion (to be used day and night)"
2426301|NCT03392545|Experimental|Combined immune adjuvants and radiation|Patients with malignant gliomas will receive combined immune adjuvants (GM-CSF, TLR ligands) and radiation. The safety and efficacy will be analyzed.
3187269|NCT00754351|Experimental|1|Bevacizumab->Docetaxel->Gemcitabine
3187270|NCT00754364|Experimental|Pemetrexed/Carboplatin|Pemetrexed (500 mg/m2 infusion) plus Carboplatin (AUC5 infusion)
2426304|NCT03392519||Chronic stroke|More than 3 months post-stroke Ischemic or hemorrhagic stroke
2426305|NCT03392506|Experimental|EBUS-TBNA-RTE|Patients do CT、 PETCT examination and EBUS-TBNA-RTE
2426306|NCT03392493|Experimental|Group A|In the phase 1 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week); In the phase 2 :12 training sessions of Standard treatment only. (60 minutes a time, 2 times a week)
2426307|NCT03392493|Active Comparator|Group B|In the phase 1 :12 training sessions of Standard treatment only(60 minutes a time, 2 times a week) ; In the phase 2 :12 training sessions of Robot-assisted hand rehabilitation(60 minutes a time, 2 times a week)
2426308|NCT03392480||Adult non-haptoglobin 2-2 group|Patients are 45 to 65 years old.
2426309|NCT03392480||Adult haptoglobin 2-2 group|Patients are 45 to 65 years old.
2426310|NCT03392480||Elder non-haptoglobin 2-2 group|Patients are elder than 65 years.
2426311|NCT03392480||Elder haptoglobin 2-2 group|Patients are elder than 65 years.
2426312|NCT03392467|Experimental|PNEUMOSTEM|human umbilical cord blood derived mesenchymal stem cell (hUCB-MSC)
2426313|NCT03392467|Placebo Comparator|Placebo|normal saline
2426314|NCT03392454||T+LRTI Patients|Patients who received Trapeziectomy with Ligament Reconstruction and Tendon Interposition.
2426315|NCT03392454||PT+TI Patients|Patients who received the Partial Trapeziectomy and Tendon Interposition
2426316|NCT03392441|Experimental|Insulin Deprivation|Insulin Deprivation in Type 1 Diabetic Patients will be performed for a short time period (4-6 hours). Changes to Age, Sex, and Gender matched controls will be compared.
2426317|NCT03392428|Experimental|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
2426318|NCT03392428|Active Comparator|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
2426319|NCT03392415|Active Comparator|Initial conservative treatment|Optimal medical therapy and option for crossover after 6 months or fulfillment of certain conditions
2426320|NCT03392415|Experimental|initial interventional treatment|CTO PCI attempt as initial strategy with medical optimization simultaneously
2426321|NCT03392389|Experimental|mRNA-1653|
2426322|NCT03392389|Placebo Comparator|Placebo|
2426323|NCT03392376|Experimental|Haloperidol injection|"Haloperidol 2,5mg x 3 daily, with additional as needed doses to a maximum of 20mg/daily.~Other name: Serenase"
2426324|NCT03392376|Placebo Comparator|Normal Saline|Saline (0,9%)
2426325|NCT03392350|Active Comparator|Behavioral Intervention arm|"A behavioral intervention consisting of a physician body scan consultation with a radiologist which included viewing self imagery followed by an 18 month behavioral intervention which included educational modules covering:~Responding to Stress More Effectively Enhancing the effects of Relaxation Nourishing your immune system Energizing your Body Welcoming Others and Strengthening Relationships"
2426326|NCT03392350|Active Comparator|Control Group|No Intervention
2426327|NCT03392337|Experimental|Open Label Narrowband UVB phototherapy|Open Label Narrowband UVB phototherapy for 12 weeks.
2426328|NCT03392324|Experimental|PRIMA|Implantation of PRIMA device
2426329|NCT03392311|Experimental|AD-MSCs plus Calcipotriol ointment group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 2 million cells/kg at week 0, week 2, week 4, week 6, week 8 with a duration for treatment for 12 weeks. The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
2426330|NCT03392298|Experimental|CCA group|Participants in CCA group will be treated with 15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd)， once daily for 4 weeks.
2426331|NCT03392298|No Intervention|Control group|Participants in Control group will be treated with nothing, but followed up for 4 weeks.
2426332|NCT03392285||Internal fixation|Patients above 65years old with an undisplaced femoral neck fractures treated with primary internal fixation with screws.
2426333|NCT03392285||Hip arthroplasty|Patients above 65years old with a displaced femoral neck fractures treated with primary hip arthroplasty.
2426396|NCT03391804|Experimental|ALLN-177|ALLN-177 7,500 units (2 capsules)
3187271|NCT00754364|Active Comparator|Gemcitabine|Gemcitabine 1250 mg/mq
3187272|NCT00754403|Experimental|Pioglitazone 30 mg QD + Metformin 1000 mg QD|
3187273|NCT00754403|Active Comparator|Metformin 1000 mg QD|
3187274|NCT00754416||S.E.S prosthesis|Consecutive series of patients with a S.E.S prosthesis.
2426335|NCT03392272|Active Comparator|Sutures|Müller's Muscle-Conjunctival Resection (MMCR) using the usual procedure
2426336|NCT03392259|No Intervention|Control group|conventional treatment
2426337|NCT03392259|Experimental|App group|conventional treatment + use of smartphone app.
2426338|NCT03392246|Experimental|Osimertinib + Selumetinib|"Selumetinib are to be administered orally intermittently (4 days on, 3 days off)~Osimertinib are to be administered orally on a daily basis"
2426339|NCT03392233|Experimental|Phase II open lable Study|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time.
2426340|NCT03392220|Experimental|undergo unilateral (affected side) neck dissection (II-IV)|patient undergo affected side neck dissection, along with the excision of the laryngeal primary tumor
2426341|NCT03392220|Experimental|undergo bilateral neck dissection (II-IV)|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
2426342|NCT03392207||Health Care Professionals|Health care professionals receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
2426343|NCT03392207||Elderly|Elderly (age 60 or more) receiving the seasonal influenza vaccine (2018) produced by Butantan Institute.
2426346|NCT03392181|Experimental|18F-DCFPyL|
2426351|NCT03392155|Experimental|Training & Nutrition|Participants receive performance training twice a week for 12 weeks and group and individual nutritional counseling during the 12 weeks.
2426352|NCT03392142|Experimental|tabelecleucel|Tabelecleucel will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects will receive intravenous (IV) tabelecleucel at a dose of 2 x 10^6 cells/kg on Days 1, 8 and 15, followed by observation through Day 35. Treatment will continue until maximal response, unacceptable toxicity, initiation of non-protocol therapy, or failure of multiple tabelecleucel cell products.
2426353|NCT03392129|Experimental|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week, 40 minutes each session) of treatment with the Ai Chi Method and educational interventions in relation to asthma.
2426354|NCT03392129|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
2426355|NCT03392116|Experimental|Part A: NGM120|Single Dose
2426356|NCT03392116|Placebo Comparator|Part A: Placebo|Single Dose
2426357|NCT03392116|Experimental|Part B: NGM120|Multiple Dose
2426358|NCT03392116|Placebo Comparator|Part B: Placebo|Multiple Dose
2426359|NCT03392103|Experimental|postoperative CRT|postoperative CRT: Treatment including postoperative radiotherapy (IMRT) with concurrent chemotherapy of Raltitrexed. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on w1 and w4).
2426360|NCT03392090|Experimental|More Good Days video&brief questionnaire|"Participants will watch the More Good Days video and will be given a brief questionnaire and wallet card to help identify their goals and preferences about information and care~The More Good Days video is developed to help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments.~The 3-page brief questionnaire is designed to help patients identify their preferences about information and care and to help encourage a conversation between patients and their doctors and health care team about their goals and preferences~The wallet card will help patients think about questions they may want to ask their providers when considering treatments."
2426361|NCT03392077||Group A: cervical dilatation|patients who will have cervical dilatation during Caesarean section
2426362|NCT03392077||Group A: non cervical dilatation|patients who will have not cervical dilatation during Caesarean section
3146417|NCT00100308|Placebo Comparator|2|Standard treatment plus placebo
2426364|NCT03392051|Experimental|Clopidogrel Dosing|Multiple doses of Clopidogrel to obtain pharmacokinetic information.
2426365|NCT03392051|Experimental|Clopidogrel in combination with ISIS 681257|Multiple doses of clopidogrel administered with 2 doses of ISIS 681257 at 2 individual timepoints to obtain pharmacokinetic information.
2426366|NCT03392038|Experimental|Thin ADM|Periodontal root coverage surgery using a coronally positioned tunnel and thin acellular dermal matrix (ADM GBR)
2426367|NCT03392038|Active Comparator|Thick ADM|Periodontal root coverage surgery using coronally positioned tunnel surgery and thick acellular dermal matrix graft (ADM)
2426368|NCT03392025|Active Comparator|Flaxseed|Daily consumption of 30 grams flaxseed for 3 months
2426369|NCT03392025|Active Comparator|Flaxseed and the Mediterranean-like diet|Daily consumption of 30 grams flaxseed in adjunct to the Mediterranean-like diet for 3 months
2426370|NCT03392025|Placebo Comparator|Placebo|Daily consumption of Placebo for 3 months
2426437|NCT03391531|Active Comparator|levobupivacaine|Echo-guided bilateral subcostalTAP block will be performed using levobupivacaine [Chirocaine®] 0.375% Epi 1/200000.
3146418|NCT00100477|Other|Arm 1|
3146419|NCT00100542||1|All HIV infected and uninfected participants and their caregivers.
3146420|NCT00100568|Experimental|1|All participants will be given an ARV regimen of lamivudine/zidovudine and efavirenz at study entry. If toxicity or treatment failure occurs, some participants may require changes in their ARV regimens.
3146421|NCT00100646|Experimental|1|Highly active antiretroviral therapy (HAART) consisting of lamivudine, lopinavir/ritonovir, and stavudine for 16 weeks with three structured treatment interruptions for 2, 4, and 8 weeks each; rabies vaccine at Weeks 16, 17, 22 and 92.
3146422|NCT00100646|Active Comparator|2|Continuous HAART consisting of lamivudine, lopinavir/ritonovir, and stavudine throughout the study; rabies vaccine at Weeks 16, 17, 22 and 92.
3146423|NCT00100685|Experimental|Arm 1|Volociximab administered intravenously at a dose of 10 mg/kg qowk
3146424|NCT00100685|Experimental|Arm 2|Volociximab administered intravenously at a dose of 15 mg/kg qwk
3146425|NCT00100750|Experimental|Treatment (gemcitabine hydrochloride, tipifarnib)|Patients receive tipifarnib PO BID on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2426374|NCT03391973|Experimental|Arm 1 - Pembrolizumab|Arm 1 - Pembrolizumab injection dosed at 200 mg given Q3 weeks by IV infusion on Day 1 of each 3 week cycle.
2426375|NCT03391947|Experimental|semilunar coronally positioned flap|A semilunar incision will be done following the curvature of the gingival margin and ending about 2 to 3 mm short of the tip of the papillae. The most apical distance of this incision to the gingival margin will be obtained by adding the bone sounding measurement to the recession height. Perform a split-thickness dissection coronally from the incision, and connect it to an intrasulcular incision. The tissue will be collapsed coronally, covering the denuded root. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite. Finally, the area will be covered with a periodontal dressing. This is called semilunar coronally positioned flap.
2426376|NCT03391947|Active Comparator|coronally advanced flap|Coronally positioned flap will be initiated with two vertical incisions, extending from a mesial and distal linear angle at the cementoenamel junction (CEJ) and go beyond the mucogingival junction. A split thickness flap will be prepared by sharp dissection mesial and distal to the recession and connected with an intra crevicular incision. On the facial aspect of the tooth, a full thickness flap, approximately 3-4 mm apical to crest of alveolar bone. Then, the flap will be returned and sutured it at 1 mm coronal to the CEJ after de-epithelize the papillae. The coronally repositioned gingival margin will be stabilized by coronally anchored suture with composite stops on the buccal surface of the tooth using flowable composite and sutured in the papilla region and releasing incision. Finally, the area will be covered with a periodontal dressing.
2426377|NCT03391934|Experimental|Cetuximab+ FOLFIRI|Cetuximab (Produced by CinnaGen Co.): 400 mg/m2 weekly in the first dose and 250 mg/m2 in the next doses Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
2426378|NCT03391934|Active Comparator|Cetuximab + FOLFIRI|Erbitux® (Produced by Merk Co.): 400 mg/m2 weekly Irinitecan: 180 mg/m2 biweekly Leucovorin: 400 mg/m2 biweekly Fluorouracil: 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly
2426379|NCT03391921|Active Comparator|ARM B: 3 doses (0, 2 and 6 months)|ARM B: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 3 doses at 0,2 and 6 months intramuscularly
2426380|NCT03391921|Experimental|ARM A: 2 doses (0 and 6 months )|ARM A: All patients will receive the 9-valent vaccine against HPV (Gardasil9) 2 doses at 0 and 6 months intramuscularly. A third facultative dose will be given if antibodies measured at month 7 are insufficent.
2426381|NCT03391908||MP - SG 01|Patients with unstable angina type acute coronary syndrome: patients aged at least 18 years, who have signed the informed consent, and present an unstable angina-type acute coronary syndrome with maximum 48h before presentation, defined as the presence of typical angina pain, with duration of more than 5 minute, accompanied by ECG changes.
2426382|NCT03391908||MP - SG 02|Patients with acute myocardial infarction (STEMI or NSTEMI) that occurred 30 days before randomization: patients aged at least 18 years, who have signed the informed consent, and present with acute myocardial infarction (STEMI or NSTEMI) defined as typical changes on the ECG (ST elevation of minimum 1 mm in at least 2 consecutive leads - STEMI; ST-T changes for NSTEMI) accompanied by increased levels of cardiac troponin I or T, or CK-MB of more than 2x the normal reference value of the laboratory.
2426383|NCT03391895|Active Comparator|Control Group|Patients in this group will receive a home based exercise program. Home based exercise program includes deep diaphragmatic breathing exercises, resistive local expansion exercise on the collapsed areas in scoliosis concave sides, dynamic lumber stabilization, strengthening of inter scapular muscles, posture and stretching exercises once a day for 8 weeks. One of the exercise sessions was supervised by physiotherapist each week.
2426384|NCT03391895|Experimental|Training Group|In addition to home based exercise program, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in our clinic per week, other sessions will be performed at home.
3146426|NCT00100854|Active Comparator|Arm I|Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.
3146427|NCT00100854|Experimental|Arm II|Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.
3146428|NCT00100880|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 2-3 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which an estimated 25% of patients experience dose-limiting toxicity."
3146429|NCT00100893|Experimental|Dietary Supplement: grape seed proanthocyanidin extract|Administered orally.
2426389|NCT03391856|Experimental|intervention arm|NAC 400mg p.o tid from day 60 to day 90 post transplant
2426390|NCT03391856|Other|controlled arm|Supportive therapy including platelet infusion:prophylactic platelet transfusion was given when platelet count <20000/ul
2426391|NCT03391843|Experimental|FOLFOXIRI+Cetuximab|FOLFOXIRI+Cetuximab regimen:Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h and cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle for 4-6 cycles.
2426392|NCT03391830|Active Comparator|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
2426393|NCT03391830|Placebo Comparator|Placebo|Placebo
2426394|NCT03391817|Active Comparator|Intervention arm|Fecal transplant from a thin donor
2426395|NCT03391817|Placebo Comparator|Placebo arm|Fecal transplant made from patients own feces
3146430|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level A|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
2426397|NCT03391791||Genetically engineered T Cell Receptor- treated|Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial
2426398|NCT03391778|Experimental|Participants receiving GSK adoptive cell therapy|
3187275|NCT00754429|Experimental|A|Losartan 50mg qd for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
3187276|NCT00754429|Active Comparator|B|Amlodipine 5 mg q.d for 30 weeks, if blood pressure > 140/90, or mean arterial Bp ≧ 15% of baseline, then add on diuretics.
3187277|NCT00754455|Experimental|Low dose|
3187278|NCT00754455|Experimental|Mid dose|
2426403|NCT03391752||Royal Alexandria|Administrative records
2426404|NCT03391752||Pasqua Regional hospital|Administrative records
2426405|NCT03391752||Concordia Hospital|Administrative records
2426406|NCT03391752||Niagara General Hospital|Administrative records
2426407|NCT03391752||Hospital 6|Administrative Records
2426408|NCT03391752||Hospital 7|Administrative Records
2426409|NCT03391752||Hospital 8|Administrative Records
2426410|NCT03391752||Hospital 9|Administrative Records
2426411|NCT03391752||Hospital 10|Administrative records
2426412|NCT03391739|Experimental|Arm 1|CART-19 cells treat
2426413|NCT03391726|Experimental|Arm 1|CART-19 cells treat
2426414|NCT03391713|No Intervention|Control|No exposure to waiting room posters
2426415|NCT03391713|Active Comparator|Intervention|During the second half of the study (two weeks), there will be an education poster in the waiting room of the clinic, fashioned after the Face, Arms, Speech, Time (FAST) poster developed by the American Heart Association (AHA), but in Malay.
2426416|NCT03391700|Active Comparator|Moderate muscle relaxation|Rocuronium is administered to maintain moderate relaxation during operation. This is conventional muscle relaxation level of this institute.
2426417|NCT03391700|Experimental|Deep muscle relaxation|Rocuronium is administered to maintain deep relaxation during operation.
2426418|NCT03391687||Amylase Test|gastric cancer patients receiving radical gastrectomy
2426419|NCT03391674|Experimental|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
2426420|NCT03391674|No Intervention|Observational|Observational
2426421|NCT03391661|Experimental|Chronic Pain and the Brain|This condition is a 15 to 20-minute exercise that patients complete in which they examine variables in themselves that suggest that their pain is driven by central nervous system processes / their brains.
2426422|NCT03391661|Placebo Comparator|Health Behavior Control|This 15 to 20-minute exercise is designed as a control condition that has face validity as helpful and that relates to health. Thus, patients are asked to examine various domains of their own health behavior as engaged in over the past 24 hours (e.g., nutrition, sleep, exercise, hygiene, social connections).
2426423|NCT03391648||Cesarean|
2426424|NCT03391635|Experimental|Electroacupuncture|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand needles (0.30×50mm or 0.30×70mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.After acupuncture，the needle handle will be connected with the electrode in the electroacupuncture instrument.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 0.1mA-1.0mA."
2426425|NCT03391635|Active Comparator|TranscutaneousElectricNerveStimulation|"The treatment consists of 3 times a week for 8 weeks.Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used for ST25, SP14 and ST37.~The parameters of the electric acupuncture apparatus：Dilatational wave，the frequency is 2/10Hz，the electric current intensity is 2mA-5mA."
2426426|NCT03391609|Placebo Comparator|control group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
2426427|NCT03391609|Active Comparator|Dex. group|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
2426428|NCT03391596|Experimental|Internet-based ACT intervention|"Group Internet-based ACT intervention will receive a 12-week Internet-based, acceptance and commitment therapy intervention"
2426429|NCT03391596|Active Comparator|Standardized rehabilitation|"Group Standardized rehabilitation will receive a standardized rehabilitation program in the rehabilitation center"
2426430|NCT03391596|Other|Support by caregiver associations|"Group Support by voluntary caregiver associations will receive support given by caregiver associations"
2426431|NCT03391583|Experimental|Standard of Care plus Education|Educational material will be provided at three time points along with the current standard of care provided in tertiary health care setting
2426432|NCT03391583|No Intervention|Standard of Care|Current standard of care provided in tertiary health care setting
2426433|NCT03391570|Active Comparator|COX-2 inhibitor (Celecoxib)|Celebrex; COX-2 inhibitor
2426434|NCT03391570|Placebo Comparator|Placebo drug (Ramnos)|Ramnos; Lactobacillus casei variety rhamnosus
2426435|NCT03391557|Experimental|Patients with the UE examination|Patients with enlarged intrathoracic lymph nodes(≥1cm) and/or 18-FDG high uptake (SUV Max > 2.5) without bleeding tendency, abnormal coagulation function and serious cardiac dysfunction were finally selected.
2426436|NCT03391544|Experimental|V4c toric ICL implantation Group|V4c toric ICL implantation Group
3187279|NCT00754455|Experimental|High dose|
3187280|NCT00754455|Placebo Comparator|Placebo|
3187281|NCT00754481|Active Comparator|1|
3187282|NCT00754481|Experimental|2|
3187283|NCT00754507|Experimental|1|colesevelam tablets and atorvastatin tablets
3187284|NCT00754507|Placebo Comparator|2|colesevelam HCl placebo tablets and atorvastatin tablets
3187285|NCT00754520|Experimental|Ceramic On Metal|This arm utilizes the ceramic on metal articulation using the M2a-38™ mm cup.
3187286|NCT00754520|Active Comparator|Metal on Metal|This arm utilizes the metal on metal articulation using M2a-38™ mm cup.
2426438|NCT03391531|Placebo Comparator|Saline|Echo-guided bilateral subcostal TAP block will be performed with saline Epi 1/200000 in the control group.
2426439|NCT03391505|Experimental|Treatment Group 1|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
2426440|NCT03391505|Experimental|Treatment Group 2|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
2426441|NCT03391505|Placebo Comparator|Control Group|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
2426442|NCT03391492||influenza group|All consecutive patients older than 18 years ,admitted to the ICU with respiratory distress with microbiologically confirmed diagnosis of influenza
2426443|NCT03391492||control group|All consecutive patients older than 18 years, admitted to the ICU for respiratory distress due to community-acquired pneumonia (CAP) and with a microbiologically confirmed absence of influenza,
3187287|NCT00754533|Other|1|Continuous training
3187288|NCT00754533|Other|2|Interval training
2426447|NCT03391440|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
2426448|NCT03391427|Experimental|Lidocaine|This group will receive lidocaine infusion perioperatively
2426449|NCT03391427|Experimental|Ketamine|This group will receive ketamine infusion perioperatively
2426450|NCT03391427|Experimental|Lidocaine+ketamine|This group will receive a combination of lidocaine and ketamine infusion, perioperatively
2426451|NCT03391427|Placebo Comparator|placebo|This group will receive saline infusion as placebo perioperatively
2426452|NCT03391414|Experimental|hypertonic bicarbonate|subjects will be administered a solution of 8.4% hypertonic bicarbonate by nebulizer
2426453|NCT03391414|Active Comparator|hypertonic saline|subjects will be administered a solution of 7% sodium chloride by nebulizer
2426454|NCT03391401||Adip1|Patients with morbid obesity (i.e. BMI >35 kg/sqm) and age >18 scheduled for bariatric surgery (all standard procedures included)
2426455|NCT03391388|Experimental|Cohort I (3D-CRT APBI)|Patients undergo 3D-CRT APBI for 3-5 days.
2426456|NCT03391388|Experimental|Cohort II (proton APBI)|Patients undergo proton beam radiation therapy APBI for 3-5 days.
2426457|NCT03391388|Experimental|Cohort III (brachytherapy APBI)|Patients undergo brachytherapy ABPI for 3-5 days.
2426458|NCT03391375|Experimental|DNA-Protein|Co-administration of DNA-HIV-PT123 and AIDSVAX B/E at week 0, 4 and 24
2426459|NCT03391362|Experimental|Stereotactic Radiation|"Stereotactic radiation will begin within 14 days of the MRI used for radiation planning~Lesions <2 cm in maximum diameter will be treated with stereotactic radiosurgery, generally 20 Gy in 1 fraction~Lesions between 2.0 and 3.0 cm in maximum diameter will generally be treated to 18 Gy in 1 fraction~Lesions >3 cm will be generally be treated with stereotactic radiotherapy to 30 Gy in 5 fractions"
2426460|NCT03391349||Group I|GROUP I: 35 generalized severe chronic periodontitis subjects without type II diabetes mellitus and systemically healthy.
2426461|NCT03391349||Group II|GROUP II: 35 generalized severe chronic periodontitis subjects diagnosed with type II diabetes mellitus.
2426462|NCT03391323|Other|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
2426463|NCT03391323|Other|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
2426464|NCT03391310|Experimental|Honey dressing group|In this group, the wound will be cleaned with normal saline and then honey (medicated ) will be applied to cover the wound surface. The dressing will be changed once soiled (alternate day in most cases). The dressing will be applied for a maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
2426465|NCT03391310|No Intervention|Standard treatment group|In this group, the wound will be first cleaned with 'povidone iodine' and then covered with hydrocolloid dressing changed alternate day for maximum period upto 8 weeks (in cases of stage IV ulcers) or till healthy granulation tissue appears, whichever is earlier.
2426466|NCT03391297|Experimental|60-minute Prolonged Exposure Therapy|This condition is a modified version of Prolonged Exposure Therapy for PTSD. It consists of weekly 60-minute sessions, with at least 20 minutes imaginal exposure.
2426467|NCT03391297|Active Comparator|90-minute Prolonged Exposure Therapy|This condition is standard Prolonged Exposure Therapy. It consists of 10 to 15 weekly sessions, each lasting about 90 minutes, with 40-60 minutes imaginal exposure.
2426468|NCT03391284|Experimental|Oral|1000 mg acetominophen oral
2426469|NCT03391284|Active Comparator|Intravenous|1000 mg acetominophen intravenous
2426470|NCT03391271|Experimental|photobiomodulation therapy (PBMT)|During photobiomodulation therapy (PBMT) or low-level laser therapy, visible and/or (near)-infrared laser light is used at the affected area to improve tissue repair and thereby promote functional recovery of peripheral nerves
2426471|NCT03391271|Placebo Comparator|Placebo group|No PBMT
2426472|NCT03391258|Experimental|Bone Regeneration with GLAM technique|At the beginning of each surgery, a venipuncture will be performed, to obtain the L-PRF membranes. Also, two white topped tubes will be centrifuged for 3 minutes to obtain PRP. After implant placement, achieving a primary stability of at least 45 Ncm, the stiff bone-block (L-PRF membranes and PRP combined with bovine xenograft) will be used in the buccal plate of the pre-maxilla, to enhance bone volume in the esthetic area.
2426473|NCT03391245||Cirrhotic patients with or without infection|"We will include admitted patients with liver cirrhosis irrespective of the underlying etiology during 6 months in Al Rajhi Tertiary Liver Hospital, Assiut, Egypt. They will be divided into 2 Groups. Group I: Cirrhotic patients with evidence of infections at any site and Group II: Cirrhotic patients without evidence of infections.~Diagnosis of infection will based on related clinical symptoms and signs with laboratory and radiological findings."
2426505|NCT03390933|Experimental|Fluoxetine Group|Approximately 96 patients will be enrolled into the intervention (Phase II) over the duration of the entire study.
2427270|NCT03385655|Experimental|Durvalumab and Tremelimumab immunotherapy|
2426474|NCT03391232|Experimental|PolyPEPI1018 CRC Vaccine|The vaccine contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 dominant epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses.
2426475|NCT03391219|Active Comparator|intravitreal Bevacizumab|
2426476|NCT03391219|Active Comparator|intravitreal Bavacizumab and Fasudil|
2426477|NCT03391206||presence of BCRL|presence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
2426478|NCT03391206||absence of BCRL|absence of breast cancer related lymphedema after surgical treatment using Inbody 720 and arm circumference measurement
2426479|NCT03391193|Experimental|Multi-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal containing) in multi-dose presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
2426480|NCT03391193|Active Comparator|Single-dose Quadrivalent Influenza Vaccine|Quadrivalent influenza vaccine (split-virion, inactivated, 2017-2018 formulation, thiomersal free) in single-dose syringe presentation. Participants aged 9 to 17 years will receive 1 dose and subjects aged 6 months to 8 years will receive 2 doses 28 days apart
2426481|NCT03391180|Experimental|ICON Remineralization|Firstly, Conditioning of the WSL surface by 15% HCL gel (Icon-Etch, DNG) and subsequent application of the drying solution (Icon-Dry, DMG), Numbers of additional etching intervals have been determined by visual assessment after each of the etch/dry intervals to achieve individual, customized intensities of WSL surface conditioning.
2426482|NCT03391180|Active Comparator|CPP-ACPF|Participants in group 2 (CPP-ACPF) were treated with applying a pea sized amount of ACC-ACPF plus on a gloved finger of the examiner and rubbed the surface of the labial tooth for 4 minutes with advising the patient to avoid drinking and eating for the next 30 minutes of application.
2426483|NCT03391167|Sham Comparator|Control|Peroperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
2426484|NCT03391167|Experimental|ESP Block|In addition to routine analgesic protocol; before anaesthesia induction; bilateral ultrasound guided erector spinae plane block (ESP) (intervention) will be performed via USG guidance at Th9 level.Standard Pain Followup and Monitorization will be performed.
2426485|NCT03391154|Active Comparator|levothyroxine|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will receive 50 ug of levothyroxine (eltroxin 50) aspen,Egypt throughout the pregnancy
2426486|NCT03391154|No Intervention|control|100 pregnant female with TSH of> 2.5 mU/L but less than 4 mU/L after biochemical diagnosis of pregnancy will not receive any drug throughout the pregnancy
2426489|NCT03391089|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2426490|NCT03391076|Experimental|FilmArray group|Patients in this group will use FilmArray Respiratory Panel to test potential viral pathogens.
2426491|NCT03391076|No Intervention|Routine test group|Patients in this group will use clinical routine methods to test potential viral pathogens.
2426492|NCT03391063|Experimental|reinforced polyamide denture base|metal reinforced polyamide denture base
2426493|NCT03391063|Active Comparator|conventional acrylic resin denture base|conventional heat cured acrylic resin denture base
2426494|NCT03391050|Experimental|APR-246 + Dabrafenib|
2426495|NCT03391037||Intervention|diagnostic criteria for volume assessment were heart rate (HR), mean arterial blood pressure (MABP), central venous pressure (CVP), and urine output hourly (UOP) in ml/hr. During period of hypovolemia, all enrolled patients had left IJV scanned (T0) and measured by one anesthesiologist experienced in point-of-care ultrasound. This point-of-care anesthesiologist is not involved in the anesthetic management of the patient and blinded to the volume status of the patient values. Hypovolemic patients were given a fluid bolus in the form of ringer acetate 5 ml / Kg. Ultrasonic and hemodynamic measurements are reassessed 10 minutes (T 10) after the fluid resuscitation.
2426496|NCT03391024|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2426497|NCT03391011|Experimental|BBL Experimental Navigation System|As this is a single arm trial, all participants receive treatment.
2426498|NCT03390998||Peripartum SCAD|Female patients who experienced any SCAD event that occurred during pregnancy or up to 1 year post-delivery
2426499|NCT03390998||Non-peripartum SCAD|Female patients who experienced any SCAD with event onset outside of the pregnancy period
2426500|NCT03390972|Experimental|Dexmedetomidine|Volunteers are given an intravenous infusion with dexmedetomidine, with an effect-site target concentration of 0.6 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests the effect-site target concentration is raised to 1.2 ng/ml and the swallowing series is repeated.
2426501|NCT03390972|Placebo Comparator|Placebo|Volunteers are given an intravenous infusion with saline 0,9% with target controlled infusion pump in corresponding doses as in the dexmedetomidine arm.
2426502|NCT03390959|Experimental|Proprioceptive Training|The group participates in proprioceptive training that promotes sensory integration.
2426503|NCT03390959|Other|Control Group|The group continues in their daily lives with phone monitoring.
2426504|NCT03390946|Experimental|four-drug interval-compressed regimen|"Interventions for 'four-drug interval-compressed regimen': Drug: methotrexate, cisplatin, doxorubicin, ifosfamide.~Newly diagnosed oseteosarcoma patients under 40 years are eligible. Neoadjuvant chemotherapy with four drugs in an interval-compressed schedule will be done as a single arm.~Duration of neoadjuvant chemotherapy will be 10 weeks like that of conventional three-drug regimen, although four-drugs are employed in the current protocol.~After tumor resection operation, participants will be divided to poor responder group and good responder group based on 90% necrosis rate of a tumor specimen.~Poor responder group and will be assigned to 'Poor responder group adjuvant chemotherapy' and good responder will be assigned to 'Good responder group adjuvant chemotherapy'."
2426506|NCT03390920|Experimental|Umbilical Allograft|The study is nonrandomized with one arm. Depending on the body area being treated, the amount of the product utilized will be either 1.0cc's or 2cc's.
3187289|NCT00754585||I|"All participants will perform the five Chair Support tasks: (1) quiet standing, sitting, (2) upper back unsupported, (3) sitting, upper back unsupported with Logic Back in place, (4) sitting in a standard ergonomic chair, and (5) sitting in a standard ergonomic chair with Logic Back in place. Aside from the Quiet Standing trials which will be performed first, the order of Chair Support will be randomized. Participants will perform the Chair Support task for 30 minutes while quietly watching a movie DVD of their choice. The DVDs provided will the light in content without a lot of suspense or emotion. Data will be collected for the final two minutes of each 30-minute trial."
2426508|NCT03390881|Experimental|Fasting condition|Effects of cumulated negative energy balance (fasting over 480 min) on breath acetone changes
2426509|NCT03390881|Active Comparator|Sugar condition|Effects of sugar consumption on breath acetone changes
2426510|NCT03390881|Active Comparator|Fat condition|Effects of fat consumption on breath acetone changes
2426511|NCT03390868|Experimental|Intervention arm|Phase 1, participants in the intervention group will take part in an web-based training for staff working with people with intellectual disabilities and challenging behaviour aiming to in a more effective way communicate to prevent challenging behaviour. The participants (staff) will by their own, go through the web-based training program during working hours. Measurement are conducted before intervention, at intervention completion an average of 12 weeks, and for a 3 month follow up after completed intervention
2426512|NCT03390868|Other|control arm|Control arm: participants in the control-group will maintain regular care and have the opportunity to receive the web-based training for staff working with people with intellectual disabilities and challenging behaviour in phase 2.
2426513|NCT03390855|Experimental|Broccoli sprout and follow up|Daily consumption of 30 g of raw, fresh, broccoli sprouts, not cooked, during 10 weeks (70 days), followed by other 90 days of no ingestion of broccoli sprouts
2426516|NCT03390829||Patients|
2426517|NCT03390829||Doctors|
2426518|NCT03390816||Transversal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital
2426519|NCT03390816||Longitudinal|Elderly people, who are more than 70 years old, suffering from cancer, waiting for a treatment decision and taken care of in a hospital Forward-looking follow-up of 6 months of a sub-sample during the first year
2426520|NCT03390803||patients with hemifacial spasm|
2426521|NCT03390803||healthy control subjects|
2426522|NCT03390790|Experimental|Lidocaine gel|If assigned to this arm, participants have lidocaine gel 2% applied to their external urethra and vagina one time prior to the urodynamics procedure.
2426523|NCT03390790|Placebo Comparator|Lubricant gel|If assigned to this arm, participants will have a standard lubricant gel applied to their external urethra and vagina prior to the urodynamics procedure.
2426524|NCT03390777|Active Comparator|surgery only|Surgery consisting in debridement/removal of affected tissue/s will be performed.
2426525|NCT03390777|Active Comparator|surgery and PRGF|Surgery consisting in debridement/removal of affected tissue/s will be performed. Platelet Rich Growth Factor (device) will be produced by a venous blood sampling of the patient and applied to the treated area
2426526|NCT03390764|Active Comparator|4:1 closure group|Patients randomized to and receiving the intervention small stitch 4:1 technique for closure of the abdominal wall.
2426527|NCT03390764|Active Comparator|RTL plus 4:1 closure group|Patients randomized to and receiving the intervention reinforced tension-line suture plus small stitch 4:1 technique for closure of the abdominal wall.
2426528|NCT03390751||Aged patients|Data collection of patients admitted to the orthopedic department of the University Hospital of Toulouse for surgical management of a fracture of the upper end of the femur in emergency or for the installation of a hip or knee prosthesis.
2426529|NCT03390738|Experimental|Intravenous nivolumab 240mg|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal.
2426530|NCT03390725|Experimental|A Healthy School Start Plus intervention|The intervention consists of 4 components given to all participants in the experimental group: 1) A health information brochure regarding child's health; 2) Motivational Interviewing with the parents by the school nurse concerning the child; 3) classroom activities for the children with home assignments; and 4) a web-based self-test of type-2 diabetes risk by parents with recommendation to contact primary health care in case of elevated risk.
2426531|NCT03390725|Active Comparator|Control|Treatment as usual in school health services plus the health information brochure regarding child's health (component 1 of the intervention)
2426532|NCT03390712||Paliperidone Palmitate|Patients who have received a minimum of 3 months of treatment with an injection of paliperidone palmitate.
2426533|NCT03390712||Risperidone Long-acting injection.|Patients who have received a minimum of 3 months of treatment with Risperidone long-acting injection.
2426534|NCT03390699|Experimental|before and after partial maxillectomy|Microbial profile among patients before and after partial maxillectomy
2426535|NCT03390686|Experimental|HD204 (Bevacizumab biosimilar)|HD204 + Carboplatin/Paclitaxel
2426536|NCT03390686|Active Comparator|Avastin (Bevacizumab)|Avastin® + Carboplatin/Paclitaxel
2426537|NCT03390673|Experimental|HD204|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2426538|NCT03390673|Active Comparator|EU-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2426539|NCT03390673|Active Comparator|US-licensed Avastin|Bevacizumab Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
2426540|NCT03390660||birth cohorts|born in 1994-1997, 1998-2001, 2002-2005, 2006-2009, 2010-2014
2426541|NCT03390647|Experimental|Cohort A1|Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.
2426542|NCT03390647|Experimental|Cohort B1|Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.
2426543|NCT03390647|Experimental|Cohorts A2-A4|Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.
2426544|NCT03390608||Women with T1ab breast cancer.|
2426545|NCT03390595|Experimental|Avelumab plus gemcitabine/carboplatin|2 cycles of induction avelumab 10mg/kg every 2 weeks followed by 6 cycles of carboplatin/gemcitabine plus avelumab (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8 and avelumab 10mg/kg day +15) every 3 weeks followed by avelumab monotherapy 10mg/kg every 2 weeks until progressive disease or intolerance.
2426546|NCT03390595|Active Comparator|Gemcitabine/carboplatin alone|patients will receive 6 cycles of carboplatin/gemcitabine (carboplatin 5AUC day +1, gemcitabine 1000mg/m2 day +1 and +8) every 3 weeks.
2426547|NCT03390582||Hashimoto's thyroiditis|Hashimoto's thyroiditis (HT) is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers.
2426548|NCT03390582||healthy controls|healthy controls are all from normal volunteers
2426549|NCT03390582||treatment_naive GD|GD is primarily a humoral disease where autoantibodies are generated against the thyroid stimulating hormone receptor (TSHR) leading to hyperthyroidism.
2426550|NCT03390582||treated GD|GD patients treated by Methimazole Pill
2426551|NCT03390569|Experimental|Exercise in GBM|All patients will be assigned a three-month exercise intervention according to their own capabilities and current activity levels
2426552|NCT03390556|Experimental|Asthma education|
2426553|NCT03390543|Experimental|Device group (Group D)|Arm Description: Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound and simple needle guide device.
2426554|NCT03390543|Placebo Comparator|sono only group (Group S)|Patients in this group are assigned to receive internal jugular vein catheterization guided by ultrasound without simple needle guide device.
2426555|NCT03390530|Active Comparator|Thyroxine treatment|Intravenous thyroxine in a dose of 8 µg/kg/day divided into two doses (every 12 hours)
2426556|NCT03390530|Placebo Comparator|Placebo treatment|Intravenous placebo treatment every 12 hours.
2426557|NCT03390517|Experimental|ICG group|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice with the addition of intraoperative imaging using fluorescence angiography with indocianyne green to assess colon and rectal tissue perfusion.
2426558|NCT03390517|No Intervention|Standard|A sigmoid and rectum resection with colorectal anastomosis will be performed according to the surgeons standard practice.
3146431|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Dose Level B|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
3146432|NCT00100906|Active Comparator|ATRA Followed by IL-2 - Level C|"Patients were assigned to one of three ATRA dose levels, at a 1:1:1 ratio, using a randomly permuted list assignments, with the assignment generally being made on the initial day of treatment.~Week 1: One dose daily of IL-2 for 5 days followed by 2 days off.~Weeks 2-6: One dose daily of IL-2 for 5 days followed by 2 days off.~After the IL-2: 2-3 weeks rest, with no treatment. During this time a repeat physical exam, history and X-ray scans will be performed. If there has not been progression (worsening) of the patient's tumor, they will continue to a second 8-week treatment schedule.~This schedule will be the same as the first, unless the patients dose had to be reduced. If so, patient's will get that reduced dose. It consists of 1 week of ATRA, 1 week of rest, followed by 6 weeks of IL-2. The same blood tests are collected during that second cycle."
3146433|NCT00100945|Experimental|gefitinib|"Patients receive oral gefitinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease recurrence or unacceptable toxicity.~Quality of life is assessed at baseline, 4 weeks, every 12 weeks during study treatment, and then at the end of study treatment.~Patients are followed every 3 months for up to 5 years."
3146434|NCT00101075|Experimental|XELOX|"Oxaliplatin 130 mg/m2 day 1 every 3 weeks~Capecitabine 1700 mg/m2/day days 1-14 every 3 weeks. -- Patients will be evaluated for response at the end of cycle 2 and at the end of every even cycle thereafter."
3146435|NCT00101088|Experimental|Treatment (imatinib mesylate, temsirolimus)|Patients receive temsirolimus IV over 30 minutes once on days 1, 8, 15, and 22 and oral imatinib mesylate once daily on days 1-28. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression
3146436|NCT00101114|Experimental|Treatment (sorafenib tosylate, interferon alpha-2b)|Patients receive oral sorafenib twice daily on days 1-28 and interferon alfa subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426565|NCT03390478|No Intervention|Control Group|The participants that will be assign to the control group will receive institutional usual care.
2426566|NCT03390478|Experimental|Combined Intervention Group|The participants that will be assigned to the experimental group will receive the Combined Intervention Program
2426567|NCT03390465|Other|Arm1(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426568|NCT03390465|Other|Arm2(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426569|NCT03390465|Other|Arm3(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426570|NCT03390465|Other|Arm4(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426571|NCT03390465|Other|Arm5(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426572|NCT03390465|Other|Arm6(N=6)|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
2426702|NCT03389594|Active Comparator|Surgical guide designed from voxel size 0.4m|Surgical guide will be designed based on CBCT voxel size 0.4 mm
2426703|NCT03389568|Experimental|Intervention for caregivers of ICU patients|
3146437|NCT00101153|Experimental|Tipifarnib with conventional induction and consolidation|
3187290|NCT00754637||510(k) Inclusion Criteria|Any person meeting the inclusion criteria for the device may be included in this study. These patients tend to be those seeking relief from painful or debilitating knee joint disease.
3187291|NCT00754663|Active Comparator|1|exercise training
2426573|NCT03390452|Experimental|Intervention|"The parents will receive Mobile phone messages about oral hygiene and healthy dieting of their children through teachers.~The message format will be text and images, depending upon the education/ literacy level of the parents. Parents will be reminded and information reinforced, at frequent intervals for a period of six months.~Oral hygiene of School children will be assessed before intervention, after 6 months interval"
2426574|NCT03390452|No Intervention|Control|The primary school children in the control group will not receive any intervention via their parents or teachers (in-active controls) but will be observed on selected outcome measures for baseline data, then at six month interval to compare for differences (if any) with intervention group.
2426575|NCT03390439|Active Comparator|Nd-Yap 1340nm laser|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of Nd-yap 1340nm laser.
2426576|NCT03390439|Experimental|Microneedling|The randomly assigned segment of the abdomen will receive 5 sessions with monthly intervals of dermaroller 2,5mm.
3187292|NCT00754663|Placebo Comparator|2|control arm: normal behavior, no additional exercise will be advised
3187293|NCT00754689|Active Comparator|Arm 1|Metformin 500mg twice daily (bid) + placebo
2426579|NCT03390413|Active Comparator|Robot|
2426580|NCT03390413|Experimental|Cryo|
2426581|NCT03390400|Active Comparator|Anterior Capsulotomy before Lens Fragmentation|Anterior capsulotomy will be performed by femtosecond laser before lens fragmentation
2426582|NCT03390400|Active Comparator|Lens Fragmentation before Anterior Capsulotomy|Lens fragmentation will be performed by femtosecond laser before anterior capsulotomy
2426583|NCT03390387|Experimental|Dexa intermittent|Induction therapy with intermittent Dexamethasone administration (1-15 days - 6 mg/m2, 15-22 day - pause, 22-29 days - 6 mg/m2).
2426584|NCT03390387|Active Comparator|Dexa constant|Induction therapy with continuous Dexamethasone administration (6 mg/m2 1-29 days).
2426585|NCT03390387|Active Comparator|Dexa|Therapy with Dexamethasone (6 mg/m2) as basic glucocorticoid preparation.
2426586|NCT03390387|Experimental|Medrol|Therapy with Methylprednisolone (60 mg/m2) as basic glucocorticoid preparation.
2426587|NCT03390387|Experimental|IDA|Induction and consolidation therapy with Idarubicin
2426588|NCT03390387|Active Comparator|DNR|Induction and consolidation therapy with Daunorubicin
2426589|NCT03390387|Experimental|Protocol Ib+|Two-phase induction therapy (additional second phase of induction - protocol Ib)
2426590|NCT03390387|Active Comparator|Protocol Ib-|Standard induction therapy (without second phase)
2426591|NCT03390387|Active Comparator|Bortezomib-|Consolidation therapy without Bortezomib
2426592|NCT03390387|Experimental|Bortezomib+|Consolidation therapy with Bortezomib 1.3 mg/m2 N12 (N4 in each reinduction)
2426593|NCT03390374|Experimental|Nystatin group|Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day
2426594|NCT03390374|No Intervention|Control group|Sterile water 1 mL three times a day for oral hygiene
2426595|NCT03390361|Active Comparator|LCS|Laser cataract surgery will be performed. 5-minutes after LCS aqueous humour will be collected and frozen in -80° celsius.
2426596|NCT03390361|Placebo Comparator|MCS|Manual cataract surgery will be performed. Aqueous humour will be collected and frozen in -80° celsius before MCS starts.
2426598|NCT03390322|Experimental|Duodenal Glycemic Control™|
2426599|NCT03390309|Other|Partially Hydrolyzed Formula|Infant was identified and got 1 or more scores by using infant feeding & stool pattern questionnaire at Visit 1 will be assigned into experimental group randomly
2426600|NCT03390309|Placebo Comparator|Normal Formula|Normal Formula
2426601|NCT03390296|Experimental|Arm A (anti-OX40 antibody PF-04518600)|Patients receive anti-OX40 antibody PF-04518600 IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426602|NCT03390296|Experimental|Arm B (azacitidine, venetoclax, GO)|Patients receive azacitidine IV over 10-40 minutes or via injection SC on days 1-7 or 1-5 and 8-9. Patients also receive venetoclax PO on days 1-28 and GO IV over 2 hours on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426603|NCT03390296|Experimental|Arm C (azacitidine, GO, avelumab)|Patients receive azacitidine and GO as in Arm B. Patients also receive avelumab IV over 60 minutes on days 1 and 14. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426604|NCT03390296|Experimental|Arm D (azacitidine, venetoclax, avelumab)|Patients receive azacitidine and venetoclax as in Arm A and avelumab as in Arm C. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426605|NCT03390296|Experimental|Arm E (azacitidine, avelumab, anti-OX40 antibody PF-04518600)|Patients receive azacitidine and avelumab as in Arm C and anti-OX40 antibody PF-04518600 as in Arm A. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426606|NCT03390296|Experimental|Arm F (GO, glasdegib)|Patients receive GO IV over 2 hours on days 1, 4, and 7, and glasdegib PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2426607|NCT03390283||Observational (Online survey)|Participants complete online survey on an iPad over 20 minutes.
2426608|NCT03390270||Patients with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
3187294|NCT00754689|Active Comparator|Arm 2|Metformin 1000mg bid + placebo
2426610|NCT03390244|Experimental|FCVB Implant|All subjects in this study are in the experimental treatment arm and will receive the FCVB implant
3187295|NCT00754689|Active Comparator|Arm 3|Rimonabant 20mg once daily (od) + placebo
2427271|NCT03385655|Experimental|Carboplatin platinum based chemotherapy|
3187296|NCT00754689|Experimental|Arm 4|Rimonabant 10mg bid (from week 2) in combination with metformin 500mg bid
3187297|NCT00754689|Experimental|Arm 5|Rimonabant 10mg bid (from week 2) in combination with metformin 1000mg bid
3187298|NCT00754702|Experimental|1|Vinorelbine metronomic/Lapatinib
3187299|NCT00754715|Experimental|AZD2516|
3187300|NCT00754715|Placebo Comparator|Placebo|
3187301|NCT00754728|Experimental|I|
3187302|NCT00754754|Experimental|Brain Retraction Monitoring Sensor|
2426611|NCT03390231|Experimental|Stem Cell Educator|"The Stem Cell Educator (SCE) technology involves a closed-loop system that circulates a patient's blood through a blood cell separator, briefly cocultures the patient's immune cells with adherent CB-SCs in vitro, and returns only the educated immune cells to the patient's circulation. Several mechanistic studies with clinical samples and animal models have been conducted to demonstrate the proof of concept and clinical safety of SCE therapy. They suggest that SCE therapy may function via CB-SC induction of immune tolerance in the autoimmune T cells and pathogenic monocytes/macrophages that are encountered through the action of the autoimmune regulator (AIRE) and other molecular mechanisms. Following induction of immune tolerance in the immune cells, the immune balance and homeostasis may be restored when treated cells are returned in vivo."
2426612|NCT03390218|Experimental|TAO (Therapy Assisted Online)|TAO participants will attend a once weekly group in a computer lab. Each participant will complete an interactive educational module using an evidence based protocoled treatment for anxiety and/or depression, and have a brief session with the group leader to discuss application of the content. Participants will have access to a companion app they may use between sessions to practice skills and reinforce learning.
2426613|NCT03390218|Active Comparator|Treatment as usual|After the completion of a psychosocial assessment, and development of a treatment plan, clients are offered individual and group therapy sessions, case management services, and medication management services depending on the diagnoses. Individual and group therapy is often generic in nature as well, although some structured, evidence-based treatments are offered such as Psycho-Education Multi-Family Group and Illness Management Recovery.
2426614|NCT03390205||Patients|
2426615|NCT03390205||Controls|
2426616|NCT03390192|Experimental|Dual-mode stimulation|"Dual-mode stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and active tDCS. 1 Hz of rTMS is applied over the contralesional M1 for 20 minutes with simultaneous application of anodal tDCS on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2426617|NCT03390192|Active Comparator|Single sham stimulation|"Single sham stimulation is applied over the bilateral primary motor cortex (M1) using active rTMS and sham tDCS. 1 Hz of rTMS over the contralesional M1 was applied for 20 minutes with simultaneous application of tDCS with sham mode (no stimulation) on the ipsilesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2426618|NCT03390179||diabetes|Patient with non insulin diabetes
2426619|NCT03390179||control|Patient without diabete
3187303|NCT00754819|Active Comparator|1|Colchicine 1mg daily oral
3187304|NCT00754819|Placebo Comparator|2|Placebo 1 capsule daily oral
2426622|NCT03390153|Experimental|semi flexible socket group|A new form of residuum containment is the semi-flexible carbon fiber prosthetic socket. A semi-flexible carbon fiber socket is constructed with the same security for the subject in mind, and is even more lightweight than a rigid socket. The carbon fiber and resin used in a semi-flexible socket may provide the same durability and stability as previous designs, but will deform, intentionally, without failing (breaking). This distinct feature of semi-flexible sockets makes them a potential option for people living with limb loss. By moving slightly with the residual limb, the socket-user-interface should experience fewer forces/stresses, and yield greater comfort for the prosthetic user.
2426623|NCT03390153|Active Comparator|rigid fiber socket group|A rigid carbon fiber socket is constructed for security and is mechanically lightweight to ensure stability and efficient build height. Carbon is used for its durability and stability. It proves to be a detriment in comfort and flexibility. The standard for carbon fiber weaves come in two forms: Unidirectional (UD) and Bidirectional (BD). UD carbon fiber has a zero-degree alignment, which is highly durable when compressed, but has low torsional durability. The BD carbon fibers are aligned in a 90 degree angle allowing for moderate compression and torsional strength. When oriented at 45 degrees to the line of progression, fibers become more flexible and exhibit greater torsional strength. Resins and glass composites are added to ensure security and sturdiness.
2426624|NCT03390140|Experimental|Group|ReInventing Yourself after SCI structured group CBT and ReInventing Yourself after SCI study-specific workbook
2426625|NCT03390140|Active Comparator|Indiv|ReInventing Yourself after SCI study-specific workbook and ReInventing Yourself after SCI YouTube videos
2426626|NCT03390140|No Intervention|Control|No group sessions, no YouTube videos, no workbook
2426627|NCT03390127|Experimental|Group P|After LMA Supreme™ insertion, PEEP of 7 cmH2O would apply during general anesthesia with mechanical ventilation.
2426628|NCT03390127|No Intervention|Group Z|After LMA Supreme™ insertion, PEEP would not apply during general anesthesia with mechanical ventilation.
3187305|NCT00754858|Experimental|belotecan and Cisplatin|belotecan 0.5 mg/m2 and Cisplatin 60mg/m2
3187306|NCT00754871|Experimental|Arm 1|
3187307|NCT00754871|Experimental|Arm 2|
3187308|NCT00754871|Experimental|Arm 3|
3187309|NCT00754871|Experimental|Arm 4|
3187310|NCT00754884|Experimental|A|200 U.I. of intranasal salmon calcitonin
3187311|NCT00754884|Placebo Comparator|B|intranasal saline solution and glycerol
3187312|NCT00754897||1|"We will do a database search to identify children less than 1 year of age that have undergone inguinal hernia surgery during the years of 1999-2007, and children who have had inguinal hernia surgery between the ages of 1 and 3 years during the years 1999-2007.~We will then do a telephone interview of the parents of these children to determine if there are siblings that are within three years of age and have not have any exposure to anesthetics agents or sedatives before their 3rd birthday."
3187313|NCT00754910||Group 1|Patients receive porfimer sodium IV over 3-5 minutes and undergo irradiation with red light 48 hours later. Patients receive 2 more treatments at 2-day intervals.
3187314|NCT00754975|Experimental|I|JACTAX LD DES
3187315|NCT00754975|Active Comparator|II|TAXUS™ Libertè™ DES
3187316|NCT00754988|Placebo Comparator|Placebo|Once daily oral administration of placebo (matching sitagliptin). Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
3187317|NCT00754988|Active Comparator|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin. Once weekly sc injection of placebo (matching taspoglutide). Continued treatment with metformin at prescribed doses.
3187318|NCT00754988|Experimental|Taspoglutide 10 mg|Once weekly subcutaneous (sc) injection of 10 mg of taspoglutide. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
2426634|NCT03390075||ResearchNow NuVal shoppers|a convenience sample of 665 shoppers at two NuVal chains.
2426635|NCT03390062|Experimental|apatinib|apatinib 500 mg orally daily until the untolerabale toxicities、desease progress or death
2426636|NCT03390049|Active Comparator|Fractional CO2 Laser Treatment|Fractional CO2 laser will be applied to the entire vestibule, anteriorly to the fourchette, and laterally to the labia majora. This takes approximately 5 minutes to complete. A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. EMLA cream will be applied to the introitus for 20 minutes and wiped clean and dried prior to each laser session. Subjects will be advised to avoid intercourse for at least 3 days after each laser session because a mild inflammatory reaction may last up to 48 hours after a laser session. Topical lidocaine 5% ointment may be used for any vulvar discomfort post-procedure.
2426637|NCT03390049|Sham Comparator|Sham Laser Treatment|A treatment cycle will consist of three laser sessions separated by 6 weeks +/- 1 week. The procedures will take place in the outpatient clinic. Subjects assigned to sham laser will undergo the same pre-treatment with EMLA cream and will receive the same post-treatment instructions as the fractional CO2 laser subjects.
2426638|NCT03390036|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
2426639|NCT03390036|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
2426640|NCT03390036|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
2426641|NCT03390023||Hispanic Women|Hispanic women who have been pregnant within the past 5 years.
2426642|NCT03390023||Close Family Member|Close family member of participants in Group 1 - Hispanic Women.
2426643|NCT03390010|Active Comparator|Extra medication group|"-Procedure : Giving misoprostol plus syntocinon and methergibe drugs during CS~this group in which prevention of uterine atony is made by intrauterine misotac plus the usual syntocinon and methergine during cesarean section"
2426644|NCT03390010|Active Comparator|Active management of labour group|"Procedure: Giving syntocinon and methergine drugs during cesarean section~this group in which prevention of uterine atony is made by the usual active management of labour syntocinon and methergine during cesarean section"
2426645|NCT03389984|Experimental|Adalimumab|
2426646|NCT03389971|Active Comparator|multi-sidehole catheter|
2426647|NCT03389971|Experimental|USAT catheter|
2426648|NCT03389945|Active Comparator|25G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 25 gauge spinal needle.
2426649|NCT03389945|Experimental|27G Dural Puncture Epidural Block|Patients will receive a dural puncture epidural block with a 27 gauge spinal needle.
2426650|NCT03389932|No Intervention|Standard of Care (Control)|For patients who are randomized to the control condition and who are or become potentially eligible for transplant during their enrollment in the study, they will not receive any additional interventions during the study period. Patients in this condition will only receive the education that is administered by the KPSC Kidney Transplant Program and will not receive any educational materials designed for the intervention group of this study.
2426651|NCT03389932|Experimental|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
2426652|NCT03389906|Experimental|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants).
3187319|NCT00754988|Experimental|Taspoglutide up-titrated to 20 mg|Once weekly sc injection of 10 mg of taspoglutide for the first 4 weeks, then up-titrated to once weekly sc injection of 20 mg of taspoglutide from week 5 onwards. Once daily oral administration of placebo (matching sitagliptin). Continued treatment with metformin at prescribed doses.
3187320|NCT00755001||with Plasma HA|BiHapro Hip stem with PPS Ti + Plasma HA
2426655|NCT03389880|Active Comparator|Patellar denervation|
2426656|NCT03389880|Experimental|Non-patellar denervation|
2426657|NCT03389867|Experimental|Male Sexual Health Formulation|Kaempferia parviflora extract 100mg daily
3187321|NCT00755001||with BoneMaster HA|BiHapro Hip stem with PPS Ti + BoneMaster HA
3187322|NCT00755014|Experimental|2|Forty subjects are randomized to a group (n=20) that consumed red wine (100 ml) or a group (n=20) that consumed beer (250 ml) daily for 3 weeks
3187323|NCT00755053|Active Comparator|Clotrimazole tablet (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
3187324|NCT00755053|Experimental|Clotrimazole ovule (Canesten, BAY-B5097)|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
3187325|NCT00755066|Experimental|F|Fluticasone propionate 200 µg intranasal
3187326|NCT00755066|Placebo Comparator|P|Placebo intranasal spray
3187327|NCT00755092|Active Comparator|1|Doula for Nulliparous women
3187328|NCT00755092|Active Comparator|2|Doula for Multiparous women
3187329|NCT00755118|Experimental|1|LoHP/AIO/Avastin->CPT-11/AIO/Erbitux
3187330|NCT00755144|Experimental|1|ROCC
3187331|NCT00755144|Active Comparator|2|LCS
3187332|NCT00755157|Experimental|1|Docetaxel(metronomic)/Bevacizumab
3187333|NCT00755170|Experimental|1|Vinorelbine metronomic + bevacizumab
3187334|NCT00755209|Placebo Comparator|Transamin|"Drug: tranexamic acid~Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours"
3187335|NCT00755248||1|Pts undergoing CABG or OPCAB
3187336|NCT00755287|Active Comparator|insulin glargine|insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment
3187337|NCT00755287|Experimental|taspoglutide 10 mg|taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment
3187338|NCT00755287|Experimental|taspoglutide 10 mg/20 mg|taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment
2426662|NCT03389841|Active Comparator|Intervention|Education of the caregiver
2426663|NCT03389841|No Intervention|No intervention|Usual care
2426665|NCT03389815|Experimental|WX-0593 Tablets|The first part is a dose-escalation design in patients with ALK/ROS1-positive solid tumor. The second part is an expansion in non-small cell lung Cancer (NSCLC) characterized by abnormalities in ALK expression.
2426666|NCT03389802|Experimental|Stratum 1|The recurrent, progressive, or refractory primary malignant non-brainstem CNS tumor patients will be treated with APX005M.
2426667|NCT03389802|Experimental|Stratum 2|The newly diagnosed diffuse intrinsic pontine gliomas (DIPGs) patients will be treated with APX005M.
2426668|NCT03389789|Experimental|Oral glucose solution + maternal holding|Infants will receive 2 mL of oral glucose solution two minutes before the heel-prick and will be held in the mothers' lap (maternal relationship) throughout the painful procedure.
2426669|NCT03389789|Experimental|Breastfeeding|Infants will be breastfed two minutes before the heel-prick and throughout the painful procedure.
2426670|NCT03389789|Active Comparator|Oral glucose solution|Infants will receive 2 mL of oral glucose solution given two minutes before the heel-prick on a changing table.
2426671|NCT03389789|Active Comparator|Oral expressed breastmilk|Infants will receive 2 mL of expressed breastmilk given two minutes before the heel-prick on a changing table.
2426672|NCT03389763|Experimental|SPI-guided remifentanyl|remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, SPI will be monitored on-line; when delta SPI>15, infusion speed of remifentanyl will be increased by 50%
2426673|NCT03389763|Experimental|PRD-guided remifentanyl|solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute, PRD measurement every 15 minutes; when PRD>5% infusion speed of remifentanyl will be increased by 50%
2426674|NCT03389763|Experimental|BBS-guided remifentanyl|BBS assessment every 5 minutes, solution remifentanyl solution will be administered intravenously at a rate 0,25 mcg/kg of body weight/minute; when BBS>2, infusion speed of remifentanyl will be increased by 50%
2426675|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxymorphone|Intravenous (IV) Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2426676|NCT03389750|Active Comparator|Intravenous Challege Drug: Oxycodone|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2426677|NCT03389750|Active Comparator|Intravenous Challege Drug: Morphine|IV Dose Range: 0, 18, 32, 56 mg/70kg of the participant's body weight
2426678|NCT03389750|Active Comparator|Intravenous Challege Drug: Hydromorphone|IV Dose Range: 0, 5.6, 10, 18 mg/70kg of the participant's body weight
2426679|NCT03389750|Placebo Comparator|Intravenous Challege Drug: Placebo|IV saline
2426680|NCT03389737|Experimental|Experimental|Experimental group will have monthly contact with the physicians, during which the athletes will receive individualized care and guidance in support of their performance goals.
2426681|NCT03389737|Active Comparator|Control|Control group will not have monthly contact with the physicians.
2426682|NCT03389724|Experimental|Group capoten (Intervention arm)|Patients will receive prophylactic ACE-I(Capoten®) at day 1 of initiation of chemotherapy and is to be continued for 1 year after the end of treatment. Patients will remain on this arm until they experience any of the study primary or secondary end-point where they will be off-study and will receive cardiotoxicity treatment independently.
2426683|NCT03389724|No Intervention|Group standard treatment (Control arm)|Patients will not receive ACE-I as prophylaxis, and will be monitored and evaluated for first signs of cardiotoxicity based on the above mentioned end-points.
2426684|NCT03389698|Active Comparator|Heatlthy Control Group|cognitively normal (CN) subjects in two age groups: young(20-40) and old (65-85)
2426685|NCT03389698|Active Comparator|Amnestic mild cognitive impairment (aMCI)|32 participants who have aMCI.
2426686|NCT03389685|Experimental|Platelet Rich Plasma|Platelet Rich Plasma will be prepared using Genesis CS EmCyte PurePRP II system.
2426687|NCT03389685|Placebo Comparator|Saline Placebo|Unmarked syringe with 5 ml of saline
2426688|NCT03389672||spinal anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2426689|NCT03389672||epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2426690|NCT03389672||combined spinal-epidural anesthesia|The anesthesia technique were applied with modified approach and conventional approach
2426691|NCT03389659|Experimental|Vitamin D3 group|vitamin D3 2000IU (400IU*5pills） po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
2426692|NCT03389659|Placebo Comparator|control group|placebo 5 pills po. qd continue to disease progression plus XELOX (oxaliplatin 130mg/m2 d1; capecitabine 1000mg/m2 bid po. d1-14; q3w) or mFOLFOX (oxaliplatin 85mg/m2，d1; leucovorin 400mg/m2，d1；5-fluorouracil 400mg/m2，d1; 5-fluorouracil 2400mg/m2 continue 46h, q2w)
2426693|NCT03389646|Active Comparator|Treated with Device: Including sham|"Treated with CERAMENTTM|G or V for filling of bone defects in the tibia and/or femur and/or the acetabulum."
2426694|NCT03389646|No Intervention|Control|Control without CERAMENT device
2426695|NCT03389633|Experimental|Rehabilitation group|this group follows a 3 months rehab program
2426696|NCT03389633|No Intervention|No rehabilitation|This group does not follow a rehab program
2426697|NCT03389620|Active Comparator|Transforaminal Cervical Epidural Corticosteroid Injections|
2426698|NCT03389620|Experimental|Lateralized Interlaminar Epidural Corticosteroid Injections|
2426699|NCT03389607||diabetic|the patients must have diabetic disease
2426700|NCT03389607||control|the patients must not have diabetic
2426701|NCT03389594|No Intervention|Surgical guide designed from voxel size 0.2mm|Surgical guide will be designed based on CBCT voxel size 0.2mm
2426853|NCT03388424||quantification of microbiota in Brain|Patients of both sex with neural disorders and diseases
3187339|NCT00755300||1|Standard Total Knee Replacement
3187340|NCT00755300||2|Computer Guided Knee Replacement
3187341|NCT00755352|Experimental|1|pravastatin tablets and Welchol tablets
2426706|NCT03389542|Experimental|Early mitral valve repair|Surgery will be performed within 3 months after randomization. Clinical interview will be performed at discharge, at 6 months and afterwards yearly until the end of follow-up. Echocardiography will be performed at discharge, at 6 months and at the end of follow-up.
2426707|NCT03389542|Active Comparator|Conservative management|Patients will be followed up by clinical interview and echocardiography every 6 months.
2426708|NCT03389516|Active Comparator|Polymem breast pads|
2426709|NCT03389516|Active Comparator|Lanolin|
2426710|NCT03389503|Active Comparator|Right radial approach|Right radial approach for coronary angiography and coronary intervention
2426711|NCT03389503|Active Comparator|Left radial approach|Left radial approach for coronary angiography and coronary intervention
2426712|NCT03389490|Experimental|Active|Insulin glargine 300U/ml
2426713|NCT03389490|Active Comparator|Control|Neutral Protamine Hagedorn insulin
3146438|NCT00101179|Experimental|Arm I|"Patients receive azacitidine subcutaneously on days 1-10 and oral MS-275 on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses* of MS-275 until the maximum tolerated dose (MTD) is determined. Patients receive adjusted doses of azacitidine based on clinical response. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 9 additional patients are treated at the MTD."
3146439|NCT00101205|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2426716|NCT03389464|Experimental|confrontation group|computer-based confrontation with dysfunctional beliefs
2426717|NCT03389464|No Intervention|control group|no computer-based confrontation with dysfunctional beliefs
2426718|NCT03389451|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
3146440|NCT00101231|Experimental|Treatment (flavopiridol)|Patients receive flavopiridol IV over 30 minutes followed by a 4-hour infusion on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of unacceptable toxicity or disease progression.
3146441|NCT00101244|Experimental|Treatment (ispinesib)|"Patients receive SB-715992 IV over 1 hour on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SB-715992 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 10 additional patients are treated at the MTD."
2426721|NCT03389425|Experimental|SIMPLE weightloss group|
2426722|NCT03389412|Experimental|Treatment without evaluating the home recordings, medicin.|Children will receive desmopressin without evaluating the home recordings.
2426723|NCT03389412|Experimental|Treatment without evaluating the home recordings, alarm.|Children will receive conditional alarm without evaluating the home recordings.
2426724|NCT03389412|Active Comparator|Treatment based on home recordings, polyuria.|Children with polyuria based on the home recordings will receive desmopressin.
2426725|NCT03389412|Active Comparator|Treatment based on home recordings, reduced bladder capacity.|Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
2426726|NCT03389412|Active Comparator|Treatment based on home recordings, both.|Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
2426727|NCT03389412|Active Comparator|Treatment based on home recordings, none.|Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
2426728|NCT03389399||Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days|This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.
2426729|NCT03389386||Congestive Heart Failure (NYHA II-IV)|"N=90~Patients with a clinically documented diagnosis of congestive heart failure (CHF), as assessed per New York Heart Association (NYHA) functional classification will be prospectively and consecutively enrolled in this group. Patients will be of both sexes, enrolled in 1:1 ratio.~All subjects in this group will undergo blood withdrawal for laboratory analysis, transthoracic echocardiography (TTE) examination and will be treated with the Standard-of-care treatment according to their current clinical condition at admission."
2426730|NCT03389386||Healthy Control Group|"N=30~Healthy volunteers (both sexes, enrolled in 1:1 ratio) with a negative history of cardiovascular diseases will be enrolled in this group that will serve as a study control.~All subjects in this group will undergo blood withdrawal for laboratory analysis and transthoracic echocardiography (TTE) examination."
2426731|NCT03389373|Other|Child with full primary dentition|All children who match inclusion criteria are eligible to have a saliva sample obtained which will act as a proxy for bacterial levels. High bacteria levels are correlated with a higher risk of developing cavities.
3146442|NCT00101270|Experimental|Treatment (irinotecan hydrochloride, oxaliplatin)|Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2426784|NCT03388918|Experimental|Intervention group|"The intervention group has three steps:~Step I: Titration of medicine ( 0-3 months)~Step II: Telerehabilitation program at healthcare center or by call center ( 3 months)~Step III: Rehabilitation in everyday life ( 6 months)~The patients is monitoring vital signs such as blood pressure, pulse, weight, steps, respiration, and sleep. Have access to a Heart Portal that is an information cite on heart failure. Via the portal patients can see measured values & communicate with staff. Every other week the patients fill in an online questionnaires on symptoms, sleep and well being."
3187342|NCT00755352|Placebo Comparator|2|pravastatin tablets and Welchol placebo tablets
2426733|NCT03389334|Experimental|massage group|Subjects will complete the SF-36, ODI, demographics surveys and then will receive pre-treatment range of motion, muscle strength and visual analogue pain scale prior to massage. Then will have a 45-minute myofascial release massage. Then they will fill out the visual analogue pain scale again. (Approximately 90-minutes) The second and third visits: visual analogue scale prior to the treatment; 45-minute massage, by the same therapist who treated them during the initial visit, and will fill out a second visual analog pain scale following the treatment. (Approximately 60-minutes) The fourth visit: visual analogue pain scale and 45-minute massage; post-treatment SF-36, ODI surveys, visual analogue pain scale, post-treatment range of motion and muscle strength.
2426734|NCT03389321|Experimental|Treatment A-B|All subjects will receive treatment A followed by treatment B. Treatment A consists of a single oral dose (1 mg) of riociguat (Adempas) on Day 1. Treatment B consists of a loading oral dose of 30 mg macitentan (Opsumit) (3 tablets of 10 mg) on Day 5, then 10 mg of macitentan once daily from Day 6 to Day 15, with a concomitant administration of riociguat (1 mg) on Day 10.
3187343|NCT00755378|Experimental|1|
2426736|NCT03389295|Experimental|Reduced Target Delineation and Radiation Doses|All patients were assigned to receive induction chemotherapy (IC) followed by IMRT with adjuvant chemotherapy (AC). IMRT was administered 2 weeks after IC, and AC was administered 1 month after IMRT. IC or AC (TPF regimen) comprised docetaxel (60 mg/m2/day, day 1), cisplatin (25 mg/m2/day, days 1-3), and 5-fluorouracil (500 mg/m2/day with a 120-h infusion) administered once every 3 weeks for two cycles. During radiotherapy, involved retropharyngeal lymph nodes and intracavity lesions of the primary tumor were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) of the primary tumor were delineated according to the pre-IC volume of the primary tumor as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for delineation. The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
2426737|NCT03389269||Obese patients treated with AspireAssist|Healthy, obese with BMI > 27, treated with AspireAssist for weight management, the postprandial glucose metabolism will be tested with a meal test
2426738|NCT03389269||Matched controls|Healthy, obese with BMI > 27, the postprandial glucose metabolism will be tested with a meal test
2426739|NCT03389256|Experimental|apatinib combine with EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
2426740|NCT03389256|Active Comparator|EGFR-TKI|Every 4 weeks 1 cycle, evaluated the efficacy and safety once every 2 cycles, treat until disease progression or intolerable toxicity
2426741|NCT03389243|Experimental|metamizol|analgesic drug
2426742|NCT03389243|Experimental|paracetamol|analgesic drug
2426743|NCT03389243|Experimental|metamizole & paracetamol|analgesic drugs
2426744|NCT03389230|Experimental|Arm I (intratumoral/intracavitary delivery)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to alternative delivery routes for the optional infusions.
2426745|NCT03389230|Experimental|Arm II (dual delivery Tcm enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tcm cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
2426746|NCT03389230|Experimental|ARM III (dual delivery Tn/mem enriched)|Patients receive autologous HER2(EQ)BBzeta/CD19t+ Tn/mem cells via intratumoral/intracavitary catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
2426747|NCT03389217|Experimental|Real-tDCS + rehabilitation programme|The real transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 minutes over the the left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
2426748|NCT03389217|Active Comparator|Sham-tDCS + rehabilitation programme|The sham transcranial Direct Current Stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over left dorsolateral prefrontal cortex and rehabilitation programme for prevention and management of pain.
2426749|NCT03389204|Active Comparator|Breast surgery and exercise|Patient that underwent breast surgery only without other intervention with exercise of the upper limb and instruction to continue after discharge.
2426750|NCT03389204|Active Comparator|Breast surgery and no exercise|Patient after breast surgery alone are discharged without exercise and instructions.
2426751|NCT03389204|Active Comparator|Breast, axilar surgery with exercise|Patients that underwent surgery of the breast and axilar lymph node surgery with exercise of the upper limb and instruction to continue after discharge.
2426752|NCT03389204|Active Comparator|Breast, axillar surgery without exercise|The patients that underwent surgery of the breast and axilar nodes samples or dissection are discharged without exercise and instructions.
2426753|NCT03389191|Experimental|Patients with Viral Uveitis|Oral acyclovir 100 mg three times a day (TID).
2426851|NCT03388437|Active Comparator|NIPPV|Initial setting; PIP can be increased by 2 cm H 2 O from the pre-extubation PEEP of 5-6 cm for 72 hours post extubation
3187344|NCT00755378|Placebo Comparator|2|
3187345|NCT00755391|Placebo Comparator|supportive psychotherapy|supportive psychotherapy: 14 sessions
3187346|NCT00755391|Active Comparator|cognitive behavior therapy|cognitive behavior therapy: 14 sessions
3187347|NCT00755404|Active Comparator|A|
3187348|NCT00755404|Experimental|B|
3187349|NCT00755443|Experimental|2|
3187350|NCT00755443|Placebo Comparator|1|Bare metal stent
3187351|NCT00755456|Active Comparator|Glucose solution|
2426754|NCT03389178||stress group (SG)|"We will identify prospective subjects according with the inclusion criteria of the study, consistent on singleton pregnant women between 18 to 45 years of age in their third trimester (at least 28 weeks gestation). Upon acceptance participants will enter to Phase I-IV.~Women and participants will be categorized as stressed or controls after scoring the Cohen Perceived Stress Scale-10 (PSS-10). The PSS-10 has been validated in German speaking populations and will be a quick tool for screening stress among prospective subjects. For the purposes of the current study, a participant with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
2426755|NCT03389178||control group (CG)|"For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control.~Recruitment will continue until reaching the aimed cohort of n=75 subjects/group."
2426756|NCT03389165|Experimental|Elderly adults|Stair climbing with and without a wearable hip assist robot
2426757|NCT03389139|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia. (Near infrared spectroscopy (spinal anesthesia))
2426758|NCT03389139|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia. (Near infrared spectroscopy (general anesthesia)).
2426759|NCT03389126|Experimental|Avelumab|Avelumab 10 mg/kg every 2 wks until disease progression or unacceptable toxicity
2426760|NCT03389113|Experimental|Whole body vibration group|Whole body vibration group performed five sessions of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
2426761|NCT03389113|Active Comparator|Exercise only group|The control group performed the same session without vibration.
2426762|NCT03389100|Experimental|18F-MK6240 injection|intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), IV, total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
2426763|NCT03389087|Experimental|Apatinib and Etoposide Capsule|Apatinib and Etoposide Capsule
2426764|NCT03389061|Active Comparator|sofosbuvir/velpatasvir tablet|Single-dose sofosbuvir/velpatasvir as a whole tablet in a fasted state.
2426765|NCT03389061|Experimental|sofosbuvir/velpatasvir crushed|Single-dose crushed sofosbuvir/velpatasvir in a fasted state.
2426766|NCT03389048|Experimental|degenerative lumbar spine disease|patients who suffer from unilateral degenerative lumbar spine disease, undergo SLR test while being recorded by PMD-200
2426767|NCT03389035|Experimental|CARCIK-CD19|
3187352|NCT00755456|Experimental|Glucose and L-carnitine solution|
3187353|NCT00755469|Experimental|1|
2426770|NCT03389009||smartphone abusers|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
2426771|NCT03389009||smartphone non users|"Auto refractometer without cycloplegia Uncorrected visual acuity (logMAR conversion). Anterior segment slit lamp examination UBM examination settings :Supine decubitus position.5150 Vumax (Sonomed, USA) under standard illumination Parameters that will be measured: corneal thickness, anterior chamber depth, angle to angle distance, cornea-posterior capsular lens distance, lens thickness, pupillary diameter, angle of anterior champer and trabecular-ciliary process distance.~Cycloplegic refraction UBM examination will be repeated after cycloplegia with the same settings. The patients found to have spasm of accommodation will be subjected to ways to relief the spasm of accommodation and repetition of UBM if possible"
2426772|NCT03388996||Benign ovarian disease|The group consists of patients of benign ovarian diseases and health conditions (eg infertility), who would accept the tests of pelvic microbiomes.
2426773|NCT03388996||Malignant ovarian disease|The group consists of patients of high grade serous carcinoma, who would accept the tests of pelvic microbiomes.
2426774|NCT03388983|Experimental|6-week prehabilitation group|6-week prehabilitation
2426775|NCT03388983|No Intervention|Control group|Patients will receive standard preoperative care (including information about the surgery from an orthopedic surgeon, and a pamphlet summarizing tips of maintaining proper posture and staying active). The usual postoperative care does not include routine rehabilitation program though a short course of rehabilitation may be given based on orthopedic surgeons' discretion.
2426776|NCT03388970|Experimental|research group|normal saline 100ml+ vitamin K1 20mg ivgtt qd day0 and day1。
2426777|NCT03388970|Placebo Comparator|placebo group|normal saline100ml + normal saline 2 ml ivgtt qd day0 and day1
2426778|NCT03388957|Experimental|Propranolol|Patients in this group will be given Propranolol 0.5 mg/Kg orally.
2426779|NCT03388957|Experimental|Midazolam|Patients in this group will be given Midazolam 0.5 mg/Kg orally.
2426780|NCT03388957|Experimental|Propranolol and Midazolam|Patients in this group will be given Propranolol and Midazolam with a dose of 0.5 mg/Kg orally for each drug.
2426781|NCT03388944|Experimental|PCT group|PCT group
2426782|NCT03388944|No Intervention|Standard practice group|No intervention
2426783|NCT03388931|Experimental|Study group|Increased dose of radiation therapy for locally advanced squamous cell carcinoma of the larynx or hypopharynx. Patients will also receive standard-of-care chemotherapy with the treatment regimen to be determined by the treating physicians.
2426785|NCT03388918|No Intervention|Traditional rehabilitation group|"This group follows the International Cardiac Guidelines. There are three steps in this arm:~Step I: Titration of medicine (3 months).~Step II: Traditional rehabilitation at the healthcare center ( 3 months).~Step III: Everyday life with HF ( 6 months)~The participants do not have access to the Heart Portal and is not monitoring any vital signs."
2426786|NCT03388905|Experimental|Wearable Cardioverter Defibrillator group|
2426852|NCT03388424||Control|Healthy people of both sex
3187354|NCT00755482|Active Comparator|1|Subjects were given Aquamin F
3187355|NCT00755482|Placebo Comparator|2|Subjects were given a maltodextran placebo
2426789|NCT03388879|Experimental|Circular frame external fixator|A Taylor Spatial Frame should consist of 2 rings with 4 half pins/K-wire attached to each ring. If possible 3, not hydroxyapatite-coated, half pins and one K-wire should be attached to each ring. The half pins/K-wire should be spread in distance and direction for optimum stability.
2426790|NCT03388879|Active Comparator|Intramedullary nail|Nailing technique according to Karladani and Styf published technique (ref: Karladani AH, Styf J. Percutaneous intramedullary nailing of tibial shaft fratures: a new approach for prevention of anterior knee pain. Injury, Int. J. Care Injury 32 (2001) 736-39)
2426791|NCT03388866|Active Comparator|Mite extract sublingual immunotherapy|"Use of mite extract sublingual immunotherapy (SLIT) with increasing weekly doses of extracts of mite Dermatophagoides pteronyssinus, as represented below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Monthly Dilution Schedule Dilution of mite extract~1st and 2nd weeks (1st month) 1: 1000000 v: v 3rd and 4th weeks (1st month) 1: 100000 v: v~1st and 2nd weeks (2nd month)1: 10000 v: v 3rd and 4th weeks (2nd month) 1:1000 v: v~1st and 2nd weeks (3rd month) 1: 100 v:v 3rd and 4th weeks (3rd month) 1:10 v:v 3rd to 18th month 1:10 v: v"
2426792|NCT03388866|Placebo Comparator|SLIT placebo|"Patients in the control group will be submitted to the same administration schedule, but with allergen extract diluent (doubly distilled water solution and glycerin), as described below:~Weekly dose schedule Monday Wednesday Friday~st week 1 drop 2 drops 4 drops~nd week 6 drops 8 drops 8 drops~Intervention: Placebo - Immunotherapy allergen diluent"
2426793|NCT03388853|Experimental|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
2426794|NCT03388853|Placebo Comparator|Placebo|Placebo once daily for four weeks
2426795|NCT03388840|Experimental|Adipose derived stem cells suspention|suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
2426796|NCT03388840|Active Comparator|Platelet rich plasma|platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
2426797|NCT03388827|Experimental|Laminaria|Laminaria tent was introduced in the cervical canal
2426798|NCT03388827|Active Comparator|Laminaria plus Misoprostol|Laminaria and Misoprostol were introduced
2426799|NCT03388814|Active Comparator|Bupivacaine Group|Those patients randomized to surgeon infiltration will have a skin wheal performed with lidocaine at the site where an actual pectoralis nerve block would be performed as visualized using ultrasound. Surgeons performing infiltration techniques will be blinded to the contents of the injectate and those patients randomized to surgeon infiltration will receive pharmacy study drug labeled bupivacaine injected in the same fashion and volume as the saline group for oncologic and plastic surgery.
2426800|NCT03388814|Experimental|Pectoralis Nerve block Group|Those patients who are randomized to pectoralis nerve block will have randomization immediately preoperatively and will undergo the nerve block procedure using local anesthetic in the standard fashion. Those patients randomized to pectoralis block will have a standard volume of normal saline injected for oncologic and plastic surgery.
2426801|NCT03388801|Experimental|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
2426802|NCT03388788|Experimental|Normal Weight|Healthy lean controls [18.5<BMI<25 kg/m2 and WC <94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
2426803|NCT03388788|Experimental|Overweight|Healthy obese [30≤BMI<40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging using radiopharmaceuticals (11C-meta-hydroxyephedrine, 11C-CGP12177, and O15-water).
2426804|NCT03388775||Patients with deep venous thrombosis|"Five-year prospective records of deep venous thrombosis have been collected by the RHEUNI group of five public schools in the State of São Paulo.~Demographic data of patients will be evaluated along with the main risk factors, clinical picture, diagnostic methods, use of different drugs to treat the disease and its complications."
2426805|NCT03388762|Active Comparator|GlucoSupreme™ Herbal|Each daily serving of four GlucoSupreme™ Herbal tablets includes extracts from: cinnamon bark (Cinnamomum cassia) 500 mg, banaba leaf (Lagerstroemia speciosa standardized to 1% corosolic acid) 200 mg, kudzu root (Pueraria lobata standardized to 40% isoflavones) 200 mg, fenugreek seed (Trigonella foenum-graceum standardized to contain 60% saponins) 200 mg, and gymnema leaf (Gymnema sylvestre standardized to contain 25% gymnemic acid). Additionally, American ginseng root (Panax quinquefolius standardized to contain 5% ginsenosides) 200 mg, and berberine HCl derived from bark (Berberis aristata) 500 mg. Other ingredients include Cellulose (capsule), microcrystalline cellulose, silicon dioxide, and vegetable stearate.
2426806|NCT03388762|Placebo Comparator|Control|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
2426807|NCT03388749|Experimental|Liposomal annamycin|
2426808|NCT03388736|No Intervention|No lavender|No mist will be diffused into the environment.
2426809|NCT03388736|Active Comparator|0,1 lavender|0,1 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
2426810|NCT03388736|Active Comparator|0,3 lavender|0,3 ml lavender oil diluted in 120 ml water will be diffused into the environment with (17-33 ml mist output per hour).
2426811|NCT03388723||Arm 1: Discovery phase|"Approximately 150 women with Gestational Diabetes Mellitus (GDM) and 150 controls, and their offspring will be recruited in Pune (from KEM Hospital and Vadu). The objective will be:~Identification of epigenetic signatures~Measurements of B vitamins and 1-C metabolites in mothers' blood and cord blood~Glucose, insulin and lipids in mothers during pregnancy~Anthropometry and blood pressure"
2426812|NCT03388723||Arm 2: Validation phase|Approximately 200 women with Gestational Diabetes Mellitus (GDM) and 200 controls, and their offspring will be recruited in Punjab, and 150 stored cord blood samples of GDM offspring in Pune will be investigated to validate the epigenetic signatures discovered in Arm 1.
2426813|NCT03388723||Arm 3: Stability phase|"Approximately 500 offspring of women with Gestational Diabetes Mellitus (GDM) from Pune (~ half below 10 years and the rest over 10 years) will be investigated to study:~Stability of epigenetic signatures in offspring through childhood and adolescence~Relation of these signatures with phenotype"
2426814|NCT03388671|Active Comparator|TAB Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Transversus abdominis plane block.
2426815|NCT03388671|Active Comparator|Psoas Block|Patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided psoas block.
3187356|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin 3 mg QD|
3187357|NCT00755495|Experimental|Ramelteon 8 mg QD and Doxepin Placebo QD|
3146443|NCT00101296|Experimental|Treatment (tipifarnib)|Patients receive oral tipifarnib twice daily on days 1-7 and 15-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing relapse after previously achieving CR may receive additional tipifarnib at the current dose level for newly registered patients.
3187358|NCT00755495|Active Comparator|Ramelteon Placebo QD and Doxepin 3 mg QD|
3187359|NCT00755495|Placebo Comparator|Placebo|
3187360|NCT00755508|Experimental|Ramelteon 4 mg QD and Gabapentin 400 mg QD|
3187361|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin 800 mg QD|
2426826|NCT03388593|Placebo Comparator|Placebo|Placebo in addition to standard therapy
2426827|NCT03388593|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
2426828|NCT03388580||BAL|patients undergoing elective bronchoalveolar lavage
2426829|NCT03388567|Experimental|Staff pharmacy whith intervention|Staff pharmacy who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
2426830|NCT03388567|No Intervention|Staff pharmacy without intervention|Staff pharmacy who will receive only pharmacy information
2426831|NCT03388554|Active Comparator|Active tDCS|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
2426832|NCT03388554|Sham Comparator|Sham tDCS|In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.
2426833|NCT03388541|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
2426834|NCT03388541|Placebo Comparator|Placebo|NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
2426835|NCT03388528|Experimental|Treatment Group|This is a single arm study where forty patients with a genetically or biochemically proven diagnosis of mitochondrial disease will be recruited from the mitochondrial CRESTA clinic and / or Medical Research Council Mitochondrial Disease Patient Cohort Study in Newcastle. All forty patients will be assessed prior to and following a 12 week low residue diet study intervention.
2426836|NCT03388515|Experimental|SSS11, 1.5mg|SSS11, 1.5mg, iv, single dose at Day 1;
2426837|NCT03388515|Experimental|SSS11, 3.0mg|SSS11, 3.0mg, iv, single dose at Day 1;
2426838|NCT03388515|Experimental|SSS11, 6.0mg|SSS11, 6.0mg, iv, single dose at Day 1;
2426839|NCT03388515|Experimental|SSS11, 12.0mg|SSS11, 12.0mg, iv, single dose at Day 1;
2426840|NCT03388515|Experimental|SSS11, 24.0mg|SSS11, 24.0mg, iv, single dose at Day 1;
2426841|NCT03388502|Experimental|Text Messaging (SMS) Bot|Patients undergoing total joint (hip & knee) arthroplasty will be enrolled in their physician's automated 'Text Messaging (SMS) Bot' in addition to receiving the routine perioperative education and instructions.
2426842|NCT03388502|Active Comparator|Routine Perioperative Instructions|Patients undergoing total joint (hip & knee) arthroplasty will receive only their 'Routine Perioperative Instructions'.
2426843|NCT03388489|Experimental|Mind-Body Walking|breathing, walking and meditation
2426844|NCT03388489|No Intervention|Usual care|maintain their daily activity
2426845|NCT03388476||Suspicion of pulmonary hypertension|At Patients with suspicion of pulmonary hypertension, which get a right heart catheterization, in the context of the study the exhaled air, precious the endtidal carbon dioxide (CO2), before or after the right heart catheterization will be measured through capnography.
2426846|NCT03388463|Active Comparator|Omeprazole group|Patients received intravenous bolus of 80 mg omeprazole followed by 8mg/h infusion for the whole period of ICU stay.
2426847|NCT03388463|Placebo Comparator|Placebo group|Patients received intravenous omeprazole 40mg bolus dose once daily followed by normal saline infusion.
2426848|NCT03388450|Active Comparator|Omega 3|Patients received enteral nutrition supplemented with 1000 mg omega-3.
2426849|NCT03388450|Placebo Comparator|Placebo|Patients received enteral nutrition supplemented without 1000 mg omega-3.
2426850|NCT03388437|Experimental|NI-NAVA|Initial setting; NAVA level of 2; PEEP of 5-6 cm H 2 O, apnea time 5-10 seconds, target Edi maximum between 10-15 and minimum < 5 for 72 hours post extubation
3187362|NCT00755508|Experimental|Ramelteon 8 mg QD and Gabapentin Placebo QD|
3187363|NCT00755508|Active Comparator|Gabapentin 800 mg QD|
3187364|NCT00755508|Placebo Comparator|Placebo|
3187365|NCT00755521|No Intervention|B|
2426860|NCT03388398||Mother-Infant Pairs|Mothers or caregivers (at least 16 years of age) and their infants who are 9 to 18 months of age at the time of their survey.
2426861|NCT03388398||Mothers or caregivers|Mothers or caregivers (at least 16 years of age) who are 19 to 36 months postpartum at the time of the survey.
2426862|NCT03388398||Healthcare staff|Healthcare staff (employed staff and volunteers at least 18 years of age) at all participating healthcare facilities.
2426863|NCT03388398||Providers|Health care providers (at least 18 years of age) at select participating healthcare facilities.
2426864|NCT03388398||Patients|Patients (at least 18 years of age) receiving care at select participating healthcare facilities.
2426865|NCT03388385|Placebo Comparator|Placebo|Intervention: 250 mL Sodium Chloride 0.9% Intravenous Solution, representing control infusion, over 30 minutes.
2426866|NCT03388385|Active Comparator|Ferric carboxymaltose|Intervention: 1000 mg Ferinject in 250 mL 0.9%NaCl, representing medication in study infusion, over 30 minutes.
2426867|NCT03388372|Experimental|Nimotuzumab plus RT and temozolomide.|Nimotuzumab, administered once a week intravenously in addition to radiotherapy with concomitant and adjuvant temozolomide (TMZ) after surgery.
2426868|NCT03388359|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment.
2426869|NCT03388359|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen (Dermatophagoides pteronyssinus, Dosimeter ProvoX (Ganshorns)); Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation (eosinophils, fibrobralst, airway smooth muscle cells); Inhibition of Wnt and Smad signaling pathways; Extracellular matrix turnover and deposition assessment."
2426870|NCT03388346|Experimental|68Ga PSMA PET scan|Ga-68 PSMA-HBED-CC PET
2426871|NCT03388333||Atrial fibrillation ablation group|Patients undergoing catheter ablation for the treatment of atrial fibrillation.
2426872|NCT03388333||Electrophysiological study group|Patients undergoing a diagnostic electrophysiological study without ablation.
2426873|NCT03388333||Atrial flutter ablation group|Patients undergoing catheter ablation of right atrial flutter at the cavotricuspid isthmus.
2426874|NCT03388320|Experimental|Participants receiving A-CHESS|Participants will be provided access to the smartphone application A-CHESS (intervention) that will be downloaded to their phone.
2426875|NCT03388307|Experimental|unilateral laminotomy|patients with lumbar canal stenosis who undergo unilateral laminotomy for bilateral decompression
2426876|NCT03388307|Experimental|decompressive laminectomy|patients with lumbar canal stenosis who undergo decompressive laminectomy
3187366|NCT00755521|Experimental|A|adding Etoricoxib to the basic therapeutic regimen
3187367|NCT00755534|Experimental|1|Irinotecan+Erbitux -> XELOX+Erbitux
2426879|NCT03388281||Patients with implanted pacemaker|Patients with implanted cardiac pacemaker registered in pacemaker database of the Department of Cardiology at the Medical University Vienna were included.
3187368|NCT00755534|Experimental|2|XELOX+Erbitux ->Irinotecan+Erbitux
3187369|NCT00755547|Experimental|High Intensity|70-85% of peak oxygen uptake for 30 min 3-5 days/week.
2426882|NCT03388255|Experimental|Polydeoxyribonucleotides|"PLACENTEX: Polydeoxyribonucleotides 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
2426883|NCT03388242||Normal control people|These people are age-matched with the patients with MCI. No intervention is applied.
2426884|NCT03388242||Patients with MCI|These patients have met the criteria for diagnosing MCI. No intervention is applied.
2426885|NCT03388242||Patients with AD|These patients are diagnosed with AD. No intervention is applied.
2426886|NCT03388216|Experimental|Stage I - Drug: INM004 Dose 1|
2426887|NCT03388216|Placebo Comparator|Stage I - Placebo Dose 1|
2426888|NCT03388216|Experimental|Stage I- Drug: INM004 Dose 2|
2426889|NCT03388216|Placebo Comparator|Stage I- Placebo Dose 2|
2426890|NCT03388216|Experimental|Stage II- Drug: INM004 Repeated Dose|
2426891|NCT03388216|Placebo Comparator|Stage II- Placebo Repeated Dose|
2426892|NCT03388190|Active Comparator|Control Arm|The control arm will consist of intermittent treatment with the Nordic FLOX regimen in terms of 8 cycles before break until disease progression, when therapy is reintroduced and administered for another 8 cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
2426893|NCT03388190|Experimental|Experimental Arm|The experimental arm will consist of repeat 2 cycles of the Nordic FLOX regimen followed by 2 cycles of nivolumab for a total of 8 individual cycles before break until disease progression, when therapy is reintroduced and administered for another total of 8 individual cycles before a new break. This schedule will be continued until progressive disease on ongoing therapy (PFS), unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
2426927|NCT03387995||Middle cerebral artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2426928|NCT03387995||Posterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2426929|NCT03387995||Internal carotid artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
3187370|NCT00755547|Experimental|Low Intensity|40-55% of peak oxygen uptake for 60 min 3-5 days/week
3187371|NCT00755547|No Intervention|Sedentary Control|Regular activities of daily living for 6 months
3187372|NCT00755560|Active Comparator|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
3187373|NCT00755560|Placebo Comparator|Placebo|Placebo BID for 15 days
3187374|NCT00755573|Active Comparator|Pregabalin|Pregabalin 300 mg - 600 mg BID
3187375|NCT00755573|Placebo Comparator|Placebo|Placebo arm
2426894|NCT03388177|Experimental|Treatment as usual + Yoga-based therapy|The yoga-based therapy (YBT) group will receive YBT in addition to treatment-as-usual (TAU). YBT will be administered with a manualized protocol and delivered in a group format consisting of nine weekly sessions of 1,5 hours. Group sessions consist of hatha yoga practices of physical postures, breathing practices, and meditation. Each session has a different theme. The practices will primarily consist of yoga exercises (80%) and meditation (e.g., breathing practices) (20%). Between sessions, participants complete an online module with additional psychoeducation and a practice video to encourage home practice for 30-45 minutes a day. YBT will be delivered by a psychologist who is also a trained yoga teacher.
2426895|NCT03388177|Other|Treatment as usual|The treatment as usual (TAU)-only condition will consist of interventions recommended by the Dutch guidelines for depression. These include the combination of pharmacotherapy (antidepressant medications) and psychotherapy (e.g., cognitive behavioral therapy [CBT], interpersonal psychotherapy). Lentis mental health clinicians will administer TAU. In order to improve ability to interpret study results, the investigators will record frequency, content (e.g., cognitive restructuring), format (group versus individual), and intensity of contact within TAU. Such quantification of TAU will allow us to address alternative explanations (e.g., contact time) in the case of positive results for YBT.
3187376|NCT00755586|Experimental|A|
3187377|NCT00755586|Experimental|B|
2426898|NCT03388151|Active Comparator|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
2426899|NCT03388151|Active Comparator|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
3187378|NCT00755586|No Intervention|C|
3187379|NCT00755599|Active Comparator|1|Vaginal speculum examinations done without stirrups.
2426902|NCT03388125|Active Comparator|Injection Sclerotherapy|5% ethano lamine oleate
2426903|NCT03388125|Active Comparator|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
2426904|NCT03388112|No Intervention|antibiotics|the patients in this arm will not receive probiotics.
2426905|NCT03388112|Experimental|probiotics concurrent with antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks concurrent with antibiotic.
2426906|NCT03388112|Experimental|probiotics after antibiotic|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis for 2 weeks after antibiotic.
2426907|NCT03388099||patients with FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
2426908|NCT03388099||patients without FSH/LH polymorphisms|Infertile patients will undergo an ovarian stimulation with FSH and/or hMG. Doses will be chosen according to BMI, Antral follicle count, AMH and age.
2426909|NCT03388086||Onabotulinum 300 units|
2426910|NCT03388086||Onabotulinum 200 units|
2426911|NCT03388073|Experimental|Berry extract I|Plant-based antioxidant-rich berry-based extract.
2426912|NCT03388073|Experimental|Berry extract II|Plant-based antioxidant-rich berry-based extract.
2426913|NCT03388073|Experimental|Berry extract blend|Blend of plant-based antioxidant-rich berry-based extracts.
2426914|NCT03388073|Placebo Comparator|Placebo|
2426915|NCT03388060|Active Comparator|Ultrasound guided SWL|ultrasound guided SWL for Radiolucent stone
2426916|NCT03388060|Active Comparator|Dissolution therapy|Dissolution therapy for Radiolucent stone
2426917|NCT03388060|Active Comparator|Combined ultrasound guided SWL and dissolution therapy|Combined treatment for Radiolucent stone.
2426918|NCT03388047|Experimental|Barrett's Esophagus patients|Multi-Spectral Endoscopic Imaging
2426919|NCT03388034||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing"
2426920|NCT03388034||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by swabbing~Blood sampling:~A blood sample collected by fingerprick"
2426921|NCT03388034||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
2426922|NCT03388021|Experimental|routine use of completion angiography after thromboembolectomy|"this group will undergo surgical revascularization followed by routine completion angiography assisted with one of these adjuvant techniques as:~Thromboembolectomy under fluoroscopic guidance using Fogarty over the wire~Balloon angioplasty and/or stenting~Intraarterial thrombolysis~Aiming to correct any residual angiographic lesion as:~Residual thrombus~Retained embolus~Atheromatous plaque"
2426923|NCT03388021|Active Comparator|if the results were not satisfactory intraoperatively as fail|this group will undergo surgical thromboembolectomy. if the results were not satisfactory intraoperatively as failure to advance the Fogarty catheter or to get satisfactory inflow or backflow or Extraction of intimal fragments.patient will undergo diagnostic angiography and endovascular or surgical intervention according to result of diagnostic angiography.
3187380|NCT00755599|Active Comparator|2|Speculum examination with feet in stirrups.
3187381|NCT00755638|Experimental|single|8 subjects (6 active and 2 placebo)
2426926|NCT03387995||Anterior communicating artery aneurysm|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
3187382|NCT00755651|Experimental|H Pipelle|Endometrial sample obtained using the H Pipelle
3187383|NCT00755651|Active Comparator|Pipelle|Endometrial sample obtained with standard Pipelle
3187384|NCT00755664|Active Comparator|Low-dose complex B-vitamins|Intervention group receives Low-dose complex B-vitamins every day. Low-dose complex B-vitamins contain 400µg of folic acid, 2mg of vitamin B6, 10µg of vitamin B12 and 50mg vitamin C. Daily supplementation lasts for 12 months
3187385|NCT00755664|Placebo Comparator|Vitamin C|Control group receives Vitamin C (50mg)every day. Daily supplementation lasts for 12 months.
3187386|NCT00755677|Other|pulses|Interventional. Participants are registered sequentially to undergo daily consumption of pulses for eight weeks
2426930|NCT03387995||Vertebrobasilar system aneurysms|Contains 5 subgroups:LVIS stent,Solitire stent,Enterprise stent,Neuroform stent and Pipeline stent.
2426931|NCT03387982||Balloon Cryotherapy Treatment Group|Subjects will undergo endoscopic balloon cryotherapy for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
2426932|NCT03387982||RFA Treatment Group|Subjects will undergo radio frequency ablation treatment for dysplastic Barrett's Esophagus as per standard of care. The treatment type (balloon cryotherapy vs RFA) is determined by the endoscopy physician at the time of the procedure and is based on several clinical factors including co-existing medical conditions, the anatomy of the esophagus, and the length and amount of tissue affected with Barrett's.
2426933|NCT03387969||meningitic group|Children suffering from fever , disturbed consciousnessand convulsion admitted in emergency department attending to assiut University Children Hospital aged between 2-18 years old
2426934|NCT03387956|Active Comparator|Atropine group|Atropine group (A): Patients received intrathecal heavy Marcaine, 2 ml, 0.5% plus 300 µg morphine and 100 µg atropine (0.5ml), and intravenous injection of 2ml normal saline.
2426935|NCT03387956|Active Comparator|Dexamethasone group|Dexamethasone group (D): Patients received intrathecal heavy Marcaine 2 ml, 0.5% plus 300 µg morphine (0.5ml), and intravenous 8 mg dexamethasone (2ml).
2426936|NCT03387956|Active Comparator|Dexamethasone and Atropine group|Dexamethasone and Atropine group (DA): Patients received intrathecally as group A, plus intravenous injection of 2 ml, dexamethasone 8 mg. Postoperative follow-up of both nausea and vomiting was done over 24 hours postoperative.
2426937|NCT03387943|Experimental|PLD plus Cisplatin|liposomal doxorubicin(PLD) 35 mg/m2,iv,d1, plus cisplatin 75 mg/m2,drip,d1-3, once every 21days, for 6 cycles, to progression or intolerance.
2426938|NCT03387930||Low back pain group|Participants will be followed up over 2 years to monitor the course of low back pain
2426939|NCT03387930||Asymptomatic group|Participants will be followed up over 2 years to monitor the incidence and course of low back pain
2426942|NCT03387904|Experimental|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt. Both should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2426943|NCT03387904|Active Comparator|Irinotecan|Irinotecan Day 1,8 ivgtt and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2426944|NCT03387891||Cancer patients|Cancer patients admitted to hospital for treatment or monitoring of health condition
2426945|NCT03387878|Other|Single Arm Study|This is a single arm study with no comparator
2426946|NCT03387852|Experimental|SAR440340/REGN3500 Monotherapy|SAR440340/REGN3500 administered by subcutaneous (SC) injections every 2 weeks for 12 weeks and coadministration of dupilumab placebo by SC injection every 2 weeks for 12 weeks
2426947|NCT03387852|Active Comparator|Dupilumab Monotherapy|Dupilumab administered by SC injection every 2 weeks for 12 weeks and coadministration of SAR440340/REGN3500 placebo by SC injections every 2 weeks for 12 weeks
2426948|NCT03387852|Experimental|SAR440340/REGN3500 and Dupilumab Coadministration|SAR440340/REGN3500 administered by SC injections every 2 weeks for 12 weeks and coadministration of dupilumab administered by SC injection every 2 weeks for 12 weeks
2426949|NCT03387852|Placebo Comparator|Placebo|Coadministration of matching placebos for SAR440340/REGN3500 and dupilumab administered by SC injections, respectively, every 2 weeks for 12 weeks
2426950|NCT03387839||Medial-Pivot Knee Prosthesis|
2426951|NCT03387839||Posterior-Stabilized Knee Prosthesis|
2426952|NCT03387839||Cruciate-Stubstituting Knee Prosthesis|
2426953|NCT03387826|Experimental|Ticagrelor|Ticagrelor 60mg twice daily followed by Prasugrel 5mg once daily
2426954|NCT03387826|Active Comparator|Prasugrel|Prasugrel 5m once daily followed by Ticagrelor 60mg twice daily
2426955|NCT03387813|Experimental|Randomized Arm - Treatment Group|"Management of subjects based on pulmonary artery (PA) pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2426956|NCT03387813|Experimental|Randomized Arm - Control Group|"Management of subjects per standard of care (signs, symptoms, weight etc.) without knowledge of PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2426957|NCT03387813|Experimental|Single Arm|"Management of subjects based on PA pressure information derived from the CardioMEMS™ HF System.~All subjects will receive a CardioMEMS™ HF System."
2426958|NCT03387800|Experimental|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
2426959|NCT03387800|Active Comparator|Basic health education messages|Members of the control group will receive health education messages that will also be sent to the intervention group through WeChat. The messages include topics on physical and psychological aspects of perceived severity of smoking and perceived benefits of smoking cessation, and tips/skills on resisting situational temptations that may lead to relapse.
2426960|NCT03387787|Experimental|GlucoTab Treatment Arm|Recruited patients will be treated with insulin degludec and insulin aspart. insulin doses will be calculated by the GlucoTab system
2426963|NCT03387761|Experimental|Cohort 1: Ipi + Nivo|"Day 1: Ipilimumab 3 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v."
2426964|NCT03387761|Experimental|Cohort 2a: high-Ipi + low-Nivo|"Day 1: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Days 22: Ipilimumab 3 mg/kg + Nivolumab 1 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
2426965|NCT03387761|Experimental|Cohort 2b: low-Ipi + high-Nivo|"Day 1: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Days 22: Ipilimumab 1 mg/kg + Nivolumab 3 mg/kg i.v.~Day 43: Nivolumab 3 mg/kg i.v.~Radical cystectomy or nefro/ureterectomy with appropriate lymph node dissection, day 56-84"
2426966|NCT03387748|Experimental|Gesture elicitation|Observation: hand gesture elicitation task
2426967|NCT03387735|Placebo Comparator|Treatment as usual (TAU) + Internet|Patients will be given access to helpful websites such as National Institute on Aging.
2426968|NCT03387735|Experimental|Treatment as usual (TAU) + ElderTree|Patients will be given access to the ElderTree website for 12 months which provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.
2426969|NCT03387709|Experimental|Pistachio-enriched diet|Participants in this group will be individually counseled on a lower calorie diet, receive pistachios to be consumed daily for four months, and receive print materials on incorporating pistachios into their diet.
2426970|NCT03387709|Active Comparator|General dietary guidance diet|Participants in this group will receive general dietary guidance as part of a 4-month long group intervention.
2426973|NCT03387670|Active Comparator|Simvastatin|
2426974|NCT03387670|Placebo Comparator|Placebo|
2426975|NCT03387657|Experimental|Sotagliflozin + Hydrochlorothiazide (HCTZ)|Sotagliflozin to be administered alone in Period 1. HCTZ to be given in Period 2 for 4 days followed immediately by HCTZ and sotagliflozin for 5 days.
2426976|NCT03387644|Active Comparator|Pregabalin (PG)|Patients received 150 mg pregabalin one hour before the procedure.
2426977|NCT03387644|Placebo Comparator|Control placebo (C)|Patients received placebo tablet one hour before surgery.
2426978|NCT03387618|Experimental|Investigational Scan|new-generation digital PET/CT imaging technology
2426979|NCT03387605|Active Comparator|Ivabradine|Initiation at dose 5 mg PO x 1 dose and further increased in 12 hours to 7.5 mg PO twice per day if patient is stable with mean BP≥ 60 mmHg, systolic blood pressure ≥ 90 mmHg and HR ≥100 bpm
2426980|NCT03387605|Placebo Comparator|Placebo|Matching placebo given PO twice per day
2426981|NCT03387592|Active Comparator|FOLFIRI regimen|CPT-11 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by Calcio levofolinate 200 mg/m2, given as a 2h i.v. infusion on days 1 every 2 weeks followed by 5-Fluorouracil 400 mg/m2 given as bolus, and then 5-Fluorouracil 2400 mg/m2 given as a 48 h continuous infusion on day 1, every 2 weeks, until progression or for a maximum of 12 cycles
2426982|NCT03387592|Experimental|CAPTEM regimen|Capecitabine 750 mg/m2 twice a day on days 1-14 in combination with Temozolomide 200 mg/m2 daily on days 10-14, every 4 weeks, until progression or for a maximum of 6 cycles
2426985|NCT03387566|Experimental|HB002.1M 0.3mg|Participants received a 0.3mg dose of HB002.1M via intravitreal (IVT) injection.
2426986|NCT03387566|Experimental|HB002.1M 0.5mg|Participants received a 0.5mg dose of HB002.1M via intravitreal (IVT) injection.
2426987|NCT03387566|Experimental|HB002.1M 1.0mg|Participants received a 1.0mg dose of HB002.1M via intravitreal (IVT) injection.
2426988|NCT03387566|Experimental|HB002.1M 2.0mg|Participants received a 2.0mg dose of HB002.1M via intravitreal (IVT) injection.
2426989|NCT03387566|Experimental|HB002.1M 3.0mg|Participants received a 3.0mg dose of HB002.1M via intravitreal (IVT) injection.
2426993|NCT03387540||Myocarditis induced by Immune check point inhibitor|Case reported in the World Health Organization (WHO) of myocarditis of patient treated by ICI, with a chronology compatible with the drug toxicity
2426994|NCT03387527|Experimental|Prostate Cancer Decision Aid|The research intervention will be exposure to the screening decision aid. Patients will receive standardized counseling including population based risks and benefits of prostate cancer screening. Then, patients will be given opportunity to review the screening decision aid prior to offering a decision on whether or not to undergo prostate cancer screening. The patient decision aid will be a computer application that generates predicted risks associated with prostate cancer.
2426995|NCT03387514|Experimental|18F-DCFPyL whole body PET/CT scan|18F-DCFPyL whole body PET/CT scan at three time-points
2426996|NCT03387501|Experimental|PRGF|Plasma rich in growth factors (PRGF) administration
2426997|NCT03387488|Experimental|Treatment|StingrayTM, Medtronic®
2426998|NCT03387475|Experimental|Deferasirox|efficacy of 3.5mg/kg/day
2427000|NCT03387449|Experimental|Bimanual Arm Training|Children in the study will all receive the same treatment, which includes 9 weeks of training on the bimanual arm trainer robotic device.
2427001|NCT03387436|No Intervention|1.) Treatment as usual (TAU)|Patients assigned to this arm will receive palliative treatment as usual.
2427002|NCT03387436|Sham Comparator|2.) Sham-Intervention|Patients assigned to this arm will receive an sham intervention with unspecific supportive therapy (i.e. listening, empathy etc., but no specific intervention rationale) and palliative treatment as usual.
2427003|NCT03387436|Experimental|3.) Study-Intervention|Patients assigned to this arm will receive the study-intervention and palliative treatment as usual.
2427004|NCT03387410|Experimental|Intravenous IRDye 800BK|Patients undergoing laparoscopic bowel resection & laparoscopic donor nephrectomy
2427005|NCT03387397||Lower Medications (LM) cohort|Patients will be assigned to the Lower Medications (LM) cohort group (N=85) if they received a drug regimen of less than five different medications/day during the study period.
2427006|NCT03387397||Higher Medications (HM) cohort|Patients will be assigned to the Higher Medications (HM) cohort group (N=85) if they received a drug regimen of more than 5 different chronic medications/day during the study period.
2427007|NCT03387371|Active Comparator|Ultrasonics & Gracey Curettes|Scaling and root planning is done with ultrasonics and gracey curettes in 24 hours with two visits.
2427008|NCT03387371|Experimental|Ultrasonics & Gracey Curettes & Laser|Scaling and root planning is done with ultrasonics, gracey curettes and Er:YAG laser in 24 hours with two visits.
2427009|NCT03387358||Historical Comparison Group|This group includes patients who were admitted to St. Paul's Hospital ICU (Vancouver BC, Canada) from September 2014 to September 2015, and had a small bore feeding tube in place at some point during their ICU admission, and were matched to key variables to the prospective observational treated group.
2427010|NCT03387358||Prospective Observational Treated Group|This group includes all patients who were admitted to St. Paul's Hospital ICU from Nov. 2017 to Dec. 2018, and nasal bridle securement device for small bore feeding tubes at some point during their ICU admission. The clinical indicators for a nasal bridle securement device outlined in our nursing practice standards include one or more of the following: recurrent nasoenteric tube dislodgement; confused and/or agitated patients; fluoroscopically or endoscopically placed nasoenteric tube; history of difficult tube placement; facial burn victims with nasoenteric tube; and/or oily skin causing decreased adhesion of traditional securement.
2427011|NCT03387345|Experimental|bread-50/50-steelcut-80/20-flake-rice|25 g of available carbohydrate was delivered to participants via (1) white bread, followed by (2) 50/50 rice-barley mix, followed by (3) 100% steel cut barley, followed by (4) 80/20 rice-barley mix, followed by (5) 100% barley flakes, followed by (6) 100% rice
2427012|NCT03387345|Experimental|50/50-steelcut-80/20-flake-rice-bread|25 g of available carbohydrate was delivered to participants via (1) 50/50 rice-barley mix, followed by (2) 100% steel cut barley, followed by (3) 80/20 rice-barley mix, followed by (4) 100% barley flakes, followed by (5) 100% rice, followed by (6) white bread
2427013|NCT03387345|Experimental|steelcut-80/20-flake-rice-bread-50/50|25 g of available carbohydrate was delivered to participants via (1) 100% steel cut barley, followed by (2) 80/20 rice-barley mix, followed by (3) 100% barley flakes, followed by (4) 100% rice, followed by (5) white bread, followed by (6) 50/50 rice-barley mix
2427014|NCT03387345|Experimental|80/20-flake-rice-bread-50/50-steelcut|25 g of available carbohydrate was delivered to participants via (1) 80/20 rice-barley mix, followed by (2) 100% barley flakes, followed by (3) 100% rice, followed by (4) white bread, followed by (5) 50/50 rice-barley mix, followed by (6) 100% steel cut barley
2427015|NCT03387345|Experimental|flake-rice-bread-50/50-steelcut-80/20|25 g of available carbohydrate was delivered to participants via (1) 100% barley flakes, followed by (2) 100% rice, followed by (3) white bread, followed by (4) 50/50 rice-barley mix, followed by (5) 100% steel cut barley, followed by (6) 80/20 rice-barley mix
2427016|NCT03387345|Experimental|rice-bread-50/50-steelcut-80/20-flake|25 g of available carbohydrate was delivered to participants via (1) 100% rice, followed by (2) white bread, followed by (3) 50/50 rice-barley mix, followed by (4) 100% steel cut barley, followed by (5) 80/20 rice-barley mix, followed by (6) 100% barley flakes
2427017|NCT03387332|Experimental|APG-1252|The starting dose for this study was 40 mg and 1 patient would be enrolled at this dose level. The dose escalation will convert to a standard 3+3 design following the occurrence of DLT or two ≥ Grade 2 adverse event or at doses 80 mg.
2427020|NCT03387306||Patient group|This grup included 38 patients with NTG.
2427021|NCT03387306||Control group|This group included 38 healthy controls.
2427022|NCT03387293|Experimental|LGI-LII Breakfast|Low glycemic index, low insulin index (LGI-LII) breakfast as a test meal
2427023|NCT03387293|Experimental|LGI-HII Breakfast|Low glycemic index, high insulin index (LGI-HII) breakfast as a test meal
2427024|NCT03387280||proximal RCA stenosis|The stenosis site is before the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
2427025|NCT03387280||distal RCA stenosis|The stenosis site is after the the right ventricular branch of right coronary artery (RCA) according to the coronary angiograms.
2427026|NCT03387280||left circumflex coronary artery stenosis|The stenosis site is located at the left circumflex coronary artery according to the coronary angiograms.
2427028|NCT03387254|Experimental|VR + active brain stimulation|Exposure to a virtual reality world with active transcranial electric stimulation
2427029|NCT03387254|Sham Comparator|VR + sham brain stimulation|Exposure to a virtual reality world with sham transcranial electric stimulation
2427030|NCT03387241|Experimental|Fluticasone/ Formoterol (Flutiform)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/5 µg Mid dose: 125/5 µg High dose 250/10 µg Dosing Frequency:BID Mode of Administration:Inhaled"
2427099|NCT03386747|No Intervention|control group|The rest of pregnant women and their children who will not receive the intervention
2427031|NCT03387241|Active Comparator|Fluticasone/ salmeterol (Seretide)|"Dosage Form:2 puffs~Unit Strength:~Low dose: 50/25 µg Mid dose: 125/25 µg High dose 250/25 µg Dosing Frequency:BID Mode of Administration:Inhaled"
2427032|NCT03387228|Experimental|Pain education group (PEG)|Pain education based on Explain Pain developed by Moseley and Butler in 2003.
2427033|NCT03387228|Active Comparator|Control group (CG)|Evidence based physiotherapy care brief education, superficial heat, massage, and exercise.
2427034|NCT03387215|Experimental|10 mg ITI-214|Single oral dose
2427035|NCT03387215|Experimental|30 mg ITI-214|Single oral dose
2427036|NCT03387215|Experimental|75 mg - 150 mg ITI-214|Single oral dose
2427037|NCT03387215|Placebo Comparator|Placebo|Single oral dose
2427038|NCT03387202||pelvic organ prolapse|"Participants received Laparoscopic lateral suspension with mesh as part of routine medical care in apical prolapse, thus, the investigator does not assign a intervention but studies the effects.Vaginal length, bladder neck mobility and pelvic floor biometry with AP hiatal diameter and pelvic organ descent measurements are measured by Transperineal ultrasound to assess anatomic success in the preoperative and at postoperative 18th months. POP-Q assessment and translabial usg for objective success; Female Sexual Function Index (FSFI), Michigan Incontinence Severity Index (M-ISI), Prolapse Quality of Life questionnaire (PQoL), Pelvic Organ Prolapse Symptom Score (POP-SS) and Visual Analog Score (VAS) are used to assess subjective success."
2427039|NCT03387189||Quality Improvement Project|Quality Improvement Project: Regions Hospital
2427040|NCT03387189||No Quality Improvement Project|No Quality Improvement Project: The comparison group is Methodist Hospital, where the Quality Improvement project is not occurring.
2427041|NCT03387176||zonulin ≤17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
2427042|NCT03387176||zonulin >17.5 ng/ml|Pediatric patients with difficult-to-manage nephrotic syndrome will be stratified based on the plasma zonulin concentration into two groups
2427043|NCT03387163||Sacubitril/Valsartan|Chronic systolic heart failure patients newly prescribed in mg. twice daily.
2427044|NCT03387163||ACEi/ARB|Chronic systolic heart failure patients receiving ACEi/ARB and no s/v
2427045|NCT03387150|Experimental|Group 1: VRC07-523LS|Participants in Group 1 will receive 2.5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2427046|NCT03387150|Experimental|Group 2: VRC07-523LS|Participants in Group 2 will receive 5 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2427047|NCT03387150|Experimental|Group 3: VRC07-523LS|Participants in Group 3 will receive 20 mg/kg of VRC07-523LS by IV infusion at Weeks 0, 16, 32, 48, and 64.
2427048|NCT03387150|Experimental|Group 4: VRC07-523LS|Participants in Group 4 will receive 2.5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
2427049|NCT03387150|Experimental|Group 5: VRC07-523LS|Participants in Group 5 will receive 5 mg/kg of VRC07-523LS by SC injection at Weeks 0, 16, 32, 48, and 64.
2427050|NCT03387150|Experimental|Group T6 VRC07-523LS|Participants in Group T6 will receive 2.5 mg/kg of VRC07-523LS by IM injection at Weeks 0, 16, 32, 48, and 64.
2427051|NCT03387150|Placebo Comparator|Group P6: Placebo|Participants in Group P6 will receive 2.5 mg/kg of placebo by IM injection at Weeks 0, 16, 32, 48, and 64.
2427052|NCT03387137|Experimental|Group 1: RSV 6120/∆NS2/1030s Vaccine|RSV-seropositive children will receive a single dose of 10^5.7 plaque-forming units (PFUs) of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
2427053|NCT03387137|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (Day 0).
2427054|NCT03387137|Experimental|Group 2: RSV 6120/∆NS2/1030s Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5.0 PFUs of RSV 6120/∆NS2/1030s vaccine at study entry (Day 0).
2427055|NCT03387137|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (Day 0).
2427056|NCT03387111|Experimental|NANT Squamous Cell Carcinoma (SCC) Vaccine|Combination of agents will be administered in this study: Aldoxorubicin HCl, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, N-803, avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, necitumumab, SBRT.
2427057|NCT03387098|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ehtyl esters, oxaliplatin, SBRT.
2427058|NCT03387085|Experimental|NANT triple negative breast cancer (TNBC) Vaccine|A combination of agents will be administered to subjects in this study: Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, SBRT.
2427059|NCT03387072||Patients affected with CIQTP|Patients affected with catecholamine-induced QT prolongation (CIQTP)
2427060|NCT03387072||Healthy relatives of patients affected with CIQTP|Healthy relatives of patients affected with CIQTP identified during the familial screening
3187387|NCT00755690|Active Comparator|1|"High/ Low Phosphate diet I. A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet.~II. A five-day low phosphate diet / A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder III. A five-day high phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet.~IV. A five-day high phosphate diet / A five-day low phosphate diet / A five-day low phosphate diet with the addition of a phosphate binder.~V. A five-day low phosphate diet with the addition of a phosphate binder / A five-day low phosphate diet / A five-day high phosphate diet.~VI. A five-day low phosphate diet with the addition of a phosphate binder / A five-day high phosphate diet / A five-day low phosphate diet."
3187388|NCT00755690|Active Comparator|2|High/ Low Phosphate diet
3187389|NCT00755690|Active Comparator|3|High/ Low Phosphate diet
3187390|NCT00755703|Experimental|Group 1|There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
2427275|NCT03385616|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS)
3187391|NCT00755703|Experimental|Group 2|There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
2427067|NCT03387007|Experimental|Intervention|Two teachers from each of the schools included in this arm received training on providing psycho-social support to their students to be implemented in their regular routine school activities
2427068|NCT03387007|No Intervention|Control|The teachers from the schools in this arm did not receive training on psycho-social support
3187392|NCT00755703|Experimental|Group 3|There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
2427070|NCT03386981||1|Professional athletes: Professional athletes belonging to different discipline
2427071|NCT03386968|Experimental|Video gaming|A child's usual physical therapy session will be replaced with a session utilizing Active video games and the Rutger's V-step.
2427072|NCT03386968|Active Comparator|Usual care|Children will receive their usual care in the physical therapy program at Blythedale.
2427073|NCT03386955|Experimental|BPI-7711 treatment|"Phase I: Patients in dose escalation group will receive single dose of BPI-7711 on day -7 and start receive the 21 days/cycle continuous treatment once a day after 7 day washout period. Patients in the extension group will receive BPI-7711 once a day with the selected doses.~Phase IIa: Patients will receive BPI-7711 capsule(recommend phase 2 dose) as the first line treatment."
3187393|NCT00755703|Placebo Comparator|Experimental: Group 4|There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
2427075|NCT03386929|Experimental|Avelumab, Axitinib, Palbociclib|"For the Phase 1:~Avelumab is administered intravenously (IV) on Day 1 and Day 15 of each Cycle (one cycle = 28 days) in combination with axitinib po bid and palbociclib po (7 days off; 21 days on).~For the Phase 2:~Avelumab, axitinib and palbociclib are administered at the recommended dose (RP2D) as determined during the phase 1 part of the study."
2427076|NCT03386916||Patient with a CT scan guide percutaneous biopsy of lytic bone|Patient with a CT scan guide percutaneous biopsy of lytic bone metastases register on CHU Grenoble Alpes radiology software between January 2010 and June 2017
2427077|NCT03386903|Experimental|Ture acupuncture group|After recruiting, patients are assigned to the ture acupuncture group by randomization,and then receive ture acupuncture treatment. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
2427078|NCT03386903|Placebo Comparator|Sham acupuncture group|After recruiting, patients are assigned to the sham acupuncture group by randomization,and then receive sham acupuncture stimulation. patients are scanned by MRI at the baseline and 3 month post-treatment respectively.
2427079|NCT03386903|No Intervention|Healthy group|Healthy subjects without intervention except scanned brain image by MRI at the baseline.
2427080|NCT03386877|Experimental|Dental pulp stem cells|Test sites (n=15) Periodontal regeneration using micro-grafts of Dental pulp stem cells seeded onto collagen sponge
2427081|NCT03386877|Active Comparator|coagulum|control sites (n=14) Periodontal regeneration using coagulum and collagen sponge alone
2427082|NCT03386864||Control|
2427083|NCT03386864||Insulin Resistant|
2427084|NCT03386864||Type 2 Diabetes|
2427085|NCT03386838|Experimental|Nivolumab and BMS-986205|Nivolumab administered in combination with BMS-986205
2427086|NCT03386838|Active Comparator|EXTREME study regimen|Cetuximab + Cisplatin/Carboplatin + Fluorouracil
2427087|NCT03386825||Regorafenib_DoT<4 months|DoT < 4 months
2427088|NCT03386825||Regorafenib_4 months ≤ DoT < 12 months|4 months ≤ DoT < 12 months
2427089|NCT03386825||Regorafenib_DoT ≥ 12 months|DoT ≥ 12 months
2427090|NCT03386799||Patient in wheelchair|Patient in wheelchair with E-motion device
2427091|NCT03386786|Experimental|Intervention (Health Partner)|The mobile health (mHealth) product, Health Partner for Knees and Hips (Health Partner), is a combination of a mobile application (app) and a web-based portal.
2427092|NCT03386786|Other|Control|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
2427093|NCT03386773|Experimental|Intervention|Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
2427094|NCT03386773|Active Comparator|Control|Control patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Patient-reported outcomes measures will be collected pre-and-post-intervention.
2427095|NCT03386760|Experimental|A- Ultra-Speed Picosecond laser|Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
2427096|NCT03386760|Active Comparator|B- Nanosecond laser|Utilisation of Nanosecond laser for tattoo depigmentation
2427097|NCT03386747|Experimental|Home Visiting Group|Intervention: Home visits to improve parenting behaviors
2427098|NCT03386747|Experimental|Center based parenting group|Intervention: Center based parenting groups
3187394|NCT00755729|Experimental|OCH|fast from midnight the night before surgery, and consume 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
3187395|NCT00755729|No Intervention|FSD|fast from midnight the night before surgery, and no preoperative oral carbohydrate loading
3187396|NCT00755742|Experimental|Group 1 - Viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
2427100|NCT03386734|Experimental|SLN biopsy only|Sentinel lymph node (SLN) biopsy only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
2427101|NCT03386734|Active Comparator|SLN biopsy + PLN dissection|SLN biopsy + full pelvic lymph node dissection (PLN) will be performed. The radical hysterectomy or trachelectomy will be done.
3146444|NCT00101348|Experimental|Treatment (erlotinib hydrochloride, cetuximab, bevacizumab)|"Part 1: Patients receive oral erlotinib once daily on days 1-28. Patients also receive cetuximab IV over 3 hours on day 1 and over 1 hour on days 8, 15, and 22.~Cohorts of 3-6 patients receive escalating doses of erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Part 2: Patients receive erlotinib as in part 1 at the MTD and cetuximab as in part 1. Patients also receive bevacizumab IV over 1½ hours on day 1 and over 1 hour on day 15.~Cohorts of 3-6 patients receive escalating doses of bevacizumab until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~In both groups, courses repeat every 28 days in the absence of unacceptable toxicity or disease progression."
3146445|NCT00101387|Experimental|Lumbar PENS + exercise|Lumbar PENS twice a week for six weeks combined with general conditioning and aerobic exercise
3146446|NCT00101387|Active Comparator|Lumbar PENS|Lumbar PENS twice a week for 6 weeks
3146447|NCT00101387|Placebo Comparator|Control PENS|Control lumbar PENS twice a week for 6 weeks
3146448|NCT00101387|Active Comparator|Control PENS + exercise|Control PENS twice a week for 6 weeks along with general conditioning and aerobic exercise
3146449|NCT00101491|Experimental|1|
3146450|NCT00101491|Other|2|Attention Control Comparator
3146451|NCT00101569|Experimental|A1|
3146452|NCT00101569|Experimental|A2|
3146453|NCT00101595|Experimental|1|
3146454|NCT00101608|Experimental|1|
3146455|NCT00101712|Experimental|Vildagliptin|
2427272|NCT03385642||Chondromimetic|Treatment of osteochondral defect in the knee with Chondromimetic device(s) in previous study 0MCM0107
3146456|NCT00101712|Placebo Comparator|Placebo|
3146457|NCT00101725|Experimental|125 mg crofelemer|
3146458|NCT00101725|Experimental|250 mg crofelemer|
3146459|NCT00101725|Experimental|500 mg crofelemer|
3146460|NCT00101725|Placebo Comparator|placebo|
3146461|NCT00101790|Active Comparator|1|
3146462|NCT00101829|Experimental|Rituximab Treatment|Participants will receive rituximab at study entry and at Week 2
3146463|NCT00101881|Active Comparator|Monophasic Shock|Administration of monophasic waveform defibrillation
3146464|NCT00101881|Active Comparator|Biphasic Shock|Administration of biphasic waveform defibrillation
3146465|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFOX-4|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFOX-4
3146466|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFOX-4|125 mg QD AMG 706 + FOLFOX-4
3146467|NCT00101894|Experimental|50 mg QD AMG706 + panitumumab + FOLFIRI|50 mg QD AMG706 + panitumumab + FOLFIRI
3146468|NCT00101894|Experimental|Part 2 AMG 706 (MTD) + FOLFIRI|Maximum Tolerated Dose of AMG 706 established in Part 1b + FOLFIRI
3146469|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFIRI|100 mg AMG 706 + FOLFIRI
3146470|NCT00101894|Experimental|75 mg QD AMG 706 + panitumumab + FOLFOX-4|75 mg QD AMG 706 + panitumumab + FOLFOX-4
3146471|NCT00101894|Experimental|75 mg BID AMG 706 + panitumumab + FOLFIRI|75 mg BID AMG 706 + panitumumab + FOLFIRI
3146472|NCT00101894|Experimental|125 mg QD AMG 706 + panitumumab + FOLFIRI|125 mg QD AMG 706 + panitumumab + FOLFIRI
3146473|NCT00101894|Experimental|125 mg QD AMG 706 + FOLFIRI|125 mg QD AMG 706 + FOLFIRI
3146474|NCT00101894|Experimental|100 mg QD AMG 706 + panitumumab + FOLFIRI|100 mg QD AMG 706 + panitumumab + FOLFIRI
3146475|NCT00101894|Experimental|75 mg QD AMG 706 + FOLFOX-4|75 mg QD AMG 706 + FOLFOX-4
3146476|NCT00101894|Experimental|100 mg QD AMG 706 + FOLFOX-4|100 mg QD AMG 706 + FOLFOX-4
3146477|NCT00101894|Experimental|50 mg QD AMG 706 + panitumumab + FOLFOX-4|50 mg QD AMG 706 + panitumumab + FOLFOX-4
3146478|NCT00101894|Experimental|75 mg QD AMG706 + panitumumab + FOLFIRI|75 mg QD AMG706 + panitumumab + FOLFIRI
3146479|NCT00101920|Experimental|ABX-EGF|Open-label, single arm panitumamab monotherapy
3146480|NCT00101972|Experimental|RAV12|
3146481|NCT00101998|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.
3146482|NCT00101998|Experimental|Alvimopan 1 mg Once Daily (QD)|"0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.~A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment."
3146483|NCT00101998|Experimental|Alvimopan 1 mg Twice Daily (BID)|0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.
3146484|NCT00101998|Placebo Comparator|Placebo|Placebo was administered orally BID for 3 weeks.
3146485|NCT00102011|Experimental|Study I- Arm I|Participants undergo baseline screening colonoscopy
3146486|NCT00102011|Other|Study I- Arm II|Participants receive standard care
3146487|NCT00102011|Experimental|Study II- Arm I|Participants undergo baseline screening colonoscopy. Participants are given individualized recommendations for further surveillance based on the results of the colonoscopy.
3146488|NCT00102011|Active Comparator|Study II- Arm II|Participants undergo a baseline fecal occult blood test (FOBT). Participants are given individualized recommendations for further surveillance based on the results of the FOBT. Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT.
3146489|NCT00102141|Experimental|Arm 1|
3146490|NCT00102141|Experimental|Arm 3|
3146491|NCT00102141|Experimental|Arm 4|
3146492|NCT00102141|Placebo Comparator|Arm 5|
3146493|NCT00102141|Experimental|Arm 2|
3146494|NCT00102323|Placebo Comparator|Placebo|
3146495|NCT00102323|Experimental|AMG 531|Active Investigational Product
3146496|NCT00102336|Experimental|AMG 531|Active investigational product
3146497|NCT00102336|Placebo Comparator|Placebo|
3146498|NCT00102388|Experimental|vildagliptin|
3146499|NCT00102388|Active Comparator|Gliclazide|
3146500|NCT00102453|Experimental|Solution|All enrolled participants were give pentoxifylline in this pilot protocol.
3146501|NCT00102466|Experimental|Vildagliptin|
2427119|NCT03386708|Experimental|hUC-MSC intrauterine injection group|Human umbilical cord mesenchymal stem cells (hUC-MSC) (SCLnow 19#)
2427120|NCT03386708|Placebo Comparator|NS intrauterine injection group|Normal saline (NS) (2ml)
2427121|NCT03386708|Experimental|hUC-MSC intravenous injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2427122|NCT03386708|Placebo Comparator|NS intravenous injection group|Normal saline (NS) (30ml)
2427123|NCT03386695|Other|Education by Pamphlets|Half of the women in each group will be provided an information pamphlet on the risk factors, methods of early detection, prevention, signs and symptoms of cervical cancer and how to use the self samplers at home.
2427124|NCT03386695|Other|Health education programme|Half of the women in each group will be invited to specially organised camps in their neighbourhood for Health Education and distribution of self samplers.
2427125|NCT03386682|Experimental|ESTYME MATRIX|Participants who meet the requirements for breast augmentation or breast reconstruction surgeries and have been implanted with one or two ESTYME® MATRIX Breast Implant(s)
2427126|NCT03386669|Experimental|F-18 AV-45 THK-5351|F-18 AV-45 THK-5351 imaging
2427127|NCT03386656|Experimental|Amchafibrin|Estimated total blood loss, measured using the formula described by Nadler. A difference in estimated blood loss greater than or equal to 245 ml will be considered clinically relevant.
2427128|NCT03386656|Placebo Comparator|Saline Solution 0,9%.|Comparator of tranexamic acid
2427129|NCT03386643|Experimental|Bifidobacterium animalis subsp. lactis|"Intervention:~Bifidobacterium animalis subsp. lactis HN019"
2427130|NCT03386643|Active Comparator|Clobetasol propionate 0.05%|"Intervention:~Clobetasol propionate 0.05%"
2427131|NCT03386630|Experimental|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
2427132|NCT03386630|Experimental|Hyperbaric bupivacaine+morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
2427133|NCT03386617|Experimental|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
2427134|NCT03386604|Experimental|Whey protein + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive whey protein and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
2427135|NCT03386604|Placebo Comparator|Placebo + Rehabilitation|Pulmonary rehabilitation will last 8 weeks covering 3 weekly sessions of supervised exercise and a weekly educational session. Patients will receive placebo (maltodextrin) and will be instructed to take it daily for breakfast, diluted in milk or water (if they do not drink milk).
2427136|NCT03386591|Experimental|Mucosal Atomization (1 administration)|One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)
2427137|NCT03386591|Experimental|Mucosal Atomization (2 administrations)|Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart
2427138|NCT03386591|Experimental|Narcan 2mg|One Intranasal administration of 2 mg naloxone using Narcan nasal spray
2427139|NCT03386591|Experimental|Narcan 4mg|One Intranasal administration of 4 mg naloxone using Narcan nasal spray
2427140|NCT03386591|Experimental|Intramuscular auto injector|One Intramuscular administration of 2 mg naloxone using Evzio auto-injector
3146502|NCT00102466|Active Comparator|Gliclazide|
3146503|NCT00102609|Experimental|Trabectedin and doxorubicin|Doxorubicin (50 to 75 mg/m2) administered intravenously on Day 1 followed by trabectedin (0.9 to 1.3 mg/m2) administered intravenously on Day 1 every 3 weeks for up to 6 cycles. Dexamethasone 20 mg administered intravenously will be given within 1 hour before the start of doxorubicin. Patients may receive filgrastim for unmanageable neutropenia.
3146504|NCT00102622|Experimental|Arm 1: Paclitaxel + tgDCC-E1A|80 mg/m^2 intravenous Paclitaxel and intraperitoneal (IP) tgDCC-E1A starting dose 1.8 mg DNA/m^2 weekly for six treatments every 7 days.
3146505|NCT00102622|Active Comparator|Arm 2: Paclitaxel Alone|Weekly single agent intravenous Paclitaxel 80 mg/m^2 for six treatments every 7 days.
3146506|NCT00102635|Experimental|4-HPR + FTI|SCH66336 daily for 21 days each cycle and with 4-HPR daily on days 1-7 only. On day 1 of cycle 1, 4-HPR only beginning SCH66336 on day 2 of cycle 1.
3146508|NCT00102661|Experimental|CAMPATH-1H|15 mg infused daily for continuous infusion x 7 days; starting day 10, CAMPATH-1H 30 mg subcutaneously three times weekly for 11 additional weeks.
3146509|NCT00102726|Active Comparator|Arm 1|SB-497115-GR 50mg. administered orally daily on days 2 through 11 for each 21-day cycle.
3146510|NCT00102726|Active Comparator|Arm 2|SB-497115-GR 75 mg administered orally dailey on days 2-11 of each 21-day cycle.
3146511|NCT00102726|Active Comparator|Arm 3|SB-497115 100mg administered orally daily on days 2 through 11 of each 21-day cycle.
3146512|NCT00102726|Placebo Comparator|Placebo Arm|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
3146513|NCT00102908|Experimental|1|Participants will receive zoledronate at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
3146514|NCT00102908|Placebo Comparator|2|Participants will receive zoledronate placebo at study entry; their assigned intervention will be given in a 20- to 30-minute infusion on an outpatient basis
3146515|NCT00102934|Experimental|1|Participants will receive enfuvirtide for 6 months
3146516|NCT00102973|Experimental|TLK286 in Combination with Carboplatin|
3146517|NCT00102973|Active Comparator|Doxorubisin HCl Liposome Injection|
3146518|NCT00103038|Experimental|Diagnostic (ferumoxytol, gadolinium, DCE-MRI, DSC-MRI)|Patients receive ferumoxytol non-stoichiometric magnetite IV beginning approximately 15 seconds after start of 3T DSC-MRI and GBCA IV approximately 1 minute and 50 seconds after start of 3T DCE-MRI on day 1. Patients also undergo MRI without contrast at baseline and on day 2. Imaging with ferumoxytol, GBCA and without contrast repeats every 3 weeks for a total of 6 more imaging sessions over up to 5 years.
3146519|NCT00103168|Experimental|Imatinib mesylate|400 mg/day for 2 years
2427145|NCT03386565|Active Comparator|control group|"Sodium chloride solution 10 mL IV just before induction of anesthesia~IV infusion during the surgery"
2427146|NCT03386565|Active Comparator|lidocaine group|"lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia~IV infusion during the surgery"
2427147|NCT03386552|Experimental|Isifera+|Subjects are pertubated with Isifer+ solution containing lidocaine 0.5 mg/ml
2427148|NCT03386552|Placebo Comparator|Buffer|Subjects are pertubated with a buffer solution without lidocaine
2427149|NCT03386539|Experimental|Everolimus/Low-Dose Tacrolimus|"Everolimus approximately 0.6 mg/m2/dose taken by mouth every 12 hours for 30 months. Everolimus dose will be adjusted to achieve a trough concentration of 3-8 ng/ml.~Tacrolimus 0.0125 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 3-5 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 2.5-4.5 ng/mL.)"
2427150|NCT03386539|Active Comparator|Tacrolimus/Mycophenolate Mofetil|"Tacrolimus 0.05 mg/kg/dose by mouth every 12 hours for 30 months. (Tacrolimus dose will be adjusted to achieve a trough concentration of 7-10 ng/ml until subjects are 1 year post-heart transplant. After 1 year post-heart transplant the tacrolimus dose will be adjusted to achieve a trough concentration of 5-8 ng/mL.)~Mycophenolate mofetil 600 mg/m2/dose by mouth every 12 hours for 30 months."
2427151|NCT03386526|Experimental|APG-1387 for Injection|APG-1387 will be explored sequentially using a standard 3+3 escalation scheme at the dose escalation phase and up to 20 patient per group at the dose expansion phase.
2427153|NCT03386500|Other|Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|One arm includes all enrolled patients.
2427154|NCT03386487|Active Comparator|PF-04457845|Subjects will be randomized to Fatty Acid Amide Hydrolase (FAAH) Inhibitor; 4 mg PF-04457845 QD x 8 weeks
2427155|NCT03386487|Placebo Comparator|Placebo|Subjects will be randomized to placebo
2427158|NCT03386461|Experimental|Exercise + Omega 3 supplementation|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly (Senior Fitness, and Faculty of Physical Education and Sport). Subjects will take 5 capsules od Calanus oil (containing approx. 250 mg EPA and DHA per day).
2427159|NCT03386461|Placebo Comparator|Exercise + placebo|Subjects will be enrolled in physical activity program that consists of combined aerobic and resistive training 3 times a week for 4 months. Training will be supervised by physiotherapists experienced in exercise training of elderly. Subjects will take 5 capsules od placebo per day (provided by Calanus oil company, containing sunflower oil).
2427164|NCT03386422|Experimental|Mindfulness Self-Compassion Intervention MSC|"Mindfulness Self-Compassion (MSC) is a standardized program to increase self-compassion. It has been developed by Neff and Germer. The structure of the program is similar to de Mindfulness-Based Stress Reduction program (MBSR), with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with practical and experiential exercices in sessions and between sessions.~The MSC program focuses primary on helping patients to develop self-compassion, and it includes Mindfulness just as a secondary component.~The MSC program will be conducted by a clinician trained in this specific program."
2427165|NCT03386422|Active Comparator|Cognitive-Behavioural Intervention CBT|"It has been adapted a Cognitive-Behavioural Intervention for Chronic Pain by Moix and Kovacs. Our program will have 8 sessions, with duration of sessions between 2 and 2 hours and a half. The frequency of the sessions is one per week for 8 weeks, with homework between sessions.~During these 8 sessions we will train the following techniques: psychoeducation about pain, relaxation training, cognitive restructuring training, solving problem training, psychoeducation about emotions, interpersonal skills and time organization."
2427166|NCT03386409|No Intervention|Baseline|Participants receive the standard of care recommendations for safe firearm storage device usage.
2427273|NCT03385629|Experimental|CSM theory-based Arm|CSM theory-based didactic education and skills training Practice EMR changes
2427274|NCT03385629|Active Comparator|AAP-based Arm|AAP-based didactic education
3146520|NCT00103168|No Intervention|Control|
3146521|NCT00103181|Active Comparator|Group 1: WBI|Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5-7 weeks.
3146522|NCT00103181|Experimental|Group 2: PBI|Patients undergo partial-breast irradiation (PBI) twice daily on 5 days over a period of 5-10 days. This may be delivered by intracavitary brachytherapy, MammoSite or other single-entry intracavitary device, or 3-dimensional conformal accelerated partial breast irradiation.
3146523|NCT00103220|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146524|NCT00103246|Experimental|Topical silicon phthalocyanine 4 (Pc 4) + photodynamic therapy|Topical silicon phthalocyanine 4 (Pc 4) followed by photodynamic therapy.
2427167|NCT03386409|Experimental|Free Device|Participants receive the standard of care recommendations for safe firearm storage device usage In addition, the study intervention is provision of a free safe firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
2427168|NCT03386409|Experimental|Low Cost Device|Participants receive the standard of care recommendations for safe firearm storage device usage. In addition, the study intervention is the provision of a low cost ($5) firearm storage device (lock box, trigger lock and/or cable lock) for firearm storage at the time of enrollment.
2427169|NCT03386396|Experimental|High protein/low carbohydrate|A breakfast shake will be made with high protein/low carbohydrate mixture.
2427170|NCT03386396|Experimental|High carbohydrate/low protein|A breakfast shake will be made with high carbohydrate/low protein mixture.
2427171|NCT03386383|Experimental|Intervention|Participants will receive an initial individual session, physical activity tracker, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group immediately after baseline assessments.
2427172|NCT03386383|No Intervention|Wait List Control|Participants will receive a physical activity tracker and be advised to maintain their current activity. After 3 months, participants will receive an initial individual session, weekly behavioral lessons, tailored feedback summaries, and access to a Facebook group.
2427173|NCT03386370|Other|"Treatment by Indigo mechanical thrombectomy system"|Acute or Chronic clot: if chronic (> 14 days) no intervention given via Indigo
2427174|NCT03386357|Experimental|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases.
2427175|NCT03386357|Active Comparator|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w) without radiotherapy
2427179|NCT03386331|Other|Diet and Exercise|
2427180|NCT03386318||day surgery patients|20 patients female 30-60 years of age
2427181|NCT03386305|Experimental|EnvarsusXR arm|Patients are converted to once daily EnvarsusXR (study drug). The patients continue taking this medication for 9 months of the study. Initial dosage will be 0.8 times the total daily dose of tacro bid, due to higher bioavailability. All subsequent dose adjustments will be based on maintenance of target tacro trough levels within range of 5-12 ng/ml.
2427182|NCT03386305|Active Comparator|Standard of care arm|Post Liver Transplant patients take Tacrolimus twice daily as a part of standard of care. Those participating in the study will continue to take tacrolimus twice daily, as apart of their regular care. As a part of the study, they will complete the medication adherence and quality of life instruments.
2427183|NCT03386279|Other|Sequence 1|Sequential allocation to PF-04965842 600 mg (oral, single dose), placebo (oral, single dose), and moxifloxacin 400 mg (oral, single dose)
2427184|NCT03386279|Other|Sequence 2|Sequential allocation to PF-04965842 600 mg (oral, single dose), moxifloxacin 400 mg (oral, single dose), and placebo (oral, single dose)
2427185|NCT03386279|Other|Sequence 3|Sequential allocation to placebo (oral, single dose), PF-04965842 600 mg (oral, single dose), and moxifloxacin 400 mg (oral, single dose).
2427186|NCT03386279|Other|Sequence 4|Sequential allocation to placebo (oral, single dose), moxifloxacin 400 mg (oral, single dose), and PF-04965842 600 mg (oral, single dose)
2427187|NCT03386279|Other|Sequence 5|Sequential allocation to moxifloxacin 400 mg (oral, single dose), PF-04965842 600 mg (oral, single dose), and placebo (oral, single dose)
2427188|NCT03386279|Other|Sequence 6|Sequential allocation to moxifloxacin 400 mg (oral, single dose), placebo (oral, single dose) and PF-04965842 600 mg (oral, single dose)
2427189|NCT03386253|Experimental|active tDCS|Participants receive active tDCS for five consecutive days before attempting to quit smoking
2427190|NCT03386253|Sham Comparator|sham tDCS|Participants receive sham tDCS for five consecutive days before attempting to quit smoking
2427191|NCT03386240|Experimental|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures|Use of Monocryl Plus, Vicryl Plus and PDS Plus Suture (Triclosan-coated sutures) will be used exclusively throughout the entire procedure.
2427192|NCT03386240|Placebo Comparator|Vicryl, monocryl, PDS (not coated with triclosan)|Use of Monocryl, Vicryl and PDS Suture (equivalent uncoated sutures) will be used exclusively throughout the whole procedure.
2427193|NCT03386227|No Intervention|Prophylactic antibiotics|Current standard of care in our practice for a fresh in vitro fertilization cycle is to administer one dose of 1 gram oral azithromycin on day one of the IVF cycle start to both the male and female partner. In cases of same-sex couples, only the female undergoing the embryo transfer receives prophylaxis. This will serve as our control arm entitled: prophylactic antibiotics.
2427194|NCT03386227|Experimental|No antibiotic prophylaxis.|Couples randomized to the no-antibiotic treatment group will not be prescribed oral antibiotic prophylaxis.
3146525|NCT00103272|Experimental|Treatment (17-AAG and bortezomib)|"Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 1-6 hours on days 1, 4, 8, and 11 and bortezomib IV over 3-5 seconds on days 4, 8, and 11 of course 1 and on days 1, 4, 8, and 11 of all subsequent courses.~Treatment repeats every 21 days for 3-12 courses provided patient is receiving clinical benefit. Patients achieving objective response may discontinue therapy to undergo stem cell transplantation."
3146526|NCT00103324|Experimental|Treatment|Patients receive oral lapatinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146527|NCT00103337|Experimental|Arm I (500 mg cilengitide)|Patients receive lower dose cilengitide IV over 1 hour twice a week for 6 weeks.
3146528|NCT00103337|Experimental|Arm II (2000 mg cilengitide)|Patients receive higher dose cilengitide IV over 1 hour twice a week for 6 weeks.
3146529|NCT00103389|Active Comparator|docetaxel|treated with docetaxel alone
3146530|NCT00103389|Experimental|PI-88+docetaxel|treated with docetaxel and PI-88
3146531|NCT00103454|Experimental|Arm 1|
3146532|NCT00103519|Experimental|DITPA 180 mg/day|DITPA 180 mg/day BID
3146533|NCT00103519|Experimental|DITPA 360 mg/day|DITPA 360 mg/day BID
3146534|NCT00103519|Placebo Comparator|Placebo|Placebo BID
3146535|NCT00103532|Experimental|Healthy Choices - Motivational Enhancement Intervention|Motivational enhancement intervention
3146536|NCT00103532|Active Comparator|Standard Care|Standard care/individualized referrals
3146537|NCT00103701|Experimental|1|
3146538|NCT00103727|Experimental|talnetant|200mg, 400mg, 600mg) twice a day
3146539|NCT00103727|Placebo Comparator|placebo|placebo
2427198|NCT03386201|Experimental|Intravenous methylene blue|
2427199|NCT03386188|Experimental|Healthy arm|posterior parietal cortex (PPC) transitory inactivation
2427200|NCT03386162|Experimental|Experimental arm (Arm A3)|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days ± 3 days.
2427201|NCT03386162|Active Comparator|Control arm (Arm B3)|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
2427202|NCT03386149|Experimental|Experimental Group|In the experimental group, 2.5g of Bosinji granule (Tsmura Co., Tokyo, Japan) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
2427203|NCT03386149|Active Comparator|Control Group|In the control group, Loxonine tab. (loxoprofen 60mg, Dong Wha Pharm Co., Ltd, Seoul, Korea) will be orally administered three times a day at 30 minutes after the meal for 6 weeks. During the same period, acupuncture treatment on 20 predefined acupoints will be conducted once a week.
2427204|NCT03386136|Experimental|Hospitalized Ileus or Pseudo-Obstruction Patient|Hospitalized inpatient diagnosed with ileus, bowel obstruction or colonic pseudo-obstruction [clinician interpretation or small bowel diameter ≥3.5 cm, cecal diameter ≥ 9 cm, sigmoid colon diameter ≥ 6 cm] provided with 100% oxygen via non-rebreather face mask, for 6 hours
2427205|NCT03386123|Experimental|Cognitive Behaviour Therapy for Insomnia (CBTi)|"A standard CBTi programme for the treatment of primary insomnia, with six, 2 hour, group sessions over eight weeks. There will be minor adaptations for tinnitus, including making specific reference to tinnitus and psycho-education about tinnitus. Every session concludes with provision of a homework task and a sleep diary to complete over the next week. The CBTi course will be supported by providing participants with a CD with some relaxation exercises and a booklet that covers the information given in the session.~CBTi includes: Sleep restriction, stimulus control, Sleep hygiene, Relaxation training, Paradoxical intention, Cognitive therapy: Targeting unhelpful beliefs about sleep and worry, Behavioural experiments: Testing unhelpful beliefs and adjusting sleep related behaviour."
2427206|NCT03386123|Active Comparator|Standard Audiological Care (SAC)|"A group intervention that fits with reported audiological treatment of people with tinnitus and significant sleep impairment. This involves psycho-education about tinnitus, habituation, sleep and sleep hygiene. Relaxation will be advised and information provided. A bedside sound generator, as used in routine clinical practice will be provided. Information will be based on standard advice given by hearing therapists/audiologists and will not include specific psychological techniques which are not part of SAC. The group will be generally supportive.~SAC tends not to involve repeated meetings; after the initial session, there will be one follow up session 8 weeks later. Follow up will allow for question and answer, and reports on what has been useful. Both sessions will last for 2 hours"
2427207|NCT03386123|Placebo Comparator|Sleep Support Group (SSG)|"Participants will meet in a group, which will offer equivalent contact with therapists and a supportive group milieu as CBTi. It will focus on the potential benefits of a supportive group and will not include specific advice.~Participants will complete 2-week sleep diaries as baseline and outcome measures at the four time-points, which will be checked within the session to ensure that participants know how to complete them correctly. The SSG will meet in a group for six sessions, over eight weeks, each of 2 two hours duration."
3187397|NCT00755742|Active Comparator|Group 2 - Non-viremic / Non-cirrhotic|13 obese and insulin resistant, non-cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy.
2427210|NCT03386097||Type 2 diabetes patients|
2427211|NCT03386097||Healthy controls|
2427212|NCT03386084|Experimental|direct application of microwave diathermy and motor control|
2427213|NCT03386084|Placebo Comparator|application of microwave diathermy without therapeutic effects|
2427214|NCT03386058|Experimental|Intervention|Temporary device deactivation
2427215|NCT03386045|Active Comparator|Optimal SBRT|Participants in this group will be randomised to either SBRT ( 36 to 45 GY in 5 fractions) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the SBRT (5 treatments) and one third will get the standard fractions.
2427216|NCT03386045|Active Comparator|Optimal Booster|Participants in this group will be randomised to either standard radiotherapy plus SBRT (45 Gy in 20 fractions plus 20-30 Gy in 2 fractions-Booster) or standard radiotherapy (60 Gy in 20 fractions). The allocation is 2 to 1. This means that two thirds of the participants on the trial will get the Booster arm and one third will get the standard fractions.
2427263|NCT03385681|No Intervention|Control Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate in the study.
3146540|NCT00103727|Active Comparator|risperidone|3mg twice a day
3146541|NCT00103779|Experimental|1|
3146542|NCT00103792|Experimental|1|mycophenolate and steroids as remission induction, followed by azathioprine maintenance therapy
3146543|NCT00103792|Active Comparator|2|cyclophosphamide
3146544|NCT00103883||HIV Infected Teens -ATN Clinical Sites|HIV infected teens who are referred to or engaged in care at any of the 15 ATN clinical sites during the course of the study.
3146545|NCT00103883||HIV Positive - ATN Clinical Sites|Youth who test HIV positive at ATN-managed or ATN-affiliated HIV Counseling and Testing Sites (CTS) during the course of the study.
3146546|NCT00103883||HIV Positive - BCHD STD Clinic|Youth who test HIV positive at the BCHD STD Clinic during the course of the study.
2427220|NCT03386019|Experimental|Sprinters|Sprinters will be recruited from the track and field team of National Taiwan Normal University (NTNU) in this study. After individuals' enrollments and baseline data collections, all subjects will receive all three different treatments (massage, cold water immersion and static stretching) in randomized orders a week apart, respectively. Outcome measures are: visual analogue scale (VAS) score, lower leg volume, pressure pain threshold and horizontal jump distance. All measurements will be recorded at baseline, immediately after exercise, immediately after treatment, and 10 minutes after treatment as the follow up.
2427221|NCT03386006|Experimental|Noom Coach for Bariatric Health|Self-monitoring will be conducted through Noom Coach for Bariatric Health, and individuals will receive a specialized set of instructions on how to use the app.
2427222|NCT03386006|No Intervention|Usual Care|"The control group will be a usual care condition in which participants are free to seek any assistance for their bariatric surgery care during the study period."
2427223|NCT03385993|Experimental|Mediation and Relaxation Intervention|Patients will undergo a technology based guided meditation and relaxation exercise through use of an application on a tablet or virtual reality headset.
2427224|NCT03385980||Post-mortem patients|Post-mortem oncological patients (within 2-6 hrs from death, maximum time for tissue preservation).
2427225|NCT03385967|Active Comparator|ropivacaine only|0.5% ropivacaine
2427226|NCT03385967|Active Comparator|ropivacaine with dexmedetomidine|25ml of 0.5%ropivacaine with 0.25mcg/kg of dexmedetomidine
2427227|NCT03385954|Experimental|Intervention|distance education curse with 8 hours to be accomplished in 2 weeks,
2427228|NCT03385954|Experimental|Control|Wiil receive a lecture of 30 minutes
2427229|NCT03385941||Osteoporotic|Femal, 50-80 years of age with established diagnosis of osteoporosis, based on prior DXA scan with T-score <-2.0 at any site and/or history of fragility fracture
2427230|NCT03385941||Non-osteoporotic|Female, 27-40 years of age, no established history of osteoporosis
2427231|NCT03385928|Active Comparator|Tranexamic acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl (or in 50ml syringe with 0.9% NaCl) over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
2427232|NCT03385928|Placebo Comparator|Normal Saline (0.9% NaCl)|100 mls (or in 50ml syringe) intravenous 0.9%NaCl over 10 minutes followed by 500 ml intravenous 0.9% NaCl infusion over 8 hours.
2427233|NCT03385915||TAVI cohort|Patients who underwent transcatheter aortic valve implantation for aortic valve stenosis
2427234|NCT03385915||SAVR cohort|Patients who underwentsurgical aortic valve replacement for aortic valve stenosis
2427235|NCT03385902|Experimental|optimal start group|The DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE reaching to 30-35, which defined as the optimal start time.
2427236|NCT03385902|Active Comparator|late start group|the DIFE will be used as the assessment of initiation time of dialysis. Patients in this group will start dialysis when their results of the DIFE less than 30, which defined as late start time.
2427237|NCT03385889|Experimental|Cervical Spine Mobilization Group|Subjects with cervicogenic headache who will be assigned to cervical spine mobilization group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
2427238|NCT03385889|Experimental|Cervical Spine Manipulation Group|Subjects with cervicogenic headache who will be assigned to cervical spine manipulation group and receive intervention directed to C1/2 of ipsilateral side of unilateral dominant headache.
2427239|NCT03385889|No Intervention|Control Group|No intervention. Subjects in this groups will wait for 5 minutes between pre- and post-testing of dependent variables.
2427241|NCT03385863||early preterm infants with RDS|gestational age<34 weeks
2427242|NCT03385863||near term infants with RDS|34 weeks≤gestational age< 37 weeks
2427243|NCT03385863||term infants with RDS|Gestational age ≥ 37 weeks
2427244|NCT03385850|Experimental|early enteral nutrition|
2427245|NCT03385850|Active Comparator|delayed enteral nutrition|
2427246|NCT03385837||Heart Failure Patients|Cardiac Rehabilitation in Advanced Heart Failure Patients
2427247|NCT03385824|Experimental|Self-Advocacy for Independent Life (SAIL)|10 week treatment program to improve self-advocacy skills. Includes 4 in-person group sessions (3 hours per session) and two supportive phone calls; workbook and home assignments.
2427248|NCT03385824|No Intervention|Control|SAIL workbook provided at the conclusion of the study.
2427249|NCT03385811||Medical Professionals|no intervention, only questionnaire survey
2427250|NCT03385798|Active Comparator|Endo-GIA|
2427251|NCT03385798|Experimental|Endo-wrist|
2427252|NCT03385759|Active Comparator|UKA|Medial unicompartmental knee arthroplasty
2427253|NCT03385759|Active Comparator|TKA|Total knee arthroplasty
2427254|NCT03385746|Experimental|polyamide|metal reinforced polyamide denture base material
2427255|NCT03385746|Active Comparator|heat cured acrylic resin|conventional heat cured acrylic resin denture base
2427256|NCT03385733|Experimental|Inspiratory muscle training group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with %30 MIP at home.
2427257|NCT03385733|No Intervention|control group|Patients will continue 8 weeks, 5 days, 2 times 15 minutes training program with 9 cmH2O pressure at home.
2427258|NCT03385720|Experimental|Experimental group|
2427259|NCT03385720|Active Comparator|Control group|
2427260|NCT03385707|Experimental|CGM and Microbiota|Participants will wear a Dexcom continuous glucose monitor (CGM) and activity monitor for two weeks. They will not be aware of sensor glucose values. A stool sample will be collected. The investigators will evaluate relationships between patterns of postprandial glycemia, recorded by CGM, food intake, and microbiome composition.
2427261|NCT03385694||Assessment|All the patients operated on Van Nes Rotationplasty for bone tumors at IOR and long term surviving
2427262|NCT03385681|Experimental|Intervention Group|The study will be conducted by nurses at 3 postoperative units with children and adolescents after surgery. All nurses working with patients in these units will be asked to participate. Tailored Educational Intervention is administered to this group.
2427276|NCT03385603|Experimental|Fear-based Dilator Progression group|Participants in this group will complete a home dilator program using levels of pain-related fear to progress through the program.
2427277|NCT03385603|Active Comparator|Standard Dilator Progression Group|Participants in this group will complete a standard home program based on dilator manufacturer instructions for use.
2427278|NCT03385590|Experimental|Soy-fiber-maize|Complementary food composed of soybean, soy fiber and maize flours.
2427279|NCT03385590|Active Comparator|Maize|Complementary food composed of maize flour.
2427280|NCT03385577|Experimental|Yoga Intervention|"The intervention, Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer, is a 10-week, manualized, group yoga program. Sessions are 60 minutes in duration, once a week, across the course of 10 weeks. The 10-week program is comprised of five modules, each of which will take two sessions to complete: (1) Getting Started, (2) Cultivating a Mindful Attitude, (3) Self-Care and Compassion, (4) Finding Peace and Acceptance, and (5) The Power of the Present Moment."
2427281|NCT03385564|Experimental|BI 655064|
2427282|NCT03385564|Placebo Comparator|Placebo|
2427283|NCT03385551||ARM 1|Patients who have been prescribed by the physician within the standard clinical practice 10 micrograms of estradiol vaginal tablets. One tablet intravaginally once daily for two weeks. Thereafter one tablet twice per week with at least a 3-days interval between treatments
2427284|NCT03385551||ARM 2|Patients who have been prescribed by the physician within the standard clinical practice promestriene 10mg./g vaginal cream. 1 gr. one application once daily intravaginally for two weeks. Thereafter one application twice per week with at least a 3-days interval between treatments
2427285|NCT03385538|Experimental|Clopidogrel non-responders|Increasing doses og Clopidogrel depending on PRU values measured on VerifyNow
2427286|NCT03385525|Experimental|BIIB074 150 mg and Valproic Acid 500 mg|Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
3146547|NCT00103896||HIV Infected Youth in Treatment/Care|HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
2427290|NCT03385499|Other|negative control group|blood additional samples on negative control group
2427291|NCT03385499|Other|positive control group|blood additional samples on positive control group
2427292|NCT03385499|Other|seroconversion group|blood additional samples on seroconversion group
2427293|NCT03385486|Experimental|TBX-3400|TBX-3400 by intravenous infusion
2427294|NCT03385473|Active Comparator|Pharmacological Adequation (PA)|Pharmacological adequation based on the Pharmacogenomic Index and therapeutic drug monitoring results.
2427295|NCT03385473|No Intervention|Standard of Care (SOC)|Without pharmacological adequation
2427296|NCT03385460|Experimental|ESWL BOTOX|Each patient will be subjected to Low Energy Shock Waves.The target dose of low energy shock waves will be 3000 shock delivered into SP region in 3 horizontal points at SP transverse crease . all patients will be catheterized using nylaton catheter 16 ch, the study group will be injected with 100 IU botulinium toxin A. vial will be dissolved in saline half of the estimated bladder capacity. All patients will be kept for 2 hours without micturation giving a chance of BOTOX absorption .
2427297|NCT03385447|Experimental|Physical Activity|Participants were subjected to a 12-week exercise program targeting the federal physical activity guidelines.
2427298|NCT03385434|Experimental|Endorings-assisted screening colonoscopy|146 patients with an indication for screening endoscopy will receive an Endorings-2-assisted colonoscopy.
2427299|NCT03385434|No Intervention|Standard screening colonoscopy|146 patients with an indication for screening endoscopy will receive a standard colonoscopy.
2427300|NCT03385408|Experimental|HILT group|High-intensity laser therapy application through HIRO 3.0 device
2427301|NCT03385408|Sham Comparator|Placebo group|Sham high-intensity laser therapy application through HIRO 3.0 device
2427302|NCT03385395|Experimental|OctaAlpha1|
2427303|NCT03385395|Active Comparator|Glassia®|
2427304|NCT03385382||Dexamethasone group|Patients with diabetic macular edema receiving dexamethasone
2427305|NCT03385382||ranibizumab|Patients with diabetic macular edema receiving ranibizumab
2427306|NCT03385369|Placebo Comparator|Placebo Japanese Descent|Participants of Japanese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
2427307|NCT03385369|Experimental|MEDI0382 50 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 50 mcg MEDI0382.
2427308|NCT03385369|Experimental|MEDI0382 100 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
2427309|NCT03385369|Experimental|MEDI0382 150 mcg Japanese Descent|Participants of Japanese descent will receive a single subcutaneous dose of 150 mcg MEDI0382.
2427310|NCT03385369|Experimental|Placebo Chinese Descent|Participants of Chinese descent will receive a single subcutaneous injection of placebo matching to MEDI0382.
2427311|NCT03385369|Experimental|MEDI0382 100 mcg Chinese Descent|Participants of Chinese descent will receive a single subcutaneous dose of 100 mcg MEDI0382.
2427312|NCT03385356|Active Comparator|1000 IU of vitamin D per day|Half of randomized patients will receive 1000 IU of vitamin D per day
2427313|NCT03385356|Active Comparator|4000 IU of vitamin D per day|Half of randomized patients will receive 4000 IU of vitamin D per day
2427314|NCT03385343|Experimental|VLE imaging of stage EAC|All subjects will receive VLE imaging for staging EAC. Volumetric laser endomicroscopy (VLE) is an imaging platform that uses infrared light to generate cross-sectional views of the human esophagus with microscopic resolution.
2427315|NCT03385330|Active Comparator|LOWER oxygen saturation target group|Oxygen saturation target range 90--94%. The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
2427316|NCT03385330|Active Comparator|HIGHER oxygen saturation target group|Oxygen saturation target range greater than or equal to 96%.The study intervention will begin in the hospital and will continue at home until 6 months CA. Overnight continuous oximetry will be transmitted wirelessly to the study team. In hospital, inspired oxygen will be adjusted as needed to maintain target SpO2. Monitoring will continue after discharge, and oxygen flow will be titrated monthly according to a standardized algorithm.
2427317|NCT03385317|Experimental|Mindfulness|
2427318|NCT03385304|Experimental|10% povidone-iodine (1% free iodine) in purified water|The povidone-iodine solution will contain 10% povidone-iodine (1% free iodine) in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions for use (e.g., technique of application, duration of application, drying time, drying techniques, replacement of draping, etc.).
2427319|NCT03385304|Experimental|4% chlorhexidine gluconate (CHG) in purified water|The CHG solution will contain 4% CHG in purified water as the only active ingredient. Operating room personnel will apply the solution to the operative site as the final preoperative skin antisepsis preparation immediately prior to commencing surgical fixation. They will apply the solution as per manufacturer's directions (e.g., technique of application, duration of application, drying time, replacement of draping, etc.).
2427320|NCT03385291|Experimental|patients with disorders of consciousness|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
2427321|NCT03385291|Experimental|healthy control group|3 minutes stimulation with music,name,and noise separately,each are separated with a 5 minutes washout period.
2427322|NCT03385278|Experimental|real-sham|the group first received real rTMS,then sham one.
2427323|NCT03385278|Experimental|sham-real|the group first received sham rTMS,then real one.
2427324|NCT03385265|Experimental|DIPPer Academy|Families randomized to this group will participate in the DIPPer Academy curriculum.
2427325|NCT03385265|Active Comparator|Standard of Care Control|
2427326|NCT03385252|Experimental|Egg Group|Egg Intervention: Provision of eggs to caregivers of enrolled infants, with instructions to prepare and feed one egg to the infant each day for 6 months time. Households will be visited twice weekly to provide eggs and monitor intake.
2427327|NCT03385252|Active Comparator|Control Group|Control Group: Caregivers will receive a food basket at the end of the study. Throughout the trial, households will be visited twice weekly and asked about food intake.
2427328|NCT03385239|Placebo Comparator|Pooled Placebo|Participants in each cohort (A,B,C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).
2427329|NCT03385239|Experimental|Cohort A: ISIS 678354: 10 mg Q4W|Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.
2427330|NCT03385239|Experimental|Cohort C: ISIS 678354: 15 mg Q2W|Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.
2427331|NCT03385239|Experimental|Cohort D: ISIS 678354: 10 mg QW|Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.
2427332|NCT03385239|Placebo Comparator|Cohort B: ISIS 678354: 50 mg Q4W|Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.
2427333|NCT03385226|Experimental|Pembrolizumab with radiotherapy|"All patients will receive~single 200mg pembrolizumab IV infusions given 3-weekly until 2 years post study entry, termination of treatment, disease progression or unacceptable toxicity~radiotherapy, 12Gy in 3 fractions"
2427334|NCT03385213||Relapse|Patients who suffered colorectal cancer relapse after curative surgery
2427335|NCT03385213||Remission|Patients who get remission after curative surgery
2427336|NCT03385200|Active Comparator|A|Application and measurement of tumor size using contrast agent-enhanced diagnostic and therapy supporting (with SonoVue®) ultrasound
2427337|NCT03385200|No Intervention|B|Application and measurement of tumor size using contrast agent-enhanced diagnostic ultrasound
2427338|NCT03385187|Other|NightOwl HSAT|Patient undergoes a NightOwl sleep apnea test whilst simultaneously undergoing a sleep study with a Type I sleep monitor (Lab-PSG) and optionally a Type IV sleep monitor.
2427339|NCT03385174|Other|Carbon monoxide|Each participant receives CO inhalation
2427340|NCT03385161|Active Comparator|botulinum toxin A|"Intraprostatic injection of botulinum toxin A (onabotulinumtoxinA; 100 IU) through transrectal ultrasonography.~One vial (100 IU) is dissolved in 10 ml saline and injected in the transition zone of each lobe of the prostate in 3 sites; basal, middle and apical.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle was introduced to the prostate."
2427341|NCT03385161|Active Comparator|Ethanol|"Intraprostatic injection of dehydrated ethanol through transrectal ultrasonography.~An amount equal to 25% of prostate volume was injected distributed over 6-8 sites among both prostatic lobes with an average of 2 ml per site.~one gm intramuscular ceftriaxone started and continued 3 days. A rectal enema performed the night before the procedure. The anal area sterilized A 21 gauge needle introduced to the prostate."
2427342|NCT03385148|Experimental|colorectal patients|the colorectal patients undergo 68Ga-Sgc8 PET/CT
2427343|NCT03385135|Active Comparator|Allopurinol group|Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks
2427344|NCT03385135|No Intervention|No Allopurinol group|Optimal medical therapy alone
2427345|NCT03385109||Senhance Treated|All patients enrolled who go on to have a surgery in which the Senhance system is used
2427346|NCT03385096|Experimental|BUCY+VP-16|For MM patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -8 and -6；CY 60 mg/kg/day on days -5 and -4; VP-16 10mg/kg/day on days -3 and -2.
2427347|NCT03385096|Active Comparator|Melphalan|For MM patients undergoing auto-HSCT，Melphalan conditioning regimen was Melphalan 200mg/m2 on day -2.
2427379|NCT03384992|Experimental|Group 16|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and cognitive restructuring for week 3.
2427556|NCT03383822|Experimental|Intranasal insulin|40 IU of intranasal insulin
2427348|NCT03385083|Experimental|ACTIVITY TRACKER|Subjects in Cohort A will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Cohort A will then meet with researchers via telehealth at 2 weeks and 4 weeks with researchers to review step counts and reaffirm targets. Subjects in Cohorts A will be reassessed in person at the conclusion of the six week period.
2427349|NCT03385083|Placebo Comparator|Control|Subjects in Cohort B will receive standard of care treatments in addition to a Fitbit Flex 2 activity tracker for six weeks and recommendation for daily step counts at initial visit. Subjects in Cohorts B will be reassessed in person at the conclusion of the six week period.
2427350|NCT03385070||Salt-sensitive group|"Patients (n:163)with HT who presented at the emergency service at least once with a minimum increase in their systolic and diastolic blood pressure of 10% after consuming salty foods were included in the SSH group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2427351|NCT03385070||Salt resistance group|"Patients(n:142) who did not exhibit this increase were included in the SRH group~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2427352|NCT03385070||Control group|"Sex- and age-matched patients(n:124) without a HT diagnosis were included in the control group.~Biomicroscopic lens examination,urine analysis for salt intake estimation,blood pressure measurements"
2427353|NCT03385057|Active Comparator|Ibuprofen Arm|
2427354|NCT03385057|Active Comparator|Acetaminophen|
2427355|NCT03385044|Active Comparator|Cuff sealing by MOVT|MOVT (minimal occlusive volume technique). The cuff sealing will be confirmed with MOVT, then the intracuff pressure will be measured.
2427356|NCT03385044|Active Comparator|Cuff sealing by VE/VI ratio|VE/VI ratio of Spirometer. The cuff sealing will be confirmed with VE/VI ratio of a spirometer, then the intracuff pressure will be measured.
2427357|NCT03385031||group 1|whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment
2427358|NCT03385031||group 2|simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment
2427359|NCT03385031||group 3|patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment
2427360|NCT03385018|Experimental|Laparoscopic group|Arm Description: Laparoscopic radical total gastrectomy with D2 (or D2-#10) lymph node dissection
2427361|NCT03385018|Active Comparator|Open group|Open radical total gastrectomy with D2 (or D2-#10) lymph node dissection
3146548|NCT00103896||BVI Individuals|Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
2427364|NCT03384992|Experimental|Group 1|Participants were exposed to the following conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2427365|NCT03384992|Experimental|Group 2|Participants were exposed to the one of the following usual care conditions: general health for week 1, diet-general information for week 2, and diet-BCSS information (breast cancer survivor-specific) for week 3.
2427366|NCT03384992|Experimental|Group 3|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2427367|NCT03384992|Experimental|Group 4|Participants were exposed to the following conditions: cognitive restructuring for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
2427368|NCT03384992|Experimental|Group 5|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3. Telephone coaching was given.
2427369|NCT03384992|Experimental|Group 6|Participants were exposed to the following conditions: scheduled worry practice for week 1, general health for week 2, and diet-general information and diet-BCSS information (breast cancer survivor-specific) for week 3.
2427370|NCT03384992|Experimental|Group 7|Participants were exposed to the following conditions: cognitive restructuring for week 1, worry practice for week 2, and General Health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2427371|NCT03384992|Experimental|Group 8|Participants were exposed to the following conditions: cognitive restructuring for week 1, scheduled worry practice for week 2, and General Health and Diet (General and BCSS) for week 3.
2427372|NCT03384992|Experimental|Group 9|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3. Telephone coaching was given.
2427373|NCT03384992|Experimental|Group 10|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, general health for week 2, and Diet - General and BCSS for week 3.
2427374|NCT03384992|Experimental|Group 11|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2427375|NCT03384992|Experimental|Group 12|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, cognitive restructuring for week 2, and General health and Diet (General and BCSS) for week 3.
2427376|NCT03384992|Experimental|Group 13|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and General health and Diet (General and BCSS) for week 3. Telephone coaching was given.
2427377|NCT03384992|Experimental|Group 14|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, scheduled worry practice for week 2, and General health and Diet (General and BCSS) for week 3.
2427378|NCT03384992|Experimental|Group 15|Participants were exposed to the following conditions: Diaphragmatic breathing and relaxation for week 1, worry practice for week 2, and cognitive restructuring for week 3. Telephone coaching was given.
2427380|NCT03384979|Placebo Comparator|TBW protocol|Patients will receive a contrast agent dose based on their TBW as a standard clinic protocol.
2427381|NCT03384979|Experimental|LBW protocol|Patients will receive a contrast agent dose based on their calculated LBW.
3187398|NCT00755742|Experimental|Group 3 - Viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with chronic hepatitis C (HCV RNA positive) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who are naive to antiviral therapy, relapsed or not responded to antiviral therapy.
3146549|NCT00103896||HIV Serosurvey Individuals|HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
3146550|NCT00103922|Experimental|Arm 1|
3146551|NCT00103935|Placebo Comparator|Group A1|Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
3146552|NCT00103935|Placebo Comparator|Group A2|Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
3146553|NCT00103935|Experimental|Group B|Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
2427392|NCT03384888|Experimental|ano-M1-cat-SO5 tDCS|Participants will receive active transcranial direct current stimulation (tDCS) (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 5 consecutive days.
2427393|NCT03384888|Experimental|ano-M1-cat-SO10 tDCS|Participants will receive active transcranial direct current stimulation (active tDCS). The electrodes will be placed on left M1 for anodic stimulation and on the right supraorbital region for cathodic stimulation on 10 consecutive days.
2427394|NCT03384888|Sham Comparator|Sham tDCS|Participants who receive stimulation of the simulated type (sham tDCS), following the protocol of the ano-M1-cat-SO5 group.
2427395|NCT03384875|Experimental|CytoSorb Device|Standard of care plus treatment with CytoSorb device installed on the Cardiopulmonary bypass (CPB) machine
2427396|NCT03384875|Placebo Comparator|Control|Standard of care
2427397|NCT03384862|Experimental|Nutritional Intervention Arm|5 μg vitamin B12 plus 400 μg folic acid
2427398|NCT03384862|Placebo Comparator|Control Arm|Placebo
2427399|NCT03384849||MRI patients|Up to 200 patients of different age, weight and sex, which undergo MRI examinations.
3146554|NCT00103935|Experimental|Group C|Exenatide lead-in followed by exenatide LAR 2.0 mg weekly
2427401|NCT03384823|Experimental|EDP-938 SAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
2427402|NCT03384823|Experimental|EDP-938 MAD Cohorts|EDP-938 Dose 1, Dose 2, Dose 3, and Dose 4 oral suspension, once daily for 7 days
2427403|NCT03384823|Placebo Comparator|EDP-938 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
2427404|NCT03384823|Placebo Comparator|EDP-938 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 7 days
2427405|NCT03384797||Healthy Volunteers|
2427406|NCT03384797||Parkinson's Disease|
3146555|NCT00103961||1|Treatment-naive and treatment-experienced HIV-infected adults
3146556|NCT00104091|Experimental|1|40 mL of TP-38 at a 100 nanograms/mL concentration
2427409|NCT03384771||MBSR Students|community-dwelling adults who register for relevant MBSR courses at UMass CFM, UCSF, or participating community sites
2427410|NCT03384771||MBSR Teachers|those teaching MBSR courses at UMass CFM, UCSF, or participating community sites
2427411|NCT03384771||Raters|experience mindfulness teachers, recruited by invitation, who will participate in MBI-TAC training
2427412|NCT03384758|Active Comparator|mild to moderate PAD|
2427413|NCT03384758|Active Comparator|Diabetes mellitus|
2427414|NCT03384758|Placebo Comparator|Healthy volunteers|
3146557|NCT00104312||1|Participants with symptomatic knee osteoarthritis
3146558|NCT00104312||2|Participants without symptomatic knee osteoarthritis, age-matched as controls
3146560|NCT00104494|Experimental|1|CF, Zinc acetate
3146561|NCT00104494|Experimental|2|CF, Placebo
3146562|NCT00104494|No Intervention|3|Controls
3146563|NCT00104559|Experimental|1|Participants will receive the computer-based tutorial for VT and then the standard paper consent form for AT
3146564|NCT00104559|Experimental|2|Participants will receive the standard paper consent form for VT and then the computer-based tutorial for AT
3146565|NCT00104559|Experimental|3|Participants will receive the computer-based tutorial for AT and then the standard paper consent form for VT
3146566|NCT00104559|Experimental|4|Participants will receive the standard paper consent form for AT and then the computer-based tutorial for VT
3146567|NCT00104585||1|People with young onset Parkinson's disease and their family members
3146568|NCT00104598|Active Comparator|Gain Framed Absitnence Program|Gain framed video and printed messages encouraging smoking abstinence with Bupropion.
3146569|NCT00104598|Active Comparator|Loss Framed Abstinence Program|Loss framed video and printed messages encouraging smoking abstinence with Bupropion.
3146570|NCT00104611|Active Comparator|TMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 6 weeks
3146571|NCT00104611|Placebo Comparator|Placebo|Treatment 5 days/week for up to 6 weeks
3146572|NCT00104689|Experimental|Capecitabine + Oxaliplatin|Patients receive oral capecitabine once daily on days 1-14 and oxaliplatin IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity
3146573|NCT00104702|Experimental|Concentrated and Focalized Radiotherapy|
3146574|NCT00104715|Experimental|Hormonotherapy + chemotherapy|
3146575|NCT00104715|Active Comparator|Hormonotherapy alone|
3146576|NCT00104741|Active Comparator|radiotherapy alone|
3146577|NCT00104741|Experimental|Radiotherapy + androgene deprivation|
2427421|NCT03384719|Experimental|35 g protein (30% milk + 70% rapeseed)|35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening
2427422|NCT03384719|Experimental|35 g protein (54% milk + 46% rapeseed)|35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening
2427423|NCT03384719|Active Comparator|35 g protein (100% milk)|35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening
2427424|NCT03384706|Active Comparator|Cognitive Processing Therapy (CPT)|PTSD Psychotherapy CPT will be implemented using the Cognitive-Only version, excluding the trauma account.
2427425|NCT03384706|Experimental|Accelerated Resolution Therapy (ART)|PTSD Psychotherapy
2427426|NCT03384706|No Intervention|Wait List Control|Wait List control will include a 7 week minimal attention control period with weekly check-in calls to ensure that the participant has not experienced any significant worsening in their symptoms that might require interventions, (e.g. suicidal intent).
2427428|NCT03384667|Experimental|MMDT group|
2427429|NCT03384667|Placebo Comparator|Placebo group|
3146578|NCT00104754|Experimental|liposomal SN-38|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete or partial response or patients with stable disease (SD) who were previously treated before study enrollment receive up to 4 additional courses of treatment. Patients with CNS-only disease progression receive whole brain radiotherapy (WBRT). After completion of WBRT, these patients also receive up to 4 additional courses of treatment. Patients with disease progression to sites other than the CNS or patients with SD who were previously untreated before study enrollment are removed from the study.~Quality of life is assessed at baseline, before each treatment course, and then annually for 3 years.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 2 years."
3146579|NCT00104767|Experimental|celecoxib|
3146580|NCT00104845|Experimental|human gp100 DNA vaccine|Patients receive human gp100 DNA vaccine intramuscularly (IM) once in weeks 1, 4, and 7. Patients then receive mouse gp100 DNA vaccine IM once in weeks 10, 13, and 16.
2427433|NCT03384628|Active Comparator|First Pair Senofilcon A contact lens|The first pair of Senofilcon A contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the first pair Senofilcon A contact lens and subsequent removal.
2427434|NCT03384628|Active Comparator|Second pair Senofilcon A contact lens|The second pair of contact lenses is applied (according to the fitting schedule), allowed to settle before assessment of the second pair Senofilcon A contact lens and subsequent removal.
2427435|NCT03384628|Active Comparator|Third pair Senofilcon A contact lens|The third pair of Senofilcon A contact lens is applied (according to the fitting schedule), allowed to settle before assessment of the third pair Senofilcon A contact lens and subsequent removal.
2427436|NCT03384615|Experimental|Compassion-focused therapy|
2427437|NCT03384615|No Intervention|Waitlist control group|
2427438|NCT03384602|Active Comparator|Dalcroze Eurhythmics program|music-based multi-task exercise intervention
2427439|NCT03384602|Active Comparator|home exercise strength program|simple strength training program to perform individually at home
2427440|NCT03384602|No Intervention|Control group|no change in the daily activities, no exercise intervention
2427441|NCT03384589|Active Comparator|Group 1: 3 doses of PCV13|PCV13, 0.5ml intramuscular at 2, 4 and 12 months of age
2427442|NCT03384589|Experimental|Group 2: 2 doses of PCV13|PCV13, 0.5ml intramuscular at 2 and 12 months of age
2427443|NCT03384576|Experimental|Music intervention|Participants listen to music in the waiting room
2427444|NCT03384576|Active Comparator|No music|Participants will not have music in the waiting room
2427445|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-6 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427446|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-6 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427447|NCT03384563|Placebo Comparator|Placebo 1-6 months|
2427448|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 6-12 months|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427449|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 6-12 months|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427450|NCT03384563|Placebo Comparator|Placebo 6-12 months|
2427451|NCT03384563|Active Comparator|Dexmedetomidine 0.5 mcg/kg 1-3 years|Precedex 0.5mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427452|NCT03384563|Active Comparator|Dexmedetomidine 1 mcg/kg 1-3 years|Precedex 1 mcg/kg intravenous administered over 10 minutes prior to surgical procedure. Assigned sevoflurane concentration.
2427453|NCT03384563|Placebo Comparator|Placebo 1-3 years|
2427454|NCT03384550|Active Comparator|Control|"Participants in this arm receive no incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2427495|NCT03384251|Experimental|Intervention group|This group shall be given a comprehensive sex education in approximately six sessions.
2427496|NCT03384251|No Intervention|Control group|This group will not be given any form of education.
3146581|NCT00104845|Experimental|mouse gp100 DNA vaccine|Patients receive mouse gp100 DNA vaccine IM once in weeks 1, 4, and 7. Patients then receive human gp100 DNA vaccine IM once in weeks 10, 13, and 16
2427455|NCT03384550|Experimental|Financial Incentives|"Participants in this arm receive financial incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2427456|NCT03384550|Experimental|Charity Incentives|"Participants in this receive charity incentives.~As all participants, participants in this arm receive self-regulation coaching on 50% of the days during the intervention period. For each participant, days during the intervention period are randomly allocated to a coaching or a no coaching condition using an allocation ratio of 1:1.~As all participants, participants in this arm also receive either an action planning, a coping planning or no planning condition each Sunday during the intervention period. Participants are randomized to one out of nine sequences of planning interventions according to a uniform and strongly balanced intervention schedule"
2427457|NCT03384537|Experimental|Listerine total care zero|Listerine total care zero
2427458|NCT03384537|Active Comparator|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
2427459|NCT03384524|Active Comparator|Combination regiment|A combination regiment of Bromocriptine (2.5 mg/day), Metoprolol (25 mg/day) and Tamsulosin (0.4 mg/day)
2427460|NCT03384524|Placebo Comparator|Placebo|Three placebo pills, matching the external appearance of active drugs
2427461|NCT03384511|Experimental|Apatinib & RGD PET/CT|All of the patients will receive apatinib at oral dose of 250 mg twice daily (500 mg/day) at least 30 days.One treatment cycle is defined as 4 weeks.18F-ALF-NOTA-PRGD2 PET/CT scan will be performed berore and after one cycle of therapy. Treatment interruptions or dose reductions to 250 mg/day will be allowed for the management of adverse events. The maximum allowable period of treatment interruption is 1 week during each treatment cycle, and the dose should be re-escalated to 500 mg/day after adverse events mitigation. Treatment will not stop until disease progression, intolerable toxicity, or patients' request for withdrawal from the study.
2427462|NCT03384485|Other|antiphospholipid syndrome|blood test in patients that diagnosed with antiphospholipid syndrome to diagnose Fabry's disease
2427463|NCT03384459|Experimental|Experimental group|"For a total period of 12 months, perform the 308-nm excimer laser treatment once a month.~At this time, the dose of the 308-nm excimer laser is based on the 50% of the maximum dose that the patient received for the treatment.~Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2427464|NCT03384459|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2427465|NCT03384446|Active Comparator|Tooth-borne treatment|A cleaning aid that resembles tooth cleaning instruments and is empirically used for implant surface cleaning.
2427466|NCT03384446|Experimental|Implant-specific treatment|A cleaning aid that has been specifically designed for implant surface cleaning.
2427467|NCT03384433|Experimental|exosome or vesicle|CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
2427468|NCT03384420|Experimental|Intervention CD34+ cells enriched with MNV-BLD|Intervention CD34+ cells enriched with MNV-BLD
2427469|NCT03384407|Experimental|Open label|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
2427470|NCT03384394|Placebo Comparator|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
2427471|NCT03384394|Active Comparator|High-flow Nasal Cannula Oxygen Therapy|High-flow Nasal Cannula Oxygen Therapy
2427472|NCT03384368|Placebo Comparator|Screw-Distraction (SD) group|six pedicle screws were implanted firstly, then distraction was achieved.
2427473|NCT03384368|Experimental|Distraction-Screw (DS) group|four pedicle screws were implanted firstly, then distraction was achieved, two additional screws were introduced at the fracture level at last.
2427474|NCT03384355||Class 0|no visible or palpable varicose veins
2427475|NCT03384355||Class 1|telengiectasia ( thread veins, spider veins, broken veins)
2427476|NCT03384355||Class 2|varicose veins
2427477|NCT03384355||Class 3|edema
2427478|NCT03384355||Class 4|skin changes (pigmentation, eczema, lipodermatosclerosis, atrophie blanche)
2427479|NCT03384355||Class 5|healed venous ulcer
2427480|NCT03384355||Class 6|active venous ulcer
2427481|NCT03384342|Experimental|Experimental group|"For a total period of 12 months, perform Narrow-band UV-B therapy treatment once a month.~At this time, the dose of Narrow-band UV-B therapy therapy is based on the 50% of the maximum dose that the patient received for the treatment."
2427482|NCT03384342|No Intervention|Control group|"Check for signs of enlarged vitiligo lesions at 3-month intervals for a total period of 12 months.~If recurrence of vitiligo is observed during the follow-up period, visit the clinic and check for recurrence."
2427487|NCT03384303|Other|LBPL-RYGB|
2427488|NCT03384303|Other|S-RYGB|
2427489|NCT03384290|Placebo Comparator|Placebo|
2427490|NCT03384290|Experimental|PRS-060|
2427491|NCT03384277|Experimental|Steroid+Rituximab|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）+Rituximab 375mg/m2 for one dose.
2427492|NCT03384277|Active Comparator|Steroid +Cyclophosphamide|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks （ then tapering gradually, 8 weeks in total）+ Cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
2427493|NCT03384264|Experimental|TG|
2427494|NCT03384264|No Intervention|CG|the CG maintained their normal physical activity habits over the study
2427497|NCT03384238|Experimental|Cohort 1a|A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. Cohort 1a will receive 25 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
2427498|NCT03384238|Experimental|Cohort 1b|Cohort 1b will receive 50 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
2427499|NCT03384238|Experimental|Cohort 1c|Cohort 1c will receive 75 mg of Panitumumab IRDye800 with a 100 mg unlabeled test/loading dose of Panitumumab.A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
2427500|NCT03384238|Experimental|Cohort 1d|Cohort 1d will receive a 50 mg dose of Panitumumab IRDye800 and no test/loading dose. A test/loading dose of 100 mg of unlabeled Panitumumab (fixed dose) will be administered via a 60 minute IV infusion prior to infusion of the Panitumumab IRDye800. The surgical resection will then occur 2 to 5 days after infusion. Intraoperative imaging will be performed using the intraoperative optical imaging devices
2427501|NCT03384238|Experimental|Cohort 2- Dose Expansion|Cohort 2 will receive the optimal dose of Panitumumab-IRDye800 as determined in Cohort 1
3146582|NCT00104910|Experimental|Treatment (brachytherapy, radiation, cetuximab, cisplatin)|Patients receive cetuximab IV over 1-2 hours and cisplatin IV on days 1, 8, 15, 22, 29, and 36 (weeks 1-6). Patients also undergo external beam radiotherapy to the para-aortic and pelvic lymph nodes OR whole pelvis once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33 (weeks 1-5). Patients then receive either 1 or 2 applications of low-dose rate brachytherapy in weeks 6-8 OR 5 applications of high-dose rate (HDR)* brachytherapy once weekly in weeks 4-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3146583|NCT00104962|Experimental|Treatment (lenalidomide)|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2427506|NCT03384199|Experimental|Dose escaltion|insertion of 3 fiducial markers, prostate will receive 78 Gy with dose escalation to prostate focal lesion up to 87 Gy
2427507|NCT03384186|Experimental|Danicopan Modified Release Prototype Tablets|"Participants received danicopan once each period as a single oral dose as follows:~Period 1: Danicopan Modified Release Prototype 1 under fasted conditions. Period 2: Danicopan Modified Release Prototype 2 under fasted conditions. Period 3: Danicopan Modified Release Prototype 3 under fasted conditions. Period 4: Danicopan Modified Release Prototype 2 under fed conditions.~There was a washout period of at least 14 days between each danicopan dosing."
2427509|NCT03384160|Active Comparator|Group 1-Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction
2427510|NCT03384160|Active Comparator|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction
2427511|NCT03384147|Experimental|Drinking|"Occasional drinkers assigned to start with a 3week drinking period (women 1 u/day - men 2 u/day)~Followed by crossover without washout to 3 week abstaining period"
2427512|NCT03384147|Experimental|Abstaining|"Habitual drinkers assigned to start 2 weeks of abstaining from alcohol~Followed by crossover without washout to 3 weeks drinking (women 1 u/day - men 2 u/day)"
2427513|NCT03384134|Experimental|Pain Buddy|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily diaries using Pain Buddy and will also be taught cognitive and behavioral coping skills, like deep breathing, imagery, and relaxation, to deal with pain and symptoms. The skills will be taught through the electronic tablet. Pain and symptom information, collected daily by Pain Buddy, will be sent to a health care provider on the oncology treatment team, who will contact patients when certain thresholds are reached and will instruct the patients on best ways to control pain and symptoms.
2427514|NCT03384134|No Intervention|Control|Children in this condition will continue with the care that has been prescribed for cancer- and chemotherapy-related pain and symptoms, which may include medications, medical visits, physical interventions, etc. Participants in this condition will complete daily pain diaries using Pain Buddy, but will not receive skills training or remote monitoring of data.
2427515|NCT03384121|Experimental|Rifampin|All subjects
2427516|NCT03384108|Experimental|In Vivo|Infusion of 5-13C-Glutamine intravenously in healthy subjects prior to undergoing a bone marrow aspiration.
2427517|NCT03384108|Placebo Comparator|Ex Vivo|Healthy subjects will undergoing a bone marrow aspiration and then the plasma cells acquired will be cultured ex vivo in cell culture media containing 5-13C-Glutamine.
2427518|NCT03384095|Experimental|Hyaluronic Acid|Subjects in this arm will be given 100 mg of hyaluronic acid in capsule form. Subject in this arm will be asked to 1 capsule take twice daily for 26 weeks.
2427519|NCT03384095|Placebo Comparator|Placebo|Subjects in this arm will be given a placebo comparator capsule that is identical to the hyaluronic capsule containing microcrystalline cellulose as the sole ingredient. Subjects in this arm will be asked to take 1 capsule twice daily for 26 weeks.
2427520|NCT03384082|Experimental|Hysteroscopic treatment|Hysteroscopic surgery
2427521|NCT03384082|No Intervention|Control group|No treatment
2427522|NCT03384069|Experimental|Group-based Cognitive Behavioral Therapy (CBT)|The Group-based CBT will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
2427554|NCT03383848|No Intervention|Control Group|Subjects in the control group will receive standard of care, and will receive emails with links to the surveys to be filled out in the REDCap secure web application throughout the study.
2427555|NCT03383835|Experimental|Omega-3 Supplementation|Participants will take the dose of omega-3 supplementation (600mg DHA and 300mg EPA) daily for 6 months.
2427523|NCT03384069|Experimental|Phone-based Cognitive Behavioral Therapy (CBT)|This intervention will follow the same protocol as the group-based CBT, but without the opportunity for group-interaction. It will incorporate psycho-education about cognitive behavioral skills and written materials to support learning and application of the psycho-educational content. The intervention will be culturally tailored to incorporate beliefs/attitudes, health literacy, effective communication, and motivational strategies, which focus on African Americans.
2427524|NCT03384069|No Intervention|Standard of care|Participants will continue to receive care and follow up from their primary care providers, that incorporates general education regarding lifestyle activities and AD prevention.
2427525|NCT03384056||Self Pressurized Airway Device with Blocker|
2427526|NCT03384056||Proseal Laryngeal Mask Airway|
2427527|NCT03384043|Experimental|Smartphone Personal Assistant|"Participants will use the personal assistant feature of the smartphone (Cortana) to provide reminders to perform prospective memory tasks at the appropriate time and location. In the current study, participants will press a button and verbally state Cortana, I need to remember to... for time--based tasks (...take my medicine at 7pm) and event--based tasks (pick-up milk at the grocery store)."
2427528|NCT03384043|Active Comparator|Implementation Intention|"The implementation intention is a memory strategy, in which individuals verbally state when/where they will perform a prospective memory intention. In the current study, participants will verbally specify an external cue in a When…then format and record doing so using the smartphone's voice recorder app. They will use the implementation intention strategy for time--based tasks (When it is 7pm, then I will remember to take my medicine), and event--based tasks (When I am at the grocery store, then I will remember to pick--up milk)."
2427529|NCT03384030|Experimental|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
2427530|NCT03384017|Experimental|TSCS and gait training|
2427531|NCT03384004|Experimental|Irrigation Technique 1|Patients randomized into this group will be treated using EndoVac Pure followed by Ultrasonic Irrigation.
2427532|NCT03384004|Experimental|Irrigation Technique 2|Patients randomized into this group will be treated using EndoVac Pure only.
2427533|NCT03383991|Experimental|Reverse Total Shoulder Arthroplasty|
2427534|NCT03383991|Active Comparator|Hemiarthroplasty|
2427535|NCT03383978|Experimental|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
2427536|NCT03383965|Experimental|ICAR30 T cells|anti-CD30 CAR-T cells. Patients receive ICAR30 T cells infusion.
2427537|NCT03383952|Experimental|ICAR19 CAR-T cells|Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
2427538|NCT03383939|Experimental|group A|"10 patients randomly allocated received nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month.~Intervention: nebulised alpha1-antitrypsin 250mg (diluted in 10ml injectable solution) once a day during 1 month"
2427539|NCT03383939|Placebo Comparator|group B|"9 patients randomly allocated received 10ml 0.9%NaCl saline solution nebulised once daily during 1 month.~intervention: 10ml 0.9% Sodium Chloride saline solution nebulised once daily during 1 month."
2427540|NCT03383939|No Intervention|Control|10 patients without bronchiectasis were initially compared wiht bronchiectasis patients (group A + B) to define baseline levels of A1-AT and neutrophil elastase in BAL
2427541|NCT03383926|Experimental|Group 1|Suture confection of theTobacco-pouch of 4.5cm from the anal margin.
2427542|NCT03383926|Experimental|Group 2|Suture confection of theTobacco-pouch of 6cm from the anal margin.
2427543|NCT03383913|Experimental|Intervention|The intervention arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure baseline and outcome assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firsbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. Participants placed in the intervention arm will receive 4-6 weeks of Heart Rate Variability Biofeedback training. All measures will be repeated at the end of the six week period.
2427544|NCT03383913|No Intervention|Control|The control arm baseline visit will include: Institutional Review Board (IRB) consent, PROMIS measure assessments, instructions on placement of Firstbeat device and use of Firsbeat journal, resting HRV recording using Firstbeat software for 15 minutes, saliva collection, and distribution of actigraph watch to quantify sleep quality. The control group will receive their usual care for SCD and complete baseline and post-baseline outcome assessments without any HRV-B training. All measures will be repeated at the end of the six week period.
3146584|NCT00104988|Experimental|Thalidomide and Temozolomide|Patients receive oral thalidomide once daily on days 1-56 and temozolomide once daily on days 1-42. Courses repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3146585|NCT00105040|Experimental|Levetiracetam (LEV)|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
3146586|NCT00105040|Placebo Comparator|Matching Placebo (PBO)|Oral tablets and oral solution.
3146587|NCT00105053|Experimental|vaccine group|
2427551|NCT03383861||SSRI long-term user|Adults, 655 with an SSRI prescription ≥180 days and identified in the National Health and Nutrition Examination Survey (NHANES) data.
2427552|NCT03383861||Non-user|Adults, 12,372 non-users, were identified in the National Health and Nutrition Examination Survey (NHANES) data.
2427553|NCT03383848|Experimental|Experimental Software Group|Subjects in the experimental group will be provided with free access to the medication management software online, which will be able to be accessed on the SmartPhone/SmartDevice and home tablet(s) or computer(s) of their choice, through any browser. They will also be provided with links to the surveys to be filled out in the REDCap secure web application throughout the study.
3146588|NCT00105144|Experimental|1|lower dose
3146589|NCT00105144|Experimental|2|higher dose
3146590|NCT00105144|Active Comparator|3|
2427557|NCT03383822|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
2427558|NCT03383809|Experimental|Strawberry juice with inulin|One dose of 300 g of strawberry with 10 g of inulin will be given to subjects in the form of juice
2427559|NCT03383809|Experimental|Strawberry juice|One dose of 300 g of strawberry juice will be given to subjects in the form of juice
2427560|NCT03383809|Experimental|Inulin|One dose of 10 g of inulin will be given to subjects in the form of a drink
2427561|NCT03383796|Experimental|3D approach|Three dimensional laparoscopic resection for pCCA
2427562|NCT03383796|Experimental|open approach|Open resection for pCCA
3187399|NCT00755742|Active Comparator|Group 4 - Non-viremic / Cirrhotic|13 obese and insulin resistant, cirrhotic, non-diabetic (by fasting glucose), non-genotype 3 patients with cured chronic hepatitis C (HCV RNA negative) will undergo 24 week lifestyle intervention comprising diet, physical activity (monitored by pedometers) in combination with behavior modification counseling. This arm includes patients who have cleared hepatitis C virus with previous antiviral therapy
3187400|NCT00755781|Active Comparator|CIS|CIS in addition to standard immunosuppressive regimen.
3187401|NCT00755781|No Intervention|SOC|Standard of care (SOC) therapy for lung transplant recipients
3187402|NCT00755794|Experimental|1|Montelukast
2427567|NCT03383770|Active Comparator|Tuohy|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A tuohy needle is used."
2427568|NCT03383770|Active Comparator|Facet|"After a careful disinfection of the puncture site, under sterile conditions and under ultrasonographic control with the application of nerve stimulation (settings: stimulation current primary 2.0 mA with stepwise reduction over 1.0 mA to 0.5 mA, pulse width 0.1 ms, pulse frequency 2 Hz) of the N. ischiadicus blocked by 20 ml ropivacaine 0.75 %. (electrical nerve stimulation and ultrasound) If no motor response can be triggered by stimulation, the closest possible needle-nerve distance is generated at a pulse strength of 1mA and regional anesthesia is performed. (protective nerve stimulation) Subsequently, the transplantation into the supine position and the further procedure specific to the operation (use of other regional procedures in combination or general anaesthesia).~A facet needle is used."
3187403|NCT00755820||EXP-DCS/Exposure-D-cycloserine|Exposure Therapy + D-Cycloserine
2427570|NCT03383744|Experimental|Vitamin A supplementation 1|Vitamin A status assessed at Baseline and one month after the administration of 200,000 IU of vitamin A
2427571|NCT03383744|Experimental|Vitamin A supplementation 3|Vitamin A status assessed at Baseline and three months after the administration of 200,000 IU of vitamin A
2427572|NCT03383731|Active Comparator|Group 1|Group 1: The patients in Group 1 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
2427573|NCT03383731|Experimental|Group 2|Group 2: The patients in Group 2 are treated by the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
2427574|NCT03383718||DSE+/FFR+|Patients with positive Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve Revascularisation
2427575|NCT03383718||DSE+/FFR- or DSE-/FFR+ or DSE-/FFR-|"Patients with positive Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with positive Fractional Flow Reserve~Patients with negative Dobutamine Stress Echocardiography and with negative Fractional Flow Reserve~Optimal Medical Treatment/OMT"
2427576|NCT03383705|Experimental|Treatment arm|
3187404|NCT00755820||EXP-PBO|Exposure Therapy + Placebo
3187405|NCT00755820||SP|Supportive psychotherapy
3187406|NCT00755833||A|
3187407|NCT00755859|Experimental|1|Six month steroid course plus azathioprine
2427581|NCT03383666|Experimental|Treatment Group|PulseRider® Aneurysm Neck Reconstruction in conjunction with coil embolization for unruptured wide-neck intracranial aneurysms.
2427582|NCT03383640|No Intervention|Control|Control Group: Standardized post operative rehabilitation, where active exercises of the replanted digits is postponed until radiologic healing of the amputated bone.
2427583|NCT03383640|Other|Intervention|Intervention Group: Early active exercises of the replanted digits started between day 5 and 7 after surgery, as instructed by hand therapist
3187408|NCT00755859|Active Comparator|2|six month steroid course
3187409|NCT00755872|Experimental|1|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
3187410|NCT00755872|Experimental|2|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
3187411|NCT00755872|Experimental|3|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
3187412|NCT00755872|Experimental|4|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
3187413|NCT00755898|Active Comparator|1|Patients with a medical diagnosis of cancer appearing at outpatient clinics for treatment and/or monitoring of their disease status
3187414|NCT00755898|Active Comparator|2|Healthy adult volunteers
3187415|NCT00755950|Experimental|1|280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3187416|NCT00755950|Placebo Comparator|3|Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3187417|NCT00755950|Experimental|2.|420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)
3187418|NCT00755963|Experimental|1|
3187419|NCT00755963|Experimental|2|
3187420|NCT00755963|Placebo Comparator|3|Placebo
3187421|NCT00755976|Experimental|Epirubicin hydrochloride (75mg/m2 i.v.) Sulindac: 600mg|
3187422|NCT00755989|Placebo Comparator|1|group to receive topical gel without morphine
2427588|NCT03383601||Users of IQOS with HeatStick|Individuals (men and women) between the ages of 40 and 59 (inclusive) with a minimum of 10 pack-year smoking history who switched to and predominantly (>70%) use Heated Tobacco product IQOS/heatstick
2427589|NCT03383601||Smokers of combustible cigarettes|Individuals (men and women) between the ages of 40 and 59 (inclusive) who are currently smoking combustible cigarettes with a minimum of 10 pack-year smoking history
3187423|NCT00755989|Experimental|2|Morphine gel
3187424|NCT00756015|Active Comparator|Early Motion|Other: Early range of motion post-operative therapy protocol.Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
3187425|NCT00756015|Other|Immobilization|Immobilization following rotator cuff repair.
2427593|NCT03383575|Experimental|Arm I (enasidenib, azacitidine)|Patients who are HMA-naive receive enasidenib PO QD on days 1-28 and azacitidine IV over 30-60 minutes or SC on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2427594|NCT03383575|Experimental|Arm II (enasidenib)|Patients relapsed and/or refractory to HMA therapy receive enasidenib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2427595|NCT03383562||morning group|patients in the morning group are operated during 8:30 a.m. to 2:00 p.m.
2427596|NCT03383562||afternoon group|patients in the morning group are operated during 2:00 p.m. to 8:00 p.m.
2427597|NCT03383562||night group|patients in the morning group are operated during 8:00 p.m. to 12:00 p.m.
2427598|NCT03383549|Experimental|Tele-rehabilitation|Tele-rehabilitation arm undergo a home-based rehabilitation combined protocol, made up of cognitive and physical exercises
2427599|NCT03383549|No Intervention|Control group|Control group receives only verbal instructions to train cognitive and physical conditions. Instructions will aim to promote daily and leisure activities.
2427600|NCT03383536||Phase 1|Healthy control participants will provide neuroeconomic game responses to form a pool of potential responses for participants to interact with during Phase 2.
2427601|NCT03383536||Phase 2: PTS-SA|posttraumatic spectrum-socially anhedonic
2427602|NCT03383536||Phase 2: PTS-nonSA|posttraumatic spectrum-non-socially anhedonic
2427603|NCT03383536||Phase 2: HC|healthy controls
3187426|NCT00756028|Experimental|1|Patients receiving short protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-antagonist (Orgalutran®: Ganirelix)
3187427|NCT00756028|Active Comparator|2|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®: Nafarelin)
3187428|NCT00756041|Experimental|TAK-128 100 mg QD|
3187429|NCT00756067|Experimental|Formulation 1|
3187430|NCT00756067|Experimental|Formulation 2|
3187431|NCT00756067|Experimental|Formulation 3|
3187432|NCT00756067|Experimental|Formulation 4|
2427611|NCT03383510|Experimental|Climate friendly group|The climate friendly group will receive instructions to eat according to a climate friendly diet, i.e., to replace the majority of their intake of animal based products with plant based food.
2427612|NCT03383510|Experimental|Organic group|The organic group will receive instructions to eat an organic diet, i.e., to replace at least 50% of their normally consumed food with organic equivalents.
2427613|NCT03383510|Experimental|Climate friendly and organic group|The climate friendly and organic group will receive instructions to consume a climate friendly and organic diet, i.e, to replace the majority of their intake of animal based products with plant based food AND to consume at least 50% organic food products.
2427614|NCT03383510|Placebo Comparator|Control group|The control group will receive instructions to eat according to the Nordic Nutrition Recommendations.
2427615|NCT03383497||Idiopathic Parkinson Disease|
2427616|NCT03383497||Other Parkinsonian syndromes|
2427617|NCT03383484|No Intervention|No intervention|No OMT, yoga, acupuncture, or other interventions.
2427618|NCT03383484|Experimental|OMT intervention|Weekly OMT for 3 months
2427619|NCT03383484|Experimental|Yoga intervention|Yoga 3 times per week for 3 months
2427620|NCT03383471|Experimental|Invossa K Inj.|Invossa K Inj.
2427621|NCT03383471|Placebo Comparator|Placebo|Placebo control
3187433|NCT00756067|Experimental|Formulation 5|
3187434|NCT00756067|Experimental|Formulation 6|
2427624|NCT03383445|Other|TAVR|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local abesthesia, Imaging guidance during the TAVR procedure, and post-procedural TAVR management.
2427625|NCT03383445|Other|SAVR|SAVR procedure will be performed using standard techniques, with no limitation in terms of type and size of the valve prosthesis or surgical procedure (e.g. enlargement of the aortic root).
2427626|NCT03383432|Other|Trans-abdominal ultrasound intrauterine device group.|Those will be subjected to intrauterine device insertion under trans-abdominal ultrasound guidance. In this method the participant will be asked to have a full bladder. Full bladder helps to displace the bowel out of the pelvis and acts as an acoustic window for high frequency sound waves and to straighten the angle between the uterine body and cervix in anteverted uterus, performing the function of the tenaculum. Then, then ultrasound will be done and the intrauterine device will be introduced vaginally under ultrasound vision.
3187435|NCT00756067|Active Comparator|23 valent pneumococcal vaccine|
2427627|NCT03383432|Other|Uterine Sounding Sparing intrauterine device group|The sonographer performs ultrasound using transvaginal probe to evaluate the uterine position and the endometrial length in the sagittal view of the uterus. The intrauterine device was inserted directly into the uterine cavity without using uterine sounding.
2427628|NCT03383419|Experimental|Treatment|Epclusa® will be started within 14 days of quantifiable viremia and continued for 12 weeks. Within 24 hours prior to first-dose of treatment, HCV genotype will be sent from transplant recipient.
2427629|NCT03383406|Experimental|I Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM)|
2427630|NCT03383393||adenosine|Intracoronary bolus of adenosine (adenocor)
2427631|NCT03383393||GP IIb/IIIa|Intracoronary bolus of Integrilin (eptifibatide)
2427632|NCT03383393||Nitroglycerine|Intracoronary bolus of nitroglycerine (nitronal)
2427633|NCT03383380|Experimental|Rapamycin|Treatment for patients with activated phosphoinositide 3-kinase δ syndrome
2427634|NCT03383367|Experimental|Tempo Colo|
2427635|NCT03383341|Experimental|Cricket powder protein|Participants were provided with frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. The amount of intervention food consumed daily contained 25 grams of cricket protein powder.
2427636|NCT03383341|Placebo Comparator|Placebo Control|Participants were provided with a placebo comparator that included frozen 70 gram breakfast muffins and pre-mixed powder packets to prepare smoothies. Participants were asked to consume one muffin package and one smoothie (mixed with water or choice of milk/milk substitutes) daily for 14 days. These foods were formulated to taste and appear similar to the cricket intervention foods but did not consume any cricket powder.
2427637|NCT03383328|Active Comparator|NSAID + prednisolone, preoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
2427638|NCT03383328|Active Comparator|NSAID + prednisolone, postoperative|"Combination of NSAID- and prednisolone eye drops. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day Prednisolone acetate 1% w/v, eye drops, 1 drop 3 times pr. day"
2427639|NCT03383328|Experimental|NSAID, preoperative|"NSAID eye drops as monotherapy. Treatment is initiated 3 days prior to surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
2427640|NCT03383328|Experimental|NSAID, postoperative|"NSAID eye drops as monotherapy. Treatment is initiated on the day of surgery and administered 3 times pr. day for 3 weeks.~Ketorolactrometamol 5 mg/ml, eye drops, 1 drop 3 times pr. day"
2427641|NCT03383328|Experimental|Drop-less surgery|"A depot of dexamethasone is administered subtenonally during surgery.~Dexamethason Krka 4 mg/ml solution for injection/infusion. 0,5 ml equivalent to 2 mg of dexamethasone is administered once."
2427642|NCT03383315|Experimental|Group 1|Intravenous tramadol 50mg + intravenous metoclopramide 10mg
2427643|NCT03383315|Active Comparator|Group 2|Intravenous tramadol 50mg + placebo (normal saline)
2427644|NCT03383302|Experimental|Arm 1 Tolerabilty|This is a single arm study of nivolumab administered on completion of stereotactic body radiotherapy (SBRT) to patients with early stage NSCLC. The first 5 patients to enroll must have Eastern Co-operative Oncology Group (ECOG) performance status < 2 at the time of first dose of investigational medical product (IMP). An Independent Data Monitoring Committee (IDMC) will meet when the first 5 patients have reached 3 months follow up from their 1st dose of nivolumab or have withdrawn consent to follow-up. The IDMC, if satisfied with the safety data from the initial 5 patients, may recommend escalation to include recruitment of patients with ECOG performance status of 2.
2427645|NCT03383289|Experimental|R-REM training|3 module training for frontline staff in assisted living facilities related to recognizing and management of resident-to-resident elder mistreatment
2427646|NCT03383289|No Intervention|Control condition|Usual care
2427647|NCT03383276|Experimental|IL-1Ra|
2427648|NCT03383263||Children with juvenile arthritis|Children with diagnosed polyarticular juvenile arthritis according to International League of Associations for Rheumatology (ILAR) criteria treated with HUMIRA (adalimumab) in the routine clinical settings in the Russian Federation
2427649|NCT03383250|Experimental|Meal ingestion|
2427650|NCT03383237|Experimental|Apatinib|Apatinib 500mg/d,q.d.,p.o.
3146591|NCT00105339||Illustration Style Preference Group|Ten participants at each site will be invited to attend a focus group to determine their comfort with and preference for one of four styles of illustration. The same two concepts will be presented in each of the four styles and ratings will be obtained from all participants. Detailed information on why participants rated each of the styles the way they did will also be obtained by reviewing comments on the rating sheets and audiotapes of the groups. Groups will be run by the study coordinator at the Florida and New York sites, and by Dannie Hoffman, protocol coordinator, in Los Angeles, using a focus group script developed by Dr. Murphy.
3146592|NCT00105339||Review of Draft Focus Group|Lori Perez will travel to each site from Westat and conduct Review of Draft Focus Groups with adolescents and young adults (n per site = approximately 10 - 15) to collect final feedback on the adolescent friendly version (present key pieces of the adolescent friendly version and obtain feedback on the wording and the illustrations). Based on the focus group feedback, the research team will finalize the adolescent friendly materials.
3146593|NCT00105339||Comprehension/Recall Assessment|The assessment will be read to the participants to preclude reading problems. Responses will be recorded by the interviewer on the assessment instrument.
3146594|NCT00105365|Placebo Comparator|walking shoes|walking shoes
3146595|NCT00105365|Experimental|walking shoes + shoe insert|walking shoes + shoe insert
3146596|NCT00105547|Experimental|1|800 mg BID
3146597|NCT00105547|Placebo Comparator|2|BID dosing
3146598|NCT00105573|Experimental|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy for depression.
3146599|NCT00105573|Experimental|Interpersonal psychotherapy/child-parent psychotherapy|Participants will receive interpersonal psychotherapy for depression plus 1 year of in-home, child-parent psychotherapy.
2427661|NCT03383185||Non-hormonal contraceptive|Users of non- hormonal intrauterine device during the 5 years follow-up
2427662|NCT03383185||Hormonal contraceptives|Users of combined oral contraceptive, progestin-only pills, depot-medroxyprogestereone acetate during 5 years follow-up
2427663|NCT03383172|Experimental|ICPS with internal school facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by the early educator of the class, who is part of the school personnel.This internal facilitator will be trained in the program. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
2427664|NCT03383172|Active Comparator|ICPS with external facilitator|Schools with preschool students. All consented students in the class will participate in the ICPS preschool program, adapted to the Chilean reality and culture. The program is manualized and will be delivered by an external trained early educator, who is part of the research team. The early educator of the class, who is part of the school personnel, will also be trained to collaborate with all the program activities with the external facilitator. Each of the 59 sessions lasts around 20 minutes, delivered 2 to 3 times a week, during 5 months. ICPS content includes vocabulary and concepts about emotions, and the development of problem-solving skills, practising alternative solutions, consequences and the sequential thought (solutions-consequences). Interactive techniques (e.g. games, role-playing, and the use of stories, illustrations and puppets), and guided discussion strategies are used to solve problems.
2427665|NCT03383172|No Intervention|Control Group|School in the control group will continue to carry out their normal academic and prevention activities.
2427666|NCT03383159||Observation group 1|Patients who suffered metachronous adenoma after proximal colorectum cancer surgery.
2427667|NCT03383159||Control group 1|Patients who do not suffere metachronous adenoma after proximal colorectum cancer surgery.
2427668|NCT03383159||Observation group 2|Patients who suffered metachronous adenoma after distal colorectum cancer surgery.
2427669|NCT03383159||Control group 2|Patients who do not suffered metachronous adenoma after distal colorectum cancer surgery.
3146600|NCT00105573|Active Comparator|Enhanced community standard|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
3146601|NCT00105599|Other|Arm 1|
2427672|NCT03383133|Experimental|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (1.0 g)) or dehydroepiandrosterone (75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (0.75 g).
2427673|NCT03383120|Experimental|Laser|Mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette. Adjunctive sub-mucosal diode laser application according to the instructions of the manufacturer (settings: 810 nm, 2.5 W, 50 Hz, 10 ms), 3x for 30 seconds, using a 400-µm thick fiber (Doctor Smile Wiser diode laser, Orcos Medical AG, Küsnacht, Switzerland), will be performed three times at one week intervals (days 0, 7, and 14).
2427674|NCT03383120|Active Comparator|Surgery|Active control includes mechanical debridement of the implant surface using an ultra-sonic device with saline irrigation and plastic curettes, followed by soft tissue curettage using a metallic curette at day 1. An open flap debridement procedure is performed at day 14 using normal saline for implant decontamination. Adjunctive systemic antimicrobials will be prescribed; Amoxi-mepha 500mg 3x/day and Metronidazole 500mg 3x/day, for 1 week. A chlorhexidine 0.2% mouth rinse will also be prescribed 2x/day for one week. Suture removal and prophylaxis are performed 7-10 days post-operatively.
2427675|NCT03383107||Cohort 1a - Prostate Cancer|Standard fractionation RT to 81 Gy in 45 fx over 9 weeks
2427676|NCT03383107||Cohort 1b - Prostate Cancer|Hypofractionated RT to 36.25 Gy in 5 fx over 1-2 weeks
2427677|NCT03383107||Cohort 2a - Breast cancer|Standard fractionation breast and nodal RT to 50 Gy in 25 fx over 5 weeks
2427678|NCT03383107||Cohort 2b - Breast Cancer (Partial Breast )|Partial breast RT to 30 Gy in 5 fx over 2 weeks
2427679|NCT03383094|Active Comparator|Control-radiotherapy/cisplatin|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent cisplatin 100 mg/m2 every 3 weeks for 3 cycles (7 weeks)
2427680|NCT03383094|Experimental|Experimental-Radiotherapy/pembrolizumab|Intensity-modulated radiation therapy to 70 Gy in 33-35 fractions over 6.5 weeks plus concurrent and adjuvant pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
2427681|NCT03383081|Experimental|Low dose mesenchymal stem cells|Low dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
2427682|NCT03383081|Experimental|High dose mesenchymal stem cells|High dose group: intra-articular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#)
2427683|NCT03383081|No Intervention|Control groups|No intervention
2427684|NCT03383068|Other|control|metformin(1000-1500mg/d) treated for 6 months, reverse to normal glucose tolerance
2427685|NCT03383068|Experimental|acarbose|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with acarbose (100mg tid ) for 3 months
2427686|NCT03383068|Experimental|Exenatide|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Exenatide 10μg/bid ) for 3 months
2427687|NCT03383068|Experimental|Orlistat|metformin(1000-1500mg/d) treated for 6 months, can not reverse to normal glucose tolerance, then treat with Orlistat(0.12mg/tid ) for 3 months
2427688|NCT03383055|Experimental|CMV positive cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
2427689|NCT03383055|Experimental|CMV negative cohort|CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT
2427690|NCT03383042|Experimental|Cohort 1|Single-ascending cohort 1
2427691|NCT03383042|Experimental|Cohort 2|Single-ascending cohort 2
2427692|NCT03383042|Experimental|Cohort 3|Single-ascending cohort 3
2427693|NCT03383042|Experimental|Cohort 4|Single-ascending cohort 4
2427694|NCT03383042|Experimental|Cohort 5|Single-ascending cohort 5
2427695|NCT03383042|Experimental|Cohort 6|Multiple-ascending cohort 1
2427699|NCT03383029|Experimental|iEAT|Children with food refusal will participate in the iEAT program.
3146602|NCT00105625||Group 1|
2427701|NCT03383003|Experimental|High dose dual therapy|Esomeprezole (Nexium)40 mg tid. and amoxicillin (Amolin) 750 mg qid. for 14 days
2427702|NCT03383003|Active Comparator|Non-bismuth quadruple therapy|Esomeprezole (Nexium) 40 mg bid.,clarithromycin (Klaricid) 500 mg bid., amoxicillin (Amolin) 1 g bid. and metronidazole (Flagyl) 500 mg bid. for 7 days
2427703|NCT03382990||STEMI|Patients with STEMI treated with PCI and stent placement (DES or BMS)
2427704|NCT03382990||NSTEMI|Patients with NSTEMI treated with PCI and stent placement (DES or BMS)
3146603|NCT00105638|Other|Arm 1|
3146604|NCT00105651|Other|Arm 1|
3146605|NCT00105664|Other|Arm 1|
3146606|NCT00105677||Group 1|
3146607|NCT00105690|Other|Arm 1|
2427710|NCT03382964|Active Comparator|VLA1553 low dose|VLA1553 with 3.2x10^3 TCID50/ 100 µL (microliter). Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL (milliliter)
2427711|NCT03382964|Active Comparator|VLA1553 medium dose|VLA1553 with 3.2x10^4 TCID50/ 1 mL Re-vaccination at Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
2427712|NCT03382964|Active Comparator|VLA1553 high dose|VLA1553 with 3.2x10^5 TCID50/ 1 mL Re-vaccination at Month 6 or Month 12 with VLA1553 with 3.2x10^5 TCID50/ 1 mL
2427713|NCT03382951||Healthy children|Each study is an observational study with no group assignments and no control/placebo.
2427714|NCT03382938|Active Comparator|Dexmedetomidine|Drug: dexmedetomidine (Dexmed) 20 mL solution of dexmedetomidine used for wound infiltration
2427715|NCT03382938|Active Comparator|Ropivacaine|Drug: ropivacaine 20 mL solution of ropivacaine 0.375% used for wound infiltration
2427716|NCT03382938|Active Comparator|Dexmedetomidine - Ropivacaine|Drug: dexmedetomidine (Dexmed) combined with Drug: ropivacaine 20 mL solution of dexmedetomidine 1γ/kg within ropivacaine 0.375% used for wound infiltration
2427717|NCT03382938|Placebo Comparator|0.9 % saline|Drug:0.9 % saline solution (Normal saline). 20 ml with 0.9 % saline solution used for wound infiltration
2427724|NCT03382886|Experimental|Nivolumab and bevacizumab, all patients|
2427725|NCT03382873|Active Comparator|Group Lifestyle Balance (GLB)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who achieve >2.5% weight loss at week 5 will remain in the GLB arm.
2427726|NCT03382873|Experimental|Group Lifestyle Balance Plus (GLB+)|Implement the first 4-sessions of the core 16-session phase of the GLB intervention for diabetes prevention to all participants. Determine percent weight change at week 5. Those who fail to achieve >2.5% weight loss at week 5 will transfer to the GLB+ arm.
2427727|NCT03382860||Ventriculoperitoneal dysfunction|Patients with suspected ventriculo-peritoneal (VP) shunt dysfunction are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The patients are approached within this time frame.
2427728|NCT03382860||Normal Pressure Hydrocephalus (NPH)|Patients with suspected NPH (triad of cognitive dysfunction, urine incontinence of urge type, abnormal gait) are admitted to the neurosurgical department for intracranial pressure monitoring for 24 hours. The following day an infusiontest is performed, where data is collected.
3146608|NCT00105703|Other|Arm 1|
3146609|NCT00105716|Other|Arm 1|
3146610|NCT00105729|Other|Arm 1|
3146611|NCT00105742|Other|Arm 1|
3146612|NCT00105755|Other|Arm 1|
3146613|NCT00105768|Other|Arm 1|
3146614|NCT00105781|Other|Arm 1|
3146615|NCT00105794|Other|Arm 1|
3146616|NCT00105807|Other|Arm 1|
3146617|NCT00105820|Other|Arm 1|
3146618|NCT00105833|Experimental|Arm 1|Multifaceted collaborative intervention for depression based in primary care
3146619|NCT00105833|No Intervention|Arm 2|Treatment as usual
3146620|NCT00105846|Other|Arm 1|
3146621|NCT00105859|Other|1|
3146622|NCT00105872|Other|Arm 1|
3146623|NCT00105885|Experimental|Arm 1|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
3146624|NCT00105885|No Intervention|Arm 2|Patients randomized to receive routine care will be scheduled to see their psychiatric medication provider at the recommended interval.
3146625|NCT00105898|Experimental|Arm 1|Intervention group
3146626|NCT00105898|Active Comparator|Arm 2|Comparator
3146627|NCT00105898|Sham Comparator|Arm 3|Comparator
3146628|NCT00105911|Other|Arm 1|
3146629|NCT00105950|Experimental|Lapatinib|Single arm study of lapatinib with no comparator arm.
3146630|NCT00106041|Other|Arm 1|Palliative Care Nurse Case Management
3146631|NCT00106067|Experimental|Arm 1|In the intervention arm, Patients and their family caregivers have access to a coping and communication support practitioner (CCSP) (see intervention description) in addition to receiving the usual care in the site.
3146632|NCT00106067|No Intervention|Arm 2|In the control arm, Patients are receiving the usual care in the site.
3146633|NCT00106145|Experimental|Part I - Arm 1|
3146634|NCT00106145|Experimental|Part II - Arm 1|
3146635|NCT00106145|Experimental|Part III - Arm 1|
3146636|NCT00106145|Experimental|Part IV - Arm 1|
3146637|NCT00106145|Experimental|Part V - Arm 1|
3146638|NCT00106171|Experimental|1|Participants will receive HAART for 1 year
3146639|NCT00106171|No Intervention|2|Participants will receive no treatment
3146640|NCT00106197|Experimental|1|Participants will receive bupropion in the sleep study
3146641|NCT00106210|Experimental|1|Behavioral Intervention (experimental)
3146642|NCT00106210|Active Comparator|2|Behavioral Intervention 2
3146643|NCT00106223|Experimental|1|Group receiving immediate treatment with cognitive behavioral therapy
3146644|NCT00106223|Active Comparator|2|Waitlist control group to begin CBT 3 months after other CBT group begins treatment
3146645|NCT00106288|Experimental|1|
3146646|NCT00106288|Active Comparator|2|
3146647|NCT00106301|Experimental|FK228 (romidepsin)|romidepsin
2427734|NCT03382808|Experimental|SEE Training|The training sequence comprises four weekly sessions using a modified dote-probe paradigm (fearful vs. neutral expression).
2427735|NCT03382808|Active Comparator|GAZE Training|The GAZE training sequence comprises four weekly sessions using a modified dote-probe paradigm (averted vs. directed gaze).
2427736|NCT03382795|Experimental|EGFR retreat group|
2427737|NCT03382782|Active Comparator|Behavioral Weight Loss Intervention|"Participants will enroll in the BWLI program for 12 months. BWLI consists of a 8-month initial intervention phase followed by 4-month maintenance phase. The initial intervention phase comprises four types of contact:~1-hour to 1-hour, 30 minute group weight-management class led by facilitator (once per week; 26 classes followed by a one week break and an additional 8 weight management review classes)~45 minute, physical activity led by facilitator (one-two times per week);~20 minute, monthly individual visit with facilitator to address barriers to goals and appropriate skills; and~weigh-in during weight management group and individual visits (once each week)."
2427738|NCT03382782|Experimental|BWLI & Peer Navigator|"Participants randomly assigned to this condition will begin simultaneously with BWLI and run concurrently across the eight months of the intervention. Peer navigators will meet individually and face-to-face with research participants in time and places convenient to the person as needed. Specific practices are determined by the research participant with the peer navigator and may include:~partnering with participant on BWLI homework;~meeting with participant and BWLI facilitator individually;~attending all other health care appointments; and~partnering on tasks that arise out of those appointments."
2427739|NCT03382782|Active Comparator|Integrated Care (Treatment as Usual)|Participants in this arm will receive integrated care from their usual provider, which is treatment as usual. Integrated care is mental health specialty and general medical care providers working together to address the physical and behavioral health care needs of patients. One-third of research participants will be randomized to integrated care alone.
3146648|NCT00106327|Experimental|1|6-month supervised treadmill exercise program
3146649|NCT00106327|Experimental|2|6-month supervised lower extremity progressive resistance training program
2427742|NCT03382756|Experimental|Group A|"Period 1: 1 capsule of test drug(CKD-337) administered under fasting condition~Period 2: 1 capsule of test drug(CKD-337) under high fat diet condition"
2427743|NCT03382756|Experimental|Group B|"Period 1: 1 capsule of test drug(CKD-337) under high fat diet fed condition~Period 2: 1 capsule of test drug (CKD-337) administered under fasting condition"
2427744|NCT03382743|Active Comparator|Group A (Lidocaine group)|5 sprays of endocervical Lidocaine 10% spray ( AstraZeneca, bedforshire) are used 3 minutes before office hysteroscopy
2427745|NCT03382743|No Intervention|Group B (control group)|office hysteroscopy is done without analgesia
2427746|NCT03382730|Other|Oral Chlorhexidine Mouth Rinse|Application of chlorhexidine gluconate mouth rinse per unit protocol.
2427747|NCT03382730|Experimental|De-Adoption of Oral Chlorhexidine Mouth Rinse|No application of chlorhexidine gluconate mouth rinse. Oral care bundle.
2427748|NCT03382717|Experimental|Excilor Forte|
2427749|NCT03382717|Active Comparator|Loceryl 5%|
2427750|NCT03382704||Patients undergoing biopsy|Patients undergoing biopsy (incisional or excisional) of peri-ocular lesions. Pre-operative examination for presence or absence of lanugo hairs
2427751|NCT03382691|Experimental|EXPERIMENTAL|Blood pressure check using mobile device and control device
2427752|NCT03382652||Patients who received the Continuum Metal on Metal System|Patients requiring total hip arthroplasty, who meet the inclusion/exclusion criteria and received the Continuum Metal on Metal System
2427757|NCT03382626|Active Comparator|tDCS plus Computer-assisted training|Patients will receive 10 sessions of active anodal tDCS on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for electroencephalogram (EEG) electrode placement) plus Computer-assisted cognitive training (games to improve working memory, attention, and executive function).
2427758|NCT03382626|Sham Comparator|tDCS sham plus Computer-assisted training|Patients will receive 10 sessions of sham anodal tDCS on the left prefrontal cortex dorsolateral plus Computer-assisted cognitive training (games to improve working memory, attention and executive function).
2427759|NCT03382613||Quality Improvement (QI) Program|Hospitals assigned to the QI program arm will begin the 4-month Preparatory Phase which is designed to introduce the institutional baseline reporting tools and materials related to performance improvement, and gain insight into their gaps in treatment, followed by 15 month Implementation Phase, which will consist of education, process, and engagement activities that are targeted at the hospital and healthcare provider level and then the Measurement Period at which time hospitals will complete a final survey to document specific interventions that were successfully implemented and perform a final retrospective chart review on selected patients.
2427760|NCT03382613||Usual Care|Hospitals assigned to the Usual Care arm will not participate in the structured QI program but will continue with their standard hospital practice in treating patients with atrial fibrillation (AF) at risk for ischemic stroke. Hospitals will also complete a final survey and final retrospective chart reviews during the Measurement Period.
2427803|NCT03382288|Experimental|Examination of participants|Examination of participants by means of the investigational device, Eyestar 900 as well as the comparative devices.
3146650|NCT00106327|Active Comparator|3|Diet/nutrition control group
3146651|NCT00106340|Experimental|Vildagliptin|
3146652|NCT00106340|Active Comparator|Glimepiride|
3146653|NCT00106418|Experimental|Romidepsin|13 mg/m^2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
3146654|NCT00106483||Coronary Artery Risk Development in Young Adults|There were no interventions.
3146655|NCT00106496|Experimental|1A|
3146656|NCT00106496|Active Comparator|1B|
3146657|NCT00106496|Experimental|2|Open label
3146658|NCT00106496|Experimental|3A|
3146659|NCT00106496|Placebo Comparator|3B|
2427761|NCT03382600|Experimental|Pembrolizumab + Oxaliplatin +TS-1 (Cohort 1)|Participants receive Pembrolizumab 200 mg every 3 weeks (Q3W) plus oxaliplatin 130 mg/m^2 Q3W by intravenous (IV) infusion plus TS-1 twice daily (BID) by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
2427762|NCT03382600|Experimental|Pembrolizumab + Cisplatin +TS-1 (Cohort 2)|Participants receive Pembrolizumab 200 mg Q3W plus cisplatin 60 mg/m^2 Q3W by IV infusion plus TS-1 BID by continuous oral administration for 14 days, followed by a recovery period of 7 days. Study treatment will be started on Day 1 of each 3-week course.
2427763|NCT03382587||Aflibercept|Treatment-naive wet age-related macular degeneration patients under routine intravitreal aflibercept treatment in a treat-and-extend scheme
2427768|NCT03382548|Active Comparator|Short antibiotic treatment duration for VAP (7 days or less)|
2427769|NCT03382548|Active Comparator|Long antibiotic treatment duration for VAP ( 8 days or more)|
2427770|NCT03382535|Active Comparator|Voice therapy|An individually tailored voice therapy where the order and length of voice treatment methods will depend on the nature of each subject's voice problems. The intervention will take eight weeks and average of eight sessions (a' 45 min).
2427771|NCT03382535|Experimental|Voice therapy with carryover strategies|A voice therapy as described above and an enhanced carryover program. By carryover we mean the process of extending new vocal skills outside the clinic. It includes supplementary tasks and reminders that will be tailored individually out of those direct and indirect methods that the subjects have adopted during therapy sessions. Additionally, the teachers will be doing vocal warm-up and relaxation exercises together with their pupils int the beginning and in the middle of a school day. The intervention will take eight weeks.
2427772|NCT03382535|Other|Control group|No intervention during eight weeks since this group will act as a temporary control group. After eight weeks, half of the participants in this group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
2427775|NCT03382496||Lung Cancer patients in France|Lung Cancer patients treated by nivolumab in real life condition in France from October 2016 to October 2017
2427776|NCT03382483||EXOGEN Treated|Patients prescribed EXOGEN and treatment initiated
2427777|NCT03382483||Non-EXOGEN Treated|Patients in insurance claims database who have not been treated with a bone growth stimulator; derived via propensity score subclassification
3146660|NCT00106496|Experimental|4|Open label
2427779|NCT03382431|Experimental|PC786|Repeat dose
2427780|NCT03382431|Placebo Comparator|Placebo/vehicle|Repeat dose
2427784|NCT03382405|Experimental|mRNA-1647|
2427785|NCT03382405|Experimental|mRNA-1443|
2427786|NCT03382405|Placebo Comparator|Placebo|
2427787|NCT03382392||ALS|
2427788|NCT03382392||control 1|
2427789|NCT03382392||control 2|
2427790|NCT03382379|Experimental|Active|Participants in the active arm will receive 2 milliamp anodal transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
2427791|NCT03382379|Placebo Comparator|Sham|Participants in the Sham arm will receive sham transcranial Direct Current Stimulation (tDCS) over the Dorso-Lateral Pre-Frontal Cortex (DLPFC).
2427792|NCT03382366|Other|Sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the second group."
2427793|NCT03382366|Other|Non-sarcopenic Group|"This group is composed by 20 osteoporotic postmenopausal women, previously (pre-recruitment) classified as non-sarcopenic by the DXA.~This group will undergo the same evaluations/intervention of the first group."
2427794|NCT03382353|Active Comparator|No Treatment (NT)|Educational training
2427795|NCT03382353|Experimental|Partial Treatment (PT)|Nutritional supplementation & Counselling on a brain-healthy diet
2427796|NCT03382353|Experimental|Full Treatment (FT)|Nutritional supplementation & Counselling on a brain-healthy diet & Physical exercise training & Computerized cognitive training
2427797|NCT03382340|Experimental|Imx-110|
2427798|NCT03382327|Experimental|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review.
2427799|NCT03382314|Experimental|HDDO-1614|Bazedoxifene + Cholecalciferol combination drug
2427800|NCT03382314|Active Comparator|Bazedoxifene + Cholecalciferol|Co-administration of Bazedoxifene and Cholecalciferol
2427801|NCT03382301|Experimental|Ciclosporin A preconditioning|Ciclosporin A preconditioning before renal artery stenosis dilation
2427802|NCT03382301|Placebo Comparator|NaCl preconditioning|
3146661|NCT00106522|Experimental|1|
3146662|NCT00106522|Experimental|2|
3146663|NCT00106522|Placebo Comparator|3|
3146664|NCT00106548|Experimental|1|
3146665|NCT00106548|Experimental|2|
3146666|NCT00106548|Placebo Comparator|3|
3146667|NCT00106574|Experimental|1|
3146668|NCT00106574|Placebo Comparator|2|
3146669|NCT00106613|Experimental|FK228 (romidepsin)|13 mg/m2 of romidepsin
3146670|NCT00106678||Infected through risk behaviors|
3146671|NCT00106678||Infected perinatally or through blood/blood products.|
2427806|NCT03382249|Placebo Comparator|OMC and pseudo-SDT|Optimal medical care (OMC) and pseudo-SDT are administrated in this arm. OMC is established according to the standards established by the 2017 China Guidelines for the Diagnosis and Treatment of Carotid Artery Stenosis in order to promote best practices for risk factor management. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
2427807|NCT03382249|Experimental|OMC and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
2427808|NCT03382236|Experimental|Real osteopathy|
2427809|NCT03382236|Placebo Comparator|Sham osteopathy|
2427810|NCT03382210||ERP group|A prospective series of patients (N=100) undergoing elective colorectal resection and completing a standardized enhanced recovery protocol in 2013-2015 (ERP group) at the S. Anna University Hospital in Ferrara (Italy).
2427811|NCT03382210||Pre-ERP group|A retrospective series of patients (N=100) operated on at the the S. Anna University Hospital in Ferrara (Italy) in 2009-2011 (Pre-ERP group), before the introduction of ERP methodology.
2427812|NCT03382197|Experimental|Nebulization|control intervention, will only perform nebulization;
2427813|NCT03382197|Experimental|Positive expiratory pressure valve|Intervention, will perform nebulization associated with positive expiratory pressure valve in the airways (EPAP)
2427814|NCT03382197|Experimental|Nonivasive ventilation|intervention, will perform nebulization associated with non-invasive ventilation Bi-level mode;
2427815|NCT03382184|Experimental|Fraxel DUAL 1550 nm|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth. 25 patients with alopecia will be part of this group.
2427816|NCT03382184|Experimental|Halo Hybrid Laser 1550 nm|The Halo laser will be used per protocol due to the dynamic thermal optimization technology for hair regrowth. 25 patients with alopecia will be part of this group.
2427817|NCT03382171|Experimental|FoodforCare group|The intervention group will receive meals from FoodforCare at Home. The FoodforCare at Home concept consists of five to six small protein and energy enriched meals that will be delivered twice a week. After an individual intake, the composition of the dishes will be tailored to the needs of the patient in terms of composition, diet, taste, flavor and portion size. Besides the meals, patients in the intervention group will also receive an information leaflet about the importance of protein during treatment and how to reach their protein requirements.
2427818|NCT03382171|No Intervention|Usual care group|The control group will continue their usual diet for 3 weeks and have no restrictions to their diet.
2427819|NCT03382158||Type I PPB|Type I PPB is an early manifestation of this malignant disease, cured in some cases by surgery. Surgical guidelines are presented. It is unknown whether adjuvant chemotherapy improves cure rates for individuals with Type I PPB. If the treating physicians select adjuvant chemotherapy treatment, chemotherapy options include a 22-week regimen: 4 courses of vincristine, actinomycin D and cyclophosphamide (VAC) followed by 3 courses of vincristine and actinomycin D (VA). Therapy decisions are the responsibility of the treating institution.
2427820|NCT03382158||Types II and III PPB|Types II and III PPB are aggressive sarcomas. Surgery and chemotherapy are necessary in all cases. Surgical guidelines are presented. Many children with Types II or III PPB receive a single-arm multi-agent chemotherapy neo-adjuvant/adjuvant regimen of IVADo (ifosfamide, vincristine, actinomycin, doxorubicin) for 36 weeks. Second and possible 3rd look surgery may be considered for local control. Radiation therapy may be considered. Specific therapy decisions are the responsibility of the treating institution.
2427821|NCT03382158||Type Ir PPB|Type Ir (regressed) PPB is a unique, purely cystic tumor which lacks a primitive cell component. The International PPB/DICER1 Registry will enroll and follow participants with Type Ir PPB, regardless of age.
2427822|NCT03382158||DICER1 Gene or Cond Assoc with DICER1|PPB and the associated conditions found in PPB families suggest a familial tendency to formation of tumors. The International PPB/DICER1 Registry for PPB, DICER1 and Associated Conditions study will enroll and follow participants who have the DICER1 gene mutations or conditions associated with PPB or DICER1.
2427824|NCT03382132|Experimental|momHealth|Participants will receive support and information via the momHealth program.
2427825|NCT03382132|Active Comparator|Control|Participants will receive the normal support they would normally receive if they were not in a study.
2427826|NCT03382119||Patients having Fontan cardiac surgery|"This group includes pediatric patients, aged 2-5 years, who have had a Fontan operation. This surgery corrects a heart defect found at birth in which the heart has only one ventricle.~Patients will have an Ultrasound with ARFI imaging."
2427827|NCT03382119||Patients with Liver disease|"This group includes pediatric patients, aged 2-5 years, who have chronic liver disease caused by biliary atresia.~Patients will have an Ultrasound with ARFI imaging."
2427828|NCT03382106|Experimental|Smoking Cessation Group 1|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
2427829|NCT03382106|Placebo Comparator|Smoking Cessation Group 2|80 normal smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews), between the ages of 21 and 65 will be studied to assess inflammation and heterogeneity of Perfused Blood Volume prior to and following a 3 month smoking cessation program. In 40 of the 80 subjects during the smoking cessation program, we will provide three times per day placebo oral tablet for the full 3 months of the smoking cessation period. We select a three-month cessation program to maximize the likelihood of compliance with cessation yet providing enough time for a resolution of lung injury to take place. Pulse wave velocity, carotid artery compliance and stiffness and pressure wave reflection will be measured.
2427897|NCT03381625|Experimental|BMX-010 0.03%|200 subjects will receive BMX-010 0.03% twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
2427830|NCT03382106|Experimental|Non-Smokers Group 1|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. We will provide 10 females and 10 males three times per day Sildenafil 20 milligrams (MG) (Viagra) for the full 3 months.
2427831|NCT03382106|No Intervention|Non-Smokers Group 2|20 non-smokers will be recruited (defined by Pulmonary Function Tests, questionnaires and interviews) between the ages of 21 and 65 will be studied to compare the heterogeneity of Perfused Blood Volume with that of smokers for a 3 month period of time. 10 females and 10 males will not receive any medication for the full 3 months.
2427832|NCT03382093|Active Comparator|Personalized Feedback Intervention|A brief, personalized computer-delivered transdiagnostic intervention (PFI) that addresses smoking and anxiety sensitivity (AS) to reduce smoking, increase quit attempts, reduce perceived barriers to cessation, reduce AS and negative affective symptoms, and increase adaptive coping skills.
2427833|NCT03382093|Active Comparator|Smoking Information Control|Standard, computer-delivered smoking cessation treatment/information.
2427834|NCT03382080|Experimental|Dream School Program (DSP)|The Dream School Program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
2427835|NCT03382080|Experimental|DSP and Mental Health Support Team|"A combination of the universal Dream Schoop Program (see description above) and the selective/indicative intervention Mental Health Support Team which is aimed at specific students at risk of dropping out of upper secondary school. It is a systematization of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school"
2427836|NCT03382080|No Intervention|Control|The control group are upper secondary schools who run classes and the school as usual, and do not introduce new programs similar to the Dream School or Mental Health Support Team during the project period.
2427837|NCT03382067|Active Comparator|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa ® chocolate + 7.2g caster sugar + 5g Melissa containing 374 mg (-)-Epicatechin/100g chocolate and 2,69% of rosmarinic acid in Melissa leaves
2427838|NCT03382067|Placebo Comparator|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor ® chocolate + 5g oat bran containing < 0,0009 mg (-)-Epicatechin/100g
2427839|NCT03382054||Older surgical patients|Male and female patients with age 65 years and above scheduled for surgery
2427840|NCT03382041|Experimental|Carbon Fiber Implant|There is an alternative to the standard treatment, which is carbon fiber implants (tibial nails), especially in the prophylactic reinforcement of bones susceptible to pathological fractures following metastatic tumors. The new carbon fiber has also been used in the treatment of tibial non-union (non- healing bone); which has shown satisfactory outcomes.
2427841|NCT03382041|Active Comparator|Titanium Implant|The standard of practice in the treatment of fractures of the tibial shaft and other long bones has been the intramedullary nailing using titanium or stainless steel implants.
2427842|NCT03382015|Active Comparator|Group 1|Receives 28 days of active test product (BKR-013) in Part 1 of the study and receives 28 days of placebo in Part 2 of the study, following a washout period.
2427843|NCT03382015|Placebo Comparator|Group 2|Receives 28 days of placebo in Part 1 of the study and receives 28 days of active test product (BKR-013) in Part 2 of the study, following a washout period.
2427845|NCT03381976|Active Comparator|Intervention 2X/week (G2X)|This group performed resistance training twice a week (Tuesdays and Thursdays)
2427846|NCT03381976|Active Comparator|Intervention 3X/week (G3X)|This group performed resistance training three sessions a week (Mondays, Wednesdays, and Fridays).
2427847|NCT03381976|No Intervention|Control group (GC)|This group did not perform any type of organized physical exercise during the study period.
2427848|NCT03381963||Aromatase inhibitors|
2427849|NCT03381963||Tamoxifen|
2427850|NCT03381937|No Intervention|Spontaneous breathing|Spontaneous breathing without mechanical ventilation
2427851|NCT03381937|Experimental|Conventional mechanical ventilation|Conventional mechanical ventilation, with patient ventilator usual parameters
2427852|NCT03381937|Experimental|Speech specific mechanical ventilation|Mechanical ventilation with specific parameters to improve speech
2427853|NCT03381924|Experimental|Intervention group|Neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
2427854|NCT03381924|Placebo Comparator|Control group|Routine clinical practice
2427855|NCT03381911|No Intervention|E-Consent|This arm is the standard of care, where the consent form is presented to the subject on a computer screen and he/she can scroll ahead and back as needed. There is also an option to have each screen read aloud.
2427856|NCT03381911|Experimental|ECA Consent|"In this arm an Embodied Conversational Agent (ECA) which is a computer generated character reads the consent form aloud to the subject, and also describes each section using a pre-loaded script. In addition, the character performs teach-back, where she asks the subject a question about the section that was just described, and then repeats the section if the question is answered incorrectly."
2427857|NCT03381898|Experimental|Telehealth Coordinated Allied Health|rural persons with Parkinson's disease will receive telehealth exercise, speech therapy, medication management for 8 weeks. Exercise, speech therapy, and medication management are usual care for persons with Parkinson's disease. Having the 3 areas coordinated in delivery via telehealth is the new delivery that our aims address
2427858|NCT03381885|Experimental|Intervention Group|"A nudge grounded in behavioral economic theory (nudge=gentle incentive, preserving freedom of choice)"
2427859|NCT03381885|Placebo Comparator|Control|"No nudge"
2427898|NCT03381625|Placebo Comparator|Placebo|100 subjects will receive placebo twice daily for 7-28 days applied to psoriasis or atopic dermatitis lesions.
2428394|NCT03377946|Experimental|probiotics on type 2 diabetes|take probiotics
3146672|NCT00106691|Experimental|toremifene 20mg|
3146673|NCT00106691|Placebo Comparator|Placebo|
2427862|NCT03381859|Experimental|Treatment Arm|Patients to receive 12 weeks of Elbasvir (50mg) / Grazoprevir (100mg)
2427863|NCT03381846|Experimental|MOHS treatment arm|Patients who have their dermatofibrosarcoma protuberans excised with MOHS surgery.
2427864|NCT03381833|Active Comparator|Group A - Delayed therapy|standard chelation therapy alone for 26 weeks followed by standard chelation therapy plus LJPC-401 for 26 weeks
2427865|NCT03381833|Active Comparator|Group B - Immediate therapy|standard chelation therapy plus LJPC-401 for 52 weeks
2427866|NCT03381820|Experimental|music listening|Participants who were randomized into intervention group were assigned to listen to the music everyday (day 1st to day 30th), at anytime of day that was suitable with their lifestyles but not at the time of BP measurement. During day 31st -120th, participants did not listen to the music. Other treatment was the same as the control arm.
2427867|NCT03381820|No Intervention|control|control arm received conventional hypertension treatment.
2427868|NCT03381807|Experimental|TCRA and intrauterine infusion of hAESCs|hAESCs is infused into uterine cavity after TCRA.
2427869|NCT03381794||Patients with corneal transplantation|Aim is to include all patients in Germany treated with the different types of corneal transplantation with an interim-assessment of the period between 2001 and 2016.
2427870|NCT03381781|Experimental|Experimental group|Patients with p53 mutations will be treated with Decitabine,Arsenic Trioxide and Cytarabine.
2427871|NCT03381768|Experimental|Study group|3 vaccines of PD-L2 peptide followed by 12 vaccines of PD-L2 and PD-L1 peptide, over the course of one year.
2427872|NCT03381755|Experimental|half-dose ticagrelor|
2427873|NCT03381755|Active Comparator|standard-dose ticagrelor|
2427878|NCT03381729|Experimental|Dose A|Intrathecal administration 6.0 X 10^13 vg of onasemnogene abeparvovec-xioi
2427879|NCT03381729|Experimental|Dose B|Intrathecal administration 1.2 X 10^14 vg of onasemnogene abeparvovec-xioi
2427880|NCT03381729|Experimental|Dose C|Intrathecal administration 2.4 X 10^14 vg of onasemnogene abeparvovec-xioi
2427881|NCT03381716||male|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
2427882|NCT03381716||female|Drug:Beta-blocker,Angiotensin II receptor blocker,Angiotensin-converting enzyme,Calcium-channel blocker,Aspirin,Statin
2427883|NCT03381703|Experimental|Part 1|Investigate the absorption, metabolism, and excretion of YH12852
2427884|NCT03381703|Experimental|Part 2|Investigate the absolute bioavailability of YH12852
2427885|NCT03381690||Epidural (ED) emergent C-sec|
2427886|NCT03381690||Non-ED emergent C-sec|
2427887|NCT03381690||Non-ED elective C-sec|
2427888|NCT03381677|Experimental|Pedicle Lengthening Osteotomy|Lumbar decompressive surgery via Pedicle Lengthening Osteotomy Procedure with the Altum® Device
2427889|NCT03381677|Active Comparator|Control group|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) using either a midline or paramedian incision with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System, Stryker Xia 5.5 System, Medtronic CD Horizon Solera 5.5 Systemor Innovative Surgical Designs True Spinal Fixation System; and~DePuy Synthes Concord TLIF cage, Stryker UniLIF TLIF cage, Medtronic Capstone TLIF cage or Meditech Talos TLIF cage."
2427890|NCT03381664|Experimental|AVP-923-20/10 capsule|Participants will receive a single AVP-923-20/10 (dextromethorphan hydrobromide [DM] 20 milligram [mg]/quinidine sulfate [Q] 10 mg) capsule administered orally.
2427891|NCT03381664|Experimental|AVP-923-20/10 via applesauce|Participants will receive the contents from a single AVP-923-20/10 capsule mixed and consumed in 1 tablespoon of applesauce.
2427892|NCT03381664|Experimental|AVP-923-20/10 via nasogastric feeding tube|Participants will receive the contents from a single AVP-923-20/10 capsule solubilized in feeding solution and administered through a nasogastric feeding tube.
2427893|NCT03381651|Active Comparator|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 50.4Gy/28F/5.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 6 wks; Surgery: 4-6 weeks after nCRT
2427894|NCT03381651|Active Comparator|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|Neoadjuvant chemoradiation: RT: 41.4Gy/23F/4.6W; CT: paclitaxel 50mg/m2 d1, qw + CBP AUC2 d1, qw, weekly for 5 wks; Surgery: 4-6 weeks after nCRT
2427895|NCT03381638||Normal Volunteer|Volunteers who report to have never had a concussion and are not at high risk of getting a concussion are scanned to obtain a baseline of all ages, sex, race, etc. All patients will be scanned with the Blink Reflexometer.
2427896|NCT03381638||Concussion Protocol|Athletes who had a potential concussion and will go through any stage of the approved protocol, are scanned by the Blink Reflexometer device. Results are then analyzed prior to unblinding the clinical diagnosis from an Athletic Trainer and/or Neurologist.
3146674|NCT00106782|Other|1|Real TEP
3146675|NCT00106782|Other|2|Sham Stimulation
3146676|NCT00106899||1|Mild Cognitive Impairment (MCI); scans performed at screening/baseline, 6, 12, 18, 24, and 36 months
3146677|NCT00106899||2|Early Alzheimer's disease (AD); scans performed at screening/baseline, 6, 12, and 24 months
3146678|NCT00106899||3|Unaffected/normal controls; scans performed at baseline/screening, 6, 12, 24, and 36 months
3146681|NCT00106977||Family|Family members (typically parents or siblings) of probands with Muenke syndrome are alsoeligible to participate.
3146682|NCT00106977||Patient|Subjects who have had confirmation of a p. Pro250Arg mutation in FGFR3 by a CLIA-certified laboratory.
3146683|NCT00107016|Experimental|RAD001 + letrozole 2.5mg|
3146684|NCT00107016|Active Comparator|Letrozole 2.5mg|
3146685|NCT00107081|Active Comparator|Standard|Continued inpatient i.v. antibiotics
3146686|NCT00107081|Experimental|Experimental|Switch to outpatient p.o. antibiotics
3146687|NCT00107107|Active Comparator|Pramlintide Acetate|Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
2427899|NCT03381599|Experimental|Bone marrow aspirate|This study will utilize one group of participants. This group of participants will have bone marrow aspirate and a blood sample collected from the iliac crest and subsequently analyzed with the Arthrex Angel system. Thirty days following bone marrow aspiration, participants will receive a subcutaneous Filgrastim injection on four serial days. On the fifth day, a peripheral blood sample sample will be obtained.
2427900|NCT03381586|Experimental|Group A|1.0 mg/ml ALT-803
2427901|NCT03381586|Experimental|Group B|2.0 mg/ml ALT-803
3146688|NCT00107185|Experimental|Vaccine|
3146689|NCT00107237|Experimental|AEE788 200 mg + RAD001 5 mg|AEE788 200 mg qd, RAD001 5 mg qd
2427904|NCT03381547|Active Comparator|A|Pegilodecakin: Dose level depending on weight will be 0.8 mg or 1.6 mg, dose formulation 4 mg/mL.
2427905|NCT03381547|Active Comparator|B|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 4 mg/mL.
2427906|NCT03381547|Active Comparator|C|Pegilodecakin: Dose level depending on weight will be 0.4 mg or 0.8 mg, dose formulation 2 mg/mL.
2427907|NCT03381534|Placebo Comparator|stent assisted angioplasty|patient randomly assigned to this group would be undergone stenting of vertebral artery origin without embolic protection device
2427908|NCT03381534|Experimental|stenting with EPD|patient randomly assigned to this group would be undergone stenting of vertebral artery origin with embolic protection device
2427909|NCT03381521|Experimental|Group A|Ultrasound-guided nerve hydrodissection with 10cc normal saline
2427910|NCT03381521|Active Comparator|Group B|Ultrasound-guided nerve hydrodissection with 5cc normal saline
2427911|NCT03381508||The study population|"The study population corresponds to patients with obstructive sleep apnea syndrome treated via continuous positive pressure and monitored according to usual practice with the latest Brizzy device.~Intervention: Brizzy continuous positive pressure device"
2427912|NCT03381495|Experimental|Epidural analgesia during labor|The epidural analgesia technique was used to maintain analgesia for parturients who request labor analgesia.First, we injected a test dose of 5ml 1% lidocaine . If not adverse effects were observed 10 minutes after the test dose, the parturient then received a bolus injection of an initial dose of 8-10 ml mixed liquids of 0.075% ropivacaine and 0.2ug/ml sufentanil citrate. We then connected the epidural catheter with a patient-controlled epidural analgesia (PCA) pump, which provided patients the same mixed solution at 8-10ml/h until the delivery of neonates.
2427913|NCT03381495|No Intervention|Non-epidural analgesia during labor|Women who refused epidural labor analgesia were included in the non-epidural analgesia group, and they don't receive epidural analgesia during labor
2427914|NCT03381482||Controls|Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.
2427915|NCT03381482||Asymptomatic cases with high risk to develop AD|Group 2: 10ml of CSF and 6x5ml of blood will be collected
2427916|NCT03381482||Cases with isolated cognitive complaint|Group 3: 10ml of CSF and 6x5ml of blood will be collected
2427917|NCT03381482||Prodromal AD|Group 4: 10ml of CSF and 6x5ml of blood will be collected
2427918|NCT03381482||Mild to moderate probable AD-type dementia|Group 5: 10ml of CSF and 6x5ml of blood will be collected
2427919|NCT03381469|Experimental|Periodontitis patients undergoing NSPT|Case group participants will receive comprehensive periodontal treatment also known as non-surgical periodontal therapy (NSPT) that will be completed by the end of week 20-21 of gestation.
2427920|NCT03381469|Active Comparator|Periodontitis Patients undergoing supragingival scaling|The control group participants with periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
2427921|NCT03381469|Active Comparator|Without Periodontitis undergoing supragingival scaling|Placebo group participants without periodontitis will receive oral hygiene instruction and single visit supragingival scaling of all teeth at their baseline visit.
2427922|NCT03381456|Experimental|Healthy subject|LICI
2427923|NCT03381456|Experimental|Dystonic subject|LICI
2427924|NCT03381443||ERC|all students assessed by the methods used by the European Resuscitation Council
2427925|NCT03381443||AHA|all students assessed by the methods used by the American Heart Association
2427926|NCT03381430|Experimental|Gefitinib + Radiotherapy|Experimental: Gefitinib Gefitinib 250 mg/day oral daily Radiotherapy Total dose 50-54Gy, divided dose 1.8-2Gy
2427927|NCT03381417|Experimental|Pegcyte (Nanogen pegfilgrastim)|6 mg in each cycle
2427928|NCT03381417|Active Comparator|Neulastim (Roche pegfilgrastim)|6 mg in each cycle
2427929|NCT03381404|Experimental|[14C] MT-8554|
2427930|NCT03381391|Experimental|Feedback intervention condition|
2427931|NCT03381391|No Intervention|Assessment-only control condition|
2427932|NCT03381365|Experimental|investigational arm|
2427933|NCT03381352|Experimental|Chemo-radiotherapy with IMRT technique|Radiotherapy with IMRT technique concurrent with Capecitabine and MMC chemotherapy
2427936|NCT03381313|Experimental|Anomic Patients|Pure Anomic Patients underwent to conditioned word repetition training or traditional one.
2427937|NCT03381300|Other|Single cohort|
2427938|NCT03381287|Experimental|500mg HTD1801|
2427939|NCT03381287|Experimental|1000mg HTD1801|
2427940|NCT03381287|Experimental|2000mg HTD1801|
3146690|NCT00107237|Experimental|AEE788 150 mg + RAD001 5mg|AEE788 150 mg qd, RAD001 5 mg qod
3146691|NCT00107250|Experimental|AZD2171 + Standard chemotherpay regimens|
3146692|NCT00107263|Experimental|Arm I: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients also receive zoledronate IV over 15 minutes once every 6 months.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
3146693|NCT00107263|Experimental|Arm II: letrozole + zoledronate|"Patients receive oral letrozole once daily. Patients with radiologic evidence of bone loss after 1 year of letrozole therapy receive zoledronate as in arm I.~Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity."
3146694|NCT00107289|Experimental|Radiation|
2427943|NCT03381261|Experimental|Botulinum toxin type A injection arm|All patients will be injected with Botulinum toxin on one side of the back of the head.
2427946|NCT03381235|Experimental|Moderate exercise|Subjects in the moderate exercise group will participate in Spin exercise designed by Dr. Nocera.
2427947|NCT03381235|No Intervention|Mild exercise|Sessions will be focused on balance and stretching.
2427948|NCT03381209|Experimental|Group A|Sugammadex given in a dose of 2mg/kg based on ideal body weight
2427949|NCT03381209|Experimental|Group B|Sugammadex given in a dose of 2mg/kg based on adjusted body weight
2427950|NCT03381209|Experimental|Group C|Sugammadex given in a dose of 2mg/kg based on actual body weight
3146695|NCT00107341|Experimental|bortezomib + paclitaxel + carboplatin|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, and 8 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years."
3146696|NCT00107419|Experimental|pemetrexed|pemetrexed
3146697|NCT00107432|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2427956|NCT03381157||Cystic Fibrosis Group|
2427957|NCT03381157||Control Group|
2427958|NCT03381144|Experimental|Part 1: GDC-0334|Participants in up to 7 cohorts will receive single, ascending doses of GDC-0334 under fasting conditions.
2427959|NCT03381144|Placebo Comparator|Part 1: Placebo|Participants in up to 7 cohorts will receive single doses of placebo under fasting conditions.
2427960|NCT03381144|Experimental|Part 2: GDC-0334|Participants in up to 3 cohorts will receive single doses of GDC-0334 under fasting or fed conditions.
2427961|NCT03381144|Placebo Comparator|Part 2: Placebo|Participants in up to 3 cohorts will receive single doses of placebo under fasting or fed conditions.
2427962|NCT03381144|Experimental|Part 3: GDC-0334|Participants in up to 4 cohorts will receive multiple, ascending doses of GDC-0334 under fasting or fed conditions.
2427963|NCT03381144|Placebo Comparator|Part 3: Placebo|Participants in up to 4 cohorts will receive multiple doses of placebo under fasting or fed conditions.
2427964|NCT03381118|Experimental|Ara-C+HaploLymphocyte+Nivo|"Patients treated with nivolumab, intermediate dose cytarabine and haploidentical lymphocyte infusion:~[Cytarabine 500-1000 mg/m2 bid D-4, -3, -2 + G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells infusion D0~+ Nivolumab 40 mg D+5] х 2-3 cycles"
2427965|NCT03381118|Experimental|Ara-C+ Nivo|"Patients treated with nivolumab and intermediate dose cytarabine:~[Cytarabine 500-1000 mg/m2 bid D+1, +2, +3 + Nivolumab 40 mg D+1] х 2-3 cycles"
3146698|NCT00107445|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2½ hours on day 1. Approximately 1-2 days later, patients undergo tumor resection or biopsy. Patients' tumor tissue samples undergo immunohistochemistry and flow cytometry to detect EF5 binding levels. Patients' blood is drawn immediately before and 30-60 minutes and 1-2 days after receiving EF5 to measure systemic EF5 binding levels.
2427967|NCT03381079|Experimental|Surgical group|In this arm, the adults with high myopia will be given posterior scleral reinforcement.
2427968|NCT03381079|No Intervention|Control group|In this arm, the adults with high myopia will not be given any surgical treatment.
2427969|NCT03381066|Experimental|Intercalating arm|gefitinib, pemetrexed,cisplatin
2427970|NCT03381066|Active Comparator|chemotherapy alone arm|Vinorelbine, cisplatin
2427971|NCT03381053||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
2428261|NCT03378986||Bilateral THA|Patients who underwent to simultaneous bilateral total hip arthroplasty
3146699|NCT00107458|Experimental|Treatment 1|VPA Target Trough Concentration 75-100 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
3146700|NCT00107458|Experimental|Treatment 10|VPA Target Trough Concentration 100-150 mcg/mL, week 1 VPA dose: 15 mg/kg/day, divided tid
3146701|NCT00107458|Experimental|Treatment 20|VPA Target Trough Concentration 150-200 mcg/mL
3146702|NCT00107471|Experimental|Dose Level I (0.5 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n)
3146703|NCT00107471|Experimental|Dose Level 2 (0.6 mg/m^2)|Radiation Therapy + Topotecan hydrochloride daily before each dose of irradiation (radiation therapy) + filgrastim (G-CSF) (p.r.n.)
3146704|NCT00107497|Active Comparator|Control|50Gy in 25 fractions of radiation therapy over 5 weeks
3146705|NCT00107497|Active Comparator|Test group 1|30Gy in 5 fractions of radiation therapy over 5 weeks
3146706|NCT00107497|Active Comparator|Test group 2|28.5Gy in 5 fractions of radiation therapy over 5 weeks
3146707|NCT00107510|Experimental|docetaxel + carboplatin + pegfilgrastim + surgery|"Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day 1. Patients also receive pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~No more than 6 weeks after completion of chemotherapy, patients undergo definitive surgery.~After completion of study therapy, patients are followed every 6 months until disease progression and then annually for up to 5 years. Patients who do not complete all 4 courses of chemotherapy or do not undergo surgery are followed every 6 months for up to 5 years."
3146708|NCT00107549|Experimental|1|All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine
3146709|NCT00107562|Experimental|Intervention|The cohort will be comprised of up to 4 index participants and from 1-4 of their network members for a possible range of 8-16 subjects in each cohort (average of 12 per cohort). The vast majority of the intervention will be delivered to both females and males together, but it would be beneficial, and appropriate for this adolescent population, to deliver certain exercises with the two genders separated.
3146710|NCT00107588|Experimental|Reinforcement for homework completion|
3146711|NCT00107588|Active Comparator|Reinforcement for Abstinence|
3146712|NCT00107588|Active Comparator|Case Management|
2427972|NCT03381053||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
2427973|NCT03381040|Active Comparator|Group A|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with adequate skin envelope (normal or thick skin). Treated with Restylane Lyft.
2427974|NCT03381040|Active Comparator|Group B|Poor structural support/volume (atrophy of soft tissues, leading to loss of projection) with poor skin envelope (thin skin). Treated with Restylane Volyme.
2427975|NCT03381027|Experimental|Interventional Arm- Baby Massage|Interventional Arm= Baby Massage
2427976|NCT03381027|No Intervention|Control Arm- no Baby Massage|Control Arm= no Baby Massage
2427977|NCT03381001|Active Comparator|embryo transfer after embryo thaw|Embryos will be transferred at the same day of the thawing procedure
2427978|NCT03381001|Experimental|embryo transfer after thaw and culture|Embryos will be transferred one day after thawing procedure
2427979|NCT03380988|Experimental|Fiber-enriched buckwheat pasta|Acute test meal
2427980|NCT03380988|Active Comparator|Corn pasta|Acute test meal
2427981|NCT03380975|Experimental|Montelukast 10 mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis.
2427982|NCT03380962|Experimental|Clazakizumab|All twenty patients will receive clazakizumab monthly. Patients will receive up to 6 doses pre-transplantation. If patients are transplanted during the study, they will then receive 6 doses of clazakizumab (monthly) and a 6 month protocol biopsy will be performed. Based on the biopsy results and clinical labs PI will determine if patients should continue monthly doses for up to another 6 doses and day 330 post-transplantation. Patients who received 12 post-transplant doses of clazakizumab will then undergo a 12 month protocol biopsy.
2427983|NCT03380949|Experimental|PPI (Pain Pupillary Index)|Opioid administration (remifentanil) in intervention group is guided by PPI derived from video-pupillometry performed with the AlgiScan™ by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following a nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 mA and displays the PPI as numerical index between 0 and 10. A low PPI score indicates deep, a high score light analgesia. A PPI score of 2-3 is supposed to represent an optimal level of analgesia. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if PPI score is calculated more than 3. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is <1.
2427984|NCT03380949|Experimental|SPI (Surgical Pleth Index)|Opioid administration (remifentanil) in intervention group is guided by SPI derived from photoplethysmography performed by the device CARESCAPE™ B650 Patient Monitor by GE Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate of remifentanil will be increased by 0.03 µg/kg/min if SPI score is calculated more than 50. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 20.
2427985|NCT03380949|Experimental|NOL (Nociception Level)|Opioid administration (remifentanil) in intervention group is guided by NOL derived from finger photoplethysmography performed with the device PMD200™ manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level and fluctuations, skin temperature and finger motion. It is presented on a scale from 0 (no pain) to 100 (extreme pain). A NOL score between 10 and 25 has been proposed as the target range. A remifentanil bolus of 30 µg will be administered and the infusion rate will be increased by 0.03 µg/kg/min if NOL score is calculated more than 25. Remifentanil infusion will be decreased by 0.03 µg/kg/min if PPI score is calculated below 10.
2427986|NCT03380949|Active Comparator|Control|Opioid administration (remifentanil) in control group is guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
2427987|NCT03380936|Active Comparator|Arm 1 - conversion to Envarsus XR|Optimize: conversion to Envarsus XR (Tacrolimus Extended Release Oral Tablet [Envarsus]) with goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol
2427988|NCT03380936|Active Comparator|Arm 2 - plasma exchange and IVIG|Treat clinical AMR: Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
2427989|NCT03380923|Experimental|Moderate Intensity (MOD)|"Endurance Training (ET): 3 d/wk x 30 minutes (min) of steady-state, moderate-intensity exercise on a treadmill or stationary cycle ergometer at target heart rate (HR) = 65-75% of maximum oxygen consumption rate (VO2max). The two modes (treadmill, bicycle) are offered for variety, and each subject is required to use each mode at least 1 d/wk to prevent bias.~Resistance training (RT): 2 d/wk consisting of a prescription engaging all major muscle groups in 10 movements. Excluding abdominal crunches, target intensity is 12 repetitions/set to volitional fatigue. Subjects complete 3 sets of each movement, with ~60 seconds (s) rest between sets. For each movement, resistance increases when 14 repetitions are achieved for 2 of 3 sets.~HR is monitored throughout each session and stored for analysis."
2427990|NCT03380923|Experimental|High Intensity (HI)|"RT: The 2 d/wk RT prescription differs from the MOD arm only in intensity and rest intervals. The same approach to progression applies, but HI RT intensity targets 8-10 repetitions per set; thus, resistance loads increase when 10 repetitions are achieved for 2 of 3 sets. The HI arm performs superset training, pairing movements stressing different muscle groups, with only 30-45 s between.~ET: In lieu of steady-state endurance exercise, the HI arm performs high-intensity interval training (HIIT) 3 d/wk using a mix of challenging, explosive movements at maximal intensity. 10 x 30 s maximal intensity intervals are separated by 30 s rest intervals.~HR is monitored throughout each session and stored for analysis."
2427991|NCT03380910|Experimental|Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
2427992|NCT03380910|Other|Not Ready to Quit|Current patients who speak Spanish, smoke cigarettes, and are not ready to quit will be included. The intervention includes an interdisciplinary team approach using pharmacy and behavioral health trainees to provide smoking cessation services.
2427993|NCT03380897|Active Comparator|Outpatient group|"After insertion of induction catheter for labor, women of the outpatient group can go home and assess their pain with visual analogy scale at home. The intervention is to go home.~Intervention for outpatient group was to go home."
2427994|NCT03380897|Placebo Comparator|Inpatient group|"After insertion of induction catheter for labor, women of the inpatient group assess their pain with visual analogy scale in the ward. The intervention is to stay at ward.~Intervention for inpatient group was to stay at ward."
2427995|NCT03380884|No Intervention|Control|Control group will remain in their habitual life style and no vibration used
2427996|NCT03380884|Experimental|Vibration Group|The intervention group will undergo Low-magnitude high-frequency vibration (LMHFV) at 35Hz, 0.3g (peak to peak magnitude), displacement of <0.1mm, 20 min/day, at least 3 times per week, for 6 months in community centres
2427997|NCT03380871|Experimental|NEO-PV-01/Adjuvant + pembrolizumab + chemotherapy|Pembrolizumab at a dose of 200 mg administered by intravenous infusion (IV) plus chemotherapy with carboplatin (AUC 5) + pemetrexed (500 mg/m2) every 3 weeks for 4 cycles. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with pembrolizumab.
3187436|NCT00756080|Experimental|1|After receiving a 7-day oral supplementation with citrulline, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with placebo, as a cross-over study design will be used.
2428000|NCT03380832||Type 2 diabetes for at least 10 years|This is an observational study in which we will quantify vestibular thresholds in individuals who have had type 2 diabetes for at least 10 years. Normative data has recently been published and subjects with diabetes will be compared to a model that includes age effects.
2428001|NCT03380819|Experimental|Genome sequencing|Patients undergo exome or whole-genome sequencing, and their patients receive an interpreted clinical report.
2428002|NCT03380806|Active Comparator|Arm 1|Conventional Radiotherapy (CRT) Prostate Boost Pelvic Radiation LHRH agonist
2428003|NCT03380806|Experimental|Arm 2|Stereotactic Body Radiotherapy (SBRT) Prostate Boost Pelvic Radiation LHRH agonist
2428004|NCT03380793|Experimental|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
2428006|NCT03380767|Experimental|POC group|In this group, patients will be treated according to the information gathered by TEG or ROTEM assays.
2428007|NCT03380767|Experimental|Conventional group|In this group, patients will be treated according to the information gathered by conventional laboratory assays (platelet count, fibrinogen level, PT or INR and d dimer for fibrinolysis)
2428008|NCT03380754|Experimental|Carbohydrate Rich Drink|Group A will receive the carbohydrate rich drink, Nutricia preOp. This is the intervention group.
2428009|NCT03380754|Placebo Comparator|Placebo Drink|Group B will receive placebo, Nestle Splash Lemon Flavor Water (Placebo) (similarly flavored and appearing water, however with no calorie, carbohydrate or nutritional content).
2428010|NCT03380754|No Intervention|No Drink|Group C will not receive any drink. This group will follow normal protocol.
2428011|NCT03380741||Group1|Tumour present on histology and MRI following biopsy/LLETZ
2428012|NCT03380741||Group 2|Tumour absent on MRI following biopsy/LLETZ
2428013|NCT03380741||Group 3|Tumour recurrence present at the vaginal vault on MRI
2428014|NCT03380741||Group 4|Tumour recurrence absent at the vaginal vault on MRI
2428015|NCT03380741||Group 5|Normal cervix at colposcopy
2428016|NCT03380728|Experimental|Group 1|Ibogaine Hydrochloride 240 mg on day 1, placebo on day 4, placebo on day 7
2428017|NCT03380728|Experimental|Group 2|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, placebo on day 7
2428018|NCT03380728|Experimental|Group 3|Ibogaine Hydrochloride 240 mg on day 1, Ibogaine Hydrochloride 320 mg on day 4, Ibogaine Hydrochloride 400 mg on day 7
2428019|NCT03380715|Active Comparator|right nostril in patients with rhinitis|Intervention : Administration of either 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity or
2428020|NCT03380715|No Intervention|Left nostril in patients with rhinitis|No nasal decongestion administration into the left nostril
2428021|NCT03380715|Active Comparator|Right nostril in patients with rhinitis|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
2428022|NCT03380702|Active Comparator|whitening photoactivation gel|exposure to hydrogen gel and photoactivation for teeth whitening
2428023|NCT03380702|Placebo Comparator|placebo|exposure to gel without active whitening substance and the same photoactivation source as active comparator
2428024|NCT03380689|Experimental|SIRB2|Biweekly combination therapy with S-1, Irinotecan, and Bevacizumab
2428025|NCT03380676||Oromandibular dystonia group|Patients with idiopathic oromandibular dystonia, either focal or associated to other dystonic features including generalized dystonia
2428026|NCT03380676||Healthy subjects|Healthy subjects (normal neurological examination), each being age-matched to a subjet of the oromandibular dystonia group
2428027|NCT03380663|Active Comparator|RIC - Healthy|Healthy subjects undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
2428028|NCT03380663|Active Comparator|RIC - HF|Heart failure patients undergoing Remote Ischemic Conditioning (RIC) by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet.
2428029|NCT03380663|Active Comparator|BFRE - Healthy|Healthy subjects undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
2428030|NCT03380663|Active Comparator|BFRE - HF|Heart failure patients undergoing low intensity blood flow restricted resistance exercise (BFRE) conducting 4 sets of bilateral knee extensions at 30% of 1RM until concentric contraction failure. The sets are intercepted by 30 seconds of rest (during rest the cuff's are still inflated).
2428031|NCT03380663|Active Comparator|TRT - Healthy|Healthy subjects undergoing heavy intensive resistance training (TRT) undergoing 4 sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
2428032|NCT03380663|No Intervention|Control - Healthy|No intervention.
2428033|NCT03380663|No Intervention|Control - HF|No intervention.
2428034|NCT03380650|Other|durg-coated balloon dilation|The drug-coated balloon will be used to treat the femoropopliteal occlusion.
2428035|NCT03380650|Other|directional atherectomy and LDD|The directional atherectomy and local drug delivery will be used to treat the femoropopliteal occlusion.
2428036|NCT03380637||Pregnant and non-pregnant females|The pregnant females posted for elective lower segment cesarean section and non-pregnant females posted for elective surgeries are scanned by ultrasound in the pre recovery room. The visibility of the gastric antrum is assessed. The qualitative and quantitative assessment is made and is compared.
3187437|NCT00756080|Placebo Comparator|2|After receiving a 7-day oral supplementation with placebo, each subject will be admitted to the Clinical Investigation Unit for a half day, after an overnight fast,and will receive a 5-h intravenous infusion of L-[1-13C]leucine (i.e.; leucine labeled with 13C, a stable isotope of carbon) from 8 am to 1 pm. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, the keto acid of leucine, using gas chromatography-mas spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. The subject will then leave the hospital, take no treatment for13 days (wash-out period). The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with citrulline, as a cross-over study design will be used.
3187438|NCT00756132||Bloods Only (B)|Women aged 18-65 years with a newly diagnosed locally advanced or high risk operable breast cancer
2428039|NCT03380611|Experimental|Wakame|Subjects will receive capsules containing wakame
2428040|NCT03380611|Experimental|Spirulina|Subjects will receive capsules containing spirulina
2428041|NCT03380611|Placebo Comparator|Control|Subjects will receive capsules containing microcrystalline cellulose
2428042|NCT03380598|Active Comparator|Usual care|Usual care according to regular treatment routines at the clinic during 6 months.
2428043|NCT03380598|Active Comparator|CLOSS|Usual care plus using a web based support system for self-monitoring weight at physical activity.
2428044|NCT03380585|Experimental|Reciproc|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc single-file system. The intervention is foraminal enlargement with the Reciproc single-file system.
2428045|NCT03380585|Active Comparator|ProTaper Next|The active comparator is foraminal enlargement with the ProTaper Next multi-file system. Endodontic treatment is identical to experimental group except file systems used. In this group, ProTaper Next multi-file system will be used in enlarging apical foramina.
2428048|NCT03380559|Experimental|Group A : Association (botulinum toxin + corticoid)|
2428049|NCT03380559|Placebo Comparator|Group C : placebo of toxin + corticoid :|
2428050|NCT03380559|Active Comparator|Group T : botulinum toxin + placebo corticoid|
2428051|NCT03380546|Experimental|acarbose|The women will receive acarbose with a progressive increase of dose according to post prandial glucose values and digestive tolerance, with a maximal dose of 3 x 100 mg /day
2428052|NCT03380546|Active Comparator|prandial insulin|The women will receive prandial insulin according to usual practice (routine care according to French recommendations): before each meal, with dose titration according to post prandial values.
2428053|NCT03380533|Active Comparator|Buprenorphine Patch|"Buprenorphine 10mg Patch + Placebo Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
2428054|NCT03380533|Active Comparator|Tramadol Tablet|"Placebo Patch + Tramadol 50mg Tablet + Multimodal Oral Scheme~Multimodal Oral Scheme:~Diclofenac 75mg c 12h Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)"
2428055|NCT03380520|Experimental|Ferric carboxymaltose|Ferric carboxymaltose according to SmPC
2428056|NCT03380520|Placebo Comparator|Placebo|Normal saline (0.9%)
2428059|NCT03380494|Experimental|Overhead perturbation training technique|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
2428060|NCT03380494|Active Comparator|Non-perturbed exercise|Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied via a weight held in the hand- such that the glenohumeral joint is exposed to a load but without a perturbation of joint position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
2428061|NCT03380481||SECRETS-TCM|Stroke patients who treated by western medicine and/or traditional Chinese medicine in southern China
2428062|NCT03380468|Experimental|Cisplatin plus pemetrexed|Drug: cisplatin 75mg/m2 iv Drug: pemetrexed 500mg/m2 iv
2428063|NCT03380468|No Intervention|Observation|Observation and follow up only
2428064|NCT03380455|Experimental|Treatment period A & B|"Treatment period A: Subjects receive a single oral dose of 500 mg lucerastat on Day 1 under fasted conditions.~Treatment period B: From Day 3 to Day 9, subjects receive a b.i.d. (every 12 h) oral dose of 800 mg cimetidine under fasted conditions (Treatment period B1; from Day 3 to Day 5). On Day 6, subjects receive a single oral dose of 500 mg lucerastat concomitantly with the morning dose of 800 mg cimetidine under fasted conditions (Treatment period B2; from Day 6 to Day 10)."
2428065|NCT03380442|Experimental|Psilocybin group|This group will receive a single oral 25mg dose of psilocybin under surveilled and safe conditions.
2428066|NCT03380442|Active Comparator|Ketamine group|This group will receive a single intranasal 125mg dose of ketamine under surveilled and safe conditions.
2428067|NCT03380442|No Intervention|No-treatment group|This group will be included in the study as a no-treatment group, so that natural time-dependent changes in depressive symptoms can be controlled for and thus the antidepressive effects of ketamine and psilocybin treatment can be verified
2428073|NCT03380416|Experimental|Portfolio Diet|The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
2428074|NCT03380416|Active Comparator|MUFA Diet|The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)
2428075|NCT03380403|Active Comparator|PDT|Methylene blue and Photon Irradiation , every each week, until total ulcer healing.
2428076|NCT03380403|Active Comparator|Ciprofloxacin|Diabetic foot patients were treated on conventional way, using antibiotics and surgery.
2428078|NCT03380377|Experimental|Clazakizumab (Anti-IL-6 Monoclonal)|All ten patients will be receiving clazakizumab (Anti-IL-6 Monoclonal) monthly for six months. Then patients will be scheduled for six month protocol biopsy. If biopsy and all clinical labs show benefit or stability (up to PI discretion), patients will continue receiving clazakizumab monthly for another six months. All patients completing twelve doses of clazakizumab will be scheduled for a twelve month protocol biopsy and last study visit. If at the 6 month protocol biopsy, no improvement was seen, PI will have patient come for their last study visit on month 12 post enrollment.
2428079|NCT03380364|Experimental|Group Undergoing Hysterosopy|This group will include 75 women with unexplained infertility. 5 mm rigid sheath Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.
3146713|NCT00107627|Active Comparator|1|Skin staples;
3146714|NCT00107627|Active Comparator|2|Monocryl subcuticular sutures.
2428082|NCT03380338|Experimental|Exercise program|Twice weekly exercise program, combined aerobic and strenght training
2428083|NCT03380325|Experimental|Iloprost first|Cross-over starts with iloprost intervention, then second clamp without iloprost.
3146715|NCT00107627|Active Comparator|3|Caprosyn subcuticular sutures.
3146716|NCT00107640|No Intervention|Usual care|Patients not assigned to the experimental condition received usual care, which may or may not have included alcohol education.
3146717|NCT00107640|Experimental|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
3146718|NCT00107770|Other|1|ALS patient
3146719|NCT00107835|Experimental|S-Caine Peel|
3146720|NCT00107887|No Intervention|1|Subjects in clinics that have not received the intervention
3146721|NCT00107887|Experimental|2|Subjects at clinics that have received the intervention
3146722|NCT00107926|Experimental|licarbazepine|
3146723|NCT00107926|Placebo Comparator|Placebo|
3146724|NCT00107965|Experimental|1|
3146725|NCT00107965|Experimental|2|
3146726|NCT00107965|Experimental|3|
3146727|NCT00107965|Placebo Comparator|4|
3146728|NCT00107965|Experimental|5|
3146729|NCT00107965|Experimental|6|
3146730|NCT00107965|Experimental|7|
3146731|NCT00107965|Placebo Comparator|8|
3146732|NCT00108004|Experimental|Pramlintide|"Pramlintide acetate injection is a clear, colorless, sterile solution for SC injection.~It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43-mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative"
3146733|NCT00108108|Experimental|HCD122|
3146734|NCT00108147|Experimental|1|Circuit Training
3146735|NCT00108147|Active Comparator|2|Cardiac Rehabilitation
3146736|NCT00108147|Active Comparator|3|Flexibility and toning
3146737|NCT00108173|Other|Arm 1|
3146738|NCT00108186|Other|Arm 1|Celecoxib is an FDA approved drug for other indications such as osteoarthritis. It is not FDA approved for non-small cell lung cancer.
3146739|NCT00108225|Active Comparator|Arm 1|30% carbohydrate, 30% protein, 40% fat
3146740|NCT00108225|Placebo Comparator|Arm 2|55% carbohydrate, 15% protein, 30% fat
2428084|NCT03380325|Experimental|Iloprost second|Cross-over starts without iloprost intervention, then second clamp with iloprost.
2428085|NCT03380286||Coronary Stenosis|
2428088|NCT03380260|Experimental|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
2428089|NCT03380260|No Intervention|Control Condition|No manipulation of paranoid ideation
2428090|NCT03380234|Experimental|Intervention|8 worksheets and around 15 online quizzes and 30 WhatsApp messages.
2428091|NCT03380234|Other|Control|Control students will receive the following minimal intervention to reduce their intention to smoke and SHS - a leaflet on smoking and SHS published by the Department of Health.
2428092|NCT03380221|Experimental|Watermelon|
2428093|NCT03380221|Active Comparator|Low fat cookies|
2428094|NCT03380195|Experimental|Watermelon juice|
2428095|NCT03380195|Active Comparator|Sport drink|
2428096|NCT03380195|Active Comparator|Sugar water|
2428097|NCT03380195|Placebo Comparator|Water|
2428098|NCT03380182|Experimental|Acupuncture/Acupressure Group|Bilateral P6 point acupuncture will be performed intra-operatively by the PI, who has UC Davis Medical Center privilege for this specific acupuncture, while the patient is under anesthesia. Patient will be sent home with an acupressure band, which is to remain on for 24 hours post operatively.
2428099|NCT03380182|Sham Comparator|Control Group|Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
2428100|NCT03380169|Experimental|Advance dressing|Prophylactic advance wound dressing
2428101|NCT03380169|Active Comparator|Conventional gauze dressing|Prophylactic conventional wound dressing
2428102|NCT03380156|Experimental|Interventional|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour.
2428103|NCT03380156|Placebo Comparator|Control|Sham TVS will be performed by use of a Tragus stimulator device with electrodes attached to the ear lobule. Stimulator will be applied continuously for 1 hour.
3146741|NCT00108251|Placebo Comparator|1|placebo tablet
3146742|NCT00108251|Experimental|2|eplerenone tablets
2428106|NCT03380130|Experimental|SIRT and Nivolumab|SIRT (selective internal radiation therapy) will be performed in a single session using SIR-Spheres resin microspheres. After 3 weeks, nivolumab 240 mg every 2 weeks will be initiated
2428107|NCT03380117|Experimental|eBridge Online Counseling|In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students have the opportunity to engage with eBridge counselors via online dialogues, in which students and counselors exchange messages using a secure website.
2428108|NCT03380117|No Intervention|Control|In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
2428109|NCT03380104|Experimental|Single Arm|Intradural Spinal Cord Stimulation; Administration of Questionnaires
3146743|NCT00108316|Other|Arm 1|
3146744|NCT00108381|Experimental|Arm 1|Standard and Tailored Conditions
3146745|NCT00108407|Experimental|1|Integrated Cognitive Behavioral Therapy
3146746|NCT00108407|Experimental|2|Twelve Step Facilitation Therapy
2428116|NCT03380065|Active Comparator|Late deflation of TR band|"first 3ml of air removed from the TR band after TWO hour of sheath removal. Then, 3ml of air removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then wait for another 15minutes for the next deflation."
2428117|NCT03380065|Active Comparator|Early deflation of TR band|"First 2ml of air is removed from the TR band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then push the 2ml of air back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
2428118|NCT03380052||Gastric cancer|Patients who were diagnosed with gastric cancer
2428119|NCT03380052||Control|Healthy participants or benign disease patients such as benign gastric ulcers, duodenal ulcers, reflux esophagitis, or non-erosive reflux disease
2428120|NCT03380039|Experimental|CAR-BCMA T cells|"In this study, autologous T cells transduced with a BCMA-targeted chimeric antigen receptor (CAR-BCMA T cells) are used to treat patients with refractory or relapsed multiple myeloma.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR-BCMA T cells infusion.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
3146747|NCT00108576|Placebo Comparator|Arm 1|Look-a-like placebo
3146748|NCT00108576|Experimental|Arm 2|Divalproex
3146749|NCT00108602|Other|1|
3146750|NCT00108615|Experimental|1|pioglitazone
3146751|NCT00108615|Active Comparator|2|metformin
3146752|NCT00108771|Experimental|ZR-02-01 matrix fentanyl Patch|ZR-02-01 matrix fentanyl patch
3146753|NCT00108771|Placebo Comparator|Placebo Patch|
3146754|NCT00108810|Experimental|Transdermal Ketoprofen Patch with CHADD|
3146755|NCT00108810|Placebo Comparator|Placebo patch and a dummy heating unit|
3146756|NCT00108901|No Intervention|Control|Children were not provided with an after-school exercise intervention. They were free to do their usual activities. Families were offered a monthly healthy lifestyle class.
3146757|NCT00108901|Experimental|Low Dose|This group was assigned to receive a 20 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
3146758|NCT00108901|Experimental|High dose|This group was assigned to receive a 40 min/day aerobic exercise program offered 5 days/week after school. Families were offered a monthly healthy lifestyle class.
3146759|NCT00109213|Active Comparator|1|Lumbar Laminectomy without Fusion
2428123|NCT03380013|Experimental|OMT group|Osteopathic Manipulative Therapy (OMT); two treatments between day 4 and 7 of life
2428126|NCT03379987|Experimental|PVB morphine|
2428127|NCT03379987|Active Comparator|PVB bupivacaine|
2428128|NCT03379974|Experimental|ARM A: DDAVP followed by exercise|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise intervention"
2428129|NCT03379974|Active Comparator|ARM B: DDAVP alone|"Intervention #1: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
2428130|NCT03379974|Experimental|ARM C: Exercise intervention|"Intervention #1: Exercise intervention~Intervention #2: no further intervention (rest)"
2428131|NCT03379974|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise intervention~Intervention #2: DDAVP Inhalant Product intervention The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
2428132|NCT03379948||Group 1 with central venous line|lab investigation Complete blood count blood culture
2428133|NCT03379948||Group 2 with only peripheral line|lab investigation Complete blood count blood culture
2428134|NCT03379935||Bipolar radial head arthroplasty|Patients treated with bipolar head arthroplasty due to radial head fracture
2428135|NCT03379935||Unipolar radial head arthroplasty|Patients treated with unipolar head arthroplasty due to radial head fracture
2428136|NCT03379922|Experimental|Stress balls|The first arm will be given stress balls to squeeze during their treatment and will also receive standard care (the offer of oral analgesia)
2428137|NCT03379922|Experimental|Headphones|The second arm will be given headphones to listen to music during their treatment and will also receive standard care.
2428138|NCT03379922|No Intervention|Control|The control group will receive standard care (the offer of oral analgesia)
2428139|NCT03379909|Experimental|Treatment arm|Metformin orally at doses up to 1500 mg twice daily for 3 months.
2428140|NCT03379896||Sepsis|Patient diagnosed with sepsis according to the new sepsis definition (infection+SOFA≥2).
2428141|NCT03379896||Control|Age-matched healthy control
2428142|NCT03379883|Placebo Comparator|Pulsed radiofrequency (P-RF)|Patients will receive both intra articular RF and genicular nerve RF ablation
2428143|NCT03379883|Experimental|Platelet rich plasma (PRP)|Patients will receive intra-articular platelet rich plasma (PRP)
3146760|NCT00109213|Active Comparator|2|Lumbar Laminectomy with Pedicle Screw Instrumented Fusion
3146761|NCT00109291|Placebo Comparator|Placebo|Single injection of placebo administered intravenously
2428146|NCT03379857|Other|Cannabis User|
2428147|NCT03379844|Experimental|Holmium-166 radioembolization|
2428148|NCT03379818|Experimental|Specific word training intervention|This training programme will be similar to a typical word learning intervention. Infants will be introduced to 28 real objects and their names (e.g. biscuit, trousers). These objects will be divided into 7 sets of four words, and during each session, infants will be presented with one of this sets. Each session will consist of a 15 min play session in which each object will be presented at least 10 times and each object name will be mentioned at least 10 times. Additionally, techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used.
2428149|NCT03379818|Experimental|Shape training intervention|In the shape training intervention, infants will be presented with four novel words paired with four novel sets of objects. Each set consists of two exemplars with the same shape but with different colors and textures, and a contrasting object. Each set will be presented in a play session, and the name of the objects will be mentioned at least 10 times. The other three sets of exemplars will be presented in the same way. Each session will last 15 minutes. This intervention is based on a study conducted by Smith and colleagues (2002), where they found that typically developing infants that are taught to attend to shape at 17 months old, can enhance significantly their word learning.
2428150|NCT03379805||Fontan-Kreutzer operated patients|Patients with a Fontan-Kreutzer circulation. No interventions are done. (The intervention is the operation done 15-20 years ago)
2428151|NCT03379805||Healthy Control subjects|Age, gender and weight matched control subjects
2428152|NCT03379792|Active Comparator|Lean T1D|
2428153|NCT03379792|Active Comparator|Obese T1D|
2428154|NCT03379792|Active Comparator|Non-diabetic|
2428155|NCT03379779||Pneumonia patient with respiratory failure|Sputum and stool sampling day 1, 3 and 7 after enrolling into study
2428156|NCT03379766|Experimental|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
2428157|NCT03379766|Active Comparator|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
3146762|NCT00109291|Experimental|Peginesatide 0.025 mg/kg|Single peginesatide dose of 0.025 milligram per kilogram (mg/kg) administered intravenously.
3146763|NCT00109291|Experimental|Peginesatide 0.05 mg/kg|Single peginesatide dose of 0.05 mg/kg administered intravenously.
3146764|NCT00109291|Experimental|Peginesatide 0.10 mg/kg|Single peginesatide dose of 0.10 mg/kg administered intravenously.
3146765|NCT00109369|Experimental|Active|Provider and patient receive Diabetes Information System services
3146766|NCT00109369|No Intervention|Control|Usual Care
3146767|NCT00109395|Active Comparator|Lorazepam Intermittent bolus|lorazepam administered by intermittent bolus
3146768|NCT00109395|Active Comparator|lorazepam continuous infusion|lorazepam administered by continuous infusion
3146769|NCT00109395|Active Comparator|midazolam continous infusion|midazolam administered by continous infusion
3146770|NCT00109408|Experimental|1|
3146771|NCT00109408|Active Comparator|2|
3187439|NCT00756132||A-Cog|Women aged 18-65 years newly diagnosed with LABC/high risk who are willing and able to complete cognitive testing.
3187440|NCT00756132||Control (C)|Healthy women aged 18-65 years who are willing and able to complete cognitive testing.
3187441|NCT00756132||A1-Cog|Women newly diagnosed locally advanced or high risk breast cancer that qualify for cognitive testing but have a condition related to elevated serum levels of cytokines or other inflammatory markers.
3187442|NCT00756145|Experimental|1|Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline
2428163|NCT03379714||Patients with ruptured or unruptured intracranial aneurysms|
2428164|NCT03379701||CRSwPolyps with no Eosonophilia|CRS patients with nasal polyposis, and no eosonophilia.
2428165|NCT03379701||CRSwPolyps with Eosonopholia|CRS patients with nasal polyposis and eosonophilia.
2428166|NCT03379701||CRS without Polyps|Patients with chronic rhinosinusitis and no nasalpolyposis.
2428167|NCT03379701||PCD|Patients with Primrary ciliary dyskinesia .
2428168|NCT03379701||AFRS|Patients with allergic fungal rhinosinusitis.
2428169|NCT03379701||allergic rhinitis|Patients with allergic rhinitis
2428170|NCT03379701||Control|Healthy subjects.
2428171|NCT03379688||Cardiac surgery patients|Patients undergoing cardiac surgery at Charité Campus Mitte
2428172|NCT03379675|Experimental|Treatment A: JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 once daily for 7 days.
2428173|NCT03379675|Experimental|Treatment B: JNJ-53718678 80 mg + Placebo|Participants will receive 80 mg dose of JNJ-53718678 along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
2428174|NCT03379675|Placebo Comparator|Treatment C: Placebo|Participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
3187443|NCT00756145|Experimental|2|Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline
3187444|NCT00756145|Experimental|3|Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline
2428179|NCT03379636|No Intervention|no tape|tests are realised without any shoulder tape
2428180|NCT03379636|Experimental|kinesiotape|tests are realised with a kinesiotape applied according to Dr Kase model, over the deltoid muscle and over the acromioclavicular joint
2428181|NCT03379636|Sham Comparator|sham tape|tests are realised with a sham tape, applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area
2428182|NCT03379623|Experimental|Intervention group|
2428183|NCT03379623|No Intervention|Usual care group|
2428184|NCT03379597|Experimental|Probiotics Group|"Probiotics add-on treatment :（live Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules, Oral）, each capsule contain more then 1.0*10^7 CFU.~Bifico: 840mg Bid."
2428185|NCT03379597|No Intervention|Control Group|No probiotics or dietary fiber group.
2428186|NCT03379597|Experimental|Dietary fiber Group|Prebiotics add-on treatment: dietary fibers compound powder, 30g bid
2428187|NCT03379597|Experimental|Dietary fiber Probiotics group|Dietary fiber and probiotics group: receiving both Bifico 840mg Bid and dietary fiber 30g bid.
2428188|NCT03379584|Experimental|SGN-CD48A|SGN-CD48A
2428189|NCT03379558||Cohort 1 : alirocumab exposed|Pregnant women diagnosed with primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and exposed to alirocumab during the current pregnancy.
2428190|NCT03379558||Cohort 2 : disease matched comparison|Pregnant women diagnosed of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and unexposed to alirocumab during the current pregnancy.
2428191|NCT03379558||Cohort 3 : non disease comparison|Healthy pregnant women who do not have a known diagnosis of primary hypercholesterolemia and atherosclerotic cardiovascular disease, or primary hypercholesterolemia associated with familial hypercholesterolemia and have no known exposure to a known human teratogen.
3187445|NCT00756171|Experimental|1|Verum; colesevelam
2428193|NCT03379532|Active Comparator|BCI-NMES|Electrical stimulation of paretic upper limb is triggered contigent to voluntary motor cortex activation of the patient, as detected by the brain-computer interface.
2428194|NCT03379532|Sham Comparator|Sham-NMES|Electrical stimulation of paretic upper limb is applied independently of motor cortex activation of the patient by using a prerecorded session of another patient.
2428195|NCT03379519|Experimental|Multi-domain Attention Training (MAT)|Training sessions of the MAT group is 45 minutes/day, 3 sessions/week, for 12 weeks (36 sessions).
2428196|NCT03379519|Active Comparator|Passive information activities (PIA)|The training sessions of PIA is the same as MAT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions).
3187446|NCT00756171|Placebo Comparator|2|placebo
2428198|NCT03379493|Experimental|ET190L1 ARTEMIS™ T cells|ET190L1 ARTEMIS™ T cells administered by intravenous (IV) infusion
2428199|NCT03379480|Active Comparator|Yoga arm|Patients with Schizophrenia will undergo 12 sessions of yoga. According to randomization one group of patients will start yoga immediately after recruitment ,whereas another group will go into wait list for 12 weeks after which they will also undergo Yoga treatment.
2428200|NCT03379480|No Intervention|Control arm|Healthy volunteers who will not receive yoga.
2428395|NCT03377946|Experimental|probiotics on pre-diabetes|take probiotics
3187447|NCT00756184|Active Comparator|A|Intervention will consist of intensive teaching on the nature of glaucoma, value of IOP control, need to adhere to medical therapy and counseling on the proper use of travoprost eye drops.
2428201|NCT03379467|Experimental|SMS Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization"
2428202|NCT03379467|Experimental|Interactive Reminder|"Single SMS at each of the following times:~3 days before immunization~1 day before immunization~Day of immunization On the day of immunization, study participants are required to respond back through SMS notifying us that child got vaccinated or if not, the reason for delay in immunization. In case of no response, 2 additional reminders will be sent at:~1 day after scheduled immunization date~1 week after scheduled immunization date"
2428203|NCT03379467|No Intervention|Control|Subjects in this arm will not receive any intervention
2428204|NCT03379441|Experimental|Experimental|"Pembrolizumab 200 mg Q3W IV infusion Day 1 of each 3 week cycle until:~PD,~unacceptable toxicity,~investigator choice,~patients IC withdrawal,~up to a maximum of 24 months (35 administrations) Experimental"
2428205|NCT03379441|No Intervention|Observation|
2428206|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 560 mg|In Phase I, starting dose of Ibrutinib will be 560 mg orally per day. 3 patients will be enrolled first. If none of these have DLTs, 3 new patients will be enrolled at the next higher Ibrutinib dose level (840 mg orally per day). If 1 of these 3 patients have a DLT, expand this arm to 6 patients. If 2 or more of these 6 patients have a DLT, enroll 3 patients in lower dose lever (420 mg).
2428207|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 840 mg|If no patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this higher dose is tolerated.
2428208|NCT03379428|Experimental|Trastuzumab plus Ibrutinib 420 mg|If 2 or more patients in 560 mg arm have DLTs, this arm will be opened in Phase I to see how this lower dose is tolerated.
2428209|NCT03379428|Experimental|Phase II- Trastuzumab plus Maximum Tolerated Dose|Maximum tolerated dose from Phase I will be used here in Phase II.
2428210|NCT03379415|Experimental|Meniscus Injured|These meniscus patients will be recruited to participate in a single session to wear 4 different pairs of shoes
2428211|NCT03379415|Experimental|Footwear|4 Different types of trainers will be used to see the difference in gait in meniscectomy patients
2428212|NCT03379402||Adult patients presenting with sepsis|Adult patients, both males and females, presenting with sepsis will be approached for participation in the study.
2428216|NCT03379363||Pediatric Cushing Syndrome Patients|Pediatrics patients with endogenous Cushing syndrome who received at least one dose of Korlym
2428217|NCT03379350|Experimental|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
2428218|NCT03379350|No Intervention|control group|Patients in control group are managed with gravity drainage (water seal only, without suction) all the time after operation.
2428219|NCT03379337|Experimental|Dental imaging|4 incisors and 4 canine teeth of subjects were imaged with the experimental and the commercial device.
2428220|NCT03379324|Active Comparator|Superiority of augmented repairs|Assess pain, function, and structural integrity of the rotator cuff at 3 months, 6 months, 1 year, and 2 years post-operation
2428221|NCT03379324|Active Comparator|Fat degeneration of supraspinatus muscle|MRI assessment the quantity and disposition of fat within the supraspinatus muscle body compared to pre-operation MRI, at 1 year and 2 years post-operation
3146772|NCT00109421|Experimental|Experimental arm|In the experimental condition, the intervention group will receive the half-day Project ÒRÉ intervention. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires. A subset of groups will participate in a process evaluation focus group immediately following the program.
3146773|NCT00109421|No Intervention|Attention control group|The attention control group will receive a standard health promotion control program which has been used previously with similar populations. All participants will complete pre-, post- and 3-month follow-up self-administered questionnaires.
3146774|NCT00109486|Experimental|Arm 1|
3146775|NCT00109512|Placebo Comparator|placebo|
2428228|NCT03379220||Subdural ECoG (Group 1)|For patients who require craniotomy to treat TBI, a subdural electrode strip will be placed intraoperatively following evacuation of a hematoma or contusion, as required. Electrode strips will be used for subsequent electrocorticography (ECoG) during intensive care. Patients will also undergo continuous scalp EEG monitoring.
2428229|NCT03379220||Burr Hole ECoG (Group 2)|For patients who do not require surgery but do require invasive monitoring, an intraparenchymal ECoG electrode array will be placed through a cranial burr hole. Depending on other monitoring needs, the location of injuries, and other clinical considerations, the burr hole may be the same as used for placement of other probes or may be separate. In cases of focal injury, the burr hole will be placed to allow electrode targeting to a lobe with significant primary lesion(s). Patients will also undergo continuous scalp EEG monitoring.
2428230|NCT03379220||EEG (Groups 1-3)|Continuous EEG recordings will be made using Ag/AgCl electrodes placed on or beneath the scalp (subdermal wire) according to standard practice. The default montage will employ eight lead electrodes for each hemisphere following the 10/20 system (Right: Fp2, F4, C4, P4, O2, F8, T4, T6; left: Fp1, F3, C3, P3, O1, F7, T3, T5). Other montages with more dense placement of electrodes in the region of ECoG monitoring may also be used.
2428231|NCT03379207||"Community Acquired Pneumonia group"|"Participants admitted to Intensive Care Unit (ICU) of University Hospital of Tours (France) for Community Acquired Pneumonia.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 1, 7, and every week during ICU stay Tracheal Aspirates for research purpose: only for mechanically ventilated participants, at inclusion, day 1, 7, and and every week during ICU stay~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
3146776|NCT00109512|Experimental|NBI-56418 75 mg|
3146777|NCT00109512|Experimental|NBI-56418 150 mg|
2428232|NCT03379207||"Control group"|"Participants admitted to Intensive Care Unit of University Hospital of Tours (France) for whom invasive mechanical ventilation is required for an estimated duration of at least 48h, without diagnosis of pneumonia or shock.~Interventions:~Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose, at inclusion, day 3, 8, and 15 during ICU stay Tracheal Aspirates for research purpose: at inclusion, day 3, 8, and 15 during invasive mechanical ventilation period,~Surplus of Broncho-alveolar lavage fluid: only if performed for diagnosis purpose by the treating investigator (indication left at his discretion)"
2428233|NCT03379194|Experimental|'Antibiotic stewardship program'|Physicians receive quarterly over 24 months, first in January 2018 postal mail a feedback on their antibiotic prescriptions and updated antibiotic resistance information from the community. With the first letter, educational material, evidence-based guidelines for conditions leading to most outpatient prescriptions in primary care and leaflets for on using antibiotics wisely are provided. Additional material is made available on a study website that can be accessed by each physician in the intervention group by an unique access code.
2428234|NCT03379194|No Intervention|Control|No intervention
2428235|NCT03379181|Experimental|Propranolol 80 mg|Patients receive a single dose of 80 mg propranolol p.o.
2428236|NCT03379168|Placebo Comparator|Placebo Injection|Patients who are randomized to the placebo group will receive an injection of 7cc of sterile saline in the affected knee.
2428237|NCT03379168|Active Comparator|Corticosteroid Injection|Patients who are randomized to the corticosteroid group will receive an injection of 2cc (80mg) of triamcinalone acetonide injectable suspension mixed with 5 cc of 1% plain lidocaine for a total of 7cc of fluid injected in the affected knee.
2428238|NCT03379168|Experimental|Lipogems Injection|Patients who are randomized to the Lipogems treatment group will undergo a lipoaspiration from their abdomen and autologous injection of the harvested adipocytes into their knee. It is standard to harvest three to four times more adipose tissue than is planned to be injected to account for tissue processing by the Lipogems device. The investigators plan to inject 7cc of autologous adipose tissue. Thus, the investigators will harvest between 25 and 30 cc of adipose tissue from each patient. The tissue will be processed immediately and 7cc will be injected. Any remaining adipose tissue will be disposed of immediately in biohazardous waste.
2428239|NCT03379155|Experimental|Active Group|Internet-based self-help
2428240|NCT03379155|No Intervention|Waiting List Group|
2428241|NCT03379142|Other|Behavioral: Faith-Based messages|We will send faith-based messages one week prior to Ramadan and twice a day during Ramadan.
2428242|NCT03379103|Active Comparator|GP - sevoflurane|GP - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with 1 MAC sevoflurane for 15 minutes before the installation of ischemia by tourniquete
2428243|NCT03379103|Placebo Comparator|GC - control|GC - patients will be anesthetized with sevoflurane associated with subarachnoid anesthesia and will be preconditioned with intravenous propofol for 15 minutes before the installation of ischemia by tourniquete.
2428244|NCT03379077|Experimental|LTP Plus Supported Implementation|LTP Plus Supported Implementation group participants will receive intervention by trained LHWs of HANDS, co-facilitated and supervised by senior trained PILL researchers, expert in delivering LTP plus intervention
2428245|NCT03379077|Active Comparator|LTP Plus|Participants in LTP Plus arm will receive LTP plus intervention by trained LHWs of Health and Nutrition Development Society (HANDS).
2428246|NCT03379064|Experimental|culturally adapted Cognitive Behavior Therapy|We will use The STreSS CBT manual developed by Schroder and his colleagues
2428247|NCT03379064|No Intervention|Treatment As Usual|The Treatment As Usual (TAU) group will receive regular treatment they have been receiving already as prescribed by the physician.
3146778|NCT00109538|Experimental|Lonafarnib|Lonafarnib 200 mg twice daily, oral, continuously
3146779|NCT00109538|Placebo Comparator|Placebo|Placebo, BID, oral
2428250|NCT03379038|Experimental|Progressive Physical Therapy (PPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions.~Total 42 sessions were performed in 6 weeks (7 days/week). Intensity: The aim of the PPT was to improve the patient's level of spasticity, strength and activity level."
2428251|NCT03379038|Placebo Comparator|Maintenance Physical Therapy (MPT)|"Duration: Each child was given 40-minute session. Frequency: Two sets were performed, 5-10 active assisted sit-ups in each set at least once a day. Furthermore, the subjects were advised to use CP chair and standing frame/wall corner for sitting/standing position respectively for at least 15-30 minutes once a day. These exercises were followed by reflex inhibiting postures in sitting and lying positions. Total 42 sessions were performed in 6 weeks (7 days/week).~Intensity:The aim of the MPT was to maintain the patient's current level of spasticity, strength and activity level."
2428252|NCT03379025|Experimental|Early Intervention Group|JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
2428253|NCT03379025|Other|Delayed Intervention Group|After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
2428254|NCT03379012|Experimental|Testosterone and Targeted therapy|Testosterone undecanoate (Nebido®) and Targeted therapy (sunitinib or pazopanib)
2428255|NCT03379012|Active Comparator|Control|Targeted therapy (sunitinib or pazopanib) only
2428256|NCT03378999|Placebo Comparator|Control|Placebo capsules containing microcrystalline cellulose
2428257|NCT03378999|Experimental|Rhodospirillum rubrum 0.25 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day
2428258|NCT03378999|Experimental|Rhodospirillum rubrum 0.5 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day
2428259|NCT03378999|Experimental|Rhodospirillum rubrum 1.0 gram/day|Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day
2428260|NCT03378986||Unilateral THA|Patients who underwent to unilateral total hip arthroplasty
3146780|NCT00109655|Experimental|1|
3146781|NCT00109720|Experimental|1|Patients in the experimental group received the services of a Diabetes Self-Management Consultant (DSC)
3187448|NCT00756184|Placebo Comparator|B|"Intervention with travoprost therapy and TDA monitoring. Patients of this arm will also be prescribed travoprost and will be followed up in a standard clinical fashion. This group will receive a comparable amount of personal physician attention, but will not be given adherence, or glaucoma education and will not be told that their adherence will be monitored. Their attention placebo intervention will discuss the importance and techniques of good eye health (sunglasses, vitamins, cataract development, etc but no details, or discussion of either glaucoma or adherence) will insure that the study results are not a result of a change in physician attention to a patient, per se, rather than adherence training."
3187449|NCT00756197|Experimental|Cryo Spray Ablation Group 1|4 cycles of 10 seconds each
2428264|NCT03378960|Other|omeprazole|omeprazole 20 mg
2428265|NCT03378934|Experimental|Berberine Arm|In the Berberine Arm, patients will receive berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4±1 weeks (Stage 3) in addition to standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
2428266|NCT03378934|Active Comparator|Control Arm|In the Control Arm, patients will receive standard treatment, including aspirin 100 mg once daily and clopidogrel 75 mg once daily for 12±1 weeks.
3187450|NCT00756197|Experimental|Cryo Spray Ablation Group 2|2 cycles of 20 seconds each
2428269|NCT03378908|No Intervention|Conventional Treatment 6 meals|Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
2428270|NCT03378908|Experimental|Intervention Treatment 3 meals|Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
2428271|NCT03378895|Experimental|adults aged 35 to 55 years|
2428272|NCT03378817|Active Comparator|Conventional cold storage|Conventional static cold storage (CCS) on temperature 0-4 °C from organ procurement (historical case matched group)
2428273|NCT03378817|Experimental|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
2428274|NCT03378804|Experimental|PIEB-PCEA|"Programmed intermittent epidural bolus (PIEB) application of ropivacaine 0.2% with patient-controlled epidural analgesia:~The background rate is set at 6ml per hour. The patient-controlled bolus function is programmed with 4ml at a lock-out interval of 30min."
2428275|NCT03378804|Active Comparator|CEI-PCEA|"Continous epidural analgesia with patient-controlled analgesia using ropivacaine 0.2%:~The background rate is set at 6 ml / h continuously. The patient-controlled bolus function is programmed in with 4ml at a lock-out interval of 30min."
2428276|NCT03378791|Experimental|Group A|Iron bisglycinate (27mg of elemental iron)
2428277|NCT03378791|Active Comparator|Group B|Ferrous fumarate (115mg of elemental iron)
2428278|NCT03378778||Less than 33% Tooth Structure remaining|Root canal treatment followed by CAD CAM restoration
2428279|NCT03378778||33%-50% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2428280|NCT03378778||50% -66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2428281|NCT03378778||More than 66% tooth structure remaining|Root canal treatment followed by CAD CAM restoration
2428282|NCT03378765||African origin adults|African origin adults from Ghana, Jamaica, Seychelles, South Africa and USA between the ages of 30- 50.
2428283|NCT03378752||Atelectasis formation using HFJV|Computed tomography scans are performed every 15 minute during the first 45 minutes during general anaesthesia using high frequency jet ventilation.
2428284|NCT03378726|Experimental|Standard Counseling and Micronutrients|Participants will receive standard services provided by the Ministry of Health, including powder micronutrients. Children receive 1 gram of powdered micronutrientes for 60 days between 6 and 12 months of age, and 60 daily packets per year from the time they are 1 year old until 5 years old.
2428285|NCT03378726|Experimental|SPOON Group Counseling with SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group counseling, which is a new form of social communication in which participants will learn relevant lessons in a group format. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
2428286|NCT03378726|Experimental|Group, Interpersonal Counseling, SQ-LNS|Participants will receive the supplement SQ-LNS in addition to SPOON group and interpersonal counseling, which will consist of both participants learning relevant lessons in group format as well as in formats in which participants will work one-on-one with an instructor. SQ-LNS consists of a 20g nutrient supplement package that is to be consumed daily between 6 and 24 months of age.
2428287|NCT03378713|Experimental|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application.
2428288|NCT03378713|Active Comparator|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
2428289|NCT03378713|Active Comparator|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
2428290|NCT03378700|Experimental|Brief Hope Intervention Group|In addition to the pre-dialysis educational programme on self-care and treatment options for ESRF patients as per the control group, brief hope intervention will be offered: a four-weeks individual intervention. Two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between. A booklet modified from the goal worksheet in Lopez et al. (2000) will be prepared for the participants for reviewing their planned goals, recording achieved targets and successful experiences.
2428328|NCT03378479|Other|Standard of Care|standard of care treatment for influenza pneumonia (at the investigators discretion)
2428329|NCT03378466|Experimental|Unfractionated Heparin (UFH)|UFH initiated at 18 IU/kg/hr
2428330|NCT03378466|Other|Venous thromboprophylaxis (VTE)|as per local standard
2428291|NCT03378700|Active Comparator|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
2428292|NCT03378687||status epileptius|Cases were patients 29 days to 18 years who were diagnosed with status epileptius in 35 hospitals in China between January 1， 2013 and December 31，2015.
2428293|NCT03378674|Experimental|Group A|remifentanil infusion of 0,15 mcg/Kg/min
2428294|NCT03378674|Active Comparator|Group B|remifentanil infusion of 0,3 mcg/Kg/min
2428295|NCT03378661|Experimental|BZN STD Regimen|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2428296|NCT03378661|Experimental|BZN 300 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2428297|NCT03378661|Experimental|BZN 300 mg - 2 wks|"Benznidazole (100 mg and 50 mg) tablets by mouth, every 12 hours for 2 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 6 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2428298|NCT03378661|Experimental|BZN 150 mg - 4 wks|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2428299|NCT03378661|Experimental|BZN 150 mg - 4 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in two separate daily doses for 4 weeks, followed by:~Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, every 12 hours for 4 weeks.~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
2428300|NCT03378661|Experimental|BZN 300 mg (weekly) 8 wks / E1224 300 mg|"Benznidazole (100 mg and 50 mg) tablets by mouth, once weekly for 8 weeks (total 8 days of intermittent treatment) and Benznidazole Placebo (100 mg and 50 mg) tablets by mouth, in the other 6 days of the week for 8 weeks~Three E1224 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks. (total dose: 3000 mg)."
2428301|NCT03378661|Placebo Comparator|Placebo|"Benznidazole Placebo (100 mg and 50mg) tablets by mouth, every 12 hours for 8 weeks.~Three E1224 Placebo 100 mg capsules by mouth, everyday on days 1 to 3, followed by three E1224 Placebo 100 mg capsules by mouth, once weekly (starting on week 2) for 7 weeks."
2428302|NCT03378648|Experimental|CHF6366 active|
2428303|NCT03378648|Placebo Comparator|CHF6366|
2428304|NCT03378648|Active Comparator|Comparator|
3187451|NCT00756223|Experimental|Arm A|BI 831266 24h infusion on day 1 and day 15 every 4 weeks
3187452|NCT00756223|Experimental|Arm B|BI 831266 24h infusion on day 1 every 3 weeks
3187453|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.005 mcg/kg|
2428308|NCT03378622|Experimental|Anchor|Anchor used for mesh attachment
2428309|NCT03378622|Active Comparator|Suture|Suture used for mesh attachment
2428310|NCT03378609|Other|Vocal Fatigue Index (VFI)|Standardized Questionnaire assessing vocal fatigue
2428311|NCT03378596|Experimental|L-citrulline & L-arginine|L-citrulline (6 grams) L-arginine (8 grams)
2428312|NCT03378596|Active Comparator|L-citrulline & Placebo|L-citrulline (6 grams) Placebo (6 grams)
2428313|NCT03378596|Active Comparator|L-arginine & Placebo|L-arginine (8 grams) Placebo (6 grams)
2428314|NCT03378596|Active Comparator|Placebo|Placebo (6 grams)
2428315|NCT03378583||control,|control normal ventilation
2428316|NCT03378583||sellick,|ventilation while sellick manoeuvre is applied
2428317|NCT03378583||low paratracheal esophagus compression|ventilation while low paratracheal esophagus compression is applied
2428318|NCT03378570|Active Comparator|5.5cm Rule Group|rTMS will be targeted at a left prefrontal target 5.5cm anterior to the primary motor strip identified on the scalp during motor threshold testing.
2428319|NCT03378570|Active Comparator|F3 Group|rTMS will be targeted at the left prefrontal scalp target identified as F3 according to the 10-20 EEG system.
2428320|NCT03378544|Experimental|Experimental arm|Patients with suicidal ideation and depression will receive psychosocial interventions adapted from the WHO mental health Global Action Programme Intervention Guide (mhGAP-IG). The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity.
2428321|NCT03378544|No Intervention|Control group|Patients with suicidal ideation and depression will be trained on how to refer patients suffering from depression, using a referral note to the nearest health centre for further treatment
3187454|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.05 mcg/kg|
2428323|NCT03378505|Experimental|Mobile App|Half of the students randomly assigned
2428324|NCT03378505|Experimental|Reflection|Half of the students randomly assigned
2428325|NCT03378492|Active Comparator|Standard Epidural|Participants in this group will have epidurals placed using standard practice.
2428326|NCT03378492|Experimental|Ultrasound Guided Epidural|Participants in this group will have epidurals placed using standard practice with the assistance of ultrasound.
2428327|NCT03378479|Other|SOC + 'Posaconazole 18 MG/ML'|standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)
3187455|NCT00756249|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
2428333|NCT03378427|Experimental|Tedizolid Phosphate 200 MG [Sivextro]|All included patients will receive prolonged (>= 6 weeks) tedizolid treatment given orally.
2428334|NCT03378414|Experimental|Intravenous infusion group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2428335|NCT03378414|Experimental|Intrathecal injection group|Umbilical cord mesenchymal stem cells (SCLnow 19#)
2428336|NCT03378414|No Intervention|Control groups|No intervention
2428337|NCT03378401|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2428338|NCT03378401|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2428339|NCT03378388||Vedolizumab|Participants diagnosed with UC or CD, who fail or are intolerant to a previous biologic treatment or with contra-indication to anti-tumor necrosis factor alpha (TNF alpha) after failure of conventional treatments without exclusion except participant refusal, and were potentially eligible for a treatment with vedolizumab will be observed from the first prescription during consultation over a period of 24 months.
2428340|NCT03378362|Experimental|Partial denervation of the wrist joint|Patients will be operated with a partial denervation of the wrist through a single dorsal approach.
2428341|NCT03378349|Experimental|Internet-delivered CBT over 10 weeks|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that aim to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
2428342|NCT03378349|Placebo Comparator|Treatment as usual wait list|Patients randomized to the treatment as usual wait list arm will receive standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health. Thus, the treatment as usual arm will control for the provision of basic patient information, but without the guidance of a psychologist or any CBT interventions.
2428343|NCT03378336||Observational Group|This is an observational study with only one group/cohort with no intervention
2428344|NCT03378323|Active Comparator|Multiple injection local anesthetic|Ultrasound guided axillary plexus block with multiple injections of local anesthetic
2428345|NCT03378323|Experimental|Single injection local anesthetic|Ultrasound guided axillary plexus block with a single injection of local anesthetic
2428346|NCT03378310|Experimental|Reference tablet followed by BMS-986205 tablet with free base|BMS-986205 reference tablet (treatment period 1) followed by BMS-986205 tablet with free base (treatment period 2).
2428347|NCT03378310|Experimental|BMS-986205 tablet with free base followed by reference tablet|BMS-986205 tablet with free base (treatment period 1) followed by BMS-986205 reference tablet (treatment period 2).
2428348|NCT03378297|No Intervention|Feasibility study cohort|
2428349|NCT03378297|Experimental|Metformin|850 mg
2428350|NCT03378297|Experimental|Acetylsalicylic acid|160 mg
2428351|NCT03378297|Experimental|Olaparib|300 mg x 2
2428352|NCT03378297|Experimental|Letrozol|2.5 mg
2428353|NCT03378284|Experimental|Tegoprazan(Test drug)|Tegoprazan drug QD for 7 days
2428354|NCT03378284|Active Comparator|Active comparator drug|Active comparator drug QD for 7 days
2428355|NCT03378271|Experimental|FGM/CGM|"each patient will have a CGM and a FGM, subcutaneous glucose sensors, the data will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose minimum 3 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study"
2428356|NCT03378245|Experimental|Telemedicine Intervention|Multidisciplinary telemedicine education of staff and providers on best practices for behavioral modification as well as education on best practices for pharmacologic therapies.
2428357|NCT03378232|Placebo Comparator|Placebo Olive Oil|Placebo supplement with olive oil
2428358|NCT03378232|Experimental|High EPA Supplement|Supplements providing up to 3g per day of Omega-3, with increased EPA
2428359|NCT03378232|Experimental|High DHA Supplement|Supplements providing up to 3g per day of Omega-3, with increased DHA
3146782|NCT00109720|Active Comparator|2|This Arm was a Enhanced Usual Care Control group who continued with their usual care but also they and their physicians received the results of all metabolic assessments obtained during the study.
3146783|NCT00109746|Active Comparator|Chromium Picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
3146784|NCT00109746|No Intervention|Placebo|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
2428363|NCT03378206|Experimental|Hinged 8-figure plate|Hinged 8-figure plate is a novel devise that has modifications in order to improve the treatment effect of conventional 8-figure plate. This arm will be used to verify the effectiveness and feasibility of the modification.
2428364|NCT03378206|Active Comparator|conventional 8-figure plate|Conventional 8-figure plate is widespread method to treat genu varum and valgus. This arm, as a comparator, will be the control group to verify the feasibility of the novel hinged 8-figure plate.
2428365|NCT03378167|Experimental|MICROBIOTA|Patients randomized to the INTERVENTION arm will receive a baseline fecal microbiota transplant (FMT) colonoscopic infusion at Week 0, followed by twice-weekly oral microbiota capsule (OMC) therapy for 6 weeks (including Week 0). (n = 30)
2428396|NCT03377946|Placebo Comparator|placebo on type 2 diabetes|take placebo
2428397|NCT03377946|Placebo Comparator|placebo on pre-diabetes|take placebo
3146785|NCT00109759|Experimental|RagweedMATAMPL|
3146786|NCT00109759|Placebo Comparator|Placebo|
3187456|NCT00756249|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
3187457|NCT00756249|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
3187458|NCT00756249|Placebo Comparator|Placebo|
2428366|NCT03378167|Placebo Comparator|PLACEBO|Patients randomized to the CONTROL arm will receive a baseline normal saline (NS) colonoscopic infusion at Week 0, followed by twice-weekly dextrose-containing oral placebo capsule (OPC) therapy for 6 weeks (including Week 0). (n = 15)
2428367|NCT03378154|Experimental|Tracheal Intubation in infants using Macintosh laryngoscopes|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the Macintosh laryngoscope
2428368|NCT03378154|Experimental|Tracheal Intubation in infants using King vision|Children < 1 year of age posted for elective or emergency surgical procedure will be administered general anaesthesia by means of orotracheal intubation with the help of the King vision videolaryngoscope
2428369|NCT03378141|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention. Intervention includes provision of IFA and calcium supplements, interpersonal counseling on diet during pregnancy and consumption of IFA and calcium, community mobilization, and adequate weight-gain monitoring during pregnancy
2428370|NCT03378141|No Intervention|A&T-non intensive|A&T-non intensive arm only receives standard MNCH services
2428371|NCT03378128|Experimental|diagnostic laparoscopic assessment after neoadjuvant chemo|All patients will undergo a diagnostic laparoscopic assessment of disease following neoadjuvant chemotherapy
2428372|NCT03378102|Experimental|Interferon (IFN)-gamma-secreting HAdV antigen specific T cells|"Virus-specific, antigen selected cells will be obtained using the CliniMACS® Prodigy System. The donor will be screened for their ability to produce an IFN-gamma- secretion response to HAdV by testing the donor's mononuclear cells with the Miltenyi Rapid Cytokine Inspector kit. Donors with appropriate IFN-gamma secretion response will undergo a steady state leukapheresis. The investigational product (IP) will be generated using the CCS-IFN enrichment program with an approximate duration time of 15 hours. IP will be suspended in 0.9 normal saline + 2.5% albumin and distributed for infusion and infused within 4 hours as a bolus on day 0.~Subjects will receive virus-specific, antigen selected T cells within a targeted range of 1 x 10^3- 2 x 10^5 per kg of recipient weight."
2428373|NCT03378089|Experimental|Music Therapy|Participants in the experimental group will be given choices about how to proceed with the session: active or passive, improvisation, re-creative or receptive songs, or receptive (relaxation). Three music therapy sessions will be completed, the first within 24 hours of admission, the second 24-96 hours of session 1, and the final session the day before stem cell infusion.
2428374|NCT03378089|Active Comparator|No Music Therapy|Participants randomized to the standard care group will be asked to rate the same symptoms as those in the experimental group. This will mark the beginning of a 45-minute control condition period during which the participants may fill the 45-minute time-period in whatever ways they choose.
2428377|NCT03378063|Experimental|transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be given to the infants with BPD.
2428378|NCT03378063|Active Comparator|no transplantation of mesenchymal stem cell|transplantation of mesenchymal stem cell will be not given to the infants with BPD.
2428379|NCT03378050|Experimental|Intervention group|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages."
2428380|NCT03378050|Active Comparator|Control group|"Participants is the control group will be placed on a waiting list for 12 weeks. They will receive the intervention, after they complete the 12-week follow-up assessment. Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
2428381|NCT03378037|Experimental|Acupuncture group|Disposable acupuncture needles will be inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
2428382|NCT03378037|Sham Comparator|Control group|Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes.
2428383|NCT03378024||diabetic mellitus patients|"Measure the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) of pre-exercise and post-exercise by the oscillometric (Omron Colin co.).~And follow up for 3 years to identify of the correlation with PAD outcome."
2428384|NCT03378011|Active Comparator|UVA1 phototherapy|UVA1 phototherapy in acral vitiligo
2428385|NCT03378011|Active Comparator|Topical PUVA|Topical PUVA in acral vitiligo
2428386|NCT03377998|Experimental|vitiligo patients|lesional skin biopsy to measure ERDR1 level
2428387|NCT03377998|Experimental|controls|normal skin biopsy to measure ERDR1 level
2428388|NCT03377985|Active Comparator|axillary brachial plexus block group|Patients placed in the supine position with arm to be blocked abducted and externally rotated. After sterilization of the axilla ultrasound device with high frequency of 8-12 MHZ, linear transducer was put parallel to the anterior axillary fold at axilla to identify the axillary artery, lateral, medial and posterior cords of the brachial plexus in relation to the axillary artery. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the probe, 7-10 ml of bupivacaine 0.5% was injected around each cord of the brachial plexus
2428389|NCT03377985|Active Comparator|supraclavicular brachial plexus block group|patients placed in the supine position with the head of the bed elevated 30 degrees and patient's head turned away from the side to be blocked after skin disinfection, ultrasound device was put transversely parallel to and above the middle third of the clavicle, the probe was tilted till identification of the subclavian artery, 1st rib, pleura and brachial plexus lateral to the subclavian artery and above the 1st rib. Lidocaine 1% was infiltrated subcutaneously 1 cm lateral to the lateral side of the probe. A needle was inserted in plane 1 cm lateral to the probe when adjacent to brachial plexus 25 ml of bubivacaine 0.5% was injected around the brachial plexus
2428390|NCT03377972||WHO diagnostic standard|
2428391|NCT03377972||Japan diagnostic standard|
2428392|NCT03377959|Experimental|Pilates Group|Pilates Method Mat classes and Ballet Classes three times a week, totaling 24 session of each.
2428393|NCT03377959|Other|Ballet Group|Ballet Classes three times a week, totaling 24 sessions.
2428398|NCT03377933|Experimental|probiotics and quadruple therapy|Patients are given two-week compound Lactobacillus acidophilus probiotic (1 g t.i.d.), followed by a quadruple antibiotic regimen (esomeprazole [20 mg b.i.d.] + bismuth potassium citrate [220 mg b.i.d.] + tetracycline [750 mg b.i.d.] + furazolidone [100 mg b.i.d.]) for 10 days as rescue therapy.Meanwhile perform endoscopy and take gastric mucosa specimens for gene sequencing before and after the application of probiotic.
2428399|NCT03377920|Experimental|Severe asthma patients; COPD patients|Cross sectional study Lung function measurement
2428400|NCT03377907|Active Comparator|Ketamine in hematoma block|Ketamine used in hematoma block
2428401|NCT03377907|Active Comparator|ketamine intravenous anesthesia|ketamine used in local intravenous anesthesia
2428402|NCT03377907|Active Comparator|lidocaine intravenous anesthesia|2.5 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
2428403|NCT03377894|Active Comparator|• Group (A) blunt incision|"100 primigravidas at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy.~undergoing blunt uterine incision expansion"
2428404|NCT03377894|Active Comparator|• Group (B) sharp incision|100 primigravidas, at term who underwent elective transverse lower segment Cesarean section for the first time among the age group of 20 - 37 years with a singleton pregnancy undergoing sharp uterine incision expansion
2428405|NCT03377881|Other|Traditional|The traditional/control arm consists of PSA testing and if PSA>3ng/ml a systematic biopsy of the prostate is performed.
2428406|NCT03377881|Experimental|STHLM3+MRI/Fusion|The experimental arm consists of a Stockholm3 bloodiest and if elevated, an MRI is recommended with targeted biopsies to prostate lesions.
2428407|NCT03377868|Other|Patients with Amyotrophic lateral sclerosis|Patients diagnosed with amyotrophic lateral sclerosis
2428408|NCT03377868|Other|Control|Parallel cohort of healthy age and sex matched subjects
2428409|NCT03377855|Experimental|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
2428410|NCT03377842|Active Comparator|FOLFOX regimen|FOLFOX regime alone.
2428411|NCT03377842|Experimental|Apatinib and FOLFOX regimen|Apatinib combine with FOLFOX regimen.
2428412|NCT03377829|Experimental|Percutaneous laser ablation(PLA)|Eligible participants with PTMC will be randomly assigned to this group and undergo percutaneous laser ablation(PLA). All the process is under the detection of real-time ultrasound.After surgery, all the patients will accept contrast-enhanced ultrasound(CEUS), regular ultrasound follow-up, thyroid functional detection, fine-needle aspiration biopsy(FNAB), neck CT.Per and post-operative complications, need of drug treatment, length of hospital admission and customer satisfaction will be registered.
2428413|NCT03377829|Active Comparator|Surgery|Eligible participants with PTMC will be randomly assigned to this group and undergo total/subtotal thyroid surgery.
2428414|NCT03377816|Experimental|Art Therapy|The AT intervention is an 8-week group intervention comprised of 8 1.5 hour weekly sessions conducted by an experienced Art Therapist who received special training in conducting the treatment protocol as designed.
2428415|NCT03377816|Sham Comparator|Mandala group|The comparison group will color prefabricated shapes. The same art materials as in the intervention group will be on the table as will the same instrumental music.
2428420|NCT03377777||Infants|Outwardly healthy male and female infants at 6-7 months or 12-13 months. No intervention.
2428421|NCT03377764||Landmark Technique|Control group
2428422|NCT03377764||Ultrasound guided technique|Neuroaxial block using Ultrasound guidance
2428423|NCT03377751|Experimental|Additional posterior wall isolation|Operator will perform pulmonary vein isolation (PVI) and additional posterior wall isolation if low voltage area exists more than 10% of the left atrium
2428424|NCT03377751|Experimental|Voltage-guided substrate homogenization|Operator will perform pulmonary vein antrum isolation (PVI) and additional substrate modification based on the degree of low voltage area.
2428425|NCT03377751|Active Comparator|PVI only group|Operator will perform PVI only
2428426|NCT03377738|No Intervention|anti-smoking therapy|All patients will be given only an intervention for tobacco cessation which will depend on the individual's cessation phase
2428427|NCT03377738|Experimental|anti-smoking therapy + spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase. In addition, in this group will be given a spirometry test as a motivational element for dishabituation.
2428428|NCT03377725|Experimental|Experimental group|MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.
2428429|NCT03377725|Active Comparator|Controlled group|MDS patients of the controlled group will be treated with decitabine alone.
2428430|NCT03377712||Brachial Plexus Injury group|Patients who will be submitted to the surgical procedure and monitored for the repercussions of the surgery. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation, functional capacity, pain evaluation, function and quality of life
2428431|NCT03377712||Paired group|Healthy individuals who will be matched by sex and age with the group of patients who will effectively undergo the surgical process. Interventions: optoelectronic plethysmography, diaphragmatic ultrasound, postural evaluation and functional capacity.
3187461|NCT00756301|Active Comparator|Traditional Technique|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
2428434|NCT03377686||Asthma|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with doctor's diagnosed asthma
2428435|NCT03377686||Cystic fibrosis|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years with CF
2428954|NCT03374306|Placebo Comparator|Artifical tear|Group receiving placebo for 18 months
2428436|NCT03377686||Healthy|Inflammation markers in exhaled breath will be used in 20 children aged 6 to 16 years old without respiratory diseases
2428437|NCT03377660||Sandostatin|This cohort will be the group who are undergoing routine clinical treatment with a long-acting somatostatin analogue to minimise abnormal gut hormone signalling, and thus reduce early satiety.
2428438|NCT03377660||Mirtazapine|This cohort will be the group who are undergoing routine clinical treatment with a tetracyclic antidepressant to stimulate appetite.
2428439|NCT03377647|Active Comparator|Year two intervention|Both interventions will occur in the Tuba City Agency during year two.
2428440|NCT03377647|Active Comparator|Year three intervention|Both interventions will occur in the Chinle Agency during year three.
2428441|NCT03377647|Active Comparator|Year four intervention|Both interventions will occur in the Fort Defiance during year four.
3187462|NCT00756301|Experimental|Alternative Technique|Local anesthetic (Lidocaine) injected using an alternative technique (inserting the numbing needle into the deeper tissues first and injecting numbing medication from there up to the skin).
3187463|NCT00756301|No Intervention|No Anesthetic|No local anesthetic is used.
2428444|NCT03377621|Experimental|Whole Body Vibration|OSA subjects will be asked to use whole body vibration machine for 30 minutes, 3 times a week for 6 weeks in between visits.
2428445|NCT03377608||Depo-Provera|
2428446|NCT03377608||Non-hormonal contraception|
2428447|NCT03377595|Experimental|TAP (Transversus Abdominis Plane) block|20-mL dose of EXPAREL 266 mg expanded in volume with 20 mL normal saline plus 20 mL 0.25% bupivacaine for a total volume of 60 mL m.A 2-point classic TAP block will be performed under ultrasound guidance within 1 hour (± 30 minutes) following skin incision closure of the C-section.
2428448|NCT03377595|Experimental|Wound infiltration|20 mL of EXPAREL 266 mg expanded in volume with 40 mL normal saline for a total volume of 60 mL, infiltrated in the fascia prior to skin closure with attention to infiltrate the angles of the incision.
2428449|NCT03377582|Active Comparator|Conventional therapy|Exercise-based cardiac rehabilitation
2428450|NCT03377582|Experimental|Virtual reality based therapy|Exercise-based virtual reality
2428451|NCT03377569||Group #1|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring prior to DBS surgery and in patient polysomnography with neural recording after DBS surgery.
2428452|NCT03377569||Group #2|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation on at night, and in patient polysomnography after DBS surgery.
2428453|NCT03377569||Group #3|Patients with Parkinsons Disease who will undergo Deep Brain Stimulation surgery. At home sleep monitoring after DBS surgery with DBS stimulation off at night, and in patient polysomnography after DBS surgery.
3187464|NCT00756340|Experimental|1|"Dose Level 0, Bevacizumab IV every 2 weeks 8 mg/kg, Everolimus 4 mg/m^2~Dose Level 1 (starting dose), Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 4 mg/m^2~Dose Level 2, Bevacizumab IV every 2 weeks 10 mg/kg, Everolimus 5 mg/m^2"
2428455|NCT03377543|Experimental|Control Sleep/Non-Active Placebo or 81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2428456|NCT03377543|Experimental|Sleep Restriction/81mg Aspirin Pill|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2428457|NCT03377543|Experimental|Sleep Restriction/Non-Active Placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 11-day in-hospital stay
2428458|NCT03377530||Premature neonates infected with bacillus Species|The investigators studied retrospectively eleven cases of these infections in our NICU and reviewed series and report cases in literature.
2428459|NCT03377517|Experimental|ResearchTreatment Plan|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
2428460|NCT03377504|Experimental|mirror group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. Mirror therapy will be applied to the mirror group for 30 minutes per day in addition to this routine treatment.
2428461|NCT03377504|Active Comparator|control group|Routine physical therapy and exercise program will be applied to all patients for a total of 4 weeks, 5 days a week, 1 hour/day. A total of 20 sessions of treatment will be given to each patient.
3187465|NCT00756353||Wave 1|
3187466|NCT00756353||Wave 2|
2428464|NCT03377478|Experimental|Lung Transplant|Patients will be transplanted with HCV positive lung. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).
2428465|NCT03377465|Experimental|Experimental Group|Patients with stroke of undetermined cause age 18-65
2428466|NCT03377465|Active Comparator|Comparative group|Healthy patients age 18-65
2428467|NCT03377452|Experimental|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
2428468|NCT03377452|Experimental|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
2428469|NCT03377439||Group A|Participants with platelet counts <32×10^9/L.
2428470|NCT03377439||Group B|Participants with platelet counts between 32×10^9/L and 132×10^9/L.
2428471|NCT03377439||Group C|Participants with platelet counts >132×10^9/L.
2428472|NCT03377426|Experimental|LYS228|IV infusion
2428473|NCT03377426|Active Comparator|Standard of care|IV infusion of standard of care antibiotics for at least 5 days
2428474|NCT03377400|Experimental|study arm|Concurrent radiotherapy with chemotherapy (5FU/CDDP) and immune checkpoint inhibitors (durvalumab/tremelimumab), and followed by consolidation immune checkpoint inhibitors
2428475|NCT03377387|Experimental|capecitabine 7/7 with neratinib|"In the phase I portion of the study, a 3+3 design will be used. Once the MTD is reached, the phase II portion will enroll up to 24 patients. Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Patients will be seen on Day 1 of each cycle (+/- 3 days).~The MD has been determined as 240mg of neratinib and 1000mg BID of capecitabine."
2428476|NCT03377374|Experimental|Probiotic|L. reuteri ATCC PTA 5289 + L. reuteri DSM 17938 at a dose of 2x10^8 Colony Forming Units (CFU)
2428477|NCT03377374|Placebo Comparator|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
2428484|NCT03377348|Other|subconjunctival injection of triamcinolone acetonide|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
2428485|NCT03377335|Experimental|Dapagliflozin|"Dapagliflozin (10mg daily) as add-on to metformin (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
2428486|NCT03377335|Placebo Comparator|Metformin alone|"Metformin alone (stable doses ranging from 1500 to 3000 mg daily).~The total duration of treatment is 6 months."
2428487|NCT03377322|Active Comparator|Treatment|Probiotics capsules
2428488|NCT03377322|Placebo Comparator|Placebo|Placebo capsules containing maltodextrin
2428489|NCT03377309|Experimental|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
2428490|NCT03377296|Experimental|Plasmodium Vivax infection|"Both volunteers will be infected with Plasmodium Vivax (as described below in full in Interventions). i.e., there is only one arm to this study."
2428491|NCT03377283|Active Comparator|AP-KTx/LTx|Transplant recipients receiving an rATG-perfused kidney or liver
2428492|NCT03377283|Placebo Comparator|CP-KTx/LTx|Transplant recipients receiving a control-perfused kidney or liver.
2428493|NCT03377270|Experimental|RST|Respiratory Swallow Training Arm
2428494|NCT03377270|No Intervention|Standard of Care|Standard of Care Arm
2428495|NCT03377270|Other|Home Practice Arm|RST + Home Practice Arm
2428496|NCT03377257|Active Comparator|Active group|The treatment with oral zolmitriptan is 2.5mg when headache attack.
2428497|NCT03377257|Experimental|Experimental group|The treatment with zolmitriptan by sublingual administration is 2.5mg when headache attack.
3187467|NCT00756366|Active Comparator|1|Heart Failure-OSA Group, randomized to early CPAP
3187468|NCT00756366|Active Comparator|2|Heart Failure-OSA Group, randomized to late CPAP
3187469|NCT00756366|Other|3|Heart Failure- no OSA, no CPAP therapy, observational group
2428501|NCT03377231|Experimental|Prevention|
2428502|NCT03377231|Experimental|Treatment|
2428503|NCT03377218|No Intervention|Control|Without additional iodine supplementation.
2428504|NCT03377218|Experimental|Iodine|Receiving iodine.
2428505|NCT03377218|Experimental|Iodine + Selenium|Receiving iodine and selenium.
2428506|NCT03377205|Active Comparator|Plate|Compression screws and neutralization plate.
2428507|NCT03377205|Experimental|Intramedullary nail|Acumed Fibular Rod System
2428508|NCT03377179|Experimental|ABC294640 +/- HCQ treatment|Part 1: All participants will be receiving ABC294640, 500 mg twice a day (BID), continuously in 28 day cycles Part 2: All participants will be receiving ABC294640, 500 mg twice a day (BID) and HCQ at a determined level, continuously in 28 day cycles
2428509|NCT03377166|Active Comparator|Vertigo|Participants with vestibular disorder
2428510|NCT03377166|Active Comparator|Control|Participants without vestibular disorder
2428511|NCT03377153|Active Comparator|Hesperidin and Flaxseed|
2428512|NCT03377153|Placebo Comparator|control|
2428513|NCT03377140|Active Comparator|Hesperidin|2 capsuls of Hesperidin
2428514|NCT03377140|Placebo Comparator|control|2 capsuls of placebo
3187470|NCT00756379|Experimental|Intensive lifestyle modification|P.E.T. guided comprehensive therapy program. The study intervention is Comprehensive therapy program for risk factor modification. The Comprehensive program of atherosclerotic risk factor modification involves treatment to target lipid levels, blood pressure and diabetes control, smoking cessation, very low fat diet and aerobic exercise program. This is in addition to standard current medical therapy as provided by primary physician. No experimental medications or procedures will be used.
2428537|NCT03376971|Experimental|Diagnostic (lung biopsy)|Patients undergo extraction of up to 3 additional lung biopsies from target lesions that are at least 2-3 cm in diameter using the 19 gauge SuperCore biopsy needle or the 20 gauge Rotax needle. The extracted tissue is imaged via confocal fluorescence microscopy using a variety of fluorescent contrast agents, such as fluorescein sodium, methylene blue, indocyanine green and then undergo hematoxylin and eosin processing.
3187471|NCT00756379|No Intervention|Current standard of care|Current standard of care medical management as provided by primary physician.
3187472|NCT00756392|Other|1|
3187473|NCT00756405|Active Comparator|Diet Group|Increased antioxidant diet and placebo pill.
3187474|NCT00756405|Active Comparator|Supplement Group|Usual diet and antioxidant supplement.
3187475|NCT00756405|Placebo Comparator|Placebo|Usual diet and placebo pill.
3187476|NCT00756418|Experimental|1|
3187477|NCT00756418|Active Comparator|2|
3187478|NCT00756431|Active Comparator|Screw without HA Coating (Hiploc)|
3187479|NCT00756431|Experimental|Screw with HA Coating (Hiploc)|
3187480|NCT00756483||M, 1|Male patients that have undergone total knee replacement
3187481|NCT00756483||F, 1|Female patients that have undergone total knee replacement
3187482|NCT00756483||M, 2|Male patients that have undergone total hip replacement
3187483|NCT00756483||F, 2|Female patients that have undergone total hip replacement
3187484|NCT00756509|Experimental|nilotinib|nilotinib
3187485|NCT00756535|Experimental|1|Group-based exercise training during hospitalization
3187486|NCT00756535|Active Comparator|2|Usual treatment and rehabilitation during hospitalization
3187487|NCT00756587|Active Comparator|I|Group one received feeding by bottle as the standard method of feeding in the NICU
2428517|NCT03377114|Active Comparator|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
2428518|NCT03377114|Experimental|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
2428519|NCT03377101|Active Comparator|Arm I (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses and palbociclib PO on days 1-21. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
2428520|NCT03377101|Experimental|Arm I (fulvestrant, palbociclib, copanlisib)|Patients receive fulvestrant IM on days 1 and 15 of course 1 and day 1 of subsequent courses, palbociclib PO on days 1-21, and copanlisib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in absence of disease progression or unacceptable toxicity.
2428521|NCT03377088|Placebo Comparator|Almond Oil|Patients will be given Almond Oil for inhalation on cotton balls as a control. Almond Oil has been shown to act as a placebo when compared to our variable, Rosa Damascena oil. To ensure blinding, this arm will act to always deliver a scent to a patient, blinding them to whether they are receiving a known aromatherapy or a common scent.
2428522|NCT03377088|Experimental|Rose Oil|Patients will be given Rosa Damascena oil on cottons balls as a variable. This oil has been shown to significantly lower acute pain levels on the visual analog pain scale when compared to placebo of distilled water or Almond Oil.
2428523|NCT03377075||Healthy subjects|
2428525|NCT03377049|Experimental|Acetazolamide Challenge|Participants entered into the study as a cohort, will because of their participation, undergo only two additional digital subtraction angiogram (DSA) imaging acquisitions. These will be done in conjunction with their standard diagnostic DSA evaluation and consist of two CBCTPs, one before and one after administration of 1 g acetazolamide through a peripheral IV line. Each CBCTP will require administration of 75-100 mL iodinated contrast medium also through an intravenous line. Neither of these imaging studies will be used for clinical decision making, but would be processed and evaluated at later date for a formal analysis of the results. Following completion of diagnostic imaging subjects will receive the usual standard of care for treatment of their ruptured aneurysm i.e. endovascular embolization or open surgical clipping.
2428526|NCT03377036|Experimental|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
2428527|NCT03377036|Active Comparator|2D-FFDM|2D full-field digital mammography
3146787|NCT00109785|Experimental|PET Scans|The first group of positron emission tomography (PET) scans is performed within 2 weeks before the first dose of chemotherapy. The second group of PET scans occur no more than 7 weeks after chemotherapy and prior to local therapy, either surgery or radiation therapy. The PET scan before initiation of chemotherapy consists of 4 imaging sessions. There is one iodine I-124 iododeoxyuridine (IUdR) PET scan (3 imaging sessions) at 1, 4-8, and 24 hours after IUdR infusion, followed by one fludeoxyglucose (FDG) PET scan (1 imaging session) 45 minutes after FDG infusion.
3146788|NCT00109798|Experimental|Temozolomide, Topotecan|Patient will take on days 1-5 of a 28-days schedule. Take Topotecan on days 2-6 of the 28 day schedule
3146789|NCT00109811|Experimental|Treatment|Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.
2428531|NCT03377010||Hematopoietic Stem Cell Transplant (HSCT) Survivor|Study participants will be administered a Dietary Intake - Food Frequency Questionnaire and a Receptivity to Participating in Diet Interventions Questionnaire.
2428532|NCT03376997|Experimental|Perampanel: 30-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 milligram (mg) dose of perampanel intravenous (IV) infusion (30-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2428533|NCT03376997|Experimental|Perampanel: 60-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2428534|NCT03376997|Experimental|Perampanel: 90-minute IV infusion and 12 mg oral tablet|Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (90-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
2428535|NCT03376984|Active Comparator|Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. For all the patients into the control arm of the study, the root canals will be filled with gutta percha (current standard of care), using the vertical condensation obturation technique (standard of care RCT technique).
2428536|NCT03376984|Experimental|ND and Amox modified Gutta Percha|Subjects in both arms of the study will be receiving standard of care RCT and routine follow-up examinations/assessments at 6 months, 1 year, and 2 years post RCT. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, gutta percha modified with nanodiamonds and amoxicillin (NDGX) will be used for the middle and coronal thirds.
3146790|NCT00109824|Experimental|Arm I|Patients receive decitabine IV over 1 hour on days 1-5 or 1-10. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3146791|NCT00109824|Experimental|Arm II|Patients receive decitabine as in stage 1 and valproic acid PO TID on days 5-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3146792|NCT00109863|Experimental|Hu14.18-IL2 Treatment|Hu14.18-IL2 will be given on days 1, 2, and 3 of each course of therapy as a 4 hour continuous IV infusion at a daily dose of 6 mg/m2. Treatment courses will be repeated every 28 days at the same dose.
2428538|NCT03376958|Experimental|Apatinib|Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
2428539|NCT03376945||trail cohort|n-3 FAs
2428540|NCT03376945||control cohort|Structolipid
2428541|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (100/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FF/UMEC/VI (100/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol metered dose inhalers (MDIs) as a rescue medication throughout the study.
2428542|NCT03376932|Experimental|Subjects receiving FF/UMEC/VI (200/62.5/25) mcg+ CIS|Eligible subjects will receive SITT of FF/UMEC/VI based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FF/UMEC/VI (200/62.5/25) mcg inhalation powder via ELLIPTA DPI, once daily in the morning or evening with the CIS. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2428543|NCT03376932|Active Comparator|Subjects receiving FP/SAL(250/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving mid-dose of ICS during pre-study will be administered with FP/SAL (250/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2428544|NCT03376932|Active Comparator|Subjects receiving FP/SAL(500/50) mcg + TIO 5 mcg|Eligible subjects will receive MITT of FP/SAL+ TIO based on their pre-study ICS dosage strength (mid- or high-dose). Subjects receiving high-dose of ICS during pre-study will be administered with FP/SAL (500/50) mcg inhalation powder via DISKUS DPI with sensor, twice daily given in the morning or evening plus TIO 5 mcg via RESPIMAT inhaler without sensor, once daily in the morning or evening. Subjects will also receive albuterol/salbutamol MDI as a rescue medication throughout the study.
2428545|NCT03376919|Experimental|CLs++|CLs ++ gait training
2428546|NCT03376906|Experimental|Obese Subjetcs|The subjects were welcomed for a visit to the Laboratory of Studies of Physical Training Applied to Health, where they performed an evaluation of body composition, maximal ergospirometric exercise test, and three experimental sessions (HIIE 1, HIIE 3 and Control) in a random order, which were performed with a 96 h interval between them.
2428547|NCT03376893||SCA with overt stroke|Participants have sickle cell disease and a history of overt stroke.
2428548|NCT03376893||SCA with silent stroke|Participants have sickle cell disease and a history of silent stroke.
2428549|NCT03376893||SCA with no stroke|Participants have sickle cell disease and no history of stroke.
2428550|NCT03376880||Obese Boys|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
2428551|NCT03376880||Obese Girls|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.
2428552|NCT03376880||Normal Weight Boys|Normal weight boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
2428553|NCT03376880||Normal Weight Girls|Normal weight girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI between 16th and 84th percentile.
2428554|NCT03376880||Obese Boys Misdiagnosed with Asthma|Obese boys group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
2428555|NCT03376880||Obese Girls Misdiagnosed with Asthma|Obese girls group defined by a Tanner score ≤ 3 in 8-12 yr olds with a BMI > 95th percentile, which will be expressed as a percentage above the 95th percentile < 150% of the 95th percentile.This group will have a prior diagnosis of asthma without confirmation by lung function testing.The absence of asthma will be confirmed by a negative response (<10% increase in FEV1) to spirometry before and after bronchodilator (and on visit 2 by a negative bronchial challenge test [<10% decrease in FEV1]; i.e., EVH).
2428556|NCT03376867||Healthy volunteers|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
2428557|NCT03376867||Volunteers with chronic pain|Conditioned pain modulation (2 stimuli test: heat and pressure points) before and after conditioning stimuli (cold water bath).
2428558|NCT03376854|Experimental|Hypothermia + Neuromuscular blockade|Deep sedation and Neuromuscular blockade (NMB) and surface temperature management to maintain core temperature between 34 and 35°C for 48h, then rewarm to 36°C at 0.33°C per h and NMB discontinued when core temp reaches 35.5°C.
2428559|NCT03376854|Active Comparator|Standard of care|Acetaminophen and surface temperature management to maintain core temperature between 37°C and 38°C. Rewarming to 37°C for hypothermia ≤36°C with continuous renal replacement therapy.
2428560|NCT03376841|Experimental|Severe hepatic impairment|Cenicriviroc tablet; single-dose oral administration
2428561|NCT03376841|Experimental|Normal Hepatic function|Cenicriviroc tablet; single-dose oral administration
2428562|NCT03376828|Active Comparator|Hypertensive T group|Hypertensive T group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) Macintosh laryngoscopy using intubated
2428563|NCT03376828|Active Comparator|Hypertensive VL group|Hypertensive VL group: Patients participating in the study were randomly assigned hypertensive (preoperative systolic blood pressure <180 mmHg and diastolic blood pressure <100 mmHg) C-Mac Videolaryngoscope using intubated
2428564|NCT03376828|Sham Comparator|Non-hypertensive T group|Non-hypertensive T group: (Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg) Macintosh laryngoscopy using intubated
2428606|NCT03376685|Experimental|Sprint Exercise Training (SIT)|This group is performing SIT training for 6 weeks in duration. Intervention: Behavioral: Sprint Exercise Training (SIT)
2428565|NCT03376828|Sham Comparator|Non-hypertensive VL group|Non-hypertensive VL group: Preoperative systolic blood pressure < 140 mmHg and diastolic blood pressure < 100 mmHg C-Mac Videolaryngoscope using intubated
2428566|NCT03376815||prostate ,traditional sample method|Samples from 100 patients with prostate carcinoma were obtained by traditional sampling method
2428567|NCT03376815||prostate ,landscape sample method|Samples from 100 patients with prostate carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428568|NCT03376815||liver, traditional sample method|Samples from 100 patients with liver cancer were obtained by traditional sampling method.
2428569|NCT03376815||liver,landscape sample method|Samples from 100 patients with liver cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428570|NCT03376815||esophageal ,traditional sample method|Samples from 100 patients with esophageal carcinoma were obtained by traditional sampling method.
2428571|NCT03376815||esophageal ,landscape sample method|Samples from 100 patients with esophageal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428572|NCT03376815||GIST,traditional sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by traditional sampling method.
2428573|NCT03376815||GIST,landscape sample method|Samples from 100 patients with gastrointestinal stromal tumor were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428574|NCT03376815||colorectal ,traditional sample method|Samples from 100 patients with colorectal carcinoma were obtained by traditional sampling method.
2428575|NCT03376815||colorectal ,landscape sample method|Samples from 100 patients with colorectal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428576|NCT03376815||pancreatic ,traditional sample method|Samples from 100 patients with pancreatic carcinoma were obtained by traditional sampling method.
2428577|NCT03376815||pancreatic,landscape sample method|Samples from 100 patients with pancreatic carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428578|NCT03376815||lung cancer,traditional sample method|Samples from 100 patients with lung cancer were obtained by traditional sampling method.
2428579|NCT03376815||lung cancer,landscape sample method|Samples from 100 patients with lung cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428580|NCT03376815||Renal ,traditional sample method|Samples from 100 patients with renal carcinoma were obtained by traditional sampling method.
2428581|NCT03376815||Renal carcinoma,landscape sample method|Samples from 100 patients with renal carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428582|NCT03376815||Breast cancer,traditional sample method|Samples from 100 patients with breast cancer were obtained by traditional sampling method.
2428583|NCT03376815||Breast cancer,landscape sample method|Samples from 100 patients with breast cancer were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428584|NCT03376815||cervical ,traditional sample method|Samples from 100 patients with cervical carcinoma were obtained by traditional sampling method.
2428585|NCT03376815||cervical ,landscape sample method|Samples from 100 patients with cervical carcinoma were obtained by landscape sampling method to testify the clinical value and significance of tumor landscape pathological diagnosis .
2428586|NCT03376802|Experimental|SAR425899|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 19 days
2428587|NCT03376802|Placebo Comparator|Placebo|Repeated once daily SC doses of placebo administered over 19 days
2428588|NCT03376789|Active Comparator|MYL-1501D (Process V Product)|MYL-1501D (Process V Product)
2428589|NCT03376789|Active Comparator|MYL-1501D (Process VI Product)|MYL-1501D (Process VI Product)
2428590|NCT03376776||Eyes with epiretinal proliferation|The eyes with epiretinal proliferation around the macular hole detected with optical coherence tomography
2428591|NCT03376776||Eyes without epiretinal proliferation|The eyes without epiretinal proliferation around the macular hole detected with optical coherence tomography
2428594|NCT03376750|Experimental|CO - OP via telerehabilitation + standard care|10 CO-OP videoconferencing sessions from an occupational therapist . Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
2428595|NCT03376750|Experimental|CO - OP via face to face + standard care|10 CO - OP face to face sessions from an occupational therapist. Each session will be utilized to guide the participants to achieve their self-identified goals, focusing on problem-solving for daily life situations and on the ability to implement the discussed strategies for a variety of activities.
2428596|NCT03376750|No Intervention|control group - standard care|standard care as given from public health service
2428597|NCT03376737|Experimental|Apatinib + Pemetrexed|Apatinib + Pemetrexed
2428598|NCT03376724|Experimental|Functional exercise|
2428599|NCT03376724|Active Comparator|Control Group|
2428600|NCT03376711|No Intervention|Standard Care Group|Participants in this arm of the study will not have access to the online peer support program until the end of the 12-week trial.
2428601|NCT03376711|Experimental|Online Peer Support Program|Participants in the online peer support program arm of the intervention will have access to the website for 12 weeks.
2428602|NCT03376698|Active Comparator|Colchicine 0.5 mg|
2428603|NCT03376698|Active Comparator|Colchicine 0.25 mg|
2428604|NCT03376698|Placebo Comparator|Placebo|
2428605|NCT03376685|Experimental|Endurance Exercise Training (END)|This group is performing END training for 6 weeks in duration. Intervention: Behavioral: Endurance Exercise Training (END)
2428607|NCT03376672|Experimental|Ixazomib,lenalidomide,dexamethasone|Ixazomib capsules 4Mg Oral capsule on days 1, 8 and 15 in 28d cycle, lenalidomide 25 milligram capsules on days 1-21 in 28d cycle, dexamethasone 40 milligram capsules on days 1, 8, 15, 22 in 28d cycle
2428608|NCT03376672|Experimental|High risk maintenance arm|Ixazomib capsules 4Mg Oral capsule on days 1, 8, 15, lenalidomide 10 milligram on days 1-21 in 28d cycle
2428609|NCT03376672|Experimental|Standard and low risk maintenance arm|Lenalidomide
2428613|NCT03376646|Experimental|Cohort A: Dissolve™|
2428614|NCT03376646|Active Comparator|Cohort A: Resolute™ Integrity|
2428615|NCT03376646|Experimental|Cohort B: Dissolve™-2.00mm|Cohort B is single arm.
2428616|NCT03376633|No Intervention|Control group|These youth will not receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2] or after, and will not have contact with WOW clinicians. Control youth will be able to receive all other services available through their school as they normally would, such as access to the school counselor and after school programs.
2428617|NCT03376633|Experimental|WOW Group and Individual Counseling|These youth will receive Working on Womanhood (WOW) services during academic years 2017-18 and 2018-19 [Cohort 1] or 2018-19 and 2019-20 [Cohort 2]. These young women will participate in weekly group therapy and skill-building sessions, led by master's level clinicians, and will also receive individual support and therapy from their clinicians as-needed.
2428618|NCT03376620|Sham Comparator|10% Urea cream|Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
2428619|NCT03376620|Active Comparator|Active cream with 1,4 diaminobutane|Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
2428620|NCT03376607|Experimental|Intervention group 1|Intervention group 1 will receive access to the newly-established HBCP programme.
2428621|NCT03376607|Experimental|Intervention group 2|Intervention group 2 will receive access to the newly-established HBCP programme, and facilitated access to a mobile health application.
2428622|NCT03376607|No Intervention|Control group|The control group will receive routine practice.
2428623|NCT03376594|Active Comparator|Benjakul Extract|Benjakul Extract 100 mg capsule by mouth 3 times a day for 42 days
2428624|NCT03376594|Placebo Comparator|Loratadine|Loratadine 10 mg capsule by mouth 3 times a day for 42 days
2428625|NCT03376581|Experimental|Prospective treatment|
2428626|NCT03376568||Narcolepsy with RBD & Control|Narcolepsy with REM sleep disorder lable(20) and Control subjects lable(20)
2428627|NCT03376568||Narcolepsy with /without RBD|Narcolepsy with REM sleep disorder lable(20) and Narcolepsy without REM sleep disorderlable (20)
2428628|NCT03376555|Active Comparator|Baseline|Subjects on normal personal diet Acetylcholine (ACh) Dose Response, Local heating (LH), and Flow Mediated Dilation with nitroglycerin experiments
2428629|NCT03376555|Experimental|Low Sodium, No Cheese|"Diet contains 1,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2428630|NCT03376555|Experimental|Low Sodium, Cheese|"Diet contains 1,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2428631|NCT03376555|Experimental|High Sodium, No Cheese|"Diet contains 5,500 mg sodium per day Diet does not contain dairy cheese~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2428632|NCT03376555|Experimental|High Sodium, Cheese|"Diet contains 5,500 mg sodium per day Diet contains 6 oz dairy cheese per day~After 8 days on diet:~Acetylcholine Dose Response, Local heating, and Flow Mediated Dilation with nitroglycerin experiments"
2428633|NCT03376542|Experimental|Cardiopulmonary exercise testing|All patients included in the study will perform cardiopulmonary exercise testing prior to surgery
2428634|NCT03376529|Experimental|SPR741/Ceftazidime (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + ceftazidime1.0 gram IV over 1 hour, and ceftazidime 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
2428635|NCT03376529|Experimental|SPR741/Piperacillin/tazobactam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + piperacillin/tazobactam 4.5 grams IV over 1 hour, and piperacillin/tazobactam 4.5 grams IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
2428636|NCT03376529|Experimental|SPR741/Aztreonam (N=9)|Nine (9) participants will be enrolled and assigned to receive SPR741 400 mg IV over 1 hour, SPR741 400 mg IV over 1 hour + aztreonam 1.0 gram IV over 1 hour, and aztreonam 1.0 gram IV over 1 hour in a randomized sequence. One treatment will be administered during each of 3 dose periods within the assigned treatment arm.
3187488|NCT00756587|Experimental|II|Group 2 received all feeding by cup
2428638|NCT03376503|Experimental|Pegcyte (Nanogen pegfilgrastim)|pegcyte 6 mg in the first cycle
2428639|NCT03376503|Active Comparator|Neulastim (Roche pegfilgrastim)|Neulastim 6 mg in the first cycle
2428640|NCT03376477|Experimental|Lenalidomide plus GM-CSF Vaccine plus Prevnar13|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Prevnar vaccine will be administered with the GM-CSF vaccine administration."
2428641|NCT03376477|Placebo Comparator|Lenalidomide Only|Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment. Patients will also get placebo GM-CSF vaccine and placebo prevnar13. Placebo will be saline.
2428642|NCT03376477|Placebo Comparator|Lenalidomide plus GM-CSF Vaccine|"Patients will continue on a standard dose of lenalidomide as a single agent until progression, or treatment limiting toxicity, following enrollment.~Patients assigned to vaccine therapy will receive injections on day 14 (+/-3 days) of cycles 1, 2, 3 and 6 from enrollment, and then annually thereafter. Patients will also be administered a placebo prevnar13 vaccination. Placebo will be saline."
2428643|NCT03376464|Experimental|single injection technique (SIT)|40 U of Xeomin Cosmetic delivered directly into the region where the three masseter heads overlap.
2428644|NCT03376464|Experimental|multi-injection technique (MIT)|A distribution of 40 U (8 U distributed in 5 different areas) of Xeomin Cosmetic over the width of the masseter while respecting the upper limit of the anterior border of the masseter and the inferior insertion of the masseter. The injections are separated by a 1cm distance and the dose is equally distributed across these sites.
2428645|NCT03376451|Other|Patients in EndoSearch|EndoSearch will conduct on only one cohort divided in two groups : patients affected by endometriosis and patient unaffected (controls). All of these patients need a laparoscopic surgery for endometriosis indication (endometriosis group) or another indication which is not endometriosis (controls). However, nothing in the surgery or the patient medical care will be different between the two groups : patients will be treated exactly the same.
2428646|NCT03376438||Prospective observational cohorts|1) Atrial flutter without fetal hydrops; 2) Atrial flutter with fetal hydrops; 3) Supraventricular tachycardia without fetal hydrops; and 4) Supraventricular tachycardia with fetal hydrops
2428647|NCT03376412|Experimental|Single Arm Treatment.|All patients will be unilaterally implanted in the non-dominant eye with the Raindrop Near Vision Inlay for the compensation of presbyopia.
2428648|NCT03376386|Other|HNSCC receiving (chemo)radiotherapy|Imaging
2428649|NCT03376373|Experimental|active|Neurofeedback for FER
2428650|NCT03376373|No Intervention|control|waiting list
2428651|NCT03376347|No Intervention|Conventional arm|Institutional Standard of Care with intention to keep MAP> 65 mmHg. The FlotracIQ will be connected, but fully covered.
2428652|NCT03376347|Active Comparator|Treatment arm|FlotracIQ with HPI algorithm.
2428653|NCT03376334|Experimental|Motor Imagery (MI)|Those meeting the inclusion criteria were selected (n=22). Each participant was necessary to complete the Movement Imagery Questionnaire in a quiet room. Finally, each participant assigned a score by using a 7-point scale regarding the ease/difficulty associated with representing each movement mentally. Next their baseline balance measurement was performed using the SEBT. Later this group had 9 motor imagery sessions, each session for 15 minutes, 3 sessions (alternate days) per week for a total of 3 weeks. Reassessment of balance was done after every 3 sessions.
2428654|NCT03376334|No Intervention|Control (C)|Those meeting the inclusion criteria were selected (n=10). Baseline measurement of SEBT was done on day 1, end of week 1, end of week 2 and end of week 3.
3187489|NCT00756626|Experimental|1|Intervention group receives bottle weaning intervention from WIC nutritionist
3187490|NCT00756626|No Intervention|2|Control standard of care
2428657|NCT03376308||Group 1|"Venous diameter measurements were made via the USG in the hand dorsum. Transverse venous diameter ≤2mm was defined group 1.~Anesthesia induction drugs were all treated in the same order and dose. Pain score, withdrawal movement score and hemodynamic response was recorded."
2428658|NCT03376308||Group 2|"Venous diameter measurements were made via the USG in the hand dorsum.Transverse venous diameter >2mm was defined group 2.Anesthesia induction drugs were all treated in the same order and dose.~Pain score, withdrawal movement score and hemodynamic response was recorded."
3187491|NCT00756639|Experimental|Radiation|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks. On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
2428660|NCT03376282|Other|HBOT treatment|HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
2428661|NCT03376282|No Intervention|Standard treatment|follow up with the standard recommended treatment
2428662|NCT03376269|Active Comparator|Combined HBOT/psychotherapy|combined concurrent intervention of HBOT and creative art psychotherapy.
2428663|NCT03376269|Other|psychotherapy|single intervention with creative art psychotherapy
3187492|NCT00756691||1|First 5 consecutive 18F-FAZA avid subjects that undergo up to 5 PET scans, 13 blood and 2 urine samples over 4.5 hours
3187493|NCT00756691||2|Next 5 consecutive 18F-FAZA avid subjects that undergo up to 4 PET scans, 8 blood and 2 urine samples over 5.5 hours
3187494|NCT00756704|No Intervention|Baseline Period|
3187495|NCT00756704|Experimental|Intervention Period|
3187496|NCT00756743|Experimental|PF-04802540|
3187497|NCT00756743|Placebo Comparator|Placebo|
3187498|NCT00756756|Experimental|1|post MI post PCI and G-CSF infusion
3187499|NCT00756756|Placebo Comparator|2|post MI and post PCI only placebo infused
3187500|NCT00756769||1|Patients with SLE
3187501|NCT00756769||2|Related unaffected controls
3187502|NCT00756769||3|Unrelated unaffected controls
3187503|NCT00756782|Experimental|A|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days
3187504|NCT00756782|Placebo Comparator|B|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
3187505|NCT00756795|Experimental|Attention Control|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Patient will be taught how to keep the Activity diary to record walking and physical activities.~Structured Interview will be conducted at baseline and post-intervention. All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis"
3187506|NCT00756821||SMA cohort|Subjects between the ages of 2-12 years diagnosed with SMA Type I, II, or III.
2428666|NCT03376243|Experimental|Emollient (LIPIKAR BAUME AP+)|Daily application of Lipikar Baume AP+ emollient AND Structured parent education
2428667|NCT03376243|No Intervention|Control|Only structured parent education
2428668|NCT03376230||Control patients|
2428669|NCT03376230||Crohn's disease patients|
2428670|NCT03376230||Ulcerative colitis patients|
2428671|NCT03376217|No Intervention|Control|IPTp delivered at antenatal clinic
2428672|NCT03376217|Experimental|Intervention|IPTp delivered by HSAs
2428673|NCT03376204||Adult subjets|Adult subjets diagnosed with bronchiectasis by high-resolution computed tomography with symptomatology in stable phase, matched by by sex and age with healthy subjects.
2428674|NCT03376178|Experimental|six-hole group|lidocaine and ropivacaine injection through catheters
2428675|NCT03376178|Active Comparator|end-hole group|lidocaine and ropivacaine injection through catheters
3146793|NCT00109889|Other|MRI and PET|Magnetic resonance imaging and positron emission tomography
3146794|NCT00109941|Experimental|metenkephalin, OGF-opioid growth factor|DRUG All subjects treated with met-enkephalin (also called OGF) 250 ug/kg iv weekly over 45 minutes
2428678|NCT03376139|Experimental|Zonisamide (up to 400 mg/day)|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
2428679|NCT03376139|Placebo Comparator|Placebo|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
2428680|NCT03376126||MI-ILP|
2428681|NCT03376113|Experimental|VHS group|Patients will be asked to make links between critical situations and appropriate solutions in the volitional help sheet (VHS).
2428682|NCT03376113|No Intervention|Control group|Patients will be asked to read the VHS. This is an active control group. That means all patients in this study will be exposed to situations and solutions in the VHS.
2428683|NCT03376100|Active Comparator|Control Group|Patients with distal forearm fractures randomized to Hematoma Block.
2428684|NCT03376100|Active Comparator|Intervention Group|Patients with distal forearm fractures randomized to Ultrasound guided nerve block
2428685|NCT03376074|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 2 hours
2428686|NCT03376074|Active Comparator|Conventional cold storage|
2428689|NCT03376048|Experimental|Wound infiltration plus TAP|Wound infiltration placed by surgeon + TAP-LAP placed laparoscopically guided by surgeon
2428690|NCT03376048|Active Comparator|Wound infiltration|Wound infiltration placed by surgeon
2428691|NCT03376035|Active Comparator|Unilateral breast reconstruction|Temperature measurements are obtained from the reconstructed breast and compared to the non-reconstructed breast.
2428692|NCT03376035|Experimental|Bilateral breast reconstruction|Temperature measurements are obtained from both reconstructed breasts and the core temperature is measured as well for comparison.
2428693|NCT03376009||Liver transplant assessment patients|"Adult patients admitted to the Scottish Liver Transplant Unit for liver transplant assessment, over a 6 month study period will be considered for recruitment.~Interventions:~Blood sample for serum and plasma biomarkers:~Urine sample for biomarkers Cardiac bio-impedance (Cardioscreen Medis) Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor) Optical Coherence Tomography (Spectralis OCT) Arterial Spin Labelling Magnetic Resonance Imaging"
2428694|NCT03375996||FLACS group|Patient presenting cataract and scheduled for laser-assisted cataract surgery
2428695|NCT03375983|Experimental|Blood-stage infection of P.vivax|This is a single arm study that plans to enroll 20 patients and each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1.0 × 10^7 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last 3-6 months from the day of successful infection and will be terminated by antimalarial drugs.
2428696|NCT03375970|Experimental|Collaborative Care of TCM and Western Medicine|
2428697|NCT03375970|Active Comparator|Western Medicine|
2428698|NCT03375957|Experimental|ATx201 2% Gel|
2428699|NCT03375957|Experimental|ATx201 4% Gel|
2428700|NCT03375957|Placebo Comparator|ATx201 Gel Placebo|
2428701|NCT03375944|No Intervention|control group|Cardiac supervision
2428702|NCT03375944|Other|study group|Cardiac supervision and rehabilitation
2428703|NCT03375931|Experimental|prayer group|
2428704|NCT03375931|Active Comparator|non-prayer group|
2428705|NCT03375918|Other|Healthcare Trainees - Cluster 1|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2428706|NCT03375918|Other|Healthcare Trainees - Cluster 2|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2428707|NCT03375918|Other|Healthcare Trainees - Cluster 3|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2428708|NCT03375918|Other|Healthcare Trainees - Cluster 4|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
3146795|NCT00110032|Experimental|Group 1 (fluorine F 18 EF5, PET)|Patients receive fluorine F 18 EF5 (^18F-EF5) IV followed by whole brain and whole body PET scanning OR whole body PET scanning only. Patients then receive nonradioactive EF5 IV over 1-2 ½ hours.
3146796|NCT00110032|Experimental|Group 2 (EF5, PET)|Patients receive nonradioactive EF5 IV over 1-2½ hours followed by ^18F-EF5 IV. Patients then undergo whole brain and whole body PET scanning.
3146797|NCT00110032|Experimental|Group 3 (EF5, PET)|Patients receive nonradioactive EF5 and ^18F-EF5 as in group 2. Patients then undergo whole brain PET scanning.
2428709|NCT03375918|Other|Healthcare Trainees - Cluster 5|Within each academic year, trainee clusters are randomized to 1 of 5 start date training times for Other: CONSULT-BP Educational Intervention. Each arm has a pre-intervention (control) period and a post-intervention (exposure) period.
2428710|NCT03375905|Experimental|cNEP|cNEP treatment
2428711|NCT03375892|Active Comparator|Prone Position with DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
2428712|NCT03375892|Active Comparator|Supine Position with DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
2428713|NCT03375892|Active Comparator|Prone Position with no DIBH|For prone positioning, patients will be positioned with alpha cradle casts, and a prone breast board.
2428714|NCT03375892|Active Comparator|Supine Position with no DIBH|For the supine positioning, patients will be positioned with the breast board currently in use in the Department of Radiation Oncology.
2428715|NCT03375879|Active Comparator|Bandage contact lens|Placing a bandage contact lens in one eye.
2428716|NCT03375879|No Intervention|Sham contact lens (immediate removal)|Sham contact lens will be placed on other eye, placing it and immediately removing it so patient does not know which eye will have a bandage contact lens.
2428717|NCT03375866|Active Comparator|Pretzels|
2428718|NCT03375866|Experimental|Mixed nuts|
2428719|NCT03375853|Active Comparator|Control Condition|Participants will complete computer based response training tasks that will incorporate pictures of birds, flowers, and mammals. As part of the computer based training, participants will be instructed to respond or inhibit response to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the experimental condition, only the appearance and context of the stimuli will be different (i.e., non-food versus food items). The computer tasks described above comprise the Generic Response Training Control Intervention.
2428720|NCT03375853|Experimental|Experimental Condition|"Participants will complete computer-based response training tasks that will incorporate pictures of healthy food, unhealthy food, and glasses of water. As part of the computer-based training, participants will be instructed to respond or inhibit responses to certain of these stimuli in order to bring about a change in the participant response to certain stimuli. These tasks will be structured identically to those presented in the control condition, only the appearance and context of the stimuli will be different (i.e., food versus non-food items). The computer tasks described above comprise the Computer Based Response Training Weight Loss Intervention. To optimize the intervention, we narrowed the low-calorie food stimulus set to make a better distinction between high-calorie and low-calorie foods and we changed the filler images (water and furry mammals) in the go/no-go task from 100% go to 50% go and 50% no-go to measure learning of stimulus-specific respond associations."
2428721|NCT03375840|Experimental|Text-only PWL, immediate post|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2428722|NCT03375840|Experimental|Text-only PWL, delay posttest|"Exposure to 9 FDA-mandated warning labels~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2428723|NCT03375840|Experimental|Low-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2428724|NCT03375840|Experimental|Low-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited little emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2428725|NCT03375840|Experimental|High-emot PWL, immediate posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered immediately following last exposure to warning labels"
2428726|NCT03375840|Experimental|High-emot PWL, delay posttest|"Exposure to 9 warning labels paired with image that elicited high emotion~Posttest measures (e.g., memory, risk perceptions, quit intentions) administered 6 weeks after last exposure to warning labels"
2428727|NCT03375827|Experimental|Survey QOL|"Study participants will be provided with the Individualized Goals of Care Discussion Guide (IGCDG) consisting of a brief pamphlet and the IGCDG questionnaire.~Participants will be asked to complete the IGCDG questionnaire prior to their next visit.~Participants will also complete an 8-week follow-up survey after the clinic visit to evaluate the impact on patient satisfaction with care, communication, and care received."
2428728|NCT03375814|Experimental|Experimental group|The group that takes the main drug. They received the conventional treatment group and crocin.
2428729|NCT03375814|Placebo Comparator|Placebo group|The group that takes the Placebo.
2428730|NCT03375801|No Intervention|control group/pre intervention|the first 164 patients will receive care as usual and will make the decision together with their clinician without support of the decision aid. They will be asked to fill out the questionnaires.
2428731|NCT03375801|Experimental|intervention arm|another 164 patients will receive the decision aid as support for the decision making process with their clinician.
2428732|NCT03375788|Experimental|Tesamorelin|tesamorelin (brand name Egrifta) 2mg daily given subcutaneously
2428733|NCT03375788|Placebo Comparator|Placebo|identical placebo given subcutaneously daily
2428734|NCT03375775|Experimental|Treatment group|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
2428735|NCT03375775|Active Comparator|Control group|No immunotherapy, symptomatic treatment These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
2428736|NCT03375762|Experimental|Usual care plus RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Remote ischemic perconditioning (RIPerC) using an electronic tourniquet.
2428737|NCT03375762|Sham Comparator|Usual care plus Sham RIPerC|Usual care for stroke code patients, with or without revascularization therapies, with Sham remote ischemic conditioning (RIPerC)
2428808|NCT03375229|Active Comparator|Group Off|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be directly on the trigger point. The intervention will be administered one time.
2429063|NCT03373617||General anesthesia group|Patients in general anesthesia group are scheduled to undergo RIRS under general anesthesia.
2428738|NCT03375749|Experimental|Standing Desk Intervention|Each participant allocated to the experimental group will receive a low-cost, cardboard, fixed-height standing desk converter (https://oristand.co/) that will be placed in their regular office environment, along with their usual sitting desk. The participants will be instructed on how to use the fixed-height standing desk converter (herein referred to as standing desk) as a way to break up sitting time every 30 minutes. In addition, each participant will be provided with information about the health benefits of breaking up sitting time.
2428739|NCT03375749|Other|Waitlist Control|Control group participants will not encounter any changes to their regular office environment. They will be provided with the standing desk and behaviour change strategies 6-months post-intervention.
2428740|NCT03375736|Experimental|Intervention arm|Whole body vibration will be provided by an equipment, GalileoTM Med L Plus (Novotech Medical GmbH). The study participant will stand still on the vibration platform with both knees slightly flexed.
2428741|NCT03375723|Experimental|Information on anatomy and physiology, and breathing technique|"Information on anatomy and physiology, and breathing technique~Information about anatomy~Information about physiology~Breathing technique"
2428742|NCT03375723|Active Comparator|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
2428743|NCT03375710|Experimental|Cordella™ Heart Failure System|Cordella™ Heart Failure System and implant of Cordella™ Pulmonary Artery Sensor System (CorPASS)
2428744|NCT03375697|Experimental|SAD (Part 1): Healthy Subjects|In Part 1, single ascending intravenous (IV) doses of JNJ-63733657 or placebo will be administered to sequential cohorts (Cohorts 1 to 5) of healthy subjects on Day 1. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. Here, SAD indicates single ascending dose.
2428745|NCT03375697|Experimental|MAD (Part 2): Subjects With Alzheimer's Disease (AD)|In Part 2, multiple ascending IV doses of JNJ-63733657 or placebo will be evaluated at three dose levels in sequential cohorts in subjects with prodromal or mild AD; 3 doses will be administered over a period of 8 weeks (Day 1, Day 29, Day 57). The starting dose will be decided based on the data from Part 1. Escalations will be done based on safety and tolerability similar to Part 1. Doses will not exceed those tested in Part 1. Here, MAD indicates multiple ascending dose.
2428746|NCT03375684|Active Comparator|Control Group|Patients in this group will receive conventional chest physiotherapy, two times a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
2428747|NCT03375684|Experimental|Training Group|In addition to conventional chest physiotherapy programme, patients in this group will also receive inspiratory muscle training for 15 minutes, twice a day, 7 days a week for 8 weeks. One exercise session will be supervised in a clinic per week, other sessions will be performed at home.
2428748|NCT03375671|Experimental|Ketamine|Single administration of Ketalar® (ketamine hydrochloride injection, USP); 5 mg/kg, IM
2428749|NCT03375671|Active Comparator|Midazolam + haloperidol|Single administration of combination of: Midazolam injection (5 mg, IM) and haloperidol injection (5mg, IM)
2428750|NCT03375658|Experimental|Intervention arm|All vital signs registered as part of usual care are used for modelling patients state and trajectories and made available to clinicans via the Patient Deterioration Warning System in nursing and physician offices.
2428751|NCT03375658|No Intervention|Control arm|Usual care
2428752|NCT03375632|Experimental|Uric acid-overproduction Type|
2428753|NCT03375632|Experimental|Uric acid-underexcretion Type|
2428754|NCT03375619||Participants who received CAR-20/19-T cells.|Participants who received CAR-20/19-T cells in study NCT03019055.
2428755|NCT03375606|Experimental|CSL730|
2428756|NCT03375606|Placebo Comparator|Placebo|
2428757|NCT03375593|Experimental|Narcotic|Hydrocodone 5mg/Acetaminophen 500 mg Tab
2428758|NCT03375593|Experimental|Non Narcotic|Ibuprofen 600mg Tab + acetaminophen 500 mg Tab
2428759|NCT03375580|Placebo Comparator|TLC group|transform life custom (TLC) group
2428760|NCT03375580|Active Comparator|TLC + metformin group|transform life custom (TLC) combined with 0.5g metformin, PO tid
2428761|NCT03375580|Experimental|TLC + CZT capsules group|transform life custom (TLC) combined with 2.52 Compound Zhenzhu Tiaozhi capsules (four tablets), PO tid
2428762|NCT03375580|Active Comparator|TLC + simvastatin group|transform life custom (TLC) combined with 20mg simvastatin, PO qn
2428763|NCT03375567|Experimental|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
2428764|NCT03375567|Active Comparator|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
2428765|NCT03375541|No Intervention|Control|Natural discussion of disease modifier selection conducted without augmentation by risk aversion calculator
2428766|NCT03375541|Experimental|Calculator|Natural discussion of disease modifier selection conducted with augmentation by risk aversion calculator
2428767|NCT03375528|Experimental|coronary artery disease patients|To define the Matrix metalloproteinases expression level in the neointimal hyperplasia induced by DES implantation
2428768|NCT03375515|Experimental|PCA IV Hydromorphone titration|PCA titration using programmable pump: bolus hydromorphone at 0.5mg (for opioid intolerance) or hydromorphone dose equivalent to 10% to 20% of the total opioid taken in the previous 24 hours with a lockout time 15 min (for opioid tolerance) was administered by the patients educated. No basal infusion was set in the pump.Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The titration will be done on the patient's request (manipulation by the patient himelf/herself) in 24hrs.
2428809|NCT03375229|Placebo Comparator|Placebo group|This group was composed of 14 subjects. The application of dry needling and LLLT turned off will be 1.5 cm medially from the trigger point. The intervention will be administered one time.
2428769|NCT03375515|Active Comparator|non-PCA IV Hydromorphone titration|Non-PCA titration administered by a nurse or clinician: Initial hydromorphone doses were same with PCA titration. Repeated assessment of NRS score with a interval of 15 minutes until stable pain control. Then Repeated assessment of NRS score with a interval of 1 hour. The dose of hydromorphone increased by 50%-100% if pain unchanged or increased, or repeat same dose if pain decrease to 4-6. The titration will be done on the patient's request (manipulation by a nurse) in 24hrs.
2428770|NCT03375502|Experimental|MG1111(Varicella vaccine)|A single injection of 0.5ml MG1111 will be administered subcutaneously at Visit 1
2428771|NCT03375502|Active Comparator|Comparator(Varicella vaccine)|A single injection of 0.5ml comparator will be administered subcutaneously at Visit 1
2428772|NCT03375489|Experimental|Telehealth|"Patients will meet with the PC clinician in person within four weeks of enrollment~Subsequent visits with the PC clinician will be conducted with the patients in their home or other location using video at least every four weeks~Patients may be scheduled to meet with the PC clinician in the clinic if requested by the patient or a clinician"
2428773|NCT03375489|Active Comparator|In Person PC|"Patients will be scheduled for their first In-person PC visit within four weeks of enrollment and then at least every four weeks thereafter until the patient is no longer coming into the clinic~PC visits will be scheduled on the same day as an oncology visit if possible"
2428774|NCT03375476||Vascular surgical patients|Patients undergoing elective vascular non-cardiac surgery in general anesthesia
2428775|NCT03375463|Experimental|Tirzepatide Test Part A|SC dose of tirzepatide solution formulation
2428776|NCT03375463|Experimental|Tirzepatide Reference Part A|SC dose of tirzepatide lyophilized formulation
2428777|NCT03375463|Experimental|Tirzepatide Formulation Part B|IV dose of tirzepatide formulation
2428778|NCT03375463|Experimental|Tirzepatide Part C|Titrated SC doses of tirzepatide solution formulation
2428779|NCT03375463|Placebo Comparator|Placebo Part C|SC dose of placebo matching tirzepatide dose
2428780|NCT03375450||Observation|Cohort of patients with COPD
2428782|NCT03375424||1st subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced Vedolizumab (VDZ) therapy (n=1.800). A former therapy with other biologics is allowed. More than 30% of these Vedolizumab patients will be biologics-naiv.
2428783|NCT03375424||2nd subpopulation|IBD-patients (age at enrollment: 18-80 years) receiving a newly introduced anti-TNF-alpha therapy other than VDZ (n=350) in biologics-naiv patients.
2428784|NCT03375424||3rd subpopulation|IBD patients (age at enrollment: 18-80 years) with an early disease (n=350), who were first diagnosed <2 years before the start of documentation in the Investigator initiated non-interventional study (NIS) but have not yet received and are not planned to receive biologics in the near future.
2428785|NCT03375411|Experimental|INC1-Bare metal stent|Percutaneous coronary implantation of the device (Stent INC-1) following the standard procedure of stent placement
2428786|NCT03375398|Experimental|3 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 3 tablets Sugardown™
2428787|NCT03375398|Placebo Comparator|Rice only|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice
2428788|NCT03375398|Experimental|6 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of white rice consumed with 6 tablets Sugardown™
2428789|NCT03375385|Other|Hemodynamic parameters|
2428790|NCT03375385|Other|Ramsay sedation score|
2428791|NCT03375385|Other|Intraoperative side effects|
2428792|NCT03375385|Other|recovery of sedation|
2428793|NCT03375372|Active Comparator|Group 1 (Treatment Group)|Subjects receive intervention of Scaling and Root Planing (S&RP) procedure under local anesthesia, plus a specified Oral Hygiene Regimen (OHR)
2428794|NCT03375372|No Intervention|Group 2 (Delayed treatment)|Subjects have delayed treatment scaling and root planing procedure and OHR at 36 weeks (Final visit) These subjects are not followed beyond completion of the treatment.
2428795|NCT03375359||cfDNA screening|Pregnant women who are referred for FTS or for further follow-up examinations in case of a suspected anomaly or increased nuchal translucency at 11-13 weeks' gestation can be recruited for this study.
2428796|NCT03375346|Experimental|Whole body vibration group|Whole body vibration group performed a single session of whole body vibration exercise via a vibrating platform (Galileo® Advanced Plus, Novotec Medical, Pforzheim, Germany) with a magnitude of 20 Hz and an amplitude of 4 mm.
2428797|NCT03375346|Active Comparator|Exercise only group|The control group performed the same session without vibration.
2428798|NCT03375333||20GPs|20 general practitioners, who use ultrasound in the examination of patients.
3146798|NCT00110071|Experimental|Treatment (chemoradioimmunotherapy)|Patients receive a dosimetric dose of iodine I 131 tositumomab IV over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV QD on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0.
3146799|NCT00110110|Experimental|CEV Chemo + Cyclosporine & Focal Therapy|Systemic carboplatin (28 mg/kg/dose), etoposide (12 mg/kg/dose) and vincristine sulfate (0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated) chemotherapy given with cyclosporin A (33 mg/kg/dose). Following 4-6 cycles CEV chemotherapy (depending on tumor stage) given every 3 weeks, focal laser therapy and/or cryosurgery are applied for tumor consolidation. Filgrastim is given after each chemotherapy cycle to prevent severe neutropenia.
2428804|NCT03375281|Experimental|No touch group|RFA for small HCC would be done by using no touch technique
2428805|NCT03375255|Experimental|SRP-5051|"Patients will be sequentially assigned to receive 1 of the 5 escalating dose levels of SRP-5051 on Day 1.~Patients who complete the study and continue to meet safety eligibility criteria will have the opportunity to enroll in an open-label extension study to continue to receive SRP-5051."
2428806|NCT03375242||crizotinib|
2428807|NCT03375229|Active Comparator|Group On|This group was composed of 15 subjects. The application of dry needling and Low-Level Laser Therapy (LLLT) turned on will be directly on the trigger point. The intervention will be administered one time.
2428815|NCT03375203|Placebo Comparator|Placebo|Participants will receive matching placebo to JNJ-42847922 as oral capsules at normal study bedtime on Nights 1 through 14.
2428816|NCT03375203|Experimental|JNJ-42847922 5 milligram (mg)|Participant will receive JNJ-42847922 5 mg dose as oral capsules at normal study bedtime on Nights 1 through 14.
2428817|NCT03375203|Experimental|JNJ-42847922 10 mg plus Placebo|Participant will receive JNJ-42847922 10 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
2428818|NCT03375203|Experimental|JNJ-42847922 20 mg plus Placebo|Participant will receive JNJ-42847922 20 mg as oral capsule and one placebo capsule at normal study bedtime on Nights 1 through 14.
2428819|NCT03375203|Experimental|Zolpidem plus Placebo|Participants will receive Zolpidem 5 mg plus one placebo capsule or 10 mg dose as oral capsule at normal study bedtime on Nights 1 through 14.
2428820|NCT03375190|Experimental|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
2428821|NCT03375190|Experimental|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM, Devon, UK) at insertion site
2428822|NCT03375190|Experimental|Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
2428823|NCT03375190|Experimental|Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
2428824|NCT03375190|Experimental|Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
2428825|NCT03375190|Experimental|Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
2428826|NCT03375164|Experimental|Cohort A|Patients between 3 months to 3 years of age, will receive intravenous SRP-9001.
2428827|NCT03375164|Experimental|Cohort B|Patients between 4 to 7 years of age, will receive intravenous SRP-9001.
2428828|NCT03375151|Experimental|EEG based feedback|The therapist will give feedback to the participants during the exercise based on their performance.and use the feedback from the EEG analyzed data to direct cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
2428829|NCT03375151|Other|Standard practice based feedback|The therapist will give feedback to the participants during the exercise based on their performance.
2428830|NCT03375151|Other|No feedback|The participants will perform the exercise without feedback during practice.
2428831|NCT03375138|Experimental|Process E PPQ belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
2428832|NCT03375138|Experimental|Process C belatacept|10 mg/kg, single dose by intravenous (IV) infusion.
2428833|NCT03375125|Experimental|Probiotic|L. reuteri DSM 17938 + L. reuteri ATCC PTA 5289), dose of 2x10^8 Colony Forming Units (CFU). One lozenges will be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day
2428834|NCT03375125|Placebo Comparator|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
2428835|NCT03375112|Experimental|Fascia Iliaca Compartment Block|A Fascia Iliaca Compartment Block will be administered in the block room.
2428836|NCT03375112|Placebo Comparator|Control|The patients will be brought back to the block room, prepped, and a blunt needle will be touched to the skin. A band aid will be applied over the site.
2428837|NCT03375099|Experimental|Lethal Means Counseling|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners.
2428838|NCT03375099|Active Comparator|Lethal Means Counseling plus Gun Locks|National Guard Personnel will receive a single 15-25 minute session of lethal means counseling. The session will focus on increasing the safety of current storage practices for personal firearms (e.g., storing unloaded in a secure location separate from ammunition) as well as planning to voluntarily and temporarily store firearms away from the home during any future hypothetical suicidal crisis. This intervention utilizes a motivational interviewing framework in an effort to remain sensitive to the views and culture of firearm owners. Individuals in this condition will also receive a free gun (cable) lock for each of their personal firearms.
2428839|NCT03375099|Active Comparator|Health and Stress Reduction|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework.
2428881|NCT03374826|Experimental|Dedicated axillary hybrid PET-MRI axilla|
2428882|NCT03374813|Experimental|MimetikOss|Ridge preservation bone grafting after tooth extraction
2428883|NCT03374813|Active Comparator|Bio-Oss|Ridge preservation bone grafting after tooth extraction
2428840|NCT03375099|Active Comparator|Health + Stress Reduction plus Gun Locks|Individuals in this condition will take part in a single 15-25 minute session focused on reducing health vulnerabilities in one of four areas: diet, exercise, sleep, or stress. This condition is designed to control for the effects of active interaction with a clinicians (e.g. common factors). As with the experimental condition, this session will utilize a motivational interviewing framework. Individuals randomized to this condition will also receive a free gun (cable) lock for each of their personal firearms. This will control for whether the effect of the provision of gun locks is accounted for by the simultaneous use of lethal means counseling.
2428841|NCT03375086|Experimental|Single arm|Patients will receive APX3330 orally, twice per day until disease progression
2428842|NCT03375073|Experimental|Positive communication|Positive communication during medical transmission
2428843|NCT03375073|No Intervention|Non-optimized communication|Medical transmission with non-optimized communication.
2428844|NCT03375047|Experimental|Low Dose|8 mg MRT5005
2428845|NCT03375047|Experimental|Low/Mid Dose|12 mg MRT5005
2428846|NCT03375047|Experimental|Mid Dose|16 mg MRT5005
2428847|NCT03375047|Experimental|Mid/High Dose|20 mg MRT5005
2428848|NCT03375047|Experimental|High Dose|24 mg MRT5005
2428849|NCT03375047|Placebo Comparator|Placebo Comparator|Normal Saline 0.9% USP
2428850|NCT03375047|Experimental|Daily Dose|20 mg MRT5005 delivered in 5 consecutive daily doses of 4mg
2428851|NCT03375034|Experimental|NDMC 20mg|oral single dose
2428852|NCT03375034|Experimental|NDMC 60mg|oral single dose
2428853|NCT03375034|Active Comparator|Clonazepam 1.5mg|oral single dose
2428854|NCT03375034|Placebo Comparator|Placebo|oral single dose
2428855|NCT03375021|Experimental|Sequence 1 PL|Eligible subjects were randomized to Sequence 1 PL in which they received placebo (P) followed by crossover to CX717 200 mg low dose (L) of active treatment
2428856|NCT03375021|Experimental|Sequence 2 PH|Eligible subjects were randomized to Sequence 2 PH in which they received placebo (P) followed by crossover to CX717 800 mg High dose (H) of active treatment
2428857|NCT03375021|Experimental|Sequence 3 LP|Eligible subjects were randomized to Sequence 3 LP in which they received CX717 200 mg Low dose (L) of active treatment followed by crossover to placebo (P)
2428858|NCT03375021|Experimental|Sequence 4 HP|Eligible subjects were randomized to Sequence 2 PH in which they received CX717 800 mg High dose (H) of active treatment followed by crossover to placebo (P)
2428859|NCT03375008|Experimental|Imaging diagnostic and biopsy|47 subjects who are suspected NASH from June 2016 to December 2017.
2428862|NCT03374982|Experimental|DentalVibe On|DentalVibe will be turned on during local anesthetic injection at one appointment.
2428863|NCT03374982|No Intervention|DentalVibe Off|DentalVibe will be be turned off during local anesthetic injection at one appointment.
2428864|NCT03374969|Experimental|Attachment and Biobehavioral Catch-Up|
2428865|NCT03374969|Active Comparator|Developmental Education for Families|
3146800|NCT00110188|Experimental|Ridaforolimus|50 mg of ridaforolimis intravenously over 30 minutes, weekly
3146801|NCT00110227|Experimental|Tai Chi|12-week tai chi program
3146802|NCT00110227|Active Comparator|Heart Health Education|12-week attention control
2428869|NCT03374930|Other|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
2428870|NCT03374917|Experimental|ABBV-951|ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
2428871|NCT03374904|Active Comparator|Control Group|Patients in control group will attend to four session of Play Therapy plus inpatient treatment as usual during four weeks
2428872|NCT03374904|Experimental|Video Feedback|Once a week, after play therapy, individual or group video feedback session will be done.
2428873|NCT03374891|No Intervention|Participants will fill out surveys|These participants will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
2428874|NCT03374891|Active Comparator|Educational video and/or handout|These participants will receive an educational video and/or handout about the defibrillator process. Then they will fill out surveys in regard to their experiences, opinions, and knowledge of the defibrillator process.
2428875|NCT03374878|Experimental|oral contraceptive and training|Users of oral contraceptive training for 10 weeks
2428876|NCT03374878|Placebo Comparator|no oral contraceptive and training|Non-users of oral contraceptive training for 10 weeks
2428877|NCT03374865||Video-mediated consultation|Consultations using Facetalk videocommunication software
2428878|NCT03374865||Face-to-face consultation|Traditional face-to-face consultations
2428879|NCT03374852|Experimental|CPI-613 + mFOLFIRNOX|"CPI-613: 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port mFOLFIRNOX (given immediately after CPI-613 administration): Oxaliplatin (Eloxatin) at 65 mg/m2 given as a 2-hr IV infusion via a central venous port~Folinic acid at 400 mg/m2 given as a 90-min infusion immediately after oxaliplatin, and concurrently with irinotecan (Camptosar).~Irniotecan at 140 mg/m2 given as a 90-min IV infusion via a central venous port via a Yconnector.~Flurouracil (5FU) at 400 mg/m2 as bolus followed by a 46-hr infusion at 2400 mg/m2, starting immediately after completion of folinic acid and irinotecan"
2428880|NCT03374839|Experimental|TIL + IL-2 + Nivolumab|"A first cohort of 3 patients will be done to ensure that the combined treatment (TIL + IL-2 + Nivolumab) would not cause severe autoimmunity pathologies.~For this first cohort, a dose of 0.5 billion of TILs per injection will be administered. After the opinion of the Data and Safety Monitoring Committee (DSMC), the sponsor will make the decision of the second cohort of 8 patients who will receive between 1 and 20 billion of TIL."
3146803|NCT00110253|Experimental|S-Caine Peel|
3146804|NCT00110279|Experimental|1|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops.
3146805|NCT00110279|Experimental|2|One vaccination with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. This Arm will enroll 4 weeks after Arm 1. Enrolled volunteers must have participated in Arm 1.
3146806|NCT00110344|Experimental|Arm 1|
3146807|NCT00110344|Placebo Comparator|Arm 2|
3146808|NCT00110383|Experimental|1|Supervised therapy
2428886|NCT03374787|Experimental|Fusion sound processor|The sound processor picks up the sound and transfer it to the implant that convert the sound to vibrations that are transmitted to the inner ear.
2428887|NCT03374774||Participants with Type 2 Diabetes Mellitus|Participants will be prescribed and treated with commercially available BIAsp 30 according to routine clinical practice at the discretion of the treating physician, independent of this study. The study will gather data over the course of routine treatment on willingness to pay for BIAsp 30 in FlexPen® or Penfill®.
2428888|NCT03374761|Experimental|Families First Home Visiting Program|10 group sessions conducted weekly and 4 home visits for the duration of the program. Sessions and visits of the Families First Home Visiting Program cover child development, parenting skills, parent-child communications, and positive discipline practices. The intervention is delivered by para-professional community facilitators, trained in the program.
2428889|NCT03374761|No Intervention|Control Group|The control group receives the standard, government run, services provided by community health workers in West Java. Once the evaluation of the intervention arm is completed, participants in the control arm will be offered the intervention.
2428890|NCT03374735|Experimental|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
2428891|NCT03374722||Mechanically ventilated critically ill patients|Mechanically ventilated critically ill patients who receive opioid as continuous infusion for more than 24 hours
2428892|NCT03374709|Experimental|Treatment Group|This arm includes subjects who have been prescribed Oxtellar XR 150Mg Extended Release Tablets.
2428893|NCT03374696|Experimental|Intervention group|The intervention SAFETY was performed in school facilities by professional actors and staff from the municipality's youth guidance center within the county. The actors first enacted a play portraying youths and problems with condom use. Next, a value exercise was held by the youth guidance center staff. The class continued with chlamydia games held by the youth guidance center staff, providing information on symptoms, protection, how to get tested, treatment and consequences. The youth guidance center staff and the actors, playing students, then held a condom school. Lastly, the students came up with new endings to the play. All replays were enacted and the students gave feedback on the new endings. The class ended with condoms being handed out.
2428894|NCT03374696|Active Comparator|Control group|The intervention in the control group contained standard education from school staff, based on the sex education guidelines of the Swedish National Agency for Education. Students got education on human sexuality, reproduction, menstruation, love, sex, pregnancy and how STIs and unwanted pregnancy are prevented.
3187507|NCT00756821||Control cohort|Healthy children between the ages of 2-12 years. These children may be either genetically-related siblings of SMA children (genetically confirmed non-carriers of SMA),or unrelated children.
3187508|NCT00756834||Mammography Image Collection|Acquired images
3187509|NCT00756834||CAD Radiologist Reader|Retrospective reader study
2428898|NCT03374670|Experimental|Cohort 1|Zimura dosage 1 + Eylea 2 mg
2428899|NCT03374670|Experimental|Cohort 2|Zimura dosage 2 + Eylea 2 mg
2428905|NCT03374644|Experimental|ETCO2 monitoring with nasal cannula|SentriTM ETCO2 adult nasal cannula (Intersurgical ® code 1144002) will be placed into patient's nostril following radial artery catheter insertion. A baseline (without oxygen flow) ETCO2, PaO2, SPO2, RR and PaCO2 will be recorded. Oxygen will then be administered at 2,4, and 6 liters per minute for a period of five minutes.ETCO2, PaCO2 and PaO2 will be recorded for each level of oxygen administration.Sedation will be given during intra-operative period with the target of Observer Assessment of alertness/sedation scale (OAA/S) score of 3. During intraoperative period, oxygen will be administered at 2 and 4 liters per minute for a period of five minutes. ETCO2, PaCO2 and PaO2 level will be recorded during each level of oxygen administration.
2428906|NCT03374631|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing
2428907|NCT03374631|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing
2428908|NCT03374618|Experimental|systemic lupus erythematosus|adult with systemic lupus erythematosus
2428909|NCT03374618|Experimental|systemic sclerosis|adult with systemic sclerosis
2428910|NCT03374618|Other|healthy volunteers|healthy volunteer (adult)
2428911|NCT03374605|Experimental|Active tDCS|
2428912|NCT03374605|Sham Comparator|Sham tDCS|
2428913|NCT03374592|Active Comparator|Conventional Radiotherapy|8Gy in 1 fraction or 20Gy in 5 fractions
2428914|NCT03374592|Experimental|Volumetric Intensity-Modulated Arc Therapy|8Gy in 1 fraction or 20Gy in 5 fractions
2428915|NCT03374579|Experimental|CO2 gap|The patients will receive fluid bolus and observe changes in co2 gap and gap/ ratio in them.
2428916|NCT03374566||Screened patients|Immunodeficiency screening: Heparinized peripheral blood is obtained from patients with severe EBV infections for immunological function assays and genetic analysis, when current screening is performed after parents' information and consent.
2428917|NCT03374553|Experimental|MINIject 636 implant|"MINIject 636 implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
2428918|NCT03374540||Rivaroxaban|Patients who initiated Oral anticoagulant (OAC) treatment with rivaroxaban
2428919|NCT03374540||Vitamin K antagonist (VKA)|Patients who initiated OAC treatment with VKA
2428920|NCT03374527||Psoriasis|Patients with psoriasis vulgarism without clinical signs of PsA
2428921|NCT03374527||Psoriatic Arthritis (PsA)|Patients with a diagnosis of psoriatic arthritis and cutaneous psoriasis
2428922|NCT03374527||Control group|Healthy subjects
2428953|NCT03374306|Experimental|Atropine 0.01%|Group receiving atropine treatment for 18 months
3187510|NCT00756847|Experimental|1|
3187511|NCT00756860|Active Comparator|2|30 subjects will be randomized on Day -1
3187512|NCT00756860|Experimental|1|30 subjects will be randomized on Day -1
2428923|NCT03374514|Experimental|DEX|Topical dexamethasone will be placed at a concentration of 20mg / ml in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy in the cochlear implant surgery, paying special attention to the round window membrane completely submerged in the liquid, to the insertion of the electrode assembly
2428924|NCT03374514|Placebo Comparator|SF|Sterile isotonic saline solution will be placed in a single dose in the tympanic cavity of the middle ear through posterior tympanotomy during cochlear implant surgery, paying special attention to the fact that the round window membrane is completely submerged in the liquid, prior to insertion of the electrode array
2428925|NCT03374501|Experimental|2 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 2 tablets of Sugardown™
2428926|NCT03374501|Experimental|4 tablets Sugardown™|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink consumed with 4 tablets of Sugardown™
2428927|NCT03374501|Placebo Comparator|Soft drink|Repeated-measures, open cross-over design: 10 subjects consumed three different test meals comprising of soft drink
3146809|NCT00110383|No Intervention|2|Inhaled steroid use as usual care
3146810|NCT00110409|Experimental|1|Intervention participants will receive information focusing on asthma self-management, education, self-efficacy, and social support while in the hospital emergency room. Telephone reinforcement will occur for 8 weeks following study entry.
2428930|NCT03374475|Placebo Comparator|Lead-in period: Placebo|Participants who successfully complete the baseline examination visit at the clinical site/unit, will be treated with placebo (2 capsules taken orally) for the duration of the lead-in period which will last up to 3 weeks. Investigators and participants will be blinded to exact duration of each participant-specific lead-in period throughout the study.
2428931|NCT03374475|Experimental|Treatment period: JNJ-42847922 or Placebo|Placebo lead-in period responders and non-responders will be randomized to receive either placebo or 20 milligram (mg) JNJ-42847922 or 40 mg JNJ-42847922 for 5 Weeks. Participants will swallow JNJ-42847922 20 mg (2*10-mg capsules) or JNJ-42847922 40 mg (2*20-mg capsules) or 2 matching placebo capsules once daily for 5 Weeks.
2428932|NCT03374475|Placebo Comparator|Withdrawal period: Placebo|Participants who will complete the treatment period prior to the end of Week 8 will enter the withdrawal period where they will be treated with placebo (2 capsules taken orally) for the remaining time of the double-blind phase of the study. Investigators and participants will be blinded to exact duration of each participant-specific withdrawal period.
2428933|NCT03374462|Experimental|Telemedicine Intervention|All participants will receive the study intervention, which consists of home-based telemedicine visits with a diabetes specialist, at a frequency determined by the patient's degree of glycemic control (every 4, 6, or 8 weeks).
2428934|NCT03374449|Experimental|continuation of the RAS-inhibitors|in the continuation of the RAS-inhibitors arm the treatment will be continued until the morning the day of surgery.
2428935|NCT03374449|Active Comparator|discontinuation of the RAS-inhibitors|In this arm : discontinuation of the RAS-inhibitors 48 hours before surgery Patients won't receive the drug on the morning of the day of the surgery.
2428936|NCT03374436|Experimental|High-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals)
2428937|NCT03374436|Experimental|High-Carbohydrate Active|"Participants will remain seated for 9 hours (except for using the restroom) while consuming a high-carbohydrate diet (3 meals) but will complete 8 stair climbing sprint snacks once per hour involving ascending 3 flights of stairs at a vigorous pace (~20 seconds each)."
2428938|NCT03374436|Active Comparator|Low-Carbohydrate Sedentary|Participants will remain seated for 9 hours (except for using the restroom) while consuming a low-carbohydrate diet (3 meals)
2428939|NCT03374423|Active Comparator|intercostal nerve group|pulsed radiofrequency on intercostal nerves (2-5)
2428940|NCT03374423|Active Comparator|dorsal root ganglion group|pulsed radiofrequency on dorsal root ganglion (2-5)
2428941|NCT03374397|Active Comparator|SurgiGuard|Surgiguard Non-woven Drug : SurgiGuard Non-woven 6g during surgery
2428942|NCT03374397|No Intervention|Bipolar electrocauterization|Bipolar electrocauterization during surgery Drug(-)
2428947|NCT03374345|Experimental|SDT group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2428948|NCT03374345|Placebo Comparator|Placebo group|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
2428949|NCT03374332|Experimental|Treatment 1: Gemtuzumab Ozogamicin and DLI Dose Level 1|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients < 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^7 CD3+ cells and maximum of 2x10^7 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
2428950|NCT03374332|Experimental|Treatment 2: Gemtuzumab Ozogamicin and DLI Dose Level 2|"Patients ≥70 years old: GO 6mg/m2 (2mg/m2 each dose)~Patients: < 70 years old: GO 9mg/m2 (3mg/m2 each dose)~Day 8: The product will be administered unprocessed on day 8 (same day as leukapheresis) with a minimum of 1x10^8 CD3+ cells and maximum of 2x10^8 CD3+ cells/kg irrespective of the number of CD34+ cells.~Patients who show a transient response to therapy can receive up to two additional donor leukocyte infusions with GO 6mg/m2 (2mg/m2 each day, capped at 4.5mg) for all patients regardless of age administered on days 1,4, and 7, no sooner than 35 days status post their last cellular infusion."
2428951|NCT03374319|Experimental|Intervention group|Modified amputation procedure
2428952|NCT03374319|Active Comparator|Control group|Amputation procedure with TMR and/or RPNI construction
3146811|NCT00110409|Active Comparator|2|Participants in the control group will receive standard emergency room education about asthma.
3146812|NCT00110422|Experimental|A1|
3146813|NCT00110422|Active Comparator|B1|
3146814|NCT00110448|Active Comparator|1|Aspirin use
2428955|NCT03374293|Experimental|Experimental Group|Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
2428956|NCT03374280|Experimental|pemetrexed/cisplatin intercalating gefitinib|"pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 ;gefitinib 250mg d3-20d, to 4 cycles.~pemetrexed 500mg/m2 d1; gefitinib 250mg d2-20d to disease progression or untolerable"
2428957|NCT03374280|Active Comparator|pemetrexed/cisplatin|pemetrexed 500mg/m2 d1; cisplatin 30mg/m2 d1-2 to 4 cycles. pemetrexed 500mg/m2 d1 to disease progression or untolerable
2428958|NCT03374254|Experimental|Pembrolizumab + Binimetinib (Cohort A)|During Part 1, participants in Cohort A will receive a standard dose (DL1) of pembrolizumab (200 mg) intravenous (IV) every 3 weeks (Q3W) plus binimetinib orally at a starting dose of 30 mg twice a day (BID). Based on dose-limiting toxicities (DLT) assessed during the initial 21 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (Dose Level 2 [DL2]). Once a preliminary RP2D for binimetinib is identified in Part 1 for Cohort A, participants will receive pembrolizumab 200 mg IV Q3W plus binimetinib orally at the preliminary RP2D during Part 2.
2428959|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 (Cohort B)|During Part 1, participants in Cohort B will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus mFOLFOX7 (oxaliplatin 85 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; fluorouracil [5-FU] 2400 mg/m^2 over 46-48 hours) IV every 2 weeks (Q2W). Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of mFOLFOX7 may be de-escalated to oxaliplatin 70 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours] IV Q2W. Once a preliminary RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D during Part 2.
2428960|NCT03374254|Experimental|Pembrolizumab + mFOLFOX7 + Binimetinib (Cohort C)|After an RP2D for mFOLFOX7 is identified in Part 1 for Cohort B, participants may enroll in Cohort C and receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus mFOLFOX7 at the RP2D determined for Cohort B Q2W plus binimetinib orally at the RP2D determined for Cohort C in Part 1.
2428961|NCT03374254|Experimental|Pembrolizumab + FOLFIRI (Cohort D)|During Part 1, participants in Cohort D will receive a standard dose (DL1) of pembrolizumab 200 mg IV Q3W plus FOLFIRI (irinotecan 180 mg/m^2; leucovorin [calcium folinate] 400 mg/m^2; 5-FU 2400 mg/m^2 over 46-48 hours) IV Q2W. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of FOLFIRI may be de-escalated to irinotecan 150 mg/m^2; leucovorin (calcium folinate) 400 mg/m^2; 5-FU 2000 mg/m^2 over 46-48 hours) IV Q2W. Once a preliminary RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D during Part 2.
2428962|NCT03374254|Experimental|Pembrolizumab + FOLFIRI + Binimetinib (Cohort E)|After an RP2D for FOLFIRI is identified in Part 1 for Cohort D, participants may enroll in Cohort E and receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the preliminary RP2D Q2W in combination with binimetinib orally at a starting dose of 30 mg BID during Part 1. Based on DLTs assessed during the initial 28 days of Cycle 1, the dose of binimetinib may be escalated to 45 mg orally BID (DL2). Once a preliminary RP2D for binimetinib is identified in Part 1 for this cohort, participants in Part 2 will receive pembrolizumab 200 mg IV Q3W plus FOLFIRI at the RP2D determined for Cohort D Q2W plus binimetinib orally at the RP2D determined for Cohort E in Part 1.
2428963|NCT03374241|Experimental|Cohort 1|HM15211 or Placebo (single dose, subcutaneous injection)
2428964|NCT03374241|Experimental|Cohort 2|HM15211 or Placebo (single dose, subcutaneous injection)
2428965|NCT03374241|Experimental|Cohort 3|HM15211 or Placebo (single dose, subcutaneous injection)
2428966|NCT03374241|Experimental|Cohort 4|HM15211 or Placebo (single dose, subcutaneous injection)
2428967|NCT03374241|Experimental|Cohort 5|HM15211 or Placebo (single dose, subcutaneous injection)
2428968|NCT03374228|Experimental|BMS-986205|Single oral dose of BMS-986205 tablet on the morning of Day 1 followed by a 15-minute infusion of [13C]BMS-986205 solution for intravenous administration starting 01:45 hours after the oral dose administration
3146815|NCT00110448|Active Comparator|2|No aspirin use
3146816|NCT00110526|Experimental|Ad.hIL-12|
3146817|NCT00110552|Experimental|1|Sage capsules taken by mouth
3146818|NCT00110552|No Intervention|2|No intervention, no-pill as control
3146819|NCT00110591|Placebo Comparator|Placebo|Intravenous placebo for PRO 140
2428978|NCT03374163|Experimental|treatment group who recived intralipid|71 patients who recived intralipid on day of embryo transfer day, pregnancy day.
2428979|NCT03374163|No Intervention|control group|71 patient not recived intralipid
2428980|NCT03374150|Experimental|high protein|High protein (HP) group were given counseling about weight loss program by applying low calorie-high protein diet with diet menu composition of 22-30% protein, along with instructions for allowed cooking method.
2428981|NCT03374150|Active Comparator|standard protein|Active comparator receiving standard protein (SP) proportion were counseled about weight loss program by means of low calorie-balanced composition diet with menu comprised of 12-20% protein.
3146820|NCT00110591|Experimental|PRO 140 dose 1|0.1 mg/kg PRO 140 by intravenous infusion
2428983|NCT03374124||postoperational CRS|observe the symptoms and endoscopic appearance
2428984|NCT03374111|Experimental|Experimental group|15g of Colla corii asini granule( produced by Dong-E E-Jiao Co., Ltd) ， taken once daily for 8 weeks
3146821|NCT00110591|Experimental|PRO 140 dose 2|0.5 mg/kg PRO 140 by intravenous infusion
3146822|NCT00110591|Experimental|PRO 140 dose 3|2.0 mg/kg PRO 140 by intravenous infusion
3146823|NCT00110591|Experimental|PRO 140 dose 4|5.0 mg/kg PRO 140 by intravenous infusion
3146824|NCT00110656||Kidney Transplant|All patients entered into the study will have received a kidney transplant.
3146825|NCT00110669|Active Comparator|High Dose Prednisone|"Subjects who are randomized to the high-dose prednisone arm of the study will receive the following starting dose:~•Prednisone at 10.0 mg/kg/wk (divided into two doses given on Saturday and Sunday)"
3146826|NCT00110669|Active Comparator|Daily Prednisone|"Subjects who are randomized to the daily prednisone arm of the study will receive the following starting dose:~•Prednisone at 0.75 mg/kg/d"
2428985|NCT03374111|Placebo Comparator|Control group|a Simulate Agent of Colla corii asini granule， similar in size, shape，color and taste to Colla corii asini granule, taken once daily for 8 weeks
2428986|NCT03374098|Experimental|Education|Attend an hour-long classes once per week for three weeks
2428987|NCT03374098|Experimental|Home Visitation|Receive home visits that focus on the social determinants of health and attend hour-long classes once per week for three weeks
2428988|NCT03374085|Experimental|Administration of CC-92480 in combination with dexamethasone|Escalating doses of CC-92480 and in combination with a fixed dose of dexamethasone administered according to different dosing schedules
2428989|NCT03374085|Experimental|Administration of CC-92480 monotherapy|Escalating doses of CC-92480 Monotherapy administered according to different dosing schedules
2428990|NCT03374072|Experimental|Siblings FORWARD|Siblings who participate in the Siblings FORWARD program will participate in videoteleconference sessions with an Arc community provider. The content and format of the program is still being finalized. In the initial conception of the program, we proposed 6 sessions: Session 1 will focus on assessment and motivation (Sibling and adult with ASD). In Session 2, the sibling will learn family communication strategies. Session 3 will provide the sibling with information about adult services and how to navigate the service system. Session 5 will be a joint session with the family members with ASD. In the final session, the sibling will develop a plan of action outlining their involvement in family future planning.
2428991|NCT03374072|Active Comparator|Information Only Condition|We will create an information packet for siblings in the control condition. Siblings in the control condition will receive the same tip sheets and packet of information about resources for adults with ASD as those distributed in Session 3 of the Siblings FORWARD program.
2428992|NCT03374059|Experimental|Exercise|Exercise group received a home exercise program treatment for 4 weeks including isometric exercises for neck muscles and postural correction exercises for neck region.
2428993|NCT03374059|Experimental|Exercise and Life modification|This group received life modification suggestions additional to home exercise treatment program for 4 weeks.
2428994|NCT03374059|No Intervention|Control Group|Control group did not receive any treatments
2428995|NCT03374046|No Intervention|Control Group|Standard care
2428996|NCT03374046|Experimental|Apneic Oxygenation Group|"During apneic period of intubation attempt, patient will be placed on nasal cannula~If 0-2 years: 3L/min NC of 100% FiO2~If > or = to 2 through17 years: 5L/min NC of 100% FiO2"
2428997|NCT03374033|No Intervention|NUTR (Nutrition) 0_STIMUL(Stimulation) 0|Standard Nutrition and no Physical Stimulation
2428998|NCT03374033|Experimental|NUTR 0_STIMUL +|Standard Nutrition and Physical Stimulation
2428999|NCT03374033|Experimental|NUTR +_STIMUL 0|Enhanced Nutrition, and no Physical Stimulation
2429000|NCT03374033|Experimental|NUTR +_STIMUL +|Enhanced Nutrition and Physical Stimulation
2429001|NCT03374020||Intermediate AMD|
2429002|NCT03374020||Advanced AMD|
2429003|NCT03374020||DR without macular edema|
2429004|NCT03374020||DR with macular edema|
2429005|NCT03374007|Experimental|GB226 1mg/kg single-dose|Geptanolimab, 1mg/kg, i.v., single-dose
2429006|NCT03374007|Experimental|GB226 3 mg/kg single-dose|Geptanolimab, 3mg/kg, i.v., single-dose
2429007|NCT03374007|Experimental|GB226 10mg/kg single-dose|Geptanolimab 10mg/kg, i.v., single-dose
2429008|NCT03374007|Experimental|GB226 1mg/kg multiple dosing, every 2 weeks|Geptanolimab, 1mg/kg, i.v., q2w*6
2429009|NCT03374007|Experimental|GB226 3mg/kg multiple dosing,every 2 weeks|Geptanolimab, 3mg/kg, i.v., q2w*6
2429010|NCT03374007|Experimental|GB226 10mg/kg multiple dosing, every 2 weeks|Geptanolimab,10mg/kg, i.v., q2w*6
2429011|NCT03374007|Experimental|GB226 280mg multiple dosing|Geptanolimab, 280mg, i.v., q3w
2429012|NCT03374007|Experimental|GB226 3mg/kg multiple dosing|Geptanolimab, 3mg/kg, i.v., q2w
2429013|NCT03373994||18F-FDG PET/CT initial-time imaging|PET/CT imaging was underwent 5min after 18F-FDG injection.
2429014|NCT03373994||18F-FDG PET/CT balanced-time imaging|PET/CT imaging was underwent 60min after 18F-FDG injection.
2429015|NCT03373981|Experimental|intervention|rTMS
2429016|NCT03373968|Experimental|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2429017|NCT03373955||Immunotherapy,chemotherapy,radiotherapy|Pembrolizumab will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent.The peripheral blood will be collected at 3 weeks,2 months, 6 months,an average of 1 year
2429018|NCT03373942||Primary Open Angle Glaucoma (POAG)|The study included 30 eyes of 30 patients diagnosed with POAG who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
2429019|NCT03373942||Pseudoexfoliation Syndrome (PEX)|The study included 30 eyes of 30 patients diagnosed with PEX glaucoma who presented to Glaucoma Unit of İzmir Katip Çelebi University Atatürk Training and Research Hospital
2429020|NCT03373942||Control|The control group included 30 eyes of 30 healthy individuals with similar age distribution with POAG and PEX group
2429021|NCT03373929|Other|PFO Closure Rate|Evaluate closure rate of clinically relevant septal defects including PFO, ASD (less than 1 cm with redundant septal tissue), trans septal puncture sites, repair of ASA (when an appropriate PFO or small ASD defect is present) and rate of recurrent neurologic embolic event in patients with cryptogenic stroke and PFO
2429022|NCT03373929|Other|Published PFO Device Closure|Compare PFO closure rate and safety of closure of septal occluders in published PFO clinical trials.
2429023|NCT03373916|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will address protective factors such as hope and belongingness.
2429057|NCT03373669|Active Comparator|Shanchol Dose-interval Group 1|Participants in Dose-Interval Group 1 (DIG-1) will receive the oral cholera vaccine, Shanchol, according to the manufacturer instructions: in 2 doses at Day 0 and two weeks later (Day 14).
2429058|NCT03373669|Experimental|Shanchol Dose-Interval Group 2|Participants in Dose-Interval Group 2 (DIG-2) will receive the Adjusted Dose oral cholera vaccine, Shanchol, with a delayed second dose. The vaccine will be given at Day 0 and six months later.
3146827|NCT00110695|Experimental|A|
2429024|NCT03373916|Active Comparator|Enhanced Usual Care (EUC)|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
2429025|NCT03373903|Placebo Comparator|Placebo once daily for 16 weeks|
2429026|NCT03373903|Experimental|BEZ235 once daily for 16 weeks|
2429027|NCT03373903|Experimental|BEZ235 twice daily for 16 weeks|
2429028|NCT03373903|Experimental|BEZ235 plus RAD001 once daily for 16 weeks|
3187513|NCT00756873|Placebo Comparator|1|
3187514|NCT00756873|Experimental|2|Etoricoxib 90 mg qd.
2429031|NCT03373877|Experimental|Dose 1: PU-H71 225 mg/m2 + ruxolitinib|Cohort 1
2429032|NCT03373877|Experimental|Dose 2: PU-H71 300 mg/m2 + ruxolitinib|Cohort 2
2429033|NCT03373877|Experimental|Dose 3: PU-H71 400 mg/m2 + ruxolitinib|Cohort 3
2429034|NCT03373877|Experimental|Dose 4: PU-H71 600 mg/m2 + ruxolitinib|Cohort 4
2429035|NCT03373864|Experimental|Unilateral spinal anesthesia|In this arm, the patients will have a hypobaric lateral spinal anesthesia. Sedation can be added for the patients comfort.
2429036|NCT03373864|Active Comparator|General anesthesia|In this arm, the patients will have a general anesthesia.
2429037|NCT03373851||Zalviso|Patient willing to participate to the study, and scheduled for major functional surgery (arthroplasty, valgisation osteotomy, DIEP flap surgery, total body lift procedures) will be consented to use the Zalviso device in postoperative period as a main analgesia method.
2429038|NCT03373838||Census|Epidemiological study. Sociodemographic and medical survey.
2429039|NCT03373838||Qualitative interview|Individual qualitative interview.
2429040|NCT03373825|Experimental|Arm 1|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask participants to use the take-home rapid drug test to test their urine for presence or absence of fentanyl.
2429041|NCT03373825|Experimental|Arm 2|50 participants will receive a kit containing 10 Rapid Response fentanyl test strips. We will ask the participants to use the take-home rapid drug test to test the residue of their drug (ie. instruct them to test bags, cookers, spoons, etc.) for the presence or absence of fentanyl.
2429042|NCT03373812|Active Comparator|anterior approach|patients having involutional ptosis undergoing anterior approach surgical ptosis repair (Levator advancement)
2429043|NCT03373812|Active Comparator|posterior approach|patients having involutional ptosis undergoing posterior approach surgical ptosis repair (mullerectomy)
2429044|NCT03373799|Experimental|Group 1|Video-Based Rehabilitation Group
2429045|NCT03373799|Active Comparator|Group 2|Physiotherapist-Supervised Rehabilitation Group
2429046|NCT03373786|Experimental|RG-012 Single Dose|1.5 mg/kg RG012 subcutaneous injection
2429047|NCT03373786|Experimental|RG012 Every Other Week|1.5 mg/kg RG012 subcutaneous injections every other week
2429048|NCT03373773|Active Comparator|Home Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter at home."
2429049|NCT03373773|Active Comparator|Office Removal|"Patients will be randomly allocated to two groups: subjects in one group will remove their indwelling Foley catheter at home and will have voiding assessment remotely based on their voiding characteristics (a Force of Stream of >5/10 indicates that the patient has adequate bladder function), and the other group will follow up in the office for Foley catheter removal and voiding trial.~Subjects in this arm will remove the Foley catheter in a medical office."
2429050|NCT03373760|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1 for courses 1-4 and durvalumab IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2429051|NCT03373747|Experimental|Reliability of IET|In phase 1, the first of familiarization is to the participants understand the test and familiarize with the equipment after 24 to 48 hours, the participants will do the test applied twice at the same day with 10 minutes of rest. For realization of the IET the participants will be instructe to make the maximum effort as possible and mantain until they can't resiste. After one week the retest session will be doing. The order between the evaluators will be changed in the test and retest sessions.
2429052|NCT03373747|Experimental|Physiological analysis of IET|In phase 2, the participants will be submitted two sessions, familiarization session and test session. In the test session there is be two teste applied in the same day with approximately 20 minutes of rest. In the first test, thers is gas analysis during all the test until seven minutes after the test and blood lactat concentrate will be colected before the test with 10 minutes of rest, immediately after the teste and in the first, in the third, fifth and seventh minutes after the test. In the second test will be assess the muscular activation porcentage of lateral vastus muscle by means of twitch interpolation technique there is be performe before and after the test.
2429053|NCT03373708|Experimental|EC follow T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
2429054|NCT03373708|Experimental|TC follow endocrine|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for four cycles followed by goserelin acetate+tamoxifen for young patients/ letrozole for postmenopausal patients
2429055|NCT03373695|Experimental|Dissolve™|
2429056|NCT03373695|Active Comparator|SeQuent®Please|
2429059|NCT03373656|Experimental|low antibody titers|Antibody titers lower than protection level
2429060|NCT03373656|Other|high antibody titers|Antibody titers higher than protection level
3187515|NCT00756873|Experimental|3|Etoricoxib 120 mg qd. (day 0-7) Etoricoxib 90 mg qd. (day 8-14)
3187516|NCT00756899||Obese|Chilren with BMI of >95th percentile
3187517|NCT00756899||Non-obese|Children with BMI of <85th percentile
3187518|NCT00756912|Experimental|1|
2429064|NCT03373617||Spinal anesthesia group|Patients in spinal anesthesia group are scheduled to undergo RIRS under spinal anesthesia
2429065|NCT03373604|Experimental|Cognitive impairment|Alzheimer's disease (mild cognitive impairment or mild stage Alzheimer's disease dementia)
2429066|NCT03373604|Active Comparator|No cognitive impairment|Healthy controls
3187519|NCT00756925||1|Cocaine dependent females
3187520|NCT00756925||2|Cocaine dependent males
3187521|NCT00756951|Placebo Comparator|1|Placebo
2429070|NCT03373578|Active Comparator|earmuffs|Preterm newborns with earmuffs during the Quiet time
2429071|NCT03373578|No Intervention|control|Preterm newborns without earmuffs during de Quiet time
2429072|NCT03373565|Active Comparator|Radial|Coronary angiography using radial approach
2429073|NCT03373565|Experimental|palmar|Coronary angiography using palmar approach
2429074|NCT03373552||non responder Group|"Platelet function assay:~High platelet reactivity: PRU>208"
2429075|NCT03373552||responder Group|"Platelet function assay:~PRU<208"
2429076|NCT03373526|Active Comparator|Aerobic Physical Training|Aerobic Training
2429077|NCT03373526|Experimental|Combined Physical Training|Inspiratory Muscle Training Aerobic Training
2429078|NCT03373513|Active Comparator|Robotic single-site hysterectomy|Robotic single-site hysterectomy is performed in this arm
2429079|NCT03373513|Active Comparator|Multiport Laparoscopy|Multiport Laparoscopic hysterectomy is performed in this other arm
2429080|NCT03373500|Experimental|Low Salt Diet|Dietary salt reduction: Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
2429081|NCT03373500|No Intervention|Standard Treatment|Patients will be instructed to continue with their usual diet, therefore no advice will be given about salt reduction.
2429082|NCT03373487|Experimental|Early-intervention group|Patients follow the evidence-based cognitive rehabilitation program ReMind, which is provided via an iPad. It incorporates psychoeducation, strategy training and retraining. The intervention commenced 3 months after surgery and patients were advised to spend 3 hours per week on the program for 10 weeks.
2429083|NCT03373487|Other|Waiting-list control group|The waiting-list control group will be offered the same cognitive rehabilitation program after they have undergone all study assessments one year after surgery.
2429084|NCT03373474|Experimental|local distribution points association|Participants will receive warm acupuncture with the local distribution acupoints association on the affected arm only.
2429085|NCT03373474|Experimental|local-distal points association|Participants will receive warm acupuncture with the local-distal acupoints association on the affected arm, unaffected arm, abdomen, and legs.
2429086|NCT03373474|No Intervention|waiting-list|Patients in the waiting-list group will not receive any acupuncture treatment during the study. However, for ethical consideration, 20 free acupuncture treatments will be offered after the study is completed.
2429087|NCT03373461|Placebo Comparator|Placebo|Placebo to LNP023
2429088|NCT03373461|Experimental|LNP023 dose 1|Dose 1 of LNP023
2429089|NCT03373461|Experimental|LNP023 dose 2|Dose 2 of LNP023
2429090|NCT03373461|Experimental|LNP023 dose 3|Dose 3 of LNP023
2429091|NCT03373448|Active Comparator|Labrida BioClean|Labrida BioClean- chitosan device.The brush bristles of the test device (Labrida BioClean® LABRIDA AS, Oslo Norway) are made of the biopolymer chitosan. Any debris left from the chitosan bristles is completely biocompatible and will dissolve or be resorbed thus not causing harm to the tissues surrounding the implant. Chitosan is made from chitin derived from shell of marine crustaceans such as shrimp and crab, however chemically modified and thus not even considered to be animally derived. Chitosan has been approved for use in e.g., surgical bandages, as a haemostatic agent and as dietary supplement used in a wide range of nutritional and health products. Chitosan has also been documented to be non-allergenic and it has been suggested that chitosan has anti-inflammatory properties.
2429092|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided with titanium curettes.
2429093|NCT03373435|Experimental|Treatment Group 1|patients will receive two dose regimens of exendin 9-39 and one placebo
2429094|NCT03373435|Experimental|Treatment Group 2|patients will receive two dose regimens of exendin 9-39 and one placebo (in a different sequence than Treatment Group 1)
2429095|NCT03373422|Experimental|BAY1128688 (dose 1)|One BAY1128688 tablet (lowest dose) in the morning, one placebo tablet in the evening
2429096|NCT03373422|Experimental|BAY1128688 (dose 2)|One BAY1128688 tablet (first intermediate dose) in the morning, one placebo tablet in the evening
2429097|NCT03373422|Experimental|BAY1128688 (dose 3)|One BAY1128688 tablet (second intermediate dose) in the morning, one placebo tablet in the evening
2429098|NCT03373422|Experimental|BAY1128688 (dose 4)|One BAY1128688 tablet (second intermediate dose) in the morning and one in the evening
2429099|NCT03373422|Experimental|BAY1128688 (dose 5)|One BAY1128688 tablet (highest dose) in the morning and one in the evening
2429100|NCT03373422|Placebo Comparator|Placebo|One placebo tablet in the morning and one in the evening
2429101|NCT03373409|Experimental|Albuterol DPI 90mcg|Participants will receive albuterol 90mcg via the albuterol DPI
2429102|NCT03373409|Experimental|Albuterol DPI 180mcg|Participants will receive albuterol 180mcg via the albuterol DPI
2429103|NCT03373409|Active Comparator|Albuterol HFA MDI|Participants will receive albuterol 180mcg via the HFA MDI inhaler
2429104|NCT03373396|Other|Case group with Metavir score between F1 and F4|Patient with Metavir score between F1 and F4 will be assigned to the case group. Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
2429139|NCT03373175|Experimental|Ventilator 3 vs Ventilator 4|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed.Interventions: Basal record PS10 record PS15 record PS 20 record
3187522|NCT00756951|Active Comparator|2|SCV-07 at a dose of 0.02 mg/kg
3187523|NCT00756951|Active Comparator|3|SCV-07 at a dose of 0.10 mg/kg
3187524|NCT00756990|Experimental|Single group|Depot Naltrexone
3187525|NCT00757016|Placebo Comparator|B|0.99 ml saline solution 9mg/ml and 0.01 ml fat emulsion will be given once to the sacrospinous ligament insertion.
2429105|NCT03373396|Other|Control group with Metavir score of between F0|Patient with Metavir score of F0 will be assigned to the control group. Collected data will contain epidemiological and biological data. Blood samples with chlordecone dosage will be performed.
3187526|NCT00757016|Active Comparator|A|1 ml triamcinolone 20mg/ml (Lederspan), Meda AB, Solna, Sweden) and 1 ml lidocaine hydrochloride 10mg/ml (Xylocain), Astra Zeneca, Södertälje, Sweden)
3187527|NCT00757029|Other|open label|
3187528|NCT00757042|Active Comparator|AMG 157|Six subjects in each cohort (cohort 1 to 8) will receive AMG 157 in Part A 18 subjects in cohorts 9 and 10 (Part B) will receive AMG 157
3187529|NCT00757042|Placebo Comparator|placebo|2 subjects of each cohort (cohort 1 to 8) will receive placebo in Part A 6 subjects in cohorts 9 and 10 (Part B) will receive placebo
3187530|NCT00757055|Active Comparator|1|Patients on ivabradine titrated to heart rate
2429111|NCT03373357|Other|Patient not SAHOS|The medical follow-up of patients no SAHOS will be assured by the investigators of the unity of cardiovascular explorations: phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.
2429112|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|The patients who have a SAHOS sailed by the ventilation in PPC will be estimated and followed in 3 months then every 6 months by the investigators of the service of pneumology and the unity of cardiovascular explorations. The control of the material and its tolerance, the data supplied by the service providers (bodies of ventilation at home) will be estimated by the investigator of the service of pneumology. IDE the unity of cardiovascular explorations will plan and will realize a 2nd one MAPA after 3 months of ventilation in PPC.
2429113|NCT03373344|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
2429114|NCT03373344|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer."
2429115|NCT03373331|Experimental|Experimental Group|Participants in the experimental group will receive emotional processing training exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
2429116|NCT03373331|Placebo Comparator|Control Group|"Participants in the control group will meet with the examiner the same frequency and for the same duration as those in the experimental group.~They will receive placebo control exercises administered on a laptop computer.~."
2429117|NCT03373318|Experimental|Experimental|Human Albumin
2429118|NCT03373318|Active Comparator|Control|Plasmalyte
2429119|NCT03373305|Experimental|Treatment (brentuximab vedotin, lenalidomide)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-14. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2429120|NCT03373292|Experimental|Venous stenting (Group-1)|Patients in this group will undergo venous stenting treatment at once after enrollment.
2429121|NCT03373292|Experimental|Stenting one-month after routine medical treatment (Group-2)|Patients in this group will undergo routine medical treatment for one month, followed by venous stenting intervention.
2429122|NCT03373266|Active Comparator|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
2429123|NCT03373266|Active Comparator|isoflurane|anesthesia was maintained with isoflurane 1-2%.
2429124|NCT03373253||Participants With Diagnosis of Depression|This study will evaluate participant's socio-demographic, disease-related and treatment-related characteristics along with outcomes in routine clinical practice across the European region. Only data available within clinical practice, through routine therapeutic procedures and diagnostic assessments, will be recorded. Individual participant information will be recorded from participant's medical records or by use of specific questionnaires.
3187531|NCT00757055|Placebo Comparator|2|No therapy given
3187532|NCT00757068|Active Comparator|SBT|Women assigned to SBT (blue) will receive a six month program that offers to help them stay quit after having a baby.
2429127|NCT03373227|Experimental|Prospective|25 adult male or female recipients of a heart transplant will be prospectively enrolled to once-daily therapy with Envarsus tablets. Time of initiation will follow current standard of care.
2429128|NCT03373227|No Intervention|Retrospective|25 age/gender-matched subjects who are receiving twice daily dosing with Prograf will be identified from the transplant center database and contacted to be consented, after which their results will be analyzed retrospectively.
2429129|NCT03373214|Experimental|30 µg Na-GST-1 + CPG 10104|
2429130|NCT03373214|Experimental|100 µg Na-GST-1 + CPG 10104|
2429131|NCT03373214|Experimental|100 µg Na-GST-1|
2429132|NCT03373201|Experimental|Tasimelteon|
2429133|NCT03373201|Placebo Comparator|Placebo|
2429134|NCT03373188|Active Comparator|Arm I (surgery)|Patients undergo surgery.
2429135|NCT03373188|Experimental|Arm II (VX15/2503, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2429136|NCT03373188|Experimental|Arm III (VX15/2503, ipilimumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2429137|NCT03373188|Experimental|Arm IV (VX15/2503, nivolumab, surgery)|Patients receive anti-SEMA4D monoclonal antibody VX15/2503 IV over 60 minutes and nivolumab IV over 60 minutes on day 1. Beginning 22-36 days after administration, patients undergo surgery.
2429138|NCT03373175|Experimental|Ventilator 1 vs Ventilator 2|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record Pressure Support 10 (PS 10)record Pressure Support 15 (PS 15) record Pressure Support 20 (PS 20) record
3187533|NCT00757068|Experimental|CBT|Women assigned to CBT (pink) will receive a six month treatment designed to provide support and address the concerns of women who have just had a baby and do not want to resume smoking.
3187534|NCT00757081|Experimental|1|
3187535|NCT00757094||I|Patients planning to observe fasting while receiving chemotherapy during the month of Ramadan
3187536|NCT00757107|Experimental|Taperloc Microplasty|Patients with primary osteoarthritis with Taperloc microplasty non inferiority
2429140|NCT03373175|Experimental|Ventilator 5 vs Ventilator 6|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
2429141|NCT03373175|Experimental|Ventilator 7 vs Ventilator 8|2 Ventilators will be evaluated for patient. All parameters will be monitored and the differences will be analyzed. Interventions: Basal record PS10 record PS15 record PS 20 record
2429143|NCT03373149|Experimental|Growth hormone/HPuFSH/GnRH antagonist|The patients receive growth hormone
2429144|NCT03373149|Active Comparator|HPuFSH/GnRH antagonist|Growth hormone is not used
2429145|NCT03373136|Experimental|Cold snaring|Polypectomy will be done without electrocautery
2429146|NCT03373136|Active Comparator|Hot snaring|Polypectomy will be performed with electrocautery
2429147|NCT03373123|Experimental|Single arm study|Patients will receive CTA, Endoscopy, and rEndosc per protocol. Intervention: Procedure: Endoscopy
2429151|NCT03373097|Experimental|GD2-CART01|After a lymphodepleting regimen the patients will receive 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells.
3146828|NCT00110747|Experimental|S-Caine Peel|
2429153|NCT03373071|Experimental|CD19-CART01|Following the lymphodepleting treatment, with patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose
2429154|NCT03373058|Experimental|Experimental group|"Cytoreductive surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available.)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
2429155|NCT03373058|Active Comparator|Control group|"Cytoreductive surgery~6 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour(Docetaxel 75 mg/m^2, if paclitaxel is not available)+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks."
3146829|NCT00110747|Placebo Comparator|Placebo Peel|
3146830|NCT00110760|Experimental|S-Caine Peel|
3146831|NCT00110760|Placebo Comparator|Placebo Peel|
3146832|NCT00110773|Experimental|S-Caine Peel|
3146833|NCT00110773|Placebo Comparator|Placebo Peel|
3146834|NCT00110799|Active Comparator|Arm B|SB-497115-GR 30mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
2429162|NCT03373019|Experimental|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
2429164|NCT03372980||Case|
2429165|NCT03372980||Control|
2429166|NCT03372967||Comprehensive Vaccination History Review|Patients who receive a comprehensive vaccination history review at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
2429167|NCT03372954|Experimental|Bone marrow autologous cells concentrate (BMAC)|retrograde administration on non-selected BMAC via coronary sinus
2429168|NCT03372954|Placebo Comparator|Control|standard treatment o heart failure
3146835|NCT00110799|Active Comparator|Arm C|SB-497115-GR 50mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3146836|NCT00110799|Active Comparator|Arm D|SB-497115-GR 75mg administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3146837|NCT00110799|Placebo Comparator|Arm A|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
3146838|NCT00110877|Experimental|002|LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
3146839|NCT00110877|Experimental|001|TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV
3146840|NCT00110916|Experimental|Anakinra|anakinra
3146841|NCT00110916|Placebo Comparator|placebo|placebo
3146842|NCT00110942|Active Comparator|Minor sub-study AMG 108|N = 15
3146843|NCT00110942|Placebo Comparator|Minor sub-study placebo|N = 15
3146844|NCT00110942|Active Comparator|Main sub-study AMG 108|N = 73
3146845|NCT00110942|Placebo Comparator|Main sub-study placebo|N = 73
3146846|NCT00110955|Experimental|Darbepoetin alfa - Group A|
3146847|NCT00110955|Placebo Comparator|Placebo- Group B|
3146848|NCT00110981|Experimental|Single-arm|
3146849|NCT00111020|Experimental|Arm 1|
3146850|NCT00111085|Experimental|Clazosentan 1 mg/h|intravenous clazosentan at 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3146851|NCT00111085|Experimental|Clazosentan 5 mg/h|intravenous clazosentan at 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3146852|NCT00111085|Experimental|Clazosentan 15 mg/h|intravenous clazosentan at of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3146853|NCT00111085|Placebo Comparator|Placebo|intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
3146854|NCT00111098|Experimental|darbepoetin alfa|
3146855|NCT00111137|Active Comparator|rHuEPO|
3146856|NCT00111137|Experimental|Darbepoetin alfa|
3146857|NCT00111176|Other|1|Endovascular Repair
3146858|NCT00111176|Other|2|Surgical
3146859|NCT00111189|Experimental|001|Paliperidone Palmitate 25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
3146860|NCT00111189|Placebo Comparator|002|Placebo Placebo every 4 wk up to 24 mo
3146861|NCT00111254|Experimental|1|In group I, acute effect group, each subject will undergo microdermabrasion of the hip/buttock. Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device). 4mm punch biopsies will be performed in the treated area at 4hrs, 8hrs, and 24hrs post-treatment. In addition, one 4mm punch biopsy will be obtained from adjacent untreated skin.
2429173|NCT03372915|Active Comparator|Standard Exposure|This arm will receive exposure therapy conducted according to standard care practices.
2429174|NCT03372915|Experimental|Exposure + Inhibitory Learning|This arm will receive exposure therapy conducted according to principles of inhibitory learning.
2429175|NCT03372902||normal mammograms (BI-RADS 1 or 2)|
2429176|NCT03372902||suspicious lesion group (BI-RADS 4)|
2429177|NCT03372889|Active Comparator|Patient educaiton materials Print based|Patients are randomly assigned to view print based educational material.
2429178|NCT03372889|Active Comparator|Patient educaiton materials Media Based|Patients are randomly assigned to view media based educational material.
2429179|NCT03372876|Experimental|Protein-carbohydrate (PC) (protein intake after exercise)|ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon. The resistance exercise was performed equally by both groups.
2429180|NCT03372876|Placebo Comparator|Carbohydrate-protein (CP) (protein intake far to exercise)|ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. The resistance exercise was performed equally by both groups.
2429181|NCT03372863||Cardiac surgery patients|
2429182|NCT03372850|Experimental|Sequence Group 1|Period 1: Reference Drug(HGP1705) Period 2: Test Drug(HIP1601)
2429183|NCT03372850|Experimental|Sequence Group 2|Period 1: Test Drug(HIP1601) Period 2: Reference Drug(HGP1705)
2429184|NCT03372837|Experimental|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on Day 2 and Day 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
2429185|NCT03372824||Pregnant women|Primiparas above 25 years of age, singleton pregnancy
2429186|NCT03372811|Active Comparator|TC cream (10%)|
2429187|NCT03372811|Placebo Comparator|Vehicle|
2429188|NCT03372785||Complete revascularization group|Complete Revascularization of CTO and non-CTO lesions
2429189|NCT03372785||Non-CTO revascularization group|Non-CTO vessel revascularization
2429190|NCT03372772|No Intervention|Control group|Control group - patients with only levothyroxine therapy
2429191|NCT03372772|Experimental|Intervention group|Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy
2429192|NCT03372759|Active Comparator|study group air|airtamponade
2429193|NCT03372759|Sham Comparator|study group saline|saline
2429194|NCT03372746||1|Participants across multiple sites with AMD from the original cohort of study participants enrolled in the AREDS2
2429195|NCT03372733|Experimental|Group 1|Subjects randomized to the control olive oil arm will take the equivalent to 3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil
2429196|NCT03372733|Experimental|Group 2|Subjects randomized to the control olive oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the palmitoleate-rich oil arm will take the equivalent to3g of control /day in two divided doses (4 capsules a day) for 8 +/- 2 weeks and cross-over to the control olive oil
2429197|NCT03372720|Experimental|Arm I (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy at 3 time points 30 days apart.
2429198|NCT03372720|Sham Comparator|Arm II (sham laser therapy)|Patients undergo sham laser therapy at 3 time points 30 days apart. Patients may then crossover to Arm I.
2429199|NCT03372707|Experimental|Intervention Arm|Patients randomized to the intervention arm will have the results of the Cuff Leak Test (CLT) (whether failed or passed) communicated to the treating physician; the treating physician will decide whether to proceed with extubation or not based on the CLT results. It is at the discretion of the treating physician to provide corticosteroids (4-5 mg of intravenous dexamethasone every six hours for up to 24 hours, with the last dose given one hour preceding extubation) and/or delay extubation by 24 hours should the patient fail the CLT.
2429200|NCT03372707|No Intervention|Control Arm|In the control arm of this trial; the treating physicians and healthcare workers will be blinded to the results of the Cuff Leak Test (CLT); therefore, the Respiratory Therapist (RT) will proceed with extubation without delay or administering systemic steroid, regardless to the CLT results.
2429201|NCT03372694|Experimental|Chemotherapy+Training+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Rehabilitation training is mainly composed of gymnastic qigong, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
2429202|NCT03372694|Experimental|Chemotherapy+Education+TCM|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe, detoxication and resolving masses recipe. Patients will take harmonizing stomach recipe granules for the first week after chemotherapy and syndrome differentiation granules in TCM for second weeks from the end of chemotherapy. The patient will take TCM granules for 3 months."
2429203|NCT03372694|Placebo Comparator|Chemotherapy+Education+Placebo|"Adjuvant Chemotherapy is performed within 6 weeks after operation. Patients who received rehabilitation education will not accept rehabilitation training.~Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages. The patient will take placebo granules for 3 months."
2429204|NCT03372681|Experimental|Antiperistaltic|In this group patients undergo the distal gestrectomy with antiperistaltic Billroth II + Braun anastomosis
2429205|NCT03372681|Active Comparator|Isoperistaltic|In this group patients undergo the distal gestrectomy with isoperistaltic Billroth II + Braun anastomosis
2429206|NCT03372668|Other|All Participants|Each study participant will progress through the three, 4-week study periods in the ABA withdrawal design in the same, designated order. The first and third 4-week study periods (or the A periods) have no intervention and only consist of twice weekly data collection. The second 4-week study period (or the B period) will include the twice weekly delivered massage therapy combined with components of mirror therapy intervention.
2429207|NCT03372642||Subtalar endorthesis|Patients who underwent subtalar endorthesis for flexible pediatric flatfoot
2429208|NCT03372629|Experimental|ID-085, single ascending dose (Part A)|ID-085 administered at different single dose levels in a sequential manner, and in a maximum of 6 dose levels starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort)
2429209|NCT03372629|Placebo Comparator|Placebo, single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to ID-085
2429210|NCT03372629|Experimental|ID-085 multiple ascending dose (Part B)|ID-085 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be either 10 or 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A
2429211|NCT03372629|Placebo Comparator|Placebo, multiple ascending dose (Part B)|Matched placebo administered as single ascending doses in parallel to ID-085
2429212|NCT03372616||All participants|Aortic blood pressure, LV filling pressrue, and LV volume will be measured in all participants. Meanwhile, echocardiography and non-invasive aortic blood presure measurement will be performed. Three devices will be used in non-invasive aortic blood presure measurement, including Sphygmocor (AtCor Medical, Australia), PulsePen (DiaTecne SRL, Italy), and Mobil-O-Graph (IEM, Germany). In conclusion, all participants will receive invasive and non-invasive left ventricular diastolic function assessment, together with invasive and non-invasive aortic blood pressure assessment.
3187537|NCT00757107|Active Comparator|Taperloc Standard|Patients with primary osteoarthritis Taperloc standard
3187538|NCT00757120||1|This group will include current and former smokers who have emphysema.
2429215|NCT03372590|Experimental|NICU-based rehabilitation bundle|Patients identified to be at high risk for cerebral palsy will be enrolled after parental consent is obtained to the NICU rehabilitation program. This program consists of maternal-driven evidence based intervention that include: vocal soothing, scent exchange, comforting touch, kangaroo care, and infant massage. These intervention will be provided at GA-appropriate intervals.
2429216|NCT03372590|Other|Standard of care|Infants not participating in the intervention study will be provided with standard or care. Interventions include kangaroo care, physical therapy and infant massage provided by NICU staff.
2429217|NCT03372577|Experimental|patient and partner|
2429218|NCT03372577|Experimental|patient ,partner and cardiac rehabilitation team|
2429219|NCT03372577|Active Comparator|Treatment as usual|
3187539|NCT00757120||2|This group will include current and former smokers who do not have emphysema.
3187540|NCT00757133|Experimental|1|Conventional laparotomy closure
2429224|NCT03372538||multidisciplinary team group|500 patients of placenta accreta managed by obstetricans and urologists
2429225|NCT03372538||obstetricians only group|500 patients of placenta accreta managed by obstetricans only
2429226|NCT03372525|Experimental|HFOV|Ventilated infants were randomized to HFOV.
2429227|NCT03372525|Active Comparator|CMV|Ventilated infants were randomized to CMV.
2429228|NCT03372512||Fluid overload (Liters) ≥ median|
2429229|NCT03372512||Fluid overload (Liters) < median|
2429230|NCT03372499|Experimental|nutritional management group|diet management strategy for encephalopathy
2429231|NCT03372499|No Intervention|control group|Current ordinary guidance for patients after TIPS placement performed by trained nurse in the inpatient department
2429232|NCT03372486|Active Comparator|Bupivacaine plus naloxone|Patients will receive brachial plexus block using bupivacaine plus naloxone.
2429233|NCT03372486|Placebo Comparator|Bupivacaine|Patients will receive brachial plexus block using bupivacaine.
2429234|NCT03372473|Experimental|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg one dose a day
2429235|NCT03372473|Active Comparator|Montelukast|Montelukast 5mg one dose per day
2429236|NCT03372460|Active Comparator|Active Stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /25 min per day, for 6 sessions over the course of 2 weeks (3 sessions per week).
2429414|NCT03371277|Experimental|Arm1|patients with Parkinson's disease treated with deep brain stimulation.
3187541|NCT00757133|Active Comparator|2|Laparotomy closure with mesh augmentation
3187542|NCT00757159|Experimental|1|
3187543|NCT00757159|Active Comparator|2|
3187544|NCT00757185|Experimental|1|GNRH antagonist alone
3187545|NCT00757185|Experimental|2|GnRH with Testosterone
3187546|NCT00757198|Experimental|1|remifentanil o.1 mcg/kg/min
3187547|NCT00757198|Active Comparator|2|remifentanil 0.3 mcg/kg/min
3187548|NCT00757224|No Intervention|non-smoking|
3187549|NCT00757224|No Intervention|smoking parents A|
3187550|NCT00757224|Experimental|smoking parents B|Parents will be educated on the hazards of passive smoke exposure and ways to reduce it
2429237|NCT03372460|Sham Comparator|Sham Stimulation|Sham tDCS will include a 30-second ramp up to 1mA, 30 seconds of stimulation at 1mA, followed by a 30-second ramp down to off. The device will remain off for the remainder of the session. This process will be used for each of the 6 sessions during a 2 week period.
2429238|NCT03372447|Experimental|Megadose multivitamin complex|Intramuscular injection of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
2429242|NCT03372421|Experimental|Social Story|Participants will read information about what to expect from the assessment in the format of a Social Story
2429243|NCT03372421|Active Comparator|Standard Information|Participants will read standard information about what to expect from the assessment.
2429244|NCT03372408||Program Clients|Parkdale Parents' Primary Prevention Project (5P's) clients
2429245|NCT03372395|Other|Group 1|Standard treatment plus short-term (3 months) vaginal Lactobacillus rhamnosus BMX 54 implementation
2429246|NCT03372395|Experimental|Group 2|Standard treatment plus long-lasting (6 months) Lactobacillus rhamnosus BMX 54 administration
2429251|NCT03372356||Neuroendocrine tumors|Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.
2429252|NCT03372330||Sepsis with PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index < 0.9 or vascular Duplex confirmed peripheral artery disease.~* Standard care for sepsis and PAD"
2429253|NCT03372330||Sepsis without PAD|"Patients admitted to the intensive care unit with the diagnosis of sepsis (quick SOFA score >=2) and with ankle-brachial index >= 0.9 or vascular Duplex found no evidence of peripheral artery disease.~* Standard care for sepsis"
2429254|NCT03372317||Non-demented elders|Participants aged 55-90 that are cognitively normal or have mild cognitive impairment will receive 18F-MK-6240 to identify the presence of tau protein in the brain.
2429255|NCT03372304|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 10 mL, every 8th hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
2429256|NCT03372304|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
2429257|NCT03372304|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0.2 %, 10 mL. Lock-out time: 4 hours.
3146862|NCT00111254|Experimental|2|In group II, chronic effect group, each subject will undergo microdermabrasion of the face at weekly intervals for six weeks. Treatment will consist of 3 passes in different directions with the microdermabrasion handpiece (horizontal, vertical, and oblique). Aluminum oxide abrasion and negative pressure will be increased as tolerated by the patient. Two 2mm punch biopsies will be obtained prior to the first treatment and one week following the sixth treatment.
3146863|NCT00111345|Experimental|1|Daunoxome, standard risk
2429260|NCT03372278||Patients who received the Maxera Cup|Subjects in need of a total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Maxera Cup.
2429261|NCT03372265|Experimental|API+PCA|Infusion of ropivacaine 0.2 %, 15 mL, every 10th hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2429262|NCT03372265|Active Comparator|CI+PCA|Continuous infusion of ropivacaine 0.2 %, 6 mL/hour. Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2429263|NCT03372265|Active Comparator|PCA only|Patient-initiated bolus of ropivacaine 0,2 %, 15 mL. Lock-out time: 5 hours.
2429264|NCT03372252|Experimental|Successful weaning|Patients extubated after the success of the breathing test in spontaneous ventilation under artificial nose and always extubated after seven days.
2429265|NCT03372252|Experimental|Failure to wean|Patients who failed the breathing test in spontaneous ventilation under artificial nose and not extubated or patients extubated after the success of the weaning test in spontaneous ventilation under artificial nose but reintubated within seven days.
2429266|NCT03372239|Experimental|Part 1: Bioavailability and Food Effect|"Subjects will be randomized to receive the following 3 regimens in randomized sequence:~Single dose of Indoximod base formulation under fasting conditions~Single dose of Indoximod HCL (salt) formulation under fed conditions~Single dose of Indoximod HCL (salt) formulation under fasting conditions"
2429267|NCT03372239|Experimental|Part 2: Single Ascending Dose|
2429306|NCT03371953|Active Comparator|Atracurium group|Atracurium 0.6 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
2429307|NCT03371953|Active Comparator|Vecuronium-Atracurium group|Vecuronium 0.04 mg/kg + atracurium 0.3 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
3146864|NCT00111345|Active Comparator|2|Idarubicin, standard risk
3146865|NCT00111345|Experimental|3|Daunoxome, high-risk, 2-CDA
3146866|NCT00111345|Active Comparator|4|Idarubicin, high-risk, nothing
3146867|NCT00111358|Active Comparator|Lifestyle Modification|Goals derived from the AACE and NCEP-ATP III guidelines and the Diabetes Prevention Program are as follows: <35% calories from fat, < 7% calories from saturated fat, up to 10% calories from polyunsaturated fat, reduction of trans fatty acid intake, up to 20% calories from monounsaturated fat, and 25-35g of fiber per day. 3 hrs of physical activity/week at moderate intensity, >10,000 steps in daily activity, measured by pedometer. The curriculum is modeled after the Diabetes Prevention Program. Subjects will complete lifestyle sessions in the offices of the Program in Nutritional Metabolism or in the Clinical Research Center at MGH with protocol study staff trained to implement the curriculum.
3146868|NCT00111358|Placebo Comparator|Control|
3146869|NCT00111436|Experimental|50 mg|50 mg once weekly
3146870|NCT00111436|Experimental|100 mg|50 mg twice weekly
3146871|NCT00111501|Experimental|Targeted Internet Intervention|Web-based self help intervention developed to include specific cultural tailoring relevant to the LGBT community
3146872|NCT00111501|Active Comparator|Standard Intervention|Standard self-help internet-based intervention with no LGBT relevant information included
3146873|NCT00111527|Active Comparator|1|Normal RV pacing
3146874|NCT00111527|Experimental|2|Echo-guided optimization of pacing
3146875|NCT00111540|Experimental|Exenatide|Exenatide 5 mcg for 4 weeks (transition) then 10 mcg to study termination
3146876|NCT00111566|Active Comparator|18 Hour infusion|
3146877|NCT00111566|Experimental|4 hour infusion|
2429268|NCT03372226|Experimental|Online self-help program|"The intervention group receives the login data for the online program directly following the baseline assessment. The program consists of 10 modules with many interactional exercises and homework-sheets.~Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse."
2429269|NCT03372226|No Intervention|Wait-list control group|The participants of the wait-list control condition do not receive any new intervention during the intervention period of 8 weeks, but may continue any treatment that has already been started before, including medication. Participants in the wait-list control condition receive full access to the program after completion of the post-assessment.
2429270|NCT03372213||2003-2004|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2429271|NCT03372213||2005-2006|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2429272|NCT03372213||2011-2012|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2429273|NCT03372213||2013-2014|Adults 20-64 at or below 130% of the federal poverty level who completed one 24-hour dietary recall
2429274|NCT03372200|Experimental|FYU-981|
2429275|NCT03372200|Active Comparator|Febuxostat|
2429276|NCT03372187|Experimental|DIET-MS|This group will follow a low glycemic load diet plan prescribed to them by a health coach and will receive information on exercise as well. This group will have weekly calls with the telehealth coach and will be provided access to the eHealth platform.
2429277|NCT03372174|Experimental|Mechanical ventilation group|patients with mechanical ventilation during cardiopulmonary bypass for cardiac surgery
2429278|NCT03372174|Active Comparator|Control group|patients without mechanical ventilation during cardiopulmonary bypass for cardiac surgery
2429279|NCT03372161|Experimental|SP-102|SP-102
2429280|NCT03372161|Placebo Comparator|Placebo|Placebo
2429281|NCT03372148|Experimental|pHRMi in evaluation of swallowing function|Pharyngeal High Resolution Manometry and Impedance (pHRMi) evaluation of swallowing function at baseline, 3 months post radiation, then at 9 months
2429282|NCT03372135||Trendelenburg group|Patients in trendelenburg group take trendelenburg position and have CO2 pneumoperitoneum. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested.
2429283|NCT03372135||Control group|Patients in control group take horizontal position. Cerebral oxygen monitor will be needed. Take notes per hour for HR, MAP, CVP, SpO2, SrO2 and etCO2.Preoperative and postoperative ABG, S-100beta , CRP and cognitive dysfunction scales will be tested
2429284|NCT03372122|Active Comparator|SAGE Chlorhexidine Gluconate Cloth|Ready to use disinfectant cloth
2429285|NCT03372122|Active Comparator|HUBS with Hibiclens|Dry cloths to be used with water and disinfectant
2429286|NCT03372109|Active Comparator|Modified Fasting Arm|Dietary Supplements administered daily for 52 days with a meal replacement shake administered two days per week for the study duration
2429287|NCT03372109|Placebo Comparator|Placebo|Multivitamin tablet administered daily for 52 days
2429290|NCT03372070|Experimental|cNEP|silicone collar applied to anterior neck
2429294|NCT03372044|Experimental|PF-06865571|Treatment
2429295|NCT03372031|Experimental|Active-Passive|Active Piano training (8 sessions in two weeks) followed by listening to piano training (8 sessions in 2 weeks) (Passive condition)
2429296|NCT03372031|Experimental|Passive-Active|Passive piano training listening (8 sessions in two weeks) followed by active piano training (8 sessions in two weeks)
2429297|NCT03372018|Experimental|Promotora-led intervention (PLI)|PLI -DPP protocol was developed from original DPP materials and culturally tailored for the target population based on formative research. The core PL-DPP curriculum includes 14 group sessions of 90 minutes duration. One promotora will lead each session in Spanish using behavioral strategies to discuss lifestyle behaviors, exploring such topics as being active, low-fat diets, portion control, self monitoring, problem solving and life-style changes.
2429298|NCT03372018|Active Comparator|Usual care (UC)|UC participants will receive standard educational materials in Spanish discussing mental health and diabetes prevention. UC participants will be encouraged to continue all routine medical care during the study.
2429299|NCT03372005|Experimental|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
2429300|NCT03372005|No Intervention|Control|This group functions as a control group, that will continue the normal lifestyle throughout the study.
2429301|NCT03371992|Other|Lung Cancer Patients|Lung cancer patients receiving one of three standard of care immunotherapy drugs including nivolumab, pembrolizumab or atezolizumab. 3D-EX will be performed on biopsies from patients enrolled in the study to correlate with the patient's evaluation of response by RECIST.
3146878|NCT00111579|Active Comparator|1|CAIV-T
2429303|NCT03371966|Active Comparator|High Nitrate Beetroot Juice|Beetroot juice high in nitrate will contain approximately 10.0 mmole nitrate per 120 ml.
2429304|NCT03371966|Placebo Comparator|Low Nitrate Beetroot Juice|Beetroot juice low in nitrate will contain approximately 0.5 mmole nitrate per 120 ml.
2429305|NCT03371953|Active Comparator|Vecuronium group|Vecuronium 0.08 mg/kg will be administered at induction of anaesthesia for facilitating muscle relaxation
3146879|NCT00111579|Other|2|TIV
3146880|NCT00111592|Active Comparator|1|current usual care
3146881|NCT00111592|Experimental|2|treatment protocol with clear indications for therapy
3146882|NCT00111605|Experimental|1|HIV gag DNA vaccine or placebo on Days 0, 28, and 84
2429308|NCT03371940|Experimental|Talk therapy (CBT)|"Participants randomized the talk therapy arm received 10 weeks of CBT or talk therapy. The goal of CBT was to provide individuals with skills and concepts that they may use to: 1) manage and reduce depressive symptoms; 2) prevent the onset and severity of future depressive episodes; and 3) generalize these skills to diabetes management.~CBT interventionists facilitated patient management of depressive symptoms by providing participants with:~Education about depression and the cognitive-behavioral therapy model;~A safe relationship for participants to explore their symptom patterns and try to new tools to address them;~Coaching as participants fully engage emotional and behavioral strategies."
2429309|NCT03371940|Experimental|Exercise (EXER)|Participants randomized to the exercise arm were enrolled in a 12-week physical activity intervention designed to increase aerobic physical activity. Participants were asked to complete 100 minutes of aerobic activity in Week 1, 125 minutes in Week 2, and 150 minutes per week of physical activity in Weeks 3-12. In addition, participants received 6 exercise training classes in which safe exercise practices were introduced and practiced, free access to a local exercise facility, use of a pedometer, completion of activity logs each week, and received an exercise workbook that addressed social and motivational aspects of physical activity.
2429310|NCT03371940|Experimental|Talk therapy + exercise (CBT+EXER)|Participants randomized to the combination therapy received both talk therapy and exercise as detailed above.
2429311|NCT03371940|Placebo Comparator|Usual care (UC)|Participants randomized to usual care received no study intervention.
2429312|NCT03371927|No Intervention|Standard Feeding Method|The control group consisted of prescribed volumes of oral and/or gavage feedings at two or three hour intervals per feeding.
2429313|NCT03371927|Experimental|SINC Feeding Protocol|Safe individualized nipple-feeding competence (SINC) protocol
2429314|NCT03371914|Experimental|Treatment: Management + data training|"The treatment group in the study will receive a 5-day training. The first two days of the training will consist of introducing the data collection tools and collecting baseline data. Days three through five of the training will consist of a variety of management topics.~On a monthly basis, the treatment group will receive data visualizations that will compare their site's performance that month to pervious performance and to other sites in the study. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis."
2429315|NCT03371914|No Intervention|Control: data training only|The control group will receive only a 2-day training which will focus on data collection alone. Both treatment and control groups will collect information regarding input costs and number of services provided on a monthly basis.
2429316|NCT03371901|Experimental|Physical therapy with BFR-LLST|
2429317|NCT03371888|Experimental|PRP injections|Intramuscular injection of Platelet-Rich Plasma into the masseter and temporalis muscle
2429318|NCT03371888|Placebo Comparator|0,9% NaCl injections|Intramuscular injection of 0,9% NaCl into the masseter and temporalis muscle
2429319|NCT03371875|Experimental|Transition Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. Physicians will then be given reminders based on the subject's deficiencies in transition management, and given the opportunity to intervene.
2429320|NCT03371875|No Intervention|Control Clinics|Clinics in this arm will assess the adolescent's readiness for youth-to-adult transition using the TRAQ questionnaire. No reminders will be provided to providers for care transition.
2429321|NCT03371862|Experimental|Test group|
2429322|NCT03371849|Experimental|Group 1|Reference Drug → Test Drug
2429323|NCT03371849|Experimental|Group 2|Test Drug → Reference Drug
3187551|NCT00757250|Experimental|1|Dose Cohort 1: 50 mcg/kg/day of TXA127
2429325|NCT03371823|Other|Normotensive|Normotensive PMW will complete an experimental visit to assess vascular function. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visit to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
2429326|NCT03371823|Experimental|Hypertensives|Hypertensive women will be tested at baseline and then administered Losartan 50 mg once a day at night for 14 days. Vascular function is measured at baseline and again after 2 weeks of losartan. All women will wear an ambulatory BP monitor during the 24 hours preceding the experimental visits to confirm BP classification. Large blood vessel function will be assessed using two non-invasive techniques: 1. Flow Mediated Dilation (FMD) 2. Pulse Wave Analysis and Pulse Wave Velocity. ET-1 mediated vasoconstrictor tone is assessed by measuring the cutaneous blood flow during microdialysis perfusions of ET-A and ET-B receptor antagonist. ET-1 production, ET-A and ET-B receptor expression is assessed from antecubital vein endothelial cells and skin punch biopsy samples.
2429327|NCT03371810|Experimental|Bright light therapy|"Mobile therapeutic light (10.000 LUX), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
2429328|NCT03371810|Experimental|Physical exercise|"Aerobic exercise of moderate-to-vigorous intensity three days a week plus muscle-strengthening exercises two days a week during 10 weeks in total.~Additional treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise) is allowed."
2429329|NCT03371810|No Intervention|Treatment as usual|Stable treatment as usual comprising pharmacotherapy, group based or individual cognitive behavioural therapy (not including elements of bright light therapy or exercise).
2429330|NCT03371797||Treatment group|Valsartan, Amlodipine single pill combination.The recommended dosage of AVSAR (Valsartan/Amlodipine) is one tablet per day.
2429331|NCT03371784|Active Comparator|Hydrocortisone|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to i.v hydrocortisone administration.
2429332|NCT03371784|Placebo Comparator|Placebo|Patients who meet the inclusion criteria, with a CWP above the derived cutoff, with continuous elevation of the pressure line, who are randomized to placebo (sodium chloride 0.9%).
2429333|NCT03371771|Experimental|Volunteer-delivered Behavioral Activation|
2429337|NCT03371745|Active Comparator|PGS-FET|The PGS-FET arm involves deferred transfer of embryos following cryopreservation at the blastocyst stage following pre-implantation genetic screening. This arm will culture embryos to day 5/6/7 (blastocyst stage). The embryos will be cryopreserved following trophectoderm biopsy. A subsequent frozen embryo transfer cycle will be performed during which 1 euploid (chromosomally normal) embryo will be thawed and transferred.
2429338|NCT03371745|Active Comparator|FET|"The Freeze only arm involves the deferred transfer of embryos following cryopreservation. In this arm embryos will be cryopreserved. A subsequent frozen embryo transfer cycle will be performed during which one or more embryos will be thawed and transfered based on local clinical site, age-specific embryo number transfer guidelines."
2429339|NCT03371745|Active Comparator|Fresh|The Fresh arm will have an immediate embryo(s) transfer based on local clinical site, age-specific embryo number transfer guidelines within the stimulation cycle.
3187552|NCT00757250|Experimental|2|Drug Cohort 2: 100 mcg/kg/day TXA127
3187553|NCT00757250|Experimental|3|Drug Cohort 3: 200 mcg/kg/day TXA127
2429342|NCT03371719|Placebo Comparator|Arm 1 (Radiation Therapy + Placebo)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive placebo PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months) in the absence of disease progression or unacceptable toxicity.
2429343|NCT03371719|Experimental|Arm 2 (Radiation Therapy + Apalutamide)|Patients undergo external beam radiation therapy on Day 1 for 7.5 weeks. Beginning on Day 1 of radiation therapy, patients receive apalutamide PO QD on Days 1-30. Treatment repeats every 30 days for up to 6 courses (6 months)in the absence of disease progression or unacceptable toxicity.
3146883|NCT00111605|Experimental|2|HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84
3146884|NCT00111605|Experimental|3|HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84
2429346|NCT03371693|Experimental|HIPEC|"Patients will undergo a CRS plus HIPEC and IVCT. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the abdominal cavity is bathed in a warm solution of anti-cancer medications for 60 minutes.~A single drug lobaplatin(30mg/m2)will be administered in normal saline via HIPEC and it will be continued for 60 minutes in the hyperthermic phase (41°C-43°C). HIPEC will be performed at the 1st, 3rd and 5th day after CRS. The intravenous chemotherapy(IVCT) will start from 7th-14th day after CRS."
2429347|NCT03371693|Other|Non HIPEC|Patients will undergo only CRS and IVCT. Patients will receive standard platinum-based combination doublet chemotherapy for 6-8 cycles after CRS.
2429348|NCT03371680|Experimental|Injection of stable isotopes|Injection of 1-13 Carbon Leucine and deuterated water: all patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
3146885|NCT00111605|Experimental|4|HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84
3146886|NCT00111605|Experimental|5|HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273
2429351|NCT03371641|Other|Alcoholic exposure group|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
2429352|NCT03371641|Other|Control|Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire
2429353|NCT03371628|Experimental|Group VNI 1h|Intervention: Non invasive ventilation, applied for 1 hour
2429354|NCT03371628|No Intervention|Group O2|Oxygen therapy
2429357|NCT03371602|Experimental|control group|non-septic mesocolic programmed abdominal or thoracic surgery: gastrectomy, esophagectomy, pancreatectomy, hepatectomy
2429358|NCT03371602|Experimental|sepsis group|Abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
2429359|NCT03371602|Experimental|mechanical ventilation group|Patient in brain death for whom a multi-organ sampling is planned
2429360|NCT03371602|Experimental|mechanical ventilation - sepsis group|Patient under controlled mechanical ventilation to undergo abdominal or thoracic surgery in a septic context (peritonitis, mediastinitis, pleural abscess)
2429361|NCT03371589|Experimental|no P.O corticosteroids|Steroids injection
2429362|NCT03371576||2 different torical intraocular lenses|
2429363|NCT03371563||elderly patients|
2429364|NCT03371563||middle-aged patients|
2429365|NCT03371563||controls|
2429366|NCT03371563||young patients|
2429367|NCT03371550|Experimental|Radiochemotherapy|Induction chemotherapy with docetaxel and cisplatine and concomitant radiotherapy
2429368|NCT03371537||Hepatectomy|Patient undergoing laparotomy for liver resection. The aim is to measure the flow rates in the portal vein and the hepatic artery.
2429369|NCT03371524||Native valves_30 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.
3146887|NCT00111605|Experimental|6|HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273
3146888|NCT00111605|Experimental|7|HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84
3146889|NCT00111631|Experimental|1|
3146890|NCT00111631|Experimental|2|
3146891|NCT00111631|Experimental|3|
3146892|NCT00111631|Placebo Comparator|4|
3146893|NCT00111644|Experimental|1|
3146894|NCT00111644|Experimental|2|
3146895|NCT00111644|Active Comparator|3|
3146896|NCT00111670|Experimental|1|
3146897|NCT00111670|Experimental|2|
3146898|NCT00111670|Experimental|3|
3146899|NCT00111670|Experimental|4|
3146900|NCT00111670|Placebo Comparator|5|
3146901|NCT00111683|Experimental|MK-0457|Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration
3146902|NCT00111696|Experimental|MEDI-522|Drug
2429370|NCT03371524||Native valves_30 and 60 seconds loops|Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.
2429371|NCT03371524||Bioprosthesis_30 seconds loops|Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.
2429372|NCT03371511||MiLC Cohort|"Participants donated HM from two consecutive pumping sessions at home. Women pumped once with their own pump and milk collection kit, and once with a sterile and sterile collection kit. Both pumping sessions occurred at participants' homes between 0700 and 1100 hours. The second pumping session occurred within 3 hr (+/- 30 min) after the beginning of the first. Randomization was used to determine which pump was used first. Women elected from which breast they donated their HM and were asked not to nurse on that side 2 hr before the first pumping session and not until after the second. Before women pumped with their own pump, swabs were taken of the breast from which HM was donated, the women's dominant hand, their own bottle/flange, their own pumps (port of pump and tubing), and their babies' mouths.~There was only one group but stratified enrollment was used to ensure equal numbers of women whose infants consumed HM only and women whose infants consumed HM and complementary foods."
2429373|NCT03371498|Experimental|Methylprednisolone Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive methylprednisolone
2429374|NCT03371498|Placebo Comparator|Control Group|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L will receive placebo
2429375|NCT03371485|Active Comparator|Arm A|Patients with advanced NSCLC, to receive AST-VAC2.
2429376|NCT03371485|No Intervention|Arm B|Patients with advanced NSCLC, receiving no AST-VAC2 treatment and serving as a control for Arm A.
2429377|NCT03371485|Active Comparator|Arm C:|Patients with previously treated NSCLC, currently disease free, to receive AST-VAC2 in the adjuvant setting.
2429378|NCT03371485|No Intervention|Arm D:|Patients with previously treated NSCLC, currently disease free, receiving no AST-VAC2 treatment and serving as a control for Arm C.
2429379|NCT03371472|Other|VALE - PVL leak sizing balloon - mitral|Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon
2429380|NCT03371472|Other|VALE - PVL leak sizing balloon - aortic|'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon
3187554|NCT00757250|Experimental|4|Drug Cohort 4: 300 mcg/kg/day TXA127
3187555|NCT00757250|Experimental|5|Extended dosing cohort at 300mcg/kg TXA127 for 2 x 28-day treatment cycles, with an extended follow-up period to week 34.
2429383|NCT03371446||Smokers/Non-smokers|It was an experimental study with parallel controls, comparing two groups, a group with patients who smoked for more than 10 years, consuming 10 more cigarettes per day and diagnosing chronic periodontitis (case) and another group (control) were non-smokers with chronic periodontitis, according to the standard of World Health Organization (WHO) definition of the smoking population
2429384|NCT03371420|Experimental|124I-PU-AD|A single dose of 124I-PU-AD will be administered by intravenous (IV) injection
2429385|NCT03371407||Parkinsonian patient under dopaminergic medication|
2429386|NCT03371407||Parkinsonian patient without dopaminergic medication|
2429387|NCT03371407||Control participants|
2429388|NCT03371394||median 1|
2429389|NCT03371394||median 2|
3187556|NCT00757276||1|"All patients > 18 years who are tested for the diagnosis of DI because of a history of polyuria (> 40 ml/kg per 24 hours) in the presence of polydipsia Patients with known DI will be contacted whether they agree to participate in the study and to undergo again a water deprivation test to measure copeptin to confirm the diagnosis.~The investigators hypothesize that basal copeptin levels can reliably differentiate between the 5 groups(central, nephrogenic, psychogenic and partial forms) with a sensitivity and specificity >80%."
3187557|NCT00757289|Experimental|1|PRP injection
2429392|NCT03371368|Other|Gastric Bypass Diabetic and Non-diabetic|Roux-en-Y gastric bypass surgery
2429393|NCT03371368|Other|Sleeve Gastrectomy Diabetic and Non-diabetic|sleeve gastrectomy surgery
2429394|NCT03371368|Active Comparator|Very Low Calorie Diet Diabetic and Non-diabetic|very low calorie diet
2429395|NCT03371368|No Intervention|Obese Control Group|Non-diabetic obese subjects
2429396|NCT03371368|No Intervention|Lean Control Group|Non-diabetic lean subjects
3187558|NCT00757289|Active Comparator|2|Corticosteroid Injection
3187559|NCT00757302|Experimental|I|For the first 10 patients, only a pre-operative procedure will be performed.
3187560|NCT00757302|Experimental|II|The last 100 patients will receive the complete procedure.
3187561|NCT00757315|Experimental|1|
2429401|NCT03371342|Experimental|MEDITOXIN|
2429402|NCT03371342|Active Comparator|BOTOX|
2429403|NCT03371329|Experimental|Group 1 MSC dose .5 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for 3 participants.
2429404|NCT03371329|Experimental|Group 2 MSC dose 1 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 1 x 10^6/kg for next 3 participants.
2429405|NCT03371329|Experimental|Group 3 MSC dose 2 x 10^6/kg IV|Intravenous infusion of MSC (mesenchymal stem cell) dose 2 x 10^6/kg for next 3 participants.
2429406|NCT03371329|Experimental|Group 4 MSC dose 0.5 x 10^6/kg I|Intraventricular infusion of MSC (mesenchymal stem cell) dose .5 x 10^6/kg for final 3 participants.
2429407|NCT03371316|Experimental|Hemicraniectomy Surgery with Viashield|All patients requiring a hemicraniectomy surgery will receive the anti-adhesion barrier of amnion patch.
2429408|NCT03371303||diabetology|
2429409|NCT03371303||cardiology|
2429410|NCT03371303||rheumatology|
2429411|NCT03371303||geriatrics|
2429412|NCT03371290|Experimental|Mirror Therapy Intervention|
2429413|NCT03371290|Active Comparator|Control Intervention|
3187562|NCT00757315|Active Comparator|2|
3187563|NCT00757328||1|Ambulatory bipolar I and II patients, clinically stabilized for at least the two months prior to recruitment and who had at least one acute episode (depressive, manic, hypomanic or mixed) within the year prior to recruitment.
3187564|NCT00757341|Experimental|SKI-606|
3187565|NCT00757354|Experimental|Metal on Metal cementless hip|Metal on Metal cementless hip arthroplasty
2429415|NCT03371277|Experimental|Arm2|patients with Parkinson's disease treated without deep brain stimulation.
2429416|NCT03371264||Cohort R1 and Cohort T1|Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
2429417|NCT03371264||Cohort R2 and Cohort T2|Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)
2429418|NCT03371251|Experimental|Phase 1b: BOS161721 20, 60, 120 mg|Participants will be randomized to receive a 20 milligram (mg), 60 mg, or 120 mg subcutaneous (SC) dose of BOS161721. Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
2429419|NCT03371251|Placebo Comparator|Phase 1b: Placebo 20, 60, 120 mg|Participants will be randomized to receive a 20 mg, 60 mg, or 120 mg SC dose of placebo. Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
2429420|NCT03371251|Experimental|Phase 2: BOS161721|Participants will be randomized to receive a 120 mg SC dose of BOS161721 (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of BOS161721 on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
2429421|NCT03371251|Placebo Comparator|Phase 2: Placebo|Participants will be randomized to receive a 120 mg SC dose of placebo (as determined from Phase 1b of the study). Participants may receive a total of 7 SC monthly doses of placebo on Days 0, 30, 60, 90, 120, 150, and 180, followed by safety follow-up visits on at Days 210, 240, and 270.
2429422|NCT03371238|Experimental|Floorball|
2429423|NCT03371238|No Intervention|Control|
2429424|NCT03371225|Experimental|Active tDCS and Active Exercise|Active tDCS for 20 min Active exercise (60-70% max HR) for 30 min
2429425|NCT03371225|Active Comparator|Sham tDCS and Active Exercise|Sham tDCS for 20 min Active exercise (60-70% max HR) for 30 min
2429426|NCT03371225|Active Comparator|Active tDCS and Sham Exercise|Active tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
2429427|NCT03371225|Sham Comparator|Sham TDCS and Sham Exercise|Sham tDCS for 20 min Sham exercise (within 5% baseline HR) for 30 min
3146903|NCT00111748|Active Comparator|1|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:VTD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg Days 1-14 Every 21 days"
3187566|NCT00757367|Experimental|TI Inhalation Powder|TI Inhalation Powder, single dose, 60 units
2429430|NCT03371199|Active Comparator|Sodium arm|Sodium tablets
2429431|NCT03371199|Placebo Comparator|Placebo arm|Placebo tablets
2429432|NCT03371186|Experimental|Bundled RMNCH Intervention|Stepped wedge, cluster-controlled implementation science trial of 5 bundled intervention components (1. Community Health Worker, 2, Continuous Surveillance, 3. CB-Integrated Management of Newborn and Childhood Illness, 4. Group Antenatal and Postnatal Care, and 5. Balanced Post-Partum Contraceptive Counseling) implemented across 40 village clusters in Achham District, Nepal and 40 village clusters in Dolakha District, Nepal (covering a total population of approximately 300,000) in coordination with district authorities and study staff. The investigators anticipate the experimental arm will enroll approximately 12,000 women and their children over the 18mo enrollment period.
2429433|NCT03371173|Experimental|Ferric maltol 30 mg (Feraccru®)|Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
2429434|NCT03371147|Experimental|CancerLife|Arm A will be asked to download a mobile application called CancerLife. CancerLife is a stand-alone application that is NOT integrated into the patient's electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.
2429435|NCT03371147|No Intervention|Usual care|Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.
2429436|NCT03371134||Sarcopenic group|Harvesting of muscular biopsies Muscular biopsies will be harvested from old sarcopenic patients undergoing hip replacement surgery
2429437|NCT03371134||Control group|Harvesting of muscular biopsies Muscular biopsies will be harvested from young patients undergoing Anterior Cruciate Ligament (ACL) reconstruction surgery
2429438|NCT03371121|Other|Chondro-gide - Geistlich|Arthroscopic use of chondro-gide to treat symptomatic osteochondral talar lesion
2429439|NCT03371108|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection solution for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0 mL prefilled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
2429440|NCT03371108|Active Comparator|Lantus®|Lantus® solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL prefilled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
2429441|NCT03371095|Experimental|Infliximab|Infliximab 5mg/kg intravenously at week 0, 2, 6, 12, and 18
2429442|NCT03371095|Active Comparator|Cyclophosphamide|Cyclophosphamide 0.7g/m2 intravenously at week 0, 4, 8, 12, 16 and 20
2429443|NCT03371082|Experimental|Gan & Lee Insulin Glargine Injection|Gan & Lee Insulin Glargine Injection for subcutaneous injection, 100 U/mL, in the integrated, disposable 3.0-mL pre-filled Gan & Lee injector pen. Subjects randomized to the Gan & Lee Insulin Glargine Injection group will participate in the study for 26 weeks.
2429444|NCT03371082|Active Comparator|Lantus®|Lantus® (insulin glargine injection) solution for subcutaneous injection, 100 U/mL, in the SoloStar® 3.0 mL pre-filled insulin pen. Subjects randomized to the Lantus® group will participate for 26 weeks.
2429445|NCT03371069||users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
2429446|NCT03371056|Experimental|Woman at low risk of infection|Women with systematic vaginal sample for detection of GBS will be included.
2429447|NCT03371056|Experimental|Woman with high risk of infection > 37 SA|Women with premature rupture of membranes (> 12 hours before labor) but > 37 SA will be included.
3187567|NCT00757380|Active Comparator|Group 1|Trypan Blue
2429448|NCT03371056|Experimental|Women with premature rupture of membranes (<37SA)|Woman with high risk of infection <37SA
2429449|NCT03371056|Experimental|Women with premature delivery or premature delivery threat|Woman with high risk of infection <37SA and Women with premature delivery or premature delivery threat
2429450|NCT03371043||users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
3146904|NCT00111748|Active Comparator|2|"Stratification:~CA13/hypodiploidy at diagnosis versus no CA13/hypoploidy at diagnosis~Prior Velcade vs. No prior Velcade~TREATMENT:~VATD Velcade 1.0 mg/m2 Days 1,4, 8,11 Thalidomide 100 mg Daily qhs Dexamethasone 20 mg Days 1, 2, 4,5, 8, 9, 11, 12 Adriamycin 2.5 mg/m2 Days 1-4 & Days 9-12 Lovenox 40 mg Days 1-14 Every 21 days"
3146905|NCT00111787|Experimental|Overall study|A Single arm study with 2 cohorts of participants. Cohort A consists of participants with tumors overexpressing HER2 and/or EGFR. Cohort B consists of participants with tumors expressing EGFR without overexpressing HER2.
3146906|NCT00111852|Experimental|Desmoteplase, low dose|Desmoteplase 90 mcg/kg, intravenous administration.
2429455|NCT03371004|Experimental|DM-CHOC-PEN + Radiation|4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) - 39-89.7 MG/M2 iv once and then 3-weeks later radiation - 15-30 Gy will be administered
2429456|NCT03370991|Experimental|Blueberry|22 g/day freeze-dried blueberry powder for 12 weeks
2429457|NCT03370991|Placebo Comparator|Control|22 g/day placebo powder for 12 weeks
2429458|NCT03370978|Experimental|Text Messaging|Receives text messages to remind of upcoming follow-up appointment with primary care doctor. Also provides opportunity for subjects to text ED staff for follow-up care concerns or to reschedule primary care appointment.
2429459|NCT03370978|No Intervention|Usual Care|Received usual care including follow-up phone calls if clinically indicated.
2429460|NCT03370965|Experimental|Patients with optic neuritis|
2429461|NCT03370952|Active Comparator|new approach|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:~Delivery of affected ovary outside the abdominal cavity:~A transverse mini-laparotomy is done (2-3 cm) in the midline 2 cm above the symphysis pubis.~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
2429462|NCT03370952|Active Comparator|Laproscopic ovarian cystectomy|classic laparoscopic ovarian cystectomy
2429464|NCT03370900|No Intervention|Learning and Assessment at 12 months|Study participants will complete an 80 case learning set followed by a 20-case post test. The study intervention in this group is a 20-case test at 12 months.
2429465|NCT03370900|Experimental|Testing Every Two Months|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests without any feedback at 2, 4, 6, 8, 10, 12 months.
2429466|NCT03370900|Experimental|Low Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 6 months, the 20-case post-test will be delivered with feedback.
2429467|NCT03370900|Experimental|High Bolus Feedback|Study participants will complete an 80 case learning set followed by a 20-case post test. Study participants in this group will receive the following study interventions: 20-case post tests at 2, 4, 6, 8, 10, 12 months. At 4, 8, and 12 months, the 20-case post-test will be delivered with feedback.
2429468|NCT03370887|Experimental|Low dose AZD8601 (3 mg)|8 patients will be randomised to receive 3 mg AZD8601
2429469|NCT03370887|Experimental|High dose AZD8601 (30 mg)|8 patients will be randomised to receive 30 mg AZD8601
2429470|NCT03370887|Placebo Comparator|Placebo|8 patients will be randomised to receive placebo injections
2429471|NCT03370874|Experimental|ALLO-ASC-DFU|Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
2429472|NCT03370874|Placebo Comparator|Vehicle Sheet|Hydrogel sheet without Allogenic mesenchymal stem cell
2429473|NCT03370848|Experimental|Psyllium plus Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER~Psyllium 1.7gm wafers - take 2 wafers (3.4 grams total) along with aspirin 30 minutes prior to niacin ER"
2429474|NCT03370848|Active Comparator|Aspirin and Niacin ER|"Niacin ER 500mg tablet - take 1 niacin ER 500mg tablet at least two hours before bedtime for two weeks, then increase niacin ER to two 500mg tablets (1,000 mg total) for two weeks, then increase to three niacin ER 500mg tablets (1,500 mg total) for two weeks.~Aspirin 325mg tablet - take 1 aspirin 325 mg tablet 30 minutes prior to niacin ER"
2429475|NCT03370835|Experimental|Sequence 1|"Metoprolol-succinate-ER 25mg daily weeks 0-2, 50mg daily weeks 2-4, 100mg daily weeks 4-6, 200mg daily weeks 6-8, 100mg daily week 9, 50mg daily week 10~Carvedilol 3.125mg twice daily weeks 10-12, 6.25mg twice daily weeks 12-14, 12.5mg twice daily weeks 14-16, 25mg twice daily weeks 16-18"
2429476|NCT03370835|Active Comparator|Sequence 2|"Carvedilol 3.125mg twice daily weeks 0-2, 6.25mg twice daily weeks 2-4, 12.5mg twice daily weeks 4-6, 25mg twice daily weeks 6-8, 12.5mg twice daily week 9, 6.25mg twice daily week 10~Metoprolol-succinate-ER 25mg daily weeks 10-12, 50mg daily weeks 12-14, 100mg daily weeks 14-16, 200mg daily weeks 16-18"
2429477|NCT03370822||Study Participants|Women who have continuous fetal monitoring using the MONICA AN24 device. The MONICA AN24 is a wearable monitor with five adhesive electrodes placed on the mother's abdomen. This records the fetal heart rate, maternal heart rate and uterine contractions.
2429478|NCT03370809|Experimental|patients over 75 years old with cancer discovery|Elderly patients with cancer have a 18F-FDG PET whole body performed routinely in the initial assessment . A cerebral recording is added 45 minutes after the 18F-FDG injection and just before the registered whole body
2429479|NCT03370796|Experimental|Reminiscence Therapy|The Reminiscence program will consist of a set of sessions thematically sequenced topics that address the life course of the participant. Each session will integrate a group of activities that will be developed in group and will have a didactic character, privileging subjective interests and interpersonal communication.
2429480|NCT03370796|No Intervention|Control Group|The control group shall participate in the institutional care provided by the professionals of each RSE.
2429482|NCT03370757|Active Comparator|3-hour bundled care|Infants in this group will have their diaper changed every 3 hours during 3-hour bundled care.
2429483|NCT03370757|Active Comparator|6-hour bundled care|Infants in this group will have their diaper changed every 6 hours.
2429484|NCT03370744||Subjective cognitive decline, SCD|The inclusion criteria for SCD are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) failure to meet the following criteria for MCI.
2429485|NCT03370744||Normal control, NC|NC are individuals who have no self-report persistent decline in cognitive capacity, and with neither worry nor concern about their cognition. Without measurable cognitive impairment according to results of standard assessments.
2429486|NCT03370744||Mild cognitive impairment, MCI|MCI are defined by an actuarial neuropsychological method proposed by Jak and Bondi. Participants are considered to have MCI if any one of the following three criteria are met with a total Clinical Dementia Rating (CDR) score of 0.5 as well as failure to meet the criteria for dementia: (1) having impaired scores (defined as >1 SD below the age-corrected normative mean) on both measures within at least one cognitive domain (i.e., memory, language, or speed/executive function); (2) having impaired scores in each of the three cognitive domains sampled; (3) the Functional Activities Questionnaire (FAQ) ≥9.
2429487|NCT03370744||Alzheimer's disease, AD|The diagnosis of AD syndrome is based on the diagnostic guidelines for dementia due to AD delivered by the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) with a total CDR score of 1.
2429488|NCT03370744||Subjective Cognitive Decline plus, SCD-plus|The inclusion criteria for SCD-plus are as following: (1) presence of self-perceived continuous cognitive decline compared to previous normal status and unrelated to an acute event; and (2) concerns (worries) associated with memory complaint; and (3) failure to meet the following criteria for MCI.
2429489|NCT03370731|Experimental|Adenotonsillectomy|Surgical management, i.e. adenotonsillectomy, including adenoidectomy, tonsillectomy or adenoidectomy combined tonsillectomy
2429490|NCT03370731|Other|Nonsurgical management|Nonsurgical management, including nasal irrigation, inhaled corticosteroids etc.
2429491|NCT03370718|Experimental|Treatment (cabozantinib)|Patients receive cabozantinib PO QD in the absence of disease progression or unacceptable toxicity.
2429492|NCT03370705|Active Comparator|CT group|78 patients will be treated by conventional treatment : antiplatelet therapy + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l
2429493|NCT03370705|Experimental|Sulodexide + CT group|"78 patients will be treated by :~Sulodexide (250ULS, twice daily , oral administration)~Conventional treatment : antiplatelet agents + ACE inhibitor +/- Statin in patients with cholesterol total level > 1,35 g/l"
2429494|NCT03370666|Experimental|HFNT|HFNT performed with any available device. The flow will be initially set at 60 liters per minute and temperature at 37° C. The target will be an oxygen saturation (SpO2) of 88-92%. In case of patient not tolerating these settings, flow and temperature will be titrated to the maximum tolerated level.
2429495|NCT03370666|Active Comparator|NIV|NIV must be delivered by full or oronasal mask with any available ventilator. The ventilator settings will be decided according to the usual practice: maximal tolerated inspiratory pressure to obtain a measured or estimated expired tidal volume of 6-8 mL·kg-1 of body weight and a positive end expiratory pressure (PEEP) between 3 and 5 cmH2O. An interface rotational strategy will be allowed among only different types of masks.
2429496|NCT03370653|Experimental|Double-blind - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
2429497|NCT03370653|Experimental|Double-blind - odiparcil 500 mg per day|1 tablet of placebo and 1 tablet of odiparcil 250 mg per os, twice daily (BID)
2429498|NCT03370653|Placebo Comparator|Double-blind - placebo|2 tablets of placebo per os, twice daily (BID)
2429499|NCT03370653|Experimental|Open Label - odiparcil 1000 mg per day|2 tablets of odiparcil 250 mg per os, twice daily (BID)
2429500|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 1|An oral 25 mg dose of SEP 363856 once daily for 3 days, then 50 mg dose of SEP-363856 once daily for 7 days.
2429501|NCT03370640|Experimental|SEP-363856 Part 1 Cohort 2|An oral 50 mg dose of SEP 363856 once daily for 3 days, then 75 mg dose of SEP-363856 once daily for 7 days.
2429502|NCT03370640|Experimental|SEP-363856 Part 2 Cohort 3|An oral 25 mg dose of SEP 363856 once daily for 3 days, 50 mg dose of SEP 363856 once daily for 4 days, and then 75 mg dose of SEP-363856 once daily for 7 days.
2429503|NCT03370627|Experimental|Patient|
3146907|NCT00111852|Experimental|Desmoteplase, high dose|Desmoteplase 125 mcg/kg, intravenous administration.
3146908|NCT00111852|Placebo Comparator|Placebo|Dose-Match Placebo, intravenous administration.
2429506|NCT03370601|Other|Optimisation strategy|increase of Infliximab dose from 5mg/kg every 8 weeks to Infliximab 10 mg/kg every 8 weeks
2429507|NCT03370601|Other|Addition strategy|same dose of Infliximab ( 5mg/kg every 8 weeks) with addition of immunosuppressive agent: Azathioprine or Mercaptopurine
2429508|NCT03370588|Experimental|dexmedetomidine infusion group|
2429509|NCT03370588|Active Comparator|normal saline infusion group|
2429510|NCT03370575|Experimental|ethiodized poppyseed oil|
2429511|NCT03370575|Active Comparator|the second-generation non-ionic monomer contrast|
2429512|NCT03370562|Active Comparator|Dexmedetomidine|Patient will receive 10 mcg of dexmedetomidine in 5 ml of normal saline, administered by slow intravenous injection
2429513|NCT03370562|Placebo Comparator|Placebo|Patient will receive 5 ml of normal saline, administered by slow intravenous injection
2429514|NCT03370549|Experimental|AWARE intervention|Group psychotherapy intervention for Asian-American women
2429515|NCT03370549|Other|Waitlist control|Delayed AWARE intervention for Asian-American women
2429517|NCT03370510|Experimental|Pivotal Response Treatment (PRT)/oxytocin (OXT) nasal spray|Participants will receive oxytocin nasal spray 45 minutes prior to each PRT session.
3146909|NCT00111865|Experimental|Exercise|Aerobic Exercise Training
3146910|NCT00111865|No Intervention|Usual Care|
3146911|NCT00111956|Experimental|Etanercept|
3146912|NCT00111956|Placebo Comparator|Placebo|
3146913|NCT00111982|Experimental|Liatermin|Bilateral continuous infusion of liatermin for up to 24 months.
3146914|NCT00112008|Experimental|darbepoetin alfa|
3146915|NCT00112021|Experimental|Pramlintide Acetate|
3146916|NCT00112021|Placebo Comparator|Placebo|
2429518|NCT03370510|Placebo Comparator|Pivotal Response Treatment (PRT)/placebo nasal spray|Participants will receive a placebo nasal spray 45 minutes prior to each PRT session.
2429519|NCT03370497|Active Comparator|Whey protein hydrolysate|Whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2429520|NCT03370497|Experimental|Whey protein hydrolysate plus milk mineral supplement|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2429521|NCT03370484|Placebo Comparator|Control|Water with artificial sweetener
2429522|NCT03370484|Experimental|Milk mineral supplement|Milk Minerals containing 1000 mg calcium with artificial sweetener and water
3187568|NCT00757380|Active Comparator|Group 2|Brillant Blue
3187569|NCT00757393|Active Comparator|1|
2429525|NCT03370458|Experimental|Lactobacillus plantarum DR7|"Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum DR7, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 weeks.~Intervention: Dietary Supplement: Lactobacillus plantarum DR7"
2429526|NCT03370458|Placebo Comparator|Placebo|"Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.~Intervention: Dietary Supplement: Placebo"
2429527|NCT03370432||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
2429528|NCT03370432||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
3187570|NCT00757393|Experimental|2|
3187571|NCT00757406||1|Test group - Lymphedema sufferers
2429531|NCT03370406|No Intervention|Control Group|Control group will receive neither 5-fluorouracil (5FU) injection nor topical Imiquimod 5% cream. This group will receive standard of care only. Lesion will be surgical resected on day 21 of study.
2429532|NCT03370406|Experimental|5FU Group|5-fluorouracil (5FU) Group participants will receive a 1ml intralesional injection of 5FU 50mg/ml aqueous injectable solution. One injection will be administered weekly for 3 weeks. Injections will occur on d0, d7, and d14. Standard of care will be administered on d21 of study and lesion will be surgical resected.
2429533|NCT03370406|Experimental|5FU + Imiquimod 5% Group|5-fluorouracil (5FU) + Imiquimod 5% cream Group participants will receive intralesional 5FU as in the previous group, additionally participants will also receive three-times-weekly topical application of 5% imiquimod to the same lesion. Standard of care will be administered on d21 of study and lesion will be surgical resected.
2429534|NCT03370393|Experimental|Pathways for African-Americans' Success|Subjects will complete a 6-week Pathways for African-Americans' Success (PAAS) intervention. This is a weekly, 1.5 hour/session, family intervention for 6 weeks.
2429535|NCT03370393|No Intervention|Wait-list|Subjects will be on waiting list for active intervention and will receive the PAAS intervention at the end of the study (same as active intervention).
2429536|NCT03370367|Experimental|Arm A|13-cis retinoic acid will be dispensed in 3.75 mg and 5 mg gelatin capsules. Take 2 capsules once a day for up to 2 years.
2429537|NCT03370367|Placebo Comparator|Arm B|Take 2 placebo pills once a day for up to 2 years.
2429538|NCT03370354||Control group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is > 18, the patient will be in the control group.
2429539|NCT03370354||troubled sleeping patterns group|First questionnaire (spiegel questionnaire) will allow a score on 30. If the score is < 18, the patient will be in the troubled patterns group.
2429540|NCT03370341|Experimental|Active anodal tDCS|Active anodal tDCS followed by behavioral testing Intervention: Device: active anodal tDCS
2429541|NCT03370341|Sham Comparator|Sham tDCS|Sham tDCS followed by behavioral testing Intervention: Device: sham tDCS
2429542|NCT03370328|Experimental|Peppermint oil|post-op surgical patients
2429543|NCT03370328|Experimental|Ginger oil|post-op surgical patients
2429544|NCT03370328|Experimental|Peppermint and ginger oil|post-op surgical patients
2429545|NCT03370315|Experimental|Dance Group|"This group will be undergo dance classes two times a week, for 12 weeks. 24 sessions.~Intervention administered: Dance classes inspired by the rhythm of Forró and Samba."
3187572|NCT00757406||2|Control group - healthy volunteers
3187573|NCT00757419|Experimental|1|
3187574|NCT00757419|Placebo Comparator|2|
3187575|NCT00757458|Active Comparator|1|TCI with EDTA
3187576|NCT00757458|Active Comparator|2|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol containing EDTA
3187577|NCT00757458|Active Comparator|3|Re-filling of propofol syringe (Diprivan®-Astra Zeneca) with propofol without EDTA
3187578|NCT00757458|Active Comparator|4|Target controlled infusion of propofol without EDTA
3187579|NCT00757471|Active Comparator|Group 1|Brillant Blue
3187580|NCT00757471|Active Comparator|Group 2|Indocyanine Green
3187581|NCT00757510||Congenital heart disease|All subjects will have known or suspected congenital heart disease
3187582|NCT00757523|Active Comparator|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation).
3187583|NCT00757523|Experimental|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation).
3187584|NCT00757536|Active Comparator|Group 1|
3187585|NCT00757536|Active Comparator|Group 2|
3187586|NCT00757562|Experimental|DL|Desloratadine syrup once daily
3187587|NCT00757562|Placebo Comparator|Placebo|placebo syrup once daily
3187588|NCT00757575||1|
3187589|NCT00757640|No Intervention|B|no cholecystectomy
3187590|NCT00757640|Experimental|A|cholecystectomy
3187591|NCT00757653|Active Comparator|1|Stem with plasma sprayed porous Titanium 6Al4V alloy + Plasma sprayed HA
3187592|NCT00757653|Experimental|2|
3187593|NCT00757653|Active Comparator|3|
3187594|NCT00757679|Experimental|Milnacipran|
3187595|NCT00757679|Placebo Comparator|Placebo|
2429546|NCT03370315|Experimental|Walking Group|"This group will be undergo walking training two times a week, for 12 weeks. 24 sessions.~Intervention administered: Walking program with 3 different moments."
2429550|NCT03370276|Experimental|Phase I - Affiliate Sites Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
2429551|NCT03370276|Experimental|Phase I - Moffitt Site Only|"Nivolumab and dose escalation of Cetuximab.~Dose Level 1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 500 mg/m^2; Nivolumab 240 mg.~Dose Level -1:~Lead-in Day -14 before Cycle 1 only: Cetuximab 500 mg/m^2; Nivolumab - none. Cycle 1 Day 1 and all subsequent doses every 2 weeks (Q2W): Cetuximab 250 mg/m^2; Nivolumab 240 mg."
2429552|NCT03370276|Experimental|Phase II - Affiliate Sites Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
2429553|NCT03370276|Experimental|Phase II - Moffitt Site Only|Nivolumab and Cetuximab at recommended Phase II dose (RP2D).
3146917|NCT00112073|Experimental|0.15 mg/kg active bapineuzumab|
3146918|NCT00112073|Placebo Comparator|0.15 mg/kg placebo|
2429556|NCT03370224|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
2429557|NCT03370224|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
2429558|NCT03370211|Experimental|experimental intervention|The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums (RM).The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise.
2429559|NCT03370211|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
2429560|NCT03370198|Experimental|Dose-level 1|The dose-level 1 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2429561|NCT03370198|Experimental|Dose-level 2|The dose-level 2 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2429562|NCT03370198|Experimental|Dose-level 3|The dose-level 3 arm will use a 3+3 design. NKR-2 cells will be administered every 2 weeks (14 days) for a total of 3 administrations (hepatic transarterial administrations) within 4 weeks (28 days)
2429563|NCT03370185|Experimental|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
3146919|NCT00112073|Experimental|0.5 mg/kg active bapineuzumab|
3146920|NCT00112073|Placebo Comparator|0.5 mg/kg placebo|
3146921|NCT00112073|Experimental|1.0 mg/kg active bapineuzumab|
2429567|NCT03370159|Experimental|Treatment (CPI-613, docetaxel)|Patients receive CPI-613 IV over 2 hours on days 1 and 3, and docetaxel IV on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients that achieve stable disease after 6 courses then receive CPI-613 alone on days 1and 3. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2429568|NCT03370146||TKA patients - Experimental Group|
2429569|NCT03370146||TKA patients - Control Group 1|
2429570|NCT03370146||Healthy subjects - Control Group 2|
2429571|NCT03370133|Experimental|Bimekizumab cohort|Subjects will receive bimekizumab for 52 weeks.
2429572|NCT03370133|Active Comparator|Ustekinumab cohort|Subjects will receive ustekinumab (dose 1 or dose 2 depending on subjects weight) for 52 weeks. Placebo will be administered at pre-specified time points to maintain the blinding.
2429573|NCT03370133|Placebo Comparator|Placebo|Subjects will receive placebo up to week 16 and bimekizumab starting at week 16 through week 52.
2429616|NCT03369821||Study 1: T1D (Control)|"Age 0-70 years (matched to above)~Clinical diagnosis of T1D (diagnosed age 1-20 years)~Insulin treated from diagnosis."
3146922|NCT00112073|Placebo Comparator|1.0 mg/kg placebo|
3146923|NCT00112073|Experimental|2.0 mg/kg active bapineuzumab|
3146924|NCT00112073|Placebo Comparator|2.0 mg/kg placebo|
3146925|NCT00112099|Active Comparator|1|Procedure/Surgery: Surgery: Splenectomy
3146926|NCT00112099|Experimental|2|Procedure/Surgery: Surgery: Spleen-preservation
3146927|NCT00112229|Experimental|group 1|Melan-A analog peptide + CpG + Montanide
3146928|NCT00112229|Experimental|group 2|Melan-A natural peptide + CpG + Montanide
3146929|NCT00112229|Experimental|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
3146930|NCT00112229|Experimental|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
3146931|NCT00112320|Active Comparator|1|Standard PVR
3146932|NCT00112320|Experimental|2|PVR plus RV remodeling
3146933|NCT00112346|Active Comparator|A|
3146934|NCT00112346|Active Comparator|B|
3146935|NCT00112372|Experimental|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
3146936|NCT00112398|Active Comparator|Standard (paramedic) prehospital care|
3146937|NCT00112398|Experimental|Physician prehospital care|
3146938|NCT00112476|Experimental|Treatment (bryostatin, temsirolimus)|Patients receive bryostatin 1 IV over 1 hour on days 1, 8, 15, and 22 and temsirolimus IV over 30 minutes once on days 8, 15, and 22 during course 1. On subsequent courses patients receive bryostatin 1 and temsirolimus once on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2429575|NCT03370107|Active Comparator|Active rTMS and H coil|
2429576|NCT03370107|Placebo Comparator|sham rTMS and Hcoil|
2429577|NCT03370094||patients with suspected stroke|patients with suspected stroke due to paramedic's initial evaluation of face, arm, and speech function will be diagnosed with audio-video-streaming of suspected stroke symptoms and signs
2429578|NCT03370081|Experimental|CAPNO+|END TIDAL CO2(EtCO2) is monitoring and PACU nurses can see the values delivered by the capnography device
2429579|NCT03370081|No Intervention|CAPNO-|END TIDAL CO2(EtCO2) is monitoring but PACU nurses cannot see the values delivered by the capnography device
2429580|NCT03370068|Experimental|ICSI|All the oocytes in this group (from one ovary) will undergo insemination by ICSI.
2429581|NCT03370068|Active Comparator|Conventional IVF|All the oocytes in this group (from the other ovary) will undergo insemination by conventional IVF.
2429582|NCT03370055|Active Comparator|LeucoPatch®|Usual wound care and LeucoPatch® treatment for 8 weeks, with the offer of additional 8 weeks treatment with LeucoPatch®
2429583|NCT03370055|Placebo Comparator|Control|Usual wound care for 8 weeks, with the offer of 8 weeks of LeucoPatch® treatment after the first 8 weeks
3187596|NCT00757692|Experimental|A|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
3187597|NCT00757692|Active Comparator|B|Bicalutamide at 50 mg will be administered orally, daily and continuously.
2429586|NCT03370029||Primary ciliary dyskinesia patients|Primary ciliary dyskinesia patients will be included in study. Inclusion and exclusion criteria were considered.
2429587|NCT03370029||Healthy individuals|Those without diagnosed chronic disease will be included in study. Inclusion and exclusion criteria were considered.
2429588|NCT03370016|Experimental|Reduction in pressure|This group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
2429589|NCT03370016|Active Comparator|Stand Amount of Pressure|This group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
2429590|NCT03369990|Experimental|Botulinum toxin type A|DWP450
2429591|NCT03369990|Placebo Comparator|Placebo|Normal Saline
2429592|NCT03369977|Experimental|BioGlue Surgical Adhesive|Subjects in the BioGlue group will receive BioGlue as an adjunct for traditional surgical repair of the sinus of Valsalva.
2429593|NCT03369977|Other|Traditional Surgical Repair|Subjects in the control group will receive traditional surgical repair of the sinus of Valsalva.
2429594|NCT03369964|Experimental|Atezolizumab + Emactuzumab|Participants will receive Atezolizumab and Emactuzumab on Day 1 of each 21- day cycle
2429595|NCT03369964|Active Comparator|Atezolizumab + Emactuzumab + Obinutuzumab|"Participants will receive Atezolizumab, Emactuzumab, and Obinutuzumab on Day 1 of each- 21 day cycle (starting in cycle 2)~(Atezolizumab starting in cycle 2); and Obinutuzumab on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2-8."
2429597|NCT03369938|Experimental|exercise training intervention|
2429598|NCT03369938|No Intervention|usual care|
2429599|NCT03369925|Placebo Comparator|Placebo|
2429600|NCT03369925|Experimental|Cognizin|
2429601|NCT03369912|Experimental|Active|CSJ148
2429602|NCT03369912|Placebo Comparator|Placebo|5% dextrose
2429603|NCT03369886|Other|Early glaucoma group|Patients whose visual field mean deviation is > -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
2429604|NCT03369886|Other|Advanced glaucoma group|Patients whose visual field mean deviation is < -6dB OCT angiography will be taken but there are no difference between patients' group. The same OCT angiography protocol will be applied to all patients' group.
2429605|NCT03369873|Experimental|Nursing Orientation with guidance manual|The patients received the nursing orientation with validated guidance manual of cardiac catheterization.
2429606|NCT03369873|No Intervention|Routine Nursing Orientation|The patients received the routine nursing orientation about cardiac catheterization.
2429607|NCT03369860|Experimental|Healthy Subjects|Healthy Subjects take part in the experimental manipulation
2429608|NCT03369847|Experimental|Inhaled Corticosteroids|"Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer x 28 days.~Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer x 28 days"
2429609|NCT03369847|No Intervention|Standard Care|Patients allocated to this group will not receive an asthma controller medication from the emergency department. The intervention group will receive prescriptions for inhaled albuterol and oral corticosteroids as per standard treatment.
2429610|NCT03369834|No Intervention|Control Group|the volunteers of this group will not be submitted to the intervention.
2429611|NCT03369834|Experimental|Red LED group|in the volunteers of this group will be applied Red Light-emitting diode device with the length 620nm wave along the entire tibialis anterior muscle and bilateral sural triceps.
2429612|NCT03369834|Active Comparator|LED group infrared|in the volunteers of this group will be applied Infrared Light-emitting diode device with the wavelength of 940nm throughout the tibialis anterior muscle and bilateral sural triceps.
2429613|NCT03369834|Active Comparator|LED group mixed|in the volunteers of this group will be applied Infrared and Red Light-emitting diode device with the wavelength of 940nm and 620nm throughout the tibialis anterior muscle and bilateral sural triceps.
2429614|NCT03369834|Placebo Comparator|Sham Group|LED device off.
2429615|NCT03369821||Study 1: Existing EET1D (Case)|"Aged 0 to 70 years~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed <12 months~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)."
2429617|NCT03369821||Study 2: Newly diagnosed EET1D (Case)|"Aged 0 to 24 months at recruitment~Clinical diagnosis of diabetes <24 months (+ evidence of WHO diabetes criteria)~Negative genetic test for mutations causing non-autoimmune neonatal diabetes~Type 1 diabetes genetic risk score >50th centile of T1D reference group, or monogenic cause of T1D (e.g. STAT3 or FOXP3 mutation)"
2429618|NCT03369821||Study 2: NDM (Control)|"Diagnosis of diabetes <24 months~Age 0 to 24 months at recruitment~Diagnosis of NDM (confirmed by Exeter Molecular Genetics Laboratory)."
2429619|NCT03369808|Experimental|7.5μg H7N9 Vaccine|Participants will receive 2 doses of 7.5μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2429620|NCT03369808|Experimental|15μg H7N9 Vaccine|Participants will receive 2 doses of 15μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2429621|NCT03369808|Experimental|30μg H7N9 vaccine|Participants will receive 2 doses of 30μg hemagglutinin antigen of H7N9 vaccine at 21-day intervals.
2429622|NCT03369808|Placebo Comparator|Aluminum hydroxide adjuvant|Participants will receive 2 doses of aluminum hydroxide adjuvant at 21-day intervals.
2429623|NCT03369808|Placebo Comparator|Phosphate buffer solution|Participants will receive 2 doses of phosphate buffer solution at 21-day intervals.
2429624|NCT03369795|Experimental|Study Drug|Methotrexate 10mg
2429625|NCT03369795|Placebo Comparator|Placebo|Pills equivalent to other study arm (10 mg)
2429626|NCT03369782|Placebo Comparator|Placebo|Placebo alternative for rocuronium and for sugammadex
2429627|NCT03369782|Active Comparator|Rocuronium|Rocuronium as bolus and in syringe pump Sugammadex just before reduction of the joint
2429628|NCT03369769|Experimental|Canine & Adult Handler Activity|Unstructured 10-minute small group interaction with canine & handler
2429629|NCT03369769|Active Comparator|Toy and Adult Handler Activity|Unstructured 10-minute small group interaction with toy & handler
2429631|NCT03369717|Experimental|Antibiotics|To receive postoperative antibiotics
2429632|NCT03369717|No Intervention|No antibiotics|Will not receive any postoperative antibiotics
2429635|NCT03369665|Experimental|Mavenclad®|
2429636|NCT03369652|Experimental|Intervention|Medication history by pharmaconomist. Medication review by pharmacist, patient interview, and conference with physician in hospital, telephone contact to general practitioner after discharge, medication report sent to primary care.
2429637|NCT03369652|No Intervention|Control|Medication history by pharmaconomist. Usual care by physicians.
2429638|NCT03369626|Other|FareWell Program|All participants receive the FareWell Program intervention in this evaluation study
3146939|NCT00112528|Experimental|gemcitabine + bevacizumab + oxaliplatin|"Patients receive gemcitabine IV over 100 minutes and bevacizumab IV over 30-90 minutes on days 1 and 15. Patients also receive oxaliplatin IV over 120 minutes on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR.~After completion of study treatment, patients are followed every 3-6 months for up to 5 years."
3146940|NCT00112554|Experimental|Induction therapy arm I|Patients receive cytarabine IV continuously on days 1-3 and VNP40101M IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
3146941|NCT00112554|Active Comparator|Induction therapy arm II|Patients receive cytarabine as in arm I and placebo IV over 30-60 minutes on day 2 (at least 12 hours after the start of cytarabine).
3146942|NCT00112658|Experimental|Folfirinox|
3146943|NCT00112658|Active Comparator|Gemcitabine|
3146944|NCT00112684|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive alvocidib IV over 4½ hours once weekly in weeks 1-4. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2429645|NCT03369600|Experimental|Healthy Controls|Women Supersonic Imagine Aixplorer SWE Ultrasound Imaging on two separate occasions.
2429646|NCT03369600|Experimental|FIB-Sx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to elective hysterectomy for treatment of symptomatic uterine fibroids.
2429647|NCT03369600|Experimental|FIB-Mx|Women receiving Supersonic Imagine Aixplorer SWE Ultrasound Imaging prior to and at two points during elective medical therapy for treatment of symptomatic uterine fibroids.
2429648|NCT03369587|Experimental|Diverging lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of diverging lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
2429649|NCT03369587|Active Comparator|Parallel lines|What: Handwriting practice at home delivered through handwriting workbooks. The workbook consists of parallel lines. Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines. Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines. They will be asked to do this daily, but at least 5 days a week for 6 weeks. Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
2429650|NCT03369574||chronic rhinosinusitis and eosinophilic asthma|Adults over the age of 18, diagnosed with poorly controlled moderate to severe asthma with an eosinophilic phenotype (defined by blood eosinophil count of 150 µL or greater within 6 weeks of enrollment) who are initiating/undergoing reslizumab therapy and also carry a physician diagnosis of chronic rhinosinusitis with nasal polyposis
2429651|NCT03369561||normal cardiac patient|"Full history and clinical examination ECG on the left and right side Echocardiography and measurement of both left and right ventricular functions Laboratory investigation including cardiac enzymes, CK, CK MB, and cardiac troponin I.~Serum urea and creatinine and the calculated e GFR"
2429652|NCT03369548|Experimental|Apple/ Polyphenol|Participants will be asked to consume 2 Renetta Canada apples (with skin) and 2 placebo capsules every day for 8 weeks.
3146945|NCT00112697|Experimental|Arm 1|
2429653|NCT03369548|Experimental|Oats / Prebiotic|Participants will be asked to consume 40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
2429654|NCT03369548|Experimental|Lactobacillus reuteri NCIMB 30242 / Probiotic|Participants will be asked to consume 2 probiotic capsules and 40g cornflakes with semi-skimmed milk every day for 8 weeks.
2429655|NCT03369548|Placebo Comparator|Placebo / cornflakes|Participants will be asked to consume 40g cornflakes with semi-skimmed milk and 2 placebo capsules every day for 8 weeks.
2429656|NCT03369535|Placebo Comparator|Baseline|Baseline corresponds to typical American diet
2429657|NCT03369535|Active Comparator|PROT rich diet|Protein rich diet for 6 weeks
2429658|NCT03369535|Active Comparator|MUFA rich diet|MUFA rich diet for 6 weeks
2429659|NCT03369535|Active Comparator|CARB rich diet|CARB rich diet for 6 weeks
2429660|NCT03369522||Construction|100 recordings that will be used for the algorithm development
2429661|NCT03369522||Validation|100 recordings for the validation of the algorithm
2429662|NCT03369509||hypersensitivity drug reaction|Patient followed in the allergology department for the realization of immunoallergological test after suspicion of hypersensitivity drug reaction.
2429663|NCT03369496||MoNNET-HA Panel|Adults 25 years and older residing in the Montreal Metropolitan Area
2429664|NCT03369483||CPAP|At the end of the abdominal surgical procedure, mechanical ventilation withdrawal and extubation, patients will receive Continuous Positive Airway Pressure CPAP). CPAP will be be delivered using any commercially available CPAP equipment. CPAP will be started as soon as possible after the end of surgery. The starting airway pressure (PEEP) will be 5 cmH2O. PEEP may be changed at the discretion of the responsible physician. The maximum permissible PEEP during the trial intervention period will be 10 cmH2O. CPAP may be continued after the four-hour trial intervention period has finished, at the discretion of the responsible physician.
2429665|NCT03369470|Experimental|App Dexterity|
2429666|NCT03369470|Active Comparator|Theraband|
3146946|NCT00112697|Experimental|Arm 2|
3146947|NCT00112749|Experimental|Study Arm|Please see intervention description
3146948|NCT00112853|Experimental|Treatment (tipifarnib, etoposide)|"Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD."
2429672|NCT03369405||Periodontally healthy patients|Patients that have no history of periodontal treatment and that have been scheduled for routine prophylaxis appointments in the predoctoral clinics at the School of Dental Medicine, University at Buffalo.
2429673|NCT03369405||Periodontitis, group 1|Patients that have been referred from the pre-doctoral dental clinics to the Postgraduate Periodontics clinic for advanced periodontal disease. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
2429674|NCT03369405||Periodontitis, group 2|Patients referred to a faculty practice periodontist over the course of his clinical career due to chronic periodontitis that could not be treated by the referring general dentist. Clinical attachment loss, pain, mobility, bleeding, suppuration, and probing depths > 4 mm more likely to be prevalent.
2429675|NCT03369392|Experimental|Feasibility Cycle 1|Participants use the initial PANDA application.
2429676|NCT03369392|Experimental|Feasibility Cycle 2|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1.
2429677|NCT03369392|Experimental|Feasibility Cycle 3|Participants use the PANDA application after modifications are made based on suggestions from participants in cycle 1 and 2.
2429678|NCT03369379|Active Comparator|D3 Vitamin|In this group subjects will receive 1 vitamin D3 capsule of 50,000 units, each week, for 12 weeks.
2429679|NCT03369379|Placebo Comparator|Placebo|In this group the subjects will receive 1 placebo capsule each week for 12 weeks.
2429680|NCT03369366|Experimental|Reconstruction and Dental Rehabilitation|Placement of NobelActive dental implants (minimum of three) using integrated osteotomy and implant placement guide.Placement of provisional screw-retained prosthesis (all while flap is still pedicled to vascular supply). Inset of flap/implant/prosthesis/custom plate construct (KLS Martin Mandibular Reconstruction Implant).
2429727|NCT03369093|Experimental|Amoxicillin arm|Amoxicillin arm: Patients will receive two doses of Amoxicillin and single dose of Gentamicin daily for 3-5 days
3146949|NCT00112931|Active Comparator|Watch and Wait|Watch and Wait - no treatment
3146950|NCT00112931|Experimental|Arm C Rituximab 4 and Rixuximab Maintenance|4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks
3146951|NCT00112996|Experimental|Arm I: Alpha-Lipoic Acid|Oral alpha-lipoic acid three times daily for at least 24 weeks in the absence of unacceptable toxicity.
3146952|NCT00112996|Placebo Comparator|Arm II: Placebo|Oral placebo three times daily for at least 24 weeks in the absence of unacceptable toxicity.
3146953|NCT00113035||Patients with late onset Pompe Disease|
3146954|NCT00113074|Active Comparator|1|Weight management and BP control program
3146955|NCT00113074|Active Comparator|2|Self-help materials targeting lifestyle modification
3146956|NCT00113139|Experimental|Telephone-based coping skills|Telephone-based coping skills intervention
3146957|NCT00113139|Active Comparator|Usual Care|
3146958|NCT00113347|Experimental|Erlotinib + Docetaxel|Erlotinib 100, 125, or 150 mg orally daily except days receive Docetaxel 15 mg/m^2 or 20 mg/m^2 intravenously with Concomitant Boost Radiation to Head/Neck
3146959|NCT00113438|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
3146960|NCT00113438|Experimental|60 mg/m2 Combretastatin A-4 Phosphate|
3146961|NCT00113503|Active Comparator|Azathioprine weight-based dose|
3146962|NCT00113503|Experimental|Azathioprine individualised dose|
3146963|NCT00113633|No Intervention|Control Subjects|These subjects will receive standard discharge instructions that recommend follow-up with a PCP within 3-5 days.
2429687|NCT03369327|Experimental|sofosbuvir/daclatasvir|Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic
2429688|NCT03369314||Patients Receiving octaplasLG®|The data will be collected in all patients who have received at least one infusion of octaplasLG®
2429689|NCT03369301||Gammanorm|Patients on Gammanorm per standard of care
2429690|NCT03369301||Other Subcutaneous Immunoglobulin|Patients on subcutaneous immunoglobulin treatments other than Gammanorm
2429691|NCT03369275|Experimental|Mesenchymal Stromal Cells (MSCs)|Intravenous infusion of 300 million Allogeneic, Bone Marrow-Derived Human Mesenchymal Stromal Cells
2429692|NCT03369275|Placebo Comparator|Placebo|Intravenous infusion of Placebo, with excipients
2429693|NCT03369262|Experimental|Active|"OBE022 plus atosiban:~OBE022 will be given orally from Day 1 to Day 7. OBE022 treatment will be initiated ideally simultaneously or at a maximum within 24 h after atosiban start.~Loading dose: 1 000 mg on Day 1.~Maintenance dose on Day 1: 500 mg in the evening if loading dose was administered in the morning. If loading dose was administered in the afternoon, then the next dose will take place on the morning of Day 2.~Maintenance dose from Day 2 to Day 7: 500 mg twice a day (only morning dose on Day 7)~Atosiban will be administered over 48h as per label."
2429694|NCT03369262|Active Comparator|Placebo|"OBE022 matching placebo plus atosiban:~OBE022 matching placebo administration will follow the same regimen as the active group.~Atosiban will be administered over 48h as per label."
3146964|NCT00113633|Experimental|Intervention Subjects|As part of the intervention, the family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups. For children reporting persistent asthma symptoms, a letter will be given to the family to bring to their PCP stating that screening revealed symptoms that may require further treatment with controller medications. A mailed reminder to schedule a follow-up appointment will be sent to the family.
3146965|NCT00113659|Active Comparator|1|Participants in this arm will receive Lactobacillus GG.
3146966|NCT00113659|Placebo Comparator|2|Participants in this arm will receive a placebo.
3146967|NCT00113672|Experimental|A|Increase healthy eating and increase healthy activity
2429710|NCT03369210|Experimental|Liberal|Liberal group (patients receive a RBC unit each time Hb falls ≤ 9 g/dl (≤ 5.6mmol/l) with a target range for the post-transfusion Hb level of 9-10.5 g/dl (5.6-6.5 mmol/l)).
2429711|NCT03369210|Active Comparator|Restrictive|Restrictive group (patients receive a single RBC unit each time Hb falls ≤ 7.5 g/dl (≤ 4.7 mmol/l) with a target range for the post-transfusion Hb level of 7.5-9 g/dl (4.7-5.6 mmol/l).
3146968|NCT00113672|Experimental|B|Increase healthy eating and decrease unhealthy activity
3146969|NCT00113672|Experimental|C|Decrease unhealthy eating and increase healthy activity
2429714|NCT03369184|Experimental|Supplemental oxygen|Inhalation of oxygen 6 L/min through an open face mask
2429715|NCT03369184|Sham Comparator|Ambient air|Breathing ambient air through an open face mask
2429716|NCT03369171|Experimental|patients with MYO armband|
2429719|NCT03369145|Experimental|High-fat diet|Participants will consume a hypercaloric, high-fat diet. Participants will be provided with all the food during the week and will be instructed to consume all of the foods provided and no extra calorie containing food or drink. In the event of leftover food, participants will be asked to return the food for measurement and subsequent subtraction from their total energy intake.
2429720|NCT03369145|No Intervention|Control diet|Participants will consume their normal 'habitual' diet for seven days which will be compared to their habitual diet recorded by a three day food diary before commencing the two diets. Participants will be instructed to carry on as normal and eat their usual diet and this period will be used as a comparator to the high-fat diet. They will also be told to record their food intake for 3 days during the diet to quantify their control diet.
2429721|NCT03369132|Experimental|Angiflash|
2429722|NCT03369132|Placebo Comparator|Placebo|
2429723|NCT03369119|Active Comparator|Montelukast|Children received 4 mg oral montelukast granule daily until discharge.
2429724|NCT03369119|Placebo Comparator|Placebo|Children receive 4 mg oral placebo montelukast granule daily until discharge
2429725|NCT03369106||Multiple Sclerosis siblings|Group of siblings having multiple sclerosis, n=120 Composite severity score calculation for all subjects
2429726|NCT03369093|Active Comparator|Ampicillin arm|Ampicillin arm: Patients will receive four doses of parenteral Ampicillin and single dose of Gentamicin daily for 3-5 days
3146970|NCT00113672|Experimental|D|Decrease unhealthy activity and decrease unhealthy eating
3146971|NCT00113698|Placebo Comparator|1|
3146972|NCT00113698|Active Comparator|2|Ace inhibition (enalapril)
3146973|NCT00113789|Active Comparator|Pegfilgrastim|
3146974|NCT00113789|Placebo Comparator|Placebo|
3146975|NCT00113815|Experimental|003|topiramate 25 mg/kg/day
3146976|NCT00113815|Experimental|002|topiramate 15 mg/kg/day
3146977|NCT00113815|Experimental|001|topiramate 5 mg/kg/day
3146978|NCT00113815|Experimental|004|placebo placebo
2429728|NCT03369080||Danish National Cohort|This study includes all patients with a new Spinal Cord Injury hospitalized at Clinic for Spinal Cord Injuries, Rigshospitalet or Spinal Cord Injury Center of Western Denmark
2429729|NCT03369067|Experimental|Artificial Pancreas Therapy|Subjects will use the Tandem t:slim X2 with Control-IQ Technology + Dexcom G6 to automatically modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
2429730|NCT03369067|Placebo Comparator|Sensor Augmented Pump Therapy|Subjects will use a Dexcom CGM G5 and their Continuous Subcutaneous Insulin Infusion devices (insulin pumps) to modulate their insulin delivery and control their glycemia. In addition a Dexcom G5 Share/Follow system will be used to remote monitor the participants and ensure safety.
2429731|NCT03369054|Experimental|Minority Stress|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
2429732|NCT03369054|Active Comparator|Treatment as Usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
2429733|NCT03369028||2d and 3D image|A 2D and 3D image of the participants' face will be taken. It will at least last 2-3 sec.
2429734|NCT03369015|Experimental|Placebo, then 10 mg d-amphetamine, then 20mg d-amphetamine|
2429735|NCT03369015|Experimental|Placebo, then 20 mg d-amphetamine, then 10mg d-amphetamine|
2429736|NCT03369015|Experimental|10 mg d-amphetamine, then placebo, then 20mg d-amphetamine|
2429737|NCT03369015|Experimental|10 mg d-amphetamine, then 20mg d-amphetamine, then placebo|
2429738|NCT03369015|Experimental|20 mg d-amphetamine, then 10mg d-amphetamine, then placebo|
2429739|NCT03369015|Experimental|20 mg d-amphetamine, then placebo, then 10mg d-amphetamine|
2429740|NCT03369002|Experimental|Normal|"Child-Pugh Score: N/A~Subjects will receive a single 10 mg oral dose of seladelpar"
2429741|NCT03369002|Experimental|Mild Impairment|"Child-Pugh Score: A (5 to 6 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2429742|NCT03369002|Experimental|Moderate Impairment|"Child-Pugh Score: B (7 to 9 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2429743|NCT03369002|Experimental|Severe Impairment|"Child-Pugh Score: C (10 to 15 points)~Subjects will receive a single 10 mg oral dose of seladelpar"
2429744|NCT03368989||treatment with radium-223 Dichloride (Xofigo)|
2429745|NCT03368976||Interscalene|
2429746|NCT03368976||Supraclavicular|
2429747|NCT03368976||Infraclavicular|
2429748|NCT03368976||Transversus Abdominus Plane|
2429749|NCT03368976||Paravertebral Space|
2429750|NCT03368976||Fascia Iliaca|
2429751|NCT03368976||Femoral Nerve|
2429752|NCT03368976||Saphenous Nerve via Adductor Canal|
2429753|NCT03368976||Popliteal Sciatic Nerve|
2429754|NCT03368963|Experimental|Treatment (Nal-IRI, TAS-102)|Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Cycles repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2429755|NCT03368950|Experimental|Intervention|Participants in this arm are invited to undertake an 8-week online mindfulness course
2429756|NCT03368950|Active Comparator|Wait list|Participants in this arm are informed they are on a wait list and are required to wait 8 weeks, before being invited to take part in the intervention itself (an 8-week online mindfulness course).
3187598|NCT00757718|Active Comparator|CPAP treatment|Subjects will have repeat polysomnography on the second night, while wearing a continuous positive airway pressure (CPAP) device. Morning bloodwork will be drawn for inflammatory mediators.
2429758|NCT03368924|Other|SCA patients (SS genotype)|"To compare the level of anti band 3 antibodies in steady state and during vaso-occlusive crises in SCA patients.~To assess the relationship between level of biomarkers of oxidation of SS RBCs, altered hemorheological parameters, biomarkers of cellular activation (microparticles) and anti band 3 antibodies rate, taking into account the alpha-globin genes status.~To study the relationship between level of anti band 3 antibodies and severity of these VOC using an index of clinical severity (IS2) calculated at the end of SCA patients hospitalization for VOC.~To study early clinical (including the activity of the autonomic nervous system activity) and biological items to evaluate the relationship between these items and severity of VOC."
2429759|NCT03368911|Experimental|Reinforced tube group|use an reinforced endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
2429760|NCT03368911|Active Comparator|Conventional tube group|use an conventional endotracheal tube for endotracheal intubation during general anesthesia undergoing thyroidectomy
3187599|NCT00757718|Experimental|Oral appliance|Subjects will have repeat polysomnography on the second night, while wearing an oral appliance, as well as a Breathe-Right nasal strip. Morning bloodwork will be drawn for inflammatory mediators.
3187600|NCT00757731|Experimental|Minalcipran 100 mg|
3187601|NCT00757731|Experimental|Minalcipran 150 mg|
2429764|NCT03368885|Experimental|Experimental area PCI|"In this arm, in addition to the standard care for Polio eradication program activities of CGPP project, the following interventions are added:~Maternal dietary diversity; Diet diversity in complementary feeding; Exclusive breast feeding; Community mobilization; Capacity building; Convergence;Use of existing platforms VHSND; Strategic Use of Data"
2429765|NCT03368885|No Intervention|Control area PCI|This arm will receive standard care with respect to Polio eradication program activities of CGPP such as awareness generation around Polio and routine immunization, hand washing and sanitation
2429766|NCT03368872|Experimental|Astaxanthin and exercise|Astaxanthin formulation intake for one month followed by a 3-month exercise training program with astaxanthin formulation intake.
2429767|NCT03368872|Placebo Comparator|Placebo and exercise|Placebo intake for one month followed by 3-month exercise training with placebo intake.
3187602|NCT00757731|Experimental|Minalcipran 200 mg|
2429770|NCT03368846|Experimental|[14C]-Varlitinib|
2429771|NCT03368833||Caudal block|Patients that receive regional anesthesia in the form of a caudal block prior to surgery as part of their standard of care.
2429772|NCT03368833||Control|Patients who do not receive a caudal block.
2429775|NCT03368794|Experimental|Intervention|Telephone alert signal from ambulance staff to out-patient substance use disorder treatment facility, for active outreach aiming to locate and include the patient in long-term evidence-based treatment for the substance use disorder.
2429776|NCT03368794|Active Comparator|Control|Information-only. Ambulance staff hand over written information to the individual about how to seek treatment for the substance use disorder.
2429777|NCT03368781|Experimental|AcQMap Imaging and Mapping|Use of the AcQMap Imaging and Mapping System as a diagnostic modality in an ablation retreatment procedure for recurrent atrial fibrillation following a failed AF ablation.
2429778|NCT03368768||Contact group email of Mahidol-Oxford Research Unit (MORU)|The investigator aims to have at least 100 adult people who could provide information for the total of one year. This expects that at least 20 of those 100 people would have common cold or diarrhea at least one time over one year period. This should provide more than 80% power to detect whether the proportion of having antibiotics when they have common cold or diarrhea was lower than 50% or not. The hypothesized proportion was 20% as stated by the national strategy against AMR in Thailand
2429779|NCT03368755|Experimental|Cases (IUGR)|50 school-aged children (7-10 years old) exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with controls Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance
2429780|NCT03368755|Active Comparator|Controls|"100 school-aged children (7-10 years old) not exposed to IUGR (birth weight <10th percentile & fetal ultrasound documentation) and of comparable gestational age with cases.~Intervention: Cardiopulmonary Exercise Testing and Respiratory Muscle Strength and Endurance"
2429781|NCT03368742|Experimental|SGT-001 - Dose Level 1|Single IV infusion of SGT-001 at starting dose
2429782|NCT03368742|Experimental|SGT-001 - Dose Level 2|Single IV infusion of SGT-001 at next ascending dose
2429783|NCT03368742|No Intervention|Untreated Control|Untreated control group. After 1 year, treatment-eligible control patients will receive SGT-001 at the selected dose.
2429787|NCT03368716|Experimental|Acceptance-based Behavioral Treatment|Family acceptance-based behavioral treatment (ABBT) will be piloted with 16 child-caregiver pairs. At weeks 0 (pre-treatment), 9 (mid-treatment), and 18 (post-treatment), feedback regarding the feasibility and acceptability will be collected from participants through surveys and semi-structured group interviews to refine the family ABBT protocol.
2429788|NCT03368703|Experimental|COPD patients|COPD patients group
2429789|NCT03368703|Active Comparator|Healthy subjects|Healthy subject group, matched with COPD patients group on age, weight and BMI
2429790|NCT03368690|Experimental|Oligopin®|"Dietary supplement, Polyphenolic extract from pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Children and adolescent 20-50 kg body weight: 25 mg Oligopin®/day; > 50 kg body weight: 50 mg Oligopin®/day Adults 40-60 kg body weight: 100 mg Oligopin®/day; > 60 kg body weight: 150 mg Oligopin®/day"
2429791|NCT03368690|Placebo Comparator|Placebo|Placebo treatment ( identical capsules containing maltodextrin and magnesium stearate )
3146979|NCT00113828|Experimental|Transplantation|T-cell depleted HLA-matched peripheral blood stem cell transplantation
3146980|NCT00113893|Experimental|Scio-469 30 Milligram (mg)|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
2429794|NCT03368664|Experimental|alemtuzumab|- alemtuzumab - Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, prednisolone, H1 antagonist [antihistamine], H2 antagonist, paracetamol, acyclovir) will be administered prior alemtuzumab administration. - Type: Experimental
2429795|NCT03368651|Experimental|treatment group|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
2429796|NCT03368651|No Intervention|control group|no neo-adjuvant treatment before operation
2429797|NCT03368638|Experimental|Intervention|
3146981|NCT00113893|Experimental|Scio-469 60 mg|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
2429799|NCT03368599|Experimental|Bronchoscope guide group|DLT is advanced into the main bronchus through the guide of fiberoptic bronchoscope (Bronchoscope guided advancement).
2429800|NCT03368599|Active Comparator|Conventional group|DLT is advanced blindly to the main bronchus level (Conventional advancement).
2429801|NCT03368573|No Intervention|Control Arm|Participants in the control arm will undergo standard treatment as usual for ADHD. This will involve the clinician reviewing the child's symptom improvement once on medication and altering the dose according to their clinical judgement which may be informed by rating scales (completed by the parent, teacher and/or young person) and interviews with the parent and young person.
2429858|NCT03368144|Experimental|ClearLumen II Peripheral Thrombectomy System|Patients treated with the ClearLumen II Peripheral Thrombectomy System
2430461|NCT03363763|Placebo Comparator|Arm 3|Placebo ointment applied topically hs x 12 weeks
2429802|NCT03368573|Experimental|Experimental Arm|Participants in the experimental arm (QbTest) protocol will also undergo standard assessment as usual plus a QbTest. If a QbTest was not conducted within 12 weeks prior to starting medication (as part of the ADHD diagnostic assessment procedure) the young person will sit a QbTest at baseline (off medication). Once on medication they will sit another QbTest 2-4 weeks after commencing medication and again 8-10 weeks later (and no later than 12 weeks).
2429803|NCT03368560|Active Comparator|Sudarshan Kriya Yoga|Thirty participants with treatment-resistant late life depression (TR-LLD) will attend 5 instructional days of Sudarshan Kriya Yoga (SKY), followed by 3 weekly follow-ups, and 8 weeks of bimonthly follow-ups. Participants will also practice SKY for 25 minutes per day at home. These participants will attend 4 mental health assessments at weeks 0, 4, 8, and 12. Thirteen of the recruited TR-LLD will attend an MRI at baseline and post-intervention.
2429804|NCT03368560|No Intervention|Control|The seven recruited age-matched controls will complete a screening appointment and an MRI only for comparison. Demographic information will also be collected from the control participants. These individuals will not undergo the study intervention.
2429805|NCT03368547|Experimental|Diagnostic (68Ga-PSMA-11, PET/CT)|Patients receive 68Ga-PSMA-11 IV and undergo PET/CT scan over 20-50 minutes on day 1.
2429806|NCT03368534|Experimental|Skin Wound Patients|Patients will receive ART for wound healing and will be followed for 28 days to determine success of the procedure.
2429807|NCT03368521|Other|Back pain screening group|Includes the Group of patients where the care giver has used the back pain screening tests studied in order to judge how to proceed with rehabilitation, which level of rehabilitation is appropriate.
2429808|NCT03368521|No Intervention|treatment as usual|The Group get treatment as usual, where the care giver base the rehabilitation plan without taking the scorings from the screening tool into consideration.
2429809|NCT03368508|Experimental|Experimental group|the real-object rotatable 3D images were used in demonstrating these three techniques. The photogrammetry technique was used to produce the 3D images.
2429810|NCT03368508|Active Comparator|Control group|The control group received similar materials, but the only difference was that all the images were two-dimensional.
2429811|NCT03368495|Experimental|Co-administration of MMR/YF|Participants randomized to this arm will receive both MMR and yellow fever vaccines on Day 0.
2429812|NCT03368495|Active Comparator|MMR followed by YF|Participants randomized to this arm will receive MMR vaccine on Day 0 followed by yellow fever vaccine on Day 28.
2429813|NCT03368495|Active Comparator|YF followed by MMR|Participants randomized to this arm will receive YF vaccine on Day 0 followed by MMR vaccine on Day 28.
2429814|NCT03368482|Experimental|Brain Gym Exercises|Brain Gym® (BG) is a movement-based program originally designed to improve learning capabilities through the performance of mind-body exercises. BG can be considered as an interesting field of research due to the need of identifying novel therapies which might be more pleasant for older adults who tend not to be prone to participating in conventional exercise programs and might have a positive effect on their cognitive function. In spite of this, scientific evidence regarding the effects of BG on people with cognitive impairment is scarce.
2429815|NCT03368482|Active Comparator|Standard Exercises|A traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
2429816|NCT03368469|Experimental|transcranial direct current stimulation|Transcranial direct current stimulation (35 sq cm anode over left dorsolateral prefrontal cortex, 35 sq cm cathode over right supraorbital area, 1 mA current, 20 min per treatment session, 1 session per day, 10 treatment sessions over two weeks)
2429817|NCT03368456|Experimental|S4E App Intervention|Participants in the S4E condition will first receive the intervention in the waiting area via iPads provided for them. Content includes the theoretically driven components of Storytelling for Empowerment: (a) Storytelling scenarios, (b) drug use and HIV/STI knowledge development, (c) interactive activities, (d) increasing self-efficacy to prevent/reduce sexual risk and drug use behaviors, and increase HIV/STI testing, (e) clinician-youth communication, and (f) highlighting prevention principles
2429818|NCT03368456|Placebo Comparator|Usual Care Condition|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
2429819|NCT03368443|Active Comparator|Single-room group|The participants assigned to the Single-room group will receive treadmill training and overground gait training in one room (Room A) throughout the training sessions.
2429820|NCT03368443|Experimental|Two-room group|The participants in the Two-room group will receive treadmill training and overground gait training in 2 rooms (Room A and B) in an alternating order.
2429821|NCT03368430|Experimental|Melatonin|10 mg melatonin capsule was given to participants in the test group once per day for only 2 months after performing scaling and root planing (SRP) during the whole 6- month period of the study.
2429822|NCT03368430|Placebo Comparator|Placebo|Matching placebo capsule was given to the control group once daily for 2 months after receiving scaling and root planing (SRP) during the whole 6- month period of the study.
2429823|NCT03368417|Active Comparator|Usual Care|Usual care from SingHealth Polyclinics which includes non-wireless HBPM. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2429824|NCT03368417|Experimental|Wireless HBPM System|Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2429825|NCT03368417|Experimental|Wireless HBPM System and Incentives|Usual care from SingHealth Polyclinics with wireless HBPM system and BP monitoring incentives. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
2429826|NCT03368404|Experimental|CBL-102 eye drops|CE marked medical device, tear substitute containing 0.24% hyaluronic acid salt, carbomer and medium chain triglycerides
2429827|NCT03368404|Active Comparator|Vismed Multi eye drops|CE marked medical device, tear substitute containing 0.18% sodium hyaluronate
2429887|NCT03367897||Bleeding ulcer/erosions|Patients with hematemesis and/or melena, anemia or positiv FOBT that during gastroscopy are diagnosed with ulcer and/or erosions of the ventricle and/or duodenum. Gastroscopy must be performed within 72 hours of the findings above.
2429828|NCT03368391|Other|Sequence 1|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 1 participants will receive the drugs in the following sequence: 1) tetracaine HCl and oxymetazoline HCl 2) 3% mepivacaine 3) 2% lidocaine with 1:100,000 epi"
2429829|NCT03368391|Other|Sequence 2|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 2 participant will receive the drugs in the following sequence: 1) 2% lidocaine with 1:100,000 epi 2) tetracaine HCl and oxymetazoline HCl 3) 3% mepivacaine"
2429830|NCT03368391|Other|Sequence 3|"All participants will be exposed to all study medications during 3 subsequent visits with a 1 week washout between visits.~Sequence 3 participants will receive the drugs in the following sequence: 1) 3% mepivacaine 2) 2% lidocaine with 1:100,000 epi 3) tetracaine HCl and oxymetazoline HCl"
2429831|NCT03368378|Experimental|Group 1|During robot-assisted radical prostatectomy after the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
2429832|NCT03368378|Active Comparator|Group 2|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
2429833|NCT03368365|Other|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®.
2429834|NCT03368352|No Intervention|Normoxia|Sleep in normal room air with no drug
2429835|NCT03368352|Placebo Comparator|Hypoxia with Placebo|Sleep in hypoxic tent after taking Placebo 1 hour before bed.
2429836|NCT03368352|Experimental|Hypoxia with Melatonin|Sleep in hypoxic tent after taking 5 mg Melatonin before bed.
2429837|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.045%)|topical Ophthalmic Drops (0.045%)
2429838|NCT03368339|Active Comparator|PR013 topical Ophthalmic Drops (0.06%)|topical Ophthalmic Drops (0.06%)
2429839|NCT03368339|Placebo Comparator|Vehicle|Placebo
2429840|NCT03368313|Experimental|Compression arm|The compression arm will receive an adjustable velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
2429841|NCT03368313|No Intervention|Control arm|No compression
2429842|NCT03368300|Other|Patients|Parkinson's patient
2429843|NCT03368300|Other|witnesses: without parkinson's disease|Subjects without parkinson's disease
2429844|NCT03368287|Experimental|activity tracker|In this study, Fitbit One, the activity tracker, will be used for every participants to evaluate the daily steps before and after surgery for one year
2429845|NCT03368274|Experimental|Signal arm study|Patients with mild symptom IgG4-RD are enrolled and inject one dosage of diprospan ,then take Iguratimod (T614), 25mg, Bid orally for three months. Firstly, we evaluate IgG4-RD responder index of patients at baseline and follow-up time.We collect the laboratory parameters and blood for lymphocytes subpopulations by flowcytometry.
2429846|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|Supply epidemiological data on this detected HTAP, and allow the characterization of the clinico-biological paintings and the mortality which are associated to them.
2429847|NCT03368248||All neonatal resuscitation services.|All professionals in contact with children were interviewed: doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical.
3187603|NCT00757744|Experimental|A|Methadone maintenance treatment with Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
3187604|NCT00757744|Active Comparator|B|Methadone maintenance treatment with standard drug counseling
2429850|NCT03368209|Experimental|OUH protocol|"The protocol constituted two outpatient visits in the clinic within one week. Each visit had a duration of approximately 2,5 hours. Prior to study, optical screenings were conducted:~Optical Coherence Tomography (OCT)~Optical screening on measuring site with WM3.4.~Subjects were measured by the following scheme: ABL measurement, two optical measurements on WM3.4 #1 followed by two optical measurements on WM3.4 #2."
2429851|NCT03368209|Experimental|Home 1 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue was used for reference."
2429852|NCT03368209|Experimental|Home 2 protocol|"Optical screening (OCT and device) was conducted at baseline visit in the Department of Endocrinology M at Odense University Hospital.~WM3.4 was subsequently delivered to subject's home and the subject measured 30 days in a 60 days period of time. HemoCue and CGM/FGM was used for reference."
3187605|NCT00757757|Experimental|MCS110|
2429854|NCT03368183|Experimental|SCAMP arm|The SCAMP is a clinical decision support tool. See Mendu et al. CJASN 2017.
2429855|NCT03368183|Active Comparator|"Control arm SHAM SCAMP"|The control arm will be a form that asks questions about indications for renal replacement therapy but does not provide suggestions about when to initiate renal replacement therapy, as is being done in the active SCAMP arm. The goal of the control group is to test whether the SCAMP clinical decision support influences provider practice patterns and improves care.
3187606|NCT00757770|Experimental|Group HRV Lot A|
3187607|NCT00757770|Experimental|Group HRV Lot B|
2430508|NCT03363425|Active Comparator|Dexmedetomidine|
3187608|NCT00757770|Experimental|Group HRV Lot C|
3187609|NCT00757770|Active Comparator|Group Placebo|
2429859|NCT03368131|Experimental|Trastuzumab XELOX and radiotherapy|Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. XELOX：Capecitabine 825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45 Gray (unit)Gy/25f （1.8Gy/f/d，5 f/w）
2429860|NCT03368131|Active Comparator|XELOX and radiotherapy|Capecitabine：825~1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2429861|NCT03368118|Experimental|ABX464 Treatment arm|All subjects will receive ABX464 at 50 mg o.d for an overall period of 48 months.
2429862|NCT03368105|Experimental|LP299v group|Participants: one capsule of LP299v orally per a day during the entire period of antibiotic therapy.
2429863|NCT03368105|Placebo Comparator|Placebo group|Participants: one capsule of placebo orally per a day during the entire period of antibiotic therapy.
2429864|NCT03368092|Experimental|Dornase alfa|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
2429865|NCT03368092|Placebo Comparator|Placebo|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
2429866|NCT03368079|Experimental|Negative Pressure Suction Device|
3187610|NCT00757809|Experimental|QD|Once daily
2429869|NCT03368027|Experimental|Stress management program|A cognitive-behavioral program of coping with psychological stress for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
2429870|NCT03368027|Active Comparator|Standard intervention|Usual activities performed in the association where they attend (supervised by a psychologist) for 3 months (with a total of 12 sessions), one session per week, with a duration of 90 minutes per session.
3146982|NCT00113893|Experimental|Scio-469 90 mg|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3146983|NCT00113893|Experimental|Scio-469 120 mg|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
3146984|NCT00114075|Experimental|Gait analysis|Gait analysis report is available for treatment planning
3146985|NCT00114075|Active Comparator|Control|Subject has gait analysis test, but report is not available for treatment planning
2429875|NCT03367988|Experimental|Opioid-free Anesthesia|Patients will receive no intraoperative narcotics as part of their anesthesia regimen
2429876|NCT03367988|Active Comparator|Opioid Anesthesia|Patients will receive intraoperative narcotics as part of their anesthesia regimen
2429877|NCT03367962|Experimental|Highly suspected to already have aGVHD|Patients highly suspected to have aGVHD. These patients will undergo a [18F]F-AraG PET-CT scan following a biopsy taken to confirm aGVHD.
2429878|NCT03367962|Experimental|High risk of developing aGVHD|Patients at high risk of developing aGVHD will undergo a [18F]F-AraG PET-CT scan on day 4 +/- 2 days post transplant. Additionally these patients will be scanned again between day 14-21 post transplant.
2429879|NCT03367962|Experimental|Healthy Subjects|Healthy subject volunteers will undergo preliminary evaluation to ensure eligibility, receive and sign an informed consent, be enrolled in the trial, and then have a [18F]F-AraG PET-CT scan.
2429880|NCT03367949|No Intervention|Accuracy of surgical guide from Model optical scan|
2429881|NCT03367949|Active Comparator|Accuracy of surgical guide from Impression inversion Technique|
2429882|NCT03367936|Active Comparator|Self-monitoring group|All subjects will use a smartphone to self-monitor diet and monitor physical activity (Fitbit Charge 2), and a Withings or Fitibit digital scale for weight. Following randomization, participants will be oriented to Self-monitoring and provided a tutorial with images shown on the laptop and devices as well as printed materials showing the screen shots. At baseline, each participant will have a one-on-one session with the project interventionist, which covers the core principles of behavioral weight loss. The participant also will be given personalized fat, calorie, and PA goals for weight loss and information about how to access the intervention materials from the Diabetes Prevention Program (DPP) online which is publicly available (https://www.diabetesprevention.pitt.edu/).
2429883|NCT03367936|Experimental|Self-monitoring+Feedback group|All subjects will be asked to do everything the self-monitoring group is asked to do. Subjects will receive up to 4 Feedback messages per day (messages will be delivered between the hours set by the participants on the participant's phone, e.g., 8 AM and 9:30 PM). Messages will be delivered automatically, remotely and in real-time. Messages will be tailored to each participant's progress based on standardized algorithms. The Feedback program will be explained to them and how this is responsive to information entered on the self-monitoring diaries.
2429884|NCT03367923|Experimental|Arm I (exercise counseling, Fitbit, phone call)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive a short phone call at 2, 4, 6, and 8 weeks, and at 4 and 5 months to discuss the average number of daily steps over the past 2 weeks and to encourage a goal of a 10% increase over the next 2-4 week time period.
2429885|NCT03367923|Experimental|Arm II (exercise counseling, Fitbit, email/text)|Participants undergo an exercise counseling session at baseline and wear Fitbit tracker daily for 9 months. Participants receive an electronic communication (email/text) of their choice at 2, 4, 6, and 8 weeks, and at 4 and 5 months stating the average number of daily steps over the past 2 weeks and encouraging a goal of a 10% increase over the next 2-4 week time period.
2429886|NCT03367910|Experimental|FMT for MDRO UTI|Participants with eligible MDRO UTIs will receive FMT (150mL of RBX2660) via enema.
3187611|NCT00757809|Experimental|BID|Twice daily
3187612|NCT00757835|Active Comparator|Travoprost/timolol therapy|treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.
3187613|NCT00757835|Active Comparator|Latanoprost/timolol therapy|Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.
3187614|NCT00757874|Experimental|Tacrolimus cream|
3187615|NCT00757874|Active Comparator|Clobetasol cream|
2429888|NCT03367897||Peptic ulcer without bleeding|Control group for H. pylori will be patients with peptic ulcer without bleeding. These patients are systematically registered at SØ from August 2013 through the ongoing European registration study - HpEuReg study. SØ participate in this study, together with 9 other Norwegian hospitals, which is approved by REK.
2429889|NCT03367884|Experimental|Neck dissection group|Neck dissection followed by radiotherapy(50Gy) according to risk factors
2429890|NCT03367884|Active Comparator|Radiotherapy group|Definitive radiotherapy (70Gy)
2429891|NCT03367871|Experimental|Pembrolizumab, Chemotherapy, Bevacizumab|On day 1 of each 21 day cycle, participants will be administered Pembrolizumab 200mg (IV); Chemotherapy including Paclitaxel 175mg/m2 or 135 mg/m2 (IV), and Cisplatin 50mg/m2 (IV) or Carboplatin AUC 5; and Bevacizumab 15mg/kg (IV).
2429892|NCT03367858|Experimental|Motivational Interviewing (MI)|
2429893|NCT03367858|Active Comparator|Brief Adolescent Mindfulness (BAM)|
2429894|NCT03367845|Experimental|Control|Phone contacts with content not focusing on sensitivity or couples' relationships
2429895|NCT03367845|Experimental|Sensitivity Intervention|Home visits to enhance mother-infant and father-infant parental sensitivity; with COVID-19, we now conduct remote visits using Zoom
2429896|NCT03367845|Experimental|Couples Intervention|Home visits to enhance constructive couples' communication; with COVID-19, we now conduct remote visits using Zoom
2429897|NCT03367845|Experimental|Sensitivity and Couples Intervention|Home visits combining sensitivity and couples' interventions; with COVID-19, we now conduct remote visits using Zoom
2429898|NCT03367832||Paediatric surgical patients|All patients < 16 years, admitted to participating centres during the study period who undergo elective and non-elective surgery
3146986|NCT00114179|Experimental|Treatment (capecitabine, radiation, bevacizumab, gemcitabine)|"Chemoradiotherapy and bevacizumab: Patients receive oral capecitabine twice daily and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36-38. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Patients undergo reevaluation 3-4 weeks after completion of chemoradiotherapy and bevacizumab.~Patients with no evidence of disease progression proceed to maintenance therapy. Patients with a marked response may undergo surgery at the discretion of the attending surgeon and then proceed to maintenance therapy approximately 4-8 weeks later.~Maintenance therapy: Beginning within 4-7 weeks after completion of chemoradiotherapy and bevacizumab, patients receive gemcitabine IV over 30 minutes on days 1, 8, and 15 and bevacizumab IV over 30 minutes on days 1 and 15 provided that blood counts have returned to normal. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3146987|NCT00114257|Experimental|Arm I|"Patients receive decitabine IV over 1 hour on days 1-5 and 8-12 and FR901228 (depsipeptide) IV over 4 hours on days 5 and 12 OR days 5, 12, and 19. Treatment repeats every 4-6 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing complete remission for 1 year are removed from the study.~Cohorts of 6 patients receive escalating doses of decitabine and FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity."
3146988|NCT00114283|Experimental|Treatment (lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3146989|NCT00114309|Experimental|1|3 Dose Regimen
3146990|NCT00114309|Experimental|2|6 Dose Regimen
3146991|NCT00114348|Active Comparator|R-Blöcke|Blocktherapie
3146992|NCT00114348|Experimental|Prot-II-Ida|a
3146993|NCT00114361|Active Comparator|1|Ribavirin + Peg IFN
3146994|NCT00114361|Active Comparator|2|Peg IFN + Placebo
3146995|NCT00114413|Active Comparator|Reference Strategy|Participants in the reference strategy group will undergo the eNO procedure but will follow NAEPP guidelines alone for asthma treatment without eNO measurements for the rest of the study.
3146996|NCT00114413|Experimental|Biomarker Strategy|Participants in the biomarker strategy group will follow NAEPP treatment guidelines, as well as eNO measurements, to determine asthma treatment at each study visit.
3146997|NCT00114452|Active Comparator|Provacel: Cohort 1|ex vivo cultured adult mesenchymal stem cells
2429911|NCT03367780||RT with curative intent for HNSCC|several schemes for radical (chemo)radiotherapy, administered in 30-35 fractions over 6-7 weeks
2429912|NCT03367767||1|Former AREDS2 and AREDS2 Follow-On participants
2429913|NCT03367754|Experimental|1|Single dose of 200 mg (IV infusion)
2429914|NCT03367754|Placebo Comparator|2|Single dose (IV infusion)
3146998|NCT00114452|Active Comparator|Provacel: Cohort 2|ex vivo cultured adult mesenchymal stem cells
3146999|NCT00114452|Active Comparator|Provacel: Cohort 3|ex vivo cultured adult mesenchymal stem cells
2429917|NCT03367728|Placebo Comparator|TAP and Rectus Sheath Normal Saline|TAP and Rectus Sheath Block of 60 mL Normal Saline divided into 4 injections administered as in Experimental Arm.
2429918|NCT03367728|Experimental|TAP and Rectus Sheath ropivacaine|The block will be administered in the anterior abdominal wall. For the TAP block, the standard technique will be followed- at the anterior axillary line midway between the subcostal margin and iliac crest. For the rectus sheath block, a bilateral sub-xiphoid approach will be used. There will be 4 injection sites in total and the size of the needle will be standardized to an 18g spinal needle 10cms. Using laparoscopic visualization, the transversus abdominis muscles were identified lateral to the semilunar line. Ropivacaine to be infiltrated will be divided into 4 equal amounts. The procedure is then repeated 2 times in the transversus abdominis plane (20mL each) and 2 times as a Rectus Sheath Block (10mL each) with a total amount of 60 mL.
3147000|NCT00114452|Active Comparator|Provacel: Cohort 4|ex vivo cultured adult mesenchymal stem cells
3147001|NCT00114452|Placebo Comparator|Placebo|ex vivo cultured adult mesenchymal stem cells
3147002|NCT00114465|Experimental|VSL#3|Probiotic
3147003|NCT00114465|Placebo Comparator|Placebo|Placebo
3147004|NCT00114543|Active Comparator|Aggressive ELBW|In Aggressive group 1, infants with birth weights 501-750g.
3147005|NCT00114543|Active Comparator|Aggressive VLBW|In the Aggressive group 2, infants with birth weights 751-1000g.
3147006|NCT00114543|Active Comparator|Conservative ELBW|In the Conservative group 1, infants with birth weights 501-750g.
3147007|NCT00114543|Active Comparator|Conservative VLBW|In the Conservative group 2, infants with birth weights 751-1000g.
3147008|NCT00114608|Experimental|1|Electrical foot stimulation
2429922|NCT03367689|Experimental|Olaparib 300 mg|Patients whose tumours are identified as Homologous Recombination Deficient, will receive olaparib 300 mg (two tablets of 150mg) orally twice daily (bid) on days 1-28 each 28 days.
2429923|NCT03367676|Experimental|Experimental Arm|12 weeks adjuvant docetaxel plus trastuzumab
2429924|NCT03367663|Experimental|low dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
2429925|NCT03367663|Experimental|high dose|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
2429926|NCT03367650|Other|ALS's patients in Guadeloupe and Martinique|"We shall determine:~Impact of ALS in Guadeloupe and Martinique~Prevalence of the ALS in Guadeloupe and Martinique on the duration of the study~The distribution of ALS various phenotypes in our population of patients.~We shall collect the date of the beginning of the symptoms of the SLA, the date of diagnosis of ALS, the date of death for the same individual and the origin of the death, the weight, the size, the albumin, CRP; in order to establish the forecast of the various clinical forms, the description of the evolution of the nutritional state.~Search for transfers of genes TARDBP, VCP, SOD1 known and involved in the disease~Search for possible environmental factors"
2429927|NCT03367637|Active Comparator|Standard Care|"Patients in this arm will receive standard palliative care currently provided at the Rwanda Palliative and Hospice Care Organization (RPCHO).~Standard care also includes regular follow-up phone calls and home visits by the RPCHO staff, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed."
2429928|NCT03367637|Experimental|Intervention|Patients in this arm, in addition to the standard palliative care currently provided at the RPCHO, will receive biweekly frequency reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smart phone based symptom evaluation application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
2429929|NCT03367611|Experimental|Immunochemical faecal occult blood test|All participants will collect a single faecal sample for haemoglobin measurement (immunochemical faecal occult blood test, iFOBT), and be examined by colonoscopy.
2429930|NCT03367598||Normal weight|nondiabetic and nonobese individuals (18.5 kg/m2 ≤ BMI < 25 kg/m2, n=349)
2429931|NCT03367598||Overweight|nondiabetic and nonobese individuals (25 kg/m2 ≤ BMI < 30 kg/m2, n=154)
2429932|NCT03367585|Experimental|Experimental|The experimental group, which will supplement vitamin D3 50,000 IU / week, being in two capsules (25,000 IU / week each),
2429933|NCT03367585|Placebo Comparator|Placebo|The placebo group will inject two capsules of equal size, volume and coloration, composed of lactose, without the vitamin D3 supplement.
3147011|NCT00114764|Experimental|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
3147012|NCT00114764|Active Comparator|filgrastim|Filgrastim given daily after induction chemotherapy
3147013|NCT00114790|Experimental|BNCT.|Boronophenylalanine-based BNCT.
2429937|NCT03367559|Experimental|Rotavirus Vaccine|3 dose, interval for each dose is 4 weeks. The first dose will be received at 6-8 weeks of age.
2429938|NCT03367546|Experimental|rATG, FLU/CY/TBI, & Thiotepa|Anti-Thymocyte Globulin - Rabbit (rATG), Fludarabine (Fludara), Cyclophosphamide (Cytoxan, Neosar), Total Body Irradiation (TBI), & Thiotepa
2429939|NCT03367533|Experimental|ketamine plus perampanel|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive 6 milligrams (mg) oral perampanel and intravenous ketamine. Participants will then undergo a 2-hour magnetic resonance imagining (MRI) scan. The following day, participants will return for an additional scan and symptom assessment.
3147014|NCT00114868|Active Comparator|Vitamin A|48,000 IU vitamin A oral dose spread over 2 days as soon as possible after birth.
3147015|NCT00114868|Placebo Comparator|Placebo|placebo
3147016|NCT00114881||Inner-city children with asthma|Children at high risk for developing allergic diseases and asthma, on the basis of a parental history of asthma, allergic rhinitis or atopic dermatitis, and residence in the inner city
3147017|NCT00114894|Experimental|Safe Sea|
3147018|NCT00114894|Sham Comparator|Placebo|Coppertone® SPF15 (Schering-Plough)
3147019|NCT00115128||Filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
3147020|NCT00115167|Experimental|Darbepoetin alfa|
3147021|NCT00115167|Placebo Comparator|Placebo|
3147022|NCT00115180||Hispanic|Hispanic patients with long bone fractures no intervention
2429940|NCT03367533|Placebo Comparator|ketamine plus placebo|A screening session is conducted to ensure that the subject can safely receive perampanel and ketamine (physical exam, blood and urine analyses, electrocardiogram, drug and alcohol testing). The participant will then receive an oral placebo (in lieu of 6 mg oral perampanel) and intravenous ketamine. Participants will then undergo a 2-hour MRI scan. The following day, participants will return for an additional scan and symptom assessment.
2429941|NCT03367520|Experimental|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
2429942|NCT03367507|Experimental|80% Sub-symptom threshold aerobic exercise|The moderate intensity intervention group will exercise at 80% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The participants will be instructed to follow a program of moderate intensity activity in the form of their choice, we will recommend the following: stationary cycling, brisk walking, light jogging or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate wearing both the Actigraph and Polar HR monitor provided.
2429943|NCT03367507|Active Comparator|60% Sub-symptom aerobic exercise|The light (conservative) intensity intervention group will exercise at 60% of the maximum symptom free heart rate identified by their most recent graded treadmill test. The target heart rate zone will be within of the heart rate at which they experienced an increase in symptoms. The low intensity group will perform their exercise program at their own discrepancy however we will advise either of the following activities: light walking, stationary cycling or the use of any available cardiovascular exercise equipment where they can control and monitor their heart rate while simultaneously wearing both the Actigraph and polar HR monitor.
2429944|NCT03367494|Other|Subjects with Cystic Fibrosis|Diagnostic
2429945|NCT03367494|Other|Healthy Volunteers|Diagnostic
2429946|NCT03367481|Active Comparator|Control toothbrush|The participants will use a toothbrush with soft bristles.
2429947|NCT03367481|Experimental|Test toothbrush|The participants will use a toothbrush with medium bristles.
2429948|NCT03367468|Active Comparator|Physiotherapy group|Strengthening and stretching exercises,cross friction massage (supervised by physiotherapist) Mobilization techniques Daily usage of prescribed orthotic insole
2429949|NCT03367468|Active Comparator|Home exercise group|Strenthening and stretching exercises Daily usage of prescribed orthotic insole
2429950|NCT03367468|No Intervention|Control group|Follow ups Daily usage of prescribed orthotic insole
2429951|NCT03367455||ARIC and JHS participants|A combined cohort of Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS) participants
2429954|NCT03367416||Intervention|This study will test the NIATx model, an evidence-based behavioral intervention for implementing organizational change and quality improvement in community based health settings with a high proportion of underserved individuals. The goal of the study will be to use the model to identify and implement organizational changes in dental practices that will improve the no-show rate in underserved populations.
2429955|NCT03367403|Experimental|LY3002813|LY3002813 administered intravenously (IV).
2429956|NCT03367403|Placebo Comparator|Placebo|Placebo administered IV.
2429957|NCT03367390|Experimental|AID System Containing Insulin Lispro|The AID system is comprised of a continuous subcutaneous insulin infusion (CSII) pump component with a hybrid closed-loop control (HCLC) algorithm, and a continuous glucose monitor (CGM) component.
2429958|NCT03367377|Experimental|LY3209590|Escalating doses of LY3209590 administered by subcutaneous (SC) injection
2429959|NCT03367377|Active Comparator|Insulin glargine|Insulin glargine administered by SC injection
2429962|NCT03367351|Experimental|Web-Based Educational Intervention|Participants receiving the Web-Based Educational Intervention will be enrolled to the research protocol for six weeks of module-based learning and online discussion sessions and followed for a total of 3-months post CGM implementation to collect study measures.
2429963|NCT03367351|Placebo Comparator|Standard of Care|Participants will receive standard clinical care. Similar study measures will be collected to compare between groups.
3187616|NCT00757887|Experimental|EHMI8|Previously protected volunteers, N=10
2429964|NCT03367338|Active Comparator|Group A|Participants in group A consumed a 2-day very low-phosphate diet with PPR of 8 mg/g, followed by a 5-day washout period in which they adhered to usual diets, and then consumed a 2-day low-phosphate diet with PPR of 10 mg/g.
2429965|NCT03367338|Active Comparator|Group B|Compared with group A, the opposite order of low-phosphate diets will be prescribed in group B.
2429966|NCT03367325|Experimental|CDS-NVAF benefiting group|CDS-NVAF = Clinical decision support (CDS) tool for improving the adequacy of the anticoagulant therapy adequacy in non-valvular atrial fibrillation (NVAF)
2429967|NCT03367325|No Intervention|CDS-NVAF not-benefiting group|
2429968|NCT03367312|Experimental|Pulmonary Hypertension Patients on Inhaled Prostacyclin|10 subjects will Pulmonary Hypertension on a stable dose of Inhaled Prostacyclin for treatment of PH.
2429970|NCT03367286||Computed Tomography Perfusion (CTP)|
2429971|NCT03367286||Magnetic Resonance Perfusion (MRP)|
2429972|NCT03367273|Experimental|vitiligo patients|
2429973|NCT03367273|Experimental|controls|
2429974|NCT03367247|Experimental|Bolster|"Bolster provides participants with longitudinal nursing support across care settings,~A smartphone-based symptom management app,~A print and web-based symptom management toolkit,~Advance care planning to ensure that the patient receives care that is congruent with her informed preferences~BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks~Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice"
2429975|NCT03367247|Other|Enhanced Discharge Planning (EDP)|"Medication education,~Self-management strategies for symptoms,~Skills training,~A list of red flag symptoms and numbers for who to call"
2429976|NCT03367234|Experimental|Personalized Addiction-to-Health (PATH)|Cognitive Behavioral Therapy (CBT) sessions with a behavioral health consultant twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed weeks 27-52; Contingency management rewards for specified recovery behaviors which could include medication adherence, attendance at CB/RP sessions and/or CB/RP exercise participation; Medication-assisted treatment, either extended-release naltrexone once monthly or buprenorphine once daily; Peer recovery specialist support twice weekly for weeks 1-13, once weekly for weeks 14-26, as needed for weeks 27-52; Psychiatric consultation as needed.
2429977|NCT03367234|Active Comparator|Standard Care|Treatment may differ slightly by treatment program, but addiction specialty Intensive Outpatient Treatment (ASAM Level 2.1) will generally include individual therapy sessions with a counselor 1 hour per week for week; Medication-assisted treatment, either extended-release naltrexone once monthly or suboxone once daily; Group therapy sessions 9 hours per week then decreasing to 3 hours per week; Psychiatric consultation as needed.
2429978|NCT03367221|Experimental|NAVA group|NAVA ventilation
2429979|NCT03367195|Active Comparator|Treatment 1|1 Omeprazole capsule 20 mg and 1 placebo caplet of DLBS2411, twice daily
2429980|NCT03367195|Experimental|Treatment II|1 DLBS2411 caplet 250 mg and 1 placebo capsule of Omeprazole, twice daily
2429981|NCT03367182||Weekly paclitaxel + bevacizumab|
2429982|NCT03367182||Topotecan + bevacizumab|
2429983|NCT03367182||Pegylated liposomal doxorubicin + bevacizumab|
2429986|NCT03367156|Experimental|Group I (dexamethasone)|Patients receive dexamethasone PO BID on days 1-28 in the absence of disease progression or unacceptable toxicity.
2429987|NCT03367156|Active Comparator|Group II (placebo, dexamethasone)|Patients receive placebo PO BID on days 1-14 and dexamethasone PO BID on days 15-28 in the absence of disease progression or unacceptable toxicity.
2429988|NCT03367143|Experimental|L-ICE|Lenalidomide 25mg/d po d1-10, Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3, Frequency every 21 days, Total cycles 4
2429989|NCT03367130|Experimental|Intervention|HIV-positive individuals will receive the standard HIV care following the national ART guidelines. In addition, the intervention group will receive mobile phone calls. A mobile phone reminder will be made two days prior to their scheduled appointment for pills pick up. Trained research assistants will remind them of their scheduled clinic appointment of pills pick up. If the first call is missed, the second call will be made within the same day, if the second call is also missed, the final call will be made next day. The intervention will be delivered over the period of six months. Outcome assessors will not be involved in the phone calls.
2429990|NCT03367130|Placebo Comparator|Control|Control group will also receive the standard HIV care following the national ART guidelines and phone calls educating them on healthy living. Phone calls will be made once a month.
2429991|NCT03367104||Normal healthy controls|
2429992|NCT03367104||Heart failure patients|
2429993|NCT03367091|Experimental|Ekso GT gait training|"Participants will be measured during three Ekso GT gait trainings:~20-minute Ekso GT gait training with high swing assistance~20-minute Ekso GT gait training with neutral swing assistance~20-minute Ekso GT gait training with high swing resistance.~Each training will be performed on a separate day in a randomized order (within one week and controlled for time of day)."
2429994|NCT03367078||tDCS cohort|DOC patients treated according to usual care, plus anodal tDCS (prospective cohort)
2429995|NCT03367078||Historical control cohort|DOC patients treated according to usual care only (retrospective cohort of patients matched for demographic and clinical characteristics, admitted at the Montecatone Rehabilitation Institute no more than 3 years before the introduction of tDCS)
2429996|NCT03367065|Experimental|Dynamic contrast enhanced computerised tomography|
2429997|NCT03367052|Experimental|Two level Prodisc-C vivo|Two level Prodisc-C vivo cervical artificial disc replacement.
2429998|NCT03367052|Active Comparator|Hybrid|This group of patients will be treated with hybrid construct, i.e., one level of Prodisc-C vivo and one level of anterior cervical discectomy fusion (ACDF).
2429999|NCT03367039|Experimental|ProDisc-C vivo|This group of patients will be treated with ProDisc-C vivo disc replacement (single segment).
2430152|NCT03365921|Experimental|Hepatitis E vaccine lot 1|
2430153|NCT03365921|Experimental|Hepatitis E vaccine lot 2|
2430000|NCT03367039|Active Comparator|Anterior cervical discectomy fusion|This group of patients will be treated with anterior cervical discectomy fusion (ACDF) procedure (single segment).
2430001|NCT03367026|Active Comparator|Ivabradine oral product|Patients in the ivabradine treatment arm receive interventions:an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.
2430002|NCT03367026|No Intervention|control group|All patients receive established medical therapy according to current guidelines and therapeutic standards.
2430003|NCT03367013|Experimental|Intervention Group|The intervention group will receive a daily dose of 200 mg/kg of bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
2430004|NCT03367013|Sham Comparator|Control Group|The control group will receive daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
2430005|NCT03367000|Experimental|Ceprolac|Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months
2430006|NCT03367000|Placebo Comparator|Dietary counseling (DC)|Received standard diet counselling only for 6 months.
2430007|NCT03366974|Experimental|CYP inhibition + IV/PO midazolam|"Period 1: Administration of Midazolam (IV) on day 1, Co-administration of Midazolam (IV) and Grapefruit juice on day 2~Period 2: Administration of Midazolam (PO) on day 8, Co-administration of Midazolam (PO) and Grapefruit juice on day 9~Period 3: Self-administration of Clarithromycin (PO) bid regimen on day 12-14, Co-administration of Midazolam (IV) and Clarithromycin (PO) on day 15, Co-administration of Midazolam (PO) and Clarithromycin (PO) on day 16"
2430008|NCT03366961|Other|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
2430009|NCT03366935|Experimental|EPL and CEI|Those with receive a standard epidural (EPL) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
2430010|NCT03366935|Active Comparator|DPE and CEI|Those with receive a dural puncture labor epidural (DPE) and continuous epidural infusion(CEI) + patient-controlled epidural analgesia (PCEA)
2430011|NCT03366935|Active Comparator|DPE and PIEB|Those with receive a dural puncture labor epidural (DPE) and programmed intermittent epidural boluses(PIEB) + patient-controlled epidural analgesia (PCEA)
2430012|NCT03366922|Active Comparator|Control Arm|Participants will be on routine HAART only. No Artemisia Annua, Moringa oleifera will be given.
2430013|NCT03366922|Experimental|Intervention Arm 1|Participants will be given HAART and Artemisia annua leaf powder 4 g per day. They will only receive Artemisia Annua, Moringa oleifera will not be given.
2430014|NCT03366922|Experimental|Intervention Arm 2|Participants will be given HAART with Artemisia annua leaf powder of 4 grams per day and Moringa oleifera leaf powder of 10 grams per day. Both Artemisia Annua, Moringa oleifera will be given.
2430015|NCT03366909|Experimental|MBRP group|20 patients 2 groups of 10 patients
2430016|NCT03366909|Active Comparator|classic care in addictology center|20 patients
2430017|NCT03366896|Experimental|Delirium|Diagnosis of delirium according to 5th Edition of The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by Psychiatrist.
2430018|NCT03366883|Experimental|"Paclitaxel, Cisplatin Plus 5-FU (TCF)"|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks
2430019|NCT03366883|Experimental|Preoperative radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week
2430020|NCT03366870|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2430021|NCT03366870|Experimental|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2430022|NCT03366857|Active Comparator|30%|Participants allocated to these groups will receive a FiO2 of 0.3 during the operation and for two hours postoperatively.
2430023|NCT03366857|Active Comparator|80%|Participants allocated to these groups will receive a FiO2 of 0.8 during the operation and for two hours postoperatively.
3147023|NCT00115180||White|White patients with long bone fractures no intervention
2430025|NCT03366831|Active Comparator|15 minute version without questions|15 minute version of the TMW-Newborn intervention video without questions interspersed
2430026|NCT03366831|Active Comparator|15 minute version with questions|15 minute version of the TMW-Newborn intervention video with questions interspersed
2430027|NCT03366831|Active Comparator|7 minute version without questions|7 minute version of the TMW-Newborn intervention video without questions interspersed
2430028|NCT03366831|Active Comparator|7 minute version with questions|7 minute version of the TMW-Newborn intervention video with questions interspersed.
2430029|NCT03366818|Experimental|thrombectomy|thrombectomy by Versi system
2430030|NCT03366805|Active Comparator|Wound Care Video|Wound Care Patient Education Video
2430031|NCT03366805|Experimental|Pain Management Video Group|Pain Management Patient Education Video
2430032|NCT03366792|Experimental|MRI Targeted Biopsy|
2430033|NCT03366779|Other|Surgery with 6mm ACD|ACD medical device (non-experimental). Surgical device implantation after standard lumbar discectomy.
2430034|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, pemetrexed disodium)|Patients with non-squamous lung cancer receive nivolumab IV over 30 minutes, cisplatin IV over 60-120 minutes, and pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity
2430035|NCT03366766|Experimental|Cohort I (nivolumab, cisplatin, gemcitabine hydrochloride)|Patients with squamous lung cancer receive nivolumab IV over 30 minutes on day 1, cisplatin IV over 60-120 minutes on day 1, and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Courses repeat every 3 weeks for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
2430038|NCT03366740|Experimental|GB mixed full strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get the GB mixed full strength rice suji.~The allocated diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
2430039|NCT03366740|Experimental|Full strength rice suji alone|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.
2430040|NCT03366740|Active Comparator|3/4th strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn't resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.
2430041|NCT03366727|Experimental|DCB group|this group treated with drug coated balloon catheter, Orchid
2430042|NCT03366727|Experimental|PTA group|this group treated with plain balloon catheter, Admiral Xtreme
2430043|NCT03366714|Experimental|RAM cannula|nasal CPAP support with RAM cannula
2430044|NCT03366714|Active Comparator|Hudson cannula (short binasal cannula)|nasal CPAP support with Hudson cannula
2430045|NCT03366701||Patient during rehabilitation program|Patient performing a 5 weeks inpatient pulmonary rehabilitation program
2430046|NCT03366701||Patient after the rehabilitation program|Patient in their domicile after the 5 weeks program
2430047|NCT03366688|Active Comparator|IBI306|Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design
2430048|NCT03366688|Placebo Comparator|placebo|Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design
2430049|NCT03366675|Experimental|AZD2811|AZD2811 200mg IV QD CnD1 & D4 every 4weeks
2430053|NCT03366636|No Intervention|Control|"The control/comparison group will be receiving only their usual services which are offered at the agencies they frequent, including mental health services, case management, job training, educational services, and, in specific venue contexts, may receive HIV risk reduction or other sex education interventions such as Street Smart. These same services are also open to the intervention group. Usage of these services varies by site (residential vs drop-in; city (San Diego vs Los Angeles) and type of service (case management, mental health, health care, etc.)."
2430054|NCT03366636|Experimental|Project Legacy|The experimental/intervention arm will receive the Project Legacy intervention
2430055|NCT03366623|Other|Hospital clown intervention|"The performance of the hospital clown included creating a relation with the child by using different techniques in the venipuncture procedure.~The hospital clown used distraction techniques with music, songs, toys, fake tattoos (a small sticker/label with a picture applied to the skin with water), dream journeys, storytelling and making agreements in collaboration with the child, parents and healthcare personnel."
2430056|NCT03366623|Other|No hospital clown intervention|The clinical staff, defined as pediatric nurses and biomedical laboratory technologists, assisted the child in the venipuncture procedure with conventional communication, comfort and care techniques.
2430057|NCT03366610||Patients Previously Treated with Daclatasvir-Based Regimens|Patients in China Previously Treated with Daclatasvir-Based Regimens
2430058|NCT03366597|Experimental|Sevoflurane|Sevoflurane will be used as a narcotic drug in one group during cardiac surgery.
2430059|NCT03366584|Experimental|Intervention|"beta carotene 25,000 IU~vitamin D3 50,000 IU~zinc 50 mg~dexamethasone 6 mg"
2430060|NCT03366584|Active Comparator|Control|dexamethasone 6 mg
2430061|NCT03366571||Anti-viral therapy group|"Subjects who have completed the 3 years research Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis"
2430062|NCT03366571||Non anti-viral therapy group|History study from literature
2430063|NCT03366558||PD patients: early stage|Parkinson Disease patients with early stage of the disease: potentially hypokinesia, but no dyskinesia and motor fluctuations
2430064|NCT03366558||PD patients: developed stage|"PD patients having dyskinesia and motor fluctuations (described as developed stage of the disease)"
2430065|NCT03366558||No PD|Subjects not having diagnosed Parkinson Disease
2430066|NCT03366532||Nurses' Health Study|The NHS began in 1976 when 121,700 female nurses aged 33-55 years and residing in the United States responded to a baseline questionnaire.
2430067|NCT03366532||Nurses' Health Study II|The NHSII was initiated in 1989 with the recruitment of 116,671 younger female registered nurses, 24 to 44 years of age, from 14 states
2430068|NCT03366532||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was established in 1986 and was comprised of 51,529 US male health professionals ranging in age from 40 to 75 years at enrollment from 50 states
2430069|NCT03366519||patients with pulmonary embolism|patients with pulmonary embolism confirmed by tomography scan in emergency department
2430070|NCT03366506||ALS patients|"ALS patients ( suspected, possible, probable or definite per El-Escorial criteria).~Observation"
2430071|NCT03366493|Experimental|FRD, Cyctology, HPV testing|Subjects will be asked to have the FRD, Cytology, and HPV test performed on them by the study doctor or staff.
2430103|NCT03366285||Fullterm infants|Quality of bonding is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from the local elementary school.
2430104|NCT03366285||Moderate to late preterm infants|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the trauma and depression in late preterm parents study (TraDelPP) conducted 2010 to 2011."
2430072|NCT03366493|Experimental|Colposcopy Examination (and ECC if necessary)|Subjects with abnormal cytology (≥ ASCUS/AGC), positive FRD test in either the cervix or cervical canal, and/or positive HPV test will be referred to colposcopy. Subjects with a positive FRD test for the cervical canal, unsatisfied colposcopy (type II-III), and/or detection of AGC during cytology will also have to complete an ECC procedure. In addition, 10% of the subjects who tested negative for all three tests and are ≥ 25 years old will be randomly selected to complete a colposcopy as well.
2430073|NCT03366493|Experimental|Biospy|According to the colposcopy assessment, if the results show satisfied (type I) then a biopsy will be taken. Finally, a histopathological examination will be done and used as the gold standard. Subjects with a histopathological examination result of < CIN2 will be asked to come back for a follow up visit within 6 months or 1 year, according to the investigator's discretion.
2430074|NCT03366480|Experimental|Endometrial cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
2430075|NCT03366480|Experimental|Squamous non-small cell lung cancer|ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
2430076|NCT03366467|Experimental|SADE first|SADE first will initially be treated under SADE (Time 1) and receive RDE on the second encounter (Time 2)
2430077|NCT03366467|Experimental|RDE first|RDE first will initially be treated under RDE (Time 1) and receive SADE on the second encounter (Time 2)
2430078|NCT03366441|Experimental|Telephone group|The telephone group received telephone calls. All non-response and refusing donors were included for further follow-up. Donors who answered the phone call and agreed to be interviewed were asked the reasons why they had stopped donating according to a pre-designed questionnaire. All of the responsed donors were re-recruited by altruistic appeal.
2430079|NCT03366441|Experimental|SMS group|"The SMS intervention group received the following text message:Dear donors, Thank you for your donation through which your love brought hope to those helpless patients and your donated blood reignited the fire in their lives. If you can, please consider donating blood again to save a life. Thank you again for your support! . All donors either receiving or not receiving the message were included for further follow-up."
2430080|NCT03366441|No Intervention|Control group|No intervention will be giving to this group.
3187617|NCT00757887|Active Comparator|control|5 malaria-naive volunteers
2430082|NCT03366415|Experimental|Induction chemotherapy+IMRT+adjuvant chemotherapy|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), followed by gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles.
2430083|NCT03366415|Active Comparator|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25 mg/m² d1-3) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 30 mg/m² every week.
2430084|NCT03366402||Influenza A|
2430085|NCT03366402||Influenza B|
2430086|NCT03366389||Case|patients with irritable bowel syndrome
2430087|NCT03366389||Control|Healthy subjects without any gastrointestinal disorders, chronic diseases and malignancy.
2430088|NCT03366376|Experimental|Experimental|WBRT with hippocampus-sparing and SIB
2430089|NCT03366363|Experimental|Electro-acupuncture|"5 compulsory acupoints (ST35、EX-LE5、LR8、GB33 and Ashi) and 3 optional matching acupoints (stomach meridian syndrome：ST34、ST36、ST32、ST40、EX-LE2；gallbladder meridian syndrome：GB31、GB36、GB34、GB39、GB41；bladder meridian syndrome：BL39、BL40、BL57、BL60；San Yin meridian syndrome：LR7、SP9、SP10、KI10、SP4、SP6、LR3、KI3) will be chosen. Needles will be stimulated manually to achieve De Qi sensation and an electrical apparatus (Nanjing Jisheng Medical Co., Ltd., wave of 2/100Hz) will be then connected to the needles with alligator clips in pairs LR8-GB33 and two other matching acupoints. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity. Patients will receive 30-minute, 24 sessions intervention over eight weeks."
2430090|NCT03366363|Experimental|manual acupuncture|Participants in the manual acupuncture group have the same schedule as the Electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
2430091|NCT03366363|Sham Comparator|sham acupuncture|Those in the sham acupuncture group receive shallow acupuncture at non-acupoints without manipulation，Deqi or actual current output.
2430092|NCT03366350|Experimental|Consolidative allo-HSCT following CAR-T therapy|Patients who had achieved MRD-negative complete remissions through CAR-T therapy (NCT02965092) will, on their own accord, receive allo-HSCT if there are no previous HSCT, contraindications, and other restrictions.
2430093|NCT03366337|Experimental|Patients with baseline ACR > 300 mg/g but ≤ 2,500 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, 20 mg at week 4, and then to 30 mg at Week 6.
2430094|NCT03366337|Experimental|Patients with baseline ACR ≤ 300 mg/g|Patients will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg of bardoxolone methyl. They will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2 and 20 mg at week 4.
2430095|NCT03366324|Experimental|Combination of CAR-T therapy and HSCT|After patients achieve MRD- remissions through Second generation CAR-T cells, they will subsequently receive hematological stem cell transplantations within 30 days.
2430096|NCT03366311|Active Comparator|holding position|different holding position of endotracheal tube
2430097|NCT03366311|Active Comparator|stylet shapes|banana shape versus straight-to-cuff shape
2430098|NCT03366311|Active Comparator|epiglottis lift|with epiglottis lift or without
3187618|NCT00757900|Active Comparator|1|To receive a sub-unit influenza vaccine
3187619|NCT00757900|No Intervention|2|
3187620|NCT00757913|Experimental|1|n-3 enriched nutrition
3187621|NCT00757913|Placebo Comparator|2|isocaloric nutrition without n-3 supplement
3187622|NCT00757926|Experimental|1|
3187623|NCT00757926|Placebo Comparator|2|
3187624|NCT00757939|Experimental|AD Participants|Participants with a diagnosis of mild-to-moderate AD
2430105|NCT03366285||Preterm infants with skin to skin contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the skin to skin contact group. The study was conducted from 2012 to 2015."
2430106|NCT03366285||Preterm infants with visual contact|"Bonding quality is assessed at 6 to 8 years of age using the attachment story completion task. Infants are recruited from former participants of the delivery room skin to skin study (deisy) who were randomized into the visual contact group. The study was conducted from 2012 to 2015."
3147024|NCT00115180||African-American|African-American patients with long bone fracture no intervention
3147025|NCT00115193|Active Comparator|Arm A|Pegfilgrastim
2430109|NCT03366259|Active Comparator|Group A (Misoprostol group)|200 mcg rectal Misoprostol administration before cesarean section
2430110|NCT03366259|Placebo Comparator|Group B (control group)|No prostaglandins administration before cesarean section
2430111|NCT03366246|Active Comparator|lidocaine / prilocaine cream|according to randomization 2g topical nano anesthetic ( lidocaine 25mg/g and prilociane 25mg/g )was applied to one side ( left or right ) of the forehead 20 minutes before laser therapy.
2430112|NCT03366246|Placebo Comparator|placebo|according to randomization 2g of the placebo( nano anesthetic vehicle with no active ingredient ) was applied to one side ( left or right) of the forehead 20 minutes before laser therapy.
2430113|NCT03366233|Experimental|Mentally fatiguing task|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task.
2430114|NCT03366233|Placebo Comparator|Control task|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial for 90 min.
2430115|NCT03366220|Experimental|initial resuscitation with plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
2430116|NCT03366220|Active Comparator|initial resuscitation with balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
2430118|NCT03366181||heart failure patients|
3147026|NCT00115193|Active Comparator|Arm B|Pegfilgrastim
3147027|NCT00115232||1|Children without family history of early atherosclerosis
3147028|NCT00115232||2|Children with family history of early atherosclerosis.
2430122|NCT03366155|Experimental|1/Arm 1|HAIP chemotherapy + Systemic chemotherapy
3147029|NCT00115232||3|Parents of children without family history of early atherosclerosis
3147030|NCT00115232||4|Parents of children with family history of early atherosclerosis
3147031|NCT00115258|Experimental|parenteral nutrition titrated to measured REE|parenteral nutrition titrated to measured REE
2430127|NCT03366090||IBD patients|Biopsies for immunological analyses
2430128|NCT03366090||healthy controls|Biopsies for immunological analyses
2430129|NCT03366077|Active Comparator|Active|L reuteri
2430130|NCT03366077|Placebo Comparator|Placebo|Placebo
2430131|NCT03366064|Experimental|Pemetrexed and donor NK cell infusion|Eligible patients with stage 4 non-small cell lung cancer receive NK cells derived from HLA-haploidentical family donors. One week prior to NK cell infusion, patients receive pemetrexed (500 mg/m2) intravenous infusion
2430132|NCT03366051|Active Comparator|Sentinel Node Mapping plus Lymphadenectomy|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping followed by Systematic Pelvic and Para-Aortic Lymphadenectomy
2430133|NCT03366051|Experimental|Sentinel Node Mapping|Patients with high risk endometrial cancer will undergo Sentinel Node Mapping per NCCN algorithm
2430134|NCT03366038||Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy is performed following pancreaticoduodenectomy.
2430135|NCT03366025||Oocyte donors|Healthy oocyte donors undergoing ovarian stimulation with recombinant Follicular stimulating hormone
2430136|NCT03366012|Other|Cytosponge Test|This arm will include individuals without formal diagnosis of Barrett's esophagus.
2430137|NCT03365999|Active Comparator|Oral Tranexamic Acid|"Tranexamic acid will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid tablets are 650 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered."
2430138|NCT03365999|Experimental|Oral Aminocaproic Acid|"Aminocaproic acid will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic acid tablets are 500 mg each.~The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water.~For the aminocaproic acid, a total dose of 3 grams (6 tablets) divided between the 3 administrations (1 gram each, ie 2 tablets of 500 mg) will be administered."
2430139|NCT03365973||Spinal metastases of breast cancer|Patients with potentially unstable spinal metastases of breast cancer
2430140|NCT03365960|Active Comparator|Active1|watermelon rind
3147032|NCT00115258|No Intervention|standard of care|
3147033|NCT00115323|Active Comparator|1|Problem solving intervention
3147034|NCT00115323|Active Comparator|2|Attention control intervention
3147035|NCT00115388|Other|Deferred screening control group|Samples from women in the control group were stored and tested at the end of the trial
3147036|NCT00115440|Experimental|A|Active treatment arm.
2430155|NCT03365908|Experimental|Adductor Canal Nerve Block|Participant will receive an adductor canal nerve block via 15 mL 0.5% ropivacaine injection prior to OR for ACL reconstruction. Participant will receive pre-op oral medications.
2430156|NCT03365908|No Intervention|No Nerve Block|Participant will receive pre-op oral medications but no nerve block prior to OR for ACL reconstruction.
2430157|NCT03365895|Experimental|Diagnostic (non-enhanced MRI using MRN and DTI)|Patients undergo non-enhanced MRI of both lower extremities using MRN and DTI prior to initiation and after completion of standard of care chemotherapy.
3147037|NCT00115453|Experimental|A|Active treatment arm.
3147038|NCT00115505||Ancillary-Correlative (QOL, employment, informal care cost)|Patients complete the QOL Assessments comprising the Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form; Employment and Informal Care Cost Assessments; and Peripheral Neuropathy of the FACT-NTX subscale at baseline, 29-42 and 57-70 days, and at 9 and 18 months. Patients meeting the cut-off score for peripheral neuropathy on the FACT-NTX subscale at 18 months complete the Symptoms in Relation to Patient Functioning Survey, FACT-NTX subscale, the EORTC QLQ-C30, EORTC QLQ-BR23, and the Medications Used for Treating Peripheral Neuropathy at 24, 36, 48, and 60 months.
2430160|NCT03365869|Active Comparator|Sirolimus|Add sirolimus according to the protocol. Sirolimus active: 2mg po. QD
2430161|NCT03365869|Placebo Comparator|placebo|sirolimus placebo: 2mg po. QD
2430162|NCT03365856||RA patients|As routinary clinical practice and observational study
2430163|NCT03365843|Experimental|Montage bone putty|Sternal closure with conventional wire cerclage plus Montage bone putty
2430164|NCT03365843|Active Comparator|Conventional Sternal Closure|Conventional wire cerclage sternal closure only -- standard care.
2430165|NCT03365817|Experimental|Taper off|Decrease of opioid daily dose until discontinuation for up to six months.
2430166|NCT03365817|Active Comparator|Control Group|No changes on opioids and adjuvant medication for up to six months.
2430167|NCT03365804|Experimental|3D Printed Brace|This group will receive 3D printed brace
2430168|NCT03365804|No Intervention|Traditional Brace|This group will receive the traditional brace
2430173|NCT03365765|Experimental|mFOLFOX6 & apatinib|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks. Patients also take apatinib, 1 time daily, 500mg each time, lasting 1 year, from the first chemotherapy of mFOLFOX6.
2430174|NCT03365765|Active Comparator|mFOLFOX6|oxaliplatin 85mg/m2 intravenous infusion for 2 hours, intravenous infusion of leucovorin 400mg/m2 for 2 hours, intravenous infusion of 5- fluorouracil 400mg/m2, first days; 5- fluorouracil 2400mg/m2 continuous intravenous infusion for 46-48 hours, repeated 1 time every two weeks, a total of 12 cycles, 24 weeks.
2430175|NCT03365752|Experimental|Chloroprocaine|
2430176|NCT03365752|Active Comparator|Mepivacaine|
2430177|NCT03365752|Active Comparator|General Anesthesia|
2430178|NCT03365739|Active Comparator|Active Comparator 1|Treatment - Mango (pulp/flesh-500 g)
2430179|NCT03365739|Active Comparator|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
2430180|NCT03365739|Placebo Comparator|Control Comparator|Vitamin C (100 mg)
2430181|NCT03365726|Experimental|DST (dobutamine-stress-test)|dobutamine stress echocardiography performed to patients undergoing major surgery
2430182|NCT03365726|No Intervention|NDST (no-dobutamine-stress-test)|patients refused the dobutamine stress test and transesophageal echocardiography measured the troponin level in first 24 hours after surgery
2430183|NCT03365700|Active Comparator|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line.
2430184|NCT03365700|Active Comparator|Radiofrequency Ablation|Contact force-sensing radiofrequency left atrial ablation with 3D mapping system.
2430185|NCT03365687|Active Comparator|Vitamin D|Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
2430186|NCT03365687|Placebo Comparator|Placebo|Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
2430187|NCT03365674|Experimental|Vibration group|Vibrator head was applied (100Hz) on the popliteal fossa, during the trigger point injection
2430188|NCT03365674|Placebo Comparator|Placebo group|In placebo group, vibrator head was applied with switch-off sate, during the trigger point injection
2430189|NCT03365661|Experimental|ALT-803|
2430190|NCT03365648|Experimental|Lertal® + standard therapy|Lertal® double-layer tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
2430191|NCT03365648|Placebo Comparator|Placebo + standard therapy|Placebo tablets (1 tab/day for 4 weeks) plus standard therapy (antihistamine)
3147039|NCT00115531|Experimental|Arm 1|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
3147040|NCT00115531|Experimental|Arm 2|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
3147041|NCT00115544|Experimental|1|stannsoporfin 0.75mg/kg
3147042|NCT00115544|Experimental|2|stannsoporfin 1.5mg/kg
3147043|NCT00115544|Placebo Comparator|3|saline injection
2430200|NCT03365609|Experimental|T-group|T-group(triple therapy)
2430201|NCT03365609|Experimental|S-group|S-group( sequential therapy)
2430202|NCT03365609|Experimental|B-group|B-group( bismuth quadruple therapy )
2430203|NCT03365609|Experimental|C-group|C-group( concomitant therapy)
2430204|NCT03365596||Subacute stroke|
2430205|NCT03365583||Vitamin B12 deficiency|"No intervention will be administered for this study. Serum vitamin B12 <203 pg/mL is considered as vitamin B12 deficiency.~Fecal microbiota composition will be analyzed with 16S rRNA sequencing. In a subgroup of infants (n=11), fecal samples will be recollected after the treatment as usual"
2430206|NCT03365583||Vitamin B12 sufficient|Serum vitamin B12 ≥203 pg/mL is considered as vitamin B12 sufficient Fecal microbiota composition will be analyzed with 16S rRNA sequencing.
2430207|NCT03365557|Experimental|Intracuff pressure set by airway peak pressure|
2430208|NCT03365557|Other|Intracuff pressure set at 60 mmHg|
2430209|NCT03365544|Experimental|6am-2pm eating window|4 weeks of time restricted eating between 6am-2pm.
2430210|NCT03365544|Experimental|2pm-10pm eating window|4 weeks of time restricted eating between 2pm-10pm.
2430211|NCT03365531|Experimental|Alternate Daily Fasting (ADF)|Participants randomized to the ADF group will alternate between a day of ad lib feeding and a day of nearly no energy intake. Participants will be prescribed a core diet for feeding days that meets 110% of their estimated calorie needs within the fixed macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. In accordance with the ad lib feeding protocol, optional modules of similar macronutrient content will be prescribed, each providing an additional 200 kcals. Meal timing will not be restricted on these days. On fasting days, participants will be asked to consume 16 oz. of G2 Gatorade (40 kcal) in the morning and then only water or non-caloric beverages for the rest of the day.
2430212|NCT03365531|Active Comparator|Caloric Restriction|Participants randomized to the CR group will consume a diet of fixed energy designed to yield a 500 kcal/d deficit with a macronutrient distribution of 50% CHO, 20% PRO, and 30% FAT. Meal timing and caloric distribution will not be restricted.
2430213|NCT03365518|Experimental|Cognitive Behavioural Therapy (CBT)|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
2430214|NCT03365518|Experimental|Mindfulness-Based Therapy|Treatment will consist of a 4-week group lead by a trained clinician. Sessions are 2 hours in length and take place in consecutive weeks, with daily homework recommended between sessions.
2430215|NCT03365518|No Intervention|Control - Usual Care|"Participants who are randomized to the control group will not receive mindfulness or CBT treatment. They will proceed with the course of treatment they were receiving prior to enrollment in the study. As resources for couples dealing with changes to their sexual lives after prostate cancer are limited, it is anticipated that the majority of these patients will have no treatment targeting sexual intimacy during the 6-week period between completing the first and second questionnaire.~Those randomized to the control group will have the opportunity to be randomized to one of the treatment groups following their third and final questionnaire if they wish. In this case, they will be issued an additional participant ID within one of the treatment groups."
2430216|NCT03365492|Experimental|Treatment Arm|Patients with CAD who receive the BioFreedom™ Biolimus A9™ stent.
2430217|NCT03365479|Experimental|Study cohort|The study comprises a 1-day Screening period, followed by a right heart catheterization with a single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
2430218|NCT03365466||Group A|Patients who received a daily dose of 75mg LDA per day after menstruation prior to ET.
2430219|NCT03365466||Group B|Patients who received a daily dose of 5000u LMWH after menstruation prior to ET.
2430220|NCT03365466||Group C|Patients who received a daily dose of 75 mg LDA plus 5000u LMWH after menstruation prior to ET.
2430221|NCT03365466||Group D|Patients who did not receive any treatment.
2430222|NCT03365453|Experimental|frailty evaluation|all consecutive patients admitted to hospital for valvular disorders more than 69 years will be evaluated with several frailty and comorbidities scores.
2430223|NCT03365440||EP study with transseptal passage|"15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure~Focal pacing maneuvers"
2430224|NCT03365440||EP study without transseptal passage|- 15-30 minute esophageal ECG (using esoECG-3D catheter) & respiration recording during elective EP study and/or ablation procedure
2430225|NCT03365440||Healthy participants|- 60 minute esophageal ECG (using esoECG-3D catheter) & respiration recording
2430226|NCT03365427|Experimental|Application Group|People in this arm will be introduced to an APP on smart phone, and receive lessons on how to use it on their own phones. The APP will be installed and prepare to use before surgery. People will be asked and monitored on-line to regularly use the APP.
2430227|NCT03365427|No Intervention|Convention Group|People in this arm receive exactly the same treatment and lessons on post-operative rehabilitation except the reach of the APP.
2430228|NCT03365414|Other|Phase I|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP)
2430229|NCT03365414|Other|Phase II|Placebo ( Normal Saline 0.9% Infusion Solution Bag) or active comparator (Albumin (Human) 5%, USP), whichever was not not administered in Phase I
2430230|NCT03365401|Experimental|grade 1|Decompression surgery
2430231|NCT03365401|Active Comparator|grade 2|nonsurgical treatment
2430232|NCT03365388|Experimental|Sodium Hyaluronate group|Treatment of periarthritis of shoulder with Sodium Hyaluronate
2430233|NCT03365388|Active Comparator|Aerzhi group|Treatment of periarthritis of shoulder with Aerzhi
2430234|NCT03365375|Active Comparator|Usual Care Referral|Subjects will be referred for primary care provider (PCP) follow up and/or to psychiatry for further management and treatment of elevated anxiety levels according to standard of care.
2430235|NCT03365375|Experimental|MBSR Referral|Referral to a local mindfulness-based stress reduction course in addition to referral to their PCP.
2430509|NCT03363425|Placebo Comparator|Normal Saline 0,9%|
2430236|NCT03365362|Experimental|Long-Term Varenicline|Participants will receive 24 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily)
2430237|NCT03365362|Active Comparator|Short-Term Varenicline|Participants will receive 12 weeks of varenicline at standard doses (0.5 mg/day for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily), followed by matching placebo twice daily through week 24.
2430238|NCT03365362|Experimental|Directly Observed Therapy|Participants receiving directly observed therapy (DOT) will receive varenicline from opioid treatment program nurses at the same time as they receive methadone, as well as individually packaged take-home doses for self administration on evenings/weekends.
2430239|NCT03365362|Active Comparator|Self Administered Therapy|Patients receiving varenicline self administered therapy (SAT) will self-administer all varenicline doses.
2430240|NCT03365349|Experimental|living theatre|One session consisting for the patient of telling a story about his/her own life with diabetes , which is first written and then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a little play.
2430241|NCT03365349|Active Comparator|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
2430242|NCT03365336|Experimental|Intervention Group|Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.
2430243|NCT03365336|Active Comparator|Standard Care Group|Standard of care consist of 75 mg of Oseltamivir for five days and any other required provision of care. These will be determined on case by case basis by research clinician.
2430244|NCT03365323||infectious group|Patients who met the criteria according of Periprosthetic Joint Infection were identified as the infectious group.
2430245|NCT03365323||non-infectious group|Patients who didn't meet the criteria according of Periprosthetic Joint Infection were identified as the non-periprosthetic joint infection group.
2430246|NCT03365310|Experimental|Intervention Group|Participants will receive turmeric and tulsi capsule with milk(100 ml) along with standard of care treatment as determined by research physician...Each participants has to take two capsules of turmeric formula and tulsi twice daily for the study period of 3 months
2430247|NCT03365310|Active Comparator|Standard Care Group|Participants will only receive the standard of care treatment as determined by research physician
2430248|NCT03365297|Experimental|Treatment|apalutamide, 240mg (4x60mg tablets) orally, daily for a max. duration of 90 continuous days.
2430249|NCT03365284|Experimental|Smart Kneebrace|Smart Kneebrace with a smart phone app will be used during the rehabilitation after surgery for three months
2430250|NCT03365284|Placebo Comparator|without Smart Kneebrace|regular rehabilitation procedure will be applied after surgery
2430251|NCT03365271|Experimental|drainage|A drainage will be applied in this group.
2430252|NCT03365271|Active Comparator|without drainage|Non-drainage will be applied in this group.
2430253|NCT03365258|Other|High Nutritional Risk|modified NUTRIC score ≥ 5
2430254|NCT03365258|Other|Low Nutritional Risk|modified NUTRIC score < 5
2430255|NCT03365245|Other|study arm|Microperimetry and automated visual field are performed at three different days
2430256|NCT03365232|Experimental|non custom base attachment|
2430257|NCT03365232|Active Comparator|custom base attachment|
2430258|NCT03365219|Experimental|Alexis Retractor|This group received an Alexis O-Ring Wound Retractor during cesarean delivery.
2430259|NCT03365219|Active Comparator|Standard Surgical Retractors|This group received routine hand-held metal retractors as needed by the surgical team during cesarean delivery.
2430260|NCT03365180|Experimental|The Starter Kit Algorithm|Basal insulin initiation and titration using the Starter Kit Algorithm at two weeks, followed by standard of care titration during the following the next 10 weeks (maximum), or until optimal daily dose is considered identified.
2430261|NCT03365167|Active Comparator|LANAP|LANAP (Laser Assisted New Attachment Procedure)
2430262|NCT03365167|Placebo Comparator|LANAP off|laser therapy in off mode
3187625|NCT00757939|Experimental|Cognitively Normal Elderly Participants|Elderly participants with no cognitive impairment
2430264|NCT03365141|Experimental|Experimental group|"All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.~Intervention: Intralesional injection of triamcinolone acetonide (0.4mg/cc) will be performed weekly."
2430265|NCT03365141|Active Comparator|Control group|All lesions will treated with NBUVB or excimer laser weekly and application of topical tacrolimus ointment twice daily for a total of 12-week period.
2430266|NCT03365115|Active Comparator|intrathecal fentanyl|
2430267|NCT03365115|Active Comparator|intrathecal morphine|
2430268|NCT03365115|Experimental|intrathecal morphine and fentantyl|
2430269|NCT03365102|Experimental|anodal tDCS over the rIFG,|anodal tDCS over the rIFG,
2430270|NCT03365102|Experimental|anodal tDCS over the lOFC|anodal tDCS over the lOFC
2430271|NCT03365102|Placebo Comparator|sham tDCS stimulation|sham tDCS stimulation
2430272|NCT03365089|Experimental|Collateral vein ligation|Ligation of collateral veins under sonographic guidance
2430273|NCT03365089|No Intervention|Control|No collateral vein ligation.
2430274|NCT03365076|Experimental|Physical aerobic intervention|The exercise program will be varying between different aerobic activities indoor or outdoor as walking uphill and in stairs in intervals that will differ from session to session to build up the load and progression for these patients. In total, each session will be lasting approximately 45-60 minutes and a physiotherapist or personal trainer will supervise each session. Depending on the participants starting point, there will be 3 supervised session per week and two sessions where the participants do activity with low intensity (walk) by themselves and keep a log with duration (time) and intensity (using Borg scale).
2430275|NCT03365076|No Intervention|Controls|These patients will be acting as controls by not been instructed to physical activity. We will not monitor their activity either as this has been shown to increase activity by itself.
2430322|NCT03364777||lumbar surgery patients|patients undergoing lumbar surgery with or without anxiety or depression emotional state
3187626|NCT00757978|Placebo Comparator|1|Clozapine plus placebo
2430276|NCT03365063|Experimental|Active Knowledge Translation Group|Primary care clinics receiving the active knowledge translation intervention.
2430277|NCT03365063|No Intervention|Control Group|Primary care clinics receiving the current standard of care. Information on personalized risk and risk-based referral will not be provided.
2430278|NCT03365037|Experimental|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
2430279|NCT03365037|Active Comparator|Fracture healing film|Patients with acute soft tissue injury treated with fracture healing film
2430280|NCT03365024|Experimental|Computerized Intervention 1|A web-based program will deliver components of CBT-I on a time and event-based schedule. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
2430281|NCT03365024|Active Comparator|Computerized Intervention 2|A web-based program will deliver components of sleep education via an Internet platform. Pre and Post-Intervention assessments will be administered to determine the efficacy of the intervention.
3187627|NCT00757978|Active Comparator|2|Clozapine plus memantine
3187628|NCT00758004|Other|Reference|Commercial 80 mg atorvastatin tablet
2430284|NCT03364998|Experimental|BAY94-9027 and Elocta|Subjects received two treatments: 60 IU/kg BAY94-9027 in the first period, followed by 60 IU/kg Elocta in the second period, with a washout period before each treatment
2430285|NCT03364998|Experimental|Elocta and BAY94-9027|Subjects received two treatments: 60 IU/kg Elocta in the first period, followed by 60 IU/kg BAY94-9027 in the second period, with a washout period before each treatment
2430286|NCT03364985|Experimental|Cohort 1: DWP16001 Amg|DWP16001 Amg, tablets, orally, single dose administration
2430287|NCT03364985|Experimental|Cohort 2: DWP16001 Bmg|DWP16001 Bmg, tablets, orally, single dose administration
2430288|NCT03364985|Experimental|Cohort 3: DWP16001 Cmg|DWP16001 Cmg, tablets, orally, single dose administration
2430289|NCT03364985|Experimental|Cohort 4: DWP16001 Dmg|DWP16001 Dmg, tablets, orally, single dose administration
2430290|NCT03364985|Experimental|Cohort 5: DWP16001 Emg|DWP16001 Emg, tablets, orally, single dose administration
2430291|NCT03364985|Experimental|Cohort 6: DWP16001 Fmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2430292|NCT03364985|Experimental|Cohort 7: DWP16001 Gmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2430293|NCT03364985|Experimental|Cohort 8: DWP16001 Hmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2430294|NCT03364985|Experimental|Cohort 9: DWP16001 Img|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2430295|NCT03364985|Experimental|Cohort 10: DWP16001 Jmg|DWP16001 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 15days)
2430296|NCT03364972|Experimental|Experimental intraocular lens implant|'Alcon Clareon' : New monofocal, hydrophobic acrylic intraocular lens implant
2430297|NCT03364972|Active Comparator|Standard intraocular lens implant|Abbott Tecnis PCB00- Standard monofocal,hydrophobic acrylic intraocular lens implant
2430298|NCT03364959|Experimental|Flixotide|Patients inhale first Flixotide and then Qvar
2430299|NCT03364959|Experimental|Qvar|Patients inhale first Qvar and then Flixotide
2430300|NCT03364946||High Nasal Flow Therapy|Every patient in the ICU that requires High Nasal Flow Therapy
2430301|NCT03364933|Experimental|Primary intensivist and nurses|Patients randomized to the experimental arm will have a primary intensivist and a team of primary nurses assigned to them.
2430302|NCT03364933|No Intervention|Control|Patients who are randomized to the control group will receive usual care and not be assigned a primary intensivist or nurses.
2430303|NCT03364920||normal level of serum maresin-1|
2430304|NCT03364920||abnormal level of serum maresin-1|
2430305|NCT03364907||HIPEC patients|Patients with a diagnosis of peritoneal carcinomatosis who undergo HIPEC treatment with oxaliplatin.
2430306|NCT03364868|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
2430307|NCT03364868|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
2430308|NCT03364855|Active Comparator|SEBT exercise group|Star Excursion Balance Test will be used
2430309|NCT03364855|Active Comparator|KAT 2000 exercise group|Kinesthetic ability trainer will be used
2430310|NCT03364855|Active Comparator|combined exercise group|Both star Excursion Balance Test exercise and Kinesthetic ability trainer will be used.
2430311|NCT03364842|Experimental|F group|Furosemide group
2430312|NCT03364842|No Intervention|C group|Control group
2430313|NCT03364829|Experimental|COPD on Indacaterol/Glycopyrronium|COPD on indacaterol/glycopyrronium for 1 month
2430314|NCT03364816||TDR with Prodisc-C|participant underwent total disc replacement with Prodisc-C artificial disc
2430315|NCT03364816||TDR with Mobi-C|participant underwent total disc replacement with Mobi-C artificial disc
2430316|NCT03364816||TDR with Prestige-LP|participant underwent total disc replacement with Prestige-LP artificial disc
2430317|NCT03364803||Participants with Cushing's Syndrome|
2430318|NCT03364790|Experimental|group1|participant with posterior lumbar interbody fusion(PLIF or PLF)
2430319|NCT03364790|Experimental|group2|participant with total knee arthroplasty (TKA)
2430320|NCT03364790|Experimental|group3|participant with PLIF and TKA on one stage
3187629|NCT00758004|Other|Test|Pediatric appropriate atorvastatin 40mg formulation
3187630|NCT00758017|Experimental|Acupuncture 1|
3187631|NCT00758017|Active Comparator|Acupuncture 2|
3187632|NCT00758082|Active Comparator|1|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support
3187633|NCT00758082|Experimental|2|PDA-phone + phone consultations + standard visit at 3 months
3187634|NCT00758121||Observation|Heart failure patients with an implanted CRT-D
2430323|NCT03364764|Experimental|efficiency of sirolimus on PRCA|A prospective research of the sirolimus efficiency on refractory PRCA patients On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
3187635|NCT00758134|Experimental|A|Trastuzumab 6 mg/Kg
3187636|NCT00758186|Experimental|Colonic-stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction.
3187637|NCT00758186|Active Comparator|Emergency surgery|Emergency surgery: Patients underwent emergency surgery for acute left-sided malignant colonic obstruction.
2430327|NCT03364725|Experimental|Open Label Treatment Arm|Treatment arm using Glecaprevir-pibrentasvir for treatment of all patients
2430328|NCT03364712||pregnant|Pregnant women receiving routine medical care, including venipuncture.
2430329|NCT03364712||non-pregnant|Women not pregnant receiving routine medical care, including venipuncture.
2430330|NCT03364699|Active Comparator|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
2430331|NCT03364699|Experimental|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, participants were supplemented. Blood samples were collected before and after both half-marathon race.
2430332|NCT03364686|Experimental|Biotin-Labeled Red Blood Cells Infusion|Each participant will receive 2 transfusions of biotin labeled red blood cells.
3187638|NCT00758199|Active Comparator|2|Moxifloxacin
2430334|NCT03364660|Experimental|Voluntary Movement Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for voluntary movement.
2430335|NCT03364660|Experimental|Cardiovascular Epidural Stimulation|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function.
2430336|NCT03364660|Experimental|Voluntary Movement ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for voluntary movement and will also receive stand training.
2430337|NCT03364660|Experimental|Cardiovascular ES + Stand Training|Participants assigned to this group will receive epidural stimulation specific for cardiovascular function and will also receive stand training.
2430338|NCT03364647|Experimental|Arm A - Blood flow restriction training|Group will use blood flow restriction training and standard of care
2430339|NCT03364647|Sham Comparator|Arm B - standard of care plus sham|Group will receive standard of care plus a sham version of blood flow restriction training
2430340|NCT03364621||Metastatic Colorectal Cancer with Isolated Liver Metastasis|Patients with advanced colorectal cancer with isolated liver metastasis. Primary cancer must be resectable (if no archival exists) and patient must be planned for liver resection with at least 3 cycles of chemotherapy prior to liver surgery.
3187639|NCT00758199|Placebo Comparator|3|Prednisolone Acetate
3187640|NCT00758199|Active Comparator|1|Bromfenac
3187641|NCT00758212|Experimental|A|The experimental group will consist of HIV/AIDS patients(approx.50) who volunteer to receive a reduced dose Influenza vaccine using mesotherapy as a mode of injecting the vaccine intradermally.
3187642|NCT00758225|Experimental|only one arm|
3187643|NCT00758238|Experimental|myBP intervention|participants will receive access to hypertension self-management tools and support via a personal patient electronic health record
2430346|NCT03364595||Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the radial head fracture will be carried out
2430347|NCT03364595||Replacement|The operating surgeon will determine the positioning of the patient for surgery. During the surgery, they take out the the comminuted radial head and proceed replacement using artificial.
2430348|NCT03364582||Men-observed dietary pattern|Health Professionals Follow-up Study: a prospective cohort of male health professionals
2430349|NCT03364582||Women-observed dietary pattern|Nurses' Health Study: a prospective cohort of female registered nurses
2430350|NCT03364569||Participant with tranexamic acid.|The investigators followed the recommendations of one gram, two times a day, starting at the end of the surgery so as to avoid any adverse effects. The participants received two grams of Spotof ® (C.C.D laboratory, Portugal) as an oral liquid solution during three days.
2430351|NCT03364569||Participant without tranexamic acid.|This group concerns participants followed without acid tranexamic treatment. Investigators will observe the postoperative practices and complications observed, according to the surgical habits.
2430352|NCT03364543||Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs. This group will also have access to access to a social worker and a community worker.
2430353|NCT03364543||Usual Care|Access to a social worker and a community worker, but no systematic process for addressing health-harming legal needs.
2430354|NCT03364530|Other|Gemcitabine-Oxaliplatin Regimen|
2430355|NCT03364517|Experimental|Experimental group SPIA|The regulator will be asked to systematically use the tool Predictor score of the imminence of a childbirth (SPIA). This tool is used to evaluate the means to be sent following a call for imminent delivery outside the hospital.
2430356|NCT03364517|No Intervention|Control group|The classic care will be made according to the usual practices of the doctor and the center.
2430357|NCT03364504|Experimental|PXE patients|urine collection and culture of renal cells
2430358|NCT03364491|Experimental|Tranexamic Acid|Tranexamic Acid for intravenous administration
2430359|NCT03364491|Placebo Comparator|Placebo|Normal saline for intravenous administration
3187644|NCT00758238|No Intervention|usual care|participants allocated to usual care may still opt to use the personal patient electronic health record, but will not have access to the hypertension self-management tools until after the intervention period. The usual care group will be given a web-link for patient hypertension management resources
3187645|NCT00758251||1|Adult schizophrenia patients already on Seroquel XR therapy
3187646|NCT00758277|Active Comparator|Levetiracetam|
3187647|NCT00758277|Placebo Comparator|Placebo|
3187648|NCT00758303|Active Comparator|1|Low Dose TRIA-662
3187649|NCT00758303|Active Comparator|2|High Dose TRIA-662
2430360|NCT03364478|Experimental|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach. In DML group, the dissecting based on CME is performed with dorsal approach and medial approach hybridized.
2430361|NCT03364478|Active Comparator|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach. In MLA group,the dissecting based on CME is performed with meidial-to-lateral approach.
2430362|NCT03364465|No Intervention|GruopFix|one-lung ventilation with constant tidal volume
2430363|NCT03364465|Active Comparator|GroupVariable|one-lung ventilation with variable tidal volume Intervention: change of ventilatory settings
3147044|NCT00115557|Experimental|1|Performance feedback, academic detailing, practice facilitation, IT support
2430365|NCT03364413||Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
2430366|NCT03364400|Experimental|VT1021|Escalating doses of VT1021 to determine RP2D
2430367|NCT03364374||Stroke survivors|Individuals that experienced uni-hemispheric ischemic or hemorrhagic stroke
2430368|NCT03364374||Controls|Healthy controls with no history of stroke
2430369|NCT03364361|Other|Acupuncture|Feasibility Study
2430370|NCT03364348|Experimental|Cohort 1 (Ado-trastuzumab emtansine + utomilumab)|Utomilumab at escalating doses of 20 mg and 100 mg will be given intravenously in combination with the FDA-approved dose and schedule of ado-trastuzumab emtansine (3.6 mg/kg IV) every 3 weeks.
2430371|NCT03364348|Experimental|Cohort 2 (trastuzumab + utomilumab)|Utomilumab 20 mg IV + trastuzumab 6 mg/kg IV every 3 weeks. 3 subjects will be treated at this dose level. If no DLT events are recorded, then utomilumab dose will be increased to 100 mg (Dose Level 2).
3187650|NCT00758303|Placebo Comparator|3|Matching Placebo for TRIA-662
2430377|NCT03364322||Dry eye syndrome|
2430381|NCT03364296|Other|Patients hospitalized for stroke|
3147045|NCT00115557|Active Comparator|2|Performance feedback only
3147046|NCT00115570|Experimental|Insulin Glulisine|Insulin Glulisine (100UI/ml), at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine for a maximum of 26 weeks
2430384|NCT03364270|Experimental|[F-18] RDG-K5|PET/CT Imaging with administration of [F-18] RGD-K5
2430385|NCT03364244||Sildenafil|Pediatric patients receiving Revatio
3147047|NCT00115570|Active Comparator|Insulin Lispro|Insulin Lispro (100UI/ml) Subcutaneous (SC) injection , at least twice daily, in association with basal insulin therapy (NPH insulin or insulin glargine ) for a maximum of 30 weeks
2430387|NCT03364218|Experimental|Treatment Group|Subjects will receive N-Acetyl Cysteine (NAC) nebulized 2 mL of 10% NAC solution every 12 hours during their stay in the Pediatric Intensive Care Unit.
2430388|NCT03364218|No Intervention|Control Group|Subjects will not receive NAC, but will receive standard care for acute bronchiolitis.
2430389|NCT03364205|Experimental|intervention|solution-focused interview techniques
2430390|NCT03364205|No Intervention|control|This group did not apply solution-focused interview techniques.
2430392|NCT03364179||young onset dementia|
2430393|NCT03364179||late onset dementia|
2430394|NCT03364166|Active Comparator|buccinator muscle excision with skin|surgical excision of the buccinator muscle with the skin in buccal squamous cell carcinoma and neck dissection also done
2430395|NCT03364166|Active Comparator|buccinator muscle excision without skin|surgical excision the buccinator muscle without the skin in buccal squamous cell carcinoma and neck dissection also done.
2430396|NCT03364153|Experimental|Cohort 1|Zimura dose group
2430397|NCT03364153|Sham Comparator|Cohort 2|Sham dose group
3147048|NCT00115596|Experimental|Intervention Arm|"'Formal Curriculum; Low-Fidelity Simulation'~Residents randomized to the intervention arm will receive the study skills training curriculum (the intervention)."
3147049|NCT00115596|No Intervention|Control|Residents randomized to the control arm will receive standard pediatric training.
2430400|NCT03364114|Experimental|EndoRotor Resection|For the purpose of this study the EndoRotor System is investigationally indicated for use during endoscopic procedures to resect and remove refractory Barrett's esophagus tissue in conjunction with a submucosal saline injection mix using adrenaline and dye. Subjects randomized to the EndoRotor arm will be treated up to 3 times through the 9 month follow-up period to remove gross visible Barrett's.
2430401|NCT03364114|Active Comparator|Continued Ablation (Control)|The investigator shall exercise standard of care for subjects undergoing continued ablative therapies (RFA and/or Cryotherapy). These will constitute the control devices. The investigator will choose the system in this arm. Operation of each system will be done according to the manufacturer's IFU. Subjects randomized to the control arm may be treated up to 3 time through the 9 month follow-up period to remove gross visible Barrett's.
3147050|NCT00115648|Active Comparator|A|Single dose NVP + ZDV daily for the first week.
3147051|NCT00115648|Experimental|C|Arm A plus NVP + ZDV daily to age 14 weeks.
3147052|NCT00115648|Experimental|B|Arm A plus oral NVP daily to age 14 weeks.
3147053|NCT00115687|Placebo Comparator|A|placebo
3147054|NCT00115687|Experimental|B|2 mg nicotine gum
3147055|NCT00115700|Experimental|Radiotherapy+ Chemotherapy|Involved field Radiotherapy (RT) 30-36 GY plus Cyclophosphamide, Vincristine and Prednisolone (CVP) + rituximab × 6 cycles
3147056|NCT00115700|Active Comparator|Radiotherapy alone|Involved field Radiotherapy (30-36 GY) alone
3147057|NCT00115726|Experimental|1|furosemide
3147058|NCT00115726|Placebo Comparator|2|placebo
3147059|NCT00115791|Experimental|1|
3147060|NCT00115791|Placebo Comparator|2|
3147061|NCT00115856|No Intervention|Subjects studied|Single arm exploratory feasibility safety and efficacy study of MRI to image atherosclerosis in arteries
3147062|NCT00115882|Experimental|1|proactive smoking-cessation telephone counseling
3147063|NCT00115882|No Intervention|2|no-intervention control
3147064|NCT00115895|Experimental|Radioactive iodine 1,1 GBq|Low activity of radioiodine, 1,1 GBq
3147065|NCT00115895|Other|Radioactive iodine 3,7 GBq|Routine activity of radioiodine, 3,7 GBq
3147066|NCT00115960|Experimental|1|Group 1 will receive 3 vaccinations of the HIV-1 gag DNA vaccine, or placebo. Vaccinations will be given at Months 0, 1, and 3.
2430402|NCT03364101|Experimental|PowerOff|PowerOff is a nutraceutical and a blend of nine ingredients for sleep, including: melatonin; California Poppy; L-Cystine; Glycine; and Magnolia Officinalis
2430403|NCT03364101|Placebo Comparator|Placebo|The placebo pill will be manufactured at the same facility and appear identical in all aspects. However, the control agent will feature non-active ingredients with regards to sleep.Capsules will be instructed to commence on day 7 of the study after baseline appointment
2430404|NCT03364088|Active Comparator|Spinal anesthesia with tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of the tourniquet.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2430405|NCT03364088|Active Comparator|Spinal anesthesia without tourniquet|"This group will be operated under spinal anesthesia (15 mg of bupivacaine) and in continuous light propofol sedation. Surgical tourniquet is not used during the operation.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2430406|NCT03364088|Active Comparator|General anesthesia with tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) and surgical tourniquet (with the pressure of 250 mmHg or > 100 mmHg higher than systolic blood pressure) is used during the operation.~Local infiltration analgesia (LIA) will be administered during the operation. Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the removal of tourniquet. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2430407|NCT03364088|Active Comparator|General anesthesia without tourniquet|"This group will be operated under general anesthesia (propofol and remifentanil are used with target-controlled infusion (TCI) mode) without the use of surgical tourniquet.~Patients receive 1 g of intravenous tranexamic acid approximately 5 - 10 minutes before the surgical incision. Local infiltration analgesia (LIA) will be administered during the operation. Intravenous bolus of oxycodone 0.1 mg/kg (ideal body weight) is given when the closure of surgical wound begins.~Postoperatively patient-controlled analgesia (PCA) with intravenous oxycodone will be used for 24 hours."
2430408|NCT03364075|Active Comparator|Duloxetine Treatment|patients treated with Duloxetine
2430409|NCT03364075|Active Comparator|Propranolol Treatment|patients treated with Propranolol
2430410|NCT03364075|Placebo Comparator|Placebo Treatment|patients treated with placebo
2430411|NCT03364062||cemented shoulder replacement patients|A total of 350 cases of proximal humeral fracture receiving cemented shoulder replacement in Department of Orthopedics and Trauma
3147067|NCT00115960|Experimental|2|Group 2 will receive 3 vaccinations of either the HIV-1 gag DNA vaccine with a low dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
2430415|NCT03364010|Experimental|Dyslexic and non dyslexic Children|Children aged 10-12 Evaluation of proprioception Evaluation of motor learning Evaluation of written language
2430416|NCT03363997|Experimental|Test 1 vaginal ring|Single vaginal application of 1 vaginal ring containing 100 mg estriol, with delivery rate of 0.125 mg/day over 21 days
2430417|NCT03363997|Experimental|Test 2 vaginal ring|Single vaginal application of 1 vaginal ring containing 300 mg estriol, with delivery rate of 0.250 mg/day over 21 days
2430418|NCT03363997|Experimental|Test 3 vaginal ring|Single vaginal application of 1 vaginal ring containing 600 mg estriol, with delivery rate of 0.500 mg/day over 21 days
2430419|NCT03363984|Experimental|Midazolam & ID-082|Single oral administration of 2 mg midazolam on Day 1, Day 2, and Day 11. Administration of ID-082 from Day 2 through Day 11.
2430420|NCT03363971|Experimental|Experimental group|Zhi Kang Capsule, 0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery,treatment for 6 weeks.
2430421|NCT03363971|Placebo Comparator|Control group|Simulant agent for Zhi Kang Capsule,consistent with the appearance, color, odor, and usage of the Zhi Kang capsule, so that it can not be distinguished.oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery, treatment for 6 weeks.
2430422|NCT03363958|Experimental|RIC Group|Three cycles of remote ischemic conditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation); First three cycles the patient will receive 24 hours preoperatively, second three cycles the patient will receive after the induction of general anesthesia but before skin incision shortly before CABG. Remote ischemic postconditioning (5minutes ischemia and 5minutes reperfusion; lower leg ischemia achieved by pressure cuff inflation and deflation) will be administered to the patient within 60 minutes after the completion of all coronary artery bypass grafts and the restoration of coronary blood flow.
2430423|NCT03363958|Sham Comparator|Control Group|Control group will receive sham procedure near identical to intervention. That will be afforded by inflation of pressure cuff on artificial leg hidden under the draping by an assistant who is not included in the research team and does not have any connection to study design and data analysis.
2430424|NCT03363945|Active Comparator|MDR-101|A single dose will be administered via IV infusion post-kidney transplant.
2430425|NCT03363945|No Intervention|Control Arm|Subjects randomized to this arm will receive the standard anti-rejection medications that would be given to kidney transplant recipients who are outside the study.
2430459|NCT03363763|Active Comparator|Arm 1|Sirolimus 0.2% ointment applied topically hs x 12 weeks
2430460|NCT03363763|Active Comparator|Arm 2|Sirolimus 0.4% ointment applied topically hs x 12 weeks
3147068|NCT00115960|Experimental|3|Group 3 will receive 3 vaccinations of either the HIV-1 gag vaccine with a medium dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
3147069|NCT00115960|Experimental|4|Group 4 will receive 3 vaccinations of either the HIV-1 gag vaccine with a high dose of IL-15 adjuvant, or a placebo. Vaccinations will be given at Months 0, 1, and 3.
2430426|NCT03363932||Perimembranous VSD with high pulmonary flow rate|"It is an observational study, no intervention or examination will be realized for the sole purpose of the study. Patient management will be at the discretion of referral cardiologists according to the practices of the centers.~As part of the usual follow-up of these patients, the participating centers collect the clinical and echocardiography data from inclusion and the following year, as well as data from a functional assessment at baseline and at one year. and the collection of cardiovascular events at 5 years and 10 years of follow-up.~Data from a possible percutaneous or surgical closure procedure will be collected. The indication of VSD closure will be left to the discretion of participating centers. There will be no recommendation for percutaneous or surgical closure of VSD for the sole purpose of this observatory."
3147070|NCT00115960|Experimental|5|In Part B, Group 5 will receive 5 vaccinations of either the HIV-1 gag vaccine plus IL-15 DNA, or placebo. Vaccinations will occur at Months 0, 1, 3, 6, and 9.
3147071|NCT00115960|Experimental|7|In Part B, Group 7 will receive 3 vaccinations of the HIV-1 gag vaccine with a high dose of IL-15 adjuvant (maximum tolerated dose from Part A) followed by 2 vaccinations of the gag DNA vaccine with IL-12 DNA adjuvant. Some participants will receive placebo instead of this vaccine regimen. For Group 7, the HIV-1 gag vaccine with IL-15 adjuvant vaccinations will be given at Months 0, 1, and 3, and booster vaccinations will be given at Months 6 and 9.
3147072|NCT00116129|Placebo Comparator|Placebo|Placebo
3147073|NCT00116181|Experimental|continuous therapy|Subjects will receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24.
3147074|NCT00116181|Active Comparator|intermittent therapy|Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
3147075|NCT00116220|Active Comparator|Treatment 1|External beam radiation therapy + 6 months total androgen ablation
3147076|NCT00116220|Active Comparator|Treatment 2|External beam radiation therapy
3147077|NCT00116350|Experimental|Misoprostol|800 mcg sublingual misoprostol
3147078|NCT00116350|Active Comparator|Oxytocin|40 IU Oxytocin IV
3147079|NCT00116376|Experimental|AEE788 + non EIACD|
2430439|NCT03363880|Experimental|experimental group|The trauma treatment team will be established in the experimental group
2430440|NCT03363880|Active Comparator|control group|The trauma treatment team will not be established in this group，just establish the basic experimental settings
2430441|NCT03363867|Experimental|Atezolizumab, Bevacizumab and Cobimetinib (ABC)|
2430447|NCT03363841|Experimental|SCY-078|SCY-078
2430448|NCT03363828||Normal microbiota|Based on qPCR and Next gen sequencing
2430449|NCT03363828||Abnormal microbiota|Based on qPCR and Next gen sequencing
2430450|NCT03363815|Experimental|Part1:Omeprazole + Midazolam + Warfarin + Vitamin K + CC-90001|Patient will receive CC-90001, 20mg Omeprazole, 2mg Midazolam 10mg Warfarin and 10mg Vitamin K
2430451|NCT03363815|Experimental|Part 2- Rosuvastatin and CC-90001|Patients will receive CC-90001 and 10mg of Rosuvastatin
2430452|NCT03363815|Experimental|Part 3: Metformin + Digoxin and CC-90001|Patients will receive CC-90001, 500mg Metformin and 0.25mg, Digoxin
2430453|NCT03363815|Experimental|Part 4: Nintedanib and CC-90001|Patients will receive CC-90001 and 100mg of Nintedanib
2430454|NCT03363789|Active Comparator|Brisement|Patients will receive a series of brisement injections for treatment of non insertional Achilles tendinosis.
2430455|NCT03363789|Active Comparator|Physical Therapy|Patients will undergo physical therapy for treatment of non insertional Achilles tendinosis.
3147080|NCT00116376|Experimental|AEE788 + EIACD|
3147081|NCT00116402|Active Comparator|1|will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
3147082|NCT00116402|Active Comparator|2|salmeterol 50 mcg BID then crossover to combination therapy with fluticasone 220 mcg BID
3147083|NCT00116454|Experimental|lipiocis group|intra-arterial hepatic administration, one 2200 MBQ dose, duration of treatment 1 week
3147084|NCT00116454|No Intervention|control group|group untreated
3147085|NCT00116480|Experimental|Misoprostol|three tablets of active misoprostol (600 mcg) given sublingually
3147086|NCT00116480|Placebo Comparator|Placebo|three tablets resembling misoprostol given sublingually
3147087|NCT00116493|Other|1|Standard of care (Iron-folic acid + Deworming)
3147088|NCT00116493|Experimental|2|
3147089|NCT00116493|Experimental|3|
3147090|NCT00116493|Experimental|4|
3147091|NCT00116714||Observation|
3147092|NCT00116727||Drug|etanercept 50 mg/wk SC
3147093|NCT00116818|Experimental|Arm 1|
3147094|NCT00116883|Experimental|Arm 1|
3147095|NCT00116922|Active Comparator|A|Avandamet [ Rosuglitazone 2 and Metformin 500]
3147096|NCT00116935|Active Comparator|1|1 year of adjuvant imatinib mesylate 400 mg/day orally
3147097|NCT00116935|Experimental|2|3 years of adjuvant imatinib mesylate 400 mg/day orally
3147098|NCT00116974|Experimental|1|
3147099|NCT00116974|Placebo Comparator|2|
3147100|NCT00116987|Other|1|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
3147101|NCT00116987|Other|2|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
3147102|NCT00117026|Experimental|Benfotiamine|Benfotiamine 300mg/day
3147103|NCT00117026|Placebo Comparator|Placebo|Placebo for benfotiamine
3147104|NCT00117052|Active Comparator|During dialysis visit|Cinacalcet is given during the dialysis visit
3147105|NCT00117052|Active Comparator|Post-dialysis meal|Cinacalcet is administered with a post-dialysis meal
3147106|NCT00117195||PD/PS|
3147107|NCT00117208|Experimental|1|
3147108|NCT00117208|Active Comparator|2|DNase daily for 12 weeks
3147109|NCT00117208|Other|3|combination
3147110|NCT00117273|Experimental|1|
3147111|NCT00117273|Active Comparator|2|
3147112|NCT00117273|Active Comparator|3|
3147113|NCT00117299|Experimental|A|PTK/ZK o.d. 1250 mg p.o.
2430462|NCT03363750|Experimental|mind-body-skills intervention|mind-body-skills group intervention offered weekly for 10 weeks
2430463|NCT03363737|Active Comparator|Static|
2430464|NCT03363737|Experimental|Dynamic|
2430465|NCT03363724||HaGuide version 1.0 software module|Patients diagnosed with Parkinson's Disease who underwent implantation of DBS electrode in the STN for the treatment of Parkinson's Disease, using the Neuro-Omega device for navigation and procedure's MER digital recorded data is available.
2430466|NCT03363685||Low risk|For NSCLC spinal metastasis patients with 0-3 of novel survival prediction algorithm.
2430467|NCT03363685||Intermediate risk|For NSCLC spinal metastasis patients with 4-6 of novel survival prediction algorithm.
2430468|NCT03363685||High risk|For NSCLC spinal metastasis patients with 7-10 of novel survival prediction algorithm.
2430469|NCT03363672||Patients receiving surgery|No intervention will be administered. Patients included will be asked to return a questionnaire regarding chronic postoperative pain via app.
2430470|NCT03363659|Experimental|DSF-Cu with temozolomide and radiation|Disulfiram (DSF; oral) / copper gluconate (Cu; oral) dosed at 125 mg / 2 mg, twice daily. Temozolomide will be administered following the standard Stupp protocol at a dose of 75 mg/m2 for 42 days with concurrent radiation therapy. Temozolomide maintenance dose will be 150 mg/m2 once daily on Days 1-5 of every 28-day cycle while DSF-Cu is continued twice daily, as tolerated, for the duration of the Temozolomide adjuvant treatment. Patients demonstrating continued benefit from the adjuvant temozolomide after 6 cycles can continue treatment to a maximum of 12 cycles
2430474|NCT03363620|Experimental|self ligation brackets damon ormco®|the self ligation bracket (damon system) in the orthodontic treatment, was used in the experimental group with the recommended protocol damon arches sequence.
2430475|NCT03363620|Active Comparator|conventional brackets orthos ormco®|the conventional bracket (orthos system) in the orthodontic treatment, was used in the active comparator group with the recommended protocol damon arches sequence as used in the experimental group.
2430476|NCT03363607|Experimental|3D printed transfer tray group|Indirect bonding using digital 3D printed transfer tray
2430477|NCT03363607|Active Comparator|Thermoformed transfer tray group|Indirect bonding using Thermoformed transfer tray
2430478|NCT03363594||1|Diabetes Mellitus
2430479|NCT03363581||Control|Normal Weight Healthy Controls
2430480|NCT03363581||Gastric bypass|Obese patients due to undergo gastric bypass surgery
2430481|NCT03363568|Experimental|Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition involved real-time adaptive gameplay that increased in difficulty as performance increased.
2430482|NCT03363568|Active Comparator|Non-Adaptive Inhibitory Control Training|Participants played a set of three modified stop-signal reaction time tasks designed by NeuroScouting, LLC at home for approximately 5 days a week (25 min/day) for 4-weeks. This condition had no change in difficulty (non-adaptive gameplay).
2430483|NCT03363555|Experimental|SHR-1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes.
2430484|NCT03363542|Active Comparator|Fruits and vegetables rich diet|dietary education to increase fruits and vegetable consumption
2430485|NCT03363542|Active Comparator|Whole grain fiber rich diet|dietary education to increase whole grain fiber consumption
2430486|NCT03363542|Active Comparator|Fruits and vegetables and whole grain fiber rich diet|dietary education to increase fruits and vegetable and whole grain fiber consumption
2430487|NCT03363542|No Intervention|Control group|Routine care
2430488|NCT03363529|Placebo Comparator|Standard|This study arm utilizes a standard lighting condition in the patient room
2430489|NCT03363529|Experimental|Dynamic|This study arm utilizes a dynamic lighting from special designed lightfixtures in the ceiling and window sill.
2430490|NCT03363516||Cases|Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
2430491|NCT03363516||Controls|Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
2430494|NCT03363490|Other|Control|The patients in this group will only receive health education intervention.
2430495|NCT03363490|Other|Neuromuscular exercise therapy|The patients in this group will receive exercise therapy intervention.Besides, health education will be performed for every group.
2430496|NCT03363490|Other|Self-management program|The patients in this group will receive self-management intervention.Besides, health education will be performed for every group.
2430497|NCT03363490|Other|Exercise therapy+self-management|The patients in this group will receive exercise therapy and self-management intervention.Besides, health education will be performed for every group.
2430498|NCT03363477|Experimental|AB treatment sequence|Period 1-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain) Period 2-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU)
2430499|NCT03363477|Active Comparator|BA treatment sequence|Period 1-Reference Treatment B: Clexane (100 mg/mL) 100-mg SC injection, manufactured by Sanofi (EU) Period 2-Test Treatment A: enoxaparin (100 mg/mL) 100-mg SC injection, manufactured by Rovi (Spain)
3147114|NCT00117377|Experimental|1|Pimecrolimus
3147115|NCT00117377|Placebo Comparator|2|Placebo control twice daily application
3147116|NCT00117403|Experimental|1|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals, plus two placebo wafers three times per day with meals
2430503|NCT03363451||Infection Group|Patients with end stage liver disease with infection
2430504|NCT03363451||Non-infection Group|Patients with end stage liver disease without infection
2430505|NCT03363438||martinique|
2430506|NCT03363438||guadeloupe|
2430507|NCT03363425|Active Comparator|Lidocaine|
3147117|NCT00117403|Experimental|2|CoQ 400 mg, compounded as a wafer, two wafers three times per day with meals, plus one placebo capsule three times per day with meals
2430510|NCT03363412|Experimental|Underdilated TIPS|Patients will be treated with PTFE-covered stent grafts balloon-dilated to less than 8 mm.
2430511|NCT03363386|Experimental|Proprioceptive Exercise Group (PG)|Aerobic Exercise Proprioceptive Exercises
2430512|NCT03363386|Active Comparator|Resistive Exercise Group (RG)|Aerobic Exercise Resistive Exercises
3147118|NCT00117403|Placebo Comparator|3|two placebo wafers three times per day with meals, plus one placebo capsule three times per day with meals
2430514|NCT03363347||Radioiodine refractory papillary thyroid cancer|Patients with radioiodine refractory papillary thyroid cancer who received redifferentiation therapy with retinoid acid.
2430515|NCT03363347||Radioiodine sensitive papillary thyroid cancer|Patients who were in remission after one or two radioiodine therapies.
2430522|NCT03363308|Experimental|Phase 1|training for health care workers supplemented by QI teams
2430523|NCT03363308|No Intervention|Phase 2|
2430524|NCT03363295|Experimental|Intracameral moxifloxacin|Injection of 0,03ml of moxifloxacin in the anterior chamber following phacoemulsification surgery
2430525|NCT03363295|No Intervention|No - Intracameral moxifloxacin|This group won't receive any prophylaxis after phacoemulsification surgery
2430526|NCT03363282|Experimental|Mini-SLET|Simple Limbal Epithelial Transplantation
2430527|NCT03363282|Experimental|Limbal-Conjunctival Autograft|Patients treated with limbal-conjunctival autograft
2430528|NCT03363269|Experimental|ID1201 100mg|
2430529|NCT03363269|Experimental|ID1201 200mg|
2430530|NCT03363269|Experimental|ID1201 400mg|
2430531|NCT03363269|Placebo Comparator|Placebo|
3147119|NCT00117442|Experimental|Pegfilgrastim 18 mg|Pegfilgrastim 18 mg given once for mobilization
3147120|NCT00117442|Active Comparator|Filgrastim|Filgrastim given daily for mobilization
2430534|NCT03363243|Experimental|STOP Therapy Treatment group|Self-regulation Treatment for Opioid addiction and Pain (STOP) is a 12-week, rolling entry group therapy protocol that underwent initial development in a previous K23 study. Treatment consists of weekly 90-minute CBT+SR (Self Regulation) treatment with skill building exercises for co-morbid opioid addiction and pain. STOP will be provided in lieu of TAU (Treatment as Usual) group therapy.
2430535|NCT03363243|Active Comparator|Treatment as usual (TAU) group|Psychotherapy for Addiction in conjunction with medication assisted treatment. Standard community treatment for opioid addiction consists of 90-minute weekly rolling entry addiction treatment for 12 weeks to allow for the learning and rehearsal of skills designed to reduce relapse.
2430536|NCT03363230|Experimental|Mindfulness skills|
2430537|NCT03363230|Active Comparator|Interpersonal effectiveness skills|
2430538|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with low-grade glioma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a progressing/refractory low-grade glioma.
2430539|NCT03363217|Experimental|Neurofibromatosis Type 1 (NF1) with Plexiform Neurofibroma|Patients presenting with Neurofibromatosis Type 1 (NF1) and a plexiform neurofibroma
2430540|NCT03363217|Experimental|Progressing/refractory low grade-glioma, KIAA1549-BRAF fusion|Patients presenting with a progressing/refractory low-grade glioma with a KIAA1549-BRAF fusion.
2430541|NCT03363217|Experimental|Progressing/Refractory central nervous system (CNS) glioma.|Patients presenting with a progressing/refractory central nervous system glioma with an activation of the MAPK/ERK pathway who do not meet criteria for inclusion in other study groups.
2430542|NCT03363204|Experimental|BRUXENSE|Patients corresponding to selection criteria will use the BRUXENSE occlusal splint for 10 consecutive nights.
2430543|NCT03363191|Experimental|Subjects received Fluticasone Furoate/Vilanterol|Subjects will receive fluticasone furoate/vilanterol 100/25 mcg inhalation powder via ELLIPTA dry powder inhaler (DPI) once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
2430544|NCT03363191|Active Comparator|Subjects received Fluticasone Furoate|Subjects will receive fluticasone furoate 100 mcg inhalation powder via ELLIPTA DPI once daily for the 12 week treatment period. Subjects will receive salbutamol/albuterol as rescue medication on an as-needed basis.
2430545|NCT03363178|Experimental|GC3107|BCG Vaccine, 0.1mL
2430546|NCT03363165|Active Comparator|VM202|Participants will receive injections of VM202 (4 mgs) in calf skeletal muscle every 14 days for a total of four treatment days.
2430547|NCT03363165|Placebo Comparator|Placebo|Participants will receive injections of placebo in calf skeletal muscle every 14 days for a total of four treatment days.
2430548|NCT03363139||Patients with T790M mutation|Patient who has progressed to Tyrosin Kinase inhibitors and has the mutation of the gen T790M
2430549|NCT03363100|Experimental|Intervention|
2430550|NCT03363100|No Intervention|Control|
2430551|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (IntellaNav MiFi)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation
2430552|NCT03363087|Experimental|Mapping (Rhythmia) and ablation (StablePoint)|Automated high density biatrial scar mapping Pacing confirmation of scar Collection of impedance data during clinical ablation Contact force measurements
2430553|NCT03363087|Experimental|Mapping (Precision)|Automated high density left atrial mapping in AF and SR in different bipole orientations
2430554|NCT03363074|Experimental|Orthotic Insole|Device: Orthotic Insole 8-week follow-up with Orthotic Insole
2430555|NCT03363074|Experimental|Low-level Laser Therapy|Low-Level Laser 5-week follow-up
3147121|NCT00117442|Experimental|Pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for mobilization
3147122|NCT00117442|Experimental|Pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for mobilization
3147123|NCT00117468|Experimental|1|
3147124|NCT00117468|Active Comparator|2|
3147125|NCT00117481|Experimental|1|
3147126|NCT00117481|Experimental|2|
3147127|NCT00117481|Placebo Comparator|3|
3147128|NCT00117611|Active Comparator|1|Xolair administered subcutaneously, once or twice monthly (dose dependent on subject weight and serum IgE level)
3147129|NCT00117611|Placebo Comparator|2|placebo administered subcutaneously once or twice monthly
3147130|NCT00117650|Active Comparator|Low Dose|2 x 10^9 vp (viral particles)
3147131|NCT00117650|Active Comparator|Middle Dose|2 x 10^10 vp
3147132|NCT00117650|Active Comparator|High Dose|2 x 10^11 vp
2430556|NCT03363061||Antithrombotics|The patients should be on antithrombotics on the day of colonoscopy arrangement
2430557|NCT03363048|Experimental|Restricted|
2430558|NCT03363048|Experimental|Restriction plus Incentive|
2430559|NCT03363048|No Intervention|Control|
3147133|NCT00117650|Placebo Comparator|Placebo|(PBS + 10% sucrose + 0.02% polysorbate 80)
3147134|NCT00117689|Experimental|1|Standard (tacrolimus based standard therapy without induction)
3147135|NCT00117689|Active Comparator|2 Standard of Care|Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy
2430563|NCT03363022|Experimental|Standard Medical Treatment+Fecal Microbiota Transplant|
2430564|NCT03363022|Active Comparator|Standard Medical Treatment+Placebo|
2430565|NCT03363009|Experimental|Connected device with close following|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be analyzed every day and used for coaching
2430566|NCT03363009|Other|Connected device with standard coaching|Data from connected devices (arm wrist watch, connected monitor of blood pressure, connected thermometer and pulse oximeter) will be saved but not used for coaching
2430567|NCT03362996|Experimental|Experimental Group|"50 patients Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days.~Dietary Supplement: Freshly-Pressed Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)"
2430568|NCT03362996|Placebo Comparator|Control group 1|50 patients Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days. Extra Virgin Olive Oil dietary intake of the content of 50 mL (3 tablespoons from the bottle containing the product)
2430569|NCT03362996|Other|Control Group 2|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
2430570|NCT03362983|Experimental|Care HND Intervention|Integrated, multidisciplinary, person centered care at HND-centrum.
2430571|NCT03362983|No Intervention|Standard care|Standard care at separate specialty clinics and primary care as needed.
2430572|NCT03362970|Active Comparator|Standard of Care|For children randomized to the standard of care arm, the treating physician will be informed to proceed as per their usual practice and treatment patterns. If stool is unavailable a rectal swab will be collected and sent to Calgary Laboratory Services (CLS) for routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care. Home stool collection will be performed for those unable to provide a sample at enrolment and will be achieved by providing families with collection kits.
2430573|NCT03362970|Experimental|BioFire Gastrointestinal Panel FilmArray|For children randomized to the BioFire FilmArray arm, stool, if available, will be sent STAT to Calgary Laboratory Services (CLS) for the performance of the BioFire FilmArray test and routine culture. If stool is unavailable, a rectal swab will be performed and sent to CLS for the performance of the BioFire FilmArray test and routine culture. A routine stool specimen for back-up culture will still be requested as per standard of care once it is available. Treatment decisions will be at the sole discretion of the ED treating physician who receives the result.
2430579|NCT03362931|Experimental|XEN45 Glaucoma Treatment System (hereafter referred to as XEN)|XEN45 unilaterally implanted in the study eye
2430580|NCT03362918|No Intervention|Control Group|"Participants randomized to the control group will continue with their usual level of physical activity. They will track their menstrual cycles and perform daily ovulation tests.~Once all post-intervention assessments are complete, they will have the option to begin an exercise program with three supervised sessions of either high-intensity interval training or continuous aerobic exercise training free of charge. They will be given a Polar heart rate (HR) monitor as a gift for their participation in the study."
2430581|NCT03362918|Experimental|High-Intensity Interval Training|Participants randomized to this group will complete three high intensity interval training sessions per week, two of which will be supervised. They will exercise for a total of 30 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool-down.
2430582|NCT03362918|Experimental|Continuous Aerobic Exercise Training|Participants randomized to this group will complete three continuous aerobic training sessions per week, two of which will be supervised. They will exercise for a total of 50 minutes per session. Each session will begin with a five-minute warm-up and end with a five-minute cool down.
2430583|NCT03362905|Experimental|Lidocaine spray Arm|This arm will receive lidocaine spray (Lidocaine topical aerosol ®, 10%, Arab drug co., Egypt) with dose four puffs (50 ml, 10 mg/puff) will be applied to the cervical canal and cervix.
2430584|NCT03362905|Active Comparator|Lidocaine cream Arm|This arm will receive topical cream (Pridocaine ®, Global Napi, Egypt) with a dose of 2g lidocaine cream will be applied to the cervix via cotton swab.
2430585|NCT03362905|Active Comparator|Lidocaine injection Arm|This arm will receive lidocaine injection (Debocaine®, 2%, Sigma-Tec, Egypt) with a dose of 80-200 mg equivalent to 10 ml lidocaine (20 mg/ml) is injected at four and eight o'clock of the cervico-vaginal junction, and 2 ml to the area to be grasped with the tenaculum for paracervical block.
2430587|NCT03362853|Experimental|Nemonoxacin 500Mg Capsule|
2430588|NCT03362853|Experimental|Nemonoxacin 750Mg Capsule|
2430589|NCT03362853|Placebo Comparator|Placebo oral capsule|
2430590|NCT03362853|Active Comparator|Moxifloxacin 400Mg Tablet|
2430591|NCT03362840|Experimental|Early Start Denver Model (ESDM) group|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition.
2430864|NCT03360955||Spinal Anesthesia|Patients with spinal anesthesia with minimal opioid dose.
3147136|NCT00117741|Experimental|Dialectical Behavior Therapy|Participants receive standard dialectical behavior therapy and suboxone
3147137|NCT00117741|Active Comparator|Drug Counseling|Participants receive standard individual and group counseling and suboxone.
3147138|NCT00117767|Experimental|1|Terbinafine
3147139|NCT00117767|Active Comparator|2|Griseofulvin
3147140|NCT00117819|Experimental|[123I]ß CIT and SPECT imaging|To assess [123I]ß-CIT and SPECT imaging
3147141|NCT00117884|Experimental|1|
3147142|NCT00117884|Experimental|2|
3147143|NCT00117884|Experimental|3|
3147144|NCT00117884|Experimental|4|
2430592|NCT03362840|Active Comparator|Eclectic preschool intervention group|The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.
2430593|NCT03362827||Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
2430594|NCT03362827||Subjects without chronic low back pain|Participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
2430595|NCT03362814|Experimental|Experimental Group|Ravidasvir + Danoprevir + Ritonavir + Ribavirin
2430596|NCT03362814|Placebo Comparator|Placebo Group|Ravidasvir placebo + Danoprevir placebo + Ritonavir placebo + Ribavirin placebo
2430597|NCT03362801|Other|Sarcopenic|sarcopenic status the day before cystectomy.
2430598|NCT03362801|Other|not sarcopenic|sarcopenic status the day before cystectomy.
2430599|NCT03362788||VKA|"Patients receiving VKA as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
2430600|NCT03362788||NOAC|"Patients receiving a NOAC as anticoagulant treatment plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.~Treatment will be at operator's discretion or, post discharge, at prescribing physician's discretion."
2430601|NCT03362775|Other|All subjects|EEG will be recorded in all subjects before (0.0 µL/mL) and during a target controlled infusion of propofol (0.5 µL/mL and 1.0 µL/mL).
2430602|NCT03362723|Experimental|Treatment Sequence 1: ABCD|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2430603|NCT03362723|Experimental|Treatment Sequence 2: ABDC|Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 1 (one cycle is 28 days). Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2430604|NCT03362723|Experimental|Treatment Sequence 3: BACD|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment C: A single dose of new idasanutlin tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 15. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2430605|NCT03362723|Experimental|Treatment Sequence 4: BADC|Treatment B: A single dose of new idasanutlin tablet B (to investigate BE compared to tablet A) on Cycle 1, Day 1 (one cycle is 28 days). Treatment A: A single dose of the current idasanutlin tablet A formulation (reference variant) on Cycle 1, Day 8. Treatment D: A single dose of new idasanutlin tablet D (to investigate rBA compared to tablet A; rBA 2) on Cycle 1, Day 15. Treatment C: A single dose of new tablet C (to investigate rBA compared to tablet A; rBA 1) on Cycle 1, Day 22. Following completion of the BE/rBA cycle (Cycle 1), participants may continue to receive optional treatment cycles of the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
2430606|NCT03362723|Experimental|Optional Treatment Extension Arm|Following completion of the BE/rBA cycle (Cycle 1), participants who have no clinically defined progressive disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) and who recover from any prior treatment toxicity to Grade </=1 may enter the optional treatment extension phase. Participants will receive 200 mg idasanutlin orally (200-mg tablet reference formulation) daily for 5 days, followed by 23 days of rest. This extension phase will continue for additional 28-day cycles or until disease progression or unacceptable toxicity is observed.
2430607|NCT03362710|Experimental|PAD patients|"Patients referred for an arterial doppler assessment of lower limbs will be included.~Intervention is a series of examination, followed by the measurement of the ABI and an arterial echo-doppler of the lower limbs +/- transcutaneous oxygen pressure measurements in case of suspected critical limb ischemia.~A technician will perform the evaluation with simplified tools blinded to the results of vascular specialised investigations"
2430608|NCT03362697|Experimental|Probiotic|5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, PAC-A and Zinc
2430609|NCT03362697|Active Comparator|Antibiotic|Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick
2430610|NCT03362684|Experimental|FOLFOX-4 plus Cetuximab|
2430611|NCT03362684|Active Comparator|FOLFOX-4|
2430612|NCT03362671|Experimental|Treatment Group|Participants will be treated with a novel experimental implant supported mandibular advancement oral appliance, which uniquely attaches to orthodontic mini implants (OMIs) in the jaw. Participants will be fitted with OMIs per standard clinical practice prior to treatment with the novel oral appliance.
2430663|NCT03362320|Experimental|single layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with single layer fixation
2430613|NCT03362658||Patients|ALS patients (as well as patients with other related disorders such PLS, PMA, and ALS-FTD) will be recruited from ALS clinics under the direction of neurologists who are participating in this study. ALS patients should meet research criteria for suspected, possible, probable, probable laboratory supported, or definite ALS.
2430614|NCT03362658||Controls|Healthy controls who are age and gender matched to patients.
2430615|NCT03362645||Fabry cardiomyopathy|
2430616|NCT03362645||Hypertrophic cardiomyopathy|
2430617|NCT03362632||Infection Group|Patients with end stage liver disease with SBP
2430618|NCT03362632||Non-infection Group|Patients with end stage liver disease without SBP
2430619|NCT03362619|Experimental|CC-EIEs|Autologous cervical cancer specific engineered immune effectors (EIEs)
2430620|NCT03362606|Experimental|OC-CTLs|Autologous ovarian cancer specific cytotoxic lymphocytes
2430621|NCT03362593|Experimental|MEDI7219|Experimental Drug
2430622|NCT03362593|Placebo Comparator|Placebo|Placebo
2430623|NCT03362593|Placebo Comparator|Formulation without Active Drug|Formulation without Active Drug
2430624|NCT03362580||Group A|Patients diagnosed with diabetes mellitus, type 1 or type 2, aged 15 years or older
2430625|NCT03362580||Group B|Patients non-diagnosed with diabetes mellitus, aged 15 years or older
2430626|NCT03362567|Experimental|SNAGS Group|Subjects in SNAGS group were treated with application of sustained natural apophyseal glides, twice weekly for six weeks
2430627|NCT03362567|Experimental|MCT Group|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
2430628|NCT03362554|Experimental|Intervention|
2430629|NCT03362554|No Intervention|Control|
2430630|NCT03362541|Experimental|MS INFoRm group|Participants in the MS INFoRm group will be given a login and password that will take them to the MS INFoRm webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
2430631|NCT03362541|Active Comparator|Usual care control group|Participants in the usual care group will be given a login and password that will take them to a usual care webpage. Access will be granted for 3-months, starting on the date of the first login. Participants can access the website at any time, at their own volition over the 3-months.
2430632|NCT03362528|Experimental|Short term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for 30 days distributed over a time period of 60 days. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
2430633|NCT03362528|Experimental|Long term collection of IMD data|Subjects will collect spectral raman data on WM3.4NR four times a day for the initial 30 days, distributed over a time period of 60 days. Subjects will for the remaining 60 days of measurements, distributed over 120 days collect spectral data twice a day. Each timepoints are conducted in duplicate. Spectral data will be compared to standard BG measurements.
2430634|NCT03362515|Experimental|Furosemide|
2430635|NCT03362515|Placebo Comparator|Placebo|
3147145|NCT00117884|Experimental|5|
2430637|NCT03362489|Other|IVF / IVF-ICSI|In Vitro Fertilization / In Vitro Fertilization - Intracytoplasmic Sperm Injection (ICSI)
2430638|NCT03362489|Other|IUI|Intrauterine insemination
2430639|NCT03362476|Experimental|Computer-based alcohol reduction intervention.|Brief, computer-based, alcohol reduction intervention based on cognitive behavioral therapy (CBT) tailored for HIV/HCV co-infected women in conjunction with standard clinical care for current substance users.
2430640|NCT03362476|Other|Standard-of-care.|Routine counseling to avoid alcohol and drugs.
2430641|NCT03362463||Acute Coronary Syndrom|acute coronary syndrome in a real-life setting for patients hospitalized with an ACS (i.e. STEMI, NSTEMI, unstable angina)
2430642|NCT03362450||Pregnant patients seen for second or third trimester|Foetus with diagnosis of prenatal volvulus based on post-natal findings and prenatal imaging findings
2430643|NCT03362437|Experimental|Treatment A|Receive 200 mg BMS-986177 Form A without food
2430644|NCT03362437|Experimental|Treatment B|Receive 200 mg BMS-986177 Form B without food
2430645|NCT03362437|Experimental|Treatment C|Receive 200 mg BMS-986177 Form B with food
2430646|NCT03362424|Experimental|Mesenchymal stem cell group|rotator cuff repair stem cells
2430647|NCT03362424|Active Comparator|Control group|rotator cuff repair
2430648|NCT03362411|Experimental|BMS-986205 intact tablet orally then crushed tablet orally|Single, 100 mg dose
2430649|NCT03362411|Experimental|BMS-986205 crushed tablet orally, then intact tablet orally|Single, 100 mg dose
2430650|NCT03362411|Experimental|BMS-986205 intact tablet orally then suspension via NG tube|Single, 100 mg dose
2430651|NCT03362411|Experimental|BMS-986205 suspension via NG tube then intact tablet orally|Single, 100 mg dose
2430652|NCT03362398|Active Comparator|Omarigliptin|Drug: Omarigliptin 25 mg
2430653|NCT03362398|Active Comparator|Trelagliptin|Drug: Trelagliptin 100 mg
2430654|NCT03362385||OSA|
2430655|NCT03362385||Non-OSA|
2430656|NCT03362372|Experimental|INTERVENTION GROUP: MEDITERRANEAN DIET COUNSELING|During 2 years a nutritional intervention will be carried out to increase adherence to DiMet based on: annual visit of personalized nutritional education, a telephone contact for intervention reinforcement and computer access to a nutrition blog
2430657|NCT03362372|No Intervention|CONTROL GROUP: WITHOUT CHANGES IN DIET|The participants of health centers will carry out the same 5 visits (3 individual visits and 2 phone calls), although no changes are induced in their usual diet and they will not be offered access to the nutritional blog.
2430658|NCT03362359|Experimental|Ga-68-PSMA-11|
2430659|NCT03362346||Neurocritical patients|Patients with brain injury from trauma, ischemic stroke, hemorrhage stroke (intracerebral hemorrhage, subarachnoid hemorrhage), brain tumor with increased intracranial pressure, brain infection, hydrocephalus, among others.
2430660|NCT03362333|Experimental|pain neuroscience education and exercise|This group received pain neuroscience education and exercise once a week over 4 weeks
2430661|NCT03362333|Active Comparator|Exercise|This group received exercise directed at the neck and shoulder regions once a week over 4 weeks
2430662|NCT03362320|Experimental|double layer fixation|Patients with torn infraspinatus and supraspinatus tendon undergoing arthroscopy rotator cuff repair with double layer fixation
3147146|NCT00117884|Experimental|6|
2430664|NCT03362307|Active Comparator|Laser Emitting group|subjects received Low-Level Laser and Light-Emitting Diodes after implant placement
2430665|NCT03362307|Placebo Comparator|Non Emitting group|In laser emitiiing group, subjects received Low-Level Laser and Light-Emitting Diodes after implant placement and in Non-emitting group,the same device was used while device was off.
2430666|NCT03362294|Experimental|GA Depot 40mg once monthly|Monthly IM injection
2430667|NCT03362294|Experimental|GA Depot 25mg once monthly|Monthly IM injection
2430668|NCT03362281|Experimental|Ilaprazole|
2430669|NCT03362281|Active Comparator|omeprazole|
2430670|NCT03362268|Experimental|Ilaprazole|
2430671|NCT03362268|Active Comparator|omeprazole|
2430672|NCT03362255|Active Comparator|Rapid speed of injection|Rapid speed of injection (3cc/sec) during thoracic epidurography thoracic epidural catheterization
2430673|NCT03362255|Active Comparator|Slow speed of injection|Slow speed of injection (1cc/sec) during thoracic epidurography thoracic epidural catheterization
2430674|NCT03362242|Active Comparator|ARO-AAT|
2430675|NCT03362242|Placebo Comparator|Placebo|
2430676|NCT03362229|Active Comparator|FIXATION|Medial malleolus fixation, with the method of fixation left to the surgeons discretion.
2430677|NCT03362229|Active Comparator|NON-FIXATION|A well reduced medial malleolus fracture is then left without fixation ie, non-operative management.
2430678|NCT03362216|Experimental|experimental group|Treated with Compound Methyl Salicylate Liniment group
2430679|NCT03362216|Active Comparator|Control group|Treated with Diclofenac Sodium Liniment group
2430680|NCT03362203||Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
2430681|NCT03362203||Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
2430682|NCT03362190|Experimental|Cohort 1|Zimura dosage 1 + Lucentis 0.5 mg
2430683|NCT03362190|Experimental|Cohort 2|Zimura dosage 2 + Lucentis 0.5 mg
2430684|NCT03362190|Experimental|Cohort 3|Zimura dosage 3 + Lucentis 0.5 mg
2430685|NCT03362190|Experimental|Cohort 4|Zimura dosage 4 + Lucentis 0.5 mg
3147147|NCT00117884|Experimental|7|
3147148|NCT00117884|Experimental|8|
2430688|NCT03362151|Experimental|Regular pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of regular pasta. They will consume this meal on two separate occasions.
2430689|NCT03362151|Experimental|High protein pasta|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of high protein pasta. They will consume this meal on two separate occasions.
2430690|NCT03362151|Experimental|White rice|Subjects will bolus rapid acting insulin per their carbohydrate ratio just prior to a meal of white rice. They will consume this meal on two separate occasions.
2430691|NCT03362138||Dermoscopy|Dermoscopic imaging of a lesion decided to be biopsied
2430692|NCT03362099|No Intervention|Group Varenicline|Patients randomized to this group will collect polymorphisms at time zero and will receive varenicline for smoking cessation. The polymorphism result will only be known at the end of the protocol. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
2430693|NCT03362099|Active Comparator|Group Genetic|"The patients randomized to this arm will collect polymorphisms and could receive varenicline or bupropion or both depending on genetic polymorphisms for each one these drugs.~Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve."
2430694|NCT03362073|Experimental|Ketamine|continuous intravenous infusion of ketamine
2430695|NCT03362060|Experimental|PVX-410|"PVX-410 vaccine at W0, 1, 2, 3, 4, and 5 followed by booster PVX-410 vaccine doses at W10 and 28~Pembrolizumab will be administered every 3 weeks intravenously starting with week 1"
2430696|NCT03362047|Experimental|Riciguat Group|15 PAH patients will be administered Riciguat according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
2430697|NCT03362047|Experimental|Macitentan Group|15 PAH patients will be administered Macitentan according to standard of care. RV function will be evaluated 90 mintutes after first medication intake and 12 weeks after first medication intake.
2430698|NCT03362034|Active Comparator|single transfer tray|
2430699|NCT03362034|Experimental|double transfer trays|
2430700|NCT03362021||DEX|Sedation with dexmedetomidine (solution 4 γ/ml) continuously infused at a dose of 1 γ/kg/ and fentanyl 100γ iv. Dexmedetomidine infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
2430701|NCT03362021||MZM|Sedation with remifentanil (solution 50γ/ml) continuously infused at a dose of 0.2 γ/kg/min and midazolam 1 mg iv. Remifentanil infusion will start 10 min before the start of transvaginal oocyte retrieval and will stop at the end of the procedure.
2430702|NCT03362008|Experimental|Group I|Period I: administration of Zeropix Period II: administration of Champix®
2430703|NCT03362008|Experimental|Group II|Period I: administration of Champix® Period II: administration of Zeropix
2430704|NCT03361995|Experimental|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Thermogard XP3 IVTM System before and after PCI.
2430705|NCT03361995|Active Comparator|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
3147149|NCT00117884|Experimental|9|
3147150|NCT00117884|Experimental|10|
3147151|NCT00117884|Experimental|11|
3147152|NCT00117936|Experimental|1|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - high dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
2430706|NCT03361982|No Intervention|Fresh surgical testicular sperm|Fresh, surgically obtained testicular sperm
2430707|NCT03361982|Experimental|Frozen surgical testicular sperm|Surgically obtained testicular sperm that will undergo slow freezing and thawing
2430708|NCT03361969|Active Comparator|estetrol|
2430709|NCT03361969|Placebo Comparator|placebo|
2430710|NCT03361956|Experimental|Part A: Arm 1 (JNJ-56136379 or NA) (open label)|Participants with hepatitis B virus (HBV) currently not being treated and receiving JNJ-56136379 tablet (at a lower dose) orally for 24 weeks, will stop further dosing with JNJ-56136379 and start treatment with nucleos(t)ide analog (NA) (entecavir [ETV] or tenofovir disoproxil fumarate [TDF]), and enter the 24 week post treatment follow-up phase.
2430711|NCT03361956|Placebo Comparator|Part A: Arm 2 (Placebo+NA [ETV] or [TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430712|NCT03361956|Experimental|Part A: Arm 3 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 along with NA (ETV or TDF) tablet orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430713|NCT03361956|Placebo Comparator|Part A: Arm 4 (Placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430714|NCT03361956|Experimental|Part A: Arm 5 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430715|NCT03361956|Experimental|Part B: Arm 6 (JNJ-56136379 + NA [ETV or TDF]) (open label)|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose, orally for 24 weeks. The eligible participants may enter the extension phase and will receive JNJ-56136379 along with NA (ETV or TDF) from Week 24 to Week 48.
2430716|NCT03361956|Placebo Comparator|Part B: Arm 7 (placebo + NA [ETV or TDF])|Participants with HBV currently not being treated will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430717|NCT03361956|Experimental|Part B: Arm 8 (JNJ-56136379 + NA [ETV or TDF])|Participants with HBV currently not being treated will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430718|NCT03361956|Placebo Comparator|Part B: Arm 9 (placebo + NA [ETV or TDF])|Virologically suppressed participants will receive matching placebo along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430719|NCT03361956|Experimental|Part B: Arm 10 (JNJ-56136379 + NA [ETV or TDF])|Virologically suppressed participants will receive JNJ-56136379 tablet at a high dose along with NA (ETV or TDF) tablets orally for 24 weeks. The eligible participants may enter the extension phase and will continue study drugs up to 48 weeks.
2430720|NCT03361930|Experimental|CP participants|Single-day data collection for walking conditions; barefoot, with plain ankle-foot orthosis (flat foot plate) on involved side, with tone-reducing ankle-foot orthosis on involved side.
2430723|NCT03361891|No Intervention|Control|Patients receive no intervention
2430724|NCT03361891|Experimental|WalkMORE group|WalkMORE Ambulation program. Patients will ambulate with a trained WalkMORE Volunteer Coach two times per day; once in the morning (0900-1200hrs) and once in the afternoon (1300-1700hrs), Monday- Friday, until hospital discharge.
2430725|NCT03361878|Active Comparator|Metformin Tolerant|
2430726|NCT03361878|Active Comparator|Metformin Intolerant|
3147153|NCT00117936|Experimental|2|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
3147154|NCT00117936|Placebo Comparator|3|Placebo solution void (not containing) Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141), given as intramyocardial injections via a NOGA Injection Catheter, single cath lab session.
2430731|NCT03361839|Active Comparator|1|patients with RIF
2430732|NCT03361839|Placebo Comparator|2|fertile arm as r reference for result
2430733|NCT03361826|Other|DBT Only|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder.
2430734|NCT03361826|Experimental|MagPro MST with Cool TwinCoil + DBT|MST treatments will be administered using the MagPro MST with Cool TwinCoil. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
2430735|NCT03361813|Active Comparator|trans-cutaneous ultrasound guided peritonsillar infiltration|
2430736|NCT03361813|Placebo Comparator|trans-oral ultrasound guided peritonsillar infiltration|
2430737|NCT03361800|Experimental|Entinostat|Nine days prior to their scheduled surgery, entinostat 5mg PO given once weekly on day 1 and day 8
2430738|NCT03361787|Experimental|Parentship coaching intervention|
2430739|NCT03361774|Experimental|Test dentifrice|Participants in this arm will receive experimental dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 parts per million [ppm] fluoride).
2430774|NCT03361540|Experimental|Single dose of ASP8302 dose-2|Subjects will receive a single dose of ASP8302.
3147155|NCT00118066|Experimental|Arm I|Patients receive oral calcitriol once daily for 8 weeks. Treatment repeats every 8 weeks for 2 courses. After completion of course 2 (week 16), patients undergo biopsy. Patients continue to receive calcitriol for up to 3 additional weeks while the biopsy is being evaluated. Patients with persistent high-grade prostatic intraepithelial neoplasia (HGPIN) by biopsy receive 2 additional courses of calcitriol.
3147156|NCT00118066|Other|Arm II|Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
2430740|NCT03361774|Active Comparator|Control dentifrice|Participants in this arm will receive comparator dentifrice containing 0.454% SnF2 (1100ppm fluoride).
2430741|NCT03361761||experimental|therapeutic coordination apartments with formalized/official Health education program
2430742|NCT03361761||active comparator|therapeutic coordination apartments without formalized/official Health education program
2430743|NCT03361748|Experimental|Administration of bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 15 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.
2430744|NCT03361735|Experimental|Treatment (hormone therapy, SBRT, radium Ra 223 dichloride)|Beginning 4 weeks (28 days) prior to radiation therapy, patients receive leuprolide acetate or goserelin acetate, for up to 32 weeks. Patients also undergo 3-5 fractions of SBRT every 40 hours over 7-21 days beginning on day 1 of course 1, and receive radium Ra 223 dichloride IV over 1 minute on day 1 of courses 2-7. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity.
2430745|NCT03361709|Active Comparator|Dexamethasone group|Dexamethasone injected at conclusion of Phacoemulsification
2430746|NCT03361709|Placebo Comparator|Non-dexamethasone group|No dexamethasone will be injected at the conclusion of Phacoemulsification
2430747|NCT03361683|Experimental|High-flow nasal oxygen|Randomized patients will receive oxygen through a high flow nasal device capable of delivering humidified, heated air at an output rate of 40 L/min
2430748|NCT03361683|Active Comparator|Conventional oxygen|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
2430749|NCT03361670||Specimens that meet inclusion criteria|
2430750|NCT03361657||One sample|Laparoscopic surgeries will be performed according to the standard surgical and anesthesia protocols. Pneumo-peritoneum will be achieved using non-heated non-humidified CO2 with the intra-abdominal pressure (IAP) maintained at 10-12mmHg
2430751|NCT03361644|Experimental|High-Intensity Interval Training|Brief periods of vigorous physical activity separated by short periods of rest.
2430752|NCT03361644|Active Comparator|Moderate-Intensity Continuous Training|Physical activity at a sustained moderate heart rate.
2430753|NCT03361631|Experimental|arm treated with MSC|"Type 1 diabetic man~Aged from 18 to 50 years~Having a diabetes evolving for at least 10 years~Presenting at least one severe manifestation of microangiopathy, with or without dysautonomia: diabetic retinopathy, diabetic or vascular nephropathy, diabetic neuropathy, diabetic foot~Presenting an erectile dysfunction refractory to oral treatment (sildenafil, tadalafil ...)~IIEF-5 score less than or equal to 10"
2430754|NCT03361618|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
2430755|NCT03361618|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
2430757|NCT03361592|Experimental|Spinal Manipulative Therapy|The participants assigned to the intervention group received the procedure Lumbar (SMT) was performed after baseline measurements, using Diversified techniques, aiming to correct vertebral dysfunctional segments after clinical assessment. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was performed in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
2430758|NCT03361592|Sham Comparator|Sham pre-load positioning SMT|"The participants assigned to the control group received the procedure Sham (pre-load positioning MVT). The Sham (SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained for approximately 1 minute in total, 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
2430759|NCT03361579|Other|Placebo education group|Prior to the intervention during the Placebo is given, the volunteer receives a detailed information about the effect and the strength of an open-label placebo. This education is performed via a slide show and a news report video. The important terms for Placebo analgesia: positive expectations, conditioning, communication are discussed
2430760|NCT03361579|Other|Placebo non education group|No detailed Information about open-label placebo prior to the intervention. The volunteer is told about the possible strength of the Placebo effect on pain directly before the application.
2430761|NCT03361566|Experimental|low energy flux at ad libitum energy intake|physical activity: inactive energy intake: ad libitum
2430762|NCT03361566|Experimental|medium energy flux at ad libitum energy intake|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: ad libitum
2430763|NCT03361566|Experimental|high energy flux at ad libitum energy intake|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: ad libitum
2430764|NCT03361566|Experimental|Low energy flux at energy balance|physical activity: inactive energy intake: individual energy balance
2430765|NCT03361566|Experimental|medium energy flux at energy balance|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: individual energy balance
2430766|NCT03361566|Experimental|high energy flux at energy balance|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: individual energy balance
2430767|NCT03361566|Experimental|low energy flux at caloric restriction|physical activity: inactive energy intake: caloric restriction -25%
2430768|NCT03361566|Experimental|medium energy flux at caloric restriction|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
2430769|NCT03361566|Experimental|high energy flux at caloric restriction|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: caloric restriction -25%
2430770|NCT03361566|Experimental|low energy flux at overfeeding|physical activity: inactive energy intake: overfeeding +25%
2430771|NCT03361566|Experimental|medium energy flux at overfeeding|physical activity: medium (3 x 55 min treadmill running at 4 km/h) energy intake: overfeeding +25%
2430772|NCT03361566|Experimental|high energy flux at overfeeding|physical activity: high (3 x 110 min treadmill running at 4 km/h) energy intake: overfeeding +25%
2430773|NCT03361540|Experimental|Single dose of ASP8302 dose-1|Subjects will receive a single dose of ASP8302.
2430775|NCT03361540|Experimental|Single dose of ASP8302 dose-3|Subjects will receive a single dose of ASP8302.
2430776|NCT03361540|Experimental|Single dose of ASP8302 dose-4|Subjects will receive a single dose of ASP8302.
2430777|NCT03361540|Placebo Comparator|Single dose of Placebo|Subjects will receive a single dose of Placebo.
2430778|NCT03361540|Experimental|Multiple dose of ASP8302 dose-5|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
2430779|NCT03361540|Experimental|Multiple dose of ASP8302 dose-6|Subjects will receive once daily dosing of ASP8302 for 14 consecutive days at the same dose level.
2430780|NCT03361540|Placebo Comparator|Multiple dose of Placebo|Subjects will receive once daily dosing of Placebo for 14 consecutive days.
2430781|NCT03361514|Active Comparator|Supported Protocolized Discontinuation|Supported Protocolized Discontinuation (SPD) Patients will receive guidance of their GP and can have supportive meetings with the mental health assistant.
2430782|NCT03361514|Experimental|SPD + Mindfulness (MBCT)|In addition to the SPD (as mentioned above) patients are offered Mindfulness Based Cognitive Therapy (MBCT)
2430783|NCT03361501|Experimental|CaPre|
2430784|NCT03361501|Placebo Comparator|Placebo|
2430785|NCT03361488|Experimental|Trained anesthesiologist|Patient interview by anesthesiologists having obtained training to optimize structured communication
2430786|NCT03361488|No Intervention|Control anesthesiologist|Patient interview by control anesthesiologists
2430787|NCT03361475|Experimental|Intervention school|One school workshop and a small talk were conducted first at the beginning of the programme, which was to promote SME and introduce the function of SME App for students, followed by downloading and using immediately to connect family members, then let them continue to use for one month with system reminder.
2430788|NCT03361475|No Intervention|Waitlist control schools|The intervention won't be provided during evaluation period and will be provided after the evaluation period
3187651|NCT00758316|Active Comparator|1|Thoracoscopy with pleurodesis Patients will then undergo standard medical thoracoscopy in the endoscopy center including the use of moderate sedation, prophylactic antibiotics for 1 week and 20F chest tube insertion at the end of the procedure.
3187652|NCT00758316|Experimental|2|Combined thoracoscopy with pleurodesis and pleurx catheter. In the combined procedure group, a PleurxTM tunnelled catheter will be inserted under ultrasound guidance. As this procedure will be done concurrently with thoracoscopy, there is no estimated increase in endoscopy time.
2430791|NCT03361449|Active Comparator|Group 1|training with kinesthetic ability trainer.
2430792|NCT03361449|Active Comparator|Group 2|Flamingo exercise
2430793|NCT03361449|Active Comparator|Group 3|training with kinesthetic ability trainer and Flamingo exercise
3187653|NCT00758329||1|
3187654|NCT00758355||M2A magnum|Consecutive series of patients received Total Hip Resurfacing with ReCap/Magnum
2430797|NCT03361410|Experimental|Grape Powder|
2430798|NCT03361410|Placebo Comparator|Placebo Powder|
2430799|NCT03361397|Active Comparator|Lidocaine nebulization|Inhalation of 10 mL nebulized lidocaine hydrochloride via mask nebulizer 5 min before laryngeal mask insertion.
2430800|NCT03361397|Placebo Comparator|Distilled water nebulization|Inhalation of 10 mL of nebulized distilled water solution via mask nebulizer 5 min before laryngeal mask insertion in the preoperative period.
2430801|NCT03361384|Experimental|Alcohol condition|The amount of alcohol received in the alcohol condition will be determined by an algorithm developed by Curtin (Curtin, 2000). Participants in the alcohol condition will receive a dose of alcohol (target BAC = .08%), administered in a chilled beverage of 80-proof vodka mixed with tonic water and lime juice in a 1:4 ratio.
2430802|NCT03361384|Placebo Comparator|Placebo condition|Placebo participants will receive tonic water and lime juice served to enhance alcohol cues in an amount comparable to the amount that they would have received if assigned to the alcohol condition.
2430803|NCT03361384|No Intervention|Control (water)|Participants in the water control condition will receive a glass of chilled water in volume of liquid comparable to the amount that they would have received if assigned to the alcohol or placebo condition.
2430804|NCT03361371|Experimental|Interventional group|"Intervention Group: in addition to receiving the aforementioned bronchiolitis discharge instructions, this group will undergo nasal suctioning prior to each feeding as needed for 72 hours post discharge home, using exclusively the Zo-Li study device (see above under study device), with saline nose drops. Families in this group will be given the Zo-Li device at no cost and instructed in the appropriate technique and importance of using this tool.~We shall not reveal the identity of the study devices to the ED physicians in order to minimize contamination of the control group. The ED treating physicians will also be blinded to which device the infant had been randomized to. We shall also ask the ED treating physicians not to recommend specific suctioning devices to the study patients."
2430805|NCT03361371|Placebo Comparator|Control group|Control Group: this group will receive standardized routine discharge instructions describing information about bronchiolitis, expected course of illness, recommended management strategies such as fever control, augmented air humidification, need for frequent feeding and warning signs prompting return for care. This group will be suctioned prior to feeds via bulb suction (with saline drops) which is expected to provide minimal effect, due to non-sustained negative pressures generated during bulb release. Since the benefit of nasal suction in bronchiolitis is unknown, this design is ethically reasonable. However, the use of no suction would likely meet with parental resistance and enrollment would be difficult. Families in the control group will be given the bulb device at no cost and instructed in the appropriate technique of using this tool prior to feeds.
2430806|NCT03361345|Experimental|Right Side of Face|Patients will apply topical tranexamic acid to the dark spots on the one side of their face.
2430807|NCT03361345|Sham Comparator|Left Side of Face|Patients will apply the vehicle cream without any medication to the dark spots on one side of their face.
2430808|NCT03361332||Healthy subjects|
2430809|NCT03361332||Patients with Gilles de la Tourette Syndrome|
2430810|NCT03361319|Experimental|Part 1: (Phase Ib) Dose Escalation|"A dose-finding study of nintedanib (Vargatef) with nab-paclitaxel (Abraxane) with a standard 3+3 design. In the dose escalation part there will be 3 dose cohorts of nintedanib:~Dose level -1: 100mg po BID d2-7, 9-21, q21 Dose level 1: 150mg po BID d2-7, 9-21, q21 Dose level 2: 200mg po BID d2-7, 9-21, q21"
2430811|NCT03361319|Experimental|Part 1: Dose Expansion|In the dose expansion part, 6 additional patients will be enrolled at the maximum tolerated dose (MTD) of nintedanib (Vargatef) with nab-paclitaxel (Abraxane), prior to proceeding to part 2.
2430812|NCT03361319|Placebo Comparator|Part 2: (Phase II)|"A placebo-controlled, randomised, double-blind, 2-arm, phase 2 multi-centre clinical trial of nab-paclitaxel (Abraxane) with nintedanib (Vargatef) and nab-paclitaxel alone.~Arm A: nab-paclitaxel + placebo Arm B: nab-paclitaxel + nintedanib"
3187655|NCT00758355||Recap Magnum|Consecutive series of patients received Total Hip Replacement with ReCap/Magnum
3187656|NCT00758368|Experimental|Ambulatory Pump|Participants will receive apomorphine via a pump. Participants in the Continuous Delivery Arm will self-administer apomorphine continuously (12-14 hours a day) using a portable pump.
3187657|NCT00758368|Active Comparator|Subcutaneous Injections|Participants will receive apomorphine via an injection pen. Participants in the Intermittent Delivery Arm will self-administer apomorphine at intervals, via a injection, using pen injector.
2430816|NCT03361280|Experimental|Atenolol|Atenolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2430817|NCT03361280|Experimental|Bisoprolol|Bisoprolol (5 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2430818|NCT03361280|Experimental|Metoprolol|Metoprolol (50 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2430819|NCT03361280|Experimental|Carvedilol|Carvedilol (6.25 mg) administered 3 hours prior to a hemodialysis session. Blood samples are collected a multiple times during dialysis and spent dialysate is collected at the end of the dialysis session.
2430820|NCT03361267|Active Comparator|Bismuth containing quadruple therapy|If CLO test is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days If CLO test is negative, no intervention is needed
2430821|NCT03361267|Experimental|tailored therapy|If H. pylori PCR is negative, no intervention is needed If H. pylori PCR is positive and mutation is negative, triple regimen (rabeprazole 20 mg bid, amoxacillin 1000 mg bid, clarithromycin 500mg bid) are prescribed for 7 days is given If H. pylori PCR is positive and mutation is positive, Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 5100 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) are prescribed for 7 days is given
2430822|NCT03361241|Experimental|No Physiotherapeutic Intervention|Virtual reality training without physiotherapeutic intervention
2430823|NCT03361241|Active Comparator|Physiotherapeutic Intervention|Virtual reality training with physiotherapeutic intervention
3187658|NCT00758381|Experimental|A|"Sorafenib 400 mg po bid, continuously~Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days."
3187659|NCT00758381|Active Comparator|B|Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 day 1, and 8 every 21 days
2430826|NCT03361202||Atrial fibrillation group|blood sampling
2430827|NCT03361202||control group|blood sampling
3187660|NCT00758407|Active Comparator|1|
3187661|NCT00758407|Placebo Comparator|2|
3187662|NCT00758433|Active Comparator|1|Civamide patch 0.0075%
3187663|NCT00758433|Active Comparator|2|Civamide patch 0.0150%
2430832|NCT03361163|Experimental|GAS oropharyngeal challenge|"Biological: emm75 Streptococcus pyogenes (GAS M75, strain 611024)~Direct oropharyngeal application using a sterile-tipped Dacron swab after immersion for 10 seconds in a 1mL vial containing 1-3x10^4 to 1-3x10^8 colony forming units (CFU) of the challenge strain (depending on dose group allocation)."
2430833|NCT03361150|Experimental|HIT|Preoperative nutrition, relaxation strategies + high intensity interval training (HIT). HIT alternates a series of high-intensity bouts with relief period. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
2430834|NCT03361150|Active Comparator|MCT|Preoperative nutrition, relaxation strategies + high intensity interval training (MCT). MCT is continuous exercise with a constant intensity below anaerobic threshold. This will be a personalized, 3 times per week, 40-min exercise. Protein supplement will be prescribed if needed to achieve a daily intake of 1.5 g protein/kg.
3187664|NCT00758433|Placebo Comparator|3|Placebo patch
3187665|NCT00758446|Experimental|A|BLX-028914 50 mg
2430863|NCT03360955||Total Intravenous Anesthesia|Patients with total intravenous anesthesia during the cardiac surgery
3187666|NCT00758446|Experimental|B|BLX-028914 15 mg
3187667|NCT00758446|Placebo Comparator|C|Placebo
3187668|NCT00758472||Hip Resurfacing|
3187669|NCT00758511|Active Comparator|1|Orally administrated 25%sucrose before,during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
3187670|NCT00758511|Active Comparator|2|facilitated tucking before, during and after heel stick across 5 heel stick during the first 14 days of postnatal life
3187671|NCT00758511|Active Comparator|3|orally administrated 25% sucrose AND facilitated tucking before, during and after heel stick across 5 heel sticks during the first 14 days of postnatal life
3187672|NCT00758537||Patients with chronic kidney disease stage 3|
3187673|NCT00758537||patients with chronic kidney disease stage 4|
3187674|NCT00758537||patients with chronic kidney disease stage 5 (ESRD)|
3187675|NCT00758537||Controls (no kidney disease)|
3187676|NCT00758615|Experimental|I|Walking School Bus Intervention
3187677|NCT00758615|No Intervention|C|Usual school procedures for student transportation to school
3187678|NCT00758628|Active Comparator|1|Bromfenac
3187679|NCT00758628|Placebo Comparator|2|Blink
3187680|NCT00758641|Experimental|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
3187681|NCT00758641|Active Comparator|Steroid Injection|Corticosteroid injections
3187682|NCT00758654||1|Patients with suspected or known stable coronary artery disease
3187683|NCT00758654||2|Healthy subjects as a control group
3187684|NCT00758693|Experimental|1|Bendamustine + Rituximab
2430840|NCT03361124|Placebo Comparator|Control|Patient will receive standard post-partum Oxytocin (20 mU in 1 L LR) and 1 L LR over 8 hours following delivery.
2430841|NCT03361124|Experimental|Treatment|Patient will receive standard post-partum Oxytocin(20 mU in 1 L LR) an additional 20 mU Oxytocin in 1 L LR over 8 hours following delivery.
2430842|NCT03361098|Experimental|SGLT2 inhibitor + GLP-1 receptor agonist|dapagliflozin 10 mg tablet /day and exenatide twice daily subcutaneous injection (week 1-4; 5 microgram, week 5 -16; 10 microgram)
2430843|NCT03361098|Active Comparator|GLP-1 receptor agonist (exenatide) and placebo|GLP-1 receptor agonist exenatide twice daily in combination with placebo dapagliflozin
2430844|NCT03361098|Active Comparator|SGLT2 inhibitor (dapagliflozin) and placebo|SGLT2 inhibitor dapagliflozin 10 mg tablet /day in combination with placebo GLP-1 receptor agonist exenatide twice daily
2430845|NCT03361098|Placebo Comparator|double placebo|placebo dapagliflozin and placebo exenatide twice daily
2430846|NCT03361085|Experimental|Intervention|nvHAP-Prevention Bundle
2430847|NCT03361072|Experimental|Milk allergy|Milk oral immunotherapy intervention for milk allergy
2430848|NCT03361072|Experimental|Peanut allergy|Peanut oral immunotherapy intervention for peanut allergy
2430849|NCT03361072|Experimental|Egg allergy|Egg oral immunotherapy intervention for egg allergy
2430850|NCT03361046||Transcatheter Aortic Valve-in-Valve Implantation Cohort|
2430851|NCT03361033||Medulloblastoma|Participants who are survivors of pediatric medulloblastoma and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
2430852|NCT03361033||Other Brain Tumors|Participants who are survivors of other pediatric brain tumors (excluding medulloblastoma and craniopharyngioma), who have not been treated with craniospinal irradiation (CSI), and who meet eligibility criteria will be approached for their consent to participate in this study. Observational data will be collected through the administration of standard psychological questionnaires. If the participant consents, their parents, teachers and best friends will also be asked to complete questionnaires. In addition, participants will complete an online daily diary assessment of their social interactions for seven days.
2430853|NCT03361020||Hodgkin Lymphoma|Participants will be survivors of Hodgkin Lymphoma (HL) who were treated with thoracic radiation during the course of their HL, who meet eligibility criteria, and who consent to this study.
2430854|NCT03361020||Control Group|The Comparison or control group members will be recruited from healthy parents, sibling, relative or friends who accompany the participant for follow-up at SJCRH and who meet eligibility criteria.
2430855|NCT03361007||Common carotid artery access for TAVI|Patients in whom femoral artery could not be used to deliver the bioprosthesis for any reason.
2430856|NCT03360994|Experimental|WATChmAN|Patients randomized to the WATChmAN Active Surveillance arm will receive their active surveillance testicular cancer care via an online virtual clinic. Importantly, patients will follow the same surveillance schedule as patients in the standard of care arm. However, patients in the WATChmAN arm will be able to see their upcoming tests and virtual appointments online, request requisitions to perform their required testing at outside institutions, and indicate any concerns for physicians to review during the virtual visit.
2430857|NCT03360994|Active Comparator|Standard of Care|Patients randomized to the standard of care arm (in-person active surveillance) will follow the current active surveillance protocol in place at Princess Margaret Cancer Centre's Multidisciplinary Testicular Cancer Clinic. This protocol involves the same schedule of testing as the WATChmAN arm, but will require patients to come into the clinic to receive their test results (as in current practice).
2430858|NCT03360981|Active Comparator|diabetics incretin-users (arm 1)|epicardial tissue biopsy, and than treated by incretin therapy plus standard anti ischemic therapy.
2430859|NCT03360981|Placebo Comparator|diabetics never-incretin-users (arm 2)|epicardial tissue biopsy, and than treated by standard hypoglycemic drug therapy plus standard anti ischemic therapy.
2430860|NCT03360981|No Intervention|non diabetics (arm 3)|non diabetics, treated by coronary artery bypass grafting (CABG), receiving epicardial tissue biopsy, and than treated by standard anti ischemic therapy.
2430861|NCT03360968|Experimental|Treatment A-B|Patient is treated with 1 hour SPN-CPAP/PS followed by 1 hour of Variable-PS ventilation mode
2430862|NCT03360968|Experimental|Treatment B-A|Patient is treated with 1 hour Variable-PS followed by 1 hour of SPN-CPAP/PS ventilation mode
3187685|NCT00758732|Experimental|1|Docetaxel/carboplatin
3187686|NCT00758732|Experimental|2|Docetaxel/Caelyx
3187687|NCT00758797|Experimental|1|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
3187688|NCT00758810||1|Patients without cardiac rehabilitation
3187689|NCT00758810||2|Patients with cardiac rehabilitation
3187690|NCT00758849|Placebo Comparator|1|
3187691|NCT00758849|Active Comparator|2|
3187692|NCT00758888|Experimental|Treatment|Place the blocks under the pelvis for 2 minutes
3187693|NCT00758888|Active Comparator|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
3187694|NCT00758888|Sham Comparator|Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
3187695|NCT00758901||1 ROCC Knee prosthesis|Consecutive series of patients with ROCC Knee prosthesis.
3187696|NCT00758927|Placebo Comparator|2|Placebo administration for 10 weeks with exercise and diet therapy
3187697|NCT00758927|Experimental|1|Omacor 4 gram per day with exercise and diet therapy for 10 weeks
3187698|NCT00758940|Experimental|1|Acrysof ReSTOR multifocal IOL
3187699|NCT00758953|Experimental|1|
3187700|NCT00758953|Experimental|2|
3187701|NCT00758953|Placebo Comparator|3|
3187702|NCT00758953|Placebo Comparator|4|
2430865|NCT03360942||DBS Long Term Follow Up|5 participants who were in a prior study to receive DBS are enrolled to have their progress and DBS devices monitored for a period of 12 years.
2430866|NCT03360929|Experimental|experimental group|"Study drug: AZD3759 Strength: 50mg/tablet, 100mg/tablet Dose escalation:A treatment cycle consists of consecutive 21 days of dosing. two dose cohorts are planned for dose escalation, including: 150 and 250 mg twice daily.~RP2D in dose expansion."
2430867|NCT03360916|Placebo Comparator|Placebo & Exercise Group|Participants randomized to this group will undergo placebo treatment and an aerobic exercise program.
2430868|NCT03360916|Experimental|Low Statin & Exercise Group|Participants randomized to this group will undergo low statin treatment (Lipitor 20Mg Tablet) and an aerobic exercise program.
2430869|NCT03360916|Experimental|High Statin & Exercise Group|Participants randomized to this group will undergo high statin treatment (Lipitor 80Mg Tablet) and an aerobic exercise program.
3147157|NCT00118105|Experimental|Chemotherapy + Surgery + Chemotherapy|"Preoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4~Conventional surgery: After 4 cycles of chemotherapy~Postoperative Neoadjuvant Chemotherapy~Bevacizumab, 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4~Oxaliplatin, 130 mg/m^2, IV, Day 1 of cycles 1,2,3,4~Capecitabine, 1,700 mg/m^2/day divided, PO at 12 hr intervals, Days 1-14 of cycles 1,2,3,4"
3147158|NCT00118170|Experimental|Treatment (sorafenib tosylate)|"Patients receive oral sorafenib once on day 1 and then once daily, twice daily, or every other day beginning on day 8 and continuing for 3 months. Patients are re-evaluated at 3 months. Patients with responding disease may continue study treatment in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients (per treatment cohort) receive escalating doses of sorafenib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD."
2430874|NCT03360877|Other|Health-care associated infection|
2430875|NCT03360864|Experimental|Therapeutic Education Program|"Patient randomized in this arm will attend a 1 day long validated Therapeutic Education Program.~This program will take place within 6 months after biologic treatment initiation."
2430876|NCT03360864|No Intervention|No therapeutic Education Program|Patient randomized in this arm will not attend a Therapeutic Education Program within 12 months after biologic treatment initiation.
2430877|NCT03360851|Experimental|Low-dose CT|A low-dose chest CT-scan will be performed either directly from the ER or from the medical ward as soon as possible but within 24 hours of admission. The CT will be performed with a radiation dose <0.5 mSv for a 70kg patient, as a replacement or in addition to the chest radiograph. Pregnancy will be an exclusion criterion for CT because of unwanted radiation exposure. CT interpretation will be performed by a radiologist. Test results will be communicated to the treating physician. Recommendations based on the CT may be to discontinue antibiotics in case of a noninfectious diagnosis that explains the presented signs and symptoms and to start treatment for the alternative diagnosis if needed, or to re-evaluate the CAP diagnosis if no signs of lobar or bronchopneumonia are detected on the CT.
2430878|NCT03360851|Experimental|PoC-PCR|The FilmArray real-time multiplex PCR (Biofire; bioMérieux) is a Point-of-Care PCR with a panel of respiratory viruses (adenovirus, coronavirus, human metapneumovirus, human rhinovirus/enterovirus, influenza A and B, parainfluenza virus, and respiratory syncytial virus), and three atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Bordetella pertussis), which will be performed on nasopharyngeal swab samples. Test results will be made available to the treating physician immediately. The treatment recommendation could be adaptation of antibiotic treatment for a documented atypical pathogen, a recommendation to not start or discontinue antibiotics when a virus is the only detected pathogen, or a recommendation to discontinue coverage of atypical pathogens.
2430879|NCT03360851|No Intervention|Standard care|All hospitals will continue the antibiotic stewardship activities employed during the baseline period as part of standard care. A representative of the Antibiotics-team (Team consisting of clinical microbiologists, infectious diseases specialist and clinical pharmacists supervising in-hospital antibiotic use) will monitor the empirical antibiotic treatment of patients hospitalized with CAP to non-ICU wards and provide feedback if indicated.
2430880|NCT03360838||CogCheck application|Performance in the application
2430881|NCT03360812|Experimental|Intervention group|The intervention is an online training resource to improve the recognition of imminent death in palliative care patients. The intervention should take approximately 15 minutes to complete. During this time, the participants who are in the intervention arm will be shown the results of a previous study which identified how expert palliative care doctors recognise imminently dying palliative care patients. The intervention will be implemented via the website, immediately after participants have completed the first set of vignettes.
2430882|NCT03360812|No Intervention|Control group|The participants assigned to the control group will not receive this additional information and will simply be informed that they are approximately half way through the task and will be asked to continue on to the next set of vignettes.
2430883|NCT03360799||Observational (questionnaire)|Participants complete 5 questionnaires.
2430884|NCT03360786|Experimental|Specific Protocol|The intervention group will work with the study physiotherapist and perform a 10-20 minute progressive exercises twice per week. The intervention will include a series of exercises including dynamic balance, adaptation, cervical spine strength, cervical spine neuromotor control and divided attention exercises. Exercises will begin at a lower level and progress to increasingly difficult levels of each exercise type over the course of the intervention. Concussion education and injury identification will also be completed.
2430885|NCT03360786|Active Comparator|Control Protocol|The control group will continue with their standard warm up and practice schedule but have the addition of contact time with the study physiotherapist for education regarding concussion education and injury identification.
2430886|NCT03360760|Experimental|Pre surgical Chemotherapy|Immediate pre surgical chemotherapy treated with four drugs including doxorubicin, cisplatin, high-dose methotrexate (MTX) and ifosfamide in eleven weeks, and then definitive surgery followed by adjuvant chemotherapy according to chemotherapy regimen in Peking University People's Hospital(PKUPH).
2430887|NCT03360760|Other|Immediate Surgery|Immediate definitive surgery, and then post operative chemotherapy based on doxorubicin, cisplatin, high-dose MTX and ifosfamide according to chemotherapy regimen in PKUPH.
3187703|NCT00758966|Experimental|NF (Naltrexone+Fluoxetine)|Naltrexone SR 32 mg and fluoxetine 60 mg
2430889|NCT03360734|Experimental|Combination|"First part: Combination of Gatipotuzumab (GAT) and Tomuzotuximab (TOM) Treatment: 5 weeks monotherapy with TOM (Day 1: 60mg, Day 2: 660mg, Week 2: 1200mg, Week 4: 1200mg). Then combination of 1200mg TOM with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity.~Second part: Combination of GAT and TOM or an approved anti-EGFR antibody, i.e. Cetuximab, Panitumumab, or Necitumumab Treatment: One week monotherapy with TOM (Week 1, Day 1: 60mg, Day 2: 660mg). Then 1200mg TOM in combination with 1400mg of GAT every two weeks until disease progression, as long as patient does not meet any other discontinuation criterion such as unacceptable toxicity or commercial anti-EGFR antibody (dosage according to local practices) in combination with 1400mg of GAT every two weeks until disease progression or until unacceptable toxicity"
2430890|NCT03360721|Experimental|Treatment (abiraterone acetate, apalutamide, prednisone)|Participants receive abiraterone acetate PO once daily QD, apalutamide PO QD, and prednisone PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2430891|NCT03360708|Experimental|Treatment (vaccine therapy)|Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5 of courses 2 and 3, and on day 1 of subsequent courses. Treatment with malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine repeats every 21 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2430892|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - PILOT|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
2430893|NCT03360695|Experimental|Proactive Psychiatry Consultation (PPC) - Randomized Trial|"Proactive Psychiatry Consultation and Case Management is:~Patient-centered: Based on the patient's needs, the team aims to build a relationship, increase engagement, and promote continuity.~Team-based: A psychiatrist and case manager identify goals for cancer treatment, assess psychiatric history and symptoms with a focus on impact on cancer care, collaborate with community-based clinicians and caregivers, and address barriers to care.~Integrated into cancer care delivery: The psychiatry and oncology teams collaborate starting at cancer diagnosis to support patient through cancer treatment.~Systematic: The team monitors psychiatric and cancer-related symptoms and cancer care delivery to measure progress toward goals and rapidly adjust treatment as needed."
2430894|NCT03360695|Active Comparator|Enhanced Usual Care (EUC) - Randomized Trial|Study staff will send a templated email to the treating oncologist at enrollment informing the oncologists of the psychiatric diagnosis and available psychosocial services. Study staff will also inform the patient and caregiver of available psychosocial services.
2430895|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 1|"The patient or donor is not a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is not a carrier of the hepatitis B virus.~treatment 48 weeks"
2430896|NCT03360682|Experimental|HIV-1-infected solid organ transplant patients 2|"The patient or donor is a carrier of genetic characteristics that predispose to a severe allergy to Abacavir or the patient is a carrier of the hepatitis B virus.~treatment 48 weeks"
2430897|NCT03360669|Experimental|Sequence: Clinical/Research|Participants assigned to this arm will have their blood pressure measured in a clinical setting first, and in a research setting second. The sequence randomization corresponds to the intervention. Visits will be at least a day apart but within a two-week period. During the clinical visit, they will have their blood pressure measured with the Omron HEM-907, an automated office blood pressure (AOBP) device. During the research setting, participants will be guided through a series of research-driven steps such as study questionnaires and completion of consent forms. They will have their blood pressure measured in both arms with a mercury sphygmomanometer, and then 3 measurements with a mercury sphygmomanometer. AOBP measurements (Omron HEM-907) will be performed at the end of the visit.
2430898|NCT03360669|Active Comparator|Sequence: Research/Clinical|Participants assigned to this arm will go through the same measurements and procedures exception made of the research-first and clinical-second sequence. The intervention to which they are randomized corresponds to the sequence of the visits.
2430899|NCT03360656|Experimental|Transnasal Thermal Regulating Device|Consented subjects will undergo cooling via transnasal thermal regulating device for a period of 8 to 24 hours
2430900|NCT03360643|Active Comparator|Point-of-care ultrasound prior to radiology ultrasound|
2430901|NCT03360643|Active Comparator|Radiology-performed ultrasound|
2430902|NCT03360630|Experimental|Anti-PD-1 plus DC-CIK|
2430903|NCT03360630|Active Comparator|Anti-PD-1 alone|
2430904|NCT03360617|Experimental|Syringe Arm|IV antibiotics will be delivered by syringe IV push over 2-3 minutes
2430905|NCT03360617|Sham Comparator|Piggyback Arm|IV antibiotics will be delivered by IV piggyback over 30 minutes
2430906|NCT03360604|Experimental|Low GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a low glycaemic index. This is the Low Glycaemic Diet intervention.
2430907|NCT03360604|Experimental|High GI diet|This diet consists of three meals (breakfast, lunch, snack) which all have a high glycaemic index. This is the High Glycaemic Diet intervention.
2430941|NCT03360370||6 to 66 months children with significant CHD|"Children with significant congenital heart disease (CHD) aged from 6 to 66 months at the time of the study and fulfilling inclusion criteria for whom an age-appropriate questionnaire completed by parents (Ages & Stages Questionnaires, Third Edition in French (ASQ-3™) will be used to screen developmental delays."
2430942|NCT03360357|Experimental|guided drills|These people will be going through all the guided drills before being evaluated.
2431068|NCT03359408|Experimental|Dementia Care Management (DCM)|"Subjects in this arm will be provided with Dementia Care Management adapted to the intersectoral setting."
3187704|NCT00758966|Active Comparator|Fluoxetine|Fluoxetine 60 mg
2430908|NCT03360591|Experimental|Physiologically-guided strategy|"Patients randomized in this group will undergo stenting of coronary lesions showing FFR values ≤0.80 only.~Lesions showing positive FFR measurements (<0.80) must be treated with PCI, before or after TAVI.~Lesions showing clearly negative values (FFR >0.80) will not be treated with PCI before TAVI, and repeated FFR and iFR measurements after TAVI are strongly recommended.~Lesions showing borderline FFR measurements before TAVI (FFR 0.80-0.83), should be measured again (both FFR and iFR) after TAVI, and the decision of treating of deferring treatment in a given lesion will be based on the FFR value obtained after TAVI.~In all cases iFR values will be recorded for a post hoc analysis and for validation of the study endpoints according to iFR values."
2430909|NCT03360591|Other|Angiographically-guided strategy|Patients allocated in this group will undergo stenting of all coronary stenosis ≥50% as assessed by visual estimation in vessels ≥2.5mm. PCI can be performed before in a previous procedure, or after TAVI, but always within one month, ± 5 days of the valve implantation.PCI in the group randomized to the angio-guided procedure can be performed therefore, either before or after valve implantation, in the same or in different procedures. Implantation of second-generation drug eluting stents (DES) in all interventions is advised, but not mandatory, and the brand of the stent is left to the operators and center's choice.
2430910|NCT03360552|Experimental|the multidimensional score of fragility (RAI CA)|A general practitioner (MG) management strategy guided by a multidimensional evaluation (RAI-CA) on the multidimensional score of fragility (RAI-HC) of patients with mild to moderately severe dementia.
2430911|NCT03360552|Placebo Comparator|Usual care|support for patients without multidimensional evaluation (RAI-CA)
2430912|NCT03360539|Experimental|Treatment-NFP|NFP is a prenatal and infancy home visiting program for low-income, first-time mothers and their families. Registered nurses begin visiting their clients as early in the pregnancy as possible, helping the mother-to-be make informed choices. The nurses continue visiting regularly until the child is two years old.
2430913|NCT03360539|No Intervention|Control|Control group members have access to the standard of care and whatever other programs and services are available in the community.
2430914|NCT03360526|Active Comparator|PICSI|Physiological ICSI
2430915|NCT03360526|Experimental|TESA|Testicular sperm aspiration
2430916|NCT03360513||general group|Comprised 70 caucasian Brazilian individuals with normal occlusion and at least four of Andrew's six keys.
2430920|NCT03360487|Sham Comparator|Sham photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the laser will be placed for 10 minutes, without being turned on.
2430921|NCT03360487|Active Comparator|Photobiomodulation in the sublingual region|A disposable plastic wrap will cover the application pen for the purposes of hygiene, and the region will be irradiated for 10 minutes.
2430922|NCT03360487|Sham Comparator|Sham photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be pretended on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be wakely irradiated for 30 seconds (total treatment time: 10 minutes).
2430923|NCT03360487|Active Comparator|Photobiomodulation along the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
2430924|NCT03360487|Sham Comparator|Sham Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific turned-off bracelet of the DMC laser Therapy EC model.
2430925|NCT03360487|Active Comparator|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
2430926|NCT03360474|Experimental|Intervention|Patients will be placed on the delirium screening intervention protocol arm. They will be screened for delirium twice per day. If positive, they will follow the treatment algorithm and assessed at 4 hour intervals until they reach 4 negative screens. Once 4 negative screens have been reached, they will be assessed twice daily.
2430927|NCT03360461|Experimental|EMI-137|Ten participants to receive the IMP - EMI-137 1 to 3 hours before laparoscopic colonic resection surgery. Dose range 0.02mg/kg to 0.13mg/kg will be administered.
2430928|NCT03360448|Experimental|Experimental|Ad5.hAC6: Intracoronary delivery of adenovirus encoding human adenylyl cyclase type 6
2430929|NCT03360448|Placebo Comparator|Placebo Comparator|Placebo: Intracoronary delivery of formulation buffer ( 3% sucrose)
2430930|NCT03360435||Participants with transdermal patches|All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch
2430931|NCT03360422|Active Comparator|Survey group|Collect alcohol and sexual activity data via web survey from 683 young MSM to yield normative data for the alcohol and HIV preventive intervention in a follow-up study
2430932|NCT03360422|Active Comparator|Focus Group|30 young MSM who drink regularly to inform the content of the alcohol and HIV preventive intervention tested in the UH3 phase and ensure the intervention is culturally appropriate for MSM.
2430933|NCT03360422|Active Comparator|Usability Study|10 young adult MSM will test the mobile intervention in development for 30 days in order to establish usability, acceptability and correct any functionality issues.
2430934|NCT03360409|Experimental|grade 1|ACD
2430935|NCT03360409|Active Comparator|grade 2|ACDF
2430936|NCT03360409|Active Comparator|grade 3|ACDA
3187705|NCT00758966|Active Comparator|Naltrexone|Naltrexone SR 32 mg
3187706|NCT00758992||Immunodeficient mice|Please see the Study Description for complete information.
2430939|NCT03360383|Experimental|grade 1|percutaneous vertebroplasty
2430940|NCT03360383|Active Comparator|grade 2|conservative treatment
3187707|NCT00759005|Experimental|A, 4|
2430943|NCT03360357|No Intervention|Self-trained|These people will watch a video and be able to practice by themselves without having any direction regarding how and what to practice.
3187708|NCT00759044||AMD|Patients diagnosed with AMD
3187709|NCT00759044||DME|Patients diagnosed with DME
3187710|NCT00759057|Experimental|1 - Investigational|Dynesys Non-Fusion Spinal System
2430947|NCT03360318|Active Comparator|Elbow cast|Device: Elbow cast
2430948|NCT03360318|Experimental|Removable elbow brace|Device: Removable elbow brace
2430949|NCT03360305|No Intervention|Usual care|The ED clinician will perform a standard medical evaluation. This evaluation includes a focused history and exam to identify injuries. Laboratory tests and radiologic imaging may be ordered. If necessary, the patient will receive consultation with specialty services (e.g., orthopedics). The research assistant (RA) will read the CDC STEADI brochure to the patient and provide them with a printed copy at the conclusion of their visit. The RA will solicit feedback from the clinician and the patient at the conclusion of the visit using the post-visit survey.
2430950|NCT03360305|Experimental|Intervention|"ED clinician will perform standard medical evaluation, including focused history and exam to identify injuries. RA will solicit feedback from clinician and patient via post-visit survey at conclusion of visit.~PT will perform services, including integrative mobility training and lower extremity strength training and recommending outpatient services/referrals. Specific assessments and treatments will be tailored to patient.~Pharmacist will perform a medication review using the updated BEERS criteria and CDC's STEADI instrument and recommend changes to potential fall risk increasing medication. Recommendations will be communicated to ED treatment team.~Seniors will return home with standardized checklist containing details of their assessment and action plan. The checklist addresses patient's personal risk factors for the fall and required further actions."
2430951|NCT03360292|Experimental|Higher target range|Infants will be targeted to 92-97% oxygen saturation
2430952|NCT03360292|No Intervention|Standard target range|Infants will be targeted to 90-95% oxygen saturation, which is the range used as routine in the Neonatal Unit involved in the study
2430953|NCT03360279|Active Comparator|Regular balloon|Use the regular balloon to perform standard balloon angioplasty.
2430954|NCT03360279|Active Comparator|DCB (paclitaxel-coated balloon)|Use DCB (paclitaxel-coated balloon) to perform additional balloon angioplasty.
2430955|NCT03360266|Active Comparator|Profluorid group|5% Sodium Fluoride varnish (Profluorid varnish) applied over white spot lesions on maxillary anterior teeth
2430956|NCT03360266|Experimental|Enamel Pro|Sodium Fluoride with ACP varnish (Enamel Pro varnish) applied over white spot lesions on maxillary anterior teeth
2430957|NCT03360266|Experimental|MI varnish|Sodium Fluoride with CPP-ACP varnish (MI varnish) applied over white spot lesions on maxillary anterior teeth
2430958|NCT03360253|Experimental|HMilkProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
2430959|NCT03360253|Placebo Comparator|HMilkPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
2430960|NCT03360253|Experimental|IFormProb|L. reuteri DSM 17938 in drops will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together to give the product the correct rheological properties
2430961|NCT03360253|Placebo Comparator|IFormPlacebo|The placebo consists of an identical formulation except that the L. reuteri is not present
2430962|NCT03360240||Cases|Cases: patients with pregnancy that starts before the age of 19 that develops preeclampsia (mild), severe preeclampsia, gestational hypertension and eclampsia, that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
2430963|NCT03360240||controls|Are patients with pregnancy that starts before the age of 19 that without develops (preeclampsia mild), severe preeclampsia, gestational hypertension or eclampsia) that is 24 and more weeks pregnant with prenatal control started before 20 weeks of pregnancy.
2430964|NCT03360214|Other|Active PEMF + Treatment PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
2430965|NCT03360214|Other|Active PEMF + Sham PIB|Participants will receive an active device (Pulsed Electromagnetic Field (PEMF) Device) and placebo drug.
2430966|NCT03360214|Other|Sham PEMF + Treatment PIB|Participants will receive a placebo device and active drug (Bupivacaine Hydrochloride or Ropivacaine HCl).
2430967|NCT03360214|Other|Sham PEMF + Sham PIB|Participants will receive placebo drug and placebo device.
2431028|NCT03359681|Active Comparator|metformin hydrochloride|metformin, encapsulated tablet, 500mg 3 times a day for 30 days.
2431029|NCT03359681|Placebo Comparator|placebo oral capsule|placebo, encapsulated tablet, 500mg 3 times a day for 30 days.
2431030|NCT03359668|Experimental|Non-contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
3187711|NCT00759057|Active Comparator|2 - Control|Silhouette Posterior Pedicle Screw System as an adjunct to Posterior Lateral Fusion with Autograft.
3187712|NCT00759070|Active Comparator|1|Tenofovir (TDF) + emtricitabine (FTC) + efavirenz (EFV)
3187713|NCT00759070|Active Comparator|2|Tenofovir (TDF) + emtricitabine (FTC) + lopinavir/ritonavir (LPV/RTV)
3187714|NCT00759083|Experimental|1|Patients with HIT/HITTS who require anticoagulation for PCI
3187715|NCT00759122|Active Comparator|1|VENLAFAXINE
3187716|NCT00759122|Placebo Comparator|2|
3187717|NCT00759135|Experimental|1|Single therapeutic dose of 2.5 mg NX-1207
3187718|NCT00759135|Experimental|2|Single low dose of 0.125 mg NX-1207 for dose-response evaluation
3187719|NCT00759135|Active Comparator|3|5.0 mg finasteride q.d.
3187720|NCT00759200|Experimental|alb-interferon arm 1|
3187721|NCT00759200|Experimental|alb-interferon arm 2|
3187722|NCT00759200|Experimental|alb-interferon arm 3|
3187723|NCT00759200|Experimental|alb-interferon arm 4|
3187724|NCT00759200|Active Comparator|peg-interferon|
2430968|NCT03360201|Experimental|Intervention: Tuko Pamoja|The intervention, Tuko Pamoja, is delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. The content and structure has been adapted in both content and implementation model based on formative research in this context. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection.
2430969|NCT03360175||Thoracic Surgery Patients|"Inclusion criteria include: Patients scheduled to undergo thoracic surgery at Brigham and Women's Hospital, between the ages 18-85 years old. Exclusion criteria are: pre-existing chronic pain or opioid use; current treatment with corticosteroids; evidence of active infection; chronic liver disease; end-stage renal disease (CKD-5); chronic inflammatory disorders; recent major surgery or illness within 30 days; use of immunosuppressive medication; history of organ transplantation.~Pro-inflammatory eicosanoid and pro resolving lipid mediator temporal profiles will be determined pre-operatively, on post-operative day 1 and on post-operative day 14. In addition, daily pain scores will be recorded for 60 days after surgery and at 3, 6 and 12 months."
2430970|NCT03360136|Other|Multi-professional CBT-rehabilitation|24 weeks CBT-based multi-professional rehabilitation.
2430971|NCT03360123|Active Comparator|Midazolam Hydrochloride 2Mg/mL Syrup|"The participants in this arm will receive midazolam+nitrous oxide at the 1st dental appointment.~Dosage: Midazolam: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment."
2430972|NCT03360123|Active Comparator|Triazolam 0.125 MG|The participants in this arm will receive triazolam+nitrous oxide at the 1st dental appointment. Dosage: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
3187725|NCT00759213||1|Any infant with a length of stay in the NICU of at least 7 days.
3187726|NCT00759239|Experimental|1|One drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 am and 1 drop of Timolol vehicle as placebo in each eye at 9 pm for 12 weeks.
2430975|NCT03360097|No Intervention|Fresh ET|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
2430976|NCT03360097|Experimental|Frozen Embryo Transfer|The best available embryo is at expansion grade <4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.
3187727|NCT00759239|Experimental|2|One drop of Timolol vehicle as placebo in each eye at 9 am and one drop of Travoprost 0.004% / Timolol maleate 0.5% in each eye at 9 pm for 12 weeks.
2430979|NCT03360058|Experimental|Immediate access to STBD training|Immediate access to training materials and print pieces to support implementation
2430980|NCT03360058|Placebo Comparator|Delayed access to STBD training|Delayed access to training materials and print pieces
2430981|NCT03360045|Active Comparator|Tranexamic acid group|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
2430982|NCT03360045|Placebo Comparator|Placebo group|5ml normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
2430983|NCT03360045|Active Comparator|Merocel Group|Merocel packing is applied.
2430984|NCT03360032||All participants|All patients will be asked to undertake an incremental shuttle walk test and a cardiopulmonary exercise test and the results will be compared.
2430985|NCT03360019|Active Comparator|Residents in memory care or skilled nursing Facility|
2430986|NCT03360019|Active Comparator|Resident in independent living setting|
2430987|NCT03360019|Other|Care Partners|
2430988|NCT03360006|Experimental|ABBV-744 Dose Escalation|ABBV-744 will be administered at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
2430989|NCT03360006|Experimental|ABBV-744 Dose Expansion|ABBV-744 will be administered at the recommended Phase 2 dose determined during the Dose Escalation phase.
2430990|NCT03359993||Preterm infants intubated|All participants were preterm infants intubated in the delivery room for Infantile Respiratory Distress Syndrome (IRDS). The purpose of this research is to determine a premedication of intubation. This consists of describing a simple and effective method for premedication in the delivery room, using the umbilical vein, directly perforated through the Wharton jelly.
2430991|NCT03359980|Experimental|treated patients|Treated with Fecal Microbiota Transfer (FMT)
2430992|NCT03359954|Experimental|Treatment (radiation therapy, surgery)|Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.
2430993|NCT03359941|Experimental|Integrative Treatments|This study's arm is single, so all participants will receive acupuncture treatments.
2430994|NCT03359928|Experimental|Boxing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Non-contact boxing involves boxing punch pads that will be held by the one of the researchers, while wearing protective boxing gloves. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
2430995|NCT03359928|Experimental|Stair stepping|Participants will complete 3 sessions of exercise. In each of the three sessions a different exercise modality will be conducted in a randomised sequence. Stair stepping involves stepping on to and off a 35 cm Reebok exercise bench, repeatedly. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest). During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed.
2431031|NCT03359668|Active Comparator|Contrast-enhanced CT|Comparison of non-contrast CT to the standard-of-care contrast-enhanced CT of the head and neck in detection of suspicious lymph nodes
2430996|NCT03359928|Experimental|Stair climbing|"In each of the three sessions a different exercise modality will be conducted, in a randomised sequence. Stair climbing involves continuously ascending the stairs located in a public access staircase. Each exercise modality will be conducted following a high-intensity interval protocol (4 x 60 seconds of exercise interspersed with 60 seconds of rest).~During each exercise bout participants will be encouraged to exercise at an intensity that elicits a heart rate of ≥85% of maximum, which will always be followed by 60 seconds of passive recovery. Participants will complete a 5 minute warm-up and a 2 minute cool down and stretch after the exercise bouts have been completed."
2430997|NCT03359915|Experimental|Intervention Group|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
2430998|NCT03359915|No Intervention|Control Group|COPD 'standard' care in local setting - Bhaktapur, Nepal; Lima, Peru; Nakaseke, Uganda
2430999|NCT03359902|Experimental|Initial tVNS|This group will receive transcutaneous vagal nerve stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
2431000|NCT03359902|Experimental|Initial Sham|This group will receive sham stimulation, initially. Participants will be randomized between the two arms of the crossover sessions (initial tVNS vs. initial Sham). Behavioral portions of the testing will then be carried out twice, with at least 72 hours between sessions (to avoid carryover effects).
2431002|NCT03359876||Rivaroxaban|NVAF patients with renal dysfunction newly initiated on rivaroxaban 15 mg for stroke prevention
2431003|NCT03359876||Warfarin|NVAF patients with renal dysfunction newly initiated on vitamin K antagonist (warfarin) for stroke prevention
2431004|NCT03359863|Experimental|Treatment Arm|Subjects will receive Pirfenidone as part of treatment for their restrictive chronic lung allograft dysfunction (RCLAD).
2431007|NCT03359837|Experimental|Glargine based therapy|Once daily glargine plus prandial oral anti-hyperglycemic drugs
2431008|NCT03359837|Active Comparator|Premixed insulin|Twice daily premixed insulin
2431009|NCT03359824|Other|Exercise|Arm: Exercise: Combination of moderate intensity continuous training, high intensity interval training and endurance training 5 times per week for a total of 6 weeks. Out of 5 sessions three were supervised by trainer and two sessions were performed by subjects on their own.The duration of the exercise was increased progressively. The first two weeks was 30 minutes that increased to 45 minutes in the third and fourth week. It was 60 minutes for the last two weeks.
2431010|NCT03359811|Experimental|Standard-of-Care Thoracic Epidural Analgesia (TEA)|An epidural catheter placed before induction of anesthesia by an anesthesiologist. A bolus or infusion of the local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
2431011|NCT03359811|Active Comparator|4Q-TAP Blocks|Participants have an ultrasound guided 4Q-TAP block. A maximum of 80 cc of a solution consisting of 30 mg of bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) and 65 mg of liposomal bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
2431012|NCT03359798|Experimental|Narcotic counseling script|Study participants will be read a script regarding post-cesarean section narcotic use.
2431013|NCT03359798|Sham Comparator|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
2431016|NCT03359772|No Intervention|Group 1|Exercise Only Group
2431017|NCT03359772|Active Comparator|Group 2|Kinesthetic Ability Trainer Group
2431018|NCT03359746|Experimental|Treatment Group|This is a prospective, interventional, case-control study at King Faisal Specialist Hospital & Research Centre in post-renal transplant patients who are receiving Grazoprevir/Elbasvir combination. Data will be compared with matched historical controls, which will be selected according to the following matching criteria: age, time from transplant to initiation of therapy. Only patients who completed at least 48 weeks of pegylated Interferon + Ribavirin therapy in the control group and 12 weeks of therapy on the case group will be enrolled. Any patient who received at least one dose of Grazoprevir/Elbasvir combination will be included in the safety analysis.
2431019|NCT03359733|Experimental|TAK-659 100 mg Fasted + TAK-659 100 mg Fed|TAK-659 100 milligram (mg), tablet, orally under fasted state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fed state, once on Day 8 of a 15-day food effect treatment period.
2431020|NCT03359733|Experimental|TAK-659 100 mg Fed + TAK-659 100 mg Fasted|TAK-659 100 mg, tablet, orally under fed state, once on Day 1, followed by TAK-659 100 mg, tablet, orally under fasted state, once on Day 8 of a 15-day food effect treatment period.
2431021|NCT03359720||guyane|
2431022|NCT03359720||martinique|
2431023|NCT03359720||guadeloupe|
2431024|NCT03359694|Experimental|DT group|Pegylated liposomal doxorubicin and Docetaxel Treatment group Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
2431025|NCT03359694|Active Comparator|ET group|Conventional doxorubicin and Docetaxel Treatment group Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
2431026|NCT03359694|Experimental|NX group|Navelbine and Xeloda treatment group in group of Non-pCR patients Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d×4
2431027|NCT03359694|No Intervention|Control group|"no treatment group of Non-pCR patients after DT or ET neoadjuvant chemotherapy.~No drugs treatment in this group."
2431032|NCT03359655|Active Comparator|Rectal misoprostol|200 mcg of misoprostol will be administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
2431033|NCT03359655|Active Comparator|Rectal hyoscine butyl bromide|10 mg hyoscine butyl bromide administered rectally- 2 hours previously. This intervention will be performed by a third party health professional who will be blinded to the procedure.
2431034|NCT03359655|No Intervention|Sham administration|A rectal examination will be performed by a third party health professional who will be blinded to the procedure. No drug will be administered
2431035|NCT03359642|Experimental|Patients with anti-TNF alpha|12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which a first anti-TNF alpha treatment is indicated.
2431036|NCT03359642|Active Comparator|mirror group|"A mirror group of 12 spondyloarthritis and 24 inflammatory bowel diseases patients (12 Crohn's disease and 12 ulcerative colitis), in which an all but anti-TNF alpha or biotherapy treatment is indicated will be included to distinguish the specific effects on microbiota of anti-TNF alpha."
2431037|NCT03359616|Experimental|transanal total mesorectal excision|Transanally, the rectum is mobilized through the mesorectal plane according to the TME principles, assisted by the transanal surgical platform (Transanally curable surgical resection).
2431038|NCT03359616|Active Comparator|laparoscopic total mesorectal excision|By standard laparoscopic techniques, the rectal cancer will be resected by the conventional laparoscopic TME (LaTME).
2431039|NCT03359603|Experimental|Group A|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA 3 sessions per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
2431040|NCT03359603|Experimental|Group B|After recruiting, patients are assigned to the group by randomization,and then receive electro-acupuncture treatment. Patients in the group will receive EA once per week for 8 weeks. The EA stimulation lasted for 30 minutes with a dilatational wave of 2/100 Hz and a current intensity depending on the patient's comfort level (preferably with skin around the acupoints shivering mildly without pain).
3187728|NCT00759265|Experimental|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
3187729|NCT00759265|No Intervention|control|No intervention was prescribed
2431043|NCT03359577|Experimental|Psorax35|Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid. Dose: 10 capsules of 590 mg. Route of administration: oral.
2431044|NCT03359577|Placebo Comparator|MCT oil|Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil). Dose: 10 capsules of 590 mg: Route of administration: oral.
2431045|NCT03359564||micro endoscopic discectomy|the patients with lumbar disc herniation
2431046|NCT03359538|Placebo Comparator|placebo|Patients assigned to this arm will take Riluzole as usual + placebo tablets
2431047|NCT03359538|Active Comparator|Rapamycin 1 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 1 mg/m2/day
2431048|NCT03359538|Active Comparator|Rapamycin 2 mg/m2|Patients assigned to this arm will take Riluzole as usual + tablets corresponding to a Rapamycin dose of 2 mg/m2/day
2431049|NCT03359525|Experimental|Group A|Group A: Intravenous Tranexamic acid at a dose of 1 gram administered 30 min prior to skin incision and 1 gram 3 hours after the procedure. (Total dose administered is 2 grams)
2431050|NCT03359525|Experimental|Group B|Group B: Topical Tranexamic acid at a dose of 1 gram injected in to the periarticular tissues prior to closure and 1 gram injected into the joint through the drain following wound closure. (Total dose administered is 2 grams)
2431051|NCT03359525|Experimental|Group C|Group C: Combined Intravenous 1 gram given intravenous 30 min prior to skin incision and topical tranexamic acid (1 gram) injected in to the periarticular tissues prior to closure. (Total dose administered is 2 grams)
2431052|NCT03359512|Experimental|qCON monitor|Simultaneous measurement of BIS and qCON
2431053|NCT03359499|Experimental|Bacillus clausii|Bacillus clausii administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
2431054|NCT03359499|Other|Antispasmodic|Trimebutine administered orally for two weeks plus standard dietary advice for non-constipated irritable bowel syndrome
2431055|NCT03359486|Experimental|Group problem management plus|Five sessions of group low intensity psychological intervention
2431056|NCT03359486|Active Comparator|Enhanced treatment as usual|Referral to primary health care workers trained in mental health Gap Action Programme.
3187730|NCT00759278||1|Group of 30 women who are pregnant as subjects that take antihypertensive medication
3187731|NCT00759278||2|Group of 30 women who are pregnant and do not take antihypertensive medications as a control group
3187732|NCT00759291|Active Comparator|Acipimox|Acipimox treatment QID for 7 days
3187733|NCT00759291|Placebo Comparator|Placebo|Placebo treatment QID for 7 days
3187734|NCT00759304||PROOF cohort|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date.
2431062|NCT03359447|Experimental|Weekly Iron|Weekly ferrous sulfate: one dose (4mg/kg/week).
2431063|NCT03359447|Active Comparator|Daily Iron|Daily ferrous sulfate: one dose (1 mg/kg/day). Maximum daily dose: 40 mg
2431064|NCT03359434|Experimental|Two measuring methods of blood pressure|
2431067|NCT03359408|No Intervention|Care as usual|Care as usual, no intervention, just observation of natural change/ trajectories over time
2431071|NCT03359382|No Intervention|control|
2431075|NCT03359356|Experimental|Dupilumab|An initial dose of 600 mg (two 300 mg subcutaneous injections), followed by 300 mg given every other week
2431076|NCT03359356|Placebo Comparator|Placebo|Matching placebo in prefilled syringes identical to the dupilumab syringes
2431077|NCT03359343||experts|In this group, two experts distinguish a set of polyps on LCI images as adenoma or non-adenoma.
2431078|NCT03359343||non-experts|In this group, two non-experts distinguish the set of polyps(the same to experts group) on LCI images as adenoma or non-adenoma.
2431079|NCT03359343||Computer-aided diagnosis system|In this group, a newly developed computer-aided diagnosis system will be used to distinguish a set of polyps as adenoma or non-adenoma.
2431080|NCT03359330||Degradable conduit small gap tublization|patients with fresh peripheral nerve injury in the upper extremities,repaired with degradable conduit small gap tublization
2431081|NCT03359317|Experimental|jogging|At least 5 times/week
2431082|NCT03359291|Experimental|Sequence AB|Subjects participate in two study periods: During the first period (treatment A), they receive a single oral dose of rosuvastatin on Day 1. During the second period (treatment B), they receive a single oral loading dose of macitentan on Day 5 and oral doses of macitentan from Day 6 to Day 16 (i.e., 11 doses). Subjects receive a single oral dose of 10 mg rosuvastatin concomitantly with macitentan in the morning of Day 10.
2431083|NCT03359278||open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
2431084|NCT03359265|Active Comparator|Test|The test group used underpants made of precious metal fibers (germanium, titanium and phosphorus), developed by Green Energy Nano Technology Co., Ltd.
2431085|NCT03359265|Placebo Comparator|Control|The control group used commercially available underpants.
2431088|NCT03359239|Experimental|PGV 001 with Atezolizumab|Atezolizumab: programmed death-ligand 1 PGV001:personalized cancer vaccine PGV 001 - vaccine Poly ICLC- adjuvant The product is prepared within the Icahn School of Medicine at Mount Sinai (ISMMS) . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.
2431089|NCT03359226|Experimental|Submandibular gland biopsy|No treatment is being used in this study. Study participants will have bilateral submandibular gland biopsies.
2431090|NCT03359213|Experimental|JR-141 1.0 mg/kg/week|
2431091|NCT03359213|Experimental|JR-141 2.0 mg/kg/week|
2431092|NCT03359213|Experimental|JR-141 4.0 mg/kg/week|
2431093|NCT03359187|Active Comparator|Normal saline with salt/Soda|Normal saline with salt/soda rinse 4 times a day/everyday and for each time 15 ml.
2431094|NCT03359187|Experimental|Clinacanthus nutans|Clinacanthus nutans in form of mouth wash rinse 4 times a day/everyday and for each time 15 ml.
2431095|NCT03359187|Experimental|Boesenbergia rotunda|Boesenbergia rotunda in form of mouth wash 4 times a day/everyday and for each time 15 ml.
3187735|NCT00759317|Active Comparator|1|venlafaxine
2431097|NCT03359161|Experimental|In-Home Subcutaneous Furosemide Treatment ARm|Prospective, open-label arm to evaluate the clinical effectiveness of a novel formulation of furosemide delivered by subcutaneous administration.
2431098|NCT03359148||Disposable ventilator system|The experimental study group will be assigned to a disposable ventilator system combined with an auto-filled heated humidifier (HH), a closed suction catheter, and a closed aerosol therapy procedure with a valved T-adaptor.
2431099|NCT03359148||Conventional reused ventilator system|According to clinical commonly used system, the control study group will be assigned to use with conventional reused ventilator system, combined with a manually filled HH, an open suction catheter, and a conventional aerosol therapy procedure.
2431100|NCT03359135||group1|hEDS treated with rehabilitation only
2431101|NCT03359135||group 2|hEDS treated with rehabilitation associated to compression garments wearing
2431102|NCT03359109||Stainless Steel Devices|10 patients with stainless steel devices implanted
2431103|NCT03359109||Titanium or Titanium-alloy Based Devices|30 patients with titanium or titanium-alloy implanted devices
2431104|NCT03359109||De Novo Titanium Implant|10 patients undergoing de novo titanium implant placement who have had no previous orthopedic procedures
2431105|NCT03359096|Experimental|Therapeutic HGNS|Therapeutic Hypoglossal Nerve Stimulation (HGNS). Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study.
2431106|NCT03359096|Sham Comparator|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds."
2431107|NCT03359070|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
2431108|NCT03359070|Active Comparator|Group 2 - miconazole cream 2%|Topical application of miconazole cream 2%, twice a day (7 to 8 a.m. and 6 to 7 p.m.) for 14 days.
2431109|NCT03359057|Experimental|Estradiol + levonorgestrel + folic acid|Coated tablet of the test product - ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days.
2431110|NCT03359057|Placebo Comparator|Folic acid|Coated tablet of placebo coated tablet containing folic acid 0.4 mg only on the last 7 days of the cycle.
2431111|NCT03359044||Sedation + topical anesthesia|midazolam 0.1～0.2 mg/kg for sedation, 2%lidocaine for topical anesthesia
2431112|NCT03359044||General anesthesia+ topical anesthesia|propofol 4～5mg/kg、Remifentanil2～3μg/kg for induction ,insert Laryngeal Mask Airway(LMA) , 2%lidocaine for topical anesthesia
2431113|NCT03359031|No Intervention|No patient education|This group of patients will not receive any additional information beyond standard of care educational pamphlets provided by the hospital.
2431179|NCT03358602|Active Comparator|Elective neck dissection|Elective neck dissection & open partial supraglottic laryngectomy(primary tumor)
3187736|NCT00759317|Placebo Comparator|2|
2431114|NCT03359031|Other|Patient education|This group of patients will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
2431115|NCT03359018|Experimental|apatinib plus anti-PD1 therapy arm|Every patients will received apatinib 250mg or 500mg orally daily and SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
2431116|NCT03359005|Experimental|5d VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 50mg/m2/d IV over 60 minutes on days 1-5.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
2431117|NCT03359005|Active Comparator|5d x 2 VIT (irinotecan, temozolomide and vincristine)|"Irinotecan 20mg/m2/d IV over 60 minutes on days 1-5 and 8-12.~Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity."
2431118|NCT03358979||Severe eye dryness|
2431119|NCT03358979||absence of eye dryness|
2431120|NCT03358966||Early to moderate CKD (stage 1-3)|40 patients with CKD stage 1-3. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
2431121|NCT03358966||Advanced CKD (stage 4-5)|40 patients with CKD stage 4-5. All subjects performed a comprehensive metabolic analysis including measurement of Resting Energy Expenditure using indirect calorimetry, bioimpedance, doubly-labelled water technique and body size measures. Physical activity was assessed using a Stanford 7 day recall questionnaire.
2431122|NCT03358953|Other|Electronic Cigarettes|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the electronic cigarette arm. They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
2431123|NCT03358953|Other|Nicotine replacement patches|Participants wishing to quit tobacco smoking have an equal chance of being assigned to the nicotine replacement patch arm (standard care). They are supplied with a second generation e-cigarette to support their quit attempt with standard of care once weekly support sessions from NHS smoking cessation services.
2431124|NCT03358940|Other|patient with miscarriage complications or not|The day of inclusion, for patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
2431125|NCT03358927|Active Comparator|Standard Group|Deferred fast-track care
2431126|NCT03358927|Experimental|Immediate Fast-Track Group|Immediate fast-track care
2431127|NCT03358914||Adolescents with psoriasis|No assigned intervention: completion of PsoTeenQOL and other instruments for assessment of psychometric properties and further refinement of the PsoTeenQOL.
2431128|NCT03358914||Parents of adolescents with psoriasis|No assigned intervention: completion of proxy-version of the PsoTeenQOL for validation purposes
2431129|NCT03358914||Adolescents without psoriasis|No assigned intervention: completion of non-psoriasis control-version of the PsoTeenQOL for validation purposes
2431130|NCT03358901|Experimental|YC-6|6 volunteers in each level will be infused 100, 200, 400, or 600 mg of YC-6 over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
2431131|NCT03358901|Placebo Comparator|Vehicle|2 volunteers in each level will be infused 2, 4, 8, or 12 g of vehicle over 7 consecutive days: BID within 30 minutes for the first 6 days and QD on the 7th day.
2431132|NCT03358888|Active Comparator|Standard of Care|
2431133|NCT03358888|Active Comparator|Multi-modal with as needed opioids|
2431134|NCT03358888|Active Comparator|Multi-modal with one week of opioids offered|
2431135|NCT03358875|Experimental|BGB-A317|100 mg per vial, 200mg intravenous (IV), Q3W
2431136|NCT03358875|Experimental|Docetaxel|75 mg/m2 IV Q3W
2431137|NCT03358862||Myopes|Children, adolescents and young adults with existing progressive myopia equal to or exceeding -0.50 D in the year prior to beginning the use of the NaturalVue contact lens.
2431138|NCT03358849|Experimental|experimental group|
2431139|NCT03358836||Group A|Episodic treatment with FIX concentrates for bleeding episodes
2431140|NCT03358836||Group B|Prophylaxis using any FIX concentrate with an intended trough of 1-5%
2431141|NCT03358836||Group C|Prophylaxis with an extended half-life (EHL) FIX with an intended trough of >10%
2431142|NCT03358823||Angelman syndrome|Cases were children with the diagnosis meet the all 4 major criteria developmental delay, speech impairment, movement or balance disorder, and behavioral characteristics, as well as the presence of 3 of 6 minor criteria, including postnatal deceleration of head growth, seizures, abnormal EEG, sleep disturbance, attraction to or fascination with water, and drooling (summary by Tan et al., 2011). all patients meet the 4 known genetic mechanisms can cause Angelman syndrome (AS).,including maternal deletions involving chromosome 15q11.2-q13;paternal uniparental disomy of 15q11.2-q13;imprinting defectsand mutations in the gene encoding the ubiquitin-protein ligase E3A gene (UBE3A; 601623)
2431143|NCT03358810|Active Comparator|Active group|patients randomized to receive active PES
2431144|NCT03358810|Sham Comparator|Sham treatmment|Patients randomized to sham will not receive any PES.
2431145|NCT03358797|Experimental|intervention-HPP|Community participants will participate in a group-based lifestyle intervention based on the CDC Diabetes Prevention Program, and adapted to the Arabic language, Arab culture, Mediterranean Diet, and adapted to include empowerment, leadership and emotion regulation.
2431146|NCT03358797|Experimental|CBLI+RT|based on randomization, group that will be assigned to CBLI+RT will receive the CBLI curriculum (as described in the intervention-HPP arm) in addition to the resiliency training
2431147|NCT03358797|Experimental|Attention control (CBLI-)|The attention control group will receive the core curriculum of the CBLI (as described in the intervention-HPP arm) only without the resiliency training. The sessions of the resiliency training will be replaced with sessions on health topics that do not contribute to our outcome (increased resiliency) (i.e. breast cancer, osteoporosis)
2431180|NCT03358589|Other|MESTAR|All patients will have the same scans performed
2431148|NCT03358797|Experimental|Pilot|This group will not be randomized. The group will receive the CBLI content (as described in the intervention-HPP arm) in addition to the resiliency training. The aim of this pilot is to create a resiliency training manual to be implemented in the following groups that will be assigned to receive the CBLI+RT
2431149|NCT03358784||PHILOS Plate|three or four-part fractures of proximal humerus treated with internal fixation
2431150|NCT03358784||Hemi-shoulder arthroplasty|three or four-part fractures of proximal humerus treated with hemi-shoulder arthroplasty
2431151|NCT03358771|No Intervention|Usual Care|"During the initial stepped wedge phase, all sites will receive usual care. There is currently no standardized discharge care bundle for COPD in Alberta. Some electronic patient information sheets do exist; however, their content is general and use is limited. It is expected that a vast majority of patients will transition to the community on a sub-optimal medication regimen, with limited referral to additional outpatient programs and no formal follow-up organized with a primary care provider (e.g., F/U prn or F/U with Fam MD)."
2431152|NCT03358771|Active Comparator|COPD discharge care bundle|"COPD discharge care bundle:~Ensure patient has demonstrated adequate inhaler technique~Send discharge summary to family physician office and arrange follow-up~Optimize and reconcile prescription of respiratory medications~Provide a written discharge management plan, and assess patient's and care giver's comprehension of discharge instructions~Refer to pulmonary rehabilitation~Screen for frailty and comorbid condition(s)~Assess smoking status, provide counseling and refer to smoking cessation program, where appropriate"
2431153|NCT03358771|Experimental|COPD discharge care bundle & coordinator|COPD discharge care bundle as listed for active comparator arm enhanced with care coordinator support.
2431154|NCT03358745|Experimental|Standard meal, bread/butter as starter|"Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal and consists of bread and butter, soup, salad and cheese. The participants eat the bread and butter portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).~Blood samples are taken before the lunch and every 30 min postprandial for 4 h."
2431155|NCT03358745|Experimental|Standard meal with soup as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the soup portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2431156|NCT03358745|Experimental|Standard meal with cheese as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the cheese portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2431157|NCT03358745|Experimental|Standard meal with salad as starter|Subjects eat a reference lunch (reference lunch) at 11:30 am, 4 h after a defined light breakfast. The meal contains 38 g fat and 885 kcal. The participants eat the salad portion within 15 min and the remaining components of the meal are consumed within the following 15 min (total eating time=30 min).
2431158|NCT03358732|Experimental|Mock embryo transfer|The patients underwent a mock embryo transfer one day before the scheduled actual transfer
2431159|NCT03358732|No Intervention|No mock embryo transfer|The patients did not undergo mock embryo transfer one day before the scheduled actual transfer
2431160|NCT03358719|Experimental|Treatment (CDX-1401, poly ICLC, decitabine, nivolumab)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 intracutaneously and poly ICLC SC on day -14, on day 15 of courses 1-4, and then on day 1 of every 4 courses thereafter. Patients also receive nivolumab IV over 30 minutes on days 1 and 15 and decitabine IV over 1 hour on days 1-5. Courses with nivolumab and decitabine repeat every 4 weeks in the absence of disease progression or unaccepted toxicity.
3147159|NCT00118183|Experimental|Arm I|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and cetuximab IV over 1-2 hours on days 1, 8, 15, and 22. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive cetuximab alone as above in the absence of disease progression or unacceptable toxicity.
3147160|NCT00118183|Experimental|Arm II|Patients receive docetaxel as in arm I and bortezomib IV over 3-5 seconds on days 1, 8, and 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 4 courses receive bortezomib alone as above in the absence of disease progression or unacceptable toxicity.
2431163|NCT03358693||Psoriasis patients receiving ustekinumab|Ustekinumab
2431164|NCT03358693||Psoriasis patients receiving infliximab|Infliximab
2431165|NCT03358693||Psoriasis patients receiving secukinumab|Secukinumab
2431166|NCT03358693||Atopic dermatitis patients receiving dupilumab|Dupilumab
2431167|NCT03358693||Psoriasis patients receiving brodalumab|Brodalumab
2431168|NCT03358693||Psoriasis patients receiving Ixekizumab|Ixekizumab
2431169|NCT03358693||Atopic dermatitis patients receiving tralokinumab|Tralokinumab
2431170|NCT03358693||Atopic dermatitis patients receiving baricitinib|Baricitinib
2431171|NCT03358693||Atopic dermatitis patients receiving abrocitinib|Abrocitinib
2431172|NCT03358693||Atopic dermatitis patients receiving upadacitinib|Upadacitinib
2431173|NCT03358667||group A|single edentulism implant insertion tent screw 2mm augmentation peri-implant soft tissue
2431174|NCT03358667||group B|single edentulism implant insertion cover screw and membrane augmentation peri-implant soft tissue
2431175|NCT03358654|Experimental|mesenchymal stem cells|Inject mesenchymal stem cells from umbilical cord. The patients will be followed up at 1, 2, 3, and 6 months after the injection
2431176|NCT03358641||Wuchuan residents|All residents that meet the criteria can be enrolled in this group, receiving a home interview (including IPA-Q to assess the level of physical activity) and a weight-bearing posteroanterior semiflexed view of radiographs at tibiofemoral (TF) joints at baseline and 3 years later.
2431177|NCT03358628||Osteosarcoma|Osteosarcoma patients with metastatic relapsed or unresectable progressive disease (total n= up to 20) following resection of the primary lesion and adjuvant chemotherapy.
2431178|NCT03358602|Experimental|Radiotherapy|Radiotherapy & open partial supraglottic laryngectomy(primary tumor)
3187737|NCT00759343||Control Group|"The control subjects of this study will be asked to undergo renal ultrasound examination, if available, or will be asked to complete a disease history form to determine the presence or lack of a kidney stone. Urine and serum will then be taken for storage until further analysis.~Controls will be asked to undergo a screening renal ultrasound to ensure they are stone free, this will take approximately 45 minutes. If the controls are asked to complete the history form, this will not take more than 20 minutes. They will also give a blood and urine sample during this time to bring the total extra time up to at most 60 minutes for controls."
3187738|NCT00759343||Stone Group|"The stone group will undergo standard diagnostic procedures for their condition and recovery process. Serum and urine for storage and analysis will be taken prior to stone treatment and 6 weeks following stone treatment. This will allow for the determination of differences in a stone patient's protein profile while they have their stone and after they are stone free. All patients will be required to have a stone patient metabolic evaluation which includes serum and urine testing. The analysis will focus on the serum and urine sample that they provide.~The stone patient will be asked to undergo one extra tube of blood during their preoperative assessment which should only add a few seconds to their visit."
2431185|NCT03358550|Experimental|Accommodation in scotopic luminance|
2431186|NCT03358537|Active Comparator|Clear Liquid Diet|110 subjects received clear liquid diet 24 hours before colonoscopy
2431187|NCT03358537|Active Comparator|Low-residue Diet|105 subjects received a prespecified low-residue diet 24 hours before colonoscopy
2431188|NCT03358524|Experimental|Vitamin E 400 IU|Vitamin-E Capsule (alpha-tocopherol) 400 IU once per day orally for 8 weeks
2431189|NCT03358524|Placebo Comparator|Placebo|Placebo capsule once per day orally for 8 weeks
2431190|NCT03358511|Experimental|Breast Cancer Patients|All subjects will be given 2-4 weeks of probiotics prior to surgery in operable stage I-III breast adenocarcinoma tumors ≥1.0 cm. Subjects will take the probiotic three times a day.
2431191|NCT03358498||β-thalassemia group|"SICT It is a questionnaire to assess patient satisfaction with ICT regimens. It comprises 19 items assessing four domains: perceived effectiveness of ICT (PE), burden of ICT (BD), acceptance of ICT (AC), and side effects of ICT (SE). Patients rate all items on scale from 1 very dissatisfied to 5 very satisfied.~Lab methods :~full history and thorough clinical evaluation.~. Complete blood count. .3- Serum ferritin .~4-Renal function tests. 5-liver function tests."
2431192|NCT03358485|Experimental|Aolanti Weikang tablets|3，6 or 8 Aolanti Weikang tablets each time,tid
2431193|NCT03358485|Placebo Comparator|Placebo|3,6 or 8 tablets each time,tid
3187739|NCT00759369|Experimental|1|Water prescription
3187740|NCT00759382||I|Patients with non-small cell lung carcinoma treated with curative intent
3187741|NCT00759421|Experimental|1|
2431197|NCT03358459||EP|For diagnosis non-acquired epilepsy;
2431198|NCT03358446||A group|"Based on the presence of non-overlapping range between femoral artery and vein from the initial observation, the patients were divided into following two groups.~A group is the patients with non-overlapping range"
2431199|NCT03358446||S group|S group is the patients without non-overlapping range
2431200|NCT03358433|Experimental|Exercise|
2431201|NCT03358433|Active Comparator|Antidepressants|
3187742|NCT00759421|Active Comparator|2|
3187743|NCT00759434|Active Comparator|Surgery|
3187744|NCT00759434|Experimental|EVLT|
3187745|NCT00759447||3D investigational imaging|Patients enrolled will be imaged with a 3D mammogram in one of 3 speeds of acquisition
2431206|NCT03358394|Experimental|Intervention group|The intervention group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention time period(i.e., after five weeks).
2431207|NCT03358394|Experimental|Control group|"The control group will be asked to complete the outcomes measures anxiety, depression and mindfulness questionnaires at baseline, a week before the start of the intervention and at the end of the intervention after six weeks.~At the end of the pilot trial, control group will receive the full intervention. They would be sent the materials week by week as same as the intervention group."
2431208|NCT03358381|Experimental|gap balance group|The type of total knee arthroplasty will be the balance gap.The gap balance type of total knee arthroplasty will be performed.
2431209|NCT03358381|Active Comparator|measured resection group|The type of total knee arthroplasty will be the measured resection.The measured resection type of total knee arthroplasty will be performed.
3187746|NCT00759447||3D Imaging with commercial Mammography Device|
2431211|NCT03358342||ED Patients treated using ePneumonia CDS|ED patients with community-acquired pneumonia treated in ED's after roll out of ePneumonia
2431212|NCT03358342||Usual care|ED patients with pneumonia receiving usual care without electronic CDS
3187747|NCT00759460|Experimental|1|
2431214|NCT03358316||cuff tear patients|Patients with cuff tear
2431215|NCT03358303|Experimental|Telemonitoring (Medly)|Medly is a smartphone application allows heart failure (HF) patients to measure and record their daily weight, blood pressure (BP), heart rate, and self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
2431216|NCT03358303|No Intervention|Control|Standard of care: Control groups will receive standard medical care when discharged from hospital, including discharge instructions, home medications as well as follow-up in a heart failure clinic or with a primary care doctor.
3187748|NCT00759460|Active Comparator|2|
3187749|NCT00759499||Debridement|The intent of this protocol is to salvage wound material that is normally destined for destruction, so it can be used in wound-related scientific studies. This clinical wound material can be studied in order to better understand the molecular, cellular, or ecological components of the wound system. These studies may be able to provide important insights into the keys of wound healing, wound persistence, or wound deterioration.
3187750|NCT00759512|Active Comparator|Arm 1|This arm received the Kreiger/Kunz method of Therapeutic Touch in addition to Standard of Care
2431222|NCT03358277|Experimental|ADHD+DMDD Group|The subjects with comorbid ADHD and DMDD received pharmacological intervention with combination treatment of MPH+ APZ with flexible dosage according to clinical judgment for six weeks.
2431223|NCT03358264|Experimental|Type 2 diabetic patients|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to type 2 diabetic patients with HbA1c>6
2431224|NCT03358264|Experimental|Healthy volunteers|L-citrulline at a dose of 2000 mg per day for a period of 1 month will be administered to non-diabetic healthy volunteers
3187751|NCT00759512|No Intervention|Arm 2|Standard of Care
3187752|NCT00759538||1|lung transplant patients performing a three week lasting rehabilitation program
3187753|NCT00759551|Experimental|Azilsartan 2.5 mg QD|
2431228|NCT03358225||Anterior Cervical Discectomy and Fusion|The patients undergoing anterior cervical discectomy and fusion surgery
2431229|NCT03358225||Cervical Artificial Disc Replacement|The patients undergoing cervical artificial disc replacement surgery
2431230|NCT03358225||Hybrid surgery|The patients undergoing hybrid surgery(1-level ADR plus 1-level ACDF) surgery
2431231|NCT03358212||denosumab used postoperatively|the postoperative denosumab group, including patients receiving denosumab after piecemeal intralesional curettage aided by digital subtraction angiography(DSA) and balloon occlusion of abdominal aorta;
2431232|NCT03358199||Study group|PCOS women with AMH level (≥ 7 ng/ml) who underwent LOD in the preceding 3 months prior to IVF/ICSI
2431233|NCT03358199||Control group|PCOS women with AMH level (≥ 7 ng/ml) who did not undergo LOD in the preceding 3 months prior to IVF/ICSI
2431234|NCT03358186||revision of periprosthetic fracture|patients with surgically treated periprosthetic femur fracture
2431235|NCT03358173||Conservative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
2431236|NCT03358173||Operative Plate Fixation|The operating surgeon will determine the positioning of the patient for surgery. ORIF of the humeral shaft fracture will be carried out
2431237|NCT03358160||TKA|Orthopaedic patients who underwent surgical operation for total knee arthroprothesis.
2431238|NCT03358160||Rizoarthrosis|Orthopaedic patients who underwent surgical operation to treat chronic arthrosis of the thumb.
2431239|NCT03358160||Healthy Controls|Healthy age-matched controls.
3187754|NCT00759551|Experimental|Azilsartan 5 mg QD|
3187755|NCT00759551|Experimental|Azilsartan 10 mg QD|
3187756|NCT00759551|Experimental|Azilsartan 20 mg QD|
3187757|NCT00759551|Experimental|Azilsartan 40 mg QD|
3187758|NCT00759551|Placebo Comparator|Placebo QD|
2431245|NCT03358134|Experimental|Secukinumab|All patients will be treated with active treatment. (anti-IL17)
2431246|NCT03358121||Diabetics without hypoglycemia awareness|Diabetic patients without impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
2431247|NCT03358121||Diabetics with hypoglycemia awareness|Diabetic patients with impaired hypoglycemia awareness. No interventions were performed, the study is purely observational.
2431248|NCT03358108||Group A: interferon group|formerly interferon group (including interferon alone or interferon combined with other drugs)
2431249|NCT03358108||Group B:nucleoside analogue group|formerly nucleoside analogue treatment group. Each group was followed for five years
2431250|NCT03358095|No Intervention|Early surgery|Patients in this group proceed to pancreatic resection within 2 week of recruitment.
2431251|NCT03358095|Active Comparator|Preoperative biliary drainage|Endoscopic retrograde cholangiopancreatography (ERCP) is used to place an endoprosthesis to the biliary ducts to drain biliary stasis, and the patients proceed to pancreatic resection within 6 weeks of recruitment.
2431252|NCT03358082|Active Comparator|Tacrolimus group|Tacrolimus 0.03% ointment twice daily for 6 months
2431253|NCT03358082|Active Comparator|Hydrocortisone group|hydrocortisone acetate 1% ointment twice daily for 6 months
2431254|NCT03358069||deep anesthetic state|technique of Anesthesia at the time of airway device removal
2431255|NCT03358069||awake|technique of Anesthesia at the time of airway device removal
2431256|NCT03358069||emergence time (clinical): min|The duration from the time of anesthestic medications stop and the time that patient spontaneously open their eyes
2431257|NCT03358069||Emergence time (entropy): min|time from Entropy value above 60 to 90
2431258|NCT03358056|Experimental|Mindfulness-based Cognitive Therapy|
2431259|NCT03358030|Placebo Comparator|Placebo|Participants received placebo, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
2431260|NCT03358030|Experimental|Cohort A: ISIS 416858, 200 mg|Participants received ISIS 416858, 200 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
2431261|NCT03358030|Experimental|Cohort B: ISIS 416858, 250 mg|Participants received ISIS 416858, 250 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
2431262|NCT03358030|Experimental|Cohort C: ISIS 416858, 300 mg|Participants received ISIS 416858, 300 mg, subcutaneously, within 2 hours post-dialysis, once weekly from Week 1 (Day 1) through Week 26 of treatment period.
3187759|NCT00759551|Active Comparator|Olmesartan 20 mg QD|
2431296|NCT03357718|Experimental|Dexmedetomidine|2 µg/kg Precedex
3187760|NCT00759590||1|ALI/ARDS patients
3187761|NCT00759616|Experimental|1|
3187762|NCT00759629|Experimental|A|Interventional treatment group - Patients assigned to PCI will receive the loading dose of clopidogrel, aspirin plus a bolus of heparin and be transferred immediately for interventional treatment. They will receive abciximab as a bolus followed by a continuous infusion of for 12 hours.
2431263|NCT03358017|Active Comparator|ARM A - standard NACT|Standard anthracyclines/taxanes based neoadjuvant chemotherapy chosen by the investigator and administered according to clinical practice, for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
2431264|NCT03358017|Experimental|ARM B - standard NACT + Zol + atorvastatin|Standard anthracyclines/taxanes based neoadjuvant CT chosen by the investigator and administered according to clinical practice + Zoledronate 4 mg i.v. every 3-4 weeks and Atorvastatin 80 mg/die administered for 6 months, or 4.5 months in case of dose dense schedule (unless disease progression, unacceptable toxicity, patient's refusal or investigator's decision)
2431265|NCT03358004|Experimental|ARM A|Vinorelbine 50 mg, thrice a week
2431266|NCT03358004|Experimental|ARM B|Vinorelbine 40 mg thrice a week + capecitabine 500 mg thrice a day
2431267|NCT03357978|Other|A-T patients|"A-T patients aged 2 to 45 years with and without immunoglobulin G Substitution~bioelectrical impedance Analysis~blood draw~transient elastography (FibroScan)~ataxia score~Five-Times-Sit-to-Stand Test"
3147161|NCT00118222|Active Comparator|Low light dose during surgery|Arm I: During surgery, patients receive low light dose photodynamic therapy.
3147162|NCT00118222|Active Comparator|High light dose during surgery|Arm II: During surgery, patients receive high light dose photodynamic therapy.
2431270|NCT03357939|Experimental|HLX03|There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
2431271|NCT03357939|Active Comparator|Humira|There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
2431272|NCT03357926||Observation Group|
2431273|NCT03357913||Co morbidities after lung transplantation in cystic fibrosis|The population studied is the cohort of cystic fibrosis patients who received a bipulmonary transplant between 2004 and 2014 in one of the two transplantation centers in the Rhône-Alpes region.
2431274|NCT03357900|Experimental|Orthotopic liver transplantation|
2431275|NCT03357874|Experimental|Clopidogrel group|
2431276|NCT03357874|Experimental|Ticagrelor group|
2431277|NCT03357848||Study group|Surgical patients receiving nutritional support (enteral and/or parenteral nutrition) pre and/or after surgery
2431278|NCT03357848||Control group|Surgical patients without nutritional support during the perioperative period
2431279|NCT03357835||Normal Triage|Triage scoring determined by the Ministry of Health (SB ), routinely performed by an emergency medical technician (att), will be applied when the patients are admitted to emergency services. According to this scoring, patients who need urgent care and who should not wait less than 15 minutes will be considered red coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded.
2431280|NCT03357835||Software Triage|"triage maintenance / evaluation will be done with computer software called Trauma Decision System (TraumaDS) developed by us. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes. According to this scoring, patients who need urgent care and who should not wait will be considered red code, patients who should wait less than 15 minutes will be considered orange coded, patients who can wait up to 60 minutes will be considered yellow coded, patients who can wait for 120 minutes or more will be considered green coded."
2431281|NCT03357822|Experimental|Sequential combination therapy group|Patients are treated with pegylated Interferon (180ug, subcutaneously, once a week) plus entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 48/72/96 weeks
2431282|NCT03357822|Active Comparator|Nucleoside therapy group|Patients are treated with entecavir (0.5mg, orally, every day) or tenofovir disoproxil fumarate (300mg, orally, every day) for 96 weeks
2431283|NCT03357809|Experimental|Endoscopic treatment|ENDOSCOPIC MUCOSAL RESECTION AT DAY 1
2431284|NCT03357796|Experimental|Group A: LY03005 cross-over to Pristiq®|Subjects in Group A will receive an 80 mg oral dose of LY03005 and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator followed by a 4-day stay in the CRU (Period 2).
2431285|NCT03357796|Experimental|Group B: Pristiq® cross-over to LY03005|Subjects in Group B will receive a 50 mg oral dose of desvenlafaxine (Pristiq®) comparator and the subjects will stay in the CRU for 4 days (Period 1). After a washout period of up to 4 days, the subjects will be switched and will receive an 80 mg oral dose of LY03005 followed by a 4-day stay in the CRU (Period 2).
2431286|NCT03357770|Experimental|low dose of mesenchymal stem cells|Three groups of patients were enrolled in this study. Every group includes three patients. The three groups of patients were treated with high, medium and low dose of cytokine.The low-dose is 1 × 10^7cells / 3mL
2431287|NCT03357770|Experimental|medium dose of mesenchymal stem cells|the medium-dose is 5 × 10^7cells / 3mL
2431288|NCT03357770|Experimental|high dose of mesenchymal stem cells|the high dose is 1 × 10^8cells / 3mL
2431289|NCT03357757|Experimental|Avelumab with VPA|Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years.
3147163|NCT00118235|Experimental|Treatment (cisplatin, irinotecan hydrochloride, bevacizumab)|Patients receive cisplatin IV over 60 minutes and irinotecan IV over 90 minutes on days 1 and 8. Patients also receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3147164|NCT00118261|Experimental|Erlotinib, modified FOLFOX6, and bevacizumab|
3147165|NCT00118456|Experimental|1|Continuous daily dosing
3147166|NCT00118456|Experimental|2|Monday, Wednesday, Friday Dosing
3147167|NCT00118508|Placebo Comparator|A|Group A will receive active study drug
3147168|NCT00118547|Other|1|
3147169|NCT00118560|Experimental|1|treadmill walking and calf exercise
3147170|NCT00118573|Experimental|EVAR|AAA repair with endografting
3147171|NCT00118573|Active Comparator|Surveillance|Not AAA repair; surveillance
3147172|NCT00118612|Experimental|Therapeutic Regimen|
3147173|NCT00118612|Experimental|Intermediate dose|
3147174|NCT00118612|Experimental|Low dose|
3147175|NCT00118612|Placebo Comparator|Placebo|
3147176|NCT00118638|Experimental|Darbepoetin alfa 500 mcg - Group A|
2431298|NCT03357705|Experimental|synthetic|alveolar ridge preservation with synthetic bone
2431299|NCT03357705|Active Comparator|collagen|alveolar ridge preservation with bovine collagen
2431300|NCT03357692|Experimental|maxillary total edentulism|all on four implant rehabilitation with trans-sinusal implants
2431301|NCT03357679|Active Comparator|Bed up head elevated intubation|Patients positioned in the bed up head elevated position, followed by tracheal intubation
2431302|NCT03357679|Active Comparator|Glidescope assisted intubation|Glidescope is used for laryngoscopy, followed by intubation
2431303|NCT03357666|Experimental|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Glucose 200mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2431304|NCT03357666|Experimental|HUDC_VT(Glucose 400mg/Sodium chloride 200mg)|Glucose 400mg/Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2431305|NCT03357666|Experimental|HUDC_VT(Glucose 400mg)|Glucose 400mg, once a day, two tablets at a time for 7 days
2431306|NCT03357666|Experimental|HUDC_VT(Sodium chloride 200mg)|Sodium chloride 200mg, once a day, two tablets at a time for 7 days
2431307|NCT03357666|Placebo Comparator|Placebo|Placebo, once a day, two tablets at a time for 7 days
2431308|NCT03357653|Experimental|Losartan group|Losartan 50 mg daily
2431309|NCT03357653|Placebo Comparator|Placebo group|Placebo 1 pill daily which has same size, color and taste with losartan
2431310|NCT03357640|Placebo Comparator|no intervention|The women will receive one package of placebo. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
2431311|NCT03357640|Active Comparator|combined oral contraception pills|The women will receive intervention of one package of combined oral contraception pills and will be counseled about how to take oral contraception and informed of possible side effects. They also will receive a diary card for recording oral contraception intake to be returned to the physician on the next period. An appointment for the women in this group will be scheduled at one month of treatment for the second ultra-sonography. If the ovarian cyst does not show remission, the women will continue the same treatment and will follow up in another month by transvaginal ultra-sound. If the ovarian cyst still persists or progresses at the second month, the women will be followed up for third month.
2431312|NCT03357627|Experimental|Dose Escalation: TAK-659 + Venetoclax|TAK-659 40, 60, 80, or 100 milligram (mg) (tablet, orally, once daily, up to 35 days in Cycle 1 or in different intermittent schedules [7 days dosing followed by 7 days off or 14 days dosing followed by 7 days off or other intermittent dosing schedules]) along with venetoclax 200, 400, 800 or 1200 mg (tablet, orally, once daily, up to 35 days in Cycle 1). After Cycle 1, TAK-659 and venetoclax will be administered once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant.
2431313|NCT03357627|Experimental|Safety Expansion: Diffuse Large B-cell Lymphoma (DLBCL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
2431314|NCT03357627|Experimental|Safety Expansion: Follicular Lymphoma (FL) Cohort|TAK-659 tablet, orally, once daily along with venetoclax tablet, orally, once daily in a 28-day treatment cycle until disease progression, unacceptable toxicities, or discontinuation by participant. TAK-659 and venetoclax MTD/RP2D will be determined from the dose escalation phase.
2431317|NCT03357601|Experimental|High Intensity Interval Training|six 20 second bouts of high intensity interval exercise (HIIT) separated by 2 minutes of active recovery with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
2431318|NCT03357601|Experimental|MCEET|14 minutes of Moderate Endurance Training with 3 minutes and warm up and cool down on the treadmill, three times per week for five weeks
2431319|NCT03357588|Active Comparator|Control|Standard of Care monitoring
2431320|NCT03357588|Experimental|Intervention|Intensified monitoring
2431321|NCT03357575|Experimental|Mesenchymal Stem Cells from adipose|Mesenchymal Stem Cells from adipose will be injected.
2431322|NCT03357575|Active Comparator|hyaluronic acid|Hyaluronic acid will be injectied.
2431323|NCT03357562|Experimental|lung MRI|lung MRI without contrast injection
2431324|NCT03357549|Experimental|Brief Motivational Intervention|The women of this group will receive a Brief Motivational Intervention during 20 or 30 minutes.
2431325|NCT03357549|Active Comparator|Breastfeeding education|The women of this group will receive a standard education about breastfeeding during 20-30 minutes
2431326|NCT03357536|Experimental|Patients with Listeriosis|"Patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
2431327|NCT03357536|Experimental|Volunteers related with patients with Listeriosis|"Volunteers related with patients with Listeriosis.~Human biological samples :~Blood sample~Skin biopsy~Saliva"
3147177|NCT00118638|Active Comparator|Darbepoetin alfa 2.25 mcg/kg - Group B|
3147178|NCT00118651||Positive cases|"Positive radiographic findings were defined as the presence of a new air space opacities in the setting of acute respiratory symptoms. Patients with equivocal radiographic findings interpreted as possible pneumonia were considered positive cases"
2431330|NCT03357497|Experimental|Very early mobilization|This group will be mobilized in the post-operative unit by a designated physiotherapist. The intervention will be conducted accordingly with the SOMS protocol.
2431331|NCT03357497|No Intervention|Standard post-operative care|This group will receive standard post-operative care. Mobilization will only take place if the patient request it or to facilitate god post-operative care.
2431332|NCT03357484|Experimental|L-PRF|Third molar extraction sockets were filled with two leukocyte- and platelet rich fibrin (L-PRF) clots
3147179|NCT00118651||Control|Acute respiratory symptoms, negative chest radiographs, and a date of birth within five years of that of the positive case
3147180|NCT00118729|Experimental|Arm 1|
3147181|NCT00118846|Experimental|1|25 gm soy protein administered twice daily in equivalent dosages (12.5 gm)
3147182|NCT00118846|Placebo Comparator|2|Matching placebo
2431333|NCT03357484|Active Comparator|Blood clot|Third molar extraction sockets allowed to form a natural blood clot and undergo natural healing
2431336|NCT03357458|Experimental|Family Integrated Care|Study participants receive FICare, a dynamic psycho-educational intervention, while their infant(s) was/were admitted to a Level II NICU.
2431337|NCT03357458|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
2431338|NCT03357445|Other|Subgroup 1|Prospective non Controlled to Document long term performance of AVANTAGE® RELOAD
2431339|NCT03357445|Other|Subgroup 2|Randomized Controlled Trial to Evaluate wear rate of E1 liner in comparison to ArCom® liner
2431340|NCT03357432|Experimental|effects of gelatin, collagen on PINP levels|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subs
2431341|NCT03357419|Active Comparator|prophylactic antibiotic|"Each active arm patient will be given the tested drug on admission, 30-60 minutes before the surgery, by the nurses.~2 g dose of cephalexin (or Clindamycin 600 mg for patients suffering from allergy) will be given once, orally, 30-60 minutes prior to skin lesion excision"
2431342|NCT03357419|Placebo Comparator|placebo oral capsule|Each placebo arm patient will be given the placebo drug on admission, 30-60 minutes before the surgery, by the nurses
2431343|NCT03357406|Experimental|edentulism side 1|ultrasound implant site preparation
2431344|NCT03357406|Active Comparator|edentulism side 2|conventional implant site preparation
3147183|NCT00118872|Active Comparator|LGG yogurt|Lactobacillus (LGG) containing yogurt
3147184|NCT00118872|Placebo Comparator|Placebo yogurt|Regular yogurt, NOT containing LGG
2431350|NCT03357367|Experimental|PAD patients|"Experimental: PAD patients Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by TiVi system"
2431351|NCT03357354|Experimental|Obese Children in precarious situations|
2431354|NCT03357328|Active Comparator|Therapy light room|This group (4 NH units, about 35 patients) will receive light therapy administered via LED technology. The light will vary in intensity and colour temperature throughout the day. Ceiling-mounted LED-lights are installed in the living rooms of participating nursing home units. Between 07:00 and 10:00 light of 400 lux at eye level, with 4000 K, will be provided. Between 10:00 and 15:00 the light will comprise 1000 lux at eye level, with 6000 K. From 15:00 to 18:00 the light will comprise 400 lux at eye level and 4000 K. When light is on from 18:00 to 07:00, standard light (about 100 lux at eye level, 3000K) will be administered.
2431355|NCT03357328|Placebo Comparator|Standard light|"This group (4 NH units, about 35 patients) will receive standard light (100 lux at eye level, 3000K). The light will be administered between 07:00 and 18:00; and the same when light is on between 18:00 to 07:00. This represents the placebo light intervention, which at the same time ensures a constant standard light condition in all control units."
2431356|NCT03357315|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431357|NCT03357315|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431358|NCT03357289|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431359|NCT03357289|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431360|NCT03357276|Experimental|Mix vaccine|In this group, the patients will receive mix vaccine. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431361|NCT03357276|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are image examination (CT, MRI or PET scan) and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2431362|NCT03357263|Experimental|GC3114|Pre-filled syringe inj., 0.5ml, Once, IM
3147185|NCT00118924|Experimental|1|One subcutaneous vaccination with a 10^3 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination.
3147186|NCT00118924|Experimental|2|One subcutaneous vaccination with a 10^5 PFU dose of LGT(TP21)/DEN4 vaccine given in the deltoid region of either arm. A second booster vaccination will be given 6 months after the first vaccination. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
3147187|NCT00118924|Placebo Comparator|3|One subcutaneous vaccination with a placebo vaccine given in the deltoid region of either arm. A second placebo vaccination will be given 6 months after the first vaccination.
3147188|NCT00118937|Placebo Comparator|1|Single-blind placebo run-in period. Duration one month.
3147189|NCT00118937|Active Comparator|2|Metformin 2000 mg, double-masked randomized during 12 months.
3147190|NCT00118937|Placebo Comparator|3|Placebo, double-masked randomized during 12 months.
3147191|NCT00118950|Active Comparator|4|Metformin plus placebo-Repgalinide. Double-masked, randomized. Duration: Four months.
3147192|NCT00118950|Active Comparator|2|Repaglinide plus Placebo-Metformin. Double-masked, randomized. Duration: Four months.
3147193|NCT00118950|Other|1|Run-in period: Treatment: Diet-only. Duration: One month.
2431363|NCT03357263|Active Comparator|GCFLU Quadrivalent|Pre-filled syringe inj., 0.5ml, Once, IM
2431364|NCT03357237|Experimental|XYLOGLUCAN|treatment regimen with oral rehydration solution and xyloglucan
2431365|NCT03357237|Placebo Comparator|PLACEBO|rehydration solution and placebo.
2431366|NCT03357224|Experimental|Experimental: Atezolizumab|The treatment will be given for a maximum of 1-year unless confirmed disease progression or unless other criteria for treatment discontinuation are met as specified in the protocol.
2431367|NCT03357198||cough peak flow measurement|All enrolled patients will undergo measurement of cough peak flow by two methods, i.e. using a handheld electronic spirometer, and using the ventilator flowmeter, in a randomized order.
2431368|NCT03357172|Experimental|Recipient|
2431369|NCT03357172|Experimental|Donor|
2431370|NCT03357159|Experimental|cyclophosphamide and ATLG|The study will include 2 phases. In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg administered on day +3 and +4 (target dose) will be added to a standard GVHD prophylaxis consisting of anti-human T-lymphocyte immunoglobulin (ATLG, Grafalon®, formerly ATG-Fresenius S, Neovii Pharmaceuticals) 15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation in order to find the maximally tolerated dose (MTD) of post-transplant cyclophosphamide (PTCy) in combination with pre-transplant immunosuppression by ATLG. The second phase will use the MTD cyclophosphamide dose identified in the first phase.
2431371|NCT03357146||CRA|Patients with chronic retinal artery occlusion
2431372|NCT03357146||Control|Healthy
2431373|NCT03357133|Experimental|Tirofiban and alteplase|
2431374|NCT03357133|Placebo Comparator|Alteplase|
2431375|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|Patients with an invasive breast cancer on neoadjuvant chemotherapy (with the exception of cT2cN0 tumors) are preselected before the surgical procedure. They are definitely included during the post-surgery visit following the analysis of the surgical specimen (only patients whose tumor did not achieve a complete pathological response are included).
2431376|NCT03357081||CEUS|Adult patients over the age of 18 who have a clinical suspicion of an actively bleeding soft-tissue hematoma as determined by the treating emergency provider. Enrollment will be for one year or until a target of 20 patients is enrolled.
2431377|NCT03357068|Active Comparator|Control|Autogenous bone block surgery without treatment of bone surfaces.
2431378|NCT03357068|Experimental|Acid|Autogenous bone block surgery with citric acid treatment of bone block and recipient site
2431379|NCT03357055|Experimental|Ketamine arm|Ketamine group will receive an IV infusion of 0.25mg/kg of ketamine in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure patients will receive 0.25mg/kg of ketamine infusion at 10ml/hour until the end of operation.
2431380|NCT03357055|Placebo Comparator|Control arm|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation.
2431381|NCT03357042|Experimental|Persistent post-concussive symptoms|Participants who report post-concussive symptoms. 20 participants will receive the aerobic exercise and balance training intervention, 20 participants will receive standard of care treatment for concussions.
2431382|NCT03357042|Active Comparator|Healthy control|Persons without post-concussive symptoms. No intervention.
2431383|NCT03357029|Active Comparator|Gammacore Device|The GammaCore Device is a non-Invasive vagus nerve stimulator. One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks
2431384|NCT03357029|Sham Comparator|Sham Device|"The Sham GammaCore device looks and operates like the Active GammaCore device, but does not deliver a therapeutic stimulation treatment.~One stimulation dose bilaterally to the cervical vagal neck area, three times per day (morning 8 am., afternoon 2 pm, and evening 8 pm) for two weeks."
2431385|NCT03357016|Experimental|High Intensity Interval Training program (HIIT)|Subjects perform three sessions of training during 12 weeks: 35 min at 50% maximal aerobic power on bicycle.
2431386|NCT03357016|Experimental|Moderate Intensity Continuous Training program (MICT)|Subjects perform three sessions of training during 12 weeks: repeated cycles of sprinting for 8s and pedaling slowly for 12s (between 20 and 30 rpm) for a maximum of 60 repeats per session.
2431387|NCT03357016|Experimental|HIIT + Resistance Training program (RT)|Subjects perform three sessions of training during 12 weeks: Each subject performed HIIT protocol and then a single set of 8 exercises with 1 ou 2min resting period between exercises. Each set consisted of 8-12 repetitions at about 80% maximum repetition.
2431388|NCT03356990|Experimental|Resistant Starch|"Intervention:~Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose in the evening~Adult participants are asked to introduce in their diet 30 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 5 and 9 years are asked to introduce in their diet 10 grams of high RS supplement each day of the diet period (2 weeks).~Children of age included between 10 and 17 years are asked to introduce in their diet 15 grams of high RS supplement each day of the diet period (2 weeks)."
3187763|NCT00759629|Active Comparator|B|Conservative treatment group - Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards.
2431390|NCT03356964|Active Comparator|Control group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (13). The stimulation dosage will remain unchanged until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
2431391|NCT03356964|Experimental|Study group|Follicle stimulating Hormone will be applied, starting from day 3 of the cycle, the dosage will be choosen between Gonal F 150 - 225 IU, according to the ovarian reserve parameters (LaMarca et al.). As soon as ≥ 3 follicle of a size of 14mm are seen, the stimulation dosage will be reduced daily by 12.5 IU recFSH until the criteria for final oocyte maturation are met (≥ 3 follicles of ≥ 17 mm).
2431392|NCT03356951||Lateral approach group|TAR through lateral approach and subtalar fusion
2431393|NCT03356951||Anterior approach group|TAR through anterior approach and subtalar fusion
2431394|NCT03356938|No Intervention|Baseline recording|
2431395|NCT03356938|Experimental|Sleep restriction|
2431397|NCT03356925|No Intervention|Centralised Xpert®Ultra testing|Patients are selected to receive the standard of care for TB diagnosis at a centralised laboratory facility
2431398|NCT03356925|Active Comparator|Xpert Ultra Point of Care testing|Patients are selected to receive the point of care for TB diagnosis at the clinic facility they are visiting
2431399|NCT03356912|Active Comparator|Cabazitaxel plus prednisone|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks, plus prednisone 10 mg orally given daily. Premedication must be administered according to Cabazitaxel Package Insert.
2431400|NCT03356912|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously (Day 1) every 3 weeks. Premedication must be administered according to Cabazitaxel Package Insert.
2431401|NCT03356899|Active Comparator|Low dose bupivacaine 0.5% (8mg)|Bupivacaine 0.5% for spinal anesthesia
2431402|NCT03356899|Active Comparator|High dose bupivacaine 0.5% (10mg)|Bupivacaine 0.5% for spinal anesthesia
2431403|NCT03356886|Experimental|Spinal Manipulative Technique (SMT)|This protocol of combined manipulation and mobilization techniques was adopted in view of the previous findings of a systematic review in which the combination of thrust mobilization and non-thrust techniques showed greater (moderate) evidence for chronic low back pain when compared to each technique alone (limited evidence). In addition, the thrust manipulation will be administered at the thoracic spine considering that a previous study found no differences in pain intensity after lumbar spine high-velocity manipulation versus non-region-specific manipulation in patients with chronic low back pain.
2431404|NCT03356886|Active Comparator|SMT + Pain Neuroscience Education|Content: 1) Contextualization on the importance of the program; 2) Initial concepts on neuroscience and pain, 3) How context can influence pain perception; 5) human beings as a multisensory complex; 6) Pain and memory; 7) Nociception and nociceptors; 8) The incorrect concepts on pain; 9) Concepts on pain neurophysiology; 10) Types of sensitization; 11) Descending inhibitory system; 12) The danger message and the brain processing; 13) The sensitized brain and its relationship to chronic pain; 14) The contribution of other systems to pain experience; 15) How bone, muscles and nerves send sensory information all the time; 16) Fear avoidance model revisited; 17) Encouragement to change; 18) How to develop positive attitudes and 19) Concepts of gradual exposition and gradual activity
2431405|NCT03356873|Experimental|Active|Vitamin D 5000 units capsules, 20 capsules per week during four weeks (total 400,000 units)
2431406|NCT03356873|Placebo Comparator|Placebo|Identical placebo capsules, 20 capsules per week during four weeks
2431407|NCT03356860|Experimental|Durvalumab|"Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.~Durvalumab will be administered at 1500 mg IV at week 14 and week 18."
2431408|NCT03356860|Active Comparator|Standard|Patients will received paclitaxel 80 mg/m2 IV weekly from week 1 to 12 and then an association of epirubicin 90 mg/m2 IV and cyclophosphamide 600 mg/m2 IV Q 2 weeks from week 14 to 20.
2431409|NCT03356847|Experimental|SISA implant|
2431410|NCT03356834|Experimental|TDF switch to TAF|Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Tenofovir Alafenamide(TAF) 25mg daily
2431411|NCT03356834|Active Comparator|Maintaining on TDF|Maintaining on Tenofovir Disoproxil Fumarate(TDF) 300mg daily
2431412|NCT03356821|Experimental|Mesenchymal Stem Cells|All (near-)term newborns ≥36 weeks of gestation with or without clinical symptoms of PAIS but with a magnetic resonance imaging (MRI) confirmed PAIS (in the Middle Cerebral Artery region) will be eligible for this study. Following written parental consent, 10 patients will be included in our study.
2431413|NCT03356808|Experimental|Lung cancer-specific T cells|Peripheral blood mononuclear cells (PBMCs) of patients, who have cancer antigen identified lung cancer, will be obtained through apheresis, and T cells will be activated and ex vivo engineered.
2431414|NCT03356795|Experimental|Cervical cancer-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have GD2, PSMA, Muc1 or Mesothelin positive cervical cancer will be obtained through apheresis, and T cells will be activated and modified to cervical cancer-specific CAR-T cells.
2431415|NCT03356782|Experimental|Sarcoma-specific CAR-T cells|Peripheral blood mononuclear cells (PBMCs) of patients who have CD133, GD2, Muc1, CD117 or other marker positive sarcoma will be obtained through apheresis, and T cells will be activated and modified to sarcoma-specific CAR-T cells.
2431416|NCT03356769|Experimental|experimental：asprin & AEDS|Aspirin 5mg/kg，maximum 300mg; once a day plus AEDS
2431417|NCT03356769|Placebo Comparator|control: placebo & AEDS|placebo 5mg/kg，maximum 300mg; once a day plus AEDS
2431418|NCT03356756||PET MRI exam|simultaneous combined 18F-FDG PET and cardiac MRI imaging (PET MRI) performed immediately after the PET CT exam.
2431419|NCT03356743|Experimental|Ex-Vivo|
2431420|NCT03356730|Experimental|Arm vitamin D|Vitamin D 5.000 IU a day for 2 months (10 drops after lunch)
2431421|NCT03356730|Placebo Comparator|Arm placebo|Placebo for 2 months (10 drops after lunch)
2431422|NCT03356717|Experimental|educational intervention - observer tool|"Participants in this arm will be given the observer tool (OT) before the scenario and will be explained how to use it, i.e. observe all details of the scenario on the screen and tick on the OT all actions which are done by active participants.The observer tool will also be used to engage observers during the debriefing session.~The scenario will then be observed in a screen (i.e. the scenario is played by active participants in an adjacent room using direct video-recording and transmission."
2431423|NCT03356717|Active Comparator|without observer tool|Participants in this arm will not be given the observer tool (OT) before the scenario but will be asked to observe all details of the scenario on the screen.The observers will also be asked to participate during the debriefing session.
2431424|NCT03356704||General anaesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had general anesthesia
2431425|NCT03356704||continued spinal anesthesia|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had continued spinal anesthesia
2431426|NCT03356704||peripheral nerve blocks|Patient who had surgery for femoral neck fracture from January 2014 to December 2016 and had peripheral nerve blocks
2431427|NCT03356691|No Intervention|Control group|No intervention.
2431428|NCT03356691|Experimental|Complementary Spiritist Therapy|"Prayer, Spirit education, Spiritist passe and magnetized water"
2431429|NCT03356691|Other|Prayer|Prayer during 1-2 minutes
2431430|NCT03356691|Other|"Spiritist passe"|"Spiritist passe during 5-10 minutes."
2431431|NCT03356691|Placebo Comparator|Laying on of hands with intent to heal|laying on of hands with intent to heal during 5-10 minutes.
2431432|NCT03356691|Other|Fluid water or magnetized water|Spiritist healers laying on of hands hands on the glass of water and desire health, restoration of balance and health for the patient.
2431433|NCT03356691|Other|Non-fluidic water|individuals receive water without fluidification (no laying on of hands hands on the glass of water).
2431434|NCT03356665|Experimental|Clinical suspect|Diagnostic tests: Rapid diagnostic test (RDT); Serological and molecular tests on DBS
3147194|NCT00118950|Other|3|Wash-out period: Treatment: Diet-only: Duration: One month.
2431436|NCT03356639|Experimental|ASP6981 50 mg, then matching Placebo|Participants in Sequence AB will first receive ASP6981 capsules orally (50 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
2431437|NCT03356639|Experimental|Matching Placebo, then ASP6981 50 mg|Participants in Sequence BA will first receive matching placebo capsules orally during period 1. After a 14-day washout period, participants receive ASP6981 capsules (50 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
2431438|NCT03356639|Experimental|ASP6981 135 mg, then matching Placebo|Participants in Sequence CD will first receive ASP6981 capsules orally (135 mg) during period 1. After a 14-day washout period, participants receive matching placebo during period 2. Participants will receive ASP6981 capsules or matching placebo every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, ASP6981 or matching placebo will be administered under fasting conditions.
2431439|NCT03356639|Experimental|Matching Placebo, then ASP6981 135 mg|Participants in Sequence DC will first receive matching placebo capsules orally during period 1. After a-14 day washout period, participants receive ASP6981 (135 mg) during period 2. Participants will receive matching placebo or ASP6981 capsules every 12 hours on days 1 through 14 (only in the morning of day 14) of period 1 and 2. On days 1 and 14 of period 1 and 2, matching placebo or ASP6981 will be administered under fasting conditions.
2431440|NCT03356626|Experimental|ULTRACISION Harmonic Scalpel|Patients group randomized to use ULTRACISION Harmonic Scalpel when receives laparoscopic gastrectomy
2431441|NCT03356626|Experimental|Ligasure Maryland|Patients group randomized to use Ligasure Maryland when receives laparoscopic gastrectomy
2431442|NCT03356626|Experimental|Thunderbeat|Patients group randomized to use Thunderbeat when receives laparoscopic gastrectomy
2431443|NCT03356613||focus group of paramedical staff from Nancy|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2431444|NCT03356613||focus group of paramedical staff from Metz|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2431445|NCT03356613||focus group of paramedical staff from Dijon|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2431446|NCT03356613||focus group of paramedical staff from Bar-le-Duc|During the focus group, the psychologist researcher asks the group a series of question about their views and opinions on research and how to make it.
2431447|NCT03356613||Test of the tool by paramedical staff center 1|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
2431448|NCT03356613||Test of the tool by paramedical staff center 2|Paramedical staff who didn't participate to the focus group, will test the GenI tool to generate research ideas.
2431449|NCT03356600|Experimental|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy."
2431450|NCT03356587|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class) Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
2431451|NCT03356561|Experimental|Group 1: Ad26.ZIKV.001 5*10^10 Viral Particles (vp)|Participants will receive Ad26.ZIKV.001 at 5*10^10 viral particles (vp) via intramuscular (IM) route on Days 1 and 57.
2431452|NCT03356561|Experimental|Group 2: Ad26.ZIKV.001 5*10^10 vp and Placebo|Participants will receive Ad26.ZIKV.001 5*10^10 vp on Day 1 and placebo on Day 57 via IM route.
2431453|NCT03356561|Experimental|Group 3: Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at 1*10^11 vp via IM route on Days 1 and 57.
2431454|NCT03356561|Experimental|Group 4: Ad26.ZIKV.001 1*10^11 vp and Placebo|Participants will receive Ad26.ZIKV.001 1*10^11 vp on Day 1 and placebo on Day 57 via IM route.
2431455|NCT03356561|Placebo Comparator|Group 5: Placebo|Participants will receive placebo via IM route on Days 1 and 57.
2431456|NCT03356509|Experimental|Exercise|They will do a 26-min bout of high intensity interval exercise.
2431457|NCT03356509|No Intervention|No exercise|They will sit quietly for 26 minutes without access to electronic devices or reading materials.
2431458|NCT03356496|Experimental|Intervention|Patient provided with instructions and video for the use of an incentive spirometry device. Patient instructed to use incentive spirometry device as frequently as every hour while awake but at least 4 times daily for at least 10 breathing cycles for 1-3 weeks before surgery. Patient instructed to record usage and any physical complaints in a diary.
2431459|NCT03356496|No Intervention|Control|Patient receives only usual care as provided by perioperative healthcare providers.
3147195|NCT00118963|Active Comparator|3|BIAsp30 plus Metformin plus Placebo-Repaglinide. Double-Masked and randomized. Duration: 12 months.
2431462|NCT03356470||FLT/PET + biopsy|F-FDG and FLT PET/CT imaging will be obtained prior to anti-cancer treatment and 10-12 weeks after starting treatment with anti-PD-1 antibody.
2431463|NCT03356457|Active Comparator|DCA in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
2431464|NCT03356457|Placebo Comparator|Placebo in T1DM with severe hypoglycemia|12 T1DM subjects (C-peptide negative, HbA1c <7.5%) with a history of severe hypoglycemia and hypoglycemia unawareness as assessed by the Guy's and Thomas' Minimally Modified Clarke Hypoglycemia Survey, the Gold Score and the Edinburgh Hypoglycemia Survey and as evidenced by interview and glucose log and/or continuous glucose monitoring will receive a placebo oral capsule.
2431465|NCT03356457|Active Comparator|DCA in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study. Each subject will receive a single dose of 12.5mg/kg dichloroacetate (DCA).
2431466|NCT03356457|Placebo Comparator|Placebo in healthy control subjects|12 non-diabetic healthy subjects (fasting plasma glucose < 100 mg/dL, HbA1c < 6.0%), who are matched for age, gender, and weight to T1DM subjects, to serve as controls for the study will receive a placebo oral capsule.
2431467|NCT03356444|Experimental|Abiraterone group|Abiraterone acetate is administered in this arm.
2431468|NCT03356444|Active Comparator|Docetaxel group|Docetaxel is administered in this arm.
2431469|NCT03356431|Experimental|Supervised group exercise|The supervised exercise group will receive a lower extremity exercise treatment, under physiotherapist supervision for 60 min, two times a week (12 sessions).
2431470|NCT03356431|Experimental|Home-based exercise|"For the home-based exercise group, exercises will be demonstrated to the patient with the supervision and guidance of a physiotherapist in an exercise session. These patients will perform the same exercise protocol at home at least twice a week.~In addition to the initial session, subjects will perform further two supervised sessions (at one week and four weeks after the initial session).~The exercise program are the same as the supervised group exercise."
2431471|NCT03356418|Experimental|WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session
2431472|NCT03356418|Sham Comparator|Sham WBV exercise group|Subjects will perform an isometric semi-squat exercise associated with the vibratory platform. The exercise will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
2431473|NCT03356392||stroke patients|acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention: telephone call on day 90 to assess the primary outcome (mRs d90)
2431474|NCT03356379|Experimental|Patients|Patients suspected of PES will have a transcutaneous oximetry test during tiptoeing
2431475|NCT03356379|Sham Comparator|Controls|Healthy asymptomatic athletes will have a transcutaneous oximetry test during tiptoeing
2431476|NCT03356366|Experimental|Principal study|Patients pathological process will be assessed using MRI 3T
2431477|NCT03356366|Experimental|Ancillary study 1|Patients pathological process will be assessed using MRI 1,5T
2431478|NCT03356366|Experimental|Ancillary study 2|Patients pathological process will be assessed using MRI 7T
2431479|NCT03356353|Experimental|sildenafil citrate|Following enrolment, participants will be given an initial dose of sildenafil 20 mg. If tolerated, a schedule of 20 mg three times daily (tid) will be initiated. Dosage will be titrated over 3-4 days to the target dose of 40 mg tid. If the initial dose is not tolerated, the participant will be exited from the trial.
2431480|NCT03356327|Experimental|Group 1|Group 1 consisting of 30 children treated with Actitan F and standard oral rehydration (SOR)
2431481|NCT03356327|Active Comparator|Group 2|Group 2 consisting of 30 children who received only SOR.
2431482|NCT03356301|Experimental|Triathletes|Every triathlete will realize three cardiac MRI exams.The second of those will be done at the fitness peak, 2-3 weeks before the main objective of the sports season. Training will be increased between the study beginning and the first MRI, and the second exam. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
2431483|NCT03356301|Experimental|Controls|Every control subject will also realize three cardiac MRI exams if possible at the same time as the triathletes.They must be not engaged in physical activity more than 150 minutes a week on average. After each cardiac MRI, an applanation tonometry examination will aslo be performed.
2431484|NCT03356288||Asthma|20 Participants with moderate to severe asthma, as defined by British Thoracic Society (BTS) guidelines
2431485|NCT03356288||Chronic heart failure|10 Participants with a diagnosis of chronic heart failure
2431486|NCT03356288||Breathing Pattern Disorder|10 Participants with a diagnosis of Breathing Pattern Disorder
2431487|NCT03356288||Pneumonia|10 participants with a radiologically confirmed diagnosis of pneumonia
2431488|NCT03356288||Motor Neurone Disease|10 participants with a diagnosis of motor neurone disease with known hypercapnic failure.
2431489|NCT03356288||Healthy|10 Participants who have no known lung, cardiac or neuromuscular condition.
2431490|NCT03356275|Experimental|Mobile application|Psychosocial support for parents, including: brief audio mindfulness recordings, videos, and psychoeducational materials.
2431491|NCT03356249||Sepsis Group|Patients (n=500) with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions).
2431492|NCT03356236||Observation group 1|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe receive Huaier Granule are as observation group 1
2431493|NCT03356236||Observation group 2|All treatments of patients after Local Ablation are prescribed by a physician on the basis of usual clinical practice.Patients who maybe not receive Huaier Granule are as observation group 2
2431494|NCT03356223|Experimental|Abemaciclib|
2431495|NCT03356210|No Intervention|Treatment as usual (TAU)|This control group will receive treatment as usual; conventional counseling
2431496|NCT03356210|Experimental|Neurofeedback + TAU|20 sessions of symptom-based NF training in conjunction with traditional therapy
2431497|NCT03356184|Experimental|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2431498|NCT03356184|Active Comparator|The Earlysense System Device Group|The reference device -EarlySense System and Philips Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2431499|NCT03356171|Experimental|Cardiac Coherence|Patients participate to Adapted physical activity sessions and to cardiac coherence sessions
2431500|NCT03356171|Active Comparator|Adapted Physical Activity|Patients only participate to Adapted physical activity sessions
2431501|NCT03356158|Experimental|CPGJ 602 low dose|Part 1: CPGJ602, IV over 2 hours, 100 mg/m2 X 1;
2431502|NCT03356158|Experimental|CPGJ 602 normal dose|Part 1: CPGJ602, IV over 2 hours, 400 mg/m2 X 1; Part 2: CPGJ602, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time;
2431503|NCT03356158|Active Comparator|Cetuximab normal dose|Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.
3147196|NCT00118963|Active Comparator|2|BIAsp30 plus Repaglinide plus Placebo-Metformin. Double-masked and randomized. Duration: 12 months.
3147197|NCT00118963|Other|1|Run-in period of four months duration with Repaglinide 6 mg daily plus Metformin 2000 mg daily. No masking of interventions.
2431506|NCT03356132||Textured Group|Women undergoing primary and secondary breast augmentation with Silimed® Textured Silicone Gel-Filled Breast Implant.
2431507|NCT03356132||Polyurethane Group|Women undergoing primary and secondary breast augmentation with Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant
2431508|NCT03356119|Experimental|RemovAid arm|New IMD Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
2431511|NCT03356093||Patients with head and neck cancer|No intervention was provided. The patients were only asked to complete a set of questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of postoperative radiotherapy.
2431512|NCT03356080|Experimental|DLAAG|"All patients receive 1-2 cycles of induction chemotherapy,that is DLAAG,which is expected to be 6 weeks/cycle,including decitabine,cytarabine, all-transretinoic acid,and Granulocyte Colony-Stimulating Factor(G-CSF).~patients with CR after the first course of induction therapy (DLAAG) will continue to receive 1 cycle of consolidation therapy, while those with therapy failure will continue the second course of induction therapy. If CR is not achieved, quit the study.~Patients who achieve CR after induction therapy will be in accordance with the guidelines, such as the proposed active treatment of allogeneic hematopoietic stem cell transplantation"
2431513|NCT03356067|Sham Comparator|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope.
2431514|NCT03356067|Experimental|Gastric endoscopic peroral pyloromyotomy|Experimental per-oral endoscopic myotomy of the pyloric sphincter
2431515|NCT03356054|Experimental|Brentuximab vedotin-R-DHAP|Brentuximab vedotin added to R-DHAP
2431516|NCT03356041|Active Comparator|Intervention Group|The intervention group will receive the three months' lifestyle modification program by a clinical pharmacist.
2431517|NCT03356041|No Intervention|Usual care Group|The usual care group will be provided the standard medical services
2431518|NCT03356028|Other|impacted by the attack of 14 July 2016|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire following the mass trauma of 14 July 2016 in Nice on a sample of exposed pediatric population
2431519|NCT03356028|Other|control group|characterize the psycho-social factors of risk and / or protection interfering in the children's future with questionnaire of children controls
2431520|NCT03356015|Experimental|4L Polyethylene Glycol|4L-group received 4 bags of PEG and were instructed to drink 2L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
2431521|NCT03356015|Active Comparator|3L Polyethylene Glycol|3L-group received 3 bags of PEG and were instructed to drink 1L at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes, and to drink the remaining 2L 4 to 6 h before colonoscopy at the same rate.
2431522|NCT03356002|Active Comparator|High risk subjects|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:~c. Surveillance - Significant findings in previous optical colonoscopy d. Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy e. Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy f. Diagnostic - Positive FIT test g. Diagnostic - one or more of the typical symptoms:"
3147198|NCT00118989|Placebo Comparator|PLACEBO|placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
3147199|NCT00118989|Experimental|Curcuminoids C3 Complex® to be taken orally via caps|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
3147200|NCT00119002|Active Comparator|Dexamethasone|1mg of Dexamethasone/kg
3147201|NCT00119002|Placebo Comparator|Placebo|1mg/kg placebo
3147202|NCT00119028|Other|Arm 1|Non-experimental QI intervention - No comparator
3147203|NCT00119054|Other|Arm 1|
3147204|NCT00119067|Active Comparator|AVA 8-SQ|receive 8 injections of AVA SQ
3147205|NCT00119067|Experimental|AVA 8-IM|receive 8 injections of AVA IM
2431523|NCT03356002|Experimental|Average risk|"Each subject will ingest the C-Scan System capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~Average risk based on their age and demographics referred for screening for polyps."
2431524|NCT03355989|Experimental|Low Flat Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.80 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431525|NCT03355989|Experimental|Low Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $4.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431526|NCT03355989|Experimental|Low Sharp Rate without Lottery|The intervention consists of receiving a small cash incentive of $0.75 on the BCG/Penta-1/Penta-2 vaccine and $1.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431527|NCT03355989|Experimental|Low Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a small cash incentive of $3.75 on the BCG/Penta-1/Penta-2 vaccine and $5.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431528|NCT03355989|Experimental|High Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431529|NCT03355989|Experimental|High Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431530|NCT03355989|Experimental|High Sharp Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.25 on the BCG/Penta-1/Penta-2 vaccine and $3.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431531|NCT03355989|Experimental|High Sharp Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $11.25 on the BCG/Penta-1/Penta-2 vaccine and $15.00 on the Measles-1/Measles 2 vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile top - up.
2431532|NCT03355989|Experimental|Easypaisa Flat Rate without Lottery|The intervention consists of receiving a large cash incentive of $2.40 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
2431533|NCT03355989|Experimental|Easypaisa Flat Rate with Lottery|The intervention consists of a 20% chance of receiving a large cash incentive of $12.00 on every vaccine along with 3 SMS reminders before, at and after the due date. The incentive will be sent via mobile money transfer i.e. easypaisa
2431534|NCT03355989|Experimental|SMS Reminder Only|The intervention consists of only sending 3 SMS reminders before, at and after the due date.
2431535|NCT03355989|No Intervention|Control|No intervention will be provided either in the form of cash incentive or reminder SMS. Vaccination facilities will be provided as per usual.
2431536|NCT03355976|Experimental|Arm 1 Nivolumab Ovarian|Nivolumab 240 mg Day 1 Cycle = 2 weeks
2431537|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Ovarian|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
2431538|NCT03355976|Experimental|Arm 1 Nivolumab Extra-renal|Nivolumab 240 mg Day 1 Cycle = 2 weeks
2431539|NCT03355976|Experimental|Arm 2 Nivolumab and Ipilimumab Extra-renal|Nivolumab 240 mg every 2 weeks Ipilimumab 1mg/kg day 1 Cycle=6 weeks
2431540|NCT03355963|Placebo Comparator|Group A|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
2431541|NCT03355963|Active Comparator|Group B|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
2431542|NCT03355963|Active Comparator|Group C|"The treatment group C:~intervention: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test."
2431543|NCT03355950|Active Comparator|TEP group|Patients who undergo totally extraperitoneal hernia repair, TEP Repair.
2431544|NCT03355950|Active Comparator|Lichtenstein group|Patients who undergo Lichtenstein repair.
2431545|NCT03355937|Active Comparator|UEI Sperm Chip (-)|Conventional IVF treatment and using conventional sperm selection
2431546|NCT03355937|Experimental|UEI Sperm Chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
2431547|NCT03355937|Active Comparator|RIF sperm chip (-)|Conventional IVF treatment and using conventional sperm selection
2431548|NCT03355937|Experimental|RIF sperm chip (+)|Conventional IVF treatment and using sperm chip for sperm selection
2431549|NCT03355872|Experimental|HLX01|
2431550|NCT03355872|Active Comparator|Rituximab|
2431551|NCT03355859|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 4 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8 CAR+ T cells.
2431552|NCT03355846|Experimental|AAF treated with Centella® Complex|Centella® Complex 1 cps 60 mg per os
2431553|NCT03355846|Experimental|AAF treated with Proctocella® cream|Proctocella® Complex cream to be applied in anal area and anal canal
2431554|NCT03355846|Experimental|AAF treated with Flavonil® cps|Flavonil® 1 cps 300 mg per os
2431555|NCT03355846|Experimental|AAF treated with Flavonil® Cream|Flavonil® Cream Cream to be applied in anal region and anal canal
2431556|NCT03355846|Experimental|AAF treated with Rectalgan Mousse|Rectalgan Mousse cleansing cleanser for anal and perineal region
3187764|NCT00759720|Experimental|TAK-559 16 mg QD + Glyburide QD|
2431558|NCT03355807|Experimental|Group MgSO4|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4 (30 mg/kg by bolus and 10 mg/kg/h by infusion for 24 hours)
2431559|NCT03355807|No Intervention|Group Control|the control group (group C, n _ 40) received the same amount of IV saline
2431626|NCT03355339|Experimental|Binasal occlusion|Participants will be fitted with glasses covered with occlusive tape from the inner canthi to the nasal border on each lens.
3187765|NCT00759720|Experimental|TAK-559 32 mg QD + Glyburide QD|
3187766|NCT00759720|Active Comparator|Glyburide QD|
2431560|NCT03355794|Experimental|Dose level 1 (starting dose level) (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; dose calculation age dependent (>21 yrs of age 300mg daily (DIPG only); </=21 yrs of age 120 mg/m2/day) Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; dose calculation age dependent (>21yrs 2.5mg/day (DIPG only); </=21yr 1.2 mg/m2/day) BSA >/=0.75m2
2431561|NCT03355794|Experimental|Dose level 2 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.2 mg/m2/day BSA >/=0.45m2
2431562|NCT03355794|Experimental|Dose level 3 (participants </= 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 170 mg/m2/day Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 1.5 mg/m2/day BSA >/=0.45m2
2431563|NCT03355794|Experimental|Dose level 1 (DIPG participants > 21yrs)|Ribociclib administered orally; daily on days 1-21 each 28 day cycle; 300mg daily Everolimus administered orally; daily on days 1 - 28 each 28 day cycle; 2.5mg/day
2431564|NCT03355781||Schizophrenic patients|Patients will have clinical psychiatric evaluation, brain imaging and blood sample
2431565|NCT03355781||Related volunteers (first degree relative of patient)|Related volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
2431566|NCT03355781||Healthy volunteers|Healthy volunteers will have clinical psychiatric evaluation, brain imaging and blood sample
2431567|NCT03355768|Experimental|Romidepsin Arm|Control Arm: Subjects will receive Romidepsin 14 mg/m2 on Days 1, 8, 15.
2431568|NCT03355768|Experimental|Romidepsin + Pralatrexate Combination Arm|Combination Arm: Subjects will receive Romidepsin 12 mg/m2 and Pralatrexate 25 mg/m2.
2431569|NCT03355755|Experimental|Interventional Group|All participants will be included in the interventional group. Intervention will consist of walking exercise using the EksoGT exoskeleton for supported walking, running SmartAssist software.
3187767|NCT00759733||1|Pregnant women with a history of cardiac disease (study group)
2431571|NCT03355716|Placebo Comparator|Group A (placebo):|instillation of bupivacaine alone: Bupivacaine 25 ml (0.25%) after surgery completion
2431572|NCT03355716|Active Comparator|Group B|Instillation of bupivacaine and morphine: Bupivacaine 25 ml (0.25%) + Morphine (3.0 mg)
2431573|NCT03355716|Active Comparator|Group C|Instillation of bupivacaine and fentanyl: Bupivacaine25 ml (0.25%) + fentanyl (30.0 Mc)
2431574|NCT03355716|Active Comparator|Group D|Instillation of bupivacaine and Ketamine: Bupivacaine25 ml (0.25%) + ketamine (0.5 mg/kg).
2431575|NCT03355690||Stroke patients|Stroke patients are treated according to the clinical practice which can be divided into: anti-aggregation, thrombectomy and/or thrombolysis
2431576|NCT03355677|Active Comparator|Case finding clinics|The visit will be a minimum 90 minutes long at the participants own GP surgery. This will include a respiratory assessment including spirometry will performed by a RT Respiratory Nurse Specialist (RNS) and where possible a Practice Nurse or Nurse Practitioner will attend. The visit will consist of objective measurements, investigations and questionnaires
2431577|NCT03355677|Placebo Comparator|Case finding Usual care|In the control arm of the study, practices will continue with usual care according to national guidance for case finding for COPD (NICE, 2010). Matched practices will have their eligible population identified through electronic searches based on data routinely recorded in primary care run in the HHRa. Case finding yield will be measured as the percentage of patients from the eligible population identified with a respiratory diagnosis in the 12 months from study beginning to study end.
2431578|NCT03355677|Active Comparator|At Risk Case clinics|The complex case clinic will be a minimum 120 minute appointment at the participants own GP surgery. The intervention will include an initial assessment by a RT Respiratory Nurse Specialist (RNS) and followed by a joint assessment by a respiratory physician (RP) working alongside a practice clinician (GP and/or Practice Nurse/Nurse Practitioner). The visit will consist of objective measurements, investigations and questionnaires as outlined in section 3 below. A personalised disease management and action plan will be agreed jointly between the RT, practice clinician and participant. The practice clinician will undertake the necessary tasks required for the agreed management plan. The clinical responsibility for the participant will remain with the GP practice.
2431579|NCT03355677|Placebo Comparator|At Risk Usual Care|In the control arm of the study, practices will continue with usual care according to national guidance for the management of COPD and asthma . A cohort of patients matched for practice and for age, sex, disease condition and, where possible, disease control will be identified. This cohort will be monitored against markers of sub-optimal disease (medication usage, exacerbations, unscheduled visits to the practice, attendance or admission to hospital).
2431580|NCT03355664|Active Comparator|ACT|Artemether-lumefantrine for 3 days plus primaquine at hour 24
2431581|NCT03355664|Experimental|TACT|Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24
2431582|NCT03355651|Active Comparator|PROGEN Group|PROGEN + Standard Rehabilitation + ACL reconstruction
2431583|NCT03355651|No Intervention|Control Group|Standard Rehabilitation + ACL reconstruction
2431584|NCT03355638|Active Comparator|aflibercept monotherapy|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
2431585|NCT03355638|Experimental|aflibercept plus pranoprofen|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of pranoprofen (Pranoflog; Sifi SpA, Aci Sant'Antonio, CT, Italy) three times a day for 12 months. All patients were followed up for 12 months.
2431586|NCT03355638|Experimental|aflibercept plus nutraceutical|All patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients were given daily tablets of Omega-3 supplementation (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
2431587|NCT03355612|Experimental|experimental group|Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)
2431588|NCT03355612|Active Comparator|active comparator|Drug:XELOX(Capecitabine and Oxaliplatin)
2431589|NCT03355599|Other|3d camera|3d camera
2431627|NCT03355339|Active Comparator|No binasal occlusion|Participants will be fitted with non-occluded glasses.
3147206|NCT00119067|Experimental|AVA 7-IM|receive 7 injections of AVA IM
2431630|NCT03355313|Experimental|Low level light therapy 1|
2431590|NCT03355586||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being electromagnetic navigation."
3147207|NCT00119067|Experimental|AVA 5-IM|receive 5 injections of AVA IM
2431592|NCT03355560|Experimental|Nivolumab|Nivolumab starting 4-11 weeks after surgery for 6 doses.
2431593|NCT03355547||no URI (upper respiratory tract infection) symptoms|Patients without upper respiratory tract infection symptoms
2431594|NCT03355547||URI (upper respiratory tract infection) symptoms|Patients with upper respiratory tract infection symptoms
2431595|NCT03355534|Experimental|nasal dexmedetomidine|dexmedetomidine is given nasally, saline is given intravenously
2431596|NCT03355534|Experimental|intravenous dexmedetomidine|saline is given nasally, dexmedetomidine is given intravenously
2431597|NCT03355534|Placebo Comparator|normal saline|saline is given nasally and intravenously
2431598|NCT03355521|Experimental|Nordic walking Experimental|Experimental: Nordic walking Training The total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Nordic walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (NW); (c) return to the calm and ultimate stretching.
2431599|NCT03355521|Active Comparator|Free walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
2431600|NCT03355508|Other|puncture bevel up|
2431601|NCT03355508|Other|puncture bevel domn|
2431602|NCT03355495|No Intervention|Left Lateral Decubitus Position|Gold standard positioning for colonoscopy
2431603|NCT03355495|Active Comparator|Right Lateral Decubitus Position|Comparing positioning in Right Lateral Decubitus (intervention) for visualization in colonoscopy to the gold standard of Left Lateral Decubitus.
2431604|NCT03355482|Active Comparator|Depomedrol arm|Patients are treated with new or ascending doses of subcutaneous methotrexate, and receive a single intramuscular dose of Depomedrol (160mg) at baseline.
2431605|NCT03355482|Sham Comparator|Placebo arm|Patients are treated with new or ascending doses methotrexate, and receive a single intramuscular placebo injection at baseline.
2431606|NCT03355469|Placebo Comparator|LoEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
2431607|NCT03355469|Placebo Comparator|HiEx+placebo|Subjects will participate in 3 supervised training sessions and 2 unsupervised training sessions and receive placebo.
2431608|NCT03355469|Active Comparator|LoEx+metformin|If subjects are assigned to this group they will participate in the same LoEx exercise program as outlined above. But, here they will be provided metformin. Metformin is a common medication routinely used to treat high blood sugar and has secondary effects on vascular health. Subjects will not be able to find out if you are on metformin until the study is done. If their doctor needs to know, the people doing this study can find out.
2431609|NCT03355469|Active Comparator|HiEx+metformin|If subjects are assigned to this group you will participate in the same HiEx exercise program and receive metformin as outlined above.
2431610|NCT03355456|Active Comparator|Pulmonary vein isolation (PVI) alone|Radiofrequency ablation procedure to isolate pulmonary veins without other intervention performed..
2431611|NCT03355456|Active Comparator|PVI+Total LT Atrial low voltage ablation|"PVI radiofrequency ablation along with ablation of areas of low voltage identified."
2431612|NCT03355456|Active Comparator|PVI + Posterior wall ablation|PVI radiofrequency ablation along with ablation of the posterior wall.
2431613|NCT03355443|Active Comparator|Re-examination Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined in the same fashion. After that, the rest of the colon is examined in routine method.
2431614|NCT03355443|Experimental|Retroflexion Group|Routine intubation is performed. After cecal intubation, the cecum and ascending colon is examined with colonoscope tip in forward direction for the first time. Re-intubation is performed after the first examination of the cecum and ascending colon, and then this region of the large bowel is re-examined with the colonoscope tip in reverse direction (retroflexion fashion). After that, the rest of the colon is examined in routine method.
2431615|NCT03355430||moderate keratoconus group|moderate keratoconus group underwent combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
2431616|NCT03355417|Experimental|OT-SI|Occupational therapy using a sensory integration approach
2431617|NCT03355404|Experimental|"Standing Patient"|
2431618|NCT03355404|No Intervention|"Standardized management in stretcher"|
2431619|NCT03355391||Screening participants|Individuals aged 50 to 65 years who were included in the screening program of Cancer Hospital of Barretos
2431620|NCT03355378|Experimental|study group|gum chewing during spinal anesthesia and early ambulation
2431621|NCT03355378|No Intervention|Control group|no gum chewing
2431622|NCT03355365|Experimental|Intrathecal MSC-NP injection|Patients will receive six autologous stem cell injections through spinal taps every 2 months over a year.
2431623|NCT03355365|Placebo Comparator|Intrathecal saline injection|Patients will receive six placebo injections through spinal taps every 2 months over a year.
2431633|NCT03355300|Experimental|Cannabidiol Oral Solution|Cannabidiol Oral solution, dose as assigned in INS-17-103.
2431634|NCT03355287|Placebo Comparator|Traditionally Threshed Teff (TTT)|The control group will consume injera based on teff threshed under the hooves of cattle. We plan to have a certain number of teff flour suppliers, where the teff is traditionally threshed and contains at least 50 mg Fe per 100 g flour.
2431635|NCT03355287|Experimental|Lab Threshed Teff (LTT)|The intervention group will consume injera based on teff flour that has been lab threshed using a modern teff threshing machine.
2431636|NCT03355287|Active Comparator|Fortified Lab Threshed Teff (FTT)|This arm will be the positive control group consuming Ferrous Sulphate drops ( with injera that consist of lab-threshed teff. The Fe drops have to be consumed with the meal and will provide an additional 6 mg of Ferrous sulfate to the diet of the children.
2431637|NCT03355274|Experimental|Patients|Patients suspected of thoracic outlet syndrome Transcutaneous oximetry during upper arm manoeuvers
2431638|NCT03355274|Sham Comparator|controls|healthy asymptomatic subjects Transcutaneous oximetry during upper arm manoeuvers
2431639|NCT03355261|Experimental|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
2431640|NCT03355261|Experimental|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
2431641|NCT03355261|Experimental|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
2431642|NCT03355261|Experimental|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
2431643|NCT03355248|Active Comparator|Control Group - 28|The control group (post-operative cesarean section) will be prescribed 28 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
2431644|NCT03355248|Experimental|Experimental - 20|The experimental group (post-operative cesarean section) will be prescribed 20 Oxycodone Acetaminophen at the time of discharge. Both groups will also be provided with a handout on non-opioid analgesia. The groups will be assigned randomly in blocks. Specifically, the first half of the patients will automatically be placed in the experimental arm and the second half into the control arm of the study
2431645|NCT03355235||Cognitive assessment using standardized tools|cognitive assessment using standardized tools pre and post transplant.
2431646|NCT03355222|No Intervention|No Intervention|No intervention: The community receives no chickens and no special education is provided.
2431647|NCT03355222|Experimental|Experimental: providing chickens and egg shell|"Experimental: Two chickens are given to each family so that eggs are available for children and of eggshell powder for mothers.~The community receives these chickens so each designated family has an egg to give to young child. In a subgroup the mother will receive ESP (1000 mg calcium). The community receives information on using egg and has help on caring for chickens."
2431648|NCT03355209|Experimental|ZX008 0.2 or 0.8 mg/kg/day|Part 1: ZX008 is supplied as an oral solution. Subjects will be randomized to receive 1 of 2 doses of ZX008 0.2 mg/kg/day or 0.8 mg/kg/day.
2431649|NCT03355209|Placebo Comparator|Matching Placebo|Part 1: Matching ZX008 placebo is supplied as an oral solution.
2431650|NCT03355209|Experimental|Open-Label|Part 2: ZX008 is supplied as an oral solution. Study medication will be administered twice a day (BID) in equally divided doses.
2431651|NCT03355196|Experimental|LRX712|LRX712 given intra-articularly
2431652|NCT03355196|Placebo Comparator|Placebo|Placebo given intra-articularly
2431653|NCT03355183|Experimental|Healthy athletes|Muscular strength of healthy athletes who are not physically disabled and doing sports for 3 years as a professional will be measured by isokinetic dynamometer.
2431654|NCT03355170|Experimental|Lansoprazole/Domperidone|Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.
2431655|NCT03355170|Active Comparator|Lansoprazole|Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.
2431656|NCT03355157|Experimental|Palbociclib + endocrine therapy|Experimental arm for testing palbociclib + endocrine therapy.
2431657|NCT03355157|Active Comparator|Chemotherapy +/- endocrine maintenance therapy|Chemotherapy +/- endocrine maintenance as comparator arm.
2431658|NCT03355144|Experimental|Internal Medicine residents at NYU|effect of supplying Internal Medicine residents at NYU with free coffee on self reported features of psychological health, energy and burnout
2431659|NCT03355131|Experimental|Adapted NASA's Mission X program|Adapted NASA's Mission X program for the intervention group
2431660|NCT03355131|No Intervention|Mission X Control|no intervention
2431661|NCT03355105|Experimental|Objective adjustment of the MI/E exsuflation pressure|Objective adjustment of the MI/E exsuflation pressure based on the flow-volume curve generated during the cough.
2431662|NCT03355105|Active Comparator|Subjective adjustment of the MI/E exsuflation pressure|Subjective adjustment of the MI/E exsuflation pressure based on the clinical judgment of the therapist and the patient.
2431663|NCT03355092|Experimental|vBloc Therapy + Usual Care for Type 2 Diabetes|
2431664|NCT03355092|No Intervention|Usual Care for Type 2 Diabetes|
2431665|NCT03355079|Experimental|SmofKabiven® E + standard oral nutrition|SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit® will be administered at 5-7 days per week for up to 9 +/-1 weeks in addition to standard of care oral nutrition as per routine dietary counseling, to reach the patient's target energy intake.
2431666|NCT03355079|No Intervention|Standard oral nutrition|The patients will consume standard of care oral nutrition as per routine dietary counseling, to reach their target energy intake. Standard of care tube feeding or parenteral nutrition is allowed to start earliest 3 weeks after baseline visit, if required.
2431879|NCT03353662||Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6 - 59 months
3147208|NCT00119067|Experimental|AVA 4-IM|receive 4 injections of AVA IM; months 0, 2, 6 and a booster at month 42
3147209|NCT00119067|Placebo Comparator|Saline placebo IM or SQ|
3147210|NCT00119184|Experimental|External cephalic version with spinal anesthesia|External cephalic version with spinal anesthesia
2431670|NCT03355053|Active Comparator|Dexmedetomidine (Dex) very-low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~1) Group 1: Dex at 0.1 mcg/kg/h from 8PM until 7AM"
2431671|NCT03355053|Active Comparator|Dexmedetomidine (Dex) low dose group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~2) Group 2: NS at 0.3 mcg/kg/h from 8PM until 7AM"
2431672|NCT03355053|Placebo Comparator|Usual care + placebo group|"Study drug will be administered by the patient's nurse. Study drugs (50 mL of 4 ug/ ml dexmedetomidine hydrochloride or 50 ml normal saline (NS)) will be provided as clear solutions in identical 60 mL syringes. In each study arm patients will receive a continuous overnight infusion of study drug (Dex or placebo) at 0.075 ml/kg/h Dex or NS from 8PM until 7AM, for 7 consecutive nights or until leaving the ICU, depending on randomization group, as follows:~3) Group 3: NS at 0.075 ml/kg/h from 8PM until 7AM."
2431673|NCT03355027|Experimental|Alirocumab Treatment Arm|30 patients with stable cardiovascular disease to receive Alirocumab 150mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
2431674|NCT03355027|Active Comparator|Comparator Treatment Arm|30 patients with stable cardiovascular disease to receive Ezetimibe 10mg & prescribed one of the following: Atorvastatin 40mg/80mg or Simvastatin 80mg or Rosuvastatin 20mg/40mg. Dosing and dispensing to be performed at V3, V4, V5 and V6.
2431675|NCT03355014|Experimental|Gemigliptin+Metformin combination therapy group|"Part I (Fasted) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day~Part II (High fat diet) Combination therapy of gemigliptin/metformin sustained release 50/1000mg(25/500mg 2tablets), for 1day"
2431676|NCT03355014|Experimental|Gemigliptin and Metformin coadministration therapy group|"Part I (Fasted) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg~Part II (High fat diet) Coadministration therapy of gemigliptin 50mg and metformin HCL extended relese 1000mg"
2431677|NCT03355001||Skin Closure|Monosyn® Quick will be used for skin closure for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2431678|NCT03355001||Urology|Monosyn® Quick will be used in urology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2431679|NCT03355001||Gynecology|Monosyn® Quick will be used in gynecology for the adaptation of soft tissue and mucous membranes, when wound support over a period of 7 days is considered adequate.
2431680|NCT03354988|Active Comparator|physical exercise group|For the exercise group, Intervention by doing physical exercise. systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital.
2431681|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
2431682|NCT03354975|Experimental|Experiential Training|
2431683|NCT03354975|Active Comparator|Training-as-usual|
2431684|NCT03354962|Active Comparator|ARM A|
2431685|NCT03354962|Experimental|ARM B|
2431686|NCT03354949||Positioning hemiplegic.|"Positioning all hemiplegic by stroke requiring a single wheelchair even at the exit of the SSR and hemiplegic patient with sequelae.~Measurement of sitting postural control of the adult (MCPAA). Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~Propulsion speed of a wheelchair."
2431687|NCT03354923|Experimental|immediate intervention group|Immediate PEERS intervention
2431688|NCT03354923|Other|delayed intervention|delayed PEERS intervention to begin after experimental group
2431689|NCT03354910|No Intervention|Usual Care|All enrolled patients will receive Usual Care for transplant candidates at our two centers, which includes individual meetings with transplant providers, attendance at a patient group education session in the transplant center (focused on the specifics of the transplant experience), and a transplant education binder.
3147211|NCT00119184|Active Comparator|External cephalic version without spinal anesthesia|External cephalic version without spinal anesthesia
3147212|NCT00119197|Experimental|1|Killed Whole Cell Oral Cholera Vaccine
3147213|NCT00119197|Placebo Comparator|2|Heat-killed E. coli
3147214|NCT00119210|Placebo Comparator|Placebo|Sugar pill
3147215|NCT00119210|Experimental|Bupropion SR|
3147216|NCT00119236|Experimental|Arm I|Patients receive irinotecan IV over 30 minutes followed by 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)* IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable or improved disease after course 2 may receive additional courses of treatment.
3147217|NCT00119249|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3187768|NCT00759733||2|Pregnant women with no history of heart disease (control group)
2431690|NCT03354910|Active Comparator|Usual Care (UC) + House Calls (HC)|Patients and their invited guests will be scheduled for one House Call. A house call is meeting done at a patient's home with transplant health educators facilitating a discussion on topics related to living kidney donation. Patients and guests also receive an information packet containing several brochures providing information about the living donation process, common concerns and misperceptions, and donation resources and information about our transplant center (e.g., copy of our quarterly newsletter, contact information). Patients in the group will also receive Usual Care, the regular education on living donation, provided as part of their routine transplant care.
2431691|NCT03354910|Experimental|UC + HC + Peer Mentorship|Patients in this condition will receive the Usual Care and the House Calls intervention as described previously. In addition, participants will receive access to a Peer Mentor trained by the National Kidney Foundation following their House Call.
2431692|NCT03354897|Other|Treatment|16 weeks treatment 5mg/day
2431693|NCT03354884|Experimental|Cabozantinib|All subjects will receive open label Cabozantinib 60 mg orally once daily
2431694|NCT03354858||Follicular flushing|One ovary will be aspirated using follicular flushing (up to 5 times per follicle).
2431695|NCT03354858||No flushing|One ovary will be aspirated using direct aspiration (no flushing).
2431696|NCT03354845|No Intervention|Control (usual care) group|In the control group, doctors maintained the usual practice of medication review, altering and discontinuing medications as necessary, without receiving deprescribing recommendations from pharmacists.
2431697|NCT03354845|Other|Deprescribing intervention group|The five-step patient-centred deprescribing process was utilized in the intervention group.
2431698|NCT03354832||Foetal death|In-utero dead foetus weighting at least 500 g or 22-amenorrhea weeks old. In utero death means that death occurs during delivery or per partum
2431699|NCT03354832||New-born death|New-born dead during post-birth hospital stay and at least 23-amenorrhea weeks old.
2431700|NCT03354832||Birth control for foetal death|Same gender child born, and alive, in the same hospital, and born on time (37-41 amenorrhea weeks old).
2431701|NCT03354832||Birth control for new-born death|"Same gender infant born, and alive, in the same hospital, and:~for 23-amenorrhea weeks old new-born death: control new-born are born on time (37-41 amenorrhea weeks old).~for 24 to 31-amenorrhea weeks old new-born death: control new-born are premature infant (24-31 amenorrhea weeks old), and are included when their hospital stay ends.~for 32 and more-amenorrhea weeks old new-born death: control new-born are 32 and more-amenorrhea weeks old infant"
2431702|NCT03354819|Experimental|Modified MBCT|A group-based, 10-week, 7-session modified Mindfulness Based Cognitive Therapy (MBCT) will be adopted in the MBCT intervention group with a group size of 15-20. The program includes different mindfulness activities (such as mindful eating and mindful walking) and peer sharing.
2431703|NCT03354819|Active Comparator|SIRE on dementia|The frequency of the Social Interactions and Routine Education (SIRE) program is the same as that of modified MBCT which consists of seven sessions (weekly for the first four sessions and bi-weekly for the last three sessions) and each session will last about two hours for 10 weeks with group size 15-20.
2431704|NCT03354806|Experimental|Continuous peripheral nerve blocks|Ropivacaine-continous treatment using catheters for continous sciatic nerve blocks
2431705|NCT03354806|Active Comparator|Analgesic treatment|Pharmacological pain management in accordance with WHO's pain relief ladder
2431706|NCT03354793||endometriosis|Survey on first pregnancy after endometriosis diagnosis
2431707|NCT03354793||non endometriosis|Survey on first pregnancy
2431708|NCT03354780||endometriosis|Survey on first pregnancy after endometriosis diagnosis
2431709|NCT03354780||non endometriosis|Survey on first pregnancy
2431710|NCT03354767||Wasting patients|Patients with >10% loss of skeletal muscle one week after major aortic surgery
2431711|NCT03354767||Non-wasting patients|Patients with <10% loss of skeletal muscle one week after major aortic surgery
3187769|NCT00759746|Active Comparator|Weight Maintenance Education|Participants assigned to this group will receive the Weight Maintenance Education intervention. They will meet every other week during the maintenance phase of the study for a total of 16 sessions over 8 months. During the visit, participants will participate in a series of interactive workshops within child and parent groups to learn general information about healthy eating and physical activity.
3187770|NCT00759746|Experimental|SFM+ Low Dose|Participants assigned to this group will receive the SFM+ Low Dose.
2431714|NCT03354741|Other|Laser then Sham therapy|2nd cycle of chemotherapy : administration of laser therapy 3th cycle of chemotherapy : administration of a sham laser according to the same modalities
2431715|NCT03354741|Other|Sham therapy then laser|2nd cycle of chemotherapy : administration of a sham laser 3th cycle of chemotherapy : administration of laser therapy according to the same modalities
2431717|NCT03354715|Sham Comparator|Rapid prototyping Denture base|Complete Denture Using Rapid Prototyping method for fabrication of the complete denture depending on
2431718|NCT03354715|Sham Comparator|Heat Cured Conventional Complete Denture|Complete Denture using heat cured Denture base using flasking and deflasking method
2431719|NCT03354702|Experimental|Group aerobic activity (experimental)|Group aerobic exercise (experimental). Patients perform aerobic exercise per 30 minutes (moderate intensity: 70% to 85% of estimated maximum heart rate), more 10 minutes stretching, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions.
2431720|NCT03354702|Active Comparator|Group stretching (control)|Group stretching (control). Patients perform stretching per 30 minutes, once a week monitored and once without monitoring and patients have medical appointment with psychiatrist and make psychotherapy sessions
2431721|NCT03354676||MetS+|Obese group with metabolic syndrome/Data processing from Patient Medical Files
2431722|NCT03354676||MetS-|Obese group without metabolic syndrome/Data processing from Patient Medical Files
3187771|NCT00759746|Experimental|SFM+ High Dose|Participants assigned to this group will receive the SFM+ High Dose.
2431724|NCT03354650||complete blood count|blood sample is collected from infant to detect presence of sepsis
2431725|NCT03354650||c reactive protein|measuring c reactive protein in blood sample to determine neonatal sepsis
2431729|NCT03354624|Experimental|Nerve growth factor group|Three injections of sterile solutions of recombinant human nerve growth factor (NGF) will be performed in the right extensor carpi radialis muscle to induce muscle hyperalgesia.
2431730|NCT03354624|Experimental|Nerve growth factor group + delayed onset muscle soreness|Injections of nerve growth factor and eccentric exercise of the extensor carpi radialis muscle will be performed to induce muscle hyperalgesia.
3187772|NCT00759824|Experimental|1|Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
3187773|NCT00759837|Experimental|1|
3187774|NCT00759850|Active Comparator|A|Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)
2431734|NCT03354585|Experimental|Meditation Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
2431735|NCT03354585|Active Comparator|Meditatin Group|"Study volunteers will participate in a twelve-session meditation training regimen. In brief, subjects will be taught that perceived sensory events are momentary and fleeting and do not require further evaluation. There will be an emphasis on breath focus and altering one's perspective of discursive sensory events. This intervention has been found to reliably attenuate the subjective experience of pain."
2431736|NCT03354585|Active Comparator|Book Listening Control Group|Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 12 session intervention is meant to provide the control attention to the facilitator, room setting, social support, conditioning, and the time elapsed during the other respective interventions. We do not expect that this group will demonstrate significant cerebral blood flow changes as a function of the intervention.
2431737|NCT03354572|Active Comparator|NAC|receive 150 mg/kg acetylcysteïne in 200 ml saline (NaCl0,9%) prior to surgery
2431738|NCT03354572|Placebo Comparator|placebo|receive only NaCl 0.9% prior to surgery (volume identical to active comparator)
2431739|NCT03354559||pre-ECS group|Data collection from 01-01-2011 to 31-12-2012. Patients were treated according to a massive transfusion protocol with the following targets: fresh frozen plasma(FFP)/packed red blood cells(PRBCs) ratio ≥ 1:1.5, target platelet count > 100.000 x 10 9/L
2431740|NCT03354559||ECS group|Data collection from 01-01-2013 to 31-12-2014. Patients were treated according to the ECS protocol.
2431741|NCT03354546||Elective noncardiac surgery|Individuals having major noncardiac surgery following an elective hospital admission
2431742|NCT03354546||Emergency general surgery|Individuals having general surgery following an urgent hospital admission
2431743|NCT03354533|Other|Treatment with ORL-1F - L-fucose|
2431744|NCT03354520|Active Comparator|Tailored Videos|
2431745|NCT03354520|Active Comparator|Standard Videos|
2431746|NCT03354520|Active Comparator|OSA Treatment|
2431747|NCT03354507|Experimental|Sodium Bicarbonate|"Patients will receive sodium bicarbonate for 4 weeks, based on pre-calculated weight based doses. Patients are selected if they have metabolic acidosis at baseline.~< 24 kg : 1/4 teaspoon bid. 24 - 42 kg : 1/2 teaspoon bid. > 42kg : 3/4 teaspoon bid."
2431748|NCT03354507|No Intervention|Control|Patients will not receive treatment if they do not have metabolic acidosis at baseline.
2431749|NCT03354494||DSG-CTP|
2431750|NCT03354481|Experimental|Behavioral recording of arithmetic and associated information|The experiment will contain several behavioral tasks in which solving time and correct answer will be recorded. The main one will be a computerized task on arithmetic facts. There will also be three additional tasks as described below.
2431751|NCT03354468||fall prevention program time 1|orthopedic department in Kristiansund hospital before implementation of a fall prevention program
2431752|NCT03354468||no fall prevention program time 1|orthopedic department in Ålesund hospital without fall prevention program
2431753|NCT03354468||fall prevention program time 2|orthopedic department in Kristiansund hospital after implementation of a fall prevention program
2431754|NCT03354468||no fall prevention program time 2|orthopedic department in Ålesund hospital without fall prevention program
2431755|NCT03354455|Experimental|REAL TMS|30 minutes of repetitive transcranial magnetic stimulation with 100% of the patients' individual resting motor threshold.
2431756|NCT03354455|Sham Comparator|SHAM TMS|30 minutes of repetitive transcranial magnetic stimulation with 30% of the patients' individual resting motor threshold.
2431757|NCT03354442|Experimental|Modified Fixed Mandibular Retractor|All patients in this group will be treated using Modified Fixed Mandibular Retractor Appliance. This appliance will be used full-time.
2431758|NCT03354442|No Intervention|Untreated control group|All patients in this group will be observed during the period of treating the patients in the other group to assess the growth changes.
3187775|NCT00759850|Experimental|B|Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)
3187776|NCT00759850|Experimental|C|Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)
2431762|NCT03354403||Patients|Up to 50 mothers of sons of all ages diagnosed with XLRS are eligible to participate in this study. Up to 50 fathers of sons of all ages with XLRS are also eligible to participate and will serve as a comparison group.
3187777|NCT00759889||wound biopsy|diabetic foot,venous leg ulcer, decubitus ulcer
2431842|NCT03353909|Experimental|Treatment|At the end of the dilatation and curettage, new crosslinked hyaluronan gel (3ml) was applied to the uterine cavity in women assigned to the treatment group through a 15-cm sterile cannula.
2431843|NCT03353909|No Intervention|Control|At the end of the dilatation and curettage, nothing was applied to the uterine cavity in women assigned to the control group.
2431764|NCT03354377|Experimental|Vegan Diet|"Participants in this group will follow a plant-based vegan diet. The vegan group diet will be based on investigators' pilot work, which instructs participants to favor a diet built around whole grains, fruits, vegetables, and legumes. This group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide. A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course.~Interventions include intervention meetings, physical activity, and podcasts/mailings."
2431765|NCT03354377|Experimental|Omnivorous (Omni) Diet|"Participants in this group will follow a low-fat omni diet. The diet intervention for the omni group will be supplemented by the Oldways African Heritage and Health program, which includes a food pyramid guide, A Taste of African Heritage (ATAH) six-lesson nutrition and cooking program and an online course for health professionals and cooking instructors (all research and restaurant team members will complete this course).~Interventions include intervention meetings, physical activity, and podcasts/mailings."
2431766|NCT03354364|Active Comparator|Group 1|Receives pea hull fiber snack for the first 4 weeks and then control snack for the last 4 weeks of the study with 4-week washout between them.
2431767|NCT03354364|Active Comparator|Group 2|Receives control snack for the first 4 weeks and then pea hull fiber snack for the last 4 weeks of the study with 4-week washout between them
2431768|NCT03354351||NB-Group|Stepped-care model comprising a hierarchy of interventions, from the least to the most intensive, matched to the cardiac man's needs. The model involves three steps: Step 1 (therapist-guided and self-guided 3-session psychoeducational program), Step 2 (Group sessions involving care partners), and Step 3 (individual or dyadic (patient and care Partner) sessions. As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2431769|NCT03354351||ON-Group|Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2431770|NCT03354351||QC-Group|Standard Stepped-care model where men will need to follow a sequential treatment (Step 1 (self-guided), Step 2 (Group sessions), and Step 3 (individual or couple sessions). As such, if following Step 1, the mental-health symptoms of men with HD do not sufficiently subside, as identified by the screening tests, participants will qualify for Step 2. Following Step 2, men who continue to meet criteria for a clinically significant mood, anxiety, or post-traumatic stress disorder on the screening tests (PHQ9, MRDS, DASS 21, IES-R, CIS), will be invited to receive services at Step 3.
2431771|NCT03354338|Experimental|Experimental Group|Intensive Periodontal treatment and pre-medication with 2 gr of oral amoxicilline 1 hour before treatment
2431772|NCT03354338|Placebo Comparator|PLACEBO|Intensive Periodontal treatment with 2 gr of Placebo 1 hour before treatment
3188970|NCT00772655|Experimental|Study Therapy|Induction therapy with a single course of 90Yttrium-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111Indium-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 up to a maximal dose of 12.000 MBq [if platelets are below 150000/µl only 11 MBq/kg are administered). Observation for patients achieving complete clinical and molecular response or partial clinical response. Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2 (t14;18)-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
3188971|NCT00772681|Experimental|1|
2431775|NCT03354312|Experimental|Lidocaine/Articaine|Lidocaine Hydrochloride 1% Gel anesthesia / Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia
2431776|NCT03354312|Experimental|Articaine/Lidocaine|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride anesthesia / Lidocaine Hydrochloride 1% Gel anesthesia
2431777|NCT03354299|Experimental|Group I|Group I patients received 25 gram of sugar (pudding) and 50 cc of coconut milk as late night snack for a month
2431778|NCT03354299|Active Comparator|Group II|Group II patients received 50 gram of sugar (25 gram pudding and 25 gram syrup) as late night snack for a month
2431779|NCT03354286|Experimental|Developmental & Technological Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving. Identify and troubleshoot barriers to keeping young children in Auto Mode.
2431780|NCT03354286|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
2431781|NCT03354286|Experimental|Nutrition, Set Point, & C:I Ratio|Provide education on a variety of properties of food and how they affect blood glucose levels. Optimize the use of carbohydrate to Insulin ratios, insulin duration of action, and use of temporary target glucose set point in the 670G pump and the Quick bolus feature to gain better glycemic control.
2431782|NCT03354286|Experimental|Hypoglycemia management|Focus on hypoglycemia management to avoid hyperglycemia, review fear of hypoglycemia
2431783|NCT03354286|Placebo Comparator|Minimal Intervention|A short communication detailing the percentage of time spent in range and in Auto Mode and if the goals have been met.
2431785|NCT03354260|Experimental|intervention|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
2431786|NCT03354260|No Intervention|Control|
2431787|NCT03354247|No Intervention|Healthy Control|Participants in this group will attend small group sessions providing basic education about NAFLD/NASH, and about principles of healthy eating, physical activity and weight control. These sessions occur every 12 weeks and are conducted by a Master's level nutritionist or health educator. Providing basic education about diet and exercise has produced minimal weight loss in other clinical trials. The educational sessions will be included in this study in order to provide standard care to these patients and to maximize subject retention.
2431980|NCT03352986||leg ulcer|Sickle cell patients with leg ulcer as a vascular main complication
2431788|NCT03354247|Experimental|NAFLD Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants who are able to lose more than 10% of their body weight will be encouraged to do so. Participants will be seen weekly for the first 6 months and then biweekly for months 7-12. The lifestyle intervention focused on diet, exercise, and behavior modification.
2431789|NCT03354234|Experimental|Stimuli of slowly increasing intensities|"300-s check before the stimuli~LBNP is applied stepwise with 11.1 mmHg/15 s decrement to -100 mmHg, and then this value is sustained for 120 s~180-second phase of rest between stimuli~75°-HUT (5°/s) for 120 s after a 15-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~75°-HUT (5°/s) accompanied by an exposure to an LBNP of -60 mmHg increased linearly by -4 mmHg/s, and then this value is sustained for 120 s during HUT~120-s check after the stimuli"
2431790|NCT03354234|Experimental|Stimuli of rapidly increasing intensities|"120-s check before the stimuli~75°-HUT (45°/s) for 60 s after a 3-s reversing of the gravity vector (-30°)~180-second phase of rest between stimuli~LBNP decreases linearly by -20 mmHg/s to -100 mmHg, and then this value is sustained for 60 s.~180 second phase of rest between stimuli~push-pull, i.e., 3 x 75°-HUT (45°/s) preceded by -30°-HDT (45°/s) and accompanied by an exposure to an LBNP of -60 mmHg decreased linearly by -20 mmHg/s, and then this value is sustained for 30 s during HUT~120-s check after the stimuli"
2431791|NCT03354221|Experimental|Cytosponge, Diet, EEsAI Pro, Likert Scoring Scale|Patients going through the six food elimination diet (clinically) for EoE will be asked to participate. During the initial 6 week elimination period, participants will return at 2, 4 and 6 weeks to swallow the cytosponge. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the future of the 6 food elimination diet to determine if a period of 6 weeks of initial elimination is necessary. The EEsAI Pro questionnaire measures symptomatic response to the elimination of the foods. The Likert Scoring Scale measures patient experience of the cytosponge and the upper endoscopy.
2431792|NCT03354208||Group 1|patients with hypoxic-ischemic encephalopathy (HIE) receiving hypothermia therapy
2431793|NCT03354208||Group 2|patients with suspected HIE, non-confirmed
2431794|NCT03354208||Group 3|healthy, retrospectively classified as such
2431795|NCT03354195|Active Comparator|Group 1|"Group 1 - intact ACL ligament will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2431796|NCT03354195|Active Comparator|Group 2|"Group 2 - intact but fibrillated (frayed) ligament) will be accepted as functionally intact~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2431797|NCT03354195|Active Comparator|Group 3|"Group 3 - nearly completely torn ligament (>50% and disrupted) will be deemed as having functionally absent ACLs~unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system."
2431798|NCT03354182|Active Comparator|Control group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen + Bio-gide
2431799|NCT03354182|Active Comparator|Test group|Open flap surgery on mandibular type II furcations treated with Bio-oss collagen alone
2431800|NCT03354169|Experimental|Daytime Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 0800 and 1900.
2431801|NCT03354169|Experimental|Delayed Eating Condition|Participants will be asked to eat all of their meals and snacks, as provided by the study, between 1200 and 2300.
2431802|NCT03354156||High-LDL|patients with LDL cholesterol levels of >4.9 mmo/l, who have not been treated with statins in the past years, and who have an indication for treatment with statins.
2431803|NCT03354156||Control|control subjects with an LDL cholesterol level of <3.5 mmol/l
2431804|NCT03354143|Active Comparator|Standard Care|Subjects in the standard care arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 130 mmHg. Drug doses will be titrated to reach the BP target.
2431805|NCT03354143|Experimental|Intensive Treatment|Subjects in the intensive treatment arm will receive calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs to reduce 24-hour SBP ≤ 120 mmHg.
2431806|NCT03354130|Active Comparator|Tofu control|Volunteers will consume a vegetarian diet containing tofu during 3 days for 5 meals in total
2431807|NCT03354130|Experimental|Non-processed pork diet|Volunteers will consume a diet containing non-processed pork during 3 days for 5 meals in total
2431808|NCT03354130|Experimental|Bacon diet|Volunteers will consume a diet containing bacon during 3 days for 5 meals in total
2431809|NCT03354130|Experimental|Sausage diet|Volunteers will consume a diet containing sausage during 3 days for 5 meals in total
2431810|NCT03354130|Experimental|Dry-cured sausage diet|Volunteers will consume a diet containing dry-cured sausage during 3 days for 5 meals in total
2431811|NCT03354117|Experimental|Ulipristal 30mg plus Meloxicam 15mg|Each study participant will complete one menstrual cycle without medication. Her second menstrual cycle, each study participant will receive ulipristal acetate plus meloxicam at peak fertility.
2431812|NCT03354104|Experimental|Recession coverage with connective tissue graft + Emdogain®|A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with 24% EDTA (PrefGel®, Straumann, Basel, Switzerland) for 2 minutes and then washed with saline. Subsequently, EMD (Emdogain®, Straumann, Basel, Switzerland) is applied on root surfaces. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
2431844|NCT03353896|Experimental|Treatment (medical device)|Beginning 4-8 weeks after standard of care treatment, patients wear NovoTTF-200A device over 18 hours QD. Treatment continues for up to 24 months in the absence of disease progression or unacceptable toxicity.
2431911|NCT03353454|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat oral solution twice daily for 26 weeks.
2432104|NCT03352167||ED Herning|
2431813|NCT03354104|Active Comparator|Recession coverage with connective tissue graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
2431814|NCT03354091|Experimental|Intervention|Patient education program and the use of an Fitbit where the users can monitore their activity and receive minor feedback regarding physical activity.
2431815|NCT03354091|No Intervention|Control|Patient education program only.
2431816|NCT03354078|Active Comparator|interrupted sutures group|This group in which closure of the subcutaneous layer is closed by interrupted sutures
2431817|NCT03354078|Active Comparator|Continous sutures group|subcutanous tissue layer is closed by continous sutures in this group
2431818|NCT03354065|Active Comparator|Early oral feeding|TIME OF FEEDING. 48 hours after pancreatitis general management is started ( liquid diet)
2431819|NCT03354065|Experimental|Immediate oral feeding|TIME OF FEEDING: 8 hours of after pancreatitis general management is started (enteral formula)
2431820|NCT03354052|Experimental|Real-rTMS + Gloreha device|
2431821|NCT03354052|Active Comparator|Sham-rTMS + Gloreha device|
2431822|NCT03354039|Experimental|Tamoxifen 20 mg once daily|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of TAM daily.
2431823|NCT03354039|Placebo Comparator|Matching placebo once daily|Patients randomised to placebo will be administered matching placebo.
2431824|NCT03354026|Experimental|Experimental: AICH-PXZY|Removing Blood Stasis medicine with folium sennae , Polygonum cuspidatum and so on, 8 herbals, Tong-fu-xing-shen. The intervention in this group includes po AICH-PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2431825|NCT03354026|Experimental|Experimental: AICH-without PXZY|Removing Blood Stasis medicine without folium sennae and Snakegourd seed, 6 herbals, without the effect of Poxuezhuyu. The intervention in this group includes po AICH-without PXZY bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2431826|NCT03354026|Placebo Comparator|Placebo: AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin. The intervention in this group includes po AICH-placebo bid and the routine treatment of Western Medicine.Torn the medicine bag and take it after mixing with 50-80ml warm water（Or take by nasal feeding).
2431827|NCT03354013|Experimental|AOA, genetic screening, calcium pattern|"Clinical setting: Patients will undergo 100% ICSI-AOA if less than 6 mature oocytes are collected upon oocyte retrieval. If 6 or more mature oocytes are retrieved, 50%ICSI and 50%ICSI-AOA will be applied.~Furthermore, patients will give a saliva sample to do genetic screening. Genes important during oocyte activation and embryo development will be investigated.~Also, calcium pattern analysis of the patients' spermatozoa will be executed."
2431828|NCT03354000|Placebo Comparator|Take-home online training|Participants received a link to access the online tutorial videos on their own.
2431829|NCT03354000|Active Comparator|In-person online training|Participants received an in-person tutorial of how to use the patient portal website with a trained research assistant.
2431830|NCT03353987|No Intervention|Control|Preoperative counselling will be given upon recruitment Patients will be given instructions to continue their normal routine.
2431831|NCT03353987|Experimental|Cognitive Training|Preoperative counselling will be given upon recruitment Patients are taught cognitive training and are asked to perform a prescribed set of one-hour cognitive training daily for a minimum of 10 days and up to 1 month prior to surgery.
2431832|NCT03353974|Experimental|Video game therapy|Subjects belonging to the experimental group will receive a Video Game Therapy (VGT) protocol using the Xbox console. They will receive 12 sessions of treatment within 4 weeks (3 sessions per week); each session will last 1 hour. To manage possible absence lasting one or more treatment sessions, a potential window of 5 weeks will be set to ensure the achievement of all 12 sessions. Will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling
2431833|NCT03353974|Active Comparator|Balance platform therapy|"Subjects belonging to the control group will receive the same amount of therapy (12 sessions) using a balance platform (Biodex Medical Systems, Inc., Shirley, NY). Balance/rebalancing, postural stability and weight-shifting exercises ill be administered with and without visual feedback. During the first session, the tasks will be performed at an entry level, and the exercise progression will be adjusted over time according to the patients' functional level (intermediate and difficult level). Balance platform therapy offered visual feedback and knowledge of performance (augmented feedback). The physiotherapist, as during VGT, provided additional external feedback."
2431834|NCT03353961|Experimental|Adjunctive Internet-delivered ERITA|Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community. The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
2431835|NCT03353961|Active Comparator|Treatment as usual|Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
2431836|NCT03353948|Active Comparator|Metfrormin group (MET)|Drug: Metformin
2431837|NCT03353948|Active Comparator|COMBI group (COMBI)|Drug: liraglutide
2431838|NCT03353935||NERVE SPARING|Patients who underwent surgery for deep endometriosis were submitted to surgical procedures aiming at sparing the pelvic ortho- and parasympathetic nerves. The subjects were then followed with interviews using validated questionnaires, to assess the possible changes in post-operative urinary sexual and fecal function.
3188972|NCT00772694|Experimental|sorafenib|drug
3188973|NCT00772746||exercise|Respiratory and cognitive exercises in panic disorder patients.
3188974|NCT00772759|Experimental|1|Dry powder for oral inhalation
2432105|NCT03352167||ED Aabenraa|
2432106|NCT03352167||ED Odense|
3188975|NCT00772759|Placebo Comparator|2|Dry powder for oral inhalation
3188976|NCT00772785|Experimental|Probuphine|buprenorphine implant
2431845|NCT03353883|Active Comparator|(Group A) Midluteal Triptorelin depot|infertile women with impaired ovulation who will be subjected to Triptorelin sustained release(Decapeptyl depot 375 mg one injection )at D-21 of previous menstrual cycle Hormon Replacement Therapy (HRT)Cyclo-Progynova (estradiol, norgestrel)(Group A). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-HCG level and was confirmed 2-weeks later by TVU.
2431846|NCT03353883|Active Comparator|(Group B)first day Triptorelin depot|infertile women with impaired ovulation who will be subjected toTriptorelin sustained release(Decapeptyl depot 375 mg one injection) at D-1 of menses then Cyclo-Progynova (estradiol, norgestrel) (Group B). All patients received the same luteal support in the form of intravaginal progesterone two day before embryos transfer until blood pregnancy test was performed 14 days later. The classic Testart slow freezing and rapid thawing protocol was applied on stage-2 PN embryos. Endometrial thickness was measured in the midsagittal plane using transvaginal ultrasound (TVU). Clinical pregnancy was diagnosed by measurement of β-Human Chorionic Gonadotropin level and was confirmed 2-weeks later by TVU.
2431847|NCT03353870||qualitative interview|This study has only one arm
2431848|NCT03353857|Experimental|levonorgestrel|levonorgestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2431849|NCT03353857|Experimental|norethindrone|norethindrone and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2431850|NCT03353857|Experimental|desogestrel|desogestrel and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2431851|NCT03353857|Experimental|dienogest|dienogest and midazolam will be administered on Day 1, Day 15 and Day 26. rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29.
2431852|NCT03353857|Experimental|Drospirenone/ ethinylestradiol|"drospirenone/ethinylestradiol and midazolam will be administered on Day 1, Day 15 and Day 26.~rifampicin (10 mg/day) will be administered on Day 8 to Day 18 and rifampicin (600 mg/day) on Day 19 to Day 29."
2431853|NCT03353844|Experimental|Intradialytic exercise group|These patients will get intradialytic exercise every sessions of hemodiafiltration
2431854|NCT03353844|No Intervention|Standard dialysis group|regular and standard of care in every hemodiafiltration sessions (as usual) without intradialytic exercise.
2431855|NCT03353831|Placebo Comparator|Arm A: Chemotherapy + Bevacizumab + Placebo|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Placebos q14
2431856|NCT03353831|Experimental|Arm B: Chemotherapy + Bevacizumab + Atezolizumab|Chemotherapy: Paclitaxel 80 mg/m² d1, 8, 14, 22 q28 or pegylated liposomal doxorubicin 40 mg/m² q28 + Bevacizumab 10 mg/kg q14 + Atezolizumab 840 mg q14
2431857|NCT03353818|Active Comparator|Golf|In three different golf clubs patients will be introduced how to play golf. They will be taught techniques and recieve basic golf equipment. A total of 1 year membership free membership in the golf clubs will be given.
2431858|NCT03353818|Placebo Comparator|Placebo|No intervention given. No restrictions on physical activity.
2431859|NCT03353792|Active Comparator|CL/AP system|To improved glycemic control and strict avoidance of hypoglycemia via 8-week use of a CL/AP system (closed-loop/artificial pancreas) reverses brain metabolic adaptations in older adult T1DM patients.
2431860|NCT03353792|Placebo Comparator|usual care|Subjects in this control group will continue their usual diabetic care (insulin pump therapy) along with CGM recording.
2431861|NCT03353766|Experimental|Early crossbite correction|Early crossbite correction with Q-H Device
2431862|NCT03353766|No Intervention|Crossbite correction in mixed dentition|Later crossbite correction, during mixed dentition
3188977|NCT00772811|No Intervention|Flu-Mel|Conditioning chemotherapy before infusion of allogeneic stem cells will include fludarabine 30 mg/m2/day for 5 consecutive days (days -6 to -2) and melphalan 100 mg/m2 at day -2.
3188978|NCT00772824|No Intervention|1|10 patients (30 cycles) of chemotherapy will receive placebo
2431866|NCT03353727|Experimental|Orthoptic rehabilitation|
2431867|NCT03353714|Placebo Comparator|Pudendal block with saline|Pudendal block with normal saline
2431868|NCT03353714|Active Comparator|Pudendal block with bupivacaine|Pudendal block with bupivacaine
2431869|NCT03353701|Other|Adults with or without HIV infection|Participants will be asked to stop drinking for at least 30 and up to 90 days. The study will use Contingency Management (CM) with financial incentives to encourage participants to maximally reduce alcohol consumption.
2431870|NCT03353688|Active Comparator|Directional DBS guided by behavior|Directional stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation.
2431871|NCT03353688|Placebo Comparator|Omnidirectional DBS guided by behavior|"Omnidirectional (ring mode) stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by behavioral assessments during device activation."
2431872|NCT03353688|Active Comparator|Directional DBS guided by biomarkers|Directional unilateral subthalamic stimulation with the Boston Scientific Vercise PC IPG with directional DBS lead, guided by electrophysiology biomarkers measured during surgery (nested exploratory treatment arm).
2431873|NCT03353675|Experimental|TG4010/Chemotherapy/Nivolumab|
2431874|NCT03353662||Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years
2431875|NCT03353662||Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6 - 59 months
2431876|NCT03353662||Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years
2431877|NCT03353662||Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between 6 - 59 months
2431878|NCT03353662||Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years
2431880|NCT03353649|Experimental|Binge Eating Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (images of highly palatable foods for obese individuals), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets. Specifically, participants in this sample will be exposed to images of food and control non-food images. In different trials, subjects will be given a now cue instructing them to engage with the immediate hedonic properties of the stimulus or a later cue instructing them to imagine the long-term consequences of using the stimulus.~This arm includes fMRI and the now vs. later cue intervention"
2431881|NCT03353649|Experimental|Smoking Group|"(1) exposing subjects to specific stimulus sets relevant to the sample that may promote engagement of appetitive drives (tobacco-related images or smokers), and (2) exposing them to an instructional manipulation designed to engage self-regulatory processes in the presence of these stimulus sets.~A similar approach to the Binge Eating sample will be used for the smoking sample using two stimulus sets. Instead of foods and non-food control images, smokers will see smoking-related images and the same control non-food non-smoking images as the Binge Eating sample.~This Arm includes fMRI and the now vs. later cue intervention"
2431882|NCT03353636|Experimental|Natural Calm Magnesium|150mg elemental magnesium in a single oral dose
2431883|NCT03353636|Active Comparator|Magnesium Bis-glycinate|150mg elemental magnesium in a single oral dose
2431884|NCT03353636|Active Comparator|MAGSmart|150mg elemental magnesium in a single oral dose
2431885|NCT03353636|Active Comparator|Magnesium citrate|150mg elemental magnesium in a single oral dose
2431886|NCT03353636|Placebo Comparator|Placebo|
2431887|NCT03353623|Experimental|ISG-Group (Immediate Serious Game)|Children in the ISG-Group first participated in the VR-assisted rehabilitation, which consisted in 8 sessions with immersive virtual environment and wearable haptic devices, and were then crossed over and followed during an intended duration of 6 hours of conventional therapy.
2431888|NCT03353623|Experimental|DSG-Group (Delayed Serious Game)|Children from DSG-Group were followed during an intended duration of 6 hours of conventional therapy before receiving VR-assisted rehabilitation with immersive virtual environment and wearable haptic devices.
2431889|NCT03353610||Patient-reported PSVT.|Participants who recorded a PSVT diagnosis.
2431890|NCT03353610||Suspected PSVT.|Participants who do not record a PSVT diagnosis.
2431891|NCT03353610||Other subgroups.|Subgroups also may be examined ( PSVT-episode characteristics, use of a self-management technique for PSVT at home (on their own) to return heart rate back to normal).The sample size, however, may limit the extent of any subgroup analyses.
2431892|NCT03353597|Experimental|Plasma Transfusion|Plasma Transfusions with 2 units of plasma per dose, for a total of 6 doses
2431893|NCT03353584|No Intervention|Standard Care|Participants receive standard care treatment for their vaso-occlusive crisis. Participants will be randomized by age.
2431894|NCT03353584|Active Comparator|Virtual Reality|Participants receive standard care treatment for their vaso-occlusive crisis. In addition, they will have a 15-minute Virtual Reality Therapy session. Participants will be randomized by age.
2431895|NCT03353571|Other|C3 PATIENT PARTICIPANTS|This single arm prospective study is designed to produce valid scientific evidence regarding safety and efficacy of the C3 in establishing urinary drainage and allowing the control of micturition when indwelling for up to 7 days in patients. The total study population will initially include 50 subjects with open enrollment of additional subjects.
2431896|NCT03353558||Study Group (CML group)|"This group will be CML patients. In this group each participant will be asked to wear a watch Actigraph for one week.~He will be asked to fill the appropriate questionnaires, and a daily sleep diary."
2431897|NCT03353558||Control Group|"The control group will be non-CML patients, also without any known malignancy or known sleep disturbances.~They will be asked to wear the watch Actigraph for one week, and to fill the appropriate questionnaires and a daily sleep diary."
2431898|NCT03353532||Cohort|Adult patients with SSI after any surgical procedure.
2431899|NCT03353532||Case-Control|"Cases: Patients establishing S. aureus SSI Controls: Patients from the same center who did not undergo S. aureus SSI, matched by the following criteria~Type of procedure~Age~ASA score~BMI~Duration of procedure (as percentile for this procedure)~Diabetes~Sex"
2431900|NCT03353519|Experimental|Primary care model|The new model of care incorporates a multi-factorial package of service aimed at providing a review of patient needs, facilitated self-management of longer-term stroke care needs for survivors and their carers, optimised communication between patients and health and social care services, optimised communication between the different care services, and increased awareness of and access to national and local community and charity provided services.
2431901|NCT03353519|No Intervention|Usual care|The control arm will consist of the usual care currently provided for stroke survivors registered with each general practice.
2431902|NCT03353506|Active Comparator|LFMT|Lyophilized fecal microbiota transplant capsules
2431903|NCT03353506|Experimental|LSFF|Lyophilized sterile fecal filtrate capsules
2431904|NCT03353493|Experimental|MBCT + TAU|Mindfulness-based Cognitive Therapy (MBCT) a 8 week group based intervention delivered according to the protocol by Segal, Williams and Teasdale (2013) plus treatment as usual (TAU) . TAU is restricted to antidepressant medication and no psychological therapy.
2431905|NCT03353493|Other|TAU|Treatment as Usual (TAU). TAU is restricted to antidepressant medication and no psychological therapy.
2431906|NCT03353480|Other|Reference|250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US
2431907|NCT03353480|Experimental|Experimental|250mg Azithromycin tablet manufactured at Pfizer Dalian, China
2431908|NCT03353467|Experimental|Group in endoscopic surgery|Stage I patients were only treated with endoscopic surgery without additional chemotherapy. Endoscopic nasopharyngectomy included endoscopic resection , with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
2431909|NCT03353467|Active Comparator|Group in IMRT|Stage I patients were only treated with radical intensity-modulated radiotherapy without additional chemotherapy. IMRT was delivered with a dynamic multileaf intensity-modulating collimator (NOMOS, Sewickley, PA) by a slice-by-slice arc rotation approach.
2431910|NCT03353454|Experimental|Maralixibat (SHP625)|Participants will be randomized to Maralixibat oral solution (up to 600 microgram per kilogram [mcg/kg]) orally twice daily for 26 weeks.
2432107|NCT03352167||ED Slagelse|
2431912|NCT03353441|Active Comparator|Glycine (MSG)|Microencapsulated Sublingual Glycine (MSG): 1 tablet prior to TSST; 1 tablet after the TSST
2431913|NCT03353441|Placebo Comparator|Placebo|Lactose: 1 tablet prior to TSST; 1 tablet after the TSST
2431914|NCT03353441|No Intervention|No treatment|
2431915|NCT03353428|Experimental|LC-CTLs|Autologous lung cancer specific cytotoxic lymphocytes
2431916|NCT03353415|Experimental|CGM Use|Each participant will wear the DexCom continuous glucose monitor for four weeks. During the first two weeks, participants will not be able to read the sensor glucose levels. In the second two weeks, participants will be able to read the sensor glucose levels. Frequency of hypoglycemia will be compared between the two phases of the study.
2431917|NCT03353402|Experimental|Fecal Microbiota Transplant (FMT)|FMT includes a colonoscopy conducted by a gastroenterologist followed by stool capsules which will be swallowed by the patient.
2431918|NCT03353389||No AKI|Adult admissions without Acute Kidney Injury during their stay
2431919|NCT03353389||CA-AKI|Adult admissions with Acute Kidney Injury diagnosed within 48 hours during their stay (Community-acquired Acute Kidney Injury)
2431920|NCT03353389||HA-AKI|Adult admissions with Acute Kidney Injury diagnosed after 48 hours during their stay (Hospital-acquired Acute Kidney Injury)
2431921|NCT03353376|Experimental|group care with empowerment model|4 group visits a year according to empowerment model in a tertiary diabetes clinic
2431922|NCT03353376|Active Comparator|individual usual care|individual visits according to disponibility in the diabetes clinic and needs of the patients
2431923|NCT03353363|Placebo Comparator|Normal Saline|Subject will receive 20ml of normal saline infiltration
2431924|NCT03353363|Experimental|Plain Bupivacaine|Subject will receive 20ml of 0.5% plain bupivacaine infiltration (100mg)
2431925|NCT03353363|Experimental|Liposomal Bupivacaine|Subject will receive 20ml of liposomal bupivacaine infiltration (266mg) non-expanded
2431926|NCT03353350|Experimental|Efpeglenatide low dose|Efpeglenatide low dose (Prefilled syringe) administered once weekly for 56 weeks
2431927|NCT03353350|Experimental|Efpeglenatide middle dose|Efpeglenatide middle dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
2431928|NCT03353350|Experimental|Efpeglenatide high dose|Efpeglenatide high dose (Prefilled syringe) administered once weekly for 56 weeks (including titration period)
2431929|NCT03353350|Placebo Comparator|Placebo|Matching placebo (Prefilled syringe) administered once weekly for 56 weeks
2431930|NCT03353337|Experimental|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 month.
2431931|NCT03353337|Placebo Comparator|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
2431932|NCT03353324|Active Comparator|intravitreal injection of bevacizumab|
2431933|NCT03353324|Active Comparator|intravitreal injection of bevacizumab+ targeted laser|Intervention intravitreal bevacizumab injection + targeted laser photocoagulation of retinal non perfused areas
2431934|NCT03353311||Enhanced Recovery After Surgery|"Patients undergoing elective colorectal surgical resection for benign/malignant disease.~A multidisciplinary validated approach based on 24 items including Preadmission information, education and counselling Preoperative optimization (increasing exercise, stop smoking and alcohol consumption should 4 weeks before surgery) No preoperative bowel preparation Use of preoperative carbohydrate drinks Pre-anesthetic medication Prophylaxis against thromboembolism Antimicrobial prophylaxis and skin preparation Standard anesthetic protocol for rapid awakening PONV Mini-invasive surgery No nasogastric dreinage Prevention of intraoperative hypothermia Perioperative fluid management No drains in the peritoneal cavity after colonic anastomosis Early remouval of urinary drainage (24-48 hrs) Prevention of postoperative ileus (including use of postoperative laxatives) Postoperative analgesia Perioperative nutritional care Postoperative control of glucose Early mobilization Auditing"
2431935|NCT03353298|Active Comparator|Arm A|Allopurinol 300 mg
2431936|NCT03353298|Placebo Comparator|Arm B|Placebo Oral tablets
2431937|NCT03353285||Group I|Group I= egg retrieved in the follicular fluid of the first aspirate (no flushing)
2431938|NCT03353285||Group II|Group II= egg retrieved in the 1st-2nd flush
2431939|NCT03353285||Group III|Group III= egg retrieved in the 3rd-5th flush
2431940|NCT03353272|No Intervention|Impairment Based Treatment|an impairment-based conservative intervention that has been created by compiling the evidence associated with established, effective treatment interventions for rotator cuff related shoulder pain.
2431941|NCT03353272|Experimental|Impairment Based Treatment PLUS PEERC|Participants assigned to the impairment-based care plus PEERC condition will also receive the PEERC protocol. This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
3187778|NCT00759928|Experimental|Erlotinib/Sorafenib|Patients will receive erlotinib 150 mg once daily by mouth and sorafenib 400 mg twice daily by mouth. The study will begin with a 2-week run-in period (which will begin on Day 14 of the study, and continue through Day 1 of the study), in which erlotinib will be dosed alone at 150 mg once daily. Patients will continue taking erlotinib as a single agent at 150 mg once daily through Day 1. After the 2-week run-in period, patients will receive continuous dosing of both agents (erlotinib 150 mg once daily and sorafenib 400 mg twice daily) in cycles of 28 days each. Toxicity will be assessed every cycle (every 4 weeks) for all patients. Because this is not an efficacy study, restaging tumor measurements will be at the discretion of the physician every 8 weeks during treatment. Patients with objective response or stable disease will continue therapy; patients with disease progression or unacceptable toxicity will be discontinued from the study.
3187779|NCT00759980||Platelet Number|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to the total number of platelets
3187780|NCT00759980||Platelet Mass|Infants randomized to this group will be transfused based on a specific set of transfusion guidelines pertaining to a combination of platelet number and platelet size (mass)
3187781|NCT00759993|Experimental|A,1|chromium piccolinate 1000mg
2432108|NCT03352167||ED Koege|
3187782|NCT00759993|Placebo Comparator|A,2|matching placebo
3187783|NCT00760032|Experimental|Active|Ciprofloxacin
3187784|NCT00760032|Placebo Comparator|Placebo|Placebo
3187785|NCT00760045|Experimental|1|AL-43546 0.15%
2431950|NCT03353207||health Control|"No family history of RBD;~Age- and sex- matched with isolated RSWA subjects~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2431951|NCT03353207||Case with isolated RSWA|"First degree relatives of patients with iRBD;~Age 45 years or above;~Absence of dream enactment behaviors;~A total score on REM Sleep Behavior Questionnaire (RBDQ-HK) less than 19, which is the cut-off suggestive of a diagnosis of RBD;~Presence of RSWA as measured by v-PSG; RSWA is defined as the percentage of increased EMG activity (phasic or tonic) at least 10% during REM sleep for any channel.~for those individuals with moderate to severe obstructive sleep apnea (apnea-hypopnea index, AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2431952|NCT03353207||Case without isolated RSWA|"First degree relatives of patients with iRBD;~Age- and sex- matched with isolated RSWA subjects;~Absence of dream enactment behaviors;~A score of RBDQ-HK less than 19;~Absence of RSWA as measured by v-PSG;~for those individuals with moderate obstructive sleep apnea (AHI > 15/hour), effective CPAP treatment should be documented and a second night of V-PSG is required to determine RSWA."
2431953|NCT03353181|Experimental|Endoscopic scissors|Endoscopic nasobiliary drainage for malignant hilar biliary strictures at first， and application of endoscopic cutting technique followed.
2431954|NCT03353181|Active Comparator|Stent|Standard placement of biliary stent for malignant hilar biliary strictures.
2431955|NCT03353155|Active Comparator|Usual Care|Telephone and/or home visits at 1 week, and thereafter, monthly for 6 months, to check on medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges by the relevant service departments as recommended by the discharging physician.
2431956|NCT03353155|Active Comparator|CareHub|Telephone follow-up by a nurse care coordinator acting as single point of contact for medication compliance and/or medical social problems and/or physical therapy needs and/or health-related financial challenges based on automatic enrollment using ACE score cut-off at admission.
2431957|NCT03353142|Experimental|Equal Breathing|
2431958|NCT03353116|Active Comparator|maxilla first group|the maxillary osteotomy is going to be done and fixed first
2431959|NCT03353116|Experimental|mandible first group|the mandibular osteotomy is going to be done and fixed first
2431960|NCT03353103|Active Comparator|symptomatic|
2431961|NCT03353103|Active Comparator|asymptomatic|
2431962|NCT03353077|Experimental|Alpha DaRT|Alpha DaRT Seeds, Diffusing alpha-emitters Radiation Therapy.
2431963|NCT03353064|Active Comparator|Vivify + EMS|This arm will have the Telemedicine kits and get scheduled EMS home visits. The subjects will complete daily biometrics / surveys / care plans through the telemedicine kit, as specified in the activity schedule Apart from the tablet device, EMS home visits will be scheduled on Day 7, Day 21 and Day 42 from discharge. During these home visits, the EM personnel will perform a check of the NIV/NIPPV device. They are able to adjust pressures according to your Pulmonologist / Sleep doctor's prescription, and troubleshoot any issues with the mask, the humidifier, etc. They will also measure End-tidal CO2 via nasal cannula.
2431964|NCT03353064|Active Comparator|Vivify Only|"This group will receive the telemedicine tablet and kit, with the same protocol as defined above.~No EMS home visits will be set up"
2431965|NCT03353051||Group A: other - observational study|neonates ≥2000-<2500g and born with a gestation age <37 weeks.
2431966|NCT03353051||Group B: other- observational study|Group B will contain neonates >2500g and born with a gestation age <37 weeks.
2431967|NCT03353051||Group C: other - observational study|Group C will contain neonates ≥2000-<2500g but with a gestation age >37 weeks.
2431968|NCT03353051||Group D1:other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 30-48hrs.
2431969|NCT03353051||Group D2: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 42-60hrs
2431970|NCT03353051||Group D3: other - observational study|Neonate >2500g and born with a gestation age >37 weeks. These neonates will donate blood at 6-24hrs and at 144-192hrs.
2431971|NCT03353038|Active Comparator|Off-The-Shelf Pillbox vs 3D Printed Pillbox|Participants in the study were pillbox users at baseline. Participants described their experiences and preferences with their own pillbox. Then participants will be given a 3D printed pillbox. Researchers will compare participants' experiences and preferences between their off-the-shelf pillbox used at baseline and the customized 3D printed pillbox delivered to participants as part of the study.
2431972|NCT03353025|Experimental|transsphenoidal surgery treatment|Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
2431973|NCT03353025|Experimental|dopamine agonist treatment|Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
2431974|NCT03353012|Experimental|Levonorgestrel immediate post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 48-72 hr after child delivery
2431975|NCT03353012|Experimental|Etonogestrel immediate post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 48-72 hr after child delivery
2431976|NCT03353012|Active Comparator|Levonorgestrel delayed post-partum|Breast-feeding postpartum woman who receive Levonorgestrel drug implant (75 mg) between 5-7 weeks after child delivery
2431977|NCT03353012|Active Comparator|Etonogestrel delayed post-partum|Breast-feeding postpartum woman who receive Etonogestrel drug implant (68 mg) between 5-7 weeks after child delivery
2431978|NCT03352999|Other|ROHCA rescued by vaECMO|Patients experiencing a ROHCA despite advanced CPR and finally rescued with a va ECMO device.
2431979|NCT03352986||osteonecrosis|Sickle cell patients with osteonecrosis as a vascular main complication
3187786|NCT00760045|Experimental|2|AL-43546 0.25%
3187787|NCT00760045|Active Comparator|3|AL-43546 0%(Vehicle)
3187788|NCT00760045|Active Comparator|4|0.1% sodium hyaluronate ophthalmic solutio
3187789|NCT00760058|Experimental|1|AcrySof® IQ intraocular lens
2431981|NCT03352986||microalbuminuria|Sickle cell patients with microalbuminuria as a vascular main complication
2431982|NCT03352986||pulmonary hypertension|Sickle cell patients with pulmonary hypertension as a vascular main complication
2431983|NCT03352986||stroke|Sickle cell patients with strocke as a vascular main complication
2431984|NCT03352986||priapism|Sickle cell patients with priapism as a vascular main complication
2431985|NCT03352973|Experimental|active tDCS on the dlPFC|tDCS on the DLPFC Dorsolateral prefrontal cortex (DLPFC) target will be identified by the baseline functional magnetic resonance imaging (fMRI) study for regulation of craving using a separate sample. During the intervention, each participant will receive an active transcranial direct current stimulation (tDCS) intervention on this DLPFC region (1.5 mA for 20 minutes).
2431986|NCT03352973|Sham Comparator|sham tDCS on the dlPFC|Each participant will also receive a sham tDCS intervention as a controlled condition. The sham tDCS only include a 30-s ramp up and a 30-s ramp down.
2431987|NCT03352947|Active Comparator|Continuous (Standard)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-28 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-28 of a 28 day cycle
2431988|NCT03352947|Experimental|Intermittent (experimental)|Dabrafenib 150mg twice daily 12 hours apart, on days 1-21 of a 28 day cycle plus Trametinib 2mg once daily, on days 1-14 of a 28 day cycle
2431989|NCT03352934|Experimental|Avelumab|10 mg/kg Avelumab every 2 weeks
2431990|NCT03352921|Experimental|clinical pilates exercises|The experimental group will receive clinical pilates exercise training in group form for 3 weeks a week for 8 weeks. The training will be done 40-50 minutes per one day. The exercise session will be started with a 10 minute warming program, 30 minutes with the core stabilization training and the clinical pilates exercises with the postural alignment exercises will be applied and the exercise session will be ended with the 10 minutes cooling period.
2431991|NCT03352921|Active Comparator|Home exercises program|For 8 weeks the member in comparison group will be ask to do the exercise program 3 days a week at home. This group will receive a program of stretching, strengthening, and posture exercises. All the exercises in the program will be illustrated on a descriptive form with images. In terms of the follow-up during 8-week duration, the individuals will be called frequently and in the interview by the end of the study.
2431992|NCT03352908||YSP|The Yale Swallow Protocol (YSP) consists of a brief cognitive screen, a brief oral motor exam, and a 3oz water challenge (subjects instructed to drink 3oz of water without stopping). Pass/fail is determined based on the subjects ability to drink the 3oz of water uninterrupted without immediate cough.
2431993|NCT03352908||FEES|Flexible Endoscopic Evaluation of Swallowing (FEES) uses a flexible endoscope that will be passed transnasally into the pharynx by a speech pathologist specializing in dysphagia management. FEES will be treated as a placebo comparator.
2431994|NCT03352895|Placebo Comparator|control|Control group will receive placebo medication therapy
2431995|NCT03352895|Experimental|test group|resveratrol group will receive oral resveratrol (100 mg per day)
3187790|NCT00760058|Active Comparator|2|Tecnis® Aspheric intraocular lens
2431997|NCT03352869|Experimental|Exenatide|Drug: Byetta Generic name: Exenatide Dosage form: 5ug and 10ug Dosage: 10-20ug/day Frequency: twice a day Duration: 3 months
2431998|NCT03352869|Active Comparator|Metformin|Drug: Glucophage Generic name: Metformin Dosage form: 500mg Dosage: 1500-2000mg/day Frequency: 500mg three times a day/1000mg twice a day Duration: 3 months
2431999|NCT03352869|Experimental|Combination|Drug: Byetta and Glucophage Generic name: Exenatide Dosage form: Exenatide 5ug and 10ug; Metformin 500mg Dosage: Exenatide10-20ug/day; Metformin 1500-2000mg/day Frequency: Exenatide twice a day; Metformin 500mg three times a day/1000mg twice a day Duration: 3 months
2432000|NCT03352856|Active Comparator|Active|Highly purified barley starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
2432001|NCT03352856|Placebo Comparator|Placebo|Maize starch packed in sachets; Increasing doses given at clinic as follows: 0.6 g, 2 g, 6 g and 18 g. If required, continued at home with 2 x 18 g daily for 5 days.
2432002|NCT03352843|Experimental|Single arm|
2432003|NCT03352830|No Intervention|Control|All individuals in each arm will receive a new LPG cookstove. The control arm will receive an orientation for safe operation of the new LPG stove. Participants in the control arm will, however, receive no other intervention.
2432004|NCT03352830|Experimental|No Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
2432005|NCT03352830|Experimental|Delivery, No Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand.
2432006|NCT03352830|Experimental|Agent Delivery, Educational Intervention|All individuals in each arm will receive a new LPG cookstove. This intervention arm receives free direct delivery of their LPG cylinder refills upon demand. Participants in this arm also receive a health promotion intervention based on the Risks, Attitudes, Norms, Ability, and Self-Regulation (RANAS) model.
2432007|NCT03352817||Patients in cardiac rehabilitation|Eligible patients must have reached the age of majority, participate in a CR program at one of the centers cited, and agreed to respond to the study questionnaire voluntarily
2432008|NCT03352804||Patients hospitalized in internal medicine ward|Patients included are patients hospitalized in internal medicine ward.
2432009|NCT03352791|Active Comparator|DSM-H Hospice Edition|training, assigning of champions to serve as mentors and performance improvement leads, and workflow changes including caregiver education pamphlets, interdisciplinary care plans, treatment algorithms, and assessment instruments.
2432010|NCT03352791|Active Comparator|Control Arm|Usual Care
3187791|NCT00760058|Active Comparator|3|Akreos® MI60 intraocular lens
3187792|NCT00760071||1CF-patients<6|Patients with diagnoses of cystic fibrosis from birth to the age of 6 years
3187793|NCT00760071||2 controls|age matched controls
3187794|NCT00760097|Experimental|AtCDS|Transcranial direct stimulation
3187795|NCT00760110||1 Morning hypertension and normotension|Based on HBP, subjects were divided into MH and MN patients
3187796|NCT00760110||2 Clinic hypertension and normotension|Based on CBP, subjects were divided into CH and CN patients
3188979|NCT00772824|Active Comparator|2|Intravenous glutamine
2432014|NCT03352752|Experimental|Possess HTC Vive before the operation|The experimental group was wearing VR helmet before operation, and the immersion experience was selected from the video content library pre-selected. After 3 minutes of the VR experience, the surgeon started the fractional laser operation (Notify the patient). The operating area is continuous 10 maximum square spot areas.The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
2432015|NCT03352752|Experimental|Without HTC Vive before the operation|The control group was wearing a blindfold before operation. The operating area is continuous 10 maximum square spot areas. The parameters for the DEEP FX mode:35mj, 5% density, 300Hz.
2432016|NCT03352739|Experimental|DBS of the fornix, power on|
2432017|NCT03352739|Experimental|DBS of the NbM, power on|
2432018|NCT03352739|Sham Comparator|DBS of the fornix, power off|
2432019|NCT03352739|Sham Comparator|DBS of the NbM, power off|
2432020|NCT03352739|No Intervention|Control group|The patients are going to prescribe stable dosage of donepezil during observation period without surgical interference.
2432021|NCT03352726|Experimental|DBV712 Solution for Skin Prick Test|DBV712 In-House Reference Skin Prick Test preparation
3187797|NCT00760123|Experimental|1|Early Physical Therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
2432023|NCT03352700|Placebo Comparator|3L PEG|only used 3L PEG
2432024|NCT03352700|Experimental|3L PEG+Dyclonine Hydrochloride Mucilage|used 3L PEG+Dyclonine Hydrochloride Mucilage
2432025|NCT03352687|Experimental|Anterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by anterior route
2432026|NCT03352687|Experimental|Posterior SSAX|patients receiving suprascapular and axillary nerve block (SSAX) whose approach to the SS nerve is performed by posterior route
2432027|NCT03352674|Experimental|Insulin Glargine Ezelin|Drug product Insulin Glargine, Ezelin 100 U/mL (PT Kalbe Farma, Tbk)
2432028|NCT03352674|Active Comparator|Insulin Glargine Lantus|Insulin Glargine Pen Injector [Lantus]
2432029|NCT03352661||Endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
2432030|NCT03352661||No endometriosis|No drugs are administered. It is an observational study. Collect retrospectively data
2432031|NCT03352635||Native Hawaiians|One parent of Hawaiian descent.
2432032|NCT03352635||Japanese Americans|Two parents of Japanese descent.
2432033|NCT03352635||Non-Hispanic Whites|Two parents of non-Hispanic white descent.
2432034|NCT03352622|Active Comparator|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness
2432035|NCT03352622|Active Comparator|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
2432038|NCT03352596|Experimental|intervention group|Eight weeks of low fructose diet with a maximum of 12 g of fructose
2432039|NCT03352596|No Intervention|control group|Eight weeks of regular diabetic diet with a 15%pro 30%fat 55%CHO
2432040|NCT03352583|Active Comparator|Day|Group receives casein protein during the day (greater than 6 hours before bed).
2432041|NCT03352583|Experimental|Night|Group receives casein protein immediately before going to bed.
2432042|NCT03352570|Experimental|COLOVAC device|colorectal surgery performed per standard of care with deployment of the Colovac device to protect the anastomosis site
2432043|NCT03352557|Experimental|Low-dose BIIB092|Intravenous (IV) infusion once every 4 weeks OR once every 12 weeks and placebo at the other 4-week dosing visits to maintain the treatment blind.
2432044|NCT03352557|Experimental|Medium-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
2432045|NCT03352557|Experimental|High-dose BIIB092|Intravenous (IV) infusion once every 4 weeks.
2432046|NCT03352557|Placebo Comparator|Placebo|Intravenous (IV) infusion once every 4 weeks.
2432047|NCT03352544|Experimental|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week).
2432048|NCT03352544|No Intervention|Usual treatment|Usual treatment during 12 weeks, coinciding with exercise intervention time frame.
2432049|NCT03352531|Experimental|AK-105|Single-arm
2432050|NCT03352518|Experimental|IMD data collection|Subjects will intensively collect spectral raman data in a home-based setting for 5 days using WM3.4NR and comparators.
2432051|NCT03352505||control|healthy walking control participants
2432052|NCT03352505||wheelchair dancer|wheelchair users, who are performing wheelchair dancing
2432053|NCT03352505||wheelchair marathon participants|wheelchair users, who are participants in wheelchair/ handbike Marathon competitions
2432054|NCT03352505||sedentary wheelchair patients|wheelchair users, who conduct exercise bouts less than 2 times per month
2432055|NCT03352492|Experimental|Bilateral iridotomy: Superior|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
2432056|NCT03352492|Experimental|Bilateral iridotomy: Temporal|Each subject in this single-arm study undergoes bilateral laser peripheral iridotomy surgery. Each participant will undergo superior laser peripheral iridotomy in one eye and temporal laser peripheral iridotomy in the fellow eye.
2432057|NCT03352479|Other|Opioids Prescribed|Each participant in the study will be given an envelope for return of unused opioids. The percentage of returned number of opioids will be calculated based on the number prescribed
2432058|NCT03352466|Experimental|NasoShield very low dose|Single intranasal spray (Part A)
2432059|NCT03352466|Experimental|NasoShield low dose|Single intranasal spray (Part A)
2432060|NCT03352466|Experimental|NasoShield medium dose|Single intranasal spray (Part A)
2432061|NCT03352466|Experimental|NasoShield high dose|Single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
2432143|NCT03351894|Placebo Comparator|Conventional|Conventional phacoemulsification surgery
2432062|NCT03352466|Placebo Comparator|Placebo|Normal saline, single intranasal spray (Part A) or two intranasal sprays 21 days apart (Part B)
2432063|NCT03352466|Active Comparator|BioThrax|Three intramuscular injections 15 days apart (Part A)
3187798|NCT00760123|Other|2|Educational Strategy: instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors, etc.
3187799|NCT00760149|Placebo Comparator|1|50 patients, treated with the standard anti-TB regimen, including rifampicin (600 mg), isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 2 placebo tablets resembling rifampicin 300 mg.
2432066|NCT03352440|Experimental|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
2432067|NCT03352440|Experimental|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
2432068|NCT03352440|Active Comparator|Control Group - Kinect|Group with typical development that will perform the task on Kinect
2432069|NCT03352440|Active Comparator|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
3187800|NCT00760149|Active Comparator|2|50 patients, treated with rifampicin (900 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment. In addition they will receive 1 placebo tablet resembling rifampicin 300 mg.
3187801|NCT00760149|Active Comparator|3|50 patients, treated with rifampicin (1200 mg), and the other drugs in standard dosages (isoniazid (300 mg), pyrazinamide (30 mg/kg), ethambutol (15 mg/kg)), administered daily, orally, during the intensive phase of TB treatment.
3187802|NCT00760162||HSCB, Brooklyn, NY|State University of New York Brooklyn, NY 11203
2432073|NCT03352388|Experimental|Snack|Dairy- and berry-based snacks
2432074|NCT03352388|No Intervention|Reference|No snacks
2432075|NCT03352375|Active Comparator|Orotracheally Intubation|Intervention:orotracheally intubation
2432076|NCT03352375|Active Comparator|Laryngeal Mask Airway|Intervention: Laryngeal Mask Airway
2432077|NCT03352362|Experimental|caldolor|intravenous caldolor injection during intraoperative period
2432078|NCT03352362|Active Comparator|denogan|intravenous denogan injection during intraoperative period
2432079|NCT03352362|Experimental|combination|intravenous denogan and caldolor injection during intraoperative period
2432080|NCT03352349|Experimental|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
3187803|NCT00760162||2. Nephrology Associates,|Scarborough, ON CANADA, LI H IC5
2432082|NCT03352310|Experimental|Study Group|autologous UCB transfusion
2432083|NCT03352310|Other|Control Group|standard care
2432084|NCT03352284|Experimental|Straumann Pure Ceramic Implant|Replacement of single tooth gaps with a Zirconia implant
2432085|NCT03352271|Experimental|Individualized Incremental hemodialysis|ESRD patients starting an individualized (twice/week, once/week, once/10 days or less frequent) incremental hemodialysis program.
2432086|NCT03352271|Active Comparator|Thrice weekly dialysis|ESRD patients initiating a conventional thrice weekly hemodialysis program
2432087|NCT03352258|No Intervention|Observation|Subjects in this arm will only be followed and not treated (observational arm)
2432088|NCT03352258|Experimental|Treatment arm|Subjects will receive a low dose brain radiotherapy
2432093|NCT03352219|Experimental|Reality Check|Received streamed 13-episode HIV risk reduction serial drama, Reality Check, developed based on Social Cognitive Theory integrated with findings from focus groups and community advisory boards. Each character has a behavioral trajectory related to HIV. For example, one character modeled negotiating condom use with his partner when she was against it. Messages in the serial drama showed that the characters had normative support for HIV testing and condom use. One character modeled a mastery experience when she overcame her fear and got tested for HIV. Homophobia is addressed when a mother discovers that her son is gay. Over the course of the episodes, the interweaving storylines play out, with all the characters eventually achieving their positive goals.
2432094|NCT03352219|Placebo Comparator|Physical Activity Attention Control|Received streamed physical activity promotion videos designed to control for Hawthorne effects, including special attention, consisting of a series of 13 videos from YouTube on physical activity and exercise. The videos, selected to be appropriate for African Americans 18 to 24 years of age, were tailored to be gender specific and hence varied between men and women. The videos focused on the importance of physical activity, coping strategies for lack of motivation to engage in physical activity, and other challenges faced in becoming more physically active, provided specific knowledge and skills regarding how to engage in aerobic and muscle-strengthening exercises, and model aerobic and muscle-strengthening exercises in a variety of settings.
2432095|NCT03352206||2-Drug Treated Communities|"Communities who were treated with diethylcarbamazine and albendazole (DA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
2432096|NCT03352206||3-Drug Treated Communities|"Communities who were treated with ivermectin, diethylcarbamazine and albendazole (IDA) mass drug administration during the safety study entitled Community Based Safety Study of 2-drug (DA) versus 3-drug (IDA) Therapy for Lymphatic Filariasis."
2432097|NCT03352193||SOTI group|Wheat spaghetti
2432098|NCT03352193||Historical control group|No intervention
2432099|NCT03352180|Active Comparator|subscapularis tendon repair|arthroscopic reapir of subscapularis tendon
2432100|NCT03352180|Active Comparator|subscapularis tendon debridement|arthroscopic debredement of subscapularis tendon
2432101|NCT03352167||ED Hjoerring|
2432102|NCT03352167||ED Aalborg|
2432103|NCT03352167||ED Aarhus|
2432109|NCT03352154|Experimental|patients with unilateral cochlear implants submitted to P300|Patients with unilateral cochlear implants, using the speech processor at least 6 months, submitted to P300 exam before CI surgery, on speech processor activation and after 06 months.
2432110|NCT03352141|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced along the jawline with Cryolipolysis.
2432111|NCT03352128|Experimental|Creatine supplementation|7-day creatine supplementation
2432112|NCT03352128|Placebo Comparator|Placebo supplementation|7-day calcium lactate supplementation
2432113|NCT03352115|Experimental|Steroid group|Will recieve 5 day course of oral prednisolone post-operatively
2432114|NCT03352115|Placebo Comparator|Control|Will receive placebo syrup for 5 days post-operatively
2432115|NCT03352102|Experimental|Diaphragm Group (DG)|"subjects who received conventional physical therapy once a day, plus a daily session of electrical stimulation in the diaphragm.~Intervention: Electrical stimulation of the diaphragm."
2432116|NCT03352102|Active Comparator|Quadriceps Group (QG)|"subjects who also received conventional physical therapy once a day, plus a daily session of electrical stimulation in the quadriceps.~Intervention: Electrical stimulation of the quadriceps."
2432117|NCT03352102|No Intervention|Control Group (CG)|subjects who received regular treatment, i.e., conventional physical therapy, which included gross motor therapy and respiratory therapy twice a day every day, including weekend, during their stay in the ICU.
2432118|NCT03352089||Aortic stenosis group|Patients with severe aortic stenosis >70 years of age referred for aortic valve intervention
2432119|NCT03352089||Healthy volunteer group|Patients with no history of symptoms to suggest current cardiovascular disease >70 years of age
2432120|NCT03352076|Active Comparator|Oral Danatrol|200 mg orally TDS (600 mg daily) for 5-7 days
2432121|NCT03352076|Experimental|Vaginal Danazol|100 mg of Danazol Cream to be applied vaginally for 5-7 days on a single daily dose
2432122|NCT03352063|Active Comparator|Sitting with Exercise|Subjects will complete a short term training protocol while sitting >11 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
2432123|NCT03352063|Active Comparator|Walking with exercise|Subjects will complete a short term training protocol while sitting <5 hours per day. This training will be preceded by a VO2max test to aid in setting the correct intensity for training. Subjects will be asked to complete three high fat tolerance tests. One to establish a baseline, the second to determine the acute effects of training, and a third at the completion of training to determine the cumulative effect of exercise training.
2432124|NCT03352050|Active Comparator|ground beef|ground beef instead of mushrooms
2432125|NCT03352050|Active Comparator|Mushroom|2 servings of mushrooms
2432126|NCT03352037|Other|Single Arm|In this project, there is only one study group which comprises of patients with pancreatic cystic neoplasms who will undergo pancreatic PET/MRI.
2432127|NCT03352024|Other|Standard Care|Relational care used to help the patient by reducing the fear and anxiety
2432128|NCT03352024|Other|Hypnosis|Hypno-analgesia is used to help the patient by reducing the fear and anxiety
2432129|NCT03352011|Experimental|Primary Care Brief Mindfulness Training|
2432130|NCT03352011|Active Comparator|PTSD Psychoeducational Class|
2432131|NCT03351998|Placebo Comparator|Placebo|Participants receiving matching placebo oral tablet.
2432132|NCT03351998|Active Comparator|Low dose statin|Participants will receive Lipitor 20Mg Tablet to take daily.
2432133|NCT03351998|Active Comparator|High dose statin|Participants will receive Lipitor 80Mg Tablet to take daily.
2432134|NCT03351985||Delirium Group|The cardiac surgery patients with delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
2432135|NCT03351985||Non-delirium Group|The cardiac surgery patients without delirium receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
2432136|NCT03351972|Active Comparator|Bowel Prep routine|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the routine guidance of taking the contents the day before their capsule endoscopy
2432137|NCT03351972|Active Comparator|Bowel Prep Split|Participants randomised to this arm will receive their bowel prep (Klean Prep) with the guidance stating to take the first dose the day before the capsule endoscopy and the second dose the morning of the capsule endoscopy
2432138|NCT03351972|Experimental|No bowel prep|Participants randomised to this arm will be advised to drink clear liquids only ahead of their capsule endoscopy procedure
2432139|NCT03351959||ypT0 rectal cancers|Rectal cancer patients who underwent neo-adjuvant treatment followed by surgical resection and had a final pathologic diagnosis of absence of residual viable tumoral cells within the rectal wall specimen (pathologic complete response, pCR - ypT0).
2432140|NCT03351946|Active Comparator|ZEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) until start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan and immediately before start of emergence preoxygenation, this group will have the PEEP exchanged for zero PEEP (ZEEP). ZEEP will remain until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
2432141|NCT03351946|Active Comparator|PEEP at awakening|"Controlled ventilation with tidal volume of 7 mL/kg of ideal body weight and respiratory frequency 10. Fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure (PEEP) is set to 7 or 9 cm H20 (9 if BMI≥25) even after start of emergence preoxygenation.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure.~First CT scan after completion of surgery, before emergence. After the first CT scan, this group will have PEEP remained until the study subjects are extubated. Second CT scan approx. 30 min after extubation."
3187804|NCT00760162||3.New York Harbor VA Medical Center|NYU School of Medicine New York, NY.10010
3187805|NCT00760162||4.Hospital Juarez De Mexico|Madero, Mexico, D.FC.P. 07760
2432144|NCT03351894|Active Comparator|Femtosecond laser|Ziemer femtosecond laser assisted cataract surgery Intervention: Ziemer femtosecond laser assisted cataract surgery
2432145|NCT03351881|Active Comparator|Opt Out|
2432146|NCT03351881|Active Comparator|Opt In|
2432147|NCT03351881|Active Comparator|Opt Neutral|
2432148|NCT03351868|Experimental|Gene-modified autologous stem cells|Autologous hematopoeitic stem cells and mesenchymal stem cells transduced with lentiviral vector carrying the FANCA gene ex vivo
2432149|NCT03351855|Experimental|HPV-CTLs|Autologous or allogenic HPV specific cytotoxic lymphocytes
2432150|NCT03351842|Active Comparator|Arm I|Undergo surgery, followed by observation. Patients receive no further therapy
2432151|NCT03351842|Experimental|Arm II|Undergo surgery, followed by chemotherapy (cis Platinum/Carboplatin, Pemetrexed Disodium). Patients receive chemotherapy comprising cisplatin 75mg/m2 or Carboplatin AUC=5mg/ml/min, and pemetrexed 500mg/m2 in day 1. Treatment continues every 3 weeks for 4 courses.
2432152|NCT03351829|Experimental|Gene-modified autologous stem cells|Autologous stem cells transduced with lentiviral vector carrying the related gene ex vivo
2432153|NCT03351816|Experimental|Cardioversion group|Patients with persistent atrial fibrillation who are oriented for cardioversion in the course of routine care.
2432154|NCT03351816|Experimental|Ablation group|Patients with persistent or paroxystic atrial fibrillation who are oriented for ablation of AF in the course of routine care.
2432155|NCT03351803||Participants with Ashkenazi ancestry|
2432156|NCT03351790||All included participants|Patients that complete study questionnaire and have endoscopy recorded.
2432157|NCT03351777|Experimental|PR022 topical gel, 0.05%|Applied twice daily for 28 days
2432158|NCT03351777|Experimental|PR022 topical gel, 0.1%|Applied twice daily for 28 days
2432159|NCT03351777|Placebo Comparator|PR022 topical gel vehicle|Applied twice daily for 28 days
3187806|NCT00760162||5. Hospital Italiano de Buenos Aires|Buenos Aires, Argentina.
3187807|NCT00760162||6. National Hospital|Abuja, Nigeria
2432162|NCT03351751|Placebo Comparator|Placebo|Subjects receiving placebo
2432163|NCT03351751|Experimental|PF-06372865|Subjects receiving PF-06372865
3187808|NCT00760175|Active Comparator|intradermal|
3187809|NCT00760175|Active Comparator|intramuscular|
3187810|NCT00760201||1|Hospital executives, physician administrators and hospital legal counsel
3187811|NCT00760227|Other|1: HPI-C|Child Intervention Only Group
3187812|NCT00760227|Other|2: HPI-CP|Parent and Child Intervention Group
3187813|NCT00760227|No Intervention|3: SC|Standard Care Control Group- No Intervention
2432170|NCT03351725||Peripheral venous catheter indwell time more than 48 hours|
2432171|NCT03351712|Active Comparator|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Gold Standard Intervention + Activity Tracker WITHOUT Feedback (Medical Rehabilitation, Motivational Support and Psycho-Education) During the in-patient phase, participants will participate in the intensive four-week hospital-based and medically-managed rehabilitation program for weight reduction. All patients will be placed on a hypocaloric nutritionally balanced diet tailored to the individual after consultation with a dietitian. Furthermore, they will receive nutritional counseling provided by dietitians, have physical activity training provided by physiotherapists and motivational support with elements of psycho-education provided by physicians trained and informed by psychologists-psychotherapists.
2432172|NCT03351712|Experimental|Gold Standard Intervention and Activity Tracker WITH Feedback|In this experimental condition, will be provided the same rehabilitation program for the 4-weeks in-patient phase. In addition, for these subjects will be implemented a Stepped Protocol using wearable devices / activity trackers to collect information about daily physical activity and providing meaningful and informative feedbacks. The additional procedure starts during the in-patients phase, delivering and explaining the use of the wearable devices. In this meeting, longer than the one previously described for the control condition, experimenters provide information, set individualized goals and explain feedbacks which will be delivered after ending in-patients phase by the electronic wearable devices.
2432173|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|In this experimental condition, the subjects followed the normal medical rehabilitation program described above for the first experimental condition. For the out-patient phase the ACT intervention includes monthly 30 minutes skype-telephone sessions. The ACT-based interventions includes different processes: 1) Acceptance, that involves the active awareness of difficult private experiences without attempts to control or avoid unpleasant emotions. 2) Mindfulness, refers to engaging in present moment experience and adopting an open and curious attitude. 3) Defusion: Participants will be encouraged to defuse from thoughts and feelings by turning attention toward the 'noticing-self', instead of becoming attached to thoughts and 'run' through life on 'auto-pilot'. 4) Values and Commitment: encouraging participants to live in accordance with their values, participants can engage in meaningful activities despite experiencing unwanted emotions/ sensations.
2432174|NCT03351712|Experimental|ACT-Based Intervention and Activity Tracker WITH Feedback|ACT-Based Intervention and Activity Tracker WITH Feedback (Combining ACT and Behavioral Change) In the last experimental condition, obese individuals will follow the same rehabilitation program in the in-patients phase of the Behavioral Change condition, with the addition of the brief ACT intervention of 4 45-minutes sessions for a total amount of 3 hours one-to-one therapy sessions, exactly as in the ACT condition. In the out-patient phase of 16 weeks, each participant receive feedback from activity tracker following the same stepped protocol but message and feedbacks are informed by ACT therapist, including Value-based goal setting, prompt for including defusion from difficult thoughts, mindfulness cues and a set of ACT-consistent metaphors and messages.
3187814|NCT00760240||Glaucoma patients|This is a group of patients with restricted visual fields or ETDRS visual acuity of 20/60 or worse
3187815|NCT00760240||Retina patients|A group of patients with retinal pathology(ARMD, CME, diabetic retinopathy) contributing to their decreased vision.
3187816|NCT00760253||1|pure propofol by TCI pump with titration.
3187817|NCT00760253||2|10ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
3187818|NCT00760253||3|20ug/kg alfentanyl bolus and propofol TCI pump infusion with titration
3187819|NCT00760292||1|Type 2 Diabetic Patients
3187820|NCT00760292||2|Non-diabetic individuals
3187821|NCT00760305|Experimental|1|Patients who received the Pro-Self psychoeducational intervention
3187822|NCT00760305|No Intervention|2|Patients who received standard care
3187823|NCT00760344|Experimental|SYR-472 3.125 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3187824|NCT00760344|Experimental|SYR-472 12.5 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
2432180|NCT03351686|Experimental|tranexamic acid group|
2432181|NCT03351686|No Intervention|non tranexamic (control) group|
2432182|NCT03351673|Experimental|endometrial volume 2D TVS|perimenopausal women who bleed are examined by 2D TVS and the calculated endometrial volume using a specific formula and followed by endometrial biopsy for correlation with the pathological findings
2432183|NCT03351647||Group Ustekinumab|Patients presenting an active crohn's disease (HBI score ≥ 4) with an indication of treatment by ustekinumab because of failure or unacceptable side effects of previous treatments, and who have already been treated by at least one anti TNF The patients must be 18 years old or older.
2432184|NCT03351634|Experimental|Children with neurogenic incontinence with spinal dysraphism|
3187825|NCT00760344|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3187826|NCT00760344|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3187827|NCT00760344|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin stable dose therapy)
3187828|NCT00760344|Active Comparator|Sitagliptin 100 mg QD|(with lifestyle modification and/or metformin stable dose therapy)
3187829|NCT00760357||Retrospective Anaylsis|Once the patients are identified that have a full thickness wound on a limb clearly identified as having critical limb ischemia, these patients will be evaluated
2432190|NCT03351582|Experimental|Grief and Communication One Session|Group one will meet with a family therapist for one 90 minute session where the main focus will be on providing psychoeducation on grief and communication to both children and parents. This arm receives only the first session of the grief and communication family intervention.
2432191|NCT03351582|Experimental|Grief and Communication Three Sessions|Thie Group will receive all three sessions of the grief and communication family intervention.
2432192|NCT03351582|No Intervention|Control|Group three will be the control group and will not receive the grief and communication family intervention.
2432193|NCT03351569|Experimental|Immunoglobulin|Intravenous immunoglobulin 25 grams (five 100 ml bottles, 5g/100ml), in 3 hours, once a month for one year.
2432194|NCT03351569|Placebo Comparator|Saline solution|Intravenous saline solution 500 ml (five 100 ml bottles), in 3 hours, once a month for one year.
2432195|NCT03351556|No Intervention|Comparison Arm|Participants in the comparison group will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS.
2432196|NCT03351556|Experimental|Active Intervention 1|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month (~$4.50) for up to 6 months conditional on visit attendance.
2432197|NCT03351556|Experimental|Active Intervention 2|Participants will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month (~$10.00) for up to 6 months conditional on visit attendance.
2432198|NCT03351543|Experimental|Exposed group|these volunteers receive microbial inoculate
2432199|NCT03351543|No Intervention|control|these volunteers do not receive microbial inoculate
2432200|NCT03351530||Pre-diabetes|
2432201|NCT03351530||Diabetes|
2432202|NCT03351530||Diabetes with periodontal disease|
2432203|NCT03351530||Periodontal patient|
2432204|NCT03351530||Healthy person|
2432205|NCT03351517|Experimental|Tapentadol arm|Single dose of 100 mg of extended release oral tapentadol will be administered 1 hour before surgery.
2432206|NCT03351517|Placebo Comparator|Placebo arm|A comparable placebo will be administered 1 hour before surgery.
2432207|NCT03351504|No Intervention|Control (usual lighting)|Participants will continue to use their usual lighting sources.
2432208|NCT03351504|Experimental|Intervention (solar lighting)|Participants will receive an indoor solar lighting system
3187830|NCT00760396|Experimental|Group 1|40mg QD dose group
3187831|NCT00760396|Experimental|Group 2|100mg QD dose group
3187832|NCT00760396|Experimental|Group 3|200mg QD dose group
2432212|NCT03351465|Experimental|CALM|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive-behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living that directly incorporates our previously optional modules for depression into the main program. The computerized/internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed. Participants in the intervention group will be visited by the calm specialist weekly between 6 and 8 times prenatally;postpartum visits will vary based on continuing assessment of symptoms.
2432213|NCT03351465|No Intervention|Treatment as Usual|Participants will receive pre-natal care as usual, and will be visited at 4 time points by the graduate student researchers: baseline, 12 weeks post baseline, and 10 weeks postpartum.
3187833|NCT00760396|Experimental|Group 4|200mg BID dose group
3187834|NCT00760409||Radiation Injury|Radiation Injury Recurrent symptoms after radiation therapy of a brain tumor are not always the result of tumor recurrence but may represent radiation necrosis of the brain.
3187835|NCT00760409||Tumor Recurrence|Symptoms are the result of actual tumor recurrence
3187836|NCT00760422||With fever|
3187837|NCT00760422||Without fever|
3187838|NCT00760500||1|
3187839|NCT00760539|Experimental|Travoprost/Timolol BAC-free|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3187840|NCT00760539|Active Comparator|Travoprost/Timolol|Travoprost 0.004%/Timolol 0.5% ophthalmic solution, 1 drop in each eye, once daily (QD) at 9 AM (±30 minutes), for 6 weeks
3187841|NCT00760565|Experimental|1|
3187842|NCT00760565|Placebo Comparator|10|
3187843|NCT00760565|Experimental|11|
3187844|NCT00760565|Placebo Comparator|12|
3187845|NCT00760565|Placebo Comparator|2|
2432214|NCT03351452|Experimental|Real tDCS|20 min of 2 mA real anodal transcranial direct current stimulation applied via 5x7 cm rubber electrode over the VLPFC (current density: 0.057 mA/cm2) and cathodal 10x10 rubber electrode over supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2432215|NCT03351452|Experimental|Real tACS|20 min of 2 mA real transcranial alternating current stimulation in theta frequency applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase of 15 s at the beginning and the end of stimulation.
2432216|NCT03351452|Sham Comparator|Sham tES|30 s of 2 mA sham transcranial electric current stimulation applied via 5x7 cm and 10x10 cm rubber electrodes over the VLPFC (current density: 0.057 mA/cm2) and supraorbital region (current density: 0.02 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase of the memory task.
3147218|NCT00119366|Experimental|Treatment (radiolabeled monoclonal antibody, TBI, chemo, PBSC)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.~CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.~TRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.~IMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96."
3147219|NCT00119444|Other|periacetabular osteotomy|
3147220|NCT00119496|Active Comparator|Group 1|Inhaled beclomethasone (400mcg/day)
3147221|NCT00119496|Active Comparator|Arm 2|Rosiglitazone
2432221|NCT03351426|Active Comparator|Active tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will consist of 20 minutes stimulation at 2mA. Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
2432222|NCT03351426|Sham Comparator|Sham tDCS Group|Subjects will receive a total of eight tDCS sessions: 1st week five daily sessions (Monday to Friday), followed by 2nd week three sessions only (Monday, Wednesday, Friday). tDCS sessions will be sham stimulation (30-second ramp up and down). Target: left dorsolateral prefrontal cortex (DLPFC). Montage: 5x5 sponge electrodes placed over EEG 10:20 system location F3 (anode) and right supraorbital area (cathode).
2432223|NCT03351413|Experimental|Intervention|"LIVE-LiFE to Prevent Falls Among Older Fallers Intervention, which is an individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk"
2432224|NCT03351413|No Intervention|Control|- An individualized fall risk assessment provided to participant and their primary care provider
2432225|NCT03351400|Experimental|Treatment group|Stem cells administered to participants
2432227|NCT03351374||Temple Physicians Incorporated|A community-based provider, operating 32 primary care sites
2432228|NCT03351374||WhiteBark|For profit entity created by the Indiana Rural Health Association
2432229|NCT03351374||Drexel Family Intervention Science|Academic center that developed and deployed Attachment Based Family Therapy (ABFT) assessment, treatment, and prevention models with an interest in adolescents struggling with substance abuse, depression, trauma, and suicidality.
2432230|NCT03351374||Bon Secours Health System|A primary care clinic in Baltimore that provides care services to a population in a lower socioeconomic status in downtown Baltimore.
2432231|NCT03351374||Howard University Hospital CARES|A project provides free outpatient medical, dental, mental health, nutrition and social services for HIV positive uninsured and underinsured residents of the District of Columbia.
2432232|NCT03351361|Experimental|Nivolumab + Ipilimumab|
2432233|NCT03351361|Active Comparator|Chemotherapy|carboplatin and pemetrexed or carboplatin and paclitaxel
3147222|NCT00119496|Active Comparator|Arm3|Oral theophylline
3147223|NCT00119496|Active Comparator|Arm 4|Oral theophylline and inhaled beclomethasone
2432239|NCT03351322|Experimental|ENERGI-F701|ENERGI-F701, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
2432240|NCT03351322|Active Comparator|Regaine|Regaine, topical application (1 mL) on the scalp of affected area, twice daily for 12 weeks
2432241|NCT03351309|Experimental|Telephone-based cognitive behavioral therapy|Telephone-based cognitive behavioral therapy (CBT) intervention - Four session protocol plus routine perioperative management.
2432242|NCT03351309|No Intervention|Treatment as Usual|Treatment as Usual (TAU) - Routine perioperative management.
2432243|NCT03351296|Experimental|LV5FU2 + streptozotocin +/- Bevacizumab|
2432244|NCT03351296|Experimental|Capecitabine + temozolomide +/- Bevacizumab|
2432247|NCT03351244|Experimental|BI 409306 high dose|
2432248|NCT03351244|Experimental|BI 409306 low dose|
2432249|NCT03351244|Placebo Comparator|Placebo|
3147224|NCT00119522||Group 1|cohort is of individuals with a spinal cord injury who use a wheelchair as their primary means of mobility
3147225|NCT00119535|Other|Arm 1|
3147226|NCT00119548|Other|Arm 1|Randomized, controlled trial with three intervention models: Model A (traditional counseling/testing);
3147227|NCT00119548|Other|Arm 2|Model B (nurse-initiated screening, traditional counseling/testing);
3147228|NCT00119548|Other|Arm 3|Model C (nurse-initiated screening, streamlined counseling/rapid testing).
3147229|NCT00119561|Experimental|Arm 1|Telephone support groups
3147230|NCT00119561|No Intervention|Arm 2|Usual VA care
3147231|NCT00119574|Other|Arm 1|
2432245|NCT03351283|Experimental|Severe sodium restriction|"Patients will be assigned to a diet with two grams of sodium. The nutritionist will be responsible for calculating diets appropriate to the needs of each patient. The diet will not have the intention to modify the weight of the patient but only to indicate the menus that the patients will follow. All the patients will be explained the diet. Patients will be allowed a maximum intake of 1.5 liters of water per day, including the liquid of soups, juices and drinks; This will be explained in detail to the patients.~The diets will be identical in calories according to the weight of the patient. The only difference in diets will be the sodium content, which will be 2 grams of sodium vs. 3 grams of sodium."
2432246|NCT03351283|Active Comparator|Moderate sodium restriction.|Patients will be assigned to a diet with three grams of sodium.
3147232|NCT00119613|Experimental|Group 1 - darbepoetin alfa|Darbepoetin alfa 300 mcg QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
3147233|NCT00119613|Placebo Comparator|Group 2 - Placebo|Placebo QW for the first 4 weeks, followed by Q3W dosing commencing on week 5 for the remainder of the treatment period.
3147234|NCT00119639|Experimental|Arm 1|
3147235|NCT00119691|Experimental|Nesiritide + standard of care|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
3147236|NCT00119691|Active Comparator|Standard of care|Standard of care until adequate diuresis achieved
3147237|NCT00119717|Experimental|1|
3147238|NCT00119717|Active Comparator|2|
3147239|NCT00119730|Experimental|Fludarabine, Mitoxantrone, Rituximab, Zevalin|Drug: Fludarabine Given on days 1-3 of each 28-day cycle Drug: Mitoxantrone Given on day 1 of each 28-day cycle Drug: Rituximab Given on day 1 of each 28-day cycle Drug: Zevalin Given after two cycles if there is no disease progression.
3147240|NCT00119769|Placebo Comparator|1|
3147241|NCT00119769|Active Comparator|2|
3147242|NCT00119782|Experimental|1|Comprehensive worksite intervention
3147243|NCT00119782|Experimental|2|Delayed intervention control group
3147244|NCT00119795|Active Comparator|Health education control|This is an education program for older adults entitles, successful aging.
3147245|NCT00119795|Experimental|Exercise Only|Structured exercise 150 min/wk
3147246|NCT00119795|Experimental|Weight Loss|Behavioral weight loss; goal of 7%
3147247|NCT00119821|Experimental|I|Behavioral Weight Reduction
3147248|NCT00119821|Other|II|Exercise
3147249|NCT00119821|Other|III|Smoking Cessation
3147250|NCT00119912|Active Comparator|A 1 Intervention arm Flex Sig|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening. Half of invitees are additionally invited to provide a stool sample for fecal occult blood testing (Intervention arm A 2). They are drawn directly from the population registry without prior consent to be randomized - approved by Regional Ethics Committees of South-East Norway..
3147251|NCT00119912|No Intervention|B Control arm|"No screening group randomised from population age 50-64 years. As for the active intervention arm, the control group was not informed about being randomized to 'no screening' since 'no screening' was the current usual care (and still is in 2015) in Norway - approved by Regional Ethics Committees of South-East Norway."
3147252|NCT00119912|Active Comparator|A 2 Intervention arm Flex Sig + iFOBT|Randomised from the population registry, age 50-64 years and invited for Flexible Sigmoidoscopy (Flex Sig) screening plus an immunochemical test for fecal occult blood (iFOBT). As for arms A 1 and B, they are drawn directly from the population registry without prior consent to be randomized.
3147253|NCT00119925|Active Comparator|minimal intervention|professional audit and feedback on current practice
3147254|NCT00119925|Active Comparator|maximal intervention|multi-faceted intervention consisting of professional and patient elements
3147255|NCT00119977|Active Comparator|1|
3147256|NCT00120003|Experimental|Candesartan Cilexetil|Candesartan Cilexetil
3147257|NCT00120003|Placebo Comparator|Placebo|Placebo
3147258|NCT00120016|Experimental|1|Mediterranean diet
3147259|NCT00120016|No Intervention|2|non-intervention diet
3147260|NCT00120068|Other|Arm 1|
3147261|NCT00120081|Experimental|Low dose|10 mcg Na-ASP-2/Alhydrogel
3147262|NCT00120081|Experimental|Medium dose|50 mcg Na-ASP-2/Alhydrogel
3147263|NCT00120081|Experimental|High dose|100 mcg Na-ASP-2/Alhydrogel
3147264|NCT00120081|Placebo Comparator|Saline placebo|Saline placebo
3147265|NCT00120120|Experimental|1|
3147266|NCT00120120|Experimental|2|
3147267|NCT00120211|Experimental|Radiotherapy: 6 Fractions|
3147268|NCT00120211|Active Comparator|Radiotherapy: 5 fractions|
3147269|NCT00120302|Experimental|1|Pimecrolimus
3147270|NCT00120302|Placebo Comparator|2|Vehicle
3147271|NCT00120315|No Intervention|esomeprazole|Long-term users continue antisecretory medication
3147272|NCT00120315|Placebo Comparator|placebo drug|Long-term users are treated with placebo
3147273|NCT00120380|Active Comparator|Aerosolized Iloprost|
3147274|NCT00120380|Placebo Comparator|Bosentan monotherapy|
3147275|NCT00120393|Active Comparator|G1|
3147276|NCT00120393|Active Comparator|G2|
3147277|NCT00120432|Active Comparator|A|single dose vs three doses of 1%tropicamide and 10%phenylephrine
3147278|NCT00120445|Active Comparator|2|air vs perfluoropropane gas in pneumatic retinopexy
3147279|NCT00120458|Experimental|1|Anxiolytic Therapy
3147280|NCT00120458|Placebo Comparator|2|Anxiolytic Therapy
3147281|NCT00120471|Experimental|1|Pregnant participants will receive a single dose of TDF during active labor. These participants will be hospitalized at the delivery facility through Day 3 postpartum.
3147282|NCT00120471|Experimental|2|Pregnant participants will not receive TDF. Participants will be hospitalized at the delivery facility through Day 7 postpartum. Their infants will receive TDF at birth and on Days 3 and 5 after birth.
3147283|NCT00120471|Experimental|3|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. They will receive TDF during active labor and their infants will receive TDF at birth and on Days 3 and 5 after birth.
3187846|NCT00760565|Experimental|3|
3187847|NCT00760565|Placebo Comparator|4|
3187848|NCT00760565|Experimental|5|
2432254|NCT03351205|Experimental|Uterine cavity barrier only|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
2432255|NCT03351205|Experimental|hormone|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ amnion membrane+hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2432256|NCT03351179||AMI patients with HFpEF|
2432257|NCT03351179||AMI patients without HF|
2432258|NCT03351166|Experimental|Molidustat (BAY85-3934)|Molidustat group
2432259|NCT03351153|Other|X-ray group|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week.
2432260|NCT03351153|Other|CT group|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week.
2432261|NCT03351153|Other|Specimen group|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
2432262|NCT03351140||Subjects with breast cancer|Approximately 30 subjects who have confirmed diagnosis of breast cancer will be included in the study
2432263|NCT03351140||Subjects with prostate cancer|Approximately 30 subjects who have confirmed diagnosis of prostate cancer will be included in the study
2432264|NCT03351140||Subjects with NSCLC|Approximately 30 subjects who have confirmed diagnosis of NSCLC will be included in the study
2432265|NCT03351140||Subjects with multiple myeloma|Approximately 30 subjects who have confirmed diagnosis of multiple myeloma excluding smoldering/asymptomatic multiple myeloma will be included in the study
2432266|NCT03351140||Subjects with DLBCL or follicular lymphoma|Approximately 30 subjects who have confirmed diagnosis of DLBCL or follicular lymphoma will be included in the study
2432267|NCT03351127||18-29 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 18-29 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2432268|NCT03351127||30-39 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 30-39 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2432269|NCT03351127||40-49 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 40-49 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2432270|NCT03351127||50-59 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 50-59 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2432271|NCT03351127||60-69 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 60-69 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
2432272|NCT03351127||70-79 year-old group|Based on the inclusion crtiteria, 200 healthy Han people at aged 70-79 and both sexes will be recruited in the analysis. Normal reference values of ultrafast pulse wave velocity will be obtained.
3187849|NCT00760565|Placebo Comparator|6|
3187850|NCT00760565|Experimental|7|
3187851|NCT00760565|Placebo Comparator|8|
2432276|NCT03351088|Other|Preventive ligation|Preventive ligation of DVC is done after the opening of endopelvic fascia and before bladder neck dissection. DVC is ligated at the level of the apex with a 8-fashion single stich (1-0 Monocryl® CT-1 stich) trying to preserve puboprostatic ligaments and the muscle fibres of the rabdosphincter. DVC is then dissected at the end of prostatectomy before the section of the urethra.
2432277|NCT03351088|Other|Delayed ligation|Delayed ligation is done after the section of the urethra and once the prostatectomy is completed with a single stich (3-0 Monocryl® UR-6).
2432278|NCT03351075|Experimental|Intervention group|Standard physical therapy program + Modern educational program
2432279|NCT03351075|Active Comparator|Control group|Standard physical therapy program + Traditional biomedical educational program
2432280|NCT03351062|Active Comparator|Tamoxifen treatment group|Patients in this group will receive tamoxifen treatment.
2432281|NCT03351062|Active Comparator|Toremifene treatment group|Patients in this group will receive Toremifene treatment.
2432282|NCT03351049|Experimental|Reactive, Low air loss support surface|Participants in this arm will use a reactive support surface with a low air loss feature
2432283|NCT03351049|Active Comparator|Reactive, non-low air loss|Participants in this arm will use a reactive support surface without a low air loss feature
2432284|NCT03351023||Nurses' Health Study II|Nurses' Health Study II, an ongoing cohort study of 116,430 female registered nurses in the US, aged 25-42 at enrollment in 1989. Participants have been followed by biennial mailed questionnaires that elicit updated information on diet, lifestyle, and various health outcomes; the follow-up rate over 26 years exceeds 90% of the eligible person-time.
2432285|NCT03351010|Experimental|Mindfulness|Receiving education program and mindfulness training
2432286|NCT03351010|Active Comparator|Control|Receiving education program
2432287|NCT03350997|Experimental|Trial 1|Subjects will have two CGM devices placed on either side of the abdomen, near the belly button. Trial 1 Exercise - subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
2432288|NCT03350997|Experimental|Trial 2|Subjects will have one CGM device placed on one side of the abdomen. Trial 2 Exercise - subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
2432417|NCT03350087|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
3187852|NCT00760565|Experimental|9|
3188980|NCT00772824|Experimental|3|Oral Glutamine
2432291|NCT03350971|Experimental|Virtual reality training|Training with ergometer associated with training on wii videogame during 4 days
2432292|NCT03350971|Active Comparator|Control|chest physical therapy
2432293|NCT03350958|Experimental|Group 1|Participants received experimental test meal first and placebo comparator meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
2432294|NCT03350958|Placebo Comparator|Group 2|Participants received placebo comparator meal first and experimental test meal at the next study visit. Participants to fill out visit questionnaire prior to meal and every 30 minutes thereafter for 5 hours. Samples of ileostomy fluid taken at these time-points, along with blood samples in a subset of participants
2432295|NCT03350945|Active Comparator|Device:Titanium Clips|Device: Tumor localization. Preoperative endoscopic localization with titanium clips
2432296|NCT03350945|Active Comparator|Device:Intra-operative Endoscopy|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using intra-operative endoscopy detection.
2432297|NCT03350945|Experimental|Device:Carbon Nanoparticles|Device: Tumor localization. During the laparoscopic surgery,tumor is localized using carbon nanoparticles.
2432298|NCT03350932|No Intervention|Control|This group of children, will have to perform a sensory imagination task about neutral facts before choosing the portion size of a food.
2432299|NCT03350932|Experimental|Food sensory imagination|"This group, the food sensory imagination group, will have to perform a sensory imagination task foods (being the intervention) before choosing the portion size of a food."
2432302|NCT03350906|Experimental|n3-PUFA|Participants will be instructed to swallow 2 Docosahexaenoic acid (DHA)/EPA soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The DHA/EPA soft gels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. The duration of the intervention will be 6 months.
2432303|NCT03350906|Placebo Comparator|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
2432304|NCT03350893|Placebo Comparator|Control Group|Emulsion base without probiotics
2432305|NCT03350893|Experimental|Active Group|Emulsion base with probiotics
2432306|NCT03350880|Experimental|PNF in Water - PNFW|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
2432307|NCT03350880|Active Comparator|PNF on Land - PNFL|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
2432308|NCT03350867|Experimental|Personalized Insole Group|The participants will use insole with personalized support directed to your biomechanics necessities.
2432309|NCT03350867|Placebo Comparator|Placebo Group|The participants will use plane insoles.
2432310|NCT03350854|No Intervention|The non-intervention control group|In the non-intervention control group, providers are blind to the patient's preferred decision making role.
2432311|NCT03350854|Experimental|The intervention group|The provider will be informed of the patient preference in treatment decision making (preferred role) and have a discussion about this with the patient in the intervention group.
2432312|NCT03350841|Experimental|Revascularization|platelet rich plasma injected in the canals
2432313|NCT03350841|Active Comparator|root canal treatment|endodontic treatment obturated with gutta percha
3147284|NCT00120471|Experimental|4|Pregnant participants will be hospitalized at the delivery facility through Day 7 postpartum. Mothers will receive TDF during active labor and their infants will receive TDF at birth and daily for 7 days after birth.
3147285|NCT00120510|Experimental|A|Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
3147286|NCT00120510|Active Comparator|B|Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3
2432317|NCT03350802||procalcitonin pneumonia cohort|Patients who are suspected of acute pneumonia due to symptoms and imaging findings compatible with pneumonia can be enrolled in this cohort.
2432318|NCT03350789|Experimental|Real acupuncture|manual acupuncture + electroacupuncuture on acupoints, twice a week, for 4 weeks
2432319|NCT03350789|Sham Comparator|Sham acupuncture|sham acupuncture (no skin penetration) + placebo electroacupuncture without electrical stimulation on acupoints, twice a week, for 4 weeks
2432320|NCT03350763|Experimental|Plastic biliary stent|A plastic (ie Tannenbaum 10 Fr) biliary stent is used to achieve biliary decompression
2432321|NCT03350763|Experimental|Self-expandable metallic biliary stent|A self-expandable metallic biliary stent is used to achieve biliary decompression
2432322|NCT03350750|Active Comparator|Open Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to active (open shunt group)(setting 4)(110 mm H2O) at time of shunt implantation
2432448|NCT03349801||no AMD|No interventions
2432449|NCT03349801||early AMD|No interventions.
2432450|NCT03349801||intermediate AMD|No interventions.
3147287|NCT00120796|Active Comparator|1|Lamivudine alone
3147288|NCT00120796|Experimental|2|Lamivudine + Vaccine
3147289|NCT00120965|Experimental|1|Autopulse device
3147290|NCT00120965|Active Comparator|2|Manual CPR
3147291|NCT00121095|Other|1|
3147292|NCT00121108|Placebo Comparator|2|Placebo
3147293|NCT00121108|Active Comparator|1|MEDI-524
3147294|NCT00121212|Active Comparator|Surgery - Negative PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is negative, the patient will receive the curative therapy and be followed for recurrence.
3147295|NCT00121212|Experimental|Surgery - Positive PET scan|If patient is candidate for surgery with curative intent or staging lymphadenectomy, he will be enrolled in the study. If patient's PET scan is positive, the patient will receive the curative therapy and be followed for recurrence or receive alternative therapy.
2432323|NCT03350750|Sham Comparator|Closed Shunt Group|FDA-approved Certas Plus with Siphonguard, programmable CSF shunt valve setting to placebo (closed shunt group)(setting 8)(>400 mm H2O) at time of shunt implantation followed by setting to active (setting 4) (110 mm H2O) four months after the procedure.
2432324|NCT03350737|Experimental|Heparin-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with 100 IU/kg of Heparin i.v. (up to a maximum of 5000 IU) 10 minutes prior to exercise
2432325|NCT03350737|Placebo Comparator|Placebo-primed physical rehabilitation|2 exercise sessions per day for 5 days a week for 2 weeks with placebo (2 ml of Sodium Chloride 0.9% i.v.) 10 minutes prior to exercise
3187853|NCT00760604|Active Comparator|A|En bloc esophagectomy is performed through a transthoracic approach by removing the tumor-bearing esophagus, the pericardium anteriorly, both pleural surfaces laterally, as well as the thoracic duct and all other lymphoareolar tissue wedged posteriorly between the esophagus and the spine, and en-bloc resection of all nodal groups in the middle and lower mediastinum as well as the upper abdomen.
3187854|NCT00760604|Active Comparator|B|Transhiatal esophagectomy is performed through an abdominal incision and a neck incision. The stomach is mobilized, and the left gastric vessels are transected at its origin. Celiac lymph nodes are dissected, and the intrathoracic esophagus is dissected bluntly through the hiatus and through the neck. The cervical esophagus is divided at the level of the neck. After the esophagogastrectomy is performed, a gastric tube is created. An esophagogastrostomy is then performed in the neck. If a transthoracic approach is used, dissection will be as described for the transhiatal approach.
2432328|NCT03350711||Microbiota Enrichment Program (MEP)|Patients who are seeking a fecal microbiota transplant (FMT), for any reason, who will be part of a registry of patients to potentially screen for a FMT study.
2432329|NCT03350698|Experimental|active drug|Human Papilloma virus ,Gardasil, 9 valent vaccine
2432330|NCT03350685||Classic Whipple's disease (CWD)|"Classic Whipple's disease (CWD), defined as~duodenal biopsy positive by PAS/immunohistochemistry~or blood positive by PCR"
2432331|NCT03350685||Focal Whipple's disease (FWD)|"Focal Whipple's disease (FWD), defined as~joint fluid positive by PCR~but duodenal biopsy negative by PAS/immunohistochemistry"
2432332|NCT03350685||Chronic T. whipplei-associated arthritis (CTWA)|"Chronic T. whipplei-associated arthritis (CTWA) defined as chronic arthritis and~duodenal biopsy, stool, or saliva positive by PCR~duodenal biopsy negative by PAS/immunohistochemistry~joint fluid negative by PCR"
3187855|NCT00760630|Experimental|CDP LFC|all patients will have this calculation based upon diagnostic parameters with IVUS and FFR and/or CFR
3187856|NCT00760656||Research Participants|Participants with a diagnosis of childhood malignancy treated or followed at SJCRH
3187857|NCT00760656||Control Participants|Siblings, parents, relatives or friends of St. Jude patients or former patients or SJCRH employees who are not SJLIFE study team members or supervised by a SJLIFE study team members
2432336|NCT03350659|Experimental|Atomoxetine|Atomoxetine 18mg once a day.
2432337|NCT03350659|Active Comparator|Midodrine|midodrine 2.5mg twice a day (increase to 5mg three times a day if necessary)
2432338|NCT03350646|Other|Low volume (20-25 μl)|Low volume (20-25 μl)
2432339|NCT03350646|Other|High volume (40-45 μl)|High volume (40-45 μl)
2432340|NCT03350633|Experimental|Tocilizumab|Tocilizumab Injection (ACTEMRA®) , a IL-6 receptor blockade
2432341|NCT03350633|Active Comparator|Azathioprine|Imuran
2432342|NCT03350620|Experimental|NVK-002 Concentration 1|"Stage 1: Subjects will be randomized to NVK-002 Concentration 1~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
2432343|NCT03350620|Experimental|NVK-002 Concentration 2|"Stage 1: Subjects will be randomized to NVK-002 Concentration 2~Stage 2: Subjects will be re-randomized to one of the three treatment arms."
2432344|NCT03350620|Placebo Comparator|Vehicle (Placebo)|"Stage 1: Subjects will be randomized to Vehicle (Placebo)~Stage 2: Subjects will be re-randomized to one of the two experimental NVK-002 treatment arms"
2432345|NCT03350594|Active Comparator|Systemic Family Therapy|"SyFT involves the patient, the parents, and siblings over the age of 6 living at home. Therapists do not manage the issues relating to AN, which are taken on by referent psychiatrist who can be called on in case of any concern. Without denying personal suffering and its intra-psychic and meta-psychological impact, or the somatic and biological aspect of the pathology, the emphasis is on interactions around the symptom.~There will be free exchanges along the lines between therapist and family, within the family and between therapists.~Session is possible with sibling alone or the parents alone or in inter-generational mode (other family relatives)"
2432346|NCT03350594|Experimental|Multiple Family Therapy|"Each session will involve 5 families of patients suffering from AN including the parents and non-systematically the siblings. There will be exchanges in groups and mediation via different exercises involving different sub-groups according to the theme: complete families, patients on their own for problems specific to them, or  cross-parenting  exercises whereby parents adopt another patient for the duration of the exercise. This organization enables mutual support and social propping, favoring the emergence of family resources. Direct exchanges between families (between parents, siblings, or mixes) with and between therapists are also sought."
2432347|NCT03350581|Active Comparator|FAM-CT 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM with CT or MRI.
2432348|NCT03350581|Experimental|FAM 3D map group|Operator will perform radiofrequency catheter ablation using 3D map which is constructed by integration of FAM alone.
2432349|NCT03350555|Experimental|ERCP with additioned endoscopy|This arm will include participants undergoing ERCP with assistance of additioned endoscopy.
2432350|NCT03350555|No Intervention|ERCP without additioned endoscopy|This arm will include participants undergoing ERCP without assistance of additioned endoscopy as negative controls.
3187858|NCT00760682|Experimental|1|30 preoperative HBO sessions, sequestrectomy and 10 postoperative HBO sessions. The duration of each session is 90 minutes. 100 % oxygen is inhaled during decompression to 2.4 ATA.
2432451|NCT03349801||late AMD|No interventions.
2432513|NCT03349268|Active Comparator|Pulsed xenon ultraviolet light (PX-UV) Device Emitting Germicidal UV|Pulsed xenon ultraviolet light (PX-UV) Device to be used to disinfect rooms following post-discharge terminal cleaning
3187859|NCT00760682|No Intervention|2|Sequestrectomy without HBO treatment
3187860|NCT00760695|Active Comparator|A|the patients in this arm are receiving 2,5 mg dronabinol twice daily
2432352|NCT03350529|Experimental|Localised PC prior to RP|MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, index lesion(s) within prostate and if possible with 5mm angular extension (imaging based healthy tissue marginal) to both sides from the tumour boundary in transverse plane and 5 mm in coronal plane. The ablative effect is aimed to reach prostate capsule by heating the control boundary (3 mm from capsule) to temperature 57 °C. The focal approach is intended to be radical as for index lesion.
2432353|NCT03350529|Experimental|Symptomatic locally advanced PC|MRI guided transurethral HIFU ablation is targeted to main prostatic malignant tumour squeezing and/or invading the prostatic urethra and/or bladder neck. The approach is intended to be palliative.
2432354|NCT03350529|Experimental|Locally recurrent PC after EBRT|"MRI guided transurethral HIFU ablation is targeted to MRI visible, biopsy proven, local recurrent index lesion(s) within and/or surrounding prostate and if possible with 5 mm angular extension to either side from the tumour boundary in transverse plane and 5 mm in coronal plane. The approach is intended to be focal and salvage.~The whole-gland HIFU ablation approach will be considered in case of extensive organ confined recurrent prostate cancer (positive biopsies for malignancy from extensive/multiple area in prostate and/or extensive/multiple lesion(s) at baseline MRI) to cover whole prostate."
2432355|NCT03350529|Experimental|Symptomatic BPH|MRI guided transurethral HIFU ablation is targeted to adenomas of the prostate. The HIFU sector encompasses bilateral (anterolateral) transitional zones between bladder neck and verumontanum (colliculus seminalis).
2432356|NCT03350516|Experimental|Daily 500 mg Calcium|
2432357|NCT03350516|Active Comparator|Daily1500 mg Calcium (Standard dose)|
3187861|NCT00760695|Placebo Comparator|B|the patients in this arm are receiving 2,5 mg placebo twice daily
2432359|NCT03350490|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2432360|NCT03350490|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2432361|NCT03350490|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2432362|NCT03350490|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2432363|NCT03350477|Active Comparator|Cancer ablation|In this group,the patients will receive ablation therapy(e.g.cryosurgery or irrreversible electroporation) first for big tumors (>2cm).The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2432364|NCT03350477|Active Comparator|Life information rehabilitation therapy|"In this group,the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2432365|NCT03350477|Experimental|Combination therapy|"In this group,the patients will receive combination therapy,including ablation and life information rehabilitation therapy.They will receive ablation therapy(e.g. cryosurgery or irreversible electroporation)first for big tumors(>2cm),then drink QilishengImmunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2432366|NCT03350477|No Intervention|Control|In this group,the patients will recieve no special treatment and as a control group.The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2432367|NCT03350464|Experimental|Pain in PD Arm|This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.
3187862|NCT00760708||undergoing persantine stress test|
2432369|NCT03350438||PTSD Patients|patients ranging 18-60, diagnosed with PTSD following a trauma that occured over one year before the current study and do not have other health problems that may affect their everyday participation.
2432370|NCT03350438||healthy adults|healthy adults, ranging 18-60, without any health problems that may affect their everyday participation.
2432371|NCT03350425||Recently vaccinated patients|Patients who recently received pneumococcal vaccination.
2432372|NCT03350425||Patients vaccinated >2 years ago|Patients who received pneumococcal vaccination more than two years ago.
2432373|NCT03350399||level of placenta growth factor in IUGR|
2432374|NCT03350386|Experimental|Single dose|Single administration of FYU-981
2432375|NCT03350386|Experimental|Concomitant administration|Concomitant administration of FYU-981 with oxaprozin at steady state
2432376|NCT03350373|Experimental|Fasted dosing followed by fed dosing|Dosing of FYU-981 in the fasted state followed by fed dosing
2432377|NCT03350373|Experimental|Fed dosing followed by fasted dosing|Dosing of FYU-981 in the fed state followed by fasted dosing
2432378|NCT03350360|Experimental|Attention Control Training Clinic|"Attention Control Training Clinic will consist of:~6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2432379|NCT03350360|Experimental|Attention Control Training Web-delivery|"Attention Control Training Web-delivery will consist of:~6 sessions lasting approximately 10 minutes each logged into via the internet from the participants' home.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~Ideally participants will complete 2 sessions per week, allowing them to complete the trial in less than one month's time"
3187863|NCT00760721|Experimental|1|Educational small group session with HBV screening resources provided
3187864|NCT00760721|Sham Comparator|2|Educational small group discussion, diet/physical activity resources provided
2432380|NCT03350360|Placebo Comparator|Comparison Task Clinic|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard).~(Note that those receiving this arm, are invited to repeat the attention control training web-delivery arm at the end of their participation)."
2432381|NCT03350347|Experimental|Molidustat (BAY85-3934)|Molidustat group
2432382|NCT03350347|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
2432383|NCT03350334|Active Comparator|Duloxetine|The patients who will be given 60 mg duloxetine 2 hours before surgery and 24 hours after surgery.
2432384|NCT03350334|Placebo Comparator|Placebo Control|The patients who will be given 60 mg placebo 2 hours before surgery and 24 hours after surgery.
2432385|NCT03350321|Experimental|Molidustat (BAY85-3934)|Molidustat group
2432386|NCT03350321|Active Comparator|Darbepoetin alfa|Darbepoetin alfa group
2432387|NCT03350308||Patients with chronic end-stage renal failure|
2432388|NCT03350295|Experimental|GRP1 - Assess relative bioavailability(3-way cross-over)|"GROUP 1 (Treatments A, B, C) All 3 treatments in Group 1 consist of a dose of 120 mg nifurtimox (4 x 30 mg tablets). Participants received the 3 treatments in one of six treatment sequences under fed condition.~Treatment A, dose administration with fast in vitro dissolution characteristics Treatment B, dose administration with medium in vitro dissolution characteristics Treatment C, dose administration with slow in vitro dissolution characteristics"
2432389|NCT03350295|Experimental|GRP2 - Assess relative bioavailability (2-way cross-over)|"GROUP 2 (Treatments D and E) Participants received the 2 treatments in one of two treatment sequences under fed condition.~Treatment D, a single dose 30 mg nifurtimox dose with medium in vitro dissolution characteristics Treatment E, a single dose of 120 mg nifurtimox"
2432390|NCT03350282|Experimental|Mixture GAA-creatine|Mixture of guanidinoacetic acid and creatine monohydrate
2432391|NCT03350282|Active Comparator|Creatine|Creatine monohydrate
3187865|NCT00760734|Experimental|Hyperbaric oxygen therapy-TBI/PCS|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
2432395|NCT03350243|Experimental|CCENT Intervention group|Participants will be assigned a dedicated key worker that will support families through the child's first year, in addition to standard medical care, which involves a primary care provider and/or neonatal follow-up at routine times.
2432396|NCT03350243|No Intervention|Control group|Participants will receive the standard medical care at their institution, which involves a primary care provider and/or neonatal follow-up at routine times.
2432397|NCT03350230||oncofertility patients|oncofertility patients undering controlled ovarian hyperstimulation and embryo cryopreservation who carry a present or past cancer diagnosis
3187866|NCT00760734|Experimental|Hyperbaric Oxygen Therapy-PCS/PTSD|Intervention: Low pressure hyperbaric oxygen therapy, 40 or 80 twice daily, 5d/week, HBOTs at 1.5 ATA/60 minutes each. One month no treatment period between the 40th and 41st HBOT
3187867|NCT00760760|Experimental|n-3 PUFA|
2432400|NCT03350204|Experimental|Meniscus Injured|These participants will come in pre and post operation
2432401|NCT03350204|Experimental|Healthy|These participants will be used as a standardised comparison for the patient group
2432402|NCT03350191|Experimental|SAR425899 high dose|Repeated once daily subcutaneous (SC) doses of SAR425899 administered over 20 days
2432403|NCT03350191|Experimental|SAR425899 low dose|Repeated once daily SC doses of SAR425899 administered over 20 days
2432404|NCT03350178|Experimental|treated patients|Treated wit FMT
2432405|NCT03350165|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
2432406|NCT03350165|Placebo Comparator|Control Group|placebo tablet twice daily.
2432407|NCT03350152||LAM group|Have a diagnosis of AML according to World Health Organization (WHO) classification Are at least 70 years of age
2432408|NCT03350139||Patients treated with gamma knife radiosurgery|Collection of non-genetic, chronobiological, therapeutic and co-morbidities
2432409|NCT03350126|Experimental|Experimental arm|Therapy induction (12 weeks) Nivolumab (IV) and Ipilimumab (IV) - every 21 days - 4 cycles Then Nivolumab (IV) alone every 15 days - 20 cycles - until 12 months
2432410|NCT03350113|Experimental|HemoSpec|Blood Sampling for analysis in the HemoSpec device
2432411|NCT03350100|Experimental|Birhi date cultivar|A 48.46 g of freeze dried powder of Birhi date Cultivar which is equivalent to a 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 162.8 mg/100 g of GAE. and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2432412|NCT03350100|Experimental|Khassab date cultivar|A 34.5 g of freeze dried powder of Khassab date Cultivar which is equivalent to A 115g of fresh dates, contains 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and a total phenolic content of 91.52 mg/100 g of GAE. and 0.80 g of fibres,will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2432413|NCT03350100|Placebo Comparator|placebo|A 14.72 g of total sugar in which 4.6 g Glucose, 2.49 fructose and 3.4 sucrose, and 0.80 g of fibres, will be mixed into one portion of low fat yogurt (e.g. Yeo yogurt 150 g BigFish®, which gives a total energy of 299 KJ.
2432414|NCT03350087|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
2432415|NCT03350087|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
2432416|NCT03350087|Experimental|iTBS+cTBS group|Continuous theta burst stimulation (cTBS group) at first followed by intermittent theta burst stimulation (iTBS group).
2432842|NCT03346837|Experimental|Inhibition (Cohort 1)|Single oral dose BMS-986205
3187868|NCT00760760|Placebo Comparator|Control|
2432418|NCT03350087|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
2432419|NCT03350087|Experimental|VCT+optimal rTMS group|VCT+optimal rTMS group received the VCT training and optimal rTMS in addition to traditional rehabilitation.
2432420|NCT03350061|Experimental|SENSY benefit|Sensory feedback elicited by intraneural stimulation will be provided by SENSY with and without the leg prosthesis to improve walking ability, increase embodiment, and reduce metabolic cost, cognitive load and phantom pain.
2432421|NCT03350048||Training Set|"First 500 participants recruited for the Training Set:~Blood collection for optimization and validation (vs ELISA) of TransDot point-of-care test at LUMC and later for lab-based TransDot at local site laboratory~Blood, sputum, saliva and urine collection for secondary objectives and repository"
2432422|NCT03350048||Test Set|"Subsequent 300 participants to be used for the Test Set:~Fingerprick TransDot point-of-care test performed at field site after symptom screen and clinical evaluation and before CXR~Blood, sputum, saliva and urine collection for secondary objectives and repository"
2432423|NCT03350035|Experimental|IV Ganaxolone active|Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
2432424|NCT03350035|Placebo Comparator|IV Placebo, non-active|Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
2432425|NCT03350022|Experimental|Sham Feeding|
2432426|NCT03350009||High and low grade embryos|The distribution for the high and low grade embryos is based on common morphological grading criteria.
2432427|NCT03350009||High and low quality follicles|The distribution for the high and low grade oocytes is based on common morphological grading criteria and on different features of the participants such as age.
2432428|NCT03349996|Experimental|LifeStream Peripheral Stent Graft System|Patients treated with the LifeStream Peripheral Stent Graft System
2432429|NCT03349983|Experimental|MVA-BN-Brachyury/ FPV-Brachyury|
2432430|NCT03349970||TEE vs PAC|we will compare the SV measurements obtained by PAC thermodilution technique to those obtained by different TEE methods in 60 patients undergoing coronary artery bypass grafting (CABG) and/or aortic valve (AV) or aortic surgery with cardiopulmonary bypass (CPB) in 2 different cardiac centres. The LV cardiac deformation, expressed as global longitudinal strain (GLS) will be calculated off-line from the acquired images. We will also determine the intra and inter-observer reproducibility of each TEE method.
2432431|NCT03349944|Active Comparator|Moderate intensity training|Moderate continuous exercise three times pr. week for 50 min.
2432432|NCT03349944|Experimental|High intensity training|High intensity interval training three times pr. week for 15 min.
2432433|NCT03349931||Hematological patients|Hematological patients at high risk for invasive aspergillosis
2432434|NCT03349918|Experimental|Mobile Health Monitoring|Participants will monitor their blood pressure using a wireless-enabled blood pressure cuff or mood using a mobile health application once per week at baseline. The investigators will monitor their medical records to determine if a medication change has occurred. After this, the investigators will increase the frequency of notifications to monitor the participant's specific health condition to once daily for 1 month. This monitoring will continue for a study duration of 6 months.
2432435|NCT03349905|Active Comparator|Fresh transfer|"Women randomized in the non experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~All of their embryo kept in prolonged culture~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~Supernumerary blastocysts cryopreserved"
2432436|NCT03349905|Experimental|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~A frozen-thawed single embryo transfer at blastocyst stage, is planned 3-11 weeks after cryopreservation"
3187869|NCT00760773|Experimental|1|
2432438|NCT03349879||Vitamin D deficiency|serum 25(OH)D < 30 nmol/L
2432439|NCT03349879||Vitamin D insufficiency|serum 25(OH)D between 30 and 49 nmol/L
2432440|NCT03349879||Vitamin D sufficiency|serum 25(OH)D ≥ 50 nmol/L
2432441|NCT03349866|Experimental|apatinib XELOX and radiotherapy|apatinib：250mg qd po XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2432442|NCT03349866|Active Comparator|XELOX and radiotherapy|XELOX：Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy：45Gy/25f （1.8Gy/f/d，5 f/w）
2432443|NCT03349840|Active Comparator|Insulin glargine U100|Intervention: half of the subjects will be randomised to insulin glargine U100 basal insulin treatment (or continued on glargine if already treated) that will be administered daily in the evening
2432444|NCT03349840|Active Comparator|insulin degludec U100|Intervention: half of the subjects will be randomised to insulin degludec U100 basal insulin treatment that will be administered daily in the evening
2432445|NCT03349827|Experimental|Experimental|HIPEC with Docetaxel/ Lobaplatin at the time of fist surgery and twice repeat within one week after the surgery, following 2 cycles of 3-week Oxaliplatin/S1 chemotherapy combined with Apatinib and 1 cycles of 3-week Oxaliplatin/S1 chemotherapy. The second surgery, exploratory laparoscopy or laparotomy, is carried out one week later after the series of systemic chemotherapy.
2432446|NCT03349814||Appendicitis group|"Patients, who undergo a diagnostic laparoscopy, which because of the operative findings leads to an appendectomy, and the appendix is found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed."
2432447|NCT03349814||Normal appendix group|"Patients, who undergo a diagnostic laparoscopy, that either because of the operative findings (mesenteric lymphadenitis or normal diagnostic laparoscopy) does not lead to appendectomy, or leads to appendectomy, but the appendix is not found to be inflamed in the pathology report.~A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.~OR~A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed, but is not found to be inflamed in the pathology report."
3187870|NCT00760773|Experimental|2|
3187871|NCT00760773|Placebo Comparator|3|
2432452|NCT03349788|Experimental|LCA-nP|The group underwent laparoscopic radical rectectomy without preserving left colic artery. In IMA group, the dissecting based on TME is performed without preserving left colic artery. Surgeon should dissect the lymph nodes and ligated the vessel in the root of inferior mesenteric artery.
2432453|NCT03349788|Active Comparator|LCA-P|The group underwent laparoscopic radical rectectomy with preserving left colic artery. In LCA group, the dissecting based on TME is performed with preserving left colic artery. The relationship of inferior mesenteric artery, inferior mesenteric vein and LCA should be identified and ligated separately without LCA.
2432454|NCT03349775|Active Comparator|Metformin|Metformin: 500mg twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
2432455|NCT03349775|Placebo Comparator|Placebo|Placebo: 500 mgh twice daily for 1 week, followed by 1g twice daily for a total of 3 months.
2432456|NCT03349762||Observational 1|Radiotherapy or Chemotherapy
2432457|NCT03349762||Observational 2|Huaier Granule & Radiotherapy or chemotherapy
2432458|NCT03349762||Observational 3|Huaier Granules
2432459|NCT03349749||Patients undergoing fluid resuscitation|Adult patients in the intensive care unit (ICU) undergoing fluid resuscitation guided by the LiDCOplus haemodynamic monitor.
2432460|NCT03349736|Other|Pelvic Floor Muscle Training|"Women visiting antenatal (up to16 weeks of gestation) will be enrolled for the study. The women will be follow up 4 times during the antenatal visit until 37 weeks of gestation. Questionnaire data and clinical measurements(strength of PFM by Electromyograph biofeedback) will be registered at baseline and and follow-up at week 37 of pregnancy.~The treatment program will include~1) Information, educational material (leaflets, posters, and video) and individual/group exercise on PFM exercise on the 1st day of the visit. Counseling about the importance of performing PFM exercise will be provided. Women are advised to perform home PFM exercise and record in the exercise diary."
2432461|NCT03349723|Experimental|BI 1265162|BI 1265162
2432462|NCT03349723|Placebo Comparator|Placebo|Placebo
3187872|NCT00760786|Active Comparator|1|Intensive lipid lowering plus Omega3-fatty acid
3187873|NCT00760786|Active Comparator|2|Moderate lipid lowering plus Omega3-fatty acid
3187874|NCT00760786|Active Comparator|3|Intensive lipid lowering plus placebo
3187875|NCT00760786|Active Comparator|4|Moderate lipid lowering plus placebo
2432467|NCT03349697|Experimental|Active Product then Placebo|
2432468|NCT03349697|Experimental|Placebo then Active Product|
2432469|NCT03349684|Experimental|Acarbose plus metformin arm|Participants received loose combination of acarbose and metformin 3 times daily.
2432470|NCT03349684|Active Comparator|Metformin plus placebo arm|Participants received loose combination of placebo and metformin 3 times daily.
2432471|NCT03349658|Active Comparator|general anesthesia|Patients in this group were randomized to receive general anesthesia.
2432472|NCT03349658|Active Comparator|spinal anesthesia|Patients in this group were randomized to receive spinal anesthesia.
2432473|NCT03349645|Experimental|Ampion|4 mL Ampion (<5 kilodatlon (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution
3187876|NCT00760799|Active Comparator|1|Standard discectomy without anular repair
3187877|NCT00760799|Experimental|2|Standard Discectomy with anular repair
3187878|NCT00760812|Experimental|1|This group will first receive the Early Social Interaction Project parent-implemented intervention (PII) for 9 months, followed by the Early Social Interaction Project information, education, and support (IES) intervention for 9 months.
2432477|NCT03349619|Experimental|Resveratrol plus Carboxymethyl-β-Glucan|
2432478|NCT03349619|Placebo Comparator|Placebo|
2432479|NCT03349606|Experimental|Cocaine dependence|[C-11]FLB 457 PET at baseline and post d-amphetamine
2432480|NCT03349606|Experimental|Controls|[C-11]FLB 457 PET at baseline and post d-amphetamine
2432481|NCT03349580|Experimental|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
2432482|NCT03349580|No Intervention|The control group|The control group followed the hospital's standard protocol. These do not include exercises or physiotherapy before 3 months after surgery.
3187879|NCT00760812|Experimental|2|The group will first receive IES for 9 months, followed by PII for 9 months.
3187880|NCT00760825|Experimental|Vaccine|killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)
2432485|NCT03349554|Experimental|"standardized meditation technique body-scan"|
2432486|NCT03349541|Experimental|Complex Care Curriculum Intervention|Paediatric residents who are randomized to the intervention group will participate in the complex care curriculum during an academic half-day prior to the Objective Structured Clinical Examination (OSCE).
2432487|NCT03349541|No Intervention|No intervention|Paediatric residents who are randomized to the control group will attend the regular academic half-day unrelated to complex care prior to the Objective Structured Clinical Examination (OSCE).
2432488|NCT03349528|Experimental|Probiotic Supplement|The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.
2432489|NCT03349528|Placebo Comparator|Inert Compound|The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.
3187881|NCT00760851|Experimental|1|Bb-12 supplemented strawberry yogurt drink
2432843|NCT03346837|Experimental|Inhibition (Cohort 2)|Daily oral itraconazole doses for 24 days; single oral dose BMS-986205 on day 4
3187882|NCT00760851|Placebo Comparator|2|Regular strawberry yogurt drink with no Bb-12 added
3187883|NCT00760864|Experimental|TAK-715 25 mg BID|
2432492|NCT03349502|Experimental|MG4101|"MG4101 administration (Not yet commercialized)~Dosage Bwt<50 : 2.0 x109 cells (2 bags) 50≤Bwt<70 : 3.0 x109 cells (3 bags) 70≤Bwt<100 : 4.0 x109 cells (4 bags) Bwt≥100 : 5.0 x109 cells (5 bags)~Duration and frequency~Intravenous over 1 hour~Day 4, Day 11, Day 18 of each cycle"
2432493|NCT03349489|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
2432494|NCT03349489|Active Comparator|Reduction of insulin basal rate 90 minutes prior to exercise|
2432495|NCT03349476|Experimental|MFAM|"The mFAM Workstation is a computerized system used to reconstruct the shape of the left atrium of the heart, by fitting a parametric shape model to points data acquired by a catheter.~The mFAM Workstation uses recorded catheter positions and other data inputs collected from various types of multi-electrode catheters and generates output data files that can be displayed as a 3D anatomic structure."
2432496|NCT03349463|Experimental|18F-Fluciclovine|
2432497|NCT03349450|Experimental|Single Arm-Investigational|"DPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml.~Pembrolizumab 200mg Intravenously.~Cyclophosphamide 50mg Twice daily orally."
3187884|NCT00760864|Experimental|TAK-715 50 mg BID|
2432500|NCT03349424|Experimental|Stilamin group|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin in addition to postoperative conventional treatment.
2432501|NCT03349424|No Intervention|Control group|Patients in the control group will receive the postoperative conventional treatment, without addition of any new medicines.
2432502|NCT03349411||Acute Ischemic Stroke Sample|45 acute patients with first ever ischemic stroke on the right side of the brain will be recruited at NYC Health + Hospitals/Bellevue . They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS)
2432503|NCT03349411||Subacute Ischemic Stroke Sample|30 patients with first ever ischemic stroke on the right side of the brain who are within 3 months of their stroke will be recruited at Kessler Institute for Rehabilitation. They will undergo testing with the Confusion Assessment Method (CAM), Behavioral Inattention Test (BIT), Florida Mental Status Examination (FMSE); Kessler Foundation Neglect Assessment Process (KF-NAP); and Geriatric Depression Scale (GDS). These participants will also complete a research Magnetic Resonance Imaging (MRI) scan.
2432504|NCT03349398|Active Comparator|the group of Roux-en-Y|
2432505|NCT03349398|Experimental|the group of Uncut Roux-en-Y|
2432506|NCT03349346|Experimental|Cohort 1- Participants 12 to less than 18 years of age|"Participants will receive idelalisib monotherapy (from day 1 to day 21), followed by combination therapy with RICE. Upon enrollment, participants will be assigned to one of the 3 dose levels during idelalisib monotherapy (Dose level 1 = 55 mg/m^2 twice daily (BID), Dose level 2 = 85 mg/m^2 BID, Dose level 3 = 125 mg/m^2 BID) administered as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID dosing~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
2432507|NCT03349346|Experimental|Cohort 2- Participants 1 to less than 12 years of age|"Participants will receive one of the 3 doses of idelalisib monotherapy (from day 1 to day 21) followed by combination therapy with RICE. Idelalisib will be administered as as 50 mg, 100 mg or 150 mg tablets as appropriate, or as 10 mg dispersible tablets for oral suspension for participants who cannot swallow tablets. Participants will will be enrolled at dose level 1 once tolerability is demonstrated in the older cohort (Cohort 1). Thereafter, both age cohorts will be dose escalated independently.~Day 1: single dose of idelalisib~Day 2 up to Day 21: initiate and continue idelalisib BID~Day 22 for up to 12 months: idelalisib twice per day in combination with RICE. Cycles of RICE will be administered over 5 days every 3 weeks (Day 1: rituximab; Day 3: rituximab, ifosfamide, carboplatin, etoposide; Days 4 and 5: ifosfamide, etoposide) starting day 22 (or earlier if there is evidence of clinical progression while on idelalisib monotherapy) for up to 12 months."
2432509|NCT03349307|Experimental|No Intervention|
3147296|NCT00121212|Active Comparator|Radiation therapy Negative or Positive PET scan|If patient is candidate for radiation therapy with curative intent, he will be enrolled. If PET scan is negative he will receive curative therapy and be followed for PSA recurrence. If PET scan is positive he may receive confirmatory studies and then if negative, not indicated, or refused he will receive curative therapy be followed for PSA recurrence. If PET scan is positive and received positive confirmatory studies he will receive curative therapy and followed for recurrence.
3147297|NCT00121264|Experimental|Treatment (sorafenib tosylate, tanespimycin)|Patients receive oral sorafenib twice daily on days -14 to 28 in course 1 and on days 1-28 in all subsequent courses. Patients also receive 17-AAG IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3147298|NCT00121277|Experimental|SAHA (Suberoylanilide Acid) with Capecitabine|
3147299|NCT00121290|Experimental|Treatment (SJG-136)|Patients receive SJG-136 IV over 20 minutes once daily on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3147300|NCT00121303|Active Comparator|Arm A low dose Dauno|Induction 45 mg Dauno
3147301|NCT00121303|Experimental|ARM B high dose Dauno|Induction 90 mg Dauno
3147302|NCT00121303|No Intervention|Arm 1 no further treatment|
3147303|NCT00121303|Experimental|Arm 2 Mylotarg|Post induction treatment with Mylotarg
3147304|NCT00121316|Experimental|1|Pimecrolimus
3147305|NCT00121316|Placebo Comparator|2|Matching vehicle cream (placebo)
3147306|NCT00121381|Experimental|1|Pimecrolimus 1 % cream plus topical corticosteroid (TCS)
3147307|NCT00121381|Placebo Comparator|2|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
3147308|NCT00121394|Experimental|Chlorhexidine|
3147309|NCT00121524|Experimental|IV yes|Intravenous needle Epinephrine q 3 min during CPR Atropine 3 mg in initial asystole Amiodarone 300 mg iv after repeated failed defibrillation attempts
3147310|NCT00121524|No Intervention|IV no|The patient will not have an intravenous needle placed or given any drugs during CPR. If patient obtains spontaneous circulation, an intravenous needle is placed and patient can receive any drugs that are appropriate during the following treatment.
2432514|NCT03349268|Sham Comparator|Sham Device - Non Emitting Germicidal UV|Sham Device to be run in rooms following post-discharge terminal cleaning. No Germicidal UV is emitted.
2432515|NCT03349255|Experimental|intravenous (i.v.) arm|autologous ET1402L1-CART cells administered by intravenous (IV) infusion
2432516|NCT03349255|Experimental|intra-hepatic artery (i.a.) arm|autologous ET1402L1-CART cells administered by intra-hepatic artery (IA) infusion
2432517|NCT03349216|Experimental|Intravenous regional Analgesia|in this arm patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes will be deflated (hence named Rapid MiniBier's block).
2432518|NCT03349216|Experimental|Systemic Analgesia|In this arm patients will receive ketamine 1-2 mg/kg IV slow as a systemic analgesia. ketamine as a PCP derivative has both hypnotic and analgesic effects.
2432519|NCT03349203|Experimental|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks before surgery and 2 years as adjuvant therapy after surgery or till progressive disease or unaccepted toxicity.
2432520|NCT03349177|Experimental|FEC group|Fluorouracil 500mg/m2 on day 1, epirubicin 100mg/m2 on day 1 and cyclophosphamide 500mg/m2 on day 1 every 3 weeks for six cycles
2432521|NCT03349177|Experimental|EC-T group|Epirubicin 100mg/m2 on day 1 cyclophosphamide 600mg/m2 on day1 every 2 weeks for four cycles followed by docetaxel 100mg/m2 on day 1 every 3 weeks for four cycles
2432522|NCT03349177|Experimental|TC group|Docetaxel 75mg/m2 on day 1 and cyclophosphamide 600mg/m2 on day 1 every 3 weeks for six cycles
2432523|NCT03349151|Active Comparator|Early feeding|This group will be served soft meal diet served on postoperative 2nd hour on return to the ward.
2432524|NCT03349151|Placebo Comparator|On- demand feeding|This group will be served soft meal diet served whenever they wanted to eat on return to the ward.
2432525|NCT03349138|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different standard motor training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2432526|NCT03349138|Experimental|Robotic Glove|Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2432527|NCT03349138|Experimental|Electrical Stimulation|Electrical Stimulation & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2432528|NCT03349138|Experimental|Electrical Stimulation and Robotic Glove|Electrical Stimulation & Robotic Glove & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the electrical stimulation system plus 60 minutes of conventional therapy or 30-minute training with the robotic glove system plus 60 minutes of conventional therapy. Half of the sessions are allocated to the electrical stimulation system, and half are allocated to the robotic glove system. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2432529|NCT03349125||Collar On|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) on.
2432530|NCT03349125||Collar Off|Individuals who have been referred for videoflouroscopic swallow study (VFSS) as per standard of care, with a stable cervical injury, will have trials of liquids and solids with the Cervical Brace (Collar) off.
2432531|NCT03349112|Active Comparator|Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter, Participants in this group will additionally receive .8 mL of a 4% Lidocaine spray to both nares prior to HRPM.
2432532|NCT03349112|Placebo Comparator|Non-Anesthetized|A study team member will apply 1 mL of 2% viscous lidocaine to each nares prior to the passage of the catheter. Randomized participants in this group will not receive .8 mL of a 4% Lidocaine spray prior to HRPM .
3187885|NCT00760864|Experimental|TAK-715 100 mg BID|
3187886|NCT00760864|Active Comparator|Methotrexate|
2432535|NCT03349086|Active Comparator|Voice Exercise|Randomized participants in this group will undergo 45 minutes of voice exercise, including sustained pitches and pitch glides on a variety of different vocal facilitators.
2432536|NCT03349086|No Intervention|Voice Rest|Randomized participants in this group will undergo 45 minutes of voice rest.
2432537|NCT03349073|Experimental|T-1101 (Tosylate)|
3187887|NCT00760890|Experimental|A|Medicinal Iron
3187888|NCT00760890|Experimental|B|Iron fortified wet pack cereal
3187889|NCT00760890|No Intervention|C|Control
2432541|NCT03349047|Active Comparator|Behavioral Intervention|Behavioral Intervention Group - Education regarding nut allergy and will also have contact with nut.
2432542|NCT03349047|Placebo Comparator|Control|Education regarding nut allergy
3187890|NCT00760903||> 18 years moderate head trauma|Group I: (Pilot group): 5-10 patients > 18 years old, gender and race indifferent with moderate head trauma.
3187891|NCT00760903||> 18, gender and race indifferent|Group II: 30 patients > 18 years old, gender, and race indifferent with moderate head trauma
2432545|NCT03349021|Experimental|Bougiecap|Treatment with Bougiecap instead of Savary Bougie
2432546|NCT03349008|Placebo Comparator|Control group|Entecavir treatment with placebo, Magnesium Isoglycyrrhizinate placebo followed by Diammonium Glycyrrhizinate placebo
2432547|NCT03349008|Experimental|Experimental group|Entecavir combined with glycyrrhizin, Magnesium Isoglycyrrhizinate Injection followed by Diammonium Glycyrrhizinate
3187892|NCT00760903||Pediatric|Group III: 30 patients < 18 years old, gender and race indifferent with moderate head trauma (pediatric patient group)
2432617|NCT03348579||The third and final period|The third and final period will consist of all consecutive patients admitted to the participating ICUs after the formal training.
2432549|NCT03348982|Experimental|Intervention group|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session) in a hall/gymnasium of each participating school.Each intervention session will be conducted in the morning by a trained research assistant assisted by student helpers. Each intervention session will be conducted in an identical format, comprising three activities: warm-up (5 min), jogging (20 min), and cool-down (5 min). In the jogging activity, participants will be asked to jog side-by-side with the research staff around an activity circuit (57m x 50m) marked with 4 red cones.
2432550|NCT03348982|No Intervention|Control group|Participants in the control group will receive no physical intervention and will be required to follow their daily routine without participating in any additional physical activity/exercise program throughout the whole study period (T1-T3).
2432551|NCT03348969|Experimental|Intervention|Neoadjuvant Mitomycin C
2432552|NCT03348969|Active Comparator|Control|Adjuvant Mitomycin C
2432553|NCT03348956|Experimental|EPR Oximetry|All subjects in the study will receive the paramagnetic India ink injection to the foot. At three time points (pre-exposure, during-exposure or CIPN incidence, and post exposure), subjects will have three EPR oximetry readings, a neurological examination, and electrophysiologic testing.
2432554|NCT03348943|Active Comparator|Right hemiparesis, right upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
2432555|NCT03348943|Experimental|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
2432556|NCT03348943|Active Comparator|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
2432557|NCT03348943|Experimental|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
2432558|NCT03348930|Experimental|Tolcapone|Each subject will have a 4 week treatment phase with Tolcapone
2432559|NCT03348930|Placebo Comparator|Placebo|4 week placebo phase before or after Tolcapone phase depending on randomization.
2432560|NCT03348917|Active Comparator|Treatment sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)"
2432561|NCT03348917|Active Comparator|Treatment sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)"
2432562|NCT03348917|Active Comparator|Treatment sequence Group 3|"Treatment Sequence Group 3 = C -> A ->B~Treatment C = Plain non antibacterial soap - Guardian gel hand wash (not medicated)~Treatment A = Betadine® 7.5% skin cleanser (PVP-I 7.5%)~Treatment B = 4% chlorhexidine skin cleanser - Unity antiseptic hand wash (no alcohol)"
3187893|NCT00760903||Pre-evaluated|Group IV: 10-20 patients age, gender and race indifferent with moderate head trauma that have been examined with conventional MRI of the brain, MRS and DTI as clinically requested. The images of these patients will be evaluated retrospectively for data- point collection.
3187894|NCT00760903||Control Group|Group V (control group): 20 volunteers without prior history of traumatic brain injury or neurological problems.
3187895|NCT00760916|Placebo Comparator|Placebo|placebo
2432568|NCT03348878|Other|cohort of uncontrolled hypertensive patients|
2432569|NCT03348865|Experimental|Fertility Life Counselling Aid (FeLiCiA)|"Patients to undergo weekly Felicia counselling interventions for 6 weeks; making a total of 6 sessions.~Each session is expected lasts 30 mins to 1 hour."
2432570|NCT03348865|No Intervention|Control|Patients are to undergo treatment as usual.
2432571|NCT03348852|Active Comparator|Active tDCS|Active transcranial direct current stimulation
2432572|NCT03348852|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
2432573|NCT03348839|Experimental|Cluster 1|NeLLY service is implemented after 8 months.
2432574|NCT03348839|Experimental|Cluster 2|NeLLY service is implemented after 12 months.
2432575|NCT03348839|Experimental|Cluster 3|NeLLY service is implemented after 16 months.
2432576|NCT03348839|Experimental|Cluster 4|NeLLY service is implemented after 20 months.
2432577|NCT03348839|Experimental|Cluster 5|NeLLY service is implemented after 24 months.
2432578|NCT03348839|Experimental|Cluster 6|NeLLY service is implemented after 28 months.
2432579|NCT03348839|Experimental|Cluster 7|NeLLY service is implemented after 32 months.
2432580|NCT03348826|Experimental|Alteplase then Sodium Bicarbonate|Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered.
2432581|NCT03348826|Experimental|Sodium Bicarbonate then Alteplase|Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered.
2432582|NCT03348813|Experimental|HIV/STI Prevention Intervention|Two-session, small group HIV/STI prevention intervention.
2432583|NCT03348813|Active Comparator|General Health Control Intervention|Two-session, small group general health promotion intervention.
2432584|NCT03348800|Experimental|Test Side|The side in which computer controlled anesthetic delivery system will be used as dental anesthesia before dental surgery
2432585|NCT03348800|Active Comparator|Control Side|The side in which conventional syringe will be used as dental anesthesia before dental surgery
2432586|NCT03348787|Experimental|Behavioral and Cognitive Therapies|Chronic psychotic patients will have Behavioral and Cognitive Therapies
2432618|NCT03348553|Sham Comparator|control group|20 subjects do not receive any supplementation
2432619|NCT03348553|Active Comparator|Omega2|20 subjects receive an Omega-Fatty-acid Nutratceutical
2432620|NCT03348553|Active Comparator|Omega4|20 subjects receive an Omega-Fatty-acid Nutraceutical
2432621|NCT03348553|Active Comparator|Omega2+OGV|20 subjects receive an Omega-Fatty-acid Nutraceutical + encapsulated fruit, vegetable and berry-juice concentrate
2432668|NCT03348215|Other|Enhanced Treadmill Training|Treadmill walking with an immersive environment and bio mechanical support (body weight, ankle-foot -orthosis and functional electrical stimulation)
2432587|NCT03348761|Experimental|rTMS Group|"Twenty sessions of neurostimulation at the left DLPFC.~Phase I: A Magstim Super-Rapid device with a 70-mm figure-of-eight double air film coil (Magstim Ltd, UK) and Brainsight neuronavigation (Rogue Resolutions Ltd, Canada) are used. Stimulation parameters: 10 Hz, 120% resting motor threshold, 30 trains of 5 seconds with 25 seconds rest, 3000 pulses per day delivered 5 days per week (total: 60000 pulses).~Phase II: A Neuro-MS/D Advanced Therapeutic Transcranial Magnetic Stimulator (Neurosoft, Russia) with a 100-mm cooled figure-of-eight coil and Neural Navigator navigation (Brain Science Tools, the Netherlands) are used. Stimulation parameters: triplet 50 hertz, repeated at 5 hertz, 120% resting motor threshold, 20 trains of 2 seconds with 8 seconds between trains, 600 pulses per day delivered 5 days per week (total: 12000 pulses)."
2432588|NCT03348748|Experimental|Study 1 (highest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the peripheral lung undergo highest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2432589|NCT03348748|Experimental|Study 2 (lowest-dose of SBRT, surgery)|Patients with stage I or II NSCLC in the central lung undergo lowest-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2432590|NCT03348748|Experimental|Study 3 (lowest- or higher-dose of SBRT, surgery)|Patients with stage IIIA NSCLC in the any lung location undergo lowest- or higher-dose of Stereotactic Body Radiation Therapy over a single treatment fraction on day 1. Patients then undergo thoracic surgery on day 28.
2432591|NCT03348735|Experimental|Lidocaine patch 5%|Lidocaine 5% medicated plasters will be applied daily, during 12 consecutive hours.
2432592|NCT03348735|Experimental|Capsaicin 8% patch|Capsaicin 8% patches need to applied in a hospital setting during 1 hour. Re-application of these capsaicin patches will be performed upon re-occurrence of painful symptoms (mostly after 12 weeks - so not after a fixed time interval). Application of capsaicin patches will be carried out in a hospital setting (+/- 3 hours procedure).
2432593|NCT03348735|Active Comparator|Pregabaline|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe. In European clinical practice, up-titration of the dose is often carried out over a longer time-period. This study thus includes up-titration schedule for pregabalin over a period of 4 weeks. If patients develop side-effects during the intake/uptitration of pregabalin this treatment can be stopped and switched to gabapentin (300mg capsules). Gabapentin will always be the back-up treatment for failed systematic treatment with pregabalin. Dose of gabapentin will be uptitrated to maximum 1200mg per day.
2432594|NCT03348722||Active surveillance|Newly diagnosed low risk prostate cancer patients managed according to an active surveillance program
2432595|NCT03348722||Radical prostatectomy|Newly diagnosed low risk prostate cancer patients undergoing radical prostatectomy
2432596|NCT03348722||Radiotherapy|Newly diagnosed low risk prostate cancer patients undergoing radiotherapy (external or brachitherapy)
2432597|NCT03348722||Other radical treatment|Newly diagnosed low risk prostate cancer patients undergoing other radical treatments (HIFU, cryotherapy, others)
2432598|NCT03348709|Experimental|Isoosmolar|Iso-osmolar oral supplement (276 mOsm/kg)
2432599|NCT03348709|Active Comparator|Hyperosmolar|Hyper-osmolar oral supplement (681 mOsm/kg)
2432600|NCT03348696|Active Comparator|dexamethasone tapering dose|standard dexamethasone pre-medication (8mg B.I.D x 3 days commencing the day before chemotherapy) then 4mg 1x/d for 2 days followed by 2mg 1x/d for 2 days
2432601|NCT03348696|Active Comparator|dexamethasone physician choice|standard dexamethasone pre-medication (i.e. 8mg B.I.D x 3 days commencing the day before chemotherapy) then physician choice interventions
3187896|NCT00760916|Active Comparator|UT-15C 0.25 mg|UT-15C 0.25 mg
3187897|NCT00760916|Active Comparator|UT-15C 1 mg|UT-15C 1 mg
2432604|NCT03348670|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein~0.5 ml Lactated Ringer's Injection, USP"
2432605|NCT03348657|Other|Music intervention Group|Patients who participated to at least one music session provided by volunteers while being admitted to the geriatric assessment unit. Participation to the music sessions was voluntary.
2432606|NCT03348657|No Intervention|Control Group|Patients who did not want to participate to the music sessions provided by volunteers while being admitted to the geriatric assessment unit
2432607|NCT03348644|Experimental|Phosphate tablets.|800 mg oral phosphor supplement distributed over five times a day independently of any prior treatment dose.
2432608|NCT03348644|Active Comparator|High cheese intake.|Cheese with an estimated phosphate content of 800 mg distributed over 5 meals.
2432609|NCT03348644|Active Comparator|High milk intake.|800 ml of milk daily corresponding to approximately 800 mg phosphor per day.
3187898|NCT00760916|Active Comparator|UT-15C 5 mg|UT-15C 5 mg
2432611|NCT03348618|Experimental|IVIG|IVIG dose at 1 g/Kg/body weight
2432612|NCT03348605|Other|First setting ON|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality ON. The second time the gait analysis is performed in the OFF modality.
2432613|NCT03348605|Other|First setting OFF|This arm performs the Gait analysis the first time after the familiarization phase with the stimulator in the modality OFF. The second time the gait analysis is performed in the ON modality.
2432614|NCT03348592|Experimental|Oligofructose-enriched inulin (p-inulin)|Participants are on no treatment for 8 weeks, then the pre-biotic p-inulin for 12 weeks, then no treatment for 8 weeks. Inulin is derived from chicory root fiber. The dose is 16 grams of p-inulin powder per day.
2432615|NCT03348579||The before period|The before period (control phase) will consist of all consecutive patients admitted to the participating ICUs before the national guidelines publication concerning hospital-acquired pneumonia.
2432616|NCT03348579||The second period|"Intensive care units are randomized in two groups:~Standard training: The centers will receive the text of the recommendation electronically. The principal investigator of each center will then train doctors, interns, nurses and physiotherapists to the use of these recommendations (team leader). A computer presentation common to all the centers will be used and a communication strategy vis-à-vis the other caregivers of the investigative services will be put in place. All doctors, interns and nurses must have attended this theoretical training during the awareness phase."
3187899|NCT00760942|Active Comparator|1|Liquid human milk fortifier
3187900|NCT00760942|Active Comparator|2|Powdered human milk fortifier
2432622|NCT03348540|Experimental|Attention Control Training|"6 sessions in the clinic lasting approximately 10 minutes each.~Each session will consist of 128 presentations of pairs of neutral and threatening stimuli, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2432623|NCT03348540|Placebo Comparator|Comparison Task|"6 sessions in the clinic of a presumably inactive neutral-neutral stimuli intervention lasting approximately 10 minutes each.~• Each session will consist of 128 presentations of pairs of faces, followed by the presentation of a response cue (right or left arrow to be clicked on a computer keyboard)."
2432624|NCT03348527|Experimental|Stage I: Dose = 35% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 35 % of their prostate volume.
2432625|NCT03348527|Experimental|Stage I: Dose = 45% of prostate volume|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 45 % of their prostate volume.
2432626|NCT03348527|Experimental|Stage II: Dose = 16mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 16mL
2432627|NCT03348527|Experimental|Stage II: Dose = 20mL|Subject will be randomized into a group receiving one dose of 2-hydroxyflutamide depot (Liproca® Depot) equal to 20mL
3187901|NCT00760955|Experimental|TAK-583 5 mg QD|
3187902|NCT00760955|Experimental|TAK-583 50 mg QD|
2432630|NCT03348488|No Intervention|Standard ultrafiltration|standard ultrafiltration (fluid removal from the body by dialysis at the prescribed volume and rate) during a conventional treatment
2432631|NCT03348488|Active Comparator|High dose ultrafiltration|Intervention= Fixed rate high dose ultrafiltration (fluid removed from the body by dialysis) of 1 litre per hour over 1 hr instaed of standard ultrafiltration rate and volume.
2432632|NCT03348475|Experimental|Experimental Group|Binge Focused Therapy (BFT) Intervention
2432633|NCT03348462|Experimental|ethosomal anthralin|Group 1: included 10 psoriatic patients will be treated with ethosomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
2432634|NCT03348462|Active Comparator|liposomal anthralin|Group 2: included 10 psoriatic patients will be treated with liposomal preparation of anthralin. Patients will be treated with this preparation with short contact (only one hour) daily up to 8 weeks.
2432635|NCT03348436|Experimental|patients with atrioventricular nodal reentrant tachycardia|radiofrequency catheter ablation therapy
2432636|NCT03348436|Experimental|patients with atrioventricular tachycardia|radiofrequency catheter ablation therapy
2432637|NCT03348423|Experimental|DEX-IN 50 µg|Dexmedetomidine Intranasal Spray
2432638|NCT03348423|Active Comparator|Fentanyl 50 µg|Intravenous Fentanyl
2432639|NCT03348423|Placebo Comparator|Placebo|Placebo
2432640|NCT03348410|Experimental|Intervention|Motivational interviewing
2432641|NCT03348410|No Intervention|Control|Control group
2432642|NCT03348397||Contegra patients|
2432643|NCT03348397||Pulmonary homograft patients|
2432644|NCT03348384|Experimental|Cocaine use disorders|PET scan
2432645|NCT03348384|Experimental|Controls|PET scan
2432646|NCT03348371|Experimental|Oral day|Participant receive ethanol orally
2432647|NCT03348371|Experimental|i.v. infusion day|Participant receive ethanol in an i.v. infusion
2432648|NCT03348358|Placebo Comparator|control|No music during labor
2432649|NCT03348358|Experimental|Quiet music|Women hearing quiet music during labor
2432650|NCT03348358|Experimental|Rhythmic music|Women hearing rhythmic music during labor
2432651|NCT03348345|Experimental|Eat Breathe Thrive Intervention|A manualized program designed to prevent eating disorders using psychoeducation, group work, and yoga.
2432652|NCT03348345|No Intervention|Wait-List|Participants are placed on a wait-list receiving no intervention.
2432653|NCT03348332|No Intervention|Sedentary pregnant women|Pregnant women who do not exercise regularly during pregnancy
2432654|NCT03348332|Experimental|Exercise pregnant women|Pregnant women who participate in a supervised exercise program
2432655|NCT03348319||Cadaver organs|
2432656|NCT03348306|Experimental|All patients|
2432657|NCT03348293|Experimental|3D printing patient|Immediate breast reconstruction using 3D printing personalized scaffold
2432660|NCT03348267|Experimental|Protein|On the match day, 25g of protein consumed immediately after the match and then 30g at 3h (+3h) and 25g at 6h (+6h). On each day of the remaining days, 20 g of protein consumed with breakfast.
2432661|NCT03348267|Active Comparator|Placebo|On the match day, 500 ml received received orally immediately post-match and then at +3h and +6h. On the remaining days, 500 ml daily with breakfast.
2432662|NCT03348254||1|Group one will consist of patients receiving a single shot antibiotic prophylaxis preoperatively before primary arthroplasty of hip or knee
2432663|NCT03348254||2|Group two will consist of patients receiving multiple shot antibiotic prophylaxis perioperatively before and after primary arthroplasty of hip or knee
2432664|NCT03348241|Experimental|Gum Arabic group|Patients of study group was received a dose of 30 grams Gum Arabic per day as oral solution (dissolved in 250 ml purified water) for six weeks along with the chemotherapy prescribed addition to verbal instructions pertaining to the optimal nutrition and daily routine for oral hygiene.
2432665|NCT03348241|Other|Control group|Patients of control group was received only chemotherapy regimen and verbal counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
2432666|NCT03348228|Placebo Comparator|Control Group|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
2432667|NCT03348228|Active Comparator|Calcium Stone Formers|Participants willrecord a self-selected diet for 3 days and then perform two 24-hour urine collections on the last 2 days of this diet. HCA will be administered afterwards to both groups (see methods below) for 7 days
2432844|NCT03346837|Experimental|Induction (Cohort 3)|Single oral dose BMS-986205
2432669|NCT03348202||Focus Group Participants|Approximately 24 groups (6 per country; Finland, Norway, Spain, Italy) consisting participants aged 80+ recruited from: senior community centres, adult day care centres, nursing homes. Each focus group will comprise from 4 to 8 people. Attempts would be made to create gender-balanced groups.
2432670|NCT03348189||Observational|Healthy males and females
2432671|NCT03348176|Experimental|Vegetable exposure|Repeated exposure to a variety of vegetables from the start of complementary feeding
2432672|NCT03348176|Experimental|VIPP-Feeding Infants|Promotion of responsive feeding practices from the start of complementary feeding
2432673|NCT03348176|Experimental|Exposure + VIPP-FI|Combination of repeated exposure to vegetables and promotion of responsive feeding practices
2432674|NCT03348176|Sham Comparator|Control|Phone calls on development child with no information on complementary feeding
2432675|NCT03348163|Experimental|Switch ART|Switch from current antiretroviral therapy (ART) to B/FTC/TAF bfor 48 weeks
2432676|NCT03348163|Active Comparator|Continue Current ART|Continue current (ART) therapy (emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent) for 48 weeks
2432677|NCT03348150|Experimental|Gastrecomy + Cytoreductive surgery + HIPEC|
2432678|NCT03348150|No Intervention|palliative systemic chemotherapy|
2432679|NCT03348137||Ancillary-Correlative (questionnaire)|Patients take Progeny Genetic Pedigree and Family History Questionnaire. Results are reviewed by the site specific research coordinator and/or genetic counselor to assess whether a patient fulfills criteria for referral to the site specific cancer genetics clinic for further evaluation.
2432680|NCT03348124|Experimental|Intervention|"Educational lessons based on the conversational material Toolkit Children - what does it involve?, will be delivered in the classroom at school and caring for the RCB simulator during three days and nights."
2432681|NCT03348124|No Intervention|Control|Education as usual.
2432682|NCT03348111|Experimental|Air-polishing device|Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®
2432683|NCT03348098|Experimental|single arm|Apatinib Combined With Paclitaxel in Neoadjuvant Therapy of Locally Advanced Exploratory Research on Single-arm of TNBC
2432684|NCT03348072||Jehovah's witnesses|Jehovah's witnesses having undergone cardiac surgery between 1991 till 2012. Blood perfusions refused.
2432685|NCT03348072||Control|Paired control group, twice as big as the experimental group. Pairing criteria: age, sex, type of surgery performed. The control group must accept blood transfusions.
2432686|NCT03348033|Experimental|Chronic Myeloid Leukemia + NK cell|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total.~NK Cell infusion on Days 0 to 14 for 6 doses total."
3147311|NCT00121550|Experimental|Clarithromycin|Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
3147312|NCT00121550|Placebo Comparator|Placebo|Placebo comparator
2432689|NCT03348007|Experimental|HEPAR|1L of Hépar + 0.5L of low-mineral water (Hépar group).
2432690|NCT03348007|Active Comparator|VITTEL Bonne Source|1.5L of low-mineral water (Vittel Bonne Source, control group)
2432691|NCT03347994|Experimental|Minnelide 0.40 (Dose Level -1)|"Dose Level -1: 25% decrease from prior dose level~- 0.40 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2432692|NCT03347994|Experimental|Minnelide 0.53 (Dose Level 1)|"Starting Dose Level 1:~0.53 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2432693|NCT03347994|Experimental|Minnelide 0.67 (Dose Level 2)|"Dose Level 2: 25% increase from Dose Level 1~- 0.67 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2432694|NCT03347994|Experimental|Minnelide 0.80 (Dose Level 3)|"Dose Level 3: 25% increase from Dose Level 2~- 0.80 mg/m2 administered intravenously on days 1-5, 8-12, and 15-19 of a 28 day cycle"
2432695|NCT03347981|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2432696|NCT03347981|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
2432697|NCT03347968|Experimental|MEDI0382|All participants will receive MEDI0382.
2432698|NCT03347968|Active Comparator|Warfarin|All participants will receive Warfarin
2432699|NCT03347968|Active Comparator|Esmolol|All participants will receive Esmolol
2432700|NCT03347955|Experimental|Neural implantation group|Human embryonic dopamine neurons were implanted into brains of half the randomized participants (n = 20). Participants were evaluated at baseline, 4, 8, and 12 months after surgery.
2432701|NCT03347955|Sham Comparator|Sham Surgery group|This group (n = 20) received sham surgery with a steel frame affixed to their heads and four burr holes drilled into their foreheads without crossing the blood/brain barrier. Participants were assessed at baseline, 4, 8, and 12 months after surgery.
2432702|NCT03347942|Experimental|Intervention|During a period of 30 days the research participant in the intervention group will be instructed to wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before being served again if he or she feels the need.
2432703|NCT03347942|Other|Control|The control group will also serve the dish the same way, but you can serve additional portion without waiting.
2432704|NCT03347929|Experimental|Naproxen|Naproxen 500 mg twice daily
2432705|NCT03347929|Placebo Comparator|Placebo|Placebo 1 tablet twice daily
2432706|NCT03347916|Placebo Comparator|Control group|patients received strawberry juice 5 ml volume, one hour before induction.
2432707|NCT03347916|Active Comparator|Gabapentin group|patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
2432708|NCT03347890|Experimental|Liraglutide 3.0 mg|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg).
3147313|NCT00121602|Active Comparator|Roller bottle|
2432709|NCT03347890|Placebo Comparator|Placebo|35 obese patient will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Placebo by pen injector.
2432710|NCT03347877|Experimental|autologous bone-periosteal graft|The patients in experimental group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteo-periosteal cylinder graft transplantation.
2432711|NCT03347877|Active Comparator|autologous osteochondral graft|The patients in control group will undergo the surgery of arthroscopic repair Hepple V osteochondral lesions of the talus with autologous osteochondral graft transplantation.
2432712|NCT03347864|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 30-45 min later
2432713|NCT03347851||On-X AAP|Patients with prior AVR surgery with the CryoLife On-X Ascending Aortic Prosthesis (AAP).
2432714|NCT03347851||SJM Masters or Carbomedics Carbo-seal|Patients with St. Jude Medical Masters HP Valved Graft with Gelweave Valsalva™ Technology or Carbomedics Carbo-seal (including Carbo-seal Valsalva) mechanical aortic valve prostheses patients
3147314|NCT00121602|Experimental|Serum free|
2432716|NCT03347825||Robotic-assisted lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent robotic-assisted lobectomy for lung cancer.
2432717|NCT03347825||VATS (video assisted thoracic surgery) lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent VATS lobectomy for lung cancer.
2432718|NCT03347825||Open lobectomy|Pre-operative, intra-operative and post-operative clinical, surgical and oncological information will be obtained from institutional records for patients who underwent open lobectomy for lung cancer.
2432719|NCT03347812||Endovascular Aortic Repair|Patients with aortic arch lesions who only received endovascular treatment, including chimney / fenestration / branch stent-grafts technique and combination of these techniques, would be assigned to this group.
2432720|NCT03347812||Total Arch Replacement|Patients with aortic arch lesions who only received traditional open surgery for total aortic arch replacement, would be assigned to this group.
2432721|NCT03347773|Experimental|Intervention|The subjects will be assigned to receive nutritional supplement consisting of one can of ReGen 18% (19.1 g protein, 425 Kcal) daily and standard care.
2432722|NCT03347773|No Intervention|Control|The subjects will be assigned to receive standard care alone.
2432723|NCT03347760|Experimental|Experimental arm|All included patients wil receive 68Ga-dotatoc-PET/CT suspected acute myocarditis in first and an other 68Ga-dotatoc-PET/CT 6 months later
2432724|NCT03347747||Photoaged Male Subjects|45-80 year old males with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
2432725|NCT03347747||Photoaged Female Subjects|45-80 year old females with visible photoaging and the desired exposure profile/driving history and who also has spent (or are spending) at least 30 minutes in a car per day (as the driver), 5 days per week for at least 15 years of their adult life to ensure they have the type of asymmetrical exposure required for hypothesis validation. This is an multi-center trial, and study sites will range from northern to southern latitudes in North America, Australia and potentially other international sites. Study Photography + Personal & Medical History Collection via a study questionnaire will be obtained.
2432726|NCT03347734|Experimental|Eye Exercises Group (EEG)|For the individuals in the group of eye exercises (GEG), 10 repetitive eye exercises protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
2432727|NCT03347734|Experimental|Convergence Exercise Group (CEG)|For the individuals in the group of convergence exercise, 5 minutes convergence exercise protocol was organized as a home program for 6 weeks, twice a day in the morning and evening each day of the week.
2432728|NCT03347734|Experimental|Oculomotor Exercise Group (OMEG)|For the individuals in the group of oculomotor exercise, 10 repetitive, four different oculomotor exercise protocols with eye stabilization were organized as home programs for 6 weeks, twice a day in the morning and evening each day of the week.
2432729|NCT03347721|Active Comparator|Lidocaine gel|
2432730|NCT03347721|Placebo Comparator|Lubricant Gel|
2432731|NCT03347708|Experimental|High Dose IDCT|Single intradiscal injection with High Dose IDCT (9M cells).
2432732|NCT03347708|Experimental|Low Dose IDCT|Single intradiscal injection with Low Dose IDCT (3M cells).
2432733|NCT03347708|Placebo Comparator|Saline|Single intradiscal injection with saline solution.
2432734|NCT03347708|Placebo Comparator|Sodium Hyaluronate Vehicle|Single intradiscal injection with Sodium Hyaluronate Vehicle.
3147315|NCT00121654|Active Comparator|1|paresthesic SCS
3147316|NCT00121654|Active Comparator|2|subliminal SCS (75-80% of paresthesic threshold)
2432768|NCT03347422|Experimental|Part B: Response Extension Phase (sutimlimab)|In Part B, all participants will undergo blinded cross-over loading doses to allow all participants to receive sutimlimab while maintaining Part A blinding.
2432769|NCT03347409|No Intervention|Standard Perioperative (SP) care|
3147317|NCT00121654|Sham Comparator|3|low stimulation, consisting of an hour of SCS a day at 0.05 mV intensity, which does not have any significant stimulator effect (sham stimulation)
3147318|NCT00121680|Experimental|1|
3147319|NCT00121693|Experimental|Music Listening 1|Intervention: Listen to Music type 1
3147320|NCT00121693|Experimental|Music Listening 2|Intervention: Listen to Music type 2
3147321|NCT00121693|Experimental|Music LIstening 3|Intervention: Listen to Music type 3
3147322|NCT00121693|No Intervention|Control|Intervention: Listen to White noise
3147323|NCT00121732|Experimental|A|
3147324|NCT00121732|Experimental|B|
3147325|NCT00121745|Experimental|1|
3147326|NCT00121745|Experimental|2|
3147327|NCT00121745|Experimental|3|
3147328|NCT00121745|Experimental|4|
2432737|NCT03347682||Test group: Transtibial amputees|After translation/retranslation of the Prosthesis donning and doffing questionnaire, transtibial amputees will be asked to complete a quality of life evaluation Nottingham Health Profile-NHP, a satisfaction evaluation Satisfaction with Prosthesis -SATPRO and the Turkish version of the Prosthesis donning and doffing questionnaire twice (1-3 days apart).
2432738|NCT03347669|Experimental|FM patients|50 fibromyalgia patients/50 healthy subjects
2432739|NCT03347669|Active Comparator|Healthy subjects|50 fibromyalgia patients/50 healthy subjects
2432740|NCT03347643|Active Comparator|tDCS with real stimulation|A total of 25 patients will be allocated into active comparator with real stimulation with tDCS.
2432741|NCT03347643|Sham Comparator|tDCS with sham stimulation|A total of 25 patients will be allocated into sham comparator with sham stimulation with tDCS.
2432742|NCT03347630|Other|oesophagus cancer MRI|Diagnostic test
3147329|NCT00121784|Experimental|1|1
2432744|NCT03347604||Patients with abdominal obesity|Enrolling patients with abdominal obesity as defined by WHO to have waist to hop ratio of > 0.85 in women, or > 0.9 in men.
2432745|NCT03347591||Patients with rare bleeding disorders|All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
2432746|NCT03347578||Lung cancer surgery|All patients undergoing thoracic surgery for lung cancer either with thoracoscopy or thoracotomy will receive diaphragmatic Ultrasonography 2 and 24 hours after surgery
2432747|NCT03347565||Adolescents with an Eating Disorder|Females between the ages of 14-17 currently diagnosed with an eating disorder (including ARFID, Anorexia Nervosa, Bulimia Nervosa, OSFED)
2432748|NCT03347565||Healthy Controls|Females between the ages of 14-17 with no psychiatric conditions
2432749|NCT03347552|Experimental|Active Treatment|Participants in the active arm will be enrolled in the HOME Program.
2432750|NCT03347552|No Intervention|E-CARE|"Receiving enhanced care as usual. Participants at these sites are described as receiving enhanced care as usual or E-CARE because they will be recruited, enrolled and complete baseline and follow-up assessments in addition to care as usual."
2432751|NCT03347539||Nexplanon|This group is participants who choose to receive the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of implant.
2432752|NCT03347539||Removal participants|This group is participants who choose to remove the nexplanon implant. This group will only have one study interaction in the form of filling out a survey, at the time of removal. Anyone with a Nexplanon implant can have the implant removed on the mobile health unit and become part of this group - removal participants do not need to be in the Nexplanon group.
2432753|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1mg/mL + vigabatrin|
2432754|NCT03347526|Experimental|Cosyntropin Injectable Suspension, 1 mg/mL|
2432755|NCT03347526|Active Comparator|Vigabatrin|
2432756|NCT03347513|Experimental|Eradication of H-pylori|"triple attack therapy (Clarithromycin 500 mg BID for 14 days, omeprazole 20 mg BID for 14 days, metronidazole 500 mg BID for 14 days).~Followed by confirmation of eradication by repeating the H-pylori stool antigen test.~Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt."
2432757|NCT03347513|Active Comparator|No eradication of H-pylori|Iron therapy will be given twice daily for one month in the form ferrous(II)-glycine-sulphate complex 567.7 mg capsules (each capsule contains about 100 mg elemental iron) Ferro sanol duodenal ®Minapharm, Egypt.
2432758|NCT03347500||obese OA patients|"Use of patient-derived biological samples~Inclusion Criteria:~Subscription of informed consent~BMI ≥ 30~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
2432759|NCT03347500||Non-obese OA patients|"Use of patient-derived biological samples~Inclusion criteria:~Subscription of informed consent~BMI ≤ 28~age between 60-80 years included~Kelgrenn-Lawrence equal or superior to grade III~presence of synovitis~patients undergoing knee replacement~suspension of NSAIDs from one week before the surgical procedure according to the standard clinical practice~Exclusion criteria:~- HCV, HIV, HBV, TPHA infection"
2432760|NCT03347487|Experimental|Deep Brain Stimulation of Bilateral Habenula|
2432761|NCT03347474|Experimental|Bilateral surgical implantation of DBS system to NAc|
2432762|NCT03347461|Experimental|Otiprio by surgeon|Otiprio will be administered through the tympanic membrane by the otolaryngologist immediately after tympanostomy placement.
2432763|NCT03347461|Active Comparator|Ciprodex by surgeon|Ciprodex drops will be instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery.
2432764|NCT03347461|Active Comparator|Ciprodex by surgeon and parent|Ciprodex drops will be instilled by the otolaryngologist into the ear immediately after tympanostomy tube surgery. The parent or guardian will administer Ciprodex drops into the ears twice daily for five days after surgery.
2432765|NCT03347435|Experimental|Genotype/ phenotype guided group|The patients randomized to the genotype/phenotype guided group undergo genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435 genetic variants immediately after diagnosis of ACS and receive one of the ADP receptor antagonists (clopidogrel/prasugrel/ticagrelor) on the basis of an algorithm that consider genetic and clinical variables.
2432766|NCT03347435|Active Comparator|phenotype only guided group|The patients randomized to the phenotype only guided group receive clopidogrel or prasugrel or ticagrelor on the basis of the standard of care on the basis of clinical algorithm alone.
2432767|NCT03347422|Experimental|Part A: sutimlimab or Placebo|In Part A, participants will be randomized 1:1 to receive an intravenous (IV) infusion of sutimlimab or placebo.
2432770|NCT03347409|Experimental|ERAS protocol|
3147330|NCT00121875||Turner syndrome|Girls, aged 7-14, with short stature due to Turner syndrome and eligible for growth hormone therapy
3147331|NCT00121875||Control / idiopathic short stature|Girls, aged 7-14, with idiopathic short stature and eligible for growth hormone therapy
3147332|NCT00121940|Experimental|Guided Care|
3147333|NCT00121940|No Intervention|Usual Care|
3187903|NCT00760955|Experimental|TAK-583 100 mg QD|
2432771|NCT03347396|Experimental|Sutimlimab|Participants will receive an intravenous (IV) infusion of sutimlimab. Participants who complete Part A per protocol through the end of treatment visit (Day 182) will participate in Part B, and continue to receive sutimlimab up to 1 year after last patient out (LPO) in Part A.
2432772|NCT03347383|Experimental|Combination therapy DCB + stent|Patients treated with the Luminor DCB and the iVolution stent
2432773|NCT03347370||SC Peginterferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2432774|NCT03347370||SC interferon beta-1a|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2432775|NCT03347370||SC interferon beta-1b|Participants with relapsing-remitting multiple sclerosis (RRMS), currently stable on SC interferon beta treatment for three months or longer (switch between SC interferon beta treatments possible).
2432776|NCT03347357|Experimental|tacrolimus|
2432777|NCT03347344|Experimental|RILUZOLE|Riluzole PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet. The tablets will be held under a blister of 20 tablets.
2432778|NCT03347344|Placebo Comparator|PLACEBO|The placebo PMCS 50 mg is presented as a round, biconvex, 8 mm diameter nearly white film-coated tablet matching the appearance of the Riluzole used in this study
2432779|NCT03347331|Experimental|Input function group|Each subject underwent a 90 min acquisition PET scan with concomitant arterial blood sampling
2432780|NCT03347331|Experimental|Test-retest group|Each subject underwent 2 PET scans distant from 1 to 3 weeks
2432781|NCT03347305|Experimental|Patients Group DPA|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
2432782|NCT03347305|Experimental|Healthy Volunteers|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
3147334|NCT00122018|Experimental|NAC|N-acetylcysteine started day prior to surgery, continued through night of surgery
3147335|NCT00122018|Experimental|fenoldopam|fenoldopam started at surgery continued for 24 hours
3147336|NCT00122018|Experimental|NAC and fenoldopam|Both N-acetylcysteine and fenoldopam as above
3147337|NCT00122018|Placebo Comparator|Control|Placebo
2432787|NCT03347266|Experimental|VVZ-149 injections|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a 1000mg for 10 hours.
2432788|NCT03347266|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
2432789|NCT03347240|Active Comparator|Brain lesioning group|Stereotactic lesioning of the thalamus or gloves pallidus
2432790|NCT03347240|Active Comparator|Combined rhizotomy group|Combined anterior and posterior lumbosacral rhizotomy
2432791|NCT03347240|Active Comparator|Deep brain stimulation group|Bilateral globus pallidus internus deep brain stimulation
2432792|NCT03347240|Active Comparator|Intra-thecal Baclofen infusion therapy|Intra-thecal infusion pump
3147338|NCT00122031|Experimental|DBS|
3147339|NCT00122070|Experimental|A|Quetiapine at dosage of 50 to 150 mg
2432795|NCT03347214||1|People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study
2432796|NCT03347201|Experimental|Intervention Group|"Initial heparin bolus before CPB to be calculated using HMS Plus.~Following commencement of CPB further heparin requirements will be determined using the HMS Plus. ACT's will also be checked whilst on CPB and if falls below 480 seconds, additional heparin will also be given.~Following cessation of CPB the dose of protamine required to reverse residual heparin will be calculated using the HMS Plus."
2432797|NCT03347201|No Intervention|Control Group|Patients in the control arm will undergo routine heparin anticoagulation using a weight based initial dose of 400 units/kg, aiming for an ACT of >480 seconds. Further heparin doses (5000 to 10000 units) will be given if the ACT falls below 480 seconds whilst on bypass. At the end of CPB heparin will be reversed with protamine using 1:1 ratio based on the initial dose of heparin given pre-bypass. HMS Plus measures will also be conducted in this group for study purposes, but the results will not be made available to the clinicians.
3147340|NCT00122122|Other|Arm 1|
3147341|NCT00122148|Other|1|
2432800|NCT03347175|Experimental|Volume controlled ventilation|Intervention1: Ventilation with Volume controlled ventilation
2432801|NCT03347175|Active Comparator|Pressure controlled ventilation|Intervention2: Ventilation with Pressure controlled ventilation
2432802|NCT03347175|Active Comparator|CPAP mode|Intervention3: Ventilation with Continuous Positive Airway Pressure mode only
2432803|NCT03347162||Cohort 1 - Resectable patients|These patients will undergo 3 assessments: a baseline-assessment prior to surgery, a post-surgery assessment (2 week post-surgery) and a follow-up assessment 6 months after surgery (after adjuvant oncology treatment).
2432838|NCT03346876||Study group|patients with pectus excavatum
2432839|NCT03346876||Control group|healthy subjects without pectus excavatum
3147342|NCT00122161|Other|Arm 1|
3147343|NCT00122174|Other|Arm 1|
3147344|NCT00122343|Experimental|1|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
3147345|NCT00122356|Other|Anastrozole and alendronate|Patients will receive anastrozole for 5 years and alendronate for 3 years or anastrozole and alendronate treatment for 5 years.
3147346|NCT00122408|Active Comparator|1|
3147347|NCT00122408|Placebo Comparator|2|
3147348|NCT00122421|Active Comparator|pharmacist recommendation|recommendations based on chart review by pharmacist, given to pcp at time of visit
3147349|NCT00122421|No Intervention|usual care|usual care
3147350|NCT00122603|Experimental|Group 1|Atazanavir + Fosamprenavir + ritonavir
3147351|NCT00122603|Experimental|group 2|Atazanavir + saquinavir + ritonavir
3147352|NCT00122616|Active Comparator|Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy|Day0 to week 96:Peginterféron alpha-2a + Ribavirin+ HIV antiretroviral therapy
2432804|NCT03347162||Cohort 2 - Non-resectable patients|These patients will undergoing 3 assessments: a baseline-assessment prior to palliative treatment, an acute measurement 4 weeks after initiation of palliative treatment, and a 6-month long-term assessment.
2432805|NCT03347149||Pre-Phase (Control)|no Alarm Advisor Software installed
2432806|NCT03347149||Post-Phase (Observation)|Alarm Advisor Software implemented
2432807|NCT03347136|Active Comparator|Newborns with CPAP support|Newborn with mild to moderate respiratory distress randomly allocated to CPAP arm. CPAP started with Positive End Expiatory Pressure(PEEEP) 05 and increased up to PEEP 09 according to the severity of baby's condition.
2432808|NCT03347136|Experimental|Newborns with NIPPV support|Newborn with mild to moderate respiratory distress randomly allocated to NIPPV arm. NIPPV started with Intermittent Mandatory Ventilation rate 30, Peak Inspiratory Pressure 20 and PEEP 5.Increased the settings according to the severity of baby's condition
2432809|NCT03347123|Experimental|Treatment Group A|Epacadostat + nivolumab + ipilimumab
2432810|NCT03347123|Experimental|Treatment Group B|Epacadostat + nivolumab + lirilumab
3187904|NCT00760955|Placebo Comparator|Placebo QD|
2432812|NCT03347097|Experimental|TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml TIL cells ( TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
2432813|NCT03347097|Experimental|PD1-TIL cells|10 days after the end of chemotherapy or radiotherapy，the 300ml PD1-TIL cells ( PD1-TIL saline + 0.25% human serum albumin) was injected intravenously 2 times every 30 days .
2432814|NCT03347084|Active Comparator|Excitation|Excitation Paradigm: LIFUP excites the activity of hippocampal neurons.
2432815|NCT03347084|Active Comparator|Inhibition|Inhibition Paradigm: LIFUP inhibits the activity of hippocampal neurons.
2432816|NCT03347071||Prevention Course Group|The Prevention Course Group is composed of female student-athletes enrolled in the 7-week prevention course. The course occurs once a week (1 hour, 40 minute sessions) for a total of 7-weeks during the academic semester. Approximately 1 hour of each class session is lecture based, leaving 40 minutes for yoga practice administered by a certified yoga instructor. The course instructor is certified in Eat Breathe Thrive Program delivery. The course teaching assistant is certified in yoga instruction.
2432817|NCT03347071||Control Group|The Control Group is composed of female student-athletes not enrolled in the 7-week prevention course. Female student-athletes in this group will not be enrolled in the course during the period of data collection, nor will they have previously completed the course.
2432818|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
2432819|NCT03347045|Experimental|Trimodal Prehab & ERP|"Trimodal prehab includes:~Guided exercise program at Repsol Place in Calgary, Alberta 2x/week, hosted by the Total Cardiology group. Home-exercise program for another 3x/week.~Nutritional optimization with a high-protein oral supplement, along with nutritional counseling and access to a Registered Dietitian on site.~Anxiety reduction workshop and take-home anxiety reduction program."
2432820|NCT03347045|Active Comparator|No Prehab; ERP Alone|The active comparator group will be given a home exercise program, nutrition education, and a take-home anxiety reduction program.
2432821|NCT03347032|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
2432822|NCT03347032|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
2432823|NCT03347019|Experimental|accelerated rehabilitation after surgery|patients were included progressive rehabilitation programme first week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
2432824|NCT03347019|Experimental|delayed rehabilitation after surgery|Patients were not allowed to start passive shoulder exercises first three weeks after surgery. Patients were included progressive rehabilitation programme third week after arthroscopic bankart repair consisting of passive shoulder range of motion exercises, scapular retraction exercises. The exercise programme progressed from active range of motion exercises to resistive and plyometric shoulder exercises. Patients were followed for six months.
2432825|NCT03347006|Placebo Comparator|Placebo|Placebo control
2432826|NCT03347006|Experimental|Dose 1|1.5 g of omega-3 supplement
2432827|NCT03347006|Experimental|Dose 2|3.0 g of omega-3 supplement
2432828|NCT03347006|Experimental|Dose 3|4.5 g of omega-3 supplement
2432829|NCT03346993|Experimental|24C° 0,5% bupivacaine group|24C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 24C° 20 ml 0,5% bupivacaine
2432830|NCT03346993|Experimental|37C° 0,5% bupivacaine group|37C° 0,5% bupivacaine group will be performed USG guided infraclavicular block with 37C° 20 ml 0,5% bupivacaine
2432831|NCT03346980||Familial adenomatous polyposis|The Danish Polyposis Register is sited at Copenhagen University Hospital Hvidovre. From this registry consecutive familial adenomatous polyposis patients referred for esophagogastroduodenoscopy (EGD) will prospectively be enrolled in this single-center study. Both patients referred for endoscopic surveillance and interventional endoscopy are eligible.
2432832|NCT03346967|Experimental|Stem cell Administration for female patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for female patients
2432833|NCT03346967|Experimental|Stem cell Administration for male patients|Single Intravenous Administration of Autologous Adipose-derived Mesenchymal Stem Cells with Dosage at 1 million cells per body-weight kilogram for male patients
2432834|NCT03346954|Experimental|Patients with Cushing's disease|Implementation of [11C]-Methionine PET/MRI
2432835|NCT03346915|Experimental|Subjects receiving WoW and BNI|The behavioral intervention (WoW and BNI) will supplement the subject's standard of care by incorporating interactive messaging, reminders, patient education, and enhanced provider communication.
3187905|NCT00760968|Experimental|TAK-783 100 mg QD + Methotrexate|
3187906|NCT00760968|Active Comparator|Methotrexate|
3187907|NCT00760981|Experimental|Imatinib|200 mg orally daily and 400 mg orally daily for 4 weeks.
2432845|NCT03346837|Experimental|Induction (Cohort 4)|Daily oral rifampin doses for21 days; single oral dose BMS-986205 on day 8
2432846|NCT03346811|Experimental|Experimental: icotinib|Patients diagnosed with lung cancer with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
2432847|NCT03346798|Experimental|Food Photography|On the first visit, participants will engage in food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
2432848|NCT03346798|Experimental|Non-Food Photography|On the first visit, participants will engage in non-food photography on their smart phones while eating. On the second visit, participants will not use their smart phones while eating.
2432849|NCT03346785|Experimental|Food Photography|Participants will engage in food photography on their smart phones while eating
2432850|NCT03346785|Experimental|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
2432851|NCT03346785|Experimental|No Phone Use|Participants will not use their smart phones while eating
2432852|NCT03346772|Experimental|Influenza vaccination cohort|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
3187908|NCT00761020|Experimental|Mefloquine|Mefloquine 250 mg orally daily x 3 days beginning 2 days prior to challenge and then weekly for 4 weeks post challenge.
3187909|NCT00761020|Sham Comparator|Control|
2432855|NCT03346746|Experimental|Low GI diet|This diet contained three Low GI meals. This was the Low Glycaemic Diet intervention.
2432856|NCT03346746|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
2432857|NCT03346720||Participants recruited into biomedical research|Participants recruited into biomedical research where data collected may be shared with the wider research community.
2432858|NCT03346720||Frontline research staff|Frontline research staff directly involved in obtaining consent from participants in the above studies e.g. study nurses, investigators
2432859|NCT03346720||Research related staff and other stakeholders|Research related staff and other stakeholders involved in the implementation of the data sharing policy e.g. study managers, data access committee members, ethics committee members, study nurses, investigators, research collaborators, data managers and other clinical trials support staff.
2432860|NCT03346720||Community advisory board members|Community advisory board members and other community members
2432861|NCT03346707||10.5 Tesla|
2432862|NCT03346694|Active Comparator|Dressing 1: Standard Island Dressing|Standard dressing that is applied on most patients with a sternotomy wound incision immediately after cardiovascular surgery before leaving the operating room. Dressing will be removed 48 hours after surgery.
2432863|NCT03346694|Active Comparator|Dressing 2: Prevena negative pressure|Prevena negative pressure wound suction machine dressing applied to sternotomy wound incision immediately after cardiovascular surgery. Dressing will be in use for 7 days or removed sooner if participant is discharged before end of 7 day post-operative time period.
2432864|NCT03346694|Active Comparator|Dressing 3: Mepilex Border Post-Op Ag|Mepilex Border PostOp AG dressing impregnated with silver ions. Dressing will be in use for 7 days or removed earlier if patient is discharged before end of 7 days post0operative time period.
2432865|NCT03346681|Experimental|NAC and albuterol|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
2432866|NCT03346681|No Intervention|Albuterol|Albuterol will be administered via nebulization every six hours.
2432867|NCT03346668|Experimental|Topical gabapentin|gabapentin 6% solution, 1mL applied twice daily for 12 weeks
2432868|NCT03346642|Experimental|GVD and SHR-1210 with or without Decitabine|This is a two stage study. For the first stage, the participants will receive the combination of GVD chemotherapy and PD-1 antibody SHR-1210. The patients enrolled into the second stage will received the combination of GVD and SHR-1210 with low-dose decitabine primed.
2432869|NCT03346629|Experimental|Mifepristone + Misoprostol|Intervention: 200mg mifepristone followed 24-48 h later with 400mcg misoprostol (repeat Q3)
2432870|NCT03346616|Experimental|Texting Group|"The texting group received a daily text message containing a board style multiple choice question. If the participant wanted immediate feedback, the message contained a link to a website containing the answer to the question along with an explanation, the source material, and a more complete clinical vignette. One hour after the initial text message was sent, a follow up answer text message was delivered. Text messages were sent 6 days per week (Monday through Saturday) at 2 pm and 3 pm."
2432871|NCT03346616|Active Comparator|Non Texting Group|The non-texting group received access to the journal articles from which the text message content was derived, but did not receive any text messages or any of the online material or question stems.
2432872|NCT03346590|Active Comparator|16 patients with active RA|"Women over 18 years old with proven active (DAS28 >3.2) RA, diagnosed based on ACR/EULAR 2010 criteria, receiving biological anti-TNF treatment for the first time.~Covered by social security. Capable of giving informed consent and acceding to the requirements of the study. For high-resolution echocardiography: no hypertension, diabetes or history of cardiovascular disorders."
2432873|NCT03346590|Sham Comparator|8 Healthy volunteers (control group)|Healthy volunteers (control group) The healthy female controls will be enrolled from the Centre de Recherche en Nutrition Humaine (CRNH) list of volunteers and matched to the RA patients according to age ±5 years and BMI class (<25; 25-30; >30).
3187910|NCT00761033|Experimental|music|children will listen to music during procedure
3187911|NCT00761033|Other|Standard care|Standard care
3187912|NCT00761059|Active Comparator|Glucose 20%|
3187913|NCT00761059|Placebo Comparator|placebo|
3187914|NCT00761072||1|The source of data will be from spinal surgery procedures performed at CHOP from 4/1/07 to 3/31/08 using a TIVA anesthetic technique of propofol/remifentanil infusions
2432874|NCT03346577||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
2432875|NCT03346564|Experimental|Ritual training program|ritual training program for 8 weeks, biweekly
2432876|NCT03346564|Placebo Comparator|Routine care|Routine care following hospital
2432877|NCT03346551|Experimental|women with postnatal depression|
2432878|NCT03346551|Other|women without postnatal depression|
2432879|NCT03346538|Experimental|Continuous infusion high-dose group (Group H)|High-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
2432880|NCT03346538|Experimental|Continuous infusion low-dose group (Group L)|Low-dose MCI-186 will be administered as a bolus, and then as a continuous infusion. In addition, a placebo will be administered as an intravenous infusion twice a day over 30 minutes.
2432881|NCT03346538|Experimental|Approved dosing regimen group (control group)|A placebo will be administered as a bolus, and then as a continuous infusion. In addition, MCI-186 30 mg will be administered as an intravenous infusion twice a day over 30 minutes.
2432882|NCT03346525|Experimental|BPG Arm|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days
2432883|NCT03346525|No Intervention|Control Arm|No prophylaxis
2432884|NCT03346512||Cardiac surgery|Patients having undergone cardiac surgery (other than the placement of a pacemaker or defibrillator) within the CHU Brugmann hospital between 2006 and 2015
2432885|NCT03346499|Experimental|NK cells and IL-2|
2432886|NCT03346486|Placebo Comparator|Control diet|Regular diet
2432887|NCT03346486|Active Comparator|Intervention diet|Brainfood diet
2432888|NCT03346473||Adolescents aged 12-15 years in LMICs|No interventions administered
2432889|NCT03346460|Experimental|Tongue scraper group (Group 1)|Fifteen patients will be included in this group. Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
2432890|NCT03346460|Experimental|aPDT group (Group 2)|Fifteen patients will be included in this group. One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
2432891|NCT03346460|Experimental|Tongue scraper and aPDT (Group 3)|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
2432892|NCT03346434|Experimental|Part A (Open label Dupilumab): Age cohorts 1 & 2|"Age cohort 1: ≥2 years old to <6 years old~Age cohort 2: ≥6 months to <2 years old"
2432893|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 1|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
2432894|NCT03346434|Experimental|Part B (Double-blind): Dupilumab dose 2|The results of part A will be used to guide the selection of dose levels and dosing frequency for part B.
2432895|NCT03346434|Experimental|Part B (Double-Blind): Placebo|
2432896|NCT03346421||diet and physical activity|
2432897|NCT03346408||Patients|data collection obtained from patient (self-questionnaire) and algologist physician (questionnaire).
2432898|NCT03346395|Experimental|Problem solving based intervention|The problem solving based intervention contains a problem solving process and cooperation between the person on sick leave, his/her employer and health care professionals. The intervention consists of five steps: 1) Making an inventory of problems and/or opportunities related to return to work; 2) brainstorming about solutions; 3) writing down solutions, identifying the support needed to implement the solutions; 4) a three-party meeting with the person on sick leave, his/her employer and the rehabilitation coordinator; 5) evaluation of the action plan and implementation of solutions, relapse prevention. The intervention takes the form of two to five consultations. The first and fourth steps are key elements.
2432899|NCT03346395|Active Comparator|Care as usual|Medical treatment, or behavioral therapy or in combination. Meeting with a rehabilitation coordinator if that is a part or care as usual within primary health care.
2432900|NCT03346369|Experimental|Experimental single arm|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period.
2432901|NCT03346356|Experimental|Teenagers as cross-age teachers|After the initial training, the teenage teachers facilitated the curricula associated with the SHCP, Discovering Healthy Choices and Cooking Up Healthy Choices, approximately twice a month. The curricula can be viewed at http://cns.ucdavis.edu/programs/shcp/curriculum.html. Each activity provided step-by-step instructions that the teenage teachers were asked to follow. Younger youth served as participants for the classroom and garden-based activities.
2432902|NCT03346356|No Intervention|Comparison group|Youth of similar ages to the intervention group completed the same assessments, but did not receive the intervention.
2433099|NCT03345082|Sham Comparator|0.5 mg ranibizumab with sham|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
2432903|NCT03346343|Experimental|Non-invasive forced airway oscillometry|"Analyze lung function using forced airway oscillometry in preterm infants and term infants with and without lung disease with both cross-sectional and longitudinal comparisons.~Aim 1: Lung function in term and preterm infants without lung disease (anticipated n=264) Aim 2: Lung function in preterm infants with respiratory distress syndrome (RDS) who develop bronchopulmonary dysplasia (BPD) and preterm infants with RDS who do not develop BPD (anticipated n=264) Aim 3: Lung function measurements in infants with common neonatal lung diseases (including RDS, BPD, meconium aspiration syndrome, and transient tachypnea of the newborn) and controls without lung disease (anticipated n=570) Aim 4: Lung function in infants with lung disease before and after common therapeutic interventions"
2432904|NCT03346330|Experimental|TRK-750, single and multiple doses|
2432905|NCT03346330|Placebo Comparator|Placebo, single and multiple doses|
2432906|NCT03346317|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent + amnion membrane following hysteroscopic adhesiolysis.
2432907|NCT03346317|Experimental|estrogen|patients, who are with IUA, treated by uterine application of disposable balloon uterine stent+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2432908|NCT03346304|Experimental|PDT treatment (Intervention Arm)|Patients randomised to the PDT treatment (Intervention Arm) will have two courses of PDT treatment in total (for each lung treated). Follow-up is the same as for Control Arm patients: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
2432909|NCT03346304|No Intervention|Surveillance (Control Arm)|Patients randomised to the surveillance (Control Arm) will have: an AFB at 6, 12, 24, and at 36 months post-randomisation; with further AFB visits at 18 and/or at 30 months post-randomisation (dependent on lesion appearance).
2432910|NCT03346291|Experimental|Persistence Targeted Smoking Cessation|8 weekly counseling sessions + 10 weeks of over-the-counter nicotine patch
2432911|NCT03346278|No Intervention|No Text Message Intervention|Participants will receive usual care of information on CR and clinical referral to CR.
2432912|NCT03346278|Experimental|Text Message Intervention|Participants randomized to the intervention will receive usual care plus a text messaging intervention.
2432913|NCT03346265|Experimental|Group A|"Treatment A consisted in a combined exercise program of 40 min duration RMP (Monari, 2004; Monari et al., 2016) and 20 min duration of gait training with sensory cues.~RMP. RMP protocol was based on lengthening and muscular recruitment exercises by means of complex motor skills involving muscular kinetic chains in lower limbs and trunk. Each session was divided into muscular stretching exercise, aiming to increase step length and rotating trunk movements, and tailored progressive exercise therapy."
2432914|NCT03346265|Experimental|Group B|Treatment B Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code): trunk (s760), pelvis (s750), lower extremity (s750), and upper extremity (s730) including shoulder region (s720). Domains focused on were (1) warm-up exercises, (2) trunk mobility exercises, (3) postural stability (b715), and (4) transferring oneself (d420) and changing body positions (d410).
2432915|NCT03346252|Experimental|Botulinum Toxin type A|Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
3147353|NCT00122616|Placebo Comparator|HIV antiretroviral therapy|Day0 to week 96: HIV antiretroviral therapy
3147354|NCT00122642|Experimental|1|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes for patients not in the hospital.
3187915|NCT00761098|Active Comparator|1|Standard Care (albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
2432919|NCT03346226|Experimental|Dexmedetomidine Hydrochloride|Dex Group: 0.5 μg/kg of Dex is given 10 minutes before operation through injection pump during 15 minutes. After the operation starts, the initial pumping ratio of Dex is 0.5ug/kg/h and adjusted under BIS surveillance to keep BIS between 70-80 until 30 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
2432920|NCT03346226|Active Comparator|Propofol|Prop Group: Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts. Under BIS surveillance, dripping rate is adjusted to keep BIS between 70-80 until 5 minutes before the end of surgery. Meanwhile, OAA/S grade is evaluated every 15 minutes to maintain OAA/S at grade 4. If discrepancy occurs, OAA/S prevails.
2432921|NCT03346213||Major surgery|"Adult patients undergoing elective surgery~Having a CPET as part of routine care~Patients with a Hb value of < 130 g/L who are iron deficient, iron restricted/deplete or have functional iron deficiency.~Able to provide written informed consent."
2432922|NCT03346200|Active Comparator|20 mg tamoxifen|
2432923|NCT03346200|Experimental|10 mg tamoxifen|
2432924|NCT03346200|Experimental|5 mg tamoxifen|
2432925|NCT03346200|Experimental|2.5 mg tamoxifen|
2432926|NCT03346200|Experimental|1 mg tamoxifen|
2432927|NCT03346200|Placebo Comparator|0 mg tamoxifen|
2432928|NCT03346187|Experimental|A|"Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.~Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions."
2432929|NCT03346187|Experimental|B|"Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.~Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions."
2432930|NCT03346174|Experimental|AAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage. By modulating manually the functional breathing level within the vital capacity, optimal airflow will be obtained at the targeted airway generations, where secretions have been identified. A gentle increase of manual pressure on the chest during each inspiration is performed to guide the breathing of the patient towards the desired lung volume level. During expiration the breathing movement of the patient is followed gently.
2433100|NCT03345056|Other|included cases|vitrectomy done with planned foveal separation and followed for the result
2432931|NCT03346174|Experimental|BAAD|AAD is an airway clearance technique for infants based upon the principles of autogenic drainage .AAD sometimes leads to crying or resistance against therapy.Bouncing (at low amplitude:6-8 cm) in a stable upright position is a gentle up-and-down movement on a physio ball. It is not an ACT, but used to maximize the relaxation of the infant, avoiding resistance against or crying during treatment. Due to the relaxing effect of bouncing, infants appear to tolerate better AAD, increasing the effectiveness of the treatment.
3187916|NCT00761098|Experimental|2|Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
3187917|NCT00761124|Experimental|1|Educational small group session regarding prostate cancer
2432935|NCT03346122|Experimental|Cohort 1:JNJ-64991524 Dose Level (DL) 1 or Placebo(SAD Part 1)|Participants will receive a single oral dose (Dose level 1) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2432936|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 2 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 2) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2432937|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 3 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 3) of either JNJ-64991524 or placebo capsules after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2432938|NCT03346122|Experimental|Cohort 4:JNJ-64991524 DL 4 or Placebo (SAD Part 1:Fasted-Fed)|Participants will receive a single oral dose (Dose level 4) of either JNJ-64991524 or placebo capsules in a fasted condition on Day 1 and fed condition, on Day 7.
2432939|NCT03346122|Experimental|Cohort 5: JNJ-64991524 DL 5 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 5) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2432940|NCT03346122|Experimental|Cohort 6: JNJ-64991524 DL 6 or Placebo (SAD Part 1)|Participants will receive a single oral dose (Dose level 6) of JNJ-64991524 or placebo after an overnight fast (at least 10 hours) on Day 1 of Part 1.
2432941|NCT03346122|Experimental|Cohort 1: JNJ-64991524 DL 7 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 7) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and pharmacokinetics (PK) from Part 1.
2432942|NCT03346122|Experimental|Cohort 2: JNJ-64991524 DL 8 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 8) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
2432943|NCT03346122|Experimental|Cohort 3: JNJ-64991524 DL 9 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 9) JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined based on tolerability and PK from Part 1.
2432944|NCT03346122|Experimental|Cohort 4: JNJ-64991524 DL 6 or Placebo (MAD Part 2)|Participants will receive an oral dose (Dose level 6) of JNJ-64991524 or placebo capsules once daily for 14 days in fasted or fed condition in Part 2. Fasted/fed condition will be determined by tolerability and PK from Part 1.
2432945|NCT03346109|Experimental|MRLN sparing group|Patients in medial group retropharyngeal node（MRLN） sparing group will not routinely receive MRLN irradiation to 56Gy/33Fr
2432946|NCT03346109|No Intervention|MRLN prophylactic irradiation group|Patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr
2432947|NCT03346096|Experimental|Thiotepa|Thiotepa for reduce toxicity and improve outcome following transplantation
2432948|NCT03346083|Experimental|Cohort 1 Bertrixaban/Andexanet|Single oral dose 40 mg
2432949|NCT03346083|Experimental|Cohort 2 Bertrixaban/Placebo|Single oral dose 80 mg
3187918|NCT00761124|Other|2|Printed material regarding general prostate cancer information provided.
3187919|NCT00761163|Experimental|1|
3187920|NCT00761163|Experimental|2|
2433101|NCT03345043|Experimental|VAL-339851|
2433102|NCT03345043|Placebo Comparator|Placebo|
3187921|NCT00761163|Experimental|3|
3187922|NCT00761228|Active Comparator|Apomorphine|Patients will receive an ascending dosing schedule to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
3187923|NCT00761228|Placebo Comparator|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
3187924|NCT00761332||Teriparatide|Patients treated with teriparatide
3187925|NCT00761332||Antiresorptive|Patients treated with antiresorptive therapy
3187926|NCT00761358|Experimental|Z-338|
3187927|NCT00761358|Placebo Comparator|placebo|
3187928|NCT00761371|Experimental|Imiquimod|Imiquimod 5% cream
3187929|NCT00761384|Experimental|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
3187930|NCT00761397||Study Program Group|
3187931|NCT00761397||Usual Care Group|
3187932|NCT00761410|Other|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
3187933|NCT00761423|Experimental|1|Combination of eccentric exercises and injection of PRP
3187934|NCT00761423|Placebo Comparator|2|Combination of eccentric exercises and physiological saline injection
3187935|NCT00761436|Experimental|Arm 1|
3187936|NCT00761449|Experimental|1|1. lenalidomide
3187937|NCT00761475|Placebo Comparator|1|primary closure of the midline
3187938|NCT00761475|Active Comparator|2|onlay mesh supported closure
3187939|NCT00761475|Active Comparator|3|sublay mesh supported closure
3187940|NCT00761488|Experimental|1|AcrySof® Toric IOL
3187941|NCT00761501|Experimental|1|
3187942|NCT00761501|Active Comparator|2|
3187943|NCT00761501|Active Comparator|3|
3187944|NCT00761540|Experimental|A1|
3187945|NCT00761540|Placebo Comparator|A2|
3187946|NCT00761540|Experimental|B1|
3187947|NCT00761540|Placebo Comparator|B2|
3187948|NCT00761540|Experimental|C1|
3187949|NCT00761540|Placebo Comparator|C2|
3187950|NCT00761553|Experimental|1|Solid dietary supplements with exercise
2432959|NCT03346044|Active Comparator|Carpentier-Edwards SAV bioprostheses|
2432960|NCT03346044|Active Comparator|Medtronic Mosaic bioprostheses|
2432961|NCT03346031|No Intervention|Group 1|Group 1 is control group that does not listen to music
2432962|NCT03346031|Active Comparator|Music Therapy Group 2|Group 2 is the group listening to preoperative music
2432963|NCT03346031|Active Comparator|Music Therapy Group 3|Group 3 is the preoperative and peroperative music listening group (continuous)
2432964|NCT03346018||uveitis of tuberculous etiology|Analysis of aqueous humor and plasma samples: The patients with diagnosis of uveitis of tuberculous etiology, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2432965|NCT03346018||uveitis of suspect sarcoidosis|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of suspect sarcoidosis, undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2432966|NCT03346018||uveitis of undifferentiated origin|Analysis of aqueous humor and plasma samples:The patients with diagnosis of uveitis of undifferentiated origin (tuberculosis/sarcoidosis), undergone to paracentesis of anterior chamber, will can able to grant their aqueous humor and a sample of venous blood to the study of immunological markers to distinguish between uveitis of tuberculous etiology from uveitis by sarcoidosis through the analysis of the aqueous humor and the analysis of the plasma samples.
2432967|NCT03346005|Experimental|Adult patients with positive FIT test|Adult patients with a positive FIT-test will breath into an e-nose device for 5 minutes.
2432968|NCT03345992|Placebo Comparator|Placebo|After enrollment, the placebo arm will receive water for injection at a volume of 20ml diluted to a final volume of 250 ml dextrose in water 5%, infused once daily through intravenous route, within 1 hour, for a duration of four consecutive days.
2432969|NCT03345992|Active Comparator|Clarithromycin|After enrollment, the active drug arm will receive 1g of clarithromycin (500 mg powder for concentrate for solution for infusion per vial), dissolved into 20 ml water for injection and then diluted to a final volume of 250 ml dextrose in water 5%. This will be infused through intravenous route, once daily within 1 hour, for a duration of four consecutive days.
3187951|NCT00761553|Experimental|2|Solid dietary supplements without exercise
3187952|NCT00761553|Experimental|3|Liquid dietary supplements with exercise
2432972|NCT03345966|Experimental|Immunohistochemistry|"In order to provide more precised data on Bmi-1 immunoexpression in OSCC, image analyzer will be used.~The data will be obtained using the software (SIS, Germany), which comprise a light microscope (Olympus B × 60 Japan) capable of performing high speed digital image processing for the purpose of cell measurements. It will be calibrated automatically to convert the measurement units (pixels) produced by image analyzer program into actual micrometer units."
2432973|NCT03345966|Experimental|Polymerase Chain Reaction PCR|"Calculation of Relative Quantification (RQ) (relative expression):~After the RT-PCR will run, the data will be expressed in Cycle threshold (Ct).PCR data sheets will include Ct values of assessed gene and the house keeping (reference) gene which will be continuously expressed in the cell- (β-actin).To measure the gene expression of certain gene, -ve control sample shall be used. So target gene expression will be assessed and related to reference (internal control) gene as follows:~Finally, RQ was calculated according to the following equation:~∆ Ct (Cycle threshold) = Ct assessed gene - Ct reference gene~∆∆ Ct = ∆ Ct sample - Ct control gene~RQ = 2-(∆∆Ct)"
2432974|NCT03345953|Experimental|BP 1.4979|15 mg tablet BID
2432975|NCT03345953|Placebo Comparator|Placebo|Matching placebo tablet
2432976|NCT03345940|Active Comparator|Fingolimod 0.5 mg/day|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
2432977|NCT03345940|Active Comparator|Dimethyl Fumarate 240 mg twice daily|"The study drugs, FTY and DMT, are approved and available on the market and safety and tolerability profile of both the drugs is well known. In our study, patients will be treated according to the clinical practice.~Dose: FTY 0.5 mg/day or DMF 240 mg twice daily"
2432978|NCT03345927||high cardiovascular risk group|no intervention
3187953|NCT00761553|Experimental|4|Liquid supplements without exercise
3187954|NCT00761566|Experimental|1|
3187955|NCT00761566|Experimental|2|
3187956|NCT00761618|Experimental|Arm 1 - Daily|Intrapleural Catheters (IPC) drained every day
3187957|NCT00761618|Experimental|Arm 2 - 3 Times a Week|IPC drained 3 times a week
2432984|NCT03345888||resuscitation time line group|The ETCO2 will be arrange in resuscitation time line.
2432985|NCT03345888||ETCO2 time line group|The ETCO2 will be arrange in time line which the beginning time is the time of starting to show stable ETCO2 wave.
2433348|NCT03343288|Experimental|Silver HA coated implants|Silver doped hydroxyapatite coated implants
3187958|NCT00761644|Experimental|Doxil, Bevacizumab + Temsirolimus|"Doxil day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.~Bevacizumab day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.~Temsirolimus days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes."
3187959|NCT00761670|Active Comparator|1|
3187960|NCT00761670|Active Comparator|2|
3187961|NCT00761683||1|Patients diagnosed with endometriosis
3187962|NCT00761696|Experimental|IPI-926|Oral daily dosing
3187963|NCT00761709|Experimental|AL-39256|AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
2432986|NCT03345875|Other|HPV Screening|Study eligible participants will be screened for HPV using a self collected vaginal sample using a collection device and kit. Those who test positive for HPV will be offered visual assessment of the cervix for treatment (VAT) and treatment as appropriate.
2432987|NCT03345862|Experimental|Intervention|Non-pharmacological multicomponent intervention
2432988|NCT03345862|No Intervention|Control|Not intervention, usual attention
2432989|NCT03345849|Experimental|Arm A: Upadacitinib|Participants will receive Upadacitinib dose A for 12 weeks. Non-responders will receive Upadacitinib dose B for 12 weeks
2432990|NCT03345849|Experimental|Arm B: Placebo and Upadacitinib|Participants will receive placebo for 12 weeks. Non-responders will receive Upadacitinib dose A for 12 weeks.
2432991|NCT03345836|Experimental|Arm A|Participants will receive upadacitinib dose A for 12 weeks.
2432992|NCT03345836|Experimental|Arm B|Participants will receive placebo for 12 weeks.
2432993|NCT03345836|Other|Arm C|Participants will receive open-label upadacitinib dose A for 12 weeks.
2432994|NCT03345823|Experimental|Group A - Arm A|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose B.
2432995|NCT03345823|Experimental|Group A - Arm B|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive dose C.
2432996|NCT03345823|Experimental|Group A- Arm C|This is a maintenance group with 52 weeks which includes participants who achieved clinical response to upadacitinib dose A in studies M14-431 and M14-433 and will receive placebo.
2432997|NCT03345823|Experimental|Group B - Arm A|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose B.
2432998|NCT03345823|Experimental|Group B - Arm B|This is a long-term extension group with 240 weeks which includes participants who complete group A and will receive dose C.
2432999|NCT03345823|Experimental|Group B - Arm C|This is a long-term extension group with 240 weeks which includes participants who complete group A.
2433000|NCT03345810|Active Comparator|Control Arm A|Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W
2433001|NCT03345810|Experimental|Experimental Arm B|"Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3~Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W"
2433002|NCT03345810|Experimental|Experimental Arm C|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)"
2433003|NCT03345810|Active Comparator|Control Arm D|"Frail or elderly patients with metastatic NSCLC; CARG- Score > 3~Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W"
2433004|NCT03345797|Experimental|Naive patients - ARM 1|TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2
2433005|NCT03345797|Experimental|Non-naive patients - ARM 2|TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage >/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later
3147355|NCT00122642|Placebo Comparator|2|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
2433007|NCT03345771|Active Comparator|Antimicrobial Barrier Dressing|postoperative wound dressing with either anti-microbial dressing placed in the operating room from surgery to postoperative day 7
2433008|NCT03345771|Active Comparator|Closed-incision Negative Pressure Therapy|portable NPWT device placed in the operating room from surgery to postoperative day 7
2433009|NCT03345758||ECMO mode,outcome|ECMO mode includes VV-ECMO and VA-ECMO, outcome includes survive condition , physical and mental health, cognitive function and social adaptation
2433010|NCT03345745||Periodontally healthy subjects|Salivary samples
2433011|NCT03345745||Chronic periodontitis patients|Salivary samples
2433012|NCT03345745||Gingivitis patients|Salivary samples
2433013|NCT03345706|Experimental|Selective cerebral hypothermia|Selective cerebral hypothermia
2433014|NCT03345706|Active Comparator|Regular hypothermia|Regular hypothermia
2433015|NCT03345693|Experimental|Treated with MoTrack Therapy|Patients receive the MoTrack Therapy device to assist them in their at-home therapy exercises. The patient is instructed to use the MoTrack Therapy device when they want to do their at-home therapy exercises. The patients therapy in the clinic is not affected.
2433016|NCT03345680|No Intervention|Control Group|Children will be screened, both parents and children will be informed of any abnormalities in the mouth.
2433017|NCT03345680|Experimental|Interventional Group|Interventional (Dental Screening) Children will be screened for dental caries and referred to a specific hospital for treatment, namely King Saud University Dental College, treatment will be provided free of charge to the referred participants.
2433018|NCT03345667||Anti-Vegf|Use intravitreous anti-vegf
3147356|NCT00122746|Active Comparator|Radiotherapy alone|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
2433021|NCT03345641||dyads|dyads with babies and their mothers
2433022|NCT03345628||sedated|infants requiring intubation and ventilation who received sedatives for at least 3 days
2433023|NCT03345628||non-sedated|infants who received respiratory support by non-invasive ventilation and were not sedated
2433024|NCT03345615|Experimental|Intensive Monitoring|30-day ambulatory cardiac event monitoir
2433025|NCT03345615|No Intervention|Standard Care|Standard Care (no supplemental monitoring)
2433026|NCT03345589|Experimental|18-22mg/kg/d Ursodeoxycholic group|
2433027|NCT03345589|Placebo Comparator|13-15mg/kg/d Ursodeoxycholic group|
2433232|NCT03344094||MS-ocrelizumab treated|ocrelizumab 600 mg IV over 5 hours, twice a year, with loading dose of 300 mg 2 weeks apart x 2 at start
2433233|NCT03344094||MS untreated|age- and sex-matched untreated MS controls
2433028|NCT03345576|Experimental|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
2433029|NCT03345576|Sham Comparator|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
2433030|NCT03345563|Experimental|Body Mind Training (BMT)|Body mind training
2433031|NCT03345563|Active Comparator|Body Training (BT)|Body training only
2433032|NCT03345563|Other|Usual care (UC):|Control
2433033|NCT03345550|Experimental|Omega-3 Polyunsaturated Fatty Acid Treatment Arm|Participants randomized to this study arm will receive 6g DHA+EPA for one month followed by 1.2 g DHA+EPA for two months. Capsules contain fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
2433034|NCT03345550|Placebo Comparator|Placebo Arm|Participants randomized to this study arm will receive placebo drug for 3 months.
2433035|NCT03345524|Experimental|Peer-buddy system|Will meet with peer-buddy who will help with them with CPAP usage. Also will receive standard of care CPAP educational training
2433036|NCT03345524|Active Comparator|Usual Care|Will receive educational material at the same frequency that those in the experimental arm. Will also receive standard of care CPAP educational training.
2433037|NCT03345511|Experimental|Ultrasound Guided Caudal Block|30 minutes before benign canal anal surgery, a 18 G tuohy needle guided with an ultrasound probe to visualize the caudal space, a solution of bupivacaine 0.25%, Lidocaine 1% and dexamethasone 8mg was injected and needle removed.
2433038|NCT03345498||ETV 0.5 mg|Group of study participants who were started on 0.5 mg/day of entecavir
2433039|NCT03345498||ETV 1.0 mg|Group of study participants who were started on 1.0 mg/day of entecavir
2433040|NCT03345485|Experimental|Tinostamustine (EDO-S101)|"Phase 1:~Schedule A: Tinostamustine (EDO-S101), IV, 60mg/m2 up to 100mg/m2 Day 1 and 15 of each 28 day cycle~Phase 2:~The RP2D and selected schedule will be further investigated in patients with specific types of solid tumors: relapsed/refractory SCLC, soft tissue sarcoma, triple negative breast cancer, ovarian cancer and endometrial cancer."
3187964|NCT00761709|Active Comparator|XALATAN|Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks.
2433042|NCT03345459|Experimental|Internet-Based Treatment (ICare)|ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
2433043|NCT03345459|No Intervention|Usual Care|Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
2433044|NCT03345446||Patients with HF-rEF|These patients have Heart Failure with Reduced Ejection Fraction (EF < 55% per the protocol).
2433045|NCT03345446||Patients with HF-pEF|These patients have Heart Failure with Preserved Ejection Fraction (EF > 55% per the protocol).
2433046|NCT03345433|Experimental|interactive group drumming sessions|Participants will be involved in four interactive group drumming sessions (10-30 minutes each) and complete surveys and questionnaires about music and quality of life.
2433047|NCT03345420|Experimental|Treatment (hypofractionated radiation therapy)|Within 12 weeks after breast conserving surgery, patients undergo hypofractionated radiation therapy for 9 fractions over 2 weeks.
3187965|NCT00761709|Placebo Comparator|Vehicle|Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks.
3187966|NCT00761722|Experimental|Arm 1|"subcutaneous and oral azacitidine~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle."
3187967|NCT00761722|Experimental|Arm 2|"Oral Azacitidine~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
3187968|NCT00761787||1|Heart transplanted subjects.
3187969|NCT00761839|Experimental|Arm 1|These patients receive the experimental intervention--the after-care summary.
3187970|NCT00761839|Active Comparator|Arm 2|These patients are the control group and receive usual care.
3187971|NCT00761852|Active Comparator|1|Ruboxistaurin
3187972|NCT00761852|Placebo Comparator|2|Placebo
2433056|NCT03345381|Experimental|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) plus usual care
2433057|NCT03345381|Active Comparator|Usual Care|Treatment as usual
2433058|NCT03345368|Experimental|rTMS treated group|A Magstim Rapid2 Stimulator equipped with a double 70mm alpha coil P/N 3191-00 (Magstim, Wales, UK) will be used to stimulate the motor cortex. Transcranial magnetic stimulation will be applied through a coil at 10 Hz, a field intensity of 90% of the motor threshold. Stimuli will be provided in 10 trains of 100 pulses, followed by a 28 s rest period.
2433059|NCT03345368|Sham Comparator|sham rTMS group|Sham rTMS will be administered with the coil held in contact with the head but a 180 degrees from scalp, and the power parameter will be reduced by half to avoid stimulation.b
2433060|NCT03345355||patient with axial spondyloarthritis|
3187973|NCT00761878|Active Comparator|Skin treatment|
3187974|NCT00761904|Experimental|receipt of free generic samples|
3187975|NCT00761904|No Intervention|usual prescribing|
3187976|NCT00761917||1: Normal|Subjects without dry eye symptoms based on questionnaire.
3187977|NCT00761917||2: Dry Eye|Subjects with dry eye symptoms based on questionnaire.
3187978|NCT00761982|Other|bone marrow stem cells|Procedure: Infusion of autologous CD34+ stem cells into middle cerebral artery.
3187979|NCT00761995|Active Comparator|Azopt|topical eye drop dosed 1 drop 3 times daily
3187980|NCT00761995|Active Comparator|Cosopt|topical eye drop
3187981|NCT00762008||Heart Failure|
3187982|NCT00762047|Experimental|Durasphere|
3187983|NCT00762047|Sham Comparator|Sham|
2433065|NCT03345329||Periodontal patient|
2433066|NCT03345329||Healthy person|
2433067|NCT03345329||Peri-implantitis patient|
2433068|NCT03345316|Experimental|FFI-1010|
2433069|NCT03345303|Experimental|Bortezomib treatment|'Bortezomib Injectable Solution
2433070|NCT03345303|No Intervention|supportive care|supportive care
2433071|NCT03345290|Experimental|Subjects|Subjects referred to a FDG PET scan (standard PET without cerebral step) without any oncologic setting. Patients will be included as following critera: 25% of subjects will have under 40 years old, 25% between 40 and 60 yeard old et 50% higher than 60 years old.
2433072|NCT03345277||Continuous Temperature monitoring|All residents of a long-term care facility will be considered for the study over the predetermined timeframe. Residents who choose not to participate or are determined, by their care providers, to be inappropriate for inclusion will be excluded.
2433073|NCT03345264|Experimental|Cancer patients, survivors, and partners|
2433074|NCT03345251|Experimental|manipulation of endometrium|The arm is physical manipulation to the endometrium prior to ICSI By one of these interventions )Hydrotubation , Sonohysterography or endometrial scratching
2433075|NCT03345251|Placebo Comparator|no manipulation to endometrium in ICSI|This is the control group , with no manipulation to endometrium prior to ICSI No intervention to this group
2433076|NCT03345238|Experimental|Active MTP|
2433077|NCT03345238|Experimental|Latent MTP|
2433078|NCT03345238|Experimental|Out of MTP|
2433079|NCT03345225|Active Comparator|Control Group|Participants will be randomized to receive DEB-TACE utilizing a standard endhole microcatheter
2433080|NCT03345225|Experimental|Surefire Group|Participants will be randomized to receive DEB-TACE utilizing the Surefire Infusion System
2433081|NCT03345212|No Intervention|Control group|Patients in this group continue their sedentary life-style throughout the study period. Patients will be advised to perform no specific exercise training during the trial. After 15 weeks, the patients are offered to take part in the training program as well.
2433082|NCT03345212|Experimental|Training group|"Standard rehabilitation therapy includes dietary measures, massages and relaxation techniques. Additionally, patients perform exercise and respiratory therapy and mental gait training.~Patients will be informed about group allocation."
2433083|NCT03345199|Experimental|Inspiratory Muscle Trainer (IMT)|Inspiratory Muscle Trainer (IMT) provides resistance as a person inhales, thereby strengthening respiratory muscles.
3147357|NCT00122746|Experimental|Radiotherapy plus Chemotherapy|EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
3147358|NCT00122772|Experimental|EBR plus 2 HDBT fractions|External Beam Radiotherapy High Dose Brachytherapy (2 fractions of 9Gy)
2433086|NCT03345173|Experimental|CI-581a|"CI-581a will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(0.11 mg/kg 2-min bolus followed by 1.3 mg/kg over 90 min)"
2433087|NCT03345173|Placebo Comparator|CI-581b|"CI-581b will be administered during the washout phase when participants are experiencing moderate withdrawal, as well as the following day when the naltrexone titration is initiated.~(2-min saline bolus followed by 0.0125 mg/kg over 90 min)"
3147359|NCT00122772|Active Comparator|EBR plus 4 fractions HDBT|External Beam Radiotherapy High Dose Brachytherapy (4 fractions of 7Gy)
2433089|NCT03345147||Normal Vitamin A intake|Normal Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to Normal Vit. A consumption if daily Vit. A is between 250 and 600 micrograms per day.
2433090|NCT03345147||High Vitamin A intake|High Vitamin A intake will be assessed by a questionnaire directed to the consumption of food items with high VA content on the 7 days prior to the questionnaire. The daily consumption will be assessed on average. A child is assigned to High Vit. A consumption if daily Vit. A is above 900 micrograms per day.
2433091|NCT03345134|Experimental|MK-3475 and BCG|Single treatment group of high risk superficial upper urinary tract transitional cell carcinoma; combination treatment with MK-3475 and BCG
2433095|NCT03345095|Experimental|Experimental Arm|Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
2433096|NCT03345095|Active Comparator|Standard Arm|Radiotherapy + Temozolomide followed by adjuvant Temozolomide
2433097|NCT03345082|Experimental|0.5 mg ranibizumab with 2.0 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
2433098|NCT03345082|Experimental|0.5 mg ranibizumab with 0.5 mg OPT-302|0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
3147360|NCT00122772|Experimental|EBR/2 HDBT fractions/Chemotherapy|"External Beam Radiation~High Dose Brachytherapy (2 fractions of 9Gy)~Cisplatin"
3147361|NCT00122772|Experimental|EBR/4 fractions HDBT/chemotherapy|"External Beam Radiation~High Dose Brachytherapy (4 fractions of 7Gy)~Cisplatin"
3147362|NCT00122928|Experimental|High intensity environmental intervention|Intense intervention
3147363|NCT00122928|Experimental|Moderate intensity environmental intervention|Moderate intervention
2433103|NCT03345030||Unexplained infertile group|Patients diagnosed as unexplained infertility (UI) were recruited to the study. UI was diagnosed after normal standard infertility evaluation according to the guideline of The Practice Committee of the American Society for Reproductive Medicine which consist of the assesment of spermiogram, ovulation, hysterosalpingogram and if indicated ovarian reserve tests and laparoscopy. If the results of all this tests were normal, patients were accepted as UI.
2433104|NCT03345030||Control group|The control group received in vitro fertilization (IVF) for tubal factor and included only those women who had salpingectomy for ectopic pregnancy or proximal tubal obstruction because of low-grade infection or fimbrial occlusion with or without mild peritubal adhesions. Tubal infertility associated with hydrosalpinx, severe pelvic adhesions, endometriosis or pelvic inflammatory disease were excluded. Patients with male factor except oligoasthenospermia were also recruited for the study.
2433105|NCT03345004|Active Comparator|Active arm|Patients will be assigned to receive i) three (3) intralymphatic injections with 4µg Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral vitamin D 2000 IU/daily for 4 months (from Day 1 through Day 120)
2433106|NCT03345004|Placebo Comparator|Placebo arm|Patients will be assigned to receive i) three (3) intralymphatic injections of Placebo for Diamyd (GAD-alum) on Days 30, 60, and 90 and; ii) oral Placebo for vitamin D once a day for 4 months (from Day 1 through Day 120)
3147364|NCT00122928|No Intervention|Individual intervention only|Control
3147365|NCT00122993|Experimental|1|Multi-component environmental intervention to prevent excess weight gain among bus drivers
3147366|NCT00122993|No Intervention|2|Control group
3147367|NCT00123006|Active Comparator|1|Dietary Approaches to Stop Hypertension (DASH)
2433111|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
2433112|NCT03344965|Experimental|OLAPARIB QD GERMLINE MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurement q6 weeks x 24 weeks, then q 12 weeks"
2433113|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
2433114|NCT03344965|Experimental|OLAPARIB QD SOMATIC MUTATION - EXPANSION|"After the screening procedures confirm eligibility to participate in the research study:~Olaparib: Each study treatment cycle lasts 21 days (3 weeks), taking 2 times per day, 12 hours apart.~Tumor measurements q6 weeks x 24 weeks, then q 12 weeks"
2433115|NCT03344926|Experimental|ACTsmart|ACT treatment via a smart phone application
2433116|NCT03344913|Active Comparator|Adults with knee Osteoarthritis|walking 30 minutes per day, three days/week for 6 weeks.
2433117|NCT03344913|Active Comparator|Healthy controls|walking 30 minutes per day, three days/week for 6 weeks.
2433118|NCT03344900||Phase I|It is estimated that 100 participants with SCD will be enrolled for the Phase I portion which will identify barriers to hydroxyurea utilization.
2433119|NCT03344900||Phase II|It is estimated that 72 participants with SCD will be enrolled for the Phase II portion of the study which will evaluate the degree of feasibility and acceptance of mHealth intervention on hydroxyurea adherence.
2433120|NCT03344887|Active Comparator|RBC Transfusion from male donor|For the treatment of anemia
2433121|NCT03344887|Active Comparator|RBC Transfusion from female donor|For the treatment of anemia
2433122|NCT03344874|Experimental|Stethee (new stethoscope)|"Test 1: Use Stethee® to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use 3MTM Littmann® Classic IIITM to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
2433123|NCT03344874|Active Comparator|Littmann (conventional stethoscope)|"Test 1: Use 3MTM Littmann® Classic IIITM to auscultate and identify a set of 10 manikin-simulated heart sounds.~Test 2: After a 10-minute break, use Stethee® to auscultate and identify the same set of 10 manikin-simulated heart sounds but played in a different sequence to Test 1."
2433127|NCT03344822|Experimental|68Ga-PSMA PET-CT|
2433128|NCT03344796||Focus Group|"32 subjects~Focus group: It is expected that each participant will provide comments during the 2 hours of the focus group. It will take about one month to enroll the subjects. The audio files should be transcribed and the analysis completed in 60 days. The analysis will determine enablers and barriers to sun protected outdoor activities and determine strategies for achieving sun protected outdoor activities."
2433129|NCT03344796||Usability testing|"10 subjects~Usability test with structured interview: Each participant will use the sensor for 14 days and transmit data with the app installed on their mobile phone. It will take about one month to enroll the subjects. The analysis of the structured interview is completed in one week."
3147368|NCT00123006|Placebo Comparator|2|Control diet
3147369|NCT00123019|Active Comparator|1|Minimal intervention; annual weight/waist assessment, questionnaire, and advice
3147370|NCT00123019|Experimental|2|Intensive intervention. All arm 1 activities plus ongoing environmental and group interventions in worksite for two years.
3147371|NCT00123032|Experimental|1|This group will focus on improving their diet and increasing physical activity at home and at school.
3147372|NCT00123032|No Intervention|2|A control group will not receive any intervention.
3147373|NCT00123058|Experimental|Nurse administered|"Nurse Administered Intervention:~Subject received nurse administered behavioral intervention every 8 weeks via telephone for 24 months."
3147374|NCT00123058|Experimental|Nurse & BP monitor|Subjects received both a nurse administered behavioral intervention via telephone every 8 weeks for 24 months and a study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
3147375|NCT00123058|No Intervention|Usual Care|Subjects received neither home BP monitor nor nurse phone intervention.
3147376|NCT00123058|Experimental|Home BP Monitor|Subject received study provided home BP monitor. Subject recorded home BP 3 times per week for 24 months.
2433130|NCT03344796||Cohort Study 1|"60 subjects~First cohort study: It is expected that each of 60 melanoma survivors will wear the sensor and transmit data for 21 days in the warm weather months of June-Aug 2019. It will take about 2 months to enroll the subjects. Subjects will receive daily text messages in a sequence starting with behavioral facilitation, outcome expectancies, self-efficacy, and self-regulation. On day 10, participants will receive a text message prompting review and reflection on the prior 10 days of UV exposure. Participants will be randomized to receive a survey item inviting selection of strategies to achieve sun-protected outdoor activities (structured goal attainment) or submit a free text description of their strategy (unstructured goal attainment)."
2433131|NCT03344796||Structured Interviews|50 young adults, ages 18-39 will participate in structured interviews to determine their barriers and enablers of sun exposure and sun protection. Eligible subjects will have at least one hour a day outdoors with 30 minutes of the hour being consecutive. It will take about 3 months to enroll the subjects. The audio files will be transcribed and analysis completed in 60 days.
2433132|NCT03344796||Cohort Study 2|Second cohort study: 40 young adults will wear the sensor and transmit data for 28 days in summer 2020.
2433133|NCT03344783||mother-children pairs|
2433134|NCT03344770|Experimental|Active rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, with 0.16mJ/mm2 (millijoule per squared millimeter) of energy at a frequency of 20Hz on the most painful spot of the knee. The applications will be given once a week for three weeks.
2433135|NCT03344770|Sham Comparator|Sham rESWT|Application of 5,000 pulses of rESWT by a pneumatic generator, at a frequency of 20Hz on the most painful spot of the knee with 0 mJ/mm2 energy. The applications will also be given once a week for three weeks.
2433138|NCT03344744||SAH with DCI|Aneurysmal subarachnoid haemorrhage patients with delayed cerebral infarction
2433139|NCT03344744||SAH nonDCI|Aneurysmal subarachnoid haemorrhage patients without delayed cerebral infarction
2433140|NCT03344744||Control|Healthy volunteers
2433141|NCT03344731|Experimental|Experimental Group|Patient with any form ob brain damage
2433142|NCT03344731|Other|Control Group|Healthy volounteers
2433143|NCT03344705|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
2433144|NCT03344692|Experimental|Alirocumab|Alirocumab 75 mg for subcutaneous injection via a pre-filled pen. One injection every 2 weeks during a 10-weeks period (5 injections in total)
2433145|NCT03344692|Placebo Comparator|Placebo|"Placebo matching alirocumab is prepared in the same formulation as alirocumab, without the addition of protein, for subcutaneous injection via a pre-filled pen.~One injection every 2 weeks during a 10-weeks period (5 injections in total)"
2433146|NCT03344679|Other|Control group|Bupivacaine 0.25% for pectoral nerve block.
2433147|NCT03344679|Other|Adenosine|Bupivacaine 0.25% with added Adenosine 12mg for pectoral nerve block.
2433148|NCT03344679|Other|Magnesium sulphate|Bupivacaine 0.25% with Magnesium sulphate 500 mg for pectoral nerve block.
3147377|NCT00123084|Experimental|Voice/Respiratory Treatment|4 Days a week for 4 weeks with focus on high intensity voice exercises
3147378|NCT00123084|Experimental|Articulation Treatment|4 days a week for 4 weeks with focus on high intensity articulation tasks
2433151|NCT03344653|Active Comparator|Resolute Onyx stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
2433152|NCT03344653|Active Comparator|BioFreedom stent|Subjects who fulfill the inclusion criteria and none of the exclusion criteria will be randomly allocated in a 1:1 fashion to treatment with a Resolute Onyx stent or the BioFreedom stent followed by 1-month DAPT. Subjects implanted with the Resolute Onyx stent will be assessed for non-inferiority compared to those implanted with the BioFreedom stent using a composite safety endpoint of cardiac death, myocardial infarction, and definite/probable stent thrombosis, at 1 year post-procedure.
2433155|NCT03344627|Active Comparator|Meropenem standard dose|Meropenem 1 g every 8 hours
2433156|NCT03344627|Active Comparator|Meropenem high dose|Meropenem 2 g every 8 hours
2433157|NCT03344614|Experimental|raltitrexed combined with apatinib|therapeutic regimen : raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles.
2433158|NCT03344601|No Intervention|Reference Cohort|A 12-month longitudinal evaluation of physical fitness and physical activity assessments in a cohort of individuals with HD (n=60) recruited from the Enroll-HD platform study.
2433159|NCT03344601|Experimental|Physcial Activity Intervention|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to a 12-month physical activity and coaching intervention.
2433160|NCT03344601|No Intervention|Activity as usual control|Participants will be recruited from the Enroll-HD platform study and will be individually randomised (1:1) to continue with physical activity as usual for 12 months
3147379|NCT00123084|No Intervention|Subjects with PD in a no treatment group|Subjects do not receive therapy during experimental phases, and will be offered therapy at the end of the study enrollment period.
3147380|NCT00123084|No Intervention|Healthy Control Subjects|Subjects are without Parkinson disease and will not receive therapy.
3147381|NCT00123097|Experimental|Chlorinated polyethylene elastomer first|Patient receives prosthetic made from CPE then the SOC, silicon.
3147382|NCT00123097|Active Comparator|Silicon first|Patient receives prosthetic made from the SOC, silicon, followed by the CPE,Chlorinated polyethylene elastomer.
3147383|NCT00123188|Experimental|Ultrasound and Biopsy|Transvaginal Ultrasound and Endometrial Biopsy
3147384|NCT00123240|Active Comparator|High Fat/Protein Diet|
3147385|NCT00123240|Active Comparator|High Carbohydrate Diet|
3147386|NCT00123266|Experimental|Active|
3147387|NCT00123279|Experimental|1|
3147388|NCT00123279|Experimental|2|
3147389|NCT00123279|Experimental|3|
2433161|NCT03344588|Active Comparator|artery preserving varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group A (APV), testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
2433162|NCT03344588|Active Comparator|artery ligation varicocelectomy|In all patients, sub-inguinal varicocelectomy will be carried out under spinal anesthesia, by a single surgeon (KS), using surgical microscope. A 2-3 cm pre-pubic incision will be performed. The cord will be grasped with a Babcock clamp and isolated over a vessel tape. Any external cremastric veins will be identified and ligated using vicryl 3/0. After opening the spermatic fascia, the vassal compartment including the vasal, cremasteric arteries and lymphatics will be separated from the pampiniform plexus compartment and preserved. In group B (ALV), all vascular channels will be ligated without identifying or sparing the internal spermatic arteries
2433163|NCT03344575|Active Comparator|Conventional defect closure|The defect is sutured with continuous PDS 2-0.
2433164|NCT03344575|Experimental|Peritoneal bridging|The peritoneum is dissected beginning 2-3 cm from the edge of the defect. The sac is dissected all the way to the opposite edge of the defect. The peritoneal flap is pulled to the opposite side and fixated with Optifix
2433167|NCT03344549|Experimental|Teleconsultation|In the patients of the experimental group, the nutritional intervention is carried out through teleconsultation with the free technological tool chosen (the patients from home and the nutritionist from the remote clinic).
2433168|NCT03344549|Other|Face-to-face consultation|In the patients of the other group, the nutritional intervention is offered through face-to-face consultations carried out by the nutritionist of the nutrition service of the institution.
2433169|NCT03344536|Experimental|fulvestrant and Debio 1347|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter. Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated. The dosage in the phase 2 portion will be the MTD/RP2D determined in the phase 1b portion.
2433170|NCT03344523|Experimental|standard treatment + Iron succinylate|1 bottle orally, twice daily, take orally before meals
2433171|NCT03344523|Placebo Comparator|standard treatment + placebo|1 bottle orally, twice daily, take orally before meals
2433174|NCT03344497|Other|VC (Conventional Consultation/Video) Group|Subjects will receive conventional consultation and watch an animated video.
2433175|NCT03344497|No Intervention|CC (Conventional Consultation) Group|Subjects will receive conventional consultation only. Subjects will cross-over to receive animated video at the end.
2433176|NCT03344484|Experimental|Midline Approach|A midline surgical approach will be used for the exposure required to complete the lumbar fusion.
2433177|NCT03344484|Experimental|Paramedian Approach|A paramedian (i.e. Wiltse) surgical approach will be used for the exposure required to complete the lumbar fusion.
2433178|NCT03344471|Other|women with PTSD after preterm deliver|
2433179|NCT03344471|Other|women without PTSD after preterm deliver|
3147390|NCT00123279|Experimental|4|
2433181|NCT03344445|No Intervention|traditional vist|Patients receive traditional anesthesiologist visit
2433182|NCT03344445|Experimental|video-assisted|Patients watch the video, then an anesthesiologist visit
2433183|NCT03344432||With intraocular pressure high|Intracranial pressure equal or more than 20 mmHg
2433184|NCT03344432||Without intraocular pressure high|Intracranial pressure smaller than 20 mmHg
2433185|NCT03344419|Experimental|CI-581a+MET+MBRP|Administration of CI-581a at 0.71 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
2433186|NCT03344419|Active Comparator|CI-581b+MET+MBRP|Administration of CI-581b at 0.025 mg/kg during weeks 1 and 5 combined with a 12-week course in MET and MBRP
2433187|NCT03344406||Subjects with asthma|Subjects with moderate to severe asthma will be interviewed via telephone. Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
2433188|NCT03344393|Active Comparator|ketamine hydrochloride|intravenous ketamine infusion in the intraoperative period
2433189|NCT03344393|Active Comparator|normal saline|intravenous normal saline infusion in the intraoperative period
2433190|NCT03344380||Prospective cohort|Adult patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury. The GWAS will be performed with the blood obtained from enrolled patients.
2433191|NCT03344380||Retrospective cohort|In previous study performed in adult patients undergoing liver transplantation (NCT02489474, 4-2015-0411), we enrolled patients and collected data regarding the development of acute kidney injury during the first 72 hours post-liver transplantation. Among these patients enrolled in this previous study, only patients who agreed to additional use of the blood sample for research purposes will be included in the present study. The GWAS will be performed with the blood obtained from enrolled patients.
2433234|NCT03344094||Healthy control|age- and sex-matched untreated healthy controls
2433235|NCT03344094||MS interferon-treated|MS with ongoing interferon-beta therapy
3147391|NCT00123279|Experimental|5|
3147392|NCT00123279|Experimental|6|
3147393|NCT00123292|Experimental|1|
3147394|NCT00123292|Experimental|2|
3147395|NCT00123292|Experimental|3|
3147396|NCT00123292|Experimental|4a|
3147397|NCT00123292|Experimental|4b|
3147398|NCT00123305|Experimental|1|
3147399|NCT00123305|Experimental|2|
3147400|NCT00123305|Experimental|3|
3147401|NCT00123305|Placebo Comparator|4|
3147402|NCT00123318|Experimental|1|Single-arm, non-randomised feasibility study to evaluate new regimen of adjuvant chemoradiotherapy (Epirubicin, Cisplatin, 5-Fluorouracil + radiotherapy)
3147403|NCT00123357||Group 1|
2433192|NCT03344367|Experimental|JWCAR029|The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
2433193|NCT03344354|Active Comparator|Biogel 1|Biogel 1 (overglove) sterile surgical glove
2433194|NCT03344354|Active Comparator|Ansell|Ansell sterile surgical glove
2433195|NCT03344354|Active Comparator|Cardinal|Cardinal sterile surgical glove
2433196|NCT03344354|Active Comparator|Biogel 2|Biogel 2 (underglove) sterile surgical glove
2433197|NCT03344354|Active Comparator|Medline|Medline sterile sergical glove
2433200|NCT03344315|Active Comparator|autologous connective tissue graft|Soft tissue harvesting from patient palate
2433201|NCT03344315|Experimental|collagen matrix|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland Device: Collagen matrix
2433202|NCT03344302|Experimental|study group|100 women were assigned to receive an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour minutes diluted into 500 mL of normal 0.9% sodium chloride) immediately after opening the visceral peritoneum just before incising the uterine wall during Cesarean section
2433203|NCT03344302|Active Comparator|Control group|100 women were assigned to an intravenous infusion of oxytocin 30 units in a rate 125 mL/hour diluted into 500 mL of normal 0.9% sodium chloride) immediately after clamping the umbilical cord during cesarean section
2433204|NCT03344289|Experimental|Linked color imaging|When the patient is randomized for LCI, the imaging mode is switched to LCI and colonoscopic inspection will take place during withdrawal of the endoscope
2433205|NCT03344289|Active Comparator|High definition white light|When the patient is randomized for HD-WLE, the imaging mode is switched to HD-WLE and colonoscopic inspection will take place during withdrawal of the endoscope.
2433206|NCT03344276|Active Comparator|Control Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points before intervention (1 months, and 2 months). The two preoperative time points will serve as the control group.
2433207|NCT03344276|Experimental|Intervention Group|Patients, as outlined by NASCET criteria, will have between 50 symptomatic stenosis or 70% asymptomatic stenosis of the carotid artery. Patients, undergoing carotid artery stenting for carotid stenosis, will undergo cognitive testing at 2 time points after invention (1 month and 2 months). The two postoperative time points will serve as the intervention group.
3147404|NCT00123396|Experimental|Arm 1|Test the effectiveness of the BioCASES teaching modules by way of a randomized controlled trial of VAMCs using the BioTESTS to evaluate their effectiveness for increasing and sustaining VA clinician knowledge, skills, and ability to respond to bioterrorism events.
2433209|NCT03344250|Experimental|Main Study|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. Participants will receive the first and second infusions of EGFR BATs on days 14 and 21 after finishing concurrent RT and TMZ and then receive an infusion on day 21 of the first six cycles of TMZ.
2433210|NCT03344250|Experimental|Subcohort for MGMT unmethylated patients|Study participants will have cells collected by leukapheresis prior to initiating standard concurrent RT and TMZ. About 4 weeks after completion of RT/TMZ, participants will receive 8 weekly doses of EGFR BATs.
2433211|NCT03344224||normal blood lipid/protein group|
2433212|NCT03344224||abnormal blood lipid/protein group|
2433213|NCT03344211|Experimental|Arm I (enzalutamide, radium 223)|Patients receive enzalutamide PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive radium Ra 223 dichloride IV on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2433214|NCT03344211|Experimental|Arm II (enzalutamide)|Patients receive enzalutamide as in Arm I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2433215|NCT03344198|Experimental|Firefighter (Veteran) Group|Firefighters with >10yrs experience. Circuit Training exercise & Modified Mediterranean diet
2433216|NCT03344198|Experimental|Firefighter (Novice) Group|Firefighters with <10yrs experience. Circuit Training exercise & Modified Mediterranean diet
2433217|NCT03344198|Experimental|Control Non-Firefighter Group|Non-Firefighter adults. Circuit Training exercise & Modified Mediterranean diet
2433218|NCT03344185|Experimental|Low GI diet|This diet contained three meals, all with a low GI value. This was the Low Glycaemic Diet intervention.
2433219|NCT03344185|Experimental|High GI diet|This diet contained three meals, all with a high GI value. This was the High Glycaemic Diet intervention.
3147405|NCT00123435|Active Comparator|Arm 1|5-session nutritional counseling program
3147406|NCT00123435|Experimental|Arm 2|5-session nutritional counseling program + simple pedometer feedback
2433224|NCT03344146|Other|Group 1|Intake reminders followed by crossover to no intake reminders
2433225|NCT03344146|Other|Group 2|No intake reminders followed by crossover to intake reminders
2433226|NCT03344133|Experimental|Exercise|4-week moderate intensity exercise programme
2433227|NCT03344133|No Intervention|Control|4 weeks of habitual life style
2433228|NCT03344120|Active Comparator|suture stent|suture stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
2433229|NCT03344120|Active Comparator|conventional double-J stent|conventional double-J stent positioning after ureteroscopy. Intervention: administration of USSQ questionnaire.
2433230|NCT03344107|Active Comparator|Vortek double-J stent|Vortek double-J stent after RIRS.
2433231|NCT03344107|Active Comparator|Polaris Loop stent|Polaris Loop ureteral stent after RIRS.
3147407|NCT00123435|Experimental|Arm 3|5-session nutritional counseling program + simple pedometer feedback + enhanced pedometer feedback web-based feedback
3147408|NCT00123500|Active Comparator|1|Worksite Intervention
2433236|NCT03344081||Meditators|Meditators will have practiced meditation for at least the 5 years, at least 90 minutes weekly. They will have completed at least 14 days of retreat practice in the past 5 years. At least half of their meditation practice will include attention to the breath and body. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
2433237|NCT03344081||Controls|Control participants will be age- and gender-matched to each meditators. They will have little to no previous meditation experience. All participants will be MRI-compatible, healthy with no health conditions that affect breathing, have no current psychiatric disorder, and not be taking psychotropic medications.
2433238|NCT03344068|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radical radiotherapy with or without chemotherapy plus Nutren® Optimum of 7 scoops tid at begin of radiotherapy.
2433239|NCT03344068|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radical radiotherapy with or without chemotherapy plus routine diet guidance at begin of radiotherapy.
2433240|NCT03344055|Active Comparator|Colonoscopy with Endocuff Vision (ECV)|ECV-assisted colonoscopy ( with the use of Endocuff Vision (ECV) Second generation)
2433241|NCT03344055|No Intervention|Standard colonoscopy|Standard colonoscopy (without the use of Endocuff Vision (ECV) Second generation)
2433242|NCT03344042|Active Comparator|Fentanyl|100mcg Fentanyl administered into epidural space during regular contractions before cervical dilation
2433243|NCT03344042|Active Comparator|Sufentanyl|10mcg sufentanyl administered into the epidural space during regular contractions before cervical dilation
2433244|NCT03344042|No Intervention|Control|No epidural analgesia
2433245|NCT03344029|Experimental|SP Shz TIV|Participants aged 18 to 59 years will receive a single injection of SP Shz TIV.
2433246|NCT03344029|Active Comparator|Hualan TIV|Participants aged 18 to 59 years will receive a single injection of Hualan TIV.
2433247|NCT03344016|No Intervention|Standard care follow-up group|Patients will receive an information leaflet (see appendix), which advises on recommended routine follow-up according to international guidelines.
2433248|NCT03344016|Active Comparator|Special care follow-up group|In addition to the information leaflet patients will be actively contacted by the clinical center to increase the likelihood that patients meet recommended follow-up schedules.
2433249|NCT03344003||Wilate or Nuwiq prospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled prospectively
2433250|NCT03344003||Wilate or Nuwiq retrospective cohort|Evaluable haemophilia A patients with an inhibitor against FVIII enrolled retrospectively
2433251|NCT03343990||group A|Interlocking multi-twisted wires techniqe in sternal closure
2433252|NCT03343990||group B|Eight Figure techniqe in sternal closure
2433253|NCT03343977|Experimental|Every two weeks docetaxel|50 mg/m2 of docetaxel will be given on day 1 every 14 days over one hour IV infusion for up to 9 cycles (1 cycle = 14 days)
2433254|NCT03343977|Active Comparator|Every three weeks docetaxel|75 mg/m2 of docetaxel will be given on day 1 every 21 days over one hour IV infusion for up to 6 cycles (1 cycle = 21 days)
2433255|NCT03343964||Children with moderate to severe TBI|
2433256|NCT03343951||Shoulder patients|Shoulder patients referred to examination at the shoulder clinic, Silkeborg Regional Hospital.
2433257|NCT03343938|Experimental|Closed Station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
2433258|NCT03343938|No Intervention|Open flow cabinet|Embryo handling is performed inside a conventional open flow cabinet without a controlled environment.
2433259|NCT03343912|Experimental|Test 1 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.400 mg/day and Trimegestone 0.06 mg/day (Test 1) over 21 days
2433260|NCT03343912|Experimental|Test 2 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.300 mg/day and Trimegestone 0.12 mg/day (Test 2) over 21 days
2433261|NCT03343912|Experimental|Test 3 vaginal ring|Single intravaginal application of 1 vaginal ring of Estriol 0.200 mg/day and Trimegestone 0.18 mg/day (Test 3) over 21 days
2433262|NCT03343873|Experimental|Midarolam|midarolam sensation group
2433263|NCT03343873|Experimental|Propofol|propofol sensation group
2433264|NCT03343873|Experimental|dexmedetomidine|dexmedetomidine sensation group
2433265|NCT03343860|Active Comparator|Conventional|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps.
2433266|NCT03343860|Active Comparator|Non inducibility|PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT) .
2433267|NCT03343847|Experimental|Romiplostim|the study in a 2:1 randomization ratio(108 subjects to romiplostim)
2433268|NCT03343847|Placebo Comparator|Placebo|the study in a 2:1 randomization ratio (54 subjects to placebo)
3147409|NCT00123500|Placebo Comparator|2|Control Group
2433270|NCT03343821||Frail elderly patient|
2433271|NCT03343795|Experimental|study group 1|oral progesterone
2433272|NCT03343795|Active Comparator|study group 2|intramuscular progesterone
2433273|NCT03343782|Experimental|Stem cell transplantation|Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval
2433274|NCT03343769||Patient|
2433275|NCT03343769||Control|
2433276|NCT03343743|Other|Hydration|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
3147410|NCT00123513|Experimental|1|Worksite intervention for obesity prevention
3147411|NCT00123513|No Intervention|2|Control group
3147412|NCT00123526|Experimental|1|Worksite intervention
3147413|NCT00123526|No Intervention|2|Receive no intervention
3147414|NCT00123552|Experimental|1|
3147415|NCT00123552|Experimental|2|
3147416|NCT00123552|Experimental|3|
2433277|NCT03343730|Experimental|Non-mydriatic color fundus photography|All participants will receive Non-mydriatic color fundus photography with the RetinaVue camera at an already scheduled annual physical exam or follow up clinic visit with their primary care provider (PCP).
2433278|NCT03343730|Active Comparator|Standard of Care (Control)|All patients will also receive a referral for a dilated eye exam with an eye care professional. A yearly dilated exam as referred by the PCP.
2433279|NCT03343717|Experimental|rehabilitation|"Phase 1 passive mobilization with 10 repetitions on each joint motion and muscle stretching to the upper.~Phase 2 - ability to respond to 3 of 5 simple verbal commands. Beginning with passive, active-assisted or active exercises with 5 repetitions in each joint movement in the MMSS and MMII, following the sequence of phase 1.~Phase 3 - exercises of MMSS with cycle ergometer - 1 series of 1 minute or passive, active-assisted, active or active-resistidos with 5 repetitions in each joint movement, following the sequence of phase 1."
2433280|NCT03343717|Active Comparator|chest physical therapy|respiratory exercises that include techniques of bronchial hygiene maneuvers with the objective of airway clearance, pulmonary reexpansion techniques for reversal of atelectasis, passive mobilization techniques with the aim of reducing deformities and preserving joint mobility
3187984|NCT00762060||Active|Surgical site continuous local anesthetic infusion with ONQ silver Soaker System
3187985|NCT00762060||Control|Hospital standard of care for pain management (Patient controlled analgesia or epidural)
2433283|NCT03343691||Screening Population|"Cohort 1:Screening Population - Women presenting for routine XRM and / or breast US.~Participants will be followed for one year and the outcome of those who undergo an annual XRM / breast ultrasound will be recorded."
2433284|NCT03343691||Breast Cancer Population|Cohort 2:Breast Cancer Population - Women who were diagnosed with malignant breast tumors, as determined by biopsy, and have not yet begun any treatment for the disease.
2433285|NCT03343678|Experimental|Venetoclax + BI 836826|
2433286|NCT03343665|Experimental|Nivolumab 40 mg|Experimental: Nivolumab Nivolumab 40 mg IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2433287|NCT03343652|Experimental|NB|Nivolumab 3 mg/kg IV infusion on day 1,14 + Bendamustine hydrochloride 90 mg/kg IV infusion on day 1,2 up to 3 cycles. Duration of cycle 28 days
3187986|NCT00762099|Active Comparator|1|Pregabalin Group
3187987|NCT00762099|Placebo Comparator|2|Placebo group
2433290|NCT03343626|Placebo Comparator|Placebo|TAK-426 placebo-matching injection, intramuscular, once on Days 1 and 29.
2433291|NCT03343626|Experimental|Low Dose: PIZV 2 microgram (mcg)|PIZV 0.5 milliliter (mL), 2 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2433292|NCT03343626|Experimental|Medium Dose: PIZV 5 mcg|PIZV 0.5 mL, 5 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2433293|NCT03343626|Experimental|High Dose: PIZV 10 mcg|PIZV 0.5 mL, 10 mcg antigen, injection, intramuscular, once on Days 1 and 29.
2433294|NCT03343613|Experimental|LY3381916 Escalation|LY3381916 administered orally.
2433295|NCT03343613|Experimental|LY3381916 + LY3300054 Escalation|LY3381916 administered orally and LY3300054 administered intravenously (IV).
2433296|NCT03343613|Experimental|LY3381916 Expansion|LY3381916 administered orally.
2433297|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B1|"Metastatic triple negative breast cancer (TNBC)~LY3381916 administered orally and LY3300054 administered IV."
2433298|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B2|"Metastatic non-small cell lung cancer (NSCLC)~LY3381916 administered orally and LY3300054 administered IV."
2433299|NCT03343613|Experimental|LY3381916 + LY3300054 Expansion B3|"Metastatic clear cell carcinoma renal cell carcinoma (RCC)~LY3381916 administered orally and LY3300054 administered IV."
2433300|NCT03343600|Experimental|Imatinib|Imatinib (100 mg/tablet) 2# per day till D+100 after allo-HSCT or prophylaxis failure.
2433301|NCT03343600|Placebo Comparator|Placebo|Placebo 2# per day till D+100 after allo-HSCT or prophylaxis failure.
2433302|NCT03343587|Experimental|LY3375880 Single Dose|Single dose of LY3375880 administered IV or SC
2433303|NCT03343587|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered IV or SC
2433304|NCT03343587|Experimental|LY3375880 Multiple Dose|Multiple doses of LY3375880 administered IV or SC
2433305|NCT03343587|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered IV or SC
2433306|NCT03343574|Experimental|Abdominal Strengthening Exercise|All participants in this arm shall perform exercises for the strengthening of abdominal muscles for a period of three months in addition to the routine care provided to them for the management of Parkinson's Disease. The exercises are structured and need to be performed on a routine basis.
2433307|NCT03343574|No Intervention|Routine Care|All participants in this group shall continue to obtain routine care for the management of Parkinson's Disease.
2433308|NCT03343561|No Intervention|Control|Subjects would have subjects' own diet as usual
2433309|NCT03343561|Experimental|Intervention diet 1|Nutrition advice will be given to subjects to consume a healthy diet and select food with Polyunsaturated fatty acids like fish and nuts to replace subjects' own food in high fat
2433310|NCT03343561|Experimental|Intervention diet 2|Nutrition advice will be given to subjects to consume a healthy diet and select food with whole grains to replace subjects own food in carbohydrate
2433311|NCT03343561|Experimental|Intervention diet 3|Nutrition advice will be given to subjects to consume a healthy diet and select food with healthy choices in fat and carbohydrate to replace subjects' own food choice
2433312|NCT03343548|Active Comparator|Group I|magnesium group (Mg)
2433313|NCT03343548|Placebo Comparator|Group II|control group (C)
2433314|NCT03343535|Experimental|OCS|OCS Lung Preservation
2433315|NCT03343522|No Intervention|Sedentarism|Patients assigned to this arm shall not perform regular exercise training.
2433316|NCT03343522|Experimental|Exercise Training|Patients assigned to this arm will be enrolled in exercise training program.
2433317|NCT03343509|Experimental|Group A - Oral|Oral metronidazole 400mg 3 times a day for 7 days Placebo ointment applied 3 time times a day for 7 days to affected region
2433318|NCT03343509|Experimental|Group B - Topical|Topical metronidazole ointment 10% 3 times a day for 7 days Oral placebo tablets 3 times a day for 7 days
3187988|NCT00762112|Experimental|TAK-559 32 mg QD|
2433319|NCT03343483|Experimental|Volunteering|Structured social volunteering program providing peer companionship to frail, homebound older adults for at least 16 hours per month for 12 months.
2433320|NCT03343483|Active Comparator|Life Review|Self-guided program of life review for 12 months.
2433321|NCT03343470||Cushing Syndrome (active phase)|Patients displaying biochemical and clinical features of active Cushing's syndrome
2433322|NCT03343470||Cushing Syndrome (during remission)|Patients at 3-6 months from remission with cortisol levels in the normal range
2433323|NCT03343457|Experimental|Acceptance Commitment Therapy|Acceptance Commitment Therapy. Cognitive therapy
2433324|NCT03343457|Experimental|Multidisciplinary assessment|Assessment of a team. Cognitive therapy
2433325|NCT03343457|No Intervention|Control|Control group
2433326|NCT03343444|Active Comparator|Arm 1|Treatment-naïve is defined as having never received treatment for HCV with any interferon (IFN), ribavirin , or other approved or experimental HCV specific direct acting antivirals.
2433327|NCT03343444|Active Comparator|Arm 2|"Treatment-experienced is defined as:~IFN Intolerant~Non-response~Relapse/Breakthrough"
2433328|NCT03343444|Experimental|Short Track|Treatment-naïve or Treatment-experienced who achived very rapid virological responce - Negative HCV PCR after treatment with (Sofosbuvir 400mg/Ledipasvir 90mg) for 1 week
2433329|NCT03343418|Active Comparator|desmopressin|Patients randomized to this group receive desmopressin 0,3 microgram.kg-1 as an intravenous infusion given during 20 min.
2433330|NCT03343418|Placebo Comparator|Placebo|Patients randomized to the control group will receive the infusion of 100 mL 0.9% saline (SF0,9%).
2433331|NCT03343405|Experimental|Intervention: Online Mind/Body|Participants randomized to the intervention group (i.e., Online Mind/Body Program for Fertility) were provided the 10 online modules provided weekly (one module per week), intended to be completed over 10 weeks. Additionally, participants received weekly therapeutic feedback.
2433332|NCT03343405|No Intervention|Wait-List|After 10-weeks being in the wait-list group, participants had the potential to participate in the intervention protocol if they desire.
2433333|NCT03343392|Experimental|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
2433334|NCT03343392|Placebo Comparator|Placebo group|One hour before in-office bleaching patients received either placebo.
2433335|NCT03343379|Other|Healthy cohort|Core stability test
2433336|NCT03343366|Experimental|Test Group 1|The participants in this group will receive a combination of ultrasonic scaling and hand instrumentation required for planing of the root surfaces (SRP) followed by systemic AAT followed by routine warm salt water rinses for 3-5 days and OHI. SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth. Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days. OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
2433337|NCT03343366|Active Comparator|Test Group 2|The participants in this group will receive a combination of Scaling Root Planing followed by routine warm salt water rinses for 3-5 days and OHI. Same procedure for SRP and OHI will be followed as that followed in Test Group 1
2433338|NCT03343366|Other|Control Group 3|The participants in this group will receive only routine warm salt water rinses for 3-5 days and Oral Hygiene Instructions as that followed in Test Group 1 and Test Group 2. However, after completing six (6) months of evaluation they will be provided DT either in the form of SRP+MET or SRP only in addition to OHI, whichever would be found to have a significant beneficial effect on CP.
2433339|NCT03343353|Experimental|LED red group (630nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
2433340|NCT03343353|Experimental|LED infrared group (940nm)|The leds will initially be measured in the photobiophysics laboratory of the University of São Paulo - Ribeirão Preto, regarding wavelength parameters, beam divergence, nominal power and fluency. The application will be in the graft donor area (scalp) of burn patients. The applied fluence will be 4J / cm2.
2433341|NCT03343353|Sham Comparator|Group Sham|This group will not receive irradiation by led light. You will only receive the routine care of the hospital unit to which you are hospitalized. These patients will be evaluated in the same way as the other two intervention groups, and also by a blind evaluator.
2433342|NCT03343340|Experimental|Early CRRT|Early Continous Renal Replacement Therapy within 6 hours + Standard Medical Therapy
2433343|NCT03343340|Active Comparator|Late CRRT|Late Continous Renal Replacement Therapy + Standard Medical Therapy
2433344|NCT03343327|Experimental|Chronocort®, then Cortef®|Single dose of 20mg Chronocort® (oral administration), followed by a single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration).
2433345|NCT03343327|Active Comparator|Cortef®, then Chronocort®|Single dose of 20mg Cortef® Immediate Release Hydrocortisone Tablets (oral administration), followed by a single dose of 20mg Chronocort® (oral administration).
2433346|NCT03343314||Hospitalized patients due to a severe, symptomatic aortic sten|Patients who agreed to participate in the study, aged ≥75 years, with severe and symptomatic aortic stenosis, and hospitalized in one of the medical and surgical centers participating in the study
2433347|NCT03343301|Other|Phase 1 Study of FPA144 + mFOLFOX6|"Phase 1 dose escalation of FPA144 administered intravenously over approximately 30 minutes in cohorts of 3-6 patients to evaluate for the recommended dose (RD) of FPA144 for phase 3. mFOLFOX6 administered 30 minutes after the end of the FPA144 infusion as follows:~Oxaliplatin 85 mg/m2 intravenously over 2 hours on day 1~Leucovorin 400 mg/m2 intravenously over 2 hours. Can be administered concurrently with oxaliplatin using a Y-connector on day 1~Immediately after completion of oxaliplatin and leucovorin, administer 5-fluorouracil (5-FU) 400 mg/m2 intravenously over 5 minutes~Immediately after the 5-FU bolus, 5-FU 2400 mg/m2 as a continuous intravenous infusion over 46 hours.~Treatment is repeated every 2 weeks."
2433349|NCT03343275|Experimental|Experimental|"Dietary supplement : Lit-Control® pH Down~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
2433350|NCT03343275|Placebo Comparator|Placebo|"Placebo:~Pharmaceutical form: capsules~Administration : oral~Dose: 3 capsules/day.~• Sanitary product : Lit-Control® pH Meter~In vitro diagnosis sanitary product~Use:Urinary pH evaluation"
2433351|NCT03343262|Experimental|"ta-VNS yidan-pi"|"Device:ta-VNS & Electro-acupuncture(yidan-pi auricular acupoints):2 times per day,2 days per week for 12 weeks"
2433352|NCT03343262|Placebo Comparator|"ta-VNS jian"|"Device:ta-VNS & Electro-acupuncture(jian auricular acupoints):2 times per day,2 days per week for 12 weeks"
2433353|NCT03343249|Experimental|Study Visits|"The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured.~Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete."
3147417|NCT00123578|Experimental|Lorazepam|Lorazepam for the treatment of mild GHB withdrawal.
2433355|NCT03343223|Experimental|Intervention Group|"Public health personnel identify PrEP-eligible clients.~PrEP-eligible clients are given a list of PrEP providers in Iowa and a brochure with info on getting PrEP. Clients are referred to a PrEP navigator, who facilitates linkage to clients' choice of TelePrEP or to community PreP providers.~Public health clients choosing TelePrEP complete a video visit with the tele-pharmacist and obtain PrEP relevant lab tests.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
2433356|NCT03343223|No Intervention|Control Group|"Public health personnel identify PrEP-eligible.~Public health personnel give PrEP-eligible clients a list of PrEP providers in Iowa, and a brochure with information on getting PrEP.~The client initiates contact with a PrEP provider in Iowa and schedules an appointment.~PrEP medication is mailed to the client and follow up video visits and lab testing are performed.~Within 7 days of enrollment, the subject will complete a survey regarding PrEP beliefs (20 minutes).~30 to 40 days after enrollment, the subject will complete a second survey with 4 questions about initiation of PrEP since study enrollment (10 minutes).~6 months following enrollment, a study team member will obtain medical records for the subject from PrEP providers in Iowa to determine if the subject has initiated and been retained in PrEP."
2433357|NCT03343210|Experimental|cancer patient|cancer patient
2433358|NCT03343210|Active Comparator|no cancer patient|no cancer patient
2433359|NCT03343197|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
2433360|NCT03343197|Experimental|AG-881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.
2433361|NCT03343197|No Intervention|No Treatment Pre-Surgery|Subjects will not receive treatment prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 or AG-881.
2433362|NCT03343184|Active Comparator|SEE and incremental restoration|50 teeth will receive restorations using SEE Strategy and Incremental Restoration
2433363|NCT03343184|Experimental|SEE and bulk restoration|50 teeth will receive restorations using SEE Strategy and Bulk Fill Restoration
2433364|NCT03343184|Experimental|SET and incremental restoration|50 teeth will receive restorations using SET Strategy and Incremental Restoration
2433365|NCT03343184|Experimental|SET and bulk restoration|50 teeth will receive restorations using SET Strategy and Bulk Fill Restoration
2433366|NCT03343145|Experimental|Test Drug Group|Leucostim 5µg/kg/day
2433367|NCT03343145|Active Comparator|Reference Drug Group|Neupogen 5µg/kg/day
2433368|NCT03343132||Subacute SCI|
2433369|NCT03343132||Chronic SCI|
2433370|NCT03343132||Controls|
2433371|NCT03343119||Hospitalised patients|No intervention
2433372|NCT03343119||Healthy volunteers|No intervention
2433373|NCT03343119||Dog owners (healthy volunteers)|No intervention
2433374|NCT03343119||Veterinarians (healthy volunteers)|No intervention
2433375|NCT03343119||Pig farmers (healthy volunteers)|No intervention
2433376|NCT03343106|Experimental|ACT plus ERP|Sessions 1 and 2 involved information-gathering, discussion of the ACT model of OCD and ERP, and introduction to self-monitoring of rituals. Session 3 involved the development of an exposure hierarchy and response prevention plan, and further explanation of the ACT-based approach to ERP which focuses on learning flexible responding in the presence of obsessions, anxiety, and urges to ritualize. Exposure practices (sessions 4-16) were procedurally similar to the ERP condition, but focused on the facilitation of ACT processes rather than on fear extinction. Homework exposure practice was linked to the participant's goals and values. Session 16 included an ACT model of relapse prevention focusing on following one's values in the presence of obsessive thoughts and compulsive urges.
2433427|NCT03342781|Active Comparator|Diffuser-mask group|The patients received oxygen therapy (8-15 L/min) from an OxyMask (Southmedic, Inc., Barrie, ON, Canada) to maintain oxygen saturation (SpO2) > 92%. Oxygen therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h. The oxygen flow rate was then decreased to 2 L/min and the patient was monitored while breathing room air.
2433430|NCT03342768|Other|Sugar sweetened beverages|Messages will be sent 1-2 times per week containing information on the adverse health effects of sugar sweetened beverages.
3147418|NCT00123578|Active Comparator|Pentobarbital|Pentobarbital for the treatment of mild GHB withdrawal.
2433377|NCT03343106|Experimental|ERP alone|ERP followed Kozak and Foa's treatment manual. Sessions 1 and 2 included information-gathering, psychoeducation about the cognitive-behavioral model of OCD and rationale for ERP, and introduction to self-monitoring of rituals. Session 3 was dedicated to developing the treatment plan (exposure hierarchy, response prevention plan). Sessions 4-16 included in-session prolonged and repeated gradual exposure therapy (in vivo and imaginal as needed), the assignment of daily exposure practices for between-sessions, and instructions to refrain from rituals (response prevention in session and between sessions), along with self monitoring of any rituals that were performed. Session 16 also addressed discontinuation and relapse prevention.
2433378|NCT03343093|Experimental|Intervention Evaluation Control Group|Surveys at 3 month intervals
2433379|NCT03343093|Experimental|Intervention Evaluation Test Group|We will evaluate the effects of an educational, tailored, online rehabilitation program addressing sexual and urinary outcomes after treatment by surveying at 3 month intervals
2433386|NCT03343054|Experimental|talazoparib|0.75 mg/day or 1.0 mg/day
3147419|NCT00123617|Experimental|Phase III cardiac rehabilitation|Phase III group-based cardiac rehabilitation classes, weekly
3147420|NCT00123617|No Intervention|Monitoring|Normal daily living, no extra visits to study centre
2433389|NCT03343028||Psychotherapy|The investigators will assess and acquire data on these Veterans across the course of the project prior to and after receiving Prolonged Exposure (PE) or Cognitive Processing Theory (CPT) treatment at VA Palo Alto (VAPAHCS) and the Albuquerque VA. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva at baseline on these Veterans and again 3 months after treatment to assess prediction and durability of the clinical and brain/behavioral metrics. All study assessments will take place at Stanford University/VAPAHCS. Subjects will be recruited through VAPAHCS and Albuquerque VA. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
2433390|NCT03343028||Healthy Controls|The investigators will assess and acquire data on these Veterans who do not have history of PTSD and have no history of any Axis I psychiatric disorder, are taking psychotropic medication, or use illicit drugs. They will acquire fMRI, behavioral, EEG, TMS/EEG, and saliva once. All study assessments will take place at Stanford University. Subjects will be recruited through public flying, online ads and VAPAHCS. Subjects will complete a clinical assessment including: neuroimaging, self-report questionnaires completed via computer or paper-and-pencil, cognitive testing, saliva, and TMS and EEG assessments.
2433391|NCT03343015||Traditional CR establishing|establishing a CR in traditional way with occlusal wax rims during complete dentures therapy
2433392|NCT03343015||Gothic arch method|establishing a CR with gothic arch tracing device during complete dentures therapy
2433393|NCT03343002|Experimental|fentanyl at 10-15 min before end of surgery|
2433394|NCT03343002|Active Comparator|fentanyl at end of surgery|
2433428|NCT03342781|Active Comparator|HFNC group|The patients received oxygen therapy at a high flow rate from a Precision Flow nasal cannula (Vapotherm, Inc., Stevensville, MD, USA). We selected a 1.9 mm pediatric cannula, which can dispense 1-20 L/min of oxygen. The initial oxygen flow rate was 1 L/kg/min and the FiO2 was 100%. The initial flow rate was increased by 1 L/kg/min until the SpO2 reached 92%. The initial FiO2 was decreased once the SpO2 was greater than 92% and the oxygen flow rate was maintained. HFNC therapy was halted if SpO2 was maintained at a level greater than 92% for more than 4 h at a FiO2 value of 21%, and the patient was transferred to a ward.
3147421|NCT00123656|Active Comparator|1|fluticasone
3147422|NCT00123656|Active Comparator|2|esomeprazole
3147423|NCT00123669|No Intervention|Control|Patient will not receive Inj Progesterone 500 mg
3147424|NCT00123669|Experimental|Treatment|An intramuscular injection of 500mg depot hydroxy-progesterone 5-14 days prior to surgery.
3147425|NCT00123838|Experimental|Single Group Assignment|Calypso® 4D Localization System
3147426|NCT00123916|Experimental|Benznidazole|40 - 80 days (according to body weight) treatment with benznidazol
3147427|NCT00123916|Placebo Comparator|Placebo|40 - 80 days (according to body weight) treatment with matching placebo
3147428|NCT00123929|Active Comparator|1|doxorubicin
3147429|NCT00123929|Other|2|docetaxel
3147430|NCT00123981|Active Comparator|CCABG|Coronary artery bypass surgery using cardiopulmonary bypass
3147431|NCT00123981|Experimental|OPCAB|Coronary artery bypass surgery NOT using cardiopulmonary bypass
3147432|NCT00124046|Active Comparator|Surgical|
3147433|NCT00124046|Active Comparator|Medical Treatment|
3147434|NCT00124059|Experimental|Type A SERO|
3147435|NCT00124059|Experimental|Type B SERO|
3147436|NCT00124059|Placebo Comparator|Type A PLA|
3147437|NCT00124059|Placebo Comparator|Type B PLA|
3147438|NCT00124124|Experimental|1|KLH and peptide pulsed DCs
3147439|NCT00124124|Experimental|2|KLH, peptides plus Montanide
3147440|NCT00124150|Experimental|M|Intravenous magnesium sulfate infusion for 14 days.
3147441|NCT00124150|No Intervention|S|Saline infusion without additional magnesium sulfate.
3147442|NCT00124189|Other|open label|Sequential dose cohort, open label, escalation trial evaluating one infusion duration of 2 hours
3147443|NCT00124202|Placebo Comparator|a fatty meal vs normal saline|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
3147444|NCT00124228|No Intervention|1|Antibiotic following hospital Protocols according the cause of the infection .
3147445|NCT00124228|Active Comparator|2|Antibiotic following hospital Protocols according the cause of infection plus albumin
3147446|NCT00124254|Experimental|1|Surgical group undergoing SMPA
3147447|NCT00124254|Active Comparator|2|Nosurgical group
3147448|NCT00124280|Experimental|previously treated with chemotherapy only|patients previously treated with chemotherapy only (at most 2 prior regimens one of which must have been platinum-based) and no EGFRI
3147449|NCT00124280|Experimental|previously treated with chemotherapy + small|patients previously treated with chemotherapy (at most 2 prior regimens one of which must have been platinum-based) and with one small molecule EGFRI
3147450|NCT00124293||Factor VII|
3147451|NCT00124306|Active Comparator|1|Amitryptiline
3147452|NCT00124306|Placebo Comparator|2|Placebo will be dosed exactly as active arm.
3147453|NCT00124319||1|Incoming cadets at the U.S. Naval, Air Force, or Military Academies
3147454|NCT00124345|Experimental|1|
2433397|NCT03342976|Active Comparator|Cases|"Pre-frail subjects will use an ICT platform (my-AHA platform) embedded in a mobile phone and a fit-band that will continuously monitor physical and cognitive activities.~Interventions regarding physical, cognitive, psychological and social domains will be prescribed and monitored through the my-AHA platform. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
2433398|NCT03342976|Placebo Comparator|Controls|"Pre-frail subjects will be followed according to best standard of care protocols. Interventions regarding physical, cognitive, psychological and social domains will be prescribed. In addition, sleep and dietary habits will be investigated and tailored interventions will be suggested."
3147455|NCT00124501|Active Comparator|SMT|Standard Medication Treatment
3147456|NCT00124501|Experimental|BART|Biofeedback-assisted Relaxation Training plus SMT
3147457|NCT00124540|Placebo Comparator|1|placebo resembling misoprostol
2433406|NCT03342924|Experimental|Flanker test and physical fitness test|Participants performed a computer-based Flanker Task measuring cognitive control and physical fitness tests: two-minute walk, vertical jump, one-minute curl-ups, and handgrip strength. Body composition variables included: body mass index, percent body fat, waist circumference, and sagittal abdominal height. General linear models were performed to evaluate impacts of physical fitness and body composition on cognition, adjusting for age and sex.
2433407|NCT03342911|Experimental|Treatment (nivolumab, paclitaxel, carboplatin)|Patients receive nivolumab IV over at least 30 minutes on day 1, paclitaxel IV on days 1 and 8, and carboplatin IV on days 1 and 8. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2433411|NCT03342885|Experimental|Intervention group|Participants enrolled into the intervention group receive specific sleep ergonomics guidance
2433412|NCT03342885|Active Comparator|Control group|Participants enrolled into the control group will receive general sleep ergonomics guidance
2433413|NCT03342872|Experimental|Core Training|
2433414|NCT03342872|Experimental|Core Training & Facilitation|
2433415|NCT03342872|No Intervention|Control|
2433416|NCT03342859|Experimental|Vilaprisan group|Vilaprisan 2 mg oral daily over 8-12 weeks
2433417|NCT03342859|Active Comparator|Ulipristal group|Ulipristal 5 mg oral daily over 8-12 weeks
2433418|NCT03342859|No Intervention|Control group|Patients undergoing surgery without any prior treatment, as control group
2433419|NCT03342846|Active Comparator|High Frequency rTMS in PD|The first group received 20 Hz rTMS on M1 daily for 10 days 5 sessions every week.
2433420|NCT03342846|Active Comparator|Low Frequency rTMS in PD|The second group received 1 Hz rTMS on M1 daily for 10 days 5 sessions every week.
2433421|NCT03342833|Active Comparator|Blood flow restriction|
2433422|NCT03342833|Sham Comparator|Usual training|
2433423|NCT03342820|Experimental|Quadriceps muscle fatigue|Quadriceps muscle fatigue
2433424|NCT03342807|Experimental|Group Insulin|
2433425|NCT03342807|Experimental|Group Aphesis|
2433426|NCT03342794|Other|preexisting posterior capsule defects|congenital cataracts with a preexisting posterior capsule defect
2433429|NCT03342768|Experimental|TID|Messages will be sent 1-2 times per week containing information that aims to denormalise the tobacco industry.
3147458|NCT00124540|Experimental|2|misoprostol
3147459|NCT00124566|Experimental|1|Irofulven + prednisone
3147460|NCT00124566|Experimental|2|Irofulven + capecitabine + prednisone
3147461|NCT00124566|Active Comparator|3|Mitoxantrone + prednisone
3147462|NCT00124605|Experimental|Treatment (pamidronate disodium and arsenic trioxide)|Patients receive pamidronate IV and over 2 hours on days 1 and 15 and arsenic trioxide IV over 2 hours on days 1-5 and 15-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3147463|NCT00124683|Experimental|1|Nicotine Patch + Bupropion
3147464|NCT00124683|Placebo Comparator|2|Nicotine patch + placebo
3147465|NCT00124722|Experimental|0.45 mg/kg Zemuron|0.45 mg/kg Zemuron
3147466|NCT00124722|Active Comparator|0.6 mg/kg Zemuron|0.6 mg/kg Zemuron
3147467|NCT00124722|Experimental|1.0 mg/kg Zemuron|1.0 mg/kg Zemuron
3147468|NCT00124761|Other|Surgery + Whole Brain Radiotherapy|
3147469|NCT00124761|Experimental|RadioSurgery + Whole Brain Radiotherapy|
3147470|NCT00124787|Experimental|Dimenhydrinate|dimenhydrinate PO x 4 doses
3147471|NCT00124787|Placebo Comparator|Placebo|placebo PO x 4 doses
3147472|NCT00124839|Other|1|Blinded sequential administration: naltrexon 50 mg (3 weeks)- placebo (3 weeks)- placebo (1 week)
3147473|NCT00124839|Other|2|Blinded sequential administration: 200mg naltrexone (3 weeks) - placebo (3 weeks)- placebo (1 week)
3147474|NCT00124839|Other|3|Blinded sequential administration: placebo (3 weeks) - 200mg naltrexone (3 weeks) - placebo (1 week)
3147475|NCT00124839|Other|4|Blinded sequential administration: placebo (3 weeks) - 50mg naltrexone (3 weeks) - placebo (1 week)
3147476|NCT00124852|Placebo Comparator|High Oleic Sunflower Oil|
3147477|NCT00124852|Active Comparator|400 mg EPA+DHA/day|low dose fish oil
3147478|NCT00124852|Active Comparator|1800 mg EPA+DHA/day|high dose fish oil
3147479|NCT00124878|Active Comparator|Arm 1 Male circumcision|Men receive circumcision after randomization; procedure is generally provided within two weeks. A man randomized to the intervention arm who then declines circumcision for 6 or more months is considered a cross over.
3147480|NCT00124878|No Intervention|Arm 2|Men wait for two years of follow up before being offered male circumcision
3147481|NCT00124969|Active Comparator|1|Amlodipine
3147482|NCT00124969|Placebo Comparator|2|Placebo
3147483|NCT00125008|Experimental|1|Typhoid Vi vaccine
3147484|NCT00125008|Active Comparator|2|Hepatitis A vaccine
3147485|NCT00125047|Experimental|1|Typhoid Vi polysaccharide vaccine
3147486|NCT00125047|Active Comparator|2|Inactivated Hepatitis A vaccine
3147487|NCT00125216|Other|Arm 1|Single subject design - participant receives three administrations of the same treatment
3147488|NCT00125255|Experimental|S-Caine Peel|
3147489|NCT00125255|Placebo Comparator|Placebo Peel|
2433431|NCT03342742|Experimental|Daily Caloric Restriction|The daily caloric restriction group will be instructed to reduce energy intake by a 34% daily energy deficit from baseline individual weight maintenance energy requirements.
2433432|NCT03342742|Experimental|Intermittent Fasting|Participants in the intermittent fasting group will be instructed to reduce energy intake to ~20% of estimated energy requirement (delivered as a single meal) three non-consecutive days per week, resulting in a weekly energy deficit of ~34% (similar to the daily caloric restriction group).
2433433|NCT03342729|Experimental|Intervention Group|Immediate exposure to the 10-week Aging Mastery Program (AMP)
2433434|NCT03342729|Placebo Comparator|Wait-list Group|Class to start 3 months after the Intervention Group
2433437|NCT03342703||Patients with Liver Fibrosis Measurement|Group1: Patients will undergo an Ultrasound to correlate fibrosis measurements obtained using standard-of-care MRI.
2433438|NCT03342703||Patients with Liver Steatosis Measurement|Group 2: Patients will undergo an Ultrasound to correlate steatosis measurements obtained using standard-of-care MRI.
2433440|NCT03342677|Other|Single Arm|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver MRI with Primovist before hepatic transplantation.
3147490|NCT00125385|Experimental|Cohort 1|Dose group
3147491|NCT00125385|Experimental|Cohort 2|Dose Group
2433443|NCT03342651|Other|Observational research|Vitamin D levels and respiratory complications; observational research.
2433446|NCT03342625|Experimental|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI
2433447|NCT03342612|Experimental|Brain Magnetic Resonance Imaging (MRI)|Neuroimaging protocol to assess brain changes after minor head trauma and over the time.
2433448|NCT03342599|Experimental|GNC Alpha Lipoic Acid Supplement|600mg/daily ingestion of GNC alpha lipoic acid with no change in lifestyle for 8 weeks
2433449|NCT03342599|Placebo Comparator|Cellulose Fiber Placebo|600mg/daily ingestion of Vital Nutrients placebo (cellulose starch) with no change in lifestyle for 8 weeks
3147492|NCT00125385|Experimental|Cohort 3|Dose Group
2433451|NCT03342573|Experimental|Single Arm|Patients with a biopsy proven diagnosis of PRP
2433453|NCT03342547|Experimental|Intestinal stem cell-derived enteroids|Duodenal biopsy samples and saliva will be collected from participants and then processed in laboratory to generate intestinal stem cell-derived enteroids.
2433454|NCT03342534|Active Comparator|Anodal tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the contralesional supraorbital front of the patient.
2433455|NCT03342534|Active Comparator|High definition (HD) anodal tDCS|A single HD anode is placed over the primary motor cortex of the stroke affected hemisphere, 4 HD cathodes are placed over the affected hemisphere around the anode.
2433456|NCT03342534|Active Comparator|Bihemispheric tDCS|The anode is placed over the primary motor cortex of the stroke affected hemisphere, the cathode over the primary motor cortex of the contralesional hemisphere.
2433457|NCT03342534|Sham Comparator|Sham tDCS|The electrodes are placed as in one of the active arms, but only a ramp up current is applied during 30 seconds and then switched off. This induces similar sensations for the patients, but no change in excitability.
2433458|NCT03342508|Experimental|Fetal Pillow Inflated (FPI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The anesthesiologist will then inflate the Fetal Pillow. The obstetrician will not be aware to inflation of Fetal Pillow~Cesarean delivery will then be performed~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
2433459|NCT03342508|No Intervention|Fetal Pillow Not Inflated (FPNI)|"A Fetal Pillow will be inserted vaginally by the obstetrician after catheterization of the bladder (if it has not been previously performed). Once the Fetal Pillow is in place, the woman's legs will be placed flat on the operating table. The Fetal Pillow will not be inflated.~Cesarean delivery will then be performed. The obstetrician will continue to be able to use conventional methods for delivery of a second stage arrest including hand from below and reverse breech extraction.~The circulating nurse will deflate the Fetal Pillow following delivery. The obstetrician will remove the Fetal Pillow at the end of the procedure. The obstetrician will then fill out a survey regarding the delivery."
2433460|NCT03342495|Experimental|Patient Navigator Arm|"Patient Navigator (Social Worker) will assist youth adapt and attach to adult delivered healthcare for up to 24 months.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences.~Up to 100 participants will be provided the opportunity to be interviewed at baseline and end of study about their transition experience."
2433647|NCT03341221||One group|Diagnosis of ascites in infants and children by history, examination and investigations
3147493|NCT00125385|Experimental|Cohort 4|Dose Group
3147494|NCT00125385|Experimental|Cohort 5|Dose Group
3147495|NCT00125450|Experimental|A|Chest Physiotherapy with Forced Expiratory Technique
3147496|NCT00125450|Active Comparator|B|Aspiration
3147497|NCT00125502|Experimental|I|n=200; 20 micrograms gB with MF59
3147498|NCT00125502|Placebo Comparator|II|n=200; placebo (normal saline)
3147499|NCT00125567|Experimental|1|Stalevo (levodopa/carbidopa/entacapone)
3147500|NCT00125567|Active Comparator|2|Levodopa/carbidopa
3147501|NCT00125606|Active Comparator|conditioning therapy with 12 Gy TBI / cyclophosphamide 120|
3147502|NCT00125606|Experimental|conditioning therapy with 8 Gy TBI / fludarabine 120|
3147503|NCT00125645|Experimental|Irbesartan|Tablet Irbesartan 150 mg once daily
3147504|NCT00125723|No Intervention|No Intervention|
2433461|NCT03342495|Other|Usual Care Arm|"Youth will receive usual care from their pediatric clinics in preparation and transfer to adult care.~Participants will receive 5 issues of a provincial generic newsletter on topics around transition.~Participants will be asked to complete a health questionnaire at baseline and 4 more times during 24 months.~Participants will be asked to complete a transition readiness questionnaire at baseline and 4 more times during 24 months.~Participants will be provided the opportunity to journal online about their experiences."
2433462|NCT03342482|Placebo Comparator|Placebo|5 g of placebo (sugar and salt) will be administered in veggie capsules
2433463|NCT03342482|Experimental|MSG|5 grams of MSG will be administered in veggie capsules
3187989|NCT00762125|Experimental|Cognitive restructuring and coping skills training (CR+ST)|
3187990|NCT00762125|Experimental|Exposure therapy (ET)|
3187991|NCT00762125|Experimental|Combination (COMB) treatment|
2433468|NCT03342456|Experimental|group 1|week1 to week2：Doxycycline Hyclate Enteric-Coated Capsules 0.1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily
2433469|NCT03342456|Active Comparator|group 2|"Amoxicillin Capsules 1g,orally,twice daily,taken with meals, Ilaprazole Enteric-Coated Tablets 5mg,orally,twice daily, Furazolidone Tablets 0.1g,orally,twice daily,taken with meals, Bismuth Potassium Citrate Tablets 220mg,orally,twice daily.~week3 to week4：Ilaprazole Enteric-Coated Tablets 5mg,orally,once daily"
2433470|NCT03342443|Experimental|memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
2433471|NCT03342443|Placebo Comparator|placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
2433472|NCT03342430||Early Dieting in Girls cohort|A cohort of 197 non-Hispanic white girls, observed from age 5 to age 15 years
3147505|NCT00125723|Other|Intervention|PI Discretion
3147506|NCT00125736|Experimental|E0671 combination group|
3147507|NCT00125736|Placebo Comparator|placebo combination group|
3147508|NCT00125775|Active Comparator|1|Engerix-B 40 mcg dose
3147509|NCT00125775|Active Comparator|2|Engerix-B 80 mcg dose
2433478|NCT03342391|Other|Treatment Phase|Treatment Phase will evaluate the effectiveness of Transnasal Esophagoscopy (TNE) as an acceptable form of monitoring Eosinophilic Esophagitis
2433480|NCT03342352|Experimental|Arm A|Nivolumab plus epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
2433481|NCT03342352|Active Comparator|Arm B|EXTREME regimen.
2433482|NCT03342352|Experimental|Arm C|Nivolumab plus placebo for epacadostat in combination with platinum (carboplatin/cisplatin) plus 5-fluorouracil.
2433579|NCT03341689|Experimental|Placebo/High Dose Psilocybin|Subjects in this arm receive placebo in the first session and high dose psilocybin in the second session.
2433681|NCT03340974|Experimental|Arm A: SBRT + Avasopasem (GC4419)|
3147510|NCT00125827|Experimental|1|Single-arm, dose escalation
3147511|NCT00125879|Experimental|1|
3147512|NCT00125918|Placebo Comparator|1|Placebo
3147513|NCT00125918|Active Comparator|2|2.5 mg tadalafil
3147514|NCT00125918|Active Comparator|3|10 mg tadalafil
3147515|NCT00125918|Active Comparator|4|20 mg tadalafil
3147516|NCT00125918|Active Comparator|5|40 mg tadalafil
3147517|NCT00125970|Experimental|1|DNA HIV vaccine administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine administered at Month 6
3147518|NCT00125970|Placebo Comparator|2|DNA HIV vaccine placebo administered at study entry and at Months 1 and 2 and adenoviral vector HIV vaccine placebo administered at Month 6
3147519|NCT00126048|Active Comparator|1|Oral atorvastatin 40mg
3147520|NCT00126048|Placebo Comparator|2|Placebo
3147521|NCT00126100|Experimental|1|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
3147522|NCT00126100|Placebo Comparator|2|Patients were randomly assigned to receive subcutaneously a daily dose of placebo for 5 days.
3147523|NCT00126217|Experimental|1|
3147524|NCT00126217|No Intervention|2|
3147525|NCT00126308|Experimental|Immediate|poly-L-lactic acid injections
3147526|NCT00126308|Active Comparator|Delayed|poly-L-lactic acid injections
3147527|NCT00126334|Active Comparator|1|Liberal transfusion threshold
3147528|NCT00126334|Experimental|2|Conservative transfusion threshold
3147529|NCT00126373|Placebo Comparator|Sugar pill|Placebo (sugar) pill with identical look to bupropion
3147530|NCT00126373|Experimental|buproprion|bupropion pill
3147531|NCT00126412|Experimental|123I-mIBG (Meta-iobenzylguanidine)|"All subjects received 123I-mIBG injection over at least 1 to 2 minutes through a cannula (or indwelling catheter in the vein). After the injection of 123I-mIBG was complete, the cannula was flushed with at least 5 mL of 0.9% sodium chloride solution over a maximum of 10 seconds.~All subjects ≥18 years of age and children with a weight of ≥70 kg were to receive an intravenous injection of 370 ±10% MBq (333 to 407 MBq [9.0 to 11 mCi] of 123I-mIBG). Doses of 123I-mIBG for children <18 years of age (with a weight of 8-70 kg) were to be calculated on the basis of a reference activity for an adult scaled to body weight according to the schedule proposed by the European Association of Nuclear Medicine (EANM) Paediatric Task Group; for children <8 kg, a scaled activity or a fixed minimum activity of 80 ±10% MBq (72 to 88 MBq [1.9 to 2.2 mCi]) was permissible."
3147532|NCT00126516|Active Comparator|1|Angiotensin II Receptor Antagonists group
3147533|NCT00126516|Active Comparator|2|Angiotensin-converting Enzyme Inhibitors group
2433483|NCT03342339|Other|patients with Parkinson's disease|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
2433484|NCT03342339|Other|witnesses|"cognitive examination : mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test~viewing of video : scale of differential emotions and Positive and Negative Affect Scale~Test of Iowa Gambling Task"
2433485|NCT03342326|Other|patient with Alzheimer's Disease|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
2433486|NCT03342326|Other|healthy volunteer|"Exposure to familiar songs : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.~Music Experience Questionnaire : questions about the past music training~Implicit tasks memory : a) Completion of trigrams : freely complete the first 3 letters of a word. b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not.~For volunteer over 65 years : Mini Mental State Examination, 5 words by Dubois and fluence verbal test"
2433487|NCT03342313|Experimental|healthy weight|BMI (kg/m2) ≥ 18.5 and < 23
2433488|NCT03342313|Experimental|Overweight|BMI (kg/m2) ≥23 chewing 15 times and 50 times per bite
2433489|NCT03342300|Experimental|Arm A|participants will recieve pegylated liposomal doxorubicin (50 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
2433490|NCT03342300|Placebo Comparator|Arm B|participants will recieve pirarubicin (60 mg/m²d1) plus ifosfamide (2 g/m²/d d2-3), dacarbazine (300 mg/m²/d d2-3).
2433491|NCT03342274|Experimental|Lifestyle Program Intervention|Participants receive usual care and group weight loss sessions adapted from the Diabetes Prevention Program delivered by Community Health Workers.
2433492|NCT03342274|Other|Wait list|Participants receive usual care and after 1 year receive the Lifestyle Program intervention
2433493|NCT03342261||HCV patients with mixed cryoglobulinemia|HCV patients with or without HIV presenting a mixed cryoglobulinemia and treated with direct-acting antiviral agents
2433494|NCT03342248|Experimental|access to the social network|This group is made up of carers who have access to the social network via a digital platform developed during step 1. This network will offer features from step 1 (sharing experiences on a forum, monitoring health status )
2433495|NCT03342248|No Intervention|no access to the network|"This group consists of caregivers who do not have access to the social network via a digital platform developed during step 1.~Access to the social network will be offered to all carers at the end of the study, especially those assigned in the control group to limit their refusal to participate."
2433496|NCT03342235|Experimental|Surgical Group|Participants randomized to PRK surgery will be referred to a study surgical center. The participant will have a preoperative exam within 7 days prior to surgery and surgery within 60 days after randomization. Participants will continue prescribed 2 hours per day of patching between randomization and the day of surgery.
2433497|NCT03342235|Active Comparator|Non-surgical Control Group|For participants assigned to the non-surgical control group, patching will be prescribed for 2 hours per day with optical correction, and will continue until the 8-month primary outcome visit.
2433498|NCT03342222|Experimental|PEEK Interference Screws|PEEK Interference Screws provided by Ruijin Hangzhou Martins Medical Equipment Co., Ltd.
2433499|NCT03342222|Active Comparator|Biosure PK interference screw|Biosure PK interference screw from Smith & Nephew plc.
2433500|NCT03342209|Experimental|HFNC therapy|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy will be implemented to CO-poisoned patients. Oxygen flow rate will be started 60 L/min and be decreased as the patient has requested.
2433501|NCT03342196|Experimental|Thiotepa + Fludarabine + Melphalan + KGF|Melphalan 100 mg/m2 on day -8 Thiotepa 10 mg/kg on day -7 Fludarabine 160 mg/m2 in divided doses given on days -6, -5, -4 and -3. Keratinocyte Growth Factor (KGF) 60mcg/kg IV on day -11, -10, and -9 and 0, +1, and +2.
2433502|NCT03342183|Experimental|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation). To be administered on a monthly basis from the baseline visit to the year 1 visit.
2433503|NCT03342183|Sham Comparator|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
2433504|NCT03342170||CIRRAL|alcoholic cirrhosis
2433505|NCT03342170||CIRVIR|Viral cirrhosis
3187992|NCT00762125|Active Comparator|Attention control (AC) treatment|
3187993|NCT00762138|Other|Autologel System|Autologel System produces platelet rich plasma gel
3187994|NCT00762151|Placebo Comparator|Negative Control|Regular Toothpaste
3187995|NCT00762151|Active Comparator|Positive Control|Standard anti-plaque and anti-bacterial toothpaste.
2433510|NCT03342131||STEMI group|The study population consists of 150 patients with ST-elevated acute myocardial infarction (STEMI) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded. Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
2433580|NCT03341689|Experimental|Low Dose Psilocybin/Placebo|Subjects in this arm receive low dose psilocybin in the first session and placebo in the second session.
2433682|NCT03340974|Placebo Comparator|Arm B: SBRT + Placebo|
3187996|NCT00762151|Active Comparator|Prototype|AN0128 Toothpaste
2433511|NCT03342131||NST-ACS group|The study population consists of 150 patients with non-ST elevated acute myocardial infarction (NST-ACS) including unstable angina pectoris (UAP),who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA at 0 , 7days and 12 months after admission.
2433512|NCT03342131||Control group|150 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Control group. Circulation wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission.
2433513|NCT03342118|Experimental|Phloroglucin group|patients taken Phloroglucin(Flospan®)
2433514|NCT03342118|Placebo Comparator|Normal saline placebo group|patients taken normal saline placebo
2433515|NCT03342105|Experimental|Cettum (Electrical moxibustion)|The patients in this group will receive Cettum (Electrical moxibustion) treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
2433516|NCT03342105|Active Comparator|Acupuncture|The patients in this group will receive acupuncture treatment applied by a certified Korean Medicine Doctor with more than 6 years of traditional Korean medicine college education.
2433517|NCT03342092||Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation
2433518|NCT03342079|Experimental|Group 1|local anesthetic + placebo
2433519|NCT03342079|Experimental|Group 2|local anesthetic + nitrous oxide
2433520|NCT03342079|Placebo Comparator|Group 3|Placebo + nitrous oxide
2433521|NCT03342066||A|Cariogram
2433522|NCT03342066||B|CAMBRA
3187997|NCT00762190|Experimental|TAK-559 32 mg QD + Insulin|
3187998|NCT00762190|Active Comparator|Insulin|
2433525|NCT03342040|Experimental|TAP block|Patients undergoing laparoscopic ventral hernia repair with TAP block with 0.2% ropivacaine under ultrasound guidance
2433526|NCT03342040|Active Comparator|No TAP block|Patients undergoing laparoscopic ventral hernia repair without TAP block
3147534|NCT00126542|Experimental|Treatment (bevacizumab, erlotinib hydrochloride)|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive oral erlotinib once daily on days 1-21. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to 1 of the study drugs may continue treatment with the remaining study drug alone in the absence of disease progression or unacceptable toxicity.
3147535|NCT00126607|Experimental|Treatment (trastuzumab)|Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3147536|NCT00126620|Experimental|OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)|Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle. Three dose levels assessed.
3147537|NCT00126724|Active Comparator|1|1x10^11 DRP/mL tgAAC94
2433531|NCT03342014|Experimental|All patients|All patients will have the same intervention (3DPD and UAD acquisitions ; blood sample)
2433533|NCT03341988|Other|Ombitasvir (25 mg ), Paritaprevir (150 mg ) once daily|Ombitasvir (25 mg once daily), Paritaprevir (150 mg once daily), Ritonavir (100 mg once daily)Ribavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) given to 50 chronic HCV infected patients with renal impairment for 12 week
3147538|NCT00126724|Active Comparator|2|1x10^12 DRP/mL tgAAC94
3147539|NCT00126724|Active Comparator|3|1x10^13 DRP/mL tgAAC94
3147540|NCT00126724|Placebo Comparator|4|
3147541|NCT00126763|Experimental|Matrix Transdermal Fentanyl Patch|
3147542|NCT00126789|Experimental|ZR-02-01|ZR-02-01 matrix transdermal fentanyl patch
3147543|NCT00126880|Experimental|600mg BID ATC|600mg BID ATC
3147544|NCT00126880|Experimental|800mg BID ATC|800mg BID ATC
3147545|NCT00126880|Active Comparator|150mg BID 3TC|150mg BID 3TC
2433544|NCT03341949|Experimental|Patient with chronic kidney disease|Determination of the Cluster of Differentiation 146 (CD146)
2433792|NCT03340194||Systemic sclerosis patients|
3147546|NCT00126984|Experimental|Group A|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation A
3147547|NCT00126984|Experimental|Group B|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation B
3147548|NCT00126984|Experimental|Group C|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation C
3147549|NCT00126984|Experimental|Group D|Subjects of 12-14 months of age or 3-5 years of age who will receive formulation D
3147550|NCT00126984|Active Comparator|Group E|Subjects of 12-14 months of age who will receive Meningitec and subjects of 3-5 years of age who will receive Mencevax ACWY.
3147551|NCT00127075|Experimental|NOMA + estradiol|Oral NOMA (LUTENYL® 10 mg/day) combined with transdermal Estradiol (DERMESTRIL SEPTEM® 75 mcg, once a week),
3147552|NCT00127075|Placebo Comparator|placebo|Matching placebo treatments
3147553|NCT00127114|Experimental|Amantadine|
3147554|NCT00127114|Placebo Comparator|Placebo|
3147555|NCT00127127|Experimental|1|1. level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
3147556|NCT00127140|Experimental|Vorinostat|Participants received (Cycle 1) once-daily vorinostat at assigned dose (100 or 200 mg) on Days 1 and 17 and twice-daily on Days 3-16. Thereafter, participants remaining on study received the same dose level therapy twice-daily for 14 consecutive days followed by 7 days of rest.
3147557|NCT00127270|Experimental|1|Darifenacin
3147558|NCT00127270|Other|2|Darifenacin in combination with Behavioral Modification Programme for Symptoms of Overactive Bladder
3147559|NCT00127335|Placebo Comparator|1|
3147560|NCT00127335|Active Comparator|2|statin administration
3147561|NCT00127452|Experimental|EPA + DHA|Margarine spread that yields 400 mg of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) per day for average margarine use of 20 grams per day
2433545|NCT03341936|Experimental|Nivolumab+Lirilumab|"The drugs will be administered intravenously. A single dose of Nivolumab and Lirilumab will be administered prior Salvage surgical resection.~In Cycle 1-3: Nivolumab will be administered on Days 1 and 15 and lirilumab will be administered on Day 1 of each 28 day long cycle~In Cycle 4-6 and beyond: Nivolumab and lirilumab will be administered on Day 1 of each 28 day long cycle."
3187999|NCT00762242||1|Blood sampling and brachial artery ultrasound
3188000|NCT00762255|Experimental|A - Phase I Dose Escalation|Dose Escalation - Irinotecan and bevacizumab are given IV on days 1 and 15 of each cycle. Vorinostat is given orally on days 1-7 and 15-21 of each cycle.
3188001|NCT00762255|Experimental|B - Treatment at Maximum Tolerated Dose (MTD)|MTD - Treatment at maximum tolerated dose
3188002|NCT00762281|Other|Treatment of Hyperopic LASIK|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
3188003|NCT00762294||644-001|Women treated for breast cancer who will be starting Arimidex or Femara
3188004|NCT00762333||Myocardial Infarction|
2433552|NCT03341897|Experimental|Surgical varicocelectomy|
2433553|NCT03341884|Experimental|Normal Hepatic Function|Participants with normal hepatic function will be administered a single oral dose of ipatasertib (100 mg).
2433554|NCT03341884|Experimental|Mild Hepatic Impairment|Participants with mild hepatic impairment (Child-Pugh Class A, score of 5 to 6, inclusive) will be administered a single dose of ipatasertib (100 mg).
2433555|NCT03341884|Experimental|Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh Class B, score of 7 to 9, inclusive) will be administered a single dose of ipatasertib (100 mg).
2433556|NCT03341884|Experimental|Severe Hepatic Impairment|Participants with severe hepatic impairment (Child-Pugh Class C, score of 10 to 15, inclusive) will be administered a single dose of ipatasertib (100 mg).
2433557|NCT03341871||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to the current local label.
2433558|NCT03341845|Experimental|axitinib and avelumab|axitinib 5MG BID and avelumab 10mg/kg Q2W
2433559|NCT03341832|Experimental|NVP-1203|NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose
2433560|NCT03341832|Active Comparator|NVP-1203-R|NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose
2433561|NCT03341832|Placebo Comparator|Placebo|NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose
2433562|NCT03341819|Active Comparator|Retained Urinary Catheter|
2433563|NCT03341819|Experimental|Non-retained Urinary Catheter|
2433565|NCT03341793|Experimental|Muscle secretion|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
2433566|NCT03341767|Experimental|Clofazimine|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
2433567|NCT03341767|Placebo Comparator|Placebo|Placebo gelatin capsule(s) taken orally every 8 hours for 5 days.
2433568|NCT03341767|Experimental|Clofazimine, no diarrhea|Subjects >/=50 kg: Clofazimine two 50mg gelatin capsules taken orally every 8 hours for 5 days Subjects <50 kg: Clofazimine 50mg gelatin capsule taken orally every 8 hours for 5 days
2433569|NCT03341754|Experimental|Group 1 (D/ChAd63-CA)|"(2-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A at 2 mg total (1 mg per construct) per dose as two 1 mL IM injections of the blended D-CA, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A boost, at a total dose of 1 x 1011 virus particles (vp) (5 x 1010 vp/construct) as a single IM injection of 0.65mL, using a needle and syringe.~Week 0 = Prime with D-CA Week 4 = Prime with D-CA Week 8 = Prime with D-CA Week 24 = Boost with ChAd63-CA Week 28 = Controlled Human Malaria Infection (CHMI)"
2433570|NCT03341754|Experimental|Group 2 (D/ChAd63-CAT)|"(3-antigen): 3 doses at 4 week intervals (Week 0, 4, and 8) of DNA prime with D-C + D-A + D-T at 3 mg total (1 mg per construct) per dose as two 1 mL intramuscular (IM) injections of the blended D-CAT, one in each arm, via Biojector 2000 needle-free injection device or an equivalent disposable syringe needle-free injection device. This will be followed after 16 weeks (Week 24) by 1 dose of ChAd63-C + ChAd63-A + ChAd63-T boost, at a total dose of 1.5 x 1011 vp (5 x 1010 vp/construct) as a single IM injection of 1.0mL, using a needle and syringe.~Week 0 = Prime with D-CAT Week 4 = Prime with D-CAT Week 8 = Prime with D-CAT Week 24 = Boost with ChAd63-CAT Week 28 = Controlled Human Malaria Infection (CHMI)"
2433571|NCT03341754|Active Comparator|Infectivity Control (IC)|"Subjects will be exposed to the bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.~Week 28 = Controlled Human Malaria Infection (CHMI)"
2433572|NCT03341741|Experimental|Tobramycin powder / Colistin|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off); and Colistin solution 2 x daily 1 Mega continuously for 112 days
2433573|NCT03341741|Active Comparator|Colistin|Colistin solution 2 x daily 1 Mega continuously for at least 30 days
3188005|NCT00762346|Experimental|1|
3188006|NCT00762398||Adult patient undergoing a surgery|Adult patient undergoing a surgery in the supine position and require an arterial line for anesthesia/surgery purposes
2433576|NCT03341715|Experimental|Mavoglurant (AFQ056)|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
2433577|NCT03341715|Placebo Comparator|Placebo|The investigators will use a single dose of the AFQ056 (200 mg) versus placebo in random assignment single-blind fashion, administered 2 hours prior to the MRI and other measures, in two separate experimental study visits.
2433578|NCT03341689|Experimental|Placebo/Low Dose Psilocybin|Subjects in this arm receive placebo in the first session and low dose psilocybin in the second session.
3188007|NCT00762437|Experimental|1|
3188008|NCT00762489|Other|TAT vs. RT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Rectal Temperature (RT).
2433581|NCT03341689|Experimental|High Dose Psilocybin/Placebo|Subjects in this arm receive high dose psilocybin in the first session and placebo in the second session.
2433582|NCT03341676|Experimental|Dexamethasone|8ml IV 3.3mg/mL dexamethasone
2433583|NCT03341676|Placebo Comparator|Placebo|8ml IV 0.9% w/v saline
2433584|NCT03341650|Experimental|High Pasta|Habitual pasta consumption equal or higher than 5 times/week.
2433585|NCT03341650|Experimental|Low Pasta|Habitual pasta consumption equal or lower than 3 times/week.
3188009|NCT00762489|Other|TAT vs. AT|This arm is comparing the Temporal Artery Thermometer (TAT) temperature to the Axillary Temperature (AT).
3188010|NCT00762554|Active Comparator|1|Epidural Depodur after epidural lidocaine
2433588|NCT03341624|Experimental|cataract surgery cataract extraction and intraocular implanta|
2433589|NCT03341611||Adults 55 and younger|
2433590|NCT03341611||Adults 55 and older|
2433591|NCT03341598|Active Comparator|CAF+R|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M- St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures will be placed to stabilize the flap in a coronal position 2 mm above the cementoenamel junction (CEJ), followed by interrupted sutures to close the releasing incisions.
2433592|NCT03341598|Experimental|CAF+R+MC|First of all, a sterile rubber dam will be placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M - St. Paul, Minnesota, USA), following the manufacturer's instructions. CAF treatment will be performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision will be made to unite the releasing incisions and the flap will be raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Additionally, this group will receive the xenogenous collagen matrix graft (Geistlich) on the recessed area before the sutures. Then, the flap will be coronally positioned and sutured to completely cover the graft.
2433593|NCT03341585|Experimental|Expiration Lente Prolongée|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of 'Expiration Lente Prolongée (ELPr)' . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
2433594|NCT03341572|Experimental|high response group|patients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
2433595|NCT03341572|Placebo Comparator|low response group|the change of CVP is less than 2.5cmH2O
2433596|NCT03341559||With Existing Diabetic Ulcers|Current DFU
2433597|NCT03341559||Diabetic Ulcers in remission|DFU in remission
3188011|NCT00762554|Active Comparator|2|Epidural Depodur after spinal bupivacaine
3188012|NCT00762554|Active Comparator|3|Epidural fentanyl infusion after epidural lidocaine or spinal bupivacaine
3188013|NCT00762567|Experimental|1|phenylephrine
2433601|NCT03341520|Experimental|interventional arm|Obinutuzumab Injection [Gazyva] 1000mg flat i.v. on week 1, 2, 3, 4, 8, 12, 16; Low dose radiation Therapy (LDRT) involved site 2 x 2 Gy in week 9
3188014|NCT00762580||Prospective|Patients with full thickness rotator cuff tears being treated with physical therapy
2433603|NCT03341494|Experimental|Gefitinib 250mg qd thalidomide 200mg qn|
2433604|NCT03341494|Active Comparator|Gefitinib 250mg qd|
2433605|NCT03341481|Experimental|Femaltiker|7.7 g of Femaltiker twice a day for 14 days of the trial.
2433606|NCT03341481|Placebo Comparator|placebo|7.7 g placebo 14 days of the trial.
2433607|NCT03341468|Experimental|Urethral catheter immobilization|Subjects randomized to the intervention group will undergo radical prostatectomy with placement of the urethral catheter per the standard of care. The urethral catheter immobilization device will be applied in the operating room prior to the patient being transported to the recovery room. Subjects will be informed on safe use of the device and must demonstrate competency in removing and replacing the device prior to discharge. Subjects will also be given an elastic leg strap, which they may use concurrently with the device. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care, at which the device will no longer be needed.
2433608|NCT03341468|No Intervention|No urethral catheter immobilization|Subjects randomized to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial per standard of care.
2433609|NCT03341455|Other|Intervention preschools|"Capacity building to support families affected by IPV & substance misuse will be provided to the intervention preschools.~Specifically, capacity building, training and support will be provided to~selected mothers on the provision of safe, confidential and relevant community-based referral and support services for women affected by IPV.~selected fathers on the provision of safe, confidential and relevant community-based referral and support to men seeking support for substance misuse problems.~intervention preschool teachers on provision of IPV and substance misuse prevention educational messages and referral pathways to services for these issues."
2433646|NCT03341234|Active Comparator|Group Control|Ultrasound guided sham block with 2 ml saline subcutaneously
3188015|NCT00762593|Experimental|1|transvaginal electrical stimulation with a home use programmable device used 30 minutes every day during 8 weeks
3188016|NCT00762593|Placebo Comparator|2|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
3188017|NCT00762658|Experimental|1|AN2728 Ointment, 5%
3188018|NCT00762658|Experimental|2|AN2728 Ointment, 2%
3188019|NCT00762658|Experimental|3|AN2728 Ointment, 0.5%
3188020|NCT00762658|Placebo Comparator|4|AN2728 Ointment Vehicle
3188021|NCT00762658|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
2433610|NCT03341455|No Intervention|Control preschool|No intervention or training will not be provided to the control group in order to assess the impact of the intervention between the control and intervention arms of the study.
2433611|NCT03341442|Experimental|No hip precautions|No hip precautions practiced after THA surgery
2433612|NCT03341442|No Intervention|Hip precautions|Hip precautions practiced per standard of care after THA surgery
2433613|NCT03341429|Experimental|Treatment|"Daily subcutaneous injection of liraglutide 3.0 mg~Study dosing of liraglutide:~Week 1: 0.6 mg once daily Week 2: 1.2 mg once daily Week 3: 1.8 mg once daily Week 4: 2.4 mg once daily Week 5-24: 3.0 mg once daily~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
2433614|NCT03341429|Placebo Comparator|Control|"Daily subcutaneous injection of placebo; the same dosage regimen as treatment to be followed.~In addition to the daily injection of liraglutide/placebo, participants in both groups will be advised to cut down approximately 500 calories from their usual food intake and to achieve a minimum of 150 minutes per week of physical activity."
2433615|NCT03341416|Experimental|Device - deep brain stimulation ON|"Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~The stimulation will remained turned ON during 3 months - phase 1 - blinded and continuous during the open-label phase"
2433616|NCT03341416|Sham Comparator|Device - deep brain stimulation Sham|"Sham stimulation: device (deep brain stimulation of the dentate nucleus in cerebellum). Intervention type: device (deep brain stimulation of the dentate nucleus in cerebellum). The intervention is a device called deep brain stimulation bilaterally placed in the sub thalamic nucleus.~During the sham stimulation the intervention will remained turned OFF during 3 months"
2433617|NCT03341403|Active Comparator|Synbiotic group|"severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive Probiotical ® (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months."
2433618|NCT03341403|Placebo Comparator|Placebo group|severe asthmatic patients (ACQ> 1.5 and beclomethasone > 200 µg per day) will receive a placebo (3 pills a day) during 3 months.
2433619|NCT03341390|Active Comparator|Aspirin|325 mg tablet, once daily for 5 days (Day -5 to -1)
2433620|NCT03341390|Experimental|BMS-986177 plus aspirin|200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
2433621|NCT03341390|Placebo Comparator|Placebo plus aspirin|200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)
2433622|NCT03341377||Lung cancer surgical patients|Patient-reported symptom assessments in patients undergoing lung cancer surgery.
2433623|NCT03341364|Experimental|ACT group treatment|Participants receiving the ACT-based group therapy.
2433624|NCT03341364|Active Comparator|ACT individual|Participants receiving individual ACT-based therapy.
2433625|NCT03341351|Active Comparator|Instructional video|The modified beef tongue video group will be given an instructional video created using the modified beef tongue model to show anatomy and proper repair of the laceration.
2433626|NCT03341351|Active Comparator|Instructional workshop|The group randomized to the modified beef tongue instructional workshop will undergo an interactive workshop using the modified beef tongue model to show anatomy and proper repair of the laceration.
2433627|NCT03341325|Experimental|animal-assisted intervention|the intervention is a real animal is presented in different forms to the participants
2433628|NCT03341325|Active Comparator|control intervention|the control intervention is a stuffed toy animal is presented in different forms to the participants
3188022|NCT00762658|Active Comparator|6|Protopic® Ointment (tacrolimus 0.1 %)
3188023|NCT00762671|Placebo Comparator|2|Placebo
3188024|NCT00762671|Active Comparator|1|Ebselen
3188025|NCT00762684|Experimental|TAK-559 32 mg QD|
3188026|NCT00762684|Placebo Comparator|Placebo QD|
3188027|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 5 mg QD|
3188028|NCT00762736|Experimental|Pioglitazone 15 mg QD + Azilsartan 40 mg QD|
3188029|NCT00762736|Active Comparator|Pioglitazone 15 mg QD|
2433637|NCT03341286|Experimental|TK3|This is a oral supplement combination of tryptophan and thiamine called TK3 to be taken three times a day
2433638|NCT03341286|Placebo Comparator|Placebo|Placebo orally, to be taken three times a day
3188030|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 5 mg QD|
3188031|NCT00762736|Experimental|Pioglitazone 45 mg QD + Azilsartan 40 mg QD|
2433641|NCT03341260|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg tablet to be administered one hour before treatment.
2433642|NCT03341260|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
2433643|NCT03341247||Low-risk of obesity|Children whose biological mother and biological father have a body mass index between 18.5 - 25 kg/m2.
2433644|NCT03341247||High-risk of obesity|Children whose biological mother has a body mass index greater than or equal to 30 kg/m2 and whose biological father have a body mass index greater than or equal to 25 kg/m2.
2433645|NCT03341234|Active Comparator|Group SPB|Ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
3188032|NCT00762736|Active Comparator|Pioglitazone 45 mg QD|
3188033|NCT00762749|Experimental|diphenhydramine HCl|diphenhydramine HCl / Children's Benadryl Allergy Liquid
3188034|NCT00762775|Experimental|1|Calcium supplementation and placebo
3188035|NCT00762775|Experimental|2|Vitamin D supplementation and placebo
3188036|NCT00762775|Experimental|3|Calcium and Vitamin D supplementation
3188037|NCT00762775|Placebo Comparator|4|Placebos only
3188981|NCT00772837|Experimental|1.H.Pylori Eradication Group|The eradication group will receive triple therapy (omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BID and Amoxycillin 1g BID) for 1 week for the eradication of H. pylori
3188982|NCT00772837|Placebo Comparator|2.Control Placebo Group|The control group will receive omeprazole 20 mg BID for 1 week along with placebo antibiotics for 1 week
2433648|NCT03341195|Active Comparator|1. One way SMS messages.|Parents/caregiver will receive one way educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age.
2433649|NCT03341195|Active Comparator|2. Two Way SMS messages|Parents/caregiver will receive two way (interactive) educational/reminder/proactive SMS messages related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through text messages.
2433650|NCT03341195|Active Comparator|3. One way automated calls.|Parents/caregiver will receive one way educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age.
2433651|NCT03341195|Active Comparator|4.Two way interactive automated calls|Parents/caregiver will receive two way (interactive) educational/reminder/proactive automated phone call related to routine immunization once a week till 20 weeks of age-parents will have the option to reply and receive more information related to immunization through phone call.
2433652|NCT03341195|No Intervention|5. Control Arm|One time counseling at the baseline survey.
2433653|NCT03341182|Active Comparator|normal method group (group A)|A mirror is not used in tunnel view technique (conventional manner)
2433654|NCT03341182|Experimental|mirror use group (group B)|A mirror is used in tunnel view technique
2433655|NCT03341169|Experimental|Glutamine|Intravenous glutamine infusion perioperatively for 18 hours (8 hours before surgery and 10 hours after induction of anesthesia)
2433656|NCT03341169|Placebo Comparator|Placebo|
2433657|NCT03341156|Experimental|Kcentra (PCC)|Half of subjects enrolled will be randomized to the Kcentra (PCC) group.
2433658|NCT03341156|Active Comparator|Frozen Plasma Product, Human|Half of subjects enrolled will be randomized to the standard transfusion group and receive fresh frozen plasma intra-operatively.
3147562|NCT00127452|Experimental|ALA|Margarine spread that yields 2 grams of alpha-linolenic acid (ALA) per day for average margarine use of 20 grams per day
2433660|NCT03341130|Experimental|Treatment Group|The treatment group will will be treated a mandibular advancement oral appliance following standard practices. The treatment group will also receive a mandibular repositioning splint to wear in the mornings for a minimum of 1 hour following removal of their mandibular advancement oral appliance, in an effort to reduce the side effects resulting from use of the mandibular advancement oral appliance.
2433661|NCT03341130|Experimental|Positive Control Group|The positive control group will will be treated a mandibular advancement oral appliance following standard practices. The positive control group will not receive any additional oral appliances. Side effects resulting from use of the mandibular advancement oral appliance will be managed using standard practices, including jaw stretching exercises as needed for comfort.
2433662|NCT03341130|No Intervention|Negative Control Group|The negative control group is comprised of 15 healthy individuals recruited specifically from faculty members at the UBC Faculty of Dentistry. This group will undergo the same clinical data collection as the treatment group and the negative control group but will not receive any treatment.
2433663|NCT03341117|Active Comparator|Acetylsalicylic acid|The patients were randomly assigned to received Acetylsalicylic acid 300 mg once daily for 90 days
2433664|NCT03341117|Placebo Comparator|calcined magnesia|"The patients were randomly assigned to received placebo (calcinaned magnesia),~1 capsule 300 mg before each meal for a period of 90 days."
2433665|NCT03341091|Experimental|Tai-chi group|"16-week 10-step simplified Tai-chi programme.~Two 1-hour sessions of centre-based Tai-chi training and a minimum of three 30-minute Tai-chi sessions at home on a weekly basis."
2433666|NCT03341091|No Intervention|Control group|"Group recreational activities and continue their usual lifestyles and levels of physical activity as usual for 16 weeks.~Two 1-hour sessions of group recreational activities on a weekly basis."
2433667|NCT03341078|Placebo Comparator|Placebo|Placebo Group will be dosed with a placebo oral tablet twice daily for 6 weeks. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
2433668|NCT03341078|Active Comparator|Ibudilast|Ibudilast Group will be dosed with ibudilast twice daily for 6 weeks. The first 2 weeks will be 20 mg twice daily followed by 4 weeks of 50 mg twice daily. Participants will have pre/post evaluations for neuroinflammation and associated behaviors
2433669|NCT03341078|No Intervention|Controls|Healthy controls will only undergo baseline evaluations and will not be enrolled in the drug portion of the study.
2433670|NCT03341065|Experimental|exoskeleton type robot|exoskeleton type robot assisted gait training (Lokomat orthosis)
2433671|NCT03341065|Experimental|end-effector type robot|end-effector type robot assisted gait training (G-EO system)
2433672|NCT03341052|Active Comparator|Obese Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
2433673|NCT03341052|Active Comparator|Normal Weight Participants|Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
2433674|NCT03341026|Other|Induction day 1, 4, 7, 14|Patient will come to the hospital on day 1, 4, 7 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
2433675|NCT03341026|Other|Induction day 1, 7, 10, 14|Patient will come to the hospital on day 1, 7, 10 and 14. A hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
2433676|NCT03341013|Experimental|Sequence 1|formulation 2 on Day 1 and formulation 3 on Day 10
2433677|NCT03341013|Experimental|Sequence 2|formulation 3 on Day 1 and formulation 2 on Day 10
2433678|NCT03341000|Experimental|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
2433679|NCT03340987|Experimental|Vista technique with SCTG|vestibular incision subperiosteal tunnel access combined with subepithelial connective tissue graft
2433680|NCT03340987|Active Comparator|coronally advanced flap with SCTG|coronally advanced flap combined with subepithelial connective tissue graft
3147563|NCT00127452|Experimental|EPA + DHA plus ALA|Margarine spread that yields 400 mg of EPA + DHA per day plus 2 grams of ALA per day, for average margarine use of 20 grams per day
2433687|NCT03340948|Experimental|MBSR participation|Participation in the 8 week Mindfulness Based Stress Reduction (MBSR) course.
2433688|NCT03340935|Experimental|Fasting mimicking diet|Fasting mimicking diet (FMD)
2433689|NCT03340922|Experimental|Automatic annotation of LAT (WF-method)|The annotation of LAT in each acquired point will be automatically performed using the LAT annotation tool integrated into CARTO navigation system, called Wavefront (WF). Automatic annotation of LAT performed by the CARTO system uses the maximum negative slope of the distal U-EGM to set the timing of the mapping annotation, displayed on the corresponding B-EGM. Additionally, the automatic annotation of LAT will be aided by an ECG recognition pattern algorithm (included in the last version of CARTO), which is intended to avoid wrong annotation of ventricular complexes other than the clinical PVC.
2433690|NCT03340922|Active Comparator|Manual annotation of LAT (M-method)|A detailed electrocardiogram (ECG)-gated activation map of the chamber of interest will be acquired using the CARTO navigation system. An experienced electrophysiologist will perform the annotation of LAT in each acquired point. The LAT will be measured from the onset of B-EGM (earliest positive or negative deflection) of the distal dipole of the mapping catheter to the defined reference. The use of the U-EGM as a guidance to identify the real onset of B-EGM will be decided under electrophysiologist criteria.
2433691|NCT03340909|Experimental|Prednisolone|Prednisolone tablets 5 mg
2433692|NCT03340909|Placebo Comparator|Placebo|Placebo tablets with identical appearance to the experimental drug.
2433693|NCT03340896|Active Comparator|TPF followed by radiotherapy|"Induction chemotherapy by Docetaxel 75 mg/m² day 1,cisplatin 75 mg/m² day 1 and 5 fluorouracil 750mg/m²(day 1 to day 5) 3 cycles day1, day 22, day 43 followed (for responders or stable disease patients) by radiotherapy~Radiotherapy ;70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
2433694|NCT03340896|Experimental|Cisplatin and radiotherapy|"Drug and radiation • Cisplatin: 100 mg / m² administered IV at J1, J22 and J43 of radiotherapy~. Radiotherapy 70 gray fractionization: 2Gy/day, 5days/week, for 7 weeks."
2433696|NCT03340870|Experimental|Sonazoid™ 0.12 microliter (µl)|Participants will receive single intravenous (I.V) bolus injection of Sonazoid™ 0.12 µl microbubbles (MB)/kilogram (kg) body weight.
2433697|NCT03340870|Experimental|Sonazoid™ 0.60 µl|Participants will receive single I.V bolus injection of Sonazoid™ 0.60 µl MB/kg body weight.
2433698|NCT03340857|Experimental|Intelligent electric bicycle (VELIS) sessions|Intelligent electric bicycle (VELIS) sessions with an instructor, twice a week for 6 weeks
3147564|NCT00127452|Placebo Comparator|Placebo|Margarine spread that contains no EPA, DHA or ALA (exchanged for oleic acid)
3147565|NCT00127491|Experimental|EPVent|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The intervention group will undergo transpulmonary pressure-directed controlled mechanical ventilation using parameters directed by the initial balloon measurements. Driving pressures will be adjusted to maintain a transpulmonary plateau pressure of less then 30. The PEEP setting will be set to achieve a transpulmonary end expiratory pressure of 0. Repeat PES measurements will be done at 24, 48 and 72 hours following the initial measurements. Additional measurements will be taken as clinically indicated. Ventilator management by PES measurements will continue for a period of 72 hours.
2433701|NCT03340831||CGM/BGM Group|single-group, whereby participant is their own control. Use of a Blood Glucose Meter (BGM) for 6 months is compared to use of the G5 and G6 CGM System for 6 months, with collection of major diabetes related events (mild/severe hypoglycemia and DKA).
2433702|NCT03340818|Experimental|Bone Marrow Concentrate|Patients in this group will receive injection of autologous bone marrow concentrate into the suspected painful intervertebral discs.
2433703|NCT03340818|Sham Comparator|Placebo Group|Patients in this group will receive an injection of normal saline dorsal to the transverse process. The bone marrow aspiration will be simulated for these patients.
2433706|NCT03340792|Experimental|Exoskeleton robot ambulation training|Ambulation training utilizing an exoskeleton robot
2433707|NCT03340779|Experimental|Norepinephrine alone|Administration of norepinephrine with increasing dose
2433708|NCT03340779|Active Comparator|Norepinephrine plus Dobutamine|Administration of norepinephrine and dobutamine
2433709|NCT03340766|Experimental|COHORT Ia|Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).
2433710|NCT03340766|Experimental|COHORT IIa|Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).
2433711|NCT03340766|Experimental|COHORT IIIa|Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).
2433712|NCT03340766|Experimental|Expansion Cohort|This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia, IIa, and IIIa tested in Part 1 of the study.
2433713|NCT03340753|Active Comparator|KBP-5074 Capsule|KBP-5074 (0.5 mg or 1.0 mg) in capsule formulation in a 2-period crossover design with a 2-week washout/follow-up period
2433714|NCT03340753|Experimental|KBP-5074 Tablet|KBP-5074 (0.5 mg or 1.0 mg) in tablet formulation in a 2-period crossover design with a 2-week washout/follow-up period
2433715|NCT03340740|Experimental|Cetirizine|Cetirizine 10mg (10ml) (patients age 12-17) or cetirizine 5mg (5ml) (patients age 6-11) x 1 dose at beginning of course in emergency department.
2433716|NCT03340740|Placebo Comparator|Placebo|Placebo 10ml (patients age 12-17) or 5ml (patients age 6-11) x 1 dose at beginning of course in the emergency department.
3147566|NCT00127491|Active Comparator|Control|All patients will have an esophageal balloon placed for the purpose of obtaining transpulmonary pressure measurements. The control group will be managed using the low tidal volume strategy laid out by the NIHBLI ARDSnet study. These recommendations include a set tidal volume of 6 ml/ kg. Respiratory rate and PEEP are set to maintain adequate ventilation and oxygenation. These settings will be continued for a period of 72 hours.
3147567|NCT00127634|Experimental|1|
3147568|NCT00127634|Active Comparator|2|
3147569|NCT00127647|Experimental|1|montelukast sodium 5 mg, QD 2-weeks
3147570|NCT00127647|Experimental|2|montelukast sodium 10 mg QD 2-weeks
3147571|NCT00127647|Active Comparator|3|Pranlukast 225 mg BID 2-weeks
3147572|NCT00127673|Active Comparator|1|Participants will receive no choice cognitive behavioral therapy
3147573|NCT00127673|Active Comparator|2|Participants will receive choice cognitive behavioral therapy
3147574|NCT00127673|Active Comparator|3|Participants will receive no choice sertraline
2433717|NCT03340727|Experimental|Caffeine Citrate|Caffeine citrate at 10 mg/kg/dose (5 mg/kg caffeine base) daily, in hospital. Infants will continue at home on the same dose of caffeine citrate for the first 28 days after hospital discharge.
2433718|NCT03340727|Placebo Comparator|Placebo|Placebo contains all of the excipients except for the active ingredient, caffeine citrate, (a volume equivalent to 10 mg/kg of caffeine citrate) and given daily. Infants will be continued at home on the same dose of placebo for the first 28 days after hospital discharge.
2433719|NCT03340714|Experimental|Device Feasibility (ADAMM)|Patients wear the Automated Device for Asthma Monitoring and Management (ADAMM) from the time of computed tomography (CT) simulation for radiation therapy (RT) planning throughout the entire RT course and for 4 weeks post-RT
2433720|NCT03340701|Other|Vaginal Progesterone|micronized progesterone vaginal suppository 200mg
2433721|NCT03340688|Active Comparator|Cervical cerclage + vaginal progesterone|Cervical cerclage in twin pregnancy with transvaginal cervical length ≤15mm and Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
2433722|NCT03340688|No Intervention|Vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
2433723|NCT03340675|Experimental|Oral Ifetroban - Low Dose|Weight based, once daily oral ifetroban
2433724|NCT03340675|Experimental|Oral Ifetroban - High Dose|Weight based, once daily oral ifetroban
2433725|NCT03340675|Placebo Comparator|Placebos|Matching Placebo
2433726|NCT03340662|Experimental|CC-122 Alone under fasted conditions|Single oral dose of 3 mg CC-122 administered alone under fasted conditions
2433727|NCT03340662|Experimental|CC-122 plus Itraconazole|Single oral dose of 3 mg CC-122 alone and with multiple doses of itraconazole.
2433728|NCT03340662|Experimental|CC-122 plus Fluvoxamine|Single oral dose of 3 mg CC-122 alone and with multiple doses of fluvoxamine.
2433729|NCT03340662|Experimental|CC-122 plus Rifampin|Single oral dose of 3 mg CC-122 alone and with multiple doses of rifampin
2433730|NCT03340623||Mammary reconstruction by DIEP with venous coupler|
2433731|NCT03340623||Mammary reconstruction by DIEP without venous coupler|
2433733|NCT03340597|Experimental|A1; F901318 (10 days)|F901318 : 10 days dosing orally
2433734|NCT03340597|Experimental|A2; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2433735|NCT03340597|Experimental|A3; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2433736|NCT03340597|Experimental|A4; F901318|F901318 : 10 days dosing orally, alternative dosing regimen
2433737|NCT03340584|Experimental|The intervention group|The intervention group will be received the Nine Castle Net Format taping and the traditional rehabilitation throughout all hospitalization period.We will exchange the new taping for Every two days.
2433738|NCT03340584|Other|The control group|The control group will be received the traditional rehabilitation during the hospitalization period.The traditional rehabilitation included occupational therapy and physical therapy.
2433739|NCT03340571||Alzheimer's Patients|
2433740|NCT03340571||Healthy Volunteers|
2433741|NCT03340558|Experimental|Monotherapy Cohort|The first 10 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 of each 28-day cycle. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2. No study treatment is administered while subjects are healing after surgery.
2433742|NCT03340558|Experimental|Combination Cohort|The next 15 subjects will receive Atezolizumab 840 mg IV on Day 1 and Day 15 and Cobimetinib 60 mg PO on Days 1-21 of each 28-day cycle. Cobimetinib must be held for the 7 days prior to metastatectomy. Subjects will be treated for 2 cycles before undergoing metastatectomy within 42 days of completion of Cycle 2.
2433743|NCT03340545|Other|Healthy Individuals|Healthy individuals will be imaged for comparison purposes
2433744|NCT03340545|Other|Disc Herniation|Subjects diagnosed with Intervertebral Disc Herniation will be imaged to evaluate sensitivity of the proposed method.
2433745|NCT03340532|Placebo Comparator|Sleep hygiene video|Participants will watch a sleep hygiene video
2433746|NCT03340532|Experimental|Information video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
2433747|NCT03340532|Experimental|Information + Appearance video|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
2433748|NCT03340519||Healthy Controls|Healthy Controls will undergo MR imaging to optimize MR techniques for bowel assessment and to acquire normative data
2433749|NCT03340519||Newly Diagnosed Crohns Patients|MR imaging will be performed in newly diagnosed CD patients prior to initiation of infliximab therapy in order to obtain baseline measures in the setting of active intestinal inflammation
3147575|NCT00127673|Active Comparator|4|Participants will receive choice sertraline
3147576|NCT00127829|Experimental|1|Gefitinib (IRESSA®)
3147577|NCT00127868|Active Comparator|1|oral griseofulvin and selenium sulfide shampoo 1%
2433753|NCT03340493|Active Comparator|Assigned Interventions|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
2433754|NCT03340493|Experimental|Tenecteplase|Patients will receive intravenous tenecteplase (0.4mg/kg, maximum 40mg, administered as a bolus over ~10 seconds).
2433755|NCT03340480|Experimental|NVP-1402-1|NVP-1402 was administered once a day for 24 hours
2433756|NCT03340480|Experimental|NVP-1402-2|NVP-1402 was administered once a day for 24 hours
2433757|NCT03340467|Experimental|CGM patch|Patient receives four models of CGM patches. Adhesion sites are randomly allocated (1 on each upper arm, 2 on the abdomen).
2433758|NCT03340454|Active Comparator|Health systems-level intervention|using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies;
2433759|NCT03340454|Active Comparator|CHW-led patient navigation program|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability
3147578|NCT00127868|Active Comparator|2|oral griseofulvin and ciclopirox shampoo
3147579|NCT00127868|Active Comparator|3|oral griseofulvin and ketoconazole shampoo 2%
3147580|NCT00127868|Placebo Comparator|4|oral griseofulvin and baby shampoo
3188038|NCT00762814|Experimental|Parkinson subjects with freezing|"Each subject will have been diagnosed with Parkinson disease and will serve as his/her own control. Inclusion criteria: history of consistent freezing with ambulation in a straight line and/or when turning, normal central and peripheral neurological function, at least grade 4 strength and normal joint ranges of motion in both legs, normal somatosensory function in the feet (joint position sense), except for their neurological diagnosis and use of levodopa, each must have had clear benefit from levodopa for at least some of his/her PD symptoms, and all subjects with PD must be able to walk independently for 10 feet.~Exclusion criteria include: serious medical problem that would impair the ability to undergo testing, use of neuroleptic or other dopamine-blocking drug, use of drugs that might affect balance, history or evidence of other neurological deficit that could interfere, such as previous stroke or muscle disease, or participants who are unable to provide informed consent."
3188039|NCT00762840|Experimental|Apexum|the tooth is treated by a standard root canal treatment, supplemented by Apexum Ablator protocol, in which the periapical lesion tissue is minced and removed through the root canal, in a minimally invasive fashion.
3188040|NCT00762840|Active Comparator|Control|the tooth is subject to conventional endodontic procedure alone, (standard root canal treatment)
2433764|NCT03340402|Experimental|Accelerated Partial Breast Irradiation|"Accelerated partial breast irradiation using proton beam scanning will consist of;~5 daily treatments using custom prone patient immobilization, contrast-enhanced CT planning, and daily image guidance~Radiation therapy may be delivered with photons if proton treatments cannot be delivered~Dose will be prescribed such that the gross tumor (GTV) receives the prescription dose per institutional policy and standard of care~Daily target localization will also be confirmed using AlignRTTM"
2433765|NCT03340389|Experimental|cataract surgery|cataract extraction and intraocular implantation
2433766|NCT03340376|Experimental|atezolizumab monotherapy|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle until progressive disease
2433767|NCT03340376|Experimental|atezolizumab combined with doxorubicin|A fixed dose of 1200 mg atezolizumab will be administered intravenously on Day 1 of each 21-day cycle. Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
2433768|NCT03340376|Active Comparator|doxorubicin monotherapy|Doxorubicin will be administered on Day 1 of each 21-day cycle at a dose of 75mg/m² for a total of 6 cycles or until progressive disease
2433769|NCT03340363|Experimental|environmental change|Shoppers were exposed to modifications to the supermarket environment to encourage selection of low-cost, kid-friendly meals
2433770|NCT03340363|Experimental|environmental change and messaging|Shoppers were exposed to modifications to the supermarket environment and weekly messages via text or email to encourage selection of low-cost, kid-friendly meals
3188044|NCT00762879||No treatment|
3188045|NCT00762905|Active Comparator|1|LiquiBand Laparoscopic
2433775|NCT03340324|Experimental|One arm open label V-Endo recepients|This is single arm open label trial wherein active drug is V-Endo
2433776|NCT03340311|Other|Pre-Post|"(Phase one): Each participant will receive usual care (four weeks). Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~(Phase two): Each participant will receive a BG5 wireless glucose meter with supplies enough for four weeks. Each participant will download the iGluco application to their smartphone. Education will be given on the monitor and iGluco application use. Four weeks of glucose logs will be collected at patient's provider visits and completeness recorded.~At the conclusion of phase 2, the participants will be asked to complete a satisfaction survey about the care received and their preference of monitors."
2433777|NCT03340298|Experimental|grain|25 gram fiber from whole grain products and 10 gram fiber from fruits and vegetables
2433778|NCT03340298|Experimental|fruits and vegetables|25 gram fiber from fruits and vegetables as main supplier and the remaining 10 grams from whole grain sources
2433779|NCT03340298|Experimental|grain-fruits and vegetables|17.5 gram fiber from whole grain and 17.5 gram fiber from fruits and vegetables
2433780|NCT03340285|Experimental|AkP06|first two weeks: Placebo + prescribed Diet then 4 weeks AkP06 two tablet/day before meals + Diet
2433781|NCT03340285|Placebo Comparator|Placebo|first two weeks: Placebo + prescribed Diet then 4 weeks Placebo two tablet/day before meals + Diet
2433782|NCT03340259||Newborn infants with enterostomy|Infants with enterostomy after surgery due to congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation
2433783|NCT03340246|Active Comparator|Immediate phlebectomy|Mechanochemical ablation of main trunk and immediate phlebectomy of varicosities
2433784|NCT03340246|Experimental|Delayed treatment|Mechanochemical ablation of main trunk. Evaluation of varicosities at 3 months with sclerotherapy if required
2433785|NCT03340233|Experimental|Group 1|Group 1 includes 25 healthy subjects recruited in Year 1 to undergo cardiac MRI without contrast.
2433786|NCT03340233|Experimental|Group 2|Group 2 includes 25 healthy subjects recruited in Year 2 to undergo cardiac MRI without contrast.
2433787|NCT03340233|Experimental|Group 3|Group 3 includes 33 patients with Heart Failure with Preserved Ejection Fraction (HFpEF) who will undergo cardiac MRI at baseline and at six months to assess diagnostic sensitivity of MRI measurement.
2433788|NCT03340220|Experimental|XPF-008|"Single ascending dose: Single oral dose for each cohort~Multiple ascending dose: 7 days of single oral dose daily for each cohort"
2433789|NCT03340220|Placebo Comparator|Placebo - Microcrystalline cellulose|"Single Ascending Dose: Single oral dose for each cohort~Multiple Ascending Dose: 7 days of single oral dose daily for each cohort"
2433790|NCT03340207|Experimental|Pneumaglide|After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
2433791|NCT03340207|No Intervention|non-pneumaglide|The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.
3188046|NCT00762905|Active Comparator|2|Dermabond
3188047|NCT00762944||Biomet TMJ Replacement System|All patients required total reconstruction of the temporomandibular joint (unilateral or billateral)
2433793|NCT03340181|Experimental|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb.
2433794|NCT03340181|Sham Comparator|control|patient in control group using a blood pressure cuff on an upper limb without inflating
2433795|NCT03340168|Experimental|Bisphenol-S kinetics - oral exposure|Six female volunteers will be exposed orally acute at the reference dose level(0.1 mg / kg bw). For the administration, the product will be dissolved in ethanol (100 mg / ml equivalent to 10 mg / 100 μl) and the solution will be deposited on a cookie (deposit of about 70 μl of solution on a cookie for an individual of 70 kg) and the ethanol is allowed to evaporate before giving each volunteer, with the subsequent consumption of 100 ml of water.
2433796|NCT03340168|Experimental|Bisphenol-S kinetics - dermal exposure|volunteers will be exposed dermally acute at a dose of 1 mg / kg bw. The solution will be applied to an area of 40 cm2 of the forearm and delimited by the indelible marker. The BPS will be added in suspension in an aqueous solution containing 1% of carboxymethylcellulose and administered in the form of drops (70 .mu.l for an individual of 70 kg). The treated area will be left uncoated and unwashed for a period of 4 hours. After 4 hours, the application area will be washed with water and soap. This type of application is therefore similar to an exposure of the general population via the skin (manipulation of cash receipts).
2433797|NCT03340142|Experimental|Single Arm|All patients will undergo standard of care ablation procedures. VIVO™ results will be compared to that of standard of care results, but will not be used in diagnosis or treatment.
2433798|NCT03340129|Active Comparator|Nivolumab + ipilimumab|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
2433799|NCT03340129|Active Comparator|Nivolumab + ipilimumab,concurrent SRS|"Nivolumab 1mg/kg and ipilimumab 3mg/kg Q3W x 4 doses, then nivolumab 480 mg every 4 weeks.~Stereotactic radiotherapy 16 to 22 Gy in 1 fraction or 24 to 30 Gy, hypofractionated for larger lesions. Stereotactic radiotherapy to commence within 7 days of of the baseline / planning MRI brain. Hypofractionated stereotactic radiotherapy should be completed within 14 day of the first fraction.~Any form of salvage therapy (surgery or radiotherapy) may be administered to either cohort for the treatment of intracranial disease progression."
2433800|NCT03340116||Pre-operative cohort|This cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 prior to any surgical intervention
2433801|NCT03340116||Post-operative cohort|This cohort will consist of the same study participants in the pre-operative cohort. The only difference is that this cohort will have their total blood volume, RBC volume, and plasma volumes measured using the Daxor BVA-100 AFTER burn surgery.
2433802|NCT03340103|Experimental|Experimental group A|Group A (18 newborns) will be treated with LUTEIN ofta 0,5 drops, (1 ml per Kg equal to 0,5 mg of lutein and 0,05 of zeaxantin) additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
2433803|NCT03340103|Placebo Comparator|Control group B|Group B (18 newborns) treated with Placebo solution additionaly to the standard hospital treatment foreseen. The first dose will be given within 36 hours of life, the least to 30th day of life.
2433804|NCT03340090|Experimental|Intervention|First group of patients will undergo standard CABG procedure in CPB. In addition, two pieces of Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of left internal mammary artery (LIMA) harvesting and second piece of Hemopatch will be placed beneath the sternum.
2433805|NCT03340090|No Intervention|Control|Second group of patients will undergo standard CABG procedure in CPB only.
2433806|NCT03340077|Experimental|MOR Toolkit|Medicines Optimisation Review consultation + My clinical companion (patient questionnaire about their medications)
2433807|NCT03340077|Active Comparator|Standard of Care|Current standard of care for patients with HIV receiving antiretroviral therapy, which consists of a phamacists review of ART prescriptions.
2433808|NCT03340064|Experimental|Levetiracetam|"Subjects aged 1 month to <6 months will be started on levetiracetam (LEV) 14 mg/kg/day at Visit 3. The dose may be increased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months at 2-week intervals to a maximum dose of 42 mg/kg/day. Subjects aged 6 months to <4 years will be started on LEV 20 mg/kg/day at Visit 3. The dose may be increased by LEV 20 mg/kg/day at 2-week intervals to a maximum dose of 60 mg/kg/day.~At Visit 6, subjects may enter the Second Period or enter the Down-Titration Period followed by a Safety Follow-Up Period. Subjects who do not enter the Second Period will be down-titrated. The dose will be decreased by LEV 14 mg/kg/day for subjects aged 1 month to <6 months or by LEV 20 mg/kg/day for subjects aged 6 months to <4 years at 2-week intervals to 0 mg/kg/day."
3147581|NCT00127881|Experimental|Zanolimumab|
3147582|NCT00127920|Experimental|Single Arm|Paclitaxel, Carboplatin and Avastin on day1 every 21 days
2433811|NCT03340038|Active Comparator|Specialty Ward|Patients who have been randomized into receiving post-operative care at the Non-ICU Specialty ward (intervention) after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
2433812|NCT03340038|No Intervention|Intensive Care Unit (ICU)|Patients who have been randomized into receiving post-operative care at the intensive care unit after receiving flap reconstructive surgery on their mucosal or cutaneous defect.
3147583|NCT00127946|Active Comparator|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
3147584|NCT00127946|No Intervention|placebo|This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
3147585|NCT00127985|Experimental|Active|IV 6-methyl-prednisolone
3147586|NCT00127985|Placebo Comparator|Comparator|IV Placebo
3147587|NCT00128024|Active Comparator|Statins|
3147588|NCT00128024|No Intervention|No statins|
3147589|NCT00128050|Active Comparator|1|Patients treated with recombinant FVIIa
3147590|NCT00128050|Placebo Comparator|2|Patients with spontaneous supratentorial ICH included in this arm will be treated with placebo
3147591|NCT00128076|Active Comparator|1|All-arthroscopic repair
3147592|NCT00128076|Active Comparator|2|Mini-open repair
3147593|NCT00128128|Active Comparator|Arm 1|Cranberry Juice Cocktail- 4 ounces
3147594|NCT00128128|Active Comparator|Arm 2|Cranberry Juice Cocktail-8 ounces
3147595|NCT00128128|Placebo Comparator|Arm 3|Placebo- 4 ounces
2433815|NCT03340012|Experimental|GTR + radiation-sterilize allogenic bone graft (TEST)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of radiation-sterilized allogenic bone graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
2433816|NCT03340012|Active Comparator|GTR + xenogenic graft (CONTROL)|The surgical procedure will be performed in line with minimally invasive surgical technique by Cortellini and Tonetti (2007). The intrabony defects will be debrided and the roots will be planned. The required quantity of xenogenic graft will be delivered into intrabony defects. Subsequently, a trimmed collagen membrane will be placed over graft. The flaps will be sutured with non-absorbable modified internal mattress sutures.
3188048|NCT00762957|Experimental|TAK-559 16 mg QD + Metformin QD|
2433821|NCT03339986|Experimental|Reduction|Participants will be instructed to reduce all high energy dense snacks that they serve to thier children by 50%
2433822|NCT03339986|Experimental|Replacement|Participants will be instructed to replace all high energy dense snacks with fresh fruit and vegetables
2433823|NCT03339973|Experimental|allo-APZ2-PAOD|20-30 intramuscular injections, single dose of allo-APZ2-PAOD, 150 - 225 x 10^6 cells per patient (depending on length of lower leg)
2433824|NCT03339973|Placebo Comparator|Placebo|20-30 intramuscular injections, vehicle solution (depending on length of lower leg)
2433825|NCT03339960|Active Comparator|Robotic camera controlled|
2433826|NCT03339960|Active Comparator|Human camera controlled|
2433827|NCT03339947||Travel medicine|All adult travellers who attended the consultation for travel medicine and international vaccination in Reims University Hospital.
2433828|NCT03339921|Experimental|Botulinum toxin injections|Botulinum toxin injections for chronic compartment syndrome
2433829|NCT03339921|Active Comparator|surgical fasciotomy|surgical fasciotomy for chronic compartment syndrome
2433830|NCT03339908|Experimental|patients with Multiple Sclerosis|Patients will benefit from unilateral thalamotomy by Gamma Knife radiosurgery
2433831|NCT03339895|Experimental|pvı-guided|pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery
2433832|NCT03339895|Experimental|traditional-guided|4-8 ml/kg/h infusion during surgery
2433833|NCT03339882|Experimental|Remifemin intervention|Using Remifemin during LHRH-a treatment in breast cancer
2433834|NCT03339882|No Intervention|Control|No intervention during LHRH-a treatment in breast cancer
2433835|NCT03339869|Experimental|blood sample group|Adult patient hospitalized in intensive care unit and treated for infection.
2433836|NCT03339856|Experimental|Treatment arm|Patients received selective retina therapy
3147596|NCT00128128|Placebo Comparator|Arm 4|Placebo- 8 ounces
2433838|NCT03339817|Other|Patients with severe MS|polysomnography and functional pulmonary testings.
2433839|NCT03339804|Experimental|Chemotherapy|Infusion of doxorubicin and cyclophosphamide
2433840|NCT03339791|Active Comparator|Sleeve|Morbid obese patients, 65 years old or more, submitted to Sleeve Gastrectomy
2433841|NCT03339791|Active Comparator|Bypass|Morbid obese patients, 65 years old or more, submitted to Gastric Bypass
2433844|NCT03339752|Active Comparator|Treatment A|Rosuvastatin Day 1
2433845|NCT03339752|Experimental|Treatment B1|ACT-541468 Day 5 to Day 7
2433846|NCT03339752|Other|Treatment B2|Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12
2433847|NCT03339739|Experimental|Isometric exercise Group|Group of participants which perform Isometric mandibular exercises, once a day, for 21 days
2433848|NCT03339739|Active Comparator|Isotonic exercise Group|Group of participants which perform Isotonic mandibular exercises, once a day, for 21 days
2433849|NCT03339739|Placebo Comparator|Counseling Group|Group of participants which receive education brochure and no further interventions.
3147597|NCT00128141|No Intervention|1|
3147598|NCT00128141|Experimental|2|tactile stimulus
3147599|NCT00128245|Experimental|Pimecrolimus 0.3%|ASM981 0.3%
3147600|NCT00128245|Experimental|Pimecrolimus 1%|ASM981 1%
3147601|NCT00128245|Placebo Comparator|Vehicle with carbopol|
3147602|NCT00128245|Placebo Comparator|Vehicle without carbopol|
3147603|NCT00128258|Experimental|open|open treatment
3147604|NCT00128284||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3147605|NCT00128284||Gastroparesis|Subjects with documented gastroparesis
3147606|NCT00128297|Active Comparator|Arm A: continuous administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 18 months
3147607|NCT00128297|Experimental|Arm B: alternate administration|Pamidronate 90 mg/m2 iv every 3-4 weeks, during 6 months, followed by a 6 month rest, and a new 6 months treatment period.
3147608|NCT00128310|Active Comparator|Arm A: Vinorelbine|Arm A: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8.
3147609|NCT00128310|Experimental|Arm B: Vinorelbine and Gemcitabine|Arm B: Vinorelbine 30 mg/m2 will be administered as an intravenous infusion over 6-10 minutes on Study Days 1 and 8. Gemcitabine will be administered following vinorelbine at a dose of 1200 mg/m2 as an intravenous infusion over 30 minutes.
3147610|NCT00128336|Active Comparator|Nurse support|
3147611|NCT00128336|Experimental|Intensive support|
3147612|NCT00128336|Active Comparator|High carbohydrate diet|
3147613|NCT00128336|Experimental|High mono-unsaturated fat diet|
2433855|NCT03339700|Experimental|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY 2) conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: Gemcitabine. Then patients will undergo an Allogeneic Hematopoietic Stem Cell Transplantation.
2433856|NCT03339687|Experimental|Induction of Open Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2433857|NCT03339687|Experimental|Induction of a Closed Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2433858|NCT03339674|Experimental|Intervention|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress: Psychological group intervention with 3 sessions of 60 min (Odenwald & Semrau, 2012). Contains psychoeducation on alcohol drinking related to stress and PTSD.
2433859|NCT03339674|Active Comparator|Control|Cognitive Training: Psychological group intervention with 3 sessions of 60 min. The content is paper-and-pencil based cognitive training of memory and attention functions.
2433860|NCT03339661|Experimental|Group 1_ No proph treatment|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated will depend on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if γδ T cell expansion occurs, no secondary prophylaxis treatment will be introduce, and curative treatment stops.
2433861|NCT03339661|Experimental|Group 2A_Proph treatment and γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
2433862|NCT03339661|Experimental|Group 2B_Proph treatment and no γδ T cells expansion|Patients will receive a curative treatment (ganciclovir or valganciclovir, drug administrated depends on medical opinion) during 2 to 8 weeks. When CMV QNAT becomes regative, if no γδ T cell expansion will occur, a secondary prophylaxis will be initiated during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
2433863|NCT03339648|Experimental|Professional Development Enhancement|"During the measurement period, this group will receive the intervention, described below:~Content using three of UF Lastinger Center's innovations for cost-effective teaching and learning - e-Content Clinics, Coaching, and Communities of Practice. Elements of the professional development model are as follows:~E-Content Clinics- Content Clinics are offered online using digital video technology.~Coaching- Coaching develops strong cadres of leaders that have profound expertise and substantial success in advancing teaching and learning outcomes. This approach uses existing personnel to reinforce and deepen learning through online professional development by embedding it in day-to-day activities.~Online Community of Practice- This scalable online platform allows users to create virtual communities of practice designed to strengthen the learning and collaboration network."
2433864|NCT03339648|Active Comparator|Control- Delayed Intervention|This arm will continue business as usual during the measurement period. They will receive the exact same intervention described above once data collection is complete.
2433865|NCT03339635|Experimental|Testosterone gel|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
2433866|NCT03339635|Placebo Comparator|Placebo gel|Patients will be randomized to treatment with placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
2433867|NCT03339622|Experimental|smoked cannabis (PPP001)|280 mg dried cannabis pellet -(9% THC / 2% CBD per pellet)
2433868|NCT03339622|Placebo Comparator|THC free placebo|280 mg dried extracted cannabis pellet (0% THC / 0.6% CBD per pellet)
2433869|NCT03339609||Immediate uroflow/EMG testing|Participants performed two direct repetitions of uroflowmetry in combination with EMG.
2433870|NCT03339609||uroflow measurement beforehand|Participants performed a preceding measurement of isolated uroflowmetry, followed by two randomized measurements of either isolated uroflowmetry or uroflowmetry with EMG.
2433871|NCT03339596|Experimental|Erythropoietin|4 intravenous infusions of recombinant human erythropoietin (EPO)
2433872|NCT03339596|Placebo Comparator|Saline|4 intravenous infusions of saline (1 ml NaCl)
3188049|NCT00762957|Experimental|TAK-559 32 mg QD + Metformin QD|
3188050|NCT00762957|Active Comparator|Metformin QD|
2433875|NCT03339557|Active Comparator|PFC Total Knee Replacement|PFC, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
2433876|NCT03339557|Active Comparator|NexGen Total Knee Replacement|NexGen, Conventional design Perioperative treatment will be carried out according to routine protocol of the hospital.
2433877|NCT03339557|Active Comparator|Persona Total Knee Replacement|Persona, Novel design Perioperative treatment will be carried out according to routine protocol of the hospital.
2433878|NCT03339544|Experimental|Celebrex premedication|Celebrex is a NSAID with selective COX-2 inhibition properties, is given as an intervention to assess the pain
2433879|NCT03339544|Placebo Comparator|Placebo tablets|placebo tablets to compare the efficacy of Celebrex on the intra-operative and post-operative pain accompanying endodontic treatment of teeth with irreversible pulpits
2433880|NCT03339531|Experimental|2D radiotherapy|Patients with prostate cancer were treated with 2D-radiotherapy
2433881|NCT03339518|Experimental|BRIM3 Educational intervention|Individuals will receive a booklet and counseling about risk.
2433882|NCT03339518|Other|Wait list Control|At the completion of the study, individuals in the wait list condition will receive a booklet.
3188051|NCT00762983||Group 1|Pediatric patients who are treated with Claritin for any of the following reasons: allergic rhinitis, urticaria, itching due to skin disease (eczema, dermatitis, or pruritus cutaneous)
3188052|NCT00763022|Experimental|TAK-559 16 mg QD|
3188053|NCT00763022|Experimental|TAK-559 32mg QD|
3188054|NCT00763022|Placebo Comparator|Placebo QD|
3147614|NCT00128362|Experimental|Radio guided Sentinle node biopsy|The radiolabeled Tc-99 colloid or phytate (500 Mbq) will be injected into the primary tumor 2 hours before surgery. A localized scintiscan will then be performed to confirm the radiolabeling of the sentinel node before surgery and for documentation. Isosulphan blue dye will be injected subdermal (0.5ml) over the tumor and intraparenchymal (3-4ml) towards the axilla 10-15mins before incision.
2433885|NCT03339492|Active Comparator|Active PEMF|Subjects have 2 out of 3 chance to get the active device which emits a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
2433886|NCT03339492|Sham Comparator|Control/placebo PEMF|Subjects have a 1 out of 3 chance to get the control/placebo device which does not emit a pulsed electromagnetic field (PEMF) from the RCStim Model 1114 device (right and left side models available). Double-blind randomization.
2433887|NCT03339479|Experimental|dielectric property test|The patient with lung nodules/mass is firstly arranged to be tested for dielectric property after the nodules/mass resection and cutting open.
2433888|NCT03339479|Placebo Comparator|frozen pathological examination|The resected lung nodules/mass will be sent for frozen pathological examination after dielectric property test.
2433889|NCT03339479|Other|final pathological examination|The resected lung nodules/mass will undergo the final pathological examination for final diagnosis after dielectric property test and frozen pathological examination.
3188055|NCT00763074|Placebo Comparator|Control|Conventional education of life style intervention for type 2 diabetes
3188056|NCT00763074|Active Comparator|Diet|Dietary calorie restriction
3147615|NCT00128388|Experimental|1 PFPP|Panic Focused Psychodynamic Psychotherapy
3147616|NCT00128388|Active Comparator|2 ART|Applied Relaxation Training
2433894|NCT03339427|Active Comparator|vitamin D,capsule|A total of 150 subjects were recruited in the vitamin D supplementation group.
2433895|NCT03339427|Other|control|A total of 150 subjects were recruited in the control group.
2433898|NCT03339375||control|Monitoring arterial pressure, central venous pressure and pulse pressure variation
2433899|NCT03339375||esophagela Doppler|Monitoring arterial pressure, central venous pressure Insertion of esophageal Doppler probe to patient Monitoring stroke volume, cardiac output, corrected flow time from esophageal Doppler Use stroke volume optimization goal directed therapy protocol
2433900|NCT03339362|Active Comparator|Active Procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided intra-articular facet-joint injections via a spinal needle at 2 bilateral lumbar levels, using 0.5ml 0.5% bupivacaine + 20mg methylprednisolone per joint"
2433901|NCT03339362|Sham Comparator|Sham procedure|"All patients will receive 6 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 1% Lidocaine. This a test procedure to identify the patient has a 50% pain reduction from baseline pain numerical score. If patients pass this test injection, they will be randomised to the active or sham procedure.~4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml normal saline per injection"
2433902|NCT03339349|Experimental|Enoxaparin Metabolism|Eligible patients will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.2-0.4 IU/mL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
2433903|NCT03339336|Experimental|BIIB074 350 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 350 mg tablets orally BID Double-Blind Treatment Period.
2433904|NCT03339336|Experimental|BIIB074 200 mg|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 200 mg tablets orally BID Double-Blind Treatment Period.
2433905|NCT03339336|Placebo Comparator|Placebo|Taper Period (if applicable) from neuropathic pain medication, followed by a washout period, then BIIB074 350 mg tablets orally twice daily (BID) Open-Label Run-In Period, then BIIB074 placebo-matching tablets orally BID Double-Blind Treatment Period.
2433906|NCT03339323|No Intervention|Control|Standard rehabilitation procedure
2433907|NCT03339323|Experimental|Exercise|Aerobic exercise combined with resistance training; Concentric resistance training; Eccentric resistance training
2433908|NCT03339310|Experimental|Optimizer Smart System with 2-leads|All eligible subjects will have the Optimizer Smart System implanted and receive cardiac contractility modulation therapy (CCM).
3147617|NCT00128414|Placebo Comparator|Placebo|Placebo Comparator
3147618|NCT00128414|Experimental|Colchicine|Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
3147619|NCT00128453|Placebo Comparator|Placebo|Conventional therapy plus placebo
3147620|NCT00128453|Active Comparator|Colchicine|Conventional therapy plus colchicine
3147621|NCT00128479|Experimental|mifepristone 300 mg|
3147622|NCT00128479|Placebo Comparator|placebo|
3147623|NCT00128479|Experimental|mifepristone 600 mg|
3147624|NCT00128479|Experimental|mifepristone 1200 mg|
3147625|NCT00128505|Experimental|mifepristone|
3147626|NCT00128518|Experimental|Group A : T1+P2 ● P1+P2 ● T2+P1 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3147627|NCT00128518|Experimental|Group B : P1+P2 ● T1+P2 ● P1+P2 ● T2+P1|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3147628|NCT00128518|Experimental|Group C : T2+P1 ● P1+P2 ● T1+P2 ● P1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3147629|NCT00128518|Experimental|Group D : P1+P2 ● T2+P1 ● P1+P2 ● T1+P2|T1 = perindopril T2 = Indapamide P1 = Placebo of T1 P2 = Placebo of T2
3147630|NCT00128622|Experimental|Denileukin Diftitox plus vaccine|This is a single arm Phase I safety study.
2433914|NCT03339271|Active Comparator|Technology-Enhanced Group|Family caregivers will have daily visits from the study nurse while the patient is in the hospital and will receive weekly technology-enhanced support (video chats) from the study nurse for 8 weeks after the patient is discharged from the hospital.
2433915|NCT03339271|Active Comparator|Usual Care Group|Family caregivers will have usual care support from the doctors and nurses to plan for taking care of the patient upon return home and will receive a weekly telephone call for 8 weeks after the patient is discharged from the hospital.
2433916|NCT03339258|Experimental|Doxazosin Mesylate, Extended Release|Subjects will undergo a 4-week titration phase during which doxazosin may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study medication for a 4-week stable dose phase.
2433917|NCT03339258|Placebo Comparator|Placebo|Subjects will undergo a 4-week titration phase during which the placebo may be increased to a maximum dose of 10mg at bedtime based on symptoms and tolerability. After the 4-week titration phase, subjects will continue at stable dose of study placebo for a 4-week stable dose phase.
3188057|NCT00763074|Active Comparator|Exercise|Encourage to increase exercise amount: more than 60min's of exercise with moderate activity level two times per day
3188058|NCT00763074|Active Comparator|Diet and exercise|Intervention for both of exercise and diet
2433920|NCT03339232|No Intervention|Usual Care|Participants will receive standardized information about a healthy diet, including the potential benefit of small, frequent meals and nighttime snacking . In addition, the treating hepatologist will counsel participants on the benefits of increased physical activity. These recommendations will be provided at the beginning of the study. The usual care arm reflects current clinical practice. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
2433921|NCT03339232|Other|BCAA Supplement|BCAA powder (Bulk Supplements®) will be provided as the powder was found to be easier to swallow. Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio. BCAA will be provided by the study investigators and half will be provided at baseline study visit and the second half at the week 6 visit. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity.
2433922|NCT03339232|Other|BCAA supplement plus supervised physical activity|BCAA supplement will be as described for group 2, above. Study coordinators will supervise the physical activity program for study participants at the Loyola Fitness Center. Participants will attend the fitness center one hour each week; the fitness session will consist of low-impact aerobic physical activity, beginning with walking on the indoor track and possibly building to a recumbent exercise bicycle and light resistance training. Participants will be given a list of exercises to perform at home at least two times during the week with a goal of >90 minutes of physical activity per week. Participants will be asked to keep an exercise log detailing type and duration of at home physical activity which they will return during the weekly fitness center sessions. In addition, the treating hepatologist will provide standardized information about the potential benefits of small, frequent meals, nighttime snacking and increased physical activity at the beginning of the study.
3188059|NCT00763087|Active Comparator|nonweightbearing exercise|
3188060|NCT00763087|Placebo Comparator|nonexercising control|
3188061|NCT00763087|Experimental|weightbearing exercise|
3188062|NCT00763100||Breast cancer|Patients in treatment or post-treatment for breast cancer
2433927|NCT03339193||Patients having LAAC|Patients who meet current clinical criteria for left atrial appendage closure (LAAC), ie have atrial fibrillation, a CHA2DS2-VASc score of 3 or more and a contraindication to long-term oral anticoagulation therapy and who have been approved by the OUH NHS Foundation Trust LAAC Multidisciplinary Team (MDT) as suitable for left atrial appendage occlusion in accordance with National Health Service (NHS) guidelines.
3188063|NCT00763113|Experimental|1|Vanguard PS Knee
3188064|NCT00763113|Active Comparator|2|Vanguard CR Knee
3188065|NCT00763126|Active Comparator|Spouse present,|
3188066|NCT00763126|Active Comparator|spouse absent|
3188067|NCT00763152||stability of Beacons in prostatic bed|Patients implanted with the Calypso transponders following radical prostatectomy for prostate cancer will be followed for observation of transponder stability.
3188068|NCT00763165|Active Comparator|A|
3188069|NCT00763165|Placebo Comparator|B|
3188070|NCT00763178|Experimental|PTSD|Duloxetine
3188071|NCT00763204|Experimental|1|AN2728 Cream, 2%
3188072|NCT00763204|Experimental|2|AN2728 Cream, 1%
3188073|NCT00763204|Experimental|3|AN2728 Cream, 0.3%
3188074|NCT00763204|Placebo Comparator|4|AN2728 Cream Vehicle
3188075|NCT00763204|Active Comparator|5|Betnesol®-V Creme (betamethasone 0.1 %)
3188076|NCT00763217||stroke patient cohort|Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke
3188077|NCT00763230|Experimental|active|Full active tDCS treatment
3188078|NCT00763230|Sham Comparator|sham|Placebo tDCS will be give
3188079|NCT00763295||HIV infection|
3188080|NCT00763308|Experimental|1|Participants will use the Web-based Heart Healthy program.
3188081|NCT00763308|No Intervention|2|Participants will receive treatment as usual.
3188082|NCT00763347|Experimental|SYR-619 12.5 mg QD|
3188083|NCT00763347|Experimental|SYR-619 50 mg QD|
3188084|NCT00763347|Experimental|SYR-619 100 mg QD|
3188085|NCT00763347|Experimental|SYR-619 200 mg QD|
3188086|NCT00763347|Placebo Comparator|Placebo QD|
3188087|NCT00763347|Active Comparator|Alogliptin 25 mg QD|
3188088|NCT00763373||1|Observation group
3188089|NCT00763373||2|Intervention group
2433928|NCT03339167|Experimental|metabolic availability of lysine in millet|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or cooked millet with or without lentils, which will all be provided by the investigators."
2433929|NCT03339154|Experimental|Methionine bioavailability in chickpeas|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein freecookies and/or chickpeas with or without rice, which will be provided by the investigators"
3147631|NCT00128687|Experimental|Immediate Intervention|Participants in both arms continue to receive usual medical care throughout the study period. In addition, participants randomized to Immediate Intervention receive intensive case management for Coronary heart disease (CHD) risk reduction for 15 months and then a maintenance program for a minimum of 12 months to assess the durability of initial intervention changes.
3147632|NCT00128687|Placebo Comparator|Delayed Intervention|Participants randomized to Delayed Intervention serve as control for Immediate Intervention patients for the first 15 months and then receive intensive case management for 15 months. The switching-over design not only addresses ethical concerns about withholding treatment from half the study sample, but will also enable us to assess whether the intervention had equal impact whether provided to a naïve population or to a group followed in usual care for 15 months.
3147633|NCT00128765|Active Comparator|usual care|usual care, i.e. COPD care at patient's own initiative, mostly for medical help during exacerbations
3188090|NCT00763399|Experimental|97-0549B|
2433936|NCT03339115|Experimental|Cardiovalve Transfemoral Mitral Valve|Mitral replacement valve delivered through a transfemoral access and transseptal approach
2433937|NCT03339102||Participants who received Humira®|Non-infectious intermediate, posterior, or panuveitis patients who received Humira®
2433938|NCT03339089||Participants with Rheumatoid Arthritis (RA)|This group/ cohort includes participants with RA.
2433939|NCT03339089||Participants with Plaque Psoriasis (Ps)|This group/ cohort includes participants with Ps.
2433940|NCT03339089||Participants with Ankylosing spondylitis (AS)|This group/ cohort includes participants with AS.
2433941|NCT03339076|Other|For a single-arm trial|"Inclusion Criteria with intervention replacing either a foley catheter or self intermittent catheter with the M3 Mini Catheter~Males > 50 years of age~Signed subject informed consent~Patients with actual urinary retention dependent on Foley Catheter or Intermittent Catheter~Inclusion will start once the M3 is placed and a functioning bladder is demonstrated.~Exclusion Criteria~Inability to undergo bladder catheterization with the M3 due to anatomical challenges (i.e. urethral stricture, bladder neck contracture, false passage or false passages or other history of urethral stricture)~Gross hematuria~Hypotonic Neurogenic Bladder (the placement of the M3 may isolate the cause of the retention with the bridging of the prostate as bladder dysfunction rather than prostate obstruction)."
2433942|NCT03339050|Experimental|Health for Hearts United|Health for Hearts United (HHU) is a 18-month church-based intervention to reduce CVD risk in mid-life and older African Americans.
2433943|NCT03339037|Active Comparator|Hyperbaric oxygen therapy|"60 Hyperbaric oxygen sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). each session 1.5 ATA of 100% oxygen for 1 hour.~1 meter per minute compression and decompression."
2433944|NCT03339037|Sham Comparator|Normobaric air SHAM|"60 sessions in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session at 1 ATA of 21% oxygen (air) for 1 hour.~1 meter per minute compression and decompression. after 3 months, patients will be crossed over and treated with 60 sessions of treatment"
2433945|NCT03339024|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30:Self-administered intranasal spray as needed, max thrice daily"
2433946|NCT03339024|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
2433947|NCT03339011|Experimental|SMS text message|"The content of the text messages is developed based on recommendation and advice from the Danish Health Authority about the importance of regular daily physical activity.~For 6 weeks, the text messages will be send three times per week, twice during the week days and once in the weekend, based on previous experience with SMS as motivation for chronic pain patients."
2433948|NCT03339011|No Intervention|No intervention|No attention from the study
2433951|NCT03338985|Experimental|"Group cases patients"|patients with endometrial hyperplasia or endometrial cancers
2433952|NCT03338972|Experimental|Treatment (chemotherapy, BCMA CAR-T cells)|Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator).
2433954|NCT03338946||CIED subjects|CIED interrogation
3147634|NCT00128765|Experimental|monitoring controls|regular COPD care (monitoring) provided by practice nurse according to current COPD guidelines
3147635|NCT00128765|Experimental|self-management|disease specific self-management program 'Living Well with COPD'
2433961|NCT03338907|Experimental|Oxycarbon (5% CO2 + 95% O2)|Patients will be mechanical ventilated with Oxycarbon (5%CO2 +95% O2) after normocapnia is reached until FeO2 is stable for at least 1 min ≥ 80%. At timepoint 1 immediately prior apnea NIRS and vital parameters will be registered and an bloodsample will be drawn.
2433962|NCT03338907|Placebo Comparator|Control (95% O2)|"Same procedure as arm active comparator"
2433964|NCT03338881|Experimental|[14C]-TAK-659 100 mg|[14C]-TAK-659 100 mg, solution, orally, once, in the fasted state on Day 1. Participant will have the option to continue treatment with TAK-659 100 mg, tablets, orally, once daily in a 28-day treatment cycle for up to 12 months or until disease progression or unacceptable toxicity, or the start of another anticancer therapy in post-ADME study period.
2433965|NCT03338868||Patients with MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
2433966|NCT03338868||Patients without MetS|To be a volunteer patient with a chronic non-specific musculoskeletal pain disorder, including knee osteoarthritis, rotator cuff tear, adhesive capsulitis, and non-specific low back, back or neck pain for more than 6 months.
2433969|NCT03338842|Experimental|Distractor and Lower limb VR|The training sessions consist of Phase 1 (Distractor VR) in which patients will explore VR environments and Phase 2 (Lower limb VR) in which they will play games using their VR lower-limbs.
3147636|NCT00128778|Experimental|Arm A: PLD|Pegylated liposomal doxorubicin (PLD) after induction chemotherapy in patients with metastatic breast cancer (MBC). Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to PLD (40 mg/m2) every 28 days for six cycles or to observation.
3147637|NCT00128778|No Intervention|Arm B: Observation|Patients without disease progression following first-line induction chemotherapy consisting of three cycles of doxorubicin (75 mg/m2) followed by three cycles of docetaxel (100 mg/m2) both every 21 days, were randomized to observation.
3147638|NCT00128817|Experimental|1|Concurrent Chemoradiation
2433976|NCT03338790|Experimental|nivolumab + rucaparib|Specified dose on specified days
2433977|NCT03338790|Experimental|nivolumab + docetaxel + prednisone|Specified dose on specified days
2433978|NCT03338790|Experimental|nivolumab + enzalutamide|Specified dose on specified days
2433979|NCT03338777|Experimental|Suicide plus immunogene therapy|Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.
2433980|NCT03338764|Experimental|Experimental (SM-1)|Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
2433981|NCT03338764|Placebo Comparator|Placebo|Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
2433982|NCT03338751|Active Comparator|Hearing Assistance Device (HAD) First|Tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second. Participants randomized to HAD first will use a Hearing Aid Device.
2433983|NCT03338751|Active Comparator|No Hearing Assistance Device (HAD) First|Sham hearing aid device
2433984|NCT03338738|Experimental|Patients with ESBL, antibiotic pressure|Patients with ESBL, antibiotic pressure will be included. On the day of inclusion, a stool culture is performed on the first stool issued after the start of antibiotic therapy in order to evaluate the initial flora and the relative initial faecal abundance of multidrug-resistant bacteria. In the absence of stool emission by the patient, a rectal swab will be performed. 72 hours after initiation of antibiotic therapy, a blood sample (5 ml) will be taken to determine plasma concentrations of antibiotics. In addition, a stool sample will be taken at 72 hours after the start of antibiotic therapy, at the end of antibiotic therapy and 60 days after this end to evaluate the change in initial flora and relative faecal abundance of ESBL-producing enterobacteria.
2433985|NCT03338725|Active Comparator|Patients without intervention|Patients without follow-up by clinical pharmacy model
2433986|NCT03338725|Experimental|Patients with intervention|Patients who are being monitored by a clinical pharmacy model
2433987|NCT03338699|Experimental|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
2433988|NCT03338699|Active Comparator|Mogen clamp|Mogen clamp circumcision.
2434059|NCT03338179|Experimental|Adult Patients|Schizophrenia patients aged between 18 and 45 years old
3147639|NCT00128817|Active Comparator|2|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy
3147640|NCT00128843|Experimental|Exemestane|25mg/day per VO until progression disease, after this progression the patient could receive the another drug (comparator arm) ie Anastrozole by investigator decision
3147641|NCT00128843|Active Comparator|Anastrozole|1mg/day per VO until progression disease, after this progression the patient could receive the another drug (experimental arm) ie Exemestane by investigator decision
3147642|NCT00128856|Experimental|Gemcitabine + Adriamycine + Paclitaxel|Neoadjuvant chemotherapy consisted of adriamycine 40 mg/m2, administered on day 1 as an i.v. infusion. Paclitaxel 150 mg/m2 was administered on day 2 as an i.v infusion followed by gemcitabine 2000 mg/m2 as an i.v. infusion. The three drugs were administered every two weeks for 6 cycles.
3147643|NCT00128895|Active Comparator|azathioprine, standard|standard azathioprine maintenance upto one year after diagnosis, subsequently tapering of azathioprine with 25 mg per 3 months
3147644|NCT00128895|Experimental|azathioprine, longterm|longterm maintenance with azathioprine upto four years after diagnosis, subsequently azathioprine will be tapered with 25 mg per 3 months
3147645|NCT00128908|Active Comparator|Continuous triple-class therapy|Patients will be treated with a regimen containing antiretroviral agents from 3 different classes
3188091|NCT00763425|Experimental|1|
2433993|NCT03338660|Placebo Comparator|Control (Placebo)|Subjects will receive infusion of placebo (saline).
2433994|NCT03338660|Active Comparator|Platelet storage routine|Subjects will receive infusion of platelets stored by routine method.
2433995|NCT03338660|Experimental|Platelet storage experimental|Subjects will receive infusion of platelets stored by a novel methodology.
3147646|NCT00128908|Experimental|Alternating therapy|Patients will be assigned to weekly alternating dual-class regimen
2433998|NCT03338634||Children 6 to 10|Children must be between the ages of 6-10 years-old at the time they participate. All children will be physically healthy and without diagnosed learning disorders. A parent or legal guardian must be able to accompany the child.
2433999|NCT03338621|Experimental|Drug Sensitive BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months
2434000|NCT03338621|Active Comparator|Drug Sensitive Standard Treatment|isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26
2434001|NCT03338621|Experimental|Drug Resistant BPaMZ|Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)
2434002|NCT03338608|Experimental|Vertical Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the vertical platysma incision.
2434003|NCT03338608|Experimental|Transverse Platysma Incision|Patients in this arm who have anterior cervical decompression and fusion will receive the transverse platysma incision.
2434010|NCT03338543|Experimental|percutaneous stimulation|PENS in 2/100 hertz (HZ), 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2434011|NCT03338543|Experimental|transcutaneous stimulation|TENS in 2/100 HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2434012|NCT03338543|No Intervention|Control|Conventional analgesic medication is offered.
2434013|NCT03338530|Experimental|Comprehensive School-Based Intervention|Children with HFASD assigned to the CSBI received social skills groups, computer instruction in emotion recognition, therapeutic activities, and a behavioral reinforcement system (individual daily note) during the school year and their parents participated in monthly parent training. School staff received training prior to the school year and demonstrated fidelity with the protocol. Fidelity was also monitored during the school year by research assistants.
2434014|NCT03338530|No Intervention|Business-As-Usual (BAU) Control|Children with HFASD in the BAU schools received their typical special education programming as legally-mandated. The programming received by each was carefully monitored per the following: 1) Each student's IEP was reviewed to document the legally mandated services received; 2) For those receiving counseling or speech-language services, the related-service provider completed a survey indicating specific treatment targets and the protocol for service provision; 3) Parents completed a monthly survey of any external therapeutic programming their child may have received; and 4) Fidelity measures designed for the intervention group (with sequencing requirements removed) were completed for the control condition during two 60-minute classroom observations per week by research assistants.
2434015|NCT03338517|Active Comparator|Study group|Helium Neon Laser
2434016|NCT03338517|No Intervention|Control group|No intervention
2434017|NCT03338504||Suspected type 2 myocardial infarction|The investigators will identify consecutive patients with acute myocardial injury (defined as a rise and or fall in cardiac troponin concentration on serial testing, with at least one value >99th centile) where the likely mechanism of injury is thought to be myocardial oxygen supply and demand imbalance (e.g secondary to hypoxia, hypotension, tachycardia or anaemia). Patients will be identified through screening of cardiac troponin measurements. Patients who meet both the inclusion and exclusion criteria, will be approached and those who provide consent will comprise the study population. All patients will have a Cardiac MRI scan, with invasive coronary angiography or CT coronary angiography dependent on baseline fitness. The investigators will record demographic and clinical information from the electronic patient record for patients who meet inclusion criteria but have one or more exclusion criteria.
2434018|NCT03338491|Experimental|Induction of Implemental Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce an Implemental Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2434019|NCT03338491|Experimental|Induction of Deliberative Mindset|Psychological Intervention. Participants are asked to work on a brief paper-and-pencil task that has been shown to induce a Deliberative Mindset according to the Mindset theory of action phases (Gollwitzer & Keller (2016). Mindset Theory. In: V. Zeigler-Hill, T.K. Shackelford (eds.), Encyclopedia of Personality and Individual Differences. New York: Springer).
2434020|NCT03338491|No Intervention|Control|Participants will revive no induction of any mindset.
3147648|NCT00128973||Healthy Volunteers|Healthy adult M/F 18-85 y/o.Hgb greater than or equal to 11. Wt>110 bs. No heart, lung, kidney, bleeding disorders. No hep BorC since age ll. No IV drug use. No exposure to the AIDS virus. Not pregnant.
3147649|NCT00128973||Patients|Patients with abnormalities of immune function
3147650|NCT00128973||Relatives of Patients|Relatives may be mother, father, siblings, children, grandparents, aunts, uncles, and first cousins to a patient.
3147651|NCT00129090|Experimental|R-CHOEP14 with 12x Rituximab|8 cycles of standard CHOP with etoposide in 14-day intervals. Patients with CD20+ lymphoma receive 12 doses of Rituximab (day 0,1,4,8 of cycle 1, day 1 and 8 of cycle 2, day1 of cycle 3-8 )
3147652|NCT00129233|Active Comparator|Valsartan|Valsartan group treated with 80-160mg daily valsartan without Ca channel blockers or ACE inhibitors.
3147653|NCT00129233|Active Comparator|Amlodipine|Amlodipine group treated with 5-10mg daily amlodipine without ACE inhibitors or angiotensin receptor blockers.
3147654|NCT00129298|Experimental|1|Tiagabine
3147655|NCT00129298|Placebo Comparator|2|Matching placebo
2434021|NCT03338478|Experimental|Epilepsy Patients|Patients being tapered off of levetiracetam or lamotrigine monotherapy during epilepsy video monitoring. Patients will receive the Wii Balance Board and computerized reaction time testing.
2434022|NCT03338478|Experimental|Healthy Control Group|Patients without a diagnosis of epilepsy. Control participants will receive the Wii Balance Board and computerized reaction time testing.
2434023|NCT03338465|Active Comparator|Group A|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.20 millijoules/mm2 per session)
2434024|NCT03338465|Active Comparator|Group B|3 weekly sessions of focused extracorporeal shockwave treatment (2.000 impulses at 0.01 millijoules/mm2 per session)
2434025|NCT03338452|Experimental|participants|The participants will be subjected to low energy ketogenic diet.
2434026|NCT03338439||CSII|CSII: patients with continuous subcutaneous insulin infusion
2434027|NCT03338439||MDI|MDI: patients with multi-daily injections
2434028|NCT03338426|Experimental|Experimental|Co-administration of a fixed dose combination of Fimasartan 120mg and Atorvastatin 40mg
2434029|NCT03338426|Active Comparator|Active Comparator 1|Co-administration of Fimasartan 120mg and Placebo for Atorvastatin 40mg
2434030|NCT03338426|Active Comparator|Active Comparator 2|Co-administration of Atorvastatin 40mg and Placebo for Fimasartan 120mg
2434031|NCT03338413|Experimental|Goal Management Training|
2434032|NCT03338413|Experimental|Computerized Cognitive Training|
2434035|NCT03338387|Experimental|Acipimox|Other Names: Olbetam
2434036|NCT03338387|Placebo Comparator|Placebo|"Other Names:~Placebo (for Olbetam)"
2434037|NCT03338374|Experimental|Biventricular Pacemaker|All subjects to be in a single study group experiencing all interventions.
3147656|NCT00129324|Other|Lead Reduction Arm|random assignment to receive lead hazard control intervention. Assessing lead hazards in the home. Reducing lead hazards by cleaning, painting, covering, and/or replacing/repairing interior and exterior components of the home.
3147657|NCT00129324|Other|Injury Reduction Arm|random assignment to receive injury hazard control intervention. Assessing home for potential injury hazards. Controlling hazards by 1) installing safety equipment such as stairway gates, cabinet locks, smoke & CO detectors, etc. 2) removing the hazards from the reach of a child and/or 3) restricting access to the hazards.
3147658|NCT00129337|Experimental|1|0.1 mg/kg
3147659|NCT00129337|Experimental|2|0.3 mg/kg
2434042|NCT03338348|Other|Azacitidine + Vosaroxin|"Cycle 1-8:~Azacitidine: 75 mg/m²/d subcutaneously, d 1-7; Vosaroxin: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .~Patients who have completed 8 cycles of azacitidine and vosaroxin are scheduled to maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
2434043|NCT03338322|Experimental|Twisted file adaptive|Files that are used in root canal preparation in adaptive motion
2434044|NCT03338322|Active Comparator|Reciproc|Reciproc files are used in root canal preparation with reciprocation motion
2434045|NCT03338309||iFR-guied strategy group|1,200 patients with suspected ischemic heart disease including stable angina, or acute coronary syndrome including unstable angina, non ST-segment elevation MI, or ST-segment elevation MI with non-culprit stenosis who underwent iFR measurement and enrolled at 5 centers in Republic of Korea.
2434048|NCT03338283|Experimental|Electromassage|"Electromassage and conservatory treatment. All subjects will be received a conservatory treatment (1h and 40 min) and electro-massage (10min).~The protocol will consist of six sessions, twice a week for three weeks. The duration will be 1 hour and 40 min for the conservatory treatment and 10 min for the electro-massage."
2434049|NCT03338283|Active Comparator|Conservatory Treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
3147660|NCT00129337|Experimental|3|1 mg/kg
3147661|NCT00129337|Experimental|4|3 mg/kg
2434052|NCT03338244|Active Comparator|Azithro|Communities will receive four rounds of biannual mass azithromycin.
2434053|NCT03338244|Placebo Comparator|Placebo|Communities will receive four rounds of biannual mass placebo.
2434054|NCT03338218|Experimental|Volulyte 6%|Volulyte 6% solution for infusion
2434055|NCT03338218|Active Comparator|Ionolyte|Ionolyte solution for infusion
2434056|NCT03338205|Experimental|Ketamine Treatment|"Everyone enrolled in study presenting in status asthmaticus to pediatric emergency department at Augusta University will receive a ketamine treatment, who include:~Patients with a Clinical Asthma SCore (CAS) of greater than or equal to 10 on presentation and have received at least two (appropriately dosed based on weight) albuterol treatments prior to arrival~OR~Patients with a CAS of ≥ greater than or equal to 10 that have not received treatment prior to arrival and after receiving 1 hour of treatment per the severe asthma pathway do not have a decrease in CAS of greater than 2~OR~Patients with a CAS above > 6 but less than < 10 when as measured 1 hour after initiation of standard treatment per Augusta University's moderate asthma pathway"
2434057|NCT03338192||African American/Black QST|This group will consist of a full range of socioeconomic status in African American/Black individuals with chronic low back pain.
2434058|NCT03338192||Caucasian/White QST|This group will consist of a full range of socioeconomic status in Caucasian/White individuals with chronic low back pain.
3147662|NCT00129415|Experimental|UVA1 Irradiation|UVA 1 Irradiation (Sellemed UVA1 light source) up to 130 J/cm2
3147663|NCT00129415|Experimental|UVB Irridiation|UVB Irradiation maximum dose of 4000 mJ/cm2
3147664|NCT00129428|Experimental|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
3147665|NCT00129454|Experimental|Telemedicine treatment|Psychotherapy delivered by telephone
3147666|NCT00129454|Active Comparator|In-Person treatment|Psychotherapy delivered in-person
3147667|NCT00129454|No Intervention|Assessment only|No intervention
3147668|NCT00129493|Other|Arm 1|
3147669|NCT00129519|Active Comparator|Imiquimod cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
3147670|NCT00129636|Other|Patient attending hospital clinic|patients were sent a letter especially dictated for them and a copy of the letter written by the hospital consultant to their GP to review
2434060|NCT03338179|Experimental|Aged Patients|Schizophrenia patients aged 59.5 years and above
2434061|NCT03338179|Active Comparator|Adult Controls|Controls aged between 18 and 45 years old
2434062|NCT03338179|Active Comparator|Aged Controls|Controls aged 59.5 years and above
2434063|NCT03338166||Group A|Patients with Hepatocellular carcinoma who treated with sorafenib and measure LDH serum level one month pre and post treatment
2434064|NCT03338166||Group B|Patients with Hepatocellular carcinoma who treated with trans catheter arterial chemo embolization (TACE) and measure LDH serum level one month pre and post treatment
2434065|NCT03338166||Group C|Patients with Hepatocellular carcinoma who treated surgically and measure LDH serum level one month pre and post treatment
2434066|NCT03338166||Group D|Patients with Hepatocellular carcinoma who don't receive treatment and asses LDH serum level for 3months
2434067|NCT03338153||controlled diabetes|diabetic patients with HbA1C level below 7.0%
2434068|NCT03338153||uncontrolled diabetes|diabetic patients with hbA1C level above 7%
2434069|NCT03338153||non-diabetic|patients who does not have diabetes at the time of PCI
2434070|NCT03338127||Participants|all patients recruited in the trial will be investigated for renal function test
2434071|NCT03338114|Experimental|FLX-787-ODT (orally disintigrating tablet)|FLX-787-ODT (orally disintigrating tablet)
2434072|NCT03338075||CRT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy plus concomitant Temozolomide.
2434073|NCT03338075||RT group|patients with brain metastases of more than 6 cc and treated with fractionated stereotactic radiotherapy alone.
3188092|NCT00763425|Active Comparator|2|
3188093|NCT00763438|Experimental|Sertindole|
2434076|NCT03338049|Other|Veran System|Staged biopsy sampling methodology. If lymph node staging is negative, EMN-bronchoscopy will be performed. If EMN-bronchoscopy is negative, EMN-TTNA will be performed
3188094|NCT00763477|Placebo Comparator|saline injections|
3188095|NCT00763503|Experimental|CD 2027|
3188096|NCT00763516|Experimental|Proton radiation and chemotherapy|"Proton radiation~Capecitabine chemotherapy on radiation days~Surgery~Gemcitabine chemotherapy"
3188097|NCT00763529|Experimental|Arm 1|
3188098|NCT00763529|Active Comparator|Arm 2|
3188099|NCT00763542|Experimental|I|Combined treatment: CBT for SUD plus structured writing therapy for PTSD
3188100|NCT00763542|Active Comparator|II|CBT for SUD only
2434084|NCT03337997|Experimental|Study group|All patients in this pilot study are in the same group. All receive Irreversible Electroporation.
2434085|NCT03337971|Placebo Comparator|PLACEBO|"Intervention: Dietary Supplement: PLACEBO A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
2434086|NCT03337971|Active Comparator|Milk-based protein matrix|"Intervention: Dietary Supplement: MBPM A group of subjects ingesting a liquid beverage (0.3g per kg body mass ; 1.2kcal/kg body mass) at 10:00pm, 3h post-absorptive of a standardised evening meal.~Samples for the measurement of biomarkers of change in the rate of bone turnover appearing in the blood to be collected for the immediate 4h, and excreted in urine, 24h post-ingestion"
2434087|NCT03337958|No Intervention|CONTROL GROUP|Received the standard medical and pharmacological care provided by the hospital
2434088|NCT03337958|Experimental|INTERVENTION GROUP|The group received the standard medical and pharmacological care provided by the hospital. In addition, an educational program on the use of inhalers, which included an explanation of the use of inhalers together with a ventilatory re-education program, furthermore, the technique of inhaler use was trained.
2434089|NCT03337945|Experimental|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
2434090|NCT03337932|Active Comparator|MEM-7 days doxycycline|
2434091|NCT03337932|Active Comparator|MEM-14 days doxycycline|
2434092|NCT03337932|Placebo Comparator|Controls|
2434093|NCT03337919|Experimental|Nivolumab|Up to 8 x 2-weekly cycles of nivolumab 240mg IV. Interim PET-CT scan to be performed after 4 cycles, and centrally reviewed. Patients will stop treatment after 4 cycles if they have complete metabolic response or progressive metabolic disease. If they have partial metabolic response or stable disease, they will continue to 8 cycles.
2434094|NCT03337906||Participants infected with HIV-1|Persons who become HIV-1 infected after enrollment in HIV-1 vaccine trials
2434095|NCT03337893||Breastfed|The kids who breastfed
2434096|NCT03337893||non-breastfed|The kids who did not breastfed
2434097|NCT03337880||Cases|newborns who were delivered with an extractor
3188101|NCT00763555|Experimental|1|CD 2027, 3 ug/g Oily Spray, twice a day for 8 weeks
3188102|NCT00763555|Placebo Comparator|2|
3188103|NCT00763568|Experimental|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
3188104|NCT00763594|Active Comparator|IPT|Interpersonal Psychotherapy for Major Depressive Disorder
3188105|NCT00763594|Experimental|BRT|Brief Relational Therapy adapted for treatment of Major Depressive Disorder
3188106|NCT00763607||1|Radically resected Non small cell lung cancer patients in stage I-III
3188107|NCT00763620|Experimental|1|Catheter for mini bronchoalveolar lavage
3188108|NCT00763633|Active Comparator|highB6|high vitamin B6
3188109|NCT00763633|Active Comparator|lowB6|low vitamin B6
3188110|NCT00763659|Active Comparator|1|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
3188111|NCT00763659|Active Comparator|2|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
3188112|NCT00763659|Placebo Comparator|3|Placebo
3188113|NCT00763672|Other|A|sFlt-1 status known
3188114|NCT00763672|Other|B|sFlt-1 status unknown
3188115|NCT00763685|Active Comparator|etoricoxib 120 mg|active control
3188116|NCT00763685|Placebo Comparator|2|Placebo
3188117|NCT00763685|Active Comparator|3|Paracetamol 1 g and etoricoxib 120 mg
3188118|NCT00763711|Experimental|Injection with Needle Guide|
2434098|NCT03337880||Controls|newborns who were not delivered with an extractor
2434099|NCT03337867|Active Comparator|Real-iTBS|
2434100|NCT03337867|Sham Comparator|Sham-iTBS|
2434101|NCT03337841|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV once only in the neoadjuvant phase. Pembrolizumab 200 mg IV every 3 weeks in the adjuvant phase.
2434102|NCT03337828|Active Comparator|Alcohol-free beer with regular composition|Two cans (33 cl.) per day of an alcohol-free beer with regular carbohydrates composition.
2434103|NCT03337828|Experimental|Alcohol-free beer with modified composition|Two cans (33 cl.) per day of alcohol-free beer with modified carbohydrates composition. This include the substitution of regular maltose by isomaltulose and the addition of maltodextrin (fiber).
2434104|NCT03337815|Active Comparator|Treatment of MTX and TwHF placebo|Patients were treated with Methotrexate (MTX) and Tripterygium wilfordii Hook F（TwHF）placebo.
2434105|NCT03337815|Experimental|Treatment of TwHF and MTX placebo|Patients were treated with Tripterygium wilfordii Hook F（TwHF）and Methotrexate (MTX) placebo.
2434106|NCT03337802|No Intervention|Pregnant women at standard diet|obstetrical and gynecological follow-up
2434107|NCT03337802|Experimental|Pregnant women at mediterranean diet|obstetrical and gynecological follow-up + nutritional counseling
2434108|NCT03337789|Experimental|Polygonatum sibiricum|
2434109|NCT03337789|Placebo Comparator|Placebo|
2434110|NCT03337776|Active Comparator|WhatsApp message|WhatsApp messages will be sent to invite subjects to participate CRC screening
2434111|NCT03337776|Active Comparator|Telephone call|Telephone call will be made to invite subjects to participate CRC screening
2434112|NCT03337750|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
2434113|NCT03337737|Placebo Comparator|Placebo|Placebo will be composed of microcrystalline cellulose in a gel capsule
2434114|NCT03337737|Active Comparator|Extreme Endurance|Dietary Supplement manufactured by LifeSpan International LLC
3147671|NCT00129662|Experimental|Intervention arm|Pictorial action plan
3147672|NCT00129675|Experimental|[123I]ß CIT|To assess [123I]ß CIT and SPECT imaging
3147673|NCT00129714|No Intervention|wait and see|
3147674|NCT00129714|Experimental|collar|
3147675|NCT00129714|Experimental|physiotherapy|
3147676|NCT00129753|Experimental|Alemtuzumab|
3147677|NCT00129792|Experimental|1|Has 100% expectation of receiving supplement
3147678|NCT00129792|Sham Comparator|2|Has 50% expectation of receiving supplement
3147679|NCT00129792|Other|3|Has 0% expectation of receiving supplement.
3147680|NCT00129805|Experimental|MCI-9042|
3147681|NCT00129805|Active Comparator|Aspirin|
3147682|NCT00129896|Experimental|Myocet+Taxotere+Herceptin|Myocet 50 mg/m2; Taxotere 60 mg/m2; Herceptín 4 mg/Kg (first dose) and in the following cycles 2 mg/Kg
3147683|NCT00129922|Active Comparator|Fluorouracil+Epirubicin+Cyclophosphamide|5-FU+4-Epirubicin+Cyclophosphamide
3147684|NCT00129922|Experimental|FEC followed by Paclitaxel|5-FU+4-Epirubicin+Cyclophosphamide
3147685|NCT00130026|Placebo Comparator|I|Saline placebo
3147686|NCT00130091|Experimental|Clonidine|administer with local anesthetic
3147687|NCT00130091|Placebo Comparator|Local anesthetic|Local anesthetic without clonidine
3147688|NCT00130104|Experimental|MCB|randomized to receive the metacarpal block for anesthesia
3147689|NCT00130156|Experimental|1|
3147690|NCT00130156|Experimental|2|
3147691|NCT00130169|Experimental|1|
3147692|NCT00130195|Experimental|A|
3147693|NCT00130260|Experimental|vaccine, schedule 1|3rd and 4th dose of vaccine, on original schedule
3147694|NCT00130260|Experimental|vaccine, schedule 2|3rd and 4th dose of vaccine on modified schedule
3147695|NCT00130260|Placebo Comparator|placebo, schedule 1|3rd and 4th dose of placebo, on original schedule
3147696|NCT00130260|Placebo Comparator|placebo, schedule 2|3rd and 4th dose of placebo on modified schedule
3147697|NCT00130273|Experimental|1|Participants will receive managed problem solving for 12 months
3147698|NCT00130273|Active Comparator|2|Participants will receive standard of care for 12 months
3147699|NCT00130312|Experimental|Sulodexide|Also known as KRX-101. These patients are also on ACEs and ARBs (irbesartin and/or losartan).
3147700|NCT00130312|Placebo Comparator|Placebo|These patients are also on ACEs and ARBs (irbesartin and/or losartan).
3147701|NCT00130325|Active Comparator|A|Isoniazid arm
3147702|NCT00130325|Placebo Comparator|B|Placebo of Isoniazid tablet 300mg
3147703|NCT00130364|Experimental|1|Pimecrolimus
3147704|NCT00130364|Placebo Comparator|2|Pimecrolimus vehicle cream
3147705|NCT00130377|Experimental|cell therapy|Patient receiving active biologic
3147706|NCT00130377|Placebo Comparator|control|Patient receiving placebo or standard of care
3147707|NCT00130390|Experimental|1|One nitazoxanide 500 mg tablet twice daily for 28 days
3147708|NCT00130390|Placebo Comparator|2|One placebo tablet twice daily for 28 days
3147709|NCT00130494|Experimental|Arm A: Zoledronic acid 4 mg|Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
3147710|NCT00130494|No Intervention|Arm B: Observation|Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).
3147711|NCT00130507|Active Comparator|Arm A: VX|Vinorelbine and capecitabine (VX): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days).
3147712|NCT00130507|Experimental|Arm B: VXH|Vinorelbine, capecitabine and trastuzumab (VXH): vinorelbine 25 mg/m2 iv, days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, orally, twice a day, days 1-14 each cycle (21 days) and trastuzumab 4 mg/kg iv (loading dose first week), followed by 2 mg/kg weekly.
3147713|NCT00130546|Active Comparator|1|Cypher Stent
3147714|NCT00130546|Active Comparator|2|Taxus Stent
3147715|NCT00130598|Active Comparator|1|control group: patients receive a preventive hydration with 154mEq/l saline at an ongoing rate of 1ml/kg per hour of at least 12 hours prior and after the procedure.
3147716|NCT00130598|Active Comparator|2|7h-sodium bicarbonate (according to the regimen used in a recently published study (slightly modified)14): before contrast a bolus of 3ml/kg NaHCO3 166mEq/l for one hour, followed by an infusion of NaHCO3 166mEq/l with a rate of 1ml/kg per hour until 6h after contrast.
3147717|NCT00130598|Active Comparator|3|short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg; patients with a body weight above 100kg 300ml) as a bolus 20 minutes before contrast; additionally ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl of San Pellegrino® non-sparkling mineral water at the start of the infusion. Ingestion of 500ml San Pellegrino® non-sparkling mineral water in the first 6 hours after contrast.
3147718|NCT00130611|Placebo Comparator|BNP blinded therapy|Clinical treatment without knowledge of BNP levels
3147719|NCT00130611|Experimental|BNP guided therapy|Clinical treatment based on clinical examination and BNP-levels
3147720|NCT00130676|Experimental|mifepristone 600 mg|
2434135|NCT03337672|Experimental|Dexmedetomidine group|Subjects who receive dexmedetomidine for prevention of emergence delirium
2434136|NCT03337672|Active Comparator|Midazolam group|Subjects who receive midazolam for prevention of emergence delirium
2434137|NCT03337659|Experimental|FICare Intervention Group|Study participants received Family Integrated Care (intervention) while their infant(s) was/were admitted to a Level II NICU.
2434138|NCT03337659|No Intervention|FICare Control Group|Study participants received standard care while their infant(s) was/were admitted to a Level II NICU.
2434139|NCT03337646|Other|Lisdexamphetamine|All participants will receive Lisdexamfetamine Dimesylate (LDX) at an optimized dose based on protocol
2434140|NCT03337633|Active Comparator|Experiment 1 Easy|"For the first experiment, subjects in this arm received the easy menu during the protocol."
2434141|NCT03337633|Active Comparator|Experiment 1 Hard|"For the first experiment, subjects in this arm received the hard menu during the protocol."
2434142|NCT03337633|Active Comparator|Experiment 2 Easy|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the easy menu during the protocol."
2434143|NCT03337633|Active Comparator|Experiment 2 Hard|"For the second experiment, subjects in this arm, who qualified as restrained eaters and were asked to fast for 8 hours overnight, received the hard menu during the protocol."
2434144|NCT03337620|Active Comparator|Bupivacaine|Bupivacaine is a local anesthestic that will be delivered to the SPG by the Tx360 device.
2434145|NCT03337620|Placebo Comparator|saline|Saline is being used as a placebo treatment that will be delivered to the SPG by the Tx360 device.
2434146|NCT03337607|Active Comparator|rESWT plus C-E drugs|Patients will receive rESWT, Celecoxib and Eperisone
2434147|NCT03337607|Active Comparator|rESWT alone|Patients will receive rESWT
2434148|NCT03337607|Active Comparator|C-E drugs alone|Patients will receive Celecoxib and Eperisone
2434149|NCT03337594||Control|Pediatric patients who have not been exposed to gadolinium-based contrast agent administration and who require cardiac surgery as part of their standard clinical treatment.
2434150|NCT03337594||Dotarem|Pediatric patients who have undergone routine contrast-enhanced MRI using only Dotarem contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
2434151|NCT03337594||MultiHance|Pediatric patients who have undergone routine contrast-enhanced MRI using only MultiHance contrast agent for clinical purposes and who require cardiac surgery as part of their standard clinical treatment.
2434152|NCT03337581|Sham Comparator|group 1.1|Normal saline group
2434153|NCT03337581|Experimental|group 1.2|0.25μg/kg dexmedetomidine group
2434154|NCT03337581|Experimental|group 1.3|0.5μg/kg dexmedetomidine group
2434155|NCT03337581|Experimental|group 1.4|0.75μg/kg dexmedetomidine group
2434156|NCT03337581|Experimental|group 1.5|1.0μg/kg dexmedetomidine group
2434157|NCT03337555|Active Comparator|Macintosh|intubation using Macintosh direct laryngoscope
2434158|NCT03337555|Experimental|McGrath|intubation using McGrath MAC®
2434159|NCT03337555|Experimental|Pentax|intubation using Pentax-airway scope®
3147721|NCT00130676|Placebo Comparator|matching placebo|
2434161|NCT03337529|Experimental|Vitamin C|RLS positive patients will be assessed for the severity. They will be given 200 mg Vitamin C for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
2434162|NCT03337529|Placebo Comparator|Placebo|RLS positive patients will be assessed for the severity. They will be given 200 mg placebo for 8 weeks duration. Patients will be re-assessed for the severity of restless leg syndrome.
2434163|NCT03337516|Experimental|Patients treated with Cytarabine|
2434164|NCT03337503|Experimental|THC and CDB in a 1 to 1 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 2.5 mg CBD capsule"
2434165|NCT03337503|Experimental|THC and CBD in a 1 to 2 ratio|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~2.5 mg THC with 5 mg CBD capsule"
2434166|NCT03337503|Experimental|high CBD with trace THC|"Post a self-titrating schedule of medical cannabis oil, subjects take 1 capsule three times a day at 6 hour intervals.~20 mg CBD with traces of THC"
2434167|NCT03337503|Placebo Comparator|placebo|"Post a self-titrating schedule of carrier oil, subjects take 1 capsule three times a day at 6 hour intervals.~carrier oil capsule"
3147722|NCT00130702|Experimental|Gefitinib (Iressa)|All patients will receive Gefitinib (Iressa) at a dose of 750 mg orally (three 250 mg tabs) each day.
3147723|NCT00130754|Experimental|1|Thymo
3147724|NCT00130754|No Intervention|2|
3147725|NCT00130819|Experimental|1|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
3147726|NCT00130819|Active Comparator|2|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
3147727|NCT00130845|Experimental|Octreotide Acetate in Microspheres|
3147728|NCT00130845|Placebo Comparator|Placebo|
3188119|NCT00763724||1|Duloxetine
3188120|NCT00763724||2|Venlafaxine
2434173|NCT03337464|Experimental|Parkinson's disease|Subjects with Parkinson's disease
2434174|NCT03337464|Active Comparator|Control|Subjects without Parkinson's disease
2434175|NCT03337451|Experimental|OPN-305|
2434176|NCT03337438|Other|Values-PFI|
2434177|NCT03337438|Other|Traditional-PFI with values assessment|
2434178|NCT03337438|Other|Traditional PFI no values assessment|
2434179|NCT03337425|Experimental|psychoeducational groups|Psychoeducational group therapy and standard treatment (ADHD treatment as usual)
2434180|NCT03337425|Active Comparator|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
2434181|NCT03337412|Experimental|Patients|initial assessment of physical capacities, determination of personalized objectives on the occasion of 1 to 2 workshops during the hospital checkup. Telephone Contact by the APA educator at 6 months. One-year medical visit.
2434182|NCT03337412|Experimental|Employees|"initial assessment of physical capacities, participation in 10 to 20 physical activity workshops over 6 months on working time, then employees oriented towards autonomous activities over the following 6 months.~Evaluation by computer-filled questionnaires."
3147729|NCT00130910|Experimental|1|Albendazole
3147730|NCT00130910|Placebo Comparator|2|
2434185|NCT03337386|Experimental|Inferior Vena Cava Collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
2434186|NCT03337386|Experimental|Subclavian Vein Collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
2434187|NCT03337386|Active Comparator|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
2434188|NCT03337373|Experimental|Cisatracurium|Patients who require paralysis with cisatracurium as part of their clinical care in ICU
2434189|NCT03337360|Active Comparator|Impryl|One tablet daily for 6 months
2434190|NCT03337360|Placebo Comparator|Placebo|One tablet daily for 6 months
2434191|NCT03337334|Other|Non-Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 2 mA peak amplitude (reduced if not uncomfortable). One 5*5 cm2 square patch electrodes are placed over the Motor cortex and the Prefrontal cortex respectively and a common return electrode of 10*10 cm2 over the ankle. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Prefrontal cortex stimulation and No stimulation. By the end of each session we get 4 min of Motor Cortex stimulation, 4 min of Prefrontal Cortex stimulation and 4 min of No stimulation.
2434192|NCT03337334|Other|Focused stimulation|Stimulation frequency is set similar to that of the tremor and the amplitude is set up to 5 mA peak amplitude (with the help of local anesthetic cream and amplitude is reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex and the occipital cortex respectively. Each subject follows three sessions of 12 min length each. During each session the tremor is measured while interleaving between Motor cortex stimulation, Occipital cortex stimulation and No stimulation. By the end of each session we get 3 min of Motor Cortex stimulation, 3 min of occipital Cortex stimulation and 6 min of No stimulation.
2434193|NCT03337321||ETvalid|Pregnant women attending maternal care services and having access to computational device
2434198|NCT03337295||Low-MGD|
2434199|NCT03337295||High-MGD|
2434200|NCT03337282||Observational cohort|Adults 70 years of age or older undergoing major noncardiac surgery under protocolized general anesthesia
3147731|NCT00131014||Next of Kin of deceased subj by lymphoma|Next of Kin of deceased subject by lymphoma
3147732|NCT00131014||Subject unaffected by lymphoma|Subject unaffected by lymphoma
3147733|NCT00131014||Subject affected by lymphoma|Subject affected by lymphoma
3147734|NCT00131027|Experimental|A|HD-MTX
3147735|NCT00131027|Active Comparator|B|ID-MTX
3147736|NCT00131053|Experimental|A|
3147737|NCT00131079|Experimental|PEPAF|General Practitioner's assessment of physical activity level and minimal advice in routine clinical practice supplemented by physical activity prescription to those who accepted an additional 15 minutes appointment.
3147738|NCT00131079|Active Comparator|Control|
3147739|NCT00131131|Experimental|Exercise|The intervention was an exercise program of moderate to vigorous intensity. The intervention started with 30-minute sessions three times per week, with the ultimate goal to have participants exercise four to five times per week for 45 to 60 minutes per session.
3147740|NCT00131131|No Intervention|Control|Women in the control group did not attend instructional sessions with the exercise interventionist and did not receive the motivational mailings
3147741|NCT00131144|Experimental|Octreotide Acetate in Microspheres 20 mg|20 mg will be administered im once every 4 weeks
3147742|NCT00131144|Experimental|Octreotide Acetate in Microspheres 30 mg|30 mg will be administered im once every 4 weeks
3147743|NCT00131144|Placebo Comparator|Placebo|
3147744|NCT00131235|Placebo Comparator|Control|Standard antenatal care as described in intervention
3147745|NCT00131235|Experimental|Monthly SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine, as described in intervention
3147746|NCT00131235|Experimental|AZI-SP|Standard antenatal care + monthly intermittent presumptive treatment of malaria with sulfadoxine pyrimethamine + two presumptive treatments of sexually transmitted infections and malaria with azithromycin, as described in intervention
2434201|NCT03337269|Other|Control|Subject does not receive an educational intervention
2434202|NCT03337269|Other|Educational video|Subject watches an educational video
2434203|NCT03337269|Other|Educational handout|Subject reads an educational handout
2434204|NCT03337256|Experimental|GI bleeding score|Early endoscopy in emergency department + other clinical parameters
2434205|NCT03337243|Experimental|HAM and HUMCWJ Injections (Group 1)|Participants who self-select into the Group 1 (Immediate Treatment) will be scheduled to undergo the HAM and HUMCWJ injections to the OA affected knee at the same visit.
2434206|NCT03337243|No Intervention|Control (Group 2)|Participants who self-select into Group 2 will choose to delay their HAM and HUMCWJ injection to the OA affected knee for at least 3 months or choose not to have the injections at all. Participants will be asked to keep track of pain management and therapy throughout the 3 months.
2434207|NCT03337230|Experimental|Physical Activity + Diet + Social media|Educational materials for the proposed study will be delivered via a secret social media Facebook group. These materials will promote simple, attainable forms of Physical Activity and lasting diet changes. A study moderator will deliver weekly communications to the Facebook group providing intervention content including social support, social competition and comparison, and social rewards
2434208|NCT03337217|Experimental|Prone Position|Position during colonoscopy
2434209|NCT03337217|Active Comparator|Left lateral decubitus position|Position during colonoscopy
2434210|NCT03337204|Experimental|Engaged4Life|"Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later); and 2) a one-time, 3hr workshop and peer mentoring (via phone 2X/week for 3 weeks). The workshop includes psychoeducation on the relationship between active engagement and health and well-being and a goal setting activity focused on carefully assessing and then make improvements upon existing activity portfolios. Peer mentors provide support as participants implement their goals."
2434211|NCT03337204|Active Comparator|Technology-assisted self-monitoring only|Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
2434212|NCT03337191|Active Comparator|ultrasound guided caudal block|Caudal block was performed by ultrasound guided with %0,125 levobupivacaine + 10 mq/kg morphine
2434213|NCT03337191|Active Comparator|conventional caudal block|Caudal block was performed by conventional method with %0,125 levobupivacaine + 10 mq/kg morphine
2434214|NCT03337178|No Intervention|Control|Standard of care
2434215|NCT03337178|Experimental|Blinded Fitbit|Blinded Fitbit, no step goal, and no activity feedback
2434216|NCT03337178|Experimental|Fitbit|Fitbit plus step goal and activity feedback
2434217|NCT03337165|Experimental|tolerogenic dendritic cells|Each dose of autologous monocyte-derived dendritic cells generated in the presence of IFN-α/GM-CSF and tolerized with Dexamethasone (1x106, 3x106, 5x106, 8x106 and 10x106 cells in 2.0 mL sodium chloride 0.9% solution) will be administered in RA patients through intra-articular injection (into the knee joint).
3147747|NCT00131391|Placebo Comparator|Phase A/B; Arm 1|Phase A: Arm 1: MK0364 Pbo capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 1: MK0364 Pbo capsule once daily.
3147748|NCT00131391|Experimental|Phase A/B: Arm 2|Phase A: Arm 2: MK0364 4 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 2: MK0364 4 mg capsule once daily.
3188121|NCT00763724||3|SSRI
3188122|NCT00763724||4|TCA
2434222|NCT03337126|Active Comparator|Fasting Condition|Single dose of ATI-1501(oral suspension) administered under fasting conditions; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
2434223|NCT03337126|Active Comparator|Fed Condition|Single dose of ATI-1501(oral suspension) administered under fed condition; BioAvailability and PK parameters will be measured and analyzed. These parameters will be compared to the BA and PK parameters measured after administration of a single Metronidazole Tablet
2434224|NCT03337113|Experimental|WMT + rTMS|WMT + rTMS is the Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. Both conditions are active.
2434225|NCT03337113|Active Comparator|Sham WMT + rTMS|Sham WMT + rTMS is the sham Working Memory Training + repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of rTMS. WMT is inactive.
2434226|NCT03337113|Active Comparator|WMT + sham rTMS|WMT + sham rTMS is the Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. This condition isolates the effects of WMT. rTMS is inactive.
2434227|NCT03337113|Sham Comparator|Sham WMT + sham rTMS|sham WMT + sham rTMS is the sham Working Memory Training + sham repetitive Transcranial Magnetic Stimulation arm. Both are inactive in this arm.
2434228|NCT03337100|Experimental|Co-Dispensing|Early implementation of a naloxone co-dispensing pharmacy program. Pharmacies in the phase 1 (early) naloxone co-dispensing arm will be assigned to implement the pharmacy based naloxone co-dispensing program first relative to the phase 2 arm.
2434229|NCT03337100|No Intervention|Usual Care|"Usual care/Phase 2 naloxone co-dispensing:~Pharmacies in the usual care/phase 2 naloxone co-dispensing arm will provide usual pharmacy services to patients receiving chronic opioid therapy (no naloxone co-dispensing). After 10 months, they may implement the pharmacy-based naloxone co-dispensing program."
2434305|NCT03336580|Experimental|PRX004|"Dose escalation in up to 6 dose levels~Expansion of previously studied cohort(s) from Dose Escalation~Extended dosing at RP2D"
3188123|NCT00763724||5|Multiple Antidepressants
3188124|NCT00763724||6|Depressed (not antidepressant treated)
3188125|NCT00763724||7|General population
3188126|NCT00763737|Experimental|FETO|prenatal FETO at 30-31+6 weeks and removal at 34-34+6 wks, followed by standardized postnatal care
3188127|NCT00763737|No Intervention|Expectant management|expectant management during pregnancy followed by standardized neonatal care
2434230|NCT03337087|Experimental|Treatment (nal-IRI, leucovorin, fluorouracil, rucaparib)|Patients receive liposomal irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV over 46 hours on days 1 and 15. Patients also receive rucaparib PO BID on days 4-13 and 18-27. Cycles repeat every 28 days in the absence of disease progression or unaccepted toxicity.
2434231|NCT03337074||Sperm Epigenome arm/healthy men|Men with no significant health problems.
2434232|NCT03337074||Sperm Epigenome arm/cholestatic men|Men with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis.
2434233|NCT03337074||Outcomes arm/Cholestatic fathers|Fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after the conception of their child who is now aged 16 - 25 years of age.
2434234|NCT03337074||Outcomes arm/Children of cholestatic fathers|16 - 25 years-old children of fathers who were diagnosed with a cholestatic liver condition including but not restricted to Primary Sclerosing Cholangitis and Primary Biliary Cholangitis either before or after their conception.
2434235|NCT03337061|Experimental|Experimental (Mindfulness)|This arm will receive mindfulness-based interventions through a mobile application
2434236|NCT03337061|No Intervention|Control (Sleep Advice)|This is the control arm that will receive usual care
2434237|NCT03337048|Experimental|Measurement of endpoints|"In healthy volunteers the endpoint are measured while spontaneous voiding of the bladder and while emptying the bladder using a standard intermittent catheter (SpeediCath).~In subjects with spinal cord injury or enlarged prostata the endpoint are measured while emptying the bladder using a standard intermittent catheter."
2434238|NCT03337035|Active Comparator|oral probiotics and oxytocin spray|Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
2434239|NCT03337035|Placebo Comparator|oral placebo and oxytocin spray|Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
2434240|NCT03337022|Experimental|CC-90006; Dose level 1|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2434241|NCT03337022|Experimental|CC-90006; Dose level 2|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2434242|NCT03337022|Experimental|CC-90006; Dose level 3|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2434243|NCT03337022|Experimental|CC-90006; Dose level 4|CC-90006 will be administered subcutaneously (SC) on days 1, 15, and 29.
2434244|NCT03337022|Placebo Comparator|Placebo|Placebo (saline) will be administered subcutaneously (SC) on days 1, 15, and 29.
2434245|NCT03337009|Experimental|Naloxone Navigator|"Targeted, web-based animated video (Naloxone Navigator [NN]):~This arm is a web-based intervention targeted to patients receiving chronic opioid therapy identified in the electronic health record. Participants in this arm have access to naloxone under standing orders from the pharmacy or with a prescription from their providers."
2434246|NCT03337009|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and clinicians. As part of usual care, participants can access naloxone through physician prescription or standing orders.
2434247|NCT03336996|Experimental|evaluation|To characterize and evaluate functional and anatomical changes of nerve fiber injuries after umbilical cord mesenchymal stem cells transplantation with BOLD drived-DTI
2434248|NCT03336996|Experimental|BOLD-fMRI and DTI|To determine the therapeutic efficiency of umbilical cord mesenchymal stem cells and also the utility of the integration of BOLD-fMRI and DTI.
2434249|NCT03336996|Experimental|correlate the imaging results|To correlate the imaging results with the electrophysiology outcomes
2434250|NCT03336983|Other|LHRH-A + Enzalutamide|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide until patient's progression, consent withdrawal or unacceptable toxicity
2434251|NCT03336983|Experimental|LHRH-A + Enzalutamide + Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide + Zoledronic Acid until patient's progression, consent withdrawal or unacceptable toxicity
2434252|NCT03336970|Active Comparator|Single visit root canal treatment|The teeth were treated in single-visit (SV) root canal treatment. Final root canal irrigation was performed with 5% EDTA, followed by 2.5% NaOCl and received an additional final rinse with 2% CHX before obturation.
2434253|NCT03336970|Active Comparator|Multiple visit root canal treatment|The teeth were treated in multiple visit (MV) root canal treatment. After completion of root canal instrumentation, calcium hydroxide paste was placed into the root canal. In second visit, all root canals were irrigated with 5% EDTA followed by 2.5% NaOCl before obturation.
2434254|NCT03336957|Experimental|Pregnant group|Test group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
2434255|NCT03336957|Active Comparator|Non-Pregnant|Control group, non-surgical periodontal therapy (NPT) consisted of scaling and oral hygiene instruction was applied. IL- 1β AND IL-10 in the GCF and Cg A in saliva samples were taken before and after periodontal treatment.
2434257|NCT03336918||Bipolar Disorder I or II Depressed|DSM-V Bipolar I or II Depressed treated with lithium
2434258|NCT03336918||Healthy Controls|Healthy Controls with no psychiatric history
2434259|NCT03336905|Experimental|Physical Activity and Prevention|"co-construction of supervised and non-supervised physical activity sessions with a physical activity trainer~balance sheet (at diagnosis and 4 monthes+/- 2 months later) : IPAQ, QLQC30, 6-min walk test, anthropometric evaluation~meetings and phone calls after the physical activity program to assess patient perception and satisfaction, and provide information and recommendations for cancer prevention"
2434260|NCT03336892|Experimental|Intervention|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
2434261|NCT03336892|No Intervention|Control|Enhanced usual care with written mental health resources and system navigation information.
2434262|NCT03336879|Experimental|Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2434263|NCT03336866|Placebo Comparator|Placebo|Normal saline
2434264|NCT03336866|Experimental|IXT-m200|Single 6 or 20 mg/kg intravenous dose of IXT-m200
3188128|NCT00763763|Experimental|1|imatinib in combination with chemotherapy by vincristin and dexamethasone
3188129|NCT00763776|Other|1|Liver transection by clamp crushing technique
2434267|NCT03336840|Experimental|Metformin|
2434268|NCT03336840|Experimental|Probiotics|
2434269|NCT03336840|Experimental|Metformin and Probiotics|
2434270|NCT03336827|Other|Experimental Group|Patients include in the experimental group (EG) will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will resort to usual care only after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
2434271|NCT03336827|Other|Waiting-List Control Group|Patients include in the waiting-list control group (CG) will resort to usual care only after the first assessment (T1) (i.e., before the second assessment taking place 4 months later (T2)). They will receive one individual pre-group session and 8 sessions of group intervention combining cognitive-behavioral therapy and hypnosis after the second assessment (T2) (i.e., before the third assessment taking place 4 months later (T3)).
2434272|NCT03336814|Experimental|terlipressin associated with norepinephrine|
2434273|NCT03336814|Placebo Comparator|placebo (physiologic serum) associated with norepinephrine|
2434274|NCT03336801|Active Comparator|Sevoflurane|Intervention Back surgery and sevoflurane.
2434275|NCT03336801|Active Comparator|Propofol|Intervention Back surgery and propofol.
2434276|NCT03336788|Placebo Comparator|TMS|
2434277|NCT03336788|Active Comparator|TMS with virtual reali|
2434278|NCT03336775|Experimental|acupuncture|Patients receive acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks). These patients also received corticosteroid for 4 weeks, methylprednisolone 80mg ivdrip. for 3 days, 60mg ivdrip. for 3 days, 40mg ivdrip. for 3 days, 30mg po. for 7 days, 20mg po. for 7 days, 10mg po. for 5 days and maintain.
2434279|NCT03336775|No Intervention|control|Patients receive no acupuncture. The use of corticosteroid is the same with Arm I.
2434280|NCT03336749|Experimental|Sensory group|Sensory re-learning in combination with task-specific training
2434281|NCT03336749|Active Comparator|Control group|Traditional task-specific training
2434282|NCT03336736||Pulmonary Sarcoidosis|"Self-reported and self-referred self-reported medically diagnosed pulmonary sarcoidosis.~Exercise capacity and function will be assessed."
2434283|NCT03336736||Control|Healthy age-matched control group with no known lung disease. Exercise capacity and function will be assessed.
2434284|NCT03336723|Experimental|Experimental Group|Two piece zirconia dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
2434285|NCT03336723|Active Comparator|Control Group|Two piece titanium dental implants place subcrestally with a healing abutment at baseline (T0) and rehabilitated with a zirconia dental crown T3 3 Measures on the IL1b and IL6 at T0 baseline , T2 2 month and T3 at crown placement.Microbiological samples at T2 and T3.
2434286|NCT03336710||Primary sample|Community sample of adults (18-65) from the greater Buffalo, NY region, oversampling people who are seeking mental health treatment.
2434287|NCT03336697||Parkinson's disease subjects|Patients with untreated or treated Parkinson's disease ages 45-75.
2434288|NCT03336697||Healthy control subjects|Healthy control subjects ages 45-75.
2434289|NCT03336684|Experimental|Patient Education Group|Patients will be provided with disease education literature
2434290|NCT03336684|No Intervention|Normal Group|Patients will not be provided with disease education literature
3147749|NCT00131391|Experimental|Phase A/B: Arm 3|Phase A: Arm 3: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 3: MK0364 Pbo capsule once daily.
3188130|NCT00763776|Other|2|Liver transection by the ultrasonic dissector
3188131|NCT00763789|Experimental|1|Local anaesthesia and remifentanil sedation
2434294|NCT03336632|Experimental|Chidamide|Chidamide, tablets, 5 mg/tablet, 20 mg orally twice weekly from D-7~+14 Cyclophosphamide: 50 mg/Kg intravenously D+3, +4 Cyclosporine A: intravenously then orally 3 mg/Kg D+5~D+100
2434295|NCT03336619|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
2434296|NCT03336619|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
2434297|NCT03336606|Active Comparator|Cohort I|MEDI0562 administration (90mg on day 1) followed by surgical resection (day 15)
2434298|NCT03336606|Active Comparator|Cohort II|MEDI0562 administration (30mg on days 1, 3, 5) followed by surgical resection (day 15)
2434299|NCT03336593|Experimental|QIV batch 1|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 1
2434300|NCT03336593|Experimental|QIV batch 2|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 2
2434301|NCT03336593|Experimental|QIV batch 3|1 dose of 0.5 ml of quadrivalent influenza vaccine batch 3
2434302|NCT03336593|Active Comparator|Trivalent Influenza Vaccine|1 dose of 0.5 ml of trivalent influenza vaccine
2434303|NCT03336593|Experimental|QIV (subjects 6-35 months)|2 dose of 0.25 ml of quadrivalent influenza vaccine
2434304|NCT03336593|Experimental|QIV (subjects 3-8 years)|2 dose of 0.5 ml of quadrivalent influenza vaccine
3188132|NCT00763789|Other|2|Total intravenous anaesthesia
3188133|NCT00763802||MNPDR|Type 2 diabetic patients with Mild non-prolipherative retinopathy.
2434306|NCT03336567||Subjects with hematological malignancies|It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
2434307|NCT03336567||Subjects with NSCLC or soft-tissue sarcoma|It will Include subjects with NSCLC on second or later-line therapy or soft-tissue sarcoma on second or later line therapy. Subjects will undergo a telephonic interview for up to 90 minutes.
2434308|NCT03336567||Oncologists from academic centers with CGT experience|It will include oncologists using TCR therapies, CAR-T or participating in CAR-T or TCR therapy clinical trials. Oncologists will undergo a telephonic interview for up to 60 minutes.
2434309|NCT03336567||Oncologists from community clinics|It will include oncologists from community clinics who evaluate, prescribe, treat, and actively interact with subjects with NSCLC or soft tissue sarcoma, who have used immuno-oncology (IO) therapies. Oncologists will undergo a telephonic interview for up to 60 minutes.
2434310|NCT03336554||observation group|One group of participants are under observation. This trial has two phase. Phase I: 40 participants will be enrolled. Only if epigenetic cfDNA library has been built, investigators would move on to Phase II. Another 60 participants will be enrolled for further analysis.
2434313|NCT03336528|Experimental|Degludec inpatient|Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as a basal bolus regimen with degludec once daily plus rapid-acting aspart insulin before meals. Degludec insulin 100 Units/mL, average dose: 30-45 U/day. aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day.
2434314|NCT03336528|Active Comparator|Glargine U100 inpatient|"Study participants treated with insulin prior to admission will receive 80% or 100% of the total daily dose (TDD) given as basal bolus regimen with glargine once daily plus rapid-acting aspart insulin before meals. Glargine (U-100) insulin 100 Units/mL, average dose: 30-45 U/day.~Aspart (U-100) insulin 100 Units/mL, average dose: 20-30 U/day."
2434315|NCT03336528|Experimental|Degludec post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in the degludec inpatient arm will be invited to participate in the prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus degludec once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with degludec and aspart insulin before meals.
2434316|NCT03336528|Active Comparator|Glargine U100 post-discharge|Patients with poorly controlled diabetes (HbA1c >7.5%) enrolled in glargine inpatient arm will be invited to participate in this open label prospective outpatient study. At hospital discharge, patients will be treated following an HbA1c based algorithm for a total duration of the outpatient follow-up of 3 months. Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus glargine once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with glargine and aspart insulin before meals.
2434317|NCT03336515|Other|Group A-General Recommendation|General recommendation not sleeping in supine position without the postural device
2434318|NCT03336515|Placebo Comparator|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
2434319|NCT03336515|Experimental|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
3188134|NCT00763828|Experimental|ThermoSuit-Induced Patient Cooling|The Life Recovery Systems ThermoSuit System will be used to cool STEMI patients under conditions of conscious sedation.
2434321|NCT03336476|Experimental|Videolaryngoscopy|Videolaryngoscopy the trachea will be intubated using a videolaringoscope
2434322|NCT03336476|Active Comparator|Direct laryngoscopy|Direct laringoscopy the trachea will be intubated using a laringoscope
2434323|NCT03336463||Controls|No intervention
2434324|NCT03336463||Cases|No intervention
3188135|NCT00763841|Experimental|1|Stimulation will be given daily at a particular site for three days a week
2434326|NCT03336437|Active Comparator|Estrogen Vaginal Ring|At the time of initial study visit, a estrogen vaginal ring (Estring) will be placed. Participants will retain this ring for 12 weeks.
2434327|NCT03336437|Placebo Comparator|Inactive Vaginal Placebo Ring|At the time of initial study visit, a placebo vaginal ring will be placed. Participants will retain this ring for 12 weeks.
2434328|NCT03336424|Experimental|Non-invasive investigations group|Non-invasive investigations include: ultrasound, blood exam, urine analysis and culture, uroflowmetry
2434329|NCT03336424|Experimental|Invasive investigations group|urodynamic study including: cystomanometry, pressure flow study, EMG
2434330|NCT03336411|Active Comparator|mHealth|
2434331|NCT03336411|Experimental|Personalized mHealth|
2434332|NCT03336398|Experimental|Tinnitus Distressed Patients|Tinnitus distressed patients are patients who experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
2434333|NCT03336398|Experimental|Tinnitus Patients|Tinnitus patients are patients who do not experience symptoms of anxiety or depression with tinnitus. This group will receive both 0.5 mg/kg ketamine hydrochloride in saline and placebo, saline, with Magnetic Resonance Spectroscopy scans and audiometry testing and scales.
2434334|NCT03336385|Placebo Comparator|Placebo|Maltodextrin 12 gram used as placebo
2434335|NCT03336385|Active Comparator|Naxus|Naxus contains the wheat-derived prebiotic fibre Arabinoxylan
2434336|NCT03336385|Active Comparator|Oatwell|Oatwell contains an oat-derived prebiotic beta-glucan fibre
2434337|NCT03336372|Experimental|Picato topical gel|
3188136|NCT00763841|Sham Comparator|2|
3188137|NCT00763880|Experimental|Lidocaine|Subjects randomly assigned to this arm will receive 2% lidocaine by injection into their fracture site in the form of a hematoma block.
2434338|NCT03336359|Active Comparator|LCI|Tandem colonoscopy with Linked Color Imaging system
2434339|NCT03336359|Active Comparator|NBI|Tandem colonoscopy with Narrow band imaging system
2434340|NCT03336346||DTG group|Reproductive-aged HIV-infected women taking dolutegravir-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
2434341|NCT03336346||No ART group|Reproductive-aged HIV-uninfected women using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
2434342|NCT03336346||EFV group|Reproductive-aged HIV-infected women taking efavirenz-based ART and using single-rod, etonogestrel-releasing, subdermal implant (ENG implant)
3147750|NCT00131391|Experimental|Phase A/B: Arm 4|Phase A: Arm 4: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 4: MK0364 2 mg capsule once daily.
3147751|NCT00131391|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 5: MK0364 4 mg capsule once daily.
3147752|NCT00131391|Experimental|Phase A/B: Arm 6|Phase A: Arm 6: MK0364 6 mg once daily. Phase B: Patients who continue into Part B will remain in the same treatment arm they were assigned to in Part A and will receive the following: Arm 6: MK0364 6 mg capsule once daily.
3147753|NCT00131404|Placebo Comparator|Phase A/B: Arm 1|"Phase A: Arm 1: MK0364 Pbo capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 1: MK0364 Pbo capsule once daily."
2434349|NCT03336320|Experimental|Multidomain Intervention Group|Home-based multidomain intervention composed of nutritional counselling, exercise (balance, gait, , and cognitive training provided using ICT solutions. A web platform, containing information, questionnaires, videos, games, and tests related to each one of the three components of the multidomain intervention will be made available to participants in this group.
2434350|NCT03336320|Active Comparator|Control Group|"Participants from CG will also be equipped with wrist worn accelerometers (that will record daily activity data continuously) but contrary to MIG, participants won't have access to the password encrypted application, and therefore, to the multidomain intervention. However, they will be able to access the study website with overall information on the eMIND study and links to the website of health authorities (such as http://www.mangerbouger.fr/PNNS or the World Health Organization http://www.who.int/topics/ageing/fr/) regarding healthy ageing topics. Plus, in order to control for the social aspect of MIG, participants in CG will receive monthly phone calls from the research team."
2434351|NCT03336307||Patients with Parkinson's disease|"All participants could walk independently without walking devices. All patients were taking oral administrations of levodopa (18 patients), dopamine agonists (5 patients), or both (13 patients) and were recorded in on phase. Medication was kept constant throughout the trial, and all interventions were performed at the same time of day for each patient during ON phase.~Severity of parkinsonism was evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS-II and III) and the Hoehn and Yahr staging system.~All patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease"
2434352|NCT03336294|Other|Old group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
2434353|NCT03336294|Other|Young group|Subjects involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
2434354|NCT03336281||Participants with Psoriatic Arthritis: Dermatologist Cohort|Participants who will receive ustekinumab (as a first or second line of biologic disease modifying anti-rheumatic drug [bDMARD] therapy) along with other co-medications as per clinical dematologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) Patient-Reported Outcome (PRO) data from participants participating in this study.
2434355|NCT03336281||Participants with Psoriatic Arthritis: Rheumatologist Cohort|Participants who will receive ustekinumab (as a first or second line of bDMARD therapy) along with other co-medications as per clinical rheumatologist's discretion will be observed in this study. Ustekinumab will not be provided by the sponsor. The treatment by ustekinumab must have been decided by the physician prior to the decision to include the participant in the study. Only data available from a participant's source medical records will be collected. Additionally investigators will be asked to obtain (or record where available) PRO data from participants participating in this study.
2434356|NCT03336268|Experimental|POINT|This arm will be offered both POINT services (in addition to standard emergency care) and enrollment in study data collection. If they choose to enroll in POINT, they may choose whether or not to enroll in data collection, as it is not required. Should they enroll in data collection, they will be consented and enrolled in the research study as a participant in the POINT study arm.
2434357|NCT03336268|No Intervention|Standard Care|This arm will only be offered enrollment in study data collection, as they will receive standard emergency care. If they choose to enroll, they will be consented in the research study as the Standard Care arm.
2434358|NCT03336255|No Intervention|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
2434359|NCT03336255|Experimental|SAHELI Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 16 to 20 participants who will attend 16 weekly, 90 minute group education sessions at Metropolitan Asian Family Services or Skokie Health Department. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management.
2434360|NCT03336242|Experimental|Cohort 1: Cannabidiol Oral Solution 20 mg/kg/day|Treatment Period: Cannabidiol Oral Solution 20 milligrams per kilogram per day (mg/kg/day) divided twice daily (BID) for 4 weeks.
2434361|NCT03336242|Experimental|Cohort 2: Cannabidiol Oral Solution 30 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 30 mg/kg/day divided BID for 4 weeks."
2434405|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 6|
2434362|NCT03336242|Experimental|Cohort 3: Cannabidiol Oral Solution 40 mg/kg/day|"Titration Period: Cannabidiol Oral Solution 20 mg/kg/day divided BID for 5 days, followed by 30 mg/kg/day divided BID for 5 days.~Treatment Period: Cannabidiol Oral Solution 40 mg/kg/day divided BID for 4 weeks."
2434363|NCT03336229|Active Comparator|Intervention|
2434364|NCT03336229|No Intervention|Control|
3147754|NCT00131404|Experimental|Phase A/B: Arm 2|"Phase A: Arm 2: MK0364 2 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 2: MK0364 2 mg capsule once daily."
2434372|NCT03336164|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage sold in the same campus university restaurant after the control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
2434373|NCT03336151|Experimental|Front-of-pack labelling Nutri-Score|"Introduction of the Nutri-Score front-of-pack nutrition label on every food and beverage in the campus cafeteria after a control period without food labelling.~The implementation of the label is accompanied by a communication campaign towards students in the form of posters and leaflets."
2434374|NCT03336138|Active Comparator|AMA group|Patient with telephone follow-up modality called AMA (Assistance for ambulatory patients)
2434375|NCT03336138|No Intervention|Control group|Patient with standard follow-up with no specific assistance for ambulatory patients
2434376|NCT03336125|Experimental|Vitamin D group|Intervention is vitamin D supplement
2434377|NCT03336125|Placebo Comparator|Control group|Placebo capsule contains olive oil
3188138|NCT00763880|Placebo Comparator|Normal Saline|Subjects randomly assigned to this arm will receive normal saline by injection into their fracture site
3188139|NCT00763893|Placebo Comparator|A: Placebo|placebo
2434380|NCT03336099|Experimental|Spa Treatment|Bicarbonate and sulfurated water cares in Vals-les-Bains thermal cure center, massage, cataplasm.
2434381|NCT03336086|Other|experimental|This group underwent a weight loss program
2434382|NCT03336086|No Intervention|control|This group underwent adlibitum diet + physical activity
2434383|NCT03336073|Experimental|carfilzomib, dexamethasone and cyclophosphamide|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles
2434384|NCT03336073|Active Comparator|carfilzomib and dexamethasone|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles
2434385|NCT03336060||Healthy Control|Age matched healthy subjects. Inclusion criteria for healthy controls are: male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication
2434386|NCT03336060||Subjects with ACL reconstruction|"Unilateral, primary anterior cruciate ligament tear and reconstruction (1 to 10 years ago); no serious concomitant injuries, e.g. unhappy triad); no kinesiophobia; symmetric single leg jump performance (>85 %); male (18 - 40 years, right-handed); sportive (preferably ball game sports, e.g. soccer); no acute injury or life-quality impairing diseases; no medication"
2434387|NCT03336047|Active Comparator|10,000 steps daily|Subjects will be encouraged to obtain 10 000 steps a day, monitored by a step counter (fit bit zip)
2434388|NCT03336047|Experimental|using personal activity intelligence|Subjects will be encouraged to obtain 100 PAI points per week, monitored by Mio Slice and the Mio Pai 2.0 smart phone application
2434389|NCT03336034||IBS-C|Constipation-predominant irritable bowel syndrome
2434390|NCT03336021|Experimental|Intervention|FAS program
2434391|NCT03336021|No Intervention|Comparison|Comparison group
2434392|NCT03335982|Other|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia. The feasibility, safety, success rate, and satisfaction with TET placement were evaluated for enteral nutrition or fecal microbiota transplantation.
2434393|NCT03335969|Experimental|pre colon irrigation diaries followed by post diaries|4 week bowel movement and rescue medication diaries will be compared to same diaries used 4 weeks after the colon irrigation procedure
2434394|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 1|
2434395|NCT03335956|Experimental|SAD Part 1 Active Cohort Period 1|
2434396|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 2|
2434397|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 2|
2434398|NCT03335956|Placebo Comparator|SAD Part 1 Placebo Cohort 1 Period 3|
2434399|NCT03335956|Experimental|SAD Part 1 Active Cohort 1 Period 3|
2434400|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 4|
2434401|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 4|
2434402|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 5|
2434403|NCT03335956|Experimental|SAD Part 2 Active Cohort 2 Period 5|
2434404|NCT03335956|Placebo Comparator|SAD Part 2 Placebo Cohort 2 Period 6|
2434414|NCT03335943|Experimental|CDA-2 (Cell Differentiation Agent 2)|Patients will be given CDA-2 therapy.
2434415|NCT03335930|Experimental|Morning exercise|To exercise at morning (08:00-10:00)
2434416|NCT03335930|Active Comparator|Afternoon exercise|To exercise at afternoon (14:00-16:00)
2434417|NCT03335930|Active Comparator|Evening exercise|To exercise at evening (18:00-20:00)
2434418|NCT03335917|Placebo Comparator|Normobaric Normoxia|This will serve as the exercise only control trial
2434419|NCT03335917|Experimental|Normobaric Hypoxia|This arm will provide hypoxia by reducing the amount of oxygen concentration without changing the barometric pressure
2434420|NCT03335917|Experimental|Hypobaric Hypoxia|This arm will provide hypoxia by reducing the barometric pressure without changing the oxygen concentration (terrestrial altitude exposure)
2434421|NCT03335904|Placebo Comparator|Placebo|Participants will ingest microcrystalline cellulose by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
2434422|NCT03335904|Experimental|Losartan|Participants will ingest 50 mg of losartan, an angiotensin receptor blocker, by mouth on two consecutive days. The first tablet will be consumed on day 1 at 0700 hrs. The second tablet will be consumed at 1900 hrs and the final tablet will be consumed at 0700hrs on day 2. Participants will undergo a Hyperoxic Hypercapnic Ventilatory Response Test, a Hypoxic Hypercapnic Ventilatory Response Test, and Repeated Hypoxic Apneas before and after a Hypoxic Sleep Study.
2434423|NCT03335891|Experimental|Training Group|Asthma Education Program Breathing Exercises Core Stabilization Exercises
2434424|NCT03335891|Active Comparator|Control Group|Asthma Education Program Breathing Exercises
2434425|NCT03335878||Type 1 Diabetes Mellitus Group|T1DM Group - 150 otherwise healthy children, ages 4-16 years old, diagnosed with T1DM within 3 months prior to their initial study visit. This is not a treatment study therefore there is no intervention in this study.
2434426|NCT03335878||Healthy Control Sibling Group|Sibling Control Group - 50 age and gender matched healthy siblings without a diagnosis of T1DM. This is not a treatment study therefore there is no intervention in this study.
2434427|NCT03335852|Experimental|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
2434428|NCT03335839|Experimental|Intracoronary tPA 10 mg|
2434429|NCT03335839|Experimental|Intracoronary tPA 20 mg|
2434430|NCT03335839|Placebo Comparator|Placebo|saline
2434431|NCT03335826|Experimental|Combined epidural-general anesthesia|Patients assigned to this group receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
2434432|NCT03335826|Active Comparator|General anesthesia|Patients assigned to this group receive general anesthesia and postoperative patient-controlled intravenous analgesia.
2434433|NCT03335813|Experimental|brachytherapy with multichannel balloon applicator|6 channel balloon re-positioning, multichannel brachytherapy applicator used to deliver localized radiation therapy to esophageal tumors
3188140|NCT00763893|Active Comparator|B: Losartan|Losartan
2434435|NCT03335787|Experimental|Intervention|Taping will be applied three times and will be reapplied one and two weeks later prior to first application for two weeks.
2434436|NCT03335787|Other|Control|Control group would not receive any taping in order to prevent sham taping sensory stimulation effect.
2434437|NCT03335774|Active Comparator|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
2434438|NCT03335774|Placebo Comparator|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
3188141|NCT00763906|Placebo Comparator|1|Patients were assigned to norepinephrine infused at the clinician's discretion.
3188142|NCT00763906|Active Comparator|2|Patients were assigned to norepinephrine infused under computerized fuzzy logic control.
3188143|NCT00763932|Experimental|1|
2434442|NCT03335748|Active Comparator|active control group|The program for the active control group is the same as for the experimental group, except that the degree of difficulty of the exercises remains low and invariable across trials, with three items needing to be recalled throughout.
2434443|NCT03335748|Experimental|the Cogmed program|12 exercises proposed in the Cogmed program. Eight of these target visuospatial WM and four target verbal WM. Eight exercises are preprogrammed for each session, for a total of 90 trials (Pearsons, 2014). The degree of difficulty of the trials increases as a function of the participant's performance. For each trial, the participant receives feedback on their performance.
2434444|NCT03335735|Experimental|Loss-Framed Text Messages|Loss-framed text message
2434445|NCT03335735|No Intervention|Control|Participants in this arm will not receive any intervention.
2434446|NCT03335735|Experimental|Gain-Framed Messaging Group|Gain-framed text message
2434447|NCT03335722|Active Comparator|Active TDCS and Fluency Intervention|Participants will receive 1-milliamp (mA) tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes a day for five consecutive days. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
2434448|NCT03335722|Sham Comparator|Sham TDCS and Fluency Intervention|Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes a day for five consecutive days. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session. he stimulation will be applied for the first half of a 40-minute speech fluency training paradigm, using metronome-timed speech.
2434588|NCT03334864||I Retrospective cohort|Diagnosis of advanced non-small cell lung cancer from 2012-2016
2434589|NCT03334864||II Prospective cohort|Advanced non-small cell lung cancer with driver gene mutations
3188144|NCT00763945||1|Patients representing to the hospital with acute coronary syndrome
2434449|NCT03335709|Experimental|ADL intervention|The participants are assigned to an eight-week intervention program aiming at enhancing ADL ability. The program consists of a minimum of five and a maximum of eight sessions; Session one - First meeting and occupational therapy evaluation (mandatory), Session two - Goal setting and clarifying reasons for problems related to ADL (mandatory), Session three- seven - Interventions aiming at enhancing ADL ability (Number of sessions can vary. However, a minimum of two sessions are mandatory), Session eight - Re-evaluation (Mandatory)
2434450|NCT03335683|Experimental|Phytoterapy agent|Subjects were allocated to receive 1 h and 12 h after surgery: group 1, Lenidase® (Enfarma SRL, Misterbianco, Italy)
2434451|NCT03335683|Placebo Comparator|Placebo|Subjects were allocated to received 1 h and 12 h after surgery: placebo (Sugar pill, Sucratol - Placebo Capsules).
2434452|NCT03335670|Experimental|[68Ga]Pentixafor PET scan|4 mCi (range 3-5 mCi) of [68Ga]Pentixafor is administered intravenously over 1 minute using an infusion pump. PET imaging is performed from time of infusion for about 90 minutes. Approximately 12 blood samples (~ 1 tsp) will be taken for pharmacokinetic analysis.
2434453|NCT03335657|Experimental|CBPT Treatment|The CBPT intervention delivers a patient-oriented cognitive-behavioral self-management program to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy. The program consists of six weekly telephone sessions with a trained physical therapist. Sessions cover an introduction and rationale for treatment in addition to techniques such as deep breathing, graded activity plan and goal-setting, distraction techniques, automatic thoughts, coping self-statements, being present-minded, and relapse prevention and symptom management plans. At the end of the 6th week, patients will build individualized recovery plans with selected strategies and details on frequency of practice.
2434454|NCT03335657|Placebo Comparator|Education Treatment|The education program provides a postoperative recovery and is based on education that would typically be provided by a treating physician or a physical therapist in an outpatient setting. The education program is matched to the CBPT treatment in terms of session frequency and contact with the study therapist. The therapist will call weekly to check in with the patient and encourage him/her to read the manual. Manuals contain educational information on injury patterns and symptoms, stress and recovery, benefits of physical therapy, and importance of daily exercise, and ways to promote healing. Education on sleep hygiene, energy management, healthy eating, and preventing future injury are also provided.
2434455|NCT03335631|Experimental|Group-supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
2434456|NCT03335631|Experimental|Home-based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
2434457|NCT03335618|Experimental|Active Coaching and Monitoring|
2434458|NCT03335618|Sham Comparator|Passive Monitoring|
2434459|NCT03335605||Antibody deficiency (CVID)|Subjects with antibody deficiency (CVID)
2434460|NCT03335605||Healthy controls|Age and gender-matched control subjects
2434461|NCT03335579||non-MACE|patients without major postoperative cardiac or cerebral complications
2434462|NCT03335579||MACE|patients with major postoperative cardiac or cerebral complications
3188145|NCT00763984|Active Comparator|1 Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT
2434465|NCT03335553|Experimental|Single ascending dose (SAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
2434466|NCT03335553|Experimental|Multiple ascending dose (MAD): BMS-986235 or Placebo|BMS-986235 or Placebo oral dose
2434467|NCT03335540|Experimental|Arm B|Combination therapy determined by biomarker assessment
2434468|NCT03335540|Experimental|Arm C|Combination therapy determined by biomarker assessment
2434469|NCT03335540|Experimental|Arm D|Combination therapy determined by biomarker assessment
2434470|NCT03335540|Experimental|Arm F|Combination therapy determined by biomarker assessment
2434471|NCT03335540|Experimental|Arm G|Combination therapy determined by biomarker assessment
2434472|NCT03335527|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h during mechanical ventilation, for a maximum of 3 days
2434473|NCT03335527|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group during mechanical ventilation, for a maximum of 3 days
2434474|NCT03335514||STEMI|The study population consists of 20 patients with ST-elevated acute myocardial infarction (STEMI,n = 20) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2434475|NCT03335514||NSTE-ACS|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTE-ACS,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2434476|NCT03335514||SAP|The study population consists of 30 patients with stable angina pectoris (SAP, n = 30). The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies,chronic or acute infections, severe heart failure (NYHA class 3and 4) and advanced liver or renal diseases are excluded.
2434477|NCT03335514||CONTROL|20 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group
2434478|NCT03335501|Active Comparator|Rapid-acting Aspart|Rapid-acting Aspart will be used to regulate glucose levels
2434479|NCT03335501|Active Comparator|Faster insulin Aspart|Faster insulin Aspart will be used to regulate glucose levels
2434480|NCT03335488|Experimental|Arm 1, RAVICTI|Used for Baseline, Treatment, Transition, Maintenance, and Safety. Dosing will be based on participants disease and treatment status at entry to the study. RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose.
2434481|NCT03335488|Active Comparator|Arm 2, NaPBA (sodium phenylbutyrate)|"Used for Baseline and Treatment. Sodium Phenylbutyrate (NaPBA). Dosing will be based on participants disease and treatment status at entry to the study.~NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
2434482|NCT03335475|Active Comparator|Fitbit Only|In the Fitbit Only arm, participants will receive their exercise prescription, as devised from their baseline exercise stress test results, and a Fitbit. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
2434483|NCT03335475|Experimental|Fitbit + Coaching Sessions|In the Fitbit + Coaching Sessions arm, participant will receive their exercise prescription, as devised from their baseline exercise stress test results, a Fitbit, and will have 8 sessions with a coach (interventionist) over the course of 20 weeks. They will undergo a 9 week (interim) and a 22 week assessment (follow-up).
2434484|NCT03335462|Experimental|Paravertebral injections|Lumbar paravertebral injections containing contrast will be performed. The needles are kept in their position and afterwards followed by CT scan.
2434485|NCT03335449|Experimental|Protective ventilation group|Protective ventilation (PV group) (Vt 6 ml/Kg of ideal body weight, PEEP 8-10 cmH 2 O and repeated recruitment maneuvers.
2434486|NCT03335449|No Intervention|Standard ventilation group|Standard ventilation (SV group) (Tidal Volume, Vt 10 ml/Kg of ideal body weight, Positive End Expiratory Pressure, PEEP 5 cmH 2 O, no recruitment maneuvers)
2434487|NCT03335436|Experimental|Gabapentin|Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
2434488|NCT03335436|Placebo Comparator|Placebo|Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
2434489|NCT03335423|Experimental|Oral Metformin|Oral metformin 1000mg will be given as a single dosis
2434490|NCT03335423|Experimental|Intravenous metformin|Intravenous metformin 500mg will be injected as a single dosis
2434491|NCT03335423|Experimental|Oral codeine and oral metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 1000 mg oral metformin
2434492|NCT03335423|Experimental|Oral codeine and intravenous metformin|Codeine 25 mg will be given at 5 occasions with approximately 6 hours between each dosing. The fifth and last dose will be given together with 500 mg metformin administrated as an injection.
2434493|NCT03335410||shoulder surgery|18-85 years, undergoing day case shoulder surgery during 15th Sept- 15th Oct 2017, possibility to e-mail and an internet connection, understands Finnish,
2434494|NCT03335397|Experimental|M-learning group|Participants receive mobile app (m-learning application) with interactive content (quiz).
2434495|NCT03335397|Other|Control group|Participants receive traditional learning process (books, journals available in the University library).
2434496|NCT03335384|Experimental|Measurement of Pdi|Two small balloons, which are attached to small, flexible tubes, will be put into the esophagus (food tube) and stomach through the nose. Each balloon is about 2 inches long (deflated) and about the width of a pencil tip. A gastric balloon will be inserted into subject's stomach while an esophageal balloon will be inserted into the subject's esophagus. To reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. In addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus.
2434497|NCT03335384|Experimental|Measurement of SNIPs|While the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (SNIP) while one nostril is occluded with a plug containing a nasal pressure transducer to measure airway pressure during maximal inspiration. The distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. This maneuver will be performed 10 times.
2434498|NCT03335371|Experimental|TTP399 400 mg|
2434499|NCT03335371|Placebo Comparator|Placebo|
2434500|NCT03335358|Experimental|Positive Psychology Intervention|Participants complete baseline assessments and receive a 20min training on the positive psychology activities. They are instructed to engage in at least 2 positive psychology activities alone and at least 2 as a couple each week for 8 weeks. Self-administered activities include expressing gratitude, practicing acts of kindness, focusing on the positive, fostering relationships, working toward a goal, spirituality, savoring. Post-intervention and 3-month follow-up assessments are completed.
2434501|NCT03335358|Other|Waitlist control|Participants complete a baseline assessment and are waitlisted for 4-6 weeks. They then complete another assessment, receive the 20min training on activities, and then complete the 8-week self-administered intervention (same as the experimental arm). Post-intervention and 3-month follow up assessments are also completed.
2434502|NCT03335345|Other|maximum gastric void|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its size permits) continuously for 6 hours before extubation.
2434503|NCT03335345|Other|maintaining calorie intake|maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube
2434587|NCT03334877||β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients
2434504|NCT03335332|Experimental|High intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently. All HIIT sessions will be supervised over the intervention.
2434505|NCT03335332|Active Comparator|Moderate intensity exercise|
2434506|NCT03335319|Experimental|Periodized Exercise Training Regime|The ET program will be carried out 3 times a week (60 minutes per session) on non-consecutive days for 48 weeks and supervised for both groups. Exercise prescription will be gradually progressed through various combinations of duration, frequency and/or intensity of training. Over the 1st-15th exercise sessions: MCT and anatomical resistance training; from the 16th-30th session: combined ET with HIIT and hypertrophy; from the 31st-45th exercise session, after the adjustments of the respectively time point assessments: MCT and maximal strength; from the 46th-60th exercise sessions: HIIT with hypertrophy; at the end of the 60th session until the end (6 months has passed): the same exercise prescription will repeat all over again at the same order.
2434507|NCT03335319|Active Comparator|Non Periodized Exercise Training Regime|participants will do a combined ET regime (aerobic and RT). Aerobic component: combine moderate to vigorous exercises 3 d.wk-1 on nonconsecutive days, for 20 min per session, involving major muscle groups using the available ergometers to perform continuous and rhythmic activities in nature. Resistance component: RT should be performed after the aerobic component of the exercise session to allow for adequate warm-up. Initial load should be trained initially with one set of 10-15 repetitions that can be lifted without straining (~30%-40% 1RM for the upper body; ~50%-60% 1 RM for the lower body). Each major muscle group should be trained initially with one set; multiple set regimens may be introduced later as tolerated. It will be performed 8-10 exercises of the major muscle groups.
2434508|NCT03335306||Healthy subjects in Hong Kong|
2434509|NCT03335293|Placebo Comparator|Placebo|normal saline vehicle added to subarachnoid block
2434510|NCT03335293|Experimental|100 mcg epinephrine|100 mcg epinephrine added to subarachnoid block
2434511|NCT03335293|Experimental|200 mcg epinephrine|200 mcg epinephrine added to subarachnoid block
2434512|NCT03335280||Positive for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
2434513|NCT03335280||Negative for PTEN deletion|Confirmed by immunohistochemistry of tissue biopsy
3188146|NCT00763984|Experimental|2 Bladder Health Class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
3188147|NCT00763997|Experimental|1|Dipyrone
3188148|NCT00763997|Active Comparator|2|Ibuprofen
3188149|NCT00763997|Active Comparator|3|Acetaminophen
3188150|NCT00763997|Placebo Comparator|4|Parecoxib/Valdecoxib
3188151|NCT00764010|No Intervention|1|No dietary counseling, placebo capsules for omega-3
3188152|NCT00764010|Active Comparator|2|Dietary counseling, placebo capsules for omega-3
3188153|NCT00764010|Active Comparator|3|No dietary counseling, omega-3 capsules
3188154|NCT00764010|Active Comparator|4|Dietary counseling and omega-3 capsules
3188155|NCT00764023||No treatment|
3188156|NCT00764023||human samples|
3188157|NCT00764036|Experimental|experimental arm only|add-on therapy with 100, 150 or 200 mg oral artesunate once daily
3188158|NCT00764049|Experimental|1: Single pass albumin dialysis|Patients entered in the pilot study.
3188159|NCT00764062|Experimental|1|7-day amoxicillin treatment (1g per os twice daily)
3188160|NCT00764062|Active Comparator|2|3-day amoxicillin (1g per os twice daily) + 4-day placebo treatment (1g per os twice daily)
3188161|NCT00764075|Experimental|1|guided implantation of the left ventricular lead
3188162|NCT00764075|Placebo Comparator|2|standard implantation of the left ventricular lead
3188163|NCT00764075|Experimental|Pilot Group|feasibility of guided placement of CRT-leads in 20 Patients
3188164|NCT00764088||Anaysis of Full Thickness wounds|To demonstrate the effectiveness or ineffectiveness of novel treating agents or agents used for compassionate rescue, subjects and their wounds will be analyzed retrospectively and their non-identifiable information will be compiled in the form of case studies. Subjects who demonstrated characteristics of interest (e.g. healing) as determined by the PI will be chosen for case studies.
3188165|NCT00764101|Experimental|1|9 sessions of attentional bias modification (computerized training program)
3188166|NCT00764101|Placebo Comparator|2|Attentional control condition (placebo training program)
3188167|NCT00764114|Active Comparator|1|- group A : during 6 weeks after the inclusion
3188168|NCT00764114|Active Comparator|2|-group B : during 12 weeks after the inclusion
3188169|NCT00764127||Obese Control|
3188170|NCT00764127||Normal Control|
3188171|NCT00764127||OVERWEIGHT ADOLESCENT PATIENTS UNDERGOING BARIATRIC SURGERY|
3188172|NCT00764140||2|Specific tumor growth factors (IGFs, its binding proteins,receptors; transforming growth factor alpha and beta 1 and epidermal growth factor) in the urine and serum will be measured in patients with hepatocellular carcinoma and healthy controls
3188173|NCT00764140||1|Patients with hepatocellular carcinoma and Healthy controls
3188174|NCT00764153|Other|Internal fixation|Closed reduction and internal fixation with two parallel screws (Olmed)
3188175|NCT00764153|Other|Bipolar hemiarthroplasty|Hemiarthroplasty with Charnley/ Hastings prosthesis
3188176|NCT00764166|Experimental|1|
3188177|NCT00764166|Active Comparator|2|
3188178|NCT00764179|Experimental|1|hyperproteinic milk
3188179|NCT00764179|Active Comparator|2|Normoproteinic milk
3188180|NCT00764192|Experimental|1|14 HD patients are studied before and after a single HD using a polysulphone dialyser.
3188181|NCT00764205||Study Group|Troponin measured prior to hospital arrival
3188182|NCT00764205||Control Group|Patients transported to hospital without troponin measurements enroute
3188183|NCT00764218|Experimental|SAS+HTA+|Obstructive sleep apnea syndrome and hypertension
3188184|NCT00764218|Experimental|SAS+HTA-|non hypertensive patients with obstructive sleep apnea syndrome
3188185|NCT00764218|Experimental|SAS-HTA+|hypertensive patients without obstructive sleep apnea syndrome
3188186|NCT00764218|Experimental|SAS-HTA-|non hypertensive patients without obstructive sleep apnea syndrome
3188187|NCT00764231|Experimental|Exercise|This group will undergo a 12-week home-based exercise intervention with follow-up fitness assessments.
3188188|NCT00764231|Other|Wait list control|This group will go on a 12-week wait list, during which time they will be asked not to change their exercise habits. After 12 weeks, this group will participate in the exercise intervention.
2434552|NCT03335111|Experimental|ACI with BAIPC|Beside of routine treatment for Anterior circulation infarction(ACI) patients, BAIPC group patients are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
3188189|NCT00764244|Active Comparator|1|Vitrectomy
3188190|NCT00764244|Active Comparator|2|Intravitreal triamcinolone injections
3188191|NCT00764244|Active Comparator|3|Laser photocoagulation
3188192|NCT00764257|Experimental|PREVELLE Shape|
3188193|NCT00764257|Active Comparator|Restylane|
3188194|NCT00764270|Active Comparator|Lipoic acid treatment|Participants take lipoic acid with a washout period before or after placebo.
3188195|NCT00764270|Placebo Comparator|Placebo treatment|Participants take placebo with a washout period before or after lipoic acid treatment
3188196|NCT00764283|Experimental|1|Tegaderm dressing
3188197|NCT00764283|Active Comparator|2|Epi-Fix dressing
3188198|NCT00764283|Active Comparator|3|Lockit-Plus dressing
3188199|NCT00764296||no treatment|The information obtained by the evaluation of both acute and chronic wounds is pivotal to truly understanding the intercellular tactics used by wound biofilms which work to disrupt host tissue and to evade the host's immune system.
3188200|NCT00764335||unilateral normal|total hip arthroplasty one side, normal offset of medial femoral head
3188201|NCT00764335||bilateral normal|total hip arthroplasty both sides, normal offset of medial femoral head
3188202|NCT00764335||bilateral abnormal offset|total hip arthroplasty both sides, abnormal offset of medial femoral head
3188203|NCT00764335||controls|Healthy, age-matched control group
3188204|NCT00764348||no treatment|
3188205|NCT00764374|Experimental|1|
3188206|NCT00764387|Experimental|Arm 1|
3188207|NCT00764387|Active Comparator|Arm 2|
3188208|NCT00764400|Experimental|Errorless Naming Treatment|
3188209|NCT00764400|Experimental|Verbal+Gestural Facilitation|
3188210|NCT00764413|Active Comparator|1|Both study arms receive both active treatment = methylprednisolone and an inactive treatment = Sodium chlorid (dummy)
3188211|NCT00764413|Active Comparator|2|Both arms receives both active treatment and inactive treatment = dummy. Active treatment is methylprednisolone, inactive treatment is sodium chlorid.
3188212|NCT00764426|Active Comparator|non-alcoholic beverages|dealcoholised red wine, de-alcoholised beer, water
3188213|NCT00764426|Active Comparator|alcoholic beverages|red wine, beer, ethanol
3188214|NCT00764439|Active Comparator|1|Standard NRT user direction
3188215|NCT00764439|Experimental|2|Novel NRT user direction
3188216|NCT00764530|Experimental|Investigational|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell.
3188217|NCT00764530|Active Comparator|Control Device|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head.
3188218|NCT00764556|Experimental|Tight glycaemic control|Intravenous or subcutaneous insulin to control blood glucose to 4.4-6.5mM
3188219|NCT00764569||Oral Tissue measurement|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
3188220|NCT00764582|Experimental|1|
3188221|NCT00764582|Active Comparator|2|
3188222|NCT00764595|Experimental|imatinib mesylate|All patients start imatinib mesylate as oral dose of 400 mg/d once daily after meal within 28 days after enrollment, and continue the treatment until 3 years after enrollment of the last patient.
3188223|NCT00764608||No Treatment|
3188224|NCT00764621|Experimental|Arm 1|
3188225|NCT00764621|Active Comparator|Arm 2|
3188226|NCT00764621|Active Comparator|Arm 3|
3188227|NCT00764634|Placebo Comparator|1 Placebo|
3188228|NCT00764634|Active Comparator|2 rBV A/B Vaccine|
3188229|NCT00764634|Placebo Comparator|3 Placebo|
3188230|NCT00764634|Active Comparator|4 rBV A/B Vaccine|
3188231|NCT00764647|Experimental|Single arm|Education program for family caregivers of frail elders.
3188232|NCT00764686|Experimental|1|Low disease severity group
3188233|NCT00764686|Experimental|2|Higher disease severity group
3188234|NCT00764712|Active Comparator|Matias protocol|A protocol based on the absolute glucose value - Matias protocol (Matias)
3188235|NCT00764712|Active Comparator|Bath protocol|A protocol based on the relative glucose change - Bath protocol (Bath)
3188236|NCT00764712|Active Comparator|eMPC|a computer-based model predictive control algorithm with variable sampling rate (eMPC)
3188237|NCT00764725|Active Comparator|A|MTX+SSZ+Plaquenil
3188238|NCT00764725|Active Comparator|B|MTX+Infliximab
3188239|NCT00764764|Active Comparator|I|Group I - Shoulder treatment only
3188240|NCT00764764|Experimental|II|Cervical and shoulder treatment
3188241|NCT00764777|Experimental|Stenting|
3188242|NCT00764803||2|Subjects who meet the indications for use and are implanted with the Encore MJS™ Knee System.
3188243|NCT00764803||1|Subjects who meet the indications for and are implanted with the Encore 3DKnee™ system.
3188244|NCT00764816|Active Comparator|1 grain (soy) protein diet:|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
3188245|NCT00764816|Active Comparator|2 casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
2434535|NCT03335241|Experimental|Arm 1: Fludarabine and Pegylated liposomal doxorubicin|
2434536|NCT03335241|Active Comparator|Arm 2: Pegylated liposomal doxorubicin|
3147755|NCT00131404|Experimental|Phase A/B: Arm 3|"Phase A: Arm 3: MK0364 4 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 3:~MK0364 4 mg capsule once daily."
2434538|NCT03335215|Experimental|cognitive remediation|The innovative nature of this cognitive remediation program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context.
2434539|NCT03335215|No Intervention|usual care|
2434540|NCT03335202||cf patients at the cf centre Kiel|microbiome of cf patients at the cf centre Kiel will be analyzed and correlated to standard cf care.
2434541|NCT03335189|Experimental|ASyMS-Can|TParticipants assigned to the experimental group will be provided with the encrypted, secure, pre-programmed ASyMS-Can android phone, and instructed of its use; how to report their symptomatology on a twice daily basis using the CTAQ for the first 14 days of each treatment cycle until end of the final cycle of treatment (or up to 16 weeks).
2434542|NCT03335189|No Intervention|Control|Control group will be asked to complete the study questionnaires at your clinic visits. Also, research staff will contact participants at 1 to 14 days following each chemotherapy, mid and end of each chemotherapy appointment and again within week 8 and 16 of your participation to collect information about participants' symptoms.
2434543|NCT03335176|Experimental|Endurance and Resistance Training Exercise|
2434544|NCT03335176|No Intervention|Control group|Usual care
2434545|NCT03335163|Experimental|ENG Implant Users|Healthy women using an ENG implant for at least 12 months and no greater than 36 months will be administered a 6 week titration schedule of topiramate to a max dose of 200mg bid by the final week.
3188246|NCT00764842||CLP Hip|
3188247|NCT00764855||1|Patients undergoing a surgery with general anesthesia
2434548|NCT03335137||ICU Patients with Severe Burns|Patients suffering from severe burns treated on a burn unit - Drug Level Monitoring Piperacillin/Tazobactam
2434549|NCT03335137||ICU Patients without Burns - Drug Level Monitoring|Patient suffering from disease treated on an ICU - Drug Level Monitoring Piperacillin/Tazobactam
2434550|NCT03335124|Experimental|Active substances|"Vitamin C: Vitamin C will be mixed as 1500 mg vitamin C in 50ml container, which will then be infused over 30 minutes to 1 hour. The bag will be labeled by the pharmacy as Vitamin C. The dosing schedule is 1500mg every 6 hours for 4 days or until discharge from the ICU.~Hydrocortisone: Hydrocortisone will be mixed as 50 mg of Hydrocortisone in 50 ml of 0.9 % Sodium Chloride. Patients will be treated with hydrocortisone 50mg IV q 6 hourly for 4 days or until ICU discharge.~Thiamine: Intravenous thiamine will be given in a dose of 200mg q 12 hourly for 4 days or until ICU discharge."
2434551|NCT03335124|Placebo Comparator|Control|Vitamin C placebo will consist of an identical container of 50cc normal saline (0.9% Sodium Chloride Injection) (but with no vitamin C) and will be labelled vitamin C. Placebo will be infused over 30-60 minutes as per the infusion instructions of the active vitamin. Hydrocortisone placebo will be provided in an identical 50 ml bag of 0.9% Sodium Chloride Injection. Placebo patients will receive a matching vial of 0.9% Sodium Chloride Injection.
3188248|NCT00764894||Foundation Knee|Retrospective data collection on 510(k) approved device
3188249|NCT00764907|Experimental|Arm I|During reinduction, patients receive 1 course of protocol II.
3188250|NCT00764907|Experimental|Arm II|During reinduction, patients receive 2-3 course of protocol III and interim maintenance therapy.
3188251|NCT00764907|Experimental|Arm III|During reinduction, patients are receive 2 courses of protocol II and interim maintenance therapy OR 3-block consolidation regimen and 1 course of protocol II.
3188252|NCT00764920||Skin Imaging|non-invasive imaging modalities for assessment of skin
3188253|NCT00764933|Experimental|1|Structured information
3188254|NCT00764933|Sham Comparator|2|Unspecific conversation
3188255|NCT00764959||Linear Hip|Encore Linear Hip System
3188256|NCT00764972|Experimental|Sorafenib and Vinorelbine|
3188257|NCT00764985||Syncope|
3188258|NCT00764998|Active Comparator|Fluviral|
3188259|NCT00764998|Placebo Comparator|placebo|
3188260|NCT00765011|Experimental|Group A|TPF plus concomitant treatment with cetuximab and conventional radiotherapy
3188261|NCT00765011|Other|Grupo B|Surgery
3188262|NCT00765024|Active Comparator|Albendazole|Albendazole for 7 days
3188263|NCT00765024|Experimental|ivermectin|ivermectin 200 mcg/kg single dose
3188264|NCT00765024|Experimental|ivermectin 2 doses|ivermectin 200 mcg/kg two doses in 2 weeks
3188265|NCT00765050|Experimental|CD133+ cells|CD133+ cells, obtained from peripheral blood in the treatment of diabetic patients with critic ischemia in lower limbs.
3188266|NCT00765089|Experimental|Pulmonary Vein isolation|Patients in this arm will receive pulmonary vein isolation during surgery
3188267|NCT00765089|No Intervention|Standard of care|Subjects in this arm will receive standard of care and no pulmonary vein isolation
3188268|NCT00765115|Experimental|1|100 mg LY 450139 oral
3188269|NCT00765115|Experimental|2|140 mg LY450139 oral
3188270|NCT00765115|Experimental|3|280 mg LY450139 oral
3188271|NCT00765115|Experimental|4|Placebo
3188272|NCT00765141||No treatment|
2434553|NCT03335111|Sham Comparator|ACI without BAIPC|ACI patients in this group only recieve routine treatment for ischemic stroke and are admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation using pressure 0 mmHg , followed by 5-minute cuff deflation). All subjects will take BAIPC for 1 week using 'Remote Ischemic Conditioning Equipment' .Intravenous blood collection with anticoagulant and 5ml total blood will be administered at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
2434554|NCT03335098|Experimental|Study arm|Subcutaneous bortezomib 1.3mg/m2 on days 1, 4, 8, and 11 (every 4 weeks, up to 6 cycles) Oral thalidomide 50mg daily on days 1-28 (every 4 weeks, up to 6 cycles) Intravenous or oral dexamethasone 40mg on days 1-4 (every 4 weeks, up to 6 cycles)
2434555|NCT03335085|Active Comparator|Oxytocin|Single dose of intranasally administered 24 IU of Oxytocin (Syntocinon-Spray Novartis, Switzerland)
2434556|NCT03335085|Placebo Comparator|Placebo|All ingredients except for oxytocin.
2434557|NCT03335072|Active Comparator|WHO-recommended|Annual mass azithromycin distribution of all residents
2434558|NCT03335072|Experimental|Age-based core group|Annual mass azithromycin treatment of everyone plus quarterly treatment of children
2434559|NCT03335072|Experimental|PCR infection-based core group|Annual mass azithromycin treatment plus quarterly treatment of a PCR-based cohort that would be a subset of the age-based core group.
2434560|NCT03335072|Experimental|TI-based core group|Annual mass azithromycin treatment plus quarterly treatment of a conjunctival photography-based cohort that would be a subset of the age-based core group
2434561|NCT03335059|Experimental|Synergo® RITE + MMC|Bladder radiofrequency-induced hyperthermia will be delivered in combination with each instillation of MMC in accordance with the Sponsor operational guidelines.
2434562|NCT03335046|Experimental|Intervention|The intervention arm will receive the home visit intervention, consisting of 2 visits to the home by a team consisting of a pediatric medical provider and a school teacher or school support staff member. This team will evaluate the child's home environment to assess for potential asthma triggers that may lead to school absenteeism, and provide strategies and material goods to help reduce those triggers.
2434563|NCT03335046|Other|Wait-List Control|The control group will receive standard interventions carried out by the school system for students at risk for chronic absenteeism. Following the study observation period, this control group will then receive the home visits performed for the intervention group.
2434564|NCT03335033|Active Comparator|Carotid Plaques with >70% Stenosis|Subjects being seen in the Mayo Clinic Gonda Vascular Center who have a plaque causing a > 70% stenosis will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
2434565|NCT03335033|Active Comparator|Carotid Plaques with 50-69% Stenosis|Cardiovascular high-risk patients with moderate (50-69% diameter) stenosis carotid plaques from the Mayo Clinic Gonda Vascular Center will be approached for recruitment to receive an ultrasound examination including duplex imaging, shear wave elastography and contrast-enhanced ultrasound.
2434566|NCT03335020|Placebo Comparator|Normal|Healthy volunteers. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2434567|NCT03335020|Active Comparator|Fibromuscular Dysplasia (FMD)|Subjects with diagnosis of FMD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2434568|NCT03335020|Active Comparator|Atherosclerosis|Subjects with diagnosis of atherosclerosis. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2434569|NCT03335020|Active Comparator|Spontaneous Coronary Artery Dissection (SCAD)|Subjects with diagnosis of SCAD. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2434570|NCT03335020|Active Comparator|Segmental Arterial Mediolysis (SAM)|Subjects with diagnosis of SAM. Assessment using Shear Wave Elastography, Pulse Wave Imaging, Contrast-Enhanced Ultrasound, Strain Imaging and 3-D Volume ultrasound
2434571|NCT03335007|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
2434572|NCT03335007|Placebo Comparator|Placebo|Placebo
2434573|NCT03334994|Active Comparator|Control group: immediate implant alone|Patient will be treated with immediate implant alone.
2434574|NCT03334994|Active Comparator|(Group A) immediate implant alone|Patient will be treated with immediate implant alone.
2434575|NCT03334981||exposed mother and child|mother and child who have been exposed to methadone or to buprenorphine during pregnancy
2434576|NCT03334968||Patient group|Acute ischemic stroke patients
2434577|NCT03334968||Control group|Those served as control group
2434578|NCT03334955|Experimental|polycystic ovary syndrome patients|patients with polycystic ovary syndrome performed laparoscopic ovarian drilling to induce ovulation
2434579|NCT03334942|Experimental|CFTSI|Youth and caregivers randomized to the Violence Intervention Program (VIP) and Child and Family Traumatic Stress Intervention (CFTSI) arm will receive 5 to 8 CFTSI sessions with a trained clinician and be enrolled in VIP. VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
2434580|NCT03334942|No Intervention|Violence Intervention Program|Youth and caregivers randomized to the VIP-only condition will complete a baseline assessment prior to randomization and then be enrolled in the Violence Intervention Program (VIP). VIP is the standard clinical service offered to assault injured patients treated in the CHOP ED. Participants in this arm will also complete follow-up assessments approximately 4 and 10 months following the ED visit.
2434581|NCT03334929|Experimental|Virtual Reality intervention|Participants will be wearing Virtual Reality headset called Oculus gear equipped with Samsung galaxy S7 during the trigger point injections. The VR app chosen is called Relax VR - Rest, Relaxation & Meditation, which will provide a calm beach scene with waves and soothing musics.
2434582|NCT03334929|No Intervention|control|Participants in this group will receive trigger point injections without any intervention. The trigger point injections will be performed in daily manner.
2434583|NCT03334916|Experimental|YMC026|108 subjects will be assigned in this group. They will be administered 20mL of YMC026 three times a day for 6 days.
2434584|NCT03334916|Placebo Comparator|Placebo|108 subjects will be assigned in this group. They will be administered 20mL of placebo three times a day for 6 days.
2434590|NCT03334864||III Prospective cohort|Non-small cell lung cancer in immuno-therapy;
2434591|NCT03334864||IV Prospective cohort|Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
2434592|NCT03334864||V Prospective cohort|Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
3147756|NCT00131404|Experimental|Phase A/B: Arm 4|"Phase A: Arm 4: MK0364 6 mg capsule once daily.~Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 4:~MK0364 6 mg capsule once daily."
3147757|NCT00131404|Experimental|Phase A/B: Arm 5|Phase A: Arm 5: MK0364 6 mg capsule once daily. 52 week treatment period. Phase B: Patients who continue into Phase B will remain in the same arm they were assigned to during Phase A and will receive the following: Arm 5: MK0364 6 mg capsule once daily.
3147758|NCT00131482|Experimental|10 micrograms|
3147759|NCT00131482|Experimental|30 micrograms|
3147760|NCT00131482|Placebo Comparator|Placebo|
3147761|NCT00131482|Experimental|3 micrograms|
3147762|NCT00131482|Experimental|1 microgram|
3147763|NCT00131495|Placebo Comparator|1|Placebo patch
3147764|NCT00131495|Experimental|2|Testosterone patch (300mcg/day, changed twice a week for one year
3147765|NCT00131547|No Intervention|1|Usual Clinical Care
3147766|NCT00131547|Experimental|2|Behavioral (e.g., Counseling)
3147767|NCT00131560|Other|A|
3147768|NCT00131638|Experimental|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
3147769|NCT00131638|Placebo Comparator|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
2434607|NCT03334838|Experimental|GRP 1 - Assess relative bioavailability (4-way crossover)|"GROUP 1 (Treatments A, B, C, D) All treatments in Group 1 consisted of a dose of 120 mg nifurtimox (4 x 30 mg tablets).~In Treatment A, dose administration was in a fasted state.~For the other treatments, dose administration was in a fed state:~Treatment B after a low-fat breakfast; Treatment C after a breakfast consisting of dairy products (yogurt+milk); and Treatment D after a high-calorie and high-fat breakfast."
2434608|NCT03334838|Experimental|GRP 2 - Assess relative bioavailability (2-way crossover)|"All subjects in Group 2 received a single dose of nifurtimox in each of the Treatments D and E.~In Treatment D, subjects received 120 mg nifurtimox (4 x 30 mg tablets), and in Treatment E, subjects received 240 mg nifurtimox (8 x 30 mg tablets). Both treatments were administered in a fed state, after a high-calorie and high-fat breakfast."
2434615|NCT03334799|Other|Sacroiliac belt on and off|Belt on and belt off
2434616|NCT03334786|Experimental|FLX-787-ODT (orally disintegrating tablet)|Single dose
2434617|NCT03334773|Experimental|Intervention group|Nutrition education (group inclusive of education materials)
2434618|NCT03334773|No Intervention|Control group|Only receives education materials
3147770|NCT00131846|Active Comparator|1|Diuretics use
3147771|NCT00131846|Active Comparator|2|No diuretics use
3147772|NCT00131963||Regimen 1|Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
3147773|NCT00131963||Regimen 2|Patients receive doxorubicin and cyclophosphamide as in regimen 1. Patients then receive paclitaxel IV over 1 hour once weekly for 12 weeks.
3147774|NCT00131989|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-14 or 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR may be considered for retreatment with sorafenib for up to an additional 6 courses upon disease recurrence provided the duration of CR is longer than 1 month.
3147775|NCT00132067|Experimental|Treatment (vorinostat)|Patients receive oral vorinostat twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3147776|NCT00132080|Placebo Comparator|1|Patients with acute Kawasaki disease
3147777|NCT00132119|Experimental|1|Nalmefene HCl 20 mg
3147778|NCT00132119|Experimental|2|Nalmefene HCl 40 mg
3147779|NCT00132119|Placebo Comparator|3|Placebo
3147780|NCT00132145|Other|Intervention|Behavioural
3147781|NCT00132158|Other|1|
3147782|NCT00132249||Head Injured|The Vietnam Head Injured Subjects
3147783|NCT00132249||Head Uninjured|Uninjured Vietnam Veteran Control Subjects
3147784|NCT00132262|Experimental|1|Patients randomized to this arm received an intervention based in the motivational interviewing style
3147785|NCT00132262|Active Comparator|2|Patients randomized to this arm received standard hospital care
3147786|NCT00132353||Healthy volunteers|For normative data
3147787|NCT00132353||Patients with neurological disorders|For teaching fellows electrodiagnostic techniques
3147788|NCT00132379|Experimental|1|
3147789|NCT00132418|Placebo Comparator|Placebo|placebo
3147790|NCT00132418|Experimental|Enbrel|Enbrel
3147791|NCT00132444|Active Comparator|1|0.25% gel
3147792|NCT00132444|Active Comparator|2|0.1% gel
3147793|NCT00132444|Placebo Comparator|3|
3147794|NCT00132483|Experimental|Intervention arm|
3147795|NCT00132483|No Intervention|Control|
3147796|NCT00132509|Experimental|DFIL|
3147797|NCT00132509|Active Comparator|NINDS|
3147798|NCT00132522|Experimental|Arm 1|
3147799|NCT00132613|Active Comparator|1|Procedure/Surgery: Observation alone after pericardial drainage
3147800|NCT00132613|Experimental|2|Drug: Pericardial instillation of bleomycin after drainage
3147801|NCT00132639|Experimental|1|Preoperative docetaxel-cisplatin combination chemotherapy
3147802|NCT00132639|Active Comparator|2|Preoperative docetaxel monotherapy
3147803|NCT00132665|Active Comparator|1|Procedure/Surgery: A: Radiotherapy alone
3147804|NCT00132665|Experimental|2|Drug: B: CBDCA and Radiotherapy
3147805|NCT00132704||A|The experiments in Group A will be conducted in order to determine if human tumor microvascular endothelium displays similar dose parameters as mouse tumor endothelium, and if the microvascular endothelium of tumors of different types behaves in a similar fashion in its response to IR.
3147806|NCT00132704||B|The experiments in Group B will be conducted in order to determine if tumor endothelium isolated to near homogeneity demonstrates dose parameters similar to those used in single dose radiotherapy of brain tumors.
3147807|NCT00132743|Active Comparator|1|Optimal Medical Care
3147808|NCT00132743|Active Comparator|2|Optimal Medical Care and Supervised Exercise
2434640|NCT03334682|Experimental|spironolactone|Spironolactone ARROW ® 75 mg, 150mg, orally, once a day during all the trial (12 months: 6 months on double-blinded spironolactone then 6 months on open-label spironolactone), + topical therapy during all the trial (benzoyl peroxide 5%)
2434641|NCT03334682|Active Comparator|doxycycline|(Doxycycline Sandoz 100 mg), 100mg/day during 3 months followed by placebo during 3 months, on double-blinded + topical therapy during all the trial (benzoyl peroxide 5%
2434642|NCT03334669|Experimental|Intervention|"Sites randomized to the intervention group will receive the following:~Parents Connect for Healthy Living (PConnect)~Enhanced Nutrition Support~Media Resources"
2434643|NCT03334669|No Intervention|Control|Control sites will not receive any intervention components (i.e., standard practice).
2434644|NCT03334656|Experimental|Biological Dressing|"It is a cellularized dressing of 100 cm² composed of fetal skin cells associated to a bovine collagen matrix:~Fetal skin cells were obtained from a single fetal skin sample and consist in two clinical grade banks of keratinocytes (reference BKF07 K CB1) and fibroblasts (reference BKF07 WCB F d P3) produced at the UTCG. These two clinical grade cells banks were fully characterized and secure.~The matrix is a customized type I calf collagen produced by the company Symatese. Symatese's collagen is in compliance with the European requirements"
2434645|NCT03334656|Active Comparator|Paraffin Gauze Dressing|"It is a low-adherent, sterile paraffin Tulle Gras dressing made from open weave gauze. The gauze has interlocking threads which minimize fraying when the dressing is cut to shape. JELONET® dressings are non-medicated and are used as a primary wound contact layer with paraffin present to reduce the adherence of the product to the surface of a granulating wound.~JELONET® is a product of Smith-Nephew, it has the CE-mark (n°0086) and the class of this medical device is IIa.~The features of this dressing are: Soft paraffin base, Sterile leno weave presentation, Comprehensive size range."
2434646|NCT03334643|Experimental|Non-Diabetes|Participants without clinical diagnosis of impaired glucose tolerance or type 2 diabetes and with fasting blood glucose less than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
2434647|NCT03334643|Experimental|Prediabetes/Diabetes|Participants who are clinically diagnosed with impaired glucose tolerance or type 2 diabetes, and those without the above diagnosis but with fasting blood glucose equal to or greater than 100 mg/dL. They will consume white bread or fiber mix for multiple times over a span of 2 weeks. Changes in blood glucose levels will be monitored.
3147809|NCT00132743|Active Comparator|3|Optimal Medical Care and Stent
3147810|NCT00132795|Experimental|1 Therapeutic Phone System|patients assigned to this condition will have unlimited access to the therapeutic telephone system for 4 months.
3147811|NCT00132795|Active Comparator|2 Standard care|Standard post-CBT care (i.e., no formal relapse prevention or professional treatment).
3147812|NCT00132821|Active Comparator|A|Bupropion
3147813|NCT00132821|Active Comparator|B|Transdermal nicotine patch
3147814|NCT00132821|Placebo Comparator|C|
3147815|NCT00132821|Placebo Comparator|D|
3147816|NCT00132834||Asthma/no ICS|Asthmatic children who are not currently taking ICS
3147817|NCT00132834||Asthma/ICS|Asthmatic children on ICS
2434659|NCT03334604|Experimental|Multispecies probiotic group|175 participants.
2434660|NCT03334604|Placebo Comparator|Control group|175 participants.
2434661|NCT03334591|Experimental|Apatinib 5 days' continuous use and 2 days' off|Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer
2434662|NCT03334591|Active Comparator|Apatinib 500mg continuous use|Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer
2434663|NCT03334578|Experimental|Drug: Gastrografin|"Patient will receive 30ml of Gastrografin (diluted at 1:3 ratio with water) as recommended by the manufacturer for a single dose in our population. The dose will be given via the nasogastric tube, which will then be clamped for 1 hour. Gastrografin will only be given if there is evidence of a bowel obstruction. Additionally, Gastrografin will only be given when the patient is hemodynamically stable, not receiving any inotropes, and off of invasive respiratory support. Once administered the patient will receive an x-ray at 48 hours. If Gastrografin can be viewed past the obstruction than another dose of Gastrografin (30ml at 1:3 dilution ratio with water via NG tube) can be given. If gastrografin is not viewed past the obstruction than another dose will not be given.~Generic name: Diatrizoate Meglumine, Diatrizoate Sodium"
2434708|NCT03334383|No Intervention|Control group|Patients receiving standard care: surgery in Trendelenburg position
2434709|NCT03334370||DM subjects in Hong Kong|
3147818|NCT00132834||Non-asthmatic children|Children without asthma
3147819|NCT00132899|Active Comparator|Methotrexate|Methotrexate and infliximab combination
3147820|NCT00132899|Placebo Comparator|Placebo|Placebo plus infliximab combination
3147821|NCT00133003|Active Comparator|1|
3147822|NCT00133003|Placebo Comparator|2|
3147823|NCT00133055|Experimental|Treatment booklet and telephone coaching|
3147824|NCT00133055|Other|Usual Care|
3147825|NCT00133068|Other|1|Control
3147826|NCT00133068|Experimental|2|Reduction of financial barrier
3147827|NCT00133068|Experimental|3|Computer Intervention
3147828|NCT00133068|Experimental|4|Reduction of financial barrier and Computer Intervention
3147829|NCT00133094|Other|Arm 1|
3147830|NCT00133146|Experimental|Grass MATA MPL|"300 SU/0.5 mL Grass MATA MPL (Visit 2);~800 SU/0.5 mL Grass MATA MPL (Visit 4);~2000 SU/0.5 mL Grass MATA MPL (Visit 6)"
3147831|NCT00133146|Active Comparator|Grass MATA|"300 SU/0.5 mL Grass MATA (Visit 2);~800 SU/0.5 mL Grass MATA (Visit 4);~2000 SU/0.5 mL Grass MATA (Visit 6);"
3147832|NCT00133172|Experimental|1|Steroid rapid 5-day withdrawal
2434664|NCT03334578|No Intervention|Control: Standard care|This group will be recruited from an ongoing observational study at our centre. The patients in this group have all received the standard care for treating gastroschisis and any potentially associated bowel obstruction. They have not received Gastrografin. They will be recruited between May 2010 and May 2019.
2434665|NCT03334565|Sham Comparator|Sham|Participants were exposed to unfiltered ambient air (sham) filtered air using air filtration systems in the bedroom and main living space of each residence.
2434666|NCT03334565|Active Comparator|Low efficiency|"Participants were exposed to low-efficiency (LE) HEPA-type filtered air using air filtration systems in the bedroom and main living space of each residence."
2434667|NCT03334565|Active Comparator|High efficiency|"Participants were exposed to high-efficiency (HE) true-HEPA filtered air using air filtration systems in the bedroom and main living space of each residence."
2434668|NCT03334539|Experimental|0.10% HL036 Ophthalmic Solution|0.10% HL036 Ophthalmic Solution, BID for 8weeks
2434669|NCT03334539|Experimental|0.25% HL036 Ophthalmic Solution|0.25% HL036 Ophthalmic Solution, BID for 8weeks
2434670|NCT03334539|Placebo Comparator|Placebo|Placebo vehicle Solution, BID for 8weeks
2434671|NCT03334526|Experimental|healthy volunteers|
2434672|NCT03334513||ROP group|children with retinopathy of prematurity received either bevacizumab or ranibizumab
2434673|NCT03334500|Experimental|Cohort 1|Gleason 6 (n=10)
2434674|NCT03334500|Experimental|Cohort 2|Gleason 7-8 (n=10)
2434675|NCT03334500|Experimental|Cohort 3|Gleason 9 or oligometastic disease (n=10)
2434676|NCT03334487|Experimental|Rovalpituzumab tesirine + dexamethasone|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously on Day 1 of each 6-week cycle plus oral dexamethasone 8 mg twice daily on Day -1, Day 1, and Day 2 of 6-week each cycle.
2434677|NCT03334474||young|18-35 years old
2434678|NCT03334474||middle|35-65 years old
2434679|NCT03334474||aged|65-85 years old
2434680|NCT03334461|Experimental|high concentration enamel remineralisation agent|first month brushing teeth three times per day: twice per day with high-fluorides gel (Mirafluor K gel cola 6150 ppm F pH 5.1) and once per day without toothpaste and fluoride gel next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
2434681|NCT03334461|Experimental|oral antiseptic|first month brushing teeth without toothpaste three times per day and using oral antiseptic chlorhexidine mouthwash (Curasept ADS 212 a 200ml 0,12%) twice per day next two months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
2434682|NCT03334461|No Intervention|Control|regular oral hygiene without exposure to oral antiseptic or high concentration enamel remineralisation agent three months brushing teeth three times per day with toothpaste containing low concentration of fluorides (1450 ppm)
3147833|NCT00133172|Active Comparator|2|Standard steroid maintenance
3147834|NCT00133211|Active Comparator|1|Antiarrythmic drug treatment
3147835|NCT00133211|Experimental|2|
3147836|NCT00133224|Experimental|1|
3147837|NCT00133224|Other|2|
3147838|NCT00133237|Active Comparator|A|Sirolimus-eluting stent (Cypher)
3147839|NCT00133237|Active Comparator|B|Paclitaxel-eluting stent (Taxus)
3147840|NCT00133250|Experimental|A|Abciximab
2434697|NCT03334409|Experimental|Arm A (pazopanib hydrochloride, ascorbic acid)|Patients receive pazopanib hydrochloride PO QD on days 1-28 and ascorbic acid IV three times per week. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
2434698|NCT03334409|Active Comparator|Arm B (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
2434707|NCT03334383|Experimental|Sponge group|Patients offered surgery with the retractor sponge
3147841|NCT00133250|Placebo Comparator|B|Heparin Sodium
3147842|NCT00133263|Experimental|1|
3147843|NCT00133263|Active Comparator|2|
3147844|NCT00133276|Active Comparator|1|
3147845|NCT00133276|Placebo Comparator|2|
3147846|NCT00133354|Active Comparator|Arimidex and Growth Hormone|
3147847|NCT00133354|Placebo Comparator|Placebo and Growth Hormone|
3147848|NCT00133406|Experimental|a|oral glutamine with juice for 10 days
3147849|NCT00133406|Experimental|b|PO vit A q 4 mo for 1 year plus zinc placebo
3147850|NCT00133406|Active Comparator|c|Zinc 40 mg twice weekly Plus Vitamin A Placebo for one year
3147851|NCT00133406|Placebo Comparator|d|oral glycine with juice daily for 10 days
3147852|NCT00133406|Placebo Comparator|e|Vitamin A Placebo plus Zinc Placebo for one year
3147853|NCT00133406|Experimental|f|Vitamin A q 4 months and PO Zinc for 1 year
3147854|NCT00133445|Experimental|Group A|Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
3147855|NCT00133445|Active Comparator|Group B|Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
3147856|NCT00133471|Experimental|Group 1A: 3.75 mcg A/H9N2 no adjuvant|12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.
3147857|NCT00133471|Experimental|Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.
3147858|NCT00133471|Experimental|Group 3A: 15 mcg A/H9N2 no adjuvant|12 subjects to receive 15 mcg A/H9N2 with no adjuvant.
3147859|NCT00133471|Experimental|Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.
3147860|NCT00133471|Experimental|Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.
3147861|NCT00133471|Experimental|Group 4A: 30 mcg A/H9N2 no adjuvant|12 subjects to receive 30 mcg A/H9N2 with no adjuvant.
3147862|NCT00133471|Experimental|Group 2A: 7.5 mcg A/H9N2 no adjuvant|12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.
3147863|NCT00133471|Experimental|Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant|12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.
3147864|NCT00133497|Experimental|20 mcg CMV gB + MF59|200 subjects will receive vaccine CMV gB + MF59.
3147865|NCT00133497|Placebo Comparator|Saline|200 subjects will receive saline placebo.
2434710|NCT03334357|No Intervention|Control|Non-Exercise group. We will provide general advices to control group participants thought an information meeting performed by a graduate in Sport Sciences. It will recommended to follow the physical activity recommendations for adults provided by World Health Organization
2434711|NCT03334357|Experimental|PAR group|"The volume in PAR is based on the minimum physical activity recommended (150min/week at moderate intensity).~Intensity selected for PAR aerobic training is 60-65% HRres. Strength intensity selected was 40-50% of 1 RM.~Frequency. PAR group will train 3 days/week, the minimum frequency recommended. Exercises programmed for the aerobic exercise are treadmill, cycle-ergometer and elliptical ergometer in aerobic training part and weight bearing and guided pneumatic machines (involved major upper and lower body muscle group) in resistance training.~Training load variation. We propose a gradual progression to control the exercise dose Training periodization divided in two phases of 5 weeks each one, starting with a familiarization phase (2 weeks).~Training sessions. Sessions start with a dynamic standardized warm up, which include several muscle activation exercises. Aerobic sessions include compensatory exercises. Training session will be ended with a cooling-down protocol"
2434712|NCT03334357|Experimental|HIIT group.|"The volume in HIIT 40-65 min/week at high intensity. Intensity. Two different protocols: HIIT with long intervals (Type A session), which intensity will be >95% VO2max and HIIT with short intervals (Type B session), >120% VO2max.~Training frequency two times/week. Type of exercise. Type A session are walking in treadmill with personalized slopes. Eight weight-bearing exercises in circuit form, type B session.~Training load variation. Gradual progression to control the exercise dose. Training periodization divided in: familiarization phase, phase I, phase II. Training sessions. Type A: 5 minutes in treadmill at 60% VO2max. After warm-up, participants complete sets corresponding to each training session following the corresponding characteristics. Type B: eight weight-bearing exercises (in circuit form) two times/set with an active rest (walking at 60%VO2max) as many times at as defined. Training session will be ended with a cooling-down protocol"
2434713|NCT03334357|Experimental|WB-EMS group.|"WB-EMS training program will be the same than HIIT intervention related to volume, intensity, frequency, type of exercise, training load variation, training periodization and training session. However, electrical impulse will be included in order to assess if WB-EMS training will produce an added effect compared to HIIT.~Electrical parameters:~We will apply a frequency of 15-33 Hz in type A session. And, we will apply a frequency of 35-75 Hz in type B session.~Intensity will be 80-100 mA. Impulse Width adjusted in relation to body segment: thigh zone (400μsec), glute zone (350μsec), abdominal zone (300μsec), dorsal zone (250μsec), cervical (200μsec), chest zone (200μsec) and arm zone (200μsec).~Duty cycle. We have programmed a duty cycle of 50-67% in type B session, but duty cycle in type A session will be 99%.~RPE impulse: the impulse intensity was individually adapted to generate similar values of rate of perceived exertion (RPE) in Borg CR-10 Scale 5 of 9"
2434714|NCT03334344|Experimental|Intervention Arm|Subjects whose surgeon will be viewing VR models in connection with the in addition to the source CT/MR image
2434715|NCT03334344|No Intervention|Control Arm|Subjects whose surgeon will only be viewing CT/MR images in connection with the case
2434716|NCT03334318||Allopurinol-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to allopurinol
2434717|NCT03334318||Placebo-treated|Participants in the PERL Clinical Trial (NCT02017171) randomized to placebo
2434718|NCT03334305|Experimental|Group A|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine without Autologous Hematopoietic Stem cells (HSCs)
2434719|NCT03334305|Experimental|Group B|Dose-intensified TMZ with TTRNA-DC vaccines with GM-CSF and TTRNA-xALT plus Td vaccine with Autologous Hematopoietic Stem cells (HSCs)
2434720|NCT03334279||non smokers|
2434721|NCT03334279||cigarette smokers|Cigarette smokers to be included in the study must be frequent smokers (at least 10 cigarettes a day) for a period not less than 5 years.
2434722|NCT03334279||simultaneous cigarette and cannabis smokers|frequent cigarette smokers (at least 10 cigarettes a day) and frequent cannabis smoker (at least 3 times/week) for not less than 5 years.
2434723|NCT03334266|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=169) will receive the Family Spirit Nurture (FSN) + Optimized Standard Care (OSC). The FSN home-visiting module consists of 36, 60-minute lessons delivered by trained local Family Health Coaches (FHCs), from 28 weeks gestation to 18 months postpartum. Lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
2434724|NCT03334266|Other|Control Program|The control group will receive Injury Prevention Education (IPE) + Optimized Standard Care (OSC). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. The lessons will be delivered at the following assessment time points: 36 weeks gestation, 2 weeks, 2 months, 4 months, 6 months, 9 months, 12 months, and 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities but that will not overlap in anyway with FSN content, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
3147866|NCT00133523|Placebo Comparator|Group 4: Placebo: Intramuscular|N=165 subjects administered placebo intramuscularly.
3147867|NCT00133523|Placebo Comparator|Group 3: Placebo: Nasal|N=165 subjects administered placebo intranasally.
2434727|NCT03334240|Experimental|CLS003|Digoxin and Furosemide topical formulation
2434728|NCT03334240|Placebo Comparator|Vehicle|Inactive vehicle
2434729|NCT03334227|Experimental|High-Flow nasal cannula (HFNC)|"Treatment with HFNC will be adjusted for SpO2 >92%, even with FiO2 of 0.21, if needed.~The rationale for this HFNC dosage is that minute ventilation can be already reduced with 30 L/min, but functional residual capacity and oxygenation maximally improve at higher flow. On the contrary, flow >50 L/min is uncomfortable for many patients.~In the case of clinical intolerance, flow will be reduced to 40, 30 or 20 L/min. Yet it is not tolerated, HFNC will be stopped and patients will receive conventional oxygen if required, but will be evaluated as in the HFNC group by intention to treat."
2434817|NCT03333564|Other|Control group|No intervention was given
3188273|NCT00765154|Active Comparator|Group 1|Immediate switch from NNRTI/PI to DRV/r
2434730|NCT03334227|No Intervention|Conventional therapy|"Patients assigned to the conventional treatment will receive the standard care given at hospital which consists of adding oxygen on nasal prongs or Venturi mask only if hypoxemia is suggested by SpO2 < 92% by pulse oximetry.~Target for oxygenation in both arms is SpO2 between 92% and 95%. SpO2 >95% without oxygen supply is acceptable. On the contrary, SpO2 <92% may be acceptable when needed for medical reasons, mainly chronic hypercapnic patients."
3147868|NCT00133523|Experimental|Group 1: FluMist™|N=825 subjects administered live attenuated vaccine intranasally.
3147869|NCT00133523|Experimental|Group 2: Fluzone®/Fluvirin|N=825 subjects administered inactivated vaccine intramuscularly.
2434739|NCT03334162|Experimental|Intervention group|Patients in the intervention group will perform a standardized, age-adjusted, specific playful sensorimotor training (SMT) program twice a week for 12 weeks in addition to usual care.
2434740|NCT03334162|No Intervention|Control group|Children in the control group will receive treatment as usual. The control group will be given the opportunity to participate in the intervention after study completion
2434741|NCT03334149|Experimental|Self-Monitoring of Blood Pressure|BUMP 1: using a validated home blood pressure monitor at least 3 times a week to record blood pressure BUMP 2: using a validated home blood pressure monitor daily to record blood pressure Women in the intervention groups will be encouraged to use a simple mobile tele monitoring system.
2434742|NCT03334149|No Intervention|Usual Care|Women randomised to usual care will continue to have all their BP monitoring completed by the clinical team at their antenatal assessments.
2434743|NCT03334136|Active Comparator|Vitamin D|25-hydroxyvitamin D 20.000 IU capsule given orally. Five capsules the first day and thereafter one capsule every week for 4 months.
2434744|NCT03334136|Placebo Comparator|Placebo|Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
2434745|NCT03334123|Experimental|Functional training and cycling|Participants in this group will perform 20 minutes of functional training before dialysis (in the first 8 weeks) and intradialysis cycling exercise during dialysis. Participants will also receive exercise counselling; investigators will teach them how to practice at home by practice and examples given during the 20 minutes of functional training pre-dialysis. In the second phase of additional eight weeks participants will perform the functional training at home on non-dialysis days in addition to intradialysis cycling. Kinesiologist will monitor, advice and motivate them.
2434746|NCT03334123|Active Comparator|Cycling|This active control comparator group will perform intradialytic cycling on an adapted ergometer 3 times per week for 4 months without functional training prior to dialysis procedure and without exercise counselling.
2434747|NCT03334110|Experimental|LIMA-GSV-SCVBG Group|Experimental group: The intervention：we apply a new operation on the patients with diffuse coronary artery disease(DCAD), we choose LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein.
2434748|NCT03334110|Other|BIMA-SCVBG Group|The other group：The intervention: We choose bilateral internal mammary artery composited LIMA-Right Mammary Internal Artery（RIMA） y graft， and anastomose the RIMA with selective coronary vein.
2434749|NCT03334097|Experimental|Experimental arm|There will only one experimental arm in order to study test-retest validity after having validate the questionnaire. The beginning of the maternal education takes place between 26 and 30 weeks of gestation and ends between 32 and 36 weeks of gestation. Hence, to study responsiveness, questionnaires will be filed at the beginning of the maternal education and after the two educational sessions related to childbirth.
2434750|NCT03334084|Experimental|1|Scheme 1
2434751|NCT03334084|Experimental|2|Scheme 2
2434752|NCT03334084|Experimental|3|Scheme 3
2434753|NCT03334071|Active Comparator|Exercise Intervention|Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
2434754|NCT03334071|No Intervention|Negative Control|Patients in the control arm will not undergo an exercise training program.
2434755|NCT03334071|No Intervention|Observational|Patients who do not enrol in RCT will be enrolled in the observational arm
2434756|NCT03334058|Experimental|ARGX-113|
2434757|NCT03334045||Stress patients|Patients diagnosed with work-related Adjustment disorder
2434758|NCT03334045||Controls|Healthy controls
3147870|NCT00133536|Experimental|1|100 subjects 45 mcg of influenza A/H5N1.
3147871|NCT00133536|Placebo Comparator|2|20 subjects saline placebo.
3147872|NCT00133549|Experimental|2|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): CRM-PS; Vaccine dose 3 (month 8): PS.
3147873|NCT00133549|Experimental|1|Vaccine dose 1: CRM-PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): PS.
3147874|NCT00133549|Active Comparator|3|Vaccine dose 1: PS; Vaccine dose 2 (month 4): saline placebo; Vaccine dose 3 (month 8): saline placebo.
3147875|NCT00133601|Experimental|1|CBT-1
3147876|NCT00133601|No Intervention|2|Control Group
3147877|NCT00133666|Experimental|1|
3147878|NCT00133666|Active Comparator|2|
3147879|NCT00133718|Other|Structured multi intervention|Structured multi intervention to reach predefined glycemic and blood pressure goals as well as activity and weight goal
3147880|NCT00133718|Other|Standard of care|Standard care with or without structured care according to national guidelines
3147881|NCT00133744|Active Comparator|A, 1|
3147882|NCT00133744|Experimental|A, 2|
3147883|NCT00133744|Experimental|A, 3|Multiple micronutrient supplement
3147884|NCT00133770|Experimental|IV pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
3147885|NCT00133796|Experimental|Heceptin|Herceptin administered to enrolled subjects
3147886|NCT00133887|Experimental|1|patients receiving Rapamycin
3147887|NCT00133887|Active Comparator|2|patients receiving anticalcineurin treatment
3147888|NCT00133900||Cohort|Metastatic Hormone Refractory Prostate Cancer Patients
2434759|NCT03334032||Inpatient treatment for Anorexia nervosa|"Adolescents with anorexia nervosa assessed~at baseline: on admission to inpatient treatment~at follow-up: 6 months after admission on outpatient basis"
2434760|NCT03334032||Controls|Adolescent healthy and normal weight controls (matched for gender and age), assessed at one point of time
2434761|NCT03334019||subjects|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
2434762|NCT03334006|No Intervention|A: Control group|Standard of Care
2434763|NCT03334006|Active Comparator|B: Pentaglobin®|Standard of Care + Pentaglobin®
2434764|NCT03333993|Experimental|Intervention Group|Patients in this group will be submitted to 10 sessions of Mat Pilates exercises, performed twice a week, lasting 60 minutes, for a period of 5 weeks (from the beginning to the end of radiotherapy). The program will consist of group sessions of up to 4 patients, supervised by a specialized physiotherapist. In addition, they will be guided to follow with the home exercises, according to the institutional routine.
2434765|NCT03333993|Active Comparator|Control Group|Patients assigned to this group will not participate in the Mat Pilates exercises and will be instructed to maintain the home exercises for upper limbs, guided by physiotherapists in the postoperative period, according to the institutional routine.
3188274|NCT00765154|Active Comparator|Group 2|Switch after 10 weeks from NNRTI/PI to DRV/r
2434767|NCT03333928|Active Comparator|500mg HTD1801, bid|
2434768|NCT03333928|Active Comparator|1000mg HTD1801, bid|
2434769|NCT03333928|Placebo Comparator|placebo, bid|
2434770|NCT03333915|Experimental|High-grade ovarian cancer and triple negative breast cancer|
2434771|NCT03333902|Experimental|QLB type 2|"Ultrasound-guided, Inject at the point posterior to quadratus lumborum muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
2434772|NCT03333902|Experimental|QLB type 3|"Ultrasound-guided, Inject at the point between the quadratus lumborum and the psoas major muscle, 0.2% ropivacaine 30mL in each side for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
2434773|NCT03333902|Experimental|QLB type 2+3|"Ultrasound-guided, conduct both QLB type 2 and 3, 0.2% ropivacaine 15mL in each point of injection, for a total of 60mL.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
2434774|NCT03333902|Active Comparator|epidural anesthesia group (EA)|"Epidural catheter placement was conducted when finishing spinal anesthesia. After surgery, 30 mL saline (placebo) was Injected at the point posterior to the quadratus lumborum in each side for a total of 60mL. We used a single bolus of 0.15% ropivacaine + 2 mg morphine (diluted in 6 ml saline) via epidural cathether.~Subjects also receive an intravenous patient controlled analgesia (PCA) pump of 0.5 mg/mL morphine for 48 hours."
2434775|NCT03333889|Active Comparator|E-max hybrid crown|E-max hybrid crown Lithium Disilicate based ceramic which is characterized by high strength and optimum esthetics and considered a gold standard in anterior restorations
2434776|NCT03333889|Experimental|Vita Enamic hybrid crown|Vita Enamic hybrid crown polymer infilltrated ceramic network(hybrid ceramic) characterized by low modulus of elasticity that acts as cushion on implants.
3188275|NCT00765167|Placebo Comparator|A|
3188276|NCT00765167|Active Comparator|B|
3188277|NCT00765167|Active Comparator|C|
2434780|NCT03333850|Experimental|Visual feedback of physical activity|Participants in the exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation AND a monitor placed at their bedside that displays information about their physical activity level, in terms of time spent bedridden, sitting, standing and walking. This information will be visible to the health personnel, the patients and their relatives.
2434781|NCT03333850|Active Comparator|No feedback of physical activity|The participants in the non-exposure cohort will receive usual hospital care and continuous measurement of physical activity by sensors collecting physical activity level during hospitalisation. No visual feedback is provided.
2434782|NCT03333837|Active Comparator|Dance Group|The Dance Group will participate in 1-hour group improvisational dance lessons 2x/week for 12 weeks. Improvisational dance classes are grounded in 4 principles that shape the tone of the class and result in a sense of social belonging: non-judgment, non-competitiveness, curiosity, and playfulness. The following training strategies are used to maintain: active imagination, variability, and pacing.
2434783|NCT03333837|Active Comparator|Non-group Dance|The Non-group dance intervention is designed to capture the same dance movement and auditory stimuli as the group class without social interaction. Recordings of the dance instructor teaching a dance class will be played. This will ensure participants hear comparable music and receive comparable verbal auditory cues to prompt dance movements that students in the group class will hear, without interacting with other people. Improvisational dance is particularly suited for this means of delivery because the primary method of instruction is verbal auditory cueing. Participants will be asked to follow the same schedule as participants in the Dance Group arm and complete 2 one-hour dance sessions each week.
2434784|NCT03333837|Active Comparator|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
2434841|NCT03333408|Active Comparator|Group A (Antibiotic)|Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.
3188278|NCT00765180|Active Comparator|2|The investigators evaluate beneficial effect of colonoscopy using narrow band imaging (NBI) for colorectal adenoma detection.
3188279|NCT00765180|Experimental|1|The investigators evaluate the beneficial effect of colonoscopy with a transparent retractable extension (TRE) device on colorectal adenoma detection rate.
3188280|NCT00765219|Experimental|1|CBT with ACS
3188281|NCT00765219|Experimental|2|CBT with Counselor
3188282|NCT00765219|Active Comparator|3|Usual Care
2434785|NCT03333837|Sham Comparator|No Contact|A No Contact condition captures the condition of no added social contact and no added dance movement. Participants randomized to the No Contact condition will be asked to continue their current disease management and lifestyle for 12 weeks
2434786|NCT03333824|Experimental|Wee-1 kinase inhibitor AZD1775|To evaluate the effect of multiple doses of AZD1775 on the PK of substrates for CYP3A (midazolam), CYP2C19 (omeprazole), CYP1A2 (caffeine) and to evaluate the effect of multiple doses of AZD1775 on QT interval
2434787|NCT03333798|Experimental|Cognitive-Behavioral Intervention|Cognitive-Behavioral Intervention with community worker support.
2434788|NCT03333798|Active Comparator|Standard psychosocial care|Standard psychosocial care delivered by health services.
2434789|NCT03333785|Experimental|Intervention group|Primary care providers whose patients have been randomized to the intervention group will receive an invitation from their patient's cancer specialist provider to communicate using eOncoNote. Primary care providers and cancer specialist providers will use eOncoNote in addition to usual methods of communication.
2434790|NCT03333785|No Intervention|Control group|Primary care providers whose patients have been randomized to the control group will receive usual care (i.e. their primary care providers will not access eOncoNote to communicate with the cancer specialist providers and vice versa) and will be able to contact each other via telephone, fax, and mail consultation letters and progress notes, as per usual care.
2434791|NCT03333772|Experimental|REAL-T Intervention|The current feasibility study will evaluate the feasibility of implementing the REAL-T RCT by enrolling 10 participants who are 18-30 years of age, conducting the REAL-T intervention with all participants over a 3-month period, evaluating pre-to-post changes in their health and quality of life, and assessing the process of implementing the study (feasibility and participant satisfaction).
2434792|NCT03333759|Experimental|Laser Treatment|"Patients will receive one laser treatment (week 0) with the Erbium YAG laser at a 2940nm wavelength (Alma - Harmony XL Laser) and parameters corresponding with their acne scar severity. They will then return to the clinic 1, 4 and 8 weeks (7, 30, and 56 days + 7 days) after the treatment for their scars to be evaluated under optical coherence tomography.~Laser parameters are as follows:~iPixelEr 2940nm Erbium:YAG Module: mild scars: 7 by 7 (7X7) mm tip, energy 1400-1600 millijoules/P (mJ), pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap moderate scars: 7X7 mm tip, energy 1600-1800 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap severe scars: 7X7 mm tip, 1800-2000 mJ/P, pulse energy 5 Hz, 2-6 stacks, pulse mode L, 2-3 passes, 10% overlap"
2434794|NCT03333733|Experimental|HENRY|Children's Centres within local authorities that have been randomised to the experimental arm, HENRY, will receive staff training to deliver the training and be asked to implement at least two programmes per year. Parents enrolled to attend HENRY programmes will then be invited to take part in the research.
2434795|NCT03333733|No Intervention|Waiting list control|Children's Centres within local authorities that have been randomised to the control arm will continue with usual practice. Parents attending another programme (Stay and Play) will be invited to take part in the research. At the end of the follow-up period, they will be offered training to deliver HENRY programmes although this will not be compulsory.
2434796|NCT03333720|Experimental|Intervention|Intervention is phenylalanine-free protein substitute. Following a 7 day baseline period, all recruits will receive the new phenylalanine-free protein substitute daily for 28 days in addition to routine nutritional management. The study product prescription will be specified on an individual basis by the metabolic Dietitian responsible for the patient's nutritional management and will be dependent on age, bodyweight and medical condition of the patient, but will wholly replace their currently prescribed tablet protein substitute and multivitamin supplements.
2434797|NCT03333707|Experimental|Active|Participants will be provided will full access to the Pacifica app.
2434798|NCT03333707|No Intervention|Wait List|Participants will be placed on a wait list and will receive access to the app after 1 month.
2434799|NCT03333694|Experimental|CLL442|Cutaneous Cream application twice daily
2434800|NCT03333694|Placebo Comparator|Placebo|Placebo Cutaneous Cream application twice daily
2434801|NCT03333681|Experimental|Refractory rheumatoid arthritis patients|Autologous mesenchymal stem cells
2434802|NCT03333668|Active Comparator|Lisdexamfetamine - Placebo|
2434803|NCT03333668|Active Comparator|Guanfacine - Placebo|
2434804|NCT03333668|Experimental|Lisdexamfetamine - Guanfacine|
3147889|NCT00133913||Cohort|Patients with measurable metastatic colorectal cancer about to start a new line of chemotherapy.
2434806|NCT03333642|Experimental|Duodenal Ileal interposition|Duodenal Ileal Interposition with Sleeve Gastrectomy.
2434807|NCT03333629|Experimental|Enhanced early detection|Providers will receive training to administer enhanced early detection strategies.
2434808|NCT03333629|No Intervention|Usual care|Providers will not change their early detection strategies, but will be monitored.
2434809|NCT03333616|Experimental|Nivolumab+Ipilimumab|"Nivolumab and Ipilimumab are administered intravenously every 3 weeks for a total of 4 maximum doses. After combination therapy, nivolumab will be administered as monotherapy every 4 weeks.~Doses are determined per protocol."
2434810|NCT03333603|Experimental|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
2434811|NCT03333590|Experimental|Cohort 1 (Minimal Efficacious Dose) rAAVrh74.MCK.GALGT2|N = 3 [2.5 x E13 vg/kg per leg, delivered bilaterally (total 5.0 x E13 vg/kg)]
2434812|NCT03333590|Experimental|Cohort 2 (Dose Escalation) rAAVrh74.MCK.GALGT2|N=3 [5 x E13 vg/kg per leg, delivered bilaterally (total 1.0 x E14 vg/kg)]
2434814|NCT03333564|Experimental|VD3 group|treated with 50,000 IU VD3 / week
2434815|NCT03333564|Experimental|omega3-FA group|1000 mg wild salmon and fish oil complex (contains 300 mg of omega3-FA) once daily
2434816|NCT03333564|Experimental|VD3 and Omega-3FA group|50,000 IU VD3 / week and 1000 mg wild salmon and fish oil complex (contains 300 mg of omega-3FA) once daily
3147890|NCT00133965||1|Dignity Psychotherapy
3147891|NCT00133965||2|Supportive Psychotherapy
3147892|NCT00133965||3|Standard Palliative Care
3147893|NCT00134030|Active Comparator|Maintenance therapy group 1 arm I|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 17, 22, and 26 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 17. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 16, 20, 21, 24, 25, 28, and 29.
2434818|NCT03333551|Experimental|Patients with AL cardiac amyloid|Patients enrolled will be patients > 18 years of age with a clinical diagnosis of cardiac AL amyloidosis (typical echocardiographic or MRI findings, NT-ProBNP levels above 332 pg/mL, cardiac or extra cardiac histological evidence of light chain amyloidosis) with plans to undergo plasma cell directed chemotherapy.
2434819|NCT03333538|Experimental|Stage 1 (component A)|a single administration of component A (VSV) of vaccine
2434820|NCT03333538|Experimental|Stage 1 (component B)|a single administration of component B (Ad5) of vaccine
2434821|NCT03333538|Experimental|Stage 2 (Primary Group)|150 people who will receive the vaccine in the therapeutic scheme: the sequential introduction of components A and B with an interval of 21 days
2434822|NCT03333538|Placebo Comparator|Stage 2 (Controll Group)|50 people who will receive placebo in the therapeutic scheme: the sequential introduction of components A (placebo) and B (placebo) with an interval of 21 days
2434823|NCT03333525|Experimental|Insulin dose-CARB counting HPM group|HPM (high protein meal), contained 36 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2434824|NCT03333525|Experimental|Insulin dose-CARB counting HPFM group|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2434825|NCT03333525|Experimental|Insulin dose-CARB+FPU counting-HPFM|HPFM (high protein-high fat meal), contained 36 g protein,30 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting plus fat-protein counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2434826|NCT03333525|Active Comparator|Insulin dose-CARB counting SM group|SM (standart meal), contained 24 g protein,17 g fat, 70 g carbohydrate and 11.5 g fiber, was given to the subjects in breakfast meal (08.30 h) in the hospital. The glycaemic index (GI) of meal was 60.40. The insulin dose for meal was calculated according to the carbohydrate counting (insulin-to-carbohydrate ratio-ICR and fat-protein unit-FPU).Capillary blood glucose values were collected and recorded before (0 min) and every 30 minutes thereafter for 240 minutes.
2434827|NCT03333512|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants have a daytime nap opportunity of 1.5 hours.
2434828|NCT03333512|No Intervention|No nap|After each night with a 6.5-hour sleep opportunity, participants do not have a daytime nap opportunity, but instead watch documentaries.
2434829|NCT03333499|Placebo Comparator|the control group|YanXinShi placebo pills
2434830|NCT03333499|Experimental|YanXinShi group|YanXinShi pills
2434831|NCT03333499|Active Comparator|Trimetazidine group|Trimetazidine pills
2434832|NCT03333499|Other|YangXinShi and Trimetazidine group|YanXinShi and Trimetazidine pills
3147894|NCT00134030|Experimental|Maintenance therapy group 1 arm II|Patients receive doxorubicin, cisplatin, and high-dose MTX as in arm I. Patients than receive PEG-interferon alfa-2b subcutaneously once daily on day 1 in weeks 30-104.
2434834|NCT03333473|Experimental|Intervention|The intervention will be applied to health facilities in one district in Indonesia and one county in Kenya. The intervention package will work within existing public and private health facilities to strengthen and assess the effectiveness of facility and provider level PPFP service provision and counseling, and expand method choice for women during antenatal, early labor, and post-pregnancy pre-discharge periods. Training within the intervention package include provider-lever PPFP counseling and service provision (PPFP Clinical and Counseling Skills), as well as provider and facility-level leadership management and governance training (Facility-Level Leadership Management and Governance Training).
2434835|NCT03333473|No Intervention|Control|The health facilities control district in Indonesia and county in Kenya will continue with their standard counseling and service provision throughout the study period. At the conclusion of the study period, the facilities in these areas will receive the same intervention that Intervention facilities received prior to study startup.
2434836|NCT03333460|Experimental|Active Comparator: Active rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive active stimulation targeting the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 15 Hz and 100% of the individual resting motor threshold, for a total of 40 trains (60 stimuli per train, inter-train interval of 15 second, total duration 13 minutes). Each session will be repeated twice/daily for 10 consecutive days for 2 weeks, during the continued treatment phase. Following this, the participants will receive the maintenance intervention of 2 sessions per week for 3 months (rTMS follow-up), at the same parameters described above. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2434837|NCT03333460|Placebo Comparator|Sham Comparator: Sham rTMS (15 Hz)|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with the software necessary for the operator to remain blind to the stimulation condition. Also, the software will be pre-programmed by a staff member that will not be involved in data collection and analysis. The sham condition will match the number of pulses delivered during the 15Hz session and will use the same coil placement but the intensity of stimulation will be set a 3% of the individual resting motor threshold so to ensure that the participant will feel similar scalp sensations experienced by participants receiving active rTMS, but brain tissue will not be stimulated. Device: MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
2434838|NCT03333447||Study Population|Patients of any age or gender with confirmed diagnosis of type 1 Gaucher disease, treated with VPRIV® at the beginning of the study. Patients should have one MRI data in the 5 previous years before starting VPRIV® treatment (up to 3 months after initiation of VPRIV®.
2434839|NCT03333434|Other|AFO - Ankle_7 group|AFO is active comparator, ANKLE7 is the experimental treatment
2434840|NCT03333434|Other|Ankle-7 - AFO group|AFO is active comparator, ANKLE7 is the experimental treatment
2434842|NCT03333408|No Intervention|Group B (no Antibiotic)|Group B will not be given postoperative oral antibiotics upon discharge.
2434843|NCT03333395|Active Comparator|HS Group (study group)|
2434844|NCT03333395|Active Comparator|S Group (control group)|
2434845|NCT03333382|Active Comparator|Plastic Biliary Stent|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary plastic biliary stent placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
2434846|NCT03333382|Active Comparator|FCSEMS|Subjects with anastomotic bile leaks following orthotopic liver transplant (OLT) will have a temporary fully covered self-expanding metal stent (FCSEMS) placed across the site of the leak during retrograde cholangiopancreatography (ERCP).
2434847|NCT03333369|Active Comparator|Madopar Arm|A single dose of a cachet filled with 200 mg levodopa/50 mg benserazide
2434848|NCT03333369|Placebo Comparator|Placebo Arm|A single dose of a cachet filled with Dextrose
2434849|NCT03333356|Experimental|Experimental Arm|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).
2434850|NCT03333356|No Intervention|Standard Arm|Surveillance
2434851|NCT03333343|Experimental|Arm 1|EGF816+ trametinib in escalation phase
2434852|NCT03333343|Experimental|Arm 2|EGF816 + ribociclib in escalation phase
2434853|NCT03333343|Experimental|Arm 3|EGF816 + LXH254 in escalation phase
2434854|NCT03333343|Experimental|Arm A|EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)
2434855|NCT03333343|Experimental|Arm B|EGF816 + trametinib in expansion phase
2434856|NCT03333343|Experimental|Arm C|EGF816 + ribociclib in expansion phase
2434857|NCT03333343|Experimental|Arm D|EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)
2434858|NCT03333343|Experimental|Arm E|EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)
2434859|NCT03333343|Experimental|Arm F|EGF816 + gefitinib in expansion phase
2434860|NCT03333343|Experimental|Arm G|EGF816 + INC280 in expansion phase (patients with known resistance mechanism)
2434861|NCT03333330|Experimental|Carotid imaging with Visipaque 320 and SonoVue|"Patients undergo to brain MRI, carotid contrast-enhanced CTA, duplex ultrasound, CEUS, blood sampling, clinical structured interview.~Intervention is related to the administration of contrast agents:~Visipaque 320 for contrast-enhanced CTA, and SonoVue for CEUS"
3188283|NCT00765271|Active Comparator|Group 2|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Raltegravir 400 mg (2 x 200mg tablets) twice daily from days 2 to 15 Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 16 to day 29)
3188284|NCT00765271|Active Comparator|Group 1|Abacavir 600 mg (2 x 300mg tablet) once daily throughout the study (days 1- 30) Darunavir/ritonavir 900 (3 x 300mg tablets)/100 (1 x 100mg capsule) mg once daily from day 2 to day 15) Raltegravir 400 mg (2 x 200mg tablets) twice daily from day 16 to 29
3188285|NCT00765284||Treatment|Ten subjects will be low HDL-C male volunteers who will receive aspirin and Niaspan
2434865|NCT03333304|Experimental|PCT group|Procalcitonin measurement and Discontinuation of antimicrobials according to Procalcitonin kinetics
2434866|NCT03333304|No Intervention|Standard of care|Standard practice
2434867|NCT03333291|Experimental|Fecal transplantation|Duodenal transfer of healthy donor fecal suspension
2434868|NCT03333278|Active Comparator|Vitamins|intravenous: Ascorbic acid (Vitamin C: 1.5g every 6 hours) Thiamine (Vitamin B1: 200mg every 12 hours) Hydrocortisone (50mg every 6 hours)
2434869|NCT03333278|Other|Control|Hydrocortisone (50mg every 6 hours)
2434870|NCT03333265|Experimental|100mg Berberine hydrochloride group|Berberine hydrochloride 100mg tablet by mouth, two times per day for 6 months
2434871|NCT03333265|Experimental|300mg Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 6 months
2434872|NCT03333265|Placebo Comparator|Placebo oral tablets|identical-appearing placebo tablets by mouth, two times per day for 6 months
2434873|NCT03333252|Experimental|Intervention Condition|Exposing caregivers to caregiving-related information and care recipients to cognitive training tasks
2434874|NCT03333252|Placebo Comparator|Control Condition|Exposing caregivers to Nutrition and Health promotional material. The care recipients are exposed to plain words games from computer.
2434875|NCT03333239|Experimental|psychodynamic psychotherapy|
2434876|NCT03333239|Experimental|cognitive behavioral psychotherapy|
2434877|NCT03333239|Active Comparator|psychodynamic family intervention|
2434878|NCT03333226|Experimental|ARM lymph node preservation|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node preservation will be performed.
2434879|NCT03333226|Active Comparator|ARM lymph node removal|All patients will be sent to both rSLNB and photodynamic Axillary Reverse Mapping (ARM) to evaluate the crossover between SLN and ARM lymph node. In case of SLN metastases, an ALND with ARM lymph node removal will be performed.
2434880|NCT03333213|Experimental|Gua Sha therapy|Patients' backs were first covered with Tumarol N Balsam. The study physician then applied a round-edged instrument (the inside smooth edged lip of a metal cap) to patients' skin in downward strokes. Patients were treated twice with a 7-day interval.
2434881|NCT03333213|No Intervention|Waitlist control group|Treatments in the control group were not regulated but patients were asked to continue their self-directed medical care. They were offered the Gua Sha therapy once the trial was concluded.
2434882|NCT03333187|Experimental|Arm A|Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy
2434883|NCT03333187|Active Comparator|Arm B|Treatment with Ruxolitinib continuous therapy
2434884|NCT03333174|Experimental|Servo-controlled Oxygen Environment|Oxygen will be provided by servo-controlled oxygen environment with adjustment of oxygen concentration (FiO2) to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
2435004|NCT03332602|Experimental|free FeSO4 with eudragit polymer|wheat bread fortified with free FeSO4, and eudragit polymer
3188286|NCT00765284||Placebo|Five subjects will be low HDL-C male volunteers who will receive only aspirin.
2434885|NCT03333174|Active Comparator|Nasal Cannula Oxygen|Oxygen will be provided by nasal cannula with adjustment of flow rate and FiO2 to keep infant's oxygen saturation target range at 91-95% in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.
2434886|NCT03333161|Experimental|Higher TcCO2|"The investigators will evaluate the effects of attempts to increase blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg higher from baseline (to max of 70 mm Hg), as long as pH is >7.2. The first 24 hours of the data collection will be the baseline data. Over the next 72 hours, the investigators will evaluate 3 interventions in a cross-over manner, with the initial intervention randomly assigned: Intervention 1 (24-48h of data; Increase TcCO2 by 5 mm Hg), Intervention 2 (48-72h; TcCO2 back to baseline), and Intervention 3 (72-96h; increase TcCO2 again by 5 mm Hg)."
2434887|NCT03333161|Active Comparator|Lower TcCO2|"The investigators will evaluate the effects of attempts to decrease blood carbon dioxide levels within a narrow range of 5 mm Hg (well within the range of usual clinical practice) in a cross-over manner for 24 hours at a time, over a 4-day period, and use Cardiorespiratory Monitoring to evaluate control of breathing.~The investigators will attempt to adjust PCO2 by 5 mm Hg lower than baseline (to minimum of 40 mm Hg), as long as pH is <7.45."
2434888|NCT03333148|Experimental|Arm A - Nestle IMPACT Immunonutrition|Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
2434889|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
2434890|NCT03333135|Experimental|HK100 Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
2434891|NCT03333135|Sham Comparator|HK100 Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Hong Kong 100 races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
2434892|NCT03333135|Experimental|UTMB Pulsed Electromagnetic Field|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use the pulsed electromagnetic field (PEMF) for the two weeks prior to the race.
2434893|NCT03333135|Sham Comparator|UTMB Pulsed Electromagnetic Field Sham|20 athletes (ideally a mix of elite and amateur level athletes and veteran (40-65y) and young (20-39y). Athletes will be recruited at the 2018 and 2019 Ultra Trail du Mont Blanc (UTMB) races. In addition, these athletes will use a PEMF device that doesn't produce electromagnetic fields (sham) for the two weeks prior to the race.
2434894|NCT03333122||Breast Conserving Therapy|Patient who undergo breast conserving therapy or breast conserving therapy with oncoplastic therapies will complete the BREAST-Q Lumpectomy survey module.
2434895|NCT03333122||Mastectomy|Patients who undergo mastectomy will complete the BREAST-Q Mastectomy survey module.
2434896|NCT03333122||Mastectomy with Reconstruction|Patient who undergo breast reconstruction will complete the BREAST-Q Reconstruction survey module. This group will be further subdivided based on implant or autologous tissue reconstruction.
3188287|NCT00765297|Experimental|1|Healthy young 18-40years
3188288|NCT00765297|Experimental|2|Healthy elderly
3188289|NCT00765310|Active Comparator|Lipoic Acid|600 mg R-alpha lipoic acid in morning on empty stomach (two 300 mg capsules)
2434900|NCT03333096|Other|Glaucoma and mild cognitive impairment|"Device: Ocusweep test battery Neuropsychological test battery~Ocusweep system compared to neuropsychological testing"
2434901|NCT03333083|Experimental|Raltegravir + Lamivudine|
2434902|NCT03333070|Active Comparator|Treatment Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: treated arm will receive probiotic containing Lactobacillus reuteri for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
2434903|NCT03333070|Placebo Comparator|Placebo Arm|"25 consecutive children diagnosed with functional constipation will be treated with full dose PEG (Polyethylene glycol 3350) treatment (dose of ~1g/kg/day) for 12 weeks.~After 12 weeks of treatment they will be randomized: control arm will receive placebo for 12 weeks while tapering the PEG dose Dose of 5 drops per day for 48 weeks"
3188290|NCT00765310|Placebo Comparator|Placebo|Placebo two caps every morning on empty stomach
3188291|NCT00765323|Active Comparator|1|84 mg octreotide implant for 6 months
3188292|NCT00765323|Active Comparator|2|Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks
3188293|NCT00765349||All patients undergoing major surgery|
2434908|NCT03333044|Experimental|CHW-led health coaching|Group sessions
2434909|NCT03333044|Experimental|HIT-enabled & CHW led|Supportive care enabled by mobile devices.
2434910|NCT03333044|Experimental|CHW & Physician Feedback|Patient setting progress communicated to physician via PHI
3188294|NCT00765401||Group A|The subject with positive breath Test for H.pylori and/or positive stool antigen test
2434912|NCT03333018||Aclidinium bromide monotherapy|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
2435005|NCT03332602|Experimental|free FeSO4 with Hyaluronic Acid|wheat bread fortified with free FeSO4, and hyaluronic acid
2435006|NCT03332602|Experimental|encapsulated FeSO4 3.2%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading
3188295|NCT00765401||Group B|The subject with negative breath Test for H.pylori and negative stool antigen test
3188296|NCT00765414|Experimental|1|
2434913|NCT03333018||Aclidinium bromide and formoterol|In DUS1, all new users of aclidinium either on monotherapy or with concomitant formoterol will be included. In addition, in DUS2, all new users of the fixed-dose combination of aclidinium/formoterol and any other new fixed-dose combinations of LAMAs and LABAs that become available during the study and that are captured in each database will be included.
2434914|NCT03333018||New users of other COPD medication|New users of other COPD medications (tiotropium, other LAMAs, LABA, LABA/ICS, LAMA/LABA), prescribed as recorded in the database.
2434915|NCT03333005|Experimental|APX001 with Standard of Care Anti-fungal agent|
2434916|NCT03332992|Experimental|Viral changes + General intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
2434917|NCT03332992|Experimental|Viral changes + Behavioral intentions|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
2434918|NCT03332992|Experimental|Viral changes + Accountability|Script language discusses a) that previous years' shots do not protect against current year influenza (viral changes) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
2434919|NCT03332992|Experimental|Protect others + General intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a general question asking whether the respondent intends to get a flu shot (general intentions).
2434920|NCT03332992|Experimental|Protect others + Behavioral intentions|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question asking when / where the respondent will get a flu shot (behavioral intention).
2434921|NCT03332992|Experimental|Protect others + Accountability|Script language discusses a) that getting the flu shot protects others who can get particularly sick (protect others) and b) poses a question that implies the patient's care team will be notified of intent to vaccinate (accountability to providers).
2434922|NCT03332966||Participants|"The adolescent psychiatric organizations of the Helsinki University Central Hospital (serving the capital region's 1.1 million inhabitants), the Tampere University Hospital (catchment area of 500.000 inhabitants), and the Oulu University Hospital (catchment area of 500.000 inhabitants) have agreed to implement the data collection as part of routine intake assessments for patients aged 15-17. All consenting patients are enrolled; the only exclusion criterion is a previous diagnosis of psychotic disorder.~The participants fill in psychiatric self-report questionnaires, and their structured diagnostic interview data are collected with their permission."
2434923|NCT03332953|Other|E-cigarette|Subjects will be asked to vape various e-cigarettes at three concentrations of nicotine and sweet flavor (9 stimuli per subject). The subject will be asked to make ratings for the overall liking or disliking of the e-cigarette, followed by ratings on perceived intensities of sensations.
2434924|NCT03332940|Experimental|Tc99m-sulfur colloid + Tc99m-tilmanocept|All subjects will receive a single IV injection of unfiltered sulfur colloid radiolabeled with 8 mCi Tc99m on study day 0. All subjects will receive a single IV injection of 200 mcg tilmanocept radiolabeled with 8 mCi Tc99m on study day 3.
2434925|NCT03332927|Experimental|Egg based breakfast foods|Study products delivering two eggs/day, 6 days per week, will be administered for the 4-week treatment period.
2434926|NCT03332927|Active Comparator|Non-egg based breakfast foods|Study products delivering non-egg based control breakfast foods will be administered 6 days per week for the 4-week treatment period.
2434927|NCT03332914|Active Comparator|First group|control group fisrt and after washing out Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10
2434928|NCT03332914|Active Comparator|Second group|"Microcurrent therapy: Channel A: 100µA; 200 Hz Duration of each treatment session: 30 minutes Number of sessions: 10~after washing out control group"
2434929|NCT03332888|Experimental|Interventional Group|For this trial, HMA-CD20 will be given as an intravenous infusion of 1000 mg I.V twice in a month separating them by fourteen days starting at the baseline visit. The dose for both HMA-CD20 dosages willbe identical at the screening visit after the participant's eligibility has been established, and it will remain thesame for both infusions. The standard dose for HMA-CD20 is 1,000 mg per intravenous infusion on day 1 and day 15.
2434930|NCT03332875|Experimental|OurRelationship - 1 Coach Call|OurRelationship online program plus a single call with a coach.
2434931|NCT03332875|Experimental|OurRelationship - 4 Coach Calls|OurRelationship online program plus four calls with a coach.
2434932|NCT03332862|Experimental|Discontinuous ablation|perform discontinuous ablation of ipsilateral pulmunary veins.
2434933|NCT03332862|Active Comparator|Continuous ablation|perform continuous ablation of ipsilateral pulmunary veins.
2434934|NCT03332849|Experimental|Cohort 1|T1DM: Multiple dose subcutaneous administration
2434935|NCT03332849|Experimental|Cohort 2|T1DM: Multiple dose subcutaneous administration
2434936|NCT03332849|Experimental|Cohort 3|T2DM: Multiple dose subcutaneous administration
2434937|NCT03332849|Experimental|Cohort 4|T2DM: Multiple dose subcutaneous administration
2434938|NCT03332836|Experimental|Cohort 1|Single dose subcutaneous administration (Dose A)
2434939|NCT03332836|Experimental|Cohort 2|Single dose subcutaneous administration (Dose B)
2434940|NCT03332836|Experimental|Cohort 3|Single dose subcutaneous administration (Dose C)
2434941|NCT03332823|Experimental|SME Ambassadors training & program|- SME Ambassadors will participate in train-the-ambassador workshops and provide voluntary services and promote mental well-being activities to vulnerable groups.
2434942|NCT03332810|Experimental|SME family based physical activity|Adults and family members will participate into one core session and one booster session
2434943|NCT03332810|Active Comparator|Gathering activity|Adults and family members will participate into two gathering activities
3147895|NCT00134030|Active Comparator|Maintenance therapy group 2 arm I|Patients receive doxorubicin, cisplatin, and high-dose MTX as in group 1 arm I.
2435007|NCT03332602|Experimental|encapsulated FeSO4 20%|wheat bread fortified with encapsulated FeSO4 in a microsphere with 20% Fe loading
3147896|NCT00134030|Experimental|Maintenance therapy group 2 arm II|Patients receive doxorubicin IV continuously over 48 hours on days 1-2 in weeks 12, 20, 28, and 36 and cisplatin IV over 4 hours on days 1 and 2 in weeks 12 and 28. Patients also receive high-dose MTX IV over 4 hours on day 1 in weeks 15, 19, 23, 27, 31, 35, 39, and 40. Patients receive ifosfamide IV over 4 hours on days 1-5 in weeks 16, 24, and 32 and on days 1-3 in weeks 20 and 36 and etoposide IV over 1 hour on days 1-5 in weeks 16, 24, and 32.
3147897|NCT00134069|Experimental|Treatment (sorafenib, irinotecan, cetuximab)|Patients will receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 8 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 3-6. Patients will then receive sorafenib by mouth once or twice a day and a 1- to 2-hour infusion of cetuximab once a week for 6 weeks. They will also receive a 1½-hour infusion of irinotecan once a week in weeks 1-4. Treatment may repeat every 6 weeks for as long as benefit is shown.
3147898|NCT00134160|Active Comparator|1|High-dose ARB monotherapy
3147899|NCT00134160|Active Comparator|2|Combination therapy of ARB with Calcium Channel Blocker
3147900|NCT00134277|Active Comparator|Infragenual dilatation with stenting|
3147901|NCT00134277|Active Comparator|Infragenual dilatation with cutting balloon|
3147902|NCT00134277|Active Comparator|Laser therapy|
3147903|NCT00134277|Placebo Comparator|Infragenual dilatation|
3147904|NCT00134303|Experimental|NASH|
3147905|NCT00134355|Experimental|PTK787|"PTK787:~250 mg orally twice daily x 2 wks, then 250 mg orally am, 500 mg orally pm x 1 wk, then 500 mg orally twice daily"
3147906|NCT00134420|Active Comparator|Growth Hormone Treatment|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done 1st for eligibility and this group received GH (growth hormone) (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)immediately after randomization
2435008|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A|wheat bread fortified with encapsulated FeSO4 in a microsphere with 3.2% Fe loading, and encapsulated Vitamin A as microspheres
3147907|NCT00134420|Other|GH treatment delayed by one year|Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing, and Neuropsychological Testing was done first for eligibility and this group received growth hormone (Nutropin AQ) 0.3 mgs per kg per week (standard dosing for GH)after one year of observation
3147908|NCT00134537|Experimental|1|Interspinous process and dynamic stabilization
3147909|NCT00134537|Active Comparator|2|Conservative Care
3147910|NCT00134615|Experimental|RQP-MH|These participants receive the RQP-MH intervention
3147911|NCT00134628|Active Comparator|A|Hyperbaric Oxygen Therapy
3147912|NCT00134628|Sham Comparator|B|Normal Air
3147913|NCT00134654|Active Comparator|Group A|Premarin once a day
3147914|NCT00134654|Active Comparator|Group B|Premarin 3 times a day
3147915|NCT00134680|Experimental|Letrozole & Trastuzumab|Letrozole 2.5 mg tablets daily and Trastuzumab 2 mg/kg by IV weekly
3147916|NCT00134745|Active Comparator|4 mg estradiol|
3147917|NCT00134745|Placebo Comparator|2 mg estradiol|
3147918|NCT00134758|Experimental|1|"Ursodeoxycholic acid during 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
3147919|NCT00134758|Placebo Comparator|2|
3147920|NCT00134823|Experimental|dosing decision support|weight based dosing decision support
3147921|NCT00134823|No Intervention|no decision support|no weight based dosing decision support
3147922|NCT00134966|Experimental|1|
3147923|NCT00134966|Active Comparator|2|
3147924|NCT00135005|Experimental|AMN107 + STI571|
3147925|NCT00135083|Experimental|1|"Once daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime,Pre-Supper, Pre-Lunch"
3147926|NCT00135083|Experimental|2|"Twice daily:~Insulin glulisine Dosing: Supper & Lunch, Lunch & Breakfast, Breakfast & Supper~Monitoring Needed at: Bedtime & Pre-Supper, Pre-Supper & Pre-Lunch, Pre-Lunch & Bedtime"
3147927|NCT00135083|Experimental|3|"Twice daily:~Insulin glulisine Dosing: Supper, Lunch, Breakfast~Monitoring Needed at: Bedtime, Pre-Supper, Pre-Lunch"
3147928|NCT00135096|Experimental|1|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
3147929|NCT00135096|Experimental|2|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
3147930|NCT00135122|Placebo Comparator|2|Placebo in six days
3147931|NCT00135135|Other|1|
3147932|NCT00135161|Experimental|Intensity modulated radiation therapy (IMRT).|
3147933|NCT00135278|Other|CSF Drainage|
3147934|NCT00135278|Other|No CSF Drainage|
3147935|NCT00135304|Experimental|Cinacalcet and low-dose Vitamin D|Cinacalcet and low-dose IV Vitamin D
3147936|NCT00135304|Active Comparator|Vitamin D alone|Escalating doses of IV Vitamin D alone
3147937|NCT00135343|Experimental|A|
3147938|NCT00135343|Experimental|B|
3147939|NCT00135395|Active Comparator|A|
3147940|NCT00135395|Active Comparator|B|
3147941|NCT00135408|Active Comparator|A1|
3147942|NCT00135408|Active Comparator|A2|
3147943|NCT00135421|Experimental|A1|
3147944|NCT00135421|Active Comparator|A2|
3147945|NCT00135421|Placebo Comparator|A3|
3147946|NCT00135447||A|
3147947|NCT00135499|Experimental|R-ACVBP|Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
3147948|NCT00135499|Active Comparator|R-CHOP|Rituximab, Doxorubicin, Cyclophosphamide, Vincristine, Prednisone
3147949|NCT00135525|Experimental|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
3147950|NCT00135525|Placebo Comparator|Placebo|
3188297|NCT00765440|Placebo Comparator|Arm I|Patients receive standard oral or enteral nutrition (IMPACT® placebo) over 7 days prior to surgery and over 7 days after surgery.
3188298|NCT00765440|Experimental|Arm II|Patients receive oral or enteral neoadjuvant IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant standard nutrition (IMPACT® placebo) over 7 days after surgery.
3188299|NCT00765440|Experimental|Arm III|Patients receive oral or enteral IMPACT® nutrition over 7 days prior to surgery and enteral adjuvant IMPACT® nutrition over 7 days after surgery.
2434974|NCT03332758||RD treated with vitrectomy|Vitreous fluid from retinal detachment treated with pars plana vitrectomy
2434975|NCT03332758||RD treated with external drainage|Subretinal fluid from retinal detachment treated with external drainage.
2434976|NCT03332758||Macular holes treated with vitrectomy|Vitreous fluid from patients treated for macular hole
2434977|NCT03332758||ERM treated with vitrectomy|Vitreous fluid from patients treated for epiretinal membrane
2434978|NCT03332745||Severe aortic stenosis|Patients with severe aortic stenosis who are scheduled to undergo aortic valve replacement surgery
2434979|NCT03332745||Control group|Patients scheduled to undergo non-aortic valve cardiac or elective ascending aortic surgery
2434980|NCT03332732|Experimental|Part 1A|In Part 1A, subjects will receive single doses of VNRX-5133 and VNRX-5022 alone and in combination. All subjects will receive all treatments in the sequence specified by the randomization schedule..
2434981|NCT03332732|Experimental|Part 1B|In part 1B, subjects from Part 1A will receive metronidazole with or without VNRX-5133 + VNRX-5022. All subjects will receive all treatments in the sequence specified by the randomization schedule.
2434982|NCT03332732|Experimental|Part 2 - 2A|Multiple dose administration of Low Dose VNRX-5133 + VNRX-5022
2434983|NCT03332732|Experimental|Part 2 - 2B|Multiple dose administration of High Dose VNRX-5133 + VNRX-5022
2434984|NCT03332732|Placebo Comparator|Part 2 - 2C|Multiple dose administration of Placebo (matching VNRX-5133 + VNRX-5022)
2434985|NCT03332719|Active Comparator|Enbrel®|Enbrel® 50 mg injectable solution in autoinjector SureClick® contains: 50 mg etanercept and excipients/Once a week Methotrexate 15 to 25 mg /Once a week
2434986|NCT03332719|Experimental|Enerceptan®.|Enerceptan®. Injectable Solution in prefilled syringes Source: GEMABIOTECH S. A. Formulation per unit: 1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg /Once a week
2434987|NCT03332706||SG|Study Group is the group where the patients during observation suffer from spontaneous abortion or missed abortion,
2434988|NCT03332706||CG|Control Group is where the patients carry the normal live fetal for at least 8 weeks
2434989|NCT03332693|Active Comparator|No exercise|Volunteers will not participate in exercise
2434990|NCT03332693|Active Comparator|Light exercise|Volunteers will participate in one short exercise
2434991|NCT03332693|Active Comparator|Heavy exercise|Volunteers will participate in heavy exercise
2434992|NCT03332680|Experimental|EmbryoGlue® (laboratory culture medium)|"laboratory culture medium~laboratory embryo culture medium, embryos are placed in this media prior to transfer into uterus via embryo transfer procedure to facilitate IVF. EmbryoGlue contains Hyaluronic acid."
2434993|NCT03332680|Active Comparator|Standard control medium|"laboratory culture medium~In standard procedure embryos are placed in a media prior to transfer into uterus via embryo transfer procedure to facilitate IVF."
2434994|NCT03332667|Experimental|131I-MIBG with Dinutuximab|Patients will receive 131I-MIBG on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
2434995|NCT03332667|Experimental|131I-MIBG with Dinutuximab and Vorinostat|Patients will receive vorinostat on days 0-13. 131I-MIBG will be received on day 1. Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab and 131I-MIBG dose will be based on the dose level assigned at the time of patient registration. Patient will receive GM-CSF on days 8-17 and 29-38 at 250 mcg/m2. All patients will receive autologous hematopoietic stem cell infusion on day 15 (+/- 2) of therapy
2434996|NCT03332654||Multiple sclerosis|Prevalence and risk factor of stress urinary incontinence in women with multiple sclerosis and included in the database over 15 years from December 1999 to June 2014, who had undergone a urodynamic test
2434997|NCT03332641|Experimental|Citron peel Extract|Citron peel extract for 12 weeks
2434998|NCT03332641|Placebo Comparator|Placebo|Placebo for 12 weeks
3188300|NCT00765453|Experimental|Intracoronary|Patients will be randomised in a 1:1 ratio to receive intracoronary injections of bone marrow derived stem/progenitor cells or placebo infusion through a percutaneous route
2435000|NCT03332615|Active Comparator|Clinicians with MI coaching|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
2435001|NCT03332615|Placebo Comparator|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
2435002|NCT03332602|Experimental|free FeSO4|wheat bread fortified with free FeSO4
2435003|NCT03332602|Experimental|free FeSO4 and empty microspheres|wheat bread fortified with free FeSO4, and empty microspheres
3188301|NCT00765453|Placebo Comparator|Placebo|Placebo infusion
3188302|NCT00765479|Experimental|Arm I|Patients receive an oral soy protein isolate beverage once daily.
3188303|NCT00765479|Placebo Comparator|Arm II|Patients receive an oral casein placebo beverage once daily.
3188304|NCT00765492|Experimental|1|
3188305|NCT00765492|Placebo Comparator|2|
3188306|NCT00765505|Experimental|1|Exercise Group
3188307|NCT00765505|Experimental|Health Education Group|
3188308|NCT00765518|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
3188309|NCT00765518|Other|Standard of Care|Standard of care therapy only.
3188310|NCT00765544|Experimental|Arm 1|Anklebot
3188311|NCT00765544|Experimental|Arm 2|Body-weight supported treadmill training
3188312|NCT00765544|Experimental|Arm 3|Combination therapy (Anklebot and BWSTT)
2435009|NCT03332602|Experimental|encapsulated FeSO4 3.2%, encap. Vitamin A, free folicacid|wheat bread fortified with encapsulated FeSO4 as microsphere with 3.2% Fe loading, encapsulated Vitamin A as microspheres and free folic acid
2435010|NCT03332602|Experimental|FeSO4 embedded in Hyaluronic Acid|wheat bread fortified with FeSO4 that is embedded in hyaluronic acid.
2435011|NCT03332589|Experimental|Monotherapy Safety Run-in: E6201|"E6201 320 mg/m^2 administered IV over 2 hours twice weekly on Days 1, 4, 8, 11, 15 and 18, repeated every 28 days (=1 cycle).~Dose reductions for toxicity are 240 mg/m^2 (Dose Level -1) and 160 mg/m^2 (Dose Level -2) twice weekly."
2435012|NCT03332589|Experimental|Combination Safety Run-in: E6201 Plus Dabrafenib|Dose Level 1: E6201 320 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -1: E6201 240 mg/m^2 twice weekly plus dabrafenib 150 mg BID. Dose Level -2: E6201 240 mg/m^2 twice weekly plus dabrafenib 100 mg BID. Dose Level -3: E6201 160 mg/m^2 twice weekly plus dabrafenib 100 mg BID Dose Level -4: E6201 160 mg/m^2 twice weekly plus dabrafenib 75 mg BID. Dose Level -5: E6201 160 mg/m^2 twice weekly plus dabrafenib 50 mg BID.
2435013|NCT03332589|Experimental|Expansion: E6201 Plus Dabrafenib|A total of up to N=18 will be treated at the E6201 plus dabrafenib combined MTD.
2435014|NCT03332576|Experimental|Cohort 1|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
2435015|NCT03332576|Experimental|Cohort 2|"6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)~Low dose cyclophosphamide"
2435016|NCT03332576|Experimental|Cohort 3|"3 Doses DPX-Survivac (1 prime, 2 boost q8w)~Low dose cyclophosphamide"
2435017|NCT03332576|Experimental|Cohort 4|"5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)~Low dose cyclophosphamide"
2435018|NCT03332576|Experimental|Cohort 5|"5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)~Low dose cyclophosphamide"
2435019|NCT03332563|Experimental|WebMAP Mobile|Adolescent participants assigned to this arm will receive access to the WebMAP mobile program delivering cognitive-behavioral intervention for chronic pain. Parents of adolescents will receive access to cognitive-behavioral strategies for parents on the WebMAP parent web site.
2435020|NCT03332563|No Intervention|Usual care|Participants assigned to this arm will receive usual care from the pain or specialty clinic during the non-exposure periods in the stepped wedge design.
2435021|NCT03332550||purulent peritonitis|Hinchey 3
2435022|NCT03332550||faecal peritonitis|Hinchey 4
2435023|NCT03332537|No Intervention|Control|Participants will be provided an online interactive platform to access electronic modules (total of 10) on: IBS-related pain neurophysiology and the brain-gut axis and self-management strategies. There is no additional intervention.
2435024|NCT03332537|Experimental|Personalized IBS Pain SM|Participants will be enrolled in the online platform. After completion of the modules, they will be scheduled for a consultation with a research nurse about their level of peripheral and central sensitivity, self-evaluation of IBS-pain SM, goal setting and self-monitoring of IBS-pain and physical activity. They will be asked to document their pain and all symptom SM behaviors daily for the next 10 weeks. At the 6-week follow-up visit, the researcher will review the online activities of the participant, go over the previously selected goals with the participants. The study nurse will acknowledge accomplishment of goals and assist in problem-identification and solving.
2435025|NCT03332524|Experimental|Arm 1 Product SP160412|oral route, 9 doses (Capsule) of SP160412 (Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg combined) in the 72 hours-period from first dose to last dose.
2435026|NCT03332524|Placebo Comparator|capsules Ibuprofen&placebo|2 capsules Ibuprofen and 1 placebo, oral route, 9 doses of Ibuprofen 400 mg with Placebo (Capsule) in the 72 hours-period from first dose to last dose,
2435027|NCT03332524|Placebo Comparator|Capsule Chlorpheniramin&placebo|capsule Chlorpheniramine 4mg and 1 Placebo, 3/72 hours-period from first dose to last dose, oral route
2435028|NCT03332511|Experimental|Investigational arm|Oral nilotinib 300mg twice daily with a 12-hour interval
3188313|NCT00765557|Active Comparator|MiraLAX|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to MiraLAX versus placebo.
2435030|NCT03332485|Experimental|ECP Colon Prep Kit|
2435031|NCT03332485|Active Comparator|MoviPrep®|
2435032|NCT03332472|Experimental|Telemedicine group|Telematics visit in front of the conventional visit face to face
2435033|NCT03332472|Placebo Comparator|Conventional group|Group with conventional medical visit
3188314|NCT00765557|Placebo Comparator|Placebos|The Investigational Drug Pharmacist will be blinded to all patient data, and physicians and nurses evaluating patients will be blinded to randomization of these patients to placebo versus MiraLAX.
3188315|NCT00765583|Experimental|restylane|Restylane arm with different re-treatment schedules
2435036|NCT03332446|Experimental|cooling|strength training and cold water immersion
2435037|NCT03332446|No Intervention|control|strength training and no cold water immersion
2435038|NCT03332433|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
2435039|NCT03332433|Experimental|High-flow nasal cannula group|Oxygen(up to 60L/min) supplied with high-flow nasal cannula
2435040|NCT03332420||Observational 1|Huaiqihuang Granule
2435041|NCT03332420||Observational 2|Standard treatment+Huaiqihuang Granule
2435042|NCT03332420||Observational 3|Standard treatment
2435043|NCT03332394||Healthcare Professionals|Includes nurses, physicians, and allied health professionals who care for patients on the 6NW (Respirology ward) of the General campus at TOH who have implemented and worked with the COPD care pathway during the study duration.
2435044|NCT03332394||COPD Patients|Adult patients admitted to the 6NW (Respirology ward) of the General campus at TOH with a primary diagnosis of acute exacerbation of COPD (AECOPD). The diagnosis is based on the admitting physician's assessment of the patient in the emergency room.
3188316|NCT00765596||1 RYGB|Subjects undergoing RYGB with gastric tube placement
3188317|NCT00765596||2 Matched controls|Subjects matched by BMI, age, gender to RYGB group
3188318|NCT00765609||1|Using the information distributed with over-the-counter medication (The Patient Information Leaflet or PIL)
3188319|NCT00765609||2|Paediatric Analgesia Slide (the new device)
3188320|NCT00765622||G2|G2 = control group (no incontinence)
3188321|NCT00765622||G1|G1 = urinary incontinence
2435047|NCT03332368||TCM exposure group|TCM exposure group were treated with traditional Chinese medicine while the other do not treated with that
2435048|NCT03332355|Experimental|PAC-1 in combination with temozolomide|Temozolomide (PO) will be dosed at 150 mg (adjusted for body size area [m2]) daily for 5 days starting on day 8 at cycle 1, and then for each successive cycle. In Component 2, the first PAC-1 dose will be 1 dose level lower than the PAC-1 MTD established in Component 1, and the maximum dose will not exceed 450 mg. PAC-1 will be taken in the morning on days 1-21 in each 28-day cycle.
2435049|NCT03332342|Experimental|Daily rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed daily.
2435050|NCT03332342|Active Comparator|Weekly rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed weekly.
2435051|NCT03332342|Experimental|Occasional rinse of ocular surface|Eye wash of the ocular surface with one teaspoon of saline immediately upon awakening, performed on two separate occasions
2435052|NCT03332329|Experimental|Sequential combination arm|Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
2435053|NCT03332316|Placebo Comparator|DEXA0|Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally
2435054|NCT03332316|Experimental|DEXA1|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally
2435055|NCT03332316|Experimental|DEXA2|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally
2435056|NCT03332316|Experimental|DEXA4|Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally
2435057|NCT03332303|Experimental|Experimental: Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC)|"Estradiol Vaginal Cream, USP, 0.01%, administered once daily for 7 days.~Intervention: Drug: Estradiol Vaginal Cream, USP, 0.01%"
2435058|NCT03332303|Active Comparator|Active Comparator: Estrace® Cream|"Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%), administered once daily for 7 days.~Intervention: Drug: Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%)"
2435059|NCT03332303|Placebo Comparator|Placebo Comparator: Placebo (Test vehicle cream) Vaginal Cream|"Placebo (Test vehicle cream) Vaginal Cream, administered once daily for 7 days.~Intervention: Drug: Placebo (Test vehicle cream) Vaginal Cream"
2435060|NCT03332290|Active Comparator|sport training|training course lasting 10 days. It included 10 days of multisports practice once (2h) per day.
2435061|NCT03332290|Experimental|diving|diving course lasting 10 days. It included 10 days of diving once (2h) per day. Diving will be carried out using air at a maximum depth of 30-meters
2435062|NCT03332264|Experimental|Drug coated balloon catheter|"PTA with paclitaxel coated SeQuent Please OTW"
2435063|NCT03332264|Active Comparator|Drug coated stent|"PTA with paclitaxel coated Eluvia Vascular Stent System"
2435064|NCT03332264|Active Comparator|Uncoated stent|PTA with bare nitinol stent (as commonly used in site)
2435065|NCT03332251|Experimental|Posture Correction Girdle|The design of posture correction girdle will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure
2435066|NCT03332251|No Intervention|Control|No treatment will be provided for control participants.
2435067|NCT03332238|Placebo Comparator|Placebo|Patients will receive an injection of vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
2435068|NCT03332238|Active Comparator|Cell Therapy|Patients will receive an injection of stromal vascular fraction material suspended in vehicle (Ringer's solution) into their supraspinatus muscle and tendon at the time of rotator cuff repair
2435069|NCT03332225|Experimental|Anakinra|Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
2435070|NCT03332225|Placebo Comparator|IV Placebo|Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
2435071|NCT03332225|Experimental|Recombinant human interferon-gamma|Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days
3188322|NCT00765635|Experimental|2|Taponoto ® (potassium carbonate 20 mg/1 ml, ethyl alcohol, glycerol 480, thymol 0.4; Teofarma Iberica S.A., Barcelona, Spain),
3188323|NCT00765635|Placebo Comparator|3|sterile saline solution (NaCl 0.9%, Braun Medical SA, Barcelona, Spain).
2435074|NCT03332199|No Intervention|Control|Participants in the control group received standard treatment from oncologists and nurses at Hanoi Medical University Hospital.
2435075|NCT03332199|Experimental|Intervention|In addition to standard care provided by oncologists and nurses at Hanoi Medical University Hospital as described above, participants assigned to the intervention group received the psychoeducational intervention delivered by the nurse researcher.
2435076|NCT03332186|Experimental|Mild Renal Impairment|Mild renal impairment defined as eGFR 60 to <90 mL/min/1.73 m^2
2435077|NCT03332186|Experimental|Moderate renal impairment|Moderate renal impairment defined as eGFR 30 to <60 mL/min/1.73 m^2
2435078|NCT03332186|Experimental|Severe renal impairment|Severe renal impairment defined as eGFR <30 mL/min/1.73 m^2, not requiring dialysis
2435079|NCT03332186|Experimental|Normal renal function|Normal renal function defined as eGFR ≥90 mL/min/1.73 m^2
2435080|NCT03332173|Experimental|BGB-3111|
3188324|NCT00765635|Experimental|1: Chlorobutanol|ceruminolytic product, Otocerum® (Chlorobutanol 50 mg/1 ml, phenol 10 mg/1 ml, turpentine essence 0.15 ml/1 ml, ethyl alcohol; Reig Jofre laboratories, Barcelona, Spain),
3188325|NCT00765687|No Intervention|Observation|
2435083|NCT03332147|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2435084|NCT03332147|Active Comparator|reference group-Earlysense system|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2435085|NCT03332134|Experimental|Married Couple Dyad|Husband-wife dyads will receive the intimate partner violence (IPV) intervention program over the course of six weeks.
2435086|NCT03332134|No Intervention|Control Group|Husband-wife dyads in the control group will not receive an intervention.
3147951|NCT00135551|Active Comparator|angiotensin receptor blockers|benidipine+angiotensin receptor blockers, titlation scheme
2435088|NCT03332108|Experimental|Intervention|Those allocated to the intervention arm will be enrolled in the mHealth intervention (EpxBreastfeeding) for six months, and will also be asked about breastfeeding status at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
2435089|NCT03332108|Other|Control|Those in the control arm will be asked about breastfeeding status (exclusive, supplementing, or formula only) at their six-week postpartum follow up visit (standard of care) as well as during phone interviews at three and six months postpartum.
3147952|NCT00135551|Active Comparator|β-blockers|benidipie+β-blockers, titlation scheme
3147953|NCT00135551|Active Comparator|thiazide diuretics|benidipine+thiazide diuretics, titlation scheme
2435092|NCT03332082|Experimental|Tooth positioner treatment group|The participants that meet the inclusion criteria will be treated with tooth positioner.
2435093|NCT03332069|Experimental|Study|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin 10 modulated electro-hyperthermia treatments (55 minutes at a maximum of 150W)
2435094|NCT03332069|Active Comparator|Control|50 Gy external beam radiation administered in fractions of 2 Gy 3 Doses of 8 Gy High Dose Rate brachytherapy up to 3 doses of 80mg/m2 of Cisplatin
2435095|NCT03332056|Active Comparator|Belladonna and Opium (B&O) suppository|A single belladonna and opium suppository, dose-weight calculated, administered immediately following patient positioning prior to instrumentation. The pharmacologically active ingredients that are present in the belladonna extract consist of atropine and scopolamine. Opium is compound drug that is composed of 20 alkaloids. The principle alkaloid that derives the majority of its effect is its morphine content and acts as a narcotic analgesic by increasing the pain threshold or the magnitude of stimulus required to evoke pain.
2435096|NCT03332056|Placebo Comparator|Placebo Suppository|placebo suppository
2435097|NCT03332043|Experimental|HIRREM|Subjects in the experimental arm will receive an in-office, open-label course of acoustic stimulation linked to brain activity (High-resolution, relational, resonance-based, electroencephalic mirroring, HIRREM).
2435098|NCT03332043|Active Comparator|Ambient Nature Sounds|Subjects in the active comparator arm will receive an in-office, open-label course of acoustic stimulation not linked to brain activity (ambient natures sounds).
2435099|NCT03332017|Experimental|Arm A|Approximately 140 subjects to receive BGB-3111 and obinutuzumab
2435100|NCT03332017|Experimental|Arm B|Approximately 70 subjects to receive obinutuzumab
2435101|NCT03332004|Experimental|Indocyanine Green arm|All the enrolled patients met the inclusion criteria. No patients have been excluded from the study. All patient have been subjected, during laparoscopy, to an accurate inspection of the abdomen and all the visible endometriotic lesions have been described. Subsequently, 0.25 mg /(kg BW) Indocyanine Green were administered intravenously during surgery and a second look of the abdomen and pelvis with the Near Infrared Vision has been made, in order to identify the fluorescent lesions. All the lesions has been described and localized pre and post the Indocyanine Green injection and then removed and properly cataloged
2435102|NCT03331978|Experimental|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
2435103|NCT03331978|No Intervention|Control - No Treatment Education|The Usual Care control group will only receive standard of care through their HIV clinics.
2435106|NCT03331952||Invasive pneumococcal disease study (PCV-D)|"Prospective study of children with invasive pneumococcal disease / probable bacterial meningitis (PCV-D)~Clinical procedures~At study enrolment:~Admission clinical findings / laboratory results will be recorded.~A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status, household structure, environmental exposures, and recent antimicrobial use.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) may be performed as part of a child's diagnostic work up. CXRs will be read and interpreted primarily by the AHC radiologists. All CXR will subsequently be re-read by two study clinicians and interpreted according to the WHO paediatric radiologic pneumonia criteria.~Laboratory procedures~• Residual routine clinical specimens further analysed as part of the study protocol:~Blood and cerebrospinal fluid culture specimens.~EDTA / serum specimens.~Urine."
3147954|NCT00135577|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally once in the morning and once in the evening.
3147955|NCT00135577|Experimental|Alvimopan 1 mg Once Daily (QD)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg in the morning and received placebo in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan in the morning and placebo in the evening for 3 days, then 1 mg of alvimopan in the morning and placebo in the evening for the remaining 3 weeks."
3147956|NCT00135577|Experimental|Alvimopan 1 mg Twice Daily (BID)|"Participants who did not have an interruption in blinded investigational product between the original study and the extension study received Alvimopan 1 mg once in the morning and once in the evening.~Participants who had an interruption in blinded investigational product between studies received 0.5 mg of alvimopan once in the morning and once in the evening for 3 days, then 1 mg of alvimopan once in the morning and once in the evening."
3147957|NCT00135577|Placebo Comparator|Placebo|Placebo was administered orally once in the morning and once in evening.
3147958|NCT00135590|Experimental|1|Protein pulse-feeding
2435107|NCT03331952||Pneumonia study (PCV-P)|"Prospective study of children hospitalised with clinical and/or radiologic pneumonia (PCV-P)~Clinical procedures As described for PCV-D.~Radiology procedures As part of routine clinical management at AHC, a digital chest radiograph (CXR) is performed on all children with an admission diagnosis of pneumonia. CXRs will be handled as described for PCV-D.~Laboratory procedures~Study specific specimens:~o Nasopharyngeal swab at enrolment.~Residual routine clinical specimens further analysed as part of the study protocol:~As described for PCV-D."
2435108|NCT03331952||Pneumococcal colonisation study (PCV-C)|"Cross-sectional pneumococcal colonisation surveys in children attending the AHC out-patient department (PCV-C)~Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees.~Clinical procedures~• Subjects will be recruited from the OPD waiting area after nurse triage. A questionnaire will be administered to the parent / guardian or caretaker to assess the child's immunisation status (by review of the handheld immunisation card where possible), household structure, environmental exposures, and recent antimicrobial use.~Laboratory procedures • Study specific specimens:~o Nasopharyngeal swab at enrolment. A nasopharyngeal swab will be collected from each participant and these will be processed as described for PCV-P."
2435109|NCT03331939|Experimental|No stimulation|All patients will receive three different stimulations
2435110|NCT03331939|Other|Beta (25-30 Hz)|Vagal nerve stimulator will be set to Beta (25-30 Hz)
2435111|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to Theta (5 Hz)
2435112|NCT03331913|Active Comparator|intradermal / submucosal injection group|intradermal / submucosal injection at pain area
2435113|NCT03331913|Experimental|intra-masseter injection group|intra-masseter injection on the ipsilateral of pain involved
2435114|NCT03331900|Placebo Comparator|Placebo|
2435115|NCT03331900|Active Comparator|COR388 TBD mg|
2435116|NCT03331887|Active Comparator|E-max CAD crowns retained with Fiber Reinforced Composite Post|"The modulus of elasticity of FRC post is (18-22 GPa) resembling that of dentin. Ideally the remaining tooth, the fiber post and the composite cement create a monoblock in which the loads are uniformly dissipated, ensuring a behavior similar to healthy teeth with a lower risk of root fracture. Using lithium disilicate e.max restorations is documented in literature as a successful restoration."
2435117|NCT03331887|Experimental|E-max CAD Endocrowns|Endocrowns have several advantages over conventional crowns like adequate function and esthetic with less chair time reduced number of interfaces in the restorative system. Stress concentration is less because of the reduction in the nonhomogenous material present. The preparation design is conservative compared to the traditional crown. Supragingival margin prevents interferences with periodontal tissues so involvement of the biological width is minimal. The application and polymerization of resins is also better controlled. Emax ceramic material have a high mechanical strength and are capable of being acid etched, with the adhesive capacity of adhesive systems and resinous cements, made it possible to restore endodontically treated teeth, without cores and intraradicular posts.
2435118|NCT03331874||Basal Cell Carcinoma|Diagnosis of Basal Cell Carcinoma by Reflectance confocal microscopy
2435119|NCT03331861|Experimental|Metformin|Metformin for 6 months
2435120|NCT03331861|Placebo Comparator|Placebo|Matched placebo for 6 months
2435121|NCT03331848|Placebo Comparator|PLACEBO|
2435122|NCT03331848|Experimental|PXT002331 - 20mg|
3188326|NCT00765700|Active Comparator|Ketoprofen 10% Cream|"Topical Ketoprofen 10% Cream~1gram three times daily for 7 days"
3188327|NCT00765700|Placebo Comparator|Placebo|"Topical placebo cream~1gram three times daily for 7 days"
2435125|NCT03331822|Experimental|Light|High illuminance ,white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux.
2435126|NCT03331822|No Intervention|No Light|Ambient, standard white fluorescent environmental light will serve as control.
2435127|NCT03331809|Active Comparator|Control|
2435128|NCT03331809|Experimental|Two-hand|
2435129|NCT03331796|Experimental|Active rTMS (Bilateral DLPFC)|One-third of participants will receive active rTMS to the right and left dorsolateral prefrontal cortex (DLPFC).
2435130|NCT03331796|Experimental|Active rTMS (Bilateral LPC)|One-third of participants will receive active rTMS to the right and left lateral parietal cortex (LPC).
2435131|NCT03331796|Placebo Comparator|Placebo rTMS (Inactive)|One-third of participants will receive placebo/inactive rTMS, either to the DLPFC or the LPC. Those receiving placebo rTMS will serve as the control group.
2435132|NCT03331783|Experimental|Test of new adhesive strips|"On the peristomal skin 4 different patches are applied to the skin (Standard hydrocolloid adhesive patch; LT-2, LT21 and 33-20. There is a bag welded to each patch. Tthe bag contains real output.~The difference between the four patches is that they are made of four different adhesives.~The primary endpoint is measured after 8 hours and 24 hours."
2435133|NCT03331770|Experimental|BAK-free latanoprost ophthalmic emulsion|Patients with primary open-angle glaucoma who were using BAK-containing latanoprost ophthalmic solution for ≥ 6 months (baseline), switched to a new formulation of latanoprost ophthalmic product
2435134|NCT03331757|Experimental|Glucose as reference food|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from D-glucose, tested three times, in different weeks as reference food along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435135|NCT03331757|Experimental|Fir honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from fir honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
3188328|NCT00765713|Experimental|CPAP|Continuous positive airway pressure
3188329|NCT00765713|No Intervention|Conventional|Hygienic-dietetic recommendations
3188330|NCT00765739|Experimental|1|The group who will get neuromuscular electrical stimulation (NMES)
3188331|NCT00765739|Active Comparator|2|The group who will do the voluntary muscle contraction
3188332|NCT00765752||1 Primary Insomnia|Individuals with insomnia not related to another identified cause.
2435136|NCT03331757|Experimental|Heather honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from heather honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435137|NCT03331757|Experimental|Citrus honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from citrus honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435138|NCT03331757|Experimental|Pine honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from pine honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435139|NCT03331757|Experimental|Thyme honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from thyme honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435140|NCT03331757|Experimental|Chestnut honey|Eleven metabolically healthy, normal weight subjects (male: 2, female: 9) after 10-14 hr fast, consumed 50g available carbohydrate from chestnut honey, tested once, along with 300ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first drink.
2435144|NCT03331705||Use of new cystoscope|Patients in which the cystoscope is used.
2435145|NCT03331692|Other|TIVA group|"The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under totally intravenous anesthesia.~During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed."
2435146|NCT03331692|Other|VA group|The participants scheduled for elective ENT procedures or for elective discectomy. The surgery was performed under volatile anesthesia. During procedure, monitoring of the proper level of general anesthesia both clinical and instrumental was performed.
2435147|NCT03331679|Experimental|2 Wk HIIT|2 weeks of High Intensity Interval Training
2435150|NCT03331653|Experimental|Dry Needling and Ischemic Compression at the Trigger Point|Dry Needling and Ischemic Compression at the Trigger Point
2435151|NCT03331653|Active Comparator|Intervention at 1.5 cm from the Trigger Point|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
2435152|NCT03331640|Experimental|OFF|
2435153|NCT03331640|Experimental|FOLFIRI|
2435154|NCT03331627|Active Comparator|STR001-IT/STR001-ER|
2435155|NCT03331627|Active Comparator|STR001-IT/STR001-ER Placebo|
2435156|NCT03331627|Placebo Comparator|STR001-IT placebo/STR001- ER placebo|
2435157|NCT03331614|No Intervention|Control Group|This group will continue with their current treatment regimen during the course of the study. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
2435158|NCT03331614|Active Comparator|Active Treatment Group|This group will continue with their current treatment regimen during the course of the study. In addition they will be given an active intervention with the Flowaid FA-100 SCCD device to utilize at home daily. They will be monitored with daily questionnaires, and at the end of trial visit will also undergo a QST evaluation.
2435159|NCT03331588|Active Comparator|Subxiphoid uniportal VATS|Standard Subxiphoid single-port video assisted thoracic surgery, no use of rib-spreader.
2435160|NCT03331588|Active Comparator|Intercostal uniportal VATS|Standard Intercostal single-port video assisted thoracic surgery, no use of rib-spreader.
2435161|NCT03331575|Experimental|Arm1(Hypofractionated Radiotherapy)|Hypofractionated Radiotherap（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
2435162|NCT03331575|Placebo Comparator|Arms2（Conventional Radiotherapy）|Conventional Radiotherapy（PTV-G60Gy/30Fx,2Gy/Fx; PTV-C 50.4Gy/30Fx, 1.8Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
2435163|NCT03331562|Active Comparator|pembrolizumab & paricalcitol|pembrolizumab 200 mg IV q 3 weeks and paricalcitol 25 mcg IV 3 xs per week
2435164|NCT03331562|Placebo Comparator|pembrolizumab & placebo|pembrolizumab 200 mg IV q 3 weeks & placebo- normal saline IV 3 xs per week
2435165|NCT03331549||Myocardial infarction|
2435166|NCT03331549||Control group|
2435167|NCT03331536||Roux en Y Gastric Bypass Pre-menopausal|Pre-menopausal women undergoing Roux en Y Gastric Bypass
2435168|NCT03331536||Roux en Y Gastric Bypass Post-menopausal|Post-menopausal women undergoing Roux en Y Gastric Bypass
2435169|NCT03331536||Sleeve Gastrectomy Pre-menopausal|Pre-menopausal women undergoing Sleeve Gastrectomy
2435170|NCT03331536||Sleeve Gastrectomy Post-menopausal|Post-menopausal women undergoing Gastric Sleeve
2435171|NCT03331523|Experimental|Calcipotriene/betamethasone dipropionate|
2435172|NCT03331523|Active Comparator|Taclonex®|
2435173|NCT03331523|Placebo Comparator|Placebo|
3147959|NCT00135590|Active Comparator|2|Spread diet
3147960|NCT00135603|Active Comparator|A|appendectomy, actual usual treatment
2435176|NCT03331484|Other|Ticagrelor and Rivaroxaban|All participants will be prescribed ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily for a year.
3147961|NCT00135603|Active Comparator|B|antibiotic therapy
3147962|NCT00135668|Active Comparator|1|Nitroprusside infusion 0.3 mcg/kg/min
3147963|NCT00135668|Active Comparator|2|nitroprusside infusion 1 mcg/kg/min
3147964|NCT00135668|Active Comparator|3|nitroprusside infusion 2 mcg/kg/min
3147965|NCT00135668|Active Comparator|4|nitroprusside 3 mcg/kg/min
3147966|NCT00135733|Active Comparator|A|Amevive
3147967|NCT00135733|Placebo Comparator|B|Placebo
2435177|NCT03331471|Active Comparator|alveolar recruitment maneuver|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O and applying alveolar recruitment maneuver (PEEP 10 cmH2O for 3 breath - PEEP 15 cmH2O for 3 breath and PEEP 20 cmH2O for 10 breath) immediate before and after pneumoperitoneum
2435178|NCT03331471|Experimental|conventional ventilation|FIO2 0.5, TV 6 ml/kg of ideal body weight, PEEP 5 cmH2O applying during anesthesia
2435179|NCT03331458|Experimental|subjects with prostate cancer|
2435180|NCT03331445|Experimental|160 ppm Nitric Oxide|
2435181|NCT03331432|Placebo Comparator|Placebo|Taking daily placebo capsules for 4 weeks
2435182|NCT03331432|Experimental|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks
2435183|NCT03331419||Males with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
2435184|NCT03331419||Females with Chronic Fatigue Syndrome|Two brief high effort exercise tests on consecutive days in our laboratory in order to provoke abnormalities in ME/CFS patients with respect to autonomic function, symptom exacerbation, and activity limitations.
2435185|NCT03331406|Experimental|12-week physical activity program|"The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.~At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.~Exercise Trainer --A exercise trainer will be assigned to design a physical activity program."
2435186|NCT03331393||RA patients treated with Abatacept|Treated with Abatacept as a first-line biologic
2435187|NCT03331393||RA patients treated with TNFi|Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic
3147968|NCT00135759|Placebo Comparator|Group 1|Drug
3147969|NCT00135759|Experimental|2|experimental
3147970|NCT00135759|Experimental|3|experimental
2435191|NCT03331367|Active Comparator|Total Cyrotherapy of the Prostate|Patients who will undergo total cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
2435192|NCT03331367|Active Comparator|Focal Cryotherapy of the Prostate|Patients who will undergo focal cryotherapy of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post cryotherapy, 3 months post cryotherapy)
2435193|NCT03331367|Active Comparator|Cyberknife SBRT of the Prostate|Patients who will undergo Cyberknife SBRT of the prostate will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post Cyberknife, 3 months post Cyberknife)
2435194|NCT03331367|Active Comparator|Radical Prostatectomy|Patients who will undergo a radical prostatectomy will be evaluated for immune markers using a blood draw and urine sample collected at three timepoints (baseline, 2-3 weeks post surgery, 3 months post surgery)
2435195|NCT03331354|Active Comparator|Self-help resources|a self-help vocational manual
2435196|NCT03331354|Experimental|Compass|a distant learning vocational program
3147971|NCT00135785|Active Comparator|1|Bupropion
2435198|NCT03331328|Sham Comparator|Control/sham|The CO2 laser will not be activated but the same procedure of moving the probe inside the vagina in a systematic manner including depressing the foot pedal at similar frequency will be performed. The smoke evacuator will also be activated, laser eye glasses and masks worn by the laser team and the subject. However, the laser will remain in the standby mode.
2435199|NCT03331328|Active Comparator|Treated|Active arm subjects will be treated intravaginally with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm and the smart stack parameter from 1 to 3. For the vulva, the dot power will be reduced to 26 watts, dwell time 800 μs, dot spacing 800 μm and the smart stack parameter of 1.
2435202|NCT03331302|Active Comparator|COPD patients - Xe-133|COPD patients who will be assessed with Xenon-133 scintigraphy (Standard diagnostic study)
2435203|NCT03331302|Experimental|COPD patients - Hyperpolarized Xe-129|COPD patients crossed over from the Active Comparator Arm who will be assessed with hyper polarized Xenon-129 MRI (Experimental diagnostic study)
2435204|NCT03331289|Placebo Comparator|Placebo|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2435205|NCT03331289|Active Comparator|Exenatide|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2435206|NCT03331289|Active Comparator|Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
2435207|NCT03331289|Active Comparator|Exenatide and Dapagliflozin|we will examine whether the coadministration of exenatide plus dapagliflozin will prevent the increase in EGP and result in an additive or even synergistic decrease in plasma glucose conc compared to each agent alone.
3147972|NCT00135785|Placebo Comparator|2|Placebo
3147973|NCT00135811|Active Comparator|1|Cyclosporin
3147974|NCT00135811|Active Comparator|2|MMF and Dexamethasone
3147975|NCT00135902|Active Comparator|17P plus Omega-3 Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus Omega 3 supplements, 4 capsules per day for up to 5 weeks. Each capsule contained 200 mg of docosahexaenoic acid (DHA) and 300 mg of eicosapentaenoic acid (EPA).
3147976|NCT00135902|Placebo Comparator|17P plus Placebo Supplement|Weekly 17 alpa hydroxyprogesterone caproate (17p) injections plus placebo capsules, 4 capsules per day for up to 5 weeks
3147977|NCT00135941|Experimental|1|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
2435208|NCT03331276|Experimental|BBN|An experimental Infant Formula, Milk-Based Powder with Iron, for healthy term infants 0 to 12 months of age with high Sn-2 Palmitate, Alpha Lactalbumin and Osteopontin to better mimic human milk.
2435209|NCT03331276|Active Comparator|Brand|A Commercially available Infant Formula, for healthy term infants 0 to 12 months of age (Enfamil TM, Milk-Based Powder with Iron)
2435210|NCT03331263|Experimental|Abdominal application of 2% CHG|
2435211|NCT03331263|Experimental|Groin application of 2% CHG|
2435212|NCT03331263|No Intervention|Control treatment with no application|
2435213|NCT03331250|Experimental|Eribulin|"Eribulin administered twice per cycle intravenously~Each cycle contains 21 days~Dosing is per the FDA label for other cancers"
2435214|NCT03331237|Active Comparator|LVS group|interscalene injection
2435215|NCT03331237|Active Comparator|ISO group|in this group all patients will receive ISO block.
2435216|NCT03331224|Experimental|OTSC|Initial treatment with the OTSC for non-variceal upper GI-bleedings with high risk of recurrency.
2435217|NCT03331224|Active Comparator|Standard therapy|Endoscopic standard therapy (two techniques e.g. clip and injection)
2435218|NCT03331211||Chmotherapy combined with TKIs|Patients with ALL were treated by chmotherapy and TKIs(PDT-NFH-2016)
3147978|NCT00135941|Experimental|2|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
3147979|NCT00135954|Other|late intervention|cyclophosphamide and steroids started at time of renal insufficiency
3147980|NCT00135954|Experimental|early intervention|immediate start of cyclophosphamide and steroids
3147981|NCT00136032|Active Comparator|1|
2435225|NCT03331172|Experimental|High Intensity Focused Ultrasound|
2435226|NCT03331159|Experimental|NanoBone|The participants were treated with anterior lumbar interbody fusion (ALIF) with a new nanocrystalline hydroxyapatite embedded in a silica gel matrix (NH-SiO2)
2435227|NCT03331159|Active Comparator|Homologous bone|The participants were treated with anterior lumbar interbody fusion (ALIF) with homologous bone
2435228|NCT03331146|Placebo Comparator|Control group|saline infusion will be administered after induction of general anesthesia
2435229|NCT03331146|Active Comparator|Sodium Nitrite|sodium nitrite will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
2435230|NCT03331133||Identical Twins|Twins develop from one zygote with no intervention
2435231|NCT03331133||Dizygotic Twins|Twins develop from two different zygote with no intervention
2435232|NCT03331120|Active Comparator|Control Group|"1--Control group~. Conventional treatment:~moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine."
2435233|NCT03331120|Experimental|Study or Experimental Group|"2--Experimental or study group:~moist hot pack.~manual therapy.~Therapeutic Exercise.~Home program routine.~ambulatory mirror image functional re-training through wearing 3D adjustable cervical thoracic Posture Corrective orthosis (CTPCO) For 10 weeks(3Times/week for 20 minutes)."
2435236|NCT03331081|Experimental|Group Bladder Training|Patients will receive verbal instructions on bladder function (filling and bladder emptying phases), pelvic floor musculature on bladder function; orientation on urinary positioning and habits (urinary frequency); and the definition and major risk factors responsible for urinary incontinence.
2435237|NCT03331081|Active Comparator|Group TMAP|In this group the patients will perform TMAP in isolation. The training protocol aims at the work of strength and muscular hypertrophy, with concentric-isometric muscular action and load of 100% of the maximum voluntary contraction.
2435238|NCT03331081|Active Comparator|Group Bladder Training + TMAP|In this group, the patients should perform the proposed exercises for the Bladder Training Group and the exercises proposed for the TMAP Group. The training protocol of this group will consist of exercises that have as objectives: to improve the control over the urgency and urge-incontinence; increase bladder capacity, and thus prolong the intervals between urinations; to restore confidence in bladder control; and improve MAP strength and hypertrophy.
2435239|NCT03331068||Patients with prostate cancer|online questionnaire of MAX-PC
2435240|NCT03331055|Experimental|percutaneous stimulation|PENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2435241|NCT03331055|Experimental|trancutaneous stimulation|TENS in 2/100HZ, 30 min for each time, twice a day, for 3 days. With conventional analgesic medication if necessary.
2435242|NCT03331055|No Intervention|Control|Conventional analgesic medication is offered.
2435247|NCT03331029|Other|transesophageal echocardiography|Comparison of 3D Ultrasound with transesophageal echokardiography
2435310|NCT03330574||Effect of medical/surgical intervention|Patients will undergo standard treatment based on their medical history and we will observe the PERG changes induced by these treatments (eye drops, laser or surgery) with the Diopsys® ERG Vision Testing Systems.
3147982|NCT00136032|Placebo Comparator|2|
3147983|NCT00136123|Experimental|Implants|
3147984|NCT00136136||Normal healthy term newborn|Normal healthy term newborns
3147985|NCT00136136||Ill term newly born without brain damage|Ill term newly borns without brain damage
3147986|NCT00136136||Preterm newly born without brain damage|Preterm newly borns without brain damage
3147987|NCT00136149|Experimental|Immediate implants|
3147988|NCT00136175|Experimental|Arm I|Patients with clinical stage T2 with hydronephrosis or T3 bladder cancer will receive 3 cycles of chemotherapy (200mg/m^2 paclitaxel on day 1, carboplatin on day 1, and 800 mg/m^2 gemcitabine on days 1 and 8 of each 21 day cycle).
3147989|NCT00136175|Experimental|Arm II|Patients with T4 or lymph node positive disease will receive up to 6 cycles of paclitaxel, carboplatin, and gemcitabine.
3147990|NCT00136201|Experimental|1|armDesc1
2435248|NCT03331016|Other|Waitlist Control Group|Waitlist Control Group will serve as control group for 6 months, receiving no intervention during that time but completing periodic surveys to assess outcomes among controls (knowledge, attitudes, behaviors). They will also later receive the intervention (training program) and be followed for 6 more months.
2435249|NCT03331016|Experimental|Intervention Group|Intervention Group will receive the intervention (training program) right away, then will be followed for 6 months.
2435250|NCT03331003|Experimental|low level light therapy|1 group uses the investigational device on the left side, and the subjects will have half part receiving low level light therapy (red light-emitting diode and laser irradiation)
2435251|NCT03331003|Placebo Comparator|non-LLLT wavelength group group|the control device on the right side, other half with non-low-level laser therapy wavelength (white light-emitting diode light bulb coating with red paint to make the irradiating light close to the red).
2435252|NCT03330990|Other|Entrectinib / Midazolam|
2435253|NCT03330977|Other|Before and after use of compression garments|"At inclusion, patients will only have medication prescription as usual but without compression garments, and thus, for 4 months.~4 months after inclusion, patients will continue medication but will also be prescribed compression garments Then every 6 months, until 26 months, patients will come back to have new compression garments (as usual practice)"
2435254|NCT03330964|Experimental|electroacupuncture group|The experimental group adopted chemotherapy combined with electro-acupuncture stimulated related acupoints for 3 days running.
2435255|NCT03330964|No Intervention|control group|The control group received chemotherapy only(same as the experimental group),but no electroacupuncture treatment.
2435256|NCT03330938|Experimental|CBI and Resilience|8 sessions total, once a week, 2 hours long each, consistent of 6 sessions of Cognitive-behavioral Intervention (CBI) plus 2 sessions to improve resilience strengths.
2435257|NCT03330938|Active Comparator|Cognitive-behavioral Intervention|8 sessions total, once a week, 2 hours long each. Cognitive-behavioral Intervention (CBI) without resilience strengthening.
2435258|NCT03330925|Experimental|ElastiMed's SACS|Healthy Subjects which the Elastimed's SACS will be tried on
2435259|NCT03330912|Experimental|Seat Height Intervention|"Randomly assigned 5 wheelchair seat heights ranging from very low (2 below) to very high (2 above) the lower leg length of the participant."
2435260|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
2435261|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
2435262|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant IB160|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant IB160) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
2435263|NCT03330899|Active Comparator|15 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (15 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 15 mcg of the monovalent H7N9 antigen per dose"
2435264|NCT03330899|Active Comparator|7.5 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (7.5 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 7.5 mcg of the monovalent H7N9 antigen per dose"
2435265|NCT03330899|Active Comparator|3.75 mcg H7N9 + adjuvant SE|"Participants in this arm will receive one dose of the combination (3.75 mcg H7N9 antigen + adjuvant SE) at Day 0 and another dose at Day 28.~Each dose after combination = 0,5 ml 3.75 mcg of the monovalent H7N9 antigen per dose"
2435266|NCT03330899|Active Comparator|15 mcg H7N9 without adjuvant|"Participants in this arm will receive one dose of the 15 mcg H7N9 antigen without adjuvant at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
2435267|NCT03330899|Placebo Comparator|Placebo (PBS)|"Participants in this arm will receive one dose of Placebo (PBS) at Day 0 and another dose at Day 28.~Each dose = 0,5 ml"
2435268|NCT03330873|Experimental|Foley catheter|After the completion of hysteroscopic adhesiolysis, Foley catheter was inserted and inflated with normal saline which was removed on the 7th day after surgery.
2435269|NCT03330873|Experimental|Disposable balloon uterine stent|After the completion of hysteroscopic adhesiolysis, disposable balloon uterine stent was inserted and inflated with normal saline which was removed on the 7th day after surgery.
2435270|NCT03330860|Experimental|Neuromarketing strategy|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
2435271|NCT03330860|Active Comparator|No-capsule group|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
3147991|NCT00136227|Experimental|Lifestyle counseling|Behavioral: small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention
3147992|NCT00136279|Experimental|School plus parent|Adolescents receive school-based curriculum (either Project TNT or Making a Difference) and mothers receive the Linking Lives curriculum
3147993|NCT00136279|Active Comparator|School-only|Adolescents receive school-based curriculum and parents received a control curriculum on helping their child choose a high school
2435311|NCT03330561|Experimental|PRS-343|
2435312|NCT03330548|Active Comparator|TeleMOVE!|Veterans randomized to the control arm will participate in TeleMOVE!, an arm of the Management of Overweight Veterans (MOVE!) program. TeleMOVE! is telehealth treatment program within the VA designed to improve the lives of Veterans by assisting with weight management and health promotion. This program includes daily interaction with in-home messaging technologies and clinician contact as needed
3147994|NCT00136279|Experimental|Parent-Only|In the sex risk reduction portion of the study only, a second experimental group consisted of parents receiving the Linking Lives intervention and adolescents receiving no in-school intervention
3147995|NCT00136305|Experimental|Pictorial Asthma Action Plan|
3147996|NCT00136305|Active Comparator|Written Asthma Action Plan|
3147997|NCT00136370|Experimental|1|Chlorhexidine Vaginal Wipe
3147998|NCT00136370|Placebo Comparator|2|Sterile water external genital wipe
2435277|NCT03330808|Experimental|Epidural with general anesthesia|Epidural anesthesia with 0.2% ropivacaine 10 ml
2435278|NCT03330808|No Intervention|General anesthesia alone|Sevoflurane and nitrous oxide.
3147999|NCT00136409|Experimental|Mono-Therapy Gleevec|Gleevec administered orally at a pre-determined dose once daily.
2435280|NCT03330782|Experimental|Elderly|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.
2435281|NCT03330782|Active Comparator|Adult|Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.
2435282|NCT03330769||Patients with active Psoriatic Arthritis|Patients with clinically diagnosed PsA with clinically active joint disease starting a new course of treatment.
2435283|NCT03330756|Active Comparator|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
2435284|NCT03330756|Experimental|Laparoscopic Mini Gastric Bypass|laparoscopic Mini gastric bypass
2435285|NCT03330743|No Intervention|Usual care|
2435286|NCT03330743|Placebo Comparator|Parent Mentor|
2435287|NCT03330743|Active Comparator|Parent Mentor with Positive Deviance|
2435288|NCT03330730|Experimental|Experimental|"Patients with oncological follow up and home-care service package IsereADOM:~Objects connected to patients' home (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer) with graduated protocol for medical platform support.~Digital linkbook (different from the medical file) accessible to the patient and the standard care actors.~Referent sentinel: a field actor to coordinate the care. Preferred contact of the patient outside the center Motivational coaching: 1 to 2 axes to be defined by the investigator among the following axes (physical activity, nutrition and hydration, drug compliance, medical follow-up, chronic and moral pain, acceptance of the disease and treatments)."
2435289|NCT03330730|No Intervention|Control|Patients with oncological follow up only
2435290|NCT03330717|Placebo Comparator|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
2435291|NCT03330717|Experimental|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
2435292|NCT03330717|Experimental|General anesthesia with preoperative session of hypnosis|Patients interested in hypnosis but too anxious to have surgery while on hypnosis sedation will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation using technology of virtual reality
2435293|NCT03330704|Active Comparator|Standard Therapy|This group will receive 3% hypertonic sodium chloride for the management of their cerebral edema. 3% Sodium Chloride is the generic name of this intravenous fluid preparation.
2435294|NCT03330704|Experimental|Balanced Therapy|This group will undergo two simultaneous infusions. 23.4% sodium chloride and 8.4% sodium bicarbonate will be infused at the same time in various ratios for management of cerebral edema with a balanced approach
2435295|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v1|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
2435296|NCT03330691|Experimental|Patient-derived CD19- and CD22 specific CAR v2|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
2435297|NCT03330678|Experimental|Probiotic (VSL#3)|Probiotics will be given to women included in study arm
2435298|NCT03330665|No Intervention|Control|No meditation
2435299|NCT03330665|Experimental|Intervention|Meditate using headspace app 3 times a week
2435300|NCT03330639|Experimental|Experimental Group|This group will receive the capsaicin. The Study Drug ICX72 or sinus buster which is a homeopathic blend of capsicum annum and eucalyptol, that is readily available over the counter.
2435301|NCT03330639|Placebo Comparator|Placebo Group|This group will receive saline. The Placebo formulation contained saline and eucalyptol in a concentration that matched the control.
2435302|NCT03330626|Active Comparator|IO group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the intake-output balance.
2435303|NCT03330626|Experimental|InBody group|Fluid overload will be removed in the patients who received continuous renal replacement therapy, but the amount of fluid removal are guided by the bioimpedance analysis (InBody S10).
2435304|NCT03330613|Other|Inhalational anesthesia|Inhalational anesthesia is an anesthesia procedure using by respiratory tract. PAEDS used to for postanesthesia pediatric patients.
2435305|NCT03330613|Active Comparator|Total intravenous anesthesia|Total intravenous anesthesia (TIVA) is an anesthesia procedure using vascular infusion method.PAEDS used to for postanesthesia pediatric patients.
2435306|NCT03330600|Experimental|aquatic physicotherapy group|For the experimental group, we will associate kinesiotherapy with immersion in water.
2435307|NCT03330600|Placebo Comparator|immersion group|The control group will be submitted to immersion in the water, contained in flexion with the towel and maintaining the same care as the experimental one.
2435308|NCT03330574||Variability of the device|We will study the repeatability and reliability of the Diopsys® ERG Vision Testing Systems in normal non-glaucomatous people and in those with suspicion of glaucoma or confirmed glaucoma.
2435309|NCT03330574||Diagnosis and progression of glaucoma|Patients who have a suspicion of glaucoma and patients with confirmed glaucoma will be included. PERG data obtained by the Diopsys® ERG Vision Testing Systems will be analyzed to study the PERG changes in different clinical situations, such as early glaucoma and progression of glaucoma.
3148000|NCT00136435|Other|Only Arm for this study|Only Arm for this study
3148001|NCT00136474|Active Comparator|Group 1|Amifostine plus radiation therapy
3148002|NCT00136474|Active Comparator|Group 2|Radiation therapy alone
3148003|NCT00136500||Individuals affected with ALS|This population be sporadic or familial ALS.
3148004|NCT00136500||Unaffected individuals from families in which the genetic cause of ALS is known|This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
3148005|NCT00136500||Individuals affected with an ALS-related neurodegenerative disease|This would include FTD, MSP, IBMPFD, etc.
2435313|NCT03330548|Experimental|Culinary Rx|Veterans randomized to the experimental arm will participate in Culinary Rx. Culinary Rx is an online instructional cooking and nutrition course that healthcare professionals can prescribe to patients who need to transition away from a Standard American Diet to a more health-supportive, whole foods, plant-based lifestyle. In partnership with The Plantrician Project, this course will focus on teaching the foundational cooking skills needed for long-term behavioral change, coupled with lifestyle education around nutrition and resources that will help users successfully face the many challenges inherent to dietary change.
2435314|NCT03330535|Active Comparator|Verbal oral hygiene instructions|Participants will receive verbal oral hygiene instructions during routine orthodontic visits.
2435315|NCT03330535|Experimental|Reminders once a week|Participants will receive active reminders once a week.
2435316|NCT03330535|Experimental|Reminders three times a week|Participants will receive active reminders three times a week.
2435317|NCT03330535|Experimental|Daily reminders|Participants will receive active reminders daily.
2435318|NCT03330522|Experimental|Intervention|"The active intervention is Love, Sex, & Choices, a 12-episode, online HIV prevention intervention video series accessed on study provided smartphones. Each episode is up to 20 minutes in length. Study participants receive one episode per week for 12 weeks on study provided smartphones."
2435319|NCT03330522|Active Comparator|Control Comparison Group|The control comparison intervention is twelve messages in text that promote HIV prevention behaviors and open communication with male sex partners. Study participants receive one message per week for 12 weeks on study provided smartphones.
2435320|NCT03330509|Experimental|Cluster 1|Control: 1-4 months; SPARK intervention: 5-20 months
2435321|NCT03330509|Experimental|Cluster 2|Control: 1-8 months; SPARK intervention: 9-20 months
2435322|NCT03330509|Experimental|Cluster 3|Control: 1-12 months; SPARK intervention: 13-20 months
2435323|NCT03330509|Experimental|Cluster 4|Control: 1-16 months; SPARK intervention: 17-20 months
2435324|NCT03330496||Preterm infants|preterm neonates (34-37 weeks gestational age, n=15)
2435325|NCT03330496||Term infants|term newborns (37-42 weeks gestation, n=15)
2435326|NCT03330496||Small infants|1-3 month-old infants (n=15)
2435327|NCT03330496||Older infants|3-6 month-old infants (n=15)
2435328|NCT03330483||Female Speedicath nelathon|Evaluation of pain or discomfort in female patients at/during/after Speedicath nelathon-tip catheter insertion
2435329|NCT03330483||Female nelathon|Evaluation of pain or discomfort in female patients at/during/after standard nelathon-tip catheter insertion
2435330|NCT03330483||Male Speedicath tiemann|Evaluation of pain or discomfort in male patients at/during/after Speedicath tiemann-tip catheter insertion
2435331|NCT03330483||Male tiemann|Evaluation of pain or discomfort in male patients at/during/after standard tiemann-tip catheter insertion
2435332|NCT03330470|Experimental|exercise and carnosine supplementation|exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily
2435333|NCT03330470|Experimental|exercise and supplementation with placebo|exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily
2435334|NCT03330470|Experimental|stretching controls and carnosine supplementation|stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily
2435335|NCT03330470|Experimental|stretching controls and supplementation with placebo|stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily
3188333|NCT00765752||3 Healthy comparison subjects|Healthy subjects with no history of insomnia
3188334|NCT00765791|Active Comparator|1|Level IIB is dissected
3188335|NCT00765791|Active Comparator|2|Level IIB is not dissected
3188336|NCT00765804|Active Comparator|Low Dose: DP 7.5 mA-min at 2.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 7.5 mA-min at 2.5 mA
2435340|NCT03330444||LD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota mainly composed of different species of the genus Lactobacillus, determined by NGS sequencing.
2435341|NCT03330444||NLD microbiome receptive to the ERA test|Receptive patients by the ERA test with an endometrial microbiota composed of different pathogenic bacteria such as Streptococcus and Gardnerella, or not dominated by bacteria of the genus Lactobacillus, determined by NGS sequencing.
2435342|NCT03330431|Experimental|Experimental group 1 (personal expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with personalized examples and stories before undergoing a PMR session.
2435343|NCT03330431|Experimental|Experimental group 2 (factual expert)|Participants watch a video of an expert describing the positive effects of Progressive Muscle Relaxation (PMR) with factual information (not personal) before undergoing a PMR session.
2435344|NCT03330431|Active Comparator|Control group|Participants read a neutral text before undergoing a Progressive Muscle Relaxation (PMR) session.
2435345|NCT03330418|Experimental|Placebo Comparator|Participants received placebo weekly administered subcutaneously for 48 times in the double-blind treatment period.Once the participants relapse,they should advance to the open phase.All participants were treated with the test drugs.
2435346|NCT03330418|Experimental|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 48 times.Starting with the forty-ninth dose,the trial went into the open phase . All participants were treated with the test drugs.
3188337|NCT00765804|Active Comparator|High Dose: DP 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) 10.5 mA-min at 3.5 mA
3188338|NCT00765804|Placebo Comparator|Placebo: 10.5 mA-min at 3.5 mA|Ocular Iontophoresis with Placebo (sodium citrate buffer solution 100 mM at 10.5 mA-min at 3.5 mA)
3188339|NCT00765830|Experimental|1|50mg qd vildagliptin
2435360|NCT03330392|Experimental|AGP|take two tablets per day (500 mg/day) for 8 weeks.
2435361|NCT03330392|Placebo Comparator|Placebo|take two tablets per day for 8 weeks.
2435362|NCT03330379|Experimental|continuous adjustment strategy|patients assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff
2435363|NCT03330379|No Intervention|usual care|patients with usual care
2435364|NCT03330366|Experimental|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
2435365|NCT03330366|Placebo Comparator|Placebo|take two capsules per day for 8 weeks
2435366|NCT03330353||Neurodegenerative Diseases|Individuals with neurodegenerative diseases
2435367|NCT03330340||Percutaneous vertebroplasty|All PVPs are performed by experienced spine surgeons under optimal fluoroscopic guidance. The procedure takes place under sterile conditions. Local anesthesia is administered to the periosteum of the targeted pedicle via skin. Polymethylmethacrylate bone cement is injected under continuous fluoroscopic guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. Patients are encouraged to stand up and walk with brace immediately after operation and the brace are required to be worn for 3 months. Furthermore, all patients will take oral bisphosphonates treatment together with supplemental calcium and vitamin D.
2435368|NCT03330340||Conservative treatment|In conservative treatment group, the patients were required horizontal bed rest for the initial 2 weeks after diagnosis. Then, they were encouraged to stand up and walk with brace and assistance. The bed rest time was extended if the back pain worsened when they stood up and walked. The brace should be worn in 3 months. For pain medication, nonsteroidal anti-inflammatory drugs (NSAIDs) were prescribed for every patient. Additional analgesics, such as tramadol and morphine, would be added in case NSAIDs were not effective. Two weeks after diagnosis, physical therapy was started. All patients are put on osteoporosis medication, bisphosphonates together with supplemental calcium and vitamin D.
2435369|NCT03330327|Experimental|Part 1|Intravenous (IV) infusion of HM12470
2435370|NCT03330327|Experimental|Part 2: Sequence 1|Intravenous (IV) infusion of HM12470
2435371|NCT03330327|Experimental|Part 2: Sequence 2|Intravenous (IV) infusion of HM12470
2435372|NCT03330314|Experimental|Part 1|Intravenous (IV) infusion
2435373|NCT03330314|Experimental|Part 2: Cohort A|Intravenous (IV) infusion (Dose A)
2435374|NCT03330314|Experimental|Part 2: Cohort B|Intravenous (IV) infusion (Dose B)
2435375|NCT03330314|Experimental|Part 2: Cohort C|Intravenous (IV) infusion (Dose C)
2435376|NCT03330301||Exposed|"Individuals born between June1983 and May1985 were exposed to the mandatory vitamin D margarine fortification during fetal life.~Cases: individuals defined as having one of the aforementioned diseases of interest from the registers"
2435377|NCT03330301||Non-exposed|"Individuals born between September1986 and August 1988 were not exposed to the mandatory vitamin D margarine fortification during fetal life.~Controls: cohort of matched disease-free individuals"
3148006|NCT00136500||Healthy controls|
3148007|NCT00136565|Experimental|Experimental|Velcade, Doxorubicine, Cyclophosphamide, Vindesine, Bleomycin, Prednisone
2435476|NCT03329703|Experimental|Immediate-Treatment|This group will receive Project UPLIFT immediately after completing surveys.
3148008|NCT00136578|Experimental|Subjects receiving carboplatin and SB-715992|Subjects will receive carboplatin on Day 1 as an intravenous (IV) infusion over 30 minutes followed by 1-hour IV infusion of SB-715992 once every 21 days.
3148009|NCT00136591|Active Comparator|A|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle. Subjects in this treatment arm will receive a total of 8 cycles of treatment,
3148010|NCT00136591|Experimental|B|
3148011|NCT00136656|Active Comparator|1|cefixime antibiotic treatment by oral route
3148012|NCT00136656|Sham Comparator|2|ceftriaxone antibiotic treatment by venous infusion and cefixime antibiotic treatment by oral route during six days
3148013|NCT00136682|Active Comparator|(PCEA)|patient-controlled epidural analgesia PCEA involves having an epidural catheter placed before surgery.The epidural catheter will be used during surgery to give drugs, such as morphine and a local anesthetic bupivacaine, which will help control pain. After surgery, a constant flow of pain-reducing medicine, such as morphine, will be given through the catheter. This is controlled by the patient.
3148014|NCT00136682|Active Comparator|PCA|patient-controlled intravenous analgesia (PCA) PCA involves placing a tube into the patient's vein after surgery. The tube is connected to a pump that is controlled by the patient. The pump holds a medicine, such as morphine, that eases pain.
3148015|NCT00136708|Experimental|NRP Training (Intervention)|Training in AAP neonatal resuscitation training program
3148016|NCT00136708|Other|Control|
3148017|NCT00136734|Experimental|1|methylphenidate
3148018|NCT00136734|Placebo Comparator|2|placebo
3148019|NCT00136747|Experimental|BUPROPION|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3148020|NCT00136747|Experimental|placebo|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3148021|NCT00136747|Experimental|memantine|Participants receive 20 mg bid of memantine, placebo, or bupropion in a double-blind crossover design and are maintained on active or placebo medication for 5 or 10 days before the inpatient testing
3148022|NCT00136786|Placebo Comparator|Intervention 1|"Each participant receives three consecutive interventions.~Placebo~Bupropion~Memantine"
3148023|NCT00136786|Placebo Comparator|Intervention 2|"Bupropion~Memantine~Placebo"
3148024|NCT00136786|Placebo Comparator|Intervention 3|"Memantine~Placebo~Bupropion"
2435388|NCT03330249|Experimental|Split Cisplatin and radiotherapy|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy
2435389|NCT03330249|Active Comparator|Cisplatin and radiotherapy|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy
2435392|NCT03330223||Clopidogrel|clopidogrel 75mg qd;aspirin 100mg qd, n=30
2435393|NCT03330223||Ticagrelor|ticagrelor 90mg bid; aspirin 100mg qd, n=30
3148025|NCT00136825|Placebo Comparator|2|Identical appearing placebo pill containing lactose powder, packaged to have similar odor as N-Acetylcysteine in capsule form
3148026|NCT00136825|Experimental|1|N-Acetylcysteine
2435396|NCT03330184|Experimental|Berberine Hydrochloride group|2/day, 16 weeks
2435397|NCT03330184|Experimental|Bifidobacterium group|2/day, 16 weeks
2435398|NCT03330184|Experimental|Berberine Hydrochloride and Bifidobacterium group|2/day, 16 weeks
2435399|NCT03330184|Placebo Comparator|placebo|bifidobacterium mimetic capsules berberine mimetic tablets,2/day, 16 weeks
2435400|NCT03330171|Other|HIV-unexposed children|HIV-unexposed children enrolled in a randomized open label study on the pneumococcal conjugate vaccine (PCV1+1) will be invited to participate in this study. Children enrolled in the PCV1+1 study will receive all vaccines included in the South African public immunization program. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
2435401|NCT03330171|Other|HIV-exposed children|A cohort of HIV-exposed children will be recruited. Measles vaccine (0.5 mL, subcutaneous injection) will be adminstered at 6 months of age and 12 months of age. Varicella vaccine (0.5 mL, subcutaneous injection) or Hepatitis-A vaccine (0.5 mL, intra-muscular injection) will be administered to the participants at 18 months of age as an additional benefit for participating in the study.
2435403|NCT03330145|Experimental|children who lost a parent to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
2435404|NCT03330145|Active Comparator|children who lost a parent not to cancer|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
2435405|NCT03330132|Active Comparator|Standard vaccine|Once-annual administration of standard vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435406|NCT03330132|Experimental|Alternating standard vaccine & adjuvanted vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435407|NCT03330132|Experimental|Alternating adjuvanted vaccine & standard vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435408|NCT03330132|Experimental|Alternating standard vaccine and high-dose vaccine|Alternating once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435409|NCT03330132|Experimental|Alternating high-dose vaccine and standard vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of standard inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435410|NCT03330132|Experimental|Alternating adjuvanted vaccine and high-dose vaccine|Alternating once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435477|NCT03329703|Active Comparator|Waitlist Control|This group will receive Project UPLIFT after waiting approximately 3 months to begin the intervention.
2435587|NCT03329014|Placebo Comparator|Placebo Powder|Powder containing 20 mg placebo for intranasal administration
3148027|NCT00136864|Experimental|1|PET Imaging
3148028|NCT00136864|No Intervention|2|Standard Imaging
3148029|NCT00136890|No Intervention|1|Conventional Staging
3148030|NCT00136890|Experimental|2|PET Imaging
3148031|NCT00136903|Active Comparator|Prochymal - 2 million cells|Prochymal - 2 million cells/kg actual body weight, intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses
3148032|NCT00136903|Active Comparator|Prochymal - 8 million cells|Prochymal - 8 million cells/kg actual body weight intravenously on study Days 1 and 4 plus daily methylprednisolone 2 mg/kg intravenously or prednisone 2.5 mg/kg orally. Subjects will also continue cyclosporine, tacrolimus, and/or MMF at full therapeutic doses
3148033|NCT00137176|Experimental|Rebif + Lipitor|
3148034|NCT00137189|Experimental|Music therapy|See published study protocol
3148035|NCT00137189|Other|Standard care|See published study protocol
3148036|NCT00137202|Active Comparator|2|
3148037|NCT00137215|Active Comparator|A|
3148038|NCT00137241||Group 1|
3148039|NCT00137254|Active Comparator|A|
3148040|NCT00137306|Other|Arm 1|
3148041|NCT00137501|Other|A|High dose Nifedpine arm
3148042|NCT00137501|Other|B|Low dose Nifedipine arm
3148043|NCT00137566|Experimental|1 Paracetamol|Paracetamol as per protocol
3148044|NCT00137566|Placebo Comparator|2 Placebo|Inactive placebo as per protocol.
3148045|NCT00137592|Experimental|Lifestyle counseling|Behavioral: small media, group education (multicomponent)
2435411|NCT03330132|Experimental|Alternating high-dose vaccine and adjuvanted vaccine|Alternating once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435412|NCT03330132|Experimental|High-dose vaccine|Once-annual administration of high-dose inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435413|NCT03330132|Experimental|Adjuvanted vaccine|Once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435414|NCT03330132|Experimental|Recombinant vaccine|Once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
2435415|NCT03330132|Experimental|Alternating recombinant vaccine and adjuvanted vaccine|Alternating once-annual administration of recombinant hemagglutinin inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter, and once-annual administration of MF59 adjuvanted inactivated influenza vaccine (northern hemisphere formulation) prior to the northern hemisphere winter throughout 4 years study period.
3188340|NCT00765830|Placebo Comparator|2|Placebo
3188341|NCT00765869|Experimental|1|Bowel cancer screening decision aid, DVD and Question Prompt List (QPL)
2435418|NCT03330106|Experimental|Part A: Pevonedistat 25 mg/m^2 + Pevonedistat 50 mg/m^2|Pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
2435419|NCT03330106|Experimental|Part A: Pevonedistat 50 mg/m^2 + Pevonedistat 25 mg/m^2|Pevonedistat 50 mg/m^2, infusion, intravenously, once on Day 1 of Cycle 1, followed by pevonedistat 25 mg/m^2, infusion, intravenously, once on Day 8 of Cycle 1.
2435420|NCT03330106|Experimental|Part B: Pevonedistat|Pevonedistat 25 mg/m^2 in combination with docetaxel 75 mg/m^2 or pevonedistat 20 mg/m^2 in combination with carboplatin plus paclitaxel 175 mg/m^2, infusion, intravenously, once on Day 1 in each 21-day treatment cycle followed by pevonedistat 25 mg/m^2 or 20 mg/m^2 infusion, intravenously, once on Days 3 and 5 in each 21-day treatment cycle for up to 12 cycles or symptomatic deterioration or PD, treatment is discontinued for another reason, or until the study is stopped. The combination and dose of pevonedistat will be based on investigator discretion.
2435421|NCT03330093|Experimental|Sleep Extension|1-month educational and problem solving behavioral intervention about sleep.
2435422|NCT03330093|Active Comparator|Health and Safety|1-month educational and problem solving behavioral intervention about health and safety.
2435423|NCT03330080||Ecological momentary assessment (EMA)|The ecological momentary assessment (EMA) will be used for participants to complete surveys from home on two occasions each day over seven days.
2435424|NCT03330067|Sham Comparator|Cold and dry CO2 pneumoperitoneum|Pneumoperitoneum is created by insufflation of standard cold (19-21°C) and nonhumidified (0%) CO2 directly from a standard CO2 tank or wall source.
2435425|NCT03330067|Experimental|Warm and humidified CO2 pneumoperitoneum|The humidification and warming device to be used is the Insuflow Synergy Port (Lexion Company, FDA approved) which is a specialized 5 mm port that delivers warmed (95° F) and humidified (95% relative humidity) CO2, the source of which is a standard CO2 tank or wall source.
2435426|NCT03330054||Group A|50 patients Type 2 Diabetes without renal impairment will be examined using fundoscope
2435427|NCT03330054||Group B|25 patients Type 2 Diabetes with chronic kidney disease not on replacement therapy (stage I-IV) will be examined using fundoscope
2435428|NCT03330054||Group C|25 patients Type 2 Diabetes with end stage renal disease on haemodialysis will be examined using fundoscope
3188342|NCT00765869|Experimental|2|Bowel cancer screening decision with DVD only
3188343|NCT00765869|Active Comparator|3|Australian Government Bowel Cancer Screening consumer information booklet
2435431|NCT03330028|Experimental|Hyperthermic Intraperitoneal Chemoperfusion (HIPEC)|Participants receive heated Mitomycin, Cisplatin, and Paclitaxel as a liquid that is injected through 3 to 4 small incisions into the abdomen over about 1 hour.
3188344|NCT00765908|Experimental|A|Patients undergoing elective PCI will be randomised to 90 second balloon inflations rather than the standard less than 30 second inflations in order to induce peri-ischaemic conditioning.
3188345|NCT00765908|Active Comparator|B|Control group. These patients will have a standard procedure with balloon inflations of 30 seconds or less as per standard.
2435434|NCT03329976||patient|any person about to undergo combined surgery for cataract and ERM
2435435|NCT03329963|Experimental|Lifestyle intervention Group|Behavioral therapy for weight loss and Exercise Training
2435436|NCT03329963|Active Comparator|Healthy lifestyle intervention Group|Group education sessions that focus on diet exercise and social support.
2435437|NCT03329950|Experimental|CDX-1140|Part 1: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance, or two years of treatment.
2435438|NCT03329950|Experimental|CDX-1140 and CDX-301|Part 2: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, intolerance or two years of treatment. A fixed dose of CDX-301 is injected once a day for five days before cycles 1 and 2 of CDX-1140.
2435439|NCT03329950|Experimental|CDX-1140 and pembrolizumab|Part 3: Eligible patients will receive CDX-1140, based on cohort assigned, in 3 week cycles until progression, or intolerance, or two years of treatment. A fixed dose of pembrolizumab will also be given in 3 week cycles.
2435440|NCT03329950|Experimental|CDX-1140 and chemotherapy|Part 4: Eligible patients will receive CDX-1140, based on cohort assigned, in 4 week cycles until progression, or intolerance, or two years of treatment. Chemotherapy will also be given according to standard of care.
3188346|NCT00765921|Experimental|1.0 mg ranibizumab|1.0 mg intravitreal injection given bi-monthly for 22 months
2435442|NCT03329924||Pre-implementation cohort|These patients are being exposed to the current standard of care, which does include some early mobilization practices, but not a formalized program.
2435443|NCT03329924||post-implementation cohort|These patients will have been exposed to the fully executed early mobilization program.
3188347|NCT00765921|Experimental|0.5 mg ranibizumab|0.5 mg intravitreal injection given bi-monthly for 22 months
3188348|NCT00765934|Other|Rapydan|Internal control. Blood from both arms will be drawn. Only one arm of the subject is treated with Rapydan.
3188349|NCT00765973|Experimental|A|Arm A: TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
2435446|NCT03329898|Experimental|dried biological amnion graft|dried biological amnion graft patients, who are with IUA, treated by uterine application of dried biological amnion graft + disposable balloon uterine stent + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2435447|NCT03329898|Sham Comparator|disposable balloon uterine stent only|disposable balloon uterine stent patients, who are with IUA, treated by uterine application of disposable balloon uterine stent only + hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
3188350|NCT00765973|Experimental|B|Arm B: TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
3188351|NCT00765986||1|Patients with inoperable NSCLC undergoing RT or Chemo-RT
3188352|NCT00766012|Experimental|1|4 dose panels receiving a specified volume of AZD2066 oral solution once daily for 11 days
2435451|NCT03329872||Patients group|Patients follow-up in hospital will have data collection
2435452|NCT03329859|Experimental|Interventional arm|"High resolution standardized laparoscopic cholecystectomy Patients in which laparoscopic cholecystectomy was performed after high Resolution standardization and Training of the OR Team according to the Standard."
2435453|NCT03329859|Active Comparator|Control arm|No 'High resolution standardized laparoscopic cholecystectomy' Patients in which laparoscopic cholecystectomy was performed in the conventional way without prior standardization
3188353|NCT00766012|Placebo Comparator|2|Included in each dose panel
3188354|NCT00766025|Experimental|Rosuvastatin Calcium|
2435456|NCT03329833|Experimental|Motivational Interviewing|Participants will talk to a coach on the phone who will employ Motivational Interviewing as a coaching style.
2435457|NCT03329833|Experimental|Web-Based Application|Participants will use a Web-Based Application to track their daily physical activity.
2435458|NCT03329833|Experimental|Combination MI and App|Participants will have both a coach by phone who will employ Motivational Interviewing as a coaching style and use a Web-Based Application to track their daily physical activity.
2435459|NCT03329833|No Intervention|Educational Program|Participants will get to use a website that contains information relevant to patients with Parkinson's Disease.
2435460|NCT03329820||1 Uncomplicated CHB|Patients with chronic CHB infections but normal liver function and without cirrhosis or hepatocellular carcinoma
2435461|NCT03329820||2 CHB with impaired liver function (LF) or CC w/o tx|CHB with impaired liver function or compensated cirrhosis, not on anti-viral treatment
2435462|NCT03329820||3 CHB with impaired LF or CC with tx|CHB with impaired liver function or compensated cirrhosis, on anti-viral treatment.
2435463|NCT03329820||4 Decompensated cirrhosis|Patients with CHB infection and cirrhosis complicated by one or more of the following: variceal bleeding, hepatic encephalopathy or ascites.
2435464|NCT03329820||5 Hepatocellular carcinoma|Patients with confirmed diagnosis of hepatocellular carcinoma
2435465|NCT03329807|Experimental|Experimental rTMS and conventional sensory therapy|"Device: Repetitive Transcranial Magnetic Stimulation (rTMS) The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.~Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week."
2435466|NCT03329807|Sham Comparator|Sham Comparator|"control The control group received rTMS sham stimulation (same area as the experimental group) in 10 sessions, 5 days per week, and Sham conventional sensory therapy in the paretic upper limb The sham stimulation will be applied so that it is perceived by the patient as real. Thus during the rTMS sessions the same procedures of the active rTMS sessions will be applied, however the stimulation will be performed with two coils: a coil coupled to the stimulator positioned away from the patient's scalp, yet not visible to the patient so that the patient Perceive only the characteristic sound of the stimulation, and the other coil, disconnected from the stimulator positioned on the volunteer's head.~For the SHAM group, all sensory therapy activities will be performed, however only with the non-affected member. Patients will be convinced that a transfer of skills from one member to another can occur through the connections between the hemispheres."
2435467|NCT03329781|Experimental|Trial|350 mg of BCM-95, 1 capsule per day, for 21 days.
2435468|NCT03329781|Placebo Comparator|Control|350 mg of starch, 1 capsule per day, for 21 days
2435469|NCT03329755|Experimental|Experimental|
2435470|NCT03329755|Other|Standard|
2435471|NCT03329742|Placebo Comparator|Control protein diet arm|20% protein content
2435472|NCT03329742|Experimental|Low protein diet arm|10% protein content
2435473|NCT03329729||Hyperlipidemic patients|
2435474|NCT03329716|Other|Immediate Brace Weaning|Immediate weaning of brace
2435475|NCT03329716|Other|Gradual Brace Weaning|Nocturnal brace wearing for 6 months prior to stopping brace
2435749|NCT03327870||1|Sjogren's Syndrome
3188355|NCT00766064|Experimental|Paliperidone Dosing|Paliperidone Dosing up to 6 weeks, with a maximum dosage of 6mg
3188356|NCT00766103|Other|crossover: hypo- and hypercarbia|
3188357|NCT00766129|Experimental|T|Implantation of Taxus stent into saphenous vein graft
3188358|NCT00766129|Experimental|C|Implantation of Luc-Chopin stent into saphenous vein graft
3188359|NCT00766155|Active Comparator|Arm I|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients may receive additional chemoradiotherapy on days 36-38. Patients then undergo surgery. Beginning 4-8 weeks after surgery, patients receive capecitabine twice daily on day 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3188360|NCT00766155|Experimental|Arm II|Patients receive oral capecitabine twice daily and undergo concurrent 3-dimensional conformal radiotherapy 5 days a week on days 1-33. Patients also receive oxaliplatin IV over 1 hour on days 1, 8, 15, 22, and 29 prior to radiotherapy followed by surgery. Patients may receive additional chemoradiotherapy on days 36-38. Beginning 4-8 weeks later, patients receive oxaliplatin IV over 2 hours on day 1, and oral capecitabine twice daily on days 1-15. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3188361|NCT00766168|Active Comparator|Control|FluoroPerm 30 RGP lens daily wear
3188362|NCT00766168|Experimental|HDS HI 1.54|New rigid gas permeable contact lens material material
3188363|NCT00766181||1: Lifestyle|Observatonal
2435483|NCT03329664|Experimental|CIK Intervention plus routine treatment|Patients who receive their routine treatment (chemotherapy, radiation therapy) + Cytokine-induced killer cell infusion
2435484|NCT03329664|Active Comparator|Control|Patients who receive routine treatments only (chemotherapy, radiation therapy)
2435485|NCT03329651|Experimental|Metformin treatment|
2435486|NCT03329651|Placebo Comparator|Placebo treatment|
2435487|NCT03329638|Experimental|DE-127 Ophthalmic Solution low dose|
2435488|NCT03329638|Experimental|DE-127 Ophthalmic Solution medium dose|
2435489|NCT03329638|Experimental|DE-127 Ophthalmic Solution high dose|
2435490|NCT03329638|Placebo Comparator|Placebo Ophthalmic Solution|
2435491|NCT03329625|Experimental|Pathways Triple P|Families randomized to the Pathways Triple P received a 14 week home based intervention.
2435492|NCT03329625|Active Comparator|Services as Usual|Families randomized to the services as usual condition received services as usual through the Missouri Children's Division
2435493|NCT03329612|Experimental|Intervention|This group will undergo remote ischemic preconditioning with serial inflations of the blood pressure cuff to 200 mmHg followed by deflation for reperfusion for a period of 5 minutes each for a total of 4 cycles.
2435494|NCT03329612|Sham Comparator|Control|This group will undergo serial inflations of the blood pressure cuff to 40 mmHg followed by deflation for a period of 5 minutes each for a total of 4 cycles.
2435495|NCT03329599|Experimental|Polypill|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
2435496|NCT03329599|No Intervention|Usual Care|Will continue to take separate, individual secondary preventive medications as prescribed
2435497|NCT03329586|Experimental|Training|
3188364|NCT00766181||2: Lifestyle|Observational
3188365|NCT00766207|Experimental|multi-faceted decision support|Multi-faceted decision support
3188366|NCT00766207|Active Comparator|control|stream-lined clinical alert
3188367|NCT00766220|Active Comparator|SIR-Spheres + Therapy|SIR-Spheres with Cetuximab + Irinotecan Therapy
2435502|NCT03329560|Experimental|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
2435503|NCT03329547|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= SKF101804 cefixime 400 mg test capsules and B= cefixime 400 mg reference capsules. Subjects will receive single oral dose of treatment A in treatment period 1 on Day 1 and treatment B in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
2435504|NCT03329547|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B= cefixime 400 mg reference capsules and A= SKF101804 cefixime 400 mg test capsules. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days. Subjects will receive single oral dose of treatment B in treatment period 1 on Day 1 and A in treatment period 2 on Day 1. Treatment periods 1 and 2 will be separated by a washout period of 7 to 14 days.
2435505|NCT03329534|Experimental|Subjects with GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health care professional will be administered for one month's time.
2435506|NCT03329534|Active Comparator|Subjects without GRDs|An intervention of a change in diet, specifically a gluten free diet taught by a health-care professional will be administered for one month's time.
2435507|NCT03329521|Experimental|Multi-component quality improvement intervention|A multi-component quality improvement intervention will be provided at chronic kidney disease (CKD) programs.
2435508|NCT03329521|No Intervention|Usual Care|CKD programs will continue to support access to kidney transplantation and living kidney donation as they usually do for CKD patients.
2435509|NCT03329508|Experimental|P2B001|Fixed dose combination once daily capsule of pramipexole and rasagiline
2435510|NCT03329508|Experimental|rasagiline capsule|rasagiline Once daily capsule
2435511|NCT03329508|Experimental|Pramipexole capsule|Pramipexole once daily capsule
2435512|NCT03329508|Active Comparator|Pramipexole Extended Release|pramipexole ER tablet titrated to optimal dose of 1.5, 3.0 or 4.5mg
2435513|NCT03329495|Active Comparator|SMA-orientated right hemicoloectomy|SMA-orientated right hemicoloectomy
2435514|NCT03329495|Experimental|SMV-orientated right hemicoloectomy|SMV-orientated right hemicoloectomy
2435515|NCT03329482|Experimental|Pulse Ultrasound Group A|This is the Pulse Ultrasound group. Twenty five patients will be in this group.
2435516|NCT03329482|Experimental|Kneading Massage Group B|This is kneading massage group . Also 25 patients will be in this group.
2435750|NCT03327870||2|Sicca
3188368|NCT00766220|Active Comparator|Therapy Only|Cetuximab + Irinotecan Therapy
3188369|NCT00766233|Active Comparator|1|Hyperthermal treatment once per week
3188370|NCT00766233|Active Comparator|2|Hyperthermal treatment 3 times a week
3188371|NCT00766246|Experimental|First-line|Carboplatin, docetaxel, bevacizumab Open-label, single arm with treatment period up to 6 cycles. Patients completing a total of 2 to 6 cycles of first-line without disease progression will be eligible for maintenance.
3188372|NCT00766246|Experimental|Maintenance|Bevacizumab Open-label, single arm with treatment period up to 18 cycles.
3188373|NCT00766259||1|Hemodialysis
3188374|NCT00766259||2|Intensive care
2435517|NCT03329469||Experimental: 1: Toshiba CT-FFR Arm|All patients who consent will receive Toshiba CT-FFR and medically acceptable care based on the study protocol, commonly accepted standards of care, and the patients condition.
2435518|NCT03329456|Other|Ropivacaine|Single arm intervention
2435519|NCT03329443|Placebo Comparator|placebo|
2435520|NCT03329443|Active Comparator|Spironolactone|
2435521|NCT03329430|Experimental|Foot orthoses|Customize foot orthoses
2435522|NCT03329417|Active Comparator|Traditional occupational therapy|The program includes 30 minutes of traditional occupational therapy (sensorimotor facilitation techniques, such as: Rood, Bobath and propriocetive-neuromuscular-facilitation), followed by 20 minutes of motor task specific training in each treatment session.
2435523|NCT03329417|Active Comparator|Mirror therapy using a mirror box|The program includes 30 minutes of mirror therapy, followed by 20 minutes of regular motor task specific training in each treatment session.
2435524|NCT03329417|Experimental|Virtual reality based mirror therapy|The program includes 30 minutes treatment session of virtual reality mirror therapy, followed by 20 minutes of motor task specific training in each treatment session.
3188375|NCT00766259||3|vascular patients with open wounds
3188376|NCT00766259||4|nursing home
2435527|NCT03329391|Experimental|Intervention Group|The intervention group will receive a 8-week nurse-led psychosocial care group,which involve 90 minutes session every week.
2435528|NCT03329391|No Intervention|Control Group|The control group will receive usual care, which refers to the pharmacological therapy provided by psychiatrists in the Psychiatric Department.
3148046|NCT00137605|Experimental|Pneumovax/immediate|
3148047|NCT00137605|Experimental|Pneumovax/delayed|
2435531|NCT03329365||ESUS/ETUS|Patients with embolic ischemic stroke or transient ischemic attack of undetermined source
2435532|NCT03329365||SSS-CVTUS|Patients with superior sagittal sinus cerebral venous thrombosis of undetermined source
3148048|NCT00137605|Experimental|Prevnar/immediate|
2435534|NCT03329339|No Intervention|2 L PEG with ascorbic acid group|
2435535|NCT03329339|Experimental|1 L PEG with ascorbic acid with PLD|
2435536|NCT03329313|Active Comparator|Low sodium concentration|Concentration of sodium in dialysate at 140 mmol/l ( Lowering sodium concentration dialysate)
2435537|NCT03329313|Sham Comparator|High Sodium Concentration|Concentration of sodium in dialysate at 145 mmol/l (Highing sodium concentration dialysate)
2435538|NCT03329300|Other|All participants|Family-based Behavioral Treatment (FBT)
2435539|NCT03329287|Experimental|SCBT + Drug|Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
2435540|NCT03329287|Active Comparator|Psychological Placebo + Drug|Participants receive supportive and relaxation therapy at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
2435541|NCT03329287|Active Comparator|Drug|Participants only take SSRIs and/or SNRIs through the trial at a recommended dosage.
2435542|NCT03329274||Patients with Erdheim-Chester Disease|
2435543|NCT03329261|Active Comparator|Arm 1 (single dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
2435544|NCT03329261|Active Comparator|Arm 2 (double dose)|Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily double dose of clopidogrel (150 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
2435545|NCT03329248|Experimental|NANT Pancreatic Cancer Vaccine|A combination of agents will be administered to subjects in this study: ALT-803, ETBX-011, GI-4000, haNK, avelumab, bevacizumab, capecitabine, cyclophosphamide, fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, oxaliplatin, SBRT
2435546|NCT03329235|Experimental|Intraosseous and intra-articular|injection of PRP 2 ml
2435547|NCT03329235|Active Comparator|intra-articular PRP|injection PRP 2 ml
2435548|NCT03329235|Active Comparator|Intra-articular injection of HA|injection of HA 2 ml
2435549|NCT03329222|Experimental|Intervention group|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
2435550|NCT03329222|Active Comparator|Control group|Standard cow's milk with prebiotics mixture
3188377|NCT00766259||5|skin infections
3188378|NCT00766259||6|control- ambulatory care clinic patients with no infections
2435554|NCT03329183|Experimental|HD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive high-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course.)
2435586|NCT03329014|Experimental|40 mg Solution Remimazolam|Solution containing 40 mg remimazolam for intranasal administration
3148049|NCT00137605|Experimental|Prevnar/delayed|
3148050|NCT00137735|Active Comparator|1|Gabapentin
3148051|NCT00137735|Placebo Comparator|2|Placebo
3148052|NCT00137787|Experimental|1|
3148053|NCT00137787|Active Comparator|2|
3148054|NCT00137800|Experimental|Tarceva|Chemotherapy Single Agent Systemic
3148055|NCT00137852|Experimental|Cisplatin/CPT-11/Celecoxib/XRT/Surgery|Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
3148056|NCT00137865|Experimental|EGEN-001|
3148057|NCT00137995|Experimental|R-ICE|R-ICE + R-BEAM /ASCT Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
3148058|NCT00137995|Experimental|R-DHAP|R-DHAP + R-BEAM /ASCT Rituximab, Cisplatine, Cytosine Arabinoside, Dexamethasone BCNU, Etoposide, Cytarabine, Melphalan Autologous Stem Cell Transplantation
3148059|NCT00138008|Active Comparator|1|Drug: endocrine therapy
3148060|NCT00138008|Experimental|2|Procedure/Surgery: radiotherapy
2435555|NCT03329183|No Intervention|SD-FOLFIRI|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFIRI regimen (Irinotecan 180mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
2435556|NCT03329183|No Intervention|SD-FOLFOX-6|Advanced CRC patients with Wild-type UGT1A1*6 and *28 receive standard-dose FOLFOX-6 regimen (Oxaliplatin 130mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
2435557|NCT03329170|Experimental|CHD intervention|educational intervention using motivational interviewing
2435558|NCT03329170|No Intervention|CHD control|At 24 and 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
2435559|NCT03329170|No Intervention|Healthy control|At 36 months of age the parents of the child will fill in a questionnaire via internet, designed to assess oral health behaviour. At 36 months of age the child will be offered to participate in a clinical dental examination.
2435560|NCT03329157|Other|Rebuilding Bridges|This is a one-group study and the group will receive the Rebuilding Bridges intervention
2435561|NCT03329144|Experimental|Cognitive Behavioural Therapy|The women in this arm will receive a 9-week CBT-based curriculum delivered by Public Health Nurses to help build resilience and optimize mood, anxiety, and emotion regulation while attending a supported school program in Niagara Region.
2435562|NCT03329131|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during each neurotoxic chemotherapy agent infused treatments by Elasto gel™ Hypothermia gloves and socks. Patients will wear the glove and sock for 15 minutes prior to treatment start and 15 minutes following treatment completion, for a total of 30 minutes.
2435563|NCT03329118|Experimental|SHR3824 1Omg,Simavastatin 40mg|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
2435564|NCT03329105|Experimental|Sea Salt Mouth Rinse|
2435565|NCT03329105|Active Comparator|Standardized Oral Health Practices|
3148061|NCT00138177|Experimental|Treatment (vorinostat, mFOLFOX)|"Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD."
3148062|NCT00138216|Experimental|Oral Irinotecan, temozolomide and vincristine sulfate|see detailed description
3148063|NCT00138437||Leprosy Patients (Group 1)|All leprosy patients
2435570|NCT03329066|Experimental|MAST - Managing Asthma & Sleep in Teens|This is an eight week intervention consisting of 4 group and 4 individual tailored coaching sessions that focuses on both asthma and sleep. In this behavioral medicine intervention, teenagers learn ways to better care for their asthma and sleep hygiene. Teen sessions are delivered in school. Their caregivers will receive four educational booklets that correspond to each group session; topics mirror the objectives of each group and the booklets are sent at the time of each group.
2435571|NCT03329066|Active Comparator|ASMA - Asthma Self-Management for Adol|ASMA is an evidence-based intervention for students, caregiver education, and education for students' medical providers. The student intervention consists of 3 group sessions & 5 individual tailored coaching sessions. All sessions are held at school. The caregiver intervention includes 3 educational booklets that correspond to the timing of the student group and 4 brief telephone-counseling sessions to review the booklets, answer questions, and provide strategies to support adolescents' steps to care for their asthma. With caregiver permission, we mail students' healthcare providers a toolkit consisting of (1) a letter informing them their patient is participating in ASMA and is being directed to them for clinical evaluation and (2) summaries of key NHLBI guidelines for treating asthma.
2435572|NCT03329066|Placebo Comparator|Information & Referral Control Group|The information-and-referral control intervention is a student-only intervention that consists of 3 group sessions and 5 individual sessions. Sessions are held once a week at school, where students will receive guideline-based information about asthma and other health topics relevant to adolescents (e.g., nutrition, safety). Students will be referred to their medical providers for asthma and other health concerns; if they do not have a provider, they are given referrals in their community.
2435573|NCT03329053|Experimental|Experimental group|Patients randomized into the experimental group will undergo behavioural counselling. During the 30-minute long consultation patients will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support system EXPERT tool.
2435574|NCT03329053|Active Comparator|Control group|Patients randomized into the control group will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, also in the domain of recommendations for physical activities.
2435575|NCT03329040||Primipara mothers|Infant to primipara mothers, i.e. the first infant to the mother - No intervention
2435576|NCT03329040||Multipara mothers|Infant to multipara mothers, i.e. not the first infant to the mother - No intervention
2435577|NCT03329027|Experimental|Vibrating Mode 1|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2435578|NCT03329027|Experimental|Vibrating Mode 2|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2435579|NCT03329027|Sham Comparator|Sham|Patients will receive sham capsule for 8 weeks of treatment (5 capsules/week)
2435580|NCT03329014|Experimental|Intravenous Remimazolam|4 mg intravenous remimazolam as an intravenous control
2435581|NCT03329014|Experimental|10 mg Powder Remimazolam|Powder containing 10 mg remimazolam for intranasal administration
2435582|NCT03329014|Experimental|10 mg Solution Remimazolam|Solution containing 10 mg remimazolam for intranasal administration
2435583|NCT03329014|Experimental|20 mg Powder Remimazolam|Powder containing 20 mg remimazolam for intranasal administration
2435584|NCT03329014|Experimental|20 mg solution Remimazolam|Solution containing 20 mg remimazolam for intranasal administration
2435585|NCT03329014|Experimental|40 mg Powder Remimazolam|Powder containing 40 mg remimazolam for intranasal administration
2435588|NCT03329014|Placebo Comparator|Placebo solution|Solution containing 20 mg placebo for intranasal administration
2435589|NCT03329001|Experimental|Stage 1: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase
2435590|NCT03329001|Experimental|Stage 1: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
2435591|NCT03329001|Experimental|Stage 2: Tablet-Capsule Sequence|Single dose niraparib tablet followed by single dose niraparib capsule followed by optional daily dosing extension phase.
2435592|NCT03329001|Experimental|Stage 2: Capsule-Tablet Sequence|Single dose niraparib capsule followed by single dose niraparib tablet followed by optional daily dosing extension phase
2435593|NCT03329001|Experimental|Stage 3: High fat meal-fasted sequence|Single dose niraparib tablet with a high fat meal followed by single dose of niraparib tablet in a fasted state.
2435594|NCT03329001|Experimental|Stage 3: Fasted-high fat meal sequence|Single dose niraparib tablet in a fasted state followed by single dose Niraparib tablet with a high fat meal.
2435597|NCT03328975|Active Comparator|Dexamethasone|Group 1 will receive an injection of 4mg of dexamethasone 4 mL of 1% lidocaine.
2435598|NCT03328975|Placebo Comparator|Placebo|Group 2 will receive an injection of 5 mL of 1% lidocaine (placebo).
2435599|NCT03328962|No Intervention|Control group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/17 to 15/3/18. Their smoking status will be observed over a period of six months.
2435600|NCT03328962|Experimental|Intervention group|Newly diagnosed cancer patients at their first consultation for treatment at an oncological hospital Department, who report to be smoking, recruited from 15/09/18 to 15/3/19. The intervention group will receive structured smoking cessation counselling based on MI and adapted for the cancer setting combined with provision of smoking cessation medication (nicotine replacement therapy) while in the control group there will be standard care which may vary from hospital to hospital. Their smoking status will be observed over a period of six months.
3188379|NCT00766272|Experimental|Arm 1|Body-weight supported treadmill training
2435602|NCT03328936|Experimental|Arm I (melphalan hydrochloride for 3-day severe neutropenia)|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for for predicted 3-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
2435603|NCT03328936|Experimental|Arm II (melphalan hydrochloride or 5-day severe neutropenia))|Patients receive personalized dose of melphalan hydrochloride IV on day -2 for predicted 5-day duration of severe neutropenia and undergo standard of care autologous stem cell transplant on day 0.
2435604|NCT03328923|Experimental|500mg brown seaweed powder|2 x 250mg capsules InSea2® (brown seaweed powder)
2435605|NCT03328923|Placebo Comparator|Placebo|2 x capsules microcrystalline cellulose (bulking agent) (0mg InSea2®)
2435606|NCT03328910||Analgesia monitoring|After anesthesia induction, all participants received standard anesthesia monitoring, SPI monitor (GE Healthcare, Helsinki, Finland) and bispectral index (BIS). BIS was kept between 40-60, whereas no specific target was determined for SPI. At the end of surgery, anesthesia was terminated and the patients were stimulated to wake up. After the participants were able to breathe spontaneously and obey verbal commands, extubation was carefully performed, and the monitoring of SPI was stopped.
3188380|NCT00766285|Active Comparator|TIV|50 subjects to receive 45 mcg of TIV administered on Day 0 and Day 28.
3188381|NCT00766285|Experimental|rHAO|50 subjects to receive 405 mcg of rHAO administered on Day 0 and Day 28.
3188382|NCT00766298|Experimental|1|Weight Loss
2435610|NCT03328884|Other|nal-IRI|This is a single arm study. After signing the informed consent form, patients will start treatment with nal-IRI. nal-IRI will be administered at a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy.
2435611|NCT03328871|Experimental|Fractional CO2 Laser and PRP injection|One of the striae gravidarum areas will be treated by fractional laser once every three months for 2 times combined with PRP injection once a month for 6 times.
2435612|NCT03328871|Experimental|Nanofat grafting and PRP injection|Another area will be treated by nanofat grafting once every three months for 2 times and PRP therapy once a month for 6 times.
2435613|NCT03328858|Other|Ketogenic Diet|Participants will be provided a consultation with a ketogenic dietitian, and test the tolerance to the diet in an inpatient mode
3188383|NCT00766298|Experimental|2|Exercise
3188384|NCT00766298|Experimental|3|Exercise and Weight Loss
3188385|NCT00766311|Other|1|This single-arm feasibility trial will evaluate the administration of an aggressive exercise regimen.
3188386|NCT00766324|Experimental|A|
3188387|NCT00766324|Experimental|B|
3188388|NCT00766337|Experimental|Dose Group 1|
3188389|NCT00766337|Experimental|Dose Group 2|
3188390|NCT00766337|Placebo Comparator|Dose Group 3|
3188391|NCT00766350|Active Comparator|amitriptyline|
3188392|NCT00766350|Experimental|quetiapine|
3188393|NCT00766389||1|Defined glaucoma patients
3188394|NCT00766389||2|Glaucoma suspects and normal controls
2435622|NCT03328819|Experimental|Acupuncture for Depression/Acupuncture for pain|
2435623|NCT03328819|Experimental|Acupuncture for pain/Acupuncture for Depression|
2435624|NCT03328793|Experimental|Music Intervention (Intervention Group)|"The patients will assist to a live music session of 30 minutes which will be given by musicians (volunteers) and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
2435625|NCT03328793|Active Comparator|Documentary watching (Control Group)|"The patients will watch a documentary for 30 minutes in the presence of a volunteer and will undergo:~mood assessment~emotion assessment~mobility assessment~communication assessment"
2435626|NCT03328780||Hemoglobin determination|In this study classical laboratory determination, determination with HemoCue® and Rad-67™ will be performed to compare precision of those three methods as well as their correlation.
2435627|NCT03328767|Experimental|Early activity and Mobilisation intervention|Patients will be randomised within 48 hrs of commencing ECMO. Patients unable to initially receive active physical training will receive passive physical training for a minimum of 20 minutes and a maximum of one hour per day to maintain joint and muscle activity until active physical training is commenced. The intervention involves a progression of exercises with the objective of rehabilitating the patient at the highest level of exercise possible for the patient for the longest period of time that can be tolerated (up to 60 minutes) at each session, based on our published ICU mobility scale now used internationally in ICU trials. This is performed with or without IMV (including both endotracheal tubes or tracheostomies).
2435628|NCT03328767|No Intervention|Standard Care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
2435629|NCT03328754|Experimental|Group 1 Powerscope|Powerscope placed bilaterally for class II correction
2435630|NCT03328754|Experimental|Group 2 Forsus|Forsus placed bilaterally for class II correction
2435631|NCT03328741|Experimental|Joint Academy|Online osteoarthritis treatment
2435632|NCT03328741|Active Comparator|The BOA program|Face-to-face osteoarthritis treatment
2435633|NCT03328728|Experimental|Cellular Matrix / A-CP HA Kit|One intra-articular injection of a combination of PRP and non-crosslinked HA
2435634|NCT03328728|Active Comparator|Synvisc-One|One intra-articular injection of a crosslinked HA
2435635|NCT03328715|Active Comparator|study group|only patients with diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
2435636|NCT03328715|Sham Comparator|controll group|only patients without diabetic macular edema will be recruited in that arm, stand-alone OCT and intraoperative OCT will be performed before and after surgery
2435637|NCT03328702|Experimental|Continue Positive Airway Pressure|Continue Positive Airway Pressure during VFSE
2435638|NCT03328689|Experimental|Physical activity in the community|The physical activity program will include an individualized exercise program delivered in community exercise facility plus education..
2435639|NCT03328689|Active Comparator|Control group standard care|Participants from the control group will receive no additional intervention other than being encouraged to continue with their physiotherapists or chiropractor recommendation which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
2435640|NCT03328676|Experimental|"Avidekel  cannabis oil 20:1 CBD:THC"|The cannabis oil will be mad out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-THC) and Cannabidiol (CBD) in a 1:20 ratio and at a concentration of 30% CBD and 1.5% Δ9-THC. Each Avidekel oil drop is approximately 0.04 ml in volume containing about 12 mg CBD and 0.6 mg Δ9-THC.
2435641|NCT03328676|Placebo Comparator|placebo oil|Patients in the control group will receive placebo.
2435642|NCT03328663|Experimental|CARE intervention|"Six psychological intervention sessions in-person or via video conferencing conducted by a trained psychologist~The CARE intervention contain 3 component~a psychoeducational component to address preparednessmanage expectations, and develop caregiving skills~a psychosocial component focusing on coping strategies, mindfulness, and facilitating acceptance while living with uncertainty~a self-care component to promote caregiver health and well-being"
2435643|NCT03328663|Active Comparator|Standard transplant care|"Standard Transplant Care~Social work consults to help caregivers only upon request"
2435644|NCT03328650||Proximal Humerus Fracture Patients|As part of their routine care, patients who have experienced a proximal humerus fracture that requires operative fixation will receive the A.L.P.S® Proximal Humerus Plating System. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
2435645|NCT03328637|Experimental|Intervention|Patients in the intervention group will be provided Cognitive Behavioral Therapy (CBT). CBT is a common psychological intervention based on the notion that thoughts trigger the emotions. In CBT patients are trained to monitor their thoughts and identify those that trigger addictive feelings and actions while they learn new coping skills and ways to prevent a relapse (Beck, Wright, Newman & Liese, 2001). The treatment period of CBT is three months consisting of a weekly session and total 12 sessions. Initial stage of therapy is behavioral, centering on specific behaviors and situations. Latter on there is more of a focus on the cognitive assumptions and distortions that have developed and the effects of these on behavior.
2435646|NCT03328637|No Intervention|Control|Control group will not receive CBT however, primary care service providers and mental health professionals will provide any required routine care according to their clinical judgment and available resources.
2435648|NCT03328598|Experimental|Positive psychology therapy group|This arm will be given a positive psychological group intervention developed from an foreign psychotherapy.
2435649|NCT03328598|Experimental|Resilience promotion therapy group|This arm will be given a resilience group intervention developed from our pervious research results.
2435650|NCT03328598|Active Comparator|Controlled routine activity group|This arm will continue to participate in conventional community activities.
2435651|NCT03328585|Active Comparator|CBT-I in person|
2435652|NCT03328585|Experimental|CBT-I via telemedicine|
2435653|NCT03328585|Other|Waitlist Control|Patients in this arm will receive in person CBT-I treatment after conclusion of the study.
2435654|NCT03328572|Active Comparator|E-max Endocrowns|all patients in this arm will receive e-max endocrowns
2435655|NCT03328572|Experimental|Cerasmart Endocrowns|all patients in this arm will receive Cerasmart endocrowns
2435656|NCT03328559|Other|early stage bronchial cancer|Early stage which can benefit from a surgical resection. A taking will be made in preoperative then in every consultation of follow-up after the intervention
2435657|NCT03328559|Other|advanced stage bronchial cancer|Patients locally moved forward or at a metastatic stage handled by chemotherapy
2435658|NCT03328533|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
2435659|NCT03328533|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine bitartrate infusion by a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min). The rate will be then adjusted according to the patient blood pressure. The infusion will stop in case of reactive hypertension. The infusion will start again when blood pressure returns to normal reading. Infusion will be increased by 20% if hypotension occurred.
2435660|NCT03328520|Experimental|First Year Students in Wellness FYIs|
2435661|NCT03328507|Experimental|BLI4900|BLI4900 Bowel Preparation
2435662|NCT03328507|Active Comparator|PEG Control|Polyethylene glycol-based bowel preparation
2435663|NCT03328494|Experimental|Part A: Monotherapy (BOS172722)|BOS172722 will be administered on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies.
2435664|NCT03328494|Experimental|Part A: Combination therapy (BOS172722 + Paclitaxel)|BOS172722 will be administered on Cycle 0 Day 1 and on Days 1, 2, 8, 9, 15, and 16 in Cycle 1 and subsequent 28-day cycles in participants with histopathologically confirmed advanced nonhaematologic malignancies. The participants will also receive 80 milligrams per meters squared (mg/m^2) paclitaxel as an intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. During dose escalation, further exploration of the treatment schedule for the BOS172722-paclitaxel combination will be initiated. In such combination cohorts, BOS172722 will be administered with paclitaxel on Days 1, 8, and 15 only of each treatment cycle (except for Cycle 2 Day1), and will not be administered on Day 2, 9, and 16. These alternative schedules will be explored to further characterize the pharmacokinetics and tolerability of such a dosing regimen.
2435665|NCT03328494|Experimental|Part B: Combination therapy (BOS172722 + Paclitaxel)|Participants with triple-negative breast cancer will be treated with oral BOS172722 at the recommended Phase 2 dose (RP2D) established in Part A on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle and IV paclitaxel at 80 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
2435666|NCT03328481|Experimental|Loss-of-resistance|Patients in this group will receive Loss-of-resistance Quadratus lumborum block with 30 ml bupivacaine 0.25% in addition to general anesthesia.
2435667|NCT03328481|Active Comparator|Ultrasound-guided|Patients in this group will receive Ultrasound-guided Quadratus lumborum block type-II with 30 ml bupivacaine 0.25% in addition to general anesthesia.
2435668|NCT03328468|Experimental|Breathing Exercise|
2435669|NCT03328455|Experimental|Active training|Adaptive training tailored to each individual's thresholds will be used. Specifically, a two-alternative forced-choice TOJ task will be used, where participants will be asked to judge the temporal order of the stimulus pair (an auditory beep and a visual flash) with varying SOAs. On each training day, the range of SOAs will be established for individuals based on their thresholds determined from the pre-training TOJ assessment given on the same day. The maximum SOA will be 0.2 log units greater than their estimated threshold and will be used for both visual leading (positive SOA) and auditory leading (negative SOA) stimuli. Feedback will be provided after each response.
2435670|NCT03328455|Sham Comparator|Passive training|To control for pure practice or exposure effects, a second group of elderly participants will undergo passive training. Participants will be exposed to the stimulus pair with varying SOAs, similarly as in the active training group. The maximum SOA for each individual will be likewise determined by his or her threshold from the TOJ assessment. However participants will not be asked to perform the TOJ task and no feedback will be provided. Instead, participants will perform an oddball task in which they are asked to detect a stimulus that occurs less frequently than the standard one. Having an oddball task in both auditory and visual modalities will ensure that participant's attention is divided between the two modalities as required in the active training task.
2435671|NCT03328442|Experimental|Vista technique|The vista technique with PRF membrane uses a Vestibular incision subperiosteal tunnel access in combination with Platelet rich fibrin membrane to treat gingival recession defects.
2435672|NCT03328442|Active Comparator|modified coronally advanced flap|A modified coronally advanced flap utilising Platelet rich fibrin membrane to treat gingival recession defects.
2435673|NCT03328429|Other|Marsupialization|Bartholin gland marsupialization will be done to all patients with Bartholin abscess.
2435674|NCT03328429|Other|Excision|Bartholin gland excision will be done to all patients with Bartholin abscess.
2435675|NCT03328416|Experimental|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
2435676|NCT03328403|Experimental|Aspiration First|Aspiration thrombectomy with large bore catheters
2435677|NCT03328403|Experimental|Stent retriever first|Thrombectomy with a licensed stent retriever device
2435678|NCT03328390|Experimental|Quadratus lumborum block Group|ultrasound guided
2435679|NCT03328390|Active Comparator|Transversus abdominis plane block Group|ultrasound guided
2435680|NCT03328364||enzalutamide (mCRPC pre-chemo)|Patients treated with enzalutamide prior to chemotherapy
2435681|NCT03328364||enzalutamide and chemotherapy (mCRPC post chemo)|Patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel)
2435682|NCT03328351|Experimental|manual group|"The Manual therapy (Mobilization):~Cervical postero-anterior vertebral mobilization glides: the mobilization was grade 3 for 2 min 3 set~Cervical lateral vertebral glides: the mobilization was grade 3 for 1 min 3 set.~Strengthening Exercises for deep neck flexor muscle"
2435751|NCT03327870||3|Incomplete Sjogren's Syndrome
2435752|NCT03327870||4|Healthy Volunteers
2435683|NCT03328351|Sham Comparator|sham group|"Superficial soft tissue massage~Strengthening Exercises: for deep neck flexor muscles for 10 seconds and repeating it for 10 times ."
3188395|NCT00766402|Experimental|Tramadol/Acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
2435685|NCT03328312|Active Comparator|Sugammadex|For reversal of rocuronium neuromuscular- block we will use Sugammadex
2435686|NCT03328312|Placebo Comparator|neostigmine+atropine|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
2435687|NCT03328312|Experimental|neostigmine+atropine+sugammadex|For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.
2435688|NCT03328299|Active Comparator|Dexmedetomidine group|patients were given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine + dexmedetomidine 1 μg•kg-1 diluted in 20 ml saline
2435689|NCT03328299|Placebo Comparator|bupivacaine group|patients will given ultrasound guided TAP-block with 20 ml of 0.5 % bupivacaine
2435690|NCT03328286|Experimental|Weekly group meeting w/psychotherapist|All the participants fulfilling the eligibility criteria are asked to take part in an additional Intervention. The Intervention is a weekly group Meeting with a psychotherapist to discuss issues or Problems the Group members have
2435693|NCT03328260|Experimental|Treatment|
2435694|NCT03328247|No Intervention|Control|Control group will attend their routine melanoma follow-ups
2435695|NCT03328247|Experimental|Intervention|The intervention group will use the ASICA app in addition to their routine follow-ups
2435696|NCT03328234|Experimental|SIB-IMRT combined chemotherapy with IFI|
2435697|NCT03328234|Experimental|SIB-IMRT with IFI|
3148064|NCT00138437||Household Contacts (Group 2)|Household contacts with known contact with leprosy patients
3148065|NCT00138437||Healthy Individuals (Group 3)|Healthy persons with no known contact with leprosy patients
2435700|NCT03328195|Active Comparator|Neuro RX Gamma synchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril.The synchronous device delivers a synchronized pulse frequency of 40 Hz from all LED clusters.
2435701|NCT03328195|Sham Comparator|Sham light therapy|Sham Neuro RX Gamma device having the same appearance and sound as the Neuro RX Gamma device but does not emit the near-infrared light.
2435702|NCT03328195|Active Comparator|Neuro RX Gamma asynchronous|Neuro RX Gamma device delivering near infra-red light through four diodes positioned over the scalp and one positioned inside the nostril. The asynchronous device alternatively delivers pulses from the intranasal and anterior LEDs vs. from the posterior LEDS.
2435704|NCT03328169|Active Comparator|CBT-I|Cognitive Behavioral Therapy for Insomnia
2435705|NCT03328169|Experimental|Mindfulness|Mindfulness-Based Therapy
2435706|NCT03328156||patient with STEMI will treated by PPCI|Primary angioplasty procedure The procedure will be performed using a standard angioplasty technique. A bolus of100 IU kg of heparin will be administered intra-arterially after insertion of the vascular catheter. The target lesions will initially treated with appropriate balloon predilatation as necessary, followed by intracoronary stenting. After stent implantation, heparin will be routinely administered. The sheaths will be removed the same day.
2435707|NCT03328156||patient with STEMI will treated by Thrombolytic therapy|oral clopidogrel (300 mg), Low-flow nasal oxygen, oral acetylsalicylic acid (325 mg), Will be given to each patient. Streptokinase will be given intravenously at 1.5 million units over approximately 60 min. Reperfusion afterTT will be assessed according to clinical criteria .
2435708|NCT03328143|Experimental|Treatment with Lavender|Lavender (Lavandula angustifolia) aromatherapy will be administered at regular intervals using a nasal inhaler.
2435709|NCT03328130|Experimental|Cohort 1 - Low Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the lowest dose. Dose-escalation will be performed after DSMC assessment.
2435710|NCT03328130|Experimental|Cohort 2a - Medium Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the medium dose. Confirmatory dose will be determined after DSMC assessment.
2435711|NCT03328130|Experimental|Cohort 2b - High Dose|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the highest dose. Confirmatory dose will be determined after DSMC assessment.
2435712|NCT03328130|Experimental|Cohort 3 - High Dose (confirmatory cohort)|Biological: AAV2/5-hPDE6B Unilateral (one eye), subretinal, administration of the confirmatory dose.
2435713|NCT03328117|Active Comparator|Intervention|
2435714|NCT03328117|Placebo Comparator|Placebo|
2435715|NCT03328104|Experimental|Everolimus in combination with standard chemotherapy|A treatment course lasts 28 days, during which participants take everolimus by mouth every day and also get standard chemotherapy via IV on certain days.
2435716|NCT03328091|Active Comparator|Traditional pre-test genetic counseling|"In-person consultation with licensed genetic counselor at the Center for Cancer Genetics and Prevention before genetic testing~Participant is given a pamphlet introducing prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is given the Genetic Testing Information for Decision Making packet. After the genetic counseling session, patient is asked if they would like to proceed with genetic testing."
2435717|NCT03328091|Experimental|Pre-test video education|"Participant is given a pamphlet that describes the basics of prostate cancer genes, genetic testing~Participant is sent electronic family history tool~Participant is approached in clinic by research staff at a pre-planned time~The patient is given the Genetic Testing Information for Decision Making packet~The pre-test video education is a short video. Information will be provided about the basics of genetics and mutations, the potential benefits, risks, and limitations of genetic testing, and the possible results the participant may receive"
3148066|NCT00138463||West Nile Virus (WNV) Neuroinvasive Disease Cohort|Fever (temperature > 38 C) documented by a health care provider AND: at least one of the following, as documented by a health care provider and in the absence of a more likely clinical explanation: acutely altered mental status; other acute signs of central or peripheral neurologic dysfunction; or cerebrospinal fluid (CSF) pleocytosis associated with illness clinically compatible with meningitis.
2435718|NCT03328078|Experimental|CA-4948 dose escalation|Part A1: Dose-level cohorts with up to 6 patients each will be used to define the Maximum Tolerated Dose (MTD) for CA-4948.
2435719|NCT03328078|Experimental|CA-4948 and ibrutinib dose escalation|Part A2: Evaluate escalating dose levels of oral CA-4948 in combination with 560 mg daily (QD) of oral ibrutinib (or 420 mg QD for WM/LPL and CLL/SLL). Separate escalation will be performed for each of these ibrutinib doses. The starting dose of CA-4948 to be used in combination will be 200 mg twice a day (BID). It is anticipated that 12 to 18 patients will be required to establish optimal combination dosing.
2435720|NCT03328078|Experimental|CA-4948 and ibrutinib dose expansion|"In expansion phase, the CA-4948 recommended Phase 2 dose (RP2D) in combination with ibrutinib will be administered in Non-Hodgkin Lymphoma (NHL) disease-specific cohorts. Up to 46 NHL patients will be enrolled in each of the following 4 NHL disease-specific cohorts:~Cohort 1 - Marginal zone lymphoma (MZL)~Cohort 2 - ABC diffuse large B-cell lymphoma (DLBCL) or extranodal subtypes: Leg-, testicular-, or NOS-type~Cohort 3 - Primary central nervous system lymphoma (PCNSL)~Cohort 4 - Patients receiving ibrutinib monotherapy who have developed adaptive, secondary resistance. Indications include:~Mantle Cell Lymphoma (MCL), MZL, CLL/SLL, or WM/LPL~Indications for which ibrutinib is National Comprehensive Cancer Network (NCCN)-listed (e.g., PCNSL)~Patients with NHL and known myddosome mutations~Patients may be candidates for maintaining ibrutinib while CA-4948 will be added for resistance reversal. A brief gap of ibrutinib therapy of <3 weeks is acceptable."
2435721|NCT03328065||Stable patients, early responders to treatment and caregivers|
2435722|NCT03328065||Stable patients and intermediate responders and c|Stable patients and intermediate responders to treatments and caregivers
2435723|NCT03328065||Doctors|
2435724|NCT03328065||Patients in therapeutic escape and their caregivers|
2435725|NCT03328052|Experimental|MYnd Analytics PEER Online directed therapy|Patients in this arm will receive anti-depressants as recommended by the PEER Online algorithm as described below.
2435726|NCT03328052|Sham Comparator|Conventional therapy|Patients in this arm will receive anti-depressants as chosen by the physician without guidance by the PEER Online algorithm.
3148067|NCT00138463||West Nile Virus Fever Cohort|Temperature > 38 C as documented by a health care provider.
3148068|NCT00138476|Experimental|Group 4: 0.48 RT-PCR units or Placebo|Group 4: dosage group of 10 subjects will receive 0.48 RT-PCR units of Lot 42399 NV or placebo control (8 subjects will receive NV and 2 subjects will receive placebo control).
3148069|NCT00138476|Experimental|Group 3: 4.8 RT-PCR units or Placebo|Group 3: dosage group of 12 subjects will receive 4.8 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
3148070|NCT00138476|Experimental|Group 2: 48 RT-PCR units or Placebo|Group 2: dosage group of 12 subjects will receive 48 RT-PCR units of Lot 42399 NV or placebo control (10 subjects will receive NV and 2 subjects will receive placebo control).
2435731|NCT03327987||31-90 days|Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2435732|NCT03327987||91-180 days|91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2435733|NCT03327987||181-365 days|181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
2435734|NCT03327974|Other|depressed patients|"All patients performed the same evaluation : ecological momentary assesement throught smartphone and 3 sheduled visits.~All patients are depressed patients."
2435735|NCT03327961||scaffold|Patients receiving during PCI the implantation of at least one scaffold
2435736|NCT03327948|Experimental|Treatment group|Urinary Urgency Incontinence
2435737|NCT03327935|Experimental|Nutrition|Oral nutritional supplements and dietetic advice
2435738|NCT03327935|Experimental|Nutrition and exercise|Oral nutritional supplements, dietetic advice and exercise training
2435739|NCT03327935|No Intervention|Control|Standard Hospital Procedure
2435740|NCT03327922|Experimental|Vicryl absorbable suture placed 2 cm apart|Wound closed with sutures spaced 2 centimeters apart will be treated in a simple, interrupted subdermal suture pattern
2435741|NCT03327922|Experimental|Vicryl absorbable suture placed 1 cm apart|Wound closed with sutures spaced 1 centimeter apart will be treated in a simple, interrupted subdermal suture pattern
2435742|NCT03327909|Experimental|TAKE|Participants in TAKE units will be advised to take all antihypertensive medications as prescribed, including on the morning of dialysis.
2435743|NCT03327909|Experimental|HOLD|Participants in the HOLD units will advised to hold the dose of the antihypertensive medications prior to the dialysis session on the morning of the dialysis days. Participants can choose whether they wish to take the antihypertensive medication that was held at any time after the dialysis session has ended.
2435744|NCT03327896||OCHIN EHR|"Patients who were established patients at OCHIN Primary Care Clinics in 2015 and had a face to face visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2435745|NCT03327896||OneFlorida EHR|"Patients who were established patients at OneFlorida Primary Care clinics in 2015 and had a face to fact visit at the clinic in 2015.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2435746|NCT03327896||Oregon Medicaid|"Clients who were continuously insured through Oregon Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2435747|NCT03327896||Florida Medicaid|"Clients who were continuously insured through Florida Medicaid in 2015 and had a claim with an Evaluation and Management Current Procedure Terminology (CPT) code indicating an office visit listing a Primary Care provider as the performing provider. Florida Medicaid data is limited to clients who were 22 years or younger.~Inclusion criteria for specific outcomes varies by criteria for demoninator specification for the metric."
2435748|NCT03327883||1/Patients medical records|Medical records of patients with metastatic bladder cancer
3148071|NCT00138476|Experimental|Group 1: 4800 RT-PCR units or Placebo|Group 1: dosage group of 11 subjects will receive 4800 reverse transcription polymerase chain reaction (RT-PCR) units of Lot 42399 Norwalk Virus (NV) or placebo control (9 subjects will receive NV and 2 subjects will receive placebo control).
3188396|NCT00766402|Active Comparator|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
3148072|NCT00138476|Experimental|Validation Group: 4.8 and 0.48 RT-PCR units|Validation Group: dosage group of 12 subjects, 4 will receive 4.8 RT-PCR units and 8 will receive 0.48 RT-PCR units of Lot 42399 NV. No placebo control.
3148073|NCT00138554|Experimental|vildagliptin 50 mg qd + pioglitazone 45 mg qd|vildagliptin 50 mg qd + pioglitazone 45 mg qd for 28 weeks
3148074|NCT00138554|Experimental|vildagliptin 50 mg bd+ pioglitazone 45 mg qd|vildagliptin 50 mg bd + pioglitazone 45 mg qd for 28 weeks
2435757|NCT03327831|Experimental|Open Label Treatment Arm|This study has a single, open label treatment arm. Patients will have topical aminolevulinic acid applied to the actinic keratoses in the treatment area (face/scalp) and will spend 2 hours outdoors in the shade to activate the medication. The patient then follow up in clinic 3 months and 6 months after their treatment to have the number of actinic keratoses counted.
2435758|NCT03327818||conservative surgery group|
2435759|NCT03327818||hysterectomy group|
2435760|NCT03327805|Experimental|Short Term Choline Supplementation|Participants will be asked to consume 1000 mg of choline bitartrate for 2 weeks prior to and during the testing period.
2435761|NCT03327805|Placebo Comparator|Short Term Placebo Supplementation|Participants will be asked to consume 1000 mg of placebo (maltodextrin) for 2 weeks prior to and during the testing period.
2435762|NCT03327792|Experimental|200 mg Mavoglurant|200 mg mavoglurant once daily for 7-10 days
2435763|NCT03327792|Placebo Comparator|Placebo|Placebo once daily for 7-10 days
2435764|NCT03327766||RPL group|history of unexplained recurrent pregnancy loss (defined as two or more consecutive missed miscarriage before 14 weeks of gestation).
2435765|NCT03327766||Control group|womens coming for contraception after normal pregnancy outcome.
2435766|NCT03327753|Experimental|Motor control exercises|A primary goal of the motor control exercise program is to regain control and coordination of the spine and pelvis using principles of motor learning such as segmentation and simplification. The whole intervention is based on assessment of the individual patient's motor control impairments and the patient's individual treatment goals (set collaboratively with the therapist).
2435767|NCT03327753|Experimental|Graded activity|A primary goal of the graded activity program is to increase activity tolerance by performing individualized and submaximal exercises in addition to ignoring illness behaviors and reinforcing well behaviors. The intervention uses cognitive behavioral approaches to deal with fear of movement and self efficacy.
2435768|NCT03327740||Subjects on DTG based ARV with ABC|These are subjects who begin a DTG based ARV regimen that includes ABC
2435769|NCT03327740||Subjects that start DTG based ARV regimen but without ABC|These are subjects who begin a DTG-based ARV regimen that does not contain ABC
2435770|NCT03327740||Subjects on other integrase inhibitor based regimen with ABC|These are subjects who begin other integrase inhibitor based regimens (RAL and EGV) that contains ABC
2435771|NCT03327740||Subjects on other integrase inhibitor based regimen but no ABC|These are subjects that start non-ABC containing RAL or EGV based regimens
2435772|NCT03327740||Subjects that start any other DTG based ARV regimen|These are subjects who begin any other DTG based ARV regimen that will include DTG as monotherapy or two-drug regimens
2435773|NCT03327727|Experimental|VL-2397|Investigational agent VL-2397 600 mg IV infusion administered every day for 28 days (4 weeks) followed by 2 weeks of standard treatment
2435774|NCT03327727|Active Comparator|Standard (First-Line) Treatment|Investigator selected standard treatments of voriconazole, isavuconazole, or liposomal amphotericin B administered every day for 42 days (6 weeks) per product package insert
2435775|NCT03327714|Experimental|Mindfulness and compassion|Children aged between 6-16 years old will perform 5-10 minutes daily mindfulness and compassion training in school. The intervention will last for 10 weeks.
2435776|NCT03327714|No Intervention|Control group|The control group consists of children who do not perform mindfulness in school.
2435777|NCT03327701|Active Comparator|Experimental|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
2435778|NCT03327701|Placebo Comparator|Placebo|Subjects will receive placebo 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
2435779|NCT03327688|Active Comparator|POCUS group|Point-of-care ultrasound
2435780|NCT03327688|No Intervention|Radiologist group|Traditional diagnostic way
2435781|NCT03327688|Active Comparator|DVT POCUS group|DVT group after POCUS education
2435782|NCT03327688|No Intervention|DVT traditional group|DVT group traditional diagnostic way before educational intervention
2435783|NCT03327675|Experimental|68Ga-PSMA PET/MR|Hybrid 68Ga-PSMA PET/MR scan
2435784|NCT03327662|Experimental|Interventional|Active CTC assessment: Patients will receive first line docetaxel until progression by CTC, and/or disease progression according to treating clinician or completion of 10 cycles. CTC results will be available to the treating clinician to guide decision-making. A progressing CTC count on Day 1 will require confirmation with a second CTC count performed on Day 15 (-/+ 5 days) of that cycle. If a patient is found to have two successive CTC determinations showing progression by CTCs, the clinician will receive a recommendation to discontinue docetaxel on the following cycle.
2435785|NCT03327662|No Intervention|Control|Patients will receive first line docetaxel until disease progression according to treating clinician or completion of 10 cycles. Patients and treating clinicians will not be disclosed to the results of CTC determinations.
2435788|NCT03327636|Experimental|High Intensity Focused Ultrasound|Apply the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the papillary thyroid microcarcinoma.
2435789|NCT03327636|No Intervention|Active surveillance|The participants will be monitored by the doctors actively, like more frequent in follow-up to observe their current situation.
2435790|NCT03327623||Hypertrophic Cardiomyopathy (HCM)|Subjects with a diagnosis of Hypertrophic Cardiomyopathy
2435791|NCT03327623||Control|Subjects who are healthy volunteers
2435792|NCT03327610|No Intervention|BASELINE|The subjects were kept in their current ventilatory mode.
2435990|NCT03326297|No Intervention|No specific intervention|No specific intervention, prescriptions by pediatrician
2435793|NCT03327610|Experimental|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 20Lpm.
2435794|NCT03327610|Experimental|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory flow of 50Lpm.
2435795|NCT03327610|Experimental|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 1 second.
2435796|NCT03327610|Experimental|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1) with an inspiratory time of 3 seconds.
2435797|NCT03327610|Experimental|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 10% of peak inspiratory flow.
2435798|NCT03327610|Experimental|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV) with a cycling off of 25% of peak inspiratory flow.
2435799|NCT03327597|Active Comparator|Abnormal Non-MGUS|Participants previously diagnosed with MGUS, multiple myeloma or other lymphoproliferative disease.
2435800|NCT03327597|Experimental|MGUS group arm 1|Participants diagnosed with MGUS, randomized to group 1.
2435801|NCT03327597|Experimental|MGUS group arm 2|Participants diagnosed with MGUS, randomized to group 2.
2435802|NCT03327597|Experimental|MGUS group arm 3|Participants diagnosed with MGUS, randomized to group 3.
2435803|NCT03327597|Active Comparator|Normal group|Participants without MGUS.
2435804|NCT03327597|Active Comparator|Controls|Participants without MGUS, matched to MGUS participants by age and gender.
2435805|NCT03327584|Active Comparator|Ultrasound Guided Arthrocentesis|The patients in this group will have ultrasound guided arthrocentesis.
2435806|NCT03327584|Active Comparator|Landmark Guided Arthrocentesis|The patients in this group will have landmark guided arthrocentesis.
3188397|NCT00766441|Active Comparator|1|Sitagliptin 100mg
3188398|NCT00766441|Active Comparator|2|Sulphonylurea
2435809|NCT03327558|Experimental|Apriso 0.375G ER CAP|Apriso 0.375G ER Cap
2435810|NCT03327558|Active Comparator|APRISO 375 mg extended-release capsules|APRISO 375 mg ER cap
2435811|NCT03327545|Experimental|Experimental Group 1|Neural mobilization for a total of 12 minutes
2435812|NCT03327545|Experimental|Experimental Group 2|Soft tissue techniques and Stretching right side of the craniocervical for a total of 12 minutes
2435813|NCT03327545|Placebo Comparator|Control group|Control group
2435814|NCT03327532|Experimental|Patients hospitalized for acute heart failure|"One arm study.~Patients hospitalized for acute heart failure will undergo the following evaluations:~Clinical examination centered on congestion~Cardiopulmonary and peritoneal ultrasound~Blood sample retrieved for biological assessment and biobanking~Telephone interview"
2435815|NCT03327519|Experimental|SHUTi|Self-guided, automated, interactive, and tailored web-based program
2435816|NCT03327519|Experimental|Emmi|A program that is an animated online video that walks patients through important information about a health topic, condition or procedure.
2435817|NCT03327506|Experimental|hypnosis group|Intervention: hypnosis session the eve of the surgery
2435818|NCT03327506|Active Comparator|premedication|alprazolam 0,5 mg the eve and the morning of the surgery
2435819|NCT03327493|Other|Refractory cardiogenic shock under ECLS|
2435820|NCT03327480|Experimental|neoprene CMC orthosis|We will prescribe a neopren CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
2435821|NCT03327480|Experimental|thermoplastic CMC orthosis|We will prescribe a neoprene CMC orthosis for patients in Group 1 and a thermoplastic CMC orthosis for patients in Group 2
2435822|NCT03327454||Benepali|Treatment of participants with the Benepali pre-filled pen takes place in accordance with the prescribing information and standard medical practice.
2435823|NCT03327441|Experimental|Almonds|
2435824|NCT03327441|Active Comparator|Omelette|
2435825|NCT03327428||Patients with Sickle Cell Disease|Patients with any sickling condition, including among others Sickle Cell Anemia, HbSC Disease, HbS-betaThal, excluding Sickle Cell Trait.
2435826|NCT03327415||Age groups|Eleven age groups that took into account the previous surveys and the key stages of child development were defined: 15 days to 3 months, 4, 5, 6, 7, 8-9, 10-11, 12- 17, 18-23, 24-29, and 30-35 months.
3188399|NCT00766480|Experimental|Regimen 1|Patients receive low-dose cisplatin IV on days 1 and 29 and low-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy on days 1-4 and 29-32. Patients undergo salvage surgery if needed.
2435828|NCT03327389|Experimental|Dexmedetomidine (Group D)|Dexmedetomidine infusion during surgery Dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
2435829|NCT03327389|Placebo Comparator|Control (Group C)|0.9% NaCl infusion during surgery 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
2435830|NCT03327376||Characteristic and regularity of CRT|The patients who have a central venous catheterization conduct the daily ultrasound-screening for CVC-related Thrombosis (DUCT).
2435831|NCT03327363|Experimental|ICT base monitoring group|In the ICT-based centralized monitoring group, both subjects and medical staff receive feedback regarding decreased lung function and exacerbation in asthma symptoms in the form of text messages
2435832|NCT03327363|Placebo Comparator|control group|Use standard asthma treatment
2436054|NCT03325868|Experimental|Ulipristal|Ulipristal acetate 5mg daily for 12 weeks
3188400|NCT00766480|Experimental|Regimen 2|Patients receive high-dose cisplatin IV on days 1 and 29 and high-dose fluorouracil IV on days 1-4 and 29-32. Patients also undergo concurrent radiotherapy and salvage surgery as in regimen 1.
3188401|NCT00766519|Experimental|Optimization|volume optimization: continuous monitoring of the respiratory-induced arterial pulse pressure variation during surgery and systematic minimization to 10% or less by volume loading
3188402|NCT00766519|Active Comparator|control; standard volume administration|standard volume administration
3188403|NCT00766545|Experimental|cilostazol|cilostazol oral tablet 100 mg, twice daily
3188404|NCT00766545|Placebo Comparator|placebo|placebo of cilostazol, twice daily
2435833|NCT03327350||WATCHMAN transplantation|This group will receive WATCHMAN device implantation.Device implantation included concomitant antithrombotic medication to facilitate device endothelialization: warfarin and aspirin for 45 days. To assess for device stability, peridevice leaks, and device-related thrombus, transesophageal echo (TEE) imaging was performed at 45 days, 6 months, and 12 months. When the 45-day TEE revealed minimal residual peridevice flow (jet width ≤5 mm) and no device-related thrombus, warfarin will be stopped and replaced by clopidogrel, 75 mg daily, until the 6-month visit, after which only aspirin was continued. If an adequate seal is not obtained or a thrombus is detected, patients continue taking warfarin until an adequate seal is attained or thrombus is resolved before transitioning to aspirin.
2435834|NCT03327350||Oral anticoagulant therapy|"This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).~For patients taking warfarin, international normalized ratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Follow-up visits occurred twice annually after the first year, with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected."
2435835|NCT03327337|Experimental|experimental group|operate with Arthroscopic Assisted Balloon Tibioplasty on this group patients
2435836|NCT03327337|Other|control group|operate with open reduction and internal fixation on this group patients
2435838|NCT03327311||Bellafill 1 week post-injection|n=2. Histopathology conducted 1 week post-injection
2435839|NCT03327311||Bellafill 1 month post-injection|n=2. Histopathology conducted 1 month post-injection
2435840|NCT03327311||Bellafill 2 months post-injection|n=2. Histopathology conducted 2 months post-injection
2435841|NCT03327311||Bellafill 3 months post-injection|n=2. Histopathology conducted 3 months post-injection
2435842|NCT03327311||Bellafill 6 months post-injection|n=2. Histopathology conducted 6 months post-injection
2435843|NCT03327298|Other|accuracy of pedicle screw insertion|postoperative CT lumbar spine axial and sagittal views.
2435844|NCT03327285|Experimental|C-CAR011|The amount of cells received：1.0-5.0×10^6 CAR+T cells/kg
2435845|NCT03327272|Active Comparator|Local injection of methylprednisolone|Drug: methylprednisolone Injection of 80mg methylprednisolone injectable suspension at surgical site prior to incision closure
2435846|NCT03327272|Placebo Comparator|Local injection of saline|Administration of saline at surgical site prior to incision closure.
2435847|NCT03327259|Active Comparator|Activity Planning Only|
2435848|NCT03327259|Experimental|Enhanced Activity Planning|Activity planning with therapist guided activity practice.
2435849|NCT03327246|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients who are plan to undergo a major elective surgery in Assuta Ashdod and are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community for two periods of time: (1) Pre habilitation plan for a month prior to surgery (2) a period of 3 months post discharge.
2435850|NCT03327246|No Intervention|No Intervention: Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
2435851|NCT03327233|Experimental|Intervention group|Implementing the Connecare system to support integrated care for complex patients with an unplanned admission to Assuta Ashdod who are discharged back to the community with an emphasis on Connecare self managment system for the patient and close follow up and coordination of all of the medical, health and social care in the community by a Maccabi integrated care nurse for a period of 3 months post discharge.
2435852|NCT03327233|No Intervention|Matched control group|The control group will be selected from Maccabi's database and will be patients who are matched 1:1 with the intervention sample and live in another community similar to Ashdod in socioeconomic characteristics who undergo the same elective major surgery in other hospitals
3188405|NCT00766558||1 Disclosure|Traumatic writing prompts provided. Participant is assigned a potential stress-producing topic for written disclosure.
3188406|NCT00766558||2 control|Received nontraumatic writing prompts. Participant assigned a non-stressful writing condition
2435855|NCT03327207||Study group|Children who receive Growth hormone treatment. Non Interventional
2435856|NCT03327207||Control group|Healthy children . Non Interventional
2435857|NCT03327194|Experimental|ADHEAR Audio processor|
2435858|NCT03327181|Experimental|COPD|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
2435859|NCT03327181|Active Comparator|Healthy older adults|The subject will arrive fasted. A catheter will be inserted in the arm for stable tracer SCFA infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable tracers will be administered by the research nurse. Stable tracers are given to measure SCFA metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet, and a variety of functional measurements.
2435860|NCT03327168|Active Comparator|Adenosine|Perfusion is measured using PET/CT during intravenous infusion (0.14 mg/kg/min) of adenosine.
2435861|NCT03327168|No Intervention|Room temperature|Perfusion and A2A receptor density is measured using PET/CT in resting room temperature conditions.
2435862|NCT03327168|Experimental|Cold exposure|Perfusion and A2A receptor density is measured using PET/CT during controlled cold exposure.
2436174|NCT03324919||Urticaria, HRQL|Patients with a medical diagnosis of Urticaria were enclosed.
3188407|NCT00766623|Experimental|High fat meal|A high fat milkshake containing 95g of fat
3188408|NCT00766623|Experimental|Control meal|Milkshake comparable with a normal breakfast
2435863|NCT03327155|Experimental|TDF/FTC (300mg/200mg) once daily|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.
2435864|NCT03327129||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
2435865|NCT03327129||Patients with SI|Subjects will have suicidal ideation (Hamilton Depression Rating Scale suicide item >=2).
2435866|NCT03327116|Experimental|Methotrexate|
2435867|NCT03327103|No Intervention|Enhanced Usual Care|Receive standard care
2435868|NCT03327103|Experimental|Decision Intervention|Receives decision aid intervention that encompasses balance sheets, navigation, audio files, and interaction -- Cancer Health Aid to Manage Preferences and Improve Outcomes through Navigation (CHAMPION)
2435869|NCT03327090|Experimental|Experimental Kinesio Tape|"The Kinesio Tape original brand was used in this study (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque). The application of the experimental Kinesio Tape was as Dr. Kenzo Kase demonstration for muscle facilitation (Kase. et al., 2003):~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~The tape was in tension (15%- 35%) and the muscles were stretched during the application."
2435870|NCT03327090|Sham Comparator|Sham Kinesio Tape|"Same tape brand was used, but different application techniques were utilized for the three muscles.~Gluteal maximus muscle.~Quadriceps muscle.~Gastrocnemius muscle and soleus muscle (triceps surae).~There were no tension on the tape and no muscle stretching during the application."
2435871|NCT03327077|No Intervention|Control Group|
2435872|NCT03327077|Experimental|Intervention Group|Music group
3148075|NCT00138632|Experimental|1|
3148076|NCT00138632|Experimental|2|
3188409|NCT00766623|Experimental|High fat meal 2|A high fat milkshake containing 95g of fat
3188410|NCT00766623|Experimental|High fat meal 3|A high fat milkshake containing 95g of fat
2435877|NCT03327038|Experimental|Psychological Intervention|Patients will be randomized to the intervention group after they have complete the study screening form. Patients randomized to the intervention group will receive a multifaceted intervention consisting of the following components (administered over an 8 week period): (1) Web-Based Cognitive Behavioral Therapy: (2) Short Questionnaires; (3) Ongoing Nurse Monitoring.
2435878|NCT03327038|Active Comparator|Control|Patients will be randomized to the control group after they have completed the study screening form. Patients randomized to the control group will receive the usual standard of care that is available to patients with moderate anxiety or depression. Additionally, control patients will completed detailed questionnaires for assessment of primary and secondary outcomes.
2435879|NCT03327025|Experimental|Intervention|
2435880|NCT03327012|Experimental|Treatment of Panlongqi Tablet|Patients were treated with Panlongqi Tablet.
2435881|NCT03327012|Placebo Comparator|Treatment of Panlongqi Placebo|Patients were treated with Panlongqi Placebo Tablet.
3188411|NCT00766623|Experimental|Control meal 2|Milkshake comparable with a normal breakfast
3188412|NCT00766623|Experimental|Control meal 3|Milkshake comparable with a normal breakfast
2435887|NCT03326973||online or telephone survey|This is a cross-sectional survey. Our main method of communication with patients will be email. Participants will complete a single online or telephone survey at a minimum of 12 months post initial treatment of checkpoint inhibitors and remain on maintenance therapy.
2435888|NCT03326960||Sevoflurane|Patients in Sevoflurane group are maintained with sevoflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
2435889|NCT03326960||Propofol|Patients in Propofol group are maintained with propofol through intravenous administration guided by Narcrotrend index monitoring.
2435890|NCT03326960||Desflurane|Patients in Desflurane group are maintained with desflurane from an anesthesia machine through the laryngeal mask airway guided by Narcrotrend index monitoring.
2435891|NCT03326947|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
3148077|NCT00138632|Placebo Comparator|3|
3148078|NCT00138684|Experimental|Venesection therapy|
3148079|NCT00138684|No Intervention|no venesection therapy|
3148080|NCT00138736|Experimental|A|MBL until the patient's absolute neutrophil count (ANC) is above 500/microL blood.
3148081|NCT00138853|Active Comparator|Tantalum knee|Tantalum Tibial component, uncemented
3148082|NCT00138853|Active Comparator|Titanium Knee|Titanium Tibial Component, screw fixed
3148083|NCT00138944|Placebo Comparator|1|Placebo
3148084|NCT00138944|Active Comparator|2|Eplerenone
3148085|NCT00139074|Active Comparator|1|quetiapine fumarate monotherapy
3148086|NCT00139074|Experimental|2|Quetiapine + sodium valproate
3148087|NCT00139113|Experimental|HAVRIX 6 and 12 mos; mother antibody pos|HAVRIX administered to infants born to anti-HAV positive mothers at ages 6 and 12 months
3148088|NCT00139113|Active Comparator|HAVRIX age 6, 12 mos; mom antibody neg|HAVRIX administered to infants born to anti-HAV negative mothers at ages 6 and 12 months
3148089|NCT00139113|Experimental|HAVRIX ages 12, 15 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 12 and 15 months
3148090|NCT00139113|Active Comparator|HAVRIX ages 12, 15 mos; mom antibody-|HAVRIX administered to infants born to anti-HAV negative mothers at ages 12 and 15 months
3148091|NCT00139113|Experimental|HAVRIX ages 15,21 mos; mom antibody +|HAVRIX administered to infants born to anti-HAV positive mothers at ages 15 and 21 months
3148092|NCT00139113|Active Comparator|HAVRIX ages 15,21 mos; mom antibody -|HAVRIX administered to infants born to anti-HAV negative mothers at ages 15 and 21 months
3148093|NCT00139152|Placebo Comparator|Placebo|Saline placebo
3148094|NCT00139152|Experimental|Xolair|Xolair treatment
3148095|NCT00139256|Experimental|Betamethasone|Betamethasone injection
3148096|NCT00139256|Placebo Comparator|Placebo|Placebo injection
3148097|NCT00139360|Experimental|1|Active drug
3148098|NCT00139386|Active Comparator|Candesratan|
3148099|NCT00139386|No Intervention|Non-candesartan|
3148100|NCT00139451|Active Comparator|Nutrition and Growth Hormone|
3148101|NCT00139451|Active Comparator|Observation and Growth Hormone|
2435892|NCT03326947|No Intervention|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
2435893|NCT03326934|Sham Comparator|Milk Chocolate|Each subject consumes a Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
2435894|NCT03326934|Experimental|Dark Chocolate|Each subject consumes a Trader Joe's 72% Cacao Dark Chocolate bar: 47g, 34g cacao, total flavanols: 316.3 mg.
2435895|NCT03326921|Experimental|Treatment (CD4+ and CD8+ HA-1 TCR T cells)|Patients receive fludarabine for 1-3 doses 3-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV over 1 hour.
2435896|NCT03326908|Other|Normal conditions of light exposure|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCTs will be produced under the same lighting conditions (photopic).~At baseline~20 minutes after baseline~25 minutes after baseline~45 minutes after baseline~60 minutes after baseline"
2435897|NCT03326908|Other|Light variations|"Spectral Domain Optical Coherence Tomography (SD-OCT):~Five SD-OCT will be performed:~at baseline, in a room with photopic artificial lighting (400 lux)~after a period of adaptation to the dark (20 minutes in the dark: 0 lux)~after 5 min of retinal glare, obtained by means of a projection of light of 1000 lux on the fundus of eye~15 minutes after this period of retinal glare, in photopic artificial lighting~30 minutes after the period of retinal glare, in photopic artificial lighting"
3188413|NCT00766688|Experimental|25 mg/day AVE5530|
2435899|NCT03326882|Active Comparator|Glidescope|A device for endotracheal intubation
2435900|NCT03326882|Active Comparator|Macintosh laringoscope|A device for endotracheal intubation
3188414|NCT00766688|Experimental|50 mg/day AVE5530|
3188415|NCT00766688|Placebo Comparator|Placebo|
2435909|NCT03326830|Active Comparator|Standard oxygen therapy|Standard oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system. The flow will be tapered to target an SpO2 ≥ 95%
2435910|NCT03326830|Experimental|High-flow nasal oxygen (HFNO)|Experimental: High-flow nasal oxygen (HFNO) group Device that delivers humidified and warmed high-flow oxygen at flows between 30-60L/min HFNO will be initiated at a flow rate between 30-60 L/min and FiO2 titrated for a target of SpO2 ≥ 95%.
2435911|NCT03326817|Active Comparator|Control Group|This group will receive standard care.
2435912|NCT03326817|Experimental|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
3148102|NCT00139490|Experimental|A|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
3148103|NCT00139490|Active Comparator|B|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
2435915|NCT03326791|Experimental|Intervention group|Acetylsalicylic acid 160 mg once daily until recurrent disease or a total period of 3 years.
2435916|NCT03326791|Placebo Comparator|Control group|Placebo Oral Tablet once daily until recurrent disease or a total period of 3 years.
2435917|NCT03326778||AVR + CABG|Patient receiving AVR combined with CABG
2435918|NCT03326765|Other|Children|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
2435919|NCT03326765|Other|Adults|Questionnaires electroencephalogram (EEG) Actigraphy polysomnography
2435920|NCT03326752|Experimental|Dose Escalation Cohort 1-5|"Cohort 1-4~DV281 - Dose Level 1-5~DV281 in combination with nivolumab~DV281 is administered via a breath actuated nebulizer"
2435921|NCT03326752|Experimental|Dose Expansion (RP2D)|"4 Cohorts~Preliminary Recommended Phase 2 dosing of DV281 in combination with nivolumab~Cohort 1: Non-squamous and non-EGFR/ ALK mutation and progressed on anti-PD-1/L1 therapy~Cohort 2: Non-squamous and EGFR/ ALK mutation and progressed on targeted therapy~Cohort 3: Squamous and anti-PD-1/ L1 therapy experienced~Cohort 4: Squamous and anti-PD-1/L1 therapy naive~DV281 is administered via a breath actuated nebulizer."
2435922|NCT03326739|Active Comparator|Ultrasound Guided A-Line Placement|Patients in this group will have ultrasound guided arterial line placement.
2435923|NCT03326739|Active Comparator|Landmark Guided A-line Placement|Patients in this group will have landmark guided arterial line placement.
2435924|NCT03326726|Experimental|Chlorhexidine Gluconate|2% CHG
2435925|NCT03326713|Experimental|Telephone Counseling & Navigation (TCN)|Telephone Counseling
2435926|NCT03326713|Active Comparator|Mailed Targeted Print (TP)|Mailed Targeted Print
2435927|NCT03326713|Other|Usual Care (UC)|Control
2435928|NCT03326700|Active Comparator|Laparoscopic hernia repair.|Intervention: inguinal hernia repair.
2435929|NCT03326700|Active Comparator|Open hernia repair.|Intervention: inguinal hernia repair.
2436175|NCT03324919||Lupus erythematodes, HRQL|Patients with a medical diagnosis of Lupus were enclosed.
3148104|NCT00139490|Placebo Comparator|C|Usual Care group
3148105|NCT00139529|Experimental|1|Participants will receive an educational intervention during pregnancy combined with a motivational interviewing program using telephone counseling to prevent postpartum relapse to tobacco use.
3148106|NCT00139529|Active Comparator|2|Participants will receive an educational intervention during pregnancy.
3148107|NCT00139542|Active Comparator|CONTROL|AED Treatment protocol following AHA Guidelines 2000 recommendations for cardiac arrest resuscitation.
3148108|NCT00139542|Experimental|STUDY|AED treatment protocol with prolonged CPR intervals, single shocks, fewer rhythm analysis and pulse checks.
3148109|NCT00139581|Experimental|1|Pimecrolimus b.i.d.
3148110|NCT00139581|Experimental|2|Pimecrolimus o.d. and placebo o.d.
3148111|NCT00139594|Experimental|licarbazepine|
3148112|NCT00139815|Active Comparator|Enoxaparin|
3148113|NCT00139815|Experimental|Fondaparinux|
2435930|NCT03326687|Experimental|Treatment ABAB|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
2435931|NCT03326687|Experimental|Treatment BABA|Participants will receive anomia treatment in isolation and will perform a physical endurance task in isolation during A phases. They will receive anomia treatment in combination with performing a physical endurance task during B phases.
2435932|NCT03326674|Experimental|Arm A: Tesetaxel (oral) and capecitabine (oral)|Tesetaxel (27 mg/m2) once every 21 days on Day 1 of each 21-day cycle; and capecitabine (825 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 1,650 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
2435933|NCT03326674|Active Comparator|Arm B: Capecitabine (oral)|Capecitabine (1,250 mg/m2) twice daily (in the morning and evening after a meal, for a total daily dose of 2,500 mg/m2) beginning with the evening dose on Day 1 through the morning dose on Day 15 of each 21-day cycle
2435934|NCT03326661|Active Comparator|Needle aspiration|Patients treated with aspiration will receive standard antibiotic treatment according to clinical guidelines: Penicillin and metronidazole or Clindamycin alone in case of penicillin allergy. These patients will be treated in the outpatient clinic and will be examined again the day after inclusion. Aspiration will be done if necessary. At this first control visit the clinician will schedule the next visit based on findings.
2435935|NCT03326661|Active Comparator|Tonsillectomy a chaud|Patients treated with tonsillectomy a chaud are admitted for intra-venous treatment with penicillin and metronidazole until surgery. Antibiotic treatment is discontinued after surgery and the patient may be discharged from the hospital the day after surgery.
2435936|NCT03326648|Experimental|Strength training + protein supplement|Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
2435937|NCT03326648|Experimental|Protein supplement|Daily protein supplementation for 10 weeks.
2435938|NCT03326635||frailty group|frailty score ≤ 3
2435939|NCT03326635||non-frailty group|frailty score >3
2435940|NCT03326622|Experimental|moderate exercise + standard care|This group performed a moderate exercise protocol with training zone determined by Cardiopulmonary Exercise testing added to standard care program based on American Academy of Neurology guidelines.
2435941|NCT03326622|Active Comparator|Standard care|This group performed a standard care program based on American Academy of Neurology guidelines, without exercise intensity control.
2435942|NCT03326609|Experimental|Volume: 2.5 mL|Perineural injection of ropivacaine 10 mg, 2.5 mL. Concentration: Ropivacaine 4 mg/mL.
2435943|NCT03326609|Experimental|Volume: 5 mL|Perineural injection of ropivacaine 10 mg, 5 mL. Concentration: Ropivacaine 2 mg/mL
2435944|NCT03326609|Experimental|Volume: 10 mL|Perineural injection of ropivacaine 10 mg, 10 mL Concentration: Ropivacaine 1 mg/mL
2435945|NCT03326609|Experimental|Volume: 15 mL|Perineural injection of ropivacaine 10 mg, 15mL Concentration: Ropivacaine 0.67 mg/mL
2435946|NCT03326609|Experimental|Volume: 20 mL|Perineural injection of ropivacaine 10 mg, 20mL Concentration: Ropivacaine 0.5 mg/mL
2435947|NCT03326596|Experimental|ProphylacticTranexamic Acid|Once consented, patients to receive 1000mg/10ml normal saline infusion of TXA with the delivery of the infant's anterior shoulder.
2435948|NCT03326583|No Intervention|No Intervention: Pre-Treatment|This arm is the 2 week observation period before the start of the Patiromer treatment phase.
2435949|NCT03326583|Experimental|Intervention: Treatment|This arm is the 12 week treatment phase. Participants will take 8.4 grams of Patiromer once daily for one week, during which serum potassium and gastrointestinal symptoms will be evaluated. If tolerated and in the absence of hypokalemia, the dose will be up-titrated to 16.8 grams once daily for the remaining 11 weeks.
2435950|NCT03326583|No Intervention|No Intervention: Post-Treatment|This arm is the 2 week observation period after the Patiromer treatment phase.
2435951|NCT03326570||Bronchoscopy Data Collection|Medical information collected after bronchoscopy for up to 2 years.
2435952|NCT03326557|Active Comparator|Membrane sweeping|Membrane sweeping involves the insertion of a digit past the internal cervical os followed by three circumferential passes of the digit causing separation of the membranes from the lower uterine segment. When the cervix is closed, a massage of the cervical surface for 15 to 30 seconds will be performed instead. Membrane sweeping will be undertaken twice a day at 8 to 10 hours apart.
2435953|NCT03326557|Active Comparator|Transcervical Foley catheter insertion|Transcervical Foley catheter No. 18 F will be inserted under aseptic technique into the endocervical canal surpassed beyond the internal os. The balloon will be inflated with 60 ml of sterile water and the catheter is plastered to patient's thigh with gentle traction. The catheter will be checked for its position and the traction at 6 hours interval. If it were expelled spontaneously, it would not be re-inserted. Otherwise, the catheter will be removed after 24 hours.
2435954|NCT03326544|Experimental|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
2435955|NCT03326544|Experimental|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
3188416|NCT00766714|Experimental|1|Cook K-SOFT-5100 catheter
3188417|NCT00766714|Active Comparator|2|Frydman classical catheter
3188418|NCT00766740|Active Comparator|1|thrombectomy
2435959|NCT03326505|Active Comparator|Injection of Umbilical cord derived UC- MSCs|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients
2435960|NCT03326505|Active Comparator|injection of UC- MSCs and SPT|Allogenic Umbilical Cord derived stem cells injected intrathecally to enrolled MS patients along with a supervised physical therapy program
2435961|NCT03326505|Active Comparator|Supervised Physical Therapy (SPT)|Supervised physical therapy program without stem cells
2435962|NCT03326492||Patients bitten by a snake|"Any patient over 5 years old going to a participating center for curative care following a snake bite.~Participation to the study does not change usual follow-up of patients. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient."
2435963|NCT03326479||Retrospective|Subject who have previously had MI Profiling performed prior to 11/11/2016 are eligible for this study. No drug intervention is required for this study.
2435966|NCT03326453|Experimental|Mini Dental implant|2 mini dental implant of diameter 2.8 mm with length 10 mm will be inserted mandiblular ridge ≥5 mm mesial to the mental foraminato support overdentures for the intervention group.
2435967|NCT03326453|No Intervention|conventional implant|two slandered implant diameter 3.7 mm and length 10 mm will be placed in interforaminal region of mandiblular ridge support overdenture for the compartor group.
2435968|NCT03326440|Other|Study Arm|Patients with a histological diagnosis of prostate cancer are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system prior to the start of Radiotherapy.
2435969|NCT03326440|Other|Control Arm|Patients with a histological diagnosis of prostate cancer who are shown how Radiotherapy is planned and given using 3D images on the VERT (Virtual Environment Radiotherapy) system following completion of Radiotherapy.
2435970|NCT03326427|Experimental|Skill Training Group|A twelve sessions protocol of the Skill Training Group of the Dialectical Behavior Therapy.
2435971|NCT03326427|Active Comparator|Treatment as Usual|Patients will have one psychiatric session to control their medication adherence.
2435972|NCT03326414|Other|Constant PEEP - low tidal volume|PEEP is 10mbar, tidal volume is set to 4-5ml/kg IBW
2435973|NCT03326414|Other|Constant PEEP - high tidal volume|PEEP is 10mbar, tidal volume is set to 8-10ml/kg IBW
2435974|NCT03326414|Other|constant tidal volume - low PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 3mbar
2435975|NCT03326414|Other|constant tidal volume - high PEEP|tidal volume is 8ml/kg IBW, PEEP is set to 12mbar
2435976|NCT03326401||Case (AMD group)|Case group including 100 patients diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
2435977|NCT03326401||Control (Non-AMD group)|Case group including 100 patients not diagnosed with age-related macular degeneration (50 women, 50 men).Demographic data and dietary intake of different food groups were assessed by a standardized interviewer-assisted questionaire with the method of face-to-face interview. The questionaire form, prepared to determine socio-demographic features of individuals participating in the research, was applied by the research with the method of face-to-face interview. The body weight of the individuals were measured with a calibrated electronic scale,anthropometric measurements were measured by the researcher. Participants' dietary intake was assessed using food frequency questionaire (FFQ). The FFQ included 65 food items traditionally consumed in Turkey. Foods were classified into the following food categories: milk and dairy products, meat and meat products, fruits, vegetables, breads and cereals, beverages, and desserts.
3148114|NCT00139828|Other|A|The amount of Nonafact® to be administered and the frequency of treatment is based on the SmPC and should always be determined on the basis of the clinical effectiveness in the individual patient
2435979|NCT03326375|Experimental|SBRT (Stereotatic body radiotherapy)|Treatment of SBRT in HCC patients who have incomplete response after first TACE
2435980|NCT03326375|No Intervention|TACE (Transarterial chemoembolization)|Treatment of repeated TACE in HCC patients who have incomplete response after first TACE
2435981|NCT03326362|Experimental|High intensity resistance training (HIRT)|"12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions. The HIRT performed the squat, deadlift and lunge exercises, as these exercises induce high core muscles activity. HIRT started with two weeks of low intensity exercises emphasizing the activation of core muscles (pelvic elevation with feet on the floor, superman, static supine bridge on bosu), and the technique of the selected resistance exercises (e.g. squat, deadlift, and lunges). Participants performed 3 sets of 10 repetitions per exercise. In the third and forth weeks, participants performed the exercises from the previous weeks and also static unipedal forward flexion on bosu and dynamic unipedal forward flexion and the main exercises with a load corresponding to (50% of the 1 RM load (Brzycki, 1993).~From the 5th to the 12th week, participants performed only the selected resistance exercises with progressive higher intensities (from 12RM to 8RM)."
2435982|NCT03326362|Active Comparator|Low intensity resistance training (LIRT)|12 weeks of two weekly training sessions, with at least 48 hours of interval between sessions.The LIRT group performed very low intensity and volume exercises (i.e. 1 set per exercise). Exercises started with participants lying on a firm surface, with the back supported, knees bent and feet flat on the floor. Then, participants performed the following exercises: 1) inhaling and exhaling and then isometrically contract in gluteal and abdominal muscles for 20 seconds and relax; 2) raising the head, lifting the chin and shoulders toward the chest for 20 seconds and relax; 3) raising one knee towards the chest and raising the head and shoulders likewise in the second exercise for 20s, relaxing, and changing the leg.; 4) raising both knees towards the chest in the same time that raise the head and shoulder off the floor during 20 seconds and relax.
2435983|NCT03326349|Experimental|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) 5 days per week over 6 weeks.
2435984|NCT03326349|Sham Comparator|Ictus.online|Itus.online 5 days per week over 6 weeks
2435985|NCT03326336|Other|Cohort|3 dose escalation cohorts (low, medium and high dose) with 3 subjects per cohort followed by an extension cohort at the highest-well tolerated dose with 3 to 9 subjects.
2435987|NCT03326310|Experimental|Azacitidine and selumetinib|Subjects will receive azacitidine subcutaneously on days 1-7. Selumetinib will be administered on days 8-21. Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression.
2435988|NCT03326297|Experimental|Osteopathy manual therapy|Osteopathy manual therapy applying the following treatment: Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
2435989|NCT03326297|Active Comparator|Measures to support and education to the family|Measures to support and education to the family that consist on pedagogical intervention in parents, health education.
3148115|NCT00139841|Experimental|1|bendamustine
3148116|NCT00139958||1|
3148117|NCT00139958||2|
3148118|NCT00140010|Experimental|A|30,000 units of erythropoietin beta in one vial; 3 vials as one set per patient
2435991|NCT03326284|Experimental|15g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 15g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2435992|NCT03326284|Experimental|35g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2435993|NCT03326284|Experimental|60g protein hypocaloric diet|Following a 5-day hypocaloric diet the subjects (n=10) will ingest 60g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2435994|NCT03326284|Experimental|35g protein energy balanced diet|Following a 5-day energy balanced diet the subjects (n=10) will ingest 35g of protein and their mixed muscle protein synthesis response will be monitored using tracer kinetics.
2435995|NCT03326271||Lubinus SP2 stem|Patients treated with a cemented Lubinus SP2 stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
2435996|NCT03326271||Exeter stem|Patients treated with a cemented Exeter stem for a femoral neck fracture. Both total hip arthroplasty and hemiarthroplasty are included.
2435997|NCT03326258|Experimental|Treatment (glembatumumab vedotin, nivolumab, ipilimumab)|Patients receive glembatumumab vedotin IV over 90 minutes and nivolumab IV over 60 minutes on day 8 of course 1 and on day 1 of subsequent courses. Patients in melanoma expanded cohort also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 21 days for 4 courses in the absence of disease progression or unaccepted toxicity and courses with glembatumumab vedotin and nivolumab repeat every 21 days in the absence of disease progression or unaccepted toxicity.
2435998|NCT03326245|Active Comparator|1:Oral MP- IV PL|Oral Methylphenidate /IV Placebo
2435999|NCT03326245|Active Comparator|2 Oral PL/IV MP|Oral Placebo/IV Methylphenidate
2436000|NCT03326245|Placebo Comparator|3: Oral PL/IV PL|Oral Placebo/IV Placebo
2436001|NCT03326232|Experimental|Blinded continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter).
2436002|NCT03326232|Experimental|Real time continuous glucose monitoring|The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
2436003|NCT03326219|Other|Aethoxysklerol clarivein during leg amp|Clarivein treatment with Aethoxysklerol in 5 patients during lower or upper leg amputation
2436004|NCT03326206||COPE participants|Individuals living with diabetes seen at a study site who were enrolled in the COPE programmatic intervention during the study period. Participation in COPE consists of receiving home visits by a Navajo Community Health Representative (CHR) once or twice a month for a period of at least 12 months. CHRs use structured patient coaching materials to support behavior change. CHRs also check vital signs, monitor blood glucose levels through finger sticks, and facilitate access to appointments and medical refills. CHRs communicate regularly with providers through electronic health record documentation and case management rounds. In-person or telephone communication is be used to address acute issues that may arise.
2436005|NCT03326206||Non-COPE participants|Individuals living with diabetes seen at a study site, did not participate in the COPE programmatic intervention, and had comparable baseline characteristics.
2436006|NCT03326193|Experimental|Participants receiving niraparib+ bevacizumab|Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) via a 30 minute (min) intravenous (IV) infusion on Day 1 of each 21-day cycle. Niraparib will be administered orally once a day continuously throughout each 21-day cycle. On Day 1 of each cycle, niraparib will be administered upon completion of bevacizumab infusion. The starting dose of niraparib will be based on the participant's Baseline actual body weight or platelet count.
2436007|NCT03326180|Experimental|Liposomal bupivacaine (EXPAREL)|266mg/20ml EXPAREL mixed with 80ml 0.9% normal saline and 100mg/20ml 0.5% plain bupivacaine hydrochloride. Administered as a single dose intra-operatively by periarticular infiltration.
2436008|NCT03326180|Active Comparator|Bupivacaine hydrochloride alone|"100ml 0.9% normal saline mixed with 100mg/20ml 0.5% plain bupivacaine hydrochloride.~Administered as a single dose intra-operatively by periarticular infiltration."
2436009|NCT03326167||Patients with or suspected coronary heart disease|
2436010|NCT03326141|Active Comparator|Otago+PAM+Health / Wellness topics|"Condition 1:~Otago Exercise Program adapted for delivery to small groups; a physical activity monitor such as a Fitbit (PAM); and, information about health and wellness (8) topics guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2436011|NCT03326141|Experimental|Otago + PAM + Interpersonal strategies|"Condition 2:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Interpersonal behavior change strategies; and, information about health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2436012|NCT03326141|Experimental|Otago, PAM, Intrapersonal strategies|"Condition 3:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g.,Fitbit); 5 Intrapersonal behavior change strategies; and, health and wellness topics (1) guided by content in the National Institute on Aging (NIA) and Centers for Disease Control and Prevention websites."
2436013|NCT03326141|Experimental|Otago,PAM, Inter+Intra strategies|"Condition 4:~Otago Exercise Program adapted for delivery to small groups; a PAM (e.g., Fitbit); 5 Interpersonal behavior change strategies; and, 5 Intrapersonal behavior change strategies"
2436014|NCT03326128|Active Comparator|BUP-300|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 300 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
2436015|NCT03326128|Experimental|BUP-450|Participants will receive Bupropion hydrochloride extended release for 12 weeks and titrate to a maximum dose of 450 mg/day and will also receive standard smoking cessation counseling for 8 weeks.
2436016|NCT03326115|Experimental|Peer Visitation Program (PVP)|Participants in this group will begin participation in the Peer Visitation Program (PVP) beginning at amputation date with the initiation window ranging from immediately pre-operative to 7 days post operative.
2436017|NCT03326115|No Intervention|Delayed Peer Visitation (NoPVP)|Not participating in a Peer Visitation Program for 60 days post-operatively, followed by participation and completion in a PVP 60 days later than the PVP group for a total of 120 days.
3148119|NCT00140075|Experimental|B|"ET (8 cycles)~T = docetaxel or paclitaxel"
2436018|NCT03326102|Experimental|DHP107|"The 12 eligible subjects will receive DHP107 and be taken blood samples for PK analysis on Day 1, 8 of cycle 1.~Total 48 subjects (including PK subjects) will receive DHP107 200 mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days."
2436019|NCT03326102|Experimental|IV paclitaxel|Total 24 subject will receive IV paclitaxel 80 mg/m2 weekly.(3 weeks on/1 week off)
2436020|NCT03326089|Active Comparator|High flow oxygen supplementation|Pulmonary rehabilitation with constant high flow supplementary oxygen supply FiO2 50% for 2 months (Group A).
2436021|NCT03326089|Placebo Comparator|Oxygen supplementation upon hypoxemia|Pulmonary rehabilitation without oxygen supply unless upon resting or exercise induced hypoxemia for 2 months (Group B).
2436022|NCT03326076||Primary donor-derived cell-free DNA|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
2436023|NCT03326076||Control|A matched control cohort of 1000 patients with planned renal surveillance biopsies at 12 months post-transplantation but were not managed with donor-derived cell-free DNA (AlloSure®) or KidneyCare will be retrospectively selected
2436024|NCT03326076||Secondary donor-derived cell-free DNA|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
2436025|NCT03326076||Primary KidneyCare®|300 patients with planned renal surveillance biopsies at 12 months post-transplantation
2436026|NCT03326076||Secondary KidneyCare®|1200 patients without planned renal surveillance biopsies at 12 months post-transplantation
2436027|NCT03326063|Active Comparator|Ifetroban|Subjects will be randomized to receive ifetroban (200 mg dose per day) for 4 weeks.
2436028|NCT03326063|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo for 4 weeks.
2436029|NCT03326050|Placebo Comparator|gemifloxacin and Rifampicin|first group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once dailygroup will be given the usual regimen given for free by the Ministry of Health in Egypt; Rifampicin 300 mg twice daily for three months..
2436030|NCT03326050|Placebo Comparator|gemifloxacin and ciprofloxacin|. group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily group will be given a short course (four weeks) of oral Ciprofloxacin 750 mg twice daily
2436031|NCT03326050|Placebo Comparator|gemifloxacin and placipo|.group will be given a short course (four weeks) of oral Gemifloxacin 320 mg once daily
2436032|NCT03326024||A|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and underwent laparoscopic ovarian drilling from more than two years.
2436033|NCT03326024||B|Patients with Polycystic Ovary Syndrome at reproductive age (20-35) diagnosed according to Rotterdam criteria and didn't undergo laparoscopic ovarian drilling
2436034|NCT03326011|Experimental|Gait training group|Gait training with Samsung Hip Assist v1 All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions.
2436035|NCT03325998|Experimental|Gait training group|"Gait training with Samsung Hip Assist v1~All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions."
2436036|NCT03325985|Experimental|Nurse-led telephonic case management|"Telephonic nurses will contact patients within 72 hours of enrollment~Patients will speak with the telephonic nurse over the phone once a week (or as often as needed) for a duration of 6 months."
2436037|NCT03325985|Active Comparator|Facilitated, outpatient specialty palliative care|"Patients will be scheduled for their first in-person palliative care visit within two weeks of enrollment and then once a month for 6 months.~Clinic visits will be scheduled the same day as other specialty appointments if possible"
2436038|NCT03325972|Experimental|IV dexmedetomidine|Dexmedetomidine is an alpha-2-adrenergic agonist. It is commonly used for sedation and as an adjunct to general anesthetics.
2436039|NCT03325972|Placebo Comparator|Placebo|saline placebo
2436040|NCT03325959|Active Comparator|Hyperbaric oxygen therapy|60 daily hyperbaric oxygen treatment sessions will be administrated 5 days per week. Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group.
2436041|NCT03325959|Active Comparator|Pharmacotherapy|"patients will be offered pharmacological treatment with one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica. Treatment with Lyrica will start at a dose of 75 mg at bedtime while treatment with Cymbalta will start at a dose of 30 mg a day (in the morning). After a period of 6 weeks patients will be evaluated and dose will be adjusted as necessary. Patients may also be switched from one medication to the other based according to clinical judgment.~Crossover: After 3 months of either pharmaceuitical or HBOT, once the 2nd evaluation is completed, all patients in both groups will be offered to switch to the alternative treatment group."
2436042|NCT03325946||Children and Adults with Cerebral Palsy|
2436043|NCT03325946||Children and Adults with Microcephaly|
2436044|NCT03325946||Children and Adults with other Neuromotor Impairments|
2436045|NCT03325933|Experimental|Resistance Training 1|Participants will perform resistance training with high training loads and low repetitions (high load/low rep resistance training).
2436046|NCT03325933|Experimental|Resistance Training 2|Participants will perform resistance training with low training loads and high repetitions (Low load/high rep resistance training).
2436047|NCT03325933|No Intervention|Wait-list control|This group will be offered the option of participating in either experimental group after the study is completed.
2436048|NCT03325920|Experimental|Sleep bruxism group|25 sleep bruxism subjects wear the DIABRUX for five consecutive nights.
2436049|NCT03325920|Experimental|non-sleep bruxism group|25 non-sleep bruxism subjects wear the DIABRUX for five consecutive nights.
2436050|NCT03325907|Experimental|template-guided biopsy|Participants receive transthoracic lung biopsy guided by navigational template.
3188419|NCT00766740|Active Comparator|2|Standard PCI
3188420|NCT00766766|Experimental|1|Experimental Intervention Group
3188421|NCT00766766|No Intervention|2|Standard Care Control
2436668|NCT03321240||The direct surgery group|Group with a direct surgery
3188422|NCT00766779|Experimental|Transplant Arm|Hematopoietic cell transplantation after Reduced Intensity Conditioning
3188423|NCT00766779|Active Comparator|Conventional Chemotherapy|The non-transplant treatment approach for consolidation
3188424|NCT00766792|Experimental|1|Nocturnal dialysis
3148120|NCT00140075|Experimental|A|"EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles~T = docetaxel or paclitaxel"
3148121|NCT00140101|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
2436057|NCT03325829||Patients with colonic diverticula|No interventional study
2436062|NCT03325803|Experimental|150μm-AFL-PDT|
2436063|NCT03325803|Experimental|350μm-AFL-PDT|
2436064|NCT03325803|Experimental|500μm-AFL-PDT|
2436065|NCT03325790|Placebo Comparator|Placebo|Placebo
2436066|NCT03325790|Experimental|200mg SPI-1005 twice daily (BID)|200mg SPI-1005 BID
2436067|NCT03325790|Experimental|400mg SPI-1005 BID|400mg SPI-1005 BID
2436068|NCT03325777|Experimental|Approach Bias Retraining Group|Individuals in this condition will receive seven sessions of ABR training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
2436069|NCT03325777|Sham Comparator|Control Group|Individuals in this condition will receive seven sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
2436070|NCT03325764|Other|sleeve gastrectomy|Assessment before and after sleeve gastrectomy
2436071|NCT03325751||Healthy subjects|
2436072|NCT03325751||Glaucoma subjects|Patients with primary open-angle-, pseudoexfoliation- or primary angle-closure glaucoma
2436073|NCT03325725|Experimental|NewBreez LD Intra-laryngeal implant|
2436074|NCT03325712|Experimental|Dose Group 1|
2436075|NCT03325712|Experimental|Dose Group 2|
2436076|NCT03325712|Experimental|Dose Group 3|
2436077|NCT03325712|Experimental|Dose Group 4|
2436078|NCT03325712|Experimental|Dose Group 5|
2436079|NCT03325712|Placebo Comparator|Placebo|
2436080|NCT03325712|Experimental|Dose Group 8|
2436081|NCT03325699|Experimental|Intervention|Participants assigned to the intervention group will have access to the SMART4MD health application and participate in clinical visits every 6 months
2436082|NCT03325699|No Intervention|Control|Participants assigned to the intervention group will NOT have access to the SMART4MD health application and participate in clinical visits every 6 months
2436083|NCT03325686|Experimental|vitamin D supplement|D
2436084|NCT03325686|Placebo Comparator|control|P
2436087|NCT03325660|Active Comparator|study group|whole body vibration
2436088|NCT03325660|No Intervention|control group|No intervention
2436089|NCT03325647|Experimental|Visit 1 Drug, Visit 2 Placebo|Subjects in this group will be randomized to receive Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses, beginning at visit 1, and Placebo Injectable Saline beginning at visit 2.
2436090|NCT03325647|Experimental|Visit 1 Placebo, Visit 2 Drug|Subjects in this group will be randomized to receive Placebo Injectable Saline beginning at visit 1, and Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution every 4 weeks x 3 doses beginning at visit 2.
3148122|NCT00140101|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
2436092|NCT03325621|Active Comparator|PRS-080#022-DP|Experimental: PRS-080#022-DP Hepcidin antagonist, repeated administrations, ascending doses
2436093|NCT03325621|Placebo Comparator|PRS-080-Placebo#001|Experimental: PRS-080-Placebo#001 Comparator treatment, repeated administrations
2436094|NCT03325608|Experimental|Intervention|The POISED care management team consisting of specially-trained nurses functioning as care managers (CMs) and para-professionals in the role of care manager assistants (CMAs) will conduct a biopsychosocial/environmental needs assessment by phone within 48 hours of emergency room discharge if not possible during the ED stay.
2436095|NCT03325608|Placebo Comparator|Usual Care|will receive referrals to services at the time of enrollment.
2436096|NCT03325595|Active Comparator|Experimental: AEF0117|Subjects in Cohorts 1 through 4 receive active treatments. Subjects in Cohorts 1 through 4 will receive a single dose of 0.2, 0.6, 2 and 6mg respectively of AEF0117 on Day1.
2436097|NCT03325595|Placebo Comparator|Placebo Comparator: Placebo|Subjects in Cohorts 1 through 4 will be randomly assigned in an 6:2 allocation to receive active or placebo treatments.
2436098|NCT03325569|Active Comparator|NGT|NGT - normal glucose tolerance. Women with PCOS and normal glucose tolerance
2436669|NCT03321227|Experimental|Snack skipping|No snack provided
3148123|NCT00140114|Other|A|A: Vaginal misoprostol (cytotec)
3148124|NCT00140114|Other|B|Sublingual misoprostol (Cytotec)
3148125|NCT00140465|Active Comparator|1|75 mg Clopidogrel Maintenance Doses
3148126|NCT00140465|Active Comparator|2|150 mg Clopidogrel Maintenance Doses
3148127|NCT00140504|Experimental|MedCheck|Electronic medication safety queries via PatientSite portal
3148128|NCT00140504|No Intervention|Usual care|No electronic medication safety messages via PatientSite portal
3148129|NCT00140530|Experimental|1|Due to randomisation patients got a Paclitaxel-eluting stent
3148130|NCT00140530|Experimental|2|Due to randomization patients got a Rapamycin-eluting stent.
3148131|NCT00140582|Experimental|A : rituximab maintenance|Maintenance with rituximab for 2 years
3148132|NCT00140582|No Intervention|B : no maintenance|No further treatment
3148133|NCT00140660|Experimental|R-ACVBP|addition of rituximab to standard ACVBP chemotherapy
3148134|NCT00140660|No Intervention|ACVBP|standard ACVBP chemotherapy
3148135|NCT00140712|Experimental|Ropinirole|single dose .25mg of IR formulation, .05mg of RLS controlled release
3148136|NCT00140738|Experimental|Group A|"Patients receive study vaccinations in 3 consecutive cycles:~In Cycle 1 each patients will receive six vaccinations at two-week intervals followed by evaluation.~In Cycle 2, subjects will patients six vaccinations at two-week intervals followed by evaluation.~In Cycle 3, subjects will patients six vaccinations at three-week intervals."
2436099|NCT03325569|Active Comparator|IGH|IGH - impaired glucose homeostasis Women with PCOS and impaired glucose homeostasis - that means impaired fasting glucose or impaired glucose tolerance.
3188425|NCT00766792|Active Comparator|2|Standard dialysis
2436102|NCT03325543|Experimental|Intervention Group|The treatment program is based on the motor learning concepts of PFMs. The steps of learning a correct muscle contraction will be separate into four levels: 1. Understand 2. Search 3. Find 4. Learn. Feedback from the PF is mandatory. The intervention program will last four weeks, and will contain four outpatient consultations (1 session per week) lasting 60 minutes each session.
2436103|NCT03325543|Active Comparator|Control Group|The control group will receive only verbal instructions about the anatomy and function of the PFM, and to perform the contraction of the PFMs.
2436104|NCT03325530||Focus Group|
2436105|NCT03325504|Experimental|hBM-MSCs-Low Dose|Autologous Cultured Mesenchymal Stem Cells +Biomaterial (Low Dose): 100x106 cells
2436106|NCT03325504|Experimental|hBM-MSCs-High Dose|Autologous Cultured Mesenchymal Stem Cells+Biomaterial (High Dose): 200x106 cells
2436107|NCT03325504|Active Comparator|Autologous Illiac crest graft|Autologous Iliac Crest Grafting
2436108|NCT03325491|Experimental|Acipimox plus exercise training|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for 6 weeks.
2436109|NCT03325491|Placebo Comparator|Placebo plus exercise training|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
2436110|NCT03325465|Experimental|Pembrolizumab and epacadostat|"Patients will receive neoadjuvant immunotherapy either with anti-PD-1 (pembrolizumab) alone or anti-PD-1 in combination with IDO1 inhibition (epacadostat). Patients will receive Pembrolizumab every 3 weeks over a period of 8 weeks as well as epacadostat starting on day 1 for the duration of pembrolizumab treatment.~All patients will undergo baseline biopsy (mandatory, sampling ≥ 4 areas to represent the tumor), as well as baseline imaging (and for exploratory analysis collection of blood for baseline ctDNA testing and TCR analysis)."
2436111|NCT03325452|Experimental|cardio-respiratory arrest|
2436112|NCT03325439|Experimental|Brivaracetam (BRV)|Exploratory Cohort and Confirmatory Cohorts
2436113|NCT03325426|No Intervention|Usual care|
2436114|NCT03325426|Experimental|Physical activity tracker|
2436115|NCT03325413|No Intervention|Control|Usual care with assessment only (no study-related intervention)
2436116|NCT03325413|Other|Implementation|Implementation of intervention measures
2436117|NCT03325413|Other|Full-scale intervention|
2436118|NCT03325400|Other|Non-fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
2436119|NCT03325400|Active Comparator|Fluoride toothpaste|Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation.
2436120|NCT03325387|Experimental|LY3305677|Escalating doses of LY3305677 administered by subcutaneous (SC) injection
2436121|NCT03325387|Placebo Comparator|Placebo|Saline solution administered by SC injection
2436122|NCT03325374||BLB patients|Patients admitted for urgent MRI with possible cauda equina syndrome will be consented for questionnaires and examination.
2436123|NCT03325361|Experimental|TD|
2436124|NCT03325361|No Intervention|NTD|
2436125|NCT03325348|Experimental|Oral Nifedipine|Nifedipine 10mg oral tablet & 1ml 0.9%N/Saline will be given every 15 minutes up till one hour
2436126|NCT03325348|Active Comparator|IV Labetalol|IV labetalol 20 mg and mint tablet will be given every 15 minutes up till one hour
2436127|NCT03325335|Active Comparator|Midazolam premedication group (Group P)|Patients of group P were premedicated with intramuscular midazolam 0.05 mg/kg 30 minutes before surgery.
2436128|NCT03325335|Other|Control group (Group N)|Patients of group N were not premedicated with midazolam (Do not use placebo). [Treatment of Glycopyrrolate (0.2 mg, IM) 30 minutes prior to surgery is not intervention because it is a routine practice of this center. (-> removed from interventions)]
2436129|NCT03325322|Experimental|Treatment|Fisetin 20 mg/kg/day, orally for 2 consecutive days
2436130|NCT03325322|Placebo Comparator|Placebo|Placebo capsules orally for 2 consecutive days
2436131|NCT03325309||Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
2436132|NCT03325296|Experimental|LEO 124249 ointment 30 mg/g|Ointment to be applied on the eyebrow twice daily.
2436133|NCT03325296|Placebo Comparator|LEO 124249 ointment vehicle|Ointment to be applied on the eyebrow twice daily.
2436134|NCT03325283|Experimental|Protembo device treatment|Patients who consent to participate in the PROTEMBO SF Trial and in whom the ProtEmbo Cerebral Protection System is used or is attempted to be used.
2436135|NCT03325270|Experimental|ferrous fumarate|labeled iron as Ferrous Fumarate
2436136|NCT03325270|Experimental|ferrous fumarate and GOS|labeled ferrous fumarate + prebiotics
2436137|NCT03325270|Experimental|ferrous sulfate and GOS|labeled ferrous sulfate + prebiotics
2436138|NCT03325244||All participants|All participants will use a portable EEG monitor and FITBIT to monitor sleep and activity before and after night call
2436235|NCT03324438|Active Comparator|Home Telehealth T1D (CoYoT1-HR)|Home Telehealth T1D (C2oYoT1-HR), standard of care delivered via Telehealth for high-risk youth
2436236|NCT03324438|Experimental|Personalized Adherence Feedback|C2oYoT1-HR+Personalized Adherence Intervention
2436237|NCT03324438|Experimental|Personalized Behavioral Health|C2oYoT1-HR+Personalized Behavioral Health
2436139|NCT03325231||Bladder Cancer Patients|Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
2436140|NCT03325218||Questionnaire Set A|
2436141|NCT03325218||Questionnaire Set B|
2436142|NCT03325205|Experimental|Active tDCS|Participants receive anodal tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
2436143|NCT03325205|Sham Comparator|Sham tDCS|Participants receive sham tDCS over DLPFC. Each sessions lasts for 20 minutes, with a total of 15 stimulations: 6 acute sessions, 9 maintenance sessions.
2436144|NCT03325192|Placebo Comparator|Standard of care|Subjects in this arm will receive placebo only (100mL of normal saline) into the pleural space delivered via the newly placed tunneled intrapleural catheter
2436145|NCT03325192|Experimental|Rapid pleurodesis protocol|Subjects in this arm will receive the chemical pleurodesing agent of 10% iodopovidone solution delivered to the pleural space via the newly placed tunneled intrapleural catheter
2436146|NCT03325179|Experimental|participants received treatment|100 participants who are diagnosed as simple obesity under the standards of... are planned to enrolled in the trial. Each will receive Thread-embedding therapy.
2436147|NCT03325166|Experimental|Treatment (pembrolizumab, ferumoxytol MRI)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years (or up to 32 cycles) in the absence of disease progression or unacceptable toxicity. Patients also receive ferumoxytol IV and undergo MRI at baseline, 12 weeks after radiation, at suspected radiographic progression, and 6 weeks after suspected radiographic progression.
2436148|NCT03325127||Radium-223 concomitant with Abiraterone or Enzalutamide|Approximately 150 medical charts from mCRPC patients within the network will be collected
3148137|NCT00140738|Experimental|Group B|Patients receive study vaccinations as second-line therapy
2436151|NCT03325088|Other|Severe Asthma|patients affected with severe asthma s defined by ERS-ATS (European Respiratory Society - American Thoracic Society) without long term oral corticosteroids treatment
2436152|NCT03325088|Other|Mild to moderate Asthma|patients affected with untreated mild to moderate asthma
2436153|NCT03325088|Other|Controlled Sample|smooth muscle cells from Tracheobronchial rings of non-asthmatic cadaveric donor
2436154|NCT03325075|Experimental|VAL-181388|
2436155|NCT03325075|Placebo Comparator|Placebo|
2436156|NCT03325062|Experimental|Experimental: MOVE|Movement pattern training in addition to contemporary progressive rehabilitation
2436157|NCT03325062|Active Comparator|CONTROL|Contemporary progressive rehabilitation
2436158|NCT03325049|Experimental|The health-promoting conversations|In the intervention group, there were 3 health-promoting conversations with each family after the discharge. The health-promoting conversations were held within an approximately 4- to 8-week period with an interval of 2 weeks between conversations. A closing letter was sent 2 to 3 weeks after the final conversation that summarized all of the conversations and that provided further opportunities for reflection.
2436159|NCT03325049|Active Comparator|Control Arm|Usual Care
2436160|NCT03325023|Active Comparator|Active Comparator:|Dietary modification + Probiotic supplementation (Sanprobi Super Formula)
2436161|NCT03325023|Placebo Comparator|Placebo Comparator|Dietary modification + placebo.
2436164|NCT03324997|Experimental|Restylane|half the chest to be treated with Restylane Silk
2436165|NCT03324997|Placebo Comparator|Placebo|half-chest injections with saline as a placebo to Restylane Silk.
2436166|NCT03324984|Experimental|1% Chloroprocaine (PF)|1% Chloroprocaine is an ester-linked local anesthetic with the shortest duration of action of all local anesthetics.
2436167|NCT03324984|Active Comparator|0.75% bupivacaine|0.75% bupivacaine is a amino-amide anesthetic local anesthetic. It is hyperbaric in nature due to addition of dextrose.
2436168|NCT03324971|Experimental|Diabetic patients with non-adherence and poly-pharmacy|Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
2436169|NCT03324958|Experimental|Virtual Reality Helmet|Patients will use a virtual reality helmet during brachytherapy applicator's setting up. The use of virtual reality helmet has already been assessed during oncologic treatments, and seems to reduce pain and anxiety. The use of virtual reality helmet has never been assessed to reduce the pain or anxiety associated with brachytherapy applicators' setting up.
2436170|NCT03324958|Active Comparator|No Virtual Reality Helmet|Patient wont use virtual reality helmet during brachytherapy applicator setting up, as in current practice.
2436171|NCT03324945|Experimental|Neurocognitive Assessment +/- FMRI|All participants receive pre- and post-chemotherapy neurocognitive assessments. A sequentially-assigned subset also receive pre- and post-chemotherapy Functional Magnetic Resonance Imaging (FMRI) procedures.
2436172|NCT03324932|Other|AI+denosumab VS only AI|We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.
2436173|NCT03324919||Psoriasis, HRQL|Patients with a medical diagnosis of Psoriasis were enclosed.
3148138|NCT00140751|Experimental|Simplification|The patients included in this arm are on Monotherapy of Kaletra (Lopinavir/ritonavir)during 48 weeks
3148139|NCT00140751|No Intervention|Continued|The patients included in this arm continue their treatment without any changes
3148140|NCT00140790|Active Comparator|Valsartan 40mg|Standard Dose valsartan
3148141|NCT00140790|Active Comparator|Valsartan 160mg|High Dose valsartan
3148142|NCT00140907|Placebo Comparator|1|Placebo
3148143|NCT00140907|Active Comparator|2|Losartan
3148144|NCT00141011|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
3148145|NCT00141011|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
2436176|NCT03324906|Active Comparator|tDCS active Prader-Willi Syndrome|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
2436177|NCT03324906|Active Comparator|tDCS active Obese Subjects|The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation). The start ramp, when the current will be changed from zero to 2mA (two milli amps), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes.
2436178|NCT03324893|Experimental|[F18]-FCH PET/MRI|Patients with primary hyperparathyroidism planned for parathyroidectomy
2436179|NCT03324880|Experimental|rhPTH(1-84)|Participants will receive rhPTH(1-84) 50 microgram (mcg) subcutaneous (SC) injection once daily (QD), titrated within the dose range of 25-100 mcg QD as an adjunctive treatment with active vitamin D and calcium supplements based on metabolic response.
2436180|NCT03324880|Placebo Comparator|Placebo|Participants will receive placebo matched to rhPTH(1-84) as SC injection QD with active vitamin D and calcium supplements.
2436181|NCT03324867|Experimental|Intranasal Insulin 40 IU|40 IU of Humulin-R via nose Before surgery and everyday after surgery up to POD 7
2436182|NCT03324867|Placebo Comparator|Intranasal Normal Saline|Normal Saline via nose Before surgery and everyday after surgery up to POD 7
2436183|NCT03324854|Experimental|mosquito net mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the mosquito net mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
2436184|NCT03324854|Active Comparator|prolene mesh|The open ventral hernia repair were carried out with rives technique, followed by the placement of the prolene mesh, and left active-close drainage, 30 minutes before the incisión, prophylactic antibiotic 1gm of cefalotin was administered.
2436185|NCT03324841||MI Profiling|Subjects must have undergone Caris MI Profiling in order to be eligible for the study. No required intervention is dictated by the protocol.
2436186|NCT03324828|Active Comparator|Hydroxyzine+no clowns|Patients will receive hydroxyzine solution and no additional intervention
2436187|NCT03324828|Experimental|Hydroxyzine+clowns|Patients will receive hydroxyzine solution and clowns intervention
2436188|NCT03324828|Active Comparator|Placebo+clowns|Patients will receive placebo solution and clowns intervention
2436189|NCT03324828|No Intervention|Placebo+no clowns|Patients will receive placebo solution and no additional intervention
2436190|NCT03324815|Active Comparator|Morphine- Methadone|Morphine 5mg/6h plus metadone: 2,5mg/12h
2436191|NCT03324815|Active Comparator|Morphine|Morphine: 5mg/6h
2436192|NCT03324802|Experimental|Arm 2 (hypofractionated radiation therapy, 5 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo hypofractionated radiation therapy in 5 daily fractions for 5 days.
2436193|NCT03324802|Experimental|Arm I (radiation therapy, 15 fractions)|Within 12 weeks of breast cancer surgery or adjuvant chemotherapy, patients undergo standard radiation therapy in 15 daily fractions for 10 days.
2436194|NCT03324789|Experimental|Single Implant Partial Over-denture|The design will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
2436195|NCT03324789|Active Comparator|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
2436196|NCT03324776|Other|Afrezza Inhalant Product|Patients will be instructed to follow a Weekly Treat-to-Target BG Testing Regimen and make Afrezza dose changes according to an Afrezza Titration Algorithm
2436197|NCT03324763||stool sampling|
2436198|NCT03324737|No Intervention|Standard Care Arm|Subjects in the standard care arm will be informed of their increased risk of developing type 2 diabetes in the future, and given general lifestyle verbal advice to maintain a healthy weight, eat a well-balanced diet and do regular exercise during their 6 week postnatal visit. Women found to have impaired fasting glucose (6.1-6.9 mmol/L) or impaired glucose tolerance (2H post glucose of 7.8-11.0 mmol/L) will be issued a letter reinforcing lifestyle changes namely weight loss (if raised BMI), diet, exercise, and encouragement to consult a family physician to discuss the appropriateness of starting medications that can prevent the progression to type 2 diabetes, or restore the blood glucose to normal levels. Those with a normal OGTT result will just be informed that it is normal.
2436199|NCT03324737|Active Comparator|Interactive Smartphone App Arm|"Participants will download the INTERACTIVE SMARTPHONE APP and will be briefed on its use by our team of nutritionists/dieticians, exercise physiologists and life style coaches. Weight: Participants will be reminded that the goal is satisfactory weight loss.~NUH occupational therapist-trained lifestyle coaches, exercise physiotherapists, and clinical nutritionist/ dietician will interact with participants through real-time chats channels via the APP; all culturally appropriate and customized to the Singapore context."
2436200|NCT03324724|Experimental|Adolescents with Eating Disorder|Adolescents with bulimia nervosa or binge eating disorder, with one or more of their parents, will receive integrative cognitive-affective therapy for adolescents (ICAT-A).
2436201|NCT03324711|Other|Elderly patient (65 and more)|Ederly patients seen in geriatric day hospital, from creole culture.
2436202|NCT03324685|Experimental|BIIB074 150 mg and Oral Contraceptive|Participants will receive BIIB074 in tablet form in 150 mg doses every 8 hours on prescription (TID) on days 1-7 and on days 26-32. OC will be taken in tablet form (ethinyl estradiol 30 micrograms and levonorgestrel 150 micrograms) once daily (QD) on days 12-32.
2436203|NCT03324672|Active Comparator|TRIGGER|
2436204|NCT03324672|Experimental|TRIGGER+CURETAPE|
2436205|NCT03324659|Experimental|Exercise and Meditation|The Exercise and Meditation group will practice mindfulness meditation immediately before walking treadmill exercise, five days per week for four weeks.
2436206|NCT03324659|Sham Comparator|Control|The Control group will listen to an audio book followed by quiet rest, five days per week for four weeks.
2436208|NCT03324620|Experimental|pre active HSCT|"Candidates for transplantation of hematopoietic progenitors since May 12, 2012, regardless of sex and age, who agree to participate in the study and sign informed consent.~In the pre-transplantation visit with the physiotherapist: Measures of muscle mass and strength, quality of life questionnaires, program presentation, fitness assessment and lifestyle determination. The exercises will be personalized, stimulating your practice before admission and involving the family. During admission, the team will encourage the patient to remain active by adapting to the symptoms. At discharge, measures of resistance, exercise tolerance and quality of life at discharge, in the month after discharge, 3 months after discharge, 6 months after discharge and 12 months after discharge."
2436209|NCT03324620|No Intervention|control group|"Patients' candidates for transplantation of hematopoietic progenitors prior to May 12, 2012, regardless of gender and age, who meet the inclusion criteria and are collected correlatively until completing 104 subjects.~Clinical history review to calculate the days of hospitalization in the different hospitalization units during the transplant. As well as the number and type of complications and the use of health resources. Status vitae. Baseline review of functional tests and exercise tolerance."
3188426|NCT00766805|Active Comparator|EVL + Drugs|Patients randomized to the EVL plus drugs therapy received EVL plus beta-blocker (propranolol) and nitrate (ISMN).
2436211|NCT03324594|Active Comparator|Group A|Participants will be first given (1) WONDALEAF-CAP, followed by (2) WONDALEAF-ON-MEN, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2436212|NCT03324594|Active Comparator|Group B|Participants will be first given (1) WONDALEAF-CAP, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2436213|NCT03324594|Active Comparator|Group C|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) durex-TOGETHER, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2436214|NCT03324594|Active Comparator|Group D|Participants will be first given (1) WONDALEAF-ON-MEN, followed by (2) WONDALEAF-CAP, and last with (3) durex-TOGETHER after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2436215|NCT03324594|Active Comparator|Group E|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-ON-MEN, and last with (3) WONDALEAF-CAP after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
2436216|NCT03324594|Active Comparator|Group F|Participants will be first given (1) durex-TOGETHER, followed by (2) WONDALEAF-CAP, and last with (3) WONDALEAF-ON-MEN after completion of four times usage for each condom type. The participants will be asked to complete four times of usage for each condom type within three to four months. There will be a baseline survey before the use of the first condom type, and subsequent evaluations upon completion of each condom type.
3148146|NCT00141024|Experimental|1|Group 1 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3148147|NCT00141024|Experimental|2|Group 2 will receive 4 vaccinations of the EP-1043 vaccine or placebo. Vaccinations will be given at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
3148148|NCT00141024|Experimental|3|In Part B, Group 3 will receive 4 vaccinations of either the EP-1043 vaccine or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
2436220|NCT03324568|Other|Educational handout|
2436221|NCT03324568|Experimental|Video plus educational handout|
2436222|NCT03324555|Experimental|ORIC-101|
2436223|NCT03324529|Experimental|Participants in the NYU takotsubo registry|"10 patients with a confirmed history of takotsubo syndrome~10 age- and sex-matched healthy controls with no significant history of cardiac or neurological illness"
2436224|NCT03324516|Experimental|Experimental Group|Patients included in this arm will undergo a traditional bony pterional approach for their craniotomy. A superior cuff of temporal muscle will be left attached to the temporal bone.
2436225|NCT03324516|Active Comparator|Control|Patients included into this arm will receive a traditional pterional approach for their craniotomy. The temporal muscle will be detached in its entirety.
2436226|NCT03324503|Experimental|Glucocorticoid ≥ 30 mg/day|≥ 30 mg/day prednisone or prednisolone as per local clinical practice of sarcoidosis initial induction therapy will be taken orally preferably before, during, or immediately after meals or with food or milk, at approximately the same time of day for 8 weeks.
2436227|NCT03324490|Active Comparator|TSA group|Thoracic Spinal Anesthesia; Bupivacaine 0.5% (hyperbaric) 7.5mg, Fentanyl 25 µg & Dexmedetomidine 5 µg by intrathecal injection
2436228|NCT03324490|Active Comparator|TEA group|Thoracic Epidural Anesthesia; Bupivacaine 0.5% (isobaric) 25-50 mg & Fentanyl 10-20 µg by epidural injection
2436229|NCT03324477|Experimental|preload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14 cannula over 15-20 min before the induction of spinal anaesthesia.
2436230|NCT03324477|Experimental|coload group|Patients will receive 4 ml/kg of hypertonic saline 3% via G14cannula at the maximal possible rate at the time of identification of C.S.F .
2436231|NCT03324464|Experimental|CET-Working Memory (WM)|Central Executive Training: Working Memory
2436232|NCT03324464|Active Comparator|CET-Behavioral Inhibition (BI)|Central Executive Training: Inhibitory Control
3188427|NCT00766805|Placebo Comparator|EVL alone|Patients assigned to the EVL group underwent variceal band ligation alone till variceal obliteration.
3188428|NCT00766818|Experimental|1|Kaletra
2436238|NCT03324438|Experimental|C2oYoT1-HR + Adherence + Behavioral|C2oYoT1-HR + both Personalized Adherence Feedback + Personalized Behavioral Health (C2oYoT1-HR + Adherence + Behavioral)
2436239|NCT03324425|Experimental|Simvastatin|Simvastatin 80 mg in combination with anti-HER2 therapy regimen
2436240|NCT03324412|Active Comparator|Treatment of MTX|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF）placebo.
2436241|NCT03324412|Experimental|Treatment of MTX and TwHF|Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F（TwHF).
2436242|NCT03324399|Experimental|High Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
2436243|NCT03324399|Experimental|Low Amino Acid levels|"Comparison between high amino acid levels and low amino acid levels of clinical global assessments, muscle strength and spasticity and functional assessments.~Patients taking proprietary probiotic"
2436244|NCT03324386|Experimental|Individual Orientation|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients: Experimental: individual orientation: receiving individual orientation required by an embracement strategy characterized by 7 nursing visits at 20-day intervals, for 4 months);The ntervention is composed by relational strategies characterized by interpersonal relationships
2436245|NCT03324386|Experimental|VLE for Distance Learning|This was a prospective randomized clinical study conducted with the following 4 groups of hypertensive patients:Experimental: a technological education strategy for distance learning (DL), using a technological education strategy (E-Care of Hypertension) for Distance Learning (DL) characterized by 7 nursing visits at 20-day intervals, for 4 months). The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in educational environments remotely accessed for health education specifically for hypertensive patients
2436246|NCT03324386|Experimental|E-blended Learning|This was a prospective randomized clinical study with the patient received experimental intervention: a technological education strategy with E-blended Learning modality with E-Care of Hypertension, associated with face-to-face consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months. The intervention is composed by the use of equipment-oriented techniques or audio-visual aids in presential educational environments intended for health education specifically for hypertensive patients
2436247|NCT03324386|No Intervention|No intervention|No type of intervention was performed making 2 nursing visits at baseline and 1 after 120 days (No intervention)
2436249|NCT03324360|Experimental|Control Participants Part I|A MRI with injection of hyperpolarized 13C pyruvate.
2436250|NCT03324360|Experimental|Intracranial Metastasis Part II|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment.
2436251|NCT03324360|Experimental|Intracranial Metastasis Part III|MRI with injection of hyperpolarized 13C pyruvate prior to radiation treatment. MRI with injection of hyperpolarized 13C pyruvate1-5 days following radiation treatment.
2436252|NCT03324347|Experimental|Therapydog|A certified therapydog (together with a certified dog-handler) will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
2436253|NCT03324347|No Intervention|No therapydog|No therapydog will be present in the dental clinic while the child will undergo a clinical dental examination by licenced pediatric dentist.
2436254|NCT03324334||Study group|Patients with ulcerative colitis Interventions to be administered: Thyroid antibodies and Thyroid sonography
2436255|NCT03324334||Control group|normal control subjects selected from general population at random Interventions to be administered: Thyroid antibodies and Thyroid sonography
2436256|NCT03324321|Experimental|Hyperventilation Protocol|This will involve sustained periods of 90-seconds of hyperventilation at two levels (-5mmHg and -10mmHg below baseline EtCO2) to a maximum lower level threshold of EtCO2 24mmHg/CBFV 33cm/s regulated using a metronome. Two-minute washout periods of normal respiration will be allowed between successive measurements. Each incremental reduction in pCO2 will be repeated on two occasions during the same session. Further assessments will be conducted 10-14 days following baseline assessments.
2436257|NCT03324308|Experimental|Interventional Group|"Participants undergoing dynamic computed tomography myocardial perfusion imaging.~Intervention: Diagnostic Test: Dynamic Computed Tomography Angiography Imaging"
2436258|NCT03324295||cortical cataract|patients with age related cortical cataracts who are otherwise healthy
2436259|NCT03324295||ocular problems|systemically healthy subjects with ocular problems other than cataract
2436260|NCT03324295||impaired renal functions|patients with impaired renal functions and are not on dialysis
2436261|NCT03324282|Experimental|Arm A: GC + avelumab group|
2436262|NCT03324282|Active Comparator|Arm B: GC group|
2436263|NCT03324269|Other|NOL|"After tracheal intubation and before surgical incision, a calibration Tetanus test of 100Hz, 60 mAmp during 30 sec at remifentanil level (Ce) of 4 ng/ml will be done (starting NOL below 10).~According to the NOL response, there will be an increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 or decrement of 1 ng/ml if NOL gradient < 10. Ideal remifentanil Ce is the remifentanil Ce at which the variation of NOL index will be less than 10 units at a NOL starting value below 10. Thus this individual remifentanil Ce will be the remifentanil level programmed before surgical incision. NOL and hemodynamic responses will be recorded during the entire duration of surgery."
2436264|NCT03324256|Active Comparator|Energy drink and placebo gum|Commercially-available energy drink (16oz) + 2 pieces of placebo gum
2436265|NCT03324256|Active Comparator|Caffeinated drink and placebo gum|Commercially-available caffeinated drink (16oz) + 2 pieces of placebo gum
2436266|NCT03324256|Active Comparator|Control drink and energy gum|Control drink (16oz) + 2 pieces of energy gum
2436267|NCT03324256|Placebo Comparator|Control drink and placebo gum|Control drink (16oz) + 2 pieces of placebo gum
2436268|NCT03324256|Active Comparator|Energy drink and total sleep deprivation|Commercially-available energy drink (16oz) + 2 pieces of placebo gum following total sleep deprivation
2436269|NCT03324243|Experimental|Crenolanib|
2436270|NCT03324217|Experimental|Motor Imagery Group|The participants in the motor imagery group were given instructions to perform a daily training composed of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant only had to imagine that he was performing that task, placed in the standard position with the tennis ball in the hand. Once the first set was completed, the participant had to take a 2-minute break before starting the second set, in which they had to complete the set both imagining and actively performing the isometric contractions with the tennis ball.
2436271|NCT03324217|Experimental|Action Observation Group|The participants in the action observation group were given instructions to perform a daily training comprised of two sets of activities. The main set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions. In the first set, the participant simply watched a video that showed a forearm performing the task, placed in the standard position and with the tennis ball in the hand. Once that first set was completed, the participant took a 2-minute break before starting the second set, in which they performed the 10 isometric contractions with the tennis ball while they watched the video.
2436272|NCT03324217|Active Comparator|Control Group|The participants in the control group were given instructions to perform a daily training of a single set. The set consisted of 10 isometric hand grip contractions for 3 seconds each with a tennis ball, leaving a 20-second break between contractions.
2436273|NCT03324204|Experimental|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis is placed on proper knee alignment during exercise. Most of the women exhibit excessive medial rotation and adduction of the femur, resulting in knee valgus. The women will be instructed how to correct their abnormalities using mirrors as visual feedback. All exercises will be completed without pain. If the exercises are too easy, the level of difficulty will be increased individually in accordance with the rehabilitation protocol
2436274|NCT03324204|Active Comparator|Shock Wave Therapy|The ESWT group will will meet the therapist twice in the first week, and once a week after it. ESWT will be applied to the iliotibial band and tensor fascia latae with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session.
2436275|NCT03324191|Placebo Comparator|Placebo|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and placebo drink within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2436276|NCT03324191|Experimental|Tea beverage|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and tea within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2436277|NCT03324191|Experimental|Tea extract (medium concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a medium concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2436278|NCT03324191|Experimental|Tea extract (high concentration)|"Participants will consume 567 ml of plain water at least 1 hour before testing the trial.~Information on dietary compliance will be collected. Participants will then be cannulated in an arm vein and a baseline fasting blood sample will be taken. Participants will be asked to consume a standard study meal challenge (providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein) and concentrated tea extract at a high concentration within 15 min. Serial blood samples will be collected at baseline, 30, 60, 90, 120 and 180 min. The intervention will end once the 180 min sample is collected.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
2436279|NCT03324178|Experimental|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training performed once a day over the course of four weeks (four sessions each week)
2436280|NCT03324178|Active Comparator|Video game control group|Sixteen 30-minute sessions of playing video games once a day over the course of four weeks (four sessions each week)
2436281|NCT03324165|No Intervention|Usual Care Arm|Patients randomized to Usual Care Arm will be managed as per current best practice that is based on the individual doctor's discretion.
2436282|NCT03324165|Experimental|Intervention Arm|Patients randomized to Intervention Arm will be managed as per the proposed algorithm, which is based on the computation of Alvarado Score.
2436283|NCT03324152|Experimental|High-intensity interval training (HIIT) - myositis|12-week, 3d/w, HIIT
2436284|NCT03324152|Active Comparator|Standard low-intensity home exercise control (CG)|12-week, 5 d/w, home exercise.
2436285|NCT03324152|Active Comparator|High-intensity interval training (HIIT) - healthy|12-week, 3d/w, HIIT.
2436286|NCT03324139|Experimental|Study Group|Treatment with low molecular weight Heparin.
2436287|NCT03324139|Placebo Comparator|Control Group|Treatment with Placebo.
2436288|NCT03324126||Targeted fortification|In the targeted protein fortification group, breast milk samples were analyzed daily via mid-infrared spectroscopy and additional protein was provided to maintain an intake of 4.5 g/kg/day.
2436351|NCT03323645||Patients with penile prostheses|
2436289|NCT03324126||Adjustable fortification|"In the adjustable protein fortification group, blood urea nitrogen (BUN) levels were monitored weekly, and if the level was < 5 mg/dL, the amount of protein fortification was gradually increased to an estimated maximum level of 4.5 g/kg/day"
2436290|NCT03324113|Experimental|SAR408701 Monotherapy|SAR408701 Dose escalation administered as a single agent intravenously, on Day 1 and once every two weeks, to patients with malignant solid tumors
2436291|NCT03324100||Allergic Rhinitis Patients|
2436292|NCT03324100||Healthy Controls|
2436293|NCT03324087||Adult patients with ITP|The investigators are undertaking a multi-center, prospective trail of 1000 adult ITP patients and use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
2436294|NCT03324061|Experimental|Fulvestrant for Injectable Suspension|Fulvestrant for Injectable Suspension (500 mg/vial)
2436295|NCT03324061|Active Comparator|Faslodex (R)|Faslodex (250 mg/mL)
2436296|NCT03324048|Other|Patients anxious|Patients anxious will be perform relaxation session.
2436297|NCT03324035|Experimental|Treatment|Patients on this arm will receive amitriptyline on flexible doses, starting from 25mg (1 capsule) and titrated to 50mg (2 capsules) or 75mg (3 capsules), based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
2436298|NCT03324035|Placebo Comparator|Placebo|Patients on this arm will receive placebo on flexible doses, starting from 1 capsule and titrated to 2 capsules or 3 capsules, based on brief pain inventory (BPI) questionnaire, applied weekly for 3 consecutive weeks. All patients will receive tramadol as a supportive drug for the treatment of neuropathic pain, they are instructed to take 50mg every 8 hours, if pain present.
2436299|NCT03324009|Experimental|2-stage screen|All patients will be enrolled in the two-stage cervical cancer screening protocol
2436300|NCT03323996||Health Professionals|Health Professionals attending a training in therapeutic education
2436301|NCT03323996||Patients|Patients of the health Professionals recruited for the study
2436302|NCT03323983||Normal lung clearance index|
2436303|NCT03323983||Elevated lung clearance index|
2436304|NCT03323970||Physicians|
2436305|NCT03323957||Patients|all infants admitted for care
2436306|NCT03323944|Experimental|Cohort 1: huCART-meso cells via intravenous infusion (IV).|Subjects will receive a single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells on day 0 via intravenous infusion.
2436307|NCT03323944|Experimental|Cohort -1: low dose huCART-meso cells via intravenous infusion|In the event that 2 DLTs occur among subjects enrolled in Cohort 1, then enrollment in Cohort 1 will be stopped and the dose will be de-escalated by 10-fold to 1-3x10^6 cells/m2. Subjects will receive a single dose of 1-3x10^6 cells/m^2 lentiviral transduced huCART-meso cells on day 0.
2436308|NCT03323944|Experimental|Cohort 2 - huCART meso cells via intraperitoneal infusion (IP)|Eligible subjects will receive a single dose of 1-3x107/m2 lentiviral transduced huCART-meso cells on day 0 via intraperitoneal (i.p.) administration. The initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
2436309|NCT03323944|Experimental|Cohort 3 - huCART meso cells via intrahepatic infusion (hepatic arterial infusion)|Eligible subjects will receive a single dose of 1-3x107/m2 lentiviral transduced huCART-meso cells on day 0 via intrahepatic delivery (Hepatic Arterial Infusion). The initial intrahepatic infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart.
2436310|NCT03323931|Active Comparator|(1) standard therapy|Standard therapy based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the therapist reinforces the adaptive behavior of the child.
2436311|NCT03323931|Experimental|(2) robot--enhanced intervention|A treatment developed on the same principles as standard therapy, based on Applied Behavioral Analysis (ABA) and Cognitive-Behavior-Therapy (CBT). It implies structured activities in which the robotic agent reinforces the adaptive behaviors of the child, under the supervision of the therapist.
2436312|NCT03323918|Experimental|ImPACT|Project ImPACT will be provided in 18 weekly intervention sessions, during which parents will learn how to stimulate their children's social imitation, social engagement, language and play skills. First, parents are taught techniques that promote interaction with the child (one technique per session, through demonstration and coaching). In the second half of the intervention, parents are taught direct teaching techniques, e.g., to promote language or play, again by means of demonstration and coaching. After completion of the program, families will receive guidance every 2-3 weeks for an additional 12 weeks, during which the support will generally not focus on social-communicative abilities, although ImPACT follow-up sessions might be given if necessary.
2436313|NCT03323918|Active Comparator|TAU|Treatment as usual (TAU) will be provided at the typical frequency, which is every 2-3 weeks. TAU can include targeting eating and sleeping problems, adaptive skills, or other goals. TAU will not include forms of intervention explicitly targeting social communicative skills. However, limited guidance on social communication development can be given if explicitly asked by parents.
2436314|NCT03323905|Experimental|MR Guided High Intensity Focused Ultrasound|
2436315|NCT03323892|Active Comparator|'normal' abstinence duration|Patients follow the normal abstinence duration as asked by the physician (2-7 days). This sperm will be used to inject half of the oocytes Intervention = second sperm sample
2436316|NCT03323892|Experimental|short abstinence duration|"Patients will be asked to produce a second sperm sample, 2 hours after the first. This sperm will be used to inject the other half of the oocytes.~Intervention = second sperm sample"
2436317|NCT03323879|Experimental|LDR/HDR|MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy
2436318|NCT03323866|Active Comparator|Mometasone nasal spray|Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
2436319|NCT03323866|Experimental|Budesonide irrigation|2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months
2436535|NCT03322332||NonDM-0|Nondiabetics without significant stenoses (> 50%) in the coronary arteries
3188429|NCT00766844|Experimental|Active|Spinal cord stimulation
3188430|NCT00766857|Experimental|1. Exenatide|
2436322|NCT03323840|Experimental|Incentivized Care|Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement.
2436323|NCT03323827||Aim 2a|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2a. Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) nondiabetics 20 subjects will be enrolled"
2436324|NCT03323827||Aim 2b|"Specific Aim 2. To determine how the cytosolic and mitochondrial protein acetylomes are regulated by muscle contraction in insulin sensitive and resistant human volunteers.~Protocol 2b (muscle contraction and acetylation) Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 32 subjects will be enrolled"
2436325|NCT03323827||Aim 3|"Specific Aim 3. To determine how acetylation of the mitochondrial inner membrane adenine nucleotide translocase ANT1 regulates protein structure and function.~Subjects. Two groups (aged 21-65) will be studied: lean (BMI<25), healthy insulin sensitive subjects, and obese (BMI>30) 20 subjects will be enrolled."
2436326|NCT03323814||short-sleepers|subset of participants will be recruited who report less than typical work/ weekday sleep in order to examine whether enhancing sleep with stimulation will reduce the amount of extra sleep subjects usually get on the weekends.
2436327|NCT03323814||shift-workers|An additional subset of participants will be recruited who work evening shifts to see if enhanced sleep can counteract some of the effects of schedule shifting.
2436328|NCT03323814||normal-sleepers|The first cohort will be used to optimize the the type and duration of sensory stimuli that will optimally enhance slow-waves.
3188431|NCT00766857|Active Comparator|2. Insulin glargine|
2436330|NCT03323788||Aim 1|Aim 1. To determine whether the transcription factor expression response to exercise is dysregulated in muscle from type 2 diabetic patients. We will test the hypothesis that MZF1, NFKB1, RELA, SP1/KLF and EGR1 responses to an acute exercise bout are reduced in insulin resistant patients with type 2 diabetes.
2436331|NCT03323788||Aim 2|"Aim 2. To determine how insulin resistance changes the response of post-translational modifications of SP1/KLF family and MZF1 transcription factors to acute exercise in muscle from type 2 diabetic patients. We will test the hypothesis that:~SP1/KLF2, 4, and 6 and phosphorylation/acetylation and MZF1 phosphorylation is altered in response to acute exercise.~The response of SP1/KLF2, 4, and 6 phosphorylation and acetylation and MZF1 phosphorylation to acute exercise is abnormal in patients with type 2 diabetes."
2436332|NCT03323788||Aim 3|"Aim 3. To define the response of miRNAs to acute exercise in healthy and insulin resistant muscle from obese and type 2 diabetic patients. We will test the hypotheses that:~The exercise-induced increases in expression of miR-378 members and miR-128 are lower in obese and type 2 diabetic muscle than in lean healthy controls.~FOXO1 expression, a target of miR-378 and miR-128, is higher in obese and type 2 diabetic muscle and this is accompanied by decreased FOXO1 phosphorylation.~The exercise-induced increases in expression of miR-30 family members, miR-10a, miR-422a, and miR-532 are lower in obese and type 2 diabetic muscle.~There are novel miRNAs that regulate the transcriptional program induced by acute exercise and are dysregulated in insulin resistance."
2436333|NCT03323788||Aim 4|Aim 4. To determine whether treatment with PPAR-Alpha agonist fibrate derivatives suppresses the normal gene expression response to acute exercise. We will test the hypothesis that Gemfibrozil treatment inhibits the normal transcriptional response to exercise.
2436334|NCT03323762|Experimental|RIC|"RIC treatment arm The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes.~The treatment will be carried out on the morning of day 2 to day 7 by the participants themselves at their home."
3188432|NCT00766870|Experimental|1|
3188433|NCT00766870|Experimental|2|
3188434|NCT00766870|Experimental|3|
3188435|NCT00766870|Other|4|
3188436|NCT00766870|Placebo Comparator|5|
3188437|NCT00766896|Active Comparator|Aspirin Sensitive|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time >= 150 seconds~Chrono-Log Model 700 Whole-Blood: < 1Ω with 0.75 mM of arachidonic acid~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) > 0.50~Chrono-Log Model 700 Whole-Blood: with collagen at 1 mg/L < 10Ω~Plateletworks: aggregation <60% with arachidonic acid will be considered sensitive~VerifyNow Aspirin Assay (Accumetrics): < 550 aspirin reaction units (ARUs)~Impact-R (Diamed) < 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
2436342|NCT03323710|Experimental|Propranolol plus Sunitinib|
2436343|NCT03323697|Experimental|Herbal|SZ-05 (2.5 gr; 3 capsules twice a day)
2436344|NCT03323697|Active Comparator|Selective serotonin reuptake inhibitor|Escitalopram (10 mg capsule plus 5 placebo capsules)
2436345|NCT03323684|Experimental|Quadratus lumborum block Group (QL)|Quadratus lumborum block will be performed
2436346|NCT03323684|Experimental|Transversus abdominis plane Group (TAP)|Subcostal transversus abdominis plane will be performed
2436347|NCT03323684|Experimental|Control group (C)|Postoperative analgesia will be accomplished with conjunction of paracetamol and ketorolac
2436348|NCT03323671|Experimental|premenstruation group|preemptive mefenamic acid 500mg tablets every 8 hours starting 2 days before anticipated menstruation and during the first 2 days of the cycle
2436349|NCT03323671|Experimental|menstruation group|mefenamic acid 500mg tablets every 8 hours during the first 2 days of the cycle
2436350|NCT03323658|Experimental|Prevention (bexarotene)|Group 1 will apply 10mg bexarotene topically to one breast QOD for 4 weeks; Group 2 will apply 10mg bexarotene topically to one breast QOD for 1 week and then daily for 3 weeks after confirmation that toxicity is at an acceptable range; Group 3 will apply 10mg bexarotene topically to one breast QOD for 1 week, then daily for 1 week, and then 20mg daily for 2 weeks after confirmation that toxicity is at an acceptable range.
2436352|NCT03323632|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
2436353|NCT03323619||GA|No intervention. General anesthesia is decided by the physicien according to his usual practice
2436354|NCT03323619||LASed|No intervention. Local anesthesia with sedation is decided by the physicien according to his usual practice
2436355|NCT03323606|Active Comparator|Gambling Internet Intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
2436356|NCT03323606|Experimental|Gambling Internet Intervention + CYD|The G+A intervention condition will consist of the G-only intervention and an online intervention for drinking. The online drinking intervention chosen is Check Your Drinking, a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2436357|NCT03323593|Active Comparator|iv|
2436358|NCT03323593|Active Comparator|drip|
2436359|NCT03323593|Active Comparator|atomizer|
3148149|NCT00141024|Experimental|4|In Part B, Group 4 will receive 4 vaccinations of either the DNA vaccine EP-HIV-1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6.
3148150|NCT00141024|Experimental|5|In Part B, Group 5 will receive 4 vaccinations of either the protein vaccine EP-1043 plus DNA vaccine EP-HIV- 1090 or placebo. Vaccinations will occur at Months 0, 1, 3, and 6. This group was discontinued as of 12/26/06.
2436362|NCT03323567|Experimental|MD Muscle Collagen group|Group with collagen intramuscular injections
2436363|NCT03323567|Experimental|Lidocaine 2% group|Group with 2% Lidocaine intramuscular injections
2436364|NCT03323567|Placebo Comparator|Saline|Group with 0,9% NaCl intramuscular injections
2436365|NCT03323554|Experimental|Ustrap®|Ustrap is a new adjustable-pressure 4-arm device
2436366|NCT03323554|Active Comparator|AMS 800®|Artificial sphincter currently considered the gold standard device in this field
2436367|NCT03323541||Group of patients treated with Zarxio|All consecutive patients, treated for lymphoma or myeloma, which underwent autologous stem cell transplantation in the University Hospital of Brest. All these patients were treated with biosimilars of Filgrastim: Zarzio®.
2436368|NCT03323528|Active Comparator|Dorithricin|"Dorithricin throat lozenges is a fixed combination of three active substances: Benzalkonium Chloride-Benzocaine Topical plus tyrothricin. Lozenge has to be sucked slowly until it fully dissolves in the mouth and dosed up to 8 lozenges per day. Test product without mint oil.~Intervention: The initial dose is administered at the study site. Patients administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
2436369|NCT03323528|Placebo Comparator|Placebo|"Placebo Oral Tablet is taken orally. Placebo consists of a lozenge with matched appearance and the same excipients as those of the Dorithricin lozenge. The initial dose (2 lozenges simultaneously) is administered at the study site.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
2436370|NCT03323502|Experimental|ACP Specialist Program|The ACP Specialist will work with nursing home leaders to: i. Consolidate nursing home ACP procedures; ii. Train and educate staff; and iii. Facilitate ACP with patients who have Alzheimer's Disease/related dementias and their family caregivers.
2436371|NCT03323502|No Intervention|Usual Care|Facility will followed usual ACP procedures.
2436372|NCT03323489|Experimental|celiac radiosurgery, single fraction|Celiac Plexus Radiosurgery
2436373|NCT03323476|Experimental|Discontinuation of maintenance treatment|
2436374|NCT03323476|Active Comparator|Maintenance of immunosuppressive treatment|
3148151|NCT00141193|Placebo Comparator|A|
3148152|NCT00141323|Experimental|lasofoxifene 0.5 mg/day|
2436377|NCT03323450|Experimental|High grade gliomas(WHO grade III or IV; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
2436378|NCT03323450|Experimental|Low grade gliomas(WHO grade II; n=15)|The two groups will follow identical study timelines. Participants will receive a 1 hour training session on CogMed® (PI or trained graduate student). Participants will complete 5 weeks of CogMed® training within their own home. It consists of 25 training sessions. Each session lasts 30-45 minutes.The study team will check in with participants once a week via phone or email. Brief neuropsychological evaluations will be conducted at 4 time points. Each assessment will take approximately 30-60 minutes. Each participant will receive a $25 gift card to the VCU medical center gift shop at two time points.
2436379|NCT03323437|Experimental|Patient|Medication-free individuals during first-episode of psychosis who will receive 4 weeks of treatment with risperidone
2436380|NCT03323437|No Intervention|Control|Healthy, psychosis-free controls who will not receive risperidone
2436381|NCT03323424|Experimental|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice, but also a Stereotactic Body Radio-Therapy (SBRT).
2436382|NCT03323424|Active Comparator|Systemic treatment|Patients with metastatic breast, colorectal or head or neck cancers and corresponding with the inclusion criteria will receive a systemic treatment, according to the usual practice.
2436576|NCT03321994|Experimental|Stereotaxic unit, navigation|
3148153|NCT00141323|Placebo Comparator|placebo|
2436383|NCT03323411||Intervention and attention control|the Advance Care Treatment Plan experimental group received education on dementia cardiopulmonary resuscitation and tube feeding. The attention control group received education on exercise stress control diabetes and hypertension
2436386|NCT03323385|Experimental|N1539 30 mg|N1539 (meloxicam injection for IV use) 30 mg every 24 hours
2436387|NCT03323385|Placebo Comparator|IV Placebo|IV Placebo every 24 hours
2436388|NCT03323372|Active Comparator|control group|In group 1 (G1-control), the operator applied a desensitizing gel based on 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2% ®, FGM , Joinville, Santa Catarina, Brazil) with the aid of a custom silicone tray, which was made from a model obtained from the patient, with a vacuum plasticizer. A small layer of the gel was placed on the surface of the tray that was in contact with the vestibular face of the upper anterior teeth of the participants. The tray remained in position in the mouth for 10 minutes, according to the manufacturer's specifications.
2436389|NCT03323372|Experimental|experimental group|In group 2 (G2-intervention group), the operator applied a desensitizing gel containing 3% potassium nitrate and 0.25% sodium fluoride (Ultra EZ®, Ultradent Products Inc, South Jordan, UT, Estados Unidos) with the help of a tray in which the material is stored on the vestibular surfaces of the upper anterior teeth of the participants. The tray remained in position in the mouth for 15 minutes, according to the manufacturer's specifications.
2436390|NCT03323359|Experimental|Hemopatch 45x90 mm - CE 0297 Class III|Hemopatch + Common surgical techniques
2436391|NCT03323359|Other|Standard Surgery Technique|Common surgical techniques
2436392|NCT03323346|Experimental|Disulfiram with copper|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed. Patients will take disulfiram after their evening meal.~Patients will avoid alcohol and other disulfiram-drug interactions will be considered.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
2436393|NCT03323333|Experimental|Intervention|
2436395|NCT03323294||Healthy Lean|Healthy lean individuals (n=20) defined with a Body Mass Index (BMI) ≥ 5th percentile and <85th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
2436396|NCT03323294||Healthy Obese|Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
2436397|NCT03323294||Obese Insulin Resistant|Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
2436398|NCT03323294||Type 2 Diabetes or Insulin Resistant|Obese individuals with Type 2 Diabetes or insulin resistance (n=20)
2436401|NCT03323255|Active Comparator|cTBS stimulation|continuous theta-burst TMS stimulation (1200 pulses, 50Hz, separated in two sequences of 600 pulses)
2436402|NCT03323255|Sham Comparator|SHAM stimulation (placebo)|SHAM stimulation
2436403|NCT03323242|No Intervention|Control group|Recipient hepatectomy using conventional bipolar coagulation devices, surgical suture ligatures, and surgical clips (or any dissecting / coagulating device other than LS)
2436404|NCT03323242|Experimental|LS group|Recipient hepatectomy applying LigaSure.
2436405|NCT03323242|Experimental|USD group|Recipient hepatectomy applying Harmonic Ultrasonic dissector.
2436406|NCT03323229|No Intervention|Usual care (control group)|Patient receives care as usual.
2436407|NCT03323229|Experimental|Enhanced communications & ultrasound|The paramedic will record a brief video summary of the patient's condition, then remotely supported point of care ultrasound scans will be performed, and both file types sent to the hospital for review and feedback from the consultant.
2436408|NCT03323216||No diabetes|Patients without diabetes
2436409|NCT03323216||Type 2 diabetes|Patients with diagnosis of type 2 diabetes (new/established)
2436410|NCT03323216||Prediabetes|Patients with an intermediate state of hyperglycemia with glycemic parameters above normal but below the diabetes threshold.
2436411|NCT03323190|Experimental|Inpatient COPD patient|All COPD patients meeting the inclusion criteria of this study will be exposed to inpatient COPD education and tested at a later date to determine if knowledge on COPD was gained.
2436412|NCT03323177|Experimental|Nutritional supplementation gender specific formula|Patients at this arm will continue to consume the study formula until final height. The formula is a gender specific powder added to water containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
2436413|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
3148154|NCT00141323|Experimental|lasofoxifene 0.25 mg/day|
3148155|NCT00141440|Experimental|1|COPD patients
3148156|NCT00141531|Active Comparator|Apaziquone|
2436419|NCT03323138|Experimental|Ex-PRESS and phacoemulsification|A treatment session of PACG coexisting cataract treated with phacoemulsification combined with P50 Ex-PRESS miniature glaucoma device (Alcon Laboratories, Fort Worth, Texas, USA).
2436420|NCT03323112||Influenza vaccine recipients|Health care workers vaccinated by their occupational health care according to the routine praxis.
2436421|NCT03323099|Experimental|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
2436422|NCT03323099|Placebo Comparator|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
2436425|NCT03323073|Active Comparator|Bipolar disorder type I or II|a single resting state fMR for patients with bipolar disorder type I or II with acute depressive state
2436426|NCT03323073|Active Comparator|Unipolar disorder|a single resting state fMR for patients with monopolar disorder with acute depressive state
2436427|NCT03323073|Other|Healthy volunteers|a single resting state fMRI for subjects without psychiatric disorders assessed by the SCID
2436428|NCT03323060||Male and/or females ≥ 22 yrs old|≥ 22 years of age requiring transanal procedures in the areas of the anus, rectum, and distal colon Transanal endoscopic surgical procedure
2436429|NCT03323047|Experimental|Group 1|Acetaminophen and High-dose dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia.
2436430|NCT03323047|Active Comparator|Group 2|Acetaminophen and Low-dose Dexamethasone: a single dose of oral acetaminophen (15 mg/kg) 1 hr pre-operatively and intravenous administration of low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
2436431|NCT03323047|Placebo Comparator|Group 3|Placebo oral tablet and Low-dose Dexamethasone: an oral placebo given 1 hr pre-operatively and intravenous administration of low dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia.
2436432|NCT03323034|Experimental|Treatment (pevonedistat, temozolomide, irinotecan)|Patients receive pevonedistat IV over 60 minutes on days 1, 8, 10, and 12, temozolomide PO daily on days 8-12, and irinotecan IV over 90 minutes on days 8-12 of cycle 1. Beginning cycle 2, patients receive pevonedistat IV over 60 minutes on days 1, 3, and 5, temozolomide PO daily on days 1-5, and irinotecan IV over 90 minutes on days 1-5. Treatment repeats every 28 days for cycle 1 and 21 days for subsequent cycles for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
2436433|NCT03323021|Experimental|Treatment with DHACM|Partial nephrectomy patched with DHACM
2436434|NCT03323021|Active Comparator|Control without DHACM|Partial nephrectomy without DHACM.
2436435|NCT03323008|Experimental|Training Prototype|Testing of 3 modules
2436436|NCT03322995|Experimental|Restaging: Response to Treatment|After the first restaging evaluation, further treatment will be based on treatment response. Patients who demonstrate a response [decline in carbohydrate antigen 19-9 (CA19-9) values] and radiographic response, along with preserved performance status) will be maintained on the first line chemotherapy for an additional two months.
2436437|NCT03322995|Experimental|Restaging: Patients with Stable Disease|Patients who do not have a significant decline in CA19-9 values will be changed to a second-line therapy for an additional two months.
2436438|NCT03322995|Experimental|Restaging: Local Disease Progression|After the first restaging evaluation, further treatment will be based on treatment response. If, at the initial restaging, the patient has local disease progression amenable to surgical resection, he or she will receive chemoradiation, rather than continued chemotherapy, so the window of opportunity for surgical resection is not lost.
2436439|NCT03322982|Experimental|MS Diet|34 people with MS following low-fat diet
2436440|NCT03322982|No Intervention|MS Wait-List|34 people with MS following usual diet
2436441|NCT03322982|No Intervention|Diet Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Diet group
2436442|NCT03322982|No Intervention|Wait-List Healthy Control|20 controls with no diagnosis of MS, age and sex-matched to members of the MS Wait-List group
2436443|NCT03322969|Experimental|receiving modified chemotherapy|Paclitaxel/DDP
2436444|NCT03322969|Active Comparator|receiving the original chemotherapy|XELOX/SOX
2436445|NCT03322956|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
2436446|NCT03322956|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
2436577|NCT03321994|Active Comparator|Conventional biopsy technique|
3148157|NCT00141544|Experimental|1|
3148158|NCT00141544|Active Comparator|2|
3148159|NCT00141557|Experimental|1|
3148160|NCT00141557|Active Comparator|2|
3148161|NCT00141648|Experimental|1|Chemotherapy followed by radiotherapy to begin 3 weeks after the last cycle.
3148162|NCT00141661|Experimental|Low Dose Arm|
3148163|NCT00141661|Experimental|High Dose Arm|
3148164|NCT00141661|Placebo Comparator|Placebo Control|
3148165|NCT00141687|Experimental|Early External Cephalic Version Group|Early external cephalic version (ECV) procedure performed between 34 weeks and 0/7 days and 35 weeks and 6/7 days of gestation
3148166|NCT00141687|Active Comparator|Delayed External Cephalic Version Group|Delayed external cephalic version (ECV) procedure performed at or after 37 weeks and 0/7 days of gestation
3148167|NCT00141713|Experimental|1|etanercept treatment for GVHD
3148168|NCT00141856|Other|1|
2436449|NCT03322891|Experimental|Educational Supplement|Participants diagnosed with prostate cancer will receive education for treatment options and treatment side effects.
2436450|NCT03322878|Experimental|Intravenous magnesium group (Group IV)|Group IV (n=30) will receive intravenous (IV) 20 ml magnesium SO4 (50 mg/ kg 10% MgSO4(magnesium sulphate) diluted in normal saline to a total volume of 20 ml(milliliter) ) and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg) .
2436451|NCT03322878|Active Comparator|Caudal magnesium group (Group CA)|Group CA (n=30) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% and 50 mg Magnesium SO4 diluted in normal saline with total volume of 1mL/kg).
2436452|NCT03322878|Placebo Comparator|Placebo group (Group P)|Group P (n=30) ) will receive IV 20 ml normal saline and caudal anaesthesia using (bupivacaine 0.25% diluted in normal saline with total volume of 1 mL/kg).
2436453|NCT03322865|Experimental|One Arm|Obinutuzumab i.v.
2436454|NCT03322839|Experimental|Multifaceted implementation strategies|The school-management will participate in a one-day training. In addition each intervention school will form an implementation team that is responsible for the implementation of the guideline within their school. The implementation teams will participate in 4-5 workshops in order to support the implementation process.
2436455|NCT03322839|Active Comparator|Single implementation strategy|The control-schools will only receive training to the school-management.
2436456|NCT03322826|Active Comparator|Lymphadenectomy|systematically Lymphadenectomy of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
2436457|NCT03322826|Experimental|systematic sampling of the lymph nodes|systematic sampling of the lymph-node stations ATS 2, 4, 7, 8, 9,10,11 on the right side and ATS 5, 6, 7, 8, 9,10,11 on the left side
2436458|NCT03322813|Experimental|ExAblate 4000 - Type 2|ExAblate BBBD
2436459|NCT03322800|Experimental|AK0529 100 mg, Pilot|This is an open pilot arm and male subjects enrolled into this arm will be only administered with an oral single dose of 100 mg AK0529. The dose group begins treatment on Day 1.
2436460|NCT03322800|Experimental|AK0529 100 mg|Subjects will be administered with an oral single dose of 100 mg AK0529 or placebo. The dose group begins treatment on Day 1.
2436461|NCT03322800|Experimental|AK0529 300 mg, food effect|A 3x3 cross-over study is designed in this group to evaluate the food effect following a standard Chinese meal or a high fat meal in the same subjects, comparing with the PK profile of AK0529 under fasted condition. Subjects will be administered with an oral dose of 300 mg AK0529 or placebo on Day 1 of each cycle.
2436462|NCT03322800|Experimental|AK0529 600 mg|Subjects will be administered with an oral single dose of 600 mg AK0529 or placebo. The dose group begins treatment on Day 1.
2436463|NCT03322800|Experimental|AK0529 300 mg, MAD|Subjects will be administered with the multiple doses of 300 mg AK0529 or placebo on Day 1-7.
2436464|NCT03322800|Other|Placebo|For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose group (except the pilot group). The placebo is administered at the same time (and of the same dosage) as the AK0529 subjects.
2436465|NCT03322787|No Intervention|Oxygen|The training will be performed using oxygen by the Venturi mask with the FiO2 set during the run - in session.
2436466|NCT03322787|Experimental|HFO|The training will be performed using the HFO device during the run - in session at iso_FiO2 as in the Control Group (Oxygen by Venturi mask).
2436467|NCT03322774|Sham Comparator|Attention Control|This group receives sleep hygiene education, which serves as a credible control intervention to digital cognitive behavioral therapy for insomnia (dCBT-I). This intervention mimics the web-based patient contact inherent in dCBT-I but is inert with respect to sleep outcomes.
2436468|NCT03322774|Experimental|Stepped Care Model|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will begin treatment with face-to-face Cognitive Behavioral Therapy for Insomnia with a trained staff member in behavioral sleep medicine."
2436469|NCT03322774|Sham Comparator|Stepped Care Model Control|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Following initial treatment with dCBT-I, individuals who do not experience remission of their insomnia will receive sleep hygiene education, serving as a credible control intervention for comparison to the Stepped Care Model."
2436470|NCT03322774|Experimental|digital CBT-I|"This group receives digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) through the third party program, Sleepio. Treatment includes weekly sessions of CBT-I administered over the internet in hour-long video sessions. Daily sleep diaries are recorded online for individual tailoring of treatment."
2436471|NCT03322761|Experimental|Systematic exercise training|Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.
2436472|NCT03322761|Active Comparator|Educational program|Educational program on physical activity and health, consisting of four educational sessions in the intervention period.
2436473|NCT03322761|No Intervention|Standard treatment alone|Data from The Danish MS Registry will serve as control-data for standard treatment alone.
2436474|NCT03322748|Experimental|Experimental group|Usual physical therapy+ strengthening of lower limbs muscles
2436475|NCT03322748|Other|Control group|Usual physical therapy
2436476|NCT03322735|Experimental|anti-tumor response of BCMA CAR-T|"Drug: Cyclophosphamide patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days.~Drug: Fludarabine Fludarabine 25-30mg/m2/day IV for 3 days. Biological: BCMA CAR-T BCMA CAR-T cells will be administered after completion of the chemotherapy."
2436477|NCT03322709||Robotic-assisted kidney transplant|Adult patients undergoing robotic kidney transplantation. The transplant operation will be undertaken using the da Vinci systems robot in minimally invasive fashion.
2436478|NCT03322709||Open kidney transplant|Adult patients undergoing kidney transplantation via an open approach.
2436479|NCT03322709||Donor nephrectomy|Adult patients undergoing donor nephrectomy will have a scan of their abdominal wound to compare wound healing.
2436480|NCT03322696||Cirr-PVT|Cirrhotic patients developing over 1 yr period thrombosis of portal vein or collaterals
2436481|NCT03322683|Experimental|EXPERIMENTAL GROUP|The intervention for this group consisted of 5 massage sessions with the PHYSIUM device for a month.
2436482|NCT03322683|Experimental|CONTROL GROUP|"The multimodal physical therapy program includes 10 sessions of:~ultrasound pulsatil therapy (US) for 10 minutes.~transcutaneous electric nerve stimulation (TENS) for 20 minutes.~massage for 20 minutes."
2436483|NCT03322670||Signs of CAP and a positive chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
2436484|NCT03322670||Patients directly hospitalized|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and who are directly hospitalized before complementary examinations
2436485|NCT03322670||Control patients|Healthy Patients (age-matched with a radiologically confirmed CAP patient)
2436486|NCT03322670||Patients with partial participation|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and who can not or do not want to perform all the complementary examinations of the study
2436487|NCT03322670||Signs of CAP and a negative Chest X-Ray|Patients with at least 2 signs suggestive of CAP on presentation at general practice (one general sign of infection and one sign of pulmonary localization) and and a chest X-Ray not compatible with CAP
3148169|NCT00141895|Active Comparator|A|Vaginal Cytotec at doses of 400 microgram every 4 hours until delivery
3148170|NCT00141895|Active Comparator|B|Sublingual Cytotec at doses of 400 microgram every 4 hours until delivery
2436490|NCT03322644|Experimental|Internet-based CBT intervention|In addition to standard medical care, participants in the Internet-based CBT group will receive access to the Pancreatitis Pain Course and will be asked to complete all online modules over 2 months using their own smartphone or computer. A coach will guide participants through the weekly lessons.
2436491|NCT03322644|No Intervention|Wait list control group|Participants assigned to the Wait list control group will be asked to continue with any recommendations made by their clinic provider and will not be offered any internet-based content until after they complete the 5 month assessments (i.e. Months 5-7).
2436492|NCT03322631|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
2436493|NCT03322631|Placebo Comparator|Placebo|Placebo administered SC.
2436494|NCT03322618|Experimental|SpA HLA-B27 +,|
2436495|NCT03322618|Experimental|SpA HLA-B27-|
2436496|NCT03322618|Active Comparator|healthy subject|
2436497|NCT03322592|Active Comparator|EUS-FNB with ROSE|Intervention: Rapid on-site evaluation (ROSE) In the EUS-FNB with ROSE arm, the material obtained with the first pass will be processed for ROSE using the touch imprint technique. The biopsy specimen is carefully pressed onto the slide, allowing the superficial cells to adhere, and then gently lifted with forceps thereby creating a touch imprint of the specimen on the slide. In case of inadequate sample, a second pass will be done and the touch imprint technique will be repeated up to a maximum of 3 passes. In case of adequate ROSE at the first or the second pass, the additional passes will be performed as EUS-FNB and the material obtained placed directly into formalin or other fixative for subsequent histopathological evaluation.
2436498|NCT03322592|Active Comparator|EUS-FNB without ROSE|Intervention: histologic evaluation In the FNB alone arm, 3 needle passes will be performed and the samples obtained will be placed directly in a vial containing formalin (or other fixative according to the local individual protocol). Macroscopic on-site evaluation (MOSE) of acquired sample will be then performed by the endoscopist.
2436499|NCT03322579|Experimental|Patients with Eustachian tube dysfunction|
2436503|NCT03322553|Experimental|Plication group|In patients allocated to endoscopic plication, endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of GE junction around the GERD-X device
2436504|NCT03322553|Sham Comparator|Sham Group|In sham procedure, identical technique will be followed by positioning the plicator inside the stomach but sutures will not be applied.
2436578|NCT03321981|Experimental|Cohort 1 doublet|
3148171|NCT00141908|Placebo Comparator|Placebo progesterone injection|Placebo IM injections
3148172|NCT00141908|Active Comparator|Progesterone injections|17-hydroxyprogesterone caproate weekly injections
3148173|NCT00141986|Experimental|Vitamin D-higher dose|Vitamin D 2000 IU per os once daily
3148174|NCT00141986|Active Comparator|Vitamin D-lower dose|Vitamin D 400 IU per os once daily
3148175|NCT00142051|Experimental|1|inhaled NO
3148176|NCT00142051|Placebo Comparator|2|room air inhalation
3148177|NCT00142090|Experimental|2|3% Hypertonic saline
3148178|NCT00142090|Placebo Comparator|1|Normal saline
3148179|NCT00142103|Experimental|CPG10101|
3148180|NCT00142103|Experimental|CPG10101 + pegylated interferon|
3148181|NCT00142103|Experimental|CPG10101 + ribavirin|
3148182|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin|
3148183|NCT00142103|Active Comparator|Pegylated inteferon + ribavirin|
3148184|NCT00142103|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
3148185|NCT00142181|Experimental|Campath-1H|30 mg IV three times a week, 6-12 weeks.
3148186|NCT00142207|Active Comparator|1|Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine
3148187|NCT00142207|Active Comparator|2|Device: Insecticide-treated mosquito bed net
3148188|NCT00142207|Active Comparator|3|"Combination of Drug + Device:~Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine Device: Insecticide-treated mosquito bed net"
3148189|NCT00142233|Experimental|ANTOX (vers.)1.2|"Adults and children aged 10+ will take two ANTOX (vers)1.2 tablets three times per day. (Antioxidant treatment: daily: 300 μg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine) plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one ANTOX (vers)1.2 tablet three times daily (Antioxidant treatment: daily: 150 μg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine) plus one placebo Magnesiocard (2.5 mmol) tablet three times a day."
2436509|NCT03322501|Experimental|Intervention|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
2436510|NCT03322488|Experimental|Patients with Crohn's Disease|20 patients with Crohn's Disease. Intervention: Fistulodesis
2436511|NCT03322488|Experimental|Patients without IBD|20 patients without underlying Inflammatory Bowel Disease. Intervention: Fistulodesis
2436512|NCT03322475|Experimental|Facial skin rejuvenation|Facial skin rejuvenation using PiQo4 laser system
3188438|NCT00766896|Active Comparator|Platelet with hyperreactivity to aspirin|"For PFA-100 using a cartridge with C-EPI (collagen-epinephrine): occlusion time < 150 s~Chrono-Log Whole-Blood: above or = 1Ω with 0.75 mM of AA~Chrono-Log Whole-Blood: with collagen at 1 mg/L and 5 mg/L, according to the formula 1 - (Rate of aggregation with 1 mg / Rate of aggregation with 5 mg) below 0.50~Chrono-Log Whole-Blood: with collagen 1 mg/L above or = 10Ω~Plateletworks: aggregation of more than 60% with arachidonic acid will be considered resistant~VerifyNow Aspirin Assay (Accumetrics): ≥ 550 aspirin reaction units (ARUs)~Impact-R (Diamed) > 3.2% platelet aggregates on the surface of the plate after incubation with arachidonic acid"
2436514|NCT03322449|Experimental|Animal Diet|during this Arm, the participants will receive a diet enriched in animal products
2436515|NCT03322449|Experimental|Plant Diet|during this Arm, the participants will receive a diet enriched in plant products
2436516|NCT03322436||AMI patients treated by PCI|AMI patient treated by PCI at risk to develop Heart Failure
3188439|NCT00766909|Experimental|CsA|Cyclosporine
3188440|NCT00766909|Experimental|Tac|Tacrolimus
2436519|NCT03322410|Experimental|Patients|
2436520|NCT03322397|Experimental|Kindness to Others|Participants will complete the 'Other-Focused Acts of Kindness Intervention' by performing acts of kindness for others. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
2436521|NCT03322397|Active Comparator|Kindness to Self|Participants will complete the 'Self-Focused Acts of Kindness Intervention' by performing acts of kindness for themselves. They be asked to complete 3 kind acts for others throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will report on their kind act later that day.
2436522|NCT03322397|Sham Comparator|Daily Report|Participants will complete the 'Daily Reports' and be asked to report their daily activities throughout the week for 4 weeks. They will receive text messages three days per week (either Tuesday, Thursday, and Saturday or Wednesday, Friday, and Sunday) and will list activities from their day.
2436524|NCT03322371|Other|Health Subjects in Sleep Lab|Adult patients (> 18yrs old) scheduled for a standard of care PSG (sleep study) lasting at least 8 hours for any condition. Patients will undergo simultaneous 2-lead limited EEG recording with experimental device. 2-lead limited electroencephalography recording
2436525|NCT03322371|Other|ICU patients, not sedated or ventilated|Adult ICU patients (> 18yrs old) anticipated to stay in the ICU overnight (minimum 8 hours) with a Glasgow Coma Scale of 13 or greater, not intubated and not sedated. Patients will undergo simultaneous 2-lead limited electroencephalography recording
2436526|NCT03322371|Other|ICU patients, sedated and ventilated|Adult ICU patients (> 18yrs old) who are intubated, sedated, ventilated, and anticipated to stay in the ICU overnight (minimum 8 hours). Patients will undergo simultaneous 2-lead limited electroencephalography recording
2436527|NCT03322358|No Intervention|Control|No changes to normal sleep habits.
2436528|NCT03322358|Experimental|Naps only|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
2436529|NCT03322358|Experimental|Home sleep aids only|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
2436530|NCT03322358|Experimental|Home sleep aids + Sleep incentives|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful. In addition, they will be given a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
2436531|NCT03322358|Experimental|Naps + Home sleep aids|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
2436532|NCT03322358|Experimental|Naps + Home sleep aids + Sleep incentives|"After a baseline period, participants in this condition will be provided with: 1) the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days, 2) a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish, and 3) a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period. The sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful."
2436533|NCT03322345||Dopamine Added|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add continuous dopamine infusion to their current therapies.
2436534|NCT03322345||No dopamine added (control)|Patients with protein losing enteropathy (PLE) that have an exacerbation such that their treating physicians decide to add new therapies to their current therapies but that do not require the addition of continuous dopamine infusion.
3188441|NCT00766909|Placebo Comparator|Placebo|placebo/saline
2436536|NCT03322332||NonDM-L|Nondiabetics with significant stenosis in the left anterior descending (LAD) coronary artery or in the Left main (LM) coronary artery, but without significant stenosis in the right coronary artery (RCA)
2436537|NCT03322332||NonDM-R|Nondiabetics without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
2436538|NCT03322332||NonDM-LR|Nondiabetics with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
2436539|NCT03322332||DM-0|Patients with type 2 diabetes mellitus (T2DM) without significant stenoses in the coronary arteries
2436540|NCT03322332||DM-L|T2DM patients with significant stenosis in the LAD or in the LM, but without significant stenosis in RCA
2436541|NCT03322332||DM-R|T2DM patients without significant stenosis in the LAD and in the LM, but with significant stenosis in the RCA
2436542|NCT03322332||DM-LR|T2DM patients with significant stenosis in the LAD or in the LM and with significant stenosis in the RCA
2436543|NCT03322319|Experimental|left Ventricular Hypertrophy|Patients with left ventricular wall thickness measuring 15mm or more, or patients with a suggestive left ventricular echogenicity. Procedure/surgery will be performed following a diagnostic tree.
3188442|NCT00766935||1 - lymphoedema group|Females with previously diagnosed unilateral Lymphoedema of the arm, who have had a mastectomy or breast conservation surgery with axillary sampling or dissection, with or without adjuvant therapy.
3188443|NCT00766935||2 - healthy individuals|Healthy females aged between 18-75 years chosen randomly from the population of Queensland, Australia.
3188444|NCT00766948||No Treatment|
3188445|NCT00766961|Active Comparator|TAE group|Trans-catheter arterial embolization
3188446|NCT00766961|Active Comparator|Surgery group|Surgery
2436549|NCT03322267|Experimental|Pembrolizumab|Adjuvant cisplatin-chemoradiotherapy followed by pembrolizumab
2436550|NCT03322228|Experimental|Music Therapy|1 music therapy session, lasting approximately 45 min-1 hr
2436551|NCT03322215|Experimental|Palbociclib and fulvestrant|"Combination of palbociclib and fulvestrant~Palbociclib:~125 mg capsule administered orally once daily for 21 consecutive days followed by 7 days off treatment. Dose modification is recommended based on individual safety and tolerability.~Fulvestrant:~500 mg administered intramuscularly on days 1 and 15 of cycle 1, and then on day 1 of each subsequent 28-day cycle."
2436552|NCT03322215|Active Comparator|Capecitabine|1,000 mg/m2 tablet administered orally twice daily for 2 weeks followed by one week of rest. Depending on adverse reactions, both dose escalation and dose reductions will be performed.
2436553|NCT03322202|Experimental|Motivational Interviewing|Physical and Occupational Therapists will have 16 hours of training in Motivational Interviewing and use these techniques during sessions with patients.
2436554|NCT03322202|No Intervention|Control|Therapists will not participate in additional training.
2436555|NCT03322150|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
2436556|NCT03322150|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
2436557|NCT03322137|Active Comparator|SNA-120 (0.05% )|Pegcantratinib Ointment
2436558|NCT03322137|Active Comparator|SNA-120 (0.5%)|Pegcantratinib Ointment
2436559|NCT03322137|Placebo Comparator|Vehicle|
2436560|NCT03322124|Experimental|Octenidine Mouthwash|0.1% Octenidinedihydrochlorid Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2436561|NCT03322124|Placebo Comparator|Placebo|Placebo Solution for oromucosal use, mouth rinse with 10 ml for 30 s, 10 applications over 5 days
2436562|NCT03322111|Experimental|Cyclofusion|
2436563|NCT03322098|Active Comparator|Atropine group|Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
2436564|NCT03322098|Active Comparator|Glycopyrrolate group|Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
2436565|NCT03322085|Experimental|paroxysmal AF with radiofrequency ablation|radiofrequency catheter ablation therapy
2436566|NCT03322085|Experimental|persistent AF with radiofrequency ablation group|radiofrequency catheter ablation therapy
2436567|NCT03322085|Experimental|paroxysmal AF with cryoballoon group|cryoballoon ablation therapy
2436568|NCT03322072|Experimental|Real-Time Position Transponder Beacons|Patients in this arm will each be receiving 3 implanted real-time position transponder beacons (Calypso beacons)
2436569|NCT03322059|Active Comparator|Control|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.~Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values."
2436570|NCT03322059|Experimental|Intervention|"The core intervention will include educational materials, access to a basic smartphone app and a Fitbit. Participants will receive a weekly email with a step goal that will increase 10% beyond the previous weeks values.~Participants will be in the form of a charitable donation in their name to a cancer charity."
2436571|NCT03322046||Therapeutic Lifestyle Change (TLC) Intervention Group|TLC group received CVD risk lecture, enrolled in lifestyle program, received follow-up visits from team practitioner after each blood draw, access to food journaling portal for 12 month period, telephonic coaching
2436572|NCT03322046||Control Group|Control group received CVD risk lecture, then baseline, 3, 6, 12 month blood draws and 3 day food journals prior to each blood draw.
2436573|NCT03322033|Experimental|Type A Dissection|High risk subjects with ascending thoracic aortic pathologies including type A aortic dissection who are suitable for endovascular repair
2436574|NCT03322020|Experimental|CK 18 Gy|Patients who receive Cyberknife boost dose of 18 Gy in 3 fractions
2436575|NCT03322020|Experimental|CK 21 Gy|Patients who receive Cyberknife boost dose of 21 Gy in 3 fractions
3188447|NCT00766974|Active Comparator|1|Anti-embolism Knee High compression stocking
3188448|NCT00766974|Active Comparator|2|20-30mmHg Knee High Jobst Compression Stocking
3188449|NCT00767013|Experimental|AVS, CAD|DSCT
3188450|NCT00767026|Experimental|1|
3188451|NCT00767026|Active Comparator|2|
3188452|NCT00767052|Experimental|Active|AZD1236 tablet
3188453|NCT00767052|Placebo Comparator|Placebo|Placebo tablet
3188454|NCT00767052|Other|Relative bioavailability|AZD1236 Oral suspension
3188455|NCT00767052|Other|Relative bioavailability tablet|AZD1236 tablet
2436584|NCT03321955|Experimental|Subjects with Painful Neuropathy|All subjects will be implanted with the Medtronic Synchromed II pump, and treated with the same algorithm for dose adjustment for painful neuropathy with Ziconotide 100 micrograms/ml.
2436585|NCT03321942|Active Comparator|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure.
2436586|NCT03321942|Placebo Comparator|Control group|Treatment of chronic renal failure patients with conventional methods.
2436587|NCT03321929|Experimental|LUM Imaging System|Single dose of LUM015 (1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. All subjects undergo lumpectomy as standard of care and will have the study intervention, guidance by intraoperative imaging using the LUM Imaging Device
2436588|NCT03321916|Experimental|Subthreshold Photothermal Therapy|
2436589|NCT03321916|Sham Comparator|Sham|
2436590|NCT03321903||1: Intraoral Squamous Cell Carcinomas|Intraoral squamous cell carcinomas that are resected and receive adjuvant radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), or in both instances. Patients whose tumor is within 5 mm of the surface will have injections of India ink into the tumor itself and measurements made in the tumor prior to surgery. Patients whose tumor is deeper than 5 mm of the surface could participate only in the measurements of the postsurgical radiation field. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the postsurgical radiation field as appropriate.
2436591|NCT03321903||2: Cutaneous Malignant Tumors|Patients with primary cutaneous malignant tumors (including but not limited to squamous cell carcinoma, basal cell carcinoma, or melanoma) whose tumor is within 5 mm of the surface and whose treatment plan includes surgical resection and/or postsurgical radiation therapy. These patients may receive a Carlo Erba Ink injection before surgical tumor resection, after tumor resection (in the postsurgical radiation field), in both the tumor and the postsurgical radiation field, or in the tumor prior to radiation therapy. EPR Oximetry measurements will be made in the tumor and/or, if applicable, over the course of radiation in the tumor or postsurgical radiation field as appropriate.
2436592|NCT03321903||3: Breast Cancers|Breast cancer patients whose treatment plan includes surgical resection followed by radiation therapy. All patients who receive a surgical resection will receive a Carlo Erba Ink injection in the radiation field after sufficient healing has occurred to the area to be injected, as determined in consultation with the treating physicians, and using topical anesthetic or local anesthetic, if the patient so desires. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
2436593|NCT03321903||4: Other tumors|Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.
2436594|NCT03321890|Experimental|Combination therapy regimen|Chidamide + prednisone+cyclophosphamide+etoposide+methotrexate
2436595|NCT03321877|Experimental|Study group|All included patients underwent dose reduction.
2436596|NCT03321864|Experimental|Study arm|All patients recruited to the study (this arm) will have an additional transrectal ultrasound whilst already under GA for TP biopsy.
2436597|NCT03321851|Other|V-Sensor Device User|This diagnostic medical device is designed to detect the user's 5 vital signs. Each user tests two sensors, each sensor is mounted on a smartphone. Each vital sign is compared to an equivalent reference device obtained by the healthcare provider.
2436598|NCT03321838|Experimental|Accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
2436599|NCT03321825|Experimental|Belotero® Volume Lidocaine|Subdermal injection
2436600|NCT03321825|No Intervention|No treatment|
2436601|NCT03321812|Experimental|decalcification bone scaffold|Decalcification bone scaffold is a novel tissue engineered acellular matrix scaffold with the closest biomechanics and structure to normal cartilage.
2436602|NCT03321812|Active Comparator|Microfracture|Microfracture is a conventional treatment for cartilage lesions of the knee.
2436603|NCT03321799|Active Comparator|Sterile Antimicrobial Dressings|Control group, current hospital standard. AQUACEL is left in place for 7 days unless it becomes saturated over 50%, which requires a premature dressing change.
2436604|NCT03321799|Experimental|NPWT|"Experimental group. Negative pressure wound therapy bandage applied intra-operatively by a physician on the treatment team.~The dressing will be removed after 7 days postoperatively, or if the battery power stops earlier."
2436605|NCT03321786||Legionnaires' Disease Volunteers|Volunteers who have been diagnosed/survivors of Legionnaire's Disease
2436606|NCT03321786||Healthy Volunteers|Volunteers who are healthy.
2436607|NCT03321773|Experimental|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
2436608|NCT03321773|Active Comparator|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
2436609|NCT03321760|Experimental|Run-In Dose 1|10 Gy dose delivered to the primary tumor & 10 Gy to the hilar (N1) node over 5 fractions
2436610|NCT03321760|Experimental|Run-In Dose -1|10 Gy dose delivered to the primary tumor & 9 Gy to the hilar (N1) node over 5 fractions
2436611|NCT03321760|Experimental|Run-In Dose -2|10 Gy dose delivered to the primary tumor & 8 Gy to the hilar (N1) node over 5 fractions
2436612|NCT03321760|Experimental|Phase 2|The maximum tolerated radiation dose to the hilar (N1) node from the run-in period will be used during Phase 2.
2436670|NCT03321227|Experimental|Whole eggs|2 whole large eggs as a snack
3148190|NCT00142233|Experimental|Magnesium|"Adults and children aged 10+ will take two Magnesiocard (2.5 mmol) tablets three times per day (total dose: 15 mmol = 365 mg per day) plus two placebo ANTOX (vers)1.2 tablets three times a day.~Children aged five to nine years of age will take one Magnesiocard (2.5 mmol) tablet three times a day (total dose: 7.5 mmol = 182 mg per day) plus one placebo ANTOX (vers)1.2 tablet three times a day."
3148191|NCT00142233|Placebo Comparator|Placebo|"Adults and children aged 10+ will take two placebo ANTOX (vers)1.2 tablets three times a day, plus two placebo Magnesiocard (2.5 mmol) tablets three times per day.~Children aged five to nine years of age will take one placebo ANTOX (vers)1.2 tablet three times a day, plus one placebo Magnesiocard (2.5 mmol) tablet three times per day."
3148192|NCT00142246|Experimental|1|Intermittent preventive treatment with antimalarial drug combination(SP and amodiaquine)
3148193|NCT00142246|Placebo Comparator|2|Dual placebo comparator
2436618|NCT03321734|Experimental|Extended Caffeine Treatment|Infants in the extended caffeine treatment arm will, beginning the next day after stopping routine caffeine treatment, receive 5 mg/kg/day of caffeine base and increase to 5 mg/kg/twice-a-day (BID) of caffeine base beginning at 36 weeks + 0 days PMA and continuing the BID doses through 42 weeks + 6 days PMA.
2436619|NCT03321734|Placebo Comparator|Placebo|Infants in the placebo arm will, beginning the next day after stopping routine caffeine treatment, receive the equivalent (to study drug) volume of placebo daily and increase to the equivalent (to study drug) volume placebo BID through 42 weeks + 6 days PMA.
2436622|NCT03321682|Experimental|Functional Training|Patients in the functional training group, in addition to maintaining their usual care, will perform functional training including exercises for core strength, power training, knee dominance, hip dominance, horizontal pressure, vertical pressure, horizontal pull and vertical pull, using unstable surfaces.
2436623|NCT03321682|Active Comparator|Strength Training|These group, in addition to maintaining their usual care, will perform the exercise protocol as recommended by the American Heart Association.
2436624|NCT03321669|Active Comparator|Increased Fat Diet|
2436625|NCT03321669|Sham Comparator|Low Fat Diet|
2436626|NCT03321656|Active Comparator|Tacrolimus|0.1 - 0.2 mg/kg/day in 2 divided doses every 12 hours orally
2436627|NCT03321656|Experimental|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
2436628|NCT03321643|Experimental|Treatment (rituximab, gemcitabine, oxaliplatin, atezolizumab)|"INDUCTION PHASE: Patients receive rituximab IV, gemcitabine IV, and oxaliplatin IV every 2 weeks. Starting cycle 2, patients also receive atezolizumab IV over 30-60 minutes every 2 weeks. Treatment repeats every 14 days of cycle 1 and every 28 days for up to 4 cycles in the absence of disease progression or unaccepted toxicity.~MAINTENANCE PHASE: Patients receive rituximab IV and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unaccepted toxicity."
3148194|NCT00142428|Experimental|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
2436634|NCT03321552|Experimental|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
2436635|NCT03321539|Experimental|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21days for three cycles
2436636|NCT03321539|Active Comparator|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles
2436637|NCT03321526|Experimental|JNJ-42847922|Participants will receive 20 mg of JNJ-42847922 as a starting dose and matching placebo (1 capsule of 20 mg JNJ-42847922 and 1 capsule of matching placebo) once daily for 14 days. After Day 14, if needed, JNJ-42847922 dose can be increased to 40 mg (2*20 mg capsules) and flexible dose of JNJ-42847922 (20 or 40 mg) will be taken once daily until Day 167. Dose of JNJ-42847922 (20 or 40 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
2436638|NCT03321526|Active Comparator|Quetiapine Extended-Release (XR)|Participants will receive 1 capsule of quetiapine XR 50 mg along with 1 capsule of matching placebo once daily for 2 days, followed by 1 capsule of quetiapine XR 150 mg along with 1 capsule of matching placebo once daily from Day 3 to Day 14. After Day 14, if needed, quetiapine XR dose can be increased to 300 mg (2*150 mg capsules) and flexible dose of quetiapine (150 or 300 mg) will be taken once daily until Day 167. Dose of quetiapine XR (150 or 300 mg) will be adjusted by investigator based on the participant's clinical response and tolerability. Participants will continue to take their baseline SSRI/SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases.
2436639|NCT03321513|Active Comparator|Aflibercept Group|2.0 mg intravitreous aflibercept
2436640|NCT03321513|Experimental|Bevacizumab + Deferred Aflibercept Group|1.25 mg intravitreous bevacizumab + deferred intravitreous 2.0 mg aflibercept if eye meets switch criteria
2436641|NCT03321500|Experimental|Versacyl soft liner|Versacryl soft liner are flexible biocompatible materials with a reported predictable long term performance, durable bonding to acrylic denture bases, high fatigue endurance, excellent wear characteristics and solvent resistance with almost no free monomer in the processed material
2436642|NCT03321500|Active Comparator|Silicone-based soft liner|Resilient liners were introduced in the1950s and have been used since then as a gold standard material to increase the tolerance, retention and comfort of complete dentures. Resilient liners also known as 'soft liners' can be classified as temporary or permanent, cold-cured or heat-cured.Resilient liners can be divided into two main types: plasticized acrylic resins and silicone elastomers.
2436671|NCT03321227|Experimental|Egg whites|2 egg whites as a snack
2436643|NCT03321487|Experimental|Stage I Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a small volume of the primary motor cortex
2436644|NCT03321487|Experimental|Stage II Cohort|Blood-Brain Barrier opening with MRgFUS. BBB opening of a larger volume of the primary motor cortex
2436645|NCT03321474|Experimental|modified gull wing preparation|Gullwing preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation
2436646|NCT03321474|Active Comparator|conventional preparation|"In conventional preparation of veneer it circumvents the contact areas and extends palatally in the incisal third of the tooth only. The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines placed facially to the proximal contacts~Gull wing (dog leg) preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally. This preparation design helps to hide the restoration margin when viewed from an angle, especially in discoloration.~The preparation thickness is defined by a 0.5 mm facial and 1.5-2.0 mm incisal reduction with the proximal finish lines The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
2436647|NCT03321461|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. Then TMTP1-ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
2436648|NCT03321461|Active Comparator|ICG|The ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. ICG spray was applied thoroughly to the ectocervix for 30 minutes. After cleaned by NS, fluorescent detected sites will be removed.
2436649|NCT03321448|Experimental|TMTP1|The TMTP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this TMTP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2436650|NCT03321448|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2436651|NCT03321435||placenta previa group|
2436652|NCT03321435||Normal control group|
2436653|NCT03321409||The general population|People who take the physical examination in Renji Hospital between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
2436654|NCT03321409||The patients with suspected CAD|Patients with suspected CAD between 18 to 80 years old without any previously confirmed serious medical conditions or mental disorders.
2436656|NCT03321344|Experimental|Test Arm|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
2436657|NCT03321331|Experimental|Lark (JITAI)|"Participants in the intervention arm will use for 12 weeks the pro version of a mHealth app called Lark, developed by Lark Technologies Ltd. Lark is a coach app, which uses several variables to generate smart and empathic conversations. Variables include activity, sleep, meals, weight, and height data, weight goal set by the user/Lark coach, activity goal set by user/Lark coach, starchy food goal set by user/Lark coach. Lark uses all these variables to create a dynamic coaching system, constantly changing and adapting to the user in the moment and over time. For these features, Lark provides a just in time adaptive intervention (JITAI)."
2436658|NCT03321331|Active Comparator|MyFitnessPal (no JITAI)|"Participants in the control arm will be assigned to use MyFitnessPal. Similar to the intervention arm, they will be instructed to use the app for 12 weeks. MyFitnessPal does not include JITAI components, but allows users to keep track of their caloric intake and energy expenditure. MyFitnessPal has features that can be associated with effective behavior change techniques, including: self-monitoring of behavior and outcomes, goal setting and feedback (similar to Lark). In MyFitnessPal, social support is limited to comments and 'likes' from friends of its restricted user community, therefore tackling the techniques of social comparisons and social reward."
2436659|NCT03321318|Experimental|A group|AK-R215, test drug
2436660|NCT03321318|Active Comparator|B group|reference drug, Bazedoxifene 20mg, Cholecalciferol 800IU
2436661|NCT03321292|Experimental|L-arginine and Acetylesalicylic acid|L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
2436662|NCT03321292|Active Comparator|Acetylesalicylic acid75mg|acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
2436663|NCT03321279|No Intervention|Control|Participants' daily step counts will be for weeks 2-13 after hospital discharge. Participants will be asked to complete surveys at 5, 9 and 13 weeks post-discharge.
2436664|NCT03321279|Experimental|Intervention|Participants' daily step counts will be monitored for weeks 2-13 after hospital discharge. Participants will have a weekly step goal that increases from baseline by 10% each week of the intervention (12 weeks). Participants will engage in a social incentive-based gamification based on points and levels that leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. Participants will receive daily feedback for the step counts and weekly feedback for levels. Participants will be asked to identify a support partner, who will receive weekly reports with the the participant's points and levels balance.
2436665|NCT03321266||Patients treated for a anorectal fistula|Patients who were treated for a anorectal fistula with a Biodesign Fistula plug
2436667|NCT03321240||The SEEG group|Group with the SEEG analysis
2436674|NCT03321214|Experimental|Light use of Nima|Ten participants will be randomized to receive 12 capsules every other month (18 capsules for the 3 months which is considered light use).
2436675|NCT03321214|Experimental|Moderate use of Nima|Ten participants will be randomized to receive 12 capsules per month (36 capsules for the 3 months which is considered moderate use).
2436676|NCT03321214|Experimental|Heavy use of Nima|Ten participants will be randomized to receive 24 capsules per month (72 capsules for the 3 months which is considered heavy use).
2436677|NCT03321201|Experimental|Cauterization|
2436678|NCT03321201|Active Comparator|Fibrin glue|
2436679|NCT03321188|Experimental|HIPEC + adjuvant IV chemotherapy|"HIPEC~HIPEC will be administered intraoperatively one time only.~*HIPEC cisplatin will be administered at rate of 100 milligram per meter squared (mg/m2)~Administration of HIPEC will have a duration of 90 minutes.~Adjuvant IV chemotherapy~IV Paclitaxel~Dose: 80mg/m2 IV over 1 hour~Schedule: Days 1, 8 and 15~Cycle Length: 3 weeks (21 days)~IV Carboplatin~Dose: Area under the curve (AUC) 6 IV~Schedule: Day 1~Cycle Length: 3 weeks (21 days)"
2436680|NCT03321175|Experimental|Subcutaneous irrigaton|Patients will receive 200 cc subcutaneous saline irrigation before skin incision closure.
2436681|NCT03321175|No Intervention|Subcutaneous no irrigation|Patients will not receive subcutaneous saline irrigation before skin incision closure.
2436682|NCT03321162||double scan protocol|In C1(double scan technique) , after CT scan for patient wearing scan appliance , two optical scan for the model with and without scan appliance.
2436683|NCT03321162||triple scan protocol|In C2 (triple scan technique) , after CT scan for patient wearing scan appliance , CT scan for scan appliance alone .
2436684|NCT03321149|Experimental|RiseTx|Participants were given access to the RiseTx application and an activity monitor to participate in the five phase intervention.
2436685|NCT03321136|Placebo Comparator|Placebo, LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436686|NCT03321136|Placebo Comparator|LSD-25, LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436687|NCT03321136|Placebo Comparator|LSD-50, LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436688|NCT03321136|Placebo Comparator|LSD-100, LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436689|NCT03321136|Placebo Comparator|LSD-200, LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436690|NCT03321136|Placebo Comparator|LSD-200-Ketanserin, Placebo, LSD-25, LSD-50, LSD-100, LSD-200|Cross-over within-subjects design with all treatment conditions, separated by a wash-out phase
2436691|NCT03321123|Experimental|CRA treatment|"The drug for this trial is autologous T cells transduced with the lentiviral vector pLTG1563 (MB-CART19.1). The dose is 2x10e6 ~2x10e7 MB-CART19.1/kg.~A leukapheresis for the patient will be performed for MB-CART19.1 generation. All patients will receive lymphodepleting chemotherapy with fludarabine 30 mg/m2/d intravenously (iv) on days -5,-4,-3 and -2 cyclophosphamide 500 mg/m2/d iv on day -3,-2 before CAR T cell transfer to enhance the in vivo expansion of CAR T cells."
2436692|NCT03321110|Experimental|Placebo|Placebo
2436693|NCT03321110|Experimental|Q10-150|coenzyme Q10 150 mg/d.
2436694|NCT03321110|Experimental|Q10-300|coenzyme Q10 300 mg/d.
3188456|NCT00767065|Active Comparator|Cardiac Computed Tomography (CCT)|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. CCT will be available Monday to Friday from 9am until 5pm. Patients will be entered into the study provided CCT can be undertaken within 24 hours of troponin result. Therefore, the only period during which a patient will be ineligible for inclusion will be between 5pm on a Friday and 9am the following Sunday. Studies will be reported at CWH by one of 2 experienced radiologists trained in CCT and results passed to the referring team on the same day.
2436697|NCT03321084|Experimental|MatPilates|In the beginning was nominated Contrology, but today is known as Pilates. Created by Joseph Humbertus Pilates. This technique is based on respiration, balance, flexibility, proprioception and muscular strength. One of the main work is on the power house (core), biomechanical axis of the body, composed of muscles: rectus abdominis, paravertebral, multifidus, diaphragm, and those of the perineal center.
2436698|NCT03321084|Other|Control|It continues in your daily life with phone monitoring.
2436699|NCT03321071|Experimental|Healthy Summer Learners|Similar to typical summer day camp procedures, students attending Healthy Summer Learners will be dropped-off and picked-up at camp. The physical activity component of the program was designed with the expertise and input from B&G Club youth program staff. The academic component was informed by school district personnel. The program was also designed to be analogous to typical summer day camp program in terms of operating weeks (10 weeks) length of program day (i.e., 8am-5pm), and program component time blocks (~45min-1hr time blocks).
2436700|NCT03321071|Active Comparator|21st Century Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
2436701|NCT03321071|No Intervention|Passive control|Children in this condition will not attend a summer program.
2436702|NCT03321045|Experimental|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab [89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.
2436703|NCT03321032|Experimental|Amphilimus-eluting stents|Polymer-free Amphilimus-eluting stents
2436704|NCT03321032|Active Comparator|Zotarolimus-eluting stents|Biolinx Polymer-based zotarolimus-eluting stents
2436705|NCT03321019||Healthy controls|Men and women between the ages of 45 and 85 years without Parkinson's disease, or any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
2436706|NCT03321019||Parkinson's disease|Men and women between the ages of 45 and 85 years with Parkinson's disease, and without any history of neurologic disorder/disease, head or neck cancer, or chronic respiratory illness.
2436709|NCT03320993|Active Comparator|Low Protein-Low Fat study|Subjects will receive a mixed meal with carbohydrates (70g) plus a low content of proteins and fats
2436710|NCT03320993|Experimental|High Protein-High Fat study|Subjects will receive a mixed meal with the same carbohydrates content of arm 1 (70g), but a greater amount of fats and proteins
2436711|NCT03320993|Experimental|High Protein-High Fat & alcohol study|Subjects will receive the same mixed meal of the High Protein-High Fat study plus 0,7g of alcohol per Kg of weight
2436712|NCT03320980||RALPPS|Patients with initial volume of FLR < 40% which underwent RALPPS and major liver resection (as the second stage of RALPPS) for hilar and intrahepatic cholangiocarcinoma
2436713|NCT03320980||Portal vein embolization (PVE)|Patients with initial volume of FLR < 40% undergoing PVE and major liver resection for hilar and intrahepatic cholangiocarcinoma
2436714|NCT03320954|Experimental|Anomia treatment|Phase 2 portion of the research during which participants with acquired brain injury will perform intervention activities.
3188457|NCT00767065|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will undergo further care as dictated by the responsible clinician. Except for CCT, all standard investigations will be available to the responsible clinician and may be used at their discretion. CCT does not form part of current in-patient management at our hospital.
3188458|NCT00767091|Active Comparator|Active treatment|A: transdermal rivastigmine at 4.6 mg per day during one month then 9.5 mg per day during 5 months.
3188459|NCT00767091|Placebo Comparator|placebo|transdermal patch of placebo
3188460|NCT00767130||1|receiving atorvastatin
3188461|NCT00767130||2|receiving simvastatin
2436720|NCT03320915|Experimental|Cholecalciferol|Cholecalciferol 5mg (200,000 IU)
2436721|NCT03320915|No Intervention|Usual care|Usual care
2436722|NCT03320902|Active Comparator|Sudden death counselling|The emergency physician of the prehospital EMS who intervenes at the scene will systematically give the family member allocated to the intervention the option to attend a sudden death counselling during the first month after the event.
2436723|NCT03320902|No Intervention|Usual practice|The physician will act as usual. The relatives will not systematically benefit from this option.
2436724|NCT03320889|Other|Pamphlets plus Review with Expert Educator|Educational Intervention includes Pamphlets plus Review with Expert Educator
2436725|NCT03320889|Other|Pamphlets only|Educational Intervention includes Pamphlets only
2436726|NCT03320876|Experimental|filgotinib|
2436727|NCT03320863|Active Comparator|Active or Enso Group|Active Enso device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
2436728|NCT03320863|No Intervention|Sham Group|Sham device use for one month, at least one hour daily, including coaching via a smartphone app and coaching phone calls regarding device usage.
3188462|NCT00767130||3|receiving rosuvastatin
3188463|NCT00767156|Active Comparator|SBA24 capsule plus Omega7 cream|the subjects took SBA24 sea buckthorn oil capsule and apply Omega7 cream
3188464|NCT00767156|Active Comparator|SBA24 capsule plus base cream|the subjects took SBA24 sea buckthorn oil capsule and apply a base cream
3188465|NCT00767156|Active Comparator|Omega7 Cream|The subjects Omega 7 Sea Buckthorn Oil Cream, twice per day
3188466|NCT00767156|Placebo Comparator|Base cream|The subjects use base cream on the face, twice per day
3188467|NCT00767169|Experimental|coated implant and control|
3188468|NCT00767182||Pregnant patients with VPP antecedent|Pregnancy women consulting for an scan during their 12th week of amenorrhea at the University Hospital of Saint Etienne will be studied in this clinical trial. They have an history of VPP (Vascular Placental Pathology). They will have to give a blood sample.
3188469|NCT00767195||1. Control group|Patients in the intensive care unit who have no pulmonary edema
2436737|NCT03320837||Breastfeeding group|Infant are exclusively fed with breast milk
2436738|NCT03320837||Mixed feeding group|Infants are fed with mixed nutrition with breast milk and Rontamil Complete 1®
2436739|NCT03320837||Infant formula group|Infant are fed exclusively with Rontamil Complete 1®
3188470|NCT00767195||2. Study group 1|Patients with cardiogenic pulmonary edema in the intensive care unit
3188471|NCT00767195||3. Study group 2|Patients with non-cardiogenic pulmonary edema in the intensive care unit
2436742|NCT03320811||"group celiac disease"|
2436743|NCT03320811||"group no celiac disease"|
2436744|NCT03320798||"group Bullous pemphigoid"|Patients consulting at dermatology department of Reims Teaching Hospital for bullous pemphigoid between 1997 and 2011.
2436745|NCT03320772|Experimental|TMVP1|The TMVP1-ICG (WuXi AppTec, Shanghai, China) powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of TMVP1-ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2436746|NCT03320772|Active Comparator|ICG|The ICG powder was diluted in 20 ml of aqueous sterile water to a concentration of 1.0 mg/mL. 0.4ml of this ICG solution was injected into the cervix, divided into 3 and 9 o'clock position, in the operating room. During the laparoscopy, the PinPoint S1 Novadaq (PinPoint Endoscopic Fluorescence Imaging System, NOVADAQ, Mississauga, ON, Canada), 30° laparoscopes were used for fluorescent detection.
2436747|NCT03320759|No Intervention|No rehabilitation|
2436748|NCT03320759|Experimental|Rehabilitation|
2436749|NCT03320746|Experimental|Activity trackers|The participants were requested to wear a commercial wrist-worn activity tracker (Polar Loop 2, Polar, Kempele, Finland) every day and night for 12 months.
2436750|NCT03320746|No Intervention|No activity trackers|Control group members were requested to abstain from the use of any type of activity trackers and they were informed that they will receive the activity trackers and guidance for using them after the follow-up.
2436805|NCT03320408||Repaired AAA|These patients are included while they already had had AAA repair (both elective and emergency repair).
3188472|NCT00767208|Experimental|type 2 diabetic subjects|
3188473|NCT00767208|Experimental|overweight healthy subjects|
3188474|NCT00767221|Experimental|A|The patient is his own control. Endpoint variables are measured before, during and after treatment.
2436751|NCT03320733|Experimental|Surgical|"Includes patients who will undergo surgery for their pancreatic cysts.~In addition to the routine pre-operative CT abdomen performed for surgical planning purposes, these patients will receive Dual Energy CT scan with subtraction imaging before surgery."
2436752|NCT03320733|Experimental|Surveillance|"Includes patients who are undergoing surveillance for their pancreatic cysts.~Dual Energy CT scan with subtraction imaging will be performed in addition to the standard-of-care surveillance method of MRI scans."
2436753|NCT03320720|Experimental|Home Treatment|Patients with acute mental illness are treated at their houses by a mobile and multiprofessional care team instead of being treated as inpatients if their medical condition permits.
2436754|NCT03320720|Active Comparator|Treatment-as-usual|Patients with acute mental illness are treated as inpatients in a psychiatric clinic.
2436755|NCT03320707|Experimental|Daratumumab|Participants will receive a single subcutaneous (SC) dose of daratumumab in each of first 7 dose cohorts. Doses will be escalated based on review of pharmacokinetic, pharmacodynamic, and safety data of previous cohort. Participants in Cohort 8 will receive single SC daratumumab formulation containing recombinant human hyaluronidase (rHuPH20).
2436756|NCT03320707|Placebo Comparator|Placebo|Participants will receive placebo as a single SC dose in each of first 7 cohorts.
2436757|NCT03320694|Experimental|metformin|Metformin will be given until 2500mg in divided doses till normoglycemia is achieved and will be continued till delivery
2436758|NCT03320694|Active Comparator|Insulin|Insulin will be give as 3 regular injection and one intermediate acting injection at bedtime till normoglycemia is achieved and will be continued till delivery
2436759|NCT03320681|Active Comparator|Active Stimulation|Acupuncture needles will be inserted into the auricular zones and electrical stimulation will be given for 20 minutes.
2436760|NCT03320681|Other|Dry Needling|Acupuncture needles will be inserted into the auricular zones for 20 minutes. However, no electrical stimulation will be given
2436761|NCT03320668|No Intervention|Individual OEP|"Randomized subjects (65 to 80-year-old) receiving individual Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.~An OEP leader trained nurse/physiotherapist will perform in its community consult individual education to each participant in five sessions: In the 1st, 2nd, 4th and 8th week and one reinforcement session after six months. A telephone call to each participant (following a predefined telephonic interview protocol) will be carried out in the months without training session to perform the follow-up."
2436762|NCT03320668|Experimental|Group OEP|65-80 year-old randomized subjects receiving group Otago Exercise Program (OEP) training in a total of nine Primary Care Centers.
2436763|NCT03320655|Active Comparator|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
2436764|NCT03320655|Experimental|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
2436765|NCT03320642|Experimental|Itacitinib + Calcineurin Inhibitor (CNI) -Based Interventions|Itacitinib in combination with a CNI-based intervention.
2436766|NCT03320629|Experimental|apatinib and S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
2436767|NCT03320629|Active Comparator|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
2436768|NCT03320616|Experimental|Sequence 1|4 single doses of EYP001a: Period 1 first dose morning fasted, second dose morning fed; Period 2 first dose evening fasted, second dose evening fed
2436769|NCT03320616|Experimental|Sequence 2|4 single doses of EYP001a: Period 1 first dose evening fasted, second dose evening fed; Period 2 first dose morning fasted, second dose morning fed
2436770|NCT03320616|Experimental|Sequence 3|4 single doses of EYP001a: Period 1 first dose morning fed, second dose morning fasted; Period 2 first dose evening fed, second dose evening fasted
2436771|NCT03320616|Experimental|Sequence 4|4 single doses of EYP001a: Period 1 first dose evening fed, second dose evening fasted; Period 2 first dose morning fed, second dose morning fasted
2436772|NCT03320603|Other|Phase 1|Prospective collection of data on a standard eCRF (without reminders of recommendations). Prothrombin Complex Concentrate given as standard of care.
2436773|NCT03320603|Other|Phase 2|Prospective collection of data on expert data collection tool (expert eCRF reminding recommendations at each step of the management of severe bleeding). Prothrombin Complex Concentrate given as standard of care.
2436774|NCT03320590||Couple|Couple with female aged under 37 years
2436775|NCT03320577|Active Comparator|Class instruction of breathing exercises|Class participation/instruction weekly for 6 weeks and requested to practice Pranayama breathing exercises of 15 minute duration for an additional 4x during the week; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2436804|NCT03320408||Acute AAA|These are the patients that are included while they presented in the participating hospitals because either a symptomatic or ruptured AAA. For this group, a different recruitment procedure exists which has been approved by the appropriate medical ethical committee.
2438159|NCT03310827|Placebo Comparator|Gene Test Report Only|Participant receives standard diet plan
2436776|NCT03320577|Active Comparator|DVD instruction of breathing exercises|Received DVD with instructions and 15 minute Pranayama breathing exercises of 15 minute duration. Participants requested to practice breathing exercises 5x during the week for 6 week intervention; completed log that indicated time/date/duration of practice; weekly blood pressure measurements and turn in logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2436777|NCT03320577|Placebo Comparator|Control|Completed log that indicated time of eating dinner; weekly blood pressure measurements for the 6 week intervention; control participants also turned in dinner time logs; week 10 and week 18 blood pressure measurements also obtained. Survey instruments completed at baseline, week 6, 10, 18.
2436779|NCT03320551|Experimental|Nutrition Education Immersion Program|Assessing if a one week lifestyle interventions can lead to long term health benefits.
2436780|NCT03320538|Experimental|Hou Gu Mi Xi|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2436781|NCT03320538|Experimental|Hou Gu Mi Xi + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (once 10 mg, once a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2436782|NCT03320538|Placebo Comparator|Placebo + rabeprazole|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive Placebo of Hou Gu Mi Xi (once 10 g, twice a day) plus rabeprazole (10 mg/d, qd).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2436783|NCT03320538|Placebo Comparator|Placebo|"Basic treatment period (0 to 2rd week): Patients with infection of Helicobacter pylori receive rabeprazole (once 20 mg, twice a day), bismuth potassium citrate (once 0.3 g, twice a day), amoxicillin (once 1 mg, twice a day), and furazolidone (once 0.1 g, twice a day), and patients without infection of Helicobacter pylori only receive rabeprazole (once 20 mg, twice a day) and bismuth potassium citrate (once 0.3 g, twice a day).~Maintain treatment period (3rd to 6th week): Patients in this arm receive placebo of Hou Gu Mi Xi (once 10 g, twice a day).~Recuperation period (7th to 52th week): Patients in this arm receive Hou Gu Mi Xi (once 10 g, twice a day).~Extensional observational period (53 to 104 weeks): no intervention."
2436784|NCT03320525|Experimental|Experimental|The active substance used in the T-ChOS capsule formulation is a chitooligosaccharide blend.
2436785|NCT03320512|Experimental|P3|Participants will use P3
2436786|NCT03320512|Experimental|P3+|Participants will use P3+
2436787|NCT03320512|Placebo Comparator|Control|Participants will receive the standard of care
2436788|NCT03320499||echo doppler at the bed|
2436789|NCT03320499||echo doppler in the vascular exploration platform|
2436790|NCT03320486|Experimental|Group 1 - dapaconazole cream 2%|Topical application of dapaconazole cream 2%, once daily, during 42 days.
2436791|NCT03320486|Active Comparator|Group 2 - ketoconazole cream 2%|Topical application of ketoconazole cream 2%, once daily, during 42 days.
2436792|NCT03320473|Experimental|IC-8 IOL|IC-8 IOL implantation after removal of KAMRA ACI 7000 PDT inlay
2436793|NCT03320460|Experimental|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ =660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
2436794|NCT03320460|Active Comparator|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days. Laser device will be positioned over the lesion but will be switched off to mask the treatment. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
2436795|NCT03320447|Experimental|MAL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
2436796|NCT03320447|Experimental|AFL-PDT|Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT or MAL-PDT
2436797|NCT03320434|Experimental|PRT-2761 0.5%|
2436798|NCT03320434|Experimental|PRT-2761 1%|
2436799|NCT03320434|Active Comparator|Patanol|
2436800|NCT03320434|Active Comparator|Pred-forte|
2436801|NCT03320434|Placebo Comparator|PRT-2761 0%|
2436802|NCT03320421|Experimental|SIB group|"Radiation therapy:~daily 5 days per week for 3 weeks. 43.5 Gy in 15 fractions to the whole breast 49.5 Gy in 15 fractions to the tumor bed boost"
2436803|NCT03320408||Asymptomatic AAA|These patients will be included while their AAA is asymptomatic and while they are under surveillance by their vascular surgeon.
2436806|NCT03320395|Experimental|Small bowel RFA treatment|Five small bowel samples each of the duodenum, jejunum and ileum will be recruited treated.
3188475|NCT00767247||1|Male or female with arterial hypertension
2436808|NCT03320356||shoulder pain|Patients presenting inflammatory, degenerative, or post-traumatic shoulder pain and consulting at Orthopaedic Department, Reims Teaching Hospital.
2436809|NCT03320343||Patients recruited for pelvic imaging examination|
2436810|NCT03320330|Experimental|Treatment (pepinemab)|Patients receive pepinemab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for 13 cycles in the absence of disease progression or unacceptable toxicity.
2436811|NCT03320317||Colorectal cancer|
2436813|NCT03320291|Experimental|Regjoint|
2436814|NCT03320278||SPIDS,TMH|There will be two tests in this study for evaluation. Both of them will be measured in same group.
2436815|NCT03320265|Experimental|PC-mAb|Phosphorylcholine human monoclonal antibody, i.v. infusions
2436816|NCT03320265|Placebo Comparator|Placebo|Placebo to PC-mAb, i.v. infusions
2436817|NCT03320239|Experimental|the online-RASSL intervention group|HIV risk assessment and tailored suggestions, free HIV testing link
2436818|NCT03320239|Experimental|intervention group 2|HIV risk behavior investigation and routine education
2436819|NCT03320239|Placebo Comparator|the control group|The placebo control: HIV/AIDS knowledge assessment, routine education
3148195|NCT00142467|Experimental|Bevacizumab, Gemcitabine, Oxaliplatin|For cycle 1 (14 days), bevacizumab 10 mg/kg was administered alone on day 1. For cycle 2 and beyond (28 days/cycle), bevacizumab 10 mg/kg was administered on days 1 and 15, gemcitabine 1,000 mg/m2 was administered as a dose rate infusion at 10 mg/m2/min followed by oxaliplatin at 85 mg/m2 on days 2 and 16. All drugs were administered intravenously until progression, intolerance, patient withdrawal, or death.
3188476|NCT00767260|Experimental|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
3188477|NCT00767260|Experimental|BM-MNC|Autologous Bone Marrow mononuclear cell Infusion
2436823|NCT03320187|Experimental|Group A|Nitroglycerin as Nitroderm TTSⓇ skin patch is applied on the upper chest alongside with regular induction of labor protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
2436824|NCT03320187|Placebo Comparator|Group B|Placebo patch is applied on the upper chest alongside with regular induction of labour protocol ( 3gm/ 8 hours DinoprostoneⓇ vaginal tablet in the posterior vaginal fornix)
2436825|NCT03320174|Active Comparator|Tafenoquine 200 mg (2 x 100 mg tablets)|Tafenoquine 200 mg (2 x 100 mg tablets) daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
2436826|NCT03320174|Placebo Comparator|Placebo|Placebo daily for three consecutive days, followed by study treatment (tafenoquine 200 mg or placebo) once per week for 51 weeks
2436827|NCT03320148|Experimental|Physiotherapist-led primary care model for back pain|The PT-led primary care model for back pain will involve incorporating a PT within the primary care team at the first point of contact for people with back pain at no cost to the patient. Patients in this model will be given the choice of seeing the PT or family doctor. They will be encouraged to book with the PT except when the primary reason for visit is for medication renewals or when the patient has additional health concerns that need attention from their physician in the same visit. There will be 4 key components of the PT led primary care intervention: 1) Initial assessment and screening; 2) Brief individualized intervention at the first visit; 3) Health services navigation; 4) Providing additional PT care for people with an unmet need.
2436828|NCT03320148|Active Comparator|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada. This usually includes a visit to a primary care physician, who would perform a history and physical examination, provide LBP education, and prescribe medications and/or refer based on their assessment findings and patient preferences.
2436829|NCT03320135|Active Comparator|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative application in proximal class-II furcation.
2436830|NCT03320135|Active Comparator|Open Flap Debridement|Open flap debridement in proximal class-II furcation.
2436831|NCT03320122|Experimental|Telemedicine|Medical Direction will be provided by pediatric physiatrists using telemedicine.
2436832|NCT03320122|Active Comparator|In-Person Pediatric Physiatrist|Medical Direction will be provided by pediatric physiatrists in-person.
2436833|NCT03320122|Active Comparator|In-Person Non-Pediatric Physiatrist|Medical Direction will be provided by contracted physicians (i.e., non-pediatric physiatrists) in-person care.
3188478|NCT00767260|Experimental|HOT|hyperbaric oxygen therapy
2436835|NCT03320083|Active Comparator|Educational care derived from POSSUMS|Intervention group were offered a sleep education session using behavioral change counseling communication skills, derived from the POSSUMS approach developed by Douglas P and Whittingham K. However we could not use Acceptance and Commitment Therapy (ACT), because none of the investigators had sufficient training on ACT at the time the study was conducted.
2436836|NCT03320083|No Intervention|Usual Care|General anticipatory guidance given
3188479|NCT00767260|Active Comparator|Control|stand medical therapy (enhanced hemoglucose monitor, health and diet counseling and insulin injection)
3188480|NCT00767299|Experimental|1|
3188481|NCT00767299|Placebo Comparator|2|
3188482|NCT00767377|Experimental|EOF5 Group|The regimen of 5-day Continuous infusion of FU combined with Epirubicin and Oxaliplatin will be used in the patients recruited in this trial.
2436841|NCT03320031|Experimental|combined group|Drug: linagliptin&premixed insulin Treated with linagliptin 5mg/d combined with premixed insulin for 12 weeks.
2436842|NCT03320031|Active Comparator|linsulin group|Drug: premixed insulin Treated with premixed insulin for 12 weeks.
3188483|NCT00767390||ACL Patch|
3188484|NCT00767403|Experimental|1|
3188485|NCT00767403|Active Comparator|2|
3188486|NCT00767403|Active Comparator|3|
3188487|NCT00767416|Experimental|Cohort 1 MEDI-559|MEDI-559
3188488|NCT00767416|Placebo Comparator|Cohort 1 Placebo|Placebo
3188489|NCT00767429|Experimental|1|subjects with fall risk
2436843|NCT03320018|Experimental|Hydrogen/Minocycliine|"Hydrogen will be infused into aqueous solution (normal saline or water) at as high a concentration as possible (saturation = 1.6 ppm), and administered intravenously or orally respectively, q 8 hours for 3 days.~Similarly, Minocycline will be administered either i.v. or p.o. once daily for 5 days."
2436844|NCT03320018|Placebo Comparator|Placebo Hydrogen/Placebo Minocycline|Normal saline will be substituted for both Hydrogen and Minocycline for intravenous administration. Water will be substituted for hydrogen when administered p.o., and placebo capsules will be substituted for minocycline.
2436845|NCT03320005|Active Comparator|ResistanceTraining Group|The RT program has the following features: 05 classes performing two weekly sessions; day shift; sessions with maximum duration of 1 (one) hour; 02 series; 08 to 12 repetitions; interval between sets of 01 to 02 minutes; exercises: bench press, seated leg press 45°, pull forward, Earth, rowing standing calf standing, power lifting, abdominal and development.
2436846|NCT03320005|No Intervention|Non training group|sedentary elderly
2436847|NCT03319992|No Intervention|Conventional treatment|The conventional treatment arm was conducted according to a set of exercises that were specifically designed in order to match the robotic treatment. Patients received both physical therapy (PT) and occupational therapy (OT) session, administered by the physiotherapists of the hospital. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals.
2436848|NCT03319992|Experimental|Robotic treatment|The patients enrolled in the robotic arm are going to be undergone a series of passive, assisted and active mobilization in upper limb task-oriented exercises implemented in 3d virtual environments. Briefly speaking, these tasks promote the upper arm multi-joints coordination during the execution of reaching movements and grasping actions of fixed virtual objects displaced in the space.
2436849|NCT03319966||Oculomotor Dysfunction|This group consists of subjects with mTBI who have been diagnosed with OMD by objective OD measurements. These subjects will undergo neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury per usual clinical standard of care at the HCMC TBI Clinic.
3188490|NCT00767442||1|Health volunteer
3188491|NCT00767442||2|Patient with suspected oral mucosa lesion
3188492|NCT00767468|Experimental|Bilirubin Normal to 3x Upper Limit of Normal|
3188493|NCT00767468|Experimental|Bilirubin >3x to 6x Upper Limit of Normal|
3188494|NCT00767481|Experimental|Travoprost/Brinzolamide PM, Vehicle AM|Travoprost/Brinzolamide PM, Vehicle AM
3188495|NCT00767481|Experimental|Travoprost/Brinzolamide AM, Vehicle PM|Travoprost/Brinzolamide AM, Vehicle PM
3188496|NCT00767481|Active Comparator|Cosopt|Cosopt BID
3188497|NCT00767494|Experimental|1|Travoprost/Brinzolamide AM, Vehicle PM
3188498|NCT00767494|Experimental|2|Travoprost/Brinzolamide PM, Vehicle AM
2436859|NCT03319927|Experimental|Integrated pest management|The intervention consists of an integrated pest management (IPM) educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for child care center directors and providers on IPM policies and practices including the providers' practices and beliefs. The workshop includes IPM videos, IPM Toolkit, and IPM toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
2436860|NCT03319927|Active Comparator|Physical activity|The intervention consists of a physical activity educational workshop and consultation. The child care health consultants (CCHCs) conduct the educational workshop for the child care center directors and providers on physical activities center policies and best practices over 7 months. The workshop includes a Physical Activity Toolkit and toolbox. The (CCHCs) meet with center directors to review the results of the Baseline observational Checklists and to identify center-specific intervention goals. The intervention also includes 7 monthly child care health consultation visits where the CCHC and director review the center's progress towards the intervention goals, discuss problems, and share resources.
2436861|NCT03319914||ST-003 Observational|Calciphylaxis patients who participated in the ST-001 CALISTA
2436862|NCT03319901|Experimental|Venetoclax + Chemotherapy|"Venetoclax is administered orally once daily for 21 days in each cycle~Standard Chemotherapy will be administered every 28 days"
2436863|NCT03319888|Experimental|cpap group|CPAP treatment plus conservative treatment with lifestyle modifications.
2436864|NCT03319888|Active Comparator|control group|Conservative treatment with lifestyle modifications.
2436865|NCT03319849|Experimental|NT-501|
2436866|NCT03319849|Sham Comparator|Sham|
2436867|NCT03319836||Pre-very high protein enteral nutrition|20 enterally fed critically ill adult patients prior to the introduction of a very high protein enteral nutrition formula [2015].
2436868|NCT03319836||Post-very high protein enteral nutrition|20 enterally fed critically ill adult patients post the introduction of a very high protein enteral nutrition formula [2016].
2436869|NCT03319823|Experimental|Thiazide Therapy Group|• Group (1): Thiazide Therapy Group: Men without diabetes, and mild hypertension - a sleeping systolic blood pressure of 125-139 mm Hg, and an awake average blood pressure of < 160 mm Hg
3188499|NCT00767494|Active Comparator|3|AZOPT AM and PM
3188500|NCT00767494|Active Comparator|4|TRAVATAN PM, Vehicle AM
3188501|NCT00767559|Active Comparator|1|"Variable dose warfarin: 5 mg beginning the night before surgery, followed by 5mg the PM of surgery*, and then variable daily dose,until day 30 follow-up.~(target INR 2.0-2.5)"
3188502|NCT00767559|Active Comparator|2|"Fondaparinux:~2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*,or 6-8 hours after epidural catheter removal, and continued until follow-up (28 days +/-2) from day of surgery."
3188503|NCT00767559|Active Comparator|3|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily follow-up at Day 28 (+/-2 days from surgery)."
3188504|NCT00767585||A:|70 women with hormone-dependent or hormone-independent early breast cancer that have completed their chemo- and/or radiotherapy just recently (up to 6 months after completion of therapy)
3188505|NCT00767585||B|70 women with hormone-independent early breast cancer, 24-36 months after completion of chemo- and/or radiotherapy
3188506|NCT00767585||C|70 women with hormone-independent early breast cancer, 54-66 months after completion of chemo- and/or radiotherapy
2436870|NCT03319823|Experimental|Combination Therapy Group|• Group (2): Combination Therapy Group: Men with diabetes, or with more severe hypertension - a sleeping blood pressure of ≥ 140 mm Hg, or an awake average blood pressure of ≥ 160 mm Hg.
3188507|NCT00767585||D|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of tamoxifen therapy
2436872|NCT03319797|Other|Treatment with NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte transplantation)
2436873|NCT03319784|Active Comparator|Ketorolac (Toradol) Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Ketorolac group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
2436874|NCT03319784|Active Comparator|Steroid Injection Group|Patients will be randomized into two patient groups: Ketorolac (Toradol) injection group (n=30) and or Steroid injection group (n=30). Patients assigned to Steroid group will receive a single dose of 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000. Patients will be blinded to the kind of injection they receive, but the physicians who perform the injection will not be blinded for the medical record purposes. The injection will be done under ultrasound guidance to the subacromial space.
2436875|NCT03319771|Experimental|Treadmill Walking Exercise Training|12 weeks of supervised, progressive treadmill walking exercise training
2436876|NCT03319771|Active Comparator|Stretching-and-toning Exercise Training|12 weeks of supervised, stretching-and-toning exercise training
2436877|NCT03319758|Experimental|thin or dehiscences buccal plate|Immediate implant placement used bone augmentation in combination with an absorbable collagen membrane with thin or dehiscences buccal plate.
2436878|NCT03319745|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity. About 4 weeks after treatment, patients then undergo radical cystectomy per standard of care.
2436879|NCT03319732|Experimental|AERT 80 mg|Arbaclofen extended release tablet, 20 mg
3188508|NCT00767585||E|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy
3188509|NCT00767585||F|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of tamoxifen therapy
2436882|NCT03319706|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
2436883|NCT03319706|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
2436884|NCT03319693||Mucosal melanoma|Incident Mucosal melanoma in the Champagne-Ardenne region 2004-2014
2436885|NCT03319680|Active Comparator|Citrate dialysate|Hemodialysis with citrate dialysate during 16 weeks
2436886|NCT03319680|No Intervention|Acetate dialysate|Hemodialysis with acetate dialysate during 16 weeks
3188510|NCT00767585||G|70 women with hormone-dependent early breast cancer, 54-66 months after initiation of aromatase inhibitors therapy
3188511|NCT00767585||H|70 women with hormone-dependent early breast cancer, 24-36 months after initiation of aromatase inhibitors therapy following 24-36 months of initial tamoxifen therapy
3188512|NCT00767598|Active Comparator|A|Vardenafil
2436890|NCT03319654|Experimental|Spontaneous cycle IUI|"DNA fragmentation by TUNEL assay~DNA fragmentation will be measured both at the time of the diagnostic work-up as at the time of insemination."
2436891|NCT03319641|Experimental|PSMA-PET/CT scan|PSMA-PET/CT imaging in advanced ACC/SDC
2436892|NCT03319628|Experimental|Dose Escalation|"XMT-1536 (upifitamab rilsodotin) treatment is administered in groups of patients who will receive doses that increase over time.~This cohort is closed to enrollment."
2436893|NCT03319628|Experimental|Dose Expansion - Ovarian Cancer|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~Patients with ovarian cancer will enroll until sites approve UPLIFT."
2436894|NCT03319628|Experimental|Dose Expansion - NSCLC adenocarcinoma|"Once the maximum tolerated dose or recommended Phase 2 dose is achieved in dose escalation, new groups of patients will receive XMT-1536 (upifitamab rilsodotin) at this fixed-dose.~This cohort is closed to enrollment."
2436895|NCT03319628|Experimental|Pivotal Cohort (UPLIFT)|Patients with platinum-resistant ovarian cancer will receive XMT-1536 (upifitamab rilsodotin) to further confirm the efficacy
2436896|NCT03319628|Experimental|QTc Sub-Study|For sites participating in the sub-study, patients with platinum -resistant ovarian cancer will have the option to enroll in this sub-study to evaluate potential changes in the QTc interval following administration of XMT-1536.
2436897|NCT03319615|No Intervention|Habitual dietary intake|Habitual dietary intake
2436898|NCT03319615|Experimental|Energy Restriction|Match period (to comparator) of dietary energy restriction
2436899|NCT03319602|Active Comparator|Oxygenation only with nasal canula|intervention: classical oxygenation with nasal canula (High flow)
2436900|NCT03319602|Experimental|Oxygenation with double trunk masknasal canula|oxygenationwith DTM above nasal canula
2436901|NCT03319589|Experimental|Supplement Arm|School children (age 6 to 6.5) will receive their supplement 5 days a week in the morning before school starts. They will either receive the supplement at school or at the community health center depending on the preference of the villagers after recruitment. Young children (age 24 to 30 months) will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers.
2436902|NCT03319589|No Intervention|Control Arm|Children in the active intervention village will be compared with assessment-only controls in a separate village having comparable demographic characteristics
2436903|NCT03319576|Experimental|Early feeding|Patients randomized to early feeding will be fed 4 hours following gastrostomy tube placement
3188513|NCT00767598|Active Comparator|B|Sildenafil
3188514|NCT00767598|Active Comparator|C|Udenafil
3188515|NCT00767637|Experimental|Arm 1|
3188516|NCT00767663|Experimental|1|dipyridamole
3188517|NCT00767663|Placebo Comparator|2|placebo
3188518|NCT00767689|Experimental|vitamin B6|patient receiving xeloda and vitamin B6
2436904|NCT03319576|No Intervention|Standard feeding|Patients randomized to standard feeding will be fed 24 hours following gastrostomy tube placement
2436905|NCT03319563|Experimental|local anesthetic-epinephrine group|"after general anesthesia, the Infiltration cocktail was done by the surgeon at three levels:~Subcutaneous: before incision at a volume 20 ml/10 cm/side.~Muscular Paravertebral: before opening the thoracolumbar fascia, using the same previous volume.~Neural paravertebral: after exposure of the transverse processes. A volume of 5 ml/per each process of the same cocktail, 1 cm deep to the surface of the corresponding process before pedicular screws fixation after negative blood aspiration."
2436906|NCT03319563|Placebo Comparator|saline group|after general anesthesia, the same infiltration volume and technique using normal saline.
2436907|NCT03319550|Experimental|Casein|"LPS + 36 hour fast and bedrest + Casein (9% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping."
2436908|NCT03319550|Experimental|Whey|"LPS + 36 hour fast and bedrest + Whey (11% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
2436909|NCT03319550|Experimental|Leucine-enriched whey|"LPS + 36 hour fast and bedrest + Leucine-enriched whey (16% leucine) - 0.6 g protein/kg bodyweight, 1/3 as bolus and 2/3 as sipping"
2436910|NCT03319537|Experimental|Pevonedistat|
2436911|NCT03319537|Experimental|pevonedistat in combination with pemetrexed and cisplatin|
2436912|NCT03319511|Active Comparator|paravertebral group|ultrasound guided, in sitting position, or lateral position, at T2 and T4 levels, using 22 G spinal needle, in plane technique, traversing the costo-transverse ligament
2436913|NCT03319511|Experimental|spinal group|Ultrasound guided, In the lateral decubitus or sitting position, the puncture performed via para-median approach, at the T4-T5 or T5-T6 interspace, with a 27G spinal needle. After piercing the ligamentum flavum, the needle's stylet removed and the hub observed for free flow of CSF; injection when there is a flow of clear CSF.
2436914|NCT03319498|Active Comparator|Peppermint Oil Vapor|Exposure of the perineum to the vapor of the active comparator, 2 ml peppermint oil. The perineum will NOT come into contact with the oil directly.
2436915|NCT03319498|Placebo Comparator|Mineral Oil Vapor|Exposure of the perineum to the vapor of the placebo comparator, 2 ml mineral oil. The perineum will NOT come into contact with the oil directly.
2436916|NCT03319485|Experimental|ExAblate Pallidotomy|ExAblate treatment for Advanced Idiopathic Parkinson's Disease
2436917|NCT03319485|Sham Comparator|Sham ExAblate Pallidotomy|Sham (fake) treatment
2436918|NCT03319472||Benign Pleural Effusion|Patients that will be diagnosed within a month from admission with any non-malignant cause of pleural effusion, including but not limited to effusions caused by common or tuberculous or fungal infection, heart failure, etc. Documentation of the etiology will be required for inclusion in this group, including but not limited to bacteriology, virology, PCR, radiology, heart echocardiogram or catheterization, as appropriate.
2436919|NCT03319472||Malignant Pleural Effusion|Patients that will be diagnosed within a month from admission with any malignant cause of pleural effusion, including but not limited to effusions caused by lung, breast, colon, ovary, mesothelial, hematopoietic, prostate, or any other cancer. Diagnosis will be based on verification of the presence of malignant cells in the pleural fluid or tissues. Patients with cancer and an effusion without such documentation will be assigned to the benign group if an alternative diagnosis is made. In any other case, they will be excluded.
3188519|NCT00767689|Placebo Comparator|2 placebo|patient receiving xeloda and placebo
3188520|NCT00767715|Experimental|A|Patients will be given olanzapine
3188521|NCT00767715|Active Comparator|B|Patients will be given either haloperidol or zuclopentixol
2436923|NCT03319433||Group I (Perfusion Index <3.5)|Those parturient with perfusion index <3.5 when baseline monitors are attached while the patient is being prepared for surgery.
2436924|NCT03319433||Group II (Perfusion index >3.5)|Those parturient with perfusion index >3.5 when baseline monitors are attached while the patient is being prepared for surgery.
2436925|NCT03319420|Experimental|LO2A|1 drop of sodium hyaluronate instilled into each eye 4 times daily
2436926|NCT03319420|Active Comparator|Systane Ultra UD|1 drop of Systane Ultra UD instilled into each eye 4 times daily
3188522|NCT00767728|Active Comparator|1|Mesalamine pellets
2436928|NCT03319394|Experimental|The First Twenty|TF20 group completed a structured exercise program. Once a week a trained firefighter with current CPR and First Aid certifications met with the group to assess progress and answer questions about the workouts or the program. The rest of the time, the participants completed the workouts on their own time. Workouts contained a combination of aerobic (e.g., running, rowing, jumping), body weight (e.g., air squats, pushups, situps), and weight lifting (e.g., presses, back squats, lunges) exercises with workouts designed to use equipment available in an exercise/gym facility (e.g., weight racks, benches). Sixty-minute TF20 sessions included a warm-up, workout and cool down. All sessions were able to be logged online in TF20 program.
2436929|NCT03319394|Active Comparator|Comparison|The Comparison Group followed and documented their regular workout routine for 14 weeks. Once a week, a trained firefighter with current CPR and First Aid certifications met with the group to discuss questions. Participants were able to choose when to complete their workouts.
2436930|NCT03319381||w/o SOP|Time period 1: 2000-2006, without new SOPs
2436931|NCT03319381||SOP|Time period 2: 2010-2012, after implementation of the new SOPs
2436932|NCT03319368|Experimental|Intervention: Targeted gown and glove use|Additional gowns and gloves used for high risk care activities
2436933|NCT03319342|Experimental|Group I (acts of kindness to others)|Participants perform small acts of kindness or generosity for others 3 times per week for 4 weeks and complete weekly online questionnaires.
2436934|NCT03319342|Experimental|Group II (acts of kindness to self)|Participants perform small acts of kindness for themselves 3 times per week for 4 weeks and complete weekly online questionnaires.
2436935|NCT03319342|Experimental|Group III (self-kindness meditation)|Participants direct kind, loving thoughts to themselves, via guided meditation, 3 times per week for 4 weeks and complete weekly online questionnaires.
3188523|NCT00767728|Placebo Comparator|2|Placebo
3188524|NCT00767741|Experimental|with treatment|
3188525|NCT00767754|Other|paroxetine cr|single arm
3188526|NCT00767780||3|Patients suffering from ankle fractures and instability
3188527|NCT00767780||4|Patients suffering from hip osteoarthritis
2436936|NCT03319342|Active Comparator|Group IV (track daily activities)|Participants keep track of their daily activities, focusing on factual information rather than thoughts and feelings, on 3 separate days each week. At the end of the week, participants report on their activities and complete several online questionnaires.
2436937|NCT03319329||critically ill adult patients|"Part I: A cross-sectional study to compare validity of several predictive equations used to predict REE in critically ill adult patients for staying ≤ 5 days, 6 - 10 days and > 10 days by using indirect calorimetry (IC) as the reference standard.~Part II: To develop predictive equation for the estimation of energy requirement by identifying variables that might influence REE of mechanically ventilated critically ill patients.~Part III: To validate the newly developed predictive equation for the estimation of energy requirement by using Ten fold cross-validation approach"
2436938|NCT03319316|Experimental|Cohort 1 - Non-squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
2436939|NCT03319316|No Intervention|Cohort 1 - Non-squamous - Arm B|Patients receive a maintenance treatment of pemetrexed
2436940|NCT03319316|Experimental|Cohort 2 - Squamous - Arm A|Patients receive a maintenance treatment of durvalumab + tremelimumab
2436941|NCT03319316|No Intervention|Cohort 2 - Squamous - Arm B|Patients will have observation
3188528|NCT00767780||5|Patients who underwent total knee replacement or total hip replacement
3188529|NCT00767780||1|Patients suffering from bilateral knee osteoarthritis
2436944|NCT03319264|Experimental|Patients with SpA|"Patients included in this single group study will have 3 interventions to assess the severity of muscle loss :~dynamometry exam~walking test~Dual-energy X-ray Absorptiometry (DXA) measurement Quality of life will be assessed with Sarcopenia & Quality of Life (SARQOL) questionnaire. Patients will also fill a Life habits Questionnaire."
2436945|NCT03319238||Patient cohort|Neuropathic pain patient taking ketamine
2436946|NCT03319225||Tetraplegia|Persons with Tetraplegia
2436947|NCT03319225||Paraplegia|Persons with Paraplegia
2436948|NCT03319225||Neurologically-intact|Neurologically-intact controls
3188530|NCT00767780||2|Patients suffering fron non specific low back pain
2436950|NCT03319199|Active Comparator|Primary treatment Arm|"patients with a diagnosis of NAFDL will be randomly receive trial product SLIM WATER that contains L-CARNITINE and MAGNESIUM for a duration of 16 weeks."
2436951|NCT03319199|Placebo Comparator|Placebo Arm|"patients with a diagnosis of NAFDL will be randomly receive placebo for the initial 8 weeks and continue another 8 weeks with the trial product SLIM WATER."
2436952|NCT03319186|Experimental|EDIT Management|
2436953|NCT03319186|Active Comparator|Standard Care|
3188531|NCT00767793|Placebo Comparator|Arm 1|One drop in each eye every 12 hours for seven days
3188532|NCT00767793|Experimental|Arm 2|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
2436956|NCT03319160||Retrospective|Patients who have already completed use of LifeVest before start of the study
2436957|NCT03319160||Prospective|Patients receiving a LifeVest prescription in clinical routine
2436958|NCT03319147|Placebo Comparator|Placebo|4g of maltodextrin
2436959|NCT03319147|Active Comparator|Active|4g of essential amino acids
3188533|NCT00767793|Experimental|Arm 3|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
3188534|NCT00767793|Experimental|Arm 4|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
3188535|NCT00767871|Experimental|Escitalopram|escitalopram (10-20mg) to panic patients
2436963|NCT03319121|Experimental|Empirical therapy group|Participants will be given extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks
2436964|NCT03319121|Experimental|Guided therapy group|Participants will be give Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
2436965|NCT03319108|Other|Low Comorbidity Index Score|CCI; 1-3 as Group 1
2436966|NCT03319108|Other|High Comorbidity Index Score|CCI; 4 and above as Group 2
2436967|NCT03319095|No Intervention|Control|Control group: participants will receive only verbal instructions on PFM anatomy and function during the first assessment when women will be required to contract their pelvic floor muscle. The participants will have no contact with the service until the second assessment
2436968|NCT03319095|Active Comparator|Intervention|Intravaginal Electrical Nerve Stimulation: participants will be submitted to Intravaginal Electrical Nerve Stimulation
2436969|NCT03319082||CXL Group|Patients with corneal ectasia following refractive surgery who had corneal collagen cross-linking in one or both eyes according to the Photrexa Viscous and Photrexa prescribing information
2436970|NCT03319069|Experimental|group (1)|Hypofractionated radiotherapy women with T3-4 and /or 4 or more axillary nodes involvement post mastectomy. Hypofractionated radiotherapy 43,5 GY/15 fractions (f) /3w. to chest wall and supraclavicular nodal region.
2437127|NCT03317873|Experimental|wild type AA (CC)|All participants with the wild type genotype AA (CC) will be allocated to this group
3188536|NCT00767897||CKD stage 3 or 4|Girls and Boys age 9-18 with CKD stage 3 or 4
3188537|NCT00767897||On dialysis|Girls and Boys age 9-18 who are on dialysis
3188538|NCT00767897||Transplanted|Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
3188539|NCT00767897||Healthy|Girls and Boys age 9-18
3188540|NCT00767949|Experimental|1|iSONEP
3188541|NCT00767962|Other|1|talc pleurodesis under medical thoracoscopy
3188542|NCT00767962|Other|2|pleurodesis under video-assisted thoracoscopy surgery
3188543|NCT00767975|No Intervention|2|For patients who diagnosed with LTBI, they choose to receive LTBI treatment depends on their willingness; if they choose not, then they are in no intervention arm.
3188544|NCT00767975|Experimental|1|Provided INH 6m or RMP 4 m; whether enter treatment arm is determined by patient's willingness
3188545|NCT00767988|Active Comparator|A|Urex-cap-5 capsules (2x10^9 cfu each of RC-14 and GR-1) 1:1 ratio
3188546|NCT00767988|Placebo Comparator|B|Capsule 1:1
3188547|NCT00768014||1|Healthy term pregnant women in labor without any pain relief
3188548|NCT00768014||2|Healthy term pregnant women received TENS
2436971|NCT03319069|Active Comparator|group(2)|Conventional fractionated radiotherapy breast cancer women with T3-4 and/ or 4 or more axillary nodes involvement post mastectomy. Conventional fractionated radiotherapy 50 Gray(GY)/25 fractions (f)/5w to chest wall and supraclavicular nodal region.
2436972|NCT03319056|Active Comparator|Real purification|Air purifier turned on
2436973|NCT03319056|Sham Comparator|Sham purification|Air purifier turned off
2436974|NCT03319043|Experimental|treatment group|patients are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and additional Chanqin granules 10g three times a day. All granules will be taken orally with 200 ml warm water.
2436975|NCT03319043|Placebo Comparator|controlled group|patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation and Chanqin analogous granules. All granules will be taken orally with 200 ml warm water.
2436976|NCT03319030||Duchenne Muscular Dystrophy (DMD)|Enrolls boys with a genetically confirmed diagnosis of DMD.
2436977|NCT03319017||Multiple-trauma patients|The patients who are diagnosed with multiple-trauma and have blood test in an emergency room. The patients with multiple-trauma are defined as the patients who have trauma in more than two regions.
2436978|NCT03319004|Experimental|Compare bispectral index and phase lag entropy|
2436979|NCT03318991|Active Comparator|GreenLight laser|180W Greenlight laser is used for vaporesection of the prostate.
2436980|NCT03318991|Active Comparator|Thulium laser|200W Thulium laser is used for enucleation of the prostate.
2436981|NCT03318978|Experimental|25 ng dose|Capsule containing 25 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2436982|NCT03318978|Experimental|50 ng dose|Capsule containing 50 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2436983|NCT03318978|Experimental|100 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2436984|NCT03318978|Experimental|250 ng dose|Capsule containing 100 ng (2.7 nCi) [14C]-benzo[a]pyrene (BaP)
2436985|NCT03318952|Experimental|lidocaine then articaine|For the first dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed. For the second dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
2436986|NCT03318952|Experimental|articaine then lidocaine|For the first dental procedure a single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered. For the second dental procedure 2% lidocaine with 1:100,000 epinephrine will be administered with a buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed.
2436987|NCT03318939|Experimental|Poziotinib|"Cohort 1: Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC (closed to enrollment)~Cohort 2: Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC (closed to enrollment)~Cohort 3: Treatment naïve patients with EGFR exon 20 insertion-mutant positive NSCLC (fully enrolled)~Cohort 4: Treatment naïve patients with HER2 exon 20 insertion mutant positive NSCLC~Cohort 5: Patients who meet the criteria for enrollment in Cohort 1 to 4, but the enrollment in the respective cohort has been closed~Cohort 6: Patients with acquired EGFR mutation who progressed while on treatment with first-line osimertinib~Cohort 7: Patients with EGFR or HER2 activating mutations"
2436988|NCT03318913|No Intervention|Health control|Health young subjects free of diabetes mellitus and nutritional intervention
2436989|NCT03318913|Placebo Comparator|DM Placebo|Sucralose
2436990|NCT03318913|Active Comparator|DM FHP|Fish protein hydrolysates
3148196|NCT00142480|Experimental|Capecitabine, Oxaliplatin, Bevacizumab|There are two phases of study treatment. Phase I includes all patients and will last 6 weeks. During this phase, oxaliplatin will be given intravenously (IV) on days 1, 8, 22, and 29; bevacizumab will be given IV on days 1, 15, and 29; capecitabine will be administered orally on days 1-14 and 22-35. Radiation therapy will be given once daily for 5 days (Monday-Friday) per week for a total of 28 treatments. Phase II has two groups: 1) patients who had tumors removed prior to entering study and 2) patients who entered the study with advanced disease. Patients who had their tumors removed prior to entering the study will be treated with the above 6-week regimen twice for a total of 12 weeks of treatment. Patients who were unresectable prior to entering the study but then were deemed resectable after treatment on trial will undergo resection. Following surgical recovery (8-10 weeks) they will be treated again with the above 6-week regimen twice for a total of 12 weeks of treatment.
2436992|NCT03318887||Sofosbuvir/daclatasvir|Patients with hepatitis C virus (HCV) infection treated with sofosbuvir/daclatasvir combination therapy with or without ribavirin between February and September 2014
3148197|NCT00142493|Experimental|1|
3148198|NCT00142493|Experimental|2|
3148199|NCT00142493|Experimental|3|
3148200|NCT00142493|Experimental|4|
3148201|NCT00142493|Placebo Comparator|5|
2437035|NCT03318562|Experimental|TNBC Cohort|female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable TNBC and have received >=1 prior cancer therapy regimen for metastatic disease
2437128|NCT03317873|Experimental|mutation VV (TT)|All participants with the mutation genotype VV (TT) will be allocated to this group
3148202|NCT00142532|Experimental|1|At the time of pre-op preparation, 18 semi-permanent intradermal acupuncture studs will be placed at acupuncture points in the back, two will be placed in the legs and two in the ear. All studs will be replaced when the epidural is removed or, for patients without epidurals, shortly before discharge. The new leg and auricular studs will then be removed at eleven days; the new back studs will be removed at the three week post-discharge consult.
3148203|NCT00142532|Placebo Comparator|2|"The treatment is the same as for the true acupuncture group, with the following exceptions. The studs in the back will be dummy studs have no needle and that have been used in previous research at MSKCC. The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
3148204|NCT00142584|Experimental|1-NEB|Nebivolol
3148205|NCT00142584|Active Comparator|2-MET|Metoprolol
3148206|NCT00142610|Experimental|vitamin|500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks
3148207|NCT00142610|Placebo Comparator|Placebo|
2437000|NCT03318848|Experimental|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
2437001|NCT03318848|No Intervention|Simulation without video|The students of the control group performed the simulation of the bed bath procedure, with the aid of a tutor.
2437002|NCT03318835|Experimental|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
2437003|NCT03318835|Active Comparator|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
2437004|NCT03318822||Q-Collar|Subjects wearing the Q-Collar
2437007|NCT03318796|Other|Interventional|Coronary artery stenting of De novo bifurcation lesions MB & SB
2437010|NCT03318770||All patients|All eligible patients enrolled in the GIMEMA LAL2116 study who have completed 12 months follow-up will be included in this group.
2437011|NCT03318757|Experimental|Group 1- Bupivacaine extended release liposome injection|Bupivacaine extended release liposome injection (Exparel TM) is a novel formulation of bupivacaine designed to achieve long-acting postoperative analgesia.
2437012|NCT03318757|Active Comparator|Group 2- Bupivacaine HCl|Bupivacaine HCl (Marcaine) is a local anesthetic that reduces the flow of sodium in and out of nerves which decreases the initiation and transfer of nerve signals in the area in which the drug is applied.
2437013|NCT03318744|Experimental|aspirin 100mg|Participants will be given aspirin 100mg once per day.
2437014|NCT03318744|Placebo Comparator|placebo|Participants will be given placebo oral tablets once per day.
2437015|NCT03318731|Placebo Comparator|Sugar Pill|Maltodextrin (matches the weight of the active treatment). Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2437016|NCT03318731|Experimental|Fenugreek Extract, Low Dose|300mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2437017|NCT03318731|Experimental|Fenugreek Extract, High Dose|500mg Taken 1-hour prior to workout on training days and each day of overreaching week. On rest days, will consume in the morning with breakfast.
2437018|NCT03318718|Experimental|TOF measurement|TOF and MEP measurement after Anesthesia with non-depolarizing NMBA Rocuronium
2437019|NCT03318692|Experimental|MySpine System|pedicle screw implantation (spondylodesis) using the MySpine System. post surgery CT.
2437020|NCT03318692|Active Comparator|free-hand|Freehand (fluoroscopically controlled) implantation of pedicle screw (spondylodesis). Post surgery CT
3148208|NCT00142623|Experimental|1|"Use of five tailored take-home DVDs aimed at reducing exposure to ETS"
3148209|NCT00142623|No Intervention|2|Usual care
2437023|NCT03318653||HD - Hemodialysis|Patients with end stage renal disease treated with hemodialysis
2437024|NCT03318653||PD - Peritoneal dialysis|Patients with end stage renal disease treated with peritoneal dialysis
2437025|NCT03318640|Experimental|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month.
2437026|NCT03318640|No Intervention|Control|Patient will have usual medical care.
2437027|NCT03318627|Other|Tension Measuring|Measuring intraoperative tension of rotator cuff tendon with sterile spring Balance.
2437028|NCT03318614|Experimental|Probiotics M-63 group|Participants assigned to the M-63 group were given a sachet of B. infantis M63 (Morinaga Milk Industry Co., Ltd., Japan) to consume daily in addition to advice of good hygiene and sanitation practices.
2437029|NCT03318614|Placebo Comparator|Control group|No probiotic intervention was given to the control group over three months other than advice of good hygiene and sanitation practices.
2437030|NCT03318601|Experimental|cirrhotic patients with ascites|cirrhotic patients with ascites requiring prolonged hospitalization
2437031|NCT03318588||Case|Patients undergoing vitrectomy for primary retinal detachment
2437032|NCT03318588||Control|Patients undergoing vitrectomy for idiopathic macular hole
2437033|NCT03318575|Experimental|autoRIC|The autoRIC device will be used on subjects randomized to the treatment group.
2437034|NCT03318575|Sham Comparator|autoRIC Sham|The autoRIC Sham device will be used on subjects randomized to the control group.
3148210|NCT00142688|Experimental|1|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
3148211|NCT00142688|Active Comparator|2|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
3148212|NCT00142740||1 - HIV Positive|Participant in parent study ATN 024, aged 12-24 years, testing HIV positive. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 024.
3148213|NCT00142740||2 - HIV Negative|Participant in parent study ATN 025, aged 12-24 years and testing negative for HIV infection. All eligible youths must be negative for HBV core antibody, HBV surface antigen, and HBV surface antibody at the time of enrollment in to ATN 025.
3148214|NCT00142753|Active Comparator|A1: ATN 024 Energix-B Standard Adult Dose|
3148215|NCT00142753|Experimental|A2: ATN 024 Engerix-B Increased Adult Dose|
3148216|NCT00142753|Active Comparator|A3: ATN 024 Twinrix Standard Adult Dose|
3148217|NCT00142753|Experimental|B1: ATN 025 Recombivax|
3148218|NCT00142753|Experimental|B2: ATN 025 Twinrix|
3148219|NCT00142805|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
3148220|NCT00142805|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
3148221|NCT00142831|Experimental|1|Bupropion-SR, 150 mg/day x 3 days, then 300 mg/day for 13 weeks
3148222|NCT00142831|Placebo Comparator|2|Identical Placebo
2437036|NCT03318562|Experimental|HCC Cohort|male and female subjects who have histologically or cytologically confirmed advanced HCC not amenable to surgical resection and have failed >=1 systemic therapy, which must include sorafenib, or are intolerant to multikinase inhibitor therapies
2437037|NCT03318549||Glaucoma|Patients with diagnosed glaucoma
2437038|NCT03318549||Suspicious of having glaucoma|Patients with suspicious of having glaucoma based on intra-ocular pressure or optic nerve photographs with glaucoma appearance
2437039|NCT03318549||Non-glaucomatous optic neuropathies;|Patients with optic neuropathies that do not look glaucomatous-like
2437040|NCT03318549||Age-related macular degeneration (AMD)|Patients with diagnosed age-related macular degeneration
2437041|NCT03318549||Retinal degenerations|Patients with other retinal degenerations excluding AMD
2437042|NCT03318549||Other diseases of visual pathways|Other diseases of the visual pathway not included in the previous groups
2437043|NCT03318549||Healthy control group|Patients labeled as healthy controls for not having any other eye diseases that would be included on the other groups
2437044|NCT03318536||No Granisetron|120 Patients prior to changes of intern standards of caesarean section. Before march 2017 no patient undergoing elective caesarean section received Granisetron as a matter of routine.
2437045|NCT03318536||With Granisetron|120 Patients after changes of intern standards of caesarean section. After march 2017 all patient undergoing elective caesarean section received Granisetron as a matter of routine.
3148223|NCT00142844|Experimental|Naltrexone|Naltrexone
3148224|NCT00142844|Experimental|Disulfiram|Disulfiram
3148225|NCT00142844|Experimental|Naltrexone and Disulfiram|Naltrexone and Disulfiram
3148226|NCT00142844|Placebo Comparator|Placebo|Placebo
2437050|NCT03318497|Experimental|Diagnostic (Interim FLT PET/CT)|"The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.~Procedure: Computed Tomography~Drug: 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
2437051|NCT03318484|Active Comparator|Optimal Medical Care|Optimal medical care (OMC) only is administrated in this arm. OMC is established according to the standards established by the 2016 ACC-AHA Guidelines for the Management of Patients with Peripheral Artery Disease in order to promote best practices for risk factor management.
2437052|NCT03318484|Experimental|Optimal Medical Care and SDT|OMC and sonodynamic therapy (SDT) are administrated in this arm.
2437053|NCT03318471|Active Comparator|Group M|received 50 mg/kg MgSo4 in 100 ml 0.9 NaCl 15 minutes prior to anesthesia induction over 15 minutes
2437054|NCT03318471|Placebo Comparator|Group S|received 100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes.
2437055|NCT03318458|Experimental|Pilates group|
2437056|NCT03318458|No Intervention|No intervention group|
2437057|NCT03318445|Experimental|Rucaparib and irinotecan|"Rucaparib will be taken twice daily by mouth for 7-14 days in 21 or 28 day cycles. Irinotecan will be administered by IV for 90 minutes every 14 days, or every 21 days if not tolerated.~During the dose escalation phase, the maximum tolerated dose for combining Rucaparib and irinotecan will be determined. The dose for rucaparib during dose escalation will range from 300 mg to 600 mg, depending on the progression of study. The dose for irinotecan during dose escalation may range from 40 mg/m2 to 150 mg/m2.~During the dose expansion phase, patients who have received prior PARP inhibitors will be given rucaparib and irinotecan at the maximum tolerated dose levels determined during the dose escalation phase."
2437058|NCT03318445|Experimental|Rucaparib only|During the dose expansion phase, patients who have not received prior PARP inhibitor therapy will take 600 mg of rucaparib by mouth daily. Patients who progress on single-agent rucaparib will be given the option to cross-over to the combination treatment arm and receive rucaparib in combination with irinotecan at the maximum tolerated dose levels determined during dose escalation.
2437059|NCT03318419|Experimental|Cladribine group|Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm
2437061|NCT03318393|Active Comparator|Unfractionated heparin group|Patients randomized to this arm will undergo usual care using unfractionated heparin as the primary anticoagulant.
2437062|NCT03318393|Experimental|Bivalirudin group|Patients randomized to this arm will receive anticoagulation with bivalirudin
3148227|NCT00142870|Placebo Comparator|A|
2437064|NCT03318367|Experimental|Supportive care (virtual reality education module)|After undergoing a previously planned CT simulation scan, patients complete a virtual reality education module to learn more about radiation therapy for prostate cancer. Patients also complete questionnaires before and after the module.
2437065|NCT03318354|Experimental|Test|Torrent's Olmesartan Medoxomil Tablets 40 mg
2437066|NCT03318354|Active Comparator|Reference|Daiichi Sankyo Inc's Benicar Tablets 40 mg
2437125|NCT03317886|Active Comparator|mesenteric approach|mesenteric approach starts from lymph node dissection around the superior mesenteric artery and performs Kocher's maneuver finally during pancreaticoduodenectomy.
2437164|NCT03317574|Experimental|MEDITOXIN|
3148228|NCT00142883|Active Comparator|pregabalin|pregabalin compared to placebo
3148229|NCT00142883|Placebo Comparator|Placebo|Placebo compared to pregabalin
3148230|NCT00142922|Experimental|1|Attended Breaking Down Barriers program
3148231|NCT00142922|Active Comparator|2|Attention control group
3148232|NCT00142922|Active Comparator|3|Indivdual attention control group
3148233|NCT00142948|Experimental|Naltrexone|Naltrexone Oral 50 mgs daily
3148234|NCT00142948|Placebo Comparator|Placebo|1 to 1 comparison of Naltrexone to placebo
3148235|NCT00142961|Experimental|1|Atomoxetine prescribed daily
3148236|NCT00142961|Placebo Comparator|2|placebo controlled arm
3148237|NCT00143039||NIH/SSIUGR fetuses|Group 1 includes pregnancies complicated by a fetus with either Non-Immune Hydrops or Severe Symmetrical IUGR.
3148238|NCT00143039||Control-Normal fetus|Group 2 includes all normally appearing fetuses on U/S who will be having a diagnostic amniocentesis as part of their routine care.
2437072|NCT03318289|Experimental|Ving Tsun (VT) group|Participants in the VT group will receive VT exercise intervention for 12 weeks.
2437073|NCT03318289|No Intervention|Control group|No intervention but can continue daily activities.
2437074|NCT03318276|Experimental|SID142|Patients administrate SID142 (Cilostazol 200mg, Ginkgo biloba leaf extract 160mg) once a day for 12 weeks
2437075|NCT03318276|Active Comparator|Rinexin® Tab|Patients administrate Rinexin® Tab (Cilostazol 100mg, Ginkgo biloba leaf extract 80mg) twice a day for 12 weeks
2437076|NCT03318263|Other|experimental|
2437077|NCT03318250|Active Comparator|Burst3D|"This is a device progamme setting which is being compared against DR6-LF.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant. Once device is implanted participants are assigned progammes in a randomized manner."
2437078|NCT03318250|Active Comparator|DRG-LF|"This is a device progamme setting which is being compared against Burst3D.~Intervention for this arm is the dorsal root ganglion neurostimulation device implant which will occur at trial implant.Once device is implanted participants are assigned progammes in a randomized manner."
2437079|NCT03318237||Patients with focal epilepsy|Patients undergoing ultra high field MRI of the brain
2437080|NCT03318211|Active Comparator|MgSO4 discontinuation|after delivery , no Extradoses of MgSO4 were given
2437081|NCT03318211|Active Comparator|MgSO4 continuation|After delivery , Mg Sop4 was given at a rate of 1 gram /hour for 24 hours after delivery
2437082|NCT03318198|Active Comparator|Intervention Arm|Attendings on the interventional arm attended daily work rounds with the resident teams in addition to established work rounds on the previously admitted patients on the care team.
2437083|NCT03318198|Placebo Comparator|Control Arm|Attendings crossed over to the control arm in which they did not attend work rounds with the team and only say new admissions with the resident team. This was usual care.
2437084|NCT03318185|Experimental|gasless single-port laparoscopic surgery|radical resection of rectal carcinoma is performed by gasless single-port laparoscopic-assisted surgery.
2437085|NCT03318185|Sham Comparator|conventional laparoscopic surgery|radical resection of rectal carcinoma is performed by conventional laparoscopic surgery.
2437086|NCT03318172|Experimental|Group C spinal cord stimulator|Spinal cord stimulator (SCS) implantation with conventional stimulation mode therapy during 2 weeks followed by 2 weeks with high-density stimulation mode therapy.
2437087|NCT03318172|Active Comparator|Group H spinal cord stimulator|Spinal cord stimulator (SCS) implantation with high-density stimulation mode therapy during 2 weeks followed by 2 weeks with conventional stimulation mode therapy.
2437088|NCT03318159|Other|posaconazole prophylaxis group|aplastic anemia / hypoplastic myelodysplastic syndrome patients undergoing antithymocyte globulin treatment and receiving posaconazole as prophylaxis antifungal agent
2437089|NCT03318146|Experimental|EXP-LP punctum plug|EXP-LP is a novel and innovative drug delivery system aiming to improve patient compliance and outcomes. EXP-LP punctum plug, is a non-invasive insert that replaces eye drops and provides sustained therapy for glaucoma, dry eye and other major eye diseases. EXP-LP is a combination of an ophthalmic prostaglandin drug (Latanoprost). The prostaglandin drug works by increasing the natural outflow of fluid from inside the eye
2437090|NCT03318146|Active Comparator|XALATAN®|XALATAN® (latanoprost ophthalmic solution) is an eye drop used to treat high eye pressure/intraocular pressure in people with open-angle glaucoma or ocular hypertension. XALATAN is administrated once a day
2437091|NCT03318133|Experimental|GA group|"general anesthesia(GA) group:~Open peripheral vein fluid infusion, radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring~Propofol (1.5-3mg/kg), cis-atracurium(0.1-0.15mg/kg) and sulfentanyl(0.2-0.6μg/kg) anesthesia-induced intubation, mechanical ventilation to maintain normal PETCO2~Use sevoflurane, propofol and sulfentanyl to maintain anesthesia, and add cis-atracurium as needed~Transfer to ICU after surgery"
2437092|NCT03318133|Experimental|CLSB group|"combined lumbar plexus and sacral plexus block(CLSB) group:~Open peripheral vein fluid infusion~In lateral position (affected side upward), ultrasound-guided lumbar plexus block (0.375% ropivacaine, Lumbar 2-3 or/and 3-4vertebral space level, 25ml), then sacral plexus block (0.375% ropivacaine, 20ml)~Radial arterial cannulation under local lidocaine anesthesia and arterial blood pressure monitoring, and blockade effectiveness was evaluated 30min after nerve block~After reaching satisfactory blockade, target-controlled infusion of propofol was used to maintain Ramsay sedation score between 5-6 points, monitoring PETCO2 through nasopharyngeal airway, maintain autonomous respiration, and add small-dose fentanyl (10-20μg/time) as needed~Transfer to ICU after surgery"
3148239|NCT00143130|Experimental|Single Arm|
3148240|NCT00143182|Experimental|1|Asenapine
2437126|NCT03317886|Active Comparator|conventional approach|Conventional approach starts from Kocher's maneuver and finally performs lymph node dissection around the superior mesenteric artery during pancreaticoduodenectomy.
3148241|NCT00143182|Active Comparator|2|Olanzapine
3148242|NCT00143273|Experimental|Lasofoxifene Dose 1|0.05 mg
3148243|NCT00143273|Experimental|Lasofoxifene Dose 2|0.25 mg
3148244|NCT00143273|Experimental|Lasofoxifene Dose 3|0.5 mg
3148245|NCT00143273|Placebo Comparator|Placebo|0 mg
3148246|NCT00143468|Experimental|1|ALI/ARDS patients and healthy subjects
3148247|NCT00143494|Experimental|1|Critically hill, mechanically ventilated patients
3148248|NCT00143533|Other|1|
3148249|NCT00143559|Other|1|
3148250|NCT00143572|Other|1|
3148251|NCT00143611|Experimental|Resatorvid 1.2 mg/kg/day|
3148252|NCT00143611|Experimental|Resatorvid 2.4 mg/kg/day|
3148253|NCT00143611|Placebo Comparator|Placebo|
3148254|NCT00143624|Experimental|1|The first group will receive 8 mg of the study drug (rosiglitazone).
3148255|NCT00143624|Placebo Comparator|2|The second group will be given a placebo.
3148256|NCT00143637|Experimental|2|Office dust with added glucan
3148257|NCT00143637|Experimental|1|Clean air exposures in climate chamber
3148258|NCT00143663|Experimental|Lapaquistat Acetate 100 mg QD|
3148259|NCT00143663|Placebo Comparator|Placebo QD|
3148260|NCT00143676|Experimental|Lapaquistat Acetate 50 mg QD + Atorvastatin|
3148261|NCT00143676|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin|
3148262|NCT00143676|Active Comparator|Atorvastatin|
2437095|NCT03318107|Experimental|Transvaginal probe (Photoacoustic + ultrasound imaging)|"A transvaginal imaging probe using ultrasound and photoacoustic imaging will be inserted into the vagina and will use different frequencies of lights to create images~This will occur before the first standard of care treatment, mid-treatment, end of treatment, and approximately 3 months after the end of treatment for a total of 4 imaging time points"
2437096|NCT03318094|Placebo Comparator|Intact Day|Saline
2437097|NCT03318094|Experimental|Blocked Day|Phentolamine
2437098|NCT03318094|Active Comparator|Vasodilator Comparison|Sodium Nitroprusside
2437099|NCT03318081|Active Comparator|cognitive function rehabilitation group|The main content of cognitive function rehabilitation esecutive function,including working memory,sustained attention, response inhibition function and cognitive flexibility, 45 minutes a day over 6 weeks period.
2437100|NCT03318081|Active Comparator|cognitive bias modification group|The main content of cognitive bias modification groups were changing ATS related attention bias, 45 minutes a day over 6 weeks period.
2437101|NCT03318081|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center
2437102|NCT03318068|Experimental|Yoga intervention arm|The group will receive a weekly yoga session for the duration of 10 weeks. The yoga sessions will be delivered in person for 3 weeks during the intervention, coordinated with existing clinic visits. The other 7 sessions will be delivered via skype. The participant will be asked to fill out questionnaires during each of the three in-person yoga visits asking about psychological symptoms and quality of life.
2437103|NCT03318055||Single group study|"The study population will include patients presenting for elective surgery, who fulfil the inclusion criteria of all surgical disciplines undergoing elective surgery period during the period of the study.~Inclusion Criteria:~> 18 years of age Non-cardiac patients Non-obstetric patients Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
2437104|NCT03318042|Experimental|Child-teenagers-walnuts-pomegranate|Intake of walnuts or pomegranate juice for 3 days
2437105|NCT03318029|Placebo Comparator|Placebo UK trial|Placebo and living in the UK
2437106|NCT03318029|Active Comparator|Vitamin D UK trial|Vitamin D supplementation and living in the UK
2437107|NCT03318029|Placebo Comparator|Placebo Brazil Trial|Placebo and living in the Brazil
2437108|NCT03318029|Active Comparator|Vitamin D Brazil Trial|Vitamin D supplementation and living in Brazil
2437109|NCT03318016|Experimental|Cyclophosphamide|"Cohort -1: Cyclophosphamide 500 mg/m2~Cohort 1: Cyclophosphamide 1000 mg/m2~Cohort 2: Cyclophosphamide 2000 mg/m2~Cohort 3: Cyclophosphamide 3000 mg/m2~Cohort 4: Cyclophosphamide 4000 mg/m2"
2437110|NCT03318003|Experimental|Auto-PAP Therapy|
2437111|NCT03318003|No Intervention|No Therapy|
3148263|NCT00143689|Experimental|Lopinavir/ritonavir, Zidovudine, Lamivudine|"Participants will be randomly assigned to receive one of the following drug combinations:~lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day;~Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day;~Combivir and lopinavir/ritonavir twice a day."
3148264|NCT00143715|Experimental|1|Low dose oral vitamin K + warfarin cessation
2437114|NCT03317977|Experimental|Reach for Control|Reach For Control is a multi-component, home-based family therapy that targets the multiple causes of poor adolescent asthma management across individual, family and community systems.
2437115|NCT03317977|Active Comparator|Michigan MATCH|Program endorsed by the State of Michigan for treatment of poorly controlled asthma.
2437116|NCT03317964||Saliva - cardiomyopathy|Saliva sample for genetic testing from subjects who developed cardiomyopathy
2437117|NCT03317964||Saliva - no cardiomyopathy|Saliva sample for genetic testing from subjects who do not have cariomyopathy
2437118|NCT03317951|Experimental|Novel integrated care concept (NICC)|The care center is at the heart of the NICC structure. It will be available 24/7. It is the core platform to share information for all NICC patients in the care process and serves as integration point between the professional groups. The care center is utilizing the NICC platform for care coordination and patient monitoring. The NICC platform enables patient management from the distance and allows treating physicians to observe and follow the health status of patients daily. Using the NICC tablet, patients provide information from home about their health status. They will receive feedback about their therapy, measurements and reminders and motivation to follow care plans. The communication allows for a regular evaluation of the patient's situation, a review of the therapy and coordination of necessary adjustments with care providers. The general intervention rules are based on the current European Society of Cardiology (ESC) guidelines for treating AF, HF and TRH patients.
2437119|NCT03317951|Active Comparator|Standard care|Patients will be treated according to current practice as described in the guidelines of the European Society of Cardiology (ESC). For AF, this has been provided by Kirchhof et al. (2016 Eur Heart J). HF treatment will follow the 2016 ESC guideline for HF (Ponikowski et al., 2016 Eur Heart J), and TRH will be treated according to the ESC treatment guideline for arterial hypertension (Mancia et al., 2013 Eur Heart J).
2437120|NCT03317938|Experimental|Fecobionics studies|
2437121|NCT03317912|Active Comparator|Lidocaïne 2%|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
2437122|NCT03317912|Placebo Comparator|Placebo (for Lidocaïne)|Bolus 0.075ml/kg/h, following by continuous infusion 0.1ml/kg/h during surgery and 0.066ml/kg/h during 24h
2437123|NCT03317899|Experimental|Group I (auto HSCT tbo-filgrastim)|Beginning on day 3 after auto Hematopoietic Cell Transplantation (HSCT), patients receive tbo-filgrastim SC daily for 12-14 days.
2437124|NCT03317899|Experimental|Group II (auto HSCT)|Patients undergo auto Hematopoietic Cell Transplantation (HSCT).
2437165|NCT03317574|Active Comparator|BOTOX|
3148265|NCT00143715|Placebo Comparator|2|
3148266|NCT00143741|Other|Lipitor|
3148267|NCT00143910||Renal transplant recipient|Recipients of successful renal transplant
3148268|NCT00143923|Active Comparator|1|Intervention: 6 months of individualized advice regarding Nutrition, Exercise, Stress Management Counseling for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 1
3148269|NCT00143923|Placebo Comparator|2|Intervenition: 6 months of Usual care for participants who are at intermediate or high Framingham risk for CVD and are randomized to Arm 2. No active Nutrition, Exercise, Stress Management Counseling
2437129|NCT03317860|Sham Comparator|Sham tDCS plus RTP|Single session of bilateral sham parietal cortex tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
2437130|NCT03317860|Active Comparator|Active tDCS plus RTP|Single session of bilateral active parietal cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
2437131|NCT03317847|Experimental|Bromfenac|Patients randomized to this arm will receive Bromfenac 0.09 % Ophthalmic Solution BID for 2 weeks
2437132|NCT03317847|Active Comparator|Dexamethasone|Patients randomized to this arm will receive Dexamethasone 0.1 % Ophthalmic Suspension QID for one week and BID for the following week
2437133|NCT03317834||Study Population|Total Knee Replacement with Navio Surgical Systems
2437134|NCT03317808|Active Comparator|Heavy slow resistance exercise|
2437135|NCT03317808|Placebo Comparator|Traditional supervised exercise|
2437138|NCT03317769|Experimental|Experimental Treatment|Computerized cognitive training for 18 hours and structured social skills training for 9 hours over a 9 week period.
2437139|NCT03317769|Active Comparator|Active Comparator|Commercially-available computerized training for 18 hours and 9 hours of unstructured support group sessions over a 9 week period.
2437140|NCT03317756|Experimental|Patient Variation 1|Patient Educational Intervention: Patient will receive intervention videos and will be required to complete the baseline and follow-up surveys.
2437141|NCT03317756|Experimental|Patient Variation 2|Patient Control: Patients will receive an attention control and will be required to complete the baseline and follow-up surveys.
3188549|NCT00768014||3|Healthy term pregnant women received epidural anesthesia
2437143|NCT03317730|Experimental|RT + Xtampza ER|This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
2437144|NCT03317717|Experimental|botulinum toxin 2U|
2437145|NCT03317717|Experimental|botulinum toxin 5U|
2437146|NCT03317717|Experimental|botulinum toxin 10U|
2437147|NCT03317717|Experimental|botulinum toxin 20U|
2437148|NCT03317717|Experimental|botulinum toxin 30U|
2437149|NCT03317704|Active Comparator|speed endurance training (SET)|Training 6 weeks 3 times pr. week
2437150|NCT03317704|No Intervention|Controls|Asked to continue their usual life style
2437151|NCT03317704|Active Comparator|speed endurance training (SET) II|Training 6 weeks 3 times pr. week
2437152|NCT03317691||ST segment Elevation Myocardial Infarction|ST segment Elevation Myocardial Infarction patients' diagnosis was confirmed by coronary artery angiography. The prior surgery electrocardiogram need to be collected.
2437153|NCT03317678|Experimental|BioKefir (BKP)|BioKefir™ (Lifeway Foods) is a lactose-free fermented milk drink containing 12 different species of bacteria within the lactobacillus, bifidobacterium, and streptococcus generas totaling approximately 20 CFU per 3.5 ounce serving. The product also contains 2 g of fiber, including pectin and inulin. These fibers, especially inulin, are prebiotics that may function along with the probiotic species to support gastrointestinal health. The product is available commercially. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The probiotic will be provided in individual 3.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
2437154|NCT03317678|Placebo Comparator|Non-fermented Milk (NFM)|The NFM is dairy-based product ultra-filtered to remove lactose. In addition to being matched to lactose, the NFM contains similar energy, fat, and protein content as the probiotic. Participants will be asked to consume 3.5 ounces twice daily, preferably at morning and nighttime. The NFM control will be provided in 11.5 ounce unlabeled containers. These quantities will be started on the first day of the intervention phase of the study (day 0, visit 0) and remain unchanged until the end of the intervention phase on day 56 (visit +4). Administration will be discontinued then.
2437155|NCT03317665||Standard of care|Mesh for hernia repair: Standard of care products used by the Investigator for open ventral hernia repair procedure
2437156|NCT03317652|Experimental|Sodium nitroprusside and CO2 reactivity|"The subject rests in the supine position throughout the study that lasts for approximately three hours.~Interventions are:~Hyperventilation~6% CO2 breathing~Infusion of sodium nitroprusside"
2437157|NCT03317639|Experimental|an intervention arm|Hospitals in the intervention arm will receive a multi-components intervention based on the Behaviour Change Wheel model
2437158|NCT03317639|No Intervention|a control arm|hospitals in the control arm will receive no intervention and maintain existing care
2437159|NCT03317626|Experimental|Cold Stimulus|The study procedure will beto use a coldstimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted
2437160|NCT03317613|Experimental|Capsaicin|Cancer patients presenting neuropathic pain secondary to their anti cancer treatments will receive patch of capsaicin (qutenza) on the painful zones..
2437161|NCT03317600|Active Comparator|Lidocaine block|
2437162|NCT03317600|Placebo Comparator|Isotonic saline block|
2437163|NCT03317587|Experimental|INSPIRE|
2437166|NCT03317561||Myocardial injury|Subjects who have had an increase in troponin T level (> 99 percentile) in the perioperative period shall form the cases.
2437167|NCT03317561||Control|Subjects who do not have an increase in troponin T level (< 99 percentile) in the perioperative period shall form the controls.
2437168|NCT03317548||fresh embryo transfer|patients with fresh day 3 embryo transfer after oocyte pick up, the hormone including FSH, LH, E2 and progesterone was test before embryo transfer for analysis. The clinical outcomes including implantation and pregnancy were checked and recorded.
2437169|NCT03317548||frozen embryo transfer|"freeze-all embryo was performed after oocyte fertilization, the hormone including FSH, LH, E2 and progesterone was test before oocyte pick up and embryo transfer for analysis.~vitrification of pronuclear stage embryo (zygote) and frozen embryo transfer"
2437170|NCT03317535|Other|Local anesthesia/conscious sedation|Patients will be injected by propofol (adjusted by bispectral index scale ≥70 ) and /or remifentanil（0.01-0.06μg/kg/min）. Patients will maintain spontaneous breathing.
2437171|NCT03317535|Other|General anesthesia|Patients will be induced with remifentanil (0.2-0.8 μg/kg), propofol (1-2mg/kg) and rocuronium (0.6 mg/kg). Anesthesia will then be maintained keep the BIS between 40 and 60 with propofol and remifentanil. After tracheal intubation, patients will be kept with controlled ventilation.
2437172|NCT03317522||Belfast HAPO|"All pregnant women who attended the Royal Victoria Maternity Hospital, Belfast were eligible to participate unless they met one or more exclusion criteria.~All eligible women from the Belfast centre were invited to take part in a prospective observational study involving an additional fasting serum sample for lipids at 28 weeks gestation and long term follow up of their HAPO offspring. Only those women who had remained blinded to oral glucose tolerance test (OGTT) results during pregnancy were included (fasting plasma glucose ≤5·8 mmol/L and 2-hour glucose ≤11·1 mmol/L). Offspring from these pregnancies had anthropometric measurements performed within 72 hours of birth and at age 5-7 years."
2437173|NCT03317509|Active Comparator|Real rTMS|Each patient received high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days
2437174|NCT03317509|Sham Comparator|Sham rTMS|Each patient received rTMS with the same pulse as the first group but with the coil placed perpendicular to the scalp.
2437175|NCT03317496|Experimental|Group A Cohort A1|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
2437176|NCT03317496|Experimental|Group A Cohort A2|Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
2437177|NCT03317496|Experimental|Group A Cohort A3|Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
2437178|NCT03317496|Experimental|Group A Cohort A4|Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
2437179|NCT03317470|Active Comparator|Phase I:|"In Phase 1 of the study (first five months), the investigators will enroll new patients when they call them to remind them of their first colposcopy appointment. If patients consent, the investigators also will assess their basic needs during the call. Those who screen positive for at least one unmet basic need, will be referred to the 2-1-1 helpline at their clinic visit (or this information will be sent to them if they miss their clinic visit).~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~For patients in phase 1, the follow-up survey will only assess acceptability of the basic needs survey (five questions)"
2437180|NCT03317470|Experimental|Phase 2:|"-In Phase 2 of the study (second five months), new colposcopy patients will be approached and consented in a similar fashion as in Phase 1 and asked to complete the basic needs survey. However, this time, patients who screen positive with at least one unmet basic need will be offered assistance by a life navigator (a trained case manager) who will contact the patients by phone within 2 business days of completing the survey.~The life navigator will connect patients with community resources in each area to help with their unmet basic needs.~All women enrolled in our study will be asked to complete our basic needs survey and take a follow-up survey at the time of their first colposcopy visit.~Patients enrolled in phase 2 will be asked the same five questions in addition to seven more assessing perceived effectiveness of the life navigator"
2437181|NCT03317457|Experimental|Durvalumab and Tremelimumab|"Cycles/courses 1-3:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks~Cycles/courses ≥4:~Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks"
2437182|NCT03317457|Active Comparator|Doxorubicin|Doxorubicin 75 mg/qm q3wks for 6 courses
3188550|NCT00768105|Experimental|1|
2437186|NCT03317405|Experimental|Cohort I (Z-endoxifen hydrochloride)|Participants apply Z-endoxifen hydrochloride gel to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
2437187|NCT03317405|Placebo Comparator|Cohort II (placebo)|Participants apply placebo to both breast skin and keep it untouched over at least 4 hours once daily for 21-28 days before breast surgery.
3148270|NCT00143923|No Intervention|3|No intervention for all participants who are at low Framingham risk for CVD or have preexisting CVD prior to study entry/ No active Nutrition, Exercise, Stress Management Counseling
3148271|NCT00143936|Active Comparator|Low Carb|Low Cabohydrate Diet: 20 week of weekly group behavior modification, 20 weekly bi-weekly, bi-monthly to finish
2437424|NCT03315585|Experimental|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
3148272|NCT00143936|Active Comparator|Low Calorie|Low Calorie Diet: 20 weeks of weekly behavior modification, 20 weekly of bi-weekly, bimonthly to finish 2 years
3148273|NCT00143988||Treadmill Test exertion females|
3148274|NCT00143988||Treadmill test exertion males|
3148275|NCT00143988||Sexual activity exertion females|
3148276|NCT00143988||Sexual activity exertion males|
3148277|NCT00144001||Group 1|
3148278|NCT00144014|Experimental|V10153, 1.0 mg/kg|Single acute intravenous bolus dose
3148279|NCT00144014|Experimental|V10153, 2.5 mg/kg|Single acute intravenous bolus dose
3148280|NCT00144014|Experimental|V10153, 5.0 mg/kg|Single acute intravenous bolus dose
3148281|NCT00144014|Experimental|V10153, 7.5 mg/kg|Single acute intravenous bolus dose
3148282|NCT00144014|Experimental|V10153, 10 mg/kg|Single acute intravenous bolus dose
3148283|NCT00144040|Other|Arm 1|
2437193|NCT03317353|Experimental|Vestibular rehabil.: CDP|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
2437194|NCT03317353|Experimental|Vestibular rehabil.: optokinetic stimuli|Group B. Patient has to stand in a dark room, wiht optokinetic stimuli around him/her. Ten sessions (one per day, five per week, two weeks), with progressive increase of stimulus speed (from 30º/sec the first day to 100º/sec the last), duration of session (from 5 minutes the first day to 15 minutes the last), stimulus complexity (horizontal stimuli in the first sessions, progressively adding vertical and rotating stimuli) and support surface difficulty (initially hard surface, last sessions on foam).
2437195|NCT03317353|Experimental|Vestibular rehabil.: home exercises|Group C. The patient is given a list of exercises (and explained how to do them) to stabilise eye position and improve postural control. They are to be performed twice a day for two weeks. Approximate duration of each session: 15 minutes. The exercises must be supervised by a family member to verify adherence to the programme.
2437196|NCT03317353|No Intervention|Control group|Group D. No vestibular rehabilitation is developed.
2437197|NCT03317340||Patient Undergoing Urodynamics|
2437198|NCT03317327|Experimental|Nivolumab|Nivolumab, intravenous every 2nd week (1 cycle = 2 weeks), dose escalation schedule (1.0, 3.0 mg/kg), for a maximum of 12 months or until disease progression.
2437199|NCT03317301|Experimental|Experimental|Experimental: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
2437200|NCT03317301|Active Comparator|Active comparator|Comparator: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
2437202|NCT03317275|Experimental|injection based on 18F-Fluoride-PET/MRI|One group will undergo facet injection(s) according to the 18F-Fluoride-PET/MRI result, with standard injections performed under CT-guidance. The Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
2437203|NCT03317275|Active Comparator|injection based on clinical practise|The control group will undergo facet injections blinded to the 18F-Fluoride-PET/MRI results, but based on current standard clinical practise (MRI and clinical correlation). Pain assessment by VAS immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
2437204|NCT03317249||Pregnant Healthy|Pregnant females aged between 18-45 years who do not have IST syndrome
2437205|NCT03317249||Pregnant IST|Pregnant females aged between 18-45 years who have IST syndrome
2437206|NCT03317236|Experimental|Reference - Test|A new extended release formulation containing quetiapine 50 mg (T) followed by a branded formulation (R).
2437207|NCT03317236|Experimental|Test - Reference|A branded formulation (R) followed by a new extended release formulation containing quetiapine 50 mg (T).
3148284|NCT00144417|Active Comparator|HRZE|isoniazid, rifampin, pyrazinamide, ethambutol, moxifloxacin-placebo
3148285|NCT00144417|Experimental|MRZE|moxifloxacin, rifampin, pyrazinamide, ethambutol, isoniazid-placebo
2437210|NCT03317210|Other|iron therapy with good response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. The maximum total iron dose was 1,600 mg, therefore therapy was stopped if the maximal iron sucrose dose was administered, or target Hb > 10.5 g/dL was achieved.
2437211|NCT03317210|Other|iron therapy with poor response|Patients with an Hb level between 9.0 and 9.9 g/dl received 200 mg iron sucrose intravenously twice weekly. If response to therapy with iron sucrose was poor (i.e. Hb increase <0.7 g/dl after 2 weeks), patients additionally received recombinant human erythropoietin (10,000 U EPREX®, Janssen-Cilag, Baar, Switzerland).
2437212|NCT03317210|Other|iron therapy and erythropoietin|Patients with an Hb between 8.0 and 8.9 g/dl received 200mg iron sucrose and recombinant human erythropoietin intravenously twice weekly.
2437213|NCT03317197|Placebo Comparator|Control Group|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only~Control group receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Saline solution"
2437214|NCT03317197|Active Comparator|Experimental Group 1|"Using Vasopressin [20 IU/CPR cycle] injection until the 5th cycle~Experimental Group 1 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Saline solution"
2437215|NCT03317197|Active Comparator|Experimental Group 2|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 2 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Saline solution~Syringe No. 2 : Steroid"
3148286|NCT00144456|Experimental|1|
3148287|NCT00144456|Active Comparator|2|
3148288|NCT00144482|Experimental|1|
3148289|NCT00144482|Placebo Comparator|2|
3148290|NCT00144495|Experimental|1|patient whose ΔHb is less than 1.0g/dL on the day of 7th administration
3148291|NCT00144495|Experimental|2|patient whose ΔHb is 1.0g/dL or above on the day of 7th administration
3148292|NCT00144508|Experimental|1|
3148293|NCT00144508|Other|2|continue current treatment
3148294|NCT00144521|Experimental|1|
3148295|NCT00144521|Active Comparator|2|
3148296|NCT00144534|Experimental|1|
3148297|NCT00144547|Experimental|1|
3148298|NCT00144586|Experimental|1|
3148299|NCT00144599|Experimental|1|
2437216|NCT03317197|Experimental|Experimental Group 3|"Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)~Experimental Group 3 receives intravenous injection of 1 mg epinephrine every cycle (about 3 minutes) during CPR and uses syringe No. 1, 5 times (every 3 minutes), and syringe No. 2, one time (in the first cycle). After each injection, inject 10 mL saline solution additionally.~Syringe No. 1 : Vasopressin~Syringe No. 2 : Steroid"
2437217|NCT03317184|Experimental|Periumbilical incisions|
2437218|NCT03317184|Experimental|Pfannenstiel incision|
2437219|NCT03317171|Experimental|Treated group|oral administration of flavonoids, DHA and EPA, once a day for 24 weeks.
2437220|NCT03317171|Placebo Comparator|Placebo group|oral administration of placebo compound, once a day for 24 weeks.
2437221|NCT03317158|Experimental|Phase 1: (cohort 1):|Durvalumab monotherapy (cohort 1)
2437222|NCT03317158|Experimental|Phase 1: (cohort 2a) & (cohort 2b):|"(cohort 2a) - Durvalumab plus BCG~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)"
2437223|NCT03317158|Experimental|Phase 2: (cohort 2a), (cohort 2b), & (BCG re-treatment)|"(cohort 2a) - Durvalumab plus BCG~(cohort 2b) - Durvalumab plus External Beam Radiotherapy (EBRT)~(BCG re-treatment) - Cross-over to Durvalumab Monotherapy"
2437224|NCT03317145|Active Comparator|Arm A (NMES followed by IPC)|Arm A (NMES followed by IPC). Following baseline blood flow measurements using ultrasound, the neuromuscular electrostimulation (NMES) device will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The NMES device will be removed. After a 30 minute rest period, the intermittent pneumatic compression (IPC) device will be fitted, activated for 10 minutes and then blood flow measurements repeated.
2437225|NCT03317145|Active Comparator|Arm B (IPC followed by NMES)|Arm B (IPC followed by NMES). Following baseline blood flow measurements using ultrasound, the intermittent pneumatic compression device (IPC) will be fitted and allowed to operate for 10 minutes. Blood flow measurements will then be repeated. The IPC device will be removed. After a 30 minute rest period, the neuromuscular electrostimulation (NMES) device will then be fitted, activated for 10 minutes and then blood flow measurements repeated
2437226|NCT03317132|Experimental|Individual Placement and Support|One year of IPS Support
2437227|NCT03317132|No Intervention|Treatment as usual|Treatment as usual
2437228|NCT03317119|Experimental|Treatment (TAS-102, trametinib)|Patients receive trifluridine and tipiracil hydrochloride PO BID on days 1-5 and 8-12 and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2437229|NCT03317080||patients with lung cancer|patients with stages I-IV lung cancer eligible for surgery
2437230|NCT03317067|Experimental|dexmedetomidine|Patients in the Dexmedetomidine (interventional) group will be treated with a continuous infusion of dexmedetomidine in case of agitated delirium.
2437231|NCT03317067|Placebo Comparator|Normal Saline (NaCl 0.9%)|Patients in the Normal Saline (control) group will be treated with a continuous infusion of normal saline in case of agitated delirium.
2437232|NCT03317041|Experimental|Tecar treatment group|The capacitive-resistive electric transfer (Tecar) therapy treatment group will receive 45 minutes of Tecar therapy treatment.
2437233|NCT03317041|No Intervention|Control group|Participants will test passively in a sitting position for 30-min period
2437234|NCT03317028|Experimental|high dose of CS02|Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.
2437235|NCT03317028|Experimental|middle dose of CS02|Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.
2437236|NCT03317028|Experimental|low dose of CS02|Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.
2437237|NCT03317028|Placebo Comparator|placebo control|Subjects will receive placebo combined with a stable dose of metformin monotherapy.
2437238|NCT03317015|Experimental|Group A - Nasacort®|Nasacort® will be sprayed twice in each nostril once every morning
2437239|NCT03317015|Active Comparator|Group B - Flixonase®|Flixonase® will be sprayed twice in each nostril once every morning
3188551|NCT00768105|Placebo Comparator|2|
3188552|NCT00768131|Experimental|A1 FISH (+)|
3188553|NCT00768131|Active Comparator|B1 FISH (+)|
2437243|NCT03316989||obese children|Children and adolescents with BMI according to the CDC greater that 95%ile
2437244|NCT03316989||normal weight|Children and adolescents with BMI according to the CDC less than the 85%ile
2437245|NCT03316989||obese with the MetS|obese children with metabolic syndrome compared to obese children with out the MetS and normal weight children
3188554|NCT00768131|Experimental|A2 FISH (-)|
3188555|NCT00768131|Active Comparator|B2 FISH (-)|
2437248|NCT03316963|Experimental|Drug-induced sleep endoscopy (DISE) with Neostigmine|Artificial sleep will be induced by intravenous administration of propofol with micro boluses until clinical sleep is achieved with spontaneous respiration and observed apneas under monitored anesthesia care. Endoscopy will be performed with visualization on a monitor and recording on a digital recorder. After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate.
2437249|NCT03316950|Experimental|IntraGen RF|Patients will undergo treatment with radiofrequency device, using the device's standard protocol. Patients will have 3 treatments space one month apart. Each treatment will be a total of 20 minutes for internal treatment only. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2437250|NCT03316950|Sham Comparator|IntraGen Sham|Patients will undergo all acts of receiving radiofrequency treatment, but no direct energy will be applied. Patients will have 3 sham treatments space one month apart. Each treatment session will be a total of 20 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2438263|NCT03310177||healthy control|The healthy controls without chronic obstructive pulmonary disease
3188556|NCT00768157|Experimental|antiviral group|Drug: antiviral treatment(lamivudine or entecavir) after the Procedure/Surgery (radical resection of HBV-related HCC)
2437251|NCT03316950|Experimental|DiVA|Patients randomized into the DiVA treatment group will receive treatment per DiVA protocol. Patients will have a total of 3 treatments, space 1 month apart. Each treatment will last approximately 10 minutes. Prior to treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2437252|NCT03316950|Sham Comparator|DiVA Sham|Patients randomized into the DiVA sham group will undergo all acts of receiving DiVA treatment, but not direct energy will be applied. Patients will have a total of 3 treatments, spaced 1 month apart. Each treatment will last approximately 10 minutes. Prior to sham treatment, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken 3 months after final treatment.
2437253|NCT03316950|Experimental|Dual Treatment|Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
2437254|NCT03316937|Experimental|Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
2437255|NCT03316937|Experimental|Non Teflon Scaler|The buccal and lingual surface of the 23 participants' crowns will be randomly assigned to receive scaling and root planing with either Teflon scalers, or non-Teflon scalers after implant crown delivery. Each patient will act as their own control.
2437258|NCT03316898|Placebo Comparator|Placebo|Two placebo capsules once daily for 28 Days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2437259|NCT03316898|Experimental|AGN-242071 5 mg|One AGN-242071 5 mg capsule plus one placebo capsule once daily for 28 days. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2437260|NCT03316898|Experimental|AGN-242071 15 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-242071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2437261|NCT03316898|Experimental|AGN-242071 25 mg|AGN-242071 starting at a dose of one 5 mg capsule plus one placebo capsule once daily for 5 days followed by AGN-24071 15 mg total dose (one 5 mg and one 10 mg capsules) once daily on Days 6 to 10 followed by AGN-242071 25 mg total dose (one 5 mg and one 20 mg capsules) on Days 11 to 28. Dose can be adjusted based on safety and tolerability. All participants are on a stable dose of 10 mg donepezil and, if receiving memantine, also on a stable dose of memantine as prescribed by the physician as per standard of care.
2437262|NCT03316885|Experimental|Clareon IOL|Clareon® aspheric hydrophobic acrylic intraocular lens implanted as a replacement of the human crystalline lens during cataract surgery
3148300|NCT00144599|Placebo Comparator|2|
2437264|NCT03316859|Experimental|Naloxegol|naloxegol 25 mg pill
2437265|NCT03316859|Placebo Comparator|Placebo|placebo pill
2437266|NCT03316846|Experimental|Internet-delivered therapy|10 week, guided and individually tailored internet-delivered cognitive behavioral therapy.
2437267|NCT03316846|No Intervention|Wait list control group|Wait list control group, receives treatment at later point.
2437268|NCT03316820|Experimental|Treatment A|K0706 tablet
2437269|NCT03316820|Experimental|Treatment B|K0706 tablet
2437270|NCT03316820|Experimental|Treatment C|K0706 tablet
2437271|NCT03316820|Experimental|Treatment D|K0706 capsule
2437274|NCT03316794|Experimental|SC-005|SC-005 intravenous (IV) (various doses and dose regimens)
2437275|NCT03316781|Experimental|HLX03 group|
2437276|NCT03316781|Active Comparator|adalimumab group|
2437277|NCT03316755|No Intervention|without pamphlet|a group not exposed to pamphlet
2437278|NCT03316755|Experimental|With pamphlets|a group exposed to pamphlet
2437279|NCT03316742|Experimental|Intervention 1|Participants randomized to intervention 1 will complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant will attend twelve one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
2437499|NCT03315273|Active Comparator|Control|"Healthy volunteers matched for age, sex and educational level will be assessed with the same test battery including~a motor imagery ability questionnaire (MIQ-RS)~a mental rotation test~a chronometry test (TDMI)"
3148301|NCT00144612|Experimental|1|
3148302|NCT00144625|Experimental|1|
3148303|NCT00144651|Experimental|1|
3148304|NCT00144664|Experimental|1|MRA(Tocilizumab)
3148305|NCT00144755|Active Comparator|R-CHOP21|8 cycles of R-CHOP21
3148306|NCT00144755|Experimental|R-CHOP21, Darbepoetin alfa|8 cycles of R-CHOP21 + prophylactic darbepoetin alfa
3148307|NCT00144755|Experimental|R-CHOP14|8 cycles of R-CHOP14
3148308|NCT00144755|Experimental|R-CHOP14, Darbepoetin alfa|8 cycles of R-CHOP14 + prophylactic darbepoetin alfa
3148309|NCT00144807|Experimental|R-AC|rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation
3148310|NCT00144846|Other|Arm 1|
3148311|NCT00144872|Experimental|Subjects receiving lamotrigine|Eligible subjects will receive chewable dispersible tablets of lamotrigine with a starting dose of 0.3 milligrams per kilogram administered orally.
3148312|NCT00144885|No Intervention|1|
3148313|NCT00144898|Experimental|Sentinel Node Resection|Sentinel Node Resection
3148314|NCT00144898|Other|Conventional Axillary Dissection|Conventional Axillary Dissection
3148315|NCT00144911|Experimental|Arm 1|
3148316|NCT00144989|Active Comparator|1|Etoposide and cisplatin after chemoradiotherapy
3148317|NCT00144989|Experimental|2|Irinotecan and cisplatin after chemoradiotherapy
2437280|NCT03316742|Experimental|Intervention 2|Participants randomized to intervention 2 will complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant will attend 12 one hour classes discussing weight loss adherence in addition to barriers experienced. Changes in weight will be recorded throughout the study.
2437281|NCT03316729|Experimental|DS-9231|In conjunction with standard of care, participants will receive an intravenous infusion delivering DS-9231 at ascending dose levels in Cohort 1, 2, and 3
2437282|NCT03316729|Placebo Comparator|Placebo|In conjunction with standard of care, participants will receive an intravenous infusion delivering only saline solution as matching placebo comparator
2437283|NCT03316716|No Intervention|Control Group|Women randomised to the control group will receive the hospital's current standard of care which is the peri-operative administration of room-temperature (25°C) IV fluids (Hartman's solution) started before the insertion of regional anaesthesia and continued until the transfer of the woman to the postnatal ward.
2437284|NCT03316716|Experimental|active warming group|Women randomised in the intervention group will recieve warm IV fluids. The IV fluids (Hartman's solution) will be warmed to 39°C with the use of Hotline™ device.
2437285|NCT03316703|Active Comparator|Conventional open surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the conventional open to implant placement without subsequent arthrodesis.
2437286|NCT03316703|Experimental|Minimally invasive percutaneous surgery|Fixation of a proximal vertebra, a vertebra distal to the fractured vertebra, and also of the fractured vertebra with a pedicle fixation system using the percutaneous minimally invasive approach to implant placement without subsequent arthrodesis.
2437287|NCT03316690|Experimental|Metformin treatment|
2437288|NCT03316690|Placebo Comparator|Placebo treatment|
2437289|NCT03316677|Other|colorectal resection and anastamosis|"Intraoperative testing of colorectal anastomoses~Insert a Foley catheter through the anus into the rectum.~Insufflate the Foley balloon with 5 cc of air.~fill the pelvic space with 500 CC of warm saline~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~Remove the saline from the pelvic space.~Inject methylene blue in to the rectum up to a pressure of 35 mmH2o measured by external manometer~Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
2437290|NCT03316664|Experimental|INT|Integrated Neurocognitive Therapy (INT) is a manualized psychological intervention that consists of 30 sessions administered by a therapist and a co-therapist in an open group of 6-8 patients. Sessions will take place twice a week, and each session should last 90 min.
2437291|NCT03316664|Active Comparator|IPT|Integrated Psychological Therapy (IPT) is a manualized psychological intervention that consists of 5 modules which can be completed in a variable number of sessions that will be administered by a therapist and a co-therapist in an open group of 6- 8 patients. Sessions will take place twice a week, and each session should last 60 to 90 min.
2437292|NCT03316664|Other|CoC|COGPACK is a computer-based neuropsychological cognitive training program. It will be administered by a trainer in an open group of 6- 8 patients. Sessions will take place twice a week, and each session will last 45 - 60 minutes.
2437293|NCT03316651|Experimental|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
2437294|NCT03316638|Experimental|W0101 - Cohort A1|This is a 14 days treatment cycle cohort in a 2 weeks schedule
2437295|NCT03316638|Experimental|W0101 - Cohort A2|This is a 21 days treatment cycle cohort in a 3 weeks schedule
2437296|NCT03316638|Experimental|W0101 - Expansion Phase|Will be initiated after completion of cohorts A1 and A2
2437297|NCT03316625|Experimental|Bone mineral density|Bone densitometry measurement : Measurement of bone mineral densitometry with bone densitometry
2437298|NCT03316612|Experimental|Intervention group|"Ingredients: Vaccinium Myrtillus L. extracts, and excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet, 650mg per tablet with 150mg Vaccinium Myrtillus L. extracts, twice a day, 2 tablets each time.~The intervention period is about 3 months."
2437299|NCT03316612|Placebo Comparator|Placebo group|"Ingredients: excipients (cellulose microcrystalline, mannitol, silica, magnesium stearate, coating agent)~Brown oval tablet without Vaccinium Myrtillus L. extracts, 650mg per tablet, twice a day, 2 tablets each time.~The intervention period is about 3 months."
2437300|NCT03316599|Experimental|Ficlatuzumab + Gemcitabine and Nab-Paclitaxel|"Ficlatuzumab will be administered intravenously days 1 and 15 of a 28 day cycle~Gemcitabine 1000 mg/m2 and Nab-Paclitaxel 125mg/m2 will be administered IV days 1, 8, and 15 of a 28 day cycle.~Dosage of Ficlatuzumab is determined by dose level to which the patient is assigned at time of enrollment."
2437302|NCT03316573|Experimental|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks for 35 cycles
2437303|NCT03316560|Experimental|Group 1: Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 1 of rAAV2tYF-GRK1-RPGR study drug.
2437304|NCT03316560|Experimental|Group 2: Phase 1/2 Dose Escalation and Low Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug.~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 2 of rAAV2tYF-GRK1-RPGR study drug. This will be the low dose group for the phase 2 expansion."
2437305|NCT03316560|Experimental|Group 3 and Group 4 Phase 1/2 Dose Escalation|Group 3 male subjects at least 18 y/o and Group 4 male subjects at least 6 y/o treated with Dose 3 of rAAV2tYF-GRK1-RPGR study drug.
3148318|NCT00145184|Placebo Comparator|Placebo|Placebo
3148319|NCT00145184|Experimental|Multivitamins|Multivitamin supplement containing the following vitamins: B1, B2, Niacin, B6, Folate, B12, C, and E
2437306|NCT03316560|Experimental|Group 5 Phase 1/2 Dose Escalation and High Dose Group Phase 2 Dose Expansion|"Phase 1/2 Dose Escalation: male subjects at least 18 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug.~Phase 2 Dose Expansion: male subjects at least 8 y/o treated with Dose 5 of rAAV2tYF-GRK1-RPGR study drug. This will be the high dose group for the phase 2 expansion."
2437307|NCT03316560|Experimental|Group 6 Phase 1/2 Dose Escalation|Male subjects at least 18 y/o treated with Dose 6 of rAAV2tYF-GRK1-RPGR study drug.
2437310|NCT03316534|Placebo Comparator|Placebo|Placebo
2437311|NCT03316534|Active Comparator|Aspirin|Aspirin (100 mg/daily)
2437312|NCT03316521|Experimental|Single Ascending Dose (SAD)|"In the SAD arm subjects will be sequentially included in one of up to six cohorts (dose levels). All cohorts will include at least four subjects each. Additional subjects may be added in any cohort if necessary.~AMY-101 will be administered as a SQ or IV injection. Subjects in each cohort will be dosed sequentially, to allow for close safety monitoring. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee. Subsequent dose levels will be administered until either the maximum tolerated dose (MTD) or the study maximum dose (SMD) is reached based on specified dose escalation criteria."
2437313|NCT03316521|Experimental|Multiple Dose (MD)|Depending on the results of the SAD, multiple doses of AMY-101 will be administered at the dose which has been identified as the dose which saturates target C3, for a duration that results to an exposure level equivalent to the maximum exposure achieved in the SAD. The dose and dosing interval will be determined based on the PK data obtained in the SAD part of the study. Each MD cohort will include at least four subjects and may be expanded with additional subjects if necessary. Between each cohort, safety data will be analyzed, evaluated and reviewed by the internal Safety Review Committee.
2437314|NCT03316495|No Intervention|without pamphlet|NOT EXPOSED TO PAMPHLETS
2437315|NCT03316495|Experimental|with pamphlet|EXPOSED TO PAMPHLETS
2437316|NCT03316482|Experimental|Leuplin DPS 11.25mg s.c. every 12 weeks|Open
2437317|NCT03316469|Experimental|Group A: CC & ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
2437318|NCT03316469|Experimental|Group B: CC & no ovulation|AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels.
2437319|NCT03316456||AL Patients Undergoing Induction Chemotherapy|Adults undergoing inpatient induction chemotherapy for newly diagnosed/relapsed acute leukemia.
2437320|NCT03316443|Active Comparator|(Group G)|Glidescope group: 45 patients will be intubated by Glidescope (Group G). For endotracheal intubation with glidoscope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
2437321|NCT03316443|Experimental|(Group M)|Macintosh group: 45 patients will be intubated by Macintosh laryngoscope (Group M).The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first, the laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced
2437322|NCT03316430||Patients|Patients coming before 16 weeks of gestation at their first planned prenatal visit at the Hôpital Femme Mère Enfant, who planned to deliver at the Hôpital Femme Mère Enfant
2437323|NCT03316417||Patients under immunotherapy|All patients with Immune Checkpoints inhibitors treatment (Nivolumab, Pembrolizumab, ipilimumab, Atezolizumab), for dermatologic, pneumologic, or oncologic cancer treated on Centre Hospitalier Lyon Sud are included.
2437324|NCT03316404||Cohort 1|Cohort 1 of the study will collect blood samples from participants in various states of the disease. After qualification and informed consent, accepted participants will be sent a blood collection kit and will be asked to complete a study-related questionnaire.
2437325|NCT03316404||Cohort 2|Cohort 2 may be conducted at selected clinical sites where MS treatment-naïve patients who are entering a new treatment paradigm will be sought. At the clinical site, patients will be qualified, consented, and a small amount (up to 1mL) of blood will be collected. Between approximately 1 week and 6 months of treatment on the new drug, the participant will be sent another blood collection kit for microsample collection and a brief questionnaire at home. A final sample will be collected between 3 and 6 months after the start of treatment. Within 6 months of initiating treatment, the site will be asked to provide information regarding the health and treatment status of the participant.
2437326|NCT03316391||Pre-eclampsia|Patients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
2437329|NCT03316365|Experimental|Continuous RAS|The experimental group (continuous treatment) trained daily with RAS for 24 weeks.
2437330|NCT03316365|Active Comparator|Intermittent RAS|The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks.
3148320|NCT00145197|Experimental|Improving the Delivery of Effective Care to Minorities|
2437541|NCT03314974|Experimental|TBI Regimen|
2437542|NCT03314974|Experimental|Non-TBI Regimen|
3148321|NCT00145314|Active Comparator|A|FLOX: 5-fluorouracil/folinic acid/oxaliplatin; Nordic Regimen; given continuosly
3148322|NCT00145314|Experimental|B|FLOX: 5-fluorouracil/folinic acid/oxaliplatin and cetuximab
3148323|NCT00145314|Experimental|C|FLOX given intermittently and maintenance cetuximab
3148324|NCT00145379|Experimental|Metformin|
3148325|NCT00145379|Placebo Comparator|Placebo comparator|
3148326|NCT00145522|Experimental|1|
3148327|NCT00145522|Active Comparator|2|
3148328|NCT00145535|Experimental|1|Titanium sapphire laser treatment
3148329|NCT00145535|Active Comparator|2|Argon laser treatment
3148330|NCT00145613|Other|1|
3148331|NCT00145639|Other|1|
2437331|NCT03316352|Experimental|Ultrasound-assisted|Ultrasound-assisted paramedian technique spinal anesthesia will be performed. A Preprocedural ultrasound scan will be performed for skin marking of entry site of spinal needle. Spinal anesthesia will be performed via paramedian approach using the skin marking site as entry point. 0.5% heavy bupivacaine will be administered into intrathecal space.
2437332|NCT03316352|Active Comparator|Landmark-guided|In these patients, spinal anesthesia will be performed via paramedian approach using conventional landmark palpation technique. Landmark-guided paramedian technique spinal anesthesia will be performed. 0.5% heavy bupivacaine will be administered into intrathecal space.
2437333|NCT03316339|Experimental|Dexmedetomidine|
2437334|NCT03316339|Active Comparator|Control|
2437335|NCT03316326|Experimental|SIROX|Tegafur-gimeracil-oteracil potassium, irinotecan, oxaliplatin combination
2437336|NCT03316313||Date of birth|Those people born within the years 1945-1965
2437337|NCT03316300|Experimental|NT-501|
2437338|NCT03316300|Sham Comparator|Sham|
2437339|NCT03316287|Experimental|Hearing aid + mobile phone|
2437340|NCT03316287|Experimental|Hearing aid + mobile phone + biosensor|
3148332|NCT00145678|Experimental|dynamic deconstructive psychotherapy|weekly individual psychotherapy of 50 minute duration lasting 12-18 months
3148333|NCT00145678|Active Comparator|optimized community care|eclectic weekly individual and group psychotherapy, as well as drug and alcohol rehabilitation
2437343|NCT03316248|Experimental|visual feedback|participants in the experimental group were applied usual prosthetic rehabilitation with visual feedback methods. 9 sessions for three days were applied.
2437344|NCT03316248|Active Comparator|Usual prosthetic rehabilitation|participants in the control group were applied usual prosthetic rehabilitation. 9 sessions for three days were applied.
2437345|NCT03316222|Experimental|Dose escalation|Dose escalation using 3+3 design with dose limiting toxicity (DLT) observation period of 28 days.
2437346|NCT03316222|Experimental|Dose Expansion|Additional patients will be enrolled into the recommended dose. These additional patients will undergo all of the same assessments as the patients enrolled in dose escalation with the exception of PK sampling.
2437347|NCT03316196|Experimental|COGENT|Participants will be Veterans assigned to the active cognitive training (see below for details).
2437348|NCT03316196|Sham Comparator|Non-Training|Participants will be Veterans assigned to a non-training cognitive program matched for time and memory demands (see below for details).
2437349|NCT03316183|Experimental|Intervention Group|"Maintain rSO2 values at or above 75% of the baseline~Midline position~Target CO2 of ≥40 mmHg, target MAP >60 mm Hg~Maintain cerebral perfusion pressure >50 mm Hg~Target pump flow 2.5 L/m2/min~If rSO2 persistently below treatment threshold:~FiO2 is increased~or propofol 50-100 mg bolus is administered~If Hct below 20% packed red blood cells will be transfused~timeline: before induction, after time-out has been performed, and will continue until 24 hours post surgery."
2437350|NCT03316183|No Intervention|Control Group|Patients in the control group will be managed under the attending physician's discretion. Cerebral oximetry data will be collected in the same fashion as in the intervention group, but the measurements will be blinded to the physician. Blood samples will be collected for metabolomic profiling in the same fashion and at identical time points as the intervention group for later analysis.
2437353|NCT03316157|Experimental|Rehabilitation|Advanced cancer patients will receive an 8 week rehabilitation intervention consisting of physical exercise and nutritional supplementation, along with standard care
2437354|NCT03316157|No Intervention|Waiting list Control|Standard care alone for the 8 week trial period, followed by participants being offered the rehabilitation programme
2437355|NCT03316144|Experimental|1 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2437356|NCT03316144|Experimental|3 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2437357|NCT03316144|Experimental|10 mg/kg Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 10mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2437360|NCT03316118|Active Comparator|Group 1|Patient will receive genicular nerve block with bupivacaine
2437361|NCT03316118|Placebo Comparator|Group 2|Patient will receive normal saline as the nerve block
3148334|NCT00145743|Experimental|1|Patient's reported questionaire, profile in 10 dimensions (EORTC) and referees' report with treatment recommendations
3148335|NCT00145743|Experimental|2|Patient's reported questionaire; no recommendations given
3148336|NCT00145769|Active Comparator|Short Course Radiotherapy|Short Course (SC) pre-operative radiotherapy, followed by surgery and adjuvant chemotherapy
3148337|NCT00145769|Active Comparator|Long Course Radiotherapy|Long Course (LC) radiotherapy delivered with concurrent chemotherapy, followed by surgery and adjuvant chemotherapy
3148338|NCT00145769|Active Comparator|Surgery|Patients will receive initial surgery followed by post-operative management according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Adjuvant therapy for rectal cancer.
3148339|NCT00145847|Active Comparator|Naltrexone|Naltrexone 50 mg per day, directly administered as 100 mg on Mondays, 100 mg on Wednesdays and 150 mg on Fridays
3148340|NCT00145847|Placebo Comparator|Lactose pill|
3148341|NCT00145886|Experimental|rhPTH|Subjects will be treated rhPTH for 12 months
3148342|NCT00145912|Experimental|Intrinsic Motivation|PCP motivational interview + Internet program
3148343|NCT00145912|Active Comparator|Extrinsic Motivation|PCP breif advice + Internet Program
3148344|NCT00145925|Placebo Comparator|Blood pressure|Perindopril indapamide vs placebo
3148345|NCT00145925|Other|Glucose control|Standard versus intensive glucose control
3148346|NCT00145951||1|
3148347|NCT00145951||2|
3148348|NCT00145951||3|
3148349|NCT00146081|Experimental|A|Family Program: Participants who have identified at least 1 family member or friend to enroll in SHARE with them, who are randomly assigned to program A, are invited to bring their enrolled family member or friend (co-participant) with them to the study intervention group sessions as their supportive team member.
2437364|NCT03316079|Active Comparator|Chest physiotherapy techniques|Manual chest physiotherapy techniques applied
2437365|NCT03316079|Experimental|Chest physiotherapy techniques + Mechanical in-exsufflation|Mechanical insufflation-exsufflation in addition to manual chest physiotherapy techniques
2437366|NCT03316066|Experimental|Group 5|stellate ganglion block with ropivacaine 0.2% 5 mL
2437367|NCT03316066|Active Comparator|Group 2|stellate ganglion block wit ropivacaine 0.2% 2 mL
2437368|NCT03316053||Tissue Sample for genetic testing|Biopsy sample
2437369|NCT03316040|No Intervention|Control 1|This arm represent control schools. No JIC will be implemented.
2437370|NCT03316040|Experimental|Treatment 1|This arm implements the JIC among a random subset of students within the pre-defined grade.
2437371|NCT03316040|Experimental|Treatment 2|This arm implements the JIC among indegree central students within the pre-defined grade.
2437372|NCT03316040|Experimental|Treatment 3|This arm implements the JIC among edge betweeness central students within the pre-defined grade.
2437373|NCT03316014||Adverse drug reaction|Children from 0 to 17 years inclusive with ADR notifications recorded in the French pharmaco-vigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014
2437374|NCT03316001||cases|patients with a CT scan from January to August 2008 for which mesenteric panniculitis was diagnosed
2437375|NCT03316001||controls|"patients with a CT scan from January to August 2008 for which mesenteric panniculitis wasn't diagnosed and matched by gender and age with cases patients"
2437376|NCT03315988|Experimental|Vegan diet|"Intervention Description and Definition The participants will be asked to follow a diet that excludes foods hypothesised to support the syntheses of TMAO, particularly meat (any), eggs and fish (any). A number of studies suggest that dairy products may also have an effect in modulating TMAO production whereas other studies do not. Therefore, in order to avoid any potential contaminating or confounding effect, dairy products will also be avoided.~The diet employed in this study is broadly aligned to a vegan diet. The term vegan will be used to aid behaviour change and food choice. For example, an increasing array of products are now pack marked as vegan. The participants will be asked to keep their diet similar to their original and the Registered Dietitian involved in this study will plan their weekly menus accordingly."
2437377|NCT03315975|Experimental|Influenza vaccination cohort|Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.
2437378|NCT03315962|Experimental|Aim 1: DHO Intervention Arm|A selection of DHO or TB district supervisors that are randomized to the multicomponent SPIRIT intervention.
2437379|NCT03315962|No Intervention|Aim 1: DHO Control Arm|A selection of DHO or TB district supervisors that are randomized to the country standard of care, but not to receive the study intervention.
2437382|NCT03315936|Experimental|Single rising dose part|
2437383|NCT03315936|Experimental|Relative bioavailability (rel BA) part|
2437384|NCT03315923|Experimental|Rituximab|Patients in this group will receive 1g of rituximab in 500 cc normal saline serum through intravenous infusion as one treatment course. The treatment course will be repeated in 6 months. Along with rituximab, 100 mg methylprednisolone, 10 mg chlorpheniramine, and 500 mg acetaminophen will also be injected to decrease side effects of rituximab.
2437385|NCT03315923|Experimental|Glatiramer acetate|Patients in this group will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection.
3148350|NCT00146081|Active Comparator|B|Coach Program: Participants who identify 1 or 2 family members or friends to enroll in SHARE with them, who are randomly assigned to program B, are invited to attend the study intervention group sessions without their enrolled family or friend (co-participants). The co-participants receive the same written materials, but act as supportive team members outside of the group sessions only. They are invited to attend special field workshops and personal counseling sessions with their co-participants.
3148351|NCT00146081|Experimental|C|Team Program: Participants who do not identify 1 or 2 family or friend co-participants, and are randomly assigned to program C, are paired with other unrelated enrollees in their group sessions as supportive team members.
2437422|NCT03315611|Experimental|AD, sensitized, not treated|Allergen challenge chamber
2437423|NCT03315598|Experimental|An open-labeled, single-arm, exploratory pilot study|Electroacupunture for 2months
3148352|NCT00146081|Active Comparator|D|Individual Program: Participants who do not identify 1 or 2 family members or friends to enroll in SHARE with them, and are randomly assigned to program D, attend group sessions as individuals.
3148353|NCT00146107|No Intervention|1|
3148354|NCT00146107|Experimental|2|Weight loss
3148355|NCT00146107|Experimental|3|Exercise
3148356|NCT00146107|Experimental|4|Weight loss and exercise
3148357|NCT00146159|Experimental|1|1st group: 12 mg Mitoxantrone/m²
3148358|NCT00146159|Experimental|2|2nd group: 9mg Mitoxantrone/m²
3148359|NCT00146159|Experimental|3|3rd group: 5mg Mitoxantrone/m²
3148360|NCT00146224|Active Comparator|Epoetin alfa RB|
3148361|NCT00146224|Experimental|Epoetin alfa DT|
3148362|NCT00146250|Experimental|Nitrous oxide|Nitrous oxide 70% as balance gas in inspired mixture
3148363|NCT00146250|Experimental|Nitrogen|Nitrogen instead of nitrous oxide 70% as balance gas in inspired mixture
3148364|NCT00146263|Active Comparator|Savyon|Computerized cognitive training using the Savyon software
3148365|NCT00146263|Placebo Comparator|Control|Usual activity
3148366|NCT00146315|Active Comparator|Control|Secondary prevention program for coronary heart disease
3148367|NCT00146315|Experimental|Supervised exercise|
3148368|NCT00146471|Active Comparator|2|
3148369|NCT00146471|Placebo Comparator|1: Diazepam plus Placebo|
3148370|NCT00146523|Experimental|mifepristone 600 mg|
3148371|NCT00146523|Placebo Comparator|matching placebo|
3148372|NCT00146575|Experimental|1|randomized patients get sirolimus stent
3148373|NCT00146575|Experimental|2|randomized patients get paclitaxel stent
3148374|NCT00146653||Xa|An additional 20 patients will be enrolled to address the validation of heparin concentrations calculated by the Hepcon machine with laboratory-measured heparin concentrations. These patients will not be randomized and therefore will not receive an intervention. .
3148375|NCT00146679|Placebo Comparator|Usual Care (UC)|Usual Care provided by providers
2437390|NCT03315897|Active Comparator|Erythropoietin|12 intravenous infusions of recombinant human erythropoietin (EPO)
2437391|NCT03315897|Placebo Comparator|Saline|12 intravenous infusions of saline (1 ml NaCl)
2437392|NCT03315884|Experimental|Iliac segment recanalization and stenting Iliac segment CFA|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)
2437393|NCT03315884|Active Comparator|Iliac segment recanalization, stenting and plastic CFA patch|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch
3148376|NCT00146679|Active Comparator|Psychoeducational Telephone CounselingTC|Education and Counseling for ICD patients provided through Telephone Contact
3148377|NCT00146679|Active Comparator|Psychoeducation through Groups (SG)|Education and Counseling for ICD patients provided in a group setting with other ICD Patients
3148378|NCT00146835||Cohort A|The primary study cohort includes all infants from SCKP who have begun their primary course of vaccine with PEDIARIX co-administered with Prevnar and for whom at least one dose of PEDIARIX was administered prior to the infant's 9-month birthday and safety follow-up information is available.
3148379|NCT00146835||Cohort B|This Historical cohort includes age-, gender- and area-matched infants who received at least one dose of DTaP vaccine co-administered with 7Pn between 1 January 2002 and 29 April 2003.
3148380|NCT00146835||Cohort C|"This delayed Pediarix use clinics cohort includes all infants who, during the enrollment period for Cohort A, begin their primary course of vaccination with a DTaP vaccine co-administered with 7Pn. It is age-, gender-, and area-matched in a similar manner to Cohort B."
2437399|NCT03315819|Experimental|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique. The procedure must be performed within 15 days of dislocation.
2437400|NCT03315819|Active Comparator|Immobilization interne rotation|Immobilization of the shoulder during 3 weeks
2437401|NCT03315806|Active Comparator|Beetroot Juice|Beetroot juice containing 9 mmol of nitrate per dose
2437402|NCT03315806|Placebo Comparator|Placebo juice (nitrate depleted)|Beetroot juice nitrate-depleted
2437407|NCT03315767|Other|cirrhosis patients|"ARFI-elastography and portal vein flow measurement: Liver and spleen of patients with a scheduled HVPG-investigation will be examined by an ARFI-elastography-investigation. Additionally the portal vein flow will be assessed.~This examination will be done at d0 before the start of beta-blocker-administration and repeated as monitoring for portal hypertension treated by beta-blocker after 6 and 12 weeks, respectively.~HVPG-measurement: HVPG-values will be assessed at d0, after 6 and after 12 Weeks, respectively."
2437408|NCT03315754|Experimental|TOOKAD Soluble 4 mg/kg|TOOKAD® Soluble VTP treatment consist of the combination of a single, 10-minute IV infusion of TOOKAD® Soluble at the dose of 4 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
2437409|NCT03315741|Experimental|Patient centered approach|Drug titration of maximum dose over 3-8 weeks
2437410|NCT03315728||Quality Improvement Strategy|First Nations communities partners are a diverse group of Indigenous communities reflecting wide variation in contextual factors: healthcare delivery and funding models; population size; remoteness; governance structures; and access to primary, secondary and tertiary care. Four diverse communities will partner in the program (two in Ontario and two in Atlantic Canada). All four communities will undertake an 18- month Quality Improvement Strategy intervention where they develop community-driven and culturally-relevant initiatives to improve diabetes care and management in their community
2437414|NCT03315676|Active Comparator|Oral Bonoprazan|Daily intake of Bonoprazan
2437415|NCT03315676|Active Comparator|Oral Esomeprazol|Daily intake of Esomeprazol
2437416|NCT03315663|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
2437417|NCT03315663|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
2437418|NCT03315637|Experimental|Fetoscopic repair of spina bifida|This is a single arm study, all patients will receive a fetoscopic repair of the spina bifida
2437419|NCT03315624|Other|Hemodiafiltration HDF|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration sessions with the dialyzer FX CORAL 600 (TD 16-1), the dialyzer FX CorDiax 600 or the dialyzer FX 600. In each week the patient is assigned to one type of dialyzer.
2437420|NCT03315611|Active Comparator|AD, sensitized, treated|Allergen challenge chamber and Treatment for 12 day with 'Eucerin AtopiControl Lotion' (for the body) and 'Eucerin AtopiControl facial cream' (for the face): 1,2 g twice daily.
2437421|NCT03315611|Experimental|AD, not sensitized, not treated|Allergen challenge chamber
3148381|NCT00146900|Experimental|Prolonged Exposure (CBT)|Twelve 1.5 hours weekly sessions of Prolonged Exposure cognitive behavioral therapy
3148382|NCT00146900|Active Comparator|Cognitive Therapy|Twelve 1.5 hours weekly sessions of Cognitive Therapy without exposure to traumatic reminders.
3148383|NCT00146900|Experimental|SSRI (escitalopram)|Twenty milligrams daily of escitalopram (blinded capsules)
3148384|NCT00146900|Placebo Comparator|Placebo|Two concealed placebo pills resembling 10mg escitalopram tablets
3148385|NCT00146900|No Intervention|Waiting List|Twelve weeks of waiting list no intervention group
3148386|NCT00147004|Experimental|1|hydrocortisone sodium succinate
3148387|NCT00147004|Placebo Comparator|2|Placebo
3148388|NCT00147056|Experimental|ExAblate transcranial system|MR Guided Focused Ultrasound
3148389|NCT00147095||HEALTHY NON-SMOKER|Healthy non-smoker participants
3148390|NCT00147095||HEALTHY SMOKER|Healthy smoker participants
3148391|NCT00147095||COPD and smoking|Smoking participants with COPD
3148392|NCT00147121|Active Comparator|1|Rituximab+Standard CHOP
3148393|NCT00147121|Experimental|2|Rituximab+bi-Weekly CHOP
3148394|NCT00147134|Active Comparator|1|Procedure/Surgery: open colectomy
3148395|NCT00147134|Experimental|2|Procedure/Surgery: laparoscopic colectomy
3148396|NCT00147303|Experimental|group L|25mg sarpogrelate
2437429|NCT03315533|Experimental|Duloxetine 30 milligrams (mg)|
2437430|NCT03315533|Placebo Comparator|Placebo|
2437431|NCT03315533|Experimental|Duloxetine 60 milligrams (mg)|
2437432|NCT03315520|Experimental|Relapsed/refractory malignant lymphomas|Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen
2437433|NCT03315507|Experimental|PB1046 Injection|PB1046 Subcutaneous Injection
2437434|NCT03315494|Experimental|SKI-O-703 200 mg (once daily)|SKI-O-703 capsule (1 x 200 mg)
2437435|NCT03315494|Experimental|SKI-O-703 400 mg (once daily)|SKI-O-703 capsule (2 x 200 mg, once daily)
2437436|NCT03315494|Experimental|SKI-O-703 200 mg (twice daily)|SKI-O-703 capsule (1 x 200 mg twice daily)
2437437|NCT03315494|Placebo Comparator|Placebo|Placebo capsule
2437438|NCT03315481|Active Comparator|SAX catheter insertion|Ultrasound guided cather insertion in the short axis (SAX) of the adductor canal. Injection of lidocaine through the catheter
2437439|NCT03315481|Active Comparator|LAX catheter insertion|Ultrasound guided cather insertion in the long axis (LAX) of the adductor canal. Injection of lidocaine through the catheter
3148397|NCT00147303|Experimental|group M|50mg sarpogrelate
3148398|NCT00147303|Experimental|group H|100mg sarpogrelate
3148399|NCT00147355|Other|A|Ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3148400|NCT00147355|Other|B|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
2437444|NCT03315442|Sham Comparator|Caffeine Group|Caffeine group consumed 200mg of caffeine one time.
2437445|NCT03315442|Experimental|Energy Drink Group|The energy drink group consumed 1 16 ounces energy drink one time.
2437446|NCT03315429|Other|Stress testing arm|Stress testing of patients with functional mitral regurgitation.
2437447|NCT03315416||NHS Sample|Children diagnosed with speech sound disorder aged 2-5 years
2437448|NCT03315403||Patients with CAP|"Patients with a diagnosis of radiographically-confirmed CAP at the emergency department will undergo the usual diagnostics. For the study an extra nasopharynx sample, saliva sample and blood sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
2437449|NCT03315403||Related controls|"Of related controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
2437450|NCT03315403||Unrelated controls|"Of unrelated controls a nasopharynx sample, oropharynx sample and saliva sample will be collected.~A questionnaire will be filled in. LytA PCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva)"
2437451|NCT03315403||Patients with stable COPD|"Of stable COPD patients a nasopharynx sample, oropharynx sample and saliva sample will be collected. And if available also a sputum sample.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
3148401|NCT00147355|Other|D|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
2437546|NCT03314922|Experimental|Parsaclisib|
3148402|NCT00147355|Other|C|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
3148403|NCT00147381|Experimental|Campath-1H 20 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 20 mg IV infusion over 3-6 hours.~Day 1: Same protocol of Campath-1H and methylprednisolone as on Day 0.~Day 2: No treatment~Day 3: Initial dose of Tacrolimus 0,1 mg/kg/d (0,05 mg/kg/bid)~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3148404|NCT00147381|Active Comparator|Tacrolimus|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3148405|NCT00147381|Experimental|Campath-1H 30 mg|"Day 0: Immediately post transplant surgery patients will receive methylprednisolone 250 mg IV followed one hour later by Campath-1H 30 mg IV infusion over 3-6 hours.~Day 1: No treatment.~Day 2: Initial dose Tacrolimus 0.1 mg/kg/d (0.05 mg/kg.bid).~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
3148406|NCT00147459|Active Comparator|booster|no antibody and boosted
3148407|NCT00147472|Other|PET|All patients receive PET scan and conventional CT imaging.
3148408|NCT00147485|Experimental|1|
3148409|NCT00147550|Experimental|1|
3148410|NCT00147732|Active Comparator|1|Accelerated radiotherapy
3148411|NCT00147732|Experimental|2|ARCON
3148412|NCT00147771|Experimental|1|
3148413|NCT00147797||Pravastatin group|Patients in the pravastatin group were consecutively recruited in four department of infectious diseases if they fulfilled the following criteria : (1) HIV-infected treated with HAART for > 12 months 2) with dyslipidemia, defined as fasting serum LDL cholesterol > 160 mg/dL before initiation of pravastatin, (3) treated with pravastatin > 12 months and one more coronary risk factor.
3148414|NCT00147797||COotrol group|The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART > 12 months 2) fasting serum LDL cholesterol > 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
3148415|NCT00147836|Active Comparator|CSII|Patients in continuous subcutaneous insulin infusion group received Human Insulin (Novolin-R, Novo Nordisk) with an insulin pump (H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland);
2437452|NCT03315403||Patients with exacerbation of COPD|"Of patients with a diagnosis of an exacerbation of COPD at the emergency department a nasopharynx sample, oropharynx sample and saliva sample will be collected apart from the usual diagnostics. If available also a sputum sample will be collected.~A questionnaire will be filled in. LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)"
2437453|NCT03315390|Experimental|Intervention-group|Narrative Exposure Therapy (NET): for GP-practice adapted version of narrative exposure therapy during 3 sessions (à 45 minutes)
2437454|NCT03315390|Active Comparator|iTAU group|Improved Treatment-as-usual: 3 GP consultations with patients according to guidelines and adapted to patients' needs
2437455|NCT03315377|Active Comparator|Lunate-Capitate Fusion (LCF)|Operation with a Lunate-Capitate Fusion (LCF) for SLAC or SNAC arthritis.
2437456|NCT03315377|Active Comparator|Four Corner Fusion (4CF)|Operation with a Four Corner Fusion (4CF) for SLAC or SNAC arthritis
2437457|NCT03315364|Experimental|Liporaxel® (oral paclitaxel)|"28 days (4 weeks) will be set as one cycle of administration and Liporaxel® will be administered for 3 weeks, twice a day, every morning and evening (D1, D8, D15) and will take a week off on 4th week.~Liproaxel® 200mg/m2 will be orally administered twice a day (morning, evening) 1 hour after meal for D1, D8, D15 of every cycle. 10 hour-interval is recommended for between each administration."
2437458|NCT03315364|Active Comparator|Taxol® (IV paclitaxel)|"28 days (4 weeks) will be set as one cycle and for every 3 week administration, 1 week off dose period will be given.~Taxol® 80mg/m2 will be administered via IV and it must be diluted before drip administration. Dilute with 0.9% sodium chloride injection solution to make final concentration of 0.3-1.2 mg/mL."
2437459|NCT03315351|Experimental|Study Procedure|Brachytherapy. PET-scan.
2437460|NCT03315338|Experimental|SAD Part 1 Active Cohort A|CORT118335, 25 mg
2437461|NCT03315338|Placebo Comparator|SAD Part 1 Placebo oral capsule Cohort A|
2437462|NCT03315338|Experimental|SAD Part 1 Active Cohort B|CORT118335, 75mg
2437463|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort B|
2437464|NCT03315338|Experimental|SAD Part 1 Active Cohort C|CORT118335, 225mg
2437465|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort C|
2437466|NCT03315338|Experimental|SAD Part 1 Active Cohort D|CORT118335, 675mg
2437467|NCT03315338|Placebo Comparator|SAD Part 1 Placebo Cohort D|
2437468|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fasting|CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast
2437469|NCT03315338|Experimental|SAD Part 2 Active Cohort A, Fed|CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast
2437470|NCT03315338|Placebo Comparator|SAD Part 2 Placebo PD Effect Cohort B|
2437471|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335|
2437472|NCT03315338|Experimental|SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335|
2437473|NCT03315338|Experimental|MAD Part 3 Active Cohort A|CORT118335, 375mg qd for 14 days
2437474|NCT03315338|Placebo Comparator|MAD Part 3 Placebo Cohort A|Placebo qd for 14 days
2437475|NCT03315338|Experimental|SAD Part 4 Active Cohort A|CORT118335, 100mg
2437476|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort A|
2437477|NCT03315338|Experimental|SAD Part 4 Active Cohort B|CORT118335, 300mg
2437478|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort B|
2437479|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fasting|CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast
2437480|NCT03315338|Experimental|SAD Part 4 Active Cohort C, Fed|CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast
2437481|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fasting|Supplied as suspension for oral dosing given after an overnight fast
2437482|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort C, Fed|Supplied as suspension for oral dosing given after a high-fat breakfast
2437483|NCT03315338|Experimental|SAD Part 4 Active Cohort Part D|CORT118335, 1500mg
2437484|NCT03315338|Placebo Comparator|SAD Part 4 Placebo Cohort D|
2437485|NCT03315338|Experimental|MAD Part 5 Active Cohort A|CORT118335, 150mg
2437486|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort A|
2437487|NCT03315338|Experimental|MAD Part 5 Active Cohort B|CORT118335, dose to be determined
2437488|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort B|
2437489|NCT03315338|Experimental|MAD Part 5 Active Cohort C|CORT118335, dose to be determined
2437490|NCT03315338|Placebo Comparator|MAD Part 5 Placebo Cohort C|
2437491|NCT03315325|Experimental|Adult men|The average age was 25.80±0.37 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2437492|NCT03315325|Experimental|Middle age men|The average age was 47.00±0.77 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2437493|NCT03315325|Experimental|Advance age men|The average age was 73.20±0.91 years and intervention human kisspeptin-10 was administered in single iv bolus dose (1 µg/kg BW). Serial blood samples were collected for 30 min pre and 120 min post-kisspeptin injection periods at 30 min interval.
2437494|NCT03315312|Active Comparator|Fissure sealant|
2437495|NCT03315312|Experimental|Fluoride varnish|
3188557|NCT00768157|Active Comparator|control group|Procedure/Surgery (radical resection of HBV-related HCC) without Drug of antiviral treatment - close observation without antiviral treatment
3188558|NCT00768170|Experimental|1|MK0633
2437498|NCT03315273|Experimental|Traumatic brain injury|"Patients who have suffered a traumatic brain injury will be assessed with a test battery including~a motor imagery ability questionnaire (MIQ-rs)~a mental rotation test~a chronometry test (TDMI)"
2437547|NCT03314909|Experimental|Hemodialysis (HD)|Patients in this group would receive hemodialysis for 3 days consecutively besides conservative therapy.
3188559|NCT00768183|Experimental|Regimen A|KADIAN Capsule + alcohol (under fasting conditions)
3188560|NCT00768183|Experimental|Regimen B|KADIAN Capsule + alcohol (under fed conditions)
2437501|NCT03315247|No Intervention|Treatment as Usual|Participants assigned to the Treatment as Usual group will attend routine clinic visits at the Toronto Western Hospital Bariatrics Surgery Program (TWH-BSP). These visits generally include education on bariatric surgery and nutrition. Patients meet with select members of the multidisciplinary team at 1, 2, and 3 years post-surgery, and may attend an optional monthly support group. Participants' service utilization (i.e., attendance at optional sessions) will be documented and compared across groups.
2437502|NCT03315247|Experimental|Telephone-Based CBT|"The Tele-CBT intervention will be delivered 1 year following bariatric surgery. Participants will receive 6 weekly Telephone-based Cognitive Behavioural Therapy sessions and 1 final booster session 1 month later, all approximately 55-minutes in duration and scheduled at a time convenient for the participants."
2437503|NCT03315234||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
2437504|NCT03315234||0 < SYNTAX score < 23|Low SYNTAX group
2437505|NCT03315234||SYNTAX score ≥ 23|Intermediate-High SYNTAX group
3188561|NCT00768183|Experimental|Regimen C|KADIAN Capsule + water (under fasting conditions)
3188562|NCT00768183|Experimental|Regimen D|Morphine sulfate IR oral solution + water (under fasting conditions)
2437510|NCT03315195|Experimental|Preoperative oral nutritional supplement|Oral nutritional supplement 500 kcal/day for 14 days and dietary advice
2437511|NCT03315195|No Intervention|Conventional treatment|Dietary advice
2437512|NCT03315182|Experimental|Cohort 1 (Low Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 1 (Low Dose): 2 X 10E13 vg/kg (n=2 participants)"
2437513|NCT03315182|Experimental|Cohort 2 (Med Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 2 (Med Dose): 5 X 10E13 vg/kg (n=4-5 participants)"
2437514|NCT03315182|Experimental|Cohort 3 (High Dose) rAAV9.CMV.hNAGLU|"Subjects will receive a single infusion:~• Cohort 3 (High Dose): 1 X 10E14 vg/kg (n=4-8 participants)"
2437515|NCT03315169|Active Comparator|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity as per normal practice.
2437516|NCT03315169|Experimental|External dressing|External application of a non-adherent dressing to the perianal abscess cavity.
2437517|NCT03315156||Patients|patients with AOM
2437518|NCT03315143|Experimental|Sotagliflozin|Sotagliflozin dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
2437519|NCT03315143|Placebo Comparator|Placebo|Placebo dose 1 (1 tablet), once daily with possible uptitration in the first 6 months to dose 2 (2 tablets)
2437520|NCT03315130|Experimental|0.1 mg/kg zilucoplan (RA101495)|
2437521|NCT03315130|Experimental|0.3 mg/kg zilucoplan (RA101495)|
2437522|NCT03315130|Placebo Comparator|Placebo|
3188563|NCT00768209|Experimental|Treatment A|
3188564|NCT00768235|Experimental|1: yoga group|Yoga group
3188565|NCT00768235|No Intervention|2: control group|
2437526|NCT03315091|Experimental|Treatment sequence 1 (Fasted-Fed)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
2437527|NCT03315091|Experimental|Treatment sequence 2 (Fed-Fasted)|To assess the PK of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in either a fed or fasted condition.
2437528|NCT03315078|Experimental|Gene-Modified CD34+ HSCs|Participants will receive palifermin on Days -6, -5, and -4 and then busulfan on Days -3 and -2. On Day 0, participants will undergo the gene transfer treatment with infusion of the gene-modified CD34+ HSCs. They will receive palifermin on Days 1, 2, and 3.
2437529|NCT03315065|Other|Patients diagnosed with Lung cancer|patients diagnosed with Lung cancer and Thoracic radiotherapy
2437530|NCT03315052|Experimental|Budesonide treatment arm|Patients treated with budesonide in place of prednisone as part of immunosuppressive regimen
2437531|NCT03315052|Active Comparator|Standard immunosuppression arm|Patients treated with standard immunosuppression after liver transplant
2437532|NCT03315039|Experimental|Liposomal annamycin|
3188566|NCT00768274|Experimental|Arm A|Low-dose apabetalone (RVX000222) or placebo
2437534|NCT03315013|Experimental|SLATE|The SLATE arm will be administered the SLATE II algorithm and initiated on ART immediately if eligible under the algorithm. Patients not eligible under the algorithm will be referred for standard care.
2437535|NCT03315013|No Intervention|Standard|The standard arm will be referred to standard care after study enrollment.
2437536|NCT03315000|Experimental|Vilanterol|Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta® inhaler
2437537|NCT03315000|Experimental|Fluticasone|Fluticasone (100mcg) monotherapy inhaled through Ellipta® inhaler
2437538|NCT03315000|Placebo Comparator|Placebo|Lactose powder inhaled through Ellipta® inhaler
3188567|NCT00768274|Experimental|Arm B|apabetalone (RVX000222) Dose-escalation or placebo
3188568|NCT00768274|Experimental|Arm C|high-dose apabetalone (RVX000222) or placebo
3188569|NCT00768326|Experimental|Zicronapine. Study Part A|
3188570|NCT00768326|Experimental|Zicronapine. Study Part B|
3188571|NCT00768326|Experimental|Zicronapine. Study Part C|
3188572|NCT00768326|Experimental|Zicronapine. Study Part D|
3188573|NCT00768326|Experimental|Zicronapine. Study Part E|
3188574|NCT00768326|Placebo Comparator|2A, 2B, 2C, 2D, 2E|
3188575|NCT00768339|Experimental|1|Single agent AEG35156 as 2hr IV infusion, weekly dosing in Patients with relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas
3188576|NCT00768352|Other|Education Intervention|
3188577|NCT00768365||group 1|patients with adrenal incidentaloma
3188578|NCT00768365||group 2|Thirty-five subjects comparable for sex, age, and BMI were enrolled as a control group (group 2).
3188579|NCT00768365||group 3|The other control group (group 3) of 35 healthy individuals matched for sex, age, BMI, metabolic syndrome criteria, cardiovascular risk parameters, menopausal status, smoking status, consumption of alcohol, usage of antihypertensive drugs, insulin or oral hypoglycaemic agents to perform a 1:1 case-control analysis.
2437548|NCT03314909|Experimental|Hemoperfusion (HP)|Patients in this group would receive hemoperfusion for 3 days consecutively besides conservative therapy.
2437549|NCT03314909|Experimental|HP-HD|Patients in this group would receive hemoperfusion and hemodialysis concurrent therapy for 3 days consecutively besides conservative therapy.
2437550|NCT03314909|No Intervention|Conservative|Patients in this group would receive basic supportive treatment, gastric lavage, glucosteroid and immunosuppressive drugs without any hemopurification.
2437551|NCT03314896|Experimental|Laparoscopic surgery for T4 colon tumor|Laparoscopic surgery for T4 colon cancers
2437552|NCT03314896|No Intervention|Open surgery for T4 colon tumor|Conventional open surgery for T4 colon cancers
2437553|NCT03314883|Experimental|D-US ARF|Diaphragmatic evaluation, i.e thickening fraction (%) and excursion (millimeters), will be performed 3 times in the first two hours after acute hypoxic - hypercapnic respiratory failure (ARF) patients admission
2437554|NCT03314870|Other|Retrospective study|Tumoral tissue of 100 patients with breast cancer treated with neoadjuvant chemotherapy.
2437555|NCT03314870|Other|Prospective study|Tumoral tissue and plasma of 120 patients with breast cancer treated with neoadjuvant chemotherapy.
3188580|NCT00768378|Experimental|Perceived stimulation|When subjects assigned to the perceived stimulation group increase the intensity of the stimulus, they will feel a tingling sensation on the tongue. The tingling will move on the tongue in relation to where the head/body moves.
2437557|NCT03314831||Sepsis|Patients with sepsis or septic shock admitted on Intensive Care Unit.
2437558|NCT03314831||Systemic Inflammatory Response Syndrome|Patients with Systemic Inflammatory Response Syndrome non-infectious etiology.
2437559|NCT03314831||No inflammation|Patients without systemic inflammation.
2437560|NCT03314818||Ultrasound 3D Imaging|To investigate natural history of subclinical atherosclerosis as determined by 3D carotid ultrasound.
2437561|NCT03314805|Placebo Comparator|Control|Placebo
2437562|NCT03314805|Experimental|Treatment|Astragalus polysaccharides 500 mg
2437563|NCT03314792|Active Comparator|Oxycodone|Active comparator drug administrated.
2437564|NCT03314792|Experimental|Tapentadol|Experimental drug administrated.
2437565|NCT03314766||IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally under the protocol ACU-P14-029
3188581|NCT00768378|Experimental|Subliminal stimulation|When subjects assigned to the subliminal stimulation group increase the intensity of the stimulus, the device provides a stimulus that is below their conscious awareness, so they will not be able to perceive it. The stimulus will move on the tongue in relation to where the head/body moves.
3188582|NCT00768391|Experimental|IMC-3G3|All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
2437568|NCT03314740|Active Comparator|Arm A|Intravenous administration of weekly Paclitaxel (dosage: 80 mg/mq) for a maximum of 6 cycles. Cycle is defined as 4 weeks.
2437569|NCT03314740|Experimental|Arm B|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 7 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
2437570|NCT03314740|Experimental|Arm C|"Oral administration of two experimental drugs:~Cediranib 20 mg/day given 5 days per week~Olaparib 600 mg / day (i.e. 300 mg twice a day) 7 days per week until progression, unacceptable toxicity, patient or physician decision to discontinue or death."
2437571|NCT03314727|No Intervention|Control group|Drink 200 ml soup with no added salt
2437572|NCT03314727|Experimental|High salt (NaCl) intake|Group 2: Drink 200 ml soup with 3 g added salt Group 3: Drink 200 ml soup with 3 g added salt plus 500 ml water Group 4: Drink 200 ml soup with 3 g added salt plus 750 ml water
2437573|NCT03314714|Experimental|Acute bout of endurance exercise|Intramyocellular lipid metabolism will be assessed in insulin resistant and healthy, sedentary individuals after an acute bout of endurance exercise.
2437574|NCT03314701|Active Comparator|Group 1|"Biphasic Intermittent Positive Airway Pressure (BIPAP) group:~Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
2437575|NCT03314701|Active Comparator|Group 2|"Airway Pressure Release Ventilation (APRV) group:~high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
2437576|NCT03314688|Active Comparator|Usual Care Group|"Standardized breast cancer follow up care and materials regarding treatment (i.e., chemotherapy and endocrine therapy when relevant).~Lifestyle intervention books for breast cancer survivors at the end of the 2-year study. Women will also be offered a counselling session with a registered study dietician at the end of the study."
2437577|NCT03314688|Experimental|Dietary/Physical Activity Intervention|Eleven 30-min counseling sessions over six months (weekly, then biweekly, then monthly) with additional sessions in the latter 6 months (5 additional monthly sessions for a total of 16 sessions), timed with their oncology visit or via telephone if not coming in for oncology visit. Sessions focus on motivating health dietary choices and physical activity (home-based program).
2437578|NCT03314675|Other|CRT-D Measurements|Pre-specified measurements and additional follow-ups
3188583|NCT00768404|Experimental|A|
3188584|NCT00768417||Participants|Participants completed all 3-arms of this cross-over design study.
3188585|NCT00768456|Active Comparator|1|Local infiltration with Ropivacaine
3188586|NCT00768456|Placebo Comparator|2|Local infiltration with Placebo (NaCl)
3188587|NCT00768482|Experimental|Probuphine|Patients are first inducted on SL BPN, and then switched to 4 Probuphine implants
3188588|NCT00768495||One Cohort|
3188589|NCT00768508|Experimental|Ondansetron|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy
3188590|NCT00768508|Experimental|Naltrexone|Naltrexone 50 mg/day + Cognitive Behavioral Therapy
3188591|NCT00768508|Experimental|Ondansetron + Naltrexone|Ondansetron 4 ug/kg b.i.d. + Naltrexone 50 mg/day + Cognitive Behavioral Therapy
3188592|NCT00768508|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
3188593|NCT00768547||By protocol|Where the test are predefined
3188594|NCT00768547||By degression|The group where the doctor decided which test are to be taken.
2437582|NCT03314649||Observational study|Patients with gastric cancer and non-cancerous disease planned to have laparotomy
2437583|NCT03314636|Experimental|PET-CT-positive patients|Carfilzomib 20/36mg/m2 days 1,2,8,9,15,16 Lenalidomide 25mg days 1-21 Dexamethasone 40mg days 1,8,15,22 28 day cycles 4 cycles
2437584|NCT03314610||Patients enrolled|Patient with parkinsonian syndromes and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes. A first record of gait speed will be at strong desire to void. A second record will be after voiding or catheterization Gait records consist on : 3x 10 meter walk test, 1x double task 10 meter walk test, 1x Timed up and Go test and 1x GMT
2437585|NCT03314597|Active Comparator|Balance exercise group|Each of the ten sessions was composed of 45 minutes of balance exercises, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
2437586|NCT03314597|Experimental|Mobile platform exercise group|Each of the ten sessions was composed of 45 minutes mobile platform training, each treatment being followed by a 15-min final phase of lower limb stretching, performed with the assistance of a physiotherapist. Sessions were repeated two or three times a week, with at least one rest day between one session and the next, over four successive weeks. Each patient was treated on-phase, at the same time of the day across sessions.
2437587|NCT03314584|Experimental|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
2437588|NCT03314584|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex.
2437589|NCT03314571||non applicable|
2437590|NCT03314558||COPD patients following a pulmonary rehabilitation program|COPD patients following a pulmonary rehabilitation program
2437591|NCT03314545|Other|laminate veneers with coronal posts|anterior endodontically treated teeth restored with laminate veneers with coronal posts
2437592|NCT03314545|Other|post, core and crown|anterior endodontically treated teeth restored with post, core and crown
2437593|NCT03314532|No Intervention|Surgery group|We will completely resection of the visible tumor and made the resection margin negative. We will use regular/irregular resection of the liver tumor tissue, hemihepatectomy or extended hepatectomy.
2437594|NCT03314532|Experimental|TILA-TACE group|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
3188595|NCT00768573||1. Taste test|
3188596|NCT00768586||1|Extreme premature infants under the 28th week of gestation.
2437597|NCT03314506|Experimental|Trial|Subjects will need to come to the Substrate Metabolism Laboratory in the morning around 7:00 AM. After about a 15-30 minute rest, the study team will collect a blood sample from the subject's hand or forearm. The study team will also obtain a small sample of fat tissue from the area just underneath the skin near the belly button. Next, subjects will exercise on a treadmill at a moderate intensity for about 1 hour. Immediately after exercising the study team will collect a blood sample. The subject will remain resting in the laboratory for 3 hours after exercise, and then the study team will collect another blood and fat tissue sample. Upon completion, the subject will be provided a snack before leaving the laboratory.
2437598|NCT03314493|Experimental|Spironolactone group|Spironolactone oral tablet 25mg/day, for 12 months
2437599|NCT03314493|No Intervention|Control group|No spironolactone use
2437600|NCT03314480||Midfacial fracture suspected patients|Patients who are suspected of maxillofacial fracture
2437601|NCT03314480||Mandibular fracture suspected patients|Patients who are suspected of a mandibular fracture
2437602|NCT03314467||Cases DR|diabetic patients with diabetic retinopathy (DR)
2437603|NCT03314467||Cases other|diabetic patiens with other/multiple ocular disorder(s)
2437604|NCT03314467||Control|diabetic patients without ocular abnormalities
2437605|NCT03314454|Active Comparator|Elevated Mental Status|Elevated score on Patient Health Questionnaire
2437606|NCT03314454|Active Comparator|Non-elevated depressed mood|Lower score on Patient Health Questionnaire
2437607|NCT03314454|Active Comparator|Social Drinking status|The social drinker group will be those who consume alcohol regularly but with infrequent heavy drinking days.
2437608|NCT03314454|Active Comparator|Heavy drinker status|The heavy drinker group will be those who consume alcohol regularly with frequent heavy drinking days.
2437609|NCT03314441|Experimental|Yoga|Patients receiving Yoga lessons for 3 months
2437610|NCT03314428|Experimental|Gait retraining|Runners will be taught how to modify their running gait through multiple laboratory sessions and in-field training.
2437667|NCT03314025|Placebo Comparator|Placebo|The patients in the Placebo group will receive a placebo oral capsule (sugar) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
3188597|NCT00768612|Experimental|1|Lowest dose
3188598|NCT00768612|Experimental|2|Middle dose
3188599|NCT00768612|Experimental|3|Highest dose
3188600|NCT00768612|Active Comparator|4|Positive Control
3188601|NCT00768638|Active Comparator|Atorvastatin 10mg|
3188602|NCT00768638|Active Comparator|Atorvastatin 40mg|
3188603|NCT00768690|Other|1|Healthy volunteers, receiving daily doses of 200 mg ABT-333 or placebo, BID for 10 days; and on Study Day 11 receiving a single dose of 200 mg ABT-333 or placebo + 400 mg ketoconazole
3188604|NCT00768690|Other|2|Healthy volunteers, receiving 400 mg ABT-333 or placebo, BID
3188605|NCT00768690|Other|3|Healthy volunteers, receiving 600mg ABT-333 or placebo, BID
2437611|NCT03314415|Experimental|Early robotic intervention|Participants randomized to the early robotic intervention will attend robotic assistance sessions for a two-week period earlier in the study (during the first half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
2437612|NCT03314415|Experimental|Late robotic intervention|Participants randomized to the late robotic intervention will attend robotic assistance sessions for a two-week period later in the study (during the latter half of the study, approximately). Each participant will attend ten 15-minute robotic assistance sessions to interact with a robot (Aldebaraan Nao H25).
2437613|NCT03314402|Experimental|group 1|Jaktinib Dihydrochloride Monohydrate
2437614|NCT03314402|Placebo Comparator|group 2|Placebo
2437615|NCT03314389|Experimental|Cochet bonnet esthesiometer|To examine sensation
2437616|NCT03314376|Experimental|Prehabilitation program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
2437617|NCT03314376|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 6-week intervention.
2437618|NCT03314363|Other|all patients|Classic CRRT with citrate predilution
2437619|NCT03314337|No Intervention|Distal Pancreatectomy without pancreatic stent|
2437620|NCT03314337|Experimental|Distal Pancreatectomy with pancreatic stent|pancreatic stent will be placed in the main pancreatic duct during the operation
2437621|NCT03314324|Experimental|ODM-201|
2437622|NCT03314324|Active Comparator|Enzalutamide|
2437623|NCT03314311|Experimental|Rehabilitation Programme|12 week multi-disciplinary intervention prescribing exercise, individual dietary counselling and education sessions.
2437624|NCT03314311|No Intervention|Control|Usual care control arm
2437625|NCT03314298|Experimental|testosterone anastrozole implant|testosterone 80mg Anastrozole 4 mg single as a subcutaneous pellet
2437626|NCT03314285|Other|Neck Pain|Patients with chronic mechanical neck pain will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
2437627|NCT03314285|Other|Healthy volunteers|Healthy volunteers without any disease will be evaluated for sleep quality by the Pittsburgh Sleep Quality Scale.
2437630|NCT03314259|Experimental|Tamsulosin|Patients will then consume oral tamsulosin 0.4mg every morning daily for 5 days prior to elective surgery
2437631|NCT03314259|Placebo Comparator|Placebo|Patients will then consume placebo every morning daily for 5 days prior to elective surgery
2437632|NCT03314246|Other|Intervention|FAST user
2437633|NCT03314246|Other|Control|Standard of care
2437635|NCT03314220|Experimental|standard care plus preoperative preparation|experimental group received standard care plus preoperative preparation, which included a tour, a cartoon video depicting a boy's surgical journey and familiarization with medical equipment.
2437636|NCT03314220|No Intervention|standard care|
2437637|NCT03314194|Experimental|Plant Based Diet Group|Study aims for two cohorts of 20 females each, being tested over 6 days in two conditions: habitual diet versus plant based diet.
3148416|NCT00147836|Active Comparator|MDI|Patients in MDI group were treated with pre-meal Novolin-R, and Human Insulin NPH (Novolin-N, Novo Nordisk) at bedtime. Initial insulin doses were 0.4-0.5 IU/kg and total daily doses were divided into 50% of basal and 50% of bolus injection in CSII group and 30%-20%-20%-30% in multiple daily insulin injection group
3148417|NCT00147836|Active Comparator|OHA|In oral hpoglycemic agents group, the patients with 20 kg/m2<BMI≤25kg/m2 were initiated with Gliclazide (Diamicron, Servier) 80mg Bid (maximum to 160mg Bid), the patients with 25kg/m2<BMI≤35kg/m2 were initiated with Metformin (Glucophage, BMS) 0.5 Bid (maximum to 2.0g/d), the combination of Diamicron and Glucophage was used in patients who could not achieve glycaemic control goal with one OHA or with FPG≥11.1mmol/l at randomization
3148418|NCT00147901|Experimental|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
3148419|NCT00147914|Active Comparator|1|cefdinir
3148420|NCT00147914|Active Comparator|2|amoxicillin/clavulanate
3148421|NCT00147979|Experimental|1|PTFE with bounded heparin
2438264|NCT03310164||COPD|Smokers with clinically stable chronic obstructive pulmonary disease (COPD)
3148422|NCT00147979|Active Comparator|2|PTFE without bounded heparin
3148423|NCT00147992|Experimental|implants|
3148424|NCT00148031|Experimental|1|On-site (MMT Clinic) HCV evaluation and treatment
3148425|NCT00148031|Active Comparator|2|Off-site (GI Clinic) HCV evaluation and treatment
3148426|NCT00148096|Placebo Comparator|1|Mechanical heat recovery ventilation units installed but not fully functional
3148427|NCT00148096|Active Comparator|2|Mechanical heat recovery ventilation unit installed and active
3148428|NCT00148174|Experimental|Phone calling|Phone calling to encourage improved adherence
3148429|NCT00148239|Experimental|Caregiver Only|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
3148430|NCT00148239|Experimental|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
3148431|NCT00148239|Active Comparator|Control|Participants are provided with written materials at beginning of study; nothing thereafter
3148432|NCT00148278|Experimental|1|norepinephrine plus dobutamine
3148433|NCT00148278|Active Comparator|2|epinephrine
2437645|NCT03314168|Active Comparator|Control group|Patients who are randomized in control group will receive the usual care in their respective hospital.
2437646|NCT03314168|Experimental|Single-set group|Patients who are randomized in Single-set (SS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. One-single set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between the exercises.
2437647|NCT03314168|Experimental|Multiple-sets group|Patients who are randomized in Multiples-set (MS) group, will receive 12-week of combined training, twice a week, composed by 10 resistance exercises and 20-25 minutes aerobic exercise at 80-95% of the second ventilatory threshold heart rate in a cycle. Regarding resistance exercises, three set will be performed per exercise at 60-80%1-RM, with 1-1,5min of rest between sets and the exercises.
3148434|NCT00148304||Group 1|
2437649|NCT03314142|Experimental|Glucose as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2437650|NCT03314142|Experimental|White bread as reference food|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2437651|NCT03314142|Experimental|Bread enriched with coarse wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2437652|NCT03314142|Experimental|Bread enriched with fine wheat bran|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2437653|NCT03314142|Experimental|Bread enriched with fine wheat and carob|Ten healthy, normal weight subjects (male: 7, female: 3) after 10-14 hr fast, consumed 50g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 50g available carbohydrates from bread enriched with coarse wheat bran (CB), bread enriched with fine wheat bran (obtained by milling the coarse bran) (FB) and the FB in which 10% of the flour was substituted with carob seed flour (CSFB), tested once, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2437654|NCT03314129|Experimental|Contrast sensitivity|UltimEyes
2437655|NCT03314129|Experimental|Perceptual organization|Contour Integration Training
2437656|NCT03314129|Experimental|Contrast sensitivity + Perceptual org.|UltimEyes + Contour Integration Training
2437657|NCT03314129|Active Comparator|Cognitive remediation|MyBrainSolutions
2437658|NCT03314116|Experimental|video group|guided by a 7-minute video that explains the importance of using ear plugs and correct installation.
2437659|NCT03314116|No Intervention|control group|instructed to use earplugs properly, including practical exercises by a medic
2437660|NCT03314103|Experimental|Vaccine|live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
2437661|NCT03314103|Placebo Comparator|Placebo|Placebo with no live virus
2437662|NCT03314090|Experimental|Silicone Gel Group|Intervention: Silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day (BID). The amount being similar in size to a grain of rice.
2437663|NCT03314077||Standard managed subjects|COPD patients accepted standard COPD management.
2437664|NCT03314077||Controls|COPD patients didn't accepted standard COPD management or quality control, who are from hospital subjects with a retrospective cohort study.
2437665|NCT03314064|Experimental|HIV positive subjects continuing DTG|HIV positive subjects who complete taking DTG in studies ING112276, ING113086, ING114915, ING111762 and those subjects who end participation in study 200304 in which they received either DTG or LPV/RTV will be included in this study.
2437666|NCT03314025|Experimental|Tamsulosin|The patients in the Experimental group will receive Tamsulosin Hydrochloride 0.4 MG (milligrams) once a day for 5 days before the surgery, one capsule on the day of the surgery and one on the day after. The intervention will consist of a total of 7 capsules
3148435|NCT00148356|Experimental|1|ZoMaxx™ Drug-Eluting Stent System
3148436|NCT00148356|Active Comparator|2|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
3148437|NCT00148369||Observational Group|Subjects previously administered GDNF and have discontinued the drug.
3188606|NCT00768690|Other|4|Healthy volunteers, receiving 1000mg ABT-333 or placebo, BID
2437668|NCT03314012|Experimental|Catheter-Based Carotid Body Ablation|All subjects undergo catheter-based ablation of the carotid body using the Cibiem Transvenous Ultrasound System (CTUS).
2437669|NCT03313999|Other|Durometer Measurement|All patients participating in the study will receive standard of care treatment for their lymphedema. As part of the study they will be measured by the durometer in addition to other, standard diagnostics to further characterize their lymphedema progression.
2437670|NCT03313973|Experimental|with self stretching same muscle|
2437671|NCT03313973|Sham Comparator|with self stretching forearm muscle|
2437672|NCT03313960|Active Comparator|"One Drop | Premium with Afrezza"|
2437673|NCT03313960|Other|"One Drop | Premium without Afrezza"|
2437674|NCT03313947|Other|Difficult Airway|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
2437675|NCT03313947|Other|Obstructive Sleep Apnea|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
2437676|NCT03313947|Other|Predictive Obstructive Sleep Apnea|"The following 6 questions will be asked during the preoperative visit:~While sleeping, does your child snore more than half the time?~While sleeping, does your child always snore?~Have you ever seen your child stop breathing during the night?~Does your child occasionally wet the bed?~Did your child stop growing at a normal rate at any time since birth?~Is your child overweight"
2437677|NCT03313934|Placebo Comparator|Hyaluronic Acid Filler with Saline|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with saline. This arm will act as a control to evaluate the efficacy of PRF with hyaluronic acid.
2437678|NCT03313934|Experimental|Hyaluronic Acid Filler with Platelet Rich Fibrin (PRF)|For each subject, one tear trough will be injected with hyaluronic acid filler mixed with Platelet Rich Fibrin (PRF). This study seeks to determine the efficacy of PRF in volumization of the tear trough and improvement of skin quality. This is the experimental condition.
2437679|NCT03313921|Experimental|Online Manifest Refraction|All participants will undergo three assessments of refractive error, in random order. All will perform an unsupervised manifest refraction with the use of a computer screen and their smartphone. Next, a regular manifest refraction assessment performed by an optometrist will function as active comparator. An automated refraction assessment will be performed to relate the quality and repeatability of the online refraction to another unsupervised method of refraction assessment.
2437680|NCT03313908|Experimental|breast surgery|during the breast surgery, detection of the tumor lesion with indocyanine green fluorescence and with radioactive seed localization, in each subject
2437681|NCT03313895|Active Comparator|Cycling Only|Moderate-intensity cycling, 3 times a week for 6 months, supervised by an exercise specialist
2437682|NCT03313895|Active Comparator|Cognitive Training Only|Computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
2437683|NCT03313895|Experimental|ACT|Moderate-intensity cycling followed by computerized cognitive training, 3 times a week for 6 months, supervised by a specialist
2437684|NCT03313895|Sham Comparator|Stretching and Mental Stimulation Activities|Stretching and mental stimulation activities, 3 times a week for 6 months, supervised by a specialist
2437685|NCT03313882||donor|donor: normal heart samples from donor
2437686|NCT03313882||ICM|ICM: heart samples with ischemic cardiomyopathy
2437687|NCT03313882||NICM|NICM: heart samples with non-ischemic cardiomyopathy
2437688|NCT03313869|Experimental|Control|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol No cocktail during the protocol~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
2437689|NCT03313869|Experimental|Cocktail intervention|"Intervention: Reduction in daily steps up to 2000-3000 steps per day and no structured physical activity + High dose ingestion of fructose (3g/kg/day) glucose (0,5g/kg/day)in the last 10 days of the protocol + Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)~Healthy male volunteers in the active range of population (10000 to 15000 steps per day) aged 20-45 years, 22 BMI 27 158 cm height 190 cm, Certified as healthy by a comprehensive clinical assessment."
2437690|NCT03313856|Placebo Comparator|Placebo|The patients were randomly assigned to received placebo (calcinaned magnesia), 1 capsule before each meal for a period of 90 days.
2437691|NCT03313856|Experimental|Guazuma ulmifolia plus Tecoma stans|The patients were randomly assigned to received the herbarium mixture (GU/TS) , 1 capsule of 400mg, before each meal for a period of 90 days.
2437692|NCT03313830|Experimental|Whey Protein Hydrolysate (WPH)|The intervention consists of Whey Protein Hydrolysate (WPH) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
2437693|NCT03313830|Experimental|Intact Whey Protein (WHEY)|The intervention consists of Intact Whey Protein (WHEY) ingestion by young healthy subjects to determine rates of muscle protein synthesis.
2437694|NCT03313804|Experimental|Immune Checkpoint Inhibitor + Radiation|Immune checkpoint inhibitor (Nivolumab OR Pembrolizumab OR Atezolizumab) PLUS Radiation Therapy (Stereotactic Body Radiation Therapy OR fractionated radiation therapy)
2437695|NCT03313791|Experimental|Whey protein concentrate|portion size that contains 25 g of protein, oral, single administration
2437696|NCT03313791|Experimental|Yoghurt|portion size that contains 25 g of protein, oral, single administration
2437697|NCT03313791|Experimental|50%whey-50% casein (Standard)|portion size that contains 25 g of protein, oral, single administration
2437698|NCT03313791|Experimental|50%whey-50% casein (Alternative)|portion size that contains 25 g of protein, oral, single administration
2437699|NCT03313791|Experimental|Micellar Casein Isolate- WPH|portion size that contains 25 g of protein, oral, single administration
2437700|NCT03313791|Experimental|Micellar Casein Isolate - Na-caseinate|portion size that contains 25 g of protein, oral, single administration
2437701|NCT03313791|Experimental|Micellar Casein Isolate|portion size that contains 25 g of protein, oral, single administration
2438394|NCT03309293|Experimental|cases|
2437702|NCT03313791|Experimental|UHT milk|portion size that contains 25 g of protein, oral, single administration
2437703|NCT03313791|Experimental|Recombined milk|portion size that contains 25 g of protein, oral, single administration
2437704|NCT03313791|Experimental|Recombined 50% whey milk|portion size that contains 25 g of protein, oral, single administration
2437705|NCT03313791|Experimental|Ca-caseinate|portion size that contains 25 g of protein, oral, single administration
2437706|NCT03313791|Experimental|Milk protein isolate|portion size that contains 25 g of protein, oral, single administration
3148438|NCT00148525|Experimental|social cognitive theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory and delivered by an automated telephone system.
3148439|NCT00148525|Experimental|Goal Systems Theory|This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory.
3148440|NCT00148525|No Intervention|Comparison group|comparison group
3148441|NCT00148538|Active Comparator|1|resistance exercise
2437711|NCT03313765|Experimental|Intervention|
2437712|NCT03313765|Active Comparator|Standard-of-care|
2437713|NCT03313752|Placebo Comparator|A - placebo|Green, plain, diamond shaped, film coated tablet (orally), not containing active ingredient; once daily, for 4 weeks
2437714|NCT03313752|Experimental|B - experimental drug|Dapagliflozin tablet available at dose of 10 mg, once daily, for 4 weeks
2437715|NCT03313739|Experimental|Intervention group|An Educational Program
2437716|NCT03313739|No Intervention|Control group|This group(n=30) received no intervention.
2437717|NCT03313726|Experimental|GnRh-antagonist A|
2437718|NCT03313726|Experimental|GnRh-antagonist B|
2437719|NCT03313713|Active Comparator|Beta-glucans|Beta-glucans, 3 g per day, per 8 weeks, at breakfast
2437720|NCT03313713|Placebo Comparator|Placebo|Placebo, 3 g per day, per 8 weeks, at breakfast
2437721|NCT03313700|Experimental|Robotic Distal Gastrectomy|Robotic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
2437722|NCT03313700|Active Comparator|Laparoscopic Distal Gastrectomy|Laparoscopic Distal Gastrectomy will be performed for the treatment of patients assigned to this group.
2437723|NCT03313674|Experimental|Seasonal Affective Disorder|The primary objective is to use neuroimaging paradigms to identify perturbations in neural circuits of SAD patients when they are clinically depressed in the winter, after bright light therapy treatment, and when they are healthy in the summer
2437724|NCT03313674|No Intervention|Major Depressive Disorder|SAD patients will be compared to unipolar depressed patient cohort, who will be imaged in the winter and the summer.
2437725|NCT03313674|No Intervention|Healthy Controls|SAD patients will be compared to healthy controls, who will be imaged in the winter and the summer.
2437726|NCT03313661|Experimental|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
2437727|NCT03313661|Active Comparator|Gliclazide|gliclazide (60-120 mg) once daily
2437728|NCT03313661|No Intervention|Placebo|Placebo
2437729|NCT03313648|Experimental|Laparoscopic Hepatectomy|Improvements in laparoscopic technology mean that LH now has superior short-term efficacy and similar long-term efficacy to open surgery , and LH has shown significant advantages in applications involving recurrent HCC.
2437730|NCT03313648|Active Comparator|Radiofrequency Ablation|With recent technological advances, RFA has become the most widely investigated new first-line therapeutic option for recurrent HCCs . Numerous large studies have demonstrated the advantages of RFA, which include its ease of use, safety, effectiveness, minimal invasiveness, and minimal morbidity and mortality .
2437731|NCT03313635||Men presenting with low-T|Men presenting with low-t will undergo a blood draw for evaluation of prealbumin levels.
3148442|NCT00148538|Active Comparator|2|Aerobic and Resistance exercise
2437733|NCT03313596|Active Comparator|LT-only|patients received orthotopic LT and subsequent immunosuppression therapy
2437734|NCT03313596|Experimental|LT+ADV-TK|ADV-TK therapy was administered in addition to orthotopic LT and subsequent immunosuppression therapy
2437735|NCT03313583||Blood product recipients|All patients who received at least one blood product on the day of the study
2437736|NCT03313557|Experimental|Wee-1 kinase inhibitor AZD1775|To assess the safety of AZD1775 following oral dosing of the capsule formulation in patients with advanced solid tumours in patients who have previously completed 1 of the AZD1775 clinical pharmacology studies and not have met any requirements to permanently discontinue treatment with AZD1775.
2437737|NCT03313544|Experimental|NIVOLUMAB PATIENTS|
2437738|NCT03313531||Study group 1|Patients with severe hemophilia A
2437739|NCT03313531||Study group 2|Healthy volunteers
2437740|NCT03313531||Study group 3|Healthy volunteers ) that at previous measurements have been shown to have a TGC>2SD of the median of the control population.
2437741|NCT03313531||Treated HA person|One patient with severe hemophilia A (HA) will be treated with two factor FVIII concentrates, one with standard half- life (Advate™) and one with a pro-longed half-life (Adynovate™) at two separate occasions
2437742|NCT03313518|Active Comparator|Anodal tDCS|Transcranial Direct Current Stimulation using anodal electrode, 15 patients received real anodal tDCS 2mA for 20 minutes for 10 consecutive days.
2437743|NCT03313518|Sham Comparator|sham group|Fifteen patients received sham anodal tDCS 2mA for 20 minutes for 10 consecutive days.
2437744|NCT03313505||Patients who had been tested for S100B protein|
2437745|NCT03313505||Patients who have benefited from another strategy|
2437851|NCT03312777|Placebo Comparator|Placebo|Oral placebo (overencapsulated microcrystalline) administered every 6 hours for nine doses, coadministered with paroxetine.
3148443|NCT00148564|Active Comparator|Olanzapine|
3148444|NCT00148564|Active Comparator|Zpirasidone|
3148445|NCT00148590|Active Comparator|Memantine plus Risperidone|6 weeks 20 mg Memantine as add-on treatment to Risperidone
3148446|NCT00148590|Placebo Comparator|Placebo plus Risperidone|6 weeks 20 mg Placebo as add-on treatment to Risperidone
3148447|NCT00148616|Active Comparator|Memantine plus Risperidone|24 weeks memantine add on treatment to risperidone
3148448|NCT00148616|Placebo Comparator|Placebo plus Risperidone|24 weeks placebo add on treatment to risperidone
2437746|NCT03313492|Active Comparator|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society) will be accessible via our website."
2437747|NCT03313492|Active Comparator|Original UV4.me|Participants will view the original UV4.me web intervention, which includes educational modules, personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individuals, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator. The website content will remain the same, with the exception of updating photos, statistics, and cultural references for the current year.
2437748|NCT03313492|Experimental|Enhanced UV4.me2|Participants will view an enhanced version of the UV4.me website. Improvements to the website are based on user feedback from the original UV4.me trial, as well as reviews and models of effective e-Health interventions and implementation strategies.
2437749|NCT03313479||Group 1|GA and Dexmedetomidine
2437750|NCT03313479||group 2|GA and peribulbar
2437751|NCT03313479||group3|GA and xylocaine gel
2437752|NCT03313466|Experimental|iCBTI|Intervention: An internet-based cognitive behavioral therapy program for insomnia (iCBTI) that is tailored to the individual's needs based on responses to questions.
2437753|NCT03313466|Active Comparator|Usual care|Intervention: A group class on insomnia provided at each Kaiser Permanente Southern California medical center.
2437754|NCT03313453|Experimental|Aircleaner group|PuriCare (HEPA Air Cleaner) in active mode
2437755|NCT03313453|Placebo Comparator|Control comparator|Mock device of PuriCare in active mode
2437756|NCT03313440|Experimental|high fibre|A 10 day increase in daily wheat fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
2437757|NCT03313440|Experimental|low fibre|A 10 day control intervention with no additional wheat fibre. Products are provided in boxes that must be consumed each day during the intervention.
2437758|NCT03313427|Experimental|Intervention|Usual care Early physical therapy intervention at the UCIN and after discharge, at home; based on the family-centered model.
2437759|NCT03313427|Other|Control|Usual care
2437760|NCT03313414|Experimental|Treatment with Sofosbuvir/Velpatasvir|14 days of treatment with Sofosbuvir/Velpatasvir tablet
2437761|NCT03313388|Experimental|Tart Cherry Juice|290 mL per day of Tart Cherry juice for 7 days
2437762|NCT03313388|Active Comparator|Gatorade|290 mL per day of Gatorade for 7 days
2437763|NCT03313375|No Intervention|Control|Subjects will have no intervention. They will be resting in a chair for the entire length of the visit (4-5 hours) where blood pressure will be taken every 10 min, while other non-invasive cardiac measures are taken (I.E. Cardiac output, systemic vascular resistance, heart rate variability).
2437764|NCT03313375|Active Comparator|Continuous exercise|Subjects will be asked to perform a 45 min exercise bout. After a warmup, the exercise will be 30 minutes at a continuous level. After the exercise period subject will remain in the lab and blood pressure will be measured every 10 minutes for the remainder of the visit (4 hours) while other non-invasive cardiac measures are taken continuously as discussed above.
2437765|NCT03313375|Experimental|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. After a warmup period, the subjects will complete a 4x4 protocol in that they will alternate 4, 4 minute higher intensity exercise bouts with 3, 3 minute lower intensity bouts. After the exercise, subjects will remain in the lab and blood pressure will be measured every 10 minutes for 4 hours, while other non-invasive cardiac measures are taken continuously as discussed above.
2437766|NCT03313362|Experimental|Subjects admitted to Epilepsy Monitoring Units in the VAMC|Subjects being monitored by standard of care, video EEG, in the Epilepsy Monitoring Units in the VAMC will all be placed on a Seizure Monitoring and Alerting System (SPEAC System).
2437767|NCT03313349|Other|Usual Provision (UP)|"Usual Provision~Psychotherapy: 1. cognitive therapy 2.family intervention"
2437768|NCT03313349|Other|Enhanced/Need-Based Provision (ENP)|"Enhanced/need-based Provision~Psychotherapy: 1.cognitive therapy 2.family intervention"
2437769|NCT03313336|Active Comparator|Cohort 1|EMLA Test Patch.
2437770|NCT03313336|Active Comparator|Cohort 2|EMLA Reference Patch.
2437771|NCT03313336|Placebo Comparator|Cohort 3|Placebo patch.
2437772|NCT03313323|Experimental|Zirconium-ipilimumab|Zirconium-ipilimumab is an experimental tracer and is administered at start of ipilimumab treatment and after second infusion 3 weeks later
3188607|NCT00768690|Other|5|"Healthy volunteers, receiving 1600mg ABT-333 or placebo, BID*~*After review of the data from previous groups, and in accordance with the protocol, this arm was not dosed."
2437774|NCT03313297|Active Comparator|AZD4017|400mg oral AZD4017 twice daily for 35 days
2437775|NCT03313297|Placebo Comparator|Placebo|A placebo tablet containing microcrystalline cellulose and sodium stearyl fumarate to match the active tablets in size, shape and colour.
2437776|NCT03313284|Experimental|Study Group|
2437777|NCT03313271||a cohort of patients with lymphoma in China|establish a cohort of patients with lymphoma in China and follow up the patients for a long period of time
2437778|NCT03313258|Active Comparator|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
2437779|NCT03313258|Experimental|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
2437780|NCT03313232|Experimental|Fragrance allergic patients|Patients with a previous positive patch test to oxidized R-Limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
2437781|NCT03313232|Experimental|Possible fragrance allergic patients|Patients with a previous doubtful patch test to oxidized R-limonene. Patients will have an initial patch test dilution series with oxidized R-limonene performed on the back followed by twice daily exposure to oxidized R-limonene at three different concentrations and a vehicle control on the forearms for up to three weeks.
2437782|NCT03313232|Experimental|Healty controls|Healthy controls with no contact allergy to oxidized R-limonene. Healthy controls will have en initial diagnostic patch test with oxidized R-limonene performed followed by twice daily exposure to oxidized R-limonene at one concentration and a vehicle control on the forearms for up to three weeks.
2437783|NCT03313219|Experimental|Gentuximab Injection|Patients are assigned to a dose level at the time of study entry and scheduled to receive i.v. of a single dose. The patient enter the subsequent multiple dose i.v. in a 7-day cycle if no DLT in 21 days after the first dose. The study period of each subject will be up to 4 cycles until the tumor progression or unacceptable toxicity. The MTD will be determined by assessing DLT in each cohort from cohort 1 to 6, using a 3+3 dose escalation model. Cohort A begin at 4mg/kg IV and the dose escalated in separate cohorts from 8mg/kg IV, 12mg/kg IV，16mg/kg IV and 20mg/kg IV. If there is no DLT observe in any of these 3 patients in 7 weeks, then the trial proceeds to enroll 3 patients into the next higher dose cohort. If one subject develops a DLT at a specific cohort, an additional 3 patients are enrolled into that same dose cohort. Development of DLTs in more than 1 of 6 patients in a specific dose cohort suggests that the MTD has been exceeded, and further dose escalation is not pursued.
2437784|NCT03313206|Experimental|Patients with Resectable head and neck mucosal melanomas|
2437785|NCT03313193|Experimental|Arm A|Acupressure for Children in Treatment for a Childhood Cancer + usual care
2437786|NCT03313193|No Intervention|Arm B|Usual care alone
3188608|NCT00768729|Experimental|1|"Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily.~Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months."
2437788|NCT03313167||Atrial Fibrillation-potential Patients|individuals 65 years of age or older with moderate-to-high risk of stroke
2437789|NCT03313154||Neuropsychiatric screening (treatment+)|Subjects affected by chronic hepatitis HCV-related, undergoing new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
2437790|NCT03313154||Neuropsychiatric screening (treatment-)|Subjects affected by chronic hepatitis HCV-related, in wait list for new antiviral drugs treatment, will be screened by psychiatric and neuropsychological questionnaires/tests
2437791|NCT03313141|Experimental|Subjects|Only one arm is considered
2437792|NCT03313128||Historic intervention|Infants born into the historic intervention arm of sanitation trial (NCT02362932)
2437793|NCT03313128||Historic control|Infants born into the historic control arm of sanitation trial (NCT02362932)
2437794|NCT03313115||No Sleep/Wake Protocol Implementation|No implementation of the sleep/wake protocol. A subset of participants in this group will have light and sound levels in the room recorded.
2437795|NCT03313115||Sleep/Wake Protocol Implementation|The sleep/wake protocol will be implemented. A subset of participants in this group will also have light and sound levels in the room recorded.
2437796|NCT03313102|Experimental|Horton disease|
2437797|NCT03313102|Experimental|control|
2437798|NCT03313089||PSAN + MNP|"PSAN (Papas más nutritivas project) + MNP (micronutrients powders):~Children of the families beneficiaries of Community Schools of Family Agriculture of the municipalities of Cumbal, Carlosama Guachucal and Túquerres, who are part of the project Papas más nutritivas and exposed to project activities in which they work on topics related to food and nutritional security, equity and gender, production and entrepreneurship, Additionally, the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses (specified in the MNP only group). After the delivery of MNP, advising, measurements of weight and height, clarification of doubts regarding fortification with MNP, nutrition education, and accompaniment by the project staff will take place."
2437799|NCT03313089||MNP only|"Cohort of exposed to MNP (micronutrients powders):~Children who will receive MNP delivered through the hospital or institutional health service providers of the municipalities of Guachucal and Carlosama, following the protocol for the home fortification with MNP that is 12 months in total approximately, will be made 2 deliveries of 60 doses: the first period consists of the taking of MNP for 2 months, followed by a rest period of 4 months and continues again by another MNP intake for 2 months and rest for 4 months, and exposed to dissemination of basic information with regard to MNP and monitoring by growth and development that is routinely performed by health staff."
3188609|NCT00768768|Active Comparator|1|Iontophoretic Dose Level 1
3188610|NCT00768768|Active Comparator|2|Iontophoretic Dose Level 2
3188611|NCT00768768|Active Comparator|3|Iontophoretic Dose Level 3
3188612|NCT00768768|Active Comparator|4|Iontophoretic Dose Level 4
2437804|NCT03313063||PE|Women with a history or preeclampsia, between 18 - 50 years of age, 0.5 - 20 years postpartum
2437805|NCT03313063||Control|Age-matched women without any birth complications, between 18 - 50 years of age, 0.5 - 20 years postpartum
3188613|NCT00768768|Active Comparator|5|Iontophoretic Dose Level 5
3188614|NCT00768781|Active Comparator|Mindfulness-Based Stress Reduction|
3188615|NCT00768781|Active Comparator|Mindfulness-Based Therapy for Insomnia|
3188616|NCT00768781|Other|Behavioral Therapy for Insomnia (Delayed treatment condition)|
2437812|NCT03313011||Progressive Apraxia of Speech|
2437813|NCT03312998|Experimental|Xrays|
2437814|NCT03312985|Experimental|ACAF surgery|Underwent anterior controllable antedisplacement and fusion
2437815|NCT03312985|Placebo Comparator|ACCF surgery|Underwentanterior controllable antedisplacement and fusion
2437816|NCT03312972|Experimental|HDR Brachytherapy|HDR Brachytherapy implant, Up to 30 Gray (Gy) to target lesion in one to two fractions.
2437817|NCT03312959|Experimental|hyperbaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml hyperbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
2437818|NCT03312959|Active Comparator|isobaric bupvacaine group|Peribulbar block will be performed using a total volume of 7 ml 6ml isorbaric bupivacaine 0.5% + hyaluronidase (50 IU) in 1ml saline
2437850|NCT03312777|Active Comparator|Tramadol|Oral tramadol 50 mg (overencapsulated 50 mg tablet) administered every 6 hours for nine doses, coadministered with paroxetine.
2437819|NCT03312946|Experimental|Treatment oscillating vibro|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks. Being performed twice a week, with a total duration of 50 minutes to the session, being 10 sessions total to end the treatment.
3188617|NCT00768794|Active Comparator|Acidolphilus|In the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
2437821|NCT03312920|Experimental|active anodal tDCS|active anodal tDCS with Face Name associate Memory task
2437822|NCT03312920|Sham Comparator|Sham tDCS|sham tDCS with Face Name associate Memory task
2437823|NCT03312920|Experimental|active cathodal tDCS|active cathodal tDCS with Face Name associate Memory task
2437830|NCT03312894|Experimental|Cohort 1 (Ketamine Responders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
2437831|NCT03312894|Placebo Comparator|Cohort 1 (Ketamine Responders): Placebo|TAK-653 placebo-matching tablets, orally, once daily up to Day 56
2437832|NCT03312894|Experimental|Cohort 2 (Ketamine Nonresponders): TAK-653 6 mg|TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 1 and 2; followed by TAK-653 tablets, orally, once daily on Days 3 and 4; followed by TAK-653 tablets plus TAK-653 placebo-matching tablets, orally, once daily on Days 5 to 7; followed by TAK-653 tablets, orally, once daily on Days 8 to 56.
2437833|NCT03312894|Placebo Comparator|Cohort 2 (Ketamine Nonresponders): Placebo|TAK-653 Placebo-matching tablets, orally, once daily up to Day 56
2437834|NCT03312881||neuropathic pain|Children with clinical diagnosis of neuropathic pain. Interventions: patient reported outcome measures, quantitative sensory testing, neuroimaging
2437835|NCT03312881||non-neuropathic pain|Children with clinical diagnosis of non-neuropathic pain. Interventions: patient reported outcome measures
2437836|NCT03312868|Experimental|Prospective Arm|Prospective arm with patients being treated with SBRT
2437837|NCT03312855|Experimental|Revacept 80 mg|single dose, intravenous
2437838|NCT03312855|Experimental|Revacept 160 mg|single dose, intravenous
2437839|NCT03312855|Placebo Comparator|Placebo|single dose, intravenous
2437840|NCT03312842|Experimental|CS1001|
2437841|NCT03312816|Placebo Comparator|Placebo|0 mg/d added POP
2437842|NCT03312816|Active Comparator|low dosage|low added POP
2437843|NCT03312816|Active Comparator|Medium dose|medium added POP
2437844|NCT03312816|Active Comparator|Hige dose|high added POP
2437845|NCT03312803|Active Comparator|Mini autogenous skin grafts|we take the autogenous skin graft from the same patient then cut it into small pieces then we spread it over the burn wound on one limb then cover these small pieces with homogenous skin graft taken from another person.
2437846|NCT03312803|Active Comparator|Autogenous skin graft|we take the regular autogenous one piece skin graft from the same patient and cover the burn wound on the other limb then we make a comparison between both limbs
2437847|NCT03312790|Experimental|augmented reality device|Tasks realized using augmented reality device
2437848|NCT03312790|Other|Real condition|Same tasks than augmented reality realized in normal/real condition
2437849|NCT03312777|Experimental|Omnitram|Oral Omnitram 20 mg (overencapsulated 10 mg tablets) administered every 6 hours for nine doses, coadministered with paroxetine.
3188618|NCT00768807|Sham Comparator|Sham CPAP|Patients submitted to SHAM CPAP use for 06 months
3188619|NCT00768807|Active Comparator|CPAP|OSA patients submitted to 06 months of CPAP treatment
3188620|NCT00768820|Experimental|1|
3188621|NCT00768846|Active Comparator|1|Endeavor Resolute Stent
2437852|NCT03312764|Experimental|Online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants in the online program receive paced curriculum, access to a live health coach, interactive group message forums, and connected weight scale and activity monitoring devices.
2437853|NCT03312764|Active Comparator|Enhanced Standard Care|All participants randomized to the standard-care/control group (SC) will be offered the opportunity to attend a single 90-minute diabetes prevention class with a trained health professional (MPH, RD, or related advanced degree). The class will focus on healthful eating based on the current MyPlate recommendations, guidance on gradual increases in moderate intensity physical activity, and action planning to be shared with friends and/or family. Control participants will also be given the opportunity to participate in the online digital intervention upon completion of the 12-month follow-up assessment.
3148449|NCT00148642|Experimental|1|silver salts coated endotracheal tube
2437855|NCT03312738|Experimental|Everolimus + Exemestane|Everolimus 10mg/Day + Exemestane 25mg/Day
2437856|NCT03312738|Active Comparator|Placebo + Exemestane|Placebo of everolimus in combination with exemestane 25 mg daily
2437857|NCT03312725||Patients with ruptured or unruptured intracranial aneurysms.|
2437858|NCT03312712||Participants with sarcoidosis|"Bronchoscopy, BAL collection, and PFTs* [SoC] *if required~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan"
2437859|NCT03312712||Healthy volunteers|"Part A:~PFTs~Screening, research and safety bloods~Dynamic 18F-FDG PET/CT scan~Part B:~PFTs~Screening, research and safety bloods~Baseline and post challenge Dynamic 18F-FDG PET/CT scans~LPS/saline challenge"
2437860|NCT03312699|Experimental|Group A IIV4|Group A: Up to 30 healthy volunteers 18-40 years old, will be given seasonal quadrivalent inactivated influenza vaccine (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437861|NCT03312699|Experimental|Group B High Dose IIV3|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal high dose trivalent inactivated influenza vaccine (Fluzone High Dose) Fluzone® high dose vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437862|NCT03312699|Experimental|Group B Fluad|Group B: Up to 15 healthy volunteers 65 plus years old, will be given seasonal adjuvanted trivalent inactivated influenza vaccine Fluad®. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437863|NCT03312699|Experimental|Group A Hepatitis A (HepA)|Group A: Up to 30 healthy volunteers 18-40 years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437864|NCT03312699|Experimental|Group B Hepatitis A|Group B: Up to 30 healthy volunteers 65 plus years old, will be given inactivated Hepatitis A vaccine Vaqta® in year 1 of the study and a booster 12 months post primary Vaqta vaccination. Each volunteer will complete a total of 4 visits per vaccination: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437865|NCT03312699|Experimental|Group A Typhoid VI|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif®. This arm represents those randomized to Typhoid VI. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437866|NCT03312699|Experimental|Group A Oral Typhoid|Group A: Up to 15 healthy volunteers 18-40 years old, will be randomized to either Typhoid Vi Polysaccharide Vaccine, Typhim Vi®, or Typhoid Vaccine Live Oral Ty21a, Vivotif® (Oral Typhoid). This arm represents those randomized to Oral Typhoid. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8 (from date of last oral dose), Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437867|NCT03312699|Experimental|Group B Typhoid VI|Group B: Up to 30 healthy volunteers 65 plud years old, will be given Typhoid Vi Polysaccharide Vaccine (Typhoid VI), Typhim Vi® vaccine. Each volunteer will complete a total of 4 visits: Day 0 (pre-immunization), Day 6-8, Day 12-16, and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2437868|NCT03312686||Eosinophilic Esophagitis patients|PPI treatment
2437869|NCT03312673||Asthma population|Patients (men and women) asthmatic smokers and non-smokers followed routinely in the pulmonology department, Croix-Rousse Hospital, Hospices Civils of Lyon.
2437870|NCT03312660|Experimental|Prebiotic group.|Group of 22 families consuming a fermented dairy product with prebiotic components, once a day for 4 months.
2437871|NCT03312660|Placebo Comparator|Placebo group|Group of 22 families consuming a dairy product with similar characteristics regarding color, flavor and nutritional composition, not containing the prebiotic components, once a day for 4 months.
2437872|NCT03312647||Latent tuberculosis infection|Identified subjects with latent tuberculosis infection (LTBI) using whole-blood interferon-r release assays. All enrolled subjects were treated with one of the recommended regimens for LTBI treatment: 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid plus rifampin. Blood, urine sampling, and monitoring frequencies of adverse reactions of anti-TB drugs were performed.
3148450|NCT00148642|Placebo Comparator|2|uncoated endotracheal tube
3188622|NCT00768846|Active Comparator|2|Xience V Stent
3148451|NCT00148681|Experimental|Lower Risk Regimen|
3148452|NCT00148681|Experimental|Higher Risk Regimen|
3148453|NCT00148694|Experimental|Intervention single arm|Cisplatin 75mg/m2 q21 days x 4 pre-surgery
3148454|NCT00148876|Active Comparator|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression and discontinuation of Trastuzumab.
2437874|NCT03312621|Experimental|Intervention|The intervention group received all aspects of enhanced usual care but was also assigned a healthcare transition nurse who coordinated the delivery of specific intervention services. These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
2437875|NCT03312621|No Intervention|Control|The control group received enhanced usual care which provides standardized healthcare transition-specific written information including a written transition policy, as well as insurance and guardianship information. Participants were also provided with a transition readiness assessment and entered into a healthcare transition registry to facilitate tracking and communication.
2437876|NCT03312608||mild myelopathy (JOA>12)|40 patients (JOA>12) suffering from symptomatic or asymptomatic degenerative cervical myelopathy scheduled for surgery or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
2437877|NCT03312608||moderate myelopathy|40 patients (JOA≤12) suffering from symptomatic degenerative cervical myelopathy scheduled for surgery (anterior and/ or posterior decompression) or conservative treatment. The radiological inclusion criteria are cervical spinal stenosis associated with or without intramedullary high signal intensity lesion on T2-weighted MRI. Exclusion criteria are other pathologies in the vicinity of the corticospinal tract above the lesion site (i.e. tumor, infarction), neuroinflammatory disease, high grade paresis of the upper extremity (BMRC<3), the existence of a cardiac pacemaker, deep brain stimulation electrodes or pregnancy. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
2437878|NCT03312608||healthy control|As a control group, 40 subjects will be included into the study. Exclusion criteria and examination protocol are identical with the patient group. By means of navigated transcranial magnetic stimulation the resting motor threshold, recruitment curve, cortical silent period and motor area will be determined.
3188623|NCT00768859|Experimental|1|paclitaxel, trastuzumab and carboplatin
2437880|NCT03312582|Experimental|Manual debridement and 1% metformin gel|
2437881|NCT03312582|Placebo Comparator|Manual debridement and placebo|
2437882|NCT03312569||Intracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an intracorporeal anastomosis due to begin or malignant Right Colon Disease.
2437883|NCT03312569||Extracorporeal Anastomosis|Participants will undergo either robotic-assisted or laparoscopic surgery with an extracorporeal anastomosis due to begin or malignant Right Colon Disease.
2437884|NCT03312556|Placebo Comparator|Placebo pill or patch or sham CPAP|Placebo pill or patch or sham CPAP
2437885|NCT03312556|Active Comparator|CPAP (continuous positive airway pressure)|Continuous positive airway pressure during the night
3188624|NCT00768885|Active Comparator|PureVision 1|PureVision soft contact lens design #1.
3188625|NCT00768885|Experimental|PureVision 2|PureVision soft contact lens design #2
2437888|NCT03312530|Experimental|A: Cobimetinib|Participants will receive the standard single-agent cobimetinib dose of 60 milligrams (mg) (3 tablets of 20 mg each) orally (PO) daily on Days 1-21 of each 28-day cycle until disease progression. Upon progression, participants will be allowed to receive treatment with cobimetinib and atezolizumab at the recommended Phase II dose of cobimetinib 60 mg PO on Days 1-21 plus atezolizumab intravenous (IV) infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2437889|NCT03312530|Experimental|B: Cobimetinib + Venetoclax|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2437890|NCT03312530|Experimental|C: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib PO daily on Days 1-21 of each 28-day cycle plus venetoclax PO daily on Days 1-28 of each 28-day cycle, at the dose level identified in the safety run-in phase plus atezolizumab IV infusion at a fixed dose of 840 mg on Day 1 and Day 15 of each 28-day cycle. Treatment will continue until the participant has disease progression, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2437891|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses, in 28-day cycles, to identify the dose level with acceptable safety.
2437892|NCT03312530|Experimental|Safety Run-In: Cobimetinib + Venetoclax + Atezolizumab|Participants will receive cobimetinib (on Day 1-21) plus venetoclax (on Day 1-28) at escalated doses and atezolizumab (on Day 1 and Day 15) at a fixed dose of 840 mg IV, in 28-day cycles, to identify the dose level with acceptable safety.
3188626|NCT00768911|Experimental|1|
3188627|NCT00768924||1|Spinal fusion patients
3188628|NCT00768937|Experimental|Treatment arm|all patients will be treated with sorafenib
2437896|NCT03312504|Experimental|Neuromuscular Training Warm-up|Schools randomized to the intervention arm receive a workshop outlining a neuromuscular training program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consist of high-intensity aerobic, strengthening, agility, plyometric, and balance components. The workshop is designed to last two hours, and includes a video outlining the warm-up components, practice time, and group discussions for action planning to address potential barriers to the program.
3188629|NCT00768950||Spondyloarthropathies|Patients with spondyloarthropathies (ankylosing spondylitis, reactive arthritis, psoriatic arthritis and spondylitis, enteropathic arthritis and spondylitis, juvenile-onset spondyloarthritis, and undifferentiated spondyloarthritis) as defined by the AMOR criteria
2437897|NCT03312504|Placebo Comparator|Control Standard-of-practice Warm-up|Schools randomized to the control arm receive a workshop outlining a standard-of-practice program to be used as a warm-up for 15 minutes at the beginning of each physical education class. The warm-up consists of aerobic exercises and static stretching. The workshop is designed to last one hour, and includes an explanation and demonstration of the exercises, but no video or practice time.
2437898|NCT03312478|Other|Case|Known cases of type 1 diabetes mellitus as described in the inclusion criteria for cases
2437899|NCT03312478|Other|Control|Age-matched non-diabetic controls as described in the inclusion criteria for controls
2437900|NCT03312465||AS Domelock System Subjects|Subjects that receive the Anatomical Shoulder Domelock System
2437901|NCT03312452|Experimental|Infusion pump group|Study subjects assigned to this group will receive intravenous fluid via an infusion pump (Hospira plum pump) during their surgery.
2437902|NCT03312452|Active Comparator|Gravity drip group|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
2437903|NCT03312439|Active Comparator|Intervention group|Will be given advice as described above
2437904|NCT03312439|No Intervention|Control group|Consisting of subjects from the general Swedish population.
2437905|NCT03312426|Experimental|BMS-986205 under fasted conditions then with high-fat meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a high-fat meal (Day 15).
2437906|NCT03312426|Experimental|BMS-986205 with high-fat meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a high-fat meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
2437907|NCT03312426|Experimental|BMS-986205 under fasted conditions then with light meal.|Single, 100 mg dose of BMS-986205 under fasted conditions (Day 1) followed by single, 100 mg dose of BMS-986205 with a light meal (Day 15).
2437908|NCT03312426|Experimental|BMS-986205 with light meal then under fasted conditions.|Single, 100 mg dose of BMS-986205 with a light meal (Day 1) followed by single, 100 mg dose of BMS-986205 under fasted conditions (Day 15).
2437909|NCT03312413|Experimental|Dexmedetomidine low dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.2μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2437910|NCT03312413|Experimental|Dexmedetomidine median dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.5μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2437911|NCT03312413|Experimental|Dexmedetomidine high dose group|Patients in this group are received dexmedetomidine hydrochloride iv infusion of 0.7μg·kg-1·h-1 from incision to 20-30 minutes before the end of surgery
2437912|NCT03312413|Placebo Comparator|Control group (normal saline group)|Patients in this group are received saline iv infusion of 5mL·h-1 from incision to 20-30 minutes before the end of surgery
2437915|NCT03312387|Experimental|Essential Amino Acid and Exercise|Participants will be provided with essential amino acids during exercise training.
2437916|NCT03312387|Placebo Comparator|Placebo and Exercise|Participants will be provided with placebo supplement during exercise training.
2437917|NCT03312374||stage II CRC|Patients with stage II colorectal cancer
2437918|NCT03312374||stage III CRC|Patients with stage III colorectal cancer
2437919|NCT03312361|Experimental|15% Oxygen|All participants will breath in 15% oxygen for 2 hours
3188630|NCT00768963|Experimental|1|Patients will receive one injection of ranibizumab 3 days prior to surgery
2437921|NCT03312335|Experimental|Low-dose Aldesleukin (Proleukin®)|
2437922|NCT03312322|Experimental|CWT with high-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2437923|NCT03312322|Experimental|CWT with low-frequency electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2437924|NCT03312322|Experimental|CWT with sham electrical nerve stimulation|This study has a cross-over design. Patients will achieve CWT with either sham, high-frequency or low-frequency lumbar transcutaneous electrical nerve stimulation in a randomised order.
2437925|NCT03312309|Experimental|RIF group|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
2437926|NCT03312283|Experimental|QL1205|QL1205 injection (0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
2437927|NCT03312283|Active Comparator|Lucentis|Lucentis® injection(0.5mg) by vitreous injection once a month for three months（D1、D29、D57）
2437928|NCT03312270|Experimental|Multimodality information Comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
2437929|NCT03312257|Experimental|Multifocal D +2.50 add & 0.01% atropine|"The Biofinity Multifocal D with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine."
2437930|NCT03312244|Experimental|Pyridostigmine|Pyridostigmine 180mg/d slow-release formulation
2437931|NCT03312244|Placebo Comparator|Placebo|Placebo
3188631|NCT00768963|Experimental|2|Patients will undergo one injection of ranibizumab at the time of surgery
3188632|NCT00769028|Experimental|AIMSPRO|
3188633|NCT00769028|Placebo Comparator|Placebo|
3188634|NCT00769041|Placebo Comparator|placebo|
3188635|NCT00769041|Active Comparator|moxifloxacin|
3188636|NCT00769041|Experimental|avanafil therapeutic|avanafil 100mg - therapeutic dose
2437939|NCT03312205|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells
2437940|NCT03312192|Active Comparator|Plate and Cage|ACDF with interbody cage and anterior plating.
2437941|NCT03312192|Active Comparator|Stand Alone Cage|ACDF with stand alone interbody cage without anterior plating
2437942|NCT03312179||diabetics STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
2437943|NCT03312179||non diabetics STEMI|Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
2437944|NCT03312179||diabetics incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
2437945|NCT03312179||diabetics never-incretin-users STEMI|Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
2437946|NCT03312166|Experimental|Compression device|
2437947|NCT03312153|Experimental|Neem (Azadirachta indica)|Neem (Azadirachta indica) (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
2437948|NCT03312153|Active Comparator|2.5%sodium hypochlorite|2.5% sodium hypochlorite, anti-bacterial root canal irrigant solution
2437949|NCT03312140|Other|Choline Chloride|Patients receive choline chloride (1g Choline) three times a day for 12.6 weeks as a food supply
2437950|NCT03312127|Experimental|GORE Excluder|GORE Excluder Iliac Branch Endoprosthesis arm with 'ILIAC ENDOPROSTHESIS GORE EXCLUDER'
2437952|NCT03312101|Experimental|Experimental|exercise program
2437953|NCT03312101|No Intervention|Control|observation
2437954|NCT03312075||cystic fibrosis patients|Sputum and blood samples
2437955|NCT03312062|Experimental|Foam Rolling Group|The participants in this group will receive foam rolling exercise.
2437956|NCT03312062|No Intervention|Control Group|The participants in this group will receive no foam rolling. They will only be evaluated.
2437957|NCT03312036|Experimental|CPFA Patients|Patients affected by acute or acute on chronic liver failure who undergo Coupled plasma filtration and adsorption (CPFA) to recover their basal liver function or as a bridge to liver transplantation. The intervention is CPFA treatment which lasts 6 hour length. The intervention can be repeated for a maximum of 5 times.
3148455|NCT00148876|Experimental|Capecitabine and Trastuzumab|Capecitabine 2500 mg/m² orally day 1-14 q day 22 until progression + Trastuzumab 6 mg/kg body weight every 3 weeks i.v. as a 90 min infusion until progression
3148456|NCT00148889|Sham Comparator|2|Sham-stimulation
2437964|NCT03311997|No Intervention|Non-operative treatment|Active rehabilitation program
2437965|NCT03311997|Active Comparator|Operative treatment|Surgical reattachment of hamstring tendons using suture anchors followed by active rehabilitation program
2437966|NCT03311984||LMWH qd|receiving Low-molecular-weight Heparin（LMWH）qd
2437967|NCT03311984||LMWH q12h|receiving Low-molecular-weight Heparin（LMWH）q12h
2437968|NCT03311971|Sham Comparator|Conventional therapy|Patient undergoing conventional analgesic therapy after total knee replacement
2437969|NCT03311971|Experimental|Virtual reality glasses|Patient undergoing conventional analgesic therapy after total knee replacement and treated with virtual glasses
2437970|NCT03311958|Experimental|Nivolumab|
2437971|NCT03311945|Experimental|Raltegravir + Lamivudine|Lamivudine (300 mg QD) plusRaltegravir (1200 mg QD)
2437972|NCT03311932|Active Comparator|Cortef® Tablets - fasted|Single dose of 20mg Cortef® Tablets - fasted arm
2437973|NCT03311932|Experimental|Infacort® - fasted|Single dose of 20mg Infacort® - fasted arm
2437974|NCT03311932|Active Comparator|Cortef® Tablets - fed|Single dose of 20mg Cortef® Tablets - fed arm
2437975|NCT03311932|Experimental|Infacort® - fed|Single dose of 20mg Infacort® - fed arm
2437976|NCT03311906|Experimental|Test side|Scaling and Root Planing 0.8% Hyaluronic acid gel
2437977|NCT03311906|Active Comparator|Control Side|Scaling and Root Planing
2437978|NCT03311893|Active Comparator|health personnel|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
3148457|NCT00148889|Active Comparator|1|Active GPI-DBS
3148458|NCT00148902|Experimental|All treated subjects|All subjects received Lapatinib in Combination with Docetaxel (Taxotere)
3148459|NCT00148915|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) ibandronate tablet orally once monthly for one year.
3148460|NCT00148915|Placebo Comparator|Placebo|Participants will receive ibandronate matched placebo tablet orally once monthly for one year.
3148461|NCT00149071|Active Comparator|A|rTMS
3148462|NCT00149071|Sham Comparator|B|sham rTMS
3148463|NCT00149110|Experimental|A|Sleep deprivation in combination with light and duloxetine
3148464|NCT00149110|Active Comparator|B|Exercise and duloxetine
3148465|NCT00149162|Active Comparator|1|Patients treated by Proleukin
3148466|NCT00149162|No Intervention|2|Without Proleukin
3148467|NCT00149175||Neurodegenerative disorders with cognitive impairment|
3148468|NCT00149175||Control|
3148469|NCT00149175||At risk reactive|
3148470|NCT00149292|Experimental|LY2140023|40 mg LY2140023 BID for 28 days
3148471|NCT00149292|Active Comparator|Olanzapine|15 mg Olanzapine once daily (QD) for 28 days
3148472|NCT00149292|Placebo Comparator|Placebo|placebo for 28 days
2437979|NCT03311893|Placebo Comparator|population|natural orifice surgery evaluation of the awareness of the use of transvaginal, transoral and trananal approach in surgical excision and the difference between the health staff and population
2437980|NCT03311880|Experimental|Intervention|There is no control group for this study. Therefore all participants receive the intervention.
2437981|NCT03311867|Active Comparator|Braided Suture|Patient in this group will have a cerclage with ethibond suture material
2437982|NCT03311867|Active Comparator|Non- Braided Suture|Patient in this group will have a cerclage with prolene suture material
2437983|NCT03311854|Experimental|Emapalumab|
3188637|NCT00769041|Experimental|avanafil supratherapeutic|avanafil 800mg - supratherapeutic dose
3188638|NCT00769054|Active Comparator|1|Local Infiltration with Ropivacaine
3188639|NCT00769054|Placebo Comparator|2|Local Infiltration with Placebo
3188640|NCT00769080||1|Standard Treatment plus PSP
3188641|NCT00769080||2|Standard Treatment
2437989|NCT03311828|Experimental|Diagnostic (Copper 64Cu-DOTA-daratumumab, PET)|Patients receive daratumumab IV over 10-45 minutes, and within 6 hours, patients receive copper 64Cu-DOTA-daratumumab IV on day 0. Patients undergo PET on days 1 and 2.
2437990|NCT03311802||1|
2437991|NCT03311789|Experimental|PD-1 inhibitor + Gemcitabine+Cisplatin|Patients will be enrolled in the experimental arm and will receive Gemcitabine on day 1 and 5 (1000mg/m2 ) +Cisplatin on day 1(75mg/m2)+ PD-1 inhibitor on day 3 (Nivolumab 3mg/kg, or SHR-1210 200mg) every 3 weeks. If there is continued benefit after 6 months, PD-1 inhibitor will be administered as maintenance treatment until tumor progression or death.
2437992|NCT03311763|Active Comparator|Counseling alone|Group 1: physical activity assessment, brief counseling session + physical activity wearable
2437993|NCT03311763|Experimental|Group exercise|Group 2: Group 1 intervention components + referral to a free, community-based, EIM practitioner led group exercise program (two, 1 hour classes/week for 8 weeks).
2437994|NCT03311750|Experimental|Panitumumab|On day 1 of each cycle patients will receive panitumumab followed by 5-fluorouracil and leucovorin in combination with either irinotecan (FOLFIRI regimen) or oxaliplatin (FOLFOX regimen) or followed by irinotecan monotherapy. This treatment will be repeated every 2 weeks for FOLFIRI and FOLFOX regimens and every 3 weeks for irinotecan monotherapy.
2437995|NCT03311737|Experimental|general anesthesia group|The patients in this group receive general anesthesia preoperatively, and use patient controlled intravenous analgesia postoperatively.
2437996|NCT03311737|Active Comparator|epidural group|The patients in this group receive general anesthesia combined with epidural anesthesia, and use patient controlled epidural analgesia postoperatively.
3188642|NCT00769093|Active Comparator|Group 1|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The first study group (n=6) will receive bevacizumab, the antiangiogenic agent for three weeks, then dexamethasone for three weeks.
3188643|NCT00769093|Active Comparator|Group 2|Both groups will receive an intravenous chemotherapeutic drug (carboplatin). The second study group (n=6) will receive dexamethasone for 3 weeks, then switch to bevacizumab, the antiangiogenic agent, for 3 weeks.
3188644|NCT00769106|No Intervention|B (control group)|regular treatment and follow up
3188645|NCT00769106|Experimental|A (CIK group)|cytokine-induced killer cell treatment plus regular treatment and follow up
2438001|NCT03311711|Experimental|SPIRIT-in person|Patients and surrogates who participate in the SPIRIT intervention in person.
2438002|NCT03311711|Experimental|SPIRIT-remote|Patients and surrogates who participate in the SPIRIT intervention remotely, via teleconference.
2438003|NCT03311711|Active Comparator|Usual care|Patients and surrogates who receive the standard information about advance directives that is provided at the time of diagnosis.
2438040|NCT03311451|Other|C2 CryoBalloon 180 Ablation System|C2 CryoBalloon 180 Ablation System will be used to ablate visible Barrett's esophagus
2438084|NCT03311282|Experimental|Feeding Bottle 4m+|10 infants aged 4 months (+/- 10 days): 4-6 m bottle. 4-6 months, 250 ml, non-angled teat), for infants aged 4 months (+/- 10 days) / over 9 weeks of participation.
2438527|NCT03308331|Active Comparator|Healthy control nonsmokers using nicotine patch|
3188646|NCT00769145|Experimental|Ranibizumab|Patients to receive two injections of 0.5 mg ranibizumab subconjunctivally
3188647|NCT00769158|Experimental|Topiramate + Naltrexone|Combination of Topiramate and Naltrexone
3188648|NCT00769158|Placebo Comparator|Placebo|
3188649|NCT00769171|Active Comparator|Arm 2|
3188650|NCT00769171|Experimental|Arm 1|
3188651|NCT00769197||1|Children with birth/time of neurologic insult less than 28 weeks of gestation
3188652|NCT00769197||2|Children with birth/time of neurologic insult at more than 28 weeks of gestation
3188653|NCT00769210|Experimental|A|
3188654|NCT00769236|Other|1|Patients with crohn disease
3188655|NCT00769236|Other|2|Patients reached by hemorrhagic first side-colitis
3188656|NCT00769236|Other|3|Patients controls
3188657|NCT00769262|Active Comparator|Aggressive Weaning|Infants will be weaned from the isolette using our current NICU standard of care.
3188658|NCT00769262|Experimental|Conservative Weaning|Infants will be weaned from the isolette using a modified conservative weaning schedule.
3188659|NCT00769275||1|Screening at start study with Adenosine vasodilator stress Tc-99m Sestamibi SPECT imaging
3188660|NCT00769275||2|No screening
3188661|NCT00769288|Experimental|I|Patients will receive a 1-hour infusion of FAU on days 1-5.
3188662|NCT00769301||1|Not hospitalized cancer patients under active treatment
3188663|NCT00769301||2|Caregivers of these cancer patients
3188664|NCT00769353|Experimental|Cognitive Behavioral Therapy-PASCET|Primary and Secondary Coping Enhancement Training (PASCET)
3188665|NCT00769353|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy (SNDT)
3188666|NCT00769366|Experimental|Psychotherapy|Psychotherapy and medical therapy
3188667|NCT00769366|Active Comparator|Control|Optimal medical therapy
3188668|NCT00769379|Experimental|Arm I (standard WBI)|Patients undergo standard WBI over 5-6 weeks.
3188669|NCT00769379|Experimental|Arm II (WBI, trastuzumab)|Patients receive trastuzumab IV over 30-90 minutes once in weeks 1 and 4. Patients also undergo WBI as in Arm I.
2438004|NCT03311698|Experimental|Intervention|Households receiving the intervention will receive (1) Interventions to promote homestead food production, increase agricultural production and food diversity, (2) nutritional counselling, including locally adapted instructions on the mix and quantity of food suitable for children of ages 6-24 months, and (3) a health-focused intervention, including information on micronutrient supplementation, integrated management of child illnesses, and prevention and management of child malnutrition with a focus on the first 1,000 days.
2438005|NCT03311698|No Intervention|Control|Households receive the standard of care in the area for agricultural and health services.
2438006|NCT03311685|Experimental|Laparoscopic POP repair|"Patients undergoing laparoscopic surgery for the repair of pelvic organ prolapse.~vaginal tactile imager"
2438007|NCT03311685|Experimental|Vaginal POP repair|Patients undergoing vaginal surgery for the repair of pelvic organ prolapse. vaginal tactile imager
2438008|NCT03311672|Experimental|Cohort 1 - Immunotherapy Alone|Approximately 10 patients will be enrolled in the immunotherapy alone cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
2438009|NCT03311672|Experimental|Cohort 2 - Immunotherapy with Stereotactic Radiation|Approximately 10 patients will be enrolled in the immunotherapy with stereotactic radiation therapy cohort under a larger two-year industry-funded, investigator-initiated single-institution, phase II, open-label clinical trial (NCT03217071; Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer) in which patients with stage I-IIIA non-small cell lung cancer (NSCLC) are randomized to receive two cycles of systemic immunotherapy (pembrolizumab, a PD-1 inhibitor) with or without immune-priming stereotactic radiation therapy (SRT, 12 Gy) to the lateral half of the primary lung tumor prior to resection.
2438012|NCT03311633|Experimental|3 week percutaneous pinning group|Percutaneous pinning time will be for three weeks and short cast immobilization for six weeks.
2438013|NCT03311633|Active Comparator|6 week percutaneous pinning group|Percutaneous pinning time will be for six weeks and also short cast immobilization.
2438014|NCT03311620|Other|Endobronchial ultrasound transbronchial needle aspirate|
2438015|NCT03311607|Other|Cohort treated with AmBisome 15 mg/kg|280 patients, receiving AmBisome
2438016|NCT03311594|Experimental|Low Alcohol Consumption and No Pain Induction|Condition 1: Low alcohol consumption Condition 2: No pain group
2438017|NCT03311594|Experimental|Low Alcohol Consumption and Pain Induction|Condition 1: Low alcohol consumption Condition 2: Pain group
2438018|NCT03311594|Experimental|Moderate Alcohol Consumption and No Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: No pain group
2438019|NCT03311594|Experimental|Moderate Alcohol Consumption and Pain Induction|Condition 1: Moderate alcohol consumption Condition 2: Pain group
2438020|NCT03311594|Placebo Comparator|Placebo Alcohol Consumption and No Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: No pain group
2438021|NCT03311594|Experimental|Placebo Alcohol Consumption and Pain Induction|Condition 1: Placebo alcohol consumption Condition 2: Pain group
2438022|NCT03311594|Placebo Comparator|Control and No Pain Induction|Condition 1: No alcohol consumption Condition 2: No pain group
2438023|NCT03311594|Experimental|Control and Pain Induction|Condition 1: No alcohol consumption Condition 2: Pain group
2438024|NCT03311581|Experimental|Propofol group|propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
2438025|NCT03311581|Active Comparator|Sevoflurane group|sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml
2438026|NCT03311568|Experimental|surgery in general anaesthesia|10 patients. ultrasound for microcirculatory assessment applied.
2438027|NCT03311568|Experimental|open chest cardiac surgery|10 patients. ultrasound for microcirculatory assessment applied.
2438028|NCT03311568|Experimental|critical septic shock at ICU|20 patients. ultrasound for microcirculatory assessment applied.
2438029|NCT03311568|Experimental|healthy volunteers|10 subjects. ultrasound for microcirculatory assessment applied.
3148473|NCT00149305||Patients with gouthy diathesis|
2438031|NCT03311529|Experimental|Applied Relaxation|
2438032|NCT03311529|No Intervention|usual care|
2438033|NCT03311516|Experimental|Group A|Group A = intervention group (new functional insulin therapy) who adjusts the insulin bolus according to a dose titration algorithm taking into account the lipid and protein content in addition to that of carbohydrates. The functional insulin therapy is based on a Carbohydrate / Lipid / Protein count
2438034|NCT03311516|Other|Group B|Group B=control group (functional insulin tehrapy) who adjusts the insulin bolus taking into account only the carbohydrate content. The functional insulin therapy is based on a Carbohydrate count only.
2438035|NCT03311503|Experimental|Treatment arm|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
2438036|NCT03311490|Experimental|Intervention|Participants allocated to the intervention group will use Spraino® as a measure to prevent lateral ankle sprains.
2438037|NCT03311490|No Intervention|Control|"Participants allocated to the control group will be a do-as-usual comparator. This implies, that the participants can treat and prevent lateral ankle sprains in any way they wish, except using Spraino®."
2438038|NCT03311477|Experimental|ABBV-399|ABBV-399 via intravenous administration at escalating dose levels.
2438039|NCT03311464|Experimental|Arm A|Participants receiving adalimumab for Pyoderma Gangrenosum active ulcer(s).
2438528|NCT03308331|No Intervention|Healthy control nonsmokers using placebo patch|
3148474|NCT00149305||Healthy subjects|
3148475|NCT00149318||Patients with Fabry disease|
3148476|NCT00149357||1, 2 ,3|Group 1 Women with unprovoked VTE and No Known Thrombophilia Group 2 Women who are investigated for VTE and are negative (Control) Group 3 Women with unprovoked VTE who have Thrombophilia
3148477|NCT00149383|Placebo Comparator|2|
3148478|NCT00149383|Experimental|1|
3148479|NCT00149409|Placebo Comparator|Placebo|4 gelatine capsules/d
3148480|NCT00149409|Active Comparator|1g/d Omacor|
3148481|NCT00149409|Active Comparator|4g/d Omacor|
2438041|NCT03311438|Other|Oral health intervention program|Oral Health intervention program: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
2438042|NCT03311425|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
2438043|NCT03311425|Placebo Comparator|IV dexamethasone|Intraoperative systemic (IV) steroid (dexamethasone) only.
3148482|NCT00149422|Active Comparator|NT-proBNP guided treatment group|In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.
3148483|NCT00149422|Placebo Comparator|Clinically guided arm|Heart failure treatment guided by clinical assessment.
3148484|NCT00149461|Experimental|Written Asthma Action Plan Group|Participants randomized to the written asthma action plan group received an asthma action plan form along with asthma education from their specialist physician.
3148485|NCT00149461|No Intervention|No Written Instructions Group|Participants randomized to the usual care group received no written instructions other than prescriptions from their specialist physician.
3148486|NCT00149500|Experimental|Coaching group for lifestyle changes|Patients received monthly phone calls with coaching for lifestyle changes over 2 years.
3148487|NCT00149500|No Intervention|Routine pediatric care|This group receives routine care with their pediatrician.
3148488|NCT00149513|Experimental|1|Targeted nurse case management
3148489|NCT00149513|Active Comparator|2|Usual Care
3148490|NCT00149552|Active Comparator|Zinc gluconate|Zinc supplementation
3148491|NCT00149552|Placebo Comparator|Placebo|Placebo
3148492|NCT00149656|Placebo Comparator|1|
3148493|NCT00149656|Experimental|2|Multivitamins
3148494|NCT00149656|Experimental|3|Multivitamins with Selenium
3148495|NCT00149656|Experimental|4|Selenium
3148496|NCT00149760|Active Comparator|Augmented Standard Medical Care|Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
3148497|NCT00149760|Experimental|Cognitive-Affective Behavior Therapy|Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
3148498|NCT00149773|Experimental|Cognitive Therapy + Enriched Usual Care|"The cognitive therapy intervention consists of approximately 12 (1-hour) sessions over the course of a 4-month period. The main therapy components include:~Using problem-solving and cognitive restructuring techniques to target hopelessness, reasons for living and dying, coping with loss, and perceived medical comorbidity that lead to suicidal ideation.~Improving social resources.~Improving adherence to medical regimen.~Targeting Suicidal Cognitions."
3188670|NCT00769405|Experimental|Arm I|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery). Patients also undergo CHIP comprising oxaliplatin intraperitoneally during surgery and hyperthermia for 30 minutes.
2438064|NCT03311399|Experimental|Home Visit|"Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Intervention: SSI Screening Tool used in home visits by CHWs"
2438065|NCT03311399|Experimental|Phone Call|"Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone. Intervention: SSI Screening Tool used via phone call follow-up"
2438066|NCT03311399|No Intervention|Standard of Care|Individuals in Arm 3 will not have any additional contact beyond standard of care.
2438067|NCT03311386||Patients in AIS receiving actilyse|the patients will receive actilyse intaravenously in a dose of 0.9mg/kg once
2438072|NCT03311360||drug-coated balloon|patients with vertebral artery origin stenosis treated with drug-coated balloons
2438073|NCT03311360||bare metal stent|patients with vertebral artery origin stenosis treated with bare metal stent
2438074|NCT03311347|Experimental|100%O2 breathing|Primary aim, item 1
2438075|NCT03311347|Experimental|Air breathing|Primary aim, item 1
2438076|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Nivolumab|
2438077|NCT03311334|Experimental|DSP-7888 Dosing Emulsion in combination with Pembrolizumab|
2438078|NCT03311321|Placebo Comparator|Placebo-Control|The placebo-control group will take four placebo softgel capsules (similar in taste and appearance to the vitamin K2 supplements) every day for 8 weeks.
2438079|NCT03311321|Experimental|Vitamin K2 (360-mcg/d)|The experimental group will take four 90-mcg of vitamin K2 (menaquinone-7; 360-mcg) softgel capsules every day for 8 weeks.
2438080|NCT03311308|Active Comparator|Pembrolizumab|Pembrolizumab (Keytruda), 200 mg, by IV, every three weeks, for up to 2 years; after the first three doses, dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
2438081|NCT03311308|Experimental|Pembrolizumab and Metformin Combination|Pembrolizumab (Keytruda), 200mg, by IV, every three weeks, for up to 2 years will be taken in combination with Metformin, 500mg, twice a day, for nine weeks; after the first three doses, pembrolizumab dosing can be changed to 400mg IV every 6 weeks, at the treating physician's discretion.
2438082|NCT03311295|Experimental|ARTO System|
2438083|NCT03311282|Experimental|Feeding Bottle 0m+|10 infants aged 0-4 weeks (+/- 7 days): 0-4 m bottle. 0-4 months, 250 ml, 2 angled teats: newborn (also referred to as low flow) and infant (also referred to as medium flow), for infants aged 0-4 weeks (+/- 7 days) / over 9 weeks of participation.
2438158|NCT03310827|Experimental|Personalized Nutrition|Participant receives gene test results with diet plan (personalized nutrition)
2438085|NCT03311282|Experimental|Feeding Bottle 6m+|10 infants aged 6-10 months (+/- 10 days): 6m+ bottle. 6 months and over, 250 ml, longer teat) for infants aged form 6 to 10 months (+/- 10 days) / over 9 weeks of participation.
2438086|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 0m+|10 infants aged 0-4 weeks (+/- 7 days)
2438087|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 4m+|10 infants aged 4 months (+/- 10 days)
2438088|NCT03311282|No Intervention|exclusively or prevalently breast-fed infants 6m+|10 infants aged 6-10 months (+/- 10 days) (at least 2 breastfeeding sessions per day)
2438089|NCT03311269|Active Comparator|ClariVein RES 1% Injection|Sodium Tetradecyl Sulfate 1% Injection single administration
2438090|NCT03311269|Active Comparator|ClariVein RES 3% Injection|Sodium Tetradecyl Sulfate 3% Injection single administration
2438091|NCT03311243|Experimental|β-Thalassemia major (TM- β)|
2438092|NCT03311243|Active Comparator|Systemically healthy controls|
3188671|NCT00769405|Experimental|Arm II|Patients undergo surgery and receive standard systemic chemotherapy comprising leucovorin calcium IV followed by fluorouracil IV over 30 minutes. Systemic chemotherapy will continue for at least 6 months (before and after surgery).
3188672|NCT00769418|Experimental|1|odanacatib (MK0822)
3188673|NCT00769418|Placebo Comparator|2|placebo to odanacatib (MK0822)
3188674|NCT00769431|No Intervention|Focus group|
2438097|NCT03311217|Experimental|Intervention group|Healthy retail strategies will be implemented in tribally owned convenience stores in these communities. Specific strategies include pricing discounts, promotional signage, incorporation of new product, and placement of healthier items on shelves.
2438098|NCT03311217|No Intervention|Control group|No intervention will be implemented in the stores in the control communities.
2438099|NCT03311204|Experimental|Microblepharon Exfoliation|This treatment is provided using BlephEx tool from Optimed Pty Ltd.
2438100|NCT03311204|Experimental|Eyelid cleansing using Lid Hygenix|Foam-based hypoallergenic cleanser used as a control treatment in this study.
2438101|NCT03311191||Younger Women|Women ages 20-30 who are not pregnant will be painted with oxygen sensing bandage
2438102|NCT03311191||Younger Men|Men ages 20-30 will be painted with oxygen sensing bandage
2438103|NCT03311191||Older Women|Women ages 55-65 who are not pregnant will be painted with oxygen sensing bandage
2438104|NCT03311191||Older Men|Men ages 55-65 will be painted with oxygen sensing bandage
2438105|NCT03311178|Experimental|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
2438106|NCT03311152|Experimental|HCC-free cirrhotic patients|"Cirrhotic patients enrolled in an HCC screening program by abdominal ultrasound and AFP every six months and followed at the Department of Hepatology of the University Hospital of Nancy. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
2438107|NCT03311152|Experimental|HCC-positive cirrhotic patients|"Cirrhotic patients followed at the Department of Hepatology of the University Hospital of Nancy who presents an HCC according to the AASLD guidelines. Each patient included will undergo a diagnostic test called Epi proColon 2.0 CE from Epigenomics, Inc (Berlin, Germany) also known as Plasma mSEPT9 test."
2438108|NCT03311139||AF and ACS patients: No PCI|Patients with Atrial Fibrillation and Acute Coronary Syndrom who did not undergo a Percutaneous Coronary Intervention
2438109|NCT03311139||AF and ACS patients: PCI without stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI without stent implantation (NOMESCO code FNG00-96 except FNG05)
2438110|NCT03311139||AF and ACS patients: PCI with stent|Patients with Atrial Fibrillation and Acute Coronary Syndrom who underwent PCI with stent implantation (NOMESCO code FNG05)
2438111|NCT03311126|Experimental|Bendamustine + Obinutuzumab (BO)|"Induction chemoimmunotherapy (28 day cycles):~Bendamustine 90 mg/m2 IV days 1 & 2 every 28 days X 4-6 cycles~Obinutuzumab:~Cycle 1: 100 mg IV day 1, 900 mg IV day 2, 1000 mg IV days 8 & 15~Cycles 2-6: 1000 mg IV day 1~Consolidation phase:~Obinutuzumab 1000 mg IV weekly X 4 doses~Maintenance phase (8 week cycles):~Obinutuzumab 1000 mg IV on day 1 of cycles 1-8"
2438112|NCT03311113||Patients with osteoarticular infection|To evaluate drug adherence to oral antibiotic therapy in patients treated for bone and joint infection for a minimum expected duration of 6 weeks.
2438113|NCT03311100||Lung cancer|
2438114|NCT03311100||Central Nervous System Cancers|
2438115|NCT03311100||Head and Neck and upper aero-digestive tract cancers|
2438116|NCT03311100||Skin cancers|
2438117|NCT03311100||Sarcomas|
2438118|NCT03311100||Urothelial cancer|
2438119|NCT03311100||Hepatocarcinoma|
2438120|NCT03311074|Experimental|Strimvelis treatment receivers|Approximately 15 subjects with ADA-SCID who were previously received Strimvelis will be included in the analysis and a total of 5 blood samples will be collected from each subject at approximately annual interval.
2438121|NCT03311061|Experimental|DREAMS|"The experimental group will be exposed to the DREAMS curriculum including the supplemental technology based application.It is composed of 10 modules: Introduction; Self Exploration; Healthy Relationships; Adolescent Sexuality; Attitudes and Adolescent Sexual Activity; Consequences of Sex - HIV/STI; Consequences of Sex - Pregnancy; Managing Pressure to Engage in Sexual Activity through the Lens of Social Media; Financial Literacy; Careers; Post secondary Education; Wrap up and Close Out.~The technology app will include curriculum support and additional resources.~Students will have access to the mobile app after the in school programming ends. The intent is for students to have access to portions of the app that deal with self developed goals and progress monitoring for goals, and resource material. This is similar to a student having continued access to a textbook/other class materials."
2438154|NCT03310866|Active Comparator|fiberoptic, airway|Classical fiberoptic intubation assisted by side fenestrated airway and head tilt- chin lift- jaw thrust by 2 anesthetist
2438155|NCT03310866|Experimental|fiberoptic, Machintosh|oral Fiberoptic bronchoscopic intubation assisted by Macintosh Laryngoscope, by 2 anesthetist
2438156|NCT03310853|Experimental|Probiotic|Combination of two probiotic strains in one capsule
2438122|NCT03311061|Active Comparator|Non DREAMS|The control group experience will include health curriculum already adopted by the school district. Continued services as usual. The control group schools, for the most part, lack any formal pregnancy prevention services. All schools claim that lessons developed by the teachers meet the Texas Essential Knowledge Standards (TEKS). No outside services are provided to students and school based services are limited. The services offered at the schools is predominately abstinence based. Students attending the schools would need to initiate any services that are available within the community. The control group will not have access to the DREAMS curriculum or the technology-based application to enhance the DREAMS curriculum. The technology-based application will be a closed, password protected, system during the research trial.
2438123|NCT03311048|Experimental|Hospital|Hospital cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2438124|NCT03311048|Experimental|University|Campus (university) cleaning workers Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2438125|NCT03311048|Experimental|Housekeeper|Housemaid (cleaning workers) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2438126|NCT03311048|Experimental|Control|Office workers (no relationship to cleaning) Nasal swab was collect to upper airways inflammation evaluation. Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
2438127|NCT03311035|Experimental|Group A|patients undergoing ligation of intersphincteric fistula tract (LIFT technique)
2438128|NCT03311035|Experimental|Group B|patients undergoing Seton method
2438129|NCT03311022|Experimental|Treatment 1|One tablet of test product (Nefopam Hydrochloride 30mg Tablets) containing 30mg nefopam hydrochloride.
2438130|NCT03311022|Active Comparator|Treatment 2|One tablet of reference product (Acupan® 30mg Tablets) containing 30mg nefopam hydrochloride.
2438131|NCT03311009|Experimental|GLPG1972|
2438132|NCT03311009|Placebo Comparator|Placebo|
2438133|NCT03310996|Experimental|tDCS Active arm|The experimental arm will have the tDCS stimulation electrodes placed on the scalp and the current will be delivered over 20 minutes
2438134|NCT03310996|Placebo Comparator|tDCS Sham arm|The sham arm will have electrodes placed over the scalp and will be given the current for 10 seconds after which it will be ramped down and stopped.
2438135|NCT03310983||ADORE Participants|Participants enrolled in the ADORE study are invited to participate in this study.
3188675|NCT00769457|Experimental|1|Arm with activated OptiVol / Carelink-system, event-triggered physician alert and physician access to Cardiac Compass data
3188676|NCT00769457|No Intervention|2|Arm with standard ICD - CRT-D therapy, no OptiVol and no Carelink
2438140|NCT03310944|Active Comparator|Sotagliflozin dose 1 (reference formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2438141|NCT03310944|Experimental|Sotagliflozin dose 2 (prototype p1 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2438142|NCT03310944|Experimental|Sotagliflozin dose 3 (prototype p2 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2438143|NCT03310944|Experimental|Sotagliflozin dose 4 (prototype p3 formulation)|Single oral dose on Day 1 of one of the four period in fasting condition
2438144|NCT03310931||End and non-END groups|END was denied as NIHSS score increase of 2 or more than 2 within 7 days after admission
2438145|NCT03310918|Experimental|Collaborative palliative and oncology care|"1st palliative care visit within 96 hours of randomization in the outpatient or hospital~In outpatient setting: At least once weekly for the first 30 days and then at least twice per month thereafter palliative care clinic visits or contact via telephone~During hospital admissions to MGH: At least twice weekly palliative care visits"
2438146|NCT03310918|Active Comparator|Standard leukemia care|"Palliative care consults only upon request~Standard Leukemia care"
2438147|NCT03310905|Experimental|Isolated Abdominal Wall Transplant|
2438148|NCT03310905|Experimental|Abdominal Wall with Solid Organ Transplant|
2438149|NCT03310892|No Intervention|Usual Care|Participants in this arm will Usual scheduling process without any intervention
2438150|NCT03310892|Experimental|Generic Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the study team member will ask the participant a series of 7 questions then receive a generic message encouraging colonoscopy scheduling."
2438151|NCT03310892|Experimental|Tailored Message|"Participants in this arm will receive a telephone call from a study team member, and if no answer, up to two additional attempts will be made. During the telephone call, the participant will answer a series of 7 questions then receive a tailored message encouraging colonoscopy scheduling, which will be determined by their responses to the preceding questions."
2438152|NCT03310879|Experimental|Participants with CCND1, CCND2, or CCND3|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
2438153|NCT03310879|Experimental|Participants with CDK4 or CDK6|"Abemaciclib will be administered orally on a daily basis~Dosage will be determine by the PI"
2438157|NCT03310853|Placebo Comparator|Placebo|Non active ingredients in a capsule
2438160|NCT03310814|Experimental|Personalized nutrition intervention|Participant receives gene-test results plus personalized nutrition information from a registered dietician
2438161|NCT03310814|Placebo Comparator|Usual nutrigenomics intervention|Participant receives usual nutrigenomics intervention (direct-to-consumer)
2438162|NCT03310801||LAAO with DAPT|patients with AF who underwent PCI and treated with LAAO(either ACP or Watchman) and DAPT
2438163|NCT03310801||Conventional antithrombotic therapy|patients with AF who underwent PCI and treated with conventional antithrombotic therapy
3188677|NCT00769470|Active Comparator|Arm I|Patients receive trastuzumab IV over 90 minutes on day in course 1. Patients receive docetaxel IV, carboplatin IV, and trastuzumab IV over 30 minutes on day 1 in course 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188678|NCT00769470|Experimental|Arm II|Patients receive oral lapatinib ditosylate once daily on days 1-21 in course 1. Patients receive docetaxel IV and carboplatin IV on day 1 and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7.Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2438166|NCT03310762|Experimental|Alma Sana Bracelet Arm|Subjects in this arm will receive a vaccine reminder and tracker bracelet developed by Alma Sana Inc. This bracelet uses a combination of symbols and numbers to denote the entire vaccine schedule a child is supposed to receive before the age of 2 years. Shapes indicate vaccines, and numbers signify the child's age.
2438167|NCT03310762|Experimental|Simple Silicon Bracelet Arm|Subjects in this arm will receive a simple silicon bracelet. This bracelet has six symbols to remind parents that their child needs to get at least six vaccination visits before he reaches 2 years of age. The first five symbols are represented by a crescent shape and the sixth symbol is represented by a star shape to denote that the child is fully immunized.
2438168|NCT03310762|No Intervention|Control Arm|Subjects in this arm will not receive any bracelet/intervention.
2438169|NCT03310749|Other|Treatment sequence A|Gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days and gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days.
2438170|NCT03310749|Other|Treatment sequence B|Gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days, metformin 1000 mg twice a day during 7 days
2438171|NCT03310749|Other|Treatment sequence C|Metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d + metformin 1000 mg twice a day during 7 days, gemigliptin 50 mg q.d. during 7 days
3188679|NCT00769470|Experimental|Arm III|Patients receive trastuzumab IV over 90 minutes on day 1 and oral lapatinib ditosylate daily on days 1-21. Starting on day 22, patients receive docetaxel IV, carboplatin IV, and trastuzumab IV three times a week and oral lapatinib ditosylate once daily on days 1-21 in courses 2-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3188680|NCT00769496|Experimental|Arm 1|
2438174|NCT03310710|Experimental|treatment with Viabahn BX stent|Treatment with Viabahn BX stent as branch device in fenestrated EVAR
3188681|NCT00769509|Experimental|preterm formula|Assessment of energy expenditure of preterm infant during fed with preterm formula
2438176|NCT03310684||Hypertensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Antihypertensive medication type and dosage will be recorded. Blood and urine samples will be collected at baseline and yearly for three years. All subjects will receive baseline and yearly echocardiograms. Subjects with overweight/obesity (BMI >=85th percentile for age and sex) will receive baseline and yearly ultrasounds of the liver to evaluate for hepatic fat infiltration. Auscultated, continuous and ambulatory blood pressure will be measured at baseline and yearly.
2438177|NCT03310684||Normotensive with Obesity|"Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will receive a baseline ultrasound of the liver to evaluate hepatic fat infiltration as per standard of care.~Blood and urine will be collected at baseline to measure liver function (AST, ALT) and uric acid, angiotensin ll, and angiotensin-(1-7)."
2438178|NCT03310684||Healthy Normotensive|Clinical data will be collected from the electronic medical record, including height, weight, age, sex, parent-reported race, and past medical and family histories. Subjects will have baseline echocardiograms. Blood pressure will be measured at baseline and at one year. Continuous blood pressure and ambulatory blood pressure monitoring will be assessed at baseline. Blood and urine samples will be used to measure uric acid, FGF23, klotho, and albumin, as well as the predictors angiotensin ll and angiotensin-(1-7).
2438179|NCT03310671||CASES|"Cases:~Age ≥ 65 years at the time of cardiac ultrasound~Genetically diagnosed HFH or in a first-degree relative~History of hypercholesterolemia with LDLc levels> 220 mg / dL without lipid-lowering treatment"
2438180|NCT03310671||Controls|"Genetically Similar~Siblings of the normocholesterolemic case, defined by LDLc <190 mg / dl without lipid-lowering treatment.~In the absence of available siblings, first cousins may be included.~In the presence of several siblings available, the same sex will be included,~Environmentally similar~Stable partner of the case with cohabitation> 25 years"
2438181|NCT03310658|Experimental|Single Study Site: UANL|As the only study arm, 10 enrolled subjects received vaginal cuff closure with the Zip-Stitch Soft Tissue Closure System as part of Total Laparoscopic Hysterectomy.
2438182|NCT03310645|Experimental|Dose 1 of BAY1817080|"Study Part 1:~Oral dose 1 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2438183|NCT03310645|Experimental|Dose 2 of BAY1817080|"Study Part 1:~Oral dose 2 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2438184|NCT03310645|Experimental|Dose 3 of BAY1817080|"Study Part 1:~Oral dose 3 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2438185|NCT03310645|Experimental|Dose 4 of BAY1817080|"Study Part 1:~Oral dose 4 of BAY1817080 twice daily with a loading dose administered three times on Day 1"
2438186|NCT03310645|Placebo Comparator|Placebo|"Study Part 1:~Oral dose of matching placebo twice daily with a loading dose administered three times on Day 1"
2438187|NCT03310645|Experimental|Placebo+BAY1817080|"Study Part 2:~Randomized crossover design in cough patients Placebo+4 different doses of BAY1817080"
2438188|NCT03310645|Experimental|BAY1817080+Placebo|"Study Part 2:~Randomized crossover design in cough patients 4 different doses of BAY1817080+Placebo"
3188682|NCT00769509|Active Comparator|human milk with fortifier|Assessment of energy expenditure by indirect calorimetry during fed with human milk with fortifier
2438189|NCT03310632|Experimental|Antroquinonol with SOC|"Antroquinonol will first be conducted by dose escalation(200mg TID and 300mgTID) to characterize the safety of antroquinonol in combination with the standard of care (SOC) (nab-paclitaxel + gemcitabine) and to identify the MTD of antroquinonol in patients with metastatic pancreatic cancer.~At the cohort expansion part of the study, up to an additional 40 patients will be enrolled at the MTD or MFD/RD."
3148499|NCT00149773|No Intervention|EnrichedUsual Care Condition|"The Enriched Care (EC) condition will be used as the treatment comparison for this study. EC consists of usual care patients may obtain in the community as well as the assessment and referral services provided by the study case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health treatment in the community.~The primary role of the study case manager is to establish a strong relationship with patients in order to retain the patients in the study for the duration of the study period."
3148500|NCT00149786|Experimental|1|Those adolescents receiving family based therapy
3148501|NCT00149786|Active Comparator|2|Those adolescents receiving individual therapy
3148502|NCT00149812|Experimental|Intervention|"Intervention: Keeping Families Strong Cognitive Behavioral and Communication intervention with mothers recovering from depression and their children, 9 years and older."
3148503|NCT00149916|Experimental|Mycophenolate sodium (enteric coated)|
3148504|NCT00149968|Experimental|Myfortic|
2438196|NCT03310606|Other|Peritonitis|"Patient received for antibiotic treatment a B lactam according to French recommendation :~type of antibiotic : cefotaxime or ceftriaxone or piperacilline/tazobactam or imipenem~dose : cefotaxime 2g / cetriaxone 2g / piperacilline 4g / imipenem 1g"
2438197|NCT03310593|Experimental|Cannabidiol|Cannabidiol 150-300mg per day for 12 weeks.
2438198|NCT03310593|Placebo Comparator|Placebo|Cannabidiol comparator for 12 weeks.
3188683|NCT00769522|Experimental|FCR|
3188684|NCT00769522|Experimental|BR|
2438202|NCT03310567|Experimental|Epacadostat + pembrolizumab|
2438203|NCT03310554|Experimental|26cm suspended overlength biliary stents group|
2438204|NCT03310554|Experimental|30cm suspended overlength biliary stents group|
2438205|NCT03310554|Other|ordinary plastic biliary stents group|
2438206|NCT03310541|Experimental|Prostate, Previously treated with Enzalutamide|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Enzalutamide 160 mg PO once daily
2438207|NCT03310541|Experimental|ER+ Breast, Previously treated with Fulvestrant|28-DAY CYCLE AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week + Fulvestrant 500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
2438208|NCT03310541|Experimental|Advanced Solid Tumors|28-DAY CYCLE AZD5363 480mg PO twice daily for 4 days on, 3 days off, every week
2438209|NCT03310528||Obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2438210|NCT03310528||Did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2438211|NCT03310528||Trauma - obeyed fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2438212|NCT03310528||Trauma - did not obey fasting guidelines|Scheduled GI endoscopy procedure with planned oral-gastric tube placed. Complete interview questionnaire. Gastric ultrasound exam prior to upper GI endoscopy procedure.
2438213|NCT03310515||HIV-1 uninfected high risk subjects|The study will involve HIV-1 uninfected high risk MSM and TGW subjects. They will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment. Visits will include Baseline screening for HIV followed by screenings at Day 1, Weeks 5, 9, and 8 week intervals thereafter until study conclusion. Screening for other STIs will occur at Baseline, Week 9, and every 16 weeks thereafter.
2438214|NCT03310489|Experimental|Digitalized cognitive-behavioral intervention|
2438215|NCT03310489|Active Comparator|Psychoeducation about anxiety|
2438216|NCT03310476|Experimental|Baked, consumed chilled potatoes|
2438217|NCT03310476|Experimental|Boiled, consumed hot potatoes|
2438218|NCT03310463|Experimental|Cohort 1, Normal Renal Function|Healthy control participants matched to participants enrolled in Cohort 4 (creatinine clearance ≥90 milliliters per minute [mL/min] estimated by the Cockcroft-Gault equation) will receive ETX2514SUL as a single dose of up to 1000 milligrams (mg) ETX2514 and 1000 mg sulbactam given by concurrent 3-hour intravenous (IV) infusion.
2438219|NCT03310463|Experimental|Cohort 2, Mild Renal Impairment|Participants with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to <90 mL/min/1.73 meters squared [m^2] calculated by the Modified Diet in Renal Disease [MDRD] equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2438220|NCT03310463|Experimental|Cohort 3, Moderate Renal Impairment|Participants with moderate renal impairment (eGFR ≥30 to <60 mL/min/1.73 m^2 calculated by the MDRD equation) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2438261|NCT03310190||Participants receiving venetoclax|Participants with Chronic Lymphocytic Leukemia (CLL) receiving venetoclax.
2438262|NCT03310177||COPD|The smokers who are diagnosed as chronic obstructive pulmonary disease according to GOLD guideline.
3148505|NCT00150072|Experimental|imatinib|
3148506|NCT00150098|Experimental|lifestyle counselling|Education
3148507|NCT00150124|Experimental|block-replacement therapy|BRT regimen until 3 months after 131I therapy
3148508|NCT00150124|Active Comparator|methimazole|methimazole stopped 8 days before 131I therapy
3148509|NCT00150488|Experimental|1|Uracyst®
3148510|NCT00150631|Placebo Comparator|active (candesartan)|12 mo treatment with candesartan
3148511|NCT00150631|Placebo Comparator|placebo|12 mo placebo treatment
3148512|NCT00150644|Experimental|1|
3148513|NCT00150644|Experimental|2|
3148514|NCT00150644|Placebo Comparator|3|
3148515|NCT00150670|Experimental|1|TS-1 and cisplatin
3148516|NCT00150670|Active Comparator|2|TS-1
2438221|NCT03310463|Experimental|Cohort 4, Severe Renal Impairment|Participants with severe renal impairment (eGFR <30 mL/min/1.73 m^2 calculated by the MDRD equation) and not on hemodialysis (HD) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
2438222|NCT03310463|Experimental|Cohort 5, ESRD on a Stable HD Regimen|Participants with end-stage renal disease (ESRD) on a stable HD regimen (determined by medical history) will receive ETX2514SUL as a single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hour IV infusion.
3188685|NCT00769535|Experimental|HSP70 and TNF polymorphisms|
3188686|NCT00769548|Experimental|Arm 1|Neoadjuvant total androgen suppression (TAS) given 2 months before and during radiation therapy (RT) to the whole pelvis followed by a prostate boost.
3188687|NCT00769548|Experimental|Arm 2|Neoadjuvant TAS given 2 months before and during RT to the prostate only.
2438226|NCT03310437||Primary PCI|In primary PCI we use arterial sheath , wires ,heparin ,intracoronary stents
2438227|NCT03310437||Thrombolytic|In patients recieving thrombolytics they continue on LWMH for 72h ,plus aspirin , clopedogril , BB, statins
3188688|NCT00769548|Experimental|Arm 3|RT to the whole pelvis followed by a boost to the prostate followed by 4 months of TAS.
3188689|NCT00769548|Experimental|Arm 4|RT to the prostate only followed by 4 months of TAS.
3188690|NCT00769574|Experimental|1|Patients with coronary syndrome
3188691|NCT00769574|Other|2|Subjects without coronary syndrome
2438232|NCT03310398||Anxiety|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
2438233|NCT03310398||Depression|elevated anxiety (as indicated by a GAD-7 score of 8 or higher)
2438234|NCT03310385|Experimental|High-dose GHX02 group(1,920mg/day)|4 tablets of the GHX02, three times daily for 7 days
2438235|NCT03310385|Experimental|Standard-dose GHX02 group(960mg/day)|2 tablets of the GHX02 and 2 tablets of the placebo, three times daily for 7 days
2438236|NCT03310385|Placebo Comparator|Placebo control|4 tablets of the placebo, three times daily for 7 days
2438237|NCT03310372|Experimental|ultrafractionated brain irradiation - temozolomide|
2438238|NCT03310359|Active Comparator|Astaxanthin (12 mg)|Subjects will be given capsules containing a set oral dose of astaxanthin (12 mg) and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
2438239|NCT03310359|Placebo Comparator|Placebo|Subjects will be given capsules containing placebo and instructed to take two capsules each morning after (up to 1 hr) the morning meal for a total of up to 24 weeks (168 days on study drug).
2438240|NCT03310333|Experimental|Cook cervical ripening|the device is introduced by a resident or a doctor. No traction on the probe was done. It is left in place for maximum 12 hours. Oxytocin is added at the end of the first 6 hours even if device is fallen. An epidural analgesia can be started before or after the installation of oxytocin
2438241|NCT03310333|Active Comparator|Dinoprostone vaginal group|"the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.~After 24 hours, it is removed. If they are any contraction, oxytocin is started with or without epidural analgesic."
2438242|NCT03310320|Placebo Comparator|Placebo|Placebo for AZD0284 oral solution
2438243|NCT03310320|Experimental|AZD0284|AZD0284 oral solution 2.5 mg/mL
2438244|NCT03310307|Active Comparator|vitamin D3|50,000 IU
2438245|NCT03310307|Placebo Comparator|Placebo|Similar in size, shape and color to vitamin D3
2438246|NCT03310294|Placebo Comparator|placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)
2438247|NCT03310294|Active Comparator|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS), 90 grams)
2438248|NCT03310281|Active Comparator|ALK-T03|AKL-T03 is a digital intervention that requires the subject to navigate a character through a game-like space, while collecting objects, in a fixed period of time.
2438249|NCT03310281|Active Comparator|AKL-T09|AKL-T09 is a digital intervention that requires the subject to spell as many words as possible, by connecting letters in a game-like grid, in a fixed period of time.
3188692|NCT00769587|Experimental|Thalidomide|Use of thalidomide
3188693|NCT00769626|Experimental|Early Treatment|
3188694|NCT00769626|Active Comparator|Usual Care|
2438253|NCT03310242|Experimental|Sunlight Exposure|Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
2438254|NCT03310242|Experimental|Vitamin D Supplementation|Supplementation of vitamin D3 500 IU/day for 8 weeks
2438255|NCT03310242|Placebo Comparator|Placebo|Intake of placebo for 8 weeks
2438256|NCT03310216|Experimental|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
2438257|NCT03310216|Active Comparator|Order II of visual inspection|Participants in group II are provided EDTRS first and AI visual inspection system later.
2438258|NCT03310203|Experimental|Obese women: central obesity|OGTT with iron
2438259|NCT03310203|Experimental|Obese women: peripheral obesity|OGTT with iron
2438260|NCT03310203|Experimental|Lean women|OGTT with iron
3188695|NCT00769665||Systane Ultra|Systane Ultra
3188696|NCT00769665||Sensitive Eyes|Sensitive Eyes
3188697|NCT00769678|Active Comparator|Stimulation of diaphragm|
3188698|NCT00769691||Group A|Adult patients undergoing cardiac surgery
3188983|NCT00772850||Antegrade nailing, humeral fractures|We included patient's age and gender, fracture location, fracture cause, presence of nail removal, post-operative period and comorbidity or associated disease as independent variables. Fracture location was either humeral neck or humeral shaft. Humeral neck fractures were defined as fractures above surgical neck of the humerus. Meanwhile, humeral shaft fractures were defined as fractures below surgical neck of the humerus and 5 cm above the olecarnon fossa. Humeral shaft fractures were separated into three groups: proximal third shaft fractures, middle third shaft fractures and distal third shaft fractures. Fracture causes included simple falls and traffic accidents.
2438265|NCT03310164||healthy control|Age-matched subjects without chronic obstructive pulmonary disease (COPD)
2438266|NCT03310151|Experimental|Intervention|Group follows usual care plus imagined movements in a home exercise plan. The exercises will be taught to the subject by reading through an exercise booklet with them, this ensures the advice is standardised. The imagined movement programme will consist of imagined wrist movement in all planes. The frequency of approximately 10-15 minutes, four times a day has been selected as a practical compromise of previous investigations, (Moseley, 2004 and Frenkel et al., 2014), and mirrors routine advice.
2438267|NCT03310151|No Intervention|control|Follows usual care
2438268|NCT03310138|Active Comparator|Dorsolateral Prefrontal Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left dorsolateral prefrontal cortex (10Hz, 110% of resting motor threshold) using a MagVenture MagPro B60 coil."
2438269|NCT03310138|Active Comparator|Motor Cortex|"Intervention: Real Transcranial Magnetic Stimulation~Real Transcranial Magnetic Stimulation will be delivered to the left primary motor cortex (10Hz, 80% of resting motor threshold) using a MagVenture MagPro B60 coil."
2438270|NCT03310138|Placebo Comparator|Sham stimulation|"Intervention: Sham Transcranial Magnetic Stimulation~Sham Transcranial Magnetic Stimulation will be delivered to the prefrontal cortex (10Hz, 110% of resting motor threshold) using the integrated sham system on the MagVenture MagPro B60 coil."
2438271|NCT03310125|Experimental|Colchicine|Oral colchicine 0.5mg
2438272|NCT03310125|Placebo Comparator|Placebo|Placebo oral tablet
2438273|NCT03310112|Experimental|4-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.
2438274|NCT03310112|Active Comparator|2-week MBAT|Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.
2438275|NCT03310112|No Intervention|No training control (NTC)|Participants will receive no intervention but will be tested before and after a no-training interval.
2438276|NCT03310099|Experimental|Dietary Intervention|Dietary intervention aimed at increasing UFA consumption. The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated [MUFA] and polyunsaturated fatty acids [PUFA]), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
2438277|NCT03310086|Experimental|Traditional fixed appliance|"Fixed orthodontic appliances will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2438278|NCT03310086|Experimental|Fixed appliance and corticision|"Fixed orthodontic appliances with corticison will be applied for aligning and leveling of lower anterior teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2438279|NCT03310073|Experimental|bOPV (bivalent OPV Bio Farma)|"bOPV one dose corresponds to 2 drops (0.1ml). The vaccine shall be given orally.~The subject received bOPV, Pentabio and IPV according to the study schedule."
2438280|NCT03310060|Active Comparator|Tisseel combined Tranexamic acid|"Drug: Tisseel® Applied on potential bleeding sites. The entire content was 4 mL.~Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery"
2438281|NCT03310060|Placebo Comparator|Tranexamic acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg before surgical incision and 3 hours after surgery
2438282|NCT03310047|Experimental|Right-low, left-high|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 5 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 10 mL.~This will be repeated after 24 hours."
2438283|NCT03310047|Experimental|Right-high, left-low|"The right-side perineural catheter will be subject to intervention drug Infusion, Lidocaine, 0.5%, 10 mL Lidocaine and the left side perineural catheter will be subject to intervention Infusion, Lidocaine, 0.5%, 5 mL.~This will be repeated after 24 hours."
2438284|NCT03310034|Active Comparator|Intervention|
2438285|NCT03310034|Placebo Comparator|Control|
3188699|NCT00769717|Experimental|Wellness-Centered|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
2438296|NCT03310008|Experimental|Dose level 1 (escalation|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2438297|NCT03310008|Experimental|Dose level 2 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2438298|NCT03310008|Experimental|Dose level 3 (escalation)|The dose escalation arm will use a 3+3 design to determine the maximum tolerated dose.
2438299|NCT03310008|Experimental|Recommended dose level (expansion)|The dose expansion arm will use the maximum tolerated dose.
2438300|NCT03309995|Experimental|Zinc lozenges|Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days, as early as possible from the start of the cold symptoms.
2438301|NCT03309995|Placebo Comparator|Placebo lozenges|The placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste.
2438395|NCT03309280||Patient at risk for OSA scheduled for Cardiac surgery|Patients with a positive STOP-Bang and DES-OSA score (that means patients at risk for OSA)
2438302|NCT03309982|Experimental|Plant polyphenol blend|The study product (4 g) consists of 3 g of a mix a maltodextrins, and 1 g of anthocyanin-rich plant polyphenol blend containing: 1) 100 mg bilberry extract; 2) 300 mg black currant extract; and 3) 600 mg black rice extract.
2438303|NCT03309982|Placebo Comparator|Placebo|The placebo (4 g) consists of a mix of maltodextrins (3.85 g) and Red Dye No. 40 (0.125 g) and Blue Dye No. 1 (0.025 g).
2438304|NCT03309969||observation group|Subjects with suspicious iliac vein compression syndrome were included in the observation group.
2438305|NCT03309956|Other|Holter Monitor and Zio Patch|All subjects will wear the Holter monitor and Zio patch for a total of 48 hours.
3188700|NCT00769717|Active Comparator|Weight-Centered|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
2438308|NCT03309930|Experimental|Comprehension Acquired Brain Injury|All participants will be exposed to 3 conditions: (a) written text, (b) auditory output (synthetic speech), and combined conditions for study 1. For study 2 participants will be repeatedly exposed to synthetic speech output to determine the influence on comprehension. Participants are not required to participate in both studies.
2438309|NCT03309917|Experimental|Changes in mean arterial pressure|"The study is conducted from one hour after incision and lasts for approximately half an hour. Measurements are conducted at three levels of mean arterial pressure:~MAP set at 80-85 mmHg for 5 min.~MAP set at 70-75 mmHg for 5 min.~MAP set at 60-65 mmHg for 5 min.~Blood pressure control is by infusion of noradrenaline. When the evaluations have been conducted blood pressure control is according to clinical practice. Measurements include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, frontal lobe and muscle oxygenation, depth of anesthesia, and arterial and central venous blood gas variables."
2438310|NCT03309904|Experimental|Knee Control training program|The Knee Control program is a neuromuscular training program that consists of 6 different exercises, with 4 levels of progression and one pair-exercise, for each exercise. The Knee Control program takes about 10 minute to complete after familiarization. In addition, a 5-minute running warm-up is instructed to coaches. Coaches are to perform the Knee Control program + the 5 minute warm-up at all training sessions during the season, and the 5 minute warm-up before all matches.
2438311|NCT03309904|No Intervention|Control group - usual training|The control group teams receive no intervention, and coaches are instructed to carry out their normal training and warm-up practice throughout the season.
2438312|NCT03309891|Experimental|Cohort 1|GX-H9 subcutaneous injections (weekly)
2438313|NCT03309891|Experimental|Cohort 2|GX-H9 subcutaneous injections (weekly)
2438314|NCT03309891|Experimental|Cohort 3|GX-H9 subcutaneous injections (twice-monthly)
2438315|NCT03309891|Active Comparator|Cohort 4|Genotropin subcutaneous injections (daily)
2438316|NCT03309878|Experimental|Arm I (pembrolizumab, mogamulizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1 and mogamulizumab IV over 60 minutes on days 1, 8, and 15 of cycle 1, then day 1 of subsequent courses. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2438317|NCT03309878|Experimental|Arm II (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2438318|NCT03309865|Experimental|Combined diet and vedolizumab|Intervention: vedolizumab injection (300mg, IV infusions at week 0, 2, 6, 14) and concurrently on structured semi-vegetarian diet; Duration of Therapy: 14 weeks
2438319|NCT03309839||neonates with cardiac surgery under cardiopulmonary bypass|
2438320|NCT03309826|Experimental|PAP Treatment Arm|Automated positive airway pressure titration then treatment with fixed PAP.
2438321|NCT03309826|Active Comparator|Nasal Dilator Strip|Nightly use of nasal dilator strip
2438322|NCT03309813|Experimental|Transcranial ExAblate|ExAblate Transcranial MR Guided Focused Ultrasound (MRgFUS)
2438323|NCT03309813|Sham Comparator|Sham Transcranial ExAblate|ExAblate MRgFUS Sham Procedure
2438324|NCT03309800|Experimental|Experimental|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
2438325|NCT03309800|Placebo Comparator|Placebo comparator|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
2438329|NCT03309774|Experimental|Complex Regional Pain Syndrome (CRPS)|"Children 6 to 12 years old child with Complex Regional Pain Syndrome (CRPS) type 1 will be included.~They will have questionnaires, holter electrocardiogram, blood pressure and relaxation sessions."
2438330|NCT03309761||Patients aged 55-60|
2438331|NCT03309748|Active Comparator|Dental Prophylaxis|Standard dental prophylaxis
2438332|NCT03309748|Active Comparator|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis + aPDT
2438333|NCT03309735||1|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
2438334|NCT03309735||2|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
2438335|NCT03309735||3|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
2438336|NCT03309722||early stage|
2438337|NCT03309722||advanced|
2438338|NCT03309709|No Intervention|watch-and-wait patients|patients who receive a watch-and-wait approach
2438339|NCT03309709|Experimental|Progesterone patients|Treatment consists of 7 days of 25 mg subcutaneous progesterone administered from 18° to 25° day of the menstrual cycle and repeated for 3 cycles
2438563|NCT03308071|No Intervention|Usual care|These patients will be enrolled in the study and usual care will be provided.
3188701|NCT00769730||1|Patients with hepatocellular carcinoma caused by hepatitis B virus who will be treated by transcatheter arterial chemoembolization were included.
3188702|NCT00769756||2|"Financial incentive~For the parents the financial incentive was 5 euros for every kilogram of weight-loss. For children the weight loss was calculated differently, taking into account the individual need of each child to lose weight. Children with a body mass index between the 90th and 97th age-adjusted BMI-percentile were asked to maintain their weight, and were paid in dependence on how well they managed to achieve this goal. Children with age-adjusted BMI-percentiles between 97 and 99, or above the 99th age-adjusted BMI-percentile received 5 euros per weight losses of respectively 500 g or 1 kg."
3188703|NCT00769756||1|The telemedical equipment consisted of a weighing scale for each family, an accelerometer for each participant, and a Homebox for each family which received the data from the scale and the accelerometers via bluetooth and transfered them via a telephone link to a server in Munich.
2438344|NCT03309683|Experimental|Clip group|Olympus Quick Clip Pro - Single Use Repositionable Clips will be used for Prophylactic clipping after EMR
2438345|NCT03309683|No Intervention|Control group|Standard treatment after EMR (as described in the detailed study description above)
2438346|NCT03309670||Formers young patients|all patients hospitalized between 2006 and 2010 in the Pass'Aje unit
3188984|NCT00772876|Experimental|P1446A-05|Single arm of the study drug. This being a dose escalation study, patient will receive a dose depending on the stage of the trial.
2438348|NCT03309644||Peripheral nerve block|Peripheral nerve block
2438349|NCT03309644||No peripheral nerve block|No peripheral nerve block
2438350|NCT03309618|Experimental|Treatment group|20 participants received low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val) per orally once daily for 30 days.
2438351|NCT03309618|Placebo Comparator|Control group|16 participants received placebo per orally once daily for 30 days.
2438354|NCT03309592|Other|Combination Therapy|Qualifying participants will begin combination therapy with ambrisentan pill 5 mg daily and tadalafil pill 20 mg. After one week of therapy, patients will increase tadalafil pill to 40 mg daily and continue ambrisentan pill 5 mg daily. On day 15, patients will increase ambrisentan pill to 10 mg daily and continue at 40 mg of tadalafil pill daily.
2438355|NCT03309579|Experimental|Liberal RBC Transfusion Strategy|Hemoglobin value of ≤100g/L
2438356|NCT03309579|Active Comparator|Restrictive RBC Transfusion Strategy|Hemoglobin value of ≤80g/L
2438357|NCT03309566|Experimental|Test - Reference|A new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
2438358|NCT03309566|Experimental|Reference - Test|A branded formulation (R) followed by a new formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T).
2438359|NCT03309553|Active Comparator|Current Primary Care Referral Process|In villages randomized to the current primary care process, families will be notified if their children screen positive in exactly the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation. The list of referred children is also given to the Norton Sound Audiology Department, who reaches out to families to schedule appointments during the next available audiology clinic.
2438360|NCT03309553|Experimental|Expedited Telemedicine Referral|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
2438361|NCT03309540|Experimental|experimental group (EGR)|"Physical therapy intervention.~In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises)."
2438362|NCT03309540|Sham Comparator|Sham group (SGR)|"Physical therapy intervention.~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze and Evidence Based Practice Therapy. The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
2438363|NCT03309527|Experimental|e-aid Cognitive Behavior Therapy|Participants receive e-aid cognitive behavior therapy. Every week, this group will receive researcher guided individual customized sleep restriction and stimulus control therapy.
2438364|NCT03309527|Active Comparator|e-aid Sleep Hygiene Education|Participants receive e-aid sleep hygiene education which consists of general sleep health education and the guidance on questionnaires. Every week, this group will receive researcher guided sleep hygiene.
2438365|NCT03309514|Experimental|Treatment|
2438366|NCT03309501|Experimental|Tong-Luo-Qu-Tong Plaster group|Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
2438367|NCT03309501|Active Comparator|Qi-Zheng-Xiao-Tong Plaster group|Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses
2438368|NCT03309488||Food allergic|Patients with a positive oral challenge to the food being studied.
2438369|NCT03309488||Non food allergic|Patients with a negative oral challenge to the food being studied.
2438370|NCT03309475|Experimental|SocialMIND|The experimental arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and mindfulness-based social cognition group training (SocialMind), specifically designed for patients with first episode psychosis by the research team. There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 5 monthly sessions.
2438371|NCT03309475|Active Comparator|Psychoeducational Multicomponent Intervention|The active comparator arm will receive treatment as usual (both psychotropic treatment and psychosocial treatment) and a psychoeducational multicomponent intervention for psychosis.There will be a first phase (intensive intervention) consisting of 8 weekly sessions and a second phase (follow-up sessions) consisting of 4 fortnightly sessions and 7 monthly sessions.
2438372|NCT03309462|Experimental|Re-biopsy tissue sample|The gene testing of re-biopsy tissue sample diagnosed with NSCLC will be performed with NGS using Illumina Miseq squencer and Cobas.
2438373|NCT03309462|Experimental|Peripheral blood sample|The peripheral blood sample will be extracted with DNA and performed with NGS using Illumina Miseq squencer and ddPCR.
3148517|NCT00150748|Experimental|Levetiracetam|Subjects received treatment up to 1764 days during the Evaluation Period. Up to 4000 mg/day (or 80 mg/kg/day for children and adolescents less than 50 kg). Oral tablets of 166, 250, or 500 mg Levetiracetam twice daily (b.i.d.).
3148518|NCT00150826|Active Comparator|Quinapril|This arm will receive quinapril which will be started at 40mg daily and titrated to 80mg daily by the end of the first week. After treatment on the maximum tolerated dose for 16 weeks, patients will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
3148519|NCT00150826|Placebo Comparator|Placebo|This arm will receive placebo for 16 weeks and will be reevaluated with coronary angiogram with coronary flow reserve measurements and assessment of angina using the Seattle Angina Questionnaire.
2438377|NCT03309436|Experimental|Use Clomiphene Citrate protocol|Ovulation induction: regular Clomiphene Citrate protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. At the same time, take CC 100mg/d until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
2438378|NCT03309436|Active Comparator|Procedure|Ovulation induction: regular GnRH antagonist protocol. Start use rFSH or HMG from day 2/3 of the menstrual cycle, the initial dosage is determined by patients' age, BMI, antral follicle number, FSH, E2, AMH and past ovarian response, usually 150-225IU/d, until hCG injection. When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection. The dosage of Gn will be adjust by serum E2, P, LH and the development of follicular.
2438379|NCT03309423||Respiratory disease|Patients with acute respiratory insufficiency admitted to the ICU and with pH <7,35 or >7,45
2438380|NCT03309423||Metabolic disease|Patients with acute metabolic disease admitted to the ICU and with pH <7,35 or >7,45
2438381|NCT03309423||Sepsis|Patients with acute sepsis admitted to the ICU and with pH <7,35 or >7,45
2438382|NCT03309410||Pre-study|In the pre-study, venous samples were collected in paired 2 mL ABG syringes and 4.5 mL tubes from each of the 10 patients, to determine which blood collection method was preferred. VBG samples were collected via a butterfly needle with a three-way stopcock in conjunction with routine venous blood sampling upon admission. VBG samples were collected by the biomedical laboratory technician in the same manner as PVB samples in the normal clinical setting. Results from the pre-study were used to determine the preferred blood collection method in the main study. In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission.
2438383|NCT03309410||Main study|In this study, paired ABG and VBG samples were collected simultaneously from each of the 20 patients. The ABG samples were collected by the responsible physician. Allocation to either the pre-study or the main study was performed by simple quasi-random allocation in order of admission. The clinical indication for ABG analysis was decided by the responsible physician in the ED upon patient admission and based on national guidelines and criteria.
2438384|NCT03309358|Experimental|Inhaled SNSP113|
2438385|NCT03309358|Placebo Comparator|Inhaled Placebo|
2438386|NCT03309345||Case group, PKU group|Children and adults (10 - 45 years old) with PKU attending the metabolic medicine clinics in the area of National Health Services (NHS) Greater Glasgow and Clyde (GGC) will be approached for recruitment. Participants will be free from history of acute and chronic illness (other than PKU) requiring regular appointments to the doctor and/or chronic use of medication or major gastrointestinal surgery where major part of the gut has been resected as these conditions are known to impact on energy expenditure and dietary intake. Pregnant or lactating women will also be excluded from participation. People with learning or mobility difficulties or those with incapacity to provide informed consent will be excluded too. The clinical treatment team will evaluate patients' capacity to consent before considering them to participate in the study.
2438387|NCT03309345||Control group, healthy control|Gender, BMI and age matched healthy people will be recruited as a control group. Pregnant or lactating women will be excluded from participation. Those with any chronic illnesses or bone injuries will also be excluded.
3148520|NCT00150839|Active Comparator|1|Probands receive mirtazapine and venlafaxine
2438389|NCT03309319|Experimental|Ros|Rosiglitazone：2 times a day, 4mg each time（4mgBid）
3148521|NCT00150839|Placebo Comparator|2|Patients receive mirtazapine and placebo
3148522|NCT00150878|Other|12 Gy/Cyclophosphamide|Standard intensity conditioning
3148523|NCT00150878|Experimental|8 Gy /Fludarabine|Reduced-intensity conditioning
2438393|NCT03309293|Other|controls|biological samples bank
3148524|NCT00150995|Experimental|Tetrathiomolybdate|Patients will be started on a dose of 60mg Tetrathiomolybdate at bedtime and 40mg 3 times per day.
3148525|NCT00151034|Experimental|Herceptin|"Herceptin - 4mg/kg day 1 of cycle 1; 2mg/kg day 8 and 15 of cycle 1 and subsequent cycles.~Paclitaxel - 200mg/m^2 on day 1 Carboplatin - AUC 5 on day 1 Gemcitabine - 800 mg/m^2 on day 1 and 8"
3148526|NCT00151047|Experimental|Docetaxel and Capecitabine|
3148527|NCT00151060|Experimental|Estramustine, Etoposide and Paclitaxel|
3148528|NCT00151073|Experimental|Zoledronate Alone|Zoledronate is given alone for the first cycle. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
2438396|NCT03309280||Patient not at risk for OSA scheduled for Cardiac surgery|Patients with a negative STOP-Bang and DES-OSA score (that means patients not at risk for OSA)
2438397|NCT03309267||Intercostal block|Anesthesia induction was performed to all patients .At the end of the operation some patients were performed with intercostal block by the chest surgeon. For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2438398|NCT03309267||Serratus anterior plane block|Anesthesia induction was performed to all patients. At the end of the operation some patients were performed SAPB under Ultrasound guidance by the same anesthetist.For 24 hours postoperatively, tramadol was administered with patient-controlled analgesia (PCA) All patients were extubated after the operation and transferred to ICU.
2438399|NCT03309254|Experimental|High Glycemic Index|White Bread with Turkey breast meat (2 slices) Turkey Breast (7 slices) Chamomile Tea with 25 grams glucose Almonds 15 grams
2438400|NCT03309254|Experimental|Low Glycemic Index|Multi-grain Bread with Turkey breast meat (2 slices) Turkey Breast (6 slices) Chamomile Tea with 25 grams fructose Cashews 10 grams
2438401|NCT03309241|Experimental|Cohort 1|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2438402|NCT03309241|Experimental|Cohort 2|Single Ascending Dose in crossover design with placebo substitution. Administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2438403|NCT03309241|Experimental|Cohort 3 (optional)|Single Ascending Dose administration under fed or fasted conditions as tablet or solution formulation. At least 7 days washout between doses in an individual subject.
2438404|NCT03309228||Qualitative Research|Semi-structured interviews with patients, relatives and general practitioners.
2438405|NCT03309215|Experimental|Patients with nickel allergy|Experimental stimulation with nickel discs
2438406|NCT03309215|Experimental|Persons without nickel allergy|Experimental stimulation with nickel discs
3188704|NCT00769756||3|The basic diet for all participants was supported by a list giving the calorie contents of a large variety of food-stuffs. The dual diet group received a second list giving the glycemic index (GI) for a large variety of carbohy-drates. Emphasis was placed on a preference for low-GI carbohydrates but not on avoidance of carbohydrates as required by the Atkins diet.
3188705|NCT00769769|Experimental|Telephone-based psychotherapy|
3188706|NCT00769769|Active Comparator|Face-to-face psychotherapy|
2438411|NCT03309176|Active Comparator|Standard group|Intervention:Medroxyprogesterone acetate (Provera) 10 mg daily for 10 days will be used prior to starting ovulation induction with clomiphene citrate (CC) and between anovulatory cycles. On cycle day (CD) 3 CC 50 mg is administered daily for 5 days. Follicle growth will be monitored by ultrasound, starting from CD11. Anovulatory patients (defined as no follicle ≥ 14 mm) on CD20, will receive Provera 10mg daily for 10 days. The CC dosage will be increased in the next cycle. On CD3 patients will receive CC 100 mg daily for 5 days with ultrasounds performed from CD11 onwards. Anovulatory patients will receive Provera 10mg daily for 10 days. In the next cycle the CC dose will be increased to 150 mg, starting from CD3, daily for 5 days with ultrasounds starting from CD11-20.
2438412|NCT03309176|Experimental|Stair Step group|Intervention: Stair step protocol without medroxyprogesterone acetate 10 mg prior to ovulation induction with clomiphene citrate (CC), nor in between anovulatory cycles. After performing an ultrasound to check for the presence of cysts or any other abnormalities and a negative pregnancy test, patients will receive CC 50 mg daily for 5 days. Ultrasounds will be performed on CD11-14. If there is no response on CD14 (no follicle ≥ 14 mm), the dose of CC is immediately increased to 100 mg CC daily for 5 days and an ultrasound is performed 1 week following the last ultrasound. If there is no response, 150 mg CC daily is initiated immediately for 5 days and the ultrasound is repeated 1 week after the previous ultrasound.
2438413|NCT03309163|Active Comparator|Group T|All patients receive the patient-controlled intravenous analgesia with Tramadol.
2438414|NCT03309163|Placebo Comparator|Group H|All patients receive the patient-controlled intravenous analgesia with Hydromorphone.
2438415|NCT03309163|Placebo Comparator|Group E|All patients receive the patient-controlled epidural analgesia with Ropivacaine.
2438416|NCT03309150|Experimental|M6620 Monotherapy or Combination Therapy|
2438417|NCT03309137|Experimental|Antiseptic device|Patients who are randomized to receive the device will receive Chlorhexidine at a dose of 0.24-0.42 mg/installation into all intravenous lines. The intervention will be administered every 24 hrs and as needed for as long as the intravenous is in place
2438418|NCT03309137|No Intervention|Routine Care|Patients who are randomized to routine care (no device, no intervention) will receive normal saline flush as per standard ICU care.
2438419|NCT03309124|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
2438420|NCT03309124|Experimental|Baked potato with skin|Baked russet potato
2438421|NCT03309124|Experimental|Mashed potatoes|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
2438422|NCT03309124|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
2438423|NCT03309124|Experimental|Meal skipping|No food given
2438424|NCT03309111|Experimental|ISB 1342|Part 1: Cohorts of multiple ISB 1342 dose levels; Part 2: One dose regimen until disease progression or other discontinuation criterion is met
2438425|NCT03309098||Ankle Injury|Person who injures their ankle
2438426|NCT03309085|Experimental|Single arm|Repeated CT scan
2438429|NCT03309059|Placebo Comparator|water and soap|Will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water in the area and subsequent diaper placement disposable. This type of procedure is standardized in the medical clinic wards of the hospital under study, and for this reason, it was defined as control.
2438491|NCT03308643|Placebo Comparator|Placebo|Patients will receive pure normal saline infusion at the same rate and volume just before the surgery after the induction of general anesthesia.
2438492|NCT03308630|Experimental|Energy Alignment and Mantra|
2438430|NCT03309059|Active Comparator|zinc oxide|will be composed of elderly patients who present with fecal and / or urinary incontinence and who, therefore, need to implement measures to prevent the development of IAD with the use of soap and water sanitation and application of zinc oxide . The patient presenting with urinary and / or fecal eliminations will undergo such intervention and then the placement of the disposable diaper used by the hospital.
2438431|NCT03309059|Experimental|Non-Irritant Barrier Film|will be composed of the elderly patients who present fecal and / or urinary incontinence and that, therefore, it is necessary to implement measures to prevent the development of ICD with the use of soap and water hygiene and application of Non Irritant Barrier Film. The patient who presents with urinary and / or fecal eliminations will undergo this intervention and then the placement of the disposable diaper used by the hospital.
2438432|NCT03309046|Experimental|REACH Individual Session|The individual sessions intervention focuses on education, skills building, and support. It will be delivered in six sessions by telephone over three months. A Caregiver Notebook will include comprehensive materials for all sessions and topics. Treatment fidelity will be monitored and ensured through assessment of intervention delivery, receipt, and enactment. The intervention is targeted and individualized to the concerns of the specific caregiver and care recipient through a risk assessment. The Risk Assessment (RA) assesses the main caregiving risk areas for the specific caregiving dyad. The RA is used to tailor the intervention for care recipient behaviors or safety issues and/or caregiver centered issues/concerns related to health, physical and emotional well being, and/or social support.
2438433|NCT03309046|Active Comparator|Education Webinar|For the education webinar sessions, topics addressing each of the caregiving risk factors topics but without the skills building or cognitive restructuring components present in the individual intervention sessions will be available online in webinars. The education webinar sessions will focus on general information about post 9/11 concerns, problem behaviors, caregiver health, caregiver emotional well-being, and red flags. Education webinar session participants will not receive the Caregiver Notebook until they have completed their 6 month interviews. Parents will be able to view all 6 webinars at any time during the first 3 months. Each session will last approximately thirty minutes through PowerPoint slide presentation format with a pre-recorded script.
3148529|NCT00151073|Experimental|Docetaxel and Estramustine|Docetaxel and Estramustine are given for the first cycle of therapy. All subsequent cycles consist of Docetaxel (70mg/m^2) given on day 2, Estramustine (280mg) given orally three times per day on days 1-3, and Zoledronate (4mg) given intravenously on day 2.
2438437|NCT03309007|Experimental|Metformin|Metformin started at 500 mg po twice daily (BID), and then titrated up to 1000 mg po q morning (AM) and 500 po q evening (PM) over the course of 1 month, as tolerated.
2438438|NCT03309007|Placebo Comparator|Placebo Oral Tablet|Near-identical CaCO3 as a Placebo Oral Tablet will be started at 648 mg po BID, and then titrated up to 1296 mg po q AM and 648 mg po q PM over the course of 1 month, as tolerated.
2438439|NCT03308994||Oral first line disease modifying treatments|
2438440|NCT03308994||Injectable first line disease modifying treatments|
2438441|NCT03308981|Experimental|REThink therapeutic online game|REThink group will play twice the seven levels of the game, divided into seven modules.
2438442|NCT03308981|Active Comparator|REBE group|Participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
2438443|NCT03308981|No Intervention|Wait-list|Participants will not receive any intervention.
3148530|NCT00151086|Experimental|Estramustine and Vinorelbine|Treatment will consist of 28-day cycles with estramustine at a dose of 140mg orally 3 times per day on days 1-3 and 8-10 and vinorelbine orally on days 2 and 9 beginning at dose 50mg/m^2.
3148531|NCT00151112|Experimental|1|combination of lateral position and 20° Trendelenburg Position
3148532|NCT00151112|Active Comparator|2|standard positioning
2438447|NCT03308955|Active Comparator|Grup B|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
2438448|NCT03308955|Sham Comparator|Grup S|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+ 400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
3148533|NCT00151125|Experimental|A|rhIL-11 (Interleukin-11, Neumega) 25 mcg/kg subcutaneously daily for 7 days
3148534|NCT00151125|Experimental|B|rhIL-11 (interleukin-11, Neumega) 50 mcg/kg subcutaneously daily for 7 days
3148535|NCT00151125|Experimental|C|rhIL-11 (Interleukin-11, Neumega) 10 mg/kg subcutaneously daily for 7 days
3148536|NCT00151177|Experimental|A|treatment with three nights of CPAP ventilation starting the first night of admission
3148537|NCT00151177|No Intervention|B|usual Stroke Unit care
3148538|NCT00151216|Experimental|Group A-Severe Stages of LINCL|"Group A will include n= 5 children with a total disability score of 0 to 4 (the severe forms of the disease; the staging based on a modification of the scale of Steinfeld et al.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
3148539|NCT00151216|Experimental|Group B-Moderate Stages of LINCL|"Group B will include n=6 children with a total disability score of 5 to 6, a moderate stage of the disease.~All subjects will receive 3x10^12 particle units of the AAV2CUhCLN2 vector."
3148540|NCT00151229|Active Comparator|strict control|systolic blood pressure control: less than 140 mm Hg
3148541|NCT00151229|Active Comparator|moderate control|systolic blood pressure control: 140 mm Hg to 149 mm Hg
3148542|NCT00151242|Active Comparator|1|
3148543|NCT00151242|Experimental|2|
3148544|NCT00151346|Active Comparator|CSE|"Subjects assigned to this group will receive combined spinal-epidural (CSE) to relieve pain during labor. For CSE, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer directly into the spinal canal (a smaller amount than is given for traditional epidural), followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. CSE is not experimental."
3148545|NCT00151346|Active Comparator|Traditional Epidural|"Subjects assigned to this group will receive traditional epidural to relieve pain during labor. For the traditional epidural, subjects receive a small amount of a local anesthetic and a small amount of a narcotic pain killer into the epidural space, followed by a small amount of both of these medications that is continuously infused into the epidural space through a catheter that is left in place. The traditional epidural is not experimental."
3148546|NCT00151398|Experimental|A|
2438454|NCT03308916|Experimental|Liver stiffness measurement|Transient elastography in fasting state
2438455|NCT03308890|Active Comparator|Arm 1|0.5mg Entecavir QD for 6 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
2438456|NCT03308890|Active Comparator|Arm 2|0.5mg Entecavir QD for 12 months after cessation of TDF and clinical observation for up to 6 months after the end of study follow-up.
2438457|NCT03308890|No Intervention|Arm 3|No consolidation arm and observation only and clinical observation for up to 6 months after the end of study follow-up.
2438458|NCT03308877|Experimental|Brief Motivational Intervention (BMI)|
2438459|NCT03308877|Active Comparator|Standard Care (SC)|
2438460|NCT03308864|Experimental|Interpersonal Psychotherapy for Adolescents (IPT-A)|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
2438461|NCT03308864|Active Comparator|Treatment as Usual|All adolescents who present at Child and Adolescent Outpatient Service (CAOS) for a diagnostic intake evaluation and who report any symptoms of depression.
2438462|NCT03308851|Experimental|Piezocorticision and osteoperforation group|All participants in this arm will receive the piezocorticision and osteoperforation procedures on the upper jaw on the left and the right side.
2438463|NCT03308851|No Intervention|Control|The participants in this arm will receive no treatment, but will have the same monitoring as the experimental group.
2438464|NCT03308838||Cases|Cases consisted of Costa Rican adults who were diagnosed as survivors of a first acute myocardial infarction.
2438465|NCT03308838||Controls|Controls consisted of healthy individuals randomly identified from the underlying source population in Costa Rica and matched to each case by age, sex, and area of residence.
2438470|NCT03308812|Active Comparator|Health360x|Participants will use the Health360x application for 6 months.
2438471|NCT03308812|Experimental|Health360x plus health coach|Participants will use the Health360x application and received personalized health coaching for 6 months.
2438475|NCT03308786|Experimental|IL2 treatment|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks, in addition to combination antiretroviral therapy.
2438476|NCT03308747|Experimental|High systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: ≥ 1.7 pg/ml and hs-CRP: > 2.0 mg/L.
2438477|NCT03308747|Active Comparator|Low systemic inflammation|Individuals assigned in the high systemic inflammation group will be characterized by IL6: < 1.7 pg/ml and hs-CRP: < 1.0 mg/L.
2438478|NCT03308734|Experimental|Exercise Intervention Group|Reduced-Exertion High-Intensity Interval Training Following baseline testing, participants will start a 6-week training protocol involving reduced-exertion high-intensity training on a cycle ergometer based in a gym in Gloucestershire used by the Macmillan Cancer Support's Next Steps project.
2438479|NCT03308734|No Intervention|Control Group|Following baseline testing, participants will receive usual care only.
2438482|NCT03308708|No Intervention|Control group|
2438483|NCT03308708|Experimental|NE group|
2438484|NCT03308682|Experimental|177Lu-DOTA-EB-TATE dosimetry calculation|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
2438489|NCT03308656||Induced labor in term pregnancies|100 singleton nulliparous patients are planning to complete the study period. Study group constitute of third trimester pregnancies between 37-40 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2438490|NCT03308643|Experimental|Oxytocin infusion|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
2438493|NCT03308604|Experimental|Patients with locally advanced cervical cancer|
3148547|NCT00151398|Experimental|B|
3148548|NCT00151398|Experimental|C|
3148549|NCT00151398|Active Comparator|D|
3148550|NCT00151424|Experimental|1|asenapine 5-10mg BID
3148551|NCT00151424|Placebo Comparator|2|Placebo
3148552|NCT00151424|Active Comparator|3|olanzapine 10-20 mg QD
3148553|NCT00151515|Experimental|1|Topical 5% minoxidil foam formulation used twice daily
3148554|NCT00151554|No Intervention|Control group|
3148555|NCT00151554|Experimental|Intervention group|
3148556|NCT00151567|Experimental|1|Tamsulosin
3148557|NCT00151567|Placebo Comparator|2|Placebo
3148558|NCT00151580|Experimental|1|Ribavirin maintenance treatment
3148559|NCT00151580|Placebo Comparator|2|
3148560|NCT00151593|Experimental|1|Celsior preservation solution
3148561|NCT00151632|Experimental|MMF+FK|Low doses of tacrolimus in association with mycophenolate mofetil
3148562|NCT00151632|Active Comparator|FK|Full recommended doses of tacrolimus
3148563|NCT00151671|Experimental|1|Perioperative Oral Nutritional Supplementation
3148564|NCT00151671|Placebo Comparator|2|Placebo of Perioperative Oral Nutritional Supplementation
3148565|NCT00151736|Experimental|Chlorambucil|Regime A
3148566|NCT00151736|Experimental|R-etodolac with chlorambucil|Regime B
3148567|NCT00151827|Experimental|Olmesartan medoxomil|Olmesartan oral tablets 20 mg or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
3148568|NCT00151827|Experimental|Losartan|Losartan over encapsulated tablets 50 mg and 100 mg plus olmesartan placebo.
3148569|NCT00151957|Experimental|Methylphenidate transdermal system|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
2438494|NCT03308591|Experimental|NACT|The patients will receive 2 courses of platinum based chemotherapy before surgery, 2-3 weeks after each course, doctors will appraise the effect of the chemotherapy. Patients who are sensitive to the treatment will undergo radical hysterectomy and pelvic lymph node dissection 3 weeks after chemotherapy. And 2-3weeks after the surgery, patients will receive adjuvant chemotherapy according to the pathological risk factors.
2438495|NCT03308591|Active Comparator|PST|The patients in this group will undergo radical hysterectomy and pelvic lymph node dissection directly, and 2-6 weeks after the surgery, they will receive adjuvant chemotherapy according to the pathological risk factors.
2438496|NCT03308578|Experimental|Atorvastatin|Subjects randomized to this arm will be started on a lower dose of atorvastatin 40 mg daily for the first 4 weeks. If they are tolerating this dose without significant problems, atorvastatin will be increased to 80 mg daily.
2438497|NCT03308578|Placebo Comparator|Placebo Oral Capsule|Subjects randomized to this arm will receive placebo capsules matching study drug.
3148570|NCT00151970|Active Comparator|Methylphenidate Transdermal System|The duration of MTS patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
2438499|NCT03308552|Active Comparator|SIB-IMRT combined chemotherapy followed by chemotherapy|"SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.~Concurrent chemotherapy: Paclitaxel and platinum based drug are administered once a week for at least 5 weeks during radiotherapy treatment days."
2438500|NCT03308552|Placebo Comparator|SIB-IMRT Alone followed by chemotherapy|SIB-IMRT: Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
2438501|NCT03308539||myocardial infarction patients|transthoracic echocardiography and cardiac magnetic resonance
2438502|NCT03308500|Experimental|High-intensity intermittent games HIIG|High-intensity intermittent games (HIIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 75% ≤ - RPE 6-8.
2438503|NCT03308500|Active Comparator|Moderate-intensity games (MIG)|Moderate intensity games (MIG): complete a supervised 12-weeks. Twice per week child-specific games program, intensity HRmax 60-74% ≤ - RPE 4-5.
2438504|NCT03308487|Active Comparator|vitamin D3 (1000 IU)|group 1
2438505|NCT03308487|Active Comparator|vitamin D3 (2000 IU)|group 2
2438506|NCT03308461|Experimental|Fecal microbiota transplantation (FMT)|Patients underwent single FMT in this studyAll patients were assessed before FMT and during 12-week follow-up after FMT.
2438507|NCT03308448|Active Comparator|Group 1|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 300 units/kg/day for three consecutive days (total:900/kg in 3 days)
2438508|NCT03308448|Active Comparator|Group 2|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days (total:1800/kg in 3 days)
2438509|NCT03308448|Active Comparator|Group 3|Intervention is Intra-Venous injection of Eprex or EPO [recombinant human erythropoietin, Pooyesh Darou Biopharmaceuticals CO., Tehran, Iran, 4000 unit/ml solution in prefilled syringe], 600 units/kg/day for three consecutive days then repetition of the same treatment in month 1 (Total: 3600/kg in 2 set of 3-day treatment, 1 month apart)
2438510|NCT03308422||Parents of 2-6-years-old children|Parents of preschool children in Nancy agglomeration
2438511|NCT03308409|Active Comparator|Protocol 1|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
2438512|NCT03308409|Experimental|Protocol 2|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six initial sessions, one per week, with 3000 pulses at 0.20 mj/mm2, at a frequency of 4Hz for six weeks, followed by monthly maintenance sessions (every 4 weeks) for five months. At all of the shockwave sessions, 2000 pulses will be distributed to the body of the penis and 1000 pulses will be applied to the base.
2438513|NCT03308409|Experimental|Protocol 3|Low-intensity extracorporeal shock wave therapy (Li-ESWT): Six monthly sessions in which 3000 pulses will be applied at 0.20 mj/mm2, at a frequency of 4Hz, with 2000 pulses distributed to the body of the penis and 1000 pulses applied to the base
2438514|NCT03308396|Experimental|Single Arm|"This is a non-randomized, single arm, open label Phase Ib/II study.~Phase Ib:~Days 1-5~Guadecitabine:~Dose 0: 60 mg/m^2~Dose -1: 45 mg/m^2~Phase II:~Days 1-5 Guadecitabine (at Ph II dose)~Day 8 Durvalumab (1500 mg IV) Day 8 Durvalumab (1500 mg IV)"
2438515|NCT03308383|Experimental|TRANSTHORACIC ECHOCARDIOGRAM|Individuals who visit pre-anaesthetic check up (PAC) clinic for minor surgery which includes plastic, rhino-otolaryngeal, ophthalmologic, orthopaedic, abdominal, urological, gynaecological surgeries, who are free of cardiac disease or any known risk factors for the cardiac disease like chronic alcoholism, chronic smoking, metabolic syndrome, morbid obesity
2438516|NCT03308370|Experimental|Platelet rich plasma|intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
2438517|NCT03308357||All six subjects|2 patients with ulcerative colitis; one with active disease and one in remission. 2 patients with Crohn's disease; one with active disease and one in remission. 2 healthly controls. Single blood sample from each participant, serum collected, that serum will be spiked with known concentrations of the originator infliximab and the biosimilar infliximab and then run on a range of assays to measure infliximab drug concentrations
2438518|NCT03308344|Experimental|Spouse Trainers (MT-ST)|Participants will engage in a short-form mindfulness training delivered by their peers who underwent an extensive training practicum.
2438519|NCT03308344|No Intervention|Wait-list control|Participants will be tested before and after a no-training interval and may receive training at a later time.
2438520|NCT03308344|Experimental|Mindfulness Expert (MT-ME)|Participants will engage in a short-form mindfulness training delivered by an expert mindfulness trainer.
2438521|NCT03308331|Experimental|HIV-1 smokers|
2438522|NCT03308331|No Intervention|HIV-1 nonsmokers|
2438523|NCT03308331|Active Comparator|Healthy control smokers|
2438529|NCT03308318||the supratemporalis approach|patients operated upon with zygomaticofacial or craniofacial fractures using the supratemporalis approach
2438530|NCT03308292|No Intervention|Control Group|
2438531|NCT03308292|Experimental|Intervention Group|"A moderate-intensity aerobic physical exercise programme was carried out during the months of March to May 2017 (12 weeks), with a frequency of three sessions per week (36 sessions in total) with a duration of 45 minutes per session. The intensity was controlled through the Borg 1982 modified scale of perceived exertion (RPE). It is a scale from 0 to 10, considering 0 as nothing at all and 10 as very very strong, setting the moderate intensity as value"
2438532|NCT03308279||Asinthomatic|The only group evaluated
2438533|NCT03308266||CLP children with pain-related TMD|
2438534|NCT03308266||CLP children with no TMD|
2438535|NCT03308266||CLP children with painfree TMD|
2438536|NCT03308253|Other|Standard of Care|Patients will receive the standard of care for vascular procedures as it is provided at Hamilton General Hospital
2438537|NCT03308253|Experimental|Antibiotic Impregnated Beads|Patients will have their wound packed with calcium sulfate beads prior to closing. The beads will be infused with the antibiotics vancomycin and tobramycin.
2438538|NCT03308240|Experimental|Magic Therapy Group|"Medical student magicians who have completed MagicAid training will provide the therapy.~Three or four tricks will be performed per patient at the discretion of the magician to cater to patient age and cognition capabilities. Patients in the experimental group may be given the opportunity to learn a magic trick that has been presented to them as well."
2438539|NCT03308240|No Intervention|Standard Child Life Therapy Group|Stony Brook Child Life Specialists will provide standard therapies available to all patients, such as pet therapy, art therapy, music therapy.
2438540|NCT03308227||Experimental Group|septic shock patients;
2438541|NCT03308227||Conrol Group|non-septic shock patients;
2438542|NCT03308214||septic shock|Patients with septic shock treat with Imipenem
2438543|NCT03308214||non-septic shock|Patients with infection but not septic shock treat with Imipenem
2438544|NCT03308201|Experimental|Hemay022 and Exemestane|"Part one: Hemay022 in combination with exemestane will be taken orally once daily. Planned dose escalation of Hemay022 will be 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Hemay022 in combination with exemestane will be taken in OTR dose until disease progression, intolerable toxicity or death."
2438545|NCT03308201|Experimental|Hemay022 and Letrozole|Part two: Hemay022 in combination with letrozole will be taken in OTR dose until disease progression, intolerable toxicity or death.
2438546|NCT03308201|Experimental|Hemay022 and Fulvestrant|Part two: Hemay022 in combination with fulvestrant will be taken in OTR dose until disease progression, intolerable toxicity or death.
2438547|NCT03308188|No Intervention|Treatment As Usual|Participants randomized to Treatment As Usual will receive treatment for chronic pain as typically provided by their clinician -- they will receive no extra treatment from the study.
2438548|NCT03308188|Experimental|E-Health+|Participants randomized to the E-health+ arm will receive treatment as typically provided by their clinician plus a 4-month subscription to the E-health program, which is an internet based chronic pain program.
2438549|NCT03308175|Experimental|flat fixed anterior bite plane|"Bands selection will be done for upper 6s. Alginate impressions taken and molar bands are fitted in place into the impressions. Impressions for upper and lower arches are poured with stone plaster. Mounting on simple hinge articulator will be done.~Lingual arches (diameter 1 mm) with anterior acrylic bite plates with thickness enough to separate posterior teeth 4mm .~The acrylic bite planes were in occlusion with the lower anterior teeth and extended sagittally 2-3mm beyond edges of lower incisors.~Finishing ,polishing and cementation into patient's mouth with glass ionomer cement."
2438550|NCT03308175|Experimental|modified inclined fixed anterior bite plane|"In modified inclined fixed anterior bite plane,the modification is that some indentations will be done in the acrylic part where the lower anteriors will fit such that mandible will be held in a more forward position. These indentations will be relieved lingually to overcome it's flaring effect on mandibular incisors .The inclined plane will be 60 degrees to occlusal plane.~Functional bite will be taken to position the mandible in the proper position forward.~Bite taken edge-to-edge for appliance construction. Mounting upper and lower casts on simple hinge articulator for construction of modified flat fixed anterior bite plane"
2438551|NCT03308162|Experimental|Group Intervention|Cognitive behavioral experiential group therapy for health behavior change
2438552|NCT03308136|Experimental|subcutaneous anesthesia group (group A)|
2438553|NCT03308136|Active Comparator|muscle anesthesia group (group B)|
2438554|NCT03308123||Health Care Professionals|Health care professionals
2438555|NCT03308123||Carers of hip-fracture patients with moderate/severe|Carers of hip-fracture patients with moderate/severe
2438556|NCT03308123||Discharged hip-fracture patient with memory difficulty|Discharged hip-fracture patient with memory difficulty
2438557|NCT03308110|Other|Relative Bioavailability Cohort|Relative Bioavailability cohort
3188707|NCT00769782|Experimental|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
2438560|NCT03308084|Active Comparator|Local Depomedrol plus IV dexamethasone|Local intraoperative application of methylprednisolone (Depomedrol) plus standard systemic (IV) dexamethasone
2438561|NCT03308084|Placebo Comparator|IV dexamethasone|Standard systemic (IV) dexamethasone only
2438562|NCT03308071|Experimental|Hypnosis Group|Participants will undergo a brief hypnotic assessment, a single hypnosis session with an MD trained in hypnosis, and be given a phone number to listen to a guided self-hypnosis recording for 1 week pre-op until 2 weeks post-op.
2438566|NCT03308045|Experimental|pEYS606|Cohort 1 (pEYS606 lower dose); Cohort 2 (pEYS606 intermediate dose); Cohort 3 (pEYS606 higher dose); Extension Cohort (pEYS606 maximum tolerated dose)
2438567|NCT03308032|Experimental|Intervention|Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course. Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons. For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both
2438568|NCT03308032|Active Comparator|Control|"Participants assigned to the intervention arm will be invited to connect to a webpage, through either computer or tablet / iPad, where they can login to receive the SDL course.~Immediately after the login, and weekly thereafter, participants will receive emails to remind them of the login passwords, to provide them with tracking data on their progress in going through the training lessons (see below). For those who login but do not proceed to take baseline assessment for longer than two days, study staff will contact participants, via the email address or telephone number that was entered during initial registration for login, to answer any questions they might have and to provide assistance to those who have not been able to log onto the site. Those who sign up without taking any courses for 10 days will receive a reminder call by study staff. Intervention arm participants will be invited back via both"
2438569|NCT03308019|Experimental|Adjunctive photodynamic therapy|This arm will be given scaling and root planing (SRP) with adjunctive photodynamic therapy (aPDT)
2438570|NCT03308019|Active Comparator|Dental scaling|This arm will be given scaling and root planing (SRP) only
2438571|NCT03308006|Experimental|Stem cells therapy|
2438572|NCT03307993|Experimental|Idalopirdine|"Idalopirdine 60 mg once daily for 10 day (up to 14 days possible), adjunct to donezepil (patients individualized maintenance dose)~If high receptor occupancy cannot be verified, the receptor occupancy following a higher dose (up to 60 mg twice daily for 10-14 days) will be assessed in Cohort 2."
2438573|NCT03307980|Experimental|PF-06838435 Dose-Escalation|Single intravaneous infusion of PF-06838435. After 2 participants receive initial dose, data will be evaluated and a decision will be made to escalate or reduce the dose being evaluated, increase the number of participants receiving the dose, or stop dosing. Multiple iterations may be undertaken.
2438574|NCT03307967|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.
2438575|NCT03307954|Experimental|Ekso Therapy|Up to 12 weeks of Ekso Therapy. Three sessions per week. One hour per session
2438576|NCT03307954|Active Comparator|Control|Up to 12 weeks of usual physiotherapy care. Three sessions per week. One hour per session.
2438577|NCT03307941|Other|Single arm (classic 3+3 design)|
2438578|NCT03307928|Experimental|Cardiopulmonary Exercise Test Protocol|All subjects performed an incremental cardiopulmonary exercise test (CPET) to maximum exercise tolerance. All the procedures were performed in agreement with the American Thoracic Society/American College of Chest Physicians guidelines for cycle ergometer tests.
2438579|NCT03307928|Experimental|Polysomnography Assessment|All hypertensive subjects were submitted to a polysomnography exam to diagnose OSA. The OSA diagnose was confirmed by the apnea/hypopnea index (AHI) and classified as follows: AHI < 5 events/h, absence of OSA; 5 ≤ AHI ≤ 15 events/h, low OSA; 15 ≤ AHI ≤ 30 events/h, moderate OSA; AHI > 30 events/h, severe OSA.
3148571|NCT00151970|Placebo Comparator|Placebo|The duration of placebo patch wear was 9 hours per day. A new patch was applied each morning upon awakening.
3148572|NCT00151970|Active Comparator|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
3148573|NCT00151983|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
2438583|NCT03307902|Experimental|Imiquimod + ID HBVv|topical imiquimod + intradermal hepatitis B vaccination
2438584|NCT03307902|Active Comparator|Aqueous + ID HBVv|topical aqueous + intradermal hepatitis B vaccination
2438585|NCT03307902|Active Comparator|Imiquimod + IM HBVv|topical imiquimod + intramuscular hepatitis B vaccination
2438586|NCT03307876||groups that are fac + and -|autologous PPP injection is given to all patients. Prior to injection, a lavage of the disc space is taken to test for FAC.
2438587|NCT03307863|Experimental|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
2438588|NCT03307863|Experimental|Topiramate-Implant|Women with epilepsy using topiramate for at least 3 months will have an etonogestrel-releasing implant inserted
2438589|NCT03307863|Active Comparator|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
3148574|NCT00151983|Placebo Comparator|Placebo patch|Placebo patch applied daily for 8 weeks
3148575|NCT00152113|Other|1|
3148576|NCT00152126|Other|1|
3148577|NCT00152139|Other|1|
3148578|NCT00152178|Experimental|1|UFT (uracil, tegafur) and tamoxifen
3148579|NCT00152178|Active Comparator|2|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
3148580|NCT00152191|Experimental|1|UFT (uracil, tegafur)
3148581|NCT00152191|Active Comparator|2|CMF(cyclophosphamide, methotrexate, and fluorouracil)
2438590|NCT03307850|Experimental|Observation of Exercise|Observation During Exercise and Stress
2438597|NCT03307824|Experimental|IfabondTM|Use of the synthetic glue IfabondTM
2438598|NCT03307824|Active Comparator|sutures|Glue-Free Suture Technique
2438599|NCT03307811|Experimental|22 gauge needle liver biopsy|EUS-LB will be performed using a 22 g FNB needle. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
3148582|NCT00152204|Experimental|1|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
3148583|NCT00152204|No Intervention|2|
3148584|NCT00152217|Experimental|1|TS-1 (S-1)
3148585|NCT00152217|Other|2|Surgery alone
3148586|NCT00152230|Experimental|1|UFT (uracil, tegafur)
3148587|NCT00152230|Other|2|Surgery alone
3148588|NCT00152243|Experimental|1|UFT (uracil, tegafur)
3148589|NCT00152243|Other|2|Surgery alone
3148590|NCT00152256|Experimental|1|
3148591|NCT00152256|Experimental|2|
3148592|NCT00152256|Placebo Comparator|3|
2438611|NCT03307772|Placebo Comparator|placebo drink|The placebo drink consists of fermented low-fat milk with no added Lactobacillus GG.(placebo)
2438612|NCT03307772|Active Comparator|LGG Drink (|The probiotic drink consists of fermented low-fat milk with added Lactobacillus GG. (probiotics)
2438613|NCT03307772|Active Comparator|FOS Drink|The prebiotics drink consists of fermented low-fat milk with fructooligosaccharides. (prebiotics)
2438614|NCT03307772|Active Comparator|LGG e FOS Drink|The probiotics and prebiotics drink consists of acidified low-fat milk with added Lactobacillus GG and fructooligosaccharides (prebiotics and probiotics)
2438615|NCT03307759|Active Comparator|SABR plus pembrolizumab|SABR followed by pembrolizumab
2438616|NCT03307759|Active Comparator|Pembrolizumab plus SABR|Pembrolizumab followed by SABR after cycle 1
3148593|NCT00152269|Experimental|1|
3148594|NCT00152269|Experimental|2|
3148595|NCT00152269|Placebo Comparator|3|
3148596|NCT00152282|Experimental|1|
3148597|NCT00152282|Experimental|2|
3148598|NCT00152282|Experimental|3|
3148599|NCT00152282|Placebo Comparator|4|
3148600|NCT00152295|Experimental|1|
3148601|NCT00152321|Experimental|A|Multifaceted intervention
3148602|NCT00152321|Active Comparator|B|Usual Care
3148603|NCT00152360|Experimental|Xenical (Orlistat)|Investigating the effectiveness of Xenical on cardiovascular risk factors in the patients of St. Paul's Hospital Lipid Clinic
3148604|NCT00152438|Experimental|1|Oral micronized progesterone
3148605|NCT00152438|Placebo Comparator|2|Placebo
3148606|NCT00152477|Experimental|Carboplatin/Paclitaxel|Carboplatin and paclitaxel alone.
3148607|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 10mg|Carboplatin and paclitaxel plus CDP791 10mg/kg
3148608|NCT00152477|Experimental|Carboplatin/Paclitaxel/CDP791 20mg|Carboplatin and paclitaxel plus CDP791 20mg/kg
3148609|NCT00152542|Experimental|Inhaled nitric oxide|
3148610|NCT00152542|Placebo Comparator|Placebo|
3148611|NCT00152568|Experimental|Child Passenger Safety Technician services|
3148612|NCT00152633|Active Comparator|Losartan|Treatment with Losartan.
3148613|NCT00152633|Active Comparator|Betablocker|Treatment with Metoprolol.
3148614|NCT00152698|Active Comparator|Irbesartan|
3148615|NCT00152698|Placebo Comparator|Placebo|
3148616|NCT00152776|Placebo Comparator|Group I|ovaria comp 10 Globuli 3 times per day 24 weeks - Placebo 12 weeks
3148617|NCT00152776|Placebo Comparator|Group II|Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 24 weeks
3148618|NCT00152776|Placebo Comparator|Group III|ovaria comp 10 globuli 3 times per day 12 weeks - Placebo 12 weeks - ovaria comp 10 globuli 3 times per day 12 weeks
3148619|NCT00152815|Experimental|Vitamin E|alpha-tocoperol, capsules, 2 per day
3148620|NCT00152828|Experimental|Celecoxib|Celecoxib
3148621|NCT00152854|Active Comparator|A, 1, acetaminophen|acetaminophen
3148622|NCT00152854|Placebo Comparator|B placebo|placebo PO qid
3148623|NCT00152867|Active Comparator|1|Dexamethasone
3148624|NCT00152867|Placebo Comparator|2|Placebo
3148625|NCT00152893|Experimental|Chromium|400 μg (200 μg pills, twice per day) of Cr-nicotinate
3148626|NCT00152893|Placebo Comparator|Placebo|Identical looking placebo (di-calcium phosphate)
3148627|NCT00152906|Experimental|Stereotactic RT or highly conformal RT|
3148628|NCT00153205|Placebo Comparator|Introduction of A Clinical Pharmacist|
3148629|NCT00153205|Experimental|Technological|
3148630|NCT00153231|Experimental|Infracoccygeal sacropexy|Intervention: IVS
3148631|NCT00153231|Active Comparator|Sacrospinofixation|Intervention: Sacrospinofixation
3148632|NCT00153257|Other|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
3148633|NCT00153257|No Intervention|No device|standard anterior colporrhaphy
3148634|NCT00153426|Experimental|lifestyle counseling|Women assigned to lifestyle change intervention arm for nutrition and physical activity with print-based tailored health communications and a computer-based interactive nutrition program targeting health behaviors of diet and physical activity. Women in a control group did not receive the intervention.
3148635|NCT00153504|Experimental|Housing and Health Study housing rental assistance|
3148636|NCT00153504|Active Comparator|Standard local practice housing assistance|
3148637|NCT00153530|Active Comparator|1|1 chemotherapy with radiotherapy
3148638|NCT00153530|Experimental|2|chemotherapy without radiotherapy
3148639|NCT00153634|Experimental|1|Antibiotic regimen assignment based on biofilm susceptibility test results
2438617|NCT03307746|Active Comparator|ARM A- Rituximab and Varlilumab|Patients in ARM A willl receive Cycle1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 2: varlilumab 3 mg/kg IV Cycles 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
2438618|NCT03307746|Active Comparator|ARM B - Rituximab and Varlilumab|Patients in ARM B will receive Cycle 1 Day 1: rituximab 375 mg/m2 IV Cycle 1 Day 8: varlilumab 3 mg/kg IV Cycle 2 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 1: rituximab 375 mg/m2 IV Cycle 3 Day 2: varlilumab 3 mg/kg IV Cycle 4 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 1: rituximab 375 mg/m2 IV Cycle 5 Day 2: varlilumab 3 mg/kg IV Cycle 6 Day 1: rituximab 375 mg/m2 IV
2438619|NCT03307733|No Intervention|Control Group|Control group received usual care plus a blinded Fitbit pedometer.
2438620|NCT03307733|Active Comparator|Intervention|Intervention group received a Fitbit pedometer with individualised physical activity targets and behaviour change techniques which were delivered via a closed Facebook group
2438621|NCT03307720|Active Comparator|Poor responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
2438622|NCT03307720|Experimental|Poor responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment."
2438623|NCT03307720|Active Comparator|Normo responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
2438624|NCT03307720|Experimental|Normo responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment."
2438625|NCT03307720|Active Comparator|High responders. Classical trigger|"Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
2438626|NCT03307720|Experimental|High responders. Agonist trigger|"Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)~Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment."
2438627|NCT03307707||Heart Failure (HF)|subjects with a Left Ventricular Ejection Fraction (LVEF) <50% or LVEF >50% and E/e'>10.
2438628|NCT03307707||No Heart Failure (NHF)|subjects with LVEF>50%
2438629|NCT03307694||MAC-SWEI, standard SWEI, ultrasound|Participants in this group will receive all three imaging techniques
2438630|NCT03307694||Standard SWEI, ultrasound|Participants in this group will receive two imaging techniques
2438631|NCT03307681|Experimental|White bread|Matched for energy content and available carbohydrate content of potato treatments
2438632|NCT03307681|Experimental|Baked potato with skin|Baked russet potato
2438633|NCT03307681|Experimental|Mashed potato served hot|Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato
2438634|NCT03307681|Experimental|Fried French fries|Matched for available carbohydrate content of baked potato
2438635|NCT03307681|Experimental|Meal skipping|No food given
2438636|NCT03307668|Experimental|CaReS-1S|
2438637|NCT03307668|Active Comparator|Microfracture|
2438638|NCT03307655|Experimental|Control (fertile semen donors)|Sperm from fertile men (donors who attend the IVI Murcia clinic) will be included in this arm.
2438639|NCT03307655|Experimental|Patients (subfertile men)|Sperm from patients (subfertile men, i.e. men who possess one altered spermiogram parameter, according to the WHO 2010 guidelines) will be included in this arm.
2438640|NCT03307642|No Intervention|SLIV + usual communication|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV
2438641|NCT03307642|Active Comparator|SLIV + usual communication + text|Parents receive usual communication from school (paper consent packets & automated voice mails) about SLIV plus a series of text messages informing them about the usual communication for SLIV
2438642|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohorts 1-3|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 treatment given to 3 cohorts of 4 patients as 1 of 3 doses, 400mg, 800mg and 1200 mg.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
2438643|NCT03307629|Experimental|NOX66 + Radiation treatment (combined) in cohort 4|"NOX66 administered on Days 1-16 and radiation treatment given on Day 2 to 9 of 2-week cycle.~NOX66 dose will be either one of 3 doses 400mg, 800mg and 1200 mg based on interim analyses of safety data and tumour response at WEEK 6 of 3 dose cohorts of 12 total patients. The Safety Steering Committee will inform on dose for cohort expansion.~Radiation treatment of 20Gy given over 5 daily fractions to selected target lesion/s for all cohorts."
2438644|NCT03307616|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
2438645|NCT03307616|Experimental|Arm B (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm A. Patients also receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 43.
2438646|NCT03307616|Experimental|Arm C (nivolumab, RT)|Patients receive nivolumab IV over 1 hour on days 1, 15, 29, and 43. Patients also undergo RT QD for 5 days during days 15-47 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
2438647|NCT03307616|Experimental|Arm D (nivolumab, ipilimumab, RT)|Patients receive nivolumab as in Arm C, ipilimumab as in Arm B, and RT as in Arm C in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery within 2 weeks after day 71.
2438680|NCT03307278|Experimental|Steroid resistance in HDM allergic patients|
2438681|NCT03307278|Experimental|Steroid resistance in non HDM allergic subjects|
2438682|NCT03307265|Experimental|Imbalance correction|
2438648|NCT03307603|Experimental|Yttrium-90 + Nivolumab|240 mg Nivolumab intravenously, beginning at 2 weeks after Yttrium-90 treatment and given every 2 weeks until progression or toxicity. Additional dose at 2 weeks prior to Y-90 will be given if the first 3 patients do not have toxicity. If any of the first 3 patients have toxicity, the schedule can be relaxed to begin 3 weeks after Y-90 treatment.
2438649|NCT03307590|Active Comparator|D group|Dexmedetomidine with bupivacaine group Caudal dexmedetomidine 1.5 microgram/kg with bupivavaine (0.25%) 1.25 ml/kg were administered
2438650|NCT03307590|Active Comparator|B group|Bupivacaine only group Caudal bupivavaine (0.25%) 1.25 ml/kg without dexmedetomidine was administered
2438651|NCT03307577|Experimental|UHE-101 cream, 1%|Cream is applied twice a day
2438652|NCT03307577|Placebo Comparator|Vehicle cream|Cream is applied twice a day
3148640|NCT00153634|Active Comparator|2|Antibiotic regimen assignment based on conventional susceptibility test results
2438654|NCT03307551|Active Comparator|CLADS group|Anaesthesia will be induced and maintained with Propofol administered by CLADS. Its administration rate will be controlled by a feedback loop facilitated by BIS monitoring. A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
2438655|NCT03307551|Active Comparator|Manual group|Anaesthesia will be induced and maintained with propofol administration by an intravenous infusion pump. Its administration rate will be controlled manually to maintain a target BIS of 50 during induction and maintenance of anaesthesia.
2438656|NCT03307538|Experimental|Stereotactic body radiation therapy|
2438657|NCT03307512|Experimental|Dance 501|Dance 501(Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
2438658|NCT03307512|Active Comparator|Insulin Lispro|Insulin Lispro (Humalog®) will be administered by subcutaneous injection
2438659|NCT03307499|Experimental|Treatment|NeoPatch
2438660|NCT03307486||Gestational diabetes|Women diagnosed with GDM according to the IADPSG criteria, either by abnormal fasting plasma glucose or by abnormal oral glucose tolerance test.
2438661|NCT03307473||e-bike|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
2438662|NCT03307460|Experimental|uPAR PET/MRI|68Ga-NOTA-AE105 is injected once for performing a PET/MRI scan
2438663|NCT03307447|Experimental|Treatment arm|Cosentyx (Secukinumab) 300 mg subcutaneous injection at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks until 16 weeks
2438664|NCT03307434|Experimental|experimental group|experimental group is composed of athletes will be followed the Athletics Injury Prevention Program
2438665|NCT03307434|Active Comparator|control group|control group is composed of athletes will be continued their regular training
2438666|NCT03307421|Other|debriefing without instructor|Team debriefing without an instructor will be organized as follows. The pairs of participants will be placed in a room with direct access to the video recording of their passage on the simulator. Two documents will be made available to help participants structure their debriefing: one targeting non-technical skills, based on the TEAM Score, and one recalling recommendations on ACR care. Despite its absence at the time of the debriefing, the instructor will be present during the briefing and during the simulation.
2438667|NCT03307421|Other|debriefing with instructor|"The team debriefing with an instructor will begin immediately after the simulator run and will be governed by the principle of no judgment described by Rudolph .~A portion of the video of the participants' pass may be reviewed and used to support the debriefing (depending on the utility judged by the debrief). Each center will use its own team of trainers, but it will have a predefined plan and predefined objectives, which are provided in advance in order to obtain a standardized debriefing. Moreover, these trainers will not be beginners but will have some expertise in the pedagogy of simulation. They will have to have a DU in a simulation or pedagogy trainer (recommendations from SofraSim) and will have to carry out 15 debriefings per year"
2438668|NCT03307395|Experimental|Middle Meningeal Artery Embolization|
2438669|NCT03307382|Experimental|SpyGlass DS Cholangioscopy|ERCP with cholangiogram will be performed to assess the common bile duct (CBD) and intrahepatic ducts (IHD) for presence of a stricture. Once a biliary stricture is confirmed on cholangiogram during ERCP, SpyGlass DS Cholangioscopy would be performed. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy. Endoscopic stenting will be performed in standard fashion for biliary drainage to relieve the obstructive jaundice.
3148641|NCT00153647|Active Comparator|1|Cap-assisted Colonoscopy
3148642|NCT00153647|Placebo Comparator|2|Regular Colonoscopy
3148643|NCT00153660|Active Comparator|NSAID #1|Celecoxib and Naproxen Placebo
2438673|NCT03307330||Obstructive Sleep Apnea|Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) >=5
2438674|NCT03307330||Non-Obstructive Sleep Apnea|Non-Obstructive sleep apnea is defined as having Apnea hypopnea index (AHI) < 5
3148644|NCT00153660|Active Comparator|NSAID #2|Naproxen and Celecoxib Placebo
3148645|NCT00153673|Active Comparator|1|Celecoxib + Famotidine
3148646|NCT00153673|Active Comparator|2|Dologesics + Famotidine
3148647|NCT00153686|Experimental|Capsule Endoscopy|Capsule Endoscopy examination of small intestine
3148648|NCT00153686|Other|Mesenteric Angiogram|Mesenteric Angiogram of the small intestine
3148649|NCT00153712||Non NSAID non-Hp|Patient of history of peptic ulcer bleeding with Hp-ve and without prior history of taking NSAID or Aspirin within 30 days
3148650|NCT00153712||Helicobacter pylori +ve|Patient with Hp+ve at peptic ulcer bleeding
3148651|NCT00153751|Experimental|Traditional Chinese Medicine|They are Common peony root, other herbs.
3148652|NCT00153751|Active Comparator|Holopon|Holopon
3148653|NCT00153751|Placebo Comparator|placebo|Placebo
3148654|NCT00153764|Placebo Comparator|multivitamin|1 tablet morning and evening
3148655|NCT00153868|Active Comparator|1|Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
3148656|NCT00153868|Active Comparator|2|darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
2438693|NCT03307239|Experimental|cold application (experimental group)|subjects in the experimental group (n = 30) received cold application of 600 g ice packs 15 minutes before CTR
2438694|NCT03307239|Sham Comparator|tap water packs application (sham group)|subjects in the sham group (n = 30) received tap water packs.
2438695|NCT03307226|Experimental|Youth Development Accounts (YDA)|"Youth Development Accounts (YDA)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)"
2438696|NCT03307226|Experimental|YDA + Multiple Family Groups (MFG)|"YDA + Multiple Family Groups (MFG)~Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development~Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs)~Multiple Family Groups sessions focused on strengthening family relationships and mental health"
2438697|NCT03307226|No Intervention|Usual Care|Usual Care consisting of curricula delivered at secondary schools in Uganda including Life Planning Skills, and Adolescent Sexual Reproductive Health
2438698|NCT03307213|Experimental|BioFreedom™CoCr|Patients with CAD will receive the BioFreedom™CoCr stent if randomised to this arm.
2438699|NCT03307213|Active Comparator|BioFreedom™ SS|Patients with CAD will receive the BioFreedom™SS stent if randomised to this arm.
2438700|NCT03307187|Experimental|GLB-AIM|GLB-AIM (Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility) is a 12-month intervention that promotes 5% weight loss by reducing calories and increasing exercise (150 minutes of moderate physical activity). The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls and participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
2438701|NCT03307187|No Intervention|wait-list control|During the initial 6 month intervention period the control group received several contacts from the study staff via mail that included information on general health (e.g., managing stress, getting good sleep), holiday cards, and scheduling reminders for the 3 and 6 month testing.
3188708|NCT00769795|Experimental|Experimental|Bicalutamide 50 mg daily for 12 weeks Goserelin 10.8 mg SC once IMC-A12 10 mg/kg IV every three weeks for 12 weeks
3188709|NCT00769834||CKD|The cohort comprises of patients who are diagnosed to have chronic kidney disease as defined by the K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease-2002.
2438704|NCT03307161|Active Comparator|Parkinsons fwd posture manual treatment|Subject will receive the intervention, osteopathic manual treatment protocol.
2438705|NCT03307161|No Intervention|Parkinsons forward posture|Subjects will receive counseling.
2438706|NCT03307161|No Intervention|Parkinsons without forward posture|Subjects will receive counseling.
2438707|NCT03307148|Experimental|ATRA in combination with Gemcitabine and Nab-Paclitaxel|Patients will receive ATRA, Gemcitabine and nab-Paclitaxel in 28 day cycles. ATRA will be administered for 6 cycles whereas Gemcitabine/nab-Paclitaxel will be administered until disease progression.
2438708|NCT03307135|Experimental|Simple Assessment group|Intervention is a single evaluation with the MSPMI by two evaluators.
2438709|NCT03307135|Experimental|Hospitalization group|Evaluation with the MSPMI by two evaluators on two consultations separate by a 7 days interval.
2438710|NCT03307135|Experimental|Treatment group|Evaluation with the MSPMI by two evaluators before and after specific therapies proposed on our usual practices (Selective tibial neurotomy, anesthetic block or botulinum toxin intramuscular injection).
2438711|NCT03307122|Active Comparator|Routine Infant Formula 1|Routine infant formula with probiotic
2438712|NCT03307122|Active Comparator|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
2438714|NCT03307096|Experimental|Microperc surgery|Patient is turned into prone position and the desired calyx is punctured by 4.8F microperc under fluoroscopic or sonographic guidance. No tract dilation is needed. A 200um holmium laser fiber will be used to break stone into less than 2mm. Pull out microperc without drainage tube left.
2438715|NCT03307096|Active Comparator|FURS|Patient is placed in the lithotomy position, pull out the pre-inserted double J, and place guidewire into the renal pelvis. A 12/14 Fr ureteral access sheath (UAS) is advanced into the proximal ureter over the guidewire, and flexible ureteroscope is passed through the UAS. The stones are fragmented smeller than 2mm using a 200um holmium laser fiber. Fragments are removed using a stone basket for stone analysis if necessary, a double J stent is placed at the conclusion of the procedure and removed post-operative 4 weeks.
2438716|NCT03307070|Active Comparator|Active Group|Participants who are randomized to begin the Cognitive Behavioral Therapy for individuals with TBI immediately after screening. This treatment is a version of Cognitive Behavioral Therapy (CBT) adapted specifically for patients who have experienced a moderate to severe Traumatic Brain Injury (TBI).
2438717|NCT03307070|Other|Waitlist Control|Participants who are randomized to be put on a waitlist after screening. After 12 weeks of being on the waitlist, participants will be offered the Cognitive Behavioral Therapy for individuals with TBI
3188710|NCT00769847||Sagittal synostosis|Male and female infants from 1-6 months of age with isolated, single suture sagittal craniosynostosis.
3188711|NCT00769873|Active Comparator|Lovenox|Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days after laparoscopic splenectomy
3188712|NCT00769873|No Intervention|No Lovenox|Patients do NOT receive Lovenox post laparoscopic splenectomy
3188713|NCT00769899|Experimental|1|
3188714|NCT00769899|Placebo Comparator|2|
3188715|NCT00769912|Experimental|1|50% N2O- 50%O2 mixture administration during the intervention
3188716|NCT00769912|Placebo Comparator|2|Placebo (air) during the intervention
3188717|NCT00769925|Experimental|Therapist Assisted Bibliotherapy-Primary Care (TAB-PC)|
2438718|NCT03307057|Experimental|Social Communication Growth Charts (SCGC)|Infants with a sibling who is diagnosed with ASD, who are randomized to receive the Social Communication Growth Charts (SCGC) intervention.
2438719|NCT03307057|No Intervention|Usual care|Infants with a sibling who is diagnosed with ASD, who are randomized to receive usual care.
2438720|NCT03307057|Experimental|Parent-Implemented (P-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a parent-implemented (P-I) condition of a naturalistic developmental behavioral intervention (NDBI) based on the Early Social Interaction model.
2438721|NCT03307057|Experimental|Clinician-Implemented (C-I) Condition|Participants showing early signs of ASD at 12 months of age, randomized to receive a clinician-implemented (C-I) condition NDBI based on a hybrid model.
2438722|NCT03307044|Experimental|Treatment (fractional CO2 laser therapy)|Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.
2438723|NCT03307031|Experimental|High Volume Group|Performed four weekly sessions, during 10 weeks with 45 to 55 minutes per session.
2438724|NCT03307031|Experimental|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
2438725|NCT03307031|Placebo Comparator|Control Group|Did not exercise, during 10 weeks.
2438726|NCT03307018|Experimental|Bronch|Postoperative systematic bronchial aspiration.
2438727|NCT03307018|No Intervention|Control|In this arm bronchial aspiration with bronchoscope will not be done.
3188718|NCT00769925|Experimental|Cognitive Behavior Therapy-Primary Care (CBT-PC)|
2438730|NCT03306992|Experimental|Personalized Exercise Program|
2438731|NCT03306992|No Intervention|Standard of Care - No Exercise|
2438732|NCT03306979|Active Comparator|N-acetylcysteine|Participants randomized into the N-acetylcysteine arm will be receiving N-acetylcysteine for 24 weeks.
2438733|NCT03306979|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 24 weeks.
2438734|NCT03306966||Colon cancer patients|Patients with colon cancer (ascending colon) eligible for laparoscopic or open segmental colectomy.
2438735|NCT03306953|Active Comparator|Rectus muscle approximation|Three sutures will be done for the the purpose of rectus muscle approximation in cesarean section.
2438736|NCT03306953|No Intervention|Control|No approximation for the rectus muscle will be done for the control group in cesarean section.
2438737|NCT03306940|Placebo Comparator|unilateral injection group|Patients of unilateral group were injected botulinum toxin type A to the affected hemiface.
2438738|NCT03306940|Experimental|bilateral injection group|Patients of bilateral group were injected botulinum toxin type A to the affected hemiface and normal hemiface. The intervention of the bilateral group was that the normal side was injected.
2438739|NCT03306927|Experimental|Whole yellow pea|Chili containing 25g available carbohydrate from whole yellow peas. Intervention: Whole yellow pea chili
2438740|NCT03306927|Experimental|Split yellow pea|Chili containing 25g available carbohydrate from split yellow peas. Intervention: Split yellow pea chili
2438741|NCT03306927|Placebo Comparator|Rice-PPGR|Chili containing 25g available carbohydrate from long grain white rice. Intervention: Rice chili
2438742|NCT03306927|Placebo Comparator|Rice-Satiety|Rice chili with the same calories as the pea chili. Intervention: Rice chili
2438743|NCT03306914|Active Comparator|Albumin group|Albumin resuscitation Albumin 5%
2438744|NCT03306914|Experimental|Hydroxyethylstarch group|Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
2438745|NCT03306901|Experimental|Concurrent Chemoradiotherapy|"Patients receive 2 courses (every 3 weeks) of chemotherapy including cisplatin (45-60mg/m2) intravenously over 1 hour on day 1 and 5-fluorouracil (3,200 ~ 4,000mg/m2) intravenously for 4 to 5 days.~Patients receive a total of 45 Gy radiation therapy (5 days a week for 5 weeks)."
2438746|NCT03306901|Active Comparator|Esophagectomy|Patients receive surgical resection, including Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy.
2438747|NCT03306888|Experimental|Physical Activity Coaching Intervention|The intervention will entail one face-to-face coaching session (approximately 1 hour) to be held approximately 1 week following the baseline assessment, and three remote video sessions (via secure Webex connection via computer or smart phone, or phone call if internet/smart phone is not available to participant) lasting approximately 20 minutes.
2438748|NCT03306875|Experimental|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
2438749|NCT03306862|Experimental|Whole yellow pea|Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
2438750|NCT03306862|Experimental|Split yellow pea|Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
2438751|NCT03306862|Placebo Comparator|Potato|Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup
2438752|NCT03306849||Regular menstrual cycles|Women will be assigned to this category if they report a history of regular menstrual cycles (every 21 to 35 days). Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2438753|NCT03306849||Normoandrogenic anovulation|Women will be assigned to this category if they do not have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2438754|NCT03306849||Hyperandrogenic anovulation|Women will be assigned to this category if they have clinical or biochemical androgen excess and report a history of irregular menstrual cycles (<21 days or >35 days), including women with a pre-existing diagnosis of PCOS. Recruitment will be targeted such that equal numbers of lean (BMI <25kg/m2) and overweight or obese (BMI >24.9kg/m2) participate.
2438755|NCT03306836|Experimental|Standard dose group of Heparin Sodium|First infused with 5000 IU of Heparin Sodium, then continuous infusion at a rate of 18 IU / kg.h during the hybrid operation.
2438756|NCT03306836|Active Comparator|Low dose group of Heparin Sodium|infusion Heparin Sodium at a rate of 18 IU / kg.h during the hybrid operation.
2438757|NCT03306823||aneurysm|For cerebral aneurysm with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
2438758|NCT03306823||arteriovenous malformations|For arteriovenous malformations with hybrid operation, anticoagulation program is decided by different surgeons based on their experience and record the patient's intraoperative activated coagulation time changes in detail.
2438759|NCT03306810|Active Comparator|AG service|"In the Active Comparator Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients in the Päijät-Häme Central hospital will be optimized and individualized in the patients in personal manner."
2438760|NCT03306810|No Intervention|Without AG service|"In the No intervention Arm: Screening, follow-up and treatment of dysglycemias in the elective orthopedic prosthetic surgery (knee / hip) patients follows the current protocol of Päijät-Häme Central hospital."
2438761|NCT03306797|Experimental|SONICHAND|The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises (4 weeks, daily)
2438762|NCT03306797|Other|STANDARD REHAB|The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training for 4 weeks (daily)
2438763|NCT03306771||Metabolic syndrome risk factors|Candidates for bariatric surgery who have metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
2438764|NCT03306771||No metabolic Syndrome risk factors|Candidates for bariatric surgery who lack metabolic syndrome risk factors will be evaluated by Ultrasound duplex before the bariatric surgery and 6,12 and 24 months post surgery for Intimal-Media Thickness and Carotid artery velocity
2438765|NCT03306758|Experimental|Experimental: sodium bicarbonate|
2438766|NCT03306758|No Intervention|No Intervention|
2438767|NCT03306745|Experimental|Study group|"1 soft capsule/day containing 500mg omega-3 fatty acids~one tablet/day containing 800mg folic acid, 70mg selenium, 30 mg Vitamin E, 4 mg catechin, 12 mg glycyrrhizin, and 30 mg coenzyme Q10"
2438768|NCT03306745|Placebo Comparator|Control group|200µg folic acid - two capsules per day
2438769|NCT03306732|Active Comparator|Thiamine group|
2438770|NCT03306732|Placebo Comparator|Placebo group|
2438771|NCT03306719||Study Group|The intervention group will be women with premature preterm rupture of membranes (pProm), suffering from IAI
2438772|NCT03306719||Control Group|Pregnant women without IAI
3172989|NCT00606983|Experimental|2|oral administration of Tamsulosin
3172990|NCT00606996|Experimental|IPT-G|Group Interpersonal Psychotherapy
3172991|NCT00606996|Active Comparator|PSYCHOED|Psychoeducation
3172992|NCT00607009|Experimental|Intervention|ALIVE - received emails about chosen behavioral intervention path - physical activity, fruits/vegetables or fats/sugars
2438777|NCT03306693|Experimental|Emotional skills|3 group sessions where patients are going to learn how to identify, express and regulate their emotions
2438778|NCT03306693|Sham Comparator|Relaxation and talking group|3 group sessions where patients are going to follow relaxation instructions and after a non directive talking group about cancer
2438779|NCT03306680|Experimental|Patients with ultra-central NSCLC T1-3 (<6cm) N0 M0|"Level-1 Dose per fraction: 4Gy Number of fractions: 15 Total Dose: 60 Gy~Level 0 Dose per fraction: 6Gy Number of fractions: 10 Total Dose: 60 Gy~Level 1 Dose per fraction: 7.5 Gy Number of fractions: 8 Total Dose: 60 Gy"
2438780|NCT03306667|Experimental|Normal group|Healthy control subjects
2438781|NCT03306667|Experimental|Mild hepatic-insufficient group|Patients with mild hepatic impaired function (Child-Pugh A)
2438782|NCT03306667|Experimental|Moderate hepatic-insufficient group|Patients with moderate hepatic impaired function (Child-Pugh B)
2438783|NCT03306667|Experimental|Severe hepatic-insufficient group|Patients with severe hepatic impaired function (Child-Pugh C)
2438784|NCT03306654|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
2438785|NCT03306654|Placebo Comparator|Active control|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2438786|NCT03306654|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2438789|NCT03306628|Experimental|Early Laser Therapy|a group which will receive laser therapy to one breast incision at the first post-operative visit
2438790|NCT03306628|Experimental|Late Laser Therapy|a group which will receive laser therapy to one breast incision 6 weeks after surgery
3172993|NCT00607009|No Intervention|Control|no intervention
3172994|NCT00607035|Experimental|A|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
2438793|NCT03306602|Experimental|Bulk Fill Composite|In the experimental cavity, Filtek Bulk Fill Posterior Restorative (3M ESPE) will be placed in 5 mm increments, eliminating the need for additional layers or multiple steps.
2438794|NCT03306602|Active Comparator|Layered Composite|The control restoration will be filled with Filtek Z350 XT (3M ESPE) using the 2 mm incremental layering technique.
2441566|NCT03286881|Experimental|Group 4|
3172995|NCT00607035|Experimental|H|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
3172996|NCT00607061|Other|1|Full term newborn babies with gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile.
3172997|NCT00607061|Other|2|Low birth weight newborn babies (gestational age < 32 weeks of amenorrhea and/or weight of birth < 1500 g and/or weight of birth < third percentile for their gestational age.
3172998|NCT00607061|Other|3|Full term newborn babies (gestational age > 37 weeks of amenorrhea and weight of birth > tenth percentile).
3172999|NCT00607074|Experimental|1|
3173000|NCT00607100||1|Patients with Band atrophy of the optic nerve
3173001|NCT00607100||2|Normal Controls
3189111|NCT00774436|Experimental|Patients scheduled to receive Focal Cryotherapy|After enrollment, patients will undergo a repeat transrectal ultrasound- guided prostate biopsy (minimum of 12 cores) to confirm the low-risk nature of their cancer. For study purposes, patients must meet the original entry crieteria on this repeat biopsy. If the patient meets the repeat-biopsy enrollment criteria, they will be treated with focal cryotherapy, meaning cryoablation of the regions of the prostate containing cancer. Efficacy is defined as all negative biopsy cores at the site of the focal ablation on a repeat transrectal biopsy 6 months after cryoablation. At baseline (prior to the re-staging biopsy), 3 months after focal cryotherapy, and at 6 months after focal cryotherapy (prior to the repeat prostate biopsy used to define efficacy), the patient will complete quality of life questionnaires as standard for all patients in the Urology Service.
2438797|NCT03306576|Experimental|ELS Extra composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
2438798|NCT03306576|Active Comparator|ELS composite|Commercially available composite resin restorative that will be used for direct restoration as per manufacturer's instructions
2438799|NCT03306563|Experimental|Patients with suspected TBI|The group will consist of patients who have arrived in the hospital with head injury and suspected isolated TBI. Sample collection (up to five times) and assessment of neurological status.
2438800|NCT03306563|Active Comparator|Orthopedic patients|The group will consist of patients with orthopedic injury, but without a head injury and suspected TBI. Sample collection (once).
2438801|NCT03306563|Sham Comparator|Controls|The group will consist of healthy controls who do not have a recent trauma history. Sample collection (once).
2438802|NCT03306550|Active Comparator|aspirin arm|only take aspirin (100mg,qd) orally for 10 days treatment course
2438803|NCT03306550|Active Comparator|salvianolate injection arm|only inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
2438804|NCT03306550|Experimental|aspirin and salvianolate injection arm|take aspirin (100mg,qd) orally and inject salvianolate(200mg+5%Glucose Injection 250ml，iv) for 10 days treatment course
2438805|NCT03306524|Experimental|SIPPV_VG_0_08|SIPPV VG ventilation for 15 minutes slope time = 0.08 seconds inspiratory time = 0.40 seconds
2438806|NCT03306524|Experimental|PSV_VG_0_08|PSV VG ventilation for 15 minutes slope time = 0.08 seconds maximum inspiratory time = 0.60 seconds
2438807|NCT03306524|Experimental|SIPPV_VG_0_16|SIPPV VG ventilation for 15 minutes slope time = 0.16 seconds inspiratory time = 0.40 seconds
2438808|NCT03306524|Experimental|PSV_VG_0_16|PSV VG ventilation for 15 minutes slope time = 0.16 seconds maximum inspiratory time = 0.60 seconds
2438809|NCT03306524|Experimental|SIPPV_VG_0_24|SIPPV VG ventilation for 15 minutes slope time = 0.24 seconds inspiratory time = 0.40 seconds
2438810|NCT03306524|Experimental|PSV_VG_0_24|PSV VG ventilation for 15 minutes slope time = 0.24 seconds maximum inspiratory time = 0.60 seconds
2438811|NCT03306524|Experimental|SIPPV_VG_0_32|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
2438812|NCT03306524|Experimental|PSV_VG_0_32|PSV VG ventilation for 15 minutes slope time = 0.32 seconds maximum inspiratory time = 0.60 seconds
2438813|NCT03306524|Experimental|SIPPV_VG_0_40|SIPPV VG ventilation for 15 minutes slope time = 0.32 seconds inspiratory time = 0.40 seconds
2438814|NCT03306524|Experimental|PSV_VG_0_40|PSV VG ventilation for 15 minutes slope time = 0.40 seconds maximum inspiratory time = 0.60 seconds
2438815|NCT03306511||Case|Football players with a previous self-reported hamstring strain injury in the preceding 12 months
2438816|NCT03306511||Control|Football players without a previous self-reported hamstring strain injury in the preceding 12 months
2438817|NCT03306498||hepatic encephalopathy patients|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d for 3 days
2438818|NCT03306498||hepatic encephalopathy patients-amino|The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
2438819|NCT03306485||Patients with GERD symptoms refractory to PPI therapy|"Patients with proven GERD (gastro-esophageal reflux disease) off PPI (proton pump inhibitor) (Los Angeles grade B, C or D esophagitis and/or esophageal acid exposure > 5% on pH monitoring performed off PPI).~These patients have persistent heartburn and/or regurgitation despite double dose proton pump inhibitor. Patients are referred for esophageal high resolution impedance manometry and ambulatory 24-h pH-impedance monitoring on proton pump inhibitor."
2438820|NCT03306472|Active Comparator|Arm A: Letrozole|Arm A: 15 days of Letrozole 2.5mg daily
2438821|NCT03306472|Experimental|Arm B: Letrozole + Megestrol Acetate (40mg)|Arm B: 15 days of Letrozole 2.5mg daily + Megestrol acetate 40mg daily
2438822|NCT03306472|Experimental|Arm C: Letrozole + Megestrol Acetate (160mg)|Arm C: 15 days of Letrozole 2.5mg daily + Megestrol acetate 160mg daily.
2438823|NCT03306459||1/PCOS|The authors will select 30 PCOS patients who met the more strict and conservative Rotterdam diagnostic criteria (Rotterdam phenotype A) which include the presence of oligo-anovulation (cycles lasting >35 days or amenorrhea) and hyperandrogenemia /hyperandrogenism (hirsutism or obvious acne or pronounced alopecia). All patients should have bilateral polycystic ovaries morphology on ultrasound. Additionally, the authors have decided to enroll PCOS patients that are all without pregnancy desire at the moment they fill out the questionnaires, in order to control for the potential confounding role of infertility on psychological outcomes. Different pituitary, adrenal, ovarian, thyroid or metabolic diseases will be excluded
2438824|NCT03306459||2/CONTROL|The authors will enroll a control group of 30 women, age- matched with the PCOS women, from consecutive women controlled in the same outpatient clinic who met the following inclusion criteria: history of irregular menstrual cycle in absence of severe gynecologic and non-gynecologic diseases. This PCOS sample will be entirely constituted by women with no pregnancy desire; therefore, with the aim to limit the potential effect of the unfulfilled wish to conceive in the final results; additionally, infertile women will not admitted into the control group.
2438825|NCT03306446|Experimental|Adalimumab in monotherapy|Start Adalimumab in monotherapy at 160 mg at inclusion, 80 mg on 2nd week and 40 mg/week each other week over 12 months.
3189112|NCT00774449||1|individuals, who have undergone double (DLTx) or heart and lung transplantation (HLTx) at Hannover Medical School 6 months prior to inclusion
2438870|NCT03306095||Delayed refeeding group|Food Intake by patient with in 4 hours i.e > 4 hours after the EVL procedure
2438834|NCT03306407|No Intervention|Baseline Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received standard pre-travel advice
2438835|NCT03306407|Active Comparator|Intervention Group|Group screened for colonization with ESBL-producing Enterobacteriaceae pre- and post-travel after having received pre-travel advice with special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
3173002|NCT00607152|Experimental|1|IV infusion at a dose level of 0.20mg/kg per day
2438837|NCT03306381|Experimental|Dietary intervention subject group|n=130. Participants on low FODMAP-similar diet during 4-week study period.
2438838|NCT03306381|No Intervention|Control group|n=20. Participants on traditional IBS diet during 4-week study period.
2438839|NCT03306368|No Intervention|Treatment as Usual (TAU)|Participants receiving treatment as usual post-residential detox. TAU clinic-based treatment receiving standard clinic-based XR-NTX.
2438840|NCT03306368|Experimental|Youth Opioid Recovery Support (YORS)|"Youth Opioid Recovery Support consists of the following component:~Home delivery of XR-NTX, family framework, assertive continuing care incorporates outreach, home delivery of evidence based psychosocial treatment and case management in a model that specifically targets engagement and motivation in youth, contingency management."
2438841|NCT03306355|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2438842|NCT03306355|Active Comparator|IOL implantation active comparator|hydrophilic, trifocal intraocular lens POD F
2438843|NCT03306342|Experimental|IOL implantation experimental|hydrophobic, trifocal intraocular lens POD F GF
2438844|NCT03306329|Experimental|DNS-7801 (low-dose)|
2438845|NCT03306329|Experimental|DNS-7801 (high-dose)|
2438846|NCT03306329|Placebo Comparator|Placebo|
2438847|NCT03306316|Experimental|Experimental|Experimental Arm
2438848|NCT03306316|Placebo Comparator|Control|Placebo Control Arm
2438849|NCT03306303||Quartile 1 of plasma melatonin|Quartile 1 of plasma melatonin
2438850|NCT03306303||Quartile 2 of plasma melatonin|Quartile 2 of plasma melatonin
2438851|NCT03306303||Quartile 3 of plasma melatonin|Quartile 3 of plasma melatonin
2438852|NCT03306303||Quartile 4 of plasma melatonin|Quartile 4 of plasma melatonin
2438853|NCT03306290|Other|Bariatric surgery candidate|"Patients included in this study belong to this arm and put up with intervention Serum dosage of antibiotic prophylaxis CEFOXITIN"
2438855|NCT03306264|Experimental|ASTX727|ASTX727 (cedazuridine + decitabine) - Cycle 1 or Cycle 2 (crossover)
2438856|NCT03306264|Active Comparator|IV decitabine|Dacogen (decitabine for injection) - Cycle 1 or Cycle 2 (crossover)
2438857|NCT03306238|Active Comparator|Open/Hasson|This group will undergo initial laparoscopic port insertion by the open or Hasson approach and then undergo the remaining laparoscopic surgery as usual
2438858|NCT03306238|Active Comparator|Closed/ Veress|This group will undergo initial laparoscopic port insertion by the closed or Veress approach and then undergo the remaining laparoscopic surgery as usual
2438859|NCT03306212|Experimental|Casting Group|Patients treated by botulinum toxin A and occupational therapy and intermittent serial casting
2438860|NCT03306212|Active Comparator|Control Group|Patients treated by botulinum toxin A and occupational therapy
2438861|NCT03306186|Experimental|HemoSpec|Diagnosis of sepsis using HemoSpec device
3173003|NCT00607152|Active Comparator|2|100mg tablets, administered orally, according to standard medical practice
3173004|NCT00607178|Experimental|Influenza vaccine|Enrolled patients who are randomly assigned to receive influenza vaccine
2438864|NCT03306147|Experimental|Chronic pain or long-acting opioid use|Education of pain and promotion of adjunct and non-pharmacologic alternative therapies will be completed to engage patients in assessing their pain and seeing the effectiveness of their treatment. Patients will receive 3 follow-up interventions: 2 phone calls with a pharmacist or student pharmacist at weeks 2 and 6, and a follow-up visit with a pain or primary care physician.
2438865|NCT03306134||BETA-BLOCKERS|Patients taking beta-blockers with or without dysphagia
2438866|NCT03306134||NO BETA-BLOCKERS|Patients not taking beta-blockers with or without dysphagia
2438867|NCT03306121|Experimental|TPF+CCRT|Patients receive induction chemotherapy with paclitaxel liposome (135mg/m2 on day 1) ,cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) .
2438868|NCT03306121|Active Comparator|CCRT+ PF|Patients receive concurrent IMRT and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) , then followed by three cycles of adjuvant chemotherapy with cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles four weeks after radiotherapy.
2438869|NCT03306095||Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
2440717|NCT03292913|Other|Control Group|Receives standard of care
3173005|NCT00607178|Placebo Comparator|Placebo|Enrolled patients who are randomly assigned to receive placebo of influenza vaccine
3173006|NCT00607217|Experimental|CAD-Exp|Enrolled coronary artery disease patients who are randomly assigned to receive influenza vaccine
3173007|NCT00607217|Placebo Comparator|CAD-Control|Enrolled coronary artery disease patients who are randomly assigned to receive placebo of influenza vaccine
3173008|NCT00607217|Experimental|Healthy-Control|Enrolled healthy subjects serve as control for CAD-Exp
3173009|NCT00607230|Experimental|E|BCG vaccination
3173010|NCT00607230|Placebo Comparator|P|Saline vaccination
3173011|NCT00607256|Experimental|Open Label|
3173012|NCT00607282|Placebo Comparator|Placebo|normal control group
3173013|NCT00607282|Experimental|Udenafil|oral administration of placebo for Udenafil (Dong-A Pharmaceutical co., Ltd, Seoul, Korea)
3173014|NCT00607295|Experimental|1|Clino-san 2ml vaginal application 3 times per week for 12 weeks
3173015|NCT00607295|Placebo Comparator|2|placebo 2ml vaginal application 3 times per week for 12 weeks
3173016|NCT00607308|Experimental|0.1 mg/kg|
3173017|NCT00607308|Experimental|0.5 mg/kg|
3173018|NCT00607308|Experimental|1 mg/kg|
3173019|NCT00607308|Experimental|5 mg/kg|
3173020|NCT00607308|Placebo Comparator|Placebo|
3173021|NCT00607308|Experimental|10 mg/kg|
2438872|NCT03306069|Experimental|Control|Nutritional therapy / no exercise
2438873|NCT03306069|Experimental|HIIT|High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy
2438874|NCT03306069|Experimental|MIIT-HR|Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy
2438875|NCT03306069|Experimental|MIIT-LT|Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding ~70-75% HRmax) combined with Nutritional therapy
2438876|NCT03306056|Experimental|Control|Nutritional therapy / no exercise
2438877|NCT03306056|Experimental|Standard Strength Training|Nutritional therapy combined with a Standard Strength Training program
2438878|NCT03306056|Experimental|Low-volume Strength Training|Nutritional therapy combined with a low-volume Strength Training program
2438879|NCT03306056|Experimental|Whole-body Electromyostimulation|Nutritional therapy combined with Whole-Body Electromyostimulation
2438881|NCT03306030|Active Comparator|Split group|Split-dose of 4l PEG was used before and on the day of colonoscopy
2438882|NCT03306030|Experimental|Three times group|Three times-dose of 4l PEG was used before and on the day of colonoscop of 4l PEG was used before and on the day of colonoscopy
2438883|NCT03306017|Experimental|LAVD implantation|Ten patients before and after LAVD implantation had blood sampling
2438884|NCT03306004||Health Care Providers|Providers answer questionaires
2438885|NCT03306004||Mothers|Mothers answer questionaires
2438886|NCT03305978|Experimental|Ultra low dose chest CT|
2438887|NCT03305978|Active Comparator|Low dose chest CT|
2438888|NCT03305965|Experimental|Patient navigation|
2438889|NCT03305965|No Intervention|Care as usual|
2438890|NCT03305952|Experimental|Compassion|CBCT was facilitated in an eight weekly, 2-h sessions format through didactics, class discussion, and guided meditation practice. Topics covered in order were: Week 1: Developing attention stability and mental clarity. Week 2. Open awareness of sensations, feelings, and emotions. Week 3: Self-Compassion. Week 4: Practice in impartiality and cultivation of social connection. Week 5: Practice in appreciation, gratitude, social interconnection, and interdependence. Session 6: Practice in affection (endearment) for developing undifferentiated affection for others. Week 7: Development of the aspirational wish that all beings be happy and free from suffering and its causes. Week 8: Active compassion
2438891|NCT03305952|Active Comparator|Treatment as usual|Treatment as usual (TAU) consisted of usual periodical visits to psycho oncologist based on hospital's regular calendar. Hospital's standard treatment was applied to participants. The standard treatment consists of counselling interventions, cognitive-behavioural interventions, family interventions, third generation interventions.
2438892|NCT03305939|Experimental|Intervention|Participants randomized in to the intervention group will receive group sessions, monthly phone calls, and telephonic prompts (text/voice recording).
2438893|NCT03305939|No Intervention|Control|Control group participants will be referred to their usual doctor for ongoing management, with no attempt made to influence this. They will not get any part of the intervention but will receive the usual care (if any exists). Any abnormal OGTT results during the follow-up visits will be provided to the patient and their doctor. This is entirely consistent with current usual care.
2438894|NCT03305926|Active Comparator|Conventional CVR|
2438895|NCT03305926|Experimental|eCVR|
2438896|NCT03305913|Experimental|Dose Level 1|TAS-102 25 mg/m2 BID (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
2438897|NCT03305913|Experimental|Dose Level 2|TAS-102 35 mg/m2 BID (days 1-5 and 8-12), Regorafenib 120 mg daily (3 weeks on, 1 week off)
2438898|NCT03305913|Experimental|Dose Level 3|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 160 mg daily (3 weeks on, 1 week off)
2438899|NCT03305913|Experimental|Dose Level -1a|TAS-102 25 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
2438900|NCT03305913|Experimental|Dose Level -1b|TAS-102 35 mg/m2 BID, (days 1-5 and 8-12) Regorafenib 80 mg daily (3 weeks on, 1 week off)
2438901|NCT03305913|Experimental|Dose Level -2a|TAS-102 30 mg/m2 BID (or 35 mg/m2 a.m. and 25 mg/m2 p.m.), (days 1-5 and 8-12) Regorafenib 120 mg daily (3 weeks on, 1 week off)
2438904|NCT03305874||Study Group|Prospectively, inpatients undergoing percutaneous coronary intervention (PCI) will be consented, and the computer-based contrast induced nephropathy (CBCIN) risk score will be calculated and displayed to the operator, along with suggested standard CIN-avoidance strategies during the PCI. Following the PCI, serum creatinine will be measured as per treating physician, but those who undergo at least two consecutive daily serum creatinine measurements starting the day after the procedure will be included in the study. These patients will be called 6 months and 12 months post-procedure to determine mortality and re-hospitalization status.
2438905|NCT03305874||Comparator Group|Retrospectively, inpatients who underwent PCI and had at least two consecutive daily serum creatinine measurements will be selected. These patients will then be matched to the prospective patients, and matched by age and gender. Baseline CBCIN score will be calculated and other demographic and outcomes information will be obtained from medical records review.
2438906|NCT03305861|Experimental|ThuLEP|Thulium laser enucleation of prostate
2448973|NCT03248323||pre-con|
3173022|NCT00607334|Experimental|GP|Children with Developmental Language Impairments were enrolled in this group.
3173023|NCT00607334|Experimental|GC|Children with normal language development were enrolled in this group.
3173024|NCT00607347|Experimental|A|The subjects will be undergoing a oral glucose tolerance test.
3173025|NCT00607360|No Intervention|Standard Drug Court|Participants received standard services from drug court
3173026|NCT00607360|Experimental|Drug Court plus Therapeutic Workplace|Participants receive standard drug court services plus therapeutic workplace intervention
3173027|NCT00607399|Experimental|Single arm|
3173028|NCT00607412|Experimental|1|Present focused, integrated psychotherapy for PTSD and substance use disorders
3173029|NCT00607412|Active Comparator|2|Supportive therapy using 12-step model
3173030|NCT00607425||1|Non-small cell lung cancer patients
3173031|NCT00607425||2|Healthy control subjects
3173032|NCT00607451|Experimental|1|
3173033|NCT00607451|Experimental|2|
3173034|NCT00607451|Experimental|3|
2438907|NCT03305861|Experimental|Green LEP|Greenlight laser enucleation of prostate
2438908|NCT03305848|Other|Oral nitroglycerin solution|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes
3189113|NCT00774462|Experimental|1|
3189114|NCT00774475|Placebo Comparator|1: standard therapy|clopidogrel 75 mg/day
3189115|NCT00774475|Active Comparator|2: doubled therapy|clopidogrel 150 mg/day
3189116|NCT00774501|Experimental|treatment of metastatic liver disease|The intervention is the use of image guidance with general anesthesia and suspended ventilation during treatment delivery. This will allow precise localization and delivery of dose to the tumor.
3189117|NCT00774514|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
3189118|NCT00774514|Experimental|NO2 exposure|1 hour exposure to nitrogen dioxide at 4ppm during intermittent exercise
2438915|NCT03305783||Patients having cholecystectomy|Healthy, normal weight patients (BMI<27) undergoing elective cholecystectomy will have a meal test performed before and after surgery.
2438916|NCT03305783||Healthy controls|Healthy matched controls will have one meal test performed.
3189119|NCT00774527|No Intervention|ArmI(CyATG)|•Conditioning therapy will start on day -5 in patients who are randomized to receive Cy+ATG. Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter
3189120|NCT00774540|Experimental|1|Ketorolac
2438919|NCT03305757|Active Comparator|conventional wound closure|The skin flaps will not undergo further treatment in this group.
2438920|NCT03305757|Experimental|flap fixation with vicryl sutures|The skin flaps will be sutured on to the pectoral muscle after having performed the mastectomy.
2438921|NCT03305757|Experimental|Artiss tissue glue|ARTISS tissue glue will be applied to the skin flaps after mastectomy
2438922|NCT03305744||Endurance Athlete with Atrial Fibrillation|These are middle-aged athletes who are diagnosed with paroxysmal Atrial Fibrillation in the last 4 years, but are otherwise free of disease.
2438923|NCT03305744||Endurance Athlete without Atrial Fibrillation|These are middle-aged athletes who will serve as our control group- they have not been diagnosed with AF or any other disease.
3189121|NCT00774540|Placebo Comparator|2|saline
2438925|NCT03305718|Experimental|Meal sequence: 3C1A2B4D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3C1A2B4D."
2438926|NCT03305718|Experimental|Meal sequence: 2A3D4C1B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2A3D4C1B."
2438927|NCT03305718|Experimental|Meal sequence: 2D4B3A1C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2D4B3A1C."
2438928|NCT03305718|Experimental|Meal sequence: 3B2C1D4A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3B2C1D4A."
2438929|NCT03305718|Experimental|Meal sequence: 4C2B1A3D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4C2B1A3D."
2438930|NCT03305718|Experimental|Meal sequence:1B4D3C2A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1B4D3C2A."
3189122|NCT00774553|Experimental|1|AZD1656
3189123|NCT00774553|Placebo Comparator|2|Placebo
3189124|NCT00774592|Experimental|1|Focus on Youth in the Caribbean (FOYC) plus Caribbean Informed Parents and Children Together (CImPACT)
3189125|NCT00774592|Experimental|2|FOYC plus Goal For It (GFI)
2438931|NCT03305718|Experimental|Meal sequence:4A1C2D3B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4A1C2D3B."
2438932|NCT03305718|Experimental|Meal sequence:1D3A4B2C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1D3A4B2C."
2438933|NCT03305718|Experimental|Meal sequence: 4D3B2C1A|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 4D3B2C1A."
2438934|NCT03305718|Experimental|Meal sequence: 3A4C1B2D|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 3A4C1B2D."
2438935|NCT03305718|Experimental|Meal sequence: 1C2A3D4B|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 1C2A3D4B."
2438936|NCT03305718|Experimental|Meal sequence: 2B1D4A3C|"In this study, each participant was randomized to a sequence of the 4 meat meals and to a sequence of the 4 potato meals. The four meat meals consist of a beef meal, a pork meal, a chicken meal or a control meal (1-4). The four potato meals consist of french fries, chips, boiled potatoes or rice (A-D). The test meal consists of one meat meal that was served together with a potato meal. Four different test meals were served in four interventions, separated by a washout period of minimum 12 days. Six hours after the test meal an ad libitum meal was served, consisting of vegetable stew with pasta.~Each participants randomized to this arm is exposed to 4 test meals in the order 2B1D4A3C."
2438937|NCT03305705|Experimental|Treatment Arm 1|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
2438938|NCT03305705|Experimental|Treatment Arm 2|Patients will be treated with 0.9% sodium chloride (placebo) at Visit 1 and with iron carboxymaltose in 6 weeks at Visit 2. The patients will be blinded with respect to the treatment sequence.
2438939|NCT03305692|Experimental|ECG Belt|Use ECG Belt body surface mapping system to optimize CRT programming.
2438940|NCT03305692|Experimental|Echocardiography|Use mitral inflow echocardiography to optimize CRT programming.
2438941|NCT03305679|Experimental|Direct provisional technique|Patients here will be subjected to the direct provisional technique
2438942|NCT03305679|Active Comparator|Indirect Provisional technique|Patients here will be subjected to the indirect provisional technique
3189126|NCT00774592|Active Comparator|3|Wonderous Wetlands plus GFI
3189127|NCT00774592|Experimental|Grade 10-BFOOY+CImPACT|Youth receives HIV intervention; parents receive parental monitoring intervention
3189128|NCT00774592|Experimental|Grade 10 BFOOY+GFI|Youth receive HIV prevention intervention and parents receive attention control intervention on career planning
2438946|NCT03305627|Experimental|Short PAP|Perioperative antibiotic prophylaxis will be stopped after 24h
2438947|NCT03305627|Active Comparator|Extended PAP|Perioperative antibiotic prophylaxes will be continued for 48h or more (until all indwelling urinary catheters have been removed)
2438948|NCT03305614|Active Comparator|Aphasia therapy and tDCS|
2438949|NCT03305614|Sham Comparator|Aphasia therapy and sham-tDCS|
2438950|NCT03305588|Experimental|130 Gy Radiation & Unframed Virtual Cone|130 Gy Virtual Cone Radiosurgery Unframed (Face Mask)
3189129|NCT00774592|Experimental|BFOOYand no parent intervention|Youth receive HIV prevention intervention; parents receive no intervention
3189130|NCT00774592|Placebo Comparator|Health and FAmily life|Youth receive standard of care (current curriculum); parents receive no intervention
2438988|NCT03305406||Focus Group Participants|Semi-structured focus groups
2438989|NCT03305406||Interview Participants|One-on-one interviews
3189131|NCT00774605|Experimental|Varenicline free base solution|
3189132|NCT00774605|Experimental|Varenicline transdermal delivery system|
3189133|NCT00774618|Experimental|Resection|Those subjects undergoing resection with or without plate fixation
3189134|NCT00774618|No Intervention|Nonoperative|These patients were not considered candidates for surgical intervention by the investigators, declined surgical intervention, or did not receive insurance approval for surgery
2438953|NCT03305562||Retrospective cohort|The cohort of patients seen prior to the implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected retrospectively.
2438954|NCT03305562||Prospective cohort|The cohort of patients seen initially seen after implementation of a standardized clinical management protocol on 10/01/2017 whose data is collected prospectively.
2438955|NCT03305549|Active Comparator|TIW Dialysis Strategy|Conventional thrice-weekly acute intermittent hemodialysis treatment schedule.
2438956|NCT03305549|Experimental|Conservative Dialysis Strategy|Conservative acute intermittent hemodialysis strategy, in which hemodialysis is not continued unless specific metabolic or clinical indications for RRT are present.
2438957|NCT03305536|Active Comparator|Interventional|1000 mcg/day of Vitamin K2 + 5000 IU/day Vitamin D3 as a treatment to decalcifiy the valve
2438958|NCT03305536|Active Comparator|interventional|5000 IU/day of Vitamin D3 will be given to measure the progression of the disease along the time of the study
2438959|NCT03305523|Experimental|Thermocautery|Circumcision with thermocautery technique was applied all participants
2438960|NCT03305510||Vitamin D deficiency|The level of vitamin D is below 20ng/ml.
2438961|NCT03305510||Vitamin D insufficient|The level of vitamin D is between 20ng/ml and 30ng/ml.
2438962|NCT03305510||Vitamin D sufficient|The level of vitamin D is above 30ng/ml.
2438963|NCT03305484||Symptomatic Contact Lens Wearers|Contact lens wearers who present to the eye care practitioner's office with a symptomatic red eye
2438964|NCT03305471|Experimental|Part A: DS-2330b PIB, then Tablet|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast.
2438965|NCT03305471|Experimental|Part A: DS-2330b Tablet, then PIB|On a non-dialysis day, participants are given a single 250 mg dose of DS-2330b in tablet form [Treatment A2] right after breakfast. At least 3 days will be allowed to let the first dose wash out. Then on a non-dialysis day the participants are given a single 250 mg dose of DS-2330b PIB [Treatment A1] right after breakfast.
2438966|NCT03305471|Placebo Comparator|Part B: Placebo|Participants are given placebo three times daily [Treatment B1]
2438967|NCT03305471|Experimental|Part B: DS-2330b PIB|Participants are given 400 mg of DS-2330b PIB three times daily [Treatment B2]
2438968|NCT03305471|Experimental|Part B: DS-2330b PIB + Sevelamer|Participants are given 400 mg of DS-2330b PIB along with 1.6 grams of sevelamer three times daily [Treatment B3]
2438969|NCT03305471|Experimental|Part B: Placebo + Sevelamer|Participants are given placebo along with 1.6 grams of sevelamer three times daily [Treatment B4]
2438970|NCT03305471|Experimental|Part C: DS-2330b Tablet + Sevelamer|Participants are given one 250 mg dose of DS-2330b in tablet form along with 1.6 grams of sevelamer three times daily [Treatment C]
2438971|NCT03305458|Active Comparator|Treatment as usual|Trauma Focused Cognitive Behavioral Therapy
2438972|NCT03305458|Experimental|Tablet-Facilitated TF-CBT|Standard treatment with the addition of in-treatment/session iPad activities
2438973|NCT03305445|Experimental|Pts with Diffuse Large B Cell Lymphoma|"Patients with DLBCL not eligible for autologous stem cell transplant. All patients will receive dual checkpoint blocking antibody (DCBA) therapy of ipilimumab and nivolumab given at three week intervals, two times before, and two times following immunotransplant in which T cells (in whole PBMCs) are cryopreserved and re-infused (adoptive T cell transfer or ATCT) following lymphodepleting chemotherapy regimen, currently being employed in adoptive T cell therapies."
2438974|NCT03305432|Experimental|PPI group|take preoperative PPI for 10 days
2438975|NCT03305432|Active Comparator|Control group|take placebo for for 10 days preoperative
3189135|NCT00774631|Experimental|Hypothermia|mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming
3189136|NCT00774631|Active Comparator|No hypothermia|no hypothermia, according to local recommendations and guidelines of medical societies and literature
3189137|NCT00774644|Experimental|1|clarithromycin 500 mg tablets of Ranbaxy Laboratories Limited
3189138|NCT00774644|Active Comparator|2|BIAXIN® 500 mg tablets containing clarithromycin 500mg tablets
3189139|NCT00774683||Sub-study Group A|Six HIV-positive African American women from the main study, CID 0706
3189140|NCT00774696|Experimental|1|Clarithromycin 500 mg Tablets
3189141|NCT00774696|Active Comparator|2|BIAXIN® 500 mg tablets
3189142|NCT00774709||1|
3189143|NCT00774722|Experimental|Metronidazole|
3189144|NCT00774722|Placebo Comparator|Placebo|
3189145|NCT00774735|Experimental|Sequence 1|
2459807|NCT03174496||Children aged 4-7 years|
3189146|NCT00774735|Experimental|Sequence 2|
3189147|NCT00774761|Experimental|1|
3189148|NCT00774761|Experimental|2|
3189149|NCT00774761|Active Comparator|3|
3189150|NCT00774761|Active Comparator|4|
3189151|NCT00774761|Active Comparator|5|
3189152|NCT00774774|Placebo Comparator|2|No intervention
3189153|NCT00774774|Experimental|1|Mask
3189154|NCT00774813|Active Comparator|A|Nexalin 1.3mA device + placebo antidepressant
3189155|NCT00774813|Active Comparator|B|Nexalin 15mA device + placebo antidepressant
3189156|NCT00774813|Placebo Comparator|C|Placebo device + SSRI (Citalopram or similar)
3189157|NCT00774826|Experimental|1|R-CVP x 3; Restaging if> RP then R-CVP x 5
3189158|NCT00774826|Experimental|2|R-CHOP x 3; Restaging if > RP then R-CHOP x 3 plus 2 Rituximab
3189159|NCT00774826|Experimental|3|R-FM x 3; Restaging if > RP then R-FM x 3 plus 2 Rituximab
3189160|NCT00774839||Newly diagnosed stage II-III colon cancer 65 years or older|Medicare-eligible (≥ or = to 65 years) patients diagnosed with stage II - III colon cancer, are at least 4 months into chemotherapy and up to 7 months post-chemotherapy.
3189161|NCT00774865||Surgical|Patients who have previously undergone robotic bypass surgery
3189162|NCT00774878|Experimental|Arm A|
3189163|NCT00774878|Active Comparator|Arm B|
3189164|NCT00774917|Experimental|Numen|
3189165|NCT00774943|Active Comparator|AMG 557|
3189166|NCT00774943|Placebo Comparator|Placebo|
3189167|NCT00774956|Experimental|1|Subject with shoulder impingement
2438990|NCT03305393|Other|Adaptiv CRT|Adaptiv CRT algorithm in Medtronic FDA approved CRT devices to be programmed as ON at 6 month follow-up visit
2438991|NCT03305380||Patients with a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the first group of the retrospective part of the study.
2438992|NCT03305380||Patients without a pulmonary event|(under anti-PD1 or anti-PD-L1) This is the second group of the retrospective part of the study.
2438993|NCT03305367|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
2438994|NCT03305367|Experimental|Hydrolyzed pine nut oil low dose|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
2438995|NCT03305367|Experimental|Hydrolyzed pine nut oil high dose|Standard OGTT supplemented with 6 g of hydrolyzed pine nut oil
2438996|NCT03305354|Experimental|CBTI app intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide
2438997|NCT03305354|Active Comparator|CBTI app+Physical Activity Intervention|Cognitive Behavioral Therapy for Insomnia delivered for 6 weeks via the CBT-I Coach app with use guided by a self-management guide plus self-management guidance on increased step counts
3173035|NCT00607451|Experimental|4|
2438999|NCT03305328|Experimental|Active|Participants within the Active condition receive 30 minutes of alpha-frequency Transcranial Alternating Current Stimulation (tACS) stimulation for four consecutive days. Participants are stimulated at their baseline peak alpha frequency, or the frequency at which they exhibit maximal power within the 8 to 12 Hz range. Stimulation was administered over occipitoparietal sites, where tACS current models showed maximal effect over the dorsal extrastriate.
2439000|NCT03305328|Sham Comparator|Sham Control|Participants within the Sham condition receive 30 minutes of sham Transcranial Alternating Current Stimulation for four consecutive days, during which no current was passed. To control for awareness of the Sham stimulation, all Sham control participants receive a brief, 10 second pulse of random noise stimulation at the beginning and end of the 30 minutes.
2439001|NCT03305315||Cases|Diseases of the temporomandibular joint
2439002|NCT03305315||Controls|Asymptomatic subjects
2439003|NCT03305289|Active Comparator|pulsed radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
2439004|NCT03305289|Active Comparator|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
2439005|NCT03305276||general population|the study is open to all population, (14-90 years, male/female) to verify the impact of lifestyles (mediterranean style) on intermediate and hard endpoint.
2439006|NCT03305263|Experimental|Hydroxychlorochine HCQ|Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
2439007|NCT03305263|Placebo Comparator|Hydroxychlorochine HCQ Placebo|Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
2439008|NCT03305250|Active Comparator|Interventional Arm|Using an Implantable Loop Recorder fo continuous rhythm monitoring and home follow-up. This will be combined with standard care procedure, which will include annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
2439009|NCT03305250|No Intervention|Standard of Care Arm|The standard of care with annual ECG, 24 hour Holter/5 day ECG monitoring and further investigation dependent on symptom status.
2439010|NCT03305237|Experimental|big breakfast (BB) to big dinner (BD)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BB energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BD energy restriction diets for 4 weeks
2439011|NCT03305237|Experimental|big dinner (BD) to big breakfast (BB)|Phase 1: no intervention, habitual diet for 4 days and then 4day maintenance diet Phase 2: consumption of BD energy restriction diets for 4 weeks Phase 3: washout for 1 week, controlled maintenance diet Phase 4: consumption of BB energy restriction diets for 4 weeks
2439012|NCT03305224|Other|Ra-223 + Enzalutamide|
2439013|NCT03305211|Other|Biological sample|biological sampling will be performed on patients requiring renal biopsy and well-phenotyped patients (diagnosis of renal disease)
2439014|NCT03305198|Experimental|Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry will have a capillary blood sampling from the earlobe
2439015|NCT03305185|Experimental|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
2439016|NCT03305185|Active Comparator|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
2439017|NCT03305172|No Intervention|Control|Subjects in the Control treatment are not given any financial incentive to achieve the goal.
2439018|NCT03305172|Experimental|Gain Treatment|Financial Incentive: Each subject in the Gain treatment will earn a certain amount of money for each day the goal is achieved. The money earned will be added to a virtual account that the subject has, and will be paid to the subject at the end of the intervention period.
2439019|NCT03305172|Experimental|Loss Treatment|Financial Incentive: Each subject in the Loss treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. For each day that the subject does not achieve the goal, a small portion of that money will be deducted from the virtual account. The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
2469944|NCT03104946||Severe Retinopathy|
3174392|NCT00622960|Active Comparator|High CHO diet|Those subjects assigned to a high carbohydrate diet
2439020|NCT03305172|Experimental|Gain Streak Treatment|Financial Incentive: Each subject in the Gain Streak treatment get an increasing amount of money added to his/her virtual account for every continuous day that they achieve the goal. The maximum cumulative amount per week is same as in the other treatment conditions. The payment is reset at the beginning of each week, or if the subject misses the goal on any day. The money in the virtual account will be paid to the subject at the end of the intervention period.
2439021|NCT03305172|Experimental|Loss Streak Treatment|Financial Incentive: Each subject in the Loss Streak treatment will be given a certain amount of money in his/her virtual account at the beginning of every week. An increasing amount of money will be deducted for each consecutive day the subject does not achieve the goal. The payment is reset at the beginning of each week, or when the subject achieves the goal (i.e., deductions are reset when the streak is broken). The balance that is left in the virtual account will be paid to the subject at the end of the intervention period.
3189168|NCT00774956|Active Comparator|2|Healthy persons
3189169|NCT00774969|Experimental|All|6 patients with Perianal Crohn's Disease and 10 healthy Volunteers
2439024|NCT03305146|Experimental|single arm|"For inoperable patients with indeterminate cystic lesions of the pancreas,a EUS FNA will be performed and molecular biology analysis of pancreatic intra-cyst fluid collected by EUS FNA will be performed.~For operable patients, after the pancreatic surgery, molecular biology analysis of extemporaneous pancreatic tissue specimen biopsy will be conducted."
2439025|NCT03305107|Experimental|Exercise and Chocolate Milk|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of chocolate milk"
2439026|NCT03305107|Experimental|Exercise and Water|"Children will exercise on a cycle ergometer with a 3-min warm-up, 7 repeated bouts of 60-sec exercise at 90% of peak power output and 60-second recovery, and a 3-min cool down.~Children will then drink 240mL of water"
2439027|NCT03305107|Experimental|Sitting and Chocolate Milk|Children will quietly sit for 20 minutes Children will then drink 240mL of chocolate milk
2439028|NCT03305107|Experimental|Sitting and Water|Children will quietly sit for 20 minutes Children will then drink 240mL of water
2439029|NCT03305094|Active Comparator|Control group|"Sham remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 20 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The sham ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.~A 20 mm Hg blood pressure cuff on the right arm does not induce ischemia."
2439030|NCT03305094|Experimental|Intervention group|Remote ischemic preconditioning on the right arm is induced with a blood pressure cuff inflation at 200 mm Hg for 5 min and followed by a 5 min reperfusion at 0 mm Hg. The ischemia-reperfusion cycle is performed 3 times for a total of 30 min. This procedure is done after anesthetic induction, but before the patient is placed on cardiopulmonary bypass.
3189170|NCT00774982|Experimental|1 6MP Test Formulation|1 x 40 mg Oral Tablet, 6 MP Delayed Release Test Formulation, for targeted ileal delivery
3189171|NCT00774982|Active Comparator|2. 6MP Reference Formulation|2 x 50 mg oral tablet, PURINETHOL
2439033|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in shoulder surgery.|Arm 1 shoulder replacement, both primary and reverse
2439034|NCT03305068|Placebo Comparator|the use of a COX-II inhibitor in arhroscopic shoulder surgery.|Arm 2 arthroscopic rotator cuff repair
3189172|NCT00775008|Experimental|podcast|
3189173|NCT00775008|Active Comparator|Web group|
2439037|NCT03305042||21-54 y|Ages 21-54 y
2439038|NCT03305042||55-74 y|Ages 55-74 y
2439039|NCT03305042||>75 y|Age >75 y
2439040|NCT03305029|Experimental|SCNT-hES-RPE Cells|Pars plana vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells (SCNT-hES-RPE Cells) in Patients with Advanced Dry Age-related Macular Degeneration(AMD)
2439042|NCT03305003|Active Comparator|Communication modality: spiral notebook|
2439043|NCT03305003|Experimental|Communication modality: mobile application|
2439044|NCT03304990||Family History of CA|Hereditary cancer genetic screening based on risk factors
2439045|NCT03304990||Risk Factors for CA|No dx of CA
2439046|NCT03304990||Suspected or Confirmed Diagnosis of CA|Suspected or confirmed diagnosis of cancer
2439047|NCT03304964|Experimental|100 mg FP-025 (b.i.d)|
2439048|NCT03304964|Experimental|200 mg FP-025 (b.i.d.)|
2439049|NCT03304964|Experimental|400 mg FP-025 (b.i.d)|
2439050|NCT03304964|Experimental|200 mg FP-025 (single dose; fasted)|
2439051|NCT03304964|Experimental|200 mg FP-025 (single dose; fed condition)|
2439946|NCT03298347|Active Comparator|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP.
3189174|NCT00775034|Experimental|1|Study group (Tisseel®)
3189175|NCT00775034|Other|2|Control group
3189176|NCT00775047|Experimental|Pharmacy|Women receive their second and third depot-medroxyprogesterone acetate injections at the pharmacy by clinical pharmacists
3189177|NCT00775047|Active Comparator|Planned Parenthood clinic|Women receive their second and third depot-medroxyprogesterone acetate injections per usual care at their Planned Parenthood clinic.
3189178|NCT00775073|Experimental|Treatment|Bevacizumab (Avastin) & Everolimus (RAD001)
3189179|NCT00775099|Experimental|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
3189180|NCT00775099|Experimental|Diesel Exhaust Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 during intermittent exercise
3189181|NCT00775099|Experimental|Filtered Diesel Exposure|1 hour exposure to diesel exhaust with all particulates filtered out using teflon filter with intermittent exercise
3189182|NCT00775099|Experimental|PALAS Exposure|1 hour exposure to pure carbon particles produced by PALAS generator during intermittent exercise
3189183|NCT00775112|Experimental|1|with pillow
3189184|NCT00775112|No Intervention|2|without pillow
3189185|NCT00775151|Experimental|1|amlodipine 10 mg tablet of Ranbaxy
3189186|NCT00775151|Active Comparator|2|Norvasc® 10 mg tablets
2439052|NCT03304951|Experimental|Synopsis® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid sinus access
2439053|NCT03304938|Active Comparator|Lavender oil|
2439054|NCT03304938|Placebo Comparator|vehicle (Almond oil)|
2439055|NCT03304925|Experimental|Fat Reduction|The treatments are designed to see if the fat can be reduced in the flanks with a new applicator design.
2439056|NCT03304912||Cohort|The cohort will be comprised of women who inject drugs who are eligible for PrEP.
2439057|NCT03304899|Experimental|Case group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive Fibrinogen concentrate after common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...).~Fibrinogen Concentrate(IV injection): Each vial contains 1gr fibrinogen concentrate. Fibrinogen concentrate will be given until serum fibrinogen level riches to 200 mg/dl.~Dose (mg/kg body weight) = ([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
2439058|NCT03304899|Active Comparator|Control group|"Severe isolated Traumatic Brain injury patients with serum fibrinogen level under 200 mg/dl that receive common emergency resuscitation. Instruction:~Airway control & breathing.~Circulation (Serum therapy, Epinephrine,Packed cell, FFP and ...)."
2439059|NCT03304886||Migraineurs|with a migraine
2439060|NCT03304886||Control|Participants without migraine
3189187|NCT00775164|Experimental|pioglitazone|Pioglitazone: 15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
3189188|NCT00775164|Active Comparator|Metformin|Metformin XR; 1000 mg once daily for 16 weeks.
2439063|NCT03304860|Experimental|CRC screening Survey|Residents with parents eligible for CRC screening will be asked to provide their e-mail address, solely for the use of distributing the follow up survey so it can be linked to 2 brief (3-5 min) surveys
2439064|NCT03304847|Other|Ablation|Radio-frequency catheter ablation
2439065|NCT03304834|Experimental|ECHOPULSE|Arm of patient treated by HIFU
3150943|NCT00214682|Experimental|Mental health literacy|This MHL intervention comprised 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
3150944|NCT00214682|Placebo Comparator|Placebo tablet|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
2439068|NCT03304808|Experimental|device|
2439069|NCT03304808|Active Comparator|behavioral|
2439070|NCT03304808|No Intervention|waiting list|
2439071|NCT03304795||Vitamin D deficiency|Serum 25-hydroxyvitamin D level is less than 50 nmol/L.
2439072|NCT03304795||Normal|Serum 25-hydroxyvitamin D level is 50 nmol/L or greater.
2439073|NCT03304782||Preterm birth|Data collected using Fitbit activity tracker from women with delivery prior to 37 weeks gestation
2439074|NCT03304782||Full-term birth|Data collected using Fitbit activity tracker from women with delivery after 37 weeks gestation
2439075|NCT03304769|No Intervention|IV placement no Virtual reality|Patient will have IV placed in traditional manner, with no virtual reality headset
2439076|NCT03304769|Experimental|IV placement with Virtual Reality|Patient will have IV placed with Virtual Reality headset distraction
2439077|NCT03304756|Experimental|CAP|Cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
2439078|NCT03304743||Post-menopausal women|A cohort of 124 consecutive post-menopausal women that performed a DXA scan within the previous 12 months
2439079|NCT03304730||facet inflammatory signs|patients with facet inflammatory signs identified on MRI
2439080|NCT03304730||no facet inflammatory signs|patients without facet inflammatory signs identified on MRI
2439081|NCT03304717|Experimental|TDF/FTC then Placebo|This is a double-blind, placebo-controlled, 2 arm, cross-over trial involving 34 children with clinical findings and molecular confirmation of Aicardi Goutieres Syndrome, who also have an abnormal interferon signature. For arm 1, half of the patients will receive TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for the first 6 months of the study. There will be a one month washout period before starting on placebo for 6 months.
2439082|NCT03304717|Experimental|Placebo then TDF/FTC|For arm 2, half of the patients will receive placebo for the first 6 months of the study. There will be a one month washout period before starting on TDF/FTC (a combination of Tenofovir [TDF] and Emtricitabine [FTC]) for 6 months.
3150945|NCT00214682|Active Comparator|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
3189189|NCT00775177|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
2439089|NCT03304665||Healthy Volunteers|Healthy Volunteers
2439191|NCT03303924|Experimental|ETX2514 and sulbactam|Healthy male and female subjects, non-smoking, will receive multiple doses of ETX2514 1.0 g and sulbactam 1 g via intravenous (IV) infusion every 6 hours with each dose of medication infused over 3 hours.
2439094|NCT03304613|Active Comparator|Standard Web-based Cognitive Behavioral Therapy (e-CBT)|"Patients randomized to e-CBT will undergo Standard Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management Program and meet with a study medical assistant (MA) for an orientation session. The MA provides an overview of the program, explains the rationale for treatment, and directs them to the FibroGuide website. FibroGuide features the CBT modules that will be used by both groups. Patients will complete one module per week. Materials needed for the 8-week intervention including the instructions for each activity and forms for the written aspects of an activity (worksheets) will be provided in the first visit and available online. The FibroGuide website evolved from the evidence-based website Living Well with Fibromyalgia that has established efficacy for improving functional status and reducing pain."
2439095|NCT03304613|Experimental|Resilience-Enhanced web-based CBT Program|"Patients randomized to PRISM will undergo Promoting Resilience through Innovative Self-Management (PRISM) and meet with the MA for an orientation session. The MA describes the program, explains the rationale for treatment, and directs them to the FibroGuide and PRISM websites. Materials and worksheets are provided in the first visit and available online. The e-CBT elements retained are the core elements of CBT for pain, while the resilience-based activities capitalize on the best practices for positive activities interventions including having multiple overlapping activities, making favored activities standard practice beyond the study and having a coaching component."
2439096|NCT03304613|No Intervention|Usual Care|Patients randomized to the usual care only group will have no contact with the study MAs. Usual care patients return for the same follow-up assessments (and electronic medical record review) at 8 weeks and at 6 and 12 months. Whereas major surgery including surgeries for pain, are exclusion criteria, spine and pain injections will be permitted.
2439099|NCT03304587|Experimental|Arm 1: Bright blue-green light|"Bright blue-green light (~515nm; 12,000 lux) for 30 minutes once a day.~For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory~On 2 randomly selected days, the participants will wear a light meter during wake time"
2439100|NCT03304587|Active Comparator|Arm 2: Dim red light|"Dim red light (5 lux) (control group) for 30 minutes once a day.~--For those who have scores of ≤41 (evening types) on Horne-Ostberg Morningness-Eveningness Questionnaire (MEQ), light will be delivered within 30 minutes of waking for 14 consecutive mornings. For those who receive scores of ≥59 (morning types), light will be delivered between 1900-2000 hours for 14 consecutive evenings.~Light therapy will be self-administered using a light visor cap~Each participant will make (3) overnight visits to the sleep laboratory --On 2 randomly selected days, the participants will wear a light meter during wake time"
2439101|NCT03304574|No Intervention|Control|Participants will complete the electronic health assessment only and will not receive integrated personalized feedback
2439102|NCT03304574|Experimental|Intervention|Participants will complete the electronic health assessment and will receive integrated personalized feedback
2439103|NCT03304561|Experimental|traditional rehabilitation|patients in this groups is going to recieve traditional rehabilitation programme for 3 months after ACL recontsruction
2439104|NCT03304561|Experimental|Cross-over training|patients in this programme is going to recieve isokinetic exercise programme targeting unilvolved limb during rehabilitation. for the first 4 weeks after ACL reconstruction traditional rehabiitation programme is going to applied to the subjects. after 4 weeks, isokinetic strenghtening programme at 60˚/second angular velocity, between 0-90 degree knee flexion until 3 months after ACL reconstructon
2439105|NCT03304548||All subjects with PAH|A total of 8 to 10 US-English speaking PAH subjects will be recruited. They will take part in a 30-minute telephone concept elicitation interview. All interviews will be audio-recorded and transcribed verbatim.
3174393|NCT00622973|Other|A|Diffusion-weighted MRI
3174394|NCT00622973|Other|B|Sinerem (USPIO)- enhanced MRI
2439108|NCT03304509|No Intervention|Face-to-face follow-up|Face-to-face follow-up after hospital discharge
2439109|NCT03304509|Experimental|Telematic follow-up|Telematic follow-up after hospital discharge
2439110|NCT03304496|Experimental|Nitroglycerin|"The intervention group will receive a subcutaneous cocktail with 0,5 ml of 500 mcg of nitroglycerin + 1 ml of 2% simple lidocaine."
2439111|NCT03304496|Placebo Comparator|Control|The placebo group will receive a subcutaneous injection with 0,5 ml of 0,9% saline solution + 1 ml of 2% simple lidocaine.
2439112|NCT03304483|Experimental|Athletes|246-km running
2439113|NCT03304470|Experimental|ATx201 2% CREAM|
2439114|NCT03304470|Placebo Comparator|ATx201 Cream Vehicle|
2439115|NCT03304457|Active Comparator|Olanzapine|Olanzapine will be prescribed at a dose of 10mg once daily orally for 6 weeks
2439116|NCT03304457|Experimental|Lurasidone|Lurasidone will be prescribed at a dose of 80mg/day once daily orally for 6 weeks
2439117|NCT03304444|Active Comparator|Bupivacaine HCl in TAP block|"When performing a bilateral TAP with Bupivicaine 0.25% and the incision is below the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials).~When performing a bilateral TAP with Bupivicaine 0.25% and the incision extends above the umbilicus: 30 ml of 0.25% bupivacaine is drawn up and given on each side after identification of planes by the anesthesiologist (need 2 vials). A 3rd vial of 30 ml 0.25% bupivacaine will be drawn up and is directly infiltrated into the surgical site (above and below the fascia prior to closure of fascia) extending above the umbilicus by the surgeon."
3174395|NCT00622986|Experimental|A1|perimenopausal women
3174396|NCT00622986|Placebo Comparator|A2|perimenopausal women
3174397|NCT00622986|Experimental|B1|early staged postmenopausal women
3174398|NCT00622986|Placebo Comparator|B2|early staged postmenopausal women
3174399|NCT00622999||All|All patients
3174400|NCT00623025|Experimental|1|
3174401|NCT00623025|Placebo Comparator|2|
3174402|NCT00623051|Experimental|1|Male circumcision by experimented doctor or nurse
2439118|NCT03304444|Experimental|Liposomal Bupivicaine in TAP block|When performing a bilateral TAP with liposomal bupivacaine and the incision is below the umbilicus: the 20 ml vial of liposomal bupivacaine containing 266 mg, will be diluted with 20 ml of 0.25% bupivacaine (containing 50 mg of bupivacaine) and 20 ml saline (60 ml total). That total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
2439119|NCT03304431|No Intervention|Control group(Group C)|After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
2439120|NCT03304431|Other|Group L|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
2439121|NCT03304418|Experimental|Radium Ra 223 dichloride and radiation, all patients|
2439122|NCT03304405||Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
2439123|NCT03304392|Experimental|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
2439124|NCT03304392|Active Comparator|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
2439125|NCT03304379|Experimental|Dosing regimen 1|
2439126|NCT03304379|Experimental|Dosing regimen 2|
2439127|NCT03304379|Experimental|Dosing regimen 3|
2439128|NCT03304379|Experimental|Dosing regimen 4|
2439129|NCT03304366||Patients with primary pterygium|"All eyes have primary pterygium and seeking for surgery due to Cosmetic problems, ocular irritation, and, or visual impairment.~All selected patients will undergo complete ophthalmological examination including refraction, best corrected visual acuity, keratometry, and pentacam (scheimpflug imaging) preoperatively then will be followed up 2 and 6 months post pterygium excision."
2439130|NCT03304353|Experimental|Self-managed protocol|
2439131|NCT03304353|Active Comparator|Predetermined protocol|
2439132|NCT03304340|Experimental|TENS+SR|For each participant in the transcutaneous nerve stimulation (TENS) group, standard rehabilitation (SR) in addition a TENS stimulator (BioTENS, Skylark Device & Systems Co., Ltd) was applied with 0.2-ms pulses at 100 Hz in the constant mode within the subject's sensory level without muscle contraction via (5 × 3.5 cm) electrodes attached to the motor points of the tibia anterior (TA) and quadriceps muscles on the affected lower extremity. For the TENS group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
2439133|NCT03304340|Experimental|FES + SR|For each participant in the functional electrical stimulation (FES) group, standard rehabilitation (SR) in addition two dual-channel FES stimulators (MEDTRONIC Respond Select; EmpiInc) were used. The FES was delivered with 0.3-ms pulses at 30 pps and the stimulation intensity was set to the movement threshold to induce visible muscle contractions. For the FES group, the given electric stimulation treatment lasted for 30 min per session, once per day, 5 days a week, for 2 weeks.
2439134|NCT03304340|Active Comparator|SR-only|All the participants received functional training and motor relearning physiotherapy treatment as early standard rehabilitation (SR) for 30 minutes per day, 5 days a week throughout the study. Subjects in the SR group received only SR .
2439135|NCT03304327|Experimental|Mindfullness and Yoga|Subjects will receive yoga training either at their home or at the Center for Living Campus at Duke. Subjects will complete their yoga assignments for 5 consecutive days, along with a symptom checklist. On the 6th day, subjects will complete the symptom checklist and mail all checklists to the study team
2439136|NCT03304314|Experimental|Pseudotumor cerebri (PTC) patients|
2439137|NCT03304314|Experimental|Control|
2439138|NCT03304301|Experimental|experimental group|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and expose to sunlight (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months.
2439139|NCT03304301|No Intervention|control group|Participants will receive routine care.
2439140|NCT03304288|Experimental|low-dose rituximab & ATRA|rituximab 100mg once weekly for 6 weeks and oral all-trance retinoid acid 20mg/m^2 qd for 12 weeks.
2439141|NCT03304288|Active Comparator|low-dose rituximab|rituximab 100mg once weekly for 6 weeks
2439142|NCT03304275|Experimental|Emergency Department vaccination group|Pertussis (Tdap) vaccine offered/administered in the Emergency Department
2439143|NCT03304275|Experimental|Public Health referral group|Public Health referral for Pertussis (Tdap) vaccine administration offered
2439144|NCT03304262|Active Comparator|Cathodal tDCS + rTMS|Participant will receive 10 minutes of cathodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2439145|NCT03304262|Active Comparator|Anodal tDCS + rTMS|Participant will receive 10 minutes of anodal tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2439146|NCT03304262|Sham Comparator|Sham tDCS + rTMS|Participant will receive 10 minutes of sham tDCS between M1 and M2 timepoints, and rTMS for 900 1Hz pulses at 0.85 of Resting Motor Threshold at M2.
2439147|NCT03304249|Experimental|iAmHealthy|Participants randomized to this arm receive the iAmHealthy Healthy Lifestyles Program.
2439148|NCT03304249|Active Comparator|Control|Participants randomized to this group receive comparable content delivered via a newsletter.
2470076|NCT03104088||Healthy controls|
2439149|NCT03304236||Myelopathy hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists).
2439150|NCT03304223|Experimental|[18F]FB-IL2 PET scan|Renal transplant recipients with a clinical suspicion for renal transplant rejection.
2439151|NCT03304210|Experimental|Abraxane 35 mg/m²|PIPAC with Abraxane (35 mg/m²) will be administered every 4 weeks for 3 cycles.
2439152|NCT03304210|Experimental|Abraxane 70 mg/m²|PIPAC with Abraxane (70 mg/m²) will be administered every 4 weeks for 3 cycles.
2439153|NCT03304210|Experimental|Abraxane 90 mg/m²|PIPAC with Abraxane (90 mg/m²) will be administered every 4 weeks for 3 cycles.
2439154|NCT03304210|Experimental|Abraxane 112.5 mg/m²|PIPAC with Abraxane (112.5 mg/m²) will be administered every 4 weeks for 3 cycles.
2439155|NCT03304210|Experimental|Abraxane 140 mg/m²|PIPAC with Abraxane (140 mg/m²) will be administered every 4 weeks for 3 cycles.
2439156|NCT03304197|Experimental|Dehydrated|90 minutes cycling, without the ingestion of any fluids, followed by a 15 minute cycling time trial test
2439157|NCT03304197|Experimental|Hypotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g sucrose, 3g glucose) drinks, followed by a 15 minute cycling time trial test
2439158|NCT03304197|Experimental|Isotonic|90 minutes cycling, with the ingestion of six 250 ml carbohydrate (6g glucose, 3g fructose) drinks, followed by a 15 minute cycling time trial test
2439159|NCT03304197|Experimental|Placebo|90 minutes cycling, with the ingestion of six 250 ml taste-matched water drinks, followed by a 15 minute cycling time trial test
2439162|NCT03304158|Experimental|FCHV visit-diabetes|
2439163|NCT03304158|No Intervention|FCHV no visit-diabetes|
2439164|NCT03304132||Upper aerodigestive squamous cell cancers (UADSCC) cases|From PLCO and ACS CPS II, identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
2439165|NCT03304132||Controls|From PLCO and ACS CPS II, we have identified 140 UADSCC cases. These cases are frequency matched 3:1 (420 controls) by incidence density sampling for study (ACS. PLCO),
2439170|NCT03304093|Experimental|Nivolumab|Nivolumab 3mg/kg every 2 weeks
2439171|NCT03304080|Experimental|HR-positive, Her2-positive Metastatic Breast Cancer|Women and men with HR-positive, HER2-positive Metastatic Breast Cancer on trial of anastrozole, palbociclib, trastuzumab and pertuzumab
2439172|NCT03304067|Experimental|Intervention|
2439173|NCT03304067|No Intervention|Control|
2439176|NCT03304041|Experimental|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
2439177|NCT03304041|Placebo Comparator|Traditional dietary advice|"Traditional dietary advice (TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~Traditional dietary advice for 3 weeks"
2439178|NCT03304028|Other|Refusal Group|"Refusal Questionnaires Intervention:~Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal."
2439179|NCT03304028|Other|Interventionnal Group|Connected Devices for 3 months (36 patients will be equipped with CDs-spirometer, oxymeter, scales, podometer watch and AURA device for sleep quality and analyze) Educationnal Intervention Connected Devices for 12 months Interviews
2439180|NCT03304015|Experimental|Intervention: Behavioral Change Communications|
2439181|NCT03304015|No Intervention|Control: No intervention|
3173036|NCT00607464|Experimental|1|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
3173037|NCT00607464|No Intervention|2|Standard care
2439184|NCT03303976|Experimental|Pneumo1-low dose|Arm A: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2439185|NCT03303976|Experimental|Pneumo1-mid dose|Arm B: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2439186|NCT03303976|Experimental|Pneumo1-target dose|Arm C: intramuscular injection monovalent bioconjugate pneumococcal vaccine
2439187|NCT03303976|Active Comparator|Pneumovax23|Arm D: intramuscular injection multivalent plain polysaccharide vaccine
2439188|NCT03303963||Rifampicin resistant and susceptible patients|Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)
2439189|NCT03303963||Rifampicin resistant patients|Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment
3173038|NCT00607490|Experimental|Cognitive-behavioral Therapy|10 weekly individual 60-minute sessions
2439353|NCT03302663|Other|Patients attending for a clinical scan|Patients attending for a clinical scan will be offered 2-4 extra sequences. The additional sequences and compare them to the currently established ones.
3173039|NCT00607490|Active Comparator|Supportive Psychotherapy|10 weekly individual 60-minute sessions
3173040|NCT00607503|Experimental|1|
3173041|NCT00607516|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
3173042|NCT00607516|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
3173043|NCT00607529||1|Patients having a creatinine drawn
3173044|NCT00607542|Active Comparator|1|starting dose of baclofen 2.5 mg PO TID with dose escalation as tolerated
3173045|NCT00607555||Observation|Premature infants over 23 weeks of gestation and less than 1.25 kilograms at birth, who are tolerating feedings, and are clinically stable
3173046|NCT00607568|Experimental|1|atomoxetine 40mg per day
3173047|NCT00607568|Placebo Comparator|2|second arm is placebo, sugar pill
3173048|NCT00607581|Experimental|1|"The participants receive up to 9 28-day cycles of~cyclophosphamide: 500 mg orally on days 1, 8, 15;~lenalidomide: 15 mg orally on days 1-21;~dexamethasone: 40 mg orally on days on days 1, 8, 15, 22."
3173049|NCT00607607|Experimental|A|Ovarian Cancer Patients
2439194|NCT03303898|Other|asymptomatic carriers|
2439195|NCT03303898|Other|uninfected patient|
2439196|NCT03303872||AF-pacemaker registry|
3173050|NCT00607607|Experimental|B|Endometrial Cancer Patients
2439198|NCT03303833||Persons with Lynch syndrome|
2439199|NCT03303807|Other|Extracorporeal CO2 removal|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)
2439202|NCT03303781||BE + CR|Belgian ischemic heart disease patients with cardiac rehabilitation program
2439203|NCT03303781||BE-CR|Belgian ischemic heart disease patients without cardiac rehabilitation program
2439204|NCT03303781||Si + CR|Singapore (Asian) ischemic heart disease patients with cardiac rehabilitation program
2439205|NCT03303781||SI -CR|Singapore (Asian) ischemic heart disease patients without cardiac rehabilitation program
2439206|NCT03303768||Pregnant women|Pregnant woman with suspected coarctation of isolated aorta or woman followed in the last 12 for suspected coarctation of the aorta isolated during pregnancy
2439207|NCT03303742|Experimental|feather edge finish line marginal design|intervention
2439208|NCT03303742|Active Comparator|deep chamfer finish line marginal design|comparator
2439209|NCT03303729|Experimental|Meat hydrolysate & Cluster Dextrin|Meat hydrolysate containing 25g of protein given together with 75 grams of Cluster Dextrin.
2439210|NCT03303729|Active Comparator|Meat hydrolysate & placebo|Meat hydrolysate containing 25g of protein given together with 75 grams of Glucose.
2439211|NCT03303703|No Intervention|Control|Usual cardiac rehabilitation and social phone calls for attention control.
2439212|NCT03303703|Experimental|Intervention|RENEwS intervention is five 60-minute group educational sessions.
2439213|NCT03303690|Experimental|Ankle Spacer (AS)|This arm will surgically receive the to be implanted ankle spacer in their ankle.
2439214|NCT03303677|Active Comparator|Saline|Post operative endoscopic sinus surgery patients using Saline nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2439215|NCT03303677|Experimental|Saline and budesonide|Post operative endoscopic sinus surgery patients using saline + budesonide nasal sinus irrigations to be performed twice daily. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2439216|NCT03303677|Experimental|saline, budesonide, and topical antibiotic|Post operative endoscopic sinus surgery patients using saline + budesonide + topical antibiotic nasal sinus irrigations. The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole. All patients will begin with normal saline irrigations immediately following surgery as per our department's standard of care. At their first one week post op appointment they will then begin treatment per the treatment arm.
2439217|NCT03303664|Experimental|IMPROVE Protocol|The intervention is composed of 4 parts: 1) a multidisciplinary team that recommends, develops, approves, monitors the components of the intervention and training? 2) monitoring of medication sedation risk using established scale 3) restriction of medication dispensing via enhanced technology 4) health professional training on multimodality pain management including complementary and alternative therapies.
2439218|NCT03303664|No Intervention|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
2439219|NCT03303651|Experimental|PPI (Pain Pupillary Index)|Opioid administration guided by Pain Pupillary Index (PPI) derived from Videopupillometry performed with the device AlgiScan manufactured by IDMed, Marseille, France. The device measures the degree of pupillary reflex dilation (PRD) following an electric nociceptive stimulation. It automatically increases the intensity of the electric stimulation from 10 to 60 milliampere depending on the degree of PRD and afterwards displays the PPI. The numerical index ranges from 0 to 10. A low PPI score indicates a deep analgesia, a high PPI score indicates an insufficient or light analgesia. A PPI score of 2 or 3 is supposed to represent an optimal level of analgesia according to the manufacturer. 5 µg sufentanil will be administered every 5 minutes if PPI score is calculated more than 3.
2439220|NCT03303651|Experimental|SPI (Surgical Pleth Index)|Opioid administration (sufentanil) guided by by Surgical Pleth Index (SPI) derived from photoplethysmography performed by the device CARESCAPE B650 Patient Monitor from the manufacturer GE (General Electrics) Healthcare, Helsinki, Finland. Included in the monitoring system is a software that continuously calculates the SPI from normalized heart rate and pulse wave amplitude derived from finger plethysmography. The numerical index ranges between 0 (low sympathetic tone) and 100 (high sympathetic tone). A SPI score between 20 and 50 has been proposed as the target range to guide analgesics (15 - 17). 5 µg Sufentanil will be administered every 5 minutes if SPI score is calculated more than 50.
2439245|NCT03303456|Experimental|Clinical high risk (CHR)|Subjects at clinical high risk (CHR) for psychosis and/or bipolar disorder, aged 13-30 years. CHR participants will have no history of psychosis and will demonstrate attenuated psychotic symptoms consistent with the Structured Interview for Prodromal Syndromes (SIPS), or genetic risk (first-degree relative with psychosis) in conjunction with a substantial drop in functioning over the past year. Assigned Mobile health application - Ginger.io
2439381|NCT03302455|Experimental|eCBTI|This group will receive a 1-week of eCBTI treatment and will receive 3 months of follow-up.
3173051|NCT00607633||1|Patient with essential hypertension and LVH under treatment with candesartan or candesartan HCT
3173052|NCT00607646|Experimental|1|Hyperinsulinemic (high dose insulin) hypoglycemic clamp studies with oral administration of DHEA or placebo prior to each clamp x 2 on day 1. Day 2 hyperinsulinemic hypoglycemia. Participant randomized to either DHEA or placebo for baseline trial (arm 1) and 6 weeks treatment.
3173053|NCT00607646|Experimental|2|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
3173054|NCT00607646|Experimental|Arm 3 (optional)|Individuals will be asked to return after at least 2 months and repeat the trial they did not complete (for example, placebo if they were in the DHEA trial before). Again Day 1 would consist of two hyperinsulinemic clamps with placebo or DHEA given orally. Day 2 hyperinsulinemic hypoglycemic clamp with oral administration of placebo or DHEA.
2439221|NCT03303651|Experimental|NOL (Nociception Level)|Opioid administration (sufentanil) guided by Nociception Level (NOL) derived from finger photoplethysmography performed with the analgesia monitoring device PMD200 manufactured by Medasense, Ramat Gan, Israel. The device continuously calculates the NOL with a multi-parametric approach from pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature and finger motion. The composite algorithm of the device analyses the data and the numerical index NOL is presented on a scale from 0 (no pain) to 100 (extreme pain) (18). A NOL score between 10 and 25 has been proposed as the target range to guide analgesics. 5 µg Sufentanil will be administered every 5 minutes if NOL score is calculated more than 25.
2439222|NCT03303651|Active Comparator|Control|Opioid administration (sufentanil) guided according to standard clinical practice of the attending anesthesiologist based upon changes of heart rate, blood pressure, lacrimation and sweating of the patient.
2439223|NCT03303638|Other|Multi-sensory Environment during bathing|The MSE intervention will be provided by an interactive waterproof fiber optic kit that includes: a light-emitting diode (LED) wall-washer light, a waterproof fiber optic cable that can be controlled by a waterproof switch held by the participant while bathing, showering, and or tub bathing, and a mobile MSE cart. The wall-washer LED light creates the illusion that the room is painted a variety of bright colors that can be changed by the veteran being bathed. The mobile MSE cart includes an LED solar projector providing visual sensory stimulation by projecting scenes on the wall, an aroma therapy diffuser and a portable bubble tube to create positive distraction during the bathing process.
2439224|NCT03303625|Experimental|Cohort 0: Adults (Ad26.RSV.preF)|Participants aged greater than or equal to (>=) 18 to lesser than or equal to (<=) 50 years will receive vector Ad26.RSV.preF at 1*10^11 viral particles (vp) via intramuscular (IM) route (Group 1) on Day 1 and 29.
2439225|NCT03303625|Placebo Comparator|Cohort 0: Adults (Placebo)|Participants aged >= 18 to <= 50 years will receive placebo via IM route (Group 2) on Day 1 and 29.
2439226|NCT03303625|Experimental|Cohort 1: RSV seropositive Toddlers (Ad26.RSV.preF)|RSV seropositive participants aged >=12 to <=24 months will receive Ad26.RSV.preF at 5*10^10 vp via IM route (Group 3) on Day 1 and 29.
2439227|NCT03303625|Placebo Comparator|Cohort 1: RSV seropositive Toddlers (Placebo)|RSV seropositive participants aged >= 12 to <= 24 months will receive placebo via IM route (Group 4) on Day 1 and 29.
2439228|NCT03303612|Other|EP-based approach/pacemaker implant|"Subjects will undergo an EP study prior to hospital discharge and will receive a pacemaker implantation if the HV interval is ≥65 msec.~In the case where the electrical slowdown is not confirmed by the electrophysiological study, the participant will not have a pacemaker implantation."
2439229|NCT03303612|Other|Compared transcutaneous cardiac monitor|Subjects will undergo a minimum of 72 hour ECG monitoring in hospital and receive transcutaneous monitoring prior to hospital discharge for a duration of 30 days.
2439230|NCT03303599||HCV Genotypes 1, 2, 3, 4, 5, or 6 participants|Participants receiving combination therapy with the glecaprevir plus pibrentasvir (GLE/PIB) regimen according to standard of care, international guidelines and in line with the current local label.
2439231|NCT03303586|Active Comparator|Asthma group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
2439232|NCT03303586|Active Comparator|Healthy group|Participants will be randomized to wear compression stockings or to control group for two weeks and cross over in the end of the period. When assigned to wear compression stockings, they will be instructed to put the stockings on as soon as they get up in the morning and to remove them just prior to bedtime for two weeks. If they have become loose, a new pair will be fitted. They will be given a diary to record the time they put on and remove the compression stockings each day. They will be telephoned after one week to check the fit of the compression stockings.
2439233|NCT03303573||recombinant human erythropoietin group|cerebral palsy patients who had received erythropoietin from January 2013 to November 2016
2439234|NCT03303547|Experimental|MRI-Pathology N1c matching group|MRI mapping will be used to guide pathologists to sample areas of the mesorectum where tumour deposits are likely to be present.
2439235|NCT03303534|Experimental|PCR|pre-operative protein calorie restricted (PCR) group. participants randomized to this arm will consume scandishake diet (strawberry, caramel, banana cream, vanilla) mixed with almond milk for three days inpatient prior to planned elective carotid endarterectomy. Water is ad libitum for this cohort. Nutritionists will prepare shakes so participants will achieve 30% calorie restriction and severe protein restriction during the three days on the diet.
2439236|NCT03303534|No Intervention|control regular diet|participants in this cohort are randomized to the control group and will have no dietary restriction three days in patient prior to planned elective carotid endarterectomy
3189190|NCT00775177|Active Comparator|2|Adoxa ® 100mg tablets of Bradley Pharmaceuticals, Inc
3189191|NCT00775216|No Intervention|Standard care|Standard behavioral counseling
2439239|NCT03303508|Other|anti-ds DNA|anti-ds DNA
2439240|NCT03303495|Experimental|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1; l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1; 5-FU - bolus 400 mg/m2 IV bolus Day 1; 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
2439241|NCT03303495|Experimental|CPT-11 +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1; CPT-11 180 mg/m2 IV 90 min Day 1
2439242|NCT03303482|Experimental|Intervention Group|
2439243|NCT03303482|No Intervention|Waitlist Control Group|
3189192|NCT00775216|Experimental|Intervention|"Behavioral counseling intervention augmented with an interactive health promotion telephone helpline"
2439352|NCT03302676|No Intervention|Control|Patients continue with daily routine to relieve oral discomfort. No chewing gum allowed.
3189193|NCT00775242|Experimental|Estradiol and progesterone injection|Comparison of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P
3189194|NCT00775255|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
3189195|NCT00775255|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
2439246|NCT03303456|Experimental|First Episode Psychosis (FEP)|First Episode Psychosis (FEP) subjects aged 13-30 meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder. FEP participants will be ascertained three years or less from illness onset and have diagnoses of affective (i.e. bipolar) and non-affective psychosis (i.e. schizophrenia) according to DSM-IV criteria. Assigned Mobile health application - Ginger.io
2439247|NCT03303456|Experimental|Healthy Controls (HC)|Healthy individuals with no current/past axis I disorders according to DSM-IV criteria and no first-degree relative with a psychotic disorder. Assigned Mobile health application - Ginger.io
2439248|NCT03303443||Younger|20-40 years old patients
2439249|NCT03303443||Elderly|over 60 years old patients
2439250|NCT03303430||Surgery group|This patient's group will benefit from a endarteriectomy in order to treat their carotid stenosis.
2439251|NCT03303430||Stenting group|This patient's group will benefit from a stenting of their carotid in order to treat their stenosis.
2439255|NCT03303391|No Intervention|Standard Care|This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist
2439256|NCT03303391|Experimental|IBPS Group|This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.
2439257|NCT03303378|Experimental|Melatonin group|Patients will receive a total intravenous melatonin dose of 11.61 mg (aproximately 166 μg/kg).
2439258|NCT03303378|Placebo Comparator|Control group|Patients will receive the same dose of placebo.
2439259|NCT03303365|Experimental|Treatment based on SPACE MRI sequence|Cyberknife SRS of all suspect intracranial lesions visible in SPACE up to 10 simultaneous lesions
2439260|NCT03303365|Active Comparator|Treatment based on MPRAGE|Cyberknife SRS of all suspect intracranial lesions visible in MPRAGE up to 10 simultaneous lesions
2439261|NCT03303352|Experimental|Fast Pass First, Slow Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as fast pass first, slow pass second."
2439262|NCT03303352|Experimental|Slow Pass First - Fast Pass Second|"Each patient will receive 2 EUS FNA passes, 1 fast and 1 slow, with a 22 gauge EUS needle, with suction syringe, employing the fanning technique, 10 jabs for each pass.~A fast pass has an advancing mean acceleration jab (to movement) higher than 1 g, while a slow pass has an advancing mean acceleration jab of less than 1 g (where 1 g equals 9.8 m/s2). Both movements will have a slow fro withdrawal movement, from the point of maximum advance into the lesion to the lesion entry site.~For each patient, the passes order with be either done as slow pass first, fast pass second."
3150946|NCT00214682|Active Comparator|Pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
3150947|NCT00214760|Experimental|PGET|
3150948|NCT00214760|Active Comparator|PMMA|
2439266|NCT03303326|Experimental|Immediate Interview|A 60-minute interview about women's health conducted immediately after baseline questionnaires.
2439267|NCT03303326|No Intervention|Delayed Interview|The interview is conducted after the follow-up questionnaires are completed, rather than after baseline.
2439268|NCT03303313|Experimental|Cemdisiran|
2439269|NCT03303287|Experimental|intervention|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
2439270|NCT03303287|No Intervention|control|usual
2439271|NCT03303274|Experimental|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally before subclavian venous catheterization.
2439272|NCT03303274|No Intervention|Supine|Catheterization of right subclavian vein in supine position.
2439273|NCT03303248|Experimental|Web-based Educational Intervention|This group of participants will be given access to a web-based educational resource in addition to the standard of care.
2439274|NCT03303248|No Intervention|Standard of Care|This group will be given only the standard of care during their clinic visit.
2439275|NCT03303235|Experimental|IV Methergine|"IV methylergonovine group~-IM 0.9% NaCl (1 ml)) + IV methylergonovine (2 mcg/ml) infusion (100 ml)"
2439276|NCT03303235|Active Comparator|Conventional|"IM methylergonovine group~-200 mcg IM methylergonovine (1 ml) + IV 0.9% NaCl infusion (100 ml)"
2439277|NCT03303222||patients on dialysis|patients with kidney disease treated by dialysis
2439278|NCT03303222||patients with chronic kidney disease|patients with chronic kidney disease not treated by dialysis
2503910|NCT02873832||MPS|
3150949|NCT00214773||Observational|No intervention. This is an observational program.
3150950|NCT00214825|Experimental|1|MR antagonist (Eplerenone) + placebo
3150951|NCT00214825|Placebo Comparator|2|Hydrochlorothiazide plus potassium
3150952|NCT00214916|Active Comparator|A|conventional insulin therapy (using Actrapid IV)
3150953|NCT00214916|Experimental|B|intensive insulin therapy (using actrapid IV)
3150954|NCT00214968|Experimental|Modafinil|Subjects began taking Provigil at a dosage of 100 mg/day (1 tablet) and increased their dosage by 100 mg/day each week for up to 4 weeks
3150955|NCT00215046|Experimental|Drug|no randomization, all patients receive experimental drugs
3150956|NCT00215111|Experimental|Low carbohydrate, reduced glycemic load, control diet|
3150957|NCT00215293|Experimental|Cervical Cage|Cervical I/F Cage
3189196|NCT00775281||1|
3189197|NCT00775281||2|
2439281|NCT03303183|Active Comparator|Direct Ear Scanner|Digitale impression via direct ear scanner
2439282|NCT03303183|Active Comparator|Silicone Ear impression|Impression via silicone
2439283|NCT03303170|Experimental|Sebacia Microparticles|
2439284|NCT03303170|Active Comparator|Nd:Yag Laser|
3189198|NCT00775281||3|
3189199|NCT00775294|Experimental|maraviroc|Single arm trial looking at the pharmacokinetics of maraviroc in healthy volunteers.
3189200|NCT00775307|Placebo Comparator|B|Placebo 400 mg/day (24 weeks)
2439288|NCT03303131||Period A|Children discharged as recovered from September 2007 to March 2009 with at least 15% of their weight at admission
2439289|NCT03303131||Period B|Children discharged as recovered from April 2009 to December 2011 with Children discharged as recovered from September 2007-March 2009 with MUAC ≥ 124 mm
2439290|NCT03303118|Other|Left|No product administration will be done in this study.
3189201|NCT00775307|Experimental|A|Pazopanib 400 mg/day (24 weeks)
3189202|NCT00775320||Brain tumor FLT-PET|Those diagnosed with a brain tumor and are to undergo surgery
3189203|NCT00775333||1|Patients with diabetes and carpal tunnel syndrome
3189204|NCT00775333||2|Non-diabetic patients with carpal tunnel syndrome
3189205|NCT00775359|Experimental|1|Fenofibrate 160mg Tablets of Ranbaxy
3189206|NCT00775359|Active Comparator|2|TriCor® 160 mg Fenofibrate Tablets
3189207|NCT00775372|Experimental|1|clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories
3189208|NCT00775372|Active Comparator|2|Biaxin® granules 250 mg/5 mL oral suspension
2439299|NCT03303066|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
2439300|NCT03303066|Placebo Comparator|Placebo (Double-blind, Three times a week)|Fixed starting doses (different doses for lower body weight & higher body weight); dose adjustments to hemoglobin levels are allowed during the study.
2439301|NCT03303053|Experimental|Group1:Cholestyramine+standard treatment|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
2439302|NCT03303053|Experimental|Group2:Prednisolone+standard treatment|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
2439303|NCT03303053|Active Comparator|Group 3: Standard treatment alone|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
2439304|NCT03303040|Experimental|Stimulation|Electrical stimulation of hemidiaphragm
2439305|NCT03303040|No Intervention|Control|No stimulation of hemidiaphragm
2439306|NCT03303027|Experimental|6-0 fast absorbing gut suture|6-0 fast absorbing gut used to suture wound
2439307|NCT03303027|Experimental|5-0 fast absorbing gut suture|5-0 fast absorbing gut used to suture wound
2439308|NCT03303014|Experimental|5-0 Prolene|Half of the wound will be treated with 5-0 prolene
2439309|NCT03303014|Experimental|5-0 Fast Absorbing Gut|Half of the wound will be treated with 5-0 fast absorbing gut
2439310|NCT03303001|Experimental|Subacromial high volume infiltration|This group received an subacromial infiltration guided by ultrasound, of 50 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 8 mL of lidocaine simple plus 10 mL of ropivacaine 7.5% plus 30 mL of saline solution.
2439311|NCT03303001|Active Comparator|Subacromial conventional infiltration|This group received an subacromial infiltration guided by ultrasound of 10 mL of solution. This solution mix: 2 mL of methylprednisolone (40 mg) plus 3 mL of lidocaine simple plus 5 mL of ropivacaine 7.5%
2439312|NCT03302988|Experimental|Everted closure|Wound eversion will be achieved through buried vertical mattress suture or cuticular suture based on surgeon's preference, either buried vertical mattress suture or cuticular sutures
2439313|NCT03302988|Active Comparator|Planar closure|The planar side of the same wond will be closed with traditional buried simple closure and running cuticular sutures
3189209|NCT00775385|Active Comparator|A|Standard chemotherapy
2439315|NCT03302962|Experimental|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
2439316|NCT03302962|No Intervention|Routine Asthma Education Literature|"The remaining 54 cases were randomized to the control arm and received written materials related to patient-centered asthma control."
2439317|NCT03302949|No Intervention|Control|Control arm will not receive the intervention, but will receive standard 6-month anti-tuberculosis regimen and nutritional supplements provided by various NGO's (on irregular basis).
3189210|NCT00775385|Experimental|B|Customized treatment
3189211|NCT00775398||A|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who received topical THROMBIN-JMI® during the study surgery.
3189212|NCT00775398||B|Subjects with anti-topical bovine thrombin antibodies pre-surgery, who did not received THROMBIN-JMI® during the study surgery.
3189213|NCT00775398||C|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did receive THROMBIN-JMI® during the study surgery.
3189214|NCT00775398||D|Subjects with no anti-topical bovine thrombin antibodies pre-surgery and who did not receive THROMBIN-JMI® during the study surgery.
3189215|NCT00775424|Experimental|PENNVAX-B alone|PENNVAX-B alone
3189216|NCT00775424|Experimental|PENNVAX-B+IL12|PENNVAX-B+IL12
3189217|NCT00775424|Experimental|PENNVAX-B+IL15|PENNVAX-B+IL15
3189218|NCT00775424|Placebo Comparator|PLACEBO|PLACEBO
3189219|NCT00775476|Active Comparator|NAC|2.4 g - 4.8 g of NAC daily starting after 3 month open label titration period.
3189220|NCT00775476|Placebo Comparator|Placebo|2.4 g - 4.8 g of placebo per day after 3 month open label titration period.
3189221|NCT00775489|Active Comparator|1|Steroid nasal spray (beclomethasone)
3189222|NCT00775489|Placebo Comparator|2|Normal saline nasal spray
3189223|NCT00775502|Experimental|BIW-8962, monoclonal antibody|
3189224|NCT00775515|Experimental|one|laparoscopic prostatectomy
2439318|NCT03302949|Experimental|Intervention|Intervention arm will receive standard 6-month anti-tuberculosis regimen, nutritional supplements provided by various NGO's (on irregular basis), and receive the study intervention of daily supplement of 62.5g Lacprodan® DI-8090
3189225|NCT00775541|Experimental|Vitamin C|2 gms vitamin C
3189226|NCT00775554|Other|traditional hematoma block|people will receive traditional hematoma block for closed forearm fractures
2439321|NCT03302923|Experimental|Brisk walking 1|1 time a week of 9 months brisk walking
2439322|NCT03302923|Experimental|Brisk walking 3|3 times a week of 9 months brisk walking
2439323|NCT03302923|No Intervention|Control group|No brisk walking session
2439324|NCT03302910|Experimental|Short Stay Unit|Subjects are assigned to the short stay unit (SSU) for approximately 23 hours treatment and observation period. In the SSU, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
2439325|NCT03302910|Active Comparator|Standard of Care|Subjects are assigned to inpatient hospitalization. During hospitalization, patients will receive usual care for AHF, which includes loop diuretics and nitroglycerin, as needed.
2439326|NCT03302897|Experimental|2 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Low dose of antigen.
2439327|NCT03302897|Experimental|10 μg LEP-F1 + 5 μg GLA-SE|Three intramuscular injections of LEP-F1 + GLA-SE at Days 0, 28, and 56. Higher dose of antigen.
2439328|NCT03302884|Experimental|Biological sampling in ovarian carcinoma|Blood and tumor samples
2439329|NCT03302871|Experimental|İntensive Therapy Group|Children who received Botulinum toxin type A to plegic upper limb would be treated by transcranial direct current stimulation and a hybrid training model of CIMT and BIT
2439330|NCT03302871|Active Comparator|Control Group|Children who received Botulinum toxin type A to plegic upper limb would continue their usual care
2439331|NCT03302845|Experimental|Omeprazole|Subjects will receive one 40 mg omeprazole capsule per day for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
2439332|NCT03302845|Experimental|Famotidine|Subjects will receive one 40 mg famotidine tablet given twice daily for 4 days and one 250 mg telotristat ethyl tablet on two separate occasions.
2439333|NCT03302832|Active Comparator|Standard Care Physical Therapy|The participants randomized to the Standard Care Physical Therapy group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of sessions will be 2-3 x per week for the initial 2 weeks, followed by 2 x per week until the culmination of physical therapy. The frequency and duration of sessions will be determined by the treating physical therapist based upon the clinical needs and progress of the specific participant.
2439334|NCT03302832|Experimental|Physical Therapy and in-Home Equipment|The participants randomized to the experimental group will begin outpatient physical therapy services after discharge from inpatient care, on day 4 or 5 post-Total Knee Arthroplasty. The frequency of physical therapy sessions will be 1 x per week throughout the duration of the study period. In addition, this group will utilize in-home exercise equipment daily.
2439335|NCT03302819|Experimental|Breast cancer accuracy|Patients with a known or suspected (and subsequently proven) breast cancer
2439336|NCT03302819|Experimental|Imaging characteristics and performance|Patients attending the symptomatic clinic
2439337|NCT03302819|Experimental|Tumour response in neoadjuvant treatment|Patients who are being treated with neoadjuvant chemotherapy or endocrine treatment
3189227|NCT00775554|Other|ultrasound guided hematoma block|pts. will receive a hematoma block using bedside ultrasound to guide the placement
3189228|NCT00775567|Active Comparator|1|30g fructose dissolved in water twice a day
3189229|NCT00775567|No Intervention|No Intervention|
3189230|NCT00775580|Experimental|1|atenolol 100 mg Capsules of Ranbaxy
3189231|NCT00775580|Active Comparator|2|Tenormin 100mg capsules
2439343|NCT03302754|Other|Alemtuzumab|"Patients less than 15kg will be given 0.6mg/kg alemtuzumab divided over days -14, -13, and -12 (0.2mg/kg/dose).~Patients greater than 15kg will be given a 3mg test dose on day -14 in order to limit the first dose to no more than 3 mg per the manufacturer's recommendation. This will be followed by 0.23mg/kg/dose on days -13 and -12 (to equal a total dose of approximately 0.5-0.6mg/kg).~Alemtuzumab will be drawn into a sterile syringe and given to patients subcutaneously."
3189232|NCT00775619|Active Comparator|2|Coreg® 12.5 mg tablets
3189233|NCT00775619|Experimental|1|Carvedilol 12.5 mg tablets
2439346|NCT03302728|Experimental|Lenalidomide & brentuximab vedotin|Brentuximab vedotin 1.8mg/Kg Lenalidomide 15 mg
2439347|NCT03302715|Experimental|Mucosal biopsies|Only blood samples and mucosal biopsies
2439348|NCT03302702|Other|Exercise program|Treatment group
2439349|NCT03302689|Experimental|Ropivacaine|TAP-block with Ropivacaine Solution
2439350|NCT03302689|Experimental|Levobupivacaine|TAP-block with Levobupivacaine Solution
2439351|NCT03302676|Active Comparator|Intervention|"Patients use tasteless and sugar free chewing gum up to 5 times a day for 1 month.~Daily registrations in a patient dairy."
2503912|NCT02873832||Control|
3189234|NCT00775632|Active Comparator|Standard of Care|The current standard of care for GVHD prophylaxis at Princess Margaret Hospital is cyclosporine and Mycophenolate or cyclosporine and methotrexate.
3189235|NCT00775632|Experimental|Cyclosporine and Campath|The efficacy of experimental arm will be tested against standard of care for prevention of Chronic extensive GVHD.
3189236|NCT00775697|Experimental|Montelukast|the single arm will receive montelukast
3189237|NCT00775710|Active Comparator|1|Non-invasive ventilation is maintained during three nights after recovery of an episode of hypercapnic respiratory failure.
3189238|NCT00775710|No Intervention|2|Discontinuation of NIV after the recovery of hypercapnic respiratory failure, without prolong it during night.
3189239|NCT00775736||A|
3189240|NCT00775749|Experimental|1|The nicotine patch will be applied prior to surgery and remain on the right upper back for 24 hours.
3189241|NCT00775749|Placebo Comparator|2|The placebo patch has no active ingredients and the same inactive ingredients as the nicotine patch. It will be administered the same fashion as the nicotine patch.
3189242|NCT00775762|Active Comparator|aspirin|
3189243|NCT00775762|Active Comparator|clopidogrel|
3189244|NCT00775762|Active Comparator|clopidogrel plus aspirin|
2439354|NCT03302663|Other|Patients who have requested a TOP|Women who have requested a termination of pregnancy (TOP) will be asked if they are willing to have a fetal MRI at 3T performed prior to the TOP. The images obtained will be compared to either images done clinically at 1.5T before the TOP request (if done and with the patients consent) or to images obtained at 1.5T of a similar gestation and pathology that the investigators obtained in a previous research study.
2439355|NCT03302663|Other|Patients with fetal heart abnormality|The investigators plan to recruit patients with a fetus with heart abnormality on ultrasound and compare the MRI findings with the ultrasound findings and the clinical outcome.
2439356|NCT03302663|Other|Patient fetal bone abnormalities|The investigators would like to ask women who have a fetus with bone abnormalities if they would be willing to have a fetal MRI. The findings will be compared to the ultrasound findings and the clinical or pathological findings after delivery.
2439357|NCT03302650|Experimental|Angiotensin group|Patients will receive Angiotensin II at a starting dose of 20 ng/Kg/min. During the first 30 minutes after randomization, the angiotensin II infusion will be titrated to achieve a mean arterial pressure of 65-75 mmHg while the norepinephrine infusion will be withdrawn and stopped. Following a stabilization of 60 minutes, the angiotensin II infusion is titrated to achieve a mean arterial pressure of 85-95 mmHg. Following a 30 minutes wash-in period and a 60 minutes stabilization period, a third set of measurements will be taken. Then, the angiotensin II infusion will be withdrawn in small steps and replaced by a norepinephrine infusion which will then be titrated to achieve a mean arterial pressure of 65-75 mmHg. Then, the final set of measurements will be taken.
2439358|NCT03302650|Placebo Comparator|Normal saline group|Patients will receive normal saline infusion in addition to norepinephrine infusion. The same mean arterial pressure levels (65-75 mmHg > 85-95 mmHg > 65-75 mmHg) will be achieved by titration of the norepinephrine infusion. Identical wash-in and stabilization periods will be kept as in the study group. Measurements will be taken at the same time points as in the study group. The maximum dose of norepinephrine applied will be 0.7 mcg/kg/min.
2439359|NCT03302637||Cases|subjects with histology-confirmed incident pancreatic cancer, with no prior history of cancer (except non-melanoma skin cancer), a valid consent, and pre-diagnostic oral wash samples.
2439360|NCT03302637||Control|selected by incidence density sampling63 among cohort members who had no cancer prior to selection, provided a valid consent and an oral wash. Controls were frequency matched to cases by cohort, age at cohort entry (5 year), sex, race, and calendar year of cohort entry.
2439361|NCT03302624||Patients who were included in ELVIS study|
2439362|NCT03302611|Experimental|Surf Therapy|Participants receive a physical activity-based intervention, which in this arm is surf therapy. Each service member is paired with a surf instructor who typically works with them each week for the length of the program.
2439363|NCT03302611|Active Comparator|Hike Therapy|Participants receive a physical activity-based intervention, which in this arm is hike therapy. During hike therapy, service members may hike together or at a self-selected pace.
2439364|NCT03302598|Other|patients with enterocutaneous fistula|
2439365|NCT03302585|Experimental|High-Dose Vitamin D Treatment Group|"Patients in this arm will receive:~-5 days of high-dose oral vitamin D3 (50,000 IU daily x 5), followed by 85 days of moderate dose oral vitamin D3 (10,000 IU daily x 85 days)"
2439366|NCT03302585|Placebo Comparator|Placebo/Standard Vitamin D3 Group|"Patients in this arm will receive Placebo/Standard of Care Vitamin D3:~-5 days of placebo, followed by 85 days of standard of care dose of oral vitamin D3 (4,000 IU daily x 85 days)"
2439367|NCT03302572|Experimental|Brief information group|Patients will be given brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
2439368|NCT03302572|No Intervention|Control group|"Patients who fall into a control group will only be attended to their reason for visiting and will be asked for the necessary data to obtain the independent variables if they do not appear in their history. If the patient in this group wants the information, he will be excluded from the study because he refuses to participate."
2439370|NCT03302546|Active Comparator|Incremental Hemodialysis|Subjects on this arm will be treated with 2 hemodialysis sessions of at least 4 hour per week.
2439371|NCT03302546|Active Comparator|Conventional hemodialysis|Subjects on this arms will be treated with 3 hemodialysis sessions of at least 3.5 hour per week.
2439372|NCT03302533||Primary arthroplasty|All patients who received TEA for an acute trauma with fracture of the distal humerus.
2439373|NCT03302533||Secondary arthroplasty|All patients who received TEA due to a failed reconstruction or non-operative treatment after a distal humerus fracture.
2439374|NCT03302520|Experimental|Novomax|Novomax(R) ceramic glass spacer for interbody fusion
2439375|NCT03302520|Active Comparator|PEEK cage|PEEK cage for interbody fusion
2439376|NCT03302507|Experimental|BESS, biportal endoscopic spine surgery|Biportal endoscopic decompression surgery for lumbar spinal stenosis
2439377|NCT03302507|Active Comparator|ULBD, unilateral laminotomy bilateral decompression|Minimally invasive ULBD for lumbar spinal stenosis
3150958|NCT00215293|Active Comparator|Graft Spacer|Autograft or allograft with a plate, or autograft alone.
3150959|NCT00215306|Experimental|Lumbar TDR|CHARITÉ Artificial Disc
2439380|NCT03302481|Experimental|Experimental Group|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
2512843|NCT02811822|Experimental|Dose 2|
3150960|NCT00215306|Active Comparator|ALIF|Anterior Interbody Fusion with BAK Cage
3150961|NCT00215319|Experimental|TSM Cage|Lumbar I/F with cage and pedicle screws
3150962|NCT00215332||Training- CHARITE|Non-Randomized Training (TDR with CHARITE)
3150963|NCT00215332||CHARITE|Randomized Subjects treated by Lumbar Total Disc Replacment with CHARITE
3150964|NCT00215332||Control|Randomized Subjects treated by ALIF with BAK cage
3150965|NCT00215501|Experimental|Group A|Oral capecitabine
2439382|NCT03302455|No Intervention|Control|This group does not receive any interventions during first 3 months of clinical study. If the participants still have no remission from insomnia after 3 months, will be recommended to enter the standardized insomnia treatment (medication and / or non-drug treatment).
2439383|NCT03302429|Experimental|PRF/ BCP|"Biphasic calcium phosphate (BCP)bioceramic bone substitute combined with platelet rich fibrin PRF"
2439384|NCT03302429|Active Comparator|autogenous bone graft|Autogenous bone graft involving utilizing bone obtained from the same individual receiving the graft
3189245|NCT00775775||TBI|Patients with moderate to severe TBI
2439386|NCT03302403|Experimental|CAR T cell|"In this study, autologous T cells transduced with a chimeric antigen receptor are used to treat patients with malignant tumors:~CAR-CD19 T cell is for the treatment of B-cell Leukaemia/Lymphoma; CAR-BCMA T cell is for the treatment of Myeloma; CAR-GPC3 T cell is for the treatment of Hepatocellular Carcinoma; CAR-CLD18 T cell is for the treatment of Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction.~Route of administration: Intravenous injection.~Lymphodepletion conditioning:~Lymphodepletion will be conducted several days prior to CAR T cell infusion, which may improve in vivo cell count and survival of T cells.~A combination of fludarabine and cyclophosphamide will be used for lymphodepletion."
2439387|NCT03302390||Biopsy of Skin with Psoriasis|Shave biopsy of psoriasis lesion
2439388|NCT03302377|Experimental|Physical activity intervention|Participants will receive an individual counseling session in the clinic to help them set physical activity and step goals. They will then receive a Fitbit wrist monitor and help personalizing the Fitbit app. They will send weekly emails to their physicians reporting their goals and current activity. They will return at 12 weeks to engage in a semi-structured interview to give their overall impressions of the intervention.
2439389|NCT03302364||risperidone patients|patients that are in accordance with DSM-IV-TR schizophrenia diagnostic criteria, based on concise International Neuropsychological Interview(MINI)
2439390|NCT03302351|Experimental|Dexmedetomidine|1st group will include 30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
2439391|NCT03302351|Experimental|Ketamine|2nd group will include 31 patients will receive intravenous ketamine 0.4 mg/kg.
2439392|NCT03302351|Experimental|Dexmetedomidine-Ketamine combination|3rd group will include 33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg and low dose ketamine 0.25mg/kg.
2439393|NCT03302338|Experimental|SAFE group|SAFE group: simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
2439394|NCT03302338|Placebo Comparator|Placebo|Placebo group: distilled water 2.5 ml/kg every 3 hours enterally given.
2439395|NCT03302325||Stage IV solid tumors|adult patients with stage IV cancer that are starting a new line of treatment
2439396|NCT03302312||Participants|Service members who received at least one SGB study procedure as part of the clinical effectiveness trial during the three months prior to qualitative data collection or service members who received at least one SGB for PTSD symptoms at a study site in the three months prior to qualitative data collection.
2439397|NCT03302312||Providers|Behavioral Health or other (e.g., Family Medicine) clinicians who have referred or could potentially have referred service members for SGB for PTSD symptoms, as well as physicians who provide SGBs.
2439398|NCT03302299|Experimental|Isoniazid & pyridoxine|Isoniazid 300 mg oral tablet: 300 mg daily by mouth for 6 months. Pyridoxine 25 mg oral tablet: 25mg daily by mouth for 6 months.
2439399|NCT03302286|Active Comparator|Mannitol Prime|This group will undergo cardiac surgery with heart-lung machine with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
2439400|NCT03302286|Active Comparator|NonMannitol Prime|This group will receive a priming solution of Ringer´s acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
2439401|NCT03302273|Experimental|Corneal Epithelial Stem Cell Transplant|The treatment will consist of transplantation (via self-administration) of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material four times daily in both eyes for a three month interval.
2439402|NCT03302260|No Intervention|Control|Participants in the control arm will receive standard postpartum clinical care through the participants' usual healthcare providers. No intervention will be administered. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
2439403|NCT03302260|Experimental|CardioPrevent® Program|In addition to standard care, participants randomized to the intervention arm will also receive the CardioPrevent® Program. This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context. Participants in both arms will receive educational material about the risk of CVD, and CVD prevention for women with HDP from the Preeclampsia Foundation.
3189246|NCT00775788|Experimental|Implant Failure|
3189247|NCT00775788|Experimental|Post mastectomy breast reconstruction|
3189248|NCT00775788|Experimental|Congenital malformations|
2439407|NCT03302221|Other|Group control|In the control group, local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
2439408|NCT03302221|Experimental|Paravertebral Block Group|In Group Paravertebral Block, patients received standardized general anaesthesia supplemented by paravertebral Block. The USG approach for TPVB was used with the patient in the lateral position at the T4-T6 level according to the incision protocol in our centre.
2439409|NCT03302221|Experimental|Epidural Block Group|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography ;general anesthesia combined with epidural block
2439410|NCT03302208|Active Comparator|pregabalin group|
2439411|NCT03302208|Placebo Comparator|placebo group|
3189249|NCT00775788|Experimental|Breast Ptosis|
3189250|NCT00775788|Experimental|Micromastia|
3189251|NCT00775788|Experimental|Asymmetric Breasts|
3189252|NCT00775801|Experimental|Treatment|FLD
3189253|NCT00775801|Active Comparator|Control|
3189254|NCT00775814|Experimental|Candesartan + Hydrochlorothiazide QD|
3189255|NCT00775814|Active Comparator|Hydrochlorothiazide QD|
2439412|NCT03302195|Active Comparator|Control group|"Heparin dose and cardiopulmonary bypass pump flow rate are calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2439413|NCT03302195|Experimental|Intervention group A|"Heparin dose is adjusted for lean body weight and cardiopulmonary bypass pump flow rate is calculated using total body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2439414|NCT03302195|Experimental|Intervention group B|"Heparin dose is calculated using total body weight and cardiopulmonary bypass pump flow rate is adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2439415|NCT03302195|Experimental|Intervention group C|"Heparin dose and cardiopulmonary bypass pump flow rate are adjusted for lean body weight.~An initial 400 IU/Kg Heparin dose will be administered, with an additional dose of 75 IU/kg if the activated clotting time remains below the 425 seconds target value. The cardiopulmonary bypass pump flow rate of 2.4 L/min/m2 of body surface area will be calculated."
2439416|NCT03302182|Experimental|fasting group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fasting condition.~For group1:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group2:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
2439417|NCT03302182|Experimental|Fed group|"During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg or NORVIR tablet 100mg under fed condition.~For group3:~cycle 1:Ritonavir Tablet 100mg cycle 2:NORVIR tablet 100mg~For group4:~cycle 1:NORVIR tablet 100mg cycle 2:Ritonavir Tablet 100mg"
2439418|NCT03302169|Experimental|Posterior Rhabdosphincter Reconstruction|Patients in who posterior rhabdosphincter reconstruction is performed
2439419|NCT03302169|Active Comparator|Standard Technique|Patients in who posterior rhabdosphincter reconstruction is NOT performed, Standard technique.
2439420|NCT03302156|Other|Healthy Control Non-Dosimetry Group|The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6
2439421|NCT03302156|Other|Patient Group|The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40
2439422|NCT03302156|Other|Dosimetry Group|Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6
2439423|NCT03302143|Active Comparator|Control|Guided bone regeneration with Bovine Bone Mineral
2439424|NCT03302143|Experimental|Experimental|Guided bone regeneration with freeze dried bone allograft
2439425|NCT03302130|Experimental|Imaging healthy volunteers|Mood induction: positive, negative, neutral mood (using subjects own memories) Arterial spin labeling MRI Physiological monitoring
3189256|NCT00775827|Experimental|1|fenofibrate 160 mg tablets of Ranbaxy Laboratories
3189257|NCT00775827|Active Comparator|2|Tricor 160 mg tablets
2439428|NCT03302078|Experimental|Treatment T|Fed state
2439429|NCT03302078|Experimental|Treatment R|Fasted state
2439430|NCT03302065|Experimental|Test Product 1 Tiotropium|4 inhalations
2439431|NCT03302065|Experimental|Test Product 2 Tiotropium|4 inhalations
2439432|NCT03302065|Experimental|Test Product 3 Tiotropium|4 inhalations
2439433|NCT03302065|Active Comparator|Reference Tiotropium|2 inhalations
2439434|NCT03302039|Experimental|Single shot|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered.
2439435|NCT03302039|Active Comparator|Fixed infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred.
2439436|NCT03302039|Active Comparator|Variable infusion|Spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure.
2439437|NCT03302026|Experimental|Real-time neurofeedback training group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In this arm, participants will complete four sessions: an intake session and 3 neurofeedback scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
2439438|NCT03302026|No Intervention|No-feedback control group|We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. In the control group arm, participants will complete four sessions: an intake session and 3 scanning visits with no neurofeeback. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm. Secondary outcomes include changes in brain activity in areas related to craving and self-control, and self-reported craving for cigarettes.
2439439|NCT03302013|Experimental|Vanguard XP Knee Replacement Surgery|Participants randomised in this group will receive the Vanguard XP Bi-cruciate Retaining Knee Replacement System. This total knee replacement device (Vanguard XP) and surgical procedure retain the anterior cruciate ligament in the knee.
2439440|NCT03302013|Active Comparator|Vanguard CR Knee Replacement Surgery|Participants randomised to this group will receive the Vanguard CR Single Cruciate Retaining Knee Replacement Surgery. This total knee replacement device (Vanguard CR) and surgical procedure sacrifice the anterior cruciate ligament and replaces it with artificial support. This is currently the standard practice for knee replacement surgery in the NHS.
2439947|NCT03298334|Active Comparator|Receives Vaginal Seeding|
2439441|NCT03302000|Experimental|Visual stimulation|"Early visual stimulation (EVS) will be implemented by caregivers.~Three phases:~the caregiver will establish eye-to-eye contact with the infant. The caregiver will communicate with the infant talking, singing, changing facial expressions, touching his/her face. Total duration of this part of stimulation is between 2 and 3 minutes~the caregivers will present visual contrast cards at a distance of 15-20 centimetres~the caregiver will present two toys to the infant~Stimulation will last for 28 days (4 weeks) in total, one time a day for 10-15 minutes, all days week."
2439442|NCT03302000|Other|standard care|Caregivers will receive an Illustrated Handbook, according to the age range of birth to three months. Assessors will explain all information contained in the handbook after the first assessment and randomisation.
2439443|NCT03301987|Experimental|Therapeutic exercise|
2439444|NCT03301974|Experimental|conjunctival autograft with fibrin glue|Conjunctival autograft with fibrin glue done for patients of group 1 after pterygium excision
2439445|NCT03301974|Experimental|sutured conjunctival autograft|Sutured conjunctival autograft done for patients of group 2 after pterygium excision
2439446|NCT03301974|Experimental|sutureless and glue-free conjunctival autograft|Sutureless, glue-free conjunctival autograft done for patients of group 3 after pterygium excision
2439447|NCT03301948|Experimental|Overfeed|Experimental trial where participants are provided with 50% higher energy intake than their estimated requirements on the first day of the trial.
2439448|NCT03301948|Experimental|Energy Balance|Experimental trial where participants are provided with an energy intake equal to their estimated requirements on the first day of the trial.
2439449|NCT03301922|Experimental|Work-focused metacognitive therapy|Work-focused metacognitive therapy
2439450|NCT03301922|Other|Waiting list|Waiting list
3150966|NCT00215501|Experimental|Group B|5-fluorouracil
3150967|NCT00215514|Experimental|ECF followed by 5-FU/RT followed by ECF|
3150968|NCT00215527|Experimental|intrathecal laronidase|laronidase dose 1.74 mg, route intrathecal, frequency every 30 days, duration three months
3150969|NCT00215605|Experimental|1|
2439455|NCT03301870|Experimental|ATx201 GEL, 2% - intact skin|ATx201 GEL, 2% applied intact skin
2439456|NCT03301870|Experimental|ATx201 GEL, 4% - intact skin|ATx201 GEL, 4% applied to intact skin
2439457|NCT03301870|Experimental|ATx201 GEL, 2% - abraded skin|ATx201 GEL, 2% applied to abraded skin
2439458|NCT03301870|Experimental|ATx201 GEL, 4% - abraded skin|ATx201 GEL, 4% applied to abraded skin
2439459|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - intact skin|ATx201 GEL Placebo applied to intact skin
2439460|NCT03301870|Placebo Comparator|ATx201 GEL Placebo - abraded skin|ATx201 GEL Placebo applied to abraded skin
2439461|NCT03301870|Active Comparator|Negative Irritant Control - intact skin|Negative (low) Irritant Control applied to intact skin
2439462|NCT03301870|Active Comparator|Negative Irritant Control - abraded skin|Negative (low) Irritant Control applied to abraded skin
2439463|NCT03301870|Active Comparator|Positive Irritant Control - intact skin|Positive (high) Irritant Control applied to intact skin
3150970|NCT00215618|Experimental|1|Uterine Balloon Therapy with post procedure curettage
3150971|NCT00215618|Experimental|2|Uterine Balloon Therapy without post-procedure curettage
2439470|NCT03301818|Experimental|Patients undergoing USI repair|
2439471|NCT03301805|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.
2439472|NCT03301792|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration.
3150972|NCT00215735|Experimental|APC Treatment|wound debridement and treatment with APC
3150973|NCT00215774|No Intervention|No antiarrhythmic treatment|Control group
3150974|NCT00215774|Experimental|B-Flecainide treatment|4 weeks treatment with flecainide
3150975|NCT00215774|Experimental|C-Flecainide treatment|6 months flecainide treatment
3150976|NCT00215826|Active Comparator|1|650 IU
3150977|NCT00215826|Active Comparator|2|1300 IU
3150978|NCT00215852|Active Comparator|1|500 IU
3150979|NCT00215852|Active Comparator|2|1000 IU
3150980|NCT00215852|Active Comparator|3|2000 IU
3150981|NCT00215878|Placebo Comparator|1|Adjuvant 6 weeks treatment with placebo (~2g /day)
3150982|NCT00215878|Experimental|2|Adjuvant 6 weeks treatment with D-serine (~2g /day)
3150983|NCT00215904|Placebo Comparator|1|
3150984|NCT00215904|Experimental|2|
3150985|NCT00215956|Experimental|Dose Escalation and Radiation, Followed by Surgery|Preoperative treatment with radiation and oral topotecan for up to 5 weeks, followed by surgery.
3150986|NCT00215982|Experimental|Combination Therapy|Capecitabine in Combination with Irinotecan and Oxaliplatin
3150987|NCT00215995|Experimental|Cisplatin, Irinotecan and ZD1839|As outlined in Detailed Description.
3150988|NCT00216021|Experimental|Single Group Assignment|Capecitabine + Oxaliplatin
3150989|NCT00216034|Active Comparator|1|TS-1 Group: The group treated with TS-1 mono-therapy
3150990|NCT00216034|Experimental|2|TS-1+PSK Group: The group treated with combination therapy using TS-1 and PSK
3150991|NCT00216047|Experimental|Single Group Assignment|Trastuzumab + PTK787 for HER2 positive patients
2439473|NCT03301792|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a six session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 2-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by a health educator and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
3189258|NCT00775840|Experimental|Candesartan QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
3189259|NCT00775840|Placebo Comparator|Placebo QD + Heart Failure Therapy|(with angiotensin-converting enzyme-inhibitors/beta-blockers)
2439476|NCT03301766|Experimental|Lidocaine 5% patch|"Patients will receive a 7 day supply (21 patches) of lidocaine 5% patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
2439477|NCT03301766|Active Comparator|Non-medicated patch|"Patients will receive a 7 day supply (21 patches) of non-medicated patches upon discharge from the emergency department in addition to standard therapy at the discretion of the treating emergency department physician."
3189261|NCT00775866|Experimental|MRI guided prostate biopsy|
2439480|NCT03301727|Active Comparator|In-person CBT-I Treatment|Participants receive 6 in-person weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
2439481|NCT03301727|Active Comparator|Online CBT-I Treatment|Participants receive 6 online weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
2439482|NCT03301727|Other|Wait-list Control|Participants are placed on a wait-list for 6 weeks before receiving either in-person or online 6 weekly 1.5-hour sessions of cognitive-behavioural therapy for insomnia (CBT-I) for pregnant women, supervised by a registered, licensed clinical psychologist.
3189262|NCT00775879|Experimental|A|2.5% target concentration
3189263|NCT00775879|Active Comparator|B|2.5% manually selected
3189264|NCT00775905|Experimental|1|amlodipine 10 mg tablets of Ranbaxy
2439486|NCT03301701|Experimental|Arm 1|Radical prostatectomy
2439487|NCT03301701|Active Comparator|Arm 2|Radiotherapy
2439488|NCT03301688|Experimental|A group (JS001 20161002)|The subjects of A group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161002.
2439489|NCT03301688|Experimental|B group (JS001 20161108)|The subjects of B group will use 3 mg/kg doses every 2 weeks.Drug batch number is 20161108.
2439490|NCT03301675|Experimental|Orange juice|Orange Juice: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) plus 100% orange juice (500 mL/d) during 12 weeks.
2439491|NCT03301675|No Intervention|Control|Control: Thirty-eight individuals with MetS were submitted to a healthy diet (energy was based on individual actual weight) during 12 weeks.
3189265|NCT00775905|Active Comparator|2|Norvasc® 10 mg tablets
3189266|NCT00775918|Experimental|1|Doxycycline monohydrate 100mg tablets of Ranbaxy
3189267|NCT00775918|Active Comparator|2|Adoxa ® 100 mg tablets of Bradley Pharmaceuticals Inc
2439495|NCT03301636|Experimental|Pembrolizumab + Indoximiod|
2439496|NCT03301636|Experimental|Nivolumab + Indoximiod|
2439581|NCT03301090|Experimental|Cohort B|REGN3048+REGN3051 10 mg/kg (5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
3189268|NCT00775957||1|FLT-PET Scan
3189269|NCT00775957||2|FDG-PET Scan
3189270|NCT00775996|Experimental|1|15 mg clorazepate dipotassium tablets of ranbaxy
3189271|NCT00775996|Active Comparator|2|(TranxeneeT-Tab®) 15 mg clorazepate dipotassium tablets
3189272|NCT00776022|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
3189273|NCT00776022|Active Comparator|2|Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
3189274|NCT00776035||heart failure|Obesity related Heart failure population
3189275|NCT00776048||ABI|Acquired brain injury with lower limb spasticity
3189276|NCT00776048||Healthy Controls|Age matched healthy controls
3189277|NCT00776074|Experimental|Leuprorelin (GF)|
3189278|NCT00776074|Experimental|Leuprorelin (GC)|
3189279|NCT00776087|Experimental|1 = Home Monitoring|Remote monitoring of ICD and CRT-D function and patient status
3189280|NCT00776087|Active Comparator|2 = No Home Monitoring|Home Monitoring option is switched off
3189281|NCT00776113|Active Comparator|2|Carvedilol 12.5 mg tablets
3189282|NCT00776113|Experimental|1|Carvedilol 12.5 mg tablets
3189283|NCT00776126||1|All enrolled subjects will undergo digital breast tomosynthesis.
3189284|NCT00776139|Experimental|1|Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc.
3189285|NCT00776139|Experimental|2|Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs
3189286|NCT00776165|Experimental|1|Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)(Shantha) Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
3189287|NCT00776165|Active Comparator|2|Neupogen (rhG-CSF) Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
3189288|NCT00776191|Active Comparator|Physioneal 35 vs. 40|Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks, followed by Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks.
3189289|NCT00776191|Active Comparator|Physioneal 40 vs. 35|Physioneal 40® Glucose solution Bicarbonate 25 mmol/l, Lactate 15 mmol/l, and Calcium 1.25 mmol/l for eight weeks followed by Physioneal 35® Glucose solution with Bicarbonate 25 mmol/l, Lactate 10 mmol/l, and Calcium 1.75 mmol/l for eight weeks
3189290|NCT00776204|Active Comparator|1|Drug Eluting Stent
3189291|NCT00776204|Active Comparator|2|Drug Eluting Stent
3150992|NCT00216073|Active Comparator|1|Capecitabine + Oxaliplatin + trastuzumab. Patients must be HER2 positive.
3150993|NCT00216112|Experimental|Investigational Treatment|Imatinib Mesylate + Docetaxel
2439499|NCT03301610|Experimental|Mobile Education Delivery|The participants in the study arm will receive comprehensive pain management education delivered using mobile iPads at the point of care. The mobile based education modules will be inclusive of the use of the pain rating scale and assessment of pain; communication with healthcare providers; daily expectations for pain and pain management; pharmacologic and non-pharmacologic treatment options; medication side effects and safety; and discharge instructions including safe handling of opioids, disposal, tapering, and when to call the provider. It will also include an interactive pain and discomfort menu, knowledge based questions, and medication tracking log.
2439500|NCT03301610|Placebo Comparator|Standard verbal and written education|The control group will receive the current standard of care which consists of verbal instruction and pain management educational pamphlets. At a minimum, the patients will receive two educational pamphlets titled Your Pain and Discomfort Management Menu and Communicating About Your Pain. Verbal instruction is nurse dependent. At a minimum the nurse will provide the two pamphlets to the patient and follow-up with the patient to address any questions.
2439501|NCT03301597|Other|Control Arm|The Control Arm will receive standard of care (SOC) chemotherapy without the infusion of NLA101. SOC chemotherapy will be determined by local PI and must be a standard regimen for untreated de novo or secondary AML that will result in moderate to severe myelosuppression and will be given with curative intent.
2439502|NCT03301597|Experimental|Low Dose Arm|The Low Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of low-dose NLA101.
2439503|NCT03301597|Experimental|Medium Dose Arm|The Medium Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of medium-dose NLA101.
2439504|NCT03301597|Experimental|High Dose Arm|The High Dose Arm will receive standard of care (SOC) chemotherapy with the infusion of high-dose NLA101.
2439505|NCT03301584|Active Comparator|Enhanced collaboration|"Enhanced OT and PT collaboration to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
2439506|NCT03301584|Active Comparator|Usual Care Treatment|Standard rehabilitation
2439507|NCT03301571|Other|All patients|"All patients will receive the treatment (CABG) and postoperatively three different interventions:~Change in preload and afterload~Change in inspired oxygen~Change in pacemaker modes"
2439508|NCT03301558|Active Comparator|Low dose sodium bicarbonate|Low dose 1500 mg sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take one capsule with breakfast, one with lunch and one with dinner (schedule 1-1-1).
2439509|NCT03301558|Active Comparator|High Dose sodium bicarbonate|High dose 3000 mg of sodium bicarbonate (Nephrotrans®) per day (500mg tablets 3x/day) for 14 ± 3 days. The patients will be advised to take two capsules with breakfast, two with lunch and two with dinner (schedule 2-2-2).
2439510|NCT03301545|Active Comparator|Fast-Track to Bariatric Surgery|Patients will undergo standard of care for bariatric surgery patients in Manitoba and receive preoperative evaluation by the Centre for Metabolic and Bariatric Surgery (CMBS) team of nurses, dietitians, psychologist, and kinesiologist. Patients must attend the standard appointments and achieve the personalized program goals to be approved for laparoscopic Roux-En-Y gastric bypass surgery. Once approved, one of four surgeons performs surgery (within 12 months of randomization). Patients are followed post-operatively (by surgeon) at 6 weeks, and at 6 and 12 months. Pharmacologic glycemic control will be determined by an endocrinologist as per a standardized post-operative protocol. Post-procedural multidisciplinary follow-up occurs based on established CMBS guidelines (phone call 1 week post-operatively and an appointment at 3 and 12 months). Patients receive surgery within the current publically funded bariatric surgery program; no additional direct costs incurred by the patients.
2439511|NCT03301545|No Intervention|Best Diabetic Care Group|Patients will receive the best available medical practice for the treatment, education, and follow-up T2DM based on Manitoba Diabetes Care Recommendations and Diabetes Canada's clinical practice guidelines. Patients will have access to a general physician, endocrinologist, and a diabetes education nurse. An Endocrinologist will deliver the program to patients. Diabetes care, education and self-management support services will be provided by the Victoria General Hospital (VGH) Diabetes Education Centre; led by a registered nurse and dietitian. Patients will undergo individual diabetes management instruction which may include counseling on topics such as diet, exercise, smoking cessation, medications, diabetic complications, and blood sugar testing. Medical therapies, including pharmaceutical agents, will be determined on an individual basis as per standard protocol. There will be no direct patient-related medication costs (publicly funded).
2439512|NCT03301545|No Intervention|Retrospective Cohort|A retrospective cohort of non-Indigenous bariatric surgery patients from the Centre for Metabolic and Bariatric Surgery Program will allow comparison with the intervention group. The cohort will be age and gender matched.
3150994|NCT00216138|Active Comparator|1|Docetaxel + Capecitabine
3150995|NCT00216151|Active Comparator|A|Patients will be randomly assigned by study number to receive 4mg of zoledronic acid every three months.
2439516|NCT03301480||No contraception/18-19 years old|
2439517|NCT03301480||Use of ENG-I/18 - 19 years old|
2439518|NCT03301480||LNG-IUS/18-19 years old|
2439519|NCT03301480||No Contraception/ 25 - 45 years old|
2439520|NCT03301480||Use of ENG-I/25 - 45 years old|
2439521|NCT03301480||LNG-IUS/25-45 years old|
3150996|NCT00216151|No Intervention|B|Patients will be randomly assigned by study number to observation only.
3189292|NCT00776204|Active Comparator|3|Drug Eluting Stent
3150997|NCT00216164|Experimental|1|Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2439524|NCT03301454|Experimental|Arm A|Pursuit of chemotherapy.
2439525|NCT03301454|No Intervention|Arm B|Interruption of chemotherapy, best supportive care
2439528|NCT03301428|Experimental|Retrain pain educational website|Participants will be invited to consult an educational website developped for patients with chronic pain
2439529|NCT03301428|Experimental|Booklet|Participants will be invited to read an educational booklet for patients with chronic pain
2439530|NCT03301428|No Intervention|Control|Participants in this group will receive the 2 educational tools at the end of the study
3150998|NCT00216190|Experimental|Dexmedetomidine|
2439532|NCT03301402|Active Comparator|Filter|
2439533|NCT03301402|No Intervention|No filter|
2439534|NCT03301389||Control group|
2439535|NCT03301389||Pretreatment group|Patients in pretreatment state
2439536|NCT03301389||Anthracycline-based chemotherapy (3 months)|Patients who received anthracycline-based chemotherapy 3 months ago
2439537|NCT03301389||Anthracycline-based chemotherapy (6 months)|Patients who received anthracycline-based chemotherapy 6 months ago
2439538|NCT03301389||Anthracycline-based chemotherapy (more than 1 year ago)|Patients who received anthracycline-based chemotherapy more than 1 year ago
2439539|NCT03301389||Other therapy group|Patients who have been treated with other therapies (other chemo-therapies, combined radiation therapy, target agent therapy, hormone therapy)
2439540|NCT03301350|Experimental|Neoadjuvant Chemotherapy|"Regimen A (cycles 1-4):~Paclitaxel 80 mg/m2; administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks) Carboplatin AUC=2 (dose calculation by determining creatine clearance with Cockroft Gault using adjusted body weight); administer intravenously on day 1, 8, 15 of cycles 1, 2, 3, 4 (every 3 weeks)~Regimen B (cycles 5-8):~Doxorubicin 60 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Cyclophosphamide 600 mg/m2; administer intravenously on day 1 of cycles 5, 6, 7, 8 (every 2 weeks) Pegfilgrastim (for use on Doxorubicin/Cyclophosphamide cycles only), filgrastim, or biosimilar support on day 2 - 3 of cycles 5, 6, 7, 8 (every 2 weeks)~There is a one week break between the end of cycle 4 and the beginning of cycle 5.~Regimen C:~Surgical intervention for management of breast cancer diagnosis; procedure and timing as determined by surgical team."
2439541|NCT03301337|Experimental|Hydrolyzed meat protein|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2439542|NCT03301337|Experimental|Minced Meat|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2439543|NCT03301337|Experimental|Beef|D5-phenylalanine intrinsically labelled hydrolyzed meat protein (0.6 g per kg lean body mass), which will be consumed together with a full meal.
2439544|NCT03301311|Experimental|Specific Carbohydrate Diet (First)|Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.
2439545|NCT03301311|Experimental|Modified Specific Carbohydrate Diet (First)|Participants will be following a modified Specific Carbohydrate Diet (MSCD). In addition to the foods in the SCD, allowed foods will expand to include organic rice, oats, sweet potatoes, grade A maple syrup and cocoa. Gluten, corn products, milk products (except yogurt and hard cheeses), sweeteners (except honey), and process foods are still restricted.
2439553|NCT03301285||Children with osteoporosis associated to multiple disabilities|Treated with zoledronic acid
2439556|NCT03301259|Experimental|wave -one reciprocating system|"The reciprocating single file systems WaveOne (Maillefer, Ballaigues, Switzerland) provide more flexibility of the M-wire Ni-Ti alloy, greater resistance to cyclic fatigue and better handling of narrow and curved canals than the traditional Ni-Ti instruments Root canal preparation will be done with theWaveOne System with strict adherence to the manufacturer's instructions. After coronal preflaring with File ISO 21 taper 8% instrument with 2.5% sodium hypochlorite as the irrigant, working length was determined and a glide path will created.~The Red file R 25 taper 8% will be used for preparing the mesial canal; and the Black ISO 40 taper 8% file will be used for preparing the distal canals where there is only a single canal."
2439582|NCT03301090|Experimental|Cohort C|REGN3048+REGN3051 30 mg/kg (15 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
3150999|NCT00216190|Active Comparator|Midazolam|
3151000|NCT00216216|Active Comparator|1|Pemetrexed for patients with chemosensitive and chemoresistant relapsed small cell lung cancer.
3151001|NCT00216255|Experimental|Pagoclone|.15mg, .30mg, .60mg
3151002|NCT00216255|Placebo Comparator|Placebo|Placebo
3151003|NCT00216281|Active Comparator|clozapine with AZT added|Clozapine augmented with Atomoxitine up to 40mg
3151004|NCT00216281|Placebo Comparator|placebo|Subjects will have a placebo pill added to their clozapine regimen.
3151005|NCT00216372|Experimental|1|
3151006|NCT00216372|Placebo Comparator|2|
3151007|NCT00216411|Experimental|Dysport|
3151008|NCT00216411|Placebo Comparator|Placebo|
3151009|NCT00216463|Experimental|A|Slow load with every other week maintenance
3151010|NCT00216463|Experimental|B|Slow load with every other week maintenance
3151011|NCT00216463|Experimental|C|No load; once weekly maintenance
3151012|NCT00216463|Experimental|D|No load; once weekly maintenance
3151013|NCT00216463|Experimental|E|No load; once weekly maintenance
2439557|NCT03301259|Experimental|OneShape|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
2439558|NCT03301246|Experimental|Artimes Pro Low Profile Dilatation Catheter|Subjects who require initial pre-dilatation using the study device, and then undergo definitive therapy using additional PTCA catheters and stents, according to standard of care will be enrolled in this study.
2439559|NCT03301233|Active Comparator|estradiol valerate|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma). One tablet every 12 hour from 2nd day of the cycle till the day of trigger of ovulation).
2439560|NCT03301233|Experimental|estradiol valerate and sildenafil|oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25 mg, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
3151014|NCT00216580|Experimental|Risperidone, long-acting injectable|
3151015|NCT00216619|Experimental|Open Label Phase|Topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening. Until Week 26
2439563|NCT03301207|Experimental|Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)|Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).
2439564|NCT03301194||RAMP-HT patients|HT patients who have enrolled into the RAMP-HT between 1 October 2011 and 31 March 2012 and fulfilled the inclusion criteria and without any exclusion criteria
2439565|NCT03301194||Usual care patients|HT patients receiving usual care in GOPCs who have never enrolled into RAMP-HT on or before 31 March 2017 and fulfilled the inclusion criteria and without any exclusion criteria
2439566|NCT03301181|Experimental|Arm A|Approximately 20 subjects to receive BGB-3111 and rifampin
2439567|NCT03301181|Experimental|Arm B|Approximately 20 subjects to receive BGB-3111 and itraconazole
2439568|NCT03301168|Experimental|BPX-501 T cells and Rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.~Rimiducid: Dimerizer drug administered to subjects who present with Grade I-IV acute GVHD with inadequate response to steroids within 48 hours of treatment or mild to severe chronic GVHD with inadequate response to steroids within 7 days of treatment."
3189293|NCT00776217|Experimental|1|loratadine 10 mg orally disintegrating tablets
2439571|NCT03301142|Experimental|Device laser|treatment with application of Erbium Laser: YAG 2940nm, SMOOTH mode, one session per month for three months (n=20
2439572|NCT03301142|Active Comparator|kinesiotherapy|with supervision twice a week for three months (n=20)
2439573|NCT03301129|Experimental|Traditional cigarette|smoke one Traditional cigarette (with a mean nicotine content of 0.6 mg according to package label) and in a sub-group smoke a sham cigarette (an traditional cigarette without combustion).
2439574|NCT03301129|Experimental|Electronic cigarette|smoke a tobacco-flavored Electronic cigarette (9 puffs approximately equivalent to 0.6 mg of nicotine content) and in a sub-group smoke a sham cigarette (an electronic cigarette without nicotine).
2439575|NCT03301129|Experimental|Heat-not-burn tobacco products (IQOS)|smoke one IQOS cigarette (with a mean nicotine content of 0.6 mg according to package label).
2439576|NCT03301116|Experimental|Healthy Moves|Home care aides (HCAs) will be trained to deliver Healthy Moves for Aging Well (Healthy Moves), a gentle physical activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the three chair-bound moves. Home care clients will be asked to do the three moves every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
2439577|NCT03301116|Active Comparator|Active Mind|Home care aides (HCAs) will be trained to deliver Active Mind for Aging Well (Active Mind), a gentle thinking activity program, to their clients. On the first home care visit after the training, HCAs will introduce the program, assess their clients' readiness for the activity and have their clients set personally meaningful goals, and teach the activity. Home care clients will be asked to do a word search puzzle every day. HCAs remind clients of their activity as part of their regular home care visits throughout the 4-month intervention period.
2439578|NCT03301103|Placebo Comparator|Placebo|"The placebo will consist of low-lactose isonitrogenous soy product, and will be matched in appearance and flavour to PTM202.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
2439579|NCT03301103|Experimental|PTM202|"PTM202 is a dry powder for reconstitution, comprised of a proprietary mixture of dried bovine colostrum and dried whole egg.~After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14)."
2439580|NCT03301090|Experimental|Cohort A|REGN3048+REGN3051 3 mg/kg (1.5 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2439948|NCT03298334|Sham Comparator|No Vaginal Seeding|
3151016|NCT00216619|Experimental|Double Blind and Roll Out Phase|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26).
3151017|NCT00216710|Experimental|Home Visited Mothers|Mothers randomized to the home visited group received AK State-funded home visiting services. Frequency of home visits was determined by home visiting staff based on mothers' needs. Mothers could receive home visiting services until their child turned 3 years old
2439583|NCT03301090|Experimental|Cohort D|REGN3048+REGN3051 50 mg/kg (25 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2439584|NCT03301090|Experimental|Cohort E|REGN3048+REGN3051 100 mg/kg (50 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2439585|NCT03301090|Experimental|Cohort F|REGN3048+REGN3051 150 mg/kg (75 mg/kg of each mAb) single infusion IV, n=6; placebo IV, n=2
2439586|NCT03301077||General population|recruited from schools and other institutions like job-centers or child and adolescent psychiatries
2439587|NCT03301064|Experimental|Intervention Condition: MET/SBCM|The combined Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM) intervention will be used in the proposed study. The intervention consists of three 1-hour sessions. The sessions are structured to provide feedback to participants about their risks associated with alcohol use and to help them identify barriers and motivators to change. The sessions will aim to reduce drinking by promoting self-efficacy to change, setting goals and fostering utilization of medical, mental health and social services as needed. A comprehensive list of referrals will be provided. Sessions will occur 1-2 weeks apart.
2439588|NCT03301064|Active Comparator|Control Condition: Alcohol education brochure|Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
2439589|NCT03301051|Experimental|Quadrivalent VLP Vaccine|Single dose - 30 µg/strain of Quadrivalent VLP Vaccine
2439590|NCT03301051|Placebo Comparator|Placebo|Single dose - Placebo
2439591|NCT03301038|Experimental|All Subjects|
2439592|NCT03301025|Active Comparator|Pregabalin group|(n=53):
2439593|NCT03301025|Placebo Comparator|placebo group|(n=53):
2439594|NCT03301012|Active Comparator|Recovery Support as Usual Control|Participants in the control and experimental condition will have access to post treatment recovery support services as usual.
2439595|NCT03301012|Experimental|Smartphone Addiction Recovery Coach (SARC) - Assisted Relapse Prevention|Participants in the experimental condition will receive a smartphone, a calling/texting/data plan, and the SARC-YA mobile applications for the first 6 months post treatment discharge. Experimental participants will 1) complete a 2-3 minute recovery-focused ecological momentary assessment (EMA) at 5 random times a day, receive feedback on their current answers, and provided access to behavioral charting of their past answers over time; and 2) receive continuous access to a suite of self-initiated ecological momentary interventions (EMI) to support their recovery via tool box of coping tools, apps related to getting support, and apps related to maintaining a healthy lifestyle.
2439596|NCT03300999|Experimental|Ginger Tea|"End of the second menstruation cycle - Start of the third menstruation cycle: Subjects will take ginger tea daily, avoid home remedies, refrain from taking pain medications and supplements, and keep track of ginger tea intake by placing a check mark each day in the daily log checklist.~Start of the third menstruation cycle - End of the third menstruation cycle: Subjects will drink ginger tea daily. Subjects will rate discomfort using the visual analog pain scales and the symptom checklist at the end of each day during menstruation.~After the third menstruation cycle ends: Subjects will meet with student investigators at a location convenient to the subject to turn in daily logs, visual analog pain scales, and symptom checklists."
2439597|NCT03300999|No Intervention|No Ginger Tea|"End of the first menstruation cycle - Start of the second menstruation cycle: Subjects will not take ginger tea, avoid home remedies, and refrain from taking pain medications or supplements.~Start of the second menstruation cycle - End of the second menstruation cycle: Subjects will rate discomfort using the visual analog pain scales and symptom checklist during menstruation. Subjects will meet with student investigators at a convenient location to the subject and will complete surveys and questionnaires. Subjects will be given daily logs, visual analog pain scales, symptom checklists, and supplies for the ginger tea."
2439598|NCT03300986||Functional Electrical Stimulation (FES) users|
2439599|NCT03300973|Active Comparator|urodynamics study group|65 patients with stress urinary incontinence were randomly chosen to have urodynamic study before surgery
2439600|NCT03300973|Active Comparator|surgery only group|60 patients with stress urinary incontinence were randomly chosen to have surgery without urodynamics study
2439601|NCT03300960|Experimental|Provera|
2439602|NCT03300960|Active Comparator|Orgalutrán Ganirelix (GnRH antagonist)|
2439603|NCT03300947|Experimental|High-dose Psilocybin|Psilocybin 300 mcg/kg once per week, every week, for 8 weeks
2439604|NCT03300947|Experimental|High- or Low-dose Psilocybin|Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks
2439605|NCT03300947|Placebo Comparator|High-dose Psilocybin or Lorazepam|Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks
2439606|NCT03300934|Experimental|closed loop glucose control system|Closed loop glucose control system
2439607|NCT03300934|No Intervention|CSII Pump treatment|CSII Pump treatment without the integrated algorithm and glucose sensor
2439608|NCT03300921|Experimental|Arm A|Arm A: 50mcg IV weekly
2439609|NCT03300921|Experimental|Arm B|Arm B: 12mcg PO daily
2439610|NCT03300908|Experimental|Project ADHERE|Participants will receive a 3-session antiretroviral medication adherence and risk reduction intervention called Project ADHERE.
2439611|NCT03300908|Active Comparator|Control MACE|Participants will receive a one-session antiretroviral medication adherence intervention called MACE.
2439612|NCT03300895|Experimental|High-intensity interval training|
2439613|NCT03300895|Active Comparator|Moderate-intensity continuous exercise|
2439614|NCT03300882||CMV+ First Lung Transplant Recipients|Participants enrolled in one of four North American sites in clinical research study CTOT-20 (Clinical Trials.gov ID: NCT02631720) who are cytomegalovirus positive by serology (e.g., CMV Recipient positive).
2439615|NCT03300856||Chart Review|Existing records of patients within the NINDS database who have had TMS performed to measure central motor conduction time (CMCT).
3189294|NCT00776217|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
2440830|NCT03292120|Experimental|patients with septic shock|
3189295|NCT00776243||wDM|Early diabetes
3189296|NCT00776243||pDM|Poorly controlled diabetic patients
2439619|NCT03300804|Active Comparator|20-herb formulation|Active herb
2439620|NCT03300804|Placebo Comparator|Placebo|Placebo herb formulation
2439621|NCT03300791||Admitted|We will include patients who had beeb admitted by an acute heart failure in hospitalization ward
2439622|NCT03300778|Experimental|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
2439623|NCT03300778|Placebo Comparator|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
2439624|NCT03300765|Experimental|Apatinib with IMRT|Participants will receive apatinib (0.5g, daily) for two cycles followed by intensity modulated radiation therapy (Primary site and lymph nodes: 66 Gy/33F, metastatic site: 40-60Gy/20-30F)
3189297|NCT00776256|Active Comparator|1|effect of beta-glucan
3189298|NCT00776256|Active Comparator|2|effect of fructo-oligosaccharide
2439627|NCT03300726||MCI due to AD or mild AD dementia|The clinical diagnoses of amnestic MCI due to AD or mild AD dementia will be made according to standard clinical criteria as described by the National Institute of Aging -Alzheimer's Association Working Group and supported by CSF biomarker data for tau, p-tau181, and Aβ42. This includes evaluation for other systemic or neurological disorders which could account for the cognitive impairment, and inclusion of results from ancillary structural imaging (CT or structural MRI), neuro-psychometric testing, and FDG-PET imaging (when available) into the diagnostic scheme. All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
2439628|NCT03300726||Normal controls|Normal cognition will be defined as cognitive performance on detailed neuropsychometric testing that falls within 1 SD of age-, gender-, and education-matched norms in all cognitive domains, and no subjective report of cognitive decline from an individual's baseline (i.e. CDR 0). All participants in this group will undergo clinical and cognitive evaluations, CSF analysis, and functional MRI during resting state and semantic memory tasks.
2439629|NCT03300713|Experimental|F+ group (Mocitraining program)|including 8 pediatricians' clusters. F+ pediatricians will attend a specific training focused on mother-child interactions, maternal psychiatric disorders, particularly PND screening and early interventions for non-psychiatric physician.
2439630|NCT03300713|Sham Comparator|F- group (usual follow-up)|grouping 8 pediatricians' clusters. They will not receive the initial training on early interactional disorders and PND screening
2439631|NCT03300687|Active Comparator|Active|Subjects will receive FX-322 as an intratympanic injection
2439632|NCT03300687|Placebo Comparator|Placebo|Subjects will receive Placebo as an intratympanic injection
3189299|NCT00776256|Active Comparator|3|effect of beta-glucan and fructooligosaccharide
3189300|NCT00776256|Placebo Comparator|4|no beta-glucan nor fructooligosaccharide
2439635|NCT03300661|Experimental|Mediterranean Style|Educational intervention with personalized suggestions to improve diet and physical activity
2439636|NCT03300648|No Intervention|Unual care|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees
2439637|NCT03300648|Experimental|Mechanical ventilation|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intubation and mechanical ventilation for a maximum of 7 days
2439638|NCT03300648|Experimental|Hypertonic saline|Hospitalization in a high dependency pediatric unit with skilled nursing, intravenous artesunate followed by oral artemisinin combination therapy, intravenous fluids, nasogastric feeding, elevation of the head of the bed by 30 degrees, along with intravenous 3% hypertonic saline for a maximum of 7 days
2439639|NCT03300635|Other|Fibromyalgia patients|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
2439640|NCT03300635|Other|Healthy controls|All study subjects, both patients and healthy controls, will attend all three interventions: Mental distress and relaxation test, Glucose tolerance test, and Exercise test
2439641|NCT03300609|Experimental|Arm I (panitumumab, leucovorin calcium, fluorouracil)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive panitumumab IV over 30 minutes, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
2439642|NCT03300609|Active Comparator|Arm II (capecitabine)|"INDUCTION Patients receive panitumumab IV over 30-60 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil over 46-48 hours on day 1. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE:~Patients receive capecitabine PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
2439643|NCT03300596|Experimental|brief intervention to prevent suicide attempt|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
2439644|NCT03300596|Other|standard of care|Individuals presenting to hospital following a suicide attempt who are age 18-plus and screen positive for alcohol or drug use problem
2439645|NCT03300583||ILD patients|Patients from all types of ILD who are under the care of the two collaborating hospitals.
2440156|NCT03296865|No Intervention|Without taping|Evaluations without taping
3189301|NCT00776269|Experimental|argon laser|
3189302|NCT00776282|Experimental|1|loratadine 10 mg orally disintegrating tablets
3189303|NCT00776282|Active Comparator|2|loratadine 10 mg orally disintegrating tablets
3189304|NCT00776321|Placebo Comparator|1|
3189305|NCT00776321|Experimental|Eprotirome dose 1|
3189306|NCT00776321|Experimental|Eprotirome dose 2|
2439646|NCT03300583||Family/Carers|Family and carers of patients with ILD who are or have been treated in the two collaborating hospitals.
2439647|NCT03300583||Clinicians|Clinicians from the two collaborating hospitals and GPs from the nearby areas who treat and refer patients with ILD.
3189307|NCT00776334|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
2439651|NCT03300544|Experimental|Treatment (T-VEC, capecitabine, chemoradiation)|Patients receive talimogene laherparepvec intralesionally via endoscopy on weeks 1, 4, 6, and 8. Patients receive 5-fluorouracil IV by bolus and over 46 hours, leucovorin IV bolus, and oxaliplatin IV over 2 hours on weeks 2 and 4. Patients also receive capecitabine orally PO BID followed by radiation therapy for 28 fractions on days 1-5 of weeks 8-13. Patients undergo resection surgery on weeks 21-25.
2439652|NCT03300531|Experimental|P-PRP|Blood will be drawn and pure platelet-rich plasma will be injected into the tendon.
2439653|NCT03300531|Experimental|PRP|Blood will be drawn and platelet-rich plasma will be injected into the tendon.
2439654|NCT03300531|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) )
2439655|NCT03300518|Other|pretreatment group|the pretreatment group underwent a modified treatment protocol with pretreatment with estogen administering during the cycle preceding the IVF/ICSI cycle. daily dose of 4 mg (2 mg twice a day) estradiol valerate was given orally in the middle luteal phase which is confirmed seven days after ovulation monitoring by the ultrasound up to 2 days of the next menstrual cycle.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
2439656|NCT03300518|Other|control groups|In the control groups standard GnRH-antagonist protocol was applied.Recombinant FSH (Puregon) was initiated on menstrual cycle day 2- 3 at an initial dose of 300 IU/day.A daily administration of ganirelix (0.25 mg Orgalutran; Organon) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger.
2439657|NCT03300505|Experimental|ARRx + Enzalutamide|"Phase 1b: All registered subjects will be treated with ARRx (ASO) in combination with enzalutamide. ARRx will be given intravenously on Days 1, 4, 8, 11, 15 on cycle 1, then on days 1, 8, 15 in subsequent 21-day cycles. Enzalutamide will be taken daily in 21 day cycles starting Day 1 of cycle 1. Treatment will continue until clinical or radiologic progression or unacceptable toxicity.~Phase 2: Subjects will be treated with ARRx (ASO) at the maximum tolerated (MTD), in combination with enzalutamide until clinical or radiologic progression or unacceptable toxicity. (Schedule of administration as in phase 1b.)"
2439658|NCT03300492|Experimental|NK-DLI|"Preemptive immunotherapy with ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses following haplo-HSCT."
3151018|NCT00216710|No Intervention|Control Mothers|Mothers randomized to the control group did not receive home visiting services, but were offered referrals to other community-based services, as was usual protocol with home visiting agencies were operating at capacity.
3151019|NCT00216749||Cilostazol|Cilostazol Treatment Patients who were in stable states after the occurrence of cerebral infarction (except cardiogenic cerebral embolism)
2439663|NCT03300453|Experimental|rAAV2/5-hNAGLU|Each patient will receive 960 µL of vector suspension. The vector suspension will be deposited simultaneously at 16 sites, each deposit containing 2.4x 1011 vg (4x1012 vg in total).
2439664|NCT03300440|Experimental|Intervention group|Probiotics and vitamin B7
2439665|NCT03300440|Placebo Comparator|Control group|Placebo and vitamin B7
2439668|NCT03300414||Collection of blood specimen|Collection of blood specimen from patients will be performed during the course of routine medical care at UC Davis with no prospective follow up period. The duration anticipated to enroll all 10 study subjects will be 1 year. The estimated date for the investigator to complete analysis and publication is 2 years.
2439669|NCT03300414||Liver Biopsy slides|Up to twenty (20) de-identified hepatocellular carcinoma (HCC) tissue sections on biopsy slides or frozen sections and associated information such as age, sex, race, ethnicity, treatment status, pathological diagnoses, and date of procedure will be obtained from UC Davis Cancer Center Biorepository (CCB) and outside tissue biobanks, including, but not limited to, Cooperative Human Tissue Network (CHTN). The duration anticipated to complete analysis and publication is 2 years.
3151020|NCT00216853||Patients with Recurrent UTI|
3151021|NCT00216853||Healthy controls|
3151022|NCT00216944|Active Comparator|1|Premedication with atropine and morphine
3151023|NCT00216944|Active Comparator|2|Premedication with glycopyrronium, thiopental, suxamethonium and remifentanil
2439670|NCT03300401|Experimental|Diagnostic (CEUS)|Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
2439671|NCT03300388|Placebo Comparator|Control|Dietary advice for a healthy diet supplemented with placebo (olive oil).
2439672|NCT03300388|Experimental|Omega-3|Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA).
2439673|NCT03300388|Experimental|Resistance Training|Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program.
2439674|NCT03300388|Experimental|Omega-3 + Resistance Training|Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program.
2439675|NCT03300375|Active Comparator|Home-Based Resistance Exercise Intervention Group|Participants in the HBRX group will be coached through six phases of the intervention with two weeks per phase. Exercise will use body weight and resistance exercise bands. A set of commercial elastic resistive bands and a stability pad (TheraBand, Inc.) will be provided to each participant to keep for personal use after their participation in the study. The use of elastic bands for resistance training can induce similar results in neuromuscular adaptations as well as strength to those achieved by weight machines and free-weights.
2439676|NCT03300375|Experimental|Wait-List Control Condition Group|Participants who are assigned to the CON group will wait to participate in the resistance training after a three month wait period. Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time. The participants will be contacted by phone on a monthly basis during the study period to determine if any changes in LBP symptoms have occurred. At month three, these participants will also receive the elastic resistive bands and a stability pad.
2439677|NCT03300362|Experimental|Seasonal influenza & MVA-NP+M1|Two vaccinations will be administered: Seasonal influenza vaccine & MVA-NP+M1
2439678|NCT03300362|Placebo Comparator|Seasonal influenza & saline placebo|Two vaccinations will be administered: Seasonal influenza vaccine & sodium chloride
2439679|NCT03300349||axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have developed breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme
2439680|NCT03300349||No axillary lymphadenectomy sequels|Patients who have suffered from axillary lymphadenectomy due to breast cancer between 2014 and 2016 and who have not develped breast cancer-related lymphedema and/or shoulder disability who fulfill or not a preventive programme.
2439681|NCT03300349||Fulfillment of a preventive programme|Patients who fulfil a preventive programme for axillary lymphadenectomy sequels
2439682|NCT03300349||No fulfillment of a preventive programme|Patients who do not fulfil a preventive programme for axillary lymphadenectomy sequels
3189308|NCT00776334|Active Comparator|2|Monopril® 40mg tablets
3189309|NCT00776347|Experimental|donepezil|
2439685|NCT03300323|Active Comparator|IV Fluid challenge administration _5|4ml/kg intravenous fluid challenge administered over 5 minutes
2439686|NCT03300323|Active Comparator|IV Fluid challenge administration 20|4ml/kg intravenous fluid challenge administered over 20 minutes
2439687|NCT03300310|Experimental|with nursing visit|a nurse visit is scheduled twice a week during 3 months at patient home.
2439688|NCT03300310|Experimental|without nursing visit|no nursing visit
2439689|NCT03300297|Active Comparator|Cervical Spine Thrust Joint Manipulation|Thrust Manipulation delivered to C0/1 and C2/3 on both the right and left side
2439690|NCT03300297|Sham Comparator|Cervical Spine Sham Manipulation|Sham Manipulation delivered to C0/1 and C2/3 on both the right and left side
2439691|NCT03300284||Thyroid cancer|This study does not involve any intervention, but rather data collection on patient and physician preferences and beliefs, communication, and patient psychological outcomes.
2439692|NCT03300271|Other|No intervention (Education)|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
2439693|NCT03300271|Experimental|Mobile Application (Self monitoring)|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
2439694|NCT03300271|Experimental|Mobile Application (Personal coaching)|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
2439695|NCT03300258|Other|Non-Stroke Pilot Group|Robotic therapy. Aerobic therapy. Subjects without stroke, pilot subjects tested during early phases while the device and therapeutic task specifications are developed, and throughout the project while the device and tasks are refined.
2439696|NCT03300258|Other|Non-Stroke Comparison Group|Robotic therapy. Healthy controls enrolled (age 50-85) to contribute to a normative data set on motor learning using the robotic protocols designed for stroke.
2439697|NCT03300258|Experimental|Robotic Training Group|Robotic therapy. Subjects with Stroke who will perform the targeted training task: exercise using novel tasks on a robotic recumbent cycle.
2439698|NCT03300258|Active Comparator|Aerobic Training Group|Aerobic therapy. Subjects with Stroke who will perform aerobic pedaling, duration-matched to the Robotic group.
2439699|NCT03300245||patients with nasal septal deviation|Maxillofacial CT scan
2439700|NCT03300232|Experimental|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
2439701|NCT03300232|No Intervention|Treatment as Usual|Participants randomized to the treatment as usual control condition will not undergo the CBT therapy.
2439702|NCT03300219|Experimental|telerehabilitation|Telerehabilitation refers to the use of technologies to provide rehabilitation services to people in their homes. The intervention will be performed by real-time video-conferencing using an iPad® and Skype™, a software program that allows video calls over the Internet
2440835|NCT03292081|Experimental|OFDI-guided PCI|
2439703|NCT03300206||Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging.
2439704|NCT03300206||Standard of Care|Each of the participating sites will currently be using a vacuum assisted breast biopsy system along with a specimen radiography system (or other specimen imaging system).
2439705|NCT03300193||Tremor patients|Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)
2439709|NCT03300167|Experimental|CE-marked coronary artery catheter|use of a novel CE-marked coronary artery catheter to obtain spatially-separated intravascular samples for laboratory measurement.
2439710|NCT03300154|Experimental|Financial incentives|
2439711|NCT03300154|Experimental|Framing (SMS)|
2439712|NCT03300154|No Intervention|Usual care|
3151024|NCT00216970|No Intervention|1|"Patients will receive nutritional support in which the contents of arginine = 0, glutamate = 0 and proline = 0.~Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients."
3151025|NCT00216970|No Intervention|2|In arm 2 patients will receive nutritional support which will provide glutamine 0.5g/kg/day. Stable isotope tracer studies will be conducted to investigate the whole body protein metabolism and the utilization of arginine in critically ill burn patients.
3151026|NCT00216983||1|"Fasting condition to measure:~quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients~Evaluating the rate of proline de novo synthesis from glutamate or ornithine in burn patients"
3151027|NCT00216983||2|We will study the quantitative relationships among proline, ornithine and glutamate with an emphasis on evaluating the rate of proline disposal and its conversion to ornithine and glutamate in burn patients. When the patients are receiving regular TPN or TPN depleted with proline - arginine - glutamate.
3151028|NCT00216983||3|We wull evaluate the rate of proline de novo synthesis from glutamate or ornithine in burn patients when the patients are receiving regular TPN or TPN depleted proline-arginine-glutamate.
2439718|NCT03300128|Experimental|Incredible Years - ASD|The intervention, The Incredible Years Parent Program for Autism Spectrum and Language Delays (IY-ASD; more information is here: http://www.incredibleyears.com/programs/parent/autism-spectrum-language-delays/) is a 14-week course that meets for 2 hours every week. Ideally, an IY-ASD group will be composed of approximately 10 parents and other primary caregivers of children who have autism.
2439719|NCT03300128|Active Comparator|Circle of Parents|"Circle of Parents, the comparison condition, is an open parent support group led by a parent leader. (For more information, see http://circleofparents.org/). Participants are encouraged to share resources and other support both during groups, and between meetings."
2439720|NCT03300115|Experimental|AC0010|Each participant will be given AC0010 300mg bid.
2439721|NCT03300102||Patients with suspected or confirmed renal cell carcinoma|Patients with suspected or confirmed renal cell carcinoma who have consented will either donate tissue, or complete a structured questionnaire or a semi-structured interview. Not all patients will have all three interventions, each patient must have at least one.
2439722|NCT03300089|Active Comparator|General Anaesthesia|General Anaesthesia during surgery
2439723|NCT03300089|Experimental|Regional Anaesthesia|Regional Anaesthesia during surgery
2439724|NCT03300063|No Intervention|control|Standard Medical care
2439725|NCT03300063|Active Comparator|Low Flow Nocturnal Oxygen|This group will receive standard medical care as well as low flow oxygen during sleep.
2439771|NCT03299738|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
2439772|NCT03299725|Experimental|Treatment arm|
2439773|NCT03299712|Other|ArteFill|This post-approval study will evaluate the continuing safety of ArteFill® as an injectable implant for correction of nasolabial folds over the course of five years post implantation, with a focus on determining the incidence of granuloma formation. Incidence of adverse events and subject satisfaction with respect to the subject's personal expectations will be assessed.
3151029|NCT00216996||Burn patients|Receiving standard TPN with or without glutamine enrichment
3151030|NCT00217009|Active Comparator|Narrowband Ultraviolet B (TL-01UVB) Therapy|treatments - 3x weekly for 15 months
3151031|NCT00217009|Active Comparator|Topical Psoralen plus ultraviolet A (PUVA)|Treatments - 3x weekly for 15 months
3151032|NCT00217100|Active Comparator|Multi Vitamin Formulation|
3151033|NCT00217100|Placebo Comparator|Sugar pill|
3151034|NCT00217165|Placebo Comparator|placebo|cellulose
3151035|NCT00217165|Active Comparator|active drug|taurine
3151036|NCT00217217|Experimental|Active EEP-MRSI treatment|20 minutes of active treatment with theEcho-Planar Magnetic Resonance Imaging (EP-MRSI)
3151037|NCT00217217|Sham Comparator|Sham comparator EP-MRSI|Sham treatment (20 minutes) with the Echo-Planar Magnetic Resonance Imaging (EP-MRSI).
2439733|NCT03300011|Experimental|recanalisation CTO lesion successful|Patients with CTO lesion performed PCI strategy and successfully recanalisation the CTO lesion with implanted stents .
2439734|NCT03300011|No Intervention|recanalisation CTO lesion failure|Patients with CTO lesion performed PCI strategy and failure recanalisation the CTO lesion with PCI wire and balloon..
2439735|NCT03300011|No Intervention|OMT|Patients with CTO lesion optimal medicine treatment without PCI
2439736|NCT03299998||BLOCK+|Patients who underwent maxillary and mandibulary block before surgery
2439737|NCT03299998||BLOCK -|Patients who did not undergo maxillary and mandibulary block before surgery.
2439738|NCT03299985|Experimental|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
2439739|NCT03299985|Sham Comparator|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
2439740|NCT03299972|Placebo Comparator|Control|
2439741|NCT03299972|Experimental|Whey Protein|
2439742|NCT03299972|Experimental|Resistance Exercise + Control|
2439743|NCT03299972|Experimental|Resistance Exercise + Whey Protein|
2439744|NCT03299959|Experimental|Agili-C|
2439745|NCT03299959|Active Comparator|Surgical Standard of Care (SSOC)|
2439746|NCT03299946|Experimental|Arm 1|
2439747|NCT03299920|Active Comparator|Intervention|Patients will receive standardized instruction from a study nurse, tailored to understanding pain management after nerve blocks and maximizing utilization of non-opioid analgesics.
2439748|NCT03299920|Other|Control|Patient will receive conventional instructions on postoperative pain management.
2439749|NCT03299907||COPD|Subject with FEV1/FVC post BD < 0.7 or LLN
2439750|NCT03299907||Non COPD|Subject with FEV1/FVC post BD >= 0.7 or LLN
2439751|NCT03299894|Experimental|systematic calculation of qSOFA|Usual procedure for patient triage AND systematic calculation of qSOFA at Emergency Department triage in patients admitted with a suspected or proven bacterial infection.
2439752|NCT03299894|No Intervention|no systematic calculation of qSOFA|Usual procedures for patient triage at Emergency Department admission and management of suspected or proven bacterial infection. No systematic calculation of qSOFA.
3151038|NCT00217243||Pain study Netherlands|20 healthy subjects 20 patients with a traumatic unilateral peripheral nerve injury 20 patients with CRPS I
3151039|NCT00217256|Experimental|1|Endeavor Drug Eluting Stent
2439755|NCT03299868|Experimental|Routine PICC group|PICC is initially routine insertion at the time of admission of hospice-palliative care unit
2439756|NCT03299868|Active Comparator|General IV group|PICC is inserted if 3 or more times of IV insertion trial per day is required for IV access
2439757|NCT03299842|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
3151040|NCT00217256|Active Comparator|2|Cypher Drug Eluting Stent
3151041|NCT00217269|Experimental|1|Endeavor Drug Eluting Stent
2439760|NCT03299803|Experimental|Men's Healing Pathways|Men with physical disabilities will receive a 15 session weekly peer implemented program
2439761|NCT03299803|No Intervention|Control group|Telephone contact only
2439762|NCT03299790|Active Comparator|training group 1: HIIT|high-intensity interval exercise training group (T2DM patients)
2439763|NCT03299790|Active Comparator|training group 2: MIT|moderate-intensity exercise training group (T2DM patients)
2439764|NCT03299790|No Intervention|Detraining period|Follow-up: detraining of group 1 and 2 (T2DM patients)
2439765|NCT03299790|No Intervention|Healthy controls|
2439766|NCT03299777||Control group|A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period
2439767|NCT03299777||Preeclampsia group|All patients diagnosed with preeclampsia will undergo the fibroscan test.
2439768|NCT03299764|Experimental|Intervention|Non-invasive ventilation with pursed lip breathing ventilation device
2439769|NCT03299764|Active Comparator|Control|Non-invasive ventilation with standard non-invasive ventilation device
2439770|NCT03299751|Experimental|NICU newborns of at least 7 days of life with suggestive signs|
2440836|NCT03292081|Active Comparator|IVUS-guided PCI|
3151042|NCT00217269|Active Comparator|2|Taxus Drug Eluting Stent
3151043|NCT00217308|Experimental|Lactobacillus|
3151044|NCT00217308|Placebo Comparator|Placebo capsules|
3151045|NCT00217373|Experimental|Arm I|"COURSE I: Patients receive recombinant vaccinia-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive sargramostim (GM-CSF) SC on days 1-4 and IFN-α-2b* SC on days 9, 11, and 13.~COURSES II-IV: Patients receive recombinant fowlpox-CEA(6D)-TRICOM vaccine SC on day 1. Patients also receive GM-CSF as in course 1 and IFN-α-2b* SC on days 1, 3, and 5.~NOTE: *The initial cohort of 6 patients does not receive IFN-α-2b.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients who do not have progressive disease or unacceptable toxicity may receive recombinant fowlpox-CEA (6D)-TRICOM vaccine, GM-CSF, and IFN-α-2b every 28 days for 2 more courses and then every 3 months for up to 2 years."
3151046|NCT00217412|Experimental|Arm I|Group 1 (solid tumor or lymphoma patients): Patients receive oral SAHA once daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients may be treated at the MTD.
3151047|NCT00217412|Experimental|Arm II|Group 2 (leukemia patients): Patients receive SAHA as in group 1 at the MTD.
3151048|NCT00217412|Experimental|Arm III|Group 3 (select solid tumor patients): Patients receive oral isotretinoin twice daily on days 1-14. Patients also receive SAHA once daily on days 1-28 OR once on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.The MTD of SAHA is determined as in group 1. An additional 6 patients may be treated at the MTD.
2439776|NCT03299660|Experimental|Avelumab|Long course chemoradiotherapy (LCCRT) comprised of 50.4 Gy radiotherapy in conjunction with 5FU (225mg/m2/day continuous infusion)/Capecitabine (825 mg/m2 BID on RT days) over 5. 5 weeks, followed by 4 cycles of Avelumab. This is then followed up with surgical resection
2439777|NCT03299647||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
2439778|NCT03299647||TD group|Typically development controls without lifetime diagnosis with ADHD
2439779|NCT03299621|Experimental|PLE (Phase Lag Entropy) monitoring|Investigators monitor the change of PLE value using the sensor of PLEM™ during propofol anesthesia.
2439780|NCT03299621|Experimental|Muscle relaxant injection|Investigators monitor the change for PLE value using the sensor of PLEM™ before and after the injection of muscle relaxant.
2439781|NCT03299582|Experimental|Healthy subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects without cancer
2439782|NCT03299582|Experimental|Healthy subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects without cancer
2439783|NCT03299582|Experimental|Cancer subjects (Hypothermia)|To investigate the safety and tolerability of limb hypothermia in subjects with breast cancer being treated with paclitaxel chemotherapy.
2439784|NCT03299582|Experimental|Cancer subjects (Cryocompresion)|To investigate the safety and tolerability of cryocompression in subjects with cancer being treated with taxane-based chemotherapy.
2439785|NCT03299569||Takotsubo cardiomyopathy|All patients diagnosed with Takotsubo cardiomyopathy in Scotland since 2010.
2439786|NCT03299569||Myocardial Infarction|An equal number of myocardial infarction patients in NHS Grampian since 2010.
2439787|NCT03299556||WHT|The WHT group includes only patients newly enrolled in the Geisinger MPP program who consent to participate in the study. WHT subjects will be recruited over 1 year, with 1 year of follow-up.
2439788|NCT03299556||Historic Control|Patients who were enrolled in the MPP in the preceding year. These patients received the MPP educational program but received no WHT as part of their treatment.
2439789|NCT03299556||Concurrent Control|Patients being treated for chronic pain in the Geisinger Medical Pain Management (MPM) program over the same time period as the WHT group. These subjects do not receive the MPP educational program nor use WHT as part of their treatment
2439790|NCT03299543||Healthy adults|Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples
2439791|NCT03299530||patients with corneal astigmatism|Patients who had received phacoemulsification surgery with or without implantation of toric IOL are with a certain amount of corneal astigmatism.
2439792|NCT03299517|Experimental|lidocaine|"Initial dose: antiarrythmic drugs Lidocaine (1.5 mg / kg EV in 30 minutes).~Adittional dose: Lidocaine (0.75 mg / kg EV in 30 minutes)."
2439793|NCT03299517|Experimental|amiodarone|"Initial dose: antiarrythmic drugs Amiodarone (5 mg / kg EV in 30 minutes)~Adittional dose: Amiodarone (3 mg / kg EV in 30 minutes)"
2439794|NCT03299491|Experimental|MWA+IEC intervention|
2439795|NCT03299491|Experimental|IEC intervention|
2439796|NCT03299491|No Intervention|Control|
2439797|NCT03299478||NSCLC patients|
2439798|NCT03299465|Experimental|Yoga arm|A six-week restorative yoga intervention consisting of a weekly, 60-minute yoga group class led by a certified yoga instructor along with twice-weekly home practice using yoga DVD.
2439799|NCT03299452|Experimental|Alphacait-guided therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.
2439803|NCT03299426|Experimental|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Children will receive a single 0.5-ml dose of Vi-TCV administered by the intramuscular route.
2439804|NCT03299426|Active Comparator|Meningococcal A Conjugate Vaccine (MCV-A)|Children will receive a single dose of MCV-A administered by the intramuscular route. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
2439805|NCT03299413|Experimental|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be given as a cell suspension in aseptic buffered solution in disposable vials with no preservative agents. The cells will be injected every two weeks at a total of three doses, 120 million cells in 10mls divided on two IV boli for each dose
2439806|NCT03299400|Experimental|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
2439807|NCT03299387|Active Comparator|Oral Nitrofurantoin|Participants will randomized to oral nitrofurantoin
2439808|NCT03299387|Active Comparator|Intravesical Gentamicin|Participants will be randomized to intravesical gentamicin
2439809|NCT03299374|Active Comparator|Falls Group|Falls prevention intervention
2439810|NCT03299374|Experimental|Pilates Group|Pilates intervention
2439811|NCT03299348|Experimental|Active Treatment Group|This group will get the AgingPLUS intervention program which addresses negative views on aging, low internal control beliefs, and deficient goal planning skills.
2439812|NCT03299348|Placebo Comparator|Active Control Group|"This group will get a generic health education program, called the 10 Keys to Healthy Aging. The control program will control for the effect of social contact and will not address the intervention targets of the active treatment group. The health education program will only provide information related to some of the most important health conditions, such as cardiovascular disease, cancer, type 2 diabetes, and clinical depression, and how these conditions can be managed."
2439813|NCT03299335|Other|Early-stage sIMB patients|
2439814|NCT03299335|Other|Late-stage sIMB patients|
2439815|NCT03299335|Other|Control subjects|
2439816|NCT03299322|Placebo Comparator|Control Group|80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
2439916|NCT03298555|No Intervention|Control|This group will only receive standard care.
2439817|NCT03299322|Experimental|High dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
2439818|NCT03299322|Experimental|Low dose Treatment Group|Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.
3151049|NCT00217477|Experimental|Paricalcitol IV in combination with Gemcitabine IV|Patients receive gemcitabine hydrochloride IV over 80 minutes on days 1, 8, and 15 and paricalcitol IV over 15 minutes on days 7 and 14 in course 1. Beginning in course 2, patients receive paricalcitol IV over 15 minutes on days 1, 8, and 15 and gemcitabine hydrochloride IV over 80 minutes on days 2, 9, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2439820|NCT03299296|Experimental|Rivaroxaban arm|Rivaroxaban 10 Milligrams
2439821|NCT03299296|Active Comparator|Enoxaparin Arm|'Enoxaparin 40 Milligrams /0.4 Milliliters Prefilled Syringe
2439822|NCT03299283||Respiratory/Pharyngitis|Subject presents with signs/symptoms of respiratory infection including but not limited to fever, cough, sore throat (pharyngitis), runny nose, myalgia, headache, chills, or fatigue
2439823|NCT03299283||Gastrointestinal|Subject presents with suspected gastroenteritis (e.g. diarrhea, vomiting, nausea, etc.) with duration of symptoms less than or equal to 7 days
2439824|NCT03299270||Group 1|Elderly patiences with solid malignancy
2439825|NCT03299257|Active Comparator|donepezil treatment|donepezil with 10 mg will be administered for 30 days.
2439826|NCT03299257|Placebo Comparator|placebo treatment|placebo with 10 mg placebo will be administered for 30 days.
2439829|NCT03299231|Active Comparator|Aerobika|Group of participants with COPD, hospitalized for severe exacerbation and using the active oscillating positive expiratory pressure device (OPEP). The device is a hand held one. Used mostly in subjects with bronchiectasis for mucus clearing. Estimated number of subjects in this arm is 80. The device has an adjustable resistance which will be set by a health care provider in the study team. The device is to be used three times daily from 10 to 20 minutes according to subject's effort.
2439830|NCT03299231|Sham Comparator|Sham device|Group of participants using the same looking device which is devoid from nebulizer port valve so it is not functioning (sham device). The sham arm is a control arm. It will be used as the active comparator three times daily for 10 to 20 minutes according to subject's effort
2439831|NCT03299218|No Intervention|Control|Receiving current Government of Punjab health services
2439832|NCT03299218|Experimental|Cash-based transfers|Cash-based transfers only by BISP
2439833|NCT03299218|Experimental|Cash with SBCC|Cash-based transfers and Social & behaviour change communication (SBCC)
2439834|NCT03299218|Experimental|Cash with SNF (Wawamum)|Cash-based transfers and SNF (Wawamum)
2439835|NCT03299218|Experimental|Cash,SNF (Wawamum) & SBCC|Cash-based transfers, SNF (Wawamum) and SBCC
2439836|NCT03299205|Experimental|Exercise|Aerobic exercise program using treadmill.
2439837|NCT03299192|Experimental|Tai Chi|twice weekly classes for 12 weeks and then weekly for 6 weeks, every other week for 6 weeks and monthly for 3 months
2439838|NCT03299192|Active Comparator|Health Education|twice weekly classes for 12 weeks
2439839|NCT03299192|Active Comparator|Usual Medical Care|the usual care to which participants are entitled by their health insurance
3151050|NCT00217516|Experimental|Arm I|Patients receive oral selenium for 3-6 weeks.
3151051|NCT00217516|Placebo Comparator|Arm II|Patients receive oral placebo for 3-6 weeks.
2439842|NCT03299166|Experimental|BHV-4157|
2439843|NCT03299166|Placebo Comparator|Placebo|
2439844|NCT03299153|Experimental|Intervention group|patients in this group were received 200 ml/d barberry juice for tow month
2439845|NCT03299153|No Intervention|control group|patients in this group received no intervention
2439846|NCT03299140|Other|Family Focused Therapy|Only 1 arm
2439847|NCT03299127|Experimental|imagery rescripting|bibliotherapy, intervention is provided by pdf-manual (either short or long version, i.e. 2 active arms, each 1/3 of sample receives either short or long version)
2439848|NCT03299127|No Intervention|wait-list control|wait-list control, participants receive intervention manual upon completion of post-assessment (1/3 of sample)
2439849|NCT03299114|Active Comparator|Intervention Group|Treated with warm whirlpool
2439850|NCT03299114|Placebo Comparator|Placebo group|Treated with sham whirlpool
3151052|NCT00217542|Experimental|Treatment (chemotherapy, biological therapy)|Patients receive azacitidine SC once daily on days 1-4 and 15-17 and recombinant interferon alfa-2b SC on days 8, 10, 12, 15, 17, 19, 22, 24, and 26 during course 1. Beginning in course 2 and for all subsequent courses, patients receive azacitidine SC once daily on days 1-3 and 15-17 and interferon alfa-2b SC on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26. Treatment repeats every 28 days for up to 12 total courses in the absence of disease progression or unacceptable toxicity.
3151053|NCT00217607|Experimental|Paclitaxel|"Paclitaxel 80 mg/m² Day 1, Day 8 and Day 15. No treatment on Day 22.~1 cycle = 28 days.~Treatment duration: 6 cycles (=6 months)"
2439854|NCT03299062|Active Comparator|Parkinson's Disease with Voice Dysfunction Patients|• Twenty people with Parkinson's Disease requiring evaluation of voice dysfunction by an Ear, Nose, and Throat (ENT) doctor
2439855|NCT03299062|Active Comparator|Other Neurodegenerative Disorders with Voice Dysfunction|• Twenty people with other neurodegenerative disorders requiring evaluation of voice dysfunction by an ENT doctor.
2439944|NCT03298373|Experimental|11β-MNTDC|11β-MNTDC capsules administered orally (200 mg or 400 mg).
3151054|NCT00217633|Experimental|Treatment (pelvic exenteration)|Patients undergo pelvic exenteration within 14 days after study entry.
3151055|NCT00217646|Experimental|Arm I|Patients receive oral sorafenib once or twice daily on days 1-5, 8-12, and 15-19.
3151056|NCT00217646|Experimental|Arm II|Patients receive oral sorafenib once or twice daily on days 1-14.
3151057|NCT00217711|Active Comparator|Arm A|Oxaliplatin, Irinotecan, and Capecitabine
3151058|NCT00217737|Active Comparator|Arm A (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
2439856|NCT03299062|Placebo Comparator|Voice Dysfunction|Twenty people with voice tremor and/or presbylarynx, but no evidence of Parkinson's other neurodegenerative disease, requiring evaluation of voice dysfunction by an ENT doctor.
3189310|NCT00776360|Experimental|oxytocin, gastric emptying|Oxytocin is given to study the gastric emptying rate
3189311|NCT00776360|Placebo Comparator|oxytocin|sodium chloride is given to study gastric emptying rate
3189312|NCT00776373|Experimental|Arm 1|Rapamycin in combination with High Dose Etoposide and Cytarabine (HiVAC)
3189313|NCT00776399|Experimental|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
2439861|NCT03299036|Experimental|Taiwan ACE Beads with doxorubicin|The use of Taiwan ACE Beads (T-ACE) microspheres embolization with doxorubicin as a treatment for patients with hepatoma.
2439862|NCT03299010||DM patient|Patients with a documented clinical diagnosis of DM and were receiving care in the Hospital Authority (HA) primary care General Out-Patient Clinics (GOPC) and Family Medicine Clinics (FMC) on or before 1 July 2006 identified from the HA clinical management system (CMS) database.
2439863|NCT03298997|Experimental|Ligation and Hemorrhoidopexy|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Introduction of a proctoscope. Identification of the hemorrhoidal nodules (3rd, 7th, 11th hour). Confirmation of the hemorrhoidal artery location, through palpation. Ligation of the hemorrhoidal nodules using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Placement of a fixative suture in the hemorrhoidal nodule and then performance of hemorrhoidopexy Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to pudendal nerve block. Using an atraumatic 25 Gauge (G) needle, a 20ml lidocaine solution (diluted with saline in a 1:1 rate) will be administered bilaterally, medially to the ischial tuberosity.~10 minutes before the operation, the patient will receive 1-2.5mg midazolam and 0.1-0.2 mg fentanyl."
2439864|NCT03298997|Active Comparator|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"The patient will be placed in the Lloyd-Davies position. Provision of a sterile field, using a 10% povidone iodine solution. Rectal dilatation will be performed with a 10% xylocaine gel. Use of a proctoscope combined with a Doppler sensor. After the hemorrhoidal artery localization, Z ligations will be placed, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~The proper artery ligation will be confirmed by the absence of the Doppler signal.~In the presence of residual hemorrhoidal tissue hemorrhoidopexy will be performed, by applying a continuous suture.~Placement of a hemostatic gauze in the surgical field. Prior to operation, the patients will be submitted to spinal anesthesia. Using an atraumatic 25 Gauge (G) needle, a levobupivacaine 5mg/ml and fentanyl 25mg solution, will be administered at the height of lumbar (L)2-L3 or L3-L4."
2439866|NCT03298971||Survivors of Childhood Osteosarcoma|Survivors of Childhood Osteosarcoma were invited to fill in a set of questionnaires.
2439867|NCT03298971||Healthy Subjects|Healthy Subjects were invited to fill in a set of questionnaires.
2439868|NCT03298958|Placebo Comparator|Placebo Oral Tablet|Subject will be randomized to take the Placebo once daily for 2 years or until disease recurrence
2439869|NCT03298958|Active Comparator|Sirolimus (Rapamycin) 0.5 mg/day for 2 years|Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence
2439872|NCT03298919|Experimental|Exercise Videogames|Exercise videogames 3 times weekly for 12 weeks followed by 6 months of home practice
2439873|NCT03298919|Active Comparator|Standard Exercise|Exercise using aerobic equipment such as stationary bikes and treadmills 3 times weekly for 12 weeks followed by home practice
2439874|NCT03298919|No Intervention|Wellness Control|Weekly mailings on general health and wellness topics for 12 weeks followed by monthly mailings for 6 months.
2439875|NCT03298906|Experimental|Esketamine + Ticlopidine|Participants will self-administer one 14 milligram (mg) spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg (Treatment A) in Treatment Period 1. After that participants will receive 250 mg of ticlopidine tablets orally twice daily on Day -9 through Day 1, and will self-administer one 14 mg spray of intranasal esketamine into each nostril at Time 0 and again 5 minutes later in the morning of Day 1, a total dose of 56 mg (Treatment B) in Treatment Period 2. A washout period of greater than or equal to (>=)10 days will separate the esketamine self-administrations between 2 treatment periods.
2439876|NCT03298893|Experimental|Nivolumab + radiochemotherapy|5 weeks of radiochemotherapy + nivolumab followed by 5 months of nivolumab alone
3189317|NCT00776425|Experimental|Epoetin Beta 150 IU/kg|Participants with solid and lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 150 IU per kg of body weight thrice weekly.
3189318|NCT00776425|Experimental|Epoetin Beta 30000 IU|Participants with lymphoid malignancies will receive subcutaneous or intravenous epoetin beta at a dose of 30000 IU once weekly.
3189319|NCT00776438|Experimental|Study Group 1|Adult, age 18 to 40 years
2439945|NCT03298347|Experimental|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP.
3189320|NCT00776438|Experimental|Study Group 2|Adult, age 18 to 40 years
3189321|NCT00776438|Experimental|Study Group 3|Elderly, age 60 to 85 years
3189322|NCT00776438|Experimental|Study Group 4|Elderly, age 60 to 85 years
3189323|NCT00776451||1|Subjects diagnosed with Dry AMD
3189324|NCT00776477|Experimental|1|
3189325|NCT00776477|Active Comparator|2|
3189326|NCT00776490|Experimental|1|Glimepiride 1 MG Tablets of ranbaxy
3189327|NCT00776490|Active Comparator|2|AMARYL® 1 mg tablets
3189328|NCT00776503|Experimental|B|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 1-(7 or 10 or 14)
3189329|NCT00776503|Experimental|A|Cytarabine 10mg/m2 day 1-14 Vorinostat 400mg/d day 15-(21 or 24 or 28)
3189330|NCT00776516|Experimental|1|mirabegron alone
3189331|NCT00776516|Experimental|2|mirabegron and rifampin
3189332|NCT00776529|Experimental|A Sensorimotor first|In each of nine sessions: first sensorimotor exercises, then strengthening exercises
3189333|NCT00776529|Experimental|B Sensorimotor & strength alternated|In each of nine sessions: Strength and sensorimotor exercises alternated
2439880|NCT03298828|Experimental|CD19 CAR|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR T-cells.
2439881|NCT03298828|Experimental|CD19 CAR and PD-1 knock out|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19 CAR and PD-1 knock out engineered T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19 CAR and PD-1 knock out engineered T-cells.
2439882|NCT03298815|Active Comparator|Amniotic Fluid Eye Drops (AFED) - All participants, One eye|
2439883|NCT03298815|Placebo Comparator|Saline Solution - All participants, One eye|
2439884|NCT03298802|Active Comparator|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
2439885|NCT03298802|Placebo Comparator|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for fourteen days postpartum
2439886|NCT03298789|Experimental|Experimental condition|7 series of static stretching will be conducted in the experimental condition. Activation exercises will be performed after 7th series of static stretching.
2439887|NCT03298789|Other|Control|7 series of static stretching will be conducted in the control condition.
2439888|NCT03298776|Active Comparator|standard white light endoscopy|Patients will undergo the standard of care which is standard white light endoscopy
2439889|NCT03298776|Experimental|Endoscopy and I-Scan|Patients will undergo standard of care endoscopy plus the I-Scan
2439890|NCT03298763|Experimental|Phase 1 - RP2D finding study|Phase I of the trial aims to establish the recommended MSCTRAIL dose when given in combination with cisplatin/pemetrexed chemotherapy in metastatic non-small cell lung cancer (NSCLC) patients
2439891|NCT03298763|Active Comparator|Phase 2 Intervention Arm|"Cisplatin 75mg/m2 and Pemetrexed 500mg/m2 on day 1 followed by MSCTRAIL (at the recommended phase 2 dose) on day 2. This schedule will be repeated after 21 days for 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
2439892|NCT03298763|Placebo Comparator|Phase 2 Control Arm|"cisplatin 75mg/m2 and pemetrexed 500mg/m2 on day 1 and placebo on day 2. This will be repeated after 21 days for up to 3 cycles.~Patients will then receive a further 1-3 cycles of pemetrexed/ cisplatin alone. They may then be eligible for maintenance pemetrexed according to clinical response as directed by their Oncologist in line with local standard of care."
2439893|NCT03298750|Experimental|Mechanical stimulation|Mechanical stimulation of ovarian tissue
3189334|NCT00776542|Experimental|1|Minocycline 100 mg tablets of ranbaxy
2439895|NCT03298724|Experimental|TAPP Intervention|The Teachers and Partners intervention will be provided
2439896|NCT03298698|Experimental|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
2439897|NCT03298698|Active Comparator|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
2439898|NCT03298685||CF patient and parents cohort in 3 CF center|All adolescents for whom the transition to the adult center is scheduled within six months and their parent will be interviewed before and after transition.
2439899|NCT03298672|Experimental|NDX-1017|NDX-1017 will be administered via subcutaneous injection
2439900|NCT03298672|Placebo Comparator|Placebo|Placebo will be administered via subcutaneous injection
2439903|NCT03298646|Experimental|Lidacaine hydrochloride|"Adding 10 ml of 2% Lidocaine hydrochloride on hysteroscopic saline media during office hysteroscopy to test its efficacy in reducing pain.~22 women."
2439904|NCT03298646|Active Comparator|Diclofenac|"100 mg Diclofenac oral tablet is administered 1 hour before the procedure to test its efficacy in reducing pain.~22 women."
2439905|NCT03298633|Active Comparator|Intracytoplasmic Sperm Injection|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in group A will undergone Intracytoplasmic Sperm Injection (ICSI) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
2439906|NCT03298633|Active Comparator|Conventional IVF|On the day of oocyte retrieval, qualified participants will be randomized into either of two groups. Participants in this group will undergone Conventional In Vitro Fertilization (IVF) procedure, other standard assisted reproductive treatments are similar and parallel between two groups.
2439907|NCT03298620|Experimental|Intervention|Electric toothbrush
2439908|NCT03298620|Active Comparator|Control|New standard manual toothbrush
2439909|NCT03298607|Placebo Comparator|Placebo|2 capsules daily for 2 months containing inactive substances
2439910|NCT03298607|Active Comparator|Serelys PMS|2 capsules daily for 2 months containing pollen extract
2439911|NCT03298594|Experimental|specific cervicograph|Specific cervicograph, including an alert line (normal progression of cervical dilation, i.e. 1 cm per hour) and an action line 2 hours after the alert line. This should be completed after the diagnose of active labor
2439912|NCT03298594|No Intervention|Usual cervicograph|The usual cervicograph in our unit is not having lines
2439913|NCT03298581|Experimental|Halobetasol propionate spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
2439914|NCT03298568|Experimental|DAOsin treatment|Patients suffering from histamine intolerance and a diamin oxidase activity below 10 Units/ml get a DAOsin treatment for one month 3 times a day.
2439915|NCT03298555|Experimental|Mobile phone based intervention|This group will receive the smartphone app HealthyMoms between gestational week 14 and 37. The app will contain information and support to achieve a healthy weight gain and lifestyle during pregnancy. This group will also receive standard care.
2439917|NCT03298542|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
2439918|NCT03298542|Placebo Comparator|Group 2: Placebo|Participants will receive a SC matching placebo to golimumab.
2439919|NCT03298529|Experimental|Traditional egg pasta|"Traditional egg pasta. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta made with 8 eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2439920|NCT03298529|Experimental|Pasta with only eight egg whites/kg flour|"Pasta with only eight egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only eight egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2439921|NCT03298529|Experimental|Pasta with four eggs/kg flour|"Pasta with four eggs/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with four eggs/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2439922|NCT03298529|Experimental|Hyperproteic pasta (with added gluten and albumin)|"Hyperproteic pasta (with added gluten and albumin). 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with added gluten and albumin. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2439923|NCT03298529|Experimental|Pasta with only four egg whites/kg flour|"Pasta with only four egg whites/kg flour. 12 healthy subjects, after a 10 to 12-hour overnight fasting period, will assume fettuccine pasta with only four egg whites/kg flour. The serving size is calculated to contain 50 g of carbohydrates according to nutritional analysis of the product."
2439924|NCT03298516|Experimental|Arm A: DCLL9718S|Participants will receive escalating doses of DCLL9718S intravenously (IV) in each 21-day cycle to determine MTD and RP2D in dose-escalation stage followed by DCLL9718S IV at RP2D in each 21-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
2439925|NCT03298516|Experimental|Arm B: DCLL9718S and Azacitidine|Participants will receive escalating doses of DCLL9718S (starting dose: at least one dose level below a completed and tolerated DCLL9718S monotherapy in Arm A) IV in each 28-day cycle and azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) or IV on Days 1-7 of each 28-day cycle to determine MTD and RP2D of DCLL9718S in dose-escalation stage followed by DCLL9718S IV at RP2D in each 28-day cycle and azacitidine 75 mg/m^2 SC or IV on Days 1-7 of each 28-day cycle in dose-expansion stage until disease progression, unacceptable toxicity, or any other discontinuation criteria are met. Azacitidine may also be given on Days 1-5 and Days 8-9 depending on institutional preference.
2439926|NCT03298503|Active Comparator|early stage or non-freezers PD|"early stage defined as modified Hoehn and Yahr scale 1, 1.5 and 2, means that symptoms involved unilateral or bilateral without impairment of balance.~non-freezers defined as without freezing of gait, means that patients without transient inability to generate effective stepping."
2439927|NCT03298503|Experimental|moderate stage or freezers PD|"moderate stage defined as modified Hoehn and Yahr scale 2.5 and 3, means that symptoms involved unilateral or bilateral without impairment of balance.~freezers defined as with freezing of gait, means that patients have transient inability to generate effective stepping."
2439928|NCT03298477|Other|Single Arm|Single Arm Safety and Effectiveness Confirmatory Study of EVAS using the Nellix® System
2439929|NCT03298464|Experimental|NGM313|
2439930|NCT03298464|Active Comparator|Pioglitazone|
3173055|NCT00607646|Experimental|Arm 4|Following 6 weeks randomized treatment, Day 1 hyperinsulinemic hypoglycemic clamps x 2 with DHEA or placebo dose given prior to each clamp. Day 2 hypoglycemia with prior dose of randomized treatment.
3173056|NCT00607659||Chlamydia Positive|Adolescent females, 11-21 years old, evaluated for pelvic examinations or STI screening will be asked to participate in this study. Participants are being asked to give us permission to collect:additional cervical or vaginal swabs, rectal swabs, blood draws where three tablespoons of blood, a urine pregnancy test, and a comprehensive health history. You may be asked to provide a urine specimen at the initial visit instead of having a cervical swab. The study team will obtain a cervical swab when you come back for your follow-up appointments. If your culture is positive for Chlamydia, you will be asked attend 3 additional follow-up appointments after 3 months, 6 months, 1 year, 2 years, and 3 years .
2439935|NCT03298425|Active Comparator|Treatment NMES|Patients allocated to the NMES group will be given an information booklet on NMES machines. The Cefar Compex three electrical stimulator will be used. Participants are expected to use the NMES machine for half an hour and complete bed exercises twice daily. Patients should relax during the NMES as completing both does not demonstrate better results, due to unsynchronised activation of the NMES (Gregory & Bickel, 2005). Using the machine once daily will allow for the recovery of the muscle. A voluntary contraction would normally be 20-30Hz but due to the high intensities of the NMES (35-75Hz) it can cause muscle fatigue (Maffiuletti, 2011).
2439936|NCT03298425|Placebo Comparator|Placebo NMES|The placebo group will act as the control group. They will be expected to complete the same regime as previously described above, however these machines will be on TENS setting (80-100Hz) as even low Hz can trigger motor stimulation (Paillard 2008). This setting is designed as a sensory stimulus therefore will have no effects on muscle strength however the patient will feel a small twitch sensation. This setting is not painful and will have no effect on muscle fatigue. The patient will not be expected to complete the bed exercises and the TENS session together.
2439938|NCT03298399|Experimental|MSC dose level 1|The first three subjects (minimum) will receive four weekly infusions of MSCs.
2439939|NCT03298399|Experimental|MSC dose level 2|If no significant side effects are encountered at dose level 1, then subsequent subjects will receive four infusions of MSCs given twice weekly.
2439940|NCT03298399|Experimental|MSC dose level 3|If dose level 2 is well tolerated, then subsequent subjects will receive six infusions MSCs given twice weekly.
2439941|NCT03298386|Experimental|"Intervention Group STOPP/START"|Training of General Practitioners with the tool STOPP/START Systematic medication review by GP with STOPP/START
2439942|NCT03298386|No Intervention|Control group|Patient's usual care by the general practitioner (who will not be trained in the STOPP/START tool)
2439943|NCT03298373|Placebo Comparator|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
2439949|NCT03298321||Vidaza patients|This study will be performed on adults with Acute Myeloid Leukemia and atrial fibrillation. Only patients treated for the first time with vidaza® within an hospital hematology unit will be included.
2439950|NCT03298308|Experimental|Brainwave|Brainwave analysis after cranial electric stimulation
2439951|NCT03298295|Experimental|Insertion of Insulin Infusion Catheters|Non-diabetic patients scheduled for abdominoplasty will be inserted continuous subcutaneous insulin infusion (CSII) catheters of two different materials into the part of the abdomen which will be removed during surgery.
2439952|NCT03298282||Imaging Registry|Imaging cohort: Patients with intermediate lesions
2439955|NCT03298256||Lenke type 1 AIS|Patients will be given a new prescription for a custom made Boston type thoracic-lumbo- sacral-orthosis (TLSO) braces. All patients will undergo low dose biplanar X-rays using the EOS ® machine system.
2439956|NCT03298243|Experimental|Stroke Cohort - Optimize Delivery|Aim 1 intervention: Vibrotactile stimulation. An optimal location and style of vibrotactile feedback for reach and stabilization behaviors will be determined.
2439957|NCT03298243|Experimental|Stroke Cohort - Extended Training|Aim2 intervention: Vibrotactile stimulation. Progressive training from simple to more complex reaching and stabilizing tasks using vibrotactile feedback to guide performance
2439958|NCT03298230|Experimental|REmotely SuPervised Exercise Training|12- week home based exercise programme consisting of bi-weekly, hourly sessions at the time and place of the participant's choosing. They will wear a fitness tracker which will automatically upload their exercise data to an online platform which can be monitored by the research team and used to provide additional motivation.
2439959|NCT03298230|Active Comparator|Supervised Exercise Training|As per NICE guidance. 12 week, bi-weekly, one hour sessions of supervised exercise training.
2439961|NCT03298204||Chemoradiotherapy|
2439962|NCT03298204||Chemoradiotherapy following chemotherapy|
2439963|NCT03298204||Chemoradiotherapy followed by chemotherapy|
2439964|NCT03298191|Experimental|Magnesium sulphate|
2439965|NCT03298191|Experimental|Ritodrine|
2439966|NCT03298191|Experimental|Calcium channel blocker|
2439968|NCT03298165|Experimental|disinfection the cavity with diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
2439969|NCT03298165|Placebo Comparator|no cavity disinfection|placebo is used as no cavity disinfection will be done as after excavation the restoration will be placed .
2439970|NCT03298152|Active Comparator|Emax CAD Endocrowns|Using lithium disilicate e.max restorations is documented in literature as a successful restoration. Two different ceramic crowns systems were investigated clinically for three-years and howed that patient was satisfied with the final restoration
2439971|NCT03298152|Experimental|Cerasmart Endocrowns|A new material CERASMART (Force Absorbing Flexible nano ceramic CAD/CAM block) with high density of ultrafine glass particles with 71 wt% filled nano-composite. It combines high strength and unique aesthetics. full homogeneous and even distribution nano ceramic network lead to unique physical properties for cerasmart . Uniform scuttle (very short inter-particle distance) of silanated and bonded particles is key to delivering CERASMART's™ with exceptional strength, retention, acceptable level of marginal adaptation
2439972|NCT03298139|Experimental|parabolic flights|parabolic flights in normogravity (1g), hypergravity (1.8g) and microgravity (0g).
2439973|NCT03298126|Active Comparator|TR BAND Protocol A|In this group, air removal from TR band was initiated after 2 hours of TR band application. 3 ml of air was removed periodically at an interval of 15 minutes until all the air is eliminated from the band. In case of bleeding or hematoma while deflating air, 4 ml of air was re-injected and observed for 30 minutes until next attempt was made to deflate the band. The data including the attempts made at deflating TR band, time and amount of air injected along with the response to each deflation i.e. occurrence of bleeding or hematoma was noted down in the proforma
2439974|NCT03298126|Active Comparator|TR BAND PROTOCOL B|In this group deflation was initiated after 2 hours of TR band application as described by Cohen and Alfonso. [6] 5 ml of air was deflated at first attempt. Next attempt was carried out after 15 minutes in which further 5 ml was removed. After 15 minutes, the remaining 2 ml of air was released from the band. In case of bleeding or hematoma at any attempt, 6 ml air was re-injected and interval for 15 minutes taken to attempt further air deflation. All the attempts and its response were recorded in the proforma filled out by the assessor.
3189335|NCT00776542|Active Comparator|2|Minocin 100mg tablets
3189336|NCT00776568|Active Comparator|2|
2439977|NCT03298100||Postmenopausal women|
2439978|NCT03298087|Experimental|Experimental Arm|Radical prostatectomy (and post-operative fractionated radiotherapy for pT=3a, pN1, or positive margins), metastasis directed SBRT, and complete ADT with LHRH analog leuprolide, abiraterone acetate with prednisone, and apalutamide (ARN-509) for a total of six months of systemic therapy.
2439979|NCT03298074|Experimental|Apatinib plus Etoposide|Apatinib,500mg,PO.QD, continuous administration Etoposide,100mg, PO.QD，D1-D10, Q3W
2439980|NCT03298074|Active Comparator|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
2439981|NCT03298061|Experimental|Subjects from clinical study MEA115921|Subjects who participated in clinical study MEA115921 and who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included. Eligible subjects will receive subcutaneously administered mepolizumab at a dose of 300 mg SC every 4 weeks.
3189337|NCT00776568|Experimental|1|
3189338|NCT00776581||1|Records regarding combined spinal-epidural analgesia (CSEA) with patient-controlled analgesia (PCA) pump
3189339|NCT00776581||2|Records regarding combined spinal-epidural analgesia with intermittent bolus injection (IBI)
3189340|NCT00776581||3|Records regarding epidural analgesia (EA) with patient-controlled pump
3189341|NCT00776581||4|Records regarding epidural analgesia with intermittent bolus injection
3189342|NCT00776607|Experimental|Insulin|Insulin: NovoMix 30. Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal.
3189343|NCT00776607|Active Comparator|Tablet|Patients will progress from lifestyle modification to metformin, to metformin with Rosiglitazone and finally insulin depending on HbA1c levels.
3189344|NCT00776620|Experimental|1|Glimepiride 1 MG Tablets of Ranbaxy
2439987|NCT03298022|Experimental|AbGn-168H|intravenous doses of AbGn-168H
2439988|NCT03298009|Placebo Comparator|Treatment 1|placebo oral capsule will be administered once daily, for 2 weeks
2439989|NCT03298009|Experimental|Treatment 2|Canagliflozine 100mg once daily, for 2 weeks
2439990|NCT03297996||SIT|Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT)
2439991|NCT03297996||NYU|New York University (NYU) Human Microbiome and Colorectal Tumor study
2439992|NCT03297983|Experimental|First M7583 Tablet:Fasted, Then PiC:Fasted, Then Tablet:Fed|
2439993|NCT03297983|Experimental|First M7583 PiC:Fasted, Then Tablet:Fasted, Then Tablet:Fed|
2439994|NCT03297970||Bogota School Children Cohort|"Children are classified according to exposure levels of:~Micronutrient biomarker indicators:~Ferritin~Hemoglobin~Mean corpuscular volume~Zinc~Vitamin A~Vitamin B12~Folate~Vitamin D~Serum fatty acids~Inflammatory biomarkers:~C-reactive protein~Diet~Socioeconomic status indicators~Anthropometric indicators~Incidence of infectious morbidity symptoms~DNA biomarkers"
2439995|NCT03297957|Experimental|Arm 1: Goggle Imaging|-Patient will then be taken to the operating room for this surgical procedure. Prior to starting the operation, the patient will undergo injection of ICG around the tumor per standard techniques while in the operating room. Those undergoing intraoperative visualization of parathyroid glands will not have any administration of ICG as these glands autofluoresce. Patients will then undergo the standard SLN biopsy procedure (those undergoing parathyroid visualization will not undergo this). The surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance or parathryroid visualization. After this is performed, the goggle system will be removed and the procedure will be completed per normal.
3189345|NCT00776620|Active Comparator|2|AMARYL® 1 mg tablets
2439997|NCT03297931|Active Comparator|Commercial corn chips + Onion dip|Corn chips + onion dip
2439998|NCT03297931|Experimental|Commercial pulse chip + pulse spread|Pinto bean chip + hummus
2439999|NCT03297931|Experimental|Novel pulse chip + pulse spread|Yellow pea chip + hummus
2440000|NCT03297931|Experimental|Commercial pulse chip + non-pulse spread|Pinto bean chip + onion dip
2440001|NCT03297931|Experimental|Novel pulse chip + non-pulse spread|Yellow pea chip + onion dip
2440002|NCT03297931|Experimental|Non-pulse chip + pulse spread|Corn chips + hummus
2440003|NCT03297918|Active Comparator|Intervention group|Patients will be asked to participate in a structured singing and respiratory training for 12 weeks.
2440004|NCT03297918|No Intervention|Control group|no intervention
2440005|NCT03297905|Experimental|Complementary and Integrative Therapies|Chiropractic, Acupuncture, Yoga, Biofeedback (if indicated), and Foam roller instruction
2440006|NCT03297905|Active Comparator|Standard Rehabilitative Care|Cognitive Behavioral Therapy (CBT) 60-minute orientation, CBT psychoeducation group, and Physical therapy/occupational therapy
2440007|NCT03297879|Experimental|exenatide group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
2440008|NCT03297879|Active Comparator|metformin group|The drug-naïve, overweight or obese patients with newly diagnosed T2D
2440009|NCT03297866||Incentive schemes 1|No incentive will be given after completing the follow-up survey
2440010|NCT03297866||Incentive schemes 2|Receiving $100 supermarket coupon after completing the follow-up survey
2440011|NCT03297866||Incentive schemes 3|Receiving $200 supermarket coupon after completing the follow-up survey
2440012|NCT03297866||Incentive schemes 4|Receiving $100 supermarket coupon before completing the follow-up survey and another $100 supermarket coupon after completing the follow-up survey
2440013|NCT03297840||Treatment|Patients with Borderline Personality Disorder receiving DBT treatment. Measurement takes place at the beginning of the treatment and a second time after 12-weeks treatment.
2440014|NCT03297840||Waitlist|Patients with Borderline Personality Disorder on the waitlist for inpatient DBT treatment. Measurement takes place twice at baseline and after 12-weeks waiting.
2440015|NCT03297827||Patients with stroke|Adult stroke patients with the stroke diagnosis will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
2440016|NCT03297827||Patients without stroke|Age/Sex matched adult control patients without the diagnosis of stroke, myocardial infarction, inflammatory flare, acute trauma, neurodegenerative or neuroinflammatory disease (AD, PD, TM, PSP, etc.) except MS will be recruited on admission to the University of New Mexico Hospital. Serum and Urine measurement of cytokines from two sets of serum and urine samples will be done on the admission and at the 24-hour mark respectively, form the specimens collected for the clinical purposes and are meant to be discarded. Consent will be taken from the patients to use these samples for our study.
2440017|NCT03297814|Active Comparator|Platelet lysate|A total of 5 ml platelet lysate will be intramuscularly injected in 4 doses with 2 week interval
2440018|NCT03297814|Placebo Comparator|placebo|A total of 5 ml of Normal Saline will be intramuscularly injected in 4 doses with 2 week interval
2440019|NCT03297801||Fish oil group|Women who chose to supplement with fish oil, rich in omega-3 polyunsaturated fatty acids, during gestation or lactation.
2440020|NCT03297801||No fish oil group|Women who chose not to supplement with fish oil during gestation or lactation.
2440021|NCT03297788|Experimental|Arm A: SRS|Patient receive stereotactic radiosurgery (SRS), dose prescription according to the size of radiated brain metastases
2440022|NCT03297788|Active Comparator|Arm B: WBRT|Patients receive whole brain radiotherapy (WBRT)
2441567|NCT03286881|Active Comparator|Group 5|
3189346|NCT00776633|Experimental|Short triple|6 weeks triple therapy
3189347|NCT00776633|Active Comparator|Long triple|6 months triple therapy
3189348|NCT00776646|Experimental|1|hydrochlorothiazide 50 mg tablet
3189349|NCT00776646|Active Comparator|2|hydrochlorothiazide 50 mg tablet
3189350|NCT00776672|Experimental|1|fosinopril sodium 40 mg tablets of Ranbaxy
2440023|NCT03297775||Evidence of interstitial lung disease|"Subjects who screen positive for ILD will be followed annually until study closure.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
2440024|NCT03297775||No evidence of interstitial lung disease|"Subjects who screen negative for ILD will be followed five years after the initial screen and re-screened with a chest CT scan to check for evidence of new lung disease.~Assessments are as follows:~Clinical - Demographics (e.g., age, sex, self-reported race, etc.), Health related behaviors, including smoking history, Co-morbidities and medications, Respiratory symptom assessment (e.g., cough, dyspnea), Rheumatologic assessment (e.g., disease duration, disease severity, treatment)~Physiologic - Forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO), 6-minute walk distance~Radiologic - Assessment for airways disease, interstitial lung abnormalities~Genetic - DNA, RNA~Biologic - Serum, Plasma, Sputum"
2440025|NCT03297762|Experimental|Gamification|Use of continuous glucose monitor (Dexcom G5) with proactive intervention and incentives for time in use.
2440026|NCT03297762|Active Comparator|Standard care|Use of continuous glucose monitor (Dexcom G5) per usual care.
2440027|NCT03297736|Active Comparator|Control|Subjects receive the control device.
2440028|NCT03297736|Experimental|Investigational device|Subject receives the 3D CAD/CAM autograft prosthesis implant.
2440029|NCT03297723||Experimental arm|The experimental group will be constituted after the medical staff was trained to TPE. Cancer patients will benefit from a PEP aiming at learning how to better manage their pain.
2440030|NCT03297723||Controle arm|The control group will be constituted before the training of the medical staff to TPE. Patients' pain will be managed conventionally.
2440031|NCT03297710|Experimental|Treatment (TAS-102, radiation therapy)|Patients receive trifluridine/tipiracil hydrochloride combination agent TAS-102 PO BID and undergo radiation therapy in 10 fractions on days 1-5 and 8-12 in the absence of disease progression or unacceptable toxicity.
2440032|NCT03297697||Arm 1: Lymphotrack|-Patients will be treated with frontline chemotherapy per the treating physician's discretion. Collection of the pre-treatment tumor biopsy to identify the tumor-specific clonotype and peripheral blood samples at various time points for assessment of minimal residual disease using the LymphoTrack MRD assay. The results of these studies will be performed in batches and therefore will not be available to patients and clinicians to make clinical decisions.
2440033|NCT03297671||Pregnant Women|2000 pregnant women from the communities in the catchment area of THQ Johi and DHQ Dadu. Rh negative women will receive two RhIg prophylaxis injections.
2440034|NCT03297671||Lady Health Visitors (LHVs)|3-5 LHVs who are full time employees at THQ Johi and DHQ Dadu. LHVs will perform ELDONCARD test and provide RhIg prophylaxis injections.
2440035|NCT03297658|Active Comparator|electro-acupuncture (EA) intervention|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects will receive electro-acupuncture (EA) (treatment) mixed frequency( continuous plus dense disperse) will be at 2Hz and 100 Hz the amplitude will be 1000 microA.
2440036|NCT03297658|Sham Comparator|sham electro acupuncture|Micro electrodes will be placed at PC 4 and 6 , LI 4 and ST36. subjects Receive sham (control) will not have stimulation.
2440037|NCT03297645|Experimental|Arm 1|school + asthma education + home environment remediation
2440038|NCT03297645|Experimental|Arm 2|asthma education + home environment remediation
2440039|NCT03297645|Active Comparator|Arm 3|enhanced standard of care
2440040|NCT03297632|Experimental|Intervention Group|Receives instructor-based functional resistance exercise. 45 minutes per session. 3 times per week, during 10 weeks in total.
2440041|NCT03297632|No Intervention|Control group|Asked to normally active according to their current lifestyle
2440042|NCT03297632|Active Comparator|Home-based group|Receives home-based exercises with written instructions and digital video support. 45 minutes per session. 3 times per week, during 10 weeks in total.
2440043|NCT03297619|Experimental|ACT self-help book condition|Participants in this condition will be assigned to read The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness by Fleming and Kocovski (2013), a self-help book based on acceptance and commitment therapy.
2440044|NCT03297619|Active Comparator|CBT self-help book condition|Participants in this condition will be assigned to read The Shyness and Social Anxiety Workbook by Antony and Swinson (2008), a self-help book based on cognitive-behavioral therapy for social anxiety.
3151059|NCT00217737|Experimental|Arm B (combination chemotherapy, bevacizumab)|Patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in Arm A and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab alone for 12 additional courses in the absence of disease progression or unacceptable toxicity.
3151060|NCT00217737|No Intervention|Arm C (observation)|Patients undergo observation.
3151061|NCT00217776|Active Comparator|Open Airways Educational Intervention|Children in this arm will receive the Open Airways educational program which is an evidenced based asthma educational program for children, developed by the investigator.
3151062|NCT00217776|Active Comparator|Open Airways and Peer Asthma Action Intervention Education|Children in this arm will receive BOTH the Open Airways asthma education program and the Peer Asthma Action education program.
3189351|NCT00776672|Active Comparator|2|Monopril® 40mg tablets
2440058|NCT03297593|Experimental|nivolumab and ipilimumab|"Patients start treatment with nivolumab (240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter).~After 2 weeks, ipilimumab (1mg/kg every 6 weeks) will be introduced. As soon as a radiographic complete response (CR) or partial response (PR) is observed, ipilimumab has to be stopped and only the single-agent treatment with nivolumab is continued. Once ipilumimab has been stopped because of a response, it will not be re-started later on."
2440059|NCT03297567|Experimental|verbal guidance and booklet|verbal guidance and a booklet on the importance and benefits of movement during hospital stay, as well as what the patients should do to increase the level of physical activity.
2512845|NCT02811822|Experimental|Dose 3|
2440060|NCT03297567|No Intervention|No Intervention|The control group will not receive any type of intervention
2440061|NCT03297554|Experimental|m-health approach|See intervention description
2440062|NCT03297541|Experimental|m-health approach|All dyads will receive the m-health approach.
2440063|NCT03297528|Experimental|study group|Participants receive chemotherapy and donor lymphocyte infusions based on the state GvHD, even the participants have a negative result of minimal residual disease (MRD). If the participants have no GvHD,they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD.
2440064|NCT03297528|No Intervention|control group|Participants don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD,in dispite of whether or not GvHD.
2440065|NCT03297515|Experimental|Omega 3 fatty acids|Omega 3 fatty acids
2440066|NCT03297515|Placebo Comparator|Placebo|Placebo (sunflower oil)
2440067|NCT03297502|Experimental|Pimecrolimus cream, 1%|
2440068|NCT03297502|Active Comparator|Elidel (pimecrolimus) cream 1%|
2440069|NCT03297502|Placebo Comparator|placebo|
2440070|NCT03297489|Experimental|Diagnostic (intravital microscopy)|Patients receive fluorescein sodium injection IV. Patients also undergo observation of primary and metastatic tumors via microscopy over 15-20 minutes during the course of standard of care surgery.
2440071|NCT03297476||high-risk group|"Selected by High-risk subtype detection panels"
2440072|NCT03297476||non high-risk group|"Selected by High-risk subtype detection panels"
2440073|NCT03297463|Experimental|Phase Ib (Dose Escalation)|
2440074|NCT03297463|Experimental|Phase II (Dose Expansion)|
2440075|NCT03297450|Active Comparator|Aphasia therapy and tDCS|
2440076|NCT03297450|Sham Comparator|Aphasia therapy and sham-tDCS|
2440077|NCT03297450|Sham Comparator|Standard of care and sham-tDCS|
2440078|NCT03297424|Experimental|PLX2853|"Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.~Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL."
2440079|NCT03297411|Active Comparator|Brief Temporoparietal ECT|Brief Pulse Temporoparietal ECT
2440080|NCT03297411|Active Comparator|Ultrabrief Temporoparietal ECT|Ultrabrief Pulse Temporoparietal ECT
2440081|NCT03297411|Active Comparator|Brief Frontoparietal ECT|Brief Pulse Frontoparietal ECT
2440082|NCT03297411|Active Comparator|Ultrabrief Frontoparietal ECT|Ultrabrief Pulse Frontoparietal ECT
3189352|NCT00776685|Experimental|learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
2440086|NCT03297385|Experimental|Prostatectomy after enzalutamide|"This is a single-arm study. Patients will have biopsies, after which they will receive enzalutamide for 3 months.~After 3 months they will have a prostatectomy."
2440088|NCT03297359|Experimental|Weight adjusted dalteparin|"Participants will receive a daily subcutaneous injection of weight-adjusted dalteparin (See Table below) at a dose of approx. 200 IU/kg beginning on the day of enrolment and for a one month.~91 to 95 kg: 18,000 IU daily ( or 1 prefilled syringe of 18,000 IU) 96 to 105 kg: 20,000 IU daily ( or 2 prefilled syringes of 10,000 IU) 106 to 120 kg: 22,500 IU daily ( or 2 pre-filled syringes (10,000 and 12,500 IU)) 121 to 130 kg: 25,000 IU daily ( or 2 prefilled syringes of 12,500 IU) 131 to 145 kg: 27,500 IU daily ( or 2 pre-filled syringes (12,500 and 15,000 IU)) 146 to 150 kg: 30,000 IU daily ( or 2 prefilled syringes of 15,000 IU)~≥ 151 kg: 33,000 IU daily ( or 2 prefilled syringes (15,000 and 18,000 IU))"
2440089|NCT03297346|Other|Breast cancer patients treated with RT|"Cardiac imaging and circulating biomarkers measurements to evaluate:~myocardial dysfunction and deformation (ECHO-ST)~coronary artery lesions and coronary artery calcium score (CT)~myocardium including tissue abnormalities, cardiac morphology and function (MRI)~blood-based biomarkers of cardiovascular changes (BLOOD)"
2440090|NCT03297333|Experimental|Resistance training group|Resistance training will consist of a supervised circuit training 3 sessions/week for approximately 45-50 min/session. The circuit will include 7 strength exercises engaging the major muscle groups (leg press, rows, back squats, weighted crunches, deadlifts, bench press, and squat jumps with weights). The participants will perform 3 sets of 10 repetitions with resting periods of 30 seconds between exercises, and 2 minutes between sets. The overall OMNI-Resistance Exercise Scale per set will range between 8-10. Heart rate and exercise energy expenditure during the workout will be monitored. The load will be changed depending on the participants' perception when needed. In addition, the intensity will be monitored assessing Lactate concentrations at baseline and at the end of each session. Circuit will be repeated until meeting the targeted exercise energy expenditure of 450-500 kcal/session.
2440091|NCT03297333|Experimental|Aerobic interval training group|Aerobic interval will consist of a supervised aerobic interval training sessions 3 times/week. Duration will range between 45-50 min/session depending on the exercise energy expenditure. Each interval will have a total duration of 5 min, and it will be divided into 2 periods. The first period will consist of 3 minutes of high-intensity activity, and the second period the intensity will be reduced for 2 minutes. The speed/incline will be changed depending on the participants' heart rate and perception using the Borg's rating of perceived exertion as needed. Heart rate and exercise energy expenditure during the workout will be monitored. Intensity will be monitored assessing Lactate concentrations at the end of each session. Intervals will be repeated until meeting the targeted exercise energy expenditure (450-500 kcal/session).
2440092|NCT03297333|No Intervention|Control group|Participants in the control group will not participate in the training programs.
2440093|NCT03297320|Active Comparator|Team Referrals|In-depth conversations about Goals of Care and ACP (the intervention) will be held for the patients referred to the research team by the three healthcare teams in Internal Medicine at London Health Sciences Centre (University Campus)
2440157|NCT03296865|Experimental|Kinesio taping|Kinesio taping was apllied only one time. It was removed after intervention.
2441802|NCT03285243|Sham Comparator|Blue light - non monochromatic|
2440094|NCT03297320|Active Comparator|Random selection|A random selection of patients (not referred to the research team by the healthcare team) in Internal Medicine at London Health Sciences Centre (University Campus) will be selected to have in-depth conversations about Goals of Care and ACP (the intervention)
3189353|NCT00776685|Experimental|learning to cope with your sensation seeking|cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
3189354|NCT00776685|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
2440099|NCT03297281|Experimental|S1: maintenance|Maintenance of OAC in surgery of BPH by PVP.
2440100|NCT03297281|Active Comparator|S2 : discontinuation|Discontinuation of OAC in surgery of BPH by PVP.
2440101|NCT03297268||Phase 1-Controlled Validation & Study Planning|Phase 1 is focused on refining and ultimately verifying BESI's basic sensing and notification functionality and validating BESI's environmental assessments in a controlled setting - namely the laboratory and homes of two healthy volunteers. This phase also serves to support further requirements gathering to refine BESI for community-based deployment. No interventions are delivered.
2440102|NCT03297268||Phase 2 - In-situ Validation and Ethnographic Analysis|Phase 2 starts the deployment of the technology within a community context, with the goals of validating the system's ability to assess agitation and environmental events in-situ and developing the cyber-sociophysical system models based on the dyad-specific relationship between agitation and the environment. A hybrid remote ethnographic methodology will be used, combining remote BESI measurement and caregiver diaries and a time-series design for the administration of the assessment battery.
2440103|NCT03297268||Phase 3 - Intervention with Home-Based Caregivers|Phase 3 is the intervention phase and the full realization of BESI. The goal is to employ the validated assessment capabilities and the developed modeling techniques to enable real-time, dyad-specific caregiver notifications that empower a caregiver to intervene with the PWD and/or environment before agitation escalation. In addition to validation of the BESI's ability to provide such appropriate notifications, Phase 3 will also serve as a pilot study about the effect that these notifications have on caregiver empowerment (as measured by self-efficacy) and the frequency and severity of PWD agitation, thus providing proof-of-concept for BESI's potential to improve dyad outcomes and motivating a larger-scale followup study to establish proof-of-practice.
2440104|NCT03297229|Experimental|Peer mentoring|Peers will be patients with hypertension that have already been adequately controlled within the last six months. They will be selected within each center by the staff of the center and invited to participate in the study.
2440105|NCT03297229|Experimental|Self-monitoring|Each participant will receive a blood pressure monitor. The study nurse will teach the participant on how to use the device.
2440106|NCT03297229|No Intervention|Control|Usual care
3189355|NCT00776685|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3189356|NCT00776698|Experimental|1|
2440109|NCT03297203|Experimental|groupe1|patients in septic shock (group 1) in the medical intensive care unit of the Timone Hospital.
2440110|NCT03297203|Active Comparator|groupe 2|patients with a bacterial sepsis alone, during a 6 months period.
2440111|NCT03297190|Active Comparator|SMS|Participants will receive SMS messages on nutrition and health related topics
2440112|NCT03297190|Active Comparator|Interpersonal|Participants will receive interpersonal counselling on nutrition and health related topics
2440113|NCT03297190|Active Comparator|SMS + Interpersonal|Participants will receive SMS messages on nutrition and health related topics as well as interpersonal counselling on nutrition and health related topics
2440114|NCT03297190|No Intervention|Usual Care|
2440115|NCT03297177|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF Via Closed Syringe Microcannula
2440116|NCT03297177|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (tSVF) via enzymatic digestive isolation & concentration in Centricyte 1000 closed system to create AD-cSVF
2440117|NCT03297177|Experimental|Sterile Normal Saline Infusion|Sterile Normal Saline to Re-Suspend Autologous cSVF pellet for delivery via intravascular (IV) route
2440118|NCT03297164||optimized group|the patients in this group have been given the suggestive treatment from guideline.
2440119|NCT03297164||un-optimized group|the patients in this group have not been given the suggestive treatment from guideline.
2440120|NCT03297151|Sham Comparator|CONTROL|"Intervention: Dietary Supplement: Non-essential amino acids A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g non-essential amino acids dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry.~Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2440121|NCT03297151|Active Comparator|PROTEIN|"Intervention: Dietary Supplement: Whey Protein Concentrate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Concentrate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2440122|NCT03297151|Active Comparator|HYDROLYSATE|"Intervention: Dietary Supplement: Whey Protein Hydrolysate A group of subjects ingesting a liquid beverage (per kilogram body mass: 0.33g of Whey Protein Hydrolysate dissolved in water ) prior to completion of a prescribed resistance exercise training (RET) session.~Muscle Contractile Function to be conducted prior to and following the RET session by laboratory-based ergometry. Muscle Protein Synthesis induced by RET to be measured by deuterium incorporation in to skeletal muscle sampled by microbiopsy."
2440123|NCT03297125||Eligible Subjects|All enrolled subjects undergoing Optune therapy.
2440158|NCT03296865|Placebo Comparator|Placebo|Placebo was apllied only one time. It was removed after intervention.
2440159|NCT03296852|Experimental|Healthy Volunteers|
3189357|NCT00776724|Active Comparator|1|docetaxel-epirubicin for 4 cycles before surgery
2440125|NCT03297099|Experimental|Robot-assisted Laparoscopic operation|Da Vinci surgical robot can overcome limitations of conventional laparoscopic surgery in terms of vision and instrumentation flexibility, making the minimally invasive treatment of complex hepatolithiasis possible.
2440126|NCT03297099|Active Comparator|Open surgery|The indication of laparoscopic surgery is mainly for early regional type hepatolithiasis. Open surgery is the traditional treatment method for heptolithiasis.
2440127|NCT03297086|Active Comparator|Bi-Flex|Medicontur Bi-Flex 677MY IOL was implanted into 24 eyes of 12 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
2440128|NCT03297086|Active Comparator|ReStor|and Alcon Acrysof Restor SN6AD1 IOL was implanted into 36 eyes of 18 patients during cataract surgery. Angle kappa, biometric data and IOL decantation were measured.
2440129|NCT03297073|Experimental|major hepatic surgery|resection greater than or equal to three hepatic segments
2440130|NCT03297073|Experimental|hepatic surgery|resection less than three hepatic segments
2440131|NCT03297073|Experimental|hepatic surgery recovery|
2440132|NCT03297060|Experimental|SSL Implementation Strategy|Science to Service Implementation Strategy for SBIRT adherence
2440133|NCT03297060|No Intervention|Standard Care|Standard Care SBIRT services
2440134|NCT03297047|Active Comparator|upper arm combi cast|standardized treatment
2440135|NCT03297047|Experimental|forearm combi cast|Treatment with a forearm combi cast should be a sufficient immobilization
3189358|NCT00776724|Experimental|2|Tailored regimens, base on immunohistochemical study of the tumor biopsy tissue, for 4 cycles before surgery.
3208494|NCT00975338||Retrospective Non-LIFEspan|Non-LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
3208495|NCT00975338||LIFEspan Staff|All staff affiliated with the LIFEspan model of linked transition care
2440139|NCT03296995|Experimental|flash glucose monitoring system|Subjects in the arm measure blood glucose by flash glucose monitoring system.
2440140|NCT03296982||Blood Sample|Blood will be sampled by direct venipuncture on 8 occasions.
2440141|NCT03296969|Active Comparator|rectus muscle approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
2440142|NCT03296969|Active Comparator|rectus muscle non approximation|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
2440143|NCT03296956|Active Comparator|Day-5 postpartum - Active dietary supplement|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
2440144|NCT03296956|Placebo Comparator|Day-5 postpartum - Placebo|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Placebo"
2440145|NCT03296943|Experimental|Essential oil|Essential oil is prepared from the product of Thailada with manufacture standard ID 1087/2548 by Thailand Ministry of Industry. Essential oil is extracted by a cold compressed method from the lavandula angustifolia (lavender) grown in Australia.
2440146|NCT03296943|Sham Comparator|Perfume|Perfume is the synthetic perfume of lavender flavor without essential oil.
2440147|NCT03296930|Active Comparator|first drug group|Sofosbuvir 400 MG Oral Tablet
2440148|NCT03296930|Active Comparator|second drug group|Ombitasvir/paritaprevir/ritonavir
2440149|NCT03296917|Experimental|IMP - PrEP-001|"In Viral Challenge arm cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~In the Safety arm's first dose cohort:~A nasal dose of 6400 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1).~Then assuming no significant safety issues with the lower dose (as determined by blinded review by the DSMB team), the Safety arm's second dose cohort will consist of:~A nasal dose of 12800 μg PrEP-001 equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)"
2440150|NCT03296917|Placebo Comparator|Placebo - G-004|"In the Viral Challenge arm and each Safety Arm cohort:~A nasal dose of placebo equally divided over both nostrils on 2 consecutive days (Day -2 and Day -1)."
2440151|NCT03296904|Experimental|CLs++|Baseline assessment, intervention, final assessment
2440152|NCT03296891|Active Comparator|PoCUS Guided Resuscitation of Shock|Participants randomized to this arm of the study will undergo PoCUS guided resuscitation of shock.
2440153|NCT03296891|No Intervention|Usual Care|Participants randomized to the 'usual care' arm of the study will be suggested to have the following guide resuscitation: 1) Pulse pressure variation (PPV), stroke volume variation (SVV) and/or systolic pressure variation (SPV) on their arterial line, 2) central venous pressure (CVP) and oxygen saturation(ScvO2) measurement, 3) Passive leg raise (PLR) maneuver, and/or 4) pulmonary artery catheter
2440154|NCT03296878|Other|Own-Price Elasticity|"The price of eggs will vary (own-price elasticity) while the price of other foods in the mock grocery store will remain constant."
2440155|NCT03296878|Other|Cross-Price Elasticity|"The eggs will remain constant while the price of other foods in the mock grocery store will vary (cross-price elasticity)."
3208496|NCT00975338||Caregivers|Parents of participating youths
2440160|NCT03296826||BRCA1/2 variant carriers|Japanese women who carry BRCA 1/2 variants.
2440161|NCT03296813|Active Comparator|Torsemide|Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.
2440162|NCT03296813|Active Comparator|Furosemide|"Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.~For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows:~1 mg oral torsemide = 2-4 mg oral furosemide~1 mg oral or intravenous bumetanide = 40 mg oral furosemide"
3189359|NCT00776750|Experimental|influenza vaccination|All participants received a standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection. The vaccine contained 15 μg hemagglutinin of each of the following influenza strains: A/ New Caledonia/20/99 (H1N1), A/ Panama/2007/99 (H3N2), and B/Shangdong/7/97, recommended by WHO as components of the influenza vaccine for the epidemic season 2003/2004.
3189360|NCT00776763|Experimental|Avastin|
3189361|NCT00776802|Experimental|GCS-10|
3189362|NCT00776828|Active Comparator|TAT|triple antiplatelet therapy : aspirin, clopidogrel and cilostazol
3189363|NCT00776828|Placebo Comparator|DAT|dual antiplatelet therapy : aspirin, clopidogrel
3189364|NCT00776841|Placebo Comparator|Placebo|Placebo control single dose
3189365|NCT00776841|Experimental|Dose 1|Dose 30 mg
3189366|NCT00776841|Experimental|Dose 2|Dose 100 mg
2440171|NCT03296774|Placebo Comparator|Usual Care|Usual postpartum care
2440172|NCT03296774|Experimental|Healthy Beyond Pregnancy|Web-based program for postpartum care and education and scheduling. Incentive for committing and returning for postpartum care.
2440173|NCT03296761||ESM-1<5ng/ml|
2440174|NCT03296761||ESM-1≥5ng/ml|
2440175|NCT03296748|Active Comparator|TOT only group|60 patients with stress incontinence and asymptomatic grade 2 cystocele.
2440176|NCT03296748|Active Comparator|concomitant repair group|63 patients with stress incontinence and asymptomatic grade 2 cystocele.
2440177|NCT03296735|Experimental|Ipsilateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
2440178|NCT03296735|No Intervention|Supine|Measuring the cross-sectional area of right subclavian vein in supine position.
2440179|NCT03296735|Active Comparator|Contralateral tilt|Measuring the cross-sectional area of right subclavian vein in the 20 degree left tilting posture.
2440180|NCT03296722|No Intervention|Control group|The control group comprised 41 patients, which was to go once a month to receive nutritional intervention with the prescription of a hypocaloric diet on the part of the nutritionist. The control group had a monthly monitoring for 3 months.
2440181|NCT03296722|Experimental|Intervention group|The intervention group made up of 42 patients using the transtheoretical model and MI through sessions group and sessions individual with topics of healthy eating habits taught by a nutritionist, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy and confrontation of barriers given by a psychologist. The intervention group had a monthly monitoring for 3 months. The diet that was prescribed to the intervention group was with the characteristics of the DASH diet.
2440182|NCT03296709|Active Comparator|PPC m|
2440183|NCT03296709|Experimental|PPC z|
2440186|NCT03296683|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2440187|NCT03296670|Experimental|alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
2440188|NCT03296670|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
2440189|NCT03296657|Experimental|stannous fluoride toothpaste|0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
2440190|NCT03296644|Active Comparator|PowerScope2 group (G1)|Class II correction using PowerScope2
2440191|NCT03296644|Active Comparator|Forsus group (G2)|Class II correction using Forsus
2440192|NCT03296631||children|"Enrollment of 15 to 20 children (< 9 months old) at the early beginning of their entry in nursery (crèche) between August and November 2017.~This cohort will be followed during a maximum period of 36 months . Diapers with fresh stools will be collected once a week per child and then frozen.~Spontaneous personal day care informations given by the parents to the nurses and recorded in each child's daily logbook will be collected for the research. No specific interviews will be conducted."
2440193|NCT03296618|Experimental|NSI-566 neural stem cell implantation|
2440194|NCT03296605||Obesity|Patients with obesity already received bariatric surgery
2440195|NCT03296605||Healthy control|Volunteers with normal body weight and already received abdominal surgery
2440226|NCT03296410|Active Comparator|two measles attenuated live vaccine|infants vaccinated with two measles attenuated live vaccine at 8 months old
2440227|NCT03296410|Active Comparator|live attenuated Japanese encephalitis vaccine|infants vaccinated with live attenuated Japanese encephalitis vaccine at 8 months old
3189367|NCT00776841|Experimental|Dose 3|Dose 300 mg
3189368|NCT00776841|Experimental|Dose 4|Dose 900 mg
3189369|NCT00776841|Experimental|Dose 1 repeated|Dose 30 mg for 4 days
3189370|NCT00776841|Experimental|Dose 2 repeated|Dose high for 4 days
3189371|NCT00776867|Experimental|perifosine|This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level.
3189372|NCT00776880||1|Patients assessed with ASA physical status scale
3189373|NCT00776880||2|Patients assessed with PPS scale
3189374|NCT00776906|Experimental|1|PTX-coated balloon
3189375|NCT00776906|Active Comparator|2|Bare balloon
3189376|NCT00776932||Knee OA|Those over the age of 50 who have frequent pain in their knee that has lasted for at least six months.
3189377|NCT00776958||Ovarian or Breast Cancer Study Registry|
3189378|NCT00776971|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
2440196|NCT03296592||Investigational subjects|"Patients who have been diagnosed with cervical spondylotic myelopathy and who will be undergoing surgical correction for this diagnosis.~Visit 1 Investigational subjects will undergo a clinical assessment. Patients will undergo a DBSI MRI~Visit 2. 6 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 3 12 months after surgery, investigational subjects will undergo a clinical assessment~Visit 4 18 months after surgery, investigational subjects will undergo a clinical assessment.~Visit 5 24 months after surgery, investigational subjects will undergo a clinical assessment and a DBSI MRI."
2440197|NCT03296592||Control group|Healthy volunteers aged 45-65 Visit 1: DBSI MRI Visit 2: 24 months after first MRI, patient will undergo the second MRI
2440198|NCT03296579|Active Comparator|Conventional asthma therapy.|Bilevel Positive Airway Pressure group(BiPAP). BiPAP settings at 15/5 cm H2O by face mask with background rate 10 to 15/min. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
2440199|NCT03296579|Experimental|Non-invasive ventilation (CPAP).|Continuous Positive Airway Pressure group (CPAP). CPAP settings at 8 to 10 cm H2O. Standard steroid dose plus hourly salbutamol and oxygen to keep SaO2 > 92%.
2440200|NCT03296579|Experimental|Non-invasive ventilation (BiPAP)|Standard steroid dose, hourly salbutamol, oxygen as needed, nebulized ipratropium q 6 hrly, magnesium sulfate 50 mg/kg IV (4 doses q 6 hrly), loading dose of aminophylline 6 mg/kg IV if no progress.
3189379|NCT00776971|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
3189380|NCT00776971|Active Comparator|Semi-skimmed milk|202kJ/100mL
2440203|NCT03296553|Experimental|Valganciclovir|Oral Valgancyclovir 900 mg twice in a day during 4 weeks prior to initiation of cART (combined antirretroviral therapy) until suppression of HHV-8.
2440204|NCT03296553|Active Comparator|Antiretroviral combinations|Standard treatment with cART according to current HIV Therapy Mexican guidelines.
2440205|NCT03296540|Active Comparator|Uncrushed|6 Integral tablets Prasugrel as loading dose
2440206|NCT03296540|Experimental|Crushed|6 Crushed tablets Prasugrel as loading dose
3189381|NCT00776971|Placebo Comparator|Water|0kJ/100mL
3189382|NCT00777010|Active Comparator|Healthy high carbohydrate diet|Participants will follow a typical, higher carbohydrate dietary intervention with emphasis on lower glycemic carbohydrate foods and monounsaturated fatty acid consumption
2440209|NCT03296514|No Intervention|Wait List Control|Will receive voucher for MBSR after study is concluded
2440210|NCT03296514|Other|Intervention|These people will receive the MBSR
2440211|NCT03296501|Experimental|Autologous ADRC injection|
2440212|NCT03296488|Experimental|Nalbuphine Sebacate|receive single dose of NALDEBAIN (150 mg Nalbuphine Sebacate, 75 mg/ml, 2 ml/vial) intramuscularly 24±12 hours before surgery.
2440213|NCT03296488|Active Comparator|Fentanyl Citrate|receive intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
2440214|NCT03296475|Experimental|Midline Ventral Hernia|"Main inclusion criteria:~Patients with midline hernia defects.~Patients with either a maximal ventral hernia axial width of greater than 5cm or a loss of domain of greater then 20%.~Patients aged ≥ 18 years old.~Midline hernias closed in the midline with primary fascial closure with or without mesh augmentation.~Midline ventral hernias of VHWG grade 2 or 3."
2440215|NCT03296462|Experimental|Hip external rotation exercise (alone)|Standardised hip external rotation exercise training - over 12 week period
2440216|NCT03296462|Experimental|Hip external rotation + PFM exercises|Standardised hip external rotation plus pelvic floor muscle exercises - over 12 week period
2440217|NCT03296462|Active Comparator|pelvic floor muscle exercises (alone)|Standardised pelvic floor muscle exercises - over 12 week period (usual care)
2440218|NCT03296449|No Intervention|One-Lung Ventilation|During one-lung ventilation, when the chest is open, the non-dependent lung is collapsed and manipulated by the surgeon. It is the routine procedure during video-assisted thoracic surgery.
2440219|NCT03296449|Active Comparator|CPAP to non-dependent lung|"The patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-dependent lung at a pressure of 2-3cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
2440220|NCT03296449|Experimental|HFJV to non-dependent lung|"The patient is randomly assigned to the study arm High-frequency jet ventilation (HFJV). HFJV will be applied for 20 minutes to the non-dependent lung with a driving pressure of a 0.6 atm, respiratory rate 100 cycles per minute using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland)."
2440221|NCT03296436|Experimental|Treatment Group|Group that will be receiving the investigational product
2440222|NCT03296423|Placebo Comparator|Placebo|One intradermal injection of 0.1ml of sodium chloride 0.9%
2440223|NCT03296423|Active Comparator|Vaccination|One intradermal injection of 0.1ml of BCG (BCG vaccine Bulgaria strain 1331; Intervax)
2440224|NCT03296410|Experimental|EV71 and two measles attenuated live vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and two measles attenuated live vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2440225|NCT03296410|Experimental|EV71 and attenuated Japanese encephalitis vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) and live attenuated Japanese encephalitis vaccine at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2440831|NCT03292094||Black men|294 young healthy men were included (clinic normotensive, non-HIV)
3189383|NCT00777010|Experimental|Carbohydrate restricted, ketogenic diet|Paricipants will follow a carbohydrate restricted dietary intervention designed to induce ketone metabolism
3189384|NCT00777075|Active Comparator|L-arginine|
3189385|NCT00777075|Placebo Comparator|placebo|
3189386|NCT00777114|Experimental|All patients|
3189387|NCT00777127|Experimental|1|Aldara 5% Cream
3189388|NCT00777127|Active Comparator|2|Solaraze 3% Gel
3189389|NCT00777140|Active Comparator|1. Deferoxamine|Intravenous deferoxamine: bolus of 10mg/Kg (initiated during tPA infusion) and perfusion of 20/40/60 mg/Kg/day during 72h. Three different doses (3 steps), 15 patient in the active arm for each dose.
3189390|NCT00777140|Placebo Comparator|2. Placebo|Saline solution: Bolus and perfusion during 72h. 5 patients in the placebo arm in each step (randomization 3:1)
3189391|NCT00777166|Active Comparator|1|oxytocin 5 units
2440228|NCT03296410|Active Comparator|EV71 vaccine|infants vaccinated with enterovirus type 71 inactivated vaccine (human diploid cell) at 8 months old, and vaccinated with the second dose of enterovirus type 71 inactivated vaccine (human diploid cell) at 9 months old.
2440229|NCT03296397|Active Comparator|HPV Quadrivalent vaccine (QHV)|Gardasil
2440230|NCT03296397|Placebo Comparator|Placebo|Normal Saline
2440231|NCT03296384|Other|Patients with schizophrenia|
2440232|NCT03296384|Other|Relatives|
2440233|NCT03296371||Ancillary-Correlative (biospecimen collection)|Patients and their parents undergo collection of saliva or buccal mucosa samples for genetic mutational analysis. Germline DNA from saliva or buccal mucosa is evaluated via whole exome sequencing.
2440234|NCT03296358|No Intervention|Control group|Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
2440235|NCT03296358|Experimental|Experiment 1|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
2440236|NCT03296358|Experimental|Experiment 2|Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
3189392|NCT00777166|Active Comparator|2|oxytocin, 10 units
3189393|NCT00777192||Symptoms in Colorectal Cancer|Colorectal Cancer Patients Receiving Oxaliplatin Chemotherapy
2440239|NCT03296319|Active Comparator|echocardiography guided fluid resuscitation|
2440240|NCT03296319|Experimental|clinically guided fluid resuscitation|
2440241|NCT03296306|Active Comparator|6 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional two to four cycles of chemotherapy (totally six cycles)
2440242|NCT03296306|Experimental|4 cycles arm|Patients without evidence of disease progression or unacceptable toxicities after completion of two or four treatment cycles of cisplatin based chemotherapy (GP, GP-S, MVAC, HD-MVAC with GCSF) were randomly assigned to receive additional zero to two cycles of chemotherapy (totally four cycles)
2440243|NCT03296293|Other|Group I:IVPD≤3mmHg|Effect of PEEP at 5cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 10cmH2O on ICP in Group I:IVPD≤3mmHg Effect of PEEP at 15cmH2O on ICP in Group I:IVPD≤3mmHg
2440244|NCT03296293|Other|Group II:3mmHg<IVPD≤6mmHg|Effect of PEEP at 5cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 10cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg Effect of PEEP at 15cmH2O on ICP in Group II:3mmHg<IVPD≤6mmHg
2440245|NCT03296293|Other|Group III:IVPD>6mmHg|Effect of PEEP at 5cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 10cmH2O on ICP in Group III:IVPD>6mmHg Effect of PEEP at 15cmH2O on ICP in Group III:IVPD>6mmHg
3189394|NCT00777218|Active Comparator|1|
3189395|NCT00777218|Active Comparator|2|
2440248|NCT03296267|Other|gastroduodenoscopy|all participants undergo a gastroduodenoscopy to use the biopsies in an Ussing chamber experiment.
2440249|NCT03296254|Experimental|Course A|Body Mindfulness Exercised followed by Sitting Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
2440250|NCT03296254|Experimental|Course B|Sitting Mindfulness Exercises followed by Body Mindfulness Exercises. Written material and sound recordings will be offered as support elements.
2440251|NCT03296241|Experimental|Laser|One session of non-ablative Er:YAG laser (2940 nm) treatment of the vaginal wall, introitus and vestibule.
2440252|NCT03296241|Sham Comparator|Sham control|The sham control group was treated with the same procedure but with zero intensity settings - without receiving therapeutic irradiation (placebo).
2440253|NCT03296228||Hong Kong|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~supine side-bending and fulcrum bending films"
2440254|NCT03296228||Turkey|"Radiation: Flexibility Radiographs (supine, supine side-bend, FB)~Radiation: Flexibility Radiographs (awake traction)~Radiation: Flexibility Radiographs (STUGA)~supine side-bending, fulcrum bending films, awake traction and supine traction under GA"
2440255|NCT03296215||Observational|Patterno of admitted cases in Respiratory Intensive Care Unit at Assiut University Hospitals and Outcome
2440256|NCT03296202||HIV patients|4500 patients infected with HIV-1
2440257|NCT03296189|Active Comparator|Local anaesthetic|Post-ureteroscopy intraluminal injection of alkalinised high concentration levo-bupivicaine in the renal pelvis
2440258|NCT03296189|Active Comparator|Local anaesthetic + steroid|Post-ureteroscopy intraluminal injection of 10 mls alkalinised high concentration levo-bupivicaine with l dexamethasone in the renal pelvis
2440259|NCT03296189|Placebo Comparator|Placebo|Post-ureteroscopy intraluminal injection of 10 mls normal saline (placebo) in the renal pelvis
2440260|NCT03296176|Experimental|presymptomatic|
2440261|NCT03296176|Experimental|symptomatic|
2440262|NCT03296176|Other|controls|
3189396|NCT00777218|Active Comparator|3|
3189397|NCT00777231|Experimental|Sickle Cell Disease|Recipients treated with an enriched hematopoetic stem cell infusion
2440265|NCT03296150|No Intervention|Control arm : Information|Patients will receive the usual standard information delivered to patients
2441803|NCT03285243|Experimental|Monochromatic blue light|
3189398|NCT00777231|Experimental|Non-Malignant Disorders|Recipients treated with an enriched hematopoetic stem cell infusion
3189399|NCT00777231|Experimental|Aplastic Anemia|Recipients treated with an enriched hematopoetic stem cell infusion
3189400|NCT00777231|Experimental|Sickle Cell Disease : Extended Protocol|Recipients treated with an enriched hematopoetic stem cell infusion and Campath 1H conditioning
3189401|NCT00777244|No Intervention|Follow-up|Arm B
3189402|NCT00777244|Experimental|Mitotane|Arm A
3189403|NCT00777270|Experimental|1 continuous|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
3189404|NCT00777270|Experimental|2 interrupted|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
3189405|NCT00777309|Experimental|1|Erlotinib (150 mg) once daily plus ARQ 197 (360 mg) twice daily.
3189406|NCT00777309|Active Comparator|2|Erlotinib (150 mg) once daily plus ARQ 197 placebo twice daily
2440266|NCT03296150|Experimental|Intervention arm : Therapeutic educational program|"Patients will receive the therapeutic educational program PRESTAGE"
2440267|NCT03296137|Experimental|All participants|
2440268|NCT03296098|Experimental|ulipristal acetate|Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
2440272|NCT03296059|Experimental|RBC transfusion with conventional treatment|Besides conventional treatment,neonates diagnosed with ARDS is treated with RBC transfusion.
2440273|NCT03296059|Active Comparator|conventional treatment|neonates diagnosed with ARDS is treated with conventional treatment.
2440274|NCT03296046||PPBL patients|
2440277|NCT03296020|No Intervention|control group|"After the surgery, during the hospitalization ,the control group would get as is customary in our ENT department :acetaminophen syrup+ syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take( as is customary in our ENT department): acetaminophen syrup ( as necessary) and other painkillers ( as necessary).~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
2440278|NCT03296020|Experimental|"case group-HONEY"|"After the surgery, during the hospitalization ,the case group would instructed to use honey twice a day( 5 ml- one tea spoon each time)+acetaminophen syrup + syrup oxycode( as necessary).~After the discharge from the hospital - the patients would take:acetaminophen syrup ( as necessary) and other painkillers+honey twice a day( 5 ml- one tea spoon each time) .~The families would ask to follow treatment protocols for 7 days and will fill a questionnarie every day during the 7 days."
2440279|NCT03296007|Experimental|Mindfulness Meditation App|Participants randomized to this arm will use a smartphone app to practice mindfulness meditation for 12 minutes.
2440280|NCT03296007|Active Comparator|Mindfulness Meditation No App|Participants randomized to this arm will not use a smartphone app, but will receive instructions to practice mindfulness meditation for 12 minutes.
2440281|NCT03295994|Active Comparator|Operative|surgery + post-operative physical therapy
2440282|NCT03295994|Active Comparator|Non-Operative|non-operative physical therapy
3151063|NCT00217776|No Intervention|Control Arm|Children in the Control Arm will be interviewed in person at baseline, 12 month and 24 months.
3151064|NCT00217854|Other|Open label inhaled fluticasone|Patients are treated with open label high dose fluticasone for 30 days then discontinued. Comparisons are pre- and post- treatment single arm.
2440285|NCT03295968|No Intervention|Water and Rest|
2440286|NCT03295968|Experimental|Water and High Intensity Exercise|
2440287|NCT03295968|Experimental|Ibuprofen and Rest|
2440288|NCT03295968|Experimental|Ibuprofen and High Intensity Exercise|
2440289|NCT03295955|Active Comparator|Postop antibiotics group|Prescribe Amoxicillin Clavulanate
2440290|NCT03295955|No Intervention|No postop antibiotics|Do not prescribe Amoxicillin Clavulanate
2440291|NCT03295942|Experimental|OMP-336B11|Intravenous (in the vein) infusions of OMP-336B11
2440292|NCT03295916|Experimental|Systemic therapy plus SBRT to OM|Stereotactic Body Radiotherapy (SBRT) up to 5 OM sites
2440293|NCT03295903|Placebo Comparator|Placebo|Sugar pill that will have no effect.
2440294|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (1 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
2440295|NCT03295903|Active Comparator|Cannabidiol (1 dose)|Only cannabidiol supplement.
2440296|NCT03295903|Active Comparator|Cannabidiol and herbal capsules (2 dose)|Cannabidiol supplement with added ginseng, ginkgo biloba, and organic hemp oil.
2440297|NCT03295903|Active Comparator|Cannabidiol only (2 dose)|Only cannabidiol supplement.
2440298|NCT03295890|Sham Comparator|Sham Needling|Intervention = Sham Needling
2440299|NCT03295890|Active Comparator|Active Needling|Intervention = Active Needling
2440300|NCT03295877|Experimental|RO7171009: SAD|Patients will receive a single dose of RO7171009, in multiple escalating cohorts.
2440301|NCT03295877|Experimental|RO7171009: MD|Patients will receive RO7171009 at maximum tolerated dose (MTD), identified during the SAD stage for three doses.
2440302|NCT03295864|Experimental|Patients with Chiari type 1 malformation|Tympanometry measurement at inclusion and 6 months after surgery
2440303|NCT03295864|Experimental|Healthy volunteers|Tympanometry measurement at inclusion. Every healthy volunteer will be match with a patient for his age and his BMI (body mass index).
2440832|NCT03292094||White men|284 young healthy men were included (clinic normotensive, non-HIV)
3151065|NCT00217867|No Intervention|1|Usual Care, defined as the usual hospital discharge process as delivered by nurses and doctors.
3151066|NCT00217867|Experimental|2|Use of animated computerized character to prepare subjects for discharge by reviewing information provided to subjects in a printed After Hospital Care Plan packet, followed by telephone system to reinforce the discharge.
3151067|NCT00217893|Experimental|1|Combination of counseling, cotinine feedback, and contingent incentives.
3151068|NCT00217893|Active Comparator|2|Usual education program
3151069|NCT00217919|Experimental|1|Health-Counselor Mediated Telephone Counseling Intervention
3151070|NCT00217919|No Intervention|2|Usual care
3151071|NCT00217984|Experimental|Intensive intervention|Extended cognitive behavior therapy (16 sessions) plus nicotine patches and lozenges
3151072|NCT00217984|Other|Usual care|Referral to the smoking cessation clinic
2440304|NCT03295851|Experimental|IV Ferric Carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
2440305|NCT03295851|Active Comparator|Oral Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily
2440306|NCT03295838|Experimental|Mentalization-based Treatment|MBT was conducted according to the treatment manual developed by Bateman & Fonagy. Patients were offered individual sessions with a psychotherapist and group sessions with 6-8 participants and 1-2 group therapists for 18 months. An introductory psycho-educational component (9-12 sessions) was also offered focusing on explicit mentalising skills (i.e. understanding one's own or others' intentions). Group and individual MBT focused on implicit mentalising towards self and others.
2440307|NCT03295825|Other|Biomarker|Blood sampling
2440308|NCT03295799|Experimental|Patient Self-Management|Patients will go through a preparatory phase (creation of warfarin dosing chart, process for documentation and retrieval of labs), a practical training phase (formulate warfarin management plan with support) and then perform patient-self management of their own warfarin.
2440309|NCT03295799|No Intervention|Anticoagulation Clinic Care|Patients will not have their care altered, and will continue to be managed by our Anticoagulation Clinic.
2440310|NCT03295786|Placebo Comparator|Placebo|Patients randomized to this group will receive 6 monthly infusions of placebo/vehicle
2440311|NCT03295786|Experimental|CDNF mid-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to mid-dose
2440312|NCT03295786|Experimental|CDNF high-dose|Patients randomized to this group will receive 6 doses of CDNF titrated to high-dose
2440313|NCT03295773||Symptomatic stroke patient|Patients who are found signal void in a relevant intracranial internal carotid artery or middle cerebral artery (stenosis >60%) will proceed to a 3-Dimensional rotational angiography (3DRA) at baseline and in 12 months. All recruited patients will receive dual antiplatelet agents for 4 weeks, followed by aspirin alone. The investigator or neurologists shall regularly review the patients and treat the conventional cardiovascular risk factors based on four pre-specified goals, for example, LDL <1.8, HbA1c <6.0, blood pressure <140/90 and no smoking. The morphologic changes of the cerebral plaques with the intensity of the risk factor control in pre and post will be correlated.
2440314|NCT03295760||Children with cyclic vomiting syndrome|Children followed at Children's Hospital of Nancy treated with Q10 coenzyme for cyclic vomiting syndrome
2440315|NCT03295747|Experimental|Peppermint oil soft gel|Children will be randomized to receive either 180 mg, 360 mg, or 540 mg of peppermint oil.
2440316|NCT03295734|Active Comparator|Perindopril|4 mg qd titrated to 8 mg qd perindopril + aerobic exercise
2440317|NCT03295734|Active Comparator|Losartan|50 mg qd titrated to 100 mg qd losartan + aerobic exercise
2440318|NCT03295734|Active Comparator|HCTZ|12.5 mg qd titrated to 25 mg qd HCTZ + aerobic exercise
3151073|NCT00218010||Methadone maintained lactating women|Methadone maintained women who chose to breastfeed their infants provided breast milk and plasma samples for this study.
3151074|NCT00218049|Experimental|1|50 mg of GBR 12909
2440322|NCT03295708|Experimental|experimental group|the experimental group will be given 4 fish oil capsules (1g/one capsule)twice daily after two meals at roughly the same time each day,lasting for the first 6 months.fish oil capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.
2440323|NCT03295708|Placebo Comparator|control group|the control group will be given 4 soybean oil capsules ( placebo capsule,1g/one capsule) twice daily after two meals at roughly the same time each day,lasting for the first 6 months.placebo capsule will be provided by the Hunan Kangqi100 Biological Technology Co.Ltd.The placebo capsule's appearance and flavor are made the exactly the same as the fish oil capsules .
2440324|NCT03295695|Experimental|Cardiac Imaging - All Participants|Study agent: 2-deoxy-2-[18F]fluoro-D-glucose (FDG). Fluoro-D-glucose-positron Emission Tomography: Participants will undergo a PET-CT scan with Fluoro-D-glucose-labeled (FDG-labeled) red blood cells (RBCs) within 2 weeks of obtaining an echocardiogram prior to start of chemotherapy. A repeat FDG-RBC PET-CT scan will be completed within two weeks of obtaining their follow-up echocardiogram to determine post-therapy cardiac ejection fraction. If the participant has an echocardiogram obtained prior to completion of chemotherapy, an attempt will be made to obtain a FDG-RBC PET-CT scan within two weeks of the echocardiogram.
2440325|NCT03295656|Experimental|IV Contrast-Enhanced US|IV sulfur hexafluoride lipid-type A microspheres, 0.03 mL/kg, 2 doses per examination, total dose not to exceed 4.8 mL. Single examination per patient.
2440326|NCT03295643|Other|Mobile smoking cessation program|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
2440328|NCT03295617||spinal thoracic herniation|
2440329|NCT03295604|Experimental|test group|Miller class I-II gingival recession defects operated with sub epithelial connective tissue graft (SCTG) in addition with enamel matrix derivatives (EMD) (Emdogain ®, Switzerland ) in SCTG+EMD group.
2440330|NCT03295604|Experimental|control group|Miller class I-II gingival recession defects operated with only sub epithelial connective tissue graft (SCTG). No drug or something else were used
2440331|NCT03295578|Experimental|Personalized feedback group|In between the two measurement periods, the personalized feedback group will receive an explanation and personalized feedback on their self-measured data (interstitial glucose, cognition, wellbeing and food intake).
2440332|NCT03295578|Placebo Comparator|General feedback group|The generic feedback group will receive a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
2440333|NCT03295565|Active Comparator|A: Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
2440334|NCT03295565|Active Comparator|B: Abiraterone OR Enzalutamide|"At physician's discretion:~Abiraterone 1000mg oral, taken daily Prednisone 5mg oral, 2 times a day OR Enzalutamide 160mg oral taken daily"
2440335|NCT03295552|Experimental|DC|DNA demethylating agent decitabine plus carboplatin
2440336|NCT03295539|Other|Acute or Chronic clot|If chronic clot, no intervention given via Indigo
2440373|NCT03295331||GINA-defined clinical diagnosis of Asthma|All patients with GINA-defined clinical diagnosis of Asthma seen at respiratory clinic from January to August 2016 with age 18 and above
2440337|NCT03295526|No Intervention|Control group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and systematic pelvic lymphadenectomy
2440338|NCT03295526|Experimental|Experimental group|IB-IIA Cervical Cancer Patients with positive lymph node metastasis confirmed by intraoperative frozen pathological examination who will undergo radical hysterectomy and selective enlarged lymph node dissection.
2440339|NCT03295513|Active Comparator|veneered zirconia full coverage restorations|InCoris zirconia material (TZI-Densupply sirona)
2440340|NCT03295513|Experimental|Monolithic zirconia full coverage restorations|InCoris (TZI-Densupply sirona)
3151075|NCT00218049|Experimental|2|75 mg of GBR 12909
3151076|NCT00218049|Experimental|3|100 mg of GBR 12909
3151077|NCT00218114|Experimental|1|Divalproex sodium (Depakote). This is a parallel groups design lasting a total of six weeks. Participants will be on a fixed-flexible dosing schedule. The dose of depakote will be raised to 750mgs or 1000mgs, depending on weight, in two weeks to achieve blood levels between 50-130 micrograms per milliliter. If a patient does not achieve this blood level on 750mgs or 1000 mgs, the dose may be raised during the second week.
2440344|NCT03295487|Active Comparator|Group A|post menopausal female with genuine stress incontinence treated by TVT-O and local estrogen cream for 3 months after surgery
2440345|NCT03295487|Active Comparator|Group B|post menopausal female with genuine stress incontinence treated by TVT-O only
2440346|NCT03295474||Rehabilitation using telehealth technology|
2440347|NCT03295461|Active Comparator|test group|SRP+ 10% Emblica officinalis irrigation
2440348|NCT03295461|Active Comparator|positive control group|SRP + 0.2% Chlorhexidine irrigation
2440349|NCT03295461|Active Comparator|negative control group|SRP + 0.9% Saline irrigation
2440350|NCT03295461|Active Comparator|test gropup|SRP +10% E. officinalis gel application
2440351|NCT03295461|Placebo Comparator|control group|received SRP+ placebo gel application.
2440352|NCT03295448|Active Comparator|Fat - Sugar - Fiber|Intervention: consuming diets rich in fat, rich in sugar, and rich in fibers during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440353|NCT03295448|Active Comparator|Fat - Fiber - Sugar|Intervention: consuming diets rich in fat, rich in fiber, and rich sugar during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440354|NCT03295448|Active Comparator|Sugar - Fiber - Fat|Intervention: Consuming diets rich in sugar, rich in fiber, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440355|NCT03295448|Active Comparator|Sugar - Fat - Fiber|Intervention: Consuming diets rich in sugar, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440356|NCT03295448|Active Comparator|Fiber - Sugar - Fat|Intervention: Consuming diets rich in fiber, rich in sugar, and rich in fat during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440357|NCT03295448|Active Comparator|Fiber - Fat - Sugar|Intervention: consuming diets rich in fiber, rich in fat, and rich in fiber during treatment periods 1, 2, and 3, respectively. Treatment periods are separated by one week of habitual diet.
2440358|NCT03295422|Active Comparator|RF ablation PVI alone|RF catheter ablation of pulmonary veins alone
2440359|NCT03295422|Experimental|RF ablation PVI plus LPAW|RF catheter ablation PVI plus left atrial posterior wall
2440360|NCT03295409|Experimental|Experimental: Standard self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things I value about myself~remember things that I have succeeded in~think about what I stand for~think about things that are important to me~If…___________________________________________________________________"
2440361|NCT03295409|Experimental|Experimental: Familial self-affirmation|"Participants are asked to form a self-affirming implementation intention at the end of a questionnaire:~The beginning to a sentence appears below. Below it are 4 different ways of completing the sentence. On the lines below, please write out the beginning of the sentence and then complete it with 1 of the 4 options we have given you.~If I feel threatened or anxious, then I will…~think about the things my family and I value about ourselves~remember things that my family and I have succeeded in~think about what my family and I stand for~think about things that are important to my family and me~If…__________________________________________________________________"
2440362|NCT03295409|No Intervention|Control|Participants are asked to complete a questionnaire.
3151078|NCT00218114|Placebo Comparator|2|This is a parallel groups design lasting a total of six weeks. Participants will be on matching placebo for 250 mgs divalproex sodium (Depakote).
3151079|NCT00218127|Experimental|1|LAAM WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day for 20 weeks
2440365|NCT03295383|Experimental|Rituximab treatment|"Rituximab at a dose of 1000 mg (or matching placebo) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197~cyclophosphamide placebo will be administered orally once daily"
2440366|NCT03295383|Active Comparator|Cyclophosphamide treatment|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally. patients older than 75 years: 1 mg/kg/day, orally.~Rituximab placebo (NaCl 0.9 %) will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197"
2440367|NCT03295370|Experimental|Active Group|Needle electrical stimulation of accessory spinal nerve
2440368|NCT03295370|Sham Comparator|Sham Group|Needle of accessory spinal nerve without electrical stimulation
2440369|NCT03295357||Patients with extubation while on ECLS|
2440370|NCT03295357||Patients without extubation|
2440371|NCT03295344||Patients|
2440372|NCT03295344||Healthy volunteers|
3151080|NCT00218127|Experimental|2|LAAM MaxEffect to 48 mg Adjust to effect (+/-)
2441906|NCT03284502|Experimental|Stage 1|Dose-escalation
3189407|NCT00777322|Experimental|Interventional study|Patients with known keratoconus or pellucid marginal degeneration will be invited to join the study. The study is partly a continuation in the management of patients who have had previous keratophakia, who will have near-normal or supra-physiological levels of corneal thickness. It is also intended for patients with relatively mild keratoconus who have sufficient corneal thickness to allow a limited laser ablation whilst still leaving a residual stromal bed of at least 350μ.
3189408|NCT00777348|Experimental|1|DSCG + Reproterol
3189409|NCT00777348|Active Comparator|2|DSCG
2440377|NCT03295305|Experimental|Action Based Cognitive Remediation|
2440378|NCT03295305|Active Comparator|Unstructured support group|
2440379|NCT03295292|Sham Comparator|Standard Surgery with Vehicle|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL Fibrin Sealant (sham) without cells.
2440380|NCT03295292|Experimental|Standard Surgery with Stem Cells|After the standard surgical procedure (PRK/PTK or CXL), patients will receive 50uL of a mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in the thrombin component of Fibrin Sealant (TISEEL, Baxter).
3189410|NCT00777348|Active Comparator|3|Reproterol
3189411|NCT00777348|Placebo Comparator|4|Placebo
3189412|NCT00777361|Experimental|AZD3480 iv|Single iv infusion AZD3480
2440384|NCT03295253|Experimental|Female patients with Stress Incontinence|Female patients who will undergo autologous adipose tissue harvesting/grafting using Lipogems and grafting in urethra/bladder neck
2440385|NCT03295240|Experimental|BR-I in combination with VEN|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered in combination with VEN (Venetoclax).
2440386|NCT03295227|Experimental|Pembrolizumab|"Part 1: Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of every 21 day Cycle.~Part 2: Participants received Pembrolizumab at the maximum tolerated dose from Part 1."
2440387|NCT03295214|Active Comparator|Acetaminophen 975mg Per Os|975mg of Acetaminophen given by mouth
2440388|NCT03295214|Active Comparator|Acetaminophen 1000mg Intravenous|1000mg of Acetaminophen given intravenously
3189413|NCT00777361|Experimental|Oral [14C] AZD3480|Single oral dose [14C]AZD3480
3189414|NCT00777374|Experimental|1|Allergen containing patch
2440391|NCT03295188|Experimental|Intervention Group|Two 0.5 mg plasmalogen capsules per day
2440392|NCT03295188|Placebo Comparator|Placebo Group|Two placebo capsules containing no plasmalogen per day
2440393|NCT03295175||Congenital Megaprepuce|Congenital Megaprepuce Hematoxylin-eosin and smooth muscle actin markers
2440394|NCT03295175||Hypospadias|Hypospadias Hematoxylin-eosin and smooth muscle actin markers
2440395|NCT03295175||Control|Circumcision for non-medical reasons. Hematoxylin-eosin and smooth muscle actin markers
2440396|NCT03295162|Experimental|Sepsis A Group|neonates diagnosed with Sepsis and will receive melatonin. 10 mg product as a total dose of 20 mg .together with conventional treatment of Neonatal sepsis
2440397|NCT03295162|Sham Comparator|Sepsis B Group|neonates diagnosed with Sepsis and willnot receive melatonin., they will recieve only the conventional treatment of Neonatal Sepsis
2440398|NCT03295162|No Intervention|Control|healthy neonates, in whom sepsis will be ruled-out on the basis of absence of any clinical or laboratory evidence suggestive of infection.
2440399|NCT03295136|Experimental|Health Promotion Training for Women Employees|Groups of women employees will participate in a 20 session health promotion training course. The course will include health education and health promotion knowledge and skills, as well as leadership and project building skills, including empowerment, change process, recruiting partners and more. The first 15 sessions will be weekly session, while the remaining five will take place every couple of months throughout the following year.
2440400|NCT03295110|Experimental|Functionalities of the Lili Smart Solution activated|Lili Smart solution consists of an application for caregivers (web / mobile), a GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 / 24 and 7/7.
2440401|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Lili Smart watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
2440402|NCT03295097|Other|Clinical Decision Support System|The Clinical Decision Support System is composed of pharmacogenomic results and a pharmacist evaluated drug to drug interaction review. This system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions.
2440403|NCT03295084|Experimental|Irinotecan|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily for 14 days within 3 week treatment cycle
2440404|NCT03295084|Experimental|Irinotecan with Capecitabine|Dose escalation study in cohorts of minimum 3 patients of an Irinotecan tablet taken once daily in combination with Capecitabine tablet taken twice daily for 14 days within 3 week treatment cycle
2440405|NCT03295071||Single-group study|This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).
2440406|NCT03295058|Experimental|Non ATG regimen|the first 50% of patients will receive Fludarabine + cyclophosphamide prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
2440407|NCT03295058|Experimental|ATG regimen|the other 50% will receive Cyclophosphamide + ATG prior to hematopoietic cell transplantation. GVHD Prophylaxis: Cyclosporine A All the patient will do allogenic stem cell transplantation from peripheral blood
2440833|NCT03292094||Black women|312 young healthy women were included (clinic normotensive, non-HIV)
3189415|NCT00777374|Placebo Comparator|2|Placebo patch
3189416|NCT00777387|Active Comparator|1|slow-freeze
3189417|NCT00777387|Active Comparator|2|vitrification
3189418|NCT00777400|Experimental|1|Efalizumab will be started on Day 0 until the end of the study at Week 24. At the end of the first week, after efalizumab is started, cyclosporine or tacrolimus will be decreased by 50% and at 2 weeks the dose of cyclosporine or tacrolimus will be completely discontinued. At 12 weeks Cellcept or myfortic will be discontinued and the patient will be converted to sirolimus for the remainder of the study.
3189419|NCT00777413|Experimental|1|Minocycline 100 mg tablets of Ranbaxy
2440408|NCT03295032|Experimental|group-based ACT|Stroke survivors were randomised into group-based ACT intervention consisting of 2hr sessions for four consecutive weeks.
2440409|NCT03295032|No Intervention|Waiting list control|Waiting list control - received treatment as usual.
2440410|NCT03295019|Experimental|Test Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2440411|NCT03295019|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their placebo mouth spray, 2 times daily (morning and evening), for the 4 week duration of the study.
2440412|NCT03295006||Previous Therasphere treatment|Patients who had received TheraSphere yttrium-90 microspheres
3151081|NCT00218127|Experimental|3|LAAM Fixed Dose up to 48 mg 48 mg
2440414|NCT03294967|Active Comparator|Caffeine|To determine the effect of caffeine on ocular circulation in high myopes by consuming 200 mg caffeine capsule
2440415|NCT03294967|Placebo Comparator|Vitamin E|To determine the effect of caffeine on ocular circulation in high myopes by consuming and 200 International Unit vitamin E control capsule, as control
2440416|NCT03294954|Experimental|GINAKIT cells + cytoxan + fludara|"Cyclophosphamide and fludarabine will be administered prior to the GINAKIT cells.~Day -4: Cyclophosphamide and Fludarabine~Day -3: Cyclophosphamide and Fludarabine~Day -2: Fludarabine~Day -1: Rest~Day 0: GINAKIT cells"
3189420|NCT00777413|Active Comparator|2|Minocin 100mg tablets
2440418|NCT03294928|Experimental|progressive increasing of PEEP level|four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level.
2440419|NCT03294915|Active Comparator|Resistant Starch|Green banana flour
2440420|NCT03294915|Placebo Comparator|Placebo|Maltodextrin, cellulose and guar gum
2440421|NCT03294902||Critical Limb Ischaemia (CLI) Group with tibial arterial dis|Up to 20, but at least 8 subjects with a Rutherford grade 4 or 5 critically ischemic foot, where the primary intention is to treat at least one occluded tibial vessel or 2 severely stenosed tibial vessels. The treatment of SFA stenoses of less than 70%, as confirmed by duplex or CT, is acceptable in parallel in this group.
2440422|NCT03294902||Peripheral Artery Disease (PAD) Group with SFA disease|Up to 20, but at least 8 subjects with a clinical diagnosis of claudication and duplex or CT-confirmed SFA stenoses greater than 70%, with no intention of primarily treating any tibial disease at this encounter.
2440423|NCT03294902||PAD-free group (Healthy Volunteer Group)|Up to 20 subjects with no clinical diagnosis of peripheral vascular disease.
2440424|NCT03294863|Experimental|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive will be applied to 1/2 of the cutaneous wound
2440425|NCT03294863|Placebo Comparator|Standard of Care|Another 1/2 of cutaneous wound will be treated per standard of care
2440428|NCT03294824||patients who reactivate CMV or AdV after allogeneic HSCT|allotransplanted patients who reactivated respectively CMV (n=30) and AdV (n=10)
2440429|NCT03294824||Control group: allogeneic HSC transplanted patients|allotransplanted patients who didn't reactivate CMV
2440430|NCT03294824||Healthy donors group|healthy donors serologically + for CMV
2440431|NCT03294811|Experimental|Telemonitoring group|Recieve a smartphone with an application to coach them, a blood pressure monitor and scale.
2440432|NCT03294811|No Intervention|Control group|Control group (usual care, without telemonitoring)
2440433|NCT03294798|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 600-900μg,once per two weeks.
2440434|NCT03294798|Active Comparator|Pegasys|Pegasys 180 mcg, once per week
2440435|NCT03294785|Experimental|Chuna manual therapy|The Chuna manual therapy group will receive Chuna manual therapy alone. Chuna manual therapy will employ a semi-standardized treatment plan of Chuna manual therapy through Chuna technique selection based on physician judgement of techniques from Chuna Medicine (Korean Society of Chuna Manual Medicine for Spine & Nerves: Chuna Medicine: Seoul: Korean Society of Chuna Manual Medicine for Spine & Nerves; 2017) and osteopathic manipulative medicine. The Chuna techniques employed in this study are divided into cervical, thoracic and rib cage, lumbar, pelvic, sacral, pubic, and hip joint area techniques. Chuna manual therapy sessions will be administered 2 sessions/week over a period of 5 weeks (total 10 sessions). The time duration of 1 Chuna manual therapy session will consist of approximately 10-20 minutes of diagnosis and approximately 10 minutes of treatment.
2440436|NCT03294785|Active Comparator|Usual care|The usual care group will receive usual care alone. Usual care will be limited to physical therapy and conventional medication in this study. Usual care will be provided with reference to a list of most frequently used treatments in neck pain-related patients from Korean Health Insurance Review and Assessment (HIRA) 2014 statistics. Frequency and types of physical therapy used will be recorded in a separate electronic case report form for outcome assessor blinding purposes.
2440437|NCT03294772|Experimental|Hand sanitizer group|DCCs received alcohol-based hand sanitizer and a program educational. Characteristics of the hydroalcoholic gel (Alco aloe gel): chlorhexidine digluconate at 0.2% solution, phenoxyethanol 1%, benzalkonium chloride 0.1%. aloe barbadensis 5%, ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 70%, ph = 7-7,5.
2440438|NCT03294772|Experimental|Liquid soap group|DCCs received soap and program educational. The liquid soaps used for handwashing in this study did not contain specific antibacterial component, ph= 5.5.
2440439|NCT03294772|No Intervention|Control group|No hand sanitizer or educational program were used.
3151082|NCT00218166|No Intervention|A|Within subject design
3151083|NCT00218179||Cases|Lung cancer cases diagnosed prior to 2007 among baseline smokers in the PLCO
3151084|NCT00218179||Controls|Subjects without lung cancer among smokers at baseline in the PLCO study
3151085|NCT00218218|Experimental|1|Transdermal nicotine, 42 mg
3151086|NCT00218218|Experimental|2|Transdermal nicotine, 21 mg
3151087|NCT00218218|Placebo Comparator|3|placebo patch
3151088|NCT00218231|Experimental|1|300 mg/day bupropion-sr
3151089|NCT00218231|Placebo Comparator|2|0 mg bupropion-sr
3151090|NCT00218244|Active Comparator|1 Controlled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under a controlled use condition.
2440440|NCT03294759|Experimental|Bio-ACL (Amion)|Intervention: ACL Autograft Reconstruction with Amion Collagen Scaffold. Stem Cells isolated from bone marrow aspirate from distal femur will be injected inside the Amion Collagen Scaffold.
2440441|NCT03294759|Active Comparator|Control|Intervention: Normal ACL Autograft Reconstruction with either patella or hamstring autograft will be performed in the control group.
2440442|NCT03294746|Other|Clinical evaluations and Thoracic CT scan scoring of DIILD|
2440443|NCT03294733|Other|Ultrasound|Ultrasound wrists to determine carpal tunnel size
2440444|NCT03294720|Experimental|Bio ACL Reconstruction|Normal ACL reconstruction with either patellar or hamstring autograft will be done and prior to fixation the graft will be wrapped in a amion collagen wrap. Bone marrow aspirate will be obtained from distal femur at the time of the arthroscopy and stem cells isolated using the Arthrex Angel System. These stem cells with be under direct visualization impregnated into the ACL autograft amion wrap complex.
2440445|NCT03294707|Experimental|AG10 single oral dose|AG10 oral tablet, administered by mouth, once
2440446|NCT03294707|Placebo Comparator|Placebo single oral dose|Placebo Oral Tablet, administered by mouth, once
2440447|NCT03294694|Experimental|Ribociclib and PDR001 (Cohort A)|"The treatment regimen is defined as ribociclib + PDR001.~Treatment will be administered on an outpatient basis.~The study will use a 3 + 3 dose escalation design to determine the MTD/RP2D.~Three to six evaluable patients will be enrolled in each cohort in the dose escalation phase.~Once the RP2D of the combination of ribociclib + PDR001 is determined, there will be an expansion cohort.~Cohort A expansion will assess the combination of ribociclib + PDR001 in 12 patients with metastatic ovarian cancer."
2440448|NCT03294694|Experimental|Ribociclib, PDR001 and Fulvestrant (Cohort B)|"The treatment regimen is defined as ribociclib + PDR001 + fulvestrant .~Treatment will be administered on an outpatient basis.~There will be a safety run-in using the MTD/RP2D of ribociclib + PDR001 from Cohort A with the addition of fulvestrant in an initial 6-12 patients.~Once the safety of the combination of ribociclib + PDR001 + fulvestrant is established, there will be an expansion cohort.~Cohort B expansion will assess the combination of ribociclib + PDR001 + fulvestrant in 24 patients with hormone receptor-positive metastatic breast cancer (HR+ MBC)."
3189421|NCT00777426||Thai HAD individuals (25 cases)|
2440450|NCT03294668|Experimental|KONTAKT Australia|A social skills group training
2440451|NCT03294668|Active Comparator|Super Chef|A social cooking group
2440452|NCT03294655|No Intervention|No contact control|the no contact control group will do nothing
2440453|NCT03294655|Experimental|Intervention|the intervention condition will come to the lab for a 1 hour Pilot Resilience Building Intervention including a presentation on resilience and strategies to boost adherence, of which they will chose five to integrate in their daily life over the following 4 weeks
2440454|NCT03294642|Experimental|Trial 1|Water Intervention: In one of the 3 cycling trials, participants will receive only water and no carbohydrate supplementation during the 2 hour cycling challenge.
2440455|NCT03294642|Experimental|Trial 2|Carbohydrate Gel Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of commercially available gels (15g every 15 minutes) during the 2 hour cycling challenge.
2440456|NCT03294642|Experimental|Trial 3|Potatoes Intervention: In one of the 3 cycling trials, participants will receive carbohydrate supplementation in the form of pureed russet potato (15g every 15 minutes) during the 2 hour cycling challenge.
3189422|NCT00777426||Thai Non-HAD individuals (25 cases)|
3189423|NCT00777426||Thai Non-infected individuals (10 cases)|
2440459|NCT03294616|Experimental|scleroderma patients-0|for acute study: The experiment in patients will be performed in 4 randomized sessions on separate days (at least 3 days apart): one control session with sham-TEA and 3 TEA sessions at various parameters. TEA will be applied on both acupoints ST36 and PC6; the following sets of parameters will be tested for TEA at ST36: A) standard parameters: the set used in the previous SSc study: 25 Hz, 0.3ms, 2s-on and 3s-off; B) same as A but pulse width of 0.6ms; C) same as B but 0.1s-on and 0.4s-off. For TEA at PC6, 25 Hz will be replaced by 100Hz because TEA at PC6 is used to treat symptoms and 100Hz is believed to be better than 25Hz. The patient will be fasted overnight, and the test will last 2 hours (1 hour fasting and 1 hour postprandial).
2440460|NCT03294616|Experimental|scleroderma patient-1|for chronic study: 2 weeks of Sham transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
2440461|NCT03294616|Experimental|scleroderma patients-2|for chronic study: 2 weeks of transcutaneous electroacupuncture treatment, 2 weeks of wash out, 2 weeks of transcutaneous electroacupuncture/Sham transcutaneous electroacupuncture treatment. Best parameter gained from acute study will be used.
2440462|NCT03294603|Experimental|[14C]-CC-220 solution|A single oral dose of 1 mg [14C]-CC-220 solution, containing approximately 1.4 μCi of radioactivity, will be administered on Day 1 under fasted conditions.
2440463|NCT03294590|Experimental|Oral health text messages (OHT)|Participants in this arm will receive the OHT parent targeted text messages to reduce caries and improve oral health behaviors among low income families visiting community-based, urban pediatric clinics.
2440464|NCT03294590|Active Comparator|Child wellness text messages (CWT)|Participants in this arm will receive the CWT parent targeted text messages to improve child wellness (e.g., reading time, safety) among low income families visiting community-based, urban pediatric clinics.
2440465|NCT03294577|Active Comparator|TAC + Pegfilgrastim|"Phase 3:TAC + Pegfilgrastim (6 mg)+ D5W placebo~D5W Placebo: 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W"
2440466|NCT03294577|Experimental|TAC + Pegfilgrastim + Plinabulin|Phase 3: TAC+ Plinabulin (40 mg) + Pegfilgrastim (6 mg)
3189424|NCT00777439|Other|Domperidone|All eligible subjects will receive domperidone in an open label, single group assignment.
3189425|NCT00777452||1|active surveillance
3189426|NCT00777452||2|radical prostatectomy
3189427|NCT00777452||3|external beam radiotherapy
3189428|NCT00777452||4|high intensity focused ultrasound
3189429|NCT00777465||KDIGO 0|Patients with no acute kidney injury after cardiac surgery
3189430|NCT00777465||KDIGO 1|Patients with acute kidney injury KDIGO stage 1 after cardiac surgery (Increase in SCr by ≥ 0.3 mg/dL (≥ 26.5 lmol/L) or 1.5 to 1.9 times baseline)
2440467|NCT03294564|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
2440468|NCT03294564|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
2440469|NCT03294551|No Intervention|Standard of Care Control|Usual source of care
2440470|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Autodialer|HPV Vaccine Reminder Recall - Autodialer: Receive up to 4 reminders via telephone (live call or voicemail) - includes brief educational message + providers name + providers telephone number
2440471|NCT03294551|Experimental|HPV Vaccine Reminder Recall - Texting|HPV Vaccine Reminder Recall - Texting: Receive up to 4 reminders via text message - includes brief educational message + providers name + providers telephone number
3189431|NCT00777465||KDIGO 2|Patients with acute kidney injury KDIGO stage 2 after cardiac surgery (2.0 to 2.9 times baseline SCr)
3189432|NCT00777465||KDIGO 3|Patients with acute kidney injury KDIGO stage 3 after cardiac surgery (3.0 times baseline or more; or increase in SCr to ≥ 4.0 mg/dL; or initiation of renal replacement therapy)
3189433|NCT00777504|Active Comparator|A|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group A now stop the orale angiogenesis inhibitor.
2440475|NCT03294525||Escitalopram-for MDD|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
2440476|NCT03294525||Duloxetine-for MDD|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
2440477|NCT03294525||Mirtazepine-for MDD|Eligible patients were assigned to mirtazepine treatment based on investigators' clinical practice.
2440478|NCT03294525||other antidepressant-for MDD|Eligible patients were assigned to other antidepressant treatment (including sertraline, paroxetine, fluoxetine, venlafaxine, etc) based on investigators' clinical practice.
2440479|NCT03294512|Experimental|Heart Failure Patients|Patients who are seen at Intermountain Medical Center with heart failure, based on the Intermountain-specific Heart Failure Identification and Risk Stratification, will be screened for this study. The Principal Investigator and/or his delegate will confirm the presence of heart failure, based on established standard of care criteria for diagnosis.
2440480|NCT03294486|Experimental|Combination of TG6002 and flucytosine (5-FC, Ancotil®)|All patients within a given cohort will be treated with the same dose schedule of TG6002, administred as 3 weekly IV infusions at days 1, 8 and 15. following the 1st and 2nd infusions of TG6002, patients will be given oral 5-FC for 3 days starting on day 5 and 12 . following the 3rd infusion, patients will be given oral 5-FC for 21 days starting on day 19.
2440481|NCT03294473|Experimental|Autodial R/R|R/R Autodialers:Participants in this group will receive up to 3 influenza vaccination reminders via telephone call - with a brief educational message + practice name + practice phone number
2440482|NCT03294473|Experimental|Text Message R/R|R/R Texting: Participants in this group will receive up to 3 influenza vaccination reminders via text message - with a brief educational message + practice name + practice phone number
2440483|NCT03294473|Experimental|Postcard R/R|R/R Mailed Postcard:Participants in this group will receive up to 3 influenza vaccination reminders via postcard - with a brief educational message + practice name + practice phone number
2440484|NCT03294473|No Intervention|Standard of Care Control|Participants in this group will not receive any influenza vaccination reminders
2440485|NCT03294460|Experimental|1|Alcohol self-administration (IV ethanol for sessions 1 and 3, oral for session 2)
2440486|NCT03294447|Experimental|Fall Prevention Intervention by OT|Fall prevention interventions implemented by an OT in a geriatric primary care setting for a client immediately following the provider visit within the office.
2440487|NCT03294434||High Grade Glioma|Diffusion tensor Imaging (DTI-MRI) scan to be performed pre-operatively and pre-radiotherapy
2440488|NCT03294421|Active Comparator|standard closed tympanomastoidectomy|In this group it will be performed the standard technique for closed tympanomastoidectomy, in which a surgical microscope is used.
2440489|NCT03294421|Experimental|combined access tympanomastoidectomy|In this group a closed tympanomastoidectomy with combined access will be performed. This technique combines the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation.
2440490|NCT03294408|Other|Imaging|multimodal imaging and clinical assessment
2440491|NCT03294395|Active Comparator|Ceftriaxone im|Current standard treatment. Ceftriaxone 500mg (single intramuscular dose) + placebo (single oral dose)
2440492|NCT03294395|Experimental|Ertapenem im|Ertapenem 1000mg (single intramuscular dose) + placebo (single oral dose)
2440493|NCT03294395|Experimental|Fosfomycin po|Fosfomycin oral suspension 6g (single oral dose) + placebo (single intramuscular dose)
2440494|NCT03294395|Experimental|Gentamicin im|Gentamicin sulfate, injectable 5mg/kg (single intramuscular dose) + placebo (single oral dose)
2440495|NCT03294382|Experimental|Botulinum toxin|5U Botulinum toxin in 0.1 mL normal saline, administered in one of the intercanthus
2440496|NCT03294382|Placebo Comparator|Normal Saline|0.1 mL normal saline, administered in the other intercanthus
2440497|NCT03294369||Cohort of the study|A sample from the general population aged 18 years or older, randomly selected from a database of sanitary cards stratified by age and gender.
2440498|NCT03294356|Experimental|FT210771 Group|7 day at-home use of electronic cigarette FT210771 followed by a 2 day in-clinic period.
2440499|NCT03294356|Experimental|FT210751 Group|7 day at-home use of electronic cigarette FT210751 followed by a 2 day in-clinic period.
2440500|NCT03294356|Experimental|6T30134157764 Group|7 day at-home use of electronic cigarette 6T30134157764 followed by a 2 day in-clinic period.
2440501|NCT03294356|Experimental|G41A7C071 Group|7 day at-home use of electronic cigarette G41A7C071 followed by a 2 day in-clinic period.
2440502|NCT03294356|Experimental|M011161212 Group|7 day at-home use of electronic cigarette M011161212 followed by a 2 day in-clinic period.
2440503|NCT03294356|Experimental|FT21002 Group|7 day at-home use of combustible cigarette FT21002 followed by a 2 day in-clinic period.
2440624|NCT03293550||patients over 65 years undergoing elective surgery|patients over 65 years undergoing elective cardiac surgery or elective hip or knee surgery
2512846|NCT02811822|Experimental|Dose 4|
2440504|NCT03294343|Experimental|HBOCS|For carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome), if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy only by laparoscopy and long-term follow-up are provided.
2440505|NCT03294343|Experimental|Lynch syndromes|for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11, , if they demand for risk-reducing surgeries, counseling, decision-making analysis, then salpingo-oophorectomy with hysterectomy by laparoscopy and long-term follow-up are provided.
2440506|NCT03294343|Other|Refusal to surgery|For carriers with any mutation genes (BRCA1, BRCA2, ATM, BRIP1, RAD51, RAD51C, RAD51D, STK11, MLH1, MSH2, MSH6, PMS2 and EPCAM) but refusal to any risk-reducing surgeries, counseling, decision-making analysis, and then long-term follow-up are provided.
2440507|NCT03294330|Experimental|Patients with Melanoma or Breast Cancer|The SPY machine used in conjunction with the IC-green kit will be used exclusively to identify sentinel nodes in patients diagnosed with Melanoma or Breast Cancer who are undergoing sentinel lymph node biopsy.
3208497|NCT00975351|Experimental|IV dose of 5-methyltetrahydrofolic acid|IV test dose of 13C5-labelled 5-methyltetrahydrofolic acid to all eligible volunteers, followed by regular blood samplings over 2hr period taken via a cannula.
2440510|NCT03294291|Active Comparator|Quadratus Lumborum block group|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.7 ml/kg bupivacaine 0.25 % injected unilaterally at the posterior border of the quadratus lumborum muscle.
2440511|NCT03294291|Active Comparator|Caudal block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory caudal block wil performe with bupivacaine 0.7 ml/kg as 0.25%.
2440512|NCT03294278|Active Comparator|Ablation plus ICD|Epicardial ablation by radio-frequency
2440513|NCT03294278|Active Comparator|ICD alone|Implantation of ICD
2440514|NCT03294265|Experimental|Peer support group|"Patients who accept to participate in the protocol and are randomized to the intervention group will be invited to five sessions, one per bimester, that will be carried out in our facilities until their next appointment to the centre (fifth visit). All of them will be coordinated by a group leader.~Interventions are made each bimester in 2 hours in peer support sessions in which the patients discuss and reinforce the following topics: grief stages, control goals, self-care activities, adequate diet planning and diminish sedentary lifestyle."
2440515|NCT03294265|Active Comparator|Control group|"Patients who accept to participate in the protocol and are randomized to the control group will receive weekly messages and reminders about self-care to their cell phones via WhatsApp.~Interventions are made by sending each week a self-care reminder via WhatsApp and questionnaires about self-care activities and drugs"
2440516|NCT03294252|Experimental|Oxaliplatin|The experimental drugs used in this protocol are Oxaliplatin, 5-Fluorouracil and L-Folinic acid. All are used as part of their marketing authorization, with the exception of Oxaliplatin as regards its mode of administration specific to the CIPPA procedure (injection and nebulisation in intraperitoneal).
2440517|NCT03294239|Experimental|Group A (Transurethal group)|Patients will have trans urethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone disintegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
2440518|NCT03294239|Experimental|Group B (Percutaneous group)|Patients will have per cutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the mid line 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
2440519|NCT03294226|Experimental|AuraGain|After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
2440520|NCT03294226|Active Comparator|I-gel|After anesthetic induction, I-gel is inserted for airway management. Size of the device is selected according to the patient's weight; size 1.5 for 5-10kg, size 2 for 10-20kg.
3208498|NCT00975364||blood sampling|Consented volunteers provide a one-off blood sample
2440522|NCT03294200|Experimental|Tricinch Coil System treatment|
2440525|NCT03294174||Opioid naive|Patients who have not been exposed to opioids, but will receive ropivacaine injection
2440526|NCT03294174||Opioid exposure|Patients who have been exposed to(> 6months), but not currently taking opioids, but will receive ropicacaine injection
2440527|NCT03294174||opioid tolerance|Patients who have been actively taking opioids with a tolerant dose based on FDA guideline, but will receive ropivacaine injection
2440528|NCT03294161|Experimental|Immucillin DI4G|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + Immucillin DI4G 2% by topical use once a day at the ulcer for 20 days .
2440529|NCT03294161|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate by intravenous route at 20mg/kg/day during 20 days + placebo for topical use once a day at the ulcer for 20 days.
2440530|NCT03294148|Experimental|Placebo|The open-label placebo treatment the investigators will use is based on past open-label placebo trials (Kam-Hansen et al., 2014; Kaptchuk et al., 2010; Kelley et al., 2012). Prior to treatment administration, patients will view a brief (~3 min) video summarizing scientific findings regarding the therapeutic power of placebo treatments. The video will describe established findings regarding placebo and suggest that placebos may still work even when patients know the treatment is a placebo. The video will state that believing in the placebo is not necessary, and the investigators ask only that patients keep an open mind. Patients will then receive a subcutaneous injection of 1ml medical grade saline into the lower back. The injection will be administered near the location of the pain, as specified by the participant. The investigators will use a standard needle used in subcutaneous injections of 27 gauge with a length from 1in to 1.5in.
2440531|NCT03294148|Experimental|Psychotherapy|Psychotherapy will consist of one initial medical history session with Co-I Schubiner, followed by twice weekly 50 minute psychotherapy sessions for 4 weeks with a therapist, for a total of 9 sessions maximum. The purpose of the initial medical history session is to help evaluate the likelihood that the patient's back pain is caused by structural conditions in the back. Dr. Schubiner will then speak with patients for a 1 hour session in which he collects their medical history and discusses different possible causes of their back pain with them. This session will be conducted by phone, by HIPAA-compliant Zoom, or by another HIPAA-compliant videoconferencing technology in consultation with the OIT team at Dr. Schubiner's hospital.
2440532|NCT03294148|No Intervention|Waitlist|Wait-listed patients will be asked not to change their treatment regime for the 4 weeks in between their two fMRI sessions. Wait-listed patients in the placebo injection arm will be offered the opportunity to receive the placebo treatment (optional). Waitlisted participants in the psychotherapy arm will be given a copy of Dr. Schubiner's book and free access to his online self-help program (optional to accept these).
2440533|NCT03294135|Experimental|Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 28 (+10) and 300 (+21), booster vaccination of 55 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2440534|NCT03294135|Experimental|Accelerated/Rapid Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 66 subjects in study V48P7 on Days 0, 7 (+3) and 21 (+7), booster vaccination of 9 subjects in study V48P7E1 (NCT00387634) 40 subjects received their booster vaccination before enrolment in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2440535|NCT03294135|Experimental|Accelerated Conventional Group|Subjects will receive a second booster vaccination six months after the blood draw only in case they result to be with an NT titre below 10 and who belonged to the following vaccination schedule in the primary studies: Primary vaccination of 133 subjects in study V48P7 on Days 0, 14 (+3) and 300 (+21), booster vaccination of 109 subjects in study V48P7E1 (NCT00387634), no vaccination in study TBEV POLYGELINE FREE (V48)-023 EXT 021 (V48P7E2) (NCT01562444).
2440536|NCT03294122||PCa patients - Discovery cohort|External beam radiotherapy for prostate cancer
2440537|NCT03294122||HNCa patients - Discovery cohort|External beam radiotherapy for head and neck cancer
2440538|NCT03294122||PCa patients - Validation cohort|External beam radiotherapy for prostate cancer
2440539|NCT03294122||HNCa patients - Validation cohort|External beam radiotherapy for head and neck cancer
2440542|NCT03294096|Experimental|experimental group|
2440543|NCT03294096|Active Comparator|control group|
2440544|NCT03294083|Experimental|Part 1, Dose escalation|"Pexa-Vec will be administered via IV infusion at a dose of 3 x 10^8 pfu once per week for 4 treatments. Based on the occurrence of dose-limiting toxicities, patients may subsequently be enrolled to receive Pexa-Vec on the same schedule at a dose of 1 x 10^9 pfu.~Cemiplimab will be administered via IV infusion every 3 weeks."
2440545|NCT03294083|Experimental|Part 2-Arm A, Pexa-Vec (IT) and Cemiplimab|"Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
2440546|NCT03294083|Experimental|Part 2-Arm B, Cemiplimab|"Cemiplimab will be administered via IV infusion every 3 weeks.~At disease progression, Pexa-Vec will be administered via IT (intratumoral) injection every 2 weeks for 3 treatments. Cemiplimab will continue every 3 weeks."
2440547|NCT03294083|Experimental|Part 2-Arm C, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
2440548|NCT03294083|Experimental|Part 2-Arm D, Pexa-Vec (IV) and Cemiplimab|"Pexa-Vec will be administered via IV infusion once per week for 4 treatments.~Cemiplimab will be administered via IV infusion every 3 weeks."
2440549|NCT03294070|Experimental|Fimasartan 60 mg + amlodipine besylate 5 mg|Fimasartan 60 mg + amlodipine besylate 5 mg. In subjects with a DBP equal to or greater than 90 mmHg and / or SBP equal to or greater than 140 mmHg at week 8, the investigator will have the option, according to his clinical criteria, to add 12.5 mg of HCTZ QD (in these cases, the subject will receive one 60 mg Fimasartan tablet plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate tablet.
2440550|NCT03294057|Experimental|ICT programs + Tele-coaching programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. And a trained nurse provides tele-coaching programs to subjects. After that, subjects will conduct self-management health care and tele-coaching programs for 12 weeks. After 3 months, they finish self-management ICT + coaching programs, and then they fill out the questionnaire.
2440551|NCT03294057|Experimental|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
2440552|NCT03294057|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
2512944|NCT02811237|Other|HESTIA group|
2440553|NCT03294044|Experimental|ICT programs|ICT programs that include health information learning by disease, and self-management based on Smart Management Strategy for Health (SMASH) are provided. After that, subjects will conduct self-management health care for 12 weeks. After 3 months, they finish self-management ICT programs, and then they fill out the questionnaire.
2440554|NCT03294044|Active Comparator|A book about chronic disease|Subjects in the group get a book about chronic disease for patients. After 3 months, they finish reading the materials, they fill out the questionnaire.
2440555|NCT03294031|Experimental|Pilates|The Pilates program covered a 12-week period, two weekly sessions. In one session, exercises were performed on a mat (Mat Pilates), and in the second session in standing and sitting position. The programme included warm-up exercises, the main part of the session and cooling activities.
2440556|NCT03294031|Active Comparator|Conventional Exercise|The conventional exercise programme covered a 12-week period, two weekly sessions. The programme aimed at improving aerobic capacity, muscular resistance, balance and flexibility. The program combined land-based and water-based exercise sessions.
2440557|NCT03294018||Bradycardia during sugammadex administration|Recording any heart rate changes during planned administration of sugammadex.
2440558|NCT03294005||Subjects with nodular goiter|Enrolled subjects with nodular goiter had thyroid sonography and thyroidectomy from 2002 January to 2016 December in CMUH. Total enrolled subject about 2000. These subjects were confirmed by pathology. Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients. Gray scale ultrasonography was routinely performed in every subject. Color Doppler ultrasonography for blood flow and thyroid fine needle aspiration was not absolute done in routine procedure. All data at least was interpreted by 3 endocrinologists under the blind method. Each subject was analyzed under thyroid echogenicity, margin, calcification, inclusion, grooving change and size & ratio size of tall and transverse.
2440559|NCT03293992|Experimental|0.01% RO7058584 or Matching Placebo|
2440560|NCT03293992|Experimental|0.1% RO7058584 or Matching Placebo|
2440561|NCT03293992|Experimental|1% RO7058584 or Matching Placebo|
2440562|NCT03293992|Experimental|RO7058584 and Latanoprost 0.005%|
2440563|NCT03293940|Experimental|Cryoablation Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.~Participants will have the option to crossover to tPNB 90 days post the initial intervention."
2440564|NCT03293940|Active Comparator|Control Group|"After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.~Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention."
2440565|NCT03293927|Experimental|Fentanyl + Dexmedetomidine|
2440566|NCT03293927|Experimental|Dexmedetomidine + Fentanyl|
2440567|NCT03293927|Experimental|Fentanyl only|
2440568|NCT03293927|Experimental|Dexmedetomidine only|
2440569|NCT03293914|Experimental|Intervention|Participants will be invited to enroll in an occupational therapy (OT) lifestyle redesign intervention focused on diabetes management. The intervention includes approximately 8 one-hour OT sessions over 4 months.
2440570|NCT03293914|No Intervention|Usual Care Control|Participants will not be contacted; outcome data will be extracted from medical records.
2440571|NCT03293901|No Intervention|Rest|
2440572|NCT03293901|Active Comparator|Exercise|Militarily relevant exercise
2440573|NCT03293875|Other|HIV testing promoted by members of the social network|Research staff will initiate the recruitment of seeds by recruiting four to six seeds per city. Counselors, at the partner organizations, will begin by administering a rapid HIV test and provide pre and post-test counseling to seeds. Counselors, who will be trained in the social network assessment methodology, will then ask seeds to list other drug users in their social network who they believe are at risk of contracting HIV. Counselors will then provide participants with 3 coupons to recruit identified network members for an HIV test. Referred participants who engage in high-risk behavior will be also provided with 3 coupons to refer their own network members for an HIV test.
2440574|NCT03293875|Other|Peer network behavioral intervention|Two peer leaders will be selected from each city to deliver the intervention sessions. Peer leaders will recruit drug users they know who will be asked, in turn, to recruit other drug users in their networks. Peer leaders will deliver the intervention to 300 drug users (150 per border city) in cycles composed of small social networks of 5-6 drug users.
2440575|NCT03293862|Active Comparator|Suture group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture only, without mesh, aiming a suture length to wound length ratio higher than four. Randomization occurs after fascial closure.
2440576|NCT03293862|Experimental|Prophylactic mesh group|Patients randomized to this arm will undergo midline laparotomy closure using a PDS 0 continuous suture aiming a suture length to wound length ratio higher than four AND further polypropilene onlay mesh. Randomization occurs after fascial closure.
2440577|NCT03293849|Experimental|Patient Navigation Arm|After an assessment of supportive care needs, a patient navigator will present assessment results and develop and implement a personalized supportive care intervention plan based on the findings in collaboration with a multidisciplinary supportive care team, formed by oncologists and pain and palliative care specialists. The developed plan will be sent to the treating oncologist and oncology team.
2440578|NCT03293849|No Intervention|Control Arm|Assessment results will be provided in printed and electronic form to the treating oncologist for their review. Referrals or interventions for patients allocated to the control arm will be coordinated by the treating oncologist without involvement from the patient navigator or the study team.
2440579|NCT03293836|Experimental|Radiofrequency treatment|Radiofrequency ablation of insufficient saphenous and perforating veins plus multilayer compressive bandage treatment
2440580|NCT03293836|Active Comparator|Multilayer Compressive Bandage only|Receive only compressive treatment
2440655|NCT03293316|Experimental|2mA Transcranial Random Noise Stimulation|The only factor that varies for the 2mA tRNS condition is that the high frequency noise has a peak-to-peak of -1 mA to 1mA as opposed to -.5 mA to .5 mA. Again, the stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
2440834|NCT03292094||White women|312 young healthy women were included (clinic normotensive, non-HIV)
2440581|NCT03293823|Experimental|vision-based speed of processing (VSOP) cognitive training|use the INSIGHT online program (Posit Science), which includes five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
2440582|NCT03293823|Active Comparator|active control|The standardized computerized leisure activities program - MLA, including crossword puzzle, Sudoku, etc. will be used
2440583|NCT03293797|Experimental|Abbreviated Mindfulness-based Therapy|5 week, abbreviated group MBT treatment for depression and anxiety
3151091|NCT00218244|Active Comparator|2 Uncontrolled use|Reduction in tobacco toxicants by switching to a lower nicotine tobacco product under an uncontrolled use condition.
3189434|NCT00777504|Active Comparator|B|When PD is being determined the patient will continue with the oral angiogenesis inhibitors for 2 more weeks. After 2 weeks, an Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI). After evaluating these scans patients in group B continue with angiogenesis inhibitors for 2 more weeks. After these 2 weeks(so 4 weeks after inclusion) another Avastinscan will be made and/or a dynamic contrast enhanced MRI (DCE-MRI) and a FDG-PET-scan.
2440586|NCT03293771||Stage 1 Focus Groups|The focus groups will involve transgender women who have completed gender confirmation surgery who volunteer to discuss their postoperative experience regarding bladder function, genital complaints, and sexual function.
2440587|NCT03293771||Stage 2 Questionnaire Groups|Stage 2 participants will be asked to complete a questionnaire packet after surgery followed by a second questionnaire completion 2 weeks later. Participants' operative notes and postoperative visit records will be reviewed.
2440588|NCT03293745|Active Comparator|Face to Face CBT-I (F2F)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered in-person, one-on-one with a qualified and experienced therapist.
2440589|NCT03293745|Experimental|Telemedicine CBT-I (TM)|Participants in the F2F arm will receive a standard 6-session course of Cognitive-Behavioral Therapy for Insomnia (CBT-I) delivered via the American Academy of Sleep Medicine (AASM) Sleep Telemedicine system. This telemedicine system provides an online videoconference platform in which a qualified and experienced therapist will deliver CBT-I to participants who will call in to the video therapy sessions with their provider from their homes using a webcam. All aspects of the treatment will remain identical to standard CBT-I delivered face-to-face, as described above, with the exception that the telemedicine technology will be used to deliver the treatment via video conference.
2440590|NCT03293732|Active Comparator|HA antigen only|All subjects in this group received 2 doses of 22.2 μg HA antigens
2440591|NCT03293732|Experimental|7.5 μg of DCB07010|All subjects in this group received 7.5 μg of DCB07010 in 22.2 μg HA antigens twice.
2440592|NCT03293732|Experimental|15 μg of DCB07010|All subjects in this group received 15 μg of DCB07010 in 22.2 μg HA antigens twice.
2440593|NCT03293732|Experimental|30 μg of DCB07010|All subjects in this group received 30 μg of DCB07010 in 22.2 μg HA antigens twice.
2440594|NCT03293732|Experimental|45 μg of DCB07010|All subjects in this group received 45 μg of DCB07010 in 22.2 μg HA antigens twice.
2440595|NCT03293719||Ceramic|Patients receiving BPK-S Integration UC implant made from BIOLOX delta ceramic
2440596|NCT03293719||CoCr|Patients receiving BPK-S Integration UC implant made from CoCr (metal)
2440597|NCT03293706|Active Comparator|CHO Control 1 Glucose|25 g glucose
2440598|NCT03293706|Active Comparator|CHO Control 2 Glucose|25 g glucose
2440599|NCT03293706|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
2440600|NCT03293706|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
2440601|NCT03293706|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
2440602|NCT03293706|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
2440603|NCT03293693|Experimental|Test meal 1|Test meal with 0.5 g beta-glucan
2440604|NCT03293693|Experimental|Test meal 2|Test meal with 3.5 g beta-glucan
2440605|NCT03293693|Experimental|Test meal 3|Test meal with 8 g beta-glucan
2440606|NCT03293680|Experimental|Pembrolizumab Arm|1 group, Pembrolizumab (MK-3475) 200 mg, every 3 weeks
2440607|NCT03293667|Other|Exploratory arm|
3189435|NCT00777517|Other|Reference|Commercial 10 mg Lipitor formulation tablet
2440611|NCT03293641|Experimental|Zinc Sulfate Tablet|Zinc Sulfate Tablet 10 mg, 3 times a week plus Standard of Care for 6 months
2440612|NCT03293641|Placebo Comparator|Control Arm|Standard of Care for 6 months
2440613|NCT03293628|Experimental|Conization With Vaginal Packing|Experimental Arm. Haemostasis at the end of the procedure using vaginal packing and Monsel's solution.
2440614|NCT03293628|Active Comparator|Conization Without Vaginal Packing|Haemostasis at the end of the procedure using only Monsel's solution.
2440615|NCT03293615|Experimental|Dermatomyositis (DM)|Patients with dermatomyositis according to ENMC criteria
2440616|NCT03293615|Active Comparator|Non-dermatomyositis inflammatory myopathies|Patients with other inflammatory myopathy than dermatomyositis according to ENMC criteria
2440617|NCT03293615|No Intervention|No myopathy|Patients without myopathy on muscle biopsy
2440618|NCT03293602|Experimental|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
2440619|NCT03293589||OR|patients treated with open revascularization
2440620|NCT03293589||EVT|patients treated with endovascular revascularization
2440621|NCT03293576|Experimental|Intervention|Volitional help sheet
2440622|NCT03293576|No Intervention|Control|Short Zimbardo's time perspective inventory (Orosz et al. 2017)
2440625|NCT03293537|Experimental|Patients with dementia|The subject will be informed of the procedure and their task before the sensors are attached. Electrodermal activity (EDA) and heart rate (HR) will be continuously monitored while the subject views the image sequence on a PC monitor. EDA will be measured using electrodes attached to the middle (D3) and ring finger (D4). Heart rate will be measured using an infrared pulseoximeter attached to one of the free digits of the hand. A pulseoximeter is a non-invasive sensor, using tissue absorption of infrared light to determine blood-oxygen saturation (SaO2). EDA and HR will be recorded concurrently using commercial software. Data analysis will involve both commercial and in-house software.
2440626|NCT03293524|Experimental|Treatment Arm 1|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 1 will receive intravitreal GS010 in both eyes.
2440627|NCT03293524|Placebo Comparator|Treatment Arm 2|Subjects will be randomized to treatment arm 1 or treatment arm 2 in a 1:1 allocation. Subjects in treatment arm 2 will receive GS010 in one eye and placebo intravitreal injection in the other eye.
2440628|NCT03293511|Experimental|Order of administration: oxytocin - placebo|Participants first receive oxytocin (24 IU). After a washout period of 2 weeks, they receive placebo nasal spray
2440629|NCT03293511|Experimental|Order of administration: placebo - oxytocin|Participants first received placebo nasal spray. After a washout period of 2 weeks, they then receive oxytocin (24 IU).
2440630|NCT03293498|Experimental|Group A|Low dose NanoFlu - Day 0; Fluzone HD - Day 21
2440631|NCT03293498|Experimental|Group B|High dose NanoFlu - Day 0; Fluzone HD - Day 21
2440632|NCT03293498|Active Comparator|Group C|Fluzone HD - Day 0; Saline - Day 21
3189436|NCT00777517|Other|Test|Atorvastatin pediatric formulation
2440634|NCT03293472|Experimental|Ropivacaine|"Experimental: 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm.~supplementary bolus doses of ropivacaine as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period"
2440635|NCT03293472|Active Comparator|Bupivacaine|"0.5% v Bupivacaine mg (isobaric) loading dose of 0.5% bupivacaine, 3.0 ml for the patients < 160 cm tall, 3.3 ml for 161-170 cm tall, 3.6 ml for 171-180 cm tall, and 4.0 ml > 180 cm.~and supplementary bupivacaine bolus dose as required, followed by 0,12% bupivacaine 1 ml/h for the postoperative period"
2440636|NCT03293459|Experimental|Shunt Occlusion +SMT|Shunt Occlusion +SMT
2440637|NCT03293459|Active Comparator|Standard Medical Treatment (SMT)|
2440638|NCT03293446|Experimental|Patients with chronic kidney disease|
2440639|NCT03293446|Active Comparator|Healthy controls|
2440640|NCT03293433||Patient with lung cancer|Patient with pulmonary nodule showed in scanner (defined as a rounded picture higher than 5 mm and less than 30 mm in the lung parenchyma) presenting at one of the 3 participant services and meeting the inclusion criteria and exclusion. A blood punction will be performed in order to extract micro RNA.
2440641|NCT03293407||BAYQ6256_Ventavis|Patients with pulmonary hypertension who agree to be treated with Ventavis (Iloprost) at the discretion of physician
3189437|NCT00777530|Experimental|1|
3189438|NCT00777543|Other|Control|The control is the wholegrain bread enriched with bran that has not been pretreated.
2440644|NCT03293368|Experimental|Platelet rich plasma|0.5 ml of autologous platelet rich plasma prepared using a double spin technique described by Mostafa et al., 2013 will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
2440645|NCT03293368|Active Comparator|Croticosteroids|0.5 ml of triamcinolone acetonide 40 mg will be injected in the center of eroded oral mucosa in patients suffering from oral lichen planus.
2440646|NCT03293355|No Intervention|Control|Standard of care
2440647|NCT03293355|Experimental|Intervention|"The VPN intervention has 2 in-person sessions:~1) Providing training on service integration and team building for CHW and tools for them to network more effectively with OPC and MMT treatment providers as well as reach out to their patients; and 2) Learning to use effective communication tools such as motivational ruler and decision balance sheet to work more effectively with their patients and use Facebook group to facilitate collaboration among providers and e-chat for patient engagements. Sessions will occur once a week for two weeks, with each session featuring a different set of themes and relevant activities."
2440648|NCT03293342|Experimental|D CBT|Dentist administered cognitive behaviioral treatment
2440649|NCT03293342|Active Comparator|Control|Treatment as usual
2440650|NCT03293329|Experimental|Diaphragm manual therapy|3 diaphragm stretching techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2440651|NCT03293329|Experimental|Diaphragm hipopressive exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures. 20 people are recruited in order to the inclusion criteria for the study. They have rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2440652|NCT03293329|Active Comparator|Shoulder myofascial trigger points treatment|A ischemic compression technique in infraespinatus and supraespinatus myofascial trigger points performed by a physical therapist is employed in this group. 20 people are recruited in order to the inclusion criteria for the study. They had rotator cuff injuries diagnosed by ultrasounds or magnetic resonance.
2440653|NCT03293316|Sham Comparator|Sham Transcranial Random Noise Stimulation|The sham tRNS condition involves 30 seconds of 1.5 mA tRNS, with a ramping period of 30 seconds at the onset and offset. This procedure ensures that, in both the Active and Sham conditions, participants experience the sensations associated with the onset of transcranial electrical stimulation (e.g., tingling sensation)
2440654|NCT03293316|Experimental|1mA Transcranial Random Noise Stimulation|The 1mA tRNS condition consists of 1 mA peak-to-peak (-.5 mA to .5 mA) high frequency noise (100-500 Hz), with amplitude values that are normally distributed and have a mean of zero. The stimulation is delivered for 20 minutes, with a ramping period of 30 seconds at the onset and offset.
2440656|NCT03293303|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
3189439|NCT00777543|Experimental|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
2440657|NCT03293303|No Intervention|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
2440658|NCT03293290|Experimental|PrEP|For participants who are eligible for PrEP and willing to participate, subjects on PrEP will be followed for 1 year with quarterly assessments.
2440659|NCT03293277|Experimental|A1|20µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
2440660|NCT03293277|Experimental|A2|20µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 20µg Dexmedetomidine or Placebo is administered intranasally on Day 8
2440661|NCT03293277|Experimental|B1|40µg Dexmedetomidine or Placebo is administered intranasally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intravenousally on Day 8
2440662|NCT03293277|Experimental|B2|40µg Dexmedetomidine or Placebo is administered intravenousally on Day 1, and 40µg Dexmedetomidine or Placebo is administered intranasally on Day 8
2440663|NCT03293277|Experimental|C|80µg Dexmedetomidine or Placebo is administered intranasally on Day 1
2440664|NCT03293264|Experimental|Exercise training group|The intervention group will be encouraged to perform 150 min of exercise training per week for 6 months. Subjects will be provided with individual feedback and exercise Training prescriptions. After month 6 subjects will be randomized to three different groups for follow-up observation.
2440665|NCT03293264|No Intervention|Waiting-control group|The control group will be provided with general informations on a healthy lifestyle. After 6 months wait-list-control months subjects will receive the guided exercise training intervention for 6 months.
2440666|NCT03293251||uveitic/ POAG|Outcomes, success rates, complications of trabeculectomy with MMC in Uveitic glaucoma
2440667|NCT03293251||POAG|Outcomes, success rates, complications of trabeculectomy with MMC and I stent in this groups
3189440|NCT00777569|Experimental|Extra-low nicotine cigarettes|
3189441|NCT00777569|Experimental|Nicotine-free cigarettes|
3189442|NCT00777569|Active Comparator|Medicinal Nicotine|
3189443|NCT00777595|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
2440672|NCT03293225||add H2RA|Add antihistamines to standard drug therapy
2440673|NCT03293225||change ns-H1RA|Change to ns-H1RA in standard medication
2440674|NCT03293225||ns-H1RA(3-4 tabs)|Standard treatment with ns-H1RA 4X dose
2440675|NCT03293225||ns-H1RA(3-4kinds)|Use of NS 4 kinds for standard treatment
2440676|NCT03293199|Active Comparator|Chest tube drainage|This group will undergo chest tube drainage as an intervention for spontaneous pneumothorax treatment.
2440677|NCT03293199|Active Comparator|Needle aspiration|This group will undergo repetitive needle aspiration as an intervention for spontaneous pneumothorax treatment.
2440678|NCT03293186|Experimental|Use MEDICLORE|use mediclore at the end of surgery
2440679|NCT03293186|No Intervention|No antiadhesive product|use no antiadhesive product at the end of surgery
2440680|NCT03293173|Experimental|Group A|Biologically low risk group, R-CHOEP-14
2440681|NCT03293173|Experimental|Group B|Biologically high risk group, DA-EPOCH-R
2440682|NCT03293160||Treatment group|The set of patients in the sample who are offered enrollment in care management services.
2440683|NCT03293160||Control group|The set of patients in the sample who are not initially offered enrollment in care management services (will be offered enrollment after six months).
2440684|NCT03293147|Experimental|Arm A|Intervention group: Non-adherent hypertensive patients randomised in Arm A will receive standard clinical care plus HPLC-MS/MS-guided intervention.
2440685|NCT03293147|Active Comparator|Arm B|Control group: Non-adherent hypertensive patients randomised in Arm B will receive clinical standard care.
2440686|NCT03293147|Active Comparator|Arm C|Control group: Adherent hypertensive patients randomised in Arm C will receive clinical standard care.
2440687|NCT03293121|Experimental|Strength and Coordination Training|The strength and coordination group will perform a progression of exercises utilizing body weight and resistance bands as resistance. Exercises include squats, lunges, jumps etc. typical of a normal strength training program.
2440688|NCT03293121|Active Comparator|Walking|The walking group will be instructed to walk 3x/week, progressing from 30 to 45 min over 8 weeks.
2440689|NCT03293108|Experimental|AryoGen Pharmed Denosumab|"Arylia (Denosumab Prefilled Syringe produced by AryoGen Pharmed) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
2440690|NCT03293108|Active Comparator|Amgen Denosumab|"Prolia® (Denosumab Prefilled Syringe produced by Amgen) 60 mg/1 ml in a prefilled syringe.~Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12. Along with, all women will receive daily supplements containing at least 1000 mg of elemental calcium (divided into two doses) and at least 400 IU vitamin D daily during 18 months of the study."
2440691|NCT03293095||Acute musculoskeletal pathology patients|Musculoskeletal pathology patients that they will perform functional tasks measuring with motion sensors and motion capture.
2440692|NCT03293095||Match control|Healthy people of the same age as the acute musculoskeletal pathology subjects. They will perform functional tasks measuring with motion sensors and motion capture.
2440693|NCT03293069|Experimental|Deferiprone|Half of participants will receive twice-daily oral deferiprone taken over 12 months.
2440694|NCT03293069|Placebo Comparator|Placebo|Half of participants will receive the placebo Twice-daily oral placebo taken over 12 months
2440695|NCT03293056|Experimental|High-intensity Interval Hydrogynmastics|High-intensity Interval training Hydrogynmastics, 2x/week, for 3 months.
2440696|NCT03293056|Active Comparator|Hydrogynmastics Continuous Moderate|Hydrogynmastics Continuous Moderate training (HCM), 2x/week, for 3 months.
3189444|NCT00777595|Experimental|Treatment B|Single supratherapeutic dose of CHF 4226 pMDI
3189445|NCT00777595|Placebo Comparator|Treatment C|Single dose of placebo
3189446|NCT00777595|Active Comparator|Treatment D|Single dose of moxifloxacin
3189447|NCT00777621|Active Comparator|Calorie restriction|
3189448|NCT00777621|Active Comparator|Exercise|
3189449|NCT00777621|Experimental|Calorie restriction and exercise|
2440697|NCT03293043|Experimental|Experimental Group|After initial screening, appropriately obtained informed consent and confirmation of eligibility at time of transplant, those recipients (a total of 12 subjects) who agree to continue as participants will receive reconditioned marginal lungs should the lungs on the device meet acceptable criteria to proceed with clinical transplantation.
2440698|NCT03293030|Experimental|Dupilumab treatment|15 subjects will receive dupilumab for a treatment period of 52 weeks (i.e. last injection on week 50). All subjects will undergo skin biopsies for molecular profiling.
3151092|NCT00218244|Placebo Comparator|3 Behavioral|Reduction in smokeless tobacco use using behavioral techniques only.
3151093|NCT00218270|Experimental|1|Reduction of tobacco use by substituting tobacco free snuff.
3151094|NCT00218270|Placebo Comparator|2|Reduction of tobacco use by using behavioral techniques.
2440702|NCT03293004|Experimental|Hydrolyzed collagen|First, we aim to determine the optimal amount of hydrolyzed collagen with a constant dose of vitamin C in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of hydrolyzed collagen (control (0 g), 5 10, 20 and 30 g hydrolyzed collagen) with a constant dose of vitamin C (50 mg). Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
2440703|NCT03293004|Experimental|Vitamin C|Second, we aim to determine the optimal amount of vitamin C with the determined optimal dose of hydrolyzed collagen in humans to increase a marker of collagen synthesis (PINP). In a randomized, double-blinded, crossover design subjects consume a nutritional supplement with varying doses of vitamin C (0 (control), 50, 250 and 500 mg) with an optimized dose of hydrolyzed collagen as determined from the first arm. Each intervention will be separated by a 6-day wash out. Subjects will be asked to consume the supplement 1 hour before 6-min of jump rope exercise. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours and 24 hours blood samples will be collected. Blood samples will be used for PINP analysis.
2440704|NCT03293004|Experimental|Optimized Collagen and Vitamin C supplement|The findings from the first 2 arms of the study will be used to inform a training-based study aimed to determine whether exercise together with this optimal dose of hydrolyzed collagen and vitamin C is sufficient to improve rate of force development (RFD) and performance. A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
2440705|NCT03293004|Placebo Comparator|Gummy Placebo|A gummy food will be developed with the optimized dose of hydrolyzed collagen and vitamin C as well as a placebo. In a randomized, double-blinded, parallel design with subjects undertake a 3 week exercise protocol. The supplement or placebo will be ingested 1 hour prior to each exercise session (Monday/Wednesday/Friday). Exercise testing to assess rate of force development (RFD) will take place at the end of each week (Fridays) and these outcomes will be the basis for determining the effects of the nutrition intervention on performance.
2440706|NCT03292978|Experimental|probiotics intervention|"The probiotic is provided in sachets as a 2g powder dried with corn starch.~The powder is orally taken once daily for 4 weeks.~The powder contains totally 11 log 10 colony forming units(CFU) of probiotics.~The types of probiotics are Lactobacillus.rhamnosus, Lactobacillus.acidophilus, Bifidobacteria.animalis and Bifidobacteria.longum."
2440707|NCT03292978|Placebo Comparator|non-probiotic control|The placebo is corn starch alone provided and the shape, color, weight,flavor and taste are same with the powder of probiotics intervention.
2440708|NCT03292965|Active Comparator|Neostigmine|"At the end of surgery, administrating neostigmine to participants according to the protocol below:~when train-of-four (TOF) 2-3, administrating neostigmine 50mcg/kg when TOF 4 with fade, administrating neostigmine 40mcg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
2440709|NCT03292965|Active Comparator|Sugammadex|"At the end of surgery, administrating sugammadex to participants according to the protocol below:~when TOF=0 and post-tetanic count (PTC)=1 or more, administrating sugammadex 4mg/kg when TOF=1 or more, administrating sugammadex 2mg/kg when TOF 4 without fade, administrating neostigmine 20mcg/kg"
2440713|NCT03292939|Other|vaginal progestrone group|cohort of patients who received 400mg vaginal progestrone .
2440714|NCT03292926|Active Comparator|Adductor Canal Block (ACB)|The adductor canal block will be ultrasound-guided sonosite. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22 gauge (G)/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.
2440715|NCT03292926|Active Comparator|Adductor Canal Block & IPACK (ACB/IPACK)|"The adductor canal block will be ultrasound-guided. The anesthesiologist will administer 15 cc bupivacaine 0.5% with 2 mg preservative-free dexamethasone with a 22G/4 inch Chiba needle to the mid-thigh of the surgical limb while subject lays in the supine position post IV sedation.~The IPACK will be ultrasound-guided with c60 sonosite probe (5-2Hz). While laying in the prone or supine, frog-leg position the IPACK will be administered using a 22G/4inch Chiba needle. The anesthesiologist will identify the popliteal artery at the popliteal crease and move cephalad just beyond the femoral condyles at the confluence with the femur. Then the anesthesiologist will identify the space between the femur and the popliteal artery and moving from medial to lateral place the needle in between the popliteal artery and femur with the tip ending 2-3 cm lateral to the artery and inject 25 cc bupivacaine 0.25% with 2 mg preservative-free dexamethasone."
2440716|NCT03292913|Experimental|Intervention Group|Receives the Positive Health Check intervention plus standard of care
3151095|NCT00218283|Experimental|1 - Nicotine Lozenge|Use of nicotine lozenge plus behavioral counseling to help reduce tobacco use prior to quit date.
3151096|NCT00218283|Placebo Comparator|2 Behavioral counseling|Use of behavioral counseling alone to help reduce tobacco use prior to quit date.
3151097|NCT00218322|Placebo Comparator|1|Treatment with placebo or atomoxetine for 12 weeks.
3151098|NCT00218322|Experimental|2|
3151099|NCT00218413|Experimental|1|
3151100|NCT00218413|Experimental|2|
2440718|NCT03292887||Elaprase Treated|Participants with Hunters Syndrome received or receiving treatment with Elaprase as prescribed by their physician following locally approved prescribing information.
2440719|NCT03292887||Elaprase Non-Treated|Participants received no treatment for Hunters Syndrome.
2440720|NCT03292874|Other|Paired imaging|Single arm, paired imaging of high resolution MRI (hrMRI) and stand MRI (sMRI)
3151101|NCT00218413|Experimental|3|
3151102|NCT00218413|Experimental|4|
2440723|NCT03292848|Experimental|10 to <13 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 1.5 mg the second dose of 3 mg.
2440724|NCT03292848|Experimental|6 to <10 Years of Age|Two doses will be administered with a washout period of 14 days between the first dose of 0.75 mg and the second dose of 1.5 mg.
2440725|NCT03292822|Experimental|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties.
2440726|NCT03292822|Active Comparator|Paclitaxel|chemotherapeutic drug
2440729|NCT03292796|Other|Stop prostaglandin eye drops post op|Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
2440730|NCT03292796|Other|Continue prostaglandin eye drops post op|Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost
2440731|NCT03292783|Experimental|NOV150101 (ABL001)|
2440732|NCT03292770|No Intervention|Control Group|Embryo transfer will be performed as per clinic's routine protocol, where cervical mucus is gently removed with a cotton swab. No manipulation of the cervical canal is executed.
2440733|NCT03292770|Experimental|Flushing Group|"A catheter will be used to perform a flushing of the cervical canal with culture media. The Flushing Catheter has a flared proximal end that is designed to affix to a standard Luer slip syringe and a pre-curved distal closed end, with a biseled opening on the side, 2mm from the tip, in which liquid flushes towards the outside of the cervical canal.~Device: Cook Flushing Catheter J-IUIC-352200 (3.5fr 20cm flushing catheter with positioner closed end) (CEE approval)."
2440734|NCT03292757|Experimental|Mesenteric ICG|Indocyanine green injected into the small bowel mesentery during oesophagectomy.
2440735|NCT03292757|Experimental|Feeding jejunostomy ICG (cream)|Indocyanine green mixed with cream infiltrated into the feeding jejunostomy.
2440736|NCT03292744|Experimental|Alfacalcidol|Alfacalcidol 0,5 mcg once daily for 90 days
2440737|NCT03292744|Placebo Comparator|Placebo|Amylum same capsule form, weight and colour with treatment arm
2440738|NCT03292731|Active Comparator|hydroxyprogesterone caproate 250 mg|Pregnant subject will receive 250mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
2440739|NCT03292731|Experimental|hydroxyprogesterone caproate 500 mg|Pregnant subject will receive 500mg of hydroxyprogesterone caproate Intramuscular injection weekly from 16 0/7-36 6/7 weeks or delivery which ever occurs first.
2440740|NCT03292718|Experimental|use of MyCyFAPP|use of MyCyFAPP during 6 months
2440741|NCT03292705|Experimental|PEP+CCI|"PEP: The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains.~CCI. VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention.~Intervention format and fidelity The PEP+CCI group will practice PEP for the first 4 weeks and VSOP for the following 6 weeks."
2440742|NCT03292705|Active Comparator|control+CCI|For the control + CCI group, an inert control condition, consisting of nothing outside of the ordinary, will be implemented for the first 4 weeks, and CCI for 6 more weeks.
2440745|NCT03292679|No Intervention|Control|Subjects that are randomized into Arm A will have their fractures repaired in the usual fashion i.e. using plates that are bent by free hand.
2440746|NCT03292679|Experimental|3D template|Subjects that are randomized into Arm B will have custom models of relevant portions of their facial skeleton printed and used as templates for bending and shaping plates for stabilizing the fracture(s).
3151103|NCT00218413|Experimental|5|
3151104|NCT00218452|Experimental|Lifestyle counseling|
3151105|NCT00218517|Experimental|1|
3151106|NCT00218517|Placebo Comparator|2|
3151107|NCT00218556|Experimental|Depression prevention|Cognitive behavioral treatment for depression.
3151108|NCT00218556|No Intervention|Control|Treatment as usual.
3151109|NCT00218569|Experimental|1|Naltrexone
3151110|NCT00218569|Experimental|2|Placebo
3151111|NCT00218582|Experimental|1|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
3151112|NCT00218582|Active Comparator|2|Standard psychiatric day treatment
3151113|NCT00218595|Experimental|DBT|
3151114|NCT00218595|Active Comparator|I/GDC|
3151115|NCT00218608|Placebo Comparator|Placebo|Placebo (microcrystalline cellulose) was suspended in the methadone during weeks 3-14.
3151116|NCT00218608|Active Comparator|Disulfiram at 62.5 mg|Disulfiram at 62.5 mg was suspended in the methadone during weeks 3-14.
3151117|NCT00218608|Active Comparator|Disulfiram at 125 mg|Disulfiram at 125 mg/day was suspended in methadone during weeks 3-14.
3151118|NCT00218608|Active Comparator|Disulfiram at 250 mg|Disulfiram at 250 mg/day was suspended in methadone during weeks 3-14.
3151119|NCT00218660|Experimental|1|Nal + BRENDA
3151120|NCT00218660|Placebo Comparator|2|Placebo + BRENDA
3151121|NCT00218660|Experimental|3|Nal + CBT
3151122|NCT00218660|Placebo Comparator|4|Placebo + CBT
3151123|NCT00218673|Experimental|experimental|social network
3151124|NCT00218673|No Intervention|control|testing and counseling
3151125|NCT00218686|Experimental|1|behavioral social network risk reduction intervention
2440754|NCT03292627||mid age|mid age: 50-70 years old
2440755|NCT03292627||old age|old age: age older than 70 years old
2440757|NCT03292601|Experimental|Feedback Group|Patients in the Feedback Group will receive their brace-wear (Cinch Smart Strap) compliance data via the Wellinks phone application (Cinch Mobile App). Patients will also receive their brace-wear compliance information at their standard of care follow-up visits.
2440758|NCT03292588|Experimental|Mepolizumab|Intervention: Mepolizumab plus guidelines-based standard of care asthma treatment.
2440759|NCT03292588|Placebo Comparator|Placebo|Intervention: Placebo for mepolizumab plus guidelines-based standard of care asthma treatment.
2440760|NCT03292575||Stroke related to CAAF|
2440763|NCT03292549||Patients|Robotic partial surgery
2440764|NCT03292536|Experimental|Merestinib, all patients|
2440765|NCT03292523||Hyperventilation syndrome|
2440766|NCT03292510|Experimental|GO-OUT Group|Participants attend 1-day walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. The same activities are completed during both sessions within the same week. Each session includes a 10-minute warm-up, a distance walk, practice of a specific outdoor walking skill, a distance walk, and a 10-minute cool down. The warm up and cool down include stretching, functional strengthening exercises and balance exercises taught during the workshop. The program incorporates the principles of task-specific training by emphasizing repetitive practice of progressively more difficult outdoor walking tasks. The outdoor walking program is conducted in one or more large park settings given the mental health benefits of exercising in a natural environment.
2440767|NCT03292510|Active Comparator|Workshop Group|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
2440768|NCT03292497|Experimental|Treatment algorithm|"Mitral valve will be replaced if posterior leaflet tethering angle >=25 degrees.~Mitral valve will be repaired if posterior leaflet tethering angle <25 degrees"
2440769|NCT03292497|Active Comparator|No treatment algorithm|Mitral valve will be repaired or replaced at surgeon's discretion.
3151126|NCT00218686|Active Comparator|2|voluntary counseling and testing (VCT
2440771|NCT03292471|Experimental|Inhibitory only|Inhibitory 1Hz rTMS will be applied continuously for 1200 pulses (20 minutes) 5 days per week across 2 weeks (10 sessions total).
2440772|NCT03292471|Experimental|Excitatory primed|The inhibitory sequence described above will be preceded for each session by priming stimulation which will consist of intermittent 6-Hz rTMS applied in 5 second trains with 25 second intervals between trains for a total 600 pulses (10 minutes).
2440773|NCT03292458|Experimental|Clinical response to sodium oxybate|In contrast to placebo but similar to alcohol, sodium oxybate is expected to be most effective in reducing voice symptoms in alcohol-responsive SD and VT.
2440774|NCT03292458|Experimental|Primary markers of clinical response|The clinical outcome is expected to be determined by selective modulation of functional abnormalities in the brain regions controlling speech sensorimotor processing and integration in association with underlying gene variants.
2440775|NCT03292445|Experimental|Immune tolerance after kidney transplant|Immune tolerance after kidney transplant will be induced by transfusion of enriched donor blood stem cells and T cells to initiate blood cell mixed chimerism in patients conditioned with total lymphoid irradiation and rabbit anti-thymocyte globulin after kidney transplant. Patients will receive corticosteroids for 14 weeks with gradual dose reduction. They will also receive 12 months of mycophenolate mofetil and 18 months of tacrolimus with dose tapering beginning 9 months post-transplant and continuing as long as mixed chimerism is maintained and there is no evidence of graft versus host disease and no kidney rejection evident. Patients losing chimerism will continue on low dose immunosuppressive drug doses unless additional kidney rejection therapy is needed.
3151127|NCT00218712|Experimental|1|Participants will receive personalized cognitive counseling
2512946|NCT02811237|Other|sPESI group|
3151128|NCT00218712|Active Comparator|2|Participants will receive standard counseling
3151129|NCT00218725|Other|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
3151130|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
3151131|NCT00218790|No Intervention|Control group|The control group received standard dialysis at a temperature of 37 degrees Celcius
3151132|NCT00218790|Experimental|Experimental group|Subjects in the experimental group received cool dialysate during treatment
3151133|NCT00218803|Experimental|1|
3151134|NCT00218803|Other|2|
3151135|NCT00218816|Experimental|1|
3151136|NCT00218816|Other|2|
3151137|NCT00218842|Experimental|exercise group|individualized exercise
3151138|NCT00218842|No Intervention|control group|care as usal
3151139|NCT00218855|Placebo Comparator|A|
3151140|NCT00218855|Active Comparator|B|
3151141|NCT00218868||skin scrape|
3151142|NCT00218894||post cataract surgery|
3189450|NCT00777647|Experimental|Sugar-sweetened soft drink|54g sugar/L, 180kJ/100mL
3189451|NCT00777647|Experimental|Aspartame-sweetened soft drink|1.5kJ/100mL
2440782|NCT03292393|Active Comparator|Group Contingency Management|During the intervention phase, the Group Contingency Management (GCM) arm will continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a home blood pressure monitoring reading using the HBPM. Participants in the GCM arm will receive a payment after each phone call, dependent on their medication adherence assessment. The GCM arm will also receive an additional payment based on their group's medication adherence.The intervention administered is the Financial Reward and Social Norms.
2440783|NCT03292393|Active Comparator|Individual Contingency Management|During the intervention phase, those in the Individual Contingency Management (ICM) arm will also continue to take their hypertensive medication for the four-month period but will receive a payment after each phone call, dependent on their medication adherence assessment.The intervention administered is the Financial Reward.
2440784|NCT03292393|Placebo Comparator|Control Arm|During the intervention phase, those in the control arm will be asked to continue to take their hypertensive medication for the four-month period and will receive a randomized phone call once a month to obtain a pill count and a blood pressure reading using the HBPM. Those in the control arm will only be paid for their participation in the study regardless of medication adherence assessment.
2440785|NCT03292380||Caffeine intake recall|All subjects completed 24-hour urine collection, and subsequently completed the 24-hour Caffeine Intake Recall (CIR-24) developed by the research group and the Caffeinated Beverage Frequency Questionnaire (CBQ) developed by the Fred Hutchison Cancer Centre. The order of completing the CIR-24 and the CBQ was alternated each day of data collection.
2440786|NCT03292367||ldTRA|Patients who are planned to perform coronary angiography will be enrolled via left distal radial artery
2440787|NCT03292354|Active Comparator|Body Weight (BW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on body weight.
2440788|NCT03292354|Active Comparator|Cardiac output (CO)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on cardiac output.
2440789|NCT03292354|Active Comparator|Lean Body weight (LBW)|Patients referred for CCTA in this group receive a personalised contrast media protocol. Contrast media administration based on Lean Body Weight.
2440790|NCT03292354|No Intervention|Control group|Patients in this group will be included retrospectively and have received the standard CM injection protocol previously used in our department.
2440791|NCT03292341|Experimental|Patients|"Patients diagnosed with larynx cancer and ex-larynx cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2440792|NCT03292341|Experimental|Clinicians|"2.Clinicians Radiotherapy-oncologists, ENT(Ear-Nose-Throat)-specialists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2440793|NCT03292341|Experimental|Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
2440794|NCT03292328|Experimental|Yoga Arm|After randomization, participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
2440795|NCT03292328|Active Comparator|Wait List Control Arm (WLC)|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
2440796|NCT03292315|Experimental|Exenatide 2 MG Injection [Bydureon]|20 subjects will be randomized to receive once weekly injection of Exenatide (Bydureon 2mg) for 26 weeks.
2440797|NCT03292315|Other|No Intervention|10 subjects will be randomized to receive no intervention for 26 weeks.
2440798|NCT03292302|Placebo Comparator|Placebo Comparator Arm|
2440799|NCT03292302|Active Comparator|Active treatment|ELX-02
2440800|NCT03292289|Experimental|Study process|Pre- and post-operative consultations. Stomatherapy consultation. Questionnaires
2440801|NCT03292276|Experimental|Amadeo training|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The robotic exercises will be carried in passive modality (15 minutes), passive/plus (15 minutes), assisted modality (15 minutes).
2440802|NCT03292276|Active Comparator|occupational therapy|All participants will receive 40 sessions of treatment (45-minute) for 8 consecutive weeks (5 days/week). The control group will receive the same amount of training by physiotherapist skilled in occupational tharapy.
2440803|NCT03292263|Experimental|Mel+Nivo|Autologous Stem Cell Transplant Drug: Melphalan 140-200 mg/m^2, Nivolumab100 mg iv days -3, +17
2440804|NCT03292250|Experimental|Arm1: BYL719|Experimental: BYL719 BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
2440805|NCT03292250|Experimental|Arm2: Poziotinib|Experimental:Poziotinib Poziotinib is a pan-HER tyrosine kinase inhibitor.(oral class)
2440806|NCT03292250|Experimental|Arm3: Nintedanib|Nintedanib is a potent small molecule triple receptor tyrosine kinase inhibitor (PDGFR, FGFR 1-3,VEGFR 1-3 ,VEGFR- 2) is considered to be the crucial receptor involved in initiation of the formation as well as the maintenance of tumour vasculature.(oral class)
2440807|NCT03292250|Experimental|Arm4: Abemaciclib|Abemaciclib represents a selective and potent small molecule CDK4 and CDK6 dual inhibitor with broad antitumor activity in preclinical pharmacology models.(oral class)
3189452|NCT00777647|Active Comparator|Semi-skimmed milk|202kJ/100mL
3189453|NCT00777647|Placebo Comparator|Water|0kJ/100mL
2440808|NCT03292250|Experimental|Arm5: Durvalumab,Tremelimumab|"Durvalumab is a human immunoglobulin (Ig) G1 kappa (IgG1κ) monoclonal antibody (mAb) that blocks the interaction of PD-L1 with PD-1 on T-cells and CD80 on immune cells and is engineered to reduce antibody-dependent cell-mediated cytotoxicity.(IV class)~Tremelimumab is specific for human CTLA-4; cluster of differentiation a cell surface receptor that is expressed primarily on activated T cells and acts to inhibit their activation.(IV class)"
2440809|NCT03292237|No Intervention|Standard Nutrition Arm|"In ICU:~After enrolment, patients allocated to the standard nutrition therapy (control) group will commence or continue nutrition via an enteral tube to a target rate according to unit protocol including the use of promotility agents and the placement of nasojejunal feeding tubes if required.~PN will only be used if the above methods have been attempted, or an absolute contraindication to EN develops.~Unless there is specific indication for a compounded PN solution, the PN used in the standard care group will be the same as used in the intervention arm.~After ICU:~Nutrition management will be as per usual site management at that hospital.~Nutrition intake amounts will be recorded 3 times per week using provided study documents and assessment tools."
2440810|NCT03292237|Experimental|Intensive Arm|"Intervention~In ICU:~Supplemental PN will be commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation~The need for the intervention will be based on the adequacy of nutrition provision from both PN and EN and assessed daily until ICU discharge~If there is an actual or anticipated interruption of EN for greater than 2 hours the PN must be run at 20 kcal/kg calculated body weight until EN is recommenced. After the interruption, EN should be recommenced as per local protocol.~After ICU:~An intensive nutrition intervention will be provided on the ward in the intervention group. This will include daily review from dedicated study dietitians and a clearly protocolized hierarchical management plan which reflects best practice clinical management."
2440811|NCT03292211|Experimental|early mobilization|early mobilization group will commence rehabilitation consisting of out-of-bed mobilization (including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.)
2440812|NCT03292211|Other|early standard intervention|early standard intervention included bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and the facilitation techniques during the period in a stroke center.
2440813|NCT03292198|Active Comparator|Compression Group|"Subjects in the Compression Group will wear 20-30 mmHg sleeves and gauntlets daily for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention (garment wearing) will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is still abnormal, garment wearing continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
2440814|NCT03292198|Experimental|Therapy Group|"Subjects in the Therapy Group will wear 20-30 mmHg sleeves and gauntlets daily and receive Manual Lymphatic Drainage 3x/week for a maximum of 4 weeks. L-dex will be performed at the end of each week. If the L-dex score has reversed back into normal range, intervention will be discontinued and the subject will resume the surveillance schedule of screenings. If the L-dex score is abnormal, intervention continues. If L-dex score is abnormal even at the end of the 4 weeks, the subject will be removed from the study and referred to standard lymphedema therapy.~An abnormal L-dex is defined by 7 or more units change compared to the subject's pre-surgical baseline."
2440815|NCT03292185|Experimental|IDeglira-IDeg-Liraglutide|Treatment sequence first Insulin Degludec/Liraglutide, then Insulin Degludec, then Liraglutide
2440816|NCT03292185|Experimental|IDeglira-Liraglutide-IDeg|Treatment sequence first Insulin Degludec/Liraglutide, then Liraglutide, then Insulin Degludec
2440817|NCT03292185|Experimental|IDeg-Liraglutide-IDeglira|Treatment sequence first Isulin Degludec, then Liraglutide, then Insulin Degludec/Liraglutide
2440818|NCT03292185|Experimental|IDeg-IDeglira-Liraglutide|Treatment sequence first Insulin Degludec, then Insulin Degludec/Liraglutide, then Liraglutide
2440819|NCT03292185|Experimental|Liraglutide-IDeg-IDeglira|Treatment sequence first Liraglutide, then Insulin Degludec, then Insulin Degludec/Liraglutide
2440820|NCT03292185|Experimental|Liraglutide-IDeglira-IDeg|Treatment sequence first Liraglutide, then Insulin Degludec/Liraglutide, then Insulin Degludec
2440821|NCT03292172|Experimental|Group 1 - Escalation Dose: RO6870810 + Atezolizumab|Participants will be administered escalating doses of RO6870810 (0.3 milligram per kilogram [mg/kg], 0.45 mg/kg, and 0.65 mg/kg) subcutaneously (SC) once daily (QD) along with fixed dose of atezolizumab 1200 mg intravenously (IV) on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2440822|NCT03292172|Experimental|Group 2 - Sequential Dose: RO6870810 + Atezolizumab|Participants will be administered RO6870810 monotherapy (starting dose 0.30 mg/kg) during the first 14 days of 21-day Run-in period. Following the Run-in period, participants will continue to receive RO6870810 at the same dose in combination with fixed dose of atezolizumab 1200 mg IV every 3 weeks in 21-day cycles.
2440823|NCT03292172|Experimental|Group 3 - Expansion in TNBC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2440824|NCT03292172|Experimental|Group 4 - Expansion in OC Group: RO6870810 + Atezolizumab|Participants will be administered dose of RO6870810 established in Group 1 (either 0.3 mg/kg, 0.45 mg/kg, or 0.65 mg/kg) SC QD along with fixed dose of atezolizumab 1200 mg IV on Day 1 of each cycle (21 day cycles), every 3 weeks. RO6870810 will be given during the first 14 days.
2440825|NCT03292159|Experimental|RAVANS|
2440826|NCT03292159|Sham Comparator|Sham stimulation|
3151143|NCT00218920|Experimental|strength training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
2440829|NCT03292133|Experimental|EGF816 + Gefitinib|"All patients will receive gefitinib orally once daily~EGF816 will be administered orally once daily~Participant will be requested to maintain a medication diary of each dose of medication"
2515621|NCT02792920|Other|CoCr-EES|
2440837|NCT03292068|Experimental|Acupuncture, acupressure|"Intervention with Pyonex-needles & Usual care; applied to the acupoints LI4 , LI11, PC6 and ST36 bilaterally before surgery. Pyonex needles are embedded in a 2 mm round plastic piece sitting on a round, skin friendly patch of about 8 mm in diameter. The patch can remain for seven days. The needle can be stimulated by gently touches the plastic bubble by the patch.~Intervention Acupressure & Usual care; a 'kulplåster (1.5 mm a ball on a small piece of adhesive tape) both ears before postoperative drug administration. Kulplåster can remain for ten days or until they fall off. Children and their parents will be asked to fill in a diary of when the needle is stimulated, for what reason and when the symptoms are alleviated. In the diary is also filled in on the kulplåster remains."
2440838|NCT03292068|Experimental|Timbal diet|"Timbal diet including ice cream & Usual care.The specially designed diet, originally made for patients suffering of dysphagia, named timbalkost will be used. The specially designed food/diet, timbalkost will be given as lunch and dinner. The consistency of timbalkost is smooth. It does not require more thorough processing of the mouth. As a snack, a protein-enriched ice cream, made with egg yolks and cream, will be made available. The food will be given to the child for 3-7 days depending on how quickly the child can return to normal food. A powder that jellify liquids to facilitate swallowing will also be used if and when needed. The children or their parents will be asked to fill in a food diary during one week after surgery."
2440839|NCT03292068|Other|Extended telephone counseling|Extended telephone counseling & Usual care : A nurse will contact the child, or the child´s parents, by telephone on day 1, 3, 5 and 10 for extended telephone counseling postoperatively (POD), to provide support and information. The child's well-being will be assessed, response given to queries and concerns, advice and explanations related to the problems expressed or identified, proper interventions will be promoted and reassurance provided. The nurse will fill in a protocol on what topics the counseling was about at each call and the child and/or parent a diary.
2440840|NCT03292042|Experimental|Experimental Group|"This group will carry out the lifestyle intervention (Physical health promotion program) during 6 months.~The group will attend a session per week."
2440841|NCT03292042|No Intervention|Control group|usual care
2440842|NCT03292029|Other|T50 Calcification Inhibition Test (CIT)|Measurement of T50 CIT and fetuin-A serum values
3189454|NCT00777686||MRI/MRS Scanning|Magnetic resonance imaging with magnetic resonance spectroscopy (MRI/MRS Scanning)
3189455|NCT00777699|Experimental|1|
3189456|NCT00777712||Diabetics (HbA1c level >8%) with infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer with infection. N=50
2440846|NCT03292003||Journey II BCS Total Knee System|Subjects having TKA with Journey II BCS Total Knee System
3189457|NCT00777712||Normoglycemic- with infection|Non-Diabetic patients with wound(s) 4 weeks or longer with infection. N=50
2440848|NCT03291977|Experimental|Fluorescein sodique FAURE|Fluorescein (Fluorescéine sodique FAURE) will be given intravenously during the induction of the anesthesia
2440849|NCT03291977|Active Comparator|White-light surgery|"In the control arm, the surgery will be performed under classical conditions (so-called  white-light  surgery)."
2440850|NCT03291951|Experimental|Resistance training group|Participants randomized to the resistance training (RT) group will receive an in-person and telephone-based intervention to promote home-based resistance training. The exercise intervention will begin by the 3rd adjuvant chemotherapy visit and continue exercise through the completion of post-operative chemotherapy. Participants will work with an exercise professional with expertise working with oncology patients.
2440851|NCT03291951|No Intervention|Usual care group|Participants randomized to the usual care (U) group will be instructed to refer to their physician regarding what forms of exercise are safe for them, given their medical history. The U group will be told to continue whatever exercise program they have been undertaking up to enrolling in the study, but not to increase exercise or begin weight-lifting over the period of study participation.
2440852|NCT03291938|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7 of cycle 1 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of cycle 1 and then on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity."
2440853|NCT03291925|Experimental|Selective invasive angiography based on CT/CCTA imaging|Patients will undergo selective invasive angiography based on CT/CCTA imaging. Decision to procede with additional invasive CA will be based on adequacy of CT/CCTA evaluation and likelihood of significant coronary artery disease.
2440854|NCT03291925|Active Comparator|Invasive Cardiac Angiography|Patients will undergo systematic invasive angiography.
2440855|NCT03291912|Experimental|Chuna Manual Therapy (CMT)|"Chuna manual therapy (CMT), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
2440856|NCT03291912|Active Comparator|Usual Care (UC)|"Usual care therapy (UC), 2 sessions/week, 6 weeks (12 sessions in total)~Usual care consists of physical therapy and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~Patients will be educated about cause and risk factors of cervicogenic dizziness, general neck muscle functions, self-exercising for relieving the symptoms.~CMT and UC group will receive the same UC regimen."
2440857|NCT03291899|Experimental|Experimental single arm|"Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:~Oxaliplatin-85 mg/m2 IV Day 1~Leucovorin-400 mg/m2 IV Day 1~Irinotecan-180 mg/m2 IV Day 1~Fluorouracil (FU)-400 mg/m2 IV bolus Day 1~Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1"
2440858|NCT03291886|Experimental|Arm A (exemestane, Entinostat)|"5 mg KHK2375 will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
2441166|NCT03289546|Experimental|Mindfulness training only|1 mindfulness training class (1 hour) every week for 8 weeks.
2440859|NCT03291886|Placebo Comparator|Arm B (exemestane, Entinostat(placebo))|"KHK2375 Placebo will be administered to subjects once weekly. EXE001 will be administered at a dose of 25 mg once daily orally.~Pre/perimenopausal female patients also receive luteinizing hormone-releasing hormone (LH-RH) agonist."
2440860|NCT03291873|Active Comparator|topography guided PRK in one eye|Topography-guided (placido disk- based) using T-CAT Contoura treatment.
2440861|NCT03291873|Active Comparator|Q-value adjusted ( custom Q) PRK in the other eye|The target Q will be estimated according to a nomogram considering the patient's age
2440862|NCT03291847|Experimental|Buprenorphine-naloxone treated|Participants receiving buprenorphine-naloxone treatment for opioid use disorder during pregnancy
2440863|NCT03291847|Active Comparator|Methadone treated|Participants receiving methadone treatment for opioid use disorder during pregnancy
2440864|NCT03291821|Experimental|DuoStim|Two controlled ovarian stimulation within the same menstrual cycle using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
2440865|NCT03291821|Active Comparator|Conventional Stimulation|Two controlled ovarian stimulation in different menstrual cycles using human menopausal gonadotropin 225 IU/day subcutaneously, GnRH antagonist in a dose of 0.25 mg/day subcutaneously and 0.2 mg of GnRH analog to induce oocyte maturation. It will be followed by ovarian puncture, oocyte isolation, intracytoplasmic sperm injection and trophectoderm biopsy at the blastocyst stage. Preimplantation genetic test and MitoScore will be performed in all the embryos prior to the embryo transfer. At this step embryos will be frozen to wait for the results. Chromossomally normal embryos will be thawed and transferred to the uterus in a deferred cycle. A pregnancy test will be performed when appropriate.
2440866|NCT03291808|Experimental|Weight loss intervention|Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
2440867|NCT03291795|Experimental|Exercise Intervention|
2440868|NCT03291782|Experimental|D-0120 Dose 1|D-0120 Dose 1 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2440869|NCT03291782|Experimental|D-0120 Dose 2|D-0120 Dose 2 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2440870|NCT03291782|Experimental|D-0120 Dose 3|D-0120 Dose 3 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2440871|NCT03291782|Experimental|D-0120 Dose 4|D-0120 Dose 4 Patients will get D-0120 single agent or placebo of matching size during dose escalation
2440872|NCT03291782|Experimental|D-0120 Dose 5|D-0120 Dose 5 Patients will get D-0120 single agent once in the fasted state and once in the fed state.
2440873|NCT03291756||Multiple Sclerosis|Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible
2440874|NCT03291743|Experimental|First Degree Relative|A total of 112 high risk first-degree relatives will be enrolled in total. Patients with Crohn's Disease will be given information about the study when in clinic for routine care to share with their first degree relatives (FDR). Screening will be done using capsule endoscopy.
2440875|NCT03291743|Active Comparator|Healthy Controls|This study will also enroll 35 healthy controls who will be age and sex matched to the first degree relative (FDR) population. Enrollment will begin after 20-25 FDR's have passed screening and will continue at this interval until all controls have been enrolled. Controls will be initially screened by colonoscopy. If enrolled they will undergo capsule endoscopy as well
2440876|NCT03291730|Experimental|Hand Lettering|"The participant will engage in art-therapy by tracing and coloring a detailed letter or word~Participants will also be guided through a relaxation breathing and journaling exercise that can be incorporated into the art activity."
2440877|NCT03291717|Experimental|Bridging Community Gaps Photovoice (BCGP)|The BCGP program is a 6-month photovoice-based intervention to help individuals with psychiatric disabilities enhance their community participation.
2440878|NCT03291717|No Intervention|Services as Usual|Individuals in this group continue with their regular mental health services with no additional intervention.
2440879|NCT03291704|Experimental|Thermal Therapy|Heat application using at home thermal therapy device
2440880|NCT03291691||Standard of care: SCI|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided sciatic nerve block. N=15.
2440881|NCT03291691||Standard of care: FEM|Patients at Charite, with lower limb surgery undergoing a protective performed ultrasound guided femoral nerve block. N=15.
2440882|NCT03291691||Standard of care: ISB|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided interscalene plexus block. N=15.
2440883|NCT03291691||Standard of care: AXP|Patients at Charite, with upper limb surgery undergoing a protective performed ultrasound guided axillary plexus block. N=15.
2440884|NCT03291678|Experimental|new laparoscopic orchiopexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum with closure of internal ring
2440885|NCT03291678|Active Comparator|classic laparoscopic orchoipexy|this group will subjected to classic laparoscopic orchiopexy by delivery of abdominal undescended testis to subdartos pouch of scrotum
2440920|NCT03291392||Atherosclerosis|"Patient with intracranial stenosis or extracranial stenosis equal to or more than 70% would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
2440921|NCT03291392||Family members|"The stroke patient who had family history of stroke, their parents and siblings would also be invited to join the study for blood taking or buccal swab/ saliva collection.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
2441167|NCT03289546|Experimental|Aerobic training only|3 aerobic training sessions (1 hour) per week for 12 weeks.
2440886|NCT03291652||Symptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
2440887|NCT03291652||Asymptomatic stroke patient|"DSA and 3DRA will be performed with access through a 4F sheath at the right femoral artery. Angiograms of intracranial arteries will be obtained by contrast injection at internal carotid artery and vertebral artery ostium from a 4F H1 catheter. Each injection will contain 10ml of iopaminro 300 diluted in 1:1 with normal saline. Each angiographic run will capture a complete series of images from the arterial phase to the end of the venous phase. A 3-dimensional rotational angiogram (a scan time of 4 seconds with 120 images) will be obtained for evaluation of plaque morphology.~2. The access site will be closely observed for hemostasis after the procedure. The neurological status and renal function will be monitored.~Diagnosis procedure: DSA/3DRA"
2440889|NCT03291600|Experimental|Virtual Psychiatric Care Group|Participants randomized to the intervention group will have the option to receive video-based psychiatrist care in addition to care as usual. Participants will be assigned to begin immediately after randomization.
2440890|NCT03291600|No Intervention|Control Group|Women allocated to the control condition will receive care as usual (in-person psychiatric care) from the study site to which they were referred.
2440891|NCT03291587|Experimental|Intervention - Key Informant|NCORP site coordinator will call each participant to administer a 5 minute telephone survey within 14 days of the lung cancer screening clinic visit. A participant contact log is appended. This assessment focuses on exposure to the intervention and subsequent quit attempts.
2440892|NCT03291587|No Intervention|Usual Care|Data collection from Patients: demographics, health status, smoking history, quitting behavior, perceptions of lung cancer risk and worry, impact of screening on tobacco use behavior, and exposure to the intervention. (baseline, <14 days, 3 months, and 6 months)
2440893|NCT03291574|Experimental|Electroacupuncture group|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
2440894|NCT03291574|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu
2440895|NCT03291561|Experimental|Electroacupuncture group|Electroacupuncture Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
2440896|NCT03291561|Placebo Comparator|Sham electroacupuncture group|Sham acupuncture at Baihui, Nei guan, bilateral Zu, sanli and bilateral Tian shu.
2440897|NCT03291548|Experimental|Quinoa Biscuit|The quinoa-enriched biscuits containing 7.11g quinoa flour.
2440898|NCT03291548|Placebo Comparator|Control biscuit|The placebo control biscuit: an iso-energetic, matched product in terms of appearance, taste, texture and smell.
2440899|NCT03291535|Placebo Comparator|Control|This arm will consist of the usual care of management of hypertension by a clinical pharmacist.
2440900|NCT03291535|Active Comparator|Intervention|This arm will consistent of usual care plus the addition of a blood pressure cuff that will allow patients to upload data to the electronic health record via a secure portal.
2440901|NCT03291522||Men with azoospermia|Ultrasound-guided rete testis flushing and aspiration
2440902|NCT03291509|Active Comparator|In-person Group|Participants randomized to this group will have a health educator to their house for in-person meetings. Participants will use paper forms to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
2440903|NCT03291509|Experimental|Computer Group|Participants randomized to this group will use an iPad to talk to the health educator via video conference meetings. Participants will use the iPad to track progress in other parts of the study. Participants will be asked follow the Enhanced Stop Light Diet (eSLD) and take part in structured physical activity each week.
2440904|NCT03291496||Preterm Neonates|Blood collection Preterm. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
2440905|NCT03291496||Term Neonates|Blood collection Term. From blood, the speed, directionality, and persistence of PMN chemotaxis using microfluidic devices and transcriptomic analysis will be measured.
2440906|NCT03291496||Healthy Adult|One-time whole blood draw of 1ml collection
2440907|NCT03291483|Experimental|whole body vibration group|basketball players had done exercises on whole body vibration platform.
2440908|NCT03291483|Sham Comparator|plyometric training|Basketball players had done same plyometric exercises
2440911|NCT03291457||Glucocorticoids + Tocilizumab|Participants with RA who are receiving glucocorticoid treatment will be observed for up to 52 weeks after starting tocilizumab.
2440912|NCT03291444|Experimental|CAR-T cells combined with peptide specific dendritic cell|CAR-T cells combined with Eps8 peptide specific dendritic cell,or CAR-T cells combined with WT1 peptide specific dendritic cell
2440913|NCT03291444|Active Comparator|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
2440914|NCT03291431|Active Comparator|Active iTBS|
2440915|NCT03291431|Sham Comparator|Sham iTBS|
2440916|NCT03291418|Experimental|ATB-346 OR Placebo|Intervention: Drug: ATB-346 dosed orally at 250 mg once daily for 14 days Intervention: Drug: Placebo (for ATB-346) dosed once daily for 14 days
2440917|NCT03291418|Active Comparator|Naproxen sodium|Intervention: Drug: naproxen sodium dosed orally at 550 mg twice daily for 14 days
2440918|NCT03291405||Body Mass Index less than 30|
2440919|NCT03291405||Body Mass Index more than 30|
2441062|NCT03290274|Experimental|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation at Basal nucleus of Meynert
2517680|NCT02778750||Rapid Decliner Group|
2440922|NCT03291392||Normal subjects|"Normal subjects without ischemic stroke or intracranial/extracranial stenosis would be invited to join the study for blood taking.~Biobank: Gene expression or biomarkers exploration for atherosclerotic-related genetic diseases"
3189458|NCT00777712||Diabetics (HbA1c level >8%) without infection|Poorly controlled diabetes in patients with HbA1c level >8% who have wound (s) 4 weeks or longer without infection. N=50
2440924|NCT03291366|Experimental|MSC|infusion of aUCMSC and conventional therapy
2440925|NCT03291366|Active Comparator|conventional|conventional therapy
2440926|NCT03291353|Experimental|AML Patients|pembrolizumab 200 mg given IV once every three weeks
3151144|NCT00218920|Experimental|continuous moderate-intensity aerobic training|Over a 12-week period, 13 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
3151145|NCT00218920|Experimental|high-intensity interval aerobic training|Over a 12-week period, 14 subjects performed three programmed exercise sessions per week; two supervised by the study investigators in the research laboratory and one performed at home or in a gym, according to instructions.
2440929|NCT03291327|Active Comparator|Investigational product (Lactobacillus A)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (A) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2440930|NCT03291327|Active Comparator|Investigational product (Lactobacillus B)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Lactobacillus (B) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The lactobacilli will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2440931|NCT03291327|Placebo Comparator|Placebo Product (P)|"All volunteers considered to be suitable for the study will receive a pre-baseline dental prophylaxis. At baseline (BL) they will be instructed to abstain from all methods of tooth cleaning in mandible for 2 weeks (2W) apart from the fluoride toothpaste provided. A soft gum shield provided will cover the mandibular teeth whilst brushing and will be removed 10 minutes after brushing. Gingival health assessments and gingival crevicular fluid (GCF) and bacterial plaque samples be undertaken at BL and 2W. At 2W, all participants will receive a dental prophylaxis following the collection of samples and will be asked to resume their normal oral hygiene regime.~Placebo (P) in the form of a lozenge to be taken twice daily (in the morning and in the evening). The placebo will be in the form of a lozenge, which should be placed on the tongue and allowed to dissolve. Any undissolved particles may be swallowed by the participant."
2440932|NCT03291314|Experimental|Axitinib + Avelumab|On day 1 of the treatment phase, patients recruited to this arm will initiate concomitant continuous daily treatment with axitinib (InlytaTM, 5 mg comp BID) in combination with avelumab (10 mg/kg IV Q2 weeks)
2440933|NCT03291314|Experimental|Axitinib (+Avelumab)|"On day 1 of the treatment phase, patients recruited to this arm will initiate treatment with continuous daily axitinib (InlytaTM, 5 mg comp BID).~Patients who tolerate treatment with axitinib and are able to taper the dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone (or an equivalent dose of another oral corticosteroid) will initiate combination therapy with avelumab (10 mg/kg IV Q2 weeks) on day 43, following the the first MRI-based tumor response evaluation in week 6.~Patients who do not tolerate monotherapy with axitinib, or cannot decrease their daily dose of corticosteroids to a maximal daily dose of 8 mg methylprednisolone will not be allowed to initiate avelumab treatment."
2440934|NCT03291301|Experimental|CBT Group|Cognitive Behavioral Therapy for Insomnia
2440935|NCT03291301|Experimental|Combined Group|Cognitive Behavioral Therapy for Insomnia plus Acupressure
2440936|NCT03291301|No Intervention|Wait-list Control Group|
2440938|NCT03291249|Placebo Comparator|Group A|Group A will receive placebo solution for 30 consecutive days
2440939|NCT03291249|Experimental|Group B|Group B will receive 0.5 mg Foralumab Solution daily for 30 consecutive days
2440940|NCT03291249|Experimental|Group C|Group B will receive 2.5 mg Foralumab Solution daily for 30 consecutive days
2440941|NCT03291249|Experimental|Group D|Group B will receive 5.0 mg Foralumab Solution daily for 30 consecutive days
3151146|NCT00218933|Active Comparator|moderate exercise training|
3151147|NCT00218933|Experimental|high intensity exercise training|
2529671|NCT02699229||Benign|Tissue sample
3151148|NCT00218933|No Intervention|controls|
3151149|NCT00218946|No Intervention|control|no fluid, no pacifier
3151150|NCT00218946|Experimental|water|water, no pacifier
3151151|NCT00218946|Experimental|sucrose|Sucrose, no pacifier
3151152|NCT00218946|Experimental|pacifier|No fluid, pacifier
3151153|NCT00218946|Experimental|water and pacifier|water, pacifier
3151154|NCT00218946|Experimental|sucrose and pacifier|sucrose, pacifier
3151155|NCT00218959|Experimental|Narrative Exposure Therapy|carried out according to the manual as outlined by Schauer et al. (2005) (second revised edition 2011) 10 sessions of 90 min duration
2440948|NCT03291158|Experimental|Minocycline IV|Open label Minocin IV
2440949|NCT03291145|Experimental|Beta Blockers|With and without Beta Blockers
2440950|NCT03291145|Experimental|Spironolactone|With and without Spironolactone
2440951|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
2440952|NCT03291093|Experimental|18F-Flutemetamol PET/MRI dynamic|"All included patients will be patients with a recent stroke and a significant carotid plaque.~The first 5 patients will undergo a slightly longer scan protocol to determine optimal scan time for the use of 18F-Flutemetamol in atherosclerosis imaging."
2440953|NCT03291093|Experimental|18F-Flutemetamol PET/MRI CEA|10 patients will be selected from patients that will undergo carotid endarterectomy (CEA) and will undergo the the optimized (shorter) scan protocol with 18F-Flutemetamol. The decision for this operation is made by the surgeon and neurologist and based on clinical standards and is thus independent of study participation.
2440954|NCT03291093|Experimental|18F-Flutemetamol PET/MRI|The remaining 10 patients will undergo the optimized (shorter) scan protocol with 18F-Flutemetamol.
3151156|NCT00218959|Active Comparator|treatment as usual|mainly help with such as sleep problems, depressive symptoms, problems related to asylum status, and other practical matters. Focus on everyday issues and the limited focus on the traumatic events, in line with reports from the National Center on Violence and Traumatic Stress.
3151157|NCT00218972|Active Comparator|AIT: aerobic interval training|High intensity interval training on treadmill at > 90% of maximal HR for four bouts of four minutes with warm up, active pauses and cool down, three times per week for 12 weeks.
2440961|NCT03291054|Experimental|Epacadostat and pembrolizumab|Subjects will receive epacadostat and pembrolizumab
3151158|NCT00218972|Active Comparator|MIT, moderate intensity training|Moderate intensity treadmill continuous exercise at 70% of maximum heart rate for 47 minutes (in order to ensure isocaloric training amount), three times per week for 12 weeks.
3151159|NCT00218972|Active Comparator|Recommendation of regular exercise|No training intervention, general advice as prescribed in guidelines.
2440964|NCT03291028||Patients treated with immune check point blocker|Patients who were treated with immune checkpoint inhibitor targeting PD1 and developed metastatic lesion later
2440965|NCT03291028||Patients treated with targeted/ observational therapy|Patients who were not treated with immune checkpoint inhihibitor and developed metastatic lesion following other targeted therapy
2440966|NCT03291015|Other|radiographic guided treatment|radiographic guided treatment of kienbock disease using plain x ray for determine treatment plan
2440967|NCT03291015|Other|arthroscopic guided treatment|arthroscopic guided treatment of kienbock disease using wrist arthroscopy for determine treatment plan (Wrist arthroscopy)
3151160|NCT00218985|Experimental|exercise training|
3151161|NCT00218985|No Intervention|physician's advice|patients follow their physician's advice in regard to physical activity.
3151162|NCT00219271|Experimental|Zoledronic acid|4 mg IV infused over 15 minutes every 3 months
3151163|NCT00219297|Experimental|Single Arm|
2440972|NCT03290976|No Intervention|Control Group|The control group will consist of patients who choose not to undergo CIM treatments for their CIPN-related symptoms. Participants in this arm of the study will receive standard conventional supportive care, as provided by their oncology health care professionals (HCPs), and closely monitored for any changes in the severity of their CIPN-related symptoms.
2440973|NCT03290976|Active Comparator|Intervention Group A: Single Modality (acupuncture)|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture x2/week, for 6 weeks.
2440974|NCT03290976|Active Comparator|"Intervention Group B: Multi-modality (acupuncture plus)"|Patients choosing to undergo CIM treatments, in addition to standard conventional care: Acupuncture with additional CIM treatment modalities, x2/week, for 6 weeks.
2440975|NCT03290963|Active Comparator|Ketamine plus Lithium|Lithium will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of lithium treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and lithium treatment .
2440976|NCT03290963|Placebo Comparator|Ketamine plus Placebo|Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
3173057|NCT00607659||Control/Chlamydia Negative|Some participants with negative cultures will be included in this study as a control group. The same specimens, exams and blood draws will apply for those subjects with visits at 3 months, 6 months, 1 year, 2 years, and 3 years
3173058|NCT00607685|Experimental|1|The participants will receive a subconjunctival injection of a mixture of 5FU with hyaluronic acid.
2440979|NCT03290937|Experimental|Treatment (irinotecan hydrochloride, cetuximab, utomilumab)|Patients receive irinotecan hydrochloride IV over 90 minutes and cetuximab IV over 1-2 hours on days 1 and 15, and utomilumab IV over 1 hour on day 2. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2440980|NCT03290924|Experimental|Intervention|Low-dose high-frequency health worker training approach to update skilled birth attendants in key evidence-based intrapartum and immediate newborn care practices
2440981|NCT03290924|Active Comparator|Comparison|Training on data collection and reporting
2440982|NCT03290898|Active Comparator|Training group|"Supervised High intensity interval training (HIIT) 3 times a week for 6 months.~Training session:~10 minutes warm up (Low-moderate intensity) 30 minutes intervention (16 minutes HIIT) 10 minutes cool down(Low-moderate intensity)"
2440983|NCT03290898|No Intervention|Control group|Control group, usual lifestyle. Aside from training intervention, all other visits are the same as intervention group (training).
2440984|NCT03290885|Experimental|Combined use of contact aspiration and stent retriever|Combined use of contact aspiration and stent retriever mechanical thrombectomy for recanalization
2440985|NCT03290885|Active Comparator|Stent retriever mechanical thrombectomy alone|Stent retriever mechanical thrombectomy alone for recanalisation
2440986|NCT03290872|Active Comparator|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral Valve Annuloplasty Ring Repair using Carpentier Edwards Physio 2 Complete flexible mitral ring
2440987|NCT03290872|Active Comparator|Simplici T Partial flexible mitral annuloplasty ring|Mitral Valve Annuloplasty Ring Repair using Simplici T Partial flexible mitral annuloplasty ring
2440988|NCT03290859||Training intervention|Train anesthesia providers who deliver propofol sedation for GI endoscopy procedures to follow a uniform propofol monotherapy administration guideline to titrate propofol monotherapy infusion to effect according to a standardized protocol.
2440989|NCT03290859||Effectiveness of training intervention|Compare the effectiveness of training intervention and standardized titration to effect through aggregate data for metrics of recovery times.
2440990|NCT03290846|Experimental|Secretin study|PET and MRI scannings will be performed twice. Subjects will be given secretin hydrochloride and placebo on separate days. In addition, subjects will undergo cold exposure PET scanning once.
2440991|NCT03290833|Experimental|Robotic|The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
2440992|NCT03290833|Active Comparator|Conventional|In conventional therapy group, participants will receive an one-hour of one-on-one treatment (1-hour sessions, 3 times/week, 30 total sessions) from an occupational therapist, focusing on arm and hand function.
2440993|NCT03290820|Active Comparator|Controlled Group|The patients in the Controlled Group are allocated to receive radiotherapy and concurrent chemotherapy.
2440994|NCT03290820|Experimental|Experimental Group|The patients in the Experimental Group are allocated to receive radiotherapy and concurrent chemotherapy plus daily aspirin.
3173059|NCT00607685|Active Comparator|2|Participants will receive a subconjunctival injection of 5 Fluorouracil only.
2440996|NCT03290781|Experimental|Ontamalimab 25 mg|Participants will receive 25 milligram (mg) of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 25 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe once in every 4 weeks (Q4W) up to Week 52.
2440997|NCT03290781|Experimental|Ontamalimab 75 mg|Participants will receive 75 mg of ontamalimab or placebo and achieved a clinical response in one of the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive 75 mg of ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
2440998|NCT03290781|Placebo Comparator|Placebo|Participants will receive 25 mg or 75 mg ontamalimab or placebo matched to ontamalimab in the induction studies (SHP647-301 [NCT03259334] and SHP647-302 [NCT03259308]) will receive placebo matched to ontamalimab as maintenance treatment subcutaneously using a prefilled syringe Q4W up to Week 52.
2441000|NCT03290755||MSM co-infected HIV-HCV|
2441001|NCT03290742||Patients without documented infection.|Patients without infection during 30 day follow-up after radical cystectomy.
2441002|NCT03290742||Patients with documented infection.|Patients with documented any kind of infection (urinary tract infection, blood infection/septic shock, surgical site infection) during 30 day follow-up after radical cystectomy.
2441003|NCT03290729|Experimental|narrow ridge|edentulous site with crestal bone width comprised between 3,5 and 5 millimeters wedge shape implants insertion
2441004|NCT03290716|Experimental|SS+SSSC|Salt substitute plus stepwise salt supply control
2441005|NCT03290716|Experimental|SS only|Salt substitute only
2441006|NCT03290716|Experimental|SSSC only|Stepwise salt supply control only
2441007|NCT03290716|No Intervention|control|No salt substitute and no stepwise salt supply control
2441008|NCT03290703|Experimental|Part 1: GDC-0853 (Effect of Formulation)|Participants will receive five single oral doses of test formulations of GDC-0853 co-administered with rabeprazole in the fasted state.
2441009|NCT03290703|Experimental|Part 2: GDC-0853 (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of one GDC-0853 formulations selected from Part 1 of this study. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
2441010|NCT03290703|Experimental|Part 3: GDC-0853 Optimized (Effect of Food and Rabeprazole)|Participants will receive three single oral doses of an optimized tablet formulations of GDC-0853. One dose will be administered in the fasted state, one dose will be administered in the fed state, and one dose will be co-administered with rabeprazole in the fed or fasted state, depending on randomization.
2441063|NCT03290261|Experimental|Patients with reccurent cystitis|Patient perform 3 hypnosis sessions
2441064|NCT03290248|Placebo Comparator|Vehicle|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
3173060|NCT00607711|Experimental|Single arm|
3173061|NCT00607737|Experimental|1|insulin detemir
3173062|NCT00607737|Placebo Comparator|2|saline
3173063|NCT00607750|Placebo Comparator|1|
2441011|NCT03290690||All Subjects|"All subjects in this study will have their wounds imaged and assessed in the following manner:~Capture and save ST-image Capture and save FL-image Identify discrete locations of cyan (blue/green) fluorescent bacteria (FL_C) Acquire sample of tissue where cyan fluorescent bacteria are present (using curette method) Consent patient for inclusion in this study Note location of sample acquisition by annotating FL-image obtained in step 2 Send sample for microbiology analysis Note naming of microbiology sample on Case Report Form"
2441012|NCT03290677|Experimental|CT-guided Percutaneous Cryoablation of Lung Tumor|"Image-guided core needle biopsy to confirm cancer will be perform~Patients will undergo cryoablation as a standard procedure~cryoablation will be performed with a three-cycle freeze-thaw phase protocol~Non-contrast CT images will be obtained in 3 to 5 minutes intervals to visualize the evolving ablation zone"
2441013|NCT03290651|Experimental|Probiotic Natural Health Product - RepHresh Pro-B|One capsule contains 2.5 billion CFU of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
2441014|NCT03290651|Placebo Comparator|Placebo|Placebo. It is the same composition as the active capsule, without the bacteria.
2441015|NCT03290638|Experimental|Dehydrated Human Amnion Chorion Membrane|This membrane was investigated to evaluate its use as an open barrier for guided bone regeneration (GBR) after tooth extraction and to determine whether intentional exposure of this membrane to the oral environment compromises ridge dimensions and bone vitality for implant placement.
2441016|NCT03290638|Active Comparator|Type I Bovine Collagen Membrane|This membrane has been tested as an open barrier for GBR after tooth extraction. The intentional use of this membrane to the oral environment did not compromise ridge dimensions and bone vitality for implant placement.
2441017|NCT03290625|Experimental|DexKet|Intranasal DEXMEDETOMIDINE (2.0 mcg/kg, maximum 100 mcg) + KETAMINE (1.0 mg/kg, maximum 100 mg)
2441018|NCT03290625|Active Comparator|Dex|DEXMEDETOMIDINE (2.5 mcg/kg, maximum 100 mcg)
2441019|NCT03290612|Experimental|Vitamin C then Placebo|Participants will receive a 1.5g dose of Ascorbic Acid upon wake for the first visit, and a placebo tablet on the second visit.
2441020|NCT03290612|Experimental|Placebo then Vitamin C|Participants will receive a placebo tablet upon wake for the first visit, and a 1.5g dose of Ascorbic Acid on the second visit.
2441021|NCT03290599||No Post operative cognitive dysfunction|Patients who did not have any change or a change less than 4 points between MMT1 and MMT3
2441022|NCT03290599||Post operative cognitive dysfunction|Patients with a difference more than 4 points between MMT1 and MMT3
2441023|NCT03290573|Active Comparator|Dorsum of hand group|short peripheral venous catheter place in the dorsum of the hand
2441024|NCT03290573|Experimental|Forearm group|short peripheral venous catheter place in the forearm
2441025|NCT03290560|Experimental|Recombinant human tissue kallikrein|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
2441026|NCT03290560|Placebo Comparator|Placebo|A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.
2441027|NCT03290547|Other|arm-1|Cutera enLighten laser treatments that allows the user to choose a wavelength between 640nm to 800nm.
2441028|NCT03290534|Experimental|CivaSheet Directional LDR Brachytherapy|FDA Cleared CivaSheet directional Pd-103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
2441029|NCT03290521|Experimental|A - Yes Washing (SL)|In this group, the washing process is continued. In particular, 1000cc of laced ringer is instilled by changing the position of the patient in Trendelenburg and Anti-Trendelenburg so that the liquid contacts not only the internal surgical wounds but the whole wall of the abdominal cavity.
2441030|NCT03290521|Experimental|B- No Washing (NL)|No washing was performed before the end of surgery
2441031|NCT03290508||Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
2441032|NCT03290508||No Prolaris Testing|Patients with newly diagnosed favorable intermediate-risk localized prostate cancer who DO NOT undergo Prolaris testing
2441033|NCT03290495|Active Comparator|isonly|This arm will receive spinal anesthesia. then this arm will receive saline during isoflurane anesthesia. this arm will serve as a control group.
2441034|NCT03290495|Active Comparator|isoket|this arm will receive spinal anesthesia. then will receive isoflurane inhalation. during isoflurane inhalation, this arm will receive single injection of ketamine. at end of anesthesia, effect of ketamine on recovery will be monitored.
2441035|NCT03290482||EE Study Patients 2000-2008|"All patients with the diagnosis of EE from the study period 2000 to 2008. Sixty patients participated in the 10 year follow up phone interview and questionnaire. These are the subjects we will contact to see if they are interested in participating in this study.~If interested in participating, subjects will complete:~Evaluation by the PI physical examination~Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) questionnaires~Barium Esophagram with maximal and minimal esophageal diameter measurement~EsophaCap cytology"
2441036|NCT03290469|Experimental|15 day cWGS and Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 15 days of the sample receipt while still undergoing standard of care (SOC).
2441037|NCT03290469|No Intervention|Standard of Care|Enrolled cohorts receive the results of the clinical whole genome sequencing (cWGS) after 60 days of the sample receipt while still undergoing standard of care (SOC).
2441038|NCT03290456|Experimental|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day will be administered from Day 1 to Month 12
2441039|NCT03290456|Placebo Comparator|Placebo 5mg/day extended of 12 additional months|Placebo 5mg/day will be administered from Day 1 to Month 12
2441040|NCT03290443|Experimental|Enasidenib (CC-90007) tablet|Subjects will receive one 100 mg enasidenib (CC-90007) tablet the morning of Day 1 which will be administered in the fasted state.
2441065|NCT03290248|Active Comparator|B 244 1x (low dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
2441066|NCT03290248|Active Comparator|B244 4x (mid dose)|"Intranasal application:~1 pump (140ul) per nostril BID for 14 days"
2441067|NCT03290235|Experimental|PEG-somatropin-1|Dosage 0.2mg/kg/w
2441068|NCT03290235|Experimental|PEG-somatropin-2|Dosage 0.1-0.2mg/kg/w
2441041|NCT03290430|Experimental|Group Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 1-2 hours. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2441042|NCT03290430|Experimental|Individual Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 sessions over 4 week, each lasting between 30-45 minutes. During these sessions, participants will learn about how to quit smoking by changing habits. Sessions may be audio or video taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2441043|NCT03290430|Experimental|Telephone Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 phone calls over 4 week, each lasting between 30-45 minutes. During these phone calls, participants will learn about how to quit smoking by changing habits. Sessions may be audio taped.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2441044|NCT03290430|Experimental|Video Counseling|"Participants will be asked to complete a set of surveys that should take about 30 minutes to finish. The surveys will ask questions about the participant, their health history, their desire to quit smoking, and their beliefs and attitudes. There will be 8 video calls over 4 week, each lasting between 30-45 minutes. During these video calls, participants will learn about how to quit smoking by changing habits. Sessions may be recorded.~The study team will use text messaging as a way to keep in contact with all participants. Participants will have the option of getting text-based support throughout the program no matter which session format they chose. Subjects will receive up to 8 weeks of nicotine replacement therapy."
2441045|NCT03290417|No Intervention|Unmodified Diet|Patients are under active surveillance with no modification to their diet, as is standard of care for low risk prostate cancer
2441046|NCT03290417|Experimental|Diet modification|Patients receive Vitamin D, Omega-3 and turmeric curcumin as dietary supplements
2441047|NCT03290391|Experimental|LINC-II|LINC-II is a multi-faceted intervention combining pharmacological therapy (i.e., ART and naltrexone for opioid use disorder) and 12 months of strengths-based case management delivered to coordinate care across the narcology and HIV health care systems.
2441048|NCT03290391|No Intervention|Standard of Care|Participants randomized to the control group will receive the narcology hospital's standard of care, which is detoxification with or without stabilization. Prior to discharge, those identified as HIV-infected are given contact details for an HIV clinic, not an appointment. Upon discharge, patients are encouraged to receive outpatient narcology treatment, monthly, for 1 year. For this study, with regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care and a resource card containing harm reduction information.
2441052|NCT03290365|Active Comparator|Platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee. Patients received one dose of PRP injection. One week later, the one dose of HA is injected for intervention group.
2441053|NCT03290365|Placebo Comparator|Platelet rich plasma + normal saline|Patients received one dose of PRP injection. One week later, the one dose of normal saline is injected for control group.
2441054|NCT03290352||Head and neck cancer patients|Patients with oral cavity, tongue, gingival, pharyngeal, laryngeal, or salivary gland cancer and cervical lymph node metastasis who received free flap reconstruction would be enrolled in this study. However, we excluded the patients with distant metastasis identified in their medical records, and those undergoing reconstruction other than anterolateral thigh, fibular bone and radial forearm flaps.
2441055|NCT03290326|Experimental|tACS|Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.
2441056|NCT03290313|Experimental|shu gan yi yang capsule|4 capsules / time, 3 times / day, taking 8 weeks
2441057|NCT03290313|Placebo Comparator|shu gan yi yang capsule capsule simulation agent|4 capsules / time, 3 times / day, taking 8 weeks
3151164|NCT00219336|Experimental|Self-motivational Choices|Students and nonstudents were mailed a brochure prepared as part of the PHC study intervention, Making Healthy Choices for a Healthy Baby in English or Mujeres y Salud Eligiendo Opciones Saludables in Spanish. This brochure allows women to make informed decisions about preventing an AEP. The MF materials included nonstigmatizing messages about drinking and contraception embedded among other health messages. Similar to Project CHOICES, this group also received a brochure on birth control practices.
3173064|NCT00607750|Experimental|ATG003|
2441061|NCT03290274|Experimental|Deep brain stimulation (fornix)|Deep brain stimulation at fornix area
2441161|NCT03289598|No Intervention|Controlgroup|
3173065|NCT00607763|Experimental|1. Micafungin|
3173066|NCT00607776|Active Comparator|1|Systane
3173067|NCT00607776|Experimental|2|Blink tears
3173068|NCT00607841|Experimental|Dose Escalation Cohort 1|Ispinesib given on days 1 and 15 of a 28 day cycle.
2441069|NCT03290222||TRACK|Children will be followed for four weeks (3 to 5 weeks) after the inclusion in the study. Parents will complete the TRACK questionnaire in both visit and will answer additional questions about respiratory symptoms and use of medication.
2441070|NCT03290209|Experimental|Laparoscopic D1 Lymphadenectomy|Laparoscopic D1 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
2441071|NCT03290209|Active Comparator|Laparoscopic D2 Lymphadenectomy|Laparoscopic D2 Lymphadenectomy will be performed for the treatment of patients assigned to this group.
2441072|NCT03290196|Other|EXPAREL 1.3 % in 20 ML Injection|"EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% [13.3 mg/mL]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~size of surgical site~volume required to cover the area~individual patient factors that may impact the safety of an amide local anesthetic~maximum doe of 266 mg (20 mL)"
2441073|NCT03290183||Intrathoracic malignancy|Patients with (strong suspicion of) intrathoracic malignancy and an indication for tissue collection by CT-guided, transthoracic or thoracoscopic approach undergo additional imaging with confocal laser endomicroscopy (CLE).
2441074|NCT03290170|Experimental|Measured resection technique|Measured resection surgical technique
2441075|NCT03290170|Experimental|Gap Balancing Technique|Gap Balancing surgical technique
2441076|NCT03290157|No Intervention|Control group|Regular colonoscopy preparation paper based information provided
2441077|NCT03290157|Other|ColoprAPP group|Regular colonoscopy preparation paper based information provided plus usage of a downloaded SPA (ColoprAPP) as a reminder system for colonoscopy preparation
2441078|NCT03290144||with diabetes|
2441079|NCT03290144||without diabetes|
2441080|NCT03290131|Active Comparator|AERT 40 mg|40 mg Arbaclofen Extended-Release Tablets
2441081|NCT03290131|Active Comparator|AERT 80 mg|80 mg Arbaclofen Extended-Release Tablets
2441082|NCT03290131|Placebo Comparator|Placebo|Placebo
2441083|NCT03290118|Experimental|Traffic Light|"Participants in this group will be provided with a survey that shows the food and beverage packages with traffic light front of pack labels only.~Intervention is the Nutrition Rating System - Traffic Light"
2441084|NCT03290118|Experimental|Star System|"Participants in this group will be provided with a survey that shows the food and beverage packages with health star rating front of pack labels only.~Intervention is the Nutrition Rating System - Health Star Rating"
2441085|NCT03290118|Experimental|Warning Label|"Participants in this group will be provided with a survey that shows the food and beverage packages with warning front of pack labels only.~Intervention is the Nutrition Rating System - Warning Labels"
2441086|NCT03290118|No Intervention|Control|Participants in this group will be provided with a survey that shows the food and beverage packages without any front of pack labels.
2441087|NCT03290105||study population|Consecutive critically-ill patients admitted to the ICU and receiving invasive mechanical ventilation for more than 48 hours
2441088|NCT03290092|Experimental|Treatment|
2441090|NCT03290066|Active Comparator|Kinesiotape|"Kinesiotape will be applied as a self-treatment. All participants will be instructed in an indvidual session and will receive a tutorial video to remember the kinesiotaping procedure. 3 band of a special and hypoallergenic tape (Kinematix Tex) will be attached to the abdominal (2 strips) and lower back (1 strip).~Patients will be taped for four days , ıt will start at the beginning of the menstruation."
2441091|NCT03290066|Active Comparator|Usual care|"Participants will use the usual self-care for primary dysmenorrhea. It will start at the beginning of the menstruation.~They will note the treatment indicating the dosage in a calendar."
2441092|NCT03290053|Experimental|CE-5S A: Treatment arm|Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion
2441093|NCT03290053|Sham Comparator|CE-5S A: Control arm|Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion
2441094|NCT03290053|Experimental|CE-5S B: Treatment arm|Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion
2441095|NCT03290053|Sham Comparator|CE-5S B: Control arm|Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion
2441098|NCT03290014||Good sleepers|COPD patients with good sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
2441099|NCT03290014||Bad sleepers|COPD patients with poor sleep quality according to CASIS score will be studied with polysomnography, actigraphy and OSLER test
2441100|NCT03289988||Normal group|Normal group(control group): patients with negative colonoscopy findings (n= 238).
2441101|NCT03289988||Low risk adenoma group|Low risk adenoma group: patients having at least one low risk adenoma (n=250).
2441102|NCT03289988||High-risk adenoma group|High-risk adenoma group: patients having at least one of following criteria (more than 1 cm in size, villous or tubulovillous histologic type, high-grade dysplasia findings) (n=316).
2441103|NCT03289988||Colon cancer|Colon cancer: histologically confirmed colon cancer patients (n=160).
3151165|NCT00219336|Active Comparator|Information Only|Students and nonstudents were mailed a brochure prepared by the CDC. The brochure (English: Think Before You Drink: You Can Hurt Your Unborn Baby; Spanish: Piénselo Antes de Beber: Puede Lastimar a Su Futuro Bebe), available at the CDC website, targets women of childbearing-age, discusses FAS and the negative effects of a mother's drinking on her unborn child, and recommends calling Alcoholics Anonymous or an alcohol treatment program for help to stop drinking. The CDC brochure did not contain information about how to contracept effectively.
3151166|NCT00219362|Experimental|ALVAC-HIV 4 injections|Arm A: injection of ALVAC-HIV(vCP1452) for a total of 4 injections (W0, W4, W8, W20)
3151167|NCT00219362|Experimental|ALVAC-HIV 3 injections|Arm B: injection of ALVAC-HIV(vCP1452) for a total of injections (W4, W8, W20)
2441162|NCT03289585||Hidradenitis Suppurativa Cohort|Patients with Hidradenitis Suppurativa (ages 18-99 years old) will be asked to complete a series of questionnaires on how Hidradenitis Suppurativa impacts quality of life.
3151168|NCT00219362|Placebo Comparator|Placebo - 4 injections|Arm C1: injection of placebo for a total of 4 injections (W0, W4, W8, W20)
3151169|NCT00219362|Placebo Comparator|Placebo - 3 injections|Arm C2: injection of placebo for a total of 3 injections (W4, W8, W20)
2441109|NCT03289949|Other|Project 1: Occupancy of psilocybin/ketanserin|After baseline MRI & 5-HT2AR PET-imaging, participants will be allocated to undergo either one oral dose of psilocybine or one oral dose of ketanserin. After drug administration, participants will undergo two CIMBI-36 PET scans.
2441110|NCT03289949|Other|Project 2: Long term effects of psilocybin|After baseline MRI & CIMBI-36 PET-imaging, participants will receive one dose of oral psilocybine intervention. One and 12 weeks after dosing, participants will undergo post-intervention PET-scan.
2441111|NCT03289949|Other|Project 3: Functional connectivity and synaptic plasticity|After baseline MRI scanning and CIMBI-36 PET, participants will undergo one psilocybine-intervention fMRI scan and one ketanserin-intervention fMRI scan. If P2 shows there are long term effects of psilocybine on 5-HT2AR levels, psilocybine will be fixed as the second intervention. If not, interventions will be randomized.
2441112|NCT03289936|Experimental|Start ventilation with NIPPV|Alternatively vented with NIPPV and SNIPPV
2441113|NCT03289936|Experimental|Start ventilation with SNIPPV|Alternatively vented with SNIPPV and NIPPV
3151170|NCT00219375|Experimental|E1|This arm is conducted as a separate study (12-601-0001)
3151171|NCT00219375|Experimental|E2|This arm is conducted as a separate study (12-603-0001).
2441116|NCT03289910|Experimental|Arm A (veliparib, topotecan hydrochloride, carboplatin)|Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2441117|NCT03289910|Active Comparator|Arm B (topotecan hydrochloride, carboplatin)|Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2441118|NCT03289897|Experimental|Study Arm-LiverMultiScan|Patients will be scanned using the LiverMultiScan. Follow-up will be determined by the results of the scan.
2441119|NCT03289897|No Intervention|Control Arm|Standard of care as per guidelines of the local centre
2441120|NCT03289884||Control Group (CE1)|"All patients must have cystic lesions which must exceed 30mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~Patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent."
2441121|NCT03289884||CE group (CE2-4)|"All patients must have hepatic CE, as confirmed by positive blood tests, with lesions identified on the standard of care MRI/CT scan, one or more of which must exceed 20 mm in diameter.~All patients must be aged 16 or over and able to provide informed consent.~All patients will have an MRI scan (not involving ionising radiation)~Patients wil have an 'Ultrasound scan (not involving ionising radiation)'~Exclusion criteria include pregnancy and any contraindication to MRI (pacemaker, metallic implants, claustrophobia) and inability to give consent.~Patients from the CE group undergoing surgery or aspiration will have fluid samples sent for analysis as part of standard clinical care. These cyst fluid samples will then be transported to the MRI scanner for Ex vivo scanning."
2441122|NCT03289871|Experimental|Excilor|2 applications per day for 6 months
2441123|NCT03289871|Active Comparator|Loceryl 5%|1 application per week for 6 months
2441126|NCT03289845|Other|BHX implant|All patients implanted with BHX implant
2441127|NCT03289832|Active Comparator|Crucera-SGS®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third days of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
2441128|NCT03289832|Active Comparator|Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a non-cruciferous diet and to ingest daily for 10 days, Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks, for a total of 8 skin-punch biopsies per individual."
2441129|NCT03289832|Active Comparator|Crucera-SGS® and Meriva 500-SF®|"Drug: Subjects will follow a cruciferous vegetable-free diet and will first undergo a 10 day nonintervention phase. For the second phase they will be instructed to maintain a cruciferous vegetable-free diet and to ingest daily for 10 days, Crucera-SGS® as a source of glucoraphanin which is converted to sulforaphane; 9 capsules (450 mg or 1.03 mmol GR) and Meriva 500-SF® as a source of curcumin; 2 capsules (1000 mg or 2.72 mmol total curcuminoids) per day.~On the 7th day of each phase, they will be asked to fast overnight, come in to the clinic, provide urine and blood, and receive a dose 2-times their M.E.D. at up to 5 sites on the upper buttocks. Following the first and third day of chromometer readings, 2 biopsies will be taken from the upper buttocks for a total of 8 skin-punch biopsies per individual."
2441163|NCT03289559|No Intervention|Control|
2441164|NCT03289559|Placebo Comparator|GnRH antagonist + Placebo Gel|
2441165|NCT03289559|Active Comparator|GnRH antagonist + Testosterone Gel|
3151172|NCT00219375|No Intervention|conventional therapy|This arm is conducted as a separate study (12-602-0001)
3151173|NCT00219401|Experimental|Neonatal 7vPCV|Receive study vaccine (Prevnar) at birth, 1 and 2 months
3151174|NCT00219401|Experimental|Infant 7vPCV|Receive the study vaccine (Prevnar) at 1, 2 and 3 months
3151175|NCT00219401|Placebo Comparator|Control|Do not receive study vaccine (Prevnar)
3151176|NCT00219427||1|
3151177|NCT00219440|Experimental|A|ACTOS plus standard diet
2441130|NCT03289819|Experimental|Pembrolizumab/Nab-Paclitaxel|"This is a phase II, one-arm, open label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple negative breast cancer.~All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.~After the 25th patient has started trial treatment, all further included patients will receive 1 additional cycle of pembrolizumab i.v. 200 mg q3w monotherapy before starting regular trial treatment.~Clinical and bioptic tumor assessment will be performed after each treatment phase. Study treatment will be applied until state of the art surgery, onset of unacceptable toxicities, progression or withdrawal of consent."
2441131|NCT03289806||Cases|Glaucoma surgery
2441132|NCT03289806||Controls|Strabismus surgery
2441133|NCT03289793|Experimental|Group A|"Children will be assigned to this group in a random fashion according to a ratio 2:1 with respect to group B (see below).~20 subjects will be included in this group."
2441134|NCT03289793|Active Comparator|Group B|Children will be assigned in this group in a random fashion. 10 subjects will be included in this group.
2441135|NCT03289793|Active Comparator|Group C|"Will be included in this group children who meet the inclusion criteria and who, with their families, are motivated to participate in the study but cannot claim to be part of groups A or B (because of logistical constraints: living too far away to comply with the frequency of the visits required by the training).~Group C allows to follow the natural evolution of children with ADHD with no intervention."
2441136|NCT03289767|Experimental|Curved-tube|Giving additional curve to the endotracheal tube by simple preparation.
2441137|NCT03289767|No Intervention|Control|No other manipulation of the endotracheal tube is done.
2441138|NCT03289754|Experimental|ConforMIS iTotal Knee with iPoly Insert|The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.
2441139|NCT03289741|Experimental|Octreotide then Lanreotide|Each patient on study will receive three injections of intramuscular (IM) octreotide Long Acting Release (LAR). Octreotide LAR for 3 injections followed by lanreotide for 3 injections
2441140|NCT03289741|Experimental|Lanreotide then Octreotide|Each patient on study will receive three injections of deep subcutaneous (subq) lanreotide. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
2441141|NCT03289728|Experimental|Strategy guided by ischemia imaging|"Non-invasive imaging (SPECT or DSE) will be performed. High-risk Patients judged to high risk by imaging (according to ESC guidelines (5)) will undergo coronary angiography aimed at myocardial revascularization and have optimal medical treatment, according to ESC guidelines.~- Low or intermediate risk patients will receive optimal medical treatment."
2441142|NCT03289728|Active Comparator|Systematic coronary angioplasty|Patients will routinely undergo invasive coronary angiography aimed at myocardial revascularization.
2441143|NCT03289715|Experimental|arm 1|on demand humidification
2441146|NCT03289689|Experimental|Whole body vibration|"The subjects in the WBV group performed one series of five consecutive repetitions of 60 sec unsynchronised multidimensional WBV (Zeptoring, Scisen GmbH, Germany; 4 Hz, amplitude 3mm) with a 1-min pause between administrations, three times a week. The construction of this device is designed to perform a nonharmonious generation of oscillating movements in vertical and horizontal planes in order to prevent occurrences of resonance and habituation of receptors.~During the intervention, subjects wore thin-soled gymnastic-type shoes, carrying out in a squatting standing position, with slight flexion at the hips, knees and ankle joint, on the vibration platform."
2441147|NCT03289689|No Intervention|Control|The controls did not receive any training.
3189459|NCT00777712||Normoglycemic- without infection|Non-Diabetic patients with wound(s)4 weeks or longer without infection. N=50
3189460|NCT00777712||Diabetics (HbA1c level<8%) with infection|Patients with controlled diabetes with HbA1c level<8% who have wound (s) 4 weeks or longer and also with infection. N=50
2441150|NCT03289663|Active Comparator|Control|The arm will receive bednets treated with conventional insecticide (Pyrethroid)
2441151|NCT03289663|Experimental|Experimental|The arm will receive bednets treated with new generation of insecticides (synergistic combination of insecticides)
2441154|NCT03289637|Experimental|Active intervention|"In the group randomised to active treatment and with a screening level of 25-OH-vitamin D 25-50nmol/L an intervention with 1600IE daily of vitamin D will be given.~In those randomised to active treatment and with a screening level of 25-OH-vitamin D of <25nmol/L, an intervention of 2400IE of vitamin D will be given."
2441155|NCT03289637|Placebo Comparator|Placebo|In the group randomised to placebo and with a screening level of 25-OH-vitamin D <50 mol/L, the participants will be given placebo.
2441156|NCT03289624|Experimental|SHARE for Chronic Conditions|"Six weekly SHARE for Chronic Conditions (SHARE-CC) sessions will be conducted in the dyad's home or another location preferred by the participants. A care plan (the SHARE plan) is created that reflects the mutual decisions made by the dyad as a result of their participation in the SHARE-CC program. The SHARE plan is intended to help the caregiver (CG) ensure the PWCC's values and preferences are supported when decisions have to be made in an emergency or in the end stages of the disease. SHARE plans will be documented in a notebook that also contains information on key topics and provides links to local and online resources and services."
2441157|NCT03289624|No Intervention|Health Coaching|Six 30-minute weekly telephone calls to provide information and education related to the PWCC's conditions and information about services and care options will be conducted.
2441158|NCT03289611|No Intervention|Control|Usual management
2441159|NCT03289611|Experimental|Experimental|Ambulatory management if sFlt-1 / PlGF ratio is below 38 Usual management if sFlt-1/PlGF is between 38 and 85. If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued
2441160|NCT03289598|Experimental|Interventionsgroup|
3208499|NCT00975377|No Intervention|No hair removal|Patients randomized to the no hair removal cohort will not undergo any preoperative hair removal.
2441168|NCT03289546|Experimental|mindfulness + aerobic training|2 aerobic training sessions + 1 mindfulness training class every week for 8 weeks, then continue with 3 aerobic training sessions/ week for 4 additional weeks.
2441169|NCT03289546|No Intervention|Usual care|
2441171|NCT03289520|Experimental|Clopidogrel|
2441172|NCT03289520|Placebo Comparator|Placebo|
2441173|NCT03289507|Active Comparator|Treatment1|Longvida Capsule formulation A
2441174|NCT03289507|Active Comparator|Treatment 2|Longvida Capsule formulation B
2441175|NCT03289507|Experimental|Treatment3|Curcuma longa extract of Rhizomes
2441176|NCT03289494|Active Comparator|Diet A|Balanced diet high in Slowly Digestible Starch
2441177|NCT03289494|Placebo Comparator|Diet B|Balanced diet low in Slowly Digestible Starch
2441180|NCT03289468||Group1|Endometrial Benign Disease
2441181|NCT03289468||Group2|Endometrial Cancer and Precancerous Lesions
2441183|NCT03289442|Experimental|supine position group|
2441184|NCT03289442|No Intervention|left lateral position|
2441185|NCT03289429|Experimental|Atorvastatin|Atorvastatin and intravenous placebo
2441186|NCT03289429|Experimental|Magnesium sulfate|Magnesium sulfate and tablets placebo
2441187|NCT03289429|Placebo Comparator|Control|intravenous placebo and tablet placebo
2441188|NCT03289416|Other|Platelet Rich Plasma (PRP)|Blood will be drawn from the patient using the Pure PRP II system into a syringe with anticoagulant (sodium citrate). 1 mL of blood will be separated and sent to a lab for analysis. Remaining blood will be separated into a single concentrating device and centrifuged to separate red blood cells from plasma and platelets. The plasma and platelets will be separated off with a syringe and re-centrifuged to separate the platelets from the plasma. 1 mL will be separated and sent to a lab for analysis leaving 6 mL for injection. Both the 1 mL of blood and the 1 mL of PRP will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F. Physician will then inject the PRP into the affected knee joint.
2441189|NCT03289416|Other|Bone Marrow Concentrate (BMC)|Bone marrow will be harvested from the posterior iliac crest using the PureBMC system. 50 mL of bone marrow will be drawn into one syringe containing 10 mL of sodium citrate. Marrow will be filtered and centrifuged for separation of the bone marrow concentrate. Plasma and cell concentrate will be separated off with two syringes and re-centrifuged to separate the cell concentrate from the plasma. After plasma is drawn off, BMC will be drawn into a syringe for injection into affected knee. BMC production procedure results in 7 mL of product and 1 mL will be separated and sent to a lab for analysis. Both 1 mL of BMA and 1 mL of BMC will be sent to an independent lab to undergo analysis for CBC, TNC, human CD34+ hematopoietic stem/progenitor cell assay and CFU-F.
2441190|NCT03289403|Experimental|Study group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D and immunomodulatory drugs(prednisolone, hydroxychloroquine, azathioprin, IV immunoglobulins)
2441191|NCT03289403|Active Comparator|Control group|Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D.
2441192|NCT03289390||Acetaminophen to close PDA|Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen
2441193|NCT03289377|Experimental|RDAD training to APNs|Half-day workshop to provide APNs with all skills necessary to conduct RDAD in their clinical settings. A subset of the trained APNs will implement RDAD as part of their ongoing care of persons with ADRD.
2441194|NCT03289364|Experimental|Penguin Cold Caps|Penguin Cold-cap therapy will commence at least 50 minutes prior to chemotherapy infusion, and will continue for 4 hours following completion of chemotherapy.
2441195|NCT03289351|No Intervention|2-drug Therapy|ceftriaxone/metronidazole
2441196|NCT03289351|Experimental|1-drug Therapy|piperacillin-tazobactam
2441197|NCT03289338|Experimental|Zoledronic acid|Bisphosphonate Zoledronic acid
2441198|NCT03289338|Active Comparator|Methylprednisolone|Glucocorticoid Methylprednisolone
2441199|NCT03289338|Placebo Comparator|Placebos|Placebo normal saline
3151178|NCT00219440|Experimental|B|Actos plus structured diet
3151179|NCT00219440|Experimental|C|Metformin plus standard diet
2441202|NCT03289312||Sepsis|Diagnosis of new onset sepsis within 24h without history of tumor, hematological or immunological disease, and treatment with chemotherapy agents or corticosteroids within 6 months prior to or during the hospitalization.
2441203|NCT03289312||Health control|Health vonlunteers
2441204|NCT03289299|Experimental|Arm A|Non-high dose treatment in 3 phases Induction 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Consolidation 6 cycles: carfilzomib, lenalidomide, daratumumab, dexamethasone Maintenance 12 cycles: lenalidomide, daratumumab
2441205|NCT03289286|Other|Patients with breast cancer operated in ambulatory|
3151180|NCT00219466|Active Comparator|1|
2441207|NCT03289260|Experimental|Interventional Arm|Imiquimod 5% cream therapy Fulguration
2441208|NCT03289260|Placebo Comparator|Placebo Arm|Placebo cream therapy Fulguration
2441244|NCT03289000||ConforMIS PS Group|Patients who have undergone a total knee replacement with the ConforMIS iTotal PS Knee Replacement System
2441714|NCT03285880|Experimental|Procedural memory|Napping v. wake effect on a procedural memory task (motor sequence learning or mirror tracing)
3151181|NCT00219466|Active Comparator|2|
3151182|NCT00219531||control|subjects with no irritable bowel syndrome or gastrointestinal complaints and regular menstrual cycle.
3151183|NCT00219531||IBS|women with IBS symptoms and normal menstrual cycle.
3151184|NCT00219674|Active Comparator|2|Group II
3151185|NCT00219674|Active Comparator|3|
3151186|NCT00219674|Active Comparator|4|
3151187|NCT00219674|Active Comparator|1|Group I
3151188|NCT00219687|Active Comparator|1|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions only
3151189|NCT00219687|Active Comparator|2|When a 911 call is determined to be a cardiac arrest, the caller reporting the event who needs or desires instructions to perform CPR while waiting for EMS to arrive will receive dispatcher-assisted CPR instructions with chest compressions and breaths
3151190|NCT00219739|Experimental|Imatinib mesylate 400 mg|
2441209|NCT03289247|No Intervention|Regular|"Regular closure:~The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure."
2441210|NCT03289247|Experimental|Additional tissue adhaesive|The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
2441214|NCT03289221|Experimental|Experimental Group|Thirty (30) consecutive patients indicated for treatment of prostate cancer with HIFU (FocalOneR, Edap TMS, France) will be selected to the manometry study before the treatment together with the application of specific questionnaires (Cleveland Clinic Incontinence Score-CCIS, Fecal Incontinence Quality of Life Score-FIQLS, and Rome IV for functional constipation. This evaluaton will be conducted again after the treatment.
3151191|NCT00219739|Experimental|Imatinib mesylate 600 mg|
2441219|NCT03289182||MabThera|Participants with NHL will be administered 1400 milligrams (mg) and those with with CLL will be administered 1600 mg MabThera subcutaneously at the discretion of the physician in accordance with local clinical practice and local labeling, and will be observed for 6 years.
2441220|NCT03289169|Experimental|MEDITOXIN|Meditoxin(Botulinum toxin type A)
2441221|NCT03289156|Active Comparator|Arousal Reappraisal|Brief educational intervention about the stress response and arousal reappraisal
2441222|NCT03289156|Active Comparator|Exercise|Three 5-minute bouts of aerobic exercise at increasing intensities
2441223|NCT03289156|Experimental|Arousal Reappraisal + Exercise|Brief educational intervention about the stress response and arousal reappraisal followed by three 5-minute bouts of aerobic exercise at increasing intensities with practice applying the arousal reappraisal learned earlier.
2441224|NCT03289156|No Intervention|Control|Time-matched rest
2441225|NCT03289143|Experimental|Dose 1 Semorinemab|
2441226|NCT03289143|Experimental|Dose 2 Semorinemab|
2441227|NCT03289143|Experimental|Dose 3 Semorinemab|
2441228|NCT03289143|Placebo Comparator|Placebo|
2441229|NCT03289117|Experimental|Novel gel installation device procedure|"Catheter change with novel device.~Each subject will undergo catheter change with novel gel instillation device procedure"
2441230|NCT03289117|Active Comparator|Standard procedure|"Catheter change with standard procedure.~Each subject will undergo catheter change with standard procedure"
2441231|NCT03289104|Active Comparator|Steel Wires|In this arm, patients will have their sternum closed with steel wires.
2441232|NCT03289104|Experimental|ZipFix Sternal Closure System (Plastic Cables)|In this arm, patients will have their sternum closed with the ZipFix system.
2441233|NCT03289091|Experimental|water-based continuous aerobic training|Participants who will be randomized for the intervention in the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
2441234|NCT03289091|Experimental|water-based interval aerobic training|Participants who will be randomized for the intervention in the interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
2441235|NCT03289078|Experimental|Thermal care|Spa Treatment realised daily 6 days a week during 18 days
2441236|NCT03289078|No Intervention|Standard Care|Usual care
3151192|NCT00219739|Experimental|Imatinib mesylate 400 mg +Peg interferon|
3151193|NCT00219739|Experimental|Imatinib mesylate 400 mg +Cytarabine|
3151194|NCT00219830|Experimental|1 - home-based walking program|Based on medical record held in general practice, patients who had not attended a formal cardiac rehabilitation program after myocardial infarction and were enrolled in home-based walking programme
2441242|NCT03289026|Experimental|aripiprazole group|Patients receive aripiprazole treatment
2441243|NCT03289013|Experimental|Testing of new adhesive strips|"Each subject will test six adhesive strips on pre-stripped skin.~Standard adhesive 1~Standard adhesive 2~LT-2~LT-21~LT-25~33-20~The six strips are applied on the abdominal skin. The order of the adhesive strips on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of adhesive strips will be measured at 5 visits."
2529673|NCT02699229||Normal|Tissue Sample
3151195|NCT00219830|No Intervention|2 - cardiac rehabilitation|Based on medical record held in general practice, patients who are identified as having attended a Cardiac Rehabilitation program following myocardial infarction - 'usual care'
3151196|NCT00219856|Experimental|1|Anesthesic induction and maintenance with intravenous propofol.
3151197|NCT00219856|Active Comparator|2|Anesthesic induction with intravenous penthotal and maintenance with inhaled desflurane.
3151198|NCT00219882|Experimental|1|standardized turmeric root extract
3151199|NCT00219934||Group A|acute or early in the course of HIV-1 infection, independent of decisions regarding therapy with HAART.
3151200|NCT00219934||Group B|subjects who were diagnosed with acute HIV-1 infection in the past and have been participating in an ADARC/Rockefeller University Hospital treatment protocol for acute HIV-1 infection, and currently have a viral load consistently less than 50 copies/ml on current treatment
2441247|NCT03288974||Post Marketing Survey of MM patients treated with POMALYST®|As a method of POMALYST® PMS, Drug Use Examination (DUE) is planned and designed to comply with the regulatory requirement in consequence of approval of a new drug in Korea. This DUE is a non-interventional, observational and post-marketing surveillance, which is conducted as a regulatory required procedure to evaluate product safety of a new drug treatment in clinical routine practice in Korea. And this DUE will be conducted in compliance with the local guideline [standard for Re-examination of New Drugs, etc.] as a post approval commitment.
2441248|NCT03288948|Active Comparator|Standard Contrast Increment|
2441249|NCT03288948|Experimental|Reduced Contrast Increment|
2441250|NCT03288948|Experimental|No Contrast Increment|
2441251|NCT03288935|Active Comparator|Group 1 (TICM only)|Assigned to TICM group after reception & placement.
2441252|NCT03288935|Active Comparator|Group 2 (TICO only)|Assigned to TICO group after reception & placement.
2441253|NCT03288935|Active Comparator|Group 3 (TICM & TICO)|Assigned to both TICM and TICO group after reception & placement.
2441254|NCT03288935|No Intervention|Group 4 (None)|No additional intervention after reception & placement
2441255|NCT03288922|Experimental|Limited BF OL-HDF with SHF|Limited blood flow pre-dilution online hemodiafiltration using super high-flux dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of protein-bound toxin removals with the control period.
2441256|NCT03288922|Active Comparator|High-efficiency OL-HDF|High-efficiency post-dilution online hemodiafiltration using standard high-flux dialyzer was assigned as the control period.
2441257|NCT03288909||Early onset Parkinson's disease|Idiopathic Parkinson's disease within 1 year of symptom onset
2441258|NCT03288909||Idiopathic REM Sleep Behavior Disorder|Idiopathic REM Sleep Behavior Disorder
2441259|NCT03288909||Age-matched healthy controls|Age-matched healthy controls
2441260|NCT03288896|Experimental|Alerta Alcohol|Intervention Group: The Experimental Group receives the Alerta Alcohol intervention, which consists of four sessions at school (baseline questionnaire, two sessions in three scenarios: at home, celebrations, and public places, and a final evaluation). The adolescents are provided with answers related to their views of each scenario; this information is used to provide highly specific feedback regarding their knowledge, risk perception, self-esteem, attitude, social influence (modelling, norms and social pressure), self-efficacy and action plans. In addition, two booster sessions are given at home to reinforce the contents of the three scenarios. Evaluation takes place after four months.
2441261|NCT03288896|No Intervention|Control Group|Control Group: The Control Group just completes the baseline and the evaluation questionnaires and then they are allowed to receive the intervention as well (as a waiting list control condition). Evaluation takes place after four months from baseline
2441262|NCT03288883|Active Comparator|Fractional Microablative CO2-laser|
2441263|NCT03288883|Active Comparator|Photothermal Non-ablative Erbium:YAG-laser|
2441264|NCT03288870|Experimental|BCD-100 monotherapy|Patients will receive solution of BCD-100 in a dose 3 mg/kg every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity
2441265|NCT03288870|Active Comparator|Docetaxel monotherapy|Patients will receive solution of docetaxel in a dose 75 mg per square meter every 3 weeks as intravenous infusion until progression of the disease or signs of intolerable toxicity, maximum 6 cycles
2441266|NCT03288857|No Intervention|Bulb Aspirator|If randomized to the bulb aspirator group, the patient will be sent home with a bulb aspirator to use for home nasal secretion management
2441267|NCT03288857|Experimental|Nasal Oral Aspirator (NeilMed Naspira)|If randomized to the nasal oral aspirator group, patient will be sent home with a nasal oral aspirator to use for home nasal secretion management
2441268|NCT03288844||HOLOCORE Patients|Patients who completed the main HOLOCORE clinical trial will undergo to Ophthalmologic examinations, Digital pictures collection and QoL questionnaires (NEI VFQ 25 and EQ-5D-3L/Y) will be performed/administered at each study visit
2441269|NCT03288831|Active Comparator|Normal Subjects, Gluten Drink|Normal subjects will drink a solution containing 6 grams of gluten one time.
2441270|NCT03288831|Placebo Comparator|Normal Subjects, Placebo Drink|Normal subjects will drink a solution without gluten one time.
2441271|NCT03288831|Active Comparator|Celiac Subjects, Gluten Drink|Subjects with celiac disease will drink a solution containing 6 grams of gluten one time.
2441272|NCT03288831|Placebo Comparator|Celiac Subjects, Placebo Drink|Subjects with celiac disease will drink a solution without gluten one time.
2441273|NCT03288831|Active Comparator|Gluten Sensitivity, Gluten Drink|Subjects with non-celiac gluten sensitivity will drink a solution containing 6 grams of gluten one time.
2441274|NCT03288831|Placebo Comparator|Gluten Sensitivity, Placebo Drink|Subjects with non-celiac gluten sensitivity will drink a solution without gluten one time.
2441275|NCT03288818|Experimental|low dose TSEBT, mechlorethamine hydrochloride gel|Patients undergo low dose TSEBT for 2 weeks. After 30 days of observation, patients receive mechlorethamine hydrochloride gel topically daily at week 7 and then once weekly up to week 54.
2441276|NCT03288792|Experimental|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
3151201|NCT00219947||high risk|Blood draw from individuals known to be or at high risk for HIV-infection
2441279|NCT03288753|Experimental|Adults and children above 14 years old|"Visit 1:~Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2"
2441715|NCT03285880|Experimental|Emotional memory|Napping v. wake effect on an emotional memory task (emotional faces or storybook)
3151202|NCT00219947||diagnosed|Blood draw f rom individuals diagnosed with HIV infection
3151203|NCT00219999||HCV infection|current HCV infection, including intravenous drug users
3151204|NCT00219999||cryoglobulinemia|cryoglobulinemia and without HCV infection
3151205|NCT00219999||chronic liver disease|chronic liver disease not due to hepatitis C virus infection
3151206|NCT00219999||Sustained Virologic responders|successfully treated for HCV infection
2441280|NCT03288753|Experimental|children up to 14 years old|"Visit 1 Satisfaction questionnaire on Neuro 1~Visit 2 (15 days after V1):~Satisfaction questionnaire on Neuro 2~Visit 3 (3 months after V2):~Satisfaction questionnaire on Neuro 2~The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions."
2441281|NCT03288740|Experimental|Semaglutide 0.5 mg|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide.
2441282|NCT03288740|Placebo Comparator|Semaglutide 0.5 mg placebo|Participants will enter a 13 weeks treatment with 4 weeks dosing at dose level 0.25 mg and 9 weeks at 0.5 mg semaglutide placebo.
2441283|NCT03288740|Experimental|Semaglutide 1.0 mg|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide.
2441284|NCT03288740|Placebo Comparator|Semaglutide 1.0 mg placebo|Participants will have 13 weeks treatment with 4 weeks dosing at dose level of 0.25 mg, 4 weeks at 0.5 mg, and 5 weeks at 1.0 mg semaglutide placebo.
2441285|NCT03288727|Experimental|Negative IF result|
2441286|NCT03288727|Experimental|Positive IF result|
3189461|NCT00777712||Diabetics (HbA1c level <8%) without infection|Patients with controlled diabetes with HbA1c level <8% who have wound (s) 4 weeks or longer and also without infection. N=50
3189462|NCT00777725||1|Chronic stable left sided HF patients
2441289|NCT03288701|Experimental|Body Composition Analysis|Daily measurement of the Body Composition using electrical Bioimpedance Analysis in a scale (seca mBCA 515). Including total body water and weight.
2441290|NCT03288688|Experimental|Exercise program and education|An exercise program in the form of home exercise videos will be given to the participants in this group. They will be asked to perform a minimum of two 35-minute exercise sessions per week, over a period of 11 weeks. They will also be required to attend three group exercise sessions, to confirm correct execution of the exercises. A short educational presentation on injury prevention will be offered at the beginning of the study, followed by three informative e-mails over the course of the study.
2441291|NCT03288688|No Intervention|No intervention|Participants in this group will be asked to continue their usual activities.
2441292|NCT03288675|Active Comparator|Active aiTBS - active CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive active CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
2441293|NCT03288675|Experimental|Active aiTBS - sham CCT+SSRI|Patients receive active aiTBS treatment in the first week, and starting from week 3 receive a control training for a period of 4 weeks in combination with an antidepressant (SSRI)
2441294|NCT03288675|Experimental|Sham aiTBS - aiTBS - active CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week receive CCT for a period of 4 weeks in combination with an antidepressant (SSRI)
2441295|NCT03288675|Experimental|Sham aiTBS - aiTBS - sham CCT+SSRI|Patients receive sham aiTBS treatment in the first week, real aiTBS treatment in the third week, and starting from the fifth week control training for a period of 4 weeks in combination with an antidepressant (SSRI)
2441296|NCT03288662|Experimental|CT and histopathological classification|With each histopathological type of thymic epithelial tumors, we measure the maximun diameter in chest CT scan. Comparison of some characteristics of the tumor on preoperative chest CT scans and histopathological type of thymic epithelial tumors .
2441297|NCT03288649||Anorexia nervosa|adolescents with anorexia nervosa (N=20 ?), their parents (N=20), their physicians (N=20)
2441298|NCT03288649||Anxiety based school refusal|adolescents with anxiety based school refusal (N=20 ?), their parents (N=20), their physicians (N=20)
2441299|NCT03288649||Depression|adolescents with depression (N=20 ?), their parents (N=20), their physicians (N=20)
2441300|NCT03288636|Experimental|Experimental|"PKGroup:~Ravidasvir + Danoprevir/ Ritonavir"
2441301|NCT03288636|Placebo Comparator|Placebo|"Placebo Group:~Placebo"
2441302|NCT03288623|Experimental|Dark Chocolate|Dark chocolate (85% cocoa) 40 mg per day for 30 days
2441303|NCT03288623|Placebo Comparator|White/Milk Chocolate|White chocolate or Milk chocolate administration in tablet (<35% cocoa) per day for 30 days
2441304|NCT03288610||With inflammatory response|"Patients with postoperative inflammatory response as defined by the occurrence of severe SIRS and/or postoperative vasodilation syndrome.~Severe SIRS is defined by meeting at least 2 SIRS criteria during 6 consecutive hours or at least 3 SIRS criterias. Classical SIRS criteria include: temperature >38,3 or <36°C, heart rate >90/min, respiratory rate >20/min or PaCO2 <32mmHg, GB>12000 ou <4000 c/mm3.~Postoperative vasodilation syndrome is defined by the need of continuous infusion of norepinephrine (whatever the dose) to maintain the mean arterial pressure above 60 mmHg associated to a cardiac index above or egal to 2.2 L/min/m2.~Patients without postoperative severe SIRS and without postoperative vasodilation syndrome"
2441305|NCT03288597||A: advanced and metastatic neuroendocrine tumors|Advanced and metastatic neuroendocrine tumors receive syestematic treatment
2441306|NCT03288597||A: advanced and metastatic neuroendocrine carcinomas|Advanced and metastatic neuroendocrine carcinomas receive syestematic treatment
2441307|NCT03288584||Tocilizumab|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
2441308|NCT03288584||Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
2441309|NCT03288584||Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
2441310|NCT03288571|Experimental|Wharton Jelly Mesenchymal stem cells|"Intervention: Wharton Jelly Mesenchymal stem cells Site: Renal parenchyma Route of administration: ultrasound guided- intra-parenchymal total of 3 sites in each kidney.~Number of doses: 3 doses 2 weeks apart for each kidney. Time interval between each dose: 2 weeks Total volume of cell suspension infused: 3 ml/kidney; each site will receive a 1 ml cell suspension with a total volume of 3 ml in each kidney."
2441311|NCT03288558|Experimental|Intervention Group|Subjects randomized to the intervention group will receive a comprehensive perioperative mechanical ventilation strategy that includes a bundle of protective settings (use of PEEP, recruitment maneuvers and continuation of mechanical ventilation during CPB).
2441312|NCT03288558|No Intervention|Control Group|Subjects randomized to the control group will receive mechanical ventilation according to the current usual care.
3151207|NCT00219999||normal|normal, healthy volunteers
3151208|NCT00220025|Experimental|NBUVB|
3151209|NCT00220038||Normal|700 healthy adult volunteers will be drawn from the New York City area
3151210|NCT00220285|Experimental|Arm 1|
3151211|NCT00220285|Experimental|Arm 2|
3151212|NCT00220298|Experimental|Arm 1|
3151213|NCT00220311|Experimental|Arm 1|
3151214|NCT00220324|Experimental|Arm 1|
3151215|NCT00220337|Experimental|1|Open label active treatment
3151216|NCT00220584|Experimental|Open donepezil|open donepezil
3151217|NCT00220753|Active Comparator|Active air cleaner|Two Icleen IQAir air cleaners with active filters supplied
3151218|NCT00220753|Placebo Comparator|Placebo air cleaner|Two Icleen IQAir air cleaners with placebo filters supplied
2441325|NCT03288532|No Intervention|Arm A (active monitoring)|Participants randomised to Arm A will be allocated to active monitoring for 1 year, in line with current standard-of-care in resected primary RCC at high or intermediate risk of relapse
2441326|NCT03288532|Experimental|Arm B (durvalumab monotherapy)|Participants randomised to Arm B will receive durvalumab (1500mg) 4 weekly for 1 year (13 cycles maximum)
2441327|NCT03288532|Experimental|Arm C (durvalumab + tremelimumab)|Participants randomised to Arm C will receive durvalumab (administered as per arm B, i.e. 13 cycles maximum) and tremelimumab (75mg) on day 1 and week 4 visits (i.e. 2 cycles)
2441328|NCT03288506|Experimental|Google Hangout (VC) group|This group receive peer led support for depression via Google Hangouts for 8-weeks
2441329|NCT03288506|No Intervention|Waiting list control group|Waiting list
3151219|NCT00220766|Experimental|Group 1|Infusion #1 (Week 0)Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min) ; Infusion #2 (Week 3-4)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min)
3151220|NCT00220766|Experimental|Group 2|Infusion #1 (Week 0)Dextrose (0.08 mL/kg/min), then IGIV-C, 10% (0.14 mL/kg/min); Infusion #2 Dextrose (0.14 mL/kg/min), then IGIV-C, 10% (0.08 mL/kg/min)
3151221|NCT00220818|Experimental|Lansoprazole 1.0 mg/kg QD|
3151222|NCT00220818|Experimental|Lansoprazole 2.0 mg/kg QD|
3151223|NCT00220844|Experimental|Nortriptyline|
3151224|NCT00220844|Experimental|Placebo|
3151225|NCT00220922|Experimental|1|injection site reactions with the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
3151226|NCT00220922|Experimental|2|injection site reactions without the use of alcohol wipes prior to performing the patients' daily Copaxone® injection
2441338|NCT03288480|Other|PT-112|This is a single arm study of PT-112, which is administered to patients with relapsed or refractory MM
2441339|NCT03288467|Active Comparator|Root canal treatment with 5% NaOCl|Root canal treatment with 5% NaOCl: 5 ml of 5% sodium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 5% sodium hypochlorite.
2441340|NCT03288467|Active Comparator|Root canal treatment with 1% NaOCl|5 ml of 1% soium hypochlorite was used during root canal treatment after each instrument change.After root canal instrumentation, canals irrigated with 5ml of 17% EDTA solution for 1 minute followed by final wash with 5ml of 1% sodium hypochlorite.
2441341|NCT03288454|Experimental|Cohort 1|ciraparantag (60 mg)
2441342|NCT03288454|Experimental|Cohort 2|ciraparantag (120 mg)
2441343|NCT03288454|Experimental|Cohort 3|ciraparantag (30 mg)
2441344|NCT03288454|Placebo Comparator|Placebo|placebo (saline for injection)
2441345|NCT03288441||antiplatelet only|"Patients receiving antiplatelet medication, but not anticoagulation. Antiplatelet drugs include any class, dose or duration of any platelet aggregation inhibitor.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
2441346|NCT03288441||anticoagulant-based|"Patients receiving only anticoagulants or both anticoagulant and antiplatelet medication combined. This includes any class, dose or duration of any antiplatelet or anticoagulant drug.~This refers to the antithrombotic regimen when the current thrombocytopenia, or risk thereof (i.e. predicted), was first identified (even if the treatment is subsequently stopped)"
2441347|NCT03288428|Experimental|nalbuphine|using nalbuphine for patient controlled analgesia
2441348|NCT03288428|Active Comparator|morphine|using morphine for patient controlled analgesia
2441349|NCT03288402|Experimental|ongoing fasted|ongoing fasted following 10 h overnight fast; series blood samples CgA over 180 min
2441350|NCT03288402|Experimental|intake of caffeine containing beverages|10 h overnight fast; intake of caffeine containing beverages; series blood samples CgA over 180 min
2441351|NCT03288402|Experimental|intake of 5 item English breakfast|10 h overnight fast; intake of 5-item English breakfast; series blood samples CgA over 180 min
3151227|NCT00220987|Experimental|Intensive Insulin therapy|Intensive Insulin therapy
3151228|NCT00220987|Active Comparator|Conventional Therapy|conventional insulin therapy
3151229|NCT00221013|Experimental|Higher intensity CRRT regimen|
3151230|NCT00221013|Active Comparator|Lower intensity CRRT regimen|
3151231|NCT00221026|Experimental|drug|ECP + Uvadex given for 12 weeks.
3151232|NCT00221039|Experimental|DRUG+ECP|UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.
3151233|NCT00221065|No Intervention|1|Control
3151234|NCT00221065|Experimental|2|CPAP
3151235|NCT00221169|Other|surgical candidates|surgical candidates who underwent PET CT evaluation
3151236|NCT00221247|Active Comparator|Group 1|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy with acupuncture
3151237|NCT00221247|No Intervention|Group 2|Intensely administered (5 times per week for 12wk) physical therapy, occupational therapy, and hydrotherapy without acupuncture
3151238|NCT00221325|Experimental|Rituximab Plus MTX|
3151239|NCT00221442|Active Comparator|zonisamide|zonegran (zonisamide)
3151240|NCT00221442|Placebo Comparator|Sugar pill|fake pill
3173069|NCT00607841|Experimental|Dose Escalation Cohort 2|Ispinesib given on days 1 and 15 of a 28 day cycle.
2441352|NCT03288389|Placebo Comparator|Placebo|Participants will take 4 placebo wafers per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
2441353|NCT03288389|Active Comparator|NTFactor Lipids®|Participants will take 4 NTFactor Lipid® wafers (4 g) per day for 42 days. Subjects will be asked to take the Fibromyalgia Combined Symptom Survey (see attachments, based on validated survey instruments) on-line on Day 0 (before starting supplement/placebo) and on Days 1, 2, 3, 7, 14, 21, 30 and 42.
3151241|NCT00221468|Experimental|Quetiapine|Patients will begin 100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
3151242|NCT00221507|No Intervention|Historical Cohort|This study will first examine risk factors in a defined population of inner city children, using a historical cohort.
2441356|NCT03288350|Experimental|mDCF + Avelumab|"Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil, followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of docetaxel, cisplatin, 5-fluorouracil and avelumab.~Docetaxel as a one-hour 40 mg/m2 IV infusion on day 1. Cisplatin 40 mg/m2 IV infusion on day 1. 5-FU 1000 mg/m2/day over 2 days. Avelumab 10 mg/kg following the completion of the mDCF regimen."
2441357|NCT03288337||Hidradenitis Suppurativa Cohort|Patients with HS who are eligible to fill out the series of quality of life questionnaires
2441359|NCT03288311|Active Comparator|Protocolized Post-extubation Respiratory Support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
2441360|NCT03288311|Active Comparator|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
2441361|NCT03288298|Experimental|luteolin|a natural extract derived flavinoids
2441362|NCT03288298|Active Comparator|nano-luteolin|nano-particles derived from a natural extract luteolin
2441363|NCT03288272|Active Comparator|Arm 1 - WBRT 10 x 2 Gy|Arm 1 - WBRT 10 x 2 Gy Whole brain radiotherapy with a total dose of 20 Gy in single fractions of 2 Gy
2441364|NCT03288272|Active Comparator|Arm 2 - WBRT 15 x 2 Gy|Arm 2 - WBRT 15 x 2 Gy Whole brain radiotherapy with a total dose of 30 Gy in single fractions of 2 Gy
2441365|NCT03288272|Active Comparator|Arm 3 - Best Supportive Care|Symptomatic treatment includes steroids, pain medication, nutritional support etc.
2441366|NCT03288259|Experimental|Obese patients|Obese patients undergoing Local Anesthetics and Transnasal Endoscopy.
2441367|NCT03288246|No Intervention|Standard-of-care|Participants in the standard-of-care arm will receive a standard laboratory-based viral load test at baseline, 3, and 6 months.
2441368|NCT03288246|Experimental|Point-of-care|Participants in the point-of-care arm will receive a point-of-care viral load test at baseline, 3, and 6 months.
2441369|NCT03288233||Primary Group|
3151243|NCT00221507|Active Comparator|Reminder Recall Outreach|"To determine how well Reminder Recall Outreach will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
3173070|NCT00607841|Experimental|Dose Escalation Cohort 3|Ispinesib given on days 1 and 15 of a 28 day cycle.
2441373|NCT03288194|Experimental|Problem-Solving Treatment|Problem-Solving Treatment is a structured, yet flexible, form of cognitive-behavioral psychotherapy intended to increase problem-solving skills.
2441374|NCT03288194|Active Comparator|Time Management|Time Management is a structured, yet flexible, intervention intended to increase creativity.
2441375|NCT03288181|Experimental|Muscle Stretch Group|This is the group who applies the splint to stretch the calf muscles as per the described protocol for 4 weeks.
2441376|NCT03288181|No Intervention|Control Arm|This is the group who has undergone no splint for 4 weeks.
2441377|NCT03288168||0-18 y/o Patients with Medulloblastoma|Patients treated with comprehensive treatments including surgery, chemo-therapy with / without (less than 3 y/o) radiation, during the period of Jan 2008 and Dec 2012, whose tumor samples will be tested by NanoString and Histochemistry methods, are enrolled in this cohort group.
2441378|NCT03288155|Experimental|Flavonoid rich cocoa|Dark cocoa beverage rich in flavonoids
2441379|NCT03288155|Placebo Comparator|Low flavonoid cocoa|A control cocoa beverage low inn flavonoids
2441380|NCT03288142|Experimental|Intervention|"The intervention group will receive all the interventions provided to the control group. In addition, intervention group participants will install on their mobile phone the hypertension personal control program (HPCP) (Lark HTN Pro), which is a smartphone application. The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD. The HPCP has blood pressure, medication, and weight monitoring, including periodic reminders for the user to measure blood pressure, measure weight, and take their medication(s). The HPCP provides real-time feedback based on user input, such as out-of-range measurements and has additional features designed to encourage behavior change in areas such as dietary intake, physical activity, sleep, and stress reduction. Users can set goals and receive guidance and feedback through the app."
2441381|NCT03288142|No Intervention|Control|Control group participants will be provided with a home blood pressure monitoring device (HBMD) (Omron BP761N Bluetooth Smart Automatic Upper Arm Blood Pressure Monitor) and will be instructed in its use at the baseline study visit. Participants will also receive an information sheet describing home blood pressure monitoring that gives advice for how to respond to different home readings. At the baseline visit, participants will be instructed to install an Omron application to their smart phone device (to monitor use of the HBMD). Participants will continue to receive all routine care, including anti-hypertensive medications as prescribed by their regular clinicians.
2441716|NCT03285867||HCC received TACE|observational study set only one group with HCC received TACE
2441382|NCT03288129|Experimental|Perampanel|Perampanel will be administered orally once daily (QD) at bedtime. At the beginning of the Titration Period, oral perampanel will start at a dose of 2 milligrams (mg) QD. Doses of perampanel will then be up titrated in increments of 2 mg at no less than 2-week intervals according to the investigator's judgment. At the 4 mg dose, the investigator will confirm whether further dose escalation is needed based on participant response and tolerability. The investigator may adjust dosing further or leave the participant at 4 mg. The maximum dose is 12 mg. During the 39-week Maintenance Period, participants will continue to receive the perampanel dose level that was administered at the end of the Titration Period.
2441383|NCT03288116||patient|Scheimplug imaging and contrast and sensitivity test
2441384|NCT03288116||early disease|Scheimplug imaging and contrast and sensitivity test
2441385|NCT03288116||normal|Scheimplug imaging and contrast and sensitivity test
3173071|NCT00607854|Experimental|Zevalin|Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen
2441387|NCT03288090||Treated|
2441388|NCT03288090||Non-treated|
2441389|NCT03288077|Experimental|Triptophan beverage|Proprietary blend of nutritional interventions aimed at increasing sleepiness
2441390|NCT03288064|Experimental|Corinthian currant supplementation|Corinthian currant supplementation: 1.5 g CHO/kg BW prior to exercise
2441391|NCT03288064|Experimental|Glucose supplementation|Glucose drink (Top Star 100, Esteriplas, Portugal) supplementation: 1.5 g CHO/kg BW prior to exercise
2441392|NCT03288064|Placebo Comparator|Water ingestion|Water ingestion: 7 ml/kg BW prior to exercise
2441393|NCT03288051|Active Comparator|Crystalloid group|
2441394|NCT03288051|Active Comparator|Colloid group|
2441395|NCT03288038|Experimental|RSV5mg + EZE 10mg|Rosuvastatin 5mg/Ezetimibe 10mg
2441396|NCT03288038|Active Comparator|RSV5mg|Rosuvastatin 5mg
2441397|NCT03288038|Experimental|RSV10mg + EZE10mg|Rosuvastatin 10mg/ Ezetimibe 10mg
2441398|NCT03288038|Active Comparator|RSV10mg|Rosuvastatin 10mg
2441399|NCT03288038|Experimental|RSV20mg + EZE10mg|Rosuvastatin 20mg/Ezetimibe 10mg
2441400|NCT03288038|Active Comparator|RSV20mg|Rosuvastatin 20mg
2441401|NCT03288025|Experimental|Nutrition and Exercise|5 days a week of moderate exercise and biweekly diet counseling on Low Glycemic Index/ Mediterranean Diet for 12 weeks.
2441402|NCT03288025|No Intervention|Standard of Care|Counseling at baseline on diet as recommended by USDA and on the benefits of regular aerobic exercise.
2441403|NCT03287999||Haemophilia patients|Persons with haemophilia A or B - 240 to be recruited
2441404|NCT03287999||Healthy volunteers|Healthy volunteers - 10 to be recruited
2441405|NCT03287986||Suicide attempters|Depressed patients over 60 years of age with a personal history of suicide attempts scanned with MRI
2441406|NCT03287986||Patient controls|depressed patients over 60 years of age without a personal history of suicide attempt scanned with MRI
2441407|NCT03287986||Healthy Controls|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts, scanned with MRI
2441408|NCT03287973|Active Comparator|Lifestyle modification program group|Patients with apnea-hypopnea index (AHI) ≥ 15/hr on home sleep study will participate in a dietitian-led lifestyle modification program (LMP) for 6 months. Patients will attend dietary consultation weekly in the first 4 months, and then monthly in the following two months.
2441409|NCT03287973|Other|CPAP group|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
2441410|NCT03287960|Experimental|setmelanotide|setmelanotide subcutaneous injection once daily
2441411|NCT03287960|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
2441413|NCT03287934|Experimental|digital light processing stent|according to the allocation, the experimental group will receive a digital light processing stent for immediate implant drilling and placement after atraumatic extraction of the target tooth.
2441414|NCT03287934|Active Comparator|selective laser sintering|according to the allocation, the intervention for the control group will be a selective laser sintering stent after atraumatic extraction of the target tooth for immediately implant placement. the selective laser sintering stent will be adapted and drilling will be done through the stent.
2441415|NCT03287921||mono bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
2441416|NCT03287921||dual bronchodilatation|patients with COPD and features of hyperinflation and small airway disease
2441420|NCT03287895|Experimental|Intervention - Decision Support|In addition to the regular conversation about CPR that a patient's physician may have with them, participants will be given a two-part intervention. First, the participant will receive a values clarification tool which helps them rate and understand which relevant values are most important to them. There are two forms of this tool, a full and simplified version. All participants in this arm will receive both, in randomized order. The second aspect of the intervention is an educational video about the potential risks and benefits of CPR, which all participants in this arm will receive.
2441421|NCT03287895|No Intervention|Control|Participants in this arm will receive usual care, the regular conversation about CPR that their physician may have with them.
2441422|NCT03287882|No Intervention|Standard of care|"Preconception period: none~Pregnancy period: daily iron (60 mg) and folic acid (400 µg) supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily iron and folic acid supplementation to 6 months postpartum"
2441527|NCT03287180|Active Comparator|Control group|Participants in the control condition will attend weekly individual medical management sessions with the MD who will also provide a prescription for a combination of buprenorphine/naloxone 4/1 (approximately 25 minutes in duration).
2441907|NCT03284502|Experimental|Stage 1b|Dose-escalation
2441423|NCT03287882|Experimental|MMN supplementation and life skills education|"Preconception period: twice-weekly MMN supplementation and bi-monthly group session including life skill based education materials~Pregnancy period: daily MMN supplementation from confirmation of pregnancy; daily balanced energy protein supplements will additionally be provided to those participants who are underweight at the confirmation of pregnancy for the duration of the pregnancy~Postpartum period: daily MMN supplementation to 6 months postpartum"
2441425|NCT03287856|Experimental|Treatment|Transcatheter Aortic Valve Implantation (TAVI) in failing surgical bioprosthesis
2441428|NCT03287830|Experimental|Intervention|Text message influenza vaccine reminders
2441429|NCT03287830|No Intervention|Usual care|"Season 2017-18: Usual care has no text message~Season 2018-19: Usual care includes on text message with a link to American Academy of Pediatrics parenting information page. The purpose is to provide those randomized to usual care with tangible benefit that is not related to the study."
3151244|NCT00221507|Active Comparator|Case Management|"To determine how well Case Management will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
3151245|NCT00221507|Active Comparator|Patient Navigation|"To determine how well Patient Navigation will increase immunization rates and well child care delivery in those children most at risk for falling through the cracks. These studies will be conducted in the Denver Health community health network, the largest integrated community health care system in the United States."
3151246|NCT00221546|Active Comparator|DHA-rich supplement|
2441437|NCT03287765||Experimental 18F-AV-1451|
3151247|NCT00221546|Placebo Comparator|Placebo|
3151248|NCT00221598|Experimental|hemodialysis|
2441440|NCT03287739||Single-group study|Assessment of behavioral biometric impairments
2441441|NCT03287726|Experimental|probiotics|
2441442|NCT03287726|Placebo Comparator|placebo|
2441443|NCT03287713|Active Comparator|Conventional oxygen (EPIDOC)|Patients randomized in conventional oxygen (EPIDOC) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to flow needed to maintain SpO2 ≥ 90% during training with both systems.
2441444|NCT03287713|Active Comparator|Nasal High-Flow oxygen therapy (EPIDOAF)|Patients will be randomized in nasal High-Flow oxygen therapy (EPIDOAF) group will perform a Pulmonary Rehabilitation Program. Oxygen will be titrated to FiO2 needed to maintain SpO2 ≥ 90% during training with both systems.
2441445|NCT03287700||Focus group participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK) OR Adults who have been referred to a UK auditory implant programme for assessment for cochlear implantation but who have not yet been implanted
2441446|NCT03287700||Online patient survey participants|Adults who have received a cochlear implant on the National Health Service (NHS) at an auditory implant service in the United Kingdom (UK)
2441447|NCT03287700||Online clinician survey participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2441448|NCT03287700||Trial design workshop participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2441449|NCT03287700||Manufacturer's forum participants|Representatives of manufacturers of cochlear implants who provide devices on the NHS
2441450|NCT03287700||Care pathway working group participants|Clinicians who deliver the current care pathway for cochlear implantation at auditory implant programmes providing NHS services in the UK
2441451|NCT03287687|Active Comparator|Air for insufflation|In this arm of patients, air which is currently used as standard of care will be used for insufflation
2441452|NCT03287687|Experimental|Carbon dioxide gas for insufflation|in this arm of patients, carbon dioxide (CO2) will be used for insufflation during endoscopy
2441568|NCT03286868|Placebo Comparator|Standard of Care TKA|Standard of Care Total Knee Arthroplasty (TKA): No data from the Verasense sensor will be used to influence the surgery
3151249|NCT00221702|Experimental|A|Peg Intron 100 mcg SC/week for 36 months
3151250|NCT00221702|Active Comparator|B|Intron A 3 X 3 MIU, weekly, sc, for 18 months
3151251|NCT00221715|Experimental|1|bypass by autologous saphenous vein
3151252|NCT00221715|Active Comparator|2|bypass by dacron or PTFE Prosthesis
3151253|NCT00221767|Experimental|1|Brindley technique (bladder system)
3151254|NCT00221767|No Intervention|2|Reference group
3151255|NCT00221793|Experimental|1|Deep Brain Stimulation of the Subthalamic Nucleus
3151256|NCT00221793|Active Comparator|2|Later Deep Brain Stimulation of the Subthalamic Nucleus
3151257|NCT00221845|Active Comparator|Conventional BP Control|Targeted 24-hour mean arterial pressure will be the 50th-95th percentile for age.
3151258|NCT00221845|Experimental|Intensified BP Control|Targeted 24-hour mean arterial pressure will be the 5th to 50th percentile for age.
3151259|NCT00221897||Healthy individuals|healthy controls with or without myopia
3151260|NCT00221897||Persons at risk for or with primary open angle glaucoma|with or without myopia with a diagnosis of glaucoma, glaucoma suspect and ocular hypertension
3151261|NCT00221923||Healthy individuals|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
3151262|NCT00221923||Persons at risk for or with primary open angle glaucoma|They will be considered if they are above 30 years old. There is no upper age limit. Subject can be either male or female, and from African or European Descent. They must speak, read, and understand English. They can be diagnosed with other health disorders.
3151263|NCT00221962|Other|Open label treatment with aripiprazole|After 1-3 week screening phase, entered six week open trial of aripiprazole initiated at 2.5mg/day. DOsing was increased weekly in 2.5mg increments in order to reach maximum dose of 10mg/d.
3173072|NCT00607906|Experimental|Subjects receiving treatment in cohort A1|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 5 milligrams, 15 milligrams, 50 milligrams, or 100 milligrams.
2441454|NCT03287661|Experimental|Treatment Condition|An Online 8-week Acceptance-based Behavioural Therapy for chronic pain.
2441455|NCT03287661|No Intervention|Wait-list Control Condition|Wait-list Control group (8-weeks)
2441461|NCT03287609|Active Comparator|Evolocumab|Evolocumab 140 mg/mL, pre-filled auto-injector pen, 3 injections at day 1 and week 4
2441462|NCT03287609|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, 3 injections at day 1 and week 4
2441463|NCT03287596|Experimental|HEALTHY VOLUNTEERS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium"
2441464|NCT03287596|Experimental|SPA + NON-SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2441465|NCT03287596|Experimental|SPA + SYMPTOMATICS|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2441466|NCT03287596|Experimental|MECHANIC TENDINOPATHY|"3D sequence ZTE2 DP without gadolinium~3D Sequence UTE without gadolinium~3D Sequence ZTE2 DP with gadolinium~3D sequence UTE with gadolinium"
2441467|NCT03287583|Experimental|SBIRT|SBIRT intervention for Gambling
2441468|NCT03287583|Other|Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
2441469|NCT03287570|Experimental|Cettum (Electric moxibustion)|The patients in this group receive Cettum (Electric moxibustion) treatment prescribed by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
2441470|NCT03287570|Active Comparator|Traditional indirect moxibustion|The patients in this group receive traditional indirect moxibustion treatment using the same points, applied by a certified Korean Medicine Doctor with more than 6 years of Oriental Medicine College education.
2441471|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
2441472|NCT03287544|Experimental|Combined rehabilitation|Linguistic training as well as communication training.
2441473|NCT03287544|Active Comparator|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
2441474|NCT03287531|Experimental|conventional therapy (group I)|"Exercise therapy.~For muscles around TMJ :~Masetter Lateral Pterygoid Medial Pterygoid Temporalis Digastric~Pulsed ultrasound at 0.3 to 0.6 watts per sq cm over the lateral poles of the temporomandibular joint condyles with a small sound head for 2 to 3 minutes per side"
2441475|NCT03287531|Experimental|low level laser therapy (groupII)|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
2441476|NCT03287518|Active Comparator|Verum|WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
2441477|NCT03287518|Placebo Comparator|Placebo|"The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect.~One (1) ml IP should be taken with breakfast and one (1) ml with supper every day."
2441478|NCT03287505|Experimental|Abilify IM Depot 300mg by once|300 mg dose group: single-administration of Aripiprazole IM Depot (300 mg) in 12 subjects;
2441479|NCT03287505|Experimental|Abilify IM Depot 400mg by once|400 mg dose group: single-administration of Aripiprazole IM Depot (400 mg) in 12 subjects.
3173073|NCT00607906|Experimental|Subjects receiving treatment in cohort A2|Eligible subjects will receive oral immediate release capsules of SB-756050 with doses of 100 milligrams, 200 milligrams, 300 milligrams, or 400 milligrams.
3173074|NCT00607906|Experimental|Subjects receiving treatment in cohort A3|Eligible subjects will receive oral immediate release capsules of SB-756050 with a dose of 150 milligrams. Subjects will also receive oral modified release capsules of SB-756050 with doses of 150 milligrams, 300 milligrams, or 400 milligrams.
2441482|NCT03287479|Experimental|Gavi®|surplus or all fertilized oocytes will be cryoperserved by utilizing the closed, semi-automated Gavi® vitrification system
2441483|NCT03287479|Active Comparator|Cryotop®|surplus or all fertilized oocytes will be cryoperserved by utilizing the open, manual Cryotop® vitrification system
2441484|NCT03287466|Experimental|SpO2 88-92%|The intervention is targeted oxygen therapy (TO2T) to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88-92%.
2441485|NCT03287466|Active Comparator|Current best practice|The control group will have no specific SpO2 targets. Clinicians will be able to target SpO2 according to parameters they feel are suitable for the patient, according to standard UK practice.
2441528|NCT03287167|Experimental|1 month DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month， then will be given aspirin and placebo for next 5 months.
3173075|NCT00607906|Experimental|Subjects receiving treatment in cohort A4|Eligible subjects will receive SB-756050 in this additional cohort.
3173076|NCT00607906|Experimental|Subjects receiving treatment in cohort B1|Eligible subjects will receive oral modified release capsules of SB-756050 with doses of 50 milligrams, 150 milligrams or 400 milligrams. Subjects will also receive immediate release oral capsules of SB-756050 with a dose of 150 milligrams.
3173077|NCT00607932|Experimental|Brassica Vegetables Diet Intervention|
3173078|NCT00607932|Experimental|Pill|
3173079|NCT00607945|Placebo Comparator|0 g CLA|Avandia (Rosiglitazone) 4-8mg/day OR other diabetes medication currently prescribed to participant, 0 g CLA, 8 g Placebo oil (based on typical American diet)
3173080|NCT00607945|Experimental|3.2 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 3.2 g CLA, 4.8 g placebo oil (based on typical American diet)
3173081|NCT00607945|Experimental|6.4 g CLA|Avandia 4-8mg/day OR other diabetes medication currently prescribed to participant, 6.4 g CLA, 1.6 g placebo oil (based on typical American diet)
3173082|NCT00607958|Experimental|1|dose reduction
3173083|NCT00607971|Experimental|1|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
3173084|NCT00607984|Experimental|single|
3173085|NCT00608010|Experimental|1|Vitrification
3173086|NCT00608010|Active Comparator|2|Slow freezing
2441486|NCT03287453|Experimental|Screening (educational intervention)|Participants attend educational sessions comprising of an inflatable colon interactive exhibit that allows visitors to walk through a colon while seeing images, a PowerPoint presentation that contains messages that are tailored to meet the cultural and linguistic needs of Black/African Americans, Appalachians, and Hispanics/Latinos, and or flip books/flip charts. Participants also receive a copy of the study information sheet which contains the basic elements of informed consent and a pre-education session knowledge survey.
2441487|NCT03287440|Active Comparator|COPD Wellness With Health Advocate|This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.
2441488|NCT03287440|Active Comparator|COPD Wellness|This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.
2441489|NCT03287427|Experimental|TetMYB Vaccine & BGB-A317|
3173087|NCT00608049|Experimental|1|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/high GI, and low carbohydrate/low GI
3173088|NCT00608049|Experimental|2|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/high GI, high carbohydrate/low GI, low carbohydrate/low GI, and low carbohydrate/high GI
2441492|NCT03287401||Patients with general anesthesia|Patients with general anaesthesia are monitored with electroencephalography and the results will be associated with the risk for PACU delirium
2441493|NCT03287388|Experimental|No Rocuronium|Phase 1: no neuromuscular blockade
2441494|NCT03287388|Experimental|Rocuronium (moderate NMB)|Phase 2: moderate neuromuscular blockade (TOF 1-3)
2441495|NCT03287388|Experimental|Rocuronium (deep NMB)|Phase 3: deep neuromuscular blockade (PTC 0-1)
2441496|NCT03287375|Experimental|PIPAC|Peritoneal metastases (PM) from colorectal or appendiceal cancer will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using oxaliplatin 92 mg/m2 in 150 ml dextrose. Peritoneal metastases (PM) from other GI or gynecologic cancers will be treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) using cisplatin 7.5 mg/m2 in 150 ml saline combined with doxorubicin 1.5 mg/m2 in 50 ml saline. PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg and the aerosolised chemotherapy will be nebulized at a maximum pressure of 200 PSI and a flow rate of 0.5 ml/min. There is no upper number of allowed PIPAC treatments, but they will be planned in series of 3 with 5 weeks interval.
2441497|NCT03287362|Experimental|ST-arm|one-third of the patients is randomized to schema therapy
2441498|NCT03287362|Active Comparator|CBT-arm|one-third of the patients is randomized to cognitive behavioral therapy
2441499|NCT03287362|Placebo Comparator|IST-arm|one-third of the patients is randomized to individualized supportive therapy
2441500|NCT03287349||Patients with severe reactions to radiation|Two 12.5 mL blood draws and photograph of severe reaction, and autoimmune testing in patients without prior testing.
2441501|NCT03287336|Experimental|Cohort 1|Dose of Tranexamic acid 5mg/kg will be administered.
2441502|NCT03287336|Experimental|Cohort 2|Dose of Tranexamic acid 10 mg/kg will be administered.
2441503|NCT03287336|Experimental|Cohort 3|Dose of Tranexamic acid 15 mg/kg will be administered.
2441504|NCT03287323|No Intervention|Usual Care Group|One hundred patients of a control group will receive standard intensive care treatment (Usual Care Group).
2441505|NCT03287323|Other|Proactive Palliative Care|One hundred patients will additionally be offered a palliative care Intervention (Proactive Palliative Care Group).
3189463|NCT00777725||2|Predominant right sided HF patients secondary to valvular heart disease, pulmonary artery hypertension (PAH), chronic obstructive pulmonary disease (COPD), or thrombotic disease and etc
3189464|NCT00777725||3|Acute decompensated left sided heart failure patients who have volume overload and have been admitted for diuresis
3189465|NCT00777725||4|Control subjects with no evidence of heart disease.
3189466|NCT00777738|Experimental|bortezomib|bortezomib
3189467|NCT00777777|Experimental|1|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3189468|NCT00777816|Active Comparator|1|
3189469|NCT00777816|Placebo Comparator|2|
3189470|NCT00777842|Experimental|1|Device
3189471|NCT00777868|Experimental|1|
3189472|NCT00777868|Experimental|2|
2441516|NCT03287284|Active Comparator|LLLT Group|Active Low Level Laser Therapy application with a dose of 240 Joules before resistance training
2441517|NCT03287284|Placebo Comparator|Placebo Group|Placebo Low Level Laser Therapy application before resistance training
2441518|NCT03287271|Experimental|Defactinib (VS-6063) +Carboplatin/Paclitaxel|
2441519|NCT03287258|Active Comparator|three program|200 patients are subjected to educational Pelvic floor dysfunction prevention program with perineal massage and Pelvic floor muscle exercise.
2441520|NCT03287258|Active Comparator|one program|200 patients are subjected to educational Pelvic floor dysfunction prevention program
3173089|NCT00608049|Experimental|3|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/high GI, and low carbohydrate/low GI
2441522|NCT03287232|Placebo Comparator|Placebo|
2441523|NCT03287232|Experimental|Prasterone|
3189473|NCT00777868|Experimental|3|
3189474|NCT00777868|Placebo Comparator|4|
2441526|NCT03287180|Experimental|Experimental group|Participants in the experimental group will attend one individual assessment with the study physician for combination of buprenorphine/naloxone 4/1 prescription and urinalysis, along with one weekly Adolescent Community Reinforcement Approach (A-CRA) session (approximately 50 minutes).
2441565|NCT03286881|Experimental|Group 3|
3189475|NCT00777894|Experimental|Radiation: 3-dimensional conformal radiation therapy|
3189476|NCT00777907|Active Comparator|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed. Stents are not allowed in this arm.
3189477|NCT00777907|Experimental|Pipeline|Placement of 1 or more Pipeline Embolization Device(s)(PED) into the parent artery at the target aneurysm.
3189478|NCT00777933|Active Comparator|cyclosporine|
2441529|NCT03287167|Active Comparator|6 months DAPT intervention|After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
2441530|NCT03287154|Experimental|Active tDCS stimulations|Patients in this arm will receive 10 tDCS active stimulations of 2 mA (1 stimulation per day from Monday to Friday during 2 weeks).
2441531|NCT03287154|Sham Comparator|Sham tDCS|"Patients in this arm will receive 10 sham stimulations (1 stimulation per day from Monday to Friday during 2 weeks).~As soon as the power will have reached the maximal intensity as in the active arm, the stimulation will be stopped."
2441532|NCT03287141|Sham Comparator|First intervention|The subjects did a shuttle walk test without any previous intervention.
2441533|NCT03287141|Experimental|Second intervention|Subjects underwent 30 minutes of noninvasive ventilation (CPAP) and then re-performed the shuttle walk test.
2441534|NCT03287141|Experimental|Third intervention|Subjects underwent 30 minutes of noninvasive ventilation (Bi-pap) and then re-performed the shuttle walk test.
2441535|NCT03287115|Experimental|Broccoli|Subjects will consume a dose of broccoli on day 11
2441536|NCT03287102|Other|Temporal inverted ILM peeling group|The internal limiting membrane is peeled from the temporal side of the fovea only
2441537|NCT03287102|Other|Complete ILM peeling group|The internal limiting membrane is completely removed around the fovea
3189479|NCT00777933|Experimental|Tacrolimus|
3189480|NCT00777959|Experimental|Open Label|ridaforolimus (MK8669)+ bicalutamide
2441540|NCT03287076|Experimental|Active|Patients will receive exenatide injections
2441541|NCT03287076|No Intervention|Standard Care|Standard care for stroke as per hospital protocol
2441543|NCT03287037|Experimental|tDCS over DLPFC|Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours.
2441544|NCT03287024|Experimental|BeGrow Stent System|All enrolled subjects will receive the BeGrow Stent System
2441545|NCT03287011|Active Comparator|Control tooth paste|controlled fluoridated toothpaste will be provided for brushing to both the groups initially
2441546|NCT03287011|Experimental|Shoplaque tooth paste|Fluoridated toothpaste with organic plaque disclosing dye will be given to the test group second visit
2441547|NCT03286998||placenta previa|pregnant women with singleton living healthy fetus diagnosed as having placenta previa by grey scale ultrasound (placental tissue covers the internal cervical os or within 2 cm from it)
2441548|NCT03286985||General ICU patients|No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay >72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.
2441549|NCT03286972||PET/MRI|"All participants will undergo a diagnostic PET/CT and a Radiation Treatment Planning CT per SOC procedures. In addition, all participants will undergo an additional imaging set consisting of a PET/MRI. It is anticipated that most patients will undergo the PET/MRI on the same day as their PET/CT negating the need for a second injection of the FDG radioisotope used for SOC PET imaging. All participants will receive gadolinium contrast per SOC dosing guidelines for the MRI portion of the PET/MRI. Both SOC MMRI pulse sequences and investigational sequences will be utilized in this study.~If a second dose of the radioisotope is need to complete the PET/MRI (unable to perform both PET scans on the same day) only a 50% dose of FDG will be administered due to the increased sensitivity the PET/MRI scanner."
2441550|NCT03286959|Active Comparator|PCR WITH CALCIUM HYDROXIDE|PCR WITH CALCIUM HYDROXIDE : A layer of dycal (dentsply) was placed adjacent to pulpal or axial wall after mixing as per manufacturer recommendations followed by etching and restoration with composite using incremental technique.
2441551|NCT03286959|Active Comparator|PCR WITH RMGIC|PCR WITH RMGIC: A layer of resin modified liner ( GC Fuji II ) was placed adjacent to pulpal or axial wall and light cured for 40 sec. afterwards the cavity was restored with composite as in other groups.
2441552|NCT03286959|Active Comparator|PCR WITH DIRECT COMPOSITE|PCR WITH DIRECT COMPOSITE: After partial caries excavation , etching and bonding was done directly without using any liner and cavity was restored with composite as in other groups
2441553|NCT03286946|Experimental|Blunt-type block needle|block with Blunt-type block needle.
2441554|NCT03286946|Active Comparator|Sharp-type block needle|block with Sharp-type block needle.
2441555|NCT03286933|Experimental|Yoga therapy intervention|Participants will participate in weekly yoga therapy sessions and have the opportunity to use the home video online.
2441556|NCT03286920||Oral natural diet|As for patients in oral natural diet group, the the participants shall receive oral natural diet.
2441557|NCT03286920||Oral nutrition supplement group|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
2441558|NCT03286920||Tube feeding nutrition supplement group|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive tube feeding nutrition supplement providing 750-1500kcal/d.
2441559|NCT03286907|Experimental|Online videos|Participants will watch two online videos, complete a self-administered online tutorial, and receive reminders at Month 1, 2, 4, 6 & 8
2441560|NCT03286907|Experimental|Online videos and MI|Participants will watch two online videos, complete a self-administered online tutorial, received motivational interviewing (MI), and receive reminders at Month 1, 2, 4, 6 & 8
2441561|NCT03286907|Active Comparator|Control group|Participants will receive online messages about mental health problems and stress reduction exercises
2441562|NCT03286894||1264 healthy schoolchildren|There is only one study group consisting of 1264 children recruited at school.
2441563|NCT03286881|Experimental|Group 1|
2441564|NCT03286881|Experimental|Group 2|
3189481|NCT00777959|Experimental|Ridaforolimus|ridaforolimus (MK8669)+ bicalutamide
2441569|NCT03286868|Experimental|TKA with Verasense sensor|Total Knee Arthroplasty (TKA) with Verasense sensor for Intraoperative Balancing: Surgeon will attempt to optimize the intraoperative pressures using the data from the Verasense sensor
2441570|NCT03286855|Experimental|Vibrating Mesh Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Aerogen Ultra (CE 0050) vibrating mesh Nebuliser.
2441571|NCT03286855|Active Comparator|Standard Hospital Care Group|Patient's admitted with an acute exacerbation of COPD and prescribed nebulised combined salbutamol 2.5mg/ipratropium bromide 0.5mg (Combivent) are randomised to receive their treatment via the Hudson micromist small volume nebuliser which is the standard of care at our institution.
3173090|NCT00608049|Experimental|4|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: high carbohydrate/low GI, high carbohydrate/high GI, low carbohydrate/low GI, and low carbohydrate/high GI
3189482|NCT00777959|Placebo Comparator|Placebo|Placebo + bicalutamide
3189483|NCT00777972|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets by Ranbaxy Laboratories Limited
3189484|NCT00777972|Active Comparator|2|Monopril ®.-HCT 20-12.5 mg tablets by Bristol-Meyers Squibb following a single oral dose (1 x 20-12.5 mg tablet
3189485|NCT00777985|Experimental|1|
2441577|NCT03286816|Experimental|Lactate infusion|Subjects will receive an intravenous lactate infusion to elevate plasma lactate levels
2441578|NCT03286816|Placebo Comparator|NaCl infusion|As a control condition, subjects will receive intravenous NaCl infusion
2441579|NCT03286803|Experimental|Arm A|Inactivated Poliovirus vaccine
2441580|NCT03286803|Active Comparator|Arm B|fractional dose inactivated poliovirus vaccine
2441581|NCT03286803|Experimental|Arm C|inactivated poliovirus vaccine
2441582|NCT03286803|Active Comparator|Arm D|fractional dose inactivated poliovirus vaccine
2441583|NCT03286777|Placebo Comparator|Placebo|Mannitol and silicon dioxide
2441584|NCT03286777|Experimental|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide
2441585|NCT03286777|Experimental|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant
2441586|NCT03286764|Placebo Comparator|Placebo|Distilled water spray as a placebo during Colonoscopy
2441587|NCT03286764|Experimental|Peppermint Oil|Peppermint Oil spray during Colonoscopy
3189486|NCT00777985|Active Comparator|2|
3189487|NCT00777998|Experimental|A|Auto-Allo Tandem Stem cell Transplantation plus maintenance therapy with Thalidomide and DLI
2441590|NCT03286725|No Intervention|Control Group|The Control Group will be asked to continue with their normal PE lessons.
2441591|NCT03286725|Experimental|Intervention Group|'Physical Education (PE) Programme'
2441592|NCT03286712|Experimental|Incident Peritoneal Dialysis|After signing informed consent form, the patients will be started on Renogen® at 150 units/kg/week. Oral iron supplements will be started at 105 mg elemental iron per day. If the patients will not have an increase in Hb by 1-2 g/dl or an increase in the reticulocyte count after the first month of treatment, the dose of Renogen® will be increased to 200 units/kg/week. If there will still be no increase in the Hb or reticulocyte count in the second month, other causes of anemia will be ruled out. If the Hb/Hct will increase beyond the target, the Renogen® dose will be reduced by 50 units/kg/week. If the Hb/Hct will be below target, the Renogen® dose will be increased by 50 units/kg/week.
2441593|NCT03286699|Active Comparator|DIET|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant.
2441594|NCT03286699|Active Comparator|DIET-PA|This group will be prescribed a Dietary Intervention that reduces energy intake by 500-1000 kcal/day and induces a weight loss of approximately 1-2 pounds per week during the intervention, with the weight loss goal individualized to each participant. In addition, this group will be prescribed moderate-intensity Physical Activity Intervention that will progressively increase to the goal of 250 minutes/week.
2441595|NCT03286686|Experimental|Experience 1|
2441596|NCT03286686|Experimental|Experience 2|
2441597|NCT03286686|Experimental|Experience 3|
2441598|NCT03286686|Experimental|Experience 4|
2441599|NCT03286686|Experimental|Experience 5|
2441600|NCT03286686|Experimental|Experience 6|
2441601|NCT03286673|Experimental|calcium phosphate|Pentacalcium hydroxy-triphosphate (Ca5(PO4)3OH) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2441602|NCT03286673|Experimental|Tricalcium Phosphate|β-tricalcium phosphate (Ca3(PO4)2) as incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2441603|NCT03286673|Experimental|Calcium carbonate|Calcium carbonate (CaCO3) was incorporated in wholemeal and crispy wafer bread in order to achieve a additional calcium intake of 1000 mg/d.
2441604|NCT03286673|Active Comparator|Placebo|Wholemeal and crispy wafer bread without additional calcium additive.
2441605|NCT03286660|Other|COPD patients|"All convenient COPD patients admitted in real life for a rehabilitation program were included.~Exercises consist on a Chair Rise Tests and short questionnaire were added to the usual tools for the evaluation."
2441606|NCT03286647|Experimental|NORMALGRIEF|Oral hygiene instruction
2441607|NCT03286647|Experimental|COMPLICATEDGRIEF|Oral hygiene instruction
2441608|NCT03286647|Active Comparator|CONTROLS|Oral hygiene instruction
3173091|NCT00608049|Experimental|5|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/high GI, and high carbohydrate/low GI
2441717|NCT03285854||Children with CKD stage 3-5 and dialysis|Children of all ages with an eGFR <60ml/min/1.73m2, including those on dialysis
2441908|NCT03284502|Experimental|Stage 2 (Cohort I and II)|Dose-expansion
3189488|NCT00777998|Active Comparator|B|Auto-Auto Tandem stem cell Transplantation plus maintenance therapy with Thalidomide
3189489|NCT00778011|Active Comparator|1|
3189490|NCT00778011|Active Comparator|2|
3189491|NCT00778011|Active Comparator|3|
3189492|NCT00778024|Experimental|1|fluoxetine HCL 40 mg capsules of ranbaxy
2441609|NCT03286634|Experimental|SR|"Standard Risk (SR) :~CNS 3 or CNS 2 regardless of response OR Time-point #1 (Day 15 induction) Flow MRD ≥ 1% (treatment will not be de-escalated even MRD <0.01% by TP#2) OR Time-point #2 (Day 1 IDMTX/MP of Consolidation) ≥0.01%~SR strategy:~All SR patient will have to receive two doses of anthracycline and 12 L-asparaginase doses during induction except those who are escalated to SR at time point 2 when MRD ≥0.01%.~During the first year of maintenance phase (48 weeks; 4x12 weeks blocks), cyclophosphamide and cytarabine bolus will be administered at 4 weekly interval."
2441610|NCT03286634|Experimental|LR|"Low Risk (LR):~Time-point #1 (Day 15 induction) Flow MRD <1% AND Time-point #2 (Day 1 IDMTX/MP of Consolidation) <0.01% AND CNS 1 only~LR strategy:~For LR patients, one dose of anthracycline and 3 doses of L-asparaginase will be omitted during induction.~Following re-induction I, interim maintenance and additional block of re-induction ie. re-induction II prior to maintenance phase will be omitted for LR patients."
2441611|NCT03286621||Children with Autism Spectrum Disorder|Children with an Autism Spectrum Disorder according to DSM-5 criteria
2441612|NCT03286621||Typically Developing Children|Typically developing children
2441613|NCT03286621||Children with Delayed Development Disorders|Children with Delayed Developmental Disorders other than ASD
2441614|NCT03286595|Experimental|Early Psychosis (EP)|EP participants will be individuals who are either a) at clinical high risk (CHR) for developing psychosis and/or bipolar disorder, or b) First Episode Psychosis (FEP) participants meeting criteria for schizophreniform disorder, schizophrenia, schizoaffective disorder or another psychotic, non-schizophrenia diagnosis including those with bipolar disorder.
2441615|NCT03286595|Experimental|Clinicians|Clinicians/treatment team members who are providing treatment services to the EP participants at one of the three early psychosis clinics.
2441616|NCT03286582|Experimental|AC-203|
2441617|NCT03286582|Active Comparator|Clobetasol|
2441618|NCT03286569|Active Comparator|Active upper Wilson appliance|Active upper arch Wilson quadhelex appliance
2441619|NCT03286569|Placebo Comparator|Non active upper expansion appliance|Non-Active upper arch Wilson quadhelex appliance
2441620|NCT03286556|Experimental|Autoantibody Reductive Therapy|"Therapeutic Plasma Exchange (TPE) consisting of 1x estimated plasma volume exchanges for 3 successive days (1-3) and then, after a one day interval to enable equilibration of autoantibodies between intra- and extra-vascular spaces, again on days 5, 6, 9, 11, 13, and 15.~Rituximab: One gm i.v. will be administered on day 6 and day 15 after completion of the TPE on those days.~Intravenous immunoglobulin (IVIG): 0.5 gm/kg/day i.v. on days 16-19~All subjects in this trial, including patients in this arm, will receive identical empiric antibiotics and steroids. The steroid dose is: Prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 6 and 15, as a premedication prior to the rituximab."
2441621|NCT03286556|Active Comparator|Treatment as Usual (TAU)|The same steroid regimen as described for the experimental arm, i.e., prednisone 60 mg (p.o.) on day 1, followed by 20 mg/day on days 2-5, 7-14, and 16-19 (or the i.v. methylprednisolone equivalent), and methylprednisolone 100 mg i.v. administered on days 6 and 15, as well as empiric antibiotics.
3189493|NCT00778024|Active Comparator|2|PROZAC® 40 mg capsules
3189494|NCT00778037|Experimental|1|Cyclobenzaprine hydrochloride 10 mg tablet of ranbaxy
2441624|NCT03286530|Experimental|Ruxolitinib|Following a standard of care allogeneic stem cell transplantation, participants will be started on Ruxolitinib. Ruxolitinib is administered orally 2 times per day at a fixed dose. Each study treatment cycle lasts 28 days. Up to 24 cycles.
2441625|NCT03286517|Experimental|Tanner Stage I|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 9.5 µg/BW.
2441626|NCT03286517|Experimental|Tanner Stage II|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 11.50 µg/BW.
2441627|NCT03286517|Experimental|Tanner Stage III|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 12.67 µg/BW.
2441628|NCT03286517|Experimental|Tanner Stage IV|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 15.11 µg/BW.
2441629|NCT03286517|Experimental|Tanner stage V|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 20.5 µg/BW.
2441630|NCT03286517|Experimental|Adult Group|A 1ml blood sample was obtained for 30 minutes pre and 120 minutes post-kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) injection periods at 30 min intervals (-30, 0, 30, 60, 90, 120). The dose was 1 µg/kg.
2441631|NCT03286504|No Intervention|Standard-of-care|Adolescents randomized to the standard arm will receive monthly HIV care in the GHESKIO Adolescent Clinic. Clinical care is provided in an individual exam room by a nurse. The patient is sequentially referred to the laboratory, social worker, and pharmacy for medication refills. A typical visit, including wait time, lasts 3 hours.
2441632|NCT03286504|Experimental|FANMI - Cohort Care|Adolescents randomized to FANMI will receive all monthly HIV care in the community room of the Prince Albert School in Village of God. Adolescents will be grouped in cohorts of 5-10 peers. The entire visit will take ~ 2 hours.
2441633|NCT03286491||Patients presenting with acute coronary syndrome|Patients presenting to emergency department with acute coronary syndrome
2441634|NCT03286478|Experimental|Mindfulness|Mindfulness-based body image intervention
2441635|NCT03286478|Experimental|Dissonance|Cognitive dissonance-based body image intervention
2441636|NCT03286478|Experimental|Confident Me|Dove Confident Me body image intervention
2441637|NCT03286478|No Intervention|Control|Classes as usual, assessment-only control group.
3189495|NCT00778037|Active Comparator|2|Flexeril® 10 mg tablets
3189496|NCT00778050|Experimental|1|amoxicillin tablets for oral suspension 600 mg by Ranbaxy Laboratories Limited
3189497|NCT00778050|Active Comparator|2|Amoxil ® for oral suspension 400 mg/ 5 mL by SmithKline Beecham Pharmaceuticals (600mg dose)
2441641|NCT03286413|Experimental|microwave ablation|Microwave ablation（MWA）refers to all electromagnetic methods of inducing tumor destruction by using devices with frequencies greater than or equal to 900MHz. The rotation of dipole molecules accounts for most of the heat generated during MWA. Water molecules as dipoles attempt to continuously reorient at the same rate in microwave's oscillating electric field. As a result of microwave transmission, the water molecules flip back and forth billions of times a second. The vigorous movement of water molecules produce friction and heat, thus inducing cellular death via coagulation necrosis. The microwave unit (KY-2000, Kangyou Medical, Nanjing, China) is capable of producing 100 Watts of power at 2450 MHz.The needle antenna has a diameter of 1.6 mm (16G) and a length of 10 cm. The active tip length is 3mm and 5mm.
2441642|NCT03286413|Active Comparator|cryoablation|Clinically, cryosurgery is accomplished by placing a cryoprobe(up to 3.5 mm) through a stab incision into the tumor under ultrasound guidance.Liquid nitrogen is utilized under low operating pressure as cryogen which is controlled by the computer modulated cryogen regulator. The cryoprobe achieves rapid freezing by means of an active freeze zone at its distal tip.
3189498|NCT00778063|Placebo Comparator|saline|intranasal saline will be given 30 minutes prior to surgery
2441644|NCT03286387|Experimental|Memory for naturalistic episodes|Encoding of episode in real life situations (using Smartphones) or in a virtual environment, followed by memory retrieval (either behavior only or with fMRI, in successive studies)
2441645|NCT03286374|Other|Occupational rehabilitation|The participants will receive the current occupational rehabilitation program at Muritunet.
2441646|NCT03286361|Experimental|BeGraft Peripheral + Stent Graft System|Patients treated with the BeGraft Peripheral Plus Stent Graft System
2441647|NCT03286335|Experimental|Proton Radiation|"Radiation therapy will be delivered typically five (5) days per week on weekdays~Proton Radiation dose be determine by histology"
2441648|NCT03286322|Experimental|manual therapy cervical spine|
2441649|NCT03286322|Sham Comparator|control group|
2441650|NCT03286309|Experimental|EMG-driven soft robot hand|subjects will receive EMG-driven soft robot hand system.
2441651|NCT03286309|Placebo Comparator|sham group|subjects will receive passive pre-programmed soft robot hand system.
2441652|NCT03286296|Experimental|LZM009|
2441654|NCT03286257|Experimental|Exercise Intervention|Participants will complete a partially supervised 4 month exercise program consisting of 3-5 sessions/week at a moderate intensity (40-75% heart rate (HR) reserve) at Liverpool Lifestyles gyms. Participants will be given free access to the Wellness Key System© when using the Lifestyles exercise equipment which allows researchers to remotely track the exercise intensity of participants accurately.
2441655|NCT03286244|Experimental|CM082 plus paclitaxel|"In dose-escalation part, patients will be treated in dose levels at the following daily doses of CM082 and paclitaxel to establish the MTD and RP2D:~CM082 100mg qd + paclitaxel 80mg/m2/day; CM082 150mg qd + paclitaxel 80mg/m2/day; CM082 200mg qd + paclitaxel 80mg/m2/day; In dose-expansion part, patients will be treated at the RP2D established in dose escalation part."
2441656|NCT03286231||Healthy volunteers|Healthy volunteers who will undergo contrast-enhanced CT imaging of the gluteal venous vasculature in the prone and jackknife positions
2441662|NCT03286205|Active Comparator|Weekly Dosage|weekly dose of 100mg
2441663|NCT03286205|Active Comparator|3 week dosage|every 3 week dosage.
2441664|NCT03286192|Experimental|Single-Arm Intervention|All participants in this arm receive compassion cultivation training
2441665|NCT03286166||Study arm|"20 subjects will undergo one session of PRP in which 60 cc of blood is drawn and centrifuged into 3 months of autologous serum tears.~• Subjects will utilize autologous tears twice daily in the study eye."
2441666|NCT03286166||Control Arm|Subjects in the control arm will receive study vehicle to be used twice daily in the left eye.
2441667|NCT03286153|Experimental|Ideal Body Weight First|Randomized to receive factor product based on ideal body weight first
2441668|NCT03286153|Experimental|Actual Body Weight First|Randomized to receive factor product based on actual body weight first
2441669|NCT03286140|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with deferred treatment of superficial reflux (usually once the ulcer has healed)
2441670|NCT03286140|Experimental|Early arm|Early endovenous treatment of superficial venous reflux(within 2 weeks) in addition to standard compression therapy
2441671|NCT03286127||PCU (unit)|Those patients who received specialised palliative care on a palliative care unit.(palliative care unit)
2441672|NCT03286127||IPCC (hospital)|"Those patients admitted to a regular hospital ward who received specialised palliative care from an inpatient palliative care consultation team.~(inpatient palliative care consultation team)"
2441673|NCT03286127||OPCC (outpatient)|Those patients who received specialised palliative care at home from an outpatient palliative care consultation team. (outpatient palliative care consultation team)
2441674|NCT03286114|Experimental|Pembrolizumab|
2441675|NCT03286101|Experimental|0.5% Ivermectin Lotion|
2441676|NCT03286101|Placebo Comparator|Vehicle control|
3173092|NCT00608049|Experimental|6|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/high GI, low carbohydrate/low GI, high carbohydrate/low GI, and high carbohydrate/high GI
3173093|NCT00608049|Experimental|7|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/high GI, and high carbohydrate/low GI
3173094|NCT00608049|Experimental|8|Participants will follow four diet plans, each for a period of 5 weeks, in the following order: low carbohydrate/low GI, low carbohydrate/high GI, high carbohydrate/low GI, and high carbohydrate/high GI
2441713|NCT03285880|Experimental|Declarative memory|Napping v. wake effect on a declarative memory task (storybook)
2441870|NCT03284749|Placebo Comparator|Normal maternity pads|Maternity pads without copper, to be used for 14 days after delivery
3173095|NCT00608075|Other|1|Manic Patients
3173096|NCT00608075|Other|2|Depressed Patients
3173097|NCT00608088|Active Comparator|1|Usual Care
3173098|NCT00608088|Active Comparator|2|Health Nurse/Peer Councelor Intervention
3173099|NCT00608101|Experimental|1|Day 1 hyperinsulinemic euglycemic clamps with either 0.2 mg fludrocortisone, 0.75 mg Dexamethasone, or both given orally before each morning and afternoon clamp. Day 2 hyperinsulinemic hypoglycemic glucose clamp.
2441680|NCT03286075|Experimental|Anode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (anode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
2441681|NCT03286075|Experimental|Cathode tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (cathode on the left DLPF).~Subjects will receive a 30-minutes session of 2mA tDCS. Facial emotion recognition task and attentional and working memory tasks with measurement of eye-tracking, heart rate, respiratory frequency and skin conductance will be conducted before and after the session."
2441682|NCT03286075|Placebo Comparator|Placebo tDCS|"The subjects in this arm will undertake a unique session of tDCS on the DLPFC (placebo).~Subjects will receive a 30-minutes SHAM session of tDCS."
2441683|NCT03286062|Experimental|VM110|Escalating dose of agent VM110 given to patients to visualize occult cancer with laproscopic infra red detect
2441684|NCT03286049||Healthy children (HC)|10 healthy children
2441685|NCT03286049||Children with non allergic rhinitis (NAR)|10 children with non allergic rhinitis
2441686|NCT03286049||Rhinitis children, perennial allergy (PAR)|10 rhinitis children, sensitized to perennial allergens
2441687|NCT03286049||Rhinitis children, seasonal allergy, outside season (OSR)|10 rhinitis children sensitized to seasonal allergens, observed outside the allergen season
2441688|NCT03286049||Rhinitis children, seasonal allergy, within season (WSR)|10 rhinitis children sensitized to seasonal allergens, observed during the allergen season
2441689|NCT03286036||Lung cancer patients|Patients with lung cancer who undergo surgical resection of the tumor
2441690|NCT03286023||Stereotactic radiation|Stereotactic radiation for brain metastases
2441691|NCT03286010|Experimental|Intervention|Participants in the W@H group will be assembled in small groups of 6-12 participants and attend 12-biweekly sessions over a 24-week intervention period. The sessions will be led by a trained peer leader and will be held in a variety of convenient locations in close geographic proximity to participants' home postal codes. Participants will receive a manual containing copies of learning exercises and educational material. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention).
2441692|NCT03286010|No Intervention|Control|Participants in the control group will be eligible to participate in the study, but cannot participate because there are no groups within their geographical region. They will be offered the W@H program after their 26-week follow up.
2441693|NCT03285997|Experimental|GC3110A|One injection: Day 0 Two injection: Day 0 and Day 28
2441694|NCT03285997|Active Comparator|GCFLU Pre-filled syringe inj.|One injection: Day 0 Two injection: Day 0 and Day 28
3189499|NCT00778063|Experimental|dexmedetomidine|2 mcg/kg dexmedetomidine will be given intranasally 30 minutes prior to surgery
3189500|NCT00778076|Active Comparator|HAG|Patients that will receive a Hyaluronic acid treatment course consisting of 3 consecutive injections one week apart.
3189501|NCT00778076|Placebo Comparator|PG|Those patients that receive 3 consecutive placebo injections one week apart.
3189502|NCT00778089|Other|Open Label Single Arm|All enrolled subjects will have a skin test composed of Bovine Collagen and Lidocaine.
3189503|NCT00778115|Experimental|1|Loperamide HCl 2 mg and simethicone 125 mg tablets of ranbaxy
3189504|NCT00778115|Active Comparator|2|Imodium® Advanced caplets
2441703|NCT03285945||PET3|Post-therapeutic FDG PET/CT performed after 3 days of steroid treatment
2441704|NCT03285945||PET10|Post-therapeutic FDG PET/CT performed after 10 days of steroid treatment
2441705|NCT03285932|Experimental|Post-operative SRS of resection cavity|"High-resolution contrast-enhanced post-operative MRI imaging in preparation for Cyberknife SRS. Cyberknife SRS of the resection cavity and all potential additional metastases diagnosed in the treatment planning MRI (up to 10 lesions)~Resection cavity:~7 x 5 Gy @ 95%-isodose~Potential additional brain metastases:~20 Gy @ 70%-isodose (lesions < 2 cm max. diameter) 18 Gy @ 70%-isodose (lesions 2 - 3 cm max. diameter) 6 x 5 Gy @ 70%-isodose (lesions > 3 cm max. diameter)"
2441706|NCT03285932|Other|Post-operative WBRT|Post-operative WBRT will be performed according to the following dose regimen: 10 x 3 Gy
2441707|NCT03285919|Experimental|Case - stroke survivor|Stroke survivor, 6mon post stroke resulting in right-sided hemiparesis, 53yrs old, had completed a 2mon rehabilitation program prior to the study. He underwent 30 training sessions with the Balance Assessment Robot (BAR™) within a 10-week period, each consisting of 10-15min of unperturbed treadmill and 30-45min of perturbation training. Perturbations were delivered in the forward, backward, left and right direction, occurring every 6sec, at the left leg initial contact and the right leg initial contact. Two training sessions were spent to determine adequate treadmill speed (0.4m/s) and perturbation amplitude (60N), followed by the first assessment session. After the last training session, assessment was repeated using the same parameters plus 90N perturbation amplitude.
2441708|NCT03285919|Active Comparator|Control - matched healthy subject|Healthy male, height- and weight-matched to the Case. He was assessed according to the same protocol as the Case using the Balance Assessment Robot (BAR™) at perturbation amplitudes 60 and 90 N.
2441709|NCT03285906|Experimental|Treatment group|Apatinib：500 mg，po，qd
2441710|NCT03285893||Native Hawaiian cigarette smokers|oral cell DNA adducts
2441711|NCT03285893||White (European Americans) cigarette smokers|oral cell DNA adducts
2441712|NCT03285893||Japanese American cigarette smokers|oral cell DNA adducts
3189505|NCT00778128|Experimental|1|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 1 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 8."
3189506|NCT00778128|Experimental|2|"Step 1: Dose escalation - oral CP-4126~Step 2: Oral CP-4126 on day 8 and 15 in a 4 week schedule. One dose (only) gemcitabine IV on day 1."
2441718|NCT03285854||Healthy age and gender matched children|"All children <18 years~Normal renal function (eGFR 90-120ml/min/1.73m2 [calculated by Schwartz formula] in children >1 year and serum creatinine <35μMol/L in children <1 year)~Weight, height and BMI within 2 SD of normal using WHO growth charts In order to make this study as 'real-life' as possible, free-living UK children on their usual diet and dietary supplementation (including Ca and Vit D), if any, will be included, but analysis will account for medication doses and blood levels."
2441719|NCT03285841||Cervical Sites|Imaging complete cervix from endocervical canal to transformation zone to ectocervix.
2441720|NCT03285841||Vulvar sites|Imaging vulvar lesions
2441721|NCT03285828|Other|First group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
2441722|NCT03285828|Other|Second group|Students received three four-hour sessions of a basic motivationnal interviewing training over a one week period. The students interviewed for 15 minutes a caregiver playing the role of a patient, six weeks before and three weeks after the training.
2441723|NCT03285815|Experimental|Proton Therapy 60 CGE|60 CGE (3CGE X 20) for 4wks
2441724|NCT03285815|Experimental|Proton Therapy 47 CGE|47 CGE (4.7CGE X 10) for 2wks
2441725|NCT03285802|Experimental|Letrozole and Everolimus|Letrozole 2.5mg daily q 30 days Everolimus 10mg daily q 28 days
2441726|NCT03285789|Experimental|Dyslexics with reduced visual attention span|21 subjects diagnosed dyslexics with reduced visual attention span
2441727|NCT03285789|Experimental|Dyslexics with normal visual attention span|
2441728|NCT03285789|Active Comparator|controls|
2441729|NCT03285776||Study group|Children with coordination disorder between the ages of 5 to 7 years.
2441730|NCT03285776||control group|children with typical development between the ages of 5 to 7 years.
3189507|NCT00778141|Experimental|1|metformin HC1 750 mg extended-release tablets
2441732|NCT03285750||Diabetic group|Patients with recently diagnosed type 2 diabetes
2441733|NCT03285750||Controls|Age- and BMI-matched normoglycemic subjects
2441734|NCT03285737|Experimental|Whey protein supplement|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
2441735|NCT03285737|Active Comparator|Collagen peptide supplement|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides.
3189508|NCT00778141|Active Comparator|2|Glucophage® XR 750 mg tablets
3189509|NCT00778154||Alendronate 3 to < 5 years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) 3- 5 years.
3189510|NCT00778154||Risedronate 3 to < 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) 3-5 years.
3189511|NCT00778154||Alendronate ≥ 5 Years|Alendronate (any combination of 10 mg daily or 70 mg once weekly) for greater than or equal to 5 years.
3189512|NCT00778154||Risedronate ≥ 5 Years|Risedronate (any combination of 5 mg daily or 35 mg once weekly) for greater than or equal to 5 years.
2441741|NCT03285698|Other|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue.
2441742|NCT03285698|Experimental|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue.
2441743|NCT03285685|Experimental|tDCS M1|active tDCS Participants will receive active transcranial direct current stimulation.
2441744|NCT03285685|Experimental|tDCS DLPF|active tDCS Participants will receive active transcranial direct current stimulation.
2441745|NCT03285685|Sham Comparator|tDCS sham|tDCS Sham Participants will receive sham transcranial direct current stimulation.
2441746|NCT03285672|Experimental|Arm 1|FP-101
2441747|NCT03285672|Placebo Comparator|Arm 2|Placebo Comparator
2441748|NCT03285659|Experimental|Intervention: INDI Implementation|Primary care centres which will implement the collaborative (INDI) care model for depression
2441749|NCT03285659|No Intervention|Control: no INDI implementation|Primary care centres in which the collaborative care strategy INDI will not be implemented, but will be compared in terms of their clinical practice towards depression
3189513|NCT00778180|Experimental|1|furosemide 80 mg tablets of Ranbaxy
3189514|NCT00778180|Active Comparator|2|Lasix® (furosemide) 80 mg tablets
2441798|NCT03285269||Shock Group|Patients presenting with signs and symptoms of shock will undergo the E-RUSH ultrasound protocol and bioreactance before and after a passive leg raise maneuver.
3189515|NCT00778193|Placebo Comparator|Placebo|
3189516|NCT00778193|Active Comparator|Naproxen|
3189517|NCT00778193|Experimental|Aspirin|
3189518|NCT00778193|Experimental|Clopidogrel|
3189519|NCT00778193|Experimental|Celecoxib|
3189520|NCT00778219||A|Patients needing intubation of single lumen tracheal tube and performed using laryngoscope
3189521|NCT00778219||B|Patients needing intubation of single lumen tracheal tube and performed using lightwand
3189522|NCT00778219||C|Patients needing intubation of double lumen endobronchial cath and performed using laryngoscope
3189523|NCT00778232|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
3189524|NCT00778232|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd
3189525|NCT00778245|Experimental|1|cefprozil 500mg tablets of Ranbaxy
3189526|NCT00778245|Active Comparator|2|CEFZIL ® 500 mg tablets of Bristol-Myers Squibb Company, USA
3189527|NCT00778271|Experimental|1|Gabapentin 400mg capsules
3189528|NCT00778271|Active Comparator|2|Neurontin® 400 mg capsules
3189529|NCT00778284|Experimental|1|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets of Ranbaxy
3189530|NCT00778284|Active Comparator|2|Augumentin chewable tablets of Glaxosmithkline
3189531|NCT00778297|Experimental|Group 1|
3189532|NCT00778297|Active Comparator|Group 2|
3189533|NCT00778323|Experimental|A,2, II|
3189534|NCT00778349|Experimental|1|Metformin solution 100 mg/mL under fasting condition
3189535|NCT00778349|Experimental|2|Metformin solution 100 mg/mL, after low fat meal
3189536|NCT00778349|Experimental|3|Metformin solution 100 mg/mL, after high fat meal
3189537|NCT00778362||Splenectomy|all patients received splenectomy (patient list will be applied from Dept. of Pathology) at National Taiwan University Hospital in the last 20 years.
2441752|NCT03285633|Other|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
2441753|NCT03285620|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral dose of AL-034 (oral solution) (the starting dose in Cohort 1 of Part 1 will be 0.2 milligram [mg]) or matching placebo under fasted condition (Cohorts 1 to 5 or optional Cohort 7) on Day 1. Participants may receive AL-034 in a fed state (Cohort 6) to evaluate the effect of food on the pharmacokinetics (PK) of AL-034.
2441754|NCT03285620|Experimental|Part 2: Multiple-Dose Administration (MAD)|Participants will receive multiple oral doses of AL-034 or matching placebo for 4 consecutive weeks either once weekly (Qwk - for 4 doses) or every two weeks (Q2wk - for 3 doses) under fed or fasted conditions. The starting dose for Part 2 will be determined based on the initial PK and safety/tolerability data from Part 1.
2441755|NCT03285607|Experimental|Dose Level 1:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
2441756|NCT03285607|Experimental|Dose Level 2:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
2441757|NCT03285607|Experimental|Dose Expansion:MCS110/Doxorubicin/Cyclophosphamide/Paclitaxel|"MCS110 will be administered intravenously over 60 minutes (up to 120 minutes permitted) on a 28-day cycle. The dose of MCS110 given will depend on the dose level to which a given patient is enrolled.~The standard neoadjuvant chemotherapy regimen of dose-dense doxorubicin/ cyclophosphamide followed by weekly paclitaxel consists of:~doxorubicin 60 mg/m^2 IV Q2W during Weeks 1 through 8 (total of 4 doses)~cyclophosphamide 600 mg/m^2 Q2W during Weeks 1 through 8 (total of 4 doses)~paclitaxel 80 mg/m^2 IV QW during Weeks 9 through 20 (total of 12 doses)~Surgery will be performed approximately 4-6 weeks after the end of the last cycle of treatment (Week 20-22). It is outside the scope of this study as part of each patient's standard of care. Both types of surgery (lumpectomy or mastectomy) are allowed. The decision on surgical approach and timing will be at the discretion of the treating surgeon."
3189538|NCT00778388|Active Comparator|IC43 50|IC43 50 mcg with AI(OH)3
3189539|NCT00778388|Active Comparator|IC43 100 with|IC43 100 mcg with AI(OH)3
3189540|NCT00778388|Active Comparator|IC43 100 w/o|IC43 100 mcg w/o AI(OH)3
2441761|NCT03285581|Other|Arm-1|Device:Treatment Subject(s) will receive 2 RF treatments
2441762|NCT03285568||Palbociclib|women at least 18 years old, with ER+, HER2- advanced breast cancer, and were receiving palbociclib
3189541|NCT00778388|Active Comparator|IC43 200|IC43 200 mcg with AI(OH)3
3189542|NCT00778388|Placebo Comparator|Placebo|Placebo (0,9% NaCl)
3189543|NCT00778401|Experimental|1|Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited
3189544|NCT00778401|Active Comparator|2|Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd.
2441799|NCT03285256|Experimental|Experimental Memory Training|Experimental memory training program
2441800|NCT03285256|Active Comparator|Comparator Memory Training 1|Comparator memory training program
3189545|NCT00778414|Experimental|1|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension of ranbaxy
3189546|NCT00778414|Active Comparator|2|Augmentin ES - 600
3189547|NCT00778427|Experimental|1|metformin hydrochloride 1000 mg tablets of Ranbaxy
3189548|NCT00778427|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
3189549|NCT00778453|Experimental|Hospital-based mCIT|Hospital-based modified constraint-induced therapy(mCIT)
3189550|NCT00778453|Experimental|Hospital-based BIT|Hospital-based bilateral isokinematic training (BIT)
3189551|NCT00778453|Experimental|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
3189552|NCT00778453|Experimental|Home-based BAT|Home-based bilateral arm training(BAT)
3189553|NCT00778453|Experimental|Home-based TR|Home-based traditional rehabilitation (TR)
3189554|NCT00778453|Experimental|Home-based mCIT|Home-based modified constraint-induced therapy (mCIT)
3189555|NCT00778466|Experimental|1|metformin hydrochloride 1000 mg tablets of ranbaxy
3189556|NCT00778466|Active Comparator|2|GLUCOPHAGE® (metformin hydrochloride) 1000 mg tablets
3189557|NCT00778479|Experimental|Sepraspray|Receive Sepraspray
3189558|NCT00778479|No Intervention|Control|no treatment
3189559|NCT00778492||No Treatment|Patients with the history of ingestion of aspirin and/or ADP receptor antagonist (clopidogrel or ticlopidine) for at least 7 days prior the surgery. All patients undergoing cardiac surgery with the use of cardiopulmonary bypass on elective and urgent basis.
3189560|NCT00778505|Experimental|1|closed-loop administration of propofol and remifentanil using bispectral index as the controller
3189561|NCT00778505|Active Comparator|2|manual administration of propofol and remifentanil according to bispectral index values
3189562|NCT00778518|Active Comparator|1|low dose
3189563|NCT00778518|Active Comparator|2|Medium dose
3189564|NCT00778518|Active Comparator|3|High Dose
3189565|NCT00778544|Experimental|1|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension of Ranbaxy
3189566|NCT00778544|Active Comparator|2|Augmentin ES-600
2441769|NCT03285516|Experimental|START|The Safety Aid Reduction Treatment (START) protocol will consist of eight group sessions, delivered once weekly, lasting approximately one hour in duration. START will be delivered in-person by the PI and group co-leader.
2441770|NCT03285503|Experimental|400 mg group|Aripiprazole IM depot 400mg will be administered every four weeks for 20 weeks after drug switch / steady dose of oral aripiprazole tablets (each subject will receive 5 intramuscular injections totally).
3189567|NCT00778557|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL (Ranbaxy Laboratories Limited, India)
3189568|NCT00778557|Active Comparator|2|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
3189569|NCT00778557|Active Comparator|3|Cefzil TM (CEFPROZIL) for oral suspension equivalent to 250mg/5mL anhydrous, cefprozil (Bristol-Myers Squibb Company, New Jersey USA)
3189570|NCT00778570||ASA|Participants treated for Excimer laser vision correction using Advanced Surface Ablation (ASA).
2441775|NCT03285464|Active Comparator|Hip|This group will perform a known hip strengthening program
2441776|NCT03285464|Experimental|Trunk|This group will use the trunk as a lever to strengthen the hip
2441777|NCT03285438|Experimental|Reduced dose of DOAC|A reduced dose of DOAC (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) during a mean follow-up period of 24 months (12 to 48 months)
2441778|NCT03285438|Active Comparator|Full dose of DOAC|A full dose of DOAC (Apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily) during a mean follow-up period of 24 months (12 to 48 months).
3189571|NCT00778570||LASIK|Participants treated for Excimer laser vision correction using Laser-Assisted In Situ Keratomileusis (LASIK)
3189572|NCT00778583|Experimental|1|Nitrofurantoin 100 mg capsules of Ranbaxy
2441781|NCT03285386|Experimental|Priming Exercise|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
2441782|NCT03285386|Active Comparator|Control|Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling only.
3189573|NCT00778583|Active Comparator|2|Macrobid 100 mg capsules
2441784|NCT03285360|Experimental|sylc bioactive glass|"Sylc is a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment.~Steps:~Isolation: D.M. will make proper isolation for the teeth using cotton rolls.~Hand piece: NSK Prophymate Neo will be used to deliver the powder particles on the sensitive areas. Air stream adjusted at 40-46 psi.~Application: The hand piece will be held at constant distance (3-4mm) away from the tooth surface, with 60-80 degrees on the buccal surfaces. The powder will be applied for 5-10 seconds per tooth in a circular movement.~Suction: High volume suction will be used on lingual side of the teeth to suck any particles, and avoid patient from swallowing it."
2441785|NCT03285360|Active Comparator|fluoride varnish (Bifluorid 10)|"fluoride varnish Bifluorid 10(by VOCO) will be used. It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.~The single dose form will be used, to make sure the amount of fluoride varnish used is standardized.~Steps:~Preparation: The tooth will be properly cleaned, and the surface will be air-dried.~Dispensing: The foil will be pierced using a micro- tim, the opening will be enlarged, the brush will be wet in a circular movement.~Application: Thin coat will be applied on the tooth surface. The varnish will be left from 10-20 seconds then air dried.~Concerning the storage of the Bifluoride 10, it will be stored in refrigerator at the operative clinic to avoid exposure to high temperature or sunlight."
2441786|NCT03285347|Experimental|Brain+ Evolution|"Intervention: Training with computer-based programme Brain+ Evolution for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
2441787|NCT03285347|Experimental|Scientific Brain Training PRO|"Intervention: Training with computer-based programme Scientific Brain Training PRO for 8 weeks, receiving follow-ups every second week.~Computer-based cognitive training."
2441788|NCT03285347|No Intervention|Control group|This Group receives no intervention except for the same amount of follow-ups as the two training Groups. This is done to ensure that an effect of training is not aqtually due to the follow-up's with a professional.
2441789|NCT03285334|Experimental|XP-endo Shaper|The XP-endo Shaper is an innovative single instrument manufactured from Max wire. Its special ability to shift crystalline structure at body temperature in order to adapt to the root canal wall, has provided a unique instrument with the promise of anatomical shaping.
2441790|NCT03285334|Active Comparator|iRace|rotary files
2441791|NCT03285321|Experimental|Arm 1|Nivolumab 480mg IV every 4 weeks for up to 6 cycles
2441792|NCT03285321|Experimental|Arm 2|Nivolumab 3mg/kg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)
3189574|NCT00778596|Experimental|Prednisolone priming|Prednisolone priming 4 weeks, then treated with telbivudine.
3189575|NCT00778596|Placebo Comparator|Placebo priming|Placebo priming for 4 weeks, then followed a telbivudine treatment for 2 years.
3189576|NCT00778609|Experimental|Arm 1|
2441796|NCT03285282|Active Comparator|Intervention|Thoracolumber interfascial plane block
2441797|NCT03285282|No Intervention|Control|
2441801|NCT03285256|Active Comparator|Comparator Memory Training 2|Alternative comparator memory training program
3189577|NCT00778609|Active Comparator|Arm 2|
3189578|NCT00778661|Experimental|1|amoxicillin 400mg + clovalunic acid 57.5mg tablets of Ranbaxy
3189579|NCT00778661|Active Comparator|2|Augmentin® tablets of glaxosmithkline
3189580|NCT00778674|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
3189581|NCT00778674|Active Comparator|2|Lotensin® HCT tablets
3189582|NCT00778700|Experimental|Treatment 1: Ruxolitinib|Ruxolitinib -- 0.5 percent phosphate cream
3189583|NCT00778700|Experimental|Treatment 2: Ruxolitinib|Ruxolitinib -- 1.0 percent phosphate cream
3189584|NCT00778700|Experimental|Treatment 3: Ruxolitinib|Ruxolitinib -- 1.5 percent phosphate cream
2441804|NCT03285217|Experimental|HMB|HMB Group (n=30) will receive received twice a day for 3 months a specialized, nutrient-dense ready-to-drink liquid (Abbott Nutrition) with 350 kcal, 20 g protein, 11 g fat, 44 g carbohydrate, 1.5 g calcium-HMB, 160 IU vitamin D and other essential micronutrients.
2441805|NCT03285217|Active Comparator|Control|Control Group (n=30) will receive twice a day for 3 months another supplement with similar composition in macro- and micro-nutrients but without HMB
2441806|NCT03285204||ALS patients|
2441807|NCT03285204||Friedreich Ataxia patients|
2441808|NCT03285204||Healthy control|
2441809|NCT03285191||Subjects participating in the CE interview|Thirty subjects (comprised of n=15 csDMARD-IR and n=15 bDMARD-IR) will participate in the CE interview.
2441810|NCT03285191||Subjects participating in interview and real-time data capture|Ten of the thirty CE interview participants will be offered the opportunity to participate in the real-time data capture App substudy.
2441811|NCT03285178|Experimental|IW-1701 (Olinciguat) Low Dose|
2441812|NCT03285178|Experimental|IW-1701 (Olinciguat) Medium Dose|
2441813|NCT03285178|Experimental|IW-1701 (Olinciguat) High Dose|
2441814|NCT03285178|Experimental|IW-1701 (Olinciguat) Higher Dose|
2441815|NCT03285178|Placebo Comparator|Placebo|
2441816|NCT03285165|Active Comparator|DEX I|Trauma Patients without TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
2441817|NCT03285165|Active Comparator|DEX II|Trauma Patients with TBI received 0.2-0.7 mcg/kg/h dexmedetomedine infusion.
2441818|NCT03285165|Active Comparator|Propofol I|Trauma Patients without TBI received 10-70 mcg/kg/h propofol infusion.
2441819|NCT03285165|Active Comparator|Propofol II|Trauma Patients with TBI received 10-70 mcg/kg/h propofol infusion.
2441822|NCT03285139|Experimental|Immediate Intervention|Group CBT for PPD. Women in the treatment group will attend a 9-week group Cognitive Behavioural Therapy intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton and designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. The CBT intervention will be delivered by lay-peers.
2441823|NCT03285139|Experimental|Wait List Controls|Group CBT for PPD 9 weeks after enrollment. The women in this arm of the study will receive the same Cognitive Behavioural Therapy intervention as in the immediate intervention arm, however they will begin the CBT group 9 weeks after enrolling in the study.
2441824|NCT03285139|No Intervention|Healthy Controls|No treatment. The participants in this arm of the study will not be suffering from postpartum depression and will not receive the Cognitive Behavioural Therapy treatment. Healthy controls will complete study measures upon enrollment in the study, 9 weeks later as well as 6 months later.
3189585|NCT00778700|Placebo Comparator|Treatment 4: Placebo|Placebo cream
2441826|NCT03285087|Experimental|DEX 0.2 μg/kg/h|Patients will receive dexmedetomidine for sedation with initial maintenance dose rate of 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of -2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
3189586|NCT00778713|Experimental|1|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets of Ranbaxy laboratories Limited
3189587|NCT00778713|Active Comparator|2|Monopril ® - HCT 20-12.5 mg tablets by Bristol Meyers Squibb following a single oral dose (1 x 20/12.5 mg tablet)
2441829|NCT03285048|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Training is comprised of 8 weeks of active cognitive training using Brain HQ auditory and visual training tasks. Training is twice per week for up to 2 hours. Also included is a Bridging Group at each training session. The Bridging group provides information about cognitive training and compensatory strategies to generalize the benefits of training to daily life.
2441830|NCT03285035||Non-operable esophageal cancer|Cryotherapy treatment
2441831|NCT03285022|Experimental|Zinc modified glass ionomer|Zinc modified glass ionomer (chemfill rock) galss ionomer used as restoration for posterior teeth in case of partial caries removel
2441832|NCT03285022|Active Comparator|Conventionel glass ionomer|Conventional glass ionomer used as restoration for posterior teeth in case of partial caries removel
2441833|NCT03285009|Other|Training intervention|See information elsewhere
2441834|NCT03284983|Experimental|10 mm suture spacing|The investigators aim to determine how suture spacing affects cosmetic outcome of wound healing. One side (1/2 of the wound length) was sutured with 10 mm suture spacing
2441835|NCT03284970||Rebif (interferon beta 1a)|This study will retrospectively collect the data from the subjects who had been treated with Rebif subcutaneously (SC) at a dose of 44 micro-grams three times a week.
2441836|NCT03284970||Tecfidera (dimethyl fumarate)|This study will retrospectively collect the data from the subjects who had been treated with Tecfidera.
2441837|NCT03284957|Experimental|Amcenestrant Monotherapy: Arm #1 Part A Dose Escalation, Part B Dose Expansion|"Part A: Amcenestrant will be administered orally once daily (QD). Treatment will begin with an identified starting dose. Administration of higher doses to subsequent participants is based on occurrence of DLTs and evaluation of target saturation and PK parameters at initial and subsequent doses, until maximum administered dose (MAD) is reached. Drug will be administered in a 28-day cycle.~Part B: When the dose escalation phase ends, the recommended dose will be administered for the expansion cohort. Drug will be administered in a 28-day cycle."
3189588|NCT00778726|Experimental|1|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets of Ranbaxy
3189589|NCT00778726|Active Comparator|2|Lotensin® HCT tablets
3189590|NCT00778739|Experimental|1|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
3189591|NCT00778739|Active Comparator|2|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
2441838|NCT03284957|Experimental|Amcenestrant/Palbociclib: Arm #2 Part C Dose Escalation, Part D Dose Expansion|"Part C: Amcenestrant will be administered in combination with palbociclib: amcenestrant starting oral daily dose will be one dose level below monotherapy RD and palbociclib will be dosed at fixed standard dose. Administration of higher dose of amcenestrant (with standard palbociclib dose) to subsequent participants will be based on occurrence of DLTs at initial and subsequent doses, until MAD of amcenestrant is reached. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle).~Part D: Based on the results in Part C, participants will be administered either: 1) a determined amcenestrant dose (RD) with standard dose of palbociclib in combination therapy, or 2) one of two randomized dose levels of amcenestrant with standard dose of palbociclib in combination therapy. Drugs will be administered in a 28-day cycle (palbociclib will be administered for 21 days of cycle)."
2441839|NCT03284957|Experimental|Amcenestrant/Alpelisib: Arm #3 Part F Safety Run-In, Part G Dose Expansion|"Part F: Amcenestrant will be administered in combination with alpelisib at a fixed standard dose. Additional dose levels of amcenestrant with alpelisib could be explored if needed based on the safety and PK results. Lower dose of alpelisib could be explored based on the PK results and safety profile from the initial combination administration. Both amcenestrant and alpelisib will be administered in a 28-day cycle.~Part G: Based on the conclusion in Part F, participants will be administered the determined RD of amcenestrant and alpelisib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
2441840|NCT03284957|Experimental|Amcenestrant/Everolimus: Arm #4 Part H Dose Escalation, Part I Dose Expansion|"Part H: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of everolimus. Additional dose levels of amcenestrant with everolimus could be explored if needed based on the safety and PK results. Both amcenestrant and everolimus will be administered in a 28-day cycle.~Part I: Based on the conclusion in Part H, participants will be administered the determined RD of amcenestrant and RD of everolimus given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
2441841|NCT03284957|Experimental|Amcenestrant/Abemaciclib: Arm #5 Part J Dose Escalation, Part K Dose Expansion|"Part J: Amcenestrant will be administered at the determined RD in combination with 2 dose levels of abemaciclib. Additional dose levels of amcenestrant with abemaciclib could be explored if needed based on the safety and PK results. Both amcenestrant and abemaciclib will be administered in a 28-day cycle.~Part K: Based on the conclusion in Part J, participants will be administered the determined RD of amcenestrant and RD of abemaciclib given in the combination in an expansion cohort. Both study drugs will be administered in a 28-day cycle."
2441842|NCT03284944||Control (Before) Period|Use of standard-volume blood collection tubes (6 weeks)
2441843|NCT03284944||Intervention (After) Period|"Use of small-volume (soft-draw) blood collection tubes (6 weeks following 2-week washout period)"
2441844|NCT03284931|Experimental|SAGE-217 high dose|SAGE-217
2441845|NCT03284931|Experimental|SAGE-217 low dose|SAGE-217
2441846|NCT03284931|Placebo Comparator|Placebo|Placebo
2441847|NCT03284918|Experimental|Plant stanol ester|Cereal based snack bar with added plant stanol ester (0.8 g plant stanols/bar). Two bars consumed daily as a snack, between meals, for 4 weeks (1.6 g plant stanols/d).
2441848|NCT03284918|Placebo Comparator|Placebo|Cereal based snack bar without plant stanol ester. Two bars consumed daily as a snack, between meals, for 4 weeks (0 g plant stanols/d).
2441849|NCT03284905|Active Comparator|Probiotics|
2441850|NCT03284905|Placebo Comparator|Placebo|
3151264|NCT00221975|Active Comparator|Lithium + Divalproex + Lamictal|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the lamotrigine group were titrated up to a minimum dose of 150 mg and maximum dose of 200 mg per day.
2441854|NCT03284866|Experimental|Arm I, recombinant HPV 9-valent vaccine|Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
2441855|NCT03284866|Placebo Comparator|Arm II, saline|Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
2441856|NCT03284853|Experimental|Netarsudil/Latanoprost 0.02%/0.005%|PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
2441857|NCT03284853|Active Comparator|GANFORT®|GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
2441858|NCT03284840||Adults (18-65 years)|
2441859|NCT03284840||Elderly (65-74 years)|
2441862|NCT03284814|Active Comparator|Standard product group|This group will be included in a single dose cross over study, and in multiple dose study with standard product (SP: CoQ10 hard capsules; 100 mg)
2441863|NCT03284814|Active Comparator|Comparative product group|This group will be included in a single dose cross over study, and in multiple dose study with comparative product (CP: CoQ10 soft-gel capsules; 100 mg)
2441864|NCT03284814|Experimental|Investigational product group|This group will be included in a single dose cross over study, and in multiple dose study with investigational product (IP: CoQ10 syrup; 100 mg)
2441865|NCT03284788|Experimental|ABT Weight Loss Intervention|Adolescent girls will attend healthy lifestyle sessions that include nutritional education and physical activity education and build skills in the areas of values clarification, mindfulness, self-regulation skills, acceptance of uncomfortable states, goal-setting, problem solving, and self-monitoring.
2441866|NCT03284762||Treatment-naïve NVAF patients in Korea and Taiwan|Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation
2441867|NCT03284749|Experimental|Copper impregnated wound dressing|Wound dressing impregnated with 3% copper oxide ions, to be applied for 7 days after caesarean section
2441868|NCT03284749|Placebo Comparator|Normal wound dressing|Wound dressing without copper, to be applied for 7 days after caesarean section
2441869|NCT03284749|Experimental|Copper impregnated maternity pads|Maternity pads impregnated with 3% copper oxide ions, to be used for 14 days after delivery
2441871|NCT03284736|Experimental|Periapical surgery with membrane|"After retrofilling of teeth with MTA , defect was covered with collagen resorbable membrane.~healiguide collagen type 1 resorbable membrane covering the defect by extending 2-3 mm in every direction."
2441872|NCT03284736|Active Comparator|Periapical surgery without membrane.|After retrofilling of teeth with MTA, flap was closed without application of collagen resorbable membrane.
3151265|NCT00221975|Placebo Comparator|Lithium + Divalproex + Placebo|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL. Divalproex was then initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL. Patients meeting the criteria of being non-responsive to lithium plus divalproex were randomly assigned to receive lamotrigine or placebo. Patients randomized to the placebo group were giving matching placebo.
3151266|NCT00222001||HMO Patients|Measurement of telephone triage outcome.
3151267|NCT00222014|Experimental|1|TIPS réalisé avec prothèse couverte de PTFE
3151268|NCT00222014|Active Comparator|2|Paracenthese and albumine perfusion
2441879|NCT03284697|Active Comparator|DPC with Ca(OH)2|Direct pulp capping with Ca(OH)2.
2441880|NCT03284697|Active Comparator|DPC with MTA|Direct pulp capping with MTA
2441881|NCT03284684||circulating DNA plasma level test|
2441882|NCT03284671|Experimental|bifocal stimulation|Transcranial direct current Bifocal stimulation
2441883|NCT03284658||Observation|Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1
2441884|NCT03284645||ART Before or Early in Pregnancy|HIV positive pregnant women who started antiretroviral therapy (ART) before or early in pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
2441885|NCT03284645||ART Started Third Trimester|HIV positive pregnant women starting antiretroviral therapy (ART) during the third trimester of pregnancy for prevention of mother-to-child transmission of HIV and for their own health.
2441886|NCT03284645||ART Started Postpartum|HIV positive women starting antiretroviral therapy (ART) after delivery for prevention of mother-to-child transmission of HIV and for their own health.
2441887|NCT03284632||Smokers|
2441888|NCT03284632||E-cigarette users|
2441889|NCT03284632||Non-smokers|
2441890|NCT03284619|Experimental|treatment arm|Single arm study, 5 patient with bone metastasis will be enrolled for palliative treatment with the Magnetic resonance imager linear accelerator (MR-Linac).
2441891|NCT03284606|Experimental|TAPING|taping in conjunction with common rehabilitation for hemiplegic patients
2441892|NCT03284606|Placebo Comparator|NO TAPING|Common rehabilitation for hemiplegic patients without taping
2441893|NCT03284593||intensive chemotherapy group|patients treated with intensive chemotherapy
2441894|NCT03284593||Azacitidine group|patients treated with azacitidine
2441895|NCT03284580|Experimental|Ergonomic intervention group|Ergonomic intervention program at home for caregivers
2441896|NCT03284580|Experimental|Postural + kinesiotherapy intervention group|A postural + kinesiotherapy intervention program at home for caregivers
2441897|NCT03284580|Other|Control or conservative group|A conservative intervention by general information for caregivers
2441898|NCT03284567|Active Comparator|Football fitness|"Participants in the intervention group will practice soccer for 52 weeks two times weekly. A soccer instructor will be in charge of all training sessions. The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors. Participants will be told to avoid hard tackles and other actions that carry a risk of injury."
2441899|NCT03284567|No Intervention|Control group|Participants in the control group will receive verbal advice about the benefits of exercise and physical activity.
2441900|NCT03284554|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2441901|NCT03284554|Sham Comparator|Non-encapsulated nutrients|"Nutrients known to be able to stimulate GLP-1 and PYY release if they are encapsulated to provide release at pH ≈7.0 (in the distal part of the ileum). The same capsules in a non-coated form will be provided in order to study the effect of the coating.~The non-encapsulated nutrients will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2441902|NCT03284554|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum).~The placebo capsules will be provided 30 minutes prior to the ad libitum test breakfast and 3 hour prior to the ad libitum test lunch, respectively."
2441903|NCT03284541|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
2441904|NCT03284541|Active Comparator|Existing Public Health Practice|The control condition consists of the single-session Couples-Based HIV Counseling and Testing protocol for HIV-negative couples, the single-session Life-Steps medication adherence protocol for HIV-positive couples, or both intervention delivered jointly to serodiscordant couples
2441905|NCT03284515||All women|Women who are between 16-32 weeks gestation and who have not previously received a pertussis vaccination in pregnancy.
3151269|NCT00222040|Experimental|1|Levovist
3151270|NCT00222040|No Intervention|2|No specific intervention
3151271|NCT00222053|No Intervention|1|No specific intervention
3151272|NCT00222053|Active Comparator|2|Biphosphonates
3151273|NCT00222053|Experimental|3|Thalidomide
2441911|NCT03284476||ICU patients|Collection of medical data of Patients with peritonitis (nosocomial or community-acquired) or Patients with post-operative peritonitis
2441912|NCT03284463|Active Comparator|Glibenclamide|Glibenclamide Tablets
2441913|NCT03284463|Placebo Comparator|Placebo|Placebo for Glibenclamide
2441914|NCT03284450|Experimental|Dance performance fitness test (DPFT)|
2441915|NCT03284450|Active Comparator|Sport specific repeated sprints (SSRS)|
2441916|NCT03284437|No Intervention|Usual Care|Usual medical care provided to patients in the ICU.
2441917|NCT03284437|Experimental|Early Cognitive Training|Usual medical care provided to patients in the ICU plus additional activities designed to engage the patient's attention and cognition. Activities are chosen by the family member from an activity cart according to the level designated by occupation therapy.
3151274|NCT00222066|Experimental|1|Fetal ovarian cyst aspiration performed as soon as possible
3151275|NCT00222066|No Intervention|2|Expectative
3151276|NCT00222118|Experimental|1|intervention group
2441923|NCT03284372|Experimental|Intervention 1|Text Message Only
2441924|NCT03284372|Experimental|Intervention 2, Incentive|Text message + Incentive
2441925|NCT03284372|No Intervention|Cohort|For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19. The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
2441926|NCT03284372|No Intervention|Control|The baseline cohort serves as the control group in this cmRCT. Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2). However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
2441927|NCT03284372|No Intervention|Adolescent Allergy Advisors|We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language. These advisors will not be part of the cohort multiple randomized controlled trial.
2441930|NCT03284346|Experimental|Arm I (CARE)|Patients undergo supervised exercise sessions comprised of CARE over 50 minutes 3 days weekly for 16 weeks. Patients receive a Polar heart rate monitor to monitor heart rate during the CARE sessions.
2441931|NCT03284346|Active Comparator|Arm II (standard stretching)|Patients undergo a standard stretching program 3 days weekly for 16 weeks. After 16 weeks, patients may undergo supervised exercise sessions comprised of CARE as in Arm I.
2441932|NCT03284333|Experimental|other|no arm
2441933|NCT03284307|Experimental|Drug Administrated|Sedatives will be administered to participants while their brain activity is measured.
2441934|NCT03284294|Placebo Comparator|Placebo|Oral placebo daily for 8 weeks
2441935|NCT03284294|Active Comparator|Vitamin D|Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
2441936|NCT03284281|Experimental|Interventional arm|Active TVNS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 8 hours daily (4 hours twice daily) for 1-week post discharge.
2441937|NCT03284281|Placebo Comparator|Control arm|No stimulation will be performed.
2441938|NCT03284268|Experimental|Dose escalation of VCN-01|Dose lower : 2E+9 viral particules/eye Dose medium: 2E+10 viral particules/eye Dose high: 2E+11 viral particules/eye
2441939|NCT03284255|Experimental|study group|in this group the subject will accept the treatment of BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System
2441940|NCT03284255|Active Comparator|control group|in this group the subject will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
2441941|NCT03284242|Experimental|Autologous Treg Infusion|This will be a single intravenous (IV) infusion. A participant's own expanded regulatory T cells will be added to Albumin, and administered to them. The amount of the solution will be approximately 300 ml and the infusion will take about 3 to 4 hours.
2441943|NCT03284216|Other|Normal glycemia + exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered, but an exercise bout will be completed.
2441995|NCT03283891|No Intervention|control|No intervention during the different times of measurement. Educational intervention will be delivered after the last measure.
3151277|NCT00222118|Other|2|Attention control
3151278|NCT00222118|Other|3|Usual care
3151279|NCT00222144|Experimental|1|Gleevec and Taxotere
3151280|NCT00222248|Experimental|Pelvic floor muscle training|Weekly group session of education and exercise to music incorporating pelvic floor muscle training incorporating motor control, strength, endurance, power and functional training in a variety of different positions.
3151281|NCT00222248|Active Comparator|Bladder training|Weekly group session of education regarding deferral techniques, timed voiding parameters and gentle exercise to music.
3151282|NCT00222261|Active Comparator|1, aspirin|Aspirin 160 mg
3151283|NCT00222261|Active Comparator|2, clopidogrel|Clopidogrel 75 mg
3151284|NCT00222274|Experimental|1|RSA Biofeedback: RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
3151285|NCT00222274|Active Comparator|2|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
3151286|NCT00222326|Experimental|Pelvic floor muscle training|Pelvic floor muscle training: clinic and rooms exercise training
2441944|NCT03284216|Experimental|Steady-state hyperglycemia + exercise|Participants will be studied during experimental steady-state hyperglycemia-induced via a variable-rate intravenous glucose infusion, and an exercise bout will be completed.
2441945|NCT03284216|Experimental|Fluctuating hyperglycemia + exercise|Participants will be studied during experimental fluctuating hyperglycemia-induced via repeated intravenous glucose injections, and an exercise bout will be completed.
2441946|NCT03284216|No Intervention|Normal glycemia, no exercise|Participants will be studied in the fasting state under normal blood glucose conditions whereby no glucose will be administered and no exercise will be completed.
2441947|NCT03284203|Experimental|SpiroPD|Participants in the intervention arm will be given a handheld spirometry device to take home and use daily for 30 consecutive days.
2441948|NCT03284190||ASDH Copenhagen, Denmark|
2441949|NCT03284190||ASDH Odense, Denmark|
2441950|NCT03284190||ASDH Århus, Denmark|
2441951|NCT03284190||ASDH Ålborg, Denmark|
2441952|NCT03284190||ASDH Lund, Sweden|
2441953|NCT03284190||ASDH Linköping, Sweden|
2441954|NCT03284190||ASDH Gothenburg, Sweden|
2441955|NCT03284190||ASDH Stockholm, Sweden|
2441956|NCT03284190||ASDH Uppsala, Sweden|
2441957|NCT03284190||ASDH Umeå, Sweden|
2441958|NCT03284177|Experimental|C13-CAC|
2441959|NCT03284164|Experimental|Healthy Subjects|Healthy Subjects matched to RI subjects Tenofovir Exalidex (TXL)
2441960|NCT03284164|Experimental|Severe RI|Severe Renal Impairment subjects Tenofovir Exalidex (TXL)
2441961|NCT03284138|Active Comparator|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
2441962|NCT03284138|Sham Comparator|Placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
2441963|NCT03284125||Facial paralysis|Patients affected by facial paralysis treated by LTM The aim is to evaluate the improvement of the swallowing disorders after surgery.
2441964|NCT03284112|Placebo Comparator|Control|School population without the Old SCHOOL Hip-Hop program, but with the My Plate program.
2441965|NCT03284112|Experimental|Intervention|School population with the Old SCHOOL Hip-Hop program.
2441966|NCT03284099|Experimental|intervention|ACEIs or ARBs will be switch to be taken before bedtime
2441967|NCT03284099|Active Comparator|control|ACEIs or ARBs will be taken in the morning as usual
2441968|NCT03284086|Other|paraplegic|Well-trained participants with a spinal cord injury (<Th1) were included in this group.
2441969|NCT03284086|Other|able bodied|Upper-body trained, able-bodied participants were included in this group.
2441970|NCT03284073|Experimental|Uterus Transplantation|Patients undergo transplantation of the uterus from a live donor
2441971|NCT03284060|Experimental|Cognitive remediation program|
3151287|NCT00222326|No Intervention|Usual care|Usual care as provided by the surgeon and hospital staff
3151288|NCT00222352||central laboratory cTnI test|Control Group
2441978|NCT03284008|Experimental|Manual manoeuver + stretching|Patients will receive a manual manoeuver treatment and education to perform stretching exercises at home.
2441979|NCT03284008|Active Comparator|stretching exercise|Patients will receive education to perform stretching exercises at home.
2441980|NCT03283995||cardiogenic shock without SCA|
2441981|NCT03283995||cardiogenic shock with SCA|
2441982|NCT03283995||SCA,|
2441983|NCT03283995||acute left heart failure with severe alteration of LVEF|
2441984|NCT03283982|Active Comparator|Robotic IPOM|Robotic Ventral Hernia Repair with IPOM: The da Vinci® Surgical System robotic platform (Intuitive Surgical, Inc.) will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
2441985|NCT03283982|Active Comparator|Laparoscopic IPOM|Laparoscopic Ventral Hernia Repair with IPOM: The standard laparoscopic platform will be used to perform a minimally invasive ventral hernia repair with intraperitoneal mesh placement.
2441986|NCT03283969|Placebo Comparator|Control Powder|Isocaloric powder
2441987|NCT03283969|Experimental|Freeze Dried Strawberry Powder|Contains freeze dried strawberries
2441988|NCT03283956||Patient records|Medical records of all patients who underwent DC bead TACE.
2441989|NCT03283943|Experimental|Durvalumab and focal radiotherapy|Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
2441990|NCT03283930|Experimental|Active ABMT|Active attention bias modification will be provided in addition to individual cognitive behavioral therapy
2441991|NCT03283930|Placebo Comparator|Placebo|Placebo attention bias modification will be provided in addition to individual cognitive behavioral therapy
2441992|NCT03283917|Experimental|Treatment (daratumumab, ixazomib, dexamethasone)|Participants receive daratumumab IV over 3.5-6.5 hours on days 1, 8, 15, and 22 of courses 1-2, on days 1 and 15 of courses 3-6, and on day 1 of courses 7-12. Participants also receive ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unaccepted toxicity.
2441993|NCT03283904|Experimental|Multicomponent PA intervention|Intervention schools will adopt a multicomponent intervention by integrating physical activities into different parts of the school day
2441994|NCT03283891|Experimental|educational intervention|Various pedagogical activities to mobilise Watson's ten Carative Factors
2441996|NCT03283878|Experimental|Study Group 1|"Patients in Group #1 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. No further antibiotic administration will be given.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. In addition, the use of clindamycin as an alternative is also permitted at a minimum recommended dose."
2441997|NCT03283878|Experimental|Study Group 2|"Patients in Group #2 will receive a single weight-based dose of prophylactic cefazolin antibiotic that is administered intravenously within less than 60 minutes prior to skin incision in elective total knee arthroplasty. In addition, two weight-based doses of cefazolin will be administered within 24 hours postoperatively.~< 120 kg - patients will receive 2 grams of cefazolin~≥ 120 kg - patient will receive 3 grams of cefazolin~Patients with documented allergy/anaphylactic reaction to penicillin or cephalosporin may receive intravenous vancomycin monotherapy or dual therapy with vancomycin and gentamicin as an alternative. If allergic, patients will also receive two weight-based doses vancomycin postoperatively but not gentamicin postoperatively. In addition, the use of clindamycin as an alternative is also permitted. Vancomycin schedule: one dose preoperatively, one dose 8-12 h postoperatively, one dose 24 h postoperatively (opt.)."
2441998|NCT03283865|Experimental|Ultrasound|"The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure.~All study participants will have ultrasound used for caudal block."
2441999|NCT03283839|Other|Temporomandibular disorder|
2442000|NCT03283839|Other|Without temporomandibular disorder|
3151289|NCT00222352||Point of Care cTnL testing|Experimental Group
3151290|NCT00222417||Myringoplasty|Patients subject to myringoplasty for tympanic membrane perforations.
2442003|NCT03283813|Active Comparator|Active group - Zinc and Myo-inositol|This arm will receive a supplementation with Zinc and Myo-inositol once a day.
2442004|NCT03283813|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without Zinc and Myo-inositol inside.
2442005|NCT03283800|Experimental|Copper impregnated compression stocking|Copper compression stocking containing 2-3% copper ions to be worn on one leg, daily for 8 weeks.
2442006|NCT03283800|Placebo Comparator|Normal compression stocking|Similar compression stocking without copper to be worn on the other leg, daily for 8 weeks
2442010|NCT03283761|Experimental|Treatment Arm|All patients in Stage I (N=12) and Stage II (N=25) will receive FOLFOX-A on days 1 and 15 of each cycle (1 cycle = 28 days). Nab-paclitaxel will be given at a dose of 150 mg/m^2 IV over 30 minutes, followed by oxaliplatin IV 85 mg/m^2 and leucovorin IV 400 mg/m^2 over 2 hours, and 5-FU as a continuous IV infusion over Day 1 and Day 2 (for a total dose of 2400mg/m^2 over 46-48 hours.). Radiographic assessment will be performed at baseline and every other cycle (starting with Cycle 3) to evaluate response to treatment by RECIST Version 1.1 guidelines. Patients may continue to receive treatment until disease progression or unacceptable toxicity.
2442011|NCT03283748|Experimental|Measurement of Motor Movements|Wearable Accelerometer Sensors manufactured by leading manufacturers will be given to the participants to be worn around hands and legs. These sensors will be used to measure accelerations which will be impacted by the motor movements.
2442012|NCT03283735|Experimental|Elderly Enablement|The investigators will give enablement tools and talks with their GPs about how to issue the problem of polypharmacy.
2442013|NCT03283735|No Intervention|Control|This will be the control group.
2442017|NCT03283670|Experimental|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
2442018|NCT03283670|Experimental|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, in known N-methyl-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
2442019|NCT03283670|Placebo Comparator|Placebo Gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen
2442020|NCT03283657|Experimental|DiRECT|DiRECT consists of the following components that will be delivered by medical assistants before patients' routinely scheduled office visits: 1) a prediabetes decision aid focused on type 2 diabetes (T2D) risk and treatment options for preventing T2D; 2) a 'think aloud' exercise; and 3) formulating a preliminary treatment plan for T2D prevention.
3151291|NCT00222417||Otosclerosis|Patients subject to stapes surgery
3151292|NCT00222430|Active Comparator|A|Usual standard coronary angiographic procedure
3151293|NCT00222430|Experimental|B|Fluoroscopy-guided coronary angiography
3151294|NCT00222469|Experimental|1|3-agent treatment group
3151295|NCT00222534|Experimental|Acetazolamide|Acetazolamide 250 mg Three times a day for five days
3151296|NCT00222534|Placebo Comparator|Placebo|Placebo, one tablet Three times a day for five days
3151297|NCT00222612|Active Comparator|A or B with 2DI|3 or 4 drug induction plus 2 delayed intensifications
3151298|NCT00222612|Experimental|C plus 2DI|Intensified treatment including Capizzi maintenance
3151299|NCT00222612|Experimental|A or B with 1DI|Reduced intensity treatment
3151300|NCT00222716|Experimental|Structured|Behavioral Intervention: Structured counseling behavioral intervention focused on problem solving.
3151301|NCT00222716|No Intervention|Usual Care|Control arm
3151302|NCT00222716|Experimental|Inidividualized|Behavioral Intervention: Individualized nurse counseling behavioral intervention focused on problem-solving
3151303|NCT00222742|Experimental|A|Induced moderate hypothermia (32-33 C)
3151304|NCT00222755|Experimental|1|Behavioral Care Management
3151305|NCT00222755|No Intervention|2|Usual Care
2442021|NCT03283657|Active Comparator|Usual Care (UC)|Participants randomized to standard care will receive routine medical care without the medical assistant delivered DiRECT intervention.
2442022|NCT03283644||Patients with a BMI over 40|Participants were aged between 27-65 years, BMI >40 , Co-Morbidities associated with obesity including sleep apnoea, hypertension, depression, hypercholesterolaemia and type 2 diabetes, Undergoing Gastric Band surgery
2442023|NCT03283644||Lean, healthy individuals|Participants were aged between 27-65 years, BMI<28 , Systemically healthy, taking no prescribed medication
2442024|NCT03283631|Experimental|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
2442025|NCT03283618|No Intervention|Control Group|The control group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) as well as caloric and step goals, but no health coaching. They will complete the same pre- and post-intervention measurements and consultations with the medical doctor and registered dietitian.
2442026|NCT03283618|Experimental|Video Conference-based Health Coaching|The video conference-based health coaching group will receive the mHealth devices (scale, blood pressure cuff, and accelerometer watch) meet the medical doctor at baseline and at 12 weeks via the Amwell® app using their smartphone. The participants will receive health coaching by meeting weekly (12 times) with the registered dietitian (RD) to discuss behavior modification, exercise, and nutrition goals.
3151306|NCT00222846|Active Comparator|A|Attention control
2442028|NCT03283592|Experimental|Rank-Heat Plot|The intervention group will receive an online survey to evaluate their interpretation of the results from the NMA with a rank-heat plot including results from 2 outcomes that were selected by our knowledge users (#injurious falls, #fractures).
2442029|NCT03283592|Active Comparator|SUCRA (surface under the cumulative ranking) Plot|The control group will receive an online survey to evaluate their interpretation of the results from the NMA with the SUCRA plots including results from the same 2 outcomes that will be presented to the intervention group (i.e., #injurious falls, #fractures).
2442030|NCT03283579||Pregnant women|
2442031|NCT03283566|Active Comparator|Hydroxychloroquine|Administered pre-transplant through 3 months after surgery.
2442032|NCT03283566|Placebo Comparator|Placebo|Placebo treatment following the same schedule as Arm 1 (i.e. Hydroxychloroquine).
3151307|NCT00222846|Experimental|B|Intervention
3151308|NCT00222872|Active Comparator|1 - PTHrP Group|Group receiving study drug: PTHrP(1-36)
2442037|NCT03283488|Experimental|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
2442038|NCT03283488|Active Comparator|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
2442039|NCT03283475|No Intervention|control group|"- Control group will include 60 adult individuals between 18 and 35 years old who have body mass index (BMI) between 19 and 25, not complaining of any thigh contour deformities or skin redundancy with no history of body weight fluctuations. This group will be divided into two subgroups, 30 males and 30 females.~The following measurements will be recorded :- Weight, height, thigh length, hip circumference, maximum buttocks circumference, upper thigh, middle thigh and lower thigh circumferences."
2442040|NCT03283475|Active Comparator|patient group|"- Patient group will include 30 patients suffering from thigh lipodystrophy and contour deformities who will undergo surgical intervention after their assessment.~After assessment, one of the following techniques will be selected:-~Liposuction only.~thigh lift.~Liposuction assisted thigh lift."
2442041|NCT03283462|Active Comparator|AMAZ-02|
2442042|NCT03283462|Placebo Comparator|Placebo|
3151309|NCT00222872|Placebo Comparator|2 - Single Blind Placebo Group|Receives placebo injections daily via subcutaneous injection
2442046|NCT03283410|Experimental|Single Study Arm|All patients will be sequentially allocated in the single study arm. All patients will receive some propofol dose.
2442047|NCT03283397|Experimental|EK-12|This arm will be treated with 12 mg EK-12 in 2 mL 0.9 % NaCl solution (SC, three times per week) for 144 weeks
3151310|NCT00222937|Experimental|A|Patients are enrolled in Lessac-Madsen Resonant Voice Therapy.
3151311|NCT00222937|Experimental|B|Patients are enrolled in Casper Based Confidential Flow Therapy.
3151312|NCT00222976|Experimental|1|A Naproxen PO + placebo PR
3151313|NCT00222976|Experimental|2|B Placebo PO + Naproxen PR
3151314|NCT00222989|Other|no label study|1
3151315|NCT00223002|Experimental|1|PI
3151316|NCT00223002|Experimental|2|Chlorohex
3151317|NCT00223041|No Intervention|A (therapy with fluvastatin 80mg retard)|kidney transplants receive in addition fluvastatin 80mg retard for 3 years
3151318|NCT00223041|Placebo Comparator|B|no therapy with fluvastatin
3151319|NCT00223145|Experimental|Arm 1|Androgen blockade for 6 months + Radiotherapy 70 Gy
3151320|NCT00223145|Experimental|Arm 2|Androgen blockade for 6 months + Radiotherapy 76 Gy
3151321|NCT00223145|Active Comparator|Arm 3|Radiotherapy alone with 76 Gy
3151322|NCT00223171|Active Comparator|Arm 1 : 36 months AB + RT|Androgen blockade : 36 months of androgen blockade : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 12 Q 3 months + radiation therapy : pelvis 44 grays , prostate 70 grays (2 grays/fraction)
3151323|NCT00223171|Experimental|Arm 2 : 18 months AB + RT|Androgen blockade 18 months : bicalutamide 50 mg die for one month, goserelin 10.8 mg x 6 Q 3 months + radiation therapy ( pelvis 44 grays , prostate 70 grays ,2 grays/fraction)
3151324|NCT00223210|Active Comparator|Quetiapine|
3151325|NCT00223210|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3151326|NCT00223249|Active Comparator|Quetiapine|Quetiapine
3151327|NCT00223249|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3151328|NCT00223353||Lower Limb Amputee|
3151329|NCT00223353||Amputee and Normals and Clinical Case Study|"Amputee:~Lower limb below/above knee amputee~Normals:~Health adult~Clinical Case Study:~Individual case studies"
3151330|NCT00223405||metal-ceramic (D'Sign) o|Metal ceramic crown will be placed
2442048|NCT03283397|Active Comparator|INF Beta-1a|This arm will be treated with 44 mg INF Beta-1a in 0.5 mL solution (SC, three times per week) for 144 weeks
2442049|NCT03283384|Other|Advise letrozole, treatment choice free.|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of <1% in the biopsy taken after those two weeks of treatment are advised to stay on letrozole treatment until surgery. However, treatment choice is free.
2442050|NCT03283384|Active Comparator|Chemotherapy|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
2442051|NCT03283384|Experimental|Ribociclib plus letrozole|All patients initially start with two weeks of letrozole treatment. Patients with a Ki67 of ≥1% in the biopsy taken after those two weeks of treatment are randomized between chemotherapy (standard AC-T chemotherapy) or ribociclib plus letrozole (ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks)).
3189592|NCT00778752|Experimental|A|"Lenalidomide-treatment starts between 100 and 180 days after allogeneic stem cell transplantation. Three dose-levels will be investigated.~Dose-level -1: 2.5 mg/d if 2.5mg capsules are available, day 1-21, otherwise 5 mg every other day, day 1-21~Dose-level 0: 5 mg/d, day 1-21~Dose-level 1: 10 mg/d, day 1-21~Dose-level 2: 15 mg/d, day 1-21"
3189593|NCT00778765|Experimental|1|400 mg Gabapentin Capsules of Ranbaxy
2442054|NCT03283358|Experimental|Person-centered follow up|The intervention program is a person-centered health promotion program led by a nurse and consists of two telephone calls (15 minutes each) at two weeks and nine months after surgical treatment for Intermittent Claudication and three visits (45 - 60 min) at six weeks, six months and one year after treatment. The program includes a baseline assessment, an individual plan for self-care and educational information about Intermittent Claudication, received treatment and secondary prevention (medication and modifiable risk factors). The purpose is to enhance self-care in terms of adherence to medication and to recommended changes of lifestyle.
2442055|NCT03283358|No Intervention|Standard follow up|Standard follow-up consist of two follow up appointments á 20 minutes at four-six weeks and one year after surgical treatment of Intermittent Claudication. The patients meet a vascular surgeon at the first follow up and a vascular nurse or a surgeon at the second follow up visit.
2442056|NCT03283345|Active Comparator|postmenopausal women|postmenopausal female breast cancer patients who underwent modified radical mastectomy
2442057|NCT03283345|Active Comparator|premenopausal women|premenopausal female breast cancer patients who underwent modified radical mastectomy
3189594|NCT00778765|Active Comparator|2|Neurontin® 400 mg Gabapentin Capsules
3189595|NCT00778778|Experimental|1|Cefprozil 500mg tablets of ranbaxy
3189596|NCT00778778|Active Comparator|2|CEFZIL ® 500 mg cefprozil tablets of BMS, USA
3189597|NCT00778778|Active Comparator|3|CEFZIL ® 500 mg tablets, BMS Canada
3189598|NCT00778791|Experimental|1|metformin HC1 750 mg extended-release tablets
3189599|NCT00778791|Experimental|2|Glucophage® XR 750 mg tablets
2442064|NCT03283293|Experimental|Target volume delineation after NACT|
2442065|NCT03283280|Experimental|Short fiber RC|Short fiber reinforced resin composite restoration (Ever X Posterior, Gc Europe) that is used in high stress bearing areas as direct onlay restoration.
2442066|NCT03283280|Active Comparator|Nanohybrid RC|Nanohybrid resin composite (GrandioSO, VOCO GmbH Germany ) that can be used to make indirect restorations in posterior teeth.
2442067|NCT03283267|Experimental|ZS 5g, qd|Subjects randomized to this arm will receive ZS 5 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
2442068|NCT03283267|Experimental|ZS 10g, qd|Subjects randomized to this arm will receive ZS 10 g qd in conjunction with breakfast during the ZS treatment period and will be continued with a standard diet.
2442069|NCT03283254|Experimental|Practical Resources for Effective Postpartum (PREPP)|A psychotherapeutic preventive intervention that involves psychoeducation and cognitive behavioral techniques.
2442070|NCT03283254|Active Comparator|Enhanced Treatment as Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community and monitoring
2442071|NCT03283241|Active Comparator|Zolidd One ExHex|Coated titanium implant
2442072|NCT03283241|Sham Comparator|One ExHex|Uncoated titanium implant
2442073|NCT03283228||CD11b and CD56 markers|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
2442074|NCT03283228||Haematological parameters in cases of adult AML|Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML
2442075|NCT03283202|Experimental|Avadomide (CC-122) plus R-CHOP-21|Avadomide (CC-122) by mouth (PO) at varying dose levels (Ph 1) on Days 1 through 5 and Days 8 through 12 plus Rituxan 375 mg/m2 by intravenous (IV) infusion, cyclophosphamide 750mg/m2 by IV infusion, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 (max is 2.0 mg) IV and 100 mg PO prednisone/prednisolone on Days 1 through 5 of each 21-day treatment cycles for up to 6 total treatment cycles (approximately 18 weeks or 4 months)
2442076|NCT03283189||Group 1|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
2442077|NCT03283189||Group 2|Pregnancy follow-up in the only maternity type III of the region (CHU) and in an urban area (around Clermont-Ferrand)
2442078|NCT03283189||Group 3|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
2442079|NCT03283189||Group 4|Pregnancy follow-up in the only private maternity (type II) of the region and in an urban area (around Clermont-Ferrand)
2442080|NCT03283189||Group 5|Pregnancy follow-up in a type I maternity and in a rural area (around Saint-Flour)
3189600|NCT00778804|Experimental|telemedicine|Web-based monitoring in addition to usual clincial care with quarterly visits
3189601|NCT00778804|No Intervention|Control|Ususal care with quarterly visits
3189602|NCT00778843|Experimental|Viusid|
3189603|NCT00778843|Placebo Comparator|Placebo|Placebo three oral sachets daily during 24 weeks
3189604|NCT00778856|Experimental|Hand Transplant|
3189605|NCT00778882|Experimental|VM106|
3189606|NCT00778908|Experimental|A|Late-course accelerated hyperfractionated IMRT with concomitant cisplatin chemotherapy
2442082|NCT03283176||Sofo-Dacla with Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir with Ribavirin
2442083|NCT03283176||Sofo-Dacla without Ribavirin|Chronic Hepatitis C related Liver Cirrhosis patients who will take sofosbuveir, Daclatasvir without Ribavirin
2442084|NCT03283163|Experimental|Chronic Pain//PTSD group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
2442085|NCT03283163|Active Comparator|Trauma-exposed healthy control group|This group will receive baseline and endpoint maximum load exercise testing which will inform their individualized exercise prescription (based on a progressive methodology) of aerobic exercise training aimed at meeting specific heart rate ranges over time (increasing up to 80% of maximum HRR between the midpoint and endpoint (6-12 weeks).
2442086|NCT03283150|Active Comparator|Remifentanil|Remifentanil will be administered to subjects during microelectrode recordings (MER).
2442087|NCT03283150|Active Comparator|Propofol|Propofol will be administered to subjects during MER.
2442088|NCT03283150|Active Comparator|Dexmedetomidine|Dexmedetomidine will be administered to subjects during MER.
2442089|NCT03283137|Experimental|TGR-1202 and pembrolizumab|All patients will receive TGR-1202 and pembrolizumab. Patients will start receiving TGR-1202 daily for 6 weeks (2 cycles). Pembrolizumab will be given every 3 weeks for 8 cycles. If the daily dose of TGR-1202 (dose level 1) is tolerated in the first cohort the dose will be increased which is the only and final dose escalation. If TGR-1202 is not tolerated the dose will be decreased.
2442090|NCT03283124|Active Comparator|self-cut mesh procedure|This procedure is transvaginal mesh implantation surgery for POP patients. Self-cut mesh procedure is an economic pelvic reconstructive surgical operation with use of specially designed puncture needles and self-cut mesh, which mainly provide anterior and apical compartments support, with posterior compartment reinforced by bridge technique repair. The mesh pieces used in this surgery was cut from a single piece of mesh material(TiLOOP 10*15cm) which is much cheaper and readily available. Patients could have transvaginal hysterectomy concomitantly.
2442091|NCT03283124|Active Comparator|mesh-kit procedure|This procedure is transvaginal mesh implantation surgery for POP patients.Mesh-kit procedure is refered to pelvic floor reconstructive surgery with titanium-coated meshes kit(TiLOOP TOTAL6).Patients could have transvaginal hysterectomy concomitantly.
2442092|NCT03283111|Experimental|autologous stem cell transplantation|Lymphoma patients received autologous stem cell transplantation for the first time
2442095|NCT03283085|Experimental|25 mg Ontamalimab|Participants will be receiving 25 milligram (mg) of ontamalimab solution for injection subcutaneously (SC) every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
2442096|NCT03283085|Experimental|75 mg Ontamalimab|Participants will be receiving 75 mg of ontamalimab solution for injection SC every 4 weeks until the participant withdraws from the study, or the investigator or sponsor decide to withdraw the participant, or the sponsor decides to close the study, or the program is stopped.
2442097|NCT03283072|Sham Comparator|Sham|normoxia for 2 minutes, normoxia 1 minute x 8 using hypoxicator
2442098|NCT03283072|Experimental|Trubower|15 bouts of hypoxia for 1 minute, normoxic 1 minute using hypoxicator
2442099|NCT03283072|Experimental|Hayes|15 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
2442100|NCT03283072|Experimental|Tester|8 bouts of hypoxia for 2 minutes, normoxic 1 minute using hypoxicator
2442101|NCT03283059|Experimental|Octohydroaminoacridine Succinate Tablet|Octohydroaminoacridine Succinate Tablet 4mg P.O. tid
2442102|NCT03283059|Active Comparator|Aricept|Aricept 5mg/day P.O.
2442103|NCT03283059|Placebo Comparator|Placebo|Placebo P.O. tid
2442104|NCT03283046|Experimental|Nivolumab + Ipilimumab + Dexamethasone + Lenalidomide|"The first 4 study cycles are 21 days long, and all remaining cycles are 28 days long.~On Day 1 of Cycles 1-4, Nivolumab by vein over 60 minutes. Thirty (30)minutes after Nivolumab, Ipilimumab given by vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, Nivolumab given by vein over 60 minutes.~Lenalidomide tablets take by mouth on Days 1-14 of Cycles 1-4 and on Days 1-21 of Cycles 5 and beyond. Dexamethasone tablets taken by mouth on Days 1, 8, and 15 of Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.~For participants who are eligible for autologous stem cell transplant, those who achieve at least a partial response after at least 4 cycles of initial therapy will be eligible for:~EITHER Stem cell collection and storage OR Stem cell collection and autologous stem cell transplantation."
3151331|NCT00223405||an all-ceramic crown (IPS Empress2, Eris EXC).|All ceramic crown will be placed
3151332|NCT00223444||1|Genotype group Pro/Pro
3151333|NCT00223444||2|Genotype group Pro/Ser
3151334|NCT00223587|Experimental|A|1 week of treatment discontinuation
2442109|NCT03283020|Active Comparator|RemifentanilMNTX|Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
2442110|NCT03283020|Active Comparator|PlaceboMNTX|Volunteers are given an intravenous infusion with saline 0,9%. After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
2442111|NCT03283007|Experimental|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
2442112|NCT03283007|Placebo Comparator|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
2442113|NCT03282994|Experimental|Treatment with cryotherapy|Dermal Cooling System
3151335|NCT00223626|Experimental|Topiramate|
3151336|NCT00223626|Placebo Comparator|Placebo|
3151337|NCT00223639|Experimental|Topiramate|
3151338|NCT00223639|Placebo Comparator|Placebo|
3151339|NCT00223691|Experimental|1: active intervention|atomoxetine, pyridostigmine bromide, yohimbine, midodrine hcl, modafinil, octreotide, water intake, ranitidine hcl, diphenhydramine hydrochloride, tranylcypromine, ergotamine/ caffeine, celecoxib, pseudoephedrine, methylphenidate, indomethacin, ibuprofen, Oxymetazoline 0.05% nasal solution, acarbose, Rivastigmine tartrate, acetazolamide, carbidopa/levodopa, inflatable abdominal binder or bovril
2442114|NCT03282981|Experimental|Timolol|Timoptic-XE plus standard of care (SOC)
2442115|NCT03282981|Placebo Comparator|SOC plus non biologically active gel|SOC plus non biologically active gel (hydrogel as placebo medication)
2442116|NCT03282968|Experimental|Experimental|Regular neurophysiotherapy plus REWIRE exercises
2442117|NCT03282968|Active Comparator|Control|Regular neurophysiotherapy plus standing balance exercises
3151340|NCT00223691|Placebo Comparator|2: Placebo or sham device|placebo pill or inflatable abdominal binder (sham)
3189607|NCT00778908|Other|B|Conventionally fractionated IMRT with concomitant cisplatin chemotherapy
2442120|NCT03282942|Experimental|Exercise training protocols|Participants will be randomized in one of TWO groups: aerobic training group (AT) or strength training group (ST). Each training protocol will last 12 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
2442121|NCT03282942|No Intervention|Control Group|The individuals who will be part of the control group will be instructed to follow their daily activities, avoiding any systematic exercise program and return to the end of the 12 weeks for reevaluation.
2442122|NCT03282929|Experimental|Part 1 Group 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order.
2442123|NCT03282929|Experimental|Part 2 group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
2442124|NCT03282929|Experimental|Part 2 Group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
2442125|NCT03282929|Experimental|Part 2 Group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
2442126|NCT03282929|Experimental|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
2442127|NCT03282916|Active Comparator|Valacyclovir|The oral valacyclovir will be distributed in 500mg caplets. Patients will take 8 caplets per day.
2442128|NCT03282916|Placebo Comparator|Placebo|The oral placebo (sugar pill) will be distributed in 500mg caplets. Patients will take 8 caplets per day.
2442129|NCT03282903||Crohn's disease patients|1550 Crohn's disease patients who are symptomatically controlled.
2442130|NCT03282903||Ulcerative Colitis patients|1550 Ulcerative Colitis patients who are symptomatically controlled.
2442131|NCT03282890|Experimental|CHRP-BB|Patients assigned to the CHRP-BB will receive a weekly HIV risk reduction and PrEP adherence group level intervention led by two facilitators trained and supervised by the PI, a licensed clinical psychologist. It is a substantially shortened version of the comprehensive Holistic Health Recovery Program (HHRP)-based interventions that have been identified as demonstrating evidence of effectiveness in two randomized clinical trials. The CHRP-BB, which includes four 50-minute groups (1 group per week), will contain only content that relates explicitly to drug- or sex-related HIV risk reduction and PrEP adherence. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
2442132|NCT03282890|No Intervention|Control Condition|The time-and-attention-matched control condition for the proposed research will be a time and contact-matched, non-contaminating support group for individuals in recovery modeled after similar groups offered in the community. There will be no overlap between the content of the comparison intervention and experimental intervention although the basic structure will be the same. Thus, each participant will be asked to attend four 50-minute weekly group sessions led by two trained facilitators. Participants in both conditions will receive routine clinical services (i.e., daily methadone and case management).
2442133|NCT03282877|Experimental|iCST web-application|A computerised cognitive stimulation programme consisting of 21 sessions.
2442134|NCT03282877|No Intervention|Treatment as usual (TAU)|The control group will consist of a treatment-as-usual group and will not receive any additional intervention.
2442135|NCT03282864|Active Comparator|Bedroom air filtered by an air filtration device|The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks.
2442136|NCT03282864|Placebo Comparator|Bedroom air filtered by a placebo air filtration device|The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks.
2442137|NCT03282851|Experimental|MSB11456|
2442138|NCT03282851|Active Comparator|US-licensed Actemra|
2442139|NCT03282851|Active Comparator|EU-approved RoActemra|
2442140|NCT03282838|Experimental|DFN-15 (fasted)|
2442141|NCT03282838|Experimental|DFN-15 (fed)|
2442142|NCT03282838|Experimental|Comparator (fed)|
2442143|NCT03282825|Experimental|Decitabine|"A standard 3+3 trial design will be used for Decitabine dose escalation cohorts.~The number of cohorts is three. The subjects will be administered Decitabine on every seven days in a 28day cycle and Decitabine is sequential administered with Paclitaxel.~Cohort 1: Decitabine 15mg/m2, Cohort 2: Decitabine 20mg/m2, Cohort 3: Decitabine 25mg/m2"
2442144|NCT03282812||cases|
2442145|NCT03282812||controls|
2442146|NCT03282799|Active Comparator|Standard Dose Etonogestrel Implant|Single 68 mg etonogestrel implant
2442147|NCT03282799|Experimental|Increased Dose Etonogestrel Implant|Two 68 mg (136 mg total) etonogestrel implants
2442148|NCT03282786|Active Comparator|CD patient with CO2 insufflation|The investigators aim to include 76 Crohn's disease (CD) patients undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
2442149|NCT03282786|No Intervention|CD patient with air insufflation|The investigators aim to include 76 Crohn's disease patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
2442150|NCT03282786|Active Comparator|UC patient with CO2 insufflation|The investigators aim to include 76 ulcerative colitis patients (UC) undergoing colonoscopy in whom CO2 insufflation during endoscopy should be used.
2442151|NCT03282786|No Intervention|UC patient with air insufflation|The investigators aim to include 76 ulcerative colitis patients undergoing colonoscopy in whom air insufflation during endoscopy should be used.
3189608|NCT00778934|Experimental|1|Intimate Health Gel
3189609|NCT00778947|Active Comparator|1|
2442152|NCT03282773|Experimental|Deferred stent implantation|Drug-eluting stents are implanted 4-10 days after primary angiography and restoration of blood flow in left main coroanry artery in a secondary PCI
2442153|NCT03282773|Active Comparator|Immediate stent implantation|Drug-eluting stents are implanted immediately after primary angiography and restoration of blood flow in left main coroanry artery
2442154|NCT03282760|Experimental|Human Neural Stem Cells Suspension|Intraventricular injections of Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10,16 or 24 millions)
2442155|NCT03282734|Experimental|The smart rehab group|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for 4 weeks
2442156|NCT03282734|Active Comparator|The control group|Conventional home rehabilitation exercise education for 4 weeks
2442157|NCT03282721||redesigned|the commissure constructions of the cleft side were precised located, include the upper and lower inherent vermilion border, the interior commissure, the outline of commissure, the exterior commissure, the upper skin-mucosa junction and the lower skin-mucosa junction.
2442158|NCT03282721||classical|follows the simple-symmetry rule, the commissure of the healthy side is measured, and then the affected side is located accordingly.
2442159|NCT03282708|Experimental|Microbiome|"Caretakers of captive great apes. One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
2442160|NCT03282708|No Intervention|Anthropology|Caretakers of captive great apes. Two four-hour participant-observations of each caretaker's activities with captive great apes
2442161|NCT03282695||Surgery|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who reject ozone infiltration during waiting time.~These patients will receive standard pain treatment until the planned surgery."
2442162|NCT03282695||Ozone|"Patients on waiting list for surgery (by discectomy/microdiscectomy) who accept treatment by ozone infiltration during waiting time.~These patients will be treated primarily by ozone therapy: Infiltration of intradiscal O3/O2 + foraminal infiltration of O3/O2 + corticoid + anesthetic.~These patients will receive standard pain treatment until the planned surgery."
3189610|NCT00778947|Active Comparator|2|
3189611|NCT00778960|Experimental|Slow Breathing Group|
3189612|NCT00778960|Experimental|Meditation Group|
2442166|NCT03282669|Active Comparator|Intrathecal Morphine|Administration of 100µg intrathecal morphine to be given in the operative area.
2442167|NCT03282669|Active Comparator|Intravenous Hydromorphone|Administration of intravenous hydromorphone give IV pca in the post operative area.
2442169|NCT03282643|Experimental|Rivaroxaban 10mg daily|orally, 10 mg once daily for day1 and day 2 after femoral venepuncture
2442170|NCT03282643|Experimental|Rivaroxaban 20mg daily|orally, 10 mg twice daily for day1 and day 2 after femoral venepuncture
2442171|NCT03282643|Active Comparator|Low-molecular-weight heparin|subcutaneously, 0.4 ml once daily, before femoral venepuncture (day1) and after the day of femoral venepuncture (day 2)
2442172|NCT03282630|Experimental|active acupuncture|"Procedure/Surgery: active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
2442173|NCT03282630|Sham Comparator|sham acupuncture|Procedure/Surgery: Sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
2442174|NCT03282617|Experimental|locally recurrent or metastatic nasopharyngeal cancer|This cohort consists of patients with metastatic or locally recurrent NPC who have received systemic concurrent chemotherapy and have a favourable response of stable disease, partial or complete response. As up to 30% of these patients will suffer from relapse within 5 months of completion of chemotherapy, following definitive treatment, y, and treatment with CD137L-DC-EBV-VAX may activate T cell response against the tumor and prolong time to progression.
2442175|NCT03282617|Experimental|stage 4 locally advanced nasopharyngeal cancer|This cohort consists of patients with stage 4 locally advanced patients (N2 and N3 disease, and/or T4 disease) who are treated definitely with chemoradiation with curative intent, but who have a high risk of distant relapse. Treatment with CD137L-DC-EBV-VAX may activate antitumor T cell responses and prolong time to relapse.
2442176|NCT03282604||male|
2442177|NCT03282604||female|
3189613|NCT00778960|Experimental|Meditation and Slow Breathing Group|
3189614|NCT00778960|Placebo Comparator|Sitting Quietly Group|
2442180|NCT03282578|Active Comparator|Sternalock 360 sternal plating system|use of the SternaLock 360 system to close the sternum: 3 plates with 3 bands and measured screw length to engage but not penetrate the posterior sternal cortex, used to close the sternum
2442181|NCT03282578|Active Comparator|Sternal wires|"Stainless steel sternal wires applied in a figure of 8 configuration to close the sternum"
2442182|NCT03282565|Experimental|Functional Resistance Training|Participants will receive functional resistance training while walking on a treadmill 2-3 times a week for about 8 weeks.
2442183|NCT03282565|Sham Comparator|Control|Participants will while on a treadmill without an applied resistance 2-3 times a week for about 8 weeks.
2442184|NCT03282552|Active Comparator|Study Group 1|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 1, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The first Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=60L/min."
3189615|NCT00778973|Experimental|1|sertraline 100 mg tablets of Ranbaxy
3189616|NCT00778973|Active Comparator|2|Zoloft® 100 mg tablets
3189617|NCT00778986|Experimental|remote monitoring|group of patients that will be using the heart failure remote patient monitoring system in addition to the usual care they receive at the University Health Network Heart Failure Clinic
2442185|NCT03282552|Active Comparator|Study Group 2|"The intervention consists of the implementation of Nasal Cannula High Flow Oxygenation as an oxygen treatment at Study Group 2, whereas oxygen supply was provided via Venturi mask at the standard oxygen patients' treatment.~The second Study Group will include patients on Nasal Cannula High Flow Oxygenation with initial settings of FiO2=60% and gas flow=40L/min."
2442186|NCT03282552|No Intervention|Control group|"In the third group (control group) all patients will receive oxygen treatment according to the standard practice of our cardiac ICU department, i.e., Venturi mask with FiO2=60% and flow of 15L/min.~In this group all patients will receive the usual standard of care, with no other interventions included"
2442187|NCT03282539||LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents.
2442188|NCT03282539||LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
2442189|NCT03282526|Experimental|Whole body plethysmography|
2442190|NCT03282526|Active Comparator|spirometery|
2442191|NCT03282513|Experimental|Cohort 1A: Mild Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with mild hepatic impairment(Child-Pugh Score A.)"
2442192|NCT03282513|Active Comparator|Cohort 1B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
2442193|NCT03282513|Experimental|Cohort 2A: Moderate Hepatic Impairment|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with moderate hepatic impairment (Child-Pugh Score B.)"
2442194|NCT03282513|Active Comparator|Cohort 2B: Healthy Volunteers|"Drug: AG-120 (Ivosidenib)~A single 500 mg oral dose of AG-120 (Ivosidenib) in subjects with normal hepatic function."
2442195|NCT03282500|Experimental|Mindfulness Based Cognitive Therapy|In the experimental condition, participants will receive 12 sessions including the instruction of mindfulness skills and cognitive behavioral therapy.
2442196|NCT03282500|No Intervention|Psychoeducation on brain injury and treatment|In the control condition, participants will receive 12 sessions on the psychoeducation of brain injuries, outcomes, treatment, and support.
2442197|NCT03282487|No Intervention|Conventional immediate release hydrocortisone|
2442198|NCT03282487|Active Comparator|Modified release Hydrocortisone|12 weeks of modified release hydrocortisone (Plenadren)
2442199|NCT03282487|No Intervention|Healthy control group|Same research laboratory measurements performed in a healthy control group for comparison to patient group
2442200|NCT03282474|Experimental|Sofosbuvir|Sofosbuvir 400 MG film-coated tablet, oral administration of one tablet once daily for 24 weeks.
2442201|NCT03282461|Experimental|ABY-029|Between 3-9 patients will be administered ABY-029 as a single intravenous injection approximately 1-3 hours prior to surgery.
2442202|NCT03282448|Experimental|Family therapy|Adolescent mothers and their family members will receive a total of 10 weekly, 30-minute, video-based family therapy sessions.
2442203|NCT03282448|No Intervention|Historical comparison group|The Edinburgh Postnatal Depression Scale scores of adolescent mothers in the intervention group will be compared to those of adolescent mothers, who were previously enrolled in the home visiting programs, at the same time points.
2442204|NCT03282435|Experimental|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment
2442205|NCT03282435|Active Comparator|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive
2442206|NCT03282422|Experimental|Intervention group|Upper-limb splint and home-based protocol in specific tasks
2442207|NCT03282422|Active Comparator|Control group|Home-based protocol in specific tasks
2442208|NCT03282396|Experimental|Treatment (ibrutinib)|Participants receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for 5 years in the absence of disease progression or unacceptable toxicity.
2442209|NCT03282370|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2442210|NCT03282370|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
3189618|NCT00778986|No Intervention|control|group of patients provided with usual care at the University Health Network Heart Failure Clinic
3189619|NCT00779012|Experimental|Remicade|
2442213|NCT03282344|Experimental|participants ≥18 years old NKTR-214 and Nivolumab|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
2442214|NCT03282344|Experimental|participants 12 - 17 years old NKTR-214 0.006mg/kg and Nivo|NKTR-214 0.006mg/kg and nivolumab 360mg will be administered intravenously on day 1 of week 1 of cycle one and every 3 weeks (±3 days) thereafter.
2442215|NCT03282331|Experimental|standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2442216|NCT03282331|Other|High flow nasal oxygen therapy|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2442217|NCT03282331|Other|NonInvasive Ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
2442218|NCT03282318|Experimental|ASP6294|Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
2442219|NCT03282318|Placebo Comparator|Placebo|Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
2442220|NCT03282292|Experimental|Jugular|CVC insertion in the left or right internal jugular vein
2442221|NCT03282292|Active Comparator|Femoral|CVC insertion in the right or left femoral vein
2442222|NCT03282279||TVOR population|The data have been collected from the Humanitas Fertility Center' Department database (ART.it) from all transvaginal oocyte retrieval procedures performed between 1996 and October 2016.
3189620|NCT00779051|Experimental|1|Zolipidem 10mg tablets of Ranbaxy
3189621|NCT00779051|Active Comparator|2|Ambien® 10mg tablets
3189622|NCT00779064|Experimental|Arm 1|
3189623|NCT00779064|Experimental|Arm 2|
3189624|NCT00779077||cystic fibrosis|adults and children with cystic fibrosis
2442229|NCT03282214|Experimental|Self-management energy conservation|Thai women with breast cancer randomized to the group will receive four sessions approximately every three weeks with the PI. The women will be instructed on how to do a self-management energy conservation program.
2442230|NCT03282214|No Intervention|Control|The participants will be given two pamphlets (general issues about breast cancer and self-care activities for patients receiving chemotherapy) provided by the health care team at the study sites. The participants in the control group will be encouraged to maintain their current daily activities during the 12-week period The participants will wear a pedometer to record the number of steps which is one of the activity outcomes.
2442231|NCT03282201||Transfused|Patients in whom blood transfusion is used
2442232|NCT03282201||Nontransfused|Patients in whom blood transfusion is not used
2442233|NCT03282188|Experimental|GROUP A (Reovirus only)|Group A patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus is given. Group A patients will then receive only 1 cycle of treatment which will comprise of reovirus only at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days.
2442234|NCT03282188|Experimental|GROUP B (Reovirus plus GM-CSF)|Group B patients will receive an initial low 'immunisation' dose of intravenous reovirus (1x108 TCID50), to ensure that neutralising antibody (NAB) levels have risen by the time a full cycle of reovirus plus GM-CSF is given. Group B patients will be given a subcutaneous injection of GM-CSF (50mcg/day) for 3 days, followed by only 1 cycle of treatment which will comprise of reovirus at 1x1010 TCID50 as a 1-hour IV infusion on 2 consecutive days
2442235|NCT03282175|Experimental|Exercise|Participant in this group performed an acute resistance exercise protocol. The exercise protocol consisted of general warm-up of 10 min, followed by 8 exercises with 2 sets of 8 repetition and 1 min between sets.
2442236|NCT03282175|Experimental|Training|Participants allocated to intervention group initiated the progressive resistance training program of moderate intensity, with three weekly sessions throughout the 12-week treatment period.
2442237|NCT03282175|Active Comparator|Control group|Participants allocated to control group did not receive any placebo or treatment.
2442238|NCT03282162|Experimental|Oxytocin then placebo|Subjects will first receive oxytocin (24 IU).They then will receive placebo (24 IU) 2 weeks later.
2442239|NCT03282162|Experimental|Placebo then oxytocin|Subjects will first receive placebo (24 IU).They then will receive oxytocin (24 IU) 2 weeks later.
2442240|NCT03282149|Experimental|Dose 1|Lowest trial dose of XT-150
2442241|NCT03282149|Experimental|Dose 2|Second, escalating dose of XT-150
2442242|NCT03282149|Experimental|Dose 3|Third, escalating dose of XT-150
2442243|NCT03282149|Placebo Comparator|Saline placebo|2 of 8 participants in each cohort will randomly be assigned to placebo
2442244|NCT03282136|Active Comparator|incretin arm|T2DM with HF treated by CRTd participants will be assigned prospectively to an intervention (incretin therapy plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
2442245|NCT03282136|Placebo Comparator|conventional hypoglycemic drug arm|T2DM with HF treated by CRTd participants will be assigned prospectively to placebo comparator (placebo plus conventional hypoglycemic drug therapy) according to study protocol to evaluate the effect of the drug on cardiac deaths, all cause deaths, and hospital admission for heart failure.
3189625|NCT00779090|Experimental|Group A_RM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
2442247|NCT03282110|Experimental|ta-VNS & Electro-acupuncture|"Device:ta-VNS(transcutaneous vagus nerve stimulation):2 times per day,5 consecutive days per week for two months~Other:Electro-acupuncture:3 times per week, once every other day for two months"
2442248|NCT03282110|Active Comparator|Citalopram|citalopram for oral administration; 10mg for the first 1-3 days, 20mg for the following 4-7 days；40mg for the left days within two months
2442249|NCT03282097|Experimental|Mammogram decision aid|Will be mailed the DECAD decision aid before their next PCP visit in order to better inform their decision to continue or stop mammography.
2442250|NCT03282097|Active Comparator|Home safety guide|The home safety guide is a two-page paper pamphlet developed by the American Geriatrics Society Foundation for Health in Aging. It provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards. We selected the home safety guide to account for the attention given to the intervention group but not to provide information that would bias the control group away from talking about mammography with the patient's PCP.
2442251|NCT03282084||Unproven GERD|Subjects with no prior testing, normal prior EGD or prior LA Grade A esophagitis
2442252|NCT03282084||Proven GERD|LA Grade B-D esophagitis, long-segment Barrett's, prior positive pH study
3189626|NCT00779090|No Intervention|Group A_NRM|Patients with FRC after open endotracheal suctioning of more than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
3189627|NCT00779090|Experimental|Group B_RM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive an alveolar recruitment manoeuvre.
2442255|NCT03282058|Experimental|Silastic Stent|"At the time of surgery, if the patient is identified in the silastic stent arm, dressing of the septal donor site with silastic stents will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely."
2442256|NCT03282058|No Intervention|No Stent|"At the time of surgery, if the patient is identified in the no silastic stent arm, dressing of the septal donor site without the stent will be performed after reconstruction has been achieved and the surgeon feels that the surgery proceeded routinely - this is currently the standard of care."
3189628|NCT00779090|No Intervention|Group B_NRM|Patients with FRC after open endotracheal suctioning of less than 94% of baseline randomized to receive no alveolar recruitment manoeuvre.
3189629|NCT00779129|Experimental|Single Arm|Caelyx 35 mg/m2 and Cyclophosphamide 600 mg/m2
2442257|NCT03282045|Experimental|Lysobact Complete Sprey|"Lysobact Complete Sprey~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times and one press of the spray pump release 0.20 mL of the solution containing 4 mg lysozyme, 0.3 mg cetylpyridine and 0.1 mg lidocaine hydrochloride."
2442258|NCT03282045|Active Comparator|Tantum Verde® Spray|"Tantum Verde® Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 4 to 8 doses, 2 to 6 times a day. One press means one dose."
2442259|NCT03282045|Active Comparator|Pharyngal® Oromucosal Spray|"Pharyngal® Oromucosal Spray~Route of administration: Oromucosal spray, sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 2 to 4 doses, repeated 6 to 10 times per day. One press of the pump (one dose) releases 0.14 ml of the solution with 0.28 mg chlorhexidine digluconate and 0.07 mg of lidocaine hydrochloride."
2442260|NCT03282045|Placebo Comparator|Placebo|"Route of administration: Sprayed directly toward the affected area with the applicator while the mouth is wide open.~Dose regimen: Sprayed 3 to 6 doses a day. For a single dose, spraying pump should be pressed 5 times."
2442261|NCT03282032|Experimental|One-lung ventilation|Before surgical incision, 2-min of OLV followed by 2-min of TLV (1 cycle) is performed for 5 cycles.
2442262|NCT03282032|No Intervention|Two-lung ventilation|Maintain two-lung ventilation until surgical incision
2442263|NCT03282019|Experimental|Arm A(myAIRVO2® + HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) plus nocturnal high-flow nasal cannula therapy with the myAIRVO2 within 52weeks.
2442264|NCT03282019|Active Comparator|Arm B(HOT)|Subjects receive following protocol treatment; Home oxygen therapy (HOT) only within 52weeks.
2442265|NCT03282006|Experimental|Pivmecillinam|Patients treated with pivmecillinam
2442266|NCT03281993||CPAP-AT|After 2 hours from I-AT was performed the alternative AT by CPAP ventilation mode. Before CPAP-AT and 10 minutes after blood samples for arterial blood gases (ABG) were collected. If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%, CPAP-AT was aborterd.
2442267|NCT03281980|Experimental|Intervention (UCT+HE+PS)|The participants of this arm will receive UCT and HE along with psychosocial stimulation (PS)
2442268|NCT03281980|Sham Comparator|Government Intervention (UCT+HE)|The participants of this arm will receive only UCT and HE
2442269|NCT03281980|No Intervention|Comparison|
2442270|NCT03281967|Other|Minimally Invasive Ponto Surgery|Surgical method for installation of a bone anchored hearing system for hearing rehabilitation
2442271|NCT03281954|Placebo Comparator|Placebo|IV infusion once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
2442272|NCT03281954|Experimental|Atezolizumab|IV infusion, 1200mg, once every 3 weeks for 4 doses (Cycle 1), once every 3 weeks for 4 doses (Cycle 2) and once every 3 weeks after surgery for 1 year after first dose
2442273|NCT03281941|Other|Patients without BT|
2442274|NCT03281941|Other|Post BT|
2442275|NCT03281928|Experimental|Low Sodium plus Potassium Citrate|
2442276|NCT03281928|Placebo Comparator|Low Sodium plus placebo|
2442277|NCT03281928|Experimental|High Sodium plus Potassium Citrate|
2442278|NCT03281928|Placebo Comparator|High Sodium plus placebo|
2442279|NCT03281915||high inguinal approch|Patients undergoing high inguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
2442280|NCT03281915||subinguinal approch|Patients undergoing subinguinal varicocelectomy with normal pre operative semen parameters, post operative semen analysis parameters will be recorded
2442281|NCT03281902||Ancillary-Correlative (genetic profile analysis)|Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
2442282|NCT03281889|Experimental|Proton Radiotherapy|"Patients will be treated with Proton Beam once daily 5 days per week.~Doses will be prescribed such that maximum possible coverage is achieved"
3189630|NCT00779168|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive white button mushroom extract PO twice daily on days 1-28. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3189631|NCT00779181|Experimental|ADX415 (high dose)|A high dose of ADX415
2442285|NCT03281837|Experimental|Group 1: Hymovis plus Physical Exercise Program (PEP)|Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)
2442286|NCT03281837|Other|Group 2: Physical Exercise Program (PEP) alone alone|Specified designed Physical Exercise Program (PEP) not combined with any other intervention
2442287|NCT03281837|Other|Group 3: Cross-Over group|Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.
2442288|NCT03281824|Experimental|ALT-P7|"8 groups: 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.2 mg/kg, 4.5 mg/kg, 4.8 mg/kg,~Administration: Day 1 of each 3-week cycle"
2442289|NCT03281811|Experimental|Treatment (aminolevulinic acid hydrochloride, PDT, RT)|Patients receive aminolevulinic acid hydrochloride topically and undergo photodynamic therapy on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning at week 24, patients undergo radiation therapy daily for 4 weeks.
2442290|NCT03281798|Experimental|Fetuses with LUTO|Performance of ultrasound-guided, percutaneous fetal cystoscopy with the Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set
2442291|NCT03281785|Active Comparator|Pressure controlled mandatory ventilation mode (P-CMV)|Patients will be ventilated using pressure controlled mandatory ventilation mode
2442324|NCT03281473|Experimental|Arms B|Strategy 2 - Washout period - Strategy 1
3189632|NCT00779181|Experimental|ADX415 (mid level dose)|A mid level dose of ADX415
3189633|NCT00779181|Experimental|ADX415 (low dose)|A low dose of ADX415
2442292|NCT03281785|Active Comparator|Pressure synchronized intermittent mandatory ventilation|Patients will be ventilated using pressure synchronized intermittent mandatory ventilation mode (P-SIMV)
2442293|NCT03281785|Active Comparator|Pressure support mode (PS)|Patents will be ventilated with pressure support mode (PS)
2442294|NCT03281772||Provider|Consented providers with prescriptive privileges will use the clinical decision software - provider portal to manage study patients with uncontrolled hypertension for 6 months. Participants will conduct a baseline face-to-face visit with study patients, access the program daily to check for patient high blood pressure alerts and lab results, conduct virtual visits as needed every 7 - 10 days, track the time and number of patients managed using the program and complete two questionnaires.
2442295|NCT03281772||Patients|In a 6 month period, participants with uncontrolled hypertension will attend an initial face-to-face visit with a study provider, monitor their blood pressures 3x/week at home, enter their blood pressure readings manually or digitally into the clinical decision software - patient portal, get up to 4 blood draws, participate into up to 3 virtual visits monthly, and complete a questionnaire.
2442296|NCT03281759|Active Comparator|Active Coil Helmet|The patients will undergo 18 sessions (627 nm, 70 mW/cm2, 10 J/cm2) at four points of the frontal and parietal region for 30 s each, totaling 120 s three times per week for 6 weeks, lasting 30 minutes of transcranial LED stimulation.
2442297|NCT03281759|Placebo Comparator|Inactive Coil Helmet|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions.
2442298|NCT03281746|Active Comparator|Group I (standard prevention education)|Patients undergo dental examination at baseline and then receive standard prevention education at diagnosis discussing the effects of prolonged neutropenia on oral hygiene, importance of a regular oral hygiene regimen, and the long term clinical outcomes of oncologic patients. Patients also receive fliers with pictograms describing proper brushing, use of mouth wash, and common oral complications during therapy, as well as a bottle and prescription for chlorhexidine gluconate 0.12% rinse.
2442299|NCT03281746|Experimental|Group II (standard and one-on-one education, consultation)|Patients undergo dental examination and receive standard prevention education as in Group I. Patients also receive one-on-one prevention education and counseling with the physician and pediatric dental resident.
3151341|NCT00223717|Experimental|1: Active drug or intervention|Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt, aliskiren, local heat stress
2442301|NCT03281694|Other|Nicotine - AVL-3288 Interaction Study|Over four different test days, all participants will be tested with Placebo, Nicotine, AVL-3288, and Nicotine + AVL-3288, in a counterbalanced sequence.
2442302|NCT03281681|Experimental|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
2442304|NCT03281655|Experimental|Vulvovaginal atrophy|Postmenopausal sexually active women affected by vulvovaginal atrophy undergoing treatment (15 days, 1 application per day) with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
2442305|NCT03281629|Active Comparator|Active TMS stimulation|Real active rTMS stimulation.
2442306|NCT03281629|Sham Comparator|Sham TMS stimulation|Sham repetitive TMS stimulation.
2442307|NCT03281616|Active Comparator|Diet and Physical Activity Recording|
2442308|NCT03281616|Active Comparator|Diet and No Physical Activity Recording|
2442309|NCT03281603|Experimental|CAD/CAM complete denture|"First intervention: Constructing complete denture by CAD/CAM technology utilizing milling technique.~Second intervention:Constructing complete denture CAD/CAM technology utilizing 3D printing technique"
2442310|NCT03281603|Active Comparator|Conventional complete denture|Constructing complete denture by conventional technique of denture processing
3151342|NCT00223717|Placebo Comparator|2: Placebo|placebo pill or patch
3151343|NCT00223730|Experimental|citrulline|Patients randomized to receive oral citrulline at 3.8 gm/m2 in split BID dosing
2442317|NCT03281564||Essure®|Patients with laparoscopic removal of Essure®
2442318|NCT03281551|Experimental|PZ01 CAR-T Cells|This is a phase I study. Patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma are eligible for enrollment.
3151344|NCT00223730|Placebo Comparator|Placebo|Patients randomized to receive oral diluent for citrulline in BID dosing
2442320|NCT03281499|Experimental|da Vinci Surgical System Model IS4000|Transoral robotic surgery, followed by tailored radiotherapy
2442321|NCT03281486|Experimental|HA formulation Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2442322|NCT03281486|Placebo Comparator|Placebo Oral Spray|Subjects will be instructed to mouth spray with 0.3 ml ( 2 sprays to the mouth) of their assigned mouth spray, 2 times daily (morning and evening), using only the assigned mouth spray provided for the 4 week duration of the study.
2442323|NCT03281473|Experimental|Arms A|Strategy 1 - Washout period - Strategy 2
3151345|NCT00223743|Experimental|Zonisamide|Zonisamide administration and tremor assessment to assess efficacy in reducing essential tremor
3151346|NCT00223756|Experimental|Arm 1|interdisciplinary, outpatient blind rehabilitation
3151347|NCT00223756|No Intervention|Arm 2|usual care
3151348|NCT00223782|Other|1|
3151349|NCT00223834|Other|1|Single session orientation to available services
3151350|NCT00223847|Other|1|
3151351|NCT00223860|Other|1|
3151352|NCT00223899|Experimental|A|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
3151353|NCT00223912|Other|1|Lower-extremity functional electrical stimulation
3151354|NCT00223925|Placebo Comparator|Placebo|
2442325|NCT03281460|Experimental|with in-bag morcellation|with More-cell-Safe AMI bag morcellation
2442326|NCT03281460|Active Comparator|without any morcellation bag|without any morcellation bag
2442327|NCT03281447|Experimental|Nurse navigation|Coherent navigation and support from a family-centred viewpoint throughout the cancer trajectory, despite the individual patient's affiliation to any department.
2442328|NCT03281447|Active Comparator|Current care coordination|Department-specific coordination and answers to questions from a patient-centred viewpoint.
2442329|NCT03281434|Active Comparator|Collagen peptide|Supplement will be delivered twice daily (30g per supplement) of hydrolyzed collagen peptides
2442330|NCT03281434|Experimental|Whey protein|Supplement will be delivered twice daily (30g per supplement) of whey protein isolate
2442331|NCT03281421|Experimental|Group from posterior to anterior (GPA)|Participants in group GPA will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from posterior to anterior. The physiotherapist will be positioned in front the participant's ankle, and a belt will be posicioned above the participant's malleolus and around physiotherapist's pelvis. The therapist applies with belt a anterior slip sustained in the tibia of the participant, while the talus are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
2442332|NCT03281421|Active Comparator|Group from anterior to posterior (GAP)|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense from anterior to posterior. The physiotherapist will be positioned behind the participant's ankle. An belt will be posicioned above the participant's malleolus and around physiotherapist's trunk. The therapist applies with belt a posterior slip sustained in the tibia of the participant, while the heel and rearfoot are secured with the space between the thumb and the second finger of the hand of both hands on the physiotherapist´s. The participant will be instructed to perform a slow dorsiflexion movement at its maximum amplitude and hold five seconds in that position, returning to the initial position at the end of the five seconds.
2442333|NCT03281421|Active Comparator|Group GPA-AP|Participants in group GAP will receive a manual therapy intervention, through the technique of mobilization with movement in the ankle joint, with a slip sense both from posterior to anterior and anterior to posterior. In the group GPA-AP, will be apllied both the procedure described for the group GPA as for the group GAP. To standardized the sequence of mobilization, the first two sets will be performed with slip sense from posterior to anterior, and the last two sets will be performede with slip sense from anterior to posterior.
2442334|NCT03281408||Suspected OSA Patients Undergoing Knee or Hip Arthroplasty|These 100 subjects will be cared for and monitored in hospital following current hospital protocol. No change or intervention is to be administered. Troponin testing will be done post-op with other routine blood work.
2442335|NCT03281395||Cerebral aneurysm surgery with RVP|During surgery patients allocated to this group will undergo RVP. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
2442336|NCT03281395||Craniotomy without RVP|No rapid ventricular pacing is applied during surgery. Subjects receive Magnetic Resonance Imaging or Computed Tomography as standard of care, pre-and postoperatively. To screen for induced micro-infarcts, the contralateral hemisphere(contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels are determinated preoperatively and 24 hours postoperatively by blood sample as standard of care. Maximum cTnl level and cTnl level 24 hours will be compared.
2442337|NCT03281382|Experimental|Investigational Arm|Patients will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at one of three dose levels. Two days later, subjects will be administered (orally) 7 days of 5-fluorocytosine (5-FC) prodrug therapy. Fourteen days after completion of the 5-FC prodrug therapy course, subjects will be administered chemotherapy at the discretion of the treating physician. On an optional basis, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify the intensity, persistence, and biodistribution of HSV-1 TK gene expression in the pancreas.
3151355|NCT00223925|Experimental|Maribavir (100 mg twice daily)|
3151356|NCT00223925|Experimental|Maribavir (400 mg twice daily)|
3151357|NCT00223925|Experimental|Maribavir (400 mg once daily)|
3151358|NCT00223938|Active Comparator|1|Oral Iron
3151359|NCT00223938|Experimental|2|sodium ferric gluconate
3151360|NCT00223938|Experimental|3|sodium ferric gluconate
2443008|NCT03276884|Active Comparator|Control Infant Formula|Infant formula powder to be fed ad libitum
3151361|NCT00223964|Experimental|dose level 1|1.5 mg/kg
3151362|NCT00223964|Experimental|dose level 2|3 mg/kg
3151363|NCT00224081|Experimental|Ferric gluconate|
3151364|NCT00224081|No Intervention|standard of care|
3151365|NCT00224094|Experimental|Sequence A|Oral ERT then transdermal ERT
3151366|NCT00224094|Experimental|Sequence B|Transdermal ERT then oral ERT
3151367|NCT00224198||Lung Disease|All study individuals will be males or females that are 18 years or older and are able to provide informed consent and have been diagnosed with lung disease.
3151368|NCT00224211||I|Stable premature infants
3151369|NCT00224237||A|Participants will be self-identified, adult Latino men and women from the community setting. The sample will comprise of a convenience sample from community-based organizations, including persons of Mexican, Puerto Rican, Cuban, Dominican, Central American, South American, or other Spanish-speaking culture.
3151370|NCT00224419|Active Comparator|1 - CBT Counseling|Participants in this arm received a tailored CBT (TCBT) intervention that included: a written self-help guide, feedback about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session.
3189634|NCT00779181|Placebo Comparator|Placebo|
3189635|NCT00779194|Experimental|1|SLE subjects receiving the study drug, Rapamune.
3189636|NCT00779194|No Intervention|2|Healthy control group donating blood for the main study.
3151371|NCT00224419|Experimental|2 - Counseling + NRT|Women in this arm received the TCBT described in Arm 1, plus their choice of NRT. To minimize fetal exposure to nicotine for women in the TCBT+NRT arm, the dose of NRT are customized to the woman's current level of smoking. Women who smoke 5-10 cigarettes a day will be given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smokes per day. Those who smoke 11 cigarettes or more per day will be given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smokes per day, not to exceed 15 lozenges or pieces of gum per day.
3151372|NCT00224445|Experimental|Truvada + Ritonavir-boosted Atazanavir|All participants received Truvada plus ritonavir-boosted atazanavir
3151373|NCT00224471|Experimental|Group A|
3151374|NCT00224471|Experimental|Group B|
3151375|NCT00224471|Experimental|Group C|
3151376|NCT00224523|Experimental|Arm 1|
2442350|NCT03281356|Experimental|Intervention Group|
2442351|NCT03281343|Experimental|MI-NAV|A study therapist will deliver a motivational interviewing session with participants while they are incarcerated and serve as a role of patient navigator post-release.
2442352|NCT03281343|Active Comparator|Standard of Care (SOC)|Approximates care currently provided at the prison.
2442353|NCT03281330||persons with Multiple Sclerosis|
2442354|NCT03281330||Healthy controls|
3189637|NCT00779194|No Intervention|3|SLE subjects donating blood for Genetic sub-study
3189638|NCT00779194|No Intervention|4|Healthy control subjects donating blood for the Genetic sub-study
2442357|NCT03281291||R012-20 Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and Month 20 of study NCT03276962.
2442358|NCT03281291||R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 Month 14, Month 26, Month 38 of study NCT03276962.
2442359|NCT03281291||Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38 of study NCT03276962.
2442360|NCT03281291||Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32 of study NCT03276962.
2442361|NCT03281291||Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2 of study NCT03276962.
2442362|NCT03281239|Experimental|welder/airport agent|No drug and no placebo were used in this study.
2442363|NCT03281226|Active Comparator|RIPE (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (combined fixed dose tablet according to the weight) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months.
2442364|NCT03281226|Experimental|RIPE+NAC (2m) and RI (4m)|The patients enrolled in this arm will receive a treatment regimen with an intensive phase lasting two months of rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (combined fixed dose tablet according to the weight) plus N-acetylcysteine (NAC) and a continuation with rifampicin 150mg and isoniazid 75mg (combined fixed dose tablet according to the weight) for 4 months. The NAC is administered by means of effervescent tablet 1200 mg (two sachets of 600 mg) to be diluted in 200ml of water and administered in a 12-hour interval.
2442365|NCT03281213||Female|
2442366|NCT03281213||Male|
2442372|NCT03281187|Experimental|Nasotestt 5 mg|Participants randomized to this arm must administer one packet of Nasotestt 5 mg in each nostril (3 times a day - T.I.D) for 60 days.
2442373|NCT03281187|Active Comparator|Androgel 50 mg|Participants randomized to this arm must administer one packet of Androgel 50 mg applied once daily to skin of shoulder for 60 days.
2442374|NCT03281187|Placebo Comparator|Androgel Placebo|Participants must administer one packet of Androgel placebo applied once daily to skin of shoulder in addition to an experimental drug for 60 days.
2442375|NCT03281187|Placebo Comparator|Nasotestt Placebo|Participants must administer one packet of Nasotestt Placebo in each nostril (3 times a day - T.I.D) in addition to an experimental drug for 60 days.
2442376|NCT03281174||EV71 vaccine group|The group which received two doses EV71 vaccine (400U/0.5ml) on day 0,28 in phase III clinical trial.
2442377|NCT03281174||Placebo group|The group which received two doses placebo (0U/0.5ml) on day 0,28 in phase III clinical trial.
2442378|NCT03281161|Experimental|Sun Safe Workplaces Program|A follow up to the previous study that promoted the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers to promote policy adoption, promotional materials for sun safety, and in-person training of outdoor workers by research staff over two years. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of the SSW intervention completed 2 years after the initial intervention.
2442379|NCT03281161|Active Comparator|Attention Control|A follow up to the previous study that promoted occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff. The follow up program consists of an analysis of sun safe practices by employees and an economic evaluation of SSW completed 2 years after the initial program contact.
2442380|NCT03281148|Experimental|Computer guided implant insertion group|According to the allocation, the experimental group will receive implants immediately placed in extraction sockets using CAD/CAM surgical guides.
2442381|NCT03281148|Active Comparator|Free hand implant insertion group|According to the allocation, the control group will receive implants immediately placed in extraction sockets using traditional free hand technique.
3151377|NCT00224575|Experimental|1|Diagnosis strategy and subsequent therapeutic reassessment All patients are in that arms. They all receive the diagnosis reassessment strategy.
3151378|NCT00224640|Experimental|1|Iron chelating intervention
3151379|NCT00224718|Active Comparator|1|surgery - open repair
3151380|NCT00224718|Experimental|2|endovascular procedure
3151381|NCT00224744|Active Comparator|Classical surgical Inguinal curage|Classical Inguinal curage
3151382|NCT00224744|Experimental|Ultracision surgical Inguinal curage|
3151383|NCT00224757|Active Comparator|Aspirin|Ascal 100mg once daily
3151384|NCT00224757|Active Comparator|Coumarin derivates|Acenocoumarol or fenprocoumon
2442382|NCT03281135|Other|HPV testing|This is an experimental arm for the primary outcome, 'adherence to the procedures'. In this group self sampling will be done using the Evalyn brush for HPV testing.
2442383|NCT03281135|No Intervention|Standard care: VIA screening|Control Arm, in which women's are invited to cervical cancer screening as per standard Ethiopian cervical cancer prevention and control guideline. Uptake of screening in this group will be compared with the HPV testing arm group to test for significant differences in adherence.
2442384|NCT03281122|Experimental|Arm A|Specified dose on specified days
2442385|NCT03281122|Placebo Comparator|Arm B|Specified dose on specified days
2442386|NCT03281096|Experimental|Berberine hydrochloride group|Berberine hydrochloride 300mg tablet by mouth, two times per day for 3 years
2442387|NCT03281096|Placebo Comparator|Placebo|identical-appearing placebo 300mg tablet by mouth, two times per day for 3 years
2442388|NCT03281083|Experimental|Levothyroxine (LT4)|Levothyroxine sodium (LT4) dose titrated at TSH 0.34 - 1.70mIU/L during maximum 12 weeks, followed by a maintenance phase of 16 weeks using the dose necessary for titration.
3151385|NCT00224783|Active Comparator|CAIV-T|CAIV-T contains 3 cold-adapted influenza virus strains (A/H1N1, A/H3N2, B) concentrated and refined by centrifugal separation from the chorioallantoic membrane of specific pathogen-free (SPF) eggs, containing SPG (sucrose-phosphate-glutamate), arginine, and acid hydrolyzed pig gelatin as stabilizers. Subjects were inoculated once with about 0.1 mL of investigational vaccine in each nasal cavity (a total of 0.2 mL) using a nebulizer.
3189639|NCT00779207|Experimental|1|weight loss
2442392|NCT03281044|Experimental|FMT group|Patient group receiving active FMT capsules
2442393|NCT03281044|Placebo Comparator|Placebo group|Patient group receiving placebo capsules
2442395|NCT03281018|Experimental|Interventional arm|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session (experimental arm): The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
2442396|NCT03281018|No Intervention|Control (CAT)|CAT is performed in routine care for all patients after the announcement of the illness by a trained nurse, if possible on the same day as the consultation or before the consultation of anesthesia. This is an interview of approximately 45 minutes to listen to the patient, to answer her questions and to re-explain the information delivered to her. The patient will tackle the history of the disease and then the treatment, this time dedicated evolves according to the desire of the patient and her ability to accept the disease. The patient can express her feelings, then the family circle is evoked talking about the resource persons and the future. The purpose of this interview is to obtain the autonomy of the patient by the setting up of supportive care
2442397|NCT03281005||Retinitis pigmentosa in Part 1A|Retinitis pigmentosa patients with severe visual impairment
2442398|NCT03281005||Retinitis pigmentosa in Part 1B|Retinitis pigmentosa patients with severe visual impairment
2442399|NCT03281005||Retinitis pigmentosa in Part 2|Retinitis pigmentosa patients with severe visual impairment
2442400|NCT03281005||Healthy volunteers in Part 3|Healthy volunteers
2442401|NCT03280979|Experimental|study group1|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of MTX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
2442402|NCT03280979|Experimental|study group2|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
2442403|NCT03280940||Dolutegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a dolutegravir containing regimen
2442404|NCT03280940||Raltegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a raltegravir containing regimen
2442405|NCT03280940||Elvitegravir treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a elvitegravir containing regimen
2442406|NCT03280940||Protease inhibitors treatment group|Naïve patients having documented HIV-1 infection and starting their first antiretroviral treatment with a protease inhibitors containing regimen
2442407|NCT03280927|Experimental|Jublia®|
2442408|NCT03280914||CPAP group|Automatic Continuous Positive Airway Pressure treatment and usual care
2442409|NCT03280914||Usual care group|Usual care without Continuous Positive Airway Pressure treatment
2442410|NCT03280901|Experimental|Standard HD|HD with constant temperature of 37°C, MRI scans of the heart, kidneys and brain during HD sessions
2442411|NCT03280901|Experimental|Thermocontrolled HD|HD applying the Blood Temperature Monitor (BTM), MRI scans of the heart, kidneys and brain during HD sessions
2442412|NCT03280875|Experimental|healthy volunteers|
2442413|NCT03280862|Active Comparator|Control|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned preferentially in a posterolateral, non-apical position
2442414|NCT03280862|Experimental|Intervention|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator with the LV lead positioned according to the latest electrical activation in the CS
2442415|NCT03280849|Experimental|Patient with bilaminar chitosan implant|A 65 year old woman, right handed, started with progressive bilateral visual loss in her temporal field, over 10 months, she underwent an MRI and it was found a sellar lesion that compressed the optic chiasm, an endoscopic endonasal transsphenoidal surgery was done for the resection of the lesion, using a novel bilaminar chitosan scaffold to assist the closure of the sellar floor.
2442416|NCT03280836|No Intervention|Control|We ask that participants in the control arm do not start an exercise program.
2442662|NCT03279211|Other|Protein-free|No protein added in the test-meal, only 500 ml of water + flavour/sugar In order to determine the endogenous loss of amino acid in the digesta samples.
2442417|NCT03280836|Experimental|Exercise|"Participants in the experimental arm will be asked to complete the exercise intervention with 80% or greater adherence.~Participants will work towards the goal of 75 or more minutes a week of moderate to vigorous exercise. Participants are provided an exercise toolkit and directed on exercise progression based on personal fitness level."
2442418|NCT03280810|Experimental|Movement group|patients with schizophrenia (experimental group) have psycho-corporal training once a week, during 1 hour and a half for a period of two months
2442419|NCT03280810|No Intervention|Control group|No intervervention : patients with schizophrenia (comparator group) who don't have psycho-corporal training
2442420|NCT03280797|Other|Control|
2442421|NCT03280797|Other|Rheumatoid arthritis patients|
2442422|NCT03280771|Experimental|Hope Soap group|Children in treatment households received a bi-monthly delivery of HOPE SOAP©, a colourful, translucent bar of soap with a toy embedded in its centre
2442423|NCT03280771|Active Comparator|Control group|Children in control households received a colourful, translucent bar or soap with the toy alongside it.
2442424|NCT03280758|Experimental|Muscle strengthening group|Participants will be required to perform muscle strengthening exercises 3 hours per week. Close kinetic chain exercises will be performed progressively according to the ACSM guidelines over the 4-month intervention period. The exercise intervention will be conducted by an experienced sports trainer.
2442425|NCT03280758|No Intervention|Control group|No exercise training.
2442426|NCT03280745|Active Comparator|7.3% NaCl (intervention)|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl NaCl by infusion pump over 60 minutes.
2442427|NCT03280745|Active Comparator|0.9% NaCl (comparator)|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
2442428|NCT03280732|Experimental|Lung Ultrasound|Bedside lung ultrasound will be performed by a paediatrician with specific LUS expertise and blinded to clinical and radiological data.
2442429|NCT03280719|Active Comparator|Supine Hypofractionated Radiotherapy|"Supine Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in supine position with a median dose of 15 x 2.67 Gy prescribed to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
2442430|NCT03280719|Experimental|Prone Hypofractionated Radiotherapy|"Prone Radiotherapy and Hypofractionation:~Whole breast + regional nodal irradiation in prone position with a 15 x 2.67 Gy dose prescription to the whole breast and nodal regions. Median dose of the simultaneously integrated boost is 3.12 Gy per fraction."
2442431|NCT03280719|Experimental|Supine Accelerated Radiotherapy|"Supine Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in supine position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
2442432|NCT03280719|Experimental|Prone Accelerated Radiotherapy|"Prone Radiotherapy and Acceleration:~Whole breast + regional nodal irradiation in prone position with a median dose of 5 x 5.7 Gy to the whole breast. Lymph node regions receive a median dose of 5 x 5.4 Gy. Median dose of the simultaneously integrated boost is 6.2 Gy per fraction."
2442433|NCT03280706|Experimental|Maltodextrin|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of maltodextrin 200kcal, no protein or fat, 49,5g of carbohydrate.
2442434|NCT03280706|Active Comparator|Orange Juice|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of orange juice, 200kcal, 2,82g of protein, 0,67g of fat, 47,08g of carbohydrate.
2442435|NCT03280706|Active Comparator|Coffee with milk|Fasted pregnant woman with an empty stomach (assessed by ultrasound) will drink 500ml of coffee with milk, 200kcal, 10,6g of protein, 10,73g of fat, 14,9g of carbohydrate.
2442436|NCT03280680|Experimental|Female+male group sessions|
2442437|NCT03280680|Experimental|Female group sessions|
2442438|NCT03280680|Other|No group sessions|
2442439|NCT03280667|Experimental|Pembrolizumab plus Denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D, continued until disease progression or prohibitive toxicity
2442440|NCT03280654||Group 1:VAI levels <7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 Group 1 was defined as VAI levels <7,55
2442441|NCT03280654||group 2:VAI levels >=7,55|7,55 value was calculated as cut-off level for VAI by ROC analyse and area under curve was calculated as 0,487 group 2 was defined as VAI levels >=7,55
2442442|NCT03280641||Dabigatran Group|Patiets with atrial fibrillation received dabigatran (110mg, bid).
2442443|NCT03280641||Warfarin Group|Patiets with atrial fibrillation received warfarin (110mg, bid).The target international normalized ratio (INR):1.6-3.0
2442444|NCT03280628|Active Comparator|Absorbable Sutures|30 patients will have their laceration closed with sutures that absorb on their own and do not need to be removed.
2442445|NCT03280628|Experimental|Steri-Strips|"30 patients will have their laceration closed with a special medical tape called Steri-Strips."
2442446|NCT03280628|Experimental|Dermabond|"30 patients will have their laceration closed with a special skin glue called Steri-Strips."
3189640|NCT00779207|Experimental|2|Weight loss and exercise
3189641|NCT00779220|Placebo Comparator|1|
2442449|NCT03280602|Active Comparator|Tension band wiring (TBW)|TBW following the AO principles with 2 x 1.6 mm K-wires and wire wire cerclage.
2442450|NCT03280602|Active Comparator|Plate fixation|Plate fixation with Syntes VA-LCP olecranon plates 2.7/3.5
2442451|NCT03280589|Active Comparator|Sitting Quietly|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. Instructions will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. The total duration of this session will be approximately 40 minutes.
2442663|NCT03279198|Placebo Comparator|Usual Care (UC)|The usual care group received usual care that varies dependent upon the practice setting.
3189642|NCT00779220|Experimental|2|
3189643|NCT00779220|Experimental|3|
3189644|NCT00779220|Experimental|4:|
2442452|NCT03280589|Experimental|Deep Breathing Self Paced|Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still, and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
2442453|NCT03280589|Experimental|Deep Breathing Externally paced|Participants will have an instructional video with auditory queues prompting them to inhale and exhale at 6 bpm (approximately 4 seconds between inhale and exhale). Participants will be instructed to sit comfortably in a chair with both feet flat on the floor, hands on their lap or thighs, rest their eyes (closed or slightly open gazed cast down), release tension in the body, remain still and allow the chair to support them. There will be 4 five-minute sessions with a one-minute break in between to allow the participant to rest, adjust posture, and answer any questions. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. The total duration of this session will be approximately 40 minutes.
2442454|NCT03280589|Experimental|Sheetali/Sheetkali, self-paced:|Participant will follow on-screen instructions for Sheetali/Sheetkari with shaped lips/mouth as indicated (i.e., inhaling through the mouth held specific to each practice and exhaling through nostrils), fully filling and emptying the lungs with each breath. In Sheetali, the tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one minute rest followed by Sheetkari. In Sheetkari, the tongue is not rolled into a tube; instead, it is rolled up to touch the upper palate. The teeth are then exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary. The total duration of this session will be approximately 40 minutes.
2442455|NCT03280589|Experimental|Sheetali/Sheetkari, externally-paced|The participant will follow on screen instruction for Sheetali/Sheetkari with shaped lips/mouth as indicated, fully filling and emptying the lungs with each breath. The tongue is allowed to protrude from the mouth at a comfortable distance and rolled into a tube. Following 10 minutes of Sheetali practice, participants will have a one-minute rest before continuing. In Sheetkari the teeth are exposed and the lips are kept apart for inhalation and the mouth is closed, tongue is relaxed, and exhalation occurs through the nose. Instruction will be displayed to them with on-screen video segments while the study personnel helps explains the steps, answers questions, and monitors adherence. There will be an auditory queue to prompt the participant to breathe in and out. Study personnel will monitor their posture and breathing rate and pause the recording if additional coaching is necessary.The total duration of this session will be approximately 40 minutes.
2442456|NCT03280576||Sepsis|Patients with sepsis
2442457|NCT03280576||Cardiac Surgery|Patients undergoing cardiac surgery
2442458|NCT03280576||Healthy controls|Normal individuals
3151386|NCT00224783|Placebo Comparator|Placebo|Placebo contained 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2). Subjects received about 0.1 mL (a total 0.2 mL) of the control drug using a nebulizer.
3151387|NCT00224835|Experimental|1|Mindfulness Based Stress Reduction Class
3151388|NCT00224835|Experimental|2|Cardiac Education Class
3151389|NCT00224848|Experimental|ATP III|A novel practice-based intervention, based on the ATP III Clinical Practice Guideline, which includes the use of a personal digital assistant (PDA) based decision support tool.
3151390|NCT00224848|Active Comparator|JNC 7|A novel practice-based intervention, based on the JNC-7 blood pressure Clinical Practice Guideline, which includes the use of am automated blood pressure measurement device.
3151391|NCT00225069|Experimental|1|T2 sympathectomy
3151392|NCT00225069|Experimental|2|T2-T3 sympathectomy
3189645|NCT00779233|Experimental|1|Zidovudine tablets 300 mg of Ranbaxy
2442501|NCT03280290|Experimental|receivers|"Eligible for allo-HSCs from peripheral blood stem cells from a compatible donor HLA family (Appendix 1, the pre-transplant assessment must be enabled)~In a complete remission rate of leucocytes with ≥ 2G / L~Affiliated to social security person or beneficiary of such a scheme."
3151396|NCT00225121|Experimental|1|open label single arm trial
3151397|NCT00225173|Experimental|Treatment|"Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11~Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11~Cyclophosphamide 750 mg/m2 IV w 1, 5, 9~Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11~Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)~Bleomycin 5 u/m2 IV w 2,4,6,8,10,12~Gemcitabine 1250 mg/m2 IV w 13,15,17,19~Vinorelbine 25 mg/m2 IV w 13,15,17,19~Prednisone 40 mg/m2 PO qod w 1-10, taper"
3151398|NCT00225186|Experimental|Arm 1|
3151399|NCT00225199|Experimental|Arm 1|
3151400|NCT00225199|Placebo Comparator|Arm 2|
3151401|NCT00225225|Active Comparator|fixed calorie (500 kcal) Reduction|
3151402|NCT00225225|Placebo Comparator|Control (no diet change)|
3151403|NCT00225264|Experimental|Pioglitazone QD|
3151404|NCT00225264|Active Comparator|Glimepiride QD|
3151405|NCT00225381||metabolic gas exchange and cardiac output|
3151406|NCT00225381||mass spectrometer and anaerobic metabolism|
3151407|NCT00225381||metaboic gas exchange and type of anesthesia induction|
3151408|NCT00225381||metabolic gas exchange and PEEP|
3151409|NCT00225381||metabolic gas exchange and trendelenburg position|
3151410|NCT00225381||Patients requiring tourniquet during surgery|Patients undergoing orthopaedic surgeries requiring tourniquet intervention. Oxygen consumption and CO2 production were measured before, during and after tourniquet release.
3151411|NCT00225381||Patients prone to metabolic acidosis|Oxygen consumption and CO2 measurements taken during long surgeries prone to metabolic acidosis.
3151412|NCT00225433|Active Comparator|1|Follitropin beta
3151413|NCT00225433|Active Comparator|2|Ganirelix acetate
3189646|NCT00779233|Active Comparator|2|RETROVIR ® 300 mg tablets (GlaxoSmithKline)
3189647|NCT00779272||1|Without preoperative chemotherapy
2442471|NCT03280524|Placebo Comparator|Control Group|Control Group will receive self-care guidelines with feet
2442472|NCT03280524|Experimental|Treatment Group|Treatment will receive self-care guidelines with feet and 12 sessions of foot reflexology
2442473|NCT03280511|Experimental|Interventional|Eligible candidates will be enrolled according to in-/exclusion criteria. Two months after colon resection or immediately after adjuvant chemotherapy (if indicated), a standard laparoscopy including peritoneal lavage, peritoneal biopsies and PIPAC treatment with oxaliplatin 92 mg/m2 will be planned. This procedure will be repeated after another 5 weeks. Follow up CTs after 12, 24 and 36 months will be planned.
2442474|NCT03280498|Other|Intubation with Cole formula|ASA I-II pediatric patients in the age range of 2-10 years, planned to undergo elective surgeries under general anesthesia with endotracheal entubation,
2442475|NCT03280472|Experimental|Cognitive Bias Modification|Participants will complete three session of cognitive bias modification.
2442476|NCT03280472|Other|Symptom Tracking|Participants will track their symptoms.
2442477|NCT03280459||Ileal Conduit|Patient with ileal conduit as reconstruction of urinary diversion after robot-assisted cystectomy
2442478|NCT03280459||Neobladder|Patient with neobladder, (orthotopic, continent ileal pouch) as reconstruction of urinary diversion after robot-assisted cystectomy
2442479|NCT03280446|Experimental|30 pre-menopause and post-menopause women|Thirty healthy women with mild to moderate pelvic prolapse above the ages of 18 seeking treatment for vaginal laxity
2442480|NCT03280420|Active Comparator|early catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 3 days.
2442481|NCT03280420|Active Comparator|late catheter removal|30 patients will receive Tamsulosin hydrochloride 0.4 mg once daily and the catheter will be removed after 7 days.
2442482|NCT03280407|Active Comparator|A, capecitabine|Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy
2442483|NCT03280407|Experimental|B, FOLFOX or CAPOX|Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice
3189648|NCT00779272||2|With preoperative chemotherapy
3189649|NCT00779298||Healthy subjects|Healthy subjects, without symptoms or a prior history of gastrointestinal disease, abdominal surgery or diabetes mellitus
2442486|NCT03280368||A healthy volunteers|Pre-clinical study. Healthy volunteers. Plasma pooled and spiked with dabigatran. Measurement of plasma concentration of dabigatran with liquid chromatography tandem mass-spectrometry and the anticoagulant effect of dabigatran using coagulation assays.
2442487|NCT03280368||A patients|Pre-clinical study. Patients with atrial fibrillation treated with dabigatran etexilate.
2442488|NCT03280368||B|"Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation and intended for electrocardioversion.~Inclusion before initiation of anticoagulation."
2442489|NCT03280368||C|Patients with an indication for treatment with dabigatran etexilate for atrial fibrillation. Inclusion before initiation of anticoagulation.
2442490|NCT03280355|Experimental|Singing Training|Singing Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
2442491|NCT03280355|Active Comparator|Physical Training|Physical Training as training activity in Pulmonary Rehabilitation: 10 weeks, twice a week for 1 1/2 hour, leading to a total of 20 sessions.
2442492|NCT03280342|Active Comparator|IR-TPM (Topamax)|IR-TPM (Topamax)
2442493|NCT03280342|Active Comparator|XR-TPM (Trokendi XR)|
2442494|NCT03280329|No Intervention|Control|the patients who belong to this group will not be assigned to a regulated music therapy treatment, thus they will listen to the background sounds (alerts, voices) right in the Intensive Care environment; radio use will be allowed according to medical/ nursing judgements
2442495|NCT03280329|Active Comparator|Personalised treatment|A music therapy advice will be performed with each patient (if possible from the neurological point of view) or their caregivers to assess their musical preferences and a list of songs will be generated which will be reproduced for 2 hours per day from admission to discharge with the use of earphones.
2442496|NCT03280329|Active Comparator|Generalized treatment|"Music will be broadcasted in each patient room after the creation of a 'weekly playlist' with the following considerations:~Daily sound reproduction from 7 am to 11 pm, with 10 minutes break about every 50 minutes of music;~Spread through the environment with specifically designated speakers, at a controlled volume (30-50 dB);~Choice of playlist of music both classic and modern, with very easy listening, selected according to the daily hours to restore circadian rhythm and following predictable activities of care provided to patients (hygienic care, retail food, administration other therapies, physiotherapy, visit by relatives, …);~Mixing tracks so that there is continuity and fluidity of listening"
2442497|NCT03280316|Experimental|patients with SVMs undergoing SNM|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and undergo sacral neuromodulation (SNM)
2442498|NCT03280316|Experimental|patients with SVMs receiving BTXA|patients with SVMs are of consistent OAB after surgery and accept botulinum toxin A (BTXA) injection
2442499|NCT03280316|Experimental|patients with SVMs receiving drug|patients with SVMs are of consistent OAB (Overactive Bladder) after surgery and accept M receptor antagonist
2442570|NCT03279783|Active Comparator|LCI (Linked Color Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked Color Imaging).
3189650|NCT00779337|Experimental|Single group study|Autologous AdE1- Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes.
3189651|NCT00779350|Experimental|1|sertraline 100 mg tablets of ranbaxy
3189652|NCT00779350|Active Comparator|2|Zoloft® 100 mg tablets
3189653|NCT00779363|Experimental|Implanted Device|
3189654|NCT00779376|Experimental|1|Zidovudine 300mg tablets of Ranbaxy
3189655|NCT00779376|Active Comparator|2|Retrovir ®) 300 mg Zidovudine tablets of Glaxosmithkline
3189656|NCT00779389|Experimental|Arm A|Erlotinib 150 mg
3189657|NCT00779389|Experimental|Arm B|Dasatinib + placebo
3189658|NCT00779389|Experimental|Arm C|Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.
2442502|NCT03280290|Experimental|Donors|"Member of the siblings and HLA-matched A, B, Cw, DR, DQ~Eligible to donate peripheral blood stem cells for allo-HSCs (Appendix 2, pre donation assessment must be enabled)~Having a rate of circulating lymphocytes ≥ 1 G / L~Having a proportion of CD4 + CCR7 + ≥ 80% of the total CD4 T population~The statutes CMV and EBV are known (positive or negative).~Affiliated to social security person or beneficiary"
2442503|NCT03280277|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|Patients receive ferumoxytol IV over 15 minutes and then after 24-36 hours undergo ferumoxytol-enhanced MRI before start of neoadjuvant therapy and within 4 weeks before surgery.
3189659|NCT00779389|Placebo Comparator|Arm D|Placebo for 14-21 days
2442505|NCT03280251|Experimental|Methylphenidate and structured cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
2442506|NCT03280251|Experimental|Placebo and structured cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Structured cognitive training with CogniPlus software, twice per week during 6 weeks
2442507|NCT03280251|Experimental|Methylphenidate and pseudo cognitive training|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
2442508|NCT03280251|Experimental|Placebo and pseudo cognitive training|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
2442509|NCT03280238|Experimental|Experiment|"Individualized painful electrical stimuli, Surpass LT stimulator (EMS Biomedical, Korneuburg, Austria) with a bipolar felt pad electrode~Measurement of pupil diameter, Algiscan® (iDMed, Marseille, France)~Measurement of Analgesia Nociception Index, PhysioDoloris® (MetroDoloris, Lille, France)"
2442510|NCT03280225||VISNs requesting implementation support|VA has divided the country into regions of care and these are called Veteran Integrated Service Networks (VISNs). This group consists of VISNs with facilities that need additional implementation support to fully implement REACH VET and that agree to participate.
2442511|NCT03280212|Experimental|Tranexamic Acid Arm|"Tranexamic Acid 500 milligrams (MG)~Participants of the Tranexamic Acid (TXA) arm will receive the study drug, TXA. Participants of average body weight (60-100kg) will receive TXA according to a 500mg three times daily (TID) dose regimen. Weight deviations from this range will see dose adjustments as follows: participants <60kg will receive 500mg two times daily (BID), and participants >100kg will receive 1000mg BID."
2442512|NCT03280212|No Intervention|Control Arm|"No intervention~Participants in the control arm will not receive any additional intervention, medication, or placebo, and will serve as a comparative arm for the experimental arm."
2442513|NCT03280199|Other|Type of simulator - 1|"VR simulator with physical mannequin and probe.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2442514|NCT03280199|Other|Type of simulator - 2|"VR simulator with virtual mannequin / abdomen~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2442515|NCT03280199|Other|Type of image acquisition - 3|"US images are acquired through real US volumes from patients~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2442516|NCT03280199|Other|Type of image acquisition - 4|"US images are acquired through computer-generated images.~PLEASE NOTE THAT THE INTERVENTIONS BEING COMPARED ARE DIFFERENT TYPES OF SIMULATORS - NOT A DRUG!"
2442517|NCT03280186|Experimental|Patients With SVMs|Patients with SVMs will be included in the group and undergo surgery.
2442518|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fed|fasted
2442519|NCT03280173|Experimental|61 mgA tafamidis free acid soft gelatin capsule fasted|fed
2442520|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fed|fed
2442521|NCT03280173|Experimental|4 × 20 mg tafamidis meglumine soft gelatin capsules fasted|fasted
2442522|NCT03280147|Experimental|7-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 7-day group will not receive any further antibiotics.
2442523|NCT03280147|Active Comparator|14-day course of antibiotics|Randomization of subjects will be performed at the end of 7 days of sensitive intravenous antibiotic administration, provided the subjects meet randomization criteria. Those who are randomized to the 14-day group will receive 7 more days of the same antibiotics, to make it a total of 14 days.
2442524|NCT03280134|No Intervention|predictive nSLN-|No further axillary lymph node dissection (ALND)
2442525|NCT03280134|Active Comparator|predictive nSLN+|axillary lymph node dissection (ALND)
3189660|NCT00779415||Partial Rotator Cuff Tear|Patients who presented from 1/1/02 to 12/31/06 to Hershey Medical Center with complaint of shoulder pain and were treated by the Orthopaedic Department
3189661|NCT00779428|Experimental|A1|
3189662|NCT00779441|Experimental|1|Zolpidem 10mg tablets of ranbaxy
2442529|NCT03280095|Experimental|Treatment 1|One capsule of test product (co-codamol 15mg/500mg capsule) containing 15mg codeine phosphate hemihydrate and 500mg paracetamol.
2442530|NCT03280095|Experimental|Treatment 2|Two capsules of test product (co-codamol 15mg/500mg capsule), each containing 15mg codeine phosphate hemihydrate and 500mg paracetamol (i.e. a total dose of 30mg codeine phosphate hemihydrate and 1000mg paracetamol).
2442531|NCT03280095|Active Comparator|Treatment 3|One tablet of reference product (co-codamol 30mg/500mg tablet) containing 30mg codeine phosphate hemihydrate and 500mg paracetamol.
2442596|NCT03279627||Hyperglycemia|This group will be those who experience a BG > 250 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
3189663|NCT00779441|Active Comparator|2|AmbienÂ® 10mg tablets
3189664|NCT00779454|Other|KRAS wildtype|
3189665|NCT00779454|Other|KRAS mutation|Inclusion has been completed in the KRAS mutation arm.
3189666|NCT00779480|Experimental|KW-2449|Sequential dose escalation in separate cohorts of 3+3 design from 450 mg/day to 800 mg/day total daily dose.
3189667|NCT00779493|Active Comparator|A|Curcumin 900mg twice daily by mouth
2442532|NCT03280082|Other|MUAC Program|"At the CRENAS, MUAC as unique anthropometric criteria for admission, monitoring, and care for the SAM output will be used.~The criteria for admission include:~MUAC <120 mm~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
2442533|NCT03280082|Other|Standard Program|"Regular screenings in the communities on children between 6 and 59 months of age. Children with MUAC<125 mm will be referred to Nutrition Centers for admission.~The criteria for admission include:~MUAC<115 mm and/or~Z score <-3 and /or~Bilateral edema of grade + or ++~The criteria for release of care include:~MUAC ≥ 125 mm at 2 consecutive visits~Minimum stay 3 weeks in the program~Absence of acute medical complications~Absence of edema"
2442534|NCT03280069||Subjects between the ages of 40 - 70|Subjects who present with signs of skin laxity & evaporation dry eye will receive 3 treatments with the THERMIeyes® 20 RF System and monitored for improvements in the conditions for which they have presented.
2442535|NCT03280056|Active Comparator|NurOwn® (MSC-NTF cells)|Three Intrathecal administrations of NurOwn® (MSC-NTF cells) at bi-monthly intervals
2442536|NCT03280056|Placebo Comparator|Placebo|Three Intrathecal administrations of Placebo at bi-monthly intervals
2442537|NCT03280043||Cases|Women who underwent reduction mammoplasty and then developed a hematoma which required return to the operating room for evacuation.
2442538|NCT03280043||Controls|Women who had uncomplicated reduction mammoplasty.
2442539|NCT03280030|Experimental|Midostaurin|Patients will take study drug on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
2442540|NCT03280030|Placebo Comparator|Placebo|Patients will take placebo on day 8-21 during induction and consolidation phase; then continuously during continuation phase.
2442541|NCT03280017|Experimental|Ketamine|Participant allocated to this arm will receive intravenous ketamine infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
2442542|NCT03280017|Placebo Comparator|Normal saline|Participant allocated to this arm will receive intravenous normal saline solution infusion starting after the induction of anesthesia until the end of the surgery at the beginning of skin closure Participant will receive an ultrasound-guide thoracic paravertebral block using 0.5% plain bupivacaine prior to the induction of anesthesia
2442543|NCT03280004||Moxifloxacin group|
2442544|NCT03280004||β-lactams group|
2442545|NCT03279978|Experimental|BI 730357|
2442546|NCT03279978|Placebo Comparator|Placebo|
2442547|NCT03279965||Cystic fibrosis|Patients with known cystic fibrosis
2442548|NCT03279965||Primary ciliary dyskinesia|Patients with known primary ciliary dyskinesia
2442549|NCT03279952|Other|medication arm|CNS Stimulant
2442550|NCT03279939|Experimental|Subjects with Normal Eyes|OCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
2442551|NCT03279939|Experimental|Subjects with Pathology|OCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
2442552|NCT03279926|Experimental|PLAY|Preschoolers & their teachers will get activity trackers and the child care program/providers will get some basic information on the use of the trackers and how to integrate their use in the curriculum. A PLAY Champion will be identified to help support PLAY related activities.
2442553|NCT03279926|Experimental|PLAY Parents|Everything in Arm 1 plus one parent per child will receive an activity tracker and will get reports to help with physical activity goal setting for the family.
2442554|NCT03279926|Experimental|PLAY Teachers|Everything in Arm 1 plus an enhanced focus on teacher wellness, specifically with regard to active lifestyles for them.
2442555|NCT03279913|Experimental|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
2442556|NCT03279887||Post operative respiratory failure|"Patients with acute respiratory failure (ARF) less than 72 hours after a major cardiac surgery with cardiopulmonary bypass~ARF was defined as one of the following conditions:~If mechanical ventilation, a partial pressure of oxygen/ inspired oxygen fraction ratio (PaO2/FiO2) < 200, or failure of weaning (failure of spontaneous ventilation test, re-intubation in the first 24 hours), or need for non-invasive ventilation immediately after extubation,~If spontaneous ventilation: clinical signs of acute respiratory distress (dyspnea at least exertion, cyanosis, polypnea> 25/min, upper or intercostal swallowing, abdominal swing ...), pulse oximetry (SpO2) < 90% or PaO2 <60 mmHg despite oxygen therapy ≥ 3 L/min."
2442557|NCT03279874||German dentists|Dentists who are working in dental offices in Germany
2442558|NCT03279861|Active Comparator|Entresto|First-line anti-hypertensive: sacubitril-valsartan, starting at 24-26 mg twice daily, increasing to maximum dose of 97-103 mg twice daily
2442559|NCT03279861|Active Comparator|Usual meds|First-line anti-hypertensive: valsartan, starting at 40 mg twice daily, increasing to a maximum dose of 160 mg twice daily
2442560|NCT03279835||Absence of cognitive disorder|
2442561|NCT03279835||Asymptomatic cognitive disorder|
2442562|NCT03279835||Symptomatic cognitive impairment|
2442563|NCT03279835||HIV associated dementia|
2442564|NCT03279822||Group|
2442565|NCT03279809|Experimental|Intervention|Intervention : aspirin medication Case with aspirin medication for 6 months after stenting
2442566|NCT03279809|Placebo Comparator|Control|Control : placebo medication Case with placebo medication for 6 months after stenting
2442567|NCT03279796|Experimental|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
2442568|NCT03279796|Active Comparator|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
2442569|NCT03279783|No Intervention|WLI (White light Imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using standard white light.
2442960|NCT03277235|No Intervention|Control|Usual care
2442571|NCT03279757|Experimental|AHES 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 5 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442572|NCT03279757|Experimental|AHES 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 15 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442573|NCT03279757|Experimental|AHES 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment articaine hydrochloride 40 mg/ml + epinephrine 10 μg/ml solution (AHES) will be applied at this test region. 25 minutes after AHES application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442574|NCT03279757|Experimental|LTC 5 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 5 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442575|NCT03279757|Experimental|LTC 15 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 15 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442576|NCT03279757|Experimental|LTC 25 minutes|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreatment lidocaine 70 mg/g + tetracaine 70 mg/g cream (LTC) will be applied at this test region. 25 minutes after LTC application (under occlusion), a pain stimulus will be given at the test region with the fractional CO2 laser, 50 mJ, 5% density.
2442577|NCT03279757|Other|Unanesthetized skin|A pain stimulus will be given at unanesthetized skin with the fractional CO2 laser, 50 mJ, 5% density
2442578|NCT03279744|Experimental|Single-Arm|Radion™-pdt
3189668|NCT00779493|Placebo Comparator|B|Placebo capsule to be made by Swanson Vitamins to simulate the capsule.
3189669|NCT00779519|Placebo Comparator|Placebo|
3189670|NCT00779519|Experimental|TTP435|
3189671|NCT00779532|Active Comparator|Group A|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of one moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of one moxifloxacin capsule of 400 mg at Day 14."
2442583|NCT03279705|Experimental|Two-channel group|The colonoscopy was done with the new designed colonoscopy that integrated a separate water jet channel for infusing water. The dirty water was removed through other accessory channel.
2442584|NCT03279705|Active Comparator|One-channel group|The colonoscopy was done with the traditional colonoscopy. Water exchange was done by using the accessory channel for both infusing and suctioning of water.
2442585|NCT03279692|Experimental|Pembrolizumab|"Pembrolizumab will be administered every 3 weeks~Pembrolizumab will be administered through IV infusion"
2442586|NCT03279679|Experimental|costoclavicular group|patients in this group are assigned to receive ultrasound-guided costoclavicular infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
2442587|NCT03279679|Other|paracoracoid group|patients in this group are assigned to receive ultrasound-guided paracoracoid infraclavicular block with 0.5% ropivacaine for upper limb surgery at elbow joint and below
2442588|NCT03279666|Active Comparator|tenaculum with intracervical blockage|
2442589|NCT03279666|No Intervention|No tenaculum with intracercical blockage|
2442590|NCT03279666|Active Comparator|Tenaculum without intracervical blockage|
2442591|NCT03279666|No Intervention|No Tenaculum without intracervical blockage|
2442592|NCT03279653||SleeveGastrectomy|Sleeve Gastrectomy will be performed. Preoperative and Postoperative pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
2442593|NCT03279640|Experimental|Dual-mode stimulation|"rTMS on ipsilesional M1 + tDCS on contralesional M1~10 Hz of rTMS was applied over the ipsilesional M1 for 20 minutes with simultaneous application of cathodal tDCS on the contralesional M1.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2442594|NCT03279640|Experimental|Single stimulation|"rTMS on ipsilesional M1~10 Hz of rTMS over the ipsilesional M1 was applied for 20 minutes.~Each participant's total FMA score is assessed and their resting-state fMRI data at two times: prior to stimulation (pre-stimulation) and 2 months after stimulation (post-stimulation) are acquired."
2442595|NCT03279627||Hypoglycemia|This group will be those who experience a BG < 70 mg/dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group. All participants in this group will be asked to complete the Diabetes Management Questionnaire.
2442660|NCT03279211|Experimental|Zein protein|Zein protein included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
3189672|NCT00779532|Experimental|Group B|"Once daily intake (orally) of 4 NOMAC-E2 placebo tablets and 1 NOMAC-E2 (2.5/1.5 mg) tablet from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14."
3189673|NCT00779532|Experimental|Group C|"Once daily intake (orally) of 5 NOMAC-E2 (2.5/1.5 mg) tablets from Day 1 to Day 14.~Once daily intake (orally) of 5 NOMAC-E2 placebo tablets and 1 moxifloxacin placebo capsule at Day -1.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Day 14"
2442597|NCT03279627||Glycemic control|This group will be those who maintain BG of 70 to 250 mg /dl in the 24-48 hour time period preceding hospital discharge. Study procedures are identical for each group, but study outcomes including comprehension of discharge instructions and 1 and 3 month readmissions will be analyzed according to group category.All participants in this group will be asked to complete the Diabetes Management Questionnaire.
2442598|NCT03279614|Experimental|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
2442599|NCT03279601|Experimental|A: Capecitabine Combined With Dacarbazine(CAPDTIC)|patients in arm A will receive chemotherapy of CAPDTIC regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
2442600|NCT03279601|Experimental|B: Capecitabine Combined Temozolomide(CAPTEM)|patients in arm B will receive chemotherapy of CAPDTEM regimen: Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o.d10-14 q4W
2442601|NCT03279575|Experimental|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
2442602|NCT03279575|Experimental|Graveyard Shift|Graveyard Shift is a puzzle video game with the transformational goal of helping physicians derive key triage decision principles for themselves. They complete a three-step game loop to obtain case information, compare cases to determine similarities and differences between cases, and then explicitly state the decision principle that should drive decision making.
2442603|NCT03279575|Active Comparator|Educational program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then com
2442604|NCT03279575|Placebo Comparator|Control|Physicians in this arm will not be asked to complete any intervention.
2442605|NCT03279562|Experimental|Nalmefene and recovery coaching|Nalmefene prescribed for daily ingestion during the first 3 months of treatment; patients who maintain a successful recovery during the first 3 months of treatment will be offered an option to take Nalmefene on as needed basis, always before encountering situations or circumstances with heightened risk of alcohol or opioid use
2442606|NCT03279549|Active Comparator|dressing change group|Routine dressing change group
2442607|NCT03279549|Experimental|Dermal matrix dressing group|Limited debridement & Acellular dermal matrix dressing group.
2442608|NCT03279549|Experimental|Epidermal cell spraying group|Limited debridement & Epidermal cell spraying group
2442609|NCT03279549|Experimental|BFGF group|Limited debridement & Basic fibroblast growth factor group
2442610|NCT03279536|Experimental|Oral Lactoferrin|Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks
2442611|NCT03279536|Active Comparator|Total dose infusion (TDI) iron dextran|Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks
2442612|NCT03279523||F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
2442613|NCT03279510|Experimental|Hearing aids|All study participants will be fit with hearing aids.
2442614|NCT03279497|Experimental|Health game|Health game intervention consists of 20 minutes guided training session with the mobile health game at school and 4 weeks free usage of the game via own smart phone during free time. Smart phones are tracking the actual physical activity (steps) of the participants via activity sensors and the tracked steps work as In-App Currency enabling the participants to play the game and proceed in it.
2442615|NCT03279497|Sham Comparator|Sport and fitness application|Sport and fitness application intervention consists of 20 minutes guided training session with the app at school and 4 weeks free usage of the app via own smart phone during free time. Sport and fitness application, when turned on, tracks the physical activity (running, cycling and every-day training) of the participant.
2442616|NCT03279484|Experimental|NAVIGO 4LV implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
2442617|NCT03279471|Experimental|CBT/BIACA|These participants will receive CBT treatment using Behavioral Interventions for Anxiety in Children with Autism (BIACA). BIACA is an anxiety treatment package designed for children with ASD that includes elements of CBT and social skills training.
2442618|NCT03279471|Active Comparator|Sertraline|These participants will receive sertraline
2442619|NCT03279471|Placebo Comparator|Pill Placebo|These individuals will receive a pill placebo.
3189674|NCT00779532|Placebo Comparator|Group D|"Once daily intake (orally) of 5 NOMAC-E2 placebo tablets from Day -1 to Day 14.~Once daily intake (orally) of 1 moxifloxacin placebo capsule at Days -1 and 14."
3189675|NCT00779545|Placebo Comparator|Placebo|The placebo group was divided into 3 groups receiving 1, 2 or 4 sprays/nostril. The regimen of each placebo group was BID
2442622|NCT03279445||African American|Patient of African American race
2442623|NCT03279445||Caucasian|Patient of Caucasian race
2442661|NCT03279211|Experimental|Whey protein isolate|Whey protein isolate included in the test-meal, 30 g of zein in 500 ml (water + flavour/sugar)
2443666|NCT05074797||covid not diabetic with AKI|AKI in pt with covid_19 not diabetic
3189676|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg QD|
3189677|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg QD|
3189678|NCT00779545|Experimental|Mometasone furoate nasal spray 400 mcg QD|
3189679|NCT00779545|Experimental|Mometasone furoate nasal spray 100 mcg BID|
2442624|NCT03279419||Liver disease|"15 patients with acute or chronic liver disease of any aetiology. Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling.~Patient may or may not be receiving terlipressin therapy."
2442625|NCT03279419||Normal|"15 patients without liver disease, and without any other disease or drug known to affect the peripheral circulation.~Serial static images to be taken at up to 3 time points using thermal imaging camera. Video images using thermal camera will be used to capture warming of one hand after cooling."
2442626|NCT03279393|Active Comparator|PTSD Subjects|
2442627|NCT03279393|Active Comparator|Trauma Control Subjects|
2442628|NCT03279393|Placebo Comparator|Healthy Control Subjects|
2442629|NCT03279380|Experimental|Single-nucleotide polymorphisms (SNPs)|In the first part the Case-control study design will be used to estimate the association between multiple single-nucleotide polymorphisms (SNPs) and the endurance/power athlete status.
2442630|NCT03279380|Active Comparator|High Intensity Interval Training (HIIT)|"High intensity interval exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: 8 x 5 min at 80% PPO (between intervals 1.5 min at 75 W). Baseline measurements will include the V̇O2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
2442631|NCT03279380|Active Comparator|Low Intensity Continuous Training|"Low intensity continuous exercise on the cycling ergometer (Velodyn, Racermate ™, USA).~Protocol: continuous 60 min cycling at 50% PPO. Baseline measurements will include the V̇o2peak test and peak power output. Monitoring of physiological responses with spirometry and analysis of expired air (oxygen and carbon dioxide output) (Quark, Cosmed, Rim, Italy)."
2442632|NCT03279367||Hearing Impaired|Participants will be asked to wear an electro-encephalography (EEG) cap for measurement of brain activity whilst listening to speech stimuli. The speech stimuli will be presented through a loudspeaker positioned 1 meter in front of the participant. Participants will be asked to listen to the speech stimuli when using and without using their hearing aid. They will be asked to pay attention to the speech stimuli. This will be assured by asking them to answer questions related to the speech stimulus at random intervals. Subjects will also go through standard clinical procedures for assessing their hearing function and hearing aid setup.
2442633|NCT03279354|Experimental|Intervention group|Family Move app intervention
2442634|NCT03279354|Placebo Comparator|Control group|"HK FitNuts app intervention"
2442635|NCT03279341|Active Comparator|polyethylene glycol, osmotic laxitive|13.8g polyethylene glycol 3350 with sodium bicarbonate, sodium chloride, and potassium chloride, mixed with 125mL of water administered twice orally as a solution
2442636|NCT03279341|Active Comparator|bisacodyl, stimulant laxative|10 mg bisacodyl once daily oral administration with 125mL of water
2442637|NCT03279341|Active Comparator|prucalopride, prokinetic|2mg prucalopride, film-coated tablets (prucalopride succinate eq. 2mg), once daily oral administration with 125mL of water
2442638|NCT03279328|Active Comparator|Topical Steroid Ointment|One side of the face will receive a Topical Steroid ointment twice daily for seven days.
2442639|NCT03279328|Active Comparator|Vaseline|One side of the face will receive Vaseline twice daily for seven days.
2442640|NCT03279328|Active Comparator|Skin Barrier Moisturizer|One side of the face will receive Skin Barrier Moisturizer twice daily for seven days.
2442641|NCT03279315|Experimental|experimental period|the first period was with non-iodized salt, the second period was with iodized salt.
2442642|NCT03279302|Experimental|Group A|1 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
2442643|NCT03279302|Experimental|Group B|5 mg glepaglutide once daily, given as single SC injections on Days 1 to 7
2442644|NCT03279302|Experimental|Group C|5 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
2442645|NCT03279302|Experimental|Group D|10 mg glepaglutide once weekly, given as single SC injections on Days 1, 8, 15, 22, 29, and 36
2442646|NCT03279302|Experimental|Group E|1 mg glepaglutide, given as an IV infusion at a rate of 4 mg/h for 15 minutes on Day 1
2442647|NCT03279289|Experimental|Group A|INDUCTION PHASE: 6 cycles of FOLFIRI + aflibercept MAINTENANCE PHASE: 5FU/LV + aflibercept
2442648|NCT03279289|Active Comparator|Group B|FOLFIRI + aflibercept
2442649|NCT03279276|Experimental|Primoris|Total hip arthroplasty surgery using a Primoris® femur component, Exceed ® acetabular cup + E-poly liner ®.
2442650|NCT03279276|Active Comparator|Echo|Total hip arthroplasty surgery using a standard uncemented Echo® femur component, Exceed ® acetabular cup + E-poly liner ®.
2442651|NCT03279263|Experimental|MLR-1023 25mg QD|MLR-1023 25mg QD Tablet
2442652|NCT03279263|Experimental|MLR-1023 50mg QD|MLR-1023 50mg QD Tablet
2442653|NCT03279263|Experimental|MLR-1023 100mg QD|MLR-1023 100mg QD Tablet
2442654|NCT03279263|Placebo Comparator|Placebo|Placebo QDTablet
2442655|NCT03279250|Experimental|Arm A (LHRHa, apalutamide)|Participants receive gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician) IM once every 3 months and apalutamide PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
2442656|NCT03279250|Experimental|Arm B (LHRHa, apalutamide, abiraterone acetate)|Participants receive gonadotropin-releasing hormone analog and apalutamide as in arm A, abiraterone acetate PO QD, and prednisone PO QD. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning no less than 48 hours after completion of therapy, participants undergo radical prostatectomy.
3189680|NCT00779545|Experimental|Mometasone furoate nasal spray 200 mcg BID|
2442658|NCT03279224|Active Comparator|Allogenic FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) from a healthy, screened individual with no personal or family history of an Axis 1 disorder.
2442659|NCT03279224|Placebo Comparator|Autologous FMT|Participants Randomized to this arm will receive FMT (Fecal Microbiota Transplantation) by re-infusion of their own feces donated earlier in the study.
3189681|NCT00779571|Experimental|Crispbread|Intervention: Crispbread LCD
3189682|NCT00779571|Active Comparator|Liquid meal replacement|Intervention: LMR LCD
2442664|NCT03279198|Active Comparator|TIWeb|TIWeb (Tailored Web Intervention) program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
2442665|NCT03279198|Active Comparator|Cancer Screening Call (CSC)|CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
2442666|NCT03279198|Active Comparator|TIWeb+CSC|TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
2442667|NCT03279185||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment.
2442668|NCT03279172|Experimental|Group Direct Laryngoscope|direct laryngoscope (macintosh laryngoscope) is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Macintosh laryingoscope, BIS monitoring and tonometry would be used in Group Direct Laryngoscope.
2442669|NCT03279172|Experimental|Group videolaryngoscope|Videolaryngoscope is used in elective surgeries with maximal duration time for two hours. Standard anaesthesia was used on group and BIS monitorisation was applied. A record was made of IOP, hemodynamic changes and oxygen saturation at 3 and 10 minutes after intubation. Throat pain was evaluated by questioning the patient at 10 minutes and 24 hours after waking from general anaesthesia. The duration of intubation was recorded as the time from the laryngoscope entering the mouth to removal with end-tidal carbon dioxide on the monitor. Video laryingoscope, BIS monitoring and tonometry would be used in Group Video Laryngoscope.
2442670|NCT03279159|Experimental|Jaluronius CS cream (Difa Cooper S.p.a, Italy)|
2442671|NCT03279146|Active Comparator|Regimen A|Immediate release tablet Tenofovir exalidex (TXL)
2442672|NCT03279146|Experimental|Regimen B|New Formulation 1 Tenofovir exalidex (TXL)
2442673|NCT03279146|Experimental|Regimen C|New formulation 2 Tenofovir exalidex (TXL)
2442674|NCT03279133|Experimental|LDV/SOF for 12 weeks.|Ledipasvir 90mg/Sofosubvir 400mg fixed-dose combination (FDC) tablet for 12 weeks.
2442675|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Continuous)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (continuous).
2442676|NCT03279120|Experimental|TFV/LNG IVR (8-10mg/20μg) (Interrupted)|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer cross-sectional diameter of 5.5 mm: a longer segment (135 mm) containing white to off-white TFV paste and a shorter one (34 mm) with a translucent LNG core. Used for 90 days (3x28 days interrupted).
2442677|NCT03279120|Placebo Comparator|Placebo (Continuous)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (continuous).
2442678|NCT03279120|Placebo Comparator|Placebo (Interrupted)|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month. Used for 90 days (3x28 days interrupted).
2442679|NCT03279107|No Intervention|Control beverage with glucose powder|Standard glucose beverage with 50 g of glucose powder
2442680|NCT03279107|Experimental|Beverage with soluble corn fiber|Beverage with soluble corn fiber (50 gram of total carbohydrate)
2442681|NCT03279107|Experimental|Beverage with maltodextrin|Beverage with maltodextrin (50 gram of total carbohydrate)
2442682|NCT03279107|Experimental|Snack with soluble corn fiber|snack with soluble corn fiber (50 gram of total carbohydrate)
2442683|NCT03279107|Experimental|Snack with maltodextrin|Snack with maltodextrin (50 gram of total carbohydrate)
2442684|NCT03279094|Experimental|Haploidentical stem cell transplantation|
3151414|NCT00225563|Active Comparator|e-prescribing|Providers who used electronic prescriptions. electronic health records were used as opposed to paper based prescriptions
3151415|NCT00225563|No Intervention|Paper-based prescriptions|providers who used paper based prescriptions
2442687|NCT03279068||Without Pattern Interpretation|All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected. Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM.
2442688|NCT03279068||With Pattern Interpretation|"All women who are admitted for labor at Ayder Referral Hospital in Mekelle, Ethiopia will be asked to participate and a physician will obtain consent. If an indication arises and they are designated to receive EFM per previously established standard practice at Ayder Hospital, then their patient information will be collected.~Their labor will be managed as in Phase 1 except that EFM will be interpreted and managed as per ACOG/FIGO guidelines using paper on which fetal heart tracings will be recorded. All other aspects of their care will proceed as per standard at Ayder Referral Hospital.~Patients who require EFM will be asked to provide basic health and demographic information, along with collection of information on labor and delivery course, post-partum outcome, and neonatal outcomes. The investigators estimate enrollment of up to 1800 patients which will result in at least 300 patients who will require EFM."
2443135|NCT03276091|Experimental|COLOFIT+ Study|Personnalized motivational phone call, done by a medical physician
2442689|NCT03279055|Experimental|SHUTi|"Participants will be provided with an individual access code for SHUTi~SHUTi is delivered over 6 sessions, each taking 20-30 minutes~SHUTi is delivered by a virtual therapist~Participants will learn about the etiology and maintenance of their insomnia~Participants will learn how to maintain their sleep log~Participants will learn how to address lifestyle barriers that impact their sleep~Participants will be taught stimulus control techniques targeting non-sleep behaviors in the bedroom~Participants will learn a range of cognitive techniques that address the key cognitive factors that perpetuate poor sleep behavior~Participants will be taught how to gradually expand their restricted sleep"
2442690|NCT03279042|Experimental|Flapless corticotomy|Flapless corticotomy will be conducted in this group of patients.
2442691|NCT03279042|Active Comparator|Traditional corticotomy|Traditional corticotomy will be performed in this group.
2442692|NCT03279029|Experimental|patients with aortic valve disease (AVD).|
2442693|NCT03279029|Experimental|patients with left ventricular assist device (LVAD|
2442695|NCT03278990|Experimental|Future Self - Value Affirmation|This is a behavioral intervention whereby participants write (Value Affirmation and Future Selves Combination) for 5 minutes about 1-2 values that are important to them, as well as about a time in their life when they were particularly important. Next, for five minutes, they write a letter to themselves in 20 years.
2442696|NCT03278990|Sham Comparator|Control|In this sham comparator, participants will also write (Control Writing Exercise) --similar to the intervention above. However, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
2442697|NCT03278977|Other|ALTE group|Infants aged between 28 days and 12 months presenting severe(s) syncope(s) requiring hospitalization, for which a cause was identified during hospitalization.
2442698|NCT03278977|Other|iALTE group|Infant aged between 28 days and 12 months presenting a severe syncope(s) requiring hospitalization, for which no etiology was found during hospitalization.
2442699|NCT03278964|Active Comparator|Antro-ethmoidal technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by antro-ethmoidal technique.
2442700|NCT03278964|Experimental|Lateral wall technique|Patients in the inactive phase of Graves orbitopathy will be submitted to orbital decompression by lateral wall technique.
2442701|NCT03278951|No Intervention|Control Group|The control group received the mHealth devices but no health coaching or feedback. Participants in this group completed the same pre- and post-intervention measurements.
2442702|NCT03278951|Experimental|Video Conferencing Health Coaching|The video conferencing group participants met via the eClinicalWorks® app using their smartphone, and met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist to discuss exercise and diet goals.
2442703|NCT03278951|Experimental|In Person Health Coaching|The in person group participants met 12 times with the registered dietitian (RD) and 12 times with the exercise physiologist over the course of the study to discuss both diet and exercise regimens.
2442704|NCT03278938|Active Comparator|bupropion added to citalopram|patients who did not remit with citalopram will continue at the same dose and have bupropion added
2442705|NCT03278938|Active Comparator|citalopram added to bupropion|Patients who did not remit with bupropion will have bupropion continued at the same dose and citalopram will be added
3151416|NCT00225576|No Intervention|1|Paper prescribing, 2005 and 2007
3151417|NCT00225576|Experimental|2|Paper prescribing 2005 vs. electronic prescribing 2007
3151418|NCT00225641|Active Comparator|1 frequent control|Follow-up 6, 12, 18, 24 and 36 months after surgery
2442712|NCT03278873|Experimental|Biological-Low dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single low dose of either AAV - CNGB3 or AAV - CNGA3
2442713|NCT03278873|Experimental|Biological-medium dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single medium dose of either AAV - CNGB3 or AAV - CNGA3
2442714|NCT03278873|Experimental|Biological-high dose of either AAV - CNGB3 or AAV - CNGA3|Subretinal administration of a single high dose of either AAV - CNGB3 or AAV - CNGA3
2442715|NCT03278860|Experimental|Oxytocin then placebo|Participants first received oxytocin (24 IU). After a washout period of 2 weeks, they then received placebo (24 IU).
2442716|NCT03278860|Experimental|Placebo then oxytocin|Participants first received placebo (24 IU). After a washout period of 2 weeks, they then received oxytocin (24 IU).
2442717|NCT03278847||Enteral nutrition comparison|This comparison refers to differences in enteral nutrition during therapeutic hypothermia
2442718|NCT03278847||Parenteral nutrition comparison|This comparison refers to differences in parenteral nutrition during therapeutic hypothermia
2442719|NCT03278834|Experimental|Intervention Group|"Neuromuscular muscle stimulation machine - Muscle stimulation machine to be used on glutes and abductors on disuse atrophy setting.~Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
2442720|NCT03278834|Placebo Comparator|Placebo Group|"Neuromuscular muscle stimulation- Muscle stimulation machine to be used on glutes and abductors on TENS setting. Twice per day for 45 minutes.~Exercise - Home exercises programme once per day with 10 exercises."
3151419|NCT00225641|Other|2 less frequent control|Follow-up 12 and 36 months after surgery
3151420|NCT00225745||1|Pancreatic cancer patients
2442723|NCT03278808|Experimental|Chloroquine-Azithromycin (CQ/AZ ) Group|Subjects will receive experimental intervention of 300mg of CQ orally (PO) and 2g of AZ PO weekly for 6 weeks
2442724|NCT03278808|Active Comparator|Chloroquine (CQ) Group|Subjects will only receive 300mg of CQ orally (PO) weekly for 6 weeks
3151421|NCT00225745||2|Healthy controls
3151422|NCT00225914|Experimental|1|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
3151423|NCT00225914|Placebo Comparator|2|Subjects then enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill
3151424|NCT00225979|Experimental|SMS995|
2442725|NCT03278808|Other|CHMI Group - atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
2442726|NCT03278795|Active Comparator|PSV mode|PSV weaning group
2442727|NCT03278795|Experimental|VSV mode|VSV weaning group
2442728|NCT03278782|Experimental|Treatment (romidepsin, pembrolizumab)|Participants receive romidepsin IV over 4 hours on days 1 and 8 or day 8 of cycle 1 and days 1 and 8 of subsequent cycles and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
2442729|NCT03278769|Experimental|Ventilator setting|Positive end-expiratory pressure , Tidal volume
2442730|NCT03278756|Experimental|Cognitive Control Training|A cognitive control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive paced auditory serial addition task, where participants need to click on the sum of the last two heard digits.
2442731|NCT03278756|Active Comparator|Active Control Training|An active control training, consisting of 10 sessions of 15 minutes each, will be administered. The task in this training is an adaptive low load cognitive task, where participants need to click on the last heard digit.
2442732|NCT03278743||low to moderate tea consumption|consumption of 0.4 to 4.6 cups of tea (200 ml) per day (n=463)
2442733|NCT03278743||High tea consumption|consumption of 4.6 to 11.9 cups of tea (200 ml) per day (n=213)
2442734|NCT03278730|Active Comparator|Para-Tyrosine intervention|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Tyrosine. Strength 500 mg. Oral dose form: hard capsule. Number of Dispensed at frequency of 3x2 g daily. Duration of administration: 4 to 7 days."
2442735|NCT03278730|Placebo Comparator|Placebo|"The patients will receive the study drug during their stay at the ICU but for a maximum of 7 days.~Study drug will be dispensed by a nominated member of the study team and administered to the patients by the ICU staff via nasogastric tube in form of oral suspension. The content of the hard capsules will be dissolved in 20 ml of tap water before the dosing.~Drug name: Placebo.. Strength N/A. Oral dose form: capsule matching to Tyrosine capsule. Number of Dispnsed an frequency 3x2 g daily. Duration of administration: 4 to 7 days."
3151425|NCT00226005|Active Comparator|Vatalanib|Administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
3151426|NCT00226018|Active Comparator|1|Acceleromyography with Hand Adapter on dominant arm
2442738|NCT03278704|Other|RE training only|RE only - Progressive resistance exercise training only (leg extension, leg step up, chest press and pull down).
2442739|NCT03278704|Experimental|Concurrent RE + HIIT|RE + HIIT - Progressive resistance exercise training (leg extension, leg step up, chest press and pull down) followed by HIIT (10 x 1 min at 90% heart rate maximum).
3151427|NCT00226018|Active Comparator|2|Acceleromyography with Hand Adapter on non-dominant arm
3151428|NCT00226018|Placebo Comparator|3|Acceleromyography without Hand Adapter on dominant arm
2442742|NCT03278665|Experimental|4SC-202 + Pembrolizumab|Single arm study of 4SC-202 in combination with Pembrolizumab
2442743|NCT03278652||Patient with renal colic|
2442744|NCT03278639|Experimental|Rhythmic auditory stimulation|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by music therapists board-certified in RAS.
2442745|NCT03278639|Active Comparator|Kinesiology|Each patient will receive training for 4 weeks, 3 times per week. Each training session will last 30 minutes. Training will be performed by board-certified kinesio therapists. The objectives of the training sessions will match those of RAS.
2442746|NCT03278626|Other|Nivolimumab+Carboplatin/paclitaxel+Radiation|240 mg IVPB every 2 weeks for 2 doses, nivolumab at 240 mg every 2 weeks will be added to paclitaxel and carboplatin, which will be dosed according to the standard of care: paclitaxel 50 mg/m2 weekly for 6 weeks and carboplatin AUC 2 weekly for 6 weeks and radiation
2442749|NCT03278600|Experimental|site-specific therapy|standard treatments of sites of origin
2442750|NCT03278600|Active Comparator|standard empiric chemotherapy|standard empiric chemotherapy
2442751|NCT03278587|Active Comparator|Community-based screening|
2442752|NCT03278587|Active Comparator|Cataract camp program|
2442753|NCT03278587|Active Comparator|Community health worker program|
2442754|NCT03278587|No Intervention|No intervention|
2442755|NCT03278574|Experimental|Flexible band|Mitral valve repair with flexible posterior annuloplasty band
2442756|NCT03278574|Active Comparator|Complete ring|Mitral valve repair with complete rigid ring
3151429|NCT00226018|Placebo Comparator|4|Acceleromygraphy without Hand Adapter on non-dominant arm
3151430|NCT00226031|Active Comparator|1|Usual care.
3151431|NCT00226031|Experimental|2|Mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the family physician and a letter and educational package for the women.
3151432|NCT00226044|No Intervention|Oral omeprazole|Standard of care: A single dose of 1 mg/kg orally administered omeprazole.
3151433|NCT00226044|Active Comparator|Rectal omeprazole|A single dose of 1 mg/kg rectally administered omeprazole.
3151434|NCT00226057|Experimental|Raptiva Open Label|Raptiva administered by weekly subcutaneous injections. First dose of 0.7mg/kg. Subsequent doses will be of 1mg/kg SQ weekly.
3151435|NCT00226109|Active Comparator|A|
3151436|NCT00226252|Experimental|Instruction Only (IO)|IO participants will train on the dynamometer for the same length of time as the Feedback Group. They will only be instructed to follow what they learned from the video presented at the beginning of the training session.
3151437|NCT00226252|Experimental|Instruction and Feedback Group (FB)|The FB group will receive video training, and real time feedback from the SMART Wheel as they push their wheelchair. A monitor displaying a random combination and amount of biomechanical feedback variables will be placed in front of subjects. Subjects will be instructed to adjust their stroke to optimize their biomechanics with feedback from the screen.
2442757|NCT03278561||Early onset asthma|Sputum induction according to the European Respiratory Society (ERS) protocol. A blood sample of 100ml will be taken.
2442758|NCT03278561||Late onset asthma|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
2442759|NCT03278561||No pulmonary disease|Sputum induction according to the ERS protocol. A blood sample of 100ml will be taken.
3151438|NCT00226252|No Intervention|Control Group|Wheelchair characteristics will be noted; however, no wheelchair manipulation or changes in equipment will be performed or recommended.
2442762|NCT03278535||age group 18-29 years|CAREN-based gait analysis: 20 men and 20 women aged between 18-29 years
2442763|NCT03278535||age group 30-39years|CAREN-based gait analysis: 20 men and 20 women aged between 30-39years
2442764|NCT03278535||age group 40-49years|CAREN-based gait analysis: 20 men and 20 women aged between 40-49years
2442765|NCT03278535||age group 50-59years|CAREN-based gait analysis: 20 men and 20 women aged between 50-59years
2442766|NCT03278535||age group 60-69years|CAREN-based gait analysis: 20 men and 20 women aged between 60-69years
2442767|NCT03278535||age group 70+|CAREN-based gait analysis: 20 men and 20 women aged between 70 years and older
2442768|NCT03278522|Active Comparator|ramosetron iv at induction (I)|0.6mg of ramosetron is given to the patients intravenously at anesthesia induction
2442769|NCT03278522|Active Comparator|ramosetron iv at recovery (R)|0.6mg of ramosetron is given to the patients intravenously at end of surgery
2442770|NCT03278509|Experimental|Oral beta-blocker treatment|Patients randomized to beta-blockade will be prescribed oral beta-blocker (metoprolol succinate or bisoprolol) at a dose according to the treating physician. Metoprolol succinate will be strongly recommended as first choice. Bisoprolol will be allowed as an alternative. Atenolol (or any other beta-blocker therapy) will not be allowed. The treating physician will be encouraged to aim for a dose of ≥ 100 mg for metoprolol succinate and ≥ 5 mg for bisoprolol. Prescribed treatment and dosing will be registered. Initiation (whether the prescribed drug is dispensed) and adherence (defined as proportion of prescribed tablets that are dispensed), and persistence (time on treatment) will also be recorded via the Drug prescription registry.
2442771|NCT03278509|No Intervention|No beta-blocker treatment|Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Patients assigned to no beta-blockade also receive best evidence-based care, without beta-blockers. For blood pressure control, other drugs than beta-blockers will be recommended as first-line treatment. Regarding later use of beta-blockade, follow up is performed in the Drug prescription registry. Patients will be asked to provide future physicians with the written information about the study when beta-blockade treatment is discussed.
2442772|NCT03278496|Experimental|Recovery housing plus counseling|Intensive counseling in a 5-day per week program plus abstinence-contingent rent payment in a community recovery house. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
2442773|NCT03278496|Experimental|Recovery Housing only|Abstinence-contingent payment for recovery housing rent in absence of any formal counseling. Intervention lasts 12 weeks with follow-up at 12 and 24 weeks post treatment entry.
2442774|NCT03278496|Active Comparator|Usual Care Referral|Participants receive referral resources for community substance abuse counseling and recovery housing but no formal treatment or help with rent payments. All participate in follow-up data collection.
2442775|NCT03278483|Active Comparator|Isoniazid|Diabetic patients with a positive TST of >10mm, will be randomly assigned to receive treatment with isoniazid 300mg Oral Tablet daily plus pyridoxine 50mg daily for six months
2442776|NCT03278483|Active Comparator|Rifampin|Diabetic patients with a positive TST of >10mm, who wil be randomly assigned to receive treatment with rifampin 600mg Oral Tablets daily for three months
2442777|NCT03278470|Experimental|HL237 50mg|take oral tablet once
2442778|NCT03278470|Experimental|HL237 100mg|take oral tablet once
2442779|NCT03278470|Experimental|HL237 200mg|take oral tablet once
2442780|NCT03278470|Experimental|HL237 400mg|take oral tablet once
2442781|NCT03278470|Experimental|HL237 800mg|take oral tablet once
2442782|NCT03278470|Experimental|HL237 1200mg|take oral tablet once
2442783|NCT03278470|Experimental|HL237 1600mg|take oral tablet once
2442784|NCT03278444|Experimental|One-drug Regimes|Basic drugs therapy of HCC
2442785|NCT03278444|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride
2442786|NCT03278444|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC; Arginine hydrochloride;Trimetazidine hydrochloride
2442787|NCT03278431|Active Comparator|Albendazole triple combi|Albendazole (400 mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2442788|NCT03278431|Experimental|Pyrantel pamoate double combi|Pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2442789|NCT03278431|Experimental|Albendazole double combi|Albendazole (400 mg) + oxantel pamoate (20 mg/kg)
2442790|NCT03278431|Experimental|Mebendazole triple combi|Mebendazole (500mg) + pyrantel pamoate (20 mg/kg) + oxantel pamoate (20 mg/kg)
2442791|NCT03278418|Experimental|Tricuspid Valve Repair|Concomitant tricuspid valve repair in patients undergoing left-sided valve surgery
2442792|NCT03278418|Active Comparator|left-sided valve surgery|No concomitant tricuspid valve repair in patients in pts undergoing left-sided valve surgery
2442793|NCT03278405|Experimental|Intervention Arm|Treatment with avelumab
2442794|NCT03278392|Experimental|Psychosocial challenge task|Participants will be assigned to complete the Trier Social Stress Test (TSST) immediately after consuming a standardized breakfast drink
2442795|NCT03278392|Sham Comparator|Placebo challenge task|Participants will be assigned to complete the placebo non-stress task immediately after consuming a standardized breakfast drink
2442796|NCT03278379|Experimental|Intervention Arm|Treatment with Avelumab
2442797|NCT03278366|Experimental|Dancing students|Students will participate in dance activities from a video with their teacher in class.
2442798|NCT03278366|No Intervention|Non-Dancing Students|Students will continue with typical classroom activities in class and will not participate in dancing activities
2442799|NCT03278353|Experimental|Conservative care|Exercise and manual therapy
2442961|NCT03277222|Active Comparator|IN insulin 40 IU|Drug: IN insulin Dosage form: intranasal Dose: 40 IU Frequency: bid Duration: 16 weeks
2442800|NCT03278340|Experimental|Sun Safe Workplaces - Technology (SSW-T)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via a range of technology systems including web-enabled visits with senior managers, online training of outdoor workers, and online access to collateral materials (e.g., brochures, posters, tip cards).
2442801|NCT03278340|Active Comparator|Sun Safe Workplaces - In Person (SSW-IP)|Program promoting the adoption of sun protection policies by fire departments and state Departments of Transportation that is delivered via personal visits with senior managers and in person training of outdoor workers by research staff over two years. Collateral materials (e.g., brochures, posters, tip cards) will be provided to worksites.
2442802|NCT03278327|Other|Endoscopic resection|
2442803|NCT03278288|Experimental|WellWe-Intervention group|WellWe-intervention includes the use of WellWe-app to assess the current situation of the wellbeing of the family at home and utilizing these results using WellWe-app during the health visit in Child health clinic.
2442804|NCT03278288|No Intervention|Usual care group|Usual care includes the filling of normal paper-based questionnaires to assess the current situation of the wellbeing of the family at home and utilizing these results during the normal health visit in Child health clinic.
2442805|NCT03278275|Experimental|uPAR PET/CT|One injection of the radioligand 68Ga-NOTA-AE105
2442806|NCT03278262||>= 70 letters|Baseline VA >= 70 letters
2442807|NCT03278262||36-69 letters|Baseline VA 36-69 letters
2442808|NCT03278262||<=35 letters|Baseline VA <=35 letters
3151439|NCT00226291|Experimental|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
2442810|NCT03278236|Experimental|TRF|
2442813|NCT03278210||with EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, and its results were provided to the clinicians before surgery planification. The final surgery strategy was decided with EEG-fMRI results.
2442814|NCT03278210||without EEG-fMRI data|EEG-fMRI was performed during the pre surgical evaluation, but clinicians were blinded to the results. The final surgery strategy was decided without EEG-fMRI results.
2442815|NCT03278197|Experimental|1.Patients|"Patients diagnosed with prostate cancer and ex-prostate cancer patients:~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2442816|NCT03278197|Other|2.Clinicians|"Radiotherapy-oncologists, Urologists, General practitioners, Nurses~Interviews with patients to define their decisional needs and to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.~Navigating through the Treatmentchoice Decisional Tool and think aloud while running the tool~Questionnaires"
2442817|NCT03278197|Other|3.Other involved organizations|Patient Organizations and insurance companies Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid
3151440|NCT00226291|No Intervention|No evidence report|
3151441|NCT00226317|Experimental|Aripiprazole in depression treatment|
3151442|NCT00226356|Experimental|Supplements of L-methionine, betaine and folate|
2442821|NCT03278171||Patients in intensive care unit|Cohort of patients leaving intensive care unit after a stay of more than 72 hours
2442822|NCT03278158|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
2442823|NCT03278158|Experimental|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
2442824|NCT03278158|Experimental|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet. Discontinued after 2 patients due to good safety. Escalation to higher dose levels in whole study (1, 2 and 4 mg changed to 1, 4 and 8 mg)
2442825|NCT03278158|Experimental|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
2442826|NCT03278158|Experimental|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
2442827|NCT03278145||Pediatric acute leukemia|Patients of the Institute of Hematology and Pediatric Oncology (IHOPe) with acute leukemia (LA) who came for initial diagnosis, relapse, or at the time of their remission .
2442828|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 10,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
2442829|NCT03278132|Experimental|EV71 vaccine & blood sampling (0, 20,60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
2442830|NCT03278132|Experimental|EV71 vaccine& blood sampling (0, 30, 60)|This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
2442831|NCT03278119||Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, having mild to severe obstructive sleep apnea~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
2442832|NCT03278119||No Sleep Apnea|"Overall 56~both male and female~age group 55 to 75 years, without OSA~in good general health with no significant comorbidities~Located for the most part in boroughs of New York City"
3151443|NCT00226434|Experimental|1|
2442834|NCT03278080|Other|driving test|
3151444|NCT00226434|Active Comparator|2|
3151445|NCT00226486|Experimental|1|Identification of individual risk factors for falls and specified intervention aimed diminishing these risk factors in the individual.
3151446|NCT00226486|Placebo Comparator|2|Usual care
3151447|NCT00226668|Experimental|I|Patients will receive hCRf (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone that they may be taking
3151448|NCT00226668|Placebo Comparator|II|Patients will receive placebo hCRF (XERECEPT) 2mg/day and dexamethasone 4 mg/day along with any open-label dexamethasone they may be taking
3151449|NCT00226681|Experimental|1|
2442838|NCT03278054|Active Comparator|Manual group|Root Canal Treatment with hand instruments:Root canal treatment was done with instrumentation using manual K files.
2442839|NCT03278054|Active Comparator|ProTaper group|Root canal treatment with Protaper instruments:Root canal treatment was done using ProTaper rotary files S1, S2, F1, and F2.
2442840|NCT03278054|Active Comparator|Hybrid group|Root canal treatment with hybrid instrumentation:Root canal treatment was carried out using ProTaper and Hyflex CM files.
2442841|NCT03278041|Experimental|surgical reconstruction with submental flap|surgical reconstruction with submental flap
2442842|NCT03278041|Active Comparator|maxillary obturator|maxillary obturator
2442845|NCT03278015|Experimental|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
2442846|NCT03278015|Experimental|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
2442847|NCT03278015|Experimental|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
3151450|NCT00226681|Active Comparator|2|
2442849|NCT03277976||ThermoCool SmartTouch 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
2442850|NCT03277976||ThermoCool SmartTouch 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
2442851|NCT03277976||ThermoCool SmartTouch SF 1|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 330 for the posterior wall and 450 for the anterior wall
2442852|NCT03277976||ThermoCool SmartTouch SF 2|In this cohort are included patients who will undergo atrial fibrillation ablation using the ThermoCool SmartTouch SF Catheter and Ablation Index range: 380 for the posterior wall and 500 for the anterior wall
2442853|NCT03277963|Active Comparator|Absence of sleep apnea syndrome|Pain perception tests
2442854|NCT03277963|Experimental|Presence of sleep apnea syndrome|Pain perception tests and for severe sleep apnea syndrome, treatment by positive airway pressure (PPC) ventilation
2442855|NCT03277950|Experimental|virtual reality with feedback|Participants received training via virtual reality game with feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
2442856|NCT03277950|Active Comparator|virtual reality without feedback|Participants received training via virtual reality game without feedback, 60 minutes/day, 3 days/week for 4 weeks, then follow up after 4 weeks.
2442857|NCT03277950|Other|Healthy|Participants do not play virtual reality game.
2442858|NCT03277937|Experimental|Patients with gastric varices|Patients above 18 years old with gastric varices (GV) on the initial standard diagnostic upper endoscopy will be enrolled and treated using angiography in EUS-injection of coils + CYA. GV will be classified according to Sarin and Kumar classification. Only gastro-esophageal varices type II (GOV II) (fundal varices communicating with esophageal varices) and isolated gastric varices type I (IGV I) (fundal varices within a few centimeters of the gastric cardia) will be included. Gastro-esophageal varices type I (GOV I) will be excluded. Patients with active bleeding and history of previous bleeding due to GV (secondary prophylaxis) will be included as well as patients with high-risk GV suitable for primary prophylaxis according to Baveno VI consensus. T
3151451|NCT00226694|Active Comparator|Citalopram Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
2442860|NCT03277898|Experimental|Aerobic Exercise|Participants will complete three supervised aerobic exercise sessions each week using the treadmill, stationary bicycle or elliptical training for the duration of their chemotherapy (12-18 weeks). Aerobic exercise will be performed for 20-40 minutes at 50-75% of heart rate reserve. Participants will wear heart rate monitors during all supervised sessions (Polar Electro Inc., Lake Success, NY) and will be provided with target heart rates that will be individualized using their baseline (i.e., week 0) assessment data. Home-based exercise will be introduced in week 3. For the home-based sessions, participants will be asked to complete at least 1 session per week of 30 minutes of aerobic exercise (an activity of their choosing; e.g., walking).
2442861|NCT03277898|Other|Usual Care (Wait-list Control)|Participants randomly assigned to UC group will be advised to continue with their regular activities of daily living. Following their chemotherapy, the UC group will receive the exercise intervention (lasting 12 weeks).
2442962|NCT03277222|Placebo Comparator|IN Sterile Saline|Drug: Sterile Saline Dosage form: intranasal Frequency: bid Duration: 16 weeks
3151452|NCT00226694|Placebo Comparator|Placebo Group|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
3151453|NCT00226720|Experimental|1|at the hospital
3151454|NCT00226720|Active Comparator|2|out of the hospital
3151455|NCT00226733|Experimental|A|Interval exercise training with high intensity
3151456|NCT00226733|Active Comparator|B|Exercise training with moderate intensity
3151457|NCT00226746|Experimental|Paclitaxel and Gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions), Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
3151458|NCT00226759|Experimental|OMS103HP irrigation solution|Drug
3151459|NCT00226759|Placebo Comparator|vehicle irrigation solution|Vehicle
3151460|NCT00226772|Experimental|OMS103HP irrigation solution|Drug
3151461|NCT00226772|Placebo Comparator|vehicle irrigation solution|Vehicle
3151462|NCT00226837|Placebo Comparator|1|0% nitrous oxide
3151463|NCT00226837|Active Comparator|2|33% nitrous oxide
3151464|NCT00226837|Active Comparator|3|66% nitrous oxide
3151465|NCT00226915|Active Comparator|1|Drug: Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
3151466|NCT00226915|Experimental|2|Drug: Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
3151467|NCT00226954|Experimental|Zoledronic Acid with Intermittent Hormonal Therapy|
2442862|NCT03277872|Active Comparator|GlideScope (GVL) Blade|Patients in this arm will have the first laryngoscopy performed with the GlideScope (GVL) blade and the second one with the MacIntosh blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
2442863|NCT03277872|Active Comparator|MacIntosh (MAC) Blade|Patients in this arm will have the first laryngoscopy performed with the MacIntosh (MAC) blade and the second one with the GlideScope blade. The tool used for the third laryngoscopy, followed by intubation, (either GlideScope or MAC blade) will be decided according to a second randomization, necessary to one of our secondary objectives.
2442864|NCT03277859|Experimental|YOGA-NOW|Participant will start the SAA-TBI (yoga) about 2 weeks (+/- 2 weeks) after Study Visit 3.
2442865|NCT03277859|Active Comparator|YOGA-WAIT|Participant will start SAA-TBI (yoga) about 10 weeks (+/- 2 weeks) after Study Visit 3.
3189683|NCT00779597|No Intervention|Care as usual|Care as usual, i.e. standard pain treatment and standard care
3189684|NCT00779597|Experimental|SCION-PAIN program|SCION-PAIN program - Additionally to standard pain treatment, patients from the intervention wards received, the SCION-PAIN program consisting of 3 modules: pharmacologic pain management, non-pharmacologic pain management and discharge management.
3189685|NCT00779610|Experimental|Active|Vibration with forearm flexion (active contraction)
3189686|NCT00779610|Sham Comparator|Passive|Vibration without forearm flexion (passive)
2442870|NCT03277833|Experimental|Gynostemma Pentaphyllum(Dungkulcha) Extract|Gynostemma Pentaphyllum(Dungkulcha) Extract (400mg/d)
2442871|NCT03277833|Placebo Comparator|Placebo|Placebo
2442872|NCT03277820|Experimental|Probiotic group|Intake of 1 portion (=6 droplets) Probactiol Mini during 4 weeks.
2442873|NCT03277820|No Intervention|Control group|No intake of Probactiol Mini
2442874|NCT03277807||Active|pregnant women who are physically active (spend a minimum of 150min/week with moderate to vigorous physical activity)
2442875|NCT03277807||Inactive|pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity)
2442876|NCT03277807||risk for hypertensive disorders|pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy
3189687|NCT00779636|Experimental|Desloratadine 10 mg|
3189688|NCT00779636|Placebo Comparator|Placebo|
2442879|NCT03277781||Current smokers|
2442880|NCT03277781||Ex-smokers|
2442881|NCT03277781||Coronary heart disease|
2442882|NCT03277768||Control Group -Patent Ductus Arteriosus Absent|
2442883|NCT03277768||Study Group - Patent Ductus Arteriosus Present|
2442884|NCT03277755|Experimental|Cohort1:Participants With Moderately Impaired Hepatic Function|Participants With moderately impaired hepatic function will receive a single oral dose of AL-335 800 milligram (mg) (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of odalasvir (ODV) 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + simeprevir (SMV) 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
2442885|NCT03277755|Experimental|Cohort 2: Participants With Normal Hepatic Function|Participants with normal hepatic function will receive a single oral dose of AL-335 800 mg (2 tablets of 400 mg AL-335) on Day 1 of Part 1 followed by a single oral dose of ODV 25 mg (1 tablet of 25 mg ODV) on Day 8 of Part 1 and a combination of AL-335 800 mg (2 tablets of 400 mg AL-335) + ODV 25 mg (1 tablet of 25 mg ODV) + SMV 75 mg (1 capsule of 75 mg SMV) once daily on Day 1 to 14 of Part 2. There will be a washout period between Part 1 and Part 2 of at least 14 days. Day 8 of Part 1 will be the start of the washout period. Prior to the start of study drug administration in Part 2, a safety review will be performed by the Sponsor.
2442886|NCT03277742|Active Comparator|Control|This arm will receive the standard of care for patients with TB and DM2
2442887|NCT03277742|Experimental|Intervention|This arm will receive the community intervention
2442888|NCT03277729|Experimental|Treatment (CD20-specific CAR T cell, chemotherapy)|Patients undergo leukapheresis and may receive treatment after if needed for disease control. Patients then receive cyclophosphamide IV. Patients may also receive fludarabine IV. After 36-96 hours, patients receive CD20-specific CAR T cell infusion IV over 20-30 minutes.
2442889|NCT03277716|Experimental|TACE+MWA|Transcatheter arterial chemoembolization combined with microwave ablation: 2-3 times of TACE treatment, then followed by ablation treatment using MWA system.
2442890|NCT03277703|Experimental|Group 1 - Booster|Group 1 subjects will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 1 and year 2.
2442891|NCT03277703|Active Comparator|Group 2 - Standard|Group 2 subjects will be receive the standard single dose of influenza vaccine in year 1 but will receive a second booster dose of injectable influenza vaccine 4 weeks after initial vaccination in year 2.
2442892|NCT03277690|Experimental|Levoketoconazole|Double blind withdrawal phase: Levoketoconazole (up to a dose of 1200 mg); Double blind restoration phase: Levoketoconazole plus Placebo
2442893|NCT03277690|Placebo Comparator|Placebo|Double blind withdrawal phase: Placebo; Double blind restoration phase: Placebo plus Levoketoconazole
2442894|NCT03277677|Active Comparator|normal saline|
2442895|NCT03277677|Active Comparator|balanced solution|
2442963|NCT03277209|Experimental|All Subjects|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
2442964|NCT03277196|Experimental|Ivacaftor Arm|
3189689|NCT00779649|Active Comparator|MoviPrep|
3189690|NCT00779649|Active Comparator|HalfLytely|
3189691|NCT00779714|Experimental|A (individualized combined chemotherapy)|
3189692|NCT00779714|Active Comparator|B (DTIC monochemotherapy)|
3189693|NCT00779740|Experimental|New Formulation Group|
3189694|NCT00779740|Active Comparator|Old Formulation Group|
3208500|NCT00975377|Active Comparator|Hair clipping|Patients in the clipping cohort undergo hair removal at the surgical site. Hair removal will occur on the day of surgery immediately prior to the scheduled operation.
2442896|NCT03277664|Experimental|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
2442897|NCT03277664|No Intervention|control group|"All the device-monitored adherence data were downloaded from the background database and calculated weekly. However, feedback and reminders were not given to the caregivers. Caregivers were also asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
2442898|NCT03277651||liver fibrosis|liver biopsy proved
2442899|NCT03277651||portal hypertension|hepatic venous pressure gradient (HVPG) proved
2442900|NCT03277638|Experimental|Pembrolizumab injections 7 days before surgery|Patients will have intravenous pembrolizumab 7 days before surgery with Laser Interstitial Thermotherapy
2442901|NCT03277638|Experimental|Pembrolizumab injections 14 days after surgery|Patients will have intravenous pembrolizumab 14 days after surgery with Laser Interstitial Thermotherapy
2442902|NCT03277638|Experimental|Pembrolizumab injections 35 days after surgery|Patients will have intravenous pembrolizumab 35 days after surgery with Laser Interstitial Thermotherapy
2442903|NCT03277625||pancreaticoduodenectomy|patients undergoing pancreticoduodenectomy and having a soft, fragile and/or fatty pancreatic remnant, combined with small pancreatic duct having a Diameter <3 mm.
2442904|NCT03277612||C-Section|Infants delivered by C-section
2442905|NCT03277612||Vaginal Delivery|Infants delivered by spontaneous vaginal delivery after C-section.
2442906|NCT03277599|Active Comparator|Grup Y|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine+IV patient-controlled analgesia (PCA) tramadol
2442907|NCT03277599|Active Comparator|Grup B|ultrasound ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
2442908|NCT03277586|Experimental|Probio'Stick|
2442909|NCT03277586|Placebo Comparator|Placebo|
2442910|NCT03277573|Experimental|Salsalate|Drug: Salsalate 2 tablets twice daily (3,000 mg total daily) by mouth for 12 months
2442911|NCT03277573|Placebo Comparator|Placebo|Drug: Placebo 2 tablets twice daily by mouth for 12 months
2442912|NCT03277534|Experimental|Electrical stimulation|
2442913|NCT03277534|Sham Comparator|Control|
2442914|NCT03277521|Active Comparator|Neurologically Normal|Neurologically normal subjects (i.e., nonimpaired) will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2442915|NCT03277521|Active Comparator|Quadriplegia|Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2442916|NCT03277521|Active Comparator|Quadriplegia with upper limb reconstruction|Individuals with quadriplegia and upper limb reconstruction will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
2442917|NCT03277508|Experimental|BCI robot assisted hand therapy|Brain-computer integration robot assisted hand therapy
2442918|NCT03277508|Active Comparator|CPM robot assisted hand therapy|Continue Passive Movement robot assisted hand therapy
2442919|NCT03277495|Active Comparator|nicotine SREC|The liquid in the e-cigarette refills contains nicotine
2442920|NCT03277495|Placebo Comparator|placebo SREC|The liquid in the e-cigarette refills does not contain nicotine
2442921|NCT03277482|Experimental|Phase I Safety Lead-In|"A modified 3+3 design will be used in this trial Lead-in phase with Durvalumab* and radiation therapy~*q4 weeks durvalumab for 13 cycles or until progression"
2442922|NCT03277482|Experimental|Phase I Radiation Dose Evaluation|"Durvalumab~Tremelimumab* -- Start radiation dose from safety lead-in (level 0 or level -1) *q4 weeks durvalumab / tremelimumab for 4 cycles and continue durvalumab for 13 cycles or until disease progression"
2442923|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY with Tracker|"Standard pelvic MRI sequences will be obtained~MRI Tracker is used during catheter positioning with serial MR imaging during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
2442924|NCT03277469|Experimental|MRI Guided BRACHYTHERAPY without Tracker|"Standard pelvic MRI sequences will be obtained~Standard process is used with serial MR imaging to evaluate catheter position during implant~All patients will undergo 3D-based image acquisition for brachytherapy treatment planning per standard clinical practice~The brachytherapy modality to be used is high-dose-rate brachytherapy using an iridum-192 stepping source"
2442925|NCT03277456|Experimental|Single intramuscular injection of MVA-NP+M1 vaccine|MVA-NP+M1, a novel vaccine will be administered intramuscular. The total volume given is 0.5ml and the dose given is 1.5E8 pfu. Each volunteer will receive one single injection only over a few seconds.
2442965|NCT03277196|No Intervention|Observational Arm|
3208501|NCT00975390|Experimental|1|Carbohydrate ingestion
2443667|NCT05074797||AKI in covid_19 in diabetic|AKI in covid_19 in diabetic pt
3208502|NCT00975390|Experimental|2|Carbohydrate and protein ingestion
2442926|NCT03277443|Active Comparator|Conventional Model Surgery|"Lateral Cephalogram with analysis and tracing of facial profile.~Modified model surgical tecnique:~Obtain wax bite registration.~Record face-bow transfer.~Duplication of articulating model for surgical simulation.~Measure all casts and bases in standard model surgery fashion.~Fabricate intermediate splint & Final splint.~Condylar repositional splint."
2442927|NCT03277443|Experimental|Computer guided surgery|"Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.~Computer-aided planning for study group:~All planning will be done using specialized software (Anatomage Invivo 5.3) for preoperative surgical simulation and immediate postoperative evaluation.~Pre-operative Fabrication of computer aided surgical splint:~In the study group a stereo splint will be fabricated using rapid prototyping (RP) technique to guide the osteotomy and another one will be fabricated after virtual osteotomy to guide the surgical cuts. And stent for guided holes.~So that the osteotomy will be accomplished by the aid of computer guided templates that simulates the proper bite achieved preoperatively during surgical simulation and Planning."
2442928|NCT03277430|Experimental|Live donor uterus transplantation|Transplantation of uterus from a living donor. Immunosuppression with tacrolimus.
2442929|NCT03277430|Experimental|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor. Immunosuppression with tacrolimus.
2442930|NCT03277417||Isolated Oligohydramnios|Fetuses with amniotic fluid index (AFI) equal or less than 5 cm
2442931|NCT03277417||Isolated Polyhydramnios|Fetuses with amniotic fluid index (AFI) more than 25 cm
2442932|NCT03277417||Control Group|Fetuses with normal amount of amniotic fluid
2442933|NCT03277404|Experimental|Smear Layer Positive|Root canal treatment without smear layer removal: Root canal treatment and Irrigation with 1 ml of 2.5% sodium' hypochlorite for 1 min, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1minute.
2442934|NCT03277404|Active Comparator|Smear layer negative|root canal treatment with smear layer removal:Root canal treatment and Irrigation with 1 mL of 17% EDTA solution and ultrasonic activation, followed by ultrasonic activation of 3 ml of 2.5% sodium hypochlorite for 1 minute.
2442935|NCT03277391|Active Comparator|Serratus anterior plane block|Deep serratus anterior plane block
2442936|NCT03277391|Active Comparator|patient-controlled analgesia|patient-controlled analgesia: pump containing morphine (1mg/ml) and dehydrobenzperidol (50 mcg/ml).
3189695|NCT00779753|Experimental|Neonates|Sixteen neonates admitted to the Neonatal Intensive Care Unit (NICU) at the Hospital for Sick Children (SickKids) will be required for this study. The diagnoses will include, but are not limited to, the following: Trachea-esophageal fistula and/or esophageal atresia, Congenital diaphragmatic hernia, imperforate anus, Hirschsprung's disease, Malrotation with or without volvulus, Intestinal atresias, Gastroschisis, Omphalocele, Necrotizing enterocolitis, Respiratory distress syndrome.
3189696|NCT00779805|Experimental|1|Pseudoephedrine hydrochloride 120 mg ER tablets of Ranbaxy
3189697|NCT00779805|Active Comparator|2|Sudafed 120 mg ER tablets
2442940|NCT03277339|Experimental|Paroxetine|Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
2442941|NCT03277339|Other|Thermal cure|This study is controlled with a comparator which is the Thermal cure. Thermal cure is realized for 3 weeks.
2442942|NCT03277326|Active Comparator|ISB|Interscalene brachial plexus block
2442943|NCT03277326|Active Comparator|aSSB|Anterior Suprascapular Block
2442944|NCT03277326|Active Comparator|pSSB|Posterior Suprascapular Block
2442945|NCT03277313|Experimental|Epoch 1|Pediatric patients with primary immunodeficiency disease (PIDD) who are on intravenous (IV) or non-HYQVIA subcutaneous (SC) treatment with immunoglobulin (IV-pre-treated, SC-pre-treated) will be enrolled and treated with HYQVIA subcutaneously with a dose or interval ramp-up period of up to six weeks.
2442946|NCT03277313|Experimental|Epoch 2|"HYQVIA treatment at following intervals:~For intravenous (IV)-pre-treated participants: every 3 or 4 weeks, depending on participant's previous IV schedule.~For subcutaneous (SC)-pre-treated participants: every 3 or 4 weeks, at discretion of investigator and participant.~After one year in Epoch 2, anti-rHuPH20 binding antibody assay results during year will decide next steps in study:~Participants with anti-rHuPH20 antibody titer <160 at all time-points during study will complete the study completion visit at next possible occasion following 12-month visit.~Participants with anti-rHuPH20 antibody titer ≥160 during study and/or at last measurement will continue in Epoch 2 for additional 2 years of HYQVIA treatment and observation, and complete study completion visits at next possible occasion following 36-month visit.~Alternative treatment intervals, such as infusion every 2 weeks, may be considered for tolerability reasons, at discretion of investigator after informing sponsor"
2442947|NCT03277313|Active Comparator|Epoch 3|Approximately one year safety follow-up, if needed: for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a study drug related serious adverse event (SAE) or a related severe adverse event (AE) will be followed accordingly.
2442948|NCT03277287|Experimental|Group A|Fractional CO2 laser will be applied on cleft lip scar 3 weeks post-surgical
2442949|NCT03277287|Experimental|Group B|Fractional CO2 laser will be applied on cleft lip scar 3 months post-surgical
2442950|NCT03277287|No Intervention|Group C|No intervention
3189698|NCT00779818|Experimental|Group 1|Treatment by electrical acupuncture
3189699|NCT00779818|Experimental|Group 2|Treatment by laser
3189700|NCT00779831|Experimental|1|120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
3189701|NCT00779831|Active Comparator|2|(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
2442959|NCT03277235|Experimental|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
3189702|NCT00779844|Experimental|1|obese patients
3151468|NCT00227006|Experimental|Taste-Based Goal Setting|6-month intervention (14 lifestyle counseling classes)
3151469|NCT00227006|Active Comparator|Smart Consumers|6-month intervention (14 lifestyle counseling classes)
2442970|NCT03277157|Experimental|Probiotic|Bifidobacterium animalis ssp. lactis B94 at 15 billion CFUs per capsule
2442971|NCT03277157|Placebo Comparator|Placebo|Placebo veggie capsule.
2442972|NCT03277144|Experimental|TST-TriStaple(3lines stapler)Technology|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device.
2442973|NCT03277144|Active Comparator|OCT (other conventional techniques)|During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples.
2442974|NCT03277131|Experimental|1|Antimicrobial Dressing
2442975|NCT03277118||Cardiac Surgery Cohort|Patients aged 18 years or older who are scheduled to undergo elective cardiac surgery with cardiopulmonary bypass.
3151470|NCT00227006|Active Comparator|Community Access|Can enroll in behavioral treatment programs available in the community that do not include medication or very-low calorie diets
3151471|NCT00227032|Experimental|Subjects receiving EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
2442978|NCT03277092|Experimental|VeinViewer® group|Use of near infrared light to perform blood draw (VeinViewer®)
2442979|NCT03277092|Active Comparator|Usual care group|Blood drawing performed traditionally
2442980|NCT03277079|Active Comparator|statin + ezetimibe|Low dose statin associated with ezetimibe
2442981|NCT03277079|Active Comparator|statin + ezetimibe + Nutraceuticals|Low dose statin associated with ezetimibe and Nutraceuticals
2442984|NCT03277053|Sham Comparator|control|Patients receive an ipad with no app.
2442985|NCT03277053|Experimental|Mobile application no stoma|Patients who did not receive a stoma receive an ipad containing the app and are instructed how to use it.
2442986|NCT03277053|Experimental|Mobile application stoma|Patients who receive a stoma receive an ipad containing the app and are instructed how to use it.
2442987|NCT03277040|Experimental|Intervention (CSA membership)|Employees will gain CSA membership - they will receive bi-weekly deliveries of fresh fruits and vegetables to a central location near their place of employment.
2442988|NCT03277040|No Intervention|Control (no CSA membership)|Usual care, usual employee benefits. Employees do not gain CSA membership.
2442989|NCT03277001|Active Comparator|Enoxaparin|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
2442990|NCT03277001|Experimental|Rivaroxaban|AECOPD patients meeting the eligibility criterion by GOLD2017 in hospitalization Padua score > 4
2442991|NCT03276988|Other|Part B - Sequence A|Period 1 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection
2442992|NCT03276988|Other|Part B - Sequence B|Period 1 THYROGEN® 0.9mg x 2 (Day 1 and Day 2), IM injection. Period 2 GX-30 0.9mg x 2 (Day 1 and Day 2), IM injection
2442995|NCT03276962|Experimental|R012-20 Group|Subjects will receive full doses of RTS,S/AS01E at Month 0, Month 1, Month 2 and a full dose at Month 20.
2442996|NCT03276962|Experimental|R012-14-mD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1, Month 2 and yearly full doses at Month 14, Month 26, Month 38.
2442997|NCT03276962|Experimental|Fx012-14-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 2, Month 14, Month 26, Month 38.
2442998|NCT03276962|Experimental|Fx017-mFxD Group|Subjects will receive a full dose of RTS,S/AS01E at Month 0, Month 1 and RTS,S/AS01E 1/5th dose at Month 7, Month 20, Month 32.
2442999|NCT03276962|Experimental|Control Group|Subjects will receive rabies vaccine at Month 0, Month 1, Month 2.
2443000|NCT03276949||Healthy volunteers|Non-diabetic healthy men/women in between age group 18-80 years (all races and ethnicity) will be included for blood glucose measurements
2443002|NCT03276923||Maternal Autoimmune Disease ReseArch (MADRA) Registry|Women with autoimmune diseases who are pregnant
2443003|NCT03276910|Experimental|Eprex 20 UI/kg|6 doses at 20 IU/kg in subcutaneous use
2443004|NCT03276910|Experimental|Eprex 50 UI/kg|6 doses at 50 IU/kg in subcutaneous use
2443005|NCT03276910|Placebo Comparator|Placebo|6 injections at 1ml in subcutaneous use of sodium chloride AGUETTANT 0.9%
2443006|NCT03276897|Experimental|Nutriage SPF 30 day cream and Nutriage night cream|Application of the study products (day cream at the morning and night cream at the evening), for an uninterrupted period of 3 months.
2443007|NCT03276884|Experimental|Experimental Infant Formula|Infant formula powder to be fed ad libitum
3151472|NCT00227032|Experimental|Subjects NOT taking EIAEDs|Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
3151473|NCT00227110|Active Comparator|Pioglitazone|Pioglitazone 30 mg/d will be given for 8 weeks and titrated to 45 mg/d until the end of the 6-month study in a randomized, double-blind, study design.
3151474|NCT00227110|Placebo Comparator|Placebo|Placebo once daily is given following a randomized, double-blind, placebo-controlled study design.
3151475|NCT00227123|Active Comparator|1|Quetiapine versus Risperidone
3151476|NCT00227162|Active Comparator|Group 1|Positive affect
3151477|NCT00227162|Active Comparator|Group 2|Self-Affirmation
3151478|NCT00227162|Active Comparator|Group 3|Positive Affect and self-affirmation
3151479|NCT00227162|No Intervention|Group 4|Control group
3151480|NCT00227188||1|Children from 0-5 years of age evaluated for IPD
3151481|NCT00227279|Experimental|1|
3151482|NCT00227279|Placebo Comparator|2|
3151483|NCT00227292|Placebo Comparator|A, 2, II|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
3151484|NCT00227292|Experimental|A, 1|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
3151485|NCT00227357||Buprenorphine|Study patients receiving buprenorphine treatment
3189703|NCT00779844|Active Comparator|2|lean patients
3189704|NCT00779922|Experimental|group 1 to 5|
2443011|NCT03276858|Experimental|CRN00808 Oral Solution|CRN00808 oral solution, single-dose
2443012|NCT03276858|Experimental|CRN00808 Oral Capsule|CRN00808 oral capsule, single-dose and multiple-doses
2443013|NCT03276858|Placebo Comparator|Placebo Oral Solution|Placebo oral solution, single-dose
2443014|NCT03276858|Placebo Comparator|Placebo Oral Capsule|Placebo oral capsule, single-dose and multiple doses
2443015|NCT03276858|Other|Midazolam Oral Solution|Midazolam oral solution, two single-doses as part of the drug-drug interaction arm of the study
2443016|NCT03276845|Other|1|
2443017|NCT03276832|Experimental|Treatment (pembrolizumab, imiquimod)|Patients receive pembrolizumab IV on day 1 and apply imiquimod cutaneously on days 1-5 (Monday - Friday). Courses repeat every 21 days for up to 2 years (approximately 35 courses) in the absence of disease progression or unacceptable toxicity.
2443018|NCT03276819|Experimental|Cohort A|"Samples collection and Tobacco and alcohol status follow-up for patient with OPML:~Follow-up of the lesions (pictures, biopsies, brushes), malignant transformation oversight, smoking and alcohol status follow-up (questionnaires), blood and saliva samples"
2443019|NCT03276819|Experimental|Cohort B|"Samples collection; Psychological and Sociological evaluation; Intensive and sustained smoking cessation program; Tobacco and alcohol status follow-up for patient with resectable HNSCC requiring postoperative radiotherapy or chemoradiation and which are either current smokers motivated to quit or reformed smokers within 3 months before the diagnosis of a resectable HNSCC.~Randomization 1:1, arm 1 = minimal tobacco cessation intervention, arm 2 = intensive and sustained smoking cessation program.~Smoking and alcohol status follow-up, adhesion to the smoking cessation program, tumoral follow-up, second malignant lesion, tumoral collection, blood biomarkers research"
2443020|NCT03276819|Experimental|Cohort C|Samples collection and Tobacco and alcohol status follow-up for patients with resectable HNSCC wich are not eligible to cohort B Smoking and alcohol status follow-up (questionnaires), tumoral follow-up, second malignant lesion and OPML lesion appearance oversight, tumoral collection, blood biomarkers research
2443021|NCT03276806|Experimental|SDM + decision aid + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse, SDM and a decision aid.
2443022|NCT03276806|Active Comparator|LDCT brochure + tobacco counseling|Participants will receive tobacco dependence/smoking cessation counseling by a nurse and a LDCT informational brochure.
2443023|NCT03276793|Experimental|MRI and behavioral assessment|Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
2443026|NCT03276767|Experimental|Online intervention with SMS reminder|"Reminders will be sendt by SMS-TEXTMESSAGE if users of Endre does not log on to an assigned online session by noon on the second day."
2443027|NCT03276767|Active Comparator|Online intervention with e-mail reminder|"Reminder will be sendt by E-MAIL if users of Endre does not log on to an assigned online session by noon on the second day."
2443028|NCT03276741|No Intervention|Control Group|Routine care during labor (authorized clear liquid diet).
2443029|NCT03276741|Active Comparator|Experimental Group|"Patients in the experimental group will have a gastric soft/bland diet available, which will include lean protein, fruits, vegetables, and low-fat dairy. This will be ordered in the electronic medical record (EMR) and is a standard non-select meal, referred to as a gastric/soft bland diet that is not based on patient's preferred menu selections."
2443030|NCT03276728|Active Comparator|AMG 986 IV Dose Level A|or matching placebo
2443031|NCT03276728|Active Comparator|AMG 986 IV Dose Level B|or matching placebo
2443032|NCT03276728|Active Comparator|AMG 986 IV Dose Level C|or matching placebo
2443033|NCT03276728|Active Comparator|AMG 986 IV Dose Level D|or matching placebo
2443034|NCT03276728|Active Comparator|AMG 986 IV Dose Level E|or matching placebo
2443035|NCT03276728|Active Comparator|AMG 986 IV Dose Level F|or matching placebo
2443036|NCT03276728|Active Comparator|AMG 986 IV Dose Level G|or matching placebo
2443037|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A|or matching placebo - HV
2443038|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B|or matching placebo - HV
2443039|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C|or matching placebo - HV
2443040|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D|or matching placebo - HV
2443041|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E|or matching placebo - HV
2443042|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F|or matching placebo - HV
2443043|NCT03276728|Active Comparator|AMG 986 Oral Dose Level A - MAD|or matching placebo - HV
2443044|NCT03276728|Active Comparator|AMG 986 Oral Dose Level B MAD|or matching placebo - HV
2443045|NCT03276728|Active Comparator|AMG 986 Oral Dose Level C MAD|or matching placebo - HV
2443046|NCT03276728|Active Comparator|AMG 986 Oral Dose Level D MAD|or matching placebo - HV
2443047|NCT03276728|Active Comparator|AMG 986 Oral Dose Level E MAD|or matching placebo - HV
2443048|NCT03276728|Active Comparator|AMG 986 Oral Dose Level F MAD|or matching placebo - HV
2443049|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-HEF|Heart failure patients with reduced ejection fraction
2443050|NCT03276728|Active Comparator|AMG 986 Oral dose regimen or placebo-REF|Heart failure patients with preserved ejection fraction
3189705|NCT00779935|Experimental|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
3189706|NCT00779948||Targon FN|
3189707|NCT00779948||DHS|
3189708|NCT00779961|Experimental|Group A|Early Cleft Palate Repair (Age group 6-10 months)
3208503|NCT00975390|Experimental|3|Carbohydrate and caffeine ingestion
2443051|NCT03276702||Participants|St. Jude Children's Research Hospital patients with relapsed or progressive solid tumor will be asked to complete a questionnaire on two occasions and optional re-biopsy of tumor tissue.
2443052|NCT03276689|Experimental|Duloxetine|The patients will take 2 tab/d of duloxetine 60mg for 8 weeks. In the first 7 days dose of duloxetine will be 30mg/day in order to lower side effects and improve compliance. For duloxetine, the morning dose will be a sham pill.
2443053|NCT03276689|Experimental|Pregabaline|The patients will take 2 tab/d of pregabaline 150mg x 2/day for 8 weeks.The initial 7-days dose of pregabaline will 75mg x 2.
2443054|NCT03276689|Experimental|Placebo|The patients will take 2 tab/d placebo for 8 weeks.
2443055|NCT03276676|Experimental|All Enrolled participants|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
2443056|NCT03276663|Other|Formula fed group|Formula feeding regimen
2443057|NCT03276663|No Intervention|Human milk-fed group|
2443058|NCT03276650||critically ill AOSD patients|no intervention Data collection from hospitalisation reports (administrative, biological, clinical, outcome)
2443060|NCT03276624|Other|patients with low EF undergoing CABG|Chronic Unstable Angina patients with low ejection fraction and a viable myocardium will undergo surgical revascularization CABG
2443061|NCT03276598|Active Comparator|Amlodipine|One of the four monotherapy treatment periods.
2443062|NCT03276598|Active Comparator|Bisoprolol|One of the four monotherapy treatment periods.
2443063|NCT03276598|Active Comparator|Hydrochlorothiazide|One of the four monotherapy treatment periods.
2443064|NCT03276598|Active Comparator|Losartan|One of the four monotherapy treatment periods.
2443065|NCT03276598|Placebo Comparator|Placebo|Placebo treatment period.
2443066|NCT03276572|Experimental|All Subjects|A single dose of 225Ac-J591 will be given to subjects with documented progressive metastatic CRPC.
2443067|NCT03276559|Experimental|EMPOWER arm|"The EMPOWER arm includes six 15 minute modules delivered in a 1-on-1 format with the same interventionist, and 2 boosters (approximately 45 minutes each) conducted by phone.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the EMPOWER intervention within 3 months conducted in person and by phone."
2443068|NCT03276559|Placebo Comparator|Enhanced usual care arm|"The usual care arm indicates regular ICU support for informal caregivers (i.e. social work, chaplaincy) as recorded in the patient's medical record, a general information packet for informal caregivers, and a site-specific resource list.~Subjects who meet eligibility criteria will receive up to 4 sequential assessments before and after the usual care within 3 months conducted in person and by phone."
2443069|NCT03276546|Experimental|SHARE-D decision tool use|The intervention, a shared decision-making tool ('SHARE-D'), which is a paper-based questionnaire, will be used jointly by a health professional and patient to facilitate decision-making about initiating change in physical activity or diet behaviour
2443070|NCT03276533|Experimental|Intravenous saline, dexmedetomidine and lidocaine|
2443071|NCT03276533|Experimental|Intravenous saline, dexmedetomidine, lidocaine and combination|
2443072|NCT03276533|Experimental|Intravenous saline,dexmedetomidine plus lidocaine|
2443073|NCT03276533|Experimental|Intravenous saline, dexmedetomidine combined with lidocaine|
2443074|NCT03276520|Experimental|ethyl glucuronide|subjects being screened with ethyl glucuronide
2443075|NCT03276520|Active Comparator|ethanol|subjects being screened with ethanol
3151486|NCT00227357||Comparison|Study patients receiving methadone or no agonist treatment
2443079|NCT03276455|Experimental|Experimental|Beta-thalassemia major subjects who are 8 years age or older are transplated by autologous CD34+ cells genetically modified(autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene).
2443080|NCT03276442|Experimental|Healthy diet|'Low-fat dietary intervention' to be administered to participants
2443081|NCT03276442|Experimental|Unhealthy diet|'High-fat dietary intervention' to be administered to participants
2443082|NCT03276429||Lung Cancer patients|All patients with lung cancer that referred to a tertiary Oncology Unit.
2443083|NCT03276416||150 children with concomitant asthma and rhinitis|Baseline and one-month administration of RAPP-children, RHINASTHMA-children, C-ACT, VAS, Kiddy KINDLE, GRS. Baseline and one-month spirometry.
2443084|NCT03276390|Active Comparator|Intervention study site|"Exposure to the intervention, which is the Northwestern Medicine (TM) Hispanic Kidney Transplant Program, a culturally targeted program for Hispanic potential recipients for transplant evaluation that is implemented into the 2 study sites.~The intervention study site will provide the intervention to its Hispanic patients.~The intervention study will will also provide the routine care (control arm) to all other patients.~For the purposes of this study, Hispanic potential recipients recruited into the study will be exposed to this intervention. Non-Hispanic Whites recruited into the study will not be exposed to this intervention."
2443085|NCT03276390|No Intervention|No intervention study site|Exposure to routine transplant evaluation at the two control sites.
2443086|NCT03276377||Exposed to VKA|VKA intake Patients who have been taking VKA for at least 3 months
2443087|NCT03276377||Non-exposed to VKA|DOAC intake Patients who have been taking DOAC for at least 3 months
2443088|NCT03276364||Shock|
3151487|NCT00227461|Other|Wait control|Levitiracetam is started after a delay, with dosage and administration as described below.
3151488|NCT00227461|Experimental|Treatment first|Levitiracetam is started immediately after baseline data is collected; dosage and administration as described below.
2443091|NCT03276338|Experimental|Intervention|Participation in the HOLA intervention designed to prevention HIV
3151489|NCT00227487|Other|Stool collection, Carbohydrate administration, Questionnaires|"A stool sample will be obtained~A carbohydrate solution (lactulose plus rhamnose dissolved in tap water) will be administered during a clinically indicated endoscopic procedure.~Five questionnaires will be completed by parent/guardian"
3173100|NCT00608101|Experimental|2|Fludrocortisone will be administered in doses of 0.05mg, 0.1mg and 0.2 mg form at the start of each clamp period on day 1. Dexamethasone will be administered orally in the doses of 0.18 mg, 0.375mg and 0.75mg doses. The combination of the 0.05mg fludrocortisone and 0.18mg dexamethasone and 0.1mg of fludrocortisone and 0.375 mg doses will be administered at the start of each day 1 clamp period. Day 2 90 minutes of moderate exercise.
2443092|NCT03276338|No Intervention|Delayed-intervention|Delayed intervention with participation in HOLA intervention after follow-up data have been collected
2443093|NCT03276325|Placebo Comparator|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
2443094|NCT03276325|Active Comparator|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
2443095|NCT03276312|Experimental|Intervention|Lipogems - local injection of autologous micro-fragmented adipose tissue
2443096|NCT03276312|No Intervention|Control|Routine clinical practice
2443097|NCT03276299|Active Comparator|test 1|six minute walking test
2443098|NCT03276299|Experimental|test 2|six minute walking test
2443099|NCT03276299|Experimental|test with encouragement|six minute walking test
2443100|NCT03276299|Active Comparator|test without encouragement|six minute walking test
2443101|NCT03276286|Experimental|Nativis Voyager|Nativis Voyager combined with SOC Radiotherapy and temozolomide
2443102|NCT03276247||Asian American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and non-pregnant/non-breastfeeding.
2443103|NCT03276247||African American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and non-pregnant/non-breastfeeding.
2443104|NCT03276247||Hispanic American non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and non-pregnant/non-breastfeeding.
2443105|NCT03276247||White non-pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as white and non-pregnant/non-breastfeeding.
2443106|NCT03276247||Asian American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Asian American and pregnant or breastfeeding.
2443107|NCT03276247||African American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as African American and pregnant or breastfeeding.
2443108|NCT03276247||Hispanic American pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as Hispanic American and pregnant or breastfeeding.
2443109|NCT03276247||White pregnant|Women 25 to 44 years of age recruited in a primary care setting and self reported as White and pregnant or breastfeeding.
2443113|NCT03276208|Experimental|Massage Therapy and Mindfulness|Participants in the intervention group will receive two prenatal massages a week for a three-week period. They will also be enrolled in the mindfulness-based Craving to Quit® tobacco cessation program during this 3-week period.
2443114|NCT03276208|Active Comparator|Mindfulness|Participants will enroll in the mindfulness-based Craving to Quit® tobacco cessation program during the same 3-week period. A massage will be provided upon completion of the study.
2443115|NCT03276195||Familial TSC and families|Individuals with familial TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
2443116|NCT03276195||Sporadic TSC and families|Individuals with sporadic TSC including those with a clinical diagnosis but no genetic confirmation and individuals with a genetic diagnosis
2443117|NCT03276182|Experimental|cataract patients|cataract patients undergoing phacoemulsification
2443118|NCT03276169|Experimental|Left atrial appendage closure group|
2443119|NCT03276169|Other|Radiofrequency ablation group|
2443120|NCT03276169|Experimental|LAAC combined with radiofrequency ablation group|
2443121|NCT03276156|Experimental|Apatinib plus S-1|Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)
2443122|NCT03276143|Active Comparator|Enoxaparin|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days until venography was performed.
2443123|NCT03276143|Active Comparator|Apixaban|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received apixaban for at least 10 days until venography was performed.
2443124|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once post-surgery.
2443125|NCT03276143|Experimental|BAY1213790 0.6 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.6 mg BAY1213790 once post-surgery.
2443126|NCT03276143|Experimental|BAY1213790 1.2 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.2 mg BAY1213790 once post-surgery.
2443127|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (post-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once post-surgery.
2443128|NCT03276143|Experimental|BAY1213790 0.3 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 0.3 mg BAY1213790 once pre-surgery.
2443129|NCT03276143|Experimental|BAY1213790 1.8 mg/kg (pre-surgery)|Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received 1.8 mg BAY1213790 once pre-surgery.
2443130|NCT03276130||Part A: Retrospective register study|To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population.
2443131|NCT03276130||Part B1: Survey to HTC|The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts.
2443132|NCT03276130||Part B2: Survey to PwH|All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey.
2443133|NCT03276104|Active Comparator|IOL repositioning group|
2443134|NCT03276104|Active Comparator|IOL exchange group|
2443668|NCT05074797||covid_19 in diabetic|covid_19 in diabetic without AKI
2443137|NCT03276065|Experimental|Laser plus Standard of Care Depilation|Laser depilation to the natal cleft (pilonidal region) every 4-6 weeks for 5 treatments with either an 810nm or Nd:YAG laser dependent on Fitzpatrick skin type and tolerability. Patients and families in the intervention group will also be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free between clinic treatments.
2443138|NCT03276065|Active Comparator|Standard of Care Depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
3151490|NCT00227513|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) twice daily on days 1-14 in step A. Patients receive oral vorinostat (SAHA) twice daily on days 1-4 and 8-11 in Step B and bortezomib IV over 3-5 seconds on days 2, 5, 9, and 12 during the first course and on days 1, 4, 8, and 11 during subsequent courses in both steps A and B. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 1-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 6 additional patients receive bortezomib at the MTD. Subsequent cohorts of 3-6 patients receive escalating doses of SAHA until the MTD of that drug is determined."
3151491|NCT00227565|Experimental|pemetrexed + carboplatin + radiation|"Patients receive pemetrexed disodium IV over 10 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who develop progressive disease in the CNS only may receive whole-brain radiotherapy and then continue chemotherapy after completion of whole-brain radiotherapy for up to 6 courses.~After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for 4 years."
3151492|NCT00227656|Experimental|Capecitabine + PEG-interferon alfa-2a|Capecitabine 1000 mg/m2 orally twice daily during the first 14 days of each 3-week cycle (2 weeks on, 1 week rest), and PEG-interferon alfa-2a subcutaneously beginning at 180 mcg per week for 21 days.
2443142|NCT03276039||25 patients with non-alcoholic fatty liver disease|
2443143|NCT03276039||25 patients with NAFLD and chronic HCV|
2443144|NCT03276039||20 healthy controls|
2443147|NCT03276013|Experimental|A|Doxorubicin 60 mg/kg IV over 30 minutes on day 1 every 3 weeks up to 9 cycles in combination with Pembrolizumab (MK-3475) 200 mg IV Q3W
2443148|NCT03276000|Active Comparator|Group A|50 patients receive 200 mg oral misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy
2443149|NCT03276000|Active Comparator|group B|50 patients receive 200 mg misoprostol (Misotac; Sigma Pharm) 3h before office hysteroscopy moistened with saline solution will be inserted in posterior fornix of vagina.
2443150|NCT03275987|Experimental|Mammography treatment|Mammography direct mail coupled with a financial incentive
2443151|NCT03275987|Active Comparator|Mammography control/delayed intervention|Usual care (for 15 months); Mammography direct mail coupled with financial incentive (after 15 months)
2443152|NCT03275987|Experimental|Colonoscopy treatment|Colonoscopy direct mail coupled with a financial incentive
2443153|NCT03275987|Active Comparator|Colonoscopy control/delayed intervention|Usual care (for 15 months); Colonoscopy direct mail coupled with financial incentive (after 15 months)
2443154|NCT03275974|Experimental|Treatment|Patients receive carbon C 11 Glutamine (11C-glutamine) IV and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed.
2443155|NCT03275961|Experimental|Depressed Subjects|Subjects will undergo an 8 week behavioral program with Stress Management and Resiliency Training.
2443156|NCT03275948|Experimental|whole grain|
2443157|NCT03275948|Other|refrence|white wheat based product
2443158|NCT03275935||Training Arm|Patients that were given training in regards to proper inhalation technique of Rotahalers
2443159|NCT03275922|Other|Run-in - ZNS - Placebo - OLE|After Run-in period, subjects will be randomized to ZNS followed by placebo ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
2443160|NCT03275922|Other|Run-in - Placebo - ZNS - OLE|After Run-in period, subjects will be randomized to placebo ZNS followed by ZNS. Upon successful completion of Part 1, subjects may enroll into OLE (Part 2).
2443161|NCT03275909|Experimental|Study procedure|An experimental group the psychological treatment includes 50 sessions of integrated psychological therapy (IPT) (focused on attentional skills training, social perception skills training, verbal communication skills, social skills training, interpersonal problems solving skills) and 10 sessions of specific emotional management therapy (EMT), designed for this research and based on the contents developed by Hodel, Kern and Brenner.
2443162|NCT03275909|No Intervention|Treatment as usual|The treatment as usual is pharmacological treatment and activities in a Day Care Center.
2443163|NCT03275896|Experimental|Descemet Membrane Transplantation|Patients with severe, symptomatic Fuch's Endothelial Dystrophy (FED) will be offered Descemet Membrane Transplantation (DMT) for their condition.
2443166|NCT03275844||Group 1|Children with congenital heart disease
2443167|NCT03275844||Group 2|Control healthy subjects
2443170|NCT03275818|Experimental|nab-paclitaxel|"nab-paclitaxel (ABRAXANE) will be administered as follows:~Age ≥ 21: 125 mg/m2 days 1, 8 and 15 in cycles of 28 days~Age ≥ 6 months and ≤ 20 years: 240 mg/m2 (for patients weighing > 10 kg) and 11.5 mg/kg (for patients weighing ≤ 10 kg) on days 1, 8 and 15 in cycles of 28 days"
2443171|NCT03275805|Active Comparator|12 weeks Pavlik Treatment Arm|This arm will receive 12 weeks of full-time Pavlik Harness treatment. Patients will most likely begin the 12-week regiment at their first visit to our hip clinic.
2443172|NCT03275805|Experimental|6 weeks Pavlik Treatment Arm|This arm will receive treatment to normalization, but for no less than 6 weeks. Patients will begin their treatment around the time of their first visit to our designated hip clinic.
2443208|NCT03275558|Active Comparator|Sunitinib|A single dose of Sunitinib- 5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2443692|NCT05074914|Experimental|Adenocarcinoma of the oesophagus|curative oesophagectomy
2443173|NCT03275792|Experimental|Admission/Intravascular Volume Expansion|"Infusion of 40 mL/kg of 0.9% normal saline (NS) IV over 60 minutes~0.9% NS with 5% dextrose at 150% of standard maintenance volume~If urine output is <0.5 ml/kg/hr over a 12-hour period (AKI Stage 2), repeat 20 mL/kg bolus or boluses of 0.9% NS will be infused as long as there are no signs of central volume overload~Oral fluids ad lib along with strict input/output documentation~Fluids will be restricted if: A) Anuria for 12 hours OR B) Evidence of fluid overload~Daily laboratory tests and in-person assessment until inpatient discharge criteria reached:~A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child~Repeat hematocrit, platelet, renal function 24 and 72-hours post-discharge."
2443174|NCT03275792|Active Comparator|Outpatient Observation|"Following standard emergency department (ED) care [volume status assessed; dehydration corrected employing oral rehydration in children with mild to moderate dehydration (most common); IV if severe (rarely)], children are discharged with saline lock IV (routine procedure across Canadian pediatric EDs).~Oral fluids (preferably electrolyte maintenance solutions) ad lib following ED discharge~Additional health assessments as required~Daily blood tests at a local laboratory with results conveyed daily to the site-investigator until outpatient discharge criteria achieved; no in-person assessment given logistics (i.e. distance), impact on family, and mirroring of standard practice A) 2 - 4 days since symptom onset AND rising platelet count (>5% increase) documented over 48 hours in a clinically well child B) ≥5 days since symptom onset AND stable platelet count (<5% decrease) documented over 48 hours in a clinically well child"
2443175|NCT03275779|Experimental|Low Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
2443176|NCT03275779|Experimental|High Frequency Condition|Participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
3189709|NCT00779961|Active Comparator|Group B|Sick Kids Routine cleft palate repair (age group 10-14 months)
3189710|NCT00779974||s/p Total Shoulder Arthroplasty|The subject population for this study consists of adult patients with a primary diagnosis of osteoarthritis who have had a total shoulder arthroplasty preformed by the PI between September 2003 through December 2007.
3189711|NCT00779987|Other|Autologous serum -Systane|Crossover arm starting with autologous serum for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using artificial tears (Systane)
3189712|NCT00779987|Other|Systane- Autologous serum|Crossover arm starting with artificial tears (Systane) for 2 weeks. After a 1 week wash out with 0.9% sodium chloride, they continue with 2 weeks using autologous serum.
2443181|NCT03275753||Normal Population|VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
2443182|NCT03275753||Early Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
2443183|NCT03275753||Intermediate Dry AMD Population|VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
2443184|NCT03275753||Advanced Dry AMD Population|Clinical diagnosis of advanced dry AMD in the study eye
2443185|NCT03275740|Experimental|PF-06755347 intravenous|intravenous administration
2443186|NCT03275740|Placebo Comparator|Placebo intravenous|intravenous administration
2443187|NCT03275740|Experimental|PF-06755347 subcutaneous|subcutaneous administration
2443188|NCT03275740|Placebo Comparator|Placebo subcutaneous|subcutaneous administration
2443189|NCT03275727|Experimental|A - iACT-BC experimental group|
2443190|NCT03275727|Other|B - Waiting list control group|
2443191|NCT03275714|Active Comparator|People With a Bipolar Affective Disorder|
2443192|NCT03275714|Active Comparator|Control subjects without a psychiatric disorder|
2443193|NCT03275701|Other|Triumeq|Single Arm, Open Label
2443194|NCT03275688||Stage 1 Lung Cancer (Case)|These are the participants with identified stage 1 lung cancer.
2443195|NCT03275688||Type 1 Control|These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
2443196|NCT03275688||Type 2 Control|These are housemates of the participants with stage 1 lung cancer (cases).
2443197|NCT03275675||Patients with cancer chemotherapy|This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
2443198|NCT03275662|Experimental|Fiber Group|Participants are asked to increase their usual dietary fiber intake by 20 grams/day.
2443199|NCT03275662|Experimental|Fermented Foods Group|Participants are asked to consume 6 servings of fermented foods per day.
2443200|NCT03275636|Experimental|Haploidentical donor|Peripheral blood stem cells from Haploidentical donor
2443201|NCT03275636|Active Comparator|partially matched unrelated donor|Peripheral blood stem cells from unrelated donor with a single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent DQB1 mismatch (9/10) shown by confirmatory typing
3189713|NCT00780000|Experimental|A1|
3189714|NCT00780013|Experimental|1|metformin hydrochloride (HCI) liquid 500 mg/5 mL of Ranbaxy
2443204|NCT03275597|Experimental|SBRT followed by Durvalumab+Tremelimumab|"Therapeutic Interventions Stereotactic Body Radiotherapy (SBRT) to all sites of disease between 30 and 50 Gy in five fractions administered over two weeks.~Investigational Product(s), Dose, and Mode of Administration: to begin 7 days (+/- 3 days) after radiation Durvalumab 1500 mg via infusion Q4W (equivalent to 20 mg/kg Q4W) until disease progression in patients > 30 kg Tremelimumab 300 mg via infusion (equivalent to 4 mg/kg) in one dose in patients >30 kg Weight-based dosing should be utilized for patients ≤30 kg; durvalumab 20 mg/kg Q4W and tremelimumab 4 mg/kg"
2443205|NCT03275584|Experimental|Main arm|N-13 ammonia intravenous injection; 2 injections, 3-7 MBq/kg per injection
2443206|NCT03275571|Experimental|cCBT intervention|Over the course of 9 weeks, 30 min online sessions, once per week, with a fictive therapist.
2443207|NCT03275558|Active Comparator|Axitinib|A single dose of Axitinib - 1 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2443335|NCT03274739||Pregnant women|
3189715|NCT00780013|Active Comparator|2|Glucophage® 1000 mg tablets
2443209|NCT03275558|Active Comparator|Pazopanib|A single dose of Pazopanib-5 mg in a liquid form in the composition (Axitinib+Sunitinib+Pazopanib) of the nasal spray.
2443210|NCT03275545||Anorexia Nervosa, Weight Restored|Individuals with a recent diagnosis of anorexia nervosa (within the past 6 months), who currently have their weight in a healthy range (BMI > or = 18.5 kg/m2)
2443211|NCT03275545||Non-eating disorder Control|Individuals without a history of an eating disorder and no current DSM-5 psychiatric diagnoses.
2443212|NCT03275519|Active Comparator|Antibiotics prophylaxis cohort|Subjects were prescribed prophylactic antibiotics after the hypospadias surgery.
2443213|NCT03275519|Active Comparator|Antibiotic-sparing cohort|Subjects were not prescribed prophylactic antibiotics after the hypospadias surgery.
2443214|NCT03275506|Experimental|Pembrolizumab + Chemotherapy|"Arm B (n=60): 4 neo-adjuvant cycles of standard 3 weekly Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm B: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy.~In the arm B, patient will receive Pembrolizumab 200 mg until a maximum of 15 months in total from the beginning of the adjuvant therapy."
2443215|NCT03275506|Active Comparator|Chemotherapy alone|"Arm A (n=30): 4 neo-adjuvant cycles of standard 3 weekly carboplatin (AUC5 or 6) and paclitaxel (175mg/m²)~Arm A: carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), q3 weeks +/- bevacizumab (15 mg/kg Q3W)~The total number of cycles of chemotherapy will be 6 cycles from the start of the neo-adjuvant chemotherapy. Three additional cycles are allowed if required (maximum 9 cycles in total).~The planning of administration or not of bevacizumab will be defined before the randomization and could not be modified (stratification factor).~After chemotherapy:~- In the Arm A & B, for patients receiving bevacizumab (as standard therapy) (15 mg/kg Q3W), this will be continue until a maximum of 15 months in total from the beginning of the adjuvant therapy."
2443216|NCT03275493|Experimental|Experimental: Cohort 1|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia
2443217|NCT03275493|Experimental|Experimental: Cohort 2|This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.
2443218|NCT03275467|Experimental|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
2443219|NCT03275454|Experimental|BIVV009|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009 intravenous (IV) infusion and participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009 every 2 weeks for approximately 21 weeks in Part A (based on time to complete 11 doses of study drug). There will be a 9-week safety follow-up/washout period after administration of the last dose of study drug in Part A. Participants who have been shown to benefit from BIVV009 treatment during Part A, will receive BIVV009 (based on weight) biweekly for up to 52 weeks of BIVV009 after Last Patient In (LPI) in part B.
2443220|NCT03275441||Adult patients|Adult patients attending hospital for clinical visual electrophysiology.
2443221|NCT03275428||THRIVE group|Patients receiving non-intubated thoracic surgery for lung nodule resections using intravenous sedation and transnasal humidified rapid-insufflation ventilator exchange
2443222|NCT03275428||Double lumen group|Patients receiving non-intubated thoracic surgery for lung nodule resections using general anesthesia and double lumen endobronchial tube
2443223|NCT03275415|Active Comparator|Experimental|Curosurf + budesonide
2443224|NCT03275415|Placebo Comparator|Placebo|Curosurf + saline
3189716|NCT00780039|Experimental|Single Arm|Caelyx 30 mg/m2 in combination with carboplatin dosed to target AUC of 5 mg/mL.min.
3189717|NCT00780052|Experimental|1|c-myb AS ODN as a 24-hour continuous infusion over 7 days
3189718|NCT00780078||1|Patients intubated orotracheally for over 6 days
3189719|NCT00780091||1|classical monitoring strategy
3189720|NCT00780091||2|optimized monitoring strategy
3189721|NCT00780104|Experimental|Rapamycin + MEC|
3189722|NCT00780130||Group 1|male & female college students ages 20 to 50, asymptomatic normals
3189723|NCT00780169|Experimental|sorafenib +FOLFIRI|This is a Phase I safety study. There is only one arm of FOLFIRI administered every 14 days (2 week schedule) and sorafenib administered orally, twice daily continuously. First cycle sorafenib began at day +2 to FOLFIRI.
3189724|NCT00780182|Experimental|1|All subjects will receive three 40mg doses of CMX001 as 1)solution fasted, 2)tablet fasted and 3)tablet following a high-fat breakfast. The order in which each subject receives each of the doses will be determined by a randomization code.
3189725|NCT00780195|Experimental|1|Single 2 hour hyperinsulinemic euglycemic clamp study at ~90 mg/dl.
3189726|NCT00780195|Experimental|2|Single 2 hour hyperinsulinemic hypoglycemic clamp study at ~70 mg/dl.
3189727|NCT00780195|Experimental|3|Single 2 hour hyperinsulinemic hypoglycemic clamp at ~60 mg/dl.
3189728|NCT00780195|Experimental|4|Single, 2 hour hyperinsulinemic hypoglycemic clamp at ~50 mg/dl.
3189729|NCT00780221||control|patients without coronary artery disease
3189730|NCT00780221||case|patients with coronary artery disease
3189731|NCT00780247||Alaska residents|"50 healthy community dwelling males or females."
3189732|NCT00780247||Hawaiian residents|"50 healthy community dwelling males or females at each site"
3189733|NCT00780260|Experimental|1|5 session strengths-based case management intervention delivered by a professional case manager and a peer support specialist team
3189734|NCT00780260|Active Comparator|2|5 session strengths-based case management intervention delivered by a professional case manager.
2443236|NCT03275376|Experimental|Statin treated group|
2443237|NCT03275376|Placebo Comparator|Control group|
2443238|NCT03275363||Cognitively normal controls (CNC)|No subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
2443239|NCT03275363||Subjective cognitive decline (SCD)|Subjective memory complaints Normal HK-MoCA Normal instrumental ADL All interventions as described
2443240|NCT03275363||Mild cognitive impairment (MCI)|Subjective memory complaints Low HK-MoCA Normal instrumental ADL All interventions as described
2443241|NCT03275363||Alzheimer's dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Probable Alzheimer's disease All interventions as described except EEG with ERP
2443242|NCT03275363||Vascular dementia|Subjective memory complaints Low HK-MoCA Poor instrumental ADL Related to stroke / cerebrovascular disease All interventions as described except EEG with ERP
2443243|NCT03275350|Active Comparator|XR-NTX|Extended-release naltrexone
2443244|NCT03275350|Active Comparator|TAU|Treatment as usual
2443245|NCT03275337|Experimental|Anodal tDCS|Anodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
2443246|NCT03275337|Experimental|Cathodal tDCS|Cathodal tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
2443247|NCT03275337|Active Comparator|Sham tDCS|Sham tDCS will be performed over bilateral cerebellar hemispheres for 20-minutes.
2443248|NCT03275324||Enrolled patients|Surgical patients meeting enrollment criteria
2443249|NCT03275285|Experimental|Isatuximab + Carfilzomib + Dexamethasone (IKd)|Isatuximab (intravenous) on day 1, 8, 15 and 22 of 1st cycle, then on day 1 and 15 of subsequent cycles in combination with carfilzomib (intravenous) on day 1, 2, 8, 9, 15 and 16 + dexamethasone (intravenous or by mouth [po]) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
2443250|NCT03275285|Active Comparator|Carfilzomib + Dexamethasone (Kd)|Carfilzomib (intravenous) on day 1, 2, 8, 9, 15, 16 + dexamethasone (intravenous or po) on day 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
2443251|NCT03275272|Other|level of IGF-1 in infant|Measurment of blood level of IGF-1 In infants
2443252|NCT03275259|Experimental|Extracorporeal shock waves|Composed of 30 female patients with glandular lipodystrophy in the buttocks and posterior thigh and fat located in abdomen and flanks that received the treatment of extracorporeal shock waves with energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
2443254|NCT03275207|Placebo Comparator|control group|an equal volume of saline
2443255|NCT03275207|Experimental|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
2443256|NCT03275194|No Intervention|Control group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm does not receive additional treatment and the procedure will be finished.
2443257|NCT03275194|Experimental|HIPEC group|After achieving a complete cytoreductive surgery (no visible residual disease), the patient will be randomised and if is assigned to this arm receive a HIPEC procedure with cisplatin and doxorubicin.
2443258|NCT03275181||Prostate cancer patient/survivor with ADT history|Prostate cancer patients or survivors who have a treatment history that includes androgen deprivation therapy. This includes 1) orchiectomy (surgical castration), 2) luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or Gonadotrophin-releasing hormone (GnRH) agonists), 3) LHRH antagonist, 4) CYP17 inhibitor, or 5) anti-androgen.
2443259|NCT03275181||Prostate cancer patient/survivor without ADT history|Prostate cancer patients or survivors who have never been treated with androgen deprivation therapy.
2443260|NCT03275181||Control|Individuals with no history of prostate caner androgen deprivation therapy. Free of known clinical cardiovascular disease
3151493|NCT00227669|Active Comparator|Arm I: Gemcitabine|"Gemcitabine at Day 1, Day 8 and Day 15. No treatment at Day 22.~1 cycle = 28 days.~Treatment duration: 8 months"
3151494|NCT00227669|Experimental|Arm II: Gemcitabine + Docetaxel|"Gemcitabine at Day 1 and Day 8. No treatment at Day 15. Docetaxel at Day 8.~1 cycle = 21 days.~Treatment duration: 6 months"
2443263|NCT03275155||AFDAS|patients without history of atrial fibrillation before the qualifying stroke or transient ischemic attack who are diagnosed with atrial fibrillation during the 14 days of monitoring
2443264|NCT03275155||KAF|atrial fibrillation known before the stroke or transient ischemic attack
2443265|NCT03275155||NSR|patients without a history of atrial fibrillation who do not develop atrial fibrillation during the 14 days of cardiac monitoring
2443266|NCT03275142|Experimental|Icare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
2443267|NCT03275142|Active Comparator|No ICare Applanation|"Evaluation of corneal stability post-applanation with Icare tonometer via pre and post applanation keratometry readings with IOL Master, topography with Pentacam, fluorescein corneal staining. Patient's OD and OS are randomized into study or control, then undergo applanation with Icare. Investigator is masked as to which eye has undergone applanation."
3151495|NCT00227682|Experimental|Arsenic Trioxide|Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid
3151496|NCT00227695|Active Comparator|Arm A: Rituximab every 2 months x4|Rituximab 375 mg/m2 every 2 months x4
3151497|NCT00227695|Active Comparator|Arm B: Rituximab (5 years)|Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity
3151498|NCT00227734|Active Comparator|Arm I|Patients receive oral capecitabine twice daily on days 1-15 and oxaliplatin IV over 2 hours on day 1.
3151499|NCT00227734|Active Comparator|Arm II|Patients receive capecitabine and oxaliplatin as in arm I and cetuximab IV over 1-2 hours on days 1 and 8
3151500|NCT00227747|Experimental|Radiothérapie + Xelox|
3151501|NCT00227747|Active Comparator|Radiothérapie + Capécitabine|
3151502|NCT00227864|Placebo Comparator|Treatment as Usual|Participants are administered assessments at baseline, 1, 3 and 6 months
3173101|NCT00608127|Experimental|1|Single arm open label
3173102|NCT00608153||1|Patient with essential hypertension under treatment with candesartan or candesartan HCT
2443269|NCT03275116|Active Comparator|Twice daily dual bronchodilation|Twice daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg during 4 days
2443270|NCT03275116|Active Comparator|Once daily single bronchodilation|Once daily Tiotropium 'Respimat' 5 mcg during 4 days
3151503|NCT00227864|Experimental|Intervention|Participants complete assessments at baseline, 1, 3 and 6 months, and receive a 2-session behavioral intervention at the baseline and 1-month study appointments.
3151504|NCT00227890|Experimental|1|Motivational Interviewing followed by Cognitive Behavior Therapy (MI/CBT)
3151505|NCT00227890|Experimental|2|Relaxation Training followed by Treatment as Usual (RT/TU)
3151506|NCT00227942|Experimental|1|Participants will receive estrogen replacement therapy
3151507|NCT00227942|Experimental|2|Participants will receive treatment with zolpidem
3151508|NCT00227942|Placebo Comparator|3|Participants will receive treatment with placebo
3151509|NCT00228020|Experimental|Basiliximab|Patients will be on a regimen of Basiliximab, MMF, cyclosporine and steroids
2443278|NCT03275090|Active Comparator|Intralipid injectable product (MOFS)|20 preterm infants receive parenteral nutrition containing 20% MOFS lipid emulsion (Smoflipid ®)
2443279|NCT03275090|No Intervention|Pure Soybean oil lipid emulsion|20 preterm infants with sepsis receive the usual parenteral nutrition containing soybean oil based lipid emulsion (20% Intralipid ®) at daily increasing doses guided by serum triglycerides.
2443280|NCT03275077||Controls|Normal Healthy Volunteers
2443281|NCT03275077||ESRD patients|Patients with ESRD who have not received hemodialysis. Patients with known bleeding disorders, coexisting liver diseases, those who were on antiplatelet or anticoagulant therapy and patients who had received red blood cells, fresh frozen plasma or platelet transfusions in the past three months were excluded from the study.
2443282|NCT03275064|Experimental|LNA043 40 mg Part B|LNA043 40 mg Part B
2443283|NCT03275064|Experimental|LNA043 20 mg Part B|LNA043 20 mg Part B
2443284|NCT03275064|Experimental|LNA043 20 mg Part A|LNA043 20 mg Part A
2443285|NCT03275064|Placebo Comparator|Placebo Part A|Placebo Part A
2443286|NCT03275064|Placebo Comparator|Placebo Part B|Placebo Part B
2443287|NCT03275051|Experimental|All subjects|Subjects who have received treatment with OTL-300 in and completed study TIGET-BTHAL will be included in this study. Subjects received OTL-300 injection administered intraosseously in TIGET-BTHAL study. No study treatment will be administered in this study (207757).
2443288|NCT03275038|No Intervention|Control group|Maintain the original life style
2443289|NCT03275038|Experimental|Tai-Chi exercise group|Receive three one-hour Tai Chi exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
2443290|NCT03275038|Experimental|Aerobic exercise group|Receive three one-hour aerobic exercise sessions weekly for 24 weeks, supervised for the first 12 weeks and unsupervised for the next 12 weeks
2443291|NCT03275025|Experimental|YRA-1909 low dose|
2443292|NCT03275025|Experimental|YRA-1909 medium does|
2443293|NCT03275025|Experimental|YRA-1909 high dose|
2443294|NCT03275025|Placebo Comparator|YRA-1909 Placebo|
2443295|NCT03275012|Experimental|Group 1|Gabapentin + Morphine
2443296|NCT03275012|Placebo Comparator|Group 2|Placebo + Morphine
2443301|NCT03274973||Zomacton|
2443302|NCT03274960|Experimental|Griess, Culture and antibiotic|Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
2443303|NCT03274960|No Intervention|No Griess, culture, treatment|No Griess reagents added in urine sample, no culture test with blood agar and no treatment with antibiotic for every positive results every trimester
2443304|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 Low dose TMS|Low level cerebellar TMS. Delivered once per day for 3 days.
2443305|NCT03274947|Active Comparator|Hypothesis 2 Protocol 2 High dose TMS|High level cerebellar TMS. Delivered twice per day for 5 days.
2443306|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 2 Sham|Sham cerebellar TMS. Delivered twice a day for 5 days.
2443307|NCT03274947|Active Comparator|Hypothesis 2 Protocol 1 Cerebellar TMS|Cerebellar TMS at 10Hz, 250 pulses.
2443308|NCT03274947|Sham Comparator|Hypothesis 2 Protocol 1 Sham|Sham cerebellar TMS
2443336|NCT03274713|Experimental|Electro-acupuncture group|After recruiting, patients are assigned to the electro-acupuncture group by randomization,and then receive electro-acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
3151510|NCT00228020|Active Comparator|Basiliximab-free|Patients will be on a regimen of MMF, cyclosporine and steroids.
3151511|NCT00228163|Experimental|Teriflunomide 7 mg|
3151512|NCT00228163|Experimental|Teriflunomide 14 mg|
3151513|NCT00228176|Experimental|Rimonabant|Rimonabant 20 mg once daily
3151514|NCT00228176|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3151515|NCT00228189|Active Comparator|A|Dendritic cells pulsed with CEA-peptide
3151516|NCT00228189|Experimental|B|Dendritic cells electroporated with CEA-mRNA
3151517|NCT00228189|Experimental|C|Dendritic cells pulsed with CEA-peptide, in combination with oxaliplatin/capecitabine
3151518|NCT00228215|No Intervention|Usual care|
3151519|NCT00228215|Experimental|TIPS Intervention|
3151520|NCT00228306|Experimental|1|
3151521|NCT00228306|No Intervention|2|Control Group
3151522|NCT00228319|Active Comparator|Standard of Care Group|carboplatin and paclitaxel chemotherapy
3151523|NCT00228319|Experimental|Standar of Care + Ascorbic Acid Group|carboplatin and paclitaxel chemotherapy, plus intravenous sodium ascorbate. In addition, participants will take a mix of vitamins including oral ascorbic acid, oral mixed natural carotenoids with vitamin A and oral vitamin E.
3151524|NCT00228358|Experimental|Group A (cellular infusions after cyclophosphamide)|Patients receive low-dose cyclophosphamide IV on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
3173103|NCT00608179|Experimental|1|
3173104|NCT00608179|Experimental|2|
3173105|NCT00608179|Experimental|3|control-euglycemia
2443309|NCT03274934|Experimental|Face-to-face and online support group|Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
2443310|NCT03274934|Experimental|Only online support group|Behavioral: web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is a five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach.
2443311|NCT03274934|Experimental|Control group|Behavioral: No intervention, school counseling as usual
2443312|NCT03274921||Cardiovascular complication|patients with history of CV complications in the past 4 years had biological determination
2443313|NCT03274921||No cardiovascular complication|patients free of any CV complications had biological determination
2443314|NCT03274908||Group|
2443315|NCT03274895|Experimental|PHMB 0.08% plus placebo|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
2443316|NCT03274895|Active Comparator|PPHMB 0.02% plus propamidine 0.1%|16 drops each in a day for 5 days,8 drops each in a day for 7 days,6 drops each in a day for 7 days and 4 drops each in a day up to clinical resolution
2443317|NCT03274882|Experimental|S95005|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride (with a molar ratio of 1:0.5) was administered at 35 mg/m²/dose orally twice a day, within 1 hour after completion of morning and evening meals, for 5 days on/2 days off, over 2 weeks, followed by a 14-day rest period. This treatment cycle was repeated every 4 weeks until treatment withdrawal criteria are met.
2443318|NCT03274869||Scrub typhus without cardiovascular complications|Any participants with the scrub typhus infection without cardiovascular complication will be enrolled as a positive control group during admission and clinically followed by 1 year after discharge
2443319|NCT03274869||Scrub typhus with cardiovascular complication|Any participants with the scrub typhus infection with cardiovascular complication will be enrolled as a comparison group during admission and clinically followed by 1 year after discharge
3189735|NCT00780286|Experimental|1|
3189736|NCT00780286|Active Comparator|2|
2443322|NCT03274843|Experimental|Patient with stroke|
2443323|NCT03274830||aneXys|cases with aneXys cup and Mathys hip stem
2443324|NCT03274817|Active Comparator|Escitalopram|Escitalopram (lexapro) is presently the most widely used selective serotonin reuptake inhibitor (SSRI) antidepressant.
2443325|NCT03274817|Active Comparator|Venlafaxine|Venlafaxine is a norepinephrine, serotonin and dopamine reuptake inhibitor antidepressant.The specific form of venlafaxine which will be employed is Effexor XR (venlafaxine hydrochloride extended release capsules)
2443326|NCT03274817|Placebo Comparator|Placebo|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
3189737|NCT00780299|Active Comparator|2|control
2443328|NCT03274791||Healthy subjects|"Healthy non-smoking subjects were never smokers with normal spirometry and did not have a history of lung disease or chronic respiratory symptoms.~Information about respiratory symptoms and comorbidities were collected. Healthy subjects underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2443329|NCT03274791||COPD Never smokers|"Never smokers referred to subjects who had never smoked Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Never smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2443330|NCT03274791||COPD Smokers|"Smokers were defined as persons who had smoked > 20 packs of cigarettes in a lifetime and who continue smoking every day.~Airflow limitation in COPD was defined as a post-bronchodilator forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) ratio <70% and FEV1 reversibility of <12% and 200 mL from baseline values after inhalation of 400 µg of Salbutamol.~Information about respiratory symptoms and comorbidities were collected. Smoking subjects with COPD underwent pulmonary function tests (Spirometry). Induced sputum was collected to determine total and differential inflammatory cells counts as well as inflammatory mediators (Interleukin-8 and tumor necrosis factor-alpha)."
2443331|NCT03274778|Experimental|Ruxolitinib|Oral administration of Ruxolitinib 20mg BID for 28 consecutive days
2443332|NCT03274765||Women with ovarian stimulation|Women followed in the MAP center of the Rennes University Hospital for ovarian stimulation monitoring Dosage of oestradiol
2443333|NCT03274752|Experimental|Paroxetine|Paroxetine 20mg QD per os for 12 weeks followed by 10mg for one additional week
2443334|NCT03274752|Placebo Comparator|Placebo|Placebo oral capsule QD per os for 13 weeks
3189738|NCT00780299|Experimental|1|HDHP
3189739|NCT00780312|No Intervention|2|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse before onset of radiotherapy treatment.
2443337|NCT03274713|Experimental|Manual acupuncture group|After recruiting, patients are assigned to the manual acupuncture group by randomization,and then receive manual acupuncture treatment.Both treatments consist of 24 sessions of 30 minutes duration, administered over 8 weeks (usually three sessions per week). Participants in both groups will be evaluated at baseline, 4 weeks, 8 weeks, 12 weeks and 16 weeks.
2443338|NCT03274700|Active Comparator|Group 1: Patients receive tamsulosin|"Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.e foll The cases will be followed up as thowing:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
2443339|NCT03274700|Placebo Comparator|Patients receive placebo.|"Patients who will receive placebo up to 8 weeks duration.The cases will be followed up as following:~In the first month: abdominal ultrasonography every week, KUB abdomen and pelvis for radiopaque stones.~At the end of the second month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones.~At the end of the third month: abdominal ultrasonography, KUB abdomen and pelvis for radiopaque stones, MSCT abdomen and pelvis for radiolucent stones."
2443340|NCT03274687|Experimental|Arm I (conventional radiation therapy)|Patients undergo conventional radiation therapy for 37 fractions over 7 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
2443341|NCT03274687|Experimental|Arm II (hypofractionated radiation therapy|Patients undergo hypofractionated radiation therapy for 25 fractions over 5 weeks in the absence of disease progression or unacceptable toxicity. Patients may also receive androgen deprivation therapy for up to 6 months as per doctor recommendation.
2443342|NCT03274674|Experimental|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Apply once a week and one month after the end of the injections, the patient will be called to the control.
2443343|NCT03274674|Active Comparator|I-PRF and Microneedling|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
2443344|NCT03274661|Experimental|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
2443345|NCT03274648|Experimental|vegetarian diet|vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
2443346|NCT03274648|Experimental|Habitual diet + oral butyrate|habitual diet supplemented with 2.4g/day of oral butyrate
2443347|NCT03274648|Active Comparator|Habitual diet|habitual diet without supplementation
2443348|NCT03274635|Active Comparator|Usual Delayed Compensation, Money|Will receive delayed monetary compensation with Amazon gift card, non performance-contingent.
2443349|NCT03274635|Active Comparator|Usual Delayed Compensation, Food|Will receive delayed compensation with food-based gift card, non performance-contingent.
2443350|NCT03274635|Experimental|Individual Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card.
2443351|NCT03274635|Experimental|Individual Immediate Contingent Reward, Food|Will receive daily performance-contingent food-based gift card.
2443352|NCT03274635|Experimental|Joint Immediate Contingent Reward, Money|Will receive daily performance-contingent monetary compensation with Amazon gift card, with additional compensation contingent on pedaling activity of co-worker participant.
2443353|NCT03274635|Experimental|Joint Immediate Contingent Reward, Food|Will receive daily performance-contingent monetary compensation with food gift card, with additional compensation contingent on pedaling activity of co-worker participant.
2443354|NCT03274622|Experimental|Impact Parent Training|Parents receive 22 1.5-hour sessions with a Speech Language pathologist coaching them in the implementation of the Impact intervention
2443355|NCT03274622|Placebo Comparator|No Impact|No parent coaching is provided
2443356|NCT03274609||Suspected lung cancer|"Patients referred as part of a first diagnostic evaluation of newly detected pulmonary lesion(s) or when an indication for an invasive diagnostic procedure is found during follow-up of earlier detected pulmonary lesion.~Patients identified during per protocol CT imaging follow-up of known lesions when growth of the lesion is found and an indication for biopsy is determined by the treating physician and/or multidisciplinary board.~Patients identified when referred for surgical biopsy in case of nodule location inaccessible for CT-guided TTNA.~These will be subjected to a combined approach of modalities with the main intervention being augmented fluoroscopy guided virtual navigation.)"
2443357|NCT03274596|Active Comparator|Treatment A|Group A: received 12.5 IU of vitamin E orally every 12 hours, from 72 h of birth to 28 days old.
2443358|NCT03274596|Placebo Comparator|Treatment B|Group B: received 12.5 IU of placebo orally every 12 hours, from 72 hours of birth to 28 days old.
2443359|NCT03274583||Study Group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with atrial fibrillation as the prevalent rhythm.
2443360|NCT03274583||Control group|Patients being treated in the wards of Heart Center and Acute Internal Medicine of Turku University Hospital, Turku Finland between April and September 2017 with sinus rhythm as the prevalent rhythm.
2443361|NCT03274557|Active Comparator|Radiofrequency microtenotomy|Treatment of Achilles tendinose with radio-frequency microtenotomy
2443362|NCT03274557|Active Comparator|Phusical therapy|Supervised eccentric training
2443363|NCT03274544|Experimental|PROLUNG|Herbal formula treatment PROLUNG in additional to current therapy
2443364|NCT03274531|Experimental|Interventional Arm|Immediate referral of hypertensive patients to the attending physician based on automated office blood pressure measurements
2443365|NCT03274531|No Intervention|Observational Arm|Repeated automated office blood pressure measurements and referral of hypertensive patients to the attending physician after completion of the trial
2443502|NCT03273556|Experimental|Aliaxin® EV Essential Volume|Comparison within subjects of Aliaxin® EV Essential Volume with and without Lidocaine 0.3%
3151525|NCT00228358|Experimental|Group B (cellular infusions after ONTAK conditioning)|Patients receive denileukin diftitox IV over 1 hour on day -1 and 3 escalating doses of autologous ex vivo-expanded HER2-specific T cells IV over 30 minutes on days 1, 10, and 20.
3151526|NCT00228371|Other|1|The stimulator is switch ON during the first phase of the cross-over and switch OFF during the second phase
3151527|NCT00228371|Other|2|The stimulator is switch OFF during the first phase of the cross-over and switch ON during the second phase
3151528|NCT00228436|Experimental|Cohort 1|Peginesatide starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses.
2443372|NCT03274479|Experimental|PBF-1129_40mg|
2443373|NCT03274479|Experimental|PBF-1129_80mg|
2443374|NCT03274479|Experimental|PBF-1129_160mg|
2443375|NCT03274479|Experimental|PBF-1129_320mg|
2443385|NCT03274427|Experimental|One-drug Regimes|Basic drugs therapy of HCC by TACE.
2443386|NCT03274427|Experimental|Two-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride
2443387|NCT03274427|Experimental|Three-Drug Regimens|Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
2443388|NCT03274414|Experimental|Unresectable paranasal sinus/nasal cavity malignancy|
2443389|NCT03274401|Active Comparator|Screening Arm|Screening for atrial fibrillation using a hand-held ECG device (Zenicor intermittent ECG) at least twice daily for two weeks. In patients where AF is detected prolonged OAC therapy will be administered.
2443390|NCT03274401|No Intervention|Control Arm|Standard of care
2443391|NCT03274388|Experimental|Control|Intervention of protein-rich nutritional therapy and counseling
2443392|NCT03274388|Experimental|Intervention|Intervention of protein-rich nutritional therapy and counseling combined with whole body electromyostimulation exercise training
3151529|NCT00228436|Experimental|Cohort 2|Peginesatide starting dose of 0.075 mg/kg administered SC Q4W for a total of 6 doses.
2443394|NCT03274362|Experimental|Headspace Application Treatment Group|Participants in the treatment group will be given a free 3-month access code to Headspace. The app contains a series of sessions that guide the user through mindfulness training.
2443395|NCT03274362|No Intervention|Standard Care Control Group|Participants in the control group will be provided a list of resources that provides guidance on mindfulness and general health.
2443396|NCT03274349|Active Comparator|Control|Group of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
2443397|NCT03274349|Experimental|EMS-group|Group of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
2443398|NCT03274336|Active Comparator|interview|questionnaire after face-to-face interview
2443399|NCT03274336|Placebo Comparator|brochure|questionnaire interview plus brochure
2443400|NCT03274336|Placebo Comparator|movie|questionnaire interview plus movie
2443401|NCT03274323|Experimental|2 iStent with travoprost or latanoprost|2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery
2443402|NCT03274323|Active Comparator|trabeculectomy|Standard trabeculectomy
2443403|NCT03274310|Experimental|Surveillance + Education arm|Receipt of educational text message about ways to decrease household transmission of influenza and other respiratory infections in addition to surveillance messages
2443404|NCT03274310|No Intervention|Surveillance-only arm|No intervention solely surveillance messages
3151530|NCT00228436|Experimental|Cohort 3|Peginesatide starting dose of 0.025 mg/kg administered SC Q4W for a total of 6 doses.
3151531|NCT00228436|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered intravenously (IV) Q4W for a total of 6 doses.
3173106|NCT00608179|Experimental|4|control-hypoglycemia
3173107|NCT00608192|Active Comparator|Testing, Education, & Counseling (TEC)|HIV and hepatitis screening is done on-site, but vaccination and medical care will be provided by off-site referral. HIV and Hepatitis, Testing, Education, & Counseling (TEC) participants will receive standard HIV and hepatitis education & counseling. TEC participants will not receive case management services.
3173108|NCT00608192|Experimental|Hepatitis Care Coordination (HCC)|Participants will receive on-site HIV and viral hepatitis screening. Hepatitis A and B combination vaccination will be provided on-site. Participants will receive on-site theory-based HIV and hepatitis education, counseling, and 6 months of case management to promote adherence to HIV and HCV evaluation.
3173109|NCT00608218||Artist|
3173110|NCT00608231|Experimental|PD-STN|Parkinson's Disease -- STN target
3173111|NCT00608231|Experimental|PD - GPi|Parkinson's Disease -- GPi target
3173112|NCT00608231|Experimental|ET - VIM|Essential Tremor -- VIM target
3173113|NCT00608231|Experimental|Dystonia - GPi|Dystonia -- GPi target
3173114|NCT00608231|Placebo Comparator|PD - STN Control|Parkinson's Disease -- STN target
3173115|NCT00608231|Placebo Comparator|PD - GPi Control|Parkinson's Disease -- GPi target
3173116|NCT00608231|Placebo Comparator|ET - VIM Control|Essential Tremor -- VIM target
3173117|NCT00608231|Placebo Comparator|Dystonia - GPi Control|Dystonia -- GPi target
3173118|NCT00608283||Live Kidney Donors|People who are going to donate a kidney at one of the three transplant centers from August 2007 until June 2011
3173119|NCT00608296||1|Study subjects on lithium
3173120|NCT00608296||2|study subjects on quetiapine
3173121|NCT00608335|Experimental|1. Micafungin 3.0 mg|IV
3173122|NCT00608335|Experimental|2. Micafungin 4.5 mg|IV
3173123|NCT00608348|Experimental|1|Hyperinsulinemic euglycemic or hypoglycemic clamp with Muscle and skin sympathetic nerve activity recording in arm and/or leg
3173124|NCT00608348|Experimental|2|Exercise with insulin or no insulin infused with muscle and skin sympathetic nerve activity measurements
3173125|NCT00608361|Experimental|Treatment (dasatinib)|Patients receive dasatinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3173126|NCT00608387|Experimental|A|Participants will receive usual care from their healthcare providers and have access to a Web-based CVD risk-factor management program.
2443405|NCT03274297|Experimental|Group 1: Sequence AB (Right/Left)|A single patch of currently marketed EVRA patch (Treatment A) will be applied to the right buttock of participants on Day 1 of treatment period 1, followed by application of a single patch of transdermal contraceptive using the newly sourced adhesive component HMW PIB (Treatment B) to left buttock of participants on Day 1 of treatment period 2. The treatment periods will be separated by a washout period of 21 days.
2443406|NCT03274297|Experimental|Group 2: Sequence BA (Right/Left)|Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2443407|NCT03274297|Experimental|Group 3: Sequence AB (Left/Right)|Treatment A will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment B to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2443408|NCT03274297|Experimental|Group 4: Sequence BA (Left/Right)|Treatment B will be applied to the left buttock of participants on Day 1 in Period 1 followed by Treatment A to the right buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
2443409|NCT03274284|Experimental|chemoradiotherapy|Chemoradiation in the form of cisplatin plus conformal radiotherapy 55GY/20 fractions which is biologically effective to 64GY/32 fractions fr
2443418|NCT03274258|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 60 minutes on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2443419|NCT03274245|Experimental|Latrine Use|Men and women in villages randomized to the latrine use arm will receive the intervention package that includes activities at the community and household levels, with additional activities and hardware for mothers of children under five.
2443420|NCT03274245|No Intervention|Control Group|Men and women in villages randomized to the control group will not receive an intervention.
2443421|NCT03274245|Experimental|Qualitative Research Group|Six villages unassociated with the randomized villages will engage in qualitative research. Three villages will receive the intervention. Three villages will not receive the intervention.
2443422|NCT03274232|Experimental|SUNEKOS ® 200|The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.
2443423|NCT03274219|Experimental|bb21217 Experimental Arm|
2443424|NCT03274206|Experimental|BLS-ILB-E710c|"Drug: BLS-ILB-E710c 1,000mg~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
2443425|NCT03274206|Placebo Comparator|BLS-ILB-E710c-placebo|"Drug: BLS-ILB-E710c-placebo~Dosage and duration: 4 capsules per day for 5 consecutive days at week 1,2,4, and 8)"
2443426|NCT03274193|Experimental|Yoga|The yoga group will engage in the yoga training program which is 60 minutes per session, 2 times per week for 12 weeks.
2443427|NCT03274193|No Intervention|Control|The control group will be asked not to participate in any exercise program during the course of the study.
2443428|NCT03274180|Experimental|Nursing consultation|travel preventive consultation was performed by nurse
2443429|NCT03274180|No Intervention|Medical consultation|travel preventive consultation was performed by a doctor
2443430|NCT03274167|Experimental|Gabapentin|300 mg per day once daily before bedtime
2443431|NCT03274167|Placebo Comparator|Control|Capsule identical to the experimental arm, one tablet once daily before bedtime
2443467|NCT03273894||Paediatric patients undergoing surgery in general anesthesia|Paediatric patients undergoing surgery in general anesthesia with the expected duration over 30 minutes
2443432|NCT03274154|Experimental|Pre-Hyaluron 465 Innēov|43 caucasian female subjects have taken during a meal, for the first 4 months of trial,1 capsule and 1 tablet/die of the food supplement composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese) .
2443433|NCT03274154|No Intervention|Untreated group|23 caucasian female subjects untreated
2443434|NCT03274141||T2T Patients|RA patients managed with a treat-to-target (T2T) strategy
2443435|NCT03274141||RC Patients|RA patients managed with routine care(RC)
2443436|NCT03274128|Active Comparator|Study Group|The treatment included a comprehensive therapy: radon therapeutic baths and inhalations, kinesiotherapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
2443437|NCT03274128|No Intervention|Control Group|On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, metalloproteinase 8) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: MCGill scale and VAS scale and anxiety and depression levels - HADS scale.
2443438|NCT03274115|No Intervention|White Light (WL)|White light will be used for histology prediction of colonic polyps (hyperplastic versus adenomatous).
2443439|NCT03274115|Active Comparator|Blue Light Imaging (BLI)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps.
2443440|NCT03274102|Experimental|Group I-EV71 vaccine and EPI vaccines|Concomitant administration of EV71 vaccine with EPI vaccines: EV71 Vaccine (intramuscular injection,0.5ml,first dose)/recombinant hepatitis B vaccine（intramuscular injection,0.5ml）on day 0 and EV71 Vaccine (injection, 0.5ml,second dose)/ Group A meningococcal polysaccharide vaccine(subcutaneous injection, 150ug) on day 30.
2443441|NCT03274102|Active Comparator|Group II-EPI vaccine only|Single injection of EPI vaccine: recombinant hepatitis B vaccine (intramuscular injection, 0.5ml) on day 0 and Group A meningococcal polysaccharide vaccine (subcutaneous injection,150ug) on day 30.
2443442|NCT03274102|Active Comparator|Group III-EV71 vaccine only|EV71 Vaccine only: the first and second dose of EV71 Vaccine (intramuscular injection,0.5ml) on day 0 and day 30 respectively.
2443443|NCT03274089|Experimental|Kiosk intervention group|
2443444|NCT03274089|No Intervention|Nurse clinician control group|
3189740|NCT00780312|Experimental|1|physiotherapy
3189741|NCT00780325|Experimental|1|CG100649, single oral dose of 2 mg
2443447|NCT03274063|Active Comparator|Supported self-management|Escalation of urate lowering therapy will be supervised by clinical research team based on results of participant self-testing
2443448|NCT03274063|Sham Comparator|Usual care|Escalation of urate lowering therapy will remain the responsibility of the participants primary care physician.
2443449|NCT03274050||patient group|Surgery with robot - all patients operated in pediatric surgery department with indication of robot in the routine care (all specialities).
2443450|NCT03274050||control group|Retroperitoneal coelioscopy - patient operated for pyeloplasty
2443451|NCT03274037|Experimental|Examination of cerebral MRI elastography|The mechanical waves will be induced by pressure waves guided to the mouth of the elongated subject in the MRI
2443452|NCT03274024|Experimental|Tube implant|Ahmed Glaucoma Implant (AGI) surgery
2443453|NCT03274024|Active Comparator|Trabeculectomy|Trabeculectomy with mitomycin C surgery
2443454|NCT03274011|Experimental|Apatinib Treatment|Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
2443455|NCT03273985|Experimental|Dry needling|
2443456|NCT03273985|Experimental|Ischemic compression|
2443457|NCT03273972|Experimental|Alirocumab Treatment Arm|V2: Day 1 - Alirocumab 150mg (subcutaneous injection) V3: Day 15 +/- 3 days - Alirocumab 150mg (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
2443458|NCT03273972|Other|Comparator Treatment Arm|V2: Day 1 - Placebo (subcutaneous injection) V3: Day 15 +/- 3 days - Placebo (subcutaneous injection) plus Atorvastatin 20mg (oral) approx. 14 days prescription.
2443459|NCT03273959|No Intervention|Group control|Patients randomized to the control group will receive routine physiotherapeutic follow-up, performed by the physiotherapist of the hospital during the hospitalization period. Supervision includes inhalation therapy and respiratory physiotherapy. Respiratory exercises and thoracic maneuvers for bronchial hygiene will be performed, according to what the patient is accustomed to perform. Other techniques besides these can be added at the discretion of the physiotherapist according to the needs of the patient. In pediatric hospitalization patients also receive care from physical educators who associate recreational and recreational activities with the treatment.
2443460|NCT03273959|Experimental|Intervention group|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive a program of physical exercises, illustrated in the form of a booklet and guided by a health professional. The patient is instructed to perform physical exercises five times a week until a hospital discharge. The participant will receive with a booklet a diary to write down the days in which to carry out the proposed exercises, in case of fault he will write down the reason for not performing. The exercise protocol includes: Punching, climbing and descending steps, sit and stand, push-ups on the wall, stationary gait, abdominal, physiotherapy bridge, jumping on the floor ladder, cycling on the cycle ergometer and stretching.
3189742|NCT00780325|Experimental|2|CG100649, single oral dose of 8 mg
2443462|NCT03273933|Active Comparator|10 children with DragONE only|
2443463|NCT03273933|Experimental|10 children with DragONE and SmartOne|
2443464|NCT03273920|Experimental|Robotic gastrectomy|Robotic distal gastrectomy with D2 nodal dissection
2443465|NCT03273920|Active Comparator|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 nodal dissection
3151532|NCT00228436|Experimental|Cohort 5|Peginesatide starting dose of 0.025 mg/kg administered SC once every 2 weeks (Q2W) for a total of 12 doses.
2443500|NCT03273595|Experimental|Experimental group|
2443501|NCT03273569|Experimental|Women with placenta accreta|PDI-UC protocol
3189743|NCT00780325|Active Comparator|3|Celecoxib, single oral dose of 200 mg
2443468|NCT03273881|Active Comparator|glucose solution and insulin|Participants will receive intravenous saline solution boosted with 5% glucose + 8 units regular insulin in a rate of 125 mL/h.
2443469|NCT03273881|Active Comparator|glucose solution only|Participants will receive intravenous saline solution boosted with 5% glucose in a rate of 125 mL/h.
2443470|NCT03273868|Experimental|High velocity low amplitude manipulation|
2443471|NCT03273868|Sham Comparator|Sham manipulation|
3151533|NCT00228436|Experimental|Cohort 6|Peginesatide starting dose of 0.0375 mg/kg administered SC Q2W for a total of 12 doses.
3151534|NCT00228436|Experimental|Cohort 7|Peginesatide fixed starting dose of 4 mg administered SC Q4W for a total of 6 doses.
2443474|NCT03273842|Experimental|PF-06881894|PF-06881894 6 mg SC
2443475|NCT03273842|Active Comparator|US-approved Neulasta|US-approved Neulasta 6 mg SC
2443476|NCT03273816|No Intervention|Patients without sessions of sophrology|The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
2443477|NCT03273816|Experimental|Patients with sessions of sophrology|The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
2443478|NCT03273790||NSCLC patients|Initiated Nivolumab treatment at least once from 01 Apr. 2016 through 31 Dec. 2016
2443479|NCT03273777|Experimental|Drawing of an incision line|An incision line of 14 cm will be drawn using a conventional surgical ruler and pen before skin incision.
2443480|NCT03273777|No Intervention|No drawing of an incision line|Skin incision will be carried out without previous drawing of an incision line.
2443481|NCT03273764||Preterm neonates with RDS|Singleton Preterm neonates with gestational age between 26 completed weeks to 34 completed weeks with clinical diagnosis of RDS without any major congenital anomalies.
3151535|NCT00228436|Experimental|Cohort 8|Peginesatide fixed starting dose of 3 mg administered SC Q4W for a total of 6 doses.
3151536|NCT00228449|Experimental|Cohort 1|Conversion from epoetin alfa to peginesatide with a conversion factor (CF) of 0.033: peginesatide dose administered intravenously once every 4 weeks (Q4W) for a total of up to 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
2443484|NCT03273738||postmenopausal diabetic women|50 female patients with T2DM who visited Assiut University Hospital Diabetes Clinic in Assiut, Egypt in these patients folate level measurement, B12 level and homocysteine are measured
2443485|NCT03273738||postmenopausal without diabetes|Another 50 participants will be volunteered in the study as control.n these subjects folate level measurement', B12 level and homocysteine are measured
2443486|NCT03273712|Experimental|90Y-DOTA-tyr3-Octreotide|Patients will receive 3 doses of 90YDOTATOC followed by 90Y-DOTATOC PET scans, with 6 -8 weeks between doses. They will be followed for 6-9 months after the last treatment dose. CT or MRI scans will be given at the 3 month and 6-9 month followups plus a 68Ga-DOTATOC or DOTATATE PET scan at the 6-9 month followup. The exact dose of 90YDOTATOC therapy for each patient will be determined by dosimetry.
2443487|NCT03273699|Experimental|Mindfulness|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
2443488|NCT03273699|No Intervention|Control|"The study will be a randomized trial where subjects (N=100) will be randomly assigned to receive either 1) an eight week meditation program involving use of an EEG-based biofeedback device, or 2) wait list as per usual. The experimental design is a 2 (treatment condition: Group 1: Mindfulness, Group 2: Control) by 3 (assessment phase: baseline (week 0), mid-treatment (week 4), post-treatment (week 8)) repeated measures factorial design. Group randomization will be completed by the principal investigator, using the GraphPad Quick Calcs online calculator which offers simple random allocation into equal-sized groups"
2443489|NCT03273686|Experimental|group without NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube during the surgery.
2443490|NCT03273686|No Intervention|group with NG tube after surgery|In this goup, patients will undergo preoperative gastrointestinal decompression and investigators will discharge the NG tube 6-7 days after the surgery.
3208504|NCT00975403|Experimental|Dead space breathing|
2443493|NCT03273660|Experimental|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|
2443494|NCT03273647|Experimental|surgery plus radiation|adjuvant radiotherapy is developed in this arm
2443495|NCT03273647|No Intervention|surgery alone|No adjuvant radiotherapy,that is surgery alone is developed in this arm
2443496|NCT03273634|Experimental|Active treatment|The treatment will consist of lanzoprazole 30 mg once daily at night time
2443497|NCT03273634|Placebo Comparator|Placebo|A Placebo pill to be given with similar looking to experimental drug but contains inactive ingredient
2443498|NCT03273621||Obese|Patients with a body mass index larger than 35 kg/m2
2443499|NCT03273595|Placebo Comparator|Control|
3151537|NCT00228449|Experimental|Cohort 2|Conversion from epoetin alfa to peginesatide with a CF of 0.041: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3151538|NCT00228449|Experimental|Cohort 3|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3151539|NCT00228449|Experimental|Cohorts 4 and 9|Conversion from epoetin alfa to peginesatide with a CF of 0.050: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
3151540|NCT00228449|Experimental|Cohort 5|Conversion from epoetin alfa to peginesatide with a CF of 0.066: peginesatide dose administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
2443505|NCT03273530|Experimental|Integrated Supported Employment|Individual placement support intervention plus work-related social skills training
2443506|NCT03273530|No Intervention|Individualised Placement Support|Individual placement support intervention with pre-vocational training followed by placing individual participants to the job according to their preference and abilities
2443507|NCT03273530|No Intervention|Traditional Vocational Rehabilitation|general pre-vocational training and placement
2443508|NCT03273504|Experimental|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|"Comparison within subjects of Actapil Corpo Spray versus Placebo. The study product will be applied twice a dayon the right or left leg (tibialis area) according to a randomisation list.~The placebo product will be applied in the same way, on the controlateral leg."
2443509|NCT03273491|Experimental|Daily Self-Weighing Group|"Participants will be provided with a scale and instructions necessary to engage in daily self-weighing, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
2443510|NCT03273491|Active Comparator|Daily Temperature-Taking Group|"Participants will be provided with a thermometer and instructions necessary to engage in daily temperature-taking, first thing in the morning for the next three months.~Height and weight will be measured using standard procedures~Questionnaires will be administered at baseline and EOT: Sociodemographic questions (i.e. age, race/ethnicity, self-weighing frequency, weight goals will be collected at baseline. To assess factors that may modify reaction to intervention condition,a questionnaire will assess participant's eating attitudes, behaviors, and perception of their body.~Questionnaires (baseline, end of Week 1, 2, 3, 4 and EOT): In order to compare results with published studies assessing constructs over varying time frames, self-esteem, anxiety, and depression will be measured at baseline, weekly for the first month, and again at EOT."
2443511|NCT03273465|Experimental|Fecal transplantation|Fecal transplantation of feces from healthy donor via capsules. Oral application.
2443512|NCT03273465|Placebo Comparator|Placebo|Placebo capsules
2443513|NCT03273452|Experimental|treatment group|In this group, patients will be given prednisone 100mg,qd,d1-5; etoposide 100mg,qd,d1-5; thalidomide 100mg,qn,d1-14; Chidamide 30mg,biw;
2443514|NCT03273439|Experimental|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
2443515|NCT03273439|Sham Comparator|Sham rTMS|all procedures were identical except they were the unmagnetized steel cylinders, instead of cylindrical magnets, that were rotated. Participants were, therefore, unable to distinguish between active and sham rTMS.
3189744|NCT00780325|Active Comparator|4|Naproxen, single oral dose of 500 mg
3189745|NCT00780325|Active Comparator|5|Acetazolamide, single oral dose of 250 mg
2443518|NCT03273413|Placebo Comparator|Placebo|Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.
2443519|NCT03273413|Active Comparator|Pravastatin|Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.
2443520|NCT03273400|Experimental|Mobilisations|"The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The plinth will rest on force plates to allow the authors to analyse the force placed through the vertebrae. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.~Following the intervention all measure lumbar flexion, hamstring extensibility and sEMG activity will be recorded immediately, 5, 10, 15, 20, 30, 60 minutes post application as a single test."
2443521|NCT03273400|No Intervention|Control|All outcome measures (lumbar/hamstring range of motion; EMG activity of the Biceps Femoris and Erector Spinae) will be measured. The control group will then receive no intervention and be asked to lie supine on a plinth for the treatment duration before having the outcome measures reassessed.
2443524|NCT03273374|Experimental|IORT group|Intraoperative radiation therapy of 10 Gy delivered during surgery followed by adjuvant gemcitabine chemotherapy
2443525|NCT03273361|Experimental|Seated|Participants completed work tasks while seated.
2443526|NCT03273361|Experimental|Low Intensity Pedaling|Participants completed work tasks while pedaling at a low intensity.
2443527|NCT03273361|Experimental|Low-Moderate Intensity Pedaling|Participants completed work tasks while pedaling at a low-moderate intensity.
2443528|NCT03273348|Other|oncoplastic breast surgery|This study aim to evaluate the outcome on oncological side and patient satisfaction on the aesthetic side with skin-sparing mastectomy and immediate breast reconstruction for patients with early breast cancer .
3173127|NCT00608387|No Intervention|B|Participants will receive usual care from their healthcare providers.
2443984|NCT05009784|Experimental|Long Traffic and Water Sound|300 seconds of traffic and water sound
3173128|NCT00608400|Experimental|1|CLA 1.5 g/d
3173129|NCT00608400|Experimental|2|CLA 3.0 g/d
3173130|NCT00608400|Placebo Comparator|3|
3173131|NCT00608439|Placebo Comparator|Placebo|Placebo CAST
3173132|NCT00608439|Active Comparator|Centella asiatica selected triterpenes|Active CAST
3173133|NCT00608452||1|
3173134|NCT00608595|Experimental|Therapeutic Intervention/Celecoxib|Celecoxib
2443533|NCT03273309|Active Comparator|Vibratory Perineal Stimulus|It's thought that the vibratory perineal stimulation can produces afferent nerve impulses that goes to the sacral spinal cord (S2-S4) via the pudendal nerve and stimulates the sacral somatic response which will cause the pelvic muscle contraction.
2443534|NCT03273309|Active Comparator|Transvaginal Electrical Stimulation|Transvaginal electrical stimulation can produces direct and reflex responses of the pelvic floor muscles, being more effective in patients who can't voluntarily contract this musculature. In addition, it increases blood flow to the muscles, restores neuromuscular connections and improves muscle fiber function.
2443535|NCT03273296|Active Comparator|Amoxicillin|
2443536|NCT03273296|Active Comparator|Azithromycin|
2443537|NCT03273296|Active Comparator|Vancomycin|
3189746|NCT00780325|Placebo Comparator|6|Placebo, single oral administration
3189747|NCT00780351||SLEDD-f, vanco|Surgical ICU patients who is on slow low efficiency daily hemodiafiltration (SLEDD-f) and requires vancomycin therapy
3189748|NCT00780377|Experimental|Bradykinin|Patients have holter monitoring. Patients receive intracoronary bradykinin (0.2, 0.6, 2.0 ug/min) and have coronary sinus and coronary artery blood sampling for t-PA and O2 content.
3189749|NCT00780390|Placebo Comparator|CRPS patients without spinal cord stimulation|CRPS patients declining spinal cord stimulation therapy. Autonomic Function will be assessed at baseline and again within 2 years.
3189750|NCT00780390|Experimental|CRPS patients: candidates for spinal cord stimulator|CRPS patients who are candidates for spinal cord stimulator implant. These patients will have Autonomic Function assessments before and after the Standard of Care spinal cord stimulation implant
3189751|NCT00780429||1|MMF+cyclosporine
2443544|NCT03273244||Device monitoring|NeuroSense monitoring and ANI monitoring
2443545|NCT03273231|Experimental|ketamine group|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
2443546|NCT03273231|Placebo Comparator|control group|0.9% saline solution
2443547|NCT03273218|Experimental|Tiger catheter|Tiger simple multipurpose catheter compared to Judkins catheters
2443548|NCT03273218|Active Comparator|Judkins catheter|Judkins right and judkins left catheter
2443549|NCT03273205|Experimental|Anodal tDCS|"The first group of patients has the real stimulation and the electrodes are placed in this position:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
2443550|NCT03273205|Sham Comparator|Sham tDCS|"The second group has the sham stimulation, but the electrodes are placed in the same position as in the first group:~Anode: Left DLPFC [F3) Cathode: Right Supraorbital (FP2)"
2443551|NCT03273192|Experimental|CinnaGen adalimumab|CinnoRA® (adalimumab auto-injector devices produced by CinnaGen Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
2443552|NCT03273192|Active Comparator|AbbVie adalimumab|Humira® (adalimumab auto-injector devices produced by AbbVie Company) 40 mg/0.8 ml in auto-injector devices A single 40-mg dose of Adalimumab was subcutaneously administered to healthy subjects.
3189752|NCT00780429||2|MMF+tacrolimus
3189753|NCT00780429||3|MMF+sirolimus
3189754|NCT00780468|Active Comparator|1|Existing diet plan
2443556|NCT03273140|Experimental|Gamification Diabetes Education Program (GDEP)|"The GDEP consists of two components, which are 1) gamification app on diabetes education, and 2) usual care group (face-to-face discussion with a DNE).~1) Gamification: The development of this gamification app, a mobile-based app of serious gaming, addresses the limitation and few recommendations from the current literature review. It aimed to enhance the user experience, and to facilitate diabetes education in an effective and efficient way, aligning with ADA (2014) guidelines, work instructions, and protocols in one tertiary organization. The learning modules are framed by socio-cognitive framework and self-efficacy. The gaming concept has been implemented into a mobile app, which can be accessed via iOS and Android platforms. It takes an average of 15 minutes to complete per stage. Hence, allowing flexibility for participants to access the games anywhere and anytime using i-pad or mobile devices."
2443557|NCT03273140|No Intervention|Standard group|The control group comprises of the standard care or usual care group, which is the face-to-face session with the DNE. The content during each session is dependent upon the individual's needs and concerns, including the reason for referral to DNE by the endocrinologist. For example, teaching the individual patient on self-management of blood glucose (SMBG) and emphasizing on diet modification and exercise if necessary. Educational pamphlets on diabetes management will be given to him/her if deemed necessary. Each session will usually requires an average of 45 minutes, which is considered as long consultation that costs 16 dollars. On the other hand, short consultation is categorised as less than 30 minutes that costs around eight dollars. The difference is that there is no GDEP in the control group. However, after the completion of data collection at six months time, the control group will also receive the intervention (GDEP). This is in order to give them equal opportunity.
2443558|NCT03273127|Experimental|Abediterol 5 μg|Out of 12 randomized patients, 9 will receive abediterol 5 μg as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive Abediterol 5.0 μg QD.
2443587|NCT03272867|Placebo Comparator|Control group|Another group of volunteers will ingest a powder with the same amount of a placebo twice a day for a periode of 2 weeks
3189755|NCT00780468|Experimental|2|New diet plan
3189756|NCT00780507||1|Patients are in a state of remission
3189757|NCT00780507||2|Patients are in a flare
3189758|NCT00780520|Experimental|1|
3189759|NCT00780520|Placebo Comparator|2|
3189760|NCT00780585||1|Subjects who participated in previous Org 24448 trials
3189761|NCT00780598|Experimental|Tosedostat|oral, once daily administration of tosedostat to evaluate its efficacy, safety and tolerability
3189762|NCT00780624|Active Comparator|NIPPV|The NIPPV group receiving NIPPV treatment.
3189763|NCT00780624|Active Comparator|Control|The Control group receiving nCPAP treatment.
2443559|NCT03273127|Placebo Comparator|Placebo|Out of 12 randomized patients, 3 will receive placebo as dry inhalation powder orally once daily for 9 days. Patients will be provided salbutamol as rescue medication for use throughout the study. During the treatment period, all patients will be continued on their current ICSs. In addition, each patient will receive placebo QD.
2443560|NCT03273114|Experimental|Cognitive Functional Therapy (CFT)|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
2443561|NCT03273114|Active Comparator|Core Training Exercise and Manual Therapy (CORE-MT)|The active comparator will be the combination of Core Training Exercise and Manual Therapy (CORE-MT).
2443562|NCT03273101|Experimental|Intervention group|The sit-to-stand training is assisted by mechanical device
2443563|NCT03273101|Active Comparator|Control group|The sit-to-stand training is assisted by manual device
2443564|NCT03273088|Experimental|AryoGen Pharmed etanercept|Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.
2443565|NCT03273088|Active Comparator|Pfizer etanercept|Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.
2443566|NCT03273075|Active Comparator|Prasugrel + Cangrelor|If eligible, assigned to this arm and without contraindications to prasugrel administration, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
2443567|NCT03273075|Active Comparator|Ticagrelor + Cangrelor|If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department. Afterwards a 30 micrograms (mcg)/kg iv bolus of cangrelor followed immediately by a 4 mcg/kg/min iv infusion (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered.
2443568|NCT03273075|Placebo Comparator|Prasugrel + Placebo|"If eligible, assigned to this arm and no contraindications to prasugrel, patients will receive a loading dose of prasugrel (60 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion of placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
2443569|NCT03273075|Placebo Comparator|Ticagrelor + Placebo|"If eligible and assigned to this arm (i.e. patients who have contraindications against prasugrel (age >75years, weight <60kg, history of transient ischemic attack, ischemic stroke, intracranial bleeding, known allergy against prasugrel/Efient), patients will receive a loading dose of ticagrelor (180 mg) via nasogastric tube as soon as possible after arrival at the emergency department.~Afterwards a 30 micrograms (mcg)/kg iv bolus of placebo (0.9% NaCl) followed immediately by a 4 mcg/kg/min iv infusion placebo (0.9% NaCl) (lasting for at least 2 hours or for the duration of the revascularization procedure, whichever is longer) will be administered."
2443570|NCT03273062|Active Comparator|Study Period 1|"15 days of Tolcapone 200mg TID~OR~Placebo Comparator 15 days of Placebo pill TID"
2443571|NCT03273062|Placebo Comparator|Study Period 2|"15 days of Placebo pill TID~OR~Active Comparator 15 days of Tolcapone 200mg TID"
2443572|NCT03273036|Active Comparator|epidural steroid injection|40 mg triamcinolone acetate 1 cc
2443573|NCT03273036|Placebo Comparator|placebo injection|no injection agent
2443574|NCT03273010|Experimental|Periacryl group|Periacryl, a tissue adhesive, was applied on wound surfaces to achieve haemostasis
2443575|NCT03273010|Active Comparator|Control group|Free gingival graft was harvested from palatal region and left to heal without applying periacryl.
2443576|NCT03272984|Experimental|ERAS group|Patients will undergo the ERAS programs.
2443577|NCT03272984|Other|SC group|Patients will undergo the SC group.
2443578|NCT03272971|Experimental|Radio-frequency Ablation|Single-arm study where subjects receive radio-frequency ablation prior to a scheduled, surgical resection.
2443579|NCT03272945|Experimental|LCI|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using Linked-color imaging (LCI).
2443580|NCT03272945|Placebo Comparator|WL|Once the randomization assignment was announced, the whole colonoscopy from insertion to cecum to withdrawal of endoscope was carried out entirely by using white light (WL).
2443581|NCT03272919|Experimental|Arm 1: Investigational INF|Intraneural Facilitation (INF) treatment is an effective way to restore blood flow to damaged nerves as neuropathy is strongly impacted by reduced blood flow.
2443582|NCT03272919|Other|Arm 2: Standardized muscle stretching and strengthen|subjects will receive a standardized program of muscle stretching and strengthening exercise twice a week for six weeks under the supervision of treating physical therapist
2443583|NCT03272906|Experimental|A-tDCS & speech-language therapy|Anodal transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. The electrical current will be administered over ventral inferior frontal gyrus. The stimulation will be delivered at an intensity of 2mA for a maximum of 20 minutes.
2443584|NCT03272906|Sham Comparator|Sham-tDCS & speech-language therapy|Sham transcranial direct current stimulation (2 mA) plus speech-language therapy for 24 sessions (20-minutes per each 60-minute treatment session) over the course of 12 weeks. Electrodes will be placed as in A-tDCS. Current will be ramped up for the first 30 seconds following which the intensity will drop to 0 mA.
2443585|NCT03272880|Experimental|arts-based programming for cancer survivors and caregivers|This is a 8-week, arts-based, health, resilience, and well-being program.
2443586|NCT03272867|Experimental|Intervention group|One group of volunteers will ingest a powder with dose of 6.1 g ProManna twice a day for a period of 2 weeks
2443588|NCT03272854||Renal Transplant Recipients|A cohort or renal transplant recipients, all more than 1 year after transplantation at inclusion
2443589|NCT03272841||Transplant recipients|Renal, heart, lung, liver, small bowel, pancreas or combined transplant recipients
2443592|NCT03272815|Experimental|PD arm|Patients undergoing assessment of the chest with the percussion device (PD).
2443593|NCT03272815|Active Comparator|US arm|Patients undergoing assessment of the chest with the ultrasound (US).
2443594|NCT03272802|Experimental|Case group|"ALS patients who receive the usual treatment option (Riluzole) for this disease and Edaravone. Instructions:~Tab. Rilutek 50 mg PO q12hr on empty stomach.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 14 days in the first 28 day cycle.~Amp. Edaravone 60 mg per day IV infusion (in normal saline during 1 hour) for 10 days in the following 28 day cycles after the first cycle (for 11 cycles)."
2443595|NCT03272802|Active Comparator|Control group|"ALS patients who receive the usual treatment option (Riluzole) for this disease.~Instructions:~1. Tab. Rilutek 50 mg PO q12hr on empty stomach."
2443596|NCT03272789|Other|interviews and questionnaires|Realization of interviews (at day 0, and at 1, 2, 3 6 and 12 months) and questionnaires delivery (at day 0, and at 3, 6 and 12 months)
2443597|NCT03272776||Protector Laryngeal Mask Airway|Patients undergoing anesthesia in which airway management includes a Protector Laryngeal Mask and fulfill the inclusion criteria of the study.
2443598|NCT03272763|Experimental|F&P Toffee mask|Participants will be placed on this arm for a total of 14 ± 5 days from Visit two. Participants will be using the trial full-face mask during this treatment arm.
2443599|NCT03272750|Experimental|Bioscalin® new formulation with Galeopsis Segetum|2 placebo capsules + 1 Bioscalin with Galeopsis Segetum table
2443600|NCT03272750|Active Comparator|REFERENCE PRODUCT|2 reference product capsules + 1 placebo tablet
2443601|NCT03272750|Placebo Comparator|PLACEBO|2 placebo capsules + 1 placebo tablet
2443602|NCT03272737|Active Comparator|Traditional strength exercise|"This group will be carried out to knee extension exercise without blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
2443603|NCT03272737|Active Comparator|Strength exercise with KAATSU|"This group will be carried out to knee extension exercise with partial blood flow restriction.~Interventions:~Plethysmography;~Protocols of isometric exercise;~Pulse wave Velocity (PWV);~Flow-mediated dilatation (FMD);~Arterial pressure and blood pressure;~Quality of life (Euro Qol);~1RM test~Speed gait test~Anthropometric Assessment"
2443604|NCT03272711|Experimental|Vortioxetine plus cognitive training|Vortioxetine (10 mg) plus cognitive training 5 times weekly for 30 minutes a day
2443605|NCT03272711|Placebo Comparator|Placebo plus cognitive training|Placebo plus cognitive training 5 times weekly for 30 minutes a day
3151541|NCT00228449|Experimental|Cohort 6|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa . Doses were administered intravenously Q4W for a total of 6 doses. With transition period between epoetin treatment and start of peginesatide treatment.
2443607|NCT05075460|Experimental|Tucidinostat, Azacitidine combined with CHOP|Tucidinostat, Azacitidine combined with CHOP
2443609|NCT05075460|Active Comparator|CHOP|CHOP
3151542|NCT00228449|Experimental|Cohorts 7 and 8|Conversion from epoetin alfa to peginesatide with tiered peginesatide starting doses of 0.05, 0.075, 0.1 or 0.15 mg/kg based on total weekly doses of epoetin alfa dose. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3151543|NCT00228449|Experimental|Cohorts 10 and 11|Conversion from epoetin alfa to peginesatide with fixed peginesatide starting doses of 4, 6, 12 or 16 mg based on total weekly doses of epoetin alfa. Doses were administered intravenously Q4W for a total of 6 doses. No transition period between epoetin treatment and start of peginesatide treatment.
3151544|NCT00228579||Bariatric Surgery|Subjects will be recruited from patients undergoing bariatric surgery at Emory Bariatrics. The cost of surgical procedures will not be provided by the research study.
3151545|NCT00228631||Sickle Cell Disease Bone Marrow Transplant|Sickle Cell Disease Bone Marrow Transplant candidates
3151546|NCT00228670||IPF-Clinic|Adult patients with idiopathic pulmonary fibrosis being followed in pulmonary clinic
2443759|NCT05074394|Experimental|COVI-DROPS|40 mg of COVI-DROPS administered intranasally
2443765|NCT05074394|Placebo Comparator|Placebo|2 mL placebo administered intranasally
2443799|NCT05074043||covid19|covid 19 proven by clinical, PCR. not associated with mucor
2443800|NCT05074043||covid19 associated with mucor|covid19 associated with mucor proven by clinical, histopathological
2443843|NCT05066672|Experimental|NV-5138 400 mg oral capsules|Either 2 or 4 400 mg oral capsules administered once daily
2443851|NCT05066672|Placebo Comparator|matched placebo|2 or 4 oral capsules administered once daily
3151547|NCT00228670||Controls - Clinic|Adult subjects with no underlying pulmonary disease who are the household partner of an IPF patient being followed in pulmonary clinic
3151548|NCT00228670||IPF-Transplant|IPF patient undergoing lung transplant
2443947|NCT05039866||Subjects who received ST-920|Subjects who received ST-920 in clinical study ST-920-201
3151549|NCT00228670||Controls-Transplant|Lung tissue from organ donor
3151550|NCT00228696|No Intervention|screening|this is a screening study and no intervention.
3208505|NCT00975403|Sham Comparator|Room air breathing|
2443611|NCT05075447|No Intervention|control group|Children without any diagnosis
2443612|NCT05075447|Experimental|ADHD+ODD/CD group|Child diagnosed with ADHD+ODD/CD
2443613|NCT05075473|Experimental|Segmental Stabilization|Segmental control over the primary stabilizers (TrA, deep multifidus, pelvic floor and diaphram) is maintained. Weight of body is minimized by using drawing in maneuver. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
2443614|NCT05075473|Active Comparator|General lumber stabilization exercises|It includes exercises in closed chain with low velocity as well as low load. Time duration will be of 30 to 40 mins, thrice a week for four weeks. Hot packs will be applied for about 10 mins. In starting days, 8 to 10 reps with hold time 5 count. In later days, 12 to 15 reps with hold time increases up till 10 to 15 counts.
2443615|NCT05075434|Experimental|Intervention Group|This group will receive the protocol prescribed by the health centre (calf stretching exercises, plantar fascia, proprioception exercises, ultrasound, magnet therapy and gait re-education and proprioceptive exercises for 40-45 minutes). In addition, you will receive 15 minutes of the instrumental technique of diacutaneous fibrolysis. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
2443616|NCT05075434|Active Comparator|Control Group|This protocol will be the one prescribed by the health centre. It consists of calf stretching exercises, plantar fascia, proprioceptive exercises, ultrasound, magnetic therapy and gait re-education and proprioceptive exercises for 40-45 minutes. Participants will receive 8 treatment sessions spread over 4 weeks (2 sessions per week).
2443617|NCT05075525|Experimental|High Intensity Laser Therapy Group|Patients underwent High Intensity Laser Therapy (HILT) and exercise for 10 sessions
2443618|NCT05075525|Experimental|Ultrasound and Transcutaneous Electrical Nerve Stimulation Group|Patients will be treated by transcutaneous electrical nerve stimulation(TENS), ultrasound (US) and exercise for 10 sessions
2443619|NCT05075525|Experimental|Ultrasound and Interferential Current Stimulation Group|Patients will be treated with ultrasound (US) ,interferential current stimulation and exercise for 10 sessions
2443620|NCT05075421||Group 1 (high marker)|Patients with elevated serum markers
2443621|NCT05075421||Group 2 (normal marker)|Patients with normal value of serum markers
3151551|NCT00228865|Experimental|1|Testing performed on diabetic patients with decline in cognitive function at baseline and quarterly after the start of receiving pulsatile intravenous insulin therapy to assess continuing cognitive function ability.
3151552|NCT00228878|Experimental|Effects of Pulsatile IV insulin on QoL|Effects of Pulsatile IV insulin on Diabetic Quality of Life
2443624|NCT05075512|Experimental|experimental group|anlotinib combined with fulvestrant
2443625|NCT05075265||Methadone Group|adult patients undergoing cardiac surgery with extracorporeal circulation
3151553|NCT00228891|Active Comparator|2|Patients with diagnosed diabetic neuropathy will receive objective baseline testing and follow up testing every six months after the start of Pulsatile intravenous insulin therapy to monitor and assess diabetic neuropathy.
3151554|NCT00228891|Placebo Comparator|1|Control patients with diabetic neuropathy will receive objective testing at baseline and every six months to compare and measure results with patients who are receiving pulsatile intravenous insulin therapy.
2443629|NCT05075343|Experimental|Custom foot orthoses (CFO)|Participants with a confirmed diagnosis of PsA and foot pain received and wore custom foot orthoses (CFO).
2443631|NCT05075395|Experimental|Intervention|The PT/OT provider will assess whether the patient meets eligibility criteria. If the patient is eligible to participate, they will then introduce the study to the patient and their parent or guardian. If the patient is interested in participating, the PI or PIs research assistant (RA) will seek written informed consent. After informed consent is obtained, the PI or RA will begin pretest data collection. Then, the PT/OT provider will begin the therapy session with Paro. The PI or RA will remain in the room during therapy session to record field notes. When the therapy session is complete, the PI or RA will begin posttest data collection. The patient will remain in the study for up to 7 PT/OT sessions or until they are discharged from the PICU. The PT/OT providers will coordinate all subsequent therapy sessions with the PI/RA while the patient remains on the study protocol.
2443636|NCT05075148||Aneurysmal bone cyst|Patient aging from 0 to 30 years with diagnosis of aneurysmal bone cyst treated by percutaneous alcolisation or endovascular embolization.
2443637|NCT05075382||Pilot group|Group of 40 patients that will act as observationnal group for this study
2443639|NCT05075304|Experimental|A low dose of BDB-001|6 patients administered low dose of BDB-001 injection
2443643|NCT05075304|Experimental|A intermediate dose of BDB-001|6 patients administered intermediate dose of BDB-001 injection
2443646|NCT05075304|Experimental|A high dose of BDB-001|3-6 patients administered high dose of BDB-001 injection
2443657|NCT05075109|Experimental|High Frequency TENS|high frequency TENS (100 Hz, 200 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks combined with task related training.
2443658|NCT05075109|Experimental|Low Frequency TENS|low frequency TENS (20 Hz, 0.2 us) over the muscle belly of triceps and wrist extensors, for 5 days per week over 8 weeks with task related training.
3151555|NCT00228904|Placebo Comparator|1|Control patients with diagnosed diabetic neuropathy will receive baseline testing and testing every six months thereafter to compare and analyze results with patients treated with pulsatile intravenous insulin therapy.
2443641|NCT05075369|No Intervention|baseline Intraocular pressure|The participants will have their intraocular pressure measured with Goldmann Application Tonometry immediately prior to beginning the water drinking test.
2443642|NCT05075356|Experimental|Single participant arm|"The iToBoS intervention is a total body imaging device, to image the total skin surface in order to detect and monitor for signs of skin cancer.~The imaging process involves laying down on a bed that has a framework of cameras arched over it. The imaging process takes less then 10 minutes, and requires the participant to lay in two different positions (face-up and face-down).~The study visit also includes individual dermoscopic images taken of certain moles on the skin. This is done in combination with a clinical skin examination. Participants are given the option of providing a saliva sample for genetic research. Participants are then asked to complete a series of questionnaires.~There a three visits in total (month 0, 6 and 12), in which these procedures are repeated (except for saliva sample)."
3151556|NCT00228904|Active Comparator|2|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after the start of pulsatile intravenous insulin therapy.
2443645|NCT05075369|Active Comparator|Change in Intraocular pressure with Water drinking test|The participants will undergo the water drinking test as previously described, i.e. after drinking 800 mls of water over a 5 minute period, the intraocular pressure will be measured immediately after completion of ingestion, followed by intraocular pressure measurements every 15 minutes for 60 minutes, using etc Goldmann apllantion tonometer.
3151557|NCT00228982|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q12h as 1h infusion, 7-14d
3151558|NCT00228982|Active Comparator|Vancomycin|Vancomycin 1g q12h as 1h infusion, 7-14d
2443648|NCT05075330|Experimental|Intervention|Participants who live in the Orange Mound community of Memphis. Billboards targeting stigma reduction were posted in the community for one month.
2443652|NCT05075330|No Intervention|Control|Participants who live in the Frayser community of Memphis. No billboards (intervention) were placed here.
2443650|NCT05075486|Experimental|Intervention group|Group who recieve collaborative quality improvement during study period.
2443651|NCT05075499|Active Comparator|MS no immunomodulatory treatment|MS patients receiving no immunomodulatory treatment
2443653|NCT05075499|Active Comparator|MS Teriflunomide treatment|MS patients under treatment with Teriflunomide
2443654|NCT05075499|Active Comparator|MS Alemtuzumab treatment|MS patients under treatment with Alemtuzumab
2443655|NCT05075135|Experimental|3D-splint group|Patients wear the Swibrace 3D splint for 6 weeks of immobilization of the wrist for distal radius fractures, including the basis of the thumb for scaphoid fractures. X-rays after week 1, 3 and 6 are planned to document bone healing, together with weekly visits at the hand therapy unit to measure patient satisfaction and hand function. This results in 2-3 surgeon and 6 hand therapy visits at the Inselspital Bern, where regular check-ups on the patient's comfort in the splint are made.
2443656|NCT05075135|Active Comparator|Plaster cast group|"The control intervention is the same as the study intervention, but the participants wear the gold-standard plaster cast instead of the newly designed Swibrace 3D-splint."
2443659|NCT05075122|Experimental|Vaccination arm|Pembrolizumab flat dose iv every 3 weeks + UV1 vaccination (UV1 plus GM-CSF/Sargramostim as adjuvant per vaccination)
2443661|NCT05075122|Other|Calibration arm|Pembrolizumab flat dose iv every 3 weeks
2443669|NCT05075031||300 Newborn feeding on Breast Milk or Artificial Milk Formula rom birth to about 2 months of age|The electronic patient record of 300 Newborn feeding on Breast Milk or Artificial Milk Formula from birth to about 2 months of age would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
2443670|NCT05075031||300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year|The electronic patient record of 300 Infant feeding on Breast Milk or Artificial Milk Formula from 2 months to 1 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
2443671|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year|The electronic patient record of 300 child feeding on Breast Milk or Artificial Milk Formula from 1 year to 5 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the rates of the Control Groups
2443672|NCT05075031||300 child feeding on Breast Milk or Artificial Milk Formula from 5 year up to 15 year|The electronic patient record of 300 child feeding on Artificial Milk Formula or any source of DHA from 5 year up to 15 year would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the Control Groups
3151559|NCT00229008|Experimental|001|ceftobiprole plus placebo ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
3151560|NCT00229008|Active Comparator|002|linezolid plus ceftazidime linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
3151561|NCT00229047||Vein Stripping|Patients undergoing elective varicose vein stripping in our vascular OR. Observe circulation in the exposed soleus/gastrocnemius muscle.
3151562|NCT00229138|Experimental|reduced Tacrolimus|
3151563|NCT00229138|Active Comparator|Reference Tacrolimus|
3151564|NCT00229151|Experimental|Sleep deprivation|Sleep deprivation and sleep phase advancement
3151565|NCT00229151|Active Comparator|usual treatment|
3151566|NCT00229177|Placebo Comparator|P|
3151567|NCT00229177|Experimental|E1|
3151568|NCT00229177|Experimental|E2|
3151569|NCT00229229|Other|1|Low glycemic load diet
3151570|NCT00229229|Other|2|Canada Food Guide Diet
3151571|NCT00229229|Other|3|Low glycemic index diet
3151572|NCT00229229|Other|4|Low carbohydrate diet
3151573|NCT00229242|Active Comparator|1|Diuretic-Based Hypertension Therapy
2443660|NCT05075109|Active Comparator|Task Related Training|postural control, shoulder mobilization, weight bearing exercises, functional activities that will comprise of simple tasks to more advanced movement patterns
3151574|NCT00229242|Active Comparator|2|Non-Diuretic-Based Hypertension Therapy
2443787|NCT05074134|Experimental|[14C]-TNP-2092|
2443830|NCT05073809||Group 1|Proven or highly suspected head and neck tumour undergoing routine clinical staging of their neck LN status
2443832|NCT05073809||Group 2|Proven or suspected oral cavity cancer, amenable to intraoral examination
3151575|NCT00229255|Active Comparator|high frequency meals group|High carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
3151576|NCT00229255|Active Comparator|twice-a -day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks
3151577|NCT00229307|Active Comparator|1|
3151578|NCT00229307|Active Comparator|2|
3151579|NCT00229385|Active Comparator|1|
3151580|NCT00229385|Active Comparator|2|
3151581|NCT00229424|Experimental|1|Lafutidine group
3151582|NCT00229424|Active Comparator|2|Famotidine group
3151583|NCT00229424|Placebo Comparator|3|Placebo group
3151584|NCT00229437|Experimental|TAK-128 5 mg QD|
3151585|NCT00229437|Experimental|TAK-128 50 mg QD|
3151586|NCT00229437|Experimental|TAK-128 100 mg QD|
2444387|NCT04727970|Experimental|Tricaprilin|Tricaprilin will be administered for 5-21 days. The total daily dose (individual per subject up to a maximum of 10g/kg/day) will be split into 4 doses administered orally, approximately every 6 hours.
3151587|NCT00229437|Placebo Comparator|Placebo QD|
3151588|NCT00229450|Experimental|Treatment|0.625 mg/day of conjugated estrogen
3151589|NCT00229450|Placebo Comparator|Placebo|Daily placebo for conjugated estrogen
3151590|NCT00229502||1|Subjects receiving Avonex
2444610|NCT04535440||Rectal varices with bleed|
2444611|NCT04535440||Rectal varices without bleed|
2444641|NCT04474704|Experimental|Cheetah® non-invasive cardiac monitoring system|Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
2444643|NCT04474704|Other|Standard of care|24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
3151591|NCT00229502||2|Subjects receiving Rebif
3151592|NCT00229502||3|Subjects receiving Copaxone
2444728|NCT04398160|Experimental|HVLA manipulation|"In the intervention of the experimental group, the investigator will be primarily on the right side of the volunteer and identify C3 through the cervical reference of jaw angle, which is at the disc level between C2/C3 and then contact with the phalanges of third metacarpal in the left transverse of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
2444730|NCT04398160|Sham Comparator|Sham technique|"The investigator will be primarily on the right side of the volunteer and identify the C3 vertebra, having as anatomical reference the angle of the jaw, which is at the disc level between C2/C3 and then contact, with the phalanges of the third metacarpal, the left transverse apophysis of this vertebra.~The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally."
2444733|NCT04398160|No Intervention|No intervention group|The volunteer will be seated with 110º of hip and knee flexion using a digital goniometer and will be asked to breath normally.
2444789|NCT04333862||Healthcare workers providing healthcare|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
2444791|NCT04333862||Healthcare workers staying at home|To determine the infection rate of healthcare workers providing healthcare versus those who are staying at home, in a desynchronization work strategy
2444793|NCT04333862||Hospitalized patients|To compare the infection rate of hospitalized patients versus healthcare workers
3151593|NCT00229502||4|Healthy controls
3151594|NCT00229515|Active Comparator|1|Patients will receive abciximab infusion at standard regimen prior undergoing percutaneous coronary intervention for STEMI followed by BMS implantation in the culprit lesion
3151595|NCT00229515|Experimental|2|Abciximab followed by implantation of sirolimus-eluting stent in the culprit lesion
3151596|NCT00229515|Experimental|3|tirofiban infusion followed by bare metal stent implantation
3151597|NCT00229515|Experimental|4|tirofiban and sirolimus-eluting stent
3151598|NCT00229541|Experimental|IG|intervention group, receives counselling on medical inpatient rehabilitation by statutory health insurance, is intended to apply for a 3-wek medical inpatient rehabilitation at the co-operating clinic (Bad Bramstedt)
3151599|NCT00229541|No Intervention|KG|control group, receives usual care
3151600|NCT00229554||Group 1|Male and female veterans age 50-75 who have had one or more primary care visits at a VA Medical facility in the past two years.
3151601|NCT00229580|Experimental|1|Motivational feedback
3151602|NCT00229580|Active Comparator|2|treatment as usual
3151603|NCT00229593|Active Comparator|1|100 mg Testosterone gel daily for 3 weeks
3151604|NCT00229593|Active Comparator|2|2 mg Nestorone gel daily for 3 weeks
3151605|NCT00229593|Active Comparator|3|4 mg Nestorone gel daily for 3 weeks
3151606|NCT00229593|Active Comparator|4|100 mg Testosterone gel + 2 mg Nestorone gel
3151607|NCT00229593|Active Comparator|5|100 mg Testosterone gel + 4 mg Nestorone gel
2443662|NCT05074875||Cohort 1|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 1 subjects will undergo Visit 0 after informed consent is obtained. Eligible subjects will return for follow-up at Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks"
2443663|NCT05074875||Cohort 2|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohort 2 subjects will undergo Visit 1, within 4 (+/- 2) weeks of hospital discharge or outpatient infection, after informed consent is obtained. Eligible subjects will return for follow-up Visits 2, 3, and 4, at weeks 24, 36, and 48 weeks."
2443664|NCT05074875||Cohort 3a|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled within ≤ 12 weeks of hospital discharge or outpatient COVID- 19 infection will undergo their first study visit at Visit 1 (Weeks 6-12)."
2443665|NCT05074875||Cohort 3b|"Subjects with a diagnosis of hypoxemic respiratory failure associated with COVID-19 who meet the inclusion and exclusion criteria will be eligible for participation in this study.~Cohorts 3a and 3b subjects will undergo their first study visit between 6 and 24 weeks of hospital discharge or outpatient infection, after informed consent is obtained. Participants should not be scheduled for chest HRCTs less than 12 weeks apart, however all subjects should have an HRCT done at Week 24 for analysis purposes. To prevent scheduling of HRCTs within less than 12 weeks.~Subjects enrolled ≥ 12 weeks from hospital discharge or outpatient COVID- 19 infection will undergo their first visit within 4 weeks before week 24. Subjects that are enrolled into Cohort 3 will be followed until Week 72."
2443788|NCT05074199|Active Comparator|W-plasty|"The cosmetic appearance of scars closed in a in a zig-zag  fashion (W-plasty)."
2443790|NCT05074199|Active Comparator|Linear closure|"The cosmetic appearance of scars closed in a standard straight line fashion (linear closure)."
3151608|NCT00229593|Active Comparator|6|100 mg Testosterone Gel + 6 mg Nestorone Gel daily for 3 weeks
3151609|NCT00229593|Active Comparator|7|100 mg Testosterone Gel + 8 mg Nestorone gel daily for 3 weeks
3151610|NCT00229671|Experimental|Patients with prescriptions under 21|Pediatric visits with prescriptions. These patients parents will be given survey 1.
3151611|NCT00229671|Experimental|Patients who completed Survey 1|Patients with prescriptions under 21 whose parents complete survey 1 will be given survey 2
3151612|NCT00229697|Experimental|1|ZD1839 + Nolvadex
3151613|NCT00229697|Other|2|Nolvadex + placebo
2443926|NCT05014061|Experimental|Adenosine|Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
2443929|NCT05014061|No Intervention|Controll|Standard of care
3151614|NCT00229736|Experimental|AAV-hAADC-2 (9x10^10 vector genomes)|
3151615|NCT00229736|Experimental|AAV-hAADC-2 (3x10^11 vector genomes)|
2444129|NCT04957134|Experimental|Electro-acupuncture with lifestyle intervention|Participants will receive electro-acupuncture combined with lifestyle intervention. Participants will receive the treatment of electroacupuncture 3 times a week to fulfill a 8-session treatment course.While the intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
2444132|NCT04957134|Placebo Comparator|Sham electro-acupuncture with lifestyle intervention|Participants will receive the treatment of sham electro-acupuncture 3 times a week to fulfill a 8-session treatment course, A superficial skin penetration (2-3 mm in depth) at nonacupoints will be performed in the sham acupuncture group, without needle manipulation for De qi. The internal output power cord of the electrical acupuncture stimulation instrument is interrupted.The intervention of lifestyle intervention will be conducted for 12 weeks including the treatment period of 8 weeks and the follow-up period of 4 weeks.
3151616|NCT00229801|No Intervention|MRI|
3151617|NCT00229983|Experimental|Motivational Enhancement Therapy|Adolescents who are randomized to the experimental intervention will attend three 60-minute counseling sessions, delivered 2-4 weeks apart. The intervention will include a structured, developmentally appropriate, approach to identification of drug- and alcohol-related risks and problems, and establishment of goals for behavioral change.
3151618|NCT00229983|No Intervention|Enhanced Standard Care|Adolescents who are randomized to Enhanced Standard Care will receive the usual care at the outpatient adolescent substance abuse program. This will include an evaluation by pediatric and mental health staff and could include treatment in a group therapy program, urine drug testing, buprenorphine replacement therapy (for those dependent on opioids), and psychopharmacology evaluation and management.
3151619|NCT00230035|Experimental|1|high dose immunosuppressie therapy (HDIT) followed by HSCT (hemopoietic stem cell transplantation).
2444350|NCT04759664|Experimental|LUT014 Gel (Dose 1)|
2444352|NCT04759664|Experimental|LUT014 Gel (Dose 2)|
3151620|NCT00230035|Active Comparator|2|Currently available immunosuppressive/immunomodulatory therapy
3151621|NCT00230113|Active Comparator|1|
3151622|NCT00230113|Placebo Comparator|2|
3151623|NCT00230165||Normal|Normal, healthy volunteers 18 years of age or older of either sex and any ethnic background
3151624|NCT00230165||Glanzmann thrombasthenia|Patients with Glanzmann thrombasthenia or their relatives, inherited qualitative and/or quantitative platelet disorders, inherited disorders of white blood cells, inherited disorders of coagulation
3151625|NCT00230321|Experimental|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously for 6 weeks. The dosage for the remaining treatment is dependent of patients response during the induction phase.
3151626|NCT00230438|Experimental|External Beam Radiation Therapy|
3151627|NCT00230477|Active Comparator|Mono therapy|Hepsera
3151628|NCT00230477|Active Comparator|Combo therapy|
3151629|NCT00230542|Experimental|Carboplatin / Pemetrexed|Single Arm Study Carboplatin AUC 5 Pemetrexed 500 mg/m2
3151630|NCT00230594|Active Comparator|1|desmopressin
3151631|NCT00230594|Placebo Comparator|2|placebo
2443673|NCT05075031||Control Group|"The electronic patient record of 150 infant and child patients who feed on only cow's milk which does not provide a rich source of DHA and did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021 and compare their rates of Covid-19 infection, hospitalization and complications with the rates of the cohorts that feed on Breast Milk or Artificial Milk Formula~The electronic patient record of 150 adult patients from 15 years to 25 years who did not feed on any Artificial Milk Formula or any source of DHA would be examined and followed between March 2020 and October 2021"
3151632|NCT00230607|Experimental|Agalsidase beta|Commercially available Fabrazyme treatment at prescribed dose and regimen as determined by their treating physician
2443777|NCT05074238|Experimental|Sunscreen Application|The study participant will be instructed to start applying the sunscreen provided to them to the randomly assigned half of the wound (A or B).
2443778|NCT05074238|Experimental|No Suncreen Application|The study participant will be instructed to not apply the sunscreen provided to them to the randomly assigned half of the wound (A or B).
2443863|NCT05059678|Experimental|Group I (education material, videoconference session)|Participants receive education materials (brochure and a video) and attend 2 weekly videoconference intervention sessions over 45 minutes each. Caregivers attend 2 additional weekly intervention sessions over 45 minutes each.
2443899|NCT05059678|Active Comparator|Group II (waitlist control)|Participants receive standard of care.
3151633|NCT00230659||HHT patients|Patients with hereditary haemorrhagic telangiectasia. Blood sample to be taken.
2444009|NCT04982497|Experimental|Video game based intervention|The participants in the experimental group will receive a cognitive-behavioral intervention for active aging via an interactive online multimedia video game with a complementary App. The intervention will consist of 8 modules each approximately 70 (±25) minutes long that will be administered at a rate of 1 per week with between-session homework.
2444012|NCT04982497|Active Comparator|Control group|Individuals assigned to this group will receive online therapeutically inactive information about active aging.
3151634|NCT00230659||Controls|People without hereditary haemorrhagic telangiectasia. Blood sample to be taken.
3151635|NCT00230711|Experimental|Exercise Counseling|
3151636|NCT00230711|Placebo Comparator|Contact Control|
3151637|NCT00230750|Experimental|2|100 subjects to receive 90 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
3151638|NCT00230750|Placebo Comparator|3|40 subjects to receive saline placebo on days 0, 28, and 6 months following the 1st vaccination.
2444172|NCT04897841|Placebo Comparator|control arm|The control arm will receive 30 mL of bupivacaine HCl plus 50 mL of saline injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
2444174|NCT04897841|Experimental|Intervention: liposomal bupivacaine|The intervention arm will receive 30 mL of bupivacaine HCl plus 30 mL of saline plus 20 mL of liposomal bupivacaine injected into the lateral transversus abdominis plane via surgical approach (abdominal approach).
2444207|NCT04866563|Experimental|AX-8 to Placebo|AX-8 BID, taken for 2 weeks, followed by a 1-week washout period and then Placebo BID, taken for 2 weeks.
2444214|NCT04866563|Experimental|Placebo to AX-8|Placebo BID, taken for 2 weeks, followed by a 1-week washout period and then AX-8 BID, taken for 2 weeks.
3151639|NCT00230750|Experimental|1|100 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine on days 0, 28, and 6 months following the 1st vaccination.
3151640|NCT00230763|Experimental|Active|
3151641|NCT00230763|Other|Procedure|
3151642|NCT00230815|Experimental|Follitropin alfa injected by Pen device|
2444486|NCT04643587|Experimental|CSL787 (SAD dose 1)|Inhalation by mouth of a nebulized aerosol in healthy subjects
2444487|NCT04643587|Experimental|CSL787 (SAD dose 2)|Inhalation by mouth of a nebulized aerosol in healthy subjects
2444488|NCT04643587|Experimental|CSL787 (SAD dose 3)|Inhalation by mouth of a nebulized aerosol in healthy subjects
2444489|NCT04643587|Experimental|CSL787 (SAD dose 4)|Inhalation by mouth of a nebulized aerosol in healthy subjects
2444490|NCT04643587|Experimental|CSL787 (MAD dose 1)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
2444491|NCT04643587|Experimental|CSL787 (MAD dose 2)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
2444492|NCT04643587|Experimental|CSL787 (MAD dose 3)|Inhalation by mouth of a nebulized aerosol in NCFB subjects
2444493|NCT04643587|Placebo Comparator|Placebo|Inhalation by mouth of a nebulized aerosol
2444544|NCT04591925|Experimental|"Investigative Device - SteadiSet™ device with coil-reinforced soft polymer indwelling cannula"|Participants are randomized into the investigational device (SteadiSet™) insulin infusion set group and then switched to a Commercially available infusion set (using a soft Teflon indwelling cannula) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the investigational infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Control device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
3151643|NCT00230880|Experimental|Treatment|follow-up phone counseling
3151644|NCT00230880|No Intervention|Control|Usual care
2443676|NCT05074849|Experimental|Smart insoles + Education|Participants in this group will receive a 90-minute group session education on foot self-care strategies (daily foot hygiene and cleanliness, foot protection, use of insoles and smart watch)
2443675|NCT05074784|Active Comparator|Control Group|Tongue depressor exercise protocol for tongue strengthening for control group. Using the tongue depressor, participants will be prompted to stick their tongue out as much as they can and to push hard against the tongue depressor for 10 seconds. They will be required to repeat this action 10 times, constituting one set. They will be asked to perform 3 sets, with 30 secs of rest between each set. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
2443688|NCT05074849|No Intervention|Smart Insoles|Participants in this group will not receive a 90-minute group session education on foot self-care, but will receive foot care supplies, insoles and smart watch
2443689|NCT05074784|Experimental|Intervention Group|IOPI exercise protocol for tongue strengthening for intervention group. Using the IOPI, participants will perform 24 sets of 5 repetition at anterior position, allowing for 30 secs rest in between sets. Arrange for 5 sessions for a week; sessions can take place on consecutive days.
2443698|NCT05074849|No Intervention|Usual Care|Participants will not receive foot self-care education or the use of insoles and smart watch.
3151645|NCT00230932||Group 1|outpatients selected from random visits in primary care, oncology, and cardiology clinics
3151646|NCT00230945|Experimental|1|Patient-oriented education and support intervention
2443748|NCT05074524|Experimental|rTMS group|Active rTMS treatment will be delivered at 10 Hz, 100% resting motor threshold, 2000 pulses delivered in five seconds per train with 10-second intra-train pause, delivered once daily five days per week, Monday through Friday for 10 days (10 total treatments). This protocol is adapted from Shen and colleagues (2016), who did not report any adverse events. Liu and colleagues (2020) also used the same protocol and only reported mild side effects of dizziness, headache, and insomnia, which resolved by the 30-day follow-up. However, it is unclear whether these side effects resolved sooner than the 30-day follow-up.
2443749|NCT05074524|Sham Comparator|Placebo Group|The control group will undergo the same seat positioning and comfort measures but will not have a resting motor threshold determination. The coil will be turned 90 degrees counter-clockwise, and the side of the coil will rest on the scalp over the area of the skull corresponding to the motor cortex, so the participant will feel the coil making contact. The same treatment protocol in the active rTMS group will be initiated to mimic the sound of rTMS treatment, though no pulses will be delivered to the participant because of the coil rotation.
3151647|NCT00230945|Experimental|2|Couple-oriented education and support intervention
3151648|NCT00231166|Experimental|HCD122|
3151649|NCT00231244|Experimental|1|CYPHER Sirolimus-Eluting Coronary Stent
3151650|NCT00231257|Experimental|1|Cypher Bx Velocity
2443849|NCT05063344||Sexually active persons who self-select for syphilis testing|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
2443854|NCT05063344||Expectant mothers|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years
3151651|NCT00231257|Active Comparator|2|Brachytherapy
2443875|NCT05063344||Lay users|Participants must be a mixture of English and Spanish speaking, geographically diverse, gender diverse, ethnically and racially diverse, economically diverse, and with different levels of education; 18-64 years; 1/2 high risk sexual behavior and 1/2 low risk sexual behavior
3151652|NCT00231296|Active Comparator|Treatment with CryoCor Cryoablation System|Intervention includes ablation therapy with the CryoCor catheter for the treatment of symptomatic PAF.
3151653|NCT00231296|Active Comparator|Treatment with standard medical therapy|Intervention includes treatment with ant-arrhythmic medications alone.
2443972|NCT05046938|Experimental|intervention group|It was planned to apply 5 sessions of MI to the intervention group, and to follow-up 2 months after the interviews were completed.
2443973|NCT05046938|No Intervention|control group|No application will be made to the students in the control group, and at the end of the study, a seminar on food addiction and quality of life will be given to the students.
2443974|NCT05009784|Active Comparator|Short Traffic Sound|100 seconds of traffic sound
2443975|NCT05009784|Active Comparator|Medium Traffic Sound|200 seconds of traffic sound
2443976|NCT05009784|Active Comparator|Long Traffic Sound|300 seconds of traffic sound
2443978|NCT05009784|Experimental|Short Traffic and Bird Sound|100 seconds of traffic and bird sound
2443979|NCT05009784|Experimental|Medium Traffic and Bird Sound|200 seconds of traffic and bird sound
2443981|NCT05009784|Experimental|Long Traffic and Bird Sound|300 seconds of traffic and bird sound
2443982|NCT05009784|Experimental|Short Traffic and Water Sound|100 seconds of traffic and water sound
2443983|NCT05009784|Experimental|Medium Traffic and Water Sound|200 seconds of traffic and water sound
3151654|NCT00231452|Experimental|Late exposure group|Participants received monthly Sulfadoxine-Pyrimethamine (SP) plus Artesunate (AS) from 2.5-4.5 months of age and monthly placebo from 5.5-9.5 months of age.
3151655|NCT00231452|Experimental|Early exposure group|Participants received monthly placebo from 2.5-4.5 months of age and monthly SP+AS from 5.5-9.5 months of age.
3151656|NCT00231452|Placebo Comparator|Control group|Participants received monthly placebo from 2.5 to 9.5 months of age.
3151657|NCT00231569|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3151658|NCT00231569|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
3151659|NCT00231569|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3151660|NCT00231569|Experimental|Cohort D|Loading doses followed by weekly maintenance doses
3151661|NCT00231569|Experimental|Cohort E|Loading doses followed by weekly maintenance doses
3151662|NCT00231569|Experimental|Cohort F|Loading doses followed by extended weekly maintenance doses
3151663|NCT00231569|Experimental|Cohort G|Loading doses followed by extended weekly maintenance doses
3151664|NCT00231582|Experimental|1|1
3208506|NCT00975429|Experimental|WST11 - 4mg (TOOKAD® Soluble)|4mg/kg Treatment with WST11-mediated VTP
3151665|NCT00231673|Experimental|001|Topiramate Increasing dosing of topiramate gradually to 200 mg daily by mouth dose maintenance for 12 weeks then decreasing dose until stopped over 12 weeks
3151666|NCT00231790|Experimental|MK-0634 50 mg|All participants will receive placebo for the 1 week prior to randomization
3151667|NCT00231790|Experimental|MK-0634 125 mg|All participants will receive placebo for the 1 week prior to randomization
2443750|NCT05074511||healthy|Children in this group will be healthy category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 5th to 85th percentiles
2443751|NCT05074511||overweight|Children in this group will be overweight category according to CDC (Centers for Disease Control and Prevention) growth chart which ranged from BMI-for-age 85th to 95th percentiles .
2443752|NCT05074511||obese|Children in this group will be obese category according to CDC chart which ranged from BMI-for-age > 95th percentiles
2443753|NCT05074511||underweight|Children in this group will be underweight category according to CDC chart ranged from BMI-for-age < 5th percentiles
2443808|NCT05074082||Flap reconstruction|Patients who had a flap formation as part of a multi-visceral extended resection for advanced pelvic (rectal, urological, gynaecological, sarcomatous origin) malignancy
3151668|NCT00231790|Experimental|MK-0634 375 mg|All participants will receive placebo for the 1 week prior to randomization
3151669|NCT00231790|Placebo Comparator|Placebo|All participants will receive placebo for the 1 week prior to randomization
3151670|NCT00231907|Active Comparator|Vaccine 1: TIV. Vaccine 2: TIV.|Vaccine 1: TIV. Vaccine 2: TIV.
3151671|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: TIV.|Vaccine 1: LAIV. Vaccine 2: TIV.
3151672|NCT00231907|Experimental|Vaccine 1: LAIV. Vaccine 2: LAIV.|Vaccine 1: LAIV. Vaccine 2: LAIV.
3151673|NCT00231907|Experimental|Vaccine 1: TIV. Vaccine 2: LAIV.|Vaccine 1: TIV. Vaccine 2: LAIV.
3151674|NCT00231933|Active Comparator|1|Participants will receive standard care incorporating illness management recovery
2444142|NCT04956679||Family members in the study|Community groups that meet the inclusion criteria
3151675|NCT00231933|Experimental|2|Participants will receive illness management recovery plus person-centered planning
3151676|NCT00231933|Experimental|3|Participants will receive illness management recovery plus person-centered planning and community integration
3151677|NCT00231959|Placebo Comparator|Sugar pill|Placebo
3151678|NCT00231959|Experimental|Pramipexole|
2444484|NCT04667416|No Intervention|Standard of Care (SOC)|Participants will receive SOC for chronic ulcers of the lower extremities.
2444485|NCT04667416|Experimental|PalinGen Flow Treatment plus SOC|Participants will receive wound size-dependent dose of PalinGen Flow liquid human amniotic tissue allograft by subcutaneous injection in addition to SOC.
3151679|NCT00231972|Experimental|Project Enhance|Participants will receive the risk reduction program, Project Enhance
3151680|NCT00231972|Active Comparator|Active Comparison Condition|Participants will receive standard prevention case management
2444573|NCT04577729|Experimental|Allogenic FMT group|Allogenic FMT group: patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
2444578|NCT04577729|Placebo Comparator|Autologous FMT group|Autologous FMT group: patients receiving their own stool in terms of sham FMT.
2444712|NCT04422912|Experimental|DSG3-CAART|"Cohort A: Fractionated infusions of DSG3-CAART at increasing dose levels (4-5 groups) administered as a single cycle.~Cohort B: Consolidation of infusion of DSG3-CAART to fewer fractionations than in Cohort A using the selected dose from Cohort A (2 groups) administered as a single cycle.~Cohort C: Infusion of final selected dose and fractionation of DSG3-CAART from Cohorts A and B (1 group) administered as a single cycle"
2444749|NCT04358328|Experimental|Intervention group|The patients in the intervention arm will receive the same care and treatment as is provided to all patients in the clinical setting, including the ERAS-concept. In addition to this they will be individually assessed by a physician with geriatric profile, dietician, physiotherapist and nurse and thereafter undergo appropriate interventions (CGA and care). The intervention team will have weekly meetings regarding the patients included in the study to evaluate how long the intervention should continue before surgery, a maximum time of eight weeks will be allowed for the intervention.
2444752|NCT04358328|Active Comparator|Control group|The patients in the control group will standard care and treatment which include assessment of surgeons, anaesthesiologists and, if needed, other specialized physicians. They will be treated according to the ERAS-concept in the pre- peri- and post operative phase.
2446628|NCT03264573|Active Comparator|stem cell, PRP|Adipose derived MSCs, versus Platelet rich plasma
3151681|NCT00231985|Placebo Comparator|1|Participants will receive supportive psychotherapy.
3151682|NCT00231985|Active Comparator|2|Participants will receive habit reversal therapy.
3151683|NCT00231998|Experimental|1|
3151684|NCT00232011|Experimental|1|
3151685|NCT00232115|Experimental|1|Pimecrolimus
3151686|NCT00232115|Placebo Comparator|2|Vehicle
3151687|NCT00232193||IFNβ+DS group|IFNβ+DS group received lyophilized Avonex 30mcg IM weekly plus dexamethasone 160 mg IV every 4 weeks for 52 weeks and was treated with Avonex 30mcg IM weekly from week 53 to 104
3151688|NCT00232193||IFNβ group|IFNβ group received lyophilized Avonex 30mcg IM weekly for 104 weeks
2443679|NCT05074940|Experimental|Amivantamab|Amivantamab weekly for the first cycle and biweekly thereafter.
3151689|NCT00232219|No Intervention|Control|No fish oil exposure
2443724|NCT05074628|Experimental|Nitrofurantion|is the drug of choice for the treatment of infections caused by multidrug resistant pathogens.
2443726|NCT05074628|Active Comparator|Calcium Hydroxide|Most commonly used intracanal medicaments . Antimicrobial activity of calcium hydroxide is related to the release of hydroxyl ions in an aqueous environment.
2443736|NCT05074563|Active Comparator|Online REsOluTioN training|The active comparator arm will receive access to online REsOluTioN training to enhance resilience.
2443737|NCT05074563|Other|Control|The control arm will have no access to the online training.
3151690|NCT00232219|Experimental|Fish oil|Patients given 6g/day of fish oil containing 1.8g/d of EPA+DHA in a 1.5:1 ratio.
2443782|NCT05074147|Experimental|3 weeks antibiotherapy|Patients are treated 3 weeks with appropriate antibiotics after antibiogram evaluation.
3151691|NCT00232232|No Intervention|Control|No fish oil
2443784|NCT05074147|Experimental|6 weeks antibiotherapy|Patients are treated 6 weeks with appropriate antibiotics after antibiogram evaluation.
3151692|NCT00232232|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
3151693|NCT00232245|Experimental|Fish oil|Patients prescribed 6g/day of fish oil containing total 1.8 g of EPA+DHA in a 1.5:1 ratio
3151694|NCT00232245|No Intervention|Control|No fish oil exposure
3151695|NCT00232271|Active Comparator|clexane|patients received clexane
3151696|NCT00232271|No Intervention|non clexane|no clexane given
3151697|NCT00232284|Active Comparator|Sertaline|8 week course of sertraline 50-100mg for those who fail to respond to CBT within first 4 weeks of study entry
3151698|NCT00232284|Placebo Comparator|Placebo|8 week course of placebo
3151699|NCT00232349|Experimental|Intervention group|All subjects enrolled in study are in the intervention group.
3151700|NCT00232466|No Intervention|2|conservative therapy (no intervention)
3151701|NCT00232466|Active Comparator|1|Vertebroplasty
3151702|NCT00232492|Placebo Comparator|Placebo males|Saline physiological placebo males
3151703|NCT00232492|Active Comparator|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine males
3151704|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine males
3151705|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine males
3151706|NCT00232492|Placebo Comparator|Placebo females|Saline physiological as placebo females
3151707|NCT00232492|Active Comparator|Ketamine 0.1 mg/kg females|0,1 mg/kg ketamine females
2443999|NCT05006976|Active Comparator|NSAC health only|Treatment as usual (TAU) at NSAC, following a digital survey of health problems and the provision of a condensed report of this survey to clinician prior to consultation.
2444000|NCT05006976|Experimental|NSAC health + MBW|Treatment as usual (TAU) at NSAC, following a digital survey of health problems as well as Motivation, Barriers for return to work and Work environment (MBW), and the provision of a condensed report of this survey to clinician prior to consultation.
2444018|NCT04974086|Experimental|CDS Tool Evaluation|All participants will receive intervention and feasibility, acceptability, and usability of intervention will be assessed from each participant cohort group.
2444053|NCT04955951||polarized light group|group A (20 patients) will receive Polarized light therapy
2444055|NCT04955951||topical corticosteroid group|group B (20 patients) will receive topical corticosteroid therapy
2444056|NCT04964713||type 2 diabetes|T2DM was defined according to the WHO 2006 criteria. Assessing the left heart and right heart structure and function of T2DM by speckle tracking echocardiography.
2444057|NCT04964713||Prediabetes|According to the WHO 2006 criteria, combining impaired fasting glucose and impaired glucose tolerance as prediabetes. Assessing the left heart and right heart structure and function of prediabetes by speckle tracking echocardiography.
2444059|NCT04964713||normal glucose metabolism(NGM)|Assessing the left heart and right heart structure and function of NGM by speckle tracking echocardiography.
3151708|NCT00232492|Active Comparator|Ketamine 0,3 mg/kg females|0,3 mg/kg ketamine females
3151709|NCT00232492|Active Comparator|Ketamine 0,5 mg/kg females|0,5 mg/kg ketamine females
3151710|NCT00232622|Active Comparator|Standard infusion of streptokinase|Standard infusion of streptokinase
2444270|NCT04808518||Bx reg group|
2444272|NCT04808518||non-Bx reg group|
3151711|NCT00232622|Experimental|Accelerated infusion of streptokinase|Accelerated infusion of streptokinase
3151712|NCT00232687|Active Comparator|A1|
3151713|NCT00232687|Active Comparator|A2|
3151714|NCT00232752|Experimental|1|
3151715|NCT00232765|Experimental|1|Cypher Bx Velocity
3151716|NCT00232765|Active Comparator|2|Uncoated Bx Velocity
3151717|NCT00232791|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
3151718|NCT00232791|Active Comparator|2|CYPHER™ Sirolimus-eluting Coronary Stent
3151719|NCT00232804|Other|1|
3151720|NCT00232817|Experimental|1|Propofol anesthetic with and without nicotine
3151721|NCT00232817|Experimental|2|isoflurane anesthetic with and without nicotine
3151722|NCT00232830|Experimental|1|Cypher Sirolimus-eluting Coronary Stent
3151723|NCT00232830|Active Comparator|2|Bare-metal stent
3151724|NCT00232843|Experimental|1|Cordis SMART™ nitinol self-expanding stent.
3151725|NCT00232843|Active Comparator|2|balloon angioplasty
3151726|NCT00232856|Other|1|Cypher™ sirolimus-eluting stent
3151727|NCT00232869|Experimental|1|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
3151728|NCT00232869|Active Comparator|2|SMART™ bare-metal stent
3151729|NCT00232882|Active Comparator|1|Candesartan 16 mg for 4 weeks followed by candesartan 16 mg and hydrochlorothiazide 12.5 mg for 4 weeks
3151730|NCT00232882|Active Comparator|2|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
3151731|NCT00232882|Active Comparator|3|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
3151732|NCT00232908|Experimental|1|
3151733|NCT00233077|Experimental|Behavioral: Patient Assistance|Patient assistance programs
2443961|NCT05049005|Active Comparator|RED FOOD Intervention Group|Participants in the RED FOOD group will be taught a simplified way of identifying high-calorie foods (red foods) and reducing them using the Traffic Light Diet. Limiting the number of red foods consumed is a simple way to reduce calories without having to track calories. Participants in this group will use the study website to track their red foods and will be given a daily red food limit base on their baseline weight and will track their red foods on the study website daily. Participants will be recommended to enter their red foods at least once per day (at which time they would enter all red foods for the day), but ideally multiple times per day to reduce errors associated with recall.
2443968|NCT05049005|Experimental|GREEN FOOD Intervention Group|Participants in the GREEN FOOD group will be taught a simplified way of identifying low-calorie foods (green foods) and maximizing them using the Traffic Light Diet. Maximizing the number of green foods consumed is a simple way to reduce dietary energy density while allowing for consumption of a satisfying amount (i.e. weight and volume) of food. Maximizing green food consumption may simultaneously reduce red food consumption, thereby reducing calorie intake and promoting greater diet quality than red food reduction alone. Participants in this group will also use the study website to track their green foods and will be given a daily green food goal based on their baseline weight and will track their green foods on the study website daily. Participants will be recommended to enter their green foods at least once per day (at which time they would enter all green foods for the day), but ideally multiple times per day to reduce errors associated with recall.
2444020|NCT04975620|Experimental|Franseen needle with three symmetric cutting edges|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using the Franseen needle (Acquire FNB needle; Boston Scientific): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
2444025|NCT04975620|Experimental|Multi-blade needle with three-prong tip with one tip longer than the other two|These patients will undergo endoscopic ultrasound-guided fine needle biopsy using a multi-blade three-prong tip needle (Trident; Microtech): eight back and forth movements within the lesion will be performed with simultaneous minimal negative pressure provided by withdrawing the needle stylet slowly. Four passes of FNB will be made from each mass lesion and the specimens from each pass will be placed in different containers for cell block preparation and histologic evaluation.
3151734|NCT00233077|Other|Control: Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
3151735|NCT00233129|Active Comparator|Standard Treatment|cognitive rehabilitation day treatment program
2444199|NCT04901962|Experimental|JOBST® Confidence compression garments|The CE-marked class I medical devices JOBST® Confidence compression garments for lower and upper extremities will be tested under routine conditions according to their selected intended use. Subjects will be treated with either thigh-high compression stockings (AG) or arm compression garments without hand part (CG1), depending on their indication.
3151736|NCT00233129|Experimental|Top-Down|"cognitive rehabilitation day treatment program that incorporates systematic top down treatment of executive function deficits (problem solving and emotional regulation training), systematic treatment of attention deficits, and modular, contextual and embedded approaches to treatment."
3151737|NCT00233142|Experimental|Expressive writing|Expressive writing
3151738|NCT00233142|Sham Comparator|Neutral writing|Non-expressive writing
3151739|NCT00233168|Experimental|1|Peer medication adherence counseling
3151740|NCT00233168|Active Comparator|2|Peer life skills counseling
3151741|NCT00233194||Cohort 2|Children scheduled for adenotonsillectomy and healthy subjects, for comparison, not scheduled for such surgery.
3151742|NCT00233220|Experimental|1|Patients and doctors will take part in a multicomponent, multi-level intervention.
3151743|NCT00233220|Active Comparator|2|Patients will receive usual care.
3151744|NCT00233259|Active Comparator|1|Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
3151745|NCT00233259|Placebo Comparator|2|Control group
2444714|NCT04431466|Experimental|SOC plus ivermectin 100 mcg/kg|SOC plus ivermectin 100 mcg/kg
2444715|NCT04431466|Experimental|SOC plus ivermectin 200 mcg/kg|SOC plus ivermectin 200 mcg/kg
2444717|NCT04431466|Experimental|SOC plus ivermectin 400 mcg/kg|SOC plus ivermectin 400 mcg/kg
3151746|NCT00233506|Experimental|CPG 7909 IV|Intravenous infusions will be administered with a standard infusion pump beginning at 125 cc/hr through an intravenous catheter (central or peripheral).
3151747|NCT00233506|Experimental|CPG 7909 SQ|Subcutaneous injections should be administered in the abdominal wall, upper arm, hip, or anterior thigh. If the volume of injection exceeds 1.5 ml, the volume should be divided into equal injections at a volume less than 1.5 ml and administered in different areas of the body. The maximum dose level on this trial may require 5 - 6 injections at an equal number of sites.
3151748|NCT00233532|Other|1|
3151749|NCT00233532|Other|2|
3151750|NCT00233532|Other|3|
3151751|NCT00233571|Experimental|Adalimumab 40mg subcutaneous (SC) every other week (EOW)|Adalimumab 40mg subcutaneous (SC) every other week (EOW)
3151752|NCT00233688|Experimental|1|QUANTUM LP™ STENT GRAFT SYSTEM
2443682|NCT05074966|Experimental|mXELOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;"
2443697|NCT05074966|Active Comparator|FOLFOX plus cetuximab|"Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab：500 mg/m2, IV, d1, q2w Oxaliplatin： 85 mg/m2, IV d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w;~maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）"
3151753|NCT00233688|Active Comparator|2|Surgical intervention
3151754|NCT00233714|Active Comparator|1|Single-dose Sirolimus-Eluting Coronary stent
3151755|NCT00233714|Active Comparator|2|Double-dose Sirolimus-Eluting Coronary stent
3151756|NCT00233727|Active Comparator|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
3151757|NCT00233727|Active Comparator|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
3151758|NCT00233727|No Intervention|Delayed Evaluation and Treatment|Patients will undergo a similar screening process at entry, but will be randomized to have evaluation and treatment delayed until 6 months after screening.
3151759|NCT00233792|Other|1|sirolimus coated Bx VELOCITY stent - fast release
2444160|NCT04925713|Experimental|IFx-Hu2.0 (plasmid DNA) 0.1 mg/lesion|One hundred (100) patients will receive 0.1 mg of IFx-Hu2.0 injected intratumorally in a single lesion at a single time point and be followed-up 28 days thereafter.
3151760|NCT00233792|Other|2|sirolimus coated Bx VELOCITY stent - slow release
2444324|NCT04798911||Observational - phase 1|"Determination of Informational Needs (Months 0- 9)~Qualitative interviews with patients with SS~Interview transcriptions and thematic analysis"
2444328|NCT04798911||Observational - phase 2|"Phase 2 Development of the informational need instrument for SS [SS-INQ] (Months 9-32)~Adaptation of TINQ-BC for use in patients with SS - generation of relevant questions using themes from Phase 1 qualitative study (removal of those solely related to breast cancer from TINQ-BC) by the expert group~Pilot testing of SS-INQ for content and readability will be done via focus groups whilst structural validity will be explored using factor analysis~Testing of SS-INQ for reliability - internal consistency reliability and test-retest reliability"
2444475|NCT04647383|Experimental|OSA Cohort, Sequence A: Placebo + Lemborexant 10 mg|Participants with OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
2444477|NCT04647383|Experimental|OSA Cohort, Sequence B: Lemborexant 10 mg + Placebo|Participants with OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
2444480|NCT04647383|Experimental|COPD Cohort, Sequence C: Placebo + Lemborexant 10 mg|Participants with COPD will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
2444482|NCT04647383|Experimental|COPD Cohort, Sequence D: Lemborexant 10 mg + Placebo|Participants with COPD will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days will be maintained between the 2 treatment periods.
2444583|NCT04555967||Transcatheter aortic valve implantation|
3151761|NCT00233805|Active Comparator|1|Bare metal Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
3151762|NCT00233805|Experimental|2|Sirolimus coated modified Bx Velocity™ Balloon-Expandable Stent mounted on the Raptor® rapid exchange delivery system
3151763|NCT00233818|Other|1|
3151764|NCT00233883|Experimental|1|
3151765|NCT00233883|Active Comparator|2|
3151766|NCT00233935|Experimental|Arm I (1 capsule)|Patients receive 1 capsule of defined green tea catechin extract PO BID for the next 6 months.
3151767|NCT00233935|Experimental|Arm II (2 capsules)|Patients receive 2 capsules of defined green tea catechin extract PO BID for the next 6 months.
3151768|NCT00233935|Experimental|Arm III (3 capsules)|Patients receive 3 capsules of defined green tea catechin extract PO BID for the next 6 months.
3151769|NCT00233935|Placebo Comparator|Arm IV (placebo)|Patients receive 1-3 capsules of placebo PO BID for the next 6 months.
3151770|NCT00233974|Experimental|PET negative|Traditional breast Surgery and full axillary dissection
2443792|NCT05074186|Experimental|neurological thrombectomy device|Revascularization device is an investigational device.
2443883|NCT05068063|Experimental|Femoral Triangle + IPACK block|Patients randomized to receive a combination of femoral triangle block and active IPACK block
2443888|NCT05068063|Active Comparator|Femoral Triangle block|Patients randomized to receive a combination of femoral triangle block and sham IPACK block
3151771|NCT00233974|Experimental|PET positive|PET-probe-guided breast resection and full axillary dissection
3151772|NCT00234000|Experimental|Arm 1|see description in intervention
3151773|NCT00234091|Active Comparator|1|Immediate treatment; individuals receive HAART on Day 1 of the study
3151774|NCT00234091|Active Comparator|2|Delayed treatment; individuals receive HAART if their CD4 percentage falls below 15 percentage OR if they develop a CDC category C illness
3151775|NCT00234143|Active Comparator|Aranesp and Neupogen|solution for subcutaneous injection , syringe 500 mcg and 300 mcg respectively
2444047|NCT04968379|Experimental|Ferric Carboxymaltose|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 5.0 mg/kg dose of FCM
2444048|NCT04968379|Experimental|Injectafer|To evaluate the safety, tolerance, PK and PD profile of intravenous (IV) FCM in infants 0 to 1 year of age with IDA after receiving a 7.5 mg/kg dose dose of FCM.
3151776|NCT00234143|Active Comparator|Aranesp|solution for subcutaneous injection, 500 mcg
3151777|NCT00234143|No Intervention|Best supportive care|Red cell transfusion support
3151778|NCT00234156|Active Comparator|renal disease|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
3151779|NCT00234156|Active Comparator|normal|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
3151780|NCT00234208|Experimental|Medical thoracoscopy|
3151781|NCT00234208|Active Comparator|Simple chest tube drainage|
3151782|NCT00234221|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
3151783|NCT00234221|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's alcohol use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized alcohol treatment; or 2) provide a strategy to self-monitor alcohol use, consider consequences, and later seek assessment.
2444290|NCT04800887|Active Comparator|Extended depth of focus intraocular lens|Eyes of patients implanted with extended depth of focus lens Tecnis Eyhance
2444295|NCT04800887|Active Comparator|Monofocal intraocular lens|Eyes of patients implanted with monofocal lens Tecnis ZCB00
3151784|NCT00234221|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
3151785|NCT00234273|Experimental|Therapeutic education combining dietary and rehabilitation|Therapeutic education combining dietary and rehabilitation (APA)
3151786|NCT00234273|Active Comparator|Therapeutic education primarily focused on dietary|Therapeutic education primarily focused on dietary
2444463|NCT04664621|Experimental|HepQuant Testing|
2444550|NCT04625413|Experimental|Experimental: Experimental Arm: single|The UR-GOAL tool will incorporate conjoint analysis to elicit patient preferences as well as assessments of fitness and prognostic awareness.
2444572|NCT04549493|Active Comparator|Trauma Management Therapy|1. Trauma Management Therapy (TMT; Turner, Beidel, & Frueh, 2005): TMT is a multicomponent behavioral treatment program designed to target various aspects of chronic PTSD - reducing emotional and physiological reactivity to traumatic cues, reducing intrusive symptoms and avoidance behavior, improving interpersonal skills and emotion modulation (e.g., anger control), and increasing the range of enjoyable social activities. In this investigation and in line with our previous publications, TMT will include virtual-reality augmented exposure (i.e. olfactory stimulation, heart rate, and skin conductance); group therapy to address sleep, anger, depression, and social isolation; homework assignments; and programmed practice. In the 3-week treatment program, each participant receives virtual-reality assisted exposure in the morning followed by in vivo exposure and group therapy (SER) each afternoon for a total of 29 sessions.
2444574|NCT04549493|Active Comparator|Prolonged Exposure|2. Standard Prolonged Exposure (PE; Foa, Hembree, & Rothbaum, 2007) consists of psychoeducation, imaginal exposure to trauma memories, in vivo exposure to situations that are avoided due to their association with the trauma, and emotional processing. The standard protocol consists of 12 imaginal exposure sessions, along with in vivo exposure/homework assignments and listening to a recording of the imaginal sessions at home during the evening.
2446708|NCT03263962||Without canrenone|Patients without canrenone
3151787|NCT00234299|Active Comparator|Group A|Enteric coated aspirin 325mg, one tablet orally every day for six months prior to prostate biopsy.
3151788|NCT00234299|Placebo Comparator|Group B|Enteric coated placebo, one tablet orally every day for six months prior to prostate biopsy.
3151789|NCT00234455|Other|1|stent in the main branch with balloon angioplasty by a kissing balloon technique in the side branch (stent/PTCA group)
2443684|NCT05074836|Experimental|Formula Milk|"Formula milk designed for young children aged over 3 years;~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
2443695|NCT05074836|Active Comparator|Regular milk|"Regular milk (pure milk);~Dosage: 195 ml/time;~Frequence: 2 times /day;~Duration: 12 months"
2443705|NCT05074836|Other|Control foods|"Grain foods: e.g., bread;~Dosage: 20-40 g/time;~Frequence: 2 times /day;~Duration: 12 months"
2443743|NCT05074472|Experimental|Active Treatment: ZB131|During the Dose Escalation Stage, patients will be treated with ZB131 at increasing dose levels, beginning with a starting dose level (DL0) of 3 mg/kg once weekly, up to a maximum dose level (DL3) of 15 mg/kg once weekly.
3151790|NCT00234455|Other|2|stents in both the main and side branches (stent/stent group)
3151791|NCT00234546|Experimental|1|Dysport
3151792|NCT00234546|Placebo Comparator|2|Placebo
3151793|NCT00234598|No Intervention|Control group, usual care|Usual care with no study interventions provided; no tooth brushing intervention and no chlorhexidine intervention. Usual care
3151794|NCT00234598|Active Comparator|Tooth brushing only|Tooth brushing by study personnel three times per 24 hours (TID) without chlorhexidine application.
2444108|NCT04941742||Active eosinophilic esophagitis|
2444109|NCT04941742||Eosinophilic esophagitis in remission|
2444110|NCT04941742||No eosinophilic esophagitis|
3151795|NCT00234598|Active Comparator|Chlorhexidine only|Oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID) without tooth brushing.
3151796|NCT00234598|Active Comparator|Toothbrushing and chlorhexidine|Tooth brushing by study personnel three times per 24 hours (TID) and oral application of chlorhexidine 0.12% oral solution twice per 24 hours (BID)
3151797|NCT00234676|Experimental|1|Premarin
2444323|NCT04797325|Active Comparator|vedolizumab|
2444331|NCT04797325|Active Comparator|Standard treatment|
3151798|NCT00234702|Experimental|1|
3151799|NCT00234702|Placebo Comparator|2|
3151800|NCT00234754|Active Comparator|1|Trans-vaginal tape Surgery
3151801|NCT00234754|Experimental|2|Trans-obturator tape surgery
3151802|NCT00234806|Experimental|Telemedicine intervention group|
3151803|NCT00234806|Placebo Comparator|Control group|
3151804|NCT00234858|Active Comparator|1|
2444536|NCT04630002|Experimental|Cohort 1: GSK3640254 then DRV/RTV then GSK3640254 + DRV/RTV|Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
2444538|NCT04630002|Experimental|Cohort 2: GSK3640254 then ETR then GSK3640254 + ETR|Cohort 2 will include 3 periods. In Period 1 GSK3640254 will be given (Treatment A). In Period 2 ETR will be given (Treatment C). In Period 3 GSK3640254 (Treatment A) and ETR (Treatment C) will be administered.
2444541|NCT04630002|Experimental|Cohort 3: GSK3640254 then GSK3640254 + DRV/RTV + ETR|Cohort 3 will include 2 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 GSK3640254 (Treatment A), DRV/RTV (Treatment B), and ETR (Treatment C) will be administered.
3151805|NCT00234858|Active Comparator|2|
3151806|NCT00234871|Active Comparator|1|
3151807|NCT00234871|Active Comparator|2|
3151808|NCT00234910|Experimental|A|2 drug arm
3151809|NCT00234910|Active Comparator|B|3 drug arm, SOC
2444724|NCT04416282|Active Comparator|Albumin|i/v albumin 1g/Kg/day for next 36 hours f/b inj terlipressin 2mg/24 hours
3151810|NCT00234923|Active Comparator|1|Kaletra Monotherapy: lopinavir/ritonavir
3151811|NCT00234923|Active Comparator|2|Kaletra based triple therapy: lopinavir/ritonavir + lamivudine/zidovudine
3151812|NCT00234975|Active Comparator|HCV +|
3151813|NCT00234975|Active Comparator|HCV -|
3151814|NCT00234988|Experimental|1|
3151815|NCT00235001|Experimental|1|
3151816|NCT00235014|Active Comparator|A-1, B-1|A-1 pertains to Phase 1; B-1 pertains to Phase 2
3151817|NCT00235014|Active Comparator|A-2, B-2|A2 pertains to Phase 1; B-2 pertains to Phase 2
3151818|NCT00235014|Placebo Comparator|A-3|
3151819|NCT00235014|Active Comparator|A-4|
3151820|NCT00235027|Experimental|Adverse Drug Event Monitoring|In this intervention arm, clinicians received medication safety alerts when they prescribed medications in the electronic medical record.
3151821|NCT00235027|No Intervention|Care as Usual|In this arm, clinicians did not receive the medication safety alerts.
3151822|NCT00235040|Other|1|Intervention
3151823|NCT00235040|No Intervention|2|Control
3151824|NCT00235066|Experimental|1|Cypher Sirolimus-Eluting Stent
3151825|NCT00235079|Experimental|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
3151826|NCT00235079|Placebo Comparator|Placebo|Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
3151827|NCT00235131|Experimental|1|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
3151828|NCT00235131|Active Comparator|2|Bard® Luminexx™ 6F Vascular Stent
3151829|NCT00235144|Experimental|1|drug-eluting stent
3151830|NCT00235144|Active Comparator|2|bare-metal stent
3151831|NCT00235157|Experimental|1|Sirolimus-eluting Palmaz Genesis peripheral stent
3151832|NCT00235170|Experimental|1|Cypher Sirolimus-eluting Coronary stent
3151833|NCT00235183|Active Comparator|Quarantined FFP|Quarantined FFP
3151834|NCT00235183|Active Comparator|Methylene blue FFP|Methylene blue FFP
3151835|NCT00235183|Active Comparator|Solvent detergent FFP|Solvent detergent FFP
2443685|NCT05074927|Other|Cohort|All patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France)
3151836|NCT00235235||A|Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 day 2 of every 21-day cycle
3151837|NCT00235235||B|Capecitabine 1000mg/m2 bid days 1-14 of every 21-day cycle
3151838|NCT00235235||C|Vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle
3151839|NCT00235235||D|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
2443861|NCT05061485|Experimental|Sucrose|The participants will be served a test drink with 75g sucrose dissolved in water
2443894|NCT05061485|Experimental|Sucrose + protein|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal protein (whey protein)
2443897|NCT05061485|Experimental|Sucrose + fat|The participants will be served a test drink with 75g sucrose dissolved in water and ~ 100 kcal fat (cream)
3151840|NCT00235248|Experimental|Clopidogrel-aspirin|Clopidogrel-aspirin
3151841|NCT00235248|Active Comparator|Warfarin|Warfarin
3151842|NCT00235287|Active Comparator|A,AIIA|24 weeks of treatment with Candesartan, where Enalapril is added in the last 8 weeks.
3151843|NCT00235287|Active Comparator|A, ACE-I|24 weeks of treatment with Enalapril, where Candesartan is added in the last 8 weeks.
3151844|NCT00235287|Active Comparator|C, AIIA|8 weeks of treatment with Candesartan, followed by 8 weeks of treatment with Enalapril. The treatment in the last 8 out of the 24 weeks is a combination of Candesartan and Enalapril.
3151845|NCT00235287|Active Comparator|C, ACE|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg) , followed by 8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg) . The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
3151846|NCT00235300|Active Comparator|1 Control|Simulect (basiliximab)
3151847|NCT00235300|Experimental|2|Thymoglobulin (anti-thymocyte globulin (rabbit))
3151848|NCT00235313|Experimental|1|adaptation of the nicotine patch with salivary cotinine
3151849|NCT00235313|Other|2|normal following with a nicotine patch
3151850|NCT00235339|Active Comparator|1|Standard exercise training rehabilitation at the hospital
3151851|NCT00235339|Experimental|2|Interval exercise training on treadmills, with high intensity
2444327|NCT04792008|Experimental|YQ23 Single dose|Two-third of randomized patients will receive YQ23 as active treatment
2444332|NCT04792008|Placebo Comparator|Placebo Single dose|One-third of randomized patients will receive matching placebo
2444396|NCT04718116|Active Comparator|tapentadol 50 mg|tapentadol 50mg p.o 3 times daily for two days
2444397|NCT04718116|Active Comparator|tapentadol 75 mg|tapentadol 75 mg p.o 3 times daily for two days
2444398|NCT04718116|Active Comparator|tramadol 100 mg|tramadol 100 mg p.o 3 times daily for two days
3151852|NCT00235365|Experimental|meta-cognitive therapy|meta-cognitive therapy
3151853|NCT00235365|Active Comparator|waiting list|waiting list control
3151854|NCT00235378||1|SLE patients
3151855|NCT00235378||2|Unaffected family members of SLE patients
3151856|NCT00235378||3|Control participants
3151857|NCT00235404|Experimental|Intermediate community hospital|
3151858|NCT00235404|Active Comparator|Usual care|
3151859|NCT00235508|Active Comparator|1|Escitalopram oxalate 10 mg at bedtime
3151860|NCT00235508|Active Comparator|2|Eszopiclone 3 mg at bedtime
2445565|NCT03272113|Experimental|Intervention|Women will receive usual care as described above plus the SKIP-IT intervention
3151861|NCT00235534|Experimental|Immediate start|Initiate selected birth control method before leaving the clinic at the time of the abortion procedure.
3151862|NCT00235534|Active Comparator|Sunday start|Begin birth control the first Sunday after leaving the clinic
3151863|NCT00235690|Other|blood draws|all patients enrolled will have PK blood samples obtained around a colistin dosing
3151864|NCT00235729|Experimental|1|Lofexidine 0.8 mg QID
3151865|NCT00235729|Placebo Comparator|2|Placebo QID
3151866|NCT00235807|Other|1|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3151867|NCT00235807|Other|2|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3151868|NCT00235807|Other|3|should contain an explanation of the nature of the study group (e.g., those with a condition and those without a condition; those with an exposure and those without an exposure).
3151869|NCT00235820|Active Comparator|A|
3151870|NCT00235820|Active Comparator|B|
3151871|NCT00235820|Placebo Comparator|C|
3151872|NCT00235846|Active Comparator|Conventional vein harvest|Conventional open vein harvest from the lower leg
3151873|NCT00235846|Experimental|Endoscopic vein harvest|Endoscopic vein harvest from the calf
3151874|NCT00235898|Experimental|1|CoFactor, 5-FU
3151875|NCT00235898|Active Comparator|2|Leucovorin, 5-FU
3151876|NCT00236002|Placebo Comparator|placebo|
3151877|NCT00236119|Experimental|CEP-701 20mg|Patient Cohort 1
3151878|NCT00236119|Experimental|CEP-701 40mg|Patient Cohort 2
3151879|NCT00236119|Experimental|CEP-701 60mg|Patient Cohort 3
3151880|NCT00236119|Experimental|CEP-701 80mg|Patient Cohort 4
3151881|NCT00236158|Other|AAIR|
3151882|NCT00236158|Other|DDDR|
2443730|NCT05074602|Experimental|SHR8008|
2443731|NCT05074602|Active Comparator|Fluconazole|
2443789|NCT05074212|Experimental|Complex Linear Closure|The study participant will receive two layers of sutures to close the wound.
2443791|NCT05074212|Experimental|Second Intention Healing|The study participant will not have any sutures placed.
3151883|NCT00236210|Active Comparator|VIP program|Risk assessment, lifestyle counselling, exercise program
3151884|NCT00236210|No Intervention|Standard Care|
3151885|NCT00236223|Experimental|1|
2443995|NCT05004805|Experimental|Methylene blue Arm|The intervention is carried out in addition to the standard treatment. Administered Intervention is topical application of 0.02% Methylene blue solution in the form of repeated nasopharyngeal irrigation. The investigational drug is equipped with a spray nozzle to perform three administrations into both lower nasal passages. After three administrations on each side, it is recommended to take a deep breath so that the injected solution is distributed along the nasopharynx and oropharynx every 4 hours (5-6 times a day with a break for sleep). Duration is the period of stay of the subject, as long as there is no need for non-invasive or invasive mechanical ventilation. If the subject refuses further treatment in a hospital but does not withdraw consent to participate in the study, they should continue to take study drug after discharge from hospital, but not later than the date of the follow-up visit.
2443998|NCT05004805|Placebo Comparator|Saline solution Arm|The intervention is carried out in addition to the standard treatment. Adminestered Intervention is saline solution in the form of repeated nasopharyngeal irrigation. Dosage form, dosage, frequency and duration of intervention are the same.
3151886|NCT00236223|Placebo Comparator|2|
2444126|NCT04928300|Experimental|Group D|Dexmedetomidine infusion IV for 5 days.
2444127|NCT04928300|Experimental|Group K|Ketamine infusion 2.5 µ/kg/min for 5 days.
2444131|NCT04928300|Placebo Comparator|Group C|The same dose and duration of normal saline will be given.
3151887|NCT00236275|Experimental|1|Fluoro-L-thymidine-(18F)
3151888|NCT00236301|Active Comparator|1|17 Beta-estradiol (2mg/day)and (1mg/day)
3151889|NCT00236301|Active Comparator|2|CLIMASTON
3151890|NCT00236301|Placebo Comparator|3|placebo
3151891|NCT00236379|Experimental|001|Risperidone Target oral dose of 6 milligrams per day for for 6 months
2444534|NCT04624997||Patient suspected COVID-19|"Follow-up of patients as usual in care for infection. No specific puncture. Blood sample collect at admission and every 72h during hospitalisation for hemostasis evaluation, DNA extraction, Circulating endothelial cells measuring.~Sampling can be delayed for 24h to match a planned blood collection for care or other research."
2444564|NCT04565041|Experimental|Social Support|
3151892|NCT00236379|Experimental|002|Olanzapine Target oral dose of 20 milligrams per day for 6 months
3151893|NCT00236925|Active Comparator|Low dose Hydrocortisone|Low Dose Hydrocortisone
3151894|NCT00236925|Placebo Comparator|Placebo|Placebo
3151895|NCT00236990|Experimental|001|pentosan polysulfate sodium
3151896|NCT00237003|Active Comparator|1) assessment plus motivational interview|Participants are assigned, in this 6 month study, to an assessment-only condition or an assessment plus motivational interview condition. Two motivational interview sessions are conducted during the first month of study participation.
3151897|NCT00237107|Experimental|curettage|
2444768|NCT04341129|Experimental|Abbreviated MRI using Dotarem|Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic accuracy comparable to that of the conventional full MRI protocol. The shorter imaging times achieved with the abbreviated DCE-MRI protocols have the potential to increase efficiency and lower cost by decreasing time in the MRI suite, which in turn may make breast MRI accessible for population-based mass screening. The focus of the proposed research is the investigation of an abbreviated MRI protocol using Dotarem® (Gadoterate Meglumine) by comparing the diagnostic accuracy of dynamic contrast-enhanced breast MRIs performed with an abbreviated protocol versus a full protocol.
3151898|NCT00237133|Experimental|Letrozole|
3151899|NCT00237146|Experimental|Zoledronic Acid|
3151900|NCT00237159|Experimental|ZOL446|
3151901|NCT00237172|Experimental|Imatinib Mesylate|400 mg once daily
3151902|NCT00237198|Experimental|Letrozole|
3151903|NCT00237211|Experimental|Letrozole|
3151904|NCT00237224|Experimental|FEM345|
3151905|NCT00237380|Experimental|Ataluren|"Cycle 1: Within the first 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 4 milligrams/kilogram (mg/kg) (breakfast), 4 mg/kg (lunch), and 8 mg/kg (dinner); there will then be an interval of 14 days without treatment.~Cycle 2: Within the second 28-day period, ataluren treatment will be taken 3 times per day with meals for 14 days at doses of 10 mg/kg (breakfast), 10 mg/kg (lunch), and 20 mg/kg (dinner); there will then be an interval of 14 days without treatment."
3151906|NCT00237393|Experimental|1|Quetiapine
3151907|NCT00237393|Placebo Comparator|2|
3151908|NCT00237484|Experimental|Arm A|Remicade induction dose at Day -7 prior to initiation of PEGETRON treatment for up to 48 weeks
3151909|NCT00237484|Active Comparator|Arm B|PEGETRON treatment for up to 48 weeks
3151910|NCT00237497|Experimental|Ramelteon 8 mg QD|
3151911|NCT00237497|Active Comparator|Zopiclone 7.5 mg QD|
3151912|NCT00237497|Placebo Comparator|Placebo QD|
3151913|NCT00237549|Experimental|Intervention|The 334 general practices in Denmark, United Kingdom and the Netherlands have been randomised to screening for diabetes followed by routine care (RC group) according to national guidelines, or screening followed by multifactorial treatment (IT group).
3151914|NCT00237601||1|Women with the intention to give birth at home
3151915|NCT00237601||2|Women with the intention to give birth in a short-stay hospital setting
3151916|NCT00237627|Experimental|Part 1|Doxil + PS-341
3151917|NCT00237627|Experimental|Part 2|Doxil + Velcade
3151918|NCT00237640|Placebo Comparator|1|
3151919|NCT00237640|Active Comparator|2|
2443687|NCT05075018||Healthcare Workers with COVID-19 Infection|Healthcare workers who have been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
2443694|NCT05075018||Healthcare Workers without COVID-19 Infection|Healthcare workers who have not been diagnosed with COVID-19 in the past and currently do not have COVID-19 disease constitute this group
2443739|NCT05074537||MRI Participants|
2443740|NCT05074537||PET/CT Participants|
2443741|NCT05074537||CT Participants|
2443796|NCT05074108|Experimental|Pilot study|Adapt and pilot a nutrition-based intervention. The program will take a holistic approach to educate participants about basic nutrition and cooking skills, sleep, and mindfulness strategies to enhance mental health.
3151920|NCT00237679|Active Comparator|Neuromuscular Electrical Stimulation|Subjects will receice Neuromuscular Electrical Stimulation (NMES)-stimulated swallowing combined with exercise therapy.
3151921|NCT00237679|Sham Comparator|Unstimulated|Subjects will receive sham (unstimulated) swallow therapy combined with exercise therapy.
3151922|NCT00237731|Experimental|1|morphine 0.05
3151923|NCT00237731|Active Comparator|2|morphine 0.10
3151924|NCT00237757|Experimental|Arm 1|The experimental arm consisted of a six month staff training period with an emphasis on effective team functioning to improve patient outcomes. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing
3151925|NCT00237757|Active Comparator|Arm 2|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
2444112|NCT04943874|Other|Technology Based Intervention 1|
2444117|NCT04943874|Other|Technology Based Intervention 2|
3151926|NCT00237783|Active Comparator|standard dialysate sodium (140 mmol/L)|dialysate sodium (140 mmol/L)
3151927|NCT00237783|Experimental|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
3151928|NCT00237913|Active Comparator|A1|
3151929|NCT00237913|Active Comparator|B1|
3151930|NCT00237926|Experimental|1|aerobic exercise
3151931|NCT00237926|Experimental|2|Resistance Training
3151932|NCT00237978|Active Comparator|1|VIS and wIRA
3151933|NCT00237978|Active Comparator|2|VIS, wIRA and Adapalen
3151934|NCT00237978|Active Comparator|3|Adapalen
3151935|NCT00238030|Active Comparator|po thyroxine|placebo is iv
2444437|NCT04705779|Experimental|HARMONY|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
2444438|NCT04705779|Active Comparator|Nutrition and Exercise Education Workgroup (NEEW)|Following screening, participation includes 8 regular sessions occurring over 4 months followed by 6 monthly booster sessions. Overall, study participation will last approximately 14 months.
3151936|NCT00238030|Active Comparator|iv thyroxine|placebo is po
2444570|NCT04564976|Experimental|Social Support|
3151937|NCT00238212|Experimental|Treatment|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3151938|NCT00238251|Active Comparator|Arm I|Patients undergo whole-brain radiotherapy (WBRT) once daily on days 1-5 and 8-12 and receive oral gefitinib once daily on days 1-28. Gefitinib treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
3151939|NCT00238251|Active Comparator|Arm II|Patients undergo WBRT as in arm I and receive oral temozolomide once daily on days 1-21. Temozolomide treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity
3151940|NCT00238290|Experimental|Arm A|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
3151941|NCT00238316|Active Comparator|Letrozole|
3151942|NCT00238316|Placebo Comparator|Placebo|
3151943|NCT00238381|Other|Arm I|Patients undergo total mesorectal excision (TME) by standard methods or laparoscopically and side-to-end anastomosis rectal reconstruction.
3151944|NCT00238381|Other|Arm II|Patients undergo TME and colon-J-pouch anastomosis rectal reconstruction.
3151945|NCT00238381|Other|Arm III|Patients undergo straight coloanal anastomosis with/without temporary protective ileostomy
3151946|NCT00238394|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond CR. Patients experiencing disease progression within 5 years after completion of study treatment may receive additional courses of study treatment.
3151947|NCT00238407|Active Comparator|Arm I|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71. Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
3151948|NCT00238459||Recently infected patients|Cohort 1)Patients elcted to be immediately treated with licensed drugs:21 patients Cohort 2) Or to delay treatment until clinically indicated:16 patieints
3208507|NCT00975429|Experimental|WST11 - 6mg|6mg/kg Treatment with WST11-mediated VTP
3208508|NCT00975442|Experimental|Eccentric training|
3208509|NCT00975442|Placebo Comparator|Forearm band|
3208510|NCT00975455||Subjects with hematuria|
2443699|NCT05074992|Experimental|Ipilimumab|3mg/kg Ipilimumab IV infusion (day 1) given as a 21 day cycle for 2 cycles.
2443732|NCT05074576|Experimental|Mulligan group|In addition to the conventional treatments, Sustained Natural Apophysial Gliding (SNAG) a type of Mulligan mobilization technique is applied.
2443734|NCT05074576|Other|Control group|Electroterapy agents are applied in the contro group
2443802|NCT05074160||OLP Registry primary analysis population|Adult primary liver transplant recipients who are transplanted with an OCS perfused DBD or DCD donor liver according to the approved indication and matching eligibility criteria
2443864|NCT05065775|Experimental|Dexmedetomidine|Single intranasal 100 µg bolus dose of dexmedetomidine
3151949|NCT00238459||A vaccine,HIV-1 immunogen was not provided for evaluation|In the intial design, acandiate HIV vaccine was to be evaluated, but in August 2007 the manufacturer refused to provide vaccine to allow this study to evaluate the effect of a vaccine on control of HIV. Therefore the study became an observational study of the effects of early versus delayed initiation of antiretrovral therapy on the preservation of anti-HIV immune responses and the ability of patients to control virus after a closely monitored discontinuation of therapy.
3151950|NCT00238667|Active Comparator|Anti-platelet therapy|Aspirin, Dipyridamole, clopidogrel alone or in dual therapy
3151951|NCT00238667|Active Comparator|Anti-coagulant|Warfarin, unfractionated heparin, enoxaparin, dalteparin, tinzaparin aiming for an INR in range of 2-3. Local protocols for Heparin can be used
3151952|NCT00238875|Experimental|1|Procedure/Surgery: stereotactic body radiation therapy
2444077|NCT04962022|Experimental|Period 1|PF-07321332/ritonavir orally
2444080|NCT04962022|Experimental|Period 2|Itraconazole + PF-07321332/ritonavir orally.
3151953|NCT00238888|Experimental|Asthma control awareness|Multifaceted intervention to increase the patient awareness of the leve of asthma control
3151954|NCT00238888|Active Comparator|Usual care|Usual care
3151955|NCT00238914|Active Comparator|CE plus oral naltrexone|Compliance enhancement plus oral naltrexone
3151956|NCT00238914|Active Comparator|BNT plus oral naltrexone|Behavioral naltrexone therapy plus oral naltrexone
3151957|NCT00238953|Experimental|EC MPS|
3151958|NCT00239031|Experimental|1|
2444266|NCT04831437|Experimental|Hypofractionated|EBRT 40Gy/15fr
2444269|NCT04831437|Active Comparator|Control Group|EBRT 45Gy/ 25fr
3151959|NCT00239083|Experimental|EC-MPS|
3151960|NCT00239239|Experimental|test treatment period|
3151961|NCT00239551|Experimental|Prevacid|Effect of Prevacid at 8 weeks; EGD(esophagogastroduodenal endoscopy) at day 1 & EGD at 8 weeks
3151962|NCT00239564|Experimental|Experimental: carbidopa and levodopa|Subjects receive IPX054 100 mg, IPX054 150 mg, IPX054 200 mg, IPX054 250 mg, or IPX054 300 mg to achieve optimum dosage and dosing frequency as directed by the Investigator for 5 weeks.
3151963|NCT00239694|Experimental|1|Previously vaccinated
3151964|NCT00239694|Experimental|2|Never vaccinated
3151965|NCT00239707|Experimental|Infusion 1|Normal Saline
3151966|NCT00239707|Placebo Comparator|Infusion 2|GIP or modified GIP
3151967|NCT00239707|Placebo Comparator|Infusion 3|GIP or modified GIP, opposite of Infusion 2
3151968|NCT00239746|Experimental|1|
3151969|NCT00239746|Placebo Comparator|2|
3151970|NCT00239824|Experimental|1|Strength training of the pelvic floor muscles with follow up instructions by a physiotherapist
2444722|NCT04427501|Experimental|LY3819253|LY3819253 administered intravenously (IV)
2444723|NCT04427501|Experimental|LY3819253 + LY3832479|LY3819253 + LY3832479 administered IV or subcutaneously (SQ)
2444725|NCT04427501|Placebo Comparator|Placebo|Placebo administered IV
2444817|NCT04262115|Experimental|AM-EX|Participants in this group will be prescribed morning aerobic exercise.
2444822|NCT04262115|Experimental|PM-EX|Participants in this group will be prescribed evening aerobic exercise.
3151971|NCT00239824|Active Comparator|2|Strength training of the pelvic floor muscles without follow up instructions
2444872|NCT04166071|Active Comparator|Naltrexone|
2444873|NCT04166071|Placebo Comparator|Placebo|
2444896|NCT04119271|Other|Breathe Easy at Home Kit Products|"Families will be provided with a Breathe Easy at Home Kit. These kits will include:~a HEPA filtered upright vacuum cleaner, a HEPA-filtered Air Purifier, a Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control, and a combination of safe products to locate and kill roaches."
3151972|NCT00239980|Active Comparator|A|50 IU/kg
3151973|NCT00239980|Active Comparator|B|100 IU/kg
3151974|NCT00239980|Active Comparator|C|150 IU/kg
3151975|NCT00239993|Experimental|1|skin reactions with the use of warm compress prior to performing a Copaxone® injection
3151976|NCT00239993|Experimental|2|skin reactions without the use of warm compress prior to performing a Copaxone® injection
3151977|NCT00240006|Experimental|1|Shared Solutions®
3151978|NCT00240006|Experimental|2|Shared Solutions® and MS Center/Office Practice Partnership
3151979|NCT00240032|Active Comparator|Copaxone® with Zyrtec|
3151980|NCT00240032|Experimental|Copaxone® with placebo|
3151981|NCT00240045|Experimental|1|
3151982|NCT00240058|Other|phenylephrine infusion with and without nitric oxide clamp|Participants received phenylephrine infusion with saline followed by phenylephrine infusion with nitric oxide clamp
3151983|NCT00240084|Experimental|Nesiritide infusion|Single arm study. 24-hour infusion of B-type Natriuretic Peptide at a dose of 0.01 mcg/kg/minute.
3151984|NCT00240188|Other|1|
3151985|NCT00240214||1|sirolimus
3151986|NCT00240253|Active Comparator|Pramlintide|
3151987|NCT00240461|Active Comparator|1|200 mg COLD-fX Natural health products 2 times daily for six months
3151988|NCT00240461|Active Comparator|Arm 2|Arm 2 - 400 mg COLD FX Natural health product - 2 times daily for 6 months
3151989|NCT00240461|Placebo Comparator|3|Inactive crystalline substance. This is the placebo arm in which subject receive 200 mg of the placebo 2 times daily for 6 months. Placebo is an inactive crystalline substance.
3151990|NCT00240513|Active Comparator|Minocycline 3 mo|Minocycline 3 mo
3151991|NCT00240513|Experimental|Minocycline plus Tretinoin|Minocycline plus Tretinoin for 3 months
3151992|NCT00240565|Experimental|Arm 1|Participants underwent two phases of treatment: an initial DD, followed by a therapeutic dose. The one-day DD comprised a 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with 185 MBq (5.0 mCi) of I 131. After 7 to 14 days, the one-day therapeutic dose comprised a second 1 hr IV infusion of 450 mg unlabeled TST, followed by a 20 min IV infusion of 35 mg TST labeled with I 131 with an administered activity (MBq or mCi) determined from the dosimetry calculation.
3151993|NCT00240617|Active Comparator|arm 1|Treximet (sumatriptan/naproxen sodium) formerly known as TREXIMA
3151994|NCT00240617|Placebo Comparator|arm 2|placebo to match
2443827|NCT05073913|Other|Living kidney donors|complete vascular exploration before and one year after nephrectomy
2443860|NCT05059041|Experimental|Dilated first, non-dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained after dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained before dilation.
2443896|NCT05059041|Experimental|Non-dilated first, dilated second|Each participant will perform vision testing first through a prescription determined from wavefront measurements obtained before dilation. Second, each participation will perform vision testing through a prescription determined from wavefront measurements obtained after dilation.
2443957|NCT05016323|Experimental|HR19042 Capsules|
2443963|NCT05016323|Placebo Comparator|Placebo|
2444038|NCT04981678|Other|Buprenorphine Discontinuation|Patients instructed to discontinue buprenorphine prior to surgery
2444039|NCT04981678|Other|Buprenorphine Continuation|Patients instructed to reduce buprenorphine to 16mg the day prior to surgery and reduce to 8mg on the day of surgery.
2444069|NCT04943432|Experimental|People who inject drugs|People who inject drugs recruited from a needle exchange program who will participate in a psychosocial intervention
3151995|NCT00240630|Placebo Comparator|Arm 1|placebo to match
2444321|NCT04779424||Primary Health Care Providers (PHCPs)|Any Belgian general practitioner (GP) (including those in professional training) currently working in primary care and any other primary health care providers (PHCPs) from the same GP practice who physically manage (examine, test, treat) patients/clients (frontline PHCP).
2444384|NCT04731753||Group treated with study product|Subjects will undergo one mechanical debridement procedure with Cutimed DebriClean
3151996|NCT00240630|Experimental|Arm 2|Treximet (sumatriptan/naproxen sodium)
3151997|NCT00240682|Experimental|cetuximab|cetuximab
3151998|NCT00240773|Experimental|001|acetaminophen 4 grams daily for 12 months
3151999|NCT00240773|Active Comparator|002|naproxen 750 mg daily for 12 months
3152000|NCT00240773|Experimental|003|acetaminophen 4 grams daily for six months
3152001|NCT00240773|Active Comparator|004|naproxen 750 mg daily for six months
2444832|NCT04261686|Other|COVERA Vascular Covered Stent|COVERA Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the arteriovenous (AV) access circuit of hemodialysis subjects dialyzing with an AV fistula.
2444843|NCT04194437|Experimental|OCS Preserved Livers|This is a single-arm trial of OCS preserved livers used for transplantation.
3152002|NCT00240799|Experimental|001|acetaminophen extended release
3152003|NCT00240799|Placebo Comparator|002|placebo
2445582|NCT03272061|Experimental|Aerobic-based exercise program|
3152004|NCT00240825|Experimental|001|Acetaminophen
3152005|NCT00240825|Experimental|002|Ibuprofen
3152006|NCT00240825|Placebo Comparator|003|Placebo
3152007|NCT00240851|Experimental|001|acetaminophen extended release
3152008|NCT00240864|Experimental|001|acetaminophen
3152009|NCT00240864|Experimental|002|ibuprofen
3152010|NCT00240864|Placebo Comparator|003|placebo
3152011|NCT00240877|Experimental|1|Monovalent vaccine prior to the release of the trivalent vaccine (FluMist).
3152012|NCT00240877|Placebo Comparator|2|Placebo
3152013|NCT00240968|Experimental|3|Subjects will receive a single 45 mcg IM dose of the influenza A/H5N1 virus vaccine.
3152014|NCT00240968|Experimental|4|Subjects will receive a single 90 mcg IM dose of the influenza A/H5N1 virus vaccine.
3152015|NCT00240968|Experimental|1|Subjects will receive a single 7.5 mcg IM dose of the influenza A/H5N1 virus vaccine.
3152016|NCT00240968|Experimental|2|Subjects will receive a single 15 mcg IM dose of the influenza A/H5N1 virus vaccine.
3152017|NCT00241020|Experimental|Octreotide|
3152018|NCT00241059|Experimental|EC-MPS arm|
3152019|NCT00241111|Other|Zometa|
2443704|NCT05074914|No Intervention|Barrett's oesophagus|Weight stable patient under survelliance with Barrett's oespophagus
2443769|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination - 8 weeks apart|Astra-Zeneca vaccine 0.5 mL/dose
2443771|NCT05074368|Active Comparator|mRNA-1273 Vaccination and Heterologous ChAdOx1-nCov-19 vaccination- 8 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
2443772|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
2443773|NCT05074368|Active Comparator|The mRNA-1273 Vaccination- 4 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose
2443774|NCT05074368|Active Comparator|Heterologous ChAdOx1-nCov-19 vaccination and the mRNA-1273 Vaccination-12 weeks apart|Moderna COVID-19 Vaccine 0.5 mL/dose and Astra-Zeneca vaccine 0.5 mL/dose
2443797|NCT05074329|Active Comparator|Active|Subjects randomized to the Active group, programming parameters will be set, and therapy will be delivered for a minimum of 2-hours per day for the duration of the study.
2443798|NCT05074329|Placebo Comparator|Delayed|The delayed group will begin 2-hour stimulation/day at the 3-Month visit.
3152020|NCT00241189|Experimental|Rapamycin|Patients take oral rapamycin 6 mg daily (and dose adjusted to keep a serum trough level of 5-15 ng/ml) for one year
3152021|NCT00241189|Active Comparator|Methotrexate|Methotrexate 20 mg taken orally weekly for one year
2443857|NCT05066685||All Participants|All the particpants enrolled in the brolucizumab Patient Support Services (PSS) program
3152022|NCT00241228|Experimental|High Volume|ultra filtration : High volume : 70 ml/kg/h
3152023|NCT00241228|Active Comparator|Medium Volume|Ultra filtration : conventional volume : 35 ml/kg/h
3152024|NCT00241254|Experimental|1|Cyclophosphamide
2443987|NCT05004402||Primiparous women|Primiparous women after vaginal delivery
2444040|NCT04975581|Experimental|Rotator cuff repair Surgery with Augmentative patch|Open rotator cuff repair Surgery with additional application of augmentative human allograft patch
2444041|NCT04975581|Active Comparator|Rotator cuff repair surgery|Open Rotator cuff repair surgery
3152025|NCT00241254|Active Comparator|2|Methylprednisolone
3152026|NCT00241345|Experimental|Group A|IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load >5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load >= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is <= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
2444162|NCT04905901|Experimental|Tranexamic acid 500 mg|Nebulized tranexamic acid 500 mg 15 minutes before operation
2444163|NCT04905901|Experimental|Tranexamic acid 1gm|Nebulized tranexamic acid 1 gm 15 minutes before operation
2444164|NCT04905901|Placebo Comparator|Saline placebo|Normal saline nebulization 15 minutes before operation
2444203|NCT04878107|Experimental|SBRT/LDRT + Camrelizumab +Apatinib|SBRT（8Gy×3f） LDRT（2Gy×5f） Camrelizumab（200mg，q3w） Apatinib （250mg，qd）
2444206|NCT04878107|Active Comparator|SBRT + docetaxel|docetaxel 75mg/m2 SBRT（8Gy×3f）
2444244|NCT04856241|Experimental|Supported Implementation (Intervention)|Our supported implementation approach is designed to improve uptake of Prep-to-Play. The Prep-to-Play program consists of four components: dynamic warm-up, strength training, football fundamentals, and education. At the start of the intervention period, Prep-to-Play Physiotherapists will conduct a 3-hour workshop for coaches and influential players. Ongoing support will be provided via a range of strategies. Prep-to-Play Physiotherapists will attend training (two times) during and immediately post implementation to provide coaches with support (feedback on missing components, player technique, questions). Monthly Coaches Shed; Online drop-in session with education component to meet other coaches (peer support & networking) and ask questions. Refresher workshops will be run in pre-season 2022 for the teams who have received the intervention in 2021.
2444245|NCT04856241|Active Comparator|Unsupported implementation (Control)|"The unsupported implementation arm will be usual care. Access to the Prep-to-Play resources, including videos, downloadable manuals and posters, are freely available to coaches online. The online resources incorporate the same four concepts as described in the supported implementation - dynamic warm-up, strength exercises, football fundamentals, and education. In the control arm, no additional resources, education, or support will be provided."
2444385|NCT04729257|Other|Group A1 (Norms + Validation, 18-49 years) + Group A2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
2444386|NCT04729257|Other|Group B (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using digital tests.
2444388|NCT04729257|Other|Group C1 (Norms + Validation, 18-49 years) + Group C2 (Validation, 50+ years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: Participants' cognition is measured using digital tests.
2444389|NCT04729257|Other|Group D (Validation, 18+)|Visit 1: Participants' cognition is measured using paper-pencil tests. Visit 2: Participants' cognition is measured using paper-pencil tests.
2449892|NCT03242239|Active Comparator|EU-licensed Herceptin|
3152027|NCT00241345|Experimental|Group B|PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load <5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load >5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load >= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load <= to previous viral load then 900 mg every 12 hours for another 7 days.
2443754|NCT05074485|Experimental|Placebo plus nociceptive pain challenge, then anakinra plus nociceptive pain challenge|Pharmacological challenge (with placebo) plus nociceptive pain challenge, then pharmacological challenge (with anakinra) plus nociceptive pain challenge
2443755|NCT05074485|Experimental|Anakinra plus nociceptive pain challenge, then placebo plus nociceptive pain challenge|Pharmacological challenge (with anakinra) plus nociceptive pain challenge, then pharmacological challenge (with placebo) plus nociceptive pain challenge
2443805|NCT05073926||Persons with latent tuberculosis treated with 4 months rifampicin|Oral rifampicin 10 mg/kg (max 600mg) once daily during 4 months
2443811|NCT05073926||Persons with latent tuberculosis treated with 6-9 months isoniazide|Oral isoniazide 5 mg/kg (max 300mg) once daily in combination with 40mg vitamin B6 (pyridoxin) during 6-9 months
2443874|NCT05064293|Other|Control Arm|"Data will be collected at baseline and 6-month follow-up from the standardized instruments and automated sources for all eligible subjects randomized to the control arm.~Families who agree to participate will first be offered a formal assessment in order to ascertain the primary mental health diagnosis and any co-occurring mental health disorders. After completing the online parent/guardian self-assessment, parents/guardians will meet for 30 minutes with a mental health clinician to review their answers, discuss diagnoses, and refer the family back to their primary care provider.~Study clinicians will document clinically relevant information from their assessment in a telephone encounter and route these to the child's KP primary care provider in Epic as well as the site navigator.~Control arm participants do not receive navigation."
2443902|NCT05064293|Experimental|Navigation Arm|"6-months of telephonic support from a mental health (MH) navigator to promote early access, engagement, coordination, and personalization of mental health treatment and services as soon as early symptoms of mental health problems are detected in children.~The navigator model and implementation to be tested include:~Automated identification of early symptoms for children~Virtual collection of self-reported, standardized assessment scores~Psychologists interpreting assessment scores and providing feedback to families and PCPs~Trained clinicians serving as MH navigators to conduct family outreach, engage them in MH care, and coordinate with and between clinicians for up to 6-months~Up to 4 video-based behavioral health sessions with the MH navigator, as needed, while barriers to initiation of ongoing mental health services can be explored and addressed over the 6-month period."
2443922|NCT05037396||Brolucizumab|Participants received brolucizumab injection during the index period
2443985|NCT05002478|Experimental|Prone Group|Turn patient in prone position after surfactant administration. After 6 hours turn patient in supine position and perform EIT and LUS.
2443988|NCT05002478|No Intervention|Supine Group|Leave patient in supine position after surfactant administration. After 6 hours perform EIT and LUS.
3152028|NCT00241371|Experimental|Clofarabine|4 mg/m2 IV over 1 hour on days 1-5 of each 28 day cycle.
3152029|NCT00241384|Active Comparator|Pd-103 with 20Gy External Beam|Pd-103 with 20Gy External Beam
3152030|NCT00241384|Active Comparator|Pd-103 alone|Pd-103 alone
3152031|NCT00241410|Experimental|1|4 consecutive groups, dose escalation
3152032|NCT00241410|Placebo Comparator|2|4 consecutive groups
3152033|NCT00241423|Experimental|Exenatide|Exenatide and the subject's current oral antidiabetic agent regimen
3152034|NCT00241423|Placebo Comparator|Placebo|Placebo and the subject's current oral antidiabetic agent regimen
2444161|NCT04903288|Experimental|Eladocagene Exuparvovec|Participants will receive eladocagene exuparvovec intraoperatively at 1.8×10^11 vector genomes (vg) via SmartFlow® MR Compatible Ventricular Cannula in a single operative session. Participants will receive standard of care for their AADC deficiency during the study.
3152035|NCT00241449|Active Comparator|1|Tamoxifen
3152036|NCT00241449|Experimental|2|Fulvestrant
2444319|NCT04769427|Experimental|PDO Max thread injection to nose|
2444380|NCT04733560|Experimental|Pudendal nerve block|25 women will receive pudendal nerve blocks of 0.25% Bupivicaine 10ml administered vaginally prior to making any surgical incisions.
2444381|NCT04733560|Sham Comparator|Placebo|25 women will receive sham pudendal nerve blocks using normal saline. These will also be administed vaginally prior to making any surgical incisions.
3152037|NCT00241670|Experimental|5-aminolevulinic acid|
2444462|NCT04669561|Experimental|Single /arm|All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
2444537|NCT04625036||Group 1: COVID-19 patients|Patients, from acute care hospitals, diagnosed with COVID-19 pneumonia, with documented positive throat swab, within one month from discharge.
2444571|NCT04566419|Active Comparator|Control group|Oxygen delivered by Venturi Mask
2444575|NCT04566419|Experimental|HFNC - high flow nasal cannulae|Oxygen delivered by high flow nasal cannula (HFNC) 60 l/min
2444670|NCT04467255|Active Comparator|group a|aerobic training
2444671|NCT04467255|Active Comparator|group b|endurance training
3152038|NCT00241670|No Intervention|Conventional resection|
3152039|NCT00241722|Experimental|Alvimopan 0.5 mg Twice Daily (BID)|0.5 milligrams (mg) of alvimopan was administered orally twice daily (BID) for 12 months.
3152040|NCT00241722|Placebo Comparator|Placebo|Placebo was administered orally BID for 12 months.
3152041|NCT00241748||1|Rhabdomyolysis Case Subjects
3152042|NCT00241748||2|Heart and Vascular Health Study statin users - control group 1
3152043|NCT00241748||3|Cardiovascular Health Study statin users - control group 2
3152044|NCT00241774||NSHS95 samples|In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
2443709|NCT05075096||COVID-19 ICU cohort|All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
2443712|NCT05075096||COVID-19 hospital admission control cohort|Four random control patients per ICU patient matched on age legal gender and region. Controls selected from all patients admitted to a Swedish hospital with COVID-19 with at least one year of follow up. Not including patients in the COVID-19 ICU cohort. COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish national patient registry.
2443716|NCT05075096||General population control cohort|Four general population controls per ICU patient, matched on age, legal gender and region drawn from the total population register of Sweden. Not including ICU and hospital admitted COVID-19 patients.
3152045|NCT00241813|Active Comparator|Health Education Control Program (CTL)|Health Education Control Program (CTL)
3152046|NCT00241813|Experimental|Mindfulness Meditation|Mindfulness Meditation (MM) Program
3152047|NCT00241813|Experimental|Lifeskills|Lifeskills Program (LP)
3152048|NCT00241813|Experimental|MM plus LP|Mindfulness Meditation (MM) Program plus Lifeskills Program (LP)
2443862|NCT05066503|Active Comparator|Delirious subjects receiving active study product|Subjects will ingest an oral amino-acid containing nutritional supplement twice daily for up to 7 days.
2443880|NCT05066503|Placebo Comparator|Delirious subjects receiving placebo|Subjects will ingest a flavored, sweetened, inactive drink twice daily for up to 7 days.
2443885|NCT05066503|No Intervention|Non-delirious control subjects who receive no intervention|Subjects receive no intervention and are observed for 2-3 days.
3152049|NCT00241852|Experimental|Behavioral Intervention: Asthma: It's a Family Affair|Separate student and parent intervention groups.
3152050|NCT00241852|Active Comparator|Behavioral Control Group|Students and parents participate in an education only control group
3152051|NCT00241878|Experimental|1|Teacher-Delivered Weight Control Intervention
2444149|NCT04933669|Experimental|Imatinib neoadjuvant|Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.
2444282|NCT04818866||Patients hospitalized for Covid-19|
3152052|NCT00241878|Other|2|Teacher-Delivered General Health Intervention
3152053|NCT00241891|Other|Healthy Lifestyle (Active Intervention)|Parents and children in this program which will participate in a series of consultations and activities focused on multiple healthy interventions including healthy eating, drinking, and physical activity. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on healthy eating, drinking, and physical activity. In addition, your child will receive information on developing healthy interpersonal and social skills.
3152054|NCT00241891|Other|Healthy Drinks (Active Intervention)|Parents and children in this program will participate in a series of consultations and activities focused on a single intervention, the effects of beverage choices on diet, general health and teeth health. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on beverages and health. In addition, your child will receive information on healthy nutrition, physical activity, and interpersonal and social skills.
3152055|NCT00241891|Other|Social and Leadership Skills (Control Intervention)|Parents and children in this program will participate in a series of consultations that are designed to help your child learn strategies to make and keep friends, to express feelings appropriately, and to successfully decrease conflicts that often occur at school among children. The children will participate in a variety of age-appropriate games, activities and exercises that are focused on these friendship making strategies. In addition, your child will receive information on healthy nutrition and physical activity. There is o intervention with regards to healthy weight.
3152056|NCT00241917|Experimental|Video|
3152057|NCT00241917|No Intervention|Control|
2444605|NCT04539522|Experimental|Three-dimensionally corrective exercise for scoliosis|Experimental group will perform three-dimensionally corrective exercise for scoliosis for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home.For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
2444607|NCT04539522|Active Comparator|Conventional exercise|Control subjects will perform conventional exercise for a 60-min period for 1-2 times a week under the guidance of physical therapist in an outpatient clinic, and a 40-min period per day under the supervision of the parents at home. For moderate patients, additional brace treatment for more than 22 hours a day.The treatment regimens lasted for 12 months.
2444664|NCT04475783|Experimental|Sirolomus DCB group|Intervention with Sirolimus-coated balloon catheter
2444665|NCT04475783|Active Comparator|Paclitaxel DCB group|Intervention with Paclitaxel-coated balloon catheter
2444740|NCT04399993|Experimental|Intervention Protocol in Diaphragm|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the intervention protocol in Diaphragm. Then, all the measurements described before, will be repeated by the assessor right after the technique."
3152058|NCT00242112|Other|MRI - pathology|
3173135|NCT00608621||1-physostigmine|"Physostigmine 4 mg in 50 ml NaCl 0.9% per 24 h as syringe pump continuously for 48 hours, plus physostigmine 2mg (in NaCl 0.9% 50 ml)at termination of sedation~PCA: Patient-controlled analgesia with piritramide 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
3152059|NCT00242203|Experimental|Zometa|"Zometa 4 mg IV every 3 weeks for a total of 17 doses. The first treatment will be given at the time of the first chemotherapy treatment and will continue for approximately 1 year.~Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
2443733|NCT05074589|Experimental|Treatment group A|Irinotecan liposome plus 5-fluorouracil, Leucovorin
2443735|NCT05074589|Active Comparator|Treatment group B|Placebo plus 5-fluorouracil, Leucovorin
3152060|NCT00242203|Active Comparator|No Zometa|"Neoadjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Docetaxel 75 mg/m2 IV every 21 days for 4 cycles prior to surgery~Surgery - modified radical mastectomy or breast conserving surgery with axillary lymph node dissection~Adjuvant therapy~Epirubicin 75 mg/m2 IV every 21 days for 2 cycles~Docetaxel 75 mg/m2 IV every 21 days for 2 cycles~All patients who are found to be Her-2 overexpressing by 3+ by ICH for FSH will receive trastuzumab 6 mg/kg IV every 3 weeks for 1 year post surgery~Radiation therapy - 50-60 Gy in 1.8-2.0 Gy daily fractions to the breast or chest wall. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks"
2443848|NCT05068011||Spinal cord stimulation|Patients will receive differential target multiplexed spinal cord stimulation
3152061|NCT00242320|Active Comparator|1|Roflumilast 500 µg
3152062|NCT00242320|Placebo Comparator|2|Placebo
3152063|NCT00242359|Other|omalizumab|open-label
3152064|NCT00242424|Placebo Comparator|1|0.25 ml normal saline placebo given as injection to infants at 2 and 3 months of age
3152065|NCT00242424|Experimental|2|2005-6 Fluzone, pediatric formulation of trivalent inactivated influenza vaccine (sanofi pasteur) administered to infants at 2 and 3 months of age
3152066|NCT00242463|Experimental|nandrolone|Patients receive weekly injections of nandrolone
3152067|NCT00242463|Placebo Comparator|Placebo|
3152068|NCT00242541|Experimental|Octreotide acetate|
2444258|NCT04818138|Active Comparator|Narrowband UVB|Narrowband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
2444262|NCT04818138|Active Comparator|Broadband UVB|Broadband UVB phototherapy (full body) administered three times weekly according to individual clinical protocols.
3152069|NCT00242593|Experimental|A|oral rosiglitazone 4 mg twice daily for 18 months
3152070|NCT00242593|Placebo Comparator|B|placebo pill twice daily for 18 months
2444414|NCT04713501|Experimental|PARTS|The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
2444465|NCT04647682||One single group study|Patients aged 75 years and over Hospitalized in a French covid-19 geriatric unit Positive Covid-19 infection made by Real-time Polymerase Chain Reaction Covid-19 or suspected on thoracic lesions on computerized tomography.
3152071|NCT00242606|Active Comparator|1|Levetiracetam 2000mg/day
3152072|NCT00242606|Active Comparator|2|Lamotrigine
3152074|NCT00242866|Experimental|Arm 1|GW274150 - 5mg or 30mg
3152075|NCT00242866|Placebo Comparator|Arm 2|Placebo to match GW274150
2444803|NCT04308291||MiniMed™ 780G System|Subject will use the MiniMed™ 780G System as per standard of care.
3152076|NCT00242892|Experimental|1|Intra coronary measures of pressure
3152077|NCT00242931|Experimental|Fludarabine, TBI, Cyclosporine, MMF|"Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0 For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
3152078|NCT00242944|Active Comparator|1|Pitavastatin
3152079|NCT00242944|Active Comparator|2|Atorvastatin
3152080|NCT00243035|Experimental|Treatment (bortezomib, tipifarnib)|"Phase I: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral tipifarnib twice daily on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of tipifarnib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. An additional 6 patients are treated at the MTD.~Phase II: Patients receive bortezomib as in phase I and tipifarnib as in phase I at the MTD."
3152081|NCT00243100|Experimental|Arm I|"Patients receive oral vorinostat (SAHA) once daily on days 1-14 and gemcitabine IV over 1-2 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the MTD"
3152082|NCT00243126|Experimental|Family-Based Risk Reduction Intervention|The intervention will be delivered in five, two-hour, small group sessions, across five weeks (group will meet once per week). Each of the 5 modules consists of 3 sessions: a one-hour session for the daughters meeting together with each other, a one-hour session for the mothers meeting together with each other; and a one-hour session in which the daughters and mothers meet together. Therefore, each week, the daughters will meet as a group for one hour of each module, while the mothers meet as a group for one hour, and for one hour the mothers and daughters will all meet together.
3208915|NCT00979342|Experimental|Ibuprofen q. 8 hours|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg every 8 hours, for the first 24 hours and then PRN.
2443711|NCT05074901|Experimental|digital behavioral intervention|Digital behavioral interventions to improve mood and decrease fatigue, sleep complaints and substance usage.
2443714|NCT05074901|No Intervention|e-diaries|Ecological momentary assessment based on e-diaries on a weekly basis to evaluate sleep/wake schedules, physical activity, substance usage and nutrition.
2443837|NCT05074004|No Intervention|control group|"No intervention was applied to the control group in this process.~be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
2443838|NCT05074004|Experimental|Psychoeducation|"be receiving treatment in Clinic Day Hospital~Volunteering to participate in research"
2443932|NCT05045586|Experimental|Modified Coronally Advanced Tunnel With Connective Tissue Graft|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
2443935|NCT05045586|Active Comparator|MCAT With Cross-linked Hyaluronic Acid in Addition to CTG|Procedure: A modified microsurgical tunnel technique by Zuhr et al. (2007). Initial sulcular incisions with a microsurgical blade are followed by a split-thickness buccal flap preparations using the tunneling knives. The preparation is extended into the mucosal tissue to gain sufficient flap mobility. The papillary regions are detached in their buccal aspects with the periosteum. The root surfaces are applied with cross-linked hyaluronic acid. The graft is inserted into the tunnel and stabilized with absorbable suspensory sutures. The buccal flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
3152083|NCT00243126|No Intervention|No Treatment Control Group Condition|A no treatment control group condition will be utilized for this preliminary feasibility study. Participants in this condition, both mothers and adolescents will be assessed at baseline, immediate post-intervention, at 3-month follow-up and at 6-month follow-up.
3152084|NCT00243282|No Intervention|1|Control (Support Group)
3152085|NCT00243282|Other|2|Intervention (Mindfulness Based Breathing Therapy)
3152086|NCT00243321|Experimental|HDR brachytherapy -> IMRT|Radiotherapy
2444198|NCT04889287|Experimental|Rosuvastatin and/or elinzanetant|The participants will receive each dose of rosuvastatin and/or elinzanetant together with 240 mL of non-sparkling water in total.
3152087|NCT00243334|Experimental|1|Decision Support integrated with Order Entry
2444335|NCT04780464|Active Comparator|Standard doxorubicin|
2444341|NCT04780464|Experimental|Metronomic doxorubicin|
2444345|NCT04780464|Experimental|Metronomic oral cyclophosphamide + prednisolone|
2444430|NCT04713098|Experimental|Peripheral Nerve Stimulation|ACTIVE percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electrical current
2444433|NCT04713098|Sham Comparator|Sham|SHAM percutaneous peripheral nerve stimulation with an ultrasound-guided percutaneous lead (SPR Therapeutics, Cleveland, Ohio) and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does NOT generate electrical current
3152088|NCT00243334|No Intervention|2|Decision Support Only (not integrated with order entry)
3152089|NCT00243399|Experimental|Oxandrolone|
3152090|NCT00243438||1|Patients who have received a Vision stent and who have diabetes and/or complex lesions.
2444612|NCT04534270|Experimental|Dapagliflozin treatment|
2444666|NCT04472897|Experimental|Part A: Participants receiving GSK2556286|Participants will be randomized to receive one of the ascending doses of GSK2556286 in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A). The starting dose in Part A will be 25 milligrams (mg) and no dose escalation to the next dose will be higher than 3-folds. One cohort (Cohort 7A) will investigate the effect of food administration (high fat meal) on safety, tolerability and PK after a single dose of GSK2556286. Based on emerging data, a second food effect cohort (Cohort 8A) may also be included using a higher dose of GSK2556286.
2444667|NCT04472897|Placebo Comparator|Part A: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 8 cohorts (Cohort 1A to 8A). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 under fasting conditions (Cohort 1A to 6A) and under fed conditions (Cohort 7A and 8A).
2444668|NCT04472897|Experimental|Part B: Participants receiving GSK2556286|Participants will be randomized to receive one of the multiple-ascending doses of GSK2556286 in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 6 participants will receive a single oral dose of GSK2556286 on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A. Appropriate doses and dose regimens for Part B will be selected by the Dose Escalation Committee based on available safety, tolerability and PK data from Part A and/or any preceding repeat dose cohorts from Part B.
2444669|NCT04472897|Placebo Comparator|Part B: Participants receiving placebo|Participants will be randomized to receive matching placebo in any of the 4 cohorts (Cohort 1B to 4B). In each dosing cohort, 2 participants will receive a single oral dose of matching placebo on Day 1 up to 14 days under either fasting or fed conditions, dependent on the results from Part A.
2444721|NCT04416282|Experimental|Terlipressin + Albumin|Injection terlipressin 2 mg/24 hours infusion + i/v albumin 1g/Kg/day
3152091|NCT00243477|Active Comparator|Treatment|Escitalopram given
3152092|NCT00243477|Placebo Comparator|Placebo|Placebo given
3152093|NCT00243529|Active Comparator|MHC Class I restricted epitopes|HLA-A2.1 patients are vaccinated with dendritic cells loaded with MHC Class I restricted epitopes of tumor antigens gp100 and tyrosinase
3152094|NCT00243529|Experimental|MHC Class I and II restricted epitopes|HLA-A2.1 and HLA-DR4 patients are vaccinated with dendritic cells loaded with MHC Class I and II restricted epitopes of tumor antigens gp100 and tyrosinase
3152095|NCT00243529|Experimental|mRNA transfected DC|HLA-A2.1 and/or HLA-DR4 patients are vaccinated with dendritic cells transfected with mRNA encoding tumor antigens gp100 and tyrosinase
3152096|NCT00243607|Experimental|immediate treatment group (SBG)|immediate start of hydrotherapy (self treatment) in immediate treatment group (SBG)
2443713|NCT05074979|Other|control group|While other groups continue their exercise program for 6 weeks, this group will only be informed after COVID 19.
2443717|NCT05074979|Experimental|home exercise program group|this group will implement COVID 19 home exercise program.
2443718|NCT05074979|Experimental|telerehabilitation group|this group will implement COVID 19 telerehabilitation program.
3152097|NCT00243607|No Intervention|waiting group (WG)|start of hydrotherapy (self treatment) after waiting period of 12 weeks
3152098|NCT00243646|Active Comparator|no hormones|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with no hormones
2443822|NCT05073978||Case group|Case group with certain pregnancy outcome, e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
2443824|NCT05073978||Control group|Control group without certain pregnancy outcome,e.g., abortion, stillbirth, preterm birth, and birth defects,gestational hypertension, gestational diabetes mellitus, etc.
3152099|NCT00243646|Active Comparator|9 months of hormone therapy|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant with a 9 month course of hormone therapy
3152100|NCT00243685|Experimental|II and III|
3152101|NCT00243776||Cardiac Tissue|Cardiac tissue and cells will be obtained from participants undergoing cardiac surgical repair
3152102|NCT00243789|Active Comparator|1|Pentoxifylline
3152103|NCT00243789|No Intervention|2|Placebo
3152104|NCT00243867|Experimental|Arm A|(Taxoprexin® + carboplatin)
3152105|NCT00243867|Active Comparator|Arm B- Paclitaxel and carboplatin|(Paclitaxel and carboplatin)
3152106|NCT00243880|Experimental|lovastatin|lovastatin at escalating dosages: 1 mg/kg/day, 3 mg/kg/day, 6 mg/kg/day, 8 mg/kg/day, 10 mg/kg/day
3152107|NCT00243893|Active Comparator|Brain AVMs|This trial is to investigate the use of minocycline or doxycycline as medical therapy, can minocycline or doxycycline induce biologically significant changes in the enzyme system thought to be related to spontaneous growth/rupture of these malformations. Finally, can patients safely tolerate these medications over an extended period of time.
3152108|NCT00243893|Active Comparator|Aneurysms|
3152109|NCT00243997|Active Comparator|1|Subjects receiving the Becoming Parents Program
3152110|NCT00243997|Placebo Comparator|2|Subjects not receiving the Becoming Parents Program
2444367|NCT04744181||cases|patients who fulfill the inclusion criteria
2444368|NCT04744181||controls|Patients who underwent cardiac surgery in 2019 and 2018
2444443|NCT04703855|Experimental|HeartMate 3™ left ventricular assist system (HM3 LVAS)|Patients will be implanted with the HM3 LVAS
3152111|NCT00244023|Experimental|1|Testosterone gel (intervention)
3152112|NCT00244023|Placebo Comparator|2|one sachet of placebo gel once a day, possibly titrated to 2 sachets if insufficient efficacy
3152113|NCT00244049|Experimental|Brief clinician advice|
3152114|NCT00244075|Active Comparator|1|nutrition supplementation, recombinant human growth hormone, and exercise
3152115|NCT00244075|Active Comparator|2|nutrition supplementation only
3152116|NCT00244114||A|
3152117|NCT00244114||B|
3152118|NCT00244218|Experimental|Treatment Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
3152119|NCT00244218|Placebo Comparator|Control Arm|Drug: tetrahydrobiopterin (BH4) Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
2444716|NCT04427904|Experimental|Bupivacaine|Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
2444719|NCT04427904|Active Comparator|Lidocaine|Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
3152120|NCT00244257|Experimental|1|Cohort 1
3152121|NCT00244257|Experimental|2|Cohort 2
3152122|NCT00244257|Experimental|3|Cohort 3
3152123|NCT00244257|Experimental|4|Cohort 4
3152124|NCT00244257|Experimental|5|Cohort 5
3152125|NCT00244270|Experimental|1|totally implantable vascular access device
3152126|NCT00244335||1|PTSD Subjects
3152127|NCT00244335||2|Trauma Controls: subjects who have experienced a trauma but never developed PTSD
3152128|NCT00244426|Experimental|1|
3152129|NCT00244426|Active Comparator|2|
3152130|NCT00244439|Experimental|1|MALG
3152131|NCT00244439|Active Comparator|2|Ovide
3152132|NCT00244439|Active Comparator|3|Permethrin 1%
3152133|NCT00244478|Experimental|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
3152134|NCT00244478|Placebo Comparator|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
3152135|NCT00244504|Active Comparator|I|moxonidine group
3152136|NCT00244504|Placebo Comparator|II|placebo group
3152137|NCT00244517|Active Comparator|I|Isoflurane (only in part I)
3152138|NCT00244517|Active Comparator|II|Sevoflurane
3152139|NCT00244517|Active Comparator|III|Desflurane
3152140|NCT00244738|Active Comparator|Intervention|Patients who received castor oil for labor induction
3152141|NCT00244738|Placebo Comparator|Control|Patients who received sunflower oil as a placebo
3152142|NCT00244790|Experimental|low protein|
3152143|NCT00244803||HIV Positive FRAM 1 Participant|
3152144|NCT00244842|Placebo Comparator|1|
3152145|NCT00244842|Active Comparator|2|
3152146|NCT00244842|Active Comparator|3|
3152147|NCT00244842|Active Comparator|4|
3152148|NCT00244907|Active Comparator|Genistein vs. Risedronate|Healthy post menopausal women who have been dosed with Ca41. Intervention, 100 mg Gensitein from soy protein isolate for 50 days. After a 50 day washout risedronate (Actonel- 5mg per day) for 50 days
3152149|NCT00244907|Active Comparator|Genistein dose and source|Healthy post menopausal women will consume 5 products containing varying quantities of genistein from different sources for 50 days each in a randomized order. Each intervention period is separated by a 50 day washout period. Intervention: A) 50 mg genistein from soy protein isolate, B) 100 mg genistein from soy protein isolate, C)50 mg genistein from Novasoy, D) 100 mg genistein from Novasoy, E) 100 ng genistein from 50% Novasoy and 50% soy protein isolate
2443764|NCT05074355|Experimental|Azacitidine and Venetoclax|"A treatment cycle is 28 days long.~Azacitidine will be given by injection under the skin, once a day, for the first 6 days of every cycle.~Venetoclax will be given orally, once a day, as follows at the discretion of their study doctors:~Cycle 1:~Day 1 - 100 mg~Day 2 - 200 mg~Days 3 to 28 - 400 mg~Cycle 2:~Participants with a response to the study drugs will continue taking 400 mg from Days 1 to 21, with no study drug from Days 22 to 28 during Cycle 2.~Participants who have not yet responded to the study drugs will continue taking 400 mg from Days 1 to 28 during Cycle 2.~Cycle 3 and subsequent cycles:~Participants with a response to the study drugs will continue to take 400 mg from Days 1 to 21, with no study drug from Days 22 to 28.~Participants whose disease has not worsened will continue taking 400 mg from Days 1 to 28.~Participants have not responded to the study drugs will be withdrawn from the study."
2443840|NCT05073965|Experimental|Intervention Group|Subject receive a 1000IU vitamin D supplement dose daily for 6 months
2443841|NCT05073965|Placebo Comparator|Placebo group|Subject receive a placebo daily for 6 months
3152150|NCT00244946|Experimental|Autologous lymphocytes,carmustine,etoposide, melphalan, PBSCT|"minus Day 8 ADMIT for Hydration~minus Day 7 Carmustine 300 mg/m2 x 1 dose~minus Day 6 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 5 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 4 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 3 Etoposide 100 mg/m2 q 12 hr; Cytarabine 100 mg/m2 q 12 hr~minus Day 2 Melphalan 140 mg/m2 x 1 dose~minus Day 1 Day of Rest~Day 0 Transplant"
3152151|NCT00244959|Experimental|Anastrozole|Anastrozole (1mg, orally, daily) for 12 months as adjuvant therapy for breast cancer
2443913|NCT05029089|Experimental|Experimental: Entire Papilla Preservation Modified Technique (EPPMT)|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated (subperiosteal tunnel). Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. Microsurgical suturing technique with 7-0 materials was performed. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
2443914|NCT05029089|Active Comparator|Entire Papilla Preservation Modified Technique + EMD|Procedure: The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed. 24%EDTA was applied on the exposed root surface for 2 minutes, than rinsed and EMD was applied. Vertical incision was closed with simple single sutures(7-0),whereas due to modification of the original technique additional sling suture was applied.
2443915|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft|Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
2443916|NCT05029089|Active Comparator|EPP Modified Technique+EMD+allograft+sCTG|Procedure: After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. sCTG taken form palate was sutured to the inner part of mucosa flap. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
2444085|NCT04963569||Albumin|Participants enrolled in the ABC Sepsis trial who have been randomised to 5% Human Albumin Solution as the sole resuscitative fluid in the first 6 hours.
2444087|NCT04963569||Balanced Crystalloid|Participants enrolled in the ABC Sepsis trial who have been randomised to Balanced Crystalloid as the sole resuscitative fluid in the first 6 hours.
2444194|NCT04878315|Experimental|Treatment sequence TRR|Participants will receive Capoten (T) in period 1 followed by Captopril (R) in period 2 followed by Captopril (R) in period 3.
2444195|NCT04878315|Experimental|Treatment sequence RTR|Participants will receive Captopril (R) in period 1 followed by Capoten (T) in period 2 followed by Captopril (R) in period 3.
2444196|NCT04878315|Experimental|Treatment sequence RRT|Participants will receive Captopril (R) in period 1 followed by Captopril (R) in period 2 followed by Capoten (T) in period 3.
3152152|NCT00244972|Experimental|Treatment (sorafenib tosylate, tipifarnib)|Patients receive sorafenib tosylate PO QD or BID on days 1-28 and tipifarnib PO QD or BID on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients may be allowed to continue the treatment after the 12 courses if there is continued clinical response or disease stabilization, and patients do not have significant toxicities.
3152153|NCT00245154|Experimental|Arm I|Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
3152154|NCT00245154|Active Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel and carboplatin as in arm I.
3152155|NCT00245180|No Intervention|control|Primary and secondary data collected as in intervention arm. Dental screenings will be done once a year as a service.
2443876|NCT05064280|Experimental|Pembrolizumab|Pembrolizumab is FDA approved and commercially available for the treatment of many types of cancer, but it may not be approved for the type of cancer that you have.
2443903|NCT05064280|Experimental|Lenvatinib|Lenvatinib in combination with pembrolizumab is FDA approved for the treatment of patients with certain types of endometrial cancer.
3152156|NCT00245206|Experimental|1: Risperdal|Participants randomized to this arm will be prescribed risperdal. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
3152157|NCT00245206|Experimental|3: Aripiprazole|Participants randomized to this arm will be prescribed aripiprazole. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
3152158|NCT00245206|Experimental|4: Olanzapine|Participants randomized to this arm will be prescribed olanzapine. They will continue to be followed by their psychiatrist. In addition, they will take part in ongoing biological, cognitive, and psycho-social assessments with study staff.
3152159|NCT00245271|Experimental|1|OMS103 Irrigation Solution
2444232|NCT04870255|Active Comparator|Left Dorsolateral Prefrontal Cortex (L-DLPFC)|The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
2444233|NCT04870255|Active Comparator|Dorsomedial Prefrontal Cortex (DMPFC)|The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
2444235|NCT04870255|Sham Comparator|Sham stimulation|Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region
2444292|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
2444297|NCT04803604|Experimental|Basic social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6 months
2444299|NCT04803604|Experimental|Basic social support + communication + 1 monthly follow up call|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
2444300|NCT04803604|Experimental|Basic social support + communication + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
2444301|NCT04803604|Experimental|Basic social support + Ottawa guide + 1 monthly follow up call|2 in-person/telephone weekly sessions on 1 coaching session on providing social support, decision support tools, and a single monthly follow-up call
2444303|NCT04803604|Experimental|Basic social support + Ottawa guide + monthly follow up calls for 24 weeks|2 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
2443720|NCT05074693|Experimental|EASE App|800 participants (i.e. 200 White, 200 Black/African American, 200 Hispanic/Latinx, and 200 Native American/Indigenous individuals) with elevated anxiety sensitivity will be enrolled and randomly assigned to either 1) the EASE app developed by our team targeting sensitivity to interoceptive stress, or 2) a series of educational videos covering topics such as meditation, mindfulness, and stress reduction.
2443722|NCT05074693|Other|Educational Videos|800 participants (i.e. 200 White, 200 Black/African American, 200 Hispanic/Latinx, and 200 Native American/Indigenous individuals) with elevated anxiety sensitivity will be enrolled and randomly assigned to either 1) the EASE app developed by our team targeting sensitivity to interoceptive stress, or 2) a series of educational videos covering topics such as meditation, mindfulness, and stress reduction.
2443803|NCT05074095||1|Patients with urogenital injuries
2443806|NCT05074095||2|Patients without urogenital injuries
3152160|NCT00245271|Placebo Comparator|2|Balanced Salt Solution (BSS)
3152161|NCT00245336|Experimental|1|rThrombin
2444111|NCT04955158|Experimental|Dexmedetomidine|75 µg dexmedetomidine soaked pharyngeal pack
2444114|NCT04955158|Experimental|Ketamine|50 mg ketamine soaked pharyngeal pack
2444115|NCT04955158|Experimental|Saline placebo|20 ml 0.9% saline soaked pharyngeal pack
3152162|NCT00245336|Active Comparator|2|bThrombin
3152163|NCT00245349||FLT|Study group receiving FLT for imaging
3152164|NCT00245414|Experimental|1|Interferon (IFN)-Treated
3152165|NCT00245414|Experimental|2|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is positive at week 1
2444366|NCT04736862|Experimental|Continuous monitoring group|
2444369|NCT04736862|Active Comparator|Intermittent monitoring group|
2444407|NCT04706598|Experimental|Intravesical therapy group|"Camrelizumab(SHR-1210) is administered on the first day of each treatment cycle (D1) at a dose up to 200 mg. The recommended phase II dose(RP2D) to be decided after safety run-in.~The cycle is divided into an induction course and a maintenance course. The induction course is initiated 2 weeks after TURBT and repeat once a week for 6 weeks . After that, the maintenance course starts every 3 weeks. The maximum duration of dosing is 2 years."
2444408|NCT04706598|Active Comparator|Intravenous therapy group|Camrelizumab(SHR-1210) is administered on the first day (D1) of each treatment cycle (21 days) at a dose of 200 mg by 30-min intravenous infusion(the allowable error in infusion time is -5 min, +10 min). The maximum duration of dosing is 2 years.
3152166|NCT00245414|Experimental|3|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
3152167|NCT00245414|Experimental|4|Interferon (IFN)-Untreated and Quantitative serum HCV-RNA is negative at week 1
3152168|NCT00245427|Other|1 All macrolide antibiotics|
2444640|NCT04494035|Experimental|AVATR-Toronto|Thrombectomy of arteriovenous graft using CAPERE Thrombectomy System
3152169|NCT00245427|Other|2 All beta lactam antibiotics|
3152170|NCT00245440|Active Comparator|1|Subjects assigned Azithromycin
3152171|NCT00245440|Active Comparator|2|Subjects assigned Telithromycin
3152172|NCT00245453|Active Comparator|1 Azithromycin|
2444852|NCT04181047|Experimental|Virtual EMDR|Patients will receive 1 to 3 preparation sessions (which will include psychoeducation and preparation exercises before EMDR), followed by up to 12 EMDR sessions, delivered over encrypted Zoom videoconferencing. EMDR is an evidence based trauma therapy. These EMDR sessions will focus on the experiences, urges or negative thoughts associated with their suicidal thoughts. The sessions will be 90 minutes in length and occur twice per week. This group will also have access to usual psychiatric care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
2445583|NCT03272061|No Intervention|Control program|Maintenance of habitual physical activity levels
3152173|NCT00245453|Active Comparator|2 Clarythromycin|
3152174|NCT00245453|Active Comparator|3 Telithromycin|
3152175|NCT00245479|Other|1|
3152176|NCT00245492|Experimental|1|Chromocolonoscopy
3152177|NCT00245531||+IDU/+HIV or -HIV|
3152178|NCT00245531||-IDU and -HIV (controls)|
3152179|NCT00245622|Experimental|Tovaxin Autologous T cell vaccine|2.0 mL subcutaneous formulated with 30-45 million autologous myelin reactive T cells
3152180|NCT00245622|Placebo Comparator|Placebo|2.0 mL subcutaneous injections without autologous myelin reactive T cells
3152181|NCT00245726|Active Comparator|1|Passive (Motor Assist) Cycle
3152182|NCT00245726|Active Comparator|2|
3152183|NCT00245726|Experimental|3|
3152184|NCT00245752|Active Comparator|A|in points bilaterally inBL 67, LI 4, SP6, one in GV20.
3152185|NCT00245752|Sham Comparator|2|sham acupuncture
3152186|NCT00245804||Adult dyslexia|Adult dyslexia
3152187|NCT00245804||Minor-Dyslexia|Minor-Dyslexia
3152188|NCT00245804||Adult-Control|Adult-Control
3152189|NCT00245804||Minor-Control|Minor-Control
3152190|NCT00245830|No Intervention|No Hepatic Ischemic Preconditioning|donor will act as a sham control.
3152191|NCT00245830|Experimental|Hepatic Ischemic Preconditioning|blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
3152192|NCT00245882|Active Comparator|Care Coordination|Care Coordination with monthly follow-up by a diabetes nurse educator
3152193|NCT00245882|Active Comparator|Home Telemedicine|Active Care Management with Home Telemedicine
3152194|NCT00245895|Active Comparator|1|Aranesp
3152195|NCT00246051|Other|Sleep Hygiene Education|
3152196|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|
3152197|NCT00246051|Other|Online Sleep Disorders Screening|
3152198|NCT00246103|Experimental|Dose Escalation and Possible Expansion|Escalating doses of Valproic acid and one dose escalation step of epirubicin. Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
3152199|NCT00246194||Patients with schizophrenia|Long-acting injectable of risperidone given as per the prescription from the prescribing physician (Observational study).
3152200|NCT00246350|Active Comparator|1|8 light massage treatments
3152201|NCT00246350|Active Comparator|2|16 light massage treatments
3152202|NCT00246350|Experimental|3|8 spinal manipulation treatments
3152203|NCT00246350|Experimental|4|16 spinal manipulation treatments
3152204|NCT00246363|Experimental|Silymarin|Silymarin
2443785|NCT05074225|Experimental|ED&C|The ED&C arm will receive the standard ED&C care.
2443786|NCT05074225|Experimental|Excision|The excision arm will undergo standard excision with repair by complex linear closure.
2443828|NCT05073835|Experimental|Intervention|Semaglutide 2.4mg/week subcutaneous injection for 68 weeks. The treatment includes an initial 16-week escalation phase followed by 52 weeks of treatment at study dose, i.e., 2.4mg/week.
2443831|NCT05073835|Placebo Comparator|Control|Placebo administration, once weekly, subcutaneous injection.
2443871|NCT05051722||Cohort 1 - AUB / PMB|Women ≥45 years of age, presenting with abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB). These presenting symptoms clinically warrant evaluation such as an endometrial biopsy to assess for underlying endometrial cancer, endometrial hyperplasia or other endometrial pathology.
2443905|NCT05051722||Cohort 2 - Biopsy-provend EC or AEH or EIN|Women ≥18 years of age with biopsy-proven endometrial cancer (EC), atypical endometrial hyperplasia (AEH), or endometrial intraepithelial neoplasia (EIN) presenting for surgical management of their endometrial pathology.
2443907|NCT05051722||Cohort 3 - Cervix pathology|Women ≥18 years of age presenting for a clinically indicated colposcopy, cervical biopsy, or surgical excision, as follow-up for an abnormal Pap test or cervical mass identified on physical exam. Final clinical diagnoses within this cohort may include mild cervical intraepithelial neoplasia (CIN 1), moderate and/or severe CIN (CIN 2/3), adenocarcinoma in situ (AIS), invasive cervical cancers (adenocarcinoma or squamous cell carcinoma), or possibly benign findings.
2443908|NCT05051722||Cohort 4 - Benign Uterine Pathology|Women with any of four benign gynecologic conditions including: uterine fibroids, benign endometrial polyps, adenomyosis and endometriosis. All women enrolled in this cohort will be undergoing clinically indicated gynecologic surgery (hysterectomy, myomectomy, polypectomy, or laparoscopic tissue excision) for the specific benign gynecologic condition. Verification of the final benign diagnosis will be based on pathology diagnosis of clinically-indicated tissue removed during surgery.
2443909|NCT05051722||Cohort 5 - Healthy Control Women|Healthy women ≥45 years of age presenting for well-woman exams to serve as a control group. These women will have no clinically evident gynecologic precancers, gynecologic cancers, or clinically evident or symptomatic benign gynecologic conditions. These women will not have known or clinically-suspected AUB, PMB, fibroids, endometriosis, benign endometrial polyps, or adenomyosis, nor will they have any active gynecologic or non-gynecologic acute medical conditions.
2443924|NCT05011318|Experimental|Fatigue Manipulation|
2443994|NCT04999891||Surgical Cohort|Elderly patients aged 65 and above who are planned for hip fracture surgery.
3152205|NCT00246363|Placebo Comparator|Placebo|Placebo
3152206|NCT00246428|Experimental|1|MI
3152207|NCT00246454||1|People with delayed sleep phase syndrome (DSPS).
3152208|NCT00246454||2|People with advanced sleep phase syndrome (ASPS).
3152209|NCT00246454||3|Control group (people with intermediate sleep patterns).
3152210|NCT00246506|Active Comparator|I.|Those randomized to have clomiphene/IUI treatments first will initiate therapy with two cycles of the fertility pill called clomiphene combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
2444216|NCT04889807||Patients who need fluid perfusion|
3152211|NCT00246506|Active Comparator|II.|Those randomized to have gonadotropins/IUI treatments first will initiate therapy with two cycles of the fertility injections called FSH or gonadotropins combined with (IUI) intrauterine insemination. If not pregnant after 2 IUI cycles, the couples will then proceed to IVF.
3152212|NCT00246506|Active Comparator|III.|Those couples randomized to (IVF) in vitro fertilization will bypass IUI treatments and start IVF therapy immediately.
3152213|NCT00246532|Placebo Comparator|1: Placebo Pill|This arm contains placebo medication.
3152214|NCT00246532|Active Comparator|2: Morphine|Patients will receive oral morphine therapy.
3152215|NCT00246610|Experimental|Open-label|Non-randomized, open-label, single-arm
3152216|NCT00246636|Active Comparator|OM5/LOV111859 (double-blind study) - Antara|Antara (fenofibrate) + placebo
3152217|NCT00246636|Experimental|OM5X/LOV111860 (extension study) - Open-Label Antara + Lovaza|Open-label Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
2444527|NCT04603274|Other|upper extremity diagnosed with carpal tunnel syndrome|8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians
2444584|NCT04570358|Experimental|Static stretching|An 8-week home-based static stretching training for the calf muscles will be performed by group A. Altogether, 10 stretches are performed per leg 4 times a week.
2444585|NCT04570358|No Intervention|Control|While group A performs the 8-week static stretching training, group B acts as control group performing its daily life activities as usual.
2444587|NCT04570358|Experimental|Proprioceptive neuromuscular facilitation stretching|After group A has finished the 8-week static stretching training, group B starts with the 8-week home-based proprioceptive neuromuscular facilitation stretching training. Altogether, 10 stretches are performed per leg 4 times a week.
2444589|NCT04570358|No Intervention|Follow-up|While group B performs the 8-week proprioceptive neuromuscular facilitation stretching, group A is in its follow-up period performing its daily life activities as usual.
3152218|NCT00246636|Experimental|OM5/LOV111859 (double-blind study) - Antara + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
3152219|NCT00246662|Experimental|Sch A (18 mg/m2 vosaroxin initially)|Once weekly intravenous on days 1, 8, 15 up to 4 cycles
3152220|NCT00246662|Experimental|Sch B (9 mg/m2 vosaroxin initially)|Twice weekly intravenous administration on days 1, 4, 8, 11 up to 4 cycles
3152221|NCT00246675|Other|Standard Care|Patients will only receive frusemide as per the treating physicians treatment
3152222|NCT00246675|Other|Intervention|Patients will be given frusemide to achieve a study specified urine output target of 1-2mls/kg/hour
3152223|NCT00246688|Experimental|Sagopilone, 0.5 h infusion|Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
3152224|NCT00246688|Experimental|Sagopilone, 3 h infusion|Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks
3152225|NCT00246701|Active Comparator|Simvastatin|Simvastatin + placebo
3152226|NCT00246701|Experimental|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
3152227|NCT00246727|Placebo Comparator|Study 1: Chemotherapy plus SV or Placebo|For newly diagnosed patients who will be receiving or have received less than 4 weeks of a standard chemotherapy regimen.
3152228|NCT00246727|Placebo Comparator|Study 2: SV vs Placebo without chemotherapy|For those who have stopped or refuse standard chemotherapy but will receive best supportive care.
3152229|NCT00246857||patients referred by physician with a suspected inherited immu|patients referred by physician with a suspected inherited immune deficiency
2443858|NCT05057429|Experimental|Bioelectric Dressing on the Right Armpit and Standard Gauze Dressing on the Left Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the right armpit and will receive the standard gauze dressing for up to 8 weeks on the left armpit.
2443884|NCT05057429|Experimental|Bioelectric Dressing on the Left Armpit and Standard Gauze Dressing on the Right Armpit|Participants undergoing standard of care deroofing surgery will be randomized to receive the bioelectric dressing for up to 8 weeks on the left armpit and will receive the standard gauze dressing for up to 8 weeks on the right armpit.
2443911|NCT05029141|Experimental|Chidamide+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.
2443912|NCT05029141|Placebo Comparator|Placebo+AZA+HHT+AraC+G-CSF group|The patients are randomized into the group.
3152230|NCT00246974|Active Comparator|1|Cisplatin + Gemcitabin
3152231|NCT00246974|Experimental|2|Cisplatin + Gemcitabin + Gefitinib
3152232|NCT00247039|Experimental|Garlic extract|Garlic extract capsules
3152233|NCT00247039|Placebo Comparator|Placebo|Placebo capsules
3152234|NCT00247052|Active Comparator|diclofenac|diclofenac
3152235|NCT00247052|Placebo Comparator|2|
3152236|NCT00247078|Experimental|1|Patients with moderate or severe pain due to Black Widow envenomation
2444202|NCT04895384||Surgical Cohort|Placement of Edwards ClearSight and Masimo SET on patient intraoperatively.
2444253|NCT04837040|Experimental|Paltusotine|
2444254|NCT04837040|Placebo Comparator|Placebo|
2444329|NCT04784546||Mild COVID-19 Infection Group|Mild cases present with acute symptoms of respiratory tract infection and gastrointestinal complaints.
2444334|NCT04784546||Moderate COVID-19 Infection Group|Moderate patients experience pneumonia, they don't have clinically aberrant hypoxemia(O2 saturation is more than 90%) but they have positive findings on chest computerized tomography (CT) scans.
2444338|NCT04784546||Severe COVID-19 Infection Group|Severe patients present with pneumonia, they have hypoxemia (O2 saturation is less than 90%) and have positive findings on chest computerized tomography (CT) scans.
3152237|NCT00247078|Placebo Comparator|2|Patients with moderate to severe pain due to Black Widow envenomation
3152238|NCT00247130|Active Comparator|Omeprazole|Omeprazole (20 mg), intravenous, 2x /day
3152239|NCT00247130|Active Comparator|Ranitidine|Ranitidine (100 mg), intravenous drip infusion, 2x /day.
2444464|NCT04667247|Experimental|Mushrooms|Fomitopsis officinalis and Trametes versicolor
2444466|NCT04667247|Placebo Comparator|Placebo|Organic brown rice
3152240|NCT00247182|Other|Step 1|Minimal Intervention
3152241|NCT00247182|Active Comparator|Step 2-A|Brief motivational intervention (BMI)
2444647|NCT04483908||Cohort 1|"Disease survivors with a positive polymerase chain reaction (PCR) test > 12days (d) ago and no symptoms (~250 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
2444652|NCT04483908||Cohort 2|"Disease survivors with a positive PCR test 7 - 12d ago and no symptoms (~100 participants).~Cohort 1 & 2 are supposed to have an antibody response to different levels and should provide ability to deduce the detection limit, and estimate the true positive and false negative rates of both ELISA and POC assays."
2444655|NCT04483908||Cohort 3|Subjects with PCR negative test > 5d (~100 participants). Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates.
2444657|NCT04483908||Cohort 4|"Anonymised blood sera from the Serumbank at the Kantonsspital Basel-Land (KSBL) taken during last years influenza period (~100 participants).~Cohort 3 & 4 are the control groups. They are supposed to not have an antibody response for COVID-19 and should therefore help estimate the true negative and false positive rates."
2444711|NCT04431466|Active Comparator|Standard of care|Standard of care (SOC) treatment
3152242|NCT00247182|Active Comparator|Step 2-B|Assessment-only control
3152243|NCT00247195|Experimental|Culturally congruent assessment and treatment|Outreach by phone to primary care patients interested in mental health referral. Engagement and evaluation approach conducted using the DSM-IV cultural formulation model. Same treatment choices as in control arm (medication, interpersonal psychotherapy, and combination treatment).
3152244|NCT00247195|Active Comparator|Usual referral and treatment|Usual referral procedure from primary care: PC clinician gives patient information on how to access mental health care at research site. Usual engagement and evaluation approach without using cultural formulation model. Same treatment choices (medication, interpersonal psychotherapy, and combination treatment) as in experimental arm.
3152245|NCT00247208|Active Comparator|1|Express 2 bare metal stent
3152246|NCT00247208|Experimental|2|Taxus, paclitaxel-eluting stent
3152247|NCT00247221|Experimental|1) MI/Family Check-Up|Brief integrated individual and family intervention -- the experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up
3152248|NCT00247221|Active Comparator|2) MI only|
3152249|NCT00247234|Experimental|schema therapy|
3152250|NCT00247234|Active Comparator|standard care|standard psychiatric out-patient care
3152251|NCT00247286|Experimental|a|Weighted vaginal cones used to perform pelvic floor exercises
2443872|NCT05051696|Experimental|Oncorine (H101) with or without radiotherapy|The tumor mass was injected with H101 per day for 5 consecutive days, 3 weeks as one treatment cycle, and 1 to 4 cycles according to the condition of the patient, and the patient was treated with or without radiotherapy in sequential. The injection dose of H101 was determined by the tumor volume or maximum tumor diameter:5.0×10^11 virus particles(VP) for if tumor diameter≤5cm; 1×10^12 VP for the tumor diameter between 5cm and 10cm, and 1.5×10^12 VP for the tumor diameter>10cm.
2444043|NCT04995588|Other|Blood test|Unique blood test for all the participants included in the study to constitute a local biobank to assess in a grouped manner the prespecified outcomes
3152252|NCT00247286|Active Comparator|b|Biofeedback
3152253|NCT00247312|Active Comparator|125Gy prescription dose Pd-103|125Gy prescription dose Pd-103
3152254|NCT00247312|Active Comparator|110 Gy prescription dose Pd-103|110 Gy prescription dose Pd-103
3152255|NCT00247390|Experimental|Ramelteon 8 mg QD|
3152256|NCT00247390|Placebo Comparator|Placebo QD|
2444461|NCT04674306|Experimental|α-lactalbumin and zymosan|"Participants will be treated with successively higher doses of α-lactalbumin and zymosan in a traditional 3 + 3 phase I trial design. Treatment will involve a course of 3 vaccinations given every 2 weeks. Participants will be enrolled sequentially into 1 of 3 different dose levels each comprised of cohorts of 1-6 participants until the MTD has been identified (intra-patient dose escalation not permitted), after which the MTD will be expanded to 6 participants. Successively lower doses will be expanded to 6 participants until the lowest DL associated with immune response has been expanded. A dose level intermediate between 100 and 1000 mcg will be studied if the 1000 mcg dose is above the MTD and the 100 mcg dose does not produce the desired immunologic effect~Dose Level (DL) 1: 10 microgram (mcg) a-lactalbumin + 10 mcg Zymosan~DL2: 100 mcg a-lactalbumin + 100 mcg Zymosan~DL3: 1000 mcg a-lactalbumin + 1000 mcg Zymosan"
3152257|NCT00247403|Experimental|2DG|
3152258|NCT00247663|Experimental|Letrozole|
3152259|NCT00247715|Other|Step-up|"Stepwise treatment:~step1: antacid (+placebo proton pump inhibitor)~step2: H2-receptor antagonist~step3: proton pump inhibitor (+ placebo antacid)"
3152260|NCT00247715|Other|step-down|"Stepwise treatment:~step1: proton pump inhibitor (+placebo antacid)~step2: H2-receptor antagonist~step3: antacid (+proton pump inhibitor)"
3152261|NCT00247741|Active Comparator|lidocaine|
3152262|NCT00247741|Experimental|articaine|
2445562|NCT03272100||test side ( horizontal flap)|Horizontal incision was realised in alveolar mucosa, in order to obtain the exposure of the lateral wall of the maxillary sinus, thus accessing the sinus cavity
3152263|NCT00247832|No Intervention|1|
3152264|NCT00247832|Experimental|2|Self-directed motivation
3152265|NCT00247832|Experimental|3|Personal motivational interviewing
3152266|NCT00247936|Active Comparator|1|Combined Thoracoscopic and Laparoscopic Esophagectomy
3152267|NCT00247936|Active Comparator|2|Hand-Assisted Transhiatal Esophagectomy
3152268|NCT00248053|Other|Lower GI|
3152269|NCT00248105|Experimental|PAM|
3152270|NCT00248105|No Intervention|PC|Participants not in the PAM group will be in the PC (physician counseling) group and will receive advice on lifestyle physical activity from their rheumatologist or primary care physician.
3152271|NCT00248118|Active Comparator|Active medication|300mg bupropion HCL
3152272|NCT00248118|Placebo Comparator|Placebo|Placebo pill
3152273|NCT00248209|Placebo Comparator|Wellbutrin XL or placebo|1 arms - Wellbutrin XL or placebo
3152274|NCT00248235|Experimental|PRET|Progressive Resistance Exercise Training: upper extremity 6-8 exercises
3152275|NCT00248235|Active Comparator|Standard Care|Standard Care: physical therapy - range of motion, 6-8 strengthening exercises
3152276|NCT00248326||1|Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
3152277|NCT00248326||2|Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
3152278|NCT00248339|Active Comparator|1|PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
3152279|NCT00248339|Active Comparator|2|PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
3152280|NCT00248339|Active Comparator|3|PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
3152281|NCT00248365|Experimental|Low PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 0.33μM
3152282|NCT00248365|Experimental|High PDT intensity level|Theralux extracorporeal photochemotherapy PDT dose: TH9402 1.32μM
3208916|NCT00979342|Experimental|Ibuprofen PRN|Subjects will receive a post procedure pain management regimen of ibuprofen 800 mg PRN.
3152283|NCT00248482|Experimental|Irinotecan, Cisplatin & Gleevec™|"Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles~Gleevec™ 400 mg po BID (800mg/day)- for patients with objective response or stable disease.~Irinotecan 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles"
3152284|NCT00248586|Experimental|Standard CBT (S-CBT)|
3152285|NCT00248586|Experimental|Minimal contact CBT (MC-CBT)|
3152286|NCT00248586|No Intervention|Control|
3152287|NCT00248677|No Intervention|No Contact Control|
3152288|NCT00248677|Experimental|Behavior Family Intervention|
2444404|NCT04706533||Covid-19|Patients with confirmed SARS-CoV-2 infection presenting specifically for Covid-19
2444476|NCT04668586|Experimental|Holmium:YAG laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Holmium:YAG laser machine.
2444478|NCT04668586|Experimental|Thulium Fiber laser machine|The ureteral or renal stones planned for treatment with URS and laser lithotripsy are fragmented or dusted using a Thulium Fiber laser machine.
2444554|NCT04615117||Study Group|Patients treated with Superior Capsular Reconstruction with Allomend
2444674|NCT04461600|Experimental|AL101|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
3152289|NCT00248677|Experimental|Behavioral Parent-Only Intervention|
2444921|NCT04070300|Experimental|Interval training group|Aerobic interval training during 12 weeks 3 times a week.
2444923|NCT04070300|No Intervention|Control group|No lifestyle recommendations. Usual daily life.
3152290|NCT00248703|Experimental|Docetaxel|Patients with presence of disseminated tumor cells in bone marrow after (no-taxane) epirubicin-containing adjuvant treatment receive 6 cycles of docetaxel (100 mg/m2) 3 qw.
3152291|NCT00248768|Other|Arm 1|
3152292|NCT00248846|No Intervention|Control Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal.
2444988|NCT03965221|Experimental|LYNX|LYNX is developed using IMB model and engages youth through entering sexual diary data, earning badges, and calculating a personalized sexual protection (Sex Pro) score, which informs and motivates youth around HIV/STI testing and PrEP uptake. Behavioral skills are built through HIV/STI testing reminders, presenting options for home HIV testing and/or linkage to nearby testing services, and access to an online chat with support for HIV/STI testing and PrEP referral.
2444989|NCT03965221|Experimental|MyChoices|"MyChoices is adapted from an app for adult MSM, HealthMindr, developed using SCT. The app aims to increase HIV testing and PrEP uptake by increasing self- regulation, self-reflection, and self-efficacy around HIV testing and PrEP uptake. Brief surveys about sexual risk and protective health behaviors within the app are used to assist users in tracking and self-monitoring their behaviors and creating a personalized HIV testing plan. Quizzes, videos and infographics as well as Help me Choose, Ordering, and geofencing functions are used to maximize self-efficacy around HIV prevention and uptake of PrEP."
2444991|NCT03965221|No Intervention|Standard of Care|Provision of referrals to local HIV/STI testing and PrEP resources.
3152293|NCT00248846|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their heart disease progression and how well they had been able to engage in their doctor approved physical activity goal, which was the same as the control arm. Additionally, subjects in this arm were encouraged to use positive affect and self-affirmation techniques to motivate an increased level of participation in their physical activity goal. These subjects also received small token gifts to remind them of their study participation.
3152294|NCT00248872|No Intervention|control group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to adhere to their medication goal.
3152295|NCT00248872|Experimental|Intervention Group|This group received follow-up every 2-months for one year. Follow-up included questions about their blood pressure and how well they had been able to engage adhere to their medication goal. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level.
3152296|NCT00248885|Active Comparator|1|In this group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB.
3208917|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 1)|
2445197|NCT03786692|Experimental|Arm A|Arm A: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab Maintenance: Pemetrexed + Bevacizumab + Atezolizumab
2445199|NCT03786692|Active Comparator|Arm B|Arm B: Carboplatin + Pemetrexed + Bevacizumab Maintenance: Pemetrexed + Bevacizumab
2445407|NCT03461120|Other|Control|Bupivacaine 0.1% [or ropivacaine 0.2%] infusion for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
3152297|NCT00248885|Experimental|2|In this group (High), the goal was to maintain MAP between 80-100 mm Hg during CPB.
3152298|NCT00248911|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
3152299|NCT00248976|No Intervention|1|This is the control group, which will be monitor. No intervention will be delivered to this group.
3152300|NCT00248976|Experimental|2|This group received the experimental intervention. This is an intervention based on feedback of individualized risk profiles framed as the opportunity to reduce one's biologic age. Net-present value of individual health behaviors in years.
3152301|NCT00248989|Experimental|Placebo|
3152302|NCT00248989|Experimental|DHEA|
3152303|NCT00249015|Experimental|1|Combined Aerobic and Resistance Exercise Program: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity as well as some weight training consisting of two sets of 8-12 repetitions of 9-10 different exercises. For the aerobic exercise, participant can choose from different exercise equipment such as a treadmill or stationary bicycle.
2444231|NCT04877821|Experimental|Sintilimab + Anlotinib + Chemotherapy|Experimental: Sintilimab + Anlotinib + Chemotherapy Participants receive Sintilimab every 3 weeks (Q3W) + Anlotinib d1-14 (Q3W) + (Nab paclitaxel weekly + carboplatin (Q3W) x 4 cycles followed by epirubicin + cyclophosphamide Q3W x 4 cycles) as neoadjuvant therapy prior to surgery. After surgery, those who exhibited residual disease were treated with capecitabine (1000-1250 mg/m2) given two-times a day for 1-14 days and cycled every 21 days for a total of 6-8 cycles.
3152304|NCT00249015|Active Comparator|2|Moderate Aerobic Exercise Group: perform three exercise sessions per week consisting of about 25-30 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
3152305|NCT00249015|Experimental|3|High Aerobic Exercise Group: perform three exercise sessions per week consisting of about 45-60 minutes of aerobic exercise at a moderate-to-vigorous intensity. Again, participant can choose from different exercise equipment.
3152306|NCT00249041|Experimental|Etanercept liquid|
3152307|NCT00249054|Active Comparator|ASR hip prosthesis|DuPuy ASR hip prosthesis
3152308|NCT00249054|Active Comparator|ReCap hip prosthesis|Biomet ReCap hip prosthesis
3152309|NCT00249106|Experimental|HIV vaccine|dosage escalation of ADVAX
2444344|NCT04756804|Experimental|70% Isopropyl Alcohol novel preoperative skin antiseptic|70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation
2444347|NCT04756804|Active Comparator|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation
3152310|NCT00249106|Placebo Comparator|Placebo|Sodium phosphate
3152311|NCT00249301|Experimental|1|MLN8054
2444479|NCT04647591|Experimental|ENT Barotrauma incidence and link with risk factors|
3152312|NCT00249366|Active Comparator|Fixed-schedule treatment|Fixed-schedule administration of lorazepam for alcohol withdrawal
3152313|NCT00249366|Active Comparator|Symptom-triggered treatment|Symptom-triggered administration of lorazepam per protocol using the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar)
3152314|NCT00249405|Experimental|1|citalopram
3152315|NCT00249405|Placebo Comparator|2|Placebo
2445042|NCT03920527|Active Comparator|Six months|Six months of itraconazole
2445044|NCT03920527|Experimental|12 months|12-months of itraconazole
3152316|NCT00249431|Placebo Comparator|Placebo and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus placebo
3152317|NCT00249431|Active Comparator|Sertraline and Relapse Prevention|Patients will be treated with Relapse Prevention Therapy plus Sertraline.
3152318|NCT00249457|Experimental|Therapeutic Workplace|Contingency management. Invited to work in the Therapeutic Workplace. Completed monthly assessments.
3152319|NCT00249457|No Intervention|Usual Care Control Group|No intervention. Not invited to work int the Therapeutic Workplace. Completed monthly assessments.
3152320|NCT00249483|Placebo Comparator|Placebo|Placebo
3152321|NCT00249483|Experimental|Venlafaxine|Venlafaxine 300mg daily
3152322|NCT00249535|Experimental|1|standard treatment plus usual magnitude prize CM
3152323|NCT00249535|Experimental|2|standard treatment plus higher magnitude prize CM
3152324|NCT00249535|Experimental|3|standard treatment plus voucher CM
3152325|NCT00249561|Experimental|Recovery by Choice|A modified Therapeutic Community program.
3152326|NCT00249561|Active Comparator|Intensive Outpatient Program|Designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism.
3152327|NCT00249574|Experimental|pegInterferon|Open label, observational trial to determine the safety of HCV treatment in active IDUs stabilized on buprenorphine/naloxone
3152328|NCT00249587|Experimental|1|Methadone plus behavioral counseling consisting of adherence, self-monitoring, and motivational interviewing
3152329|NCT00249587|Active Comparator|2|Methadone plus behavioral counseling consisting of adherence
3152330|NCT00249652|Experimental|TAP|MI-based phone intervention.
3152331|NCT00249652|Other|TAU|Treatment As Usual
3152332|NCT00249691|Experimental|Topiramate|
3152333|NCT00249691|Placebo Comparator|Placebo|
3152334|NCT00249704|Experimental|C|
3152335|NCT00249704|Experimental|B|
3152336|NCT00249704|Experimental|A|
2444210|NCT04886622|Experimental|DT2216|DT2216 will be administered by intravenous infusion over 30 minutes twice weekly on a continuous basis. Each treatment cycle will be 28 days in duration. The starting dose of DT2216 will be 0.04 mg/kg and will escalate by 100% increments for the first 5 treatment groups. Thereafter, if additional dose escalations are required, escalation will follow a modified Fibonacci scheme. Treatment may continue for up to 1 year.
2444278|NCT04824417|Active Comparator|Control|Oral itraconazole
2444279|NCT04824417|Experimental|Intervention|Oral voriconazole
2444333|NCT04765358|Other|All Participants|All participants will be provided with a commercially available CGM system. Training and data collection for the study will be completed remotely. After initial CGM training (initiation of unblinded CGM use or initial training with virtual clinic) has been completed, participants will continue to be followed by the virtual clinic team for approximately six months. Psychosocial screening questionnaires are administered at enrollment and during follow up. The virtual clinical team member will follow up with the study participant if there is an elevated score on the psychosocial screening questionnaires. After the initial six months of follow up, participants who decide to continue to use CGM will be asked to extend follow up and complete questionnaires, submit HbA1c samples, and share data. During the extended follow up phase, participants will be able to contact the virtual clinic with questions or to request assistance as needed.
3152337|NCT00249704|Placebo Comparator|D|
3152338|NCT00249756|Experimental|Re-entry Modified Therapeutic Community (Re-entry MTC)|
3152339|NCT00249756|Active Comparator|Parole Supervision and Case Management|
3152340|NCT00249847|Experimental|Paroxetine|Paroxetine controlled-release (2-12.5 mg tablets, orally, every day for 4 weeks)
3152341|NCT00249847|Experimental|Conjugated equine estrogen|Conjugated equine estrogen (0.625 mg tablet, orally, every day for 4 weeks)
2444533|NCT04626427|Experimental|WavelinQ™ EndoAVF System|The WavelinQ™ EndoAVF System is indicated for the cutting and coagulation of blood vessel tissue in the peripheral vasculature for the creation of an AVF used for HD. The device is intended to be used in patients suffering from chronic kidney disease requiring HD by physicians trained and experienced in endovascular techniques. The WavelinQ™ EndoAVF System will be used for these intended purposes as part of this clinical investigation according to its instructions for use (IFU).
3152342|NCT00249860|Experimental|Interferon-beta-1a|
2444632|NCT04521296|Experimental|DWJ1248|Camostat mesylate
2444634|NCT04521296|Placebo Comparator|Placebo|Placebo
3152343|NCT00249860|Active Comparator|Ribavarin plus interferon-beta-1a|
3152344|NCT00249899|Experimental|Lapaquistat Acetate 100 mg QD|(and stable statin therapy)
2445250|NCT03675919|Active Comparator|Control group|The control group will be provided a scale, a step counter as well as access to the online portal and will remain in routine care.
2445251|NCT03675919|Experimental|TeLIPro group|The TeLIPro group will be provided a scale, a step counter, a blood glucose meter with test stripes as well as access to the online portal and will get telemedical coaching.
2445283|NCT03611569|Experimental|Lu AF82422|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
2445284|NCT03611569|Placebo Comparator|Placebo|"Part A:~Cohort A1, A2, and A3: 24 healthy subjects, with 8 subjects per cohort (aiming for an equal number of men and women) Cohort A4,A5,A6: 36 healthy subjects, with 6 non-Japanese subjects and 6 Japanese subjects per cohort (aiming for an equal number of men and women)~Part B:~Cohort B1, B2, B3: 24 patients with Parkinson's disease"
2445323|NCT03545464|Experimental|Antihistamines + placebo of cortancyl|"- In emergency department : Levocetirizine 5 mg orally. Renewable once if persistence of hives at 30 minutes.~Placebo of Cortancyl : 1mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Placebo of Cortancyl 20 mg x 2 tablets = 40mg once per day for 3 days orally"
2445417|NCT03411239|Other|Interventional arm|Patients recruited will have OBC inserted under general anaesthesia and various pressure measured
3152345|NCT00249899|Active Comparator|Stable statin therapy|
3152346|NCT00249912|Experimental|Lapaquistat Acetate 50 mg QD + Rosuvastatin|
3152347|NCT00249912|Experimental|Lapaquistat Acetate 100 mg QD + Rosuvastatin|
3152348|NCT00249912|Active Comparator|Rosuvastatin|
3152349|NCT00249964|Experimental|Combination Treatment|"Paclitaxel at 175 mg/m2 + Carboplatin at area under the curve (AUC) 5 on day 1. Then, Temozolomide at the doses described under Interventions from day 2 to day 6 (a total of 5 days).~Cycle length is 21 days."
3152350|NCT00250081|Active Comparator|Therapy Group|Therapy only
3152351|NCT00250081|Active Comparator|Surgery Group|surgical intervention
3152352|NCT00250081|Active Comparator|Botox Injections|botulinum toxin
3152358|NCT00250224|Experimental|Stent|
3152359|NCT00250237|Active Comparator|A|Patients receiving blinded medication (Haloperidol or Placebo)
3152360|NCT00250237|Placebo Comparator|B|Patients receiving blinded medication (Haloperidol or Placebo)
2444072|NCT04953286|Other|Case group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients with Amyotrophic Lateral Sclerosis
2444073|NCT04953286|Other|Control group|The procedure, specific to the study, consists in taking samples of tears and cells at inclusion, 3 months after inclusion and 6 months after inclusion on patients without neurological disease
3152361|NCT00250263|Placebo Comparator|1|Matching placebo- control arm (first year)
3152362|NCT00250263|Active Comparator|2|Drug Staloral (active group)
3152363|NCT00250406|Active Comparator|1|Percuflex Plus Ureteral Stent
2444234|NCT04863846||Clinical standard (first study phase)|Current clinical standard, non-algorithm-based decision-making (prior to implementation of the algorithm)
2444236|NCT04863846||Algorithm-based allocation (second study phase)|New algorithm-based allocation to an intubation technique (after implementation of the algorithm)
2444260|NCT04817085|Experimental|Visant Medical Canalicular Plug|Bilateral placement of the Visant Canalicular Plug inserted on Day 1
2444263|NCT04817085|Active Comparator|Commercially available canalicular plug|Bilateral placement of commercially available canalicular plug inserted on Day 1
3152364|NCT00250406|Experimental|2|TRIUMPH stent (triclosan-eluting stent)
3152365|NCT00250510|No Intervention|1|
2444392|NCT04717115||Genetic diagnosis|
3152366|NCT00250510|Experimental|2|EatRight Program inquirers with BMI's of 30 kg/m2 or greater were told that they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if certain conditions were met.
3152367|NCT00250523||Traumatic injury|ICU Patients with blunt or penetrating injury
3152368|NCT00250523||2|Healthy volunteers
3152369|NCT00250549|No Intervention|HIV counselor|Patients who tested for HIV and consent to participate in the study receive a posttest educational session with an HIV counselor. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
3152370|NCT00250549|Experimental|Post test video|Patients who tested for HIV and consent to participate in the study watch a a 15-minute HIV posttest educational video available in English/Spanish. Afterwards, patients complete an assessment tool concerning HIV prevention and transmission.
3152371|NCT00250575|Experimental|1|
3152372|NCT00250640||Group 1|
3152373|NCT00250731|Experimental|1|Telephone support and behavior change for couples
2444726|NCT04412941|Experimental|Treatment group|Myofunctional exercises + home oropharyngeal exercises + the rules of sleep hygiene
2444727|NCT04412941|Active Comparator|Control group|the rules of sleep hygiene
2444770|NCT04350541|Experimental|Interval training|Interval training will consist of 10 minutes of warm-up between 40-50% of the peak oxygen consumption (VO2peak), followed by four to six repetitions of three-minute intervals between 80-90% of VO2peak and three minutes between 40-50% VO2peak and finally, five minutes of cooling down between 30-40% of VO2peak.
2444772|NCT04350541|Active Comparator|Continuous training|The continuous aerobic training will consist of 10 minutes of warm-up with intensity between 40 and 50% of VO2peak, 20 minutes of conditioning between 60 and 70% of VO2peak and 5 minutes of cooling down between 30 and 40% of VO2peak.
3152374|NCT00250731|Active Comparator|2|Telephone support and behavior change for individuals
3152375|NCT00250731|Placebo Comparator|3|Limited diabetes self-management education
2444819|NCT04268979|Experimental|eSNAP & Caregiver Navigator|eSNAP intervention plus questionnaires
2444823|NCT04268979|No Intervention|Waitlist Control Condition|Participants randomly assigned to the waitlist control condition will only complete questionnaires during the 8-week study period. After the 8 weeks, they will then have access to the eSNAP, including completion of questionnaires and 8 weeks of Caregiver Navigator sessions as needed.
2444857|NCT04229173|Other|MSA patients|"Patients with multiple system atrophy will be examined at baseline, 6 months and 12 months via the following procedures performed at all 3 visits:~a clinical examination;~blood and cerebrospinal fluid (CSF) (optional) sampling for the assessment of selected fluid biomarkers;~MRI for the assessment of brain volume, white matter integrity and cerebral iron deposition; DAT-SPECT (Dopamine Transporter, Single Photon Emission Computed Tomography) for the assessment of presynaptic dopaminergic function"
2444859|NCT04229173|Other|Healthy volunteers|healthy. Controls will undergo an MRI scan at baseline, 6 months and 12 months, and a DAT-SPECT(Dopamine Transporter, Single Photon Emission Computed Tomography) scan at baseline and 12 months.
3152376|NCT00250744|Experimental|Arm A|
3152377|NCT00250744|Active Comparator|Arm B|
3152378|NCT00250770||1|"Healthy postmenopausal and perimenopausal women with no history of endometrial carcinoma.~Women undergoing hysterectomy for benign conditions."
3152379|NCT00250796|Active Comparator|Arm 1|Thalidomide+alpha interferon
3152380|NCT00250796|Experimental|Arm 2|Thalidomide+interferon+Octreotide
3152381|NCT00250939|Experimental|1|
3152382|NCT00251017|Active Comparator|Vancomycin|Effects of OCT2 genetic variation in renal elimination of Vancomycin
3152383|NCT00251043|Experimental|1|Participants will Psychotherapy weekly for 12 weeks
3152384|NCT00251043|Active Comparator|2|Parenting Education will include 45-minute weekly sessions for 12 week
2444986|NCT03995537||Patients with severe liver disease waiting liver transplant|Only patients with the most frequent LT indications will be eligible: complicated cirrhosis of hepatocellular carcinoma (HCC), acute or chronic decompensation of cirrhosis, with or without multi-visceral failure and fulminant hepatitis.
3152385|NCT00251056|Active Comparator|1|
3152386|NCT00251056|Active Comparator|2|
2445194|NCT03787368|Experimental|Dose 1 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 1)
2445195|NCT03787368|Experimental|Dose 2 of BAY1213790|Single intravenous infusion BAY1213790 (Dose 2)
3152387|NCT00251056|Active Comparator|3|
3152388|NCT00251056|Active Comparator|4|
3152389|NCT00251082|Experimental|A|
3152390|NCT00251082|Active Comparator|B|
3152391|NCT00251082|Placebo Comparator|C|
3152392|NCT00251095|Active Comparator|Taxol|Taxol 80mg/m2/week
3152393|NCT00251095|Experimental|TOCOSOL|TOCOSOL Paclitaxel
3152394|NCT00251121|Experimental|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
2444357|NCT04779476||Control Group|No dressing material will be used post dental extraction
2444361|NCT04779476||Alveogyl Group|Alveogyl will be placed in the dental socket after extraction
2444363|NCT04779476||Cutanplast Group|Absorbable gelatin sponges contain will be placed in the dental socket after extraction
3152395|NCT00251134|Active Comparator|1|omega-3-acid ethyl ester 90
3152396|NCT00251134|Placebo Comparator|2|olive oil
3152397|NCT00251147|Active Comparator|Open Repair|
2444904|NCT04122053|Experimental|study group|group will receive dietary advice and genotype information
2444908|NCT04122053|Active Comparator|Control group|group will receive dietary advice
2444919|NCT04075253|Experimental|VO2 peak test|All participants enrolled in the planned study on physical activity and ventricular arrhythmias and on baseline will complete an exercise treadmill test to determine VO2 peak
3152398|NCT00251147|Active Comparator|Mini-open Repair|
3152399|NCT00251160|Active Comparator|ETAC|
3152400|NCT00251160|Active Comparator|Open ICS|
2445045|NCT03918460|Experimental|Intervention|All patients enrolled are intended to be treated
2445094|NCT03905876|Other|assessment of psychological experience|Questionnaire
3152401|NCT00251173|Active Comparator|Strengths Based Case Management Model (SBCM)|The Strengths Based Case Management Model (SBCM) consists of 5 case-management sessions designed to promote linkage and engagement in assessment and treatment services, while assisting with the patient's perceived needs, as well as personal strengths and barriers to linkage and engagement.
3152402|NCT00251173|Active Comparator|Motivational Enhancement Therapy (MET)|The MET therapist will conduct 2 motivational enhancement sessions to work through the content of an educational workbook targeting the participant's substance use/abuse with the goal of negotiating a 'contract' to: 1) link to services, with the eventual goal of seeking and receiving specialized substance treatment; or 2) provide a strategy to self-monitor substance use, consider consequences, and later seek assessment.
3152403|NCT00251173|Active Comparator|Brief Informational Feedback (BIF) session|Subjects will receive brief informational feedback on the results of their alcohol screening and assessment and encouragement to seek treatment.
2445148|NCT03854370|Experimental|Baby shampoo|Baby shampoo used for surgical site prep
2445149|NCT03854370|Active Comparator|Peridex (Chlorhexidine)|Peridex used for surgical site prep
2445150|NCT03854370|Active Comparator|TechniCare (chloroxynel)|TechniCare used for surgical site prep
2445152|NCT03854370|Active Comparator|Betadine (Povidone- iodine)|Betadine used for surgical site prep
2445166|NCT03801863||Ultrasound-guided Erector Spinae Block|Patients will then be randomized into one of the two groups above. One group will receive a lumbar erector spinae block at L4 with 30ml of 0.375% ropivacaine with 50 mcg of dexmedetomidine before the procedure using ultrasound guidance. The second group will receive no peripheral nerve block to serve as the control. All patients receiving nerve blocks will have a printed image of the block thus to confirm proper spread of local anesthetic both cranially and caudally.
2445170|NCT03801863||No Ultrasound-guided Erector Spinae Block|Patients with no peripheral nerve block to serve as the control.
3152404|NCT00251212|Active Comparator|1|Therapist delivered adapted motivational enhancement therapy and skills training
3152405|NCT00251212|Active Comparator|2|Computer delivered adapted motivational enhancement therapy and skills training
3152406|NCT00251212|No Intervention|3|3: Control brochure
3152407|NCT00251251|Active Comparator|1. Optimal Medical therapy plus ICD|
2446035|NCT03268850|Experimental|LW-B|The Lost Wages B (LW-B) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a different amount. This will also include standard of care.
3152408|NCT00251251|Active Comparator|2. Optimal Medical Therapy plus CRT/ICD|
3152409|NCT00251264|Active Comparator|Open|
3152410|NCT00251264|Active Comparator|Arthroscopic|
3152411|NCT00251355|Experimental|5-FU/gemcitabine/RT|
3152412|NCT00251407|Experimental|taxotere, cisplatin, irinotecan|
3152413|NCT00251433|Experimental|Phase I|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
3152414|NCT00251433|Experimental|Phase II-A|Patients will receive OTR of lapatinib, docetaxel, trastuzumab dose determined in phase I.
3152415|NCT00251433|Active Comparator|Phase II-B|Patients will receive docetaxel and trastuzumab combination.
3152416|NCT00251602|Experimental|1|II ACE genotype
3152417|NCT00251602|Experimental|2|ID ACE genotype
3152418|NCT00251602|Experimental|3|DD ACE genotype
3152419|NCT00251602|Placebo Comparator|4|II ACE genotype
3152420|NCT00251602|Placebo Comparator|5|ID ACE genotype
3152421|NCT00251602|Placebo Comparator|6|DD ACE genotype
3152422|NCT00251628|Active Comparator|Group A|
3152423|NCT00251628|Active Comparator|Group B|
3152424|NCT00251628|Experimental|Group C|
3152425|NCT00251680|Experimental|Lapaquistat Acetate 50 mg QD|(and stable lipid-lowering therapy)
3152426|NCT00251680|Active Comparator|Stable Lipid-lowering therapy|
3152427|NCT00251732|Active Comparator|Standard dose (PPI) plus low dose TCA|Standard dose Rabeprazole(PPI) plus low dose tricyclic antidepressant(TCA)
3152428|NCT00251732|Active Comparator|Double dose PPI|Double dose proton pump inhibitor plus placebo
3152429|NCT00251732|Placebo Comparator|Standard dose PPI plus placebo x 2|Standard dose 20 mg. once daily plus Placebo before dinner and placebo before bedtime
3152430|NCT00251771|Experimental|I|
3152431|NCT00251771|No Intervention|II|
3152432|NCT00251810||general anaesthesia|
2444305|NCT04803604|Experimental|Basic social support + 1 monthly follow up call|1 in-person/telephone weekly sessions on providing social support and a single monthly follow-up call
2444307|NCT04803604|Experimental|Basic social support + monthly follow up calls for 24 weeks|1 in-person/telephone weekly sessions on providing social support and monthly follow-up calls for 6 months
2444308|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + 1 monthly follow up call|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and a single monthly follow-up call
2444309|NCT04803604|Experimental|Advanced social support + communication + Ottawa guide + monthly follow up calls for 24 weeks|5 in-person/telephone weekly sessions on providing social support, tips for good communication, decision support tools, and monthly follow-up calls for 6
2444311|NCT04803604|Experimental|Advanced social support + communication + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and a single monthly follow-up call
2444312|NCT04803604|Experimental|Advanced social support + communication + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, tips for good communication, and monthly follow-up calls for 6 months
2444313|NCT04803604|Experimental|Advanced social support + Ottawa guide + 1 monthly follow up call|4 in-person/telephone weekly sessions on providing social support, decision support tools, and a single monthly follow-up call
2444314|NCT04803604|Experimental|Advanced social support + Ottawa guide + monthly follow up calls for 24 weeks|4 in-person/telephone weekly sessions on providing social support, decision support tools, and monthly follow-up calls for 6 months
2444315|NCT04803604|Experimental|Advanced social support + 1 monthly follow up call|3 in-person/telephone weekly sessions on providing social support, and a single monthly follow-up call
2444316|NCT04803604|Experimental|Advanced social support + monthly follow up calls for 24 weeks|3 in-person/telephone weekly sessions on providing social support, and monthly follow-up calls for 6 months
2444409|NCT04709432||ECMO group|children supported by ECMO in the past 10 years
2444495|NCT04667156|Experimental|Sequence 1|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 traditional formulation (R) in the last period
2444497|NCT04667156|Experimental|Sequence 2|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 new formulation 2 (T2) in the last period
2444498|NCT04667156|Experimental|Sequence 3|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 1 (T1) in the last period
2444499|NCT04667156|Experimental|Sequence 4|Intervention: Drug: SHR6390 new formulation 1(T1) in the first period; SHR6390 traditional formulation (R) in the second period; SHR6390 new formulation 2 (T2) in the last period
2444500|NCT04667156|Experimental|Sequence 5|Intervention: Drug: SHR6390 new formulation 2(T2) in the first period; SHR6390 new formulation 1 (T1) in the second period; SHR6390 traditional formulation (R) in the last period
2444501|NCT04667156|Experimental|Sequence 6|Intervention: Drug: SHR6390 traditional formulation (R) in the first period; SHR6390 new formulation 2 (T2) in the second period; SHR6390 new formulation 1 (T1) in the last period
2444595|NCT04542096||Group1|Patients receiving invasive respiratory therapy (intubated)
2444597|NCT04542096||Group2|Patients receiving non-invasive respiratory therapy.
2444636|NCT04486716|Experimental|Ofatumumab|Investigational drug will be provided in an autoinjector for subcutaneous administration containing 20 mg ofatumumab (20 mg/0.4 ml) administered at baseline, Day 7, Day 14 and monthly thereafter
2444804|NCT04307355|Active Comparator|Active|Participants will be provided with a Transcu O2 ® Oxygen delivery system at the surgical site for 4 weeks as supportive care.
2444805|NCT04307355|No Intervention|Control|Participants will be placed in a standard dressing at the surgical site and will be followed for 4 weeks.
3152433|NCT00251836||Left-sided donor nephrectomy|Left-sided laparoscopic hand-assisted donor nephrectomy
3152434|NCT00251836||Right-sided donor nephrectomy|Right-sided laparoscopic hand-assisted donor nephrectomy
2444446|NCT04697238|Experimental|High load (11 % of body weight vests)|Subjects in this arm will carry heavy weight (11 percent of body weight) vests for 5 weeks.
2444448|NCT04697238|Placebo Comparator|Low load (1 % of body weight vests)|Subjects in this arm will carry heavy weight (1 percent of body weight) vests for 5 weeks.
2444504|NCT04636983|Experimental|BV100|BV100 intravenous infusion
2444505|NCT04636983|Placebo Comparator|Placebo|Saline intravenous infusion
3152435|NCT00252122|Experimental|1|Patients receiving ketamine are those patients, arm 1, that are sill experiencing pain after Morphine has been given.
2444586|NCT04542408|Experimental|Intensive anticoagulation strategy|In-hospital (ICU & normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC
2444588|NCT04542408|Other|Moderate anticoagulation strategy|In-hospital (ICU & normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral placebo according to the dosing rules for Edoxaban
2444644|NCT04479319||COVID-19 Pneumonia|"COVID-19 patients who have pneumonia on thorax CT~either Thorax CT + SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +"
2444650|NCT04479319||COVID-19, without Pneumonia|"COVID-19 patients who have not pneumonia on thorax CT~Thorax CT - SARS-CoV-2 RT-PCR + Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-"
2444656|NCT04479319||Non COVID-19|"Patients with viral infection symptoms who is not diagnosed with COVID-19~either Thorax CT - SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 +/-~or Thorax CT + SARS-CoV-2 RT-PCR - Clinical signs of COVID-19 +/- Any contact with someone with COVID-19 -"
2444688|NCT04437199|Active Comparator|AC-SD-03|Tricaprilin SD formulation, twice daily. Administered orally
2444695|NCT04437199|Placebo Comparator|AC-SD-03P|Placebo formulation, twice daily. Administered orally
2444732|NCT04391777|Experimental|CV-4 group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The CV-4 technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
2444734|NCT04391777|Sham Comparator|Control group|"The initial selection will be made through a questionnaire, in order to fulfill the exclusion and inclusion criteria. On the data collection day a more detailed survey is performed and informed consent is signed.~The patient waits for 5 minutes in the supine position, after which the baseline evaluation is performed.~The sham technique is performed following immediate evaluation. 15 minutes after the technique, a new evaluation of the variables is accomplished."
2444769|NCT04350294||Serious Mental Illness *RECRUITMENT IN THIS GROUP IS CLOSED|"Mothers with a serious mental illness*~*received hospitalisation, treatment or intervention from a secondary care (mental health) service in the last 5 years."
2444771|NCT04350294||Healthy Controls|Mothers with no history of mental illness, who have given birth since February 2021
3152436|NCT00252148|Active Comparator|ADMVA|ADMVA dosage escalation
3152437|NCT00252148|Placebo Comparator|Placebo|Placebo is 10mM TRIS HCl, 140mM NaCl, ph 7.7
3152438|NCT00252161|Active Comparator|1|Procedure/Surgery: Gastrectomy with more than D2 dissection
3152439|NCT00252161|Experimental|2|Drug: Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
2445506|NCT03272438|Active Comparator|No schedule control|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will also monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions.
2445511|NCT03272438|Experimental|Consistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in consistent contexts, i.e., that are very similar from day to day.
2445514|NCT03272438|Active Comparator|Inconsistent schedule condition|This group will receive an accelerometer and daily step goal. They will monitor their steps over the 9 week duration of the study. They will have the same level of contact as the other two conditions. In addition they will plan when, where, and how they will take steps in inconsistent contexts, i.e., that vary from day to day.
2445570|NCT03272204|Other|Natural Pubic Hair|Participant with natural hair crosses over to removed pubic hair
2445573|NCT03272204|Other|Removed Pubic Hair|Participant with no pubic hair crosses over to natural pubic hair
2445622|NCT03271801|Active Comparator|Child Health Education|The child health education condition will participate in a family-based obesity treatment program for the first 40 minutes of each session, followed by 20 minutes designated to education about a child health topic. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time.
3152440|NCT00252304|Experimental|Zinc|Zinc sulphate 10 or 20 mg per day
3152441|NCT00252304|Placebo Comparator|Placebo|Placebo
3152442|NCT00252317|Active Comparator|1|Captopril test dose and Trandolapril
3152443|NCT00252317|Placebo Comparator|2|
3152444|NCT00252421|Active Comparator|Nitroglycerin|Nitroglycerin ointment 15 mg/day daily for 24 month
3152445|NCT00252421|Placebo Comparator|Placebo|Placebo ointment daily for 24 month
3152446|NCT00252486|Placebo Comparator|Flax oil, placebo oil|
3152447|NCT00252525||Group 1|This is an observational study of patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2@.
3152448|NCT00252551|Experimental|1|osteosynthesis
3152449|NCT00252551|Active Comparator|2|Simple surgery
3152450|NCT00252616|Experimental|1|trophic feeds
3152451|NCT00252616|Active Comparator|2|Full-calorie feeds
3152452|NCT00252746|Experimental|ZD6474 100mg|Daily dose
3152453|NCT00252746|Experimental|ZD6474 200mg|daily dose
2444358|NCT04754542||Discontinuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to discontinue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
2444360|NCT04754542||Continuation|This study is only observing participants that received an intervention from a previous study. Participants that were randomized to continue their disease modifying therapy (DMT) in the DISCOMS study and consent to this extension trial will remain in this arm for the extension.
2444393|NCT04705545|No Intervention|molar block|No additional anchorage reinforcements besides the banding first and second molar with and tying them together at the buccal tubes (also known as molar block)
2444394|NCT04705545|Experimental|TPA group|Bands are selected and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a transpalatal archwire.
2444395|NCT04705545|Experimental|Nance button group|Bands are selected and an alginate impression taken over the bands. Bands are replaced on the tooth and an alginate impression taken over the bands. The impression will be sent to the lab for the construction of a transpalatal archwire on a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands. The appliance will be fitted a week later. Molar bands will be fitted to the permanent second molar on the same appointment, with a ligature wire tying the first molar band together at the buccal tubes. The resulting anchorage reinforcement is a molar block with a Nance button
3152454|NCT00252746|Experimental|ZD6474 300mg|daily dose
3152455|NCT00252915|Experimental|Verum|GM-CSF therapy
3152456|NCT00252928|Placebo Comparator|A|Placebo group does not receive Aquatabs.
3152457|NCT00252928|Experimental|B|Intervention arms receives Aquatabs.
3152458|NCT00252954|Placebo Comparator|1|
3152459|NCT00253045|Experimental|Motivational group|Group counseling using motivational interviewing
3152460|NCT00253071|Active Comparator|A,2|Standard treatment: treatment as usual at a community psychiatric center, private psychiatrist or general practitioner.
2444778|NCT04329312||Pulmonary arterial hypertension (PAH)|The patients with PAH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444781|NCT04329312||PH due to left-heart disease (PH-LHD)|The patients with PH-LHD received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444782|NCT04329312||Chronic thromboembolic pulmonary hypertension (CTEPH)|The patients with CTEPH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444783|NCT04329312||PH due to emphysema (PH-LD-Emphys)|The patients with PH-LD-Emphys received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444785|NCT04329312||PH due to lung fibrosis (PH-LD-Fibr)|The patients with PH-LD-Fibr received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444787|NCT04329312||PH due to combined emphysema and fibrosis (PH-LD-CPFE)|The patients with PH-LD-CPFE received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444788|NCT04329312||No PH|The patients without PH received an invasive right-heart catheterization and a thoracic CT scan as part of their routine work up.
2444808|NCT04275557||Retrospective Cohort|Retrospective chart review of pathologically-confirmed Intraductal Papillary Mucinous Neoplasm (IPMN) cases
2444809|NCT04275557||Prospective Cohort|Blood, tumor tissue samples and data will be collected.
2444839|NCT04243941|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
2444867|NCT04177758|Placebo Comparator|Control|Patients randomized to the control arm will receive placebo tablets and advised to consume their medication similar to the treatment arm.
2444868|NCT04177758|Experimental|Treatment|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
2444903|NCT04130516|Other|Active|Phase 1 open-label
2444929|NCT04070105|Active Comparator|Conventional Prosthetic Foot|In this condition, participants will walk with their standard prosthetic foot
2444932|NCT04070105|Experimental|CAESER Prosthetic Foot|In this condition, participants will walk with a new prosthesis with enhanced energy storage and return and increased range of motion. They will only wear this device in the lab for an approximately 4 hour period of time
2444969|NCT04040426|Experimental|Human split thickness skin allograft (Theraskin™)|Theraskin™ is an all-human split thickness skin allograft with a native extracellular matrix that can be used an adjunct to standard of care, for skin coverage in patients who have suffered from a diabetic foot wound in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing. Theraskin™ is an allograft tissue and will be used in compliance with homologous use by the FDA under section 361 of the PHS Act and 21 CFR Part 1271
2444970|NCT04040426|Active Comparator|Fibracol wound dressing|A commercially available wound dressing to be used per manufacturer's instructions for use on diabetic foot wounds in conjunction with offloading and Additional (outer) Dressing Application with moisture retention dressing moisture retention dressing
3152461|NCT00253071|Experimental|A, 1|"Behavioral: Prophylactic combined medical and psychological treatment~Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
3152462|NCT00253084|Other|IPX054 - CD-LD IR|Subjects received IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks and then received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks.
3152463|NCT00253084|Other|CD-LD IR - IPX054|Subjects received IPX054 Placebo b.i.d and CD-LD IR q.i.d for 2 weeks and then IPX054 200 mg b.i.d and CD-LD IR Placebo q.i.d for 2 weeks.
3208918|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 2)|
3208919|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 3)|
2444390|NCT04729257|Other|Group E (Norms, 18-49 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
2444391|NCT04729257|Other|Group F (Norms, 80-95 years)|Visit 1: Participants' cognition is measured using digital tests. Visit 2: N/A
3152464|NCT00253097|No Intervention|Control|Patients in the control group had the usual care provided at the stroke unit, that is counselling on avoiding risky health behavior, compliance with preventive medication, measurement of blood pressure and a 3 months' visit in the outpatient clinic
3152465|NCT00253097|Experimental|Intervention|Patienta allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
2444508|NCT04620551|Experimental|PD with DBS|Patients with Parkinson's Disease who opt for DBS surgery and consent to participate in the sleep study.
2444552|NCT04580888|Experimental|Intervention arm|Assessment using an early transthoracic echocardiography (after 500 mL of fluids) to identify the hemodynamic profile responsible for the acute circulatory failure associated with sepsis / septic shock and to guide ongoing treatment (therapeutic algorithm) and monitor its efficacy and tolerance.
2444555|NCT04580888|Other|Control arm|Conventional management according to current standards of care based on SSC recommendations, including a standardized fluid resuscitation of 30 mL/kg.
3152466|NCT00253110|Active Comparator|risperidone|
3152467|NCT00253110|Active Comparator|haloperidol|
3152468|NCT00253266|Experimental|Verum|Quetiapine augmentation
3152469|NCT00253266|Placebo Comparator|Placebo|"Placebo augmentation"
3152470|NCT00253279||1|16 healthy subjects will be studied. Each patient will undergo one PET Scan to measure muscle protein synthesis rate.
3152471|NCT00253279||2|48 burn patients will be studied. Each patient will have a maximum of 3 PET Scans, which will be done at different times during the first 24 months after injury. A maximum of 2 of these scans will be done while they are inpatient; one after discharge.
3152472|NCT00253318|Experimental|RAD001 + Docetaxel|RAD001 30 mg orally on Days 1 and 8. Docetaxel 40 mg/m^2 intravenous (IV) over 1 hour on Day 1. Dexamethasone 8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
2444816|NCT04282551|Experimental|oligosaccharide group 1|
2444821|NCT04282551|Experimental|oligosaccharide group 2|
2444826|NCT04282551|Placebo Comparator|placebo group|
3152473|NCT00253383|Experimental|ENABLE (concurrent palliative care)|telephone based ENABLE educational intervention
3152474|NCT00253383|Active Comparator|Usual Care|Supportive and palliative usual care services at DHMC, Behavioral
2444924|NCT04091867|Experimental|sEphB4-HSA with CRT|"sEphB4-HSA: Loading dose at fixed dose of 10mg/Kg per below schema on D1 Concurrent dose per below schema D15-43 and given on an every other week basis Concurrent chemotherapy drug (either cisplatin or carboplatin): Per treating physician discretion, and treatment plan is based per NCCN guidelines. These can be administered in tri-weekly or weekly doses during the radiation period. The participant will receive the first infusion on Day 15 (+/- 3 days).~Cetuximab:~Loading dose 400 mg/m2 on D9 Concurrent dose 250mg/m2 weekly D15± 3 day window~RT:~6930 cGy IMRT starting D15-D18"
2444965|NCT04046172|Experimental|test group|intensive periodontal treatment (IPT)
2444966|NCT04046172|Sham Comparator|control group|Control periodontal treatment (CPT)
2445000|NCT03974204|Experimental|Cerebrospinal fluid and Blood sample collection|"Collection of cerebrospinal fluid and blood samples:~At initial diagnostic assessment;~1 month and 3 months after initial diagnostic assessment, for patients classified possible, probable or confirmed according to EANO-ESMO classification, leading to specific leptomeningeal metastase treatment;~In case of symptoms leading to leptomeningeal metastase suspicion and at least 3 months after diagnostic assessment, for patients classified lack of evidence according to EANO-ESMO classification."
2445032|NCT03921541|Experimental|Pegzilarginase|Weekly IV infusions of pegzilarginase plus individualized disease management for 24 weeks
2445034|NCT03921541|Placebo Comparator|Placebo|Weekly IV infusions of placebo plus individualized disease management for 24 weeks
2445035|NCT03921541|Experimental|Pegzilarginase Long Term Extension|After completion of 24 weeks DB treatment, weekly IV infusions of pegzilarginase plus individualized disease management for an additional 150 weeks, with the option to receive treatment by SC after 8 weeks of the LTE study.
2445099|NCT03903120|Experimental|ASSIST|Study 1 and 2
2445100|NCT03903120|No Intervention|Delayed Control|Study 1 and 2
2445101|NCT03903120|Experimental|Massed ASSIST|Study 3
2445103|NCT03903120|Experimental|Distributed ASSIST|Study 3
2445121|NCT03874546|Experimental|Prognostic evaluation|Questionnaire at Day1, Day7 and 6 months.
2445146|NCT03852862|Experimental|Serratus plane block with paravertebral block|Association of Serratus plane block and paravertebral block for anesthesia
2445147|NCT03852862|Active Comparator|paravertebral block alone|Paravertebral block for anesthesia
3208920|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 4)|
2445198|NCT03787368|Placebo Comparator|Placebo|Single intravenous infusion placebo
3152475|NCT00253500|Experimental|Epirubicin|
3152476|NCT00253539|Experimental|Arm I|Participants receive oral tamoxifen once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
3152477|NCT00253539|Experimental|Arm II|Participants receive oral arzoxifene once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered the opportunity to continue treatment for an additional 6 months.
3152478|NCT00253539|Placebo Comparator|Arm III|Participants receive an oral placebo once daily once daily for 6 months in the absence of disease progression or unacceptable toxicity. After the completion of 6 months of treatment, participants are offered treatment with arzoxifene for an additional 6 months.
3152479|NCT00253578|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2444405|NCT04704869|Experimental|Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Cryoprecipitate will be given in addition to the standard of care massive transfusion protocol products, which include red blood cells, plasma, platelets and whole blood. The Cryoprecipitate will be given with 90 minutes of emergency department arrival. Cryoprecipitate dose will be 3 pools (equivalent to 15 single units).
2444406|NCT04704869|Active Comparator|Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood)|Only standard of care massive transfusion protocol products will be given, including red blood cells, plasma, platelets, and whole blood.
3152480|NCT00253682||1|HIV-uninfected infants born to HIV-infected women with in-utero exposure to HIghly Active Ani-Retroviral Therapy (HAART) who were enrolled in the Women and Infants Transmission Study (WITS).
3152481|NCT00253682||2|Historical cohort of HIV-uninfected infants born to HIV-infected women from the Pediatric Pulmonary and Cardiovascular Complications of HIV Study (P2C2 HIV) who were not exposed to HAART.
3152482|NCT00253721|Experimental|All subjects|
3152483|NCT00253734|Active Comparator|4|31 subjects to receive 15 mcg of TIV administered intramuscularly.
2444729|NCT04398030|Experimental|coil-reinforced soft polymer indwelling cannula|Participants in this arm are randomized into the coil-reinforced soft polymer indwelling cannula group and then switched to a soft Teflon indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
2444731|NCT04398030|Active Comparator|soft Teflon indwelling cannula|Participants in this arm are randomized into the soft Teflon indwelling cannula group and then switched to the coil-reinforced soft polymer indwelling cannula group after a 2-week washout/rest (±1 week). The participant will try to wear each infusion set for 7 consecutive days.
3152484|NCT00253734|Experimental|2|31 subjects to receive 6 mcg of TIV administered intradermally.
3152485|NCT00253734|Experimental|1|31 subjects to receive 9 mcg of TIV administered intradermally.
3152486|NCT00253734|Experimental|3|31 subjects to receive 3 mcg of TIV administered intradermally.
3152487|NCT00253734|Active Comparator|5|31 subjects to receive 9 mcg of TIV administered intramuscularly.
3152488|NCT00253734|Active Comparator|7|31 subjects to receive 3 mcg of TIV administered intramuscularly.
2445160|NCT03821883|Experimental|Aspirin group|Study patients assigned to Aspirin group will receive enteric coated aspirin (100 mg/day).
2445161|NCT03821883|Placebo Comparator|Control group|Study patients assigned to control group will receive placebo.
2445186|NCT03787966|Experimental|ATOPE-B|An adapted therapeutic exercise program performed before medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
2445187|NCT03787966|Active Comparator|ATOPE-I|An adapted therapeutic exercise program performed during medical treatment. 18 bouts of 1'5 hours multimodal components: aerobic, strength and fascial release exercises. Bout frequency will be adapted to the recovery status of each patient (heart rate variability training parameters and patient perception).
3152489|NCT00253734|Active Comparator|6|31 subjects to receive 6 mcg of TIV administered intramuscularly.
2445236|NCT03721120|Experimental|Liquid biopsy|Liquid biopsy will be performed at the first visit using InVisionFirst®. Treatment will be determined by (i) genomic characterization in plasma for patients with druggable alteration in first-line, (ii) after pathology results (including assessment of PD-L1 level of expression by immunohistochemistry) for patients with an informative molecular characterization on plasma and no druggable alteration in first-line and (iii) after pathology results and tissue molecular characterization for the remaining patients.
2445237|NCT03721120|No Intervention|Cytological or histological sampling|During the first visit, cytological or histological sampling will be planned and treatment will be initiated according to European Society of Medical Oncology (ESMO) recommendations; in case of a tissue sample inadequate for genomic characterization, physicians may resort to liquid biopsy according to their usual practice and available technology.
3152490|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
3152491|NCT00253786|Active Comparator|Standard therapy (Protocol A)|Protocol A: serum creatinine <1.2 mg/dl in male and <1.0 mg/dl in female.
3152492|NCT00253786|Experimental|Intensive multifactorial therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
2445339|NCT03536455|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2445341|NCT03536455|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2447012|NCT03261895|Experimental|Intervention group|Nurse-led Integrative health and wellness programme
3152493|NCT00253786|Active Comparator|Standard therapy (Protocol B)|Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
3152494|NCT00253838|Active Comparator|Restoration HA Stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating
3152495|NCT00253838|Sham Comparator|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
3152496|NCT00253877|Active Comparator|Conserve Plus Hip Resurfacing|Conserve Plus Hip Resurfacing group. Complication rate will be compared between groups.
3152497|NCT00253877|Other|Total Hip Replacement|Historical Total Hip Replacement control group of recently published conventional total hip replacement results (Williams, 2002). Complication rate will be compared between groups.
3152498|NCT00253903|Experimental|1|5 mg/day
3152499|NCT00253903|Placebo Comparator|2|
3152500|NCT00253916|No Intervention|Control Arm|No exercise measured
3152501|NCT00253916|Experimental|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
3152502|NCT00253916|Experimental|Resistance Exercise Program|Resistance Exercise Program
3152503|NCT00253955|Experimental|1|
3152504|NCT00253955|Active Comparator|2|
3152505|NCT00253968|Experimental|Eplivanserin|Eplivanserin 5 mg/day
3152506|NCT00253968|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg /day
3152507|NCT00254046|Placebo Comparator|002|Placebo 2 tablets b.i.d.96 weeks
3152508|NCT00254046|Active Comparator|001|TMC125 2 X100 mg tablets b.i.d.96 weeks
3152509|NCT00254176|Active Comparator|Cysteine|Subjects that receive cysteine
3152510|NCT00254176|Placebo Comparator|No-cysteine placebo|Subjects that do not receive cysteine but an isonitrogenous placebo
3152511|NCT00254254|Experimental|Sequence 1|Exenatide 2.5 mcg - Exenatide 5 mcg - Placebo 0.02 mL
3152512|NCT00254254|Experimental|Sequence 2|Exenatide 2.5 mcg - Placebo 0.02 mL - Exenatide 5 mcg
3152513|NCT00254254|Experimental|Sequence 3|Placebo 0.02 mL - Exenatide 2.5 mcg - Exenatide 5 mcg
3152514|NCT00254267|Experimental|Arm One|AMG 706 125mg, oral, once a day
2444701|NCT04435431|Experimental|Mesdopetam dose 1|Mesdopetam capsule (mg), dose 1, 1 capsule b.i.d. for 84 days.
2444703|NCT04435431|Experimental|Mesdopetam dose 2|Mesdopetam capsule (mg), dose 2, 1 capsule b.i.d. for 84 days.
2444707|NCT04435431|Experimental|Mesdopetam dose 3|Mesdopetam capsule (mg), dose 3, 1 capsule b.i.d. for 84 days.
2444708|NCT04435431|Placebo Comparator|Placebo|Placebo capsule, 1 capsule b.i.d. for 84 days
3152515|NCT00254306||1|"ex-ecstasy users"
3152516|NCT00254306||2|control subjects
2444836|NCT04254796|Experimental|TARA Training|
2444837|NCT04254796|No Intervention|Control|
2444863|NCT04179409|Experimental|Casimersen|This arm will involve the treatment of boys with DMD who have a duplication of exon 45, for which casimersen will target skipping of this exon.
2444865|NCT04179409|Experimental|Eteplirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 51, for which eteplirsen will target skipping of this exon.
2444866|NCT04179409|Experimental|Golodirsen|This arm will involve the treatment of boys with DMD who have a duplication of exon 53, for which golodirsen will target skipping of this exon.
2444971|NCT04024917|Experimental|Coherence cardiac|
2444975|NCT04024917|Active Comparator|Standard care|
2445002|NCT03948048||septic shock|The critically ill children with septic shock (ss group)
2445005|NCT03948048||refractory septic shock with ECMO|The critically ill children with refractory septic shock with ECMO treatment
2445008|NCT03948048||refractory septic shock without ECMO|The critically ill children prediction model th refractory septic shock without ECMO treatment
3152517|NCT00254384|Experimental|Treatment (docetaxel, cisplatin, erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Beginning within 90 days following definitive surgical resection, patients receive erlotinib hydrochloride PO daily for up to 1 year.
3152518|NCT00254423|Experimental|Arm A (once daily dasatinib)|Patients receive dasatinib PO QD for up to 15-18 years.
3152519|NCT00254423|Experimental|Arm B (twice daily dasatinib)|Patients receive dasatinib PO BID for up to 15-18 years.
3152520|NCT00254436|Experimental|Epoetin Alfa|
3152521|NCT00254553|Active Comparator|Arm 1|Testim 1% (testosterone gel)
2445105|NCT03902509|Experimental|Pirfenidone|pirfenidone + basic treatment
2445106|NCT03902509|Other|Controll|with basic treatment and without pirfenidone treatment
2445126|NCT03862066||Received Nivolumab|
2445128|NCT03862066||Nivolumab Naive|
2445182|NCT03800017|Experimental|Hyperoxia|During exercise on visit 4, participants in both groups (i.e., ILD patients and controls) will breathe supplemental oxygen (i.e., 60% oxygen) during constant-load exercise.
2445183|NCT03800017|Placebo Comparator|Healthy Controls|During exercise on visit 3, participants in both groups (i.e., ILD patients and controls) will breathe ambient air (i.e., 20.93% oxygen) during constant-load exercise.
3152522|NCT00254553|Placebo Comparator|Arm 2|Placebo
3152523|NCT00254579|Experimental|15 mg/kg CP-675,206|
2445470|NCT03339505|Active Comparator|Treatment group|Patients in treatment group will receive Salovum according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
2445471|NCT03339505|Placebo Comparator|Placebo group|Patients in treatment group will receive Placebo (egg yolk powder) according to g/kg body weight/24 hours/divided into 6 doses, during a maximum of 5 days
2445525|NCT03272555|Other|Study Participants|The participants in this arm will engage in the WILD 5 Wellness activities combining five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition.
2445557|NCT03272295|Experimental|Arm A|Reference product (product 1) x 2, Single ingredients products 2, 3, 4, 5, 6 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
2445614|NCT03271905|Experimental|Pressure-controled-ventilation (PCV)|Nebulization during mechanical ventilation on a pressure controled ventilation mode.
3152524|NCT00254618|Experimental|30 mg|30 mg/kg/day mesalamine
3152525|NCT00254618|Experimental|60 mg|60 mg/kg/day mesalamine
3152526|NCT00254618|Experimental|90 mg|90 mg/kg/day mesalamine
3152527|NCT00254631|Active Comparator|study group|pre operative medication with 20 mg oxycontine PO
3152528|NCT00254631|Placebo Comparator|placebo group|pre operative medication with placebo tablet PO
3152529|NCT00254644||Dyslexia|adults from 18-35 ans.
3152530|NCT00254644||Control|adults from 18-35 ans.
3152531|NCT00254657|Placebo Comparator|Placebo|
3152532|NCT00254657|Experimental|Levetiracetam|
3152533|NCT00254683|Experimental|PET/CT|Single arm study evaluating the use of PET/CT to assess rectal cancer response to neoadjuvant therapy
3152534|NCT00254722|Experimental|I|single arm study
3152535|NCT00254748|Placebo Comparator|1|Placebo
3152536|NCT00254748|Experimental|2|Flexible doses of 200 mg/day to 600 mg/day quetiapine fumarate
3152537|NCT00254761|Experimental|1|High dose cannabis (7.5% THC by weight)
2444546|NCT04591925|Active Comparator|Commercially available Insulin Infusion device using a soft Teflon indwelling cannula|Participants are randomized into the Commercially available insulin infusion set (using a soft Teflon indwelling cannula) group and then switched to Investigative Device infusion set (SteadiSet™) group. At the Day of Insertion (Day 0) clinic visit, study participants will insert (under supervision) the Control infusion set. Upon completion of a wear period (after 14 days or sooner, in the event that infusion set change out has occurred), participants will be asked to insert a new set at home and thus start the next 14-day wear period. After two periods participants will return to the study site to cross over into the last two periods with the Investigational Device infusion set. A total of four infusion sets will be studied in each participant, two Investigational Device infusion sets and two commercially available Teflon infusion sets.
3152538|NCT00254761|Experimental|2|Low dose cannabis (3.5% THC by weight)
3152539|NCT00254761|Placebo Comparator|3|Placebo cannabis
3152540|NCT00254800|Experimental|Sequence 1|Oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide/oral contraceptive alone
3152541|NCT00254800|Experimental|Sequence 2|Oral contraceptive 30 minutes after exenatide/oral contraceptive alone/oral contraceptive 1 hour prior to exenatide
3152542|NCT00254800|Experimental|Sequence 3|Oral contraceptive alone/oral contraceptive 1 hour prior to exenatide/oral contraceptive 30 minutes after exenatide
3152543|NCT00254826|Other|YF-VAX® plus saline|Drug: YF-VAX® plus saline
3152544|NCT00254826|Experimental|17D YF Vaccine plus Ig|Drug: 17D YF Vaccine plus Ig; one vaccine on day 0
3152545|NCT00254852|Active Comparator|O|This treatment arm includes autograft harvested from local bone and / or the iliac crest, supplemented with a demineralized bone matrix (DBM) autograft extender, Optecure.
3152546|NCT00254852|Active Comparator|A|This treatment arm includes autograft harvested from local bone and / or the iliac crest.
3152547|NCT00254891|Experimental|A|Standard of care chemotherapy plus experiment intervention (PF-3512676)
3152548|NCT00254891|Active Comparator|B|Standard of care chemotherapy
3152549|NCT00254904|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
2444861|NCT04179032|Experimental|Participants receiving belimumab 200 mg|In Part A, participants will receive 200mg/ml belimumab via auto-injector for 12 weeks. Frequency of administration will be based on body weight. Participants who weigh >=50 kilogram (kg) at Baseline will be assigned to Cohort 1 and receive 200 mg/mL belimumab QW SC. Participants who weigh >=30 kg and <50 kg at Baseline will be assigned to Cohort 2 and receive 200 mg/mL belimumab Q10d SC. Participants who weigh <30 kg at Baseline will be assigned to Cohort 3 and receive 200 mg/mL belimumab Q2W SC. In Part B (optional), dosing of SC belimumab will continue at the same frequency or may require a change in frequency according to changes in participant's body weight for 40 weeks.
3152550|NCT00254904|Active Comparator|B|Standard of Care chemotherapy
3152551|NCT00254917|Experimental|1|Concommitant recombinant hepatitis B vaccine at 0, 6 and 14 weeks of age
3152552|NCT00254917|Experimental|2|Concommitant recombinant hepatitis B vaccine at 6, 10, and 14 weeks of age.
3152553|NCT00254969|Experimental|1|
3152554|NCT00255021|Experimental|1|
3152555|NCT00255099|Active Comparator|001|TMC125 2 x 100 mg tablets b.i.d. / 96 weeks
3152556|NCT00255099|Placebo Comparator|002|Placebo 2 tablets b.i.d. / 96 weeks
2445248|NCT03680846|Other|CMM|Conventional Medical Management
2445249|NCT03680846|Active Comparator|HF10 + CMM|Addition of HF10 therapy to CMM
2445280|NCT03619902|Experimental|ANB019 Biological/Vaccine|ANB019 subcutaneous (SC) injection every 4 weeks
3152557|NCT00255112|No Intervention|1|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel. The study consists of 40 participants (5-7 years old) with SAD and their families. Participants were randomly assigned to 12 weeks of SAD-specific family-based CBT treatment or to waitlist condition.
3152558|NCT00255112|Active Comparator|2|The present study evaluates the efficacy of a family-based CBT treatment specifically tailored to children with SAD, developed at the University of Basel in comparison to a global CBT treatment. The study consists of 60 participants (between 8 and 13 years old), randomly assigned to one of the two treatments.
3152559|NCT00255229|Active Comparator|1|Irinotecan, 5FU, Glutamine
2445324|NCT03545477|Experimental|Novel treatment, curved-walking training|It consists of 20 sessions of training (three times a week for seven weeks) composed by standard physical therapy and a novel approach to locomotion rehabilitation based on curved-walking training. Each session lasts about 90 minutes.
2445325|NCT03545477|Active Comparator|Usual care|It consists of 20 sessions of training (three times a week for seven weeks) of standard physical therapy and conventional straight-walking training. Each session lasts about 90 minutes.
3152560|NCT00255229|Placebo Comparator|2|Irinotecan, 5FU, Placebo
3152561|NCT00255372|Experimental|1|
3152562|NCT00255372|Active Comparator|2|
2445539|NCT03272230|Experimental|bvFTD|"Initially especially patients diagnosed with behavioral variant frontotemporal dementia (bvFTD) according to the Rascovsky criteria (Rascovsky et al. 2011).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
3152563|NCT00255515|Experimental|1|quetiapine fumarate
3152564|NCT00255515|Active Comparator|2|Conventional treatment for schizophrenia
3152565|NCT00255515|Experimental|3|quetiapine fumarate + Cognitive Remediation Therapy
3152566|NCT00255567|Active Comparator|1|Sodium Stibogluconate (30 days)
3152567|NCT00255567|Experimental|2|Paromomycin Sulphate (21 days)
3152568|NCT00255567|Experimental|3|Sodium Stibogluconate + Paromomycin Sulphate (17 days)
3152569|NCT00255580|Experimental|1|Active cannabis (1-8% THC by weight)
3152570|NCT00255580|Placebo Comparator|2|Placebo cannabis
3152571|NCT00255606|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1 and 15 and oral prednisone once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3152572|NCT00255606|Experimental|Arm II|Patients receive docetaxel IV over 1 hour on day 1 and prednisone once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2444577|NCT04549493|Active Comparator|Compressed Prolonged Exposure|3. Compressed PE consists of 10 standard PE sessions delivered on consecutive work days. The imaginal exposure sessions take place in the morning, with in vivo exposures assigned (not therapist accompanied) for the afternoons. Patients are instructed to listen to the recordings of the imaginal exposure each night. Being most concerned with having enough time for in vivo practice, Session 1 does not start on a Monday, allowing for two full weekends in order to maximize in vivo exposures. Both versions of PE average 36 total treatment hours.
3152573|NCT00255658|Experimental|Treatment (sorafenib tosylate, temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. They also receive oral sorafenib* twice daily starting on day 8 of course 1. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *On the days of the temsirolimus infusion, temsirolimus should be taken concurrently with the morning dose of sorafenib.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
2445415|NCT03417674|Experimental|Intervention group|Lifestyle intervention with meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
2445416|NCT03417674|No Intervention|Control group|Routine care.
3152574|NCT00255749|Experimental|early intervention epoietin alfa|Patients receive epoetin alfa subcutaneously on day 1. Treatment repeats every 21 days for up to 5 courses.
2445475|NCT03272685|Experimental|Very Low Nicotine Content Cigarettes|Very low nicotine content cigarettes (0.4 mg/g nicotine; 9 mg of tar)
2445478|NCT03272685|Active Comparator|Normal Nicotine Content Cigarettes|Normal (Conventional) Nicotine Content (15.8 mg/g nicotine; 9 mg of tar)
2445501|NCT03272516|Active Comparator|Control group|This group receives treatment as usual (TAU) from his/hers physician. This treatment is different for each physician, but mainly consists of cognitive therapy, personal interviews or antidepressants or anxiolytics.
2445507|NCT03272516|Experimental|Intervention group|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol..
2445552|NCT03272321|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2445554|NCT03272321|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
2445611|NCT03271944|Other|Single group 30 post menopause females.|
2445641|NCT03271606|Experimental|ERAS group|The patients in this group receive enhanced measures perioperatively
2445644|NCT03271606|Active Comparator|Traditional group|The patients in this group receive traditional measures perioperatively
3152575|NCT00255749|Other|standard intervention epoietin alfa|Patients receive epoetin alfa as in arm I once their hemoglobin level is ≤ 10.5 g/dL.
3152576|NCT00255762|Experimental|Treatment (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin IV over 30 minutes on day 1, paclitaxel IV over 1 hour on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2445808|NCT03270696|Experimental|simultaneous administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) and rocuronium (0.6mg/kg) simultaneously, and start facemask ventilation after patient loss consciousness to induce general anesthesia.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
2445809|NCT03270696|Experimental|ordinal administration of propofol and rocuronium|"In this group, the investigator will administrate propofol (2ml/kg) first, and follow injection of rocuronium (0.6mg/kg) after patient loss consciousness and confirming facemask ventilation.~The investigator will measure the mean tidal volume (TV) applied during facemask ventilation for 1 minute."
2445858|NCT03270358|Experimental|patient with stenosis|Patient coming to the vascular surgery unit to receive surgery regarding their fistula stenosis
2445860|NCT03270358|Other|patient without stenosis|Patient coming for their dialysis
2445889|NCT03269903|Experimental|Patients|Patients with malignant dysphagia treated with the HILZO stent
2445947|NCT03269617|Placebo Comparator|Placebo Comparator|Placebo control: 1 capsule containing rice maltodextrin consumed 1x daily for 28 days.
2445952|NCT03269617|Experimental|Experimental|Bacteriophage mixture: 1 capsule containing rice maltodextrin and a mixture of 4 bacteriophages consumed 1x daily for 28 days.
2446003|NCT03269175|Other|Experimental arm 15 years ago|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
2446006|NCT03269175|Other|Placebo arm, offered treatment at MS diagnosis or at Month 24|This long term study does not imply current study medication. It looks at the status 15 years after the clinicial trial (BENEFIT)
2446103|NCT03268512|Experimental|L-PRF|One socket will be filled with L-PRF membranes and covered with at least 2 L-PRF membranes. A modified horizontal mattress will be place as suture to keep the L-PRF in place.
2446134|NCT03268213|Experimental|Fecal microbial transplantation|Treated with fecal microbial transplantation
3152577|NCT00255788|Active Comparator|Arm A|Everolimus - 28 days q 4 wk
3152578|NCT00255788|Active Comparator|Arm B|Everolimus - days 1, 8, 15 and 22 q 4wks
3152579|NCT00255814|Other|Radiation therapy dose level II: 4.0 Gy/fx|Radiation therapy dose level II: 4.0 Gy/fraction
3152580|NCT00255814|Other|Radiation therapy dose level III: 4.5 Gy/fx|Radiation therapy dose level III: 4.5 Gy/fraction
3152581|NCT00255814|Other|Radiation therapy dose level IV: 5.0 Gy/fx|Radiation therapy dose level IV: 5.0 Gy/fraction
3152582|NCT00255892||Part A - Provider Interviews|The provider interviews will be comprised of participants who are clinical providers, mental health providers, and case managers with at least 1 year of experience working with HIV-positive youth; one from each category from all 15 ATN sites will be targeted for a total of 45 participants.
3152583|NCT00255892||Part B - Youth Focus Groups|"The focus groups will be comprised of 6-8 participants per group who are between the ages of 16 and 24, diagnosed HIV+ and aware of their HIV diagnosis for between 12-24 months, and receive services at three selected ATN sites or their community partners for a total of 36-48 participants.~For the purposes of this study, youth who acquired HIV perinatally will be excluded from participation in this study."
2444718|NCT04415996|Experimental|HVLA L3/4 Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform the HVLA technique in L3/L4 joint articulation.~Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
2444720|NCT04415996|Sham Comparator|Control Group|"In each participant, blind assessors will perform pre-intervention measurements of dislocation of center of pressure (CoP), plantar pressure mean and plantar contact area in a baropodometric pressure platform.~Next, the investigator will perform a Sham technique. Then, the same measurements before described will be repeated, by the assessors 1 minute after the intervention."
3152584|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 75 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 75 mg)
3152585|NCT00255918|Placebo Comparator|Placebo|Participants will take placebo.
3152586|NCT00255918|Experimental|Dimethoxybenzylidene anabaseine 150 mg|Participants will take active experimental medication (Dimethoxybenzylidene anabaseine (DMXB-A) 150 mg)
3152587|NCT00255931|Experimental|1|
3152588|NCT00255931|Placebo Comparator|2|
3152589|NCT00255931|No Intervention|3|Usual Care
3152590|NCT00255983|Experimental|1|faropenem medoxomil
3152591|NCT00255983|Placebo Comparator|2|
3152592|NCT00256022|Active Comparator|Lactobacillus Acidophilus Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
2445246|NCT03691519|Placebo Comparator|Placebo|"During the 18 months placebo-controlled period, participants will ask to consume 3 identical 1g vegetarian control capsules (containing a 1:1 ratio of corn oil and soy oil) per day. During the following 18-month open-label extension period, placebo subjects are switched to active treatment.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment"
2445247|NCT03691519|Experimental|Omega-3 treatment|During the entire length of the study (that is, both the placebo-controlled and open-label extension periods), participants in the intervention (Omega-3 treatment) arm will ask to consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).
2445304|NCT03581513|Experimental|IMR<40 and defer PCI|Patients whose IMR<40 undergo stent implantation after an interval of 7±2 days.
2445307|NCT03581513|Active Comparator|IMR<40 and immediately PCI|Patients whose IMR<40 undergo immediately stent implantation.
2445309|NCT03581513|Experimental|IMR≥40 and defer PCI|Patients whose IMR≥40 undergo stent implantation after an interval of 7±2 days.
2445310|NCT03581513|Active Comparator|IMR≥40 and immediately PCI|Patients whose IMR≥40 undergo immediately stent implantation.
2445348|NCT03536429|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2445464|NCT03383874|Placebo Comparator|Placebo|Participants will receive capsules containing placebo for 24-weeks.
3152593|NCT00256022|Active Comparator|Lactobacillus Fermentum Arm|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3152594|NCT00256022|Active Comparator|Lactobacillus Fermentum and Lactobacillus Acidophilus|The probiotic will be given to the patient 2 a dy for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3152595|NCT00256022|Placebo Comparator|Placebo|The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
3152596|NCT00256035|Other|Unstable coronary artery disease|Patients with unstable coronary artery disease will have daily IL6 levels
3152597|NCT00256035|Other|Coronary Angioplasty Patients|Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
3152598|NCT00256035|Other|Coronary bypass grafts patients|Patients will have levels collected immediately after and 24 hours post procedure
3152599|NCT00256035|Other|Stable coronary Artery Diseaese Patients|Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
3152600|NCT00256048|No Intervention|Standard Care|Patients will receive enteral nutrition via a nasogastric tube as per standard feeding regime
2444883|NCT04149899|Experimental|Study Treatment 1|WB007 Formulation 1
2444885|NCT04149899|Experimental|Study Treatment 2|WB007 Formulation 2
2444886|NCT04149899|Experimental|Study Treatment 3|WB007 Formulation 3
2444887|NCT04149899|Active Comparator|Timolol 0.5%|Timolol maleate ophthalmic solution, 0.5%
2444922|NCT04098445||Pediatric and young adult HSCT recipients|Prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT).
2444964|NCT04046263|Experimental|Intervention|Open-label, one arm study. Patients receive sucroferric oxyhydroxide three times daily and dose is titrated to keep serum phosphate at goal.
2444999|NCT03981731|Experimental|Cardiac coherence|
2445030|NCT03923686|Experimental|LAMS plus DPS|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
2445031|NCT03923686|Active Comparator|LAMS alone|Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
3152601|NCT00256048|Active Comparator|Nasojejunal Arm|Patient will receive feeding via a nasojejunal feeding tube
3152602|NCT00256074|Other|Standard Therapy Group|Standard therapy group. Will receive high carbohydrate, low fat enteral feeding, (16.7% protein, 30% fat and 53.3% carbohydrate). The target rate is determined by the treating physician and dietician, for a minimum of 5 days following randomisation.
3152603|NCT00256074|Other|Alternative Therapy Group|2.Alternative therapy group will receive high-fat, low carbohydrate enteral feeding, (16.7% protein, 55.2% fat and 28.1% carbohydrates. At a target rate determined by the treating physician and dietician, for a maximum of 5 days following randomisation.
3152604|NCT00256087|Placebo Comparator|Standard Care|Two capsules containing placebo will be given 12 hourly
3152605|NCT00256087|Active Comparator|First active treatment|Two capsules containing probiotic lactobacillus fermentin given 12 hourly
3152606|NCT00256087|Active Comparator|Second active reatment|Two capsules containing probiotic lactobacillus acidiphilus given 12 hourly
3152607|NCT00256100|Active Comparator|One|Enoxaparin Sodium (Clexane ) is to be used in the control arm of the study
2445459|NCT03365882|Experimental|Arm I (pertuzumab, trastuzumab)|Patients receive pertuzumab IV over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2445462|NCT03365882|Experimental|Arm II (cetuximab, irinotecan hydrochloride)|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I.
2446127|NCT03268226|Experimental|CHF5993|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
2446171|NCT03267875|Experimental|single arm|Patients after aneurysm in the aorta, Men and women aged 18-100 (not including special populations), who are able to read understand and sign a written consent to participate in the research
2446286|NCT03266913|Active Comparator|Probiotic|Routine phototherapy plus probiotic oral drops at the dose of 10 drops daily
2446292|NCT03266913|No Intervention|No probiotic|Routine phototherapy
2446305|NCT03266692|Experimental|ACTR087 in combination with SEA-BCMA|
2446401|NCT03266055|Experimental|Blueberry powder|
2446402|NCT03266055|Placebo Comparator|Blueberry placebo powder|
2446420|NCT03265743||Patients with Cystic Fibrosis|Patients with Cystic Fibrosis, followed in a pediatric or mixed Cystic Fibrosis center of the region Auvergne Rhône Alpes (AuRA), aged 11 years or older.
2446459|NCT03265587||Orientation 1|Nursing staff allocated to a bed space with orientation 1
2446470|NCT03265587||Orientation 2|Nursing staff allocated to a bed space with orientation 2
2446473|NCT03265587||Floater / Control group|Nursing staff not allocated to a bed space with an orientation.
2446542|NCT03265223|No Intervention|Controls|Received 1 ml/cm normal saline (23 ml) both at intraperitoneal (=20 ml) as well as intraincisional (=3 ml) location.
2446548|NCT03265223|Active Comparator|Intraperitoneal group|Received 20 ml of 0.2% ropivacaine intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml normal saline (1ml/cm of port site incision length)
2446555|NCT03265223|Active Comparator|Intraincisional group|Received 20 ml of normal saline intraperitoneally (1 ml/cm; 16 ml along right hemi-dome, approximately equal to length of right hemi-dome of diaphragm in an average adult and 4 ml in gall bladder fossa) and 3 ml 0.2% ropivacaine (1ml/cm of port site incision length)
3152608|NCT00256100|Active Comparator|Two|Fondaparinux will be used as the anticoagulant in the sencond arm of the study
3152609|NCT00256152|No Intervention|AF Suppression OFF|
3152610|NCT00256152|Experimental|AF Suppression ON|
3152611|NCT00256178|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
3152612|NCT00256178|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
3152613|NCT00256178|Active Comparator|Simvastatin|
3152614|NCT00256230|Experimental|Disulfiram|
3152615|NCT00256269|Experimental|Oxaliplatin plus Irinotecan|Drug: Oxaliplatin-40 mg/m2 IV over 60 minutes Every 21 days. Drug: Irinotecan-60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days.
2444659|NCT04495452||Study Participants|"We will be enrolling 200 participants, this will provide a large enough sampling to assure there are at least 25 patients with significant respiratory depression and 25 with insignificant respiratory depression.~The genetic data from participants with the most respiratory depression defined as having a 20-40% decrease from initial respiratory parameters will be compared with genetic data from participants with the least respiratory depression defined as having no change or less than 10% decrease from initial respiratory parameters."
2444682|NCT04443504|Experimental|Intervention Group|
2444685|NCT04443504|No Intervention|Waitlist Group|The waitlist group will receive the intervention 3 months after the intervention group.
3152616|NCT00256321|Experimental|Celecoxib/Oxaliplatin/Capecitabine|"Oxaliplatin 70mg/m2 IV on Days 1 and 8. Capecitabine 1000mg/m2 PO BID from Days 1 through 14. Celecoxib 400mg PO BID from Days 1 through 21.~1 Cycle = 21 days."
3152617|NCT00256334|Experimental|Resveratrol|GM-CSF administration to all subjects in addition to chemotherapy treatment.
3152618|NCT00256412|Placebo Comparator|1|
3152619|NCT00256412|Active Comparator|2|Low Dose
3152620|NCT00256412|Active Comparator|3|High Dose
3152621|NCT00256503|Experimental|Insomnia|Insomnia subjects who receive 8 session cognitive behavioral therapy for insomnia.
3152622|NCT00256503|No Intervention|Good Sleeper|Good sleeper controls who receive no intervention
3152623|NCT00256516|Experimental|Eco-Atkins diet|
2445193|NCT03783689|Active Comparator|Group 1 (Treatment)|Subjects in Group 1 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
2445196|NCT03783689|Sham Comparator|Group 2 (Control)|Subjects in Group 2 will have Leads placed in the residual limb in the upper leg. These subjects will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Subjects will then have the option to crossover and receive stimulation therapy.
2445218|NCT03761394|Experimental|Intervention Group|Testing devices plus Cardea Solo device by Cardiac Insight for 14-day period.
2445219|NCT03761394|Active Comparator|Control Group|Only Cardea Solo device by Cardiac Insight for 14-day period.
2445220|NCT03761394|Experimental|Intervention Group for Extended Use|30-additional days of extended use of testing devices for adherence plus Kardia Mobile ECG device by AliveCor.
2445221|NCT03761394|No Intervention|Control Group for Extended Use|No device usage for 30-days following completion of the original 14-day period.
2445243|NCT03692325|Experimental|Nivolumab|"Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle~Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent"
2445269|NCT03644160|Experimental|Intervention Group|Physical activity and behaviour change The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity with a physiotherapist who has training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
2445272|NCT03644160|No Intervention|Control Group|The control group (Group B) will receive the same information booklet about physical activity only. This group will continue with their routine care for their condition throughout the study period.
2445288|NCT03610646|Experimental|MYL-1701P|MYL-1701P
2445289|NCT03610646|Active Comparator|Eylea|Eylea
2445335|NCT03536520|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
2445337|NCT03536520|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
3152624|NCT00256516|Active Comparator|NCEP diet|
3152625|NCT00256529||I|All subjects presenting in with dysphagia will be in this cohort.
3152626|NCT00256568||Primary Care Practices|One hundred and three prescribers, managers, nurses and office staff at seven primary care practices in Vermont
3152627|NCT00256607||coronary artery calcium (CAC)|Cohort from the VADT study, had baseline coronary atherosclerosis assessed by coronary artery calcium (CAC) measured by computed tomography. Participants were followed over the 7.5-year study for development of cardiovascular endpoints.
3152628|NCT00256633||Group 1|enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2.
2445571|NCT03272334|Experimental|Schedule #1|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 1 infusion of Pembrolizumab in week #7. No interventions within weeks #3 and 4.
2445574|NCT03272334|Experimental|Schedule #2|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 2 infusions of Pembrolizumab; the first given within weeks #3 - 4 and the second in week #7.
2445575|NCT03272334|Experimental|Schedule #3|At approximately 4 weeks following leukapheresis, 8 infusions of HER2 BATs are given twice weekly in weeks #1, #2, #5, and #6 plus 3 infusions of pembrolizumab; the first given one week prior to first BATs infusion, the second is given within weeks #3 - 4, and the third at week #7.
2445697|NCT03271450||Discontinuer at 90 Days: Warfarin|
2445700|NCT03271450||Discontinuer at 180 Days: Warfarin|
3152629|NCT00256646||Group 1|"Patients who are enrolled in the ongoing randomized clinical trial AGlycemic Control and Complications in Diabetes Mellitus Type 2."
3152630|NCT00256672|Active Comparator|1|High-dose Thoraco-Lumbar-Sacral Orthoses wear (>23hrs/day) will be compared to low-dose Thoraco-Lumbar-Sacral Orthoses wear (12hrs/day)
3152631|NCT00256672|Active Comparator|2|Low-dose Thoraco-Lumbar-Sacral-Orthoses wear (12hrs/day)
3152632|NCT00256932|Placebo Comparator|Placebo|
3152633|NCT00256932|Experimental|Alvimopan 0.5 mg once daily|
3152634|NCT00256932|Experimental|alvimopan 0.5 mg twice daily|
3208921|NCT00979368|Active Comparator|BMS-816336 or placebo (Panel 5)|
2444709|NCT04419818||Left brain damaged patients|"A group of 20 left brain damaged (LBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
2444710|NCT04419818||Right brain damaged patients|"A group of 20 right brain damaged (RBD) patients will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination and Token Test) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
2444713|NCT04419818||Healthy controls|"A group of 40 (20 young and 20 elderly) healthy controls (HC) will perform:~a computerized test battery to measure time abilities (Mental Time Travel, Time Estimation and Time Reproduction);~a neuropsychological screening (Mini Mental State Examination) to assess inclusion/exclusion criteria;~questionnaires to evaluate the time needed to execute actions and the ability to locate daily activities in time."
2444755|NCT04377451|No Intervention|Control arm|The control group will be formed of 60 overweight or obese dengue patients receiving standard of care
2444757|NCT04377451|Experimental|Intervention arm|Two cohorts receive a 5-day course of metformin treatment. In the initial phase (cohort 1), 5 young adults and 5 children (age <16) will receive a low dose of metformin. In the second phase (cohort 2), 25 adult and 25 paediatric patients will receive a weight-based dose of metformin.
2444777|NCT04330950||Surgical Cohort|Preoperative: Battery of neurocognitive tests and questionnaires (MoCA, PHQ-9, Falls History, FIFE, STOPBANG, Nutritional Survey) Postoperative in PACU: NuDESC test Postoperative 30 days: 10 minute phone interview
3152635|NCT00257127|Experimental|1|Patients will receive PCV, HBV, and MMR at study entry
3152636|NCT00257127|Experimental|2|Patients will receive PPV, HBV, and MMR at study entry
3152637|NCT00257205|Active Comparator|B|Choice of one or the other Dacarbazine or Temozolomide(CP-675,206) (choice)
3152638|NCT00257205|Experimental|A|
2445321|NCT03551938|No Intervention|Control|Receive only the standard HIV Counseling, Testing, and Referral or Couples HIV Testing and Counseling (CHTC) Session.
2445322|NCT03551938|Experimental|Intervention|Receive one 45-minute Relationship skills session for YMSM individuals and couples (the intervention) as an addition to the standard HIV Counseling, Testing, and Referral (CTR) or Couples HIV Testing and Counseling (CHTC) Session.
2445354|NCT03535675|Experimental|Muscadine Plus|Each treatment cycle consists of once daily oral dosing of 4000 mg Muscadine Plus, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of study drug and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
2445355|NCT03535675|Experimental|Placebo|Each treatment cycle consists of once daily oral dosing of 4000 mg placebos, every day throughout each 12 week (84 day) cycle. Patients may continue to receive additional cycles of placebo and will be followed every three months with standard visits with their physician until completion of 48 weeks of study treatment, disease progression, or until they wish to discontinue the drug.
2445520|NCT03272451|Experimental|culprit vessel intervention|culprit vessel PCI prior to contralateral angiography using a single transradial guiding catheter
2445523|NCT03272451|Active Comparator|traditional approach|complete coronary angiography followed by guiding catheter selection for culprit vessel PCI
2445576|NCT03272074|Experimental|Egg Group (Group A)|Participants will consume one large egg per day for 12 weeks
2445577|NCT03272074|Active Comparator|Egg White Group (Group B)|Participants will consume equivalent amounts of egg whites for 12 weeks
2445630|NCT03271788|Experimental|stroke patients and caregivers|Stroke patients will conduct two phases ( A-Phase: regular occupational therapy; B-Phase occupational therapy with additional mindfulness) Caregivers of the patients will conduct the MBSR Course (Mindfulness) together with their relatives (Phase B). In Phase A they will not receive any treatment.
2445656|NCT03271476|Experimental|Arms|Experimental: EMDR psychotherapy All the women will be in this arm and thus will receive the same intervention which is : 8 sessions (1 per week). The first session is an inclusion visit at Metz-Thionville Hospital, then 6 EMDR psychotherapy sessions and finally a last visit one month after for data recovery (questionnaire and semi-directive interview)
2445715|NCT03271333||patients with systemic sclerosis|
2445821|NCT03270566|No Intervention|Usual hard water supply|The control group will receive their usual domestic water supply.
3152639|NCT00257296|Experimental|Screening and Intervention|Use a computer-based screening tool for intimate partner violence and provide a multi-faceted intervention based on the needs of the woman and services should would like to utilize.
3152640|NCT00257296|Active Comparator|Usual Care|Use a computer-based screening tool for intimate partner violence and provide list of resources available. Also, all physicians were trained on intimate partner violence and were told they could help anyone regardless of randomization.
3152641|NCT00257400|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
3152642|NCT00257400|Active Comparator|Individual Psychotherapy|Individual Psychotherapy
3152643|NCT00257439||CKD|Elevated se-creatinine + proteinuria
3152644|NCT00257439||Healthy controls|Healthy controls, normal se-creatinine, no proteinuria
3152645|NCT00257465|Experimental|A|'Autologous, DNP-modified vaccine (M-Vax)'
3152646|NCT00257465|Experimental|B|Autologous, DNP-Modified Vaccine (MVax)
3152647|NCT00257465|Experimental|C|Autologous, DNP-Modified Vaccine (MVax)
3152648|NCT00257465|Placebo Comparator|D|0 cells
3152649|NCT00257543|Experimental|single arm study|this is a single arm study
3152650|NCT00257673|Experimental|A|Active 30 mg MEM 1003
3152651|NCT00257673|Experimental|B|90 mg MEM 1003
3152652|NCT00257673|Placebo Comparator|C|Placebo for MEM 1003
3152653|NCT00257699|Placebo Comparator|I|Ciprofloxacin placebo and Metronidazole placebo
3152654|NCT00257699|Experimental|II|Ciprofloxacin 500 mg bid po Metronidazole - total daily dose dependent on body weight
3152655|NCT00257712|Experimental|1|
3152656|NCT00257712|Placebo Comparator|2|
2444742|NCT04399993|Sham Comparator|Sham Technique|"In each volunteer, after a brief questionnaire, it will be measured the center of gravity and the range of movement of the lumbar spine before the technique.~Each volunteer will stay in supine position with arms along their body, in which their legs may be either extended or flexed.~Next, the researcher will perform the Sham technique. Then, all the measurements described before, will be repeated by the assessor right after the technique."
3152657|NCT00257738|Experimental|MAGE -A3 vaccine|for those individuals in which tumor tests positive for MAGE-A3
2444806|NCT04304651|Active Comparator|Limited cancer screening|Limited screening alone.
2444807|NCT04304651|Experimental|Limited cancer screening + FDG PET/CT|Limited screening + FDG PET/CT
3152658|NCT00257738|Experimental|HPV 16 vaccine|for patients with HPV 16 positive tumor
3152659|NCT00257803|Experimental|1|In the other group, the women will receive a small injection of oxytocin directly into the vein via their intravenous (bolus) after their baby is born.
2445127|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
2445129|NCT03877276|Experimental|5d Diet+Spinach Smoothie+Breakfast|5 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie and be provided a breakfast meal.
2445130|NCT03877276|Experimental|3d Diet+Kale Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On the final day, participants will return to the study site and drink a prepared kale smoothie and be provided a breakfast meal.
2445131|NCT03877276|Experimental|3d Diet+V Spinach Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended spinach smoothie with varying amounts of spinach and be provided a breakfast meal.
2445132|NCT03877276|Experimental|3d Diet+Blended Smoothie+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared blended smoothie and be provided a breakfast meal.
2445133|NCT03877276|Experimental|3d Diet+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and be provided a breakfast meal.
2445134|NCT03877276|Experimental|3d Diet+Sodium Oxalate Drink+Breakfast|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a prepared sodium oxalate drink and be provided a breakfast meal.
2445136|NCT03877276|Experimental|3d Diet+Spinach Smoothie+Breakfast w/ 24 Hr Urine|3 days of prepared meals with fasting on the final day. On final day, participants will return to the study site and drink a blended spinach smoothie and be provided a breakfast meal.
3152660|NCT00257803|Placebo Comparator|2|In one group, women will receive a small injection of saline (salt water) directly into the vein via their intravenous (bolus) after their baby is born.
3152661|NCT00257816|Experimental|Topotecan|Adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation.
3152662|NCT00258050|Experimental|Subjects with cancer|"In Part 1 of the study, subjects will be randomized to one of four sequences. All subjects will receive oral or intravenous (IV) midazolam on Days 1, 3, 9 and 11 as per assigned randomization scheme. Starting on Day 4 through Day 11, subjects will receive a daily dose of 1500 milligrams (mg) of oral lapatinib.~In Part 2, which will begin on Day 12, the subjects will be required to take 1500 mg of lapatinib daily until removed from the study for disease progression, adverse events, withdrawal of consent, or transfer to another lapatinib study."
2446282|NCT03266965|Experimental|Histidine Intervention Group|A total of 15 subjects will be recruited in batches of 5 until completed 15 subjects in the trial. If a subject withdraws the trial, the study will continue and enrolling subjects until 15 of them complete the trial. The subject composition (MS patient/Normal subject) 4 MS and 1 normal will be tested on a dose of L-Histidine 250 mg plus Lodosyn 50 mg BID for seven days. If there are no safety concerns, the next 5 patients will be recruited 4 MS and 1 normal to test the dose of 500 mg with Lodosyn 50 mg bid for seven days. If there are no safety concerns, then L-histidine 1,000 mg plus Lodosyn (Carbidopa) 50 mg bid will be tested in the next 5 subjects 4 MS and 1 normal for seven days.
3152663|NCT00258076|Experimental|001|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE
3152664|NCT00258115|Active Comparator|salsalate|4.0 g/d divided dosing
3152665|NCT00258115|Placebo Comparator|placebo|placebo for salsalate
3152666|NCT00258245|Experimental|Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day
3152667|NCT00258284|Experimental|Docetaxel & Capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
3152668|NCT00258388|Active Comparator|OGX011, Docetaxel and Prednisone|
3152669|NCT00258388|Active Comparator|Docetaxel plus prednisone|
3152670|NCT00258401|Active Comparator|low-residue diet|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.Patients are interviewed weekly for up to six weeks.
3152671|NCT00258401|Active Comparator|no dietary intervention|At the onset of diarrhea symptoms, patients undergo no dietary intervention but are interviewed weekly for up to six weeks.
3152672|NCT00258479|Experimental|Modafinil|
3152673|NCT00258479|Placebo Comparator|Placebo|
3152674|NCT00258479|No Intervention|Nicotine Replacement Therapy|The effects of nicotine replacement therapy will be investigated - alone and in combination with modafinil - on nicotine withdrawal in nicotine-dependent adolescents.
3152675|NCT00258518||1|ALI/ARDS patients
2444841|NCT04214028||Maviret Participants|Participants receiving glecaprevir plus pibrentasvir (GLE/PIB, other names: Maviret) as routine standard of care for HCV.
3152676|NCT00258557|Experimental|002|TMC-114/RTV two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
3152677|NCT00258557|Active Comparator|001|LPV/RTV 400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
3152678|NCT00258661|Experimental|Osteopathic Manipulative Treatment|10-minute standardized OMT protocol + 5-minute nonstandardized component, twice daily for duration of hospitalization
2444979|NCT04011540|Experimental|Intervention|Participants will receive a personalized digital data dashboards throughout the two-month study period.
2444980|NCT04011540|No Intervention|Usual Care|Usual care
2444997|NCT03960827|No Intervention|Sedentary control|The control group does not engage in any acute exercise testing protocol.
2445001|NCT03960827|Active Comparator|Sedentary EE|Participants randomized to ET first engage in a single acute exercise test of Endurance Exerciser (on a cycle ergometer) consistent with their random assignment.
2445004|NCT03960827|Active Comparator|Sedentary RE|Participants randomized to RT first engage in a single acute exercise test of Resistance Exerciser, consistent with their random assignment.
2445006|NCT03960827|No Intervention|Highly Active EE|A comparison group of highly active EE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Endurance Exerciser (HAEE) participants are tested on a cycle ergometer.
2445010|NCT03960827|No Intervention|Highly Active RE|A comparison group of highly active RE participants are recruited and engage only in the initial round of acute exercise testing. Highly Active Resistance Exerciser (HARE) participants are tested via a bout of resistance exercise.
2445047|NCT03918980|Experimental|Part 1 Dose A|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445051|NCT03918980|Experimental|Part 1 Dose B|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445055|NCT03918980|Experimental|Part 1 Dose C|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445056|NCT03918980|Experimental|Part 1 Dose D|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445058|NCT03918980|Experimental|Part 1 Dose E|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445059|NCT03918980|Experimental|Part 1 Dose F|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445060|NCT03918980|Experimental|Part 1 Dose G|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445062|NCT03918980|Experimental|Part 1 Dose H|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445065|NCT03918980|Experimental|Part 1 Dose I|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445067|NCT03918980|Experimental|Part 1 Dose J|(Single Ascending Dose) Healthy volunteers will receive a single dose of LOU064.
2445068|NCT03918980|Placebo Comparator|Part 1 Placebo|(Single Ascending Dose) Healthy volunteers will receive a single dose of placebo.
2445070|NCT03918980|Experimental|Part 2 Dose K|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445073|NCT03918980|Experimental|Part 2 Dose L|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445074|NCT03918980|Experimental|Part 2 Dose M|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445075|NCT03918980|Experimental|Part 2 Dose N|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445076|NCT03918980|Experimental|Part 2 Dose O|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445077|NCT03918980|Experimental|Part 2 Dose P|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 once daily for 12 days
2445078|NCT03918980|Placebo Comparator|Part 2 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo once daily for 12 days
2445079|NCT03918980|Experimental|Part 3 Dose Fasted|Healthy volunteers will receive a single dose of LOU064 given under fasting conditions followed by a single dose of LOU064 given after a high fat meal (cross-over design).
2445080|NCT03918980|Experimental|Part 3 Dose Fed|Healthy volunteers will receive a single dose of LOU064 given after a high fat meal followed by a single dose of LOU064 given under fasting conditions (cross-over design).
2445081|NCT03918980|Experimental|Part 4 Dose R|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
2445082|NCT03918980|Experimental|Part 4 Dose S|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take LOU064 twice daily for 12 days
2445083|NCT03918980|Placebo Comparator|Part 4 Placebo|(Multiple Ascending Dose) Healthy Volunteers with asymptomatic atopic diathesis will take placebo twice daily for 12 days
2445084|NCT03918980|Experimental|Part 5 Formulation A|Healthy Volunteers will receive a single dose of LOU064 formulation A followed by a single dose of LOU064 formulation B (cross-over design).
2445085|NCT03918980|Experimental|Part 5 Formulation B|Healthy Volunteers will receive a single dose of LOU064 formulation B followed by a single dose of LOU064 formulation A (cross-over design).
2445086|NCT03918980|Experimental|Part 6 Dose T|Subjects with atopic dermatitis will receive a twice daily dose of LOU064 for 4 weeks
2445087|NCT03918980|Placebo Comparator|Part 6 Placebo|Subjects with atopic dermatitis will receive a twice daily dose of placebo for 4 weeks
3152679|NCT00258661|Sham Comparator|Light-touch Treatment|10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs, twice daily for duration of hospitalization
3152680|NCT00258661|No Intervention|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
3152681|NCT00258687|Experimental|Treatment Arm A|GVAX for Sarcoma / Renal Cell Patients
3152682|NCT00258687|Experimental|Treatment Arm B|GVAX for Pediatric Melanoma Patients
3152683|NCT00258713|Active Comparator|1|
2444812|NCT04264962|Experimental|Yang Yin Fu Zheng Jie Du therapy|
2444813|NCT04264962|Placebo Comparator|Routine medical care|
3152684|NCT00258713|Active Comparator|2|
2445258|NCT03662126|Experimental|Part A Cohort 1|KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
2445259|NCT03662126|Experimental|Part A Cohort 2|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
2445260|NCT03662126|Experimental|Part A Cohort 3|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
2445261|NCT03662126|Experimental|Part A Cohort 4b|KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)
2445263|NCT03662126|Experimental|Part B Arm 1 KRT-232|KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)
2445264|NCT03662126|Active Comparator|Part B Arm 2 Best Available Therapy|Best available therapy at the discretion of the investigator, on a 28-day cycle.
2445409|NCT03418792|Experimental|Parotid-Sparing Head & Neck Radiation|Patients with Oropharyngeal Squamous Cell Carcinoma (OPSCC) who will be treated with parotid-sparing head & neck radiation. MRI Sialograms will be obtained to identify salivary ductal structures and stem cells to be spared during treatment.
2445423|NCT03400215|Active Comparator|Breast cancer confirmed by biopsy|Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
2445424|NCT03400215|Active Comparator|Women without any history of breast cancer|No known malignancy confirmed by at least 1-year follow up exams.
2445466|NCT03351764|Other|arm 1|these are within subject repeated measures studies across a number of conditions
2445467|NCT03351764|Placebo Comparator|arm 2|Placebo Comparator
2445482|NCT03272633|Experimental|Cohort I (initial IHC within 42 days)|Within 42 days after hematopoietic engraftment (both neutrophils and platelets) after autologous HSCT, patients receive initial treatment with IHC. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
2445484|NCT03272633|Experimental|Cohort II (initial IHC within 70 days or after relapse)|Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. Patients being treated for relapsed disease may receive initial treatment with IHC any time after relapse is documented. Patients that do not have evidence of relapse or progressive disease may be treated every 8-12 weeks for up to 3 doses.
2445522|NCT03272503|Experimental|Group 1 Pimozide 2 mg (current) or 4 mg/day (study initiation)|Pimozide will be initiated at 2 mg once daily. The maximum dose will then be administered for a target period of 22 weeks.
2445524|NCT03272503|Placebo Comparator|Group 2 Placebo|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 1
2445580|NCT03272022||women|never-pregnant women
2445581|NCT03272022||pregnant women|pregnant
2445632|NCT03271749|No Intervention|Conventional|The participants of this arm will receive the convencional pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
2445633|NCT03271749|Experimental|PROSM interventional|The participants of this arm will receive the PROSM protocol pre operative, anesthesia and postoperative care for lung resections for treatment of lung neoplasms
2445767|NCT03270787|Experimental|Compound danshen dripping pills|Compound danshen dripping pills Compound danshen dripping pills ,10pills,tid,po
2445853|NCT03270189|Experimental|orthoptic treatment|Patients with cervical dystonia occuring only during handwriting.
3152685|NCT00258713|Active Comparator|3|
3152686|NCT00258739|Experimental|1|Concomitant radiotherapy and carboplatin-docetaxel followed by docetaxel-gemcitabine
3152687|NCT00258739|Experimental|2|docetaxel-gemcitabine followed by concomitant radiotherapy with carboplatin-docetaxel
3152688|NCT00258752|Experimental|1|Interpersonal Psychotherapy-Adolescent Skills Training (IPT-AST)
3152689|NCT00258752|Experimental|2|Enhanced IPT-AST
3152690|NCT00258752|Active Comparator|3|Typical school counseling
3152691|NCT00258765|Experimental|Zoledronic Acid|
3152692|NCT00258765|Active Comparator|Docetaxel|
3152693|NCT00258843|Experimental|Group 1|Children at 18 months of age
3152694|NCT00258843|Experimental|Group 2|Infants at 2 months of age
3152695|NCT00258869||1|Emergency department patients with sepsis
3152696|NCT00258934|Experimental|1|
3152697|NCT00258934|Active Comparator|2|
3152698|NCT00259038|Experimental|Experimental Drug|
3152699|NCT00259038|Placebo Comparator|Placebo|
3152700|NCT00259064|Experimental|Gefitinib|ZD1839 + BSC (best supportive care)
3152701|NCT00259064|Placebo Comparator|Placebo|Placebo + BSC (best supportive care)
3152702|NCT00259103|Experimental|7.5 µg/kg/d|Participants who received intravenous (IV) infusion of 7.5 µg/kg/d serelaxin, all during part A.
3152703|NCT00259103|Experimental|25 µg/kg/d|Participants who received intravenous (IV) infusion of 25 µg/kg/d serelaxin, all during part A.
3152704|NCT00259103|Experimental|75 µg/kg/d|Participants who received IV infusion of 75 µg/kg/d serelaxin, some during part A and others during part B.
3152705|NCT00259103|Experimental|Placebo|Participants who received IV infusion of placebo, some during part A and others during part B.
3152706|NCT00259129|Experimental|Arm 1|
3152707|NCT00259194|Active Comparator|Alternative Observation|Moving in bed during observation after coronary angiography
3152708|NCT00259194|Experimental|Standard Observation|No moving in bed during observation after coronary angiography
3152709|NCT00259207|Active Comparator|classic surgery|classic surgery
3152710|NCT00259207|Experimental|medical surgery hybride|medical surgery hybride
2444811|NCT04294043|Experimental|Infusion of IV Gallium|Gallium nitrate will be infused continuously over 5 days at 200 mg/m2/day. Study drug will be administered via a peripheral IV catheter, a peripherally inserted central catheter (PICC) line, midline catheter, or a chronic indwelling vascular access device using an ambulatory infusion pump infused over 24 hours for 5 sequential days for each cycle. There is a maximum of 2 cycles.
3152711|NCT00259220|Experimental|drug|erythromycine
3152712|NCT00259220|Other|2|gastric lavage alone
2444914|NCT04114656|Placebo Comparator|Participants receiving Placebo|All participants will receive a single dose of placebo in either one or two of the three study periods, as per the randomization schedule.
2444915|NCT04114656|Experimental|Participants receiving GSK3858279|All participants will receive a single dose of GSK3858279 in either one or two of the three study periods, as per the randomization schedule.
2444947|NCT04064749|No Intervention|Control|Participants will receive screening (i.e. services as usual) provided by a national credit counseling program.
2444948|NCT04064749|Experimental|Intervention|Participants will receive screening services provided by the credit counseling program plus added brief intervention services by University of Maryland School of Social Work (UMSSW). Added intervention services include: 1) feedback about the individual's gambling, and 2) text messages to support the individual.
2444972|NCT04028414|Experimental|Early Weight Bearing|Patients with ankle fractures will be instructed to weight bear as tolerated (WBAT) while in a boot with a heel to toe normal gait and wean from walker or crutches to a cane or no support device. At the 6 week post op visit, patients with ankle fractures will be instructed to wean from the boot and continue full weight bearing as tolerated until full weight bearing is achieved. Patients with plateau fractures will be instructed to begin WBAT until full weight bearing is achieved.
2444974|NCT04028414|No Intervention|Delayed Weight Bearing|Patients with ankle fractures will be instructed to touch-down (toe touch or foot flat) weight bear (approximately 10% of body weight) while in the boot for. Patients will be instructed to keep foot off of floor or set ball of foot or heal on ground for balance using walker or crutches at all times. After the 6 week post op visit, patients may begin weight bearing as tolerated. Patients with tibial plateau fractures will be instructed to touch down (toe touch or foot flat) weight bear (approximately 10% of body weight) for at least 6 weeks. After the 6 week post op visit, patients may begin weight bearing as tolerated until full weight bearing is achieved.
3152713|NCT00259220|Active Comparator|3|erythromycine and gastric lavage
2445033|NCT03919669|Experimental|All Subjects|"All subjects will complete PET imaging sessions evaluating the tau PET radioligand [18F]MK-6240 at baseline, as well as at 6, 12 and 24 months post-baseline.~If unable to complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may instead be scheduled, totaling a maximum of four time points."
3152714|NCT00259324|Experimental|1|Diet and Activity
3152715|NCT00259324|Experimental|2|Diet and Activity
3152716|NCT00259324|Placebo Comparator|3|Education
2445738|NCT03271229|Active Comparator|Stem Cells|Participants will have Concentrated Bone Marrow Aspirate (BMAC) injections into symptomatic knee
2445741|NCT03271229|Active Comparator|Plasma|Participants will have Platelet-Rich Plasma (PRP) injections into symptomatic knee
2445759|NCT03270865|Experimental|Usability and Ergonomic Evaluation of Self-Positioning System|
2445802|NCT03270722|Experimental|patients with scleroderma and trouble swallowing|
2445803|NCT03270722|Experimental|patients with scleroderma but no trouble swallowing|
2445805|NCT03270722|Active Comparator|patients without scleroderma undergoing endoscopy|
2445846|NCT03270319||ICU patient|"Critically ill patients in our adult intensive care unit with the following characteristics:~advanced hemodynamic monitoring in place including pulmonary artery catheter and arterial catheter~intubated or tracheostomy in place~echocardiography requested by the treating physician~intervention of interest: hemodynamic assessment done by echocardiography and thermodilution (pulmonary artery catheter)"
2445898|NCT03270033|Active Comparator|Dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2445902|NCT03270033|Active Comparator|Dexmedetomidine|50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2445904|NCT03270033|Active Comparator|Dexamethasone and Dexmedetomidine|4 milligrams dexamethasone and 50 micrograms dexmedetomidine administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
3152717|NCT00259337|Experimental|1|
3152718|NCT00259376|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3152719|NCT00259376|Experimental|Placebo|matching placebo tablets
3152720|NCT00259402|Experimental|Oxaliplatin|
3152721|NCT00259428|Experimental|Dronedarone 400mg bid|dronedarone 400mg tablets
3152722|NCT00259428|Placebo Comparator|Placebo|matching placebo tablets
3152723|NCT00259519|No Intervention|1|Expectant management
3152724|NCT00259519|Active Comparator|2|Induction of delivery
3152725|NCT00259688|No Intervention|1|Women with gestational hypertension
3152726|NCT00259688|No Intervention|2|Women with uncomplicated pregnancies
3152727|NCT00259688|No Intervention|3|Re-test of women one to two years post-partum.
3152728|NCT00259714|Active Comparator|standard dialysate sodium|In the control phase of the study, the prescribed dialysate sodium is 140 mEq/L
3152729|NCT00259714|Experimental|dialysate sodium individualization|".Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
3152730|NCT00259727||1|
3152731|NCT00259753|Experimental|1|0.2 mg/eye
3152732|NCT00259753|Experimental|2|1.5 mg/eye
3152733|NCT00259753|Experimental|3|3.0 mg/eye
3152734|NCT00259805|Experimental|IV Infusion|
3152735|NCT00259883|Experimental|paroxetine|paroxetine 20 to 40mg/day
3152736|NCT00259909||Subjects with COPD|Subject has a confirmed clinical diagnosis of COPD, with or without chronic bronchitis.
3152737|NCT00259922|Placebo Comparator|Placebo|
3152738|NCT00259922|Experimental|Alvimopan 0.5 mg once daily|0.5 mg once daily (QD)
3152739|NCT00259922|Experimental|Alvimopan 0.5 mg twice daily|0.5 mg twice daily (BID)
2444880|NCT04151667|Experimental|A: Daratumumab & Dexamethasone|All participants will receive 1800 mg in 15 ml Daratumumab by subcutaneous injection weekly and be given 20 mg of Dexamethasone orally once a week for 2 months. Patients who receive a partial response or better will continue on this arm.
2444882|NCT04151667|Experimental|B: Daratumumab, Dexamethasone and Lenalidomide|Participants who have less than a partial response to Arm A may have Lenalidomide added to their treatment. Lenalidomide will be given orally on days 1-21 of each 28 day treatment cycle.
2444884|NCT04151667|Experimental|C: Daratumumab, Dexamethasone and Bortezomib|Participants who have less than a partial response to Arm A may have Bortezomib added to their treatment. Bortezomib will be given weekly in subcutaneous injections at a starting dose of 1/3 mg/m^2 Days 1,8 and 15 of each 28 day treatment cycle.
3152740|NCT00259935|Experimental|All treated subjects|Subjects were randomized to receive 4 mg of a new formulation and current formulation of oral topotecan on Days 1 and 8 of Course 1.
3152741|NCT00259974|Experimental|1|Rituximab
3152742|NCT00260039|Active Comparator|1|Gardasil
3152743|NCT00260039|Experimental|2|HPV VLP vaccine -Dose regimen 1
3152744|NCT00260039|Experimental|3|HPV VLP vaccine -Dose regimen 2
3152745|NCT00260039|Experimental|4|HPV VLP vaccine -Dose regimen 3
3152746|NCT00260091|Active Comparator|I.|Conventional infertility therapy
3152747|NCT00260091|Active Comparator|II.|Fast track to in vitro fertilization therapy
3152748|NCT00260130|Active Comparator|1|Consuming fruit and vegetable juice
3152749|NCT00260130|Active Comparator|2|Consuming whole fruits and vegetables
2445589|NCT03271983|Other|metronidazole gel 1|RLD gel
2445594|NCT03271983|Other|metronidazole gel 2|generic gel
2445597|NCT03271983|Other|metronidazole cream|generic cream
2445822|NCT03270449|Experimental|Multidisciplinary intervention|The 10-week intervention will include twice weekly 1-2 hours sessions with multiple professional team members to undergo education and exercise sessions. The multidisciplinary team will consist of a rheumatologist, rheumatology nurse, dietitian, physiotherapist, a trained exercise therapist, a physiologist who specializes in pain management, a psychiatrist and a mental health clinician. All intervention team members have expertise in working with individuals with chronic pain conditions. General disease information, current best practices and techniques such as self-pain management, pacing, sleep hygiene, approach to a healthy lifestyle and weight loss will be discussed. The total number of hours for the 10 week intervention is 31 hours.
2445855|NCT03270189|No Intervention|Controls|Patients without cervical dystonia.
2445873|NCT03269942|Active Comparator|Endovascular Flow-Diversion|Implantation of flow-diversion device
2445875|NCT03269942|Active Comparator|Cerebral Revascularization|Cerebral revascularization procedure with trapping of aneurysm
2445944|NCT03269799|Active Comparator|test group|vitamin C 500 mg oral capsule
3152750|NCT00260143|Experimental|Testosterone enanthate|300 mg of testosterone enanthate by intramuscular injection once weekly for 16 weeks
3152751|NCT00260143|Placebo Comparator|Placebo|Placebo (sesame oil) by intramuscular injection once weekly for 16 weeks
3152752|NCT00260156|Experimental|vildagliptin|
3152753|NCT00260156|Placebo Comparator|Placebo|
3152754|NCT00260169|Experimental|1|Participants will receive collaborative care
3152755|NCT00260169|Active Comparator|2|Participants will receive enhanced usual care
3152756|NCT00260221|Experimental|1|Arm one uses Virtual Reality Hypnosis post hypnotic suggestions to reduce pain durng wound care procedures.
3152757|NCT00260221|Experimental|2|Arm two uses Virtual Reality distraction that is administered at times other than during burn care procedure to control for both for attention and high technology.
3152758|NCT00260221|Experimental|3|Arm three use Audio administered Hypnosis without the visual technology.
3152759|NCT00260234|Experimental|PEG Islet Cells|
3152760|NCT00260273|Active Comparator|1|cognitive Behavioural Therapy
3152761|NCT00260273|No Intervention|2|supportive therapy
3152762|NCT00260338|Active Comparator|Mesenchymal stromal cell|Mesenchymal stromal cell
3152763|NCT00260351|Experimental|Group 1|Participants on Thai Red Cross, TRC-ID regimen
3152764|NCT00260351|Experimental|Group 2|Participants on Zagreb-IM regimen
3152765|NCT00260351|Experimental|Group 3|Participants on Essen-IM regimen.
3152766|NCT00260442|Placebo Comparator|Placebo|< 200 mg/day dietary cholesterol, resistance training, sedentary
3152767|NCT00260442|Experimental|Average intake|400 mg/day dietary cholesterol, resistance training, sedentary
3152768|NCT00260442|Experimental|High intake|800 mg/day dietary cholesterol, resistance training, sedentary
3152769|NCT00260481|Placebo Comparator|Control Group|During the Infusion periods, participants in the placebo condition will receive pre-treatment with hydroxyzine (50mg) followed by placebo medications administered both orally and through infusion, as well as a second dose of hydroxyzine (50mg), delivered at the same rate and delivery system to match the active condition. All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
3173136|NCT00608621||2-placebo|"NaCl 0.9% 50 ml per 24 h continuously over 48 hours, plus 50 ml NaCl 0.9% at termination of sedation~PCA: Patient-controlled analgesia with piritramid 1 mg/ml, on demand: bolus of 2 mg, maximum of 10 mg in 60 min"
3173137|NCT00608660|Experimental|A|staging acupuncture for treating Bell's Palsy
3152770|NCT00260481|Active Comparator|Prometa|During the infusion periods, participants assigned to the PROMETA pharmacotherapy condition will receive pre-treatment with hydroxyzine (50mg) followed by intravenous flumazenil (2mg) over a 2-hour period. Before bedtime, patients will again take 50mg of hydroxyzine orally, as well as 300mg of oral gabapentin (participants will titrate up their dosage of gabapentin each day - 300mg on day 0, 600mg on day 1, 900mg on day 2). All participants may receive daily multivitamins as determined appropriate by the study physician. Multivitamins are not considered active medications for the PROMETA pharmacotherapy, but may be provided to participants in both conditions at the same rates and delivery methods for the duration of the study. Because participants are treatment-seeking and use of a placebo condition is warranted, all participants will be provided with once weekly, manual-guided cognitive behavioral therapy sessions during all outpatient periods of the study.
3152771|NCT00260494|Experimental|acupuncture|acupuncture to lower extremity postoperatively
3152772|NCT00260494|Sham Comparator|sham acupuncture|sham acupuncture at same sites.
2445612|NCT03271814|Experimental|LPS-Patient|Schizophrenia patients who are randomized to receive LPS injection.
2445615|NCT03271814|Active Comparator|LPS-Healthy|Healthy controls who are randomized to receive LPS injection.
2445617|NCT03271814|Placebo Comparator|Placebo-Patient|Schizophrenia patients who are randomized to receive placebo injection.
3152773|NCT00260494|No Intervention|control|no acupuncture, otherwise the same care and measurements
3152774|NCT00260611|Experimental|Oxaliplatin and Taxotere|Patients will receive both docetaxel and oxaliplatin, IV on day 1 of each cycle. Treatment will be repeated every 21 days for up to 6 courses in the absence of disease progression, unacceptable toxicity, or >50% increase in serum PSA.
3152775|NCT00260650|Experimental|Heart PACT Program|Heart PACT Program - patient activation intervention
3152776|NCT00260650|No Intervention|Usual Care|Usual Care
3152777|NCT00260663|Other|Arm 1|
2445914|NCT03269721||Never Smoker|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
2445917|NCT03269721||Smoker/Past smoker-No Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
2445919|NCT03269721||Smoker/Past smoker-W/Airflow Limitation|Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
3152778|NCT00260676|Other|conventional ventilation, protective ventilation|
3152779|NCT00260728|Experimental|Arm 1|
3152780|NCT00260806||1|Children perinatally infected with HIV with exposure to highly active anti-retroviral therapy (HAART).
3152781|NCT00260806||2|Children with perinatally acquired HIV infection enrolled on the P2C2 Study, not exposed to HAART therapy.
2446104|NCT03268408||Intervention|"Intervention aimed at improving self-efficacy parenting which consists in sending to new parents, during the first year of life of their son, eight newsletters with advices and recommendations on child care and development (project Baby Newsletter)."
2446110|NCT03268408||Control|Usual care
2446144|NCT03268044||Weekend admission|Adults admitted to hospital at the weekend (Saturday or Sunday) and who underwent surgery
2446145|NCT03268044||Weekday admission|Adults admitted to hospital on a weekday (Tuesday to Thursday) and who underwent surgery
2446314|NCT03266562|Other|FES vs FDG|All patients will undergo two PEM studies, one with F-18 FDG and the second with F-18 FES. Co-registration of the PEM images from F-18 FDG and F-18 FES will be used to assess the heterogeneity of uptake of the F-18 FES relative to that of F-18 FDG. Heterogeneity of ER expression in the tumor will be determined by immunohistochemistry on the pathologic tissue
2446411|NCT03265925||Epilepsy patients Left Temporal Lobe|Epilepsy patients with seizures originating from the left temporal lobe
3152782|NCT00260819|Experimental|1|Experimental and Placebo Comparator administered in random order during to successive experimental phase
3152783|NCT00260819|Placebo Comparator|2|Experimental and Placebo Comparator administered in random order during to successive experimental phase
3152784|NCT00260936||HIV-negative|HIV-infected and -uninfected males, ages 12 to 24 years, of Tanner Stage 4 or 5
3152785|NCT00260936||HIV-positive, has never been on ART|HIV-positive, has never been on ART
3152786|NCT00260936||HIV-positive, non PI containing NNRTI-based regimen|HIV-positive, currently on a non-PI-containing NNRTI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of PI-containing regimen, and at least one year must have passed since receipt of last PI-containing regimen
3152787|NCT00260936||HIV-positive, non-NNRTI-containing PI-based regimen|HIV-positive, currently on a non-NNRTI-containing PI-based regimen for at least 12 weeks. Must never have received a total of more than 6 months of NNRTI-containing regimen, and at least one year must have passed since receipt of last NNRTI-containing regimen.
3152788|NCT00260975||Chemotherapy patients|Breast cancer patients treated with adjuvant chemotherapy of various types.
3152789|NCT00260975||Hormonal patients|Breast cancer patients treated with adjuvant hormonal therapy but not chemotherapy.
3152790|NCT00260988|Active Comparator|Dalteparin|Dalteparin 200 IU/kg/day for three days prior to surgery and dalteparin 5000IU daily for 3-5 days post-surgery
3152791|NCT00260988|Active Comparator|Tinzaparin|Tinzaparin 175 IU/kg/day for three days prior to surgery and Tinzaparin 4500 IU for 3-5 days post surgery
3152792|NCT00261001|Experimental|Transcutaneous|
3152793|NCT00261001|Active Comparator|Intramuscular|
3152794|NCT00261053|Other|1|Open-label i.v. administration of 100 U/kg rhC1INH
3152795|NCT00261118|Active Comparator|1 (i)|Rituximab 1g in 500 mls of 0.9% normal saline infused into a peripheral vein
3152796|NCT00261118|Placebo Comparator|2 (ii)|500 mls of 0.9% NORMAL SALINE INFUSED INTO A PERIPHERAL VEIN
3152797|NCT00261170|Active Comparator|1|bupropion and behavioral counseling
2444827|NCT04261764|Experimental|TCM-FMD|"Fasting-Mimicking Diet Combined With a Dispelling Dampness Meal Replacement Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
2444829|NCT04261764|Placebo Comparator|Normal diet|Carrying out normal diet under the guidance of a dietitian, for 12 weeks.
3152798|NCT00261170|Placebo Comparator|2|placebo medication
3152799|NCT00261196|Experimental|Collagenase|Collagenase Injection
2445177|NCT03799705||History of VACTERL or congenital malformations|1) Adults with VACTERL association; 2) adults with a history of congenital malformations resembling VACTERL association; 3) gravid and non-gravid women with a history of recurrent miscarriage, their surviving offspring, and the biological father of offspring; 4) newly diagnosed VACTERL patients identified by healthcare providers.
3152800|NCT00261196|Placebo Comparator|Placebo|Placebo Injection
3152801|NCT00261209|Experimental|Collagenase Injection|Injection of collagenase into adhesion restricting tendon gliding
3152802|NCT00261274|Experimental|Test Group A-ECO|
3152803|NCT00261274|Placebo Comparator|Control Group|
3152804|NCT00261300|Experimental|1|Pantoprazole 40 mg
3152805|NCT00261313|Experimental|Aranesp|
2445509|NCT03272477|Active Comparator|Paclitaxel+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with standard Taxane chemotherapy.~Adjuvant Therapy: Standard of care"
2445518|NCT03272477|Experimental|Endocrine+Trastuzumab+Pertuzumab|"Neoadjuvant therapy: Trastuzumab and Pertuzumab in a 3-weekly schedule in combination with endocrine therapy.~Adjuvant Therapy: Standard of care"
2445540|NCT03272126|Experimental|vitamin D bolus|vitamin D 160 000 IU given as bolus
2445542|NCT03272126|Experimental|vitamin D daily|vitamin D 4000 IU daily for 28 days
2445544|NCT03272126|Placebo Comparator|placebo|identical looking as vitamin d
2445590|NCT03271996|Experimental|Primary closure|Excision of sinus and paramedian closure according to modified Karydakis technique
2445593|NCT03271996|Experimental|Fistulectomy|Removal / fistulectomy by scalpels or trephines of primary and drainage orifices and healing of the wound by second intention
2445624|NCT03271658|Experimental|Intervention|Patient/family are randomized to either the active intervention (web based life support patient decision aid - eLSDA and decision coaching) or usual care comparison.
2445625|NCT03271658|No Intervention|Usual Care Comparison|Patients may also randomized to review current web based resources provided by the health region for seriously ill patients.
2445638|NCT03271450||Continuer at 90 Days: Dabigatran|
2445639|NCT03271450||Continuer at 180 Days: Dabigatran|
2445640|NCT03271450||Continuer at 270 Days: Dabigatran|
2445643|NCT03271450||Continuer at 90 Days: Apixaban|
2445645|NCT03271450||Continuer at 180 Days: Apixaban|
2445650|NCT03271450||Continuer at 270 Days: Apixaban|
2445652|NCT03271450||Continuer at 90 Days: Rivaroxaban|
2445654|NCT03271450||Continuer at 180 Days: Rivaroxaban|
2445655|NCT03271450||Continuer at 270 Days: Rivaroxaban|
2445657|NCT03271450||Continuer at 90 Days: Edoxaban|
2445658|NCT03271450||Continuer at 180 Days: Edoxaban|
2445659|NCT03271450||Continuer at 270 Days: Edoxaban|
2445661|NCT03271450||Continuer at 90 Days: Warfarin|
2445663|NCT03271450||Continuer at 180 Days: Warfarin|
2445667|NCT03271450||Continuer at 270 Days: Warfarin|
2445672|NCT03271450||Discontinuer at 90 Days: Dabigatran|
2445678|NCT03271450||Discontinuer at 180 Days: Dabigatran|
2445680|NCT03271450||Discontinuer at 270 Days: Dabigatran|
2445681|NCT03271450||Discontinuer at 90 Days: Apixaban|
2445683|NCT03271450||Discontinuer at 180 Days: Apixaban|
2445685|NCT03271450||Discontinuer at 270 Days: Apixaban|
2445688|NCT03271450||Discontinuer at 90 Days: Rivaroxaban|
2445691|NCT03271450||Discontinuer at 180 Days: Rivaroxaban|
2445693|NCT03271450||Discontinuer at 270 Days: Rivaroxaban|
2445694|NCT03271450||Discontinuer at 90 Days: Edoxaban|
2445695|NCT03271450||Discontinuer at 180 Days: Edoxaban|
2445696|NCT03271450||Discontinuer at 270 Days: Edoxaban|
3152806|NCT00261313|Experimental|Neulasta|
3152807|NCT00261326|Active Comparator|B|simvastatin tablets 80 mg daily
3152808|NCT00261326|Placebo Comparator|A|calcium tablets 80 mg
3152809|NCT00261365|Active Comparator|A1|
3152810|NCT00261365|Active Comparator|A2|
3152811|NCT00261378|Active Comparator|Transarterialchemoembolisation (TACE)|Conventional TACE with doxorubicin
3152812|NCT00261378|Other|DC Bead|DC Bead with doxorubicin
3152813|NCT00261456||BRCA1/2 carriers|Carriers of a BRCA1 or BRCA2 mutation.
3152814|NCT00261456||BRCA1/2/non Carriers|Do not carry a mutation in either the BRCA1 or 2 genes that has been found in other members of the family.
3152815|NCT00261547|Experimental|Rituximab|this study has only one arm as the treatment group
3152816|NCT00261690|Experimental|1|Virtual Reality distraction
3152817|NCT00261703|Experimental|1|(Docetaxel + Cisplatin + 5-FU) + Cisplatin + Radiotherapy
3152818|NCT00261703|Experimental|2|(Cisplatin + 5-FU) + Cisplatin + Radiotherapy
3152819|NCT00261703|Experimental|3|Cisplatin + Radiotherapy
3152820|NCT00261729|Experimental|1|paroxetine
3152821|NCT00261729|Placebo Comparator|2|placebo
3152822|NCT00261729|Experimental|3|prazosin
3152823|NCT00261755|Experimental|Acupuncture Group|Acupuncture treatment during labor
3152824|NCT00261755|Active Comparator|TENS Group|Transcutaneous Electric Nerve Stimulation (TENS treatment)during labor
3152825|NCT00261755|Active Comparator|Traditional Group|Traditional pain treatment during labor
2444842|NCT04190758||Patients with rheumatoid arthritis (RA)|Patients with RA meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010.
2444845|NCT04190758||Patients with psoriatic arthritis (PsA)|Patients with PsA meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR).
2444847|NCT04190758||Patients with undifferentiated arthritis|Defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease.
2444848|NCT04190758||Patients with psoriasis|Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks.
2444849|NCT04190758||General population controls|General population controls retrieved from the Population Register, matched for age, sex and residence of living to the included patients.
2444870|NCT04171063|Other|Bracing arm|Patients that will be using the thoracic compressor
2444902|NCT04126538|Experimental|Patient group|Patients with chronic kidney disease take pirfenidone capsule 400mg once orally
2444907|NCT04126538|Experimental|Control group|Healthy subjects take pirfenidone capsule 400mg once orally
3152826|NCT00261768|Experimental|1|Noise reduction on
3152827|NCT00261781|Experimental|Treadmill training|Home-based treadmill training
3152828|NCT00261781|No Intervention|Usual care|Control group
3152829|NCT00261794|Experimental|1|computer-assisted cognitive remediation (CACR)
3152830|NCT00261794|Active Comparator|2|computer-based cognitive activity
3152831|NCT00261859|No Intervention|SCA|Standard Care with Assessment
3152832|NCT00261859|No Intervention|SCNA|Standard Care No Assessment
2445361|NCT03516591|Experimental|Dose Escalation (3+3 design)|A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
2445362|NCT03516591|Experimental|Dose Expansion|Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.
2445378|NCT03482089|Experimental|Cystoprostatectomy|(Open, laparoscopic or robot-assisted ) cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection; without adjuvant androgen deprivation therapy;
2445380|NCT03482089|Active Comparator|Radiotherapy|Radiotherapy by external beam radiotherapy (81 Gy，2.4-4 Gy per fraction over 4-6 weeks); with adjuvant androgen deprivation therapy for the least 3 years
3152833|NCT00261859|Experimental|BNI|Brief Negotiated Interview
3152834|NCT00261859|Experimental|EBNI|Enhanced Brief Negotiated Interview
2445534|NCT03272152||Inflamed CD group|Inflamed ileal mucosa was obtained from inflammed lesions of active CD patients
2445537|NCT03272152||Non-inflamed CD group|Non-inflamed ileal mucosa was obtained from normal sites of active CD patients
2445538|NCT03272152||Control group|Control ileal mucosa was obtained from healthy patients
2445601|NCT03272048|Experimental|Low-Fear/Not-Temporary|
2445604|NCT03272048|Experimental|Low-Fear/Temporary|
2445606|NCT03272048|Experimental|High-Fear/Not-Temporary|
2445608|NCT03272048|Experimental|High-Fear/Temporary|
2445675|NCT03271580||Diabetic patients infected ulcers|"Diabetic patients with HbA1c<9 with who have wound 4weeks or longer with infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
2445679|NCT03271580||Diabetic patients non infected Ulcers|"Diabetic patients with HbA1c<9 who have wound 4 weeks or longer without infection with following interventions:~Finger prick test for HbA1c measurement~Punch biopsy~VAC sponge collection~Ankle brachial index"
2445717|NCT03271164|Experimental|Treatment with FBPM10 system|One breast will be randomized to be treated with FBPM10 System.
2445719|NCT03271164|Active Comparator|Treatment with standard of care|One breast will be selected to be treated with massages with vitamin E cream.
2445761|NCT03270982||Comprehensive SRS Replacement|
2445850|NCT03270150|Experimental|BTL-899 Therapy Arm|BTL-899 therapy, 3 therapies
2445892|NCT03270007|Experimental|Chemotherapy|
2445894|NCT03270007|No Intervention|Control|
2445940|NCT03269604|Active Comparator|Prophylactic antibiotic five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
2445946|NCT03269604|Active Comparator|Prophylactic antibiotic three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
2445951|NCT03269604|Experimental|Only a single dose of Prophylactic antibiotic|Only a single dose of Prophylactic antibiotic on the day of the procedure
2446021|NCT03268954|Experimental|Azacitidine + Pevonedistat|Azacitidine 75 milligram per square meter (mg/m^2), intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 and pevonedistat 20 mg/m^2, 60-minute (+/-10) infusion, intravenous, on Days 1, 3, and 5 in 28-day treatment cycles until disease progression or unacceptable toxicity.
2446023|NCT03268954|Experimental|Azacitidine|Azacitidine 75 mg/m^2, intravenous or subcutaneous, on Days 1 to 5, Days 8 and 9 in 28-day treatment cycles until disease progression or unacceptable toxicity.
2446414|NCT03265925||Healthy|Healthy controls
3152835|NCT00261924|Experimental|Intercept Platelets|Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system
3152836|NCT00261924|Active Comparator|Conventional Platelets|Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system
3152837|NCT00261976||Patients in infliximab clinical studies|All patients enrolled in selected Centocor sponsored infliximab clinical studies.
3152838|NCT00262054|Experimental|A|bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
3152839|NCT00262054|Active Comparator|B|UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.
3152840|NCT00262106|Placebo Comparator|Placebo|placebo
3152841|NCT00262106|Active Comparator|PRO 2000/5 Gel 0.5%|PRO 2000/5 Gel 0.5%
2444838|NCT04239040|Experimental|Relapsed or Refractory High Risk Neuroblastoma|"Tissue Collection of Cancerous cells during primary or clinically indicated surgical resection.~Manufacture and cryopreservation of vaccine. Treatment with vaccine, nivolumab and ipilimumab.~Vaccine injected weekly over initial 21 day cycle, biweekly for cycles 2-4 of 21 day cycle duration and cycles 5 and subsequent of 28 day cycle duration until vaccine supply is exhausted.~Intravenous infusion of nivolumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of ipilimumab every 3 weeks, for cycles 1-4. Cycles 1-4 are 21 days~Intravenous infusion of nivolumab biweekly for cycle 5 and subsequent of 28 day cycle duration. Subsequent 28 day cycles will last up to 2 years."
3152842|NCT00262288|Experimental|Recombinant Human C1INH|
3152843|NCT00262340|Experimental|1|This arm will have treatment changed based on measures of inflammation
3152844|NCT00262340|Active Comparator|2|Treatment will be changed on the basis of reported asthma symptoms
3152845|NCT00262379|No Intervention|Group A|HCV treatment with peginterferon plus ribavirin during 48 weeks
3152846|NCT00262379|Active Comparator|Groupb|HCV treatment with peginterferon plus ribavirin during 48 weeks plus epoetin beta under anemia conditions
3152847|NCT00262392|Experimental|Pamidronate|Pamidronate
2445813|NCT03270631|No Intervention|Control|Multidisciplinary rehabilitation, no interventions
2445815|NCT03270631|Experimental|FM and MCE|Subjects will have 4-5 times of fascial manipulation (FM) treatment and 4-6 times movement control exercises (MCE) at home to be done based on movement control testing (MCT). Both are given in 3 month period.
2445816|NCT03270631|Other|FM and sham-MCE|FM 4-5 times in 3 months and 4 general exercise prescription.
2445817|NCT03270631|Other|MCE and sham-FM|Sham-FM 4 times in 3 months including trigger point treatment in before decided points and 4-6 times MCE prescription and home exercises.
2445818|NCT03270631|Sham Comparator|Sham-MCE and sham-FM|4 general practice guiding and Sham-FM 4 times in 3 months including trigger point treatment in before decided points.
2445845|NCT03270267||Patients with IBD|
3152848|NCT00262392|Active Comparator|radiation|radiation
3152849|NCT00262405|Experimental|zileuton|Zileuton
2445963|NCT03269422|Experimental|MR Image Guided, Intensity-Modulated Radiotherapy|Patients enrolled in this study will undergo MR-based, image-guided, intensity-modulated radiotherapy using similar equipment, techniques, and treatment-planning procedures as currently practiced at MSKCC.
2446011|NCT03269084||Children at HLA-conferred risk for T1D|
2446022|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
2446024|NCT03268707|Experimental|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
2446093|NCT03268252||2x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given twice per year
2446094|NCT03268252||1x/year MDA|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once per year
3152850|NCT00262405|Active Comparator|azathioprine/prednisone|azathioprine/prednisone
3152851|NCT00262431|Active Comparator|Early (A)|Patients of the EARLY group (A) will be submitted to tracheostomy on day 3-5 from oro/nasotracheal intubation.
3152852|NCT00262431|Active Comparator|Late (B)|Patients of the LATE group (B) will undergo tracheostomy on day 10-12 from oro/nasotracheal intubation.
3152853|NCT00262457|Other|Arm 1|
3152854|NCT00262470|Experimental|1|Acetazolamide
3152855|NCT00262470|Experimental|2|Atomoxetine
2446237|NCT03267381||Arm 1a|Stage III melanoma diagnosis (biopsy-proven lymph node positive (this is either clinically palpable or enlarged nodes detected by imaging, which are then biopsied and have macroscopic disease).
2446241|NCT03267381||Arm 1b|Stage III after sentinel node biopsy (microscopic disease diagnosed on sentinel node biopsy).
2446248|NCT03267381||Arm 2|Stage IV- will need to stratify by current treatment with immunotherapy, targeted therapy, none
2446279|NCT03267004|Experimental|Meal Order 1|Meal A will be served to participant in meal session 1 and Meal B in meal session 2.
2446284|NCT03267004|Experimental|Meal Order 2|Meal B will be served to participant in meal session 1 and Meal A in meal session 2.
2446329|NCT03266653|Experimental|Refractory EBV|Patients with refractory EBV will get one dose of EBV specific CTLs. If they don't show a response based on EBV PCRs, patients may get up to another 4 doses of EBV-CTLs (5 doses maximum)
2446352|NCT03266211||Patients|People older than 65 years in the Auvergne-Rhônes-Alpes region who are consulting their general practitioner.
3152856|NCT00262470|Experimental|3|NO Drug
3152857|NCT00262470|Experimental|4|Clonidine
3152858|NCT00262470|Experimental|5|Entacapone
3152859|NCT00262470|Experimental|6|Indomethacin
3152860|NCT00262470|Experimental|7|Isosorbide Dinitrate
3152861|NCT00262470|Experimental|8|Mecamylamine
3152862|NCT00262470|Experimental|9|Memantine
3152863|NCT00262470|Experimental|10|Melatonin
3152864|NCT00262470|Experimental|11|Midodrine
3152865|NCT00262470|Experimental|12|Modafinil
3152866|NCT00262470|Experimental|13|Octreotide
3152867|NCT00262470|Placebo Comparator|14|Placebo (lactose tablet)
3152868|NCT00262470|Experimental|15|Propranolol
3152869|NCT00262470|Experimental|16|Sertraline
3152870|NCT00262470|Experimental|17|Normal Saline (0.9%) 1 liter
3152871|NCT00262470|Experimental|18|Drinking Water
3152872|NCT00262470|Experimental|19|Dead Space Breathing Device
3152873|NCT00262470|Experimental|Abdominal Binder|Abdominal binder with inflatable pressure over abdomen
3152874|NCT00262561|Active Comparator|Aspirin|All participants get Aspirin, and platelet reactivity measurements are performed.
3152875|NCT00262587|Placebo Comparator|Placebo|Placebo inhaler (sugar powder)
3152876|NCT00262587|Active Comparator|Seretide|Seretide inhaler
2444853|NCT04181047|Active Comparator|Treatment as usual|This group will also have access to usual care, which usually includes a family doctor or psychiatrist, mental health therapist and having access to Edmonton's community mental health programs.
2444878|NCT04159480|Experimental|Experimental - Cogito Companion|Those allocated to Experimental arm will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators. The Cogito mobile sensing platform passively gathers behavioral information through an individual's normal smartphone usage. Measurements of location, call, and text patterns are recorded.
2444879|NCT04159480|Active Comparator|Active Control|Participants randomized to the Active Control group will download MyCAP and have access to resources housed within this app for a three-month period post-consent. Participants will be provided information regarding the mHealth Tool apps, and provided basic information on how to download the apps. As noted above, participants will be provided biweekly surveys .
3152877|NCT00262665|Experimental|Org 24448|ampa receptor potentiator for the treatment of MDD
3152878|NCT00262665|Placebo Comparator|Placebo|matching placebo pill
3152879|NCT00262704|No Intervention|Group A|Control group
2444984|NCT03996720||severe sepsis|patients who diagnosed as sepsis upon PICU admission and develop organ dysfunction during PICU stay
2444985|NCT03996720||sepsis|patients recover from sepsis without developing into organ dysfunction
3152880|NCT00262704|Active Comparator|Group B|Simulated case-based customized learning
3152881|NCT00262704|Active Comparator|Group C|Simulated case based customized learning + leader feedback
2445435|NCT03384914|Active Comparator|Dendritic Cell (DC1) Vaccine|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
2445439|NCT03384914|Active Comparator|pUMVC3-IGFBP2-HER2-IGF1R (WOKVAC)|"The vaccine will be administered in two phases: a vaccination phase and a booster phase.~Approximately 6 months from the initiation of the first vaccine, patients will receive the first of 3 booster vaccines."
2445473|NCT03272672|Experimental|Braced|Össür Unloading Knee Brace used during walking protocol
2445474|NCT03272672|No Intervention|Unbraced|Walking protocol without the use of brace
2445494|NCT03272594|Experimental|Breastfeeding|
2445497|NCT03272594|Active Comparator|24% oral sucrose|
2445530|NCT03272399|Experimental|H3-L6|High Omega-3, low Omega-6 diet
2445531|NCT03272399|Active Comparator|L3-H6|Control diet containing average US polyunsaturated fatty acid (PUFA) content with low omega-3 and high omega-6 content
2445677|NCT03271593||All children admitted|All children admitted to hospital
2445733|NCT03271294|Other|Exair transvaginal mesh surgery|This is a prospective study done in 80 consecutive subjects who underwent the Exair transvaginal mesh surgery from June 2013 to August 2015. The subjects were followed at 4 weeks, 6 months and 12 months post-operatively. All eligible subjects underwent a detailed urogynecologic history and examination including a Pelvic Organ Prolapse Quantification system assessment (POP-Q).
2445760|NCT03270969|Experimental|TDF/FTC|Tenofovir Disoproxil Fumarate/Emtricitabine group HIV-uninfected transgender women receiving feminizing hormone therapy plus tenofovir disoproxil fumarate/emtricitabine
2445804|NCT03270709|Experimental|HIV+ smokers|Vitamin D3 450,000 IU orally
2445806|NCT03270709|Active Comparator|HIV- non-smokers|Vitamin D3 450,000 IU orally
2445807|NCT03270709|Active Comparator|HIV+ non-smokers|Vitamin D3 450,000 IU orally
2445810|NCT03270709|Active Comparator|HIV- smokers|Vitamin D3 450,000 IU orally
2445880|NCT03270072||Photon Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive photon therapy.
2445881|NCT03270072||Proton Therapy|The patients being treated on the Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial (NCT02603341) at Massachusetts General Hospital that were randomized to receive proton therapy
2445984|NCT03269123|Other|A device to relieve Blepharospasm|The pressure device known as Pressop1 is the intervention which is attached to the spectacles and worn for 2 weeks prior to retreatment with Botulinum Toxin injections to assess its effectiveness in controlling eyelid spasms.
2446049|NCT03268915|Experimental|patient with idiopathic pulmonary fibrosis|
3152882|NCT00262769|Experimental|A - Gemcitabine|Gemcitabine alone
3152883|NCT00262769|Experimental|B - Gemcitabine and Cisplatin|Gemcitabine and Cisplatin
3152884|NCT00262782|Experimental|Fludarabine|
3152885|NCT00262782|No Intervention|watch & wait|
3152886|NCT00262795|Experimental|F|Fludarabine
3152887|NCT00262795|Active Comparator|CLB|Chlorambucil
3152888|NCT00262899|Experimental|Rapid genetic counseling|Following randomization, participants will be informed about whether they are assigned to Usual Care (UC) or Rapid Genetic Counseling (RGC). Participants in the UC arm can schedule a genetic counseling appointment at any time during the study if they wish. Participants in the RGC agree to obtain genetic counseling as soon as possible, before they make a definitive surgery decision. RGC can be accomplished by telephone or in-person. The RGC intervention is delivered by highly experienced genetic counselors at each site. This counseling is identical to our standard genetic counseling procedure for newly diagnosed patients. Immediate DNA collection via blood or buccal cell collection is available following counseling. Phone counseling participants will be been mailed a kit for DNA collection or have the option of having the sample collected at at LCCC.
3152889|NCT00262899|No Intervention|Usual Care|Usual Care (UC) for newly diagnosed breast cancer patients does not typically include a pre-surgical genetic referral. These patients may obtain genetic counseling at their own discretion.
3152890|NCT00262938|Active Comparator|Lifestyle counseling|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling.Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
3173138|NCT00608660|Experimental|B|staging acupuncture and moxibustion for treating Bell's Palsy
2444881|NCT04150354|Experimental|Participants allocated to Cogito Companion|Participants will have access the Cogito Companion for a three-month period post-consent. Passive data collection will also occur during this period. As a secure, privacy-compliant mobile app, the Cogito Companion facilitates the non-invasive collection, transfer, integration, analysis, and reporting of objective behavioral indicators.
2444987|NCT03982602|Experimental|Subjects on Ketogenic diet|Treatment with KD will consist of 4:1 [fat]: [protein + carbohydrate] weight ratio. KD will be started as soon as the patient is ready for alimentation (while they are in neurocritical care unit). The rate of feeds will be calculated by trained dietician on service. Ketogenic diet will be continued during the entire length of ICU stay. Supplementation with vitamins, calcium and phosphorus will be done.
3152891|NCT00262938|Active Comparator|Without Counseling|Patients undergo quality of life, exercise, and clinical assessments at baseline and at 3, 6, and 12 months.
2445037|NCT03917433|Experimental|Exposure with Tactile Feedback|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
2445038|NCT03917433|Experimental|Exposure with Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. The participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
2445041|NCT03917433|Experimental|Exposure with Tactile Feedback and Point-based Rewards|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment. In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world. Also, the participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
2445043|NCT03917433|Other|Virtual Reality Exposure Therapy Alone|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
3152892|NCT00262990|Experimental|Patupilone|
3152893|NCT00262990|Active Comparator|doxorubicin|
3152894|NCT00263029|Experimental|1|
2445231|NCT03752684|Experimental|Low Oxalate Diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a low oxalate diet to determine baseline oxalate values in urine and plasma.~Subjects will be colonized with Oxalobacter formigenes (Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
2445232|NCT03752684|Experimental|Moderately high oxalate/low calcium diet|"Subjects not colonized with Oxalobacter formigenes will be equilibrated to a moderately high oxalate/ low calcium oxalate diet to enhance dietary oxalate absorption.~Subjects will be colonized with Oxalobacter formigenes(Intervention). Following colonization with Oxalobacter formigenes, urinary and plasma oxalate will be measured to determine the impact of colonization."
2445233|NCT03752684|Experimental|Oxalobacter formigenes|Subjects will ingest a liver preparation of O.formigenes
2445253|NCT03656133|Active Comparator|Standard Fractionation|Standard Radiotherapy Fractionation
2445256|NCT03656133|Active Comparator|Hyperfractionation|Hyperfractionation
3152895|NCT00263042|Experimental|Rimonabant|Rimonabant 20 mg once daily
3152896|NCT00263042|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
2445404|NCT03449576|Experimental|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.
2445405|NCT03449576|Active Comparator|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.
2445563|NCT03272113|No Intervention|Control|"Usual care to provided by smoking cessation services in the two study sites. Site one: support from a specialist advisor using motivational interviewing, one to one, group and telephone support.~Site two: a smoking cessation incentive scheme administered through community pharmacies. Women who are verified by CO testing to have stopped smoking receive £12.50 per week."
3152897|NCT00263068|Experimental|1|Up to 6.75 mg/day (optimal dosing)
3152898|NCT00263081|Experimental|Lapaquistat Acetate QD|(and current lipid-lowering treatment)
3152899|NCT00263081|Placebo Comparator|Current lipid-lowering treatment|
3152900|NCT00263185|Experimental|Active Treatment Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Vitamin 50,000 IU/wk x 8 weeks and then once a month for a total of 6 months."
3152901|NCT00263185|Placebo Comparator|Control Group|"Patients with baseline 25OH vitamin D level of 10-19 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 16 weeks and then once a month for a total of 6 months.~Patients with baseline 25OH vitamin D level of 20-29 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily.~Placebo once per week x 8 weeks and then once a month for a total of 6 months."
3152902|NCT00263185|Other|Observational Group|"Patients with a baseline Vitamin D level below 10 ng/ml.~Calcium carbonate 1000 mg/day~Vitamin D 400 units daily."
3152903|NCT00263198|Experimental|Letrozole + PTK787/ZK222584|"Letrozole 2.5 mg PO daily for 28 days (patients who have already been treated with letrozole for at least 28 days can skip this part)~Start cycle 1 with:~Letrozole 2.5 mg PO once daily~PTK787/ZK222584 250 mg BID PO for 1 week, then 500 mg BID PO for the 2nd week followed by 500 mg qAM and 750 mg QPM PO for the subsequent 2 weeks.~Subsequent cycles:~PTK787/ZK222584 500 mg qAM and 750 mg qPM PO daily~Letrozole 2.5 mg PO once daily"
3152904|NCT00263276|Experimental|Arm 1|
3152905|NCT00263276|Experimental|Arm 2|
3152906|NCT00263276|Experimental|Arm 3|
3152907|NCT00263276|Experimental|Arm 4|
3152908|NCT00263276|Experimental|Arm 5|
2445408|NCT03438630||Study cohort|All patients with a first registration (baseline) in the BOA Register between 2008 and 2016 (approximately n=75 000). These patients have sought treatment for knee and/or hip pain in primary health care in Sweden and been referred to the standardized core treatment of education and supervised exercises after confirmed clinical and/or radiographic OA diagnose.
2445410|NCT03438630||Control cohort|Covering the general Swedish population, who never have been included in the BOA register, will be recruited from the Swedish population register at Statistics Sweden and matched (1:3) to each patient in the study cohort by the same year of birth, gender and residence (as for the study cohort at baseline) (approximately n=225 000).
3152909|NCT00263276|Placebo Comparator|Arm 6|
3152910|NCT00263276|Active Comparator|Arm 7|
2445556|NCT03272386||Observational study|Observational study with patients over 18 years old, consulting for lower urinary tract symptoms in a tertiary center are included.
2445610|NCT03271970||Patients with conductive hearing loss|
2445669|NCT03271697|Experimental|AM group|Treatment group will accept Astragalus Membranaceus(AM) t.i.w treatment for 14 days from second day of admission, in addition to standard ordinary treatment.
2445674|NCT03271697|Placebo Comparator|Placebo group|Control group will accept placebo t.i.w treatment for 14 days from the second day of admission, in addition to standard ordinary treatment.
2445897|NCT03269786||cirrhotic patients with esophagel varisces|Endoscopic band ligation or injection scelerotheraby will be done for all patients
2446012|NCT03269149|Experimental|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period.
2446013|NCT03269149|Active Comparator|Educational Control|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks.
2446039|NCT03268733|Experimental|Treatment group|45 PCOS patients will receive 5 mg folic acid
2446042|NCT03268733|No Intervention|control group|45 PCOS patients will receive no folic acid
2446126|NCT03268200|Experimental|Case group|Each segment of colon (right colon, mid-colon, and left colon) was examined twice
2446128|NCT03268200|No Intervention|Control group|Withdrawal time in the each segment of colon (right colon, mid-colon, and left colon) was about 2 minutes.
2446152|NCT03267927|Experimental|Patient with OSA|
2446218|NCT03267654|Experimental|gefitinib combined with chemotherapy|gefitinib 250mg Qd combined with pemetrexed plus carboplatin: pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days.
2446219|NCT03267654|Experimental|gefitinib combined with apatinib|gefitinib 250mg Qd combined with apatinib 250mg per 21 days
2446220|NCT03267654|Active Comparator|gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
2446260|NCT03267173|Experimental|CAR-T|A single dose of Chimeric antigen receptor T cells will be administered by vascular interventional mediated as one dose infusions. According to the patient's condition and weight, the intervention dose of aE7 CAR-T cells per kilogram of body weight was treated once.
2446391|NCT03266328||group 1|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is up to 40 years old
2446393|NCT03266328||group 2|ST elevated myocardial infarction patient presented to assiut university hospital for Primary Percutaneous Coronary Intervention (PPCI) and their age is more than 40 years old
2446428|NCT03265808|Experimental|allogeneic human mesenchymal stem cells (allo-hMSCs)|Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2446433|NCT03265808|Placebo Comparator|Placebo|Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
3152911|NCT00263367|Other|hyperbaric oxygen at 1.3 ATA|Hyperbaric Oxygen at 1.3 ATA for one hour followed by measurement of glutathione in the blood
2446525|NCT03265093|Active Comparator|experimental; Corticosteroid|Intralesional corticosteroid administration
2446530|NCT03265093|Experimental|Experimental; Injectable Platelet rich fibrin|Injectable Platelet rich fibrin
2446623|NCT03264872|Experimental|Peer-Enhanced Motivational Interviewing|Both dyad members, the target client and their peer support person, in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions with a trained counselor.
2446626|NCT03264872|Other|Waitlist Control|Delayed Treatment.
2446757|NCT03263390||Anti Obesity Medications|Subjects that have demonstrated extreme response to anti obesity pharmacotherapy.
3152912|NCT00263393|Other|Algorithm-based care|An algorithm based approach to increase the identification of high-risk individuals in the community through encouraging opportunistic screening, and to increase the use of appropriate evidence based prevention strategies.
3152913|NCT00263393|Other|Health-promotion|The health promotion arm has been designed to increase knowledge of the causes of cardiovascular disease and enhance use of preventive behaviours in the general population
3152914|NCT00263432|Experimental|1|Implantation of fresh human allogenic chondrocytes
3152915|NCT00263458|Experimental|Integrated|Buprenorphine maintenance treatment delivered at an HIV primary care clinic
3152916|NCT00263458|Active Comparator|Non-integrated|Buprenorphine maintenance treatment delivered at a public health substance use disorder clinic
3152917|NCT00263484|Experimental|"dtZ regimen, Initial therapy"|"To test the efficacy of the dtZ regimen in previously untreated patients with multiple myeloma."
3152918|NCT00263601|Experimental|Allergovit 6-grasses immunotherapy|Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
2445019|NCT03934255|Experimental|Constant Routine Protocol|Participants will be kept in constant conditions for 30 hours to observe circadian physiology in the absence of light, physical activity, and meals.
2445036|NCT03921320|Active Comparator|Bilateral sympathectomy|Bilateral sequential (one surgical procedure) videothoracoscopic R4 sympathectomy
2445039|NCT03921320|Experimental|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the right (dominant) side
2445040|NCT03921320|Experimental|Contralateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy on the left (contralateral) side
2445102|NCT03905135|Experimental|1- Experimental Treatment: Dose Escalation|IL-15 by civ infusion at escalating doses of 1, 2, 3 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with avelumab by IV infusion at a dose of 10mg/kg on Day 8 and 22 of each cycle, to determine MTD
2445104|NCT03905135|Experimental|2- Experimental Treatment: Dose Expansion|IL-15 by civ infusion at the MTD on days 1-5 of cycles 1-6 with avelumab at 10mg/kg on Day 8 and 22 of each cycle
2445122|NCT03873480|Active Comparator|Intervention Arm|Participants randomized into the intervention group will receive an injection of 2.5 cc of 0.25% marcaine without epinephrine prior to the incision. The local anesthetic will be administered by the treating surgeon. All other aspects of the procedure will be kept in accordance with the standard of care for trigger thumb surgeries.
2445124|NCT03873480|No Intervention|Non-Intervention Arm|Those that are not randomized into the intervention group will receive the standard of care for a trigger thumb release, which is administration of 2.5 cc of 0.25% marcaine without epinephrine following completion of surgery. The local anesthetic will be administered by the treating surgeon.
2445151|NCT03849651|Experimental|Transplant participants|"Participants receive a conditioning regimen of ATG (rabbit),Cyclophosphamide 60 mg/kg intravenous once daily, mesna, fludarabine, thiotepa, melphalan, followed by HPC,A Infusion(TCRα/β+ and CD19+ depleted),HPC, A infusion (if needed to achieve goal CD34+ cell dose.CD45RA-depleted DLI will be given at least two weeks after engraftment. Blinatumomab will be given at least one week post-DLI, and only to patients with CD19+ malignancies. G-csf 5mcg/kg subcutaneous or intravenous daily until ANC >2000 for 2 consecutive days.~Cells for infusion are prepared using the CliniMACS system."
2445217|NCT03739905|Experimental|Blood Brain Barrier (BBB) Disruption|The ExAblate Model 4000 Type 2.0 System
3152919|NCT00263601|Placebo Comparator|Placebo|Placebo injections was given the same way: Seven injections (with 7 to 14 day intervals between each one) to reach maximum dose, followed by maintenance injections starting with 2 week intervals, followed by 4 week intervals until onset of the grass pollen season.
3152920|NCT00263627|Placebo Comparator|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
3152921|NCT00263627|Experimental|Specific Immunotherapy|Subcutaneous injections with birch pollen allergoid were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
3152922|NCT00263640|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
3152923|NCT00263640|Experimental|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
3152924|NCT00263705|Experimental|capecitabine|capecitabine 2000 mg/m² daily
3152925|NCT00263731||Group 1 (Experimental Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will receive 13-C-glucose prior to surgery
2445398|NCT03475134|Experimental|TIL-ACT +/- Nivolumab rescue|Non-myeloablative lymphodepleting chemotherapy (cyclophosphamide and fludarabine), Tumor Infiltrating Lymphocyte (TIL)-Adoptive Cell Therapy (ACT), Interleukin-2 (IL-2), Nivolumab rescue
2445419|NCT03409419||pre cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed before the treatment interventions.
2445420|NCT03409419||post cohort|Each subject will undergo a maximum of two 18F-Clofarabine PET/CT scans with each visit taking up to 4 hours. The 18F-Clofarabine PET/CT scans will be performed after the treatment interventions.
2445443|NCT03364127|Active Comparator|Experimental: Active Acupuncture|Active Acupuncture two times per week for 5 weeks
2445446|NCT03364127|Placebo Comparator|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
2445477|NCT03272698|Experimental|Ketamine (HIKER)|Patients in the HIKER arm will receive a single dose of ketamine 0.50 mg/kg, which is enough to achieve a full anaesthetic effect (i.e., unconsciousness mimicking the GA regimen above), on 8 successive weekdays.
2445479|NCT03272698|Active Comparator|Ketamine-ECT (EAST)|Patients in the EAST arm will initially receive intravenous ketamine 0.75 mg/kg, remifentanil 1 mcg/kg (to reduce discomfort), and succinylcholine 0.75 mg/kg (for safety). Based on patients' anaesthetic response, the attending anaesthesiologist is given the freedom to vary the dose of remifentanil and succinylcholine as well as administer propofol to achieve safe and acceptable anaesthetic conditions. As per the Saskatoon Health Region's care standard, patients in the EAST arm will receive eight ECT sessions (on a bi/triweekly schedule) delivered by the attending psychiatrist with either unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method.
2445496|NCT03272568|Experimental|Hemophilia A symptomatic female carriers|"Hemophilia A symptomatic female carriers with a baseline FVIII activity of ≤60% receive recombinant FVIII Fc fusion product Eloctate.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
2445499|NCT03272568|Experimental|Hemophilia B symptomatic female carriers|"Hemophilia B symptomatic female carriers with a baseline FIX activity of ≤60% receive recombinant FIX Fc fusion product Alprolix.~Some of participants will be taught to perform a hemoglobin check using a patient-operated diagnostic device for anemia AnemoCheck every other day during 2 consecutive menstrual cycles."
2445560|NCT03272243|Active Comparator|Short Segment posterior spine fixation|Short segment transpedicular screw fixation with inclusion of the index level
2445561|NCT03272243|Active Comparator|Long Segment posterior spine fixation|Long segment transpedicular screw fixation with escape of the index level
2445585|NCT03271918|Experimental|Study Group|This group received cabergoline, in a total week dose of 3.5 mg, starting 6 months after transphenoidal surgical approach with evidence of tumoral rest in MRI and pituitary adenoma hystopathological confirmation.
2445586|NCT03271918|No Intervention|Control Group|This group was followed, with clinical visits in same frequency of study group, but without intervention.
2445660|NCT03271671|Active Comparator|PSV|Pressure support ventilation
2445662|NCT03271671|Experimental|NAVA|Neurally adjusted ventilator assist
2445742|NCT03271242||Implementation support|Units and their patients where the unit according to pairwise randomization is offered systematic implementation support for 18 months for the specific practice.
2445743|NCT03271242||No implementation support|Units and their patients where the unit according to pairwise randomization is not offered systematic implementation support for 18 months for the specific practice.
2445820|NCT03270566|Experimental|Domestic ion-exchange water softener|The intervention group will have a domestic ion-exchange water softener installed prior to birth.
2445950|NCT03269799|Placebo Comparator|control group|placebo
3152926|NCT00263731||Group 2 (Control Group)|250 subjects with suspected or confirmed lung cancer undergoing surgical resection, will not receive 13-C-glucose prior to surgery
3152927|NCT00263731||Group 3 (Healthy Subjects)|250 healthy subjects (must be at least 30 years of age and have no prior history of diagnosed lung cancer) will provide 1 blood sample and 1 urine sample.
3152928|NCT00263744|Experimental|1|MEDI517
3152929|NCT00263744|Active Comparator|2|Aluminum hydroxide
3152930|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
3152931|NCT00263770|Active Comparator|outpatient surgical procedure|where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
3152932|NCT00263770|Sham Comparator|Sham surgery|an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
3152933|NCT00263783|Experimental|1|MEDI-522
3152934|NCT00263796|Experimental|Pitocin|
3152935|NCT00263796|Placebo Comparator|Placebo|
3152936|NCT00263809|Experimental|1|Treatment, Mirasol-treated platelets
3152937|NCT00263809|No Intervention|2|Reference, Untreated platelets
2445107|NCT03898037|Experimental|lifestyle intervention group|"Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up."
2445108|NCT03898037|Experimental|metformin intervention group|"Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.~The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
2445109|NCT03898037|Experimental|lifestyle combined with metformin intervention group|"Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.~The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up."
2445110|NCT03898037|No Intervention|routine clinical education group|Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures，including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.
2445135|NCT03859752|Experimental|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
2445154|NCT03832790||adolescents with type 1 diabetes|Adolescents ages 14-19 with type 1 diabetes
3152938|NCT00263939|Experimental|1 - In home intervention|In home (face to face) delivery of the study intervention, Homing in on Health
3152939|NCT00263939|Experimental|2 - Telephone intervention|Telephone delivery of the study intervention, Homing in on Health
3152940|NCT00263939|No Intervention|3 - Usual care|Patients receiving the care their usual health providers supply, without an study intervention
2445267|NCT03626311|Experimental|AKBM-3031|4g/day (2 capsules BID)
2445271|NCT03626311|Placebo Comparator|Placebo|4g/day (2 capsules BID)
2445295|NCT03605277|Experimental|Normal renal function|healthy volunteers with normal renal function
2445298|NCT03605277|Experimental|Severe renal impairment|subjects with severe renal impairment
2445300|NCT03605277|Experimental|Moderate renal impairment|subject with moderate renal impairment
2445301|NCT03605277|Experimental|Mild renal impairment|subjects with mild renal impairment
2445433|NCT03382977|Experimental|Dose Level 1|VBI-1901 low dose (0.4 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2446793|NCT03263494|Active Comparator|CGM|
3152941|NCT00264030|Other|1|PTCA
3152942|NCT00264030|Other|2|PTCA with angioguard
3152943|NCT00264043|Experimental|1|AngioGuard™ device and Bx Velocity™ stent
3152944|NCT00264069||001|
3152945|NCT00264069||002|
3152946|NCT00264095||001|
3152947|NCT00264108||1|Epoetin alfa 40 000 IU once weekly variable treatment length.
3152948|NCT00264108||2|Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
2445092|NCT03910218|Experimental|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring,Pre exposure prophylaxis (PrEP) eligibility screening,PrEP/non occupational post exposure prophylaxis(nPEP)services (labs, medication), healthcare planning/coordination, Motivational Interviewing (MI) counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
2445093|NCT03910218|Placebo Comparator|Usual care|Participants will receive the usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling,substance use treatment referrals,PrEP/nPEP referrals
3152949|NCT00264160|Experimental|AMN107|
3152950|NCT00264199|Active Comparator|1|
2445210|NCT03765567|Experimental|Intervention Arm|Subjects randomized to the Intervention Arm will receive usual care plus two (2) grams of Vancomycin powder administered topically. In the emergency room prior to surgical intervention, a qualified member of the study team or clinical team member will apply 2 grams of vancomycin powder directly to the open fracture site such that all visible surfaces of the wound are completely and uniformly covered, including bone edges.
2445212|NCT03765567|No Intervention|Control Arm|Subjects randomized to the Control Arm will receive usual care for open long bone fracture as determined by the treating physician.
2445214|NCT03765567|No Intervention|Observational Arm|Subjects who otherwise meet the criteria to be included in the study but are not able to provide consent, either themselves or through a Legally Authorized Representative, will be placed in the Observational Arm and receive usual care with no experimental intervention.
2445238|NCT03704207|Other|Nasal Nitric Oxide testing and collection of clinical data|Participants will have nNO testing is indicated. All participants in this study have some basic clinical data collected at time of enrollment. Participants with a confirmed diagnosis of PCD or in those participants with a working diagnosis of PCD in which ongoing nNO testing is performed have prospective data collection. Some participants have a confirmed diagnosis of PCD by genetics or ciliary biopsy at time of study entry and thus do not need nNO testing, but are followed prospectively with collection of basic clinical data
3152951|NCT00264199|Placebo Comparator|2|
2445402|NCT03466203|Experimental|LLF580|LLF580 every 28 days * 3
2445403|NCT03466203|Placebo Comparator|Placebo|Placebo to LLF580 every 28 days * 3
2445421|NCT03408704|Experimental|ASP-arm|This group of primary health care centers get the internal education (ASP).
2445422|NCT03408704|No Intervention|Control-arm|No intervention at all.
2445519|NCT03272542|Experimental|Prebiotic: soluble corn fiber|SCF (PromotorTM Soluble Corn Fiber 85, provided by manufacturer Tate & Lyle) will be dispensed to participants as a dry powder in sachets of 12 g SCF85 product (which is approximately 10 g fiber). Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be asked to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
2445521|NCT03272542|Placebo Comparator|Placebo|The placebo control will be maltodextrin powder in identical sachets. Participants will mix the powder into 250 mL water and consume two such beverages daily, ≥1 hour apart. (For the first week, all participants will consume one beverage daily, and subsequently increase to one beverage twice daily.) Participants will be requested to substitute these for 500 mL of their usual daily water intake but to make no other dietary changes.
3152952|NCT00264264|Active Comparator|Direct Compression|
3152953|NCT00264264|Active Comparator|Closure Device|
2445673|NCT03271632|Experimental|Single arm|CAR T cells to treat MM
2445722|NCT03271190|Experimental|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills and application in selected leisure activities (music or Spanish lessons, and videogames) over 4 months.
2445724|NCT03271190|Active Comparator|ENGAGE DISCOVERY|Educational program about brain and healthy aging complemented by learning of new information with videogames, documentaries and group discussions over 4 months.
2445790|NCT03270904|Experimental|Group 1 - Interventional Treatment|Participants in this group have been randomised to receive application of violet blue light administered by the hand held Microlight i:X device in addition to routine care of their foot ulcer. This intervention will be administered four times during the study.
2445791|NCT03270904|No Intervention|Group 2 - Usual care|This group receive routine care and no additional intervention.
3152954|NCT00264394|Experimental|Updated CHD risk profiles|Provision of regularly updated CHD risk profiles
2446794|NCT03263494|No Intervention|BGM|
3152955|NCT00264394|Active Comparator|Guidelines|Physicians received guidelines only
3152956|NCT00264420|Experimental|1|zoledronic acid plus radiation therapy
3152957|NCT00264459|Placebo Comparator|Placebo|Placebo was given the same way as a sublingual preparation.
3152958|NCT00264459|Experimental|Liquid formulation of an extract of a 6 grass pollen mixture|"Sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter. Initial treatment was applied on the first day of treatment with a starting dose of 25% of the maintenance dose. Increasing doses of 50% were applied with the second and 100% with the third dose to give the maximum (=maintenance) dose. This was followed by a daily patient selfadministered treatment with the maintenance dose."
3152959|NCT00264511|Experimental|Hyperbaric oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
3152960|NCT00264511|No Intervention|No hyperbaric oxygenation|Patients randomised to this group will receive standard trauma care.
3152961|NCT00264563||Behavioral|The intervention is basically by letting the care givers to be aware that there is active recording of iatrogenesis
3173139|NCT00608660|Experimental|C|staging electroacupuncture for treating Bell's Palsy
3152962|NCT00264589|Other|Study Population|"non-diabetic obese subjects and type 2 diabetic subjects~Intervention: 8 weeks individualized training program"
3152963|NCT00264602|Experimental|Near Infrared Imaging|The intervention to be administered is indocyanine green dye.
2445211|NCT03764995|Experimental|Abdominal Massage|
2445213|NCT03764995|Placebo Comparator|Placebo Ultrasound|
3152964|NCT00264693||P - A|Prophylactic Dosage, GFR >= 60 mL/min/1.73m^2
3152965|NCT00264693||P - B|Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2
2445254|NCT03650816||Alzheimer Disease|"Patients with Alzheimer's disease, as defined by the established clinical consensus criteria (DSM IV-TR and NINCDS-ADRDA)~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
2445257|NCT03650816||Subjective Cognitive impairment|"Patients with subjective cognitive impairment, who consulted for cognitive complaint without cognitive impairment on neuropsychological tests and normal performances according to daily life activities scores.~Doppler ultrasonography will be used in these patients to assess CVR CO2 , as a change in blood flow in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.~Biospecimen collection will be performed in these patients : a blood sample of 10 ml will be drawn in addition to the blood sample taken as part of patient usual care, to determine plasma concentration of ET-1, bigET-1, ADMA and plasma renin activity"
3152966|NCT00264693||P - C|Prophylactic Dosage, GFR < 30 mL/min/1.73m^2
3152967|NCT00264693||P - CAPD|Prophylactic Dosage, CAPD
3152968|NCT00264693||T - A|Therapeutic Dosage, GFR >= 60 mL/min/1.73m^2
3152969|NCT00264693||T - B|Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2
3152970|NCT00264693||T - C|Therapeutic Dosage, GFR < 30 mL/min/1.73m^2
2445373|NCT03493425|Active Comparator|Arm A (surgery, IMRT, cisplatin, carboplatin)|Patients undergo standard of care surgery. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV over 1-2 hours or carboplatin IV over 30 minutes (for patients who are ineligible to receive cisplatin) weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
2445375|NCT03493425|Experimental|Arm B (docetaxel, cisplatin, carboplatin, surgery, IMRT)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 1-2 hours on day 1. Patients who are ineligible to receive cisplatin receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery no later than 6 weeks following the last dose of chemotherapy. Beginning 4-6 weeks after surgery, patients undergo image guided IMRT QD for 5 fractions per week for 30 fractions. Patients with positive margins/positive ECS in lymph nodes undergo image guided IMRT QD for 5 fractions per week for 30 fractions and cisplatin IV or carboplatin IV weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.
2445559|NCT03272256|Experimental|IM156, Dose escalation|
2445599|NCT03271931|No Intervention|Usual care|Cardiologists in this arm will receive no interventions and will act as usual care
2445602|NCT03271931|Experimental|Active choice|Cardiologists in this arm will be exposed to an active choice intervention through the electronic health record (EHR) using an alert to prompt recommendations for statin therapy for patients not on guideline-based therapy. Cardiologists will be have to make an active choice to prescribe a statin at the recommended dose or not.
2445605|NCT03271931|Experimental|Passive choice|Cardiologists in this arm will be exposed to a passive choice alert within the EHR, using the same evidence-based guidelines as in the active choice arm. The passive alert will not block clinician workflow and instead will be available in the background for the cardiologist to open and then use to make a prescribing decision.
2445646|NCT03271619||Transvenous ICD|Patients with a transvenous ICD undergoing defibrillation testing.
2445648|NCT03271619||Subcutaneous ICD|Patients with a subcutaneous ICD undergoing defibrillation testing.
2445739|NCT03271359|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
2445740|NCT03271359|Experimental|Progressive counting (PC) arm|
3152971|NCT00264693||T - CAPD|Therapeutic Dosage, CAPD
3152972|NCT00264706|Other|Participant|Internal control study
3152973|NCT00264719|Active Comparator|A|Mothers with pre-term deliveries will receive metoclopramide 10 mg three times a day for the first 7 days and 2 times a day for the 8th to 10th day, and once a day for the 11th to 12th day
2445854|NCT03270111|Experimental|A2: Breast Cancer Survivor|Participants will include breast cancer survivors who take part in a weight loss intervention program. The intervention is the same for all participants.
2445856|NCT03270111|Experimental|B: High Risk Women|Participants will include women at high risk of breast cancer who take part in a weight loss intervention program. The intervention is the same for all participants.
2446032|NCT03268850|Experimental|LW-A|The Lost Wages A (LW-A) arm will be composed of kidney transplant patients meeting the inclusion criteria. This arm allows for possible wage reimbursement of living donor lost wages up to a certain amount. This will also include standard of care.
2446149|NCT03268135||Controls|Measurement of RNAs in individuals not affected by cardiovascular diseases
3152974|NCT00264719|Placebo Comparator|B|Mothers with pre-term deliveries will receive metoclopramide 10 mg 3 times a day, 2 times a day from 8th to 10th day and once a day from 11th to 12th day
3152975|NCT00264719|Active Comparator|C|Mothers with full term deliveries will receive 10 mg metoclopramide, 3 times a day for the first 7 days, 2 times a day from 8th to 10th day, and once a day for day 11 to 12
3152976|NCT00264719|Placebo Comparator|D|Mothers with full term deliveries will receive the placebo 10 mg three times a day, for 7 days, and two times a day from day 8 to day 10, and once a day from 11th to 12th day
3152977|NCT00264732|Experimental|1|
3152978|NCT00264732|Experimental|2|
3152979|NCT00264732|Placebo Comparator|3|
2445123|NCT03885401|Experimental|Enhanced care planning|The intervention consists of two components - enhanced care planning and clinical-community linkages. The enhanced care plan is created using MOHR (https://myownhealthreport.org). MOHR screens patients for unhealthy behaviors, mental health needs, and social needs. Patients identify the needs they would like to address and create a care plan, which they update quarterly. A clinical navigator and community health worker (CHW) help patients address their care plans using clinical-community linkages, which has four components. First, clinicians and clinical navigators have a resource registry identifying community programs and support - No Wrong Door (NWD) and https://navigator.aafp.org/. Second, MOHR shares information (care plans, patient narrative, and patient progress) across clinical and community team members. Third, MOHR supports messaging and video visits for team members and patients. Finally, MOHR sends care team members quarterly patient progress updates.
2445125|NCT03885401|No Intervention|Usual medical care|"Clinicians randomized to the control condition will continue to provide usual care. This includes current non-systematic assessment of health behaviors, mental health needs, and social needs. Neither clinicians nor patients will be eligible to receive CHW support or have access to NWD. Clinicians may refer some control patients to community programs as part of their current usual care. Control clinicians will be blinded as to which patients are included in the study. At the end of the study, the investigators will share with control clinicians our lessons learned, access to MOHR, and lists of useful community resources."
2445153|NCT03844087|Experimental|multiplanar neuromuscular training arm|The intervention arm will be involved in the training intervention outlined. Briefly, each participant will be asked to train on the TopSpin360 3 times per week for 3-5 sets for the duration of the study. Each set will take roughly 15-30 seconds to perform and training will take part during regularly scheduled training sessions.
3152980|NCT00264745|Experimental|1|
3152981|NCT00264745|Active Comparator|2|
3152982|NCT00264758|Active Comparator|Conventional hemodialysis|Three times per week in-center hemodialysis
2445800|NCT03270878|Experimental|Glasdegib Oral tablet then IV|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions in the first study period followed by washout. Then in the second period, a 50 mg IV solution will be infused over approximately 1.25 hours under fasted conditions.
2445801|NCT03270878|Experimental|Glasdegib IV solution followed by Oral tablet|Subjects will receive a 50 mg IV solution will be infused over approximately 1.25 hours in the fasted condition followed by washout in the first study period . Then in the second period, a single 100 mg oral tablet of glasdegib will be administered under fasted conditions
2445839|NCT03270397|Experimental|Active participants|"The first 20 students who signed up for the course: The group- theory and practice were included. No exclusion criteria were used. Full attendance in the course which includes 13 sessions was mandatory. In each session, students were assigned to different body image tasks that were discussed in the coming session. All students completed a self-report questionnaire at baseline and conclusion of the course."
2445840|NCT03270397|No Intervention|Controls|All the other students, that requested to sign up for the course but did not have a place, served as control group. All students completed a self-report questionnaire at baseline and conclusion of the course.
2446000|NCT03269214|No Intervention|control group|Patients underwent debridement of necrotic bone and the involved area closed primary
2446001|NCT03269214|Experimental|treatment group|Patients received topical Phenytoin 5%+ Tetracycline after debridement before final closure.
2446028|NCT03268798|Experimental|Wrist extension training|
2446130|NCT03268174|Active Comparator|AO+Mist|AO+Mist
2446132|NCT03268174|Placebo Comparator|Placebo|Placebo
2446246|NCT03267329|Experimental|Duowell® Tab.|Once daily during 16 wks
2446252|NCT03267329|Active Comparator|Telmisartan|Once daily during 16 wks
2446263|NCT03267030|Experimental|GRASPA|GRASPA will replace remaining PEG-asparaginase doses in case of hypersensitivity.
3152983|NCT00264758|Experimental|Frequent hemodialysis|Six times per week in-center hemodialysis
3152984|NCT00264823|Experimental|1 - Experimental|
2446362|NCT03266185|Experimental|45-minutes|45-minutes post-infusion cooling time
2446365|NCT03266185|Experimental|20-minutes|20-minutes post-infusion cooling time
2446370|NCT03266185|No Intervention|No scalp cooling|Patients who decline scalp cooling will be included as a control group to determine the incidence of paclitaxel-induced alopecia
2446416|NCT03265977|Experimental|H56:IC31|5 ug H56/500 nmol IC31, 0.5 mL Intramuscular (IM), Days 0 and 56
2446418|NCT03265977|Placebo Comparator|Placebo|Normal saline, 0.5 mL IM, Days 0 and 56
3152985|NCT00264823|No Intervention|2 - Control|
3152986|NCT00264953|Active Comparator|A|4x ABVD plus 30Gy IF-RT
3152987|NCT00264953|Experimental|C|4x BEACOPP baseline plus 30Gy IF-RT
3152988|NCT00264953|Experimental|B|4x ABVD plus 20Gy IF-RT
3152989|NCT00264953|Experimental|D|4x BEACOPP baseline plus 20Gy IF-RT
3152990|NCT00264979|Other|1|Simultaneous surgery of colorectal cancer and synchronous liver metastases
3152991|NCT00264979|Other|2|Sequential surgeries of colorectal cancer and synchronous liver metastases
3152992|NCT00265005|Experimental|All|All subjects receive active drug up to a total of 3 doses
3152993|NCT00265018|Active Comparator|Arm A|
3152994|NCT00265018|Experimental|Arm B|
3152995|NCT00265018|Experimental|Arm C|
3152996|NCT00265018|Experimental|Arm D|
3152997|NCT00265044|Other|Arm 1|
3152998|NCT00265135|Experimental|Part 1 (CNTO 328)|In Part 1 of the study, 4 intravenous infusions (IV) [injection of a substance into a vein] of CNTO 328 will be administered to patients in 4 dose levels ranging from 1, 3, 6, and 12 mg/kg on days 1, 29, 43, and 57 to determine the maximum tolerated dose for Part 2 of the study.
3152999|NCT00265135|Experimental|Part 2 (CNTO 328)|In Part 2 of the study, 2 well tolerated dose levels of CNTO 328 from Part 1 of the study will be administered every 3 weeks as 4 IV infusions to patients.
3153000|NCT00265135|Experimental|Part 3 (CNTO 328)|In Part 3 of the study, CNTO 328 at a dose level of 6 mg/kg will be administered as IV infusion every 2 weeks for at least 6 doses.
3153001|NCT00265226|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category II ATT according to RNTCP guidelines
3153002|NCT00265226|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category II ATT drugs according to RNTCP guidelines
3153003|NCT00265356|Experimental|1|PET diagnostic imaging
3153004|NCT00265356|No Intervention|2|No PET
2445329|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for six weeks.
2445330|NCT03538938|Experimental|1-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2445331|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement are for completing the counseling call.
2445332|NCT03538938|Experimental|1-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokeFreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2445333|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive the following: 1-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Patch treatment will consist of a 4 week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). The Financial Incentives are for completing the counseling call and for staying enrolled in the SmokefreeTXT program for 6 weeks.
2445334|NCT03538938|Experimental|1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. Nicotine Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2445336|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). No SmokefreeTXT text messaging in support of cessation will be offered proactively. The Financial Incentives for treatment engagement are for completing the counseling call.
2445350|NCT03536429|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
3153005|NCT00265408|Experimental|aspirin|
3153006|NCT00265408|Experimental|warfarin|
3153007|NCT00265434|Active Comparator|Dornase alfa|DBPC-cross over trial
3153008|NCT00265434|Placebo Comparator|isotonic saline|
3153009|NCT00265447|Active Comparator|Strength training|3 months of strength training
3153010|NCT00265447|Active Comparator|Aerobic conditioning|3 months of aerobic conditioning
3153011|NCT00265447|Other|Delayed exercise|delayed exercise control group
3153012|NCT00265525|Experimental|Cardio fit|
3153013|NCT00265525|No Intervention|Usual Care|
2445241|NCT03698539||Down syndrome who stutter|"This group consists of individuals with Down syndrome who stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures and stutter frequency are investigated in this group."
2445242|NCT03698539||Down syndrome who do not stutter|"This group consists of individuals with Down syndrome who do not stutter. They have a mild or moderate intellectual disability and are able to understand and produce a three word sentence.~Spontaneous hand gestures are investigated in this group"
2445244|NCT03698539||Typically developing children who stutter|This group consists of typically developing children who stutter. They function as a control group to the individuals with Down syndrome.
2445245|NCT03698539||Typically developing children who do not stutter|This group consists of typically developing children who do not stutter. They function as a control group to the individuals with Down syndrome.
2445273|NCT03629080|Experimental|HB-101 vaccine preemptive|Three doses of HB-101 vaccine will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
2445274|NCT03629080|Placebo Comparator|Placebo preemptive|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post-transplant patients will be monitored per preemptive institutional standard.
2445275|NCT03629080|Experimental|HB-101 vaccine prophylactic|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
2445276|NCT03629080|Placebo Comparator|Placebo prophylactic|Three doses of placebo will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of placebo will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
2445277|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Prophylactic Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will receive 3-6 months anti-viral prophylaxis following institutional standard.
2445278|NCT03629080|Experimental|HB-101 vaccine: CMV (+) patients-Preemptive Management|Three doses of HB-101 will be administered prior to transplantation and within proximity to the time of transplantation. However, two doses of HB-101 will be sufficient for the patients to be included in the efficacy analyses if an administration of the third dose is not feasible due to transplantation timelines. Post- transplant patients will follow pre-emptive management per institutional standard.
2445302|NCT03590002|Experimental|Electronic ICU Medical Transfer Tool|ICUs allocated to the experimental arm will have access to the electronic Medical Transfer of Care Documentation Tool within the clinical information system (CIS) in order to prepare ICU transfer of care documents for the receiving medical care team.
2445303|NCT03590002|No Intervention|Dictated ICU Medical Transfer|Usual Care, ICUs in the control group will only have access to the dictation documentation system as the standard method to prepare ICU medical transfer documents. New ICU medical staff responsible for preparing transfer documents will receive the usual training on the dictation system.
3153014|NCT00265603|Experimental|1 Arm|The investigators plan to have approximately 16 persons participate in the study of transimmunization. Transimmunization uses a device, called a UVAR-XTS instrument, to remove a portion of blood, part of which is returned, and part of which is incubated overnight before being returned to the bloodstream the next day
3153015|NCT00265629|Experimental|1|RF ablation
3153016|NCT00265642|Experimental|group verum|Drug: Irbesartan
3153017|NCT00265642|Placebo Comparator|group placebo|
3153018|NCT00265720|Placebo Comparator|Control|Written materials only
3153019|NCT00265720|Experimental|Reduced out-of-pocket expense|Reimbursed up to $500 out-of-pocket expense for colorectal cancer screening
3153020|NCT00265720|Experimental|One-on-one education|Individual education with a health educator on CRC screening
3153021|NCT00265720|Experimental|Group Education|Education on CRC screening in a small group with a health educator
3153022|NCT00265733|Experimental|paclitaxel + capecitabine|"Patients receive paclitaxel poliglumex IV (CT-2103; Xyotax™) over 10-20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 6 months for up to 5 years."
2445418|NCT03411837||Dupilumab|Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care
2445427|NCT03384212|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2445428|NCT03384212|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2445541|NCT03272230|Experimental|Healthy control|"Healthy age, sex and education matched controls~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2445705|NCT03271450||Discontinuer at 270 Days: Warfarin|
3153023|NCT00265811|Experimental|Folfox+Cetuximab|FOLFOX-4 Cetuximab alone every 2 weeks
3153024|NCT00265811|Active Comparator|Folfox|FOLFOX-4 alone every 2 weeks
3153025|NCT00265824|Active Comparator|bevacizumab alone|
3153026|NCT00265824|Experimental|Bevacizumab + erlotinib|
3153027|NCT00265863|Experimental|Patients with Malignant Ascites|Patients meeting protocol criteria enrolled with malignant ascites.
3153028|NCT00265876|Experimental|AZD0530 + Gemcitabine|
3153029|NCT00265954|Experimental|1|Individuals in this arm receive a 6 month behavioral weight loss intervention delivered on-line. Groups meet via a web chat weekly for 24 weeks and monthly for the following 12 months.
3153030|NCT00265954|Experimental|2|In-person; Individuals in the in-person condition attend weekly group behavioral weight loss sessions for 24 weeks and then monthly sessions for the following 12 months.
3153031|NCT00265954|Experimental|3|In-person+internet; Individuals in this condition receive a behavioral weight loss intervention over the internet weekly for 24 weeks and monthly for the following 12 months. Every month during the first 24 weeks and every third month during the following year they have an in-person meeting.
3153032|NCT00265967|Experimental|1|Irbesartan
2445451|NCT03384225|Experimental|CBA group|"CBA as HSCT conditioning:~cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2445453|NCT03384225|Active Comparator|FBA group|"FBA as HSCT conditioning:~fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2"
2445480|NCT03272646||Group 1 or NPS = 0|Patients undergoing surgery without alterations of the albumin and cholesterol levels, with normal NLR and LMR ratios.
2445481|NCT03272646||Group 2 or NPS >0 and < 3|Patients undergoing surgery with NPS between 1 or 2
2445483|NCT03272646||Group 3 or NPS > 2|Patients undergoing surgery with three or four alterations
2445502|NCT03272529||Patient-specific simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. This is in addition to standard prerequisite simulation training.
2445508|NCT03272529||Idealized simulated rehearsals|Participants recruited to this cohort will complete just-in-time simulation, i.e., practice a short time prior to the live event using hydrogel models that incorporate the necessary anatomy, physiology, and pathology of an ideal training case. This is in addition to standard prerequisite simulation training.
2445517|NCT03272529||Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in this group in addition to the standard.
2445548|NCT03272269|Experimental|Cohort 1, low dose|4 SC injections of IMCY-0098 or Placebo
2445550|NCT03272269|Experimental|Cohort 2, medium dose|4 SC injections of IMCY-0098 or Placebo
2445553|NCT03272269|Experimental|Cohort 3, high dose|4 SC injections of IMCY-0098 or Placebo
2445578|NCT03271866|Other|metformin treatment|
2445579|NCT03271866|No Intervention|non-metformin treatment|
2445634|NCT03271762|Experimental|MITRACLIP NT, MITRACLIP NTR/XTR, MITRACLIP G4NT/XT, MITRACLIP G4NTW/XTW Device|MitraClip NT System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
2445635|NCT03271762|Active Comparator|cardiac surgery|mitral valve repair in first intervention, valve replacement if repair not feasible
2445699|NCT03271385||hypertrophic cardiomyopathy group|The hypertrophic cardiomyopathy was diagnosed by left ventricular hypertrophy via echocardiography (wall thickness >15 mm) with either genetic determination of a pathogenic mutation or ) left ventricular hypertrophy (LVH) (end-diastolic wall thickness >15 mm) with resting left ventricular outflow tract obstruction or hypertrophy in a recognisable pattern, i.e., ventricular bulge in apical-variant HCM. And then patients with hypertrophic cardiomyopathy were evaluated by the predetermined differentiating formula.
2445704|NCT03271385||hypertensive heart disease group|The diagnosis of hypertensive heart disease was based on medical history and conventional echocardiography. Long durations of uncontrolled hypertension for at least 5 years with systolic blood pressure [BP] ≥150 mm Hg or diastolic BP ≥90 mm Hg or both in the absence of other cardiac or systemic diseases were used as criteria. And then patients with hypertensive heart disease were evaluated by the predetermined differentiating formula.
2445708|NCT03271385||control group|The healthy age-matched controls were generally volunteers with a normal electrocardiogram, normal echocardiographic examination, and overall normal CMR findings. And then patients with normal findings were were evaluated by the predetermined differentiating formula.
2445745|NCT03271125|Experimental|Treadmill group|Participants in the experimental group received supervised treadmill training
2445746|NCT03271125|Active Comparator|Resistance group|Participants in the control group were treated with Resistance exercises.
2445794|NCT03270800|Experimental|IMX101 vaccine as intradermal and sublingual application|IMX101 vaccine will be administered intradermally and sublingually
2445796|NCT03270800|Experimental|CTA control as intradermal and sublingual application|CTA mucosal adjuvans will be administered intradermally and sublingually
2445871|NCT03270475|Experimental|Exercise|12-15 training sessions of 30 min over 4-5 weeks
2445911|NCT03269812|Experimental|laparoscopic operated group|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
2445912|NCT03269812|Experimental|non laparoscopic operated group|Under general anesthesia ,abdominal exploration ,removal of a ganglionic part by soav ,duhamel procedures and trans-anal pull through procedures.
2445943|NCT03269487||Healthcare professionals in partner sites|NHS employee or student nurse involved in the delivery of care to patients on partner wards in which the PERFECTED ERP is being implemented.
2445981|NCT03269331||ARCC EBP Model|CTEP EBP Immersion Course
2445982|NCT03269331||Control Group|No CTEP EBP Immersion Course
2446045|NCT03268967|Active Comparator|Structured Admission procedure|After implementation of a structured admission procedure to all ICU patients inspired by principles of Crisis Resource Management, Closed loop communication, action cards, and staff simulation training
2446048|NCT03268967|No Intervention|Standard Care|Randomly admission procedure to all ICU patients based on the clinicians' evaluation prior implementation of the intervention.
2446086|NCT03268317||Patients with chronic hepatitis C treated by DAAs|All subjects will be given the same treatment regimen which includes Sofosbuvir 400 mg orally/24 hours (pre-breakfast) and Daclatasvir 60 mg orally/24 hours after lunch with or without ribavirin for a total period of 12 weeks.
2445305|NCT03588286|Experimental|Intervention Arm (Early EPS)|"The intervention group all undergo electrophysiologic study early after myocardial infarction (within 40 days of MI).~If the study is positive (inducible monomorphic ventricular tachycardia of cycle length greater than or equal to 200ms) participants have an ICD implanted. Participants with a negative study (no inducible arrhythmia or induced ventricular fibrillation/ ventricular flutter cycle length <200ms) are discharged without an ICD.~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
2445308|NCT03588286|Active Comparator|Control Arm (Standard Care)|"The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).~A proportion of trial patients from both the intervention and control arms at >48 hours following revascularisation for STEMI will undergo CMR to enable correlation with (1) inducible VT at EPS and (2) SCD and non-fatal arrhythmia on follow up. CMR will simultaneously assess left ventricular function, ventricular strain, myocardial infarction size, and peri-infarction injury."
2445358|NCT03529825|Experimental|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
2445359|NCT03529825|No Intervention|Retrospective comparison cohort|Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
3153033|NCT00265993|Experimental|1|enoxaparin
3153034|NCT00266058|Active Comparator|Lopinavir/ritonavir, artemethr/lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretrovirals lopinavir and ritonavir.
2445492|NCT03320200|Experimental|CNS-focused treatment|Group of subjects receiving a 10 week CNS (Central Nervous System) -focused treatment program for frozen shoulder in addition to 5 days per week home treatment program
2445493|NCT03320200|Experimental|Standard Care Treatment|Group of subjects receiving a 10 week standard care treatment program for frozen shoulder in addition to 5 days per week home treatment program based on conventional physiotherapy
2445500|NCT03272425|Experimental|Sequence ABBA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2445504|NCT03272425|Experimental|Sequence BABA|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2445513|NCT03272425|Experimental|Sequence ABAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2445515|NCT03272425|Experimental|Sequence BAAB|Treatment A: Lesinurad/Allopurinol FDC Tablets - 200/300 mg (test product); Treatment B: lesinurad, tablets, 200 mg + Zyloric®, allopurinol, tablet, 300 mg (comparator 1 + comparator 2).
2445572|NCT03272217|Experimental|Arm A - Atezolizumab + Bevacizumab|Patients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
2445620|NCT03271736|Experimental|Freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
2445621|NCT03271736|Experimental|Non-freezer|All the subjects received 2 experiments. 2 experiments contain 20 mins stepping-in-place exercise and pre-/post assessments. The difference between 2 experiments is the application of auditory cues. One of the 2 experiment includes stepping-in-place exercise with auditory cues from the metronome (Stepping-in-place exercise with external auditory cues), in the other experiment we ask the subjects to follow their internal rhythm without external auditory cues (Stepping-in-place exercise without external auditory cues). Transcranial magnetic stimulation (TMS) is applied before and after the stepping-in-place exercise.
2445647|NCT03271515|No Intervention|conventional therapy|patients accept conventional radioactive and chemical therapy.
2445649|NCT03271515|Experimental|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
2445749|NCT03271099|No Intervention|Usual Care|Usual care
2445752|NCT03271099|Experimental|Navigator|Patient navigator services provided as part of survivorship care plan
2445766|NCT03270787|Placebo Comparator|Placebo Comparator|Placebo Comparator: controlled group Placebo,10pills,tid,po
3153035|NCT00266058|Active Comparator|efavirenz, artemether, lumefantrine|Determination of the antimalarial drug levels artemether/lumefantrine in the absence and in the presence of co-administered antiretroviral efavirenz.
3153036|NCT00266097|Experimental|Part I|Oxaliplatin + Gemcitabine + Radiation
3153037|NCT00266097|Experimental|Part II|Erlotinib + Oxaliplatin + Gemcitabine + Radiation
3153038|NCT00266214|Experimental|Lidocaine Patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
3153039|NCT00266214|Placebo Comparator|Placebo|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime.
3153040|NCT00266240|Experimental|1|
3153041|NCT00266240|Experimental|2|
3153042|NCT00266240|Experimental|3|
3153043|NCT00266240|Experimental|4|
2445326|NCT03545464|Active Comparator|Association of antihistamines and cortancyl|"- In emergency department : Levocetirizine 5 mg orally Renewable once if persistence of hives at 30 minutes.~Cortancyl: 1 mg/kg (the number of tablets the patient needs to take is based on his weight and is noted on annex 4), once orally.~- At home : Levocetirizine 5 mg twice daily for 7 days (D1 to D7). If persistence of hives, levocetirizine 10 mg twice daily for 7 more days (D8 to D14).~Cortancyl : 20 mg x 2 tablets = 40 mg per day for 3 days orally"
2445356|NCT03521466|Experimental|Intervention|Smoking Cessation counseling by trained medical students with or without Nicotine Replacement Therapy
2445357|NCT03521466|No Intervention|Control|The control group will receive counseling and/or NRT at the discretion of the treating physician.
3153044|NCT00266240|Placebo Comparator|5|
3153045|NCT00266253|Experimental|1|
2445751|NCT03271086|Experimental|Relaxation breathing training|Dyads of a parent and their child in this group will receive training on how to use breathing to relax with the StressEraser in the pediatric clinic and will then practice the breathing for about 4 weeks They will also complete a baseline questionnaire and two questionnaires one month after the training.
2445754|NCT03271086|Experimental|Technology-enhanced relaxation breathing|Dyads of a parent and their child in this group will receive technology-enhanced training on how to use breathing to relax with the StressEraser and the app Breathe2Relax in the pediatric clinic and will then practice the breathing for about 4 weeks and weekly receive weekly reminder text messages to practice their relaxation breathing. They will also complete a baseline questionnaire and two questionnaires one month after the training.
2445793|NCT03270748|Experimental|Experimental|Experimental: Experimental The experimental consists in the application of a therapeutic strategy: post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies Therapeutic intervention, namely conditioning regimen and GVHD prophylaxis, are based on standard current regimens: Busulfan 0,8 mg/kg 4 times per day during 2 h infusions for 4 consecutive days (from day -6 through day -3) Fludarabine 40 mg/m2 per day for 4 days (from day -6 through day -3); GvHD prophylaxis: Cyclosporine or Tacrolimus beginning day+5 up to at least 100 days. Micofenolate 15mg/kg twice a day from day +5 to +35.
2445851|NCT03270241|Experimental|Phototherapy (NB-UVB)|Phototherapy (NB-UVB) will be administered for all enrolled subjects. The starting dosage will be 250 mJ/cm2. The dose will be increased by 10% with each treatment, as long as there are no side effects with treatment.
2445872|NCT03269981|Experimental|Whole breast irradiation|Post-lumpectomy radiotherapy to the whole breast alone.
2445874|NCT03269981|Active Comparator|Whole breast and nodal irradiation|Post-lumpectomy radiotherapy to the whole breast and regional lymph node.
2445895|NCT03269773|Experimental|FURESTEM-AD Inj.|hUCB-MSC 5.0x10^7 cells
2445899|NCT03269773|Placebo Comparator|Placebo|
2445936|NCT03269461|Experimental|30 days evaluation|Angiography and Optical Coherence Tomography evaluations
2445939|NCT03269461|Experimental|2 months evaluation|Angiography and Optical Coherence Tomography evaluations
2445941|NCT03269461|Experimental|3 months evaluation|Angiography and Optical Coherence Tomography evaluations
2445989|NCT03269201||Parkinson;s Disease|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2445991|NCT03269201||Essential tremor|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
2445992|NCT03269201||Multiple system atrophy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2445993|NCT03269201||Normal Pressure Hydrocephalus|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
2445994|NCT03269201||DYSTONIA-focal, generalized and others|"Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia~.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia"
2445995|NCT03269201||Cerebellar ataxia|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
2445996|NCT03269201||Progressive supranuclear palsy|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2445997|NCT03269201||Corticobasal degeneration|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2445998|NCT03269201||Dementia with Lewy Bodies|Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
2446528|NCT03265002|Experimental|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
3153046|NCT00266253|Experimental|2|
2445338|NCT03538938|Experimental|1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 1-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. The proactive counseling call will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2445340|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination:4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). The Financial Incentives for treatment engagement are for completing each of the four counseling calls and for staying enrolled in the SmokefreeTXT program for six weeks.
2445342|NCT03538938|Experimental|4-Call, Patch, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to two weeks prior to the target quit day and for six weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2445344|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
2445346|NCT03538938|Experimental|4-Call, Patch, No SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, two weeks of Nicotine Patch, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD). SmokefreeTXT text messaging in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
2445349|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive|Participants will receive: 4-Call Quitline Counseling, 4 weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each counseling call will last approximately 20 min. Patch treatment will consist of a 4 week supply of over-the-counter (OTC) nicotine patches (21 mg for if smoking 10 or more cigarettes per day (CPD); 14 mg if smoking fewer than 10 CPD); Lozenge treatment will consist of a 4 week supply of OTC nicotine lozenges (2-mg dose for those who do not smoke within 30 min of waking; 4-mg dose for those who smoke within 30 min of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day [TQD] and for 6 weeks following the TQD). Financial Incentives are for completing each of the 4 counseling calls and for staying enrolled in SmokefreeTXT for 6 weeks.
2445351|NCT03538938|Experimental|4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, instruction in enrolling in SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a 4-week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a 4-week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will consist of 6-8 weeks of text messages (up to 5 messages per day for up to 2 weeks prior to the target quit day and for 6 weeks following the target quit day). Financial Incentives for treatment engagement will not be offered.
2445352|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenge, No SmokefreeTXT, and Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT text messaging in support of cessation will not be offered proactively. The Financial Incentives for treatment engagement are for completing each of the four counseling calls.
3208922|NCT00979381||1|Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks
2445406|NCT03461120|Experimental|Treatment|Bupivacaine 0.3% [or ropivacaine 0.5%] infusion for 7 days via femoral and sciatic perineural catheters
2445547|NCT03272360||Chronic Pelvic Pain|
2445549|NCT03272360||Elective Tubal Ligation|
2445353|NCT03538938|Experimental|4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive|Participants will receive the following treatment combination: 4-Call Quitline Counseling, four weeks of Nicotine Patch and Nicotine Lozenges, No SmokefreeTXT, and No Financial Incentives for Treatment Engagement. Each of the proactive counseling calls will last approximately 20 minutes. The Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking). SmokefreeTXT in support of cessation will not be offered proactively. Financial Incentives for treatment engagement will not be offered.
3153047|NCT00266253|Experimental|3|
3153048|NCT00266253|Experimental|4|
3153049|NCT00266253|Experimental|5|
3153050|NCT00266253|Active Comparator|6|
3153051|NCT00266305|Experimental|Fish oil|
3153052|NCT00266305|Placebo Comparator|Olive oil|Control group
3153053|NCT00266305|No Intervention|High fish|Reference group
3153054|NCT00266331|Active Comparator|Group A, RayGel Topical Cream|RayGel Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
3153055|NCT00266331|Placebo Comparator|Arm B Placebo Topical Cream|Placebo Topical Cream applied in thin layer to the area exposed to radiation 60-90 minutes prior to radiotherapy, standard skin care between treatments.
3153056|NCT00266396|Experimental|weight-bearing recommendation|Weight-bearing recommendation after THA and TKA
3153057|NCT00266461|Experimental|TU-100 7.5g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3153058|NCT00266461|Experimental|TU-100 15g/day|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3153059|NCT00266461|No Intervention|Water|Subjects will be randomized to TU-100 7.5g, 15g, or no active treatment group. Subjects will take a daily dose divided into 3 times a day.
3153060|NCT00266474||Cross sectional CF study|Multicentric study, including 187 CF patients of all age groupr in 5 CF centres.
3153061|NCT00266565|Experimental|Anti-IL5 (Mepolizumab)|The purpose of the study is to assess the toxicity of anti-IL-5 (Mepolizumab), and to see whether it lowers eosinophils in peripheral blood and/or tissue and whether it has a steroid and/or interferon sparing effect.
3153062|NCT00266773|No Intervention|1|Control - standard care only
3153063|NCT00266773|Experimental|2|Attention Control - standard care plus 6 months TIVR receiving minimal monthly feedback
3153064|NCT00266773|Experimental|3|Standard care plus 6 months TIVR receiving detailed monthly feedback
2445720|NCT03271112|Other|Exercise program|Participation to the 12-wks exercise program
2445769|NCT03271008|Active Comparator|Macintosh laryngoscopy|In this group intubation attempt is carried out with a standard Macintosh (size 3 or 4) direct laryngoscopy blade.
2445771|NCT03271008|Active Comparator|KingVision videolaryngoscope|In this group intubation attempt is carried out with KingVision videolaryngoscope with a channeled, disposable single-use blade.
2445777|NCT03271008|Active Comparator|VividTrac videolaryngoscope|In this group intubation attempt is carried out with VividTrac Adult model using a smartphone or laptop running the VividVision proprietary software.
2445826|NCT03270592|Other|Service dogs|Single arm study using a before after design where Before represent having a regular companion dog and after represent having a certified service dog
2445945|NCT03269591|Active Comparator|Pulsed electromagnetic field|magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
2445949|NCT03269591|Experimental|diclofenac tablets|(50 mg) few hours at the onset of menstruation for 3 months
2445953|NCT03269591|Other|Visual analogue scale|was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
2445954|NCT03269591|Other|Progesterone blood level|Sample of blood was taken to detect the level of progesterone.
2445955|NCT03269591|Other|Menstrual symptom questionnaire|to assess symptoms of dysmenorrhea.
2446037|NCT03269006|Experimental|Inesfly Paint|Inesfly 5AIGRNG TM containing Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%). The formulation is vinyl paint with an aqueous base, with the active ingredients residing within Ca CO3 and resin microcapsules, allowing a gradual release of active ingredients. Microcapsules range from one to several hundred micrometers in size.
3153065|NCT00266786|Experimental|Intranasal Ketorolac Tromethamine|
3153066|NCT00266786|Placebo Comparator|Intranasal Placebo|
3153067|NCT00266838|Placebo Comparator|Lacrystat|Lacrystat
3153068|NCT00266838|Active Comparator|Maxidex|Applying Maxidex
3153069|NCT00266929||Surgical|Subjects receiving surgical treatment for Type II odontoid fracture per discretion of investigator (non-randomized allocation)
3153070|NCT00266929||Non-surgical|Subjects treated with non-operative treatment options
3153071|NCT00267033|Experimental|1|injection of orthopaedic cement into vertebral bodies
3153072|NCT00267124||1|elderly people who have normal cognition
3153073|NCT00267124||2|elderly people who have mild to moderate Alzheimer's disease
3153074|NCT00267163|Experimental|1.|
3153075|NCT00267163|Placebo Comparator|2.|
3153076|NCT00267241|Experimental|1|ALI/ARDS patients
3153077|NCT00267319|Experimental|single group|
3153078|NCT00267358|Active Comparator|RC-1291 HCl|50 mg
3153079|NCT00267358|Placebo Comparator|Placebo|
3153080|NCT00267371|Active Comparator|Test Arm with Premere investigational|PFO Closure with Premere investigational device.
3153081|NCT00267371|Active Comparator|Medical management/current medications|Patients in the control group arm will not receive the medical device and will continue medical management.
3153082|NCT00267514|Other|1|sevelamer carbonate powder x 4 weeks then, sevelamer hydrochloride x 4 weeks
3153083|NCT00267514|Other|2|sevelamer hydrochloride x 4 weeks then, sevelamer carbonate powder x 4 weeks
3153084|NCT00267566|Experimental|Treatment|50% random assignment to receive Family Help Anxiety Treatment
2445434|NCT03382977|Experimental|Dose Level 2|VBI-1901 intermediate dose (2 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2445437|NCT03382977|Experimental|Dose Level 3|VBI-1901 high dose (10 μg pp65 content) vaccine formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal intradermal injections
2445438|NCT03382977|Experimental|Dose Level 4|VBI-1901 10 μg HCMV pp65 formulated with GM-CSF (200 μg) in 0.2 mL volume, given in two equal ID injections.
2445440|NCT03382977|Experimental|Dose Level 5|VBI-1901 10 μg HCMV pp65 formulated with AS01B (50 μg of QS-21 and 50 μg of MPL per dose) in 1.0 mL volume, given in one IM injection
2445485|NCT03315832|Experimental|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
2445486|NCT03315832|Placebo Comparator|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
2445503|NCT03272490|Active Comparator|Medartis|Surgery using the Medartis Implant
2445510|NCT03272490|Active Comparator|Synthes|Surgery using the Synthes implant
3153085|NCT00267566|Experimental|Control|50% random assignment to control group to receive usual/standard care for anxiety
2445568|NCT03272087|Active Comparator|Pleuroscopy|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
2445569|NCT03272087|Active Comparator|VATS (thoracoscopy)|According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
2445588|NCT03271879|Active Comparator|Empagliflozin at a dose of 10 mg/day|Patients will be treated with 10mg Empagliflozin once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
2445592|NCT03271879|Placebo Comparator|Placebo|Patients will be treated with Placebo once daily for 8 weeks. Patient glucose levels will be monitored based on home monitoring during the treatment period.
2445684|NCT03271645|Experimental|Space from depression|Space from depression is an 8 module CBT-based intervention.
2445687|NCT03271645|Experimental|Space from Anxiety|Space from anxiety CBT is an 8 module CBT-based intervention.
2445690|NCT03271645|Experimental|Space from stress|Space from stress CBT is an 8 module CBT-based intervention.
2445692|NCT03271645|Active Comparator|Face-to-face counselling|Face-to-face counselling
2445716|NCT03271151|Experimental|"Duloxetine (Cymbalta)"|"Epidural analgesia after knee arthroplasty is not as prevalent at HSS as formerly, in large part due to the rise of local infiltration analgesia. Studies using epidural analgesia may also lack generalizability given the infrequent use of epidural analgesia at other institutions. For these reasons, we plan to use adductor canal nerve blockade + local infiltration analgesia for management of immediate postoperative pain. Patients will receive spinal anesthesia as the primary anesthetic. It is particularly important to study duloxetine (Cymbalta) in the context of local infiltration analgesia, as patients receiving local infiltration analgesia receive increased doses of opioids, compared to patients receiving epidural analgesia."
2445718|NCT03271151|Placebo Comparator|Placebo|Placebo to compare pain scores and opioid use againts Duloxetine
2445795|NCT03270995|Experimental|Group 1|Behavioral:Cognitive Existential Therapy Group 1- Weekly two-hour group sessions
2445797|NCT03270995|Active Comparator|Group 2|Behavioral: Supportive Therapy Group 2- Weekly two-hour group sessions
2445819|NCT03270410||Neonates|Babies born in Rennes University Hospital
2445859|NCT03270254|No Intervention|root surface debridement (RSD)|Standard care - root surface debridement (RSD)
2445862|NCT03270254|Active Comparator|light activated dye (PDT)|light activated dye photodynamic therapy (PDT)
2445876|NCT03269929|Experimental|Music therapy|
2445877|NCT03269929|Active Comparator|Midazolam|
2445884|NCT03269760|No Intervention|Control|Current practice of postoperative care without sleep medicine measures
2445886|NCT03269760|Experimental|Interventional Sleep Medicine|Use of a multimodal sleep pathway including non-pharmacological sleep hygiene interventions and the use of zolpidem to improve patient sleep, pain control, and subsequent recovery after undergoing total shoulder arthroplasty.
2445931|NCT03269656||AGES-Reykjavik participants|Exploring whether pre-diagnostic serum levels of 25(OH)D among older individuals living in Iceland were associated with survival after cancer diagnosis. We also assessed the risk of being diagnosed with cancer in association with 25(OH)D levels.
2445977|NCT03269357|Other|Intervention|"Clinics randomized to intervention will provide structured LARC centered counselling"
2445978|NCT03269357|No Intervention|Routine counselling|Clinics randomized to routine counselling
2446038|NCT03269019||HIT-group|The patients with heparin-induced thrombocytopenia.
2446044|NCT03269019||HITTs-group|The patients with heparin-induced thrombocytopenia with thrombosis.
2446047|NCT03269019||Control group|The patients without heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis.
2446072|NCT03268564|Experimental|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
2446146|NCT03268135||Non end-stage heart failure|Measurement of RNAs in non end-stage heart failure patients undergoing to left ventricle reconstruction
2446147|NCT03268135||End-stage heart failure|Measurement of RNAs in end-stage heart failure patients undergoing to left ventricular assisted device (LVAD)
2446148|NCT03268135||Aortic Stenosis|Measurement of RNAs in patients affected by cardiac hypertrophy leading to aortic stenosis and requiring cardiac myectomy
2445465|NCT03383874|Experimental|Probiotic-Probio-Tec BG-VCap-6.5|Participants will receive capsules containing approximately 10^9 colony forming units of the probiotic organisms, Lactobacillus GG and Bifidobacteria lactis strain Bb12 for 24-weeks.
2445476|NCT03272659|Experimental|Blue Light Cystoscopy with Cysview®|"The enema will be administered to participant. Fluorescence sigmoidoscopy will be performed with white light then blue excitation light after retention of the enema for 60 minutes, followed by a rest time of up to 30 minutes before rectoscopy.~Post-operative surgical specimens will be collected for further fluorescence microscopy studies and pathological correlation of fluoresce with malignant pathology/histology as the gold standard."
2445505|NCT03272581|No Intervention|Control Group|Control group followed routine basketball training and traditional strength training.
2445512|NCT03272581|Experimental|Training Group|Functional exercises were applied to training group for 20 weeks (2 days/week) with routine basketball training.
2445535|NCT03272165|Experimental|MEDI1341|
2445536|NCT03272165|Placebo Comparator|Placebo|
2445686|NCT03271411|Experimental|Eye movement desensitization and reprocessing (EMDR) arm|
2445689|NCT03271411|Experimental|Progressive counting (PC) arm|
2445731|NCT03271177|Experimental|7F Sheathless Guide Catheter|Patients in this arm will undergo their percutaneous coronary intervention using a 7F Sheathless guide catheter
2445734|NCT03271177|Placebo Comparator|6F Sheath/Guide Catheter Combination|Patients in this arm will undergo their percutaneous coronary intervention using a 6F Sheath/guide combination
2445857|NCT03270371|Experimental|MCO Dialysis|Theranova Dialyzer
2445863|NCT03270371|Active Comparator|Standard High Flux Dialysis|Standard High Flux Dialyzer
2445882|NCT03269877||Liver cirrhosis and hypersplenism|Patients proven to have Liver Cirrhosis and Hypersplenism based on clinical examination, Laboratory findings, and abdominal ultrasound examinaton
2445935|NCT03269526|Experimental|EGFR BATs after standard of care chemo|Subjects will undergo apheresis to collect peripheral blood mononuclear cells. Cells will be cultured for up to 2 weeks before activated T-cells will be harvested, armed with EGFR Biarmed activated T-cells, washed to remove unbound EGFRBi, and cryopreserved. Subjects will then receive one dose of standard of care chemotherapy prior to receiving EGFR BATs.
2446025|NCT03268824||Children / adolescents with drug-resistant focal epilepsy|
2446026|NCT03268824||Children / adolescents without drug-resistant focal epilepsy|
2446089|NCT03268642||Life-support Based Comprehensive Treatment Regimen group|"meet all the following conditions:~intravenous immune globulin;~large dose of glucocorticoids;~mechanical ventilation;~hemodynamic support: intra-aortic balloon pump (IABP) or/and extracorporeal membrane oxygenation (ECMO);~continuous renal replacement therapy."
2446090|NCT03268642||conventional therapy group|"meet one of the following conditions:~without/insufficient intravenous immune globulin;~without/with various doses of glucocorticoid ;~vasoactive drug;~without/delayed mechanical ventilation;~without/delayed hemodynamic support;~without/delayed continuous renal replacement therapy."
2446137|NCT03268148|Experimental|low level laser group|LaserPen is applied to the local point for 20 seconds where heel-lancing will be performed in the low level laser group.
2446139|NCT03268148|No Intervention|breast milk group|Subjects in breast milk group are given 5ml expressed breast milk by mouth using a syringe tube inserted to the participant's oral cavity over a 2-minute period before heel-lancing.
2446194|NCT03267784|Experimental|Experimental: allo-APZ2-DFU|Application of IMP on patients wound
2446234|NCT03267368|Experimental|Comprehensive Care Program|Pulmonary rehab and smoking cessation program/intervention/assessment
3153086|NCT00267579|Experimental|Treatment|50% randomized to receive Strongest Families (formerly Family Help Program): Behaviour treatment
3153087|NCT00267579|Active Comparator|Control|50% randomized to control group: standard/usual care for behaviour disorder
3173140|NCT00608660|Experimental|D|staging acupuncture along Yangming musculature for treating Bell's Palsy
2446422|NCT03266016|Experimental|REDvent-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Patients will be managed with pressure control plus pressure support ventilation using a computerized decision support tool that will recommend changes to ventilator settings approximately every 4 hr (with or without a new blood gas). If the patient is spontaneously breathing, it will incorporate real-time measures of effort of breathing (esophageal manometry) to keep it in a target range.
2446425|NCT03266016|Placebo Comparator|Control-acute|Acute Phase: The acute phase is defined as the time from intubation until the patient meets weaning criteria, passes the initial oxygenation test (decrease PEEP to 5 cmH2O and FiO2 to 0.5, maintains SpO2 > 90%), and undergoes a Spontaneous Breathing Trial (SBT). Ventilator management will be per usual care until the patient meets weaning criteria and passes the oxygenation test.
2446427|NCT03266016|Experimental|REDvent-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Patients will be managed in a pressure support/CPAP mode of ventilation with assessments or changes to the level of pressure support every 4 hours, targeting maintaining effort of breathing (esophageal manometry) in a normal range. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
2446432|NCT03266016|Placebo Comparator|Control-weaning|Weaning Phase: The weaning phase is defined as the time from the first Spontaneous Breathing Trial (SBT) until the patient successfully passes an SBT or is extubated (whichever comes first). Patients who pass the initial SBT at the end of the acute phase will not undergo weaning phase randomization. Ventilator management will be per usual care. An SBT will be conducted daily, and the weaning phase will continue until the patient passes the SBT.
2446506|NCT03265379||patients with an isolated recurrence in the chest wall|
2446507|NCT03265379||distant metastatic disease is present but who undergo FTCWR|
2446509|NCT03265379||patient with primary tumor, no distant ds, failed conventional|
2446511|NCT03265379||patients refusing to undergo surgery|
2446523|NCT03265002|Placebo Comparator|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
2445472|NCT03330795|Experimental|CD3/CD19 neg allogeneic BMT|All participants will receive a double lung transplant followed by a bone marrow (hematopoietic stem cells) transplant. The lungs and allogeneic hematopoietic stem cells will be from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
2445495|NCT03272607|No Intervention|Control|All participants in the control arm will receive medication reconciliation at admission and discharge, and identical follow up, but no prioritized deprescribing list will be generated.
2445498|NCT03272607|Experimental|Intervention|"Participants in the intervention arm will be electronically screened using an electronic software MedSafer which will generate output of PIMs that will be brought to the attention of the CTU team via the unit pharmacist as deprescribing opportunities. (Note that in the case of multiple recommendations, they will be limited and prioritized so as to avoid overwhelming the treating team.) Based on their own expert medical judgement, in collaboration with the patient/caregiver and other relevant clinicians, a decision will be made to deprescribe if appropriate by the patient's in-hospital doctors."
2445526|NCT03272347|Experimental|Islatravir 0.25 mg|Participants will be treated once daily (QD) with 0.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
2445527|NCT03272347|Experimental|Islatravir 0.75 mg|Participants will be treated QD with 0.75 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
2445528|NCT03272347|Experimental|Islatravir 2.25 mg|Participants will be treated QD with 2.25 mg islatravir, 100 mg DOR, 300 mg 3TC, and placebo to doravirine, tenofovir, lamivudine for a minimum of 24 weeks. Between week 24 through week 52, 3TC and placebo to doravirine, tenofovir, lamivudine may be discontinued. Around Week 60, participants may be switched to a selected open label dose of islatravir and DOR 100 mg QD and will continue treatment until Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
2445529|NCT03272347|Active Comparator|Doravirine, Tenofovir, Lamivudine|Participants will be treated QD with placebo to islatravir, placebo to DOR, placebo to 3TC, and doravirine, tenofovir, lamivudine consisting of 100 mg DOR + 300 mg 3TC + 300 mg tenofovir disoproxil fumarate (TDF) for a minimum of 24 weeks. Between week 24 through week 52 placebo treatments may be discontinued and participants will receive only doravirine, tenofovir, lamivudine QD open label up to Week 144. At Week 144 participants will receive the fixed dose combination of doravirine (100mg)/islatravir (0.75mg) QD open label and will continue treatment until Week 192.
2445584|NCT03272009|Experimental|Treatment A|oral EYP001a
2445587|NCT03272009|Experimental|Treatment B|oral EYP001a
2445591|NCT03272009|Experimental|Treatment C|oral EYP001a
2445595|NCT03272009|Experimental|Treatment D|oral EYP001a
2445598|NCT03272009|Placebo Comparator|Treatment E|oral placebo
2445600|NCT03272009|Active Comparator|Treatment F|oral Entecavir
2445603|NCT03272009|Experimental|Treatment G|oral EYP001a plus subcutaneous injection of Peg-INFα2a
2445607|NCT03272009|Experimental|Treatment H|oral EYP001a plus subcutaneous injection of Peg-INFα2a
2445609|NCT03272009|Placebo Comparator|Treatment I|oral placebo plus subcutaneous injection of Peg-INFα2a
2445703|NCT03271489|Experimental|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)|Elagolix plus estradiol (E2)/norethindrone acetate (NETA)
2445707|NCT03271489|Placebo Comparator|Placebo|Placebo
3153088|NCT00267592|Experimental|enzyme-inducing antiseizure drug|A single-arm study with all subjects assigned to one treatment (radiation + temozolomide + talampanel) but subjects receiving concomitant anti-seizure drugs which could increase study drug elimination had a slightly modified dose/schedule of study drug. The primary endpoint is analyzed as a single group.
3153089|NCT00267605|Experimental|Treatment|FHPADHD 50% randomized to receive Strongest Families (formerly Family Help Program): behavioural distance intervention
3153090|NCT00267605|Active Comparator|Control|ADHD Standard Care 50% randomized to receive standard/usual care for ADHD
3153091|NCT00267618|Experimental|Treatment|50% randomized to receive FHP Pain intervention
3153092|NCT00267618|No Intervention|control|50% randomized to receive standard/usual care for recurrent headache/abdominal pain
3153093|NCT00267735|No Intervention|Module 1 Only|
2446649|NCT03264144|Experimental|Intervention|Students in the schools assigned to the intervention group will receive the intervention after the baseline survey. The intervention will be a social norms campaign involving posters, table tents, flyers and an online banner.
2446813|NCT03263091|Experimental|Open-Label High Erythropoietin|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
3153094|NCT00267735|Experimental|Modules 1, 2, and 3|
3153095|NCT00267826|Experimental|1|Patients with atopic dermatitis.
3153096|NCT00267852||1.0|As per routinary clinical practice
3153102|NCT00267930|Placebo Comparator|1|Tier 1: 1 placebo capsule b.i.d Tier 2: 2 placebo capsules b.i.d
3153103|NCT00267930|Experimental|2|Tier 1: Vernakalant (oral) 1 x 300 mg capsule b.i.d
2445543|NCT03272230|Experimental|Parkinson's disease without Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
2445545|NCT03272230|Experimental|Depression|"Initially especially patients diagnosed with depression (Major Depressive Disorder, DSM-IV).~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / MRI / Neurohormonal mechanisms"
2445546|NCT03272230|Experimental|Parkinson's disease with Impulse Control Disorders (ICDs)|"Initially especially patients diagnosed with idiopathic Parkinson's disease (Hughes et al. 1992). ICDs are closely related to use of dopaminergic medications.~ECOCAPTURE / ICM_APATHY_TASKS / Cognitive and Behavioral experimental tasks / Neuropsychological assessment / Supplementary Neuropsychological assessment - Parkinson's disease / MRI / Neurohormonal mechanisms"
2445629|NCT03271827|Experimental|Apnoeic oxygenation group|Standard airway management + 3 L/min of oxygen by nasal cannula
2445631|NCT03271827|No Intervention|Standard care group|Standard airway management
2445666|NCT03271463||Reliability/Validity of SCALE Assessment|Reliability + validity of the Selective Control Assessment of Lower Extremity (SCALE) in people with chronic stroke.
2445866|NCT03270384|Experimental|Treatment|Up to 15 subjects will be enrolled and treated with the Urotronic drug coated balloon (DCB)
2445883|NCT03269890|Experimental|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks per side. once before surgery
2445885|NCT03269890|Active Comparator|US-intermediate cervical plexus block|15 mL of 0.5% isobaric bupivacaine + Epinephrine 5 microgram/ ml. per side. once before surgery
2445929|NCT03269643|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2445930|NCT03269643|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2445979|NCT03269344|Placebo Comparator|Control Arm|Standard supportive care during definitive treatment plus placebo
2445980|NCT03269344|Experimental|Experimental Arm|Gabapentin plus standard supportive care
2446061|NCT03268980||Patients group|All patients (over 18y) admitted to the Hospices Civils de Lyon the day of the study, whatever the reason, able to fullfill the questionnaire by themselves.
2446063|NCT03268980||Hospital staff group|Anyone, whatever age and trade, paid directly by the Hospices Civils de Lyon on the day of the survey, regardless of the duration of the employment contract, and present on one of the sites of the Hospices Civils de Lyon the day of the investigation.
2446065|NCT03268980||Students group|Everyone who is regularly enrolled in one of the schools or institutes of the Hospices Civils de Lyon or in one of the two faculties of medicine of the Université Lyon I, in any initial training and present on one of the sites of the faculties the day of the investigation
3153104|NCT00267930|Experimental|3|Tier 2: Vernakalant (oral) 2 x 300 mg (600 mg) b.i.d
3153105|NCT00268307|Experimental|Cell therapy|Intracoronary, one time infusion of autologous, unfractionated bone marrow mononuclear cells.
2446138|NCT03268070|Experimental|Repetitive TMS over contralateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
2446140|NCT03268070|Experimental|Repetitive TMS over ipsilateral premotor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): ipsilateral premotor cortex.
2446141|NCT03268070|Experimental|Repetitive TMS over contralateral primary motor cortex|Location of repetitive Transcranial Magnetic Stimulation (rTMS): contralateral primary motor cortex.
2446142|NCT03268070|Sham Comparator|Sham repetitive TMS over contralateral premotor cortex|Location of Sham repetitive Transcranial Magnetic Stimulation (rTMS): contralateral premotor cortex.
2446143|NCT03268070|Experimental|Single TMS over extensor carpi ulnaris spot of motor cortex|Location of single-pulse Transcranial Magnetic Stimulation (sTMS): extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1).
2446154|NCT03267745|Experimental|Amino Acid|Subjects in this arm will receive amino acid supplementation (23.7g) 3 times daily for 28 days. Amino acids will be provided in powder form to be dissolved in 8oz of water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
2446156|NCT03267745|Placebo Comparator|Placebo|Subjects in this arm will receive placebo 3 times daily for 28 days. Placebo will consist of 23.7g of excipient-matched placebo in water. Participants will also undergo single-leg immobilization (Breg brace) for 7 days (days 8-15) during the 28 day study period.
2446205|NCT03267589|Experimental|Cohort A|Intervention: MEDI9447 (CD73) + durvalumab
2446208|NCT03267589|Experimental|Cohort B|Intervention: MEDI0562 (OX40) + durvalumab
2446209|NCT03267589|Experimental|Cohort C|Intervention: MEDI0562 (OX40) + tremelimumab combination
2446261|NCT03267251|Active Comparator|Usual Clinic communication - HPV Vaccine|Standard Usual and Customary HPV Information - CDC pamphlet
2446262|NCT03267251|Experimental|Usual Care and Web App on HPV Vaccine|Usual Care and Web app on HPV Vaccine: Vacteens Web app for mobile devices
2446301|NCT03266900|Experimental|re-TURBT|Patients in this arm will receive a 2nd TURBT within 4-6 weeks of initial TURBT
2446303|NCT03266900|Active Comparator|6 BCG instillations|Patients in this arm will not receive a 2nd TURBT, but will receive 6 instillations of BCG.
2446328|NCT03266536|No Intervention|No western diet|Participants will undergo one-time testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will be finished with testing after the upper endoscopy is complete.
2447013|NCT03261895|No Intervention|control group|usual diabetes care
3153106|NCT00268372|Active Comparator|cisplatin/RT alone|cisplatin and radiation therapy
3153107|NCT00268372|Experimental|induction chemo followed by cisplatin/RT|docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by surgery and/or cisplatin and radiation therapy
3153108|NCT00268398|Active Comparator|FOLFOX4|
3153109|NCT00268398|Experimental|FOLFOX7 followed by FOLFIRI|
3153110|NCT00268476|Active Comparator|Arm A: Standard of Care|Androgen Deprivation Therapy [ADT] (plus Radiotherapy for newly-diagnosed non-metastatic disease, plus or minus Docetaxel, plus or minus Abiraterone)[Control]
2445558|NCT03272295|Experimental|Arm B|Reference product (product 1), Single ingredients products 7, 8, 9, 10, 11 and Multiple ingredient product (product 12). Single cigarette each for nicotine PK assessment and smoking behaviour assessment.
2445596|NCT03271853||SBS II|
2445665|NCT03271684|Experimental|intervention group|Will receive one session of up to one-hour per week over a six-week period in self-management in addition to their usual rehabilitation and workbook.
2445670|NCT03271684|Other|control group|Will receive booklet consist of home exercises and education besides the usual care
2445727|NCT03271255|Experimental|Arm Apatinib|"Apatinib-FOLFIRI:~Apatinib Mesylate Tablets 500 mg po qd; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
2445728|NCT03271255|Active Comparator|Arm Bevacizumab|"Bevacizumab-FOLFIRI:~Bevacizumab Injection 5 mg/kg IV over 30 minutes,day 1; Irinotecan 180 mg/m2 IV over 30-90 minutes,day 1; Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion,day 1; 5-FU 400 mg/m2 IV bolus day 1,then 1200 mg/m2/d x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion; Repeat every 2 weeks."
2445774|NCT03270852|Experimental|Enhanced reality|"Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.~ER therapy is provided 2 times a day for 10 minutes for 2 weeks (10 days of treatment week), except for time of installation, calibration, and 3 minute breaks."
2445776|NCT03270852|Active Comparator|No Enhanced reality|Patients are provided with occupational therapy and physical therapy (task-oriented OT 30 min, FES 20 min) daily for 50 minutes.
2445827|NCT03270605||CS with myomectomy|Women having uterine myoma with pregnancy and subjected to myomectomy during delivery by CS
2445830|NCT03270605||CS without myomectomy|Women having uterine myoma with pregnancy and delivered by CS without myomectomy
2445901|NCT03269916|Experimental|IBD patients|IBD patients, 17-40 years old, female
2445903|NCT03269916|Other|healthy control|17-40 years old , female, without any gynecological disease
2446014|NCT03269318|Experimental|Personalised Medicine|Personalised Medicine who will be prescribed controller medication based on genetic test, Arg/Arg or Arg/Gly - montelukast (LTRA) or Gly/Gly -salmeterol (LABA).
2446015|NCT03269318|No Intervention|Standard Care|Standard of care (Standard Care will be prescribed controller medication based on guidelines)
2446034|NCT03268694|Experimental|Cognitive and Emotion Processing Tasks|As a part of the clinical monitoring, intracranial EEG is continuously collected when the participant is at the Epilepsy Monitoring Unit at the UNC Neuroscience Hospital. We will use an FDA approved EEG amplifier/data acquisition system to collect the research data. Computer-based tasks will be presented through a laptop and task related timing information will be transmitted from the laptop to the data acquisition system. Computer-based tasks will include Working Memory task, Reward Learning Task and Facial Emotion Recognition Task
2446098|NCT03268499|Active Comparator|Lipiodol-cisplatin suspension|
2446100|NCT03268499|Active Comparator|Lipiodol-cisplatin emulsion|
2446178|NCT03268057|Experimental|VX15/2503 + avelumab|VX15/2503 at a concentration of 5 mg/kg, 10 mg/kg or 20 mg/kg with a fixed dose of avelumab at 10 mg/kg, administered intravenously on a bi-weekly dosing cycle.
2446231|NCT03267407||CrAg(+) and CM(-)|(1) Patients with CrAg positive without meningitis results will receive preemptive high-dose fluconazole to prevent developing meningitis.
2446232|NCT03267407||CrAg(+) and CM(+)|(2) Patients with CrAg positive and meningitis results will receive standard treatment for cryptococcal meningitis, following national guidelines.
2446233|NCT03267407||CrAg(-)|(3) Patients with CrAg negative results will be managed as other HIV infected patients with the standard of care, following national guidelines.
2446288|NCT03267082|Experimental|Evaluation the role of Laparoscopic management of perforated a|
2446309|NCT03266744|Other|Main study group|"Patients will have repeat CT (Computerised Tomography) scans and WB-MRI (Whole Body Magnetic Resonance Imaging) every 12 weeks until disease progression. A baseline bone scan (99mTc-MDP) will be performed.~At the point of disease progression, a repeat bone scan will be obtained in addition to the CT and WB-MRI."
2446312|NCT03266744|Other|WB-MRI sub-study group|Patients will be given the opportunity to participate in a sub-study of WB-MRI reproducibility. This involves a repeat scan of the Whole Body Magnetic Resonance Imaging (WB-MRI) diffusion-weighted sequences. This will be shorter in duration than the full WB-MRI scan and will take place within one hour of completing the full WB-MRI scan.
2446345|NCT03266393|Experimental|Arm A-Tacrolimus then Envarsus|Immediate release tacrolimus (twice a day oral formulation) 14 day run-in followed by 4 months of follow-up and then crossing over to Envarsus XR® with a 14 day run-in followed by 4 months of follow-up.
2446346|NCT03266393|Experimental|Arm B-Envarsus then Tacrolimus|Envarsus XR® 14 day run-in followed by 4 months of follow-up and then crossing over to immediate release tacrolimus (twice a day oral formulation) with a 14 day run-in followed by 4 months of follow-up.
2446368|NCT03266133|Experimental|Sleep Education Intervention|This is a two-session program designed to educate patients about healthy sleep in respect to timing, regularity, efficiency, and duration in order to promote sleep during pregnancy.
2446373|NCT03266133|No Intervention|Routine Care|Usual care
2446435|NCT03265964|Active Comparator|Uridine|Subjects randomized to this study arm will receive uridine 2000 mg daily by mouth for 4 weeks
2446437|NCT03265964|Placebo Comparator|Placebo|Subjects randomized to this arm of the study will receive placebo 2000 mg daily by mouth for 4 weeks.
2446454|NCT03265444|Experimental|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery
2446612|NCT03264911|Active Comparator|amoxicillin|Children will be randomized to receive, after consent to the study, an antibiotic (amoxicillin approximately 50 mg/kg/day) orally, twice a day for 6 days.
2446616|NCT03264911|Placebo Comparator|Placebo arm|Children will be randomized to receive, after consent to the study, a placebo orally, twice a day for 6 days.
2446644|NCT03264235|Experimental|Group 1 Exoskeleton|Both training groups will undergo inpatient physical therapy of the same duration and intensity. Group 1 will complete stair training wearing the Keeogo Exoskeleton in inpatient physical therapy.
2446645|NCT03264235|Active Comparator|Group 2 Traditional Therapy|Group 2 will complete traditional stair training in inpatient physical therapy.
2446705|NCT03263962||With canrenone|Patients with canrenone
2445564|NCT03272100||control side ( standard flap)|Trapezoidal flap was realised, using a crestal incision and two deep vertical incisions extended in the fornix to expose the lateral wall of the maxillary sinus
2445613|NCT03271892||Active surveillance|Patients under active surveillance choose to not have immediate thyroidectomy. Patients are closely monitored with respect to clinical status, ultrasound imaging, biochemical indices (thyroid function, thyroglobulin, and thyroglobulin antibodies) and any thyroid cancer-related treatments (if needed). Active surveillance is conducted at a participating study site. Criteria defining disease progression are established, and if such criteria are met, thyroid surgery is recommended to the patient. However, patients are free to choose to have thyroid surgery at any time, in the absence of disease progression. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
2445616|NCT03271892||Immediate Surgery|Patients who choose surgery, undergo thyroidectomy, as per current standards of care, by a surgeon of their choice in an institution of their choice. The treating surgeon, in discussion with the patient, will choose the extent of thyroid surgery that may be appropriate for the individual case. Post-surgical follow-up is per the discretion of the treating surgeon, endocrinologist, or other healthcare providers involved in the patient's thyroid cancer care. Thyroid cancer clinical and treatment outcomes are tracked by the study team.
2445671|NCT03271541|Experimental|Bitopertin|"Part 1 - The main study - 16 weeks in total:~Participants will undergo a 6-week dose-escalation period followed by 10 weeks of treatment at the attained target dose of bitopertin.~Part 2 - Open Label Extension (OLE) - up to an additional 12 months:~Participants will be given the option to enroll into the OLE once the 16-week treatment of Part 1 has been completed.~Participants who decide not to enroll in the OLE, at the end of Part 1 will enter a 6-week follow-up period."
2445726|NCT03271203||Subjects participating in the CE and CD interview|Thirty adult subjects from the US with erosive HOA will be asked to participate in CE and CD interviews.
2445729|NCT03271203||Subjects participating in interview and real time data capture|Ten adult subjects from the US (n=5 with erosive HOA, n=5 with non-erosive HOA) of the thirty subjects who are participating in the CE and CD interviews, will be asked to participate in the real-time data capture app task
2445782|NCT03270930||Survived|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who survived during their index 30-day hospital stay
2445784|NCT03270930||Expired|Pediatric patients in the age group of 5 to 10 years presenting with acute abdomen and undergoing emergency laparotomy who expired during their index 30-day hospital stay
2445829|NCT03270553|Experimental|Sequence 1|In Period 1, subjects receive metformin alone; in Period 2, subjects receive metformin + plazomicin
2445831|NCT03270553|Experimental|Sequence 2|In Period 1, subjects receive metformin + plazomicin; in Period 2, subjects receive metformin alone
2445847|NCT03270163|Experimental|Experimental|Magnetic and Transcutaneous electrical stimulation of quadriceps
2445921|NCT03269955|Experimental|application of TachoSil®|Fibrinogen/thrombin-coated collagen patch (TachoSil®) and fibrin glue are applied to the pancreas anastomosis site in pancreatoduodenectomy
2445925|NCT03269955|No Intervention|control|Only fibrin glue alone is applied to the pancreas anastomosis site in pancreaticoduodenectomy.
2445971|NCT03269396|Experimental|Larynx Allograft Transplantation|Cadaveric laryngotracheal transplantation
2445983|NCT03269071|Experimental|Treatment Cohort A|"See Study Description~TC-A: 0.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2445985|NCT03269071|Experimental|Treatment Cohort B|"See Study Description~TC-B: 1.4 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2445986|NCT03269071|Experimental|Treatment Cohort C|"See Study Description~TC-C: 2.8 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2445987|NCT03269071|Experimental|Treatment Cohort D|"See Study Description~TC-D: 5.7 x 10^6 ± 10% human fetal-derived Neural Stem Cells (hNSCs) / kg of body weight"
2446052|NCT03268902|Experimental|Nicotinamide and Antimicrobials|Nicotinamide Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
2446056|NCT03268902|Experimental|Antimicrobials only|Placebo Azithromycin Oral Liquid Product Nitazoxanide Oral Suspension
2446059|NCT03268902|Experimental|Nicotinamide only|Nicotinamide Placebo Placebo
2446062|NCT03268902|Placebo Comparator|No active treatment|Placebo Placebo Placebo
2446096|NCT03268369|Active Comparator|Control group|
2446097|NCT03268369|Experimental|Non lesional diurnal partial epilepsy|
2446099|NCT03268369|Experimental|Idiopathic generalized epilepsy|
2446101|NCT03268369|Experimental|Nocturnal frontal lobe epilepsy|
2446102|NCT03268369|Experimental|Epileptic patients with Vagus Nerve Stimulation (VNS)|
2446174|NCT03267901|Experimental|Walnut-Control|
2446179|NCT03267901|Experimental|Control-Walnut|
2446229|NCT03267498|Experimental|Nivolumab + chemoradiation|Patients receive nivolumab IV over 60 minutes on day 1 of courses 1-5 and 7-12. Treatment repeats every 14 days for 11 courses in the absence of disease progression or unacceptable toxicity. Beginning at course 2, patients undergo radiation therapy QD 5 days per week and receive cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 7 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
2446278|NCT03267069||alcohol liver disease|Patients with alcohol liver disease consenting to participate in the study will be administered an initial survey at inclusion and then follow-up surveys at 3, 6, 9, 12, 15, and 18 month intervals and then 2, 5, and 10 years. There is no intervention cohort, all enrolled will complete the same surveys. Recidivism will be measured by responses to survey questions, clinical interviews documented in the chart, and urine ethnyl glucuronide or blood ethanol testing.
2446323|NCT03266809||Breast Cancer Patients|"Eligible participants will be women aged 18 years or over who have the following main characteristics:~Early invasive breast cancer (stage I-III)~Due to start SAT (adjuvant or neoadjuvant chemotherapy +/- trastuzumab +/- pertuzumab)~WHO performance status 0-2."
2446438|NCT03266003|Other|Group 1: ipDOT followed by eDOT|Following 20 observable medication doses under an initial DOT study group assignment of in-person DOT (ipDOT), patients will be assigned (crossed-over) to electronic DOT (eDOT) to collect data on another 20 observable medication doses.
2446531|NCT03265002|Active Comparator|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
2446536|NCT03265002|Active Comparator|Inulin and Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
2445618|NCT03271905|Experimental|PCV and high PEEP|Nebulization during mechanical ventilation on a pressure controled ventilation mode and PEEP = 15 cmH2O.
2445619|NCT03271905|Experimental|Pressure suport ventilation (PSV)|Nebulization during mechanical ventilation on a pressure suport ventilation mode.
3189764|NCT00780637|Experimental|Bradykinin|Patients receive 0, 10, 20, and 40 ng/min/100cc forearm volume of intrabrachial bradykinin, for 5 minutes at each dose. Forearm blood flow will be measured by strain gauge plethysmography, blood samples will be obtained to measure t-PA, PAI-1 at each dose. FMD and Radial artery tonometry will also be performed under resting conditions.
3189765|NCT00780650|Experimental|1|
2445764|NCT03270813|Experimental|RAGE-Control|There are 6 research intervention sessions, which will involve Relaxation training plus RAGE-Control. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, introduction to the RAGE-Control videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
2445765|NCT03270813|Sham Comparator|Sham videogame|There are 6 research intervention sessions, which will involve Relaxation training plus Sham videogame. The first session includes a 30-minute lesson on the relationship between physiological arousal and anger, an introduction to the Sham videogame and 15 minutes of videogame play. The next 5 sessions include a 10-minute check in about symptoms and functioning, a brief presentation of a relaxation skill, and 15 minutes of videogame play.
3189766|NCT00780650|Placebo Comparator|2|
3189767|NCT00780663|Experimental|Quarfloxin|Single arm study - open label.
3189768|NCT00780702|Experimental|Arm 1|
2445933|NCT03270046|Placebo Comparator|No enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy without water enema.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication. The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale for evaluation of side effect, complication during PEG ingestion, enema and colonoscopy, and participant satisfactory."
2445934|NCT03270046|Active Comparator|Water enema group|"Consecutive participants will be randomly assigned to take a preparation regimen of 3 liter of PEG 8-16 hr. before colonoscopy and enema with sterile water until stool was clear or patient felt discomfort but not exceed 3 liter, before colonoscopy.~Before the procedure, investigators record baseline parameters. Colonoscopies underwent by experienced endoscopists and by GI fellows. During the colonoscopy, the investigators recorded video, cecal intubation and withdraw time, amount and position of polyps, rate of complete examination and complication.The video was sent to other 2 endoscopists who did not known which participant was enema to evaluate the quality of bowel cleansing by using Ottawa bowel preparation scale and Likert scale."
2445999|NCT03269292||warm autoimmune hemolytic anemia|corticosteroid either oral form or intravenous followed by oral
2446060|NCT03268863|Experimental|Virtual Reality|Google Cardboard Virtual Reality headset running an interactive game
2446064|NCT03268863|Sham Comparator|Control|Powered down Google Cardboard Virtual Reality headset
2446113|NCT03268434|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
2446116|NCT03268434|Active Comparator|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory.The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance.; 8 sessions (60min), once a week over a period of 8 weeks
3189769|NCT00780702|Placebo Comparator|Arm 2|
3189770|NCT00780728|Active Comparator|Sildenafil|
3189771|NCT00780754|Experimental|dutasteride|treatment group
3189772|NCT00780754|Active Comparator|watchful waiting strategy|
2446280|NCT03267121|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
2446353|NCT03266211||General practitioner|General practitioner of the Auvergne-Rhônes-Alpes region
3189773|NCT00780767|Experimental|Thrombectomy arm|
3189774|NCT00780780|Active Comparator|1|Triamcinolone intravitreal injection + Nepafenac eye drops
3189775|NCT00780780|Other|2|Triamcinolone intravitreal injection
3189776|NCT00780793|Active Comparator|1-M : Maintenance|Usual care
3189777|NCT00780793|Experimental|2 -S : Spacing of TNF-blocker injections|Spacing of TNF-blocker injections
3189778|NCT00780806|Experimental|1|Immunization with one dose of MnB rLP2086 vaccine at 0, 1 and 6 months
3189779|NCT00780819|Experimental|PoleStar N20 intraoperative MRI|PoleStar N20 intraoperative MRI
3189780|NCT00780832|Active Comparator|1|Caffeine reduction through diet and beverage counselling
3189781|NCT00780832|Active Comparator|2|Anticholinergic medication
3189782|NCT00780845||AKI (-)|Patients without acute kidney injury after on-pump CABG
3189783|NCT00780845||AKI (+)|Patients with acute kidney injury after on-pump CABG
3189784|NCT00780858||Ganirelix|Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
3189785|NCT00780858||Control|Patients without premature lutenization (progesterone >1,2 ng/ml) underwent a only one IUI.
3189786|NCT00780884|Experimental|acupuncture needles|Acupuncture needles named acuzone needles. The acuzone needles are sterile and single use, manufactured by DONG BANG MEDICAL CO.,LTD.
3189787|NCT00780897||1|POF patients; 18 years <Age> 40 years; Hormonal sampling; FMR1 analysis; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy; Bone Mineral Density; Pelvic Ultrasonography;
3208923|NCT00979381||2|patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
3208924|NCT00979381||3|healthy volunteers
2445623|NCT03271801|Experimental|Skills Training|The skills training condition will participate in a family-based obesity treatment program for the first 40 minutes of each session followed by 20 minutes of experiential learning about meal stimulus control strategies. Parents and children will be asked to self-monitor sugar-sweetened beverages, fruits, vegetables, and minutes of physical activity and screen time. In addition they will self-monitor the use the following stimulus control strategies: portion control, energy density and variety.
2445651|NCT03271502|Experimental|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
2445653|NCT03271502|Active Comparator|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
2445713|NCT03271320||systemic sclerosis|patients with systemic sclerosis
2445714|NCT03271320||control|Healthy subjects
2445753|NCT03271073|Experimental|Apatinib plus S1|patients with advanced gastric cancer enrolled after failure of first-line systemic chemotherapy will be given Apatinib plus S1 till progressive disease,death or non-tolerable toxicity
3189788|NCT00780897||2|Control Group No POF patients; Benign ovarian pathology; 18 years <Age> 40 years; Hormonal sampling; FMR1 analyze; FSH Receptor gene analysis; LH Receptor gene analysis; BMP15 gene analysis; GDF9 gene analysis; Connexin 37 analysis; Ovarian biopsy under specific conditions; Bone Mineral Density; Pelvic Ultrasonography
3189789|NCT00780923|Experimental|CPAP|
2445905|NCT03269747|Active Comparator|Prednisone|Prednisone 40 mg daily for 7 days
2445906|NCT03269747|Placebo Comparator|Placebo|Placebo daily for 7 days
2445932|NCT03269500||malnourished older people|The hospitalized elderly with swallowing and/or Mastication problems.
2446027|NCT03268837|Experimental|Programmed Intermittent Bolus|
2446029|NCT03268837|Active Comparator|Continuous Infusion|
2446091|NCT03268655|Experimental|Ginger extract|Ginger extract, 2000 mg daily for 6 weeks, followed by 6 week washout.
2446092|NCT03268655|Experimental|Placebo|Placebo, daily for 6 weeks, followed by 6 week washout.
2446175|NCT03267966|Experimental|Group A|Leeds Pathology Protocol (LEEPP)
2446180|NCT03267966|No Intervention|Group B|"Conventional method of pathological evaluation"
2446244|NCT03267563|Experimental|Enhanced implementation as usual (EIAU)|All clinics will receive enhanced implementation as usual (EIAU) that is initial clinical and operational training + tools for sustainment. This occurs once at the beginning of the trial.
2446250|NCT03267563|Experimental|Low-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus low-intensity (every 3 months) implementation coaching and feedback (LICF). LICF consists of quarterly clinical and operational coaching and feedback calls, as well as quarterly participation in an implementation collaborative board.
2446254|NCT03267563|Experimental|High-intensity coaching and feedback|Clinics will receive enhanced implementation as usual (EIAU) plus high-intensity (every month) implementation coaching and feedback (HICF). HICF consists of monthly clinical and operational coaching and feedback calls, monthly participation in an implementation collaborative board, and on call technical assistance.
2446296|NCT03266991|Experimental|RPT-INH|Participants treated with weekly rifapentine and isoniazid for twelve weeks.
2446298|NCT03266991|Active Comparator|control|Participants treated with daily isoniazid for six months
3189790|NCT00780949|Experimental|1: Crohn's disease patient|intestinal biopsies
2446445|NCT03265665|Experimental|ACTION Intervention|Women in the ACTION intervention will attend 1 asthma education/physical activity session and 5 group sessions in community location convenient to participants during the adoptive phase (24-weeks) and 1 group session during the maintenance phase (12-weeks). Each session will last approximately 2 hours. Participants will be given Fitbit Charge HR to monitor their daily steps and will be sent motivational, educational and reminder text messages up to 3 times per week.
2446447|NCT03265665|Other|Enhanced usual care|Women in the Enhanced usual care arm will attend 1 asthma education/physical activity session and be given a Fitbit Charge HR to monitor their daily steps. They will be given a static step goal to achieve. Only reminder text messages for data collection visits will be sent.
2446494|NCT03265392|Other|Part 1 - Bread + Water|Participants in this arm will randomly consume bread and 250 mL of water on 1 out of 3 visits of Part 1.
2446498|NCT03265392|Other|Part 1 - Bread + Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice on 1 out of 3 visits of Part 1.
2446501|NCT03265392|Other|Part 1 - Bread + Tea|Participants in this arm will randomly consume bread and 250 mL of tea on 1 out of 3 visits of Part 1.
2446502|NCT03265392|Other|Part 2 - Bread + water|Participants in this arm will randomly consume bread and 250 mL of water supplemented with 20 peas on 1 out of 3 visits of Part 2.
2446503|NCT03265392|Other|Part 2 - Bread+ Lemon Juice|Participants in this arm will randomly consume bread and 250 mL of lemon juice supplemented with 20 peas on 1 out of 3 visits of Part 2.
2446504|NCT03265392|Other|Part 2 - Bread+ tea|Participants in this arm will randomly consume bread and 250 mL of tea supplemented with 20 peas on 1 out of 3 visits of Part 2.
3153111|NCT00268476|Experimental|Arm B: Zoledronic Acid|(ADT + zoledronic acid) NO LONGER RECRUITING
2446577|NCT03264690||Microbial composition measured from IBD and non-IBD groups|Participants with inflammatory bowel disease (IBD) and non-IBD will be measured for microbial composition.
2446610|NCT03264560|Active Comparator|Synchronous Telepsychiatry (STP) group|
2446613|NCT03264560|Experimental|Asynchronous Telepsychiatry (ATP) group|
2446669|NCT03264274|Other|Aflibercept + DCE-US|Aflibercept: 4mg/kg IV every 2 weeks until discontinuation due to progression. DCE-US before treatment, and at 2 weeks and 8 weeks after the first Aflibercept administration.
3189791|NCT00781001|Placebo Comparator|1|Placebo cannabis
2446771|NCT03263286|Experimental|HandSOME|The intervention is given to this group.
2446811|NCT03263091|Experimental|FG-4592 (Open Label, Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
2449897|NCT03242239|Active Comparator|US-licensed Herceptin|
3153112|NCT00268476|Experimental|Arm C: Docetaxel|(ADT + docetaxel + prednisolone) NO LONGER RECRUITING
3153113|NCT00268476|Experimental|Arm D: Celecoxib|(ADT + celecoxib) NO LONGER RECRUITING
3153114|NCT00268476|Experimental|Arm E: Zoledronic Acid & Docetaxel|(ADT + zoledronic acid + docetaxel + prednisolone) NO LONGER RECRUITING
2445626|NCT03271775|No Intervention|control group|Patients in the control group will follow the doctor's instructions (medications and etc.) and will not participate in any physical therapy program.
2445627|NCT03271775|Experimental|PT treatment group for balance disorder|Patients in this research group will join to a 3 months' physical therapy treatment group designed to improve balance. The service for the group is provided by laboratory.
2445628|NCT03271775|Experimental|independant home computerized exercises|Patients in this group will be treated by 3 months' independent home computerized exercise program. Each patient will receive a personal access code for the exercise program. The duration of each practice is 5-10 minutes per day.
2445636|NCT03271437|Experimental|PC-trained therapists|
2445637|NCT03271437|Experimental|EMDR-trained therapists|
2445702|NCT03271398||Adult victims of sexual assault|
2445706|NCT03271398||Children who have been exposed to domestic abuse|
2445709|NCT03271398||Women with perinatal emotional complications|
2445710|NCT03271398||Teens with behavior problems and histories of abuse|
2445711|NCT03271398||Veterans with military-related trauma|
2445712|NCT03271398||Survivors of intimate partner violence|
2445755|NCT03271060|Active Comparator|Lumbar spondylolisthesis1|
2445756|NCT03271060|Active Comparator|Lumbar spondylolisthesis 2|
2445812|NCT03270579|Experimental|Part A: [18F]JNJ-64511070|Participants will receive an intravenous (IV) bolus injection of [18F]JNJ-64511070 at a dose of 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry of [18F]JNJ-64511070.
2445814|NCT03270579|Experimental|Part B: [18F]JNJ-64511070|Participants will receive an IV bolus injection of [18F]JNJ-64511070 at a dose of 185 MBq on Day 1 of Part B to measure the uptake, binding, distribution, and washout of [18F]JNJ-64511070 and to model the tissue specific kinetics of [18F]JNJ-64511070 in the human brain with the appropriate arterial IF.
2445852|NCT03270293|Experimental|Profhilo|"The intradermal procedure was performed bilaterally on the face, at level of the following five points:~zygomatic protuberance~nostril's angle~inferior margin of tragus~lip marionette lines~mandibular angle. The amount of product injected, was 0.2 ml for each injection-point."
3189792|NCT00781001|Experimental|2|Active cannabis - 1% THC by weight
3189793|NCT00781001|Experimental|3|Active cannabis - 4% THC by weight
2445964|NCT03269370|Experimental|1: Anchors Away|Family will receive access to the basic Anchors Away mobile app to test over 6 weeks.
2445966|NCT03269370|Experimental|2: Parent Enhanced Anchors Away|Family will receive access to the Parent Enhanced Anchors Away mobile app to test over 6 weeks.
2445973|NCT03269370|Active Comparator|3: Self-Help E-Book|"Group 3 will receive the Self Help e-Book as a comparative condition (families provided a kindle version copy of Helping Your Anxious Child: A Step-by-Step Guide ; Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)."
2445975|NCT03269370|No Intervention|4: Waitlist Control|Group 4 will not receive any intervention, but will be randomized into an active study arm at 6 weeks.
2446007|NCT03269045|Other|Treatment with ORL-1B.|Pediatric patients with biotinidase deficiency.
2446051|NCT03268785|No Intervention|Control|Previous admitted patients who were given conventional thyroidectomy combined with central neck lymph node dissection, without intra-operative nodes identification were enrolled into control group.
2446058|NCT03268785|Experimental|Experimental group|Newly admitted patients,from august 2016 to august 2018, who were given thyroidectomy combined with central neck lymph node dissection, with intra-operative identification of suspicious lymph nodes or parathyroid glands were regarded as experimental group.Intraoperative identification method includes Diff-quik staining and PTH test assay. 200 participants were planed for enrollment.
2446095|NCT03268486||Triple monitoring|Pregnant women with singleton term pregnancies, spontaneous or induced/augmented labor, cephalic presentation, > 18 years of age, able to provide written informed consent, no contraindications to internal FHR monitoring and no known contraindication to vaginal delivery. After giving written informed consent, women will be simultaneously monitored with scalp electrode, Doppler, trans-abdominal ECG, abdominal EHG and TOCO, as soon as internal monitoring is possible.
2446135|NCT03268109||people living with HIV|subjects infected with HIV and with cognitive complaints
2446136|NCT03268109||control subjects|subjects not infected with HIV and with cognitive complaints
2446165|NCT03267810|Experimental|Active TENS|Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
2446168|NCT03267810|Sham Comparator|Sham TENS|Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.
2446230|NCT03267524|Experimental|Supportive Care (Walking for Recovery from Surgery)|Patients and caregivers receive Walking for Recovery from Surgery prehabilitation intervention in 4 sessions 3-7 days before surgery, before discharge, and at 2 and 7 days post-discharge.
2446283|NCT03267095|Experimental|Study|.Patient in stduy Arm will receive music therapy sessions
2446289|NCT03267095|No Intervention|Control|Patient in control Arm will have cosuling for mother and follow up
2446308|NCT03266718|Other|Physical Activity Intervention|Couples will receive four 60-minute intervention sessions via videoconference with Duke staff. Study staff will provide couples with instructions for use of the iPad computer and videoconference software which will be used to deliver the intervention sessions.The first 3 sessions will be conducted weekly, with a booster session occurring approximately one month later.
2446313|NCT03266718|Other|Waitlist control|Couples will have the option to receive the intervention after they complete the follow-up survey. This version of the intervention will not include the booster session, so will last approximately 1 month in total. If they choose to receive the intervention, they will be provided with a tablet computer if they do not have one.
2446374|NCT03266484|Active Comparator|Probiotic Mixture|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo.~The probiotics sachets will be taken twice a day for 12 weeks."
2446381|NCT03266484|Placebo Comparator|Placebo|"Participants who are meeting the inclusion criteria will be randomized to either the probiotic mixture or an identical placebo~The identical placebo sachets will be taken twice a day for 12 weeks."
2446408|NCT03265925||Epilepsy patients Right Temporal Lobe|Epilepsy patients with seizures originating from the right temporal lobe
3189794|NCT00781001|Experimental|4|Active cannabis - 7% THC by weight
2445642|NCT03271710|Experimental|Peripheral balloon angioplasty|Peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries with the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection
2445721|NCT03271281|Experimental|Experimental: Angiogenesis PET/CT|One injection of the radioligand 68Ga-NODAGA-E[c(RGDyK)]2 followed by PET/CT
2445792|NCT03270956|Experimental|Renal Autologous Cell Therapy|Renal Autologous Cell Therapy (REACT) Treatment - Patients will receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
2445848|NCT03270488|Experimental|Laser Group|Laser application three times a week for 4 weeks.
2445849|NCT03270488|Placebo Comparator|Placebo group|The same equipment was used with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
3153115|NCT00268476|Experimental|Arm F: Zoledronic Acid & Celecoxib|(ADT + zoledronic acid + celecoxib) NO LONGER RECRUITING
3153116|NCT00268476|Experimental|Arm G: Abiraterone|(ADT + abiraterone acetate + prednisolone) NO LONGER RECRUITING
2446054|NCT03269162|Experimental|Jinfukang + Chemotherapy Group|
2446057|NCT03269162|Placebo Comparator|Chemotherapy Group|
2446118|NCT03268421|Experimental|Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens (FIT Teens) is a combined coping skills training and physical exercise program. Pain coping skills training, also called cognitive behavioral therapy (CBT) teaches a number of behavioral skills (e.g. breathing, relaxation, activity pacing, distraction, and calming statements). Participants also receive a specialized type of neuromuscular exercise training which focuses on core strength, gait and balance.
2446119|NCT03268421|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a psychological coping skills training using education on gate control theory of pain, behavioral strategies such as muscle relaxation and activity pacing, and cognitive strategies including distraction, problem-solving, and using calming self-statements.
2446122|NCT03268421|Active Comparator|Graded Aerobic Exercise|Graded aerobic exercise (GAE) utilizes a circuit-training approach with short intervals of exercise interspersed with brief rest breaks.
2446186|NCT03267771|Active Comparator|progesterone suppositories vaginal group|vaginal micronized progesterone suppositories (prontogest®) 400 mg, one vaginal suppository twice daily through 18 weeks of gestation.
2446188|NCT03267771|Experimental|Dydrogesterone oral tablets group|20 mg tablets (Duphaston ®), 2 tablets orally twice daily through 18 weeks of gestation.
2446281|NCT03267199||patients with high MPV,PDW,PFT|patients with high MPV,PDW,platelet function test
2446290|NCT03267199||patients with normal or low MPV,PDW, PFT|patients with normal or low MPV,PDW,platelet function test
3153117|NCT00268476|Experimental|Arm H: M1 RT|(ADT + radiotherapy to the prostate) NO LONGER RECRUITING
3189795|NCT00781027|Active Comparator|1|Torsional phacoemulsification
2446363|NCT03266237|Experimental|Healthy Adult|Healthy adult participants aged 21-40 years will be vaccinated with Vaxigrip® influenza vaccine
2446366|NCT03266237|Experimental|Healthy Elderly|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2446371|NCT03266237|Experimental|Healthy Elderly Pre-Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2446379|NCT03266237|Experimental|Healthy Elderly Frail|Healthy Elderly participants aged 65-90 years will be vaccinated with Vaxigrip® influenza vaccine.
2446413|NCT03265769|Active Comparator|Transradial approach|target vessel revascularization via radial access site is labeled as transradial approach
2446417|NCT03265769|Active Comparator|Transfemoral approach|target vessel revascularization via femoral access site is labeled as transfemoral approach
2446491|NCT03265548|No Intervention|Standard|Usual Direct view laryngoscopy
2446495|NCT03265548|Experimental|Intervention|Video laryngoscopy
2446519|NCT03265067|No Intervention|'Before' group|Patients who underwent primary PCI for STEMI prior to implementation of the RIC protol. These patients were not treated with the autoRIC device prior to PCI.
2446520|NCT03265067|Experimental|'After' group|Patients who underwent primary PCI for STEMI after implementation of the RIC protocol. These patients were treated with the autoRIC device prior to PCI.
2446570|NCT03264950|Other|SIngle Arm|All patients undergo Elastography. This is a single arm study
2446597|NCT03264651|Experimental|oral enobosarm and anastrozole|9 mg of oral enbosarm and 1 mg of anastrozole daily
2446657|NCT03264430|Active Comparator|The ketamine group|The ketamine group will receive intrathecal bupivacaine (7.5 mg) in 1.5 ml (Marcaine, Astra Zeneca, France, 0.5%) and ketamine (25mg) in 0.5 ml (Ketam, EIPICO, Egypt, 50 mg/mL),. Total volume is 2 ml will injected
2446662|NCT03264430|Placebo Comparator|The control group|group will receive only intrathecal bupivacaine (7.5 mg) in 1.5 ml plus 0.5ml normal saline to achieve total volume of 2 ml.
2446772|NCT03263572|Experimental|Treatment (blinatumomab, chemotherapy, ponatinib)|Patients receive blinatumomab IV nonstop on days 1-28 of cycles 1-5, and methotrexate and cytarabine intrathecally (by spinal tap) on days 1, 15, and 29 of cycles 1-4. Patients also receive ponatinib PO daily. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
2446886|NCT03262740|Experimental|BMS-986195 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
2446933|NCT03262155||ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
2446952|NCT03262155||No ECMO / ECLS|Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
2447037|NCT03261856||small intetsinal bacterial overgrowth|Glucose breath test, 75 g glucose in 250 ml water. Breath samples collected at baseline and every 15 min for 2 hours
2447039|NCT03261856||Fructose breath Test|Fructose breath test, 25 g fructose in 250 ml water. Breath samples collected at baseline and every 30 min for 3 hours
2447040|NCT03261856||Lactose Breath test|Lactose breath test, 25 g lactose in 250 ml water. Breath samples collected at baseline and every 30 min for 5 hours
2447067|NCT03261245||Cas|Onset of a hypertension disorder during pregnancy
2447069|NCT03261245||Controls|No hypertension disorder during pregnancy
2447239|NCT03260049||2|there was no RD at the first visit. The group 2 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection.
2445757|NCT03271138|Active Comparator|Bifidobacterium Infantis NLS Super Strain|Participants in the probiotic period will take two capsules of Bifidobacterium infantis NLS super strain (Natren LIFE START®2) three times per day for three weeks. Each capsule contains 2 x 10^9 colony-forming units (CFU) of Bifidobacterium infantis NLS super strain, for a total daily dose of 12 X 10^9 CFU. The probiotic will be kept refrigerated during transportation and throughout the study period.
2445758|NCT03271138|Placebo Comparator|Placebo|Participants in the placebo period will take two capsules of placebo three times per day for three weeks. The placebo capsules contain rice flour, hydroxypropyl and methylcellulose. The placebo will be kept refrigerated during transportation and throughout the study period.
2445786|NCT03270735|Experimental|Treatment|Snake venom thrombin
2445787|NCT03270735|Placebo Comparator|Placebo|Snake venom thrombin simulant
3189796|NCT00781027|Active Comparator|2|Longitudinal phacoemulsification
3189797|NCT00781040||Neutropenic patients|Adult AML and ASCT patients with neutropenic fever.
2445916|NCT03269708|No Intervention|Control|Participants receive standard care in cardiac rehabilitation program
2445918|NCT03269708|Experimental|Knowledge transfer group|Participants receive standard care in cardiac rehabilitation program plus education regarding telomere length
2445942|NCT03269474||Experimental Group|Blood and tissue specimen will be collected from subjects with an EB diagnosis. Tissue specimen will be collected from blistered and nonblistered skin.
2445948|NCT03269474||Control Group|Blood and tissue specimen will be collected from healthy subjects with non-EB. Tissue specimen will be collected from an inconspicuous skin area.
2446005|NCT03269227|Experimental|Accelerated hypofractionation with Tomotherapy|"Tomotherapy Treatment Planning System (TPS) will be used for treatment plannings.~Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for Gross Tumor Volume (GTV)."
2446069|NCT03268772|Experimental|PLD-IFO|pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO)
2446117|NCT03268395|Other|CO2 Measurement|Each subject will received simultaneous arterial blood gas CO2 and transcutaneous CO2 monitor assessments. The correlation of these two measurements will be compared.
2446217|NCT03268018|Other|Single arm|
3189798|NCT00781053|Experimental|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months.
3189799|NCT00781066|Experimental|1|Controlled cord traction (CCT)
3189800|NCT00781066|Active Comparator|2|No CCT
3189801|NCT00781092|Experimental|1|Systane Ultra
2446367|NCT03266146|Experimental|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
2446376|NCT03266146|Experimental|48 Weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in glucocorticoid 48 weeks of treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA). Participants will then be followed for 24 weeks.
3189802|NCT00781092|Active Comparator|2|Bausch and Lomb Sensitive Eyes
3189803|NCT00781105|Experimental|1|
2446578|NCT03264638|Experimental|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2446579|NCT03264638|Experimental|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2446581|NCT03264638|Active Comparator|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
2446647|NCT03264482|Active Comparator|THUVAP|thulium vaporization
2446650|NCT03264482|Active Comparator|M-TURP|monopolar transurethral resection
2446718|NCT03264001|Experimental|Diet-induced negative energy balance|For the diet-induced negative energy balance arm, the three trials will include one control trial (isocaloric diet; zero energy balance) and two trials of progressively increasing negative energy balance induced by calorie restriction (20% and 40% reduction of daily energy needs for weight maintenance). With respect to physical activity, all diet trials will be performed under resting conditions.
2446721|NCT03264001|Experimental|Exercise-induced negative energy balance|For the exercise-induced negative energy balance arm, the three trials will include one control trial (rest; zero energy balance) and two trials of progressively increasing negative energy balance induced by aerobic exercise (20% and 40% reduction of daily energy needs for weight maintenance); with respect to caloric intake, all exercise trials will be performed under isocaloric conditions.
2446756|NCT03263390||Bariatric Surgery|Subjects that have demonstrated extreme response to bariatric surgery.
2446904|NCT03262753||stent|Primary stent dilation treatment of coarctation of the aorta
3189804|NCT00781118|Experimental|Treatment|The Treatment arm has alerting enabled in their device during the 6-month randomization period. Treatment arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Treatment arm was re-defined as an ALARMS_ON group which included A) Control patients after the randomization period and until database lock (4/1/2014); and, b) Treatment patients both during the randomization period and after the randomization period until database lock (4/1/2014).
3208511|NCT00975468|Active Comparator|Pressure-Controlled Ventilation|The patients' lungs ventilation will be initiated with a peak airway pressure that provided a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
2445772|NCT03270839|Active Comparator|Responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
2445775|NCT03270839|Placebo Comparator|Responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2445778|NCT03270839|Active Comparator|Non-responsive to Scopolamine (Active)|Scopolamine administration - subject will take 1 tablet per os (Kwells, Hyoscine Hydrobromide 0.3mg, 1*day )
2445779|NCT03270839|Placebo Comparator|Non-responsive to Scopolamine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2445780|NCT03270839|Active Comparator|Responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
2445781|NCT03270839|Placebo Comparator|Responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2445783|NCT03270839|Active Comparator|Non-responsive to Meclizine (Active)|Meclizine administration - subject will take 1 tablet per os (Bonine 25Mg Chewable Tablet, Meclizine Hydrochloride 25mg, 1*day )
2445785|NCT03270839|Placebo Comparator|Non-responsive to Meclizine (Placebo)|Placebo administration - subject will take 1 tablet per os (Placebo Oral Tablet, no active substance in the tablet)
2445832|NCT03270462|Other|Envarsus XR|A form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant.
2445907|NCT03270137|Active Comparator|Condition A: rTMS on L-DLPFC|"Repetitive transcranial magnetic stimulation- IDLPFC. The intervention will be rTMS delivered on left dorsolateral prefrontal cortex (L-DLPFC).~Every patient will receive 15 rTMS sessions (in weekdays) along three weeks at 5 Hz of frequency and at its 100% of motor threshold. Each session will consist of 30 trains separated by 10 seconds inter-train interval and 1500 total pulses per session.~Equipment to rTMS includes a Magpro R30 stimulator (Magventure, Denmark) with an 8-shape coil model MCF-B70."
2445908|NCT03270137|Active Comparator|Condition B: rTMS on six regions|"Repetitive transcranial magnetic stimulation - Six regions. Two sub-conditions will alternate each session, starting with day 1: rTMS on Broca and Wernicke area and lDLPFC and then day 2: rTMS on left and right parietal association cortex (lPAC; rPAC) and right dorsolateral prefrontal cortex (rDLPFC).~Patients will receive 15 intervention sessions (in weekdays) along three weeks at 5 Hz frequency and 100% of motor threshold. Each area will receive 10 trains (500 pulses) separated by 10 seconds of inter-train interval that correspond to 1500 total pulses per session.~Equipment to rTMS includes a Magpro stimulator (Dantec, Denmark) with an 8-shape coil model MC-B70."
2445937|NCT03269513|Experimental|Intervention group|"Adolescent Obesity~The exercise program, nutritional counseling and oral health will last for five to three months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC).~The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week."
2445938|NCT03269513|No Intervention|Control group|
2446008|NCT03269279|Experimental|Medical abortion arm|200mg of Mifepristone and repeat doses of 400mcg of misoprostol every 3 hours administered for medical abortion in 2nd trimester
2446031|NCT03268720|Other|healthy controls|FODMAP low diet gluten-free diet
2446036|NCT03268720|Other|NCGS patients|FODMAP low diet gluten-free diet
2446074|NCT03268525|Active Comparator|Study|Marcaine 0.5 % Injectable Solution will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Marcaine 0.25%will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
2446075|NCT03268525|Placebo Comparator|Control|Sodium Chloride 0.9% will be injected before incision, and in a systematic fashion as a modified paracervical block. First, 2 ml will be injected through the vaginal fornices at 03.00, 06.00, 09.00, and 12.00 hours at 2 cm depth. Thus, 8 ml will be systematically injected around the cervical circumference before incision. In addition, 1 ml of the solution will be injected in each resection line (sacro-uterine and cardinal ligaments), adding up to a total of 10 ml. In case of performing additional anterior/ posterior colporrhaphy, additional solution of Sodium Chloride 0.9% will be prepared: 5 ml of the solution will be injected to the cutting line of the anterior/ posterior vaginal wall, respectively, prior to incision.
2446107|NCT03268278|Active Comparator|buprenorphine and local anesthetic|buprenorphine added to local anesthetic
2446112|NCT03268278|Placebo Comparator|sterile saline and local anesthetic|sterile saline (placebo) added to local anesthetic
2446169|NCT03267953|Experimental|First stage: Self-directed My Health CheckUp|Participants randomized to this group will be sent an e-mail invitation by the research team to register to the website. Once registered, participants will receive a second e-mail that will provide brief instructions on getting started and invite them to use the website for 12 weeks ad libitum. No additional contact will be provided thereafter by research team.
2446173|NCT03267953|Experimental|First stage: Minimally guided My Health CheckUp.|This group will also be invited to use the 12-week Internet-based stress management program, but they will additionally receive support via weekly telephone calls from a lay coach.
2446177|NCT03267953|Experimental|Second stage: High intensity Motivational Interviewing (MI)|After 6 weeks, response to the first stage programs will be assessed and only the non-responders will be randomized a second time to (a) continue with the first stage programs or (b) High-intensity MI. In addition to continued access to My Health CheckUp, participants in this group will also be supported with 6 weekly, telephone-based MI sessions.
2446223|NCT03267420|Experimental|Group 1|A group of 30 randomly assigned study participants that will undergo the BpTRU First, Unattended Omron Second exposure.
2446225|NCT03267420|Active Comparator|Group 2|A group of 30 randomly assigned study participants that will undergo the Unattended Omron First, BpTRU Second exposure.
2446228|NCT03267420|Active Comparator|Group 3|A group of 30 randomly assigned study participants that will undergo the Partially Attended Omron First, Unattended Omron Second exposure.
2446396|NCT03266081|Experimental|0.75% bupivacaine|
3153118|NCT00268476|Experimental|Arm J: Abiraterone * Enzalutamide|(ADT + abiraterone + enzalutamide + Prednisolone) NO LONGER RECRUITING
2445861|NCT03270423|Active Comparator|Intervention SG|Therapy during 6 months with PathMate2 design. 6 therapy visits + PathMate2 over 6 months
2445864|NCT03270423|No Intervention|Control SG|Therapy during 6 months with usual care. 10 therapy visits over 6 months
2445865|NCT03270423|Active Comparator|Intervention VD|Adapted sport session 1h/week + PathMate-S during 6 months
2445867|NCT03270423|No Intervention|Control VD|Adapted sport session 1h/week during 6 months
2445909|NCT03269864|Active Comparator|pedicled perforator flaps|"Once the perforator is identified, the flap will be designed around the perforator or perforators according to the location and size of the defect.~A tourniquet is inflated without prior exsanguination. This maneuver facilitates identification of perforators as they remain filled with the blood.~An exploratory incision along the margin of flap is made keeping the position of marked perforator in mind. The incision is made through the skin, subcutaneous tissue, deep fascia (sub-fascial approach) and the perforator vessel is directly visualized. The incision is initially always made from one side of the flap only to properly identify the perforator.~Careful and meticulous dissection is done in a blunt way isolating the perforator.~After deflation of the tourniquet, hemostasis is performed."
2445910|NCT03269864|Active Comparator|free perforator flaps|"A two-team approach is used for microvascular free tissue transfer. The first team starts exploring the limb for the recipient vessel. The second team simultaneously begins elevating the perforator flap and its vascular pedicle.~Microvascular anastomosis will be carried out under operating microscope for one artery and one or two accompanying veins."
2445967|NCT03269539||Headache Patients|Patients Referred for MRI with History of Headaches
2445969|NCT03269539||Motion prone patients|Patients without the ability to remain still for the entire protocol
2446020|NCT03269110||Mother and child(ren)|FACT 4 Child is the post-delivery follow-up of the offspring born to FACT mothers once these children are between the age of 4 - 6 years.
2446129|NCT03268161||Patients with anti-MAG neuropathy|Mutational analysis of clonal B cells
2446166|NCT03267888|Experimental|Radiation therapy, pembrolizumab|Patients undergo radiation therapy on day 1. Patients also receive pembrolizumab IV over 30 minutes on day 2 or 3. Courses with pembrolizumab repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2446272|NCT03267186|Experimental|Prevention (ibrutinib)|Beginning 60-90 days after allogeneic HCT, patients receive ibrutinib PO QD for up to 18 months post-transplant in the absence of disease progression or unacceptable toxicity.
2446311|NCT03266731|Experimental|use of aspirin and clopidogrel|
2446390|NCT03266471||Crohn's disease Patients|Patients that are seen in the Inflammatory Bowel Disease clinic with CD confirmed by endoscopy or radiology assessment who are initiating either an anti-tumor necrosis factor (TNF)-α agent (infliximab, adalimumab, certolizumab, or infliximab biosimilar), ustekinumab, or vedolizumab as part of their routine clinical care will be asked to provide blood samples, stool samples, and intestinal biopsies from standard of care colonoscopy at baseline and post therapy of at least 6 weeks duration but not more than 52 weeks.
2446394|NCT03266471||Controls|Healthy adults without IBD undergoing colonoscopy for colorectal cancer screening or other non-IBD related indication will be asked to provide blood samples, stool samples and intestinal biopsies from standard of care colonoscopy.
2446419|NCT03265756||Healthy children|250 3D facial images of healthy children under 5yrs of age in the Democratic Republic of Congo (DRC).
2446421|NCT03265756||Suspected Pneumonia|50 young children (under 5 yrs) in hospital/clinics in Butembo DRC with suspected pneumonia
2446481|NCT03265535||Healthy Volunteers|Subjects without history of coronary artery disease
2446483|NCT03265535||Subjects with coronary artery disease|Subjects with coronary artery disease and abnormal SPECT myocardial perfusion imaging within the last 12 months
2446684|NCT03264053|Experimental|SOCKET SHIELD TECHNIQUE|Socket shield is the surgical removal of the frontal aspect of the badly broken root and retaining the lingual aspect so as to prevent crestal bone loss with insertion of the dental implant behind it
2446685|NCT03264053|Active Comparator|Conventional immediate implantation|Conventional immediate implantation is the surgical removal of the entire badly broken root
2446729|NCT03263676|Experimental|Icon reusable underwear|
2446732|NCT03263676|Placebo Comparator|Disposable pad|
2446822|NCT03262974||CML patients with MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
2446825|NCT03262974||CML patients without MMR|CYP3A5*3 , CYP2C8*3 , ABCB1 2677G>T/A and SLC22A1 1222A > G SNPs on the plasma level by HPLC-UV and molecular response of imatinib by PCR
2446915|NCT03262090|No Intervention|control group|Subjects were randomly assigned to receive saline before skin incision
2446916|NCT03262090|Active Comparator|0.2ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
2446920|NCT03262090|Active Comparator|0.4ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
2446921|NCT03262090|Active Comparator|0.6ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
2446923|NCT03262090|Active Comparator|0.8ug/kg dexmedetomidine|Subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
2446925|NCT03262090|Active Comparator|1.0ug/kg dexmedetomidine|Subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
2446994|NCT03261739|Experimental|RYI- 018|The doses of RYI-018 to be evaluated in sequential cohorts will be 0.6 mg/kg, 1.2 mg/kg, and 2.5 mg/kg.
2447001|NCT03261739|Placebo Comparator|Placebo|vehicle control
2447070|NCT03261388||ABLE POWER Program|Participants on the Activity-Based Locomotor Exercise Program (ABLE) waitlist will be enrolled prior to beginning the ABLE program. This waiting period will allow outcomes to be compared (in the same participant) before receiving the intervention and after receiving the intervention.
3153119|NCT00268476|Experimental|Arm K: Metformin|(ADT + Metformin) RECRUITING IN SELECTED SITES
3189805|NCT00781118|Other|Control|The Control arm has alerting disabled in their device during the 6-month randomization period. Control arm patients also have alerting enabled in the post-randomization period. Once a patient arrives at the ER, the standard of care triage process for MI is followed and that is outside of the ALERTS Study protocol. With Amendment the Control arm was re-defined as an ALARMS_OFF group which included A) Control patients during the randomization period when the Guardian did not have alarms enabled.
2445843|NCT03270280|Placebo Comparator|Normal Saline|The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo
2445844|NCT03270280|Experimental|Nigella Sativa|The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention
2445893|NCT03270020|Experimental|Treatment arm|This is a single arm study; the study arm include all patients participating in the study who will all receive Denosumab 70 MG/ML [Xgeva]
2445958|NCT03269565|Experimental|Arm 1|BCD-100 1 mg/kg Q2W;
2445959|NCT03269565|Experimental|Arm 2|BCD-100 3 mg/kg Q3W.
2446009|NCT03269058|Experimental|Patients not treated with statins|
2446010|NCT03269058|Experimental|Patients treated with statins|
3189806|NCT00781131|Placebo Comparator|1|
2446131|NCT03268187|Experimental|Self-Alert Training|Biofeedback-based Self-Alert Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
2446133|NCT03268187|Active Comparator|Relaxation Training|Biofeedback-based Relaxation Training Vigilance Task Questionnaires accessing apathy, fatigue, depression, sleep quality, sleep behavior
2446157|NCT03267823||Heart surgery|Patients undergoing heart surgery will have blood samples tested for INR values
2446222|NCT03267680|Experimental|Arm I (IRX-2)|Patients receive cyclophosphamide IV on day 1 and IRX-2 via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
2446226|NCT03267680|Active Comparator|Arm II (placebo)|Patients receive cyclophosphamide IV on day 1 and placebo via submucosal injections in the cervix or SC for vulvar lesions on days 4-7. Patients also receive indomethacin PO TID, zinc-containing multivitamins PO QD and omeprazole PO on days 1-21. Treatment repeats every 6 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Beginning week 25, patients undergo surgical resection.
2446324|NCT03266549|Experimental|Botulinum toxin augmented surgery group|unilateral recess-resect procedure, or bilateral rectus muscle recession plus intraoperative injection of 2.5 to 5 units of botulinum toxin A into the recessed muscle.
2446325|NCT03266549|Active Comparator|conventional surgery group|unilateral recess-resect procedure, bilateral rectus muscle recession, or 3 horizontal rectus muscle surgery according to the type of strabismus and the presence or absence of deep amblyopia.The standard correction tables will be used as a guide for the amount of muscle recession and, or resection
2446423|NCT03265951|Active Comparator|Ramelteon|Ramelteon 8 mg po at bedtime
2446430|NCT03265951|Placebo Comparator|Usual care|education brochure about sleep hygiene
2446460|NCT03265509|Active Comparator|Glutamine|30 g/day Glutamine supplementation for three months
2446467|NCT03265509|Placebo Comparator|Fantomalt|30 g/day Fantomalt supplementation for three months
2446547|NCT03265210|Experimental|Relief|Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
2446554|NCT03265210|No Intervention|Referral|Referral for mental health based on clinical indication.
2446583|NCT03264729|Experimental|Isometric exercise|
2446584|NCT03264729|Active Comparator|Isotonic exercise|
2446585|NCT03264729|Active Comparator|Walking|
2446711|NCT03264040||Observation|Patients with Mannosidosis disease or high-grade suspicion for Mannosidosis disease
2446778|NCT03263455|Experimental|Kinesio Taping group|The tape in the KT group was applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension).
2446785|NCT03263455|Sham Comparator|Sham Taping group|"Patients in the ST group, smaller I-strips of KinesioTape were used and they were applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the Kinesio Taping group"
2446828|NCT03263039|Other|Treatment with pembrolizumab|Pembrolizumab will be administered at a flat dose of 200 mg as a 30 minute (-5 min/+10 min) IV infusion every 3 weeks (Q3W)
2446880|NCT03262597|Experimental|Beverage Hydration Index of beverages|Subjects will consume 4 different beverages to obtain the beverage hydration index.
3189807|NCT00781131|Experimental|2|Pregabalin 75 mg
3189808|NCT00781131|Experimental|3|Pregabalin 150 mg
2447041|NCT03261557|Experimental|CBT + SST|The treatment group will receive the intervention according to the CBSST protocol, adapted to adolescents.
2447043|NCT03261557|Active Comparator|Psychoeducation, habits and healthy lifestyle|The control group will receive 3 modules intervention: psychoeducation, habits and healthy lifestyle.
3189809|NCT00781144||1|first year osteopathic students
3189810|NCT00781144||2|fourth and fifth year osteopathic students
3189811|NCT00781144||3|experienced osteopathic clinicians
2447215|NCT03260283|Experimental|Group I|0.4 mgkg-1 of pethidine hydrochloride
2447218|NCT03260283|Experimental|Group II|2ml of ropivacaine (0.75%) with 15 mcg of fentanyl
3189812|NCT00781157|Experimental|1|
3189813|NCT00781183|Experimental|pulmonary rehabilitation|patients that are enrolled in pulmonary rehabilitation
3189814|NCT00781196|Experimental|1|Oral folic acid
3189815|NCT00781196|Placebo Comparator|2|placebo
3189816|NCT00781209|Experimental|Exp|Posterior Fossa Irradiation 37.5 Gy in 2.5 Gy fractions+Radiosurgical boost; Follow up:Contrast enhanced MRI & Mini Mental Status Examination
3189817|NCT00781248|Experimental|1|starting with active NG Shield
3189818|NCT00781248|Experimental|2|Starting with inactive NG Shield
3208925|NCT00979394||Patients with type 2 diabetes|
2445824|NCT03270449|No Intervention|Usual care|Usual care involves being referred to the local rheumatologist involved in the study. The rheumatologist and the rheumatology nurse will see the control group patients during a one hour one on one consultation appointment. During that time the patient's history will be taken, physical exam performed and investigations analyzed. If a diagnosis of fibromyalgia is confirmed, the rheumatologist and nurse will counsel the patient and provide resources for self directed management. Unless there is a concern of an alternative diagnosis, follow up will not be arranged.
2445835|NCT03270202|Experimental|PAI group|Participants randomized to the PAI-group will receive a wearable device (Mio Slice PAI wristband) that measure heart rate continuously and via an algorithm calculates a physical activity score called PAI. The weekly goal of 100 PAI can be reached by a combination of different intensities and durations and the participants will get continuous information about their current score and amount of activity needed to reach the goal. 100 PAI is expected to approximate current guidelines of 150 minutes of moderate intensity or 75 minutes of vigorous intensity for the average participant or somewhat less if the intensity of the chosen activity is high. Proper instruction in use of the device and App will be given both oral and written after baseline testing and randomization.
2445836|NCT03270202|Active Comparator|Usual care|Usual care: Participants in the control group will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
2445878|NCT03270098|Experimental|Aerobic Exercise|using traditional exercise equipment (i.e., treadmill, stationary bike) along with active-play video games (Xbox Kinect).
2445879|NCT03270098|Active Comparator|Stretching and Toning Exercise|
2445920|NCT03269630||Clinic patients (Comprehensive Pulmonary Hypertension Center)|"Pulmonary hypertension patients (WHO group 1-5)~Systemic sclerosis patients without pulmonary hypertension~Mixed connective tissue disease patients without pulmonary hypertension"
2445923|NCT03269630||Outpatient right heart catheterization patients|-Outpatients undergoing right heart catheterization for any indication
2445927|NCT03269630||Healthy controls|"Age>18~Not actively smoking~No chronic medical conditions"
2445970|NCT03269409|Sham Comparator|Hip Decompression with lactated ringers|Subjects will receive standard of care hip decompression along with an injection of approximately 5 mls. of lactated ringers.
2445974|NCT03269409|Experimental|Hip Decompression with ADRC|Subjects in this arm will have Adipose Derived Regenerative Cells (ADRC)harvested through autologous liposuction and processed outside the body using The Celution 800/GP System (Cytori Therapeutics) before having approximately 5 mls. of ADRCs transplanted into the femoral head after standard of care hip decompression.
3153120|NCT00268476|Experimental|Arm L: tE2|(Transdermal oestradiol) RECRUITING
3153121|NCT00268489|Experimental|pemetrexed + bevacizumab|"Patients receive pemetrexed disodium IV over 10 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for 5 years."
2446067|NCT03268759||PCE|Emerging adult individuals who were exposed to cocaine in-utero
2446070|NCT03268759||NCE|Emerging adult individuals who were not exposed to cocaine in-utero
2446115|NCT03268382|Experimental|APR-246 + PLD|
2446164|NCT03267849|Experimental|persons drinking water|all persons in the study will have images of the eye at baseline eye pressure, then the intervention will be to drink 2 bottles of water to increase eye pressure or decrease eye pressure, then will have images taken a second time
2446207|NCT03267628|Sham Comparator|Saline intrathecal as well as saline in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
2446210|NCT03267628|Active Comparator|Saline intrathecal as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml saline added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
2446211|NCT03267628|Active Comparator|Intrathecal morphine as well as local anaesthetic in Blocks|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml local anaesthetic both sides as a QLB2.
2446212|NCT03267628|Active Comparator|Intrathecal morphine as well as saline in Block|These 25 patients will receive 0.3ml (150mcg) morphine added to the spinal anaesthetic and 25 ml saline both sides as a QLB2.
2446310|NCT03266874||Patients who received the G7 BiSpherical Cup|Subject in need of a THA who met the inclusion/exclusion criteria and received the G7 BiSpherical cup.
2446424|NCT03265704||AGA Neonates|AGA Control Group Appropriate for gestational age newborns of healthy mothers
2446426|NCT03265704||SGA Neonates|SGA - Control Group Small for gestational age newborns of healthy mothers
2446431|NCT03265704||AGA-PIH Neonates|AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
2446436|NCT03265704||SGA-PIH Neonates|SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
2446461|NCT03265457||patient with pseudoexfoliation syndrome|The corneal Endothelial cell count will be measured by specular microscopy
2446468|NCT03265457||Normal people at same age|
2446544|NCT03265262|Experimental|Children receiving OFC during a diagnost|paediatric patients attending food allergy
2446593|NCT03264846||Group 1|PCOS participants with periodontitis
2446594|NCT03264846||Group 2|PCOS participants with periodontally healthy
2446595|NCT03264846||Group 3|systemically healthy participants with periodontitis
2446596|NCT03264846||Group 4|systemically and periodontally healthy participants
2446809|NCT03263130||COPD, Emphysema, Asthma-COPD Overlap|Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
2446967|NCT03262051||Patient with acute inflammation (surgery)|patients undergoing hip surgery
3153122|NCT00268528||Health service research (electronic pill monitoring system)|Patients receive an electronic pill monitoring system comprising an empty MEMS^? medication bottle with TrackCap? CR. The mercaptopurine prescription is filled using this system. Beginning on day 1 of the third or later course of maintenance therapy, patients take all doses of mercaptopurine from the MEMS^? medication bottle with TrackCap? CR for at least 169 days. The MEMS^? TrackCap? CR is mailed to the Coordinating Center at the end of study. Patients also receive methotrexate PO as indicated by their individual chemotherapy regimen.
3153123|NCT00268580|Experimental|Intervention|Asthma care provided using care pathway
2445913|NCT03270124|Active Comparator|No Resistance Exercise and No Activity Goal Arm|Blinded use of Fitbit with no daily activity goal and no resistance exercises
2445915|NCT03270124|Experimental|Resistance Exercise and Activity Goal Arm|Unblinded use of Fitbit with a daily activity goal (steps per day) and resistance exercises
2445961|NCT03269383|Sham Comparator|Saline|Patients will receive a stellate ganglion block but with 10ml of 0.9% saline.
2445962|NCT03269383|Experimental|Treatment|Patients will receive a stellate ganglion block with 10ml of 0.5% bupivacaine
2446163|NCT03267732|Active Comparator|1|Pegilodecakin (5 μg/kg) dosed on Day 1, and Days 4-9 SQ
2446167|NCT03267732|Active Comparator|2|Pegilodecakin (10 μg/kg) dosed on Day 1, and Days 4-9 SQ
2446242|NCT03267303|Experimental|TS-091 5mg|
2446251|NCT03267303|Experimental|TS-091 10mg|
2446255|NCT03267303|Placebo Comparator|Placebo|
2446293|NCT03267017||Patient scheduled for surgery under general anesthesia|
2446322|NCT03266770|Other|RELIEF stent placement|After meeting the inclusion criteria and being consented, patients will have the RELIEF stent inserted in the ureter during cystoscopy per standard of care for ureteral stent placement.
2446386|NCT03266367||patients|NGAL and renal functions will be measured two hours after Percutaneous coronary intervention and two days later as a follow up
2446388|NCT03266367||Healthy Group|control group
2446540|NCT03265340|Active Comparator|A|dTMS standard protocol 10 min session
2446546|NCT03265340|Active Comparator|B|dTMS standard protocol 20 min session
2446552|NCT03265340|Active Comparator|C|dTMS standard protocol 40 min session
2446603|NCT03264768|Other|control|standard care in case collateral ventilation is observed (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post allocation.
2446605|NCT03264768|Experimental|Endobronchial valves|Endobronchial valves in case collateral ventilation is absent (by Chartis) with 3 months physical activity tele coaching between 3 and 6 months post intervention.
2446676|NCT03264261|Experimental|robotic training|For the robotic training group, a controlled resistance load will be applied to the unaffected leg at the ankle and an assistance load will be applied to the pelvis.
2446677|NCT03264261|Active Comparator|treadmill training|For the treadmill training only group, a physical therapist will provide manual assistance to the affected leg at the knee and/or ankle joints as necessary during treadmill training.
2446686|NCT03263754|Experimental|Intervention|
2446688|NCT03263754|Active Comparator|Control|
2446728|NCT03263650|Experimental|Cabazitaxel + Carboplatin|Cabazitaxel, Cabazitaxel and Carboplatin intravenously on day 1 of cycles 1-6. Prednisone by mouth twice daily on days 1-21 of cycles 1-6.
2446731|NCT03263650|Experimental|Olaparib Maintenance|Participants randomized to receive Olaparib by mouth twice daily on Day 1 of cycle 7.
2446734|NCT03263650|No Intervention|Observation Only|Participants randomized to observation only beginning cycle 7.
2446765|NCT03263299|Active Comparator|cabergoline group|received cabergoline in addition to aspirin. Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer. Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
2446768|NCT03263299|Active Comparator|Aspirin group|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
2446769|NCT03263299|Active Comparator|GnRH Group|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
2446823|NCT03263013||FMD patients|patients with a diagnosis of clinically definite FMD who have been assessed at the HMCS clinic, and who have completed protocol 07-N-0190.
3153124|NCT00268580|No Intervention|Control|Standard of care provided
3153125|NCT00268593|Experimental|130 mg PI-88 + docetaxel|130 mg PI-88 7 days/week + docetaxel 75 mg/m2
3153126|NCT00268593|Experimental|250 mg PI-88 + docetaxel|250 mg PI-88 4 days/week + docetaxel 75 mg/m2
2447090|NCT03261362|Placebo Comparator|Amino acid powder with all amino acids|amino acid powder 80 g oral Administration 1 week
3153127|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD|
3153128|NCT00268697|Experimental|Lapaquistat Acetate 100 mg QD + Ezetimibe|
3153129|NCT00268697|Active Comparator|Ezetimibe|
3153130|NCT00268723|Experimental|1|levalbuterol HFA MDI 90 mcg QID
3153131|NCT00268723|Placebo Comparator|2|Placebo MDI QID
3153132|NCT00268749|Experimental|1|
3153133|NCT00268788|Active Comparator|1|Subcutaneous Ig given twice a week.
3153134|NCT00268788|Active Comparator|2|Intravenous Ig
3153135|NCT00268814|Experimental|MTF, Psycho-education, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
3153136|NCT00268814|Experimental|MTF, Case management, Heroin|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
3153137|NCT00268814|Active Comparator|MTF, Psycho-education, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
3153138|NCT00268814|Active Comparator|MTF, Case management, Methadone|Stratum: Methadone treatment failures (MTF) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
3153139|NCT00268814|Experimental|NIT, Psycho-education, Heroin|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Diacetylmorphine (i.v.)
3153140|NCT00268814|Experimental|NIT, Case management, Heroin|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Diacetylmorphine (i.v.)
3153141|NCT00268814|Active Comparator|NIT, Psycho-education, Methadone|Stratum: Not in treatment (NIT) Intervention: Psycho-education and Counselling, Drug: Methadone (p.o.)
3153142|NCT00268814|Active Comparator|NIT, Case management, Methadone|Stratum: Not in treatment (NIT) Intervention: Case Management and Motivational Interviewing, Drug: Methadone (p.o.)
3153143|NCT00268840|Experimental|unique|Taxotère - Gemzar
3153144|NCT00268853|Experimental|1|
3153145|NCT00268853|Active Comparator|2|
3189819|NCT00781261|Placebo Comparator|Control|Subjects in the control group will receive a placebo drug for a 1 year period
2446043|NCT03268889|Experimental|treatment group|In this arm, patients would be given the regimen composed of Chidamide, Cyclophosphamide, epirubicin, Vincristine and Prednisone.
2446071|NCT03268603|Experimental|Mesenchymal Stromal Cells|Autologous Adipose-derived Mesenchymal Stromal Cells (aaMSCs) will be administered intrathecally at a single dose in a volume of 5-10 mL, all patients will receive 5 x 10^7 intrathecal aaMSCs at the first injection (Visit 4). Subsequent doses may be reduced to 1 x 10^7 or increased to 1 x 10^8, based on Dose Modification Rules.
2446106|NCT03268291|Active Comparator|Standard outpatient observation|Outpatient management according to Ministry of health standards
2446111|NCT03268291|Experimental|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials;~service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators;~questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
2446162|NCT03267979|Other|Patients have a surgical operation|Patients have a surgical operation and have received analgesic treatment. One hour after the end of surgical patients will have electrocardiogram and video-pupillometer.
2446197|NCT03267602|Experimental|Continuous Positive Airway Pressure (CPAP) Therapy|
2446238|NCT03267355|Experimental|Gastrointestinal diseases|Endoscopic Ultrasound
2446266|NCT03267043|Active Comparator|Standard Care|Participants enrolled in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital.
2446267|NCT03267043|Experimental|Family Nurture Intervention (FNI)|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay.
2446268|NCT03267043|Active Comparator|Standard Care - Case Studies|Participants enrolled as case studies in Phase 1 will be receiving the current standard of care in the NICU at The Valley Hospital. These participants will be those who fall outside the inclusion criteria.
2446270|NCT03267043|Experimental|FNI - Case Studies|Participants enrolled in Phase 2 will be receiving family nurture intervention (FNI) that focuses on supporting the parents and facilitating emotional connection between mother and infant during the infant's NICU stay. These fall outside the inclusion criteria but act as a comparator to the case studies of Phase 1.
2446315|NCT03266822||Healthy control|
2446316|NCT03266822||RA patients on anti-TNF therapy|
2446318|NCT03266822||RA patients on anti-IL-6R therapy|
2446347|NCT03266406|Experimental|Effect of hyaluronidase on IOP|
2446356|NCT03266159|Experimental|Part 1: Subjects receiving GSK525762 + trametinib|Eligible subjects will receive doses of GSK525762 with a starting dose of 40 milligrams (mg), or 60 mg in combination with trametinib with a starting dose of 1 mg or 1.5 mg or 2 mg, administered orally once daily. Dose escalation will continue until the maximally-tolerated dose combination (MTC) is reached. Once the MTC is reached, subjects will be enrolled in expansion cohort and will receive a fixed dose combination.
2446358|NCT03266159|Experimental|Part 2: Subjects with SCLC receiving GSK525762+ trametinib|Eligible subjects with small cell lung cancer (SCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2446360|NCT03266159|Experimental|Part 2: Subjects with RMCRC receiving GSK525762+ trametini|Eligible subjects with Ras-mutated colorectal cancer (RMCRC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2446361|NCT03266159|Experimental|Part 2: Subjects with RMNSCLC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated non small cell lung cancer (RMNSCLC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2446364|NCT03266159|Experimental|Part 2: Subjects with RMPAC receiving GSK525762+ trametinib|Eligible subjects with Ras-mutated pancreatic adenocarcinoma (RMPAC) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2446372|NCT03266159|Experimental|Part 2: Subjects with RAST receiving GSK525762+ trametinib|Eligible subjects with Ras-pathway activated solid tumors (RAST) will receive their Part 2 dose as the dose combination of GSK525762 with trametinib selected at the end of Part 1.
2446458|NCT03265795|Experimental|PEEK patient specific implant|this PEEK (poly ether ether ketone) Patient Specific Implant containing autogenous bone graft is used in reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
2446551|NCT03265301|Other|Office hysteroscopy|
2446556|NCT03265301|Other|Conventional hysteroscopy|
2446574|NCT03264677|Experimental|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
2446575|NCT03264677|Experimental|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
2446576|NCT03264677|Experimental|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
2446630|NCT03264521||MTurk Participants|Participants who are registered users on Amazon Mechanical Turk (crowdsourcing platform) who volunteer to take survey.
2446715|NCT03264027|Experimental|Carbon dioxide|Argon fulguration will be performed using CO2 for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
2446812|NCT03263091|Placebo Comparator|Placebo (Double-blind, Three times a week)|Weight-based starting doses; dose adjustments to hemoglobin levels are allowed during the study.
2446969|NCT03262051||Patient with chronic inflammation|patients with rheumatoid arthritis
3189820|NCT00781261|Active Comparator|Zoledronic Acid|Subjects in this intervention group will be given 5mg Zoledronic acid as a single injection
3189821|NCT00781287|Experimental|Raltegravir + 3-drug anti-HIV therapy|
3189822|NCT00781287|Active Comparator|3-drug anti-HIV therapy|
3189823|NCT00781300|Active Comparator|Loteprednol|
2445988|NCT03269240|Experimental|LDHF plus m-Mentoring|"Participants will undergo pre-training assessment comprising multiple-choice questions and objective structured clinical examination (OSCE) using manikins. Training is divided into two 4-day low-dose sessions at the health facility or onsite training. Pre-training and immediate post-training assessments results will be compared. A score of ≥80% is acceptable competence (pass). During the one-month intervals between training sessions, participants practice using manikins to reinforce their competencies through simulation-based practices, facilitated by facility-based trained Peer Practice Coordinators (PPCs). The PPCs will also receive structured, monthly half-hour mentoring calls that will provide remote support, answering questions, providing guidance and reinforcing key messages. Acquisition of knowledge and clinical skills is measured."
2445990|NCT03269240|Active Comparator|Traditional training|The health providers will receive the same content of training in eight days, Off-site training, the way it's currently done in Nigeria. Both theoretical and practical through use of manikins - simulation. No reinforcement and further practice will take place once the participants are back in their work stations. Acquisition of knowledge and clinical skills is measured.
2446055|NCT03268876||Epithelial ovarial cancer|Patients primary treated with primary surgery for advanced epithelial ovarian cancer (> stage IIa) at the participating institutions will be asked to participate.
3189824|NCT00781300|Active Comparator|Dexamethasone|
3189825|NCT00781339|Experimental|Active|
2446159|NCT03267719|Experimental|laser therapy|Erbium-laser therapy will be applied
2446224|NCT03267667||obstructive sleep apnea patients|number of 90 patients will be investigated by 2D echocardiography and cardiac MRI to determine the right ventricle function
2446227|NCT03267667||healthy volunteers|number of 10 subjects will be investigated by 2D echocardiography and cardiac MRI to determine right ventricular function in healthy persons have risk factors other than cardiac or lung diseases
2446274|NCT03267147||antiCCP positive|"Patients with a positive result in the anti-CCP quick test and positive in antiCCP ELISA will be examined by Rheumatologist for detection of RA symptoms and followed-up for 3 years or until RA diagnosis~no intervention is given"
2446277|NCT03267147||antiCCP negative|Patient with negative result in antiCCP quick test or negative antiCCP ELISA will be followed-up after one year (and 3 years for ELISA negative patients) with a short questionnaire if musculoskeletal symptoms are still present or if RA was diagnosed
2446339|NCT03266796||Patients & Physical therapists|First consultations of peoples with musculoskeletal disorders and their physical therapists will be audiotaped. Audiotapes will be used to analyse the communication between the patients and their physicaltherapists to explore how much physical therapists involve their patients in the goal setting process, to see if there is a shared decision making existing.
2446378|NCT03266302|Experimental|Interventional group|Use of hemoadsorber for removal of cytokines. Participants undergoing cardiac surgery due to infective endocarditis will be treated using a hemoadsorption device (CytoSorb) within the cardiopulmonary Bypass circuit (=Intervention)
2446382|NCT03266302|No Intervention|Control group|Participants undergoing cardiac surgery due to infective endocarditis will be treated according to Standard of care (no hemoadsorption advice installed in the CPB circuit)
2446429|NCT03265782|Experimental|ibuprofen group|treatment of pda with oral ibuprofen with a loading dose 10 mg/kg/ds in the first day followed by 5 mg/kg/ds in the second ant third days then a follow up echo is done
2446434|NCT03265782|Experimental|paracetamol group|treatment of pda with oral paracetamol with dose of 15 mg/kg/ds every 6 hours for 3 days then a follow up echo is done
2446455|NCT03265483|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate
2446464|NCT03265483|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
2446466|NCT03265483|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
2446472|NCT03265483|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
2446553|NCT03265197|Experimental|Intratympanic injection of drugs;|intervention by Intratympanic injection of drugs in two studied groups; group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
2446558|NCT03265197|Active Comparator|Data management of Intratympanic drugs|intervention by Manage data of two study group as blind statistical between group A, injection of combined 2 drugs( lidocaine and dexamethasone) and group B, injection of one drug (dexamethasone only).
2446625|NCT03264716|Experimental|HepaSphere TACE (transarterial chemoembolization)|Using HepaSphere TACE (transarterial chemoembolization) for colorectal liver metastasis. TACE using HepaSphere load with doxorubicin.
2446659|NCT03264222|Other|Exposition to safety screening|One armed study with exposition to a new safety device (model QPS100) using radiofrequency technology
2446692|NCT03263988||PIEZO-Group|All patients in this study receive IBP by PICCO and piezocapacitative-interlayer-technology measurement.
2446747|NCT03263585|Active Comparator|Spinal orthosis group|Women wearing the spinal orthosis Spinomed for 6 months at least 2 hours a day.
2446748|NCT03263585|Active Comparator|Equipment training group|Women training once a week in an equipment training group led by a physiotherapist for six months.
2446750|NCT03263585|No Intervention|Control|Women in the control group get no intervention for six months.
2446806|NCT03263182||Nchelenge Facilities|Purposively selected health facilities based on criteria including: high demand for services, perceived need for support for quality improvement, and presence of a SBA to mentor.
2446892|NCT03262714|Experimental|Dancing|Elderly women randomized to the dance intervention programme.
2446899|NCT03262714|Experimental|Walking|Elderly women randomized to the walking intervention programme.
2446903|NCT03262714|Active Comparator|Stretching|Elderly women randomized to the stretching intervention programme.
3189826|NCT00781352|Active Comparator|group 1|Colorectal surgery with 65% nitrous oxide administration
3189827|NCT00781352|Active Comparator|group 2|Colorectal surgery with nitrogen administration
3189828|NCT00781378|Active Comparator|Group 1|rt-PA 100 mg continuous intravenous infusion for 2 hours
3189829|NCT00781378|Experimental|group 2|rt-PA 50 mg continuous intravenous infusion for 2 hours
2446030|NCT03268993|Other|Avmacol|You will be given a higher dose of Avmacol® each month, taking 2 Avmacol® tablets per day the first month (Cycle 1), 4 Avmacol® tablets per day the second month (Cycle 2), and 8 Avmacol® tablets per day the third month (Cycle 3). Investigators will study how Avmacol® affects your body by collecting three different tissues: 1) your cheek cells (buccal cells); 2) your urine; and 3) your blood. After you have finished three months of Avmacol®, you will return one month later for an end-of-study visit.
2446120|NCT03268629|Experimental|Mindfulness-Based Joyful Sleep|The proposed 'Joyful Sleep' program will be conducted weekly, 2 hours per session, 8 sessions, group-based in mindfulness. The content and skills are based upon MBSR, MAPs and Tai Chi. The proposed topics include: 1) mindfulness and insomnia, 2) mindful awareness of stress, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, 6) moving mindfulness meditation: the first taste of Tai Chi, 7) moving mindfulness meditation: the second taste of Tai Chi, 8) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, body scan meditation, sitting meditation, standing meditation, walking meditation, Taichi, and daily life meditation.
2446123|NCT03268629|Active Comparator|CBT-I|The CBT-I is a weekly, 2-hour, 8 session, group-based program. CBT-I includes 4 central components: stimulus control, sleep restriction, relaxation training and cognitive therapy. The aim of CBT-I is to reduce sleep-related physiologic and cognitive arousal so that restorative sleep function can be re-established.
3153146|NCT00268879|Placebo Comparator|1|Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
3153147|NCT00268879|Experimental|2|Renzapride 4 mg QD. Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
2446672|NCT03264105|Experimental|NovaPro™ Flow|NovaPro™ Flow Flowable Composite, Nanova Biomaterials company, USA
2446675|NCT03264105|Active Comparator|Conventional resin-based flowable composite|Filtek™Supreme Ultra Flowable Restorative, 3M ESPE company, USA
2446776|NCT03263273|Placebo Comparator|Topical Vehicle Gel|Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face
2446779|NCT03263273|Active Comparator|1% Topical Minocycline Gel|Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
2446786|NCT03263273|Active Comparator|3% Topical Minocycline Gel|Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face
2446817|NCT03262857|Experimental|time of start of anesthesia|
2446818|NCT03262857|Experimental|intensity of anesthesia|
2446906|NCT03262727|Experimental|BMS-986165 and Oral Contraceptive|Oral administration of contraceptive, then progress to combination
2447002|NCT03261921|Active Comparator|Dexamethasone group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + (0.1 mg/kg dexamethazone) caudally.
2447009|NCT03261921|Active Comparator|Dexmedetomidine group|In this group the Patients received 0.5 ml/kg of bupivacaine 0.25% + dexmedetomidine(1 mu/kg) caudally.
2447011|NCT03261921|Active Comparator|Combination group|In this group the patients received 0.5 ml/kg of bupivacaine 0.25% + dexamethasone(0.1mg/kg) and dexmedetomidine (1 mu/kg) caudally.
2447081|NCT03261310|Experimental|Acetaminophen & Craniotomy|Drug: Acetaminophen 1000mg administered intravenously during craniotomy
2447086|NCT03261310|Placebo Comparator|Placebo & Craniotomy|Placebo administered intravenously during craniotomy.
2447093|NCT03261310|Experimental|Acetaminophen & Laminectomy|Acetaminophen 1000mg administered intravenously during laminectomy.
2447096|NCT03261310|Placebo Comparator|Placebo & Laminectomy|Placebo administered during laminectomy.
2447114|NCT03260829|Active Comparator|vitamin C injection|orthodontic traction with vitamin C injection
2447117|NCT03260829|Placebo Comparator|orthodontic traction|orthodontic traction without vitamin C injection
2447167|NCT03260374||children with cochlear implant|"30 subjects whose age ranges from 2-6 years old who are implanted with Medel multichannel cochlear implant male and female will be included and will undergo:-~Electric compound action potential~Electric stapedial reflex threshold~Electric auditory brain stem response"
2447233|NCT03260010|Experimental|Fosfomycin Arm|Include intravenous fosfomycin in the treatment of PJI according to predetermined algorithm
3153148|NCT00268879|Experimental|3|Renzapride 2 mg BID: Two capsules are taken by mouth each morning and each evening from the day of the randomization visit until the scheduled visit at the end of Week 12.
3153149|NCT00268918|Experimental|Docetaxel / PTK787|"Docetaxel: Lead In: Given intravenously on Day 1 and Day 14 Afer Lead in: Given intravenously on day 1, 8, 15, 22 of each 28-day cycle.~PTK787: Lead In: Given orally on day 4 and day 14 After Lead In: Given orally once a day."
2447337|NCT03259347|Experimental|Counter-attitudinal therapy|Counter-attitudinal therapy (CAT) is dissonance-based group intervention. CAT consists of behavioral, written, and verbal exercises in which participants discuss the costs of pursuing the thin ideal and behaviors that are used to pursue the thin ideal. The intervention is 8 sessions long (1-hr each) and is administered by a trained facilitator who uses an intervention script. Participants will be asked to complete weekly home exercises throughout the course of the intervention.
2447338|NCT03259347|Active Comparator|Educational-support group|The educational support group intervention that is representative of typical treatment groups offered at universities and community settings. For the current study, the educational support group was designed to match the dissonance group on treatment modality (group-based), duration (8 1-hr sessions), and use of an intervention script administered by a trained facilitator. In the intervention sessions, participants will be provided with a basic education about eating disorders, support for themselves and fellow group members, and learn mindfulness techniques.Participants will be asked to complete weekly homework assignments.
3173141|NCT00608660|Experimental|E|non-staging acupuncture for treating Bell's Palsy
2446033|NCT03268928|Experimental|Story Starters Intervention|"Children will receive the the Story Starters intervention for six months. Each child will be visited by a trained Story Starter volunteer twice a week while the child is in preschool. The sessions will last 20 minutes and in each session the Story Starter volunteer and child will read books and play with toys. The Story Starter volunteers will keep a record of the number of sessions each child attends.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
2446040|NCT03268928|Other|Wait-list Control|"Children in the wait-list control arm will continue to attend preschool as normal during the randomised controlled trial (RCT) and will receive the Story Starters intervention after the RCT has finished.~Each child will receive one new book per month delivered to their home address by Dolly Parton's Imagination Library."
2446081|NCT03268616|Experimental|Healthy Subjects|increase the inspiratory threshold load step by step(30%-80%MIP),in order to increase neural respiratory drive.
2446083|NCT03268616|Experimental|Sever COPD Patients|increase the pressure support ventilation step by step, in order to decrease neural respiratory drive.
2446124|NCT03268239|Other|MRI sequences|"There will be only one arm of patients with central nervous system inflammatory disease.~Each patient will be its own control. The usual and additional MRI sequences will be performed in all patients and the number of lesions obtained in usual sequences and additional sequences will be compared in the same patient."
3153150|NCT00268931|No Intervention|True Control|This group is being enrolled as a true control group. This group will not participate in the movement training or social training however, they will be evaluated in the same way.
2446264|NCT03266939|Placebo Comparator|Placebo|
2446265|NCT03266939|Active Comparator|Active Medication|
2446326|NCT03266861||Patients undergoing exercise oximetry|Patients with PAD referred for treadmill testing and exercise oximetry
2446486|NCT03265626|Experimental|Comprehensive (Intervention 1)|A total of 586 study particpnats will be invloved on this comprehensive (main) experiment group.This arm will receive a comprehensive intervention package that include advocacy to local governors, community mobilization, awareness creation, training of community representatives and engagement partners. community mobilization through engaging husband as change agent to avert domestic violence in collaboration with community Health Extension Workers. The intervention will target married or cohabited women, partner, and community representatives (religious leaders, and elders). The intervention will be focused on physical, psychological and sexual violence, decision making, negotiation, communication on household matters, gender equality and equity norms, and their relationship with women's health. In addition, massive public information dissemination will be done in the intervention community.
2446487|NCT03265626|Active Comparator|Intervention 2|A total of 586 study particpnats will be invloved on this active comprator group. The intervention package such as advocacy to local governors, community mobilization, awareness creation and training of community representatives will be carried out for 12 months period.The main diffrence from the arm-1,here is no husband involvment in the interevntion targets. This intervention will be targeted married and cohabited women and community representatives (religious leaders, health care provider, police, politicians and associations). This group of participant will be selected from one urban and one rural Kebele in Banja District. Same tool and approach will be used to track the intervention progress.
2446488|NCT03265626|Other|Control/Comparator|"A total of 586 study partipants will be assigned to the control group that will receive the existing standard services from both urban and rural kebeles of the Guagussa Shikudad district. As comparator purpose, baseline and endline evaluation data will be taken.~-No intervention package but standard service will be maintained"
2446514|NCT03265080|Experimental|Part A|"Dose cohorts of 3 participants each will be treated. Initiation of dosing will be staggered by at least 4 weeks for participants in the first cohort, also known as intra-cohort staggering.~Two dose levels of ADXS-NEO will be explored: 1 x 10 to the 9th power and 1 x 10 to the 8th power colony forming unit (CFU)."
2446515|NCT03265080|Experimental|Part B|Two dose levels of ADXS-NEO will be explored [i.e., 1 x 10 to the 8th power and 5 x 10 to the 8th power colony forming unit (CFU)] in combination with 200mg of pembrolizumab.
2446516|NCT03265080|Experimental|Part C|ADXS-NEO will be explored at 1 x 10 to the 8th power colony forming unit (CFU) in combination with 200mg of pembrolizumab in an expansion cohort.
2446563|NCT03264976||Group 1|Patients without DR. Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years.
2446566|NCT03264976||Group 2|"Patients with mild non-proliferative DR (NPDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2446567|NCT03264976||Group 3|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2446568|NCT03264976||Group 4|"Patients with moderate NPDR. Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination. These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2446569|NCT03264976||Group 5|"Proliferative DR (PDR). Diagnosed according to Diabetic retinopathy PPP - Updated 2016.~Information and samples of all trial participants at enrollment will be collected at the inception of the study, including: basic information, basic medical records, hematological examination, ophthalmic examination.These information and examinations will be collected at regular intervals: every 12 months until 5 years."
2446592|NCT03264703||Participants with RA with cDMARD, but no anti-TNF experience|Male and female participants diagnosed with rheumatoid arthritis (RA), who have no experience with anti-tumor necrosis factor (anti-TNF) and who have experienced two or more Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) of a stable dose for at least 3 months.
2446041|NCT03269006|Experimental|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies.
2446046|NCT03269006|Experimental|ITN (KO-Tab 123)|impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin.
2446050|NCT03269006|Experimental|IRS (Delthamethrin)|indoor residual spraying with Delthamethrin in the living rooms
2446053|NCT03269006|No Intervention|Control|without any study interventions
2446105|NCT03268447|Active Comparator|Lactobacillus plantarum P8|Intervention consists of daily administration of 2g probiotic Lactobacillus plantarum P8, administered daily at a fixed dosage of 10 log CFU/sachet/day and continue for 12 weeks.
2446109|NCT03268447|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 weeks.
3189830|NCT00781417|Active Comparator|1|Cholecalciferol 50,000 IU once a week for 12 weeks then every other week for 40 weeks
3189831|NCT00781417|Placebo Comparator|Placebo|Placebo
2446441|NCT03265717|Experimental|"Group 1: Untreated high risk watch and wait"|Newly diagnosed patients not eligible for any approved treatment (using NCI Working Group criteria), but having some poor prognosis characteristics (defined by MDACC nomogram criteria). Patients will be treated by INVAC-1 for 6 months and then MRD will be assessed. Patients will subsequently be managed as per usual care. For MRD negative patients after INVAC-1 who become MRD+ during follow-up, INVAC-1 can be resumed for one year.
2446443|NCT03265717|Experimental|Group 2: Ibrutinib treated patients|Patients who are receiving ibrutinib as 1st or 2nd line treatment. After at least 12 months of ibrutinib, patients will be assessed for MRD. MRD-positive patients will be treated with ibrutinib + INVAC-1 for 6 months and at the end of the combined treatment period, MRD will be assessed. MRD-negative patients (defined as <0.01% of CLL cells in total cells analyzed) will have the option to stop or continue ibrutinib. Then, they will be followed-up regularly for two years. Patients who become MRD-positive after being MRD-negative will resume ibrutinib single agent.
2446480|NCT03265431|Active Comparator|Control|Normal subjects without history of cardiac disease or arrhythmia
2446482|NCT03265431|Experimental|Arrhythmia|This cohort consist of patients with history of recurrent VT and scheduled for EAM-guided catheter ablation as part of their clinical treatment
2446484|NCT03265431|Experimental|Treatment Failure|A subset of the Arrhythmia cohort, this group will undergo a second imaging session. This subset corresponds to patients from the Arrhythmia cohort presenting with recurrent ventricular arrhythmia following initial EAM-guided catheter ablation and requiring repeated ablation. It is estimated that 30% of the Arrhythmia cohort patients will require repeat ablation based on rate of repeat ablation procedures at MGH. T
3189832|NCT00781430|Experimental|1|
3189833|NCT00781443|Experimental|A|
2446624|NCT03264625|Experimental|Treatment group|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
2446627|NCT03264625|Placebo Comparator|Control group|Patients randomized to the placebo group will receive routine therapy for PD.
2446671|NCT03264170|Active Comparator|Prediction of pregnancy outcome|Women will receive an individualised prediction score of the pregnancy being viable at the follow-up ultrasound generated from the prediction tool.
2446673|NCT03264170|No Intervention|Control|Women will not receive the prediction score
2446695|NCT03263819||POTS|patients with postural orthostatic tachycardia syndrome diagnosis.
2446696|NCT03263819||Healthy controls|Patients with Postural orthostatic tachycardia syndrome who has peripheral neuropathy
2446752|NCT03263507|Experimental|IONIS-PKK-LRx|Ascending single and multiple doses of IONIS-PKK-LRx administered subcutaneously
2446754|NCT03263507|Placebo Comparator|Placebo (sterile saline 0.9%)|Calculated volume to match active comparator
2446836|NCT03263156|Experimental|Intervention group|The intervention will involve two face-to-face consultation sessions and one follow-up phone call with parents to help them learn sleep hygiene practices and specific behavioural strategies to improve their child's sleep and follow up on the progress.
2446843|NCT03263156|No Intervention|Waiting-list control|Children in the waiting-list control group will receive usual clinical care.
2446879|NCT03262532||Experimental|Learning TEE manipulation with a Web-based TEE simulation module
2446885|NCT03262532||Control|Learning a TEE manipulation without the Web-based TEE simulation
3189834|NCT00781443|Placebo Comparator|B|
3189835|NCT00781469||Naive patients|12 treatment naive patients who fulfil the American College of Rheumatology (ACR) criteria for RA with active disease defined by a Disease Activity Score (DAS)28 score of more than 3.2.
3189836|NCT00781469||Patients in remission|6 RA patients in remission on a stable dose of methotrexate with a DAS28 score lower than 2.6
3189837|NCT00781469||Patients still have active disease|12 patients who fulfill the ACR criteria for RA and are being treated with methotrexate but still have active disease, defined as a DAS28 score of more than 3.2
2447024|NCT03261596|Experimental|100 mg solid tablets 2x/day for 3 days|Assess the efficacy (Cure Rate/CR) and safety of 100 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
2447029|NCT03261596|Experimental|Single dose 500 mg solid tablets|Assess the efficacy (Cure Rate/CR) and safety of 500 mg dose regimen of mebendazole in children aged 6 to 18 years, inclusive, infected with hookworm.
2447049|NCT03261258||Patients|Patients hospitalised in the ICU of Dijon CHU Burgundy
2447050|NCT03261258||Proches|Relatives/close friends of patients hospitalised in the ICU of Dijon CHU Burgundy
2447104|NCT03261141||study group sixty three children|"severity and character of dysphonia APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
2447208|NCT03260686|No Intervention|Treatment as usual|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician
2447266|NCT03260075||ward cat|Patients and staff at wards that have a cat present
2446073|NCT03268577||Prevention (diet and activity tracking)|Patients complete the ASA24 about foods, cooking methods, and other aspects of diet every 2 months for up to 6 times, and complete ACT24 about activities and time reporting every 2 months for up to 6 times. Patients also complete DHQ-II questionnaires at the beginning and end of the study about the frequency and portion sizes of foods consumed over the past 12 months, provide a 7-day food checklist twice with the DHQ-II, and provide a 4-day food record twice, once every 6 months. Physical activity monitors are worn to measure movement at different intensity levels and sitting or standing periods, twice during the study with 6 months between each time they are worn.
2446150|NCT03268122|Active Comparator|Standard Contact Isolation|Patients in the standard contact isolation arm will be under the standard contact isolation strategy during the entire time they are physically located in the Medical ICU.
2446151|NCT03268122|Active Comparator|Targeted Contact Isolation|Patients in the targeted contact isolation arm will be under the targeted contact isolation strategy during the entire time they are physically located in the Medical ICU.
2446176|NCT03267706|Active Comparator|Palliative Care Comprehensive Tool|Clinicians within the study will be randomly assigned and trained on the use of the Palliative Care Comprehensive Tool
2446181|NCT03267706|No Intervention|Usual Care|Clinicians within the study will be randomly assigned to usual palliative care (without the newly introduced tool)
2446287|NCT03267238|Experimental|Fecal Microbial transplantation|Fecal Microbial Transplantation will be offered to patients eligible to be part of the study.
2446306|NCT03266705|Experimental|61 mgA tafamidis free acid soft gelatin capsule|
2446307|NCT03266705|Experimental|4x20 mg tafamidis meglumine soft gelatin capsule|
2446341|NCT03266523||Control|The CONTROL (neutral) environment corresponds to the standard environment of the imaging waiting rooms
2446342|NCT03266523||Zen|The ZEN environment will represent a clean, minimalist nature
2446343|NCT03266523||Green|The GREEN environment will represent rural landscapes, undergrowth
2446344|NCT03266523||Sea|The SEA environment will represent lakes, ponds, seaside
2446384|NCT03266224||Wryneck|those with a condition
3189838|NCT00781482|Experimental|1|This is a crossover study. Each study drug will be administered (one at a time and in random order) to each subject on separate occasions over the course of the study.
2446493|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/low sodium diet.
2446496|NCT03265353|Other|Moderate Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the moderate potassium/high sodium diet.
2446499|NCT03265353|Other|High Potassium/High Sodium Diet|Vascular function will be assessed at both the conduit artery and microvascular level after 7 days of the high potassium/high sodium diet.
2446604|NCT03264963|Active Comparator|Control|
2446606|NCT03264963|Experimental|Intervention|
2446639|NCT03264352|Active Comparator|intensive treatment group|Real antihypertensive agents will be provided for this arm, to decrease systolic BP to lower than 120 mm Hg. In this group, the following study medications will be used: tablets with Allisartan Isoproxil 240 mg (first-line medication); tablets with Amlodipine 5 mg (second-line medication). Treatment will be started with Allisartan 240 mg. If necessary to reach the BP goal, Amlodipine (first 5 mg or then 10 mg daily) will be given in addition. If intolerable side effects occur, first-line medication may be replaced by second-line medication.
2446641|NCT03264352|Placebo Comparator|standard treatment group|In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
2446699|NCT03263923|Experimental|Intervention group|Online intervention is cognitive behavioral skills' training and 4 weeks of online journaling. Participants receive cognitive behavioral skills training by online video, then participants must complete a 28 day online journal reflecting on the cognitive skills they have learned/used.
2446703|NCT03263923|Active Comparator|Comparison group|Comparator intervention is Reflective journaling training and 4 weeks of online journaling. Participants watch a reflective journaling video with specific instructions, and then the participants complete a 28 day journal using a different set of prompts to reflect on their days and describe how they handled various situations.
2446807|NCT03263520|Experimental|Group 1: nandrolone and corticosteroid|the patient will receive an application of anabolic nandrolone decanoate at a dose of 50 mg (males) and 25 mg (females), intra-muscular form, in the first and fifteenth days. In addition to the anabolic steroid, the patient will use corticosteroids (dexamethasone) at home at a dose of 4 mg daily by mouth on the morning for both sexes for 30 days.
2446808|NCT03263520|Active Comparator|Group 2: corticosteroid|Patient will take corticosteroids ( 4 mg of dexamethasone) per oral, QD at morning for 30 days
2446849|NCT03262844|Placebo Comparator|Conservative treatment|Conservative physiotherapy, intermittent catheterization, or drug treatment for bladder or bowel dysfunction
2446854|NCT03262844|Experimental|Capsule surgery|Nerve root axial decompression surgery (Capsule surgery)
2446881|NCT03262506|Experimental|Cognitive Training|
2446927|NCT03262298|Experimental|anti-CD22 CAR-T|Patients will receive a full dose CART infusion at day 0.
2447026|NCT03261882||Foreign-born Mexican-Americans|
2447033|NCT03261882||US-born Mexican-Americans|
2447035|NCT03261882||non-Hispanic Whites|
2447165|NCT03261115|No Intervention|Control group|Topical Anesthesia
2447166|NCT03261115|Experimental|Study group|No topical anesthesia
2447216|NCT03260296||University students|university students who use smartphones
2447255|NCT03259971|Placebo Comparator|Placebo (for tic disorder)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
2447260|NCT03259971|Active Comparator|PS128 (tic disorder)|The Probiotic group in tic disorder will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 2 months for Tic disorders.
2447274|NCT03260075||no ward cat|Patients and staff at wards that have no cat present
2446108|NCT03268512|Experimental|A-PRF|One socket will be filled with A-PRF membranes and covered with at least 2 A-PRF membranes. A modified horizontal mattress will be place as suture to keep the A-PRF in place.
2446114|NCT03268512|No Intervention|Control|The socket will be filled with a natural blood clot. A modified horizontal mattress will be place as suture.
2446170|NCT03268031||Glaucoma patients|Glaucoma patients will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
2446172|NCT03268031||Non-glaucoma participants|Non-glaucoma participants will take visual field test and OCT imaging of optic nerve area. All of these data will be collected as source of machine learning.
3189839|NCT00781495||type 2 diabetes mellitus|
2446291|NCT03266926||Postoperative Patients with premarin|Patients who undergo vaginal surgery at Sunnybrook Health Sciences Centre (SHSC) who require vaginal packing postoperatively and receive premarin vaginal cream coated packing.
2446294|NCT03266926||Postoperative Patients with bupivacaine|Patients who undergo vaginal surgery at Patients who undergo vaginal surgery (SHSC) who require vaginal packing postoperatively and receive bupivacaine soaked packing.
2446331|NCT03266614|Experimental|Recovery 4 US|This group receives a smartphone with the Recovery 4 US application and access to the application website.
2446336|NCT03266614|No Intervention|Services as usual|This group receives a smartphone but no access to the Recovery 4 US application.
2446380|NCT03266276|No Intervention|Treatment as Usual Control Group|Treatment as usual.
2446383|NCT03266276|Experimental|Intervention Group|Use of a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
2446457|NCT03265899|Experimental|Oxytocin|40 IU Oxytocin, intranasal application 30 min prior to the experiment
2446462|NCT03265899|Placebo Comparator|Placebo|sodium chloride solution, intranasal application 30 min prior to the experiment
2446537|NCT03265249|Experimental|Group 1|BRIDGE device will be placed prior to start of the surgery with standard of care pain control analgesia
2446543|NCT03265249|No Intervention|Group 2|Subjects will receive the standard of care pain control analgesia
2446587|NCT03264820|Experimental|Patients with scleroderma and potential arterial disease|"The patients (33) will undergo a medical examination in order to analyse their medical history, parameters and check inclusion and non-inclusion criterions.~Then will be performed :~Visit 1 :~Biology report * (* Biological evaluation carried out in all healthy subjects and in subjects whose biological check-up dates more than 2 years,+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
2446590|NCT03264820|Experimental|Healthy volunteers|"The healthy volunteers (11) will undergo :~Visit 1 :~Biology report (+ urinary pregnancy test (if applicable))~Laser measurements at the forearm (with laser speckle)~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature~Visit 2 :~Laser measurements at the level of each finger~Pain evaluation (EVA)~Measurement of blood pressure and heart rate~Environmental measures and skin temperature"
3153151|NCT00268931|Experimental|Social Training|This group underwent specific social interactions two times each day with their parents.
2446710|NCT03263793|Experimental|Behavioral vocal training|12-week vocal training program will use maximum vocal function exercises targeting vocal deficits specific to Parkinson Disease.
2446766|NCT03263429|Experimental|Panitumumab/Irinotecan/CB-839|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28, panitumumab IV over 60-90 minutes on days 1 and 15, and irinotecan hydrochloride IV over 90 minutes on day 1 and 15 (Phase I only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3153152|NCT00268931|Experimental|Movement Training|This group of preterm infants underwent movement training two times per day with their parents.
3153153|NCT00268944|Experimental|1|
2446968|NCT03261986|Other|Trident II acetabular cup|Subjects receive the Trident II acetabular cup and RSA beads and undergo a series of post-operative RSA exams.
2447007|NCT03261713|Experimental|Virtual Reality|Virtual reality training designed to train standing balance, reaching, stepping, gentle strengthening and aerobic conditioning.
2447010|NCT03261713|Active Comparator|Control|iPad apps designed to train memory, cognition, visual tracking and fine motor skills.
2447076|NCT03261414|Experimental|With preoperative hypnosis|standard care plus hypnosis followed by administration of propofol for anesthesia induction
2447087|NCT03261414|Active Comparator|Without preoperative hypnosis|standard care without preoperative hypnosis followed by administration of propofol for anesthesia induction
2447209|NCT03260725|Experimental|Internet-delivered treatment|This treatment arm entails Internet-Delivered PCIT (I-PCIT) remotely delivered in real time using videoconferencing. Families stream live parent-child interactions from their own home to a remote therapist who provides live bug-in-the-ear parent coaching via a parent-worn Bluetooth earpiece.
2447211|NCT03260725|Active Comparator|Clinic-delivered treatment|This treatment arm entails Parent-Child Interaction Therapy (PCIT) delivered in the clinic. For much of the treatment, the therapist observes family interactions from behind a 1-way mirror and provides live bug-in-the-ear parent coaching via a parent-worn earpiece.
2447234|NCT03260049||1|there was no retinal detachment (RD) at the first visit. The group 1 patients were treated with systemic antiviral medications, as well as with intravitreal antiviral injections
2447294|NCT03259464|Experimental|BI 685509|Chinese & Japanese subjects
3153154|NCT00268957|Experimental|1|sevelamer carbonate powder
3153155|NCT00268957|Active Comparator|2|Sevelamer hydrochloride
3153156|NCT00269035|Experimental|Treatment Group 1|Subjects in group 1 will receive SB-773812 tablet once daily till still steady Cp
3153157|NCT00269035|Experimental|Treatment Group 2|Subjects in group 2 will receive SB-773812 tablets once daily over 6 weeks. Risperidone tablets 6 mg once daily from Days 1-7 two tablets of 3 mg and days 8 until stable Cp 6 mg tablets
3153158|NCT00269048|Experimental|Arm 1|SB-480848
3153159|NCT00269048|Placebo Comparator|Arm 2|placebo
3153160|NCT00269282|Active Comparator|1|Self-Management (SM) (Standard Care Group)
2446158|NCT03267836|Experimental|Avelumab + Proton Therapy|"Avelumab will be started concurrently with proton therapy (up to 3 days before or after is permissible) and administered every 2 weeks for 3 months~Proton therapy 20 CGE (cobalt gray equivalent) will be given over 5 daily fractions of 4 CGE per day during weekdays~After 3 months of avelumab, patient will have a brain MRI evaluation, and radiological response will be assigned based on the iRANO criteria. Surgery will be performed as per routine clinical care~If the brain MRI after 3 months of avelumab shows complete response with no signs of residual tumor, no surgery will be indicated, and the patient may continue to take adjuvant avelumab for an additional 3 months.~After the patient has recovered from the surgery and if deemed medically eligible by the treating physician to receive additional immunotherapy, avelumab will be restarted and administered every 2 weeks for an additional 3 months"
2446199|NCT03267537|Active Comparator|Conventional office-based CBT-I|CBT-I will be delivered by a licensed clinical psychologist in weekly sessions lasting up to 1 hour. There will be 6 CBT-I sessions over the course of therapy with the option of an additional 2 treatments if deemed necessary by the clinical psychologist.
2446201|NCT03267537|Experimental|Telemedicine based CBT-I|The treatment will be the exact same as the active comparator group, with the same clinical psychologist doing the office-based CBT-I, but will be administered through a telemedicine modality
2446240|NCT03267316|Experimental|Dose escalation|Cohorts of 3 subjects will receive once weekly (Q1W) treatment with CAN04. The Dose Limiting Toxicity (DLT) observation period for each dose level will be the first 21 days of treatment with CAN04. [Completed December 2018]
2446245|NCT03267316|Experimental|Monotherapy (Q1W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W).
2446247|NCT03267316|Experimental|Monotherapy (Q1W/Q2W)|Subjects with either PDAC or NSCLC, will receive treatment with CAN04 monotherapy once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W).
2446253|NCT03267316|Experimental|Combination - NSCLC|Subjects with NSCLC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (cisplatin/gemcitabine).
2446256|NCT03267316|Experimental|Combination - PDAC|Subjects with PDAC will receive treatment with CAN04 once weekly (Q1W) for the first 6 weeks followed by treatment every second week (Q2W) in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine).
2446257|NCT03267316|Experimental|Combination - PDAC (1 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
2446258|NCT03267316|Experimental|Combination - PDAC (2,5 mg/kg)|Subjects with PDAC will receive CAN04 on Day 1 and 15 in cycles of 28 days in combination with standard-of-care therapy (nab-paclitaxel/gemcitabine). During first cycle CAN04 also to be administered on Day 8.
2446335|NCT03266601|Experimental|Recombinant Human Interferon α-2b Spray|
2446340|NCT03266601|Active Comparator|Ribavirin|
2446369|NCT03266250||spinal anesthesia Hypotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
2446377|NCT03266250||spinal anesthesia Normotensive patients|Transthoracic echocardiography of IVC before spinal anaesthesia
2446406|NCT03265886|Experimental|Warm bupivacaine at (37°c)|Warmed bupivacaine at body temperature will be administered
2446407|NCT03265886|Active Comparator|Bupivacaine at operating room temperature (23°c)|Bupivacaine at temperature of 23°C will be administered
2446442|NCT03265678||Arm|Registered participants will undergo a clinical assessment to determine whether they have high or low levels of skin ageing. The study will recruit 5 subjects with low levels of skin ageing and 5 subjects with high levels of skin ageing. Recruited patients will undergo skin punch biopsies, blood sampling and collection of lifestyle data.
2446452|NCT03265470|Experimental|Dexmedetomidine|Patients received intravenous infusion of dexmedetomidine
2446453|NCT03265470|Active Comparator|Fentanyl|Patients received intravenous infusion of fentanyl
2446524|NCT03265288|Experimental|LAU-7b|Active drug fenretinide (as LAU-7b capsules)
2446529|NCT03265288|Placebo Comparator|Placebo|Placebo oral capsule (as inactive capsules identical to active arm)
2446580|NCT03264612|Active Comparator|Swimming group|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
2446582|NCT03264612|No Intervention|Non swimming group|no intervention
2446640|NCT03264547|Active Comparator|Arm A|"Trastuzumab + pertuzumab + Taxane*~*Taxane is chosen from the following; Docetaxel or Paclitaxel"
2446642|NCT03264547|Experimental|Arm B|Trastuzumab+ Pertuzumab + Eribulin
2446713|NCT03263767|Experimental|LYMPHOID HEMOPATHY without ATG|patients with lymphoid hemopathy
2446719|NCT03263767|Experimental|MYELOID HEMOPATHY without ATG|patients with myeloid hemopathy
2446722|NCT03263767|Experimental|LYMPHOID HEMOPATHY witH ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
2446724|NCT03263767|Experimental|MYELOID HEMOPATHY with ATG|patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
2446802|NCT03263234|Active Comparator|Group 1|Group 1 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 1 starts the 8 week control period and ends with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED).
2446804|NCT03263234|Active Comparator|Group 2|Group 2 consists of elderly people with frailty and/or dementia living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are having CALED installed. Group 2 starts with the intervention consisting of 8 weeks of circadian adjusted LED-based lighting (CALED) and ends with the 8 week control period
2446805|NCT03263234|No Intervention|Group 3. Control group|"Group 3 consists of elderly people with frailty living in elderly housing in Sundhedshuset, Albertslund, Denmark, and who are not having CALED installed.~This group serves as a control for:~Physiological or mental decline in participants during the study period~Seasonal variation"
2446895|NCT03262753||surgery|Primary end-to-end surgical treatment of coarctation of the aorta
2446900|NCT03262753||balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
2446160|NCT03267797|Experimental|Treatment group|Peripheral blood mononuclear cells (PBMCs) were administered into the uterine cavity of RIF patients in this group.
2446161|NCT03267797|Placebo Comparator|Control group|Phosphate buffer saline (PBS) as placebo was injected into the uterine cavity of RIF patients in this group.
2446195|NCT03267550|Experimental|remote programming system|
2446221|NCT03267342|Experimental|All participants|low-income people with mental illness will be given one-on-one financial counseling, a weekly peer support group, supported access to mainstream banking services and access to a matched savings account for a 12-14 month period.
2446295|NCT03267160||Sepsis with cardiopulmonary failure|Patient with sepsis and also respiratory and heart involvement, confirmed by Hemodynamic parameters
2446297|NCT03267160||Sepsis without cardiopulmonary failure|Patient with sepsis without respiratory and heart involvement
2446334|NCT03266640|Experimental|Refractory CMV|Patients with refractory CMV will be given one dose of CMV specific CTLs. HLA matched donors will get Dose 2.5 × 10(4) CD3/kg recipient weight; HLA mismatched will get 0.5x10(4) CD3/kg recipient weight. Additional doses may be given for a total of 5 doses if patients do not have a response to the first dose with a reduction in viral load to normal limits.
2446444|NCT03265691|Experimental|Early hyponatremia diagnosis and treatment|The early diagnosis of hiponatremia is not a stándar procedure. In the experimental arm, hyponatremia will be diagnosed and treated early.
2446446|NCT03265691|No Intervention|No intervention|Usual pattern of work will be performed in all patients who enter in Hospital. Duration: 6 months.
2446477|NCT03265418|Experimental|BioXmark liquid fiducial markers|Placement of 4 BioXmark liquid fiducial markers, standard treatment (chemo-radiotherapy followed by surgery or wait-and-see) with extra imaging to evaluate the behaviour of the markers before, during and after the radiotherapy
2446572|NCT03264937|Experimental|Social-software management group|We set up a mini-program based on wechat application. We instruct warfarin therapy via social-software including dose adjustment, answer questions, remind monitoring INR et.al.
2446573|NCT03264937|No Intervention|Routine management group|This is the control group, Warfarin therapy was managed via traditional style without social software intervention.
2446609|NCT03264599||occiput-spine angle > or = 126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle > or = 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
2446611|NCT03264599||occiput-spine angle<126|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle < 126) will be performed to quantify the degree of fetal head flexion in respect to the trunk
2446651|NCT03264313|Active Comparator|dTMS active|patients undergoing of dTMS real
2446656|NCT03264313|Sham Comparator|dTMS Sham|patients undergoing to placebo dTMS
2446698|NCT03263910|Experimental|NPO-11|
2446704|NCT03263910|Placebo Comparator|Placebo|
3153161|NCT00269282|Experimental|2|Motivational Interviewing plus Self-Management Training (MI+SM)
3153162|NCT00269295|Experimental|Cohort 1: Arm 1|12 subjects to receive vaccine dose 1: 5 X 10^7 cfu.
2446872|NCT03262688|Experimental|INL-001|Bupivacaine HCl collagen-matrix implant
2446875|NCT03262688|Active Comparator|Infiltration|Bupivacaine HCl infiltration
2446929|NCT03262025||Operated patients who survived|Patients who were discharged in index hospital admission after operative intervention
2446931|NCT03262025||Operated patients who expired|Patients who expired in index hospital admission after operative intervention
2446943|NCT03262025||Non-operated patients who survived|Patients who were discharged in index hospital admission after being managed conservatively
2446953|NCT03262025||Non-operated patients who expired|Patients who expired in index hospital admission after being managed conservatively
2446992|NCT03261843|Active Comparator|posterior lumbar interbody fusion + platelet rich plasma|the addition of autologous platelet rich plasma to the bone graft
2447000|NCT03261843|Active Comparator|posterior lumbar interbody fusion|bone graft alone
2447053|NCT03261505|Experimental|VGAIT|
2447057|NCT03261505|Sham Comparator|VGAIT Control|
2447060|NCT03261505|Active Comparator|Real Acupuncture|
2447065|NCT03261505|Placebo Comparator|Sham Acupuncture|
2447116|NCT03260985|Experimental|Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
2447121|NCT03260985|No Intervention|Delayed Feedback Group|All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
2447207|NCT03260686|Experimental|Video Guided Group|Participants receive standard care physiotherapy for their upper limb rehabilitation, with exercises given either verbally or in writing as decided by the prescribing clinician. In addition the participants will receive a personalised video guide of their exercises, filmed during their therapy session to use for independent practice when back on the ward.
2447295|NCT03259464|Placebo Comparator|Placebo|Chinese & Japanese subjects
3153163|NCT00269295|Placebo Comparator|Cohort 1: Arm 2|6 subjects to receive placebo.
3153164|NCT00269295|Experimental|Cohort 2: Arm 1|12 subjects to receive vaccine dose 2: 5 X 10^8 cfu.
2446348|NCT03266510|Experimental|Inspiratory muscle strength training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be strong.
2446349|NCT03266510|Sham Comparator|Sham training|Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
2446357|NCT03266120|Active Comparator|Art Intervention|Participants randomly assigned to this arm will receive a hands-on art intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place indoors over a period of four weeks for a total of eight art sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
2446359|NCT03266120|Experimental|Gardening Intervention|Participants randomly assigned to this arm will receive a hands-on gardening intervention that will consist of twice weekly group sessions of approximately 60 minutes each in duration that will take place in a greenhouse over a period of four weeks for a total of eight gardening sessions. Participants will complete sets of self-report psychometric assessments and blood pressure and heart rate will be monitored before, during, and following the conclusion of the intervention.
2446409|NCT03265912||Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), mTBI (Mild Traumatic Brain Injury) patient group also called as Arm 1 in this study.
2446410|NCT03265912||Non Mild Traumatic Brain Injury|Subjects enrolled in the GE healthcare study, Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase 2), non-TBI (Non Mild Traumatic Brain Injury) patients also called as Arm 2 in this study.
2446485|NCT03265639|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
2446489|NCT03265639|Experimental|Intervention|This arm is the 8 week p-inulin treatment phase (8 grams twice daily, oral).
2446490|NCT03265639|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
2446533|NCT03265106|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/ maximum dose: 1x10^6/kg / 1x10^7/kg administered to childhood patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
2446586|NCT03264924||Phase A, Study One|Semi-structured interviews to investigate staff and patients' experiences of participating and facilitating cardiac and pulmonary rehabilitation.
2446588|NCT03264924||Phase A, Study Two|Focus group with rehabilitation stakeholders to discuss perceived feasibility and acceptability of the intervention design.
2446589|NCT03264924||Phase A, Study Three|Pilot of the intervention, using a group of exercise physiologists external to the community rehabilitation services.
2446591|NCT03264924||Phase B|Community rehabilitation service staff will participate in the intervention. Patients will then participate in the rehabilitaiton programme. Physical activity levels of patients will be recorded throughout the rehabilitation programme and for six months post-discharge. Qualitative and quantitative follow-up sessions will patients will take place at discharge (8 weeks after start of rehabilitation), and three and six months post-discharge.
2446689|NCT03263897|Experimental|Active|Receiving insufflation during an acute episode of migraine in both visits
2446690|NCT03263897|Sham Comparator|Sham|Receiving placebo insufflation during an acute episode of migraine in the first visit and receiving insufflation during an acute episode in the second visit
3153165|NCT00269295|Experimental|Cohort 3: Arm 1|12 subjects to receive vaccine dose 3: 5 X 10^9 cfu.
3153166|NCT00269295|Placebo Comparator|Cohort 3: Arm 2|6 subjects to receive placebo.
2446775|NCT03263260||implanted patients|Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent
2446826|NCT03263065|Experimental|Nopal added to test meal|test meal including nopal powder
2446832|NCT03263065|Experimental|Psyllium added to test meal|test meal including psyllium powder
2446840|NCT03263065|Experimental|Bran added to test meal|test meal including bran powder
2446871|NCT03262493|Experimental|Interventional Group|It consists of the use of the feeding tube attachment device (FTAD) to fix the enteral probe.
2446876|NCT03262493|No Intervention|Conventional Group|It consists of the fixation of the enteral probe with adhesive tape of the micropore type and plaster.
2446964|NCT03262259|Experimental|GSDG Intervention|Cities receiving a multi-component intervention, including screening and brief intervention, other evidence-based interventions (e.g., enforcement of drink-driving or underage drinking laws), and novel or partially tested interventions that warrant further evaluation.
2446965|NCT03262259|No Intervention|Comparison|Comparison cities receiving no evidence-based interventions.
2447014|NCT03261752||patient with cancer|blood sample will be collected from patient before and after treatment (surgery or chemotherapy)
2447018|NCT03261752||healthy people|blood sample will be collected for comparison
3153167|NCT00269295|Placebo Comparator|Cohort 2: Arm 2|6 subjects to receive placebo.
3153168|NCT00269308|Experimental|1|Chiropractic Manual Treatment + Home Exercise
3153169|NCT00269308|Experimental|2|Supervised Rehabilitative Exercise + Home Exercise
3153170|NCT00269308|Active Comparator|3|Home Exercise
3153171|NCT00269321|Experimental|1|
3153172|NCT00269321|Experimental|2|
3153173|NCT00269321|Active Comparator|3|
3153174|NCT00269360|Experimental|1|
3153175|NCT00269360|Experimental|2|
3153176|NCT00269360|Active Comparator|3|
3153177|NCT00269386|Active Comparator|1 (i)|Clarithromycin S/R 1g od From April 2004, clarithromycin S/R (Klaricid XL) ceased to be available and subsequent patients will receive either standard clarithromycin 500mg bd or placebo tables of identical size, colour and taste
3153178|NCT00269386|Placebo Comparator|2 (ii)|placebo tablets of identical size, colour and taste
3153179|NCT00269425|Experimental|Mediterranean diet,|
3153180|NCT00269425|Experimental|American Heart Association Step 2 diet|
3153181|NCT00269425|No Intervention|Case controlled|
3153182|NCT00269516|Experimental|1|
3153183|NCT00269516|Experimental|2|
2446206|NCT03267446|Experimental|Interventional group|Patients confirmed having one or more of the signs of morbidly adherent placenta will be examined by 3D Ultrasound and 3D power Doppler. Patients will then be prepared for the operation.Cesarean hysterectomy will be done with removal of the uterus and the placenta as one mass.Cases with focal invasion of the uterus will be given a trial for conservative management. The whole specimen will be sent for histopathological examination, and the determination of length and depth of invasion.
2446239|NCT03267290|Experimental|Sonazoid- CEUS+CEMRI or CECT+CEMRI|Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
2446285|NCT03267056||DCB arm|drug eluting balloon catheter
2446337|NCT03266627|Experimental|patients with adenoviral infection|patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
2446620|NCT03264534|Active Comparator|limbal relaxing incisions|Manually performed limbal relaxing incisions
2446622|NCT03264534|Active Comparator|astigmatic keratotomy|femtosecond laser-guided astigmatic keratotomy
2446723|NCT03263715|Experimental|Tocilizumab|Tocilizumab-based regimen (Tocilizumab Prefilled Syringe [Actemra] 162 mg s.c. administered weekly) on top of rapidly tapered Glucocorticoid [Glucocorticoids]
2446725|NCT03263715|Placebo Comparator|Placebo|Placebo [Placebos] and rapidly tapered Glucocorticoid [Glucocorticoids] treatment
2446753|NCT03263325||AKI Group|Patients developing AKI after surgery
2446755|NCT03263325||No AKI Group|Patients who do not develop AKI after surgery
2446837|NCT03263169||WE Health Tapestry|Completion of baseline measures then enrolled in a community-based personalized care intervention that consists of four core elements: volunteer support, interprofessional care, technology, social network linkage
2446844|NCT03263169||Usual Care|Completion of baseline measures with six-month delayed community-based personalized care intervention: volunteer support, interprofessional care, technology, social network linkage
2446877|NCT03262519||Patients at UCSD Sleep Medicine Clinic|Patients referred for sleep testing (either home sleep testing or in-lab full polysomnography) will be approached for participation.
2446934|NCT03262285||phacoemulsification|patients undergoing phacoemulsification surgery for senile cataract
2446945|NCT03262285||extracapsular cataract extraction|patients undergoing extracapsular cataract extraction surgery for senile cataract
2447109|NCT03261102|Active Comparator|Standard clinical care|"Adalimumab induction as per standard clinical care:~Week 0: 160 mg SC~Week 2: 80 mg SC~Followed by 40 mg SC every 2 weeks' maintenance therapy"
2447111|NCT03261102|Active Comparator|Active optimization|"Same as Standard clinical care Arm, except:~If ADAL trough ≤15 μg/ml, dose escalation with 80 mg SC at week 6 followed by 40 mg SC every week~If ADAL trough >15 μg/ml, no dose escalation and continued standard of care dosing"
2447171|NCT03260478|Experimental|Liberal Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 100 g/L.
2447172|NCT03260478|Experimental|Restrictive Transfusion Strategy|Patients will receive red blood cells transfusion if Hb ≤ 70 g/L.
2447268|NCT03259997|Active Comparator|Probiotic supplement|
2447271|NCT03259997|Placebo Comparator|Placebo|
2447367|NCT03259269||Bedaquiline and companion WHO Group 5 drugs|
2447373|NCT03259269||Delamanid and companion WHO Group 5 drugs|
3153184|NCT00269516|Experimental|3|
3153185|NCT00269516|Placebo Comparator|4|
2447486|NCT03258294|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
2447489|NCT03258294|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
3153186|NCT00269542|Experimental|1|
3153187|NCT00269542|Placebo Comparator|2|
3153188|NCT00269581|Other|1|Educational CD-Rom
3153189|NCT00269581|Experimental|2|Headstrong CD-rom
3153190|NCT00269620|Experimental|2|OrthoEvra
3153191|NCT00269620|Experimental|1|NuvaRing
2447828|NCT03255681|Experimental|Split face study|Split face study with the left side of the face receiving PRP injections and the right side of the face receiving PRP with 0.1cc of 10% calcium chloride per 1mL of PRP. The volume of PRP will be used upon the discretion of the provider for treatment of the cosmetic facial deformity but will be in equal amounts for each side on every patient participating in the study.
2447875|NCT03255447|Experimental|Immunoadsorption therapy|Peptide GAM immunoadsorption therapy
2448234|NCT03253432||Strata 0.20-0.34|Second highest probability of having familial hypercholesterolemia
3153192|NCT00269776|Experimental|001|OROS (methylphenidate HCl) Treatment A: 1 2 or 3 OROS methylphenidate 18-mg tablets + 0 1 or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3153193|NCT00269776|Experimental|002|Ritalin (methylphenidate) Treatment B: 5 10 or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3153194|NCT00269776|Experimental|003|Placebo Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A B and C.
3153195|NCT00269789|Experimental|001|OROS Methylphenidate HCl
3153196|NCT00269789|Active Comparator|002|Ritalin
3153197|NCT00269789|Placebo Comparator|003|Placebo
3153198|NCT00269802|Experimental|001|OROS methylphenidate HCl
3153199|NCT00269802|Active Comparator|002|Ritalin
3153200|NCT00269802|Placebo Comparator|003|Placebo
3153201|NCT00269815|Experimental|001|methylphenidate HCl
2446320|NCT03266679|Other|Patients receiving metacognition-based intervention|Case-Series Design - all participants receive the intervention - metacognition-based therapy (adapted version of Metacognitive Reflection and Insight Therapy developed by Lysaker & Klion) - weekly for a period of 12 months. No control/comparison group.
2446375|NCT03266432|Other|60 pregnant women|60 pregnant women diagnosed with placenta previa will take from them 3 blood samples : one pre intervention and two samples postintervention
2446450|NCT03265990|Experimental|Group A|Conventional haemrrhoidectomy,Ferguson technique
2446451|NCT03265990|Experimental|Group B|Ligasure haemorrhoidectomy
2446539|NCT03265314|Experimental|LeadHer|The LeadHer curriculum is presented to the target population over a total of 30 hours. The program addresses the following adult preparation subjects: Healthy relationships, Adolescent development, Healthy life skills, Educational and career success. The LeadHer curriculum is also accompanied by a mobile application.
2446545|NCT03265314|Placebo Comparator|Sassy Science|The Sassy Science curriculum is presented to the target population over a total of 30 hours. The program addresses the following subjects: States of Matter, Math, Engineering, Chemistry, Arts and Crafts, Sweet Treats and Celebrations. The curriculum does not have a mobile application.
2446601|NCT03264794|Experimental|trial group|Gefitinib tablets (CTTQ），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
2446602|NCT03264794|Active Comparator|control group|Gefitinib tablets (Yi Ruisha），First medication.From the 8th day of the experiment, treated with Gefitinib Tab（CTTQ）
2446654|NCT03264326|Experimental|BFR Group|Blood Flow Restriction Training with Eccentric Exercise Protocol
2446658|NCT03264326|Sham Comparator|Sham BFR Group|Sham Blood Flow Restriction Training with Eccentric Exercise Protocol
2446687|NCT03263858|Experimental|Cohort 1 and 2|
2446733|NCT03263663||Chemotherapy plus targeted treatment|Patients are treated in second-line with chemotherapy plus a targeted treatment according to the resistance mechanism to cetuximab pretreatment
2446735|NCT03263663||Chemotherapy according to physician choice standard|Patients are treated in second-line with chemotherapy according to physicians choice after cetuximab pretreatment
2446761|NCT03263338|Active Comparator|Group A|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target.
2446763|NCT03263338|Experimental|Group B|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group B.
2446767|NCT03263338|Experimental|Group C|Participants will select a time in bed target and will receive sleep tips by text messages to help reach the selected target. In addition, participants in this study arm will receive additional motivational text messages beyond those given to Group A, and unique to Group C.
3153202|NCT00269841|Experimental|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
3153203|NCT00269841|Experimental|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
2446893|NCT03262402|Experimental|HIV-infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
2446897|NCT03262402|Active Comparator|Non-HIV infected group|Patients will be treated for their chronic periodontitis (basic periodontal treatment) and samples of gingival crevicular fluid and saliva will be collected at baseline, 30 days and 60 days after the periodontal treatment for the study analysis.
2446936|NCT03262116|Experimental|Bionic Pancreas - Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
2446947|NCT03262116|Experimental|Bionic Pancreas - Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
2446958|NCT03262116|Experimental|Bionic Pancreas - BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
2447095|NCT03261661|Experimental|Reading Plus Mindset|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency. Participants also complete mindset training and activities.
2447099|NCT03261661|Experimental|Reading Embedded with Mindset|Multicomponent reading intervention (providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency) with mindset instruction specific to reading progress embedded in the intervention Participants also complete mindset training and activities.
2447101|NCT03261661|Active Comparator|Reading|Multicomponent reading intervention providing explicit and systematic instruction in phonological awareness, phonics and word recognition, and reading fluency.
2447103|NCT03261661|Active Comparator|Business as Usual|Participation in the typical reading instruction and intervention provided within participating schools.
2447120|NCT03260803|Experimental|postmenopausal osteopenic women receiveing Oligopin|postmenopausal osteopenic women receiving Oligopin ,150 mg ,once daily, 12 week
2447127|NCT03260803|Placebo Comparator|postmenopausal osteopenic women receiving placebo|postmenopausal osteopenic women receiving placebo, 150 mg,once daily,12 weeks
2447213|NCT03260309|Experimental|semi-closed system group|"Semi-closed loop infusion system tactic. Programmed iv fluid and blood infusion system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
2447214|NCT03260309|Experimental|control group|Routine infusion therapy tactic
2447382|NCT03258918|Experimental|Low-Carbohydrate Diabetes Prevention Program|At least 20 individuals with prediabetes will participate in a year-long , group-based program.
2447488|NCT03258463||Time Period 2|Women who obtained an abortion from May 1 2014-April 30 2015.
3153204|NCT00269841|Placebo Comparator|Placebo|Matching placebo will be administered at Week 0, 2 and 6.
3153205|NCT00269854|Experimental|Infliximab 5 mg/kg|
3153206|NCT00269854|Experimental|Infliximab 10 mg/kg|
3153207|NCT00269854|Experimental|Infliximab 20 mg/kg|
3153208|NCT00269854|Placebo Comparator|Placebo|
2446321|NCT03266666|Other|Intervention Arm - WellnessRX|This is a longitudinal outcome study. All participants will receive the class and grocery credit intervention.
2446387|NCT03266445|Active Comparator|FULL-BUPRENORPHINE|Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone
2446392|NCT03266445|No Intervention|LOW-BUPRENORPHINE (control)|Participants will be randomly assigned to have their daily dose of buprenorphine/naloxone reduced to 8mg on the day of surgery
2446412|NCT03265834|Experimental|Long course antibiotic therapy (28 days)|Antibiotic therapy for a duration of 28 days
2446415|NCT03265834|Active Comparator|Short course antibiotic therapy (≤10 days)|Antibiotic therapy for a duration of ≤10 days
2446456|NCT03265574|Experimental|Intervention|
2446463|NCT03265574|No Intervention|Standard care|
2446522|NCT03265236||Group1|Patients with early rheamatoid arthritis
2446527|NCT03265236||Group 2|patients with late rheamatoid arthritis
2446532|NCT03265236||Group 3|Healthy control
2446599|NCT03264885|No Intervention|Usual Care|The usual stand of care (UC) after community eye screening was to provide a GP referral letter and advice to attend a tertiary eye care facility most accessible to them
2446600|NCT03264885|Other|Incentive Care|In addition to the UC, those assigned to the ICS also received social and financial support to incentivise and improve compliance. All ICS participants were assisted with scheduling their tertiary care appointments, given telephone reminders, provided once-off transportation allowance and subsidy for their first tertiary eye-care consultation - while participants with mobility issues were assisted by volunteers.
3189840|NCT00781521|Experimental|1|Floxin otic solution twice a day for 7 days
2446712|NCT03263689|Experimental|Intervention|"ITM group were given~Local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia~100 micrograms of preservative-free morphine."
2446717|NCT03263689|Active Comparator|Control|TAP group were given only local anaesthesia (plain hyperbaric bupivacaine 10 mgs) during the spinal anaesthesia.
2446795|NCT03263403|Experimental|Test Group|"44 participants will be randomly assigned to the test group for receiving the locally produced meningococcal vaccine Ingovax ACWY (Incepta)."
2446796|NCT03263403|Active Comparator|Comparator Group|44 participants will be randomly assigned to the comparator group for receiving 'Quadri Meningo' (BiO-MeD Private Limited).
2446827|NCT03262909|Experimental|GelrinC prospective treatment arm|Patients will undergo GelrinC implantation.
2446835|NCT03262909|Other|Microfracture historical control arm|Microfracture historical control arm
2446905|NCT03262415||Study Cohort|30 adult subjects with type 1 or type 2 diabetes treated with insulin. The accuracy of the LabPatch Continuous Glucose Monitoring (CGM) will be evaluated during the study visit, comparing to YSI 2300 STAT Plus, OneTouch Verio and FreeStyle Lite.
2446942|NCT03262103|Experimental|Cohort 1|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2446954|NCT03262103|Experimental|Cohort 2|Intratumoral (IT) Poly ICLC 0.5 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2446956|NCT03262103|Experimental|Cohort 3|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2446960|NCT03262103|Experimental|Cohort 4|Intratumoral (IT) Poly ICLC 1.0 mg IT once/week (week 1+2) Intramuscular (IM) Poly ICLC 1 mg IM twice weekly (weeks 3-6) Followed by Radical Prostatectomy at Week 10
2446985|NCT03261635|Active Comparator|Ranibizumab Monotherapy|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
2446986|NCT03261635|Experimental|Ranibizumab + Indomethacin|All patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata. Moreover, patients also self- administered one drop of indomethacin three times a day for 12 months. All patients were followed up for 12 months.
3153209|NCT00269867|Placebo Comparator|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
2447078|NCT03261180|Experimental|Group I (Nestle Impact AR)|Patients receive Nestle Impact AR for 5 days before and after surgery in addition to regular diet.
2447083|NCT03261180|Active Comparator|Group II (regular diet)|Patients receive regular diet.
2447201|NCT03260582|No Intervention|Control arm (n=50)|Patients randomized to the control arm will receive usual cardiac rehabilitation care post-myocardial infarction.
2447203|NCT03260582|Experimental|Intervention arm: LifePod arm (n=100)|In addition to usual cardiac rehabilitation care, patients randomized to the LifePod arm will receive access to the LifePod® support software for six months.
2447223|NCT03260062|Experimental|PEARLS|Participants in this arm will receive 10 1-hour weekly sessions of the PEARLS intervention
2447224|NCT03260062|Active Comparator|Control|Participants in this arm will receive 10 1-hour weekly sessions of the standard of care LSL Speech Therapy
2447270|NCT03259854|Active Comparator|oxygen mask control group|patients will receive oxygen by mask will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
2447378|NCT03259048||pediatric group|pediatric group from age of one day to eighteen years.
3153210|NCT00269867|Experimental|Infliximab 3 mg/kg every 8 weeks|Infliximab 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
3189841|NCT00781534|Active Comparator|1. Ginseng|Ginseng group
2446327|NCT03266835|Other|SoundBite™ Crossing System - Peripheral|This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s).
2446385|NCT03266263|Experimental|automatic computer-led feedback|automated feedback for CPR quality provided by computers
2446389|NCT03266263|Active Comparator|instructor-led feedback|feedback for CPR quality provided by instructors
2446448|NCT03265847|Experimental|Culturally-tailored Safety Planning|Women in the intervention group receive the SDA intervention with the culturally-specific DA integrated as appropriate to the target group (i.e., immigrant, refugee or indigenous).
2446449|NCT03265847|No Intervention|Usual Care|The control group receive non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
2446465|NCT03265366|Experimental|ABPA|15 patients with ABPA
2446471|NCT03265366|Active Comparator|Severe asthma|12 patients with severe asthma
2446598|NCT03264898||FIT Group|Fecal immunochemical tests will be completed.
2446661|NCT03264339|Experimental|Smal step|Small Step Program, comprising 3 treatment focus areas (Hand use, Mobility, Communication)
2446691|NCT03263936|Other|Other|decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
2446774|NCT03263247|Experimental|Visual Imaging Training|"Participants will receive visual imaging training to facilitate learning of written information.~Intervention: Visual Imaging Training in individual sessions"
2446777|NCT03263247|Active Comparator|Psychoeducation|"Participants will receive information about memory functioning and aging.~Intervention: behavioral: Psychoeducation in individual sessions"
2446784|NCT03263247|Experimental|Alphabet Search|"Participants will receive alphabet search training.~Intervention: Alphabet Search in individual sessions"
2446842|NCT03263000||Healthy|24 healthy volunteers (HVs)
2446848|NCT03263000||Patients|24 patients with blepharospasm
2446852|NCT03263000||Patients 2|24 patients with increased blinking alone.
2446991|NCT03261583||Thoracic Surgery|Observational study. It is only a matter of collecting clinical data.
2447077|NCT03261466|Active Comparator|Active group Bifidobacterium breve BR03 and B632|This arm will receive a supplementation of probiotic containing Bifidobacterium breve B632 and Bifidobacterium breve BR03, 15 gtt/die (3x108 CFU/die) once a day.
2447089|NCT03261466|Placebo Comparator|Placebo group|This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2447138|NCT03260907|Experimental|Electroacupuncture|The patients in this group received electroacupuncture using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
2447141|NCT03260907|Experimental|Acupuncture|The patients in this group received acupuncture without electric stimulation using the same acupuncture points prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 1 years of clinical experience.
2447200|NCT03260517|Experimental|Treatment arm (Mdt Drug-Coated Balloon)|Medtronic Coronary Drug-Coated Balloon Catheter used for dilatation of the target lesion.
2447241|NCT03260023|Experimental|TG4001/Avelumab|
2447252|NCT03260023|Experimental|Avelumab|Applicable for Phase II part 2.
2447306|NCT03259399||wild genotype|Detection of genotype will be carried out through next generation sequencing, distinguish wild genotype of enalapril
2447313|NCT03259399||mutant genotype|Detection of genotype will be carried out through next generation sequencing, distinguish mutant genotype of enalapril
2447366|NCT03259191|Other|completely circumferential ARMS|
2447372|NCT03259191|Other|semi-circumferential ARMS|
2447416|NCT03258723|Experimental|Intervention|Highest risk pre-diabetic patients
2447423|NCT03258723|No Intervention|Control|Control participants in existing ECHORN sites (Puerto Rico, Barbados and Trinidad) will be recruited. ECS does not have a recruitment site in New York; therefore, the New York LIME sites will need to recruit their own control participants, through random assignment of consented participants into the intervention and control groups.
2447462|NCT03258346|Experimental|Exercise and Pomegranate Juice|Exercise training with daily consumption of pomegranate juice containing polyphenols
2447464|NCT03258346|Placebo Comparator|Exercise and Placebo|Exercise training with daily consumption of pomegranate juice with polyphenols removed
2447497|NCT03258073|Experimental|Medical simulation using scenarion execution|Study participants will be exposed to medical simulation using scenario execution. In this exercise, participants will be exposed to a scenario that simulates a medical emergency. They will be required to respond. Following their response, the participants will have a chance to share with the investigators their experiences and what they have learnt from the exposure in a debriefing session. The investigator will then provide feedback on their performance.
3189842|NCT00781534|Active Comparator|2. Ginsenosdie RE|Ginsenoside RE (a metabolite of ginseng) group
2447685|NCT03256604||Fresh left-over sputum|All fresh sputum samples that were sent to the Department of Microbiology between November 1 2015 and January 30 2016 under the standard requirements for sputum cultures at the accredited (ISO 17025 and 15189 beginning in 1993) laboratory were kept cold (4-8 ͦC) after analysis by microscope and cultures until it was collected and coded by the study nurse in the evening (left-over samples).
2447716|NCT03256500|Experimental|tDCS administered|Subjects will receive stimulation via tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
2447717|NCT03256500|Sham Comparator|Sham tDCS administered|Subjects will receive sham tDCS (Transcranial Direct Current Stimulation) for 20 minutes per day, 5 days per week, for 1 week.
2447767|NCT03256175|Experimental|Oxygen|Patient was give 15L/min of Oxygen via HFM 30 mins before and continue through out the procedure. 6 weeks post procedure, EST was arranged
2447774|NCT03256175|Placebo Comparator|Air|Patient was given Facemask without oxygen through out the procedure. 6 weeks post procedure, EST was arranged
3189843|NCT00781534|Placebo Comparator|3. Placebo|"placebo (sugar pill) group"
3208512|NCT00975468|Placebo Comparator|Volume Controlled Ventilation|The patients' lungs will ventilated with a tidal volume of 8 ml.kg-1. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
2446330|NCT03266536|Experimental|Western diet|Participants will undergo a first day of testing for blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies. Participants will then consume a Western diet for 7 days before a second day of identical testing (blood, urine, stool, and upper endoscopy with small bowel aspirates and biopsies).
2446354|NCT03266315|Experimental|Probiotics|subjects will be randomly assigned to receive FloraBaby
2446355|NCT03266315|Placebo Comparator|Placebo|subjects will be randomly assigned to receive placebo
2446505|NCT03265613|Experimental|AD-MSCs group|AD-MSCs（adipose-derived multipotent mesenchymal stem cells ） intravenous injection at a dose of 0.5 million cells/kg at week 0,week 4，week 8 with a duration for treatment for 12 weeks.
2446517|NCT03265028||Intervention|Invited to take the TRACE e-learning.
2446518|NCT03265028||Control|Not (yet) invited to take the TRACE e-learning.
2446655|NCT03264443|Active Comparator|Health education|Patients will receive weekly lectures on hypertension related topics during 12 weeks.
2446660|NCT03264443|Experimental|Combined training|Patients will complete 12 weeks of combined training (aerobic + strength exercise, 3x/week) in a pragmatic setup. In order to make the interventions more similar, contents of the health education arm will also be discussed with patients receiving this intervention.
2446709|NCT03263871|Experimental|Intervention|PTM202 and micro-nutrient sprinkles
2446714|NCT03263871|Other|Control|micro-nutrient sprinkles
2446749|NCT03263377|Active Comparator|2|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.
2446751|NCT03263377|Other|Non Intervention|A control group will be included in study design consisting of 7 schools selected randomly from 7 comparable yet adjacent Upazilas not slated for inclusion in the feeding programme. Use of a control group will enable later evaluations to attribute possible improvements in key impact/outcome variables to the intervention itself. An equal number of boys and girls will be selected from each class to enable gender analysis. Children whose cognitive abilities are are challenged by autism, mental issues or iodine deficiency will be excluded from the study.No intervention had given in this group.
2446797|NCT03263195||HIV-infected women|Pregnant women infected with HIV only and their infants.
2446799|NCT03263195||ZIKV-infected women|Pregnant women infected with ZIKV only and their infants.
2446800|NCT03263195||HIV- and ZIKV-infected women|Pregnant women infected with HIV and ZIKV and their infants.
2446803|NCT03263195||Not HIV- or ZIKV- infected women|Pregnant women not infected with either HIV or ZIKV and their infants.
2446815|NCT03262883||Chronic Critical Illness|"The patients who is over 18 years old and staying in the critical care unit at least 8 days. Additional criterias:~Prolonged mechanical ventilation (longer than 96 hours)~Tracheostomy~Sepsis~Serious injury (burn)~Stroke (hemorhagic or ischemic)~Traumatic brain injury"
3153211|NCT00269867|Experimental|Infliximab 3 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
3189844|NCT00781547|Experimental|Recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
3189845|NCT00781547|Placebo Comparator|Placebo|
2446996|NCT03261570|Active Comparator|Pyridostigmine and Placebo|Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
2447003|NCT03261570|Active Comparator|Digoxin and Placebo|Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
2447072|NCT03261375|Experimental|Renal denervation (RDN) Group|
2447074|NCT03261375|Sham Comparator|Control Group|
2447115|NCT03260777||children with Alopecia Areata|
2447118|NCT03260777||children with tinea capitis|
2447125|NCT03260777||children with trichotillomania|
2447136|NCT03260777||children with tractional alopecia|
3189846|NCT00781560||1|patients being diagnosed as dyslipidemia but not receiving Crestor®
3189847|NCT00781560||2|hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
2447253|NCT03259776||Visitors|Qualitative interviews and questionnaire survey
3189848|NCT00781573|Experimental|1|Clopidogrel (75 mg/day) is continued for another year at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
3189849|NCT00781573|No Intervention|2|Clopidogrel (75 mg/day) is stopped at the completion of the initial year of clopidogrel and aspirin administration post DES implantation
3189850|NCT00781586|Experimental|Arm 1|
2447584|NCT03257514|Active Comparator|alpha lipoic acid|51 women will receive alpha lipoic acid drug (thiotacid film coated tablets 600 mg) for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography (by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
2447585|NCT03257514|Placebo Comparator|placebo|51 women will receive a placebo drug for 6 weeks after cesarean section then uterine scar healing will be assessed by saline sonohysterography(by placing catheter in the cervical os helping to administering saline into uterine cavity then using the transvaginal ultrasound to view the uterus in the longitudinal view)
2447608|NCT03257306|Active Comparator|Magnetic double-J ureteric stent|Double-J ureteric stent removed using magnet
2447610|NCT03257306|Active Comparator|Standard double-J ureteric stent|Double-J stent removed using cystoscopy
2447676|NCT03257046|Experimental|10 mg ITI-214|Administered once daily for 7 days
2447677|NCT03257046|Experimental|30 mg ITI-214|Administered once daily for 7 days
3189851|NCT00781586|Active Comparator|Arm 2|
3189852|NCT00781586|Placebo Comparator|Arm 3|
3189853|NCT00781625|Active Comparator|Probiotic vaginal capsules|Probiotic vaginal capsule, placebo oral capsule
2446397|NCT03266068||Post Infectious IBS Case|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have developed some symptoms that might be suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2446399|NCT03266068||Post Infectious with no IBS Control|Subjects who have suffered from acute bacterial gastroenteritis within last two years and have not developed symptoms suggestive of post-infectious irritable bowel syndrome (IBS). Subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2446400|NCT03266068||Healthy Control|Healthy volunteers; subjects will receive a DNA analysis of blood sample, flexible sigmoidoscopy with colonic biopsies, small bowel and colonic gastrointestinal permeability, and stool sample analysis.
2446559|NCT03265327|Experimental|Treatment|Subjects will receive an oral supplement containing fish oil, evening primrose oil and borage oil.
2446560|NCT03265327|Placebo Comparator|Placebo|Subjects will receive an oral supplement containing coconut oil and light olive oil.
2446614|NCT03264755|Active Comparator|cortical excitability in smokers|
2446618|NCT03264755|Active Comparator|cortical excitability in nonsmokers|
2446643|NCT03264287|Experimental|3 times per week therapeutic frequency|"1.Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Huatuo Brand needle (0.20*13mm) will be used for GV14, BL13, ST2, BL2, ST7, ST6 and ashi point on the face. Huatuo Brand needle (0.3*40mm) will be used for GV20, LU5, LI11 and LI4.~2.Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Guoyiyan Brand cupping jar (size 4) will be used. 3.Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Huatuo Brand, made by the seed of Vaccaria segetalis ( Neck.)Garcke."
2446646|NCT03264287|Active Comparator|1 time per week therapeutic frequency|"The acupoints and treating procedures will be the same as the 3 times per week group. Only treating frequency is different. The treating frequency is 1 time per week.~Acupuncture: GV20, LU5, LI11, LI4,GV14,BL13, ST2, BL2,ST7,ST6 and ashi point on the face.~Moving capping: Du Meridian (from GV14 to GV3) as well as the first (from BL11 to BL28) and second (from BL41 to BL53) side lines of the Urinary Bladder Meridian of Foot-Taiyang.~Ear point tapping: Lung (CO14), Heart (CO15), Stomach (CO4), Neifenmi (CO18), Pizhixia (AT4).~Use the seed of Vaccaria segetalis ( Neck.)Garcke."
3153212|NCT00269867|Experimental|Infliximab 10 mg/kg every 8 weeks|Infliximab 10 mg/kg will be administered as infusion at Week 0, 2, 6 and every 8 weeks up to Week 52.
2446858|NCT03262792|Placebo Comparator|Placebo|Microcrystalline cellulose
2446859|NCT03262792|Active Comparator|Andrographis Paniculata 150|Andrographis Paniculata 150 mg
2446860|NCT03262792|Active Comparator|Andrographis Paniculata 300|Andrographis Paniculata 300 mg
2446878|NCT03262428||Patients|Patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2446884|NCT03262428||Caregivers|Caregivers of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2446889|NCT03262428||Health care professionals|Health care professionals involved in the care of patients with asthma, breast cancer, and stroke living in the Rhône Alpes region
2446928|NCT03262207||testicular tumours|
2446932|NCT03262207||fertile|
2446940|NCT03262207||infertile|
2447030|NCT03261674|Experimental|CBTI|Patients in this arm will receive Cognitive Behavioral Therapy for Insomnia (CBT-I)
2447034|NCT03261674|Experimental|ABTI|Arousal-Based Therapy for Insomnia (ABT-I)
2447080|NCT03261219|Experimental|Intrapulmonary Percussive ventilation|
2447085|NCT03261219|Active Comparator|Chest Physiotherapy vest|
2447112|NCT03260959||Father|Male having been the father of at least one pregnancy whatever the outcome (pregnancy pursued, or abortion)
3189854|NCT00781625|Placebo Comparator|placebo|placebo oral capsule, placebo vaginal capsule
3189855|NCT00781625|Active Comparator|Probiotic oral capsules|Probiotic oral capsules, placebo vaginal capsules
2447235|NCT03259893|Active Comparator|Standard of care group 1|Participants randomized to the standard of care group will receive guideline-directed medical therapy according to clinical standard practice at Boston Medical Center. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
2447238|NCT03259893|Experimental|Intervention group 2|The intervention group will receive the AF program which include a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Each participant will receive an AliveCor mobile ECG cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
2447335|NCT03259620|Experimental|CLS006|Furosemide Topical Gel, 0.125%
2447336|NCT03259620|Experimental|CLS006 Vehicle|Vehicle Topical Gel
2447371|NCT03258931|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
2447376|NCT03258931|Active Comparator|Midostaurin|Midostaurin following salvage chemotherapy
2447479|NCT03258307|Active Comparator|omentectomy|Preoperative
2447481|NCT03258307|Other|Omentectomy|Postoperative
2447483|NCT03258307|Other|No omentectomy|Preoperative post operative
2447521|NCT03258021||GBM with indication for TTFields|newly diagnosed GBM with clinical indication for TTFields
2447569|NCT03257605||Study group|Participants enrolled in PACE who underwent pharmacogenomics testing as part of their medical care and also consented to the use of their de-identified data for research purposes.
2447678|NCT03257046|Experimental|90 mg ITI-214|Administered once daily for 7 days
3189856|NCT00781664|Experimental|A|AN2718 Cream SF Vehicle
3189857|NCT00781664|Experimental|B|AN2718 Cream SF, 0.3%
3189858|NCT00781664|Experimental|C|AN2718 Cream SF, 1%
3189859|NCT00781664|Experimental|D|AN2718 Gel Vehicle
3189860|NCT00781664|Experimental|E|AN2718 Gel, 1.5%
3189861|NCT00781664|Experimental|F|AN2718 Gel, 2.5%
3189862|NCT00781664|Experimental|G|AN2718 Gel, 5%
3189863|NCT00781664|Experimental|H|AN2718 Gel, 7.5%
2446439|NCT03266003|Other|Group 2: eDOT followed by ipDOT|Following 20 observable medication doses under an initial DOT study group assignment of electronic DOT (eDOT), patients will be assigned (crossed-over) to in-person DOT (ipDOT) to collect data on another 20 observable medication doses.
2446492|NCT03265405|Active Comparator|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
2446497|NCT03265405|Active Comparator|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
2446500|NCT03265405|No Intervention|Observation|The subjects with sarcoidosis who do not have any indication for immunosuppressive treatment will be observed and monitored. If any treatment requiring indication arises during the observed period, the subjects will be randomized to one of the above study groups
2446541|NCT03265054||re-thrombosis|adult patients with a VTE history with at least 3 months of anticoagulant treatment, which suffered from a re-thrombosis within 5 years after stopping the anticoagulant treatment
2446550|NCT03265054||no thrombosis recurrence|adult patients with a VTE history with at least 3 months of anticoagulant treatment, without thrombosis recurrence
2446607|NCT03264781|Experimental|Cyclofem group|Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose
2446608|NCT03264781|Placebo Comparator|Placebo group|normal saline 0.5 ml IM single dose
2446635|NCT03264300|Active Comparator|Development of advanced MRI methods|Subjects with brain tumor. Subjects may be scanned using a single time-point to permit development and optimization of advanced MRI methods. Subjects may be scanned up to two times, with both visits occurring within one month, to permit analysis of test-retest reliability/repeatability.
2446636|NCT03264300|Active Comparator|Validation of rCBV accuracy|64 subjects with primary glioma and 96 subjects with recurrent glioma. Subjects will be scanned using a single time-point to validate rCBV accuracy.
2446737|NCT03263624|Experimental|Group (A)|fractional carbon dioxide laser plus tazarotene 0.1% cream
2446738|NCT03263624|Active Comparator|Group (B)|Tazarotene Cream 0.1%
2446780|NCT03263312|Experimental|Fontan Patients|All Fontan patients included in this study will be part of an exercise intervention 2-6 times/week for 3-6 months.
2446833|NCT03263104|Experimental|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402 equivalent to 2x10^9 CFU (0.1 g) with the addition of filling carrier (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2446839|NCT03263104|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) (0.12 g; 30% w/v maltodextrin and 5% w/v sucrose) as a capsular format (vegetable) to be consumed twice daily, before breakfast and dinner with 250mL of water.
2446867|NCT03262623|Experimental|Radial nerve block|Patients will receive radial nerve block guided by a nerve stimulator.
2446869|NCT03262623|Placebo Comparator|Placebo|Patients will receive placebo through radial nerve block
2446970|NCT03262350|Experimental|Yoga Group|Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
2446972|NCT03262350|No Intervention|Control Group|Participants will be required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, health habits, body image, sleep habits and loneliness and have their height and weight measured. The overall time commitment for Control Group participants is 3 hours of assessments total.
2447008|NCT03261726|Experimental|MedEl Test Electrode Placer|MedEl Test Electrode Placed at VIIIth nerve tumor resection
2447062|NCT03261453|Experimental|Treatment|Patients randomized to treatment will receive the Elipse device.
2447066|NCT03261453|Sham Comparator|Control|Patients randomized to the control arm will receive the sham device.
2447113|NCT03260855|Other|Lymphoma survivorship|This present study is based on an interventional (with an analysis of human blood sample) and on the use of different Questionnaires/Scales.
2447192|NCT03260621|Other|echocardiographic increase in left atrial pressure|
2447194|NCT03260621|Other|echocardiographic no increase in left atrial pressure|
2447275|NCT03259828|Experimental|Adjuvant image-guided radiotherapy|Adjuvant radiotherapy with image guidance via cone beam computed tomography. Treatment is identical to the current standard of care.
3153213|NCT00269867|Experimental|Infliximab 10 mg/kg every 4 weeks|Infliximab 3 mg/kg will be administered as infusion at Week 0, 2, 6 and every 4 weeks up to Week 52.
2447380|NCT03258957|Experimental|Fresh milk group|In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
3153214|NCT00269880|Placebo Comparator|Placebo and Standard Dose of Heparin|Participants will receive bolus placebo followed by 12-hour infusion of placebo and bolus heparin at a dose of 100 units per kilogram of body weight.
2447475|NCT03258450|Experimental|Psycho-behavioural intervention arm (PBI)|Participants will receive 4 sessions(PBI) that lasts approximately 60 mins.
2447478|NCT03258450|No Intervention|Waitlist Control Arm (WLC)|The WLC group receives standard usual care before being offered the same PBI protocol and assessment thereafter.
3153215|NCT00269880|Active Comparator|Abciximab and Low Dose of Heparin|Participants will receive bolus abciximab at a dose of 0.25 milligram per kilogram (mg/kg) of body weight followed by 12-hour infusion of 0.125 microgram per kilogram per minute (mcg/kg/min) and bolus heparin at a dose of 70 units per kilogram of body weight.
3153216|NCT00269880|Active Comparator|Abciximab and Standard Dose Heparin|Participants will receive bolus abciximab at a dose of 0.25 mg/kg of body weight followed by 12-hour infusion of 0.125 mcg/kg/min and bolus heparin at a dose of 100 units per kilogram of body weight.
3153217|NCT00269893|Placebo Comparator|Placebo|Participants will receive matching placebo solution bolus followed by matching placebo solution infusion up to 12 hours.
2446474|NCT03265522|Experimental|"Group 1: ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline (n=20)"
2446476|NCT03265522|Experimental|"Group 2: ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian (n=20)"
2446479|NCT03265522|Placebo Comparator|Group 3: Standard Care (control) group|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention) (n=20)"
3189864|NCT00781664|Active Comparator|I|Sodium Lauryl Sulfate, 0.5%
3189865|NCT00781677||MDD|
3189866|NCT00781690|Experimental|1|Treatment with Evodial with reduction of heparin across study period
2446847|NCT03262805|Placebo Comparator|Placebo|Placebo
2446855|NCT03262805|Active Comparator|Active|Lanconone(R)
2446862|NCT03262467|Active Comparator|Aneurysmorrhaphy with external porous prosthesis (Provena©)|
2446864|NCT03262467|Placebo Comparator|Aneurysmorrhaphy without external porous prosthesis|
2446938|NCT03262376|Experimental|Mineral + vits + botanical A|Mineral and vitamin complex combined with Botanical A
2446950|NCT03262376|Experimental|Mineral + vits + botanical B|Mineral and vitamin complex combined with Botanical B
2446959|NCT03262376|Experimental|Mineral+vits +botanical A+Botanical B|Mineral and vitamin complex combined with Botanical A and Botanical B
2446962|NCT03262376|Placebo Comparator|Placebo|Cellulose crystalline placebo
2446998|NCT03261648||hospitalized patient|100 patients will completed the 'State-Trait-Anxiety Inventory (Forme Y) questionnaire Patients will evaluated here pain answering to a pain level scale
2447005|NCT03261648||partner of the hospitalized patient|100 partners will completed the State-Trait-Anxiety Inventory (Forme Y) questionnaire
2447059|NCT03261427|Experimental|YNP-1807 Tablet(Pregabalin 330mg)|YNP-1807(Pregabalin 330mg), QD
2447064|NCT03261427|Active Comparator|Lyrica Capsule(Pregabalin 150mg)|Lyrica Capsule(Pregabalin 150mg), BID
2447142|NCT03261024|Active Comparator|Friction mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. Hook between upper laterals and canines will be fixed on the main archwire.~Nickel Titanium coil spring ( friction mechanics of retraction)will be used for maxillary en-masse retraction by extending the spring from the hook to the molar bands.~Re-activation of the coil spring will be done in the follow up visits to maintain a constant force through the study."
2447145|NCT03261024|Active Comparator|Frictionless mechanics|"Upper and lower arches will be bonded, leveled and aligned until reaching 0.019 x 0.025 st st archwires.~Miniscrews will be inserted in the buccal alveolar bone between second premolars and first molars bilaterally.~Miniscrews will be connected to the molar bands by rigid wire. Extraction of upper first premolars. Upper anterior teeth will be ligated together. T-loops retraction arch ( frictionless mechanics of retraction)will be used for maxillary en-masse retraction. The wire will be cinched distal to the molar bands.~Re-activation of the retraction loops will be done in the follow up visits to maintain a constant force through the study"
2447242|NCT03259984||Aim 1|This experiment will use the next generation sequencing reduced representation bisulfite sequencing to define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. The investigators will test the hypotheses that: (a) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (b) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (c) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance.
2447249|NCT03259984||Aim 2|This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and (b) Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise.
2447258|NCT03259984||Aim 3|This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that: (a) There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes, (b) There is altered methylation of genes involved in inflammation and cytoskeletal structure.
2447321|NCT03259672|Active Comparator|Sevoflurane|
2447328|NCT03259672|Experimental|Desflurane|
2447361|NCT03259204|No Intervention|Leg Immobilization|Routine care include that the lower limb will be immobilized in an orthosis or a below-knee plaster cast according to local routines.
2447364|NCT03259204|Experimental|Adjuvant IPC|Leg Immobilization with the addition of IPC. Patients will during lower limb immobilization receive bilateral calf IPC.
3189867|NCT00781703|Other|DIAMOND Care Model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the Patient Health Questionnaire-9 (PHQ9), treatment adjustment as indicated, psychiatric consultation, relapse prevention.
2447611|NCT03257332||EDFI Cohort|Subjects should have received surgery for rectal cancer (low anterior resection).
3189868|NCT00781716|Active Comparator|Cypher Stent|Cypher Sirolimus-Eluting Coronary Stent System
3189869|NCT00781716|Active Comparator|Endeavor Stent|Endeavor Zotarolimus-Eluting Coronary Stent System
3189870|NCT00781729|Experimental|1|Yoga, one hour class, 3 times per week, for 24 weeks
2446475|NCT03265561|Experimental|Bone allograft group|This participants will receive bone structural allograft management for vertebral reconstruction. All patients undergo surgical procedure to realize debridement of the lesion, and the application of allograft without autograft.
2446478|NCT03265561|Active Comparator|Bone auto and allograft group|This participants will receive bone structural allograft plus spongy autograft management for vertebral reconstruction. All patients undergo surgical procedure.
2446549|NCT03265184|Experimental|intervention group|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
2446557|NCT03265184|Placebo Comparator|placebo group|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
2446633|NCT03264378|Experimental|PEI-GTO-ThAI|Physical exercise intervention (PEI) supported by the GTO-ThAI Implementation Model
2446634|NCT03264378|Active Comparator|PEI-Standard|Physical exercise intervention (PEI) supported by the standard governmental administrative procedures
2446663|NCT03264118|Active Comparator|Control|Decontamination of furcation defect with scaling and root planing only.
2446664|NCT03264118|Experimental|Antimicrobial Photodynamic Therapy|Decontamination of furcation defect with scaling and root planing complemented by antimicrobial photodynamic therapy.
2446697|NCT03263832||Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
2446702|NCT03263832||Not Exposed|"Patients with a monomicrobial S. aureus orhtopaedic device-related infection who not have received antibiotherapy able to prevent biofilm formation following surgical intervention (from day 0 to day 7).~Upon inclusion, antibiograms were performed on the S. aureus isolated as part of routine procedure. S. aureus isolates was further analysed via an Antibiofilmogramme, which is an experimental element added by this research."
2446760|NCT03263481|Experimental|ERCP with intraductal secretin test|Subjects undergoing ERCP for biliary indication in which inadvertent pancreatic cannulation occurs will receive intraductal secretin testing using a one-time intravenous injection of 16 mcg of human secretin for injection administered over one minute.
2446850|NCT03263143|No Intervention|Standard of Care|
2446853|NCT03263143|Other|Early Palliative Care Consultation|
2446896|NCT03262571|Experimental|Group A|Group A includes patients undergoing lung ultrasound and physical examination.
2446901|NCT03262571|Placebo Comparator|Group B|Group B includes patients undergoing physical examination only.
2446912|NCT03262142|Active Comparator|Standard antibiotic treatment|Intravenous Piperacillin/tazobactam + oral Ciprofloxacin for 14 days
2446913|NCT03262142|No Intervention|Antibiotic-free treatment|
2447182|NCT03260400|Experimental|New Grafts|In this arm, participants will have an initial surgery to place partial muscle grafts on the amputated nerves. After a healing period, the participant will have a shorter surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After another healing period, experiments with prosthetic control and sensory feedback will begin.
2447191|NCT03260400|Experimental|Existing Grafts|In this arm, participants have already had partial muscle grafts placed on the amputated nerves to control neuroma growth. The participant will have a short surgical procedure to implant the electrodes onto the muscle grafts and in residual muscles. After a healing period, experiments with prosthetic control and sensory feedback will begin.
2447315|NCT03259542|Experimental|Arm 1|Mifepristone 300 MG alone or Mifepristone 300 MG with Itraconazole 100 MG will be administered.
2447362|NCT03259217|Experimental|stem cell product|stem cell transplant
3189871|NCT00781729|Placebo Comparator|2|Luncheon Seminar Series, once per month, for 24 weeks
3189872|NCT00781742|Experimental|1|100 mg iv once per dosing day
2447587|NCT03257579|Experimental|90 Day Supply|Intervention: At Hamilton Health Sciences a policy change implementing a standardized discharge prescription form of a 90-day supply with 3 repeats for all cardiac medications available on all wards where MI patients are managed.
2447588|NCT03257579|Experimental|Education Alone|At St. Joseph's Hospital and Niagara Health System education regarding the benefits of lengthening prescriptions to a 90 day supply with 3 repeats for all cardiac medications will be implemented.
2447589|NCT03257579|No Intervention|Control|Remaining Ontario cardiac sites will receive usual care and act as concurrent control group.
2447617|NCT03257280|Experimental|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
2447626|NCT03257280|No Intervention|control group|In our center, the classical postoperative management consisted in one week period of non oral intake and total parenteral nutrition. At the 7 day, an oral contrast image is performed to prove the correct function of the anastomosis, in witch case, a three days progressive oral diet is begin.
2447927|NCT03255161|Experimental|Immediate communication education and support group|
3189873|NCT00781742|Experimental|2|150 mg iv once per dosing day
3189874|NCT00781742|Placebo Comparator|3|
3189875|NCT00781755|Experimental|1|VAR-MI: This group will receive 1mg/day varenicline (titrated from .5mg/day) and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
3189876|NCT00781755|Placebo Comparator|2|PLA-MI: VAR-MI: This group will receive a daily placebo pill and two sessions of a motivational interviewing platform CBT treatment over the course of two weeks.
3189877|NCT00781781|Experimental|1|"High risk patients (at least one GVHD high risk criterion):~Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive)."
3208513|NCT00975494|Active Comparator|sildenafil|sildenafil 50 mg three times/day
2446508|NCT03265652|Experimental|Intense Pulsed Light (IPL) therapy|Subjects with receive 10-15 intense pulsed light (IPL) pulses on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid. Following the administration of IPL pulses, subjects will undergo meibomian gland expression.
2446510|NCT03265652|Placebo Comparator|Sham therapy|Participants will undergo a sham treatment that will mimic the intense pulsed light (IPL) therapy. The tip of the IPL lightguide will be placed in 10-15 locations on the skin of the malar region (both cheeks, from tragus to tragus including the nose) and up to 3 mm from the lid margin of the lower eyelid, but IPL pulses will not be actually delivered. Following this sham procedure, subjects will undergo meibomian gland expression.
2446526|NCT03265015|Experimental|cTBS|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern.
2446535|NCT03265015|Active Comparator|iTBS|Transcranial Magnetic Stimulation delivered in an intermittent Theta Burst Stimulation (iTBS) pattern.
2446615|NCT03264807|Active Comparator|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadnectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) could be performed in this arm
2446617|NCT03264807|Experimental|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and lymph node #14v lymphadnectomy could be performed in this arm
2446674|NCT03264131|Experimental|Open-label, Multicenter, Single-Arm|This is a single-arm intervention where patients will receive concurrent therapy with BV+CHEP [(brentuximab vedotin; 1.8 mg/kg IV, on D1 every 21 days) (cyclophosphamide 750 mg/m^2 on D1; doxorubicin 50 mg/m^2 on D1, etoposide 100 mg/m^2 IV infusion on D1-3; prednisone 100 mg orally once daily on D1-5; cycle length every 21 days)] for 2 to 6 cycles of induction therapy. After 6 cycles of BV + CHEP, responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV, every 21 days) until disease progression, withdrawal due to toxicity or death.
2446700|NCT03263741|Experimental|Paclitaxel + S-1 + Oxaliplatin group|Paclitaxel: 135 mg/m2, iv, 3h, at D1 ; S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week; Oxaliplatin: 85 mg/m2, iv, 2h, at D1.
2446783|NCT03263468|Experimental|Same sitting complete revascularization|After treatment of the IRA, subjects will undergo PCI of all suitable significant non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm).
2446788|NCT03263468|Active Comparator|Staged non-IRA PCI|Only the IRA will be intervened upon during the index primary PCI procedure. Staging of the non-IRA lesions will be performed 48 hours to 45 days after the primary PCI procedure. All suitable non-IRA lesions (≥70% by visual assessment or FFR<0.80 in 50-70% lesions with vessel diameter >2mm) will be treated with PCI irrespective of whether there are clinical symptoms or evidence of ischemia.
2446831|NCT03263078|Experimental|TIVA with Propofol in major surgery|Total intravenous anesthesia(TIVA) with Propofol
2446838|NCT03263078|Active Comparator|Sevoflurane in major surgery|Inhalation anesthesia with Sevoflurane
2446863|NCT03262545|Experimental|experimental group|apatinib 500 mg p.o. once daily
2446865|NCT03262545|Placebo Comparator|control group|placebo p.o. once daily
2446930|NCT03262337||Elderly Travelers|approximately 135 travelers with an age >= 60 years will be enrolled
2446941|NCT03262337||Chronic diseased travelers|approximately 225 travelers with a chronic disease will be enrolled
2446951|NCT03262337||Healthy travelers|approximately 640 healthy travelers with be enrolled
2447023|NCT03261817|Experimental|APA in patients|patients receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
2447027|NCT03261817|Sham Comparator|HE in patients|patients receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
2447032|NCT03261817|Active Comparator|APA in healthy volunteer controls|Healthy volunteers receiving physical activity (APA) by web during 16 weeks with 2 sessions a week
2447036|NCT03261817|Sham Comparator|HE in healthy volunteer controls|Healthy volunteers receiving Health education program (HE) by web during 16 weeks with 2 sessions a week
2447052|NCT03261193|Sham Comparator|ITM + Sham QLB|Standard spinal with intrathecal morphine for surgical anesthetic with sham saline block. Saline will be administered as a quadratus lumborum block prior to cesarean section.
2447056|NCT03261193|Experimental|ITM + Bupivacaine QLB|Standard spinal with intrathecal morphine for surgical anesthetic with ql block with bupivacaine local anesthetic. Interventional drug will be administered prior to cesarean section.
2447119|NCT03260972|Active Comparator|Chloroprocaine arm|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
2447126|NCT03260972|Placebo Comparator|Normal saline arm|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
2447164|NCT03260634||Voriconazole|"Patient was received voriconazole according to individual indication. The starting dose is 6 mg/kg iv twice daily for two dosages, followed by 4 mg/kg iv twice daily in intravenous form or a loading dose of 400 mg twice daily for two doses is used (for individuals >40 kg), followed by 200 mg twice daily, and in individuals <40 kg the maintenance dose is 100 mg twice daily in oral form.~The dosage was adjusted by drug level and toxicity. The duration of drug used was depended on indication of treatment."
2447183|NCT03260335|Experimental|Biofeedback intervention|Biofeedback prompt in text or graphic form to implement proactive anxiety management strategy, as per standard care plan
2447245|NCT03260231|Active Comparator|Intervention group|Dietary Supplement: Milled Seed Mix Intervention arm includes milled mix of flax, sesame and pumpkin seeds (18/6/6 g) in sour milk taken as dietary replacement meal during the day, and between lunch and dinner. Seeds are provided with the same producer at the Belgrade market.
2447246|NCT03260231|No Intervention|Control group|No supplement Control arm includes nutritional counseling with a similar dietary regime as for the intervention arm, but without milled seed mix. patients were instructed to avoid plant seeds during the study.
2447305|NCT03259659||irritable bowel disease patient|Patients with ulcerative proctitis and proctosigmoiditis who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
2447317|NCT03259659||healthy control|Healthy participates who meet the inclusion criteria, they will have ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index.
3153218|NCT00269893|Experimental|Abciximab and Placebo|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight of abciximab (c7E3 Fab) bolus injection followed by followed by placebo solution infusion up to 12 hours.
2446619|NCT03264586|Active Comparator|Lidocaine-prilocaine cream|"Women who were assigned randomly to receive EMLA cream had a 5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate pemetration thrug stratum corneum~EMLA cream was applied, 1 hour before the expected time of birth.~With the assistance at birth, the residue of cream was removed to prevent contact with the fetus, because sodium hydroxide, which is a component of the cream, can cause fetal eye irritation.~No additional anesthetic was applied if episiotomy was necessary.~Before commancement of perineal repair any residual cream was wiped off."
2446621|NCT03264586|Active Comparator|mepivacaine infiltration group|"In the mepivacaine group, 10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
2446666|NCT03264196|Active Comparator|Operative|Open Reduction and Internal Fixation of Condylar Head Fracture
2446667|NCT03264196|No Intervention|Conservative|Non-operatively managed Condylar Head Fracture
2446693|NCT03263884|Experimental|Real treatment group|"Transcranial magnetic stimulation (TMS) is used to stimulate small regions of the brain. During a TMS procedure, a magnetic field generator, or coil, is placed near the head of the person receiving the treatment. The coil produces small electric currents in the region of the brain just under the coil via electromagnetic induction.~The protocol used in this research includes 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses."
2446694|NCT03263884|Sham Comparator|Sham treatment group|Sham coil is used to mimic the clicking sound of the TMS coil and skin stimulation
2446791|NCT03263546|Experimental|Stepped care|Internet-delivered cognitive behavioral therapy (ICBT)
2446792|NCT03263546|Active Comparator|Gold standard treatment|Cognitive behavioral therapy (CBT)
2446819|NCT03262948|Experimental|nab-paclitaxel plus carboplatin|nab-paclitaxel 260mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
2446820|NCT03262948|Active Comparator|Paclitaxel plus carboplatin|paclitaxel 175 mg/m2,i.v., plus carboplatin AUC = 6,i.v., starting from randomization, once every 3 weeks, for 4-6 cycles, or progression, or intolerance,or death or start a new anti-tumor treatment, whichever occurs first.
2446873|NCT03262558||Patients with ECC|No intervention
2446993|NCT03261765||Multiple repeat cesarean (four or more)|
2447006|NCT03261765||Fewer repeat cesarean (two-three)|
2447068|NCT03261479||Respiratory distress|Inclusion criteria are 1) subjects 28-days to 17-years of age, 2) who have respiratory distress, and 3) who receive a chest x-ray. We will exclude subjects with known chronic lung disease.
3208514|NCT00975494|Placebo Comparator|Placebo|Placebo
2447254|NCT03259958|Experimental|Donepezil TDS|Corplex Donepezil TDS 5 mg/day followed by Donepezil TDS 10mg/day applied weekly for 5 consecutive weeks
2447259|NCT03259958|Active Comparator|Aricept|Aricept 5 mg/day followed by Aricept 10 mg/day once daily for 5 consecutive weeks
2447383|NCT03259243|Placebo Comparator|placebo group|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and prior skin closure Drug: 0.9%Nacl Other Name: NSS
2447384|NCT03259243|Experimental|Preincision Bupivacaine|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin closure Drug: 0.5% bupivacaine 10 ml (50 mg) Other Name: Marcaine 0.9%Nacl (Placebo) 10 ml Other Name: NSS
2447385|NCT03259243|Experimental|Preclosure bupivacaine|0.9%Nacl (Placebo) 10 ml were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
2447387|NCT03259243|Experimental|Bupivacaine group|0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin incision and 0.5% bupivacaine 10 ml (50 mg) were port site infiltration prior skin closure Other Name: Marcaine
2447435|NCT03258567|Experimental|Nivolumab (A)|Nivolumab, 3mg/kg IV every 2 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment (closed effective with activation of Amendment C)
2447436|NCT03258567|Experimental|Nivolumab (B)|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
2447466|NCT03258281|Active Comparator|evolocumab 420mg|75 subjects on optimal statin therapy undergoing elective PCI will receive evolocumab 420mg.
2447467|NCT03258281|Placebo Comparator|placebo|75 subjects on optimal statin therapy undergoing elective PCI will receive placebo
2447511|NCT03258086|Experimental|Blood sample|2ml blood sample of of blood will be taken for assessment of vitamin D
2447652|NCT03256929|Experimental|depression participants - intervention|personalized diet intervention based on microbiota analysis and health status
2447656|NCT03256929|Experimental|depression participants - control|General information on nutrition and health
2447674|NCT03257046|Experimental|1 mg ITI-214|Administered once daily for 7 days
3153219|NCT00269893|Experimental|Abciximab|Participants will receive 0.25 mg/kg of body weight of abciximab bolus followed by abciximab (c7E3 Fab) infusion up to 12 hours.
3153220|NCT00269906|Experimental|Abciximab (c7E3 Fab)|Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
3153221|NCT00269906|Placebo Comparator|Placebo|Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.
3153222|NCT00270153|Placebo Comparator|enalapril|
3153223|NCT00270153|Placebo Comparator|Placebo|
3153224|NCT00270218|Experimental|1|Arm 1 participants will be given an injection of VRC-HIVADV014-00-VP vaccine on Days 0 and 168.
3153225|NCT00270218|Placebo Comparator|2|Arm 2 participants will be given an injection of final formulation buffer (FFB) on Days 0 and 168.
2446629|NCT03264573|Active Comparator|Stem cell, Stem cell and PRP|Adipose derived MSCs alone, other group is injected Adipose derived MSCs, and Platelet rich plasma
3189878|NCT00781781|Experimental|2|"Low Risk patients (no GVHD high risk criterion):~Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive)."
3189879|NCT00781794|Experimental|1|Dose 1
2446810|NCT03263208|Experimental|CD19 CAR-T|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
2446821|NCT03262818|Experimental|Transvaginal Ultrasound + Ultrasound/Photoacoustic imaging|"Transvaginal ultrasound (US) prior to surgery~Immediately after the transvaginal US, US/PAI imaging will be performed~Once the surgeon has removed the ovary(ies) they will be imaged ex vivo. The in vivo and ex vivo US/PAI images will be compared with the final pathologic diagnosis"
2446918|NCT03262311|Experimental|Hypoxia marker|Administration of a single dose of the hypoxia marker Pimonidazole
3189880|NCT00781794|Experimental|2|Dose 2
3189881|NCT00781794|Placebo Comparator|3|
3189882|NCT00781807|Experimental|1|The prospective intervention group with nutrition management, home-based bicycle ergometer training program and psychosocial support
3189883|NCT00781820|Placebo Comparator|Arm 2|
3189884|NCT00781820|Experimental|Arm 1|
2447157|NCT03260751|Experimental|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
2447158|NCT03260751|Placebo Comparator|Placebo|Placebo for 12 weeks
3189885|NCT00781833|Experimental|Treatment|Intramuscular Electrical Stimulation
3189886|NCT00781846|Experimental|1|30mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
3189887|NCT00781846|Experimental|2|40mg QDx5/wk ridaforolimus plus 10mg/kg Q2wks bevacizumab for 4 weeks
2447356|NCT03259165|Experimental|Nitrate Intense Strategy|Patients randomized to the Nitrate intense strategy will be treated according to protocol with nitrates in combination with IV loop diuretics. This protocol only involves therapies used in everyday AHF clinical practice.
2447358|NCT03259165|Experimental|Diuretic Intense Strategy|Patients randomized to the Diuretic intense strategy will be treated according to protocol with IV loop diuretics in combination with nitrates. This protocol only involves therapies used in everyday AHF clinical practice.
3189888|NCT00781846|Experimental|3|40mg QDx5/wk ridaforolimus plus 15mg/kg Q3wks bevacizumab for 3 weeks
2447531|NCT03258203|Experimental|diet 1|diet with moderate in fat (40% energy) and protein(15%)
2447532|NCT03258203|Experimental|diet 2|diet with moderate in fat (40% energy) and protein(25%)
2447534|NCT03258203|Experimental|diet 3|diet with low in fat (20% energy) and protein(15%)
2447537|NCT03258203|Experimental|diet 4|diet with low in fat (20% energy) and protein(25%)
2447565|NCT03257618|Experimental|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
3189889|NCT00781872|Experimental|Treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously|Intrathecal and intravenous treatment with autologous mesenchymal stem cells (MSC) intrathecally and intravenously in patients with active multiple sclerosis, failures to respond to other treatments
3189890|NCT00781924||biopsy|
2447763|NCT03256123|Experimental|red palm shortening group|A group receiving the supplementation of red palm shortening biscuits. The subjects are expected to receive 630 µg RE of vitamin A/day by consuming the biscuits four days a week.
2447773|NCT03256123|Placebo Comparator|palm shortening group|A group receiving supplementation of palm shortening biscuits with corresponding fatty acids as red palm shortening group.
2447824|NCT03255863|Other|Questionnaire|Auto and hetero questionnaire
3189891|NCT00781976|Placebo Comparator|1|
3189892|NCT00781976|Active Comparator|2|
3189893|NCT00781989||Rheumatoid Arthritis patients|Patients with seropositive Rheumatoid Arthritis with symptom onset of less than three years
3189894|NCT00782002|Experimental|IMC-18F1|
3189895|NCT00782015|Active Comparator|almonds|3 oz/d almonds
3189896|NCT00782015|Placebo Comparator|Placebo|NCEP Step 2 diet
3189897|NCT00782028|No Intervention|Standard Care|No intervention consists of routine well child care
3189898|NCT00782028|Other|Centering parenting/Group well child care|
3189899|NCT00782041|Experimental|1|Oxaliplatin 85 mg/m² over 3 hours at Day 1 and Day 15. 5-FU 2,000 mg/m² over 4 hours at Day 1. Folinic acid 20 mg/m² Bolus at Day 1.
3189900|NCT00782054|Active Comparator|Active|moisturizer with endopeptidases
3189901|NCT00782054|Placebo Comparator|Placebo|moisturizer without endopeptidases
3189902|NCT00782080|Experimental|Sedariston|Sedariston (100 mg St. John´s Wort and 50 mg Valerian extract) capsule given orally in capsules (size 1) twice daily for eight weeks in children (6-11): 1 - 0 -1 In Adolescents (12-17 years) two capsules (size 1) twice daily: 2 - 0 - 2.
3189903|NCT00782080|Placebo Comparator|Placebo campsule|Placebo provided by the company given orally in capsules (size 1 )twice daily
3189904|NCT00782106|Experimental|1|Tolerability of subcutaneous infusions
3189905|NCT00782106|Experimental|2|Tolerability of subcutaneous infusions and pharmacokinetics
3208515|NCT00975520|Active Comparator|Radiation Therapy|Investigational Treatment
3208516|NCT00975520|Other|Observation|Observation
3208517|NCT00975533|Experimental|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM. The device is intended to improve glycemic control and induce weight loss.
3208518|NCT00975533|Active Comparator|Control|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
2446637|NCT03264365|Experimental|Intervention|Relatives participated actively in the one out of three consultation conducted by trained study nurses at two months after intensive care superimposed on standard care.
2446638|NCT03264365|No Intervention|Standard care|Relatives to former ICU patients, who had received standard care (SC) completed a questionnaire package at 3 and 12 months after the patient was discharged from intensive care. After enrollment were all contract handled by primary investigator.
2446680|NCT03264079|Experimental|Bardoxolone methyl 10 mg and Itraconazole 200 mg|Period 1: Bardoxolone methyl capsules 10 mg Period 2: two Itraconazole capsules 100 mg
2446716|NCT03263728|Experimental|Stress Cardiac MR|
2446770|NCT03263416|Experimental|Arm A|
2446773|NCT03263416|Other|Arm B|Standard
2446829|NCT03263052||Tacrolimus XR|
2446887|NCT03262649||Crohn's Disease Cohort|250 individuals in the Crohn's Disease Cohort
2446890|NCT03262649||ulcerative colitis cohort|108 individuals in the ulcerative colitis cohort
2446944|NCT03262272|Experimental|Hemodialysis|patients treated by conventionnal hemodialysis
2446955|NCT03262272|Experimental|Hemodiafiltration post dilution|patients treated by HDF post-dilution
2446995|NCT03261700|Experimental|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran?s self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care and red flags, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
2447004|NCT03261700|Active Comparator|Information and referral condition|This brochure-based intervention includes education about IPV, health effects of IPV, resources and referral options to address a wide-array of health and social issues associated with IPV, and safety planning. Participants randomized to this arm are offered resources and referrals to VA and community resources.
2447082|NCT03261401|Experimental|Part A: M5717|
2447088|NCT03261401|Placebo Comparator|Part A: Placebo|
2447091|NCT03261401|Experimental|Part B: M5717|
2447094|NCT03261401|Placebo Comparator|Part B: Placebo|
2447098|NCT03261401|Experimental|Part C: M5717|
2447129|NCT03260816|Experimental|Internet-Delivered Parent Training|Families will receive weekly sessions of Internet-delivered Parent-Child Interaction Therapy (I-PCIT), a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
2447134|NCT03260816|Active Comparator|Referrals as Usual (RAU)|Families in the referrals as usual (RAU) group will be referred to services as usual in their Early Intervention exit interview, which includes a variety of clinic-based mental health services at local community agencies. At each assessment, the access and extent of participation in other services will be monitored.
2447184|NCT03260556|Active Comparator|Pirfenidone|Pirfenidone titrated to three 267 mg tablets three times a day
2447189|NCT03260556|Placebo Comparator|Placebos|Placebo titrated to three tablets three times a day
2447240|NCT03260088||patients with pleural effusion|In patients with pleural effusion that remains undiagnosed with common diagnostic algorithm, immunoglobulin G4 will be done in pleural fluid
3153226|NCT00270218|Experimental|3|Arm 3 participants will be given an injection of VRC-HIVDNA009-00-VP vaccine on Days 0 and 28. Participants will also be given an injection of VRC-HIVADV014-00-VP on Day 168.
3153227|NCT00270218|Placebo Comparator|4|Arm 4 participants will be given an injection of phosphate buffered saline (PBS) on Days 0 and 28 and an injection of FFB on Day 168.
3153228|NCT00270244|Active Comparator|1|Participants will receive treatment as usual
3153229|NCT00270244|Experimental|2|Participants will receive group interpersonal psychotherapy for depressed adolescents
3153230|NCT00270335|Active Comparator|A|General anesthesia titrated according to a cerebral state monitor
3153231|NCT00270335|Active Comparator|B|General anesthesia titrated according to usual clinical criteria
2447480|NCT03258268|Experimental|Standard of Care with DSS|"Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
2447482|NCT03258268|Active Comparator|Standard of Care without DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
2447500|NCT03258008|Experimental|Utomilumab + ISA101b|"Utomilumab by vein every 4 weeks for up to 12 doses beginning on Cycle 1 Day 1.~ISA101b as an injection under the skin every 4 weeks for 3 doses. Participants receive 2 injections each time."
2447547|NCT03257878||Systemic sclerosis (SSc)|validated Korean version of the SF36 and EQ-5D
2447552|NCT03257878||Rheumatoid arthritis (RA)|validated Korean version of the SF36 and EQ-5D
2447554|NCT03257878||Systemic lupus erythematosus (SLE)|validated Korean version of the SF36 and EQ-5D
2447558|NCT03257878||Sjogren's syndrome|validated Korean version of the SF36 and EQ-5D
2447562|NCT03257878||Control|validated Korean version of the SF36 and EQ-5D
3153232|NCT00270361|Experimental|001|nesiritide
3153233|NCT00270361|Experimental|002|nesiritide
3153234|NCT00270361|Active Comparator|003|usual long term cardiac medications
3153235|NCT00270374|Experimental|001|nesiritide
3153236|NCT00270387|Experimental|001|Natrecor (nesiritide)
3153237|NCT00270400|Experimental|001|nesiritide
3153238|NCT00270413|Experimental|1|sutent
3153239|NCT00270413|No Intervention|2|
3153240|NCT00270439|Experimental|single arm|Removed omentum of patients with type 2 diabetes
3153241|NCT00270621|Experimental|Treatment|FHP Night time Enuresis intervention
3153242|NCT00270621|No Intervention|Control|To receive standard/usual care for Nocturnal Enuresis- No FHP Night time Enuresis INtervention
2446648|NCT03264209|Experimental|Intervention: Case management|Case management consists confirmation of hospital visit date, checking the efficacy of intervention, adverse effect and treatment compliance
2446653|NCT03264209|No Intervention|Control: usual care|Usual care is provided with life style intervention including exercise and nutrition by printed materials.
2446701|NCT03263975|Experimental|Exercise heat STress (EHS)|EHS - dehydration produced by sweating and fluid restriction; primary loss of body water accompanied by small loss of electrolytes (hypertonicity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
2446706|NCT03263975|Experimental|Lasix (LAS)|LAS - dehydration produced by Lasix (diuretic, 80 mg oral dose) administration to produce losses of body water accompanied by large losses of electrolytes (isotoncity). Interventions include rehydration with Gatorade or Enterade oral rehydration therapies.
2446789|NCT03263533|Experimental|Vorinostat Group 1 (P-V-P-P)|"This group will receive this sequence after the 1 initial week washout:~vorinstat (4 weeks) placebo (1 week) placebo (4 weeks)"
2446790|NCT03263533|Experimental|Vorinostat Group 2 (P-P-P-V)|"This group will receive this sequence after the 1 initial week washout:~placebo (4 weeks) placebo (1 week) vorinostat (4 weeks)"
2446856|NCT03262961|Active Comparator|Intervention Group|• The intervention group will be supplied with Sildenafil Citrate (Respatio® 20mg tablets manufactured by Pharma Right Group , Egypt) according to the patient's weight by the rate of (1.5 mg/kg/day) divided into three doses per day ( every 8 hours) till termination of pregnancy.
2446857|NCT03262961|Placebo Comparator|Control Group|- The control group will be supplied with a placebo drug that has the same shape, size and color but without the active ingredient and it would also be taken in a similar way. The placebo tablet will be manufactured at the faculty of pharmacy, Assiut University.
2446883|NCT03262454|Experimental|Interventions|Atezolizumab
2446939|NCT03262168|Other|Study Group One|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
2446946|NCT03262168|Other|Study Group Two|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
2446957|NCT03262168|Other|Study Group One - phase 2|Six Minute Walk Test distance <450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).
2446961|NCT03262168|Other|Study Group Two - phase 2|Six Minute Walk Test distance >450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).
2447038|NCT03261791|Experimental|Apatinib|Apatinib mesylate tablets 500 mg po qd.
2447055|NCT03261206|No Intervention|5-ASA Continuation|Half of the subjects will continue on aminosalicylate therapy using the same dose and brand for the duration of the study
2447061|NCT03261206|Experimental|5-ASA Withdrawal|Half of the subjects will discontinue their aminosalicylate therapy
2447159|NCT03260738|Experimental|"Robot Poppy group"|30 minutes of daily rehabilitation program (physical exercises dedicated to the mobility of the spine) supervised by Poppy robot during 3 weeks included in a 3hours daily (5 days a week) rehabilitation program.
2447160|NCT03260738|Active Comparator|Control group|Usual 3hours daily (5 days a week) rehabilitation program without robot during 3 weeks
2447212|NCT03260413||Pneumonia cases|Children between the ages of 1 month through 5 years of age who are admitted to Chenla Children's Healthcare between opening of the hospital (mid-2017) and early February 2018 for pneumonia and respiratory distress.
2447229|NCT03260179|Experimental|gastric carcinoma|20 gastric carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
2447230|NCT03260179|Experimental|hepatocellular carcinoma|20 hepatocellular carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
2447231|NCT03260179|Experimental|Nasopharyngeal carcinoma|20 Nasopharyngeal carcinoma patients were randomly divided into two groups: 4W on or 3w on/1w off, oral AL3810
3208519|NCT00975559||Normal volunteers|Normal study volunteers with no prior history of coronary artery disease
3208520|NCT00975559||Apical Ballooning Syndrome|Women who have had a documented Apical Ballooning event as shown by coronary angiogram
3208521|NCT00975559||Coronary Endothelial Dysfunction|Patients who have been diagnosed with Endothelial Dysfunction via a coronary angiogram with acetylcholine challenge
2447579|NCT03257553|Experimental|intervention arm|do fecal calprotectin, doppler and ultrasound for each patient
3208522|NCT00975559||Myocardial Infarction|Women diagnosed with a Myocardial Infarction who subsequently had a Percutaneous Intervention
3208523|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|
2447833|NCT03255642|Active Comparator|Melatonin 2mg|4 weeks of 2mg of prolonged release Melatonin
2447839|NCT03255642|Placebo Comparator|ClonazePAM 0.5 MG|4 weeks of 0.5mg of rivotril
2447918|NCT03255304|Experimental|health prime|
2447919|NCT03255304|Experimental|palatability prime|
2447974|NCT03254901||health care workers|health care workers in Assiut health directorate, Abutig central hospital, El-Quseya central hospital and Sahil selim central hospital in Assiut governorate .All of them will be screened for hepatitis C infection and interviewed about mode of transmission of infection
2448039|NCT03254589|Experimental|Group 1|Newly diagnosed RA patients started on subcutaneous MTX - open randomisation vs. sulfasalazine. In this group, use of NSAIDs, steroids, and/or other DMARDs, is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice .
2448040|NCT03254589|Active Comparator|Group 2|Newly diagnosed RA patients started on sulfasalazine - open randomisation vs. subcutaneous MTX. In this group, use of NSAIDs, steroids, and/or other DMARDs (except MTX), is allowed, if indicated, for symptom control. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
2448048|NCT03254589|Experimental|Group 3|RA patients on long-term treatment (> 1 year) with oral MTX, with or without other DMARDs, NSAIDs and/or steroids, switched to subcutaneous MTX (same dose). In these patients, treatment with other DMARDs, NSAIDs and/or steroids will continue. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
3208524|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|
2446652|NCT03264144|No Intervention|Control|Students in the schools assigned to the control group will not receive anything during the randomised controlled trial. They will receive the intervention materials after the trial.
2446758|NCT03263611|Placebo Comparator|placebo|subject will receive single intradiscal injection of placebo
2446759|NCT03263611|Experimental|AMG0103 low dose|subject will receive single intradiscal injection of AMG0103 low dose
2446762|NCT03263611|Experimental|AMG0103 middle dose|subject will receive single intradiscal injection of AMG0103 middle dose
2446764|NCT03263611|Experimental|AMG0103 high dose|subject will receive single intradiscal injection of AMG0103 high dose
2446870|NCT03262662|Experimental|Extended Run-In|"** 4 weeks of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
2446874|NCT03262662|Active Comparator|Standard Run-In|"** 3 weeks of placebo followed by 1 week of varenicline prior to the target quit date (TQD) **~+ 11 weeks of post-TQD varenicline~Standard varenicline dosing titration in initial week of therapy (one 0.5 mg tablet orally daily x 3 days, then one 0.5 mg tablet twice daily x 4 days); then 1 mg twice daily thereafter.~Brief individual counseling at clinic visits"
2446935|NCT03262181|Experimental|Isometric Exercise Condition|The participant will perform 5 sets of a 45-second isometric contractions at 70% of their maximum voluntary isometric contraction (MVIC). During the 45-second contraction, the participant will be provided with visual biofeedback on a computer screen (70% MVIC target line and +/- 5% error lines). The participant will be instructed to produce a level of isometric quadriceps contraction that maintains the isometric torque output line as close the target line as possible and always between the two error lines.
2446948|NCT03262181|Sham Comparator|Sham TENS Condition|"Two electrodes of the Select System TENS unit (Empi, Inc., St. Paul, MN) will be placed on either side of the patellar tendon on the test limb. The same instruction script will be used for each participant, stating, A surface electrode has been placed on either side of your patellar tendon. I will turn on the stimulation unit to emit a stimulus to your patellar tendon. This is a special sub-sensory stimulation treatment, so you will not feel anything during this period as the stimulus is set at a very low, non-detectable threshold. Please remain still during this 45-second period, letting your leg rest passively in the machine without contracting your leg muscles. After the 45-second period, the stimulation unit will be turned off and you will have a 2-minute rest period. We will repeat this same treatment/rest sequence 5 total times."
2447015|NCT03261804||Group I:internal vaginal douching users|
2447019|NCT03261804||Group II: none internal vaginal douching users|
2447063|NCT03261349|Experimental|Anti-HCV (Ledipasvir and sofosbuvir)|Harvoni® (90 mg ledipasvir and 400 mg sofosbuvir) one tablet daily for 12 weeks
2447149|NCT03261063|Experimental|Evera Implanted Group|
2447181|NCT03260543|Experimental|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
2447187|NCT03260543|Placebo Comparator|Placebo|Placebo for 12 weeks.
2447225|NCT03260153|Experimental|Deproteinised Calf Blood Serum Injection|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
2447226|NCT03260153|Placebo Comparator|Sodium Chloride Physiological Solution|Participants will be randomly assigned to receive Deproteinised Calf Blood Serum Injection or placebo within 1 hour after randomization, once a day for 14 days.
2447236|NCT03259815|Experimental|PIOS Intervention Group|"Operator-blinded pre and post-PCI coronary physiology measurements will be recorded. If FFR is <0.90, the result will be disclosed to the operator and a hyperaemic pressure wire pullback will be performed during a standard peripheral intravenous adenosine infusion (140mcg/kg/min).~The operator will then follow the PIOS protocol to attempt to obtain the target optimal post-PCI FFR result."
2447237|NCT03259815|Active Comparator|Control Group|Operator-blinded pre and post-PCI coronary physiology measurements will be recorded and the angiographically defined result will be accepted.
2447303|NCT03259594|Experimental|endophytic group|participants are with endophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
2447309|NCT03259594|Sham Comparator|exophytic group|participants are with exophytic renal cyst and undergo laparoscopic deroofing.2 day before laparoscopic deroofing, they were given intravenous 100 g of amino acids supplementation.
2447369|NCT03259113|Other|Insertable cardiac monitor|All patients will undergo monitoring using an insertable cardiac monitor (single arm)
2447406|NCT03258684|Active Comparator|vitamin C、hydrocortisone、thiamine|Intravenous vitamin C (1.5 g every 6 h for 4 days or until ICU discharge), hydrocortisone (50 mg every 6 h for 7 days or until ICU discharge followed by a taper over 3 days), as well as intravenous thiamine (200 mg every 12 h for 4 days or until ICU discharge).
2447411|NCT03258684|Placebo Comparator|normal saline|Normal saline 500ml every day for 4 days，then 200ml every day for 3 days.
2447490|NCT03258398|Experimental|Part 1: eFT508 plus avelumab dose finding Arm|subjects will receive eFT508 in combination with a fixed dose of avelumab
2447491|NCT03258398|Experimental|Part 2: eFT508 plus avelumab|subjects will receive eFT508 in combination with a fixed dose of avelumab
2447492|NCT03258398|Experimental|Part 2: eFT508 alone|subjects will receive eFT508 alone
2447499|NCT03257956|Experimental|Investigational Group|The RHEA device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2447502|NCT03257956|Active Comparator|Reference Group|The reference device and Patient Monitor Device are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
2447568|NCT03257891|Experimental|Arm 1|patients with advanced Adrenocortical- Carcinoma progressing after previous chemotherapy lines will be treated with Cabazitaxel
2447594|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC II)|Patients in this group recruited also in APPAC II trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 2 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 5 days, for a total treatment duration of 7 days. From these patients, rectal swab samples will be collected at day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
2447675|NCT03257046|Experimental|3 mg ITI-214|Administered once daily for 7 days
2446720|NCT03264027|Active Comparator|Ambient air|Argon fulguration will be performed using ambient air for insufflation. After using a disposable endoscopic catheter, argon plasma (Argon 2) (MAE, Ribeirão Preto, Brazil) will be applied in a 1-cm band around the entire circumference of the gastrojejunal anastomosis at an intensity of 90 W and a flow rate of 2 L/min.
2446781|NCT03263351|Experimental|Cognitive-behavioral therapy group|Six-session cognitive-behavioral therapy group program designed as a prevention of depression intervention for adolescents at-risk for depression. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
2446787|NCT03263351|Active Comparator|Health education group|Six-session health education group program designed as a health education curriculum for teenagers. The program is facilitated by a psychologist. Sessions are weekly for 1-hour.
2446834|NCT03263026|Active Comparator|R-CHOP + enzastaurin hydrochloride|Subjects in the R-CHOP + enzastaurin Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus a 1125 mg loading dose of enzastaurin on Day 2 followed by 500 mg daily.
2446841|NCT03263026|Placebo Comparator|R-CHOP + placebo|Subjects in the R-CHOP + placebo Arm will receive R-CHOP (Rituximab-375 mg/m2 i.v., Cyclophosphamide-750 mg/m2 i.v., Doxorubicin-50 mg/m2 i.v., Vincristine-1.4 mg/m2 i.v. (2 mg max), and Prednisone-100 mg p.o.), as directed, plus an identical number of tablets as the subjects in the enzastaurin Arm.
3208525|NCT00975572|Experimental|split-virion, adjuvanted H1N1 vaccine of 30 μg|
3208526|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|
2446989|NCT03261622|Active Comparator|Control arm|Stimulation amplitude at 90% of sensory threshold during period 1 to 3. (each period 4 weeks)
2446999|NCT03261622|Sham Comparator|Intervention arm|"Alternation of stimulation amplitude~Period - Stimulation amplitude 0.05 Volts (lowest possible)~Period - Stimulation amplitude - 50% of sensory threshold.~Period - Stimulation amplitude - 90% of sensory threshold."
2447110|NCT03261128||Group D-FOG|Filling of a self-questionnaire before each chemotherapy cure
2447169|NCT03260712|Experimental|CisGem + pembrolizumab|Patients will be enrolled in the experimental arm and will receive CisGem [25mg/m2 cisplatin + 1000mg/m2 gemcitabine, on days 1 and 8 of a 21 day cycle] plus 200 mg pembrolizumab (fixed dose) on day 1 of a 21 day cycle.
2447267|NCT03260101||one group, ApoGraft Follow up Study|Non-interventional, long-term follow-up study in subjects who received ApoGraft in study ApoGraft-01
2447296|NCT03259477|Experimental|precise segmental clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo precise segmental renal arterial clamping during laparoscopic partial nephrectomy.
2447301|NCT03259477|Active Comparator|complete clamping|These participants with clinical T1 renal cell carcinoma(RCC) undergo complete renal arterial clamping during laparoscopic partial nephrectomy.
2447354|NCT03259152|Experimental|Pre-Denosumab GctB|Specimens obtained during biopsy
2447355|NCT03259152|Experimental|Post-Denosumab GctB|Specimen after administration of Denosumab
2447407|NCT03258892|Experimental|Arm A (STG pre-chemotherapy)|Patients receive the STG before completing 4 courses of standard of care chemotherapy.
2447418|NCT03258892|Experimental|Arm B (STG post-chemotherapy initiation)|Patients complete 2 courses of standard of care chemotherapy and then receive the STG before completing 2 additional courses of standard of care chemotherapy.
2447472|NCT03258255|Active Comparator|Pudendal block group in circumcision|Nerve stimulated pudendal nerve block performed under general anesthesia
2447476|NCT03258255|Active Comparator|Penil block group in circumcision|Penil block performed by surgeon under general anesthesia
2447527|NCT03258138|Experimental|More Intensive Program (MIP)|Participants will receive the more intensive program, which combines usual care with the full version of the healthy lifestyles program. Participants in this arm will meet weekly for group health and wellness learning sessions or brainstorming group sessions. In addition, they will meet monthly for individual sessions with a multidisciplinary health team, including a family physician, physical therapist and dietician to tailor their health goal development and action plans to their particular needs and situations. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
2447530|NCT03258138|Experimental|Less Intensive Program (LIP)|Participants will receive the less intensive program, which combines usual care along with health goal development. Participants in this arm will meet at baseline to set health goals with the support of a research assistant trained in theories of health behaviour and goal setting. They will also meet every three months to measure progress in achieving their goals. They will be asked to maintain physical activity and nutrition journals for a week each every three months.
2447614|NCT03257462|Experimental|Cohort A|The first cohort of 9 patients will be administered SPR001 at dose strength of Dose A daily for 2 weeks, and escalating through Dose B per day for 2 weeks and Dose C per day for 2 weeks.
2447620|NCT03257462|Experimental|Cohort B|Cohort B will begin enrollment after Cohort A has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort B will be determined by an interim review of safety and PK/PD data from from Cohort A.
2447627|NCT03257462|Experimental|Cohort C|Cohort C will begin enrollment after Cohort B has been fully enrolled. Starting dose selection and the stepwise dosing paradigm for Cohort C will be determined by an interim review of safety and PK/PD data from from Cohort A and B.
2447669|NCT03256981|Experimental|SBRT and continued TKI therapy|"Patients will continue to receive background TKI treatment as prior to trial entry.~Simultaneous administration (SBRT & TKI) or break in TKI during SBRT will be by centre preference and determined prior to commencing recruitment.~Repeat SBRT will be permissible upon development of subsequent OPD lesions dependent on SBRT suitability and total progression lesion number at any one point remaining ≤ 3."
2447672|NCT03256981|Active Comparator|Continued TKI therapy alone|Continuation on the same background TKI treatment as prior to trial entry
3208527|NCT00975572|Placebo Comparator|Placebo control|
3208528|NCT00975572|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|
2447928|NCT03255161|No Intervention|Waitlist|
3208529|NCT00975663|Experimental|1|Optimized TDM of tacrolimus and MMF dosing
3208530|NCT00975663|Active Comparator|2|Current tacrolimus and MMF dosing strategies
3208531|NCT00975702|No Intervention|No RIPC Group|This group is the control group or the comparator group with RIPC
3189906|NCT00782145|Experimental|Arm I|"Each dyad receives institution-specific care for 6 months, which typically includes psychosocial support for the HSCT recipient and individualized or group education and support for the accompanying parent during the peri-transplant period. They also receive the Web-based Hematopoietic Stem Cell Transplantation (HSCT-) Comprehensive Health Enhancement Support System (HSCT-CHESS) intervention for 6 months. Accompanying parents also identify a companion to receive access to the HSCT-CHESS Web Site.~The HSCT-CHESS Web site provides ready access to accurate information and resources about pediatric HSCT, practical tips, organizational tools, and other supporting services for use during the transplant process. In addition to collecting data for later analysis, the Web site tracking system allows for further tailoring of information and support for the user, principally by time post transplant."
3189907|NCT00782145|Active Comparator|Arm II|Each dyad receives institution-specific usual care for 6 months as described in arm I. Accompanying parents also receive a book from the Blood and Marrow Transplant Information Network (BMT Infonet).
3189908|NCT00782197|Experimental|1|PRGF
3189909|NCT00782197|Active Comparator|2|Hyaluronic Acid
3189910|NCT00782223||1|Hip X-rays DDH
2446907|NCT03262766|Active Comparator|Acute intermittent hypoxia (AIH)|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
2446908|NCT03262766|Experimental|AIH+ Upper extremity training|"Subjects will be exposed to acute intermittent hypoxia, daily for 5 days. Each session will consist of up to 90 seconds of 9-10% Oxygen (FiO2 0.09), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for up to 45 minutes, to maintain SpO2 at 80-90%. If the SpO2 drops below 75%, hypoxia exposure will be terminated immediately.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
2446909|NCT03262766|Active Comparator|Sham AIH + Upper extremity training|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2).~Following the sham AIH protocol, subjects will receive 45 minutes of task-specific, high repetition upper extremity training. Upper extremity training will be given using an upper-limb robotic rehabilitation device, the Armeo Spring®."
2446910|NCT03262766|Sham Comparator|Sham Acute intermittent hypoxia|"Subjects will be exposed to sham hypoxia daily for 5 days. Each session will consist of up to 90 seconds of 21% Oxygen (FiO2 0.21), alternating with up to 90 seconds of 21% Oxygen (normoxic air FiO2 0.21). The delivery will be repeated up to 18 times per session each, for a total of up to 45 minutes.~There is continuous monitoring of respiratory rate, heart rate and peripheral arterial oxyhemoglobin saturation (SpO2)."
3189911|NCT00782223||2|Hip X-rays, CP
3189912|NCT00782223||3|Long standing lower Limb X-rays
3189913|NCT00782223||4|Scoliosis, AP X-rays
3189914|NCT00782223||5|Scoliosis Lateral X-rays
2447122|NCT03260998||diabetic patients type 1|electrocardiogram will be done for 60 children and adolescents with type 1 diabetes
2447131|NCT03260998||healthy persons|electrocardiogram will be done for 60 age and sex matched non diabetic children and adolescents
2447162|NCT03260673||the diabetic group|patients with type 2 diabetes scheduled to undergo cataract surgery
2447163|NCT03260673||the control group|patients without diabetes scheduled to undergo cataract surgery
2447179|NCT03260361|Experimental|Hypnosis Kinesitherapy and MEOPA|combined therapy of Hypnosis Kinesitherapy and MEOPA (HKM)
2447185|NCT03260361|Other|usual practice|physiopathology and treatments
2447232|NCT03260166|Experimental|nicotinamide|Patients will receive 10 nicotinamide tablets orally twice daily (nicotinamide 500 mg, p.o., Bid) for a period of 3 months. Each tablet contains 50 mg of nicotinamide.
2447289|NCT03259750||professional athletes|athlete who volunteered in this study that should be a member of a professional sport team, All athletes must complete self reported outcome instrument (FAAM-T)
2447299|NCT03259360|Experimental|The Put It Out Project (POP):|a culturally tailored intervention developed for SGM young adults on Facebook
2447304|NCT03259360|Experimental|Tobacco Status Project (TSP):|the original TSP intervention (non-tailored) delivered to groups of only SGM participants on Facebook
2447368|NCT03259126|Experimental|SCUT|"Use of a Small Curtain under table (SCUT) placed under the cranial part of the angiographic table"
2447374|NCT03259126|No Intervention|Control|Control Group without the SCUT
2447413|NCT03258736|Other|Caudal block|Caudal block Marcaine
2447426|NCT03258736|Other|ilionguinal/iliohypogastric block|ilionguinal/iliohypogastric block Marcaine
2447485|NCT03258463||Time Period 1|Women who obtained an abortion from January 1 2012-December 31 2012
3189915|NCT00782236|Active Comparator|Straumann BoneCeramic|In the test group, the subjects will receive the Bone Graft Material Straumann BoneCeramic in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
3189916|NCT00782236|Active Comparator|Freeze Dried Allograft Bone|In the control group, the subjects will receive Bone Graft Material Freeze Dried Allograft Bone in combination with a collagen membrane for preservation of the alveolar ridge after tooth extraction.
3189917|NCT00782249|Experimental|1|Vagus nerve stimulation paradigm #1
3189918|NCT00782249|Experimental|2|Vagus nerve stimulation paradigm #2
3189919|NCT00782249|Experimental|3|Vagus nerve stimulation paradigm #3
3189920|NCT00782262|Other|Group 1 (n=20)|BP < 140/90, no diabetes mellitus and fasting glucose < 5.5
3189921|NCT00782262|Other|Group 2 (n=20)|BP > 140/100, no diabetes mellitus and fasting glucose < 5.5
2446814|NCT03262831|Experimental|Arm 1: Yoga|"Prior to start of treatment, a yoga therapist will work with each patient to develop a personalized yoga protocol using Gentle Hatha and Restorative Yoga~Each protocol will consist of 5-10 minutes of centering poses to invite focus and relaxation, then 15-20 minutes of seated and standing active poses, ending with 5-10 minutes of guided relaxation.~The personalized practice will be given to each participant and she will be asked to practice beginning at the start of neoadjuvant treatment at least 3 times a week (but preferably daily) at home for at least 30 minutes each time. Participants will continue their personalized yoga practice during the entirety of treatment. Each participant will be asked to journal when and for how long she practices at home and make any comments as to how the practice might have made her feel~During participation, weekly follow-up calls will be made by a member of the study team to each participant randomized to the yoga arm."
2446816|NCT03262831|Active Comparator|Arm 2: No Yoga|-Patients in this arm will not receive a personalized yoga plan
2446882|NCT03262480|Active Comparator|Stroke volume optimization|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4 (Voluven) will be administered within 10 minutes and stroke volume response will be recorded .If stroke volume increase by more than 10 % for 20 minutes, the aliquot will be repeated.
2446888|NCT03262480|Sham Comparator|Central venous pressure dynamic|Colloid aliquots of 200 ml 6% hydroxy ethyl starch 130/ 0.4(Voluven) will be administered within 10 minutes and CVP response will be recorded. If CVP failed to rise sustainably for more than 2 mmHg for 20 minutes, the aliquot will be repeated.
2447022|NCT03261908||wild genotype|Through next generation sequencing, distinguish wild genotype of simvastatin
2447028|NCT03261908||mutant genotype|Through next generation sequencing, distinguish mutant genotype of simvastatin
2447051|NCT03261284|Experimental|DOAC group|Patients with elevated d-dimer levels was switched to DOAC (dabigatran 150mg, bid).
2447054|NCT03261284|Experimental|Higher-INR group|Patients' target INR was adjusted from 1.5-2.5 to 2.0-3.0 by adding warfarin dose.
2447058|NCT03261284|No Intervention|Control group|Patients continue previous strategy without change.
2447152|NCT03261011|Experimental|AK-104|Single-arm
2447199|NCT03260452|Experimental|Patients|'Abdominal subcutaneous biopsies and Blood test'
2447243|NCT03260114|No Intervention|Physical activity recommendations|Participants in this group will be advised to engage in physical activity recommendations from health authorities, i.e., 150 minutes per week of moderate intensity activity or 75 minutes per week of vigourous intensity activity or combination of both that results in same caloric expenditure.
2447250|NCT03260114|Active Comparator|PAI equal to or more than 100|Participants in this group will be advised to obtain a PAI score of 100 or more over a week.
2447257|NCT03260114|Active Comparator|PAI between 50 and 99|Participants in this group will be advised to obtain a PAI score between 50-99 over a week.
2447319|NCT03259646|Experimental|Universal Education|Train providers to integrate screening, universal education, trauma informed counseling, and mobile health (mHealth) technology through the myPlan app safety decision aid in collaboration with local IPV programs as well as the integration of documentation and quality improvement templates and measures into clinical settings.
2447325|NCT03259646|No Intervention|Standard Practice|Standard clinical practice
3189922|NCT00782262|Other|Group 3 (n=20)|BP <140/100, no diabetes mellitus, fasting glucose 5.5 - 6.9
3189923|NCT00782301|Active Comparator|Maraviroc|
3189924|NCT00782301|Active Comparator|Etravirine|
3189925|NCT00782314||1|patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month
3189926|NCT00782314||2|patients with SMART treatment with Symbicort Turbuhaler for at least 1 month
2447566|NCT03257592|Experimental|Patients with Schizophrenia Disorder|Patients with Schizophrenia Disorder will be imaged with [11C] DPA-713
2447571|NCT03257592|Experimental|Patients with Bipolar Disorder|Patients with Bipolar Disorder will be imaged with [11C] DPA-713
2447574|NCT03257592|Experimental|Control|Normal volunteers will be imaged with [11C] DPA-713
3189927|NCT00782327|Experimental|1|Losartan
3189928|NCT00782327|Placebo Comparator|2|Placebo
2447877|NCT03255408|Active Comparator|CBF Lowering and Normoxia Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
2447881|NCT03255408|Experimental|CBF Lowering and IH Sleep|Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
2447885|NCT03255408|Sham Comparator|Placebo and Normoxia Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.
2447887|NCT03255408|Placebo Comparator|Placebo and IH Sleep|Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.
2447949|NCT03254979|Experimental|Sequential engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a sequential engagement of professional categories, initiated in nursing, which finally involves the whole professional groups of the center (eg. physicians, etc), will be followed
2447952|NCT03254979|Active Comparator|Global engagement|Inter-professional collaborative practice directed by a local leader and an external facilitator to optimize the integration of a T2D primary prevention recommended clinical intervention. In this group, a global strategy of engagement with the participation of all professionals from the beginning, will be followed
2448060|NCT03254693|Active Comparator|1-step self-etch approach (SE)|According to the manufacturer's instructions.
2448065|NCT03254693|Active Comparator|selective enamel etching (SEE)|According to the manufacturer's instructions.
2448067|NCT03254693|Experimental|1-step self-etch for double time (SE2X)|According to the manufacturer's instructions, but for the double time (20 s) in the each application.
3189929|NCT00782353|Experimental|Cohort 1|Subjects randomized 8:2 (active:placebo) to receive ANA598 200 mg bid
3189930|NCT00782353|Experimental|Cohort 2|Subjects randomized 8:2 (active:placebo) to receive ANA598 400 mg bid
3189931|NCT00782353|Experimental|Cohort 3|Subjects randomized 8:2 (active:placebo) to receive ANA598 800 mg bid
3189932|NCT00782366||Genetic Testing Group|Those who will receive predictive genetic risk assessments
3189933|NCT00782366||Control|Those who will receive standard of care
2446845|NCT03262896||Patients with brain death|Ten patients with definite etiology, who were diagnosed with brain death because of Apnea test positive and / or cranial reflexes were not available and were male and female patients aged 18-72 years
2446866|NCT03262636|Other|Diagnostic value of Second Window ICG|"The primary study objective is to determine the diagnostic value of Second Window ICG (delayed, high dose IV administration of ICG) in the surgical resection of nervous system tumors.~The first objective is to determine safety/efficacy of high dose, delayed indocyanine green (second window ICG) during surgery of nervous system tumors."
2446868|NCT03262636|Other|Optimal timing and dose of SWG|"The second study objective is to calculate diagnostic test characteristics (sensitivity/specificity) of delayed, high dose indocyanine green (second window ICG) as a diagnostic aid during surgery of nervous system tumors.~The third study objective is to optimize timing and dose of second window Indocyanine Green during surgery of nervous system tumors, based on sensitivity/specificity."
2446937|NCT03262363|Experimental|Curcumin/NFE2L2 A>G|Patients in Experimental group 1 and 2 will receive 800 mg/day of curcumin (for which a bioavailability of about 90% has been demonstrated and greater than other curcuminoids, administered in two doses of 400 mg each (the presentation will be in capsules containing 400 mg of THC).
2446949|NCT03262363|Placebo Comparator|Placebo/NFE2L2 A>G|Patients in control group 1 and 2, the placebo intervention will consist of administering sucralose capsules (a substance lacking pharmacological action, with no active principle and a lower intake of glucose compared to sucrose). Patients will receive 300 mg/day of sucralose distributed in two doses of 150 mg each.
2447016|NCT03261778|Experimental|Acromion 2.0 Brace|
2447020|NCT03261778|Active Comparator|Mitella Sling|
2447079|NCT03261323|Active Comparator|Immediate breast reconstruction|The surgical schedule will follow unaltered standard protocol for immediate reconstruction right after the patient's mastectomy. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and at different time points during the follow up. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
2447084|NCT03261323|Experimental|Delayed breast reconstruction|Patients will start the reconstruction process after cancer therapy has been completed. Patients will be directed to smoking cessation and weight loss resources such as the Bariatric Institute to most directly facilitate risk reduction goals. Risk scores will be assessed at a plastic surgery appointment every 3 months. Reconstruction will proceed after the cancer treatment has been completed, according to individual patient evaluation. Patients will complete a quality of life questionnaire (Breast-Q) both pre-operatively and after the final reconstruction surgery. The patient's chart will be followed from the mastectomy surgery onwards until 1 year post-final reconstructive surgery for determining complications and hospital costs.
3189934|NCT00782405|Experimental|1|quetiapine
3189935|NCT00782405|Active Comparator|2|mirtazapine
2447330|NCT03259386||Transradial or Transhumeral amputees|High-count microelectrode arrays are implanted into the upper limb peripheral nerves of transradial or transhumeral amputees.
3189936|NCT00782431|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
3189937|NCT00782431|Active Comparator|2|Licensed egg-derived, trivalent seasonal influenza vaccine
3189938|NCT00782444|Active Comparator|Computer navigated knee replacement|Computer navigation system from Brainlab, vector vision, kolibri.
2447484|NCT03258476|Experimental|GXR and Mindfulness Skills|Guanfacine Extended Release (GXR) will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). GXR dosing will be flexible for the first 5 weeks of the study based upon patient response and tolerability to drug. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks.
2447487|NCT03258476|Active Comparator|Placebo and Mindfulness Skills|"Placebo will be started at 1 mg/day at Week 1 and tapered up by 1 mg per week to a maximum dose of 7 mg/day by week 7 (maximum of 6 weeks on drug). Placebo dosing will be flexible for the first 5 weeks of the study based upon patient response. Optimal dose will be defined as that necessary to achieve ≥ 30% reduction in symptoms and a CGI-Improvement Score ≤ 2. Upon re-evaluation at (T1) and entry into the psychotherapy protocol dosing will become fixed for the remainder of the study. Mindfulness Skills Therapy will occur for the next 10 weeks."
2447535|NCT03257982|Experimental|BCI-FES hand therapy|BCI-FES hand therapy sessions (set up and use of system)
2447549|NCT03257644|Experimental|Cohort 1|Ruxolitinib phosphate cream 0.5%.
2447551|NCT03257644|Experimental|Cohort 2|Ruxolitinib phosphate cream 1.5%.
2447553|NCT03257644|Experimental|Cohort 3|Ruxolitinib phosphate cream 0.75%.
2447556|NCT03257644|Experimental|Cohort 4|Ruxolitinib phosphate cream 1.5%.
2447560|NCT03257644|Experimental|Cohort 5|Ruxolitinib phosphate cream 0.75%.
2447563|NCT03257644|Experimental|Cohort 6|Ruxolitinib phosphate cream 1.5%.
2447660|NCT03256942|Experimental|Etermis 4® Treatment|"Etermis 4® will be applied according to the method of administration described in the current version of the Instructions for Use (IFU) until optimal cosmetic result is obtained at the discretion of the treating investigator.~Single injection session, injections into the lips."
2447666|NCT03256942|No Intervention|No Treatment|
2447696|NCT03256682|Experimental|Mobile Video Counseling|Utilize mobile imaging equipment, receive a total of 4 stress management consultations every 50 minutes at a time, once a week.
2447702|NCT03256682|Active Comparator|Offline Counseling|Receive a total of 4 stress management counseling, once a week for 50 minutes each session.
2447709|NCT03256682|No Intervention|Selfcare|Use stress management materials to manage yourself.
3189939|NCT00782444|Placebo Comparator|Conventional knee replacement|Conventional total knee replacement is performed with intramedullary guides in the traditional way.
2448042|NCT03254615|Experimental|Group 1|"Group I will receive I Prefer Plain Water only during the first grade"
3153243|NCT00270647|Experimental|Vitamin E|Active or placebo vitamin E
3189940|NCT00782457|Active Comparator|OPEN SURGERY|
3189941|NCT00782457|Experimental|LAPAROSCOPIC SURGERY|
3189942|NCT00782470||Group 1|
3189943|NCT00782470||Group 2|
3189944|NCT00782470||Group 3|
2446914|NCT03262077|Experimental|MB 1 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
2446917|NCT03262077|Experimental|MB 3 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
2446919|NCT03262077|Experimental|MB 5 min|Methylene blue 100 μM photosensitizer was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
2446922|NCT03262077|Experimental|MBS 1 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 1 min.
2446924|NCT03262077|Experimental|MBS 3 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 3 min.
2446926|NCT03262077|Experimental|MBS 5 min|Methylene blue photosensitizer 100 μM + soap was deposited in the periodontal pocket of one incisor and 1 min of pre-irradiation time was adopted to allow the drug to stain the bacterial biofilm. Then the laser emitting wavelength of 660 nm, with power of 100 mW, was applied to the mucosa during 5 min.
2446990|NCT03261869|Experimental|Cold application|Cold applied after extraction of third molar tooth.
2446997|NCT03261869|No Intervention|No Cold application|Cold application is not advised after extraction of third molar tooth
3189945|NCT00782522|Experimental|1|Eccentric training program
2447148|NCT03260764|Experimental|group A|
2447151|NCT03260764|Placebo Comparator|group B|
2447153|NCT03260764|Experimental|group C|
2447154|NCT03260764|Placebo Comparator|group D|
2447168|NCT03260439|Other|G1 (group BT)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Tramadol
2447170|NCT03260439|Other|G2 (group B or control)|The children were randomized to 2 groups (n = 53 in each group) to receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Placebo
2447312|NCT03259607|Experimental|Treatment A|Nicorette Extra Mint 2 mg Gum
2447324|NCT03259607|Active Comparator|Treatment B|Nicorette Mint 2 mg Gum
2447331|NCT03259607|Experimental|Treatment C|Nicorette Extra Mint 4 mg Gum
2447334|NCT03259607|Active Comparator|Treatment D|Nicorette Mint 4 mg Gum
2447403|NCT03258788||Non-Small Cell Lung Cancer|Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken.
2447449|NCT03258515|Experimental|Cohort 1|"Participants will receive orally single dose of study drugs in the sequence of ABC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447450|NCT03258515|Experimental|Cohort 2|"Participants will receive orally single dose of study drugs in the sequence of ACB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447451|NCT03258515|Experimental|Cohort 3|"Participants will receive orally single dose of study drugs in the sequence of BAC.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447452|NCT03258515|Experimental|Cohort 4|"Participants will receive orally single dose of study drugs in the sequence of BCA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447453|NCT03258515|Experimental|Cohort 5|"Participants will receive orally single dose of study drugs in the sequence of CAB.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447454|NCT03258515|Experimental|Cohort 6|"Participants will receive orally single dose of study drugs in the sequence of CBA.~A - AZD6094 600 mg (3X 200 mg tablet) B - Placebo C - Moxifloxacin 400 mg"
2447523|NCT03258164|Experimental|ASC|
2447524|NCT03258164|Active Comparator|Control|
2447544|NCT03257683||Selected group with cardiac ischemia|This selected study group will have a specific echocardiographic imaging protocol performed, which includes the known ischemic regions. All segments will be collected and analyzed as a pre-therapeutic baseline using specialized STE software to derive strain values. Following eight (8) weeks of ranolazine therapy, each subject will be re-interrogated with the same echocardiographic imaging protocol and have identical measurements of regional strain performed. Ranolazine will be added to the patients' usual medical therapy. Each patient will serve as their own control, from baseline to post therapeutic state.
2447583|NCT03257527|Experimental|ENHANCE group|The ENHANCE group is comprised of 12 weekly session to be completed in-person and delivered by trained group facilitators.
2447586|NCT03257527|Active Comparator|MBSR group|"The MBSR group will complete a self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook over a 12 week period."
2447618|NCT03257293|Active Comparator|Routine Cystoscopy|
2447624|NCT03257293|Experimental|Modified Cystoscopy|
2447651|NCT03257059|Experimental|Breakfast|Subject given standardized breakfast (glutinous rice) to test blood glucose response
2447655|NCT03257059|Experimental|No breakfast|Subject not given breakfast to test blood glucose response
3189946|NCT00782522|Active Comparator|2|Traditional training program
3189947|NCT00782535|Experimental|Treatment A|Single therapeutic dose of CHF 4226 pMDI
3189948|NCT00782535|Experimental|Treatment B|Single therapeutic dose of CHF 4226 pMDI
3189949|NCT00782535|Experimental|Treatment C|Single supratherapeutic dose of CHF 4226 pMDI
3189950|NCT00782535|Experimental|Treatment D|Single supratherapeutic dose of CHF 4226 pMDI
3189951|NCT00782535|Placebo Comparator|Treatment E|Single dose of placebo
3189952|NCT00782548|Active Comparator|1|Test product A (1 x 30 mg KADIAN)
3189953|NCT00782548|Active Comparator|2|Reference product B (1 x 30 mg Avinza)
2446971|NCT03262051||Patient with acute inflammation (SARS-CoV-2 infection)|patients with SARS-CoV-2 infection
2446987|NCT03261687|Experimental|Water Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
2446988|NCT03261687|Experimental|Land Exercise + advice|Each group undertook four, once weekly exercise sessions (including a warm up, cool down, relaxation, pelvic control and stability exercise). Both programmes focused on similar exercise and muscle groups, but due to the aquatic medium programmes were unable to be exactly matched.
2447071|NCT03261492|Experimental|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program and presently includes 12 lessons that can be delivered once or twice a week. The SAGE garden-based curriculum includes active games and discussion as well as activities that include watering the ECEC garden.
2447073|NCT03261492|Active Comparator|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest. The curriculum will include concepts and lessons for educating young children on fire, pedestrian, water, household, neighborhood and playground safety. The curriculum includes handouts, coloring sheets, comic books, games, and songs that can be implemented with minimal training and preparation.
2447147|NCT03260946||Palliative/Supportive care|Individuals with cancer receiving palliative or supportive care
2447186|NCT03260569|Active Comparator|Inhaled Nitric Oxide|Inhaled nitric oxide at 20 parts per million, administered once during first 36 hours following admission
2447190|NCT03260569|Placebo Comparator|Placebo|Nitrogen only, administered once during first 36 hours following admission
2447227|NCT03260140|Experimental|behavioral lifestyle intervention|The investigators will provide participants with the the behavioral lifestyle intervention
2447228|NCT03260140|No Intervention|usual care control|participant in this arm will continue with usual care
3189954|NCT00782561|Experimental|FG-3019|FG-3019 5 mg/kg
3189955|NCT00782587|Experimental|Arm 1|Single arm, open label, single dose, intravesical instillation of Chemophase (combination of rHuPH20 and mitomycin) for appropriate superficial bladder cancer patients within 6 hours of TURBT.
3189956|NCT00782600|Experimental|50 mg oral suspension|once daily for one day
2447377|NCT03258996|Experimental|Modified vestibular incision subperiosteal tunnel access|Test group: Coverage of Class III multiples gingival recessions with the application of Modified vestibular incision subperiosteal tunnel access technique and a connective tissue graft from the palate.
2447379|NCT03258996|Active Comparator|Coronally advanced flap|Control group: Coverage of Class III multiples gingival recessions with the application of Coronally advanced flap and a connective tissue graft from the palate.
2447503|NCT03258489|Active Comparator|Transcutaneous nervous electric stimulation (TENS)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after TENS. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2447504|NCT03258489|Active Comparator|Interferential electrical stimulation (IES)|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after Interferential electrical stimulation (IES). The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2447505|NCT03258489|Placebo Comparator|TENS and IES Placebo|Autonomic balance, blood pressure, and blood collection (catecholamines) will be evaluated before and after of the TENS and IES placebo. The autonomic balance will be evaluated by heart rate variability (HRV), systemic arterial pressure (SBP) will be evaluated by an Ambulatory Blood Pressure Monitor (ABPM) and catecholamines of kits.
2447592|NCT03257800|Active Comparator|ketamine-propofol group|"Ketamine (50mg/ml) at 0.5 mg.kg-1 was injected intravenously 1min prior 3 mgkg-1 of propofol and 1 min before LMA insertion in Ketamine-propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
2447593|NCT03257800|Placebo Comparator|propofol group|"0,9% saline solution ( Placebo ) at the same volume as ketamine (50mg/ml) was injected intravenously 1min prior propofol 3 mg.kg-1 and 1 min before LMA insertion in propofol group.~sevoflurane 6-7% was used on vaporizer setting with 50% nitrous oxide in oxgen prior intravenous anesthesia. The loss of eyelash reflex was considered as the desired end point for induction."
3189957|NCT00782600|Experimental|50 mg CR Type 1|once daily for one day
2447715|NCT03256617|Experimental|Provider training|
3189958|NCT00782600|Experimental|50 mg CR Type 2|once daily for one day
2447816|NCT03255694|Experimental|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for the high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
2447888|NCT03255317|Experimental|Within-participant micro-randomization|Intervention includes Reinforcers and Notifications through the app. At each available decision time, each participant is randomly assigned to either receive an engagement strategy or to not receive an engagement strategy.
2447963|NCT03255044|Active Comparator|Lipophilic statin|Atorvastatin 40 mg administered daily in addition to guideline directed therapy for heart failure.
2447969|NCT03255044|Active Comparator|Hydrophilic statin|Rosuvastatin 20 mg administered daily in addition to guideline directed therapy for heart failure.
2448076|NCT03254563||Obese with NAFLD|Patients who have NAFLD based upon ultrasound
2448077|NCT03254563||Obese without NAFLD|Patients who do not have NAFLD based upon ultrasound
2448273|NCT03253263|No Intervention|Standard Neonatal Care|Standard neonatal care alone will be provided.
3189959|NCT00782600|Experimental|50 mg SR Type 3|once daily for one day
2447025|NCT03261609||Extremely preterm (EPT)|"All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97.~Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function).~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study."
2447031|NCT03261609||Term or controls|"Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant.~Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion."
2447097|NCT03261271|Experimental|Weight Loss and Weight Maintenance|Participants will take part in a weight loss program for at least 4 weeks (and up to 16 weeks) before their prostatectomy, and a weight maintenance program for 6 months after their surgery.
2447102|NCT03261271|Active Comparator|Control|Participants will receive a standardized educational flyer about a healthy diet and exercise.
3153244|NCT00270647|Experimental|Vitamin C|Active or placebo vitamin C
3153245|NCT00270647|Experimental|Multivitamin|Active or placebo multivitamin
2447265|NCT03259841||Fasted patients for cholecyctectomy|The fasted patients for cholecyctectomy except exclusion criteria are included
2447298|NCT03259503|Experimental|Treatment (olaparib, high-dose chemotherapy, transplant)|Patients receive olaparib PO BID on days -11 to -3, vorinostat PO on days -10 to -3, gemcitabine IV over 4.5 hours on days -9 and -4, busulfan IV over 3 hours on day -9 to -6, melphalan IV over 30 minutes on days -4 and -3, and undergo peripheral blood stem cell transplant IV over 30-60 minutes on day 0. Patients with CD20+ tumors also receive rituximab IV over 3-6 hours on day -10.
2447410|NCT03258697|No Intervention|Patient-Controlled Analgesia|Patient had no local analgesic agent during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2447419|NCT03258697|Active Comparator|Peri-articular LevoBupivacaine|Patient had periarticular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2447427|NCT03258697|Experimental|Intra-articular LevoBupivacaine|Patient had intra-articular local analgesic agent, LevoBupivacaine Hydrochloride, during total joint replacement. Patient had baseline Patient-Controlled Analgesia pump.
2447469|NCT03258424|Active Comparator|PTI-428|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
2447474|NCT03258424|Placebo Comparator|Placebo|Subjects will receive once daily dosing of PTI-428 or placebo for 14 days.
2447512|NCT03258047|Experimental|CAR-T treatment|In this group, patients will be treated with autologous CAR-T, and the safety and efficacy will be evaluated
2447567|NCT03257839||Asymptomatic women with dense breast tissue|Healthy women presenting to enrollment sites for routine annual mammographic examinations, confirmed to have BI-RADS category c or d breast composition (density).
2447612|NCT03257319|Experimental|inhaled morphine + IV placebo|Arm A: inhaled titration of morphine chlorhydrate+ IV placebo
2447616|NCT03257319|Placebo Comparator|IV morphine +inhaled placebo|Arm B:IV titration of morphine chlorhydrate + inhaled placebo
2447703|NCT03256773||Notmal|No lung Disease
2447707|NCT03256773||Cystic Fibrosis|cystic fibrosis Lung Disease
2447711|NCT03256773||PCD|Primary Ciliary Dyskinesia
2447713|NCT03256773||COPD|Chronic Obstructive Lung Disease
2447748|NCT03256370||Infants with allergic diseases|allergic disease : atopic dermatitis or food allergy
2447750|NCT03256370||Healthy infants with atopic mothers|atopic mothers : mothers with asthma or allergic rhinitis or allergic dermatitis (diagnosed by doctors)
2447752|NCT03256370||Healthy infants with non-atopic mothers.|non-atopic mothers : mothers without history of asthma or allergic rhinitis or allergic dermatitis
2447769|NCT03256071|Experimental|Decitabine plus Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Decitabine plus Modified BuCy regimen consisted of decitabine,semustine,cytarabine, busulfan and cyclophosphamide.
2447772|NCT03256071|Active Comparator|Modified BUCY|For high-risk patients with Acute Myeloid Leukemia (AML) undergoing allo-HSCT, The Modified BuCy regimen consisted of semustine,cytarabine, busulfan and cyclophosphamide.
2447937|NCT03254888||Low Grade group|"• 50 tumor tissue samples from patients with Low Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy ,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using(quantitative real time polymerase chain reaction) ."
2447957|NCT03255122|Experimental|Immediate treatment|Individuals in this condition will immediately receive I-CALM treatment, which draws on videoconferencing to remotely deliver real time cognitive-behavioral therapy for early child anxiety to families in their home.
3153246|NCT00270647|Experimental|Beta-carotene|Active or placebo beta-carotene
3153247|NCT00270699|Experimental|1|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^5 PFU dose) into the deltoid region of either arm.
3153248|NCT00270699|Experimental|2|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
3153249|NCT00270699|Experimental|3|One subcutaneous vaccination with rDEN4delta30-200,201 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
3153250|NCT00270699|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3153251|NCT00270712||Retrospective Cohort|537 transplant recipient records used retrospectively
3153252|NCT00270712||Prospective Cohort|3137 transplant recipients enrolled prospectively
3153253|NCT00270738|Experimental|1|TrA training group
3153254|NCT00270738|Active Comparator|2|PFMT group
3153255|NCT00270738|Active Comparator|3|control group (PFM exercise at home)
3153256|NCT00270764||Full cohort|Adult ART patients at 3 treatment facilities in South Africa
3153257|NCT00270803|Placebo Comparator|A|Low nicotine cigarettes without THC
2447222|NCT03260257|Experimental|Schizophrenia patients|Thirty SCZ patients will receive neurofeedback to enhance gamma band response in an open-label, proof of concept study.
2447248|NCT03259919|Experimental|Metformin|Metformin 850 mg x 2 daily
2447256|NCT03259919|Placebo Comparator|placebo|Placebo 1 tablet x 2 daily
2447311|NCT03259568|Active Comparator|Active rTMS|
2447323|NCT03259568|Sham Comparator|Sham rTMS|
2447352|NCT03259230||Malignancy-Associated Hemophagocytic Lymphohistiocytosis|
2447353|NCT03259230||Absence of HLH in patients diagnosed with malignancy|
2447360|NCT03258944|Experimental|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session
2447393|NCT03258801||Pirfenidone|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are treated with Pirfenidone as bridging therapy.
2447395|NCT03258801||Control|Patients who are admitted to the lung transplantation department and fulfill the international criteria for idiopathic pulmonary fibrosis and are not treated with Pirfenidone.
3153258|NCT00270816|Experimental|interferon beta cyclical administration|Interferon ß-1b Treatment by Cyclical Administration
3153259|NCT00270816|Active Comparator|Interferon ß-1b Treatment|Interferon ß-1b Treatment
2447693|NCT03256747|Experimental|NMES group|NMES will be placed at the knee extensors, with maximal intensity tolerance evaluated by to induce visible contractions.
2447700|NCT03256747|Placebo Comparator|NMES-placebo group|NMES-placebo will be placed at the knee extensors, with minimal intensity to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
2447778|NCT03256357|Active Comparator|CIMT + AOT|"In a 2-week day camp model children receive constraint-induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Action observation training consists of 15 sessions of 1 hour. Children watch video sequences showing goal-directed actions and subsequently execute the observed actions with the affected upper limb."
2447786|NCT03256357|Placebo Comparator|CIMT + POT|"In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.~Placebo observation training consists of 15 sessions of 1 hour.This group performs the same actions after watching computer games without biological movements."
2447836|NCT03255772||Acute Chest pain|All patients admitted to the Clinical Decision Unit presenting to the Emergency Department (ED) with chest pain with risk factors suggesting a possible cardiac etiology.
2447906|NCT03255486|Experimental|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
2447977|NCT03254992|Experimental|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
2447985|NCT03254992|Experimental|ASD - Tangible task|Experimental group using Keyboard with more real activity.
2447991|NCT03254992|Active Comparator|TD - Abstract task|Control group using Kinect with more virtual activity.
2447994|NCT03254992|Active Comparator|TD - Tangible task|Control group using Keyboard with more real activity.
2448080|NCT03254485|Experimental|IW-1973 High Dose|
2448081|NCT03254485|Placebo Comparator|Placebo|Placebo to match experimental drug
2448180|NCT03253926|Experimental|Lorcaserin + Marijuana|
2448181|NCT03253926|Placebo Comparator|Placebo + Marijuana|
2448253|NCT03253354|Active Comparator|Pharyngeal stimulation|Pharyngeal stimulation given at 5Hz for 10 minutes
2448256|NCT03253354|Active Comparator|repetitive magnetic stimulation (1Hz)|repetitive transcranial magnetic stimulation at 1Hz applied for 600 pulses
2448262|NCT03253354|Active Comparator|repetitive magnetic stimulation (5Hz)|repetitive transcranial magnetic stimulation at 5Hz applied for 600 pulses
2448265|NCT03253354|Sham Comparator|Sham treatment|Sham repetitive transcranial magnetic stimulation using the coil tilt technique
2448294|NCT03252795|Experimental|Uterus transplantation|
2448312|NCT03252600|Experimental|Arm I (lenalidomide, dexamethasone, elotuzumab)|"Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on days 1, 8, 15, and 22 of courses 1 and 2 and days 1 and 15 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2448510|NCT03251469|Active Comparator|Group 1|intravenous tranexamic acid, 15mg/kg, preoperatively, single dose
3153260|NCT00270829|Experimental|1|Nesiritide given intrarenally
3153261|NCT00270829|No Intervention|2|No intrarenal drug administration
3153262|NCT00270907|Experimental|CT-2103 + Gemcitabine|CT-2103 135 mg/m^2 intravenous (IV) on Day 1. Gemcitabine 1000 mg/m^2 IV on Day 1 and 8.
3153263|NCT00270959|Experimental|1|Stepped collaborative care (combination of behavioral therapy and drug therapy)
3153264|NCT00270959|Active Comparator|2|Standard care provided to injured trauma survivors
3153265|NCT00270985|Active Comparator|nut free diet|ADA recommended diabetes diet without any nuts
2447092|NCT03261362|Active Comparator|Amino acid powder without BCAAs-reduced intake|Branched-chain amino acids reduced intake - amino acid powder lacking BCAAs 80 g oral Administration 1 week -
2447132|NCT03260920|Experimental|Low Dose|
2447140|NCT03260920|Experimental|Medium Dose|
2447144|NCT03260920|Experimental|High Dose|
2447210|NCT03260387||TPIAT|patients undergoing total pancreatectomy with islet autotransplant.
2447263|NCT03259932|Other|usual management|
2447264|NCT03259932|Experimental|physical training|
2447300|NCT03259516|Experimental|Nivo + FC|Nivolumab 1 mg/kg days 1,15 iv q28days Fludarabine 25 mg/m2 days 1-3 iv q28days Cyclophosphamide 300 mg/m2 days 1-3 iv q28days
2447307|NCT03259516|Experimental|Nivo + LDAC + ATRA|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days All-trans retinoic acid (ATRA) 45 mg/m2 po qd
2447314|NCT03259516|Experimental|Nivo + LDAC + Sildenafil|Nivolumab 1 mg/kg days 1,15 iv q28days Cytarabine 10 mg/m2 bid days 1-10 sc q28days Sildenafil 20 mg tid
2447322|NCT03259516|Experimental|Nivo + Melphalan|Nivolumab 1 mg/kg days 1,15 iv q28days Melphalan 2 mg qd days 1-10 q28days
2447326|NCT03259516|Experimental|Nivo + 5-aza|Nivolumab 1 mg/kg days 1,15 iv q28days 5-azacitidine 75 mg/m2 days 1-7 q28days
2447409|NCT03258866|Experimental|group A|In group A, Rituximab was given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22).
2447420|NCT03258866|Experimental|group B|In group B, Rituximab was given with a single dose of 375mg/m2
2447460|NCT03258359|Experimental|PACTN|Open label 3+3 dose escalation phase 1 trial; 200 to 1000 mL of immunized T cells infused at 0.3, 1, and 3 x 10e7 nucleated cells/kg body weight.
2447533|NCT03258177|Experimental|Virtual Visit Group|Participants assigned to the virtual visit group will receive a virtual visit as their postoperative follow-up visit.
2447536|NCT03258177|No Intervention|Standard In-person Group|Participants assigned to the standard in-person group will receive an in-person follow-up visit as their postoperative follow-up visit.
3189960|NCT00782613|Active Comparator|1|Two psoriatic plaques of similar surface area and severity will be identified for each subject. ALT-2074 will be applied topically twice daily to 1 of the 2 target plaques, and the placebo control to the other plaque for a period of 28 days in amounts sufficient to cover the entire surface area of the target plaque, extending to 1 cm outside of the plaque border.
3189961|NCT00782613|Placebo Comparator|2|Placebo
2447648|NCT03257124|Experimental|AZD9291 in BM or LM cohort in T790M positive|"Brain metastasis cohort (BM cohort)~Leptomeningeal metastasis cohort (LM cohort)"
2447721|NCT03256786||Active warming|preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid
2447726|NCT03256786||Control|no preoperative warming and room temperature intravenous fluid
2447776|NCT03256240|Active Comparator|side-to-side functional end anastomosis|side-to-side functional end anastomosis creation
2447781|NCT03256240|Active Comparator|Kono-S|antimesenteric functional side-to-side handsewn anastomosis, known as the Kono-S anastomosis
2447813|NCT03255707|Experimental|Group A|50 patients will receive the gold standard occlusion therapy
2447814|NCT03255707|Experimental|Group B|50 patients will receive dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
2448002|NCT03255057|Experimental|Hemolung plus SOC IMV|Low-flow ECCO2R with the Hemolung Respiratory Assist System as an alternative or adjunct to standard-of-care (SOC) invasive mechanical ventilation (IMV)
2448005|NCT03255057|Active Comparator|SOC IMV|Standard-of-care (SOC) invasive mechanical ventilation (IMV) alone
2448145|NCT03254043|Active Comparator|Treatment-as-Usual|Participants will routine methadone clinic care.
2448148|NCT03254043|Experimental|"Take-home Dosing using MedMinder Jon Electronic Pill Box"|Participants will receive 50% of their methadone dose in the morning in the clinic and 50% of their dose will be dispensed in an electronic pill box for participants to take at home later that day.
2448151|NCT03254043|Other|Choice Phase|"Participants will be allowed to select one final Treatment-As-Usual or the MedMinder Jon Electronic Pill Box for the final phase of the study."
2448201|NCT03253666||Nurses' Health Study|"See Detailed Description"
2448205|NCT03253666||Health Professionals Follow-Up Study|"See Detailed Description"
2448337|NCT03252938|Experimental|Solid tumors|Biweekly intra-tumoral injections of escalating doses (6 mg, 12 mg, 24 mg and 30 mg) of IMP321 as a monotherapy (intratumoral injections in parenchymatous organs (e.g. liver, spleen, adrenal gland, pancreas) are not allowed)
2448339|NCT03252938|Experimental|Solid tumors + peritoneal carcinomatosis|Biweekly intra-peritoneal, escalating doses of IMP321 (1 mg, 3 mg, 6 mg, 12 mg and 30 mg)
2448341|NCT03252938|Experimental|Solid tumors + chemotherapy|Subcutaneous (s.c.) injections with the optimal dose of IMP321 defined in the AIPAC trial for a maximum of 24 weeks
2448344|NCT03252938|Experimental|Solid tumors + Avelumab/IMP321 therapy|"Avelumab and IMP321 as follows:~800 mg avelumab every 2 weeks i.v. (for a maximum of 24 cycles [48 weeks])~6 mg (cohort 1) or 30 mg (cohort 2) IMP321 every 2 weeks s.c. (for a maximum of 12 cycles [24 weeks])"
2448416|NCT03252275|Experimental|Intervention|Standard HBB and ECEB training with peer learning
2448418|NCT03252275|No Intervention|Control|Standard HBB and ECEB training only
2448460|NCT03251911|Experimental|Ivacaftor (VX770)|Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
2448634|NCT03251209|Experimental|Group 1|Post-stroke participants receive the mental practice before the physical practice. The activities will be presented in a videotherapy way.
2448636|NCT03251209|Experimental|Group 2|Post-stroke participants receive the mental practice after the physical practice. The activities will be presented in a videotherapy way.
2448638|NCT03251209|Active Comparator|Group 3|Post-stroke participants receive only physical practice. The activities will be presented in a videotherapy way.
3189962|NCT00782652|Active Comparator|1|inhaled nitric oxide at 40 or 80ppm
3189963|NCT00782652|Placebo Comparator|2|inhaled nitrogen at either 40 or 80ppm
3189964|NCT00782665|Active Comparator|Group 1|Patients who have labored and subsequently delivered by cesarean section
3189965|NCT00782665|Placebo Comparator|2|Patients who electively select cesarean section
3189966|NCT00782691||Head-and-neck cancer patients.|Head-and-neck cancer patients eligible for therapeutic lymph node dissection of cervical nodes.
2447105|NCT03261141||control group sixty three children|"severity and character of dysphonia (APA using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
2447123|NCT03260842||Pancreatic Cysts|Patients with pancreatic cyst undergoing endoscopic ultrasound and/or surgery who will have bio-specimens collected
2447130|NCT03260842||High Risk Individuals|Patients with established family history and/or genetic mutations for Pancreas cancer who will have bio-specimens collected
2447197|NCT03260608|Experimental|Intervention|Telesupport: eight weekly phone calls of psychoeducation and support on the illness of their relatives. Patients will also receive printed materials on problematic behaviors about dementia.
2447198|NCT03260608|No Intervention|Control|No active intervention. Patients will only receive printed materials on problematic behaviors about dementia and no contact by the research team.
2447269|NCT03260127|Experimental|CEFT-CPT|Computerized executive function training plus Cognitive Processing Therapy for PTSD
2447272|NCT03260127|Active Comparator|WT-CPT|Word game training plus Cognitive Processing Therapy for PTSD
2447292|NCT03259412|Experimental|Fish Oil|Fish oil 5.1g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
2447293|NCT03259412|Placebo Comparator|Placebo|Olive Oil 6g/ day - Premium Omega-3, Norwegian Pure-3, Oslo, Norway
2447347|NCT03259295|Experimental|Skin tag removal initial|Removal of skin tags 1 cm or less using Digiclamp
2447348|NCT03259295|Experimental|Skin tag removal follow-up|Follow-up 2-3 months after skin tag removal.
2447365|NCT03259009||Patients with metastatic colorectal cancer|Rechallenge with an anti-EGFR monoclonal antibody in patients with metastatic colorectal cancer
2447396|NCT03258775|Active Comparator|250ml|
2447397|NCT03258775|Active Comparator|500ml|
2447459|NCT03258333||Stented bioprosthesis|Standard aortic valve replacement with stented bioprosthesis. Surgery is performed through median sternotomy, aortic and right or bicaval venous cannulation, normothermic perfusion, antegrade cardioplegia with use cardioplegic solution Custodiol. A transverse aortotomy was performed 1 to 2 cm above the right coronary artery. The aortic annulus was thoroughly débrided of calcium. Valve sizing was performed with standard manufacturers' sizers, with selection of the size that would comfortably fit within the aortic annulus. A noneverting suture technique was used in all patients with interrupted horizontal mattress 2-0 braided sutures placed around the aortic annulus, with the pledgets on the ventricular aspect.
2447461|NCT03258333||Ozaki procedure|Aortic valve reconstruction using autologus pericardium (Ozaki procedure). The autologous pericardium is harvested after routine median sternotomy. Harvested pericardium is then treated with a 0.6% glutaraldehyde solution for 10 min and then rinsed 3 times with sterilized saline each time for 6 min. After resection of the diseased aortic valve cusps, the distance between each commissure is measured using a self-developed sizing instrument. Glutaraldehyde-treated autologous pericardium is trimmed with a self-developed template corresponding to the measured value. The annular margin of the pericardial leaflet is then running-sutured to each annulus with 3-0 monofilament sutures. Commissural coaptation is secured with additional 4-0 monofilament sutures. The coaptation of the 3 cusps is then checked with negative pressure on the left ventricular vent.
2447518|NCT03258190|Experimental|Lime Powder Regimen|Participants were asked to take LPR twice a day for 6 months
2447520|NCT03258190|Placebo Comparator|Placebo|Participants were asked to take Placebo twice a day for 6 months
2447546|NCT03257670|Active Comparator|CO2RE Laser|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
2447550|NCT03257670|Active Comparator|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
2447691|NCT03256760|Experimental|Endotoxin|Endotoxin 0.8 ng/kg body weight
2447694|NCT03256760|Placebo Comparator|Placebo|Placebo
2447745|NCT03256331|Experimental|BEL-X-HG|3+3 dose escalation
3153266|NCT00270985|Experimental|almond group|calorie controlled diet with prescribed daily amount of almonds
3153267|NCT00271050|Experimental|1|
3153268|NCT00271115|Other|Moms w/preterm infants|Mothers of preterm infants who are admitted to the newborn intensive care unit.
2447831|NCT03255785|Experimental|G1 plus G3 with phaco|Cataract surgery via phacoemulsification followed by implantation of one iStent and one iStent Supra
2447981|NCT03255070|Experimental|ARX788 Phase 1a (Dose Escalation)|ARX788 will be administered every 3 weeks (Q3W) or every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will be enrolled into escalating dose levels during Dose Escalation period.
2447987|NCT03255070|Experimental|ARX788 Phase 1b (Dose Expansion)|ARX788 will be administered every 4 weeks (Q4W) via intravenous (IV) infusion. Patients will receive the maximum tolerated dose during the Dose Expansion period of the study.
2448073|NCT03254407|Other|Screening medical record|Screening medical record for possible IV-PO switch Possbile IV/PO switch communicated to prescriber by phone or e-note
2448101|NCT03254199|Experimental|Experimental|
2448105|NCT03254199|Placebo Comparator|Placebo Comparator|
2448170|NCT03253718||Healthy Volunteers|Healthy Volunteers between 18 and 68 years of age
2448516|NCT03251469|Placebo Comparator|Group 2|Intravenous normal saline, 100mg, preoperatively, single dose
3153269|NCT00271193|No Intervention|1|Control group, receives physician advice for weight loss and materials
3153270|NCT00271193|Active Comparator|2|Active treatment group, receives physician advice, materials, and brief weight loss counseling
3153271|NCT00271206|Active Comparator|Progesterone|200 mg to 400mg of progesterone
3153272|NCT00271206|Placebo Comparator|Sugar Pill|Will mirror active medication
3153273|NCT00271245|Experimental|1|200 µg selenium as selenate
3153274|NCT00271245|Experimental|2|400 µg selenium as selenate
3153275|NCT00271245|Experimental|3|200 µg selenium as selenomethionine
3153276|NCT00271245|Placebo Comparator|4|placebo
2447133|NCT03261050||R61 (Phase 1)|In R61, participants are randomly assigned to either the treatment group or the wait-list condition. Participants assigned to the treatment group receive Counter Attitudinal Therapy (CAT). Participants in the treatment group are compared with participants in the wait-list condition. Participants will complete target and outcome measures at pretest and posttest, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. Additionally, at pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Electrocardiography (ECG) data will be collected at pre and post.
2447139|NCT03261050||R33 (Phase 2)|In R33, participants from wait-list condition are assigned to receive either Counter Attitudinal Therapy or Interpersonal Therapy. Participants will complete target and outcome measures at pretest and posttest, including a 6-month follow-up, plus self-report intervention target and outcome measures at weeks 2, 4, and 6 during treatment for dosage analysis. At pre-test and post-test participants will complete two MRI brain scans where they will be exposed to pictures of women and different types of foods. This will assess participants' thin-ideal and binge food valuation. Additionally, thin-ideal valuation will be accessed outside the scanner at pre, post and follow-up. Similarly, binge food valuation will be accessed outside the scanner at pre, post, and follow-up and weeks 2, 4, and 6 during treatment for dose-response analysis. Electrocardiography (ECG) data will be collected at pre and post.
2447176|NCT03260465|Experimental|seleXys PC|seleXys PC cup combined with the optimys stem
2447178|NCT03260465|Active Comparator|RM|RM Pressfit vitamys cup combined with the optimys stem
3189967|NCT00782704||1|questionnair for Patients
3189968|NCT00782704||2|questionnaire for Nurses
2447357|NCT03259035|Experimental|chemotherapy (FOLFOX or CAPOX) followed by tumour excision|
2447455|NCT03258372|Experimental|Cohort 1|Mifepristone 300 MG, 1 tablet
2447456|NCT03258372|Experimental|Cohort 2|Mifepristone 1500 MG, 5 tablets
2447498|NCT03258216||peptic ulcer|patients who had upper GI symptoms and diagnosed as peptic ulcer by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
2447501|NCT03258216||healthy|patients who had no past history or systemic disease, diagnosed as UGI negative finding by panendoscopy, followed tongue images by Automatic Tongue Diagnosis System
2447564|NCT03257852|Experimental|ASP5094 Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
2447570|NCT03257852|Placebo Comparator|Placebo Group|To be intravenously administered ASP5094 in patients with rheumatoid arthritis (RA) treated with methotrexate.
2447631|NCT03257228||oral lichen planus and diabetes mellitus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
2447634|NCT03257228||oral lichen planus|Histopathologically confirmed samples of oral lichen planus underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking biopsy.
2447635|NCT03257228||healthy mucosa|Samples of healthy mucosa underwent immunohistochemical analysis of IGF1 and IGF2 expression. Blood glucose level was determined one day before taking mucosa samples.
2447670|NCT03256955|Other|Tof Watch SX and Tof Cuff|Patients undergoing surgery with intubation and receiving a single intubation dose of rocuronium (0.6 mg/kg) under propofol anesthesia will have monitoring of neuromuscular block with two monitors simultaneously.
2447706|NCT03256643|Experimental|Exercise|Exercise is the intervention. People be tested before the start of, and after the end of the eight (8) week exercise program.
2447710|NCT03256643|Experimental|Delayed Exercise|Delayed Exercise Group will have exercise as intervention. People be tested before the start of, and after the end of the eight (8) weeks then after exercise intervention.
2447712|NCT03256643|Experimental|Exercise and Enrichment|Exercise and Enrichment Group is the intervention. The group will be tested at the beginning and end of their exercise/enrichment program.
2447754|NCT03256279|Experimental|Heat-activated archwire|".014 NiTi heat-activated archwire in the lower arch during the first three months of the orthodonci treatment"
2447755|NCT03256279|Active Comparator|superelasticwire|"This arm are going to receive .014 NiTi Superelastic archwire in the lower arch during the first three months of the orthodonci treatment"
2447766|NCT03256045|Experimental|Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay|Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
2447856|NCT03255616|Experimental|Healthy subjects|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
2447857|NCT03255616|Experimental|Low back pain patients|Spine kinematics assessment during daily activities and brain responses to thoracolumbar mechanical and vibrotactile stimulation
2448045|NCT03254641||hypogondal men|men referred for hCG stimulation test
2448092|NCT03254290|Experimental|Experimental NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time.The new formulation has received the FDAs 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).
2448093|NCT03254290|Active Comparator|Formocresol|"Control group. This group will receive the gold standard formulation of a formocresol pulpotomy."
2448158|NCT03253939||Case group|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
2448160|NCT03253939||Control group|Cytoreductive surgery alone
2448680|NCT03250455||CTA+CTP|
3189969|NCT00782704||3|questionnaire for Physicians
3189970|NCT00782730||Bladder Scan Group|Patients who agree to enroll in the trial and allow their known bladder volumes and residual bladder volumes to be measured by actual volumes retrograde instilled, and also by bladder scanner ultrasound.
2447150|NCT03261076|Experimental|SERIOUS Intervention|All youth will be juveniles in a residential facility for post-adjudicated youth. They will be recruited into the study as they are being placed in the facility post-adjudication, to ensure that they meet criteria and will be in the facility long enough to complete the program. All qualified youth will be invited to participate in the SERIOUS intervention; once a group of youth are recruited to complete the multiple baseline design and interventionists are free (from running interventions with other participants) to work with the youth, an intervention cycle will begin.
3153277|NCT00271284|Experimental|I|
3153278|NCT00271284|Active Comparator|II|
3153279|NCT00271323|Experimental|1|Induction chemotherapy followed by concurrent chemoradiotherapy
3153280|NCT00271323|Active Comparator|2|Concurrent chemo-radiotherapy followed by consolidation chemotherapy
3153281|NCT00271336|Placebo Comparator|A|
3153282|NCT00271336|Experimental|B|
3153283|NCT00271362|Active Comparator|1|comparing 2 surgical procedures
3153284|NCT00271388|Experimental|Parameter Determination|Testing potential effects of GVS on the symptoms of neglect
2447244|NCT03259906|Active Comparator|Osteosynthesis using a posterior plate|
2447251|NCT03259906|Active Comparator|Osteosynthesis using an anterior plate|
2447457|NCT03258229|Experimental|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
2447458|NCT03258229|Placebo Comparator|Placebo|Placebo for 8 weeks
2447506|NCT03258151||wild genotype|Through next generation sequencing, distinguish wild genotype of docetaxel
2447508|NCT03258151||mutant genotype|Through next generation sequencing, distinguish mutant genotype of docetaxel
2447590|NCT03257787|Experimental|Test of a new adhesive strip|A new adhesive strip has been developed and will be tested in this investigation.
3153285|NCT00271401|Experimental|Angioplasty With Abciximab Plus Low-Dose Heparin|Participants will receive conventional angioplasty/atherectomy along with bolus abciximab 0.25 milligram per kilogram (mg/kg) of body weight followed by a 0.125 microgram per kilogram per minute (mcg/kg/minute) infusion for 12 hours plus 7 unit per kilogram per hour (U/kg/hr) continuous infusion of heparin.
3153286|NCT00271401|Experimental|Intracoronary Stent With Reo Pro Plus Low Dose Heparin|Participants will receive intracoronary stent along with receive bolus abciximab 0.25 mg/kg of body weight followed by a 0.125 mcg/kg/minute infusion for 12 hours plus 7 U/kg/hr continuous infusion of heparin (low dose).
2447719|NCT03256487|Experimental|Buprenorphine|"Patients will receive IV buprenorphine 0.3mg diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV buprenorphine 0.3mg."
2447723|NCT03256487|Active Comparator|Morphine|"Patients will receive IV morphine 0.1mg/kg (max dose 8mg) diluted to a volume of 10mL with NS in a plastic syringe administered over 3-5 minutes. At 20 minutes, the patient will be asked would you like more pain medication? If he/she answers yes, then he/she will receive a second dose of IV morphine 0.1mg/kg (max dose 8mg)."
2447791|NCT03256188|Experimental|Active classroom|Twenty elementary school teachers implemented 10, 3-minute moderate-to-vigorous physical activity breaks (50-75% of heart rate maximum), 5 days per week in their classrooms over a 16-week period.
2447817|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - anodal|Transcranial direct current stimulation - anodal (positive) 1.5 millamps for 15 minutes
2447818|NCT03255837|Experimental|Transcranial direct current stimulation (tDCS) - cathodal|Transcranial direct current stimulation - cathodal (negative) 1.5 millamps for 15 minutes
2447822|NCT03255837|Sham Comparator|Transcranial direct current stimulation (tDCS) - sham|Transcranial direct current stimulation - sham session 15 minutes
2447892|NCT03255434|Active Comparator|Folfox 4|Standard FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin 85mg/m²
2447896|NCT03255434|Experimental|Folfox 4 LBM|Adapted FOLFOX4: Oxaliplatin and simplified LV5FU2 Dose of oxaliplatin allocated according to lean body mass (LBM)
2447962|NCT03255122|Other|Waitlist|Individuals in Waitlist will participate in an initial waitlist condition, and then after post-waitlist assessment will be offered the I-CALM intervention. Accordingly families in this condition receive Delayed I-CALM.
3153287|NCT00271401|Placebo Comparator|Intracoronary Stent With Placebo Plus Standard Dose Heparin|Participants will receive intracoronary stent along with bolus placebo followed by placebo infusion for 12 hours plus 10 U/kg/hr continuous infusion of heparin (standard dose).
3153288|NCT00271440|Experimental|CHX 1.0%|1.0% CHX wiping
3153289|NCT00271440|Experimental|CHX 0.5%|0.5% Chlorhexidine
3153290|NCT00271440|Experimental|CHX 0.25%|chlorhexidine cleansing with pre-soaked pre-sealed wipe
3153291|NCT00271492|Active Comparator|I|Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
3153292|NCT00271492|Placebo Comparator|2|placebo group to be compared to the actual medication
3153293|NCT00271518|Experimental|LB03002, sustained release human hGH|LB03002
3153294|NCT00271531||1|150 subjects greater than 48 weeks post-conception and less than 18 years of age who are mechanically ventilated and have presumed bacterial pulmonary infection.
3153295|NCT00271622||Healthy volunteers|Healthy Volunteers
3153296|NCT00271622||individuals with risk for psychiatric disorders or neurodevelo|individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorders.
2447247|NCT03260049||3|there was RD at the first visit. The group 3 patients were treated with systemic antiviral medications and PPV plus silicone oil tamponade and intravitreal injection
2447320|NCT03259685|Active Comparator|Regular beverages|Sugar sweetened soft drinks
2447327|NCT03259685|Experimental|Diet beverages|Soft drinks sweetened with artificial non-nutritive sweeteners (i.e. aspartame, acesulfame-K)
2447332|NCT03259685|Experimental|Stevia beverages|Soft drinks sweetened with natural non-nutritive sweeteners (i.e. steviol glycosides)
2447389|NCT03258840|Placebo Comparator|EPA placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 2 times/day, for 8 weeks
2447390|NCT03258840|Active Comparator|EPA supplement|EPA supplement softgel (containing 2 g EPA per day), 2 times/day, for 8 weeks.
2447447|NCT03258528|Active Comparator|right lateral position group|Neonates kept in the right lateral position for 6 hours with head tilted 30 degree upward with rolled towel supports the infant back at 90 degree angle on the bed.
2447448|NCT03258528|Active Comparator|supine position group|"Neonates kept in supine position for 6 hours with head tilted 30 degrees upward.~Infants were fed while in their positions via feeding tube."
2447507|NCT03258242|Experimental|Experimental: Keluo Xin Capsule|
2447509|NCT03258242|Placebo Comparator|Placebo Comparator: Placebo|
2447573|NCT03257826|Experimental|surgery|Percutaneous Kirschner wire
2447636|NCT03257215|Active Comparator|Stoss vitamin D|Stoss vitamin D at Day 1 and daily placebo for 90 days (Day 1 to 90)
2447637|NCT03257215|Active Comparator|Daily vitamin D|Stoss placebo at Day 1 and daily vitamin D for 90 days (Day 1 to 90)
2447638|NCT03257215|Placebo Comparator|Placebo|Stoss placebo at Day 1 and daily placebo for 90 days (Day 1 to 90)
2447701|NCT03256812|Experimental|ICT-based ECG monitoring group|Continuous monitoring with ICT-based ECG monitoring will begin from the time of participation in the trial in the ICT-based monitoring group. Depending on the lifestyle pattern of the patient, the specific time will be set to allow 30 min of monitoring per day, even if there are no symptoms. If symptoms do appear, additional monitoring will be performed for at least 10 more minutes. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group.
2447708|NCT03256812|Active Comparator|Holter monitoring group|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in the Holter monitoring group
2447782|NCT03256318||Children in Sports and Rec|Children with disabilities who enter the study between ages 5 and 10 who are participating in a Sports and Recreation Program. They will receive no intervention, only surveys.
2447788|NCT03256318||Comparison Children|Children with disabilities who enter the study between ages 5 and 10 and end participation in Sports and Recreation Program at a later date. They will receive no intervention, only surveys.
3189971|NCT00782743||1|patients with required new anticoagulation with phenprocoumon 1/2 of them with a GFR< 60 ml/min and >15 ml/min
3189972|NCT00782743||2|patients with required therapy with ASS, 1/2 of them with a GFR <60 ml/min and >15 ml/min
3189973|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 4mg|inserted daily and replaced every 4 weeks
3189974|NCT00782769|Experimental|Oxybutinyn Vaginal Ring 6mg|inserted daily and replaced every 4 weeks
3189975|NCT00782808||1 HIV DNA will be stratified by high|
2447966|NCT03254771|No Intervention|Control group|In the control group, the usual explanation about the disease and the possibilities of treatment will be followed
2448046|NCT03254615|Experimental|Group 2|"Group II will receive I Prefer Plain Water during first and second grades"
2448685|NCT03250455||CTA only|
3189976|NCT00782808||2 HIV DNA will be stratified by low|
3189977|NCT00782847|Active Comparator|with DiaNe program|study subjects which participated in the DiaNe consultation and support program
3189978|NCT00782847|No Intervention|without DiaNe program|study subjects which received standard care by diabetologist and/or nephrologist
3189979|NCT00782860||unsuccessful termination|unsuccessful termination of early pregnancy failure with Misoprostol
3189980|NCT00782860||successful termination|successful termination of early pregnancy failure with Misoprostol
3189981|NCT00782873||obese subjects|BMI > 35
3189982|NCT00782899||1|Schizophrenic patients with a acute episode treated in outpatients clinics
3189983|NCT00782925|Experimental|1|"Study intervention:~A face/profile X-ray of their entire spine at baseline~Educational program~Exercise program~Self-led exercises~A follow-up at 12 and 24 months with their occupational therapist.~A follow-up at 18 months with a physical therapist.~Workers received also at the end of the educational program written standardized information about back pain (the back book, an information booklet) 1.~Coudeyre E., Tubach F., Rannou F. & all, Effect of simple information booklet on pain persistance after an acute episode of low back pain: a non- randomised trial in a primary care setting. PLoS ONE. 2007 ; 2 : e706"
3189984|NCT00782925|No Intervention|2|"Control intervention :~No intervention~A face/profile X-ray of their entire spine at baseline~A follow-up at 12 and 24 months with their occupational therapist,~A follow-up at 18 months with a physical therapist."
3189985|NCT00782938||low SAA|
3189986|NCT00782938||high SAA|
3189987|NCT00782951|Experimental|Org 28611|
3189988|NCT00782951|Active Comparator|morphine sulfate|
3189989|NCT00782951|Placebo Comparator|Placebo|
3189990|NCT00782964||1|Outpatient with major depressive disorder, who has a change in pharmacological therapeutical plan after an incomplete response or intolerance to a treatment with an adequate dosage of an antidepressant (SSRI/NSRI) (20-40 mg fluoxetine, 75-225 mg venlafaxine or equivalent) for at least 6 weeks.
3189991|NCT00782977|Sham Comparator|1|Nasal cannulae with no oxygen flow
3189992|NCT00782977|Active Comparator|2|Nasal cannulae with oxygen flow at 5 L/minute
3189993|NCT00782977|Active Comparator|3|Nasal cannulae with oxygen flow at 10 L/minute
3189994|NCT00782990|Active Comparator|tvt group|Surgical treatment for incontinence: TVT
3189995|NCT00782990|Active Comparator|Burch group|Surgical treatment for incontinence: Colposuspension
3189996|NCT00783003|Experimental|Long acting muscarinic receptor antagonist (LAMA)|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
3208926|NCT00979433|Experimental|Bubble CPAP|All neonates randomised to bubble CPAP will be put on Bubble CPAP following initial extubation in first week of life.
2447261|NCT03259971|Placebo Comparator|Placebo (for Rett syndrome)|The placebo will be dispensed to equal the volume of 1 tablet of Probiotic PS128, which is taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett syndrome
2447262|NCT03259971|Active Comparator|PS128 (Rett syndrome)|The Probiotic group will take Probiotic-Lactobacillus plantarum PS128, which contain 300mg (3x10^10 CFU) Lactobacillus plantarum PS128 and 100mg of Microcrystalline Cellulose in each tablet. It will be taken orally in 2 divided doses, 12 hours apart during the study period of 4 months for Rett Syndrome.
2447297|NCT03259529|Experimental|Gemcitabine 500|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 500 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2447302|NCT03259529|Experimental|Gemcitabine 700|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 700 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2447310|NCT03259529|Experimental|Gemcitabine 1000|"Days 1,2 Bendamustine Hydrochloride 70 mg/m2/day iv; Days 1,8,15 Gemcitabine 1000 mg/m2/day iv; Days 1,15 Nivolumab 1mg/kg/day iv; Day 0 Rituximab 375mg/kg/day iv.~Duration of cycle 28 days"
2447381|NCT03258983||The Diet, Cancer and Health cohort|
2447421|NCT03258671|Experimental|Mutation+ concurrent|IMRT concurrent with EGFR-TKI on paticipants with known sensitive EGFR mutations.
2447428|NCT03258671|Experimental|Mutation+ concomitant|IMRT concomitant with EGFR-TKI on paticipants with known sensitive EGFR mutations.
2447463|NCT03258385|Active Comparator|Vitamin B12-fortified UHT milk|Supplementation group (N=74) that will receive vitamin B12 fortified UHT milk daily
2447465|NCT03258385|Placebo Comparator|Plain UHT milk|Placebo group (N=74) that will receive plain UHT milk daily
2447519|NCT03258112|Other|catheter ablation|all patients indicated for catheter ablation of RVOT or LVOT ventricular arrhythmia are included in one arm for electrophysiological diagnosis of the origin of arrhythmia then for radiofrequency catheter ablation
2447600|NCT03257748|Experimental|LED group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
2447601|NCT03257748|Experimental|Laser group|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
2447684|NCT03256877||All participants|Patients with haematuria.
2447725|NCT03256591|Experimental|HBB plus simulation training|Participants receive training from facilitators for HBB training with simulation skills
2447729|NCT03256591|No Intervention|Control|Participants receive training from facilitators for HBB training without simulation skills
2447785|NCT03256227|Experimental|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
2447789|NCT03256227|Active Comparator|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
3153297|NCT00271635|Experimental|1|Ascorbic acid
3153298|NCT00271635|Placebo Comparator|2|Placebo
2447869|NCT03255395|Experimental|Magnetic resonance-guided focused ultrasound (MRgFUS)|Ten amputees will recieve magnetic resonance-guided focused ultrasound (MRgFUS) treatment aimed to ablate neromas, which are beleived to cuase phantom / residual limb pain
2448025|NCT03254550|No Intervention|Control phase|This is the provision of PrEP without the use of the PrEP Promotion Package. PrEP promotion in the control phase consists of each clinic displaying posters that advertise PrEP, pamphlets, and palm cards that patients can take home from the clinic.
2448027|NCT03254550|Experimental|Intervention phase|This is the provision of PrEP as in the control phase plus the addition of five PrEP promotion components, which constitute the PrEP Promotion Package (PPP). These five additions are: 1) a PrEP promotion video to be played in the waiting room, 2) T-shirts advertising PrEP to be worn by healthcare workers, iii) a flipchart to support healthcare workers' PrEP counseling, iv) an informational booklet for clients to take home, and v) self-risk assessment forms to be displayed in the waiting room.
2448126|NCT03254329||Bangladesh|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2448131|NCT03254329||Brazil|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2448133|NCT03254329||Denmark|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2448134|NCT03254329||The Gambia|Assessment of human milk nutrient composition. Approximately 500 women and their infants recruited, 250 dyads completing study
2448202|NCT03253523|No Intervention|Continued maximal medical management|
2448206|NCT03253523|Experimental|Surgical occipital nerve neurolysis|
2448266|NCT03253263|Experimental|SHP607 250 mcg/kg/24 hours|Participants will receive continuous intravenous (IV) infusion of SHP607 250 micrograms per kilogram per 24 hours (mcg/kg/24 hours) from birth up to postmenstrual age (PMA) 29 weeks +6 days.
2448270|NCT03253263|Experimental|SHP607 400 mcg/kg/24 hours|Participants will receive continuous IV infusion of SHP607 400 mcg/kg/24 hours through from birth up to PMA 29 weeks +6 days.
3153299|NCT00271700|No Intervention|Usual Care|admission to medical team floor to usual care
3153300|NCT00271700|Experimental|Intervention|consists of usual care as well as an admission order set built into BWH's proprietary computer provider order entry (CPOE) system
3153301|NCT00271713|Active Comparator|ibandronate|150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily
2447273|NCT03259854|Experimental|non invasive ventilation study group|patients will receive non invasive ventilation after successful weaning from invasive ventilation and will be monitored regarding oxygen saturation, blood pressure, respiratory rate, heart rate, arterial blood gases
2447329|NCT03259438|Experimental|Qigong|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include guided instruction in the theory and background of qigong and healing. Practice will include gentle stretching and guided qigong movement as well as seated and lying down meditations. Participants will be asked to complete about 30 minutes a day of home assignments.
2447333|NCT03259438|Active Comparator|Healthy Living (CHIP + Pre-Train)|This course will meet twice weekly for 2 hours and 15 minutes per class for ten weeks. Topics will include plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) as well as core-stretching, strengthening, and light aerobic movements through a Pre-Train exercise program. Participants will be asked to complete about 30 minutes a day of home assignments.
2447414|NCT03258879|Experimental|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
2447422|NCT03258879|Active Comparator|Dural puncture epidural|Dural puncture performed with a spinal needle, but no medication will be injected intrathecally.
2447493|NCT03258437|Experimental|DA-9401|capsules (4cap/d, 2.16 g/d) for 12 weeks.
2447494|NCT03258437|Placebo Comparator|Placebo|Placebo for 12 weeks.
3153302|NCT00271713|Placebo Comparator|2|placebo monthly plus 500mg calcium and 800 UI vitamin D daily
3153303|NCT00271752|Experimental|PCT guided|Procalcitonin guided treatment of infections in the ICU. Intervention: Intensification of antibiotics, surgery, microbiologic testing and diagnostic imaging, when Procalcitonin levels are increasing
2447764|NCT03256149|Experimental|Treatment group|Dexamethasone, 4 mg IV given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
2447770|NCT03256149|Placebo Comparator|Placebo group|Saline given at 8 hours interval, first dose received at the time of surgery (induction), 3 doses total
2447823|NCT03255876|Experimental|Enriched pomegranate juice|Participants will consume 200 ml of pure pomegranate juice enriched with grape seed and apple peel extracts concomitantly with 109 g of white bread
2447830|NCT03255876|Placebo Comparator|Placebo beverage|Participants will consume 200 ml of placebo drink concomitantly with 109 g of white bread
2447878|NCT03255369||Child exposed Zika virus proved|child born to mothers with proved zika virus in pregnancy by RT-PCR
2447882|NCT03255369||Child exposed to zika virus suspected|Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
2447886|NCT03255369||Normal Child|Normal child from mothers without Zika (IgG and IgM negative)
2448024|NCT03255018|Experimental|1|Subjects with gray-zone lymphoma (GZL) or extranodal DLBCL relapsed from or refractory to prior therapy with an anthracycline-based regimen
2448082|NCT03254394|Placebo Comparator|Placebo + FOLFOX|"Intravenous infusion of D5W solution over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
2448083|NCT03254394|Active Comparator|Lidocaine + FOLFOX|"Intravenous infusion of lidocaine hydrochloride solution in D5W over a 130 minute period.~FOLFOX:~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
2448147|NCT03254017|Experimental|Experimental Deep Brain Stimulation|Device：Suzhou Sceneray® DBS system
2448288|NCT03253029|Experimental|Treatment|(arm 1) consume five scoops total per day of Pure Encapsulations Branched Chain Amino Acid powder on an outpatient basis (take 2 scoops both in the morning and afternoon and 1 scoop in the evening)
2448290|NCT03253029|Placebo Comparator|Control|(arm 2): control group (no BCAAs provided)
2448351|NCT03252665|Experimental|alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2448352|NCT03252665|Experimental|nicorandil|nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2448353|NCT03252665|Placebo Comparator|nitroglycerin|nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
2448397|NCT03252262|Active Comparator|Jack Satter House|Residents of Jack Satter House who participated in the Vitalize 360 Program.
2448404|NCT03252262|Active Comparator|Center Communities of Brookline|Residents of Center Communities of Brookline who participated in the Vitalize 360 Program.
2448413|NCT03252262|Active Comparator|Simon C. Fireman|Residents of Simon C. Fireman who participated in the Vitalize 360 Program
2448459|NCT03251924|Experimental|BMS-986226|administered intravenously
2448461|NCT03251924|Experimental|BMS-986226 and Nivolumab|administered intravenously
2448466|NCT03251924|Experimental|BMS-986226 and Ipilimumab|administered intravenously
2448498|NCT03251261||Specimen collection|
2448595|NCT03251222|Experimental|Dexmedetomidine group|Patients who will receive Dexmedetomidine intranasal prior the sedation with remifentanil
2448600|NCT03251222|Placebo Comparator|Placebo Concentrate|Patients will recive 0.9% NaCl
2448692|NCT03250650|Active Comparator|Group 1: TTNS|Intervention for Group 1: transcutaneous tibial nerve electric stimulation (TTNS), using a Device Dualpex 961(Quark medical), with 2 silicone electrode in the tibial nerve path, being one on the lower border of the medial malleolus and another one, 10cm above. Once a week for 12 weeks. The parameters used on device were, 200 microseconds for pulse time and 10Hz for Frequency, during 30 minutes.
2448695|NCT03250650|Experimental|Group 2: ES + TTNS|Intervention for Group 2: transvaginal electric stimulation plus transcutaneous tibial nerve electric stimulation (ES + TTNS), using a Device Dualpex 961(Quark medical), with transvaginal electrode, located inside the vagina. Once a week for 12 weeks. The parameters used on device were 1milisecond for pulse time and 10Hz for Frequency, during 20 minutes. After transvaginal stimulation, the tibial stimulation will be applied like described on Group 1.
2448725|NCT03250065|Experimental|ETT Study Group|The Sensing ET Tube study Group
3153304|NCT00271752|Sham Comparator|Control|"These patients receive Standard of Care which is the recommended treatment in the given ICU"
3153305|NCT00271791|Experimental|1|Prednisone
2447276|NCT03259867|Experimental|Hepatocellular carcinoma|"PD-1 inhibitor (either Opdivo 240 mg Q2W IV or Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2447277|NCT03259867|Experimental|Colorectal cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2447278|NCT03259867|Experimental|Gastric cancer|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2447279|NCT03259867|Experimental|NSCLC|"PD-1 inhibitor (Keytruda 200 mg Q3W IV) starts at day 1, and continues until progression.~TATE treatment starts at day 8 for debulking up to 4 cycles. If escape lesion appears, two more TATE treatments can be given. Tirapazamine dose at 35 mg flat dose given before embolization."
2447649|NCT03257072|Experimental|A: 50 Necator americanus L3 larvae|Mock infections with water at week 0 and 2, infection with 50 Necator americanus L3 larvae at week 4
2447650|NCT03257072|Experimental|B: 100 Necator americanus L3 larvae|Mock infections with water at week 0, infection with 50 Necator americanus L3 larvae at week 2 and 4
2447653|NCT03257072|Experimental|C: 150 Necator americanus L3 larvae|Infection with 50 Necator americanus L3 larvae at week 0, 2 and 4
3153306|NCT00271791|Placebo Comparator|2|Placebo
2447807|NCT03256019|Active Comparator|DL user|Experienced emergency physicians who primarily used the direct laryngoscopy (DL) for endotracheal intubation during cardiopulmonary resuscitation.
2447808|NCT03256019|Active Comparator|VL user|Experienced emergency physicians who primarily used the videolaryngoscopy (VL) for endotracheal intubation during cardiopulmonary resuscitation.
2447845|NCT03255720||20 patients with Alzheimer disease|"The study will be performed at the Radiodiagnosis department of assiut university hospital.~Selection of 20 patients clinically and laboratory diagnosed as Alzheimer disease and another 20 people matched healthy controls who have no complaints of cognitive problems."
2447847|NCT03255720||20 people matched healthy controls|health control people who have no complaints of cognitive problems.
2447899|NCT03255499|Experimental|Exercise and cognitive training|This intervention includes a combination of high-intensity exercise (10min/day) and computerized cognitive training (20min/day). The software for the latter has been developed by our group, and includes 8 mini-games targeting different cognitive abilities. Both are developed for the MovinCog intervention. The intervention is personalized, based on individual performance.
2447904|NCT03255499|Experimental|Exercise|High-intensity training regimen, 10min/day. Developed for the MovinCog intervention.
2447908|NCT03255499|Experimental|Cognitive training|Computerized cognitive training, 20min/day. Developed for the MovinCog intervention.
2447911|NCT03255499|Active Comparator|Games|The active control is composed of a blend of board games, computer games, and trivia quizzes. Specific content is personalized based on individual preferences, so as to reflect the flexibility of the experimental arms.
2447945|NCT03254875|Experimental|Intervention|Individually tailored nurse navigation
2447950|NCT03254875|No Intervention|Control|Usual care
2448054|NCT03254706|Active Comparator|Peak etch-and-rinse (P1)|Application Mode - According to the manufacturer's instructions.
2448059|NCT03254706|Experimental|Peak applied for double time(P2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
2448063|NCT03254706|Active Comparator|Single Link etch-and-rinse (SL1)|Application Mode - According to the manufacturer's instructions.
2448064|NCT03254706|Experimental|Single Link double time (SL2X)|Application Mode - According to the manufacturer's instructions, but for the double time.
2448084|NCT03254160|Experimental|DNS-3379 (0.5mg)|
2448085|NCT03254160|Experimental|DNS-3379 (2.5mg)|
2448086|NCT03254160|Placebo Comparator|Placebo|
2448173|NCT03253952||Traumatic Spinal Cord Injury|Observational study - monitoring immune response and heart rate variability
3153307|NCT00271908||Cohort #1|Venue-tracking survey subjects recruited annually for 4 years: N= 320-640 (10-20 members of the population of focus per site, per year). The purpose of this cohort is to identify and track venues at which the population of focus congregates.
3153308|NCT00271908||Cohort #2|HIV-related risk survey subjects recruited annually for 4 years: N = 1280-2880 (20-30 members of the population of focus per 2-3 congregation venues, per site, per year). These subjects will complete a survey designed to assess HIV-related risk. In the fourth and final year only, HIV Antibody [Ab] assays will also be conducted with survey participants to assess HIV serostatus. The survey and HIVAb assay data will be used to evaluate the intervention within and across sites.
3153309|NCT00271960|Active Comparator|Individual Care|Participants will receive usual care for their prenatal visits
3153310|NCT00271960|Active Comparator|CenteringPregnancy|Participants will receive CenteringPregnancy(R) group prenatal care
3153311|NCT00271960|Experimental|CenteringPregnancyPlus|Participants will receive CenteringPregancy with an HIV/STD prevention component
2447359|NCT03259256|Experimental|Allogeneic transplantation of human islet|Each subject may receive 1-3 transplantations of allogeneic human islets we will inject the least dose of 3,000 IEQ/kg body weight of the recipient. Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml.
2447400|NCT03258827|Experimental|Exercise with a towel|There are 30 old adults in this group who receives exercise program with a towel.
2447402|NCT03258827|Placebo Comparator|Home-based exercise|There are 30 old adults in this group who is suggested a home-based program focuses on walking activity at fast speed.
2447468|NCT03258502|Experimental|RV521|RV521 drug substance in capsule for oral administration
2447471|NCT03258502|Placebo Comparator|Placebo|Micro-crystalline cellulose in capsule for oral administration
2447522|NCT03258125||severe EOPE|EOPE: PE starting before 34 weeks gestation Severe PE (Blood pressure more than 160/ 110 mm Hg on 2 occasions 2 hours to 2 weeks apart and proteinuria ( 24-hour urine protein >2000 mg/d).
2447525|NCT03258125||control|Healthy Pregnant women who come for termination of pregnancy by vaginal delivery or CS between 28-34 weeks gestational age.
2447557|NCT03257709|Active Comparator|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
2447561|NCT03257709|Active Comparator|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
2447681|NCT03256903|Experimental|Methoxyflurane|Patients will be supplied with up to two inhalers containing 3 mL methoxyflurane. A member of the research team will train the patient to self-administer methoxyflurane
2447683|NCT03256903|Active Comparator|Standard of Care (SoC)|Patients will be treated following standard of care (SoC) of the hospital, for emergency relief of trauma and associated pain. Any kind of analgesia administered by any route will be valid. Only administration of one analgesic (or fixed combinations) at baseline will considered SoC. Other required analgesics will be considered rescue medication.
3189997|NCT00783003|Experimental|Long acting Beta 2 agonist (LABA)|Inhaled Long Acting Beta 2 agonist (LABA) which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
3208927|NCT00979433|Other|Conventional CPAP|All neonates randomly allocated to conventional/ventilator derived CPAP.
3208928|NCT00979446|Experimental|Guided|
2447844|NCT03255967|Experimental|QI program care|DSM-H performance improvement program Patients in the performance improvement group will receive care from a care team who has received the DSM-H performance improvement program
2447846|NCT03255967|Active Comparator|Control|provide usual carereceive usual care from a care team who has not received the performance improvement program
2447891|NCT03255343|Experimental|IMDENDRIM|
2447979|NCT03255005|Active Comparator|Treatment group|Endoscopic sleeve gastroplasty (Endomina) at J0 with multidisciplinary follow-up for 1 year
2447986|NCT03255005|Active Comparator|Controled group|Diet for 6 months then Endoscopic sleeve gastroplasty (Endomina) with multidisciplinary follow-up for 1 year
2448029|NCT03254511|Experimental|enoxaparin|In the enoxaparin group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) with Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable (40 mg daily).
2448031|NCT03254511|Active Comparator|control|In the control group, patients are going to receive radiotherapy (median treatment dose will be 50.40 Gy in 25 to 32 fractions) with weekly concurrent chemotherapeutic combinations (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]) alone.
2448120|NCT03254264|Experimental|ESDM-12|an experimental group of 60 children receiving 12 hours a week of Early Start Denver Model (ESDM) intervention delivered by trained therapists during 2 years ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
2448124|NCT03254264|Active Comparator|Control group|a control group of 120 children receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
2448210|NCT03253484|Experimental|NAFL-treated wounds|NAFL treated wounds
2448211|NCT03253484|No Intervention|Control|untreated control wound
2448260|NCT03253159|Experimental|Hypnosis group|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room
2448263|NCT03253159|No Intervention|Control group|No special preparation before intravenous general anesthesia induction in the operative room
2448331|NCT03252912|Experimental|Biological samples|The CSF samples will be taken at the occasion of the first lumbar puncture performed for clinical purposes (suspected LM). If necessary for the routine diagnosis, a second and a third lumbar puncture will be performed according to the gold standard Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar puncture and transferred at ambient temperature to the Biological Resource Center of the ICM (Jean-Pierre Bleuse, Biobank number BB-0033-00059) to be processed within 1 hour Blood samples will be centrifuged at 3,000 g for 10 minutes at ambient temperature and will be aliquoted in 4 plasma and 4 serum aliquots and then stored at -80°C. Aliquots must be anonymized.
2448360|NCT03252457|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take decitabine in combination with dexamethasone at the indicated dose
2448364|NCT03252457|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose
2448393|NCT03252132|Active Comparator|12-week resistance training|
2448406|NCT03252132|No Intervention|No training|
2448499|NCT03251274|Experimental|machine bathing group|structured machine bathing for 20-min duration at evening.
2448505|NCT03251274|Active Comparator|traditional bathing group|traditional bathing at evening.
2448607|NCT03251183||Main group|Blood sampling Comprehensive Cardiovascular magnetic resonance (CMR) Transthoracic echocardiography (TTE) (EchoErgo) Invasive pressure-volume (PV) Loops Left ventricular (LV) biopsy
2448610|NCT03251183||Reproducibility group|Stress-perfusion Cardiovascular magnetic resonance (CMR)
2448613|NCT03251183||Age/gender matched control group|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
2447415|NCT03258749|Active Comparator|Formoterol|inhaled formoterol(4.5μg, bid)
2447424|NCT03258749|Experimental|Tiotropium|inhaled Tiotropium(18μg, qd)
2447470|NCT03258411|Active Comparator|Haas group (H)|Rapid Expansion of palatal suture device: tooth-tissue supported expander (Haas (H)).
2447473|NCT03258411|Active Comparator|Hyrax (Hx)|Rapid Expansion of palatal suture device: tooth anchored expander (Hyrax (Hx)).
2447477|NCT03258411|Active Comparator|Miniscrew-supported (MHx)|Rapid Expansion of palatal suture device: bone anchored expander (Temporary anchorage devices(miniscrew)-supported (MHx))
2447510|NCT03258099||wild genotype|Through next generation sequencing, distinguish wild genotype of capecitabine
2447513|NCT03258099||mutant genotype|Through next generation sequencing, distinguish mutant genotype of capecitabine
2447633|NCT03257176|Experimental|Stepping Stones and Creating Futures|Receive the 21 session intervention
2447654|NCT03257007|No Intervention|Usual Care|Participants assigned to Usual Care will continue to receive standard care from their oncology team, including access to supportive care from oncology social workers. At the end of the study, usual care dyads will receive a packet of informational materials on mindfulness meditation, receive a CD with 5 mindfulness meditation practices, and meet with the study interventionist for guidance on how to use the materials and mindfulness recordings to their advantage in coping with cancer-related challenges.
2447657|NCT03257007|Active Comparator|Mindfulness|The Mindfulness intervention will consist of six 2-hour sessions that will include guided mindfulness practices, didactics, and group discussion. The course curriculum is modeled on the Mindfulness-Based Stress Reduction program which involves intensive experiential training of participants in secular mindfulness meditation practices (i.e., body scan, sitting meditation, gentle hatha yoga with chair adaptations, compassion meditation), with an emphasis on embodying interpersonal mindfulness in dialogue.
2447686|NCT03256721|Experimental|Apatinib+docetaxel/pemetrexed|Apatinib 500mg QD PO d1-21+docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
2447687|NCT03256721|Active Comparator|docetaxel/pemetrexed|docetaxel(75mg/m2 IV d1)/pemetrexed(500 mg/m2 IV d1),q21d
2447735|NCT03256461|Experimental|Lactate clearance 10% target group|Lactate clearance falls by 10-percent every two hours.
2447736|NCT03256461|Experimental|Lactate clearance 20% target group|Lactate clearance falls by 20-percent every two hours.
2447737|NCT03256461|Placebo Comparator|Standard EGDT group|Refer to the Surviving Sepsis Campaign(SSC) 2012 sepsis guidelines within 6 h liquid resuscitation.
2447765|NCT03256110|Experimental|Intervention|Patients and providers in this arm receive the culturally-tailored Improving Communication about Serious Illness (ICSI) Intervention. The ICSI involves providing the provider and the patient with an individualized, one-page summary of patient-specific preferences for advance care planning communication that prompts the patient and the provider to have a conversation about advance care planning at the next clinical visit.
2447771|NCT03256110|No Intervention|Control|Patients and providers in this arm receive usual care.
2447843|NCT03255954|Experimental|Interpersonal Counseling-C|Interpersonal Counseling for University Counseling Centers is a psychotherapeutic intervention
2447894|NCT03255330|Experimental|Arm G1800|administration of gabapentin with a gradual increasing dose of up to 1800 mg / day
2447903|NCT03255330|Active Comparator|G0|Standardized medical treatment of central neuropathic pain: metamizole, tramadol
2447983|NCT03254966|Experimental|SHR0302 dose level 1|
2447989|NCT03254966|Experimental|SHR0302 dose level 2|
2447993|NCT03254966|Experimental|SHR0302 dose level 3|
2447998|NCT03254966|Experimental|SHR0302 dose level 4|
2448001|NCT03254966|Placebo Comparator|Placebo|
3189998|NCT00783003|Experimental|LAMA with LABA|Inhaled Long Acting Muscarinic receptor Antagonist (LAMA) and a inhaled Long Acting Beta 2 Agonist (LABA), both in development for treatment of Chronic Obstructive Pulmonary Disease and taken in combination.
3189999|NCT00783003|Placebo Comparator|Placebo|Matching placebo, no intervention.
2448144|NCT03254004|Experimental|single arm: pembrolizumab|pembrolizumab 200 mg every 3 weeks
2448167|NCT03253731||Healthy Volunteers|15 healthy volunteers
2448242|NCT03253497|Active Comparator|Chlorhexidine- benzidamine|before 15 minute anesthesia induction Chlorhexidine-benzidamine spray will be administrated to oropharynx
2448248|NCT03253497|No Intervention|Control|before 15 minute normal salin will be administrated to oropharynx
2448286|NCT03253016|Experimental|cervicall cerclage|to test vaginal microbiome distribution in women with cervical cerclage due to cervical incompetence in weeks: 12 14 18 26 32
2448287|NCT03253016|Experimental|vaginal progesterone|to test vaginal microbiome distribution in women treated with vaginal progesterone due to cervical shortening in weeks: 12 14 18 26 32
2448289|NCT03253016|No Intervention|contol|to test vaginal microbiome during pregnancies without cerclage or progesterone
2448354|NCT03252639||Patients with Renal Artery Stenosis|Patients with renal artery stenosis which may benefit from endovascular treatment will be recruited. Those patients who cannot benefit from this procedure will be excluded.
2448374|NCT03252288|No Intervention|No intervention|No intervention
2448375|NCT03252288|Experimental|Reminders only|Reminders are sent 1 week and 1 day before each scheduled vaccination date
2448376|NCT03252288|Experimental|Reminders + Conditional financial transfer|Reminders are sent 1 week and 1 day before each scheduled vaccination date; and conditional financial transfers are made for each on-time vaccination visit
2448379|NCT03252106|Experimental|Contour augmentation|
2448442|NCT03252054||Patients aged 70 or over|Patients eligible for the study will undergo screening for memory disorders, attention disorders, and malnutrition
2448475|NCT03251742|Active Comparator|Fontan patient population|
2448479|NCT03251742|Sham Comparator|Healthy volunteers|
2448534|NCT03251443|Experimental|Apatinib|A molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
2448578|NCT03251092|Active Comparator|SAD PTI-808 Active|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2448580|NCT03251092|Placebo Comparator|SAD PTI-808 Placebo|Three cohorts of SAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2448581|NCT03251092|Active Comparator|MAD PTI-808 Active|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2447495|NCT03258320|Experimental|CDMS, Surgery|"Preoperative chemotherapy using Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.~Procedure: radical prostatectomy surgery."
2447496|NCT03258320|No Intervention|Control|No neoadjuvant chemotherapy using CDMS will be done for patients who are diagnosed with localized prostate cancer but subject to direct surgery to radically remove the primary tumor.
2447526|NCT03257943|Experimental|Ivermectin Lotion, 0.5%|One 10 minute application, under at-home use conditions
2447528|NCT03257943|Active Comparator|SKLICE (ivermectin) Lotion, 0.5%|One 10 minute application, under at-home use conditions
2447529|NCT03257943|Placebo Comparator|Vehicle of the Test product|One 10 minute application, under at-home use conditions
3190000|NCT00783016|Experimental|Morphine|
2447680|NCT03256890|Experimental|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, we work to provide access within health insurance constraints.
2447682|NCT03256890|Active Comparator|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
3153312|NCT00271999|Active Comparator|1|Three times a week conventional at home hemodialysis
3153313|NCT00271999|Experimental|2|Six times a week nocturnal home hemodialysis
2447853|NCT03255629|Experimental|Treatment Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
2447854|NCT03255629|Placebo Comparator|Control Arm|Each subject will have two mixed meal tolerance tests performed. Each will be randomized to receive either glucagon or matched placebo during the first testing session. The opposite treatment will be given during the second testing session. Both participants and the study team will be blinded to the intervention being used during each session.
2447889|NCT03255278|Experimental|Safety and portable study group|"12 persons who have got a single decreased dose (0.25 of the planned dose for regular administration) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: single GamTBvac vaccination (0.25 dose)."
2447898|NCT03255278|Placebo Comparator|Placebo safety study group|12 persons who have got a single dose of placebo (0.5 ml). The intervention for the Arm: Placebo administration (0.5 ml)
2447902|NCT03255278|Experimental|Immunogenicity study group #1|"12 persons who will get a double sequential administration of the decreased dose (0.25 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.25 dose)."
2447907|NCT03255278|Experimental|Immunogenicity study group #2|"12 persons who will get a double sequential administration of the mean dose (0.5 of the planned dose for regular applying) of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (0.5 dose)."
2447912|NCT03255278|Experimental|Immunogenicity study group #3|"12 persons who will get a double sequential administration of the maximum (regular) dose of the GamTBvac recombinant subunit vaccine.~The intervention for the Arm: double GamTBvac vaccination (1.0 dose)."
2447938|NCT03254849|Experimental|empagliflozin 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 1: 25 mg/d empagliflozin + hydrochlorothiazide placebo
2447941|NCT03254849|Experimental|hydrochlorothiazide 25 mg|Each patient will take 2 tablets each day to ensure double-blind Treatment. Arm 2: 25 mg/d hydrochlorothiazide + empagliflozin placebo
2448268|NCT03253770|Experimental|Digital Cognitive Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid in the hand of the leader during crises management.
3153314|NCT00272025|Active Comparator|1|There is a 50% chance of being randomized to Escitalopram in addition to current atypical antipsychotic (minimum dose risperidone 3mg, olanzapine 10mg or seroquel 400mg) or mood stabilizer (lithium, epival or lamotrigine)
3153315|NCT00272025|Placebo Comparator|2|to be filled in
3153316|NCT00272064|Other|1|Telecare system
3153317|NCT00272064|Other|2|Self Monitoring Blood Glucose (SMBG)system.
3153318|NCT00272116|Experimental|1|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children and Vitamin A 100,000 IU to infants and 200,000 IU to older children
3153319|NCT00272116|Placebo Comparator|2|
3173142|NCT00608673|Experimental|1|Patients in arm one used twice daily pimecrolimus 1% cream on their facial discoid lupus erythematosus lesions for 8 weeks.
3190001|NCT00783016|No Intervention|Placebo|
3190002|NCT00783029||Healthy Subjects|Healthy participants between the ages of 21 and 65 years old.
2447517|NCT03257930|Experimental|injection of ethanol|use of ethanol injection in the treatment of cystic thyroid nodule
3173143|NCT00608673|Active Comparator|2|Twice daily betamethasone valerate 0.1% cream to facial lesions of discoid lupus erythematosus for 8 weeks
3190003|NCT00783042|Active Comparator|1|
2447718|NCT03256513|Experimental|model controlling|an statistical model for periprocedural blood pressure control
2447724|NCT03256513|Active Comparator|conventional controlling|an conventional strategy for periprocedural blood pressure control
2447780|NCT03256214|Experimental|Closed suction system|Patients in mechanical ventilation were aspirated with closed suction system.
2447787|NCT03256214|Active Comparator|Open suction system|Patients in mechanical ventilation were aspirated with open suction system.
2447819|NCT03255889|Active Comparator|Active|Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
2447825|NCT03255889|Placebo Comparator|Placebo|Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts
2447871|NCT03255421||Patients enrolled|"Patients over 18 years old, consulting for lower urinary tract symptoms and performing an urodynamic examination with a cystometry in a tertiary center are included.~First pressure measurement in the bladder during the classic cystometry. Second measurement of bladder pressures during the bladder emptying."
2447929|NCT03255135|Experimental|HIFU|Patients with untreated recent diagnosed localized prostate cancer candidates of focal therapy.
2447990|NCT03254758|Experimental|Mesenchymal stem cell|"Phase 1 Dose escalation : low Mid High Single administalation of ADR-001~Phase 2 The recommended dose of ADR-001"
2448033|NCT03254537|Experimental|Mediterranean Organic|
2448038|NCT03254537|Experimental|Mediterranean conventional|
2448182|NCT03253887|Experimental|Ethanol-lock therapy (ELT) Group|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters
2448185|NCT03253887|No Intervention|Control Group|This group did not receive the ethanol-lock, being only followed daily and treated according to the standard protocol in operation at this healthcare unit.
3190004|NCT00783042|Placebo Comparator|2|
2448403|NCT03252249|Active Comparator|3 months dual anti-platelet therapy|3 months dual anti-platelet therapy is the intervention.
2448414|NCT03252249|Active Comparator|12 months dual anti-platelet therapy|12 months dual anti-platelet therapy is the intervention.
2448487|NCT03251872|Experimental|Drug: Olaparib|Olaparib up to 400 mg BID (100 to 400 mg) for 16 weeks
2448500|NCT03251352||TKI Discontinuation Group|The enrolled patients will be undertaking TKI discontinuation under the conditions of informed consent and frequent monitoring according to the clinical guideline.
2448584|NCT03251235|Experimental|Treatment Group|Group receives four weekly sessions of CBT prior to experimental testing/ fMRI
2448586|NCT03251235|No Intervention|Waiting Group|Group receives four weekly sessions of CBT after experimental testing/ fMRI
2448694|NCT03250767||Integra Titan Modular Shoulder System 2.5|
2448731|NCT03250026|Experimental|Intervention (Workplace dialogue)|Intervention: Work place convergence dialogue contact
2448732|NCT03250026|Active Comparator|Care Manager|Intervention: Care Manager contact 12 weeks (Care as usual)
2448851|NCT03249389|Experimental|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
2448894|NCT03249012|Experimental|Empiric calcium and calcitriol repletion group|All patients in this group will receive post-operative calcium carbonate and calcitriol.
2448897|NCT03249012|Experimental|PTH based repletion group|Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
2449042|NCT03248245|Experimental|LOG-model schools|Experimental schools implement the LOG-model
2449044|NCT03248245|Active Comparator|Treatment as usual schools - TAU|Control schools performing interprofessional team collaboration as usual
2449250|NCT03246737||pregnant women|
2449300|NCT03246451|Placebo Comparator|Placebo|Placebo, oral tablet in 14 days and in liquid meal.
2449301|NCT03246451|Experimental|Metformin|Metformin, oral tablet 2-4 x 500 mg in 14 days and in liquid meal.
2449302|NCT03246451|Experimental|Saline|Saline infusion (9mg/mL) on experimental days
2449303|NCT03246451|Experimental|Exendin(9-39)|Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
2449346|NCT03245853|Other|Treatment|Treatment as per protocol, there is no placebo arm.
2449395|NCT03245658|Experimental|THC and CBD Mixture|32 patients with palliative pancreatic cancer, intervention with oral drops of THC, 25mg/ml and CBD 50mg/ml, daily administered for 4 weeks
2449396|NCT03245658|No Intervention|Control|32 patients with palliative pancreatic cancer, no experimental treatment,
2449458|NCT03245294|Active Comparator|Lumbar ESI with midline approach|Lumbar ESI with midline approach
3173144|NCT00608725|Other|Patients|Patients with orthostatic intolerance
3173145|NCT00608725|Other|Healthy Control Subjects|"Healthy subjects to determine normal response"
3173146|NCT00608751|Experimental|IMRT|External beam radiation with 6 MV photons will be delivered in 200 cGy daily fractions, 35 fractions over 7 weeks for a total dose of 7000 cGy.
3173147|NCT00608764||NHW COPD Participants|Non-Hispanic white participants with COPD
3173148|NCT00608764||NHW Control Group|Non-Hispanic white participants with normal spirometry (do not have COPD)
3173149|NCT00608764||AA COPD Participants|African-American participants with COPD
3173150|NCT00608764||AA Control Group|African-American participants with normal spirometry (do not have COPD)
3173151|NCT00608790|Experimental|1|
3173152|NCT00608803|Experimental|Single arm|Once the maximum tolerated dose (MTD) is determined, an expanded cohort of 20 subjects with advanced, ifosfamide and doxorubicin naive soft-tissue sarcoma subjects will be dosed at the MTD and evaluated for efficacy.
3173153|NCT00608816|Experimental|1|Hyperinsulinemic euglycemic glucose clamp study on day 1 Hyperinsulinemic euglycemic clamp study on day 2 with epinephrine infusion
3173154|NCT00608816|Experimental|2|Hyperinsulinemic hypoglycemic glucose clamp x 2 on day 1 Hyperinsulinemic euglycemic clamp with epinephrine infusion on Day 2
2447514|NCT03258060|Active Comparator|Mechanical Dyssynchrony|Those with cardiac MRI evidence of mechanical dyssynchrony
2447515|NCT03258060|Active Comparator|No Mechanical Dyssynchrony|Those without mechanical dyssynchrony on cardiac MRI
2447596|NCT03257540||Small Bone Intramedullary Nail|All study participants
2447632|NCT03257163|Experimental|Treatment (pembrolizumab, capecitabine, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks, patients undergo surgery. Beginning up to 56 days after surgery, patients receive pembrolizumab IV over 30 minutes on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Within 2-6 weeks of resting, patients continue to receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 11 courses in the absence of disease progression or unacceptable toxicity. Beginning course 4, patients undergo radiation therapy over 15-30 minutes on days 1-5 for up to 5 weeks.
2447671|NCT03256916|Experimental|Nelfinavir Arm|"If patient is randomized to nelfinavir arm then nelfinavir will be given orally with food at the dose of 1250 mg bid 5-7 days prior to start of chemoradiation.~Then Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 # will be given."
2447673|NCT03256916|Other|Standard Arm|"If patient is randomized to standard arm (Cisplatin +Pelvic EBRT and Brachytherapy).~In this patient will receive Pelvic EBRT (46Gy /23#/4.5weeks) + Weekly cisplatin 40mg/m2 & ICRT 7Gy X4 #"
2447746|NCT03256409|Experimental|Five Bar overdenture: BOD|Five systems titanium bar CARES® and synOcta® Straumann® Dental Implant System, Holding AG Inc., Basel, Switzerland (Bar overdenture: Group 1) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 1. The BOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
2447747|NCT03256409|Experimental|Five Ball Joint Overdenture: BJOD|Five systems ball joint Klockner® Implant System; Soadco Inc., Escaldes-Engordany, Andorra (Ball Joint Overdenture: Group 2) For the manufacture of the overdentures it was used as material of choice Lucitone 199® (Dentsply International Inc. York, PA) and for the adaptation of the retention systems it was used Softreliner Tough Soft® Tocuyama Dental Corporation Inc., Japan. The working protocol for determining the BJOD Ra and the adhesion of molds and yeasts and mesophyll aerobics was carried out entirely by an investigator. Patients were randomly assigned to group 2. The s BJOD were removed at 30 - 180 days for surface roughness evaluation (Ra:ųm) and the evaluation of the adhesion of mold and yeast and mesophyll aerobe (CFU/ml).
2447759|NCT03256058|Active Comparator|Reinflation after early deflation|The tourniquet would be inflated immediately before incision and deflated after the use of the cement, and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation.The total time of tourniquet inflation is controlled within 90 minutes.
2447762|NCT03256058|Placebo Comparator|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
2447821|NCT03255915|Experimental|Arm 1|Arm 1 will receive the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR for Stage 2 followed by the placebo pod-IVR during Stage 3.
2447827|NCT03255915|Experimental|Arm 2|Arm 2 will receive the placebo pod-IVR for Stage 2 followed by the Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC) pod-IVR during Stage 3.
2447900|NCT03255356||Cohort|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
2447954|NCT03254823||Severe ME/CFS patients|patients with a clinical diagnosis of ME/CFS and are house or bed bound.
2447961|NCT03254823||Household controls|Healthy human participants who are either related/non-related to, living in the same household or in close proximity to, or providing care to the severe ME/CFS patient they are paired with. They are used as an environmental control.
2448061|NCT03254680|Experimental|Turmeric Oil|stable dose of orally administered turmeric oil
2448106|NCT03254277|Experimental|Group 1A|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg.
2448107|NCT03254277|Experimental|Group 1B|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
2448108|NCT03254277|Experimental|Group 1C|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2448112|NCT03254277|Experimental|Group 2B|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg.
2448114|NCT03254277|Experimental|Group 2C|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels < 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2448116|NCT03254277|Experimental|Group 1D|HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2448118|NCT03254277|Experimental|Group 2D|HIV-infected individuals on ART with HIV-1 plasma RNA levels < 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg.
2448121|NCT03254277|Experimental|Group 1E|HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
2448123|NCT03254277|Experimental|Group 1F|HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio.
2448169|NCT03253653|Experimental|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices.
2448171|NCT03253653|No Intervention|Control|A total of 25 adult make and female nonsmokers will be recruited as a control.
2448217|NCT03253432||Strata 0-0.05|Lowest probability of having familial hypercholesterolemia
2448223|NCT03253432||Strata 0.06-0.15|Second lowest probability of having familial hypercholesterolemia
2448232|NCT03253432||Strata 0.16-0.19|Moderate probability of having familial hypercholesterolemia
2447516|NCT03258034|Experimental|Conversion treatment|after 3-4 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent.
2447591|NCT03257774|Experimental|Test of three new adhesive strips|"The subjects test three new adhesive strips~adhesive strip A~adhesive strip B~adhesive strip C"
2447619|NCT03257241|Active Comparator|A arm (DA-90)|"Induction I:~DNR 90 mg/m2 D 1-3 in 30-60 min i.v. infusion~Ara-C 100 mg/m2 D 1-7 in 24 h i.v. infusion"
2447625|NCT03257241|Active Comparator|B arm (DAC)|"Induction I:~DNR 60 mg/m2 D 1-3 in 30-60 min i.v. infusion~cladribine 5 mg/m2 D 1-5 in 2 h i.v. infusion prior to Ara-C~Ara-C 200 mg/m2 D 1-7 in 22 h i.v. infusion."
2447629|NCT03257241|Active Comparator|A arm (CLAG-M)|Cladribine 5mg/m2 in 2 h i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after cladribine infusion on days (1-5) Mitoxantrone 10 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
2447630|NCT03257241|Active Comparator|B arm (FLAG-IDA)|Fludarabine 30 mg/m2 in 30-min i.v. infusion on days (1-5) Ara-C 2 g/m2 in 4 h i.v. infusion, 2 h after fludarabine infusion on days (1-5). Idarubicin 8 mg/m2 i.v. 1xd on days (1-3) G-CSF 30MU s.c. 1xd from day 0 to 5 of the treatment (6 doses).
2447698|NCT03256864|Experimental|Tacrolimus and Everolimus BID|"TAC BID (C0 2.5-5 ng/mL) EVR BID (1.0 mg BID targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
2447705|NCT03256864|Experimental|Tacrolimus and Everolimus QD|"TAC QD (C0 2.5-5 ng/mL) EVR QD (2.0 mg QD targeted to C0 3-8 ng/mL)~Other Names:~Prograf~Advagraf~Zortress~Certican"
2447775|NCT03256305|Experimental|"personalized rTMS+drug treatment"|"Received personalized rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks"
2447779|NCT03256305|Active Comparator|Traditional rTMS +drug treatment|Received traditional rTMS treatment 15 times for 15 days;Take paroxetine for 2 weeks
2447837|NCT03255798|Other|G2 and G3 implantation|Two iStent inject stents and one iStent Supra stent
2447901|NCT03255473|Active Comparator|Dexamethasone|All subject identification (ID) numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
2447909|NCT03255473|Active Comparator|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
2447946|NCT03254914||Control Site|Measure Clinic Blood Pressure
2447948|NCT03254914||Test Site|Measure Clinic Blood Pressure and Home Blood Pressure
3190005|NCT00783055|Experimental|Treatment|12 weeks of individually tailored intervention programmes based on participants individual wishes for daily activities e.g.ADL, mobility, social, mental or creative that they want to improve, conserve - and/or to revive.
2448187|NCT03253575||Squamous Carcinoma of the Head and Neck (HNSCC)|"1st line metastatic/locally advanced~2nd line metastatic/locally advanced"
2448191|NCT03253575||Triple Negative Breast Cancer (TNBC)|1. Triple Negative Breast Cancer (TNBC) A 1st line metastatic/locally advanced B ≥2nd line metastatic/locally advanced
2448192|NCT03253575||Non-small Cell Lung Cancer (NSCLC)|1. Non-small Cell Lung Cancer (NSCLC) A ≥2nd line Stage 3B or 4
2448194|NCT03253575||Epithelial Ovarian Cancer (EOC)|1. Epithelial Ovarian Cancer (EOC) A 2nd line platinum-resistant Stage 3 or 4 B 2nd line platinum-sensitive Stage 3 or 4 C ≥3rd line platinum-sensitive Stage 3 or 4
2448196|NCT03253575||Colorectal Cancer (CRC)|1. Colorectal Cancer (CRC) A 1st line Stage 4 B Recurrent or progressive disease following treatment with both oxaliplatin- and irinotecan-containing regimens
2448221|NCT03253172|Placebo Comparator|Placebo|Placebo
2448229|NCT03253172|Experimental|Potassium Chloride|Experimental Arm 1 - Rationale is that most evidence for a positive effect of potassium comes from studies using potassium chloride
2448236|NCT03253172|Experimental|Potassium Citrate|Experimental Arm 2 - Rationale for citrate is that recent evidence indicates that alkali treatment may also be renoprotective.
2448332|NCT03252821|Experimental|High-intensity aerobic training group|High intensity interval training
2448333|NCT03252821|Active Comparator|Resistance training group|Muscle strengthening
2448334|NCT03252821|No Intervention|Control group|Usual care
2448398|NCT03252392||children with autism spectrum disorder|Children aged 3-12 years diagnosed to have mild to moderate autism spectrum disorder diagnosed by childhood autism spectrum disorder(CARS 35% or less)
2448407|NCT03252392||healthy non autistic age matched volunteers|children aged 3-12 years old never diagnosed to have autism spectrum disorder
3190006|NCT00783068|Active Comparator|GTS-21|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0).
3190007|NCT00783068|Placebo Comparator|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
3190008|NCT00783081|Experimental|low dose K-134|
3190009|NCT00783081|Experimental|mid dose K-134|
3190010|NCT00783081|Experimental|high dose K-134|
2448583|NCT03251066|Other|Test group|Proponent Nasal Spray Medical device
2448641|NCT03250780|Experimental|Patients with extensive colitis|Patients with extensive colitis, for at least 8-10 years, already on the surveillance programme or newly referred whilst attending their outpatients IBD clinic at Leeds Teaching Hospitals NHS Trust will be screened by one of the research doctors who will be performing the surveillance colonoscopy.
2448642|NCT03250442|Other|Group A: Standard Dry Dressing|The standard dry dressing is comprised of nonadherent dressing, dry gauze, cotton undercast padding, compression, and immobilization.
2448643|NCT03250442|Active Comparator|Group B: Foam, Drape, and PrevenaTM|This arm is comprised of foam, drape, the PrevenaTM Device, compression, and immobilization.
2448722|NCT03250338|Experimental|Crenolanib|Crenolanib following salvage chemotherapy
2448723|NCT03250338|Placebo Comparator|Placebo|Placebo following salvage chemotherapy
2448928|NCT03248778|Experimental|disclosure-support counseling|
2447545|NCT03257722|Experimental|Phase 1 Dose Escalation|Sequential cohorts of 3 patients will receive pembrolizumab 200 mg intravenously every 3 weeks, in addition to the oral drug, idelalisib, every day for 21 days. The first group of 3 will receive idelalisib 50 mg twice daily; the next cohort will receive idelalisib 100 mg twice daily; the last cohort will receive idelalisib 150 mg twice daily.
2447548|NCT03257722|Experimental|Phase 2 Efficacy|All patients in the efficacy assessment phase will be treated with pembrolizumab (200 mg intravenously every 3 weeks) in combination with oral idelalisib (dose not exceeding 150 mg twice daily, per the phase 1 assessment) for 18 weeks before maintenance with pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, until disease progression or unacceptable toxicity.
2447604|NCT03257397|Experimental|left iTBS and right cTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left dorsolateral prefrontal cortex (DLPFC) and continuous TBS (cTBS) over the right DLPFC
2447605|NCT03257397|Active Comparator|left and right iTBS|40 patients will receive intermittent theta-burst stimulation (iTBS) over the left and right dorsolateral prefrontal cortex (DLPFC)
2447646|NCT03257137|Experimental|Healthy Diet|This dietary pattern will represent recommendations for fiber and added sugar set forth in the 2015 Dietary Guidelines for Americans and saturated fat guidelines from the American Heart Association
2447647|NCT03257137|Experimental|Simulated Fast Food (SFF)|This dietary pattern will represent the typical American diet for fiber, added sugar, and saturated fat intake.
2447697|NCT03256825|Other|Rapid diagnostics|patients admitted to medical and surgical wards with urinary tract infections at Ålesund Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics alone will be implemented.
2447704|NCT03256825|Other|Rapid diagnostics and RADS|patients admitted to medical and surgical wards with urinary tract infections at Molde Hospital, Moere and Romsdal, Norway. Here, rapid diagnostics will be implemented in conjunction with Real-time antimicrobial stewardship decision support : rapid diagnostics and RADS.
2447749|NCT03256266||healthy controls|healthy controls
2447751|NCT03256266||patients with allergy|patients with Food intolerances or Food allergy
2447753|NCT03256266||gastrointestinal disorders|patients with inflammatory bowel disease, irritable bowel disease, gluten sensitivity, short bowel syndrome
2447756|NCT03256084|Experimental|Colorectal Cancer|"Localized stage II/III (group 1), metastatic non resectable (group 2), metastatic potentially resectable (group 3).~Additional blood samples specific for the research will be collected. Tissue samples will be taken on surgical specimens from surgery."
3190011|NCT00783081|Active Comparator|Comparator|
3190012|NCT00783081|Placebo Comparator|Placebo|
2447922|NCT03255213|Experimental|Late Onset Pompe Disease who have tongue weakness|
2447982|NCT03254836||Colorectal cancer undergoing elective surgery|"All patients eligible for elective curative intended surgery for colonic adenocarcinoma at Zealand University Hospital.~Patients will recieve treatment as per standard of care."
3190013|NCT00783107|Experimental|Cyclosporine|
2448103|NCT03254212|Experimental|Oxygen therapy|Fixed nightime oxygen therapy throughout the protocol duration
2448184|NCT03253900|Experimental|Experimental group|A group of rowers to be administered to intervention on a Stable rowing simulator, a Slides based rowing simulator or a Tilt board based rowing simulator.
2448219|NCT03253328|Active Comparator|Active Arm N-acetyl cysteine (NAC)|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to a standard adult intravenous dose of NAC (1200mg twice a day) for 6 days post-amputation.
2448222|NCT03253328|Placebo Comparator|Placebo Arm|Upon study enrollment, patients will be randomized 1:1 by Investigational Pharmacy to placebo ½ normal saline infusion (twice a day) for 6 days post-amputation.
2448362|NCT03252990||Optimization subjects|Before the enrollment of the actual study subjects, 5 stable angina pectoris patients that are scheduled for a PCI procedure at the MUMC+ will be included at the MUMC+ for a single PET-MRI scan to optimize the parameters of the coronary PET-MRI scan. All patients will receive standard, guideline-based clinical care, while PET-MRI will be performed as an additional measurement.
2448365|NCT03252990||Patients from the VieCuri hospital|15 NSTEMI or STEMI patients who underwent urgent percutaneous coronary intervention (PCI) of the culprit vessel, who are diagnosed with multivessel coronary disease and are currently scheduled for a second PCI at the VieCuri hospital will be included. These patients will be subjected to an additional 18F-choline PET-MRI examination at the MUMC+ and an additional optical coherence tomography (OCT) examination (during the PCI procedure) at the Viecuri hospital. OCT will be performed as a reference standard to validate 18F-choline PET-MRI for detection of vulnerable plaques in the coronary arteries. All patients will receive standard, guideline-based clinical care, while PET-MRI and OCT will be performed as additional measurements.
2448385|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G1)|Low level laser therapy with energy dose of 18J will be applied on left brachial artery of the subject.
2448389|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G2)|Low level laser therapy with energy dose of 36J will be applied on left brachial artery of the subject.
2448394|NCT03252184|Experimental|Phase 1 - Low level laser therapy - 1 (G3)|Low level laser therapy with energy dose of 54J will be applied on left brachial artery of the subject.
2448405|NCT03252184|Placebo Comparator|Phase 1 - Placebo low level laser therapy - 1 (G4)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
2448415|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
2448417|NCT03252184|Experimental|Phase 2 - Low level laser therapy - 2 (G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
2448419|NCT03252184|Placebo Comparator|Phase 2 - Placebo low level laser therapy - 2 (G3)|Low level laser therapy with equipment turn off (placebo) be applied on left brachial artery of the subject.
2448422|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3 (G1)|Low level laser therapy with energy dose of 30J will be applied on left brachial artery of the subject.
2448425|NCT03252184|Experimental|Phase 3 - Low level laser therapy - 3(G2)|Low level laser therapy with energy dose of 60J will be applied on left brachial artery of the subject.
3190014|NCT00783107|Placebo Comparator|Placebo|Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
3208929|NCT00979446|Active Comparator|Self-directed|
3208930|NCT00979472|Experimental|with urgency|
2447595|NCT03257423|Active Comparator|P.o. moxifloxacin (APPAC II)|Patients in this group recruited also in APPAC II trial will receive p.o. antibiotics for a total of 7 days, moxifloxacin 400 mg once per day. From these patients, rectal swab samples of faces will be collected at two time points, day 0 (before treatment) and day 1 (after beginning of treatment), serum sample before treatment initiation.
2447597|NCT03257423|Placebo Comparator|Placebo treatment (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. placebo 3 times per day for 3 days followed by p.o. placebo 3 times per day for 4 additional days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
2447598|NCT03257423|Other|Surgery (complicated appendicitis)|Patients in this group will undergo appendectomy and are recruited only in the MAPPAC trial. Rectal swab samples and biopsies from the removed appendix will be collected from these patients.
2447602|NCT03257423|Other|Surgery (uncomplicated appendicitis)|Patients in this group will undergo appendectomy either after refusing to participate in the APPAC II or APPAC III trials or after presenting with recurrent appendicitis after antibiotic or placebo therapy. Rectal swab samples of faces and biopsies from the removed appendix will be collected from these patients.
2447603|NCT03257423|Active Comparator|I.v. + p.o. antibiotics (APPAC III)|Patients in this group recruited also in APPAC III trial will receive i.v. antibiotics (ertapenem 1 g twice per day) for 3 days followed by p.o. antibiotics (levofloxacin 500 mg x 1 and metronidazole 500 mg x 3) for 4 days, for a total treatment duration of 7 days. From these patients rectal swab samples will be collected twice during the stay at the research hospital (time points 0 and 1 or 3 d) and three times at home (follow-up at one week, six months and one year). Serum samples are taken prior to treatment initiation and at 10 days after the treatment initiation.
2447639|NCT03257098|Experimental|allo-APZ2-CVU|Application of IMP on patients wound
2447689|NCT03256838|Experimental|Ferric citrate|Ferric Citrate (Nephoxil® Capsules) will be dosed three times a day (with meals).
2447784|NCT03256292||testosterone, diet, and increased physical activity|Group receiving standard of care consisting of diet and regular exercise counseling + testosterone replacement therapy
2447815|NCT03255811|Experimental|The dosage regimen|The chemotherapy response rate reached the maximum after 14-28 days, apatinib, 750 mg (QD), once a day, half an hour after meal (daily dosing time should be as same as possible), with warm boiling water delivery service. 28 days for a dosing cycle.
2447870|NCT03255538|Experimental|DFM: Mean pressure|In this group, deep friction massage will be applied with the mean pressure, previously obtained in a baseline assessment.
2447874|NCT03255538|Experimental|DFM: Mean pressure - 25%|In this group, deep friction massage will be applied will less 25% of the pressure previously obtained in a baseline assessment.
2447880|NCT03255538|Experimental|DFM: Mean pressure +25%|In this group, deep friction massage will be applied will an increment of 25% of the pressure previously obtained in a baseline assessment.
2447884|NCT03255538|No Intervention|Control session|In this group, the participants will rest for 15 minutes
2447995|NCT03255083|Experimental|DS-1205c with osimertinib|Participants receive DS-1205c (at planned doses given orally twice daily: 200 mg, 400 mg, 600 mg, 800 mg) in combination with daily 80 mg oral dose of osimertinib
2448032|NCT03254446|Experimental|TRC150094 45 mg|TRC150094 45 mg Tablet to be administered orally once a day for 50 weeks
2448035|NCT03254446|Placebo Comparator|Placebo|Matching Placebo Tablet to be administered orally once a day for 50 weeks
2448094|NCT03254030|Placebo Comparator|Inspection on withdrawal|Participants colonic mucosa will be examined only during withdrawal phase of the examination.
2448098|NCT03254030|Active Comparator|Inspection on insertion and withdrawal|Participants colonic mucosa will be examined during insertion and withdrawal phase of the examination
2448154|NCT03253913|Experimental|Treatment Arm|"Resveratrol 250mg daily for the first 8 weeks, followed by 250mg twice daily for the next 8 weeks, and then 500mg twice daily for the last 8 weeks.~Patients will be on a stable background therapy of sirolimus prior to enrolling and will continue on that regimen throughout the study."
3190015|NCT00783120|Experimental|1|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold).
3190016|NCT00783120|Sham Comparator|2|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session)
2448238|NCT03253289|Experimental|Meclizine 100 mg|Meclizine 50 mg will be taken by the patient orally twice daily for a total of 28 days(up to 35 days).
2448377|NCT03252561|Experimental|TAP block|Patients in this arm will receive ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
2448378|NCT03252561|Active Comparator|Local anaesthetic infiltration|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
2448430|NCT03252067|Experimental|azithromycin eyedrop|Each of the subjects' eyes will receive single dose of azithromycin eyedrops and then attribute the time for tear sampling at seven time points up to 24 hours.
2448447|NCT03251807|Experimental|Twin-block|The patients in this control group will be treated using the Twin-block appliance.
2448448|NCT03251807|Experimental|Twin-block combined with LIPUS|The patients in this experimental group will be treated using the Twin-block combined with LIPUS (Low-intensity pulsed ultrasound).
2448508|NCT03251599|Sham Comparator|Glyceryl trinitrate 0.2|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.2 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
2448513|NCT03251599|Active Comparator|Glyceryl trinitrate 0.5|Drug Intervention Generic name: Glyceryl trinitrate Dosage form: Ampoule for intravenous infusion Dosage: 0.5 mcg/kg/minute Frequency and duration: The infusion will start as soon as the rewarming period starts, will continue throughout the operation and throughout the first 24 hours of the postoperative period.
2448572|NCT03251040|Other|Fibrin sealant|Single arm pilot study
3208931|NCT00979472|Experimental|without urgency|
2447606|NCT03257488|Active Comparator|Screening device-Traditional device|The patients included in the A Group will be studied during the first night with the screening device (type IV portable monitoring Somnocheck micro Weinmann) and with the traditional one during the following night.
2447607|NCT03257488|Active Comparator|Traditional device-Screening device|The patients included in the B Group will be studied during the first night with the traditional device and with the screening one (type IV portable monitoring Somnocheck micro Weinmann) during the following night.
2447662|NCT03257085|Experimental|Low-carbohydrate, high-fat|Participants adhering to low-carbohydrate, high-fat diet for 8 weeks.
2447667|NCT03257085|Experimental|High-carbohydrate, moderate fat|Participants following high-carbohydrate, moderate-fat diet for 8 weeks.
2447695|NCT03256669|Experimental|umbilical incision|neonates undergone surgery by umbilical incision
2447761|NCT03256396|Experimental|Group E|PEEP set according to esophageal pressure measured
2447768|NCT03256396|No Intervention|Group C|PEEP set at 5 cm H2O
2447835|NCT03255928||VAD-implanted patients|All patients receiving a VAD implant
2447841|NCT03255928||VAD-patients suffering adverse events (AE)|VAD-patients sustaining a thromboembolic/bleeding complication over the course of support
3190017|NCT00783133|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3190018|NCT00783133|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
2448251|NCT03253146||sepsis|"Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection.~Organ dysfunction can be identified as an acute change in total SOFA score ≥2 points consequent to the infection.~The baseline SOFA score can be assumed to be zero in patients not known to have preexisting organ dysfunction.~ASOFA score ≥2 reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection. Even patients presenting with modest dysfunction can deteriorate further, emphasizing the seriousness of this condition and the need for prompt and appropriate intervention, if not already being instituted.~In lay terms, sepsis is a life-threatening condition that arises when the body's response to an infection injures its own tissues and organs."
2448257|NCT03253146||septic shock|Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L (18mg/dL) despite adequate volume resuscitation.
2448292|NCT03252925|Experimental|Experimental Group|N-Acetylcysteine
2448293|NCT03252925|Placebo Comparator|Control Group|Placebo Oral Tablet
2448382|NCT03252366|Active Comparator|GELFOAM (ABSORBABLE GELATIN)|"Sterile Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic.~it act as a space maintainer and alternative to bone filler for new bone formation in the maxillary sinus. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids its effect appears to be more physical than the result of altering the blood clotting mechanism. When placed in soft tissues, GELFOAM is usually absorbed completely within four to six weeks, without inducing excessive scar tissue"
2448383|NCT03252366|Active Comparator|XENOGRAFT (TUTOGEN)|xenografts as a sinus bone replacement graft ,The osteoconductive properties of xenografts in human sinus grafting have been well documented. They are due to both their chemical composition and their macro and micro morphology.The efficacy of xenografts as a sinus bone replacement graft may be due to combination of factors. Foremost would be the osteoconductive capacity of xenografts. In addition, they supply minerals that are necessary for bone formation, their density provides stability to the graft and the implants placed in them, and this density persists long term due to the fact that these grafts do not completely resorb.
2448488|NCT03251976|Experimental|Intervention|video decision aid
2448490|NCT03251976|Active Comparator|Usual care|
2448527|NCT03251391|Experimental|Cardiac Rehabilitation Group|Participants randomized to this group will undergo cardiac rehabilitation program.
2448537|NCT03251391|Active Comparator|Control Group|Participants randomized to this group will receive care for their condition, conventional therapy, that they would normally receive.
2448626|NCT03251027|Experimental|Treatment (IM-SRT)|Patients undergo intensity-modulated (IM)-stereotactic radiotherapy (SRT) daily over 6 weeks.
2448662|NCT03250507|Active Comparator|Bupivacaine|Patients will receive a TAP block with 60 mL 0.25% bupivacaine. this group will not receive Liposomal bupivacaine
2448664|NCT03250507|Active Comparator|Liposomal bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL saline.~this group will not receive bupivacaine. they receive only liposomal bupivacaine."
2448669|NCT03250507|Experimental|Liposomal bupivacaine and bupivacaine|"Patients will receive a TAP block with 20 mL liposomal bupivacaine and 40 mL 0.25% bupivacaine.~this group will receive the mixture of Liposomal bupivacaine and bupivacaine."
3190019|NCT00783146|Experimental|1|desloratadine
2448808|NCT03249714|Experimental|OMB 20 mg|Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.
2448813|NCT03249714|Placebo Comparator|Placebo-OMB 20 mg|Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core
2448899|NCT03249077||Digital DPP enrolled|The DPP online program is a CDC-certified translation of the DPP lifestyle intervention delivered in an online small group format of 10-15 participants.
2448900|NCT03249077||In-person DPP enrolled|In-person DPP participants will attend group sessions of ~20 participants in size at KPNW clinics. The group facilitator will use the CDC National DPP curriculum,
2448904|NCT03249077||DPP not enrolled (usual care)|Access to usual care services without restrictions.
2449093|NCT03248128|Active Comparator|Subjects receiving FF in cohort B|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 100 mcg administered once daily in the morning via ELLIPTA DPI.
2449399|NCT03245671|Active Comparator|Decadron|Patients in the Decadron group will receive epidural injections containing a total of 15 mg Decadron.
3190020|NCT00783146|Active Comparator|2|fexofenadine
3190021|NCT00783146|Placebo Comparator|3|placebo
3190022|NCT00783159|Experimental|A|Training I
2447658|NCT03256929|Experimental|pre-depression participants - control|General information on nutrition and health for pre-depression participants
2447665|NCT03256929|Experimental|pre-depression participants - intervention|personalized diet intervention based on microbiota analysis and health status for pre-depression participants
2447688|NCT03256656|Experimental|Healthy subjects|
2447690|NCT03256656|Active Comparator|Patients with SCI|
2447802|NCT03256422|Experimental|4 days / 7|Patients included in this arm will take their ARV treatment 4 consecutive days per week during 98 weeks
2447806|NCT03256422|Active Comparator|7 days / 7|Patients included in this arm will continue their ARV therapy 7 days per weeks during 48 weeks and after W48, they will take their ARV treatment 4 days per week until W98
2447905|NCT03255577|Experimental|Sentinel Lymph Node Biopsy (SLNB)|The patients will undergo SLNB with dual tracer mapping using technetium-99m sulfur colloid and isosulfan blue dye, as is standard practice at our institution for cN1 patients. Than the SLNB procedure will be performed
2447960|NCT03254927|Experimental|CDX-3379 and cetuximab|During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
2448030|NCT03254524||Patients visiting an emergency department in New York State|
2448115|NCT03254368|Experimental|0.05 mg ZGN-1061 (A)|0.05 mg ZGN-1061 subcutaneous injection once every 3 days
2448117|NCT03254368|Experimental|0.3 mg ZGN-1061 (B)|0.3 mg ZGN-1061 subcutaneous injection once every 3 days
2448119|NCT03254368|Experimental|0.9 mg ZGN-1061 (C)|0.9 mg ZGN-1061 subcutaneous injection once every 3 days
2448122|NCT03254368|Experimental|1.8 mg ZGN-1061 (CC)|1.8 mg ZGN-1061 subcutaneous injection once every 3 days
2448125|NCT03254368|Placebo Comparator|Placebo (D)|Placebo subcutaneous injection once every 3 days
3173155|NCT00608920|Experimental|SPECT lymph node mapping|"Diagnostic pelvic CT~Nuclear tracer injection (Tc-99m) - same time as the ACCULOC seed implantation~CT simulation (2 hours after prostate markers are placed)~SPECT lymphoscintigraphy (first set of images 3-6 hours after injection and second set may be obtained 18-24 hours after injection)"
3190023|NCT00783159|Experimental|B|Training II
3190024|NCT00783159|Active Comparator|C|Control
2448308|NCT03252587|Experimental|BMS-986165 Dose 1 oral administration|
2448309|NCT03252587|Experimental|BMS-986165 Dose 2 oral administration|
2448310|NCT03252587|Experimental|BMS-986165 Dose 3 oral administration|
2448311|NCT03252587|Placebo Comparator|Placebo oral administration|
2448486|NCT03251664||Anemic|Hemoglobin <11 g/l
2448489|NCT03251664||Non-anemic|Hemoglobin 11 g/l (and above)
2448503|NCT03251404|Active Comparator|Knee Control original|The Knee Control program exercise program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
2448509|NCT03251404|Experimental|Knee Control+|The Knee Control+ is an extension of the original Knee Control exercise program offering a wider selection of exercises (to increase adherence) and more physically challenging exercises (adapted for athletes in the late teens and provide further stimuli to increase player performance and neuromuscular function). The program will be performed during the warm-up to each football practice (at least twice per week) during the 12 week intervention period.
2448691|NCT03250754||Pharmacological treatment group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a prophylactic treatment alone
2448696|NCT03250754||Electroacupuncture group|Treatment decision making is based on physician's choice and patient preferences. Patients were referred to the Pain Service Unit. Patients continued with a new prophylactic treatment and additionally, received 12 sessions of acupuncture. The treatments, which included electro-stimulation.
2448751|NCT03250078||FAMILIAL PANCREATIC CANCER and/or GENE MUTATION|An inherited genetic syndrome associated with Pancreatic Cancer and/or with a strong family history of Pancreatic Cancer.
2448791|NCT03249649||Phoenix Cohort|Somali Refugee women ages 15 and older
2448793|NCT03249649||Tucson Cohort|Somali Refugee women ages 15 and older
2448815|NCT03249363|Experimental|Group A - Pulsed PVP-I Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with Povidone-Iodine (PVP-I) diluted to a 3% concentration (30g/l) in 2 l of saline performed before applying the bone graft
2448820|NCT03249363|Active Comparator|Group B - Pulsed Saline Irrigation|Group in wich the patients who underwent spinal surgery were treated with 5-10 minutes of low-pressure irrigation with only 2 litres of saline solution (without povidone Iodine) performed before applying the bone graft
2448872|NCT03249194|Experimental|HCV+ Donor Kidney Recipient|"All HCV- participants who receive an HCV+ donor kidney transplant will receive a first 'on-call' dose of Epclusa (sofosbuvir/velpatasvir; Gilead) and then three more doses on post-operative Day 1, 2 and 3. Donor HCV Genotype data will be available by Day 7 of transplant.~Patients will then be followed by serial HCV PCRs. Patients who are HCV PCR positive by Day 14 will be treated with Epclusa once daily x 12 weeks."
2448911|NCT03248908|Experimental|Intervention 1|Pupillary dilation reflex based perioperative intravenous remifentanil administration. Starting dose 5 ng/ml by continous infusion, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, the dosage is decreased with 0.2 ng/ml. When PPI score is greater than 1, the dosage is increased with 0.2 ng/ml.
2448914|NCT03248908|Active Comparator|Intervention 2|Anesthesiologist based perioperative intravenous remifentanil administration (daily practice, standard of care). Starting dose 5 ng/ml, dosage adjustments are made when deemed necessary by attending anesthesiologist.
2448915|NCT03248908|Experimental|Intervention 3|Pupillary dilation reflex based perioperative intravenous sufentanil administration. Starting dose 0.1 mcg/kg bolus, dosage adjustments are made after pupillary dilation reflex assessment every 10 minutes. When PPI score is 1, no supplementary administration is executed. When PPI score is greater than 1, a supplementary bolus of 0.1 mcg/kg is given.
2448918|NCT03248908|Active Comparator|Intervention 4|Anesthesiologist based perioperative intravenous sufentanil administration (daily practice, standard of care). Starting dose 0.1 mcg/kg bolus, dosage adjustments are made when deemed necessary by attending anesthesiologist.
3190025|NCT00783172|Experimental|OGF & Gemcitabine|Opioid Growth factor 250 ug/kg IV once a week. Gemcitabine 1000 mg/m2 weekly for 7 out of 8 weeks induction then every 3 out of 4 week cycles.
2447661|NCT03257020||Normal subject|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is within the normal range and those with no history of ocular disease, an intraocular pressure < 21 mmHg, an absence of glaucomatous optic disc appearance, and a normal visual field, they will be classified into normal group.
2447663|NCT03257020||Glaucoma patients|Measure BMO-MRW and RNFL with SD-OCT. If the BMO-MRW and RNFL is below the normal range and those with glaucomatous optic disc and two consecutive abnormal visual field test results with open angles on gonioscopy, glaucomatous optic neuropathy, RNFL defects congruent with visual field defects, they will be classified into glaucoma patients.
2447720|NCT03256708|Experimental|Prolardii|Prolardii GR Caps includes 4 strains of living lyophilized lactic bacteria (Lactobacillus rhamnosus GG, Bifidobacterium lactis B94, Lactobacillus casei 5773 and Lactobacillus acidophilus LA3), a yeast (Saccharomyces boulardii), a fructo-oligosaccharide (Actilight) and a dry extract of Inula helenium.
2447722|NCT03256708|Placebo Comparator|Placebo|Inactive ingredients
2447777|NCT03256201|Experimental|Standard Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
2447783|NCT03256201|Experimental|Enhanced Exercise Group|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
2447834|NCT03255759|Active Comparator|Molecular dx arm|Positive blood cultures are tested using a molecular ID system in addition to the standard of care (biochemical identification)
2447840|NCT03255759|No Intervention|Standard of care arm|Positive blood cultures are treated as per normal lab protocol (biochemical identification)
2447890|NCT03255460||Multiple Sclerosis individuals|Multiple sclerosis patients included in this study. Inclusion and exclusion criteria were considered.
2447895|NCT03255460||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
2447996|NCT03255031|Active Comparator|Diet Randomization-KD|Diet consists of a ketogenic diet (KD) snacks and shakes 3x p/day (high in fat). SA will receive the same KD solid snacks, in order to keep the diets blind to participants. KD will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
2447999|NCT03255031|Placebo Comparator|Diet Randomization-SA|Standard American (SA) diet consists of shakes 3x p/day in the proportions of carbohydrates, protein and fat of traditional western diet. SA will receive the same KD solid snacks, in order to keep the diets blind to participants. SA will be eucaloric such that a standard equation based on weight, height, sex and age will be used to determine how many calories are provided to each participant.
2448026|NCT03254498|Active Comparator|Endocuff assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
2448028|NCT03254498|Placebo Comparator|Cap assisted colonoscopy|Participants are randomised to undergo first either with Endocuff or cap assisted colonoscopy during colonoscopy.
2448109|NCT03254355|Experimental|Multimodal physiotherapy|12 weeks of weekly multimodal physiotherapy treatments
2448113|NCT03254355|No Intervention|Waiting-list control group|12 weeks of weekly full-body relaxation massage
2448199|NCT03253822|Experimental|Intervention group|"This group receives a baseline questionnaire before their screening invitation. Respondents are included, and those receiving a screening reminder receive the decision aid.~At least three months after their screening invitation the included citizens (baseline questionnaire respondents) will receive a follow-up questionnaire."
2448203|NCT03253822|No Intervention|Control group|This group receives a baseline questionnaire before their screening invitation. Respondents are included. At least three months after their screening invitation, baseline questionnaire respondents will receive a follow-up questionnaire.
2448207|NCT03253822|No Intervention|Historic cohort|A group of people already invited for colorectal cancer screening. This group receives a questionnaire at least three months after their screening invitation. Respondents are included in the study.
2448241|NCT03253224|Placebo Comparator|Saline|Patient who received normal saline during the operation
2448247|NCT03253224|Experimental|Magnesium|Patient who received magnesium sulfate during the operation
2448282|NCT03252977|Experimental|Tailored group|Tailored regimen of IV PCA according to pain sensitivity The regimen of IV PCA will be determined according to preoperative pain sensitivity of patients. Pressure pain threshold will be measured preoperatively in these patients using pressure algometer. Patients with low pain threshold will use high dose IV PCA containing fentanyl 1500mcg, while patients with high pain threshold will use low dose IV PCA containing fentanyl 1000mcg.
2448283|NCT03252977|Sham Comparator|control group|Regimen of IV PCA without considering pain sensitivity The regimen of IV PCA will be determined according to experimental group patient assignments. Pressure pain threshold will not be measured in these patients. Patients will use IV PCA with fentanyl 1000mcg or fentanyl 1500mcg. The determination will be paired to assignment of experimental group.
2448367|NCT03252509|Experimental|Percutaneous radiologic gastrostomy.|Outpatient percutaneous radiologic gastrostomy in patients with head and neck tumors before, during or after the oncologic treatment.
2448402|NCT03252197|Experimental|New device group|participants who are tested performance for ultrasound guided cannulation using device
2448410|NCT03252197|Active Comparator|Conventional group|participants who are tested performance for ultrasound guided cannulation using conventional method
2448452|NCT03251898||study group|pregnant women who are diagnosed as PROM or chorioamnionitis and whose gestational age is ≥ 24 weeks
2448458|NCT03251898||control group|pregnant women without PROM and chorioamnionitis
2448517|NCT03251547||NovoSeven|Non-hemophiliac patients experienced massive haemorrhage who was treated with recombinant activated factor VII
2448671|NCT03250403|Experimental|PRP injection|
2448672|NCT03250403|Active Comparator|medical treatment|
2448758|NCT03250143|Active Comparator|group A|Oral cyclosporine 3mg/kg/day (200mg/day) will be started.If there is no improvement in 1 week then escalating the dose maximum upto 5mg/kg/day.
2447679|NCT03257046|Placebo Comparator|Placebo|Administered once daily for 7 days
2447692|NCT03256539|Experimental|Sleep Intervention|Sleep treatment program (to be developed) that incorporates modified cognitive behavioral therapy for insomnia (CBT-I) and bright light therapy (BLT)
2447699|NCT03256539|Placebo Comparator|Placebo intervention|Placebo (quasi-desensitization) intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration).
2447757|NCT03256383||Adult|Patients aged 18+ years
2447758|NCT03256383||Children 7 - 17|Patients aged 7 - 17 years
2447760|NCT03256383||Children <7|Patients aged under 7 years
2447820|NCT03255850||Adolescents with CHD|Adolescents with CHD are required to complete the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES)
2447826|NCT03255850||Healthy control|Data of healthy control who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
2447829|NCT03255850||Childhood cancer survivors|Data of childhood cancer survivors who completed the Chinese version of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), Center for Epidemiological Studies -Depression Scale (CES-DC) and Rosenberg Self-Esteem Scale (RSES) are retrieved from previous studies.
2447873|NCT03255525|Active Comparator|Deep friction massage P50|In this group it was applied a pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2447879|NCT03255525|Experimental|Deep friction massage P25|In this group it was applied the percentile 25, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2447883|NCT03255525|Experimental|Deep friction massage P75|In this group it was applied the percentile 75, of the pressure previously found to be the mean pressure applied by physiotherapists during deep friction massage.
2447978|NCT03255096|Experimental|Dose Escalation Phase (Part 1)|Participants will receive either RO6870810 and venetoclax or RO6870810 and venetoclax along with rituximab until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
2447984|NCT03255096|Experimental|Expansion Phase (Part 2)|Participants will receive RO6870810 and venetoclax along with rituximab (or RO6870810 and venetoclax, if the combination of the 3 drugs is not tolerable) at a recommended dose established in dose escalation phase until disease progression, unacceptable toxicities or withdrawal from treatment for other reasons, or death.
2448128|NCT03254082|Experimental|F-1000 (fontanelle flour)|Fontenel sorghum flour
2448130|NCT03254082|Experimental|Sumac|Sumac sorghum flour
2448132|NCT03254082|Experimental|Wheat|Wheat flour
2448135|NCT03254082|Experimental|MMR|MMR cultivar of sorghum flour -- from MMR Genetics, a company that produces sorghum seed.
2448137|NCT03254082|Active Comparator|Sucrose|Table sugar
2448168|NCT03253679|Experimental|Treatment (adavosertib)|Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2448255|NCT03253367||Current/former clozapine users|This group has only one visit.
2448259|NCT03253367||New clozapine users|This group will be followed for 6 months prospectively.
2448439|NCT03252522|Experimental|Intervention|Capsules of broad spectrum micronutrients: a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants.
2448440|NCT03252522|Placebo Comparator|Placebo|Capsules of inactive placebo.
2448441|NCT03252522|Experimental|Open Label|All participants have the option to participate in an 8-week, naturalistic, open label follow-up in which the child will take the active micronutrient treatment; capsules of broad spectrum micronutrients.
2448453|NCT03251690|Experimental|Switching TDF/FTC/EFV to TDF/FTC/RPV|Switching from Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day (once daily) to Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Rilpivirine 25 mg/day (once daily) Intervention: Tenofovir/Emtricitabine/Rilpivirine
2448457|NCT03251690|Active Comparator|Continuing TDF/FTC/EFV|Continuing Tenofovir 300 mg/day + Emtricitabine 200 mg/day + Efavirenz 600 mg/day Intervention: Tenofovir/Emtricitabine/Efavirenz
2448511|NCT03251495|Experimental|Vaxchora Vaccination|Healthy subjects will receive a single dose of oral live cholera vaccine.
2448597|NCT03251170|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2448599|NCT03251170|Active Comparator|Fentanyl|2.5 mg/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2448667|NCT03250585||Sickle Cell Patients with Acute Chest Syndrome|Sickle cell patients with active acute chest syndrome (ACS) from which samples of EBC and plasma will be collected during acute illness within 48 hours of admission with or diagnosis of ACS (Time point 1) in 3 sessions each 1 hour apart (Time point 1a, 1b, and 1c), and 2 weeks after discharge when have returned to steady-state (Time point 2). Time point 2 samples will serve as control (baseline) samples.
2448935|NCT03248778|No Intervention|Treatment as Usual|
3190026|NCT00783185|Experimental|ACT|Anti-Cannabis-Consumption-Training
3190027|NCT00783185|Active Comparator|CG|Control group
3190028|NCT00783211|Experimental|1|desloratadine
2447910|NCT03255265||Acute rejection|
2447913|NCT03255265||No acute rejection|
2447951|NCT03254940|Experimental|Arm 1: WT-SM-OR-SS-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to self
2447953|NCT03254940|Experimental|Arm 2: WT-SM-OR-SS-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, summary score, compare to group
2447956|NCT03254940|Experimental|Arm 3: WT-SM-OR-SF-CS|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self
2447959|NCT03254940|Experimental|Arm 4: WT-SM-OR-SF-CG|Charge: weekly tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
2447965|NCT03254940|Experimental|Arm 5: WT-SM-MR-SS-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to self.
2447968|NCT03254940|Experimental|Arm 6: WT-SM-MR-SS-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
2447971|NCT03254940|Experimental|Arm 7: WT-SM-MR-SF-CS|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to self
2447973|NCT03254940|Experimental|Arm 8: WT-SM-MR-SF-CG|Charge: weekly tracking, self-generated motivational messages, multiple reminders, specific feedback, compare to group
2447976|NCT03254940|Experimental|Arm 9: WT-EM-OR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to self
2447980|NCT03254940|Experimental|Arm 10: WT-EM-OR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, summary score, compare to group
2447988|NCT03254940|Experimental|Arm 11: WT-EM-OR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
2447992|NCT03254940|Experimental|Arm 12: WT-EM-OR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group.
2447997|NCT03254940|Experimental|Arm 13: WT-EM-MR-SS-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
2448000|NCT03254940|Experimental|Arm 14: WT-EM-MR-SS-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders,summary score, compare to group
2448003|NCT03254940|Experimental|Arm 15: WT-EM-MR-SF-CS|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
2448004|NCT03254940|Experimental|Arm 16: WT-EM-MR-SF-CG|Charge: weekly tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group
2448006|NCT03254940|Experimental|Arm 17: DT-SM-OR-SS-CS|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to self.
2448007|NCT03254940|Experimental|Arm 18: DT-SM-OR-SS-CG|Charge: daily tracking, self-generated motivational messages, one reminder, summary score, compare to group
2448009|NCT03254940|Experimental|Arm 19: DT-SM-OR-SF-CS|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to self.
2448010|NCT03254940|Experimental|Arm 20: DT-SM-OR-SF-CG|Charge: daily tracking, self-generated motivational messages, one reminder, specific goal feedback, compare to group
2448011|NCT03254940|Experimental|Arm 21: DT-SM-MR-SS-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to self
2448012|NCT03254940|Experimental|Arm 22: DT-SM-MR-SS-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, summary score, compare to group.
2448013|NCT03254940|Experimental|Arm 23: DT-SM-MR-SF-CS|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to self.
2448014|NCT03254940|Experimental|Arm 24: DT-SM-MR-SF-CG|Charge: daily tracking, self-generated motivational messages, multiple reminders, specific goal feedback, compare to group
2448015|NCT03254940|Experimental|Arm 25: DT-EM-OR-SS-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to self
2448016|NCT03254940|Experimental|Arm 26: DT-EM-OR-SS-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, summary score, compare to group
2448017|NCT03254940|Experimental|Arm 27: DT-EM-OR-SF-CS|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to self
2448018|NCT03254940|Experimental|Arm 28: DT-EM-OR-SF-CG|Charge: daily tracking, expert-generated motivational messages, one reminder, specific goal feedback, compare to group
2448019|NCT03254940|Experimental|Arm 29: DT-EM-MR-SS-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to self
2448020|NCT03254940|Experimental|Arm 30: DT-EM-MR-SS-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, summary score, compare to group
2448021|NCT03254940|Experimental|Arm 31: DT-EM-MR-GF-CS|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to self
2448022|NCT03254940|Experimental|Arm 32: DT-EM-MR-GF-CG|Charge: daily tracking, expert-generated motivational messages, multiple reminders, specific goal feedback, compare to group.
2448097|NCT03254186|Experimental|Propranolol Hydrochloride|Two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks then will remain on a stable dose for six weeks. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
2448102|NCT03254186|Placebo Comparator|Placebo Oral Tablet|Identical placebo. The patients will be treated for eight weeks, complete a one week washout and then crossed over to another arm for eight weeks.
2448174|NCT03253861||control patients|patients without an infected pancreatic necrosis
2448177|NCT03253861||Case patients|patients with an infected pancreatic necrosis
2448218|NCT03253419|Other|Home Safety Application|Use of Home Safety application as part of assessment for home safety. The only intervention is the use of the home safety application and identification of home safety issues by the patient using this application.
3190029|NCT00783211|Active Comparator|2|fexofenadine
3190030|NCT00783211|Placebo Comparator|3|placebo
3190031|NCT00783237|Experimental|Mometasone Furoate Nasal Spray|
3153320|NCT00272181|Experimental|Dose Determination|The recommended dose (RD) for Proxinium is to be determined based on the rate of Dose Limiting Toxicities (DLT) within each dose cohort. The RD is to be established as the highest dose at which one or fewer patients out of six within a dose cohort experienced a DLT. The initial dose level is 500 μg of Proxinium in PBS (the amount of PBS used will be based on the estimated volume of the target tumour). Doses are to be escalated to a maximum of 700 μg or de-escalated to a minimum of 260 μg according to the prescribed algorithm outlined in the study protocol.
3153321|NCT00272220|Experimental|1|receive 6-week intervention of peer-delivered mDOT
3190032|NCT00783237|Placebo Comparator|Placebo Nasal Spray|
3190033|NCT00783250|Experimental|Salbutamol+Tiotropium|Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms
3190034|NCT00783250|Placebo Comparator|placebo + Tiotropium|Placebo using MDI + administration of Tiotropium after 20 minutes
3190035|NCT00783276|Placebo Comparator|Sugar Pill|Placebo
3153322|NCT00272220|No Intervention|2|
3153323|NCT00272272|Experimental|Balance and Music Listening|Music therapy
3153324|NCT00272285|Experimental|1|Intravenous (IV)
2447955|NCT03254810|Experimental|SYN060|a single 0.57 mg/kg dose of SYN060
2447958|NCT03254810|Active Comparator|Adalimumab North American source|a single 0.57 mg/kg dose of adalimumab from North American source
2447964|NCT03254810|Active Comparator|Adalimumab European source|a single 0.57 mg/kg dose of adalimumab from European source
2448062|NCT03254576||Children at high-risk for obesity|Healthy-weight children (30th-75thBMI%) with two overweight/obese parents (BMI>25)
2448066|NCT03254576||Children at low-risk for obesity|Healthy-weight children (30th-75thBMI%) with two healthy-weight parents (BMI = 18-24.9)
2448090|NCT03254251|Experimental|Stair Climbing (SC)|N=20, 12 weeks of stair climbing exercise training.
2448091|NCT03254251|No Intervention|No Exercise (CON)|N=21, No exercise for 12 weeks
2448156|NCT03253991|Experimental|MRgFUS treatment|MRgFUS device treatment, thalamotomy
2448254|NCT03253562|No Intervention|Healthy control|healthy volunteers not suffering from diabetes or hypertension
2448258|NCT03253562|No Intervention|diabetic hypertensive recently diagnosed patients|recently diagnosed patients suffers from diabetes type 2 and hypertension but didnot receive their proper treatment yet
2448261|NCT03253562|Other|Metformin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and metformin for their diabetes
2448264|NCT03253562|Other|Vildagliptin treated group|diabetic hypertensive patients which were treated with captopril for their hypertension and vildagliptin for their diabetes
3153325|NCT00272285|Active Comparator|2|Intravenous (IV)
3153326|NCT00272402|Other|1|Simulated case-based learning
3153327|NCT00272402|Other|2|EMR clinical decision support tool.
2448384|NCT03252405|Active Comparator|mask ventilation|induction is made with mask ventilation
2448387|NCT03252405|Experimental|intravenous induction|induction is made with intravenous cannulation
2448525|NCT03251339|Experimental|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
2448532|NCT03251339|Experimental|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
2448574|NCT03251053|Experimental|Electronic cigarette use|Subjects who try to switch to electronic cigarettes (EC) and subjects who successfully switch to EC.
2448576|NCT03251053|Other|Control regular cigarette smokers|Habitual smokers without EC use
2448630|NCT03250819||Corticosteroid responders|Patients who develop an increase in eye pressure after the use of corticosteroids
2448632|NCT03250819||Non-corticosteroid responders|Patients who use/used corticosteroids but didn't develop an increase in eye pressure
2448647|NCT03250546|Experimental|Haplo-identical group|
2448651|NCT03250546|Active Comparator|HLA-9/10 MMUD group|
2448719|NCT03250312|Active Comparator|The OMT group|This group will be treated by the osteopathic manipulation techniques (OMT). The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping. The total treatment time will not to exceed 20 minutes.
2448720|NCT03250312|No Intervention|The control group|"The control group will wait in another room for approximately 30 minutes.~To encourage participation in the proposed study, participants who are assigned to the control group will have an opportunity to receive OMT after the second blood draw"
2448772|NCT03250039|Experimental|Mass Balance|Cumulative recovery of radioactivity in urine and feces
2448779|NCT03250039|Experimental|Absolute Bioavailability|Oral absolute bioavailability
3190036|NCT00783276|Active Comparator|SYN115|
3153328|NCT00272402|No Intervention|3|Control group
3153329|NCT00272415|Experimental|1|
3153330|NCT00272467|Experimental|Rebamipide|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) Rebamipide 100mg, t.i.d. (before breakfast, evening, before bed).~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
3190037|NCT00783315|Active Comparator|1|Self-Directed Weight Loss Program (Control Group)
3190038|NCT00783315|Experimental|2|Call-Center Directed (CCD) Weight Loss Program
3190039|NCT00783315|Experimental|3|In-Person Directed (IPD) Weight Loss Program
3190040|NCT00783328|Experimental|1|Open label single arm trial
3190041|NCT00783341|Experimental|GAP-134|
3190042|NCT00783341|Placebo Comparator|placebo|
3190043|NCT00783354|Active Comparator|Continuous Treatment|
3190044|NCT00783354|Experimental|PRN regimen|
3190045|NCT00783380|Experimental|Virosomal influenza vaccine|
3190046|NCT00783380|Active Comparator|Subunit influenza vaccine|
3190047|NCT00783393|Experimental|Single arm|"The study consists of two steps:~Step 1, the therapeutic study phase, comprising six cycles of treatment with temozolomide, and~Step 2, the long-term treatment phase, where subjects with at least disease stabilization at the end of Step 1 may continue temozolomide treatment until unacceptable toxicity or disease progression occur, up to a maximum of 2 years from the start of treatment in Cycle 1."
2447859|NCT03255603|Experimental|Modified potato starch|Modified potato starch is a resistant starch type IV and will be used as an experimental arm.
2447860|NCT03255603|Experimental|Modified corn starch|Modified corn starch is a resistant starch type IV and will be used as an experimental arm.
2447861|NCT03255603|Experimental|Modified tapioca starch|Modified tapioca starch is a resistant starch type IV and will be used as an experimental arm.
2447862|NCT03255603|Placebo Comparator|Corn starch|Corn starch is digestible and will therefore will be used as a placebo control for the study.
2447872|NCT03255226|Experimental|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
2447923|NCT03255148|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716); single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2447924|NCT03255148|Placebo Comparator|Placebo|saline natriumchloride solution nasal spray; single intranasal dose (3 puffs per nostril)
2448037|NCT03254784|Experimental|Tablet-Capsule Crossover 1|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448041|NCT03254784|Experimental|Tablet-Capsule Crossover 2|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448044|NCT03254784|Experimental|Tablet-Capsule Crossover 3|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448049|NCT03254784|Experimental|Tablet-Capsule Crossover 4|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448056|NCT03254784|Experimental|Tablet-Capsule Crossover 5|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448058|NCT03254784|Experimental|Tablet-Capsule Crossover 6|Variations between arms dependent on timing, fasting, dose and receiving the tablet or capsule at different treatment period combinations
2448089|NCT03254121||Patients with SVR and developed HCC|HCV patients with SVR and developed HCC plus available tissue from HCC
2448157|NCT03253978|Experimental|SABR to prostate / seminal vesicles with pelvic ENI|36.25Gy / 5 fractions to prostate and seminal vesicles with additional SABR (25Gy /5 fractions) delivered to the pelvic nodes.
2448159|NCT03253978|Active Comparator|SABR to prostate and seminal vesicles only|36.25Gy / 5 fractions to prostate and seminal vesicles.
2448208|NCT03253614||Exposed group|250 children aged 6-15 years exposed to gentamicin in the neonatal period
2448209|NCT03253614||Control group|25 healthy children aged 6-15 years NOT exposed to gentamicin in the neonatal period
2448267|NCT03253198|Active Comparator|Preoperative block plus saline|Preoperative interscalene brachial plexus single-shot block using 25ml of 0.5% Ropivicaine plus postoperative 40cc local infiltration of saline
2448271|NCT03253198|Active Comparator|Preoperative block plus Bupivacaine extended-release liposome|Interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
2448302|NCT03252808|Experimental|TBI-1401(HF10) + Gem/nab-PTX|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and 1000 mg/m^2 Gemcitabine and 125 mg/m^2 Nab-paclitaxel injected by intravenous infusions.
2448304|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and TS-1 administered by oral.
2448306|NCT03252808|Experimental|TBI-1401(HF10) + TS-1 (primary and meta)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered to the primary tumor in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection and hepatic metastasis in a total volume up to 2.0 mL (injection volume will be adjusted based on the tumor size) by EUS-guided intratumoral injection or percutaneous injection and TS-1 administered by oral.
2448401|NCT03252093|Experimental|Angiotensin-(1-7)|Intervention: Drug: 200 mcg/kg/day injected subcutaneously once daily for 21 days
2448408|NCT03252093|Placebo Comparator|Placebo for Angiotensin-(1-7)|Intervention: Placebo for Angiotensin-(1-7) injected subcutaneously once daily for 21 days
2448454|NCT03251794||threatened preterm labor|women presented to the reception unit from 28-37 weeks by regular contractions and opened cervix
2448501|NCT03251586|Experimental|20-29|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448504|NCT03251586|Experimental|30-39|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448506|NCT03251586|Experimental|40-49|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448515|NCT03251586|Experimental|50-59|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448520|NCT03251586|Experimental|60-69|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
3190048|NCT00783406|Experimental|PF- 00610355|
3190049|NCT00783406|Experimental|PF-00610355|
3190050|NCT00783406|Experimental|PF -00610355|
3190051|NCT00783406|Placebo Comparator|Placebo|
3190052|NCT00783445|Experimental|1|Exercise in a community setting while supervised by a coach
3190053|NCT00783445|Active Comparator|2|Self-exercise plan based on an individualized prescription after an initial fitness evaluation
3190054|NCT00783458|Active Comparator|Nasonex Followed by Flonase|
3190055|NCT00783458|Active Comparator|Flonase Followed by Nasonex|
3190056|NCT00783471|Experimental|1|Erlotinib followed by Docetaxel
2447914|NCT03255239|Experimental|Preperitoneal mesh repair|Ventral hernia repair using polyester preperitoneal mesh repair
2447915|NCT03255239|Experimental|Retromuscular mesh repair|Ventral hernia repair using polyester retromuscular mesh repair
2447917|NCT03255239|Experimental|Suture repair|Ventral hernia repair using suture repair
2447936|NCT03254862|Experimental|Group A: CSS & AsynS|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Sequential Stimulation (ASynS) - CSS/ASynS"
2447939|NCT03254862|Experimental|Group B: CSS & AsynR|"Electrical stimulation training on both legs:~Conventional synchronous stimulation (CSS) and Asynchronous Random Stimulation (ASynR) - CSS/ASynR"
2448008|NCT03254732|Experimental|ADI-PEG 20|This is a phase 1b, open label trial of ADI-PEG 20 (36 mg/m2) weekly in combination with pembrolizumab (1 and 2 mg/kg or 200 mg) every three weeks.
2448071|NCT03254433|Experimental|BAS+|As part of the main study, participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
2448075|NCT03254433|Placebo Comparator|SC|As part of the main study, participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
3190057|NCT00783471|Experimental|2|Docetaxel followed by Erlotinib
2448183|NCT03253536||entire cohort|none (observational study)
2448212|NCT03253341|Experimental|Smart Aging Program|Participants will be enrolled into the Smart Aging Program.
2448213|NCT03253341|Active Comparator|Control Group|Participants will be enrolled into group that receives educational materials that reflect the current standard of care.
2448275|NCT03253133|Experimental|Oxaliplatin|"IP neoadjuvant chemotherapy protocol:~Oxaliplatine will be administered in IP in a total solution of 2L of serum G5%. A continuous infusion pump of Oxycodone would be administered for the entire duration of the intraperitoneal chemotherapy. Perfusion time for the intraperitoneal chemotherapy is estimated but not limited to one and a half hour.~Intravenous chemotherapy protocol:~Associated Intravenous (systemic) chemotherapy is administered during IP chemotherapy including at least LVFU2 (5FU-Leucovorin) or FOLFIRI (5FU-Irinotecan) regimens and targeted therapy if needed."
2448343|NCT03252743|Experimental|Internet-delivered CBT|Exposure-based internet-delivered CBT with ten weekly modules distributed over the internet during ten weeks, and weekly therapist support over the internet.
3190058|NCT00783484|Experimental|Cohort 1|PF-03716539 crossover, single dose escalation (doses subject to change).
3190059|NCT00783484|Experimental|Cohort 2|PF-03716539 crossover, single dose escalation (doses subject to change).
2448514|NCT03251625|Placebo Comparator|To assess the effect of multistrain probiotics on abdominal|To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients.
2448518|NCT03251625|Placebo Comparator|To assess the efficacy of a multistrain probiotic supplement|To assess the efficacy of a multistrain probiotic supplement as a treatment option for IBS in a tertiary referral centre
2448598|NCT03251144|Experimental|Switch to E/C/FTC/TAF daily|"Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be~If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months.~If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
2448677|NCT03250715|Experimental|Low Level Laser Therapy group|Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.
2448681|NCT03250715|No Intervention|Control group|This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.
2448755|NCT03250156|Experimental|MBAT with proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the proctored practice group will complete assigned, out of class mindfulness exercises during the duty day - for example, as part of their daily physical training (e.g., mindful cooldown, final 15 minutes of PT is spent engaging in a mindfulness exercise using a guided recording).
2448757|NCT03250156|Active Comparator|MBAT with non-proctored practice|Participants will engage in Mindfulness Based Attention Training (MBAT) in 4, 2-hour training classes with 1 class per week. Participants in the non-proctored practice group will complete assigned, out of class mindfulness exercises on their own time with no structured duty day support.
2448760|NCT03250156|No Intervention|No Training Control|This group will receive no intervention.
2448827|NCT03249597||1. Suspected Infection.|Adult (≥18 years), non-trauma patient transported by the ambulance, who according to the EMS suffer from an infection.
2448831|NCT03249597||2. Control|Adult (>18 years of age), non-trauma patient immediately following the included patient with suspected infection, transported in the same ambulance but without infection.
2448892|NCT03249103|Placebo Comparator|Placebo|Up to 24 subjects will receive Placebo, NYX-2925 Low Dose, and NYX-2925 High Dose
2448893|NCT03249103|Experimental|NYX-2925 High Dose|Up to 24 subjects will receive High Dose of NYX-2925
2448896|NCT03249103|Experimental|NYX-2925 Low Dose|Up to 24 subjects will receive Low Dose of NYX-2925
2448970|NCT03248661|Experimental|Intervention media condition|monthly social media contact will be used to keep people connected to the idea of completing a second screening test 12 months after their last one.
2448976|NCT03248661|No Intervention|control condition|this group will receive only a standard reminder for the annual repeat test, one month before the test due date
3190060|NCT00783484|Experimental|Cohort 3|Midazolam-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
3190061|NCT00783484|Experimental|Cohort 4|Darunavir-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
3190062|NCT00783484|Experimental|Cohort 5|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 doses subject to change).
2448138|NCT03254056|Active Comparator|Conventional Technique|The edges of the fascia will be hold by the surgical instruments. The fascial defect will be repaired by using devices which are generated for laparotomy operations.
2448139|NCT03254056|Active Comparator|Berci Technique|This instrument facilitates full thickness abdominal wall closure under the view of laparoscopic optic.
3153331|NCT00272467|Active Comparator|Omeprazole|"Dosage (1) The eradication therapy period (for all cases) Amoxicillin 2,000mg/day, clarithromycin 1,000 mg/day and omeprazole 40 mg/day. b.i.d. (morning and evening), oral administration. (2) The ulcer treatment period (on a double-blind basis) omeprazole 20mg, once daily (before breakfast)~Drug period (1) The eradication therapy period: 1 week (2) The ulcer treatment period: 7 weeks"
3153332|NCT00272480|Placebo Comparator|Placebo|Placebo in HAM/TSP 24
2448214|NCT03253471|Experimental|AL-611|
2448215|NCT03253471|Placebo Comparator|Placebo to Match AL-611|
2448280|NCT03253120|Other|Patient|Patients will drink 5dl of water.
2448281|NCT03253120|Other|Healthy volunteer|Healthy volunteers will drink 5dl of water.
2448346|NCT03252704|Experimental|High fiber - low fiber|Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top)
2448349|NCT03252704|Experimental|low fiber - high fiber|Treatment order described in arm title, conventional flour (low fiber muffin top)- resistant starch (high fiber muffin top)
2448420|NCT03252327|No Intervention|routine care|Preterm infants in the control condition will receive only usual neonatal intensive care units (NICU) care
2448421|NCT03252327|Experimental|Multiple Sensory Integrations(1)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2448424|NCT03252327|Experimental|Multiple Sensory Integrations(2)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2448427|NCT03252327|Experimental|Multiple Sensory Integrations(3)|The sensory integrations are provided through combining the use of sensory integrations ( olfactory, taste, auditory or tactile).
2448445|NCT03251833||obese|Body mass index >30 Kilogram/m2
2448446|NCT03251833||non-obese|Body mass index <30 Kilogram/m2
3153333|NCT00272480|Active Comparator|Zidvoudine plus lamivudine|Zidvoudine plus lamivudine in HAM/TSP 24
3153334|NCT00272493|Active Comparator|A|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
2448528|NCT03251300|Experimental|group A|daytime dosing of mirabegron
2448539|NCT03251300|Active Comparator|group B|nighttime dosing of mirabegron
2448615|NCT03251014|Experimental|YSS/salmon group|YSS followed by salmon
2448619|NCT03251014|Experimental|Salmon/YSS group|Salmon followed by YSS
2448646|NCT03250559|Active Comparator|ultrasound guided group|"The group of renal stones that would have percutaneous nephrolithotomy under ultrasound guidance.~Intervention: percutaneous nephrolithotomy."
2448655|NCT03250559|Active Comparator|fluoroscopy guided group|"The group of renal stones that would have percutaneous nephrolithotomy under fluoroscopy guidance.~Intervention: percutaneous nephrolithotomy."
2448756|NCT03250299|Experimental|Dose Finding|Fixed 3+3 dose escalation of BAL101553 (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
2448759|NCT03250299|Experimental|Expansion Cohort|BAL101553 at the MTD / highest dose considered safe (7 days per week), combined with RT days 1-5 for 6 weeks followed by 4 week rest.
2448824|NCT03249376|Experimental|Lumateperone|Lumateperone (ITI-007 60 mg) administered once daily every evening for 6 weeks
2448829|NCT03249376|Placebo Comparator|Placebo|Placebo administered once daily every evening for 6 weeks
2448921|NCT03248843|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1.0, 2.5, 5.0 and 10 mg/kg weekly. Dose escalation will continue until identification of MTD up to a maximum dose of 10 mg/kg.
2448975|NCT03248466|Placebo Comparator|Traditional treatment|Traditional treatment such as insulin,antidiabetes,dressing
2448981|NCT03248466|Experimental|PRG combined with BMMSCs transplantation|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG combined with BMMSCs
2448985|NCT03248466|No Intervention|PRG treatment|Traditional treatment such as insulin,antidiabetes,dressing and Autologous PRG
2449084|NCT03248128|Experimental|Subjects receiving FF/VI in cohort A|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 50/25 mcg administered once daily in the morning via ELLIPTA DPI.
2449089|NCT03248128|Active Comparator|Subjects receiving FF in cohort A|Subjects will be randomized in 1:1 ratio to receive FF with a dose of 50 mcg administered once daily in the morning via ELLIPTA DPI.
2449092|NCT03248128|Experimental|Subjects receiving FF/VI in cohort B|Subjects will be randomized in 1:1 ratio to receive a FDC of FF/VI with a dose of 100/25 mcg administered once daily in the morning via ELLIPTA DPI.
3153335|NCT00272493|Experimental|B|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
3153336|NCT00272519|Experimental|Adolescent/caregiver dyads|Eight to ten adolescent/caregiver dyads
3153337|NCT00272545|Experimental|1|Participants will receive the normalization of eating program
3153338|NCT00272545|Active Comparator|2|Participants will receive treatment as usual
3153339|NCT00272597|Other|Risperidone LAI|"Subjects treated with any antipsychotic can be switched to Risperidone LAI.~If the subject is currently treated with an antipsychotic other than risperidone, the dosage will be tapered gradually and discontinued. Simultaneously, oral risperidone will be started at 2 mg/day and increased to no more than 6 mg/day. The subject will be treated with risperidone monotherapy for at least five days prior to entering the stabilization phase of the study.~On the other hand, if the patient has already been treated for more than 5 days with risperidone monotherapy then he/she may enter the stabilization phase of the study immediately."
3153340|NCT00272649|Experimental|Single Arm|Single Arm study
3153341|NCT00272662|Experimental|Cohort 1|Peginesatide starting dose of 0.1 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 3 weeks (Q3W) for a total of 4 doses.
3153342|NCT00272662|Experimental|Cohort 2|Peginesatide starting dose of 0.15 mg/kg administered SC Q3W for a total of 4 doses.
3153343|NCT00272662|Experimental|Cohort 3|Peginesatide starting dose of 0.2 mg/kg administered SC Q3W for a total of 4 doses.
2447940|NCT03254888||High Grade group|"• 50 tumor tissue samples from patients with High Grade Bladder Cancer undergoing either trans urethral resection of bladder tumor or Radical Cystectomy,~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction) ."
2447942|NCT03254888||Safety margin group|"• 50 normal bladder urothelial tissue samples from the safety margin around the tumor(0.5cm to the tumor),~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction)."
2447943|NCT03254888||Control group|"• 50 (age and sex matched )control~The followings markers must be estimated :~Autophagy markers:~( Atg7) level using (quantitative real time polymerase chain reaction).~(LC3A)level using immunohistochemistry .~ER-stress marker: (ATF6) level using ELISA(Enzyme Linked Immuno sorbent Assay)~Oxidative stress Marker:(MDA)using chemical method~Apoptotic marker:(caspase 3) using (quantitative real time polymerase chain reaction).."
2448034|NCT03254745|Experimental|Pharmacist intervention|"Disease education (General education about rheumatoid arthritis in a verbal and written manner)~Dietary and lifestyle modifications (General recommendations as well as specific ones based on patients' baseline health status)~Counseling regarding adherence (General lecture on adherence to medications and physical rehabilitation in rheumatoid arthritis as well as specific advice based on patients health status)~Advice on medication use (General counseling on medication use as well as patient centered counseling)."
2448036|NCT03254745|No Intervention|Usual care|Patients will not be counseled by pharmacist and will be allowed to take usual care.
2448127|NCT03254342||Major depressive disorder|There is no intervention/treatment in this study.
2448129|NCT03254342||Non-depressed individuals|There is no intervention/treatment in this study.
2448179|NCT03253809|Experimental|Coronary Sinus Branch Pacing|"After cannulation, pacing impulses will be delivered via a Biotronik Vision Guidewire to 3 sites (apical, mid ventricular, and basal) within each coronary sinus branch receiving venous blood from the anterior, lateral and posterior regions of the ventricle.~ECG signals will be saved digitally for analysis"
2448227|NCT03253380|Experimental|early rehabilitation program on mechanical ventilated COPD pat|compare the effect of early rehabilitation program on mechanical ventilated COPD patient in RICU to those using current standard care as regarding (morbidity and thirty day mortality ,diaphragm function and weaning outcomes, disease exacerbation , Duration spent on machin , Length of ICU stay.
2448295|NCT03253107||responder in palliative chemotherapy|After initial chemotherapy, responder (complete remission, partial remission)
2448296|NCT03253107||non-responder in palliative chemotherapy|After initial chemotherapy, disease progression
2448297|NCT03253107||responder in adjuvant chemotherapy|complete cure and no recurrence at least 1 year after treatment
2448298|NCT03253107||non-responder in adjuvant chemotherapy|non-complete cure or recurrence within 1 year after treatment
2448348|NCT03252574|Other|Sequence AB|No mask, followed by AIR+ Smart Mask only (A), then AIR+ Smart Mask with micro-ventilator (B)
2448350|NCT03252574|Other|Sequence BA|No mask, followed by AIR+ Smart Mask with micro-ventilator (B), then AIR+ Smart Mask only (A).
2448423|NCT03252314||Subjects with ruptured aneurysms|
2448546|NCT03251456|Experimental|Tertiary care|
2448550|NCT03251456|Active Comparator|Usual care|
2448616|NCT03250936||Trampoline group|Child patients with trauma due to trampoline from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
2448621|NCT03250936||Control group|Child patients with trauma related to sport from june 2016 to december 2016 consulting in emergencies unit of Rennes' hospital
3190063|NCT00783484|Experimental|Cohort 6|Maraviroc-PF-03716539 drug-drug interaction (PF-03716539 200 mg).
3190064|NCT00783497||1|Caucasian Americans
2448818|NCT03249662|Experimental|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add Normal saline solution(NSS) to 80 ml divided to two syringes for bilateral periarticular infiltration
2448821|NCT03249662|Active Comparator|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
2448920|NCT03249155|Experimental|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture.
2448924|NCT03249155|Active Comparator|CUE - visual and auditory|patients re-learn 8 motor gestures practicing a traditional protocol combining visual and auditory cues.
2448995|NCT03248518|Active Comparator|Usual Care alone|Participants receive written information about fatigue which is designed as self-management guide.
2448998|NCT03248518|Active Comparator|CBA + usual care|In addition to usual care, participants receive a talking therapy using a cognitive behavioural approach. The talking therapy will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 8 sessions over a period of 6 months.
2448999|NCT03248518|Active Comparator|PEP + usual care|In addition to usual care, participants receive a personalised exercise programme. After an initial face-to-face assessment, the remaining programme will be delivered via telephone by a trained rheumatology health care professional who will contact the participant for 7 sessions over a period of 6 months.
2449083|NCT03247959|Experimental|Group A|Group A: Videogame distraction during extraction procedure
2449087|NCT03247959|Experimental|Group B|Group B: Video distraction during extraction procedure
2449091|NCT03247959|Active Comparator|Group C|group C: Verbatim during extraction procedure
2449114|NCT03247595|Active Comparator|Polyethylene Glycol|Polyethylene Glycol 3350: 4 Liters
2449118|NCT03247595|Experimental|Magnesium Citrate Capsules|36 Magnesium citrate capsules
2449176|NCT03247296||Group A|Patients taking Sofosbuvir and Daclatasvir
2449186|NCT03247296||Group B|Patients taking Sofosbuvir,Daclatasvir, and Ribavirin
2452920|NCT03221699|Active Comparator|intervention|Formula with ZnO
3190065|NCT00783497||2|African Americans
2447944|NCT03254797|Experimental|Stepping training with feedback|"Subjects will be instructed to perform the stepping task with external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
2447947|NCT03254797|Active Comparator|Stepping training without feedback|"Subjects will be instructed to perform the stepping task without external feedback continuously until 20 minutes (excluding resting periods) but without fatigue. Then they continue a training program of overground walking for 10 minutes.~They have to be involved in a training program of their groups 5 times/week, for 4 weeks in total."
2448047|NCT03254654|Experimental|Vinorelbine Plus Apatinib|"Vinorelbine: 20 mg/m2, D6, D13, D20~Apatinib: 250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2."
2448052|NCT03254654|Active Comparator|Vinorelbine|Vinorelbine: 25 mg/m2, D1, D8, D15
2448161|NCT03253835||Myocardial Injury|patients with myocardial injuries due to ischemic heart disease, patients with myocardial injuries due to non-ischemic heart disease.
2448162|NCT03253835||No Myocardial Injury|subjects without myocardial injuries with normal cardiac function subjects without myocardial injuries with altered cardiac function
2448197|NCT03253601|Experimental|Strategy Training: iADAPT Application|Participants will use the iADAPT mobile health application to supplement to in-person and remote intervention sessions.
2448198|NCT03253601|Active Comparator|Strategy Training: Workbook|Participants will use a printed workbook to supplement to in-person and remote (by telephone) intervention sessions.
2448246|NCT03253250|Active Comparator|Group A|The subjects will be treated by NAs (ETV, 0.5mg，qd；TDF，300mg，qd；ADV，10mg，qd）for 96 weeks
2448250|NCT03253250|Experimental|Group B|The subjects will be treated by peginterferon alfa-2a （135μg/week）combination with NAs(ETV\TDF\ADV) for 96 weeks.
2448359|NCT03252834||Patients with endometrial or ovarian cancer|
2448363|NCT03252834||Patients with colorectal cancer|
2448443|NCT03252223|Active Comparator|Women with normal menses|
2448444|NCT03252223|Active Comparator|Women with Polycystic Ovary Syndrome|
2448485|NCT03251716|Experimental|berberine adjunctive group|Only one treatment group in this study, without a preset control group,subjects who meet the criteria will entere the berberine adjunctive group
2448529|NCT03251430||Control group|38 patients without gastrectomy , who are similar background in other group, are collected from date Pathologic analysis of primary osteoporosis: investigating age and osteoporosis related changes of bone microstructure by using HR-pQCT (UMIN000023535)
2448540|NCT03251430||Distal Gastrectomy (DG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
2448543|NCT03251430||Total Gastrectomy (TG) group|38 patients with distal gastrectomy due to gastric cancer before no more than 5 years
3153344|NCT00272662|Experimental|Cohort 4|Peginesatide starting dose of 0.05 mg/kg administered SC Q3W for a total of 4 doses.
3153345|NCT00272831|Active Comparator|Cilostazol|Cilostazol 100 mg twice daily
2448686|NCT03250598|Experimental|Cohort A|
2448689|NCT03250598|Experimental|Cohort B|
2448690|NCT03250598|Experimental|Cohort C|
2448780|NCT03250052|Experimental|Part A|Period 1(fimasartan) x 7days - Period 2(fimasartan + linagliptin) x 7days
2448784|NCT03250052|Experimental|Part B|Period 1(linagliptin) x 7days - Period 2(fimasartan + linagliptin) x 7days
2448817|NCT03249480|Experimental|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
2448880|NCT03248921||High-Fit obese|Cardiac surgery patients will be segregated into the high-fit group based on 6 minute walk test distance and other measures of functional capacity
2448881|NCT03248921||Low-Fit obese|Cardiac surgery patients will be segregated into the low-fit group based on 6 minute walk test distance and other measures of functional capacity
2448948|NCT03248544|Experimental|vitamin D|Intervention patients will be received a single dose of 300000 IU vitamin D via intramuscular injection
2448949|NCT03248544|Other|control|Control patients will not be received any intervention
2449002|NCT03248336|Experimental|Vision therapy group|Twelve, 60-minute, weekly visits of office-based vergence/accommodation therapy will be administered by a trained therapist combined with procedures to practice at home (15 minutes, 5 times per week). This treatment sequence is a well-accepted approach for treatment of CI and has been successfully implemented in previous studies. Fifteen minutes of home-based therapy was prescribed to be performed 5 days per week, and compliance with home-based therapy was monitored at each visit by the therapist
3190066|NCT00783510||HUMIRA® Treatment Arm|For patients taking HUMIRA®
2449108|NCT03247582||Edoxaban|NVAF Patients treated with Edoxaban
2449157|NCT03247361|Experimental|High-intensity IMT|"High-intensity IMT + Aerobic/resistance exercise~IMT: Training loads will be adjusted weekly to the maximal inspiratory pressure (MIP). In the first 2 weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 30 sec, with 30-sec of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 10 min and 30 sec. From the third week the protocol will be of 2 min warm-up with intensity 30% of MIP. The training will have 7 peaks of intensity with 70% of MIP for 60 sec, with 60-second of passive rest between the peaks, finishing the training with 20% of MIP for 2 min, totaling 17 min.~Exercise: see group Combined aerobic/resistance exercise"
2449159|NCT03247361|Active Comparator|Low-intensity IMT|"Low-intensity IMT + Aerobic/resistance exercise~IMT:Training loads will be also adjusted weekly to the maximal inspiratory pressure (MIP). In the first two weeks as adaptation, the protocol will be of 2 minutes warm-up with intensity 20% of MIP. The training will be held with 3 sets of 15 repetitions, with 40% of MIP, finishing the training with 20% of MIP for 2 minutes. From the third week the protocol will be of 2 minutes warm-up with intensity 30% of MIP. The training will be held with 3 sets of 15 repetitions, with 60% of MIP, finishing the training with 30% of MIP for 2 minutes.~Exercise: see group Combined aerobic/resistance exercise"
2449171|NCT03247153|Experimental|Corticosteroid Therapy Patients|Corticosteroid therapy patients will be examined by echocardiography before, during and after receiving treatment
3153346|NCT00272831|Placebo Comparator|Placebo|
3153347|NCT00272857|Experimental|Single arm|
3153348|NCT00272909|Experimental|1|piclozotan IV infusion, low dose, for 72 hours.
2447967|NCT03254771|Experimental|Intervention group|In the Intervention group, the Decision Aid (DA) will be presented and explained to the patient by research personnel at a schedule previously agreed with the patient. The patient will be given a paper copy of the (DA) to take home, as well as a web link to the computer application, and oral and written instructions to review the material again and perform value clarification exercises.
2448043|NCT03254628|Experimental|Full - Train/oxy&miso/ B&M/Mentor/Phone|Helping Mothers Survive- Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of Clinical Mentor in each facility to support deliberate practice, phone-based support from district trainer for Clinical Mentor.
2448051|NCT03254628|Experimental|Partial - Train/oxy & miso/ B&M/Mentor|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask, designation of clinical mentor in each facility to support deliberate practice.
2448057|NCT03254628|Active Comparator|Comparison - Train/oxy & miso/ B&M|Helping Mothers Survive - Bleeding After Birth training and Helping Babies Breathe training done at the facility, simulator present in each facility, oxytocin and misoprostol backfill, newborn bag and mask,.
2448136|NCT03254069|Experimental|Stainless Steel Crown Arm|Children with SSCs placed and followed longitudinal. Consent was obtained from all parents and verbal assent was obtained. The following data was collected: Demographic Data of the Children, clinical examination, radiographs, treatment planning, details of stainless steel crowns placement, OBF measurements were made before the SSC placement and periodically post placement
2448140|NCT03254069|No Intervention|Control Arm|A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
2448225|NCT03253406|Experimental|Polar M400 + Facebook Group (PM400+FG)|Will be provided a Polar M400 to track physical activity and energy expenditure while also being included in a Facebook group wherein Social Cognitive Theory-based physical activity and nutritious eating tips will be provided twice weekly for 12 weeks.
2448231|NCT03253406|Active Comparator|Facebook Only Group (FG)|Included exclusively in a separate, but content-identical, Facebook group for 12 weeks.
2448330|NCT03253003|Experimental|Audéo B hearing aid line extension|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
3190067|NCT00783510||Methotrexate Treatment Arm|For patients taking Methotrexate
3208932|NCT00979511|Experimental|1 Hi-Calcium milk & exercise|
2448451|NCT03251677|Active Comparator|Total laparo hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by laparoscopy)
2448456|NCT03251677|Active Comparator|Mini-lap hysterectomy|Surgical procedure, Hysterectomy (removal of the uterus by mini-laparotomy)
2448536|NCT03251573||Normal cognitive function|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
2448538|NCT03251573||cognitive impairment|The cognitive impairment classification algorithm We classified subjects as having no, mild, or major cognitive impairment using criteria from the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) as a guideline.20 The age and/or education-adjusted raw score of each individual cognitive test was calculated and compared with the age and/or education-adjusted published norms for Chinese populations.14 Specifically, age- and education-adjusted scores less than 1.5 standard deviations (SDs) below the adjusted mean of the published population norms on all tests in all domains indicated no cognitive impairment; scores of 1.50 to 1.99 SDs and 2.0 or more SDs below the adjusted mean of the published norms on at least one test in at least one domain indicated mild cognitive impairment and major cognitive impairment, respectively
2448639|NCT03250806||newly identified aortic stenosis|Patients identified on auscultation or target echocardiography with aortic stenosis. Consecutive patients per centre with no limit to numbers.
2448674|NCT03250481|Active Comparator|'Sedation guidance with RASS-group|Sedation is guided with RASS. Targeted sedation level is RASS -3 - 0. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RASS score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
2448675|NCT03250481|Experimental|'Sedation guidance with RI|Sedation is guided with RI. Targeted sedation level is RI 40-80. Propofol: an initial rate of 2.4 mg/kg/h for one hour. Thereafter, the infusion rate of propofol is 0.8-4 mg/kg/h to reach or maintain the target RI score. Propofol bolus of 20-40 mg is allowed. Oxycodone as 3-6 mg boluses for pain management. Other opiates are not allowed. Midazolam may given if the maximum dose of propofol is reached and pain management by oxycodone restricted achievement of the target sedation level. Midazolam will supply intravenously in boluses of 1-2 mg (based on the weight of the patient), starting at 3 boluses/h for the first hour. Dexmedetomidine and other sedatives are not allowed.
2448737|NCT03250091||Gastric cancer|Gastric adenocarcinoma and other gastric malignancies
2448738|NCT03250091||Gastric mucosal dysplasia|Includes: a. High-grade dysplasia; b. Low-grade dysplasia; c. Indefinite for dysplasia
2448739|NCT03250091||High-risk IM gastritis stages|High-risk stages according to OLGIM classification: OLGIM Stage IV and OLGIM Stage III.
2448740|NCT03250091||High-risk atrophic gastritis stages|High-risk stages according to OLGA classification: OLGA Stage IV and OLGA Stage III.
3208933|NCT00979511|Experimental|2 Hi-calcium milk with passive exercise|
2447970|NCT03254953|Experimental|Sequential Intervention|"in this Sequential eHealth intervention, participants are asked to self-monitor only their body weight for the first month, then for months 2 and 3 they will be asked to also self-monitor their diet~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
2447972|NCT03254953|Experimental|Simultaneous Intervention|"in this Simultaneous eHealth intervention, participants are asked to self-monitor both their body weight and diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)~weekly personalized feedback via email~weekly skills training materials (behavioral modification lessons; tips on using different features of the app) via email~weekly action plans via email"
2447975|NCT03254953|Experimental|Control (diet-tracking only)|"participants are asked to self-monitor their diet for 3 months~participants are asked to use the MyFitnessPal app for self-monitoring~given goal to lose 5% weight by end of intervention (3 months)"
2448110|NCT03254381|Experimental|Resistance Training|Participants will use programmable weight machines along with free weights to target primary muscle groups. In addition, they will complete mini-squats, mini-lunges, and lunge walks. Participants will complete two sets of 6-8 reps. Training stimulus will be increased using the 7RM method - when 2 sets of 6-8 reps are completed with proper form and without discomfort. Investigators will record the number of sets completed and the load lifted for each exercise for each participant at every class.
2448111|NCT03254381|Experimental|Balance and Tone Training (Control)|Exercises will include stretching exercises, range of motion exercises, basic core-strength exercises, balance exercises, and relaxation techniques. Only bodyweight will be applied (i.e., no additional loading). This group controls for confounding variables such as physical training received by traveling to the training centres, social interaction, and changes in lifestyle secondary to study participation.
2448172|NCT03253796|Experimental|Open-label (OL) GLM SC QM ---> PBO SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with placebo (PBO) SC QM
2448175|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC QM|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with double-blinded (DB) GLM SC QM
2448178|NCT03253796|Experimental|OL GLM SC QM ---> DB GLM SC Q2M|In Period 1 participants are treated with OL GLM SC QM; followed by Period 2 where participants are treated with DB GLM SC Q2M
2448276|NCT03253042|Experimental|WBV exercise program|8-week exercise program associated with the vibratory platform. Each exercise session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will be connected at the beginning of each series, set at a vibration frequency of 40 Hertz (Hz) and peak-to-peak amplitude of 4 millimeters (mm) resulting in a peak acceleration of 128 ms2 (12.8 g). This should provide the equivalent of 3600 vertical vibrations, totaling 14400 vibrations per training session.
2448277|NCT03253042|Sham Comparator|Sham WBV exercise program|8-week exercise program in which each session will consist of 4 series of an isometric half-squat exercise with 1 minute and a half of duration and a rest interval of 1 minute. The vibratory platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
2448291|NCT03252730|Experimental|WO 4260 Cosmetic Product for Topical Use|WO 4260 is used to treat dry and itchy scalp
3153349|NCT00272909|Experimental|2|piclozotan IV infusion, high dose, for 72 hours.
3153350|NCT00272909|Placebo Comparator|3|placebo (normal saline) IV infusion, for 72 hours.
2448388|NCT03252158|Experimental|Decrease less healthy item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove less healthy items in 20% of slots, then fill the empty slots with healthier items."
2448396|NCT03252158|Experimental|Decrease healthier item availability|"Intervention: Availability of healthier vs. less healthy foods~Remove healthier items in 20% of slots, then fill the empty slots with less healthy items."
2448464|NCT03252002|Experimental|Single/multiple doses of 10 mg BAY1101042 or placebo|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2448467|NCT03252002|Experimental|Single/ multiple doses of 20 mg BAY1101042 or placebo|Single oral dose of 20 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2448468|NCT03252002|Experimental|Single/ multiple doses of 30 mg BAY1101042 or placebo|Single oral dose of 30 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2448469|NCT03252002|Experimental|Single/ multiple doses of 40 mg BAY1101042 or placebo|Single oral dose of 40 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2448470|NCT03252002|Experimental|Single/ multiple doses of 50 mg BAY1101042 or placebo|Single oral dose of 50 mg BAY1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
2448471|NCT03252002|Experimental|Optional: Single/multiple doses of 5 mg BAY 1101042 or placebo|Single oral dose of 5 mg BAY1101042 MR tablets or corresponding placebo followed by once daily dosing for 7 days
2448507|NCT03251313|Experimental|JS001 120mg+GP|Level 1: JS001 120mg +GP q3w,*6 cycles, then JS001 120mg q3w for maintenance therapy for up to approximately 2 years.
2448512|NCT03251313|Experimental|JS001 240mg+GP|Level 2: JS001 240mg +GP q3w,*6 cycles, then JS001 240mg q3w for maintenance therapy for up to approximately 2 years.
2448519|NCT03251313|Experimental|JS001 480mg +GP|Level 3: JS001 480mg+GP q3w,*6 cycles, then JS001 480mg q3w for maintenance therapy for up to approximately 2 years.
2448521|NCT03251313|Experimental|GP followed by JS001|sequential treatment: Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
2448573|NCT03251001|Active Comparator|Control|Sites receiving a free gingival graft
2448575|NCT03251001|Experimental|Device - Acellular dermal matrix|Sites receiving acellular dermal matrix
2448741|NCT03250091||Extensive gastric intestinal metaplasia|Intestinal metaplasia of any grade both in gastric corpus and antrum/incisura (other than OLGIM III-IV).
3153351|NCT00272935|Experimental|1|
3153352|NCT00272935|Placebo Comparator|2|
2448050|NCT03254615|Experimental|Group 3|"Group III will receive I Prefer Plain Water during first, second, and third grades"
2448095|NCT03254303|Other|60s (group E)|The Time of catheterization at 60s (group E) was applied in this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 60 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 60 s
2448099|NCT03254303|Other|90s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 90 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 90 s
2448104|NCT03254303|Other|120s (groupe L)|In this study group,after sevoflurane inhalation induction, 30 children have a catheterization after a time of 120 seconds following the eye closure and the loss of lid reflex.Difficulty with intravenous catheterization, limb movement and laryngospasm were recorded.Difficulty of catheterization in group 120 s
2448220|NCT03253874|Experimental|Intervention Site-LAC+USC Medical Center|In this arm or study site,new guidelines are disseminated to all residents attending and faculty physicians within the department of Ophthalmology and Anesthesiology. New guidelines call for the across the board elimination of pre-operative testing and visits for patients undergoing cataract surgery.
2448226|NCT03253874|No Intervention|Control Site--Harbor-UCLA Medical Center|In this arm or study site, patients will undergo standard of care for cataract surgery without any new guidelines.
2448285|NCT03253068|Experimental|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
2448357|NCT03252470||2D laparoscopic surgeries|Two-Dimensional Laparascopic Surgical Video System
2448358|NCT03252470||3D laparoscopic surgeries|Three-Dimensional Laparascopic Surgical Video System
2448411|NCT03252210|Experimental|Stereoscopic Versus Methylene Blue|"In the same participant,we perform both Stereoscopic and Methylene Blue localization。Then，compare the distance between the methylene blue's anchor point and the location of lesion,stereoscopic Localization's anchor point and the location of lesion,methylene blue's anchor point and stereoscopic Localization's anchor point.~Post Hoc Multiple Comparisons"
3190068|NCT00783523|Active Comparator|Doxycycline|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
3208532|NCT00975702|Experimental|RIPC Group|In this group deceased donors will receive Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet of the lower limb prior to organ recovery.
2448548|NCT03251287|Active Comparator|Sodium Nitrate|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
2448551|NCT03251287|Placebo Comparator|Placebo|Following entry into the study, patients will receive a single dose of oral inorganic sodium nitrate (14mmol) on two separate visits, or matching placebo, in random order (i.e. 2x nitrate visits first or 2x placebo visits first) in a cross-over fashion.
2448754|NCT03249831|Experimental|COH-MC-17 and immunosuppressants|"Participants receive COH-MC-17: a 21-day nonmyeloablative conditioning regimen (cyclophosphamide, pentostatin and rabbit anti-thymocyte globulin), followed by CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant on Day 0.~Immunosuppressants (tacrolimus and mycophenolate mofetil) given on Day -1 onwards until discontinuation post-transplant.~The minimally manipulated transplant product is manufactured using the CliniMACS device."
2448842|NCT03249428|Active Comparator|Nicotine Replacement Therapy & One-on-One Counseling|Standard NRT such as the nicotine patch, gum, inhaler, and/or lozenge as per participant liking and clinical indication deemed necessary by the expert smoking cessation nurse. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
2448845|NCT03249428|Active Comparator|Electronic Nicotine Delivery Systems & One-on-One Counseling|Electronic Nicotine Delivery Systems with nicotine. Counseling will include a number of approaches such as reviewing smoking history, development and revision of a reduced or quit plan, encouragement of self-monitoring, review of triggers and challenges, and coping skills.
2448971|NCT03248999|Experimental|Experimental|realization of a rectal swab or stool sample for all the résidents included in the study.
2449132|NCT03247829||Patients with CardioMEMS and LVAD|Patients with CardioMEMS and LVAD, previously implanted, will receive hemodynamic management using CardioMEMS
2449178|NCT03247179|Experimental|PTSD Coach Condition|PTSD Coach App
2449182|NCT03247179|No Intervention|Treatment as Usual Condition|Treatment as Usual
2449252|NCT03246971|Experimental|Wafermine™|
2449254|NCT03246971|Placebo Comparator|Placebo|
2449402|NCT03245489|Experimental|Group 1|Group 1 will be treated with Regimen A, followed by Regimen B. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks. Regimen B is pembrolizumab alone for 6 weeks.
2449403|NCT03245489|Experimental|Group 2|Group 2 will be treated with Regimen B, followed by Regimen A. Regimen B is pembrolizumab alone for 6 weeks. Regimen A is pembrolizumab, ASA and clopidogrel daily for 6 weeks.
2449426|NCT03245177|Experimental|Pembrolizumab plus radiotherapy|Pembrolizumab is given by intravenous infusion over 30 minutes at a maximum dose of 200mg. The first dose of pembrolizumab is administered 14 days prior to the initiation of radiotherapy and every 3 weeks thereafter. Radiotherapy is given as a standard dose (60-66 Gy in 2 Gy/fraction) over 40-45 days (daily on Mon-Fri) Following completion of radiotherapy, participants will continue to receive pembrolizumab every 3 weeks for up to 12 months of maintenance treatment.
2449460|NCT03245047|Experimental|Intervention group|Dietary Supplement: Oral Nutritional Supplement with AN777 Participants in the intervention group will be asked to consume two servings of oral nutritional supplement per day for 180 days. (Oral Consumption)
2449786|NCT03242824|Experimental|18F-DOPA PET|Patients will receive 18FDOPA-PET for radiation treatment planning
2448053|NCT03254589|Active Comparator|Group 4|RA patients on stable treatment (> 1 year) with other (non-MTX) DMARDs, with or without NSAIDs and/or steroids, and continued on the same treatment. The overall management, tests and outpatient rheumatology visits schedule will be similar to other patients with RA, in accordance to standard practice.
2448087|NCT03254225|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
2448088|NCT03254225|No Intervention|Control|in this arm, the group will remain sedentary for the same period of the experimental group, and they will be invited to engage on the raining program after the sedentary period
2448152|NCT03253965|Experimental|Walking: Treadmill then Overground|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
2448153|NCT03253965|Experimental|Walking: Overground, then Treadmill|Walking while receiving auditory cueing intervals from a metronome and music. Testing performed using metronome normal, metronome slow, and metronome fast speed settings as well as music normal, music slow, and music fast tempos. Subjects will also walk with no auditory cueing.
2448193|NCT03253549|Experimental|SMArTVIEW|
2448195|NCT03253549|No Intervention|Standard Care|
2448235|NCT03253276|Active Comparator|Obeticholic Acid|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
2448245|NCT03253276|Placebo Comparator|placebos|Patients with primary biliary cirrhosis are treated 3 months with OCA (active drug) or placebo in a double-blind cross-over study design.
2448323|NCT03252899||Therapists|Physiotherapists/occupational therapists experienced in working with stroke patients.
2448326|NCT03252899||Subacute stroke patients|Stroke patients less than 6 months after their stroke suffering from upper limb paresis.
2448328|NCT03252899||Chronic stroke patients|Stroke patients more than 6 months after their stroke suffering from upper limb paresis.
2448368|NCT03252444|Experimental|Biofeedback group|After 1 minute of rest, participants will perform 6 trials of bilateral, active, weighted arm elevation in the scapular plane and a therapist classifies the scapular motion into specific patterns of scapular dyskinesis. After the evaluation of scapular dyskinesis, the kinematics and surface EMG (sEMG) data will be collected during 5 trials of the same arm movements and 3 selected exercises.
2448370|NCT03252444|Active Comparator|Conscious control group|Conscious correction of scapular orientation will be taught to the subjects in the manner described in previous studies. The starting position is determined in each individual by actively positioning the scapula between maximal upward and downward rotation, external and internal rotation, and posterior and anterior tilt. Scapular assistance test (SAT) is also conducted by passively assisting patients' scapula into appropriate position to correct scapula dyskinesis
3190069|NCT00783523|Placebo Comparator|Placebo|Patients undergoing elective vascular malformation surgery will receive doxycycline100 mg twice a day, a dose shown to effectively decrease MMP or placebo, treatment for two weeks prior to surgery
3190070|NCT00783536|Experimental|1|"Clinical and demographic information~Clinical and Laboratory information"
2448554|NCT03251248|Experimental|First MSB11455 Then Neulasta|
2448556|NCT03251248|Experimental|First Neulasta Then MSB11455|
2448603|NCT03250910|Experimental|HIV/HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
2448606|NCT03250910|Experimental|HIV/HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
2448609|NCT03250910|Active Comparator|HCV compensated liver disease|Patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) received a generic version of Sofosbuvir and Velpatasvir fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
2448612|NCT03250910|Active Comparator|HCV decompensated liver disease|Patients with decompensated cirrhosis (Child-Pugh B or C) received Sofosvel® 1 tablet per day in combination with weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
2448649|NCT03250520|Experimental|glioma brain stem|
2448658|NCT03250520|Experimental|high grade recurrent brain tumor in the central nervous system|
2448708|NCT03250286|Experimental|EUS-ERCP group|EUS is performed first, and when the examiner finds bile duct stone in the EUS examination, ERCP is performed to remove the stone.
2448713|NCT03250286|Active Comparator|ERCP group|ERCP without EUS is performed in all patients.
2448747|NCT03249987|Other|Electronic bladder diary|Participants will be asked to complete the electronic diary for three days before crossing over to the paper diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
2448748|NCT03249987|Other|Paper bladder diary|Participants will be asked to complete the paper diary for three days before crossing over to the electronic diary. Patients will be asked to record the time and volume of voids, any incontinence or urgency episodes and sleep-wake times. Patients will be asked to complete a short questionnaire regarding their opinions
2448800|NCT03249688|Other|Control|Regular health advice
2448801|NCT03249688|Experimental|Multidomain 1|Multidomain lifestyle
2448802|NCT03249688|Experimental|Multidomain 2|Multidomain lifestyle + medical food
3190071|NCT00783536|Active Comparator|2|"Clinical and demographic information~Clinical and Laboratory information"
3190072|NCT00783549|Experimental|Cohort 1|6 active 2 placebo
2448937|NCT03248817|Experimental|single shot|spinal anesthesia will be performed using intrathecal bupivacaine. Then, a single shot phenylephrine (1.5 ug/Kg) will be administered
2448068|NCT03254693|Experimental|1-step self-etch additional layer (SE1+)|According to the manufacturer's instructions, but apply tree times.
3190073|NCT00783549|Experimental|Cohort 2|9 active 3 placebo
3190074|NCT00783549|Experimental|Cohort 3|Optional cohort
3190075|NCT00783549|Experimental|Cohort 4|12 active
3190076|NCT00783549|Experimental|Cohort 5|12 active
3190077|NCT00783562|Experimental|1|
2448200|NCT03253510|Experimental|Poly-amide|new thermoplastic material used as a denture base, that has excellent ethetics and flexibility
2448204|NCT03253510|Active Comparator|poly-methyl methacrylate|Polymethylmethacrylate is one of the most widely used denture base material, because of its good biocompatibility, reliability and dimensional stability
2448216|NCT03253211||State|North Carolina
2448224|NCT03253211||SCD Patients|
2448230|NCT03253211||Providers|Primary care and emergency department clinicians
2448237|NCT03253211||Year|Baseline, year 2, year 3
2448322|NCT03253055||Male Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2448325|NCT03253055||Female Athletes|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2448329|NCT03253055||Controls|DEXA, pQCT, lifestyle questionnaire, muscular strength measurements, aerobic fitness, blood draw and finger prick test.
2448380|NCT03252171|Experimental|Experimental: CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen by infusion.
2448381|NCT03252171|No Intervention|No Intervention|
2448480|NCT03251729|Experimental|Cerclage|Cervical cerclage placement along with vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
2448483|NCT03251729|Other|Control|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks.
3190078|NCT00783562|Active Comparator|2|
3190079|NCT00783575||Inflammatory Bowel Disease|Crohn's disease (CD) and ulcerative colitis (UC), collectively known as inflammatory bowel disease (IBD) are chronic, life-long, destructive inflammatory conditions of the gastrointestinal tract.
3190080|NCT00783601|Experimental|1|Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast
3190081|NCT00783601|Experimental|2|Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast
2448625|NCT03250871|Placebo Comparator|Placebo|"Placebo will be the suggestion of self-relaxation methods (for example, try to relax ,try to think of pleasant moment ) and the diffusion of white noise during surgery."
2448628|NCT03250871|Experimental|Hypnosis|"Hypnosis will be associated with the usual anesthesia. Hypnosis is a temporary modification of consciousness technique based on suggestion.~It is divided into three phases:~induction: attention of the patient fixed on an object or a part of the body,~the dissociation where the patient cuts off auditory, visual and tactile perceptions,~and finally the opening towards a hypnotic experience thanks to the imaginary."
2448656|NCT03250572||control group|
2448660|NCT03250572||NAFLD patients without hepatic fibrosis|
2448663|NCT03250572||NAFLD patients with hepatic fibrosis|
2448721|NCT03250325|Experimental|Split dose of 5x10^9 TBI-1301|Split dose of 5x10^9 TBI-1301 will be administered intravenously for 2 days following cyclophosphamide pre-treatment 750 mg/m2/d for 2 days.
2448776|NCT03249896|Experimental|Intervention|Patients in the intervention arm will receive standard medical care and in addition to that, be given the Aina or Aina Mini device for self-monitoring of blood glucose (SMBG), the Habits-GDM mobile app, and a weighing scale.
2448783|NCT03249896|No Intervention|Control|"Patients in the control arm will receive standard medical care and only be given the Aina or Aina Mini device for SMBG.~Standard medical care involves one session of face-to-face education by a diabetes nurse educator and a dietician. Patients are initiated on capillary glucose monitoring. Subsequently, standard clinical care is provided by their obstetrician. Participation in this study will not increase the frequency of clinic visits. The frequency of SMBG will be as clinically indicated and not increased as a result of participation in this study. Should the obstetrician feels that insulin is required, it will be initiated and if necessary the patient will be referred to the endocrinology service for management of insulin therapy. In some patients, the clinician may decide to prescribe metformin."
2448805|NCT03249506||Cohort 1: Non-SGLT2i new Users|This is a retrospective cohort study identifying participants with type 2 diabetes mellitus (T2DM) and established cardiovascular (CV) disease using the Military Health System (MHS) over a 3-year period. Cohort 1 included participants with incident exposure of one or more non-sodium glucose co-transporter 2 inhibitor (SGLT2i) anti-hyperglycemic agent (AHA) therapy during the study period with no prior or subsequent SGLT2i exposure throughout the study period. New users are defined as participants whose first exposure to any non-metformin AHA medication occurs greater than or equal to (>=) 365 days after their start of observation in the database with no prior exposure to any medication within the same AHA medication class in the prior 365 days.
2448810|NCT03249506||Cohort 2: SGLT2i new Users|Cohort 2 included participants with incident SGLT2i exposure during the study period regardless of prior or concurrent exposure to one or more additional AHA therapy. New users are defined as participants whose first exposure to SGLT2i medication occurs >= 365 days after their start of observation in the database with no prior exposure to the same AHA medication class in the prior 365 days.
3190082|NCT00783627||1|Patient with sickle cell disease
3190083|NCT00783627||2|Healthy volunteers
3190084|NCT00783640|Experimental|1|Lactic Acid
3190085|NCT00783666|Experimental|1|Lactic Acid
3190086|NCT00783679|Other|1|Twenty adult spontaneously breathing patients without intubation and mechanical ventilation recruited from the cardiac catheterization laboratory. All will be post-heart-transplant patients coming for yearly evaluation.
3190087|NCT00783731|Experimental|Low dose midazolam|
2448096|NCT03254173|Active Comparator|Arm A|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets ) , as half tablet daily , i.e , 15mg daily , before sleep for a duration of 8 weeks
2448100|NCT03254173|Placebo Comparator|Arm B|Placebo oral tablets , as half tablet daily before sleep for a duration of 8 weeks
2448652|NCT03250494|Active Comparator|group (I) (GI) (n=25)|
2448661|NCT03250494|Active Comparator|group (II) (GII) (n=25)|
2448666|NCT03250494|Placebo Comparator|group (III) (GIII) (control group) (n=25)|
2448726|NCT03250221||Robotic or laparoscopic myomectomy|Women who received robotic or laparoscopic myomectomy
2448782|NCT03249870|Experimental|Inotuzumab ozogamicin (INO)|
2448861|NCT03249259|Experimental|Choline alfoscerate|choline alfoscerate 400mg (2 caps - 1 cap bid)
2448866|NCT03249259|Placebo Comparator|Control|Placebo (2 caps - 1 cap bid)
3190088|NCT00783744|Experimental|1|Insulin Glargine + Glimepiride + Metformin
2448982|NCT03248700|Experimental|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
2449054|NCT03248167|Experimental|Cannabidiol (CBD 600 mg daily)|6 weeks, such that both participants and study staff are blind to treatment condition.
2449057|NCT03248167|Placebo Comparator|Placebo|6 weeks, such that both participants and study staff are blind to treatment condition.
3190089|NCT00783744|Active Comparator|2|Insulin monotherapy with premixed insulin NPH 30/70
3190090|NCT00783757|Experimental|Optical Imaging|Tomographic Optical Imaging Arm
2449194|NCT03247101|Experimental|Probiotics group|Miyarisan-BM (Clostridium Butyricum Miyairi) 40 mg po tid x 6 months
2449195|NCT03247101|Active Comparator|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
2449196|NCT03247101|Active Comparator|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
2449201|NCT03246789|Experimental|Engage-M|Participants will meet individually with a therapist once before beginning weekly group sessions for eight weeks. Each weekly session will last approximately 50 minutes. Study investigators have trained Engage-M therapists to provide participants with a group therapy approach called Engage-M. During the weekly therapy sessions, therapists will encourage participants to engage in physical and social activities that you find pleasurable or rewarding.
2449202|NCT03246789|Active Comparator|Wellness in Mind and Body (W-MH)|Participants will meet with a therapist for group therapy once a week for eight weeks. Each weekly session will last approximately 50 minutes. During these weekly sessions, the therapist will educate participants about health and mental health.
2449262|NCT03246685|Experimental|Pembrolizumab Failures|Imprime PGG + Pembrolizumab
2449265|NCT03246685|Experimental|Active Stable Disease on Pembrolizumab|Imprime PGG + Pembrolizumab
2449307|NCT03246321|Experimental|repetitive ePIPAC-OX|
2449379|NCT03245879|Active Comparator|Program 1|Implementation of a basic antibiotic stewardship program focusing on education, access to Infectious Diseases physicians, and availability of antibiotic use data.
2449382|NCT03245879|Active Comparator|Program 2|This arm increases antibiotic stewardship education and interventions. Program 2 hospitals performed audit and feedback of pre-specified antibiotics and implemented locally controlled restrictions.
2449385|NCT03245879|Active Comparator|Program 3|This arm was the most intensive antibiotic stewardship intervention. It included signficant audit and feedback, ID controlled restrictions, and ID review of designated culture/lab results.
3190091|NCT00783770||30-33 weeks|mother infant pairs with gestation of 30-33 weeks
3190092|NCT00783770||34-37 weeks|mother infant pairs with gestation of 34-37 weeks
2449579|NCT03244527|Experimental|BCAA group|Participants in the BCAA group take 40g of BCAA supplement before each aerobic exercise session. The interventions include 24 aerobic training sessions. Accordingly, the participants intake 960g of BCAA during a 8-week intervention period.
2449581|NCT03244527|Placebo Comparator|Control group|Participants in the control group take 40g of placebo before each aerobic training session. The placebo has the same caloric as the BCAA supplement but with different constitution (eg, different percentage of protein, fat and carbohydrate)
2449642|NCT03243955|Active Comparator|TEAS|True acupoint locations for placement of TENS unit pads
2449647|NCT03243955|Sham Comparator|Placebo|non-acupoint locations for placement of TENS unit pads
2449685|NCT03243500|Sham Comparator|Group C|"2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase powder 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
2449691|NCT03243500|Active Comparator|Group A|"5 mg atracurium 2.5 ml of lidocaine 2% 2.5 ml of bupivacaine 0.5% hyaluronidase 15 IU/ml~1 ml normal saline to make a total volume of 6 ml from which the patient received 5-6 ml through percaruncular peribulbar injection."
2449729|NCT03243123|Experimental|Passive mobilization|Upper limb passive mobilization assisted with robotic device
2449772|NCT03243071|Experimental|Intervention Group|The intervention group (n=50) will have access to culturally tailored website.
2449773|NCT03243071|Active Comparator|Control Group|Participants in the control group (n=50) will have access to NYU 's standard trial participation website.
2449817|NCT03242707|Experimental|Autologous adipose tissue knee injection|Fat will be removed from the abdomen and processed using the Lipogems device. Approximately 5ml of the microfragmented fat product will be injected into the knee joint.
2449819|NCT03242707|Active Comparator|Hyaluronic Acid knee injection|Hyaluronic Acid - Synvisc-One®: A high molecular weight sodium hyaluronate (HA). HA is an FDA approved, standard of care treatment.
2449924|NCT03241758||Group #1|Patients with prostate cancer who will undergo radical prostatectomy
3190093|NCT00783770||38-42 weeks|mother infant pairs with gestation of 38-42 weeks
3190094|NCT00783783||Poor metabolizers|Patients with CYP2D6 genotypes predictive of poor metabolizer phenotype
3190095|NCT00783783||Non poor metabolizers|Patients with CYP2D6 genotypes predictive of intermediate, extensive, or ultra-rapid metabolizer phenotypes
3190096|NCT00783822|Other|intervention|rapid genetic counseling and testing
3190097|NCT00783822|No Intervention|control|usual care
3190098|NCT00783861|Experimental|1|Lactic Acid (Dermacyd Femina)
2448176|NCT03253952||Traumatic Spine Fracture, Control Group|Observational study - monitoring immune response and heart rate variability acting as a control group.
2448239|NCT03253445|Experimental|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking, a self-help leaflet on smoking cessation and an additional 10-session face-to-face ACT on a weekly basis.
2448244|NCT03253445|Placebo Comparator|Control|All participants are given a brief educational talk on encouraging quitting smoking , a self-help leaflet on smoking cessation and 10-sessions of face-to-face social support on a weekly basis.
2448338|NCT03252951|Experimental|Eccentric Training|
2448340|NCT03252951|Experimental|Concentric Training|
2448342|NCT03252951|Experimental|Isometric Training|
2448345|NCT03252951|Active Comparator|Biofeedback|
2448502|NCT03251521||spasticity post-stroke|pain rating during injection with botulinum toxin The pain intensity was rated verbally on a numeric scale
2448702|NCT03250741|Active Comparator|Rotigotine 4 mg|Rotigotine transdermal patches 4 mg
2448704|NCT03250741|Placebo Comparator|Placebo|Placebo transdermal patches
2448749|NCT03250000||COPD-stable|Stable COPD patients at pulmonology consultation in Ziekenhuis Oost-Limburg (ZOL) Genk
2448750|NCT03250000||COPD-Ex|Patients admitted to the respiratory ward of ZOL Genk with a diagnosis of acute exacerbation, based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.
2448797|NCT03249701|Experimental|TEAS group|Transcutaneous Electrical Acupoint Stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao. Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2448798|NCT03249701|Placebo Comparator|Electroacupuncture group|Hand-needle on Neiguan, Quchi, Zusanli, Sanyinjiao.Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2448799|NCT03249701|Sham Comparator|sham TEAS group|Sham transcutaneous electrical acupoint stimulation on Neiguan, Quchi, Zusanli, Sanyinjiao; Intensity: maximal tolerance by subject; Time span: 30minutes before anesthesia induction and 30 minutes after wound closure.
2448822|NCT03249311|Experimental|Levomilnacipran|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2448825|NCT03249311|Active Comparator|Duloxetine (Cymbalta)|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2448830|NCT03249311|Placebo Comparator|Levomilnacipran Placebo-matched capsules|Participants will be randomly assigned to receive levomilnacipran, duloxetine, or placebo
2448888|NCT03249064||Vitiligo untreated patients|
2448890|NCT03249064||Control. Patients without vitiligo|
3153353|NCT00272948|Experimental|Prophylaxis Arm|
3153354|NCT00272948|Active Comparator|Control Arm|
3153355|NCT00273013|Experimental|Sequence 1|Subjects will receive Placebo in period 1, Singulair 10 milligrams (mg) in period 2 and GW274150 90 mg in period 3.
3153356|NCT00273013|Experimental|Sequence 2|Subjects will receive Placebo in period 1, GW274150 90 mg in period 2 and Singulair 10 mg in period 3.
2449066|NCT03248076||Fentanyl citrate|Baseline blood sample and oocyte fluid will be collected under propofol anesthesia. Fifteen minutes after administration of 1γ/kgfentanyl, it will be collected again blood sample and oocyte fluid. Cortisone and fentanyl level will be measured in all samples.
2449226|NCT03247114|Experimental|Water-glucose-sucralose-fructose-sucrose|First plain water, then glucose, then sucralose, then fructose and then sucrose
2449230|NCT03247114|Experimental|water-sucralose-glucose-sucrose-fructose|First plain water, then sucralose, then glucose, then sucrose and then fructose
2449234|NCT03247114|Experimental|Glucose-water-fructose-sucralose-sucrose|First glucose, then plain water, then fructose, then sucralose and then sucrose
2449237|NCT03247114|Experimental|Glucose-fructose-water-sucrose-sucralose|First glucose, then fructose, then plain water, then sucrose and then sucralose
2449238|NCT03247114|Experimental|Fructose-glucose-sucrose-water-sucralose|First fructose, then glucose, then sucrose, then plain water and then sucralose
2449239|NCT03247114|Experimental|Fructose-sucrose-glucose-sucralose-water|First fructose, then sucrose, then glucose, then sucralose and then plain water
2449240|NCT03247114|Experimental|Sucrose-fructose-sucralose-glucose-water|First sucrose, then fructose, then sucralose, then glucose and then plain water
2449241|NCT03247114|Experimental|Sucrose-sucralose-fructose-water-glucose|First sucrose, then sucralose, then fructose, then plain water and then glucose
2449243|NCT03247114|Experimental|Sucralose-water-sucrose-glucose-fructose|First sucralose, then plain water, then sucrose, then glucose and then fructose
3153357|NCT00273013|Experimental|Sequence 3|Subjects will receive Singulair 10 mg in period 1, Placebo in period 2 and GW274150 90 mg in period 3.
3153358|NCT00273013|Experimental|Sequence 4|Subjects will receive Singulair 10 mg in period 1, GW274150 90 mg in period 2 and Placebo in period 3.
3153359|NCT00273013|Experimental|Sequence 5|Subjects will receive GW274150 90 mg in period 1, Placebo in period 2 and Singulair 10 mg in period 3.
3153360|NCT00273013|Experimental|Sequence 6|Subjects will receive GW274150 90 mg in period 1, Singulair 10 mg in period 2 and Placebo in period 3.
3153361|NCT00273104|Active Comparator|Bariatric surgery|Bariatric surgery (gastric bypass) offered to patients after informed consent and shared decision. The surgical procedure was performed at Vestfold Hospital Trust by experienced bariatric surgeons.
3153362|NCT00273104|Active Comparator|Intensive lifestyle intervention|Intensive lifestyle intervention (1-year endurance) at a rehabilitation centre. The intervention consisted of motivation for behaviour change including calorie restriction and increased physical activity.
3153363|NCT00273286|Experimental|family diabetes management intervention|A trained health advisor will be responsible for interactions with parents and patients prior to each diabetes clinic visit (Preparation Phase), at the time of the diabetes clinic visit (Consolidation Phase) and by phone, e-mail, etc. after the clinic visit (Follow-up Phase). Using educational modules developed for the study, families will be engaged in problem identification and solving activities to improve shared parent-youth responsibility for diabetes management and foster increased adolescent's independent management capabilities.
3153364|NCT00273312|Experimental|Patupilone|was administered at 10 mg/m2, as a single intravenous infusion over 20 minutes, once every 3 weeks
3153365|NCT00273351|Experimental|[123I]B-CIT|[123I]B-CIT and SPECT imaging
2448186|NCT03253640||Patients with HAI during hospital stay|Patients who meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
2448189|NCT03253640||Patients without HAI during hospital stay|Patients who do not meet the European Centre for Disease Control (ECDC) Healthcare Associated Infection (HAI) case definitions. Case note review will be undertaken during hospital stay. Questionnaire will be administered at recruitment, pre-discharge, one, three, six and twelve months post discharge.
2448269|NCT03253185|Experimental|SC-007|SC-007 intravenous (IV) (various doses and dose regimens)
2448347|NCT03252769|Other|Self-sampling|Invitation to self-sample
2448400|NCT03252340||Drug: ADSTEM Inj.|Participants in Phase I clinical trials treated with ADSTEM Inj.
2448547|NCT03251508|Experimental|Peanut OIT/dietary peanut|Single arm study with all subjects receiving peanut OIT study drug for the initial 6 months. This is followed by daily ingestion of common dietary foods containing approximately 300 mg of peanut protein for an additional 6 months.
3153366|NCT00273559||1|subjects who remain on steroids after discharge
3153367|NCT00273559||2|Subjects will be off steroids at the time of discharge
2448766|NCT03249922||Treatment Group|"All patients who are considered candidates for spinal cord stimulator implant will be assigned to the Treatment Group. Participiants will be clinically evaluated and given the Owenstry low back disability index, WHODAS 12, Beck depression index and SF-36."
2448814|NCT03249558|Active Comparator|Morphine, Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and 60 mg of duloxetine capsules.
2448816|NCT03249558|Placebo Comparator|Morphine, Placebo Duloxetine|Subjects will take a maximum dose of 60 mg/day of extended release morphine capsules and placebo duloxetine capsules.
2448819|NCT03249558|Placebo Comparator|Placebo Morphine, Duloxetine|Subjects will take placebo morphine capsules and 60 mg of duloxetine capsules.
2448889|NCT03249051|Experimental|Indirect Calorimetry|The energy need is being determined by using indirect calorimetry and if necessary, optimized by parenteral, enteral and additive parenteral nutrition.
2448891|NCT03249051|No Intervention|Standard Care|"This group receives nutrition supply according to the hospital routine (standard care)"
2448932|NCT03248765||Chronic pain group|post-surgical opioid use measured at 1 day and 1 week.
2448936|NCT03248765||No chronic pain|post-surgical opioid use measured at 1 day and 1 week.
3153368|NCT00273572|Active Comparator|Moderate lifestyle intervention|Moderate lifestyle intervention including two group sessions and one individual counselling session with a nutritionist, at recruitment. Individual sessions with a nutritionist after 6 and 12 months on follow-up.
3153369|NCT00273572|Experimental|Intensive lifestyle intervention|Intensive lifestyle intervention, including bi-monthly group sessions with a physical activity instructor; a monthly group session with a nutritionist, and a monthly individual session with a nutritionist.
3153370|NCT00273611|Experimental|Pharmacist education|Pharmacist education about vitamin D
3153371|NCT00273611|No Intervention|Usual care|Usual care
3153372|NCT00273624|Experimental|olanzapine|10 mg Olanzapine
2449361|NCT03245996|Experimental|Subjects|Subjects with a cardiac pacemaker
2449445|NCT03245437|Experimental|Oxytocin with SCST|Oxytocin with SCST (active condition)
2449446|NCT03245437|Sham Comparator|Oxytocin with Health Management|Administration of OT with control psychosocial treatment
2449447|NCT03245437|Placebo Comparator|Placebo with SCST|Administration of Placebo with active psychosocial treatment
2449448|NCT03245437|Placebo Comparator|Placebo with HM|Administration of Placebo with control psychosocial treatment
2449517|NCT03244709|Experimental|Patients with GCA (ACR 1990 criteria)|"At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.~Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.~Week 24. TCZ tapering every 8 weeks as follows:~1 injection every 2 weeks~1 injection every 3 weeks~1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation."
2449587|NCT03244423|Placebo Comparator|Group 1|In control group will receive normal saline,
2449591|NCT03244423|Active Comparator|Group 2|Intravenous Tranexamic acid group will received Intravenous 50 mg / kg followed by infusion of 1 mg/kg/hr for six hours
2449594|NCT03244423|Active Comparator|Group 3|the topical Tranexamic acid group will receive 50 mg / kg poured before sternal closure.
2449710|NCT03243721|Experimental|Gilenya treated MS patients|Multiple sclerosis patients treated with Gilenya for at least six months. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
2449712|NCT03243721|Experimental|Healthy controls|Subjects without multiple sclerosis or other diseases of the central nervous system. This group will receive diagnostic tests: 7T MRI and Neurocognitive testing.
2449745|NCT03243149|Sham Comparator|False Feedback|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. False feedback (sham) shows a thermometer that indicates false feedback consisting of noise.
2449749|NCT03243149|Active Comparator|View Condition|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. View condition shows a thermometer that indicates true activation of ventromedial PFC minus amygdala but the participant is asked not to attempt neuroregulation.
2449755|NCT03243149|Experimental|Free Regulate|Neurofeedback from real-time acquired images (fMRI - GE Medical System) will be shown to subjects. Free regulate shows a thermometer that indicates true activation of ventromedial PFC minus amygdala while the participant attempts neuroregulation.
3153373|NCT00273624|Placebo Comparator|placebo|Placebo
3153374|NCT00273650|Active Comparator|A|Methyl-B12
3153375|NCT00273650|Placebo Comparator|B|Saline placebo
3153376|NCT00273689|Other|I|This is a crossover trial- Patients get randomly assign to albuterol or singulair and then cross overed to the alternate active medication.
3153377|NCT00273715|No Intervention|Staples|
3153378|NCT00273728|Active Comparator|HES, Septic shock, resuscitation|study group with HES 6%
2448243|NCT03253432||Strata greater than or equal to 35|Highest probability of having familial hypercholesterolemia
2448361|NCT03252496|Experimental|Combination|250 mL colloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL colloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
2448366|NCT03252496|Active Comparator|Crystalloid|250 mL crystalloid over 5 minutes followed by 500 mL crystalloid over 55 minutes then 250 mL crystalloid over 60 minutes. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 μg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine and intravenous syntocinon will be administered.
2448431|NCT03252080|Active Comparator|Education (Group A)|short-intensive education for one month
2448434|NCT03252080|Experimental|Education & holistic management(Group B)|short-intensive education for one month followed with holistic management for 6 months
2448477|NCT03251768|Experimental|Test group|"intervention: rHSA-GCSF 2.4 mg Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（2.4mg）will be injected subcutaneously at at 10 am (±90 min) on the 3th and 7th day of each chemotherapy cycle.After injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
2448482|NCT03251768|Active Comparator|Positive control group|"intervention: GCSF Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2)and Epirubicin(75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at 10 am (±90 min) from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 5.0×109/L at two contiguous times at least. (The minimum of usage was continuous 7 days ,The maximum of usage was continuous 14 days)"
2448530|NCT03251378|Experimental|3 mg Dose Escalation|3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
2448541|NCT03251378|Experimental|5 mg Dose Escalation|5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
2448545|NCT03251378|Experimental|Fruquintinib Expansion Cohort A|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
2448549|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort B|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
2448552|NCT03251378|Experimental|Metastatic Colorectal Cancer Expansion Cohort C|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
2448553|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort D|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
2448555|NCT03251378|Experimental|Metastatic Breast Cancer Expansion Cohort E|5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
2448614|NCT03250858|Placebo Comparator|Non-personalised advice|"Control group. Online (web-based) delivery of non-personalised dietary, weight and physical activity advice based on the UK general health guidelines.~This is an online trial and this arm will be using the e-Nutri web application. Participants in this group will receive online general recommendations (non-personalised)."
2448618|NCT03250858|Experimental|Personalised advice|Online (web-based) delivery of personalised dietary, weight and physical activity advice based on the individual's dietary intake, weight and physical activity levels, generated by the e-Nutri web application. Participants in this group will receive online personalised reports.
2448644|NCT03250624|Experimental|CD5024 0.3% cream|Active drug
2448654|NCT03250624|Experimental|CD5024 cream placebo|Placebo of active drug
3153379|NCT00273741|Experimental|1|methylphenidate at 20mg per day during 7 days, at 20mg or 40mg per day during 7 days and 20, 40 or 60mg per day during 14 days
3153380|NCT00273741|Placebo Comparator|2|placebo capsules
2448803|NCT03249441|Experimental|Compassion-focused therapy|Compassion-Focused Therapy (CFT) Participants were taught the main compassion-focused exercises as outlined in 'The Compassion-Mind Guide to Ending Overeating: Using Compassion-Focused Therapy to overcome Bingeing and Disordered Eating' manual (Goss, 2011) over a ten session period (weekly for 2 hours), offered over a 3 month period. Self-criticism and shame were key foci across sessions. Participants in the CFT arm also received Treatment as Usual.
2448804|NCT03249441|No Intervention|Treatment as Usual|Treatment As Usual Treatment as usual was based in the Diabetes, Endocrinology and Metabolism Clinic in Galway University Hospital. The Weight Management Service provides assessment by a multi-disciplinary team of endocrinologists, dieticians, nurse specialists and clinical psychologists. Dietary advice is given by a specialist dietician regarding weight management, assessment by the Consultant Endocrinologist with possible medication for management of diabetes and weight, and participation in a healthy lifestyle education program.
2448855|NCT03249298|Active Comparator|Crystalloids|"Bolus of crystalloids~Bolus of 250 ml crystaloids will be infused regarding the measures"
2448858|NCT03249298|Active Comparator|Colloids|"Bolus of colloids~Bolus of 250 ml colloids will be infused regarding the measures"
2448969|NCT03248505|Experimental|Conventional TENS|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude.
3153381|NCT00273767|Experimental|1|epoetin beta
3153382|NCT00273767|Placebo Comparator|2|placebo of NaCl
3153383|NCT00273780|Active Comparator|Adherence counseling|
3153384|NCT00273780|Active Comparator|Alarm device|
3153385|NCT00273780|Active Comparator|Counseling and alarm|Participants in this arm will receive both education counseling and a pocket alarm device.
2448252|NCT03253458|Experimental|Optical imaging|All consenting patients will undergo Confocal Laser Endomicroscopy or Optical Coherence Tomography imaging prior to biopsy or surgery.
2448324|NCT03252886|Active Comparator|DL user|Experienced emergency physicians who primarily use the direct laryngoscopy (DL) for endotracheal intubation during cardio-pulmonary resuscitation.
2448327|NCT03252886|Active Comparator|VL user|Experienced emergency physicians who primarily use the videolaryngoscopy (VL) for endotracheal intubation during cardio-pulmonary resuscitation.
2448372|NCT03252418|Experimental|ascorbic acid|injection of 1 ml intamucosal ascorbic acid 3 times with 1 week interval
2448373|NCT03252418|Experimental|diode laser|photothermolysis by diode laser in one session
2448391|NCT03252119|No Intervention|standard therapy group|standard treatment of viral bronchiolitis with low flow oxygen.
2448395|NCT03252119|Experimental|high flow humidified oxygen group|treatment of viral bronchiolitis with high flow humidified oxygen therapy.
2448449|NCT03251950|Experimental|Intervention group|15 week healthy eating and gardening curriculum to be implemented in Osage Nation Early Childhood Programs; 15 week healthy eating parenting curriculum to be implemented online to parents of enrolled children
2448450|NCT03251950|Other|Control group|Wait list control -- to receive intervention after serving as wait list group
2448544|NCT03251612|Other|Treatment|1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.
2448620|NCT03250949|No Intervention|Conventional-Drilling Tight Fit (Control) group|osteotomy will be achieved with no. 6 round , then widened , using a drill 1 mm larger than the final drill provided by the manufacturer. the final size of the control osteotomies were same diameter of the implant.
2448624|NCT03250949|Experimental|Over-drilling Loose Fit (Test) group|Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
2448687|NCT03250637||Colorectal cancer cases|1038 participants diagnosed with colorectal cancer from the Diet, Cancer and Health cohort.
2448688|NCT03250637||Sub-cohort members|1857 persons randomly selected within the full cohort at time of entry into the Diet, Cancer and Health cohort. These participants serve as controls for the colorectal cancer cases.
2448724|NCT03250117|Experimental|Cohort 1|Requip; One Ropinirole Implant
2448727|NCT03250117|Experimental|Cohort 2|Requip; Two Ropinirole Implants
2448728|NCT03250117|Experimental|Cohort 3|Requip; Three Ropinirole Implants
2448729|NCT03250117|Experimental|Cohort 4|Requip; Four Ropinirole Implants
2448769|NCT03249792|Experimental|Arm 1: MK-2118 IT Monotherapy|Participants receive MK-2118 via IT injection once weekly (Q1W) on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 via IT injection once every 3 weeks (Q3W) on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2448774|NCT03249792|Experimental|Arm 2: MK-2118 IT+Pembro Combo Therapy|Participants receive pembrolizumab (pembro) 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-3 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 4 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2448781|NCT03249792|Experimental|Arm 3: MK-2118 Visceral IT+Pembro Combo Therapy|Participants receive pembrolizumab 200 mg via IV infusion on Day 1 of each cycle for up to 35 cycles (approximately 2 years) and receive MK-2118 via IT injection Q1W on Days 1, 8 and 15 of Cycles 1-2 followed by MK-2118 IT injection Q3W on Day 1 of Cycle 3 and beyond, for a total of up to 35 cycles (approximately 2 years). Each cycle is 3 weeks long.
2448785|NCT03249792|Experimental|Arm 4: MK-2118 SC+Pembro Combo Therapy|Participants receive MK-2118 monotherapy via subcutaneous (SC) injection Q1W on Cycle 1 Days 1 and 8 followed by MK-2118 SC injection Q1W on Cycles 2-4 Days 1, 8 and 15, for a total of up to 36 cycles (approximately 2 years) plus pembrolizumab 200 mg via IV infusion on Day 1 of Cycle 2 and beyond for up to 36 cycles (approximately 2 years). Cycle 1 is 2 weeks long and Cycles 2 and beyond are 3 weeks long.
2448809|NCT03249350|Active Comparator|Standard Contingency Management (CM)|This group will receive standard CM for adolescent substance abuse.
2448811|NCT03249350|Experimental|Enhanced Contingency Management (CM+)|This group will receive an enhanced CM protocol for adolescent substance abuse that targets parenting more intensely.
2448962|NCT03249233|Experimental|Keratoconics wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
2448963|NCT03249233|Experimental|Keratoconics wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
2448964|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with high central clearance|Scleral contact lenses designed to provide approximately 450 microns of central clearance.
2448965|NCT03249233|Active Comparator|Healthy controls wearing ZenLens with low central clearance|Scleral contact lenses designed to provide approximately 350 microns of central clearance.
2449214|NCT03246854|Experimental|DBPR112|
2449274|NCT03246594|Experimental|Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation with a oesophageal probe placed for temperature monitoring.~Placement of oesophageal probe for temperature measurement"
2449279|NCT03246594|Experimental|No Esophageal Probe|"Participants in this group will receive ablation for atrial fibrillation without a oesophageal probe placed for temperature monitoring.~Intervention: Power limitation of RF generator"
2449413|NCT03245580|Other|Arm 1 -modified wet suction|Intervention:Procedure Core Liver Biopsy Technique: Modified Wet Suction
3153386|NCT00273780|No Intervention|Control|
3153387|NCT00273806|Experimental|1|Medical assistant identification and referral for behavioral risk factors.
3153388|NCT00273806|No Intervention|2|Usual care for behavioral risk factors.
2448272|NCT03253770|Experimental|No digital aid|No cognitive aid in the hand of the leader during crises management. Intervention : no cognitive aid in the hand of the leader during crises management.
2448274|NCT03253770|Experimental|Paper Cognitive Aid|"The paper cognitive aid is the document officially recommended to be used in case of crises by the French Society of Anaesthesia and Intensive Care.~Intervention : paper cognitive aid in the hand of the leader during crises management."
2448317|NCT03252782|Active Comparator|Functional Treatment|Acrylic Splint Herbst Appliance
2448320|NCT03252782|Active Comparator|Distalization Treatment|Mini-implant-borne Distal Jet Appliance
2448399|NCT03252535|Experimental|Cellavita HD Lower Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 1x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2448409|NCT03252535|Experimental|Cellavita HD Higher Dose|The participants randomized to this group will receive a total of 9 intravenous administrations of 2x10^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2448412|NCT03252535|Placebo Comparator|Placebo Group|The participants randomized to this group will receive a total of 9 intravenous administrations divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
2448455|NCT03251781|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation
2448535|NCT03251560|Experimental|Fuke Qianjin capsule|Fuke Qianjin capsule, 2 pills each time,three times a day, orally (0.4g/pill）,for 2months,
2448542|NCT03251560|Placebo Comparator|Placebo oral capsule|placebo pills, 2 pills each time,three times a day, orally, for 2months
2448594|NCT03250923|Experimental|silver citrate complex and acemannan|This is a single arm open pilot trial. All participants will receive study drug.
2448676|NCT03250728|Other|CDG with stroke-like history|
2448682|NCT03250728|Other|CDG without stroke-like history|
2448734|NCT03250130|Experimental|Hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
2448768|NCT03249818|Other|HITT Device|HITT device to scan eyes of participants 3 times (30 seconds each) at time of admittance to hospital for diagnosed traumatic brain injury. If patient is still in hospital 2 weeks post-enrollment, a second set of 3 tests will be performed
2448885|NCT03249181|Experimental|Dolutegravir|"Dolutegravir group (DTG+2 NRTIs) - to make best comparison with standard of care, these NRTIs should be those recommended by national policy.~Participants randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs"
2448886|NCT03249181|Active Comparator|Standard of Care (EFV + 2 NRTI backbone)|Participants randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy (EFV + 2NRTIs at both study sites).
2448929|NCT03248752|Active Comparator|Group 1 - Self monitored|Fitbit use and reports details: Participants will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device and receive a Weekly Progress Report from Fitbit.
2448934|NCT03248752|Experimental|Group 2 - Partner monitored|Fitbit use and reports details: Participant will receive a Fitbit device to wear for 3 months. They will engage with the Fitbit application on their smartphone or tablet device. Participant will also engage with their partner through the Fitbit application. They will have access to their partner's daily progress and be able to communicate through the application. They will also receive their partner's Weekly Fitbit Reports and have a weekly discussion about the Weekly Fitbit Report.
2448978|NCT03248453|Experimental|CoPS feedback|Each participant will as feedback be given the actual CoPS after reaching the cecum on the standardized Kagaku Training Model. A leaderboard with experts performances will be present for comparison.
2448979|NCT03248453|No Intervention|No CoPS feedback|No feedback is given and the participants are not aware of the CoPS
2449051|NCT03248180||Guided dose reduction (GDR)|Patients in the GDR group will be advised to reduce < 25% of their current dose of antipsychotic agents estimated on a weekly base and follow-up every 4 weeks for at least 12 weeks.
2449053|NCT03248180||Maintenance treatment group (MTG)|Patients in the MTG will be advised to stay on their current dose of antipsychotics throughout the observational period, follow-up every 12 weeks.
2449124|NCT03247803|Experimental|Air-Q SP|air-Q Self-Pressurizing intubating Laryngeal Airway, sizes 3.5 and 4.5 (Mecury Medical, Clearwater, FL, USA)
2449127|NCT03247803|Experimental|Williams Intubating Airway|Airway Intubator, Williams, Adult Female, Single Use, Molded Surlyn Plastic, 9 cm or Airway Intubator, Williams, Adult Male, Single Use, Molded Surlyn Plastic, 10 cm
2449163|NCT03247283|Experimental|Single Oral Dose of BMS-986205|
2449256|NCT03246555|Experimental|Fimasartan or Fimasartan/Hydrochlorothiazide|
2449259|NCT03246555|Active Comparator|Perindopril or Perindopril/Indapamide|
3153389|NCT00273845|Experimental|1|One session of motivational interviewing
2449349|NCT03245827|Active Comparator|Obese males with hypogonadism-active|Subjects will be randomized to receive clomiphene capsules
2449351|NCT03245827|Placebo Comparator|Obese males with hypogonadism-placebo|Subjects will be randomized to receive placebo capsules
2449353|NCT03245827|No Intervention|Obese males with normal testosterone|comparison group
2449356|NCT03245827|No Intervention|lean males with normal testosterone|comparison group
2449419|NCT03245632||Carbapenem-Resistant K. pneumoniae|Patients with clinical confirmed Carbapenem-Resistant Klebsiella pneumoniae infection.
2449422|NCT03245632||Carbapenem-Sensitive K. pneumoniae|Any patients with clinical confirmed Carbapenem-Sensitive Klebsiella pneumoniae infection.
2449468|NCT03245125||HIIT subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received at least 36 times of high-intensity interval training (HIIT)
2449470|NCT03245125||MDP subjects in HFrEF patients|heart failure patients with reduced ejection fraction (HFrEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
2449473|NCT03245125||HIIT subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received at least 36 times of high-intensity interval training (HIIT)
2454153|NCT03212716|Experimental|diltiazem|oseltamivir + diltiazem
3153390|NCT00273845|Experimental|2|Five sessions of strengths-based case management
3153391|NCT00274209||IBD patients at risk for neoplasia|Patients with long-standing ulcerative colitis or Crohn's colitis at risk for neoplasia.
2448321|NCT03252717|Experimental|blood sample|Pre-treatment blood samples will be collected: 8 samples
2448355|NCT03252483|Active Comparator|HIV Only|Those randomized to the control group were offered only an HIV test.
2448356|NCT03252483|Experimental|Bundled HCV/HIV|Those randomized to the intervention group were offered both HCV and HIV test.s
2448429|NCT03252236|Experimental|Tai Chi|Subjects in this group were trained with Tai Chi exercise. The training lasted for 12 weeks, one hour per session and twice a week. Subjects were asked to practice outside of the class 30 minutes at least once a week.
2448432|NCT03252236|Active Comparator|Conventional exercise|Subjects in this group were trained with conventional exercises. Subjects were also asked to practice the exercises outside of the class 30 minutes at least once a week
2448435|NCT03252236|No Intervention|Control|No training was given to the subjects in this group
2448478|NCT03251755|Experimental|Exercise|Exercise promotion using Dao-in (Chinese Yoga)
2448484|NCT03251755|No Intervention|Control|Usually clinical practice
2448533|NCT03251417|Experimental|Combination treatment|Combination treatment of irinotecan and apatinib.
2448622|NCT03250962|Experimental|SHR-1210-plus-Decitabine|Decitabine 10 mg/day, days 1-5; SHR-1210 200 mg, day 8, every 3 weeks.
2448623|NCT03250962|Experimental|SHR-1210|SHR-1210 200 mg, day 1, every 3 weeks.
2448645|NCT03250533|Experimental|LED 620 nm group (G-LED 620)|The LED device in the red light spectrum, with a wavelength of 620 nm, will be applied over the full extent of the wound.
2448650|NCT03250533|Experimental|LED 940 nm group (G-LED 940)|The LED device in the infrared light spectrum, with a wavelength of 940 nm, will be applied over the full extent of the wound.
2448659|NCT03250533|Experimental|Fixed diphasic current group (G-DF)|The electrical stimulation will be carried out with the fixed diphasic current of the Dualpex 071 equipment, being applied throughout the extension of the wound.
2448665|NCT03250533|No Intervention|Control group (G-C)|Volunteers from this group will not be submitted to treatment and will only be evaluated before, every 30 days, after the 12 week period and 30 days after the last evaluation. It is worth mentioning that, after the end of its participation, if the wound is not fully healed, the treatment will be offered with LED or diphasic current.
2448712|NCT03250260|No Intervention|Standard Care|Patient receives standard pre-operative preparation which involves a discussion in to the likely aesthetic outcome with their surgeon or specialist nurse
2448715|NCT03250260|Experimental|2-dimensional Portfolio|Patient views photographs of women matched for BMI, age, and breast volume who are 1-5 years post BCT pre-operatively.
2448716|NCT03250260|Experimental|3-dimensional simulation|Patient pre-operatively views a simulation of their own breast of their likely outcome after BCT.
2448763|NCT03249974||Target group|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
2448828|NCT03249571|Experimental|Flavonoid|Flavonoid supplement
2448832|NCT03249571|Placebo Comparator|Placebo|Placebo
2448940|NCT03248713|Active Comparator|Mifepristone|Mifepristone 600 mg/day in 2 tablets
2448941|NCT03248713|Placebo Comparator|Placebo|matching placebo in 2 tablets
2449003|NCT03248427|Experimental|Ribociclib + Letrozol|Ribociclib: 600mg, 3-weeks-on/-week-off treatment Letrozole: 2.5mg daily; Six 28 days cycles
2449007|NCT03248427|Other|Chemotherapy|Chemotherapy treatment will consist of four cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days) followed by weekly paclitaxel during 12 weeks.
2449060|NCT03247907|Active Comparator|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
2449061|NCT03247907|Active Comparator|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
2449063|NCT03247907|Active Comparator|Condition C: CPAP with Cold Passover humidifier|CPAP with Cold Passover humidifier with mouth leak
2449065|NCT03247907|Active Comparator|Condition D: CPAP with Modified Humidifier|CPAP with Modified Humidifier with mouth leak
2449067|NCT03247907|Active Comparator|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
2449070|NCT03247907|Active Comparator|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
2449074|NCT03247907|Active Comparator|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
2449080|NCT03247907|Active Comparator|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
2449272|NCT03246711||Totally fasting|Fasting each day from sunrise to sunset the whole month
2449273|NCT03246711||Partially fasting|means fasting from sunrise to sunset part of the month
2449277|NCT03246711||Non fasting|women who did not fast at all
2449314|NCT03246256||Group 1|Patients with acute ischaemic stroke who were administered intavenous thrombolysis or patients with acute ischaemic stroke refusing intravenous thrombolysis; recall in both cases 60 to 90 minutes after the informed consent procedure
2449315|NCT03246256||Group 2|1st of 2nd degree relatives of patients with acute ischaemic stroke, who witnessed the informed consent procedure
2449316|NCT03246256||Group 3|Stroke patients with acute or subacute ischaemic stroke with a contraindication for intravenous thrombolysis
2449317|NCT03246256||Group 4|Patients without an ischaemic stroke but similiar risk factors (admitted to the Departement of Cardiology and Pneumology, Charité, Campus Benjamin Franklin, Berlin, Germany)
2449318|NCT03246256||Group 5|Patients with acute ischaemic stroke who were administered intavenous thrombolysis - recall 24 hours after the informed consent procedure
3153392|NCT00274443|Experimental|ABI-007 and Carboplatin|ABI-007 and Carboplatin in patients with Advanced Non-Small Cell Lung Cancer.
3153393|NCT00274677|Placebo Comparator|Placebo|
3153394|NCT00274677|Experimental|lamotrigine|
3153395|NCT00274794|Other|Rituxan + Etoposide + G-CSF|
3153396|NCT00274794|Other|Etoposide + G-CSF|
3153397|NCT00274833|Experimental|Radiation Therapy, Temozolomide, and Erlotinib|
2448313|NCT03252600|Experimental|Arm II(lenalidomide,dexamethasone,elotuzumab,cyclophosphamide)|"Patients receive lenalidomide, dexamethasone, and elotuzumab as in Arm I. Patients also receive cyclophosphamide IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive lenalidomide PO on days 1-21 and dexamethasone IV on days 1, 8, 15, and 22. Patients also receive elotuzumab IV over 1 hour on day 1. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity."
2448476|NCT03251859|Active Comparator|Standard ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 45 days after myocardial infarction treated with percutaneous coronary intervention.
2448481|NCT03251859|Experimental|Reduced ticagrelor maintenance dose|Ticagrelor 90 mg twice daily for the first 30 days after myocardial infarction treated with percutaneous coronary intervention, then reduction of the maintenance dose to ticagrelor 60 mg twice daily for the next 15 days.
2448523|NCT03251365|No Intervention|Group I, Normal|Group I. After cytoreductive surgery, R0, and intestinal reconstruction, the patient after multidisciplinary study will receive adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
2448526|NCT03251365|Experimental|Group II,experimental.HIPEC-Gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
2448577|NCT03251105|Active Comparator|ProSeal group|This group received the ProSeal LMA for supraglottic airway intubation and ventilation during anaesthesia.
2448579|NCT03251105|Active Comparator|Supreme group|This group received the Supreme LMA for supraglottic airway intubation and ventilation during anaesthesia.
2448640|NCT03250793|Experimental|Neonate with congenital diaphragmatic hernia|Neonates with congenital diaphragmatic hernia in post-surgical period under mechanical ventilation during weaning of mechanical ventilation
2448668|NCT03250468|Experimental|CBT-I|Participants randomized to receive the intervention will attend 6 weekly group-based CBT-I sessions. Each 90-minute group will include 6-12 participants.
2448670|NCT03250468|No Intervention|Wait-list control|The wait-list control group will receive treatment as per our standard cardiac rehabilitation program. After completion of the 3-month follow-up questionnaire, wait-list control participants may take part in the intervention.
2448764|NCT03249961|Experimental|Placebo Brain stimulation|Participants will receive Sham TDCS, and Transcranial Magnetic Stimulation (TMS)
2448770|NCT03249961|Experimental|Excitatory Brain Stimulation|Participants will receive Anodal TDCS, and Transcranial Magnetic Stimulation (TMS)
2448847|NCT03249519|Experimental|Standard Arm|Radiation therapy: 50.4 Gy Brachytherapy: 35-40 Gy Chemotherapy: Cisplatin weekly 40mg/m^2 (6 cycles) Hyperthermia: 10 times
2448882|NCT03248934|Experimental|Patient Self-Administered Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will first complete a patient self-administered diagnostic exam.
2448883|NCT03248934|Active Comparator|Clinician-Performed Exam Group|Participants with hip pain presenting in the hip preservation clinics will be asked to complete two diagnostic exams. Participants with hip pain will next complete a clinician-performed diagnostic exam.
2448930|NCT03248804|Experimental|Soy Group|Subjects in the soy group were asked to participate in the Colorado Diet program and to consume 3 soy food items per day.
2448933|NCT03248804|Other|Non-soy Group|Subjects in the non-soy group were asked to participate in the Colorado Diet program and to avoid soy food products.
3153398|NCT00274989|Experimental|Bendamustine plus Rituximab|
3153399|NCT00275015|Experimental|High dose therapy + autologous PBSCT|"Cytoreductive treatment: (preferentially) FC (2-4 cycles)~Mobilization: Dexa-BEAM + G-CSF (1-2 cycles)~Myeloablation:~fractionated TBI (e.g. 6x2Gy) + Cyclophosphamide (2 x 60 mg/kg; d -4 to -3)~autologous peripheral blood stem cell transplantation (PBSCT) (d 0)"
3153400|NCT00275041|Experimental|cetuximab + irinotecan|"Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and irinotecan hydrochloride IV over 1½ hours on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed periodically for up to 5 years."
3153401|NCT00275054|Experimental|Cohort I (FCR)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort I receive Fludarabine, Cyclophosphamide and Rituximab (FCR) chemoimmunotherapy.
3153402|NCT00275054|No Intervention|Cohort II (W&W)|Patients with 2 or more risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) who are randomized into cohort II receive no treatment at all (watch & wait).
3153403|NCT00275054|No Intervention|Cohort III (W&W)|Patients with less than 2 risk factors out of 4 (1. unfavorable molecular cytogenetics, 2. high serum thymidine kinase levels, 3. lymphocyte doubling time shorter than 12 months, 4. unmutated IgVH gene) are assigned directly to cohort III and receive no treatment at all (watch & wait).
3153404|NCT00275067|Experimental|Radiation + temozolomide and arsenic trioxide|Radiation therapy followed by the combination of temozolomide and arsenic trioxide at the maximum tolerated dose determined in phase 1
3153405|NCT00275080|Experimental|Treatment (enzyme inhibitor, chemotherapy)|"Regimen 1 (sequential dosing): Patients receive oral vorinostat two or three times daily on days 6-21 or days 6-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Regimen 2 (concurrent dosing): Patients receive oral vorinostat two or three times daily on days 1-21, days 1-14 (patients with hematological malignancies only), or two times daily on days 1-12 (patients with solid tumors or NHL only) and decitabine IV over 1 hour on days 1-5."
2449094|NCT03247868|Experimental|Botulinum toxin+SPRInt protocol|patients affected by cervical dystonia receive botulinum toxin treatment (EMG-US guided injections in dystonic muscles) for two times at T0 and T2; after T2 patients are treated also with SPRInt rehabilitation protocol based on motor learning techniques.
3190099|NCT00783887||1|Patients with suspected or confirmed primary ciliary dyskinesia after ciliary investigations who accepted to participate to the genetic studies
2448335|NCT03252678|Experimental|A Book and Videos about ACP|Subjects in experimental group get a book of 45 pages and three videos about advanced care planning based on Smart Management Strategy for Health (SMASH). After they finish reading and watching the materials, they fill out the questionnaire.
2448336|NCT03252678|Active Comparator|A Book and Videos about Pain Control|Subjects in the group get a book and two videos about pain control for cancer patients. After they finish reading and watching the materials, they fill out the questionnaire.
2448386|NCT03252379|Experimental|Group A|Patients undergoing modified hepaticojejunostomy with gastric access loop
2448390|NCT03252379|Experimental|Group B:|Patients undergoing modified hepaticojejunostomy with subcutaneous access loop
2448392|NCT03252379|Experimental|Group C:|Group C: Patients undergoing standard hepaticojejunostomy with no endoscopic access loop
2448462|NCT03251885||women with preterm labor|pregnant women < 37 weeks of gestations with regular uterine contractions and > 3 cm dilation, > 80% effacement
2448465|NCT03251885||women with term pregnancy|pregnant women > 37 weeks of gestation
3190100|NCT00783900|Active Comparator|metoprolol|
3190101|NCT00783900|Active Comparator|biatrial pacing|
3153406|NCT00275093|Experimental|Treatment (temsirolimus)|"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD."
3153407|NCT00275132|Experimental|Erlotinib|Tarceva (OSI-774, erlotinib) PO 150mg daily
2448895|NCT03249168|Experimental|case group|Duloxetine 60mg orally 12 hours before surgery
2448898|NCT03249168|Active Comparator|Control group|Placebo (glucose powder in a tablet) orally 12 hours before surgery
2448984|NCT03248648|Active Comparator|Neostigmine group|At the end of the surgery patients receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
2448988|NCT03248648|Active Comparator|ketamine group|At the end of the surgery patients receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
2449056|NCT03248102|Experimental|Patients with suspected appendicitis|Patients with suspected appendicitis Aged 5 and up to their 16th birthday on arrival to A&E
2449112|NCT03247777|Active Comparator|Traditional strengthening|These subjects performed traditional strengthening exercises of targeted muscle groups (For example, bench press, lat pulldowns, dead lifts and wrist curls)
2449115|NCT03247777|Active Comparator|Functional Strengthening|These subjects performed exercises that either mimicked golf (diagonal chop) or that required balance and stability (single leg dead lift)
2449179|NCT03247374|Experimental|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The duration of each session will take 1 hour, including bio-feedback preparation. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The experimental group will perform this training for 45 minutes, plus they will receive a verbal feedback from the speech and language therapist."
2449227|NCT03246698|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position. Additionally they will receive standard physiotherapy.
3153408|NCT00275132|Placebo Comparator|Matched placebo|Matched placebo PO daily
3153409|NCT00275145|Experimental|Resistance Training|8 months of Resistance Exercise Training
3153410|NCT00275145|Experimental|Aerobic Exercise|8 months of Aerobic Exercise Training
3153411|NCT00275145|Experimental|Combination RT & AT|8 months of Combined Aerobic and Resistance Exercise Training
3153412|NCT00275145|Experimental|Control|Control/sedentary intervention
3153413|NCT00275171|Active Comparator|rhTSH|proceeded by 0.1 mg rhTSH
3153414|NCT00275171|Placebo Comparator|Placebo|1 ml isotonic saline
3153415|NCT00275288||Healthy Normal|
3153416|NCT00275288||Active Disease|
3153417|NCT00275366|Other|1|
3153418|NCT00275496|Active Comparator|WEX only|
3153419|NCT00275496|Active Comparator|WEX + SLND|
3153420|NCT00275496|Active Comparator|WEX+SLND+CLND|
3153421|NCT00275535|Active Comparator|Tacrolimus|Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
3153422|NCT00275535|Active Comparator|Sirolimus|Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.
3153423|NCT00275548|Other|The Preventative (Prophylaxis) Group:|This group of patients will receive study drugs for the treatment of recurring (or returning) hepatitis C before they actually develop clinical symptoms of hepatitis C.
3153424|NCT00275548|Other|The Observational Group:|This group of patients will receive the study drugs for the treatment of recurring hepatitis C only if they develop the clinical symptoms of hepatitis C infection.
3153425|NCT00275574|Experimental|acupuncture|four acupuncture treatments over a period of two weeks
3153426|NCT00275613|Experimental|Rituximab, IV infusion|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
3153427|NCT00275756|Experimental|1|
3153428|NCT00275756|Experimental|2|
3153429|NCT00275756|Experimental|3|
3153430|NCT00275951|Experimental|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
3153431|NCT00275990|Experimental|thrombectomy before stenting|thrombectomy before stenting
3153432|NCT00275990|Active Comparator|directing stenting alone|directing stenting alone
3153433|NCT00276055|Experimental|Cohort 1|1000mg/m2 gemcitabine
3153434|NCT00276055|Experimental|Cohort 2|1250 mg/m2 gemcitabine
3153435|NCT00276055|Experimental|Cohort 3|1500 mg/m2 gemcitabine
3153436|NCT00276172|Experimental|Natalizumab|Open-label natalizumab
3153437|NCT00276198|Experimental|1|Supplementation with daily sprinkle package
2448522|NCT03251586|Experimental|70-79|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448524|NCT03251586|Experimental|80-89|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448531|NCT03251586|Experimental|90-99|Participants within the above age range who have normal hearing and no history of balance disorders or unsteadiness.
2448673|NCT03250611|Experimental|Occipito-Cervical Instability|Stabilization of the occipito-cervical junction by Occipital Condyle Screw (OCS) as a sole cranial anchor, with posterior bone graft.
2448806|NCT03249402|Experimental|Oral Contraceptive Tablet + JNJ-42847922|All participants will receive one oral contraceptive (OC) tablet containing ethinyl estradiol (EE) 0.03 milligram (mg) and levonorgestrel (LN) 0.15 mg once daily on Days 1 to 21 for both cycle 1 and cycle 2. In addition, in cycle 2, participants will receive 40 mg of JNJ-42847922 once daily on Days 14 to 21. Participants will not be given OC tablet on Days 22 to 28 during cycle 1 and cycle 2 (tablet-free period).
2448873|NCT03249246||Infection only|The patients have only infection
2448874|NCT03249246||Infection + SIRS|Patients have infection plus systemic inflammatory response syndrome (SIRS)
2448875|NCT03249246||Severe sepsis|Septic patients with newly developed organ dysfunctions
2448876|NCT03249246||Septic shock|Sepsis plus sepsis related hypotension
2449220|NCT03247062|Other|Cohort study (Before-after desgin)|"Quality improvement - sleep bundle Intervention consists in a sleep bundle, an aggregate of several propositions to improve the sleep of patients.: implementation of a sleep bundle.~The entire ICU population will be observed before and after intervention."
2449299|NCT03246607||Monitoring with MicroEye & ContinuMon|72 hour study interval with monitoring using intravascular glucose monitoring system alongside routine clinical care.
2449358|NCT03245970|Active Comparator|Treatment Arm|"Treatment arm patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Intervention: Labetalol Hydrocholoride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
2449359|NCT03245970|No Intervention|Non Treatment|Non treatment Arm patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
2449404|NCT03245567|Experimental|Pre, post, delayed test|Participants will not do the PLM, but will perform a pretest, a posttest and a delayed test at 6 months
2449406|NCT03245567|Experimental|PLM group (pre, post, delayed test, PLM)|Participants will do a pretest, the PLM, a posttest and a delayed test at 6 months
2449457|NCT03245190|Experimental|Chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
2449549|NCT03244514|Experimental|Intervention group|"Implementation of the cardiovascular surgery AKI bundle~discontinuation of all nephrotoxic agents when possible~optimization of volume status and hemodynamic parameters~close monitoring of serum creatinine, fluid balance and urinary output~avoidance of hyperglycemia~considerations of alternatives to radiocontrast agents~discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period~avoidance of HES, gelatin, and chlorid-rich solutions"
2449552|NCT03244514|No Intervention|Control group|The patients will receive standard of care (according to each center)
3153438|NCT00276198|Active Comparator|2|Supplementation with Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms. According to Ministry of Health routine recommendations.
3153439|NCT00276198|No Intervention|3|No intervention except for checking outcomes at approprite times.
2449655|NCT03243877||Breast Cancer Positive|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were positive.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
2449659|NCT03243877||Breast Cancer Negative|"A 5cc blood sample will be collected from subjects who were screened for breast cancer at the treating facility and results were negative.~MammoAlert Screening Test will be performed on plasma obtained from the blood sample."
2449722|NCT03243474||65 - 69 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 65 - 69 years.
2449723|NCT03243474||70 - 74 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 70 - 74 years
2449724|NCT03243474||75- 79 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 75 - 79 years
2449725|NCT03243474||80 - 84 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 80 - 84 years
2449726|NCT03243474||85 - 89 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged 85- 89 years
2449727|NCT03243474||≥90 years|The assessment of AF prevalence with use of the monitoring system, blood pressure (BP) measurements and a blood sample collection in patients aged ≥90 years
3153440|NCT00276263|Experimental|1|
3153441|NCT00276302|Experimental|1|Schedule A: Doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration.
3153442|NCT00276302|Experimental|2|Schedule B: Doses occur on Days 1, 4, 8, 11, 15, and 18 (twice weekly for 3 weeks continuously).
3153443|NCT00276510|Experimental|1|
3153444|NCT00276510|Placebo Comparator|2|
3153445|NCT00276523|Active Comparator|Control|Control (no treatment), conventional surgery.
3153446|NCT00276523|Experimental|PEG-Intron 0.5 mg/kg|PEG-interferon alfa-2b 0.5 mg/kg subcutaneously (SQ) once a week for 3 weeks, plus surgery.
3153447|NCT00276523|Experimental|PEG-Intron 2.5 mg/kg|PEG-interferon alfa-2b 2.5 mg/kg SQ once a week for 3 weeks, plus surgery.
3153448|NCT00276523|Experimental|PEG-Intron 5.0 mg/kg|PEG-interferon Alfa-2b 5 mg/kg SQ once a week for 3 weeks, plus surgery.
3153449|NCT00276536|Experimental|Treatment|IFN weekly
3153450|NCT00276575|Experimental|Bevacizumab, Everolimus, and Erlotinib|"Dose Level Dose Bevacizumab (mg/kg q2wks) Everolimus (mg daily) Erlotinib (mg daily) -1 5 5 ---~10 5 ---~10 10 ---~10* 10* 75~10* 10* 150"
3153451|NCT00276627|Active Comparator|communication lecture|
3153452|NCT00276627|Experimental|lecture plus CD-ROM|
3153453|NCT00276640|Active Comparator|vincristine, carboplatin|standard chemotherapy group
2448582|NCT03251092|Placebo Comparator|MAD PTI-808 Placebo|Three cohorts of MAD are planned for evaluation where subjects will be randomized to PTI-808 or placebo.
2448585|NCT03251092|Active Comparator|FE PTI-808 Active|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2448587|NCT03251092|Placebo Comparator|FE PTI-808 Placebo|Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2448588|NCT03251092|Experimental|Part 2 PTI-808 + PTI-801 + PTI-428 Active|One cohort is planned where subjects will be randomized to either the triple active arm (dosed with PTI 808+PTI 801+PTI 428) OR placebo arm.
2448591|NCT03251092|Placebo Comparator|Part 2 matching Placebos|In all three cohorts in part 2, subjects will be randomized to active drug or placebo. The placebo arm for all cohorts consists of placebo capsules matching PTI-808+PTI-801+PTI-428.
2448592|NCT03251092|Experimental|Part 2 dual active arm PTI-801+PTI-428+ PTI-808 placebo|One cohort is planned where subjects are randomized to either 808 placebo + dual active arm (dosed with placebo matching PTI 808 plus PTI 801 + PTI 428) OR placebo arm.
2448593|NCT03251092|Active Comparator|Part 2 dual active arm PTI-801+PTI-808+PTI-428 placebo|One cohort is planned where subjects are randomized to either 428 placebo + dual active arm (dosed with placebo matching PTI 428 plus PTI 808 and PTI 801) OR placebo arm.
2448596|NCT03251092|Active Comparator|Part 3 CF MAD PTI-808 + PTI-801 + PTI-428|In all cohorts in Part 3, subjects will be will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
2448601|NCT03251092|Placebo Comparator|Part 3 CF MAD PTI-808 placebo+PTI-801 placebo+PTI-428 placebo|In all cohorts in Part 3, subjects will be randomized to receive 7 days of PTI-808 or placebo followed by 14 days of co-administration of PTI-808+PTI-801+PTI-428 or matching placebos. A follow-up will occur on Day 28.
2448605|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428|In cohorts 3 & 4 subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
2448608|NCT03251092|Active Comparator|Part 4 CF PTI-808 + PTI-801 + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
2448611|NCT03251092|Placebo Comparator|Part 4 CF PTI-808 placebo + PTI-801 placebo + PTI-428 placebo|In cohorts 3 & 4, subjects will be randomized to receive PTI-808 + PTI-801 with or without PTI-428 or matching placebos. A follow-up will occur on Day 42.
3153454|NCT00276640|Active Comparator|vincristine, carboplatin, etoposide|intensified induction chemotherapy group
3153455|NCT00276640|Active Comparator|radiation|radiation therapy group
3153456|NCT00276640|No Intervention|Control|Control group: wait and see strategy
3153457|NCT00276783|Experimental|Treatment Arm|Pemetrexed 900 mg/m2 every 21 days until disease progression.
2448966|NCT03248505|Placebo Comparator|Placebo TENS|TENS unit turned on, but with zero amplitude.
3153458|NCT00276835|Experimental|Genistein and Interleukin-2|
3153459|NCT00276848|Active Comparator|Fludarabine plus Cyclophosphamide|
3153460|NCT00276848|Active Comparator|Fludarabine|
3153461|NCT00276874|Experimental|Aripiprazole|Subjects receive oral aripiprazole.
3153462|NCT00276874|Placebo Comparator|Placebo|Subjects receive oral placebo
3153463|NCT00276939|Experimental|1|Low-fat, low-Glycemic Index, vegan diet
3153464|NCT00276939|Active Comparator|2|ADA diet
3153465|NCT00276965|Experimental|A|Participants will take lithium only.
3153466|NCT00276965|Experimental|B|Participants will take lithium and sertraline.
3153467|NCT00276965|Experimental|C|Participants will take sertraline only.
3153468|NCT00276978|Experimental|Aripiprazole|Aripiprazol augmentation therapy
3153469|NCT00276991|Other|"Kallunk oxide (Immunotherapy)"|"The participants were received a daily regimen of Kallunk oxide(Immunotherapy) ."
3153470|NCT00277043|Experimental|1 Test Dose|
3153471|NCT00277043|Active Comparator|2) Non test dose arm|
3153472|NCT00277160|Experimental|Treatment Group 1 (Primary Prophylaxis)|Neulasta 6mg single administration per cycle of chemotherapy starting with cycle 1
3153473|NCT00277160|Active Comparator|Treatment Group 2 (Secondary Prophylaxis)|Per Investigator's discretion
3153474|NCT00277186|Active Comparator|Intervention|Patients entering new care continuum
3153475|NCT00277186|Active Comparator|Control|Patient enter existing conventional approach
3153476|NCT00277238|Experimental|CPG10101 (0.2) + pegylated inteferon + ribavirin|
3153477|NCT00277238|Experimental|CPG10101 (0.5) + pegylated inteferon + ribavirin|
3153478|NCT00277238|Active Comparator|Pegylated interferon + ribavirin|
3153479|NCT00277238|Experimental|CPG10101 + pegylated interferon + ribavirin (rollover)|
3153480|NCT00277368||001|
3153481|NCT00277433||Atopic Dermatitis|
3153482|NCT00277433||Non-atopic control|
3153483|NCT00277472|Experimental|valsartan HCTZ|
3153484|NCT00277472|Active Comparator|HCTZ|
3153485|NCT00277537|Experimental|1|
3153486|NCT00277537|Other|2|
3153487|NCT00277589|Experimental|1|
3153488|NCT00277589|Active Comparator|2|
3153489|NCT00277589|Active Comparator|3|
3153490|NCT00277589|Placebo Comparator|4|
3153491|NCT00277641|Experimental|1|lamotrigine
3153492|NCT00277641|Placebo Comparator|2|
3153493|NCT00277654|Active Comparator|Risperidone|
3153494|NCT00277654|Placebo Comparator|Sugar pill|
3153495|NCT00277706|Experimental|FORTEO|
3153496|NCT00277706|Placebo Comparator|Placebo|
3153497|NCT00277758|Experimental|1|Interventions: 12 weeks of interleukin-2 administration, followed by 48 weeks of interleukin-2 + Ribavirin + interferon-alpha therapy, followed by 24 weeks off therapy
3153498|NCT00277758|Active Comparator|2|48 weeks of therapy with Ribavirin + interferon-alpha, followed by 24 weeks off therapy
3153499|NCT00277784||1|Individuals with age related macular degeneration
3153500|NCT00277797|Active Comparator|Biowave first|First Treatment: Biowave; Second Treatment: TENS
3153501|NCT00277797|Active Comparator|TENS first|First Treatment: TENS; Second Treatment: Biowave
2448589|NCT03251131|Experimental|Restrictive fluid management|Restrictive fluid management Targeting a negative or maximum 300ml positive daily fluid balance.
2448590|NCT03251131|No Intervention|Standard therapy|Randomized allocation of standard care at the clinician's discretion in accordance with current best practice.
2448736|NCT03250195|Other|PET/MRI|All participants will have a PET/MRI performed
2448745|NCT03249805|Experimental|Steenbeek Foot Abduction Brace (SFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The Steenbeek Foot Abduction Brace (SFAB) is a fixed metal bar attached to two leather shoes with laces. The shoes have laces and a strap. The FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
2448746|NCT03249805|Experimental|MiracleFeet Foot Abduction Brace (mFAB)|The study will follow the subject for 6 months after their enrollment, beginning at first FAB use. The MiracleFeet Foot Abduction Brace (mFAB) is an injected plastic molded bar with fabric shoes that clip off and on. The shoes have laces and a strap. Both FABs provide 10 degrees of dorsiflexion and 45 or 65 degrees of abduction, and will be equipped with sensors to measure at-home FAB compliance. After the last cast is removed, a brace will be worn for 23 hours/day for the first 3 months and the time will be gradually decreased thereafter to a 'nights and naps' protocol for a total of 12 hours/day. At follow-up appointments the brace will be checked for fit and Pirani score recorded.
2448860|NCT03249675||ARM 1|ARM 1: Retrospective Arm: Subjects tested with BNA in the past and have been diagnosed by their physician as having Post Concussive Syndrome. Study staff will contact the subjects and obtain Informed Consent. Study physicians will then review both BNA data and Clinical data. All relevant clinical data and all available BNA data will be shared with ElMindA. Subjects may be invited for an additional BNA follow up as part of the study.
2448864|NCT03249675||ARM 2|"ARM 2: Subjects will be prospectively enrolled in the study at the following time points when available:~Acute: within 2 weeks of injury~PCS: Subjects which sustained a concussion in the past 3 months or more, and are still experiencing symptoms related to the injury"
2448922|NCT03248726|Experimental|Polyethylene glycol and bisacodyl|In order to decrease the dose and frequency of polyethylene glycol, we added bisacodyl at the night before examination to facilitate the action of polyethylene glycol given solely in the morning of examination.
2448925|NCT03248726|Active Comparator|Split-dose polyethylene glycol|The standard regimen of polyethylene glycol was used in this group. The participant of this arm receives polyethylene glycol in the evening before examination and the morning of examination .
3208934|NCT00979511|Experimental|3Low-Calcium with exercise|
3153502|NCT00277810|Experimental|A|
2449233|NCT03246750|Experimental|B-MAD chemotherapy|Brentuximab Vedotin, Methotrexate, L-Asparaginase, and Dexamethasone
2449309|NCT03246464|Placebo Comparator|Single-vision spectacles|
2449311|NCT03246464|Active Comparator|Orthokeratology lenses|
2449370|NCT03245866||Aneurysmal Subarachnoid hemorrhage|Patients suffering from a ruptured cerebral aneurysm are included in the study.
3153503|NCT00277810|Experimental|B|
3153504|NCT00277810|Experimental|C|
2449505|NCT03244813|Experimental|Adapted physical activity|
2449507|NCT03244813|No Intervention|Standard care|
2449604|NCT03244540|Experimental|PCA|Subarchnoid anesthesia with bupivacaine PCA with morphine in the PACU
2449605|NCT03244540|Experimental|TAP|"Subarchnoid anesthesia with bupivacaine TAP (transversus abdominis plane block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
2449606|NCT03244540|Experimental|QLB|"Subarchnoid anesthesia with bupivacaine QLB (quadratus lumborum block) ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375 % ropivacaine administered (0.2 mL/kg) at the and of cesarean section.~PCA with morphine in the PACU"
2449730|NCT03243461|Experimental|Temozolomide + Valproic acid|E.g. Valproat-neuraxpharm®, Valproat-neuraxpharm® Lösung, Ergenyl®, Ergenyl®-Lösung oder Orfiril® Saft (Valproic acid), [10 mg/kg/d] tablet oder juice, p.o., every day in parallel to simultaneous radiochemotherapy with cytostatic drug Temodal (Temozolomid): [75 mg/m2/d] during simultaneous radiochemotherapy (7 days a week, max. 49 days); [150-200 mg/m2/d] during consolidation therapy (for 5 days every 28 days, 12 cycles), tablets, p.o. (or powder for preparation of an intravenously applicable solution).
2449848|NCT03242525||Emergency room|Twelve bleeding patients who are assigned to the emergency department receive a simultaneous blood analysis with POCT and central laboratory.
2449852|NCT03242525||Delivery room|Twelve bleeding patients who are assigned to the delivery room receive a simultaneous blood analysis with POCT and central laboratory.
2449908|NCT03242122|Active Comparator|CHO Control 1 Glucose|25 g glucose
2449915|NCT03242122|Experimental|CHO Experimental 1 Slowly Digested|25 g slowly-digested carbohydrate blend
2449919|NCT03242122|Experimental|CHO Experimental 2 Digestion Resistant|25 g digestion-resistant carbohydrate blend
2449920|NCT03242122|Experimental|CHO Experimental 3 Low Sugar|25 g low sugar carbohydrate blend
2449921|NCT03242122|Experimental|CHO Experimental 4 Maltodextrin|25 g maltodextrin
2449928|NCT03242122|Active Comparator|CHO Control 2 Glucose|25 g glucose
3153505|NCT00277862|Active Comparator|1|"Pegylated IFN- alpha 2b~Ribavirin for 24 weeks (patients with RVR)"
3153506|NCT00277862|Active Comparator|2|"Pegylated IFN- alpha 2b~Ribavirin for 36 weeks (patients with complete EVR)"
3153507|NCT00277862|Active Comparator|3|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (patients with partial EVR)"
3153508|NCT00277862|Active Comparator|4|"Pegylated IFN- alpha 2b~Ribavirin for 48 weeks (control)"
3153509|NCT00277888|Experimental|Femoral route|
3153510|NCT00277888|Experimental|Jugular route|
3153511|NCT00278070|Active Comparator|1|
3153512|NCT00278070|Active Comparator|2|
3153513|NCT00278070|Active Comparator|3|
3153514|NCT00278135|Active Comparator|1|
3153515|NCT00278135|Placebo Comparator|2|
2448617|NCT03251183||Healthy volunteers|Blood sampling Stress-perfusion Cardiovascular magnetic resonance (CMR) TTE (EchoErgo)
2448653|NCT03250429||CRS subjects|CRS subjects who have sinus surgery
2448703|NCT03250351|Experimental|Neurodynamic group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program plus neurodynamic techniques consisting of neural tissue longitudinal glide using the Upper Limb Neurodynamic Test 1 (ULNT1), the neurodynamic test sequence for the median nerve, described by Butler. With participants in the supine position, the shoulder was abducted and externally rotated, the scapula depressed, the forearm supinated, and the wrist and fingers extended. Mobilization was applied by depressing the scapula, flexing the elbow, and elevating the scapula, extending the elbow, within a pain-free range. The mobilization was applied for 2 minutes. Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
2448706|NCT03250351|Active Comparator|Control group|3 to 5 days after surgery, the participants assigned to this group will receive 9 sessions of early physical therapy plus educational program consisting of physical therapy aimed at reducing postoperative edema, treatment of the scar, the muscle pain and / or joint and recovery and integration of the upper limb functional motor patterns plus instructions with printed material about lymphatic system, lymphedema, pain, movement & pain; etc…. (educational strategy). Each session will be of 40 minutes approximately and will be held 3 sessions a week for 3 weeks.
2448794|NCT03249740|Experimental|Experimental: Phase 1 - GB-102|Subjects will be assigned to 1 of 4 cohorts to receive a single intravitreal injection of up to 2.0 mg (50 μL) GB-102.
2448795|NCT03249740|Experimental|Experimental: Phase 2 - GB-102|Low dose or high dose injected every 6 months
2448796|NCT03249740|Active Comparator|Active Comparator: Phase 2 - Aflibercept|Aflibercept 2 mg injected every 2 months
2448852|NCT03249337|Active Comparator|Glanatec(R) 3 times a day|
2448854|NCT03249337|Active Comparator|Glanatec (R) 6 times a day|
2449019|NCT03248297|Experimental|Azithromycin and amoxicillin placebo|Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.
2449021|NCT03248297|Experimental|Azithromycin + amoxicillin|Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.
2449025|NCT03248297|Placebo Comparator|Usual Care|This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)
2449077|NCT03247946|Active Comparator|Intervention group|intervention: upright head position
2449082|NCT03247946|No Intervention|Control group|no feeding position instructions
2449102|NCT03247634|Experimental|Getting Ahead Program|12 staggered cohorts will be given the Getting Ahead program, using the established Getting Ahead in a Just-Gettin'-By World program. Six practices will be used. Each participant will come in for 16 session over an eight week period and will be followed up six months post intervention
2449142|NCT03247426||Evaluation individuals with exercise|Individuals who work in sitting position and do regular exercises will be recruited.
2449144|NCT03247426||Evaluation individuals without exercise|Individuals who work in sitting position and do not perform regular exercises will be recruited.
2449169|NCT03247205|Experimental|HipERS|A trained physical therapist will visit each participant for a 1-hour session 3 times a week for the initial 2 weeks, and then 2 times a week for 4 weeks (total 14 hours over 6 weeks).
3190102|NCT00783926|Experimental|Cohort 1|60 subjects randomized in an equal number to six different vaccine doses
3190103|NCT00783926|Experimental|Cohort 2|Following review of safety data of Cohort 1, approximately 360 additional subjects randomized in an equal number to the six different vaccine doses
2449365|NCT03246087|Active Comparator|Acupuncture|Patients will receive acupuncture for plantar fasciosis. The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
2449371|NCT03246087|Experimental|Standard of Care|The standard of care home exercise program will be reviewed along with the stretching and strengthening exercises.
2449373|NCT03246087|Experimental|Crossover|At the end of the study, patients in the Standard of Care group whom are still experiencing pain and symptoms will be rolled into the acupuncture treatment arm of the study.
2449415|NCT03245476|Active Comparator|manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
2449421|NCT03245476|Active Comparator|education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
3190104|NCT00783939|Experimental|1|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
2449564|NCT03244254||Test Group|Children up to 17 years of age at recruitment undergoing endoscopy in order to diagnose or rule out Celiac disease, whose Marsh score at endoscopy is 2 or higher.
2449565|NCT03244254||Control Group|Children up to 17 years of age undergoing endoscopy as part of abdominal pain workup, whose Celiac serology is negative, and the Marsh score found at endoscopy is 0.
2449607|NCT03244072|Active Comparator|Treatment group|Intracameral injection of moxifloxacin solution after cataract surgery
2449614|NCT03244072|Placebo Comparator|Placebo group|Intracameral injection of placebo after cataract surgery
2449751|NCT03243331|Experimental|Gedatolisb + PTK7-ADC|
2449802|NCT03242837|Experimental|Army Resilience Training|Resilience training: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), in classroom, psychoeducational inputs on stress management and resilience related topics, cognitive behavioral interventions and moderated exercises
2449805|NCT03242837|Active Comparator|Diversity Management Training|Diversity Management: four training sessions of 90 minutes each (in week 3, 5, 6 and 7 of military training), classroom, psychoeducational inputs on social awareness and exercises
2449835|NCT03242395||Burn patients|Adult survivors of severe burns who have been admitted to Burns ITU for invasive ventilation within 10 years of neurocognitive assessment
2449836|NCT03242395||Controls|Healthy volunteers, controlled for age/sex/IQ
3190105|NCT00783978||1|Children with chronic lung disease
3190106|NCT00783991||IVR-PC|This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
2448627|NCT03250832|Experimental|Part 1a: TSR-033 monotherapy dose escalation|Part 1a will evaluate TSR-033 at ascending doses (20 milligrams [mg], 80 mg and 240 mg) every 2 weeks. Cohorts will be enrolled sequentially and will initially follow a 3+3 design at a starting dose of 20 mg.
2448629|NCT03250832|Experimental|Part 1b: TSR-033 monotherapy PK/PDy characterization|Part 1b will evaluate the PK profile and assess PDy data from blood and tumor tissue samples following TSR-033 treatment. The participants will begin treatment with TSR-033 on Day 1 followed by 28 days observation for collection of blood sampling for PK/PDy. Participants will receive their second dose of TSR-033 on Day 29 and every 14 days thereafter.
2448631|NCT03250832|Experimental|Part 1c: TSR-033+dostarlimab combination dose escalation|Participants will be administered ascending doses of TSR-033 in combination with dostarlimab 500 mg every 3 weeks. Planned dose levels of TSR-033 include 80 and 240 mg.
2448633|NCT03250832|Experimental|Part 2 Cohort A: TSR-033+dostarlimab combination|Part 2 Cohort A will evaluate the preliminary activity of TSR-033 in combination with dostarlimab in anti-PD-1 naive participants with third and fourth line MSS-CRC. TSR-033 will be administered every 2 weeks and dostarlimab every 6 weeks.
2448635|NCT03250832|Experimental|Part 2 Cohort B1: TSR-033+dostarlimab with mFOLFOX6|Part 2 Cohort B1 will evaluate the preliminary activity of TSR-033 administered every 2 weeks (Q2W) in combination with dostarlimab administered every 6 weeks (Q6W) along with mFOLFOX6 and bevacizumab (standard of care [SOC]) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFIRI, with or without biologics.
2448637|NCT03250832|Experimental|Part 2 Cohort B2: TSR-033+dostarlimab with FOLFIRI|Part 2 Cohort B2 will evaluate the preliminary activity of TSR-033 in combination with FOLFIRI and bevacizumab (SOC) in anti-PD-1 naive second line MSS-CRC participants who have progressed on frontline treatment with FOLFOX, with or without biologics.
2448648|NCT03250390|Experimental|patients|Patients with bronchopulmonary cancer who have not yet received therapeutic treatment.
2448657|NCT03250390|Active Comparator|controls|The controls consisted of 2 groups: smokers and non-smokers.
2448733|NCT03250208|Placebo Comparator|Control Group|Participants randomized to this group will take two placebo capsules daily during days 21-60.
2448735|NCT03250208|Experimental|Intervention group|The intervention in this study is a probiotic. Participants randomized to this group will take two capsules of a probiotic daily during days 21-60
3190107|NCT00783991||PP-PC|This group will have instruments administered through paper and pencil (PP) and PC.
2448901|NCT03248869|Active Comparator|Current Daily Survey|need description
2448902|NCT03248869|Experimental|Mobile Health App (MHA)|Participants download the mobile health app via the Apple App Store
2448950|NCT03248609|Experimental|Milano grapes|Unique grape varietal to test glycemic response.
2448951|NCT03248609|Active Comparator|Table grapes|Common grape varietal to test glycemic response and compare to the glycemic response elicited by the Milano grape varietal.
2448952|NCT03248609|Active Comparator|Grape juice|Used to test the glycemic response without a complex food matrix and compare to the glycemic response elicited by the Milano grape varietal.
2448953|NCT03248609|Placebo Comparator|Glucose beverage|Used to test the glycemic response with a standardized glucose beverage and compare to the glycemic response elicited by the Milano grape varietal.
2448994|NCT03248310||vascularized lymph node transfer (VLNT)|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
2448996|NCT03248310||non-surgical treatment|This is an observational study to assess QOL in patients who have elected to undergo or considered undergoing VLNT. There is no therapeutic intervention involved during the follow-up study period.
2449043|NCT03248063|Active Comparator|Cloxacillin|Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion.
2449045|NCT03248063|Experimental|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion.
2449247|NCT03246880|Experimental|Tamsulosin 0.2mg+Tadalafil 5mg|Tamsulosin 0.2mg+Tadalafil 5mg, po, q.d.
2449248|NCT03246880|Active Comparator|Tamsulosin 0.2mg|Tamsulosin 0.2mg, po, q.d.
2449251|NCT03246880|Active Comparator|Tadalafil 5mg|Tadalafil 5mg, po, q.d.
2449283|NCT03246386|Experimental|Obese subjects|Subjects with a BMI>35 kg/m2
2449286|NCT03246386|Active Comparator|Non-obese subjects|Subjects with a BMI>18.5 and <25 kg/m2
3153516|NCT00278265|Experimental|MTX followed by fludarabine|MTX is given with a dose of 10-20mg weekly Fludarabine is dosed with 25mg/m2 day 1-3 of 28 days, up to 4 cycles
2449437|NCT03245385|Experimental|Treatment with topical halobetasol spray 0.05%|Patients will instructed o apply halobetasol spray twice daily for 14 days and not to rub over the affected area after application of spray.
2449518|NCT03244930|Experimental|Arm 1|Plerixafor 0.12 mg/kg SC will be administered in the evening, 11 hours prior to initiation of apheresis. G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
2449572|NCT03244345|Experimental|Epileptic patient|
2449636|NCT03244033|Experimental|Contextual Survey + Contextual CDS|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will produce a variety of Contextual Clinical Decision Support, both passive and interruptive alerts.
2449640|NCT03244033|Active Comparator|Contextual Survey Only|Contextual factors obtained from patients in the Contextual Survey along with contextual red flags already stored in the EHR will not be used for CDS or to produce alerts.
2449744|NCT03243318||Presence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the presence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
2449748|NCT03243318||absence of motor evoked potentials|Those patients with Shoulder Abduction and Finger Extension (SAFE) score <8/10 with the absence of motor evoked potentials elicited by TMS over the ipsilesional motor cortex
3190108|NCT00783991||PDA-PC|This group will have instruments administered by personal digital assistant (PDA) and PC.
2448697|NCT03250364|Experimental|Multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + multilayer bandage consisting of three layers. The first was a 100% cotton tubular bandage which will be directly placed on the skin to prevent any injury (Tubinylex TM). The second layer is a paddle with the purpose of unify and increase pressure (Emulsified Latex FoamTM 8mm, Thuasne, France); and the third layer of inelastic bandages (6, 8 and/or 10 cm Rosidal K Short Stretch Bandage, Germany). All the bandage layers will be placed from caudal to cranial in a circular disposition, overlapping in one third the previous layer for a correctly cover of the limb and not to leave open spaces. The cotton tubular bandage and the short-stretch bandage could be cleaned without losing their material properties."
2448698|NCT03250364|Experimental|Simplified multilayer bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + double compression bandage consisting of two layers, made up of a first rigid cotton bandage (11 cm Bande coton Short Stretch; Thuasne, France) and a second elastic bandage (BiflexTM 16 light; Thuasne, France). The two layers will be placed caudal to cranial in a circular manner, overlapping in one third the previous layer. The elastic bandage have squares drawn to help to the physiotherapist to control the stretch they given to the bandage. The two bandages could be cleaning without losing their properties. If there was any oedema concentration or a fibrous place, a paddle pad will be put in these places (Mobiderm TM, Thuasne, France)."
2448699|NCT03250364|Experimental|Cohesive bandage group|Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + cohesive bandage consisting of a single short-stretched layer that will be put directly on the subject skin and stick on itself (10cm 3M CobanTM Minnesota Mining and Manufacturing Co, United States). It will be placed in a circular manner distal to cranial with a paddle pad in the elbow fold not to damage this moving part. This bandage will be reused twice in the same subject.
2448700|NCT03250364|Experimental|Adhesive compression bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + adhesive compression bandage consisting of an elastic bandage (BiplastTM Thuasne, France. Measures: 10cm x 2,5 m) which will put over a pre-tape bandage not to damage the skin. It will be placed in a circular disposition from distal to cranial. In each physiotherapy session, the bandage has to be replaced with a new one."
2448701|NCT03250364|Experimental|Kinesiotaping bandage group|"Manual lymphatic drainage (MLD) + upper limb (UL) exercises + educational strategy + kinesiotaping bandage consisting of K-Active Tape. The k-tape will be pasted directly on the skin and put longitudinally in thin bands in a cranio-caudal disposition. The width of the bandage will be of 5cm, and will be cut in four bands that will cover all the upper limb cranial to caudal in a spiral way surrounded it. The bandage will be placed moving the limb into internal and external rotation for putting the skin in a little stretch without lengthen the tape."
2448767|NCT03249883|Active Comparator|SACH first|Will use a SACH foot for the first three weeks of prosthetic gait training , and a 1M10 foot for the second three weeks of prosthetic gait training
2448775|NCT03249883|Active Comparator|1M10 first|Will use a 1M10 foot for the first three weeks of prosthetic gait training , and a SACH foot for the second three weeks of prosthetic gait training
3153517|NCT00278278|Experimental|Arm I|"Patients receive high-dose methotrexate IV over 24 hours on days 1 and 15 and leucovorin calcium IV every 6 hours on days 2-3 an 16-17. Four weeks later, patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
3208935|NCT00979511|Experimental|4 Low-calcium milk with passive exercise|
2448903|NCT03248856|Other|Group 1|Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.
2448905|NCT03248856|Other|Group 2|Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.
2448908|NCT03248856|Other|Group 3|Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.
2448910|NCT03248856|Other|Group 4|Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.
2448943|NCT03248583|Experimental|Default|
2448945|NCT03248583|Active Comparator|Psychoeducation|
2448946|NCT03248583|Active Comparator|Incentive|
2449004|NCT03248375|Other|Radiation Segmentectomy|Radiation Segmentectomy on Resectable HCC
2449046|NCT03248050|Experimental|Intervention pharmacy|Pharmacies in the intervention group will receive training, materials, and monitoring visits to encourage them to inform women who buy mifepristone + misoprostol or misoprostol alone to call the MSZ call centre for advice on how to use the pills before they take them.
2449048|NCT03248050|No Intervention|Control pharmacy|
2449095|NCT03247855|Other|Minimal invasive coronary artery bypass graft|
2449107|NCT03247491|Experimental|Experimental|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
2449109|NCT03247491|No Intervention|No intervention|Usual medical treatment (TAU) In this group the midwife will apply the usual treatment (childbirth education class in the third trimester of pregnancy).
2449166|NCT03247400|Active Comparator|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
2449174|NCT03247400|Active Comparator|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb compared with placebo ointment applied onto an opposite limb
2449181|NCT03247400|Placebo Comparator|Vehicle ointment|Placebo ointment applied onto limbs opposite to treated with active substances
2449257|NCT03246620|Experimental|Olanzapine|oro-dispersible tablet (wafer)(Zyprexa), 5 mg, single dose
2449260|NCT03246620|Active Comparator|Haloperidol|Haloperidol encapsulated tablet, 2 mg tablet, single dose
2449264|NCT03246620|Active Comparator|Diazepam|Diazepam encapsulated tablet, 2mg tablet, single dose
2449400|NCT03245671|Active Comparator|Kenalog|Patients in the Kenalog group will receive epidural injections containing a total of 80 mg Kenalog.
2449418|NCT03245580|Other|Arm 2- Slow Pull|Intervention: Procedure Core Liver Biopsy Technique: Slow Pull
2448742|NCT03250091||Extensive atrophy|Moderate to severe (++ or +++) atrophy both in corpus and antrum/incisura, other than OLGA III-IV.
2448743|NCT03250091||Isolated corpus atrophy|Isolated moderate-to-severe atrophy or IM in the corpus.
2448823|NCT03249623|Experimental|Beacon Caresystem|On randomisation to the Beacon group, a Beacon Caresystem will be connected to the patient. This involves connecting a pulse oximeter to the patient's finger (toe or ear) to measure pulse oximetry oxygen saturation and pulse, and placing a standard clinical respiratory gas analysis and flow sensor in the respiratory tubing connecting the ventilator to the patient. This sensor allows measurement of respiratory pressure, flow and volume; plus respiratory gas CO2 and O2.
2448826|NCT03249623|No Intervention|Standard Care|For this group mechanical ventilation is managed according to standard care. A Beacon CareSystem will be connected to the patient, as for the Beacon Randomisation group, but the system will be used solely for data collection, and advice will be disabled. Physiological variables captured in this arm of the study will mirror the intervention arm. Decision relating to weaning, extubation, reintubation and sedation including level of seniority of personnel involved in the decision tree process will be documented accordingly.
2448913|NCT03249142|Experimental|ARM A Durvalumab/chemotherapy association|
2448917|NCT03249142|Experimental|ARM B Durvalumab/Tremelimumab/chemotherapy association|
2448992|NCT03248531|Experimental|Bimekizumab|Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
2448993|NCT03248531|Active Comparator|Adalimumab|Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
2448997|NCT03248531|Placebo Comparator|Placebo|Subjects will receive several placebo applications to keep the blinding.
2449059|NCT03247894||MS patients who after labour|Patients with multiple sclerosis after labour in tertiary center was screened for progression of MS in 10 months period after labour
3190109|NCT00783991||PC-PC|This group will have all instruments administered through PC.
3190110|NCT00784004|Other|Volunteers|Ten healthy volunteers
2449164|NCT03247140|Experimental|Group I (JLP-1401)|JLP-1401(Telmisartan 80 mg, amlodipine 10 mg, rosuvastatin 20 mg)
2449173|NCT03247140|Experimental|Group II(Telmisartan/Amlodipine, Rosuvastatin)|Twinsta(Telmisartan 40 mg, amlodipine 5 mg) 2 tab and Crestor(rosuvastatin 20 mg)
2449204|NCT03246919|Placebo Comparator|Control (Group A)|One bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia. This amount of fluid is part of standard of care.
2449209|NCT03246919|Active Comparator|Intervention (Group B)|One bag of 500 ml 0.9% NaCl with 30 units of Oxytocin (Oxytocin solution) will be hung by Anesthesia when the fetal anterior shoulder delivers. After the placenta is delivered, then one bag of 500 ml 0.9% NaCl (normal saline) will be hung by Anesthesia. This amount of fluid is part of standard of care.
3190111|NCT00784004|Other|Patients|Sixteen patients with respiratory insufficiency
3190112|NCT00784017|Active Comparator|asparaginase medac|
2449308|NCT03246295||Gestational diabetes mellitus|Those women were diagnosed as gestational diabetes mellitus
2449310|NCT03246295||Control|Those women were diagnosed without gestational diabetes mellitus
2449366|NCT03245918|Other|Aprepitant Capsule Study Period #1|
2449368|NCT03245918|Other|Aprepitant Oral Suspension Study Period#1|
2449423|NCT03245541|Experimental|Durvalumab + SABR|Durvalumab + Stereotactic Ablative Body Radiotherapy
2449489|NCT03245034|Experimental|fourth-year Obstetrics and Gynecology residents|The intervention will be three sessions of auricular acupuncture therapy; there will be no control intervention.
2449519|NCT03244683|Other|Intervention|Subjects randomized to this arm will receive: An Oral Nutritional Supplementation (Ensure Surgical), home-based resistance training, and dietary counseling
2449522|NCT03244683|Other|Nutrition Counseling alone|Subjects randomized to this arm will receive: Dietary counseling along with standard of care procedures.
2449558|NCT03244319|Experimental|Edoxaban|
2449559|NCT03244319|Active Comparator|Warfarin|
2449608|NCT03244124|Active Comparator|SET (Self-Etching)|50 teeth will receive restorations using Self-Etching Application Strategy
2449613|NCT03244124|Experimental|SEE (Selective Enamel Etching)|50 teeth will receive restorations using Enamel Etching Application Strategy
2449621|NCT03244124|Experimental|ERDry (Etch&Rinse Dry)|50 teeth will receive restorations using Etch&Rinse Dry Application Strategy, leaving dentin dry (but not overdry)
2449623|NCT03244124|Experimental|ERWet (Etch&Rinse Wet)|50 teeth will receive restorations using Etch&Rinse Wet Application Strategy, leaving dentin wet
2449698|NCT03243695|Experimental|Angled abutment|According to the allocation, the experimental group will receive an angled abutment on the immediately placed implant. A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
2449700|NCT03243695|Active Comparator|Straight abutment|According to the allocation, the control group will receive on the immediately placed implant a Straight zero degree abutment . A vaccum stent will be used to fabricate a temporary crown using tooth colored auto-polymerizing resin(structur 2 SC/ QM , VOCO GmbH, Germany)
2449768|NCT03243279||Surgical|No interventions. Patients undergoing cardiothoracic surgery will be assessed for baroreflex sensitivity and the outcomes of interest.
2449780|NCT03242811|Experimental|Examination by MRI|MRI scan of knee, ankle and wrist
2449828|NCT03242668|Experimental|PVB using PVC for PCA in VATS|The VATS was performed.Paravertebral space was identified by loss of resistance technique combined with video-assisted inside thoracic space before chest close.PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA with background rate 3ml/h, bolus dose 2ml was infused through PVC.
2449872|NCT03242278||NVAF patients receiving 20 mg rivaroxaban|NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)
2449874|NCT03242278||NVAF patients receiving 15 mg rivaroxaban|NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)
2454548|NCT03209895|Experimental|Joint Health Product|
3190113|NCT00784017|Experimental|recombinant asparaginase|
3190114|NCT00784056|Experimental|1|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
3190115|NCT00784069|Experimental|1|Lactic Acid (Dermacyd Breeze)
2448752|NCT03249857|Experimental|patients|Patients suffering bipolar affective disorders and who will perform cognitive tasks + IQ + MINI + experimental task
2448753|NCT03249857|Active Comparator|control group|Healthy volunteers (Control group) who will perform cognitive tasks + experimental task
2448833|NCT03249636||ALL patients|New cases of patients with acute lymphocytic leukemia. Evaluation of markers 15 days after induction.
2449016|NCT03248349||1|Pharmacokinetics
2449062|NCT03247998|Experimental|General Anesthesia|"Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). General Anesthesia Protocol: (Melinda J. Davis, Cynthia R. Campos-Herrera, & David P. Archer, 2012; Powers et al., 2015; Talke et al., 2014). Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
2449064|NCT03247998|Experimental|Conscious Sedation with Remifentanil|"Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Patient will be monitored in accordance with standard monitoring guidelines and the rest of the procedure will proceed in accordance with standard of care.~See Detailed Description for additional details and description of follow-up procedures."
2449111|NCT03247660|Experimental|PFMT&HE group|A directly pelvic floor muscle (PFM) training protocol will be applied. Participants will performed PFM exercises in the way proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. If the evolution of the women will allow it, the last two treatment biofeedback sessions will be conducted in standing position, to train PFM in more challenging and functional situation. In this group participants will be also trained hypopressive breathing and will perform five hypopressive exercises: two postures in supine, one on four-kneeling, and two in standing position. Educational strategy will also be applied. The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes.
2449116|NCT03247660|Experimental|HE group|"Women will be instructed in thirty-three Hypopressives exercises (HE) described by the developer of the Hypopressive Abdominal Gymnastics, Dr. Caufriez plus Educational strategy.~The intervention will last 8 weeks, 2 sessions per week. Each session will last 40/50 minutes."
2449122|NCT03247660|Active Comparator|Control group|The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will also instruct in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure. The intervention will last 8 weeks, 1 session per week. Each session will last 40/50 minutes.
2449190|NCT03247257|Active Comparator|Group A: General Anesthesia|35 patients will be randomized to receive general anesthesia during their laparoendoscopic single site incision cholecystectomy.
2449192|NCT03247257|Active Comparator|Group B: Epidural Anesthesia|35 patients will be randomized to receive epidural anesthesia during their laparoendoscopic single site incision cholecystectomy.
2449211|NCT03246802|Experimental|HDR partial prostate brachytherapy|2 fractions of high dose rate prostate brachytherapy will be delivered to the site of recurrent disease as determined by mp-MRI
2449275|NCT03246581|Experimental|Test Product|tiotropium pMDI 2 inhalations
2449278|NCT03246581|Active Comparator|Commercial Product|tiotropium pMDI 2 inhalations
2449377|NCT03245957||Ischemic stroke|Patients with ischemic stroke diagnosed by MRI or CT scan
2449383|NCT03245957||Haemorrhagic stroke|Patients without haemorrhagic stroke diagnosed by MRI or CT scan
2449384|NCT03245957||Mimick stroke|Patients without haemorrhagic or ischemic stroke diagnosed by MRI or CT scan
3153518|NCT00278278|Active Comparator|Arm II|"Patients undergo external beam radiotherapy once daily, 5 days a week, for approximately 6 weeks.~Beginning on the first day of radiotherapy, patients receive cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on days 5, 12, 19, 26, and 33. Beginning seven days prior to completion of radiotherapy, patients receive ifosfamide IV over 1 hour and cisplatin IV over 1 hour on days 1-5, etoposide IV over 2 hours on days 1-3, and vincristine IV on day 5."
3153519|NCT00278330|Experimental|Arm I|Patients will receive a 1-hour infusion of flavopiridol on 5 days in week 1 and vorinostat by mouth three times a day in weeks 1 and 2. Treatment may repeat every 3 weeks for as long as benefit is shown.
3153520|NCT00278343|Experimental|Treatment (cediranib maleate)|Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
3153521|NCT00278369|Experimental|A|6 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
3153522|NCT00278369|Experimental|B|9 mcg/kg Denileukin Diftitox administered IV/daily on days -4 to -2 of standard interleukin 2 dose course
3153523|NCT00278369|Experimental|C|9 mcg/kg Denileukin Diftitox administered IV/daily on days 8-10 of standard interleukin 2 dose course
3153524|NCT00278382|Experimental|Treatment (sorafenib tosylate)|Patients receive oral sorafenib twice daily in the absence of disease progression or unacceptable toxicity.
2448761|NCT03250143|Active Comparator|group B|Oral azathioprine will be started at 1mg/kg/day.If there is no improvement in 1 week then escalating the dose maximum upto 100mg/day
2448837|NCT03249610|Experimental|Jindal Steel Pvt Ltd|Lifestyle intervention given
2448839|NCT03249610|Experimental|Maruti Udyog Ltd|Lifestyle intervention given
2448841|NCT03249610|No Intervention|Tata Capital|Control arm so no intervention given
2448844|NCT03249610|No Intervention|Powergrid Corporation|Control arm so no intervention given
2448907|NCT03249025|Experimental|Lidocaine-Ketamine Infusion|Lidocaine-Ketamine Infusions 1 time per month for 6 months. Pretreatment with Midazolam 1-3 mg IV Push or Subcutaneously and Clonidine 0.1 mg PO prior to infusion.
2448960|NCT03248622||Anti-HBc positive|Anti-HBc positive
2448961|NCT03248622||HCV positive Cohort|HCV positive Cohort
2449018|NCT03248271||Type 2 Diabetes, Insulin Naive|Study participants will be tested prior to and 3 and 6 months after starting insulin to manage their diabetes
2449052|NCT03247972||Patients with PAD|
2449110|NCT03247764||patients with epilepsy and depression|Patients with comorbidity of epilepsy and depression will be asked to use antidepressants such as selective serotonin reuptake inhibitor(SSRIs) or xylaria nigripes and followed up
2449167|NCT03247413|Experimental|Dexamethasone|Lesions where dexamethasone 4 milligram is administered post-radiofrequency ablation
2449175|NCT03247413|Placebo Comparator|Placebo|Lesions where 1 milliliter of normal saline is administered post-radiofrequency ablation
2449228|NCT03246984|Experimental|VasQ device implantation|
3153525|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21|Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3153526|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-21 + radiotherapy|Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.
3153527|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14|Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3153528|NCT00278408|Active Comparator|Interventional: 6 R-CHOP-14 and radiotherapy|Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.
2449513|NCT03244891|Experimental|Studied subjects|"Each subject will be studied during two sequential phases:~before fluid challenge~after fluid challenge~During each phase, the subjects will be studied at:~baseline - spontaneously breathing~head down position - spontaneously breathing~baseline - positive pressure ventilation~head down position - positive pressure ventilation The sequence a-b-c-d will be randomized for each subject and for each phase"
2450421|NCT03238690|Experimental|Controlled Cardiac Reloading|Heart failure patients with recent LVAD implantation after an optimum unloading phase, will undergo controlled cardiac reloading through LVAD speed adjustment reductions in a controlled reloading phase
2450489|NCT03238053|Active Comparator|Menopausal Laser|20 women with vaginal laser treatment
2450490|NCT03238053|Sham Comparator|Menopausal sham|20 women with probe, no active laser ray
2450491|NCT03238053|Active Comparator|breast cancer laser|20 women with breast cancer with vaginal laser treatment
2450493|NCT03238053|Sham Comparator|breast cancer sham|20 women with breast cancer with vaginal probe, no active laser rays
2450495|NCT03238053|Active Comparator|endometrial cancer laser|20 women with endometrial cancer with vaginal laser treatment
2450498|NCT03238053|Sham Comparator|endometrial cancer sham|20 women with endometrial cancer with vaginal probe, no active laser rays
2450500|NCT03238053|Active Comparator|overactive bladder laser|20 women with overactive bladder with vaginal laser treatment
2450502|NCT03238053|Sham Comparator|Overactive bladder sham|20 women with overactive bladder with vaginal probe, no active laser rays
2450610|NCT03237455|Experimental|study group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
2450611|NCT03237455|Active Comparator|control group|Thoracic spine x-rays+whole spine MRI blood tests constitutional and demographic data collection
2450665|NCT03237000|Experimental|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
2450711|NCT03236701|No Intervention|Control|usual diet
2450712|NCT03236701|Experimental|Intervention|egg white instead of meat or fish in two meals twice a week for three months
2450762|NCT03236350|Experimental|CRIC Treatment|An autoRIC® Device will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
2450764|NCT03236350|Sham Comparator|Sham Control|An autoRIC® Device visually identical to that used in the CRIC protocol will be placed on the upper arm daily to complete the preset protocol and will be repeated daily for 28 days.
2450823|NCT03235908||Patients with an acute psychosis|Acute psychosis in schizophrenia spectrum disorder, affective disorder and bipolar disorder; Observation only
2451063|NCT03234660|Experimental|Dexmedetomidine|dexmedetomidine infusion
2451069|NCT03234660|Placebo Comparator|control|placebo infusion
2451085|NCT03233958||Workshop participants|Participants of systemic / family constellation workshops
2451487|NCT03231527||Total Arterial coronary CABG|Total Arterial revascularization
2448765|NCT03249948|No Intervention|Standard defibrillation|All defibrillation attempts will occur using the standard defibrillation method, i.e. defibrillation pads will be placed in the anterior-anterior configuration. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2448771|NCT03249948|Other|Vector change defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. All further shocks will occur with the pads placed in the anterior-posterior position. The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2448778|NCT03249948|Other|Double-sequential defibrillation|The first three shocks will occur with defibrillation pads placed in the anterior-anterior position. For all further shocks, a second set of defibrillation pads (via a second on scene EMS or fire defibrillator) will be applied in the anterior-posterior position, and defibrillation will be carried out by sequential defibrillation shocks provided by the two defibrillators (i.e. with a short delay between the two defibrillators). The patient may also be administered antiarrythmic agents and epinephrine, as per current provincial standard.
2448838|NCT03249285|Experimental|Peri profile yes|patient with genetic Perindopril profile, receiving Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
2448840|NCT03249285|Experimental|HCTZ profile yes|patient with genetic HCTZ profile, receiving HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
2448843|NCT03249285|Active Comparator|Peri no profile|patient with no genetic profile, receiving after randomisation Perindopril treatment with 4-8 mg/day oral for 4-8 weeks
2448846|NCT03249285|Active Comparator|HCTZ no profile|patient with no genetic profile, receiving after randomisation HCTZ treatment with 12,5-25 mg/day oral for 4-8 weeks
2448906|NCT03248895|Active Comparator|Immediate (I-med)|Participants allocated to the I-med group will take part in the mobile DOT intervention for the first 6 weeks. Outcomes will be evaluated at the start (week 0) and end of the 6 week intervention period and during clinic visits at weeks 12 and 18 for follow-up
2448909|NCT03248895|Active Comparator|Delayed (D-med)|"Those participants allocated to the D-med group will have the DOT intervention started after a 6 week intervention-free interval with usual Asthma Clinic care. Outcomes in the D-med group will be assessed at baseline (week 0), week 6 (intervention start), week 12 (end of intervention), and at weeks 18 and 24 for follow-up."
2448942|NCT03248635||Focus group|Male and female adults age 40-75
2448968|NCT03248414|Experimental|Lactobacillus sakei|2 packs per day
2448972|NCT03248414|Placebo Comparator|Control|2 packs per day
2449055|NCT03248193|Experimental|Healthy subjects|To assess safety and tolerability of scalp and limb hypothermia, as well as to determine the optimal temperature and pressure to be used. Establishing the occurrence or lack of core hypothermia will be studied.
2449058|NCT03248193|Experimental|Cancer subjects|Once the optimal temperature and pressure of scalp and limb hypothermia is established in healthy patients, a group of cancer patients will undergo concomitant scalp and limb hypothermia over multiple cycles of chemotherapy to establish safety and tolerability of repeated therapy.
2449101|NCT03247712|Experimental|Treatment Cohort 1|Nivolumab administration (3 doses) and radiation (5 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2449103|NCT03247712|Experimental|Treatment Cohort 2|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2449105|NCT03247712|Experimental|Treatment Cohort 3|Radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2449106|NCT03247712|Experimental|Treatment Cohort 4|Nivolumab administration (3 doses) and radiation (3 days) therapy prior to restaging and surgical resection followed by additional administration of nivolumab (3 doses).
2449193|NCT03247218|Experimental|Single group of patients|"In this study 40 patients with SCD will be included. Twenty patients aged 18 years or older (cohort 1) and twenty patients 10 - 17 years old (cohort 2).~All the patients will receive Memantine Teva® film-coated tablets (Memantine hydrochloride) produced by Teva Pharma AG and will be provided as 5 mg, 10 mg, and 20 mg tablets packed in blister.~The study drug will be taken once a day per os, during one year."
2449207|NCT03246841|Other|Analysis of the gene panel|The laboratory will carry out the TUMOSPEC gene panel analysis at the same time as the BRCA1 and BRCA2 analysis and will return a negative (no mutation) or positive (presence of a mutation allowing enrolment of family members) result.
2449276|NCT03246633|Other|Perceptual Training|Single-Arm study, all participants will receive educational training via online modules and will be assessed after completion of the training.
2449294|NCT03246282|Experimental|Treatment Group|"Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by light emitting diode(s). A small adapter attaches directly to a standard 20-guage catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the proximal end of the catheter. Polychromatic light is emitted to illuminate the catheter near the site of catheter entrance. Concurrently, normal saline flows through the optic adapter, into and through the 20-gauge catheter.~Device: UVL1000 Treatment Station Drug: Normal Saline 0.9% Infusion Solution Bag Device: Peripheral Catheterization"
2449329|NCT03246009|Experimental|single injection-1.8mg|rHSA/GCSF,injection,1.8mg,Single subcutaneous injection,Duration 1 day
2449330|NCT03246009|Experimental|single injection-2.1mg|rHSA/GCSF,injection,2.1mg,Single subcutaneous injection,Duration 1 day
2449331|NCT03246009|Experimental|single injection-2.4mg|rHSA/GCSF,injection,2.4mg,Single subcutaneous injection,Duration 1 day
2449332|NCT03246009|Experimental|multiple injection-1.8mg|rHSA/GCSF,injection,1.8mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2449333|NCT03246009|Experimental|multiple injection-2.1mg|rHSA/GCSF,injection,2.1mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2449334|NCT03246009|Experimental|multiple injection-2.4mg|rHSA/GCSF,injection,2.4mg, subcutaneous injection,Duration 4 day,A total of 2 injections, each interval of 3 days.
2449388|NCT03245710|Experimental|Zhibai Dihuang powder|Arm: Experimental: Zhibai Dihuang Formula powder Zhibai Dihuang Formula powder: Traditional Chinese medicine formula powder product 5g by mouth, after meal, 3 times in one day for 12 weeks
2449391|NCT03245710|Placebo Comparator|placebos|Arm: placebo Comparator placebos 5g by mouth after meal, 3 times in one day for 12 weeks
3190116|NCT00784082||Homozygous SS sickle cell children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS sickle cell children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease , taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
2448927|NCT03249207|Active Comparator|IL-1Ra twice daily|
2448931|NCT03249207|Placebo Comparator|Placebo twice daily|
2448990|NCT03248401|Experimental|Cilostazol group|Cilostazol 200 mg or maximal tolerate dose
2448991|NCT03248401|Active Comparator|Aspirin group|Aspirin 100 mg
2449119|NCT03247751|Experimental|one group|one group receiving NIDEK intraocular lens
2449199|NCT03247075|Experimental|Internet-delivered Cognitive Behavior Therapy|10 weeks of guided Internet-delivered Cognitive Behavior Therapy
2449200|NCT03247075|Active Comparator|Internet-delivered Support and Counseling|10 weeks of guided Internet-delivered support and counseling
2449225|NCT03246763|Experimental|Durham County|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2449229|NCT03246763|Experimental|Richmond/Montgomery Counties|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2449231|NCT03246763|Experimental|TBD|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2449236|NCT03246763|Experimental|To be determined|"The intervention will include nutrition and fitness programming at a community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of comprehensive wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
2449336|NCT03246399|Experimental|0.03mg SM04690|0.03mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
2449337|NCT03246399|Experimental|0.07mg SM04690|0.07mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
2449338|NCT03246399|Experimental|0.15mg SM04690|0.15mg SM04690 per 0.5 mL intradiscal injection (single injection at Day 1)
3208533|NCT00975728|Experimental|Group 1 Product 825 (2-servings day)|30 subjects drinking 2 servings day of Product 825 for 8 weeks
2449432|NCT03245164|Experimental|Physiotherapy group exercises|This group continued physiotherapy group exercises for 12 weeks.
2449433|NCT03245164|Experimental|Basketball program|Basketball educaiton was presented for 12 weeks.
2449435|NCT03245164|No Intervention|Control group|This group did not continue any physical activity regularly.
3153529|NCT00278421|Active Comparator|Interventional: 6 R-CHOP-21|Arm I: Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 3 more courses of R-CHOP.
2449516|NCT03244631|Active Comparator|Lumbar Plexus Block|"A lumbar plexus 'nerve block' is a procedure in which local anesthetic (numbing medicine) is injected around a specific group of nerves to provide pain relief directly to the nerves supplying the area of the body undergoing surgery."
2449523|NCT03244631|Active Comparator|Pericapsular Injection|"The pericapsular injection is a procedure in which local anesthetic (numbing medicine) is injected around the hip joint to provide direct pain relief to the area undergoing surgery."
2448807|NCT03249493||HIV Injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
2448812|NCT03249493||HIV Non injection drug users|Blood sample on DBS. Blood sample for HIV Viral Load measurements and HIV Drug Resistance at baseline, 6, 12 and 24 months of follow up after ART initiation using Dried Blood Spot
2448884|NCT03249220|Experimental|CBMS|
2448957|NCT03248791|Active Comparator|Phenylephrine|Will receive spinal anesthesia using Bupivacaine. Then, phenylephrine infusion by a starting rate of 0.75 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
2448959|NCT03248791|Experimental|Norepinephrine|Will receive spinal anesthesia using Bupivacaine. Then, norepinephrine infusion by a starting rate of 0.1 mcg/Kg/min. The rate will be then adjusted according to the patient blood pressure
2449015|NCT03248258||Metastatic Breast Interview Participants - Shared Decision Making|Metastatic Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
2449020|NCT03248258||Early Stage Breast Interview Participants - Shared Decision Making|Early Stage Breast Patient Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
2449022|NCT03248258||Provider Focus Group -Shared Decision Making|Clinic Provider Participants will participate in a focus group on the topic of Shared Decision Making. This will be a one time, focus group interview with a trained moderator.
2449024|NCT03248258||Non-UAB Provider Shared Decision Making|Non-UAB Provider Participants will be interviewed on the topic of Shared Decision Making. This will be a one time, one-on-one interview with a trained interviewer.
2449027|NCT03248258||Early Stage de-escalation Interview Participants|Early Stage Breast Patient Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
2449029|NCT03248258||Patient Advocate de-escalation Interview Participants|Patient Advocate Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
2449032|NCT03248258||Physician de-escalation Interview Participants|Physician Participants will be interviewed on the topic of de-escalation of cancer treatment. This will be a one time, one-on-one interview with a trained interviewer.
2449033|NCT03248258||Early Stage Feedback Interview Participants|Early Stage Breast Patient Participants will be interviewed to provide feedback on a decision making tool (video). This will be a one time, one-on-one interview with a trained interviewer.
2449076|NCT03247920|Active Comparator|Oral group|"After 48 hours of intravenous antibiotics eligible neonates will switch to amoxicillin/clavulanic acid suspension for the remaining 5 days. When the oral suspension is well tolerated neonates can be discharged from hospital.~In order to investigate the pharmacokinetic profile of oral amoxicillin/clavulanic acid serum levels will be measured."
2449081|NCT03247920|Active Comparator|Intravenous group|Neonates will complete the full course of antibiotics of 7 days intravenously in hospital following local protocol.
3190117|NCT00784082||Homozygous SS children|"Hydroxycarbamide, Hydroxyurea (drug):~Homozygous SS children, aged > 3 years, of sub-Saharian Africa extraction, in a steady-state of disease, taken no drug except penicillin-V, folate or iron supplementation, hydroxyurea, divided into three groups :~children treated with hydroxyurea 20-25 mg/kg/day since at least 3 months with clinical efficacy on vaso-occlusive events~untreated children with major vaso-occlusive events~children > 5 year-old without a history of vaso-occlusive events~Controls : heterozygous AS parents or siblings of the patients, and AA siblings or healthy African unrelated subjects, aged > 3 years, taken no drug on the day of blood sampling."
3190118|NCT00784108|Other|Diagnostic tool|Modulated Imaging measure effect of Photodynamic therapy treatment
3190119|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
3190120|NCT00784121|Experimental|1|Lactic Acid (Dermacyd Breeze)
3190121|NCT00784160|Experimental|1|Lactic Acid
3190122|NCT00784186|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
3190123|NCT00784186|Experimental|misoprostol|800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
2449327|NCT03246022||Group l|SBP index was less than 30% of AHI
2449328|NCT03246022||Group 2|SBP index was less than 60% but more than 30%
3190124|NCT00784212|Experimental|Cohort 1|
3190125|NCT00784212|Experimental|Cohort II|
2449439|NCT03245333|Experimental|Stage 1-experimental group|JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）, for 52 weeks.
2449441|NCT03245333|Other|Stage 1-negative control|observed only for 52 weeks.
2449451|NCT03245294|Active Comparator|Lumbar ESI with paramedian approach|Lumbar ESI with paramedian approach
3190126|NCT00784212|Experimental|Cohort III|
3190127|NCT00784290|Experimental|1|Orantinib
3190128|NCT00784316|Active Comparator|metoprolol|
3190129|NCT00784316|Active Comparator|amiodarone|
3190130|NCT00784329|Experimental|Optical Frequency Domain Imaging|Optical Frequency Domain Imaging System used during Lung and Bronchial biopsies to detect cancerous tissue. Tissue imaging results will be compared to tissue biopsy results.
3190131|NCT00784342||Stable|Patients who are stable have not had a COPD exacerbation in the past 2 months.
3190132|NCT00784342||Exacerbation|Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
3190133|NCT00784355|Experimental|1:Laparoscopic cholecystectomy|Surgery
3190134|NCT00784355|No Intervention|2:controls|non-surgical control group
3190135|NCT00784381||1|
3190136|NCT00784381||2|These units use the same electronic prescribing system, but had no counselling software
3190137|NCT00784394|Experimental|Arm I (diindolylmethane)|Participants receive a single dose of diindolylmethane PO on day 1.
3190138|NCT00784394|Placebo Comparator|Arm II (placebo)|Participants receive a single dose of placebo orally (PO) on day 1.
3190139|NCT00784407|Active Comparator|FOCUS (group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
2448835|NCT03249324|Experimental|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will discuss potential costs of unhealthy behaviors and the benefits of healthier lifestyle choices, and how they apply not only to adults, but also to developing children. Theoretically, discussing these perspectives will make the mothers more likely to make healthier lifestyle choices in the future.
2448836|NCT03249324|Active Comparator|Usual Care (UC)|UC includes regular clinic visits, routine blood and urine screening tests, and anticipatory guidance from a primary care provider in accordance with the VA/DoD Guideline for the Management of Pregnancy. After delivery, participants receive routine well-child care in accordance with established guidelines from the American Academy of Pediatrics and the American Academy of Family Physicians.
2448955|NCT03248687|Experimental|Home follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance without any scheduled physician follow up.
2448958|NCT03248687|Active Comparator|Primary Care Physician Follow up|Patients with a distal radius buckle fracture treated in a removable splint will be provided with discharge instructions and anticipatory guidance with scheduled primary care physician follow up at 1-2 weeks post visit to the emergency department.
2449133|NCT03247478||invasive breast cancer|Patients with invasive breast cancer who underwent computed tomography (CT) reconstruction of axillary lymph node for assessment of lymph node response after NAC are eligible for this study. Axillary lymph node metastasis is confirmed by fine needle aspiration (FNA) or core needle biopsy (CNB) at initial diagnosis.
2449168|NCT03247270|Experimental|Intervention I|Physical exercise intervention: 12 week exercise program with low-intensity fitness training 3 times per week.
2449172|NCT03247270|Experimental|Intervention II|Physical exercise intervention:12 week exercise program with moderate to high-intensity fitness training 3 times per week
2449180|NCT03247270|No Intervention|Control group|Control group, who will have a physiotherapy session once and will be given general advice about physical activity.
3153530|NCT00278421|Active Comparator|Interventional: 4 R-CHOP-21 + 2 x R|Arm II: Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo restaging of their disease. Patients with disease progression proceed to salvage therapy off study. All other patients receive 1 more course of R-CHOP followed by 2 courses of rituximab alone.
3153531|NCT00278434|Experimental|Zoledronate|"100 cc of saline with 4 mg of zoledronate intravenous (IV), over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
2449339|NCT03246100|No Intervention|Control|These patients will receive no reminders from the health department and will receive usual care.
2449341|NCT03246100|Experimental|Autodialer R/R|Autodialer calls (up to 3 reminders)- with brief education message + practice name + practice phone #
2449342|NCT03246100|Experimental|Mail R/R|Mailed reminder (up to 3 reminders)-- with brief education message + practice name + practice phone #
2449378|NCT03245697||Lactating mothers|Lactating mothers recruited in Galicia (NW Spain)
2449401|NCT03245515|Experimental|BMS-986195|A single oral solution dose of BMS-986195
2449450|NCT03245242||Enhanced Recovery After Surgery|Prospectively enrolled group to receive standardized care under a set ERAS protocol/pathway.
2449453|NCT03245242||Historical usual surgical care|Recent historical patients (5 years prior to start of ERAS) that will be propensity-matched to ERAS patients to be used as controls for comparison of outcomes.
2449527|NCT03244761||The standard HFT|The high-flow oxygen was delivered via tracheostomy using a standard HFT.
2449532|NCT03244761||The modified HFT|The high-flow oxygen was delivered via tracheostomy using a modified HFT.
2449634|NCT03243929|Experimental|Intervention|All participants in the Translation of District Sun Safe Policies to Schools arm received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices.
2449635|NCT03243929|Other|Attention Control|All participants in the attention control arm received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
2449692|NCT03243617|Active Comparator|AO+Mist|Cosmetic Product AO+Mist
2449695|NCT03243617|Placebo Comparator|Placebo|Placebo
2449742|NCT03243227|Experimental|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by an experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
2449743|NCT03243227|Active Comparator|Exercise|Exercise therapy 4 sessions of exercise treatment will be provided by an experienced physiotherapist. It will include active range of motion, stretching, and strengthening exercise. patients will be given a brochure to continue the exercises as home exercise program during and after the treatment period.
2449829|NCT03242382|Experimental|Palbocilib|Palbociclib will be administered orally at a dose of 125 mg once a day for 21 consecutive days followed by 7 rest days to comprise a complete cycle of 28 days.
3153532|NCT00278434|Placebo Comparator|Saline|"100 cc of saline IV, over 20 minutes, for 3 doses one week apart~Treatment repeats every 21 days (one course) for up to 3 courses. In week 8, patients undergo surgical resection comprising loop excision or cone biopsy.~After completion of study treatment, patients are followed at week 10 by telephone."
3153533|NCT00278447|Active Comparator|1) CDM|Chronic Disease Management
3153534|NCT00278447|Active Comparator|2) Standard care|Standard care
3153535|NCT00278486|Experimental|stem cell transplantation|
2448938|NCT03248817|Active Comparator|fixed infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, fixed infusion phenylephrine will be administered at a dose of (0.75 mcg/Kg/min). the infusion will stop if reactive hypertension occurred
2448939|NCT03248817|Active Comparator|variable infusion|spinal anesthesia will be performed using intrathecal bupivacaine. Then, variable infusion phenylephrine will be administered at a starting dose of (0.75 mcg/Kg/min). the infusion will be titrated according to blood pressure
2448974|NCT03248388|Experimental|Adults with Retinitis Pigmentosa using ARGUS II|Subjects will use the ORCAM system mounted onto the Argus II eyeglasses.
2449120|NCT03247725|Active Comparator|Treatment as usual (waiting list)|Patients at this condition will receive the usual medical treatment at the pain unit, but they will not be monitored daily using the app.
2449125|NCT03247725|Experimental|Treatment as usual + app (without alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Because alarms will not be generated, physicians will not know if an undesired event is occuring despite the app is actually collecting data.
2449128|NCT03247725|Experimental|Treatment as usual + app (with alarm)|Participants at this condition will receive the usual medical treatment for their pain but also they will be monitored daily using the Pain Monitor app. Alarms will be generated in the face of certain preestablished events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
2449203|NCT03246815||universal opt-out screening for STDs|Patients who present to primary care practices who employee a universal opt-out strategy to medical assistants or nurses
2449206|NCT03246815||without universal opt-out screening for STDs|Patients who present to primary care practices who do not employee a universal opt-out strategy to medical assistants or nurses
2449263|NCT03246659|Experimental|arm 1|111In-CP04
2449266|NCT03246659|Experimental|arm 2|111In-CP04 with co-administration of gelofusine/gelaspan
2449293|NCT03246269||MoCA cohort|The German MoCA is administered once to all study participants.
2449534|NCT03244605|Experimental|Rehabilitation training plus TCM|"Rehabilitation training include aerobic exercise training and Liu Zi Jue lung exercises, which will be started in one month after operation.~Prescriptions formulated into granules origin from Professor Xu Ling in Yueyang hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.The patient will take TCM granules for 3 months."
2449536|NCT03244605|Placebo Comparator|Rehabilitation education plus placebo|"Patients who received rehabilitation education will not accept rehabilitation training.~We compromise the raw materials for the placebo including food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.~The patient will take placebo granules for 3 months."
2449584|NCT03244280|Other|MOB015B|
2449632|NCT03243916|Experimental|combination|TACE plus cyber knife
2449696|NCT03243643|Experimental|HS-1024+apatinib|"For part 1 (PK study) subjects will be given single dose of HS-10241 and then multiple dose of HS-10241 (1 cycle, each cycle 14days) and then HS-10241+aptatinib (each cycle 21 days) until PD.~For part 2 (expansion study) subjects will be given HS-10241+aptatinib (each cycle 21 days) until PD (Progression of disease)."
2449738|NCT03243266||CBC/Diff Reference Interval|Hematology routine diagnostic test
2449783|NCT03242993|Experimental|treatment group|"all patients successfully enrolled will be assigned to the treatment group:~1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol"
2449847|NCT03242655|Experimental|HCV GET-UP (Group Intervention)|HCV GET-Up (Group Evaluation and Treatment Uptake)
2449851|NCT03242655|No Intervention|Control|Individual onsite HCV treatment at a primary care center
2449923|NCT03241784|Experimental|Treatment arm|All subjects are enrolled in the one arm consisting of infusions of autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth/kg and subcutaneous injections of Interleukin-2 at a dose of 2x10 to the fifth IU/m2 three times a week.
3153536|NCT00278499||1|Female sex workers
3153537|NCT00278499||2|Female sex workers' clients (miners)
2450006|NCT03241173|Experimental|INCAGN01949 + Nivolumab|INCAGN01949 combined with nivolumab.
2450007|NCT03241173|Experimental|INCAGN01949 + Ipilimumab|INCAGN01949 combined with ipilimumab.
2450009|NCT03241173|Experimental|INCAGN01949 + Nivolumab + Ipilimumab|INCAGN01949 combined with nivolumab and ipilimumab.
3153538|NCT00278551|Experimental|heatopoietic stem cell transplant|
3153539|NCT00278577|Experimental|Autologous Hematopoietic Stem Cell Transplant|
3153540|NCT00278590|Experimental|allogeneic stem cell transplantation|allogeneic stem cell transplantation will be performed
3153541|NCT00278642|Experimental|stem cell transplantation|
3153542|NCT00278681|Experimental|I|Zinc and ORS
3153543|NCT00278694|Experimental|Chemoradiation|Neoadjuvant chemotherapy and chemoradiation
3153544|NCT00278746|Experimental|1|Zinc and ORS were promoted for treatment of diarrhea in underfive children
3153545|NCT00278746|Other|2|Promoted routine management of diarrhea in underfive with ORS
3153546|NCT00278772|Experimental|1|Divalproex
3153547|NCT00278772|Placebo Comparator|2|
3153548|NCT00278785|No Intervention|1|Control group to receive informational pamphlet on alcohol use and list of self referral agencies
2448967|NCT03248960|Experimental|iTreat Flu A+B Test and ellume.lab Flu A+B Test|"Upper respiratory tract samples from participants will be tested with:~iTreat Flu A+B Test; ellume.lab Flu A+B Test; Reverse Transcriptase Polymerase Chain Reaction (RT-PCR); and viral culture."
2449099|NCT03247699|Other|"Basel phenotyping cocktail capsule"|
2449100|NCT03247699|Other|"Basel phenotyping cocktail individual components"|
2449146|NCT03247439|Experimental|Cartiva|Synthetic Cartilage Implant
2449191|NCT03247166|Experimental|Lower Back and Leg Pain Patients|Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System
2449222|NCT03246867|Experimental|Isolytic stretching group|The participants in this group will receive isolytic stretching in modified cross body position.
2449223|NCT03246867|Experimental|Static stretching group|The participants in this group will receive static stretching in modified cross body position.
2449224|NCT03246867|Active Comparator|Control group|The participants in this group will receive no stretching. They will only be evaluated.
2449319|NCT03246217|Experimental|Therapeutic Instrumental Music Performance|Therapeutic Instrumental Music Performance is a Neurologic Music Therapy technique in which selection of instruments, spatial configurations and sequences for playing are designed to facilitate retraining of movement patterns used in everyday life. Participants will receive nine individual forty-five minute sessions of Therapeutic Instrumental Music Performance, three sessions per week.
2449321|NCT03246217|Experimental|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of sensory-enhanced motor imagery. During sensory-enhanced motor imagery, participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
2449323|NCT03246217|Experimental|Therapeutic Performance with Motor Imagery|Participants will receive nine individual sessions, three times per week: thirty minutes of Therapeutic Instrumental Music Performance, followed by fifteen minutes of motor imagery. Motor imagery will involve mental practice of previous movement exercises.
2449372|NCT03245788|Experimental|Lay Navigation|Patients with even MRN.
2449375|NCT03245788|No Intervention|Usual Care|Patients with odd MRN.
3190140|NCT00784407|Active Comparator|HARMONIC ACE (group B)|Patients submitted to total thyroidectomy with the use of the HARMONIC ACE harmonic scalpel device
3190141|NCT00784420|Active Comparator|UK-453,061|
3190142|NCT00784420|Active Comparator|Raltegravir|
3190143|NCT00784420|Experimental|UK-453,061 plus Raltegravir|
2449746|NCT03243383|No Intervention|Low-risk Group|Low-risk as determined by the predicted risk of readmission by the DERRI. The low-risk group will be followed in a prospective, observational arm of the study.
2449750|NCT03243383|Experimental|High-risk Group - Intervention|High-risk as determined by the predicted risk of readmission by the DERRI. Subjects in the high-risk group will be randomly assigned to receive either the intervention (DiaTOHC Program) or usual care (control).
2449754|NCT03243383|No Intervention|High-risk Group - Usual Care|Patients in the high-risk usual care group will receive the standard hospital discharge process and post-discharge followup.
3190144|NCT00784433|Experimental|alcohol 1|
3190145|NCT00784433|Experimental|alcohol 2|
3190146|NCT00784433|Placebo Comparator|control|
2449859|NCT03242330|Experimental|Two-piece subperiosteal implant|The two-piece subperiosteal implant will be designed with an internal connection that will receive its prosthetic counterpart later in the second stage surgery, which will retain the final prosthesis in place. Two-piece constructions allow for undisturbed submerged healing, without being exposed to the oral environment, achieved by attaining primary closure over the inserted implant body.
2449860|NCT03242330|Active Comparator|Single-piece subperiosteal implant|The single-piece subperiosteal implant will be designed in the from of a framework with protruding posts that will appear penetrating through the mucosa, and will later carry the overlying superstructure (prosthesis). Single-piece subperiosteal implants do not require a second stage surgery.
2449916|NCT03242005|Experimental|Pro-set® vs. Quick-set®|Subjects will be randomized to start with one of the study subcutaneous insulin administration sets (MiniMed® Pro-set® or MiniMed® Quick-set®). After completing the first study period,subjects will be placed in the alternative group according to the cross-over study design.
2449983|NCT03241589|Experimental|Direct to Patient Facing Apps Use|VA sites who have received the direct to patient facing apps from OCC
2449987|NCT03241589|Experimental|Control Direct to Patient Facing apps|VA sites to eventually receive the direct to patient facing apps but at present have not
2450015|NCT03241147|Experimental|Subjects with severe renal impairment (Group A)|
2450022|NCT03241147|Experimental|Healthy subjects (Group B)|
2450033|NCT03241147|Experimental|Subjects with moderate renal impairment (Group C)|
2450045|NCT03241147|Experimental|Subjects with mild renal impairment (Group D)|
2450072|NCT03240809|Experimental|Cohort 1|(ages 12 to <18 years): 140 mg SC dose of brodalumab
2450074|NCT03240809|Experimental|Cohort 2|(ages 6 to <12 years): 70 mg SC dose of brodalumab
2450144|NCT03240536|Experimental|Intervention Group|Ordering physicians who have referred to a rheumatologist in the St. Joseph's rheumatology clinic randomized to the intervention group will receive a brief Choosing Wisely form (for education of guidelines) faxed with the referral notice. At one and two years all ordering physicians will receive by fax a three question survey.
2450177|NCT03240185||Hemroidectomy patients|Patients undergoing hemorrhoid surgery who receive education regarding deep breathing exercises for pain control as part of their preoperative appointment
3190147|NCT00784446|No Intervention|XELOX, Bevacizumab, Imatinib|
3190148|NCT00784472|Active Comparator|oxycodone|
3190149|NCT00784472|Active Comparator|morphine|
3190150|NCT00784485|Experimental|Xolair injections|All subjects receive active drug (Xolair-see 'interventions').
3190151|NCT00784498|Active Comparator|midazolam/ketamine|Patients with orthopedic injuries requiring painful manipulation
3190152|NCT00784498|Active Comparator|propofol|Patients with orthopedic injuries requiring painful manipulation
2448977|NCT03248505|Experimental|Burst TENS|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
2448983|NCT03248505|Experimental|Cryotherapy|1,5 Kg crushed ice pack
2448987|NCT03248505|Experimental|Burst TENS + Cryotherapy|Carrier frequency of 100 Hz burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus an ice pack of 1,5 Kg.
2448989|NCT03248505|Experimental|Conventional TENS + Cryotherapy|Symmetrical biphasic pulsed current, with frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude plus an ice pack of 1,5 Kg.
2449086|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
2449090|NCT03247881|Active Comparator|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
2449096|NCT03247608|Experimental|Ambio Health Remote Monitoring|Ambio Health is an end-to-end remote patient monitoring system which includes a weight scale, blood pressure meter and blood glucose meter with wireless transmission of biometric readings through a home gateway to a web-based care management application that provides population health remote patient monitoring and engagement with automated delivery of the CarePlans.
2449135|NCT03247465|Experimental|"Group Fusion"|Trans aortic valve replacement with usual procedure with the addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
2449136|NCT03247465|No Intervention|"Group Control"|Trans aortic valve replacement with usual procedure
2449185|NCT03247244|Other|1|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: A (THC 10%, CBD <0.5%), B (THC 8.6%, CBD 8.6%), C (THC 0.6%, CBD 14%) and placebo D (THC <0.3%, CBD <0.3%).
2449187|NCT03247244|Other|2|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: B (THC 8.6%, CBD 8.6%), placebo D (THC <0.3%, CBD <0.3%), A (THC 10%, CBD <0.5%), C (THC 0.6%, CBD 14%).
2449188|NCT03247244|Other|3|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: C (THC 0.6%, CBD 14%), A (THC 10%, CBD <0.5%), placebo D (THC <0.3%, CBD <0.3%), B (THC 8.6%, CBD 8.6%).
2449189|NCT03247244|Other|4|Three cannabis drug product formulations with different THC and CBD contents and placebo will be used in the following order: placebo D (THC <0.3%, CBD <0.3%), C (THC 0.6%, CBD 14%), B (THC 8.6%, CBD 8.6%), A (THC 10%, CBD <0.5%).
2449221|NCT03246776|Experimental|Halometasone Triclosan Cream|All subjects receive external Use of Halometasone Triclosan Cream
2449280|NCT03246516|Experimental|Questionnaire|Auto and hetero questionnaire
2449350|NCT03246139|Experimental|Action observation, imagery & execution|
2449352|NCT03246139|Active Comparator|Action observation|
2449355|NCT03246139|Active Comparator|Control treatment|
2449408|NCT03245593||Shared Decision making for care|
2449409|NCT03245593||Standard decision making for care|
2449469|NCT03245073|Active Comparator|Exercise|Strengthening and stretching exercises for hip and knee muscles, balance and proprioceptive exercises
2449474|NCT03245073|Experimental|Action observation therapy and exercise|Video of normal human movement and Strengthening and stretching exercises for hip and knee muscles
2449520|NCT03244748||Group 1|Patients underwent ablation and continued having amiodarone after the procedure
2449526|NCT03244748||Group 2|Patients underwent ablation and not having amiodarone after the procedure
2449586|NCT03244358|Experimental|Epalrestat|Epalrestat added to standard treatment
2449649|NCT03243851|Experimental|Temozolomide+metformin|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Metformin :~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th ~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
2449651|NCT03243851|Placebo Comparator|Temozolomide+placebo|"Temozolomide :~1 cycle of 4 weeks with daily dose 50mg/m2(BSA: Body Surface Area) up to 6 cycles for 24 weeks~Placebo:~1st cycle (4 weeks)~1 week(1st~7th day) = 1,000mg/day~1 week(8th~14th day) = 1,500mg/day~2 weeks(15th~28th day) = 2,000mg/day~2nd to 6th cycle (20 weeks) = 2,000mg/day"
2449758|NCT03243422|Active Comparator|Successful aging education intervention|Individual sessions on healthy aging topics
2449762|NCT03243422|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
2449788|NCT03242772|Active Comparator|ESDM informed parent coaching + Amphetamine|Amphetamine regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The drug is an orally dissolvable, extended-release form of d- and l-amphetamine.
2449793|NCT03242772|Placebo Comparator|ESDM informed parent coaching + Placebo Oral Tablet|Placebo regimen (11 weeks total duration) will begin 2 weeks prior to initiation of ESDM informed parent coaching (8 weekly sessions) and continue through the week 11 endpoint assessment. The placebo contains no active drug and appears identical to the amphetamine (active drug).
2449845|NCT03242512|Experimental|30 mg single dose cohort|Subjects would receive a 30 mg single dose of TK006.
2449850|NCT03242512|Experimental|60 mg single dose cohort|Subjects would receive a 60 mg single dose of TK006.
2449853|NCT03242512|Experimental|120 mg single dose cohort|Subjects would receive a 120 mg single dose of TK006.
2449877|NCT03242083||Primary atrophic AMD|
2449878|NCT03242083||Secondary atrophic AMD|
2449910|NCT03241849|Other|Modified surgical technique for placenta accreta|
3190153|NCT00784511|Experimental|1 vitamin D3|vitamin D3, 4000 IU/d
2450157|NCT03240653||Patients Type III|Stratified response to EnzymeTherapy Substrate Reduction Therapy (expected) Splenectomy (and interactions)
2450159|NCT03240653||Patients Type I|Stratified response to Enzyme Therapy and Substrate Reduction Therapy- Splenectomy (and interactions)
2450250|NCT03239886|Experimental|Discontinuation|All subjects will discontinue imatinib
2450314|NCT03239457||Heberprot P treatment|Patients with diabetic foot ulcers treated with Heberprot P
2450400|NCT03239028||Danish National Birth Cohort|
3190154|NCT00784511|Placebo Comparator|2|placebo
2449012|NCT03248362|Experimental|TPTNS Intervention|Transcutaneous posterior tibial nerve stimulation (TPTNS) delivered in 30 minute sessions twice weekly over a 6 week period. The tibial nerve, which lies immediately posterior to the medial malleolus will be stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode will be positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters will be applied at 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) will be adjusted on a session-by-session basis according to individual resident comfort levels.
2449014|NCT03248362|Sham Comparator|Sham stimulation|Sham stimulation comprises low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS stimulation other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.
2449038|NCT03248011|Experimental|Flexibility|Stretching exercise
2449039|NCT03248011|Experimental|Strength|Eccentric hamstring strengthening exercise
2449040|NCT03248011|Experimental|Neuromuscular|Balance exercise
2449041|NCT03248011|No Intervention|Control|No exercise
2449121|NCT03247842|Active Comparator|suprascapular nerve RF|Eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups (Figure1); forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (PRF) followed by injection through the radiofrequency needle of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1)
2449126|NCT03247842|Active Comparator|suprascapular nerve block|and forty patients received fluoroscopically guided supra-scapular nerve injection of mL of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.
2449242|NCT03246932|Experimental|Peer-led psycho-education group|A structured, researcher-designed peer expert-led psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education and self-help, problem-solving programs by Chien et al. (2010) and Lehman et al. (2004).
2449244|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
2449246|NCT03246932|Active Comparator|Profession-led psycho-education group|A psycho-education group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.
2449305|NCT03246360|Active Comparator|Intermittent administration of cloxacillin|
2449306|NCT03246360|Experimental|continuous administration of cloxacillin|
2449381|NCT03245905|Experimental|Chidamide|Chidamide should be given at a fixed time with fixed dosage
2449449|NCT03245450|Experimental|Eribulin mesilate plus irinotecan hydrochloride|In Schedules A and B, eribulin mesilate at the dose of 1.4 milligrams per meters squared (mg/m^2) will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle. In Schedule A, irinotecan hydrochloride at the doses of 20 mg/m^2 or 40 mg/m^2 will be administered as an IV infusion on Days 1 to 5 of a 21-day cycle. In Schedule B, irinotecan hydrochloride at the doses of 100 mg/m^2 or 125 mg/m^2 will be administered as an IV infusion on Days 1 and 8 of a 21-day cycle.
2449525|NCT03244644|Placebo Comparator|Group A|Placebo is an enema of normal saline. Packaging and labeling are identical to the packaging and labeling for RBX2660 to support the study blinding
2449530|NCT03244644|Experimental|Group B|RBX2660 is an enema of a microbiota suspension in a 0.9% sodium chloride irrigation USP solution and cryoprotectant
2449612|NCT03244098|Experimental|Transition Assistance Program (TAP)|
2449619|NCT03244098|No Intervention|Standard of Care|
2449675|NCT03243825|Experimental|chemo/brachytherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) and brachytherapy before radical hysterectomy.
2449677|NCT03243825|Active Comparator|chemotherapy|Patients in this arm will receive neoadjuvant chemotherapy (paclitaxel/cisplatinum) before radical hysterectomy.
2449765|NCT03243396|Experimental|Health-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in a community setting from Community Health Volunteers.
2449767|NCT03243396|Experimental|Education-Sector Delivered CBT|These child/adolescent participants and one of their guardians will receive Pamoja Tunaweza, the locally adapted version of Trauma-Focused Cognitive Behavioral Therapy, in their school setting from teachers employed by their school.
2449810|NCT03242733||Hip fracture patients|Fasted elderly patients scheduled for hip fracture surgery except exclusion criteria are enrolled.
2449846|NCT03242473|Experimental|Lactated Ringers (LR)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
2449849|NCT03242473|Experimental|Normal Saline (NS)|The subject will be placed on 1.5x maintenance IVF with the fluids to which they are randomized. Fluid Management will be the intervention.
2449875|NCT03242070|Experimental|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
2449876|NCT03242070|No Intervention|Control Group|No specific intervention will be provided to the control group participants
3208534|NCT00975728|Experimental|Group 1 Product 824 (2 servings-day)|30 subjects drinking 2 servings-day of Product 824 for 8 weeks
2449945|NCT03241420||Chronic Lung conditions|Study participation will consist of one visit: Informed consent, complete both Lung Clearance Index (LCI) testing and spirometry.
2449947|NCT03241420||Healthy control group|Study participation will consist of one visit: Informed consent, brief questionnaire, LCI testing and spirometry.
2449075|NCT03248206|Active Comparator|PNF exercise program group|The PNF home-program exercise group: perform grade 1&2 two times a day, at least 3 times per week, for 3 sets of 12 repetitions to increase neuromuscular and musculoskeletal endurance. (Grade 1: The participants performs the diagonal- spiral pattern that will enhance the strength or movement of a targeted muscle or muscle group.; Grade 2:The participants performs PNF exercise with elastic bands . )
2449079|NCT03248206|Experimental|PNF in conjunction with tendon gliding exercise group|Patients in PNF in conjunction with TGE group will perform PNF grade 1&2 as well as tendon gliding exercise two times a day, at least 3 times per week, for 3 sets of 10 repetitions. Training duration for both the two groups is twelve weeks.
2449097|NCT03247647|Experimental|Enhanced Intervention|Participants assigned to this arm will complete a personal values task before reviewing their personalized feedback (eCheckUpToGo).
2449098|NCT03247647|Placebo Comparator|Standard Intervention|Participants assigned to this arm will complete a writing task about the food they have eaten in the past 48 hours immediately before reviewing their personalized feedback (eCheckUpToGo).
2449143|NCT03247452|Active Comparator|One-day low fiber diet|"Patients assigned to the active comparator will receive oral and written instructions about the same structured low fiber diet designed by an Endocrinologist but they will follow this diet only the day before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
2449145|NCT03247452|Experimental|Three-day low fiber diet|"Patients assigned to the experimental group will receive oral and written instructions about a structured low fiber diet designed by an Endocrinologist. They must follow this diet three days before colonoscopy.~2 liters of polyethylene glycol plus ascorbic acid will be administered"
2449170|NCT03247192|Experimental|Whey protein-placebo|"Participants received a dose of 35 grams of whey protein before resistance training (RT) and a dose of 35 grams of maltodextrin (placebo) after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2449177|NCT03247192|Experimental|Placebo-whey protein|"Participants received a dose of 35 grams of maltodextrin (placebo) before resistance training (RT) and a dose of 35 grams of whey protein after RT.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2449184|NCT03247192|Placebo Comparator|Placebo-placebo|"Participants received a dose of 35 grams of maltodextrin (placebo) before and after resistance training.~Participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, with 3 sets of 08-12 repetition maximums. The RT program was a whole-body program with eight exercises, including: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl and seated calf raise. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise."
2449215|NCT03246893|Placebo Comparator|Noninvasive positive pressure ventilation|After extubation, patient will receive non invasive positive pressure ventilation (NIV) for prevent respiratory and reintubation
2449219|NCT03246893|Experimental|High flow oxygen nasal cannula|After extubation, patient will receive high flow oxygen cannula for prevent respiratory and reintubation
2449313|NCT03246334||Cohort|Case group: critically ill patients admitted >12 hours to the ICU. Control group: critically ill patients to the ICU <12 hrs, or to Post Anaesthesia Care Unit (PACU), or Medium Care or High Dependency Unit.
2449387|NCT03245892|Experimental|Carboplatin and Paclitaxel Chemotherapy With Nivolumab (Closed)|Patients will be treated with nivolumab plus standard of care dose dense paclitaxel and carboplatin for three cycles, where each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen administered as adjuvant treatment. Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle. Carboplatin dose calculation instructions can be found in Appendix 4. Nivolumab 360mg will be infused IV over approximately 30min on Day 1 of Cycles 1-6. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks.
2449390|NCT03245892|Experimental|Nivolumab plus Ipilimumab plus Paclitaxel & Carboplatin|Patients will be treated with nivolumab plus ipilimumab plus standard of care dose dense paclitaxel & carboplatin chemotherapy for 3 cycles (up to a maximum of six), each cycle is 3 weeks, followed by cytoreductive surgery then three more cycles of the same treatment regimen. Paclitaxel 80mg/m2 IV will be administered over approx 1 hour on Days 1,8, & 15 of each 21 day cycle. Carboplatin AUC6 will be administered as an approx 30 minute IV infusion, following paclitaxel admin on Day 1 of each 21 day cycle. Nivolumab 360mg will be infused IV over approx 30 min on Day 1 of Cycles 1-6 (to 9) of each 21 day cycle. Ipilimumab 1mg/kg will be infused IV over approx 30 min on Day 1 of Cycles 1 & 3, as well as Cycle 4 & Cycle 6. Of note, if patients receive more than 3 cycles in the pre-operative setting, then ipilimumab will be administered with the first & third cycle in the post-operative setting. Nivolumab will then be infused Day 1 of each 28 day maintenance phase cycle.
2449452|NCT03245281|Experimental|Diuretic Suspension (DS)|
2449455|NCT03245281|Experimental|Diuretic Increase (DI)|
2449461|NCT03245281|Experimental|Diuretic and Medication Suspension (DMS)|
2449509|NCT03244878|Experimental|Intervention - Thrive program|Participants will receive access to the Thrive program for 8 weeks
2449869|NCT03242486|Experimental|toric intraocular lens|toric intraocular lens is implanted to all subjects
2449885|NCT03241979||laryngeal microsurgery|
2449085|NCT03247933|Experimental|Telemedicine (TeleRR)|"The intervention: Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance Respiratory Rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~The exercises dates must be sent after doing the training each day by the PDA . The dates will be monitoring by the physician ."
2449088|NCT03247933|No Intervention|Clinical Practice (Recommendation)|"No intervention. A recommendation from standard maintenance respiratory rehabilitation program with a minimum monitoring.~Clinical practice."
2449113|NCT03247621|Experimental|Whatsapp|Participants will engage in Whatsapp chats on their smartphones during the taste test
2449117|NCT03247621|Placebo Comparator|Article|Participants will read a neutral article on their smartphones during the taste test
2449123|NCT03247621|Active Comparator|No Phone|Participants will not use their phones during the taste test
3208535|NCT00975728|Experimental|Group 2 Product 825 (1 serving-day)|30 subjects drinking 1 serving-day of Product 825 for 8 weeks
2449325|NCT03246178|Other|MSD-HSCT|This group received treatment of matched sibling donor - hematopoietic stem cell transplantation (MSD-HSCT).
2449326|NCT03246178|Experimental|HFD-HSCT|This group received treatment of haploid family donor - hematopoietic stem cell transplantation (HFD-HSCT).
2449362|NCT03245775|Experimental|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
2449367|NCT03245775|Experimental|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
2449405|NCT03245502||Transfused|Patients who have blood transfusion during cardiac surgery
2449407|NCT03245502||Not-Transfused|Patients who don't have blood transfusion during cardiac surgery
2449434|NCT03245203|Experimental|Experimental group|beacizumab+ neoadjuvant chemotherapy (FOLFIRI+beacizumab)
2449436|NCT03245203|Active Comparator|Control group|neoadjuvant CRT for consecutive 5 weeks
2449499|NCT03244982|Active Comparator|Full-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
2449500|NCT03244982|Experimental|Half-Dose|Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram. If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
2449550|NCT03244579|Experimental|Dietary intervention CHO counting|Carbohydrate counting diet will be prepared according to Kulkarni, (2005). Tailored diet plans according to patient's food preference, physical activity level and appropriate insulin: Carbohydrates ratio will be prescribed for each participants. Diets were based on each participants's recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) (Thomas and Gutierrez, 2005; Kleinwechter et al., 2014). Energy requirement will be determined in the participants' pre-pregnancy weight with adding the extra requirement (450 kcal) due to pregnancy. The carbohydrate counts will be distributed into three main meals and 3 snacks.
2449551|NCT03244579|Experimental|Dietary intervention CHO Counting & DASH|The recommended intakes of energy, protein (15-25%), fat (30-40%) and carbohydrate (40-50%) will be similar to that in carbohydrate counting diet which mentioned above. DASH diet food choices will be inserted in the diet of the participants assigned for the combined diet of DASH and carbohydrate counting. The emphasis will be more on the fruits and vegetables group (>8 servings/day), whole grains (at least half of the amount of the total servings of cereals; 6-8 servings/day), fat free dairy products (2-3 servings/day), lean meat and plant proteins (0-2 servings/day) and nuts (5-7 servings/week). From the fat group olive oil will represent the main type of fat (20-25% of total fat %). Adequate intake of sodium (2000mg) will be applied into participants' diet.
2449553|NCT03244579|No Intervention|General Dietary guidlines|the general dietary advice and diet that will be prescribed by hospital for participants
2449578|NCT03244215|Experimental|The study group|"The intervention to be evaluated is the patient response and compliance to best medical treatment and prevention of recognized stroke risk factors and the recurrence of stroke and TIA in the study group and its relation to the incidence of blood biomarkers.~The Nurse practitioners at the stroke ward will withdraw blood and collect urine samples from all the subjects. All the subjects from the study group will have 2 follow up visits (1 month and at 1 year) at HGH and one telephonic follow up at 3 months. The blood samples will be used to monitor blood inflammatory biomarker levels. At the beginning of the study, all subjects will have an MRI scan to assess plaque volume (this MRI scan will be ordered as part of the standard of care as per the policies applied to all stroke patients). MRI scans will be repeated at one year to assess any progression or regression in the plaque volume of the subjects.~No drugs will be administered to the patients for the purpose of our study."
2449580|NCT03244215|Other|Control|The control group will have blood work done to assess their blood inflammatory biomarkers but not the corneal confocal imaging.
2449627|NCT03243968||Ischemic patient - IP|25 participants with myocardial ischemia detected by scintigraphy and normal coronarography
2449629|NCT03243968||Control group - CG|25 healthy non-ischemic individuals
2449697|NCT03243669|Active Comparator|Fujinon standard|
2449702|NCT03243669|Active Comparator|Fujinon HD|Fujinon high-definition
2449706|NCT03243669|Active Comparator|Fujinon HD + VC|Fujinon high-definition + virtual chromoendoscopy
2449708|NCT03243669|Active Comparator|Olympus standard|
2449711|NCT03243669|Active Comparator|Olympus HD|Olympus high-definition
2449713|NCT03243669|Active Comparator|Olympus VC|Olympus virtual chromoendoscopy
2449714|NCT03243669|Active Comparator|Olympus HD + VC|Olympus high-definition + virtual chromoendoscopy
2449715|NCT03243669|Active Comparator|Pentax standard|
2449716|NCT03243669|Active Comparator|Pentax HD|Pentax high-definition
2449718|NCT03243669|Active Comparator|Pentax VC|Pentax virtual chromoendoscopy
2449720|NCT03243669|Active Comparator|Pentax HD + VC|Pentax high-definition + virtual chromoendoscopy
2449890|NCT03242239|Experimental|ALT02|
2449161|NCT03247361|Sham Comparator|Aerobic/resistance exercise|"Sham IMT + Aerobic/resistance exercise~Aerobic session will consist of a 4-min of warm-up, 20 minutes of exercise, and 4 min of cool-down. Intensity will set by the formula: Training HR = (maximum HR - resting HR) × intensity % + resting HR. Patients will exercise using 30 seconds, high-intensity work phases 0.7% followed by 1-minute recovery bouts 0.5%. Resistance exercise will consist of dynamic lower and upper limb exercise. Upper limb exercises will include 3 sets of exercises for each muscle group performed with 10 repetitions each. Lower limb exercises will include 3 sets of exercises for each muscle group performed with 12 repetitions each. Resistance exercises will be performed at 12-MR."
2449165|NCT03247127|Other|HA-WBRT|Patients with brain metastases outside a 5-mm margin around either hippocampus and are eligible to this study will receive hippocampal avoidance whole brain radiotherapy 30 gray (Gy) in 10 fractions. The primary endpoint is Wechsler Memory Scale (Chinese) and cognitive abilities screening instrument (CASI) at 4 months.
2449213|NCT03246997|Other|Autumn Group|Intervention Group
2449218|NCT03246997|Other|Spring Group|Delayed Intervention
2449320|NCT03246243||Preterm infants|Group A will consist of preterm infants born < 37 weeks gestational age. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
2449322|NCT03246243||Term infants with HIE or at risk of brain injury|Group B will consist of term infants admitted to the NICU for therapeutic hypothermia who are at risk of HIE; admitted with concern for neonatal stroke; seizures of unknown etiology; and those admitted who are at risk of abnormal neurodevelopment such as those with hypoglycemia or NAS. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
2449324|NCT03246243||Term infants healthy at birth|Group C will consist of healthy term infants from the community and term infants admitted to who had an initial uncomplicated postnatal course that will serve as the control group. Non-nutritive and nutritive sucking will be assessed using an FDA-approved device (Nfant Feeding Solution) to measure sucking activity. Additionally, those infants who have MRI of the brain for any reason during the course of their hospital admission will also be included in the study and allocated to the appropriate group accordingly. If a subject undergoes any clinically ordered EEG, EMG, MEG, and MRI throughout the duration of their study participation before the age of three then that data will be collected from their medical record. Additionally, any neurodevelopmental testing data completed up to the age of three will be collected.
2449466|NCT03245255|Experimental|Sonazoid for pressure measurements|48 µl of Sonazoid microbubbles (GE Healthcare, Oslo, Norway) will be co-infused at a rate of 0.024 µl/kg body weight/minute together with a 0.9% sodium chloride solution infused at a rate of at least 2 ml/min.
2449538|NCT03244592|Active Comparator|Minocycline|200 mg/day
2449539|NCT03244592|Placebo Comparator|Sugar Pill|Matched placebo
2449624|NCT03244046|Active Comparator|Physiotherapy (Phys)|12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
2449625|NCT03244046|Experimental|Somatic Experiencing + phys|12 sessions of psychotherapy (somatic experiencing) and 12 sessions of guided physiotherapy for low back pain. Cognitive Behavioral Therapeutic elements included targeting Fear Avoidance Beliefs.
2449699|NCT03243682|Active Comparator|Bidirectional Shock Wave Lithotripsy|alternating bidirectional (under and over table) approach
2449703|NCT03243682|Active Comparator|Standard Shock Wave Lithotripsy|standard unidirectional approach
2449733|NCT03243201|Experimental|Colloidal Silver|The colloidal silver arm will administer intranasal colloidal silver, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day (8 mcg of silver per day), for 28 days.
2449735|NCT03243201|Placebo Comparator|Purified Water|The placebo arm will administer intranasal purified water, 2 sprays each nostril twice daily, for a total volume of 0.8ml per day, for 28 days.
2449779|NCT03243032|Experimental|Local Anesthetic Group 1|Group 1 (Pre-emptive analgesia with long acting local anesthesia - experimental group): Ibuprofen 600mg given 30 minutes prior to beginning of surgery. Surgery will be performed only using 0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg four times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
2449782|NCT03243032|Placebo Comparator|Local Anesthetic Control|Group 2 (Control / standard of care group): Placebo oral capsule (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery. Surgery will be performed using 2% lidocaine with 1:100,000 epinephrine as the local anesthesia. Following the procedure, all patients will be prescribed Chlorhexidine rinse ( 0.12%) (Rinse with 15 ml two times a day and spit) for 10 days and Antibiotics: Amoxicillin 500 mg three times a day for 7 days or if allergic to penicillin, clindamycin 300 mg 4 times a day for 7 days. Ibuprofen (600 mg) q 6 hours: prn for pain will be provided to all patients at no charge. Tramadol 50 mg (one every 4-6 hours as needed for pain; maximum 400 mg/day) for uncontrolled pain.
2449843|NCT03242551|Experimental|Neoadjuvant chemotherapy|Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
2449989|NCT03241719|Experimental|Treatment|Subjects who receive transplantation and undergo IL-2 treatment
2449183|NCT03247374|Active Comparator|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: effortful swallow, supraglottic swallow, and Masako maneuver, the first two with bolus administration, if possible. The control group will attend this training for 45 minutes, receiving verbal feedback from the speech and language therapist."
2449212|NCT03246958|Experimental|Nivolumab alone for two weeks|Ipilimumab will be administered via IV infusion, starting two weeks after Nivolumab
2449216|NCT03246958|Experimental|Ipilimumab alone for two weeks|Nivolumab will be administered via IV infusion, starting two weeks after Ipilimumab
2449304|NCT03246490|Other|All Participants|All participants complete the same study procedures, which involve drinking alcohol to a .08 blood alcohol level and walking short distances while their blood alcohol level is increasing to .08 and decreasing down to .00.
2449354|NCT03245944|Active Comparator|early angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who an early angioplasty intervention group that will undergo a routine Angioplasty at 6 weeks after AVF creation
2449357|NCT03245944|Experimental|late Angioplasty|Patients who initiated hemodialysis with a CVC, then had a new AVF created after commencing dialysis, and then had a 6-week postoperative ultrasound that revealed an immature AVF (diameter < 4 mm diameter or blood flow < 500 ml/min). These patients who a late angioplasty intervention group in which early Angioplasty will be avoided and subsequently be performed only if the 3-month ultrasound indicates persistent AVF immaturity
3190155|NCT00784537|Other|Arm A|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to first arm:~No radiotherapy."
3190156|NCT00784537|Other|Arm B|"Two courses of ABVD. Early restaging with FDG-PET scan (PET-2)~The subsequent treatment will be as it follows:~PET-2 positive patients will be high-dose salvage treatment;~PET-2 negative patients will be treated with four additional courses of ABVD (for a total of six courses).~The following restaging procedures are planned as it follows:~Optional: Whole body CT scan after the fourth course of ABVD; no therapy change will be made according to CT scan.~Mandatory: Whole body CT and FDG-PET scans after the sixth course of ABVD (PET-6).~PET-6 negative patients will be randomized to second arm:~Adjuvant radiotherapy (30 Gy) on sites of initial bulky disease."
3190157|NCT00784576||Cardiac surgery patients|Individuals consecutively scheduled for cardiac surgery
3190158|NCT00784589|Experimental|Rituximab|
3190159|NCT00784589|Active Comparator|Corticotherapy|General Corticotherapy
3190160|NCT00784615||1|Women with polycystic ovaries, oligo or anovulation and hyperandrogenism.
3190161|NCT00784615||2|Women with polycystic ovaries and oligo or anovulation without hyperandrogenism
3190162|NCT00784615||3|Women with normal ovaries, oligo or anovulation and hyperandrogenism
2449638|NCT03243994|Experimental|COPD|Patients with COPD without Cor Pulmonale
2449646|NCT03243994|Experimental|COPD + Cor Pulmonale|Patients with Cor Pulmonale in addition
2449683|NCT03243591|Active Comparator|Livionex gel|Brushing area of mucositis with Livionex gel for 30 days
2449690|NCT03243591|Active Comparator|Aquafresh gel|Brushing area of mucositis with Aquafresh gel for 30 days
2449728|NCT03243292||Treated|Subjects that received Bronchial Thermoplasty in a prior study (AIR, RISA, or AIR2)
2449731|NCT03243292||Control|Subjects that participated in prior study (AIR) or (RISA) but did not receive Bronchial Thermoplasty Treatment. Determine if the Control group of subjects asthma has progressed any different from those subjects treated with BT.
2449732|NCT03243292||Sham|Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
2449806|NCT03242915|Experimental|Pembrolizumab/Carboplatin/Pemetrexed|Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks
3190163|NCT00784615||4|Women with normal ovaries, oligo or anovulation and hyperandrogenism
2449891|NCT03242031|Experimental|1 session|
2449893|NCT03242031|Active Comparator|4 sessions|
2449978|NCT03241641|Experimental|Maintaining TAF monotherapy|- Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 96 weeks
2449985|NCT03241641|Active Comparator|Switching from TDF to TAF|"Tenofovir Disoproxil Fumarate (Viread) Tablet, 300mg, Daily Oral, 48 weeks~Tenofovir AlaFenamide (Vemlidy) Tablet, 25mg, Daily Oral, 48 weeks"
2450032|NCT03241108|Experimental|NI-0101|A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
2450041|NCT03241108|Placebo Comparator|Placebo|The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
2450090|NCT03240705|Experimental|Gratitude journaling|Students perform gratitude journaling 3 times per week on a form. This activity consists of writing elements of their day that brought happiness to them. Can be in keyword form or in sentences.
2450092|NCT03240705|No Intervention|No intervention|Students proceed with their surgical clerkship as is standard in our institution.
2450125|NCT03240432|Active Comparator|Continuous Glucose Monitor group|CGM group participants will be asked to use a Dexcom CGM sensor on a daily basis, inserting a new sensor as needed. Participants will be instructed to use the sensor according to FDA labeling. In addition, participants will be advised to check the blood glucose when symptoms or expectations do not match the CGM reading. Participants will have clinic visits at 10 days, 4 weeks, 8 weeks, 16 weeks, and 26 weeks.
2450147|NCT03240536|No Intervention|Control Group|Ordering physicians who have referred to rheumatologists in the control group will not receive the Choosing Wisely form. At one and two years all ordering physicians will receive by fax a three question survey.
2450368|NCT03238937|Other|Phrenic Nerve Stimulator|Phrenic Nerve Stimlator
2449232|NCT03246698|Experimental|Static stretching group|"The participants in this group will receive static stretching in modified cross body position.~Additionally they will receive standard physiotherapy."
2449235|NCT03246698|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
2449295|NCT03246438|Experimental|Control|Colonoscopy only outreach and follow-up
2449296|NCT03246438|Experimental|Sequential Choice|Colonoscopy outreach + mailed FIT follow-up
2449297|NCT03246438|Experimental|Active Choice|Colonoscopy + mailed FIT outreach and follow-up
2449364|NCT03245983|Experimental|Patient willing to participate|
2449416|NCT03245606||Patients with Non Alcoholic Fatty Liver Disease|"Patients (240) will undergo a medical examination in order to analyse their medical history and check inclusion and non-inclusion criterions.~Then will be performed:~a liver biopsy~an abdominal MRI~a transient elastography"
2449472|NCT03245060|Experimental|Intervention: immediate SFBT|The Intervention arm will receive up to six Adapted Solution Focused Brief Therapy (SFBT) sessions immediately post randomisation. The sessions will be spaced over 3 months. Participants will also receive all usual care.
2449477|NCT03245060|Other|Intervention: delayed SFBT|The wait-list control arm will receive the same intervention (Adapted Solution Focused Brief Therapy, SFBT) as the intervention arm, but after a delay of six months. Participants will also receive all usual care.
2449514|NCT03244774|Experimental|Apatinib plus POF|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and POF. Cohort 2: apatinib 375 mg per day and POF. Cohort 3: apatinib 500 mg per day and POF. Cohort 4: apatinib 625 mg per day and POF. Cohort 5: apatinib 750 mg per day and POF.~A dose limiting toxicity (DLT) event is defined as any of the following events in the first 4-week period:~CTCAE Grade 4 event (except for neutropenia lasting for ≤ 5 days);~Grade 3 non-hematologic toxicity (except for nausea and vomiting that could be improved with optimal supportive care, escalation of alkaline phosphatase)~If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If 2 DLTs are experienced in any cohort, the dose escalation ceased. The MTD was defined as the dose having at most two out of six patients experience DLT."
2449566|NCT03244371|Experimental|Co infected HIV and HCV patients|
3153549|NCT00278785|Experimental|2|Intervention group receives pamphlet on alcohol and self referral information in addition to brief motivational interview
3153550|NCT00278824|Experimental|50 mcg/hr matrix fentanyl patch|active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)
2449680|NCT03243799|Experimental|Intervention Group|"The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms.~Group psychoeducation."
2449688|NCT03243799|No Intervention|Control Group|Usual clinical care
2449761|NCT03243357|Experimental|TF Adaptive (First Apical Binding File)|Endodontic treatment(teeth with periapical periodontitis&radiolucence).Local anesthesia (4%Articaine with1:100,000 epinephrine),isolation with rubber dam&standard access cavity preparation.Using 2.5 %sodium hypochlorite,canal negotiation,glide path,coronal flaring with Sx(ProTaper),determining working length&first apical binding file.Intervention: Root canal instrumentation:TF Adaptive system with enlargement of the root canal performed with up to 3 files larger than the diameter of the initial apical file. Irrigation2.5%NaOCl&EDTA (Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, obturation: gutta-percha&epoxy resin sealer.
2449766|NCT03243357|Other|TF Adaptive (Control)|In the control group,endodontic treatment (teeth with periapical periodontitis&radiolucence). Local anesthesia(4% Articaine with 1:100,000 epinephrine), isolation with rubber dam&standard access cavity preparation. Using 2.5 % sodium hypochlorite, canal negotiation, determining working length&glide path. Root canal instrumentation:TF Adaptive system according to the protocol recommended by the manufacturer.Irrigation 2.5% NaOCl & EDTA(Ethylenediaminetetraacetic acid)under activation with ultrasound. Irrigation with saline solution and placement of medication based on calcium hydroxide. After 14 days, the canals will be obturated with gutta-percha and epoxy resin sealer.
2449816|NCT03242785|Experimental|Self-monitoring/Self-titration|The intervention consists of self-monitoring blood pressure at home, and subsequent medication self-titration, based on a medication adjustment plan pre-established by the family physician, in patients with uncontrolled hypertension.
2449818|NCT03242785|No Intervention|Routine care|Patients in this arm will receive routine care for high blood pressure in the primary health care center.
2449899|NCT03241953|Experimental|debridement made by ultrasonic tips|mechanical debridement made by ultrasonic polyetheretherketone coated tips developed for implant surface and combined air-flow debridement
2449907|NCT03241953|Active Comparator|implants were debrided with standard plastic curettes|dental implants were debrided with standard plastic curettes, debridement made by combined klorhegsidin rinse
2449967|NCT03241680|No Intervention|Control Group with conventional citology|Patients who do not have high grade cervical intraepithelial neoplasia and will have anal cytology performed by conventional method
2449977|NCT03241680|No Intervention|Control Group with liquid based citology|Patients who do not have cervical intraepithelial neoplasia of high grade and will have anal cytology performed by liquid based method
2449982|NCT03241680|No Intervention|CIN 2-3/Conventional Citology|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by conventional method
2450369|NCT03238937|No Intervention|no intervention|Patients without phrenic nerve stimulation
3153551|NCT00278824|Placebo Comparator|Placebo Patch|placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch
3153552|NCT00278837|Experimental|Mindfulness based meditation program|Meditation and Breast Cancer: Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress reduction and cognitive-affective-behavioral learning.
3153553|NCT00278902|Experimental|ARRY-334543|
3153554|NCT00279019|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment sequence 1; GSK233705 20 micrograms, GSK233705 100 micrograms, tiotropium and placebo.
3153555|NCT00279019|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment sequence 2; GSK233705 20 micrograms, Placebo, GSK233705 50 micrograms and tiotropium.
2449245|NCT03247114|Experimental|Sucralose-sucrose-water-fructose-glucose|First sucralose, then sucrose, then plain water, then fructose and then glucose
3153556|NCT00279019|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment sequence 3; GSK233705 20 micrograms, tiotropium, Placebo and GSK233705 50 micrograms.
2449427|NCT03245216|Experimental|aerobic exercise + motor skill practice|acute bout of aerobic exercise before motor learning
2449428|NCT03245216|Active Comparator|rest + motor skill practice|seated rest before motor learning
3153557|NCT00279019|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment sequence 4; GSK233705 20 micrograms, placebo, tiotropium and GSK233705 50 micrograms.
3153558|NCT00279019|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment sequence 5; Placebo, tiotropium, GSK233705 20 micrograms and GSK233705 50 micrograms.
3153559|NCT00279019|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment sequence 6; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and tiotropium.
3190164|NCT00784615||5|Women with out polycystic ovary syndrome
3190165|NCT00784680|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
2449615|NCT03244163|Experimental|LASER ARM|Spyglass DS cholangioscope guided laser or electrohydraulic lithotripsy
2449622|NCT03244163|Active Comparator|CONVENTIONAL ARM|Stone removal by conventional techniques, for example BML, without laser lithotripsy
2449705|NCT03243539|Experimental|Lung Protective Ventilation|Subjects with acute brain injury (traumatic brain injury and non-traumatic brain injury) will receive neuro lung protective ventilation which targets a normal arterial partial pressure of carbon dioxide with the lowest tidal volume possible (6 to 8 ml/kg predicted body weight). Protocols for oxygenation and weaning from the ventilator will also be followed.
3190166|NCT00784680|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3190167|NCT00784680|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3208536|NCT00975728|Experimental|Gruop 2 Product 824 (1 serving-day)|30 subjects drinking 1 serving-day of Product 824 for 8 weeks
3208537|NCT00975741|Experimental|Monodose device|Mometasone furoate 400 µg DPI capsules administered through a monodose device.
2449864|NCT03242291|Active Comparator|conventional resin-based flowable composite|
2449866|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|
2449912|NCT03241966||People with Parkinson's Disease|Individuals diagnosed with idiopathic Parkinson's disease without dementia.
2449917|NCT03241966||Informant|Family member, spouse, significant other, caregiver, or other close associate of someone with Parkinson's disease.
2449964|NCT03241654||the lowest trigger sensitivity|The flow trigger of ventilator was set as the lowest level of sensitivity.
2449972|NCT03241654||the highest trigger sensitivity|The flow trigger of ventilator was set as the highest level of sensitivity.
2450043|NCT03241251||parents children pediatric cancer|Screening questionnaire psychosocial risk factors
2450071|NCT03240861|Experimental|Treatment (Genetically engineered PBMC and PBSC)|"G-CSF AND PLERIXAFOR MOBILIZED LEUKAPHERESIS: Between 6 months and 3 weeks before infusion of cells, patients undergo G-CSF and plerixafor mobilization of CD34+ peripheral blood stem cells. Patients receive G-CSF SC on mobilization days 1-8 and plerixafor SC on mobilization days 4-7. Patients also undergo an unmobilized leukapheresis on day -5 before infusion of cells.~CHEMOTHERAPY CONDITIONING REGIMEN: Patients receive busulfan IV on days -4 to -2 and fludarabine IV over 30 minutes on days -3 to -2.~Patients receive LV-NYESO TCR/sr39TK PBSC IV on day 0, and after approximately 24 hours, patients receive RV-NYESO TCR PBMC IV on day 1. Beginning on day 2, patients receive aldesleukin SC BID for up to 7 days. Patients undergo blood collection for safety and immune monitoring on days 0, 1, 3, 5, 7, 14, 30, 60, 90, and 120. Patients receive 18F-FHBG IV, and after 1 hour, undergo PET/CT on days 25 and 120."
2450223|NCT03239795|Experimental|Intervention group|Family physicians' patients exposed to advertisement in waiting rooms consisting in a poster and pamphlets promoting seasonal influenza vaccination (+ usual mandatory information)
2450224|NCT03239795|No Intervention|Control group|Family physicians' patients exposed to usual laying out of waiting rooms
3208538|NCT00975741|Active Comparator|Multidose device|Mometasone furoate 400 µg DPI capsules administered through a multidose device
2450293|NCT03239301|Active Comparator|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
2450296|NCT03239301|Active Comparator|Robotic Rehabilitation + Conventional Rehab|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. A
2450333|NCT03239158|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450337|NCT03239158|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450340|NCT03239158|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
3153560|NCT00279019|Experimental|Subjects receiving treatment sequence 7|Eligible subjects will receive treatment sequence 7; tiotropium, GSK233705 20 micrograms, GSK233705 50 micrograms and Placebo.
3153561|NCT00279019|Experimental|Subjects receiving treatment sequence 8|Eligible subjects will receive treatment sequence 8; tiotropium, GSK233705 20 micrograms, Placebo and GSK233705 50 micrograms.
3208539|NCT00975754|Experimental|1|Pulmicort pMDI
3208540|NCT00975754|Experimental|2|Budesonide pMDI
2449253|NCT03246945|Experimental|Study Arm|Patient-Parent Dyad receiving photography instructions prior to taking photographs of skin conditions
2449255|NCT03246945|No Intervention|Control Arm|Patient-Parent Dyad not receiving photography instructions prior to taking photographs of skin conditions
2449285|NCT03246412|Experimental|Nevus doctor clinical decision support|"The GPs have access to the clinical decision support tool Nevus doctor."
2449287|NCT03246412|No Intervention|Control|"The GPs have no access to the clinical decision support tool Nevus Doctor."
2449363|NCT03246035|Active Comparator|Control Group (Standard Care)|The control group will receive outpatient follow-up, medication advice and lifestyle guidance as prescribed at discharge from the ED or hospital.
2449369|NCT03246035|Experimental|Intervention Group|The intervention will consist of contacting the patient 5 days post-discharge and arranging definitive outpatient follow-up and providing targeted medical and lifestyle advice based on deficient domains identified at baseline.
2449414|NCT03245554|Experimental|placebo and propranolol|We used propranolol and placebo as an control drug to treat with patients.
2449497|NCT03245138|Experimental|endoscopic third ventriculostomy|endoscopic third ventriculostomy for the treatment of iNPH
2449498|NCT03245138|Active Comparator|ventricular peritoneal shunt|Insertion of a ventriculo-peritoneal Shunt for the treatment of iNPH
2449535|NCT03244657|Experimental|Q12W group|
2449537|NCT03244657|Experimental|TAE group|
2449569|NCT03244176|Other|Open-label|Avelumab - Single-arm open label study
2449670|NCT03244007||Eyes with residual fragment|The eyes with residual fragments detected with intraoperative optical coherence tomography
2449672|NCT03244007||Eyes without residual fragment|The eyes without residual fragments detected with intraoperative optical coherence tomography
2449736|NCT03243448||The general public|people between 20-85 years old, without sympathetic hyperactivity disease
2449740|NCT03243448||Sympathetic hyperactivity diseases|Sympathetic hyperactivity diseases included: hypertension, heart failure atherosclerotic diseases, arrhythmias, cardiomyopathy, pulmonary hypertension, chronic obstructive pulmonary disease, sleep apnea, pulmonary embolism, hepatitis, liver cirrhosis, hepatopulmonary syndrome, hepatorenal syndrome, renal failure, nephritis, irritable bowel syndrome.
2449787|NCT03243006|Placebo Comparator|group Placebo|Patients in this group (Placebo Oral Tablet) received two placebo tablets
2449790|NCT03243006|Active Comparator|group Paracetamol|Patients in this group received two 500 mg paracetamol tablets
2449796|NCT03243006|Active Comparator|group Tramadol/Paracetamol combination|Patients in this group (Tramadol/Paracetamol combination ) received 2 tablets of Tramadol/Paracetamol combination (37.5mg/325mg)
2449895|NCT03241901|Active Comparator|3 Days Artemether-Lumefantrine + Placebo|"Oral tablets of artemether-lumefantrine (20-120mg):~tablet for 5-14kg;~tablets for 15-24 kg;~tables for 25 - 34kg and~tablets for above 35 Kg. The full course of treatment is 6-doses for 3 days given twice daily, at 0, 8, 24, 36, 48, 60 with the dose being given as directly observed therapy.~Oral placebo after completion of the standard 3 days-six dose regimen. A fatty snack (biscuits) will be administered together with all artemether-lumefantrine doses to optimize absorption."
2449900|NCT03241901|Experimental|6Days Artemether/Lumefantrine+Primaquine|"Artemether-lumefantrine (20-120mg) twice daily for 6 days according to body weight as in the active comparator arm.~And in addition to that, , a single 0.25 mg/kg primaquine dose (Primaquine phosphate) will be administered concomitantly with the last (i.e. twelfth) artemether-lumefantrine dose. Primaquine will be prepared and administered in an aqueous solution."
2449942|NCT03241472|Experimental|Lertozole|oral tablets 5 mg start from third day cycle for 5 days
2449943|NCT03241472|Active Comparator|clomiphene plus N- acetyl cystiene|clomiphene 100 mg plus N-acetyl cystiene 600 mg start from third day cycle for 5 days
2450003|NCT03241381||Group A : Melasma|patients with facial pigmentation in the form of melasma
2450004|NCT03241381||Group B: Non Melasma|Patients without any facial pigmentation or melasma
2450059|NCT03241004|Experimental|Intensive Care Unit|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
2450060|NCT03241004|Experimental|Operating Room|"Patients will be induced in a standard fashion using intravenous (IV) anesthetics. A continuous administration of propofol and inhalational anesthetics will be used for maintenance of anesthesia.~Baseline EEG readings will be established for 30 minutes, then EEG data will be recorded and a sleep mask applied to the patient for one hour. After one hour, eye masks will be removed for an hour and reapplied after another hour. During the hour that the mask is off, 2 hours into sedation, EEG data will again be recorded."
3208541|NCT00975754|Experimental|3|Budesonide pMDI + Aerochamber Zero-stat spacer
2450202|NCT03240237|Experimental|CCM therapy|Optimizer SMART
2450248|NCT03239678|Active Comparator|group A|100% Oxygen
2450254|NCT03239678|Experimental|group B|30% Oxygen.
2450259|NCT03239678|Experimental|group C|21% Oxygen
2450260|NCT03239678|Experimental|group D|40% Oxygen
2450263|NCT03239678|Experimental|group E|60% Oxygen
2450265|NCT03239678|Experimental|group F|80% Oxygen
2450339|NCT03239223|Experimental|Dose 1 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
2450344|NCT03239223|Experimental|Dose 2 - Multiple Ascending Dose (MAD)|ABI-1968 or Placebo topical cream applied at Day 1, Day 8, Day 15 and Day 22
2450376|NCT03238859|Experimental|Real cTBS|10 days of real cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
2449281|NCT03246529|Experimental|BL-8040 1.25mg/kg + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
2449282|NCT03246529|Active Comparator|Placebo + G-CSF|double-blind placebo-controlled setting designed to assess the safety, tolerability and efficacy of G-CSF + BL-8040 as compared to G-CSF + Placebo, for stem cell mobilization in MM.
3190168|NCT00784706|Experimental|CIT with eye-patching|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log. Participants were also asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
3153562|NCT00279019|Experimental|Subjects receiving treatment sequence 9|Eligible subjects will receive treatment sequence 9; GSK233705 20 micrograms, tiotropium, GSK233705 50 micrograms and Placebo.
2449429|NCT03245229|Experimental|Treatment A|In the morning of Day 1, a single dose of 10 mg rosuvastatin will be administered in the fasted state followed by an observation period of 96 h
2449430|NCT03245229|Experimental|Treatment B1|25 mg ACT-132577 will be administered o.d. from Day 5 to Day 12
2449431|NCT03245229|Experimental|Treatment B2|"In the morning of Day 13, a single dose of 10 mg rosuvastatin will be administered in the fasted state, concomitantly with 25 mg ACT-132577, followed by an observation period of 120 h.~Doses of 25 mg ACT-132577 will be administered o.d. from Day 14 to Day 17."
2449486|NCT03245021|Other|Open-Label|Opdivo - Single-arm open label study
3153563|NCT00279019|Experimental|Subjects receiving treatment sequence 10|Eligible subjects will receive treatment sequence 10; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and tiotropium.
3153564|NCT00279019|Experimental|Subjects receiving treatment sequence 11|Eligible subjects will receive treatment sequence 11; Placebo, GSK233705 20 micrograms, tiotropium, and GSK233705 50 micrograms.
3153565|NCT00279019|Experimental|Subjects receiving treatment sequence 12|Eligible subjects will receive treatment sequence 12; Tiotropium, Placebo, GSK233705 20 micrograms and GSK233705 50 micrograms.
3153566|NCT00279019|Experimental|Subjects receiving treatment sequence 13|Eligible subjects will receive treatment sequence 13; Placebo, GSK233705 20 micrograms, GSK233705 50 micrograms and GSK233705 100 micrograms.
3153567|NCT00279019|Experimental|Subjects receiving treatment sequence 14|Eligible subjects will receive treatment sequence 14; GSK233705 20 micrograms, placebo, GSK233705 50 micrograms and GSK233705 100 micrograms.
2449701|NCT03243487|Experimental|PAMS service|"Study participants will be randomly assigned to have their Continuous positive airway pressure therapy (CPAP) or Bilevel Positive Airway Pressure (BiPAP) therapy followed by a structured patient adherence management service (PAMS).~Interventions: Call to patient by sleep coach on days 3,7,14,32,45, 60, and 75 after participants begin PAP treatment. At each time frame sleep coach reviews CPAP adherence data on EncoreAnywhere (EA) a cloud based program collecting adherence data via wireless modem on CPAP units. Calls will not be made at days 7 and 14 if adherence is good. If problems are identified and cannot be handled over the telephone the problems will be escalated to VA MD or CPAP respiratory therapy (RT) providers for direct intervention. All patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment."
2449707|NCT03243487|Active Comparator|Standard Care (SCP)|Study participants will be randomly assigned to have their CPAP or BiPAP therapy followed by the current Sleep Center standard care process. This includes a telephone number that patients can call or problems and review of adherence data on EncoreAnywhere (EA) at 4 to 6 weeks after starting treatment. Patients are seen in sleep clinic by a VA MD sleep provider 3 months after starting treatment.
2449741|NCT03243188||Participants|Cancer patients with palliative care needs (+/- their carers)
2449903|NCT03241992|Experimental|MyChart Intervention|Subjects in the control arm will be enrolled in MyChart during the consent process and receive MyChart Disease Specific targeted IBD information and reminders as well as mood questionnaires. At week 2 subjects will receive reminders to get vaccinated with another reminder sent at 3 months. At month 1, subjects will receive the Promis Adult Short Form questionnaires for depression and anxiety through MyChart. If a subject is identified as having mild, moderate or a severe mood disorder a message will be sent to their gastroenterologist with a recommendation to discuss the results with the patient and to consider a referral to mental health services. Subjects will also receive educational information about IBD every 6 weeks along with reminders to take their medications.
2449909|NCT03241992|No Intervention|Usual Care|Subjects in the control arm will be enrolled in MyChart during the consent process if they are not previously enrolled. Enrollment in MyChart will provide them with access to their medical record and the ability to send or receive messages with their gastroenterologist or any other providers they see at our institution. For patients with IBD it is standard practice to discuss medication adherence, vaccinations, and their mood at each appointment. Subjects will receive generic, non-IBD related messages through MyChart.
2449969|NCT03241576|Experimental|Small portion size provision|Participants in this arm are served a small serving of a lunchtime food to eat (session 1).
2449976|NCT03241576|Active Comparator|Large portion size provision|Participants in this arm are served a large serving of a lunchtime food to eat (session 1).
2450024|NCT03241238|Other|Regular Brownie|Regular Brownie For the regular brownie condition (RB), participants will consume the brownie preload and then consume a meal 20 minutes later.
2450042|NCT03241238|Other|Psyllium Brownie|For the psyllium brownie (PG), participants will consume a psyllium brownie and then consume a meal 20 minutes later.
2450047|NCT03241238|Other|β-glucan Brownie|For the β-glucan Brownie (BG), participants will consume a β-glucan Brownie preload and then consume a meal 20 minutes later
2450104|NCT03240835||CCRT±NACT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin) , or treated with CCRT only
2454550|NCT03209895|Placebo Comparator|Placebo|
2449389|NCT03245814|Experimental|Service Dog|Participants in the service dog arm will receive unrestricted, non-study usual care, in addition to a trained service dog.
2449392|NCT03245814|No Intervention|Waitlist Control|Participants in the control arm will receive unrestricted, non-study usual care, while on the waitlist for a service dog.
2449454|NCT03245346|Experimental|GEA+PCEA|General anesthesia combined with epidural anesthesia will be performed during surgery and patient-controlled epidural analgesia (PCEA) will be provided after surgery.
2449459|NCT03245346|Other|GA+PCIA|General anesthesia will be performed during surgery and patient-controlled intravenous analgesia (PCIA) will be provided after surgery.
2449562|NCT03244306|Experimental|Autologous CD22-specific CAR T-cells expressing EGFRt|
2449639|NCT03244111|Active Comparator|Healthy Cognition|The intervention will be carried out as described in the study details using the simple memory tool. The group with healthy cognition may perform better on tasks since they have a higher level of cognition.
2449645|NCT03244111|Active Comparator|MCI|The intervention will be carried out as described in the study details using the simple memory tool. The group with MCI may have a lower level of performance on tasks since they have a lower level of cognition. Some tasks may take longer for the participant or need more explanation from the researcher (e.g., explanation of a question).
2449682|NCT03243552|Active Comparator|L-DOPA versus Placebo|L-DOPA or placebo (1:1 randomization). Dosing will begin at 25mg carbidopa/100mg L-DOPA in 3 divided doses, with a fixed-flexible titration schedule, allowing dose increases once per week of 100mg L-DOPA. Maximum dose is 600mg/d.
2449689|NCT03243552|Experimental|Social Skills|All participants will receive 16-week manualized social skills training.
2449756|NCT03243175|Experimental|Direct Oral Anticoagulant (DOAC)|Apixaban 5MG twice daily
2449759|NCT03243175|Experimental|Left Atrial Appendage Closure (LAAC)|Devices will be chosen by local teams.
2449763|NCT03243175|No Intervention|Control|avoiding anticoagulation and LAAC during the entire study period The standard clinical practice without OAC may include: antiplatelet drug (in case of comorbidities such as coronary heart disease) or no antithrombotic drug
2449794|NCT03242746||Control group|"The study will include 150 women of reproductive age (21-45 years) who wished to have future pregnancies and had cervical biopsy or Pap test, without any other cervical procedure, in the same calendar year.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume"
2449797|NCT03242746||LEEP group|"The study will include 150 women of reproductive age (21-45 years) planning for excisional treatment for CIN who wished to have future pregnancies. Women are included irrespective of their parity, previous obstetric history, and CIN grade.~a 3-years follow-up for pregnancy outcome~Transvaginal ultrasound for pretreatment cervical dimensions/volume~Transvaginal ultrasound for posttreatment cervical dimensions/volume in the follow-up visit~Estimation of cone dimensions/volume~Calculation of the proportion of volume/length excised"
2449821|NCT03242629|Active Comparator|oral group|
2449823|NCT03242629|Experimental|enema group|
2449868|NCT03242343|Experimental|VasQ device implantation|"Main study cohort: Prospective, multi-center, single-arm, open label, enrolling patients referred to surgical creation of new brachiocephalic fistula (BCF). The VasQ will be applied to the AV fistula in all patients. The primary effectiveness endpoint for this trial will be measured at 6 months and compared to a performance goal (PG). Safety will compare descriptively between AE rates for Steal, Infection, Aneurysm and Seroma. Patients will be followed up for an additional 18 months for a total of 2 years. Additionally, this trial has several secondary endpoints.~Supplementary study cohort: 15 patients will be prospectively enrolled which are referred to surgical creation of a new forearm arteriovenous fistula. VasQ will be applied to the AV fistula in all patients. Patients will be followed in the same manner as in the Main study cohort, however, the data will be reported separately and not be part of the analysis sets for the study primary and secondary endpoints."
2449896|NCT03241875|Placebo Comparator|placebo|Patients receive 2 capsules as placebo 2 hours before anesthesia. The capsules are delivered by the hospital pharmacy.
2449902|NCT03241875|Experimental|pregabalin|patients receive 2 capsules of pregabalin (pregabalin 75), two hours before anesthesia.
2449906|NCT03241875|Experimental|gabapentin|patients receive 2 capsules of gabapentin (gabapentin 300), two hours before anesthesia.
2449953|NCT03241524|Experimental|Exercise program for pelvic muscle floor|Training program for pelvic muscles and application of 3 questionnaires for sexual function evaluation and the use of PERFECT and Perina methods to evaluate perineal musculature.
2450025|NCT03241329||Case : endometriosis|Infertile patients with endometriosis that is the only cause of their infertility
2450034|NCT03241329||Control : tubal factor|infertile patients with tubal factor that is the only cause of their infertility
2450188|NCT03240198||COPD|
2450192|NCT03240198||Controls|
2450231|NCT03239847|Experimental|EndoPhys Sheath and Radial Arterial Line|This group of patients will have both the EndoPhys sheath and the radial arterial line placed during surgery.
2450232|NCT03239847|Experimental|EndoPhys Sheath|This group of patients will only receive the EndoPhys sheath during surgery.
2450330|NCT03239509||Bioprosthesis|All patients operated on of isolated AVR with a bioprosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2450431|NCT03238547||diabetes|Diabetes patients with normal renal function and normal urinalysis
2449340|NCT03246113|Experimental|Cannabis + Chemoradiation|Patients will receive a cannabis strain with high cannabidiol (4.8%) and low Delta-9-THC (3.23%). Patients will smoke the cannabis over a 2 hour session (from 0.5 - 2.0 cannabis cigarettes) before receiving chemoradiation therapy with radiation and concurrent temozolomide.
2449393|NCT03245684|Experimental|Pressure Support Ventilation|"after 48h of controlled ventilation the patient randomised in this arm will desedated and switched on Pressure Support Ventilation (PSV): patient's spontaneous activity will maintained and sedation will be maintained at a level of Richmond Assessment Sedation Scale (RASS) between -2 and -3. The level of pressure support (including PEEP) will be limited to ≤ 30 cmH2O; the pressure support level will ensure a tidal volume of 6 ml / Kg ideal body weight. PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol.~assessment of inflammatory response during PSV"
2449397|NCT03245684|Active Comparator|Controlled Mechanical Ventilation|patient's spontaneous activity will be shut done by sedation and/or respiratory muscles paralysis. Volume (during volume control) or pressure (during pressure control), PEEP, FiO2 and respiratory rate will be regulated according the ARDSnet protocol
2449484|NCT03245320||TITAN™ Total Shoulder System Generation 1.0|Integra TITAN™ Total Shoulder System Generation 1.0
2449521|NCT03244696|Experimental|Step Tracking|Participants will track their physical activity in steps using an accelerometer for a period of 6 months. Participants will monitor their overall step-count using the accelerometer, and daily and weekly summaries of their progress provided by the experimenters.
2449529|NCT03244696|Active Comparator|Water Tracking|Participants will track their water-intake using a smart water bottle for a period of 6 months. Participants will monitor their overall water consumption using a smart water bottle, and daily and weekly summaries of their progress provided by the experimenters.
2449561|NCT03244332|Experimental|Decompensated cirrhosis|Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.
2449563|NCT03244332|Experimental|Compensated cirrhosis|Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)
2449609|NCT03244085|Experimental|100 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (100 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2449617|NCT03244085|Experimental|200 mg BID|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (200 mg two times a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2449620|NCT03244085|Experimental|600 mg QD|Drug: QL-007 tablet; Tablet QL-007 will be administered orally daily (600 mg once a day) over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
2449657|NCT03243760|Experimental|Cohort A: Single dose CCI15106 7.5 mg /Placebo|Healthy subjects will receive single dose of either 1 capsule CCI15106 7.5 milligram (mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449661|NCT03243760|Experimental|Cohort B: Single dose CCI15106 15 mg /Placebo|Healthy subjects will receive single dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449663|NCT03243760|Experimental|Cohort C: Single dose CCI15106 30 mg /Placebo|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449664|NCT03243760|Experimental|Cohort D: Single dose CCI15106 30 mg /Placebo-BAL|Healthy subjects will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
2449665|NCT03243760|Experimental|Cohort E: Single dose CCI15106 45 mg /Placebo|Healthy subjects will receive single dose of either 45 mg CCI15106 (6 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449666|NCT03243760|Experimental|Cohort F: Single dose CCI15106 60 mg /Placebo|Healthy subjects will receive single dose of either 60 mg CCI15106 (8 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449667|NCT03243760|Experimental|Cohort G: CCI15106 7.5 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 7.5 mg CCI15106 (1 capsule) or matching placebo twice daily (BID) for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449668|NCT03243760|Experimental|Cohort H: CCI15106 15 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either 15 mg CCI15106 (2 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449669|NCT03243760|Experimental|Cohort I: CCI15106 30 mg /Placebo BID 14 Days-BAL|Healthy subjects will receive repeat dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. BAL procedures will be performed in this cohort additionally.
2449673|NCT03243760|Experimental|Cohort J: CCI15106 =<30 mg /Placebo BID 14 Days|Healthy subjects will receive repeat dose of either =< 30 mg CCI15106 (less than or equal to 4 capsules of 7.5 mg) or matching placebo BID for 14 days by inhalation via Modified Air Inlet Rotahaler™ device according to randomization. The dose for cohort J is unknown at this time and will depend on results seen in the previous cohorts.
2449674|NCT03243760|Experimental|Cohort K: Single dose CCI15106 30 mg /Placebo-COPD|COPD patients will receive single dose of either 30 mg CCI15106 (4 capsules of 7.5 mg) or matching placebo by inhalation via Modified Air Inlet Rotahaler™ device according to randomization.
2449789|NCT03243097|Experimental|Study Subjects|All subjects enrolled in the study are required to complete Phase I before entering Phase II, and Phase II before entering Phase III.
2449854|NCT03242603|Experimental|Anti-GD2 in combination with NK cells|This is a single arm study. Patients with high risk neuroblastoma who have residual measurable disease will receive a combination of 5 days of anti-GD2 with expanded activated NK cells.
2449922|NCT03242096|Experimental|Sirolimus coated balloon|Treatment of in-stent restenosis with a sirolimus coated balloon
2449927|NCT03242096|Active Comparator|Paclitaxel coated balloon|Treatment of in-stent restenosis with a paclitaxel coated balloon
2454554|NCT03209895|Active Comparator|Glucosamine / Chondroitin|
2449438|NCT03245086||Transanal hemorrhoid dearterialization (THD)|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing transanal hemorrhoid dearterialization (THD).
2449440|NCT03245086||Ferguson hemorrhoidectomy|Patients with prolapsed, non-incarcerated, reducible hemorrhoids in at least 3 columns undergoing Ferguson hemorrhoidectomy.
2449502|NCT03244956|Experimental|patients with RAS mutation|
2449503|NCT03244956|Experimental|patients with BRAFV600E mutation|
2449585|NCT03244501|Experimental|Left Frontal|An active magnet (active tSMS) will be placed over the left frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the right frontal cortex.
2449589|NCT03244501|Experimental|Right Frontal|An active magnet (active tSMS) will be placed over the right frontal cortex, while a sham magnet (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left frontal cortex.
2449595|NCT03244501|Sham Comparator|Sham Frontal|Sham magnets (sham tSMS, a nonmagnetic metal cylinder made of brass) will be placed over the left and right frontal cortex.
2449643|NCT03243838|Experimental|Experimental Group|Four cycles of docetaxel combined with apatinib followed by four cycles of epirubicin and cyclophosphamide as Neoadjuvant Treatment for Triple-Negative Breast Cancer
2449839|NCT03242616|Experimental|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)~Actinamide 1mg IM: 1 week before 1st dose, q 9 weeks (1wk before 1st cycle, 4th,7th,10th…. cycle after then.)~Folic acid 1mg daily: 1 week before 1st dose until 3 weeks after last dose~Dexa 4mg po bid on D0-2"
2449841|NCT03242616|Active Comparator|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
2449870|NCT03242161|Experimental|LabPatch-alcohol|All subjects will be administered alcohol and then monitored by a non-invasive alcohol sensor
2449993|NCT03241407|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
2449994|NCT03241407|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min. During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
2450010|NCT03241095|No Intervention|Control|
2450014|NCT03241095|Sham Comparator|Sham OMT|
2450021|NCT03241095|Active Comparator|OMT|
2450111|NCT03240926|Experimental|Loop Band|Measure accuracy of vital sign measurements
2450132|NCT03240367|Experimental|coutery|Stapler bloom will be stopped with cautery
2450137|NCT03240367|No Intervention|clips|Stapler bloom will be stopped with clipping
2450191|NCT03240224|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450195|NCT03240224|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450196|NCT03240224|Experimental|Combination therapy|"In this group, the patients will receive combination therapy, including ablation and life information rehabilitation therapy. They will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm), then drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450198|NCT03240224|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450246|NCT03239756|Experimental|60 mg single dose cohort|patients would receive a 60 mg single dose of TK006.
2450252|NCT03239756|Experimental|120 mg single dose cohort|patients would receive a 120 mg single dose of TK006.
2450258|NCT03239756|Experimental|180 mg single dose cohort|patients would receive a 180 mg single dose of TK006.
2450262|NCT03239756|Experimental|120 mg Q4W cohort|patients would receive 120 mg TK006 every 4 weeks, for a total of 3 doses.
2450311|NCT03239379|Placebo Comparator|Placebo|Normal saline
2450317|NCT03239379|Experimental|BNZ132-1-40|PEGylated BNZ-1 for Injection
3153568|NCT00279019|Experimental|Subjects receiving treatment sequence 15|Eligible subjects will receive treatment sequence 15; GSK233705 20 micrograms, GSK233705 100 micrograms, Placebo and GSK233705 50 micrograms.
3153569|NCT00279019|Experimental|Subjects receiving treatment sequence 16|Eligible subjects will receive treatment sequence 16; GSK233705 20 micrograms, GSK233705 100 micrograms, GSK233705 50 micrograms and Placebo.
3153570|NCT00279110|Experimental|A|
3153571|NCT00279110|No Intervention|B|
3153572|NCT00279149|Experimental|surgery|surgery
3153573|NCT00279175|Experimental|BMC|Intracoronary infusion of autologous bone marrow derived cells
3153574|NCT00279175|Placebo Comparator|Placebo|Intracoronary infusion of Placebo medium
3153575|NCT00279422|Placebo Comparator|placebo|
3153576|NCT00279422|Experimental|visilizumab|
3153577|NCT00279435|Placebo Comparator|placebo|
3153578|NCT00279435|Experimental|visilizumab|
3153579|NCT00279448|Experimental|A|
3153580|NCT00279448|Active Comparator|B|
3153581|NCT00279461|Experimental|A,|Arm A: Vitamin D 2,000 units daily all in one capsule for 6 months
3153582|NCT00279461|Placebo Comparator|B|Arm B: matching placebo one capsule daily for 6 months
3153583|NCT00279487|Active Comparator|Arm 1|Patients will receive 1200mg gabapentin 1-2 hours prior to surgery.
3153584|NCT00279487|Placebo Comparator|Arm 2|Patients will receive placebo 1-2 hours prior to surgery.
3153585|NCT00279617|Active Comparator|Levetricetam|open label treatment
2449442|NCT03245333|Experimental|Stage 2-experimental group|After completing the stage 1, experimental groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
2449443|NCT03245333|Other|Stage 2-negative control|After completing the stage 1, negative control groups is administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd week to the final height.
2449508|NCT03244826|Experimental|Shared Care|"For the first 90 days, patients alternate between local oncologist and DFCI for weekly visits.~From 90 to 180 days, patients alternate between local and DFCI every 2-3 weeks.~Shared Care include the following~Formal Care Coordination Plan~Patient Engagement and Education~Local Oncologist Engagement and Education~Patient/Local Oncologist/Transplant Oncologist Web Portal"
2449510|NCT03244826|Other|Usual Care|"Patients receive all follow-up care at DFCI only, which is currently the Standard Care.~Majority of routine visits in first 180 days will be at DFCI."
2449512|NCT03244826|Other|Non-Randomized|Patients receive all follow-up care at DFCI only (Standard Care).
2449556|NCT03244267|Active Comparator|Standard Education|Participants randomized to this arm will receive the standard education provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery.
2449557|NCT03244267|Experimental|Medication Reminder App + Standard Education|Participants randomized to this arm will use a smartphone app with preset reminders to take aspirin to prevent thromboembolic events after orthopedic surgery in addition to usual postoperative discharge teaching.
2449598|NCT03244150||School sample|Conducted in 1983 and included 1260 students in high school or trade school.
2449600|NCT03244150||Nationwide sample|Conducted in 1985 and included a representative sample of 2498 teenagers drawn from the Danish Civil Registration (CPR)
2449641|NCT03243864||Ceftazidime and Avibactam|Ceftazidime-avibactam pharmacokinetic monitoring
2449747|NCT03243162|Experimental|CBPT-ACLR|CBPT-ACLR program consisting of weekly phone calls.
2449752|NCT03243162|Active Comparator|Education|Education program consisting of weekly phone calls.
2449778|NCT03242850|No Intervention|Regular care group|This group will receive regular care including standard guidance on shared reading. Participants in this arm will not view the video at the time of enrollment nor will they receive the text messages throughout the 6 months of the randomized controlled trial.
2449781|NCT03242850|Experimental|Intervention group|
2449820|NCT03242681|Experimental|Endoscopy Assisted Probing|Endoscopy Assisted Probing
2449822|NCT03242681|Active Comparator|Simple Probing|Simple Probing
2449881|NCT03242213|No Intervention|Usual Care|Standard of Care
2449882|NCT03242213|Active Comparator|Mobile App|Standard of Care and Mobile App
3208542|NCT00975754|Experimental|4|Pulmicort repulses via Spira Nebuliser
3153586|NCT00279630|Experimental|type of exericse|type of exercise
3153587|NCT00279695||1|Subjects with glaucoma and age-matched normals
2450078|NCT03240718|Experimental|Laser treated HSc scar|Co2 laser treatment
2450080|NCT03240718|No Intervention|Control scar|Standard care
2450146|NCT03240601|Sham Comparator|Subthreshold|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will briefly ramp up to the lowest intensity that is first detected by the participant and then ramped down to a level no longer detected by the participant. Participants will continue their locomotor training.
2450152|NCT03240601|Experimental|Active|Individuals will undergo their standard physical therapist directed locomotor training while receiving transcutaneous spinal cord stimulation. The stimulation intensity will ramp up slowly to a level that produces parasthesia (tingling) throughout the lower extremity. This intensity will be applied for 30 minutes while participants continue their locomotor training.
2450370|NCT03238898|Active Comparator|botulinum toxin type A|Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
2450372|NCT03238898|Placebo Comparator|Normal saline|The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
3153588|NCT00279695||2|normal volunteers, two age groups, one 18-25 years old, one 50 years and older.
3153589|NCT00279695||3|subjects with tumors of the iris and ciliary body
3153590|NCT00279695||4|subjects with age-related macular degeneration and age-matched normals
3153591|NCT00279734|Experimental|Group 1|
3153592|NCT00279734|Active Comparator|Group 2|
3153593|NCT00279734|Active Comparator|Group 3|
3153594|NCT00279734|Active Comparator|Group 4|
3153595|NCT00279773|Experimental|TKI258 - dose escalation|Dose-Escalation
3153596|NCT00279773|Experimental|TKI258 - dose expansion|Dose-Expansion
3153597|NCT00279799|Experimental|Afiya group intervention + HIV prevention phone sessions|Afiya group-based intervention plus individually tailored HIV prevention phone sessions
3153598|NCT00279799|Active Comparator|Afiya group session + nutrition phone sessions|Afiya group-based intervention plus individually tailored nutrition phone sessions
3153599|NCT00279825|Other|Sequence 1|Subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR.
3153600|NCT00279825|Other|Sequence 2|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo.
2449444|NCT03245307|Experimental|Treament|In phase A, subjects receiving a single 30 mg oral dose of Nifedipine controlled-release tablets and wash-out for 2 days,a single 3 mg oral dose of warfarin tablets and wash-out for 12 days, then apatinib 750 mg once daily with a single 30 mg oral dose of Nifedipine controlled-release tablets co-administered on day 6 ,a a single 3 mg oral dose of warfarin tablets co-administered on day 9.
2449533|NCT03244943|Other|Non surgical periodontal treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia.
3208543|NCT00975754|Experimental|5|Pulmicort Turbohaler
2449753|NCT03243344|Experimental|Surgiflo|Using Surgiflo® (Absorbable Gelatin Hemostatic) for the post-operative haemostasis in endonasal surgery.
2449757|NCT03243344|Experimental|Floseal|Using Floseal® (Absorbable Gelatin Hemostatic) containing human thrombin for the post-operative haemostasis in endonasal surgery
2449760|NCT03243344|Experimental|Algosteril|Using Algosteril® (Hemostatic Sterile Wick) for the post-operative haemostasis in endonasal surgery
2449764|NCT03243344|No Intervention|Abstention|Not using device for the post-operative haemostasis in endonasal surgery
2449840|NCT03242499|Experimental|Active|Lovastatin 80mg per day for 48 weeks.
2449842|NCT03242499|Placebo Comparator|Placebo|Placebo 80mg per day for 48 weeks.
2449970|NCT03241693|Other|control group|Physiotherapy students
2449979|NCT03241693|Experimental|experimental group|Physiotherapy students
2450013|NCT03241277|Experimental|Social phobia|Patients with social phobia with no psychiatric treatment Intervention- non surgical periodontal treatment
2450016|NCT03241277|Experimental|Social phobia under Psych T|Patients with social phobia under psychiatric treatment (Psych T) Intervention- non surgical periodontal treatment
2450027|NCT03241277|Active Comparator|Controls|Patients without social phobia Intervention- non surgical periodontal treatment
2450081|NCT03240796|Experimental|minimal invasive surgery and secondary IOL implantation|
2450083|NCT03240796|Active Comparator|traditional cataract surgery and secondary IOL implantation|
2450136|NCT03240484||Spine Fusion and Total Hip Replacement|Any patient who has undergone spine fusion (SF) and total hip arthroplasty (THA). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
2450140|NCT03240484||Total Hip Replacement Group|Any patient who has had THA only (no spine fusion surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires. Patients may additionally be asked to participate in a gait analysis in a Human Movement Laboratory.
2450149|NCT03240484||Spine Fusion Only Group|Any patient who has had spine fusion only (no hip replacement surgery). Patients will undergo x-ray imaging and complete functional assessment questionnaires.
2450182|NCT03240055|Experimental|Group SE|21 patients received spinal anesthesia first. After confirmation of the level (T4-T6) of the sensory anesthesia, the sequential administration of etomidate was conducted
2450185|NCT03240055|Placebo Comparator|Group E|27 patients without spinal anesthesia in this group received sequential administration of etomidate
2450249|NCT03239834||OncAlert RAPID test in oral cavity biopsy patients.|Patients at an intermediate and high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oral Cavity.
2450255|NCT03239834||OncAlert RAPID test in oropharyngeal biopsy patients.|Patients at an intermediate to high level of clinical risk for HNSCC and scheduled for initial and immediate incisional diagnostic biopsy of their Oropharnyx
2450261|NCT03239834||OncAlert RAPID test in clinical decision to biopsy.|Patients at a lower level of clinical risk for HNSCC and not scheduled for an immediate biopsy. Patients will be offered medical management and have an initial RAPID test. All patients will return within 1-3 months for follow-up test and a possible biopsy if clinically indicated.
2450326|NCT03239197||mother infant pair|mother infant pair, singleton infant, vaginal birth
2450396|NCT03239015|Experimental|Targeted Drug Therapy Group|All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.
2450433|NCT03238365|Active Comparator|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and undergo surgery on day 31.
2450435|NCT03238365|Experimental|Arm II (nivolumab, tadalafil)|Patients receive nivolumab IV over 60 minutes on days 3 and 17 and tadalafil PO QD on days 3-31. Patients then undergo surgery on day 31.
2450520|NCT03238222|Experimental|MOSAIC Treatment|MOSAIC treatment plus Usual NHS Care. MOSAIC treatment comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) with a trained physiotherapist.
2450523|NCT03238222|No Intervention|Usual Care Comparison|Usual NHS care for people with intermittent claudication typically consists of an initial assessment, drug therapy and simple advice to walk provided by a vascular specialist and delivered in the vascular outpatient clinic.
2450579|NCT03237585|Experimental|i) Intervention arm- Receive Gender Centre's RRS package|
2450585|NCT03237585|No Intervention|No intervention|
2450648|NCT03237260|Experimental|Vedolizumab 300mg|vedolizumab open label
2450707|NCT03236740|Active Comparator|Metformin|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
2450709|NCT03236740|Active Comparator|OCP|OCP containing 35 microgram ethinylestradiol and 2-milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
2450766|NCT03236389|Experimental|Collar Wearing|subjects will wear collar during MRI testing
2450968|NCT03235141|Experimental|azithromycin eye drops by essex|In one cycle, give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the AzaSite eye drops,2.5ml/25mg，1 drop，once.
3208544|NCT00975767|Experimental|MGCD265+erlotinib|
2449456|NCT03245359|Active Comparator|Short-term ON-Q|Single port, select-a-flow pump and ON-Q 750mL ball filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery until medication has been depleted (typically 2-4 days)
2449463|NCT03245359|Experimental|Long-term ON-Q|Single port, select-a-flow pump and two 750mL ON-Q balls filled with bupivacaine 0.125% saphenous (adductor canal) nerve block and single port, fixed flow pump and two 400mL ON-Q ball with bupivacaine 0.125% wide field posterior knee block to provide analgesia from surgery up to 7 days post-operative. The second ball for each location will be provided pre-operatively, along with patient education for connection.
2449515|NCT03244735|Experimental|Modified Atkins Diet (MAD)|CCH patients that follows at least 3 months of MAD
2449592|NCT03244462|Experimental|Oral BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845~single oral dose of BAY1834845 + i.v. BAY1834845~single oral dose of BAY1834845 under fed conditions"
2449597|NCT03244462|Experimental|Oral BAY1834845 + i.v. BAY1834845|"Study Part A, cross over sequence:~single oral dose of BAY1834845+ i.v. BAY1834845~single oral dose of BAY1834845~single oral dose of BAY1834845 under fed conditions"
2449599|NCT03244462|Experimental|Oral Methotrexate|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX)~single oral dose of MTX + single oral dose of BAY1834845"
2449602|NCT03244462|Experimental|Oral Methotrexate + oral BAY1834845|"Study part B, cross over sequence:~single oral dose of methotrexate (MTX) + single oral dose of BAY1834845~single oral dose of MTX"
2449676|NCT03243708|No Intervention|Usual Care|Control: Standard order set without risk calculator (usual care)
2449678|NCT03243708|Active Comparator|Risk calculator|Intervention: VTE risk calculator embedded in the smart order set incorporated into the EHR and activated for all medical patients
2449784|NCT03242876|Placebo Comparator|Control meal|Control will be 109 g white bread and 200 mL water. The glycaemic response to the test meal will be compared to the response of the control meal.
2449791|NCT03242876|Experimental|Test meal|Test will be 109 g white bread and 200 mL water containing 3.819 g citric acid and 119 mg malic acid adjusted to pH 3.2. The glycaemic response to this meal will be compared to that of the control meal.
3190169|NCT00784706|Experimental|constraint-induced therapy|The intervention in this group resembled the intervention of the CIT+EP group, except participants did not wear the EP glasses.
2449904|NCT03242057|Experimental|NI-NAVA|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) Pi to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~If extubating to NAVA then place the catheter to optimize position and Edi 1 hr. prior to planned extubation.~ABG or CBG to be obtained at 4 hrs. post extubation~NI-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
2449911|NCT03242057|Active Comparator|NIPPV|"Wait to meet extubation criteria within 14 days postnatal age~Pre-extubation mode of invasive ventilation will be per physician discretion (NAVA, CMV, high frequency oscillator ventilation (HFOV) or high frequency jet ventilation (HFJV)) PI to determine eligibility or exclusion~Randomize to either NIPPV or NI-NAVA, 1:1 randomization~PI will not be blinded to the intervention (not feasible)~ABG or CBG to be obtained at 4 hrs. post extubation~NIPPV settings will be weaned or increased as the clinical situation demands and outlined in the protocol"
2449963|NCT03241537|No Intervention|Hormonal therapy alone|total androgen ablation or antiandrogen therapy alone for 2-3 years
2449966|NCT03241537|Active Comparator|Hormonal therapy with radiotherapy|total androgen ablation or antiandrogen therapy for 2-3 years combined with radiotherapy on whole pelvis
2450023|NCT03241264|Experimental|Module A|Lyophilized Formulation
2450037|NCT03241264|Experimental|Module B|Frozen Formulation
2450105|NCT03240978|Experimental|High intensity intervention|Exercise intervention at 70 to 80% of estimated heart rate maximum for 12 weeks.
2450107|NCT03240978|Experimental|Moderate intensity intervention|Exercise intervention at 50 to 70% of estimated heart rate maximum for 12 weeks.
2450108|NCT03240978|No Intervention|non-exercise group|Participants will not receive any type of exercise training.
2450162|NCT03240354|Experimental|Saline|Use of saline to inflate cuff of endotracheal tube
2450166|NCT03240354|Active Comparator|Control|Use of air to inflate cuff of endotracheal tube
3190170|NCT00784706|Active Comparator|conventional therapy|traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
3190171|NCT00784732|Experimental|1|
2450299|NCT03239639|Experimental|Advance care planning education session|Delivery of an advance care planning education session at the family doctor's office
2450300|NCT03239639|Sham Comparator|Wait list control|The intervention is not provided.
3190172|NCT00784732|Experimental|2|
3190173|NCT00784732|Active Comparator|3|
3190174|NCT00784745|Experimental|Dexamethasone|
3190175|NCT00784797|Active Comparator|pitocin|high dose pitocin drip 48 hours after mifepristone preparation.
3190176|NCT00784797|Active Comparator|misopristol|vaginal and oral misopristol 48 hours after mifepristone preparation.
3190177|NCT00784823|Experimental|Combined dose intense Melphalan with bortezomib (MTD)|"The purpose of this study is to determine the tolerance and potential efficacy of combining dose intense melphalan with escalating doses of bortezomib in patients with multiple myeloma undergoing autologous stem cell transplantation.~Combined dose intense Melphalan with maximum tolerated dose of bortezomib (MTD)"
2450604|NCT03237312|Other|The control group|Four punctures in each ovary were done regardless of the level of antimullerian hormone
2450607|NCT03237312|Other|The study group|The number of ovarian drills was adjusted according to antimullerian hormone level
3190178|NCT00784862|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3190179|NCT00784862|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
3190180|NCT00784862|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
2449462|NCT03245047|Placebo Comparator|Control group|Participants in the control group will be asked to consume two servings of Oral nutritional supplement per day for 180 days.(Oral Consumption)
2449501|NCT03244852||OCD Patients with Deep Brain Stimulators|Patients with deep brain stimulation for intractable obsessive compulsive disorder (OCD)
2449560|NCT03244553|Experimental|Active intervention|Prucalopride for 5 days. Dosage: day 1 2mg, days 3-5 4mg
2449588|NCT03244137||Pulmonary rehabilitation|The whole population will benefit from a comprehensive pulmonary rehabilitation program, including aerobic training, superior and inferior limb strength training, self-management and add-on to pulmonary rehabilitation as needed (i.e : electrical muscle stimulation, inspiratory muscle training, non-invasive ventilation, high flow nasal canula).
2449631|NCT03243890|Experimental|Intervention|Study drug. Supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day)
2449633|NCT03243890|Placebo Comparator|Placebo|Placebo tablet (no active treatment). The placebo tablet is matched to the study drug for taste, color, and size.
2449811|NCT03242980|No Intervention|Enhanced adherence counseling|Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
2449812|NCT03242980|Experimental|Structured EAC plus SMS|The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
2449862|NCT03242369|Experimental|PEG group|100 patients undergoing colonoscopy.
2449863|NCT03242369|Experimental|SBS group|100 patients undergoing colonoscopy
2449865|NCT03242369|Experimental|PEG 2L + ascorbic acid group|100 patients undergoing colonoscopy.
2449867|NCT03242369|Experimental|PICO group|100 patients undergoing colonoscopy.
2449914|NCT03241940|Experimental|Treatment (CD19/CD22-CAR T cells, chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and cyclophosphamide IV over 60 minutes on day -2. Patients then receive CD19/CD22-CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22-CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22-CAR T cells.
2449996|NCT03241394||Lean|Individuals with Body Mass Index (BMI) = 18.5 - 25.0 Kg/m2
2449997|NCT03241394||Obese with MS|Individuals with BMI ≥ 30.0 Kg/m2 and metabolic syndrome (MS) MS was defined as the presence of three or more of the following criteria: 1) waist circumference ≥ 102 cm in men and ≥ 88 cm in women, 2) serum triglycerides ≥ 150 mg/dL, 3) high density lipoprotein-cholesterol (HDL-C) < 40 mg/dl in men and < 50 mg/dl in women, 4) systolic blood pressure (SBP) ≥ 130 mmHg or diastolic blood pressure (DBP) ≥ 85 mmHg or antihypertensive drug treatment, 5) fasting glucose ≥ 100 mg/dL
2449999|NCT03241394||Obese without MS|Individuals with BMI ≥ 30.0 Kg/m2 but not MS
2450019|NCT03241134|Experimental|Dry needling|A single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into skin surface, fascia, into the muscle tissue at the MTrP location, and will move the needle up and down in multiple directions. In case local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
2450030|NCT03241134|Sham Comparator|Sham needling|A single sham needling session will be performed with the subject lying on the non painful side. After palpation of a taut band, and detection of a MTrP in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the skin surface at the MTrP location. The fascia and muscle tissue will not be penetrated.
2450106|NCT03240848|Experimental|artificial intelligent clinic|"Procedure: the initial diagnosis from artificial intelligent clinic Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in artificial intelligent clinic, participants in group A went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
2450109|NCT03240848|Active Comparator|normal clinic|"Procedure: the initial diagnosis from normal clinic Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.~Procedure: the final definite diagnosis from experts After making the initial diagnosis in normal clinic, participants in group B went to get the final definite diagnosis from experts with more than 10 years of clinical experience."
2450167|NCT03240341|Experimental|Patient Activation Measure (PAM)|completion of the PAM questionnaire
2450211|NCT03240003|Experimental|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of standard GC-MRT
2450213|NCT03240003|Active Comparator|non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
2450216|NCT03240003|Experimental|GC-MRT-modified|Group 3 will receive a 4-week (8-sessions) course of modified GC-MRT.
2450228|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
2450351|NCT03239535|Experimental|Mesenchymal stem cells|Mesenchymal stem cells, Intramuscular injection
2450353|NCT03239535|Placebo Comparator|Normal saline|Normal saline, Intramuscular injection
2450384|NCT03238846|No Intervention|3MF: 3-month ART dispensing at facilities|Ten sites at which patients will receive standard of care where ART is dispensed three monthly from the facility based on usual practice at the clinic. The approach will be consistent with applicable country guidelines at the time of study.
2450387|NCT03238846|Experimental|3MC: 3-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed three monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 3 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
2450391|NCT03238846|Experimental|6MC: 6-month ART dispensing in CARGs|Ten sites at which patients will receive ART dispensed six monthly in CARGs. Providers at facilities will assist in the formation of CARGs and will provide all enrolled patients with a 6 month supply of ART and associated HIV medications. All other aspects of care will be as per standard of care for the enrolling clinic.
2450446|NCT03238482|Active Comparator|Seretide Diskus|salmeterol-fluticasone 2 inhalations as a single dose
2449478|NCT03245125||MDP subjects in HFpEF patients|heart failure patients with preserved ejection fraction (HFpEF) received only multidisciplinary disease management program (MDP) and underwent less than 36 times of high-intensity interval training (HIIT) or no exercise training
2449504|NCT03244787|Experimental|patient navigation|PN will contact patients during their visits to health cancer or over the phone. During this initial contact, the PN will educate patients about CRC, screening and explore their barriers to screening. The PN will coordinate scheduling of CRC screening and remind patients about the tests. PN will explain preparation for colonoscopy and whenever feasible, accompany patient to obtain the test. Further interventions may include: reminding the patient about the test, helping with translation, insurance issues, transportation, and overcoming any other system barriers as needed.
2449506|NCT03244787|No Intervention|usual care|patients randomly assigned to the control will receive usual care and be eligible for navigation after the study period.
2449570|NCT03244228|Experimental|Part 1a SAD HTL0016878/Placebo|In Part 1a, single ascending doses of HLT0016878 or matching placebo will be administered to groups of 12 subject each (9 active, 3 placebo). Each subject will have up to four treatment sessions separated by an appropriate wash-out. Healthy, young, male subjects.
2449571|NCT03244228|Experimental|Part 1b single dose HTL0016878|In Part 1b, a single dose of HTL0016878 will be administered to 6 subjects on two occasions: once in the fasted and once the fed state. This will be open-label. Healthy, young, male or female subjects.
2449573|NCT03244228|Experimental|Part 1c single dose HTL0016878|In Part 1c, a single dose of HTL0016878 will be administered to up to 6 (optional up to 12) healthy elderly subjects This will be open-label. Healthy, elderly, male subjects.
2449575|NCT03244228|Experimental|Part 2a MAD HTL0016878/Placebo|In Part 2a, multiple doses of HTL0016878 will be administered to up to 5 cohorts (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
2449577|NCT03244228|Experimental|Part 2b MAD HTL0016878/Placebo|In Part 2b, multiple doses of HTL0016878 will be administered to up to 3 cohorts of healthy, elderly subjects (N=8, 6 active, 2 placebo) during one study session of 7 days. Healthy, young, male or female subjects.
2449628|NCT03243903|Experimental|needle-free insulin injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
2449630|NCT03243903|Active Comparator|conventional insulin pen|Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
2449686|NCT03243565|Active Comparator|OM-85|OM-85 by mouth (3.5 mg once per day, first 10 days, consecutive 3 months; 10-10-10 days, standard treatment regimen) A second cure of treatment will be given 6 months after inclusion.
2449693|NCT03243565|Placebo Comparator|Placebo|Placebo by mouth (Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate) the same posology (3.5 mg once per day, first 10 days for consecutive 3 months) A second cure of treatment will be given 6 months after inclusion.
2449770|NCT03243019|Experimental|SIROLIMUS|
2449837|NCT03242694||persistent atrial fibrillation|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
2449880|NCT03242200|Other|Mobile Health App|Participants will be prompted to complete questionnaires.
2449889|NCT03241823||Patients with hepatitis c virus related liver cirrhosis|"Patients with chronic hepatitis C virus whose ultrasound shows liver cirrhosis, fibroscan F3 and F4, Child score A and B, of any MELD score, who achieved Sustained Virological Response after direct acting antiviral drugs (Sofosbuvir, Daclatasvir ± Ribavirin)."
2449948|NCT03241628||Dressing Glove|"Fitting bespoke dressing gloves (viscose Class 1 medical device) and evaluating dressing glove performance in the management of blisters using patient recorded outcome measures. The aim is to obtain proof of concept data for the dressing glove as an acceptable alternative to patch work dressings held in place with bandages.~The study protocol recommends a daily change of the dressing glove but the patients also contribute their preference for frequency of dressing changes."
2450028|NCT03241355|Active Comparator|prebiotic inulin-type fructan|
2450035|NCT03241355|Placebo Comparator|placebo maltodextrin|
2450093|NCT03240913|Experimental|Treatment Group|
2450096|NCT03240913|Placebo Comparator|Non Treatment Group|Conventional information
2450122|NCT03240419|Experimental|Probiotics|Each probiotic capsule contains 180 mg of a standardized white to light beige fine powder consisting of freeze-dried cultures. Specifically, Bifidobacterium BB-12® and Lactobacillus rhamnosus LGG® (50%:50%). This product has a minimum potency of 6.5 billion (6.5E+9) CFU (ColonyForming Units) per capsule. Other ingredients in the powder are: microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate. Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
2450124|NCT03240419|Placebo Comparator|Placebo|Participants in this group will take one capsule containing microcrystalline cellulose, maltodextrin, silicon dioxide and magnesium stearate (all ingredients listed in the probiotic capsules except the culture) . Participants in this group will take one daily capsule orally starting at the time of recruitment (gestation week 12) and until delivery.
2450225|NCT03239691|Experimental|ACT-709478 - Single dose administration|Up to 16 subjects with photosensitive epilepsy will be studied across a maximum of 4 dose levels. Each dose level will initially be investigated in cohorts of 4 subjects undergoing a fixed sequence of study treatment administration in fed condition
2450226|NCT03239691|Placebo Comparator|Placebo|Placebo will be administered on two study days
2450274|NCT03239561|Experimental|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
2450325|NCT03239366|Active Comparator|Active arm|Active product 'BioK+ 100% probiotic: Bio-K+50B® probiotic will be administered orally for a period of 12 weeks. Dose: two (2) capsules of 50 billion (B) colony forming units (CFU) providing a dosage of 100 billion CFU per day
2450332|NCT03239366|Placebo Comparator|Placebo arm|Placebo product (without the 3 strains of bacterias) will be administered orally for a period of 12 weeks. Dose: Two (2) capsules of Placebo per day
3153601|NCT00279825|Other|Sequence 3|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Third treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
3174403|NCT00623077|Experimental|Total Marrow Irradiation (MTI) with Tomotherapy|TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
2449590|NCT03244410||immune thrombocytopenic purpura|immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture
2449626|NCT03243942|Experimental|Definity for pressure measurements|2 vials of activated Definity mixed with 50 ml saline. As per manufacturer's recommendation the infusion rate may vary between 4-10 ml/min (to provide diagnostic intracardiac contrast visibility).
2449704|NCT03243656|No Intervention|control arm|standard immunosuppressive therapy (antilymphocyte globulin and cyclosporine),
2449709|NCT03243656|Active Comparator|case arm|standard immunosuppressive therapy plus an oral dose of Eltrombopag
2449737|NCT03243214|Active Comparator|PD-MCI, TMS|The patient is treated with TMS stimulation according to protocol with an active coil.
2449739|NCT03243214|Sham Comparator|PD-MCI, Sham-TMS|The patient is treated with Sham-TMS stimulation according to protocol with an inactive coil.
2449858|NCT03242317|Experimental|Mitomycin C + Raindrop Near Vision Inlay|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the Raindrop Near Vision Inlay in Presbyopes.
2449888|NCT03242044|Experimental|Resuscitation with intact umbilical cord|This is a one arm study. Pregnant women greater than 18 years of age with a fetus with left or right sided congenital diaphragmatic hernia of age that consent to the protocol will be enrolled in the study. This is a pilot feasibility study that will assess maternal and infant tolerance to resuscitation with an intact umbilical cord as well as the optimal method for performing an advanced resuscitation with the umbilical cord intact. For this reason patients will not be randomized.
2449957|NCT03241745|Experimental|Nivolumab|Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.
2450031|NCT03241121|Experimental|Time restricted feeding|For those in the intervention phase (Part 2)
2450036|NCT03241121|Active Comparator|Regular dietary advices|For those in the intervention phase (Part 2)
2450097|NCT03240783|Experimental|Arm 1|Betamethasone OR Dexamethasone Injectable CT - fluoroscopic guided transforaminal lumbar epidural steroid
2450100|NCT03240783|Experimental|Arm 2|Normal Saline Flush, 0.9% Injectable Solution CT - fluoroscopic guided transforaminal lumbar epidural normal saline
2450101|NCT03240783|Experimental|Arm 3|"Dexamethasone Oral Tablet:~Oral dexamethasone 15 day tapered dosing is as follows: (i) days 1-5, 4 mg morning and evening, (ii) days 6-10, 2 mg morning and evening, and (iii) days 11-15, 1mg morning and evening."
2450103|NCT03240783|Other|Arm 4|Sham Injection and/or oral placebo: CT/fluoroscopic guided (parameters set to zero) transforaminal lumbar sham (needle placement down to muscle and no injection of any fluid) AND placebo oral tablets taper.
2450168|NCT03240276|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte
2450169|NCT03240276|Active Comparator|IMSI Procedure|The IMSI procedure is the injection of normal ultramorphological spermatozoa that have been selected using an inverted microscope with magnification of 6300x (MSOME)
2450268|NCT03239925|Experimental|Experimental group|all participants in this group would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
2450275|NCT03239925|Placebo Comparator|Control group|these would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode
2450331|NCT03239288|Placebo Comparator|Control digestible carbohydrate|Control baked breakfast bar
2450335|NCT03239288|Experimental|Test resistant starch type 4|Test baked breakfast bar
2450479|NCT03238313|Experimental|Plan A|Plan A is the treatment condition. It is a 23-minute video that is designed to promote effective contraceptive use, use of dual methods of protection (condom use and prescription birth control use), and HIV/STI testing in African/American and Latina young women.
2450483|NCT03238313|Active Comparator|Toxic Life Cycle of a Cigarette|The Toxic Life Cycle of a Cigarette is the counterfactual condition. It is a 17-minute video, but contains no information about reproductive health. Instead, the video teaches about the harms of cigarettes.
2450576|NCT03237741|Experimental|Treatment Sequence 1: ABC1D1|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
2450622|NCT03237247||Malignant Distal|cases with malignant distal extrahepatic cholestasis
2450624|NCT03237247||Malignant Proximal|cases with malignant proximal extrahepatic cholestasis
2450627|NCT03237247||Intrahepatic|cases with intrahepatic cholestasis
3174404|NCT00623090|Experimental|1 Website|Participants receive the Login information for the Internet we developed on prostate cancer screening.
3174405|NCT00623090|Active Comparator|2 Booklet|Participants receive the education booklet we developed on prostate cancer screening.
3174406|NCT00623090|Placebo Comparator|3 Usual Care|Usual care: participants receive no intervention.
2449511|NCT03244878|No Intervention|Wait-list Control|Participants will have no access to the Thrive program for 8 weeks upon enrollment. They will receive a link to the NIMH website to read about information on depression.
2449554|NCT03244488||HIV-Positive|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
2449555|NCT03244488||HIV-Negative|Patients will be administered each of 4 possible treatments: high dose (5 mcg/kg) scopolamine, high dose (20 mg) mecamylamine, a low dose combination (2.5mcg/kg and 10 mg) of scopolamine and mecamylamine, or placebo.
2449637|NCT03244202|Experimental|Decision Aid Plus Counselling|Participants will use a decision aid to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing. After using the decision aid the participants will speak with a genetic counsellor over the phone about their choice.
2449644|NCT03244202|Active Comparator|Genetic Counselling Only|Participants will a genetic counsellor over the phone to learn about genomic sequencing and select which incidental findings they would like to receive from genomic sequencing.
2449679|NCT03243526|Placebo Comparator|Central venous pressure group|fluid therapy to maintain CVP not 5 cmH2o
2449684|NCT03243526|Experimental|Pulse pressure variation|fluid therapy will be guided by PPV to be less than 14%
3190181|NCT00784888||Aromatase inhibitors|Early stage postmenopausal breast cancer patients under tamoxifen treatment who are switching to aromatase inhibitor treatment
2449883|NCT03242304||Control group|A control group composed of subjects without physical or psychiatric disease.
2449884|NCT03242304||Acute Ischemic Stroke group|An AIS group composed of subjects within the first 24 hours of the neurovascular event.
2449930|NCT03241797|Experimental|Patients who suggested having AIP|Patients who suggested having AIP and underwent EUS-FNA biopsy by using a standard 22-gauge aspiration needle were enrolled between January 2013 and May 2017.
2450001|NCT03241498|No Intervention|Control arm|All patients allocated to the control group, who on checking meet the study entry criteria and who consent (written informed consent) to participate in the research, will be asked to complete the three study questionnaires (see below) and will be advised that repeat questionnaires will be distributed by post at the end of the study (6 months) for completion at home and return by post. The patients will continue to receive all services provided by the GP practice (normal care) but will not receive the bespoke clinical pharmacist intervention which is being evaluated in this research study.
2450002|NCT03241498|Experimental|Intervention arm|Participants meeting all study entry criteria who are allocated to the intervention group will also be asked to complete the three study questionnaires. Having completed the questionnaires they will receive the medicines optimisation intervention by the clinical pharmacist. They will be asked to return for repeat appointments with the clinical pharmacist at 2 and 4 months and will be advised that they will be asked to complete the study questionnaires again at the end of the study (at home, via post at 6 months).
2450051|NCT03241069|Experimental|patients with acute dyspnea|"patients presenting to the emergency department with acute onset dyspnea are assessed for acute heart failure using the bio impedance technology (BIOPAC system) to measure the cardiac output in different clinical situations.~FIRST: the cardiac output (CO) is measured at the reference position. Inbetween each step the patient was put in the reference position during 5 minutes."
2450054|NCT03241069|Experimental|the sitting position|the patient is put at the sitting position and we measure the cardiac output by BIOPAC system (patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured 5 minutes later)
2450057|NCT03241069|Experimental|a passive leg rising maneuver|we make a passive leg rising and we measure the cardiac output by BIOPAC system (45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver 5minutes later.)
2450058|NCT03241069|Experimental|Valsalva maneuver|the patient was asked to perform the Valsalva maneuver and we measure the cardiac output by BIOPAC system(patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.)
2450089|NCT03240679|Active Comparator|EMR with Extracelluar Matrix|Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive Extracellular Matrix to the defect site
2450091|NCT03240679|No Intervention|EMR|assess baseline dysphagia (Mellow-Pinkas scale and Mayo Dysphagia Questionnaire). Patients with lesions that lift and are amenable to cap-assisted EMR will be randomized to receive standard of care.
2450155|NCT03240445|Experimental|Period 1|ODM-203 dosed after food
2450160|NCT03240445|Experimental|Period 2|ODM-203 dosed before food
2450164|NCT03240445|Experimental|Periods 3-6|ODM-203 dosed as a tablet or dispersion
2450278|NCT03239769|Active Comparator|conventional access group (CA)|A 4- to 5-cm incision was created, subplatysmal flaps were raised, and the strap muscles were mobilized. Then, the superior pole of the thyroid gland was exposed and the gland was delivered through the surgical incision, and the thyroid isthmus was divided. Finally, CLND was performed. The strap muscles were re-approximated with No.1 silk suture. The full-thickness skin was closed with interrupted monofilament.
2450279|NCT03239769|Experimental|aesthetic principles access group (APA)|The key difference focused on the disposal incision using aesthetic principles, which are depicted below. The incision was protected by Vaseline ointment. Excessive skin traction was avoided to prevent the injury on the skin edge. Bleeding was stanched with a low-power bipolar coagulation device. The surgical field does not have to be pulled in every direction to show the full operation field. The cervical linea alba was closed by continuous sutures with 3-0 absorbable Vicryl sutures. Interrupted sutures of 4-0 Vicryl were used to re-approximate the subcutaneous tissues. The epidermis was fixed with 3M steri-strip elastic skin closures rather than skin sutures.
2450454|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, E|salmeterol-fluticasone 2 inhalations as a single dose
3190182|NCT00784914|Active Comparator|Cohort 1|Patients do not receive temsirolimus.
2449610|NCT03244241|Active Comparator|Intervention|Basal-bolus insulin regime with Insulin Degludec and insulin aspart
2449618|NCT03244241|No Intervention|Standard|Standard treatment according to hospital guidelines with sliding scale insulin
2449681|NCT03243812|Active Comparator|SS genotype group|"Sickle cell patients with SS genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2449687|NCT03243812|Active Comparator|SC genotype group|"Sickle cell patients with SC genotype. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2449694|NCT03243812|Active Comparator|control group|"Healthy subjects. Each subject will undergo the following :~Blood sample~Maximum Voluntary Contraction (MVC) test force before and after a localized muscle endurance test~Localized muscle endurance test: 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.~Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society"
2449785|NCT03242967|Experimental|Vadadustat|Oral tablet
2449792|NCT03242967|Active Comparator|Darbepoetin alfa|subcutaneous or intravenous
2449838|NCT03242538|Experimental|Pelvic Exercise Intervention|Patients will perform two pelvic exercises prior to each external beam radiation treatment.
2449886|NCT03242226|Experimental|two spectacles|
2449887|NCT03242226|Active Comparator|single vision spectacles|
3153602|NCT00279825|Other|Sequence 4|Subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR. In Second treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR and 1 tablet of CD-LD CR Placebo. In Third treatment, subjects take 1 tablet of IPX054 200 mg Placebo, 1 tablet of IPX054 250 mg, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo. In Fourth treatment, subjects take 1 tablet of IPX054 200 mg, 1 tablet of IPX054 250 mg Placebo, 2 tablets of CD-LD IR Placebo and 1 tablet of CD-LD CR Placebo.
3153603|NCT00279877|Active Comparator|vertebroplasty|vertebroplasty
3153604|NCT00279877|Active Comparator|kyphoplasty|kyphoplasty
2450065|NCT03241017|Experimental|Durvalumab|Durvalumab 1500 mg (day 1) given every 4 weeks for a total of 12 applications (1 year).
2450114|NCT03240627|Experimental|LH-8 cutaneous solution|LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp:
2450115|NCT03240627|Placebo Comparator|Placebo cutaneous solution|Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp:
2450154|NCT03240315||COPD subjects|Subjects with GOLD stage I-IV COPD
2450190|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate|Subjects will receive pembrolizumab 200 mg IV day 1 with pralatrexate 30 mg/m2 IV day 1, 8, and 15.
2450194|NCT03240211|Experimental|Pembrolizumab plus Pralatrexate plus Decitabine|Subjects will receive pembrolizumab 200 mg IV day 8 with pralatrexate 20 mg/m2 IV day 1, 8, and 15 and decitabine 10 mg/m2 from day 1 to 5.
2450197|NCT03240211|Experimental|Pembrolizumab plus Decitabine|Subjects will receive pembrolizumab 200 mg IV and decitabine 20 mg/m2 from day 1 to 5.
2450270|NCT03239717|Placebo Comparator|Whey protein powder|Participants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
2450277|NCT03239717|Experimental|Experimental|Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
3153605|NCT00279903|Active Comparator|Cortisone|
2450404|NCT03238742|Experimental|Intervention Group|100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
2450407|NCT03238742|Placebo Comparator|Placebo group|normal saline 200 mL every 12 hours for 5 days
2450448|NCT03238430|Experimental|Ropivacaine infiltration|Continuous infiltration of local anesthetics + PCA morphine.
2450458|NCT03238430|Experimental|intrathecal morphine|Rachianalgesia + PCA morphine
2450462|NCT03238430|Active Comparator|morphine PCA|PCA morphine alone
2450608|NCT03237299||Cases|Cases: children with loco-regional complications of pharyngitis
2450609|NCT03237299||Controls|Controls: children with pharyngitis but without infectious complications
2450656|NCT03237091|Experimental|bihemispheric transcranial pulsed current stimulation (tPCS)|
2450658|NCT03237091|Experimental|unihemispheric transcranial pulsed current stimulation (tPCS)|
2450659|NCT03237091|Experimental|bihemispheric transcranial direct current stimulation (tDCS)|
2450662|NCT03237091|Experimental|unihemispheric transcranial direct current stimulation (tDCS)|
3153606|NCT00279903|Experimental|Low Dose Btx-A|
3153607|NCT00279903|Experimental|High Dose Btx-A|
3153608|NCT00279942|Active Comparator|Soy|A shake that contained 20 g of soy protein and 160 mg of soy isoflavone.
3153609|NCT00279942|Placebo Comparator|Placebo|A shake that contained 20 g of milk-based protein (casein) and no isoflavone.
3153610|NCT00280007|Experimental|1|bevacizumab infusion evey 2 weeks
3153611|NCT00280007|Placebo Comparator|2|placebo infusion
3153612|NCT00280020|Experimental|CBT|
3153613|NCT00280020|Experimental|TCC|
3153614|NCT00280020|Active Comparator|SS|
3153615|NCT00280033|Placebo Comparator|9|Saline administered on days 0 and 28.
3153616|NCT00280033|Experimental|8|45 mcg alone administered on days 0 and 28.
3153617|NCT00280033|Experimental|7|30 mcg plus aluminum hydroxide administered on days 0 and 28.
3153618|NCT00280033|Experimental|6|30 mcg alone administered on days 0 and 28.
3153619|NCT00280033|Experimental|5|15 mcg plus aluminum hydroxide administered on days 0 and 28.
3153620|NCT00280033|Experimental|4|15 mcg plus MF59 administered on days 0 and 28.
3153621|NCT00280033|Experimental|3|15 mcg alone administered on days 0 and 28.
2449574|NCT03244397|Experimental|PT group|"The participants assigned to this group will receive 16 sessions of physical therapy. Each session will last 45/50 minutes, 2 sessions a week for 8 weeks.~A directly pelvic floor muscle(PFM) training protocol will be applied. Throw vaginal palpation and in lithotomy position, participants will perform PFM exercises per the treatment proposed by the PERFECT scheme. Biofeedback exercises will be also performed in lithotomy position. Hypopressive exercises which are also home daily from the eighth session. Plus educational strategy."
2449576|NCT03244397|Active Comparator|Control group|Only educational strategy 1 session per week for 6 weeks (every session will last 40/45 minutes). The educational strategy will consist of instruction of printed materials and dimensional anatomical models about the anatomy of the pelvic floor and the physiology of the pelvic organs. It will be recommended to avoid risk factors, such as gaining weight, weight lifting, high impact sports, constipation, smoking, or drinking too much caffeine. They will be also instructed in toilet habits, and will be taught to use the knack maneuver before and during increases of intra-abdominal pressure.
2449648|NCT03244020|Experimental|LMWH for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2449650|NCT03244020|Experimental|ASA for Soft Tissue Sarcoma|Patients undergoing surgery for pelvic/lower extremity soft tissue sarcomas and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2449652|NCT03244020|Experimental|LMWH for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2449653|NCT03244020|Experimental|ASA for Primary Bone Tumor|Patients undergoing surgery for pelvic/lower extremity primary bone tumor and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2449656|NCT03244020|Experimental|LMWH for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to Enoxaparin 40Mg/0.4mL prefilled syringe subcutaneous injection daily for VTE prophylaxis
2449660|NCT03244020|Experimental|ASA for Metastatic Disease|Patients undergoing surgery for pelvic/lower extremity metastatic bone disease and are randomized to aspirin 325 mg po daily for VTE prophylaxis
2449734|NCT03243435||Native 1,5 Tesla breast MRI group|From all patients a 1,5 Tesla MRI of the breast will be obtained
2449804|NCT03242720|Active Comparator|Active Positive Airway Pressure|Active positive airway pressure for treatment of Obstructive Sleep Apnea
2449808|NCT03242720|Sham Comparator|Sham Positive Airway Pressure|Sham positive airway pressure for treatment of Obstructive Sleep Apnea
2449834|NCT03242460|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|Pomalidomide 4mg Days 1-21 Dexamethasone 20mg Days 1, 8, 15, 22 Cyclophosphamide 400mg Days 1, 8, 15
2449901|NCT03242187|Experimental|Trans-anal TME (TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
2449905|NCT03242187|Active Comparator|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
2449981|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 1: 1 to < 6 years of age|Patients will receive an intravenous (IV) loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2449988|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 2: 6 to < 12 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2449990|NCT03241550|Experimental|isavuconazonium sulfate IV cohort 3: 12 to < 18 years of age|Patients will receive an IV loading regimen of isavuconazonium sulfate, which consists of a dose every 8 hours (+/- 2 hours) on days 1 and 2, followed by once daily IV maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2449991|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 4: 6 to < 12 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2449992|NCT03241550|Experimental|isavuconazonium sulfate oral cohort 5: 12 to < 18 years of age|Patients will receive a loading regimen of isavuconazonium sulfate by oral administration, comprising one dose every 8 hours (+/- 2 hours) on days 1 and 2 (a total of six doses), followed by once daily oral maintenance dosing for up to 26 additional days (for a maximum of 28 days of dosing).
2450005|NCT03241056|Experimental|CBT for Maladaptive Beliefs about Memory|Using cognitive-behavioural therapy principles, this therapy is intended to examine and change maladaptive beliefs about memory as they pertain to compulsive checking.
2450008|NCT03241056|Active Comparator|Treatment as Usual|This is a control treatment, Treatment as Usual (TAU), which is what patients or community members would otherwise normally receive.
2450064|NCT03240991||Quality of life questionnaires|Data will be collected retrospectively and prospectively.
2450116|NCT03240640|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
2450117|NCT03240640|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
2450201|NCT03240302|Active Comparator|ICSI Procedure|The ICSI procedure is the standard procedure of selection and injection of sperm into the oocyte using a standard ICSI petri dish.
2450205|NCT03240302|Active Comparator|PICSI Procedure|The PICSI procedure is based on a selection of mature spermatozoa with CD44 receptors and their injection into the oocyte using the PICSI petri dish that has been coated with hyaluronic acid on its bottom.
2450237|NCT03239743|Experimental|Virtual Reality Group|Subjects will be given the virtual reality device to interact with prior to surgery without the use of a pre-medication.
2450239|NCT03239743|Active Comparator|Midazolam Group|Subjects will be given the drug Midazolam to help alleviate the pre-operative anxiety.
2450356|NCT03239431||Asthma group|Patients with asthma
2450380|NCT03238807|Experimental|Intervention Group|Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
2450385|NCT03238807|No Intervention|Control Group|Control Group
2449771|NCT03243110||Asthmatics requiring breathing test|"Participants must have had a diagnosis of asthma by a physician. The participant must have had a self-reported health care interaction related to asthma (physician visit, ED visit, hospitalization) in the past 5 years.~Participants must be 1 to 85 years old."
3190183|NCT00784914|Experimental|Cohort 2|48 hours after surgery, patients receive one 200 mg dose of temsirolimus IV.
2449913|NCT03241914|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2449918|NCT03241914|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG- IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2449949|NCT03241511|Experimental|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic and repeated supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene). Outcomes will be assessed at 2-, 4-, and 6-months. Throughout the course of the study, additional dental needs will be addressed with immediate referral to the subject's general dentist or clinics at the University of Connecticut.
2449954|NCT03241511|No Intervention|Control|The Control arm will receive only a single treatment session without maintenance sessions (see visit Table in Human Subject Protection section). Outcomes will be assessed at 2-, 4-, and 6-months.
2450044|NCT03241290||Use of C-ARM ARCO FP-Rk521S|C-ARM ARCO FP-Rk521S is mobile X-ray device that combines a X-Ray sensor and a sensor management software used during surgeries for real-time imaging.
2450110|NCT03240965||Volunteers <60 years|Volunteers, who are able to consent to participation in the study, as control.
2450112|NCT03240965||Volunteers >60 years|Volunteers, who are able to consent to participation in the study, as control.
2450113|NCT03240965||Stroke patients|Stroke patients with supratentorial stroke, who are able to consent to participation in the study.
2450171|NCT03240289|Other|Texting|Texting group
3190184|NCT00784940|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3190185|NCT00784940|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
2450447|NCT03238391|Experimental|Study group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 50 mmHg above the systolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
2450455|NCT03238391|Sham Comparator|Sham group|Patients will receive ischemia and reperfusion of the arm by inflating a blood pressure cuff around the arm at 10 mmHg below the diastolic blood pressure for 5 minutes, followed by 5 minutes of reperfusion and this cycle will be repeated three times
2450508|NCT03238118|Experimental|Attention bias modification training|For attention-toward-positive, stimuli are colour-pictures of 16 angry and 16 happy faces (half female). Each happy face is presented 10 times, and each angry face presented 80 times across trials, balanced across the different positions in the 3 × 3 matrix. This yielded 160 training trials (two blocks of 80 trials). Children had to mouse-click on the happy face within the 3 × 3 matrix of angry faces as quickly and as accurately as possible. The matrix disappeared after the child mouse-clicked on the correct face and the next trial began.
2450513|NCT03238118|Placebo Comparator|Attention Control Training|For attention-training-control, stimuli are 20 colour-pictures of individual birds and flowers used in prior visual-search tasks with children. Children mouse-clicked on the bird presented amongst flowers as quickly and accurately as possible. Other task parameters were similar to the attention-toward-positive task (160 training trials). No performance feedback is given in either condition.
2450515|NCT03238118|Placebo Comparator|Psychoeducation|Psychoeducation is an intervention that is characterized by informing the participant of their irritability symptoms. The goal is to teach participants how to understand their symptoms, explain their treatment modalities, recognize signs that may lead to a possible crisis, and provide tips and strategies on how to deal with irritability.
2450566|NCT03237689|Experimental|Hydrocortisone|Low dose hydrocortisone (10mg orally)
2450572|NCT03237689|Placebo Comparator|Placebo|Placebo tablets, made of starch 1500 powder
3153622|NCT00280033|Experimental|2|7.5 mcg plus aluminum hydroxide administered on days 0 and 28.
3190186|NCT00784940|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3190187|NCT00784953||1|Asthma patients who were partly controlled or uncontrolled, need to step up, or adjust dose of the controller medications to ICS/LABA
3190188|NCT00784966|Active Comparator|1|Two weeks etanercept post islet transplant
3190189|NCT00784966|Active Comparator|2|Two months etanercept treatment post islet transplant
3190190|NCT00784992|No Intervention|1|Endonasal DCR with silicone tubes (this is the control group since it is the standard procedure / gold standard, although the evidence base for the use of tubes is lacking, hence the need for this trial)
3190191|NCT00784992|Active Comparator|2|Endonasal DCR without silicone tubes (this is the 'intervention' arm)
3190192|NCT00785005||1|Females with Type 2 Diabetes
3190193|NCT00785005||2|Females without Type 2 Diabetes
3190194|NCT00785018|Active Comparator|C1-esterase inhibitor|Endotoxin 2ng/kg followed by C1- esterase inhibitor 100 U/kg infusion
3190195|NCT00785018|Placebo Comparator|Placebo|Endotoxin 2ng/kg followed by saline 0.9%(placebo) infusion
3190196|NCT00785031|Active Comparator|internet based intervention|
3190197|NCT00785031|No Intervention|usual care|Patients receive their usual care from their specialist or general practitioner.
3190198|NCT00785057||1|Hypertension patients with history of stroke
3190199|NCT00785057||2|Hypertension patients without history of stroke
3190200|NCT00785070||1|Perioperative
2449776|NCT03242902|Experimental|Light intensity 1|The light intervention includes exposure to white light (10.000 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
2449777|NCT03242902|Experimental|Light intensity 2|The light intervention includes exposure to white light (10-20 lux) at a distance of 45 cm for 30 minutes within the first half hour after awakening during 3 weeks and 4 days. This can be done while engaged in other activities, for example reading the newspaper or eating breakfast.
3153623|NCT00280033|Experimental|1|7.5 mcg plus MF59 administered on days 0 and 28.
3153624|NCT00280098|Experimental|single group|
2449894|NCT03241771|Experimental|Naloxone Navigator 1.0|Participants randomized to the Naloxone Navigator 1.0 arm will receive a link to the web-based resource. They will also receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
2449898|NCT03241771|No Intervention|Usual Care|Participants in the usual care arm will receive usual care from their health plan, pharmacy and physicians. As part of usual care, participants will have access to naloxone through standing orders (i.e., they can request it without a prescription under their usual pharmacy benefit).
2449960|NCT03241615||Neurogenic dysphagia|Patients with neurogenic dysphagia who will willing to participate in the study, being over the age of 18, normal cognitive function ([24 points according to the Mini Mental State Examination), suffering from dysphagia at least one month, and having clinically stable neurological disease will be included. Dysphagia evaluation will be performed.
2450048|NCT03241316||district-level representative rural survey|Approximately 4,800 adults in 60 villages across Thailand and Lao PDR to study health and antimicrobial resistance (AMR)-related behaviour in breadth.
2450049|NCT03241316||village-level social network census|Approximately 4,800 adults across 6 villages in rural Thailand and Lao PDR that are exposed to AMR awareness activities to study health behaviour within social networks.
2450066|NCT03240770|No Intervention|14 Day Tray + Sham|Trays worn at 14 day intervals + Sham
2450067|NCT03240770|Experimental|7 Day Tray + Sham|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
2450068|NCT03240770|Experimental|5 Day Tray + Sham|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ Sham"
2450069|NCT03240770|Experimental|7 Day Tray + VPro5|"Trays worn at 7 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
2450070|NCT03240770|Experimental|5 Day Tray + VPro5|"Trays worn at 5 day intervals (Deviation from Standard Tray Wear Time (14 Days))~+ HFV with the VPro5 device at 5 min/day"
2450150|NCT03240549|No Intervention|conventional therapy group|Treatment with previous regimen of combined chemotherapy
2450156|NCT03240549|Experimental|bevacizumab group|Adding bevacizumab to the previous regimen of combined chemotherapy
2450180|NCT03240120|Experimental|Dabigatran etexilate & Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed dabigatran 150mg twice daily from Day 6 onward till 6 months after underlying disease remission.
2450238|NCT03239821|Sham Comparator|Placebo - deflated balloon|
2450242|NCT03239821|Placebo Comparator|Placebo - inflated balloon|
2450244|NCT03239821|Active Comparator|Codeine - delfated balloon|
2450245|NCT03239821|Active Comparator|Codeine - inflated balloon|
2450294|NCT03239314|Active Comparator|group I|Group I (MS): received single shot 20 ml 0.5% isobaric bupivacaine + 2.0 ml normal saline solution injected into the adductor canal preoperatively.
2450297|NCT03239314|Active Comparator|group II|Group II (MD): received 20 ml 0.5% isobaric bupivacaine + 8.0 mg dexamethasone (2.0 ml) injected into adductor canal preoperatively.
2450357|NCT03239145|Experimental|Pembrolizumab + Trebananib|Part 1 Standard 3+3 Dose Escalation
2450358|NCT03239145|Experimental|Pembrolizumab + Trebananib (Melanoma)|Part 2 Dose Expansion
2450359|NCT03239145|Experimental|Pembrolizumab + Trebananib (Ovarian)|Part 2 Dose Expansion
2450360|NCT03239145|Experimental|Pembrolizumab + Trebananib (Colorectal)|Part 2 Dose Expansion
2450364|NCT03239145|Experimental|Pembrolizumab + Trebananib (Renal Cell Carcinoma)|Part 2 Dose Expansion
2450402|NCT03238755||Statin group|HIV-infected individuals receiving statin therapy for the duration of the study
2450405|NCT03238755||Placebo group|HIV-infected individuals receiving placebo therapy for the duration of the study
2450453|NCT03238456|Experimental|Intervention|The intervention entitled Motivating Pacifika Against Cigarettes and Tobacco (MPACT) was implemented for eight weeks starting on the quit date that the participant chose with their assigned coach during the baseline assessment. At the baseline assessment, each participant watched an introductory video that described the online smoking cessation program. The online program was accessed through the participant's Facebook account. The program included eight education modules and a forum. Participants also received automated daily text messages to provide support and encouragement during the quitting process.
2450460|NCT03238456|No Intervention|Control|Participants in the control group set a quit date within two weeks of their baseline assessment and watched an introductory video that described the smoking cessation program. They received one text message every other week over a period of eight weeks following the quit date. The messages were delivered by a web-based system not connected to the online intervention program. Participants were also given a handout listing local tobacco cessation and education resources, a link to a generic online smoking cessation program, a fact sheet on smoking and tobacco use among PI young adults, and a quit kit containing chewing gum and a stress ball.
2450497|NCT03238066|Experimental|Treatment Arm|"The physician can choose either HDR or PDR brachytherapy.~If HDR BT is chosen:~d1: hyperthermia (IHT) 60 minutes + 10Gy HDR brachytherapy (HDRBT) d22: IHT 60 minutes + 10 Gy HDRBT d43: IHT 60 minutes + 10 Gy HDRBT~If PDR BT is chosen:~d1-3: IHT 60 minutes + 30Gy PDRBT d29-31: IHT 60 minutes + 30Gy PDRBT"
3153625|NCT00280111|Experimental|1|116E AGMK
3153626|NCT00280111|Experimental|2|I321 AGMK
3153627|NCT00280111|Placebo Comparator|3|Placebo
3174407|NCT00623142|No Intervention|A|Patients in this arm were not treated with HBO prior to CABG
3174408|NCT00623142|Experimental|B|Patients in this arm were treated with HBO prior to CABG
3174409|NCT00623155|No Intervention|1|Control group
3153628|NCT00280215|Active Comparator|1|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker. Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
2449861|NCT03242564|Experimental|Active Device|"Active Device: Vevazz LED red light therapy system~Vevazz LED red light therapy system is a treatment regimen using the Vevazz LED device for fat removal using LED red light therapy."
3190201|NCT00785083|Experimental|1|
2450118|NCT03240614|Active Comparator|BMI <30 no lung disease|Patients with a BMI <30 with no lung disease
2450120|NCT03240614|Active Comparator|BMI <30 with lung disease|Patients with a BMI <30 with lung disease
2450123|NCT03240614|Active Comparator|BMI 30-35 with no lung disease|Patients with a BMI between 30 and 35 with no lung disease
2450127|NCT03240614|Active Comparator|BMI 30-35 with lung disease|Patients with a BMI between 30 and 35 with lung disease
2450130|NCT03240614|Active Comparator|BMI >35 with no lung disease|Patients with a BMI> 35 with no lung disease
2450134|NCT03240614|Active Comparator|BMI >35 with lung disease|Patients with a BMI> 35 with lung disease
2450251|NCT03239938|Experimental|Modern pain neuroscience approach|Modern pain neuroscience approach
2450257|NCT03239938|Active Comparator|Usual care evidence-based physiotherapy|Usual care physiotherapy
2450328|NCT03239392|Experimental|BNZ-1|IV PEGylated BNZ132-1-40
2450634|NCT03237546|Active Comparator|Serratus blocks|The serratus plane is interstitial tissue, below the serratus muscle. The injection of bupivacaine numbs the anterior branch of the thoracodorsal nerve. This technique allows for the medication to diffuse along the area of the serratus plane to provide numbing of that area. Upon completion of the block, the patient will be evaluated for extubation and emerged from general anesthesia if appropriate.
2450641|NCT03237546|Active Comparator|PCA-alone (no block)|All subjects will receive fentanyl intravenous patient controlled anesthesia pumps as part of standard care. The amount of fentanyl self-administered by the patient or given by a clinician during 24 hours following surgery will be compared amongst the two groups.
2450695|NCT03236883|Experimental|GEM plus GPBSC|Gemcitabine chemotherapy with mobilized GPBSC infusion:Gemcitabine 1000mg/m2 +GPBSC(2-3)*10^8/kg
2450697|NCT03236883|Other|Gemcitabine|
2450698|NCT03236883|Other|GPBSC|
2450726|NCT03236493|Experimental|PF-06700841|Multiple ascending doses of PF-06700841
2450728|NCT03236493|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
2450979|NCT03234855||LMD|Physician uses LMD during procedure.
2451040|NCT03234634|No Intervention|Group 1: patients with good collateral|
2451046|NCT03234634|Experimental|Group 2a, patient with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
2451050|NCT03234634|No Intervention|Group 2b, patients with poor collaterals|Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
2451127|NCT03234153|Experimental|Durvalumab and Tremelimumab|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
2451196|NCT03233282|Other|Cognitive Fatigability|
2451198|NCT03233282|Other|Physical Fatigability|
2451357|NCT03232216|Experimental|Vitamin D3 supplementation. Deficiency.|Vitamin D3 50.000 UI in each packet of powder for solution. Two packets every week for 5 weeks.
2451358|NCT03232216|Placebo Comparator|Placebo. Deficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 5 weeks.
2451359|NCT03232216|Experimental|Vitamin D3 supplementation.Insufficiency|Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
2451360|NCT03232216|Placebo Comparator|Placebo. Insufficiency.|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution. Two packets every week for 3 weeks.
3153629|NCT00280215|Placebo Comparator|2|Patients will take placebo for 24 months.
3153630|NCT00280228|Experimental|1|Home Based Treatment
2451452|NCT03231423|Experimental|DRAIN PLACEMENT|Effects of drainage
2451458|NCT03231423|No Intervention|DRAIN NOT PLACED|Effects of not using drain
2451539|NCT03230929|Experimental|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and monitor the monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring.
2451600|NCT03230578||Pharmacists|Actively employed and currently licensed and working in rural counties in New Mexico.
2451601|NCT03230578||Women|Reproductive age, 18-45 years old from rural counties in New Mexico and who are fluent in English.
2451714|NCT03229915|Active Comparator|Trauma-exponsed control|Will receive Cognitive Processing Therapy
3153631|NCT00280228|Active Comparator|2|Treatment as Usual
3153632|NCT00280280|Experimental|1|This study will explore the safety and effectiveness of Botox versus baclofen in treatment subjects with upper-limb spasticity due to neurological damage or a stable neurological disorder. Subjects will be randomized to one of two treatment groups: intramuscular Botox plus oral placebo or intramuscular placebo plus oral baclofen.
3153633|NCT00280319|Experimental|IPT arm|interpersonal psychotherapy for groups (IPT-G). this consists of psychotherapy provided to participants in a group format.
3153634|NCT00280319|Experimental|CP arm|Creative Play therapy consists of play activities provided to participants in groups.
3153635|NCT00280319|No Intervention|control|those who are wait-list controls
3153636|NCT00280332||A|colonic adenoma
3153637|NCT00280332||B|colonic without adenoma
3153638|NCT00280462|Active Comparator|1|Nifedipine
3153639|NCT00280462|Active Comparator|2|L-Arginin
3153640|NCT00280462|Placebo Comparator|3|Placebo
3153641|NCT00280475|Active Comparator|1|Device: Whole brain radiation therapy arm
3153642|NCT00280475|Experimental|2|Device: Salvage stereotactic radiosurgery arm
3174410|NCT00623155|Experimental|2|Test group
2449832|NCT03242447|Experimental|e-Practice Self-Regulation (e-PS-R)|e-Practice Self-Regulation (e-PSR) is the treatment condition. e-PS-R is a 'blended learning' intervention, combining online and face-to-face instruction. e-PS-R aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
2449833|NCT03242447|Active Comparator|Video Health Group|The Video Health Group is the control counterfactual condition. Youth assigned to the control group will view a video on a non-sexual health topic (the hazards of smoking).The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes. The informational video uses both narration and interviews to educate viewers on the dangers that cigarettes pose.
3190202|NCT00785083|Placebo Comparator|2|
3190203|NCT00785096||Patients|Patients who admit for a minor or major surgical intervention
3190204|NCT00785096||Nurses|Medical staff of the University Hospital of Zurich
2450206|NCT03240263|Experimental|Inspiratory muscle training|High intensity inspiratory muscle training
2450207|NCT03240263|Sham Comparator|Sham endurance training|Sham inspiratory muscle training at low intensity
2450233|NCT03239704|Experimental|Telemedicine Follow-Up and Telemedicine Monitoring|
2450234|NCT03239704|Active Comparator|Minimal Intervention|
2450318|NCT03239444|Other|Assigned Intervention|Device: Foresight ICE System The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird console. The Foresight ICE system will be used in guiding the physician during the trans-septal puncture and provide physiological information during the course of the procedure.
2450394|NCT03239054|Experimental|Study Group|Participants in the study group will complete the Parmed-X Pregnancy form and be provided with a prescription for exercise.
2450398|NCT03239054|Other|Control Group|"The control group will be provided with the ACOG Pamphlet entitled Exercise during pregnancy and will be encouraged to become physically active during their pregnancy. They will receive routine care as scheduled."
2450452|NCT03238469|Experimental|Microwave ablation|One-sided single microwave ablation (MWA) treatment in one axillary region with a miraDry device.
2450459|NCT03238469|No Intervention|No microwave ablation|Lesion intervention in the non-MWA treated contralateral axilla consists of once daily topical clindamycin 1% lotion.
2450518|NCT03238105|Experimental|Intense pulsed light|The application model will be 3 months of treatment with monthly interval between sessions, totaling 3 sessions. The parameters are as follows: frequency 15 J / cm2, pulse duration 15 ms, 1-2 passed as erythema. Eye protection for IPL will be used during all sessions.
2450519|NCT03238105|Experimental|Peeling of 10% thioglycolic acid|In the first session the acid will be applied for three minutes, and with each new session the duration time with the product will increase in three minutes, so that in the last session the duration of the application will be 9 minutes. For the application of the product will be used flexible cotton rod, sparing the region just below the eyelids of the lower eyelid 0.5cm, therefore, no other measure is necessary for eye protection. After the given time, the substance will be removed with lint with 0.9% saline solution.
2450562|NCT03237663|Experimental|One enteric capsule|
2450568|NCT03237663|Experimental|Two enteric capsule|
2450597|NCT03237429||cancer patients|The first study population will represent patients scheduled for surgery for a new diagnosed cancer pathology
2450598|NCT03237429||non-cancer patients|The second study population will represent patients scheduled for surgery not for cancer disease
3190205|NCT00785096||Physicians|Medical staff of the University Hospital of Zurich and other institutions
3190206|NCT00785109|Experimental|1|100 patients daily additional intake of 2mg vitamin k1
3190207|NCT00785109|Placebo Comparator|2|100 patients no additional intake of vitamin K
3190208|NCT00785135|Active Comparator|Standard (Treatment)|
3190209|NCT00785135|Sham Comparator|Placebo (control)|
3190210|NCT00785148|Experimental|1|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)
3190211|NCT00785174|Active Comparator|continuous positive airway pressure|respiratory assistance
3190212|NCT00785174|Active Comparator|NIPSV|respiratory assistance using face mak and ventilator to provide inspiratory pressure support and positive end expiratory pressure
2450801|NCT03235856||Keratoconus patients|This study involves a retrospective analysis of data recorded during routine clinical follow-up of keratoconus patients. As such, the impact for the patient is minimal as no additional tests need to be performed
2450869|NCT03235700|Experimental|Adenosine followed by nicorandil|
2450871|NCT03235700|Experimental|Nicorandil followed by adenosine|
3190213|NCT00785200|Experimental|Chlorhexidine|Approximately 500 detainees housed in approximately 23 detention tanks will be enrolled and receive 2% chlorhexidine-soaked disposable wash cloths (Sage Products, Inc.) to clean their skin on Mondays, Wednesdays, and Fridays for 6 months. Newly arrived detainees in the tanks will be offered enrollment in the study on a biweekly schedule.
2451035|NCT03234569|Experimental|sonoHSG|This is the research procedure and it will be added onto the standard of care procedure for all subjects.
2451111|NCT03233815||Inhaled anesthesia (Sevoflurane)|Patients undergoing cardiovascular surgery with inhaled anesthesia with sevoflurane.
3190214|NCT00785200|Placebo Comparator|Water|Approximately 500 detainees in approximately 23 detention tanks will receive water-soaked wash cloths to clean their skin each Monday, Wednesday, and Friday for a 6-month period. If detainees newly arrive to these study tanks, they will be offered enrollment on a biweekly schedule.
3190215|NCT00785200|No Intervention|Usual care|Approximately 500 detainees in approximately 23 detention tanks will be enrolled. These detainees will not receive any intervention. They will be followed for 6 months, and newly arrived detainees will be offered enrollment on a biweekly schedule.
3190216|NCT00785226|Experimental|RDEA119 with Sorafenib|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day and sorafenib from 400 mg/day to 800 mg/day.
3190217|NCT00785252|Experimental|1|EZIO
3190218|NCT00785252|Experimental|2|Central line
3190219|NCT00785265|Experimental|Group Based|60-minute group session involving other study patients who have been assigned to this condition and their guests.
3190220|NCT00785265|Active Comparator|Home-Based|60-minute educational intervention in their home, which will be delivered by an African American health educator.
2449925|NCT03241888|Active Comparator|MA|Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2449929|NCT03241888|Active Comparator|LNG-IUS|Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2449931|NCT03241888|Experimental|MA+LNG-IUS|Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.
2449951|NCT03241433|Active Comparator|High intensity interval training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 3 X 20-second sprint interval cycling -as fast as possible at 90-95% peak power low intensity- 2 X 2 minute cycling at slow pace 50W
2449956|NCT03241433|Active Comparator|Moderate intensity continuous training|Exercise training will be conducted 3 times per week using cycle ergometers at commercial fitness facilities for 12 weeks 2 minute warmup/3 minute cooldown- at 50W Intensity- 45 minutes of continuous cycling at 45-60% peak power
2449962|NCT03241433|Active Comparator|No exercise|No excercise training will be done
2450039|NCT03241212|No Intervention|Control|"At baseline enrollment: participants will be asked to fill out a demographic survey, the MWIKAD survey and the SMOD-A survey. HbA1c, frequency of Blood Glucose (BG) checks and percent of glucose values above, within and below the target range will be extracted from chart review.~Surveys (with the exception of demographics) and chart extraction will be repeated at 3 months and 6 months post enrollment."
2450046|NCT03241212|Experimental|Texting|"Participants will be asked to complete the same surveys on the same timeline as above. The texting group will be asked to provide their cell phone number to the texting software.~From baseline appointment to 26 weeks post enrollment, participants will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen."
2450087|NCT03240887|Experimental|Peer Group Connection (PGC)|Ninth-grade participants are assigned to small groups of 10-14 students that attend weekly peer group outreach sessions led by older peer leaders.
2450088|NCT03240887|No Intervention|Business as usual|Ninth grade students remain in their regularly scheduled school classes or activities during PGC outreach times.
3153643|NCT00280488|Active Comparator|1) MI with SO|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with inclusion of a significant other (SO) in prolonged, intensive alcohol treatment.
3153644|NCT00280488|Active Comparator|2) MI with patient only|Motivational Interviewing (MI), a brief, directive, non-confrontational intervention, with the individual patient
3153645|NCT00280488|Active Comparator|3) Assessment only|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
2450315|NCT03239236|Experimental|t-RSI|"Rapid sequence induction t-RSI. Traditional rapid sequence induction with Anesthetics. Preoxygenation via face mask, no ventilation with no PEEP until intubation. Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2450320|NCT03239236|Experimental|m-RSI-PEEP|"Rapid sequence induction m-RSI-PEEP. Modified rapid sequence induction with Anesthetics and PEEP. Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2450322|NCT03239236|Experimental|m-RSI-vent|"Rapid sequence induction m-RSI-vent. Modified rapid sequence induction with Anesthetics and intermittent ventilation. Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2450323|NCT03239236|Experimental|m-RSI-vent-cric|"Rapid sequence induction m-RSI-vent-cric. Modified rapid sequence induction with Anesthetics and intermittent ventilation and cricoid pressure. Same as modified rapid sequence induction with intermittent ventilation arm with additional cricoid pressure.~Aspiration of gastric air via nasogastric tube at the beginning of laparoscopy. Impression of gastric inflation at laparoscopy will be assessed by taking images of the stomach at the beginning of laparoscopy.~Arterial blood gas samples will be taken at different time points."
2450383|NCT03238768|Experimental|Enhanced Nutrition|Infants randomized to the study protocol will start on higher initial amounts of calories, proteins and fats. They will also undergo faster increases of these nutrients during their first week of life.
2450388|NCT03238768|Active Comparator|Standard Nutrition|Infants randomized to the standard nutrition protocol will start on standard amounts of calories, proteins and fats per the usual NICU routine. They will also undergo standard increases of these nutrients during their first week of life.
2450451|NCT03238508||Immediate stenting group|Conventional stenting immediate after the re-opening of infarct-related artery during primary PCI
2450456|NCT03238508||Deferred stenting group|Elective stenting following cooling down of infarct- related artery for several days after restoration of epicardial coronary blood flow during primary PCI
2450501|NCT03238079|Experimental|Open-Label 10% IGIV|"IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions.~The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo."
2450586|NCT03237754|Experimental|Real Neurostimulation|4 weeks of neurostimulation (using tDCS)
2450590|NCT03237754|Sham Comparator|Sham Neurostimulation|4 weeks of sham Treatment with the same device used for real neurostimulation
2450620|NCT03237247||Benign|cases with benign biliary stricture
2450621|NCT03237247||Calcular OJ|cases with calcular extrahepatic cholestasis
2449944|NCT03241459|Experimental|Surmodics SurVeil DCB|Surmodics SurVeil Drug-Coated Balloon is an investigational device coated with paclitaxel.
2449946|NCT03241459|Active Comparator|Medtronic IN.PACT Admiral DCB|
2450076|NCT03240874|Experimental|Usability - Focus Group|"Mobile Application Usability Testing: SweetMama Focus Groups~Focus groups: Women with a confirmed intrauterine pregnancy or postpartum until 12 weeks after delivery with gestational diabetes mellitus or type 2 diabetes mellitus will be recruited to undergo a single 1-hour focus group."
2450079|NCT03240874|Experimental|Usability - Individual Testing|"Mobile Application Usability Testing: SweetMama Individual Testing~Individual testing: Women with a confirmed intrauterine pregnancy (any gestational age) or who are up to 4 weeks postpartum, with gestational diabetes mellitus or type 2 diabetes mellitus, will be recruited to use SweetMama for 2 weeks and provide feedback."
2450082|NCT03240874|Experimental|Feasibility - Pilot Randomized Trial, SweetMama arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, SweetMama arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to receive SweetMama care will be oriented to use of SweetMama and will then use the intervention (messages, library, goal setting, and appointment reminders) throughout pregnancy and the first 8 weeks postpartum, at which point they will undergo surveys and interviews."
2450084|NCT03240874|No Intervention|Feasibility - Pilot Randomized Trial, usual care arm|"Mobile Application Feasibility Testing: SweetMama Pilot Trial, usual care arm~Women recruited to the pilot RCT phase will enroll in the study upon initiation of prenatal care for diabetes, which could be early in pregnancy at the time of first prenatal visit, or at a later point if they have transferred care to this site. Women randomized to usual care will be undergo entry and exit surveys (at 6-8 weeks postpartum) but will not interact with SweetMama."
2450145|NCT03240471|Experimental|One week of plaster cast|One week of plaster cast after a non-reduced distal radius fracture.
2450153|NCT03240471|Other|Control; four-five weeks of plaster cast|Four-five weeks of plaster cast after a non-reduced distal radius fracture, usual care.
2450183|NCT03240107|Active Comparator|levator resection|20 patients who will undergo levator aponeurosis resection technique
2450186|NCT03240107|Active Comparator|levator tucking|20 patients who will undergo two point fixation levator tucking technique
2450229|NCT03239808|Experimental|Experimental group|76 patients who start RRT with the incremental HD regimen.
2450230|NCT03239808|Active Comparator|Control group|76 patients who start RRT with the conventional HD (3 sessions per week)
3190221|NCT00785265|No Intervention|Standard Care|60-minute individual session with an African American health educator.
3190222|NCT00785278||1|Able-bodied participants: Able-bodied individuals will be asked to propel a wheelchair at a self-selected speed for a period of time during which data will be collected on their propulsion biomechanics. It is assumed, for the purpose of the study, that un-learned able-bodied individuals learning to propel a wheelchair reflect newly injured individuals who are just getting accustomed to a new chair.
3190223|NCT00785278||2|Participants with paraplegia: Individuals who are at least 1-year post injury and have used a manual wheelchair as their primary means of locomotion during this time, will be assumed to be, for the purpose of this study, experienced wheelchair users.
3190224|NCT00785304||Traumatic Brain Injury|Active Duty military blast-related TBI patients
2450475|NCT03238638|Experimental|Acquired Resistance Cohort and Suboptimal Benefit Cohort|"Patients will be divided into two cohorts. Investigators anticipate 15 patients per cohort.~Cohort 1: Acquired Resistance Cohort~Treat upon emergence of acquire resistance~Prior benefit from an9-PD-1/PD-L1 therapy defined as a. preior response, and/or b. greater than or equal to 5 months of stable disease~Progressive disease on recent scans~Intercurrent therapy is allowed~Cohort 2: Suboptimal Benefit Cohort~Treat subop. mal response/benefit, BEFORE emergence of acquired resistance~Prolonged stable disease greater than or equal to 5 months OR Subop9mal response (greater than 10% and less than 50%)~Ongoing stable disease on recent scans~Both cohorts will receive pembrolizumab and epacadostat."
2450503|NCT03237962|Experimental|High Flow Nasal Cannula|Patients are randomly assigned into High flow nasal cannula group for the exercise training
2450509|NCT03237962|Experimental|Nasal Cannula|Patients are randomly assigned into nasal cannula group for the exercise training.
2450570|NCT03237806|No Intervention|Baseline|In this phase, patients were sedated to the level of Ramsay 6 before Deep sedated or Light sedated
2450574|NCT03237806|Experimental|Deep sedation|In this Arm, patients were sedated to the level of Ramsay 5(Deep sedated) by Midazolam IV continuously
2450575|NCT03237806|Experimental|Light sedation|In this Arm, patients were sedated to the level of Ramsay 3(Light sedated)by Midazolam IV continuously
2450603|NCT03237325|Experimental|SGX942|Patients are randomized 1:1 active/placebo.
2450605|NCT03237325|Placebo Comparator|Placebo|Patients are randomized 1:1 active/placebo.
3190225|NCT00785304||Other Injury Control|Active duty military patients with other injuries but no TBI
3190226|NCT00785317|Experimental|Angemin|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP
2450791|NCT03236051|Experimental|multimodal analgesia|Patients received multimodal analgesia after laparoscopic gastrectomy .
2450794|NCT03236051|Active Comparator|PCIA analgesia|Patients received PCIA analgesia after laparoscopic gastrectomy.
2450838|NCT03235609|Active Comparator|Fentanyl|Group I (FP): will receive 0.5 µg/ kg fentanyl + 2 mg/ kg propofol IV.
2450839|NCT03235609|Active Comparator|Ketamine|Group II (KP): will receive 0.5 mg/kg ketamine + 2 mg/kg propofol IV.
2450899|NCT03235375|Experimental|Group 1: End Stage Renal Disease (ESRD)|Subjects with CrCl <20ml/min will receive MEDI0382 administered subcutaneously
2450900|NCT03235375|Experimental|Group 2: Severe and ESRD Subjects|Subjects with CrCl >20 and < 30 ml/min will receive MEDI0382 administered subcutaneously
2450901|NCT03235375|Active Comparator|Group 3: Healthy Subjects|Subjects with CrCl >90 ml/min will receive MEDI0382 administered subcutaneously
3190227|NCT00785317|Active Comparator|Activelle|1 mg of oral E2 in continuous combination with 0.5 mg of NETA
3190228|NCT00785330|Other|A|Patients receiving no rituximab as GVHD prophylaxis after allogeneic SZT and only standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
2449950|NCT03241446|Experimental|50 ug Tilmanocept|Single dose of 50 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2449955|NCT03241446|Experimental|200 ug Tilmanocept|Single dose of 200 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2449961|NCT03241446|Experimental|400 ug Tilmanocept|Single dose of 400 ug tilmanocept radiolabeled with 10 mCi technetium Tc99m
2450011|NCT03241303|Experimental|Acarbose|50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose
2450020|NCT03241303|Placebo Comparator|Placebo Oral tablets|180 mg. 2 weeks.
2450029|NCT03241303|Experimental|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
2450040|NCT03241303|Placebo Comparator|Placbo Saline|9 mg/ml placebo saline infusion on experimental day.
2450073|NCT03240757|Active Comparator|Breakfast without exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
2450075|NCT03240757|Experimental|Breakfast with exercise|Each subject of the same arm underwent 2 interventions: breakfast with/without exercise
2450163|NCT03240562|Sham Comparator|IV-PCA group|no block performing, only use intravenous patient controled analgesia(IV-PCA)
2450165|NCT03240562|Experimental|SAPB group|serratus anterior plane block(SAPB) and intravenous patient controled analgesia(IV-PCA)
2450187|NCT03240042|Experimental|Nasoendo group|Participants received nasotracheal intubation under general anesthesia for the anterior cervical spine surgery.
2450193|NCT03240042|Other|Oroendo group|Participants received orotracheal intubation under general anesthesia for the anterior cervical spine surgery.
2450220|NCT03239782|Experimental|Metabolically unhealthy|"Subjects classified as metabolically unhealthy (MONW) go on to participate in a calorie restriction intervention.~MONW subjects will participate in a supervised weight loss program to help ensure they are under a similar weekly energy deficit and achieve a 5 % weight loss at approximately the same time. Participants will be prescribed a reduced-calorie diet (~500 kcal/d below their needs for weight maintenance), and will be instructed not to change their physical activity habits, in order to achieve a weekly weight loss of ~0.5 kg.~The macronutrient composition of the diet will be the same for all groups (55-60 % of energy from carbohydrate, 15-20 % from protein, and 20-30 % from fat); no vitamins or other nutritional supplements will be given."
3153646|NCT00280501|Active Comparator|1|Quetiapine
3153647|NCT00280501|Active Comparator|2|Sulpiride
2450310|NCT03239275|Experimental|Labial biocreative therapy group|"Upper six anterior teeth will be bonded (0.018-inch slot brackets), leveled and aligned until reaching 0.017*0.025 stainless steel archwire.~Right and left bracket head mini-screw (1.6*8 mm) will be inserted under local anaesthetic into the inter-radicular space between upper second premolar and first molar at the level of mucogingival junction. Crimpable hooks (10 mm) will be crimped onto the archwire between the upper lateral incisor and canine. 200 grams retraction force will be applied using NiTi coil springs from the hooks to the minscrew on both sides. Overlay reverse curve 0.016*0.022 NiTi will be inserted posteriorly into the mini-screw and ligated anteriorly to the archwire in the midline."
2450312|NCT03239275|Active Comparator|Lingual biocreative therapy group|En masse retraction of the six anterior teeth was accomplished using a lingual retractor bonded on to the lingual surface of the 6 anterior teeth, C-palatal plate fixed near the median palatal suture with 3 micro-screws, and Nickel Titanium (Ni-Ti) closing coil springs to apply a force of 200 g per side (total 400 g) directly from the C-plate to the lingual retractor.
2450399|NCT03239041|Active Comparator|Intervention Arm|"The intervention group will have access to the services of a social navigation team. The social navigation team will consist of trained community health liaisons, a clinician and a social worker.~The social navigation team will function as follows:~The research assistant will then instruct the community health intern to review the results of the completed computerized survey. The community health intern will review the results, create a plan of action, i.e. specific referrals to community agencies and next steps needed by the caregiver and or adolescent (e.g., documents to gather, appointments to make, etc.), following pre-developed protocols for each risk area. Each plan will be reviewed with the social worker prior to presentation to the family. Each family will also receive a packet of community resources relevant to each social domain covered in the screening survey, similar to that provided to the enhanced usual care group."
2450403|NCT03239041|No Intervention|Enhanced Usual Care Arm|The enhanced usual care arm will only receive printed information regarding community resources.
2450533|NCT03237988|Active Comparator|Sequence ABC|100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed).
2450534|NCT03237988|Active Comparator|Sequence BCA|100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted).
2450536|NCT03237988|Active Comparator|Sequence CAB|100 mg CPI-444, given orally as a 1 × 100-mg tablet, 30 minutes after the start of a high-fat breakfast (fed); 100 mg CPI-444, given orally as a 1 × 100-mg capsule, after an overnight fast of at least 10 hours (fasted); 100 mg CPI-444, given orally as a 1 × 100-mg tablet, after an overnight fast of at least 10 hours (fasted).
2450599|NCT03237533|Active Comparator|Study Group|in this group patients will be treated with Dexamethasone local application
2450600|NCT03237533|Active Comparator|Control Group|in this group patients will be treated with dexamethasone, doxycycline and nystattin
2450666|NCT03237091|Active Comparator|sham-control|
2456880|NCT03194724||Low vitamin A exposure|No intervention
3153648|NCT00280501|Placebo Comparator|3|Placebo
3153649|NCT00280553|No Intervention|patient controlled analgesia (PCA) only|
3153650|NCT00280553|Other|PCA and pump with saline infusion for up to five days|
3153651|NCT00280553|Other|PCA and bupivicaine infusion for up to five days|
3153652|NCT00280579||Cases|Cases would have had their blood cyanide concentration measured
3153653|NCT00280592|Placebo Comparator|Placebo|
3153654|NCT00280592|Experimental|Cranberry|Cranberry
2449952|NCT03241563|Active Comparator|without triamcinolone|sodium Deoxycholate without triamcinolone
2449958|NCT03241563|Active Comparator|with triamcinolone|sodium Deoxycholate with triamcinolone
2450018|NCT03241199|Experimental|Imatinib Mesylate|imatinib 400mg daily
2450094|NCT03240939|Active Comparator|Dutasteride&Tadalafil|Dutasteride 0.5 mg capsule and Tadalafil 5 mg Tablet, single dose
2450099|NCT03240939|Experimental|YY-201|YY-201 capsule, singe dose
2450158|NCT03240380|Experimental|joint crisis plan|Subjects benefit from a joint crisis plan and the process of its negotiation in addition to the usual in-patient or out-patient care.
2450161|NCT03240380|Active Comparator|crisis card|Subjects benefit from a crisis card in addition to the usual in-patient or out-patient care.
2450218|NCT03240029|Experimental|Children in cancer remission|Children in cancer remission sent to ordinary schools: primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
2450219|NCT03240029|Other|Control children|Children (not in cancer remission) sent to ordinary schools (age and sex matched): primary (3rd, 4th, 5th grade) and middle (6th, 7th grade) schools.
2450272|NCT03239600|Experimental|Part I & II: GSK2618960 2 milligram per kilogram (mg/kg)|GSK2618960 2mg/kg will be administered intravenously (IV) with Methotrexate (MTX)
2450276|NCT03239600|Placebo Comparator|Part II: Placebo|Placebo will be administered IV with MTX
2450329|NCT03239249|Experimental|Intervention group: IKO-model (20 schools)|Schools randomized to experimental group will implement the IKO-drop-out prevention intervention. Each county have a project leader responsible for following up the implementation. The model is described in a manual, that schools should follow.
2450334|NCT03239249|Active Comparator|Treatment as usual (22 schools)|Schools randomized to control group will work as previously with their drop-out prevention. This include various activities, but they are not systematic as in the IKO-model.
2450412|NCT03238716|Experimental|Electric DN, NM Re-ed, Exercise|
2450415|NCT03238716|Active Comparator|NM Re-ed and Exercise|
2450441|NCT03238404|Experimental|NAC group|Patients will receive neoadjuvant chemotherapy (NAC) before the gastrectomy and ERAS.
2450442|NCT03238404|Active Comparator|Surgery alone group|Patients will not receive NAC before the gastrectomy and ERAS.
2450532|NCT03238170|Experimental|MR-Simulation|Patients will have 1 MRI scan appointment, using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan. The MR scan will be performed in the radiotherapy treatment position.
2450563|NCT03237598||male|young (≥18 and ≤45), adult (45~60), and old (>60) , n=1960
2450569|NCT03237598||female|young (≥18 and ≤45), adult (45~60), and old (>60) , n=2348
2450615|NCT03237416|Experimental|BAY1841788/Healthy subjects|Period 1: intake of Midazolam and Dabigatran etexilate at day 1 followed by Period 2: intake of Darolutamide at days 1-11 (twice daily), intake of dabigatran etexilate at days 3 and 9, intake of Midazolam at day 9
2450638|NCT03237052|Experimental|model|model aided decision
2450643|NCT03237052|Active Comparator|non-model|real-world psychiatrist decision
2450687|NCT03236831|Other|Subjects Undergoing Prospective VAD|Patients undergoing VAD placement. The investigators will provide clinical recommendations to the subject's primary care provider.
2450732|NCT03236558|Experimental|Patients with diabetes|T1D patients with blood collection
2450812|NCT03236207|Experimental|Test infant formula|Test non-commercial extensively hydrolyzed infant formula with HMOs
2450818|NCT03236207|Active Comparator|Control infant formula|Control non-commercial extensively hydrolyzed infant formula without HMOs
2450853|NCT03235466|Active Comparator|Voice Therapy|(Group 1) will undergo active training in behavioral cough suppression and laryngeal relaxation exercises, but will not receive HRVB. Traditional cough suppression and laryngeal relaxation exercises include pursed lip breathing, swallowing (water, lozenge, gum, ice chips), sustained semi-occluded voicing, discussion and mitigation of triggers, maintaining a cough journal, addressing muscle tension dysphonia if indicated, and developing prophylaxis suppression and laryngeal relaxation based on stimulability. Participants in Group 1 will receive handwritten guidance indicating exercises to practice at home.
2450856|NCT03235466|Active Comparator|Voice Therapy and Heart Rate Variability Biofeedback|Voice therapy as described in Arm 1. HRVB involves measure respiratory rate, heart rate, body temperature and skin conductance. Participants are guided through reduced breathing rate until a resonant frequency is attained. HRVB breathing simulates resonance between the baroreflex rhythm and respiration based rhythm, increasing heart rate variability and baroreceptor sensitivity. Evidence suggests HRVB improves autonomic regularity. We propose this novel modality to address centrally regulated hypersensitivity that perpetuates coughing.
2450859|NCT03235466|Active Comparator|Heart Rate Variability Biofeedback|HRVB as indicated in Arm 2. No instruction will be provided for cough suppression, laryngeal desensitization, voice tasks or hygiene that traditionally reduces cough frequency and severity. This is the experimental arm.
2450894|NCT03235193|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the CHH electronic health record.
2450896|NCT03235193|Active Comparator|Without Insight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the CHH electronic health record.
2450955|NCT03235037|Other|Sinemet|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
2451010|NCT03234543|Experimental|Remote Ischemic Conditioning|The RIC intervention consists of 5 minutes of inflation of a pneumatic tourniquet placed mid-thigh followed by 5 minutes of deflation, repeated for 3 cycles. The pressure used will be 250 mmHg for the pre-operative intervention. Subsequent tourniquet pressures will be 50 mmHg above the patient's systolic blood pressure.
2451011|NCT03234543|Sham Comparator|No Remote Ischemic Conditioning|The No RIC group will receive a sham intervention at all the same time points. The thigh tourniquet will be inflated to only 20 mmHg (to mask the intervention from the subject).
2451373|NCT03232125|Placebo Comparator|Placebo group|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
2449959|NCT03241602|Active Comparator|group of Pulmonary recruitment & Intraperitoneal libocai|
2449968|NCT03241602|Active Comparator|Group of Intraperitoneal lidocaine|
2449975|NCT03241602|Active Comparator|Group of pulmonary recruitment|
2449980|NCT03241602|No Intervention|group receive passive exsufflation through port|
2450038|NCT03241160||Children with cerebral palsy|Children with a diagnosis of spastic cerebral palsy aged between 2 to 12 years who will be referred by pediatric neurologists will be included. Children under the age of 24 months, and used any medicine and/or oral appliances that could affect the chewing performance, will be excluded. Chewing evaluation will be performed.
2450095|NCT03240900|Experimental|Electrical Stimulation Breast|Breast that will receive 1 hour of intraoperative electrical stimulation
2450098|NCT03240900|Placebo Comparator|No Electrical Stimulation Breast|The contralateral breast of the patient will receive no electrical stimulation
2450139|NCT03240393|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID
2450143|NCT03240393|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mgBID
2450148|NCT03240393|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
2450178|NCT03240146|Active Comparator|Study Group|Subjects in this group will receive an active pulsed shortwave therapy device.
2450179|NCT03240146|Placebo Comparator|Control Group|Subjects in this group will receive a placebo pulsed shortwave device that it does not emit energy.
3190229|NCT00785330|Experimental|B|rituximab in addition to standard GVHD prophylaxis
3190230|NCT00785343|Active Comparator|Conventional Treatment|
2450362|NCT03239080|Active Comparator|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
2450365|NCT03239080|Placebo Comparator|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
2450397|NCT03238794|Active Comparator|Roux-En-Y Gastric Bypass (RYGB)|Participants will have elected to have RYGB surgery per standard of care.
2450401|NCT03238794|Active Comparator|Low-calorie Diet|Participants will have a low-calorie diet prescribed by a registered dietitian.
2450504|NCT03238235|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2450507|NCT03238235|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
2450556|NCT03237767|Experimental|Moderate vs. High-intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (MIE completed first)
2450558|NCT03237767|Experimental|High-intensity vs. Moderate intensity exercise (randomised)|Compare the effects of a single session of moderate continuous exercise versus high-intensity interval exercise (HIIE completed first)
2450626|NCT03237468|Experimental|Exercise arm|This arm will perform twice weekly neck strengthening exercises.
2450717|NCT03236987|Active Comparator|Clarithromycin 1000 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Clarithromycin (500 mg twice daily)"
2450718|NCT03236987|Experimental|Azithromycin 250 MG|"The patient will received a combination of 3 antibiotics :~Rifampicin (10mg/kg once daily)~Ethambutol (15 to 20 mg/kg once daily)~Azithromycin (250 mg once daily)"
2450799|NCT03236155|Active Comparator|1 prescription|Receives 90 pills in single prescription at discharge from hospital
2450816|NCT03236155|Active Comparator|3 prescriptions|Receives 30 pill prescription at discharge from hospital. Two refills available if requested.
2450837|NCT03235570|Experimental|Pemigatinib|Part 1 is an open-label dose-escalation design based on observing each dose level for a period of 21 days. Part 2 will evaluate the recommended dose determined in Part 1.
2451008|NCT03234712|Experimental|ABBV-321|ABBV-321 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached and a recommended Phase 2 dose is determined.
2451068|NCT03234322|Experimental|Intervention group|In the intervention group the routine health check is expanded by usage of a non-invasive diabetes risk score.
2451071|NCT03234322|No Intervention|Control group|In the control group the routine health check is conducted.
2451147|NCT03233711|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
2451152|NCT03233711|Other|Arm B (clinical observation)|Patients undergo observation for up to 6 months.
2452076|NCT03227627|Experimental|VitalStim|"One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®. VitalStim® therapy involves the placement of electrodes to the muscles of the throat that is attached to a device that provides electrical stimulation. The intensity will be increased according to the subject's tolerance and when a therapeutic level is reached. Signs of reaching therapeutic level include changes in audible quality of swallows, triggers of swallows, and changes in quality of voice. This therapy is to be performed by a VitalStim® certified practitioner."
2452077|NCT03227627|Active Comparator|Traditional therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
2452150|NCT03227237||Case group|Introduction was given about research and researcher to participants. Got the assent from participants, consent from parents and collected baseline data (demographic variable, specific IPR variable) from the participants. Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants.Participants were asked to fill out IPR related information of pre delinquent period with paper & pencil mode of technique. It took for each group of participants about 40 minutes. Collected data regarding conduct variables from parents with interview technique. On each day 8-16 participants were covered.
3190231|NCT00785343|Experimental|Robotic and Conventional Therapy|
3190232|NCT00785369|Other|1|Device: In vivo reflectance confocal microscopy of pigmented lesions in vivo
3190233|NCT00785382|Placebo Comparator|1|
3190234|NCT00785382|Experimental|2|
3190235|NCT00785395|Experimental|A|
3190236|NCT00785408|Experimental|1|
2449986|NCT03241680|Active Comparator|CIN 2-3/Liquid Based|Patients with high grade cervical intraepithelial neoplasia and will have anal citology performed by liquid based method
2450012|NCT03241186|Experimental|Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV|"Cycles 1-4: Ipilimumab (1 mg/kg) + Nivolumab (3 mg/kg) IV Day 1 of each Cycle Each Cycle = 21 days~Cycles 5-15: Nivolumab IV 480 mg Day 1 of each Cycle Each Cycle = 28 days"
3153655|NCT00280631|Experimental|1|Dose Escalation Study of TLK199 Tablets From 200 mg Per day To 6000 mg Per Day
3153656|NCT00280657|Experimental|Arm 1|
2450209|NCT03239912|Experimental|Twin-block group|Functional treatment will be applied using the Twin-block appliance.
2450210|NCT03239912|Experimental|Twin-block combined with low level laser|Functional treatment will be applied using the Twin-block appliance combined with low level laser.
2450269|NCT03239652|Experimental|Taiwan ACE Beads microspheres|The maximum use of dosage will not exceed 100 milligrams. The embolization procedure usually lasts less than an hour.
2450290|NCT03239327|Experimental|study group|For the study group the enrolled women will receive 50 microgram misoprostol vaginally 60 minutes before CS
2450291|NCT03239327|No Intervention|control group|For the control group mothers enrolled will receive nothing.
2450338|NCT03239171|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450345|NCT03239171|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450348|NCT03239171|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450350|NCT03239171|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450374|NCT03238833|Experimental|luteal ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since luteal phase.
2450378|NCT03238833|Active Comparator|follicular ovarian stimulation|The controlled ovarian stimulation in in vitro fertilization cycle was started since early follicular phase phase.
2450440|NCT03238625|Active Comparator|Group 1|"Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
2450443|NCT03238625|Placebo Comparator|Group 2|"Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.~Intervention: Every individual receives two injections:~IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes."
2450492|NCT03238131|Active Comparator|IVM annually (standard treatment)|The comparator (standard treatment) IVM 200 µg/kg body weight given at 0, 12 and 24 months plus vitamin pills at 6 and 18 months.
2450494|NCT03238131|Experimental|IVM plus ALB twice annually|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, 24 months
2450496|NCT03238131|Active Comparator|IVM plus ALB once annually|IVM 200 µg/kg plus ALB 800 mg given at 0, 12, 24 months plus vitamin pills at 6 and 18 months.
2450499|NCT03238131|Active Comparator|IVM twice annually|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months
3153657|NCT00280657|Active Comparator|Arm 2|
3153658|NCT00280657|Placebo Comparator|Arm 3|
2450744|NCT03236532|Experimental|Glutamine and exercise|Glutamine dipeptide (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
3153659|NCT00280670|Experimental|Cognitive Behavioral Therapy|
3153660|NCT00280670|No Intervention|Waitlist|
3153661|NCT00280696|Experimental|Lev 0.5 g|Levetiracetam 0.5 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3153662|NCT00280696|Experimental|Lev 1 g|Levetiracetam 1 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3153663|NCT00280696|Experimental|Lev 2 g|Levetiracetam 2 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3190237|NCT00785408|Experimental|2|
2449995|NCT03241706|Placebo Comparator|Controls-saline|Each subject from Group 1 will undergo a metabolic study where saline is infused so as to not stimulate liver glucose uptake and glycogen deposition.
2449998|NCT03241706|Active Comparator|Controls-high fructose|A second group of control subjects will undergo a single metabolic study using a higher dose of fructose (6.5 mg/kg/min).
2450000|NCT03241706|Active Comparator|Controls-low fructose|Each subject from Group 1 will undergo another metabolic study where fructose (1.3 mg/kg/min) is infused so as to stimulate liver glucose uptake and glycogen deposition.
2450052|NCT03241043|Experimental|Envarsus - Advagraf|
2450055|NCT03241043|Active Comparator|Advagraf - Envarsus|
2450077|NCT03240744|Experimental|vaccine (3.0EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
3190238|NCT00785408|Experimental|3|
2450281|NCT03239548||Doctor|It refers to the doctors with minimum qualification as M.B.B.S and B.A.M.S; working on various posts in the clinical areas of all the departments of selected hospitals.
2450282|NCT03239548||Nurses|It refers to the Registered Nurses working on various posts in the clinical areas of all the departments of selected hospitals and Principals, Vice Principals of selected colleges.
2450283|NCT03239548||Key informants|It refers to the general public including patients admitted and attending O.P.D and their attendants with minimum qualification as graduation.
2450316|NCT03239210|Active Comparator|Ondansetron (OND)|24 mg/day for 4 weeks
2450321|NCT03239210|Placebo Comparator|Placebo (PL)|Placebo pill
2450449|NCT03238378|Experimental|Therapy|Brachytherapy d1-5(6) Hyperthermia d2 + 5
2450514|NCT03238144|Other|MRF +/-contrast enhanced MRI|MRF with or without contrast enhanced MRI
2450547|NCT03237832|Placebo Comparator|Cohort 1|Cohort 1 (sentinel group): 1 subject received 50 mg ARN-6039 and 1 subject placebo Cohort 1: 7 subjects received 50 mg ARN-6039 and 1 subject placebo
2450550|NCT03237832|Placebo Comparator|Cohort 2|Cohort 2 (sentinel group): 1 subject received 100 mg ARN-6039 and 1 subject placebo Cohort 2: 7 subjects received 100 mg ARN-6039 and 1 subject placebo
2450554|NCT03237832|Placebo Comparator|Cohort 3|Cohort 3 (sentinel group): 1 subject received 150 mg ARN-6039 and 1 subject placebo Cohort 3: 7 subjects received 150 mg ARN-6039 and 1 subject placebo
2450557|NCT03237832|Placebo Comparator|Cohort 4|Cohort 4 (sentinel group): 1 subject received 200 mg ARN-6039 and 1 subject placebo Cohort : 7 subjects received 200 mg ARN-6039 and 1 subject placebo
2450559|NCT03237832|Placebo Comparator|Cohort 5|Cohort 5 Period 1, fasted (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 1, fasted: 7 subjects received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed (sentinel group): 1 subject received 300 mg ARN-6039 and 1 subject placebo Cohort 5 Period 2, fed: 7 subjects received 300 mg ARN-6039 and 1 subject placebo
2450635|NCT03237169||Prospective cohort|Prospective cohort of patients with stable or stabilized coronary artery disease and de novo coronary lesions, in whom functional evaluation is performed, according do standard clinical indications.
2450677|NCT03236805|Experimental|Ketamine IV|
2450683|NCT03236805|Active Comparator|Morphine IV|
3153664|NCT00280696|Experimental|Lev 3 g|Levetiracetam 3 g/day as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3153665|NCT00280696|Placebo Comparator|Placebo|Placebo tablets as add-on therapy to ongoing treatment with 1 to 3 AED(s) administered orally twice daily (in the morning and evening).
3153666|NCT00280709|Active Comparator|1|Covered metal stent
2450798|NCT03235921|Other|nitroglycerin|nitroglycerin patch 5 mg applied to front of chest in each patient at time of admission once.
2450817|NCT03235921|Other|control group|no drug given to the patients in control group
2450840|NCT03235518||Structure Interviews with FSW|Structured interviews with 200 purposively sampled FSW will be conducted. These interviews will be conducted prior to focus group discussion (FGD) and in-depth qualitative interview (IDI) with FSW. Structured interviews will take approximately 45-60 minutes to complete and will be administered privately in Kiswahili, Dholuo or English by trained female research staff. Quantitative interviews will be administered to conduct an assessment of FSW sociodemographics, sexual behaviour patterns and HIV-related knowledge, attitudes and practices regarding HIV prevention and other factors that might affect initiation and adherence to PrEP use, ability to use PrEP covertly, HIV testing history, mobility patterns, social networks, pregnancy intentions, ability to use condoms consistently with clients, and regular partners, and interpersonal violence from clients, regular partners and the police.
2450841|NCT03235518||Focus Group Discussions with FSW|Three to five FGDs of up to 10 FSW per group will be conducted. These FGD will take place prior to FSW IDI. FSW who participated in FGDs will be ineligible for participation in the IDI. All group discussions will last approximately 1.5 to 2 hours and be conducted in Kiswahili, Dholuo or English. Each group discussion will be facilitated by trained female research staff and held in a private space at a pre-specified location. The themes that will be explored in the FGDs include: FSW social networks, participation in PrEP studies, barriers and facilitators to PrEP use and use of resource transfers for PrEP adherence. In addition, participants will complete a brief demographic survey.
3153667|NCT00280709|Active Comparator|2|Uncovered metal stent
3153669|NCT00280800|Active Comparator|1|constant CPAP
3153670|NCT00280800|Experimental|2|automatic CPAP
3153671|NCT00280813|Active Comparator|Supportive Treatment in Alcohol Recovery (STAR)|
3153672|NCT00280839|Active Comparator|topiramate|
3153673|NCT00280839|Placebo Comparator|placebo|
3153674|NCT00280969|Experimental|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
3153675|NCT00280969|Active Comparator|efavirenz arm|Patients are treated with efavirenz 300mg along with Epzicom.
3153676|NCT00280995|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3153677|NCT00280995|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
3153678|NCT00280995|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3153679|NCT00280995|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
2450017|NCT03241225|Experimental|EM/PROTECT|This group of participants will receive the EM/PROTECT intervention, a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services.
2450026|NCT03241225|Active Comparator|EM/MH|This group of participants experiencing elder mistreatment will receive support services from staff trained in linking elder mistreatment victims to community mental health services.
2450085|NCT03240822|Experimental|Penile Allotransplant and Immunosuppression Treatment|Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
2450126|NCT03240497|Experimental|Cold Exposure|A group of subjects (n=12) that will receive an extensive course in cold exposure similar in length to our previous study (total of 10 days) before the endotoxemia experiment.
2450131|NCT03240497|Experimental|Strength Ventilation|A group of subjects (n=12) that will be trained in the strength ventilation breathing technique before the endotoxemia experiment.
2450135|NCT03240497|Experimental|Cold Exposure and Strength Ventilation|A group of subjects (n=12) that will receive both the cold exposure course (same as the STV group) as well as the training in the strength ventilation breathing technique (same as the CEX group) before the endotoxemia experiment.
2450141|NCT03240497|No Intervention|Control group|A group of subjects (n=12) that will receive no training and will not be exposed to cold before the endotoxemia experiment.
2450247|NCT03240094|Experimental|Nutritional telemonitoring|Participants in the intervention group receive a telemonitoring intervention, including self-measurements of body weight, nutritional status, appetite, diet quality, and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
2450253|NCT03240094|No Intervention|Usual care|Participants in the control group receive usual care.
3153680|NCT00281008|Experimental|Cohort A|Loading doses followed by weekly maintenance doses
3153681|NCT00281008|Experimental|Cohort B|Loading doses followed by weekly maintenance doses
2450417|NCT03238703|Experimental|Treatment (AI, SERM)|Patients receive exemestane PO QD, anastrozole PO QD, letrozole PO QD, tamoxifen citrate PO QD, or toremifene citrate PO QD at the discretion of the treating physician. Treatment continues in the absence of disease progression or unacceptable toxicity.
2450472|NCT03238287|Active Comparator|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
2450478|NCT03238287|Active Comparator|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
2450526|NCT03237910|Experimental|AMSA-CPR|The professional rescuer decides to deliver the defibrillation attempt based on the AMSA value displayed in the defibrillator
2450528|NCT03237910|Active Comparator|Standard-CPR|The defibrillation is delivered based on the 2015 European Resuscitation Council CPR guidelines
2450580|NCT03237520|Experimental|Virtual Reality Therapy|Intervention: Virtual Reality therapy(VRT) reinforcing modified Constraint Induced Movement therapy(mCIMT) VRT will be administered using computer based program. mCIMT will be administered using the physical rehabilitation protocol.
2450584|NCT03237520|Active Comparator|mCIMT|Intervention: Modified Constraint Induced Movement Therapy Only mCIMT will be administered using the physical rehabilitation protocol.
2450674|NCT03236948|Experimental|WfWI Intervention|Women receive the WfWI intervention. This comprises of three main components. First, a social empowerment and health intervention. Second a livelihood strengthening intervention, including numeracy training, and vocational training. Third, a cash transfer conditional on attendance at the intervention to cover costs of attendance and provide start-up capital. The intervention is delivered over 12 months.
2450676|NCT03236948|No Intervention|Control|
2450739|NCT03236623|Experimental|Menthol Popsicle|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the experimental group will experience a menthol popsicle. After 20 minutes of the end of the popsicle, will again be questioned as to the intensity and discomfort of thirst. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
2450741|NCT03236623|No Intervention|Usual care|The patient will be questioned when the intensity and discomfort of thirst. After randomization, the patient assigned to the control group should receive the usual care consisting of absolute fasting the food and drinks.
2450864|NCT03235427||Received Radiation Therapy(RT)|Patients who had received radiotherapy will be sub-stratified into those who received treatment to the left or right breast.
2450866|NCT03235427||Did not receive Radiation Therapy (RT)|Patients who did not receive radiation treatment, but received chemotherapy, hormonal therapy, and/or surgery will be used as study controls to compare the prevalence and burden of cardiac disease as compared to radiation patients.
2450905|NCT03235232|Experimental|BREMEN eye drops|1 drop in affected eye(s), each 12 hours for 8 weeks.
2450909|NCT03235232|Active Comparator|Combigan®|1 drop of Combigan® in affected eye(s), each 12 hours for 8 weeks.
2450973|NCT03235141|Active Comparator|AzaSite|In one cycle, give the AzaSite eye drops,2.5ml/25mg，1 drop，once. In the second cycle(after 14 days elution）,give the azithromycin eye drops by essex,2.5ml/25mg，1 drop，once.
3153682|NCT00281008|Experimental|Cohort C|Loading doses followed by weekly maintenance doses
3153683|NCT00281008|Experimental|Cohort D|Loading doses followed by extended weekly maintenance doses
3153684|NCT00281034||OASIS Study Group|
3153685|NCT00281073|Active Comparator|TEE and ICE|Serial use of TEE and ICE for comparative analysis
3153686|NCT00281073|Active Comparator|ICE or TEE|
3190239|NCT00785408|Placebo Comparator|4|
3190240|NCT00785408|Placebo Comparator|5|
3190241|NCT00785408|Placebo Comparator|6|
2450200|NCT03240250||Uni-portal VATS|VATS uni-portal lobectomy and lymphoadenectomy
2450203|NCT03240250||Three-portal VATS|VATS three-portal lobectomy and lymphoadenectomy
2450389|NCT03239405||SCS|Treated via suction callibrated system
2450392|NCT03239405||Bougie|Treated with multiple tubes & bougie
2450516|NCT03238157|No Intervention|Observation|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula. These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to either observation (2:1) (standard of care)."
2450517|NCT03238157|Active Comparator|Intervention|"The study will only include those patients that are ascertained be at more than 50% risk for vision loss (20/200 or worse at 3 years) because of total radiation dose of >40 Gy to the center of the macula.1 These at risk patients included in the study will receive intravitreal triamcinolone (4 mg in 0.1 ml) injected at the time of plaque removal. If lack of IOP rise (30 mm Hg or more) at 3 months, then randomized to intravitreal Fluocinolone Acetonide (FA) implant."
2450583|NCT03237728|Experimental|0.06mg/kg,KB and Placebo|Group A:0.06mg/kg,Q8h,Day1-Day7
2450587|NCT03237728|Experimental|0.12mg/kg,KB|Group B:0.12mg/kg,Q8h,Day1-Day7
2450591|NCT03237728|Experimental|0.24mg/kg,KB|Group C:0.24mg/kg,Q8h,Day1-Day7
2450593|NCT03237728|Experimental|Placebos|Group D:Placebos,Q8h,Day1-Day7
2450733|NCT03236571|Experimental|Rehabilitation Program|It will consist of 2 sessions of 40 minutes per week, for 12 weeks on ergometric bicycle. Each session of 40 min will include 5 minutes of warm-up, 5 minutes of recovery and 6 sequences of 5 min. Each 5-minute sequence will alternate between 4 minutes of pedaling at a load corresponding to the 1st ventilatory threshold (determined in the initial maximum cardiorespiratory effort test) and 1 minute of pedaling at a load corresponding to 2nd ventilatory threshold (determined in the initial maximum cardiopulmonary stress test).
2450802|NCT03236181|Other|Saturated Fat/SFA|30 grams saturated fat (SFA) in the form of heavy whipping cream will be provided to subject in a mixed meal shake
2450815|NCT03236181|Other|Monounsaturated Fat/MUFA|30 grams monounsaturated fat (MUFA) in the form of olive oil will be provided to subject in a mixed meal shake
2450821|NCT03236181|Other|Polyunsaturated Fat Linoleic/PUFA|30 grams high linoleic polyunsaturated fat (PUFA) in the form of high linoleic sunflower oil will be provided to subject in a mixed meal shake
2450825|NCT03236181|Other|Polyunsaturated Fat Omega-3/LCn3|30 grams high omega-3 polyunsaturated fat (LCn3) in the form of fish oil will be provided to subject in a mixed meal shake
2450860|NCT03235492|Experimental|SmartAlbu|If a participant agrees, after obtaining informed consent, the investigator will measure and record temperature, blood pressure, heart rate, height and weight. The participant will be given detailed instruction on how to hold the container and will be asked to spit (or deposit) their saliva up to the indicated line. The procedure will be performed twice to study the reproducibility of the test. The participant will then be asked to have a standard blood draw of 2-3 mls of blood into a vacutainer tube for analysis of HbA1c at the central lab and 1-2 mls of blood for glycated albumin for assay analysis, and a finger stick for point of care HbA1c measurement.
3190242|NCT00785421|Experimental|A|"Patients with KPS > 80% and normal kidney function receive GFFC + LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) + Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) + Enoxaparin 40mg/d s.c."
3190243|NCT00785421|Active Comparator|B|"Patients with KPS > 80% and normal kidney function receive GFFC - LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w - Enoxaparin 1mg/kg daily s.c.).~Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) - Enoxaparin 1mg/kg daily s.c.~After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) - Enoxaparin 40mg/d s.c."
3190244|NCT00785434|Experimental|Active|Active escitalopram
2451078|NCT03234387||Cystic fibrosis (CF) with established CF-related diabetes|"Cystic fibrosis (CF) with established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat) and, where possible, diagnostic genotyping~Established CFRD in accordance with the most recent American Diabetes Association positional statement]. This statement recommends CFRD is diagnosed using a 2 hour OGTT. However, the present study will also include those based on fasting plasma glucose and glycated hemoglobin levels, when symptoms of diabetes are also present:~2 hour OGTT plasma glucose ≥ 200 mg.dL-1 (11.1 mmol.L-1)~Fasting plasma glucose ≥ 126 mg.dL-1 (7.0 mmol.L-1)~Glycated hemoglobin ≥ 48 mmol/mol~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
2451118|NCT03233815||Total Intravenous Anesthesia (Propofol)|Patients undergoing cardiovascular surgery with total intravenous anesthesia with propofol.
2451149|NCT03233516||Cases with clinical CAP|Children 1-59 months at Sachs' Children and Youth Hospital with clinical CAP (both severe and non-severe) according to WHO-criteria.
3190245|NCT00785447|Other|1|Twenty healthy subjects between 18 to 59 years of age meeting ASA I-II criteria, undergoing elective surgery, requiring general anesthesia and being able to breathe through both their nose and mouth.
3190246|NCT00785460|Experimental|Benfotiamine and Smoking|
3190247|NCT00785460|Placebo Comparator|Smoking alone|
3190248|NCT00785473|Active Comparator|1|cholecalciferol, calcium carbonate
3190249|NCT00785473|Placebo Comparator|2|capsules not containing cholecalciferol, otherwise identical to Active comparator; calcium carbonate
3190250|NCT00785499|Experimental|skim milk|skim milk
3190251|NCT00785499|Experimental|whey|Whey milk drink
3190252|NCT00785499|Experimental|casein|casein milk drink
3190253|NCT00785499|Active Comparator|water|Danish mineral water
3153687|NCT00281190||Healthy smokers|Smokers with normal pulmonary function
2450170|NCT03240328|Experimental|CAR-T therapy|Transfusing CAR-T cells at least 1 million clone every time (once or twice) based on cART after attaining plasma HIV suppression (plasma HIV RNA <50 cp/ml) and CD4+ cell count more than 350 cells/ul over 1 year by cART without active HCV or HBV infection or opportunistic infections. If the candidates reach the criteria of discontinuing cART, they will stop cART and receive close observation. Once the plasma HIV viral load rebound to over 1000 cp/ml, they will restart cART immediately.
2450227|NCT03239951|Experimental|Device|Temporary implant (iTind)
3208545|NCT00975767|Experimental|MGCD265+docetaxel|
2450612|NCT03237507||Chemotherapy Group|chemotherapy treatment（S-1 and Oxaliplatin） for patients until disease progress
2450613|NCT03237507||Chemotherapy plus HIPEC Group|Hyperthermic Intraperitoneal chemoperfusion（HIPEC）with Paclitaxel more than 2 cycles and plus chemotherapy
2450633|NCT03237039|Other|X-ray examination, fall-risk and gait|simultaneous acquisition in upright position of two full-body radiographic images, one in the coronal plane and one in the sagittal plane. In addition, 40 out of 160 subjects will undergo fall-risk assessment and gait cycle analysis evaluation.
2450748|NCT03236363|Experimental|MOVI-da 10! active breaks|It is a physical activity intervention that consists on two daily physical activity active breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
2450752|NCT03236363|No Intervention|Control|No intervention
2450755|NCT03236363|Experimental|MOVI-da10! integrated physical activity|It is an integrated physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
2450809|NCT03236025|Experimental|Experimental group|Video+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. The videos which presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy, will be sent in sequence through the smart phone to the participants in the experimental group.
2450820|NCT03236025|Active Comparator|Conditional control group|Text-message+one-sentence smoking cessation advice +general smoking cessation leaflet will be allocated to the participants in the experimental group. Text-message contains the same content with videos and will be sent in the same frequency with the videos through the smart phone to the participants in the Conditional control group.
2450822|NCT03236025|Placebo Comparator|Placebo control group|Participants in the control group will be given a one-sentence smoking cessation advice during the baseline assessment. A leaflet showed the information related to the smoking cessation will be allocated to them at the same time.
3153688|NCT00281190||COPD patients|COPD patients
3153689|NCT00281203||healthy smokers|Must be free of serious diseases that might make it dangerous to undergo bronchoscopy.
3153690|NCT00281242||Research subjects|All participants undergo the same testing in this observational trial. There is no randomization, and no interventions other than blood drawing.
2450943|NCT03235076|Experimental|Subjects with mild renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2450944|NCT03235076|Experimental|Subjects with moderate renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2450947|NCT03235076|Experimental|Subjects with severe renal impairment|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2450950|NCT03235076|Experimental|Matched healthy subject group|Single oral dose of 10 mg BAY1101042 (given as 5 mg MR tablets)
2450989|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel A|IV nesiritide 3 pmol/kg/min or placebo for nesiritide
2450992|NCT03234751|Active Comparator|Obese nondiabetic insulin resistant subjects- Panel B|IV nesiritide 2 pmol/kg/min or placebo for nesiritide
2451037|NCT03234426|Experimental|Experimental Group|manual perturbations were given in forward, Backward,right and left sideways, 10 perturbations were given,6 days in week,in fallowing positions- sitting,kneeling, standing positions
2451038|NCT03234426|Placebo Comparator|Control group|Conventional Physiotherapy were given 6 days in a week, for 30 mins for 4 weeks, includes stretching, strengthening of contralateral limbs
2451133|NCT03233776|Experimental|Anakinra|Dosage form: intravenous. Dosage: either 100 mg, 200 mg or 300 mg. Frequency: once daily. Duration: 15 days (day -2 until day +12).
3153691|NCT00281255|Experimental|allopurinol|
3153692|NCT00281255|Placebo Comparator|placebo|
3153693|NCT00281346|Experimental|transthoracic Doppler echocardiography|
3153694|NCT00281359|Experimental|With heat|heat applied to contracted tissues prior to using the active stretching orthosis.
3153695|NCT00281359|Placebo Comparator|Without heat|No heat applied to the contracted tissues prior to using the stretching orthosis
3153696|NCT00281424|No Intervention|control|no pedometer
3153697|NCT00281424|Experimental|pedometer|given pedometer
3153698|NCT00281489|Experimental|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
3153699|NCT00281489|Active Comparator|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
3153700|NCT00281515|Experimental|Lonafarnib / Paclitaxel /Carboplatin|
3153701|NCT00281515|Other|Paclitaxel/Carboplatin|Standard Chemotherapy
3153702|NCT00281554|Experimental|1|
3153703|NCT00281606|Active Comparator|LPV/r (800/200 mg) 10 ml liquid|Once daily Lopinovir/ritonavir (800/200 mg) taken as a 10 ml liquid
3153704|NCT00281606|Active Comparator|LPV/r (800/200 mg) 6 gel capsules|Once daily Lopinavir/ritonavir (800/200 mg) as 6 gel capsules
3153705|NCT00281619||Mycophenolic Acid (CellCept)|purpose of this study is to determine how fast children, who have had a recent kidney transplant, absorb, breakdown and eliminate mycophenolic acid (CellCept) following their prescribed dose
2450129|NCT03240432|No Intervention|Blood Glucose Meter group|BGM group participants will be asked to use a study blood glucose meter with test strips for a fingerstick blood glucose check with a recommendation of 4 times a day. Participants will be permitted to check a fingerstick glucose as many times a day as they choose. Participants will have a phone visits at 10 days and clinic visits at 4 weeks, 8 weeks, 16 weeks, and 26 weeks. In addition to the in-clinic study visits, the BGM group will have blinded sensor placement visits one week prior to each of the 8, 16, and 26 week visits.
2450215|NCT03239977|Experimental|Online Social Intelligence Training|The Social Intelligence Intervention (SII) is delivered online to both custodial grandmothers and their adolescent grandchild separately. This is the sole active treatment condition within this RCT.
2450217|NCT03239977|Placebo Comparator|Attention Control (AC)|The attention control (AC) condition, known as The Healthy Living program provides information about different aspects of health.
2450256|NCT03239626|Experimental|POHIM-RT|adjuvant hypofractionated IMRT for cervical cancer patients
3153706|NCT00281736|Experimental|Arm I|Patients receive HPPH IV over 1 hour on day 1. Approximately 24 hours later, the lesion is exposed to laser light endoscopically.
3153707|NCT00281736|Experimental|Arm II|Patients receive HPPH as in arm I, but at a higher dose, followed by laser light exposure.
2450342|NCT03239184|Active Comparator|Cancer ablation|In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450343|NCT03239184|Active Comparator|Life information rehabilitation therapy|"In this group, the patients will drink Qilisheng Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450347|NCT03239184|Experimental|Combination therapy|"In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then Qilisheng Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)."
2450349|NCT03239184|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450382|NCT03238820|Experimental|The robot group|Patients undergo robotic gastric gastrointestinal stromal tumors resection.
2450439|NCT03238599|Experimental|Pedometer-based activity monitoring|The physical activity of patients after autologous transplantation for lymphoma and myeloma is measured with the pedometer
2450524|NCT03238183|Active Comparator|hyaluronic acid combined dextrose group|Hyaluronic acid (2 cc) combined 25% dextrose (3.5 cc 50% dextrose plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
2450525|NCT03238183|Placebo Comparator|hyaluronic acid group|Hyaluronic acid (2 cc) combined normal saline (3.5 cc normal saline plus 3.5 cc 2% lidocaine) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined hyaluronic acid and dextrose injections to hyaluronic acid injections
2450606|NCT03237611|Experimental|low dose aprepitant or fosaprepitant|In addition to standard prophylactic antiemetics (Ondansetron 16mg and Dexamethasone 20mg) patients will be given aprepitant 125mg orally or 115mg fosaprepitant intravenously prior to the first cycle of carboplatin-based chemotherapy. No medications will be given afterwards
2450863|NCT03235661|Experimental|BiPAP|BiPAP as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
2450868|NCT03235661|Active Comparator|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
2450910|NCT03235167|Experimental|CpG DNA|CpG DNA concentrate
2450913|NCT03235167|Placebo Comparator|placebo|placebo concentrate
2450953|NCT03234959|Experimental|CareToy Intervention|Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
2450954|NCT03234959|Active Comparator|Infant Massage|Infants and their caregivers will perform 4-5 sessions (around 1 hour every 2 weeks) of Infant massage conducted by an expert child therapist. The therapist will instruct the parent in the baby's massage and provide advises on promoting development. Parents will be invited to perform infant massage five days a week, for 8 weeks. Parent will take a diary in which will record the frequency of the IM.
2451064|NCT03234348|Experimental|Magmaris|Percutaneous coronary intervention by means of Magnesium-based sirolimus-eluting bioresorbable scaffold implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
2451135|NCT03234023|No Intervention|CONTROL GROUP|The participants of this group are submitted to the standard intervention.
3174411|NCT00623168|Experimental|Treatment Only|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with Ribavirin.
2450174|NCT03240159|Active Comparator|Deg-24mg|"Single dose of Degarelix 24mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2450175|NCT03240159|Active Comparator|Deg-16mg|"Single dose of Degarelix 16mg, on day 24th of previous luteal face cycle. On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2450176|NCT03240159|Active Comparator|Deg-12mg|"Single dose of Degarelix 12mg, on day 24th of previous luteal face cycle.On day 2 of the cycle: will be measured: LH levels, estradiol levels, and FSH levels.~ON day 1 of the stimulation (depending day of the cycle): will be measured: LH levels, estradiol levels, and FSH levels.~On day 6 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 8 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels.~On day 10 of the stimulation( depending day of the cycle):will be measured: LH levels, estradiol levels, and FSH levels."
2450235|NCT03239860|Experimental|Dose 1 GNbAC1|Monthly IV
2450236|NCT03239860|Experimental|Dose 2 GNbAC1|Monthly IV
2450240|NCT03239860|Experimental|Dose 3 GNbAC1|Monthly IV
2450298|NCT03239353|Active Comparator|1.5 mg ETV XR tablet|
2450301|NCT03239353|Active Comparator|3 mg ETV XR tablet|
2450302|NCT03239353|Active Comparator|6 mg ETV XR tablet|
2450303|NCT03239353|Placebo Comparator|Placebo-to-match 1.5 mg ETV XR tablet|
2450304|NCT03239353|Other|0.5 mg ETV IR tablet|
2450306|NCT03239119|Experimental|rE-4 5 mcg|Placebo, then rE-4 5 mcg, then rE-4 5 mcg
2450307|NCT03239119|Experimental|rE-4 10 mcg|Placebo, then rE-4 5 mcg, then rE-4 10 mcg
2450308|NCT03239119|Placebo Comparator|Placebo 5 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 5 mcg
2450309|NCT03239119|Placebo Comparator|Placebo 10 mcg|Placebo 5 mcg, then Placebo 5 mcg, then Placebo 10 mcg
2450444|NCT03238664|Experimental|Arm A (laparoscopic HIFU, RARC)|Patients undergo pre-HIFU CEUS, standard of care biopsy of the bladder tumor, laparoscopic HIFU, and post-HIFU CEUS. Patients then undergo standard of care RARC.
2450445|NCT03238664|Active Comparator|Arm B (RARC)|Patients undergo standard of care RARC.
2450487|NCT03237949|Active Comparator|Phone counseling|The patient will receive standard care inside the hospital. After discharge the active comparator group will receive four phone counseling sessions. The sessions will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The counseling timing, duration, and content will be consistent with guideline-based recommendations.
2450488|NCT03237949|Experimental|Text message|The patient will receive standard care inside the hospital. After discharge the experimental group will receive extended care including text messages. Participants in this arm will be offered up to 30 text messages to help implement the quit plan discussed during the hospitalization. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages and patients unwilling to quit will receive 16 messages. The messages content follows the self efficacy theory.
3190254|NCT00785551|Experimental|1|quinine sulfate 648mg in subjects with normal renal function (CLcr > 80mL/min)
3190255|NCT00785551|Experimental|2|quinine sulfate 648mg in subjects with mildly impaired renal function (CLcr > 50 to 80 mL/min)
2450678|NCT03236896|Active Comparator|Exercise Intervention|This group will participate in a weekly exercise regimen and actively log the physical activity in a diary. They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
2450682|NCT03236896|Active Comparator|No Exercise|They will complete the daily hot flash diary, MENQOL scale and calorimeter. All subjects will complete questionnaire (MENQOL Scale,) before the start of the study, at the sixth week of the study and after the completion of the twelfth week. A 2-week baseline assessment of hot flashes using the hot flash diary and fitbit flex will be followed by 12 weeks of assessment during the exercise intervention.
2450735|NCT03236584|Active Comparator|lamivudine adefovir|
2450740|NCT03236584|Experimental|tenofovir|
2450781|NCT03236220|Experimental|N-acetyl-L-cysteine group|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine.
3190256|NCT00785551|Experimental|3|quinine sulfate 648mg in subjects with moderately impaired renal function (CLcr 30 to 50mL/min)
3190257|NCT00785590|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
3190258|NCT00785642|Experimental|1|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)
2450985|NCT03234816|Experimental|- 0.05 mcg /Kg/min group|will receive norepinephrine 0.05 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2450986|NCT03234816|Experimental|- 0.1 mcg /Kg/min group|will receive norepinephrine 0.1 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2450987|NCT03234816|Experimental|- 0.15 mcg /Kg/min group|will receive norepinephrine 0.15 mcg /Kg/min after spinal anesthesia by bupivacaine till five-minutes after delivery of the fetus
2451131|NCT03234023|Active Comparator|INTERVENTION GROUP|The participants of this group will follow recommendations of food, physical exercise, control of consumption of drugs and consumption of alcohol and tobacco.
3190259|NCT00785655|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
2450241|NCT03239964|Active Comparator|excision only group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section. Primary closure of wound in layers is achieved in all cases. A running subcuticular prolene 2/0 stitch is used to suture the skin. Group A of 73 patients will not receive further injection. The wound is painted with betadine and sealed until postoperative day 14, at which time the subcuticular stitch is removed.~Routine postoperative medications are given to all patients. They are advised to avoid direct sun exposure for the following month. No postoperative applications (eg, compression, steroid injections, etc) are used in any of the patients. All patients are reviewed once per month for 6 months."
2450243|NCT03239964|Active Comparator|excision and injection group|"Under general or spinal anaesthesia done routinely during caesarean section, total extralesional surgical excision of keloid is performed and minimal undermining followed by usual steps of caesarean section and primary closure of the wound in layers. A running subcuticular prolene 2/0 stitch is used to suture skin.In 73 patients (group B), wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue. The wound is painted with betadine and sealed until postoperative day 14 to remove the subcuticular stitch.~Routine postoperative medications are given, avoidance of direct sun exposure for one month,No postoperative applications as compression, steroid injections, etc. All patients are reviewed once per month for 6 months."
2450292|NCT03239418|Experimental|EyeStim Group|Receive an active NMES treatment to the targeted muscles controlling eyelid function.
2450295|NCT03239418|Sham Comparator|Control Group|Undergo all the same procedures as the EyeStim group except receive a sham NMES treatment.
2450313|NCT03239132|Experimental|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks, as well as meditation educational materials.
2450319|NCT03239132|Active Comparator|Control|The control will receive meditation educational materials.
2450381|NCT03238976|Experimental|Nature sounds exposure|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~Patients in the nature sounds group will be exposed to continuous nature sounds during the core needle biopsy (CNB) procedure.~The CNB procedure will continue as planned with nature sounds playing instead of the supportive dialogue. All sounds will be played out of a speaker situated in the corner of the room."
2450386|NCT03238976|No Intervention|Standard care (supportive dialogue)|"Patients will be randomly assigned to either the nature sounds group or the standard care group.~The CNB procedure will continue as planned with supportive dialogue which will be played out of a speaker situated in the corner of the room. This group follows the current standard of care."
2450438|NCT03238573||optical enhancment endoscopy|
2450521|NCT03238209|Experimental|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
2450560|NCT03237702|Experimental|MCS arm|The participants who will have Multi-Carotenoids for 8 weeks The intervention is Multi-Carotenoids 30 mg for 8 weeks.
2450646|NCT03237494||Participants at risk for hATTR and participants diagnosed with hATTR|Participants 18 years of age or older
2450790|NCT03236064|Experimental|Nerve injury to palm and fingers|Adult patients with acute clean nerve transections of the higher arm injuries in the forearm, wrist, palm and digits of the hand will be recruited
2450879|NCT03235765||Cohort A|Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
2450883|NCT03235765||Cohort B|Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
2450902|NCT03235102||People with Obesity|People with obesity, or weight loss patients. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2450904|NCT03235102||Healthcare Providers|PCPs will include family practitioners; general practitioners; internal medicine; nurse practitioners; and dietitians. Specialists will include endocrinologists and bariatric surgeons, and any of the above if they focus on obesity treatment. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2450908|NCT03235102||Employers|Employers in Canada. Potential respondents will be recruited from various Internet patient panels to participate in a cross-sectional, online survey.
2450934|NCT03234985||acute myeloid leukemia patients|Patients over 18 years with acute myeloid leukemia
2450991|NCT03234842|Experimental|Proton|Proton beam therapy of 59.4 Gy in 1.8 Gy fractions (50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
2450995|NCT03234842|Active Comparator|Photon|Photon Radiation therapy of 59.4 Gy in 1.8Gy fractions ( 50.4 Gy if unable to meet cardiac/lung- organs at risk (OAR) constraints) plus concurrent standard chemotherapy
2451055|NCT03234400|Experimental|25 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 25 mg to be replaced every 4 weeks for 8 weeks, then worn for an additional 5 weeks for a total of 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2451059|NCT03234400|Experimental|100 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 100 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2451062|NCT03234400|Experimental|200 mg Dapivirine Vaginal Ring|Participants will insert one Dapivirine Vaginal Ring, 200 mg to be used continuously for 13 weeks. Participants will continue follow-up for an additional one to three days after final VR removal.
2451130|NCT03233906|Active Comparator|Chia Seeds|10% of a participants total kcal estimated needs given in chia seeds everyday for 8 weeks.
2451134|NCT03233906|No Intervention|Control|Habitual diet with avoidance of high fiber and high omega-3 fatty acid foods.
2451187|NCT03233490|Experimental|CPR training and web corse intervention|The students performed a web course (Help Brain Heart) prior training
2451190|NCT03233490|Experimental|CPR training intervention|CPR training without web course
2450280|NCT03239769|Experimental|minimally invasive access group (MIA)|With the MIA approach, a shorter incision of between 3 and 4 cm was created. The procedure used the Harmonic scalpel as an auxiliary device. First, the isthmus was divided. Second, the lower pole of the thyroid was dissected from the adipose tissue, and the inferior thyroid vessels were divided close to the thyroid gland for mobilization. The RLN and parathyroid glands were carefully dissected. Third, the superior pole of the thyroid gland was disconnected. Finally, CLND was performed. The closure procedure for the incision was similar to that for APA.
2450324|NCT03239262|Experimental|Group GP|Thirty-five patients (35%) from our population underwent concomitant mapping and radiofrequency ablation of ganglionated plexi (Group GP).
2450327|NCT03239262|Experimental|Group LA|Sixty five patients (65%) in whom no intervention related to ganglionated plexi was performed (Group LA).
2450390|NCT03238950|Other|Porcine Group|Training conducted on Porcine model
2450393|NCT03238950|Other|Synthetic|Training conducted on synthetic model
2450527|NCT03237975|Experimental|Be the Expert for Your Own (BEYO)|BEYO is a group-based consultation project. Each group contains 1 facilitator, 1 assistant and 8 elderly patients. 5 weekly sessions are provided to let patients receive health knowledge, discuss problems and experiences, explore available resources and build up goals and solutions. Each session lasts for 40 minutes. Session 1 aims to build social network among group members and introduce group goals and tasks. Session 2-4 covers six topics: (i) healthy dietary, (ii) exercise and activity, (iii) taking medication, (iv) blood glucose monitoring, (v) reducing risks for complication, (vi) healthy coping with mental stress. Session 5 aims to review the process, summarize effective solutions, and set up plans for the future.
2450529|NCT03237975|Active Comparator|Routine health education|To neutralize the effect of extra attention from the facilitator, participants in control group will receive routine health education on topics related to type 2 diabetes. Contents for the routine education will be based on the national guideline of basic public health service for diabetes and specific implementation protocols in each community. Participants in control group will receive 5-weekly education packet at the same time with participants in intervention group. The patients will not be given any strengths-based information, but they are free to discuss their disease status with nurses or physicians at their regular follow-up appointments.
2450601|NCT03237572|Experimental|Arm A: 1st dose of pembrolizumab after HIFU|Pembrolizumab (200 mg) administered intravenously, days 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
2450602|NCT03237572|Experimental|Arm B: 1st dose of pembrolizumab before HIFU|Pembrolizumab (200 mg) intravenously, days 1, 22, 43, 64, followed by day 1 of each ensuing 3 -week cycle. Focused ultrasound tumor ablation day 15. High-intensity focused ultrasound ablation will target 50% of the tumor, up to 3 cubic centimeters.
2450636|NCT03237117|Experimental|GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. Additionally, these patients are co-treated with growth hormone (GH).
2450640|NCT03237117|Active Comparator|non-GH group|35 women with a history of RIF with donated oocytes. For receiving donated oocytes, the women are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the GH group, only that no GH is added.
2450645|NCT03237117|No Intervention|positive control group|35 infertile women undergoing their first oocyte donation attempt are included as a positive control group. Women receiving donated oocytes are treated with progressively increasing doses of oral estradiol followed by intravaginal progesterone after previous pituitary desensitization with GnRH agonist. The treatment protocol is identical to the non-GH group, with no GH added.
2450673|NCT03236844|Experimental|Gantenerumab G4|Participants will receive single dose of gantenerumab HCLF manufactured by G4 process on Day 1.
2450679|NCT03236844|Experimental|Gantenerumab G3|Participants will receive single dose of gantenerumab HCLF manufactured by G3 process on Day 1.
2450734|NCT03236597|No Intervention|Usual Desk|participants will work at their usual desk for four weeks.
2450737|NCT03236597|Experimental|Treadmill desk|Participants will be asked to use a treadmill desk for a minimum of 30 minutes per day for four weeks (Participants will sign up for a total of 30 minutes each day). Additional time may be spent on the treadmill, time permitting (two treadmills will be available to up to 10 people over the four week period).
2450778|NCT03236233|Experimental|Single dose - healthy subjects|
2450779|NCT03236233|Experimental|Repeat dose - healthy subjects|
2450780|NCT03236233|Experimental|Single dose - subjects with asthma|
2451273|NCT03233126|Experimental|KRN23|
2450336|NCT03239509||Mechanical prosthesis|All patients operated on of isolated AVR with a Mechanical prosthesis implantation between 2000-2015 and age 50-65 years both inclusive.
2450395|NCT03238885||LARC-CRT|LARC patients who will receive neoadjuvant CRT before surgical resection.
2450425|NCT03238521|Active Comparator|classical pedicle finder|Spinal osteosynthesis with classical pedicle finder
2450426|NCT03238521|Experimental|pedicle finder with impedancemetry|Spinal osteosynthesis with pedicle finder with impedancemetry
3153708|NCT00281892|Experimental|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
3174412|NCT00623207|Placebo Comparator|1|Pateints who achieve target haert rate or conclusive test will not be given Atropine
2450522|NCT03237936|Experimental|IKERVIS® (1mg/mL ciclosporin) eye drops|one drop of study medication (IKERVIS®1mg/mL) once daily in each eye at bedtime during 3 months.
2450564|NCT03237637|Active Comparator|Group A- Propranolol|Oral propranolol 1mg/kg/day as crushed tablets, in two divided doses, increased to 2mg/kg/day in two divided doses after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
2450571|NCT03237637|Experimental|Group B- Atenolol|Oral atenolol 0.5mg/kg as a single dose, increased to 1mg/kg as a single dose after 24 hours if tolerated well. Treatment will be stopped at complete clinical clearance of lesion (defined arbitrarily as >90% reduction in the size of Infantile Hemangioma as assessed by Physician Global Assessment) or after 9 months of treatment (primary end point) whichever is earlier.
2450651|NCT03237351|Active Comparator|Conventional therapy group|Patients in Conventional therapy group were received fluid therapy: intraoperative transfusion volume=maintenance fluids+deficit replacement+restoration of losses and with heart rate, mean arterial pressure, urine measurement ect.
2450653|NCT03237351|Experimental|Low value of PPV group|Patients in low value of PPV group were received fluid therapy according to PPV (3% ≤PPV < 5%) .
2450654|NCT03237351|Experimental|High value of PPV group|Patients in high value of PPV group were received fluid therapy according to PPV (5% ≤PPV < 8%) .
3174413|NCT00623207|Active Comparator|2|Patients who won't achieve tarhet heart rate or conclusive results will be given Atropine
2450890|NCT03235752|Experimental|TJ301 300mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2450891|NCT03235752|Experimental|TJ301 600mg|TJ301 300mg administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2450892|NCT03235752|Placebo Comparator|Placebo|Placebo administrations will occur on Days 0, 14, 28, 42, 56, and 70.
2450972|NCT03234894|Other|SiteSeal Endovascular|"After intervention (deployment and removal of the Site Seal endovascular adjunctive compression device), the physician determines whether or not there was laceration of the femoral nerve or laceration of the femoral artery per protocol. A series of possible minor and/or major complications are noted per protocol.~There is a secondary metric as to patient reported pain on a 1-10scale."
3174414|NCT00623220|Experimental|A|O2 and N2O
3174415|NCT00623220|Active Comparator|B|O2 only
2451075|NCT03234296|Active Comparator|Antibiotic treatment|Ertapenem 1 g x 1 intravenously for 3 days, followed by per oral levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 4 days, duration of treatment 7 days.
2451077|NCT03234296|Active Comparator|Placebo|Intravenous placebo once a day for 3 days, followed by per oral placebo for 4 days with similar p.o. tablets as in the antibiotic group.
2451151|NCT03233581|Experimental|Fitbit + Facebook + Health Coaching|Participants will use the Fitbit device and join the Facebook group. They will also receive brief weekly health coaching from a research staff. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide them with support.
2451153|NCT03233581|Active Comparator|Usual care control with Fitbit only|Participants will be loaned a Fitbit device only. They will not join the Facebook group nor receive health coaching. They will not select an adult family member or friend to receive a Fitbit device to provide them with support.
2451186|NCT03233321|Experimental|Experimental group|30 patients were selected in experimental group. Dry cold was applied to the subcutaneous injection site using ice bag filled with crushed ice with half table spoon of salt for 20 minutes after the administration of injection.Pain intensity was measured using numeric pain rating scale immediately after dry cold application and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
2451189|NCT03233321|No Intervention|Comparison group|No intervention was given. Pain intensity was measured using numeric pain rating after 20 minutes of subcutaneous injection and bruise size was assessed using bruise assessment scale after 12, 48 and 72 hrs of injection administration.
2451215|NCT03233113|Active Comparator|Exposure and response prevention|Exposure therapy with response prevention involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to prevent engaging in any safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
2451218|NCT03233113|Experimental|Exposure with judicious safety behaviors|Exposure therapy with judiciously used safety behaviors for spider phobia involves four hour-long individual sessions with a trained exposure therapist. Session 1 involves functional assessment, psychoeducation, presentation of the treatment rationale, and treatment planning. Sessions 2-4 involve a review of the model/treatment rationale, condition-specific reminders about how to strategically incorporate safety behaviors during exposure, a 30-minute in-vivo exposure trial involving a live tarantula, and post-exposure processing. Session 4 also involves a discussion of relapse prevention strategies.
2451287|NCT03232762|Active Comparator|Diet B|a high proportion of calories from whole grains
2451317|NCT03232515|Experimental|Intervention group|Evaluation,estimation and modification of the dry weight by BIVA.
2451375|NCT03232255|Experimental|Treatment Group|
3174416|NCT00623246|Active Comparator|1|Participants will receive motivational enhancement therapy (MET) for 12 weeks.
2450341|NCT03239158|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2450371|NCT03238872|Experimental|Prompt Mental Health Care|Clients in the experimental group receive short-term cognitive behavioural therapy in the form of a psycho-educational group course, guided self-help, or individual face-to-face therapy.
2450373|NCT03238872|Active Comparator|Treatment as usual|Clients in the comparison group are offered treatment as usual from their general practitioner.
2450450|NCT03238586|Experimental|WELL Program|Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.
2450457|NCT03238586|No Intervention|Standard of Care|Five-week standard of care program.
2450505|NCT03238092|Active Comparator|Estradiol group|In the late luteal phase, the participant will receive estradiol 2mg and will take orally a total of 4mg per day (2mg in the morning and 2 mg in the night) until the next menstrual bleeding. After that, the patient will descontinue the medication and proceed to the regular in vitro fertilization protocol.
2450511|NCT03238092|No Intervention|Control group|No pre-treatment will be administrated. The regular in vitro fertilization protocol will be performed.
2450512|NCT03238092|Experimental|Testosterone group|Testosterone 25mg (10mg/g) transdermal during the late luteal phase, until the next menstrual bleeding.
2450589|NCT03237793|Active Comparator|Fluorosed Group|45 patients for the fluorosis groupGROUP 1A: Patients with healthy fluorosed teeth receiving desensitising agent (potassium nitrate- RA Themoseal**) treatment. (n=15) GROUP 1B: Patients with healthy fluorosed teeth receiving diode laser treatment$. (n=15) GROUP 1C: Patients with healthy fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15)
2450592|NCT03237793|Placebo Comparator|Non Flourosed Group|45 patients for the non-fluorosis groupGROUP 2- Non Flourosed Group (n=45) GROUP 2A: Patients with healthy non fluorosed teeth receiving desensitising agent (potassium nitrate- RA Thermoseal**) treatment. (n=15) GROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment. (n=15
3153709|NCT00281892|Active Comparator|fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
3153710|NCT00281944|Experimental|Treatment (oxaliplatin, leucovorin calcium, fluorouracil)|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 followed by fluorouracil IV continuously over 46 hours on days 1-2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2450714|NCT03236727|No Intervention|Control|Data of SSEPs (amplitude and latency) before dexmedetomidine infusion.
2450716|NCT03236727|Active Comparator|Dexmedetomidine|Data of SSEPs (amplitude and latency) after dexmedetomidine infusion.
2450754|NCT03236324|Placebo Comparator|TFP block with saline|Placebo bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with 40 mL saline, single shot
2450756|NCT03236324|Experimental|TFP block with local anesthetic|Experimental bilateral ultrasound-guided nerve block [transversalis fascia plane (TFP) block] with local anesthesic of Bupivacaine-epinephrine [0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)], single shot
2450804|NCT03235973|Experimental|Fludarabine-Cladribine-Busulfan conditioning regimen|
2450855|NCT03235687|Experimental|Cohort A|Patients randomized to Cohort A will receive ExoDx Prostate (IntelliScore) test results along with a post-ExoDx Prostate (IntelliScore) test result questionnaire to evaluate impact of test results in the biopsy decision process, utility, ease of understanding and work-flow implementation.
2450858|NCT03235687|No Intervention|Cohort B|Patients randomized to Cohort B will proceed with conventional standard of care.
2450969|NCT03234881|Active Comparator|MOVE! (virtual)|Weight management delivered as Treatment-as-Usual
2450974|NCT03234881|Experimental|MOVE!+gshCBT (virtual)|Weight management delivered as Treatment-as-Usual plus use of a short duration, low-intensity CBT for recurrent binge eating.
3174417|NCT00623246|Active Comparator|2|Participants will receive educational therapy (ED) for 12 weeks.
3174418|NCT00623246|No Intervention|3|Participants will receive standard clinical care.
2451072|NCT03234270|Experimental|F35 pilots|
2451076|NCT03234270|Active Comparator|F15 pilots|
2451109|NCT03233984|No Intervention|Leaflet only|Women will only receive a leaflet about endocrine disruptor at home.
2451112|NCT03233984|Active Comparator|non immersive program|In addition of the leaflet, women will sit in the sensibilisation program that will take place in a neutral environment
2451119|NCT03233984|Experimental|immersive program|In addition of the leaflet, women will si in the sensibilisation program that will take place in an immersive environment
2451231|NCT03233152|Experimental|ipilimumab + nivolumab|"Only one study cohort will be predefined in this phase I clinical trial; a classical phase I 3+3 patient recruitment design will be used to guide patient recruitment.~Ipilimumab (YervoyTM, 50 mg/10 mL) will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (2 ml of YervoyTM, 50 mg/10mL vial).~First administration of 10 mg Nivolumab (OpdivoTM, 40 mg/4mL solution) by the intravenous route will be administered within 24 hours prior to the planned neurosurgical resection. The following administrations of 10 mg nivolumab will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary)."
2451259|NCT03232866|Experimental|Experimental group|(n = 20) will practice Pilates exercises
2451262|NCT03232866|No Intervention|Control group|(n = 20) will not carry out the intervention
2451286|NCT03232762|Active Comparator|Diet A|high proportion of calories from refined grains as a carbohydrate source
2450379|NCT03238859|Sham Comparator|Sham cTBS|10 days of sham cTBS treatment will be given (3600 pulses to the left frontal pole as defined by EEG coordinate: FP1; 60 second pause after 1800 pulses; 110% RMT including a 30 second initial ramp period 80%-110% RMT; Magventure MagPro X100 Cool Coil).
2450465|NCT03238612|Experimental|FFA, clarithromycin, oseltamivir|oseltamivir 75mg + clarithromycin 500mg + FFA 200mg all twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
2450468|NCT03238612|Placebo Comparator|Oseltamivir alone|oseltamivir 75mg + two placebo capsules (identical in appearance to clarithromycin and FFA capsules respectively) twice daily for 2 days, followed by oseltamivir 75mg twice daily for 3 days
2450530|NCT03238014|Experimental|High-intensity noninvasive ventilation|High-intensity noninvasive positive pressure ventilation aims at maximally improving PaCO2.
2450531|NCT03238014|Active Comparator|Low-intensity noninvasive ventilation|Low-intensity noninvasive positive pressure ventilation is a classic setting of noninvasive ventilation.
2450596|NCT03237559||eligible couples|Eligible couples refers to methods that are adopted by eligible couples for having physically and psychologically healthy conception and pregnancy
2450642|NCT03237208|Active Comparator|TENS|Patients receiving the real transcutaneous electrical nerve stimulation (TENS) with 100 hertz, pulse width 200 microseconds, voltage 2 milliampere
2450647|NCT03237208|Sham Comparator|placebo group|Patients receiving the application of transcutaneous electrical nerve stimulation, but transcutaneous electrical nerve stimulation will not be activated.
3174419|NCT00623259|Experimental|1|
2450730|NCT03236441|Active Comparator|RIPC Group|3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes
2450736|NCT03236441|Sham Comparator|Sham-RIPC Group|3 cycles of blood pressure cuff inflations to non-occlusive pressure of 10 mmHg for 5 minutes and deflation for 5 minutes (Control)
2450776|NCT03236142|Active Comparator|Standard Duodenal Switch (DS)|
2450777|NCT03236142|Experimental|Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS)|
2450793|NCT03235882||observational group|"Infants born 24-32 weeks.~Inclusion criteria:~Have gastric aspirate and oral secretions obtained within 45 minutes from birth via:~a naso- or orogastric tube inserted in the delivery room if clinically indicated as part of resuscitation or~a nasogastric tube inserted as part of routine management of preterm infants.~Written informed consent has been obtained"
2451318|NCT03232619|Experimental|CD19-CART with a murine scFv|All enrolled patients in this arm will receive CD19-CART with a murine scFv.
2451320|NCT03232619|Experimental|humanized CD19-CART|All enrolled patients in this arm will receive humanized CD19-CART.
2451488|NCT03231527||Saphenous vein based CABG|Saphenous vein based revascularization
2451645|NCT03230201|Experimental|Lymph node dissection|will receive Lymph node dissection during radical nephroureterectomy.
3174420|NCT00623285|Experimental|Group 1|
3174421|NCT00623285|Placebo Comparator|Group 2|
3174422|NCT00623298|Experimental|1|NET
3174423|NCT00623298|No Intervention|3|6-months baseline
3174424|NCT00623298|Experimental|2|group IPT
3174425|NCT00623324|Active Comparator|1|Aplindore titrated to safe and tolerable dose
3174426|NCT00623324|Placebo Comparator|2|
3174427|NCT00623337|Experimental|Newhints|Home visits
3174428|NCT00623337|No Intervention|Control|Community based surveillance volunteers will continue with current duties eg urging attendance at immunisation clinics and child health weeks
3174429|NCT00623350|Active Comparator|1|Acute Stroke Telephone consult for the decision of tPA within 3 hours of symptoms onset.
3174430|NCT00623350|Active Comparator|2|Acute Stroke consult via audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
3174431|NCT00623376|Active Comparator|1|first on treatment then on Placebo
3174432|NCT00623376|Placebo Comparator|2|first on placebo then on treatment
3174433|NCT00623389|Experimental|A|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
3174434|NCT00623402|Experimental|A|
3174435|NCT00623415|Active Comparator|Verum|flupirtine + interferon beta 1b
3174436|NCT00623415|Placebo Comparator|Placebo|placebo + interferon beta 1b
3174437|NCT00623519||1|Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole
3174438|NCT00623532|Experimental|CA|"Cognition and action are an inseparable whole while functioning, a new intervention based approach using familiarity based movements and non judgmental approach was labeled cognition-action."
3174439|NCT00623532|Active Comparator|AT|Adapted Tai Chi is based on Tai Chi like movements
3174440|NCT00623532|No Intervention|C|Control
3174441|NCT00623558|Active Comparator|1|Docetaxel+CDDP
3174442|NCT00623558|Experimental|2|Docetaxel+CDDP+Cetuximab
3174443|NCT00623571|Experimental|1|Patients treated by hospital-at-home service (GHHS)
3174444|NCT00623571|Active Comparator|2|Patients treated in a general medical ward (GMW)
3174445|NCT00623584|Experimental|1|Patients in this arm randomly receive a corneal graft cultured in a serum free culture medium
3174446|NCT00623584|Active Comparator|2|Patients in this arm randomly receive a corneal graft cultured in a serum supplemented culture medium
3174447|NCT00623649|Experimental|Cohort 1|VCH-916 100 mg three times a day (t.i.d.)
3174448|NCT00623649|Experimental|Cohort 2|VCH-916 200 mg (t.i.d.)
3174449|NCT00623649|Experimental|Cohort 3|VCH-916 300 mg twice daily for three days
3174450|NCT00623649|Experimental|cohort 4|VCH-916 400 mg twice daily for three days
3174451|NCT00623662|Active Comparator|1|Glucose infusion.
3174452|NCT00623662|Placebo Comparator|2|Normal saline infusion.
3174453|NCT00623675|Experimental|A|
3174454|NCT00623688|Experimental|1|Subjects receive active medication (albuterol) delivered by a Proair metered dose inhaler used with an Opti-chamber and placebo (normal saline solution) by nebulizer aerosol.
3174455|NCT00623688|Active Comparator|2|Subjects receive active medication (albuterol) delivered by nebulizer and placebo (no medicine) delivered by a demonstrator Placebo metered dose inhaler demonstrator.
2450411|NCT03238729|Experimental|CHF App|Patients will be provided with a mobile app on a smartphone for education and management of heart failure.
2450414|NCT03238729|Active Comparator|Standard of Care|Patients will be provided standard literature on heart failure management.
3190260|NCT00785681|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
3190261|NCT00785694|Experimental|B|One instillation of mitomycin C after transurethral resection in white and blue fluorescence light with Hexvix.
2450655|NCT03237390|Experimental|Treatment (gemcitabine hydrochloride, ribociclib)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and ribociclib PO QD on days 8-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2450705|NCT03236610|Experimental|tenofovir|
2450706|NCT03236610|Active Comparator|tenofovir plus entecavir|
2450757|NCT03236415|Active Comparator|Xience Drug Eluting Stent|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery disease
2450759|NCT03236415|Active Comparator|ABSORB Bioresorbable Vascular Scaffold|Patients with diabetes mellitus will be randomized to receive either a Xience drug eluting stent or an ABSORB bioresorbable vascular scaffold for treatment of obstructive coronary artery diseasee
2450827|NCT03235843|Active Comparator|Rate Adaptive Pacing ON|AAIR pacing using a MV sensor
2450830|NCT03235843|Placebo Comparator|Rate Adaptive Pacing OFF|DDI-pacing
2450862|NCT03235440|Experimental|Kids N Fitness|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
2450948|NCT03235219|Experimental|Cohort 1 to 4: JNJ-64565111 or Placebo|Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.
2450951|NCT03235219|Experimental|Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo|Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.
2451028|NCT03234725||LCI out group|The whitdrawal of the colonoscop happen in LCI mode.
2451029|NCT03234725||WL (white light) out group|The whitdrawal of the colonoscop happen in WL mode.
2451088|NCT03234049|No Intervention|Control Arm|In the control arm, teams will not receive a copy of the checklist for use.
2451089|NCT03234049|Experimental|Checklist Arm|In the intervention arm, the participants will watch a 10 minute recorded educational video demonstrating the use of the trauma checklist prior to their simulation scenario. These teams will subsequently receive a copy of the checklist for use during their simulation scenario.
2451161|NCT03233750|Experimental|Stress Inoculation Training|"Phase 1: Conceptualization / Educational Phase (60 minutes) Provision of preparatory information, to allow the participants to form accurate expectations regarding the stress environment and stress reactions.~Phase 2: Skill Acquisition and Rehearsal (60 minutes) Development and practice of cognitive restructuring techniques and relaxing training to reduce anxiety and enhance the individual's capacity to respond effectively to stressful situations, in low stress conditions.~Phase 3: Application of Coping Skills (180 minutes) Coping skills are applied in increasingly stressful conditions that approximate the real-world stressor environment."
2451162|NCT03233750|Active Comparator|Crisis Resource Management Training|The CRM training targets the non-technical skills (e.g. behavioural and cognitive skills) required for effective teamwork during crisis situations. It focuses on communication, teamwork, situational awareness and leadership
2451192|NCT03233256|Experimental|Healthy adults (18-45 yrs.)|Healthy adults (18-45 yrs.) will be recruited from the local Denver area. The investigators have elected to study a relatively homogenous sample to limit the impact of age, weight, and chronic disease on isotope fractionation in breath.
2451234|NCT03233061|Active Comparator|NO|NON OBESE WOMEN GROUP ( same age and same physical activities ) cardiorespiratory exercise testing with evaluation of peak oxygen uptake, heart rate and maximal cycling power output. Cardiorespiratory functioning is assessed during household activities such as ironing,cleaning floor,walking and climbing stairs.
2451236|NCT03233061|Experimental|OB|OBESE GROUP cardiorespiratory exercise testing with evaluation of peak oxygen uptake,heart rate and maximal cycling power output.Cardiorespiratory functioning is assessed during household activities such as ironing, cleaning floor, walking and climbing stairs
2451339|NCT03232398|Active Comparator|Apixaban|Apixaban Oral Tablet [Eliquis]
2451341|NCT03232398|Active Comparator|Warfarin|Warfarin - Vitamin K antagonist
2451369|NCT03232034|Placebo Comparator|Calcium Citrate|Calcium citrate (1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2451370|NCT03232034|Active Comparator|Milk Mineral Supplement|Milk mineral supplement (equating to 1000 mg calcium) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
3190262|NCT00785694|No Intervention|A|Multiple instillations of mitomycin C after transurethral resection in white light alone.
3190263|NCT00785720|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid)
3190264|NCT00785733||1|Moderate and severe asthma patients stabilized on Symbicort SMART
3190265|NCT00785746|Experimental|core|strength training of the core muscles.
3208546|NCT00975793|No Intervention|Standard Care|Randomised allocation of standard care at the clinician's discretion in accordance with current best practice.
2450432|NCT03238339||The Portable Home Noninvasive Ventilator treatment group|The patients maintain a stable COPD regimen, and on the basis of conventional home oxygen therapy, a portable, wearable, non-invasive ventilator will be used.
2450434|NCT03238339||Routine home oxygen therapy group|The patient maintained a stable COPD regimen and conventional home oxygen therapy.
2450473|NCT03238261|Experimental|Chemotherapy and concomitant radiotherapy|
2450477|NCT03238261|Active Comparator|Radiotherapy|
2450535|NCT03238027|Experimental|Ph1a D1: 1 mg/kg SNDX-6352|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450537|NCT03238027|Experimental|Ph1a D2: 3 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450539|NCT03238027|Experimental|Ph1a D3: 6 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450542|NCT03238027|Experimental|Ph1a D4: 10 mg/kg SNDX-6352|Three (3) patients receive next higher dose of 10 mg/kg of SNDX-6352 and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450543|NCT03238027|Experimental|Ph1b D1: 1 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive starting dose of 1 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee. If 1 DLT is observed in 1 of 3 patients, then 3 additional patients will be treated at the 1 mg/kg SNDX-6352 dose level; if none of the 3 additional patients experience a DLT (i.e. 1 of 6), the dose will be escalated to an intermediate dose of 2 mg/kg. Escalation from 2 mg/kg to 3 mg/kg will follow the general dose escalation rules described above for both study phases.
2450544|NCT03238027|Experimental|Ph1b D2: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 3 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450546|NCT03238027|Experimental|Ph1b D3: 3 mg/kg SNDX-6352+1500mg durva|Three (3) patients receive next higher dose of 6 mg/kg of SNDX-6352 every two weeks and 1500mg durvalumab every four weeks and are followed for possible DLTs. For cohorts with doses ≥3 mg/kg, a sentinel recruitment approach will be utilized. Initially 1 patient in each cohort will be treated with the combination therapy and safety will be evaluated by SRC at Cycle 1, Day 8; if no safety concerns are identified, the next 2 patients can be treated in that cohort. If one DLT is observed in 1 of 3 patients, an additional 3 patients will be enrolled at this dose level. If no DLTs are noted in any of the 3 patients, next dosing arm will commence following review by Scientific Review Committee.
2450594|NCT03237442|Experimental|group 1|
2450595|NCT03237442|Active Comparator|group 2|
2450663|NCT03237182|Experimental|Individualized treatment for drug resistant tuberculosis|Patients with drug resistance will have whole genome sequencing performed on the respective positive MGIT sample. An individualized TB treatment regimen will be provided to patients based on the whole genome sequencing results
2450668|NCT03237182|Active Comparator|Standard treatment regimen for drug resistant tuberculosis|As per South African Department of Health Standard of Care for the treatment of drug resistant tuberculosis
2450713|NCT03236675||EML4-ALK|ALK positive patients
2450715|NCT03236675||T790M EGFR|T790M positive patients
2450751|NCT03236337|No Intervention|Control|No intervention
2450753|NCT03236337|Experimental|MOVI intervention|- MOVI-da Fit! is a high intensity interval training intervention that consists on: a) 4 h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
2450808|NCT03236012|Experimental|Botulinum Toxin Therapy|"Test the effectiveness of Botulinum Toxin therapy in subjects who fail or do not tolerate Aluminum Chloride.~We plan to conduct an open label study of Botox, up to 400 units, in amputees who have failed treatment with a topical antiperspirant."
2450865|NCT03235583|Other|MotionPod Validation|Medical device validation
2450893|NCT03235271||Group A: Large-Vessel Ischemic Stroked|Group A will include subjects that present with focal neurological deficits and clinical features consistent with ischemic stroke with a large vessel occlusion (see Key Terms for definition). Subjects in this group will have a clinical presentation consistent with ischemic stroke and a large vessel occlusion confirmed through angiography. It is common practice to have the CTA completed immediately after CT imaging. Clinical presentation will include classic features of stroke syndromes that occur based on the localization of the infarct, which includes cortical symptoms that can be lateralized to the left side or right side of the brain.
2450903|NCT03235375|Experimental|Group 4: Moderate Renal Disease|Subjects with CrCl > or equal to 30 and < 60 mL/min will receive MEDI0382 administered subcutaneously
2450939|NCT03234946|No Intervention|Group A|Relatives of patients with diabetes who will only attend sessions at the center along with the patients on all the interventions of the center (except psychology and psychiatry), receiving instructions from each area on the first and fourth visit. When the patient with diabetes is in the psychology or psychiatry consultation, the relative will also be evaluated in these areas in an analogue form.
2450461|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, F|salmeterol-fluticasone 2 inhalations as a single dose
2450466|NCT03238482|Experimental|Salmeterol/fluticasone Easyhaler, G|salmeterol-fluticasone 2 inhalations as a single dose
2450561|NCT03237676|Experimental|Individualised structured cognitive rehabilitation therapy|Participants of interventional arm will receive individualised structured cognitive rehabilitation therapy at the proposed health centre (University Malaya Medical Centre, Malaysia).
2450567|NCT03237676|Active Comparator|Patient-centred cognitive therapy|Participants of conventional arm will receive an existing cognitive rehabilitation treatment available at the proposed health centre (University Malaya Medical Centre, Malaysia).
2450623|NCT03237338|Experimental|Insomnia-ture acupuncture|"True acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
2450625|NCT03237338|Sham Comparator|Insomnia-sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints will be administered on CID patients Intervention: Procedure: true acupuncture"
2450688|NCT03236974|Active Comparator|Standard arm|Fulvestrant, 500 mg
2450690|NCT03236974|Experimental|AZD9496|250 mg bd taken orally for 5-14 days
2450724|NCT03236467|Experimental|FM + PTSD|Individuals suffering from Fibromyalgia and PTSD
2450795|NCT03236259|Active Comparator|Brainport high dose|
2450796|NCT03236259|Active Comparator|Brainport low dose|
2450810|NCT03236259|Placebo Comparator|Placebo|Maltodextrin
2450880|NCT03235401||Pulmonary Arterial Hypertension patients|
3153711|NCT00281983|Experimental|Allogeneic stem cell transplantation|"Cytoreductive therapy for inducing a state of partial remission:~FC or FC-R or alternative salvage regimens (e.g. Alemtuzumab)~Conditioning regimen:~FC +/- ATG (Arm A) or FC/Busulfan +/- ATG (Arm C: refractory patients only)~allogeneic-PBSCT (from HLA-identical donor)~GVHD prophylaxis: CSA + MTX or MMF~+/- DLI (Donor lymphocyte infusions)"
3153712|NCT00282009|Active Comparator|Basic Internet|Basic Internet
2451108|NCT03234127|Other|Atherosclerosis- resistance|FH Patient without atherosclerosis
2451113|NCT03234127|Other|Control|FH patient with atheroclerosis
2451123|NCT03234127|Other|the related population without familial hypercholesterolemia|No FH patient
2451185|NCT03233451|Experimental|Interventional group|Subjects receive guided psycho-behavioral intervention once a week for 8 weeks. After 8 weeks, the subjects will receive monthly psychological counseling for 7 months.
2451188|NCT03233451|No Intervention|control group|Subjects will receive usual care and be contacted as same frequent as the intervention group.
2451311|NCT03232502|No Intervention|Control|
2451313|NCT03232502|Experimental|Intervention|
2451350|NCT03232346|Experimental|Regimen 1|Rapid Monday to Friday oral naltrexone-induction procedure
2451352|NCT03232346|Experimental|Regimen 2|5-week buprenorphine taper from maintenance dose of 8, 6, or 4mg
3153713|NCT00282009|Experimental|Enhanced Internet|Enhanced Internet
2451441|NCT03231618|Experimental|Normal weight group|20 normal-weight males taking 3 types of assigned diets in random orders
2451443|NCT03231618|Experimental|Overweight/ obesity group|20 overweight/ obesity males taking 3 types of assigned diets in random orders
2451563|NCT03230812|Experimental|Experimental: carnitine intervention (in all participants)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
2451709|NCT03229928||Stakeholder Advisory Panel|The investigators will recruit 2 parents of children with IDD, 2 special education teachers, and 2 behavior health professionals to assist with the development and initial testing of the upgraded MOCHA application features to test usability.
2451715|NCT03229928||Primary Participants|The study primarily involves recruitment of clinically referred minor patients with IDD and their parents and teachers. Parents and teachers of 10 patients with IDD and co-morbid behavior problems will be asked to collect data via the MOCHA application on the frequency, antecedents,consequences, and other correlates of specific behavioral concerns.
2451719|NCT03229928||Sensor Wearing Participants|These will be the same participants from aim 2. All participants will be offered the opportunity to wear the sensors and provide and chose which ones they would prefer to wear. Two participants will be asked to wear the sensor for 48 hours in order to pilot test the feasibility of syncing sensor and MOCHA application data collection.
2451754|NCT03229369|Active Comparator|Isolated ACL|Standard Anterior Cruciate Ligament Reconstruction only
2451755|NCT03229369|Experimental|Combined ACL and ALL|Anterior Cruciate Ligament Reconstruction associated with Anterolateral Ligament Reconstruction
2451808|NCT03229174|Experimental|Intervention phase|Droxidopa unforced titration dose (starting at 100mg by mouth TID) or matching placebo and titrated over 2 weeks up to maximum of 600 TID. Efficacy evaluation of given dose at week 4
2451816|NCT03229174|Other|Open label extension phase|All subjects allowed into a 4 week open label extension. Similar titration will start at 100mg Droxidopa three times a day (TID), but can be titrated up daily using the same dose escalation scale.
3153714|NCT00282009|Experimental|Enhanced Internet plus Phone|Enhanced Internet + proactive telephone counseling
3153715|NCT00282035|Experimental|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
3153716|NCT00282035|Other|Whole breast irradiation|Whole breast irradiation
3153717|NCT00282100|Experimental|Gefitinib (Iressa)|Open label single arm study of Gefitinib (Iressa) 250mg daily as adjuvant therapy in patients with resectable Hepatocellular Carcinoma
3153718|NCT00282126|Experimental|1|Participants will receive 90 meq of potassium citrate.
3153719|NCT00282126|Experimental|2|Participants will receive 60 meq of potassium citrate.
3153720|NCT00282126|Placebo Comparator|3|Participants will receive placebo.
3153721|NCT00282165|Placebo Comparator|placebo|four week double blind placebo treatment phase
3153722|NCT00282165|Active Comparator|naratriptan|four week double blind experimental treatment using daily naratriptan tablets
2450476|NCT03238274||Arm 1|Arm 1 is a multi-site, single visit, prospective clinical study where subjects will be enrolled based on a physician's assessment of current Lyme specific symptoms from recent contact with a tick.
2450480|NCT03238274||Arm 2|Arm 2 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease no longer than 16 months post diagnosis and no earlier than 1 week post diagnosis.
2450482|NCT03238274||Arm 3|Arm 3 will consist of subjects selected from a pool of patients that were previously determined to have Lyme disease either by the presence of the diagnostic rash (erythema migrans) or through laboratory findings and physician diagnosis based on patient symptoms. In this Arm the site may recruit by contacting subjects previously diagnosed with Lyme disease between 17 months and 50 months post diagnosis. For the subject to be enrolled, a physician must have diagnosed the subject to have Lyme disease based on clinical symptoms.
2450565|NCT03237715||Breast fed cohort|
2450573|NCT03237715||Formula fed cohort|
2450637|NCT03237078|Experimental|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
2450689|NCT03236922|Active Comparator|Pubococcygeus Sling|This is one anti-incontinence technique commonly used at the time of fistula surgery.
2450691|NCT03236922|Active Comparator|Rectus Fascia Sling|This is another anti-incontinence technique used at the time of fistula surgery, however, less commonly than the pubococcygeus.
3153723|NCT00282178|Active Comparator|1|Candesartan 16-32 mg once daily
3153724|NCT00282178|Active Comparator|2|Hydrochlorothiazide 25-50 mg once daily
2450797|NCT03236116|Experimental|Almond Group|Participants will consumed almonds every day for 6 months, but will not be allowed to consume any other nuts or nut products.
2450811|NCT03236116|Experimental|Control Group|Participants will continue with their normal eating routine for 6 months, but will not be allowed to consume any nuts or nut products.
2450849|NCT03235596|Experimental|treated arm|Patients received cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2 mA during 15 minutes. They have 10 sessions in 5 consecutive days, 2 sessions per day.
2450929|NCT03235323|Experimental|ECP group|Patients of ECP group are subjected to a standard ECP protocol one week postoperatively. A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2450931|NCT03235323|No Intervention|Control group|Patients of Control group received routine medicine treatment postoperatively
2450976|NCT03234868|Experimental|Optical impression|The optical impression system used for the study is TRIOS (3 shape). First of all, the operators in charge of taking the digital impressions are going to get trained prior the study and will calibrate (learning curve). MIS Scan bodies will be placed on the multi-unit plaforms, an x-ray will be taken in order to check the fit) and the impression will be realised following the instruction given by the system (first the maxillary and mandibular impressions followed by the bite registration). Shade will be chosen using VITA toothguide 3D master (to pick the right zirconia shade).
2450977|NCT03234868|Active Comparator|Conventional impression|Once the impression coping is placed on the multi-unit plaform, the fit will be checked with an intra-oral X-ray. The impressions will be made with medium viscosity silicon. As a second step, alginate antagonist impression will be done. Bite will not be recorded (single tooth missing). The two impressions will be placed in a hermetic plastic bag and send to lab. Shade will be chosen using VITA toothguide 3D master.
2450980|NCT03234868|Experimental|Digital workflow|The implant crowns issued from digital impressions will be done according a cast less / full digital workflow. The STL files collected from the TRIOS will be sent directly to the lab. The designing of the full zirconia crowns will be performed in the TRIOS 3SHAPE program. The resulting files will be sent to the CAM unit production (Amman Girrbach milling machine & MAZAK CNC machine: Mcenter to be specify (Berlin or Israel) to be milled (milled & sintered only) considering the direct adaption for a Multi-Unit connection. A superficial make-up will be done on the monolithic crown in the lab. And finally, the products will be delivered to the dentist.
2450981|NCT03234868|Active Comparator|Conventional workflow|"The implant crowns issued from conventional impressions will be realised by sending the impressions to the lab (Mirko Picone). The lab will pour the impressions in dental stone (class 4 scannable without powdering: extra hard and scanning powder included). Then, the technician will realize a mock-up of the crown's framework on a temporary abutment in DuraLay Resin.~The mock up will be scanned with ZIRKONZAHN scanner (or equivalent) and send this information to a central fabrication facility for milling (Amman Girrbach milling machine & MAZAK CNC machine:~Mcenter: to be specify (Berlin or Israel). The lab technician will get the Zi framework back and will apply veneer ceramic."
2451019|NCT03234621|Experimental|conventional tidal group|provide tidal volume of 6ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
2451020|NCT03234621|Experimental|low tidal group|provide tidal volume of 4ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
3153725|NCT00282178|Placebo Comparator|3|
3153726|NCT00282204|No Intervention|Control|Usual care control
3153727|NCT00282204|Experimental|Hypnosis + CD|Hypnosis plus audio cd on hypnosis
3153728|NCT00282204|Active Comparator|Audio CD on Hypnosis|Audio CD on hypnosis sessions weekly on three occasions after 34 weeks gestation
3153729|NCT00282399|Experimental|DACO-019 2mg/m^2|DACO-019 2mg/m^2 twice daily (BID)
3153730|NCT00282399|Experimental|DACO-019 5mg/m^2|DACO-019 5mg/m^2 BID
3153731|NCT00282399|Experimental|DACO-019 10mg/m^2|DACO-019 10mg/m^2 BID
3153732|NCT00282425|Experimental|Allogeneic Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation will be performed on eligible patients
3153733|NCT00282503|Active Comparator|methylprednisolone equivalent.|2mg/kg daily will be administered initially and may be tapered according to a tapering schedule provided in the protocol.
2450485|NCT03238248|Experimental|Pevonedistat and Azacitidine|"Participants will receive Azacitidine (via an injection under the skin, or via an intravenous infusion (IV bag) on days 1, 2, 3, 4 and 5 of each 28-day cycle.~Participants will receive Pevonedistat (through a vein in the arm) on Days 1, 3 and 5 of each 28-day cycle."
2450577|NCT03237897||Class attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and attend the preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
2450581|NCT03237897||Class non-attendees|A cohort of patients who are scheduled to undergo colorectal surgical procedures and do not attend the scheduled preoperative education class. Patients will be affixed with a pedometer in the postoperative period until discharge.
2450649|NCT03237273|Experimental|Single|All patients will undergo ultrasound scan using the HEAD-US Scoring System by a non-imaging specialist
2450703|NCT03236753|Experimental|Thread-Embedding Acupuncture (TEA)|The TEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm TEA on predefined 23 acupoints selected by expert group according to STRICTA. All other treatment affecting the outcomes will be prohibited during the trial period. All therapeutic procedure will be performed by acupuncture specialists who have received training for the consensus of multicenter.
2450704|NCT03236753|Sham Comparator|Sham Thread-Embedding Acupuncture (STEA)|The STEA group will be treated once a week for 8 weeks, using 29G x 40mm or 29G x 60mm sham TEA on predefined 23 acupoints selected by expert group according to STRICTA.
2450725|NCT03236402||Early young adult (20 years - 30 years)|Adults who were in the age group of 20 - 30 years was the first group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 20-30 years.
2450727|NCT03236402||Middle age adult (31 -50 years)|Adults who were in the age group of 31-50 years were in second group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 31-50 years.
2450729|NCT03236402||Late adult (51 years - 65 years)|Adults who were in the age group of 51-65 years were in third group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of 51-65 years.
2450731|NCT03236402||>65 years|Adults who were in the age group of >65 years were in fourth group. There were made two separate same age group one for rural and one for urban areas adults. Each areas age group consist 50 adults of >65 years.
2450789|NCT03236272||case group|patients with ARDS
2450792|NCT03236272||control group|patients Without ARDS
2450874|NCT03235778|Experimental|group1|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:11.78mg Volume:0.50ml Frequency:Once Duration:30min A total of 10 subjects, 2 subjects served as pre-test groups, given to the test drug；the remaining 8 subjects,6 received the test drug and 2 received the placebo.
2450875|NCT03235778|Experimental|group2|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:23.56mg Volume:1.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2450876|NCT03235778|Experimental|group3|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:47.13mg Volume:2.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2450877|NCT03235778|Experimental|group4|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:94.25mg Volume:4.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2450878|NCT03235778|Experimental|group5|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:164.92mg Volume:7.00ml Frequency:Once Duration:30min A total of 8 subjects,6 received the test drug and 2 received the placebo.
2450882|NCT03235778|Experimental|group6|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:259.16mg Volume:11.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
2450885|NCT03235778|Experimental|group7|Generic name:Felbinac Trometamol Injection;Placebo: normal saline Dosage form:Injection Dosage:377.00mg Volume:16.00ml Frequency:Once A total of 8 subjects,6 received the test drug and 2 received the placebo. Duration:30min
2451014|NCT03234673|Experimental|Group A (Tacrolimus group):|fractional CO2 laser therapy and Tacrolimus ointment 1
2451015|NCT03234673|Experimental|Group B (Calcipotriol group):|fractional CO2 laser therapy and Calcipotriol ointment
2451016|NCT03234673|Experimental|Group C (NB-UVB group):|fractional CO2 laser therapy and NB-UVB twice weekly
2451039|NCT03234257|Other|patients with carotid stenosis.|asymptomatic patients with carotid stenosis.
2451391|NCT03232177|Experimental|Anagre Cap.|twice a day
2451468|NCT03231540|Experimental|intervention group|whey protein supplement enriched enteral nutrition, with protein intake of 1.5g/kg/day; in addition to standardized exercise training
2451469|NCT03231540|No Intervention|control group|standard enteral nutrition, with protein intake of 1g/kg/day; in addition to standardized exercise training
2451507|NCT03231072|Experimental|Electrical Impedance Tomography record|Electrical Impedance Tomography monitoring of the pleural effusion evacuation.
3153734|NCT00282503|Experimental|Uvadex+ECP|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days"
3153735|NCT00282581|Placebo Comparator|placebo|
2451736|NCT03229889|Active Comparator|Flomax + Placebo|Patients will be prescribed Flomax 0.4Mg Capsule and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2451802|NCT03229044||BMI 33-39|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 33-39 kg/m2
3153736|NCT00282646|Active Comparator|1|intraarterial application of bone marrow mononuclear cells
3153737|NCT00282646|Placebo Comparator|2|intraarterial application of placebo
3153738|NCT00282685|Experimental|Intra-arterial stemcell therapy|Patients were treated with intra-arterial stemcells delivered via catheter examination
3153739|NCT00282711||1|Standard Exercise treadmill test
3153740|NCT00282711||2|Exercise treadmill testing with nuclear imaging
2450578|NCT03237741|Experimental|Treatment Sequence 2: ABC2D2|Single dose of reference capsule GDC-0134 (Treatment A) during Period 1. Single dose of prototype capsule GDC-0134 (Treatment B) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
2450582|NCT03237741|Experimental|Treatment Sequence 3: BAC1D1|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered as GDC-0134-in-applesauce preparation under fasting conditions (Treatment C1) during Period 3. Single dose of GDC-0134 prototype capsule administered under fasting conditions in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D1) during Period 4. The washout period between doses will be a minimum of 21 days.
2450588|NCT03237741|Experimental|Treatment Sequence 4: BAC2D2|Single dose of prototype capsule GDC-0134 (Treatment B) during Period 1. Single dose of reference capsule GDC-0134 (Treatment A) during Period 2. Single dose of GDC-0134 prototype capsule administered after a high-fat meal (Treatment C2) during Period 3. Single dose of GDC-0134 prototype capsule administered after a high-fat meal in combination with 20 mg rabeprazole, and following prior administration of rabeprazole once daily for 3 days (Treatment D2) during Period 4. The washout period between doses will be a minimum of 21 days.
2450680|NCT03236766|Other|No intervention|
2450701|NCT03236636|Experimental|Icaritin|Icaritin:600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
2450702|NCT03236636|Active Comparator|HUACHANSU PIAN|HUANCHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
3153741|NCT00282776|Active Comparator|TAU|Participants will receive treatment as usual
3190266|NCT00785746|No Intervention|stretch and strength|This program consists of general stretching exercises and peripheral muscle strengthening exercises with a special emphasis on strengthening the upper extremity muscles because of their importance for ADL but not necessarily balance.
2450845|NCT03235674|Experimental|High-intensity stair climbing exercise|3 x 60 seconds of stair climbing, at a vigorous pace as described by rating of perceived exertion, separated by 60 seconds of rest. Subjects will complete supervised sessions 3 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
2450848|NCT03235674|No Intervention|standard cardiac rehabilitation exercise|Subjects will complete the traditional cardiac rehabilitation program, combination of aerobic and resistance exercise 2 times/week for 2 weeks, and then continue unsupervised for the following 10 weeks.
2451030|NCT03234517|Experimental|Vaginal Clindamycin Cream Plus continuous Vaginal Probiotic|Vaginal Clindamycin Cream followed by continuous Vaginal Probiotic use for 60 days
2451031|NCT03234517|Active Comparator|Vaginal Clindamycin Cream Plus interrupted Vaginal Probiotic|Vaginal Clindamycin Cream followed by interrupted Vaginal Probiotic use
2451082|NCT03234192|Active Comparator|Therapeutic ultra sound|
2451083|NCT03234192|Active Comparator|Astym Treatment Technique|
2451084|NCT03234192|Active Comparator|Graston Treatment Technique|
2451091|NCT03233841||Living non-HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have not undergone hematopoietic stem cell transplantation (HSCT).
2451093|NCT03233841||Living HSCT Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are currently alive and have undergone hematopoietic stem cell transplantation (HSCT).
2451094|NCT03233841||Deceased Farber Disease Patients|Patients with a confirmed diagnosis of Farber disease who are deceased (including patients who may or may not have undergone hematopoietic stem cell transplantation).
2451150|NCT03233555|Active Comparator|Arm I (brochure)|Participants receive National Cancer Institute's Facing Forward brochure.
2451156|NCT03233555|Experimental|Arm II (EXCELS website)|Participants have untimed access to the EXCELS mobile web application.
2451157|NCT03233555|Experimental|Arm III (Healthcare coaching call)|Participants also receive 4 quarterly calls of 15-20 minutes each over 3 months. These calls focus on checking if patients have received preventive and cancer related follow-up care.
2451159|NCT03233555|Experimental|Arm IV (EXCELS website, health coaching calls)|Participants have access to EXCELS as in Arm II. Participants also receive 4 calls as in Arm III.
2451213|NCT03233178||SGLT2|Patients initiating SGLT2 inhibitors
2451216|NCT03233178||Liraglutide|Patients initiation liraglutide
2451220|NCT03233178||Sitagliptin|Patients initiating sitagliptin
2451222|NCT03233178||Control Group|Patients who did not initiate any new anti-hyperglycemic treatment
2451250|NCT03232918|No Intervention|Standard Dose Oxytocin|Patients randomized to the standard dose oxytocin will have their oxytocin infusion maintained at the standard of care protocol prior to placement of a combined spinal epidural for labor analgesia
2451251|NCT03232918|Experimental|Half Dose Oxytocin|Patients randomized to the half dose oxytocin will have their oxytocin infusion reduced by 50 % prior to placement of a combined spinal epidural for labor analgesia.
2451289|NCT03232788|Experimental|Test group|Bone regeneration with autogenous bone + scaffold.
2451291|NCT03232788|Active Comparator|Control group|Bone regeneration with autogenous bone + collagen membrane.
2451330|NCT03232450|Active Comparator|PFO Closure|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED), Gore Cardioform Septal Occluder.
2451332|NCT03232450|Other|Control|Subjects randomized to this arm will receive 81 mg enteric coated aspirin, a Cardiovascular Implantable Device (CIED)
2451364|NCT03232047|Experimental|Combined cognitive training|The training is combined executive function and memory training. The training is considered 'adaptive', which means that the difficulty level of the tasks increases during the sessions according to the individual level of mastering for each participant, making the patient work at their maximum capacity at all times.
2451371|NCT03232125|Experimental|Ramosetron group|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
2450631|NCT03237130||preoperative enhanced chest CT|The cohort contains patients with preoperative therapies and patients without preoperative therapies. Each patient receives regular preoperative enhanced chest CT; for patients with preoperative therapies, they usually undergo twice enhanced chest CT examination at before and after preoperative therapies, the CT images after preoperative therapies will be used for analysis
2450699|NCT03236961|Active Comparator|Intravenous & per oral antibiotics|Ertapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
2450700|NCT03236961|Active Comparator|Per oral antibiotics|Moxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
2450745|NCT03236454|Active Comparator|anodal tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of 2 mA anodal stimulation
2450749|NCT03236454|Sham Comparator|sham tDCS|DC-Stimulator MC, NeuroConn: 20 minutes of sham stimulation; Ramping up over 50 seconds at the beginning and an equal amount of time for tapering off at the end;
2450807|NCT03236103|Other|Subjects with VAD in place|Adult patients with VAD in place who are admitted to the hospital for acute medical illness. The investigators will provide clinical recommendations to the subject's primary care provider.
2450906|NCT03235297||Healthy subjects|Healthy subjects
2450911|NCT03235297||Subjects with COPD|Subjects with a diagnosis of COPD
2450935|NCT03235024|Active Comparator|B244|"B244 suspension in 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
2450938|NCT03235024|Placebo Comparator|Vehicle|"Vehicle, 30ml/bottle~Subjects will apply a total of 8 pumps of IP per application to all affected areas twice-a-day"
2451052|NCT03234699|Experimental|Single Group|
2451090|NCT03233919|Experimental|CORIC|"Comprehensive remote ischaemic conditioning (CORIC) will be induced using an automated RIC device:~Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
2451092|NCT03233919|No Intervention|Non-CORIC|Controls did not undergo comprehensive remote ischaemic conditioning.
3153742|NCT00282776|Experimental|DCM|Participants will receive care management for postpartum depression
3153743|NCT00282802||1|National Academy of Sciences/National Resource Council (NAS/NRC) World War II Veteran Twins Cohort
2451278|NCT03232970|Experimental|FPD group|This group will undergo three months of weekly lectures to incorporate more fiber in their diet.
2451280|NCT03232970|No Intervention|FPD Control group|This group will receive all the assessments before, during and after the three months program period but will not attend the weekly lectures.
2451355|NCT03232229||Tennis players|
2451367|NCT03231982|Experimental|Group I|Fixed-Dose combination of Candesartan cilexetil 8mg and Amlodipine 5mg(or Fixed-Dose combination of Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
2451368|NCT03231982|Active Comparator|Group II|Candesartan cilexetil 8mg and Amlodipine 5mg(or Candesartan cilexetil 16mg and Amlodipine 5mg), once a day for 8 weeks
2451419|NCT03231813|Experimental|SLS irritation model and Treatment|SLS induced irritation on two sites each on forearms and back Emollient cream treatment
2451425|NCT03231813|Placebo Comparator|SLS irritation model and No Treatment|SLS induced irritation on two sites each on forearms and back No treatment
2451426|NCT03231813|Sham Comparator|Sham irritation and Treatment|Sham irritation (water) on two sites each on forearms and back Emollient cream treatment
2451427|NCT03231813|No Intervention|Sham irritation and No Treatment|Sham irritation (water) on two sites each on forearms and back No treatment
2451516|NCT03231059||Experimental treatment strategy|All patients in the treatment group received acetylsalicylic acid (ASA) and ticagrelor for 1 month followed by 23 months of ticagrelor monotherapy
2451517|NCT03231059||Reference treatment strategy|"Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and ticagrelor for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy."
2451585|NCT03230669|No Intervention|Control|this arm receives treatment as usual and no intervention.
2451587|NCT03230669|Experimental|CBT4CBT|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
2451612|NCT03230305||Elderly cancer patient cohort|"Aged 70 years or over~With solid cancer irrespective of the stage~Pre-screened or screened for at least one ongoing clinical trial in the center~Informed oral consent (patient, his/her legal representant, trustworthy person or family member)~Social security affiliation"
2451665|NCT03230123|Experimental|Green banana biomass|The intervention group is constituted diet counseling plus 4.5 g of resistant starch from green banana biomass, per day, during six months.
2451667|NCT03230123|Placebo Comparator|Diet alone|The control group will receive diet counseling during six months.
2451716|NCT03229733|Experimental|Experimental group|Patients randomized to the experimental group participate in exergames training with Kinect. The supervised OT chooses different games according to the patient's needs and abilities. During therapy patients are at sitting position. The game program will be adjusted when patients got improvement. After 30 minutes of exergames training, participants will receive a 30-minutes of traditional occupational therapy.
3153744|NCT00282854||Group I: Cases|Children with rolandic epilepsy
3153745|NCT00282854||Group II: Controls|Individuals group matched to cases for ethnicity, sex and area of residence but lacking a primary brain disorder.
3153746|NCT00282893|Experimental|pTBA|Prophylactic Transluminal Ballooning Angioplasty
3153747|NCT00282893|Active Comparator|Control|currently existing therapies for the treatment of vasospasm
3153748|NCT00282906|Experimental|PET-CT|
3153749|NCT00283010|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3153750|NCT00283010|Active Comparator|Active Control|Educational DVDs
2450632|NCT03237104||acute spondylolysis|Athletes who meet the inclusion criteria and consent to participate in the pilot study will be referred directly to PT care for 2 times per week until cleared to return to sport.
2450765|NCT03236298|Active Comparator|PIEB speed of infusion 250 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 250 ml/hr by the CADD-Solis Ambulatory Infusion System.
2450767|NCT03236298|Active Comparator|PIEB speed of infusion 125 ml/hr|The programmed intermittent bolus of 10ml will be administered every 40 minutes, at a speed of 125 ml/hr by the CADD-Solis Ambulatory Infusion System.
3153751|NCT00283023|Experimental|A|Progenitor cells from the patinets with Craniotomy with V-P Shunt or ventriculostomy will be collected and cultured.
2450942|NCT03234907|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase.
2450945|NCT03234907|Placebo Comparator|Induction Phase: Placebo|Vedolizumab placebo-matching IV, infusion, at Weeks 0, 2, and 6 in the induction phase.
2450946|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q8W + Placebo Q8W|Vedolizumab 300 mg, IV, infusion, every 8 Weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching IV, infusion Q8W at Weeks 18, 26, 34, 42, 50 and 58 in the maintenance phase in participants who receive vedolizumab in the induction phase and achieve clinical response at Week 10.
2450949|NCT03234907|Experimental|Maintenance Phase: Vedolizumab 300 mg Q4W|Vedolizumab 300 mg, IV, infusion, every 4 weeks (Q4W), from Week 14 to Week 58 in the maintenance phase in participants who receive vedolizumab or placebo in the induction phase and do not achieve clinical response at Week 10.
2450952|NCT03234907|Placebo Comparator|Maintenance Phase: Placebo|Vedolizumab placebo-matching IV, infusion, every 4 weeks, Week 14 to Week 58 in the maintenance phase in participants who receive placebo in the induction phase and achieve clinical response at Week 10.
2451041|NCT03234491|Active Comparator|A-HCL low|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2451048|NCT03234491|Active Comparator|A-HCL high|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2451051|NCT03234491|Active Comparator|R-HCL|Trial arms will entail (a) HCL with RAI analog (insulin lispro or aspart) pre-meal bolus (R-HCL visit), (b) ACL with pre-meal dose titrated down to the lower dose inhaled insulin (AHCL low visit), and (c) ACL with pre-meal dose titrated up to higher dose inhaled insulin (A-HCL high visit).
2451136|NCT03234010|Experimental|FT21092 Group|7 day at-home use of electronic cigarette FT21092 followed by a 2 day in-clinic period.
2451139|NCT03234010|Experimental|FT21093 Group|7 day at-home use of electronic cigarette FT21093 followed by a 2 day in-clinic period.
2451141|NCT03234010|Experimental|FT21096 Group|7 day at-home use of electronic cigarette FT21096 followed by a 2 day in-clinic period.
2451142|NCT03234010|Experimental|FT21097 Group|7 day at-home use of electronic cigarette FT21097 followed by a 2 day in-clinic period.
2451169|NCT03233399|Active Comparator|Healthy Patients|All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).
2451171|NCT03233399|Active Comparator|PMD/PNES patients|PMD and PNES subjects will be referred by the treating
3153752|NCT00283088|Active Comparator|Group 1|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
3153753|NCT00283088|Active Comparator|Group 2|Groups 1 and 2: Parallel groups, randomized to hypothermia or no hypothermia. Both groups receive tPA as a part of standard of care.
3153754|NCT00283088|No Intervention|Group 3|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
2451301|NCT03232697|Other|Healthy subjects|Subjects will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2451304|NCT03232697|Other|Alzheimer patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2451307|NCT03232697|Other|Parkinson and Huntington patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2451308|NCT03232697|Other|Diabetic patients|Patients will be submitted to both the full version of the Montreal Cognitive Assessment and of the 5-minutes version of the Montreal Cognitive Assessment
2451361|NCT03232320|Experimental|MEDITOXIN|
2451362|NCT03232320|Placebo Comparator|Placebo|
2451403|NCT03231865||Preoperative patients|Patients present themselves before an operation to the Anesthesiologist. They are screened for study eligibility.
2451433|NCT03231670||lobar pneumonia|Inpatient with lobar pneumonia will undergo a blood sampling during their hospitalization and after resolution of the infection (2 Months)
2451449|NCT03231384|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
2451457|NCT03231384|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
2451502|NCT03231176|Experimental|Varlitinib and Capecitabine|
2451538|NCT03230825|Experimental|Oral contraceptives|Oral contraceptive agent, given for free, for 3 weeks and a follow up visit a week after treatment withdrawal.
2451542|NCT03230825|Sham Comparator|Expectant management|Expectant management for 3 weeks and a follow up visit a week later.
2451598|NCT03230565|Active Comparator|Continuous Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
2451599|NCT03230565|Active Comparator|Intermittent Bolus Infusion|Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
2450639|NCT03237624|Experimental|Functional chewing gum|Subjects given as intervention functional chewing gum device to supplement oral hygiene practices. Functional gum contains chitosan which is a food additive or generally recognized as safe food product. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
2450644|NCT03237624|Placebo Comparator|Control chewing gum|Subjects given control gum to supplement oral hygiene practices. Placebo gum does not contain any active ingredients. Individuals will use this gum 20 to 30 minutes three times per day. Subjects will brush and floss normally twice a day.
2450693|NCT03236792|Experimental|Newly Diagnosed AL Amyloidosis|Ixazomib/Cyclophosphamide/Dexamethasone. Treatment cycles will be repeated up to 6 cycles or until disease progression or until development of significant treatment-related toxicities.
2450761|NCT03236480||COPD|Patients who admitted to Peking Universtiy People's Hospital and Ningde City Hospital between January 2017 and January 2019 with AECOPD will be enrolled
2450763|NCT03236480||healthy control|People aged over 40, without any chronic respiratory disease or acute respiratory infections in the last 2 weeks, and be willing to participate in the study
2450806|NCT03235986|Experimental|nCPAP+ Nebulised Curosurf®|Curosurf® administered through nebulization
2450819|NCT03235986|Other|nCPAP alone (control)|Standard of care, respiratory support used also during experimental arms
3190267|NCT00785811|Experimental|1|L-arginine aspartate (Targifor)
3190268|NCT00785811|Placebo Comparator|2|Placebo
2451103|NCT03234088|Other|Home HF monitoring|Digital scale readings are transmitted wirelessly to the handheld device. Patients will remotely log on to a secure server to answer daily symptom questions. Patients will complete surveys after voluntarily completing the informed consent process and at study closeout.
2451148|NCT03233646|Experimental|Case|500 patients with MCI and/or AD, PD, multiple sclerosis, and Huntington's disease.or other neuro-degenerative disease
2451155|NCT03233646|Active Comparator|Controls|Controls will be recruited from the relatives/attendants of the patients , or will be patients themselves, and will not have a diagnosis of MCI/AD/PD/MS/Huntington's Disease or other neuro-degenerative disease.
3190269|NCT00785824||1 A-A Breastfeeding Mothers|Group 1: Postpartum African-American breastfeeding women at 6-8 weeks post childbirth, and again at 12-14 weeks post childbirth
3190270|NCT00785824||2 - AA Bottlefeeding Mothers|Group 2: Postpartum African-American bottlefeeding women at 6-8 weeks post childbirth and again at 12-14 weeks post childbirth.
3190271|NCT00785824||3 - AA Normal Controls|Group 3: Normal African-American non-pregnant controls who are age-matched to Group 1
3190272|NCT00785837|No Intervention|Before Hidrotherapy|
3190273|NCT00785837|Experimental|Hidrotherapy|
3190274|NCT00785850|Experimental|1|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower
3190275|NCT00785863|Placebo Comparator|Placebo|
2451429|NCT03231683|Active Comparator|Esketamine|Esketamine and remifentanil to be given alongside with propofol through target control infusion pump.
2451431|NCT03231683|Placebo Comparator|Control|Saline and remifentanil to be given alongside with propofol through target control infusion pump.
2451475|NCT03231280|Experimental|SB-061|SB-061
2451477|NCT03231280|Placebo Comparator|Placebo|Placebo
2451513|NCT03230994||Different Treatment Groups|Women would receive different pharmacotherapy from the standard approach，such as levonorgestrel-releasing intrauterine system(LNG-IUS)，Gonadotrophin releasing hormone agonist(GnRH-a),surgery,etc.
2451543|NCT03230760|Experimental|treatment|
2451578|NCT03230552|Experimental|Video group|Residents assigned to this group will watch an instructional surgical video prior to LSO surgery.
2451583|NCT03230552|No Intervention|No video group|Residents assigned to this group will not watch an instructional surgical video prior to LSO surgery.
2451643|NCT03230357|Experimental|PICC guided by EDUG|PICC(Peripherally Inserted Central Catheter)guided by ECG Doppler ultrasonic Guidance（EDUG),EDUG is a combination device which can be used for selecting the right vein and precise positioning for the catheter tip during the PICC cathetering.
2451698|NCT03230019|Active Comparator|chest tube|VATS with chest tube placement
2451701|NCT03230019|Experimental|two-lumen catheter|VATS with two-lumen catheterization
2451756|NCT03229408|Experimental|Salsalate-Treated Lean PCOS without IR|n=15
2451758|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS without IR|n=15
2451759|NCT03229408|Experimental|Salsalate-Treated Lean PCOS with IR|n=15
2451761|NCT03229408|Placebo Comparator|Placebo-Treated Lean PCOS with IR|n=15
2451763|NCT03229408|Experimental|Salsalate-Treated Obese PCOS|n=15
2451765|NCT03229408|Placebo Comparator|Placebo-Treated Obese PCOS|n=15
2451863|NCT03228550|Experimental|Efamol Active 50+ and exercise|Efamol Active 50+ Multinutrient supplement and aerobic exercise
2451865|NCT03228550|Experimental|Efamol Active 50+ and non-exercise|Efamol Active 50+ Multinutrient supplement and non-aerobic exercise
2451867|NCT03228550|Experimental|Placebo and exercise|Placebo supplement and aerobic exercise
3190276|NCT00785863|Active Comparator|Remifentanil|
3190277|NCT00785863|Active Comparator|Ketorolac and remifentanil|
3190278|NCT00785863|Active Comparator|Parecoxib and remifentanil|
3190279|NCT00785876|No Intervention|1|Control Sites
3190280|NCT00785876|Experimental|2|Intervention Sites
3190281|NCT00785915|Experimental|1|
3190282|NCT00785915|Placebo Comparator|2|given (2 subjects in each ethnic/dose group)
3190283|NCT00785941|Experimental|IMC-A12|"All patients will receive intravenous infusions of IMC-A12, with the dose depending on which cohort they are enrolled into a minimum of three patients will be enrolled in each Cohort. When all patients complete a cohort, dose escalation to the next Cohort will occur.~A treatment cycle will consist of IMC-A12 administered intravenously, once every other week for 4 weeks, for a total of 2 doses; followed by a 2-week observation period."
3190284|NCT00785954|Experimental|A1: KAI-9803|
3190285|NCT00785954|Experimental|A2: KAI-9803|
3190286|NCT00785954|Experimental|A3: KAI-9803|
3190287|NCT00785954|Placebo Comparator|A4: Placebo|
3190288|NCT00785967|Experimental|1|raltegravir 400mg bid + Truvada 1 tab qd
3190289|NCT00785967|Active Comparator|2|efavirenz 600mg qhs + Truvada 1 tab qd (or Atripla 1 tab qhs)
2450669|NCT03237026||Cohort A|Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.
2450671|NCT03237026||Cohort B|Validation cohort will be recruited in the next 24 months of the study period .
2450723|NCT03236688||MCRPC|Metastatic Castrate Resistant Prostate Cancer (MCRPC) Patients
2450772|NCT03236285|Experimental|HIIT only|Volunteers will be submitted to high-intensity interval training (HIIT) performed in fed state
2450773|NCT03236285|Experimental|CT+FAST|Volunteers will be submitted to continous training (CT) performed in the fasting state
2450774|NCT03236285|Experimental|CT only|Volunteers will be submitted to continous training (CT) performed in fed state.
2450775|NCT03236285|Experimental|HIIT+FAST|Volunteers will be submitted to high-intensity interval training (HIIT) performed in the fasting state.
2450800|NCT03235869|Experimental|Radiation Therapy + Durvalumab|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions) Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
2450842|NCT03235635||Preterm|newborn infants were born with a gestational age of less than 32 weeks
2450844|NCT03235635||Late preterm|newborn infants were born with a gestational age of greater than 32 weeks and less than 36 weeks
2450847|NCT03235635||full-term|newborn infants were born with a gestational age of greater than or equal to 37 weeks
2450956|NCT03235362|Experimental|1|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
2450958|NCT03235362|Experimental|2|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
2450960|NCT03235362|Experimental|3|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3."
2450961|NCT03235362|Experimental|4|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1706 QD for 6 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 3.~There will be a washout of at least 10 days between the last dose in one period and the first dose in the subsequent period."
2450962|NCT03235362|Experimental|5|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 3."
2450963|NCT03235362|Experimental|6|"5 subjects will be assigned In this group. Subjects will receive multiple oral doses of YHR1705+YHR1706 QD for 5 consecutive days during period 1.~Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days during period 2.~Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days during period 3."
2451023|NCT03234530||WTC responders|WTC Health Program participants
2451025|NCT03234530||Urban workers|Control group of urban workers in NYC not exposed to the dust from the WTC
2451053|NCT03234231|No Intervention|Control Group|This group receive nothing during the study period.
2451057|NCT03234231|Experimental|Intervention Group|A 3-month supervised tooth brushing programme will be provided to the students. An oral health education talk with written material delivered to the carers and the students
2451114|NCT03233997|Experimental|FT21018 Group|7 day at-home use of electronic cigarette FT21018 followed by a 2 day in-clinic period.
2451122|NCT03233997|Experimental|FT21033 Group|7 day at-home use of electronic cigarette FT21033 followed by a 2 day in-clinic period.
2451124|NCT03233997|Experimental|FT21034 Group|7 day at-home use of electronic cigarette FT21034 followed by a 2 day in-clinic period.
2451126|NCT03233997|Experimental|FT21035 Group|7 day at-home use of electronic cigarette FT21035 followed by a 2 day in-clinic period.
2451167|NCT03233503||Dutch trained taste panel|The study population consists of a sample of 15 healthy Dutch males and females, recruited in the Wageningen area.
2451168|NCT03233503||Malaysian trained taste panel|The study population consists of a sample of 20 healthy Malaysian males and females, recruited in the Subang Jaya, Selangor area.
3190290|NCT00785993|Active Comparator|Control Group|Fresh donor oocytes
3190291|NCT00785993|Experimental|Group I|vitrified donor oocytes
3190292|NCT00786006|Experimental|Arm 1|FOLFIRI.3
3190293|NCT00786006|Active Comparator|Arm 2|FOLFOX
3208547|NCT00975793|Experimental|Early Goal Directed Therapy|Randomised allocation of early goal-directed therapy (EGDT).
3208548|NCT00975819|Experimental|Sirolimus|
2451565|NCT03230656|Experimental|Early therapy 1 month post-injury|"Early cognitive-communication therapy 1 month post-injury:~working memory strategies~executive function program~divided attention program~environmental changes~identification of problematic cognitive-communication situations"
2451567|NCT03230656|Active Comparator|Waitlist therapy 2 months post-injury|"Waitlist early cognitive-communication therapy 2 months post injury:~- Same cognitive-communication therapy is administered"
2451602|NCT03230435||Anorexia nervosa|Treatment settings as usual.
2451603|NCT03230435||Healthy controls|No interventions.
2451653|NCT03230149||Molecular and genetic tests|Measurements of the alpha-GAL enzyme activity will be performed knowing that for male patients with alpha-GAL activities below the cut-off value and all female patients, a blood sampling for full genetic sequencing of all seven exons including promotors of the a-GAL gene will be done
2451751|NCT03229603|Other|Cluster of 3000 women|Cluster will be selected from an existing cervical, breast, and oral cancer screening program in Mumbai, India and its surrounding semi-urban and rural areas.
3208549|NCT00975832||women with polycystic ovary syndrome|
3208550|NCT00975832||women without polycystic ovary syndrome|
2450672|NCT03236818|Other|Upfront combination therapy|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
2450708|NCT03236649|Experimental|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
2450710|NCT03236649|Active Comparator|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
2450786|NCT03235947|Experimental|Fosfomycin disodium|"Fosfomycin disodium 4 g intravenously: 3 hours before kidney transplant surgery, 3 hours before urinary catheter removal and 3 hours prior to ureteral catheter removal.~Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours."
2450788|NCT03235947|Active Comparator|Trimethoprim / Sulfamethoxazole|"Trimethoprim / Sulfamethoxazole (160/800 mg) 1 tablet orally every 24 hours.~Intravenous placebo solution at the same time of application of fosfomycin disodium in the experimental arm."
2450861|NCT03235648|Experimental|cardiophrenic nodes excision in ovarian cancer|We are going to evaluate the comorbidites and impact of cardiophrenic lymph nodes excision in cases of advanced ovarian cancer with positive cardiophrenic lymph nodes
2450918|NCT03235245|Active Comparator|ARM A: Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then treatment will be left at the investigator choice and continued until the 2nd progression.
2450920|NCT03235245|Experimental|ARM B: Encorafenib + Binimetinib + Nivolumab + Ipilimumab|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks followed, after a week of pause, by nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections, followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression. Then patients will be rechallenged with encorafenib 450 mg QD + binimetinib 45 mg BID orally continuously until the 2nd progression.
2451042|NCT03234556|Active Comparator|Arm I (SR-Bx)|Patients undergo SR-Bx. If SR-Bx doesn't reveal clinically significant cancer, then MRI will be done in 3 months, and if lesion is present (PIRADS ≥ 3) schedule for MRUS-Bx. If there is no lesion, then no biopsy. Schedule MRI in 12 months after the initial MRI.
2451047|NCT03234556|Experimental|Arm II (MRI, MRUS-Bx, SR-Bx)|"Patients undergo MRI. Must be scheduled at least one day before MRUS biopsy.~If MRI shows no lesion present (PIRADS 1-2), then no MRUS-Bx. Schedule for SR-Bx only.~If MRI shows lesion present (PIRADS ≥ 3), perform MRUS-Bx, which will be done first and followed immediately by SR-Bx."
2451138|NCT03233802|Experimental|Individualized Assess & Treatment (IATP)|Intervention: Cognitive-Behavioral IATP consists of 12 weekly visits of individual treatment. IATP employs cellphone-based experience sampling via interactive voice response (IVR) to assess drinking, plus craving, thoughts, feelings, and coping behaviors to develop near a real-time picture of patients' high-risk situations and the ways they use to deal with them. This information will be used by the therapist and client together to problem-solve and devise adaptive coping responses to these specific high-risk situations, and develop generalized solutions to deal with other situations in the future.
2451140|NCT03233802|Active Comparator|Packaged Cognitive-Behavioral (PCBT)|Intervention: Cognitive-Behavioral PCBT consists of 12 weekly visits of individual treatment. PCBT is designed to remediate deficits in skills for coping with interpersonal (e.g., social pressure, conflict with others) and intrapersonal (e.g., craving, anger) antecedents to drinking. The treatment consists of 6 mandatory modules (e.g., managing cravings) plus 6 electives from a list of 10 (e.g., receiving criticism; scheduling pleasant activities).The treatment, based on manuals developed for our previous clinical research provides a structured experience using didactic presentations, behavioral rehearsal, and homework practice exercises.
2451143|NCT03233802|Active Comparator|Case Management (CaseM)|Intervention: Social and Instrumental Support CaseM is included to control for cohort and other common factors in treatment. During the 12 individual CaseM sessions the therapist and participant will identify problems in daily living that may be of concern, and consider community resources that might help in dealing with them (e.g., contacting a psychiatrist for depression, or finding a better place to live). The therapist's role is to explore the patient's concerns, help to identify goals and resources, provide verbal support, and troubleshoot difficulties that may arise in obtaining or following through with services. The support and attention to ancillary services has proven effective in reducing drinking in previous studies.
2451197|NCT03233412|Other|Control|Will be offered the standard treatment, which is the conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
2451199|NCT03233412|Experimental|Imiquimod|Will receive topical uterine cervix (Imiquimod) treatment for a period of 12 weeks with weekly applications (1x / week). 30-60 days afterwards they will be submitted to standard treatment with conization of the uterine cervix with loop electrosurgical excision procedure (LEEP).
3208551|NCT00975832||women from 18-40 years of age|
3208552|NCT00975845||BioCleanse Tibialis Tendon Allograft|Tibialis Tendon allograft from donor 18-65 years old
3208553|NCT00975858|Active Comparator|Percutaneous Coronary Intervention|
3208554|NCT00975858|Experimental|Off Pump Coronary Artery Bypass Surgery|
2451335|NCT03232385|Experimental|MR-US Fusion Arm|Clear Guide SCENERGY, MR-US
2451337|NCT03232385|Active Comparator|EM Fusion or No Fusion Arm|
2451440|NCT03231592|Experimental|CSA Group|This group will receive CSA Shares (a selection of fresh fruits and vegetables from a local farm) each week for 24 weeks over the summer of 2017 and 2018. The CSA does not operate over the winter.
2451445|NCT03231592|Active Comparator|Enhanced Usual Care Group|This group will receive a handout about healthy eating, in addition to routine care in their primary care practice.
2451474|NCT03231254||Chinese patients with OSA|
2451476|NCT03231254||Canada patients with OSA|
2451529|NCT03231033|Experimental|Pioglitazone|Oral administration of Actos at 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
3208555|NCT00975910|Placebo Comparator|Saline|
3208556|NCT00975910|Active Comparator|Lidocaine|
3208557|NCT00975936|Experimental|[14C]-GSK706769|Single dose of 50µg [14C]-GSK706769 containing 250 nCi
3190294|NCT00786045|Experimental|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
3190295|NCT00786045|No Intervention|Control|The investigators have devised a series of mobility-related tasks that can be easily and safely carried out at home without ongoing professional supervision
2450758|NCT03236376|Experimental|sensorimotor therapy|sensorimotor therapy will consist of 30minutes of sensory discrimination training and 30 minutes of sensorimotor training per session. The sensory discrimination training is based on on the SENSe training of Carey et all. The sensorimotor training is the same individually tailored motor therapy as described below, but with integration of sensory discrimination training aspects.
2450760|NCT03236376|Active Comparator|motor therapy|The motor therapy consists of 30 minutes of cognitive and attention-based table top games and 30 minutes of motor training per session. The cognitive-attention-based therapy consists of table top games such as chess, rush hour, or other smart games. Individually tailored motor therapy consists of a unilateral motor exercise program for the upper limb, while seated at a table, under supervision of a therapist to match the therapy and intensity provided in the other sensorimotor therapy group. This 30 minutes of motor arm training is based on a set of standardized exercises which comprise task-related practice for gross movements and dexterity including different grips and selective finger movements, and training in daily life activities, however without any attention to sensory discrimination training.
2450782|NCT03235999||Talc pleurodesis|Up to 10 patients who have had talc pleurodesis
2450783|NCT03235999||IPC|Up to 10 patients who have had indwelling pleural catheters (IPC)
2450832|NCT03235830|Active Comparator|Enhanced Standard of Care (ESoC)|Subjects received a condensed version of the American Academy of Pediatrics Bright Futures content at their scheduled well-child visits though 6 months of age. The enhanced standard of care (ESoC) materials were added, by members of the research team, to registration packets and were given to caregivers by clinic staff, who were all trained to give the ESoC. For any patients who did not receive ESoC materials at their visit, an age-appropriate ESoC was mailed to the caregiver.
2450833|NCT03235830|Experimental|Enhanced Standard of Care (ESoC) + Text|Subjects assigned to the text messaging intervention group received four educational messages per week until their child was 6 months of age in addition to the ESoC documents. The text messages directly reflected Bright Futures and ESoC content, addressing infant development, safety, care, and the most common causes of nonurgent visits in the first year. Bright Futures content was adapted both for language and length to accommodate character limits and the patient population.
3190296|NCT00786071||Rett syndrome girls|The study population consists of a well-defined group of Dutch RTT thirteen girls with complete clinical, molecular and neurophysiological work-up.
3190297|NCT00786084||1|Phase I patients who had a paraesophageal hernia repair with synthetic mesh.
3190298|NCT00786084||2|Phase I patients who had a paraesophageal hernia repair with small intestine submucosa mesh.
3190299|NCT00786097|Experimental|1|Dermacyd PH_DETINLYN (Lactic Acid)
3190300|NCT00786110|Experimental|1 arm only|"One arm only with Sorafenib plus Paclitaxel Patients enrolled will undergo strict follow-up~Intervention: Sorafenib plus Paclitaxel"
3190301|NCT00786123|Experimental|VSL#3|Patients taking probiotics (VSL#3)
2451299|NCT03232606||Asthmatic children|Asthmatic children aged 6 to 17 year old coming to follow-up at asthma clinic
2451354|NCT03232268|Experimental|HLA-mismatched microtransplantation|HLA-mismatched microtransplantation without immunosuppressive treatment
2451383|NCT03231956||Group 0|Control Sepsis Mimic Group (minor infections or asthma/COPD exacerbations) venous blood lactate levels are not required for this subgroup.
2451385|NCT03231956||Group 1|Suspected infection plus Initial Venous Blood Lactate ≥ 0 - 1.9 mmol/dL
2451386|NCT03231956||Group 2|Suspected infection plus Initial Venous Blood Lactate ≥ 2.0 - 3.9 mmol/dL
2451388|NCT03231956||Group 3|Suspected infection plus Initial Venous Blood Lactate ≥ 4.0 mmol/dL
2451436|NCT03231644||FD/MAS Patients|Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.
3190302|NCT00786123|Placebo Comparator|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
3190303|NCT00786136|Experimental|1|perioperative rosuvastatin administration for at least 5 dosages
3190304|NCT00786136|Placebo Comparator|control|blank control of perioperative statin administration
2451644|NCT03230201|No Intervention|Blank control|do not receive Lymph node dissection during surgery.
2451710|NCT03229915|Active Comparator|PTSD|Will receive Cognitive Processing Therapy
3190305|NCT00786149|Experimental|1|Participants will receive NRT and Motivational Interviewing counseling
3190306|NCT00786149|Active Comparator|2|Varenicline plus brief advice
3190307|NCT00786162|Experimental|Intervention|Internet-based hypertension self-management platform
3190308|NCT00786162|Active Comparator|Control|Installation of BP cuff for communal use at the worksite
3190309|NCT00786201|Placebo Comparator|Placebo|
3190310|NCT00786201|Experimental|CNTO 888 1 mg/kg|
3190311|NCT00786201|Experimental|CNTO 888 5 mg/kg|
3190312|NCT00786201|Experimental|CNTO 888 15 mg/kg|
3190313|NCT00786214|Experimental|Acupuncture|Patients given acupuncture treatment
3190314|NCT00786214|Sham Comparator|Sham acupuncture|Patients given sham acupuncture treatment
3190315|NCT00786227||Legacy HAQ-DI first, PROMIS 20-item short form first|To eliminate effects due to order of administration, patients with RA will be randomized to complete either the Legacy measure HAQ-DI first in the assessment battery or the PROMIS 20-item short forms first.
3190316|NCT00786240|Experimental|A|
3190317|NCT00786240|Experimental|B|
3190318|NCT00786253|Experimental|Arm 1|
3190319|NCT00786253|Experimental|Arm 2|
3190320|NCT00786266|Active Comparator|NIOSH shiftwork booklet|
3190321|NCT00786266|Experimental|Sleep Enhancement Training System|
3174456|NCT00623701|Placebo Comparator|1|sublingual placebo preparation
2450803|NCT03236129|Experimental|Treg depleted DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by Treg depleted (Donor Lymphocytes Infusion (DLI)
2450814|NCT03236129|Active Comparator|Unmanipulated DLI|Patients will receive a lymphodepleting treatment combining cyclophosphamide and fludarabine followed by a standard DLI (unmanipulated)
2450854|NCT03235531|Experimental|CIWA Protocol/BZD and Valproate|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool.~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol.~The treatment group will also receive scheduled valproate (VPA), 15 mg/kg divided over 4 doses, rounded up to the nearest increment of 50mg (i.e. a 70 kg person would be administered 300 mg IV VPA every 6 hours) for 96 hours."
2450857|NCT03235531|Active Comparator|CIWA Protocol Only|"Interventions to decrease symptoms of AWS will be made based on the CIWA tool~CIWA Score 9-14: 1 mg IV push lorazepam~CIWA Score >15: 2 mg IV push lorazepam~Patients who have a known history of alcohol withdrawal seizures or who have received greater than 4 mg IV lorazepam per CIWA protocol will be placed on a scheduled lorazepam regimen, 1 mg every 6 hours. The primary managing service may increase the scheduled lorazepam regimen above 1mg every 6 hours if needed to control withdrawal symptoms. Scheduled lorazepam will be discontinued or de-escalated following a 24-hour period in which no additional lorazepam was received per CIWA protocol."
2450907|NCT03235128||Group1|Steroid sensitive nephrotic syndrome(10 cases).
2450912|NCT03235128||Group2|Steroid resistant nephrotic syndrome(10 cases).
2450914|NCT03235128||Group3|immunosuppressive resistant nephrotic syndrome(10 cases).
2450915|NCT03235128||Group4|Refractory nephrotic syndrome(10 cases).
2450917|NCT03235128||Group5|Normal children as a healthy control group(5 cases).
2450940|NCT03234933|Experimental|Mobility Tracker|"Each patient will be provided by the research team staff with a new mobility tracker~The standard pre-operative assessment, surgical procedure and post-operative care will still be done~Measurements of each patient (steps, distance and calories) will be obtained by the research staff"
2451058|NCT03234478||GBA mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2451061|NCT03234478||non-mutation carriers without DBS|Parkinson's disease patients who have moderate to advanced disease but have not undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2451067|NCT03234478||GBA mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2451074|NCT03234478||non-mutation carriers with DBS|Parkinson's disease patients who have moderate to advanced disease and have undergone deep brain stimulation. Subjects will be tested for GBA mutation status as part of this study.
2451117|NCT03233893|Experimental|light activated calcium silicate|Apply light activated calcium silicate in deep occlusal caries lesions and taking the base line image for the first group after restoring the cavity with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
2451120|NCT03233893|Active Comparator|light activated calcium hydroxide|Apply the light activated calcium hydroxide in deep occlusal carious lesions and taking the base line image for the second group after restoring with composite restoration and taking the follow up x-ray image after one year to measure the calcific bridge formation.
2451163|NCT03233542|Experimental|Panic Disorder: CBT|Participants with Panic Disorder randomized to this arm will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2451165|NCT03233542|No Intervention|Panic Disorder: Waiting list|After the pre-treatment testing session, participants with Panic Disorder randomized to this arm will wait a length of time equivalent to that for the pre/post-treatment duration for the Panic Disorder: Cognitive Behaviour Therapy arm (approx. 3 months), before returning to the post-treatment assessment. After completing all the study procedures, participants in this arm receive also the manualised Cognitive Behaviour Therapy treatment for Panic Disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2451166|NCT03233542|Other|Anxious Control Group: CBT|All participants in the Anxious Control Group will receive a manualised Cognitive Behaviour Therapy (CBT) treatment for their diagnosed anxiety disorder, delivered in the outpatient psychotherapy centre of the Department of Clinical Psychology and Psychotherapy, Ruhr-Universität Bochum.
2451204|NCT03233243|Experimental|Patients with positive 18F-NaF plaques|Patients with 18F-NaF-positive plaques (coronary, aortic or carotid) with TBR > 1.5
2451207|NCT03233243|No Intervention|Patients without 18F-NaF-positive plaques|Subjects without 18F-NaF- positive plaques will be excluded from the pharmacological intervention study
2451260|NCT03232996|Experimental|Experimental Group|Computer Game based balance and walk rehabilitation
2451290|NCT03232775|Other|Treatment|Treatment: Physical Exam with Visual Pedagogy and Structure
2451293|NCT03232775|Other|Control|Control: Physical Exam without Visual Pedagogy and Structure
2451356|NCT03232476|Other|Loaded upper extremity|This is a one-arm study. In postmenopausal women prescribed teriparatide for osteoporosis treatment, enrolled subjects will perform voluntary loading exercises on one upper extremity. A data logger device will assist in recording exercises and determining goal force during the exercises. Each subject's non-loaded upper extremity will serve as a control.
3190322|NCT00786279|Placebo Comparator|1|150 cc daily of flavored, calorie-free beverage without alcohol
3190323|NCT00786279|Experimental|2|150 cc flavored, calorie-free beverage with 15 gm ethanol daily
3190324|NCT00786292|Other|Noisy PSV|Assisted mechanical ventilation with noisy PSV
3190325|NCT00786292|Other|PSV|Assisted mechanical ventilation with PSV
3190326|NCT00786305|Experimental|1: nebulized ceftazidime and amikacin|
2450747|NCT03236532|Placebo Comparator|Maltodextrin and exercise|Maltodextrin (20g/day) in 300 ml of water and ingest it after lunch during 7 days. In case of forgetfulness, they were suggested to ingest it soon after dinner. All participants were instructed to maintain their routine eating habits throughout the duration of the study. On the seventh and last day of supplementation, they were submitted to the resistance training session.
2450770|NCT03236090|Active Comparator|Outpatients with refractory ascites|20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
2450771|NCT03236090|Active Comparator|Patients hospitalized because bacterial infection|30 consecutive patients with cirrhosis and bacterial infections. All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
2450784|NCT03235895|Experimental|Internet based|"Six days of Instructional online CME educational material using Test-Enhanced E-Learning strategy.~Followed by one day face to face CME activity"
2450785|NCT03235895|Active Comparator|Face to Face|Three days face to face Conventional CME educational materials
2450787|NCT03235895|No Intervention|Wait listed|No CME activity will be given
2450919|NCT03235388|Experimental|Intervention|Audit filter implementation in hospital
2450921|NCT03235388|No Intervention|Control|Routine care
2450967|NCT03234920|Placebo Comparator|Group 1- Control Group|Placebo The placebo will be 200 ml of fruit juice twice a day. Placebo will be provided for 12 weeks
2450970|NCT03234920|Experimental|Group 2 - Treatment group|HMB Supplementation with 1.5 g of HMB dissolved in 200 ml of fruit juice and taken twice daily. Supplementation will be provided for 12 weeks
2451022|NCT03234647|Experimental|AHF patients|AHF patient treatment with the Doraya catheter
2451043|NCT03234244|Active Comparator|Bazedoxifene 20mg|Subjects will take bazedoxifene 1 Tablet.
2451045|NCT03234244|Active Comparator|Cholecalciferol|Subjects will take Cholecalciferol 2 Tablets.
2451049|NCT03234244|Experimental|Bazedoxifene 20mg and Cholecalciferol|Subjects will take bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
2451180|NCT03233620|Other|working age patients|Prospective cohort of 250 patients.
3153755|NCT00283088|Active Comparator|Group 4|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3153756|NCT00283088|Active Comparator|Group 5|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
2451493|NCT03231241||Episodic Headache|Participants experiencing headache of any type more than twice per year but less than 15 days per month. No interventions
2451494|NCT03231241||Chronic Headache|Participants experiencing headache more than 15 days per month for at least three consecutive months. No interventions
2451495|NCT03231241||Control|Participants reporting fewer than two headaches per year. No interventions
2451699|NCT03229694|Experimental|Tracleer (or Bosentan)|Tracleer (Tracleer 125Mg Tablet) was administered orally at two hours before surgery and six hours after surgery
2451702|NCT03229694|Placebo Comparator|Placebo|Placebo was administered orally at two hours before surgery and six hours after surgery
2451767|NCT03229395||patients with Cushing's syndrome|Patients were selected by the PI at the diagnosis.
2451768|NCT03229395||control patients|Selected patients are matched for age and sex.
2451811|NCT03229161|Experimental|IWT-group|The IWT-group follows the standardized GDM care program for GDM patients at OUH and is prescribed to a 6-week non-supervised IWT-program consisting of 3 IWT sessions per week of 40-50 minutes each.
2451815|NCT03229161|No Intervention|Con-group|The con-group follows the standardized GDM care program for GDM patients at OUH
2451937|NCT03228849|Active Comparator|Conservative Treatment|Patients were treated with 6 weeks with splinting and were then started on physical therapy for 2 weeks.
2451944|NCT03228849|Active Comparator|Surgical Treatment|Patients were treated with the new suture anchor technique and after 6 weeks were started on physical therapy for 2 weeks.
2452036|NCT03227978|Experimental|PCL mesh group|Intervention: The participants will be received thoracoscopic bullectomy and abrasion of pleura, then PCL mesh will be applied over the lung.
3153757|NCT00283088|Active Comparator|Group 6|Groups 3, 4, 5 and 6: Factorial groups, randomized to hypothermia plus tPA, hypothermia alone, tPA alone, or no treatment assignment (standard of care).
3153758|NCT00283101|Experimental|1|SGN-40
3153759|NCT00283114|Experimental|1|
2452302|NCT03225872||Osteosarcoma patients and family members|Osteosarcoma patients and family members
2452342|NCT03225638|Other|Group 1|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (upper limit) strength thigh injection of 0.65ml of saline solution (0.9%)
2452346|NCT03225638|Other|Group 2|Nominal strength thigh injection of 0.65ml of saline solution (0.9%) Low threshold (lower limit) strength thigh injection of 0.65ml of saline solution (0.9%)
2452552|NCT03224260|Experimental|Treatment B|Receive 200 mg BMS-986177 once daily or placebo
3153760|NCT00283153|Experimental|FAR|Facial affect recognition training (with computer assistance)
3153761|NCT00283153|Experimental|SEI|Stories of Emotional Inference
3153762|NCT00283166|Experimental|A|Tailored Coaching and Education
3153763|NCT00283166|Other|B|Active Control
3153764|NCT00283309|Active Comparator|Memantine|Memantine is used to determine if patients given pretreatment to corticosteroid therapy for inflammatory illnesses will show lesser declarative memory impairment than those receiving placebo. Baseline 10mg x 3 days, then 10mg BID x 4 days.
2450826|NCT03235804|No Intervention|Control Group|Those assigned to the Control group will be asked to maintain their usual dietary intake over 12 weeks. Participants' usual dietary intake is expected to reflect the North American dietary pattern (i.e. ~15% of total energy intake coming from protein, ~50% from carbohydrate and ~35% from fat).
2450829|NCT03235804|Experimental|High-Protein Group|Those assigned to the High-Protein group will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
2450872|NCT03235453|Experimental|Binary rhythm|Experimental: binary rhythm The randomized group for binary-rhythm intervention will receive a 12-week intervention with dance lessons. Classes will be divided into: Heating and stretching (5 minutes), main part (binary) (35 minutes) and relaxation (5 minutes).
2450873|NCT03235453|Experimental|Quaternary rhythm|The randomized group for the quaternary rhythm intervention will receive a 12-week intervention with dance classes. Classes will be divided into: Heating and stretching (5 minutes), main part (quaternary rhythm) (35 minutes) and relaxation (5 minutes).
2451097|NCT03234075||Control group|Patients supported without regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region and French Center region
2451099|NCT03234075||Intervention group|Patients supported with the regional organization for promotion of renal transplantation Setting : French Auvergne Rhone Alpes region
2451158|NCT03233685|Experimental|Experimental Group|Subjects will perform a visual training for 12 weeks
2451160|NCT03233685|Active Comparator|Control Group|Subjects will perform the normal training routine for 12 weeks
2451201|NCT03233295|Experimental|Vitamin D deficiency|
2451271|NCT03233048|Experimental|ORBERA™ Intragastric Balloon|Participants will have the ORBERA™ Intragastric Balloon inserted for 6 months. In addition, participants will have ongoing visits with a physician, dietitian, and psychologist before the balloon is inserted, while its in place, and for 6 months after the balloon is removed, for a total of approximately 1 year.
3174457|NCT00623701|Experimental|2|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose
2451577|NCT03230617||Intrinsic positive end expiratory pressure > 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure more than5
2451581|NCT03230617||Auto positive end expiratory pressure < 5|chronic obstructive pulmonary disease patient with intrinsic positive end expiratory pressure less than5
2451631|NCT03230318|Experimental|derazantinib|Oral administration
2451697|NCT03229707|Active Comparator|group 1 Color matching using Vita 3D master|"Outcome Name: Color Matching measured by :~Modified (USPHS) criteria"
2451700|NCT03229707|Experimental|group 2 Color matching using digital photography|"Outcome Name: Color Matching measured by Digital Photography using (Photoshop)~Software:~0 to 1: no difference in perception~1 to 2: only perceptible to a trained observer~2 to 3.5: perceptible difference~3.5 to 5: marked difference"
2451911|NCT03228524|Experimental|D-aspartato+ET|Patients will be administered oral D-aspartate (2660 mg once daily) for 6 weks. Moreover, patients will receive therapeutic exercise.
2451912|NCT03228524|Placebo Comparator|Placebo+ET|Patients will be administered oral placebo for 6 weks. Moreover, patients will receive therapeutic exercise.
2451970|NCT03228121|Experimental|Cohort A|Cohort A (Treatment Then Placebo group) will receive three days of cell therapy using the venous procedure (three consecutive days of blood harvest, cell separation and cell application). Cohort A will return in three months and receive three consecutive days of placebo.
2451971|NCT03228121|Experimental|Cohort B|Cohort B (Placebo Then Treatment group) will receive three consecutive days of placebo. Cohort B will return in three months and receive three consecutive days of cell therapy using the venous procedure.
2452084|NCT03227562|Other|Responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
2452095|NCT03227562|Other|Non responder|The 2 arms will be created according to the early response to risperidone (responder vs. non responder)
2452149|NCT03227094|Other|Standard OGTT|OGTT standard test at hospital (75g glucose beverage; 2-h test with plasma glucose collection)
2452152|NCT03227094|Experimental|Home-based OGTT (Beverage)|Home-based OGTT with CGM device, without glucose collection (75g glucose beverage; 2-h test: glycemia measured by CGM)
2452155|NCT03227094|Experimental|Home-based OGTT (Candy)|Home-based OGTT with CGM device, without glucose collection (75g of glucose (Jelly Beans); 2-h test: glycemia measured by CGM)
3174458|NCT00623740|Experimental|1: hydrocortisone|1: active arm treated with low doses of HC during the first 10 days of life
3174459|NCT00623740|Placebo Comparator|2: Placebo|2:placebo arm treated with placebo at the same conditions than active arm
3174460|NCT00623753|Experimental|A|
3174461|NCT00623792|No Intervention|1|Usual preoperative care
3174462|NCT00623792|Experimental|2|Preoperative Lifestyle Intervention
3174463|NCT00623844|Experimental|Intervention|Physical activity intervention: structured daily 30-min activity classes at preschool, activity homeworks, parent and teacher education
3174464|NCT00623844|No Intervention|Control|Keep usual activities in kindergarten
3174465|NCT00623857|Active Comparator|1|Zinc
3174466|NCT00623857|Active Comparator|2|Vitamins and minerals other than zinc
3174467|NCT00623857|Active Comparator|3|Vitamins plus zinc and other minerals
3174468|NCT00623857|Placebo Comparator|4|Placebo for all vitamins and minerals
3174469|NCT00623870|Experimental|1|
3174470|NCT00623883|Experimental|1|All identified ACF eliminated by cold or hot colonoscopic biopsy forceps
3174471|NCT00623883|Sham Comparator|2|ACF quantified and observed, re-evaluated after one year
3174472|NCT00623909|Experimental|1|To demonstrate the safety of the AvicennaTM class IV laser for application over the skin of human subjects. This study was terminated prior to subject enrollment and closed.
3174473|NCT00623922|Experimental|1|Patient education
3174474|NCT00623922|No Intervention|2|Usual care
2450843|NCT03235518||In-Depth Qualitative Interviews with FSW|30 IDI will be conducted with FSW. FSW who participated in FGDs will be ineligible for participation in the IDI. All in-depth interviews will be conducted by trained female research staff using a semi-structured interview guide. All interviews will be held in a private space at a pre-specified location within the community. The topics that will be discussed in the IDI with FSW include demographics, social support, dynamics of sex work, HIV prevention methods (including condom use), perception of HIV risk and development of PrEP intervention.
2450846|NCT03235518||In-Depth Qualitative Interviews with MC|30 IDI will be conducted with MC. All IDI will last approximately 60-90 minutes and be conducted in Kiswahili, Dholuo, or English. Each interview will be conducted by a trained male research staff using semi-structured interview guide. All interviews will be held in a private space at a pre-specified location. Topics include demographics, relationships with FSW, HIV prevention methods (including use of condoms), perception of HIV risk and development of PrEP intervention.
2450850|NCT03235518||In-Depth Qualitative Interviews with HCPs|30 IDI will be conducted with health care provider (HCP). All IDI will last approximately 60-90 minutes and be conducted in English. Each interview will be conducted by trained research staff using a semi-structured interview guide. Interviews will be held in a private space at the health facility where they work or another venue preferred by the HCP. Topics include demographics, health care needs of FSW and sources of care, HIV prevention needs of FSW, PrEP for FSW and training needs for HCP.
2450936|NCT03234998|Experimental|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks.
2450937|NCT03234998|Active Comparator|cognitive dual-task training|Participants in the cognitive dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks.
2450994|NCT03234777|Experimental|Whiteboard animation video|3 minute video on treatment, management of pediatric acute gastroenteritis
2450996|NCT03234777|Sham Comparator|Regular video|3 minute video on hand washing for infection control
2451032|NCT03234452|Experimental|Lactoflorene plus|10 ml mixture of Lactobacillus acidophilus LA-5®, Bifidobacterium animalis subsp. lactis, BB-12®, Lactobacillus paracasei subsp. paracasei, L. CASEI 431® , Bacillus coagulans BC513, zinc and B-vitamins (niacin, B1, B2, B5, B6, B12 and folic acid) twice a day
2451033|NCT03234452|Placebo Comparator|Placebo Lactoflorene plus|Identical placebo mixture without probiotics, B-vitamins and zinc. The active and placebo products had similar appearance, taste and smell and were provided in identical bottles of 10 ml with identical labelling.
2451081|NCT03234205|Experimental|MRI scan during free respiration|
2451098|NCT03233932|Active Comparator|LeuplinⓡInj|LeuplinⓡInj(=leuprorelin acetate 3.75mg)
2451101|NCT03233932|Experimental|CKD-841|CKD-841(=leuprorelin acetate 3.75mg)
2451164|NCT03233633|Other|Single treatment arm|marijuana adjuvant treatment group utilizing scheduled opioid therapy in inpatient hospice hospital setting
2451191|NCT03233269|Experimental|Music Therapy Group|Music therapy is the clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program. Music therapy is an established health profession in which music is used within a therapeutic relationship to address physical, emotional, cognitive, and social needs of individuals (American Music Therapy Association [AMTA], 2013, para 1 and 2).
2451228|NCT03233087||Top third of subjects based levels of selected biomarker.|
2451229|NCT03233087||Middle third of subjects based levels of selected biomarker.|
2451230|NCT03233087||Bottom third ofsubjects based levels of selected biomarker.|
2451249|NCT03232905|Experimental|PF-06651600|Multiple ascending doses of PF-06651600
2451252|NCT03232905|Placebo Comparator|Placebo|Multiple ascending doses of Placebo
2451288|NCT03232814|Experimental|Group-based walking|Participants will engage in one supervised outdoor group-based walking session per week for the 8 week program.
2451312|NCT03232528|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2451314|NCT03232528|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25, ST37 and CV6. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
3153765|NCT00283309|Placebo Comparator|Placebo|Inactive ingredient matching the active medication in appearance
3174475|NCT00623948|Other|Arm 1|
2451408|NCT03231930|Experimental|Intervention group|Rapid point of care testing will be done using the OraQuick HCV Ab test and the Xpert HCV RNA viral load test. All participants will undergo rapid point of care testing for hepatitis C antibodies using the OraQuick test with oral fluid, followed by point of care testing for the detection of hepatitis C virus RNA using the Cepheid Xpert HCV viral load test on the GeneXpert system. Participants who are found to have current HCV infection will be worked up for treatment at the clinic and referred to appropriate practitioners for HCV treatment. As these tests are not yet licensed for diagnostic use in Australia, confirmatory testing using standard laboratory tests will be performed for all participants.
2451479|NCT03231332|Experimental|H.pylori Eradication index|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with Clarythromycin-containing eradication therapy
2451481|NCT03231332|No Intervention|Control|Microbiome diversity detection in Participants Without H.pylori Eradication therapy
2450895|NCT03235271||Group B: Hemorrhagic Stroke|Subjects in this group will present with symptoms similar to Group A. In addition, they will present with clinical symptoms consistent of increased intracranial pressure such as nausea, vomiting, loss of consciousness and severe headache. In order for a subject to be eligible, the hemorrhage will be limited to primarily intracerebral hemorrhage with a minimum volume of 10mL. Subarachnoid hemorrhage and intraventricular hemorrhage may also be present as incidental findings. Since it is unlikely that these subjects proceed for neuro-intervention, they will not have a follow-up BrainPulse recording and they will be exited after completing study procedures.
2450897|NCT03235271||Group C: Transient Ischemic Attack|Subjects in this group will present with focal neurological symptoms consistent with stroke. In order for subjects to be eligible for this group, enrollment will need to be within 6 hours of resolution of symptoms along with a confirmation of TIA by treating team. In addition, initial and follow-up radiological imaging needs to show that there are no signs of ischemic stroke or hemorrhage.
2450898|NCT03235271||Group D: Non-Stroke Subjects|Subjects in this group will present with stroke-like symptoms but do not have a diagnosis of stroke nor TIA. In order to qualify for this group, subjects will also need to show evidence of no stroke on radiological imaging (CT and/or MRI). Diagnoses in this group may include seizure, systemic infection, brain tumor, metabolic disorder, positional vertigo, hemiplegic migraine, encephalopathy, cranial nerve injury, spinal cord injury, brachial/sacral plexus injury, peripheral nerve injury, etc.
3153766|NCT00283309|Active Comparator|Riluzole|Riluzole is given to patients receiving corticosteroid therapy for inflammatory illnesses pretreatment to determine if they show lesser declarative memory impairment than those receiving placebo. Baseline 50mg x 3 days, then 50mg BID x 4 days.
3153767|NCT00283322||Medical ICU patients|Patients admitted to a medical intensive care unit
2451054|NCT03234439|Experimental|myStrength Intervention|The myStrength intervention arm will be encouraged to utilize the chronic pain offering consisting of 6 modules. Each module has 5 activities and can take on average 5-15 minutes to complete. Study participants assigned to the myStrength intervention will have one week to complete each module. In addition to completing the required chronic pain modules, study participants in the myStrength intervention arm will have the option to also select other areas of interest and complete corresponding activities at their own pace. myStrength utilization will be recorded and analyzed.
2451060|NCT03234439|No Intervention|Waitlist Control|The waitlist control group will gain access to the myStrength platform 60 days following the start of the study.
2451105|NCT03233880|Active Comparator|Azithromycin group|Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) will be given to pregnant women at 16/20 weeks of pregnancy
2451107|NCT03233880|Placebo Comparator|placebo group|- Matching placebo orally, single dose
2451144|NCT03233568||Indirect Calorimetry group (IC group)|Group who performed indirect calorimetry. REE measured by indirect calorimetry.
2451146|NCT03233568||NO Indirect Calorimetry group (NO-IC group)|Group who did not perform indirect calorimetry. Resting Energy Expenditure calculated by Harris-Benedict formula
2451200|NCT03233347|Experimental|Treatment (combination chemotherapy, nivolumab)|Patients receive doxorubicin IV over 3-5 minutes, vinblastine IV over 3-5 minutes, and dacarbazine IV over >= 30 minutes, and brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients with PET-positive then receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. PET-positive patients then receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity. PET-negative patients receive nivolumab IV over 30 minutes on day 1 starting after AVD and BV treatment. Treatment repeats every 2 weeks for 8 cycles in the absence of disease progression or unacceptable toxicity.
3174476|NCT00623987|Active Comparator|A|warfarin treatment
2451496|NCT03231202|Experimental|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist.~The study does not interfere with local diagnostic work-up and treatment protocols."
2451498|NCT03231202|No Intervention|Observation|The control arm in this randomized controlled trial will include only NOM patients diagnosed with splenic injuries OIS grade 4 or 5 and suitable for observation alone, and will comprise clinical observation according to local routines and protocols.
2451586|NCT03230708|Experimental|Erythrocytes derived MPs containing MTX|Suspension of erythrocytes derived MPs containing MTX, qd×6, 6 units MPs a time , Two courses.
2451590|NCT03230708|Active Comparator|convention drugs|Chemotherapeutic drugs, biologicals or traditional Chinese medicine.Dosage form, dosage, frequency and duration according to respective medicine instructions.
2451647|NCT03230279|Active Comparator|Sacroiliac joint fusion|The subject will receive a sacroiliac joint fusion
2451650|NCT03230279|Active Comparator|Sacroiliac radio frequency ablation|The subject will receive a sacroiliac joint radiofrequency ablation
2451706|NCT03229811|No Intervention|Standard pre-dialysis education|Standard pre-dialysis options education including hemodialysis, peritoneal dialysis, and kidney transplantation
2451712|NCT03229811|Active Comparator|ESRD education + ACP|Standard ESRD education + conservative kidney management and advance care planning education
2451773|NCT03229460|Active Comparator|standard low flow therapy|In the standard low flow therapy is applied continuously through a nonrebreather face mask at a flow rate of 10 liters per minute or more. The rate was adjusted to maintain an oxygen saturation level of 92% or more.
2451774|NCT03229460|Experimental|high flow nasal oxygen therapy|In the high-flow-oxygen group is passed through a heated humidifier and applied continuously through large-bore binasal prongs, with a gas flow rate of 30-60 liters per minute . The fraction of oxygen in the gas flowing in the system was subsequently adjusted to maintain an Spo2 of 92% or more.
2451775|NCT03229460|Placebo Comparator|Noninvasive ventilation|In the noninvasive-ventilation group is delivered to the patient through a face mask that was connected to an ICU ventilator,with pressure support applied in a noninvasive ventilation mode. The Fio2 or PEEP level (or both) were then adjusted to maintain an Spo2 of 92% or more.
2451798|NCT03229044||BMI 18-21|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 18-21 kg/m2
2451869|NCT03228550|Experimental|Placebo and non-exercise|Placebo supplement and non- exercise
2450941|NCT03234946|Experimental|Group B|Relatives who will receive multidisciplinary care at the center The subjects from group B will be asked to be accompanied by another relative. If they accept, they will be included as a patient of the CAIPaDi program to receive all the interventions of the second, third and fourth visits in an individual form, without following the patient with diabetes.
2450988|NCT03234803|Experimental|poly-amide|poly-amide is a thermoplastic material recently introduced to be used as a complete denture material, that provide excellent aesthetics and flexibility.
2450990|NCT03234803|Active Comparator|poly-methyl methacrylate|poly-methyl methacrylate has been commonly used as a material for constructing complete dentures and proved to have high success rate and considered to be gold standard.
2451065|NCT03234504||Normal healthy volunteers|
2451095|NCT03234062|Experimental|25%Cho, 50%Cho, 100%Cho|Diets containing 137.5mg (25% Cho diet), 275mg (50% Cho diet), and 550mg (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451100|NCT03234062|Experimental|25% Cho, 100% Cho, 50% Cho|Diets containing 137.5mg (25% Cho diet) , 550mg (100% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451104|NCT03234062|Experimental|50% Cho, 25% Cho, 100% Cho|Diets containing 275mg (50% Cho diet), 137.5mg (25% Cho diet), and 550mg Cho (100% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451106|NCT03234062|Experimental|50% Cho, 100% Cho, 25% Cho|Diets containing 275mg (50% Cho diet), 550mg (100% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451110|NCT03234062|Experimental|100% Cho, 25% Cho, 50% Cho|Diets containing 550mg (100% Cho diet), 137.5mg (25% Cho diet), and 275mg Cho (50% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451116|NCT03234062|Experimental|100% Cho, 50% Cho, 25% Cho|Diets containing 550mg (100% Cho diet), 275mg (50% Cho diet), and 137.5mg Cho (25% Cho diet) will be given in that order for two weeks each with 2 weeks of washout between.
2451208|NCT03233386||Condition 1|Mexico City Cohort
2451209|NCT03233386||Condition 2|Monterrey Cohort
2451210|NCT03233386||Condition 3|Guadalajara Cohort
2451272|NCT03232944||CRT non-responders with MPP enabled|Patients enrolled and implanted with a CRT Quad system, who are identified as CRT non-responder, for which MPP is enabled.
2451390|NCT03232164|Experimental|18F-DCFPyL PET|We will have three separate sub-studies evaluating 18F-DCFPyL PET imaging of prostate cancer in three prostate cancer clinical scenarios under the following subheadings: (1) primary prostate cancer, (2) biochemical recurrence post-prostatectomy prior to radiation therapy, and (3) androgen-resistant metastatic disease.
2451423|NCT03231696||Patients receiving Regional Anesthesia|All patients 18 years or older with a peripheral nerve block at Charité - Universitätsmedizin Berlin Campus Charite Mitte from 2012 to 2016.
2451461|NCT03231488|Experimental|Mindfulness intervention|
2451463|NCT03231488|Active Comparator|Control intervention (unfocused attention)|
2451519|NCT03230981|Experimental|Healthy subjects|Optical imaging of the cornea in healthy subjects
2451572|NCT03230734|Experimental|Treatment Arm A|radium-223 initially followed by docetaxel plus prednisone at the time of progression (PD)
2451575|NCT03230734|Experimental|Treatment Arm B|docetaxel plus prednisone initially followed by radium-223 at the time of progression (PD)
2451652|NCT03230214||DNA positive patients|patients who have bacterial DNA in their samples
2451654|NCT03230214||DNA negative patients|patients who do not have bacterial DNA in their samples
2451687|NCT03229863|Experimental|Sweet Potatos|Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
2451688|NCT03229863|Experimental|Pears|Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
3174477|NCT00623987|No Intervention|B|withholding warfarin therapy
2451838|NCT03229018|Other|voxel size|200 μm and 300 μm Voxel Sizes
2451878|NCT03228706|Experimental|Intervention Group|All the participants who are randomly assigned to the intervention group will be undergoing the Know Your Medicine-Take it for Health (KYM-TIFH) program, which is a one-off structured group-based intervention (SGBI).
2451886|NCT03228706|No Intervention|Control Group|All the participants who are randomly assigned to the control group will not be given any information related to KYM-TIFH. However, they will be assigned to the venue for the control group and will be asked to fill in questionnaires with the assistance of four facilitators. A briefing on how to answer the questionnaire will be given by the main facilitator and all facilitators are allowed to answer any questions raised by respondents related to the questionnaire. However, they are not allowed to answer on behalf of the respondents. After the completion of the questionnaire, they will be informed about the subsequent follow-up measurement after three, six and twelve months. After that, they will be dismissed and having usual care provided by the health clinic as before without any changes.
2451927|NCT03228316|Experimental|the study group one|20 patients with superior hypogastric plexus block
2451928|NCT03228316|Experimental|the study group two|20 patients with superior hypogastric plexus block combined to pulsed radiofrequency on sacral nerve roots 2,3 and 4
2452027|NCT03228069|Experimental|single visit 4-site ID vaccination|Blood would be drawn from those who received a single visit 4-site ID rabies booster vaccination in the previous trial.
2452039|NCT03228069|Active Comparator|Conventional IM vaccination|Blood would be drawn from those who received a conventional intramuscular rabies booster vaccination in the previous trial.
2452100|NCT03227549|Experimental|Direct Superior Approach|The intervention being tested is the surgical approach.
2452105|NCT03227549|Active Comparator|Posterior Approach|
2452156|NCT03227068|Experimental|PEDSS - symptom management|Content for the PEDSS - symptom management includes the most commonly experienced treatment-related physical symptoms, descriptions of each symptom, strategies to reduce symptom distress, and when and how to contact the cancer care team.
2452166|NCT03226795|Experimental|interventional arm|
2456957|NCT03194139|Experimental|Crossover Design|
3153768|NCT00283322||Surgical ICU patients|Patients admitted to a surgical-trauma intensive care unit
3153769|NCT00283322||Neuro ICU patients|Patients admitted to a neuro-trauma intensive care unit
2451195|NCT03233659||BMT patients|All patients undergoing Allogeneic Stem Cell Transplantation are enrolled in the study.
2451246|NCT03233100|Experimental|FMT group|
2451334|NCT03232424|Experimental|NovoTTF-200A + Temozolomide Chemoradiation|NovoTTF-200A, concomitant with radiotherapy and temozolomide, as front-line therapy for glioblastoma
2451380|NCT03232086|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2451381|NCT03232086|Active Comparator|Concentrated PM2.5|Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2451530|NCT03231007||Innovators|Maternity units that implemented the Care Bundle to the highest level (according to an NHS survey in 2015) are categorised as 'Innovators'.
2451531|NCT03231007||Early Adopters|Maternity units that implemented the Care Bundle to the second-highest level (according to an NHS survey in 2015) are categorised as 'Early Adopters'.
2451532|NCT03231007||Late Adopters|Maternity units that implemented the Care Bundle to the third-highest level (according to an NHS survey in 2015) are categorised as 'Late Adopters'.
2451534|NCT03231007||Low Adopters|Maternity units that implemented the Care Bundle to the fourth-highest level (according to an NHS survey in 2015) are categorised as 'Low Adopters'.
2451627|NCT03230409|No Intervention|Phase 1, Retrospective|Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
2451633|NCT03230409|Experimental|Phase 2, Prospective|"Four nurse-led interventions were implemented after Phase 1:~Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits."
2451664|NCT03229941|Experimental|Restrictive|Transfusion trigger: Hb<7gm/dl
2451666|NCT03229941|Experimental|Liberal|Transfusion trigger: Hb<10gm/dl
2451692|NCT03229642|Experimental|Active rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
2451695|NCT03229642|Sham Comparator|Sham rTMS treatment|The rTMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min, with a figure-of-eight sham coil. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions.
2451821|NCT03229148|Active Comparator|General anaesthesia|In the general anesthesia group, rapid sequence induction is used. Conduction of general anesthesia and drugs used are left to the expertise of each investigating center. Systolic blood pressure has to be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary, tele-expiratory carbon dioxyde concentration (EtCO2) has to be maintained between 30 and 35 mmHg and SpO2 has to be maintained between 94 and 98 %.
2451823|NCT03229148|Active Comparator|Conscious Sedation|In the conscious sedation group, drugs choice as well as pharmacological modulation will be left to the expertise of each investigating center. A sedation level between 0 and -3 with spontaneous breathing will be targeted, using the Richmond Agitation Sedation Scale (RASS) score validated in French. The lightest sedation level will be targeted, i.e. minimal to moderate sedation according to the US recommendations for sedation / analgesia. Systolic blood pressure will be maintained between 140 and 180 mmHg with an intravenous norepinephrine infusion if necessary and SpO2 will be maintained between 94 and 98%.
2451929|NCT03228758|Active Comparator|Anterior Orientation|"The anterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 11 o'clock to 3 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
3153770|NCT00283335|Active Comparator|Gemfibrozil|1200 mg slow-release gemfibrozil (Lopid-SR) once per day
3153771|NCT00283335|Placebo Comparator|Placebo|Matching placebo tablets taken once per day
3153772|NCT00283413|Experimental|1|Symbiot Covered Stent System
3153773|NCT00283413|Active Comparator|2|Commercially available bare metal stent
3153774|NCT00283452|Experimental|Intervention Group|Participation in phone/mail-based intervention to maintain physical activity.
3153775|NCT00283452|No Intervention|Control|No intervention; participation in surveys only
3153776|NCT00283491|Active Comparator|A|
3153777|NCT00283491|Placebo Comparator|B|
3153778|NCT00283517||001|
3153779|NCT00283556|Experimental|Cohort #1|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes every (Q) 3 weeks x 15 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3153780|NCT00283556|Experimental|Cohort #2|"Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3153781|NCT00283556|Experimental|Cohort #3|"Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
3153782|NCT00283608||Anastrozole|Blood draws for baseline and six to twelve weeks.
3153783|NCT00283608||Exemestane|Blood draws for baseline and six to twelve weeks
2451009|NCT03234595|Experimental|single arm|There is 1 treatment arm with 4 dose cohorts in Phase I and 1 treatment arm in Phase IIa.
2451024|NCT03234335||Myeloma patients with severe renal impairment|Myeloma patients with severe renal impairment. Data collection will concern myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation.
2451128|NCT03234114|Experimental|1-month TT|Randomized experimental group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month (30 days) then quit aspirin till 12 months after PCI
2451129|NCT03234114|Experimental|6-month TT|Randomized control group in the OPTIMA-3 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 6 months (180 days）then quit aspirin till 12 months after PCI
2451132|NCT03234114|Experimental|12-month DT-1|Randomized experimental group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg qd for 12 months after PCI
2451137|NCT03234114|Experimental|12-month DT-2|Randomized control group in the OPTIMA-4 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI
2451247|NCT03233035|Placebo Comparator|placebo group|Intranasal placebo pulverisation
2451248|NCT03233035|Active Comparator|Ketamine group|Intranasal ketamine pulverisation
3153784|NCT00283621|Experimental|Growth Factors + Adriamycin/Ifosfamide|Growth Factors = Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta)
3153785|NCT00283660|Experimental|Active|Dietary Supplement: 10 mg zinc oxide
2451348|NCT03232359||SPE/HELLP group|This group included 24 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of pre-eclampsia, HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
2451349|NCT03232359||TTP/HUS group|This group included 13 pregnant women (gestational age of >20 weeks) who were diagnosed as having TMA with provisional diagnosis of TTP/HUS. HELLP syndrome. immature platelets fraction assessment within 12 hours of diagnosis
2451351|NCT03232359||Control group|This group included 20 pregnant women (gestational age of >20 weeks) having normal pregnancy with normal blood pressure and platelet count.
2451393|NCT03232008|Experimental|Experiment A- experimental|3g Canderel in 250ml water
2451394|NCT03232008|No Intervention|Experiment A- control|3g of maltodextrin in 250 ml of water
2451399|NCT03232008|Experimental|Experiment B- experimental|3g Canderel + 35g Lyle's Golden Syrup in 250 ml water
2451401|NCT03232008|No Intervention|Experiment B- control|3g Lyle's Golden Syrup + 35g of maltodextrin in 250 ml of water
2451435|NCT03231631|Experimental|Education plan and adherence to exercise|"Educational talk about the importance of nutrition and exercise as an important strategy to change cardiovascular risk factors at the start of the study.~It will be sent via text, whatsapp, and / or e-mail on a weekly basis three text messages that remind them of the importance of doing the exercise and how often they should do it, it will be a predetermined text."
2451437|NCT03231631|No Intervention|Control|"The blood sample will be taken for the collection of serum HDL and the aerobic capacity test measured in MET will be recorded at the beginning of the study.~A survey will be conducted at week 12 of monitoring where adherence to exercise is measured during the 12-week study."
2451478|NCT03231319|Active Comparator|fascia iliaca compartment block+ IV-PCA|
2451480|NCT03231319|Active Comparator|femoral nerve and lateral femoral cutaneous nerve block+IV PCA|
2451482|NCT03231319|Placebo Comparator|IV PCA only|
2451573|NCT03230903|Experimental|Home Telerehabilitation|The physical telerehabilitation group will receive an exercise plan, exercise equipment, a computer, and access to a daily individualized exercise plan. Participants in this group will follow the exercise plan that is sent to their computer via the telerehabilitation software. Participants will have interactions with a physical therapist and an exercise physiologist throughout training intervention.
2451574|NCT03230903|Sham Comparator|Usual Care|The usual care group will receive an individualized exercise program at baseline however participants will not receive the home telerehabilitation system or exercise equipment. Participants assigned to the usual care group will also not have access to the study physical therapist or exercise physiologist during the intervention.
2451649|NCT03230370|Experimental|enhanced upper-extremity program, EUEP|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The EUP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity.~The participants receive 20-day training over a 4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly, one group can be used as the control group of the other one."
2451651|NCT03230370|Experimental|enhanced lower-extremity program,ELLP)|"Both groups receive routine rehabilitation including daily 50 mins of physical therapy and 50 mins of occupational therapy.~The ELP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.~The participants receive 20-day training over a4-weekperiod. The additional program is designed to be specific to either upper-extremity or lower-extremity.~Accordingly,one group can be used as the control group of the other one."
2451722|NCT03229824|Experimental|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
2451726|NCT03229824|No Intervention|Standard care|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.
3153786|NCT00283660|Placebo Comparator|Placebo|Placebo (double blinded)
3153787|NCT00283699|Active Comparator|1|"albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy~placebo plus standard symptomatic therapy"
3153788|NCT00283699|Placebo Comparator|2|
3153789|NCT00283725||Galantamine|
3153790|NCT00283725||No Alzheimer's disease (AD) treatment|
3153791|NCT00283738|Active Comparator|1|
3153792|NCT00283738|Placebo Comparator|2|Sham control
3153793|NCT00283829|Other|I|Docetaxel followed by IL-2
3153794|NCT00283855|No Intervention|Control Group|No intervention
2451021|NCT03234621|Experimental|high tidal group|provide tidal volume of 8ml/kg (predicted body weight) with positive end expiratory pressure of 5cmH2O during one-lung ventilation
2451056|NCT03234283|Experimental|Study intervention group|All participants will be intubated with a video-laryngiscope by guiding the tracheal tube according to the highlighted Larynx on the Video Screen.
3190327|NCT00786305|Active Comparator|2: intravenous ceftazidime and amikacin|
3190328|NCT00786318|Experimental|ziprasidone|
3190329|NCT00786318|Active Comparator|Standard therapy|
3190330|NCT00786331|Active Comparator|A|Monochemotherapy
2451374|NCT03232021|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
2451376|NCT03232021|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
2451378|NCT03232021|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
2451448|NCT03231514|Placebo Comparator|Carbohydrate Diet & Placebo & Exercise|This group receives the carbohydrate-based diet and flavored placebo pre-workout drink. All participate in the exercise intervention.
2451453|NCT03231514|Active Comparator|Carbohydrate Diet & Carbohydrate Supplement(Carb10) & Exercise|This group receives the carbohydrate-based diet and supplemental carbohydrate. Will be compared to Carbohydrate & Placebo for effects of supplement. All participate in the exercise intervention.
2451460|NCT03231514|Experimental|Ketogenic Diet & Placebo & Exercise|This group receives the ketogenic diet and flavored placebo. It is both an experimental (vs. carbohydrate diet & placebo) and placebo control group (vs. ketogenic & supplement). All participate in the exercise intervention.
2451462|NCT03231514|Experimental|Ketogenic Diet & Carbohydrate Supplement (Carb10) & Exercise|This group receives the ketogenic diet and supplemental carbohydrate. All participate in the exercise intervention.
2451521|NCT03231046|Experimental|CBCT-US Fusion Arm|Clear Guide SCENERGY, CBCT-US
2451523|NCT03231046|Active Comparator|EM Fusion or No Fusion Arm|
2451551|NCT03230682||major depressive disorder|
2451591|NCT03230539|Experimental|UPA IUS 20 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
2451593|NCT03230539|Experimental|UPA IUS 5 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
2451595|NCT03230539|Experimental|UPA IUS 40 μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks
2451648|NCT03230240||HIPEC|Patients with carcinomatosis or other peritoneal surface malignancy
2451691|NCT03229850|Other|Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area of subclinical lipohypertrophy.
2451694|NCT03229850|Other|No Subclinical Lipohypertrophy|Insulin lispro will be injected in the abdomen into an area where there is no subclinical lipohypertrophy.
2451826|NCT03229525|Active Comparator|Trauma Related Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
2451828|NCT03229525|Sham Comparator|Neutral Expressive Writing|Participants randomized to this condition will complete six sessions during which they will write about their day, without describing emotions or opinions. Previous research has shown a significant reduction of symptoms with this type of control writing condition in participants with PTSD (Sloan et al., 2011). A researcher will review the writing to ensure compliance.
2451870|NCT03228732|Placebo Comparator|Placebo 1|"Visit 1:~Study Day 1: Hyperinsulinemia/ euglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
2451875|NCT03228732|Placebo Comparator|Placebo 2|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with placebo~Visit 2:~same as visit 1"
2451882|NCT03228732|Active Comparator|Fluoxetine|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine~Visit 2:~same as visit 1"
2451888|NCT03228732|Active Comparator|DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with DHEA~Visit 2:~same as visit 1"
3190331|NCT00786331|Experimental|B|Combination chemotherapy
3190332|NCT00786344|Experimental|Lifestyle Redesign|
3190333|NCT00786344|No Intervention|No Treatment Control|The no treatment control arm did not receive the intervention during the first six-month period. However the intervention, which has been proven to be beneficial, was administered to the control arm immediately following the 6 month assessment.
3190334|NCT00786357|Experimental|Intervention|
3190335|NCT00786370|Active Comparator|Propofol|
3190336|NCT00786370|Experimental|Dexmedetomidine|
3190337|NCT00786383|Experimental|IMC-1121B|IMC-1121B injectable solution at a concentration of 5 mg/mL in single-use vials containing 100 mg/20 mL or 250 mg/50 mL of product, administered intravenously at an initial dose of 6 mg/kg.A minimum of three patients will be enrolled into each cohort. When all patients complete a cohort, dose escalation to the next cohort will occur.
3190338|NCT00786396|Experimental|DAART|Group that will be observed daily taking their medications for a period of six months. Followed by the remaining six months of the intervention in which the subject will take medications on their own.
3153795|NCT00283855|Active Comparator|Online Self-Management|RAHelp.org
2451115|NCT03233971||Older adults|
2451121|NCT03233971||Caregivers|
2451173|NCT03233607||Antepartum Patients|Includes antepartum patients receiving prenatal care at the Broadway Practice who plan to deliver at Allen Hospital in New York City (NYC). On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
3153796|NCT00283946|Experimental|1|
2451696|NCT03229902|Experimental|mantra meditation|Each session of mantra meditation lasts for 30 minutes. The participants in each session comprise 1 subject and the PI. In each session, the subject and the PI co-participate in repetitive intonation of a pre-specified mantra. Intervention is comprised of 9 sessions, each of which occurs on a separate weekday at approximately equal intervals over a total intervention period of 3 weeks.
2451790|NCT03229577|Experimental|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga workshop is a nationally-recognized program focused on teaching yoga-based breathing techniques.
2451791|NCT03229577|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a nationally-recognized program focused on teaching mindfulness techniques.
2451792|NCT03229577|Experimental|Emotional Intelligence|Emotional Intelligence is a program developed for university students that focuses on teaching the skills of emotional intelligence such as labeling, understanding, and regulating emotions.
2451793|NCT03229577|No Intervention|Control|The control group will receive no intervention.
2451830|NCT03228979|Active Comparator|Structured Semi-Interactive Prevention|The intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines
2451834|NCT03228979|No Intervention|Control group|Patients will receive standard post stroke care for 1 year
2451887|NCT03228719|Active Comparator|Control Group|Standardized Outpatient Physical Therapy after TKR
2451897|NCT03228719|Experimental|Intervention Group|Standardized Outpatient Physical Therapy after TKR with a Physical Activity Intervention
2451958|NCT03228355|Active Comparator|Levcromakalim|
2451959|NCT03228355|Placebo Comparator|Saline|
2452038|NCT03227900|Active Comparator|Lidocaine|LIdocaine dissolved in water for injections
2452048|NCT03227900|Placebo Comparator|Placebo|Water for injections
2452088|NCT03227510||HCC Cases (Group 1)|This group will include 63 subjects and the diagnoses will be based on clinical examination, laboratory tests such as (Liver Function tests, Alpha-fetoprotein , Ultrasound, and biopsy in some cases if possible (Depends on the patients and their financial issues).
2452094|NCT03227510||Chronic Liver Diseases (group 2)|This group will be including 31 patients, and the diagnoses will be based on laboratory such as (liver function tests, viral markers, AFP,) and by ultrasound findings (shrunken liver, coarse echo-pattern, attenuated hepatic vein and finding nodular surface)
2452103|NCT03227510||Healthy Volunteer (group 3)|"It will include 32 subjects that serve as control group.~These all patients and control groups will be subject the following parameters: Biochemical tests such as (Liver function tests, viral markers, serum AFP, CBC, Kidney functions and others) and circulating MicroRNAs levels of all these subjects."
3153797|NCT00283946|Active Comparator|2|
3153798|NCT00283959|Experimental|Migalastat|Migalastat 150 mg was administered orally QOD during the 12-week treatment period and then during the optional 36-week extension period.
2452361|NCT03225456|Experimental|Oxytocin|Participants will receive two doses of 24 IU intra-nasal oxytocin (Syntocinon) in a single session
2452362|NCT03225456|Placebo Comparator|Placebo|Participants will received match placebo, again in two doses in a single session
2452456|NCT03224884|Active Comparator|Interscalene block|Patients randomized to receive an interscalene block .
2452459|NCT03224884|Experimental|Supraclavicular block|Patients randomized to receive a supraclavicular block.
2452556|NCT03224260|Experimental|Treatment C|Receive 500 mg BMS-986177 once daily or placebo
3153799|NCT00284011|Active Comparator|SAMe|Two 400 mg pills.
3153800|NCT00284011|Placebo Comparator|Placebo|Two placebo pills (identical in appearance to SAMe).
3153801|NCT00284063|Active Comparator|Group 1: N; SPP; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3153802|NCT00284063|Active Comparator|Group 2: N; SMT; N|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3153803|NCT00284063|Active Comparator|Group 3: N; SMT; SP|N = neutral MRI; SP = side posture MRI; SPP = side posture position; SMT = side posture manipulation
3153804|NCT00284063|No Intervention|Group 4: N and SP|N = neutral MRI SP = side posture MRI SPP = side posture position SMT = side posture manipulation
3153805|NCT00284102|Experimental|1|ALI/ARDS patients
3153806|NCT00284115|Experimental|Mechanical gait repetitive training|Body weight support treadmill training technique enabling nonambulatory patients to have the repetitive practice of a gate-like movement
3153807|NCT00284115|Active Comparator|Conventional rehabilitation program|Physiotherapeutic conventional rehabilitation program
3153808|NCT00284128|Experimental|ilepatril (2.5 mg ) once daily|AVE7688 oral administration
3153809|NCT00284128|Experimental|ilepatril (10 mg) once daily|AVE7688 oral administration
3153810|NCT00284128|Experimental|ilepatril (35 mg) once daily|AVE7688 oral administration
3153811|NCT00284128|Experimental|ilepatril (50 mg) once daily|AVE7688 oral administration
3153812|NCT00284128|Other|Losartan-potassium (100 mg) once daily|oral administration
2451070|NCT03234348|Placebo Comparator|Orsiro|Percutaneous coronary intervention by means of Biodegradable polymer sirolimus-eluting stent implantation after proper lesion preparation by balloon predilatation and/or manual thrombectomy.
2451086|NCT03233828|Experimental|Intralesional IL-2 Injection|Two subcutaneous intralesional injections of Aldesleukin, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
2451087|NCT03233828|Placebo Comparator|Saline Injection|Two subcutaneous intralesional injections of Saline, prepared by the pharmacy such that the contents will be masked, will be administered by the care provider in a clinic seven days apart.
2451274|NCT03232879|Experimental|Experimental 1|Motor Imagery
2451275|NCT03232879|Experimental|Experimental 2|Action Observation
2451276|NCT03232879|No Intervention|Control Group|No intervention
2451300|NCT03232632|Experimental|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
2451331|NCT03232372|Experimental|External-Connection non-submerged Imp|We will place implants with external connection and non- submerged to assess the bone loss around
2451333|NCT03232372|Experimental|Internal Connection Submerged implants|We will place implants with internal connection and submerged to assess the bone loss around
2451336|NCT03232372|Experimental|Internal Connection non-Submerged Impl|We will place Internal connection implant and non-Submerged Implants to assess the bone loss around
2451396|NCT03232099|Experimental|Red Wine group (RW)|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
2451398|NCT03232099|Active Comparator|Abstemious|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
2451432|NCT03231657|Experimental|Incorporation of the sFlt1/P1GF ratio|"Incorporation of the ratio in the diagnosis and classification of pre-eclampsia:~sFlt1/PlGF ratio >38: pre-eclampsia risk~sFlt1/PlGF ratio >85: pre-eclampsia~ISSHP pre-eclampsia definition + ratio >210: severe PE~ISSHP pre-eclampsia definition + ratio sFlt1/PlGF ratio >600: consider deliver"
2451434|NCT03231657|No Intervention|Routine clinical practice|Criteria for the definition of PE were those of the International Society for the Study of Hypertension in Pregnancy
2451579|NCT03230968|No Intervention|Phase 1 without intervention|In selected heath centers we interviewed all consenting patients older than 15 years. Before the physician consultation, we investigated sociodemographic, epidemiologic, clinical characteristics and reason for seeking health services. Immediately after consultation, we asked the patient his/her diagnoses. We confirmed all diagnoses with treating physicians. If the patient had been diagnosed with respiratory disease, we collected information on prescribed treatment, and classified the type of respiratory disease and comorbidities based on the 10th International Classification of Diseases (ICD-10). Patients were given follow up one month later.
2451584|NCT03230968|Active Comparator|Phase 2 with intervention|"We trained health personnel from the participating health centers on implementation of the proposed model based on the AIRE guidelines previously approved by the AIRE committee of the National Institute for Respiratory Diseases. The AIRE guidelines have been adapted from WHO Practical Approach to Lung Health. Once the model was in action we interviewed all consenting patients older than 15 years as in phase 1."
2451605|NCT03230331||STN DBS|Parkinson's disease (PD) patients who underwent deep brain stimulation (DBS) of the subthalamic nucleus (STN)
2451608|NCT03230331||CONTROL|Parkinson's disease (PD) patients received optimized medical treatment according to published evidence based guidelines
2451655|NCT03230162|Experimental|sildenafil citrate|50 pregnant female will be treated with sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery.
2451657|NCT03230162|Experimental|low molecular weight heparin|50 pregnant female will be treated with a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery according to body weight as follow < 50 kg 3500 units daily 50-90 kg 4500 units daily 91-130 kg 7000 units daily 131-170 kg 9000 units daily > 170 kg 75 u/kg/day
2451728|NCT03229785|Experimental|Human Umbilical Cord Blood Plasma|Six intravenous infusions of human umbilical cord blood plasma (HUCBP) during a twelve month study period. The amount of HUCBP being infused on each occasion is 50 mL.
2451764|NCT03229447|Active Comparator|E-learning intervention|The E-learning intervention consists of two 20-minute e-learning modules that combine a didactic component with testimonials from respected professionals in the fields of addiction treatment and criminal justice. Module 1 describes the nature of opioid addiction and treatment modalities. Module 2 addresses specific criminal justice concerns of cost, acceptance, usefulness, and diversion, perceived obstacles to providing MAT access as described to us by Ohio criminal justice professionals in formative phase. All courts recruited for the study are exposed to E-Learning.
2451766|NCT03229447|Experimental|Change Team Intervention|Half of the courts exposed to e-learning will be randomly assigned to a change team intervention. The change team will reinforce the information in the modules and provide instrumental assistance in linking courts to MAT providers and financial resources.
2451829|NCT03229135||Group A|Group A (CLcr≥60mL/min) : Teicoplanin was intravenously administered 3 times for moderate infections (skin, soft tissue and respiratory infections) or 6 times for severe infections(endocarditis caused by MRSA or severe pneumonia) at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
2451833|NCT03229135||Group B|Group B (40 mL/min≤CLcr<60mL/min) : Teicoplanin was intravenously administered 3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 400 mg/d.
2451836|NCT03229135||Group C|Group C (CLcr<40mL/min) : Teicoplanin was intravenously administered 2 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
2451839|NCT03229135||Group D|Group D (standard regimen) : Teicoplanin was intravenously administered 1-3 times at the loading dose of 400 mg at 12h intervals, followed by maintenance dosing 200 mg/d.
2451872|NCT03228654|Experimental|Unipolar electrocautery|vaginal hysterectomy using Unipolar electrocautery
2451876|NCT03228654|Active Comparator|Purohit's technique|Vaginal hysterectomy using Purohit's technique
2452321|NCT03225690|Active Comparator|Morphine|1 mg morphine will apply via epidural catheter before at the time point of the peritoneum closed.
2451079|NCT03234387||Cystic fibrosis (CF) without established CF-related diabetes|"Cystic fibrosis (CF) without established CF-related diabetes~Inclusion criteria:~Males and females ≥ 12 years of age~CF diagnosis based on clinical features, supported by an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired~No evidence of established, gestational or exacerbation induced CFRD in accordance with the American Diabetes Association criteria (stated above; [110]).~No contraindications to performing exhaustive exercise~Can understand and cooperate with the study protocol~No increase in symptoms or weight loss in the preceding 2 weeks"
2451080|NCT03234387||Healthy controls|Age- and gender-matched healthy control participants.
2451125|NCT03233854|Experimental|Treatment (CD19/CD22 CAR T cells, chemotherapy)|Patients receive cyclophosphamide IV over 60 minutes and fludarabine phosphate IV over 30 minutes on days -5 to -3. Patients then receive CD19/CD22 CAR T cells IV over 10-20 minutes on day 0. Patients that benefited from the first dose of CD19/CD22 CAR T cells, had no unacceptable side effects, and have enough cells left over may receive 2 or 3 additional doses of CD19/CD22 CAR T cells.
3190339|NCT00786396|No Intervention|2|SAT (standard of care) group will take their medications as directed by their physicians for the period of one year.
3190340|NCT00786435||1|Those with a cervical spinal cord injury
3190341|NCT00786435||2|Those with a thoracic spinal cord injury
3190342|NCT00786435||3|Healthy, control group
3190343|NCT00786448||Group 1|
3190344|NCT00786500|Active Comparator|Gynostemma pentaphyllum tea|
2451377|NCT03232112|Active Comparator|Exenatide 2 MG Injection|Bydureon® (exenatide) is supplied as powder and solvent for prolonged release injection (once-weekly). Bydureon® is delivered in a carton containing four pens. Each single-dose, dual-chamber pen contains 0.65 ml of diluent and 2 mg of exenatide, which are isolated until mixed by the person administering the drug. Needles are supplied with the pen.
2451379|NCT03232112|Placebo Comparator|BD PosiFlush (saline)|The placebo will be supplied for as pre-filled saline syringes (BD PosiFlush™, BD Worldwide) containing 3 ml each. Needles are bought separately.
2451415|NCT03231761|Experimental|Service user testimonial videos|Videos with service user testimonials about depression and psychosis
2451418|NCT03231761|Active Comparator|mhGAP didactic video|The intervention in the active comparator arm includes two didactic videos with instruction about depression and psychosis based on the World Health Organization mental health Gap Action Programme (mhGAP) modules for those conditions
2451424|NCT03231761|No Intervention|No video|Participants do not observe any videos prior to the assessment
2451501|NCT03231215|Placebo Comparator|controlled group|Group І (control group): the patients received 15 ml epidural plain bupivacaine (0.5%) +2 ml normal saline Group (BS).
2451505|NCT03231215|Active Comparator|dexamethasone group|Group II (dexamethasone group):- the patients received 15 ml epidural plain bupivacaine (0.5%) + 8mg dexamethasone (2ml) Group (BD)
2451544|NCT03230851|Experimental|aspirin 100mg/d therapy|Group1: aspirin 100 mg/d;
2451547|NCT03230851|Experimental|aspirin 100mg/2d therapy|Group2: aspirin ;
2451552|NCT03230851|Experimental|aspirin 100mg/3d therapy|Groups3: aspirin ;
2451555|NCT03230851|Experimental|aspirin 50mg bid therapy|Groups4: morning 50mg evening 50mg;
2451557|NCT03230851|Experimental|aspirin 75mg/d therapy|Group5: aspirin 75mg / d;
2451559|NCT03230851|Experimental|aspirin 50mg/d therapy|Group6: aspirin 50mg / d;
2451561|NCT03230851|Experimental|indobufen 100mg bid therapy|Group7: 100mg bid
2451613|NCT03230383|Experimental|Cohort 1_90mg and Matching Placebo|
2451616|NCT03230383|Experimental|Cohort 2_300mg and Matching Placebo|
2451619|NCT03230383|Experimental|Cohort 3_900mg and Matching Placebo|
2451621|NCT03230383|Experimental|Cohort 4_1800mg and Matching Placebo|
2451626|NCT03230383|Experimental|Cohort 5_3000mg and Matching Placebo|
2451629|NCT03230383|Experimental|Optional Cohort 6_TBD mg and Matching Placebo|
2451635|NCT03230383|Experimental|Optional Cohort 7_TBD mg and Matching Placebo|
2451733|NCT03229798|Active Comparator|Sumatriptan Succinate Oral Tablet|100 mg oral tablet commercial Imitrex sumatriptan succinate tablet
2451735|NCT03229798|Experimental|Sofusa Profile #1|Combination device for transdermal delivery of sumatriptan succinate Current approved dose (SC)
2451738|NCT03229798|Experimental|Sofusa Dose Profile #2|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #1
2451741|NCT03229798|Experimental|Sofusa Dose Profile #3|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #2
2451743|NCT03229798|Experimental|Sofusa Dose Profile #4|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from Sofusa Dose Profile #3
2451746|NCT03229798|Experimental|Sofusa Dose Profile #5|Combination device for transdermal delivery of sumatriptan succinate- adjust dose and flow rate to achieve PK profile based on results from prior Sofusa Dose Profile #2-4
2451801|NCT03229265|Experimental|Patiromer|
2451840|NCT03228953|Experimental|Pharmacogenomic-guided therapy group|In this group, results of pharmacogenomic testing will be provided to the treating physician within 2-5 working days. Thus, the patient's treatment provider will be able begin antidepressant adjustments based on pharmacogenomic testing report within a week of the baseline visit.
2451841|NCT03228953|No Intervention|Treatment as usual (TAU) group|For patients randomized to this group, medication treatment decisions by the treating clinicians will be made without the availability of the pharmacogenomic report; however, the test results will be provided after the study completion to the patient treating physician.
2451860|NCT03228628|Experimental|Nitrous oxide|will inhale experimental treatment (50% N2O - 50% O2)
2451861|NCT03228628|Placebo Comparator|Placebo|will inhale medical air (22% O2 - 78% N2)
3190345|NCT00786500|Placebo Comparator|Placebo tea|
3190346|NCT00786513|Active Comparator|Control Arm|
3190347|NCT00786513|Experimental|Intervention Arm|
3190348|NCT00786552|Experimental|chemotherapy|
3190349|NCT00786578||1|overweight runners (BMI>25)
3190350|NCT00786578||2|lean runners (BMI<24)
2451096|NCT03234140||"Group Genome Wide Association Studies"|"Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :~PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396~RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441~FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229~MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178~MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321~Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data."
2451102|NCT03234140||"Group EPIC"|"Patients are adults, male or female, included in the EPIC Cohort (European Prospective Investigation Into Cancer and Nutrition study between 1992 and 2000. (Sponsor IARC, Lyon, France).~The investigators plan to analyze the influence of single-nucleotide polymorphisms on circulating t(14;18) levels in these 318 healthy individuals including 100 who will develop follicular lymphoma later on, and assess if these biomarkers are helpful to refine the identification of high-risk follicular lymphoma individuals."
2451145|NCT03233672|Other|Hypo-fractionated postoperative IMRT-SIB|All patients underwent combined, intensified and modulated radiotherapy for five days a week with the following doses: 62.5 Gy to the prostate bed and 45 Gy to pelvis nodes in 25 fractions.
2451193|NCT03233373||Otolaryngology Clinic Patients|Healthy subjects with no present complaints of nasal obstructions. Patients visiting the clinic, once consented, will be asked which nostril they breathe better from. They will then be asked to perform 3-4 normal respiration cycles through their nose which will be recorded using our thermal imaging device, the Seek CompactPro thermal imager
2451258|NCT03233022|Active Comparator|Unchanged Happify|Participants use Happify as it is currently available to consumers on the main site, including all engagement elements. Users may access a wide variety of 4-week programs and use them in any way they desire for the entire study period.
2451263|NCT03233022|Active Comparator|Negatively-focused tracks|"Participants use two pre-selected Happify tracks that focus on remediating negatives (e.g. conquering negative thoughts and managing stress). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period."
2451264|NCT03233022|Active Comparator|Positively-focused tracks|Participants use two pre-selected Happify tracks that focus on improving positives (e.g. building well-being, using one's strengths). Several engagement elements are missing, including social forums, regular informational emails, and the ability to play games. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2451267|NCT03233022|Placebo Comparator|Placebo condition|Participants complete a Happify program that is designed to engage with specific activities, but that does not aim to promote positive emotion or reduce negative emotion. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2451269|NCT03233022|Sham Comparator|Distraction condition|Participants complete a series of quizzes and polls on Happify designed to engage them in thinking about well-being topics, but without giving any specific instructions for how to promote well-being. Participants gain access to 8 weeks worth of content, but may repeat the content as often as they like in the follow-up period.
2451302|NCT03232710|Experimental|pilot study group|
2451303|NCT03232710|Experimental|group 1 (under fasting condition)|
2451306|NCT03232710|Experimental|group 2 (under fasting condition)|
2451309|NCT03232710|Experimental|group 3 (under fed condition)|
2451310|NCT03232710|Experimental|group 4 (under fed condition)|
2451344|NCT03232307|Experimental|Treatment (ibrutinib, rituximab, lenalidomide, dexamethasone)|Participants receive ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Participants also receive rituximab IV on days 1, 8, 15 and 22 in course 1 and 2, on day 1 of course 3-8, and then on day 1 of every other 28-day course, lenalidomide PO on days 1-21, and dexamethasone PO weekly. Treatment with rituximab repeats every 28 days for 2 years, with lenalidomide for 1 year, and with dexamethasone for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2451442|NCT03231605|Experimental|Group 1|Group 1 is experimental group which used the Hepatitis A Vaccine product by Changchun Institute of Biological Co.,Ltd
2451444|NCT03231605|Active Comparator|Group 2|Group 2 is control group which used the Hepatitis A Vaccine product by Changchun Changsheng Life Sciences Limited
2451533|NCT03230721|Active Comparator|ThuLEP group|Patients who underwent thulium-fiber laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2451535|NCT03230721|Active Comparator|Monopolar enucleation group|Patients who underwent monopolar enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2451536|NCT03230721|Active Comparator|HoLEP group|Patients who underwent Ho:YAG laser enucleation of the prostate due to lower urinary tract symptoms caused by prostatic hyperplasia.
2451610|NCT03230591||Fabry's disease|Fabry's disease patients who were confirmed by enzyme assay and gene study
2451676|NCT03230097|Experimental|BI 409306|
2451678|NCT03230097|Placebo Comparator|Placebo|
2451739|NCT03229629|Experimental|Maternal BCC only|Mothers with child under 20 months or pregnant will receive Behavior Change Communication (BCC)
2451154|NCT03233516||Control subjects|Children 1-59 months at Sachs' Children and Youth Hospital treated for a minor orthopedic (elective (e.g. hand surgery) or acute) or minor surgical disease, e.g. minor trauma (excluding e.g. appendicitis, major burns, major trauma).
2451194|NCT03233334|Experimental|Purpose Project Group|Group receiving Purpose Project intervention.
2451261|NCT03233074||Acute Myeloid Leukemia patients|For diagnosis purpose, bone marrow sampling is performed for acute myeloid leukemia patients. 2 milliliters of this sample will be collected and analysed for the COSMOS study.
2451265|NCT03233074||Healthy donors|Healthy donors are patients undergoing cardio-vascular surgery for their usual support. During this surgery, 2 milliliters of the bone marrow will be collected, and analysed for the COSMOS study.
2451315|NCT03232723|Other|MEG Recording|Magnetic fields will be recorded using a 275-channel whole-head MEG system
2451345|NCT03232294||the study group|A total of 96 women with low risk pregnancy coming to the clinic for a routine antenatal examination in 26-28th gestational weeks were included to this study
2451382|NCT03232151|Experimental|C-ARM CBCT|A C-arm CBCT evaluation with SMART RECON novel software for the rapid assessment of time-resolved CT angiogram and CT perfusion.
3153813|NCT00284193|Experimental|feiba-VIIa, hemophilia A-inhibitor therapy|COMBINED PATIENT- TAILORED THERAPY WITH CONCOMITANT ADMINISTRATION OF BOTH DRUGS , FOLLOWING EX VIVO THROMBIN GENERATION PREDICTING ASSAYS
3153814|NCT00284219|Active Comparator|Real high frequency rTMS|The patients will undergo a series of treatments of high frequency rTMS
2451472|NCT03231358|Experimental|Intervention|"Participants randomized to the behavioral intervention called Our Family Our Future. These participants will receive an intervention to prevent sexually transmitted infections (STIs) including HIV, Chlamydia trachomatis and Neisseria gonorrhoeae; sexual risk behavior; and depression onset. This is a behavioral intervention involving adolescent-parent dyads, delivered in a group setting over 3-4 consecutive weeks."
2451473|NCT03231358|No Intervention|Control|The control arm will receive usual care (consisting of a packet of existing available brochures on HIV, STIs, mental health including places to access care).
2451527|NCT03231020||Adherent Group|Parent(s) that submitted a high rate of data transfer (top 25th percentile) with rate of data days of mHealth technology for data transfer
2451528|NCT03231020||Non-Adherent Group|Parent(s) that chose to return mHealth technology before the end of the interstage period and/or low rate of data transfer (bottom 25th percentile) with rate of data days
2451615|NCT03230344|Active Comparator|Group 1|Periodontal treatment initiated with scaling and root planing along with root canal treatment and followed by open flap debridement after 6 weeks.(Open flap debridement simultaneously with root canal treatment )
2451618|NCT03230344|Experimental|Group 2|Periodontal treatment initiated with scaling and root planing followed by open flap debridement after 6 weeks. Endodontic treatment will be initiated after 3 months of periodontal surgery.(open flap debridement and delayed root canal treatment )
3153815|NCT00284219|Sham Comparator|Sham high frequency rTMS|The patients will receive a series of sham treatments.
3153816|NCT00284258|Experimental|1|CPT-11 and TS-1
2451704|NCT03229720|Active Comparator|Audio-Visual Distraction Group|In this arm, the patient will be introduced to the audio-visual distraction device and given some instruction on how to use it and rules while using it. other than that, the dental procedure is as same as the other arm group.
2451708|NCT03229720|No Intervention|Normal Dental Environment Group|Normal Dental Environment without any distractions.
2451782|NCT03229538|Experimental|Methylprednisolone Arm|IV Methylprednisolone
2451785|NCT03229538|Placebo Comparator|Placebo Arm|IV Isotonic Saline
2452113|NCT03227276|Placebo Comparator|Placebo|
2452116|NCT03227276|Experimental|Litramine|
2452247|NCT03226314||stool sampled community patients|community patients entering emergency ward or intensive care unit in Reunion Island university hospital and having the stools sampled for bacterial analysis.
2452274|NCT03226041|Experimental|retroperitoneoscopic urologic surgery|All included patients will undergo retroperitoneoscopic renal or adrenal surgery with the transcutaneous carbon dioxide monitor.
2452340|NCT03225768|Experimental|Guided Training|
2452394|NCT03225300|Experimental|Simultaneous integrated boost|In this protocol, the newly diagnosed, primary glioblastoma patients receive SIB 69 Gy/30 fractions to preoperative tumor bed and surgical cavity, while 60 Gy/30 fractions were covering preoperatively edematous area. PTV is 5 mm.
2452442|NCT03224806|Other|Wholegrain bread|
2452443|NCT03224806|Other|White bread|
2452444|NCT03224806|Other|15% fiber-rich bread|
2452445|NCT03224806|Other|30% fiber-rich bread|
3153817|NCT00284258|Active Comparator|2|CPT-11, 5-FU and l-LV
3153818|NCT00284297|Experimental|knee arthrodesis|
3153819|NCT00284310|Experimental|wrist surgery|
3153820|NCT00284427|Experimental|1|Vitamin C
3153821|NCT00284453||1|Forty(40)subjects that have received >2 appropriate ICD shock therapies
3153822|NCT00284453||2|Twenty(20)subjects that have received 1-2(low level)appropriate ICD therapies
3153823|NCT00284453||3|Ten(10)subjects that received inappropriate therapies from their ICD
3153824|NCT00284492|Active Comparator|Lifestyle advice|
3153825|NCT00284492|Experimental|Lifestyle advice and acupuncture therapy|
3153826|NCT00284609|Experimental|1|
3153827|NCT00284609|Active Comparator|2|
3153828|NCT00284661|Experimental|FAST FIX|Inetrvention is Fast Fix repair of meniscal tear
3153829|NCT00284661|Experimental|Meniscal suturing|Intervention is Standard suturing of meniscal tear
3153830|NCT00284752|Experimental|ABI-007|
3153831|NCT00284804|Experimental|MDX-060 plus standard of care|MDX-060 in combination with gemcitabine
3153832|NCT00284804|Active Comparator|Standard of care|Gemcitabine
3153833|NCT00284817|Experimental|1|MEDI-522
3153834|NCT00284817|Experimental|2|MEDI-522
3153835|NCT00284817|Experimental|3|MEDI-522
3153836|NCT00284817|Experimental|4|MEDI-522
3153837|NCT00284817|Experimental|5|MEDI-522
3153838|NCT00284830|Active Comparator|1|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
2451179|NCT03233477||Posner-Schlossman Syndrome|"Inclusion criteria：~Clinical diagnosis of Posner-Schlossman Syndrome~Able to communicate with doctor and understand this study~Exclusion criteria:~Not be able to communicate with doctor and understand this study~One or more authorized investigators think he or she will suffer from any severe risks from the study"
2451183|NCT03233477||cataract|"Inclusion criteria：~Clinical diagnosis of age-related cataract~Prepare for cataract operation~Open angle and intraocular pressure is normally at anytime~No family history of glaucoma~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
2451184|NCT03233477||primary open-angle glaucoma|"Inclusion criteria：~Both eyes involved~Open angle~Progressive glaucomatous optic neuropathy~Specific visual field loss of glaucoma~Intraocular pressure above the up limit of normal people~Exclusion criteria:~Patients above 65 years old~With Secondary ocular hypertension~Have the history of receiving any ophthalmologic operation or anti-viral therapy~With diabetes mellitus~With autoimmune disease~Be receiving any therapy that can influence the virus-infection state and biochemical characteristics of serum and aqueous humor, or have received such therapy before one month"
2451211|NCT03233165|Experimental|Patients with diagnosed leukoplakia 1|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er:YAG laser"
2451212|NCT03233165|Experimental|Patients with diagnosed leukoplakia 2|"Patients who meet the conditions of pathohistological diagnosis of leukoplakia and clinical criteria for diagnosis of non-homogeneous leukoplakia.~Intervention using Er,Cr:YSGG laser"
2451266|NCT03232957|Experimental|No IT morphine|Spinal block with 0.5% isobaric with no intrathecal morphine
2451268|NCT03232957|Experimental|50 ug IT morphine|Spinal block with 0.5% isobaric with 50 ug intrathecal morphine
2451270|NCT03232957|Experimental|100 ug IT morphine|Spinal block with 0.5% isobaric with 100 ug intrathecal morphine
3153839|NCT00284830|No Intervention|2|conventional dual-chamber pacing
3153840|NCT00284908|Experimental|I STU-Na|Cross-over study with escalating doses
3153841|NCT00284947|Experimental|Maintenance immunosuppression|"40mg Simulect i.v, once every 28 days for 24 weeks (treatment periods)~1g MMF or 720mg EC-MPS p.o twice daily~Oral corticosteroids"
3153842|NCT00284986|Experimental|PROCHYMAL™|PROCHYMAL™
2451466|NCT03231553|Experimental|Intervention|"Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.~Receive MiQuit text message cessation programme."
2451467|NCT03231553|No Intervention|Control|Receive usual NHS antenatal care and any NHS smoking cessation support which they choose to access plus an NHS leaflet giving advice on stopping smoking.
2451564|NCT03230955|Experimental|Psychological and psycho-educational support|The intervention group (IG) [that will receive telephone-based assistance to quit (including psychological and psycho-educational support and pharmacological treatment advice, if required) provided by trained nurses who will proactively call at one week, 15 day, a month, 3, 6 and 12 months after discharge, plus the calls made by the patients during the process]
2451566|NCT03230955|Active Comparator|Control Group|The control group (CG) [that will receive only a brief counselling session after discharge]
2451640|NCT03230448||positive alcoholism|positive acute alcoholism had questionnaire about suicidal intentionality
2451641|NCT03230448||negative alcoholism|negative acute alcoholism had questionnaire about suicidal intentionality
2451659|NCT03229993|Experimental|OCT guided PCI|
2451661|NCT03229993|Experimental|OCT guided medicine|
2451662|NCT03229993|No Intervention|SPECT guided PCI|
2451663|NCT03229993|No Intervention|SPECT guided medicine|
2451727|NCT03229772|Other|Subjects indicated for dynamic nuclear medicine scanning|The trial will consist of a single arm composed of subjects with preexisting indications for dynamic nuclear medicine scanning at the site. All patients will undergo nuclear medicine scintigraphy using the GE Discovery 670 NM/CT device with and without CZT enabled during a single visit.
2451776|NCT03229434|Experimental|Widely pristine area|Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in a widely pristine area with moderate intensity (Rating of perceived exertion: ~ 11-15).
2451777|NCT03229434|Active Comparator|Anthropogenically influenced area|"Outdoor mountain hiking (approximately 6 hours, 8km, 800 altitude meters, estimated speed: 4km/h [uphill], 5.2km/h [downhill]) in an anthropogenically influenced area with moderate intensity (Rating of perceived exertion: ~ 11-15).~All characteristics of the hiking (duration, time, difference in altitude, ...) are planned to be comparable to the experimental condition except the area."
2451797|NCT03229057|Active Comparator|OCP + Placebo|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Placebo pills will be administered to individuals randomized to OCP only in order to maintain study blinding.
2451799|NCT03229057|Active Comparator|Metformin + Placebo|Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg. Placebo pills will be administered to individuals randomized to metformin only in order to maintain study blinding.
2451804|NCT03229044||BMI 25-30|Tetranectin mRNA and protein level were measure in the adipose tissues which were belonging to body mass index is 25-30 kg/m2
2451846|NCT03228940|Experimental|treatment|RVX000222 (apabetalone) 100 mg to be administered orally BID 12 hours apart.
2451884|NCT03228589|Experimental|probiotic strain|Active arm treated with the probiotic strain for 8 weeks.
3153843|NCT00285051|Experimental|Group 1|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 300 mcg of delta-8-THC per dose
3153844|NCT00285051|Experimental|Group 2|Chemo cycle 1 - IV Ondansetron Chemo cycle 2 - 600 mcg of delta-8-THC per dose
3153845|NCT00285051|Experimental|Group 3|Chemo cycle 1 - 300 mcg of delta-8-THC per dose, Chemo cycle 2 - IV Ondansetron
2451323|NCT03232541|Other|Standard care (A)|Standard care (A) with neutral communication (A1) or positive communication (A2)
2451325|NCT03232541|Placebo Comparator|Sham acupuncture (B)|Standard nausea treatment plus Sham acupuncture (B) with neutral communication (B1) or positive communication (B2)
2451326|NCT03232541|Experimental|Genuine acupuncture (C)|Standard nausea treatment plus Genuine acupuncture (C) with neutral communication (C1) or positive communication (C2)
2451363|NCT03232203||Health care providers|A HCP survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS summary of product characteristics and educational materials
2451365|NCT03232203||Parent/carer|A parent/carer survey instrument of approximately 20 questions will be provided. Survey questions will be based on the STRIMVELIS Patient Information Leaflet and educational materials
2451422|NCT03231852||Study Population|Women with a gynecologic malignancy will complete several surveys to assess their willingness to participate in clinical trials.
3153846|NCT00285051|Experimental|Group 4|Chemo cycle 1 - 600 mcg of delta-8-THC per dose Chemo cycle 2 - IV Ondansetron
2451509|NCT03231150|Active Comparator|Anatomical injection|"Once patient has been randomized, if placed in the anatomically-guided injection group, the medial band of the plantar fascia origin on the calcaneus will be palpated and marked approximately. In the clinical setting, a sham ultrasound machine will be utilized to locate the plantar fascia keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage."
2451510|NCT03231150|Experimental|Ultrasound Guided Injection|Once patient has been randomized, if placed in the USGI group, the patient will be scheduled for an ultrasound therapy in the radiology department at Penn Presbyterian Medical Center. In this setting, the patient will be informed that in order to keep them blinded, that all patients must have either injection performed in the radiology department and that the ultrasound machine utilized will either be on or off during the injection keeping the patient blinded to the treatment modality. The area will then be prepped with alcohol to the medial heel and utilizing a medial approach, an injection of 0.5 cc 0.5% bupivacaine, 0.5 cc dexamethasone and 0.25 cc triamcinolone acetamide 40 mg/mL will be administered into the area surrounding the plantar fascia. The area will then be cleaned will alcohol and dressed with a small elastic bandage.
2451596|NCT03230487|Experimental|BI 1015550|
2451597|NCT03230487|Placebo Comparator|Placebo|
2451636|NCT03230253|Experimental|Sequential training group|Exercise training for 30 minutes followed by 30 minutes of cognitive-based intervention
2451639|NCT03230253|Experimental|Dual training group|Exercise training simultaneously combined cognitive-based intervention for 60 minutes
2451642|NCT03230253|Active Comparator|Control training group|non-aerobic exercise (e.g., stretch, range of motion exercise...) and unstructured cognitive rehabilitation programs (e.g., reading newspapers, playing board games...) for 60 minutes
2451658|NCT03229954|Experimental|IV iron (Monofer) group|Iron isomaltoside(Monofer) will be injected intravenously and injection dose will be calculated using Ganzoni formula.
2451660|NCT03229954|Active Comparator|Oral iron group|Ferrous sulfate(Feroba-YOU) 160mg/day for 12 weeks will be taken per oral.
2451831|NCT03229239|Experimental|corneal stroma implantation|implant the corneal stroma to the diseased cornea of keratoconus patients
2451862|NCT03228745|Experimental|pre-operative MBSR|Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
2451864|NCT03228745|No Intervention|treatment-as-usual (TAU)|The individuals in the TAU group will receive their treatment as usual.
2452079|NCT03227367|Experimental|Test group|Mononuclear cells isolated from the peripheral blood of 25 chronic periodontitis patients were interveened with 1ml/well preparation of Platelet rich fibrin(PRF), Biphasic calcium phosphate (BCP) and PRF and BCP combination in-vitro.
2452085|NCT03227367|Other|control group|Mononuclear cells isolated from the peripheral blood of healthy individuals in-vitro.
2452141|NCT03227146|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
3153847|NCT00285090|Experimental|Early Treatment|
3153848|NCT00285090|Experimental|LateTreatment|
3153849|NCT00285090|Experimental|Total Treatment|
3153850|NCT00285090|Placebo Comparator|No Treatment|
3153851|NCT00285168||1 - Control|Usual Bone Density Report
3153852|NCT00285168||2 - Intervention|Bone Density Report with Absolute 10-year Fracture Risk Decision Aide
3153853|NCT00285233|Experimental|1|
3153854|NCT00285259|Experimental|VCL-CB01|
3153855|NCT00285259|Placebo Comparator|Placebo|PBS
3153856|NCT00285298|Experimental|Pentoxifylline|
3153857|NCT00285298|Placebo Comparator|Placebo|
3153858|NCT00285376|Experimental|1|vilazodone
3153859|NCT00285376|Placebo Comparator|2|
3153860|NCT00285389|Experimental|VAD Clorambucil Rituximab|
3153861|NCT00285402|Experimental|A|
3153862|NCT00285402|Experimental|B|
3153863|NCT00285402|Placebo Comparator|C|
3153864|NCT00285415|Other|Doc and Car|Receiving Doc and Car
3153865|NCT00285428|Experimental|Dose level 1|120 mg/m2
3153866|NCT00285428|Experimental|Dose level 2|200 mg/m2
3153867|NCT00285428|Experimental|Dose Level 3|375 mg/m2
3153868|NCT00285428|Experimental|Dose level 1B|80 mg/m2
3153869|NCT00285532||Home test kit|
3153870|NCT00285545||Good blood flow|Group with normal blood flow to small intestine
3153871|NCT00285545||Poor blood flow|Group with partial ischemia to small intestine
3153872|NCT00285558|Experimental|CBT with peer-enhanced activities|Cognitive behavioral treatment (CBT) with peer-enhanced adventure therapy. The peer intervention, ''adventure therapy,'' is based on the principles of Outward Bound and was expected to affect weight status through a positive effect on self-concept.
2451277|NCT03232931|Experimental|Multisensory Intervention|Preterm infants in the NICU who are randomized to receive a multisensory intervention, in addition to the standard of care. The multisensory intervention uses recordings of the parents' voices and nurturing touch administered in the NICU during 12 to 23 sessions of standardized, therapist-administered, auditory-tactile stimulation, dispersed over a 2 to 3 week period. The intervention includes 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
2451279|NCT03232931|Other|Standard of Care|Preterm infants in the NICU who are randomized to receive the standard of care. The standard care for preterm infants in the NICU currently follows medical protocols of skin-to-skin holding and exposure to recordings of parent's voice.
2451319|NCT03232554|Experimental|Buxue Yimu Pills|Buxue Yimu Pill 12g pill by mouth, twice daily
2451321|NCT03232554|Experimental|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pill 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
2451322|NCT03232554|Active Comparator|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
2451384|NCT03232190|Experimental|INTNIC|NICU Intervention Group Web Application Infants < 32 weeks
2451387|NCT03232190|No Intervention|CNIC|NICU Control Group No Web Application Infants < 32 weeks
2451389|NCT03232190|No Intervention|CMAT|Maternity Unit Control Group No Web Application Infants > 37 weeks
2451417|NCT03231722|Active Comparator|mFOLFOX6 + Panitumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluorouracil 400 mg/sqm iv bolus, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
2451420|NCT03231722|Experimental|mFOLFOXIRI + Panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1 (if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes) followed by~Irinotecan 150 mg/sqm iv over 60 minutes day 1, followed by~Oxaliplatin 85 mg/sqm iv over 2 hours day 1, in two-way with~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 followed by~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance with 5FU/LV plus pan at the same dose used at the last cycle of the induction treatment. 5FU/LV plus pan will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. The prosecution of pan until disease progression is recommended also if 5-FU is interrupted because of adverse events, patient's refusal or investigator's choice."
2451470|NCT03231267||"Carrierof Ec-BLSE/EPC or Kp-BLSE/EPC"|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
2451471|NCT03231267||Non-Carrier of Ec-BLSE/EPC orKp-BLSE/EPC|During resuscitation, evaluation of the acquisition or not of phages able to lyse Ec-BLSE / EPC or Kp-BLSE / EPC
2451518|NCT03231124|Experimental|LEO 32731|"Incremental dosing of LEO 32731 progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
2451520|NCT03231124|Placebo Comparator|Placebo|"Incremental dosing of placebo progressing to a maximum of 30 mg.~Days 1 - 3: 10 mg dose twice a day for three days~Days 4 - 6: 20 mg dose twice a day for three days~Days 7 - 11: 30 mg dose twice a day for five days~Days 12: 30 mg dose once in the morning"
2451545|NCT03230695|Active Comparator|Active stimulation + robotic therapy|"Active transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
2451548|NCT03230695|Sham Comparator|Sham stimulation + robotic therapy|"Sham transcranial direct current stimulation will be applied during 20 minutes prior to robotic training.~Number of interventions sessions: 1"
2451611|NCT03230500|Experimental|Computer guided immediate implant placement|For the test group, the computer aided surgical guide will be used for implant drilling and placement.
2451614|NCT03230500|Active Comparator|Free hand immediate implant placement|For the control group, free hand implant drilling and placement will be performed guided by the extraction socket walls.
2451677|NCT03230084|Experimental|Urine PDG test|Urine pregnanediol 3-glucuronide (PDG) test strip
2451682|NCT03229668|Placebo Comparator|Group I|Administration of a placebo capsule 1 hour prior to the surgical operation
2451684|NCT03229668|Experimental|Group II|Administration of 75mg of pregabalin 1 hour prior to the surgical operation
2451686|NCT03229668|Experimental|Group III|Administration of 150mg of pregabalin 1 hour prior to the surgical operation
2451784|NCT03229551|Experimental|Xylitol|This arm will evaluate the effect of topical xylitol therapy on biofilm production with the use of PCR bacterial sequencing before and after medical intervention.
2451787|NCT03229551|Active Comparator|Control|This arm is the standard of care saline irrigation solution.
2451806|NCT03229031|Experimental|ES135|
2451812|NCT03229031|Placebo Comparator|Placebo|
2451923|NCT03228147|Experimental|Supportive Care (nutrition supplement)|Patients receive 10 different nutrition supplements PO and complete questionnaires based on each sample in a single session over 60-90 minutes.
2451972|NCT03228095||Active Tuberculosis|Participants with Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
2451974|NCT03228095||Group of Control (Tuberculosis)|Participants Without Active Tuberculosis Disease Intervention: Diagnostic Test: VOC detection in breath and in skin headspace Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Breath sampling Intervention: Headspace analysis for biological material
2451366|NCT03232047|No Intervention|Waiting-list group|Participants in the control condition will conduct the same training as the intervention group after a 26-week waiting period. During the 26-week waiting period, the participants will receive assessment with the same protocol as the interventional group.
2451409|NCT03231839|Placebo Comparator|Caloric restriction (control)|daily reduction of caloric intake aimed at 400 kcal/day
2451411|NCT03231839|Active Comparator|No red meat|daily reduction of caloric intake aimed at 400 kcal/day plus no red meat intake
2451412|NCT03231839|Active Comparator|Increased fiber intake|daily reduction of caloric intake aimed at 400 kcal/day plus increased fiber intake (aim: 40gr/day)
2451464|NCT03231501|Experimental|single arm|This is a single arm study. It is an open-label study. The intervention is eptinib succinate.
2451511|NCT03231111|No Intervention|traditional group|
2451512|NCT03231111|Experimental|Multimedia group|
2451550|NCT03230799|Active Comparator|traditional cataract surgery|
2451553|NCT03230799|Experimental|minimal invasive lens surgery|
2451623|NCT03230513|Active Comparator|Self Epley Manoeuvre|Self Epley Manoeuvre.
2451628|NCT03230513|Active Comparator|Brandt-Daroff Exercise|Brandt-Daroff Exercise.
2451683|NCT03230006|Active Comparator|Unified Protocol|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) consists of 5 core skills modules based on cognitive behavioral treatment elements of proven effectiveness. As noted above, these core skills modules were designed to target (and have been shown to address) negative emotionality and aversive reactivity to emotional experiences when they occur (Boswell et al., 2013; Carl et al., 2014; Sauer-Zavala et al., 2012). These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. A final module consists of relapse prevention. As the treatment proceeds, the domains of thoughts, feelings, and behaviors are each explored in detail, focusing specifically on elucidating dysfunctional emotion regulation strategies that the patient has developed over time within each of these domains, and teaching patients more adaptive emotion regulation skills.
2451685|NCT03230006|Placebo Comparator|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
2451778|NCT03229590||Surgical dislocation|Reduction of slipped epiphysis via surgical dislocation technique
2451805|NCT03229070|No Intervention|Control Group|Control Group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) and assessments at discharge
2451807|NCT03229070|Experimental|Interval effort group|Interval effort group: Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
2451813|NCT03229070|Experimental|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
2451935|NCT03228862|Experimental|D40000|Patients are randomly assigned to receive Ergocalciferol 40000 IU once weekly
2451940|NCT03228862|Experimental|D60000|Patients are randomly assigned to receive Ergocalciferol 60000 IU once weekly
2451948|NCT03228862|Experimental|D80000|Patients are randomly assigned to receive Ergocalciferol 80000 IU once weekly
2452009|NCT03227965|Other|ELITE|
2452072|NCT03227653||Efavirenz|Children using efavirenz-based cART for at least 6 months
2452073|NCT03227653||Non-efavirenz|Children using non-efavirenz-based cART (nevirapine or Lopinavir-Ritonavir Drug Combination) for at least 6 months.
2452111|NCT03227289||Stayed in NRDS|The neonates with NRDS are stayed in NRDS
2452115|NCT03227289||Converted to ARDS|The neonates with NRDS are converted to ARDS
2452167|NCT03226964|Experimental|High flow nasal oxygen|(Optiflow; Fisher & Paykel, Auckland, New Zealand)
2452170|NCT03226964|Active Comparator|Nasal prongs|
2452208|NCT03226574|Experimental|RTX epidural injection|Epidural injection of 1.5mL/min RTX under the guidance of epidurogram.
2452264|NCT03226054|Other|PPI Taper|PPI Taper using Lifestyle Modifications, per study protocol
2452307|NCT03225846|Experimental|WVE-120102 (2 mg) or placebo|
2452308|NCT03225846|Experimental|WVE-120102 (4 mg) or placebo|
2452309|NCT03225846|Experimental|WVE-120102 (8 mg) or placebo|
2452310|NCT03225846|Experimental|WVE-120102 (16 mg) or placebo|
2452311|NCT03225846|Experimental|WVE-120102 (32 mg ) or placebo|
2452366|NCT03225443||Particle Radiotherapy|The patients will receive particle radiotherapy before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
2452367|NCT03225443||Neoadjuvant Chemotherapy|The patients will receive NACT before operation,and then radical hysterectomy, removal of pelvic lymph nodes and abdominal aorta lymph nodes would be conducted. Besides ovary reservation would be made according to the individual situation. Concurrent radiation and chemotherapy would be performed according to the clinical situation.
2452540|NCT03224377||rheumatoid arthritis patients|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
3190351|NCT00786591||Acute Pancreatitis Patients|Patients presenting with clinical features compatible with acute pancreatitis
2451372|NCT03232034|Experimental|Milk mineral supplement plus Whey Protein Hydrolysate|Milk mineral supplement (equating to 1000 mg calcium) plus whey protein hydrolysate (50 g) will be consumed by participants in the morning between 8-10 am after 8-14 h fasting. Blood samples, appetite scales and expired breath samples will be taken in a regular intervals for 2 h after ingestion.
2451416|NCT03231787|Experimental|Experimental group|"In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.~If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.~If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug."
2451421|NCT03231787|No Intervention|Control group|The control group will wait for the safety time of the drug according to the usual practice of the center.
2451451|NCT03231436|Experimental|Fixed dose of 12.5mg bupivacaine|Participants that receive the same dose of intrathecal bupivacaine and 25mcg of fentanyl, regardless of their height.
2451454|NCT03231436|Active Comparator|Height-adjusted dose of bupivacaine|Participants that receive the dose of intrathecal bupivacaine adjusted to their height and 25mcg of fentanyl
2451497|NCT03231137|Experimental|PRGF/ATV|Included 10 patients undergoing single tooth extraction and platelet rich in growth factors fibrin scaffold loaded with Atorvastatin powder (PRGF/ATV) were placed to fill the extraction socket.
2451499|NCT03231137|Experimental|ATV gel|Included 10 patients undergoing single tooth extraction and Atorvastatin gel were placed to fill the extraction socket.
2451500|NCT03231137|Experimental|PRF|Included 10 patients undergoing single tooth extraction and platelet rich fibrin (PRF) were placed to fill the extraction socket.
2451503|NCT03231137|Experimental|PRGF|Included 10 patients undergoing single tooth extraction and plasma rich in growth factors (PRGF) were placed to fill the extraction socket.
2451506|NCT03231137|No Intervention|Control|Spontaneously healed socket
2451537|NCT03230786|Placebo Comparator|Placebo|Placebo QD for 12 weeks as add-on to metformin
2451540|NCT03230786|Experimental|15µg KBP-042 QD|Up to 15µg KBP-042 QD for 12 weeks as add-on to metformin
2451541|NCT03230786|Experimental|30µg KBP-042 QD|Up to 30µg KBP-042 QD for 12 weeks as add-on to metformin
2451546|NCT03230786|Experimental|50µg KBP-042 QD|Up to 50µg KBP-042 QD for 12 weeks as add-on to metformin
2451705|NCT03230136|Experimental|Multimodal cardioprotection therapeutic strategy|
2451711|NCT03230136|Active Comparator|Traditional anesthetic and therapeutic|standard anesthetic procedure No intervention (Control).
2451795|NCT03229343|Experimental|Experimental|Supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
2451796|NCT03229343|No Intervention|standard|pneumological consultation performed at M0, M3 and M6
2451866|NCT03228823|Active Comparator|Radiofrequency Ablation|Radiofrequency ablation (RFA) will be performed after 3-month observation period. EPS and RFA will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study. In the event of polymorphic PVCs, all morphologies are to be targeted for ablation
2451868|NCT03228823|Active Comparator|Antiarrhythmic Drug|Antiarrhythmic drugs (AADs) will be only initiated after 3-month observation period. AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Investigators define successful PVC suppression only if ≥ 80% absolute reduction in PVC burden is achieved after a drug or intervention. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
2451965|NCT03228264|Experimental|High teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the experimental group 80% of the training time will be devoted to teleSLT and 20% to teleCT. Both groups receive the same amount of ucSLT.
2451967|NCT03228264|Active Comparator|Low teleSLT frequency|During four weeks all patients will do a daily two-hour training session with a tablet computer (consisting of teleSLT and teleCT) at their home. In the control group 20% of the training time will be devoted to teleSLT and 80% to teleCT. Both groups receive the same amount of ucSLT.
2452055|NCT03227822|Experimental|Short spot stenting|Short spot stenting
2452058|NCT03227822|Experimental|Long lesion stenting|Long lesion stenting
2452120|NCT03227523||subjects with copd|
2452124|NCT03227523||subjects without pulmonary disease|
2452169|NCT03226951|Experimental|Subtherhold 532 nm laser|Applying 532nm subtherhold laser with 5% duty cycle using high density low intensity protocol at the area of non central clinical significant macular edema
2452189|NCT03226600|Active Comparator|Connective Tissue Graft|Connective Tissue is harvested from the palate of the subject then placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the connective tissue graft and the recession.
2452195|NCT03226600|Experimental|OrACELL|Allograft Tissue (human dermis) is removed from packing and placed over the recession defect on the facial of the designated tooth. A coronally advanced flap is raised to cover the OrACELL graft and the recession.
2452211|NCT03226470|Experimental|T27 group|Subjects will receive suppository with T27 at 2 intervals for one month.
2452214|NCT03226470|Experimental|T512 group|Subjects will receive suppository with T512 at 2 intervals for one month.
2452216|NCT03226470|No Intervention|Control group|Observation
2452272|NCT03225898|Experimental|Resistance Exercise with Blood flow restriction|Subjects will perform 4 sets with 30, 15, 15, 15 repetitions at 30% 1RM.
2452282|NCT03225898|Active Comparator|High-intensity resistance exercise|Subjects will perform 4 sets of 8 repetitions at 70% 1RM.
3190352|NCT00786591||Control|Preoperative patients going for elective cholecystectomy
3190353|NCT00786604||1|Those with a cervical spinal cord injury
3190354|NCT00786604||2|Those with a thoracic spinal cord injury
3190355|NCT00786604||3|Healthy, control group
2451450|NCT03231566|Active Comparator|Usual education control group (CG)|The CG received the traditional hospital preoperative program, which was consistent with current preoperative TKA protocols. The CG received education covering anatomy of the knee joint, information about the joint replacement surgery, what to expect when they were admitted for surgery, what to expect immediately after surgery, pain medications, postoperative rehabilitation/physical therapy, etc. The CG received a hospital-based booklet with this information.
2451455|NCT03231566|Experimental|Experimental group (EG)|The EG underwent an additional 30-minute group PNE program, followed by the usual preoperative education program from the hospital. The PNE program used in this TKA study was an adaptation of the PNE program developed for LS. The educational program was designed to be delivered by a physical therapist in a group session to patients prior to their TKA.
2451489|NCT03231163|Placebo Comparator|No Music|
2451490|NCT03231163|Experimental|Relaxing Classical Music|
2451492|NCT03231163|Experimental|Self-Selected Relaxing Music|
2451606|NCT03230474|Active Comparator|group 1|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
2451609|NCT03230474|Active Comparator|group 2|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
2451668|NCT03230110||Chronic Hypretension in Pregnancy|Pregnant subjects between 10-20 weeks gestation with chronic hypertension (on medication or hypertensive blood pressures documented at 2 clinic visits)
2451669|NCT03230110||Normotensive in Pregnancy|Pregnant subjects between 10-20 weeks gestation with normal blood pressure, and not on any treatment for chronic hypertension and no history of chronic hypertension, and matched for body mass index (+/- 3 kg/m2) with the chronic hypertension group.
2451679|NCT03229746|Experimental|hydroxychloroquine group|hydroxychloroquine tablets 200mg ,two times/day for at least 6 month
2451680|NCT03229746|Active Comparator|vincristine group|vincristine ampoule , 1mg/ week, I.v drep over 2 hours for 4 weeks
2451681|NCT03229746|Active Comparator|azathioprine group|azathioprine tablet 50mg, dose 100-150 mg daily for 6 month
2451752|NCT03229616|Experimental|BUCY+VP-16|For DLBCL patients undergoing auto-HSCT，BUCY+VP-16 conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2; VP-16 15mg/kg/day on days -3 and -2.
2451753|NCT03229616|Active Comparator|BUCY|For DLBCL patients undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2451810|NCT03229213||Cystic Fibrosis|Cystic fibrosis patients will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
2451817|NCT03229213||Healthy|Healthy subjects will be invited to participate in the study. All participants will complete a questionnaire to assess the level of physical activity prior to evaluation. On the first visit they will perform the cardiopulmonary exercise test (CPET) to evaluate cardiorespiratory responses during exercise. On the second visit an evaluation of the cardiorespiratory responses during the use of interactive video games (Nintendo Wii or Xbox One) will be performed. During interactive games, participants will use an accelerometer to assess the level of physical activity.
2451873|NCT03228888|Experimental|Artificial Sounds|"Participants were provided headphones and a portable MP3 device which played a metronome tick at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
2451880|NCT03228888|Experimental|Ecological Sounds|"Participants were provided headphones and a portable MP3 device which played an ecological rhythmic sound obtained by actual footsteps of human at specified rhythm calculated as follows: a) if a patient's cadence was below the normality, the BPM of the stimulus was set at a value of 10% higher than one's own cadence; b) if a patient's cadence was below, but close to normality (less than 10% difference), the BPM of the stimulus was set at normality values; c) if a patient's cadence was above the normality, the BPM of the stimulus was set at a value equal to one's own cadence.~Participants performed daily 30 minutes of walking assisted by the rhythmic acoustic stimuli."
3190356|NCT00786617||Nurse-driven|Mechanically ventilated patients weaned by nurse-driven ventilator weaning protocol
2452060|NCT03227705|Active Comparator|Intravaginal progesterone|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime up to 36 6/7 weeks of gestation, Merck Canada Inc.)
2452062|NCT03227705|Experimental|Intravaginal progesterone and pessary|Once the participant agrees and signs the consent form, the use of prophylactic progesterone will begin (PROMETRIUM, 200 mg in total of progesterone, 2 vaginal capsules per day at bedtime, Merck Canada Inc.). Also, a perforated pessary (Dr. Arabin, cerclage pessary perforated) will be inserted. The pessary will be removed and the progesterone treatment will be stopped at 36 6/7 weeks of gestation.
2452081|NCT03227302||attending obstetrician|the low grade doctor who can do caesarean operation with no pregnant complications.
2452090|NCT03227302||associate chief obstetrician|The middle grade doctor who can do caesarean operation with no or mild or middle pregnant complications.
2452098|NCT03227302||chief obstetrician|the high doctor who can do all caesarean operation without limitations
2452142|NCT03227081|No Intervention|Sleep|Sleep
2452146|NCT03227081|Experimental|Sleep Deprivation|Sleep Deprivation
2452161|NCT03226860|Experimental|Gait Myoelectric Stimulator|The Gait Myoelectric Stimulator device stimulates the dorsiflexor and plantarflexor muscles at the correct time for typical walking.
2452468|NCT03224624|Experimental|self-management|Participants will be taught to monitor blood pressure and make limited adjustments to their medications
2451483|NCT03231332|Active Comparator|H.pylori Eradication comparative|Microbiome diversity detection in Participants Positive for H.pylori and undergoing Eradication therapy with high dose Amoxicillin and bismuth containing eradication therapy
2451588|NCT03230942|Experimental|Patient education program|Pre-operative education and pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
2451589|NCT03230942|Active Comparator|Control - only pos-op rehabilitation|Pos-operative rehabilitation in individuals will be undergo knee arthroplasty.
2451622|NCT03230227|Active Comparator|Bupivacaine magnesium|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
2451625|NCT03230227|Active Comparator|bupivacain only|bupivacaine 0.125% infusion in the presternum , for 48 hours
2451690|NCT03230058|Experimental|group 1|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The experimental group (Group 1) will receive 1% voriconazole eye drop (Aurolab, Madurai, India) + 5% Natamycin ophthalmic suspension eye drop hourly (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
2451693|NCT03230058|Placebo Comparator|group 2|"Once the patient is randomized to either of the 2 groups using computer-generated randomization blocks, the hospital pharmacist would provide the appropriate medications. The treating ophthalmologist, microbiologist and patients will be masked to the drug by using similar vials. The placebo group (Group 2) will receive Vehicle eye drops + 5% Natamycin ophthalmic suspension every hour (USP 5% Natamet, M.J. Pharmaceuticals, Mumbai, India).~The subjects will be hospitalized for at least 4 days with medications given by the ward nurse.~Patients will be followed up every week after being discharged until complete resolution is noted."
2451800|NCT03229096|Experimental|Apatinib plus XELOX|Patients will be given the perioperative chemotherapy of Apatinib plus XELOX once recruited
2451842|NCT03228927||twin A|Sampling of the facial and fecal microbiome
2451843|NCT03228927||twin B|Sampling of the facial and fecal microbiome
2451891|NCT03228641|Experimental|micro-excisional skin removal|Facial and neck wrinkles will be treated with micro-excisional skin removal
2451973|NCT03228108|Experimental|Targeted antimicrobial prophylaxis|"Men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prior to biopsy (equal to the active comparator arm), and men whose swabs do show ciprofloxacin-resistant bacteria will receive alternative oral antibiotics, based on culture results, in the following order:~trimethoprim/sulfamethoxazole (SXT) 960 mg orally 2 hours before and 12 hours after prostate biopsy, or~fosfomycin 3 g orally 2 hours before prostate biopsy, or~pivmecillinam/augmentin respectively 400 mg and 500/125 mg 2 hours before prostate biopsy followed by 2 days with three divided doses each day after prostate biopsy."
2451975|NCT03228108|Active Comparator|Routine empirical prophylaxis|Ciprofloxacin 500 mg orally 2 hours before and 12 hours after transrectal prostate biopsy.
2452014|NCT03227731|Active Comparator|Arm A (Intervention - Truvada)|Standard HIV Prevention strategy plus a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.
2452015|NCT03227731|No Intervention|Arm B (Control - Standard of Care)|Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery plus the offer to initiate PrEP post breastfeeding cessation
2452212|NCT03227614|No Intervention|Control|This arm of participants will not experience the intervention of having a support person of the patient's choice support the patient during their abortion.
2452213|NCT03227614|Experimental|Support Person Intervention|This arm of participants will experience the intervention of having a support person of the patient's choice support them during their abortion procedure.
3190357|NCT00786617||Physician-initated|Mechanically ventilated patients weaned by physician-initiated, non-protocol methods
2452372|NCT03225352|Experimental|Sequence 1: starting with BAYE4465 500 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2452374|NCT03225352|Experimental|Sequence 2: starting with BAYE4465 1000 mg|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2452376|NCT03225352|Experimental|Sequence 3: starting with Nurofen|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2452377|NCT03225352|Experimental|Sequence 4: starting with Dolormin Extra|Participants will participant four treatment periods with four different treatments. Treatment assignment adhere to Williams design
2452426|NCT03224936||DISE group|All patients in this study group will receive a propofol PSI controlled DISE (drug induced sleep endoscopy).
2452471|NCT03224637|Active Comparator|radiofrequency group|radiofrequency was done in the three genicular nerves upper medial and upper lateral and lower medial
2452475|NCT03224637|Active Comparator|conventional group|the patients received conventional paracetamol and non steroidal antiinflammatory
3190358|NCT00786630|Experimental|Case Management|
3190359|NCT00786630|Experimental|Facilitated Treatment Alliance|
2452642|NCT03223636||Healthy Volunteers|Healthy Volunteers
3190360|NCT00786669|Experimental|Bevacizumab+TEM/VCR/IRN/CEF|"Bevacizumab(IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles~Temozolomide (TEM) 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.~Vincristine (VCR) 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).~Irinotecan (IRN) 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles~Cefexime (CEF) 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity"
2452828|NCT03222154|Experimental|Experimental|20 volunteers who received shock wave therapy
3190361|NCT00786695|Placebo Comparator|Placebo|Identical looking Placebo
3190362|NCT00786695|Experimental|esomeprazole|esomeprazole (40 mg o d) for 14 days
2451832|NCT03228992|Active Comparator|Ibuprofen|Subjects will receive a total of 4 doses of oral ibuprofen 400 mg over a 24 hour period.
2451835|NCT03228992|Placebo Comparator|Placebo|Subjects will receive a total of 4 doses of oral placebo over a 24 hour period.
2451871|NCT03228667|Other|Cohort 1|"Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.~1a - Non-small cell lung cancer~1b - Small cell lung cancer~1c - Urothelial carcinoma~1d - Head and neck squamous cell carcinoma~1e - Merkel cell carcinoma~1f - Melanoma~1g - Renal cell carcinoma~1h - Gastric cancer~1i - Cervical cancer~1j - Hepatocellular carcinoma~1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer"
2451874|NCT03228667|Other|Cohort 2|Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
2451881|NCT03228667|Other|Cohort 3|Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
2451889|NCT03228667|Experimental|Cohort 4|Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
2451896|NCT03228667|Experimental|Cohort 5|Patients that have experienced disease progression by Investigator-assessment per irRECIST while receiving treatment in Cohorts 1-4.
2452031|NCT03228043|Experimental|Apatinib group|Apatinib combined with CAPEOX program. Apatinib tablets: 500 mg po qd from the second cycle of chemotherapy. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
2452044|NCT03228043|Placebo Comparator|Control group|CAPEOX program. Oxaliplatin: Day 1, 130mg/m2, IV infusion. Capecitabine: Day 1-14, 1000mg/m2 Twice Daily, po. A total of 6 cycles, 3 weeks apart of chemotherapy.
2452078|NCT03227497|Active Comparator|Walnut|"At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).~Treatment arm includes 56 g of whole walnuts daily."
2452086|NCT03227497|No Intervention|Control|At the beginning of the study, subjects are randomly assigned to receive either intervention treatment (whole walnuts) or no treatment (control arm).
2452144|NCT03227185|Experimental|Real - sham anodal tDCS|"Session 1: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
2452147|NCT03227185|Experimental|Sham - real anodal tDCS|"Session 1: 30 s of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase.~Session 2: 20 min of 1 mA anodal tDCS applied via 5x7 cm rubber electrodes over the DLPFC (current density: 0.028 mA/cm2). Additional ramp-up and ramp-down phase at beginning and end of stimulation lasting for 15 s. Electrodes remain attached to the participant's head for the duration of the encoding phase."
2452192|NCT03226626|Active Comparator|IVAD|IV antibiotic delivery (IVAD) alone as surgical site infection prevention. The intervention is IV antibiotics alone.
2452197|NCT03226626|Experimental|TAAD + IVAD|Both subcutaneous tumescent anesthesia & antibiotic delivery (TAAD) and IVADThe The intervention is subcutanious and IV antibiotics
2452230|NCT03226379|Other|DREAMM|"4 DREAMM interventions to reduce HIV-related meningoencephalitis mortality once access to essential diagnostic tests and medicines:~Health system strengthening~Delivery of a co-designed education program tailored to frontline healthcare workers~Implementation of an algorithm for HIV-related meningoencephalitis~Infectious diseases/AHD mentorship and laboratory capacity building"
2452270|NCT03226080|Placebo Comparator|Placebo|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given 10cc normal saline. Once skin closure has been initiated, 2mL normal saline will be administered.
2452271|NCT03226080|Active Comparator|Neuromuscular Blockade|Patients will be monitored and then sedated with midazolam, fentanyl, and ketamine as necessary per standard practice to facilitate lateral positioning. Patients will be positioned with the operative side down for the spinal blockade. Under sterile conditions, spinal anesthesia will be induced with 9mg (1.2mL) of hyperbaric 0.75% bupivacaine as per standard practice. The patient will then be given a standard general anesthetic induction consisting of propofol, succinylcholine, fentanyl, and lidocaine. At the time of incision, this group will be given IV rocuronium 0.6mg/kg in a volume of 10cc. Once skin closure has been initiated, sugammadex 200mg in 2ml will be administered.
3190363|NCT00786708||NGAL|Urine that would otherwise be discarded will be obtained from a convenience sample of patients admitted to the hospital through the emergency room who meet the inclusion / exclusion criteria for this study.
3190364|NCT00786721||Diffuse Optical Spectroscopy|muscle properties scanning
3190365|NCT00786734|Experimental|Pitavastatin Group|
3190366|NCT00786734|Other|Usual Care Group|
3208558|NCT00975936|Experimental|[14C]-GSK706769 + Ketoconazole|An oral, 5-day repeat dose of 200 mg Ketoconazole (Q12) with a concomitant single oral dose of 50 µg [14C]-GSK706769 containing 250 nCi on day 3.
2451549|NCT03230773|Experimental|Defibrillator - Model 1|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451554|NCT03230773|Experimental|Defibrillator - Model 2|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451556|NCT03230773|Experimental|Defibrillator - Model 3|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451558|NCT03230773|Experimental|Defibrillator - Model 4|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451560|NCT03230773|Experimental|Defibrillator - Model 5|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451562|NCT03230773|Experimental|Defibrillator - Model 6|Time taken to open, attach and then discharge the defibrillator on a manikin during a simulated cardiac arrest scenario.
2451617|NCT03230461|Experimental|Target compression depth 4.0-5.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2451620|NCT03230461|Experimental|Target compression depth 4.5-5.5 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2451624|NCT03230461|Experimental|Target compression depth 5.0-6.0 cm|The rescuer is asked to perform two minutes of chest compressions on a manikin, aiming to compress to the target depth at a rate of 100-120/min
2451673|NCT03230045|Experimental|Acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated by transcutaneous electrical stimulation
2451674|NCT03230045|Sham Comparator|no treatment|Electrodes are attached to Acupoint Zhongfu and Zusanli, but no stimulation is given
2451734|NCT03229655|Experimental|Sequential stent addition|ERCP with sphincterotomy and stent placement is initially performed, then additional stents are placed across the stricture during sequential ERCPs, without stent removal/exchange or stricture dilation.
2451737|NCT03229655|Active Comparator|Incremental Dilation & Stent Exchange|ERCP with sphincterotomy and stent placement is initially performed, with subsequent ERCPs involving removal of previously placed stents, stricture dilation and balloon sweeps to extract stone debris/sludge.
2451794|NCT03229083|Experimental|Use of Carevive software|Reporting and management of side effects from oral targeted therapy or immunotherapy, through Carevive software, in patients who have advanced Renal Cell Carcinoma (RCC).
2451915|NCT03228498|Experimental|Choline alphoscerate|"Drug: Choline alphoscerate 1200 mg per day and Nimodipine 90 mg per day~concomitant administration"
2451917|NCT03228498|Placebo Comparator|Placebo|"Placebo and Drug: Nimodipine 90 mg per day only~concomitant administration"
2451945|NCT03228186|Experimental|Pevonedistat plus Docetaxel|Pevonedistat 25mg/m2 days 1, 3, 5 Docetaxel 75mg/m2 day 1 21 day cycle
2452034|NCT03227926|Experimental|Screening Phase|"Patiens will be first enrolled in a Molecular Screening (MS) Phase to determine the molecular eligibility of the patients for third line panitumumab re-challenge. During MS phase, patients will be liquid biopsied (LB) at different check-points (BML which is optional, Basal Mutational Load and RML which is mandatory, Rechallenge Mutational Load) and their ctDNA tested by ddPCR to monitor the presence of RAS and EGFR ECD altered clones. Patients with no RAS and EGFR ECD mutations in the RML will be declared molecularly eligible for the Trial Phase."
2452042|NCT03227926|Experimental|Trial Phase|"Patients resulting molecularly eligible at the RML (Rechallenge Mutational Load) checkpoint, upon Informed Consent signature and having satisfied all other eligibility criteria, will be treated with panitumumab monotherapy at standard dose until documented radiological progression or unacceptable toxicity or any other reason whichever comes first."
3190367|NCT00786747|Experimental|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
3190368|NCT00786747|Active Comparator|Non-tailored control computer program|This program provides non-tailored, generic information about colorectal cancer screening, in the user's preferred language (English or Spanish).
3190369|NCT00786760||1. Men ages 18 - 44 years|
3190370|NCT00786760||2. Men ages 45 - 70 years|
2452215|NCT03226405|Experimental|Patient Navigation Program|"The study team will identify, track, and provide navigation for all adult patients referred to Cancer Center from the CHC and community partners for cancer treatment.~The Patient Navigation Program include~Education,~Appointment reminders,~Help with insurance,~Transportation,~Navigating the Cancer Center,~Assisting in finding appropriate child care,~Interpreting,~Connecting the patient to psychosocial and/or palliative care teams,~Physically escorting the patient to appointments"
2452217|NCT03226405|Active Comparator|Standard of Care|"The patients will receive enhanced usual care,~This consist of personal phone call reminders about upcoming appointments at the MGH Cancer Center"
2452263|NCT03225989|Experimental|LOAd703|LOAd703 oncolytic adenovirus administered add-on to standard of care chemotherapy or gemcitabine immune-conditioning if standard of care is no longer an option (e.g. after last line)
3190371|NCT00786773||1|GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy
3190372|NCT00786786||1|Spinal Cord Injury
3190373|NCT00786812|Other|CAMN107A2109 Extension Patients|
3190374|NCT00786812|Other|AMN107 Naive|
3190375|NCT00786851|Experimental|1|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
3190376|NCT00786877|Experimental|Improved biomass cookstove with exterior ventilation|"In phase 1, installation of an improved cookstove with ventilation to exterior is the active arm.~In phase 2, this improved biomass cookstove is the control arm."
2451576|NCT03230604|Active Comparator|Bulk-Fill composite Class I, II and V cavities|Restorative with Filtek Bulkfill composite in class I, II and V Restorative with Tetric N Ceram composite in class I, II and V
2451582|NCT03230604|Active Comparator|Z 350 xt Composite|Restorative with Z 350 xt composite in class I, II and V
2451604|NCT03230292|Experimental|Cohort 1|Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is >=50% to <75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.
2451721|NCT03230071|Placebo Comparator|Placebo|placebo identified to TMBCZG,0.1g per pill which contains 0mg TMBCZG，3 pills per time, 2 times per day for 24 weeks.
2451725|NCT03230071|Experimental|TMBCZG-high dose|TMBCZG, 0.1g per pill which contains 14mg TMBCZG, 3 pills per time, 2 times per day for 24 weeks.
2451730|NCT03230071|Experimental|TMBCZG-medium dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 2 TMBCZG pills and 1 placebo pill per time, 2 times per day for 24 weeks.
2451732|NCT03230071|Experimental|TMBCZG-low dose|TMBCZG( 0.1g per pill which contains 14mg TMBCZG) and placebo identified to TMBCZG(0.1g per pill which contains 0mg TMBCZG), 1 TMBCZG pills and 2 placebo pill per time, 2 times per day for 24 weeks.
2451780|NCT03229291|Experimental|Low Dose|Topical SM04755 solution (15 mg/mL) applied once per day for 14 days
2451781|NCT03229291|Experimental|Mid Dose|Topical SM04755 solution (45 mg/mL) applied once per day for 14 days
2451783|NCT03229291|Experimental|High Dose|Topical SM04755 solution (90 mg/mL) applied once per day for 14 days
2451786|NCT03229291|Placebo Comparator|Vehicle|Vehicle solution applied once per day for 14 days
2451814|NCT03229005|Active Comparator|A1 thick-high|group with thick tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2451819|NCT03229005|Experimental|A2 thick-low|group with thick tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2451820|NCT03229005|Active Comparator|B1 thin-high|group with thin tissue and high prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2451822|NCT03229005|Experimental|B2 thin-low|group with thin tissue and low prosthetic abutment tissue measurement implant insertion operculectomy prosthetic rehabilitation
2451903|NCT03228615|Experimental|Shared Decision Making Intervention|
2451907|NCT03228615|No Intervention|Usual Care Group|
2451942|NCT03228329|Other|cardiometry|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
2452051|NCT03228004|Experimental|Intervention Group|Participants will be provided with training on how to upload glucose data via GLOOKO and will receive reminders to upload glucose data on a biweekly basis between clinic visits.
2452108|NCT03227575|Experimental|Post-Meal Walking Group|"Following a 30-minute digestion period, the Post-Meal Walking Group will be instructed to walk following breakfast, lunch, and dinner at least 4 times per week (180 minutes of moderate intensity exercise/week). Participants will walk at a brisk pace for 15 minutes, as demonstrated in a previous study. A Garmin VivoFit activity monitor will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2452109|NCT03227575|Experimental|Traditional Exercise Group|"The Traditional Exercise Group will perform aerobic and light resistance training exercise over the 4-week intervention. A group of trained Exercise and Sports Physiology students will conduct the aerobic exercise and light resistance training program three times per week (180 minutes of moderate to high intensity exercise/week). Garmin VivoFit activity monitors will measure their physical activity across the four-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2452110|NCT03227575|No Intervention|Case Control Group|"The participant will be instructed to maintain their current diet and levels of physical activity for four weeks. Participants in this group will wear an ambulatory blood pressure monitor at baseline and at follow-up. Any change in diet and physical activity level might significantly affect the study results. The Control Group will maintain their current lifestyle for four weeks. Garmin VivoFit activity monitors will measure their physical activity throughout the 4-week intervention. The Garmin VivoFit activity monitor must be returned during the Follow-up Study Visit."
2452204|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (CAD)|
2452205|NCT03226678|Experimental|270mg or 360mg APL-2 administered subcutaneously daily (wAIHA)|
2452244|NCT03226301|Experimental|Ibrutinib until progression/relapse|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRDpositive patients (PB and BM) will continue on Ibrutinib maintenance (non-randomized group) until progression/relapse"
2452245|NCT03226301|Experimental|Arm A|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm A: Ibrutinib until progression/relapse (Continuous ibrutinib treatment until toxicity or progression)"
2452248|NCT03226301|Experimental|Arm B|"All patients receive ibrutinib + venetoclax (with delayed start and ramp up of venetoclax from cycle 3) for the 15 cycles.~MRD negative patients (PB and BM) will be randomized to Arm A or Arm B. Arm B: Observation until event.~Patients randomized to Arm B will get reinitiation of therapy during the observation period in case of:~progression according to IWCLL criteria or~MRD≥10-3 (PB) and at least one month later MRD ≥10-2 (PB).~Treatment reinitiation will consist of ibrutinib and venetoclax (with ramp up of venetoclax from cycle 1) for 12 cycles"
2452277|NCT03225976|Experimental|Infrared LED group (G-I)|The Light-Emitting Diode Device with wavelength of 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
3190377|NCT00786877|No Intervention|Traditional cookstove|In phase 1, the control arm is the traditional standard open burning cookstove in house.
3174478|NCT00624000|Experimental|1|IA administration of Alteplace vs. IV administration of Alteplace
2451630|NCT03230396|Placebo Comparator|Placebo|"Commercially-available chewing gum not supplemented with vitamins. Contains: Sugar; Dextrose; Gum Base; Corn Syrup; Natural and artificial flavors; artificial colors; carnauba wax; resinous glaze; neotame; butylated hydroxytoluene.~For saliva collection phase: No placebo is used. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2451634|NCT03230396|Experimental|Vitamingum Sport|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (1250 IU); ascorbic acid (15 mg); cholecalciferol (100 IU); dl-tocopherol acetate (7.5 IU); thiamine mononitrate (375 microg); riboflavin (425 microg); niacinamide (5 mg); calcium d-panothenate (2.5 mg); pyroxidine HCl (500 microg); cyanocobalamin (1.5 microg); folic acid (100 microg); biotin (11.25 microg).~For saliva collection phase: Subjects will chew 2 pieces for 30 min. For blood collection phase: Subjects will chew two pieces at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2451638|NCT03230396|Experimental|Vitamingum Immunity|"Same gum base as placebo but supplemented with vitamins (per piece): retinyl palmitate (2000 IU); ascorbic acid (62.5 mg); cholecalciferol (200 IU); dl-tocopherol acetate (20 IU); niacinamide (10 mg); calcium d-panothenate (10 mg); pyroxidine HCl (1 mg); cyanocobalamin (5 microg); folic acid (200 microg); biotin (75 microg); zinc sulfate (2.5 mg); sodium selenite (17.5 microg); chromium picolinate (60 microg); and potassium iodide (40 microg).~For saliva collection phase: Subjects will chew 1 pieces for 30 min. For blood collection phase: Subjects will chew 1 piece at time = 0, 0.75, 4, and 8 h for 30 min at each time point."
2451672|NCT03229980|Active Comparator|Group L|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg The content of cardioplegic solution will be (K+, 10mmol/L) lidocaine 50 mg/L, magnesium sulphate 1 gm/L,dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery. Cardioplegic infusion duration will be infused over 300s.
2451675|NCT03229980|Active Comparator|Group S|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg The content of cardioplegic solution will be (K+, 30mmol/L) lidocaine 150 mg/L, magnesium sulphate 3 gm/L, dextrose 25% 25 mL/L and sodium bicarbonate 8.4% 25 mL/L during cardiac surgery.
2451703|NCT03229681|Experimental|Baduanjin exercise group|Participants in this group received routine rehabilitation training and Baduanjin exercise
2451707|NCT03229681|Active Comparator|Routine rehabilitation group|Participants in this group only received routine rehabilitation training
2451809|NCT03229382|Experimental|Obinutuzumab 1000 mg IV infusion, day: 1, 8, 15, 22|
2451857|NCT03228797|Active Comparator|Group I|( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.
2451858|NCT03228797|Active Comparator|Group II|( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.
2451859|NCT03228797|Active Comparator|Group III|( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
2451916|NCT03228472|Experimental|real stimulation|Cranial - electrical or magnetic stimulation. Stimulation will be different according to clinical conditions, as specified elsewhere.
2451918|NCT03228472|Placebo Comparator|sham stimulation|"Patients will be treated as in the Real stimulation arm, but no electrical or magnetic stimulation will be induced."
2451946|NCT03228160|Experimental|SGI irradiation|Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
2451950|NCT03228160|Sham Comparator|Shame irradiation|Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion.
2452019|NCT03227939|Experimental|Combined Surgery Group|LSG + UPPP＆Adenoidectomy/Tonsillectomy
2452020|NCT03227939|Active Comparator|LSG Group|LSG only
2452171|NCT03226873|Experimental|Peer Navigation|PrEP-UP involves a Peer delivering PrEP education and counseling during street-based outreach followed by offer of a PrEP care appointment along with peer navigation (e.g., appointment accompaniment and reminders, etc.) for the first several PrEP visits.
2452193|NCT03226587|Experimental|Blue light|Each subject will be undergo a whole body exposure to blue light (453 nm wavelength) for 30 minutes.
2452198|NCT03226587|Placebo Comparator|Control exposure|Each participant will also undergo a control examination, where the body will be covered with a light tight foil during blue light exposure for 30 minutes.
2452220|NCT03226431|Experimental|ARINA-1|Ascorbic acid (ARINA-1) (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
2452252|NCT03226197|Experimental|Study group|Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.
2452323|NCT03225755||Adults with growth hormone deficiency|12 subjects with GH deficiency, adult or childhood onset, and not currently on GH therapy will be studied. Subjects enrolled will be those planning GH therapy and beginning this therapy as part of their routine clinical care. Subjects will be 50% female and all subjects will be on 3 months of stable hormone replacements prior to testing.
2452358|NCT03225404|Experimental|Experimental group|EPTE + EXER Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
2452359|NCT03225404|Experimental|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
2452419|NCT03225092|Experimental|PRP Injection|Ultrasound-guided platelet rich plasma injection
2452440|NCT03224702|Experimental|M6495|
2452441|NCT03224702|Placebo Comparator|Placebo|
2452486|NCT03224468|Active Comparator|Medical Marijuana Arm|This group can begin using medical marijuana immediately.
2452489|NCT03224468|No Intervention|Waitlist Control Arm|This group agrees to wait 3 months before using medical marijuana.
2452541|NCT03224260|Experimental|Treatment A|Receive 50 mg BMS-986177 once daily or placebo
3174479|NCT00624000|Active Comparator|2|IA administration of Alteplase vs.IV administration of Alteplase
3174480|NCT00624026|Experimental|1|
2451632|NCT03230422|Experimental|normal airway|Time (normal airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
2451637|NCT03230422|Experimental|difficult airway|Time (difficult airway) using the novel King Vision™ Pediatric aBlade (KV) video laryngoscope, C-MAC™ D-blade Ped (DP), C-MAC™ Miller Blade (MB), shortened as VL, compared with conventional direct laryngoscopy (DL)
2451713|NCT03229967||Exploration Cohort|Up to 150 VLBW (very low birthweight) infants enrolled from the Regional One Health NICU (neonatal intensive care unit). Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines, will be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA (ribosomal ribonucleic acid) sequencing after conclusion of initial enrollment period. ITS (internal transcribed spacer) DNA may also be used to characterize fungal communities.
2451717|NCT03229967||Validation Cohort|Up to 10 VLBW infants enrolled from the Le Bonheur Children's Hospital NICU. Weekly stool samples will be obtained. After 36 weeks infants diagnosed with BPD per NIH guidelines willl be matched with infants without BPD. Stool samples from these infants will be sent for 16s rRNA sequencing after conclusion of initial enrollment period.
2451723|NCT03229967||Well Baby Cohort|40 Well Baby Infants have been enrolled and may be used for secondary analysis of microbial community composition of the meconium.
2451771|NCT03229330|Experimental|Intervention|Low-level Light Therapy: Wavelength of 660 nm (red laser) and Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
2451772|NCT03229330|Active Comparator|Controls|Conventional treatment: Topical treatment with compressive therapy, exercises of lower extremities, resting; once a week for 16 weeks.
3190378|NCT00786877|Experimental|Phase 2 invervention arm (LPG stove)|In phase 2 of this project, households are individually randomized to either continuation of the improved biomass stove from phase 1, or a new LPG stove and gas for 12 months.
3190379|NCT00786890||no treatment|observational, no treatment needed
3190380|NCT00786929|Experimental|drainage|
3190381|NCT00786929|Active Comparator|2|Conservative treatment
2451879|NCT03228537|Experimental|Treatment (chemotherapy, surgery, RT)|"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.~SURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo EPP or PD. Patients who undergo EPP will then undergo RT.~MAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity."
2452176|NCT03226730|Experimental|Arm 1: Household Visits|Arm 1 will receive gender synchronized household visits (i.e., visits by a female community health worker to the participating married adolescent female and visits by a male community health worker to the participating husband of the married adolescent female). Approximately 10-12 visits with wives and 4-6 visits with husbands are expected to take place over the course of the project. Study Arms 1-3 will additionally receive community enabling environment activities and adolescent-specific service delivery activities to support adolescent contraception use. Community enabling environment activities will include engaging religious leaders, community leaders, and familial gatekeepers of the married adolescent wives, such as in-laws, in community dialogues on a monthly basis.
2452185|NCT03226730|Experimental|Arm 2: Small Groups|This arm will receive, in addition to the community-level components, gender synchronized group-based interventions (i.e., separate group-based interventions for husbands of adolescent wives and adolescent wives, themselves). Male-only and female-only small groups for participating husbands and wives will be held separately on bimonthly and monthly intervals, respectively. In this project, each small group will consist of 10-15 participants and will be held in places participants have deemed safe spaces (e.g., a place that has auditory and visual privacy, is safe for girls to walk to, has been designated by community leaders as a protected place for girls to meet). Approximately 8-10 female small groups and 4-6 male groups are expected to take place over the course of the project.
2452190|NCT03226730|Experimental|Arm 3: Household Visits + Small Groups|In addition to the community enabling environment components, this arm will receive a combination of household visit and small groups intervention components, as described above for Arms 1 and 2, in order to understand the combined effect of these two interventions on the outcomes of interest.
2452194|NCT03226730|No Intervention|Arm 4: Control|The fourth arm will serve as the control condition. Individuals in these villages will not receive the household, small group, or community-enabling environment intervention components.
3190382|NCT00786942|Active Comparator|1|autologous bone graft
2452278|NCT03225911|Experimental|Insole group|This group will be treated via using lateral wedge insole. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes.
2452280|NCT03225911|Experimental|Sleeve group|This group will be treated via using simple knee sleeve. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
2452293|NCT03225911|Experimental|insole + sleeve group|this group will have treated via using the later wedge insole and the sleeve together as combined treatment. lateral wedge insole is an insole with higher lateral side than medial side. This insole is inserted in the participant shoes. Simple knee sleeve is a knee support which has no metal support. This sleeve is wrapped around each participant knee.
2452326|NCT03225677||Patients with Cirrhosis|Patients with a diagnosis of cirrhosis will have a blood draw and muscle biopsy will be performed.
2452327|NCT03225677||controls|control group should have serum ALT and AST within normal range and a blood draw and muscle biopsy will be performed
3190383|NCT00786942|Experimental|2|without bone graft
3190384|NCT00786968|Experimental|intrathecal laronidase|drug laronidase, dose 1.74 mg, route intrathecal, frequency every 30-90 days, duration 1 year
3190385|NCT00786981|Other|Epidural steroid injection and physical therapy|
3190386|NCT00786981|Other|Epidural steroid injection|
3190387|NCT00787007|Experimental|1|10 mg
3190388|NCT00787007|Experimental|2|20 mg, fasted and fed
3190389|NCT00787007|Experimental|3|40 mg
3190390|NCT00787007|Experimental|4|80 mg
3190391|NCT00787007|Experimental|5|160 mg
2451646|NCT03230188||Severe Asthmatics|Individuals with severe asthma that are already enrolled in the University of Wisconsin Severe Asthma Research Program III study will fill out asthma and psychological questionnaires (non-diagnostic), will undergo Cognitive Function Testing (non-diagnostic), and will undergo a simulated and actual functional Magnetic Resonance Imaging (research grade) scan.
2451689|NCT03229876|Experimental|CD19-UCART|All patients will be treated with 1 injection of CD19-UCART. Three escalating dose-levels (5x10^6/kgBW, 7x10^6/kgBW, 10x10^6/kgBW) of CD19-UCART will be evaluated using a 3+3 design. Each CD19-UCART injection will be administered at Day 0.
2451825|NCT03229564|Experimental|EHSG-KF and STSG Transplantation|Transplantation of EHSG-KF to the experimental area and transplantation of STSG (split-thickness skin graft) to the control area
2451877|NCT03228602|Active Comparator|healthy subjects|
2451885|NCT03228602|Experimental|obese|
2451894|NCT03228602|Experimental|obese diabetic|
2451898|NCT03228602|Experimental|obese diabetic who are going to be operated on|25 of a sleeve gastrectomy and 25 of a Y gastric bypass
2451943|NCT03228342|Experimental|Ultrasound shared|Patient will be assessed with ultrasound (GUS-7 score)
2451951|NCT03228342|Experimental|Ultrasound not shared|Patient will be assessed with ultrasound (GUS-7 score)
2452010|NCT03227952|Active Comparator|Active treatment|Vibrotactile sensory stimulation
2452011|NCT03227952|Sham Comparator|Sham|Identical device. No vibration
2452074|NCT03227640|Active Comparator|stripping|standardized laparoscopic stripping technique
2452075|NCT03227640|Experimental|CO2 laser vaporization|drainage of the cyst content and vaporization of the internal wall with CO2 laser
2452158|NCT03227211||COPD exacerbated patients admitted|No specific intervention
3190392|NCT00787007|Experimental|6|320 mg
3190393|NCT00787007|Placebo Comparator|7|placebo capsule
2452324|NCT03225820||Overall Pharmacogenomics|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the usual care arm (no study-specific PGx information available to providers for these patients). Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
2452325|NCT03225820||Warfarin Sub-Study|"All patients who consent to participation will be preemptively genotyped, at no cost to the patient nor provider. A portion of the enrolled patients will be specifically recruited for the warfarin sub-study, in which patients will be randomized in 1:1 fashion to the pharmacogenomics arm of the study. Note that patients who are randomized to the Control Arm will be genotyped, but their results will be withheld (not available via GPS) for at least 90 days. For the warfarin sub-study, treating providers caring for patients assigned to both arms are permitted to dose warfarin according to their own discretion and best practices. In either arm of the study, providers may utilize any available other tools or decision-supports for guiding warfarin dosing, including pharmacy assistance.~NOTE: Warfarin is prescribed as a standard of care drug. The purpose of the study is to observe if physicians/pharmacists use the genotyped information to determine prescription habits."
2452364|NCT03225391|Experimental|Nap 1|Subjects who take, during a night shift, first a nap from 0:00 to 3:00 hours and, after 6 weeks of lavage, another nap from 3:00 to 6:00 hours.
2452365|NCT03225391|Experimental|Nap 2|Subjects who take, during a night shift, first a nap from 3:00 to 6:00 hours and, after 6 weeks of lavage, another nap from 0:00 to 3:00 hours.
2452396|NCT03225066|Experimental|Poly-L-Lactic Acid - Sculptra|Each area will be treated with a dose contained in a vial of Sculptra®. For conducting the study, six vials of the product will be available per subject, and one vial will be used in each session with up to maximum a total volume of 16mL per treated area. It will be 3 session with interval of 1 month in total.
2452477|NCT03224728||2 different Intraocular lenses|2 different intraocular lenses were compared
2452535|NCT03224338|Experimental|: Dolutegravir (DTG)|
2452601|NCT03223831|Active Comparator|Partially covered duodenal stent (PCDS)|The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.
2452603|NCT03223831|Active Comparator|Uncovered duodenal stent (UDS)|The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
2452648|NCT03223571||Early post-stroke (<2 months)|Participants within 2 months of a first supra-tentorial ischeamic stroke, that show a motor deficit of the upper-limb (Fugl Meyer upper limb score < 30/66), older than 18yrs, without aphasie, cognitive troubles or hemineglect Post-stroke participants receive 6 week of motor rehabilitation training of the paretic upper-limb.
2452651|NCT03223571||Controls|Healthy people with no history of neurological pathologies
2452705|NCT03223285|Experimental|Real Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + experimental manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
2452707|NCT03223285|Sham Comparator|Sham Treatment Group|Patients included in this group will receive 3 multifaced physiotherapy/osteopathic treatments + sham manoeuvres, 1 treatment/week. Each session will last about 30 minutes.
2452775|NCT03222895||TIGER study cohort|This is the entire patient cohort. Alle patients with resectable esophageal cancer undergoing a transthoracic esophagectomy with at least a 2-field lymphadenectomy
2452826|NCT03222154|No Intervention|Control|20 volunteers without intervention. At the end of the study they received an application of shock wave therapy.
2452827|NCT03222154|Placebo Comparator|Placebo|20 volunteers who received simulation of the application of shock wave therapy
3190394|NCT00787033|Experimental|1|Dose escalation study with Expansion Cohorts at RP2D and Schedule
3190395|NCT00787059|Experimental|Ad5.hAC6|Will receive intracoronary adenovirus encoding human adenylyl cyclase type 6
2451718|NCT03229915|No Intervention|no trauma healthy control|Scanned twice (13 weeks apart) without any intervention
2451824|NCT03229200|Experimental|Ibrutinib|Treatment with Ibrutinib, once daily until disease progression or unacceptable toxicity.
2451949|NCT03228394|Experimental|Ganaxolone|Intravenous
2451953|NCT03228394|Placebo Comparator|Placebo|Intravenous
2452012|NCT03227796|Experimental|Cohort 1 Healthy Volunteers Active|LEVI-04 0.003 mg/kg single intravenous dose Healthy Volunteers
2452013|NCT03227796|Experimental|Cohort 2 Healthy Volunteers Active|LEVI-04 Dose Level 2 (planned 0.01 mg/kg) single intravenous dose Healthy Volunteers
2452016|NCT03227796|Experimental|Cohort 3 Healthy Volunteers Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Healthy Volunteers
2452017|NCT03227796|Experimental|Cohort 4 Osteoarthritis Patients Active|LEVI-04 Dose Level 3 (planned 0.03 mg/kg) single intravenous dose Osteoarthritis Patients
2452018|NCT03227796|Experimental|Cohort 5 Osteoarthritis Patients Active|LEVI-04 Dose Level 4 (planned 0.1 mg/kg) single intravenous dose Osteoarthritis Patients
2452021|NCT03227796|Experimental|Cohort 6 Osteoarthritis Patients Active|LEVI-04 Dose Level 5 (planned 0.3 mg/kg) single intravenous dose Osteoarthritis Patients
2452022|NCT03227796|Experimental|Cohort 7 Osteoarthritis Patients Active|LEVI-04 Dose Level 6 (planned 1.0 mg/kg) single intravenous dose Osteoarthritis Patients
2452023|NCT03227796|Experimental|Cohort 8 Healthy Volunteers Active|LEVI-04 Dose Level 7 (planned 3.0 mg/kg) single intravenous dose Healthy Volunteers
2452024|NCT03227796|Placebo Comparator|Cohort 1 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2452025|NCT03227796|Placebo Comparator|Cohort 2 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2452029|NCT03227796|Placebo Comparator|Cohort 3 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2452040|NCT03227796|Placebo Comparator|Cohort 4 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2452052|NCT03227796|Placebo Comparator|Cohort 5 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2452057|NCT03227796|Placebo Comparator|Cohort 6 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2452061|NCT03227796|Placebo Comparator|Cohort 7 Osteoarthritis Patients Placebo|Placebo to match LEVI-04 single intravenous dose Osteoarthritis Patients
2452064|NCT03227796|Placebo Comparator|Cohort 8 Healthy Volunteers Placebo|Placebo to match LEVI-04 single intravenous dose Healthy Volunteers
2452093|NCT03227328|Active Comparator|Treatment Arm A|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy
2452104|NCT03227328|Experimental|Treatment Arm B|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
2452178|NCT03226782|Active Comparator|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
2452186|NCT03226782|Active Comparator|Long Intervention protocol|"Consisting of 29 exercises to be performed at home. The guideline is to perform each exercise 6 to 8 times in a gentle manner keeping your attention on movement.~This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect."
2452222|NCT03226496|Experimental|Intervention Group|This group receives a brief motivational interviewing session about PrEP
2452225|NCT03226496|No Intervention|Control Group|This group receives standard of care clinic based counseling about PrEP
3153873|NCT00285558|Active Comparator|CBT with supervised aerobic exercise|Cognitive behavioral treatment (CBT) with supervised aerobic exercise. Activities for the supervised exercise intervention included use of treadmills, stationary bicycles, and other aerobic activities selected by participants, including dance videos and brisk walking within the clinic setting.
3153874|NCT00285662|Active Comparator|1|1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
2452448|NCT03224611|No Intervention|Control group|"The flexible LMA is inserted using index finger technique"
2452454|NCT03224611|Active Comparator|Light wand group|The flexible LMA is inserted using light wand as a stylet
2452673|NCT03223467|Active Comparator|Biliopancreatic diversion|Study participants will undergo biliopancreatic diversion which is a type of bariatric surgery where a part of the stomach are removed and the remaining stomach is attached to a distal segment of the small intestine.
2452674|NCT03223467|Active Comparator|Gastric sleeve|Study participants will undergo sleeve gastrectomy which is a restrictive form av bariatric surgery where the size of the stomach is reduced.
2452676|NCT03223467|Active Comparator|Gastric bypass|Study participants will undergo gastric bypass which is a type of bariatric surgery where a small pouch of the stomach is created and attached to a segment of the small intestine.
3153875|NCT00285662|Active Comparator|2|1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
3153876|NCT00285662|Placebo Comparator|3|children of this gorup will receive only placebo dugs
3153877|NCT00285688||1|Gastroscope positive for H. pylori and resistant to clarithromycin
3153878|NCT00285688||2|Gastroscope positive for H. pylori and not resistant to clarithromycin
3153879|NCT00285805|Other|Rosiglitazone-placebo|
3153880|NCT00285805|Other|placebo-rosiglitazone|
3153881|NCT00285844|Experimental|pioglitazone|IR and IS subjects will be randomized to pioglitazone 45 mg daily for 16 wks for comparison with dietary weight loss intervention
2451720|NCT03229733|Active Comparator|Control group|Patients in the control group will receive individually tailored traditional occupational therapy consisting of the similar movement and dose as the experimental group doing by using the traditional equipment, such as climbing bar.
2451757|NCT03229356|No Intervention|Waitlist Control|BPA will be rolled out to waitlist control sites after 6 months
2451760|NCT03229356|Active Comparator|Best Practices Advisory (BPA)|Clinicians will receive an email describing the BPA and order set, along with internet links to MD Quit Line without additional supplemental education.
2451762|NCT03229356|Active Comparator|BPA+ Enhanced Education|Clinicians will receive an email describing the new smoking BPA, educational materials offered, and a small tutorial on using the BPA and a new smoking cessation smart set in Epic. Education materials will include the educational hand out and academic detailing from Maryland Quit Line counselors.
2451827|NCT03229187||neoadjuvant chemotherapy|
2451856|NCT03228810||Men >18 years old with metastatic prostate cancer|
2451914|NCT03228511|Experimental|Formerly Arm Label|
2451947|NCT03228303|Active Comparator|Chronic phase CML treated by nilotinib|Newly diagnosed
2451952|NCT03228303|Active Comparator|Chronic phase CML treated by imatinib|Newly diagnosed
2452037|NCT03227991|Active Comparator|Safety Planning Intervention|SPI is a personalized approach that focuses on early identification of warning signs and execution of systematic steps to manage suicidal thoughts, created collaboratively by the patient and clinician.
2452043|NCT03227991|Active Comparator|Risk factors and Warning signs|Patients will receive a generic suicide risk factors and warning signs information handout.
2452112|NCT03227471|Experimental|Part A: VX-445 in Healthy Subjects (HS)|Part A includes single dose escalation.
2452114|NCT03227471|Placebo Comparator|Part A: Placebo|
2452117|NCT03227471|Experimental|Part B: VX-445 in HS|Part B includes multiple-dose escalation.
2452118|NCT03227471|Placebo Comparator|Part B: Placebo|
2452119|NCT03227471|Experimental|Part C: VX-445 in Triple Combination (TC) with TEZ/IVA in HS|Multiple-dose escalation of VX-445 in TC with TEZ/IVA
2452121|NCT03227471|Placebo Comparator|Part C: Placebo|
2452123|NCT03227471|Experimental|Part D1: F/MF genotypes TC|Subjects will receive 100 mg VX-445 qd in TC with TEZ and IVA for 4 weeks.
2452126|NCT03227471|Placebo Comparator|Part D1: Placebo|Subjects will receive placebo for 4 weeks.
2452128|NCT03227471|Experimental|Part D2: F/MF genotypes TC-High|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2452130|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Mid|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2452131|NCT03227471|Experimental|Part D2: F/MF genotypes TC-Low|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks.
2452132|NCT03227471|Placebo Comparator|Part D2: Placebo|
2452133|NCT03227471|Experimental|Part E: F/F genotype - TC|Subjects will receive VX-445 in TC with TEZ and IVA for 4 weeks
2452134|NCT03227471|Active Comparator|Part E: TEZ/IVA|Subjects will receive TEZ and IVA for 4 weeks.
2452135|NCT03227471|Experimental|Part F: F/MF genotypes - TC|Subjects will receive VX-445 in TC with TEZ and VX-561 for 4 weeks.
2452137|NCT03227471|Experimental|Part F: Placebo|
2452226|NCT03226535|Experimental|Ultrasound-CT Fusion Guidance|The participants in this group (test group) will utilize the ultrasound-CT fusion system for guiding needle placement.
2452229|NCT03226535|No Intervention|CT Guidance|The participants in this group (control group) will receive the procedure with traditional CT methods and equipment, for guiding needle placement.
2452279|NCT03226119|Experimental|HTLV Infected (n=50)|Serum/plasma specimens which are HTLV I, HTLV II or HTLV I/II known positive (KP)
2452287|NCT03226119|Experimental|Neurological Disorders (n=100)|Serum/plasma specimens with symptoms or any of the following neurological disorders: Acute Disseminated Encephalitis, Amyotrophic Lateral Sclerosis, Autonomic Dysfunction, Conus Medularis Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Dermatomyositis, HAM-TSP, Meningitis, Mild Cognitive Impairment, Multiple Sclerosis, Polymyositis, Spastic Paraparesis, Sciatica
2452339|NCT03225625|Experimental|Paraspinal|Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.
2452344|NCT03225625|Experimental|Paraspinal EX|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Exoskeleton or equivalent stimulation following this treatment."
2452349|NCT03225625|Experimental|Paraspinal VR|"Bilateral paraspinal injection of bone marrow derived stem cells (BMSC) at spinal cord injury level, superior to injury level and inferior to injury level. Following paraspinal injection remaining BMSC provided intravenous and intranasal.~Virtual Reality or equivalent visualization following this treatment."
2452408|NCT03225053|Experimental|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
2452492|NCT03224845|Experimental|Cognitive behavioural skills training|
2452493|NCT03224845|No Intervention|No intervention|Participants in the control group will receive their usual clinical care and will not be discouraged from seeking any intervention.
2452508|NCT03224247|Active Comparator|Transverse splitting|transverse cutting and/or pulling of lower uterine segment during lower segment cesarean section.
2452509|NCT03224247|Active Comparator|Vertical splitting|vertical splitting,of lower uterine segment during lower segment cesarean section.
2452536|NCT03224065|No Intervention|Recommended therapy group|Guideline recommended regimen for treatment, regardless of antibiotic resistant genotype test results
2452547|NCT03224065|Experimental|Optimized therapy group|Optimized therapy based on antibiotic resistant genotype test results
2451740|NCT03229889|Active Comparator|Cialis + Placebo|Patients will be prescribed Cialis 5Mg tablet and given a bottle of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2451744|NCT03229889|Active Comparator|Cialis + Flomax|Patients will be prescribed .4mg of Flomax and 5mg of Cialis. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2451747|NCT03229889|Placebo Comparator|Placebo + Placebo|Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
2451818|NCT03229226||2016 OPPE|All faculty participating in yearly ongoing professional Practice evaluation were eligible for enrollment
2451936|NCT03228446|Experimental|Young subjects|Working memory training & attentional filter training for participants (18-30 years)
2451941|NCT03228446|Experimental|Old subjects|Working memory training, attentional filter training and no training (control) for participants (60-80 years)
2451996|NCT03227913|Active Comparator|Good chewing ability|
2451998|NCT03227913|Experimental|Impaired chewing ability|
2452041|NCT03227744|Active Comparator|Enrolled in group therapy|Patients in the group therapy arm will be enrolled in group therapy and be issued surveys.
2452050|NCT03227744|Placebo Comparator|Not enrolled in group therapy|Patients in control arm will be issued surveys
2452080|NCT03227484|Active Comparator|Empagliflozin|25mg Empagliflozin once daily over 8 weeks
2452087|NCT03227484|Placebo Comparator|Placebo|Matching placebo tablet once daily over 8 weeks
2452143|NCT03227133|Experimental|Single arm|Psychiatric interview, Neuropsychological evaluations, cardiovascular risk assessment
2452182|NCT03226821|Experimental|Tesamorelin|Subjects will be treated with tesamorelin 2 mg by subcutaneous injection daily. Enrolled subjects will have 6 visits - a baseline visit before starting tesamorelin, a visit at 1 month, 3 months, 6 months, 9 months and at 1 year of tesamorelin (GHRH analogue) therapy. Blood sampling for safety labs and clinical examinations will be performed at each visit.
2452228|NCT03226483|Experimental|Intraoperative radiotherapy|"After neurosurgical resection and proven metastasis (frozen section) a local intraoperative radiotherapy with soft energy x-rays is applied to the resection cavity.~To perform this an applicator is inserted into the situs in the tightest fit rule. The highest possible dose between 30-20 Gy is chosen depending on nearby risk structures (Optic nerve, brainstem) is prescribed. After radiotherapy the applicator is removed and the surgery will be finished in standard way."
2452298|NCT03226132|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia
2452299|NCT03226132|Active Comparator|Repeated Contact|Repeated Contact
2452368|NCT03225651|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
2452370|NCT03225651|Experimental|Psychological therapy and rehabilitation|Psychological therapy Rehabilitation in 3 months
3190396|NCT00787059|Placebo Comparator|sucrose solution|Will receive intracoronary sucrose solution
2452498|NCT03224507|Experimental|KRdD followed by auto-HCT|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22 (KRd-Dara). Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Days 8 and 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, auto-HCT is done (consolidation 1), then up to two 4-cycle blocks of KRd-Dara consolidation (consolidations 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
2452499|NCT03224507|Experimental|KRdD only|Cycle 1-Dexamethasone 40mg orally days 1/8/15/22; Lenalidomide 25mg orally days 1-21; Carfilzomib 20mg/m2 days 8/9 then @ 36mg/m2 venous days 15/16; Daratumumab 16mg/kg venous days 1/8/15/22. Cycle 2 the same except Carfilzomib 36mg/m2 venous days 1/2/8/9/15/16. Cycles 3,4 the same but no Daratumumab Day 22. Dosage adjusted for last tolerated dose (LTD). Following induction therapy, Following induction therapy, patients will receive up to three 4-cycle blocks of KRd-Dara consolidation (consolidations 1, 2 and 3). Minimum residual disease (MRD) checked after each phase. Patients with confirmed MRD(-) at or after consolidation 1 will not undergo maintenance and will be actively monitored for resurgence of MRD or clinical relapse. After consolidation if MRD+ patients will undergo standard of care lenalidomide maintenance.
2452530|NCT03224091||Patients at Psychiatric Center Ballerup|
2452550|NCT03224091||Healthy Controls|
2452554|NCT03224091||Healthy Controls recovered from an eating disorder|
2452587|NCT03223948|Active Comparator|30 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
2452588|NCT03223948|Active Comparator|45 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
2452589|NCT03223948|Active Comparator|60 litres per minute|High flow nasal oxygen delivery device 'Optiflow'
3190397|NCT00787072|Experimental|1|
2452725|NCT03223090|Experimental|Tool training group|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
2452726|NCT03223090|Active Comparator|Hand training group|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
2452856|NCT03222362||patients 85 years and above|120 consecutive patients (male and female), aged 85 years and above, who underwent pars plana vitrecromy in the Tel Aviv Medical Center during the years 01/01/2006 - 31/12/2013, and were followed by physicians in the ophthalmology department in the center until December 2015.
2452917|NCT03221998|Experimental|IV paracetamol|Patients in the first group will receive in the operating room before surgery 1 gram (100 ml) of intravenous paracetamol ( IV paracetamol) for 15 minutes intraoperative
2452918|NCT03221998|Placebo Comparator|IV saline (NaCl 0.9 %)|Patients in the second group will receive 100 mL NACL 0.9% (IV NaCl 0.9 %)intraoperative
2453070|NCT03220724|Experimental|Part A: Group 1|Participants will receive 20 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
2453071|NCT03220724|Experimental|Part A: Group 2|Participants will receive 100 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
3190398|NCT00787072|Placebo Comparator|2|
3190399|NCT00787085||Case|Patients hospitalized with a urine or blood culture positive for fungi
2451742|NCT03229629|Experimental|Maternal BCC & Paternal BCC|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC *BCC: Behavior Change Communication"
2451745|NCT03229629|Experimental|Food voucher|"Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~Food voucher"
2451748|NCT03229629|Experimental|Maternal BCC & Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Mothers or fathers with child under 20 months or pregnant will receive monthly food voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
2451749|NCT03229629|Experimental|Maternal BCC&Paternal BCC &Food Voucher|"Mothers with child under 20 months or pregnant will receive BCC~Husband/partner of the enrolled mother will receive BCC~Enrolled participants will receive monthly voucher worth 200 birr(~$10)~Within household, recipient of voucher (mother or father) will be randomly selected.~BCC: Behavior Change Communication"
2451750|NCT03229629|No Intervention|Control|Control group
3190400|NCT00787085||Control|Patients hospitalized with a urine culture negative for fungi
3208559|NCT00975949||Fluconazole Group|These subjects received fluconazole in our NICU fluconazole prophylaxis study during 1998-2000
3208560|NCT00975949||Placebo Group|These subjects received a placebo during our NICU fluconazole prophylaxis study during 1998-2000
2451909|NCT03228485||MyBPH Care|All patients enrolled in this study.
2451938|NCT03228225|Experimental|Tele cardiac rehabilitation|Following a standard intake process, patients will begin exercise in the institute and will gradually over a period of 6 months reduce the number of institution visits and will concomitantly increase the number of home \ community exercise sessions. During the entire period we will monitor program, coach and fine-tune the exercise program. Weekly exercise data will be securely transmitted to the rehabilitation team (heart rate zones, duration of exercise and type, step count, caloric expenditure, blood pressure and patients reported impressions)
2452065|NCT03228056|Experimental|uniportal VATS lobectomy|"uniportal VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2452067|NCT03228056|Active Comparator|two-ports VATS lobectomy|"two-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2452069|NCT03228056|Active Comparator|three-ports VATS lobectomy|"three-ports VATS lobectomy~thoracic epidural block (0.125% bupivacaine with epinephrine 1:50000, continuous infusion 3-4 ml/hour)~ketoprofene 100 mg i.v every 12 hours~paracetamol 1000 mg i.v every 8 hours~rescue doses of morphine in PCA system (bolus dose 2 mg i.v)~pain intensity measured in VAS scale"
2452082|NCT03227393|No Intervention|No yoga training|This will be the control arm. The patients in this arm will not receive any yoga training. They will be continued on all their home, guideline-directed heart failure medications. They will undergo the same baseline and study completion evaluation as the treatment arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
2452096|NCT03227393|Experimental|Yoga training|The patients in this arm will receive yoga training. This includes weekly group yoga sessions consisting of breathing exercises, yoga poses, and relaxation and meditation lasting for about 80-90 minutes total. Patients will be asked to do home yoga practices at least twice a week and to document the date and time. Patients in this arm will have the same baseline and study completion evaluation as the control arm, including an I-123 MIBG scan, 24-hour holter monitoring and device interrogation.
2452181|NCT03226886||All patients|"In London renal cell carcinoma patients undergo nephrectomy at centres for urological oncology, including the Royal Marsden, Guy's and St Thomas', St Georges, Charing Cross and Kings Hospitals. It is not uncommon for the same patients to undergo palliative resection for metastatic sites of disease. The majority of tissue from these resections does not undergo routine histopathological examination. As such, it is ethically feasible to use these specimens for laboratory research in the presence of patient consent. Practically, these specimens are often large, thereby offering considerable scope for a range of molecular analyses.~CAPTURE Sub-study:~We plan to enrol patients/participants into three groups:~Group A: patients with confirmed or suspected COVID-19 and a history of cancer Group B: patients without a history of COVID-19 infection and a history of cancer Group C: Hospital staff with or without a history of COVID-19"
2452233|NCT03226418|Experimental|Group I|"INTENSIVE INDUCTION THERAPY: Patients receive cytarabine intravenously (IV) on days 1-7 and idarubicin over 10-15 minutes on days 1-3 (7+3), or liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1, 3 and 5. Gemtuzumab or midostaurin are added to 7+3 as per the standard of care. Treatment continues for 1 course in the absence of unacceptable toxicity.~INTENSIVE CONSOLIDATION THERAPY: Patients who go into remission, receive cytarabine IV over 1-3 hours twice daily (BID) on days 1, 3, and 5. Treatment repeats every 4 weeks for 2-4 courses in the absence of disease progression or unacceptable toxicity. Patients treated with liposome-encapsulated daunorubicin-cytarabine receive liposome-encapsulated daunorubicin-cytarabine IV over 90 minutes on days 1 and 3. Treatment repeats every 5-8 weeks for 2 courses in the absence of disease progression, unacceptable toxicity."
2452236|NCT03226418|Experimental|Group II|"LOW-INTENSITY: Patients receive venetoclax in combination with azacitidine or decitabine or other standard of care low-intensity therapy such as azacitidine or decitabine alone or in combination with FLT3 inhibitor such as midostaurin, low-dose cytarabine in combination with glasdegib.~Venetoclax dose varies depending on drug interaction with antifungal agents. Given daily continuous for >= 3 months orally. Glasdegib dose is 100 mg oral daily.~Decitabine IV over 1-3 hours daily for 5-10 days. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant. Azacitidine IV infusion over 10 to 40 minutes days 1 -7. Treatment repeats every 4-5 weeks for >= 3 courses in the absence of disease progression, unacceptable toxicity or receipt of allogeneic stem cell transplant."
2452317|NCT03225690|Placebo Comparator|serum physiologic|2 ml serum physiologic will apply via epidural catheter before surgical incision.
2452319|NCT03225690|Active Comparator|Preemptive Morphine|1 mg morphine will apply via epidural catheter before surgical incision.
2451803|NCT03229057|Experimental|OCP + Metformin|The OCP will be started on the first Sunday after spontaneous or induced menses. All subjects with no menses the 4 weeks before randomization will be given medroxyprogesterone acetate after a negative pregnancy test (in order to induce menses). Metformin will be initiated in a step-up fashion on cycle day 1-3 of spontaneously or induced menses. Extended release pills will be utilized as they are associated with fewer gastrointestinal side effects. Subjects will begin with one tablet of metformin every night for 5 days, eventually building up to 4 tablets every night, with the maximum dose of metformin being 2000 mg.
2451852|NCT03228901|Experimental|Oxytocin|24IU Syntocinon, delivered in a single nose via a nasal spray
2451853|NCT03228901|Placebo Comparator|Placebo|Matched nasal spray
2451904|NCT03228563|Experimental|Probiotics|Taking two capsules of probiotics twice daily for 12 months.
2451908|NCT03228563|No Intervention|Healthy control|Healthy volunteers were: no hypertension (Blood pressure<140/90mmHg), no diabetes (Glucose AC 70~100mg/dl), no hyperlipidemia (Cholesterol Total 130~200mg/dL、Triglyceride<150mg/dL), no urinary protein (-) and normal renal function (eGFR>90), after signing the consent form, the stool samples will be collected.
2451962|NCT03228277|Experimental|Olmutinib|Single arm of Olmutinib, staring dose of 800 mg
2452066|NCT03227874|Experimental|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
2452068|NCT03227874|Experimental|Muffin|two muffins, each with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
2452091|NCT03227432|Experimental|Nivolumab + Elotuzumab|"22 patients will be entered, If > 4 patients achieve at least a partial response (PR) within 4 cycles an additional 18 patients will be treated.~Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5"
2452097|NCT03227432|Experimental|Nivolumab+Elotuzumab+Pomalidomide+Dexamethasone|"Nivolumab will be administered intravenously twice per cycle for cycle 1-4~Nivolumab will be administered intravenously once per cycle for cycle 5~Elotuzumab will be administered intravenously 4 times per cycle for cycle 1-2~Elotuzumab will be administered intravenously twice per cycle for cycle 3-4~Elotuzumab will be administered intravenously once per cycle for cycle 5~Pomalidomide will be administered for 21 days per cycle~Dexamethasone will be administered weekly"
2452290|NCT03226145|Active Comparator|Patients|"80 Patients : 40 FC 40 IBS-C~Will have MRI Motility and High Resolution Manometry~Then will have:~Bisacodyl 10mg once daily for 10 days, and matched placebo hyoscine butylbromide Buscopan 20mg three times daily for 10 days, and matched placebo~Both agents will have their matched placebo dispensed alongside the active product of the other agent.~All agents to be used in this study as tools for their known mechanisms of action, rather than to assess their effects."
2452294|NCT03226145|Active Comparator|Healthy Volunteers|40 HVs Will have MRI Motility and High Resolution Manometry No other interventions
2452328|NCT03225560|Experimental|Smart Phone Application|A novel smart phone application available for both Apple iOS and Google Android platforms with capabilities to populate the phone calendar with automated reminders/notifications at the appropriate times prior to the colonoscopy.
2452332|NCT03225560|Active Comparator|Traditional Paper Instructions|Traditional paper instructions for bowel preparation
3174481|NCT00624039|Other|1|ultrasound biomicrocopic examinations and pilocarpine instillation
2452566|NCT03224416|Experimental|Alcohol|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
2452570|NCT03224416|Placebo Comparator|Placebo|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
2452571|NCT03224416|Sham Comparator|True Control|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
2452616|NCT03223714|Experimental|Conbercept|"Subject receive 0.5 mg Conbercept injection into their study eyes every month (Day 0 - Month 5).~If subjects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
2452617|NCT03223714|Sham Comparator|Conbercept or sham|"Subjects receive sham injection into their study eyes every month (Day 0 - Month 5).~Subjects receive a single intravitreal injection of 0.5 mg Conbercept ophthalmic injection in month 6, followed monthly review, if he/she meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)."
2452691|NCT03223415|Experimental|Experimental arm|Detection and isolation of C. difficile carriers
2452693|NCT03223415|No Intervention|Control arm|No detection of C. difficile carriers upon admission and no implementation of contact isolation precautions for C. difficile carriers
2452740|NCT03222973|Experimental|BIIB033 (opicinumab) 750 mg|Participants with relapsing multiple sclerosis (RMS) will receive BIIB033 750 milligram (mg) intravenously (IV) as an add-on therapy to a background disease-modifying therapy (DMT) once every 4 weeks over 72 weeks in Part 1 and once every 4 weeks over 96 weeks in Part 2.
2452744|NCT03222973|Placebo Comparator|Placebo|Participants with RMS will receive placebo IV as an add-on therapy to a background DMT once every 4 weeks over 72 weeks in Part 1 and BIIB033 once every 4 weeks over 96 weeks in Part 2. The placebo looks like BIIB033 but does not contain the active ingredient that is thought to have an effect on MS disease. The placebo used in this study is sterile normal saline (water with a small amount of sodium chloride [salt]).
2452919|NCT03221699|Placebo Comparator|control|Formula without ZnO
2451837|NCT03229278|Experimental|Treatment (trigriluzole, nivolumab, pembrolizumab)|Patients receive trigriluzole PO QOD, BID, QAM or QHS on days -14 to -1. Patients then receive nivolumab IV over 60 minutes every 2 weeks beginning week 1 and trigriluzole PO QOD, BID, QAM or QHS. Once the MTD of trigriluzole with nivolumab is identified, patients receive pembrolizumab IV over 30 minutes every 3 weeks beginning week 1 and trigriluzole PO. Treatment repeats for up to 1 year in the absence of disease progression or unacceptable toxicity.
2451913|NCT03228576||TREVISE|
2451930|NCT03228199|Other|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush.
2451933|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 weeks evaluation period.
2452049|NCT03227679|Active Comparator|Metabolism-Informed Care (MIC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) recommendations were guided by Nicotine Metabolism as measured by the Nicotine Metabolite Ratio. Ultimately, after being educated about smoking cessation medication efficacy and side-effects, the participant could decide to take any medication for which they were medically cleared, but the recommendation was made based on rate of Nicotine Metabolism.
2452056|NCT03227679|Active Comparator|Guideline-Based Care (GBC)|Smoking Cessation Pharmacotherapy (varenicline, bupropion, and nicotine patch) was co-selected from those they were medically able to receive after educating participants about smoking cessation medication efficacy and side-effects.
2452083|NCT03227380|Other|radiological evaluation|to explore by thoracic densitometry with contrast the spared segments after stapling of the intersegmental plan following a thoracoscopic segmentectomy
2452159|NCT03227198|Experimental|Intramyocardial injection of stem cell|Intramyocardial injection of autologous bone marrow mononuclear cells in patients with Heart Failure
2452160|NCT03227198|Placebo Comparator|Placebo|Placebo intramyocardial injection in patients with Heart Failure
2452174|NCT03226717||Hepatitis C patients|Antiviral agents (sofosbuvir,daclatasvir,ribavirin) will be given to hepatitis C patients with arthropathy.
2452241|NCT03226548|Experimental|Experimental|Paycheck Plus: Participants will receive four times the standard Earned Income Tax Credit after filing their annual taxes
2452242|NCT03226548|No Intervention|Control|Control participants will receive the standard Earned Income Tax Credit after filing their annual taxes
2452283|NCT03226067|Experimental|GKT137831 400mg twice daily|"GKT137831 400mg twice daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening."
2452289|NCT03226067|Experimental|GKT137831 400mg once daily|"GKT137831 400mg once daily~Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. The capsules in the evening will be placebos."
2452297|NCT03226067|Placebo Comparator|Placebo Arm|Patients will self-administer 4 capsules in the morning and 4 capsules in the evening. All capsules will be placebos.
2452336|NCT03225417|Experimental|Experimental group|"Phase I: Ixazomib + Tacrolimus + Sirolimus. Ixazomib doses in this study is 3 to 4 mg of ixazomib on day +1, +8 and +15. Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day. Sirolimus at a dose of 6 mg on day -5 and then 4 mg per day.~Phase II: Ixazomib+ any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.~Starting Dose of Ixazomib according to phase I."
2452343|NCT03225417|Other|Control group|Any prophylaxis for GVHD, except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
2452391|NCT03224949||Healthy controls|
2452395|NCT03224949||Alcoholic hepatitis|
2452401|NCT03224949||Alcoholic steatosis|
2452412|NCT03224949||Alcoholic cirrhosis without HCC|
2452420|NCT03224949||Nonalcoholic steatohepatitis (NASH)|
2452427|NCT03224949||Alcoholic cirrhosis with HCC|
2452479|NCT03224572|Experimental|The study group|The study group will receive intravenous high-dose vitamin C 30 gm in 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
2452483|NCT03224572|Placebo Comparator|The control group|The control group will receive 500 ml normal saline in 1-hour infusion, once per week, and total 4-week treatment.
2452528|NCT03224169|Experimental|Intervention|Directly observed hand hygiene
2452546|NCT03224169|No Intervention|Control|No directly observed hand hygiene
2452628|NCT03223922|Experimental|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy|Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
2452690|NCT03223389|Experimental|10 gastric bypass operated patients|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
2452692|NCT03223389|Experimental|10 healthy control subjects|3 different oils ingested at separate study days will be tested against each others ability to induce gut hormone secretion.
2452732|NCT03222947||Taybi-Linder index cases|Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
2452734|NCT03222947||Blood relatives of Taybi-Linder index cases|Blood relatives of Taybi-Linder index cases who have already consented for the (re)use of their DNA samples for medical research.
2452796|NCT03222674|Experimental|Single arm|CAR T cells to treat AML
2452871|NCT03222193|Experimental|TRP group|Snoring subjects treated with the Tongue Right Positioner (TRP) medical device
2452886|NCT03221842|Experimental|C1-INH|C1-esterase inhibitor
2452888|NCT03221842|Placebo Comparator|Placebo|Excipients of C1-INH plus albumin
2452937|NCT03221504|Active Comparator|Antibiotic therapy for 10 days|After 7 days of cefuroxime treatment (oral, intravenous or sequential), patients from day 8 to day 10 will continue to receive the antibiotic (in blinded bottle).
2452938|NCT03221504|Experimental|Antibiotic therapy for 7 days|After 7 days of cefuroxime therapy (oral, intravenous or sequential), children from day 8 to day 10 will receive placebo (in blinded bottle).
2452967|NCT03221218|Experimental|Enhanced screening-informed letter|Family physicians will receive a letter that includes their patient's screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines for MTBI (2013).
2451892|NCT03228589|Placebo Comparator|Placebo|Placebo arm treated with placebo capsules (identical to active product capsule besides the bacteria) for 8 weeks.
2451926|NCT03228368||Atezolizumab (MPDL3280)|Atezolizumab 1200 milligrams (mg) will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
2451977|NCT03228082|Experimental|Home Blood Pressure Monitoring (HBPM)|"Home monitoring of blood pressure will be performed. Blood pressure measurements will be entered automatically through a smartphone application into a patient-controlled medical record ('Patients Know Best'). The data will be available to the study coordinator, who will provide patients within 1 week with feedback on the measurements. If necessary lifestyle advice will be given, in case of hypertension patients will be referred to their GP.~Once monthly a questionnaire on well-being (SF-12) and symptoms will be completed. After 6 months and 1 year patients will also receive a questionnaire on feasibility and usability of the blood pressure device."
2451982|NCT03228082|No Intervention|Control group|Patients in the control group will be asked to register their blood pressure if measured during a doctor's visit, and to note medication use if applicable. They will also be asked to complete a short questionnaire on well-being (SF-12) once per month, which will be evaluated at the end of the study. No interim contact with the study coordinator is scheduled.
2452032|NCT03227770|Active Comparator|regular hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
2452047|NCT03227770|Experimental|hemoperfusion combined with hemodialysis|Combination of hemodialysis and hemoperfusion treatment once every two week
2452092|NCT03227341|Other|patients with uncontrolled asthma.|8 week pulmonary rehabilitation program
2452102|NCT03227341|Other|patients with partially controlled asthma|8 week pulmonary rehabilitation program
2452145|NCT03227120|Experimental|Prehabilitation Exercise|Receives Prehabilitation exercise program for three times a week for eight weeks of direct outpatient exercise instruction.
2452148|NCT03227120|No Intervention|Control|Receives the usual standard of care which is a one time Strength and Flexibility written home exercise program provided during total joint education pre-surgery class.
2452175|NCT03226834|Active Comparator|MUSIC CARE|Listening for 20 min of one of the music style U sequences proposed by the medical device MUSIC CARE
2452179|NCT03226834|Experimental|PERSONAL PLAY-LIST|Listening for 20 min of patient's play-list
2452218|NCT03226444|Experimental|0.005% Lacripep|0.005% Lacripep ophthalmic solution
2452219|NCT03226444|Experimental|0.01% Lacripep|0.01% Lacripep ophthalmic solution
2452221|NCT03226444|Placebo Comparator|placebo|placebo solution
2452273|NCT03225924|Experimental|Experimental|Entospletinib + Rituximab + Cyclophosphamide + Doxorubicine + Vincristine + Prednisone
2452348|NCT03225482|Experimental|ME-CCT|8-week Motivationally Enhanced Compensatory Cognitive Training group
2452353|NCT03225482|Active Comparator|SC|8-week Goal-focused Supportive Contact group
2452414|NCT03225118||HIV/ATI|HIV-infected Adults (age 18-65 years) on ART with suppressed viremia willing to interrupt treatment and then restart once criteria is met.
2452465|NCT03224793|Experimental|BIIB059 20 mg|Participants will receive single subcutaneous (SC) dose of 20 milligram (mg) BIIB059 or matching placebo on Day 1.
2452469|NCT03224793|Experimental|BIIB059 50mg|Participants will receive single SC dose of 50 mg BIIB059 or matching placebo on Day 1.
2452474|NCT03224793|Experimental|BIIB059 150mg|Participants will receive single SC dose of 150 mg BIIB059 or matching placebo on Day 1.
2452480|NCT03224793|Experimental|BIIB059 450mg|Participants will receive single SC dose of 450 mg BIIB059 or matching placebo on Day 1.
3208561|NCT00975962|Experimental|Thrombolysis + Remote perconditioning|"Remote perconditioning (rIPerC) undertaken in ambulance on rute to hospital in case of suspected stroke.~The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC."
2452636|NCT03223688|Experimental|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training. Said therapists assisted the caregivers in improving their nurturing and parenting skills with their children, as well as their techniques with regards to influencing them.
2452638|NCT03223688|Experimental|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
2452639|NCT03223688|Active Comparator|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
2452680|NCT03223376|Active Comparator|fruquintinib+paclitaxel|treatment arm (fruquintinib+paclitaxel) : Fruquintinib once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
2452681|NCT03223376|Placebo Comparator|placebo+paclitaxel|control arm (placebo+paclitaxel): Fruquintinib placebo once daily, 3 weeks on/1week off combined with Paclitaxel 80mg/㎡ day1, 8, 15 of 4 weeks cycle.
2452793|NCT03222596|Experimental|Multiple Sclerosis Exercise|Ambulatory and non-ambulatory MS individuals that will exercise-group (MSE). Intervention is exercise training.
2452795|NCT03222596|No Intervention|Multiple Sclerosis Control (no-Exercise)|Ambulatory and non-ambulatory MS individuals that will not exercise-group (MSC).
2452881|NCT03222024||Severe ischaemic stroke|patients with severe stroke on admission
2451893|NCT03228732|Active Comparator|Fluoxetine and DHEA|"Visit 1:~Study Day 1: Hyperinsulinemia/ hypoglycemia clamp in the AM and PM. Study Day 2: Hyperinsulinemia/ hypoglycemia clamp in the AM only. 8-weeks of treatment with fluoxetine and DHEA~Visit 2:~same as visit 1"
2451954|NCT03228238|Experimental|Dual subgroup|Standard medication for variant angina plus Vitamin C+E plus Statin Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU Statin : Atorvastatin calcium 10mg
2451955|NCT03228238|Experimental|Statin subgroup|Standard medication for variant angina plus Statin Statin : Atorvastatin calcium 10mg
2451956|NCT03228238|Experimental|Vitamin subgroup|Standard medication for variant angina plus Vitamin C+E Vitamin C and Vitamin E : Ascorbic acid Tablet 1g / Tocopherol Capsule 400IU
2451957|NCT03228238|Active Comparator|Control group|Control subgroup : Standard medication for Variant angina only
2452007|NCT03227783|Active Comparator|Real tDCS|"Constant weak electric currents through scalp via two electrodes will be delivered.~Current intensity: 2mA, 20min/day"
2452008|NCT03227783|Sham Comparator|Sham tDCS|"a 1 mA current, for 30 s giving an initial sensation of tDCS while minimizing stimulatory effects~Ramp up and ramp down was over 10 s. (Ref. Loo CK et al., Br J Psychiatry 2012;200:52-9)"
2452070|NCT03227666|Experimental|Intervention Group|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
2452071|NCT03227666|No Intervention|Control group|The control group recieves a health consultation that highlights the importance of physical activity and balance exercise according to standard practice within the HAI project. They are asked to return after 4 weeks for follow up.
2452122|NCT03227406|No Intervention|Daytime Wake|Subjects are trained and retested during a single period of daytime wake
2452125|NCT03227406|No Intervention|Overnight sleep|Subjects are trained on one day and tested the next day, after a night of normal sleep
2452127|NCT03227406|Experimental|Sleep deprivation|Subjects are trained on one day and tested the next day, after a night of sleep deprivation
2452129|NCT03227406|Experimental|Daytime Nap|Subjects are trained and then retested after a daytime nap
3190401|NCT00787098|No Intervention|1|RA begins data collection with chart review for demographic and explanatory variables, collects data for baseline muscle strength. During standard care period, PM will obtain information about the plan for activity for enrolled patients (turning, complete or partial weight-bearing i.e., reverse Trendelenberg positioning, ROM, sitting and walking) through discussion with the direct providers. RA will interview one provider about factors which influence the decision to implement activity or provide bedrest, including the presence of orders for bedrest or physical therapy. If activity is planned, the PM will observe and record the type and duration of activity, drawing serum biomarkers 20 minutes before and 20 minutes after the activity. If no activity is planned or activity duration is less than 10 minutes, serum for only baseline inflammatory biomarkers will be drawn. The RA will collect outcomes data within 24 hours of discharge from the ICU.
3190402|NCT00787098|Experimental|2|Identical procedures for date recruitment, consent and data collection will occur. In this phase, the Project Manager will promote the use of the ETM protocol through coaching (e.g., reminding staff of benefits of mobility, identification of available resources, or suggesting cessation of bedrest orders) and by participating in planning at least one 20-minute activity.
3190403|NCT00787111|Experimental|Fluoxetine ODT|Fluoxetine ODT ranging from 2mg to 54mg
3190404|NCT00787163|Experimental|1|amnioinfusion
3190405|NCT00787163|No Intervention|2|expectant management
2452373|NCT03225508||Phase 1|"The first phase will be to evaluate a new lung ultrasound technique to measure diaphragmatic excursion using a linear probe in the mid-axillary line. This will involve scanning 75 healthy patients undergoing elective surgery to determine normal reference values in men and women.~The following interventions will be carried out:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe on both sides of the chest (ii) Measurement of diaphragmatic movement with a curved ultrasound probe on both sides of the chest"
2452375|NCT03225508||Phase 2|"This will involve patients undergoing an interscalene / supraclavicular brachial plexus block for their routine care, it will examine the reduction in diaphragmatic motion due to phrenic nerve palsy.~Interventions:~(i) Measurement of diaphragmatic movement with a linear ultrasound probe bilaterally.~(ii) Measurement of diaphragmatic movement with a curved ultrasound probe bilaterally.~(iii) Pulmonary function tests prior to the brachial plexus block (iv) Planned supraclavicular / interscalene block by the clinical team. (v) Repeat measurement of diaphragmatic movement with linear ultrasound, only on the side of the brachial plexus block.~(vi) Repeat measurement of diaphragmatic movement with curved ultrasound, only on the side of the brachial plexus block."
2452397|NCT03224962||diagnostic tool|Light induced fluorescence camera Caries detection dye. visual assessment method (ICDAS criteria)
2452507|NCT03224286||Incubator + <1500 g|Infants currently in an incubator with a weight of less than 1500 grams will be monitored while lying on a pressure sensitive mat.
2452510|NCT03224286||Incubator + 1500 - 2500 g|Infants currently in an incubator with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2452512|NCT03224286||Overhead warmer + <1500 g|Infants currently in an overhead warmer with a weight less than 1500 grams will be monitored while lying on a pressure sensitive mat.
2452514|NCT03224286||Overhead warmer + 1500 - 2500 g|Infants currently in an overhead warmer with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2452515|NCT03224286||Overhead warmer + >2500 g|Infants currently in an overhead warmer with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
2452517|NCT03224286||Crib + 1500 - 2500 g|Infants currently in a crib with a weight between 1500 - 2500 grams will be monitored while lying on a pressure sensitive mat.
2452519|NCT03224286||Crib + >2500 g|Infants currently in a crib with a weight over 2500 grams will be monitored while lying on a pressure sensitive mat.
2452565|NCT03224039|Experimental|Intranasal sufentanil|"Treatment arm to include~Sufentanil 0.7 mcg/kg intranasal (IN) x 1 dose~Normal saline 1ml intravenous (IV) push x 1 dose"
3190406|NCT00787176|Active Comparator|Group A|An intravenous bolus of 1000 mL Lactated Ringers initiated when the patient was positioned for epidural placement. Oxytocin management continued as per protocol.
3190407|NCT00787176|Experimental|Group B|An intravenous bolus of 1000 mL Lactated Ringers. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
2451901|NCT03228771|Active Comparator|PRGF/ATV|"Group I (PRGF/ATV) : It was included 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin loaded in PRGF derived fibrin scaffold then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.~Intervention: Atorvastatin drug loaded in platelets rich in growth factors (PRGF)."
2451905|NCT03228771|Active Comparator|ATV gel|Group II (ATV gel) : Will include 10 patients undergoing single tooth extraction followed by socket fill with 1.2% Atorvastatin in methyl cellulose gel then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
2451910|NCT03228771|No Intervention|Empty socket|Group III Empty socket( control) : Will include 10 patients undergoing single tooth extraction then suturing the socket. All patients will receive implants after taking the bone biopsy after 8 weeks for histomorphometric analysis.
2451921|NCT03228251||Observation Group 1|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months before stroke team simulation training
2451922|NCT03228251||Observation Group 2|all stroke patients receiving thrombolysis and/or thrombectomy in a time period of three months after stroke team simulation training
2451964|NCT03228134|Experimental|Hanxiao treatment group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
2451966|NCT03228134|Sham Comparator|Hanxiao control group|80 patients belongs to Hanxiao type of asthma will take Ke Chuan Liu Wei Granule placebo oral therapy twice everyday for 28 days and receive background therapy of ICS and beta2-agonist.
2451968|NCT03228134|Experimental|Xuxiao treatment group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
2451969|NCT03228134|Sham Comparator|Xuxiao control group|80 patients of deficiency type of asthma will take Yang He Ping Chuan Granule placebo oral therapy thrice everyday for 28 days and background therapy of ICS and beta2-agonist.
3190408|NCT00787176|Active Comparator|Group C|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. Oxytocin management continued per protocol.
2452172|NCT03227016|Experimental|Combination Topo/Veli|Topotecan and Veliparib in increasing doses
2452209|NCT03226561|Active Comparator|Panoptix Group|Patients will receive bilateral phacoemulsification with diffractive trifocal lenses implantation (Phaco / Panoptix)
2452210|NCT03226561|No Intervention|Control Group|Control, age-matched presbyopic group corrected with presbyopic glasses
2452276|NCT03226002|Active Comparator|Airtraq NT right nostril|nasotracheal intubation with Airtraq NT through the right nostril
2452285|NCT03226002|Active Comparator|Airtraq NT left nostril|nasotracheal intubation with Airtraq NT through the left nostril
2452314|NCT03225716|Experimental|Ibrutinib + Ulocuplumab|"Ibrutinib administered orally once daily~Ulocuplumab administered intravenously 2-4 times per cycle for Cycles 1-6"
2452360|NCT03225495|Active Comparator|Standard Implant|
2452363|NCT03225495|Experimental|Ultra-narrow Implant|
2452409|NCT03225105|Experimental|M3541 + Palliative Radiotherapy (RT)|
3190409|NCT00787176|Experimental|Group D|The maintenance infusion of 125 mL/hr of Lactated Ringers was given with no additional fluid bolus. The dose of oxytocin being administered at time of epidural placement was halved and not increased for 60 minutes until after placement.
3190410|NCT00787215||no treatment|observational: no treatment involved
2452527|NCT03224078||adult Emergency Department Patients|adult patients that were treated with any condition in one of the participating emergency departments in 2016 (n≈680.000 cases)
2452605|NCT03223935|Active Comparator|Roasted snacks|Corn nuts
2452607|NCT03223935|Experimental|Roasted chickpeas|Chickpeas
2452609|NCT03223935|Experimental|Roasted yellow peas|Yellow peas
2452611|NCT03223935|Experimental|Roasted pinto beans|Pinto beans
2452612|NCT03223935|Experimental|Roasted soybeans|Soybeans
2452613|NCT03223935|Experimental|Roasted almonds|Almonds
2452665|NCT03223519|Experimental|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C.
2452668|NCT03223519|Placebo Comparator|Placebo|
2452669|NCT03223519|Active Comparator|Ibuprofen|
2452670|NCT03223519|Active Comparator|Magnesium|
2452671|NCT03223519|Active Comparator|Vitamin C|
2452718|NCT03223129|Other|Patients with normal glucose tolerance|"Patients included in this arm will have a plasma glucose below 140 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2452722|NCT03223129|Other|Patients with impaired glucose tolerance|"Patients included in this arm will have a plasma glucose between 140 mg/dl to 199 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2452724|NCT03223129|Other|Patients with type 2 diabetes mellitus|"Patients included in this arm will have a plasma glucose above 200 mg/dl after a 2 h oral glucose tolerance test with a glucose load of 75 g.~All patients in this arm will undergo oral glucose tolerance test with increasing glucose load and a graded intravenous glucose infusion were plasma glucose levels are held at the same level as during the oral glucose tolerance test."
2452807|NCT03222687|Experimental|therapy group|Immunosuppressive therapy included tacrolimus and prednisone.
2452863|NCT03222167|Experimental|Elbasvir/ Grazoprevir|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination for 12 weeks treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated with metabolic syndrome, with or without severe fibrosis / compensated cirrhosis.
2452893|NCT03221920|Experimental|Very Low Carbohydrate Diet|The patient will be evaluated for baseline clinical and laboratory values, and counselled on very low carbohydrate diet.
2452897|NCT03221920|No Intervention|Control|The patient will be evaluated for baseline clinical and laboratory values, and counselled on normal healthy .
3153882|NCT00285844|Experimental|Dietary Weight Loss|IR and IS subjects will be randomized to dietary weight loss for 16 wks for comparison to pioglitazone intervention
3153883|NCT00285896|Active Comparator|Active|GLP-1
2452026|NCT03227718||athletic background|ex-gymnasts
2452030|NCT03227718||control|age-matched non-gymnastics background
2452151|NCT03227224|Placebo Comparator|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
2452154|NCT03227224|Experimental|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
2452288|NCT03226236|Experimental|study treatment|boost radiotherapy (XRT) plus intradermal autologous dendritic cell vaccine loaded with autologous tumor homogenate (Autologous DC vaccine) plus High-Dose IL-2
2452405|NCT03225170|Sham Comparator|Control|The control group will rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the 9th ranked item and why it might be important to someone else. The control condition is consistent with the control used in other SA intervention studies. The 9th ranked item is chosen to inhibit a reverse effect, where participants feel affirmed because they do not value something that is averse to them.
2452418|NCT03225170|Experimental|Intervention|Arm Description: Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them.
2452738|NCT03222882|Experimental|RIF group|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
2452792|NCT03222635|Experimental|Endoscopic follow-up|Patients treated with endoscopic resection (ER) for a submucosal or high-risk mucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.
2452873|NCT03222063|Experimental|Experimental group|"Experimental Group:~Experimental group consists of 30 hospitalized children.In Experimental group after taking pretest on 1st day play interventions were introduced to the children and instructions regarding the way to play with all the interventions were provided to the children. Though all the children were free to choose the play yet the younger children were given simple and easy play interventions such as drawing, coloring etc. to obtain more sensory experience whereas the older children were offered play interventions such as puzzle, building blocks, ludo etc. with high cognitive demand. The play interventions were administered for 1 hour daily for continuous 5 days.Post test assessment of anxiety was done on 5th day."
2452876|NCT03222063|No Intervention|Comparison group|Comparison Group: 30 hospitalized children were selected by purposive sampling in comparison group. Pretest anxiety was measured on 1st day . No intervention was administered. only usual medical and nursing care was administered to the hospitalized children. Post test assessment of anxiety was done on 5th day.
2452923|NCT03221803|Experimental|OT Vertical attachment|The attachment consists of a male part that is in the form of a steady with a central hole. This part is attached to the abutments .the female component is a white standard retentive clip engaging the outer walls of a steady male. It is incorporated in the partial denture together with a castable balancing pin that fits into the central hole of the steady male and aids in centering the prosthesis during the final stage of insertion; thereby ensuring a longer life to the retentive clips.
2452963|NCT03221361|Active Comparator|Thermoplastic resin group|Thermoplastic complete denture placement is done
3153884|NCT00285896|Placebo Comparator|Placebo|Placebo
3153885|NCT00285935|Experimental|Treatment with SSRI|"Depressed participants will receive 8 weeks of treatment with one of the following serotonin-specific reuptake inhibitors:~fluoxetine (Prozac®), sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)~The specific drug used for treatment will be selected by the study clinician based on clinical interviews and the participants preferences. Participants will be monitored for response and side effects by study clinician and will return after 8 weeks for a follow up study visit."
3153886|NCT00285974|Experimental|hip prosthesis|
3153887|NCT00286026|Experimental|Arm 1|Subjects residing in villages assigned to treatment arm 1 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0); will be treated with Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
3153888|NCT00286026|Experimental|Arm 2|Subjects residing in villages assigned to treatment arm 2 will receive a clinical evaluation for trachoma and provide a swab specimen of conjunctivae of the R eye at enrollment (Day 0), as well as receive an initial treatment with Azithromycin; will receive a second dose of Azithromycin at Day 30; will be re-screened (clinical evaluation and swab specimen of R eye collected) at Day 60; and again at Day 360.
3153889|NCT00286104|Active Comparator|1|Bactiseal ventricular catheter (Rifampicin- and Clindamycin-impregnated)
3153890|NCT00286104|Placebo Comparator|2|Plain ventricular catheter
3153891|NCT00286117|Experimental|1|Anastrozole
3153892|NCT00286117|Active Comparator|2|Tamoxifen
3153893|NCT00286130|Active Comparator|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
3153894|NCT00286130|Active Comparator|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
3153895|NCT00286143|Active Comparator|A|Fentanyl added to Bupivacaine via epidural catheter.
3153896|NCT00286195|No Intervention|I|Consecutive patients, open label
3153897|NCT00286208|Active Comparator|Sublingual Misoprostol|400 mcg of sublingual misoprostol
2451924|NCT03228459|Experimental|Mobile Unit Follow-up Group|In the Mobile Unit (MU), clinical, sociodemographic and anthropometric data will be recorded. Patients will be evaluated with artery ultrasound (carotid, femoral, transcranial and abdominal aorta), ankle-brachial index, pulse wave velocity, spirometry, determination of advanced glycation-end products, atrial fibrillation screening, dried blood spot test and urine analysis. Moreover, DNA, RNA, Saliva, blood and urine samples will be collected and stored in the biobank to identify new biomarkers using omic studies. Additionally, climate, air pollutant and airborne pollen data form the entire province of Lleida will be registered. Finally, a report with the exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
2451925|NCT03228459|No Intervention|Electronic Medical History Follow-up Group|Participants will be followed through their electronic medical records. Sociodemographic (age, sex, race, marital status, education and labour status), clinical and anthropometric data and will be electronically collected.
2452033|NCT03227809|Experimental|Handbook condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts
2452046|NCT03227809|Experimental|Handbook plus condition|Parents in this condition receive a handbook designed for parents of first-year college-going students the summer before school starts plus a series of text messages during students' first year of college
2452053|NCT03227809|No Intervention|Control|Parents receive treatment as usual of incoming university student parents
2452101|NCT03227458|Active Comparator|Exercise and DHEA|1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
2452106|NCT03227458|Active Comparator|Exercise and Placebo|1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.
2452107|NCT03227458|Active Comparator|DHEA only|1 study pill containing 50 mg of DHEA daily for 36 weeks
2452163|NCT03226977|Experimental|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
2452165|NCT03226977|Active Comparator|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
2452281|NCT03226171|Experimental|Dose-adjusted SK-1403|
2452380|NCT03225326|Experimental|Computer controlled 4% articaine delivery by Anaeject|
2452381|NCT03225326|Active Comparator|Conventional 4% articaine delivery by carpule syringe|
2452539|NCT03224429|Other|Decisional Needs Assessment|Caregivers and patients with sickle cell disease will participate in a semi-structured open ended interview regarding treatment decision making.
2452551|NCT03224429|Other|Beta Testing|Caregivers and patients with sickle cell disease will review the web-based Sickle Cell Decision Aid.
2452590|NCT03223870||Oximeters|Comparison of respiratory rates with other devices in normal subjects as observational with other pulse oximeters. No treatment of interventions will be performed.
2452627|NCT03223675|Experimental|Hippocampus-sparing WBRT plus SIB|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT) and simultaneous integrated boost(s) (SIB), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) containing the normal brain parenchyma; an simultaneous integrated boost up to 120 - 150% is attempted to irradiate the gross metastatic foci.
2452727|NCT03223077||Acute Campylobacter|We will enroll 150 patients with acute Campylobacter infection. Our microbiology laboratory will inform us of a culture or PCR positive case of Campylobacter infection as soon as that test result is available.
2452816|NCT03222752|Active Comparator|Treatment Group|Group receives active treatment for 6 weeks. The intervention used will be cranial electrotherapy stimulation from and Alpha-Stim AID.
2452817|NCT03222752|Sham Comparator|Sham Treatment Group|Groups receives treatment using sham cranial electrotherapy stimulation devices for 6 weeks. No actual treatment will be received. This group will not receive any treatment interventions. The same outcome measures will be used as the treatment group.
3190411|NCT00787280|Experimental|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
2452955|NCT03221543|Experimental|Resting Metabolic Rate Testing|All subjects will have the resting metabolic rate test. The ReeVue Indirect Calorimeter from Korr Medical will be used to obtain the resting metabolic rate.
2452994|NCT03221205|Sham Comparator|Sham CPAP|Patients randomized to use sham CPAP via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
2453000|NCT03221205|Experimental|Therapeutic CPAP|Patients randomized to use CPAP programmed to administer automatically pressure from 4 to 20 cm H2O via a nasal mask every night for three months, also with medical treatment for control of obesity, optimal medical treatment for diabetes mellitus.
2453089|NCT03220789|Experimental|Biologic drilling drilling at low speed|Procedure/Surgery: Drilling at low speed
2453091|NCT03220789|Active Comparator|conventional drilling drilling at convention|Procedure/Surgery: Drilling at conventional or high speed
3190412|NCT00787280|Experimental|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
2453263|NCT03219411|Active Comparator|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times daily over 12 weeks
2453264|NCT03219411|Placebo Comparator|Placebo|Placebo administered orally as capsules three times daily over 12 weeks
2453343|NCT03219086|Active Comparator|Group M|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
3190413|NCT00787293|Experimental|1|Patient is screened for study and given baseline assessments. Pending fulfillment of study eligibility criteria, patient is implanted with PTMA system.
3190414|NCT00787306|Experimental|Multi-faceted Cardiovascular Decision Support|Risk factor active surveillance, multi-disciplinary disease management and decision aid intervention
3190415|NCT00787306|Other|Control Usual Care|Usual care in a wait-list control arm that receives the experimental intervention after 6 months.
3208562|NCT00975962|Active Comparator|Thrombolysis|Thrombolysis without pretreatment with remote perconditioning
2451931|NCT03228407|Active Comparator|Non-erosive reflux disease (NERD)|Patient's with GERD refractory to PPI with no evidence of erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
2451934|NCT03228407|Active Comparator|Barrett's esophagus/erosive esophagitis|Patient's with Barrett's esophagus or with erosive esophagitis on endoscopy. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
2451939|NCT03228407|Placebo Comparator|Control|Patient's with no h/o GERD or Barrett's esophagus who are undergoing endoscopy for non-GERD related indication. Confocal endomicroscopy, endoscopic biopsies and mucosal impedance (MI) will be performed.
3190416|NCT00787345|Other|Surgery residents|general surgery residents undergoing evaluation and training in MBP during CVC placement as per department policy are eligible for the study.
2452183|NCT03226925|Experimental|Healthy volunteers on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 healthy volunteers under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2452188|NCT03226925|Experimental|Cancer patients on ventilation|Dynamic MRI acquisition will be performed at two different time points with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2452191|NCT03226925|Experimental|Planning with patients on ventilation|Planning 4D-CT will be performed with 10 patients (intended for a radiation treatment of their thoracic or upper abdominal tumours) under non-invasive mechanically-assisted ventilation with a respirator. Different ventilation modes will be compared (spontaneous, physiologic, shallow, slow and jet ventilation).
2452250|NCT03226327|Experimental|hypertension patients|
2452275|NCT03226028|Experimental|Music|"The recruiter will give the patient an ipod with earphone, in which the ipod is equipped with saved playlists of different music genres. Patient will choose the desired playlists and listen to the music for about 30 minutes, seated in a quiet environment in pre-operative waiting area before her turn for the scheduled surgery. Hospital Anxiety and Depression Scale (HADS) and EQ-5D-3L questionnaire will be conducted during this period.~Patient will be sent to the recovery room after the surgery, and will start the music listening again for 30 minutes once she is ready and feel comfortable to start the session. Pain score, HADS and EQ-5D-3L will be collected from the patient, as well as interview on her satisfaction and experience on the music listening."
2452329|NCT03225729|Experimental|CRYOBEAUTY MAINS ET DECOLLETE|"CRYOBEAUTY MAINS ET DECOLLETE is a new technology conceived to treat solar lentigo.~One side left, or right of neckline and/or hands is attributed to this device according to randomization protocol."
2452333|NCT03225729|Active Comparator|Liquid nitrogen|Liquid nitrogen is a classic cryotherapy device. One side, either left or right of neckline and/or hands are attributed to this device according to randomization protocol.
2452386|NCT03225261|Experimental|Citrus extract|Citrus extract
2452388|NCT03225261|Placebo Comparator|Placebo|Maltodextrin
2452481|NCT03224871|Experimental|Nivolumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Nivolumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks.
2452485|NCT03224871|Experimental|Pembrolizumab|Intralesional IL-2, Radiotherapy will be given to all patients. Immune checkpoint blockade with Pembrolizumab will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks.
2452516|NCT03224117|Placebo Comparator|Placebo|SQ injection
2452518|NCT03224117|Experimental|DWJ211_0.5%|SQ injection with DWJ211 0.5%
2452520|NCT03224117|Experimental|DWJ211_1%|SQ injection with DWJ211 1.0%
2452521|NCT03224117|Experimental|DWJ211_2%|SQ injection with DWJ211 2.0%
2452558|NCT03224026||Fever Without Source|Clinical diagnosis of FWS (fever of less than 7 days with no cause determined by the history and the physical exam).
2452559|NCT03224026||Healthy control|Children visiting the hospital due to a non-infectious, non inflammatory etiology
3153898|NCT00286208|Active Comparator|Oral Misoprostol|Misoprostol administered orally
3153899|NCT00286273|Active Comparator|citrate|regional anticoagulation with citrate
2452688|NCT03223363|Experimental|Development Group|Development Group is used to establish the prediction model.2D and 3D ultrasonography are performed in this group. Through statistical analysis we obtain a new model.
2452689|NCT03223363|Other|Validation group|Validation Group is used to confirm the efficacy of the prediction model.2D and 3D ultrasonography are performed in this group.Absolute and percentage error are calculated and compared with a common formula to confirm the accuracy of this new model.
2452780|NCT03222700||robotic thyroidectomy group|
2452785|NCT03222700||open thyroidectomy group|
2452845|NCT03222323|Experimental|Perineural dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml 100ug/ml dexmedetomidine perineurally
2452850|NCT03222323|Active Comparator|Systemic dexmedetomidine|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally + 100ug dexmedetomidine systemically (absorbed and redistributed from the opposite ulnar nerve block)
2452858|NCT03222323|Placebo Comparator|Placebo|Ulnar nerve block 4ml ropivacaine 5mg/ml + 1ml isotonic saline (placebo) perineurally
2452862|NCT03222323|Active Comparator|High dose Ropivacaine|Ulnar nerve block 4ml ropivacaine 7.5mg/ml + 1ml isotonic saline (placebo) perineurally
2452936|NCT03221751|Experimental|Prazosin|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
2452940|NCT03221751|Placebo Comparator|Placebo|Subjects will be titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose is 5 mg in the morning, 5 mg in the afternoon and 15 mg at bedtime.
2452989|NCT03221231|Experimental|N-acetylcysteine|
2452997|NCT03221231|Placebo Comparator|Placebo|
2453002|NCT03221231|Active Comparator|Healthy controls|
3153900|NCT00286273|Active Comparator|nadroparin|nadroparin is a low molecular weight heparin
3190417|NCT00787358|Active Comparator|ZT-031|
2451932|NCT03228758|Active Comparator|Posterior Orientation|"The posterior endoscopic myotomy of the lower esophageal sphincter will be performed between the 5 o'clock to 6 o'clock position in the esophagus determined by the usual endoscopic convention of 12 o'clock representing the most anterior aspect of the esophagus on endoluminal view.~Intervention is the endoscopic myotomy of the lower esophageal sphincter."
2452004|NCT03228030|Experimental|Thiamine mononitrate 500mg po daily|3 months on thiamine, followed by 6 week washout period, and then 3 months on placebo arm
2452006|NCT03228030|Placebo Comparator|Placebo|3 months on placebo, followed by 6 week washout period, and then 3 months on thiamine
3190418|NCT00787358|Placebo Comparator|Placebo|
3190419|NCT00787371|Experimental|0.25 Dose Group|PegIntron 0.25 mcg/kg SC QW for 12 weeks
2452224|NCT03227250||GPI DBS|patients who had freezing of gait and underwent deep brain stimulation (DBS) of the globus pallidus interna (GPi)
2452253|NCT03226210|Experimental|NovoRapid group (group Asp)|
2452254|NCT03226210|Experimental|Prandilin group (group Lis)|
2452300|NCT03225950||Chronic periodontitis donors|"Donors are medically healthy.~Slow to moderate attachment loss and bone destruction.~Good correlation between etiological factors and serverity of attachment loss."
2452301|NCT03225950||Aggressive periodontitis donors|"Donors are medically healthy.~Rapid attachment loss and bone destruction.~Familial aggregation.~No correlation between etiological factors and serverity of attachment loss."
2452303|NCT03225950||Control donors|"Donors are medically healthy.~No sign of inflammatory conditions."
2452356|NCT03225521|Experimental|HeartSteps intervention|"For activity suggestions, at each available decision time, each participant is randomly assigned to either receive an activity suggestion or not. The randomization probability is 0.6 for receiving a message and 0.4 for not receiving a message.~For activity planning, at each decision point, the participant is randomized to either receive evening planning or not at that decision time. The randomization probability for receiving planning is 0.5, and 0.5 for not receiving planning."
2452407|NCT03225235|Experimental|Hypofractionated Stereotactic SBRT|"By assuming a hypofractionated irradiation scheme, it is assumed that between the fractions sublethal radiation damage is being treated and the time factor does not significantly affect RT result. The SBRT fractional dose was determined on the basis of a Biologically Effective Dose (BED) calculation using a linear-square model, which assumes that α / β takes the following values for:~tumor (RS) = 1.5~Late rectal and bladder complications = 3.0~early rectal and bladder complications = 10.0."
2452436|NCT03224650||Surgical|Patients treated surgically for spinal metastases
2452437|NCT03224650||Non-operative|Patients treated non-operatively for spinal metastases
2452438|NCT03224650||Expectant|Patients receiving no treatment for spinal metastases
2452494|NCT03224494|Other|IBS Patients|"Patients 18 years or older with a diagnosis of irritable bowel symptom, as per Rome IV criteria. The diagnosis is established by the patient's gastroenterologist. Please see inclusion and exclusion section for more details.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
2452495|NCT03224494|Other|Healthy Controls|"Patients 18 years of age without IBS or other colo-rectal symptoms or pathology seen for other issues in the general GI clinic.~They will undergo Rapid Barostat Bag testing, and they will answer the IBS severity scoring system questionnaire (IBS-SSS) and HAD scale questionnaire."
2452525|NCT03224104|Experimental|Group A - TG02 + RT|Elderly patients with IDH1R132H-non mutant and MGMT promoter-unmethylated anaplastic astrocytoma or glioblastoma who will receive TG02 and radiation therapy.
2452534|NCT03224104|Experimental|Group B - TG02 + TMZ|Elderly patients with IDH1R132H-non mutant and MGMT promoter-methylated anaplastic astrocytoma or glioblastoma who will receive TG02 and temozolomide.
2452545|NCT03224104|Experimental|Group C - TG02|Patients initially diagnosed with anaplastic astrocytoma or glioblastoma at first relapse post TMZ/RT --> TMZ therapy who will receive TG02.
2452649|NCT03223506|Experimental|Paracetamol arm|Administration of 10 mg/ml of paracetamol
2452699|NCT03223324||Pre Term and Threatened Pre-Term Labor|abdominal fetal/maternal monitoring
2452741|NCT03222960|Experimental|Propolis-containing toothpaste|Assessment of caries risk for participants using Propolis-containing toothpaste before the treatment , after 3 months and 6 months follow up.
2452745|NCT03222960|Experimental|Fluoride-containing toothpaste|Assessment of caries risk for participants using Fluoride-containing toothpaste before the treatment , after 3 months and 6 months follow up.
2452768|NCT03222544|Experimental|Photodynamic Therapy|The photosensitizer, methylene blue, is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photodynamic therapy is applied once a day for a total of seven times.
2452772|NCT03222544|Active Comparator|Photon therapy|The placebo is applied topically to the ulcer surface and the ulcer was shielded from light for 15 min. Then the ulcer area is illuminated using a photon therapy instrument for 20 minutes. Photon therapy is applied once a day for a total of seven times.
2452830|NCT03222388||IIEF5 paper-electronic|
2452831|NCT03222388||IIEF5 electronic-paper|
2452832|NCT03222388||IIEF15 paper-electronic|
2452833|NCT03222388||IIEF15 electronic-paper|
2452836|NCT03222388||IIEF5 electronic-electronic|
2452838|NCT03222388||IIEF15 electronic-electronic|
2452913|NCT03221946|Active Comparator|Diclofenac sodium oral|Group A which included 30 patients of either gender. Dosage drug: Diclofenac sodium Dosage form: Oral medication Frequency: twice daily Dose: 50mg Duration: 2 days
2452914|NCT03221946|Experimental|diclofenac sodium patch|Group B which included 30 patients who were prescribed Drug: Diclofenac sodium Dose: 100mg Drug form: transdermal patch to equate the oral dosage of 50mg Duration: for 2 days Frequency: Once daily
2452915|NCT03221946|Other|Diclofenac sodium injection|Group C which included 30 patients of either gender Drug: diclofenac sodium intra muscular injections Dose: 75mg which was the nearest available dosage to 100 mg availability in India Frequency: once daily Duration: for 2 days
2452932|NCT03221413|Experimental|PD tACS|Persons with Parkinson disease who will be treated with tACS: Intervention: tACS (transcranial alternating current stimulation)
3190420|NCT00787371|Experimental|0.5 Dose Group|PegIntron 0.5 mcg/kg SC QW for 12 weeks
3190421|NCT00787371|Experimental|1.0 Dose Group|PegIntron 1.0 mcg/kg SC QW for 12 weeks
2451961|NCT03228381|Experimental|BOSS Device|Patients who are undergoing open chest cardiac surgery via sternotomy will receive the BOSS device to assess acute anatomical and geometric annular and ventricular changes that occur when strategically positioned an external inflatable chambers are applied to the outside of the heart.
2452059|NCT03227887|Active Comparator|Good chewing ability|
2452063|NCT03227887|Experimental|Impaired chewing ability|
2452089|NCT03227419|Experimental|Tocilizumab Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
2452099|NCT03227419|Experimental|Abatacept Prefilled Syringe|"Market approval recommendations will be respected. Treatment should be started within 7 days of randomization.~The treatment protocol has no specific provision for treatment adaptation. Treatment will be managed in compliance with the marketing approval recommendations and drug labeling described below."
2452168|NCT03227055||CKD|Children and adolescents with stage G1-G4 CKD, age 3 to 18 yr
2452196|NCT03226613|Experimental|Patients with suspected or known oropharyngeal cancer|Patients with either known or suspected oropharyngeal cancer will be asked to undergo a transcervical ultrasound and to provide a blood and oral rinse specimen.
2452249|NCT03226340|Experimental|S-amlodipine + Chlorthalidone|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
2452251|NCT03226340|Active Comparator|S-amlodipine + Telmisartan|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
2452267|NCT03225937|Experimental|Cohort A|Trastuzumab and lapatinib
2452269|NCT03225937|Experimental|Cohort B|Pertuzumab and Trastuzumab-emtansine
2452330|NCT03225664|Experimental|Treatment (trametinib, pembrolizumab)|Patients receive trametinib PO QD 14 days prior to cycle 1 and days 1-10 of each course (10 days on, 11 days off). Beginning in cycle 2, participants also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2452384|NCT03225040||Acromegaly patients on pegvisomant|25 subjects with acromegaly on pegvisomant therapy with a normal IGF-1 level for at least 1 year.
2452446|NCT03224897|Active Comparator|Cathodal tDCS|
2452447|NCT03224897|Active Comparator|Anodal tDCS|
2452449|NCT03224897|Sham Comparator|Sham tDCS|
3190422|NCT00787371|No Intervention|No-treatment Control|No treatment (no placebo)
3190423|NCT00787384|Experimental|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib was discontinued after 12 total weeks of therapy.
2452614|NCT03223701|Other|Treatment group|The group will consist of 10 patients who would be examined for fusion rates of Transforaminal Lumbar Interbody Fusion with a standalone lumbar implant device and Solum IV and the patient's bone marrow concentrate and general fluid concentrate.
2452664|NCT03223532|Active Comparator|PrePex Day 7 FRP|"Standard PrePex procedure, 1 week after device placement foreskin and device are removed.~*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision"
2452666|NCT03223532|Experimental|PrePex Day 0 FRP|On the day of device placement the foreskin is removed, the device is removed 1 week later.
2452708|NCT03223168|Experimental|Hayek RTX ventilator|Participants will receive noninvasive negative pressure ventilation.
2452758|NCT03222908|No Intervention|Control: Prescriptive Advice|Amenable patients will be enrolled into the study, their intervention will be current standard of care smoking cessation counseling by their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2452759|NCT03222908|Experimental|Intervention1: Contract Agreement|Amenable patients will be enrolled into the study, their intervention will be a smoking cessation contract with their surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2452760|NCT03222908|Experimental|Intervention2: Implementation Intentions|Amenable patients will be enrolled into the study, their intervention will be a worksheet to fill out with their smoking cessation implementation intentions that will be signed by patient and surgeon, they will undergo 3 urine tests and a chart review for outcomes.
2452805|NCT03222453|Experimental|Intervention Patient|Hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells.
2452808|NCT03222453|No Intervention|non-intervention Patient|No treatment
2452834|NCT03222206|Experimental|Salsalate|17 patients received continuous medication with salsalate 2g/day after run-in period
2452837|NCT03222206|Placebo Comparator|Placebo|17 patients received continuous medication with Placebo 2g/day after run-in period
2452916|NCT03221985|Other|Questionnaires|
2452982|NCT03221439|Experimental|Cognitive Functional Therapy|Cognitive Functional Therapy (CFT) is a behavioral intervention that addresses multiple aspects of low back pain. This approach focuses on changing the patient's beliefs, confronting their fears, educating them about pain mechanisms, increasing mental strength, and control of their body. This is done with functional tasks performed by individuals training them to reduce excessive muscle activity in the trunk and generate behavioral changes related to pain, from postures and provocative movements.
2452984|NCT03221439|Active Comparator|Manual Therapy and Exercise|The active comparator will be the combination of manual therapy and motor control exercises.
2453064|NCT03220893||Women with Dense Breast Tissue|"Subjects will have had heterogeneously dense or extremely dense breasts on most recent prior mammographic examination (Breast Imaging Reporting and Data System (BI-RADS) c or d) and be asymptomatic for breast disease.~Subjects will receive Molecular Breast Imaging (MBI) and Digital Breast Tomosynthesis (DBT) at Year 0 screening within a 24-hour period. All patients who did not receive a diagnosis of breast cancer during the Year 0 screening will undergo DBT and MBI at approximately one year (Year 1 screening), again within a 24-hour period."
2453112|NCT03220360|Experimental|indirect pulp capping group|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2453166|NCT03220126|Experimental|LY900021 - Treatment 3|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
2451976|NCT03228095||Gastric cancer|Patients with histologically confirmed gastric cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Feacal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical speciment
2451979|NCT03228095||Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
2451981|NCT03228095||High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, Stage III-IV according to OLGA (Operative Link for Gastric Atrophy Assessment), and those with incomplete type of intestinal metaplasia, but excluding those with dysplasia Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen Intervention: Headspace analysis for biological material
2451983|NCT03228095||Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Upper endoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2451984|NCT03228095||Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma) Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
2451985|NCT03228095||Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Procedure/Surgery: Histological examination of surgical specimen
2451986|NCT03228095||Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2451987|NCT03228095||Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Colonoscopy with biopsies Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material Intervention: Procedure/Surgery: Histological examination of surgical specimen
2451988|NCT03228095||Average risk general population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Diagnostic Test: Fecal sampling Intervention: Headspace analysis for biological material
2451989|NCT03228095||Pancreatic cancer|Patients with histologically confirmed pancreatic cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2451990|NCT03228095||Chronic pancreatitis|Patients with clinically and/or histologically and/or radiologically confirmed chronic pancreatitis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2451991|NCT03228095||Liver cancer|Patients with histologically confirmed primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2451992|NCT03228095||Chronic liver disease|Patients with histologically confirmed liver cirrhosis of viral or other ethiology Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2451993|NCT03228095||Upper respiratory tract acute infections|Patients with serologically confirmed infectious disease or individuals of high risk (e.g. population in season of flu epidemy). This group does not include tuberculosis Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
2451994|NCT03228095||Oncological diseases of other locations|Patients with histologically confirmed oncological diseases, excluding gastric, colorectal, pancreatic and primary liver cancer Intervention: Diagnostic Test: Breath sampling Intervention: Procedure/Surgery: Whole blood/ Plasma / serum sampling Intervention: Headspace analysis for biological material
3190424|NCT00787397|Experimental|1. Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy-Sleep
3190425|NCT00787410|Experimental|1|
2452284|NCT03226093|Experimental|Stromal Vascular Fraction|Isolation of SVF from fat tissue for re-administration into the same patient
2452378|NCT03225339|Experimental|Lifestyle Intervention|The intervention includes the use of Low Energy Diet replacement products in combination with physical activity, followed by gradual introduction of food, and increasing physical activity. Behavioural support for the lifestyle intervention will also be provided.
2452379|NCT03225339|No Intervention|Usual Care|This will be based on current clinical practice aiming to reduce diabetes symptoms and complications, and general recommendations on diet and physical activity.
2452424|NCT03224975|Experimental|patients|Patient who was burned will have fMRI.
2452425|NCT03224975|Active Comparator|control group|Healthy volunteers (control group) will have fMRI.
3190426|NCT00787436|No Intervention|1|Standard of care with normal treatment
2452153|NCT03227237||Control group|Introduction was given about research and researcher to participants. Confirmed telephonic consent from Parents.Collected baseline data (demographic variable, specific IPR variable) from the participants.Collected data about IPR on the basis of Modified Washington State Juvenile Court Assessment Scale from the participants. Participants were asked to fill out IPR related information of their past life from before 2 years with paper & pencil mode of technique. It took for each group of participants about 40 minutes. On each day 8-20 participants were covered Got the written consent form parents and collected data regarding conduct variables from parents with interview technique.
2452235|NCT03226522|Experimental|AXS-05|AXS-05 tablets taken by mouth for 5 weeks.
2452238|NCT03226522|Active Comparator|Bupropion|Bupropion tablets taken by mouth for 5 weeks.
2452239|NCT03226522|Placebo Comparator|Placebo|Placebo tablets taken by mouth for 5 weeks.
2452312|NCT03225742||urinary catheterization time; one day|the patient urinary catheterization after surgery; one day
2452313|NCT03225742||urinary catheterization time; two day|the patient urinary catheterization after surgery; two day
2452415|NCT03225274|Experimental|Experimental Group|Experimental Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then after 5 minutes of administration of Nebulization, breathing exercises as therapeutic play (balloon inflation, candle blowing, blow air into water with a straw was administered for 15 minutes once in a day for 3 days consecutively and then post-assessment was taken daily 5 minutes after the administration of breathing exercises as therapeutic play.
2452422|NCT03225274|No Intervention|Comparison Group|Comparison Group consist of 30 subjects. Pre-assessment of respiratory status among children was assessed. Then only nebulization therapy was administered and then post-assessment was taken daily after 25 minutes of administered.
2452484|NCT03224741|Placebo Comparator|Information|
2452488|NCT03224741|Active Comparator|Active Choice|
2452491|NCT03224741|Experimental|Monetary incentive|
2452529|NCT03224156||Dilated Cardiomyopathy|
2452656|NCT03223896|Active Comparator|Group A|max 8 mg/per day naloxone nasal spray
2452657|NCT03223896|Active Comparator|Group B|max 16 mg/per day naloxone nasal spray
2452675|NCT03223220|Experimental|Study Drug|Will receive Ketamine infusion, and Midazolam (Versed).
2452677|NCT03223220|Placebo Comparator|Placebo|Will receive Normal saline infusion and Midazolam (Versed).
2452717|NCT03223064|Experimental|PSMA PET-CT and USPIO MRI|
2452774|NCT03222739|Other|Device Arm|This is a single arm study comparing an ultrasound with the industry standard of x-ray to detect and monitor scoliosis curvature.
3190427|NCT00787436|Active Comparator|Thalidomide|Standard of care and treatment using Thalidomide
3190428|NCT00787462|Active Comparator|Active|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
3208563|NCT00975988||TYKERB® tablets|There is only one group. This group includes patients administrated TYKERB® tablets
2453001|NCT03221400|Experimental|Phase 1a PEN-866 Sodium (Single Agent)|Dose escalation of PEN-866 Sodium administered intravenously
2453006|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Flurouracil + Folinic Acid|Dose escalation of intravenous administration of PEN-866 Sodium in combination with fluorouracil and folinic acid
2453007|NCT03221400|Experimental|Phase 2a PEN-866 Sodium (Single Agent)|Intravenously administered PEN-866 Sodium at the Recommended Phase 2 Dose
2453008|NCT03221400|Experimental|Phase 1b PEN-866 Sodium + Niraparib|Dose escalation of intravenous administration of PEN-866 Sodium in combination with niraparib
2453069|NCT03220672|Experimental|Expertimental|The sample will receive a tailored assessment and educational intervention on Motor Control of the Pelvic Floor Muscle
3208564|NCT00976001|Other|Follow-up at an out-patient stroke unit|Information, measurement of handicap, further rehabilitation efforts, drug therapy for secondary prevention of stroke.
3208565|NCT00976001|Other|Follow-up with the general practitioner|
2453190|NCT03219762|Experimental|Nab-paclitaxel|Nab-paclitaxel (30-min infusion) 100 mg/sqm weekly on days 1, 8, 15 q 28 days.
2453251|NCT03219398|Active Comparator|8-10 mmHg|Patients receive lower pneumoperitoneum pressure
2453254|NCT03219398|Active Comparator|12-14 mmHg|Patients receive higher pneumoperitoneum pressure
2453286|NCT03219177|Experimental|Patient education group|
2453287|NCT03219177|Active Comparator|Control- Standard of care counseling|
2453339|NCT03218891|Experimental|Clinical treatment physical training|"Patients with optimized clinical treatment group that will do physical training for 12 weeks. They will do the tests in moment 1 and after 3 mounths.~The intervention is the Cardiac Rehabilitation."
2453340|NCT03218891|No Intervention|Optimized clinical treatment|Patients with optimized clinical treatment group that will not do physical training.They will do the tests in moment 1 and after 3 mounths.
2453342|NCT03218891|No Intervention|Coronary insufficiency without angina|Group with coronary insufficiency without angina and will not do physical training. They will do the tests only one moment.
2453345|NCT03218891|No Intervention|Normal healthy subjects|Group normal healthy subjects, without coronary injuries, diabetes, hypertension and another chronic disease. These group have be sedentary and will not do physical training. They will do the tests only one moment.
2453423|NCT03218228|Placebo Comparator|implants in healthy individuals|immediate placement of dental implants in individuals with healthy periodontium. the device is dental implants, radiographs, william's periodontal probe
2453433|NCT03218228|Experimental|implants in periodontitis patients|immediate implantation in patients suffering from aggressive periodontitis. the device is the dental implants, radiographs, william's periodontal probe
2453525|NCT03217617|Experimental|Single arm|Gene transfer to treat SCID-X1
2452157|NCT03227068|Experimental|PEDSS - support for the caregiver|Content for the PEDSS - support for the caregiver includes five topics and suggestions on how caregivers can care for themselves during this time.
2452184|NCT03226743|Experimental|Intervention Group|collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network
2452187|NCT03226743|No Intervention|Control Group|treatment as usual in German health care system
2452291|NCT03225885|Active Comparator|Printed Handout|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as a printed gestational age specific handout about prematurity.
2452296|NCT03225885|Experimental|Multimedia Information|Participants in this arm will receive verbal prematurity counseling from a Neonatologist or Neonatal fellow as well as have bedside access to iPad multimedia information regarding prematurity.
2452338|NCT03225612|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 60 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
2452403|NCT03224988||Normal Adults|
2452411|NCT03224988||MCI Adults|
2452439|NCT03224689|Experimental|PEEK Femoral|Subjects with a primary diagnosis of end-stage symptomatic primary knee osteoarthritis who require a uni-lateral knee prosthesis and have been evaluated as appropriate candidates for a total knee arthroplasty by the Investigator will be invited to take part in this clinical investigation.
2452496|NCT03224481|Experimental|Receive electronic reminder|Participants in the intervention group will receive tailored electronic reminders. The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
2452497|NCT03224481|No Intervention|Control group|Participants in the control group will not receive additional reminders.
2452533|NCT03224143|Experimental|Doll Therapy Intervention (DTI)|"The DTI involves the presentation of a doll produced by a Swedish brand and conceived for Doll Therapy use. It is designed to recreate the sensation of touching, looking and holding a child in the arms. The doll presentation involves five standard steps:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the object (doll or cube) to the patient.~The nurse leaves the patient alone with the object.~Interaction with the object: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the object."
2452544|NCT03224143|Active Comparator|Active control group (SI)|"The SI involves the presentation of a non-anthropomorphic object, a soft foam rubber cube covered with a coloured and velvety textile. The procedure is the following:~A nurse (whom the patient knows) accompanies the patient in the room and invites her to sit on the chair.~The nurse presents the cube to the patient.~The nurse leaves the patient alone with the cube.~Interaction with the cube: it lasts 3 minutes starting from the moment when the nurse leaves the room. This phase is interrupted if the patient drops the object before the time limit.~The nurse returns into the room and takes back the cube."
2452597|NCT03223779|Experimental|TAS-102|"Photon treatments will be performed on a linear accelerator~Photon SBRT will be given during TAS-102 dosing~TAS-102 dosing occurs on days 1 through 5 and 8 through 12~TAS-102 tablets should be taken twice a day orally"
3153901|NCT00286299|Experimental|Aerobic interval training (AIT)|AIT is 4x4 minutes interval training on a treadmill at 85 to 95 % HRpeak interspersed with 3 min of active resting periods at a work load corresponding to 70 % HRpeak between each interval. Patients performed the intervals walking or running with a minimum of 5 % inclination.
3153902|NCT00286299|Active Comparator|Computer game training (CG)|36 minutes playing supervised computer games, Tetris, Xbox
2452778|NCT03222726|Active Comparator|exercise group|6000 steps/day or 40,000 steps/week
2452781|NCT03222726|Other|less-exercise group|less than 6000 steps/day or 40,000 steps/week
2452853|NCT03222297||test group|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
2452859|NCT03222297||control group|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
2452909|NCT03221907|Experimental|GLA5PR GLARS-NF1 & Pregabalin placebo|GLA5PR GLARS-NF1 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin placebo 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
2452910|NCT03221907|Active Comparator|GLA5PR GLARS-NF1 placebo & Pregabalin|GLA5PR GLARS-NF1 placebo 150mg, 300mg tablet by mouth, every after dinner for about 3 months Pregabalin 75mg, 150mg, 300mg capsules by mouth, every after breakfast and dinner for about 3 months
2452964|NCT03221361|Placebo Comparator|conventional acrylic resin group|conventional acrylic resin complete denture placement is done
2453024|NCT03221075||Invasive Aspergillosis|
3153903|NCT00286299|Experimental|Maximal strength training (MST)|MST is performed in a leg press machine. The weight is lowered in a controlled manner in the eccentric phase until the patient reached 90 degrees in the knee joint. Then the patients has a short stop (~0.5 second) before the weight is moved as rapidly as possible to complete extension. The training volume is 4 sets of 4RM (i.e. 85-90 % 1RM). The training load is increased with 2.5-5 kg each time patients managed to perform 4 sets with the determined load or each training session.
3153904|NCT00286481|Experimental|Lapaquistat Acetate 50 mg QD + Simvastatin|
3153905|NCT00286481|Experimental|Lapaquistat Acetate 100 mg QD + Simvastatin|
3153906|NCT00286481|Active Comparator|Simvastatin|
3153907|NCT00286507|Active Comparator|ILM peeling|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with ILM peeling
3153908|NCT00286507|Active Comparator|No ILM peeling|combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas without ILM peeling
2452162|NCT03226860|Active Comparator|Ready, Set, Go! 5210 program|Nationwide Initiative which recommends eating 5 servings a day of fruits and vegetables, 2 hours a day or less of screen time, 1 hour/day or more of physical activity, and 0 sugary drinks/day. This program supports the current focus in pediatric physical therapy on life-long fitness in youth with disabilities.
3153909|NCT00286533|Experimental|Placed implants|
2452266|NCT03226106|Experimental|Physical Activity Behavior Intervention|A 12-week behavior change intervention that supplements conventional rehabilitation including: 10 telerehabilitation sessions, daily activity sensor use, education, self-monitoring, tailored feedback, barrier/facilitator identification, promotion of problem solving, action planning, and encouragement.
2452268|NCT03226106|Active Comparator|Attention Control|Conventional rehabilitation with 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
2452334|NCT03225794||Controls|Adults living in rural area of Cameroon, not infected with simian foamy viruses
2452341|NCT03225794||Simian Foamy virus infection|Adults living in rural area of Cameroon, infected with simian foamy viruses
2452392|NCT03225248|Experimental|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
2452399|NCT03225248|Active Comparator|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
2452894|NCT03221855|Active Comparator|Domperidone|Domperidone 10mg every 8 hours for 7 days.
2452898|NCT03221855|Placebo Comparator|Placebo|Placebo 10mg every 8 hours for 7 days.
2452958|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV/HIV co-infected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
2452959|NCT03221582|Experimental|EBR/GZR (Zepatier) - HCV monoinfected|Drug: Elbasvir (EBR) 50 mg and Grazoprevir (GZR) 100 mg single tablet by mouth, once daily.
2452974|NCT03221088|Experimental|Jintrolong® low dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
2452975|NCT03221088|Experimental|Jintrolong® high dose group|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
2452976|NCT03221088|No Intervention|Negative control group|Untreated Control Group
2453060|NCT03220880||Intranasal dexmedetomidine|Intranasal dexmedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
2453233|NCT03220074|Other|treatment|oral linezolid tablet 600 mg /day combine with either oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)
2453273|NCT03219346|Experimental|Oral hygiene|
2453365|NCT03218644|Active Comparator|Control group|Follow the usual treatment and perform the exercises of cervical mobility before a mirror.
2453371|NCT03218644|Experimental|Experimental group|The same procedure is followed by substituting proprioceptive exercises for craniocervical sensorimotor control with a laser instrument located on the patient's head and a target.
2453418|NCT03218384|Experimental|ferric carboxymaltose|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
2453424|NCT03218384|Active Comparator|Placebo|32 eligible subjects will be randomly assigned (1:1) to ferric carboxymaltose 750 mg or placebo (normal saline)
2453465|NCT03217838|Experimental|Part A - Group 1 Arm A: Monotherapy Dose Escalation|AZD2811 single agent on Days 1 and 4 of each 28 day cycle. Dose escalation
2453466|NCT03217838|Experimental|Part A - Group 1 Arm B: Monotherapy Dose Escalation|AZD2811 single agent on Days 1, 4, 15, and 18 of each 28 day cycle. Dose Escalation
2453468|NCT03217838|Experimental|Part A - Group 2 Arm A: AZD2811 plus Azacitidine Dose Escalation|AZD2811 on Days 1 and 4 plus Azacitidine combination therapy. Escalating doses of AZD2811
2453472|NCT03217838|Experimental|Part A - Group 3 Arm A: AZD2811 plus Venetoclax Dose Escalation|AZD2811on Days 1 and 4 plus Venetoclax combination therapy. Escalating doses of AZD2811
2453475|NCT03217838|Experimental|Part B - Group 1: AZD2811 Monotherapy Dose Expansion|Monotherapy dose expansion. Additional patients will be enrolled at the AZD2811 MTD in the dose/schedule that was found most tolerable and/or efficacious.
2453476|NCT03217838|Experimental|Part B - Group 2: AZD2811 plus Combination Drug Dose Expansion|Combination therapy (either azacitidine or venetoclax) dose expansion. Additional patients will be enrolled at the AZD2811 combination MTD based on the dose/schedule from Part A that was found to be most tolerable and/or efficacious.
2453477|NCT03217838|Experimental|Part A - Group 2 Arm B: AZD2811 plus Azacitidine Dose Escalation|AZD2811 on Days 1, 4, 15, and 18 plus azacitidine combination therapy. Escalating doses of AZD2811
2453479|NCT03217838|Experimental|Part A - Group 3 Arm B: AZD2811 plus Venetoclax Dose Escalation|AZD2811 on Days 1, 4, 15, and 18 plus Venetoclax combination therapy. Escalating doses of AZD2811
2453587|NCT03217032|Experimental|YUVA-GT-F801|Gene transfer to treat Hemophilia A
3153910|NCT00286585|Active Comparator|Inhalational anesthetic|Sevoflurane will be used as the main anesthetic in this arm, and no propofol will be administered
3153911|NCT00286585|Active Comparator|Intravenous anesthetic, propofol|Propofol will be used as the main anesthetic in this arm, and no inhalational anesthetic will be administered
3153912|NCT00286598|Experimental|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
3153913|NCT00286598|No Intervention|Control|Usual care
3153914|NCT00286611||Amifostine|Those individuals enrolled who have received amifostine as part of standard care.
3153915|NCT00286624|Experimental|1|Allogeneic islet transplantation with anti-thymocyte globulin induction and cyclosporine and RAD maintenance immunosuppression
3153916|NCT00286780|Experimental|1|
3153917|NCT00286793|Experimental|SIngle Arm Study of AT-101 in combination with Docetaxel|
2452173|NCT03226756|Experimental|Nivolumab|All patients enrolled in the study will received Nivolumab injections, 3mg/kg IV, every 2 weeks, up to 12 cycles (1 cycle = 28 days).
2452369|NCT03225365|Other|Nivolumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab treatment.~30 patients will be included in the arm."
2452371|NCT03225365|Other|Nivolumab + Ipilimumab|"Previous untreated patient with metastatic melanoma eligible for a Nivolumab + Ipilimumab treatment.~30 patients will be included in the arm."
2452398|NCT03225027|Experimental|Patients with schizophrenia|Emotional judgment task, post-experimental questionnaire, recognition task, detection task, questionnaire CAPE-42, trait emotional intelligence questionnaire and positive and negative syndrome scale.
2452406|NCT03225027|Experimental|Few psychotic experiences|Healthy participants with few psychotic experience. Participants with the lowest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
2452421|NCT03225027|Experimental|Several psychotic experiences|Healthy participants with several psychotic experiences. Participants with the highest score to the CAPE-42 test. Mini International Neuropsychiatric Interview
2452450|NCT03224533||No Nuts|"All other foods that did not include walnuts or other nuts were classified as no nuts (NN)."
2452453|NCT03224533||Other Nuts|"Foods codes describing nuts that are not walnuts (i.e. cashew nuts, pistachios, etc.) or nut-containing foods that do not commonly contain walnuts (e.g. granola) were classified as other nuts (ON)."
2452457|NCT03224533||Walnuts with other nuts|"food codes describing nut mixes and foods that commonly include walnuts were classified as walnuts with other nuts (WwON)"
2452460|NCT03224533||Walnuts with high certainty|"Foods consisting entirely or mostly of walnuts were classified as walnuts with high certainty (WwHC)"
2452538|NCT03224364|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC
2452548|NCT03224364|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
2452626|NCT03223844|Experimental|Healthy subjects|Measurement of Dextroamphetamine Sulfate-induced dopamine release and synthesis before and after amphetamine sensitization.
3208568|NCT00976040|Experimental|Early antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy within 7 days of enrollment.
2452749|NCT03223012||Participants not included in the AbbVie care program|Participants receiving adalimumab not included in the AbbVie care patient support program.
2452752|NCT03223012||Participants included in the AbbVie care program|Participants receiving adalimumab included in the AbbVie care patient support program.
2452798|NCT03222479|Experimental|treatment arm|All individual is instructed to use the application we developed for 4 weeks
2452843|NCT03222258||Early palliative care for adult|Being referred to palliative care team before totally terminating their chemotherapy among adult participants.
2452844|NCT03222258||Routine hospice care for adult|Being referred to palliative care team when their last chemotherapy is ended among adult participants.
2452846|NCT03222258||Unused palliative care for adult|haven't been under the palliative care among adult participants
2452852|NCT03222258||Palliative care for pediatrics|receiving the palliative care among pediatric participants
2452857|NCT03222258||Unused palliative care for pediatrics|haven't received the palliative care among pediatric participants
2453065|NCT03220906||Arterial line|Children undergoing surgical procedure with planned arterial cannula placement.
2453124|NCT03220438|Active Comparator|TMS|rTMS
2453131|NCT03220438|Sham Comparator|Sham TMS|A sham coil will be used. This condition controls for the auditory artifacts induced by rTMS.
2453198|NCT03220009|Active Comparator|Arm I (nivolumab, ipilimumab, surgery, active surveillance)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients undergo active surveillance for 1 year."
2453210|NCT03220009|Experimental|Arm II (nivolumab, ipilimumab, surgery, nivolumab)|"PART I: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1. Within 3-6 weeks after receiving nivolumab and ipilimumab, patients undergo surgery per standard of care. Within 84 days of last surgical resection, patients may also undergo adjuvant RT, if clinically appropriate.~PART II: Patients receive nivolumab IV over 30 minutes once every 2 weeks for 4 doses. Patients then continue to receive nivolumab IV over 30 minutes once every 4 weeks for up to 11 doses in the absence of disease progression or unacceptable toxicity."
2453261|NCT03219359|Experimental|Experimental|Hematopoietic Stem Cell Transplant followed by maintenance Vedolizumab
2453289|NCT03219008|Experimental|Depression/underload 1|This group would be treated with fluoxetine from the minimum dosage.
2453291|NCT03219008|Experimental|Depression/underload 2|This group would be treated with fluoxetine combined with cognitive behavior treatment
2453292|NCT03219008|Experimental|Depression/underload 3|This group would be treated with fluoxetine and amfebutamone from the minimum dosage.
2453293|NCT03219008|Experimental|Depression/underload 4|This group would be treated with fluoxetine + physical treatment to help to cure depressive disorder.
2453294|NCT03219008|Experimental|Atypical 1|This group would be treated with fluvoxamine from the minimum dosage.
2453295|NCT03219008|Experimental|Atypical 2|This group would be treated with fluoxetine + cognitive behavior treatment
2453296|NCT03219008|Experimental|Atypical 3|This group would be treated with fluvoxamine + lithium from the minimum dosage.
2453297|NCT03219008|Experimental|Atypical 4|This group would be treated with fluvoxamine + lithium + physical treatment
2453298|NCT03219008|Experimental|Anxiety/somatization 1|This group would be treated with mirtazapine/selective serotonin-norepinephrine reuptake inhibitors（SNRIs） from the minimum dosage.
2453299|NCT03219008|Experimental|Anxiety/somatization 2|This group would be treated with mirtazapine/SNRIs + cognitive behavior treatment.
2453300|NCT03219008|Experimental|Anxiety/somatization 3|This group would be treated with mirtazapine + SNRIs from the minimum dosage.
2452315|NCT03225833|Experimental|WVE-120101 (Dose A) or placebo|
2452316|NCT03225833|Experimental|WVE-120101 (Dose B) or placebo|
2452318|NCT03225833|Experimental|WVE-120101 (Dose C) or placebo|
2452320|NCT03225833|Experimental|WVE-120101 (Dose D) or placebo|
2452322|NCT03225833|Experimental|WVE-120101 (Dose E) or placebo|
3153918|NCT00286819|Experimental|the FEC75 regimen|"Arm A: the FEC75 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles."
2452393|NCT03225014|Active Comparator|Physical Therapy|
2452400|NCT03225014|Active Comparator|ARP Wave Therapy|
2452463|NCT03224663|Experimental|Module based learning|Module based learning is self-reading method using learner's guide module on FBNC provided by Department of Pediatrics
2452467|NCT03224663|Experimental|Mobile application based learning|"Mobile application based learning is learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters, videos, Modules."
2452543|NCT03224312||Primary aldosteronism|screened, confirmed and subtyped according to the guidelines.
2452555|NCT03224312||Essential hypertension|screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion
2452593|NCT03223818|Experimental|Fast-track Arm|Patients recruited will undergo ERAS perioperative program.
2452596|NCT03223818|No Intervention|Conventional Group|Patients recruited to conventional group will undergo conventional perioperative program
2452701|NCT03223155|Experimental|Sequential Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Sequential Arm will complete SBRT to 2-4 sites and then begin treatment with nivolumab/ipilimumab between 1-7 days after completion of SBRT.
2452702|NCT03223155|Experimental|Concurrent Arm|Patients will be randomized to either the Sequential Arm or the Concurrent Arm. Patients in the Concurrent Arm will begin treatment with nivolumab/ipilimumab first and must complete planned SBRT to 2-4 sites within 2 weeks (prior to second dose of nivolumab).
2452767|NCT03222778||hypovolemia (fluid responsiveness)|The patients with fluid responsiveness (an increase in stroke volume index of ≥12%) after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
2452770|NCT03222778||NO hypovolemia (NO fluid responsiveness)|The patients without fluid responsiveness after fluid challenge using 6 ml/kg of balanced 6% hydroxyethyl starch 130/0.4 (Volulyte; Fresenius Kabi, Bad Homburg, Germany)
2452818|NCT03222440|Experimental|SHR-1210+ Radiotherapy|Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.
2453004|NCT03221322||Control|20 kg/m2 ≤ BMI ≤ 25 kg/m2, healthy, with no eating disorder, 150 subjects, 20 - 40 years old
2453005|NCT03221322||Superlean|15 kg/m2 ≤ BMI ≤ 18 kg/m2, healthy, with no eating disorder, 150 subjects, 25 - 35 years old in particular
2453066|NCT03220802|Experimental|Test group|participants receive a daily dose of OMNI-BiOTiC PPI for three months
2453129|NCT03220425|Experimental|Insulin detemir|
2453133|NCT03220425|Active Comparator|NPH insulin|
2453321|NCT03219138|No Intervention|Electromyography|Neuromuscular function was monitored, using evoked electromyography of the adductor pollicis muscle with a neuromuscular transmission module by a non-blinded investigator.
2453324|NCT03219138|Experimental|Acceleromyography|Immediately after extubation the blinded anaesthesiologist tested with an uncalibrated acceleromyography on the contralateral arm.
2453361|NCT03218696|Experimental|Cough Syrup for adults and children|CE Marked (authorized) medical device acting by protecting the oropharynx, in a non-pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris. Dosage form: syrup Dosage: 5 ml. Duration: one night
2453368|NCT03218696|Placebo Comparator|Placebo|The placebo intervention is a similar syrup of taste and colour, with general protective components and other necessary synthetic components which may have an influence on cough, without the specific natural protective components. Dosage form: syrup. Dosage: 5 ml. Duration: one night
2453432|NCT03218319|Experimental|All patients|
2453604|NCT03216863|Experimental|8 weeks Respiratory rehabilitation|
3153919|NCT00286819|Experimental|FEC90 regimen|"Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle."
3153920|NCT00286832||Single group study|
3153921|NCT00286845||II|
3153922|NCT00286845||1|
3153923|NCT00286962|Experimental|CIPII|Intraperitoneal insulin infusion by means of an implanted insulin pump
3153924|NCT00286962|Active Comparator|CSII/ MDI|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII) or by multiple daily injections (MDI)
3153925|NCT00287001|Other|1|1= cool air cooling
3153926|NCT00287040|No Intervention|1 - Usual Care|This arm looks at mammogram adherence in those individuals who at this time are not receiving booster mammogram interventions.
3153927|NCT00287040|Experimental|2. DVD Intervention|This arm will receive the initial information provided in usual care and will also receive booster mammography interventions via DVD.
3153928|NCT00287040|Experimental|3. Telephone Counseling|This arm will receive the initial information provided in usual care and receive boosters through tailored telephone counseling.
3153929|NCT00287092|Experimental|Group 1|Participants will receive PEDIACEL vaccine
3153930|NCT00287092|Active Comparator|Group 2|Participants will receive Infanrix-IPV+Hib vaccines
2452286|NCT03225976|Experimental|Red LED group (G-V)|The Light-Emitting Diode Device with a wavelength of 620nm will be applied throughout the quadriceps femoralis extension bilaterally.
2452292|NCT03225976|Sham Comparator|Sham Group (G-S)|The Sham Light-Emitting Diode Device will be positioned throughout the quadriceps femoral muscle extension, however, there will be no light emission.
2452295|NCT03225976|Experimental|Infrared plus Red LED group (G-IV)|The Light-Emitting Diode Device with a wavelength of 620nm plus 904nm will be applied throughout the quadriceps femoralis extension bilaterally.
2452335|NCT03225586||Adults|Between 35 to 70 years of age at time of enrollment
2452430|NCT03224923|Experimental|Personalized Treatment Algorithm|"A DAPT score using various patient demographics will be calculated:~If score under 2, patients will receive only aspirin 81 mg once daily~If DAPT score is ≥ 2~A point-of-care bedside genetic test using a buccal swab will be conducted in order to determine medication regimen~Those with a positive genetic test (presence of CYP2C19*2 or CYP2C19*3), will receive 60mg Ticagrelor twice daily~Those with a negative genetic test (absence of CYP2C19*2/*3) will receive 75mg clopidogrel once daily"
2452432|NCT03224923|Active Comparator|Long-Term Ticagrelor|Patients will be given 60mg Ticagrelor twice daily with no aspirin
2452464|NCT03224559||Sham Stimulation|subject receives minimal transcranial electrical stimulation
2452466|NCT03224559||Left Side Stimulation|transcranial electrical stimulation on the left side of the head.
3190429|NCT00787462|Placebo Comparator|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
3190430|NCT00787475|Experimental|1|CHW intervention
3190431|NCT00787475|No Intervention|2|Enhanced usual care (brochure mailings)
3190432|NCT00787488|Experimental|1|Chemotherapy plus Hyperthermia
2452653|NCT03223558|Experimental|early rehab group|start of 8 weeks cardiac rehabilitation 2 weeks following surgery
2452655|NCT03223558|Active Comparator|usual care group|start 8 weeks of cardiac rehabilitation 6 weeks post surgery
3190433|NCT00787501|Active Comparator|SSRIs|Selective Serotonin Reuptake Inhibitors
2452721|NCT03223116|Experimental|Radiofrequency|Radiofrequency delivery to the gastroesophageal junction
2452784|NCT03222765|Placebo Comparator|Placebo|"Placebo~Lifestyle modification (diet and physical activity recommendations)"
2452786|NCT03222765|Experimental|Metformin|"Metformin~Lifestyle modification (diet and physical activity recommendations)"
2452788|NCT03222765|Experimental|Linagliptin|"Linagliptin~Lifestyle modification (diet and physical activity recommendations)"
2452790|NCT03222765|Experimental|Linagliptin and Metformin|"Fixed dose combination of Linagliptin and metformin~Lifestyle modification (diet and physical activity recommendations)"
2452868|NCT03222219||low implant stability quotient|dental implant insertion with low torque values
2452870|NCT03222219||medium implant stability quotient|dental implant insertion with medium torque values
2452872|NCT03222219||high implant stability quotient|dental implant insertion with high torque values
2452890|NCT03221790|Experimental|Low and High FODMAP Diets in IBS|"This study will be comprised of the following four time periods: baseline, run-in, low FODMAP diet, and high FODMAP diet. Participants will undergo baseline assessment with questionnaires on demographics, IBS symptoms (IBS symptom severity scoring questionnaire), diet, and psychological parameters. Baseline mucosal colonic biopsies will be obtained, and metabolome analysis from urine samples. These will be repeated 3 other times during each of the above time periods. Low FODMAP Diet followed by a High FODMAP Diet"
2452966|NCT03221647||Controls|Intestinal biopsies from controls, affected by gastroesophageal reflux,
2452968|NCT03221647||GCD CD (Gluten Containing Diet CD)|Intestinal biopsies from GFD patients had with negative serology (anti-tTg antibodies between 0 and 1.5 U/ml and EMA negative) and normal biopsy (Marsh T0-1).
2452972|NCT03221647||GFD CD (Gluten Free Diet CD)|Intestinal biopsies from GCD-CD patients with villous atrophy (Marsh T3a-c) had positive serology (anti-tTg antibodies >30 U/ml and EMA positive) ).
2453013|NCT03221023|Experimental|Vancomycin|These patients will receive intrawound Vancomycin-saline and IV antibiotics
2453014|NCT03221023|Placebo Comparator|Saline|These patients will receive intrawound saline + IV antibiotics alone
3190434|NCT00787501|Active Comparator|CBT|Cognitive Behavior Therapy
3190435|NCT00787540||I|Coronary Slow Flow Patients
3190436|NCT00787540||II|Coronary Artery Occlusion Patients
3190437|NCT00787553|Active Comparator|cefazolin|
3190438|NCT00787553|Active Comparator|tinidazole|
3190439|NCT00787553|Active Comparator|cefazolin plus tinidazole|
3190440|NCT00787579|Active Comparator|Bifocal spectacles|
2453221|NCT03219736|Active Comparator|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. To summarize, all moderate and severe acute asthma exacerbations receive albuterol and atrovent continuous aerosols, oral or intravenous steroids and intravenous magnesium sulfate. At the discretion of the treating physician, the patient may also receive subcutaneous terbutaline or epinephrine
2453301|NCT03219008|Experimental|Anxiety/somatization 4|This group would be treated with mirtazapine + SNRIs + physical treatment.
2453711|NCT03216538|Active Comparator|AS101 1% oral solution|Daily dose 0.4 ml administered orally
3190441|NCT00787579|Active Comparator|Prismatic bifocals|
3190442|NCT00787579|No Intervention|Single vision spectacles|
3190443|NCT00787592||Silver Sulfadiazide (SSD)|Patients that receive SSD as the topical debriding agent
3190444|NCT00787592||Collagenase|Patients that receive collagenase as the debriding agent
3190445|NCT00787657||Arm 1|
3208569|NCT00976040|No Intervention|Standard antiretroviral therapy|Subjects randomized to this arm will initiate antiretroviral therapy approximately 4 weeks after enrollment.
3208570|NCT00976053|Active Comparator|SPECT myocardial perfusion imaging|
3190446|NCT00787670|Experimental|Gastric Bypass Surgery|Gastric Bypass Surgery consists of a laparoscopic approach and includes the creation of an isolated 10-15-ml proximal gastric pouch, a retro-colic, retro-gastric Roux-en-Y gastrojejunostomy with linear stapler technique, a 100-cm Roux-limb, a 30-cm biliopancreatic limb, and a stapled end-side enteroenterostomy.
2452350|NCT03225469|Experimental|reinforced family member education group|Regular instructions will be given to all patients during the colonoscopy appointment. At least one family member who lives with the patient together will be given instruction at the basis of patent education.
2452354|NCT03225469|No Intervention|regular education group|Regular instructions will be given to the patients during the colonoscopy appointment. There will be nothing specially for family members.
2452413|NCT03225222||Low-risk PCa|No TRUS-guided biopsy
2452423|NCT03225222||Intermediate/high-risk PCa (Control)|TRUS-guided biopsy 'only' (current standard practice).
2452428|NCT03225222||Intermediate/high-risk PCa (Intervention 1)|TRUS-guided biopsy 'first'; if indicated followed by MRI and targeted biopsies.
2452429|NCT03225222||Intermediate/high-risk PCa (Intervention 2)|MRI-'first', followed by TRUS-guided and targeted biopsies.
3190447|NCT00787670|Active Comparator|Diabetes Support and Education|Diabetes Support and Eduction. Subjects attend three educational/social support sessions for 1 year after enrollment. The educational sessions offered for diabetes support and education including informational sessions on diet/nutrition and exercise. These sessions are informational only and do not teach behavioral self-regulation skills. Different nutrition and exercise topics are covered each session. Education
3190448|NCT00787670|Active Comparator|Tissue Control Group|Tissue control group includes subjects who are undergoing other non-gastric bypass abdominal surgery. A pea size piece of omentum and subcutaneous fat will be collected.
3190449|NCT00787683|Experimental|Home-monitoring|Patients receive an additional home-monitoring (remote-monitoring) device (CardioMessengerII) following Biotronik Lumax ICD implantation. The device enables regular transmission and examination of ICD information via home-monitoring. Follow-up appointments in outpatient clinic are changed compared to standard care. While follow-up 1, 12, and 24 months after ICD implantation consist of outpatient clinic appointments, follow-up 3, 6, and 18 months after ICD implantation are conducted remotely.
3190450|NCT00787683|No Intervention|Standard care|Patients randomised to the standard care group receive no home-monitoring device (CardioMessengerII) following Lumax ICD implantation. Patients have scheduled follow-up appointments at the ICD outpatient clinics at 1, 3, 6, 12, 18, and 24 months after ICD implantation.
2452640|NCT03223584||Pharmacists-Leuven|Individual interviews with approximately 5 pharmacists
2452641|NCT03223584||Pharmacists-Bruges|Individual interviews with approximately 5 pharmacists
2452643|NCT03223584||Pharmacists-Mortsel|A focus group with pharmacists and general practitioners
2452645|NCT03223584||General Practitioners-Leuven|Individual interviews with approximately 5 general practitioners
2452646|NCT03223584||General Practitioners-Bruges|Individual interviews with approximately 5 general practitioners
2452650|NCT03223584||General Practitioners-Mortsel|A focus group with pharmacists and general practitioners
2452694|NCT03223194|Experimental|Cohort 1|1.5 x 10^12 vg/kg of AT342 delivered intravenously one time
2452695|NCT03223194|Experimental|Cohort 2|6.0 x 10^12 vg/kg of AT342 delivered intravenously one time
2452696|NCT03223194|Experimental|Cohort 3|1.5 x 10^13 vg/kg of AT342 delivered intravenously one time
2452698|NCT03223194|No Intervention|Delayed-Treatment Control|Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.
3190451|NCT00787696|Experimental|Skills Training|intervention group received information, motivation and skills training: condom application, assertive communication & problem solving
3190452|NCT00787696|Active Comparator|Health Education|Comparsion group received information and motivation
2452902|NCT03222011|Active Comparator|Standard endoscopic therapy|Single endoscopic dilatation
2452906|NCT03222011|Experimental|Intensive endoscopic therapy|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
2452950|NCT03221530|Experimental|EISR-I|Participants in the Early Intervention for Suicide Risk Among Immigrant Youth (EISR-I) family-based intervention will attend 8 in-person sessions with at least one parent/guardian.
2452952|NCT03221530|Active Comparator|Enhanced usual care|Participants in the usual care arm will receive a safety planning and assessment feedback session from the research team and will receive usual care in the behavioral health clinic where the study takes place.
2453102|NCT03220334|Experimental|Apply platelet rich plasma to the artificial gastric ulcer|
2453103|NCT03220334|Placebo Comparator|Apply normal saline to the artificial gastric ulcer|
2453270|NCT03219450|Experimental|NeoVax|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134."
2453271|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5"
2453274|NCT03219450|Experimental|Neovax + Low-dose cyclophosphamide + Pembrolizumab|"NeoVax will be administered in a priming and booster phase.~The priming shots will comprise days 1, 4, 8, 15, and 22.~Booster shots will be given on days 78 and 134.~Low dose cyclophosphamide is administered twice daily on weeks -2, 1, 3, 5~Pembrolizumab will be administered starting on Week 12 Day 78 and for up to 2 years"
2453332|NCT03218982|Experimental|Active Intervention|Six weekly intervention sessions (2 hours, each) that include enhanced psycho-education and discussion of AD and cultural impacts on beliefs about dementia and caregiving, management of problem behaviors, facilitation of support seeking, and mindful Tai Chi.
2453333|NCT03218982|No Intervention|Control|Participants will receive educational materials/pamphlets on dementia and occasional phone-calls by research assistants to maintain contact, as is the standard of care in most caregiver intervention studies.
2452331|NCT03225703|Active Comparator|Exercise Leg|Left or right leg randomly assigned as exercise leg in a unilateral, exercise intervention. This will be a progressive exercise programme with the aim being to complete 50 multidirectional hops completed daily. (Hopping)
2452337|NCT03225703|No Intervention|Non exercise Leg|Randomly assigned non-exercise, control leg.
2452417|NCT03225209|Experimental|OPTIFAST|"Subjects meeting inclusion criteria will be receive OPTIFAST meal replacement (MR) in the following manner:~WK1-WK12 (5 MR/DAY)~WK13-14 (4 MR/DAY)~WK 15 (3 MR/DAY)~WK 16 (2 MR/DAY)~WK 17-18 (1 MR/DAY)~WK 19-24 (No MR)"
2452451|NCT03224715|Experimental|Actinic Cheilitis patients|
2452524|NCT03224442|Experimental|PRF with immediate implants|Immediate implants placed and covered with two prf layers
2452537|NCT03224442|Active Comparator|palatal pedicle graft|immediate implant placement followed by soft tissue augmentation by oalatal pedicle graft
2452644|NCT03223961|Experimental|Early onset arm|Intervention: early onset of Eprex60000 IU/week , at patient inclusion
2452647|NCT03223961|Experimental|Delayed onset arm|Intervention: late introduction of Eprex60000 IU/week, whenever the patient reaches the level chosen RBC transfusions (based on age, comorbidities, anticipated tolerance of anemia).
2452742|NCT03222817|Experimental|HPV Self-sampling|All participants will receive HPV self-sampling. HPV self-sampling allows an individual to screen themselves for cervical cancer in private, using a device that is similar to a tampon.
2452761|NCT03222622|Experimental|Cohort 1|65 patients with mild to moderate psoriasis will be randomized to receive 1% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2452762|NCT03222622|Experimental|Cohort 2|65 patients with mild to moderate psoriasis will be randomized to receive 2% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2452763|NCT03222622|Experimental|Cohort 3|65 patients with mild to moderate psoriasis will be randomized to receive 4% Icotinib hydrochloride cream, applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2452764|NCT03222622|Placebo Comparator|Cohort 4|65 patients with mild to moderate psoriasis will be randomized to receive placebo cream (blank cream containing no icotinib hydrochloride), applied twice daily for 12 consecutive weeks. The drug will be applied topically to the psoriasis site.
2452819|NCT03222401|No Intervention|Control Group|Control subjects will not receive an infusion or placebo
2452820|NCT03222401|Experimental|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
2452821|NCT03222401|Experimental|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
2452823|NCT03222401|Experimental|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
2452840|NCT03222076|Experimental|Arm A (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients continue nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2452841|NCT03222076|Experimental|Arm B (ipilimumab, nivolumab)|Patients receive ipilimumab IV over 90 minutes on day 1 and nivolumab as Arm A. Treatment repeats every 2 weeks for up to 3 cycles for nivolumab in the absence of disease progression or unacceptable toxicity. Patients undergo liver surgery on day 1 of week 7. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2452842|NCT03222076|Experimental|Arm C (ipilimumab, nivolumab)|Patients receive ipilimumab and nivolumab as in Arm B. Patients undergo post-treatment biopsy on day 1 of week 7, then receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks for up to 3 additional cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 weeks after surgery, patients receive ipilimumab IV over 90 minutes every 6 weeks and nivolumab IV over 30 minutes every 4 weeks up to 2 years in the absence of disease progression or unacceptable toxicity.
2452891|NCT03221816|Placebo Comparator|Placebo Oral Tablet|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The women were randomly allocated to control or experimental group (30 in each group) in a double-blind controlled clinical trial.~The control group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
2452892|NCT03221816|Experimental|Experimental group (Tenavit®)|"Sixty women were postmenopausal selected from the outpatient Gynecology Hospital Santa Marcelina that passed by routine consultations and fulfilling the inclusion criteria were invited to the study.~The experimental group received one tablet of Tenavit® (pyridoxine hydrochloride 4.00mg + folic acid 0.80mg + cyanocobalamin 0.40 mg) daily and the placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months."
2452960|NCT03221634|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg by intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 administrations (up to approximately 2 years) and receive daratumumab 16 mg/kg by IV infusion on Days 1, 8, 15, and 22 of Cycles 1-2; on Days 1 and 15 of Cycles 3-6, and on Day 1 of Cycle 7 and beyond, for up to 2 years. Each cycle is 28 days long.
2453040|NCT03220984|Experimental|Immunotherapy group|All enrolled patients receive a total of 12 times of Immuncell-LC therapy
3190453|NCT00787709|Experimental|1|Receives Pathways universal school-based health promotion curriculum from 4th-6th grade
3190454|NCT00787709|No Intervention|2|Control group of students who do not receive the intervention
2453157|NCT03220178|Experimental|CANKADO active|CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
2453159|NCT03220178|Other|CANKADO inform|CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
2453302|NCT03219008|Experimental|treatment as usual(TAU)|The investigators recommend therapy strategies according to accessible methods.
3208571|NCT00976053|Active Comparator|PET myocardial perfusion imaging|
2452347|NCT03225430|Active Comparator|Comprehensive Behavioural Intervention|"Participant will received psychoeducation about tic disorders, creating a tic hierarchy that will be revised during future sessions, introduce concept of function-based intervention, behavioral reward program, self-monitoring training, habit reversal training for their tics. They will received an introduction of relaxation techniques and diaphragmatic breathing exercise and an introduction of progressive muscle relaxation (PMR) exercise.~They will received booster sessions for three months and he will do hierarchy review, inconvenience review, function-based intervention and competing response review, review of relaxation techniques and relapse prevention review."
2452351|NCT03225430|Experimental|Cognitive psychophysiological (CoPs)|The participant will received a rational about the treatment and awareness training about tics and creating list of tics. He will identifying high and low risk situations provoking tics, do video record and make a list of inconveniences of tic. He will do a screening session of the video and muscle discrimination exercises. Worked on a situational profile with a Kelly's grill and beginning relaxation and breathing exercises. He will identifying style of planning and work on it to do an advantages and inconveniences list to adopt this style. Some behavioral and cognitive re structuration about style of planning and how to modifying. At the end, he will received a relapse prevention informations and how to generalize the learnings and a record of the therapy. Finally, he will have to practice all this techniques at home for four week and do a last session to discuss home practice and received strategies for the future.
2452487|NCT03224832|Experimental|group 1|group 1 will be Pancreatoduodenectomy With Mesopancreas. Artery-first Approach
2452490|NCT03224832|Experimental|group2|group2 will be Pancreatoduodenectomy With Mesopancreas Dissection. Standard Approach
2452615|NCT03224000|Experimental|MRI Guided Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned with MRI guidance. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
2452618|NCT03224000|Active Comparator|Standard-of-Care Intensity Modulated Radiotherapy (IMRT)|"Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~Video-strobe procedure performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.~IMRT planned by standard-of-care. Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days."
2452739|NCT03222843|Experimental|Arm 1|oral hetrombopag at an initial dose of 2.5 mg once daily
2452743|NCT03222843|Experimental|Arm 2|oral hetrombopag at an initial dose of 5 mg once daily
2452746|NCT03222843|Placebo Comparator|Arm 3|oral placebo at an initial dose of 2.5 mg once daily
2452748|NCT03222843|Placebo Comparator|Arm 4|oral placebo at an initial dose of 5 mg once daily
2452811|NCT03222518|Active Comparator|Parcetamol Group|The patient receives an envelope containing Paracetamol 1000 mg at the dose of 3 times / day + follow-up sheet + appointment card.
2452812|NCT03222518|Active Comparator|NSAID Group|The patient receives an envelope containing NSAID 20 mg piroxicam twice daily / day + follow-up sheet + appointment card.
2452815|NCT03222518|Active Comparator|NSAID + Paracetamol Group|The patient receives an envelope containing NSAID 20 mg piroxicam at a dose of 2 times/day + Paracetamol 1000 mg at a dose of 3 times / day + follow-up sheet + appointment card.
2452867|NCT03222102|Experimental|Phasix mesh|Phasix mesh will be affixed to the exposed fascia after closure of the Abdomen in the course of liver transplantation.
2452869|NCT03222102|No Intervention|Standard surgery|Surgery will be performed according to routine, without the use of Phasix mesh.
2452990|NCT03221296|Experimental|Vestibular Training (Intervention Group)|"For the actual intervention, participants will be asked to commit a total of approximately 20 minutes a day of vestibular exercise, divided into three separate sessions (i.e. three 7 minute sessions).~These will include eye movement exercises, walking and balancing. Every 2 weeks, there will be a slight change to the exercises to increase difficulty. (i.e. balancing on one leg or walking with head turns)"
2452996|NCT03221296|No Intervention|Usual Care (Control group)|Patients that are randomized to standard of care Control group will undergo Baseline and 12-week assessments including vestibular testing and questionnaires.
2453067|NCT03220867|Experimental|Treatment Sequence: AB|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive 1 milligram (mg) risperidone administered as Xian Risperdal (test) 1*1 mg oral tablet (Treatment A) on Day 1 in Period 1 followed by 1 mg risperidone administered as Gurabo Risperdal (reference) 1*1 mg oral tablet (Treatment B) on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
2453068|NCT03220867|Experimental|Treatment Sequence: BA|Participants in cohort 1 (fasting) and cohort 2 (fed) will receive Treatment B on Day 1 in period 1 followed by Treatment A on Day 1 in period 2. There will be a washout period of at least 10 days between treatments.
2453104|NCT03220347|Experimental|CC-90010 in patients with solid tumors and NHL|Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.
2453163|NCT03220126|Experimental|LY3074828 - Treatment 1|Single intravenous (IV) dose of LY3074828
2453165|NCT03220126|Experimental|LY900021 - Treatment 2|Single subcutaneous (SC) dose of LY900021 (LY3074828 coadministered with LY9999QS)
2452472|NCT03224624|No Intervention|usual care|Participants will be enrolled in the study and undergo a baseline, 6 month, and 1 year visit but their hypertension care will be per usual care.
2452511|NCT03224273|Experimental|( proximal box design)|The proximal box at least ( 1mm wide and has 6◦ divergences, and extend 2 mm apical to the isthmus ﬂoor.
2452513|NCT03224273|Active Comparator|( inlay shaped design)|The occlusal inlay has a preparation depth of 2.0 mm for the ceramic. The occlusal preparation ( 4 mm wide and extend 4mm for premolar and 6 mm for molar mesiodistally
2452522|NCT03224052||Patients with falciparum malaria|"Empirical antibiotic therapy with levofloxacin 750mg daily for 48 hours. This will be ceased if there is no laboratory or radiological evidence of infection at 48 hours.Therapy will be modified based on culture results or clinical judgment if cultures are not available.~If patients deteriorate in the first 48 hours on levofloxacin, antibacterial therapy comprising vancomycin (1.5g bd) and meropenem (1g tds) will be substituted for levofloxacin in addition to increasing supportive care as appropriate.~The dosing of all antibiotics will be adjusted according to creatinine clearance."
2452523|NCT03224052||Patients with vivax malaria|No empirical therapy will be commenced in these patients. If there is laboratory or radiological evidence of infection antibacterial therapy will be administered based on culture results or clinical judgment if cultures are not available.
2452629|NCT03223974|Experimental|Paclitaxel DCB for MB and/or SB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM(atmosphere), lasting for >30 seconds
2452632|NCT03223974|Active Comparator|DES in MB|with regular techniques
2452667|NCT03223402|Experimental|nevirapine plus lamivudine|patients from one Center switching from a Nevirapine based Regimen on Nevirapine + 3TC
2452686|NCT03223181||COMİSS|Measure of CoMiSS followed by two to four weeks eviction Cow's milk protein diet and second CoMiSS measurement
2452747|NCT03223051|Experimental|Evaluation|"Included patients will be invited to participate in 1 session, to be evaluated with the Motor Function Measure and the new test of space exploration, during 2 hours maximum, to compare scores with these 2 tests.~An occupational therapist will be required to install the patient in front of the table and to give the instructions."
3153931|NCT00287105|Other|Good risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone-good responder and achieve CR after the induction course. For protocols which do not adopt steroid prephase: patients who have M1/M2 BM at day 15 or M1 BM at day 21 and achieve CR after the induction course. Expected stratification in this group: 70-75%.
3153932|NCT00287105|Other|Poor risk Ph+ALL|For protocols which adopt a steroid prephase: patients who are Prednisone poor-responders. For protocol which do not adopt a steroid prephase: patients who have M3 BM at day 15 or M2/M3 BM at day 21. For all protocols: patients who do not achieve CR after the induction course. Expected stratification: 25-30%.
2452887|NCT03222180|Experimental|Website|Participants will be provided with password-protected access to use of the online resource created during the first phase of the project during the one year randomized controlled trial. Participants' children with T1D will receive Usual Care for T1D as described below.
2452889|NCT03222180|No Intervention|Usual Care|Participants' children with T1D will receive care for T1D at their respective institutions equivalent to that received by comparable patients who do not enroll in the trial. At all sites, Usual Care is designed to be consistent with the current American Diabetes Association Standards of Care for T1D in this clinical population.
2452983|NCT03221114|Experimental|Positive Psychological Intervention|Our culturally-tailored Positive Psychology (PP) Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
2452985|NCT03221114|No Intervention|Wait list control|Receipt after the active treatment group has completed the positive psychological intervention.
2453025|NCT03220932|Experimental|Cytoreductive surgery combined with HIPEC|All patients will start with three cycles of CT-BEV 15 mg/kg, and will then be randomly. Then one cycle of monochemotherapy without bevacizumab is administered and followed by an interval CRS and HIPEC with postoperative chemotherapy and bevacizumab (CT-BEV - 15 mg/kg once every 3 weeks) until disease progression
2453026|NCT03220932|Active Comparator|Aurelia arm|Chemotherapy and bevacizumab (CT-BEV) once every 3 weeks from enrollment until disease progression
2453117|NCT03220386|Other|Emergency Department patients|All patients will be tested for nasal MSSA/MRSA-colonization. Patients tested positive for nasal MSSA/MRSA-colonization receive a decolonization treatment. This treatment includes octinidin nasal treatment and skin washings.
2453213|NCT03220022|Experimental|Treatment (R-da-EPOCH)|Patients receive rituximab IV on day 1 (for CD20 positive patients only), etoposide IV over 96 hours on days 1-4, doxorubicin hydrochloride IV over 96 hours on days 1-4, vincristine sulfate IV over 96 hours on days 1-4, prednisone PO daily on days 1-5, cyclophosphamide IV over 1 hour on day 5, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive pegfilgrastim SC from 1 calendar day up to 48 hours or filgrastim SC beginning on day 6 for up to 10 days until ANC is satisfactory.
2453490|NCT03217630||Diabetic patients|
2453493|NCT03217630||Non-diabetic patients|
2453524|NCT03217435|Experimental|Cornea epithelial allograft|Femtosecond laser assisted corneal epithelial allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
2453528|NCT03217435|Active Comparator|Limbal conjunctival allograft|Diamond knife assisted limbus conjunctival allograft from live relatives in the treatment of limbal stem cell deficiency (LSCD)
2453629|NCT03216772|Experimental|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using the Olympus PK Morcellator in PneumoLiner containment device
3153933|NCT00287183|Active Comparator|PF-04494700 (TTP488)|
3153934|NCT00287183|Placebo Comparator|Placebo|
3153935|NCT00287196|Active Comparator|Post-operative RADIOTHERAPY|Immediate post-operative RADIOTHERAPY
3153936|NCT00287196|Experimental|Delayed Radiotherapy|OBSERVATION with delayed radiotherapy for relapse
3153937|NCT00287235|Experimental|Group 1: Standard Medical Therapy + MARS|Patients who were randomized to Group 1 received daily MARS treatments in addition to Standard Medical Therapy for 5 consecutive days.
2452473|NCT03224858|Experimental|SUMMIT intervention group|This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
2452478|NCT03224858|Active Comparator|enhanced usual care group|This group will continue to receive primary care as usual for 6 months. This includes care provided by the patient's existing primary care provider, access to a clinic's Health Resilience outreach worker, mental health consultation, and other services provided by usual care. After 6 months, the baseline survey is administered and the participant will transfer care to the intervention as described above in the SUMMIT intervention group.
2452542|NCT03224221|Experimental|Apatinib with Chemotherapy|Apatinib with Chemotherapy(Fluorouracil and platinum)，patients will receive Apatinib at 500mg/times,oral one times daily for 28 days.the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
2452553|NCT03224221|Active Comparator|Chemotherapy|Chemotherapy (Fluorouracil and platinum)，the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients.
2452591|NCT03223792|Active Comparator|Control|
2452592|NCT03223792|Experimental|Investigational|
3153938|NCT00287235|Active Comparator|Group 2: Standard Medical Therapy Only|Patients who were randomized to Group 2 received standard medical treatment only.
3153939|NCT00287248|Experimental|Assess [123I] IMPY & SPECT Imaging|To assess [123I] IMPY & SPECT Imaging
3153940|NCT00287261|Experimental|zometa|3-weekly infusion of zometa (zoledronic acid) 4 mg
3153941|NCT00287352|Placebo Comparator|Double-Blind Treatment|Olanzapine continuing with placebo
2452703|NCT03223233||No secondary suture|The participants who developed post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
2452706|NCT03223233||Secondary suture|The participants who developed post-cesarean surgical site infection and need a secondary suture for their wound care
2452794|NCT03222934||Nasal disorders|patients with nasal disorders with free sphenoid sinus
2452849|NCT03222284|Experimental|Group 1|"N=10 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 7 Day 28"
2452851|NCT03222284|Experimental|Group 2|"N=20 Device intervention~1. Cornerstones4Care Powered by Glooko App Visits Day 1 Day 28"
2452895|NCT03221933|Experimental|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses.
2452899|NCT03221933|Experimental|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided doses.
2452948|NCT03221491|Experimental|No Background Infusion Group(Group B0)|Patients in Group B0 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 0ml/h.
2452954|NCT03221491|Experimental|Low Background Infusion Group(Group B1)|Patients in Group B1 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 1ml/h.
2452957|NCT03221491|Experimental|High Background Infusion Group(Group B2)|Patients in Group B2 receive analgesic regimens using Patient-Controlled Analgesia(PCA) with background infusion 2ml/h.
2453028|NCT03220997|Experimental|Interventional|Mothers will be given six sachets of carbohydrate powder to be mixed in water . Instructions will be given to have two sachets in 800ml water at 10pm the night before and one sachet in 400ml water at 6 am on the morning of surgery. The order of the list will be decided at 8.45am on the morning of surgery by the surgical team. Mothers scheduled to have surgery later than 11am will be given a further sachet at 9.30am. Mothers scheduled for surgery after 1pm will be given a sachet at 9am and 11am.
2453032|NCT03220997|No Intervention|Standard Care|"Standard fasting instructions will given to mother:~Food until midnight before surgery 800ml water at 10pm night before surgery 400ml water at 6 am morning of surgery The order of the list will be decided at 8.45am on the morning of surgery by the surgical team.~Mothers scheduled to have surgery later than 11am will be given a further 400ml water at 9.30am. Mothers scheduled for surgery after 1pm will be given 400ml water at 9am and 11am."
3153942|NCT00287352|Active Comparator|Olanzapine, Amantadine|Standard combine with Amantadine
3153943|NCT00287378|Experimental|1|
3153944|NCT00287495|Experimental|A|Patients with AIDS-KS receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
2453153|NCT03220282|Active Comparator|Donor milk|Pasteurized donor breast milk
2453155|NCT03220282|Placebo Comparator|Preterm infant formula|Preterm formula determined by clinical practice
2453214|NCT03219905|Experimental|Kinesio-taping Group|Therapeutic Kinesio-taping
2453216|NCT03219905|Sham Comparator|Control Group|Sham Kinesio-taping
2453304|NCT03218956|Experimental|Protein intake|Dietary supplement: Protein intake
2453550|NCT03217591|Placebo Comparator|Placebo|Placebo to match experimental drug administered daily for 12 weeks
2457033|NCT03193385||Closed reduction|
3153945|NCT00287495|Experimental|B|Patients with AIDS-KS not receiving ritonavir will be given 200 mg BAY 43-9006 once daily with dose escalation up to 400 mg twice daily
3153946|NCT00287521|Experimental|AL-37807 Suspension|
3153947|NCT00287521|Active Comparator|Xalatan|
3153948|NCT00287521|Placebo Comparator|AL-37807 Vehicle|
3153949|NCT00287521|Experimental|Timolol Maleate|
3153950|NCT00287534|Experimental|1|Anastrozole
3153951|NCT00287534|Active Comparator|2|Tamoxifen
3153952|NCT00287573|Experimental|Arm 1|
3153953|NCT00287573|Active Comparator|Arm 2|
3153954|NCT00287612|Active Comparator|1|Arms:Lap. Fundo. with Mobilization of the Esophageal Junction
3153955|NCT00287612|Experimental|2|
3153956|NCT00287625|Active Comparator|1|PRP
3153957|NCT00287625|No Intervention|2|control
2452532|NCT03224208|Experimental|Single arm|"Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28. Cobimetinib will be given orally at 60 mg qd on Days 1-21 of each 28-day treatment cycle until disease progression.~Treatments will be continued until the development of progressive disease (as per Investigator assessment), unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination by the Sponsor."
2452620|NCT03223883|Experimental|Curcumin|Patients will receive curcumin (Lonvida) 2000 mg PO once a day
2452622|NCT03223883|Placebo Comparator|Placebo|Patients will receive placebo pill identical in appearance and taste to the supplement
2452682|NCT03223454|Experimental|biological amnion loaded with hAECs|Biological amnion loaded with 100 million hAECs is placed into uterine cavity immediately after TCRA.
2452683|NCT03223454|Placebo Comparator|biological amnion|Biological amnion is placed into uterine cavity immediately after TCRA.
2452684|NCT03223454|Experimental|intravenous infusion of hAECs|intravenous infusion of 100 million hAECs immediately after TCRA
2452685|NCT03223454|Experimental|intrauterine infusion of hAECs|100 million hAECs is infused into uterine cavity immediately after TCRA.
2452687|NCT03223454|Experimental|hydrogel loaded with hAECs|Hydrogel loaded with 100 million hAECs is infused into uterine cavity immediately after TCRA.
2452735|NCT03223025|Experimental|CinnaTropin®, Then Nordilet®|CinnaTropin® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of Nordilet® for three months.
2452736|NCT03223025|Active Comparator|Nordilet®, Then CinnaTropin®|Nordilet® was administered with 0.03 mg/kg daily subcutaneous injections for three months. After that, the participants received 0.03 mg/kg daily subcutaneous injections of CinnaTropin® for three months.
3153958|NCT00287638|Active Comparator|1|CPAP
3153959|NCT00287638|Placebo Comparator|2|no CPAP
2452980|NCT03221452|Other|Intervention|The intervention includes 4 every other week, 2-hour educational sessions to teach compensatory strategies along with skill development and training. Educational sessions will include content on common cognitive problems experienced by people with T2DM and discussion of compensatory strategies to improve cognitive skills as well as content on behaviors and lifestyle strategies to maintain cognitive functioning. Each participant will use the online training program (BrainHQ/Posit Science) for a minimum of 45 minutes 3 times a week and to record practice times and dates. Tasks in the computer training are arranged so that as the user moves forward, the tasks become more challenging. Each task is in a game-like format.
3153960|NCT00287651|Active Comparator|2|Patients with diagnosed Diabetic Retinopathy are enrolled as treated with pulsatile intravenous insulin or as a control patient with weekly treatment sessions. Baseline and quarterly fundus photography is performed to measure and monitor progress.
3153961|NCT00287651|No Intervention|1|Patients diagnosed with Diabetic Retinopathy are enrolled as control patients that do not receive the pulsatile intravenous insulin therapy. Control patients come into the center receive baseline fundus photography and quarterly fundus photography to measure progress and outcomes of diabetic retinopathy and are compared to the patients who receive pulsatile intravenous insulin therapy.
2453123|NCT03220269||Out-of-hospital cardiac arrest (OHCA)|An OHCA is defined as cessation of cardiac mechanical activity that occurs outside of the hospital setting and is confirmed by the absence of signs of circulation.
2453125|NCT03220269||In-hospital cardiac arrest (IHCA)|An IHCA is defined as cessation of cardiac mechanical activity that occurs inside of the hospital setting and is confirmed by the absence of signs of circulation.
2453197|NCT03219983|Active Comparator|Interscalene Block|Ultrasound guided interscalene catheter will be placed and a 30 ml .5% ropivacaine will be given pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
2453209|NCT03219983|Active Comparator|Deep soft tissue/surgical site injection|A total volume of 100ml will be comprised of 60ml of 0.9% normal saline + 20ml 0.5% bupivacaine + 20ml liposomal bupivacaine will be injected into the deep soft tissue using an 18 or 20 gauge needle prior to or after prosthesis insertion
2453241|NCT03219541|Active Comparator|Interventional Automated mobile phone text|"Subjects will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention. During the intervention, participants will receive a text question at the end of every day asking you How many cigarettes have you smoked today?"
2453242|NCT03219541|Placebo Comparator|Control Texts|The intervention will consist of a 3-day pre-quit period and then a 4-week post-quit period. Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
3153962|NCT00287677|Experimental|A|growth hormone + vaccination + HAART
2453430|NCT03218280|Active Comparator|Antioxidant Therapy|
2453439|NCT03218280|No Intervention|Antioxidant Free|
2453467|NCT03217955|Experimental|CBT-SA|"Group sessions for 4 weeks, two sessions per week, 60 minutes per session, two trainers (a CBT therapist and a CBT assistant); eight participants, and;~Individual sessions (crystallizing learned skills, focus on individual needs) during 6-8 weeks, one session per week, 45 minutes per session"
2453471|NCT03217955|Active Comparator|Standard Treatment|Participants in both study conditions will receive ST. Participants are hospitalized or attending day-treatment at the Department of Early Psychosis, Amsterdam, the psychosis department of the ABC team, Utrecht, Parnassia Den Haag and collaborating (local community) mental health centers.
2453533|NCT03217500|Experimental|Corneal epithelial autograft|pterygium resection combined with femtosecond laser assisted corneal epithelial autograft
2453542|NCT03217500|Active Comparator|Limbal conjunctival autograft|pterygium resection combined with diamond knife assisted limbal conjunctival autograft
2453548|NCT03217500|Active Comparator|Simple removal|Simple removal of pterygium
2453601|NCT03216928|Experimental|Group 1|patients with good response to anti-TNF had a blood test
2453602|NCT03216928|Experimental|Group 2|patients with moderate or non-response to anti-TNF had a blood test
2453714|NCT03216538|Placebo Comparator|Placebo|Daily dose of 0.4 ml administered orally
2452549|NCT03224377||healthy control|Complete blood count Esr Crp Liver function test Kidney function test Hepatitis markers Rheumatoid factor Urine analysis Anti cyclic citrullinated peptide antibodies Anti mutated citrullinated vimentin antibodies
3153963|NCT00287677|Experimental|B|growth hormone + HAART
2452716|NCT03223207||Control Group|The control group will include CIED patients who have been evaluated in the ED at The Heart Hospital Baylor Plano and Baylor Regional Medical Center at Plano. A minimum of 50 devices not compatible with the CareLink Express® system will be prospectively interrogated in the traditional evaluation method using the device manufacturer representative.
2452719|NCT03223207||CareLink Express|The study group will include CIED patients who present to the ED and receive a device evaluation using the CareLink Express® system. A minimum of 50 devices will be prospectively evaluated using CareLink Express®.
2452777|NCT03222791|Experimental|Algorithm-based diet|Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.
2452782|NCT03222791|Other|Mediterranean-style low-fat diet|Subjects randomized to this arm will receive nutritional recommendations according to the standard Israeli dietary approach for treating pre-diabetes: Mediterranean-style low-fat diet.
2452861|NCT03222310|Experimental|Ipatasertib|Participants will receive one 100 milligram (mg) ipatasertib tablet orally on Day 1 of treatment in treatment period 1 followed by two 100 mg itraconazole capsules orally on Days 15 to 23 along with one 100 mg of ipatasertib on Day 19 in treatment period 2. Both the treatment period will be separated by a washout period of 14 days.
2452991|NCT03221374|Experimental|Mindfulness Based Stress Reduction|Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
2452995|NCT03221374|No Intervention|Waitlist|Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.
2453046|NCT03220841|Active Comparator|Standard drug therapy|Adalimumab monotherapy, Standard Dose induction (160mg at week 0, 80mg week 2 and 40mg fortnightly thereafter)
2453051|NCT03220841|Experimental|Intensive drug therapy|Adalimumab in combination with dose optimized thiopurine, Intensive induction (160mg weekly for 4 weeks then 40mg fortnightly). Anti-TNF dose may be increased if ongoing inflammation every 4 months until study endpoint.
2453111|NCT03220399|Experimental|NVP-1603-1 (P)|"Drug: NVP-1603-1~1capsule, oral dosing"
2453113|NCT03220399|Experimental|NVP-1603-2(T)|"Drug: NVP-1603-2~1Tablet, oral dosing"
2453115|NCT03220399|Experimental|NVP-1603-1and NVP-1603-2 (P+T)|Drug: NVP-1603-1, 1capsule and NVP-1603-2, 1Tablet co-adminstration (oral dosing)
2453203|NCT03220061|Experimental|experimental|music therapy was used in the study for 30 minutes
2453206|NCT03220061|No Intervention|control|usual care was given to participant in control group
2453248|NCT03219593|Experimental|Apatinib Group|take apatinib orally (500mg/d, once a day, continuously)
2453347|NCT03219242|Experimental|Caiman device|Time sparing and post-operative outcome in ovarian cancer including bowel resection for cytoreductive surgery with Caiman device
2453453|NCT03218020||Random Subcohort|Random subcohort (~10 % of the initial cohort, study has a case-cohort design; details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
2453457|NCT03218020||Incident CVD Cases|Validated incident cases of myocardial infarction, stroke and CVD death that occured until Dec-31-2009 (details on the case-cohort design have been described by Kulathinal et al., Epidemiol Perspect Innov, 2007: www.ncbi.nlm.nih.gov/pmc/articles/PMC2216006/).
2453495|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Escalation|"Traditional 3 + 3 dose escalation design.~Starting doses: sirolimus 3milligrams (mg) loading/1mg maintenance and epacadostat 300mg twice daily (BID). If 0 in 3 subjects develops dose limiting toxicity (DLT), next 3 subjects will be treated at dose level 2 (DL2): sirolimus 6mg loading/2mg maintenance and epacadostat 300mg BID. If 1 subject in dose level 1 (DL1) develops DLT, 3 additional subjects will be enrolled in DL1. If 2 or more subjects in a total of 6 subjects, or 2 or more subjects in the initial 3 subjects develop DLT, the next 3 subjects will be treated at dose level -1 (DL-1): 3mg loading/1mg sirolimus + epacadostat 100mg BID. If only 1 subject in a total of 6 develops DLT, dose escalation to DL2 will be made for the next 3 subjects. Same algorithm will apply to DL2 except no further dose escalation/de-escalation will be made.~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
2453496|NCT03217669|Experimental|Sirolimus/Epacadostat Dose Expansion|"Once recommended phase 2 dose (RP2D) is defined, a total of 10 non-small cell lung cancer (NSCLC) patients who meet eligibility will be enrolled in the dose expansion cohort. Treatment will be sirolimus RP2D once daily and epacadostat RP2D twice daily (BID).~Sirolimus lead-in phase: loading dose on day -7 and maintenance dose starting day -6. On Cycle 1 Day 1, epacadostat 300mg BID will be added."
2453567|NCT03217318|Active Comparator|ureteral stenting with standard ureteral stent|Group 1 will receive a standard ureteral stent. Diameter: 6F, length according to surgeons' estimation and patient's height.
2453569|NCT03217318|Active Comparator|ureteral stenting with suture-stent|In Group 2, a modification of the standard ureteral stent will be inserted. The stent will be cut through obliquely according to the position of the ureteral calculus. The extend to be removed can be easily measured by the retrograde probing catheter and is replaced by a monofilament, non-absorbable suture as described previously by Vogt et al. (W J Urol, 2015). This suture can be easily attached by puncturing the bevelled stent end.
2453808|NCT03215745|No Intervention|Control group|Usual care
3153964|NCT00287677|Experimental|C|vaccination + HAART
3153965|NCT00287677|Active Comparator|D|control healthy HIV negative + vaccination
3153966|NCT00287703|Experimental|1|Active Pulsating Electro Magnetic Fields (PEMF) treatment
3153967|NCT00287703|Sham Comparator|2|5 days a week for 5 weeks for 30 minutes Sham PEMF
3153968|NCT00287755|Experimental|1|
3153969|NCT00287768|Experimental|1|Docetaxel + S-1
3153970|NCT00287768|Active Comparator|2|S-1
3153971|NCT00287820|Active Comparator|1|olanzapine
3153972|NCT00287820|Active Comparator|2|risperidone
3174482|NCT00624078|Experimental|1|Patients who arrive to emergency room with scorpion sting envenomation will be evaluated according to inclusion/exclusion criteria. After informed consent has been signed they will be assigned to unique treatment arm with Anascorp.
2452564|NCT03224013|Active Comparator|Hyperopic LASIK with crosslinking|group 1:hyperopic customized LASIK with concurrent prophylactic high-fluence cross-linking
2452568|NCT03224013|Active Comparator|Hyperopic LASIK only|group 2: hyperopic customized LASIK only
3153973|NCT00287833|Experimental|Arm I (Bowman-Birk inhibitor concentrate)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
3153974|NCT00287833|Placebo Comparator|Arm II (placebo)|Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo. Participants receive 1 of 4 escalating doses of oral Bowman-Birk inhibitor concentrate or placebo, as an orange juice suspension, on day 1.
2452797|NCT03222492|Experimental|Cohort 1: 0.6 mg/kg brentuximab vedotin|"This is the first of three ascending dose cohorts. Participants in this cohort will receive 0.6 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452799|NCT03222492|Placebo Comparator|Cohort 1: placebo|"0.6 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 0.6 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 1 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452804|NCT03222492|Experimental|Cohort 2: 1.2 mg/kg brentuximab vedotin|"This is the second of three ascending dose cohorts. Participants in this cohort will receive 1.2 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452806|NCT03222492|Placebo Comparator|Cohort 2: placebo|"1.2 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.2 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 2 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452809|NCT03222492|Experimental|Cohort 3: 1.8 mg/kg brentuximab vedotin|"This is the third/last of three ascending dose cohorts. Participants in this cohort will receive 1.8 mg/kg brentuximab vedotin (to a maximum dose 60 mg) every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Brentuximab vedotin will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452810|NCT03222492|Placebo Comparator|Cohort 3: placebo|"1.8 mg/kg placebo (to a maximum dose 60 mg). Participants in this cohort will receive 1.8 mg/kg placebo every 3 weeks from week 0 (initial dose) to week 21, a total of 8 treatments. Placebo will be administered as an intravenous infusion over 30 minutes.~Cohort 3 Randomization schedule: N=6 assigned to brentuximab vedotin: N=2 assigned to placebo."
2452927|NCT03221686|Placebo Comparator|Control|Total daily protein intake: 1.5 g protein/kg body weight
2452928|NCT03221686|Active Comparator|Intervention|55 mg zinc/day, 1251 mg vitamin C/day, and 15 g arginine/day. Total daily protein intake: 1.5 g protein/kg body weight
2452993|NCT03221283|No Intervention|control group|Participants only accept the regular scheduled in the compulsory isolated detoxification center.
2452999|NCT03221283|Experimental|Music therapy group|Use randomized controlled clinical trial design.The main content of music therapy is emotional experience , emotion regulation, emotional control and emotional expression. The experimental group received 13 group music sessions over a three-month period.
2453045|NCT03220828|No Intervention|Control|The control group will be provided standard of care, which is no use of technologies.
2453054|NCT03220828|Experimental|Intervention Group VR|Interventional arm will use technology based distractions (Virtual Reality)
2453139|NCT03220516|Experimental|single-use digital ureteroscope|Participants under this arm will undergo retrograde intrarenal surgery (RIRS) procedure under the single use digital ureteroscope.
2453142|NCT03220516|Experimental|reusable fiberoptic ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable fiberoptic ureteroscope
2453148|NCT03220516|Experimental|reusable digital flexible ureteroscopes|Participants under this arm will undergo the RIRS procedure under the reusable digital flexible ureteroscope.
2453202|NCT03219944|Experimental|Platelet Rich Fibrin for soft tissue augmentation|blood will be drawn from the patient vein for PRF. The blood sample will be centrifuged for 10-12 min. PRF membrane is obtained
2453211|NCT03219944|Active Comparator|sub epithelial connective tissue graft|The connective tissue graft will be harvested from the palate. Then the SCTG will be placed over the recipient site extending palataly and sutured.
2453255|NCT03219606|Experimental|education arm|Participants in education arm will have an organized education course of modified Rodnan Skin Scoring.
2453326|NCT03219112|Experimental|Intervention|15 cp children + 10 typically developing children (anticipated) Will have 8 weeks VR training Will have 1 VR training session
2453330|NCT03219112|No Intervention|Control|15 cp children (anticipated) Will not have 8 weeks of VR training Will not have 1 VR training session
3153975|NCT00287846|Experimental|Imatinib|400 to 800 mg/day for a maximal 12 months study duration.
2453461|NCT03217916||normotensive groups|pregnant women with normal blood pressure
2453463|NCT03217916||hypertensive groups|pregnant women with severe preclampsia
2453534|NCT03217591|Experimental|IW-1973 Low Dose|Administered daily for 12 weeks
2453540|NCT03217591|Experimental|IW-1973 High Dose|Administered daily for 12 weeks
3153976|NCT00287859|Experimental|Escalating Cohorts|"Patients receive topotecan intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29. Treatment repeats every 42 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 6 patients will be treated at the MTD."
3153977|NCT00287885|Experimental|Metronomic Docetaxel|Docetaxel will be administered by daily injection via pre-filled syringes into the patient's accessed subcutaneous port.
2452569|NCT03224039|Active Comparator|Intravenous morphine|"b. Treatment B:~Normal saline 0.3 mL IN x 1 dose~Morphine 0.1 mg/kg IV push x 1 dose"
2452652|NCT03223740|Experimental|Arm 1 pre-operative chemoradiation|Chemo1 x 2 followed by ChemRT followed by Surgery followed by Chemo2 x 2
2452654|NCT03223740|Active Comparator|Arm 2 post operative chemoradiation|Surgery followed by Chemo1 x 2 followed by ChemRT followed by Chemo2 x 2
2452700|NCT03223259|Other|Injury Prevention Workshops|Subjects will attend two Injury Prevention Workshops
2452750|NCT03222986||Sepsis with organ failure|Patients have organ failure
2452753|NCT03222986||Sepsis without organ failure|Patients have no organ failure
2452765|NCT03222557|Experimental|Electroacupuncture (EA)|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the needles
2452771|NCT03222557|Sham Comparator|Sham Acupuncture (SA)|Sterile blunt-tip needles will be placed (without skin penetration) 20 mm away from the acupoints. The needle will be first inserted through a sterile plastic tube mounted on a foam block, and then pressed on the skin. The foam block compresses to give the impression that the needle is penetrating the skin, thus providing a SA effect. 'Pseudostimulation' will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current.
2452901|NCT03221868|Experimental|Physical exercise intervention|Exercise group. Physical exercise intervention with sessions carried out as circuit-training, three times a week for 12 weeks to improve physical fitness and metabolic control. The sessions will last between 10 and 45 minutes.
2452903|NCT03221868|Active Comparator|Control|Control group consisting of women who underwent the same measurements for future comparisons and were assigned to receive information about health and counseling to practice of physical activity.
2452944|NCT03221556|Active Comparator|Engagement-Focused Care Coordination|The brief intervention in Engagement-Focused Care Coordination is the Engagement Interview. In this model, providers meet one to two times with mothers who screen positive for depression, and use techniques of shared decision-making to help mothers process the results of the screen; explore treatment options; and connect with formal mental health services. Engagement-Focused Care Coordination emphasizes referral to formal mental health services.
2452947|NCT03221556|Active Comparator|Problem Solving Education (PSE)|The brief Problem Solving Education (PSE) is a six-session cognitive-behavioral program. PSE offers immediate intervention in the PCMH, followed by referral to further treatment if symptoms persist.
2453010|NCT03221153|No Intervention|No Intervention|This is the control group. Participants in this group will take the usual course without simulation techniques.
2453012|NCT03221153|Experimental|Simulation|This is the intervention group. Participants in this group will to take the course with simulation techniques.
2453043|NCT03220763||Thirds of number of restaurant meals|Respondent self-reports of # of times/week restaurant prepared meals were consumed. The respondents will be categorized into approximate thirds.
2453100|NCT03220555|Experimental|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
2453101|NCT03220555|Active Comparator|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
2453164|NCT03220165|Experimental|Treatment|MGL-3196
3190455|NCT00787735|Experimental|Integrated Care|Integrated Substance Abuse and Psychiatric Care (ISAP). Subjects received both their substance abuse and psychiatric care within the ATS clinic. Counseling compliance will be measured over time.
3208572|NCT00976066|Experimental|GSK1521498|Subjects will receive a dose of the experimental compound GSK1521498
2453317|NCT03219229||Prepubertal children|Healthy 7-11 year old girls and boys.
2453384|NCT03218839|Experimental|HIV+ PrePex|PrePex male circumcision device
2453435|NCT03218306|Experimental|SPI guided analgesia|SPI ≤ 10 percentual points over the post-induction/pre-surgical incision value
2453440|NCT03218306|Active Comparator|Clinical Guided Analgesia|No SPI guidance
2453482|NCT03217903|Experimental|Patients with High-risk MDS With Excess Blasts|
2453531|NCT03217448|Experimental|Dabigatran etexilate group|Subjects in this group will take Dabigatran etexilate for 6 months after randomization
2453532|NCT03217448|Active Comparator|Warfarin group|Subjects in this group will take Warfarin for 6 months after randomization
2453580|NCT03217097|Experimental|Unmethylated MGMT NET - OX|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
2453583|NCT03217097|Active Comparator|Unmethylated MGMT NET - ALKY|"Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
2453584|NCT03217097|Experimental|Methylated MGMT NET - OX|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
2453585|NCT03217097|Active Comparator|Methylated MGMT NET - ALKY|"Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.~The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
2453596|NCT03216733|Experimental|COMBO|PCI with COMBO stent
2452709|NCT03223545|Experimental|Mindfulness-based cognitive therapy delivered by telephone|
2452710|NCT03223545|Placebo Comparator|Usual Care (UC)|
2452755|NCT03222856|Experimental|Pembrolizumab + eribulin|All eligible patients will be treated with MK3475 (pembrolizumab) 200 mg on day 1 of each 21-day cycle and eribulin 1.23 mg/m2 (equivalent to eribulin mesylate at 1.4 mg/m2) on days 1 and 8 of every 21-day cycle. Treatment with MK3475 (pembrolizumab) and eribulin will continue based on physician criteria. No maximum duration of treatment is specified. Study follow-up will be performed 12 months after last study dose.
2452800|NCT03222466|Experimental|Co-created PEM|A co-created PEM has been designed in collaboration with patients. Participants receiving the intervention will be asked to read and answer questions before and after viewing the co-created PEM.
2452802|NCT03222466|No Intervention|Traditional PEM|Participants will be asked to read and answer questions before and after viewing the traditional PEM created by clinicians and researchers.
2452860|NCT03222232||chronic intestinal failure patients|Patients with chronic intestinal failure on home parenteral support and enrolled in the Copenhagen Intestinal failure database between January 1, 2002 and December 31, 2015.
2453018|NCT03221270|Experimental|tACS (alpha)|20 participants: 10 Hz tACS with a peak-to-peak amplitude of 2mA for 20 minutes twice daily during 5 consecutive days of stimulation, then 40 minutes once weekly for 8 weeks of maintenance stimulation.
2453020|NCT03221270|Sham Comparator|Sham tACS (alpha)|20 participants: Will include 10 seconds of ramp in to 1 minute of 10 Hz tACS with a ramp out of 10 seconds for a total of 80 seconds of stimulation twice daily during 5 consecutive days of stimulation, then once weekly for 8 weeks of maintenance stimulation.
2453134|NCT03220451|Experimental|Adhesive elastic taping|After a 4-week observation of the pressure ulcer under investigation, adhesive elastic tape is applied around it for a 4-week period (the tape is changed twice a week), according to a planned application protocol. The ulcer is then observed for a subsequent follow-up period of 4 weeks.
2453201|NCT03219996||non-survivor group|
2453208|NCT03219996||survivor group|
3153978|NCT00287898|Experimental|Telephone Genetic Counseling|Participants randomized to this arm will receive all genetic counseling via telephone.
3153979|NCT00287898|Active Comparator|Usual Care|Participants randomized to usual care will receive standard in-person genetic counseling.
3153980|NCT00287911|Experimental|Combo Chemotherapy and Radiation|"Patients undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Some patients may also undergo brachytherapy. Patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36 and topotecan IV continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3153981|NCT00287937|Experimental|Treatment (vorinostat, paclitaxel, carboplatin)|Patients receive oral SAHA once or twice daily on days 1-14* and paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease after the completion of 6 courses may receive single-agent SAHA at the discretion of the treating physician.
2453402|NCT03218462|Experimental|Group 1|Sensory adapted dental environment (SADE) at first exam (visit 1)
2453403|NCT03218462|Experimental|Group 2|Sensory adapted dental environment (SADE) at recall exam (visit 2)
3153982|NCT00287963|Experimental|Vinorelbine + topotecan|
2453503|NCT03217656||Mother-child birth cohort|
2453519|NCT03217292|Experimental|Group S|"IV patient-controlled analgesia (PCA) tramadol+Serratus Anterior Plane Block(SAPB) Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.~20 mL of bupivacaine at a concentration of 0.25% to between serratus anterior and intercostal muscle using the in-line technique for SAPB."
2453521|NCT03217292|Active Comparator|Group T|IV patient-controlled analgesia (PCA) tramadol Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
2453692|NCT03216486|Experimental|BPS804 Dose 1|BPS804 IV Infusion
2453785|NCT03216070|Experimental|Arm1 Low Dose Dasatinib|We will give 50mg of dasatinib orally daily for 6 months
2453861|NCT03215420|Experimental|Certain or probable Meniere's disease|
2453911|NCT03214848|No Intervention|Standart of Care|Standard of care at the clinic is to discuss the abortion procedure without specific contraceptive counseling given prior to the day of abortion procedure.
2454155|NCT03212716|Placebo Comparator|oseltamivir + placebo|oseltamivir + placebo of diltiazem
3153983|NCT00288028|Experimental|Bortezomib|Bortezomib is administered as a 5 second IV bolus on days 1, 4, 8,11 or 1,8 and 15 of a 21-35 days cycle (Depending on the Dosing schedule). The dosage will be calculated based on actual weight of the patient unless the actual weight is greater than 40% above the ideal body weight. In this instance the dosage will be based on the adjusted ideal body weight. The Adjusted IBW (kg) = IBW + 0.25 x (actual body weight - IBW). The dosage will be adjusted based on the safety and toxicity profile, until a MTD is determined.
3153984|NCT00288041|Experimental|Treatment (bortezomib, paclitaxel, carboplatin)|Patients will receive an infusion of bortezomib twice in week 1 and once in week 2. They will also receive a 3-hour infusion of paclitaxel and an infusion of carboplatin once in week 1. Treatment may repeat every 3 weeks for as long as benefit is shown.
2452619|NCT03223766||Participants|Participants will be those enrolled to receive proton therapy on other protocols at SJCRH on or after November 18, 2015.
2452711|NCT03223493||People with Obesity|General population, respondents are recruited via email and/or phone through an online panel company with which respondents have provided permission to be contacted for research
2452712|NCT03223493||Healthcare Providers|Health care professionals, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes or through the AMA Masterfile
2452713|NCT03223493||Employer representatives|Employers, respondents will be recruited via email, USPS mail, and/or phone through an online panel company with which respondents have provided permission to be contacted for research purposes
2452754|NCT03222804|Active Comparator|Exclusively breastfed|Exclusive breastfeeding will be defined at screening as infants who have not consumed any infant formula after 7 days postnatal and have been exclusively breastfed without formula between day 7 of life through the end on the Lead-in period. ). Infants will consume B. infantis for twenty-one consecutive days.
2452756|NCT03222804|Active Comparator|Exclusively formula fed|Exclusive formula feeding is defined at screening as infants who consume only infant formula between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
2452757|NCT03222804|Active Comparator|Mixed fed|Mixed feeding is defined at screening as infants who consume a combination of infant formula and breast milk between day 7 of life through the end on the Lead-in period. Infants will consume B. infantis for twenty-one consecutive days.
2452874|NCT03222050|Experimental|electronic toy group|Distraction technique was given by electronic toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2452875|NCT03222050|Experimental|key toy group|Distraction technique was given by key toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2452877|NCT03222050|Experimental|Simple toy group|Distraction technique was given by simple toy during immunization and started 30 seconds before immunization and it lasted until 15 seconds
2452878|NCT03222050|No Intervention|control group|Routine care was given during immunization and no intervention was given
2452904|NCT03221777||AFOTS - Medical Illness Cases|"Patients who have AF detected for the first time in the setting of an acute non-cardiovascular medical (i.e. non-surgical ).~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2452905|NCT03221777||Medical Illness Controls|"Patients without a history of AF who are hospitalized for an acute non-cardiovascular medical (i.e. non-surgical) and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2452907|NCT03221777||AFOTS - Non-cardiac surgery Cases|"Patients who have AF detected for the first time following non-cardiac surgery.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2452908|NCT03221777||Non-cardiac Surgery Controls|"Patients without a history of AF who are hospitalized after non-cardiac surgery and do not have AF detected.~14 day patch ECG monitor at 1 month and 6 months after hospital discharge"
2452945|NCT03221465|No Intervention|Usual Care|Usual care: dietary and exercise counseling only at baseline, no other intervention.
2452946|NCT03221465|Active Comparator|Usual Care + self-monitoring of physical activity|Tracking Device control: The intervention applied is usual care and self-monitoring of physical activity. Patients will receive a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. They will be able to obtain daily feedback on step counts via the wearable device and their smartphones. They will also have a 2-week run-in period like the incentive arm.
2452951|NCT03221465|Experimental|Self-monitoring + incentives of physical activity|The intervention applied is self-monitoring of physical activity with incentives. Patients will receive a a pedometer (e.g. Misfit brand wrist pedometer) to allow for self-monitoring of physical activity. Participants will monitor daily step counts with automated feedback on goal attainment via text message. We will establish a baseline step count for each participant (during a 2-week run-in period) and then recommend a 15 percentage point increase in daily step goal every 2 weeks during the 12-week intervention period (weeks 3-14) with a maximum goal of 7,000 steps. Two health engagement questions will be sent per week to participants as well for the 12-week intervention period.
2452970|NCT03221179|Experimental|RO7049665|Participants will be administered a single SC dose of RO7049665 administered in up to 4 SC injection.
2452973|NCT03221179|Placebo Comparator|Placebo|Participants will be administered a single SC dose of matching placebo formulation administered in up to 4 SC injections.
2453029|NCT03221036|Experimental|Induction Phase: Vedolizumab 300 mg|Vedolizumab 300 mg intravenous (IV) infusion at Weeks 0, 2, and 6 during induction phase.
2453031|NCT03221036|Placebo Comparator|Induction Phase: Placebo|Matching placebo IV infusion at Weeks 0, 2, and 6 during induction phase.
2453035|NCT03221036|Experimental|Maintenance Phase: Vedolizumab 300 mg|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive vedolizumab 300 mg IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who did not achieve clinical response at Week 10 will receive vedolizumab 300 mg IV infusion every 4 weeks from Week 14 up to Week 58.
2453037|NCT03221036|Placebo Comparator|Maintenance Phase: Placebo|Participants who received vedolizumab IV 300 mg in induction phase and achieved clinical response at Week 10 will be randomized to receive placebo, IV infusion at Weeks 14, 22, 30, 38, 46 and 54. Participants who received matching placebo in the induction phase and achieved clinical response at Week 10 will continue to receive placebo at Week 14, 22, 30, 38, 46, and 54.
2453119|NCT03220243|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm.
3174483|NCT00624091|Experimental|1|Early-surgery, within 48 hours from randomization
2453406|NCT03218449||1/NC|noninfective complication
2453407|NCT03218449||2/IC|infective complication
2453446|NCT03218150||bone cement group|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
2453452|NCT03218150||titanium mesh group|patient underwent to cranioplasty reconstruction with titanium mesh
3174484|NCT00624091|Active Comparator|2|State-to-the-art group. Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
3174485|NCT00624104||1|Lean male
3174486|NCT00624104||2|Males with type 2 diabetes
2452751|NCT03222869||Laryngotracheal Stenosis|Patients with laryngotracheal stenosis will have pressure sensors placed proximal and distal to the stenosis. Pressure and air flow will be measured
3153985|NCT00288093|Experimental|Treatment (triapine, radiation therapy)|Patients undergo radiotherapy once daily, 5 days a week, for approximately 5.5 weeks (a total of 28 fractions). Patients also receive 3-AP (Triapine) IV over 2 hours 3 days a week every other week for 5.5 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of 3-AP (Triapine) until the maximum tolerated dose (MTD) is determined.
3153986|NCT00288106||Long Term Follow-Up|Follow-up data collection study for men who developed prostate cancer after participation in SWOG-9217 (PCPT)
3153987|NCT00288119||Cases|Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD
2452921|NCT03221569|Experimental|Intravenous ketamine|Arm will include 0.3 mg/kg intravenous piggyback ketamine over 10 minutes for 1 dose and a 1ml normal saline placebo via intravenous push
2452922|NCT03221569|Active Comparator|ketorolac|Arm will include 30mg ketorolac intravenous push and 50ml normal saline over 10 minutes
2452981|NCT03221348|Experimental|Open label treatment|Study drug (CHO-H01) administered on Day 1 of 28 day cycles up to 6 cycles total.
2453087|NCT03220971||proposed cross-section study|"100 subjects with NAFLD/NASH and negative anti-HCV Ab~50 subjects with HCC and negative anti-HCV Ab~50 subjects with HCC and positive for genotype-1 HCV~50 controls with all negative for NAFLD/NASH but positive for genotype-1 HCV~50 controls with all negative for NAFL, NASH and HCV"
2453088|NCT03220971||proposed longitudinal study|"50 NAFLD/NASH patients and positive for genotype-1 HCV with SVR~10 NAFLD/NASH patients and positive for genotype-1 HCV without SVR~10 HCC patients and positive for genotype-1 HCV with SVR~10 HCC patients and positive for genotype-1 HCV without SVR~50 chronic hepatitis C but not NAFLD patients with SVR~10 chronic hepatitis C but not NAFLD patients without SVR"
2453259|NCT03219476|Experimental|Neoadjuvant endocrine therapy treatment (physician's choice)|Once enrolled, patients would be treated with the current standard-of-care endocrine therapy. Choice of endocrine therapy (aromatase inhibitors or tamoxifen) would be decided by medical oncologist, following a review of the patient's medical history and menstrual status. The patient would be treated with endocrine therapy in a neoadjuvant setting for four weeks, with dosing continuing until surgery.
2453337|NCT03219047|Experimental|Cohort 2 (Co-trial cohort)|Patients receive ibrutinib at standard dose and schedule through an ongoing MD Anderson clinical trial. Patients that respond to ibrutinib but experience relapse or disease progression receive treatment based on the results of the PDX models as in Cohort 1 if they are available. Patients who experience relapse after treatment with ibrutinib are moved to Cohort I if the PDX models are not ready.
2453338|NCT03219047|Experimental|Cohort I (Traditional cohort)|Patients who have previously received ibrutinib, acalabrutinib, PI3K inhibitor ACP-319, or BTK inhibitor BGB-3111 receive treatment through ongoing clinical trials at MD Anderson or standard of care. At the same time, previously collected tissue is used to develop PDX models and suitable drugs/regimens are tested in the PDX models. Patients then receive treatment based on the results of the PDX models through another clinical trial or standard of care.
2453391|NCT03218540|Experimental|SVV group|Fluid management protocol
2453393|NCT03218540|Active Comparator|CVP group|Fluid management protocol
2453537|NCT03217526|Active Comparator|Ex Group|"EX: Standard exercise program (EX) (active range-of otion exercises, balance and mobility exercises) and walking training on the overground.~This rehabilitation program physiotherapist will be applied to participants for five days a week. Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be instructed to walk with verbal commands and encourage them to continue their walk at constant speed.The duration of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale."
2453593|NCT03216759|No Intervention|control group|Tourniquet would be tied to left upper limb of Patients who undergoing laparotomy for 30 minutes after the induction of anesthesia,but put no press on it. Other processes are consistent with conventional methods.
3153988|NCT00288119||EGD Screening|Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening
3153989|NCT00288119||Colon Screening|Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening
3153990|NCT00288119||Controls|Patients scheduled for EGD who do not meet criteria for screening
3153991|NCT00288132|Active Comparator|Usual Care|
3153992|NCT00288132|Experimental|Intervention|
3153993|NCT00288145|Active Comparator|T|Treatment arm comprises one worksite in a matched site pair; one site assigned to treatment, the other site assigned to comparison. Treatment site worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
3153994|NCT00288158|Experimental|Allopurinol|
3153995|NCT00288158|Experimental|Probenecid|
3153996|NCT00288158|Active Comparator|Placebo|
3153997|NCT00288171|Experimental|Allopurinal|Hypertensive renal transplant recipients with elevated uric acid will the treated with allopurinol and placebo in an randomized cross over fashion. Subjects will serve as their own controls.
3153998|NCT00288171|Placebo Comparator|Placebo|
3153999|NCT00288184|Experimental|Allopurinol|Hypertensive children received both placebo and allopurinol in a cross over design.
3154000|NCT00288184|Placebo Comparator|Placebo|
3154001|NCT00288223|Experimental|1|telithromycin
3154002|NCT00288249|Experimental|Arm 2|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3154003|NCT00288249|Experimental|Arm 3|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3174487|NCT00624117|Experimental|A|
3174488|NCT00624130|Experimental|Arm 1|
2452679|NCT03223467|No Intervention|No intervention|Study participants that do not want to undergo surgical treatment.
2452728|NCT03223103|Experimental|Mutation-derived tumor vaccine|MTA-based Personalized Vaccine (peptides + Poly-ICLC with Tumor Treating Fields
3154004|NCT00288249|Experimental|Arm 4|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3174489|NCT00624130|Active Comparator|Arm 2|
2452847|NCT03222271|Active Comparator|I) Extubation to NIV (S/T mode)|"The patients will receive NIV using S/T mode after extubation with the following parameters:~Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O).~Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O.~Respiratory rate (RR): 10-12 breath/minute."
2452854|NCT03222271|Experimental|II) Extubation to NIV (iVAPS) mode|"The patients will receive NIV using iVAPS mode after extubation with the following parameters:~Patient's height in cm..~Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW).~Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O~Minimum and maximum Pressure Support (PS) :8-16~Respiratory rate :10-12 breath/min."
2452896|NCT03221894||Conventional therapy with herbs|Patients were treated with conventional therapy with Chinese herbal medicine (GRAPE granules).
2452900|NCT03221894||Conventional therapy alone|In conventional therapy group, donepezil was the commonly used ChEI(cholinesterase inhibitor) to treat mild to severe AD patients. Memantine, a NMDA(N-methyl-D-aspartate ) antagonist, was given to moderate and severe AD patients. The dose of donepezil ranged from 5 to 10 mg once a day according to patients.
2452961|NCT03221608|Active Comparator|surgery alone(open/laparoscopic)|The patients with colorectal cancer (T4N0-2M0) who have a high risk of developing colorectal Peritoneal Carcinomatosis (PC) undergo curative surgery(open/laparoscopic).
2452962|NCT03221608|Experimental|surgery and HIPEC|Standard surgical treatment and HIPEC with Lobaplatin.
2453027|NCT03221049||chronic hepatitis B patients|ultrasound and radiomics
2453030|NCT03221049||patients with liver space occupying lesions|ultrasound and radiomics
2453033|NCT03221049||patients undergo ablation|ablation, ultrasound and radiomics
2453041|NCT03220633|Experimental|ATB-346|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of ATB-346.
2453042|NCT03220633|Placebo Comparator|Placebo|Subjects given single dose (SAD cohorts) or multiple doses over a 14 day period (MAD cohorts) of placebo.
2453105|NCT03220529|Active Comparator|Normal healthy subjects|Healthy subjects with normal appearing corneas respecting all the general inclusion/exclusion criteria. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2453106|NCT03220529|Active Comparator|Keratoconus subjects|Subjects classified as patients with mild, moderate, or advanced keratoconus. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2453107|NCT03220529|Active Comparator|Subjects diagnosed with PMD|Subjects with Pellucid marginal corneal degeneration (PMD). Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2453108|NCT03220529|Active Comparator|Patients before and after LASK surgery|Healthy subjects who are scheduled to undergo LASIK surgery. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2453109|NCT03220529|Active Comparator|Patients with keratoconus before and after CXL|Subjects who are scheduled to undergo collagen crosslinking treatment. Multiple axial measurements with the Brillouin Ocular Scanner on the cornea will be carried out.
2453167|NCT03220100|Experimental|Stepped Palliative Care|All participants will receive palliative care Participants will complete the Functional Assessment of Cancer Therapy-Lung (FACT-L) every six weeks FACT-L scores will be used to determine which patients need to step up to every 6 week palliative care visits Patients on step 1 of the intervention will have a palliative care visit every 9 weeks Patients on step 2 of the intervention will have a palliative care visit every 6 weeks
2453188|NCT03219853|Experimental|Lower selenium-status|
2453189|NCT03219853|Experimental|higher selenium|
2453278|NCT03219645|Active Comparator|Ginkgo and aspirin|Ginkgo Diterpene Lactone Meglumine Injection 25mg/5ml,once/day from Day 1 to Day 14. The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours;combined with Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
2453279|NCT03219645|Placebo Comparator|aspirin|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
2453303|NCT03218943|Active Comparator|APRV ventilation|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
2453309|NCT03218943|Active Comparator|BiPAP ventilation|They will start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours. Then, they will return to the initial settings ( PCV ) for 2 hours . then, they will be switched into APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours. Then left for ventilation according to the preference of the physician in charge.
2453380|NCT03218748|Experimental|Honest, Open, Proud|"The group program is about disclosure versus secrecy of one's mental illness. The groups are facilitated by two peers (soldiers with lived experience of mental illness). Each group runs for three weeks, one meeting per week, and two hours per meeting. There is one 2-hour booster session in week 6.~Fidelity to manual: rated by a research assistant who is present during the group session"
2453381|NCT03218748|No Intervention|Control group|Treatment as usual (TAU)
2453412|NCT03218241|Experimental|PRT0064445 Dose 1|Dose 1 versus Placebo
2453414|NCT03218241|Experimental|PRT064445 Dose 2|Dose 2 versus Placebo
2453416|NCT03218241|Experimental|PRT064445 Dose 3|Dose 3 versus Placebo
2453421|NCT03218241|Experimental|PRT064445 Dose 4|Dose 4 versus Placebo
2453429|NCT03218241|Experimental|PRT064445 Dose 5|Dose 5 versus Placebo
3174490|NCT00624143|Active Comparator|1|Oral Voriconazole
2452704|NCT03223142|Experimental|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received cryoablation immediately followed by radiofrequency ablation
2452737|NCT03222830|Experimental|RIF group|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
2452822|NCT03222375||Autism|Individuals with autism will have either Image converter (iSQUED™) for Hysteresis of Spiral Autowaves, Sound converter (sSQUED™) for Drift of Spiral Autowaves or Electromagnetic converter (eSQUED™) for Annihilation Autowave reverberator.
2452848|NCT03222089|Experimental|FOLFOXIGIL|"The FOLFOXIGIL chemoimmunotherapy regimen is composed by FOLFOXIRI chemotherapy and the immunotherapy of GM-CSF and IL-2.~FOLFOXIRI: Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, repeated every 2 weeks.~GM-CSF 150ug s.c. d3-7; Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
2452855|NCT03222089|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + Levoleucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1, Repeated every 2 weeks.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity."
3154005|NCT00288249|Experimental|Arm 1|Each subject was scheduled to receive one infusion of ZK 219477 every 3 weeks in one of the respective arms (16 mg/m2 in Arm 1, 12 mg/m2 in Arm 2, 22 mg/m2 [30-minute infusion] in Arm 3 and 22 mg/m2 [3-hour infusion] in Arm 4)
3154006|NCT00288288||1|Epicardial left ventricular lead placement during a clinically indicated open chest surgery
2453015|NCT03221010|Experimental|Motivational Interviewing|Intervention Group: in this group, composed of 6 randomized Basic Health Units, the professionals who coordinate the smoking groups will receive the training for the use of the Motivational Interviewing as an additional resource to the work of motivation and cognitive-behavioral approach usually performed in the groups, however , With an approach based on Motivational Interviewing.
2453016|NCT03221010|Active Comparator|Traditional cognitive-behavioral approach|Control Group: in this group composed of the remaining 6 Randomized Basic Health Units, professionals will use only the traditional cognitive-behavioral approach advocated by the Brazilian Ministry of Health's smoking program.
2453110|NCT03220256|Experimental|Lamotrigine tolerance|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks.
2453171|NCT03220113|Experimental|Dexamethasone,Lidocaine,Thiamine cohort|"Simultaneous administration of a combination of sterile dexamethasone phosphate total dose (bilaterally) of 20 mg, 4 mg/ml, Lidocaine Hydrochloride 1% 40 mg, 10 mg/ml, and Thiamine Hydrochloride 100 mg, 100 mg/ml in a single session into the accessible branches of the trigeminal nerve of the first, second, and third divisions, as well as into the greater and lesser occipital nerve. In first,patient placed in supine position then in prone position for comfortable access to injection site.~De-Novo Treatment medication 'Dexamethasone, Lidocaine, Thiamine Cohort' prepared in single 1 milliliter volume sterile syringes, using 27 Gauge-30 Gauge needles."
2453183|NCT03219788|Placebo Comparator|Group 1(Normal saline)|Patients who will receive placebo (one ml normal saline). The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2453184|NCT03219788|Active Comparator|Group 2 (Remifentanil 0.1 ug/kg)|Patients who will receive remifentanil at a dose of 0.1 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2453185|NCT03219788|Active Comparator|Group 3 ((Remifentanil 0.2 ug/kg))|Patients who will receive remifentanil at a dose of 0.2 ug/kg. The drug will be given after closure of desflurane at an exhaled MAC of 0.3.
2453234|NCT03219710|Active Comparator|Arm A|"Patient on control group (ODA) with weight category of 15-40 kg will receive:~D1-D3 Dexamethasone 3 mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg;~The patient on control group with weight category of > 40 kg will receive:~D1- Dexamethasone 3 mg/m2 , ondansetron(0.15 mg/kg ), Aprepitant 125 mg; D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg~Note: Aprepitant will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
2453237|NCT03219710|Experimental|Arm B|"weight category of 15-40 kg will receive: D1-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg and olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg)~Weight category of > 40 kg in study group will receive:~D1- Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg, ), Aprepitant 125 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D2-D3 Dexamethasone 3mg/m2, ondansetron (0.15 mg/kg,), Aprepitant 80 mg; olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) D4-olanzapine 0.14mg/kg (rounded off to nearest 2.5 mg) Note: Aprepitant & Olanzapine will be administered as single oral dose, dexamethasone and ondansetron will be administered q 8h (PO/IV)"
3154007|NCT00288288||2|Transvenous left ventricular lead implant during a clinically indicated CRT system implant
3154008|NCT00288301|Experimental|1|Special Intervention
3154009|NCT00288301|Experimental|2|Delayed intervention
3154010|NCT00288314||PTSD|
3154011|NCT00288314||CONTROLS|
3154012|NCT00288327|Experimental|1|Enhanced New Leaf Intervention
3154013|NCT00288327|Other|2|Minimum Intervention
3154014|NCT00288340|Active Comparator|1,2|
3154015|NCT00288353|Active Comparator|1|aripiprazole (Abilify)
3154016|NCT00288353|Active Comparator|2|ziprasidone (Geodon)
3154017|NCT00288418|Active Comparator|ARROWgard Blue® CVC|7-French x 20-cm, triple lumen, short-term CVC
3154018|NCT00288418|Experimental|Angiotech CVC|A 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
3154019|NCT00288431|Experimental|1|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
3190456|NCT00787735|Active Comparator|Parallel Care|Parallel Substance Abuse and Psychiatric Care (PSAP). Subjects received their substance abuse treatment at the ATS clinic. Their psychiatric care was received at Community Psychiatry. Counseling compliance will be measured over time.
3190457|NCT00787813|Active Comparator|1|N-Acetyl Cysteine
3190458|NCT00787813|Placebo Comparator|2|placebo
2452998|NCT03221621|Active Comparator|Adalimumab Monotherapy|Adalimumab injections will be administered through subcutaneously in a weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued for 2 years in total.
2453003|NCT03221621|Experimental|Adalimumab + Surgery|Patients will be treated with a combination of adalimumab and wide excision, with a maximum of three surgical interventions within the first year. Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2, continued until the last surgery.
2453061|NCT03220776|Experimental|N-Acetylcysteine|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 2,400mg N-acetylcysteine) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2453062|NCT03220776|Experimental|Gabapentin|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (i.e., 1,200mg gabapentin) (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2453063|NCT03220776|Placebo Comparator|Placebo Oral Tablet|Each 1-week condition will consist of an in-person study visit for assessment and dispensing of medication (Day 1), titration to maximum dose (Days 1-5), MRI (Day 5), and medication washout (Days 5-7).
2453122|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 1|Dose Escalation of VU319
2453127|NCT03220295|Placebo Comparator|Placebo - Dose 1|Dose Escalation of Placebo
2453132|NCT03220295|Experimental|Single Dose of VU319 under Fed State|Single dose of VU319 (50% of the maximum tolerated dose) 30 minutes after a High Fat Standard Breakfast
2453136|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fed State|Single dose of Placebo 30 minutes after a High Fat Standard Breakfast
2453143|NCT03220295|Experimental|Single Dose of VU319 under Fasted State|Single dose of VU319 (50% of the maximum tolerated dose) after overnight fast
2453149|NCT03220295|Placebo Comparator|Single Dose of Placebo under Fasted State|Single dose of placebo after overnight fast
2453151|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 2|Dose Escalation of VU319
2453152|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 3|Dose Escalation of VU319
2453154|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 4|Dose Escalation of VU319
2453156|NCT03220295|Experimental|Dose Escalation of VU319 - Dose 5|Dose Escalation of VU319
2453158|NCT03220295|Placebo Comparator|Placebo - Dose 2|Dose Escalation of Placebo
2453160|NCT03220295|Placebo Comparator|Placebo - Dose 3|Dose Escalation of Placebo
2453161|NCT03220295|Placebo Comparator|Placebo - Dose 4|Dose Escalation of Placebo
2453162|NCT03220295|Placebo Comparator|Placebo - Dose 5|Dose Escalation of Placebo
2453218|NCT03219749|Experimental|Exercise Intervention|Exercise training will take place three times per week for six weeks and involve both aerobic and resistance exercise.
2453245|NCT03219515|Experimental|Gongjin-dan|Participants will be orally administered Gongjin-dan pills of 3.75g, 1 pill/day, 8 weeks (56 days).
2453247|NCT03219515|Placebo Comparator|placebo|Participants will be orally administered placebo pills of 3.75g, 1 pill/day, 8 weeks (56 days).
2453328|NCT03219190|Experimental|LST High School Online|Provided with the prevention program, consisting of e-learning modules and classroom sessions.
2453331|NCT03219190|No Intervention|Treatment as Usual (Control)|Standard health education
2453348|NCT03218735|Experimental|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
2453349|NCT03218735|Active Comparator|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
2453459|NCT03217994|Active Comparator|37.5% gel|37.5% gel to bleach teeth
2453460|NCT03217994|Experimental|6% gel|6% gel to bleach teeth
2453547|NCT03217604|Placebo Comparator|Placebo|Placebo
2453555|NCT03217604|Experimental|PF-06852231|Single ascending doses of PF-06852231
2453603|NCT03217045||Before Protocol|72 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved before the introduction of a strict nutrition protocol
2453605|NCT03217045||After Protocol|86 premature infants born between 26 and 32 weeks gestation, over 6 months period, and involved after the introduction of a strict nutrition protocol and a washout period of 6 months
2453656|NCT03216616|Experimental|Patients with inflammatory rheumatic diseases|The patients will participate in a cognitive behavioural therapy intervention
2453673|NCT03216291|Active Comparator|Home Biofeedback|Patients will be given home biofeedback device (InTone) to take home and practice biofeedback exercises at least twice a day for six weeks of therapy. Intervention: Home device biofeedback training.
2453676|NCT03216291|Active Comparator|Office biofeedback|Patients with fecal incontinence will receive traditional office biofeedback, once weekly, over six weeks. Intervention: Regular office biofeedback training with assistance of biofeedback person..
2453804|NCT03215745|Experimental|Delirium prevention program|Delirium prevention program involved a non-pharmacologic preventive interventions that will be focused in: Delirium prevention program includes individualized non-pharmacological interventions such as multisensory stimulation, cognitive stimulation, activate the functional and family involvement.
3190459|NCT00787826|Experimental|Vaccination|Live Francisella Tularensis Vaccine
3190460|NCT00787865||Krabbe Disease|Children with infantile Krabbe disease
3190461|NCT00787865||Low Enzyme/No Krabbe Disease|Children without disease who have low enzyme levels
3190462|NCT00787865||Control|Children with no disease and normal enzyme levels
3190463|NCT00787865||Motor Disability|Children at risk of developing motor disability
3190464|NCT00787878||A|
3190465|NCT00787878||B|
3190466|NCT00787878||C|
3208573|NCT00976066|Active Comparator|Naltrexone|Subjects will receive a dose of the licensed pharmaceutical product, Naltrexone
2452865|NCT03222245||Exposed group|This group consists of participants identified as needing to start injectable therapy within 1 month from the recruitment date (50% insulin and 50% GLP-1 analogues)
2452866|NCT03222245||Non-exposed group|This group consists of participants treated with oral anti- hyperglycaemic agents (OAHAs) and their combinations
2452911|NCT03221881|Experimental|Pegylated Liposomal Doxorubicin and docetaxel|Pegylated Liposomal Doxorubicin 30-35 mg/m (2) and docetaxel 75-80 mg/m(2) were both administered on day 1,intravenous, Cycles were repeated in 3-week intervals,for 6 cycles.
2452949|NCT03221478|Active Comparator|Kinesio Taping placebo and exercises|kinesio placebo and exercises
2452953|NCT03221478|Experimental|Kinesio Taping and exercises|kinesio with tension and exercises
2452956|NCT03221478|Experimental|Kinesio Taping with tension|Kinesio Taping with tension
2452986|NCT03221166|Experimental|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti tumor necrosis factor (TNF) alpha properties
2452987|NCT03221166|Active Comparator|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
2453038|NCT03220815|Experimental|Biologic drilling drilling at low speed|
2453039|NCT03220815|Active Comparator|conventional drilling drilling at high speed|
2453044|NCT03220594||Hypogastric artery ligation (HAL)|Patients who underwent only hypogastric artery ligation performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
2453050|NCT03220594||HAL and hysterectomy|Patients who underwent both hypogastric artery ligation and hysterectomy performed during the delivery of their babies. Six months after the operation they will evaluated for their ovarian reserve via hormones and astral follicle count (AFC)
2453056|NCT03220594||Postpartum|Postpartum control group constituted of patients delivered baby without any complication and evaluated 6 months later.
2453138|NCT03220490|Experimental|Short term: interval no-interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with a 5 minutes interval between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol no time interval. Again one drop of the same two types of drugs will be given at the same order but with no time interval between them. IOP measurements will be taken in the same manner as on the first day."
2453141|NCT03220490|Experimental|Short term: No-interval interval eye|"On the first day of the study, in the selected eye the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval.~One drop of two types of IOP reduction drugs (Brimonidine and Timolol) will be given with no waiting period between the first (Brimonidine) and the second (Timolol) drop. IOP measurements will be taken every hour up to 6 hours after treatment.~On the second day of the study (two weeks after the first day) the investigators will examine the short term effect of IOP reduction of Brimonidine and Timolol with time interval. Again one drop of the same two drugs will be given at the same order but with a five minute time interval between the first and second drop. IOP measurements will be taken in the same manner."
2453147|NCT03220490|Experimental|Long term: interval no-interval eye|"In the first phase the effect of 5 minute interval between regular glaucoma drops - long term will be examined. The patients will be asked in this eye to wait 5 minutes after taking one of their IOP reduction drugs, before instilling the second type for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patients will be asked to switch to the no interval between regular glaucoma drops - long term phase in which they will be asked to take the drops for this eye at the same order but with no waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
2453150|NCT03220490|Experimental|Long term: No-interval interval eye|"In the first phase no interval between regular glaucoma drops - Long term will be examined. The patients will be asked in this eye to take both IOP reduction drugs, with no waiting period between them for a total duration of 1 month.~After the one month has passed IOP measurement will be taken and the patient will be asked to switch to the to 5 minute interval between regular glaucoma drops - Long term phase and take the drops for the same eye at the same order but with a five minute waiting period for a duration of 1 month. After the second month has passed IOP measurements will be repeated."
2453195|NCT03219827|Experimental|Patients allergic to wasp venom|"Patient with major allergic reaction to wasp venom.~Blood samples collection at visit 1, at visit 2 (4 weeks after visit 1), at visit 3 (one year after treatment onset)~After visit 1, an allergen-specific immunotherapy will be conducted as part of the classical patient care program."
2453207|NCT03219827|Experimental|Patients allergic to penicillin|"Patient with major allergic reaction to penicillin.~- Blood samples collection at visit 1 and at visit 2 (4 weeks after visit 1= end of study, none treatment will be evaluated in this arm)"
2453249|NCT03219580|Active Comparator|5-Fluorouracil Active Treatment Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The active treatment arm brow will be injected with 0.05ml of 5-Fluorouracil 50mg/ml in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
2453250|NCT03219580|Placebo Comparator|Placebo Arm|A patient who has undergone bilateral direct brow ptosis repair and has elected to participate in the study will first have each of their brows randomized to either be the active treatment arm or the placebo arm. The placebo arm brow will be injected with 0.05ml of 0.9% Normal Saline in several injections evenly spaced over the brow incision for a total of 0.3-0.6ml, repeated every three weeks for a total of 4 series of injections.
2453308|NCT03219203|Experimental|Arm A: Single dose hepatitis B vaccine|Single dose of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at entry
2453316|NCT03219203|Active Comparator|Arm B: 3-dose series of hepatitis B vaccine|3-dose series of hepatitis B vaccine group will receive a 20 µg recombinant HBV vaccine intramuscular at month 0, 1, and 6
2453355|NCT03218761||POTS Patients|"Patients who self-identify as having Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
2452882|NCT03222024||Malignant ischaemic stroke|patients without severe stroke on admission but developing it in hospital
2452884|NCT03222024||Mild to moderate ischaemic stroke|patients without severe stroke from onset to discharge
2452929|NCT03221725|Experimental|sacrospinosus fixation group|The group which sacrospinous fixation was performed
2452992|NCT03221309||Adults infected with HCV|"Phase 1 (first 100 enrolled participants) HCV-infected adults with on-going injection drug use use with opioids with 3 months of screening~Phase 2 (enrolled participants 101-200) HCV-infected adults with on-going opioid misuse of non-prescription opioids within twelve months of screening"
3154020|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 IV weekly and Lonafarnib 150 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
3154021|NCT00288444|Active Comparator|Docetaxel 30 mg/ m2and Lonafarnib 150 mg|Docetaxel 30 mg/ m^2 Intravenously weekly and Lonafarnib 150 mg by mouth twice a day daily.
3154022|NCT00288444|Active Comparator|Docetaxel 36 mg/ m2 and Lonafarnib 100 mg|Docetaxel 36 mg/ m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily
2453140|NCT03220152|Experimental|emtricitabine / tenofovir 200/300 mg|emtricitabine / tenofovir 200/300 mg Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
2453186|NCT03219957|Experimental|AT-527|
2453187|NCT03219957|Placebo Comparator|Placebo|
2453256|NCT03219697|Experimental|Parenting education program|Receive 10 weeks of group parenting education sessions with 2-4 public health nurse home visits
2453257|NCT03219697|No Intervention|Control|Receive regular health care
2453283|NCT03219125||Group 1 (cases)|occurence of incident major osteoporotic fracture less than 12 weeks
2453284|NCT03219125||Group 2 (controls)|no history of fragility fracture
2453336|NCT03218930|Other|Social marketing intervention|Participants will receive a total combination of four interventions.
3154023|NCT00288444|Active Comparator|Docetaxel 30 mg/m2 and Lonafarnib 100 mg|Docetaxel30 mg/m^2 Intravenously weekly and Lonafarnib 100 mg by mouth twice a day daily.
3154024|NCT00288691|Experimental|Arm 1|
3154025|NCT00288691|Experimental|Arm 2|
3154026|NCT00288691|Experimental|Arm 3|
3154027|NCT00288691|Placebo Comparator|Arm 4|
3154028|NCT00288730|Experimental|001|nesiritide
3154029|NCT00288769|Other|2|
2453574|NCT03217201|Experimental|Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
2453575|NCT03217201|Active Comparator|Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
2453576|NCT03217201|Experimental|Neo-Adjuvant, Experimental Light|30 minutes of experimental systematic light exposure daily for duration of chemotherapy treatment.
2453577|NCT03217201|Active Comparator|Neo-Adjuvant, Comparison Light|30 minutes of comparison systematic light exposure daily for duration of chemotherapy treatment.
2453599|NCT03216837|Experimental|Cathodal Transcranial direct current stimulation|Cathodal tDCS
2453600|NCT03216837|Sham Comparator|Sham Transcranial direct current stimulation|Sham
2453690|NCT03216590|No Intervention|Standard draping|Shoulder arthroscopy will be performed using standard draping with the shoulder exposed.
2453691|NCT03216590|Experimental|Compressive draping|After standard preparation similar to the no-intervention group, the shoulder will be draped with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA)
2454509|NCT03210181|Experimental|Block|Patients will receive superficial cervical plexus block
3154030|NCT00288795|No Intervention|1|Standard Care
3154031|NCT00288795|Other|2|Massage Treatment
3154032|NCT00288795|Other|3|Polarity Treatment
3154033|NCT00288899|Other|Arm 1|standard VA surgical iMedConsent process
3154034|NCT00288899|Experimental|Arm 2|enhanced version of VA surgical iMedConsent process (repeat-back)
3154035|NCT00288977|Experimental|islet cell transplant|
3154036|NCT00288990||1|subjects who are NAb positive
3154037|NCT00288990||2|Subjects who are antibody negative
3154038|NCT00288990||3|subjects who are BAb positive
3154039|NCT00289055|Experimental|1|Cordis SMART™ Nitinol Stent
3154040|NCT00289055|Active Comparator|2|balloon angioplasty
3154041|NCT00289068||Phacoemulsification Sleeve 2.2mm|Phacoemulsification Sleeve setting 2.2 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3154042|NCT00289068||Phacoemulsification Sleeve 2.8mm|Phacoemulsification Sleeve setting 2.8 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3154043|NCT00289068||Phacoemulsification Sleeve 3.0mm|Phacoemulsification Sleeve setting 3.0 mm Procedure/Surgery: Phacoemulsification Sleeves surgery
3154044|NCT00289081|Active Comparator|1|Rotating Platform Cruciate Retaining Knee implant
3154045|NCT00289081|Active Comparator|2|Rotating Platform Cruciate Substituting Knee implant.
3154046|NCT00289224|Experimental|1|Cholera Vaccine
3154047|NCT00289224|Placebo Comparator|2|Placebo
3154048|NCT00289237|Experimental|High intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling + offer of participation in group-based lifestyle counselling (½ year). This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
3154049|NCT00289237|Experimental|Low intensity intervention group|"Lifestyle intervention consisted of 15-30 minutes of individual lifestyle counselling. This offer was given at baseline to all participants in the group.~Persons at high risk of IHD: offer additionally given at 1- and 3-year follow-up"
3154050|NCT00289237|No Intervention|Control group|"Questionnaires regarding lifestyle and general health were sent to all participants in this group.~The importance of healthy lifestyle was not mentioned, and no intervention was offered."
3174491|NCT00624143|Active Comparator|2|IV Amphotericin B
3174492|NCT00624156||1|emotional disclosure writing intervention
3174493|NCT00624156||2|control writing
2452977|NCT03221101|No Intervention|Long Term Oxygen Therapy alone|Long Term oxygen therapy is prescribed according to the guidelines
2452979|NCT03221101|Active Comparator|Non invasive ventilation|"Home non invasive ventilation is prescribed with the following settings~PS mode~IPAP according to clinical and hemodynamic tolerance~EPAP according to air trapping~RR around 12/ min.~LOT for SaO2 > 90%~Monitoring with capnometry for settings validation"
2453034|NCT03220919|Experimental|Weight-based|Weight-based insulin insulin titration regimen
2453036|NCT03220919|Placebo Comparator|Glucose level-based|Glucose level-based insulin titration regimen
2453049|NCT03220607||Medical induced abortion|120 singleton nulliparous patients are planning to complete the study period. Study group constitute of second trimester pregnancies between 14-24 weeks of gestation. All participants were nulliparous and had no systemic illnesses. The uterocervical angle will be measured in all participants before the induction of labor.
2453137|NCT03220503|Experimental|Group (A)|consists of 25 patients will receive frozen embryo with endometrial scratching on day 7 of transfer cycle.
2453144|NCT03220503|No Intervention|Group (B)|consists of 25 patients will receive frozen embryo without endometrial scratching as control group.
2453192|NCT03219970||EGFR T790M positive NSCLC patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.
2453313|NCT03219255||Subjects receiving RELVAR 100 ELLIPTA|Subjects with a diagnosis of COPD, for which RELVAR is indicated, who are naive to RELVAR will be included.
2453360|NCT03218813|No Intervention|Control cohort ('before' group)|Control cohort ('before' group): eligible patients will receive treatment as usual (TAU) and will complete all outcome measures.
2453367|NCT03218813|Experimental|Intervention cohort ('after' group)|Eligible patients will receive the pharmacist-led intervention and will complete all outcome measures.
3174494|NCT00624182|Experimental|Phase I study|
3174495|NCT00624208|Active Comparator|1|Intravenous injection of droperidol 20 mcg.kg-1 and saline (group 1)
2453462|NCT03218124|Experimental|remifentanil|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
2453538|NCT03217344|Experimental|1-week|patients undergoing 1-week immobilization period
2453544|NCT03217344|Experimental|3-week|patients undergoing 3-week immobilization period
2453636|NCT03217149|Experimental|heliox combined with mechanical ventilation (MV)|heliox combined with mechanical ventilation (MV) is given to infant with ARDS
2453640|NCT03217149|Active Comparator|mechanical ventilation|mechanical ventilation (MV) is given to infant with ARDS
2453810|NCT03215628|Active Comparator|Group A - TCEUS with HLM|General neonatal cardiac surgery with HLM (art. switch, aortopulmonary shunts)
2453812|NCT03215628|Experimental|Group B - TCEUS with HLM|Surgery of the aortic arc
2453815|NCT03215628|Active Comparator|Group C - TCEUS without HLM|Neonatal cardiac surgery without HLM
2453851|NCT03215225||Root canal treatment|
2454358|NCT03211429|Active Comparator|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity, in order to increase their physical, social and functional activities. The cognitive behavioural intervention program, provides by psychologists, consists of eight group sessions, 60 minutes each. During each session a main theme is addressed. The themes of the program are: concerns about falls; thoughts about falling; physical exercise; asserting oneself; overcoming personal barriers; safe behaviour; and managing concerns about falls.
2454359|NCT03211429|Active Comparator|Tai chi|Subjects in the Tai Chi group undertook supervised Tai Chi training in the Yang style of 24 movements, for one hour, once a week for 8 weeks. The first 5 min was allocated for warm-up, with the rest of the time for Tai Chi practice.
2454361|NCT03211429|Active Comparator|Postural control exercise|Individually adjusted progressive and specific postural control training, provided by physiotherapists for one hour, one time per week for 8 weeks. The exercise is progressive and specific to functional postural control tasks. It comprises elements that represent activities included in, and required for, independent daily living, such as maintaining balance when sitting, standing and walking; and also reacting to loss of balance.
2454433|NCT03211039|Other|Whole Genome Sequencing|Genetic test that looks at all coding and non-coding areas of the genome
2454434|NCT03211039|Other|Whole Exome Sequencing|Genetic test that looks at all coding areas of the genome
3174496|NCT00624208|Active Comparator|2|Intravenous injection of ondansetron 0.1 mg.kg-1 and saline (group 2
2454489|NCT03210285||NF2-associated VS|Patients after surgery of a NF2- associated vestibularis schwannoma: Whole exome sequencing of blood and tumor tissue
2454498|NCT03210285||Sporadic VS|Patients after surgery of a sporadic vestibularis schwannoma: : Whole exome sequencing of blood and tumor tissue
2454547|NCT03210012||1|Three dives with different gas mixture : AIR (21% di O2 e 79% di N2), NITROX 32 (32% di O2 e 68% di N2) and TRIMIX (21% O2, 44% N2 e 35% He)
3174497|NCT00624208|Active Comparator|3|Intravenous injection of droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1 (group 3)
3174498|NCT00624208|Placebo Comparator|4|Intravenous injection of saline and saline (group 4)
3174499|NCT00624247|Other|Immediate|Individuals assigned to be approached for routine HIV testing immediately upon admission to the jail.
3174500|NCT00624247|Other|Following Day|Individuals assigned to be approached for routine HIV testing the day following admission to the jail.
3174501|NCT00624247|Other|Delayed|Individuals assigned to be approached for routine HIV testing several days following admission to the jail.
3174502|NCT00624260|Active Comparator|2|Usual follow up : Pet-TDM for current indication (high isolated markers or before a metastasis curative resection)
3174503|NCT00624260|Experimental|1|Semi-annual systematic PET-TDM (M6, M12, M18, M24, M30 and M36 after initial surgery)
3174504|NCT00624273|Other|1, active ulcers|sildenafil treatment
3174505|NCT00624299|Experimental|Botox|Botox
3174506|NCT00624299|Placebo Comparator|Placebo|Saline injection
3174507|NCT00624312|Active Comparator|1|Pre-operatively randomized to Procrit
3174508|NCT00624312|Placebo Comparator|2|Pre-operatively randomized to placebo
2452925|NCT03221803|Active Comparator|OT Cap attachment|Beveled castable bar with micro-size sphere located in first molar region, and attached to the distal surface of the waxed crowns to be cast as one piece, Nylone caps of standard retention for micro size sphere this nylon caps fit onto their spheres and located in metal housing at fitting surface on the denture and Positioning rings to maintain the space for nylon cap during construction of the partial denture metal framework.
2452978|NCT03221335|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea).
2453047|NCT03220945|No Intervention|Arm I (Control group)|Patients may receive yoga instruction for 1 week after post-test 2.
2453055|NCT03220945|Experimental|Arm II (Yoga group)|Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13.
3154051|NCT00289380||Nutrition support|Nutrition support cohort means accept nutrition support，it was defined as ≥15kal/kg/d and < 30kal/kg/d of non-protein calories (carbohydrate and/or fat) and amino acids or protein≥1g/kg/d for 5~28 consecutive days.
2453191|NCT03219931|Active Comparator|Active group - Breastfeeding infants|In this Group will be enrolled only infants who are breastfed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
2453193|NCT03219931|Active Comparator|Active Group - Bottlefeeding infant|In this active Group will be enrolled only infant who are bottle-fed. This Group will take the active product containing 5 drops of active product (108 viable cells/strain) of Bifidobacterium breve BR03 and Bifidobacterium breve B632.
2453199|NCT03219931|Placebo Comparator|Placebo group - Breastfeeding infants|In this placebo Group will be enrolled only infants who are breastfed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2453205|NCT03219931|Placebo Comparator|Placebo group - Bottlefeeding infants|In this placebo Group will be enrolled only infants who are bottlefed. This arm will receive a supplementation with a same product equal to the active product but without bifidobacterium inside.
2453269|NCT03219489|Experimental|Intervention|Clinics randomized to intervention will use the electronic medical record alert for progesterone, informed by guidelines and the foundational meta-analyses demonstrating its efficacy.
2453272|NCT03219489|No Intervention|Control|Clinics randomized to control will not use the electronic medical record alert for progesterone. The control group will receive the usual prenatal care.
2453305|NCT03219034|Experimental|Oral appliance - A|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.~Trade Name: TAP1 Oral Appliance, Airway Management Inc. Dallas, TX"
2453312|NCT03219034|Experimental|Oral appliance - B|"Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.~Trade name: SomnoDent Flex Oral Appliance, SomnoMed Inc., Plano TX"
3154052|NCT00289380||Without nutritional support|Group received only intravenous 5 to 10% glucose and electrolyte infusions
3154053|NCT00289419|Active Comparator|A|
3154054|NCT00289419|Experimental|B|
2453559|NCT03217734|Placebo Comparator|ADA and Placebo|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Placebo, Tablet, Oral, Weekly, 16 Weeks
2453561|NCT03217734|Active Comparator|ADA and MTX|Adalimumab 40 mg, Subcutaneous, Bi-Weekly, 16 Weeks Methotrexate, 2.5 mg Tablet, 10 mg Weekly, Oral, 16 Weeks
2453595|NCT03216889|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6 weeks of CBT-I.
2453597|NCT03216889|Active Comparator|Control|6 weeks of stretching and thinking games.
2453668|NCT03216330||Case|"Consented to participate in the Data Registry (H16-00264) prior to their physician appointment at the BC Women's Health Centre.~New or re-referred to the BC Women's Health Centre for Pelvic Pain and Endometriosis.~Endometriosis (previously surgically diagnosed, or current endometrioma, or current nodule)~Willing and committed to indicating pain scores and menstrual data on a REDCap survey every day for 6 weeks after the test date.~At least 18 years old"
2453670|NCT03216330||Control|"Reproductive aged female with no suspected or diagnosed endometriosis.~Have not experienced any sexual pain scores over 4/10 on a 11-point numeric rating scale, as determined on an online questionnaire prior to test day.~At least 18 years old"
2453751|NCT03215836|Other|Obese Asthmatics|BMI >/= 30 and without metabolic syndrome
2453759|NCT03215836|Other|Obese Astmatics|BMI >/= 30 and with metabolic syndrome
2453767|NCT03215836|Other|Obese non-asthmatics|BMI >/= 30
2453768|NCT03215836|Other|Non - obese asthmatics|BMI: lean > 20; Normal >/= 20 to <25; overweight </= 25 to < 30;
2453827|NCT03215537|No Intervention|observation|No Intervention
2453830|NCT03215537|Active Comparator|comprehensive intervention|preoperative: exercise counseling postoperative : symptoms counseling and pulmonary rehabilitation
2453838|NCT03215212|Experimental|earplug|Ear plug made from polyurethane with (NRR= 29 db and SNR= 37 db) administered from 10 pm to 7 am.
2453839|NCT03215212|Experimental|eye mask|eye mask (18.5 cm, width 8.5cm, height -30mm )dark coloured cloth with 2 elasticised strap, covering both eyes administered from 10 pm to 7 am.
2453840|NCT03215212|Experimental|ocean sound|Ocean sound a type of white noise administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
2453903|NCT03215043|Experimental|Group A|Individuals will receive a dose of 140 mg / d eriocitrin for 12 weeks
2453904|NCT03215043|Experimental|Group B|Individuals will receive a dose of 280 mg / d eriocitrin for 12 weeks
2453905|NCT03215043|Experimental|Group C|Individuals will receive a dose of 560 mg / d eriocitrin for 12 weeks
2453906|NCT03215043|Placebo Comparator|Group D|Individuals will receive the placebo with corn starch excipient for 12 weeks
2454043|NCT03213977|Active Comparator|Arm IV:R-CEOP90 + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
3154055|NCT00289432|Experimental|1|Behavioral: Psychoeducative intervention
3154056|NCT00289432|Active Comparator|2|The Hospitals standard follow-up support group
3154057|NCT00289523||Escitalopram|
3154058|NCT00289523||Bupropion XL|
2452934|NCT03221413|Experimental|Pain tACS|Persons with neuropathic pain who will treated with tCAS. Intervention: tACS (transcranial alternating current stimulation)
3154059|NCT00289523||Combination Therapy|Escitalopram and Bupropion XL
3154060|NCT00289627|Experimental|ipilimumab (MDX-010, BMS-734016)|
2453075|NCT03220620||GDT Group|receives goal-directed therapy
2453078|NCT03220620||Not GDT Group|receives no individualized goal-directed therapy
2453118|NCT03220321|Active Comparator|IPS e.max hybrid abutment crown|
2453120|NCT03220321|Experimental|VITA Enamic hybrid abutment crown|
3154061|NCT00289640|Experimental|1|
2453357|NCT03218579|No Intervention|No intervention|No intervention after antibiotic treatment.
2453358|NCT03218579|Active Comparator|Probiotic microbiome rehabilitation|Probiotic treatment after antibiotic treatment.
2453362|NCT03218579|Active Comparator|Bacteriotherapy microbiome rehabilitation|Bacteriotherapy after antibiotic treatment.
2453417|NCT03218371||study group (Indentation)|Eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed with scleral indentation. (Exposure)
2453425|NCT03218371||control group (Non-indentation)|eyes (participants) for whom chandelier-assisted peripheral vitrectomy under air had been performed without scleral indentation.
2453499|NCT03217942|Experimental|Low dose|All participants will receive 5 i.m injections of NGF (1 ug/0.5ml) into the tibialis anterior muscle (either left or right leg)
2453500|NCT03217942|Experimental|High dose|All participants will receive 1 high dose i.m bolus injection of NGF (5 ug/0.5ml) and 4 injections of saline (control/same volume) into the tibialis anterior muscle (either left or right leg)
2453568|NCT03217331|Experimental|CRD-102 Treatment|CRD102 Treatment
2453609|NCT03216980|Experimental|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
2453612|NCT03216980|Placebo Comparator|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
2453615|NCT03216980|Experimental|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
2453622|NCT03216980|Placebo Comparator|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
2453696|NCT03216369||carotid artery stenting and carotid endarterectomy|Symptomatic patients with unilateral ICA severe stenosis by magnetic resonance angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI before and after CAS and CEA.
2453805|NCT03215784|Placebo Comparator|Eutrophy Control|Gelatin capsules a day, from 28ª week to 36ª week gestation.
2453811|NCT03215784|Experimental|Eutrophy+ Probiotic|Capsules gastro resistant containing 2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
2453813|NCT03215784|Experimental|Obesity + Fish oil|DHA (100 mg) + EPA (137 mg) a day, from 13ª week gestation to 36ª week gestation
2453816|NCT03215784|Experimental|Obesity + Probiotic|2.5 billions colony forming unit (UFC) Lactobacillus rhamnosus GG + 2.5 billions colony forming unit (UFC) Bifidobacterium bifidum a day, from 28ª week to 36ª week gestation
2453937|NCT03215186||Cataract children|All children in this group were diagnosed as congenital cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
2453945|NCT03215186||Healthy children|All children in this group were healthy and without cataracts. The four respects of following information of CC patients were collected and confirmed: 1) demography: including age, sex, and laterality; 2) family and pregnancy-labor histories: including family history, mothers' disease and medication histories during pregnancy, premature or term infant, cesarean or eutocia, and history of oxygen inspiration/infant incubator; 3) complicated systemic diseases; 4) living environment: including radiation/pollution exposure, parental smoking, parental education level, and family income.
2454009|NCT03214237||Participants|Older adult inpatients on elderly care wards in acute hospitals within the Northumbria Hospitals NHS Foundation trust area, aged 70 or over and able to consent to involvement in the study
2454033|NCT03213821|Experimental|high protein intake|Study participants will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg Ideal Body Weight)
2454037|NCT03213821|Active Comparator|GFR based protein intake|Study participants will receive GFR based protein diet to preserve renal function.
2454092|NCT03213587|Experimental|apatinib|
2454178|NCT03212885|Experimental|1|STN Monopolar Stimulation
2454185|NCT03212885|Experimental|2|rZI + STN stimulation
2454224|NCT03212404|Experimental|CK-301 (cosibelimab)|Part 1 - Dose Escalation; Part 2 - Dose Expansion
2454268|NCT03211806|Experimental|Sedentary behavior intervention group|This group will wear an activity monitor linked to a smartphone app that will send prompts aimed at interrupting prolonged sedentary bouts
2454272|NCT03211806|Active Comparator|Monitoring-only group|This group will wear a bluetooth-enabled activity monitor but will not be prompted to change behavior
2454384|NCT03211364|Active Comparator|Angular mobilization|Angular mobilization of the shoulder joint in the frontal plane.
3154062|NCT00289640|Experimental|2|
3154063|NCT00289640|Experimental|3|
3154064|NCT00289705|Experimental|Surgery|Laparoscopic gastric bypass
3154065|NCT00289705|No Intervention|2|Traditional treatment for obesity
3154066|NCT00289796|Active Comparator|Infanrix hexa Group|Subjects received a dose of hepatitis B vaccine at birth followed by immunization with 3 doses of Infanrix hexa™ (2, 4 and 6 months of age) and one booster dose of Infanrix hexa™ between 12 and 23 months of age. All vaccines were administered by deep intramuscular injection into the left anterolateral thigh.
3154067|NCT00289835|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
3154068|NCT00289835|Other|Standard medical treatment|
2452935|NCT03221426|Experimental|Pembrolizumab+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets twice each day (BID) on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
2452939|NCT03221426|Placebo Comparator|Placebo+Chemotherapy|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle.~Adjuvant: 4 to 10 weeks post-surgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and capecitabine 1000 mg/m^2 via oral tablets BID on Days 1 to 14 of each 3-week cycle OR cisplatin 80 mg/m^2 via IV infusion on Day 1 Q3W and 5FU 800 mg/m^2 via continuous IV infusion on Days 1 to 5 of each 3-week cycle, followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
2452941|NCT03221426|Experimental|Pembrolizumab+FLOT Cohort|"FLOT=docetaxel+oxaliplatin+5FU+leucovorin (calcium folinate). Neoadjuvant: Prior to surgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin (calcium folinate) 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of pembrolizumab 200 mg via IV infusion Day 1 Q3W PLUS docetaxel 50 mg/m^2, oxaliplatin 85 mg/m^2, 5FU 2600 mg/m^2, and leucovorin 200 mg/m^2 Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by pembrolizumab monotherapy 200 mg via IV infusion on Day 1 Q3W for up to 11 additional cycles."
2452943|NCT03221426|Placebo Comparator|Placebo+FLOT Cohort|"Neoadjuvant: Prior to surgery, participants receive 3 cycles of placebo (normal saline solution) via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations).~Adjuvant: 4 to 10 weeks postsurgery, participants receive 3 cycles of placebo via IV infusion on Day 1 Q3W PLUS docetaxel 50 mg/m^2 via IV infusion, oxaliplatin 85 mg/m^2 via IV infusion, 5FU 2600 mg/m^2 via IV infusion, and leucovorin 200 mg/m^2 via IV infusion Q2W (on Days 1 and 15 of Cycle 1; Day 8 of Cycle 2, and Day 1 of Cycle 3, for 4 administrations), followed by placebo monotherapy via IV infusion on Day 1 Q3W for up to 11 additional cycles."
2453169|NCT03220191|Experimental|palbociclib tablet with/without PPI|palbociclib tablet formulation alone in period 1 + palbociclib tablet formulation plus rabeprazole in period 2
2453235|NCT03219814|Experimental|Cognitive Dissonance Intervention|"Participants in the Cognitive Dissonance condition will complete tasks from Becker et al.'s (2005) 2-session adaptation of the Body Project. In the intervention groups, participants will be asked to consider the costs of pursuing the thin ideal in verbal, written, and behavioural exercises. Participants will be asked to assume the role as a body activist, and will be given several opportunities to vocalize opposition to the social forces that drive the thin ideal throughout the sessions.~The first session will involve exercises and discussions about the thin ideal and the costs associated with pursuing it. They will be given a homework assignment to complete at home over the next week. In the following week's session the participants will engage in a role-play exercise, as well as continuing the discussion on the costs of pursuing the thin ideal."
2453236|NCT03219814|Active Comparator|Mediapsychoeducation Intervention|"Participants in the Mediapsychoeducation condition will complete two sessions of tasks as outlined for Becker et al.'s (2005) media psychoeducation group, which includes no cognitive dissonance tasks. The first session will have the participants discuss the thin ideal and the media's influence on it. They will then watch a 35-minute psychoeducational video on the influence that advertisements have on body image and perpetuating the thin ideal. They will be assigned homework to complete at home during the week between the sessions. The second session will include a discussion surrounding the attainability to the thin ideal, and this discussion will also be expanded to include all forms of media. Participants will then be asked to consider and discuss differences between media images and themselves, as well as whether achieving this ideal is realistic, and the costs in trying to achieve this thin ideal. They will then watch a 20-minute video on eating disorders."
2453238|NCT03219814|No Intervention|Waitlist Control|The participants in the Waitlist condition will be given the Cognitive Dissonance intervention between 5 and 6 weeks after their second assessment-only session (the cognitive dissonance intervention will be offered and scheduled 1 week after their 1-month online follow-up questionnaire).
2453239|NCT03219814|No Intervention|Body-Satisfied Assessment Only Condition|Body-satisfied women will be recruited to engage in the assessment portion of the study only (i.e. they will be given NO intervention but are serving as a control in terms of eye-tracking assessment). Body-satisfied women will be assessed to compare their attention to weight words with body-dissatisfied women's attention to weight words. This comparison will be done with an aim of replicating the findings of Tobin (2015), to ensure that for this particular sample, body-dissatisfied women exhibit stronger attentional biases for weight words than body-satisfied women. Attention to weight words in body-satisfied women will be assessed at two time points, one week apart, to ensure there are no spurious changes in attention in body satisfied women.
3208574|NCT00976079|Experimental|Active TENS|Active TENS therapy for 4 weeks plus standard physical therapy for same time period.
2453378|NCT03218865|Experimental|ViE High flux dialyzer|vitamin E coated polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for the patient suffering from acute or chronic renal failure
2453456|NCT03218150||autologous bone group|patient underwent to cranioplasty reconstruction with autologous bone graft
2453598|NCT03216733|Active Comparator|ORSIRO|PCI with ORSIRO stent
2452969|NCT03221218|No Intervention|Standard letter|Family physicians will receive a letter that includes generic recommendations for managing MTBI based on the Ontario Neurotrauma Foundation clinical practice guidelines (2013). Screening test results will not be provided.
2453021|NCT03221062|Experimental|Laser en Bloc Resection|Laser en Bloc Resection of bladder tumor(laser ERBT)
2453022|NCT03221062|Experimental|Hydroknife en Bloc Resection|Hydroknife en Bloc Resection of bladder tumor (Hydroknife ERBT)
2453023|NCT03221062|Experimental|conventional transurethral resection|conventional transurethral resection of bladder tumor(cTURBT)
2453128|NCT03220542|Experimental|Probiotics|Saccharomyces boulardii + Esomeprazole + Amoxicillin + Clarithromycin
2453135|NCT03220542|Experimental|Broccoli|Broccoli Sprouts Extract + Esomeprazole + Amoxicillin + Clarithromycin
2453145|NCT03220542|Active Comparator|Triple Therapy|Esomeprazole + Amoxicillin + Clarithromycin
3190467|NCT00787969|Experimental|Treatment (rituximab, cladribine, temsirolimus)|Patients receive rituximab IV on day 1 and cladribine IV over 2 hours on days 1-5. Patients then receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Patients also receive filgrastim SC on days 6-15 or pegfilgrastim SC on day 6. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3190468|NCT00787995||MPS IVA|Subjects with mucopolysaccharidosis IVA (Morquio Syndrome)
2453277|NCT03219385|Experimental|Treatment with the Mirabilis System|
2453288|NCT03218969|Experimental|Study period 1|"Ecopipam or matching placebo 25 mg by mouth for 7 days (week 1), followed by~Ecopipam or matching placebo 50 mg by mouth for 7 days (week 2), followed by~Ecopipam or matching placebo 100 mg by mouth for 23 days (weeks 3)."
2453290|NCT03218969|Experimental|Study period 2|"Matching placebo or ecopipam 25 mg by mouth for 7 days (week 7), followed by~Matching placebo or ecopipam 50 mg by mouth for 7 days (week 8), followed by~Matching placebo or ecopipam 100 mg by mouth for 23 days (week 9)."
2453373|NCT03218852|Experimental|prednisone and cyclophosphamide|"prednisone(0.5mg/kg/day*6 months)~cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
2453375|NCT03218852|Experimental|prednisone alone|"prednisone(0.5mg/kg/day*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
2453497|NCT03217981||2015|2015 - Individuals with a diagnosis of sepsis from June 2014 to May 2015
2453498|NCT03217981||2016|2016 -Individuals with a diagnosis of sepsis from June 2015 to May 2016
2453516|NCT03217357|Active Comparator|Transcranial stimulation in direct current(tDCS)active|30 minutes of active Transcranial stimulation in direct current
2453517|NCT03217357|Placebo Comparator|Transcranial stimulation in direct current(tDCS) placebo|30 minutes of placebo stimulation
2453579|NCT03217188|Experimental|fractionated full dose re-irradiation|
2453581|NCT03217188|Experimental|hypofractionated palliative re-irradiation|
3190469|NCT00788021||Tacrolimus|Recipients of deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
3190470|NCT00788021||Sirolimus|Recipients of deceased or living donor renal transplants maintained on immunosuppressive regimen using sirolimus
2453823|NCT03215485|Experimental|Intervention Group|"All intervention youth participants will receive three components:~Nutrition lessons~Virtual World learning environment~Newsletters"
2453826|NCT03215485|Active Comparator|Comparison|"All comparison youth participants will only receive one component:~1) Newsletters"
2453843|NCT03215134|Experimental|Self-criticism intervention|6 weekly face to face therapy sessions (1st assessment an intervention session of 60 to 90 minutes; sessions 2-5 are 60 minutes each) and a 2 month follow-up telephone call of upto 30 minutes.
2453888|NCT03215017|Experimental|Transanal irrigation|Manual transanal irrigation to control bowel function.
2453891|NCT03215017|Active Comparator|Medication|Medication to control bowel function.
3190471|NCT00788021||Healthy controls|Age, race and gender-matched individuals not on immunosuppressive regimens. Whenever possible an transplant recipient's donor may be recruited to serve as healthy control
3190472|NCT00788034|Experimental|Lu AA21004|
3190473|NCT00788034|Placebo Comparator|Placebo|
3190474|NCT00788047|Other|Regimen A (Reference)|
3190475|NCT00788047|Experimental|Regimen B (Test)|
2454085|NCT03213431||IQ of <90 and ≥40|Patient-Reported Outcomes (PRO) will be evaluated in a group of 30 childhood cancer survivors with global neurocognitive impairment classified by IQ of <90 and ≥40 and 30 of their parents.
2457118|NCT03193099|Other|Premanifest HTT mutation carriers|
3190476|NCT00788060|Experimental|RAD001|
3190477|NCT00788099|Experimental|1|Plitidepsin and Sorafenib
3190478|NCT00788099|Experimental|2|Gemcitabine and Plitidepsin
3190479|NCT00788112|Experimental|Vorinostat|
3190480|NCT00788125|Experimental|Dasatinib with Ifosfamide, Carboplatin, Etoposide|
3190481|NCT00788138|Experimental|1|Vitamin D3 250,000 PO Once
3190482|NCT00788138|Placebo Comparator|2|Matching Placebo
3190483|NCT00788164|Experimental|Groups 1-3|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine intramuscularly (IM) on days 1 and 29 and TA-HPV vaccine IM on day 57.
3190484|NCT00788164|Experimental|Group 4|Patients receive topical imiquimod on days 1, 29, and 57.
3190485|NCT00788164|Experimental|Group 5|Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and TA-HPV vaccine as in groups 1-3, and imiquimod as in group 4.
3190486|NCT00788190|Other|Surgery|Surgical intervention to reduce Distal Radius Fracture
3190487|NCT00788190|Other|Conservative Treatment|Conservative treatment of Distal Radius Fractures
3190488|NCT00788203||5-keys program|Counseling re family feeding behaviors.
3190489|NCT00788203||Lifestyle counseling|Counseling re healthy eating for child and family
3190490|NCT00788216||Healthy Volunteers|Women over the age of 18 without the diagnosis of cervical cancer.
3190491|NCT00788216||Cervical Cancer Patients|Women over the age of 18 with a history of cervical cancer treated with surgery or chemoradiation.
3190492|NCT00788229|Experimental|1. Study Drugs|
3190493|NCT00788229|Experimental|2. Study Drug|
3190494|NCT00788229|Experimental|3. Study Drug|
3190495|NCT00788229|Placebo Comparator|4. Placebo|
3190496|NCT00788242|Experimental|1|Administration of glucose-insulin-potassium
3190497|NCT00788242|Placebo Comparator|2|
2453048|NCT03220659|Placebo Comparator|Standard settings|Usual pacing programming
2453053|NCT03220659|Experimental|Multi-point pacing|MPP programming
2453146|NCT03220464|Experimental|Close contacts of active pulmonary tuberculosis patients|One arm study of conducting ULDCT, chest x-ray, and IGRA
2453181|NCT03219879|Experimental|Telephone-administered continuation therapy|Cognitive-behavioral continuation therapy (T-CT) delivered over the telephone by trained psychotherapist
2453182|NCT03219879|Active Comparator|Usual care|Treatment as usual
2453240|NCT03219554|Experimental|palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
2453285|NCT03219307|Experimental|NOVOCART 3D|Matrix associated autologous chondrocyte implant
2453320|NCT03218917|Experimental|INS1007 10 mg Oral Tablet|Once per day for 24 weeks.
2453323|NCT03218917|Experimental|INS1007 25 mg Oral Tablet|Once per day for 24 weeks.
2453327|NCT03218917|Placebo Comparator|Placebo Oral Tablet|Once per day for 24 weeks.
2453458|NCT03218046|Experimental|EMDR group|This is the treatment arm that will receive EMDR therapy
2453504|NCT03217643|Experimental|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
2453570|NCT03217214||EP-PT|"Existing Procedure EP- Passive Thermography PT (40 patients)~Passive Thermography (PT): 2 thermoscans of the following parts:~Both carotid artery on left and right of the neck.~Both superficial temporal artery on the left and right of forehead.~Left forearm. No relaxation time will be given between the two tests. Each thermoscanning of region will take 60 seconds. The complete procedure will take 10-15 minutes of time."
2453572|NCT03217214||EP-ATLIC/ATPC|"Existing Procedure EP- Active Thermography ATLIC/ATPC (60 patients)~Active Thermography (AT): Temperature mapping over both carotid arteries will be done with the application of maximum cooling for 45-60 seconds in pulsed or lock-in manner. Pulsed mode is continuous, lock-in cooling will be intermittent. Maximum cooling time is 45-60 seconds, using a cooling pad/ cold air blower. Continuous thermoscanning will be done from the instance of application of cooling to reaching of a fixed temperature during rewarming. Procedure will be done 2 times per subject on both carotid arteries. Relaxation time between procedures is 10 minutes. A warming pad/ hot air blower will be used after the test to bring the skin temperature to normal. The complete procedure will take 60 min."
3190498|NCT00788281|Experimental|A|laparoscopic surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
3190499|NCT00788281|Active Comparator|B|open surgery plus postsurgery adjuvant chemotherapy of FOLFOX4
3190500|NCT00788294|Active Comparator|10 mg IV|
3190501|NCT00788294|Active Comparator|5 mg SC|
3190502|NCT00788294|Active Comparator|10 mg SC|
3190503|NCT00788294|Active Comparator|19 mg SC|
2453749|NCT03215849|Sham Comparator|Routine Medical Therapy|Routine Medical Therapy
2453757|NCT03215849|Experimental|Routine Medical Therapy + LVP|Routine Medical Therapy + LVP
2453764|NCT03215849|Experimental|Routine Medical Therapy + BiVP|Routine Medical Therapy + BiVP
2453791|NCT03215602|Experimental|NEMEX and education + strength training|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for 70-90 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner. The final part of the session will consist of focused knee extensor strength training performed in gym machines (knee extension & leg-press) in a combination of low-load fatiguing exercises (knee-extension) followed by high-load exercises (leg-press).~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
2453793|NCT03215602|Active Comparator|NEMEX and education|"Participants will undergo 12 weeks of twice weekly exercise. Each exercise session will last for approximately 60 min. and will consist of 1 hour of specific exercises to optimize sensorimotor control and achieve compensatory functional stability performed in a multiple-joint weight-bearing specific manner.~Additionally, participants will receive 2 educational sessions, which include disease- and exercise specific counseling."
2453874|NCT03215277|Experimental|Bimekizumab|Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose.
2453878|NCT03215277|Experimental|Certolizumab pegol|Subjects will receive several certolizumab pegol administrations on pre-defined time points.
3190504|NCT00788307|Experimental|Experimental Arm|
3190505|NCT00788320|Placebo Comparator|Placebo|Placebo three times a week for 8 weeks
3190506|NCT00788320|Experimental|Cholecalciferol|Vitamin D3 50,000 IU three times a week for 8 weeks
3190507|NCT00788333|Experimental|A|Combination
2454516|NCT03210181|Placebo Comparator|Placebo|Patients will receive normal saline
3190508|NCT00788346|Experimental|Computerized Alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
3190509|NCT00788346|Experimental|Alerts PLUS Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
3190510|NCT00788346|No Intervention|Usual Care|Usual Care
3190511|NCT00788398|Active Comparator|Saline, gravity flow|
3190512|NCT00788398|Active Comparator|Saline, Low Pressure|
3190513|NCT00788398|Active Comparator|Saline, High Pressure|
3190514|NCT00788398|Active Comparator|Soap, Gravity Flow|
3190515|NCT00788398|Active Comparator|Soap, low pressure|
3190516|NCT00788398|Active Comparator|Soap, high pressure|
3190517|NCT00788424|Experimental|AS101 Cream|Twice daily topical application of AS101 cream on the psoriatic lesions for approx. 12 weeks is expected to clear the treated area.
3190518|NCT00788424|Experimental|Placebo|Twice daily topical application on the psoriatic lesions for 8 weeks will serve as control group.
3190519|NCT00788463|Experimental|Aerosol|
3190520|NCT00788463|Active Comparator|Spray|
3190521|NCT00788476||Childhood Cancer Survivors|
3190522|NCT00788476||Primary Caregivers|
3190523|NCT00788515|Experimental|1|
3190524|NCT00788515|Active Comparator|2|
2453073|NCT03220724|Experimental|Part A: Group 3|Participants will receive 400 mcg of CH505TF (admixed with GLA-SE) at Months 0, 2, 4, 8, and 12.
2453076|NCT03220724|Placebo Comparator|Part A: Group 4|Participants will receive placebo at Months 0, 2, 4, 8, and 12.
2453079|NCT03220724|Experimental|Part B: Group 5|Participants will receive CH505TF at Month 0; CH505w53 at Month 2; and CH505w78 at Months 4, 8, 12, and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
2453081|NCT03220724|Experimental|Part B: Group 6|Participants will receive CH505TF at Month 0; CH505TF and CH505w53 at Month 2; CH505TF, CH505w53, and CH505w78 at Month 4; CH505w53 and CH505w78 at Month 8; CH505w78 at Months 12 and 16. GLA-SE adjuvant is admixed with all the CH505 gp120 proteins.
2453082|NCT03220724|Experimental|Part B: Group 7|Participants will receive CH505 M5 (admixed with GLA-SE) at Months 0, 2, 4, 8, 12, and 16.
2453083|NCT03220724|Placebo Comparator|Part B: Group 8|Participants will receive placebo at Months 0, 2, 4, 8, 12, and 16.
3190525|NCT00788528|Experimental|Arm A|1600 mg S-2367 (velneperit)
3190526|NCT00788541|Experimental|3 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 6 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
3190527|NCT00788541|Experimental|3 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 3.75 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
2453262|NCT03219671|Experimental|nivolumab plus ipilimumab|nivolumab 240mg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks
2453334|NCT03219060|Experimental|Intervention group|MI based four individual sessions
2453335|NCT03219060|Active Comparator|Control group|Brief advice following 5As
2453350|NCT03218631|Other|Oxandrin|Administration of a single dose of approximately 0.1 mg/kg of a medium chain triglyceride (MCT) oil Oxandrin (oxandrolone) solution vs. 01.mg/kg tablets in a small cohort of healthy adults. Participants will be dosed at two time points one week apart.
2453386|NCT03218501|Active Comparator|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
2453387|NCT03218501|Active Comparator|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
2453388|NCT03218501|Placebo Comparator|Placebo|Placebo is to be administered orally once daily for 2 weeks
2453478|NCT03218007|Experimental|acute coronary syndrome|
2453511|NCT03217487|Experimental|Corneal epithelial autograft|Femtosecond laser assisted corneal epithelial autograft from the other eye in the treatment of LSCD
2453512|NCT03217487|Active Comparator|Limbal conjunctival autograft|Diamond knife assisted limbal conjunctival autograft from the other eye in the treatment of LSCD
2453535|NCT03217240||Congenital Heart Disease|Tetralogy of Fallot Repair/Pulmonary Hypertension Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
2453545|NCT03217240||Healthy Volunteer|Cardiac Magnetic Resonance - MRI Cardiopulmonary Exercise Test Blood Sampling for all participants
2453618|NCT03216876|Experimental|Healthy Controls|Healthy subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
2453625|NCT03216876|Experimental|PSC Single Dose|PSC subjects will assigned to ursolic acid taken orally as a single dose of 40 mg, 80 mg, and 120 mg
2453631|NCT03216876|Experimental|PSC Multiple Dose|PSC subjects assigned to treatment with daily oral ursolic acid at the dose determined to be optimal in the first phase of the study. The treatment will last for 24 weeks with an off-treatment follow up of 28 weeks
2453712|NCT03216447|Experimental|Experimental Arm|Switch from Prograf to Advagraf on POD 15
2453716|NCT03216447|Active Comparator|Control Arm|Continue Prograf treatment
2453738|NCT03215927|Placebo Comparator|Placebo|Subcutaneous placebo injection weekly for 24 weeks.
2453741|NCT03215927|Experimental|Abatacept|Subcutaneous injection of abatacept 125 mg weekly for 24 weeks. 24 week optional follow up phase all subjects receive abatacept 125 mg weekly.
2453792|NCT03215641|No Intervention|Control|The control group families will participate in the standard Body Works weight loss program. They will fill out brief surveys regarding their physical activity on a weekly basis, but otherwise will receive the standard curriculum. they will receive weekly feedback based on their physical activity surveys.
2453796|NCT03215641|Experimental|Intervention|The intervention group families will be given fitbits on the first day of the Body Works program. They will otherwise receive the same curriculum as the control families. the will fill out the same physical activity surveys as the control families. they will receive weekly feedback based on the objectively measured physical activity.
2453852|NCT03215329||CPAP30|Alveolar recruitment maneuver with a continuous positive airway pressure (CPAP) at 30 cmH2O during 30 seconds
2453855|NCT03215329||PEEPsteps|Alveolar recruitment maneuver with a stepwise increase and decrease in positive end expiratory pressure from 5 to 20 cmH2O.
2453893|NCT03214939|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
2453943|NCT03214627|Experimental|Anemia Control Model IV iron and ESA|"Anemia Control Model (ACM) algorithm to recommend monthly IV and ESA dose over a 6 month period~IV iron: given monthly as required - dosing recommendation by ACM over 6 a month period~Erythropoiesis-Stimulating Agent (ESA): given monthly as required - dosing recommendation by ACM over 6 a month period"
2454028|NCT03213977|Experimental|Arm I:R-DA-EPOCH|Protocol involves 8 cycles.
2454034|NCT03213977|Experimental|Arm II:R-DA-EPOCH + auto-HSCT|Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.
2454039|NCT03213977|Active Comparator|Arm III:R-CEOP90|Protocol involves 8 cycles.
2454149|NCT03213015|Experimental|Experimental|Measurement of ankle dorsiflexion ROM (range of motion) with iHand app (smartphone)
3190528|NCT00788541|Experimental|48 mg Anecortave Acetate, low volume high dose|Anecortave Acetate Sterile Suspension, 96 mg/mL, one injection of 0.5 mL in the study eye monthly for 6 months.
3190529|NCT00788541|Experimental|48 mg Anecortave Acetate, high volume low dose|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.8 mL in the study eye monthly for 6 months.
3190530|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, low volume|Anecortave Acetate Vehicle, one injection of 0.5 mL in the study eye monthly for 6 months.
3190531|NCT00788541|Placebo Comparator|Anecortave Acetate Vehicle, high volume|Anecortave Acetate Vehicle, one injection of 0.8 mL in the study eye monthly for 6 months.
3154069|NCT00289861|Active Comparator|risperdone|
2453121|NCT03220308|Other|Care-as-usual (CAU) only|Care-as-usual for children (8-16 years old) with ADHD
2453126|NCT03220308|Experimental|Mindfulness for child and parent + CAU|MYmind mindfulness training in addition to care-as-usual for children aged 8-16 years with ADHD
2453204|NCT03219918|Active Comparator|With EndoRings|Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
2453212|NCT03219918|No Intervention|NO EndoRings|Colonoscopy is performed conventionally without any caps
2453258|NCT03219619|Experimental|Cap group: Cap-EGD|Undergoing cap-assisted esophagogastroduodenoscopy
2453260|NCT03219619|Active Comparator|Duo group: Duo|Undergoing side-viewing duodenoscope
2453376|NCT03218800|Active Comparator|Intravenous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the intravenous route.
2453377|NCT03218800|Experimental|Subcutaneous Ertapenem|Patients with urinary tract infection will be treated with ertapenem by the subcutaneous route.
2453431|NCT03218293|Experimental|RIPC|Remote ischemic postconditioning（RIPC）：Patients in the RIPC group not only receive foundational treatment but also have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm using a RIPC device (IPC-906X; Beijing Renqiao Institute of Neuroscience, Beijing, China) after thrombolysis while in-hospital.
2453437|NCT03218293|No Intervention|Blank control group(BC)|Blank control group:Patients in the BC group only receive foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin, 100-300 mg/d) and lipid-lowering (atorvastatin, 20 mg/d) drugs,throughout the 14 days in-hospital period without remote ischemic postconditioning after thrombolysis.
2453489|NCT03217929|Active Comparator|Active-taVNS|
2453492|NCT03217929|Sham Comparator|Sham-taVNS|
2453610|NCT03217019|Experimental|Guidewire|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion with guidewire-assist. (Catheter over guidewire)"
2453611|NCT03217019|Active Comparator|Direct|"Radial artery puncture with direct radial pulse palpation.~24G angiocatheter insertion without guidewire-assist. (Catheter over needle)"
2453701|NCT03216551||The assumed selective lymph node dissection group|Patients with consolidation tumor ratios ≤ 0.5 tumors will be considered to have negative mediastinal metastasis. Patients with intraoperative lepidic predominant adenocarcinoma diagnosis will be considered to have negative mediastinal metastasis. Patients with an apical tumor will be considered to have negative inferior mediastinal lymph node metastasis. If both N1 nodes and visceral pleural invasion are negative, patients with peripheral non-apical-segment upper lobe tumors will be considered to have negative inferior medistinal lymph node metastasis. If N1 nodes are negative, patients with left superior segment tumors will be considered to have negative 4L lymph node metasis, and patients with left basal segment tumors will be considered to have negative superior mediastinal lymph node metastasis.
2453745|NCT03215992|Other|Men diagnosed with prostate cancer|This group will include men over the age of 18 suspected of having prostate cancer who will undergo an ultrasound guided transrectal prostate biopsy. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
2453746|NCT03215992|Other|Men without prostate cancer|This group will include men who do not have prostate cancer. Each study participant will undergo a standard prostate biopsy and DOT imaging using the Diffuse Optical Tomography (DOT) System will be performed at the same time.
3190532|NCT00788554|Active Comparator|1|
3154070|NCT00289861|Placebo Comparator|placebo|
2454322|NCT03212092|Experimental|Multivitamin, mineral & n-3 FA|The daily supplementation of multivitamin- and mineral in 2 capsules and n-3 fatty acids in 2 softgel capsules.
2454326|NCT03212092|Placebo Comparator|Placebo|The placebo consists of daily supplementation of 2 capsules with rice bran extract, hypromellose and 1.6 mg riboflavin. And 2 softgel capsules with a vegetable oil.
2454402|NCT03211312||older people with cardiac diseases|undergoing teeth extraction surgery
2454520|NCT03210480|Experimental|Group 1|Lithium sulphate prolonged-release 660 mg
2454522|NCT03210480|Active Comparator|Group 2|Lithium carbonate immediate-release 150 mg and 300 mg
2454549|NCT03209869|Experimental|Single arm|All subjects will receive Ex vivo Expanded and Activated Haploidentical Donor NK Cells + hu14.18-IL2
2454588|NCT03209622|Experimental|A intervention|"intervention = Nicotine replacement therapy (NRT): initiated in cardiology intensive care unit, Some hours after acute coronary syndrome.~Drug: One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks. The patient leave with an appointment to the external consultation for follow-up."
2454591|NCT03209622|Active Comparator|B: control|Intervention: Nicotine replacement therapy (NRT) initiated after hospital discharge, some days after acute coronary syndrome. The patient leave with an appointment to the external consultation for follow-up without pach of nicotine.One or two pachs for each ARM, depending of number of cigarettes consummed every day. The dose is decreased every 4 weeks.
2454673|NCT03209219|Experimental|Interferon Alpha 2A|Patients are treated with IFNα2a 3×10^IU α2a by subcutaneous injection or intramuscular injection daily for 4 weeks, and followed by every other day there after.
2454681|NCT03209219|Active Comparator|Cyclosporine|Patients are treated with oral CsA 100mg twice daily.
2454715|NCT03208725||Hospitalized children with severe wasting or kwashiorkor (SWK)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
2454718|NCT03208725||Community reference participants (CP)|Children recruited from the community who are seen a single appointment in the community.
2457120|NCT03193099|Other|non HTT mutation carriers|
3154071|NCT00289926|Experimental|dehydroepiandrosterone|50.0mg dehydroepiandrosterone capsule, by mouth, daily for 12 months
3154072|NCT00289926|Placebo Comparator|Placebo|Placebo capsule consists of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF manufactured to mimic dehydroepiandrosterone capsule
2453114|NCT03220360|Experimental|direct pulp capping group|Sixty children with deep caries of deciduous teeth underwent direct pulp capping, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2453116|NCT03220360|Experimental|vital pulpotomy group|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy, and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
2453179|NCT03220087||Group A - Uncontrolled CS|Patients who have had at least one episode of uncontrolled CS, according to medical criteria, since the start of their treatment for NET.
2453180|NCT03220087||Group B - Controlled CS|Patients who have not had any episode of uncontrolled CS, according to medical criteria, in the last 12 months.
3154073|NCT00289952|Experimental|Group 1|HAART + valproic acid for 16 weeks followed by HAART alone for 32 weeks.
3154074|NCT00289952|Experimental|Group 2|HAART alone for 16 weeks followed by HAART + valproic acid for 32 weeks.
3154075|NCT00289965|Active Comparator|1|in-person brief motivational intervention
2453325|NCT03219073|Sham Comparator|SHAM tDCS|SHAM tDCS using tDCS device will be used for sham stimulation where the electrodes will be placed in the same positions as for anodal M1 stimulation, but the stimulator will be turned off after 90 seconds. Therefore, the patients feel the initial itching sensation but receive no current for the rest of the stimulation period.
2453329|NCT03219073|Active Comparator|Active tDCS with a tDCS device|Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
2453404|NCT03218436|Active Comparator|CAP cohort|Cold Atmospheric plasma intervention
2453405|NCT03218436|No Intervention|Control cohort|no intervention
2453445|NCT03218098|Experimental|Smaller Incision|UVATS access for lobectomy with small skin access 4 cm
2453448|NCT03218098|Active Comparator|Traditional Incision|UVATS access for lobectomy with longer skin access 8 cm
2453565|NCT03217539|Experimental|Active Study Population|In the experimental arm, women aged 40-74 who were randomly selected to receive an invitation to undergo imaging with periodic single view mammography screening. This arm is referred to as the Active Study Population (ASP)
2453566|NCT03217539|No Intervention|Passive Study Population|In the no intervention arm, women aged 40-74 who were randomly selected to not receive an invitation to undergo periodic single view mammography screening received usual care. This arm is referred to as the Passive Study Population (PSP)
2453620|NCT03217006|Experimental|Single Arterial Group|Patients in this group will receive a single arterial graft which will be the left internal thoracic artery. Additional grafts used in this group will all be venous grafts.
2453627|NCT03217006|Experimental|Multiple Arterial Group|Patients in the group will receive multiple arterial grafts. All patients will receive at least two arterial grafts, the left internal thoracic artery with the addition of either the right internal thoracic artery or the radial artery as the second conduit. Some patients may receive additional arterial grafts consisting of the radial artery, the right internal thoracic artery, or the right gastroepiploic artery.
2453737|NCT03215875|Experimental|Fed- 60mg ER Torsemide|Adult healthy subjects will be given standardized high-fat, high-calorie meal prior to dosing
2453739|NCT03215875|Experimental|Fasting- 60mg ER Torsemide|Adult healthy subjects will fast overnight (at least 10h) prior to dosing
2453799|NCT03215719|Experimental|HPV-Positive Oropharyngeal Carcinoma (OPSCC)|Standard radiation therapy + cisplatinum
2453858|NCT03215251|Experimental|EXPERIMENTAL GROUP|Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
2453859|NCT03215251|No Intervention|CONTROL GROUP|No Intervention administered. Thirst and Dry mouth scores were assessed only. Usual care was continued.
2453872|NCT03214926|Experimental|Moving Through Glass intervention|Participants were asked to use Moving Through Glass (MTG) intervention on Google Glass for at least once a day for 3 weeks. MTG intervention includes 4 difference guided-dance/movement modules for the participants.
2453936|NCT03214770|Experimental|Light-cured calcium silicate|This biomaterial calcium silicate is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
2453944|NCT03214770|Active Comparator|Light-cured calcium hydroxide|This biomaterial calcium hydroxide is manufactured to have an anti-bacterial effect on micro-organisms within the dentin, thus allowing the inhibition of bacterial growth therefore no caries will progress. Material is injected and light-cured within the dentin and sealed with a restoration.
2453990|NCT03214133|Experimental|Epicatechin Dose Response|This arm will investigate varying doses of epicatechin on procollagen type I N-terminal propeptide (PINP) at varying doses CON, 1, 2, 3 mg/kg body mass.
2453991|NCT03214133|Placebo Comparator|Epicatechin-rich cocoa on performance|Athletes will ingest the optimized dose of epicatechin-rich cocoa vs placebo alongside maximum power training to determine if this nutritional intervention results in a greater increase in RFD and performance than maximum power training alone.
3154076|NCT00289965|Active Comparator|2|Alcohol 101plus
2454336|NCT03211637|Experimental|INTERVENTION GROUP|This group comprises 6 healthcare units equipped with a Family Health Strategy, where patients are seen by coordinating nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
3154077|NCT00289965|Active Comparator|3|AlcoholEdu (a Web-based tutorial).
3154078|NCT00290082|Active Comparator|loxapine|agitated patients were randomly assigned either to loxapine, either to midazolam group
2453168|NCT03220126|Experimental|LY900021 - Treatment 4|Single SC dose of LY900021 (LY3074828 coadministered with LY9999QS)
2453194|NCT03219801|Experimental|mesenchymal stem cells|Selected SLE patients were randomly divided into treated group and control group. In the treated group, 100-300 million allogeneic human umbilical cord derived mesenchymal stem cells were infused intravenously for one SLE patient. The possible adverse events, including immediately after mesenchymal stem cells infusions, as well as the long-term safety profiles were observed.
2453310|NCT03219151|Experimental|eMAR game|Participants provided access to eMAR simulator game in advance of simulated return-demonstration; also receive normal education pre-work related to eMAR administration
2453318|NCT03219151|Active Comparator|Normal pre-work|Participants receive normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
2453366|NCT03218774|Other|Home Group|
2453374|NCT03218774|Experimental|Center Group|
2453441|NCT03218345|Experimental|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a VIVA RF generator (STARmed, Korea)
2453536|NCT03217370|Other|all haematologists|"There will be only one arm: the haematologists will all be included in the interventional phase.~Interventions are: 1) rewriting guidelines to order blood components; 2) to show the last hemoglobin value on the orders for erytrocytes and the last platelet count on the orders dor thrombocytes and 3)implementation of a clinical decision support system in the electronic rodering of blood components to stimulate restrictive blood transfusion."
2453586|NCT03217123|Experimental|Deep Brain stimulation|After the surgery, a random sequence of contact activations (0 [Nacc],1,2 and 3), including sham (-), was generated for each patient. Each contact was activated using 130 Hz, 60 ms, and 4.5 V for three months (the sham activation was 0 V) following the patient's individual sequence, separated by one month of washout with the generator turned off
2453592|NCT03216811|Experimental|nutraceutical|after 4 weeks of lifestyle advice and changes, all subjects will receive for 8 weeks the administration of CARDIOVIS COLESTEROLO 3 mg, a nutraceutical compound containing containing red rice fermented with Monascus purpureus titrated with 3% monacolin K, hydrol mixture of olive fruit titrated with vitamin E, Coenzyme Q10 and polymethoxyflavones
2453635|NCT03216720|Active Comparator|CABG with miniaturized ECC|Elective (CABG) with conventional miniaturized extracorporeal circulation (miECC)
2453639|NCT03216720|Active Comparator|CABG with conventional ECC|Elective CABG with conventional extracorporeal circulation (cECC)
2453672|NCT03216343|Experimental|Study Arm|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle until objective disease progression
2453721|NCT03216174|Experimental|NESS-EFTR|This arm will be received non-exposure simple suturing endoscopic full-thickness resection after sentinel lymph node navigation
3190533|NCT00788554|Active Comparator|2|
3190534|NCT00788567|Experimental|1|
3190535|NCT00788606|Experimental|bevacizumab and Rituximab|This study evaluates the feasibility using the anti-VEGF drug, bevacizumab, in combination with the standard treatment Rituximab in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
2453835|NCT03215459||Cardiopulmonary Exercise Test|A cardiopulmonary exercise bike test will be administered prior to palliative chemotherapy treatment.
2453881|NCT03215069|Experimental|Empagliflozin|Empagliflozin 10 mg PO daily
2453883|NCT03215069|Placebo Comparator|Placebo|Matched placebo PO daily
2453925|NCT03214692|Experimental|Gum Arabic|The patients will receive 30 grams of Gum Arabic dissolved in 200 ml of water to ingest orally
2453959|NCT03214393||Pre-Eclampsia|pregnant women with Pre-Eclampsia will be assessed by serum antibodies and Doppler
3190536|NCT00788619|Active Comparator|Day 3 transfer|Subjects in this arm will have two embryos transferred three days after fertilization. Embryos will be selected based on the concentration of nitric oxide metabolites in the culture medium.
2454094|NCT03213392||SUPRA ORBITAL KEYHOLE CLIPPING/ COILING|Aneurysms should be either clipped or coiled to prevent re rupture general anesthesia is required to carry out these procedures.various anesthetic agents are used as an maintenance agents.
2454119|NCT03213171|No Intervention|Usual care|Usual care / Standard of care No intervention implemented
2454126|NCT03213171|Experimental|Intervention|Reception staff providing handout; Mobile tablet that provides the immediate opportunity for patients to register in the waiting room
2454175|NCT03212898|Experimental|Intervention|Specific pharmacist-led anticoagulation care
2454183|NCT03212898|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
2454227|NCT03212495|Active Comparator|dexmedetomidine (D group)|intraarticular administration of dexmedetomidine at the end of surgery
2454233|NCT03212495|Active Comparator|neostigmine (N group)|intraarticular administration of neostigmine at the end of surgery.
2454306|NCT03211988|Other|Entinostat|Eligible patients will be enrolled according to Simon's two-stage design. The dose of Entinostat is 5 mg (one tablet) orally, once every week in a 28 day cycle.
3190537|NCT00788619|Active Comparator|Day 5 transfer|Subjects will have two embryos transferred on day 5 after fertilization with selection of embryos based on morphologic criteria.
3190538|NCT00788632|Experimental|educational materials|Patient educational DVD and brochure
2454472|NCT03210545|Active Comparator|betamethasone - physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated physiological dose during one treatment period.
3190539|NCT00788632|Other|physician education|Physician web modules
3190540|NCT00788632|Experimental|System intervention|Self-referral letter with toll-free number provided
3190541|NCT00788645|Experimental|Forecast|COPD patients receiving advice and poor weather warning
3190542|NCT00788645|Experimental|No Forecast|COPD patients receiving advice and poor weather warning
3190543|NCT00788645|No Intervention|Control|Age matched non - COPD subjects
3190544|NCT00788658|Placebo Comparator|Diet modifications|Diet consultation and life style modifications for 6 sessions
3190545|NCT00788658|Active Comparator|Cognitive therapy|6 sessions of cognitive behavioral therapy
3190546|NCT00788671|Experimental|Treatment (levonorgestrel-releasing intrauterine system)|Patients undergo placement of a levonorgestrel-releasing intrauterine system.
3154079|NCT00290082|Active Comparator|midazolam|midazolam is compared to loxapine in terms of efficacy and tolerance
2453351|NCT03218709|Experimental|High-dose multi-vitamins with minerals|Generic name: High-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
2453352|NCT03218709|Experimental|Low-dose multi-vitamins with minerals|Generic name: Low-dose multi-vitamins with minerals tablets Dosage form: Capsule Frequency: Two pills daily for 6 months
2453353|NCT03218709|Active Comparator|Hypouricemic tablets|Generic name: Hypouricemic tablets Dosage form: Capsule Frequency: Six pills daily for 3 months
2453354|NCT03218709|Placebo Comparator|Placebo|Generic name: Placebo Dosage form: Capsule Frequency: Two pills daily for 6 months
2453562|NCT03217461|Experimental|Corneal epithelial autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted corneal epithelial autograft
2453563|NCT03217461|Active Comparator|Limbal autograft|Corneal dermoid tumor resection combined with femtosecond laser assisted limbal autograft
2453697|NCT03216564|Experimental|Intervention Group|Participants are treated with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) AND active vitamin D (Calcitriol) 0.25 micrograms orally per day for 26 weeks.
2453698|NCT03216564|No Intervention|Usual Care|Participants are treated with ACEI/ARB alone for 26 weeks.
2453743|NCT03215979|Experimental|PEP-Arm|In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.
2453744|NCT03215979|Placebo Comparator|Placebo-Arm|This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.
2453862|NCT03215407|Experimental|Intra-articular Tocilizumab|Tocilizumab, solution, 80mg intra-articular.
2453864|NCT03215407|Active Comparator|Intra-articular Compound Betamethasone|Compound betamethasone, solution, 14mg intra-articular
2453889|NCT03214835|Experimental|Brush biopsy for laryngeal lesion|Brush biopsy of the larynx - in addition to the standard biopsy
2453892|NCT03214835|Experimental|Brush biopsy for LPR|Brush biopsy of the larynx at the post cricoid region - in addition to the standard examination for LPR (PH monitoring double probe)
2453938|NCT03214653|Active Comparator|Propofol|Those who received target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50.
2453946|NCT03214653|Active Comparator|Sevoflurane|Those who received sevoflurane 1,5-2% as maintenance agent of anesthesia.
2454093|NCT03213418|Experimental|Contingency management|
2454130|NCT03213197|Experimental|CPR video|Patient watches a short CPR video
2454192|NCT03212937|Experimental|Selinexor and ICE Chemotherapy|
2454204|NCT03212391|Experimental|Diet+Walking|52 weeks of Diet+26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
2454207|NCT03212391|Experimental|Diet+Nordic Walking|52 weeks of Diet+26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
2454250|NCT03212157|Experimental|GT1|Optimsation of glucose infusion protocol outside the Magnetic Resonance Imaging (MRI) scanner in healthy volunteers. To establish an optimised bolus and safety of infusion protocol of intravenous glucose to maximise exchange sensitive MRI signal.
2454251|NCT03212157|Experimental|GT2|Optimsation of glucose infusion protocol inside the Magnetic Resonance Imaging (MRI) scanner in patient volunteers. To assess the reproducibility of these techniques and initial proof-of-concept study in cancer patients
2454252|NCT03212157|Experimental|GT3|Use of glucoCEST technique in staging of head and neck SCC, lymphoma and gliomas and correlating diagnostic potential with standard imaging such as FDG PET. To apply exchange-sensitive MRI in selected cancer types to assess its diagnostic potential. To study of non-glucose endogenous exchange sensitive MRI signals in (a) Prostate Cancer and (b) high grade Glioma patients.
2454267|NCT03211845|Experimental|Nutritional telemonitoring|Nutritional telemonitoring including self-measurements of body weight, nutritional status, appetite, diet quality and physical activity. Additionally, participants receive guidance on nutrition and physical activity by means of customized and general television messages and/or if necessary personal guidance by a nurse.
2454319|NCT03211702||Elderly DLBCL patients|Elderly DLBCL patients (age>=65 years) treated with R-CHOP chemotherapy
2454404|NCT03211104|Experimental|curcumin|"Curcumin extracted from curcuma longa linn.~formulation : curcumin powder 240mg/capsule~general name : Diferuloylmethane~Taking curcumin 3 times a day(1,440mg/day) for 6 months at the first off treatment in patients with prostate cancer receiving intermittent androgen deprivation therapy"
2454407|NCT03211104|Placebo Comparator|control|The control group Take a placebo containing lactose and vitamin B2. Reddish brown capsules with the same shape as curcumin.
2454437|NCT03210805|Experimental|Supplementation|Omega-3 Polyunsaturated Fatty Acids
2454510|NCT03210467||experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454519|NCT03210467||control group|patients who were untreated ever in immune-active phase took entecavir(ETV) for maintenance treatment.
3154080|NCT00290121|Active Comparator|Olanzapine|
3154081|NCT00290420|Experimental|Chloroquine profilaxis|"Prevention: chloroquine profilaxis~Prevention of malaria attacks with chloroquine profilaxis taken once a week"
3154082|NCT00290420|No Intervention|No prevention|Treatment of malaria attack with chloroquine when they occur
3154083|NCT00290511|Experimental|R-FIND + Zevalin|Fludarabine 25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4. Mitoxantrone 10 mg/m^2 IV over 5-30 minutes on Day 2. Rituximab 375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total). Zevalin 0.3 mCi/kg IV after 4 cycles of R-FND. Dexamethasone 20 mg by mouth (PO) or IV daily on Days 2-6.
3154084|NCT00290550|Other|1|MK-0457
3174509|NCT00624325|Experimental|1|12 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
2453222|NCT03219736|Active Comparator|NiPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine (EnVe Ventilator). Optimal settings for each participant should be achieved within 20 minutes of initiation of NiPPV. Pediatric asthma scores will continue to be recorded at least every hour or with every physician suggested NIPPV ventilator setting change for an 8 hour period. Furthermore, the NIPPV machine in conjunction with NM3 volumetric end tidal CO2 monitoring will record ventilatory data in this NIPPV/BiPAP group and will be compared to other study groups. The subjects will remain in the study for minimum of 4 hrs NIPPV therapy and total of 8 hours.
2453252|NCT03219463|Experimental|Regular Exercise Group|at least 30 minutes of moderate to vigorous activity at least 3 times per week. Will recieve 3 grams of ginger for 8 weeks.
2453253|NCT03219463|Active Comparator|Non Regular Exercise Group|at least 30 minutes of moderate to vigorous activity 1-2 times per week. Will recieve 3 grams of ginger for 8 weeks.
3190547|NCT00788684|Experimental|ABT-263 + rituximab|
3190548|NCT00788723|Experimental|1|Patients with severe brain injury, awake, but have cognitive problems
2453396|NCT03218475|Experimental|MR Guided Focused Ultrasound|
2453410|NCT03218176|Active Comparator|Proximal single upper limb|Laying a single tourniquet on the root of the upper limb
2453411|NCT03218176|Experimental|Proximal staggered upper limb|Laying two staggered tourniquets : one on the root of the upper limb and a second 5 cm below the previous one
2453413|NCT03218176|Experimental|Distal single upper limb|Laying a single tourniquet on the forearm
2453415|NCT03218176|Experimental|Distal staggered upper limb|Laying two staggered tourniquets : one on the forearm and a second 5 cm below the previous one
2453419|NCT03218176|Active Comparator|Proximal single lower limb|Laying a single tourniquet on the root of the lower limb
2453426|NCT03218176|Experimental|Proximal staggered lower limb|Laying two staggered tourniquets : one on the root of the lower limb and a second 5 cm below the previous one
2453434|NCT03218176|Experimental|Distal single lower limb|Laying a single tourniquet on the calf
2453438|NCT03218176|Experimental|Distal staggered lower limb|Laying two staggered tourniquets : one on the calf and a second 5 cm below the previous one
2453556|NCT03217513||Forteo|teriparatide 20-microgram once daily available in a 2.4-mL delivery device for subcutaneous injection by the patient
2453560|NCT03217513||Prolia|denosumab 60 mg administered as a single subcutaneous injection every 6 months by the health care provider
2453617|NCT03217058||Pre-implementation|The pre-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services prior to implementation of computerized screening and behavioral intervention in the clinics.
2453624|NCT03217058||Post-implementation|The post-implementation cohort includes data from 5000 HIV primary care clinic patients in Kaiser Permanente Northern California, who receive services after computerized screening and behavioral intervention have been implemented in the clinics.
2453660|NCT03216525|Active Comparator|Oral Alvimopan|Oral Alvimopan (Entereg, Merck) 12 mg between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
2453661|NCT03216525|Placebo Comparator|Matching Placebo|Matching placebo between 30 minutes and 3 hours before surgery start and twice-daily oral doses postoperatively beginning on day one (AM and PM dosing) until hospital discharge or a maximum of 7 days (15 in-hospital doses).
2453693|NCT03216252|Other|biological samples|biological samples on patients with MITOCHONDRIAL DISEASES
2453807|NCT03216096|Experimental|3% DE-089 ophthalmic solution|
3190549|NCT00788723|Experimental|2|Patients with severe brain injury and disorders of consciousness ( in minimally conscious or in vegetative state)
2453997|NCT03214185|Experimental|With PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,conventional embryo morphology evaluation and trophectoderm biopsy before blastocyst cryopreservation. Preimplantation genetic screening (PGS) will be performed to select euploid embryo. The patients will go through up to three times of frozen-thawed transfers of euploid blastocysts until ongoing pregnancy or live birth is acquired. Only one euploid blastocyst will be transferred at a time.
2454000|NCT03214185|Active Comparator|Without PGS 2.0|Patients will undergo IVF/ICSI procedure, and experience oocyte aspiration, fertilization,blastocyst formation,and conventional embryo morphology evaluation before blastocyst cryopreservation. The patients will go through up to three times of frozen-thawed transfers of good quality blastocysts until ongoing pregnancy or live birth is acquired. Only one good quality blastocyst will be transferred at a time.
2454040|NCT03213847|Other|Participants with carpal tunnel syndrome|Participants diagnosed with carpal tunnel syndrome; will be evaluated with Doppler ultrasound and superb microvascular imaging (SMI) ultrasound. The results of these two evaluations will be compared between each other in according to severity of carpal tunnel syndrome (severity will be determined by electromyography studies)
2454113|NCT03213249|Active Comparator|Arm 1: Intraoperative pocket irrigation with NS|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care saline pocket irrigation will receive 500 cc of normal saline alone per pocket."
2454114|NCT03213249|Active Comparator|Arm 2: Intraoperative pocket irrigation with NS + antibiotics|"1 gram cefazolin intravenous before surgical incision~Standard of care bilateral skin- or nipple-sparing mastectomies as determined by breast surgical oncologists~Immediate standard of care breast reconstruction with subpectoral tissue expanders and a 16 x 8 ADM sling~Standard of care antibiotic pocket irrigation will receive 500 cc of normal saline plus 1 gram cefazolin, 80 mg gentamicin, and 50,000 units bacitracin"
3190550|NCT00788723|Experimental|3|Healthy volunteers
3190551|NCT00788749|Placebo Comparator|Placebo|Placebo tablets for 2 weeks followed by fluticasone nasal drops 800mcg/d for 2 months followed by fluticasone nasal spray 400 mcg/d for 4 months
3190552|NCT00788749|Experimental|Prednisolone|25 mg Prednisolone OD for 2 weeks followed by Fluticasone nasal drops 800 mcg/d for 2 months, followed by fluticasone nasal spray 400mcg/day for 4 months
3190553|NCT00788762||Villagers in Taxiarchis|
2453314|NCT03218904|Experimental|Glucose intake|Experiment 1: study day 1- single oral dose of glucose study day 2- single oral dose of glucose with U-13C-glucose
2453319|NCT03218904|Experimental|Carbohydrates intake|Experiment 2: study day 1-single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3-single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
2453382|NCT03218722|Experimental|PCC treatment|Conventional strategy for ATC management in addition to of intravenous Pro-Thrombin Concentrate Complex (25IU/kg factor IX)
2453383|NCT03218722|Placebo Comparator|Placebo treatment|Conventional strategy for ATC management without PCC (NaCl 0.9%)
3154085|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x 2-weekly rituximab|Arm I (2-weekly rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days 0, 14, 28, 42, 56, 70, 84, and 98. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
3154086|NCT00290667|Active Comparator|Interventional: CHOP-14 + 8 x dose-dense rituximab|Arm II (pharmacokinetic-based dose-dense rituximab): Patients receive rituximab IV 375 mg/m^2 (females) and 500 mg/m^2 (males) over 4 hours on days -1, 0, 3, 7, 14, 21, 28, and 42. Patients also receive pegfilgrastim subcutaneously on day 4 of each course.
2453553|NCT03217253|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2453630|NCT03216941|Active Comparator|ketamine|assessment of agitation status with Ramsay Sedation Scale administration of ketamine 10 mg / ml IM one dose supervision of vital signs registration of time of ketamine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of ketamine administration) withdrawal of patient from the study if other medication was needed (aside of ketamine)
2453633|NCT03216941|Active Comparator|olanzapine|assessment of agitation status with Ramsay Sedation Scale administration of olanzapine 10 mg / ml IM one dose supervision of vital signs registration of time of olanzapine administration registration of time when expected outcome is obtained follow up of vital signs supervision until obsevation period expires (12 hours after admission to emergency board) registration of adverse effects registration if other interventions were applied (aside of olanzapine administration) withdrawal of patient from the study if other medication was needed (aside of olanzapine)
2453702|NCT03216460|Other|Supervised Free-Living|Subjects will undergo a 7±1 day outpatient, standard therapy phase during which sensor and insulin data will be collected. Subjects or their caregivers will manage their diabetes at home per their usual routine using the study CGM and remain on current MDI or pump therapy. This will be followed by a 5-day/4-night or from approximately 48 to 72 hours for children ages 2.0-5.9 years, hybrid closed-loop phase conducted in a supervised hotel/rental house setting, where subjects will participate in specific setpoint challenges, meal challenges, and exercise
2453817|NCT03215966|Experimental|Sequence A/B|Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
2453820|NCT03215966|Experimental|Sequence B/A|Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
2453841|NCT03215108|Experimental|Flower-CSEMS|EGIS Flower Biliary Full Covered Stent(Flower-CSEMS), Bile Duct Stent, (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
2453842|NCT03215108|Experimental|Conventional-CSEMS|Conventional-CSEMS (S & G Biotech Co., Ltd.) will be inserted by using Endoscopic Retrograde CholangioPancreatography(ERCP).
3154087|NCT00290758|Experimental|Arm I (genistein)|Patients receive oral genistein once daily for up to 6 months.
3154088|NCT00290758|Placebo Comparator|Arm II (placebo)|Patients receive oral placebo once daily for up to 6 months.
3154089|NCT00290823|Experimental|1|Participants will receive 6 mg dexamethasone daily for 10 days Participants will also receive albendazole and omeprazole.
3154090|NCT00290823|Experimental|2|Participants will receive 6 mg dexamethasone daily for 10 days, then 8 mg dexamethasone daily for 4 weeks with a 2-week taper. Participants will also receive albendazole and omeprazole.
3154091|NCT00290862|Experimental|CORTOSS|Patients prospectively randomized to be treated with Cortoss constitute treatment group.
3154092|NCT00290862|Active Comparator|PMMA|Patients prospectively randomized to be treated with PMMA constitute active control group.
3154093|NCT00290875|Other|Arm 1|We randomly allocated sites to either intervention or control. At the intervention sites, active strategies were employed to implement the rule into practice, including education, policy, and real-time reminders on radiology requisitions.
3154094|NCT00291031|Experimental|IRT|Patients randomly assigned to the IRT condition receive Imagery Rehearsal Therapy after 4 weeks since the entrance into the trial next to their treatment as usual.
3154095|NCT00291031|No Intervention|TAU|Patients that are randomly assigned to the waiting list control condition get treatment as usual (TAU) and complete the daily nightmare logs for a period of three months. These patients get the IRT intervention after waiting for 6 months.
3154096|NCT00291057|Experimental|1|MALG
3154097|NCT00291148|Active Comparator|Paroxetine|
3154098|NCT00291148|Active Comparator|pregabalin|
3154099|NCT00291200||1|Participants with basic symptoms of psychosis
3154100|NCT00291200||2|Control participants
3154101|NCT00291213|Experimental|Levetiracetram Administration|
3154102|NCT00291213|Placebo Comparator|Placebo|
3154103|NCT00291486|Experimental|Assigned Dose Level|
3154104|NCT00291525|Experimental|AVR Low Risk without warfarin|AVR Low Risk without warfarin
3154105|NCT00291525|Active Comparator|AVR low risk with standard warfarin|AVR low risk with standard warfarin
3154106|NCT00291525|Experimental|AVR High risk with lower warfarin|AVR High risk with lower warfarin
3154107|NCT00291525|Active Comparator|AVR High Risk with standard warfarin|AVR High Risk with standard warfarin
3154108|NCT00291525|Experimental|MVR with lower warfarin|MVR with lower warfarin
2453346|NCT03219086|Active Comparator|Group P|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
2453363|NCT03218553|Experimental|Dexamethasone|Standard cares plus postoperative administrations of glucocorticoid
2453370|NCT03218553|Placebo Comparator|placebo|Standard cares plus postoperative administrations of placebo
2453444|NCT03218111|Other|Healthy Normal Subjects|Healthy normal subjects 20-80 years old. All subjects will undergo the same procedures: intrathecal injection, using CT-guidance, with an MRI contrast. After injection subjects will undergo six sessions of MR imaging over a 10-12 hour period
2453501|NCT03217760||Patients|The main aim of the study is to examine the patient's induced stress during endodontic treatment in order to offer customised solutions to lessen stress. The other aims is also to evaluate the patient's pain and discomfort during endodontic treatment.
2453502|NCT03217760||Young dentists practitioners.|The other aims are to evaluate the young dentist's induced stress and to examine and compare the patient's induced stress and the young dentist's induced stress.
2453641|NCT03216681||Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
2453645|NCT03216681||Tanakan 40mg|Administered orally three times a day, one tablet each time, for 45 days.
2453703|NCT03216395|Experimental|Over-the-scope Clips|Endoscopic Application of Over-the-scope Clips
2453713|NCT03216395|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clips or pulse
2453755|NCT03215862|Active Comparator|Control|
2453761|NCT03215862|Experimental|Experimental|
2453794|NCT03215654|Experimental|Sensitization Program (SP)|Include the concepts of mental health and mental disorder, healthy and risky behaviors of mental health, and use of health services. Duration 1 hour.
2453800|NCT03215654|Experimental|Mental Health Literacy Program (MHL)|MHL module contents are: 1) Our emotions. Definitions of mental health and mental disorders. Mental health multidisciplinary team network; 2) Healthy and risky behaviors of mental health; 3) Social skills and antisocial behavior, bullying and cyberbullying; 4) Anxiety, depression, self-harm, and suicidal behaviors; 5) Eating and behavioral disorders; 6) Substance abuse (alcohol and cannabis), an psychotic disorder. Duration 6 hours.
2453803|NCT03215654|Experimental|MHL more Stigma Reduction (ER)|Includes the six teaching units of MHL and a first contact presentation with lived experience of any mental disorder, who will be delivered by a voluntary member of Activament Catalunya Associació (http://www.activament.org/es), a non-profit group specialized in reducing stigma. Duration 7 hours.
2453809|NCT03215654|No Intervention|Control group|Control group will be a waiting list condition and they will receive the full program of 7h at the next year of academic course
2453854|NCT03215264|Experimental|Single Arm|
2453873|NCT03214913|Other|EGDT Group|Early Goal Directed Therapy ：30ml/kg in the first bolus to have a CVP（central venous pressure） 8-12 mmHg and MAP（mean artery pressure ） 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenaline，red blood cell transfusion if necessary.
2453876|NCT03214913|Other|Ruijin Group|"Ruijin Strategy therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR（heart rate） <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT（hematocrit） 25%~35%."
2453920|NCT03214718|Experimental|CML patients treated with imatinib 400 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) by flowctytometry for each newly diagnosed chronic phase chronic myeloid leukemia (CML) patients treated with imatinib 400 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene level and the sokal score of the patients and deep molecular response of the patients after one year .
2453923|NCT03214718|Active Comparator|CML patients treated with nilotinib 600 mg/day|Measurement of the level of myeloid derived suppressor cells (MDSCs) for each newly diagnosed chronic phase chronic myeloid leukemia ( CML) patients treated with nilotinib 600 mg/day before starting treatment and every 3 months till one year and correlate between it and level of BCR-ABL gene, the sokal score and deep molecular response of the patients after one year .
3190554|NCT00788788|Active Comparator|1|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
3190555|NCT00788788|Active Comparator|2|Study subjects where breathing Heliox with a fraction of Helium of 50% followed by 75% and 25% with larger external resistor in comparison to medical air
2454011|NCT03214003|Experimental|SIB group|Patients in this group will receive concurrent twice-daily radiotherapy by SIB technique (95%PGTV 54Gy, 95%PTV 45Gy,both in 30 twice-daily fractions over 3 weeks, 5 days per week) and chemotherapy (etoposide and cisplatin).
2454013|NCT03214003|Active Comparator|BID group|Patients in this group will receive concurrent twice-daily standard radiotherapy (95%PTV 45Gy in 30 twice-daily fractions over 3 weeks, 5 days per week, without SIB) and chemotherapy (etoposide and cisplatin).
3190556|NCT00788788|Active Comparator|3|Study subjects where breathing Heliox with a fraction of Helium of 25% followed by 50% and 75% with larger external resistor in comparison to medical air
2454136|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Warm|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Warm condition uses water with a temperature of 44°. It induces a nystagmus with its slow phase towards the right.
2454139|NCT03213119|Experimental|Caloric Vestibular Stimulation, Left-Cold|Caloric Vestibular Stimulation (CVS) stimulates the vestibular system through thermic currents applied through small quantity of water injected in the external ear. The Left-Cold condition uses water with a temperature of 30°. It induces a nystagmus with its slow phase towards the left.
2454140|NCT03213119|Sham Comparator|Caloric Vestibular Stimulation, SHAM|The SHAM condition uses water with a temperature of 37°. It does not induce nystagmus
2454517|NCT03210246|Placebo Comparator|COC + Placebo|COC + Placebo
2453356|NCT03218761||Control Subjects|"Subjects who do not have Postural Tachycardia Syndrome.~They will have assessment of NET mRNA levels, supine plasma catechols, standing plasma catechols, and urine catechols."
2453442|NCT03218332||Former concussed pro-athletes|Biomarkers for detecting possible CTE invivo in former pro-athletes with multiple concussions: Imaging/blood/cerebrospinal fluid (CSF)/Positron emission tomography (PET-)tau/magnetic resonance imaging (MRI)/neuropsychological assessment.
2453443|NCT03218332||Healthy controls|Active Comparator
2453464|NCT03217851||Patients Presenting P. falciparum Malaria|
2453513|NCT03217552||The Emergency Department|"The study aims to evaluate the test in this environment as a potential diagnostic. All patients will be screened using the electronic patient management system within the ED.~A single sample of approximately 20ml of blood, will be obtained at the same time as a clinically indicated blood culture (triggered by clinician concern for infection). The sample will be processed as described in the laboratory manual, aliquoted and frozen for future batch analysis. This analysis will include:~The Mologic Biomarker Panel~PCT~CRP~Other inflammatory markers or pathogen detection that may augment the panels accuracy~All conventional standard of care testing will be done at the study site as part of the enrolled subject's routine clinical care."
2453514|NCT03217552||Critical Care Unit|"Two patient populations admitted to the CCU will be approached for inclusion into the study:~Patients being managed for potential infection~Patients having undergone elective major surgery and admitted to the CCU as part of their care pathway. These patients will act as controls as the majority show signs and symptoms of inflammation but rarely develop an infection.~Patients with potential infection: UCLH Critical Care Unit has approximately 1000 emergency admissions per year. Complicated infection (sepsis or septic shock) being the commonest underlying reason for admission."
2453515|NCT03217552||Patients undergoing major surgery|UCLH Critical Care admits approximately 1000 patients per year following major elective surgery. These patients frequently exhibit the features of SIRS but the incidence of infection/sepsis is low (approximately 5%) and very rare in the first 3 days' post-surgery. This group is to be studied as a negative control group to ensure the Mologic Biomarker Panel is able to detect the difference between the similar inflammatory phenotypes developed through infection and surgical trauma.
2453571|NCT03217227||Healthy Volunteer|"Healthy Volunteers will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Activity and Lifestyle Questionnaires~Fat Mass Measurement"
2453573|NCT03217227||Patients with Stable Angina|"Patients will undergo the following study procedures:~Cardiovascular Magnetic Resonance Imaging with Exercise Bike~Blood Sampling~Cardiac Catheterization~Activity, Lifestyle and Medication Compliance Questionnaires~Fat Mass Measurement~Retinal Photography (Optional)~I123 MIBG scan (Optional)"
2453700|NCT03216304|Experimental|rosuvastatin|Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at day 1)
2453707|NCT03216304|Experimental|safinamide + rosuvastatin|Film-coated tablets Safinamide will be administered at the dose 100 mg (once a day for 11 days) Film-coated tablets Rosuvastatin will be administered at the dose of 20 mg (single dose at 12)
2453770|NCT03215914|Experimental|Subjects with type 1 diabetes using MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
3154109|NCT00291525|Active Comparator|MVR with standard warfarin|MVR with standard warfarin
3154110|NCT00291616|Active Comparator|1|Pegylated Interferon-alpha2a
3154111|NCT00291616|Active Comparator|2|Thymosin alpha1 & Pegylated Interferon-alpha2a
3154112|NCT00291720|Active Comparator|Spironolactone|25mg spironolactone daily
2453931|NCT03214536|Experimental|erector spinae block|bilateral erector spine block with 20 ml 0,375% ropivacaine
2453992|NCT03214172||Cancer-associated thrombosis|Adult patients with active cancer with at least one index venous thromboembolism (VTE) and no anticoagulation use during the 6-months (baseline period) prior to the index VTE event
2454027|NCT03213951||Prostate cancer|Gleason grade group 1-5 on prostate biopsy or prostate cancer recurrence.
2454123|NCT03213080||TLD Procedure|All subjects who are enrolled and meet the eligibility criteria will undergo Targeted Lung Denervation (TLD). TLD is a bronchoscopically-guided, minimally-invasive procedure using the Nuvaira™ Lung Devervation System. The Nuvaira System is intended for the long-term maintenance treatment of airway obstruction associated with COPD. TLD uses radiofrequency (RF) energy to ablate the airway nerve trunks of the vagus nerves that travel parallel to and outside of the main bronchi and into the lungs. Ablation of the nerves opens the airways and makes breathing easier.
2454159|NCT03213002|Experimental|Capecitabine amd Temozolomide|Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.
2454234|NCT03212534|Experimental|Prediction Algorithm|
2454238|NCT03212534|No Intervention|Control|
3154113|NCT00291720|Placebo Comparator|Placebo|matching placebo medication for the control group
3154114|NCT00291733|Active Comparator|1|500mg levetiracetam for one week and 1000mg levetiracetam for one week
3154115|NCT00291733|Placebo Comparator|2|placebo
3154116|NCT00291733|Active Comparator|3|After crossover arm 3 equals arm 1
3154117|NCT00291733|Placebo Comparator|4|After crossover arm 4 equals arm 2
3154118|NCT00291928|Placebo Comparator|Dose ranging|A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
3154119|NCT00291928|Placebo Comparator|Parallel Arm RCT|a parallel group part with randomization into one of 4 treatment arms (Part B).
3154120|NCT00291941|Experimental|1|Henogen HB vaccine
3154121|NCT00291941|Active Comparator|2|Fendrix vaccine
3154122|NCT00291954|Experimental|1|Henogen hepatitis B vaccine
3154123|NCT00291954|Active Comparator|2|HBVAXPRO hepatitis B vaccine
3154124|NCT00291980|Experimental|1|HB-AS02V vaccine
3154125|NCT00291980|Active Comparator|2|HBVAXPRO vaccine
3154126|NCT00292019||Robotic prostatectomy|Patients who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robotics.
2453359|NCT03218657|Experimental|experimental group|the patients treated with levamisole hydrochloride 150mg qod +androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
2453364|NCT03218657|Other|control group|the patients treated without levamisole hydrochloride，but androgens 80mg qd+cyclosporins 3-5mg/kg*d at least for one year
2453420|NCT03218254|Other|Methylphenidate - Placebo|Methylphenidate before placebo
2453427|NCT03218254|Other|Placebo - Methylphenidate|Methylphenidate after placebo
2453485|NCT03217825|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
2453487|NCT03217825|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
2453491|NCT03217825|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
2453494|NCT03217825|Active Comparator|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
2453526|NCT03217383|Experimental|MATRx plus test|All study participants will receive the same test protocol. All participants will complete the MATRx plus theragnostic test and receive a prediction of oral appliance outcome. All participants will then receive a custom oral appliance set to the predicted protrusive position or a sham position, and outcome home sleep tests will be performed with the custom oral appliance in place to determine if the test prediction was correct.
2453590|NCT03217162|Experimental|surfactant combined with mechanical ventilation|surfactant is given to the infant with ARDS.
2453591|NCT03217162|Active Comparator|mechanical ventilation|mechanical ventilation is given to the infant with ARDS.
2453634|NCT03216707|Sham Comparator|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
2453638|NCT03216707|Active Comparator|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
2453642|NCT03216707|Active Comparator|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
2453669|NCT03216317|Active Comparator|Intervention Group|Subjects will perform three weekly sessions of isometric handgrip training consisting of four series (two in each arm) with two minutes of isometric contraction with intensity of 30% of maximum voluntary contraction with interval between the two-minute series under the guidance of the trained researcher.
2453671|NCT03216317|No Intervention|Control Group|Individuals randomized to Control Group will be encouraged to increase their level of general physical activity, but without specific recommendations on physical activity.
2453731|NCT03216213|No Intervention|Control|Vignette contains no extra information
2453733|NCT03216213|Experimental|Frame|Vignette is framed in a particular manner
2453734|NCT03216213|Experimental|Norms|Vignette contains extra information about norms
2453735|NCT03216213|Experimental|All|Vignette contains extra information about norms and is framed in a particular manner.
3190557|NCT00788801|Experimental|Baseline|
2453886|NCT03215056|Experimental|PENTHROX® (methoxyflurane)|"PENTHROX® (methoxyflurane) administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 3 mL PENTHROX® is to be vaporised in a PENTHROX® inhaler. On finishing the 3 mL dose, another 3 mL may be used.~Dose of PENTHROX® should not exceed 6 mL in a single administration.~The patient is instructed to inhale ten successive inhalations of PENTHROX® (methoxyflurane) followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 6 mL of methoxyflurane."
2453887|NCT03215056|Placebo Comparator|Normal saline|"Normal saline will be administered as a liquid for inhalation and should be self-administered under supervision of research nurse trained in its administration, using the hand held PENTHROX® inhaler.~One vial of 5 mL of normal saline is to be vaporised in a PENTHROX® inhaler. On finishing the 5 mL dose, another 5 mL may be used.~Dose of normal saline should not exceed 10 mL in a single administration.~In this study, the patient is instructed to inhale ten successive inhalations of placebo followed by additional intermittent inhalations as required.~The maximum dose administered will not exceed 10 mL of placebo (2 × 5 mL)"
2453966|NCT03214601|Experimental|Relay Branch System|Subjects who receive the Relay Branch System for repair which includes those with aneurysmal disease, penetrating atherosclerotic ulcer (PAU), and chronic uncomplicated Type B aortic dissection.
2454021|NCT03213990|Other|Continuous Infusion|The prescribed Beta-lactam is administered by a continuous infusion.
2454023|NCT03213990|Other|Intermittent infusion|the prescribed Beta-lactam is administered by intermittent infusion over 30 minutes
2454148|NCT03213041|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30-60 minutes on day 1 beginning with course 3. Courses repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2454166|NCT03212664|Other|Exercise|Schroth-based physical therapy exercises for patients who agree to participate in exercises. Will be compared to observation-only treatment
2454269|NCT03212131|Experimental|Normal hepatic function|Subjects with normal hepatic function
2454273|NCT03212131|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
2454281|NCT03212131|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
2454346|NCT03211689|Experimental|Exercise Group|Participants will engage in up to 150 minutes of exercise per week, at a level of 11-14 on the Borg Rate of Perceived Exertion scale.
2454464|NCT03210779|Placebo Comparator|Placebo|Placebo lozenges three times daily for 16 days and placebo oil once daily for 8 days
3190558|NCT00788801|Experimental|ABT-614 Low Dose|
3190559|NCT00788801|Experimental|ABT-614 High Dose|
3190560|NCT00788814|Other|Control|Control group
2453379|NCT03218865|Active Comparator|Leoceed H high flux dialyzer|polysulfone membrane manufactured by Asahi Kasei Medical, with CE mark and intended for use in hemodialysis for patient suffering from acute or chronic renal failure
2453422|NCT03218267|Experimental|Individuals after total hip replacement|Individuals after total hip replacement. Patients treated at the Out-Patient Ward of W. Dega Orthopaedic-Rehabilitation Clinical Hospital of Karol Marcinkowski University of Medical Sciences in Poznań. The examination of participants included the static posturography and one-leg standing test.
2453428|NCT03218267|Active Comparator|control group|The group with healthy individuals; without total hip replacement. The examination of participants included the static posturography and one-leg standing test.
2453552|NCT03217565|Experimental|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered intravenously (IV). For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
2453557|NCT03217565|Experimental|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension. For body weight <10 kg: 3 mg/kg; for body weight 10 to <30 kg: 2.5 mg/kg.
2453652|NCT03216824|Active Comparator|Dressing|A dressing is maintained on the CVAD exit site.
2453654|NCT03216824|Experimental|No-Dressing|The CVAD exit site is not covered with a dressing.
2453674|NCT03216278|Experimental|Treatment A|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fed
2453677|NCT03216278|Active Comparator|Treatment B|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fed
2453679|NCT03216278|Experimental|Treatment C|Dapagliflozin/metformin XR 5/500 Mount Vernon Test Product Fasted
2453681|NCT03216278|Active Comparator|Treatment D|Dapagliflozin/metformin XR 5/500 Humacao Reference Product Fasted
2453682|NCT03216278|Experimental|Treatment E|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fed
2453683|NCT03216278|Active Comparator|Treatment F|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fed
2453684|NCT03216278|Experimental|Treatment G|Dapagliflozin/metformin XR 10/1000 Mount Vernon Test Product Fasted
2453685|NCT03216278|Active Comparator|Treatment H|Dapagliflozin/metformin XR 10/1000 Humacao Reference Product Fasted
2453975|NCT03214328||Determination of causes of fetal death|Both the extensive and selective protocols will be applied to each case of IUFD recruited, so that each case will serve as its own control. For each case, determination of cause from either protocol will be performed in a blind manner with respect to the other protocol.
2454014|NCT03214016|Experimental|Pilates method group|The participants will do Mat Pilates.
2454018|NCT03214016|Active Comparator|Aerobic training group|The participants will do aerobic exercise on treadmill.
2454080|NCT03213665|Experimental|Treatment (tazemetostat)|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2454163|NCT03212742|Experimental|IMRT - Temozolomide - Olaparib|"The therapeutic regimen will be divided into 2 different periods:~Radiotherapy period The patient will start IMRT (60Gy/30fr/6 weeks), TMZ(Temozolomide) chemotherapy (75mg/m²/day), and olaparib on the same day, on a Monday (day 1), within 6 weeks after surgery. The daily dose of TMZ (75 mg/m²) will be continued until the end of radiotherapy (6 weeks) and olaparib will be continued with the same dose until 4 weeks after the end of IMRT, as a single agent.~Maintenance period TMZ will then be re-introduced 4 weeks after the end of IMRT at the dose of 150 mg/m2/day on days 1 to 5 every 28 days, for a total of 6 cycles. Concomitantly, olaparib will be daily given at the maintenance dose level up to confirmed disease progression or unacceptable toxicities.~We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously"
2454239|NCT03212339|Experimental|Mothers with children <3 years of age|Dyads of mothers with children up to 3 years of age will be attending modified Group Attachment Based Intervention (mGABI) sessions at the SPARK Center that will include a small group of other mother-child pairs and approximately two therapists. Dyads will be offered the 10 session therapeutic intervention.
2454241|NCT03212339|Experimental|Mothers with children 3-5 years of age|Dyads of mothers with children between the ages of 3 and 5 years will be attending Brief Dyadic Intervention (BDI) sessions at Child Witness to Violence and/or the SPARK Center with their child and an individual therapist. Dyads will be offered the 10 session therapeutic intervention.
2454257|NCT03212027||Patients with low-risk thymomas|low-risk thymomas include types A, AB, and B1 thymomas
2454258|NCT03212027||Patients with high-risk thymomas|high-risk thymomas include types B2 and B3 thymomas
2454259|NCT03212027||Patients with thymic carcinomas|thymic carcinomas also called types C thymomas
2454276|NCT03211819|Experimental|computer guided placement|"In the test group, the computer guided surgical guide manufactured using zenith 3D printer (Dentis, Daegu, Korea) will be used for implant drilling and placement (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) following the manufacture's instructions.~Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH, Germany) will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown."
2454283|NCT03211819|Active Comparator|free hand placement|in the control group, the implant will be placed it the socket using free hand technique and according to the manufacturing instruction's (s-Clean Tapered Implants, Dentis Co., Ltd., Woram-Dong, Dalseo-Gu, Daegu, South Korea) . The implants will be placed guided by the socket of the root. Then in implants with primary stability > 35 Ncm2, the final abutment will be placed and any further adjustment would be done immediately in the lab and repositioned in place. Then the vacuum stent will be checked in its place again intraorally, then a chair side tooth coloured autopolymerizing resin (Structur 2 SC / QM,VOCO GmbH,Germany)will be injected into the vacuum sheet corresponding to the implant site to construct the temporary crown.
2454345|NCT03211676|Active Comparator|Theranova-500|
2454351|NCT03211676|Sham Comparator|Elisio-21H|
2454403|NCT03211130|Experimental|SystemCHANGE™|
2454406|NCT03211130|Active Comparator|Attention-Control|
2454454|NCT03210779|Active Comparator|L.reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 16 days + L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA probiotic oil, topically, once daily for 8 days.
3154127|NCT00292032||Cardiac Arrest Survivors or Post Mortem Unexplained Cardiac|Probands - Unexplained Cardiac Arrest Survivors and Post Mortem Unexplained Cardiac Arrest Cases
2453447|NCT03218072|Experimental|HLX01 250 mg/m2|HLX01 250 mg/m2 administrated intravenously
2453451|NCT03218072|Experimental|HLX01 375 mg/m2|HLX01 375 mg/m2 administrated intravenously
2453454|NCT03218072|Experimental|HLX01 500 mg/m2|HLX01 500 mg/m2 administrated intravenously
2453481|NCT03217682|Experimental|Music Therapy|Music therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
2453484|NCT03217682|Experimental|Massage Therapy|Massage therapy twice a week for two weeks, each session lasting approximately 45 min-1 hr
2453518|NCT03217409|Experimental|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg Rosuvamibe ® Tablet, 1T, Once a day/8week
2453520|NCT03217409|Active Comparator|Rosuvastatin|Rosuvastatin 5mg Monorova ® Tablet, 1T, Once a day/8week
2453578|NCT03217071|Experimental|Pembrolizumab|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles, prior to surgery. Pembrolizumab will be administered via IV infusion for 30 minutes. Surgery will occur no later than 6 weeks following the last dose of pembrolizumab.
2453582|NCT03217071|Experimental|Pembrolizumab + Radiation|Patients will receive 200mg pembrolizumab on Day 1 of each 3 week cycle, for 2 cycles. Pembrolizumab will be administered via IV infusion for 30 minutes.Within the week (7 days +/- 3 days) following administration of the second cycle, a single 12 Gy dose of stereotactic radiation therapy (SRT) will be delivered to 50% of the primary tumor only. Definitive surgical resection will occur no later than 6 weeks following the last dose of pembrolizumab.
2453637|NCT03216668|Experimental|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks
2453643|NCT03216668|Active Comparator|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
2453688|NCT03216408|Experimental|Neuronox|Botulinum toxin type A for Injection
2453689|NCT03216408|Active Comparator|Botox|Botulinum toxin type A for Injection
2453722|NCT03216135||(GERD) with no Barrett's Esophagus|Squamous epithelium from patient with gastroesophageal reflux disease (GERD) with no BE or EAC diagnosed will be collected and a control sample (area with no disease).
2453727|NCT03216135||Barrett's Esophagus|BE/columnar epithelium from patient diagnosed with BE and a control sample (area with no disease).
2453728|NCT03216135||Cancer Tissue|Cancer tissue, and a control squamous epithelium from the same patient.
2453754|NCT03215888||Obese|Obese individuals undergoing bariatric surgery
2453760|NCT03215888||controls|matched non-obese controls
2453849|NCT03215238||neurosurgical patients|Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
2453850|NCT03215238||Neurointerventional patients|Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects
2454010|NCT03214289|Experimental|Fecal Microbiota Transplantation (FMT)|"Participants will receive a single dose of oral FMT, which is 15 capsules per day for 2 consecutive days (total of 30 capsules). All capsules administered to a participant are from the same unrelated donor. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Participants will be asked to drink at least 360cc of water during administration.~Treatment will be administered on an inpatient basis. In patients with no/partial response, the FMT may be repeated from the same or a different donor.~Subjects receiving any amount of the FMT capsules will be followed for at least 6 months.Stool and blood samples will be serially collected."
2454063|NCT03213600|Active Comparator|transcranial Direct Current Stimulation ( tDCS )|Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes
2454066|NCT03213600|Sham Comparator|transcranial Direct Current Stimulation ( tDCS)|Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes
2454109|NCT03213353|Experimental|Treatment sequence AB|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
2454111|NCT03213353|Experimental|Treatment sequence BA|"Treatment A (experimental): Two tablets of Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride~Treatment B (active comparator): One sachet Vicks Active SymptoMax Plus, powder for oral solution, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride"
2454120|NCT03213093|Other|Diabetic patients with a risk of diabetic foot ulcer|
3154128|NCT00292032||First Degree Family Members|First Degree Family Members of those affected by Sudden Unexplained Cardiac Arrest
3154129|NCT00292071|Other|1|IV caspofungin acetate (50 mg/m²/day)
2454215|NCT03212443|Sham Comparator|Group A|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
2454218|NCT03212443|Active Comparator|Group B|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
2454323|NCT03212183|Experimental|EPI-TAVIE|Patients assigned to this arm will be invited to complete a web-based nursing intervention called EPI-TAVIE.
2454325|NCT03212183|Other|Websites|Patients assigned to this arm will be invited to consult a validated list of predetermined conventional websites.
2454427|NCT03211377||neoadjuvant therapy group|Preoperation chemotherapy treatment for patients up to four cycles
2454430|NCT03211377||adjuvant therapy|Postoperation chemotherapy treatment for patients up to six cycles
2454432|NCT03211377||Perioperative therapy|Preoperation chemotherapy treatment for patients up to four cycles and postoperation chemotherapy up to six cycles
2454441|NCT03210623|Experimental|group A|subjects applying the stent retriever(TonbridgeMT)
2454447|NCT03210623|Active Comparator|group B|subjects applying Solitaire™
3154130|NCT00292071|Other|2|IV caspofungin acetate (70 mg/m²/day)
3154131|NCT00292097|Experimental|1|Early conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
3154132|NCT00292097|Active Comparator|2|Conventional conversion from endotracheal intubation to percutaneous tracheostomy for ventilator support of trauma patients with severe brain injury
2453450|NCT03218033|No Intervention|Control|Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules for 8 weeks. At the end of each module there were questions pertaining to the subject of each module. The control group answered the questions in provided journals and these were sent back to the investigator. All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies.
2453455|NCT03218033|Active Comparator|Social Media (SM)|"The intervention phase was 8 weeks in duration. Participants visited the Facinglupustogether.com website and participated in consecutive weekly modules. 8 The SM group answered the questions at the end of each module on a blogging site with other SM participants. SM participants were encouraged to provide feedback or questions about the material or personal questions that arose in response to each module.~All subjects completed surveys in REDCap prior to the study intervention and again 6 weeks after study completion to assess secondary outcome measures. Medication adherence was assessed by calculating a medication possession ratio by acquiring information on fill dates at the subjects' pharmacies."
2453486|NCT03217708||Children without OSA|Children for AT due to chronic tonsillitis without OSA.
2453488|NCT03217708||Children with OSA|Children with OSA for AT as determined by PSG
3154133|NCT00292110|Active Comparator|Arm Four|
3154134|NCT00292110|Experimental|Arm One|
3154135|NCT00292110|Active Comparator|Arm Three|
3154136|NCT00292110|Active Comparator|ArmTwo|
2453709|NCT03216239||Colectomy Group|Mean age 52.3 years (range:20-85), 82% females, and a mean duration of symptoms of 79.9 months in the colectomy group. The indication for colectomy was constipation (36%), diverticular disease (8%), bowel obstruction (8%), colorectal carcinoma (8%), colon polyps (6%), and other (34%).
2453717|NCT03216239||Control Group|Mean age of 49.9 years (range 18-88), 76% females, and mean duration of symptoms 77.6 months,
2453784|NCT03216057|Experimental|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 grams of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega Rx Dr.Sears Zone labs Inc.
2453787|NCT03216057|Placebo Comparator|Placebo|Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
2453860|NCT03215355|Experimental|Participants receiving Primovist|Because this is a proof of concept study, only one arm will be considered which is the patients that receive the one time contrast injection prior to their first treatment. The intervention is that although this drug is approved, an off label dosing regiment is being used to improve a separate imaging modality than what it was approved for. Based on preliminary phantom experiments and toxicity results in the literature, four times the dose was deemed safe and required to use for CBCT.
2453899|NCT03214874|Active Comparator|Demadex 20mg Tablet|Demadex (IR Torsemide) 20mg tablet once daily is the reference listed drug (RLD) and is marketed for decades to treat edema in Chronic Congestive Heart Failure (CHF) and Chronic Kidney Disease (CKD) patients
2453901|NCT03214874|Experimental|ER Torsemide 20mg Tablet|ER Torsemide 20mg tablet once daily is is the new formulation that will release the active ingredient over an extended period
2453934|NCT03214575|Active Comparator|Conventional method|For the Conventional method of ultrasound guided central venous catheter insertion,we use the ultrasound machine, eZono 4000 and linear array transducer L3-12NGS (3-12 MHz)
2453940|NCT03214575|Experimental|GPS method|For the GPS method, we use the ultrasound machine, eZono 4000 with built-in adaptive needle recognition software called eZGuide (eZono, Jena, Germany) and linear array transducer L3-12NGS (3-12 MHz).
2454047|NCT03213769|Active Comparator|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
2454052|NCT03213769|Placebo Comparator|carbapol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
2454084|NCT03213470|Other|Intracranial artery dissection|Patients with intracranial artery dissection who were diagnosed based on the clinical and radiological (including MRI) diagnoses at the symptom onset after Jan-01-2016
2454124|NCT03213236|Experimental|OSA Homemonitoring|Homemonitoring diagnostic system
2454213|NCT03212300|Active Comparator|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
2454214|NCT03212300|No Intervention|treatment as usual|standard treatment
3154137|NCT00292201|Experimental|1|Atorvastatin
3154138|NCT00292201|Placebo Comparator|2|Placebo Pill
3154139|NCT00292253|Experimental|Rebif® with Rebiject™Mini|
3154140|NCT00292253|Active Comparator|Rebif® without Rebiject™Mini|
3154141|NCT00292266|Experimental|Rebif®|
3154142|NCT00292266|Active Comparator|Avonex®|
3154143|NCT00292279|Experimental|A|
3154144|NCT00292279|Active Comparator|B|
3154145|NCT00292292|Experimental|Kineflex Lumbar Artificial Disc|Treatment arm
3154146|NCT00292292|Active Comparator|Charite|
3154147|NCT00292305|Experimental|T-crush stenting|Percutaneous coronary intervention with implantation of a stent
3154148|NCT00292305|Active Comparator|Culotte stenting|Percutaneous coronary intervention with stent
3154149|NCT00292396|Active Comparator|1|Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks
3154150|NCT00292396|Active Comparator|2|Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks
3154151|NCT00292396|Active Comparator|3|Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks
3154152|NCT00292396|Active Comparator|4|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks
3154153|NCT00292396|Active Comparator|5|Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks
3154154|NCT00292396|Placebo Comparator|6|placebo, 12 doses
3154155|NCT00292474|Experimental|TAXUS Express|
3154156|NCT00292474|Placebo Comparator|Express Bare|
3154157|NCT00292500|No Intervention|C-Port|Automated distal anastomotic device
2453470|NCT03217773|Experimental|ESD|ESD is an endoscopic procedure that enables en bloc resection of large tumors in the gastrointestinal tract, irrespective of the size of the lesion. ESD uses an electrosurgical cutting device to purposely dissect the deeper layers of the submucosa to remove neoplastic mucosal lesions in a single piece.
2453474|NCT03217773|Active Comparator|TAMIS|TAMIS is a minimally invasive means of removing large rectal neoplastic lesions not accessible by conventional transanal excision. It is performed using the GelPOINT path transanal access platform and laparoscopic instruments.
2453546|NCT03217474|Experimental|FLDEB combined with GCV orally|Femtosecond laser-assisted cornea debridement (FLDEB) combined with ganciclovir (GCV) orally.
2453549|NCT03217474|Active Comparator|GCV orally|Ganciclovir (GCV) orally only
2453606|NCT03216967|Active Comparator|IS lowering alone|50% decrease of the dose of mycophenolic acid at M1 (target AUC 20 mg.h/L)
2453607|NCT03216967|Experimental|Everolimus + IS lowering|Stop mycophenolate acid (Cellcept or myfortic) Introduction of everolimus : 2 x 0.75 mg/d per os in patiens treated by ciclosporine
2453699|NCT03216434|Experimental|PTSD Diagnosed|Veterans exposed to combat and diagnosed with PTSD. MRI using DaTscan.
2453706|NCT03216434|Experimental|Designated Combat-Experienced Controls|Veterans exposed to combat, but never diagnosed with PTSD. MRI using DaTscan.
2453752|NCT03216005|Experimental|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
2453782|NCT03215524|Experimental|ARM A|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8, 15 of each 28-day cycle for 24 cycles.~Dexamethasone, orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration, 40 mg dexamethasone weekly.~Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle."
2453786|NCT03215524|Experimental|ARM B|"Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide~Daratumumab, IV, at 16 mg/kg, or Daratumumab, SC, at 1800 mg on days 1, 8, 15 and 22 for Cycles 1 and 2, on Days 1 and 15 for Cycles 3-6, and Day 1 of each cycle for Cycle 7 and beyond for each 28-day cycle.~Cyclophosphamide, orally, at 400 mg on Days 1, 8 and 15 of each 28-day cycle for 24 cycles.~Dexamethasone,orally, at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day. On weeks without daratumumab administration,40mg dexamethasone weekly.~Pomalidomide, orally, added at first progression at 4 mg on Days 1- 21 of each 28-day cycle."
2453867|NCT03215121|Active Comparator|One handed mask airway, switch to two hands|Induction of anesthesia started as follows while children are breathing spontaneously: One handed mask airway + chin lift - 20 sec and then switch to two hands + jaw thrust - 20 sec
2453868|NCT03215121|Active Comparator|Two handed mask airway + jaw thrust|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 40 sec
2453869|NCT03215121|Active Comparator|Two handed mask airway, switch to one hand|Induction of anesthesia started as follows while children are breathing spontaneously: Two handed mask airway + jaw thrust - 20 sec and then switch to one hand + chin lift - 20 sec
2453918|NCT03214796||Albumin infusion|Patients with decompensated cirrhosis and an indication for routine human albumin infusion
2453953|NCT03214445|Experimental|resin composite with nanofiller.|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
2453962|NCT03214445|Active Comparator|sealant based on resin|30 restorations of resin composite occlusal, molars or premolars, with values of 3 or 4 for the parameter marginal adaptation according to the FDI criteria randomized assigned in this group
2453967|NCT03214445|No Intervention|Control|The restorations were evaluated without treatment about defective restoration that was considered clinically acceptable.
3190561|NCT00788840|Active Comparator|1. Insulatard|
2454051|NCT03213756|Experimental|Preoperative isometric exercise (PIE) group|In the PIE group, the patients will perform daily preoperative exercise protocol based on isometric exercises using hand grip and elastic bands. They will perform this protocol for at least six and ideally eight weeks before surgery.
2454053|NCT03213756|No Intervention|Control group|Control group patients will follow the usual surgical waiting list protocol (Estimated 1,5-2 months).
2454077|NCT03213483|Active Comparator|Subepithelial connective tissue graft|Patients will receive a coronally advanced flap surgery with a subepithelial connective tissue graft for recession coverage.
2454078|NCT03213483|Experimental|De-epithelialized free gingival graft|Patients will receive a coronally advanced flap surgery with a de-epithelialized free gingival graft for recession coverage.
2454141|NCT03213288|Active Comparator|Delphinidin type anthocyanins|Bilberry extract
2454143|NCT03213288|Active Comparator|Cyanidin type anthocyanins|Black rice extract
2454146|NCT03213288|Placebo Comparator|Placebo|No anthocyanins
2454194|NCT03212755|Experimental|group 1|25 diabetic patients without diabetic nephropathy
2454195|NCT03212755|Experimental|group 2|25 type 2 diabetic patients with diabetic nephropathy
2454196|NCT03212755|Sham Comparator|group 3|25 healthy subjects
3190562|NCT00788840|Active Comparator|2. Detemir|
3190563|NCT00788853||A|
2454277|NCT03211897||Haloperidol 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2454280|NCT03211897||Ziprasidone 20mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2454287|NCT03211897||Olanzapine 10mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
3190564|NCT00788866|Experimental|Pomegranate juice|This arm with receive 8oz of pomegranate juice per day.
3190565|NCT00788866|Placebo Comparator|Placebo|This group will take 8oz of placebo juice that lacks pomegranate daily
2453543|NCT03217526|Experimental|Ex +WT Group|Ex: A standard exercise (SE) (active range-of otion exercises, balance and mobility exercises) WT: walking training on the treadmill (WT). This rehabilitation program physiotherapist will be applied to participants for five days a week.Walking training will be applied according to the gait speed determined by GAITRite computerized gait analysis system at initial assessment. Individuals will be trained on the treadmill.The duration of walking training and the speed of walking training will be recorded every day. The walking time will be determined according to the fatigue level of the individual. The level of fatigue of the individual will be questioned according to the modified borg scale.
3154158|NCT00292526|Experimental|enalapril arm|treatment with enalapril
3154159|NCT00292552||COPD subjects|Subjects with GOLD stage II-IV COPD
2453747|NCT03215823||1. Easy endotracheal intubation|Easy endotracheal intubation
2453748|NCT03215823||2. Difficult endotracheal intubation|Difficult endotracheal intubation
2453783|NCT03215693|Experimental|X-396 capsule|225mg once daily
2453907|NCT03214822|No Intervention|HMF (standard of care)|"The HMF Control Group will receive the current standard feeding protocol of human milk fortified with bovine (cow) human milk fortifier (HMF)"
2453908|NCT03214822|Experimental|H2MF|"The H2MF Intervention Group will receive identical treatment with human-derived human milk fortifier (H2MF) replacing standard bovine HMF until the baby reaches an adjusted gestation age of 33 weeks; followed by a 5 day ween to standard HMF according to the manufacturer's recommendation."
2453933|NCT03214549|Active Comparator|gull wing preparation veneers|intervention: gull wing preparation in laminates veneers proximal margin of the preparation is placed toward the lingual .The area of the proximal margin between the contact area and the gingival papilla is placed even further to the lingual. This preparation design helps to hide the margin when the restorations are viewed from an angle.
2453941|NCT03214549|Active Comparator|conventional preparation veneers|intervention: conventional preparation in laminates veneers preparation of veneers without lingual extension of preparation in mesial and distal areas
3154160|NCT00292552||Smoker controls|Subjects with smoking history but normal lung function
3154161|NCT00292552||Non-smoker controls|Normal healthy non-smokers
3154162|NCT00292695|Experimental|chemoradiation|Chemoradiation: IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
2454062|NCT03213743|Other|before dexmedetomidine|We took blood samples before the administration of dexmedetomidine to determine exression level of microRNA in the subjects.
2454157|NCT03212807|Experimental|Investigational|Durvalumab + Lenalidomide
2454244|NCT03212547|Experimental|Experimental group|"Verbal interventions made on infants (accompanied by their mothers) who presents sustained social withdrawal detected on the child consultations (at 2, 6 and 12 months of corrected gestational age), made by neonatologists certifieds in the assess of Alarm Distress Baby Scale. Theintervention is described in a guide for Promotion of verbal interventions for interaction , and will be supplemented with a written guideline for parents."
2454246|NCT03212547|No Intervention|Control group|Control group: infants will assist at child consultations (at 2, 6 and 12 months of corrected gestational age) whit non trained neonatologists. However, these group will receive a development stimulation guide adapted of the ministerial guides for the stimulation of development of the Ministry of Health of Chile.
2454337|NCT03211754|Experimental|Obese patients|Treatment for 8 weeks
2454398|NCT03211286|Active Comparator|TXA group|Tranexamic acid, a single dose of 1 g intravenous diluted in 100 mL saline solution at the time of surgical incision
2454401|NCT03211286|Placebo Comparator|Control group|Saline solution, 100 mL intravenous at the time of surgical incision
2454439|NCT03210727|Other|single arm|This arm will be used to pilot test the Ready to CARE program (with the caregivers) and measure outcomes (in the patients).
2454511|NCT03210454|Experimental|Treatment Group 1|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention.
2454518|NCT03210454|Experimental|Treatment Group 2|Farmers associations, including men and women, will be randomized to receive the smallholder marketing intervention combined with the intimate partner violence (IPV) prevention training.
3154163|NCT00292721|No Intervention|Control|
3154164|NCT00292721|Active Comparator|Celecoxib|
3154165|NCT00292747|Experimental|drotaverine + Ibuprofen placebo|Drotaverine 80 mg plus ibuprofen placebo orally
3154166|NCT00292747|Active Comparator|Drotaverine placebo + ibuprofen|Drotaverine placebo plus ibuprofen 400 mg orally
3154167|NCT00292747|Active Comparator|Drotaverine + ibuprofen|Drotaverine 80 mg plus ibuprofen 400 mg orally
3154168|NCT00292903|Experimental|A|
3154169|NCT00292903|Active Comparator|B|
3173156|NCT00608933|Active Comparator|Arm I (intervention)|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
2453564|NCT03217695|Experimental|Mindfulness-based Yoga Arm|"8-week period, 1x/week for 45-60 minutes/session. Sessions 1-2: Participants instructed to focus their attention on their breath, and the physical sensations in their bodies while holding the yoga postures, to develop sustained and focused attention. Sessions 3-4: exploring the sensorial qualities of physical sensation in the body whether pleasant or unpleasant and to notice thoughts and label them (e.g., planning, remembering), and to the same with emotions (e.g., worry, frustration, fear) to practice disengaging from automatic associative thinking. Session 6-8: Instructor will guide participants to allow sensations of discomfort or effort to be as they are and to bring awareness to automatic patterns of reactivity. The goal is to foster distress tolerance, provide opportunities for participants to practice self-care, and allow an opportunity to observe and respond skillfully, instead of react automatically, to unpleasant stimuli (sensations, emotions)."
2453619|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
2453623|NCT03216993|Experimental|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
3190566|NCT00788879|Experimental|1|This study arm is located in Brownsville, Texas. This community is exposed to the TSSC media messages as well as may be visited by the lay health workers and see the built environment changes
2453769|NCT03215810|Experimental|TIL+ Nivolumab|Tumor-infiltrating Lymphocyte Therapy (TIL) + Nivolumab Treatment Plan: Tumor harvest, Tumor-infiltrating Lymphocytes growth, 4 cycles of nivolumab, cytoreductive chemotherapy with cyclophosphamide and fludarabine, TIL infusion, Interleukin-2 treatment.
2453797|NCT03215472|Experimental|DASH Cloud intervention|In group 1, participants will be instructed to input their dietary intake daily for three months using the Nutritionix app. A participant's data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send daily or weekly feedback text messages reflecting DASH adherence. The intervention components include tailored feedback texts, and behavioral skills training videos.
2453801|NCT03215472|Experimental|Dash Light|Group 2 participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
2453875|NCT03215290|Experimental|Trans-parenchymal compressing suture|"TCS: After liver transection, check for active hemorrhage and visible sites of bile leakage of cutting surface by stainless gauze which covered up on the raw cutting surface for 5 minutes. For patients with any positive findings including bloodstain and (or) bile staining, the cutting surface was recognized as not good cutting surface and further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
2453877|NCT03215290|No Intervention|Exposed surface (ES)|147 Patients with exposed surface (ES) were matched as control group. No TCS.
2453917|NCT03214731|Experimental|low dose Art|25mg bid Artesunate and standard of care was given to patients
2453919|NCT03214731|Experimental|high dose Art|50mg bid Artesunate and standard of care was given to patients
2453921|NCT03214731|Placebo Comparator|placebo|Placebo and standard of care was given to patients
3190567|NCT00788879|No Intervention|2|The control group is located in Laredo. This community is not exposed to the TSSC messages nor does the campaign work to actively change the built environment or use lay health workers to share physical activity and nutrition information.
3190568|NCT00788905|Experimental|A|"Subject will continue conventional hemodialysis therapy for one week (no intervention phase) and then swtich to the Allient system for two weeks (active comparator phase)."
3190569|NCT00788918|Experimental|Chronic hepatitis C treatment|30 Chronic HCV patients with pending antiviral treatment. A majority will have pending treatment with interferon and ribavirin, and the treated patients will be assessed 8-12 weeks after starting treatment for interferon-induced depression.
3190570|NCT00788918|No Intervention|Healthy Controls|50 age, sex and education matched controls (matched 1:1 to participants in the HCV patient groups (+/- treatment)
3190571|NCT00788918|No Intervention|Former HCV infected|20 Subjects with prior HCV infection identified through positive HCV antibodies, but negative HCV RNA.
3190572|NCT00788918|No Intervention|Chronic HCV patient - no treatment|20 chronic HCV patients without pending antiviral treatment.
3190573|NCT00788931|Experimental|IV LBH589 + trastuzumab + paclitaxel|i.v. panobinostat
3190574|NCT00788931|Experimental|Oral LBH589 + trastuzumab + paclitaxel|oral panobinostat
3190575|NCT00788944|Other|1|
3190576|NCT00788970|Experimental|Acupressure|Acupressure adjuvant therapy
3190577|NCT00788970|Placebo Comparator|Placebo acupressure|Sham acupressure adjuvant therapy
2454309|NCT03211884|Experimental|Problem-solving therapy|Couched within Bandura's social-cognitive theory, self-management refers to the process by which individuals accept responsibility for and take action to change their behaviors, obtain knowledge related to their situation (e.g., behavioral manifestations of a TBI) through increased awareness and use of effective personal resources (e.g., skill in every-day problem-solving). This ultimately enhances the caregivers' confidence that they can cope with caregiving and behavior-related stressors in the care recipient.
3174510|NCT00624325|Experimental|2|9 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
3174511|NCT00624325|Experimental|3|6 MU interferon alfa-2b daily continuously subcutaneous in combination with 15 mg/kg/day ribavirin
3174512|NCT00624351|Placebo Comparator|Placebo|Phosphate-buffered Saline (PBS) infusions at study weeks 0, 1, 2, and 3.
3174513|NCT00624351|Experimental|EMAB 600mg|600 mg Epratuzumab infusions at study weeks 0, 1, 2, and 3.
3174514|NCT00624351|Experimental|EMAB 100mg|100 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3174515|NCT00624351|Experimental|EMAB 400mg|400 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3174516|NCT00624351|Experimental|EMAB 1200mg|1200 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
3190578|NCT00788970|No Intervention|No treatment|Wait list group (no treatment)
3190579|NCT00788996|Experimental|Lifestyle counseling|Usual care
3208575|NCT00976079|Placebo Comparator|Placebo TENS|Placebo TENS for 4 weeks plus standard physical therapy for same time period.
2453594|NCT03216759|Experimental|intervention|"After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning.~At the beginning of anesthesia induction, 3 μg / kg / h of dexmedetomidine was infused and adjusted to 0.3 ug / kg / h after 10 min of infusion until 30 minutes before the end of the procedure.~Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap."
2453644|NCT03216655|Experimental|traditional group|phone call
2453646|NCT03216655|Experimental|new device group|wechat group
2453675|NCT03216356|Experimental|CBT + ImRs + DCS pill|The experimental arm involves cognitive-behavioral therapy, imagery rescripting techniques and d-cycloserine medication (pill).
2453678|NCT03216356|Active Comparator|CBT + ImRs + placebo|The active comparator arm involves cognitive behavioral therapy, imagery rescripting techniques and placebo medication (pill).
2453680|NCT03216356|Active Comparator|CBT + I.E. + study pill|The placebo comparator involves cognitive behavioral therapy, imaginal exposure and study pill (DCS or placebo)
3154170|NCT00293085|Active Comparator|Docetaxel|"Docetaxel (Taxotere ) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
3154171|NCT00293085|No Intervention|Comparative arm|No chemotherapy will be administered. No specific salvage therapy after progression is defined.
2453772|NCT03215797|Active Comparator|phenylephrine and norepinephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of perioperative hypotension.
2453775|NCT03215797|Other|Norepinephrine and phenylephrine|Phenylephrine 100ug/ml and Norepinephrine 5ug/ml IV infusion in postoperative time in case of hypotension
2453822|NCT03215498|Experimental|Faster aspart followed by insulin aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
2453825|NCT03215498|Experimental|Insulin aspart followed by faster aspart|Each participant will have 2 dosing visits (faster aspart and insulin aspart), the order decided by lottery
2453932|NCT03215173|Experimental|Fit After Baby Group|Fit After Baby mobile health lifestyle intervention to increase postpartum weight loss, increase postpartum physical activity, and improve postpartum diet.
2453939|NCT03215173|Active Comparator|Text4Baby Control Group|Receive text messages from the free Text4Baby program.
2454002|NCT03214263||Cross-sectional samples:|Any patient followed in the DANBIO registry may be invited to participate when they meet for a scheduled routine clinical visit. These patients provide one cross-sectional blood sample.
2454004|NCT03214263||Longitudinal samples:|Any patient followed in the DANBIO registry will be invited to participate when they start treatment with a new DMARD. Switching from csDMARD to bDMARD, or from one bDMARD to another bDMARD indicates a new baseline.
2454007|NCT03214263||Samples of other biological material:|Patients followed in the DANBIO registry may be invited to participate if scheduled for one of the following procedures: joint puncture with extraction of synovial fluid, surgery or tissue sampling involving synovia, cartilage, bone, bone-marrow or other tissues. Representative samples from the synovial fluid or relevant tissue are collected after routine diagnostic or therapeutic analyses have been done
2454030|NCT03213782|Experimental|Experimental group|Nature based sounds are administered via head phones continuously for 20 minutes.
2454035|NCT03213782|No Intervention|Control group|Usual routine care was continued
2454082|NCT03213561|Experimental|Stable and Independent Communication Brain-computer Interfaces|Each arm will receive the same intervention.
2454187|NCT03212911|Active Comparator|3-standard dose HBV vaccination group|participants will receive 3 standard doses of HBV vaccination at 0, 1, 6 months
2454190|NCT03212911|Active Comparator|4-standard dose HBV vaccination group|participants will receive 4 standard doses of HBV vaccination at 0, 1, 2, 6 months
2454206|NCT03212378||CHIP 1 - low risk patients|
2454210|NCT03212378||CHIP 2 - medium risk patients|
2454212|NCT03212378||CHIP 3 - high risk patients|
2454253|NCT03212222|Experimental|Peek Acuity Screening|Cell phone application to be used for visual acuity screening.
2454254|NCT03212222|Active Comparator|Standard Visual Screening|Standard visual acuity screening administered at Duke University Eye Center regarded as the gold standard.
2454265|NCT03211871|Active Comparator|Group D|Group D received dexmedetomidine infusion 0,5 mcg/kg/h from induction in anesthesia to extubation
2454266|NCT03211871|Placebo Comparator|Croup C|group C (control) received normal saline infusion
2454317|NCT03211728|Experimental|experimental group|
2454318|NCT03211728|Placebo Comparator|placebo group|
2454363|NCT03211455|Placebo Comparator|Control|"intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit.~Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection."
2454364|NCT03211455|Experimental|Lidocaine|Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
2454411|NCT03211013|Experimental|Immediate Oxytocin|Participants randomly assigned to this arm will receive OT nasal spray (24 IU) at laboratory visit 1 and placebo nasal spray at visit 2. The order will be masked for participants and study staff.
2454416|NCT03211013|Placebo Comparator|Delayed Oxytocin|Participants randomly assigned to this arm will receive placebo nasal spray at laboratory visit 1 and OT nasal spray (24 IU) at visit 2. The order will be masked for participants and study staff.
2454507|NCT03210168|Experimental|BioFe Medical Food|Escalating consumption of BioFe in a single cohort of up to 40 subjects with iron deficiency.
2453608|NCT03217110|Experimental|patient active rTMS|Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.
2453613|NCT03217110|Sham Comparator|patient sham rTMS|Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.
2453614|NCT03217110|Active Comparator|Control active rTMS|
2453621|NCT03217110|Sham Comparator|Control sham rTMS|
2453710|NCT03216421|Other|Low/Intermediate Grade DCIS|Subjects with Low/Intermediate Grade DCIS will complete quality of life questionnaires before and after the IORT.
2453715|NCT03216421|Other|High Grade DCIS|Subjects with High Grade DCIS will complete quality of life questionnaires before and after the IORT.
2453763|NCT03215953|Active Comparator|Group A|cast shoe plus standard wound care
2453765|NCT03215953|Active Comparator|Group B|removable walker plus standard wound care
2453779|NCT03215563||Carotid|Patients with carotid artery stenosis who either do not meet surgical criteria (< 50% by NASCET criteria for men, <70% for women), or meet criteria but do not undergo surgery (surgery declined or not offered) and are currently treated with OMT. This cohort will be recruited from the acute TIA clinics and Vascular Laboratory logbooks at Edinburgh Royal Infirmary and Western General Hospital.
2453780|NCT03215563||Non Carotid|Patients with an atherosclerotic disease in the aortic arch including origins of its major branches other than the internal carotid artery treated with OMT. Patients with a cardiac source of embolism will be excluded from the study. This group will be recruited from the acute TIA clinics and inpatients at Edinburgh Royal Infirmary and Western General Hospital.
2453833|NCT03215446|Active Comparator|propofol|
2453834|NCT03215446|Experimental|sevoflurane|
2453870|NCT03215082|Experimental|Experimental|The intervention will be an individualized impairment-based program based on a pre-determined sequence. A minimal intervention for all participants randomized to the intervention group at all sites will include general oculomotor and gaze stabilization retraining as tolerated. Intervention activities will be recorded and described in detail in a treatment log.
2453871|NCT03215082|Active Comparator|Control|Standard care for mild TBI consists mainly of general education, energy conservation, academic adaptations, and restricting children and adolescents from participation in vigorous physical activities as well as complex cognitive activities until complete symptom resolution. It is the usual approach promoted by various associations and consensus groups. In addition, in all participating centers, children and teens requiring musculoskeletal approaches to address neck pain/dysfunction will receive it as indicated, based on the clinical judgment of the local team. Participants with moderate and severe TBI will also receive rehabilitation activities as planned in their respective centers. The standard care intervention will be recorded and described in detail in a treatment log.
2453926|NCT03214783||Coronary artery disease (CAD) group|Patients enrolled with at least one coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
2453927|NCT03214783||No CAD group|Patients enrolled without coronary lesion stenosis ≥50% according to coronary computer tomography or coronary angiography will be assigned to CAD group.
2453955|NCT03214354|Experimental|Non-myeloablative conditioning|Non-myeloablative conditioning
2454005|NCT03214029||Study population|Prospective, observational cohort study of consecutives patients (goal, 2000 patients over 5 months) presenting to the emergency department, in whom serial cTnI measurements are ordered on clinical indication at Hennepin County Medical Center (Minneapolis, MN, USA) to rule-in and rule-out acute myocardial infarction.
2454038|NCT03213834|Active Comparator|Thoracoscopy Arm|Consisting of chest thoracoscopy
2454044|NCT03213834|Active Comparator|Fibrinolytic Therapy Arm|Consisting of chest fibrinolytic therapy
2454061|NCT03213444|Active Comparator|Quimioterapy 1|adjuvant chemotherapy with 5-FU isolated
2454064|NCT03213444|Active Comparator|Quimioterapy 2|adjuvant chemotherapy with 5-FU associated with oxaliplatin
2454102|NCT03213340|Experimental|Catechin Cohort 1|2 treatment - Experimental Catechin Blend; Control 1 Placebo
2454103|NCT03213340|Experimental|Curcuminoid Cohort 2|2 treatment - Experimental Curcuminoid Blend; Control 1 Placebo
2454104|NCT03213340|Experimental|Flavonoid Cohort 3|2 treatment - Experimental Flavonoid Blend; Control 2 Low-Flavonoid Blend
2454125|NCT03213106|Experimental|Transcranial Magnetic Stimulation (TMS) Stimulation|All patients will receive 5 sessions of active TMS stimulation.
2454127|NCT03213106|Sham Comparator|Sham Stimulation|All patients will receive 5 sessions of active TMS stimulation
2454150|NCT03212872|Other|Endoscopy|
2454167|NCT03212677|Active Comparator|Iron-deficient children|Previously iron-deficient children aged 6-24 months on iron therapy. Ferrous sulfate administered at 4 mg Fe/kg/d per standard of care.
2454170|NCT03212677|No Intervention|Non-iron-deficient children|Non-iron-deficient children aged 6-24 months used as a reference.
2454172|NCT03212677|Placebo Comparator|Adult Placebo|Iron-replete postmenopausal women, and men, receiving placebo daily for 4 weeks.
2454173|NCT03212677|Experimental|Adult Ferrous sulfate daily|Iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving ferrous sulfate daily (containing 120 mg Fe per day) for 4 weeks.
2454182|NCT03212677|Experimental|Adult ferrous sulfate weekly|Iron-replete postmenopausal women, and men, receiving ferrous sulfate weekly (containing 60 mg Fe per day) for 4 weeks.
2454188|NCT03212677|Experimental|Adult ferrous sulfate + micronutrient|Iron-replete postmenopausal women, and men, receiving ferrous sulfate + micronutrient supplement (containing 60 mg Fe per day) for 4 weeks.
2454189|NCT03212677|Experimental|Adult IHAT|Iron-replete postmenopausal women, and men, receiving IHAT (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving IHAT (containing 120 mg Fe per day) for 4 weeks
2454193|NCT03212677|Experimental|Adult Aspiron|Iron-replete postmenopausal women, and men, receiving Aspiron (containing 60 mg Fe per day) for 4 weeks. In Phase II, iron-replete postmenopausal women, and men, receiving Aspiron (containing 120 mg Fe per day) for 4 weeks.
3154172|NCT00293137||1|Patients enrolled into the trial must have left ventricular ejection fraction of <40% by echocardiogram within 6 months of enrollment
2454469|NCT03210948|Experimental|RTE-guided EUS-FNA|"The needle will be then inserted into the most suspicious part (dark blue) of the lesion as assessed at real time elastography."
2453628|NCT03217084|Active Comparator|MI varnish GC|MI Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDEN Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue.
2453632|NCT03217084|Active Comparator|White Varnish 3M|"White Varnish is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. White Varnish an innovative tri-calcium phosphate.~Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish . Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue."
2453686|NCT03216473|Experimental|Neuronox|Botulinum Toxin Type A for injection
2453687|NCT03216473|Active Comparator|Botox|Botulinum Toxin Type A for injection
2453720|NCT03216148|Experimental|FET-PET|All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
2453948|NCT03214666|Experimental|GTB-3550 TriKE® (Phase I: Dose Finding Component)|Patients receive a single course of GTB-3550 TriKE® at their assigned dose as 3 weekly treatment blocks. Each block consists of four consecutive 24 hour continuous infusions (over approximately 96 hours) of GTB-3550 TriKE® followed by a 72 hour break after Block #1 and #2. All treatment is given as an inpatient. The assigned dose will be calculated on a weight obtained within 5 days prior to or on day of the 1st dose. The dose is not be recalculated for subsequent treatment blocks.
2453951|NCT03214666|Experimental|GTB-3550 TriKE® Only (Phase II: Extended Component)|The treatment schedule is identical to the dose finding component. The extended component uses a Simon's MiniMax two-stage design for continued enrollment using the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
2453999|NCT03214146|Experimental|HYNRCS-Allo inj.|"2 cycles of HYNRCS-Allo inj. with 6 months interval through intrathecal injection.~*1 cycle of HYNRCS-Allo inj. is 2 times administration with 28 days interval by intrathecal."
2454042|NCT03213886|Experimental|Calcifediol (Vitamin D) loading-dose|Participants in the intervention group will receive calcifediol16.000 units (U) /day for five days
2454048|NCT03213886|Active Comparator|Calcifediol (Vitamin D) at clinical practice dose|Participants in the control group will receive 16.000 U / week for five weeks
2454083|NCT03213496|Experimental|Walk prescription|Walk prescription for all weeks before non-cardiac surgery. Duration of walk must be of 30-40 minutes every day for five days at the week or until complete 150 minutes at the week, for all weeks up to the surgery.
2454091|NCT03213496|Other|Conventional care|Currently patients do not receive exercise (walk)-prescription before non cardiac surgery.
2454121|NCT03213158|Experimental|Highly sensitized kidney transplant candidates|The study population will include all highly sensitized kidney transplant candidates on the waitlist for more than 24 months at University of Wisconsin.
2454184|NCT03212950|Experimental|Fast-CL|Glucose control using DreaMed Glucositter and Fiasp® (Fast-CL)
2454191|NCT03212950|Active Comparator|Regular-CL|Glucose control using DreaMed Glucositter and regular insulin Aspart
2454216|NCT03212352|Placebo Comparator|Misoprostol|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive an oral placebo.
2454219|NCT03212352|Experimental|Misoprostol and Mifepristone|Before medical treatment with misoprostol (two doses 400mcg (four hours apart), repeated after 24 hours if no tissue is lost), patients receive oral mifepristone (600mg).
2454256|NCT03211949|Experimental|axillary block with infiltration MCAN|With the performance of the axillary blok, 2 ml of scandicaine will be placed around the medial cutaneous ante brachial nerve (MACN)
2454271|NCT03211793|Experimental|MSC injections|Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
2454279|NCT03211793|Placebo Comparator|Placebo injections|Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
2454338|NCT03211624||Cushing syndrome|Male and female patients with Cushing syndrome caused by ACTH-producing pituitary adenoma or cortisol producing adrenal adenoma
2454344|NCT03211624||Controls|Healthy controls matched for age, gender, and educational level
3190582|NCT00789022||1|40 subjects in a First Psychotic Episode
3190583|NCT00789022||2|20 First Degree relatives
3190584|NCT00789022||3|20 Healthy subjects
2454537|NCT03210493|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454538|NCT03210493|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2454574|NCT03209856|Experimental|Vitamin D supplement|This group will receive weekly oral 50000 international units of vitamin D supplement for 8 weeks before the start of ICSI cycle. In addition, the routine care will be given.
2454576|NCT03209856|No Intervention|Routine care|This group will receive the routine care.
3190585|NCT00789048|No Intervention|Surgeon doesn't see|The surgeon doesn't see the radiograph prior to surgery
3190586|NCT00789048|Experimental|Surgeon does see|The surgeon can see the radiograph prior to surgery
3190587|NCT00789087|Active Comparator|1. Videothoracoscopic talc poudrage (VT)|
3190588|NCT00789087|Active Comparator|2. Talc slurry through a chest tube (DT)|
2453651|NCT03216577||Exposed to purpura fulminans|Patients who were admitted in the intensive care unit and survived a purpura fulminans episode
2453653|NCT03216577||Non-exposed to purpura fulminans|Patients admitted in the intensive care unit for a septic shock unrelated to a purpura fulminans, and matched to exposed patients for age, gender, and severity of illness.
3190589|NCT00789100||1|Group provided with home-based monitor
3190590|NCT00789100||2|Group receives no home-based monitor
2453866|NCT03215381|Other|[11C]AZD1390 Microdose|[11C]AZD1390 single dose not exceeding 10 ug by IV bolus
2453894|NCT03214809|Experimental|Thoracic ultrasound protocol|ABCDE algorithm with Thoracic ultrasound protocol
2453896|NCT03214809|No Intervention|No Thoracic ultrasound protocol|ABCDE algorithm without Thoracic ultrasound protocol
2453954|NCT03214614|Experimental|GLPG2451 multiple dose|Multiple doses of GLPG2451 oral suspension at up to 3 dose levels in ascending order
2453965|NCT03214614|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension
2453968|NCT03214614|Experimental|GLPG2451/GLPG2222|Multiple doses of GLPG2451 oral suspension combined GLPG2222 oral suspension at up to 2 dose levels
2453969|NCT03214614|Placebo Comparator|Combined Placebo multiple dose|Multiple doses of Combined Placebo oral suspension
2453993|NCT03214042|Experimental|trial group|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years.
2454015|NCT03213925|Experimental|RT|"After clinical response, breast magnetic resonance imaging (MRI) is performed and analyzed by two independent radiologists. Complete image response is defined by no enhanced tumor visible on any serial images.~Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region."
2454081|NCT03213691|Experimental|Treatment (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3190591|NCT00789139|Other|AF monitoring by ICM|Only one arm
2454324|NCT03211936|Active Comparator|PEEP 4|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After titrated peep we setup peep 4 and maintained during the procedure.~PEEP 4 cmH2O~Use ultrasound"
2454327|NCT03211936|Experimental|PEEP TITRATED|"We titrate peep, using tomography impedance, making ultrasound after level by level' of peep. After tritiated peep we setup the best peep for less collapse (using the tomography of electrical impedance) and maintained during the procedure.~PEEP titrated~Use ultrasound~Impedance tomography~Best PEEP for less collapse"
2454412|NCT03211299||IHL <5%|overweight and obese humans with a liver fat percentage <5%
2454415|NCT03211299||IHL 5-10%|overweight and obese humans with a liver fat percentage 5-15%
2454418|NCT03211299||IHL >15%|overweight and obese humans with a liver fat percentage >15%
2454459|NCT03210766||Nabilone|Patients affected by Failed Back Surgery Syndrome (FBSS)
2454468|NCT03210766||THC/CBD|Patients affected by Failed Back Surgery Syndrome (FBSS)
3190592|NCT00789152|Experimental|desloratadine followed by levocetirizine|Subjects in this arm received desloratadine 5 mg daily for 8 days, followed by 10 day washout period, then followed by levocetirizine 5 mg daily for 8 days
3190593|NCT00789152|Experimental|levocetirizine followed by desloratadine|Subjects in this arm received levocetirizine 5 mg daily for 8 days, followed by 10 day washout period, then followed by desloratadine 5 mg daily for 8 days
2454615|NCT03209687|Experimental|Human menopausal gonadotropin (HMG)|This group will take daily subcutaneous 75 IU (international unit) of human menopausal gonadotropin (HMG) in addition to the usual luteal phase support from the day of ovum pickup and will be continued for 2 weeks
2454619|NCT03209687|No Intervention|Routine care|This group will receive the routine care for luteal phase support
2454675|NCT03209154|Experimental|Study Group|Study Group intervention: Therapeutic drug monitoring.
2454683|NCT03209154|Active Comparator|Control Group|Control Group intervention: No intervention first 3 months. After 3 months of follow-up, half of the patients in the Control Group will be randomized to perform home blood pressure monitoring as an intervention. No intervention in the other half.
2454720|NCT03208712|Experimental|Radium-223 and Atezolizumab|"Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses~Atezolizumab 1200 mg IV once every 3 weeks until investigator determined lack of benefit, unacceptable toxicity, or 17 doses"
2454795|NCT03208374||MSK-IMPACT genetic panel testing|Participants have completed MSK-IMPACT genetic panel testing on Memorial Sloan Kettering Cancer Center protocol IRB #12-245 and/or IRB #06-107 and/or IRB # 09-141 in the last 3 years.
2454826|NCT03207724|Experimental|Xilonix plus Onivyde and 5FU|interleukin-1-alpha antagonist (Xilonix) in addition to standard chemotherapy of onivyde and 5-fluorouracil/folinic acid (leucovorin)
2454883|NCT03207581|Experimental|Immediate Coaching Intervention|Immediate Coaching Intervention arm will receive professional coaching
2454886|NCT03207581|Active Comparator|Control/Delayed Coaching Intervention|Participants randomized to the Control/Delayed Coaching will receive no intervention for the first six months of the study, at which point they cross over and receive 6 professional coaching sessions
2454908|NCT03207269|Experimental|High protein no carbohydrate|Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
2454910|NCT03207269|Active Comparator|High protein carbohydrate containing|Dietary. A low-fat yogurt will be consumed 30 minutes prior to bedtime. Protein will be matched to the high protein bedtime snack condition. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
2454916|NCT03207269|No Intervention|Control no snack|No snack will be consumed prior to bed.
3208576|NCT00976079|No Intervention|Control Group|No TENS, standard physical therapy for 4 weeks.
2454996|NCT03206710||smokers who received Vitamin C|
2454998|NCT03206710||smokers who received placebo|
2455002|NCT03206710||control group non-smokers|
2455074|NCT03206385||CK Boost pelvis|
2455129|NCT03206008|Placebo Comparator|Normal saline group|after loading normal saline 100cc in 10-20 minutes, continuous infusion of normal saline until the end of surgery
3208577|NCT00976092|Experimental|Prasugrel + Bivalirudin|60 mg prasugrel plus bivalirudin
2453694|NCT03216629|Experimental|Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will say sorry repeatedly. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
2453695|NCT03216629|No Intervention|Not Sorry|A small strip of self-adhesive dressing (3cm by 4cm) will be applied to the back of the patients' participants' hand and side of neck. After one minute of acclimatization, the dressing will be removed by the examiner. During the removal, the examiner will remain silent. Following the dressing removal, participant will rate their pain with a 10 point visual analog scale.
2453753|NCT03216083|Experimental|Tranexamic Acid|Tranexamic Acid Injectable Solution (1g intravenous) Single dose prior to the start of surgery, after the induction of anesthesia
2453758|NCT03216083|Placebo Comparator|Placebo|67mL intravenous normal saline (0.9% sodium chloride) Single dose prior to the start of surgery, after the induction of anesthesia
2453781|NCT03215550||Carotid Endarterectomy|Patients who are scheduled to undergo carotid endarterectomy for symptomatic carotid artery stenosis (≥50% by NASCET criteria for men, ≥70% for women) who are above 40 years of age.
2453950|NCT03214562|Experimental|Treatment (venetoclax, FLAG-IDA)|See detailed description.
2454031|NCT03213808||respiratory allergies|respiratory allergies (asthma, rhinitis)
2454036|NCT03213808||skin allergies|skin allergies (dermatitis, urticarial, angioedema)
2454041|NCT03213808||anaphylaxis|anaphylaxis
2454046|NCT03213808||gastrointestinal allergic conditions|gastrointestinal allergic conditions
2454050|NCT03213808||ocular allergies|ocular allergies (conjunctivitis)
2454479|NCT03210558|Active Comparator|Group A|Testosterone cream 1% (Andro-Feme® )
2454480|NCT03210558|Placebo Comparator|Group B|Placebo cream
2454487|NCT03210207||GASTROPLICATURE|"The procedure begins with division of the greater curve vessels from 4 to 5 cm proximal to the pylorus to the angle of His. Either ultrasonic energy or bipolar cautery is appropriate for this step.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum"
2454539|NCT03210142|Experimental|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation for subjects undergoing an EP, cardiac catheterization or device procedure.
2454543|NCT03209830|Experimental|Arm A|OSU6162, drug given to half of the patients after randomization
2454544|NCT03209830|Placebo Comparator|Arm B|Placebo oral tablet, drug given to halv of the patients after randomization
2454612|NCT03209700|Experimental|MSC-AFP Single Treatment Group|Eligible patients will be treated, single treatment group, no placebo arm
2454682|NCT03209206|Experimental|Docetaxel bladder instillation arm|After Surgery, intravesical chemotherapy with in 48 hrs (Docetaxel 75 mg diluted in 100 cc of normal saline)
2454686|NCT03209206|Placebo Comparator|Control arm|After Surgery, intravesical chemotherapy with in 48 hrs (Placebo, 100 cc of normal saline)
2454741|NCT03208634|Experimental|Robotic intervention|Robotic intervention.
2454880|NCT03207633|Active Comparator|First group|First group (20 patients) receive for 10 sessions of low frequency rTMS targeting right DLPFC by means of a Butterfly coil using the following parameters: 120% RMT, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
2454881|NCT03207633|Active Comparator|Second group|The second group (20 patients) will receive 10 sessions of low-frequency rTMS over the right orbitofrontal cortex (OFC) by means of a Butterfly coil using the following parameters: 120% motor threshold, 1 Hz, 3 trains, each of 500 pulses with a 40 seconds inter-train interval allowing the coil to cool.
2454882|NCT03207633|Sham Comparator|Third group|The third group (the sham condition) (20 patients) will receive sham stimulations of rTMS with the same pulse delivery as the other groups but with the coil placed perpendicular to the scalp.
3154173|NCT00293150|Active Comparator|Eplerenone|Eplerenone 25mg daily for 2 weeks Titrated to Eplerenone 50mg daily
3154174|NCT00293150|Placebo Comparator|Placebo|Placebo dosed daily
2455041|NCT03206866||patients with HCC|
2455045|NCT03206866||patients with hepatitis C Ab positive|
2455046|NCT03206866||patients with hepatitis C Ab negative|
2455098|NCT03206242||initial|0 month begin physiotherapy
2455100|NCT03206242||3 months after physiotherapy|3 months after physiotherapy
2455105|NCT03206242||6 months after physiotherapy|6 months after physiotherapy
2455352|NCT03204331|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
3154175|NCT00293176|Experimental|1|
3154176|NCT00293176|Placebo Comparator|2|
3154177|NCT00293228|Experimental|A|Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment.
3154178|NCT00293228|Active Comparator|B|B. Recently converted contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
3154179|NCT00293228|Experimental|C|C. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) immediately after recruitment
3154180|NCT00293228|Active Comparator|D|D. Remote contacts receiving isoniazid (5mg per kg up to 300 mg daily for 6 months) three months after recruitment.
3154181|NCT00293345|Experimental|Treatment (gemcitabine hydrochloride, triapine)|Patients receive 3-AP (TriapineÃÂ®) IV over 24 hours followed by gemcitabine hydrochloride IV over 100-125 minutes on days 1 and 8. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3154182|NCT00293475|Experimental|Treatment (rituximab, mannitol, methotrexate, carboplatin)|Patients receive rituximab IV over 5 hours on day 1, mannitol IA, methotrexate IA over 10 minutes, and carboplatin IA over 10 minutes on days 2 and 3. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats monthly for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3154183|NCT00293592|Active Comparator|Dexamethasone|
3154184|NCT00293592|Placebo Comparator|Placebo|
2453736|NCT03215940|Active Comparator|Delta-9-Tetrahydrocannabinol's (Delta-9-THC) effects on pain|This arm will be testing the analgesic effects of orally dosed Delta-9-Tetrahydrocannabinol on subjects with chronic non-cancer pain.
2453740|NCT03215940|Active Comparator|Cannabidiol's (CBD) effects on pain|This arm will be testing the analgesic effects of orally dosed Cannabidiol on subjects with chronic non-cancer pain.
2453742|NCT03215940|Placebo Comparator|Placebo|This Placebo arm will act as the control as standard of care medications will be continued through the study. This arm will allow us to compare the analgesic effects of the other two arms with the standard of care treatments for chronic non-cancer pain.
2453788|NCT03215680||Tanzanian Women of Reproductive Age|Healthy women of reproductive age living in Tanzania in an area with hot and temperate climate
2453789|NCT03215680||South African Women of Reproductive Age|Healthy women of reproductive age living in South Africa in an area with hot and temperate climate
2453844|NCT03215394|Experimental|Enhanced Social ABCs|Receive 4-week attention training program, followed by 12-week Social ABCs intervention. The stimuli include four gaze-contingent training tasks that will be presented on a laptop screen using custom MATLAB scripts. Each task will be presented until the infant becomes inattentive, at which point they will go to the next task or take a break. Training stimuli will be presented until toddlers become fidgety or distressed.
2453845|NCT03215394|Sham Comparator|Standard Social ABCs|Receive 4-week sham attention program, followed by 12-week Social ABCs intervention. Sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training intervention. Infants are exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (infant appropriate television clips and animations). Sham attention stimuli will be presented until toddlers become fidgety or distressed.
2453846|NCT03215394|Other|Treatment As Usual|A convenience sample of age-equivalent toddlers who meet clinical eligibility criteria but are otherwise unable or unwilling to participate in the interventions, will be used as a Treatment as Usual comparison group. The same assessments will be administered at parallel time points through an existing research study. Receive no attention training program and no Social ABCs.
2453922|NCT03214757||group with dilated cardiomyopathy without anemia|
2453924|NCT03214757||group with dilated cardiomyopathy with anemia|
2453947|NCT03214432||mild traumatic brain injury cohort|Patients with mild traumatic brain injury were defined as hospital admitted, emergency or outpatient treated, who were assigned the ICD-10 code for concussion (ICD-10 S06.0) in the national patient register at hospital discharge from the 1st of January 2003 - 31st of December 2007. Patients were working age adults between 18-60 years old and gainfully occupied or deemed available for work the week before the injury.
2453949|NCT03214432||non-injured control group|Controls were randomly selected from the Population register who were between 18-60 years old, had no diagnosis of mild traumatic brain injury during the period 1st of January 2003 - 31st of December 2007 and were gainfully occupied or deemed available for work the week preceding the time of injury. One control was matched for each mTBI case on gender, municipality and age (year of birth +/- 0,5 years). In case of no matching control the age criterion was expanded to (year of birth +/- 1 year), if still no matching control the age criterion was further expanded to (year of birth +/- 2 year). Additionally, controls were excluded according to the same criteria as the included cases.
2454029|NCT03214276|Active Comparator|Polyphenols|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of 250 mg of polyphenols (Vinitrox™)
2454032|NCT03214276|Placebo Comparator|placebo|The preceding night and one hour before the endurance test, participants were asked to absorb two capsules of placebo (similar appearance and flavour than active comparator).
2454087|NCT03213574|Active Comparator|Control Group|The control group will be administered intraoperative fluids throughout his or her surgery per the discretion of the anesthesiologist as is typical for this type of case. They will use an arterial line but without a FloTrac and therefore will have no data regarding the SVV.
2454089|NCT03213574|Experimental|Treatment Group|The treatment group will receive a FloTrac arterial line that will allow the anesthesiologist to administer intraoperative fluids based on the study algorithm.
3208578|NCT00976092|Active Comparator|Clopidogrel + Heparin|clopidogrel as loading and heparin
2454177|NCT03212703|Active Comparator|Waitlist control (WLC)|Observation surveys over an 8-week period.
2454181|NCT03212703|Active Comparator|Mindfulness-Based Skills Training (MBST)|Attendance at weekly 1.5-hour group sessions and surveys over an 8-week period.
2454225|NCT03212417|Other|Interventional trial without phases-supportive care.|This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
2454302|NCT03212079|No Intervention|Control|The participant will self motivate hi/herself to increase physical activities.
2454305|NCT03212079|Experimental|Mycoach Smart Text|The participant will receive personalized smart text messages to encourage him/her to increase physical activities
2454308|NCT03212079|Experimental|MyCoach via Amazon Alexa|The participant will interact with intelligent coach on Amazon Alexa (a digital voice assist) to help him/her become more active
2454360|NCT03211507||Case|Males with an incident diagnosis of IPF made between the 1st of February 2017 and the 5th of October 2019.
2454362|NCT03211507||Controls|Males with an incident hospital outpatient attendance between the 1st of February 2017 and the 5th of October 2019 who do not have a diagnosis of IPF. At each participating centre a control clinic is randomly selected from all control clinics that the research team is able to recruit from; this clinic is the source clinic for controls for the duration of the study.
2454485|NCT03210506|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454486|NCT03210506|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2453762|NCT03216018|Experimental|"Experimental: Prevention Program In Favor of Resilient Self"|"The program In Favor of Resilient Self delivered to adolescence aged 15-17, over 3 months. The program contained nine weekly 90-min sessions that focus on enhancing self- resilience, self-esteem, self-image, body image. All participants will complete a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
2453766|NCT03216018|No Intervention|No Intervention: control group|The control group didn't receive the intervention program, instead they received a lesson on healthy nutrition. The control group will complete the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program conclusion.
2453795|NCT03215615|Active Comparator|Group NF + TE|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with nanofilled resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
2453798|NCT03215615|Active Comparator|Group NF + UA|Nanofilled Composite - Filtek Z350 XT® - 3M ESPE (NF) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with nanofilled resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
2453802|NCT03215615|Active Comparator|Group MH + TE|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Total Etch adhesive - Adper Single Bond 2® - 3M ESPE (TE) adhesive: combined lesions will be treated with partial restoration with micro-hybrid resin composite and total-etch adhesive system (two step). Subsequently, periodontal surgery will be performed for root coverage.
2453806|NCT03215615|Active Comparator|Group MH + UA|Micro-Hybrid Composite - Charisma Classic® - Heraeus Kulzer (MH) + Universal Adhesive - Single Bond Universal® - 3M ESPE (UA): combined lesions will be treated with partial restoration with micro-hybrid resin composite and one-step self-etching adhesive system. Subsequently, periodontal surgery will be performed for root coverage.
2453853|NCT03215095|Experimental|Radioiodine (RAI) in Combination with Durvalumab (Medi4736)|Enrolled patients will be treated with durvalumab 1500 mg IV every 4 weeks. In Cycle 1/Week 3, Thyrogen 0.9 mg IM will be administered on two consecutive calendar days followed by 100 mCi (+/- 10 mCi) of RAI the next calendar day. Durvalumab will be continued every 4 weeks.
2453913|NCT03214861||Nurses Health Study|The Nurses' Health Study (NHS) was initiated in 1976 as a prospective cohort study, where 121,701 female registered nurses between the ages of 30 and 55 years were recruited from 11 US states.
2453914|NCT03214861||Health Professionals Follow-Up Study|The Health Professionals Follow-up Study (HPFS) was initiated in 1986 and recruited 51,529 US men between the ages of 40-75.
2453928|NCT03214471|No Intervention|Usual Care|usual care provided by the NHS for patients undergoing bariatric surgery.
2453930|NCT03214471|Experimental|Intervention|usual care + BARI-LIFESTYLE intervention
2454019|NCT03214302|No Intervention|control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.healthy Pregnant women with HBsAg(-), HBeAg(-)
2454022|NCT03214302|Experimental|experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation and drug withdrawal after delivery immediately, and drug withdrawal in the 6 weeks after delivery.
2454069|NCT03213639|Experimental|study group|Patients will take esomeprazole single dose of 40 mg orally once a day
2454070|NCT03213639|Placebo Comparator|control group|Patients will take an inert tablet similar in appearance, color and consistency
2454115|NCT03213314|Experimental|Main cohort|Patients undergoing liver resection
2454116|NCT03213314|Experimental|Nested cohort PVE|Patients undergoing liver resection after portal vein embolisation
2454117|NCT03213314|Experimental|Nested cohort neoadjuvant chemotherapy|Patients undergoing liver resection after neoadjuvant chemotherapy
2454118|NCT03213314|Experimental|Nested cohort TACE|Patients undergoing trans arterial chemoembolisation for presumed hepatocellular carcinoma
2454133|NCT03213067||Mitochondrial Disease Patients|"Male and Females >18 years at the time of screening~Patients must have proven genetic disease (confirmed by assessment of heteroplasmy in blood and urine samples) of the m.3243 A>G mutation.~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
2454134|NCT03213067||Healthy Control Group|"Male and Females >18 years at the time of screening~Capacity to provide informed consent taken before any study related activities.~Ability and willingness to adhere to the protocol, including all appointments.~Ability to read and converse in English."
2454160|NCT03212846|Experimental|Treatment group|Children will receive hippotherapy by a licensed physical therapist. Before riding, stretching and warming exercises of the adductor muscles will be performed. Later, the patient will be seated astride with the therapist behind. In any case, the participant had no control of the horse. Therapist will be responsible for correctly positioning the subject on the horse, but no position changes or active intervention of the subject with the therapist will be made. This positioning consists on achieving the optimal body alignment with neutral pelvis.
2454162|NCT03212846|No Intervention|Control group|Children will receive the conventional treatment, based on physiotherapy related techniques, such as neurodevelopmental treatment (twice a week).
3154185|NCT00293605||1|C-stem implant
2454414|NCT03211351|Experimental|Liposic|Liposic was applied to one eye of patients in this group
2454417|NCT03211351|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
3154186|NCT00293605||2|Charnley Implant
2454629|NCT03209401|Experimental|Niraparib and Carboplatin|"Niraparib will be administered orally, once daily for 21 days of each 21-day cycle in escalating doses depending on cohort patient is assigned to.~Carboplatin will be administered via an injection on Day 2 of a given 21-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
3154187|NCT00293605||3|Exeter Implant
3154188|NCT00293618|Experimental|Intervention|Arm of anesthesiologists and senior residents who receive a patient's individual predicted PONV risk intraoperatively
3154189|NCT00293618|Active Comparator|Usual Care|Anesthesiologists and senior residents who provide usual care: they provide PONV prophylaxis as they always have
3190594|NCT00789165|Experimental|Quinidine|Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.
3190595|NCT00789165|Active Comparator|no therapy|Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician
3190596|NCT00789178||patients with fibromyalgia|
2453847|NCT03215160|Experimental|Mobilization Exercise Group|Mobilization exercises in addition to classical exercises performed in the early post-op period
2453848|NCT03215160|Active Comparator|Classical Exercise Group|only classical exercises performed in the early post-op period
2453909|NCT03214965|Active Comparator|Facebook group|Patients of the kidney transplantation group randomly assigned to be part of a closed facebook group.
2453910|NCT03214965|No Intervention|Control group|Patients of the kidney transplantation group that do not receive specific educational interventions.
2453957|NCT03214523|Experimental|Sleep Education|The intervention will be a brief education of the importance of sleep and healthy sleep habits. Subjects will also receive a standard sleep brochure on healthy sleep (which will also be given to the other arm).
2453963|NCT03214523|No Intervention|Sleep Brochure|Subjects will receive a one page hand out on healthy sleep habits.
2454016|NCT03214159|Experimental|group 1|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: Ritonavir tablet 100mg cylcle 2 Drug: NORVIR tablet 100mg cylcle 3 Drug: Ritonavir tablet 100mg cylcle 4 Drug: NORVIR tablet 100mg"
2454020|NCT03214159|Experimental|group 2|"During the study session, healthy subjects will be administered a single dose of Ritonavir or Tablet 100mg or NORVIR tablet 100mg under fasting condition.~Intervention:~cylcle 1 Drug: NORVIR tablet 100mg cylcle 2 Drug: Ritonavir tablet 100mg cylcle 3 Drug: NORVIR tablet 100mg cylcle 4 Drug: Ritonavir tablet 100mg"
2454071|NCT03213613|Experimental|Adaptive Attention Training|The training group will engage in 15 hours of at-home training on a novel iPad-based adaptive attention training program ('Engage'). Individuals will complete thirty 30-minute sessions over six weeks. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely and analyzed over secure online servers to ensure that participants are completing training as scheduled and to deal with any unexpected road-blocks in training.
2454073|NCT03213613|Placebo Comparator|Active Control|The active control group will engage in 15 hours of at-home training on an iPad game ('Boing'). Individuals will complete game play for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with research personnel, and monetary rewards. Compliance will be monitored similarly to the adaptive attention training group.
2454075|NCT03213613|Placebo Comparator|Low-dose Adaptive Attention Training|The low-dose training group will engage in 1 hour of at-home training on 'Engage'. Individuals will complete two 30-minute sessions at the beginning and middle of a six-week period. Compliance will be monitored similarly to the adaptive attention training group.
2454132|NCT03213301|Experimental|Lurbinectedin|Lurbinectedin 3.2 mg/m2 i.v. every 3 weeks (one cycle) until progression, unacceptable toxicity or patient's withdrawal.
2454228|NCT03212612||2 groups , control and cases|"Groupe 1: (cases) 45 women who were found to have surgically and histolopathologically -confirmed endometriosis. Endometrial samples(1-2 gram) will be taken by laparoscopy which is the gold standard for definitive diagnosis of endometriosis.~Group2:(control) 45women who were free of endometriosis. Endometrial samples(1-2 gram) will be taken by punch biopsy."
2454255|NCT03212053|Other|Patients with Essential Thrombocythemia|"patients who come in consultation at diagnosis or during the follow-up for an Essential Thrombocythemia.~They will have biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)"
2454312|NCT03211832|No Intervention|Control|The control group will conduct usual public health practice.
2454314|NCT03211832|Active Comparator|Intervention|Participating local health departments will help develop and choose several dissemination activities they prefer for their local health department to receive. Dissemination activities may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes and chronic disease prevention and control.
2454332|NCT03211468|Experimental|Intervention Program|Clinical intervention designed to prevent eating disorders and promote healthy eating habits and body image among female adolescent athletes. The intervention program will include 10 45-min interactive sessions led by the researcher. Each session will include a brief theoretical background, experiential activities (artistic or cognitive / emotional) and group discussions.
2454339|NCT03211468|No Intervention|Control Group|No participation in intervention program.
2454400|NCT03211260|Experimental|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
2454435|NCT03210857|Experimental|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
2454488|NCT03210532|Experimental|Test|qd PO, Twynsta(telmisartan/amlodipine) + Crestor(rosuvastatin)
2454497|NCT03210532|Active Comparator|Reference 1|qd PO, Micardis(telmisartan) + Crestor(rosuvastatin)
2454506|NCT03210532|Active Comparator|Reference 2|qd PO,Twynsta(telmisartan/amlodipine)
2454542|NCT03209947|Experimental|Ulnar nerve ultrasound|
2453856|NCT03215303|Experimental|Continuous Positive Airway Pressure (CPAP)|Participants in the intervention group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 10cmH2O and FiO2 0.21.
2453857|NCT03215303|Placebo Comparator|CONTROL|Participants in the control group will use CPAP device, for a period of 40 minutes, with the following parameters: PEEP of 1cmH2O and FiO2 0.21.
2453879|NCT03214887|Experimental|RV-P1501-4|Gel-like product with 10 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
2453880|NCT03214887|Experimental|RV-P1501-5|Gel-like product with 100 thousand BMMNCs in each ml of 1% hyaluronan (HA) solution
2453882|NCT03214887|Experimental|RV-P1501-6|Gel-like product with 1 million BMMNCs in each ml of 1% hyaluronan (HA) solution
2453935|NCT03214679|Experimental|Accessible Care|"Accessible Care for PWID is low-threshold care provided in the needle exchange programs, where they can comfortably access services without fear of the shame or stigma that often attends them in mainstream institutions.It includes features such as an informal, nonjudgmental atmosphere, availability of walk-in appointments, and a harm reduction framework to help them identify and pursue their own personal health goals. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program."
2453942|NCT03214679|Active Comparator|Usual Care|Usual care represents the current procedure after someone tests positive for HCV antibody on site at the syringe exchange program. An on site care coordinator (not provided by study) assists with insurance and linkage to HCV medical provider at sites throughout NYC through the NYC Dept of Health Check Hep C program.
2454072|NCT03213717|Experimental|Procedure 1|Wearing a weight vest with 10 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour. The reason for this is because it has been considered that the effect may be transmitted by weight loading of the lower extremities.
2454074|NCT03213717|Active Comparator|Procedure 2|Wearing a weight vest with 1 % of body weight standing for seven hours. The study subject is allowed to sit for 10 minutes each hour.
2454076|NCT03213717|Active Comparator|Procedure 3|Wearing a weight vest with 1 % of body weight sitting for seven hours. This is a control group without loading of the lower extremities. This is also the normal working position for many sedentary jobs (e.g. office workers) and why this is of special interest for further investigation. There is a large body of investigative literature showing the negative health consequences of the sitting working position.
2454169|NCT03212859|Experimental|Coach2Move Intervention Group|Coach2Move Intervention Group
2454171|NCT03212859|Active Comparator|Usual Care|Usual care physiotherapy among older adults
2454217|NCT03212456|Experimental|Opioid-free|The patients of this group will receive opioid-free anesthesia
2454220|NCT03212456|Active Comparator|Non opioid-free|The patients in this group will receive the same induction and maintenance drugs of the experimental group but with fentanyl 3 - 5 mcg/kg on induction and during the procedure as needed.
2454275|NCT03212118|Other|Treatment as usual|"Treatment as usual untouched. This is the standard The Norwegian Labour and Welfare Administration (NAV) procedure."
2454285|NCT03212118|Active Comparator|Two talks|Two standard talks (not including elements from motivational interviewing)
2454290|NCT03212118|Experimental|Motivational interviewing|Two standard talks with a motivational interviewing content.
2454354|NCT03211559|Active Comparator|AEROBİC EXERCİSE (walking on treadmill)|Patients walked on treadmill for 8 weeks, 3 days in a week,30-40 minutes each.
2454356|NCT03211559|Experimental|Aerobic Exercise+Clinical Pilates|Patients walked on treamill for 8 weeks, 3 days in a week, 30-40 minutes each. Additionally they did clinical pilates exercise for 8 weeks, 3 days in a week.
2454410|NCT03211143|Experimental|A|"TR group~Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days~Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days"
2454413|NCT03211143|Experimental|B|"RT group~Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days~Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days"
2454442|NCT03210688|Active Comparator|High dose prednisolone|Prednisolone 1 mg/kg/day
2454448|NCT03210688|Experimental|Alfacalcidol and low dose prednisolone|Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day
2454495|NCT03210272|Experimental|Single rising dose part|Group of healthy male volunteers receive rising single doses of BI 1358894
2454502|NCT03210272|Experimental|Food effect part|Group of healthy male volunteers receive single doses of BI 1358894 with and without food
2454566|NCT03209986|Experimental|MSC group|mesenchymal stem cell transplantation via peripheral vein: 1x10E6 MSCs/kg body weight administered via peripheral vein at week 0, 4, 8.
2454568|NCT03209986|No Intervention|control|Standard medication for viral hepatitis and cirrhosis
2454604|NCT03209557|No Intervention|Control|25 pregnant women will be enrolled and provided with usual care through Healthy Beginnings or NFP but will not receive a smartwatch or the active intervention. Smoking behavior will be measured by self-report and sample testing for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly and will be identical to the intervention group. They will be compensated for sample collection and survey completion.
2454608|NCT03209557|Experimental|SmokeBeat Intervention|"25 pregnant women will be enrolled and provided with a smartwatch. The smartwatch SmokeBeat application will be active. Smoking behavior will be measured by the smartwatch for the duration of the trial. Self-reported smoking status will be collected weekly. Sample testing will occur weekly.~A second phase of the trial was initiated to evaluate a new watch. The smoking habits of participants who are receiving financial incentives to wear the watch are being compared to participants who are being given financial incentives for every day they go without smoking.~A third phase of the trial was initiated to evaluate efficacy of larger financial incentives. All participants are incentivized to wear the watch, with the experimental arm also incentivized to abstain from smoking."
2454642|NCT03209245|Active Comparator|Active AIT group|"Injection immunotherapy with Purethal Mites were administered as perennial therapy using the following regimen of injections: 1 dose- 0.1 ml, 2 doses - 0.2 ml, 3 doses - 0.5 ml every week, and 0.5 ml every four weeks during 24 months.~monitoring of allergen specific IgE monitoring of allergen specific IgG4"
2454644|NCT03209245|Placebo Comparator|non-active, placebo treatment|symptomatic treatment with concomitant use of placebo injection monitoring of allergen specific IgE monitoring of allergen specific IgG4
2453884|NCT03215199|No Intervention|Usual Care Group|The Usual Care Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Supportive care will be offered or provided according to patients' wishes.
2453885|NCT03215199|Active Comparator|NAPT Group|The NAPT Group will include adult patients undergoing primary surgical treatment for head and neck cancer. Patients will be given access to a web-based application that monitors depression, distress, and functional outcomes scores at regular intervals for 12 months. Patients will be able to alert the treatment team of decreased mood, increased distress, and functional issues impacting both. Patients will also be able to track their mood and distress levels throughout the 12 months and involve care-givers in monitoring as well.
2453915|NCT03214705||Patients with poor outcome|Follow up of patients is done for 21 days by combined clinical and radiological examination. Poor clinical outcome is associated with vasospasm leading to permanent neurological deficit, stroke or death.
2453916|NCT03214705||Patients without poor outcome|Patients who do not develop delayed cerebral ischemia or stroke, confirmed by combined clinical and radiological examination.
2453929|NCT03214458|Other|Nasal high flow with oxygen|During HFNC-oxygen, oxygen will be passed through a heated humidifier (AIRVO-2, Fisher and Paykel Healthcare) and applied continuously through large-bore binasal prongs (Optiflow+ Fisher and Paykel Healthcare), with a gas flow rate of 20-35 liters per minute or as high as the patient will tolerate and an FiO2 to keep Arterial oxygen saturation (SaO2) > 90%. Temperature will be adjusted based on patient's comfort and range from 34-37 degrees based on prior experience.
2453996|NCT03214315||Prostatectomy|Visceral adipose tissue specimen sample
2454045|NCT03213860|Active Comparator|eye mask|
2454049|NCT03213860|No Intervention|Control|
2454086|NCT03213548|Experimental|Alar facial groove Incision|Alar Base surgical modification with surgical inions in the alar facial groove
2454088|NCT03213548|Active Comparator|Alar facial groove spared|Alar Base surgical modification with surgical incisions 1mm above the alar facial groove
2454128|NCT03213145|Experimental|Part 1|
2454129|NCT03213145|Experimental|Part 2|
2454164|NCT03212820|Experimental|Biologic drilling|drilling at low speed
2454165|NCT03212820|Active Comparator|conventional drilling|drilling at conventional or high speed
2454242|NCT03212560||Newly diagnosed individuals|Newly diagnosed hematologic malignant patients included in the study. Inclusion and exclusion criteria were considered.
2454245|NCT03212560||Healthy individuals|Those without chronic disease were included in the study. Inclusion and exclusion criteria were considered.
2454300|NCT03212040|Active Comparator|14 gauge needle biopsy|breast biopsy will be performed with 14 gauge needle
2454301|NCT03212040|Active Comparator|16 gauge needle biopsy|breast biopsy will be performed with 16 gauge needle
2454378|NCT03211065|Experimental|Immunoglobulin therapy|Patients with abnormal humoral function following treatment with rituximab will be treated with 20% subcutaneous immunoglobulin.
2454457|NCT03210935||Merkel cell carcinoma|
2454467|NCT03210935||Advanced basal cell carcinoma|
2454471|NCT03210935||Cutaneous adnexal carcinomas|
3190597|NCT00789178||patients with active RA|
3190598|NCT00789204|Experimental|GPR|Global Postural Re-Education
2454616|NCT03209778|Active Comparator|Control group|Control participants without psychiatric nor neurological history
2454620|NCT03209778|Experimental|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
2454670|NCT03209284||narrow sinuses|transcrestal sinus floor elevation in narrow sinuses
2454679|NCT03209284||wide sinuses|transcrestal sinus floor elevation in wide sinuses
2454731|NCT03208738|No Intervention|Assessment only|
2454732|NCT03208738|Experimental|VetChange mobile app|
2454734|NCT03208738|Experimental|AFT + VetChange mobile app + supportive accountability tool|
2454787|NCT03208296|Experimental|Cohort A|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
2454792|NCT03208296|Experimental|Cohort B 1.5|Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
2454796|NCT03208296|Experimental|Cohort B 1.0|Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3
3154190|NCT00293644|Experimental|Pre-emptive Treatment Group|As soon as a patient becomes aware of the pregnancy, and before the Nausea and Vomiting of Pregnancy (NVP) starts, she will begin taking Diclectin®. When NVP starts, the dose will be adjusted to match symptoms.
3154191|NCT00293644|Active Comparator|Standard Treatment Group|Women randomised to this arm will not receive any Diclectin® before symptoms appear, and will be advised to commence treatment only at first sign of nausea. The starting dose of Diclectin® will be 20mg (2 tablets) at bedtime.
3190599|NCT00789204|Active Comparator|SEP|Standard Exercise Programm
3190600|NCT00789217|Active Comparator|In-house penicillin testing preparation|In-house penicillin testing prepared from alkali-treated penicillin G
3190601|NCT00789217|Active Comparator|Commercial penicillin test kit|Commercial penicillin test kit order from Diater company
2455421|NCT03204058|Active Comparator|group 3|SRP followed by 1% Metformin ( MF) gel
3190602|NCT00789217|Active Comparator|Penicillin G Sodium|Penicillin G Sodium from routine clinical use
3190603|NCT00789230|Active Comparator|primary suture|
3190604|NCT00789230|Active Comparator|mesh enforced closure|
3154192|NCT00293644|No Intervention|Natural Course Group|A third group will be randomly matched from Motherisk NVP callers who did not participate in our pre-emptive intervention and experienced severe Nausea and Vomiting of Pregnancy/Hyperemesis Gravidarum (NVP/HG) in their previous pregnancy. This group will serve as a control group for the potential effect of the early counselling. (These women will have called for the first time after NVP symptoms (of any degree) started in the current pregnancy).
3154193|NCT00293735|Active Comparator|1. Labetolol|
2453956|NCT03214497|Active Comparator|Protector group|All patients collocated randomly to the Protector Group Primary and secondary outcome Parameters are studied
2453964|NCT03214497|Placebo Comparator|Supreme group|All patients collocated randomly to the Supreme Group, Primary and secondary outcome Parameters are studied
2453994|NCT03214107|Active Comparator|Full snack given before exercise|A snack containing ~0.5g of carbohydrates per kilogram of body weight will be given 5 minutes before exercise
2453995|NCT03214107|Active Comparator|Distributed snack over exercise period|A snack containing ~0.5g of carbohydrates per kilogram of body weight distributed this way will be given: ~40% given 5 minutes before exercise, ~30% after 20 minutes of exercise and the last ~30% after 40 minutes of exercise.
2454012|NCT03213873|Experimental|HiBalance|The HiBalance program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in PD. The training will be conducted as a progressive individually adjusted group program in order to challenge the specific balance disorder of every participant and endorse progression. The intervention will be performed for an hour, 2 times/week in groups of six to eight participants for a total of 10 weeks and one home training session on their own.
2454017|NCT03213873|Active Comparator|Speech therapy|The control group will receive a group treatment (2 times/w for 10 w + 1 home training session) consisting of speech and communication therapy performed by a speech therapist. This intervention will be performed in a sitting position. The speech and communication treatment will aim at increasing vocal loudness and improving articulatory precision. Level of difficulty is gradually increased by progressing from using loud voice and clear speech in short and automatized utterances, to using the same technique in more complex sentences and situations. The group format is used to practice techniques in communicative situations and also to introduce increasing level of multitasking by combining speech training with cognitively more challenging tasks in the group training.
3154194|NCT00293735|Active Comparator|2. Magnesium Sulfate|
2454311|NCT03211767|Active Comparator|Aged garlic extract|2 capsules per day containing aged garlic extract
2454313|NCT03211767|Placebo Comparator|Placebo|2 capsules per day without aged garlic extract
2454369|NCT03211338|Active Comparator|Preterm labor placentas and progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454371|NCT03211338|Active Comparator|Term labor placentas and progesterone|IMC cells taken from term labor placentas after delivery will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454372|NCT03211338|Active Comparator|Preterm labor placentas without progesterone|IMC cells taken from preterm labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454373|NCT03211338|Active Comparator|Term labor placentas without progesterone|IMC cells taken from term labor placentas after delivery will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454374|NCT03211338|Active Comparator|Term placentas from progesterone treated pregnancies|IMC cells taken from term labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2454377|NCT03211338|Active Comparator|Preterm placentas from progesterone treated pregnancies|IMC cells taken from preterm labor placentas from women that were treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2454382|NCT03211338|Active Comparator|Term placentas not treated with progesterone in pregnancy|IMC cells taken from term placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2454387|NCT03211338|Active Comparator|Preterm placentas not treated with progesterone in pregnancy|IMC cells taken from preterm placentas from women who were not treated with progesterone during pregnancy will be analyzed for inflammation characteristics and maturation into DC cells.
2454389|NCT03211338|Active Comparator|Term postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454392|NCT03211338|Active Comparator|Preterm postpartum blood samples with progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured with progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454394|NCT03211338|Active Comparator|Term postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering at term will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454396|NCT03211338|Active Comparator|Preterm postpartum blood samples without progesterone|CD-14+ monocyte cells taken from women delivering preterm will be cultured without progesterone and will be analyzed for inflammation characteristics and maturation into DC cells.
2454460|NCT03210675|Other|Study group|Will have a PSG at home every 6 months (± 1 month) from the age of 6 months until the age of 3 years.
2454466|NCT03210675|Other|Standard Care Group|Will have a single PSG at home which will give a reference in the Down Syndrome population of 3 years old and will be used as reference to the study group
2454515|NCT03210324|Experimental|Mifepristone A group|Mifepristone tablets for 12 weeks with two follow-up
2454521|NCT03210324|Experimental|Mifepristone B group|Mifepristone tablets for 12 weeks with four follow-up
3154195|NCT00293761|Experimental|Travatan, Investigational|
3154196|NCT00293761|Active Comparator|Travatan|
3154197|NCT00293774||Standard|Standard hip replacement subjects (polyethylene)
3154198|NCT00293774||Alternative Bearing|Subjects with ceramic on ceramic total hip replacement or metal on metal hip resurfacing.
2453912|NCT03214848|Experimental|Contraceptive education prior to abortion|Addition (to the standard or care) of a brief phone contraceptive education with optional financial counseling referral prior to abortion visit.
2453952|NCT03214484|Active Comparator|electronc tablet|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
2453960|NCT03214484|Active Comparator|computer|"On ET or Computer, the AV is measured at a closer distance (40 cm and 80 cm, respectively). At this closer distance (ie near and near vision), the eccentric fixation is much more Difficult to perform, unnatural, often requiring learning in the context of low vision rehabilitation.~Our aim is to compare the evolution curves of the Visual Acuity (AV) measured in each patient on Electronic Tablet (TE)/ computer(O) and on the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, in order to check the reliability of the measurements performed by TE / O by comparing them with a well-known reference measure And is routinely practiced routinely in ophthalmology centers."
2454056|NCT03213730|Experimental|Experimental group|Standard care + 3D-MOT protocol.
2454057|NCT03213730|Active Comparator|Active control group|Standard care + visual attention task (2048 online game)
2454058|NCT03213730|No Intervention|Control group|Standard care alone
3190605|NCT00789243|Active Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, local ischaemic preconditioning will be induced by inflating a cuff around the non-dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
3190606|NCT00789243|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
2454138|NCT03213054|Experimental|OBP-301 + Radiation|OBP-301 administration on the Day 1, Day 18 and Day 32 with standard course of radiation(total 60 Gy) for 6 weeks.
2454179|NCT03212781|Experimental|intravenous iron|patients will receive intravenous iron as total dose infusion
2454186|NCT03212781|Active Comparator|oral iron|patients will receive oral iron
2454231|NCT03212469|Experimental|Patients with head and neck squamous cell carcinoma|
2454236|NCT03212469|Experimental|Patients lung cancer|
2454240|NCT03212469|Experimental|Patients with oesophagus cancer|
2454329|NCT03211910|Placebo Comparator|Standard Care of Treatment|Participants will be treated with standard of care treatment.
2454330|NCT03211910|Active Comparator|SacralSaver|SacralSaver
2454375|NCT03211325|Experimental|Healthy|"Two sequences of ten healthy volunteers each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2454380|NCT03211325|Experimental|Primary Raynaud's phenomenon|"Two sequences of ten primary Raynaud's syndrome each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2454385|NCT03211325|Experimental|Secondary Raynaud's phenomenon|"Two sequences of ten patients each will be performed :~During the first sequence, a biopsy of the gluteal area and another of the surrounding nail area of a finger will be sampled.Then, the cutaneous blood flux of the hand will be recorded at rest and during cooling and warming periods.~During the second sequence, two other biopsies of the surrounding nail area of two other fingers will be sampled."
2454453|NCT03210870|Other|Intervention|In-person nutritional education classes
2454463|NCT03210870|No Intervention|Control|no in-person nutritional education classes
2454490|NCT03210389|Experimental|lobaplatin+5-FU|Patients enrolled in this trial would get 4-6 cycles of lobaplatin + 5-FU chemotherapy.
2454558|NCT03210103|Active Comparator|Arm 1, Radiation +/- Chemotherapy|Standard Treatment (Radiation +/- Chemotherapy)
2454561|NCT03210103|Experimental|Arm 2, TOS + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
2454590|NCT03209453|Experimental|study group|children with developmental delays, under regular rehabilitation programs, participate the family work shop family work shop: 6 families in one course, 2 hours per session, one session per week, a total of 6 weeks
2454594|NCT03209453|No Intervention|control group|children with developmental delays, under regular rehabilitation programs, not participate the family work shop
2454665|NCT03209336|Experimental|A group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated by surgical resection and the radiotherapy is given during the operation after the removal of the tumour.
2454671|NCT03209336|No Intervention|B group|Colorectal cancer patients first are given antineoplastic drugs and then transfer to operative room to be treated only by surgical resection and no radiotherapy afer the removal of the tumour.
2454702|NCT03208790|Experimental|Group A|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 10mg for 3 months.
2454703|NCT03208790|Experimental|Group B|patients with oral premalignant lesions will receive Nigella sativa buccal tablets 5mg for 3 months.
2454706|NCT03208790|Placebo Comparator|Group 3|patients with oral premalignant lesions will receive placebo buccal tablets for 3 months.
2454758|NCT03208439|Experimental|EMG-driven NMES|subjects will receive EMG-driven NMES cycling exercise.
2454759|NCT03208439|Placebo Comparator|passive pre-programmed NMES|subjects will receive passive pre-programmed NMES during cycling exercise.
2455533|NCT03203499|Experimental|ANS-6637|Single ascending doses of ANS-6637 administered orally
2453958|NCT03214510|Experimental|Arm I (TAE)|Patients undergo placement of thoracic epidural catheter before surgery. Patients receive hydromorphone hydrochloride and bupivacaine via thoracic epidural catheter every 10 minutes or 3 hours as needed. Patients may receive fentanyl and bupivacaine or plain bupivacaine via thoracic epidural catheter.
2453961|NCT03214510|Experimental|Arm II (TAP)|Patients undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block. Patients receive plain bupivacaine and liposomal bupivacaine via TAP block.
2454026|NCT03213964|Experimental|Arm 1|"FATE-NK100 is a donor-derived NK cell product comprising ex vivo activated effector cells with enhanced anti-tumor activity.~FATE-NK100 is administered to determine the maximum tolerated doze/maximum feasible dose (MTD/MFD).~Interleukin-2 (IL-2) remains the only FDA approved drug that is capable of promoting NK cells activation and survival.~Lymphodepletion with Cyclophosphamide and Fludarabine."
2454065|NCT03213522|Active Comparator|Pelvic Floor Physical Therapy|PFPT group will be treated/educated with/on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
2454067|NCT03213522|Active Comparator|CranioSacral Therapy|Modified Upledger Institute 10-step protocol. Sequence of hand placements (for this protocol)/type of intervention which will mirror many of the treatment sequences described in the systematic review by Jakel and von Hauenschild (2012).
2454122|NCT03213327|Other|Case management|Case management program Utilization of the StayOk web application
2454222|NCT03212586|Experimental|Dose escalation BAY1902607|Dose 1 to 9 of BAY1902607
2454223|NCT03212586|Placebo Comparator|Dose escalation Placebo|Dose 1 to 9 of matching placebo
2454335|NCT03212105|Active Comparator|60 Second Video|The mindfulness intervention is a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
2454340|NCT03212105|Other|Educational Pamphlet|The educational pamphlet contains information about pain and stress, which patients will be able to read within 60 seconds.
2454376|NCT03211182|Experimental|lifestyle intervention group|The intervention group was given healthy lifestyle education and individualized counseling by well-trained case manager at baseline, and follow-up phone counseling thereafter.
2454381|NCT03211182|No Intervention|control group|The control group was given general verbal and written health behavior information to prevent diabetes at baseline without specific individualized advice.
2454496|NCT03210402|Active Comparator|Elevated night pacing on|
2454504|NCT03210402|Placebo Comparator|Elevated night pacing off|
3190607|NCT00789243|Placebo Comparator|3|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, sham will be performed by inflating a cuff to 10 mmHg for 5 mins followed by 5 mins of deflation. This cycle will be repeated 3 times.
3190608|NCT00789269|Experimental|1|rhubarb
2454688|NCT03208959|Experimental|Dose level 1|HTI-1090 tablets will be orally administered on an empty stomach,twice daily, BID i.e., dosing will be 12 hours apart and at approximately the same times each day
2454690|NCT03208959|Experimental|Dose level 2|100% Increment from dose level 1
2454692|NCT03208959|Experimental|Dose level 3|100% Increment from dose level 2
2454693|NCT03208959|Experimental|Dose level 4|100% Increment from dose level 3
2454697|NCT03208959|Experimental|Dose level 5|50% Increment from dose level 4
2454747|NCT03208582|Other|Single arm trial|Intervention : Risedronate Sodium (oral) Dosage: 1mg/kg/week Frequency: once/week Duration: 6 weeks
2454773|NCT03208153|Experimental|Invasive|In-hospital routine coronary angiogram and revascularization if anatomically feasible
2454778|NCT03208153|Active Comparator|Conservative|In-hospital coronary angiogram only if poor clinical course
2454870|NCT03207906|Active Comparator|Lower concentration VBP-926|VBP-926 solution applied to affected area BID
2454876|NCT03207906|Active Comparator|Higher concentration VBP-926|VBP-926 solution applied to affected area BID
2454877|NCT03207906|Placebo Comparator|Vehicle|Vehicle solution applied to affected area BID
3190609|NCT00789269|Placebo Comparator|2|
3190610|NCT00789282|Active Comparator|Usual Care Group|The 'usual care' study arm (control) will reflect current patterns of care for patients with thpe 2 diabetes in the Capital Health region
3208579|NCT00976105|Active Comparator|Part A: Zolpidem or placebo|This part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
2455140|NCT03205917|Experimental|Group 1A HIV-Uninfected|PGDM1400 low dose
2455142|NCT03205917|Experimental|Group 1B HIV-Uninfected|PGDM1400 mid dose
2455143|NCT03205917|Experimental|Group 1C HIV-Uninfected|PGDM1400 high dose
2455147|NCT03205917|Experimental|Group 2A HIV-Uninfected|PGDM1400 + PGT121 low dose
2455149|NCT03205917|Experimental|Group 2B HIV-Uninfected|PGDM1400 + PGT121 mid dose
2455152|NCT03205917|Experimental|Group 2C HIV-Uninfected|PGDM1400 + PGT121 high dose
2455154|NCT03205917|Experimental|Group 3A HIV-infected off ART|PGDM1400 + PGT121 + VRC07-523LS at 20mg/kg; HIV+ without ART
2455157|NCT03205917|Experimental|Group 3B HIV-infected off ART|PGDM1400 + PGT121 at high dose; HIV + without ART
2455210|NCT03205176|Experimental|AZD5153 + Olaparib Combination Therapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine MTD. AZD5153 will be taken as oral capsules BID in combination with 300 mg olaparib BID for 21 days.
3190611|NCT00789282|Experimental|Enhanced Care Group|In the enhanced care group(intervention arm) the participants will receive a multifactorial intervention with three main components that include: optimized medical management, 2) support for development of enhanced patient self management skills, and 3) organized proactive follow-up by chronic disease management teams to support improvement in care.
2454095|NCT03213379|No Intervention|Referent group|"The patient of the referent group will have 2 measures of actimetry:~A first one at baseline before the apomorphim set-up:the report will be provided to the investigator and a second one before the 6 months follow-up visit but this report will not be provided to the investigator."
2454096|NCT03213379|Experimental|Actimetry group|"The patient of the Actimetry group will have at least 4 measures of actimetry and the reports will be all provided to the investigator:~One at baseline before the apomorphim set-up/ the second one 8 days after the hospitalisation/ the third one 28 days after the hospitalisation and the last one before the 6 months follow-up visit One optional measure can be performed 84 days after the hospitalisation."
2454142|NCT03213132|Experimental|SHUTi for older adults|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention targeting issues specific to older adults. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
2454144|NCT03213132|Active Comparator|SHUTi for older adults with stepped care|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention optimized for older adults. This is the same intervention as the first arm but with the addition of personalized emails or phone calls to participants by study personnel at specific time points as a result of not completing assigned tasks.
2454147|NCT03213132|Placebo Comparator|Patient Education website|Participants will be assigned to a relevant patient education website. It will include information about insomnia symptoms, diagnosis, prognosis, and information about CBT strategies for the older adult. Unlike SHUTi, the content will not be tailored and will be presented all at once.
2454151|NCT03212729|Active Comparator|Control Group|CONVENTIONAL ENDODONTIC TREATMENT
2454152|NCT03212729|Experimental|Test Group|CONVENTIONAL ENDODONTIC TREATMENT ASSOCIATED WITH ANTIMICROBIAL PHOTODYNAMIC THERAPY
2454161|NCT03212651|Experimental|Patients with MIBC (Muscle Invasive Bladder Cancer)|Cisplatinum-ineligible patients with muscle-invasive bladder cancer
2454226|NCT03212625|Experimental|Urea cream 20%|144 patients spread urea cream (urea 20%)
2454229|NCT03212625|Placebo Comparator|Placebo|144 patients spread placebo cream (urea 0%)
2454286|NCT03212001||Telehomecare patients (matched cohort study)|COPD and HF patients in Telehomecare program (followed up to 18 months)
2454291|NCT03212001||Usual-care patients (matched cohort study)|COPD and HF patients in 'usual care' (followed up to 18 months)
2454295|NCT03212001||Telehomecare patients (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess patient experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
2454296|NCT03212001||Informal caregiver (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess caregiver experience with Telehomecare program.~Surveys conducted up to four times using validated survey tools."
2454297|NCT03212001||Healthcare providers (observations, interviews and surveys)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess provider experience with Telehomecare program."
2454298|NCT03212001||Administrators and Decision Makers (observations, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess administrator/decision-maker experience with Telehomecare program."
2454299|NCT03212001||Technician (observation, interviews)|"Observational fieldwork conducted to observe everyday routine activities related to Telehomecare.~In-depth interview conducted for 30-60 min using semi-structured interview guide to assess technician experience with Telehomecare program."
2454342|NCT03211611||Patients with BRCA ½ mutation|Women with BRCA 1 / 2 mutation with or without cancer Age over 18
2454349|NCT03211611||GP|GP of the patients with BRCA 1 / 2 mutation
2454391|NCT03211221|Active Comparator|Active rTMS|Active stimulation parameters will be 1-Hz, 10 seconds per train, 10 pulses per train (3 seconds inter-train interval) for a total of 160 trains (1600 pulses/session) at 130% of resting motor threshold (MT) (using the lowest value of the dominant hemisphere), once a day, 5 day/week, for 3 weeks. The coil will be positioned over the pre-SMA, targeted using the International 10-20 EEG System. Pre-SMA is defined at 15% of the distance between inion and nasion anterior to Cz (vertex) on the sagittal midline. The coil will be placed with the handle along the sagittal midline, pointing towards the occiput to stimulate bilaterally and simultaneously the pre-SMA.
2454393|NCT03211221|Placebo Comparator|Sham rTMS|Sham TMS will be administered by tilting the coil 90° off the scalp, with one wing of the coil touching the scalp. This sham-TMS approach produces a clicking sound that is very similar to an active TMS pulse and induces a voltage in the brain that is more than 75% lower than active TMS.
2454438|NCT03210844||Direct anterior approach|For the DAA group, we used single-incision direct anterior approach with a standard operation table in J Arthroplasty. 2008 Oct;23(7 Suppl):64-8. Epub 2008/10/24. . The incision size was 6-10 cm depending on the body build of the patient. The acetabularreaming was performed with an offset hemispheric reamer and acetabular component was inserted underfluoroscopic guidance. Femoral broaching was performed using a double-offset broach handle.Fluoroscopy was used to check the positioning and filling of femoral stem, as well as leg lengths.
2454473|NCT03210948|Active Comparator|Conventional EUS-FNA|A 25 G needle with a central stylet to protect the aspiration channel of the needle will be introduced though the endoscope's working channel.
2454513|NCT03210246|Experimental|COC + Vilaprisan|COC + Vilaprisan (BAY 1002670)
3208580|NCT00976105|Experimental|Part B: GSK1521498 or placebo|At least 15 hours after Part A is completed subjects will enter Part B of the study.
2454090|NCT03213431||IQ of ≥90|Patient-Reported Outcomes (PRO) will be evaluated in a group of 10 childhood cancer survivors with global neurocognitive unimpairment classified by IQ of ≥90 and 10 of their parents.
2454135|NCT03213262||General anesthesia|The effect of anxiety on the choice of anesthesia will be evaluated.
2454137|NCT03213262||spinal anesthesia|Cesarean patients with spinal anesthesia
2454232|NCT03212573|Experimental|ERAS protocol|ERAS protocol includes early oral intake (6 hours after surgery), early deambulation (6h after surgery) and multimodal analgesia (port-sites infiltration with Bupivacain 0.5% combined with postoperative intravenous analgesia)
2454237|NCT03212573|Active Comparator|Standard care|Oral intake and early deambulation begins 24h after surgery and analgesia consists in only intravenous drugs
2454274|NCT03212014|Experimental|LSVT-BIG|Participants in this group would be treated with LSVT-BIG for three months
2454282|NCT03212014|Experimental|POWER|Participants in this group would be treated with POWER for three months
2454288|NCT03212014|Active Comparator|Traditional rehabilitation|Participants in this group would be treated with traditional exercise rehabilitation for three months
2454321|NCT03211598|Other|TACE with Surefire|Subjects enrolled in the study will have their TACE procedure with the Surefire Infusion System.
2454379|NCT03211403|Experimental|SHR4640 2.5mg|6 subjects assigned to 2.5mg SHR4640 and 2 subjects assigned to placebo
2454383|NCT03211403|Experimental|SHR4640 10mg|6 subjects assigned to 10mg SHR4640 and 2 subjects assigned to placebo
2454386|NCT03211403|Experimental|SHR4640 20mg|6 subjects assigned to 20mg SHR4640 and 2 subjects assigned to placebo
2454425|NCT03210922|Experimental|Collar group|Standard of anesthetic care and nasointubation with patient wearing the Miami cervical collar.
2454426|NCT03210922|No Intervention|Non-collar group|Standard of anesthetic care and nasointubation with patient not wearing the Miami cervical collar.
2454455|NCT03210649|Experimental|CKD-519 400mg(PartⅠ: 1day)|CKD-519 400mg(100mg x 4tabs) or placebo
2454465|NCT03210649|Experimental|CKD-519 400mg(PartⅡ: 14days)|CKD-519 400mg(100mg x 4tabs) or placebo
2454570|NCT03209817|Experimental|Red cherry tomato|300 grams of red cherry tomatoes per day for four weeks (each)
2454572|NCT03209817|Experimental|Yellow cherry tomato|300 grams of yellow cherry tomatoes per day for four weeks (each)
2454582|NCT03209817|No Intervention|Control No tomato|No tomato products consumption
2454655|NCT03209063||Group 1|90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy.
2454659|NCT03209063||Group 2|90 Patients having history of two or more miscarriages.
2454710|NCT03208829|Experimental|Group 1|Rehabilitation Exercises Group 1 will be submitted to an exercise protocol based on muscle strength training, with duration of 6 weeks and frequency of two weekly sessions, lasting 45 minutes.
2454712|NCT03208829|Active Comparator|Group 2|Postoperative guidance Group 2 will receive an orientation booklet and weekly links from researchers to address possible questions.
2454752|NCT03208465|Experimental|Patients with Empagliflozin|
2454754|NCT03208465|Active Comparator|Patients with Sitagliptin|
2454765|NCT03208114|Experimental|Group A|Receiving the written information of the name of a breast milk substitute on the infant's discharge documents
2454769|NCT03208114|No Intervention|Group B|Not receiving the written information of the name of a breast milk substitute on the infant's discharge documents
2455066|NCT03206502|Experimental|Embrace+Alert App|Participants are allowed to enter the trial (to use Embrace+Alert app) whether or not they have epilepsy. People without epilepsy may use Alert in this trial even though they are not expected to have seizures, as long as they are willing to mark false positives. Since many people with epilepsy live active lives and appear perfectly healthy outwardly, it is important that their active lifestyle data not trigger false alarms. Allowing healthy participants without epilepsy to contribute active lifestyle data helps us make the detection algorithm even stronger and better.
3154199|NCT00293787|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5% in both eyes each morning at 8 a.m. and Timolol vehicle in both eyes each evening at 8 p.m. for 3 months
3154200|NCT00293787|Active Comparator|Xalatan + Timolol 0.5%|Timolol 0.5% in both eyes each morning at 8 a.m. and Xalatan in both eyes each evening at 8 p.m. for 3 months
3154201|NCT00293800|Experimental|Travoprost/Timolol|One drop Travoprost 0.004%/Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Timolol vehicle in the study eye(s) each evening at 8 p.m. for 3 months
3154202|NCT00293800|Active Comparator|Xalatan + Timolol 0.5%|One drop Timolol 0.5% in the study eye(s) each morning at 8 a.m. and one drop Xalatan in the study eye(s) each evening at 8 p.m. for 3 months
2455185|NCT03205514||NSTE-ACS with intermediate stenosis and negative FFR|Patients hospitalized because of an acute coronary syndrome without ST segment elevation and with intermediate culprit lesion with negative fractional flow reserve evaluation (>0.80).
2455201|NCT03205176|Experimental|AZD5153 Monotherapy|Patients will be enrolled in cohorts of up to 6 patients each in a dose escalating scheme to determine maximum tolerated dose (MTD). AZD5153 will be taken once per day (QD) or two times per day (BID) for 21 days as an oral capsule. Once the MTD is finalized, patients may be enrolled into an expansion cohort at the MTD.
3154203|NCT00293826|Experimental|1|196 subjects
3154204|NCT00293826|Experimental|3|196 subjects
3154205|NCT00293826|Experimental|2|196 subjects
3154206|NCT00293826|Placebo Comparator|4|196 subjects
3154207|NCT00293852|No Intervention|Usual Care|
3154208|NCT00293852|Experimental|Collaborative Care|
2454131|NCT03213028|Other|Full group|Our goal is to assess the feasibility and acceptability of incorporating family planning (FP) service delivery, using a program validated by the World Health Organization (WHO), into the established Cervical Cancer Prevention (CCP) programs of Botswana.
2454168|NCT03212924|Experimental|Pupillometry|"Measure of pupil dilatation while listening to speech (monosyllabic words) in quiet and in noise.~Evaluation of speech comprehension in quiet~Evaluation of speech comprehension in noise~Measure of cognitive functions with the MOCA (Montreal Cognitive Assessment)~Auto evaluation of listening effort in quiet~Auto evaluation of listening effort in noise"
2454203|NCT03212313|Active Comparator|Healthy Subjects|Study dose of 120 mg
2454205|NCT03212313|Experimental|Mild Hepatic Impairment|Study dose of 120 mg
2454209|NCT03212313|Experimental|Moderate Hepatic Impairment|Study dose of 120 mg
2454211|NCT03212313|Experimental|Severe Hepatic Impairment|Up to a maximum study dose of 120 mg
2454263|NCT03212196|Active Comparator|Pancreaticogastrostomy|Pancreaticogastrostomy with external drain
2454264|NCT03212196|Active Comparator|Pancreaticojejunostomy|Pancreaticojejunostomy with transanastomotic drain
2454320|NCT03211741|Other|open label|
2454452|NCT03210909|Experimental|BMS-986231 Intravenous Infusion|A single continuous intravenous infusion of BMS-986231
2454555|NCT03210129|Experimental|Motivational interviewing|Patients of the motivational interviewing group will receive standard care alongside motivational interviewing to change their behavior regarding physical activity.
2454559|NCT03210129|No Intervention|Control Group|Patients of the control group will receive standard care alone.
2454606|NCT03209635|Placebo Comparator|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
2454609|NCT03209635|Experimental|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
2454651|NCT03209297|Experimental|Direct treatment|Patients receive the TMD treatment immediately
2454652|NCT03209297|Experimental|Delayed treatment|No intervention in the first 9 weeks of the study. Afterwards, the patients receive the same treatment as the other group
2454736|NCT03208855|Experimental|CBT-I|Participants will receive 8 1-hour sessions of group Cognitive Behavioral Therapy for insomnia as part of their intensive outpatient treatment of substance use recovery
2454737|NCT03208855|No Intervention|Treatment as Usual|Participants will receive treatment as usual for substance abuse treatment as part of their intensive outpatient treatment of substance use recovery
2454766|NCT03208257|Experimental|Esmolol|Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
2454848|NCT03207984|Active Comparator|Control SCTG|Root coverage surgery with subepithelial connective tissue graft to treat multiple gingival recessions in aesthetic areas
2454852|NCT03207984|Experimental|Test MG|Root coverage surgery with Mucograft collagen matrix graft to treat multiple gingival recessions in aesthetic areas
3154209|NCT00293956||1|Full-term and near-term infants with respiratory distress in the first 24 hours of life
3154210|NCT00294008||001|Risperdal Consta flexible dosage for 24 months
2454964|NCT03206983|Experimental|Cana's Ring group|The device Cana's Ring was used during cataract surgery on these patients.
2455016|NCT03206775||Healthy controls (Phase 1)|Participants will participate in Cognitive Assessments (Phase 1) developed by Posit Science
2455024|NCT03206775||Healthy Controls, Battery A (Phase 2)|Participants will complete the Cognitive Battery A (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2455026|NCT03206775||Healthy Controls, Battery B (Phase 2)|Participants will complete the Cognitive Battery B (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2455027|NCT03206775||Healthy Controls, Battery C (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2455028|NCT03206775||Healthy Controls (Phase 3)|Participants will complete the full Posit Science cognitive assessment battery and self-report questionnaires for credit in the Research Experience Program at the University of Minnesota.
2455029|NCT03206775||Healthy Controls, Battery D (Phase 2)|Participants will complete the Cognitive Battery E (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2455030|NCT03206775||Healthy Controls, Battery E (Phase 2)|Participants will complete the Cognitive Battery C (Phase 2) developed by Posit Science while at the Minnesota State Fair.
2455031|NCT03206775||Adolescents with anxiety diagnosis (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
2455032|NCT03206775||Adolescents, healthy controls (Phase 4)|Participants will complete remote cognitive assessments and cognitive training programs developed by Posit Science.
2455087|NCT03206229|Experimental|TPI-120 (PEG-rhG-CSF)|PEG-rhG-CSF (recombinant granulocyte-colony stimulating factor conjugated with monomethoxypolyethylene glycol) Adello Biologics, LLC, Chicago, IL
2455095|NCT03206229|Active Comparator|Neulasta (PEG-rhG-CSF)|Neulasta®, (PEG-rhG-CSF) Amgen, Thousand Oaks, CA
2455170|NCT03205852||group A (benefit-inform)|filling questionnaire based on benefits of surgery
2455173|NCT03205852||group B (side effect-inform)|filling questionnaire based on side-effects of surgery
2455243|NCT03205345|Active Comparator|Emricasan (25 mg)|Emricasan 25 mg
2455245|NCT03205345|Active Comparator|Emricasan (5 mg)|Emricasan 5mg
2455246|NCT03205345|Placebo Comparator|Placebo|Matching placebo
2455354|NCT03204305|Active Comparator|Cannabis users|Smoked Cannabis plant material (0 and 25 mg THC) will be administered to volunteers who are regular cannabis users. Cannabis users will also complete a PET scan where 20 millicurie of 11C-OMAR
2455355|NCT03204305|Active Comparator|Nonuser controls|No cannabis administration. Non-user controls will complete a PET scan where 20 millicuries of 11C-OMAR
2455415|NCT03204058|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2455419|NCT03204058|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
3154211|NCT00294099|Experimental|2|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3208581|NCT00976118|Placebo Comparator|placebo|
2454176|NCT03212989|Experimental|VOR + HXTC arm|"This is an open label single arm study. All eligible participants receive the following interventions:~Step 2 - Single dose of Vorinostat (VOR) 400 mg PO~Step 4 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions~Step 5 - Vorinostat (VOR) 400 mg PO every 72 hrs x 10 doses and 2 HXTC infusions"
3190612|NCT00789295|Active Comparator|Mediterranean diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%)
3190613|NCT00789295|Active Comparator|Low-Carbohydrates diet|Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)
3190614|NCT00789308|Active Comparator|Standard of Care|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) without LMW-DS
3154212|NCT00294099|Experimental|3|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
2454405|NCT03211052|Experimental|TAK-700 + LHRH agonist + Prostatectomy|Neoadjuvant TAK-700 for 6 months with LHRH agonists prior to prostatectomy
2454409|NCT03211052|Other|Prostatectomy|Prostatectomy only-Within 28 days of randomisation
2454445|NCT03210740|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
2454456|NCT03210740|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles
2454505|NCT03210311|No Intervention|control group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform twice a day upper limb exercises at home. They are advised to use the arm as normal as possible."
2454514|NCT03210311|Active Comparator|intervention group|"Receive information: the patient receive a leaflet with information about the lymphatic system and lymphedema, clinical evaluation and conservative treatment of lymphedema~Perform skin care~Perform upper limb exercises at home twice a day. They are advised to use the arm as normal as possible~Wear a compression sleeve"
2454664|NCT03209128||Irradiation prophyllactique cérébrale|
2454744|NCT03208842||women with previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
2454745|NCT03208842||women without previous cesarean scar|"the patient will be examined son graphically at 3 visits~The first visit at less than 10 weeks gestation :trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity .~-----doppler assessment of the retro chorionic blood flow in the area behind the maximum chorionic tissue to detect sensitivity index (RI),in cases of low gestational sac Doppler assessment of peri trophoplastic blood flow will be assessed.~then the patient will be enrolled during routine ANC till delivery and data collected at32-34 weeks gestation regarding placental site will be correlated with 1st data and data at delivery ."
2454809|NCT03208179|Active Comparator|IPTp-SP|Stat course of 3 tablets of quality-assured SP (tablets of 500 mg of sulphadoxine and 25 mg of pyrimethamine) at each scheduled antenatal visit
2454811|NCT03208179|Experimental|IPTp-DP|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + placebo AZ at each scheduled antenatal visit
2454812|NCT03208179|Experimental|IPTp-DPAZ|Dihydroartemisinin-piperaquine [3 to 5 tablets of DP (tablets of 40 mg of dihydroartemisinin and 320 mg of piperaquine, based on bodyweight) daily for 3 days] + AZ tablet [1.5g over 3 days as 500mg per day] at each scheduled antenatal visit.
2454828|NCT03207685|Other|All Subjects|This is a single arm study With a device intervention of Additional Seizure Monitoring
3190615|NCT00789308|Experimental|LMW-DS|18 participants randomized to protocol immunosuppression (Daclizumab OR Basiliximab; Tacrolimus OR Cyclosporine; Mycophenolate Mofetil OR Sirolimus; and heparin) and LMW-DS
3190616|NCT00789347||1|Healthy volunteers
3154213|NCT00294099|Experimental|4|60 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3154214|NCT00294099|Experimental|8|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3154215|NCT00294099|Experimental|7|60 subjects to receive 3.75 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3154216|NCT00294099|Experimental|1|120 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3154217|NCT00294099|Experimental|5|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine with aluminum hydroxide.
3190617|NCT00789347||2|Patient with neuropathic pain
3190618|NCT00789347||3|patients without neuropathic pain
3190619|NCT00789386|Experimental|Remifentanil|
3190620|NCT00789386|Placebo Comparator|Midazolam|Active Placebo
3190621|NCT00789399|Active Comparator|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
3190622|NCT00789399|Placebo Comparator|Placebo|
3190623|NCT00789412||Expected ICU|Patients with expected postoperative admission to the ICU. Baseline measurement of SSI. Exploration prior to weaning.
3190624|NCT00789412||Unexpected ICU|Patients with unexpected stay at the ICU. No baseline measurement of SSI. Exploration in 'steady state' of analgosedation.
3190625|NCT00789425|Active Comparator|1|a standardized extract of olive polyphenols at 250 mg per day + 1000 mg of calcium per day.
3190626|NCT00789425|Placebo Comparator|2|Placebo (starch) + 1000 mg of calcium per day.
3190627|NCT00789451|Sham Comparator|1|no ischaemia - only sham. Blood pressure cuff inflation up till 10 mmHg on the upper arm for 20 mins.
2454248|NCT03212235|Experimental|Hypofractionated radiation therapy|"Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week.~After a 30-days break, adjuvant temozolomide days 1-5 every 28 days for 6 cycles."
2454270|NCT03211923||Nemaline myopathy type 6 (NEM6)|Patients diagnosed with nemaline myopathy type 6 (mutation in KBTBD13 gene). The aim is to measure five male and five female patients.
2454278|NCT03211923||Myotonic dystrophy type 2 (DM2)|Patients diagnosed with myotonic dystrophy type 2 (pathological repeat expansion in CNBP gene). The aim is to measure five male and five female patients.
2454284|NCT03211923||McArdle disease (McA)|Patients diagnosed with McArdle disease (mutation in PYGM gene). The aim is to measure five male and five female patients.
2454289|NCT03211923||Healthy controls|14 male and 10 female healthy subjects were measured in a previous study
2454293|NCT03211923||Controls with positive muscle phenomena|9 male and 8 female subjects with positive muscle phenomena but no myopathy, ruled out by normal muscle biopsy, CK level, and genetic testing. These subjects were measured in a previous study.
2454294|NCT03211923||Brody disease|4 male patients diagnosed with Brody disease (ATP2A1 mutation). All Dutch patients suffering from Brody disease (n=4) were measured in a previous study
2454353|NCT03211650|Experimental|hyaluronic acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
2454355|NCT03211650|Active Comparator|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
2454357|NCT03211650|Active Comparator|hyaluronic acid|Intra-articular injections of hyaluronic acid
2454408|NCT03211078|Experimental|super-D ENB guided-PDT|To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
2454451|NCT03210792|Active Comparator|CCO Rib Splint|Subjects were applied Chrisofix® Chest Orthosis (Manufactured Rib Splint) for Rib Fractures treatment.
2454462|NCT03210792|Experimental|Handmade Rib Splint|Subjects were applied Handmade Rib Splint for Rib Fractures treatment.
2454492|NCT03210415||Study group|Pregnant women ≥35 years old would have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
2454499|NCT03210415||Control group|Pregnant women ≥35 years old would not have spontaneous preterm labor. There's no intervention in this group, because it's an Observational Study Model.
2454552|NCT03210025|Experimental|BF-Methyldopa Tablet 250mg|During the study session, healthy subjects will be administered a single dose of BF-Methyldopa Tablet 250mg after an overnight fast of approximately 10 hours
2454556|NCT03210025|Active Comparator|Metopa Tab 250mg|During the study session, healthy subjects administered a single dose of Metopa Tablet 250mg after an overnight fast of approximately 10 hours
2454631|NCT03209609|Experimental|VEST supported vein graft|Coronary artery bypass vein graft supported with the VEST implant
2454633|NCT03209609|Active Comparator|Standard of care vein grafts|Coronary artery bypass vein grafts
2454721|NCT03208998|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454726|NCT03208998|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2454789|NCT03208309|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remainder of the study.
2454791|NCT03208309|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
2454832|NCT03207815|Experimental|Filgotinib|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.~All participants will receive filgotinib for up to 52 weeks."
2454834|NCT03207815|Placebo Comparator|Placebo|"All participants will receive a standardized prednisone burst of 60 mg/day at Day 1/Baseline followed by a protocol-defined mandatory taper schedule, to Week 15.~All participants will receive placebo to match filgotinib for up to 52 weeks."
2454944|NCT03207191|Experimental|F16IL2 + BI 836858|"Successive cohorts of patients will receive increasing doses of FI6IL2 and BI 836858 until the MTD is reached. The MTD will be defined following a Bayesian logistic regression model (BLRM) with overdose control.~Patients will go off treatment after 6 months (i.e. after 6 cycles of induction combination therapy). Patients achieving CR or CRi will receive maintenance therapy for a maximum of 6 months."
2454995|NCT03206840|Experimental|Group 1|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
2454997|NCT03206840|Experimental|Group 2|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
2455055|NCT03206489|Experimental|nHFOV|noninvasive high-frequency ventilation (nHFOV) is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
2455059|NCT03206489|Active Comparator|nCPAP|nasal continuous positive airway pressure (nCPAP) is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
3154218|NCT00294099|Experimental|6|60 subjects to receive 7.5 mcg of inactivated influenza A/H5N1 vaccine without aluminum hydroxide.
3154219|NCT00294112|Experimental|High dose|High dose (8 million cells per kg of body weight)
2455135|NCT03205995|Experimental|OMS721|Administration of OMS721
2455348|NCT03204331|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
3154220|NCT00294112|Experimental|Low dose|Low dose: 2 million cells per kg body weight
3154221|NCT00294125|Experimental|1|Participants will receive daily flavocoxid for 12 weeks.
3154222|NCT00294125|Placebo Comparator|2|Participants will receive placebo for 12 weeks.
3154223|NCT00294164|Experimental|Serostim® 4 mg daily|
3154224|NCT00294164|Experimental|Serostim® 4 mg alternate days|
3154225|NCT00294164|Placebo Comparator|Placebo|
3154226|NCT00294190|Experimental|Topotecan|
3174517|NCT00624351|Experimental|EMAB 1800mg|1800 mg Epratuzumab infusions at study weeks 0, and 2, and placebo at study weeks 1 and 3.
2454260|NCT03212209|Experimental|CPAP C- Flex-Plus by Philips Respironics|Four consecutive weeks with CPAP C- FLEX PLUS treatment. After these 4 weeks, patients will undergo full PSG with CPAP FLEX- PLUS. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2454261|NCT03212209|Experimental|CPAP with Sensawake by Fisher and Paykel|Four consecutive weeks with CPAP Sensawake treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2454262|NCT03212209|Active Comparator|CPAP fixed pressure|Four consecutive weeks with CPAP fixed pressure treatment. After these 4 weeks, patients will undergo full PSG with the same CPAP modality. Patients will also fill out Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Functional Outcome Sleep Questionnaire, and visual analogue scale assessing CPAP side effects and patient´s comfort. Adherence to 4-week treatment will be checked. Treatment is followed by 7-day washout period.
2454303|NCT03211780|Experimental|Ultrasound|
3190628|NCT00789451|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated around the upper arm for 20 minutes to induce ischaemia.
3190629|NCT00789464|Other|ARM A|Probiotics drops plus placebo elixir
2454450|NCT03210610||FMF patients|fmf patients under a constant colchicine dose
3190630|NCT00789464|Other|ARM B|TMP/SMZ elixir plus placebo drops
3190631|NCT00789503|Experimental|Bread fortified with vitamin D3 and calcium|
2454545|NCT03209739|Active Comparator|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
2454546|NCT03209739|No Intervention|No reminder|No additional reminder will be given
3190632|NCT00789516||1|Normal control
3190633|NCT00789516||2|B thalassemia regular transfusion
2454843|NCT03207971|Active Comparator|SCTG from palatal area with predominance of lamina propria|
2454849|NCT03207971|Active Comparator|SCTG from palatal area with predominance of submucosa|
2454935|NCT03207490|Experimental|Robot group|Receive 1 hour of AMADEO (robot-assisted therapy) for the hand and 1 hour of daily standard rehabilitation therapy
2454991|NCT03206905|Experimental|Endoscopic Sleeve Gastroplasty|
2454993|NCT03206905|Active Comparator|Diet and exercise only.|
2455054|NCT03206463|Experimental|Active 4 mg inhaled THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
2455057|NCT03206463|Experimental|Active 2 mg inhaled THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
2455060|NCT03206463|Placebo Comparator|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
2455068|NCT03206125||Controls|Controls
2455069|NCT03206125||ESCC Cases|ESCC Cases
2455108|NCT03206034|Experimental|Treatment|The experimental group will meet with a study team member twice a week for 4 weeks (8 sessions) and receive memory strategy training.
2455111|NCT03206034|Placebo Comparator|Control|The control group participants will meet with a study team member twice a week for 4 weeks (8 sessions) and receive control memory exercises.
2455162|NCT03205774|Sham Comparator|Supine position|patient in supine position, lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2455165|NCT03205774|Sham Comparator|30° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 30°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2455168|NCT03205774|Sham Comparator|45° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 45°), lying on the back, turned in the right lateral decubitus and turned in the left lateral decubitus in a randomized way, after prolonged fasting and 10 min after free oral intake of water
2455171|NCT03205774|Sham Comparator|90° semirecumbent position|patient in semirecumbent position (head of the bed elevated to 90°), lying on the back, after prolonged fasting and 10 min after free oral intake of water
2455231|NCT03205293|Experimental|Intervention Group|Female Schoolchildren, their mothers and teachers will be exposed to multiple interventions designed through a participatory approach, integrating the ecological model.
2455236|NCT03205293|No Intervention|Control Group|Regular school curriculum
2455261|NCT03205020||women with preterm labor|
2455263|NCT03205020||women delivered at full term|
2455306|NCT03204708|Active Comparator|iv analgesia|patients were given intravenously 100 mg of tramadol (contramal) 30 minutes before extubation after modified radical mastectomy.
2455539|NCT03203499|Placebo Comparator|Placebo|Placebo administered orally
3190634|NCT00789516||3|B thalassemia post transplantation
3190635|NCT00789542|Experimental|Intermittent Pneumatic Compression|SCD Express device applied with thigh length sleeves for up to 30 days
3190636|NCT00789542|Other|Routine care|Routine care which might include: early mobilisation, adequate hydration, aspirin if ischaemic stroke and graduated compression stockings according to local protocols.
3190637|NCT00789568|Experimental|Sapropterin Dihydrochloride 100mg/kg and placebo Moxifloxacin|A single dose of 100mg/kg of Sapropterin Dihydrochloride taken along with placebo Moxifloxacin.
2454292|NCT03211897||Midazolam 5mg Intramuscular|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
2454333|NCT03211572|Experimental|Endocrine Therapy|Anastrozole 1 mg (postmenopausal) or tamoxifen 20mg (premenopausal) are to be taken orally each evening and would be started exactly 2 weeks prior to their surgery.
2454395|NCT03211247|Experimental|Viaskin Peanut 250 mcg|
2454397|NCT03211247|Experimental|Viaskin Peanut 100 mcg|
2454399|NCT03211247|Placebo Comparator|Placebo|
2454446|NCT03210584||Imaging measurements|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Multimodal evaluation is conducted on ex vivo human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
2454503|NCT03210441||Group 1|Patients affected by breast cancer and potentially treated with taxane chemotherapy
2454508|NCT03210441||Group 2|Patients affected by breast cancer and not potentially treated without taxane chemotherapy
2454540|NCT03210064|Experimental|Apatinib and 5-Fluorouracil|Apatinib 500 mg qd po.5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
2454541|NCT03210064|Active Comparator|5-Fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
2454569|NCT03209791||Alcoholic Steatosis|This group will have 10 patients with alcoholic steatosis which is milder disease and muscle biopsies will be performed
2454571|NCT03209791||Cirrhosis|This group will consist of 10 patients with cirrhosis. We anticipate a 50% difference in these patients and the controls in the autophagy readouts and muscle biopsies will be performed
2454580|NCT03209791||Steatohepatitis|This group will have 10 patients with alcoholic steatohepatitis that have more severe necroinflammation in the liver but for a shorter duration of illness and muscle biopsies will be performed
2454584|NCT03209791||controls|This group will consist of 10 patients who are healthy and have no liver disease diagnosis and muscle biopsies will be performed
2454599|NCT03209427|Active Comparator|Group I|intrathecal injection of 100 μg morphine
2454602|NCT03209427|Active Comparator|Group II|iIntrathecal injection of 200 μg morphine
2454666|NCT03209193|Experimental|Sevoflurane|Sevoflurane (2 vol%) use as a maintenance volatile anesthetic drug during the surgery
2454674|NCT03209193|Experimental|Desflurane|Desflurane (6 vol%) use as a maintenance volatile anesthetic drug during the surgery
2454704|NCT03208777||control group|taking blood samples from apparently healthy people
2454707|NCT03208777||benign colorectal|taking blood samples from patients
2454709|NCT03208777||malignant colorectal|taking blood samples from patients
2454757|NCT03208504|Experimental|Treatment|All subjects in treatment arm will be implanted with the Single Branch Nexus™ Aortic Arch Stent graft System.
2454797|NCT03208062||Patients|"The target group corresponds to the patients admitted to our Institute who are candidates for the following surgical or biopsy procedures and collection of waste materials:~patients with osteoarthritis of the hip or knee and rehabilitated in the institute~patients with primary and secondary tumors of the skeleton~patients undergoing prosthetic examination as a result of plant infection The population will include adult subjects(>18 years included). Patients will be considered eligible for enrollment in the project if they can provide informed written consent."
3154227|NCT00294203|Active Comparator|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
3173157|NCT00608933|Other|Arm II (wait-list)|Health providers are enrolled on a wait-list. After 2 months, the educational materials in arm I (educational intervention) are made available to the wait-list health providers.
3173158|NCT00608946|Experimental|1|efficacy of the intake of 8 mg of copper daily per os for one year under observation of cognitive status unless unacceptable side effects appear
3173159|NCT00608946|Placebo Comparator|2|placebo
2454940|NCT03207204|Active Comparator|G1 - 35% Hydrogen peroxide bleaching|In-office bleaching performed with 35% hydrogen peroxide (4 sessions, 1 session/week);
2454941|NCT03207204|Active Comparator|G2 - 30% Carbamide peroxide bleaching|In-office bleaching performed with 30% carbamide peroxide (4 sessions, 1 session/week);
2454942|NCT03207204|Experimental|G3 - Violet LED bleaching 1|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 1 session/week);
2454943|NCT03207204|Experimental|G4 - Violet LED bleaching 2|In-office bleaching performed with Violet LED (405-410 nm, 4 sessions, 2 sessions/week);
2454945|NCT03207204|Experimental|G5 - Photochemical protocol 1|In-office bleaching performed Violet LED associated to 35% hydrogen peroxide (4 sessions, 1 session / week);
2454947|NCT03207204|Experimental|G6 - Photochemical protocol 2|In-office bleaching performed Violet LED associated to 30% carbamide peroxide (4 sessions, 1 session / week)
2454950|NCT03207204|Experimental|G7 - Hybrid technique 1|hybrid technique HP (Violet LED + application of 35% hydrogen peroxide + violet LED) (4 sessions, 1 session/week)
2454952|NCT03207204|Experimental|G8 - Hybrid technique 2|Hybrid technique CP HP (Violet LED + application of 30% carbamide peroxide + violet LED) (4 sessions, 1 session/week).
2455001|NCT03206645|Experimental|Carboplatin/Paclitaxel + PTC596|Carboplatin AUC 6mg/L IV on day 1; Paclitaxel 175mg/m2 IV on day 1; PTC596 PO, twice a week, on day 1, 4, 8, 11, 15 and 18 per 21-day cycle for the first 3 cycles.
2455311|NCT03204838||AML patients|Adult AML patients with the IDH mutation test performed at diagnosis.
2455441|NCT03204201|Experimental|Urethral instillation of ICG|Urethral instillation of indocyanine green (ICG)
2455621|NCT03202615|Experimental|L (lactoferrin in IDA with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 100 mg bLf granules (Pravotin sachets , Hygint, Egypt) in 1/4 glass of water twice a day before meals in addition to placebo tablets three time per day on an empty stomach.
2454310|NCT03211884|No Intervention|Usual Care|Usual care was defined as various military caregiver organizations, support groups and services available to all family caregivers of combat Veterans (e.g., Military OneSource; Operation We Are Here; Veterans Administration Program of Comprehensive Assistance for Family Caregivers; American Red Cross Military and Veteran Caregiver Network; Project New Hope; Wounded Veteran Family Care; Women for Wounded Warriors).
2454334|NCT03211494|Active Comparator|Conventional lung protective ventilation|Use of conventional lung protective ventilation, according to the ARDSnet guidelines
2454341|NCT03211494|Active Comparator|INTELLiVENT-ASV|Use of INTELLiVENT-ASV
2454368|NCT03211169|Experimental|Pediatric Biopsy Forceps directed biopsies|Biopsies of the stricture will be taken with Pediatric Biopsy Forceps after bile duct brushings have been obtained.
2454370|NCT03211169|Active Comparator|Cholangioscopy-directed biopsies|Biopsies of the stricture will be taken under cholangioscopic guidance after bile duct brushings have been obtained.
2454423|NCT03210987|Active Comparator|patient case presentation Bedside|In the bedside presentation group, patient case presentation and discussions will be at bedside with direct involvement of the patient as needed.
2454424|NCT03210987|Active Comparator|patient case presentation Outside-the-room|In the outside the room condition, case presentation and discussions will take place outside without the patient being present. After the case presentation and discussions the team will enter the room and give the patient a short summary of the medical situation, complete the medical information and examine the patient, as needed, and discuss the next steps.
2454458|NCT03210662|Experimental|Treatment (EBRT, pembrolizumab)|Beginning on day 1, patients undergo fractionated EBRT daily for 5 consecutive days a week for up to 12 or 22 treatments. Patients also receive pembrolizumab IV over 1 hour on day 2. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
2454491|NCT03210194|Active Comparator|Standard Neonatal Resuscitation Training|Standard training will be conducted through a theoretical-practical course, which will be administered once during the study period, to all health professionals of the selected facilities, according to the randomization. It is an 8-hour course, with 3 hours of theory and 5 hours of practice, which will take place during a single day. The course will be performed by staff of the Neonatal Unit of the Instituto Nacional de Salud del Niño (National Institute of Child Health, Lima, Peru), and will be coordinated by an NRP instructor accredited by the American Academy of Pediatrics. Participants who have completed their attendance to theoretical sessions, participated in the simulated practices and approved the printed exams taken the same day will we granted a Standard Certification.
2454500|NCT03210194|Experimental|MP-ICT Neonatal Resuscitation Training|The Multi-platform ICT (MP-ICT) training includes continuous certification in neonatal resuscitation and is being developed for online and offline access, and will be complemented with simulated practices on every site. The platform is being improved and adjusted to the needs of the fieldwork in Ayacucho and Cusco. The adaptations include increasing hosting; ameliorate friendly usability, uploading packages and videos, improvement of examination and certifications, and tests for readiness. The MP-ICT resource will be accessed from remote Peruvian locations through computers, personal portable devices and cell phones. To be granted an MP-ICT Certification the trainee needs to have passed the online theoretical exam, assist to the practice and approve practical skills assessment.
2454636|NCT03209349|Experimental|Water Exchange Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned the water exchange intervention arm, the insertion of the scope will be followed by infusion and suction of water to minimally distend the lumen. If the lumen does not open, the instrument will be retracted slightly and the infusion started again. As the scope is inserted and progressed through the intestinal lumen some of the infused water will be suctioned back constantly, exchanging clean for opaque water."
2454637|NCT03209349|Active Comparator|Air Insufflation Sigmoidoscopy|"As per standard practices, the patient will be walked to the procedure room and positioned in the left lateral position on the procedure bed, without pre-operative anesthesia. The procedures will be completed within the ambulatory endoscopy clinic at Kelowna General Hospital. The study will use the same colonoscopes that are already being used at KGH for colonoscopy. These are the Olympus 190 series colonoscopes. They can and will be fitted to support both water and air exchange.~For patients assigned to the air insufflation intervention arm, extended sigmoidoscopy will be performed with the minimum insufflation required to reach the cecum."
2454695|NCT03208972|Experimental|low dose hCG (Pregnyl)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination 150IU low dose hCG from day 7 until final oocyte maturation.
2454698|NCT03208972|Active Comparator|hp-FSH (Menopur)|Corifollitropin Alfa (Elonva) dosage depending on weight once administered first day of ovarian stimulation in combination with hp-FSH until final oocyte maturation.
2454724|NCT03208556|Experimental|iPD1 CD19 eCAR T cells|patients will receive a lymphodepletion chemotherapy prior to CAR T cell infusion
2454774|NCT03208348|Experimental|Pilot virtual reality|Children with anxiety will have a single visit to test the virtual reality system and measure its affects on their anxiety ratings.
3173160|NCT00608972|Experimental|Doxil, Carboplatin and Bevacizumab|
2454934|NCT03207321||Intervention|In 15 intervention villages, a balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma' - was offered daily to pregnant women and children under six years of age during 1987-1990. The meal provided on average 500 kcal energy and 20-25g of protein to women and half of those amounts to children.
2454936|NCT03207321||Control|No supplement was provided in 14 control villages.
2455050|NCT03206541||Cases|The cases are defined as individuals that present with new onset of a neurological syndrome of unknown etiology, including but not limited to encephalitis, myelitis, meningitis, polyneuropathy/Guillain-Barre syndrome and cranial nerve involvement.
2456178|NCT03199313|Active Comparator|Cohort 4 - Active|N = 6, 1800 mg sutezolid or matching placebo
3173161|NCT00609037||1|Individuals who has had a weight reduction procedure such as gastric bypass and have body contouring surgery to remove the excessive skin due to the weight loss
2454343|NCT03211637|Active Comparator|CONTROL GROUP|This group comprising 5 healthcare units equipped with a Family Health Strategy. Patients were seen by coordinating nurses who used techniques and supplies with which they were already familiar. They had no protocol in place.
2454429|NCT03211273||Patient cohort|Newly diagnosed breast, ovarian or colon cancer patients recruited 6 months post-diagnosis and followed up to 5 years post-diagnosis. No intervention.
2454436|NCT03210636|Experimental|With Use of LapSpace|evaluate ease of use, safety evaluations, surgeon and clinician feedback
3190638|NCT00789568|Experimental|Sapropterin Dihydrochloride 20mg/kg and placebo Moxifloxacin|A single dose of 20mg/kg of Sapropterin Dihydrochloride taken along with a placebo Moxifloxacin.
3190639|NCT00789568|Active Comparator|Sapropterin Dihydrochloride placebo and Moxifloxacin|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with 400mg of Moxifloxacin.
2454585|NCT03209765|Active Comparator|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
2454586|NCT03209765|No Intervention|No reminder|
2454587|NCT03209466|Experimental|Standard management and Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
2454592|NCT03209466|Placebo Comparator|Standard management and physiological saline sterile solution|Application every 24 hours, six weeks Intervention: Other: physiological saline sterile solution
2454676|NCT03209271|Experimental|Body temperature fluid|500ml Ringers Acetate infused over 15 minutes warmed to 38°C
2454685|NCT03209271|Active Comparator|Room temperature fluid|500ml Ringers Acetate infused over 15 minutes cooled to 22°C
2454748|NCT03208686|Other|Intervention Group|A single-arm intervention comprised of discussion groups, text messages, and a cloud-based cellular glucometer.
3190640|NCT00789568|Placebo Comparator|Sapropterin Dihydrocholide placebo and Moxifloxacin placebo|No placebo tablets for Sapropterin Dihydrochloride will be administered, but instead will be apple juice only, taken along with placebo of Moxifloxacin.
3190641|NCT00789594|Experimental|Laboratory Monitoring|Laboratory Monitoring
2454838|NCT03207659|Experimental|Dusting|small stones will be left to pass spontaneously.
2454839|NCT03207659|Experimental|Basketing|stones will be actively extracted.
2454957|NCT03207516|Active Comparator|Sourdough --> Brewer's Yeast|"Sourdough --> Brewer's Yeast~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
2454959|NCT03207516|Active Comparator|Brewer's Yeast --> Sourdough|"Brewer's Yeast --> Sourdough~administration of two 100 g croissants prepared with brewer's yeast after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points.~washout period: 7 days~administration of two 100 g croissants prepared with sourdough after an overnight fast.~Magnetic Resonance (MR) Imaging analysis of gastric emptying, evaluation of postprandial gastrointestinal fermentation, croissant palatability, gastrointestinal symptoms and perceptions, and serum glucose levels at several time points."
2455017|NCT03206762|Experimental|Jetstream Atherectomy+Ranger DCB or Medtronic IN.PACT DCB|Jetstream Atherectomy used in conjunction with the Ranger DCB or Medtronic IN.PACT DCB
2455021|NCT03206762|Active Comparator|POBA+DCB (Ranger or IN.PACT)|POBA and then DCB treatment (Ranger or IN.PACT)
2455102|NCT03206359||Patients|Patients with SLE
2455106|NCT03206359||Healthy subjects|
2455137|NCT03205930|Experimental|Neo-MASCT|Neoantigen Multiple Target Antigen Stimulating Cell Therapy ( Neo-MASCT)
2455202|NCT03205124|Experimental|Pre-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Once the stimulation is complete, the stimulator is detached and the patient is informed of the surgical date. The wires are taken out at the conclusion of the pre-operative appointment. These patients will have fine gauge wires for post-operative sham stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. However, the voltage will only be increased to a level they are able to sense.
2455212|NCT03205124|Sham Comparator|Sham stimulation|These patients will have the stimulator attached to their wires 3 days prior to scheduled surgical date and postoperatively as were in the previous groups. However, the voltage will only be increased to a level they are able to sense. The stimulator was then be turned off without the patients' knowledge. All connections are left in place for anhour duration. These patients will similarly have their wires removed after the conclusion of their pre-operative appointment and at the first post-operative follow-up within 1 week of surgery.
3190642|NCT00789594|Experimental|Result management|Result management
3208582|NCT00976118|Experimental|oral masitinib (AB1010)|masitinib (AB1010) 3 or 6 mg/kg/day
2454347|NCT03212066|Experimental|Intervention|Master Mind is a 25-lesson elementary school, mindfulness education substance abuse prevention program for 4th and 5th grade classrooms.
2454352|NCT03212066|No Intervention|Wait-List Control|Business as usual
2454428|NCT03211195|Experimental|Sotagliflozin - Commerical|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Commercial formulation) by mouth under fasted conditions
2454431|NCT03211195|Active Comparator|Sotagliflozin -Development|Healthy volunteers will be administered a single dose Sotagliflozin (SAR439954) tablet (Development formulation) by mouth under fasted conditions - Type: Active Comparator
2454440|NCT03210597|Experimental|hydro-aerobic|Water aerobics exercise
2454449|NCT03210597|Experimental|hydro-power|Resistance water exercise
2454461|NCT03210597|Experimental|hydro-combined|Water aerobics and resistance water exercise
2454573|NCT03209908||control group|In this group, pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml don not use any antiviral drugs during pregnancy.
2454578|NCT03209908||experimental group|pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml start to use Tenofovir Disoproxil Fumarate(TDF) antiviral treatment from the 32 weeks of gestation to block mother-to-child transmission of hepatitis B virus.
2454598|NCT03209479||Glatiramer acetate|For adults, a 20 mg dose of glatiramer acetate will be subcutaneously administered once daily. Participants will receive interventions as part of routine medical care.
2454656|NCT03209310||The children with Cerebral Palsy|Cerebral palsy (CP) can be defined as a group of disorders of movement and posture, causing activity limitation that are attributed to nonprogressive deficits that take place in the immature brain. The motor disorders of CP are often accompanied by deficits in sensation, cognition, communication, perception, behavioral and respiratory system.
2454660|NCT03209310||Control Group|Children with typical development were included in this study
2454739|NCT03208868|Active Comparator|Leucine enriched essential amino acid|Patients with cirrhosis that are given a leucine enriched essential amino acid (EEA/LEU) supplement.
2454740|NCT03208868|Active Comparator|Balanced amino acid supplement|Patients with cirrhosis that are given a balanced amino acid (BAA) supplement.
2454762|NCT03208218|Experimental|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
2454764|NCT03208218|Active Comparator|Revlimid cap.|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
2454871|NCT03208023|Active Comparator|Standard intraoperative care- no interventions|Standard intraoperative hemodynamic monitoring and treatment at Vanderbilt University Medical Center - No study interventions
2454875|NCT03208023|Experimental|RESIPI|Intraoperative implementation of RESIPI management strategy, a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical).
2454928|NCT03207334|Experimental|Midostaurin and Cytarabine|Treatment will consist of 3 phases: induction (a 28-42 day cycle), followed by consolidation (up to 4 cycles). Each cycle in the consolidation phase will last 28 days. Subjects will proceed from one phase to the next if they have achieved or maintained a complete remission or complete remission with incomplete blood count recovery by International Working Group 2003 response criteria. Patients may receive a allogeneic hematopoietic stem cell transplant between the end of the induction phase.
3190643|NCT00789594|Experimental|Both interventions|Both laboratory monitoring and result management interventions
2455115|NCT03206437|Experimental|Mindfulness-Based Stress Reduction|This group will take the 8 week MBSR course within 4 weeks of their first testing visit. When the course is finished they will come in for their second testing visit. The course meets once a week in person for 2.5 hours and participants are expected to do practices at home.
2455117|NCT03206437|Other|Waitlist|The wait-list group will not participate in the MBSR course within 4 weeks of their first testing visit. They will wait 8-16 weeks and come on for a second testing visit. After their data is collected they will be offered an MBSR course to take.
2455271|NCT03204786|Experimental|Vasopressin-Vasopressin|8 weeks of vasopressin nasal spray (16 international units twice daily)
2455272|NCT03204786|Experimental|Placebo-Vasopressin|4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)
2455273|NCT03204786|Placebo Comparator|Placebo-Placebo|8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)
2455339|NCT03204630|Active Comparator|Bifido|Infant formula containing Bifidobacterium breve CECT7263
2455342|NCT03204630|Active Comparator|Lfer|Infant formula containing Lactobacillus fermentum CECT5716
2455346|NCT03204630|Placebo Comparator|Control|Standard infant formula
2455469|NCT03203759|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vital sign and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2455471|NCT03203759|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2455502|NCT03203278|Experimental|Web-based exercise programme|Personalised exercise programme, undertaken three times a week (with no more than two rest days between sessions) for 12 weeks
2455506|NCT03203278|No Intervention|Control group|Usual care
2455549|NCT03203148||CABG Surgical Patients|Patients undergoing coronary bypass grafting with cardiopulmonary bypass
2455580|NCT03202823||Diabetics|
2455585|NCT03202823||Non-diabetics|
3190644|NCT00789594|No Intervention|Usual care|Usual care
3190645|NCT00789607|Active Comparator|MRI-guided FM|
2455788|NCT03201835|Experimental|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
2456180|NCT03199313|Placebo Comparator|Cohort 4 - Placebo|N = 2, 1800 mg sutezolid or matching placebo
3190646|NCT00789607|Active Comparator|TRUS-guided FM|
2454350|NCT03211689|No Intervention|Control Group|Participants will continue normal activities, with no new participation in exercise program (may engage in less than 75 minutes of non-structured exercise per week).
3190647|NCT00789620|Active Comparator|1|Lidocaine 1% administrated as a bolus of 1.5 mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24 h
3190648|NCT00789620|Placebo Comparator|2|NaCl 0.9% as a bolus 1.5mg/kg, then intraoperative 2mg/kg/h and postoperative 1.3mg/kg/h during 24h
3190649|NCT00789633|Experimental|Masitinib & gemcitabine|Participants receive masitinib (9 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
3190650|NCT00789633|Placebo Comparator|Placebo & gemcitabine|Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal.
2454700|NCT03208920|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 4400 mg/day x 6 months (Nordic Naturals, Watsonville, CA, USA)
2454701|NCT03208920|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4400mg/day x 6 months
3190651|NCT00789646|Experimental|NSS/Lidocaine|First injection: Normal saline Second injection: 2% Lidocaine without adrenaline
3190652|NCT00789646|Experimental|Lidocaine/NSS|First injection: 2% Lidocaine without adrenaline Second injection: Normal saline
3190653|NCT00789659|Experimental|VAC dressing|The patients whose postoperative wound will be dressed with a negative pressure (V.A.C.) dressing.
3190654|NCT00789711||A|
3190655|NCT00789711||B|
3190656|NCT00789763|Experimental|Sorafenib + gemcitabine + radiotherapy|
3190657|NCT00789789||1|
3190658|NCT00789841||Patients with NET and diarrhea.|
3190659|NCT00789893||Women with cervical, endometrial, rectal or anal cancer|Women seen in the radiation oncology clinic with cervical, endometrial, rectal or anal cancer who will receive external beam pelvic radiation or brachytherapy
3190660|NCT00789906||1|350 healthy women , aged from 18 to 89
3190661|NCT00789906||2|350 healthy men, aged from 18 to 89
2454895|NCT03207568|Experimental|Relay Pro Device|The Relay Pro thoracic stent-graft will be used to treat pathologies eligible for thoracic endovascular aortic repair (TEVAR).
2454906|NCT03207230|Experimental|Standard|All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.
2454956|NCT03207061|Other|3D ultrasound and MRI|All patients with confirmed endometrial cancer will recieve the gold standard pre-operative imaging (MRI) but will also be offered 3D ultrasound.
2454992|NCT03206801|Experimental|Intervention|Participants with high urine CXCL10 randomized to the Intervention Arm will undergo a kidney transplant biopsy to check for rejection. Biopsy-proven subclinical rejection will be treated per study protocol.
2454994|NCT03206801|No Intervention|Control|Participants with high urine CXCL10 randomized to the Control Arm will continue routine post-transplant surveillance with serum creatinine and proteinuria; serial urine samples will continue to be collected and analyzed (blinded), but not used to direct care.
2455099|NCT03206320|No Intervention|Control|
2455104|NCT03206320|Active Comparator|Reference|
2455107|NCT03206320|Experimental|New|
2455161|NCT03205839|Experimental|Acceptance-based self-help|"Participants in this group will receive the self-help booklet.~Surviving to Thriving: ACT self-help for living well with a visible difference in appearance"
2455164|NCT03205839|No Intervention|Waitlist control group|Participants in this group will be placed onto a waitlist for the four-week intervention period.
2455241|NCT03205384||surgical management|Patient older than 65 years old, undergoing urgent abdominal surgery in our center
2455242|NCT03205384||not surgical management|Patients that presents a surgical disease, but we desestimate surgical procedure
2455299|NCT03204916||Observational (cancer care delivery analysis)|"CHART REVIEW: Patient medical record data is abstracted and treatment plans are reviewed for consistency to NCCN guidelines. For each patient, induction and post-induction care is recorded as either concordant with NCCN guidelines or non-concordant with NCCN guidelines.~SITE QUESTIONNAIRE: Participating sites complete a questionnaire which is designed to capture facility-oriented data.~FOCUS GROUPS: Healthcare providers participate in focus groups over 2-3 hours to discuss facilitators and barriers to AYA ALL guideline concordance. Participants provide responses which will be recorded on a flip-chart or white board, followed by discussion of the ideas for clarification"
2455717|NCT03202121||insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
2455718|NCT03202121||non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
2455719|NCT03202121||normal control|persons without stroke or insomnia served as normal controls that contained 25 cases.
2455776|NCT03201718||Hepatitis C|Participants with Hepatitis C receiving Viekira/Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) for 12 or 24 weeks.
2455847|NCT03201068|Experimental|Probiotic supplement|Renew Life Formulas, Inc
2455850|NCT03201068|Placebo Comparator|Placebo|Placebo capsule
3190662|NCT00789919|No Intervention|1|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital for standard inpatient management of their disease.
3190663|NCT00789919|Experimental|2|Study participants (those diagnosed with mild preeclampsia) are admitted to hospital and their infant is delivered as soon as possible after 34 weeks gestation. As there is no determined optimal time of delivery in these patients, delivery is the intervention.
3190664|NCT00789932|Experimental|CBT|
3190665|NCT00789932|Active Comparator|Usual Care|
3190666|NCT00789945|Placebo Comparator|Study Arm A|Study Arm A will be the primary control arm.
2454388|NCT03211364|Active Comparator|Angular mobilization with soft tissue techniques|Angular mobilization performed in the scapular plane. Additional soft tissue techniques to eliminate limitations created by tensed muscles in order to perform capsular stretch.
2454390|NCT03211364|Placebo Comparator|Scapular mobilization|Scapular mobilization without glenohumeral movement.
2454476|NCT03210896|No Intervention|Main Group|100 subjects (70 T2D and 30 Controls) consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers.
2454477|NCT03210896|Experimental|Sub Group I|20 subjects from the main group (10 T2D and 10 Controls) to remain after providing the above samples. These patients will stay for an additional 3 hours and provide 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers at the following time intervals: 5, 30, 60, 120 & 180 minutes.
2454478|NCT03210896|No Intervention|Sub Group II|5 control subjects consent to provide 1 venous blood sample, 1 capillary blood sample and 3 breath samples using IMSPEX, Bio-VOC and ReCIVA breath samplers. This will be followed by 1 capillary blood sample and 3 breath samples every hour for a total of 5 hours.
2454493|NCT03210233|Experimental|Naive controls|Never received teicoplanin. Blood test, skin testing and challenge testing.
2454501|NCT03210233|Experimental|High Risk|Received teicoplanin and suffered suspected IgE mediated anaphylaxis. Blood test, skin testing and challenge testing.
2454512|NCT03210233|Experimental|Low Risk|Received teicoplanin previously with no adverse reaction Blood test, skin testing and challenge testing.
2454563|NCT03210051|Experimental|RIC & ET|Remote ischemic conditioning paired with endovascular treatment. RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times. Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association. It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
3190667|NCT00789945|Experimental|Study Arm B|Study Arm B will serve as the intervention arm.
3190668|NCT00790049|Experimental|ARRY-371797|
2454646|NCT03208985|Experimental|Use Phase (Ulipristal Acetate, 30 mg)|One tablet of 30 mg of ulipristal acetate for emergency contraception
2454717|NCT03208543|Experimental|HECT-CL|HECT-CL heat pack will be applied on CL lesions (50-52 degrees Celsius for 3 minutes on 7 consecutive days)
2454763|NCT03208413|Experimental|thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
2454841|NCT03207997|Experimental|Mild pulmonary fibrosis|mild pulmonary fibrosis (VFC> 75% theoretical and DLCO / VA> 55%) 2 additional unenhanced MR sequences
2454847|NCT03207997|Experimental|Moderate pulmonary fibrosis|moderate pulmonary fibrosis (VFC 50-75% and DLCO 36-55%) 2 additional unenhanced MR sequences
2454851|NCT03207997|Experimental|Severe pulmonary fibrosis|severe pulmonary fibrosis (VFC <50% theoretical or DLCO / VA <35%). 2 additional unenhanced MR sequences
2454856|NCT03207997|Active Comparator|Control group|2 additional unenhanced MR sequences
2454912|NCT03207425|Experimental|Mild hepatic impairment group|
2454917|NCT03207425|Experimental|Moderate hepatic impairment group|
2454923|NCT03207425|Experimental|Matching healthy control group|Healthy control group will be matched with the hepatically impaired population with respect to age, sex and BMI
2454965|NCT03207009|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with LentiGlobin BB305 lentiviral vector encoding human βA-T87Q-globin)
2455006|NCT03206671|Experimental|R1/R2 stage I+II|Rituximab window + standard chemotherapy without anthracyclines (Vincristine not in R1)
2455009|NCT03206671|Experimental|R2 stage III experimental arm|Rituximab window + Standard chemotherapy
2455011|NCT03206671|Other|R2 stage III standard arm|Standard chemotherapy
2455012|NCT03206671|Experimental|R3/R4 rituximab plus arm|Rituximab window + standard chemotherapy plus six additional doses of rituximab
2455014|NCT03206671|Experimental|R3/R4 standard arm|Rituximab window + standard chemotherapy
2455172|NCT03205618||daclatasvir patients in KSA, UAE, and Qatar|patients treated with daclatasvir-containing regimens in KSA, UAE, and Qatar
2455230|NCT03205319|Experimental|Intervention arm / e-learning|Patients will receive e-learning instead of upper GI endoscopy.
2455234|NCT03205319|No Intervention|Control arm / upper GI endoscopy|Patients will receive the upper GI endoscopy, i.e. standard of care
2455287|NCT03204903|Experimental|Laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using laser acupuncture during 3 sessions per week for 12 weeks.
2455298|NCT03204903|Sham Comparator|Sham laser acupuncture|The subjects are treated at acupoints including BL2, TE23, ST2, LI4, ST36, and GB37 using sham laser acupuncture (without laser output) during 3 sessions per week for 12 weeks.
2455356|NCT03204487|Experimental|Patients with glaucoma or ocular hypertension|
3190669|NCT00790049|Placebo Comparator|Placebo|
2455504|NCT03203642|Experimental|Treatment Group|50mg tesevatinib administered once daily for up to 24 months.
2455509|NCT03203642|Placebo Comparator|Control Group|Matching placebo administered once daily for up to 24 months.
2455552|NCT03202901|Experimental|B-turmactive|1 pill of B-turmactive: 500 mg hydrosoluble fraction (free curcuminoid fraction) + 19.5 mg of lipid soluble fracion (curcuminoids enriched) + 22.5 mg vitamin C.
2455554|NCT03202901|Placebo Comparator|Placebo|"Yeast brew extract (200 mg)~Excipients:~120 mg cellulose (food additive E-460) 40 mg Compritol® E ATO (food additive E-471) 4 mg Magnesium stearate (food additive E-572)"
2455612|NCT03202758|Other|Durvalumab + Tremelimumab + FOLFOX|"Durvalumab for 12 months~Tremelimumab for up to 4 doses/cycles~FOLFOX"
2455660|NCT03202329|Other|standard care|responsible surgeon has actively to ask for cardiology support (he decides whether a heart failure specialist should see the patient post-operatively)
3190670|NCT00790101|Experimental|1|Risedronate 35mg once a week
3190671|NCT00790101|Active Comparator|2|Raloxifene 60mg daily
3190672|NCT00790101|Placebo Comparator|3|
2454443|NCT03210844||Microposterior approach|The incision size was 6 - 10 cm depending on the body build of the patient. The differences of our micro-PA from Dorr's techniques were: First, no excision of the anterosuperior capsule and medial inferior capsule because the senior author believe that preservation of these structures could help to maintain the postoperative stability of the THA. Second, after the gluteus minimus muscle was elevated from the superior capsule, a superior capsulomy starting from 12 o'clock direction of acetabulum in decubitus position was made. The hip capsule was then incised in 12-to- 6-o'clock downward direction and curved down around femoral neck under the other short external rotators. We preserved short external rotators except piriformis tendon. Third, the capsular incision was continued inferiorly following 12-to- 6-o'clock downward direction of acetabulum to the transverse acetabular ligament. The tube structure of original hip capsule was divided into anterior and posterior half leaflets.
2454494|NCT03210363|Experimental|Guiana population|"Human Biological samples from Guiana population :~Two serum tubes of blood will be collected"
2454577|NCT03210077||Entropy Group|General Anesthesia using Entropy Monitoring
2454583|NCT03210077||Control Group|General Anesthesia without Entropy (Control Group)
2454589|NCT03209531|Experimental|Operant Conditioning|Participants will receive operant conditioning training and single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks.
2454595|NCT03209531|Experimental|Control|Participants will receive single pulse transcranial magnetic stimulation 2-3 times a week for about 8 weeks without operant conditioning training.
2454647|NCT03209167||DIEAP group|Patients who had undergone DIEAP flap breast reconstruction
2454650|NCT03209167||AP group|Patients who had undergone conventional abdominoplasty
2454735|NCT03208881||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2454805|NCT03208335|Experimental|rh-endostatin combination|Continuous intravenous pumping (CIP) recombinant human endostatin(rh-endostatin) 30mg/d, from 5 days before radiotherapy,for 7days,21 per cycle.Standard radiotherapy for HCC is conducted concurrently.Those patients will receive 3-5 cycles rh-endostatin after the radiotherapy is finished,4-6 cycles in all.
3190673|NCT00790114|Experimental|1|
3190674|NCT00790127|Placebo Comparator|Placebo|Placebo
2454930|NCT03207165|Active Comparator|Left ventricular [LV] +/- Biventricular dysfunction|Assessment of left ventricular [LV] or biventricular dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients identified as having biventricular dysfunction will be randomized within the LV dysfunction arm of the trial. Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
2454932|NCT03207165|Active Comparator|Right ventricular [RV] dysfunction|Assessment of right ventricular [RV] dysfunction will be based on clinical assessment, available imaging (echocardiogram, left ventriculogram, MUGA/RNA scan, cardiac MRI, etc.) and known past medical history (if available and contributory). Patients in this arm will be randomized in a 1:1 fashion to Milrinone or Dobutamine.
2454986|NCT03206892|Experimental|LESS surgery|Laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using laparoendoscopic single-site surgery (single incision through the umbilicus using modified Hasson technique).
2454987|NCT03206892|Active Comparator|conventional multi-port laparoscopy|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women using conventional multi-port laparoscopy (three port system using a closed technique on the umbilicus, left and right lower quadrant areas).
2455039|NCT03206567|Active Comparator|Nutrafol Supplement capsules|Subjects to take four (4) Nutrafol Supplement capsules by mouth daily for 180 days with a substantial meal
2455043|NCT03206567|Placebo Comparator|Placebo Capsules|Subjects to take four (4) Placebo capsules by mouth daily for 180 days with a substantial meal.
3190675|NCT00790127|Experimental|HQK-1001|HQK-1001
3190676|NCT00790140|Active Comparator|Immunonutrition Prosure|This group of patients are to be given a tube feed enriched with 2.2 g Eicosapentaenoic Acid (EPA) per day for 5 days pre surgery and 21 days post surgery
2455193|NCT03205501|Experimental|IV-tracer EMI-137|"IV-administration of EMI-137: all patients will receive 0.13 mg/kg of the fluorescent tracer EMI-137 intravenously.~Molecular Fluorescence Endoscopy: approximately 2,5 hours after tracer administration, Molecular Fluorescence Endoscopy will be performed with additional measurements of fluorescence signals."
2455277|NCT03205059|Experimental|LST MS curriculum+ Bullying/Cyberbullying serious game|
2455280|NCT03205059|Active Comparator|LST MS curriculum|
2455334|NCT03204604|Experimental|Challenge A|Challenge A includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with low calorie Ensure® shake containing no ketone esters. Dietary Supplement: Challenge A - low calorie Ensure®
2455335|NCT03204604|Experimental|Challenge B|Challenge B includes Cognitive testing - (FCSRT, Story Recall, BVRT, CogState One Card Learning), and PET scan with an Ensure® shake containing ketone esters. Dietary Supplement: Challenge B - Ensure® plus ketone esters (KE)
2455388|NCT03204175|Experimental|Fit Plus|The experimental arm will receive the Fit For School expanded intervention, which addresses pupil handwashing, toothbrushing, and school sanitation maintenance. Interventions will begin in July 2017.
2455389|NCT03204175|Active Comparator|Comparator|This group will receive the Fit Plus intervention after the trial is complete (January 2017)
2455444|NCT03203837||HCC patients|HCC patients treated with radioembolization. Plasma collection will be performed at 7 timepoints in relation to treatment.
2455472|NCT03203694|Experimental|Lower body heating|This intervention consists of 60 minutes of lower body heating (40-42 degree C) 7 days per week for 7 days.
2455525|NCT03203317|Experimental|Insulin-stimulation|2 h insulin-clamp
2455528|NCT03203317|Experimental|Exercise|10 min of maximal exercise
3190677|NCT00790140|Placebo Comparator|Standard enteral nutrition Ensure Plus|This group are to be given a standard enteral tube feed without EPA for 5 days pre op and 21 days post surgery
3190678|NCT00790153|Active Comparator|1|AZD1656
3190679|NCT00790153|Active Comparator|2|Insulin
3190680|NCT00790166|Active Comparator|CPAP + ThermoSmart™ humidity|
3190681|NCT00790166|Active Comparator|CPAP + Conventional humidity|
3190682|NCT00790166|Active Comparator|CPAP + No added humidity|
3190683|NCT00790179|Active Comparator|PCA;active comparator|Patients with intravenous PCA hydromorphone alone
2454475|NCT03210545|Active Comparator|betamethasone - supra physiological dose|Replacing participants hydrocortisone with a daily dose of betamethasone in an estimated supra physiological dose during one treatment period.
3190684|NCT00790179|Active Comparator|CFB|Patients with a continuous femoral block (CFB) + PCA hydromorphone
3190685|NCT00790179|Active Comparator|CLPB|Patients with a continuous lumbar plexus block + PCA hydromorphone
2454579|NCT03209843|Other|Successfully CTO recanalization|
2454593|NCT03209440|Active Comparator|usual outpatient palliative care|During the usual care steps, patients will receive usual outpatient palliative care
2454596|NCT03209440|Experimental|Dignity Therapy - Nurse Led|During the experimental steps as part of routine palliative care service delivery, patients receive nurse-led DT.
2454600|NCT03209440|Experimental|Dignity Therapy - Chaplain Led|During the experimental steps as part of routine palliative care service delivery, patients will receive chaplain-led DT.
2454643|NCT03209258|Other|Goal-directed care bundle|Management policy to receive a goal-directed care bundle that involves the rapid correction (<1 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 7 days or hospital discharge (or death, if sooner)
2454645|NCT03209258|Other|Usual care group|Patients receive the usual management based on local guidelines and hospital's individual policy.
2454719|NCT03208894|Experimental|with salbutamol|
2454725|NCT03208894|Experimental|with furosemide|
2454728|NCT03208894|Experimental|both furosemide and salbutamol|
2454730|NCT03208894|No Intervention|no inervention|
2454775|NCT03208270|Experimental|Antithrombin supplementation|Patients randomized to the study group will receive supplementation of antithrombin concentrate to maintain a functional antithrombin level between 80%-120%.
2454779|NCT03208270|Active Comparator|No Antithrombin supplementation|"Patients randomized to the control group will never receive supplementation of antithrombin unless heparin resistance occurs."
2454829|NCT03207880|Experimental|MLPT|Multi-level pregnancy test
2454885|NCT03207607|Experimental|Control snack|Participants received control snacks prepared by real fruits (pear, orange and mango)
2454887|NCT03207607|Experimental|Maltodextrin snack|Participants received maltodextrin snacks (maltodextrin + control snack)
2454889|NCT03207607|Experimental|Whey protein snack|Participants received whey protein snacks (whey protein + control snack)
2454891|NCT03207607|Experimental|Oat snack|Participants received oat snacks (oat + maltodextrin + control snack)
2454893|NCT03207607|Experimental|Coconut oil snack|Participants received coconut oil snacks (coconut oil + control snack)
2454894|NCT03207607|Experimental|Snack skipping|Participants received snack skipping
2454899|NCT03207178|Experimental|Mixed CD19/CD20 CAR-T Transfer|Subjects with CD19+/CD20+ B-cell lymphomas will be infused with CD19-targeting CAR T Cells and CD20-targeting CAR T Cells in one time or in parts
2454955|NCT03207139|Experimental|Ga-68 PSMA ligand|Diagnostic performance of [Ga68] PSMA-11
2454988|NCT03206814|Active Comparator|Group 1 - Usual care|Standard strategy for management of hypertension, based on three-monthly visits at the referral centre.
2454989|NCT03206814|Experimental|Group 2 - POST-strategy|Patient Optimal Strategy for Treatment (POST) for management of hypertension, based on on three-monthly visits at the referral centre + providing the patients with the ESH-CARE APP system to communicate home blood pressure measurements to the referral centre, and the referral centre with an online platform to monitor the patients' status.
2455052|NCT03206528||VSMS with ear unit|application of Vital Signs Monitoring System with ear unit for 6-10 days during hospitalization (throughout their admission period)
2455053|NCT03206528||VSMS without ear unit|application of Vital Signs Monitoring System without ear unit for 6-10 days during hospitalization (throughout their admission period)
2455076|NCT03206177|Experimental|Paclitaxel/Carboplatin + Galunisertib|
2455133|NCT03205878|Active Comparator|Control group|Patients will receive standard care, being CPAP treatment
2455134|NCT03205878|Experimental|Intervention group|Patients will receive CPAP and telecoaching
2455182|NCT03205540|Experimental|Epidural analgesia|Lumbar continuous epidural block
2455184|NCT03205540|Experimental|Bilateral ACB|Ultrasound-guided bilateral adductor canal blocks
3190686|NCT00790231||men|observation of the urinary function with and without thoracic epidural anesthesia
3190687|NCT00790231||women|observation of the urinary function with and without thoracic epidural anesthesia
3190688|NCT00790244|Experimental|Arm 2|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
2455384|NCT03204253|Experimental|rFSH + r-LH in combination|treatment group
2455385|NCT03204253|Active Comparator|rFSH alone|control group
2455451|NCT03203928|Experimental|Occupational Therapy for Women with ADHD|7-week tailored intervention for women with ADHD who have difficulty carrying out student, worker, spousal, and parenting roles due to poor time management, organization of their physical environments, management of internal and external stressors, and regulation of internal and external stimulation. Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments.
2455452|NCT03203928|No Intervention|Control|No treatment provided.
2455514|NCT03203408|Experimental|OSTENIL PLUS|A single intra-articular injection of sodium hyaluronate 40 mg/2.0 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
2455516|NCT03203408|Active Comparator|SYNVISC-ONE|A single intra-articular injection of hylan G-F 20 48 mg/6 ml at Day 2, i.e. 2 days post Baseline (Day 0 = Week 0)
2455562|NCT03203070|Active Comparator|Metamizol iv|The patients will receive only intravenous analgesia with Metamizole 2g/8 hours for control of postoperative pain.
3190689|NCT00790244|Experimental|Arm 3|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 45Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and 4.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
3190690|NCT00790244|Experimental|Group B|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
2454523|NCT03210454|No Intervention|Comparison Group 3|Women involved with farmers's associations that work independently of World Food Programmes (WFP's) assistance.
3154228|NCT00294203|Placebo Comparator|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
3154229|NCT00294255|Experimental|Risperidone|patients will receive risperidone for up to 20 weeks
3208583|NCT00976131|Placebo Comparator|Arm A|Cycle 3 of doxorubicin with Coenzyme Q10, Cycle 4 with Coenzyme Q10 Placebo
2454760|NCT03208491|Experimental|serious games|
2454761|NCT03208491|Active Comparator|usual care|
2454827|NCT03207698|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2454830|NCT03207698|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2454831|NCT03207698|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Metformin for treating furcation defect
3154230|NCT00294268|Other|1|20 weekly sessions of CBT integrated with motivational enhancement strategies
2454905|NCT03207217|Experimental|Phase I Knowledge Assessment|
2454907|NCT03207217|Experimental|Phase II Efficacy|
2454909|NCT03207217|Experimental|Phase II Acceptability|
2454972|NCT03207100|Experimental|Analgesia-first minimal sedation group|Using analgesia-first minimal sedation strategy to implement antihypertensive therapy.
2454973|NCT03207100|Active Comparator|Antihypertensive drug treatment group|Using routine antihypertensive drugs to implement antihypertensive therapy.
2455034|NCT03206606||Control Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University.
2455037|NCT03206606||Experimental Group|Primary care physicians and residents in family medicine of family medicine units affiliated with Laval University that will use the mobile application SPIRO(c) for a period of four months.
2455085|NCT03206203|Experimental|Arm 1 (atezolizumab, carboplatin)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2455093|NCT03206203|Experimental|Arm 2 (atezolizumab, carboplatin)|Patients receive carboplatin as in Arm 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may cross-over to Arm 1 upon disease progression.
2455163|NCT03205735||normal DPD result group|patients group with a normal DPD result
2455167|NCT03205735||elevated DPD result group|patients group with an elevated DPD result
2455208|NCT03205332|Experimental|Concreteness Training|Participants receive 1 session of training in concrete processing during the pre-intervention visit. They are then asked to engage in 30 minutes of concreteness practice daily, for 7 days.
2455214|NCT03205332|No Intervention|Control|Assessment only.
2455281|NCT03205033|Active Comparator|Melatonin|Melatonin 20 mg Oral Capsules, once a day at bedtime
2455282|NCT03205033|Placebo Comparator|Placebo|Placebo Oral Capsules, once a day at bedtime
2455357|NCT03204591||LC with SALI|cirrhosis patients with severe acute liver injury
2455390|NCT03204097|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2455391|NCT03204097|Active Comparator|group 2|SRP followed by 1% Alendronate (ALN) gel
2455392|NCT03204097|Active Comparator|group 3|SRP followed by Aloevera (AV) gel
2455432|NCT03203863||Puente Alto, Chile, 2009-2011.|anthropometric measures of fatness
2455465|NCT03203707|Experimental|Interpersonal and Social Rhythm Therapy+DIR|IPSRT plus referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
2455466|NCT03203707|No Intervention|Data-Informed Referral (DIR)|Referral for community treatment for any psychiatric conditions identified through the psychiatric assessment at intake.
2455535|NCT03203343|Active Comparator|PIRS group|Patients operated laparoscopically - PIRS technique
2455540|NCT03203343|Active Comparator|Marcy group|Patients operated by open modified Marcy technique
2455563|NCT03202875|Experimental|Test (T)|SAR341402: single dose injection
2455566|NCT03202875|Active Comparator|Reference 1 (R1)|NovoRapid®: single dose injection
2455575|NCT03202875|Active Comparator|Reference 2 (R2)|NovoLog®: single dose injection
2455652|NCT03202446|Experimental|Arm 1: LIT and Placebo|Patients receive laser-assisted immunotherapy along with Placebo cyclophosphamide tablets. Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
2455655|NCT03202446|Experimental|Arm 2: LIT and low-dose Cyclophosphamide|Patients will receive laser-assisted immunotherapy and low-dose cyclophosphamide (300 mg, administered orally once per week between treatment weeks 0-11 in each treatment cycle). Patients' laser-assisted immunotherapy treatment will be based on the number and size of laser-accessible solid tumors available at the time of treatment. In and around each photothermal laser-treated site will be injected 1 mL of 1% Glycated Chitosan (GC) Injection, with a total of up to 4 sites being treated per patient. The maximum dose of GC Injection that a patient can receive in 1 visit is 4 mL.
2455662|NCT03202446|Active Comparator|Arm 3: Control Arm|Patients will receive the standard of care.
2455791|NCT03201835|Experimental|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
2455793|NCT03201835|Experimental|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
2455795|NCT03201835|Experimental|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
2454524|NCT03210324|Experimental|Mifepristone C group|Mifepristone tablets for 24 weeks with four follow-up
2454575|NCT03209804|Other|Traditional neurosurgical techniques|Unsimultaneous endovascular interventional embolisation/radiotherapy followed by microsurgical resection, as traditional clinical routines.
2454581|NCT03209804|Experimental|Hybrid operating techniques|A one-stage hybrid operation combining endovascular intervention and microsurgical techniques will be conducted simultaneously
2454622|NCT03209414||Stable coronary artery disease|Patients with stable effort angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2454624|NCT03209414||Unstable coronary artery disease|Patients with unstable angina wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2454626|NCT03209414||Non-ST elevation myocardial infarction|Patients with non-ST elevation myocardial infarction wil be enrolled. Based on coronary angiography, heart team will decide on medical, percutaneous angioplasty, or bypass grafting.
2454628|NCT03209414||ST-elevation myocardial infarction|Patients with ST elevation myocardial infarction wil be enrolled. In majority of patients primary percutaneous coronary intervention will be performed. Based on coronary angiography, heart team will decide on further medical treatment, percutaneous angioplasty, or bypass grafting.
2454684|NCT03209141||Diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation
2454687|NCT03209141||Non diastolic dysfunctional hypertension|Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation
2454729|NCT03208660||Fycompa|Participants diagnosed with epilepsy and treated with Fycompa
2454767|NCT03208075|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
2454770|NCT03208075|Experimental|Low-phosphorus Diet|Diet containing 500mg of phosphorus per day
2454772|NCT03208075|Experimental|High-phosphorus Die|Diet containing 2300mg of phosphorus per day
2454859|NCT03207945|Experimental|Alirocumab|Patients randomized into the alirocumab arm will start off with 75 mg alirocumab administered every two weeks for two doses and will be upwardly titrated to 150 mg alirocumab if subjects demonstrate LDL ≥ 50 mg/dL at week 4. Subjects demonstrating LDL-C <50mg/dl will remain on the same 75mg dose throughout the trial.
2454862|NCT03207945|Placebo Comparator|Placebo|Patients randomized into the placebo arm will receive 75 mg or 150 mg or placebo administered once every two weeks throughout the trial
2455019|NCT03206658|Placebo Comparator|placebo oral capsules|Placebo capsules equal to those in the study drug, will be administered every 24 hours for the first 5 days after entry into the critical care unit
2455023|NCT03206658|Experimental|spironolactone|capsules of spironolactone 25 mg equal to placebo, will be given every 24 hours for the first 5 days after entry to the critical care unit
2455088|NCT03206307||Group 1|Group 1 will be questioned 36 months (in 2017) after their medical rehabilitation which was in 2013/2014.
2455094|NCT03206307||Group 2|Group 2 has the medical rehabilitation in 2017 and will be questioned at the end of the medical rehabilitation and 6, 12 and 18 months after that
3154231|NCT00294281|Experimental|1|Participants will undergo surgical implantation of the VNS system. This will be followed by a 2-week recovery period, then a 2-week period of gradually increasing the electrical output of the VNS system, and finally a 12-week VNS treatment period during which the electrical output level will remain constant. Follow-up will occur until Month 24.
2455238|NCT03205423|Placebo Comparator|Gabapentin 0 mg|once daily at 8am
2455240|NCT03205423|Active Comparator|Gabapentin 1800 mg|once daily at 8am
2455274|NCT03204890|Experimental|TPTNS|Transcutaneous Posterior Tibial Nerve Stimulation
3154232|NCT00294307||Advanced Practice Nurse Care (APNC)|Hospital to Home
3154233|NCT00294307||Augmented Standard Care (ASC)|Hospital only
2455412|NCT03204162|No Intervention|Teams with no CPR Coach|This will be a standardized Resuscitation team with no CPR Coach
2455416|NCT03204162|Experimental|Teams with CPR Coach|This will be a standardized Resuscitation team where one member will be the CPR Coach and provide CPR Coaching to the team.
2455473|NCT03203603||Offspring of smokers who got vitamin C|Offspring of pregnant smokers randomized to vitamin C during the initial randomized portion of the VCSIP study
2455475|NCT03203603||Offspring of smokers who got placebo|Offspring of pregnant smokers randomized to placebo during the initial randomized portion of the VCSIP study
2455477|NCT03203603||Offspring of pregnant non-smokers|Offspring of pregnant non-smokers who were followed in a similar fashion during pregnancy as the randomized pregnant smokers
2455515|NCT03203265|Other|A:Offline HIV testing and counseling|Participants in Group A will be invited to come to the Thai Red Cross Anonymous Clinic, RSAT or SWING drop-in centers in Bangkok, or SWING or Sisters drop-in centers in Pattaya. After registration, they will receive standard HIV Testing and Counseling (HTC) services.
2455517|NCT03203265|Other|B1:Offline|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only.
2455519|NCT03203265|Other|B2: Online|participants will be mailed a rapid HIV test kit. A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit, obtaining blood through finger prick, performing the testing steps, and reading the test result.
2455557|NCT03203031||Neonates with abdominal surgery and quadratus lumborum block|0-6 months children with abdominal surgery. After standard induction of general anesthesia, patients will receive 0.5 ml/kg of ropivacaine (2 mg/ml) in a quadratus lumborum block. Ultrasonography will be used to guide the injection. In the postoperative period, pain scores and analgesics consumption will be recorded until the 48th hour post surgery.
2455647|NCT03202680|Active Comparator|USDA Style Diet|Healthy, low saturated fat, United States Department of Agriculture (USDA) style diet.
2455649|NCT03202680|Experimental|Lean Beef Diet|Healthy, low saturated fat, high in lean beef diet.
2455735|NCT03202147|Active Comparator|ALZT-OP1a|ALZT-OP1a: cromolyn (17.1 mg, capsule) for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
3154234|NCT00294307||Resource Nurse Care (RNC)|Hospital only
3154235|NCT00294320|Experimental|1|250mg of Imiquimod cream application once daily 3 times per week.
2454551|NCT03209999||Fomally Employed|Mother engaged in formal employment. No intervention was assigned as this is a cross sectional study.
2454553|NCT03209999||Informally Employed|Mother engaged in informal employment. No intervention was assigned as this is a cross sectional study.
2454557|NCT03209999||Non-employed|Mother neither formally or informally employed. No intervention was assigned as this is a cross sectional study.
2454601|NCT03209661|Active Comparator|E-Cigarette 5.4% NBV|Subjects will be asked to inhale an E-Cigarette with 5.4% NBV for 6 min.
2454607|NCT03209661|Placebo Comparator|E-Cigarette 0% NBV|Subjects will be asked to inhale an E-Cigarette with 0% NBV for 6 min.
2454611|NCT03209661|Placebo Comparator|Menthol Inhaler|Subjects will be asked to inhale a sham methole inhaler (that looks identical in looks to E-cigarette) for 6 minutes. This arm is to control for a potential effect of menthole.
2454672|NCT03209102|Experimental|BPD adolescents|Adolescents suffering from Borderline Personality Disorder. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
2454677|NCT03209102|Experimental|Healthy controls adolescents|Healthy controls adolescents. Clinical assessment, Stress Elicitation Experiment, Structural and Functional MRI, salivary collections of amylase and cortisol
2454716|NCT03208608||Normal hearing older adults|Older adults with normal hearing or age-related hearing loss
2454799|NCT03208426|Experimental|Sequential therapy for 14 days|Sequential therapy for 14 days (experimental) D1-D7: (Nexium, esomeprazole 40mg bid + amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid) for 7 days D8-D14: (Nexium, esomeprazole 40mg bid + Klaricid XL, clarithromycin 500mg bid + Flagyl, metronidazole 500mg bid) for another 7 days
2454801|NCT03208426|Active Comparator|bismuth quadruple therapy for 10 days|Bismuth quadruple therapy for 10 days (active comparator) D1-D10: (Nexium, esomeprazole 40mg bid + KCB F.C. TABLETS, dibismuth trioxide 120mg qid + Flagyl, metronidazole 500mg tid + tetracycline (Brand name: Tetracycline Capsule ) 500mg qid) for 10 days
3154236|NCT00294320|Placebo Comparator|2|250mg vehicle cream for application once daily 3 times per week.
3154237|NCT00294385|Active Comparator|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
2454903|NCT03207464|Experimental|Multiple Sclerosis|Subjects meeting the definition for Multiple Sclerosis by the International Panel Criteria, with an Expanded Disability Status Scale (EDSS) less than 6.5.
2454904|NCT03207464|Experimental|Healthy Control|This group will serve as non disease population.
2454969|NCT03207087|Experimental|WEB Aneurysm Embolization Device|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms. The intended therapeutic effect of the WEB device is to line the neck of the aneurysm with a metallic structure that disrupts the inflow of blood, causing hemostasis within the aneurysm sac, and leading to thrombus formation within the implant. Subjects will be screened for study eligibility after giving informed consent.
2455013|NCT03206684|Experimental|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，with patients' weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
2455015|NCT03206684|Active Comparator|rhG-CSF|rhG-CSF was daily administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
2455103|NCT03206333||Breast cancer patients treated with radiotherapy|
2455218|NCT03205397|Experimental|Accompanying and information procedure|Preparation for anesthesia (explanations, film, booklet), the presence of a relative in the operating room and the awakening of the child.
2455227|NCT03205397|Other|Usual care|Consultation of anesthesia and the care of the child without parental presence
2455437|NCT03203876|Experimental|Part One Combination Therapy|Lirilumab and Nivolumab
2455439|NCT03203876|Experimental|Part 2 Combination Therapy|Lirilumab, Nivolumab and Ipilimumab
2455485|NCT03203460|Experimental|Exercise Group|Supervised high-intensity aerobic interval training (HIIT) during active surveillance
2455487|NCT03203460|No Intervention|Usual Care Group|The usual care group will be provided with standard active surveillance medical care.
2455534|NCT03203226|Experimental|EXPERIMENTAL GROUP|This protocol has an unique period or phase of 30 week. Experimental group will be composed by 30 volunteer who were previously randomly assigned to this group. This group will receive a intervention based on 30 1-hour session of Feldenkrais Method (1 hour per week).
2455538|NCT03203226|No Intervention|CONTROL GROUP|This protocol has an unique period or phase of 30 week. Control group will be composed by 30 volunteer who were previously randomly assigned to this group. They will not receive any intervention.
2455586|NCT03202940|Experimental|Cobimetinib + Alectinib|Alectinib administered twice daily at pre-determined dosage orally Cobimetinib administered daily at pre-determined dosage orally
2455625|NCT03202459|Active Comparator|Active Comparator: Group A - gabapentin|The patient will receive oral 600 mg gabapentin 2 h before surgery
2455634|NCT03202459|Active Comparator|Active Comparator: Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
2455635|NCT03202459|Placebo Comparator|Placebo Comparator: Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
2455696|NCT03202199|Experimental|PET/MRI|PET/MRI examination
3154238|NCT00294385|Active Comparator|Docetaxel|Arm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
3154239|NCT00294437|Experimental|zoledronic acid|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
3154240|NCT00294437|No Intervention|no intervention|no reference therapy
3154241|NCT00294567|Active Comparator|1|Amlodipine
3154242|NCT00294567|Active Comparator|2|Azelnidipine
3154243|NCT00294619|Experimental|LB03002|
3154244|NCT00294619|Placebo Comparator|Placebo|
3154245|NCT00294736|Experimental|Arm A|Arm A (Tarceva MTD established in Part I)
2454560|NCT03210038|Active Comparator|Rigid cystoscopy, water based gel on introitus|Rigid cystoscopy, Wolf 17FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
2454564|NCT03210038|Active Comparator|Rigid cystoscopy, esracain gel based on introitus|Rigid Cystoscopy, Wolf 17FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
2454565|NCT03210038|Active Comparator|Flexible cystoscopy, water based gel on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with water based gel put on introitus for 5 minutes prior to procedure.
2454567|NCT03210038|Active Comparator|Flexible cystoscopy, Esracain gel based on introitus|Flexible cystoscopy, Olympus 16FR. Pad soaked with Esracain (Lidocaine) put on the introitus for 5 minutes prior to procedure.
3190691|NCT00790244|Experimental|Arm 1|<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle (>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)
2454640|NCT03209037|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454641|NCT03209037|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2454694|NCT03208946|Experimental|High-CML diet|An isocaloric, high-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
2454696|NCT03208946|Sham Comparator|Low-CML diet|An isocaloric, low-CML content diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat.
2454742|NCT03208647||AA Group|All the patients of AA group met a AA diagnostic criteria；
2454743|NCT03208647||Control Group|The control group were chosen from other departments who were under acute infection (such as pneumonia), acute abdominal emergency (such as appendicitis), cataract surgery;
2454858|NCT03207737|Experimental|MENTOR + Telehealth|This group will complete baseline testing, the MENTOR (Mindfulness, Exercise, and Nutrition To Optimize Resilience) program, and 5-days post baseline testing before beginning a one-year telehealth program.
2454860|NCT03207737|Active Comparator|Telehealth Only|This group will complete baseline and 5-days post baseline testing before beginning a one-year telehealth program.
2454946|NCT03207477|Experimental|Prematurely born infants|Visual acuity measurement in prematurely born infants included in PREMAVISION study
2454948|NCT03207477|Active Comparator|Term born infants|Visual acuity measurement in term born control infants
2455035|NCT03206853|Experimental|Hybrid operation group|Intervene with hybrid operating techniques, eg. microsurgical clipping+endovascular coiling or with the assistant of balloon occlusion.
2455038|NCT03206853|Other|Traditional therapy group|The aneurysms will be executed by traditional procedure, including microsurgical clipping, endovascular coiling or stenting, etc.
2455077|NCT03206190|Experimental|Mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
2455079|NCT03206190|Experimental|Non-mutation carrier|The participants will be tested genetically if they carry a disease causing mutation or not. Depending on their genetic test result they will at the end of the study divided into two groups. The clinician will be blinded throughout the entire study to the genetic results.
2455082|NCT03206190|Experimental|Known-mutation carriers but presymptomatic|In a third arm (open arm) we will also include positive predictive tested participants which know that they are carrying a known mutation but are at inclusion into the study asymptomatic (according to the inclusion / exclusion criteria).
2455150|NCT03205670|Experimental|Urethroplasty with a tissue-engineered construct|The investigators will take a sample of the buccal mucosa to isolate epithelial cells. Autologous cells will be seeded on a hybrid matrix. Urethroplasty with this tissue-engineered construct will be performed. This is a single arm study with no control. All patients will undergo the surgical operation.
2455205|NCT03205475|Active Comparator|A. Above Fidelity Phase 1 and Above Fidelity Phase 2|Alternating coaching and streamed or video feedback each week through phase 1, moves to video feedback only for phase 2.
2455216|NCT03205475|Active Comparator|B. Below Fidelity Phase 1 and Above Fidelity Phase 2|Receive weekly coaching in phase 1, move to video feedback only in phase 2
2455222|NCT03205475|Active Comparator|C. Above Fidelity Phase 1, Below in Phase 2- Add Refresher|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
2455226|NCT03205475|Active Comparator|D. Above Fidelity Phase 1, Below in Phase 2- Add Peer|Alternating coaching and streamed or video feedback each week through phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
2455228|NCT03205475|Active Comparator|E. Below Fidelity Phase 1, Below in Phase 2- Add Refresher|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive a one week intensive in person refresher and then continue with weekly coaching and video feedback from the Senior Trainer (Enhanced Feedback plus intensive refresher course) for the final 12 weeks.
2455232|NCT03205475|Active Comparator|F. Below Fidelity Phase 1, Below in Phase 2- Add Peer|Receive weekly coaching in phase 1. In phase 2, the interventionist is still working toward 90% fidelity and is randomly assigned (50/50) to one of two different types of support from the Senior Trainer. The interventionist will receive weekly coaching and video feedback from the Senior Trainer plus a weekly session paired with a local interventionist at fidelity (Enhanced Feedback plus peer support).
2455349|NCT03204331|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
2454597|NCT03209583||Congenital Heart Disease|subjects have CHD and arrhythmias being treated with an implanted pacing device.
2454654|NCT03209076|Experimental|Robotic|Robotic low anterior resection
2454657|NCT03209076|Active Comparator|Laparoscopic|Laparoscopic low anterior resection
2454776|NCT03208387||Children Medulloblastoma Survivors|Participants previously treated for M0 non-disseminated medulloblastoma with cranio-spinal irradiation plus a boost to the posterior fossa
2454781|NCT03208387||Children Astrocytoma Survivors|Participants previously treated for a low grade cerebellar astrocytoma, with surgery only and neither chemotherapy nor cranial irradiation.
2454784|NCT03208387||Age-Matched Healthy Children Controls|
2454824|NCT03207646|Experimental|smartphone-based cardiac rehabilitation|The BrightHeart® mobile application is installed on the smartphone and a heart coach set up and guides the participant through a cardiac care program.
2454825|NCT03207646|No Intervention|Control|Standard-of-care alone.
2454861|NCT03207620||smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
2454863|NCT03207620||non-smoker asthmatics|"Asthma control questionnaire (ACQ) score~Spirometry~Sputum cytology"
3154246|NCT00294736|Experimental|Arm B|Arm B (150 mg Tarceva daily).
2454970|NCT03207048|Experimental|Active rTMS|10 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex (L-DLPFC) for 15 mins each time, 5 times per week for up to 6 weeks (interrupt for 1-2 weeks after 10 times).
2454971|NCT03207048|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation
2454990|NCT03206697||Aneuploid mitochondria|Mitochondrial DNA content and metabolic parameters
2455056|NCT03206515|Other|Group 1|Patients in Group 1 undergo Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath group
2455058|NCT03206515|Other|Group 2|Patients in Group 2 undergo Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function group
2455072|NCT03206138|Experimental|GX-188E, GX-I7|GX-188E + GX-I7
2455073|NCT03206138|Experimental|GX-188E, Imiquimod|GX-188E + Imiquimod
2455124|NCT03206021|Experimental|Phase I Dose-escalation|5'azacytidine will be administered on Days 1-7 at a dose of 75mg/m2/day, followed by escalating doses of Carboplatin on Day 14 in a rolling 6 design. Carboplatin will be dosed initially at AUC 4. Dose level -1 will reduce 5'azacytidine to 50mg/m2/day.
2455125|NCT03206021|Experimental|Posterior Fossa Ependymoma Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation to 20 patients with recurrent/refractory posterior fossa ependymoma.
2455127|NCT03206021|Experimental|Recurrent Brain and Solid Tumour Expansion Arm|5'azacytidine will be administered on days 1-7 and carboplatin will be administered on day 14 at the maximum tolerated dose achieved in the Phase I dose escalation up to 12 patients with recurrent/refractory brain and solid tumour.
2455174|NCT03205631|Sham Comparator|Sham Natural Frequency Patch|
2455175|NCT03205631|Active Comparator|Active Natural Frequency Patch|
2455235|NCT03205267|Experimental|Bosutinib|Drug: Bosulif 100 mg or 500 mg tablets step in dosing scheme
2455267|NCT03204968|No Intervention|control|
2455269|NCT03204968|Active Comparator|Treated|
2455331|NCT03204682|Experimental|Patients with chronic refractory endometriosis pain|The aim of the study is to evaluate the feasibility of transcranial magnetic stimulation (rTMS) for analgesia on chronic refractory endometriosis pain.
2455372|NCT03204318|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
2455375|NCT03204318|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
2455377|NCT03204318|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
2455518|NCT03203486|Experimental|Meditteranean Diet|NAFLD patients attended appointments with experienced dieticians to receive nutritional guidance based on a traditional Mediterranean Diet for 6 months.
2455588|NCT03203096|Placebo Comparator|Placebo|identically tasting and looking Placebo
2455590|NCT03203096|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium Citrate / Magnesium Oxide once daily
2455658|NCT03202524|Active Comparator|Albumin|Patients undergoing large volume paracentesis with receive 50ml of 25% albumin for every 2 L removed from their abdomen.
2455664|NCT03202524|Experimental|Fresh Frozen Plasma|Patients undergoing large volume paracentesis with receive 2 units of FFP for the first 4L removed followed by 50ml of 25% albumin for every additional 2 L removed
2455723|NCT03202095|Experimental|Open Label Treatment with Creatine|5 grams daily of oral creatine monohydrate powde
2455801|NCT03201393|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
2455802|NCT03201393|Placebo Comparator|Placebo|
2455859|NCT03201133||Patellofemoral pain syndrome with changes in proximal factors|
2455862|NCT03201133||Patellofemoral pain syndrome with changes in local factors|
2455864|NCT03201133||Patellofemoral pain syndrome with changes in distal factors|
2455905|NCT03200821|Experimental|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
2455907|NCT03200821|Active Comparator|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
2455953|NCT03200600|Experimental|Dexamethasone and flurbiprofen axetil|"Dexamethasone 10 mg is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
3154247|NCT00294827|Experimental|Liver transplantation|
3154248|NCT00294866|Active Comparator|A|Receive Paricalcitol
3154249|NCT00294866|No Intervention|B|Paricalcitol on hold
3154250|NCT00294892|Active Comparator|Carbamazepine|An oral dose of 400mg Carbamazepine is added to the 200mg oral dose Nevirapine intake prior delivery
2454605|NCT03209544|Experimental|Intervention group|The intervention group gains access to Think Life, an online self-help intervention. During 6 weeks they receive a new module on a weekly basis.
2454610|NCT03209544|No Intervention|Control group|Waitlist control group. They receive access to Think Life after 12 weeks.
2454661|NCT03209323|Experimental|sevoflurane - increasing concentrations|The patient was breathing spontaneously via the face mask and the sevoflurane concentration in the inhaled gas was doubled every 10 breaths starting from 0.3 vol. % in a sequence 0.3-0.6-1.2-2.4-4.8-8 vol. % until a minimal alveolar concentration (MAC) of 2 was obtained in the exhalation gas. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2454663|NCT03209323|Experimental|sevoflurane - vital capacity|The anaesthetic circuit was prefilled with 8% sevoflurane. The patients were asked to exhale to the residual volume. Then the patients were explained to perform a vital-capacity breath with a face mask applied tightly to their faces. Then the patients were encouraged to hold their breaths as long as possible. Thereafter, the patients were asked to breathe spontaneously. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2454667|NCT03209323|Experimental|propofol - intravenous induction|the patients were preoxygenated with 100% oxygen following which propofol was intravenously administered at a single dose of 2.5 mg/kg of body weight, after which it was infused with an infusion speed of 4 mg/kg body weight/h. Electroencephalography (EEG), bispectral index (BIS), response and state entropy (RE and SE), middle latency auditory evoked potentials (MLAEP) were monitored.
2454793|NCT03208400|Other|virtual reality exposure|one-session exposure conveyed via virtual reality technology
2454867|NCT03207919|Experimental|Lullaby Project|
2454872|NCT03207919|No Intervention|Control Group|
2454900|NCT03207373|Experimental|Stress ECG Test|The whole study cohort undergoes the same diagnostic workup including stress test (ECG)
2454966|NCT03207113|Experimental|Ned Group|"Participants in the Ned case study (patients, caregivers, clinicians) will receive access to the Ned application.~Ned (No Evident Disease) is the first application to provide patients with access to individual-level prostate-specific antigen values streamed directly from the Ontario Laboratory Information System to their own smartphone. The application aims to promote self-care by informing patients directly of their PSA results and providing them with a personalised view of their own symptoms. It supports real-time clinical decision-making by providing clinicians with patient-reported outcomes collected in-app, and includes a curated educational feed and support group links."
2455000|NCT03206736|Experimental|Loop DS Patients|Patients who receive a Loop DS procedure
2455061|NCT03206476|Experimental|Intervention group|Nutritional intervention based on the SCT and the TM
2455062|NCT03206476|Active Comparator|Control group|Nutritional information
2455110|NCT03206112||Focal Dystonia|Subjects diagnosed with Focal Dystonia
2455114|NCT03206112||Healthy Volunteers|Healthy Volunteers
2455176|NCT03205722||Melanoma patients with 1st-line Nivo treatment|Non-Interventional. Patients with advanced melanoma treated with nivolumab monotherapy prescribed as first-line therapy between June 2015 and June 2016.
3154251|NCT00294892|Placebo Comparator|Nevirapine|Standard therapy of 200mg Nevirapine oral prior to delivery
2455314|NCT03204747||Patients enrolled|"Patient with multiple sclerosis and lower urinary tract symptoms, age > 18, able to walk without human help on 50 meters, able to hold urine at least 3 minutes.~A first record of gait will be at strong desire to void. A second record will be after void Gait records consist on : 3 10meter walk test and 1 Timed up and Go test."
2455368|NCT03204474|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each]), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion)
2455371|NCT03204474|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 200 mg administered as intravenous infusion), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 200 mg administered as 2 oral tablets [100 mg each])
2455397|NCT03203967|Experimental|Epidural morphine|"Epidural morphine (2 mg morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
2455398|NCT03203967|Placebo Comparator|Epidural placebo|"Epidural placebo (5 ml normal saline) is administered through the epidural catheter at the end of surgery.~Single femoral nerve block is performed with 20 ml of 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.~Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/mL morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 mL/h."
2455529|NCT03203655|Experimental|Intervention Group|The intervention group will be enrolled in the CareMessage™ Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
2455531|NCT03203655|Other|Control Group|The control group will receive the control condition. They will hear an initial talk about weight loss but will not be enrolled in any program or intervention.
2455592|NCT03202953|Experimental|1:1 I:E ratio VCV (Group I)|volume controlled ventilation with 1:1 inspiratory to expiratory ratio After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
2455596|NCT03202953|Active Comparator|autoflow VCV (Group A)|autoflow volume-controlled ventilation After trendelenburg position, Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used.
2455856|NCT03201081|No Intervention|control group|The control group, did not participate in the motivational resistance-training program.
3154252|NCT00294918|Experimental|Serostim® (1 mg)|
2454618|NCT03209648|Experimental|Debio 1450|In Treatment Period 1, participants will receive single oral dose of Debio 1450 40 mg on Day 1. In Treatment Period 2, participants will receive itraconazole 200 mg, twice daily (BID) orally, on Day 1, followed by itraconazole 200 mg once daily (QD), on Days 2 to 4, and then single oral dose of Debio 1450 40 mg and itraconazole 200 mg on Day 5, followed by a single oral dose of itraconazole 200 mg on Days 6 and 7.
2454648|NCT03209180|Active Comparator|Carvedilol IR (Immediate Release)|Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months
2454649|NCT03209180|Experimental|CarVeDilol-SR (Slow Release)|CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months
2454746|NCT03208621||Observational group|The diagnostic tests to be investigated in this study is the use of PET and DLS in addition to the initial staging with gastroscopy and CT of patients with an advanced tumor (cT3-4)
3154253|NCT00294918|Experimental|Serostim® (2 mg)|
3154254|NCT00294918|Experimental|Serostim® (4 mg)|
2454866|NCT03207711|Active Comparator|Diet Education|All participants will receive instruction in the carbohydrate-restricted diet (CR).The study diet has approximately 10% of kcal coming from carbohydrate, typically 50 grams/day or fewer, not including fiber. Participants will be encouraged to eat a normal amount of protein, typically about 80-100 grams/day (about 20-25% of calories), and the rest of their calories from fat. Foods that are encouraged include green leafy and other non-starchy vegetables, nuts, seeds, oils (especially olive oil), fish, poultry, tofu, and avocados. Other foods consistent with the diet include berries (in modest amounts), meats, eggs, and cheese. Key foods to minimize include any sugar-sweetened foods or beverages, bread, pasta, potatoes, highly processed packaged foods, and other starchy foods.
2454873|NCT03207711|Experimental|Diet Education + Mindfulness|In addition to the carbohydrate-restricted diet described above, the Ed+MBI group will receive mindfulness training consisting of two integrated components: 1) use of a mindful eating app at home to learn and practice mindfulness skills for food-cravings and eating, and 2) in-person group-based meetings to discuss and troubleshoot how the mindfulness practices are working. Key mindfulness content includes helping people improve their relationship with food and control food cravings and using mindful eating approaches including paying attention, noticing habit loops, understanding brain science and food/sugar addiction, disrupting emotional and stress eating, cultivating acceptance and curiosity, lovingkindness, detaching from thoughts, using healthy restraint, and maintaining motivation.
2454913|NCT03207295|Experimental|Intervention-Nesiritide|A standard dose of Nesiritide(0.001ug/kg/min) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
2454918|NCT03207295|Placebo Comparator|Control-Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
2454963|NCT03206996|Experimental|Child Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
2454967|NCT03206996|Experimental|Parental Interventional|A 12 week patient-centered modified E/RP protocol for up to 5 participants with ASD and auditory hyper-reactivity. E/RP protocols will include face-to-face treatment sessions as well as the provision of home programs. Treatment fidelity checklists will be utilized each session to ensure that each participant receive the same general protocol/treatment process
2455003|NCT03206632|Experimental|BI 690517 dose group 1|
2455005|NCT03206632|Experimental|BI 690517 dose group 2|
2455008|NCT03206632|Experimental|BI 690517 dose group 3|
2455010|NCT03206632|Placebo Comparator|Placebo|Matching placebo for each dose group
2455092|NCT03206398|Other|pelvic fracture|patients with pelvic fracture will additionally be treated with anti-gravity treadmill
2455178|NCT03205982|Sham Comparator|Control|WiseApp that delivers fitness reminders
2455179|NCT03205982|Experimental|Intervention|WiseApp that delivers medication adherence reminders
2455196|NCT03205202|Active Comparator|Cocoa extract + multivitamin|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin"
2455198|NCT03205202|Active Comparator|Cocoa extract + multivitamin placebo|"Dietary Supplement: Cocoa extract (2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine)~Dietary Supplement: Multivitamin placebo"
2455204|NCT03205202|Active Comparator|Cocoa extract placebo + multivitamin|"Dietary Supplement: Multivitamin~Dietary Supplement: Cocoa extract placebo"
2455215|NCT03205202|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|"Dietary Supplement: Cocoa extract placebo~Dietary Supplement: Multivitamin placebo"
2455290|NCT03204851|Active Comparator|Venous Stasis Ulcer|Venous Stasis Ulcer
2455296|NCT03204851|Active Comparator|Pressure Ulcers|Pressure Ulcers
2455307|NCT03204851|Active Comparator|Diabetic Foot Ulcers|Diabetic Foot Ulcers
2455312|NCT03204851|Active Comparator|Wounds from a variety of etiologies|Wounds from a variety of etiologies
2455359|NCT03204422||Children's group|no intervention. participants, whose age was 5 to 18 years, were enrolled in Children's group.
2455364|NCT03204422||Adults group|no intervention. participants, whose age was over 18 years, were enrolled in Adults group.
2455409|NCT03204045|Active Comparator|fentanyl|fentanyl 1 ㎍/kg
2455413|NCT03204045|Active Comparator|oxycodone|oxycodone 0.08 mg/kg
2455418|NCT03204045|Placebo Comparator|control|isotonic saline
2455702|NCT03202212|Experimental|Mixed on-line hemodiafiltration|Mixed on-line hemodiafiltration (mOL-HDF using FX 1000 CorDiax, Fresenius Medical Care, Bad Homburg, Germany), three sessions per week, four hours per session
2455705|NCT03202212|Active Comparator|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
3154255|NCT00294970||PTSD|Patients with diagnosis of PTSD
3154256|NCT00294970||OCD|Patients with diagnosis of OCD
3154257|NCT00294970||PTSD/OCD|Patients with diagnosis of comorbid PTSD and OCD
3154258|NCT00295139|Experimental|1|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)
2454621|NCT03209596|Experimental|Orange juice|Seventeen individuals received 1 liter/day of pasteurized orange juice. Participants consumed the orange juice before and post exercise, the volume of juice per serving was 500 mL. On players' rest days, the juice was consumed throughout the day.
2454625|NCT03209596|Active Comparator|Control drink|Thirteen individuals received 1 liter/day of control drink. The participants consumed the control drink before and post exercise, the volume of drink per serving was 500 mL. On players' rest days, the drink was consumed throughout the day. The control drink consisted of an aqueous solution containing sucrose (44 g), glucose (22 g), fructose (22 g), citric acid (11g) (proportionally 2:1:1:0.5) (USDA, 2016) (with the same proportion of total sugars as the orange juice, and without all others bioactive compounds of juice), dyestuff sunset yellow (0.05 g) and orange essence.
2454658|NCT03209115|Active Comparator|calcium hydroxide and chlorhexidine|Removal of old root canal filling and placing calcium hydroxide and chlorehexidine as intracanal medication
2454662|NCT03209115|Active Comparator|calcium hydroxide|Removal of old root canal filling and placing calcium hydroxide as intracanal medication
2454722|NCT03208816|Other|single arm|symptom management program for chemotherapy patients
2454798|NCT03208361|Experimental|Penicillin V|Penicillin V, 1600000 IU every 8h during 10 days.
2454803|NCT03208361|Active Comparator|Amoxicillin|Amoxicillin, 1 g every 8h during 10 days.
3190692|NCT00790257|Experimental|Monolayer Cellular Device|Encapsulated human islets allotransplantation transplanted in subcutaneous tissue in Type 1 diabetes patient
3190693|NCT00790283|Experimental|Numen|
2454933|NCT03207152|Experimental|Influenza A/California/04/2009|Participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2454982|NCT03206944|Experimental|Group 1 ASA|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg orally once a day in the morning.
2454983|NCT03206944|Experimental|Group 2 STE|Group 2 (STE) included 32 patients receiving tomato fruit extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally once a day in the morning.
2455033|NCT03206619||Social, Local and Mobile|Patients having smoking cessation standard care (behavioral and pharmacological therapy) and using the SoLoMo mobile app that sends them motivational messages.
2455081|NCT03206281||Clinical fetal weight estimation|The fetal weight estimation will be taken by professional obstetrician durin her 39 week
2455091|NCT03206281||Sonographic fetal weight estimation|The fetal weight estimation will be taken by professional Sonographic obstetrician durin her 39 week
2455160|NCT03205891|Experimental|Brentuximab Vedotin + TAK228|"Participants receive Brentuximab Vedotin by vein on Day 1 of each cycle.~Participants take TAK228 by mouth either every day, or on a 5 days on/2 days off schedule. The study doctor will tell participant how often to take the study drug.~Each cycle is 21 days.~Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug."
2455237|NCT03205241|Experimental|n-3 PUFA|Omega-3 polyunsaturated fatty acid - 5.7g/ day for 4 weeks
2455239|NCT03205241|Placebo Comparator|Placebo|Olive Oil - 6g/ day for 4 weeks
2455275|NCT03204825|Experimental|Active TENS|Participants in the TENS groups will be provided with a TENS machine and training at the baseline visit to the Clinical research Facility (CRF). They will be instructed to use it daily as their symptoms require for 6 weeks. The active group will receive High Frequency-TENS (120 Hz, 200µs and a patient-determined intensity of ''strong but comfortable'').
2455276|NCT03204825|Placebo Comparator|Placebo TENS|Placebo TENS : Participants will receive the same model, programmed settings and instructions for use as those in the active group except that the device will be set to an ineffective stimulation (120 Hz, 200µs and a patient-determined intensity of '6mA). For the purpose of blinding, participants will be told that different dosages of TENS are being tested, some of which where the stimulation might not be perceivable even though the device is working.
2455278|NCT03204825|Experimental|Patient-Centred Education|Patient-Centred Education : a one-off three-hour workshop of structured group education (4-5 persons in each group) and three 2-weekly phone calls. The aim will be to modify patients' illness beliefs and perceptions about IC/PAD by educating them on disease pathology and management philosophy. After the workshop, each patient will be supported to set goals for walking, develop an action plan regarding how these goals will be met and encouraged to repeat this process for each new walking goal.
2455279|NCT03204825|Experimental|Patient-Centred Education + Active TENS|Combination of Patient-Centred Education arm and Active TENS arm.
2455369|NCT03204409||Symptomatic adults|adult patients (>18 years) presenting with febrile or rash illness of short duration (<72h)
2455420|NCT03204084||the LTP group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving Low-temperature Plasma Surgery System(LTP group),
2455425|NCT03204084||the control group|Patients undergoing pterygium surgery with fibrin glue and conjunctival autografting and receiving the conventional method using surgical micro knife and ophthalmic hemostasis(control group)
2455467|NCT03203694|Experimental|Walking intervention|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
2455470|NCT03203694|No Intervention|Control|Subjects will be instructed to continue their usual lifestyle for 8 weeks.
3190694|NCT00790283|Active Comparator|Vision/MiniVision|
3190695|NCT00790309||Weight loss surgery|This group will be comprised of people having weight loss surgery: Roux-en Y gastric bypass, vertical sleeve gastrectomy, or adjustable gastric banding
3190696|NCT00790309||Abdominal surgery|This group will be comprised of people having abdominal surgeries such as nissen fundoplication or cholecystectomy.
3190697|NCT00790309||Lean|This group will be comprised of normal weight healthy volunteers.
3190698|NCT00790322|Experimental|Active|
3190699|NCT00790322|Placebo Comparator|Placebo|
3190700|NCT00790348||1|Patients who on Januvia
3190701|NCT00790348||2|Patients on Janumet (Combination of Januvia and Metformin)
3190702|NCT00790348||3|Patients on Metformin
3208584|NCT00976131|Experimental|Arm B|Cycle 3 of doxorubicin with Coenzyme Q10 Placebo, Cycle 4 with Coenzyme Q10
2454668|NCT03209011|Experimental|experimental group|patients who were untreated ever in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly till 48 weeks.
2454680|NCT03209011|No Intervention|control group|patients who were untreated ever in immune-active phase took Nucleoside Analogues for maintenance treatment.
2454733|NCT03208751|Other|Exercise training|All patients were included in the exercise training group
2454794|NCT03208322||DCV + ASV at a sentinel site|patients with chronic hepatitis C (CHC) who are being given at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) for the treatment and cure of CHC at the sentinel sites for the National Pharmacovigilance Center (CNFV) in Mexico.
2454833|NCT03207828|Experimental|Behavioral activation group|This group will receive usual care for fibromyalgia with comorbid major depression plus in-group behavioral activation.
2454835|NCT03207828|Other|Usual care|"This group of participants will only receive usual care for fibromyalgia with comorbid depression.~Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) of the Red Salud Christus, the most important private medical care network in Chile. In this clinic treatment of fibromyalgia includes administering pregabalin and pain killers (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed."
2454937|NCT03207542|Experimental|B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
2454938|NCT03207542|Experimental|T-Cell Precursor Acute Lymphoblastic Leukemia (ALL)|"Participants receive Daratumumab by vein over about 4 hours on Days 1, 8, 15, and 22 of Cycles 1 and 2, Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond.~Each cycle is 28 days."
2455159|NCT03205969|Experimental|Functional mobile game|Functional mobile game for chemotherapy side effect education
2455225|NCT03205462|Experimental|Group 1|Fluorothyazinone in a dosage of 300 mg (1 tablet) will be administrated to 5 volunteers
2455229|NCT03205462|Experimental|Group 2|Fluorothyazinone in a dosage of 600 mg (2 tablets) will be received per os (oral administration) as a single dose
2455233|NCT03205462|Experimental|Group 3|on the first day of administration, the product is received according to the following regimen: the first dosage of 60 mg (2 tablets) should be taken orally 30 minutes after meals and swallowed with room-temperature water; the second dosage - 1 tablet (300 mg) - 12 hours later, and then for 5 days the subjects will receive 2 tablets per day. The duration of antibacterial therapy is 6 days. The total dose of Fluorothyazinone per treatment course is 3900 mg.
3190703|NCT00790361||Control|"Controls (healthy volunteers) will have two scans (fMRI, MRS and DTI) six months apart to determine reproducibility.~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
3190704|NCT00790361||CCS Participants|"CCS participants will have three scans (fMRI, MRS and DTI), one acutely (up to 48 hours after injury), one subacutely (15 days after injury), and one late (6 months after injury).~A blinded investigator will administer JOA, ASIA/ISCOS, NDI and SF-36 prior to the scan at all time points."
3190705|NCT00790374|Experimental|Cohort 1|6 patients have been enrolled, the cohort has been completed.
2455343|NCT03204292||IVC/Ao|ultrasound, the inferior vena cava and abdominal aorta were measured. Inferior vena cava width was assessed at an interval of approximately 1 cm distal from connection of the hepatic vein to the inferior vena cava. No significant changes were observed in the width of the inferior vena cava during various respiratory phases, because of the positive pressure ventilation. The widest value was always chosen for the data. The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava.
2455453|NCT03203785|Experimental|Carbohydrate|30g of carbohydrate (maltodextrin) diluted in 300ml of water. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
2455454|NCT03203785|Placebo Comparator|Placebo|300 ml of a non-caloric drink. Athletes will drink 100ml before and 100ml in the first and second interval between exercise.
2455543|NCT03203421|Active Comparator|Low Dose (Group 1)|One low dose of ChAdOx1 LS2 (5 x 10^9 vp) on day 0.
2455544|NCT03203421|Active Comparator|Prime-Boost (Group 2)|One high dose of ChAdOx1 LS2 (2.5 x 10^10 vp) on day 0 and one dose of MVA LS2 (2 x 10^8 pfu) on day 56.
2455545|NCT03203421|No Intervention|Control Group A|No vaccinations will be administered.
2455546|NCT03203421|No Intervention|Control Group B|No vaccinations will be administered.
2455553|NCT03202836|Experimental|vaginal progesterone|Vaginal utrogestan 400 mg, vaginal suppository, once at bed time until gestational age 37 weeks and tocolysis plus corticosteroid for 48 hours
2455555|NCT03202836|Other|no medication|only tocolysis plus corticosteroid for 48 hours
2455638|NCT03202732|Other|DiabetesFlex|"In DiabetesFlex intervention, patients are offered 3 consultations/year. One mandatory consultations (30 minutes). The patient, an endocrinologist and a diabetes nurse attend.~Two optional consultations, patients can choose between face-to-face consultations, a telephone consultation or to cancel the consultation.~Ahead of the consultations, patients fill out the AmbuFlex Diabetes questionnaire and deliver a blood and urine sample.~Based on the patient's response to the AmbuFlex Diabetes questionnaire, the result of the blood sample and the urine sample, the diabetes nurse assign the patient to a face-to-face consultation, a telephone consultation or no consultation with an endocrinologist, a diabetes nurse or a dietician."
2455639|NCT03202732|No Intervention|Standard care|"Standard diabetes care consists of 3 consultations (15 minutes)/year with a physician or a diabetes nurse by turns.~Ahead of the consultation patients send in a blood sample for measuring HgA1c, urine sample for measuring urin-albumin creatinin ratio and other blood samples depending of arrangements made in the last consultation.~Once a year in relation to a consultation, patients fill in the Problem Area In Diabetes (PAID) (20) scale together. Furthermore, based on the patients or healthcare professional judgement, patients see a dietician when needed."
2458899|NCT03180749||Patients implanted with vendor B anchor|
3190706|NCT00790374|Experimental|Cohort 2|6 patients have been enrolled in cohort 2, the cohort has been completed.
3190707|NCT00790374|Experimental|Cohort 3|5 patients have been enrolled in cohort 3. The cohort was closed after the 5th patient enrolled.
2454669|NCT03209024|Other|Control|Participants complete a 3-week home blood pressure monitoring regimen using a handwritten logbook to record all blood pressure readings.
2454678|NCT03209024|Experimental|Intervention|Participants complete a 3-week home blood pressure monitoring regimen using a smartphone app and Bluetooth® technology to wirelessly record all blood pressure readings.
2454705|NCT03208764|Experimental|Nitric Oxide treatment|
2454753|NCT03208517|Experimental|Arm 1: Regular Contact Group (WHELD +)|Regular Contact Group (WHELD elearning package + regular supervision support) A research associate will provide one face-to-face training session with participating care staff in the care home on how to use the online modules, providing a walk-through demonstration to ensure all are comfortable with the programme and its technology. The research associate will provide light touch support by returning fortnightly throughout the intervention period to the care home to observe/troubleshoot around online programme.
2454755|NCT03208517|Experimental|Arm 2: Online Contact Group (WHELD only)|Online Contact Group (WHELD elearning package only) The e-learning modules will be emailed to the care home with clearly written instructions on how to access the course.
2454756|NCT03208517|No Intervention|Arm 3: Enhanced usual practice Control Group|"Arm 3: Enhanced usual practice Control Group (with information/signposting re high quality on line e-learning and educational materials).~This will consist of a 2-page written guidance sheet on the best freely available dementia e-learning programmes and a one-off meeting with a research associate in the care home to explain the information/signposting"
2454777|NCT03208127|Experimental|Treatment with Direct Acting Antiviral Fixed Dose Combination|12 weeks of HCV treatment with medically appropriate direct acting antiviral
2454878|NCT03207932||ultrasound|CVC insertion using ultrasound
2454879|NCT03207932||landmark technique|CVC insertion using landmark technique
2454898|NCT03207308|Experimental|Vitamin A supplementation|55 children will receive a Mega-dose of preformed Vitamin A as recommended by the Senegalese Ministry of Health
2454968|NCT03207126|Other|Women needing endometrial biopsy|All women who would be offered hysteroscopy guided biopsy as standard of care will be offered ultrasound guided biopsy first.
2455018|NCT03206723|Active Comparator|Group 1|1. Standard care
2455022|NCT03206723|Active Comparator|Group 2|"Standard care~Bandage contact lens"
2455109|NCT03206268||healthy eyes|
2455112|NCT03206268||uveitis eyes|
2455145|NCT03205761|Experimental|olaparib|Patients with a positive methylation status on at least one of the two genes and lacking of known deleterious or suspected deleterious mutations in both genes could be included in the study to receive olaparib tablet formulation at 600 mg total daily dose (given in two oral administrations of 300 mg every 12 hours approximately). Patients will continue to receive their treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
2455194|NCT03205189|Other|Pre-operative prescription group|This group will have a pre-operative prescription delivered during the preoperative anesthesia clinic.
2455195|NCT03205189|Other|Postoperative prescription group|This group will receive the postoperative prescription.
2455259|NCT03205085|Experimental|CTEPH PATIENTS|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
2455260|NCT03205085|Experimental|PAH PATIENTS|patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation
2455289|NCT03204734|Experimental|Capecitabine|Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.
2455297|NCT03204734|Experimental|endocrine therapy|endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.
2455344|NCT03204461||PCOS-NIH|
2455347|NCT03204461||PCOS-Rotterdam|
2455350|NCT03204461||Controls|
2455422|NCT03204071|Placebo Comparator|Group 1|Placebo gel without active ingredient to be delivered at baseline, 6 and 12 months.
2455428|NCT03204071|Active Comparator|Group 2|Aloe vera gel to be delivered at baseline, 6 and 12 months.
2455433|NCT03204071|Active Comparator|Group 3|1% metformin gel to be delivered at baseline, 6 and 12 months.
2455505|NCT03203551|Placebo Comparator|C; Control; Saline solution|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in Saline solution (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2455508|NCT03203551|Experimental|HS0.25%; 0.25% Sodium Hypochlorite|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.25% Sodium Hypochlorite (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2455510|NCT03203551|Experimental|RC10%; 10% Ricinus communis|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 10% Ricinus communis (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2455513|NCT03203616|Experimental|Kadcyla (T-DM1)|trastuzumab emtansine given every 3 weeks at the standard dose (3.6 mg/kg) via intravenous infusion, until disease progression, intolerable toxicity or consent withdrawal. A median of 9 cycles per patient is expected
2455564|NCT03203122|Experimental|Study group|Patients are randomized to treatment of either right or left side. The other side works as control
2454689|NCT03209232|Experimental|Accelerated induction|Patients in group 1 will receive an accelerated induction of infliximab at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15.
2454691|NCT03209232|Active Comparator|Per protocol|Patients in group 2 will receive a per protocol induction of infliximab at 0,2,6 weeks (5 mg/kg) and then at week 14.
2454780|NCT03208478|Active Comparator|Adductor Canal Nerve Block group|Adductor Canal perineural catheter placement. Adductor Canal continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed in the adductor canal. A Nimbus pump (Infutronix) will be delivering the medication.
2454782|NCT03208478|Active Comparator|Femoral Nerve Block group|Femoral Nerve perineural catheter placement. Femoral continuous perineural infusion. Ropivacaine 0.2% will be administered at a continuous rate of 5 mL/hour through a perineural catheter placed near the femoral nerve. A Nimbus pump (Infutronix) will be delivering the medication.
2455040|NCT03206554|Active Comparator|LIA|Local infiltration analgesia
2455044|NCT03206554|Sham Comparator|sham LIA|Saline injections
2455083|NCT03206255||9-17y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
2455086|NCT03206255||9-14y (0,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
2455097|NCT03206255||18-26y (0,1,6m)|Participants in this arm have received 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
2455153|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
2455249|NCT03205449|Experimental|MaPa Programme|Masayang Pamilya Parenting Program: A 12-session, a group-based parenting programme focused on reducing violence against children and improving child wellbeing in low-income families with young children
2455250|NCT03205449|Active Comparator|Treatment-as-usual|Parenting Effectiveness Service programme: A family strengthening programme delivered by trained service providers on a monthly basis.
2455292|NCT03204773||HSP patients|Patients with hereditary spastic paraplegia regardless of their genetic mutation
2455302|NCT03204773||Healthy controls|healthy controls (spouses, relatives, or other healthy controls)
2455337|NCT03204370||MPS4A patients|
3154259|NCT00295139|Experimental|2|Behavioral Treatment for Substance Abuse in SPMI (BTSAS) + Critical Time Intervention (CTI)
3154260|NCT00295139|Active Comparator|3|Supportive Treatment in Addiction Recovery (STAR)
2455463|NCT03203512|Active Comparator|Intervention|Fish oil capsules
2455464|NCT03203512|Placebo Comparator|Placebo|High-oleic safflower oil capsules
2455497|NCT03203356||GHD children|about 30 prepubertal children affected by overt idiopathic GHD
2455499|NCT03203356||controls|about 30 prepubertal children with constitutional short stature without endocrine disease
2455547|NCT03203174|Experimental|Split-hand Microneedle Botulinum Toxin A|One palm with microneedle pretreatment prior to application of topical botulinum toxin A
2455548|NCT03203174|Sham Comparator|Split-hand Sham Microneedle Botulinum Toxin A|Contralateral palm with sham microneedle pretreatment prior to application of topical botulinum toxin A
2455598|NCT03202784|Experimental|BCX7353 API in capsule|fasted administration of BCX7353 API in capsule
2455603|NCT03202784|Experimental|BCX7353 blend in capsule|fasted administration of BCX7353 blend in capsule
2455607|NCT03202784|Experimental|BCX7353 blend in capsule with food|administration of BCX7353 blend in capsule following high-fat meal
2455646|NCT03202407|Placebo Comparator|calcium group|"will receive calcium-based phosphate binder (calcium carbonate ) 45-65 mg/kg orally divided 3 to 4 times/day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
2455650|NCT03202407|Experimental|sevelamer group|"will receive the recommended daily dose of the Sevelamer hydrochloride phosphate binder 120-160 mg/kg orally 3 times per day for 3 months.~all the following investigation will be done before and after consecutive 3 months of administration :~Complete blood count~Kidney function tests (serum urea and creatinine)~Serum total calcium level.~Serum phosphorus level.~Calcium × phosphorus product.~Serum parathormone level.~Serum alkaline phosphatase level.~Lipogram (Total cholesterol, High density lipoprotein, Low density lipoprotein and triglycerides).~Echocardiography regular follow up of serum phosphate , calcium and parathyroid hormone will be done every month for dose adjustment of the drug"
3154261|NCT00295165|Experimental|Arm 1|
3154262|NCT00295165|Placebo Comparator|Arm 2|
3154263|NCT00295191|Active Comparator|1|high-flux dialyser
3154264|NCT00295191|Active Comparator|2|low-flux dialyser
3154265|NCT00295191|Active Comparator|3|conventional dialysate
3154266|NCT00295191|Active Comparator|4|ultrapure dialysate
3154267|NCT00295282|Experimental|1|patients will receive active MDX-1100
3154268|NCT00295295|Experimental|Vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
3154269|NCT00295295|Active Comparator|Standing|Standing 10 min/day
3154270|NCT00295308|Experimental|Arm 1|
3154271|NCT00295308|Placebo Comparator|Arm 2|
3154272|NCT00295438|Experimental|Robot-Based Tele-Echography (TER)|ultrasound performed according to the method Tele-Echography
3154273|NCT00295438|Active Comparator|ultrasound method FAST|ultrasound performed according to the method FAST (Focused Assessment Sonography for Trauma)
3154274|NCT00295529|Experimental|Multifaceted Educational Intervention|Intervention group received an interactive workshop, portfolio of primary care appropriate genomics tools, and Gene Messengers
3154275|NCT00295529|No Intervention|No education|Educational materials at end of study
3154276|NCT00295542|Active Comparator|1|Treatment on awakening
3154277|NCT00295542|Active Comparator|2|Treatment at bedtime
3154278|NCT00295594|Active Comparator|1|
3154279|NCT00295594|Experimental|2|
2454783|NCT03208283|Active Comparator|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
2454788|NCT03208283|Active Comparator|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
3154280|NCT00295607|Active Comparator|1|
3154281|NCT00295607|Experimental|2|
2454953|NCT03207360|Experimental|Pain Coping Skills|
2454999|NCT03206827|Active Comparator|70% animal, 30% plant proteins in diet|Dietary proteins from animal sources 70% and from plant sources 30%, representing an average Finnish diet consumed at the moment.
2455004|NCT03206827|Experimental|50% animal, 50% plant proteins in diet|Dietary proteins from animal sources 50% and from plant sources 50%, containing at most 500 g red meat/week (according to the current Finnish Nutrition Recommendations).
2455007|NCT03206827|Experimental|30% animal, 70% plant proteins in diet|Dietary proteins from animal sources 30% and from plant sources 70%.
2455089|NCT03206372||Case group|The cases are the first-degree family members of propositi having had an thromboembolic venous disease in hormonal context.
2455096|NCT03206372||Control group|The controls are the first-degree family members of propositi who have never had an thromboembolic venous disease and have identical hormonal exposure
2455146|NCT03205605|Other|baseline patch|patch
2455148|NCT03205605|Other|baseline gel|gel
2455151|NCT03205605|Other|patch with heat|patch
2455155|NCT03205605|Other|gel with occlusion|gel
2455293|NCT03204721|Active Comparator|Extracorporeal photophoresis|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient.
2455304|NCT03204721|No Intervention|Controll|No procedure
2455360|NCT03204578|Experimental|AB (Midazolam OD/Dormicum)|Subjects with sequence AB will first receive the Intervention OD formulation (Period A, 30 µg Midazolam) and at the second visit the oral solution (Period B, 30 µg Dormicum ).
2455365|NCT03204578|Experimental|BA (Dormicum/midazolam OD)|Subjects with sequence BA will first receive the Intervention oral solution (Period B, 30 µg Dormicum) and at the second visit the OD disintegrating formulation (Period A, 30 µg Midazolam).
2455474|NCT03204019|Experimental|Tegafur and Temozolomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2455476|NCT03204019|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|Drugs should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2455583|NCT03202862|Experimental|ESR1 mutated|ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer after previous aromatase inhibitor therapy
3154282|NCT00295646|Active Comparator|AZ (Arimidex+Zoledronate)|Study Drugs Arimidex (Anastrozole), Zometa (Zoledronate; zoledronic acid)
3154283|NCT00295646|Active Comparator|TZ (Tamoxifen+Zoledronate)|Study Drugs Nolvadex (Tamoxifen), Zometa (Zoledronate; zoledronic acid)
3154284|NCT00295646|Active Comparator|AC (Arimidex Control)|Study Drug Arimidex (Anastrozole)
3154285|NCT00295646|Active Comparator|TC (Tamoxifen Control)|Study Drug Nolvadex (Tamoxifen)
3154286|NCT00295763|Other|1|
3154287|NCT00295789|Active Comparator|1|Drug: chemotherapy: Paclitaxel/Cisplatin
3154288|NCT00295789|Experimental|2|Drug: chemotherapy: Paclitaxel/Carboplatin
3154289|NCT00295802|Experimental|HIFU|Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
3154290|NCT00295802|Active Comparator|Cryotherapy|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
3154291|NCT00295815|Experimental|A|
3154292|NCT00295815|Active Comparator|B|
3154293|NCT00295828|Active Comparator|1|Panretinal Photocoagulation (PRP)
3154294|NCT00295828|Active Comparator|2|Panretinal Photocoagulation and Macugen Intravitreal Injection
3154295|NCT00295893|Active Comparator|Arm I|Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and docetaxel IV on day 1. Treatment repeats every 21 days for 6 courses.
3154296|NCT00295893|Experimental|Arm II|Patients receive doxorubicin hydrochloride IV and cyclophosphamide IV on day 1; treatment repeats every 2 weeks for 4 courses. Patients then receive carboplatin IV on day 1 and paclitaxel IV on days 1, 8, and 15; treatment with carboplatin and paclitaxel repeats every 4 weeks for 3 courses.
3154297|NCT00295893|Experimental|Arm III|Patients receive chemotherapy as in arm II. They also receive trastuzumab (Herceptin®) IV weekly, beginning with the first doses of paclitaxel and carboplatin.
3154298|NCT00295945||PCA|Patient-controlled intravenous analgesia
3154299|NCT00295945||PCEA|Perioperative patient-controlled epidural analgesia
3154300|NCT00295971|Experimental|Single arm of transplant|Receiving haplocompatible T cell depleted peripheral blood stem cell transplant
3154301|NCT00296010|Experimental|CASA-nil PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
2454723|NCT03208725||Hospitalized children with moderate wasting (MW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
2454727|NCT03208725||Hospitalized children without wasting (NW)|Children recruited at admission to hospital and followed up for 180 days post-discharge.
2454786|NCT03208244|Experimental|Treatment with Direct Acting Antiviral for HCV|12 weeks of treatment with HCV Direct Acting Antiviral tablet
2454854|NCT03207854||Ancillary-correlative (biospecimen collection)|Patients and healthy normal volunteers undergo collection of peripheral blood samples for analysis via flow cytometry, RNASeq, immunohistochemistry, CyTOF experiments, cell cultures, and functional studies of immune cell subsets obtained by FACS. Patients also undergo collection of bone marrow and leukopheresis/leukoreduction specimens, and single cell suspensions and bulk excised tumor biopsies are obtained from routine testing for analysis via immunohistochemistry or CyTOF.
2454922|NCT03207451|Experimental|Vorapaxar|Subjects with multiple risk factors and antiplatelet naïve to receive Vorapaxar.
2454925|NCT03207451|Experimental|Vorapaxar and Clopidogrel|Subjects with 600 mg Load /75mg QD Clopidogrel QD for ≥ 7 days to receive Vorapaxar
2454926|NCT03207451|Experimental|Vorapaxar and Aspirin|Subjects with 81mg QD Aspirin to receive Vorapaxar
2454927|NCT03207451|Experimental|Vorapaxar, Aspirin, and Clopidogrel|Subjects with 81 mg QD Aspirin+75mg QD Clopidogrel to receive Vorapaxar.
2455177|NCT03205787|Experimental|Trifolium pratense|Red clover extract; 2 gelatin capsules (398 mg extract) per day for 14 days
2455197|NCT03205228|Experimental|Flupentixol + Melitracen & placebo|Deanxit® (Flupentixol + Melitracen) 5 mg/D*4 weeks will be given
2455199|NCT03205228|Active Comparator|Proton pump inhibitor & placebo|Miracid® (Omeprazole) 20 mg/D*4 weeks will be given
2455206|NCT03205228|Active Comparator|Psychoeducation&placebo|Psychoeducation by psychologists will be advised on Day 1 and Day 14 of the study time frame
2455264|NCT03204955|Experimental|Sodium chloride /sodium acetate (16.4%)|50cc doses of sodium-chloride/sodium-acetate (16.4%) along with 30cc bag of dummy solution (PlasmaLyte).
2455265|NCT03204955|Active Comparator|Sodium chloride (23.4%)|30cc per dose of sodium chloride (23.4%) along with 50cc dummy solution bag (PlasmaLyte)
2455402|NCT03204227|Experimental|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
2455404|NCT03204227|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
3154302|NCT00296010|Active Comparator|CASA-Nil|No adjuvant therapy
2455537|NCT03203187|Placebo Comparator|No mango intake|No mango intake for two weeks
2455541|NCT03203187|Experimental|330 grams of daily mango intake|330 grams (2 cups) of daily mango intake for two weeks
2455565|NCT03202914|Active Comparator|Usual protein and phosphorus diet|protein: 1.3 g/kg/day, phosphorus: 16-20 mg/kg/day
2455576|NCT03202914|Active Comparator|Low protein and phosphorus diet|protein: 0.58 g/kg/day with ≥0.35 g of protein high in amino acids, phosphorus: 5-10 mg/kg/day
2455581|NCT03202914|Experimental|Very low protein and phosphorus|protein: 0.28 g/kg/day, phosphorus: 4-9 mg/kg/day; keto-acid and amino acid supplement (0.28 g/kg/day)
3154303|NCT00296010|Experimental|CASA-CM PLD|Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
3154304|NCT00296010|Active Comparator|CASA-CM CM|Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
2455758|NCT03201978|Experimental|GSK2894512 cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
2455760|NCT03201978|Placebo Comparator|Vehicle cream group|Subjects will receive once daily topical repeated application on approximately 5000 cm^2 intact non-occluded skin for 21 days in period 1 followed by once daily on 5000 cm^2 intact occluded skin for 21 days in period 2 (after approximately 21 days of washout period), followed by a single topical application on up to 400 cm^2 gently tape stripped skin area in period 3.
2455849|NCT03201445|Experimental|Part A (Filgotinib or Placebo)|Participants will receive double-blind filgotinib or placebo for 13 weeks
2455852|NCT03201445|Experimental|Part B (Filgotinib or Placebo)|Based on inflammatory bowel disease response status and sperm parameters, participants will continue on the blinded treatment for up to an additional 13 weeks or discontinue blinded study drug and commence open-label filgotinib.
2455855|NCT03201445|Experimental|Open-Label Filgotinib Phase|Participants will receive open-label filgotinib for up to 13 weeks.
2455858|NCT03201445|Experimental|Monitoring Phase|Participants whose sperm parameters meet a pre- specified decrease threshold at any time during the study, regardless of inflammatory bowel disease response status, will discontinue study drug and receive standard of care therapy in the Monitoring Phase.
2455861|NCT03201445|Experimental|Long Term Extension Phase|Participants qualifying to enter the Long Term Extension Phase will receive either open-label filgotinib or blinded study drug for up to 195 weeks based on the individual's response criteria.
2455964|NCT03200561|Active Comparator|S group|IVIG (2g/Kg in 12 hours)+oral prednisolone (2mg/Kg/day for 5 days)
2455967|NCT03200561|Placebo Comparator|I group|IVIG (2g/Kg in 12 hours)
2456006|NCT03200210|Experimental|Treatment with Febuxostat|Febuxostat, starting at dose 20mg/d, once a day. And adjust dose according to serum uric acid at specific visits.
2456007|NCT03200210|Placebo Comparator|Treatment with placebo|Same dose and dose adjustment as the intervention arm.
2456088|NCT03199781|Experimental|Intervention of mechanical massage with cosmetics|Patients will be treated with motorized mechanical massage and associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
3154305|NCT00296023|Experimental|stem cell transplant|
3154306|NCT00296049|Active Comparator|vancomycin|
3154307|NCT00296049|Experimental|daptomycin|
3154308|NCT00296153|Active Comparator|1|Omacor 1000mg x 4 / day
3154309|NCT00296153|Placebo Comparator|2|
3154310|NCT00296309|Active Comparator|1|
3154311|NCT00296309|Experimental|2|
2454750|NCT03208452|Placebo Comparator|Normal saline(NS) group|loading 50mL of normal saline during 10minutes before starting of surgery, after starting of surgery, continuous infusion of normal saline as placebo by 0.15mg/kg/h until the end of surgery
2454751|NCT03208452|Active Comparator|Magnesium group|loading dose of 50mg/kg magnesium sulfate during 10minutes before starting of surgery, during the surgery, continuous infusion of magnesium sulfate by 15mg/kg/h
2454800|NCT03208101|Experimental|Test group|DTP-HepB-IPV-Hib vaccine
2454804|NCT03208101|Active Comparator|Control group|DTP-HepB-Hib vaccine & IPV
2454844|NCT03207802||Cohort 3|This cohort is living at home with a chronic condition.
2454911|NCT03207529|Experimental|Treatment (alpelisib, enzalutamide)|Patients receive alpelisib PO and enzalutamide PO on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2454976|NCT03206957|Other|Study group|Down Syndrome children
2454977|NCT03206957|Other|Control group n°1|Down Syndrome children's mothers
2454978|NCT03206957|Other|Control group n°2|Age and sex matched healthy children
2454980|NCT03206957|Other|Control group n°3|Down syndrome children's healthy siblings
2455090|NCT03206294|Other|pharmacist assessment intervention group|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
3190708|NCT00790387|Experimental|1 High dose tirofiban and enoxaparin|"Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg .~Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours."
3190709|NCT00790387|Active Comparator|2 tirofiban and unfractionated heparin|"Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours.~UFH heparin was administered as a bolus of 70 U/kg and additional heparin was given to maintain the activated clotting time (ACT) at 250"
3190710|NCT00790413|Experimental|High-dose MIBG with haploidentical stem cell transplantation|High-dose MIBG followed by Fludarabine, Thiotepa and Melfalan as conditioning Before haploidentical transplantation of T-cell depleted graft
3190711|NCT00790426|Experimental|FGFR3 wild type|
3190712|NCT00790426|Experimental|FGFR3 mutant|
3190713|NCT00790439|Experimental|LMW-SD|18 participants randomized to immunosuppression with Low Molecular Weight Sulfated Dextran (LMW-SD)
3190714|NCT00790439|Active Comparator|Control Group, Standard of Care|18 participants randomized to immunosuppression without Low Molecular Weight Sulfated Dextran (LMW-SD)
3190715|NCT00790465|Active Comparator|1|dark chocolate consumption during manometry and 2 weeks treatment with dark chocolate
3190716|NCT00790465|Other|2|placebo comparator: 7 grams of placebo-chocolate at day 1 during manometry, and than crossover to treatment with dark chocolate for 2 weeks.
3190717|NCT00790491|Experimental|Lifestyle counseling|
3190718|NCT00790504||1 study group|Women with multiple gestations recruited from the prenatal care or high risk pregnancy units
3190719|NCT00790504||2 control group|Women with singleton gestation recruited from the prenatal care or high risk pregnancy units
2455449|NCT03203798|Active Comparator|Training of pelvic floor muscles|
2455450|NCT03203798|Experimental|Hipopressive abdominal gymnastics|
3190720|NCT00790517|Experimental|1|Premier Lifestyle Intervention with Dash Diet, adapted for populations with mental illnesses
3190721|NCT00790517|No Intervention|2|Usual care
2455613|NCT03202745|No Intervention|Control|The control arm will not receive any communications as a result of this study.
2455614|NCT03202745|Experimental|Patient Consequences|The patient consequences arm prescribers receive an initial patient consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for patients.
2455615|NCT03202745|Experimental|Prescriber Consequences|The prescriber consequences arm prescribers receive an initial prescriber consequences letter followed by 2 followup letters at approximately 3 month intervals. The letters focus on the consequences of inappropriate prescribing for prescribers.
2455656|NCT03202355|Experimental|Group 1 (Control)|Subjects assigned to this group receive fixed appliance orthodontic treatment only
2455661|NCT03202355|Experimental|Group 2 (OP1)|Subjects assigned to this group receive fixed appliance orthodontic treatment in conjunction with receiving daily OrthoPulse™ treatments.
2455713|NCT03202069|Experimental|Even protein intake|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
2455714|NCT03202069|Experimental|Skewed protein intake|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
2455744|NCT03201757|Experimental|ALKS 3831|Coated bilayer tablet
2455854|NCT03201081|Experimental|training group|The training group, based on motivational strategies were performed and a moderate intensity training (8 to 12 repetitions). The load was increased: during the 12 weeks from 65% 1-RM to 80% 1-RM, performing individual more than the prescribed number of repetitions (12 repetitions). A 1-2 minutes resting period was allowed between sets. There was no attempt to control the velocity of the repetitions performed. Prior to each training session, the volunteers performed a specific warmup, consisting of 10 repetitions with approximately 50% of the load used in the first and second exercises of the training session. A total of 36 sessions were performed during the training period. This group was compared with no interventions subjects.
3190722|NCT00790530|Experimental|ATO-SR|Automated Telephone Outreach with Speech Recognition
3190723|NCT00790530|No Intervention|Usual Care|Usual Care
3190724|NCT00790595|Experimental|Group A|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
3190725|NCT00790595|Experimental|Group B|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
3190726|NCT00790595|Experimental|Group C|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
3190727|NCT00790595|Experimental|Group D|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
3190728|NCT00790595|Experimental|Group E|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
3190729|NCT00790634||Parkinson's Disease|Patients with idiopathic Parkinson's disease
2454768|NCT03208049|Experimental|Sleep Restriction Therapy|Sleep Restriction Therapy (SR). The initial Time in Bed (TIB) prescription is calculated on the average total sleep time (TST) reported in the baseline sleep logs. After one week, depending on subject's daily sleep logs and adherence to treatment, the therapist suggests a new TIB prescription. Napping is neither prescribed nor proscribed. However, if subjects find themselves having difficulty staying awake during the day, they are advised to take a brief (15 to 30 minutes) nap to ensure their safety.
2454771|NCT03208049|Experimental|Cognitive Therapy|Cognitive Therapy (CT). The CT treatment module is designed to meet three general goals: 1) identify dysfunctional sleep cognitions, 2) challenge their validity, and 3) replace them with more adaptive substitutes. Several specific techniques designed to meet these goals are discussed in materials distributed to subjects. Similar to SR, subjects in CT are provided with information about relevant elements of the science of sleep and healthy sleep practices.
2454853|NCT03207893|Experimental|GEM+CGM|GEM lifestyle modification & continuous glucose monitoring
2454857|NCT03207893|Active Comparator|Routine Care|Subject's current t2d treatment
2454914|NCT03207412|Experimental|Minimally invasive implantation|Patients receive minimally invasive implantation, and 200 million hAECs is implanted into bilateral ovarian tissue by Ultrasound-guided puncture.
2454920|NCT03207412|Experimental|Intravenous infusion|100 million hAECs is administered by intravenous infusion every 30 days, for 3 times.
3190730|NCT00790634||Obsessive-compulsive disorder|Individuals with a diagnosis of obsessive-compulsive disorder
3190731|NCT00790634||OCD controls|Healthy controls, matched in age and number to obsessive-compulsive group
2455020|NCT03206580|Experimental|Concentric training|Concentric training
2455025|NCT03206580|Experimental|Concentric-eccentric training|Concentric-eccentric training
2455063|NCT03206346|Experimental|Ingavirin|Broad spectrum antiviral drug
2455064|NCT03206346|Placebo Comparator|Placebo oral capsule|Placebo capsule identical in appearance to Ingavirin capsule
2455180|NCT03205904|Active Comparator|Intervention group|Group that will be receive the diet
2455181|NCT03205904|No Intervention|control|Group that will not receive the diet
2455207|NCT03205215|Experimental|Immediate Treatment|This arm will receive hyperbaric oxygen therapy once consented.
2455219|NCT03205215|Experimental|Waitlist - to be treated|This arm will receive a hyperbaric oxygen therapy after waiting two months.
2455294|NCT03205007|Experimental|Health promotion nutrition program|Health promotion nutrition program
2455370|NCT03204565|Experimental|CAF + HA (Test)|coronally advanced flap with hyaluronic acid
2455373|NCT03204565|Active Comparator|CAF (control)|coronally advanced flap alone
2455457|NCT03203538|Experimental|Light intensity, 1000 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 1000 lux (4000 Kelvin) administered through standard room lighting.
2455458|NCT03203538|Active Comparator|Light intensity, 100 lux (4000 K)|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 100 lux (4000 Kelvin) administered through standard room lighting.
2455459|NCT03203538|Experimental|Colour temperature, 7000 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 7000 K (200 lux) administered through standard room lighting.
2455460|NCT03203538|Active Comparator|Colour temperature, 2500 Kelvin|Participants will work three consecutive simulated night shifts under full-spectrum LED-light, 2500 K (200 lux) administered through standard room lighting.
2455461|NCT03203538|Experimental|Blue light, 455 nm|Participants work one night shift with blue LED-light (peak wavelength 455 nm) administered through standard room lighting.
2455462|NCT03203538|Active Comparator|Red light, 615 nm|Participants work one night shift with red LED-light (peak wavelength 615 nm) administered through standard room lighting.
2455560|NCT03202849|Experimental|Vitamin D and A Supplementation|Participants receive a single dose of vitamin D and a single dose of vitamin A prior to HSCT.
2455570|NCT03202849|Active Comparator|Vitamin D Supplementation with Placebo|Participants receive a single dose of vitamin D and a single dose of placebo prior to HSCT.
2455616|NCT03202576|No Intervention|Nasogastric tube standard securement|Standard securement of nasogastric tube with adhesive tape
2455618|NCT03202576|Experimental|Nasogastric Tube Nasal Bridle Securement|Securement of NG with AMT Micro Bridle
2455677|NCT03202342|Experimental|Water/gluc/gluc+EB/EB/gluc+EB_cold|First Water 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
2455678|NCT03202342|Experimental|Water/gluc+EB/gluc/gluc+EB_cold/EB|First Water 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C and then Ethyl butyrate 22 C
2455679|NCT03202342|Experimental|Gluc/water/EB/gluc+EB/glucose+EB_cold|First Glucose 22 C, then Water 22 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C and then Glucose + Ethyl butyrate 0 C
2455680|NCT03202342|Experimental|Gluc/EB/water/gluc+EB_cold/gluc+EB|First Glucose 22 C, then Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C and then Glucose + Ethyl butyrate 22 C
2455681|NCT03202342|Experimental|EB/Gluc/gluc+EB_cold/water/glucose+EB|First Ethyl butyrate 22 C, then Glucose 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C and then Glucose + Ethyl butyrate 22 C
2455682|NCT03202342|Experimental|EB/gluc+EB_cold/gluc/glucose+EB/water|First Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C, then Glucose + Ethyl butyrate 22 C and then Water 22 C
2455993|NCT03200041|Other|Low Risk|350 Low risk The only intervention is a 20 ml blood sample will be taken from each participant.
3190732|NCT00790634||PD controls|Healthy controls, matched in age and number to Parkinson's disease group
3190733|NCT00790660|Experimental|ASP1941 Lowest Dose|Oral
2455051|NCT03206541||Controls|"There are two age-matched control groups:~Household controls that have lived with the case for at least three months before the onset of neurological symptoms.~Controls with a febrile syndrome of unknown etiology that do not present neurological involvement and is recruited in the same center as the case."
2455065|NCT03206164|Experimental|Asynchronous, eLearning Intervention|Participants in the asynchronous, eLearning Intervention Group will participate in the on-demand HealthMatters Program Instructor Training Course that will be continuously and readily available.
2455067|NCT03206164|Active Comparator|Synchronous, Live Webinar Comparison|Participants in the synchronous, Live Webinar Comparison Group will receive HealthMatters Program Instructor Training Course via a live instructor taught 3-part live webinar.
2455113|NCT03206060|Experimental|1/Lu-177-DOTATATE|Lu-177-DOTATATE is administered IV every 8 (+/- 2) weeks, for a total of 4 administrations. A Ga-68-DOTATATE PET and F-18-FDG-PET, as well as CT/ MRI for RECIST monitoring, will be obtained post 2 administrations and post 4 administrations. Concomitant administration of an IV infusion of an amino acid (AA solution will also be done for renal protection. Concomitant administration of an IV infusion of an amino acid (AA) solution will also be done for renal protection.
2455131|NCT03205709|Active Comparator|Training Group 1|Computerized Cognitive Training
2455132|NCT03205709|Placebo Comparator|Training Group 2|Crossword puzzles
3190734|NCT00790660|Experimental|ASP1941 Low Dose|Oral
3190735|NCT00790660|Experimental|ASP1941 Medium Dose|Oral
2455248|NCT03205098||Runners|To assess the evolution of biological markers of mesenteric ischemia during ultratrail.
2455310|NCT03204799||normal group|normal group (without diabetes diagnosis/treatment and in normoglycemia
2455313|NCT03204799||prediabetes|high risk, impaired fasting glucose, impaired glucose tolerance
2455315|NCT03204799||drug naive type 2 diabetes|type 2 diabetes, anti-hypoglycemic drug naive
2455317|NCT03204799||type 2 diabetes with metformin monotherapy|type 2 diabetes with metformin monotherapy
2455318|NCT03204799||type 2 diabetes with SGLT2 inhibitor monotherapy|type 2 diabetes with SGLT2 inhibitor monotherapy
2455320|NCT03204799||dyslipidemia with ezetimibe therapy|dyslipidemia with ezetimibe therapy
2455358|NCT03204344|Experimental|Intervention group|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking."
2455363|NCT03204344|Sham Comparator|Control group|"For all patients, routine fasting (drinking water allowed) begins from 22:00 on the day before surgery， water fasting begins from 6:00 on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided from 6:00. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, magnesium sulfate) are added when becessary."
2455400|NCT03204032|Experimental|Tegafur and Temozolomide|
2455403|NCT03204032|Active Comparator|Tegafur and Temozolomide combined with Thalidomide|
2455483|NCT03203668|Other|Choline PET/CT|Choline PET/CT imaging added to conventional imaging assessment in hyperparathyroidism (parathyroid scintigraphy, ultrasound, CT or MRI if indicated)
2455507|NCT03203239|Experimental|Red Light treatment|This is a single arm design. All subjects will be enrolled to have peripheral blood flow measured before, during, and after red light exposure.
2455594|NCT03203057||control group|10 individuals get randomised to control group.
2455599|NCT03203057||short ischemic time|10 individuals get randomised to a controlled coronary occlusion for 30 seconds
2455604|NCT03203057||intermediate ischemic time|10 individuals get randomised to a controlled coronary occlusion for 60 seconds
2455608|NCT03203057||long ischemic time|10 individuals get randomised to a controlled coronary occlusion for 90 seconds
2455657|NCT03202420|Experimental|TOPS|Participants will attend weekly TOPS meetings with standard weekly weigh ins
3190736|NCT00790660|Experimental|ASP1941 High Dose|Oral
3190737|NCT00790660|Placebo Comparator|Placebo|Oral
2455768|NCT03201653|Active Comparator|Conventional|Stump closure as our institute routine, using interrupted silk mattress suture and continuous prolene sutures.
2455773|NCT03201653|Experimental|Surgicel|Stump closure modified from our institute routine, using interrupted silk mattress suture and continuous prolene sutures with NU-KNIT SURGICEL overlying for reinforcement.
2455914|NCT03200990|Experimental|iVAC2L pVAD|Clinically indicated ventricular support for high-risk PCI with Pulsecath iVAC2L.
2455952|NCT03200548|Experimental|Relaxing acupressure plus usual care|"There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily.The True Acupressure points were chosen based on a TCM theory for treating insomnia."
2455954|NCT03200548|Experimental|Stimulating acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. Acupoints were chosen by consensus of 4 acupressure practitioners and based on a previous study design in students with sleep disturbances as well as TCM theory for treating insomnia and fatigue.
2455995|NCT03200041|Other|High Risk|150 High Risk going onto invasive diagnostic procedure. The only intervention is a 20 ml blood sample will be taken from each participant.
3190738|NCT00790686|Experimental|1|Memokath 051
3190739|NCT00790725|Other|PAV|Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
3190740|NCT00790725|Other|PS|Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
3190741|NCT00790764|Placebo Comparator|Placebo|20 individuals will receive placebo.
3190742|NCT00790764|Experimental|MESENDO|"Active combination autologous stem cell therapy. 40 individuals will receive MESENDO in either the high or low dose treatment groups."
3190743|NCT00790816|Experimental|Group 1|Study Drug
3190744|NCT00790816|Experimental|Group 2|Study Drug
3154312|NCT00296348|Active Comparator|1|
3154313|NCT00296348|Experimental|2|
3154314|NCT00296361|Active Comparator|1|
2455139|NCT03205579|Experimental|Video group|Video cancer pain education (10 minutes ) the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
2455141|NCT03205579|Active Comparator|Conventional group|Face to face cancer pain education by trained nurse (10 minutes)the knowledge includes cancer pain definition, cancer pain treatment, pain assessment and role of patient in cancer pain management.
2455211|NCT03205436|Experimental|Graft|Affinity human amniotic membrane
2455262|NCT03204994|Experimental|Tumour injection of ICG|Indocyanine green injection into tumour before or during surgery.
3154315|NCT00296361|Experimental|2|
2455532|NCT03203473|Experimental|Initial Primary Treatment|"Therapy with nivolumab IV every 2 weeks~Serial imaging assessments every 8 weeks~After confirmatory scans, patients are assigned to Arm A or Arm B."
2455536|NCT03203473|Experimental|Arm A: Persistent (PR/CR)|"Serial imaging assessments every 8 weeks~Therapy with nivolumab IV every 2 weeks~If scans persistently show PR/CR, nivolumab is discontinued until progression.~Nivolumab is re-initiated, and if there is subsequent progression, ipilimumab is added for x2 doses.~Ipilimumab IV every 3 weeks (only in patients who progress after nivolumab re-initiation)~If progression after nivolumab + ipilimumab, therapy discontinued. If SD/PR/CR, nivolumab is continued until progression."
2455542|NCT03203473|Experimental|Arm B: Persistent (PD/SD)|"Therapy with nivolumab IV every 2 weeks~Ipilimumab IV every 3 weeks~Serial imaging assessments every 8 week~If scans show SD/PR/CR, nivolumab continued until progression. If progression, therapy discontinued."
2455573|NCT03202797||Patients|
2455617|NCT03202602||Telemedicine|Patients randomized to receive telemonitoring in combination with telephone calls after CPAP start.
2455619|NCT03202602||Standard care|Patients randomized to receive usual office visits after CPAP start.
2455701|NCT03202316|Experimental|Cohort I (atezolizumab, cobimetinib, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off for 4 weeks of the safety lead-in course. Patients then receive atezolizumab IV over about 30-60 minutes every 2 weeks, cobimetinib PO daily for 3 weeks on, 1 week off, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-4. Cycles 1-4 repeat every 21 days and subsequent cycles with atezolizumab and cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455703|NCT03202316|Experimental|Cohort II (atezolizumab, eribulin)|Patients receive atezolizumab IV over about 30-60 minutes every 3 weeks for cycles 1-6 and every 4 weeks for subsequent cycles, and eribulin IV over 2-5 minutes on days 1 and 8 of cycles 1-6. Cycles 1-6 repeat every 21 days and subsequent cycles with atezolizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455751|NCT03201692|Active Comparator|Treadmill Training|40' treadmill training walking holding the handrail
2455752|NCT03201692|Experimental|Virtual Reality Treadmill Training|40' treadmill training walking with virtual visual and auditory cues
2455867|NCT03201146|Experimental|Apatinib 750mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
2455873|NCT03201146|Experimental|Apatinib 500mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy.
2455876|NCT03201146|Experimental|Apatinib 250mg + AP or AC|Phase 1 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
2455882|NCT03201146|Experimental|Apatinib|Phase 2 study of Apatinib in combination with platinum-based doublet chemotherapy(PBDC).
2455887|NCT03201146|Active Comparator|AP or AC|Pemetrexed/Cisplatin(AP) or Pemetrexed/Carboplatin(AC), The platinum-based doublet chemotherapy, as the control group in the phase 2 study.
2455920|NCT03200652|Experimental|metabolic availability of lysine in wheat|"Participants will be seen initially for pre-study assessment (2 hour). They will then be studied at 8 levels of lysine intake.~Subjects will visit SickKid's Clinical Research Center a total of 9 times, with each visit being at least one week before the next. All 9 visits must be made within 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a baked wheat bread with or without lentils, which will all be provided by the investigators."
2456015|NCT03200483|Experimental|Control Protocol|The volunteer will perform the exercise and recovery exposed to silence
2456018|NCT03200483|Experimental|Classical Music Protocol|The volunteer will perform the exercise and recovery exposed to classical music
2456020|NCT03200483|Experimental|Rock Music Protocol|The volunteer will perform the exercise and recovery exposed to rock musical style
2456092|NCT03199768||Single-bed rooms|Patients are admitted to single-bed rooms at the newly built hospital in the period 20th of March to the 1th of September 2017
2456095|NCT03199768||Multi-bed rooms|Patients are admitted at multi-bed rooms with one to two fellow patients at the old hospital in the period 15th of September 2016 to the 19th of March 2017
2456166|NCT03199313|Active Comparator|Cohort 2 - Active|N = 6, 600mg sutezolid or matching placebo
2456170|NCT03199313|Placebo Comparator|Cohort 2 - Placebo|N = 2, 600mg sutezolid or matching placebo
3154316|NCT00296413||1|Valproate monotherapy
3154317|NCT00296413||2|Valproate monotherapy with combined oral contraceptive
3154318|NCT00296413||3|Lamotrigine monotherapy
3154319|NCT00296413||4|Lamotrigine monotherapy with combined oral contraceptive
3154320|NCT00296426|No Intervention|Usual Care|control patients admitted to hospital floors received usual care
3154321|NCT00296426|Experimental|Intervention|computerized medication reconciliation tool and process redesign involving physicians, nurses, and pharmacists
3154322|NCT00296465|Experimental|Lutrepulse® 5mcg IV|5.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
2455130|NCT03206008|Active Comparator|Magnesium group|after loading magnesium sulfate dosing 50 mg/kg (100cc) in 10-20 minutes, continuous infusion of magnesium sulfate 15 mg/kg/h until the end of surgery
2455166|NCT03205696||Cases|36 youth with new diagnosis of acute/recent HIV as defined by laboratory assays Fiebig1-V with standard care of antiretrovirals (ARV) regimen provided by the clinician
2455169|NCT03205696||Controls|36 youth with newly diagnosed HIV but established HIV infection (Fiebig VI) with standard care of antiretrovirals (ARV) regimen provided by the clinician
2455200|NCT03205254|Active Comparator|Group A|Participants randomized to group A follow the 4-day Mediterranean diet and then the 4-day fast food diet with a 4-day washout period in between.
2455213|NCT03205254|Active Comparator|Group B|Participants randomized to group B follow the 4-day fast food diet and then the 4-day Mediterranean diet with a 4-day washout period in between.
3190745|NCT00790829|Experimental|A, B|Group B received a seven-milligram transdermal patch and Group A received a placebo patch.
3190746|NCT00790881|Other|Antiretroviral-naive|Antiretroviral-naive included as control group
3190747|NCT00790881|Active Comparator|Nevirapine-based antiretroviral therapy|Nevirapine-based antiretroviral therapy
2455406|NCT03203902|Active Comparator|Psychoeducation and Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute therapeutic touch will be administered."
2455411|NCT03203902|Placebo Comparator|Psychoeducation and Sham Therapeutic Touch|"6-week psychoeducation group. The following 1-hour modules will be delivered:~Week 1: Anger Management and Conflict Negotiation Week 2: Meditation and Breathing Techniques Week 3: Nutrition Week 4: Exercise, Leisure, and Recreation Week 5: Sleep Week 6: Wellness Recovery Action Plan (WRAP)~Directly after the psychoeducation group is completed, 30-minute sham therapeutic touch will be administered."
2455414|NCT03203902|No Intervention|Control|No intervention
2455489|NCT03203720|No Intervention|Standard Care (SC)|Standard Care (SC) in a specialty mood disorders clinic for youth with mood disorders.
2455490|NCT03203720|Experimental|SC + Brief Motivational Intervention|Standard Care (SC) in a specialty mood disorders clinic plus a Brief Motivational Intervention (BMI) targeting medication adherence.
2455524|NCT03203213|Experimental|Interventional arm|"Sampling of a few additional drops of blood and sending this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient~Oriented hair removal is also carried out if possible (small wick cut and not torn the size of a pencil mine of paper taken at the level of the occipital region). This technique has been used many times, and evaluates the previous consumption (memory consumption)~A urine sample is taken if possible."
2455579|NCT03203005|Experimental|IMA970A plus CV8102 and Cyclophosphamide|Investigational treatment with IMA970A, CV8102, Cyclophosphamide
2455663|NCT03202498|Experimental|Cohort 1 (4g Yaq-001)|Standard medical treatment + Yaq-001 (4 g/ day)
2455666|NCT03202498|Placebo Comparator|Cohort 1 (4g Placebo)|Standard medical treatment + placebo-control (placebo for 4 g of Yaq-001/ day)
2455667|NCT03202498|Experimental|Cohort 2 (8g Yaq-001)|Standard medical treatment + Yaq-001 (8 g/ day)
2455668|NCT03202498|Placebo Comparator|Cohort 2 (8g Placebo)|Standard medical treatment + placebo-control (placebo for 8 g of Yaq-001/ day)
2455721|NCT03201939|Active Comparator|Active Medication (Intervention arm)|ACE-inhibitor lisinopril
2455722|NCT03201939|Placebo Comparator|Placebo comparator (Control arm)|Matched placebo
2455830|NCT03201328|Active Comparator|healthy subjects|
2455834|NCT03201328|Experimental|patients with unilateral cochlear implants|
2455837|NCT03201328|Experimental|patients with bilateral cochlear implants|
2455915|NCT03200873|Active Comparator|high impulsivity|participants with high impulsivity (BIS >62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
2455916|NCT03200873|Active Comparator|low impulsivity|participants with low impulsivity (BIS between 52 to 62), receiving active and sham repetitive transcranial magnetic stimulation [intermittent theta burst stimulation (iTBS)] in a randomised order
3190748|NCT00790894|Active Comparator|1|
3190749|NCT00790894|Experimental|2|
3190750|NCT00790920|Experimental|Desmoteplase|
3190751|NCT00790920|Placebo Comparator|Placebo|
2456030|NCT03200015|Experimental|Metformin arm|Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)
2456076|NCT03199703|Active Comparator|Baylis transseptal system group|Patients randomized to the Baylis transseptal system group (Bayliss Group) will undergo transseptal puncture with a large, preformed curve 71-cm-C1 or 98-cm-C1 18-gauge NRG needle (Baylis Medical) through a TorFlex sheath (Baylis Medical), with the sheath curve selected at the discretion of the operating physician.
2456080|NCT03199703|Active Comparator|Conventional transseptal group|Patients randomized to the conventional transseptal group (Standard Group) will undergo transseptal puncture with either a large, preformed curve 71- or 98-cm 18-gauge BRK needle (BRK, BRK-1, BRK-2 needle, St. Jude Medical) through any non-Baylis sheath (for example Schwartz SL, Biosense-Webster Preface) selected at the discretion of the operating physician.
2456113|NCT03199365|Experimental|Prevention (TSSC intervention)|Participants undergo two TSSC intervention sessions delivered at participants' homes by trained CHWs over 1.5 hours.
3190752|NCT00790946|Active Comparator|Valsartan|Valsartan 80 to 160mg
3190753|NCT00790946|No Intervention|standard therapy|
3190754|NCT00790959|Experimental|SASA!|
3190755|NCT00790959|Active Comparator|Control|
3190756|NCT00790972|Placebo Comparator|2|Identical-appearing placebo
3190757|NCT00790972|Active Comparator|1|two sprays in each nostril three times daily for one week
3190758|NCT00790985|Experimental|flavocoxid 500 mg|flavonoid mixture
2455136|NCT03205800|Active Comparator|Mini-screw placement|One mini-screw (8 mm length) will be placed at the buccal plate of the extraction socket one week after the atraumatic extraction of maxillary first or second premolars in one side.
2455138|NCT03205800|No Intervention|No treatment|The other extraction socket site will be untreated.
2455183|NCT03205527|Experimental|Slip training for chronic stroke|Chronic stroke subjects in this training group will receive bilateral overground, slip perturbation training.
2455187|NCT03205527|No Intervention|Control for chronic stroke|Chronic stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
2455189|NCT03205527|Experimental|Slip training for sub-acute stroke|Sub-acute stroke survivors in this training group will receive bilateral overground, slip perturbation training.
2455190|NCT03205527|No Intervention|Control for sub-acute stroke|Sub-acute stroke subjects, after baseline walking trials, will walk for about 30 trials at their preferred walking pace to match the total trials the other groups receive before receiving a single slip each randomly on their non-paretic and paretic sides.
3154323|NCT00296465|Experimental|Lutrepulse® 10 mcg IV|10.0 mcg Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3190759|NCT00790985|Active Comparator|naproxen|nonsteroidal anti-inflammatory drug
3190760|NCT00790998|Experimental|Moxidectin|Moxidectin 8mg
3190761|NCT00790998|Active Comparator|Ivermectin|Ivermectin 150 mcg/kg
2455266|NCT03204812|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
2455362|NCT03204617|Experimental|DDDMM + CCM|DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20. At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24.
2455366|NCT03204617|Placebo Comparator|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since fifth placebo administration, administration of 0.9% sterile normal saline solution at weeks 0, 12 and 24.
2455424|NCT03203954|Active Comparator|No Training|Guided learning, standard learning: Repeat administration of standard behavioral learning task
2455429|NCT03203954|Experimental|Instructed Statistics|Guided learning, instructed statistics: Repeat administration of behavioral learning task with instructions about task statistics
2455434|NCT03203954|Experimental|Not Instructed Statistics|Guided learning, changing statistics: Repeat administration of behavioral learning task with changing task statistics
2455455|NCT03203577|Active Comparator|Hospital initiation|Initiation of mechanical ventilation in hospital initiation of Home Mechanical ventilation takes place in a hospital; this makes this arm the standard care.
2455456|NCT03203577|Experimental|Home initiation|Initiation of mechanical ventilation at home Initiation of mechanical ventilation in a patient's home setting with telemonitoring
2455498|NCT03203304|Experimental|Nivolumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, patients will receive treatment with nivolumab 240 mg will be initiated within 14 days. Patients will receive nivolumab infusions once every 2 weeks. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression is allowed as per irRC evaluation."
2455500|NCT03203304|Experimental|Nivolumab and ipilimumab|"Patients will be randomly placed in either of the two arms. All patients will undergo CT simulation and stereotactic body radiotherapy (SBRT). SBRT treatment will be completed within a 21-day window.~After the final fraction of SBRT, treatment with nivolumab and ipilimumab will be initiated within 14 days. Patients will be restaged after every 4 doses of nivolumab (every 8 weeks). Treatment beyond progression will be allowed as per irRC evaluation. Patients will receive nivolumab infusions once every 2 weeks and ipilimumab infusions once every 6 weeks."
2455642|NCT03202719|Active Comparator|IPV at ages 14 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age
2455643|NCT03202719|Active Comparator|IPV at ages 14 weeks, 18 weeks and 18 months|Participants in this arm will receive bivalent oral poliovirus vaccine (bOPV) at 6, 10 and 14 weeks of age and inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age
2455644|NCT03202719|Active Comparator|IPV at ages 14 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age
2455645|NCT03202719|Active Comparator|IPV at ages 6 weeks and 9 months|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age
2455648|NCT03202719|Active Comparator|IPV at ages 6 and 14 weeks|Participants in this arm will inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age
2455728|NCT03202043|Experimental|High dose vegetable juice|Subject will consume high dose vegetable juice daily for 8 weeks.
2455730|NCT03202043|Experimental|Medium dose vegetable juice|Subject will consume medium dose vegetable juice daily for 8 weeks.
2455732|NCT03202043|Experimental|Low dose vegetable juice|Subject will consume low dose vegetable juice daily for 8 weeks.
2455733|NCT03202043|Other|Control bottled water|Subject will consume control bottled water daily for 8 weeks.
2455815|NCT03201601|Experimental|550 mg of MYO and 150 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 150 mg of D-chiro-inositol.
2455818|NCT03201601|Active Comparator|550 mg of MYO and 13.8 mg of DCI|Volunteers will take twice at day for 12 weeks a capsule containing 550 mg of myo-inositol and 13.8 mg of D-chiro-inositol.
3190762|NCT00791011|Experimental|Cohort 4|AMG 655 (intermediate dose) with Vorinostat
3190763|NCT00791011|Experimental|Cohort 1|AMG 655 (low dose) with Bortezomib
2456042|NCT03200002|Experimental|Cyclophosphamide|Participants in this arm received intravenous cyclophosphamide (CYC) in the dose of 0.5 to 1 gram per m2 of body surface area.
2456044|NCT03200002|Experimental|mycophenolate mofetil|Patients in this arm received mycophenolate mofetil in the tablet form.
2455156|NCT03205683|Experimental|Intraneural facilitation therapy|The intraneural facilitation intervention is a novel manual physical therapy approach with anecdotal evidence in neuropathic pain symptoms through biasing blood flow from an artery through the nutrient vessels into the epineurium of an accompanying nerve. The main concept of intraneural facilitation is the use of two manual holds. The first hold is called facilitation hold and includes putting the contralateral joint in a maximal loose-pack position that is comfortable to the patient. The hypothesis with this initial hold is the nerve will have greater excursion the accompanying artery and the nutrient vessels that are clustered at the joint will be stretched. This stretch may enlarge the opening at the junction of the artery and bridging nutrient vessel, therefore consistently creating a vascular bias into the neural epineurial capillaries. Theoretically, this creates increased epifascicular vascular pressure which may be absent due to epineurial ischemia.
2455158|NCT03205683|Sham Comparator|Sham therapy|"Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm Each visit will last about 45 minutes, twice a week for 6 weeks (total 12 sessions).~Missing > 4 sessions will invalidate subject outcomes."
2455217|NCT03205410|Experimental|Patients with RIPC|intervention: remote ischemic preconditioning - three cycles of 5-min ischemia, achieved by inflation of blood-pressure cuff to 200 mmHg, followed by 5-min reperfusion while the cuff was deflated were applied to the upper left arm.
2455224|NCT03205410|Sham Comparator|Patients without RIPC|intervention: no - remote ischemic preconditioning - in controls, the cuff was placed around the arm but not inflated.
2455270|NCT03204929|Experimental|Cu(II)ATSM|Cu(II)ATSM dosed once daily
2455395|NCT03204136||tarcolimus|refractory inflammatory bowel disease patents who used tarcolimus to induce and maintain remission
2455396|NCT03204136||methotrexate|refractory inflammatory bowel disease patents who used methotrexate to induce and maintain remission
2455443|NCT03203824|Experimental|dark chocolate|Three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute. Measurements 2 and 3 will be recorded savoring dark chocolate and after fully ingesting the dark chocolate respectively.
2455445|NCT03203824|Active Comparator|non dark chocolate|three EEG measurements will be recorded: 1) at baseline, 2) during visualization of rest for one minute, and 3) during visualization of usual vigorous exercise for one minute.
2455484|NCT03203525|Experimental|Arm A (FOLFOX6, bevacizumab, NovoTTF-100L[P])|Participants receive oxaliplatin, leucovorin, and fluorouracil via pump over 46 hours on beginning on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455486|NCT03203525|Experimental|Arm B(bevacizumab,liposomal doxorubicin, DAT, NovoTTF-100L[P])|Participants receive bevacizumab IV over 90 minutes on days 1 and 15, pegylated liposomal doxorubicin hydrochloride IV over 30 minutes-3 hours on days 1 and 15, and temsirolimus IV over 60-90 minutes on days 1, 8, 15, and 22. Participants also use NovoTTF-100L(P) system over 18 hours daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455601|NCT03202771|Experimental|Home Biofeedback Therapy|Patients will use home biofeedback device to practice their maneuvers taught by the nurse.
2455606|NCT03202771|Active Comparator|Office Biofeedback Therapy|Patients will get regular office biofeedback therapy with an anal probe inserted while a nurse runs through the exercise session together.
2455653|NCT03202433|Experimental|Virtual Reality Distractor|The objective is to apply a technique, using virtual reality lenses, with relaxing audio-visual contents of no more than ten minutes, to reduce stress before and during the blood donation process and to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle
2455659|NCT03202433|No Intervention|Traditional Blood Donation Process|The objective is to respond to the level of pain perceived during donation, either post-puncture and withdrawal of the needle, without virtual reality support
2455720|NCT03202108|Experimental|Consumption of Krio|Incorporation of Krio into the daily diet.
2455772|NCT03201679||Patients with preoperative sepsis|Sepsis defined as SIRS plus a positive culture from any site.
2455774|NCT03201679||Patients without preoperative sepsis|
2455835|NCT03201341|Other|Behavioral protocol|To better understand the normal functioning of the brain within the framework of the representation of the body and of the space of action. During the experiment, physiological measurements will be recorded: electrical activity at the surface of the muscles (electromyography - EMG), scalp (electroencephalography - EEG) or skin (electrodermal response). Similarly, the movements of the arm will be recorded using an infrared kinematic system requiring simply the placement of markers at strategic points such as the tip of the thumb and forefinger, the wrist, the elbow ... Movements of the eyes can also be recorded, either with the aid of an electrooculograph (EOG) or with the aid of an infrared tracking device. Electrotactile stimulations of very low intensity and painless can also be administered.
2455838|NCT03201341|Other|Study in fMRI|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the brain areas critical for these functions and to determine their functional roles. The examination will consist of several very short scans at the very beginning and then a scan of about ten minutes intended to take a detailed anatomical image of the brain. Then, the subject will carry out the experimental task during one or more scan (s) whose cumulative duration will not exceed 45 minutes. The task accomplished is explained in detail by the experimenter.
2455840|NCT03201341|Other|Study in MEG|To better understand the normal functioning of the brain in the representation of the body and the space of action, to identify the critical brain areas for these functions and to determine their functional roles and to study how They interact.The complete examination includes a magnetoencephalography (MEG) experiment followed by an MRI examination. The task accomplished is explained in detail by the experimenter.
2456173|NCT03199313|Active Comparator|Cohort 3 - Active|N = 6, 1200 mg sutezolid or matching placebo
2455220|NCT03205124|Experimental|Pre and Post-operative stimulation|Patients randomized to this group will receive 1 hour of continuous electrical stimulation three days prior to scheduled surgical date and then again immediately post operatively. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit. As the nerve becomes accustomed to the sensation of the stimulation, the voltage is increased to the next tolerable threshold and this is repeated throughout the one-hour period. Patients randomized to this group will also receive 1 hour of continuous electrical stimulation post-operatively. These patients will have fine gauge wires for post-operative stimulation implanted at the time of surgery. In the post-operative recovery room the stimulator is attached to their wires. The frequency will be fixed at 20Hz and the voltage and duration of electrical pulses will be sequentially increased to the maximum tolerable limit for one hour.
2455288|NCT03204877|Active Comparator|Melatonin|Four capsules of Melatonin 10 mg is administered orally every hours for four hours during the study day.
2455301|NCT03204877|Placebo Comparator|Placebo|Four capsules of placebo is administered orally every hours for four hours during the study day.
2455380|NCT03204513|Experimental|Vanderbilt Powered Knee-Ankle Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Vanderbilt Powered Knee-Ankle (PKA) Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
2455381|NCT03204513|Active Comparator|Microprocessor (MP) Knee Prosthesis|"Upon screening and enrollment participants return for up to 8 prosthetic fitting sessions and up to 12 physical therapy training sessions using their own Microprocessor (MP) Knee Prosthesis. Once training is complete participants will return for up to 6 post-training assessment sessions using the Microprocessor (MP) Knee Prosthesis. The device participants begin with will be randomly selected but there will be an equal opportunity to train with both devices. In between training, there will be an 8 week wash out period to allow normalization to use of the device, reducing carryover effects. After wash-out period protocol will be repeated with second device."
2455491|NCT03203733|Experimental|'Cooral™'|oral cooling with use of cooling device
2455492|NCT03203733|Active Comparator|cryotherapy|Cryoterapy consists of ice cubes or crossed ice and used as standard treatment for oral cooling.
2455523|NCT03203200|Experimental|health literacy and technology skill building|ZETRA cognitive behavioral and structural
2455526|NCT03203200|No Intervention|Standard Counselling|Standard of care prevention counselling
2455587|NCT03202992|Experimental|Dose 1 -Single Ascending Dose (SAD)|SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study
2455589|NCT03202992|Experimental|Dose 2 -Single Ascending Dose (SAD)|SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study
2455591|NCT03202992|Experimental|Dose 3 -Single Ascending Dose(SAD)|SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study
2455593|NCT03202992|Experimental|Dose 4 -Single Ascending Dose(SAD)|SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study
2455597|NCT03202992|Experimental|Dose 5 -Single Ascending Dose(SAD)|SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study
2455602|NCT03202992|Experimental|Dose 1 - Multiple Ascending Dose(MAD)|MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2455605|NCT03202992|Experimental|Dose 2 -Multiple Ascending Dose(MAD)|MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2455609|NCT03202992|Experimental|Dose 3 -Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2455610|NCT03202992|Experimental|Multiple Ascending Dose (MAD) Cohort Expansion|MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2455611|NCT03202992|Experimental|Dose 4-Multiple Ascending Dose(MAD)|MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29
2455697|NCT03202394|Active Comparator|Active intervention|Patients will be randomized in a 1:1 ratio to either aerosolized BIO-11006 (125mg in 3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or placebo.
2455700|NCT03202394|Placebo Comparator|Placebo intervention|Patients will be randomized in a 1:1 ratio to either aerosolized placebo (3mL half normal saline) intervention twice daily plus ventilation for up to 28 days or active drug.
2455764|NCT03201796|Experimental|Group 1|Prulifloxacin 600 mg
2455766|NCT03201796|Active Comparator|Group 2|Levofloxacin 500 mg
2455819|NCT03201250|Experimental|Treatment|"Combination of cabozantinib, carfilzomib and dexamethasone~Cabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.~Carfilzomib: carfilzomib will be administered intravenously over 10 minutes, on two consecutive days, each week for three weeks (Days 1, 2, 8, 9, 15, and 16), followed by a 12-day rest period (Days 17 to 28). Each 28-day period is considered one treatment cycle.~Dexamethasone: dexamethasone will be administered at 40 mg orally or intravenously on days 1, 8,15 and 22 of each 28-day cycle (for patient age ≥ 75, acceptable to be given as 20 mg orally or intravenously on days 1, 2, 8, 9, 15, 16, 22, 23)"
2455890|NCT03200938|Experimental|PBS CIMMO|Intervention: PBS CIMMO cement
2455892|NCT03200938|Active Comparator|Zinc oxide|Intervention: Formocresol and zinc oxide
2455930|NCT03200678|Experimental|ACLR Group|experimental: ACL surgery Intervention: isokinetic assessment
2455933|NCT03200678|Other|Control group|other Intervention: isokinetic assessment
3154324|NCT00296465|Experimental|Lutrepulse® 20 mcg SC|20.0 mcg Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
2456176|NCT03199313|Placebo Comparator|Cohort 3 - Placebo|N = 2, 1200 mg sutezolid or matching placebo
3154325|NCT00296465|Placebo Comparator|Placebo IV|Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3190764|NCT00791011|Experimental|Cohort 2|AMG 655 (low dose) with vorinostat
3190765|NCT00791011|Experimental|Cohort 5|AMG 655 (high dose) with Bortezomib
2455341|NCT03204266|Experimental|Immunonutrition: ARS + Omega-3 Fatty Acids|"Participants take 1 ounce (30mls) of Arginine recovery supplement (ARS) four times daily 5 days preoperatively and 14 days postoperatively.~Participants also given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively."
2455345|NCT03204266|No Intervention|No Immunonutrition|Participants receive regular enhanced recovery after surgery (ERAS)/Optimized Surgical Journey (OSJ) education and follow up.
2455407|NCT03204149|Experimental|Treatment group|"The treatment group will be treated with the MC-8XL laser device, emitting 808 nm laser beam with a green laser beam.~Intervention: MC-8XL low level laser device and Standard wound care"
2455410|NCT03204149|Sham Comparator|Control group|"The control group will receive treatment with a sham laser device, emitting a low power green light with inactive Infrared (IR) laser for indication only.~Intervention: Sham laser device and Standard wound care"
2455478|NCT03203746|Experimental|Group I: Lycopene + SRP|Lycopene, 0.1 ml injected once in the periodontal pocket after scaling and root planing
2455479|NCT03203746|Active Comparator|Group II: SRP only|Scaling and root planing only without lycopene
2455481|NCT03203746|No Intervention|Group III: healthy subjects|No intervention
2455567|NCT03203135|Experimental|Intervention Group|
2455577|NCT03203135|No Intervention|Control Group|
2455632|NCT03202641|Experimental|PEEP_titration|"There is no randomization in this interventional, crossover, physiological study. All participants will receive the same procedures in the same order. The investigators will compare two PEEPs (PEEPARDSnet vs. PEEPLRM).~Interventions:~PEEP ARDSnet: we will select the PEEP based on low PEEP/high FiO2 table (ARDSnet).~PEEP LRM: we will perform a lung recruitment maneuver (LRM) and select PEEP based on transpulmonary pressure."
2455715|NCT03202030|Experimental|IDR|Immediate dentoalveolar restoration conducted with bone removed from the tuber
2455716|NCT03202030|Active Comparator|Bio-oss|Bovine demineralized bone (Bio-oss Collagen) applied on the buccal resorption of the immediate implant
2455742|NCT03201731||Cases|Those diagnosed with a non-organic, non-affective psychotic disorder for the first time after age 60, recruited from a Community Mental Health Team.
2455745|NCT03201731||Controls|Those aged 60 and above in contact with the same Community Mental Health Team for another mental health problem aside from a psychotic disorder or dementia.
2455756|NCT03201575|Experimental|Remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient. The remote ischemic conditioning consists in alternative inflations and deflations of the brachial cuff.
2455759|NCT03201575|Other|Control group|A brachial cuff is positioned around the arm of the patient. No inflation or deflation is made.
2455860|NCT03201159|Experimental|VLX103 150mg|In the first group, 150 mg dosing cohort, one VLX103 tablet will be administered daily for 14 days.
2455865|NCT03201159|Experimental|VLX103 300mg|In the second group, 300 mg dosing cohort, two VLX103 tablets will be administered daily for 14 days.
2455872|NCT03201159|Experimental|VLX103 450mg|In the third group, 450 mg dosing cohort, three VLX103 tablets will be administered daily for 14 days.
2455924|NCT03200769|No Intervention|Group I|AHI/h < 15
2455925|NCT03200769|Experimental|Group IIa|15 < AHI/h < 30. Randomization group. Intervention : CPAP active
2455927|NCT03200769|Experimental|Group IIb|15 < AHI/h < 30. Randomization group. Intervention : CPAP placebo during the first 3 months. After this period, the patient will have the possibility to continue with an active CPAP.
2455931|NCT03200769|Active Comparator|Group III|AHI/h > 30. Intervention : CPAP active
3190766|NCT00791011|Experimental|Cohort 6|AMG 655 (high dose) with Vorinostat
3190767|NCT00791011|Experimental|Cohort 7|Part 2 - Mantle Cell Lymphoma subjects only: AMG 655 at dose TBD with Bortezomib
3190768|NCT00791011|Experimental|Cohort 3|AMG 655 (intermediate dose) with Bortezomib
2456187|NCT03199235|Experimental|LIF + Citrus|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the lucky iron fish and citrus along with instructions for use. Followed at regular intervals.
2456191|NCT03199235|Active Comparator|enhanced standard of care|Parents of subjects > 1 year and < 5 years with anemia (Hemoglobin < 11.0 g/dL) are provided the oral iron supplementation consistent with standard of care, and then followed at regular intervals in addition to any care determined to be necessary by regular provider.
2456334|NCT03198897||Observation|Patients with a Homozygous familial Hypercholesterolemia or high-grade suspicion for Homozygous familial Hypercholesterolemia
2456377|NCT03198130|Experimental|REGN2810|REGN2810 administered IV over a 30 minute infusion
2456410|NCT03197779|Experimental|BMS-962212 Two Hour Administration|Intravenous administered over 2 hours of BMS-962212
2456413|NCT03197779|Experimental|BMS-962212 5 Day Administration|Intravenous administered over 5 days of BMS-962212
2456414|NCT03197779|Experimental|BMS-962212 and Aspirin|BMS-962212 intravenous administration, followed by aspirin oral administration, then combination administration of BMS-962212 and aspirin
2456417|NCT03197779|Placebo Comparator|Placebo and Aspirin|Placebo intravenous administration, followed by aspirin, then combination administration of placebo and aspirin
2456420|NCT03197779|Placebo Comparator|Placebo|Placebo intravenous administration
2456451|NCT03197545||Stress fracture group|110 recruits diagnosed (clinicaly and/or by imaging) with at least one stress fracture, during basic and advanced infantry trainig.
2456452|NCT03197545||Traumatic fracture group|110 infantry recruits with medical history of having at least one traumatic fracture, during their life (from birth up to date).
2456453|NCT03197545||Control group|220 healthy infantry recruits never diagnosed with stress fracture or traumatic fractures
3190769|NCT00791024|Experimental|single arm|
3190770|NCT00791050|Experimental|1 Thermo|
3190771|NCT00791050|No Intervention|2 Control|
3190772|NCT00791063|Experimental|18F ML-10|Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
3190773|NCT00791115|Experimental|prostatectomy after radiotherapy|
3190774|NCT00791141|Experimental|Cetuximab|Cetuximab in combination with radiotherapy, cisplatin and 5-FU. After chemoradiotherapy all patients receive a cetuximab maintenance therapy.
2455291|NCT03204760|Experimental|dexamethasone|Dexamethasone is a long-acting glucocorticoid with a half-life of 36 to 72 hours . It has been used safely in children with croup and bacterial meningitis . It is well absorbed both orally and parenterally .Single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg).
2455303|NCT03204760|Experimental|prednisolone|Prednisolone is relatively short acting with a half-life of 12 to 36 hours, thereby requiring daily dosing. Outpatient steroid therapy is effective once compliance is assured.. Prolonged treatment course, vomiting, and a bitter taste may reduce patient compliance with prednisolone. Oral prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses .
2455361|NCT03204500|Experimental|Active treatment with dual therapy|This group is composed by 20 ALS subjects under 600mg valproate and 600 mg of litium carbonate per day, during 21 months. The tablets are given orally with meals.
2455367|NCT03204500|Placebo Comparator|placebos|This group is composed by 20 ALS subjects under placebo. Blue tablets ( placebo of VPA) and white tablets (placebo of Li) are administered under the same conditions.
2455399|NCT03204006|Active Comparator|Dexmedetomidine group|35 patients will receive dexmedetomidine 0.5 µg/kg was administered intravenously using a syringe pump over 10 min sterile saline pre-induction of anesthesia.
2455401|NCT03204006|Placebo Comparator|Control group|35 patients will receive sterile saline 0.5 µg/kg was administered intravenously using a syringe pump over 10 min pre-induction of anesthesia.
2455468|NCT03203772|Experimental|Limb neuropathic conditions|Includes phantom limb pain, complex regional pain syndrome
2455527|NCT03203369|Experimental|Part 1: Dose Escalation|A single intravenous administration of UCART123. Dose escalation in Part 1 will include 3 doses ranging from 6.25 x 10^5 cells/kg to 6.25 x 10^6 cells/kg and continue until the Recommended Phase 2 Dose (RP2D) is identified.
2455530|NCT03203369|Experimental|Part 2: Dose Expansion|A single intravenous administration of UCART123 at the RP2D. 2 Cohorts: Patients with Relapsed/Refractory BPDCN and Newly Diagnosed BPDCN.
2455556|NCT03202979|Experimental|Group 1|Trazodone 20 mg
2455559|NCT03202979|Experimental|Group 2|Trazodone 10 mg
2455569|NCT03202979|Placebo Comparator|Group 3|Placebo
2455672|NCT03202381|Experimental|Degarelix|
2455757|NCT03202017|Active Comparator|Expiratory Muscle Strength Testing (EMST)|EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
2455761|NCT03202017|Active Comparator|EMST + Lung Volume Recruitment (LVR)|"EMST is a treatment method that has been used to improve cough function and swallowing in ALS. EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough."
2455803|NCT03201432|Other|Bare metal stent (BES) group|Percutaneous vertebral artery stenting using bare metal stents (Boston Scientific：Express SD) in patients randomized to BES group
2455804|NCT03201432|Experimental|Drug eluting stent (DES) group|Percutaneous vertebral artery stenting using drug eluting stents (Liaoning Biomedical Materials R&D Center Co., Ltd. ：YINYI) in patients randomized to DES group
2455879|NCT03201107|Experimental|Pilates group|This group receives physical training based on pilates exercises
2455885|NCT03201107|No Intervention|No intervention group|This group does not receive any treatment
2455936|NCT03200795|Experimental|Rebound exercise group|Participants randomized to this group will be instructed on the proper techniques of the desired movements (hopping) on the rebounder.
2455937|NCT03200795|Experimental|Circuit training group|The circuit training for the participants in this group will be designed for each participant. Training will take place 3 times a week for 8 weeks. The participants will undergo 10 minutes warm up before and 10 minutes cool down after the training. Resistance exercises will be performed on weight machines. Throughout the resistance training program, participants will be alternating between the bench press, seated row, lateral pull down, biceps forward, front thigh, back thigh, leg press and rowing.
2455970|NCT03200327|Active Comparator|laparoscopic promontofixation|
2455971|NCT03200327|Experimental|Anterior vaginal sacrospinofixation|
2455994|NCT03200093|Experimental|Oral vancomycin|"Oral vancomycin solution 125 mg in 2.5 mL, combined with 2.5 ml Ora-Sweet solution, to total 5 mL.~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, oral vancomycin will be taken for the duration of the systemic antibiotics plus seven days."
2455996|NCT03200093|Placebo Comparator|Placebo arm|"Ora-Sweet 5 mL~Taken by mouth once daily for:~If the total duration of systemic antibiotics is less than or equal to 14 days, placebo will be taken for the duration of the systemic antibiotics plus three days.~If the total duration of systemic antibiotics is greater than 14 days, placebo will be taken for the duration of the systemic antibiotics plus seven days."
3190775|NCT00791154|Active Comparator|ARM B|Blinded AMG 102 study drug and carboplatin or cisplatin and etoposide
3190776|NCT00791154|Placebo Comparator|ARM C|Blinded placebo and carboplatin or cisplatin and etoposide
2456185|NCT03199222|Experimental|Arm 1: Smart socket technology w/patient prompting|The prosthetic user WILL receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). Investigators will have access to the Smart Socket Technology database.
2456190|NCT03199222|No Intervention|Arm 2: Clinical protocol. No patient prompting|The prosthetic user WILL NOT receive prompting by the smart socket technology regarding improper fit and suggestions for how to a restore a proper fit (i.e socks). However, investigators will have access to the Smart Socket Technology database.
3190777|NCT00791154|Active Comparator|ARM A|Blinded AMG 479 study drug and carboplatin or cisplatin and etoposide
3190778|NCT00791206|Experimental|1|
3190779|NCT00791206|Other|2|
3190780|NCT00791245||1|DeNovo NT
2455295|NCT03204864|Active Comparator|Conventional CS lead placement|Patients will be implanted with a CRT device with or without defibrillator (P/D) as per standard clinical practice, without CS lead pacing specific optimization.
2455305|NCT03204864|Experimental|RLD Group|Patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
2455374|NCT03204435|Other|Traditional therapy|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented by stages.
2455376|NCT03204435|Experimental|Hybrid operation|Consists of microsurgical aneurysmal operating techniques, endovascular techniques for intracranial aneurysms, endovascular techniques for cerebrovascular stenosis, and carotid endarterectomy, which are presented in one-stage in hybrid operating theater.
2455431|NCT03203915|Experimental|Group 1|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo"
2455435|NCT03203915|Experimental|Group 2|"Order of treatments:~A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose"
2455436|NCT03203915|Experimental|Group 3|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose"
2455438|NCT03203915|Experimental|Group 4|"Order of treatments:~B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo"
2455440|NCT03203915|Experimental|Group 5|"Order of treatments:~C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose"
2455442|NCT03203915|Experimental|Group 6|"Order of treatments:~C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose"
2455521|NCT03203395|Experimental|Heart patients|Screening and counselling
2455578|NCT03203044|No Intervention|Regular Diet Arm|Maintains a regular diet for the duration of the study.
2455584|NCT03203044|Experimental|Soylent Diet Arm|Receives a Soylent dietary intervention on days 3-6 of the study.
2455636|NCT03202693|Experimental|PA-824|[14C]-PA-824 and unlabelled PA-824 oral suspension of 1000 mg unlabeled micronized PA-824 mixed with sufficient [14C]-PA-824 to achieve a final radiolabel dose of approximately 100 µCi/dose.
2455674|NCT03202277|Experimental|BeWell24 smartphone app|Smartphone app, linked with commercial activity monitor, to support lifestyle changes in physical activity, sleep, sedentary behavior, and dietary intake.
2455675|NCT03202277|Active Comparator|Health education smartphone app|Smartphone app with basic health education content, designed to control for non-specific treatment effects and match for smartphone app novelty.
2455754|NCT03201991|Other|Exercise Program|Participants will be asked to take part in an exercise program that is focused on quadriceps strengthening.
2455805|NCT03201471|Experimental|treatment group|In this group, the patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1; CTX 750mg/m2, ivgtt,d2; EPI 70mg/m2, ivgtt,d2; VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2, PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18; one cycle every 21 days； abbreviation： CTX： cyclophosphamide；EPI：etoposide；VCR： vincristine；Pred：prednisone； R-CHOP：the chemo-therapy regimen composed of Rituximab, cyclophosphoamide; etoposide, vincristine and prednisone.
2455880|NCT03201055|Experimental|Non Apnoeic Snorers|Patient's use the Snore Positive airway pressure device for 28 nights.
2455917|NCT03200847|Experimental|Pembrolizumab with All-Trans Retinoic Acid|Patients will receive pembrolizumab infusions every three weeks. Patients will also receive 3 days of all-trans retinoic acid treatment surrounding each of the first 4 infusions of pembrolizumab, beginning one day prior to the infusion (a total of 12 days of all-trans retinoic acid).
2455988|NCT03200522|Active Comparator|Prudent diet then Western diet|Participants randomized to this arm will received 6 days of meals consistent with a Prudent diet, followed by a washout period, and then 6 days of meals consistent with a Western diet.
2455989|NCT03200522|Active Comparator|Western diet then Prudent diet|Participants randomized to this arm will received 6 days of meals consistent with a Western diet, followed by a washout period, and then 6 days of meals consistent with a Prudent diet.
2456008|NCT03200028|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 30 treatment sessions, up to 5 sessions per week, 30 minutes per session.
2456089|NCT03199846||advanced melanoma patients|Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma
2456091|NCT03199846||Ipi monotherapy|Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.
2456093|NCT03199846||Ipi + nivo combination therapy|Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
2456096|NCT03199846||Dabrafenib + trametinib combination therapy|Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.
2456100|NCT03199846||Pembro monotherapy|Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016
2456102|NCT03199846||Nivo monotherapy|Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016
2456151|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 1 - Active|N = 2, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
2456154|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 1 - Placebo|N = 1, Initial dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours before the rest of Cohort 1 Group 2
2456158|NCT03199313|Active Comparator|Cohort 1 Sentinel Group 2 - Active|N = 4, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
2456161|NCT03199313|Placebo Comparator|Cohort 1 Sentinel Group 2 - Placebo|N = 1, Secondary dosing of Cohort 1 with 300 mg sutezolid or matching placebo, dosed 24 hours after the rest of Cohort 1 Group 1
2455309|NCT03204708|Active Comparator|catheter group|patients were placed a catheter under clavipectoral fascia and 30 ml of local anesthetic solution were given via catheter for postoperative analgesia
2455378|NCT03204448||Relevant Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
2455379|NCT03204448||Control Disease Samples|Samples are tested on BioCLIA Ro60 instrument with Ro60 assay reagents, also as comparison, tested on BioFLASH instrument with QUANTA Flash Ro60 reagents
2455446|NCT03203811|Experimental|Low Dose|2mg, HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2455447|NCT03203811|Experimental|Middle Dose|3.75mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2455448|NCT03203811|Experimental|High Dose|5mg HTI-2088 oral tablet or placebo, one dose, evaluate over 4 days
2455493|NCT03203434||Esophageal anastomotic leakage|
2455494|NCT03203434||Esophageal uncomplicated controls|
2455495|NCT03203434||Pancreatic anastomotic leakage|
2455496|NCT03203434||Pancreatic uncomplicated controls|
2455623|NCT03202654|Experimental|Corn Oil Intervention|Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
2455628|NCT03202654|Active Comparator|Coconut Oil Intervention|Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
3190781|NCT00791271|Experimental|Decitabine + Peginterferon Alfa-2b|Decitabine starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle. Peginterferon Alfa-2b starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
2455800|NCT03201705|Experimental|Refractory neuropathic leg and low back pain|Patients with refractory neuropathic leg and low back pain as result of FBSS will be enrolled in the study and receive electrocatheter implant. Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
2455813|NCT03201185|Experimental|Ramipril|After transcatheter aortic valve implantation, patients will receive ramipril before discharge plus conventional treatment (in patients without ACEI).
2455814|NCT03201185|No Intervention|No intervention|Conventional treatment after transcatheter aortic valve implantation
2456002|NCT03200353|Experimental|Active|Each patient included receive the experimental device system NATROX during 3 to 4 weeks
2456050|NCT03199924|Active Comparator|Intravenous Magnesium sulfate combined to Diclofenac|Intravenous Magnesium sulfate combined to Diclofenac
2456051|NCT03199924|Active Comparator|intravenous lidocaine combined to diclofenac|intravenous lidocaine combined to diclofenac
2456057|NCT03199924|Active Comparator|diclofenac alone|diclofenac alone
2456128|NCT03199443||Overactive bladder patients|
2456129|NCT03199443||Non Obstructive Urinary Retention patients|
2456196|NCT03199131|Experimental|CTEPH|Patients undergoing pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH).
2456198|NCT03199131|Other|Control group|Patients undergoing adult cardiac surgery without evidence of pulmonary hypertension.
2456243|NCT03198858|Other|Ablation with Carto® 3 System|Ablation with Carto® 3 System
2456246|NCT03198858|Other|Ablation CartoUnivu™|Ablation CartoUnivu™
2456292|NCT03198494|Experimental|Acoustic 1Hz Stimulation|1 Hz acoustic stimulation applied via headphones and downloadable phone application during sleep every night.
2456294|NCT03198494|Sham Comparator|Sham Background Noise|Background noise applied via headphones and downloadable phone application during sleep every night.
2456299|NCT03198494|No Intervention|Baseline Seizure Monitoring|No use of sound system; Patients record seizures in a diary.
2456359|NCT03198312|Experimental|CathiportTM|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
2456360|NCT03198312|Active Comparator|Implant Port|be used for all kinds of high concentrations of chemotherapeutic drugs, completely parenteral nutrient solution infusion, blood transfusion and blood samples.
2456492|NCT03197740|Active Comparator|aricept Tab 5mg|
2456495|NCT03197740|Experimental|donepezil patch 25cm2|
2456496|NCT03197740|Active Comparator|aricept Tab 10mg|
2456499|NCT03197740|Experimental|donepezil patch 50cm2|
2456565|NCT03196947|Experimental|Single arm, APO010 Dose escalation|
2456598|NCT03196609|Experimental|Cohorte|"This cohort will consist of patients as described below:~15 patients with non-small cell lung cancer (NSCLC)~10 patients with hepatocellular cancer:~10 patients with colorectal cancer~10 patients with breast cancer~10 patients with prostate cancer~10 patients with glioblastoma"
2455405|NCT03203889|Experimental|CRAFT-AI|Behavioral intervention: CRAFT-AI will include a maximum of 12 CSO individual counseling sessions will be provided. A functional analysis of the IP's substance use helps to identify triggers and both positive and negative consequences of use. The CSO brainstorms and decides upon ways to sever the connection between triggers and substance use, in part by introducing alternative non-substance related positive activities. In addition, the CSO and counselor collaboratively determine how to safely allow the IP to experience negative consequences due to the substance use, thereby making it less appealing for the IP to continue to use. The CSO also brainstorms and role-plays implementing the most effective and appropriate ways to suggest that the IP enter treatment.
2455408|NCT03203889|Active Comparator|12-step facilitation for loved ones|12-step facilitation for loved ones or concerned significant others (TSF-CSO) intervention is delivered in 12 individual counseling sessions. There are 8 core components to this intervention that guide a CSO to understand that the identified person (IP) has a disease. The CSO is asked to surrender to a higher power because he or she is powerless to control the IP's substance use, and to lovingly detach from the IP. The CSO works to decrease enabling behaviors. Counselors will help the CSO to work the program of Nar/Al-Anon.
2455501|NCT03203590|Active Comparator|Oral Navelbine + Carboplatin|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with Navelbine + Carboplatin.
2455503|NCT03203590|Experimental|Gefitinib|Neoadjuvant therapy Patients with EGFR mutation will be recruited and treated with gefitinib.
2455571|NCT03203018|Experimental|Women participating in HL intervention|Groups of women from disadvantaged communities will participate in a three session health literacy workshop
2455743|NCT03201926|Experimental|mealworms|mealworms
2455747|NCT03201926|Placebo Comparator|grain powder|grain powder
2455771|NCT03201510||Observational|Observational study
2455828|NCT03201354|Active Comparator|Filtration surgery with Express|Filtration surgery with Ex-PRESS + cataract extraction (Cataract surgery and IOL implantation)
2455832|NCT03201354|Active Comparator|Non penetrating surgery|- Filtration surgery with Non penetrating deep sclerectomy + cataract extraction (Cataract surgery and IOL implantation)
2455921|NCT03200899|Experimental|Memory, Attention, Problem Solving Skills in MS (MAPSS-MS)|Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
2455922|NCT03200899|Active Comparator|Usual Care plus Computer games|Participants randomized to this arm receive usual care and are referred to MY BRAIN GAMES web site.
2455977|NCT03200470||Suspected PJI|
2455998|NCT03200171||Group I|HCC patients who received DAAs for chronic HCV previously (either responders or not)
2456000|NCT03200171||Group II|HCC patients who are naive to DAAs.
3154326|NCT00296465|Placebo Comparator|Placebo SC|Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks and oral placebo clomiphene citrate for 5 days
3173162|NCT00609037||2|Normal controls include individuals who schecule to have an abdominoplasty and are within normal for height and weight
2456186|NCT03199248||the participant accepted needle assisted capsulotomy for DMC|
2456189|NCT03199248||the participant accepted aspiration for DMC only|
2456241|NCT03198910||Pulmonary arterial hypertension|
2456247|NCT03198910||Chronic thromboembolic pulmonary hypertension|
2456317|NCT03198572|Experimental|Berberine|Berberine was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
2456322|NCT03198572|Placebo Comparator|Placebo|Placebo was taken orally 0.5g three times per day for 48 weeks, based on lifestyle intervention.
2456416|NCT03197818|Experimental|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose (BDP/FF/GB) (Beclometasone dipropionate / Formoterol Fumarate / glycoppyronium Bromide)
2456418|NCT03197818|Active Comparator|Symbicort Turbuhaler 160/4.5 µg|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (160µg + 4.5 µg expresses the delivered dose; 200 µg + 6 µg expresses the metered dose) ( BUD/FF) (Budesonide/Formoterol Fumarate)
2456482|NCT03197285|Active Comparator|Control Group|All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
2456486|NCT03197285|Experimental|Experimental Group|"All patients are given a Combined Physiotherapy Protocol (CPP) consisting of: Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful). The ECRP developed by Revel et al.(Revel et al., 1994) was also applied to patients in the experimental group.~EYE-CERVICAL RE-EDUCATION PROGRAM (ECRP) This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area"
2456584|NCT03197064|Other|Fosaprepitant|Patients included in this study will be administered fosaprepitant 150 mg IV.
2456585|NCT03197051||Q1|Measure the Concentration of Syndecan-1, Heparan sulfate before anesthetic induction and immediately after weaning from cardiopulmonary bypass. Categorize the patients by serum syndecan-1 concentration(off-CPB) quartile. Q1 means a group of lowest 25% of serum syndecan-1 concentration.
2455512|NCT03203551|Experimental|CT0.5%; 0.5% Chloramine T|"Disinfection protocol:~brushing the palate (3 times a day/ 2 minutes);~brushing the total prostheses with neutral liquid soap (3 times a day/ 3 minutes);~immersing the total prostheses in 0.5% Choramine T (once a day/ 20 minutes) before the last brushing of the day;~the prostheses must be conditioned in a vessel with water during the whole night period.~Periods of analysis (Baseline, 7 and 37 days):~the prostheses will be evidenced and photographed.~the biofilm present on the inner surface of the prostheses will be collected;~photographe of the participants' palate;~collected the palate biofilm."
2455595|NCT03203083||physically active individuals|subjects who perform sports activities more than 6 hours per week
2455600|NCT03203083||non-physically active individuals|subjects who perform less than 2 hours per week of sport activities
2455626|NCT03202485|Active Comparator|Toric Implantable Collamer Lens|Subjects in this group will implant Toric Implantable Collamer Lens for high myopic astigmatism
2455633|NCT03202485|Experimental|ICL+ Astigmatic keratotomy|Subjects in this group will implant Implantable Collamer Lens and combined with astigmatic keratotomy for high myopic astigmatism
2455670|NCT03202290|Other|Gambling disorder|patients suffering from gambling disorder
2455671|NCT03202290|Other|Controls|healthy controls
2455706|NCT03202004|Experimental|GSK2894512 1% cream group|Subjects will apply a thin layer of GSK2894512 1% (10 milligrams per gram [mg/g]) topical cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
2455707|NCT03202004|Placebo Comparator|Vehicle cream group|Subjects will apply a thin layer of vehicle cream once daily to all psoriasis lesions for 12 weeks. The study staff will instruct subjects on proper topical application of cream.
2455724|NCT03201783|Other|immediate group|the intervention: immediate frozen-thawed embryo transfer (FET) which means FET will be performed in the first cycle following the stimulated IVF cycle
2455725|NCT03201783|Other|delayed group|the intervention: delayed frozen-thawed embryo transfer (FET) which means FET will be performed at least in the second cycle following the stimulated IVF cycle
2455769|NCT03201627|Experimental|treatment|
2455881|NCT03201367|Active Comparator|study group|"acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis~- treated with rivaroxaban"
2455884|NCT03201367|Placebo Comparator|control group|acute non-neoplastic PVT, compensated cirrhosis, acute PVT onset within 1 week after initial diagnosis receive placebo
2455910|NCT03200782|Placebo Comparator|Placebo-Placebo|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
2455912|NCT03200782|Active Comparator|Investigational Drug A Empagliflozin|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an 10mg of empagliflozin 2 hours before the test meal will be administered by an independent nurse to the blinded patient
2455913|NCT03200782|Active Comparator|Investigational Drug B Anakinra|subcutaneous injection of 100mg anakinra 3 hours before the test meal and an oral placebo (winthrop tablet)before the test meal will be administered by an Independent nurse to the blinded patient
2455965|NCT03200574|Other|Aortic Valve|LivaNova bioprosthetic aortic heart valve replacement
2456001|NCT03200145||Control|The control group is made by persons living in nursing homes under usual care
2456063|NCT03199937|Experimental|Flexible Futures|Flexible Futures uses cognitive behavioral therapy (CBT) techniques to target flexibility and planning by teaching core skills through personal goals chosen by students during treatment. Flexible Futures focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, how thoughts and feelings affect planning and flexibility, self-advocacy skills necessary to promote independence, application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities. Guided practice begins with concrete interventionist support, and moves to interventionist cueing, self-cueing, and finally automatic use of the skills without support. Generalization is maximized with school staff as interventionists, parent training, home and classroom extension activities, and role-playing use of strategies in novel situations. Motivation is developed using student choice and natural motivators.
2456066|NCT03199937|Active Comparator|Waitlist control group|Current standard of care
2456159|NCT03199534|Experimental|Botulinum toxin A 50u|Botulinum toxin A 50 unit injection
2456164|NCT03199534|Experimental|Botulinum toxin A 100u|Botulinum toxin A 100 unit injection
2456169|NCT03199534|Experimental|Botulinum toxin A 150u|Botulinum toxin A 150 unit injection
2456269|NCT03198923|Experimental|natural killer and natural killer T cell|The eligible patients are infused with ten doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
2456319|NCT03198429|Experimental|Embedded fathering intervention|"This condition focuses on workers' practice with fathers who have been identified as perpetrators in cases of child exposure to domestic violence. Workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the need to engage fathers as part of intervention in cases of child exposure to DV~access to a practice leader and consultant to respond to question and concerns about working with father perpetrators of DV~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases being assigned to ongoing service workers will be flagged by intake at the time they are opened to ongoing services as being a potentially appropriate referral to the Caring Dads program~clients who are then referred to CD as part of clinical service will be given access to this program at the earliest possible opportunity."
2456336|NCT03198949|Experimental|everolimus first arm|All subjects will receive everolimus during Core phase I and placebo during Core phase II.
2456337|NCT03198949|Placebo Comparator|placebo first arm|All subjects will receive placebo during Core phase I and everolimus during Core phase II.
2456384|NCT03198091|Experimental|Dun Ye Guan Xin Ning mono-therapy|
2456388|NCT03198104||Autoimmune Hepatitis Group (AIH)|Paediatric patients who have been diagnosed with autoimmune hepatitis and are about to initiate pharmacological treatment (15-30 pts.) will be scanned using MRI and fibroscan, then proceed through the standard care pathway to receive repeated blood tests and liver biopsies throughout treatment. MRI and fibroscan will be repeated before each liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to MRI data to determine it's accuracy in monitoring liver disease.
2455558|NCT03202966|Experimental|Intervention|For each child with a developmental delay enrolled in the early intervention program, individualized rehabilitation therapy will be provided by a rehabilitation professional with a focus on the one or more domains where delays were identified (i.e. speech, motor, cognition). The intervention will be delivered either as home based rehabilitation or as centre based care. Each child will receive a minimum of one therapy session per week by the CRW and a monthly therapist visit for home based care. In center based care daily therapy will be available by either a CRW or specialist.
2455669|NCT03202706||Patients|
2455708|NCT03202056|Experimental|Dry needling|Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
2455710|NCT03202056|Sham Comparator|Sham Dry needling|Sham Dry needling technique in each active myofascial trigger point once per week for 3 weeks.
2455712|NCT03202056|No Intervention|Control|Control group. No intervention.
2455767|NCT03201770|Experimental|Pyramax|Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)
2455820|NCT03201302|Experimental|School physical education class|Children who participated only in their school physical activity classes only for the entire school year.
2455823|NCT03201302|Experimental|Taekwondo|Children who participated in organized Taekwondo training for the entire school year.
2455824|NCT03201302|Experimental|Martial arts|Children who participated in organized Martial arts training for the entire school year.
2455827|NCT03201302|Experimental|Climbing|Children who participated in organized climbing training for the entire school year.
2455829|NCT03201302|Experimental|Volleyball|Children who participated in organized volleyball training for the entire school year.
2455833|NCT03201302|Experimental|Artistic gymnastics|Children who participated in organized artistic gymnastics training for the entire school year.
2455836|NCT03201302|Experimental|Swimming|Children who participated in organized swimming training for the entire school year.
2455839|NCT03201302|Experimental|Dance|Children who participated in organized dance training for the entire school year.
2455841|NCT03201302|Experimental|Basketball|Children who participated in organized basketball training for the entire school year.
2455842|NCT03201302|Experimental|Wrestling|Children who participated in organized wrestling training for the entire school year.
2455844|NCT03201302|Experimental|Football (soccer)|Children who participated in organized football (soccer) training for the entire school year.
2455846|NCT03201302|Experimental|Rhythmic gymnastics|Children who participated in organized rhythmic gymnastics training for the entire school year.
2455848|NCT03201302|Experimental|Track and field|Children who participated in organized track and field training for the entire school year.
2455851|NCT03201302|Experimental|Tennis|Children who participated in organized tennis training for the entire school year.
2455853|NCT03201302|Experimental|Combination of activities 1|Children who participated in two different weight-bearing activities for the entire school year.
2455857|NCT03201302|Experimental|Combination of activities 2|Children who participated in one weight-bearing and in one non weight-bearing activity for the entire school year.
2455946|NCT03200626||Cytokine alone or JIT plerixafor based mobilization|
2455947|NCT03200626||Routine plerixafor based mobilization|
2455948|NCT03200626||Chemomobilization|
3154327|NCT00296465|Active Comparator|Clomiphene Citrate/Placebo IV|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered intravenously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
3190782|NCT00791297|Active Comparator|1|Contraceptive Vaginal Ring delivering a daily dose of 1500 μg of CDB-2914
2456105|NCT03199586|Experimental|NP-G2-044|capsule
2456132|NCT03199300||Anthracylines-treated with toxicity|Patients with toxicity during/after treatment with anthracylines.
2456135|NCT03199300||Anthracyclines-treated without toxicity|Patients without toxicity during/after treatment with anthracylines.
2456139|NCT03199300||Trastuzumab-treated with toxicity|Patients with toxicity during/after treatment with trastuzumab.
2456146|NCT03199300||Trastuzumab-treated without toxicity|Patients without toxicity during/after treatment with trastuzumab.
2456153|NCT03199300||Cisplatin-treated with toxicity|Patients with toxicity during/after treatment with cisplatin.
2456157|NCT03199300||Cisplatin-treated without toxicity|Patients without toxicity during/after treatment with cisplatin.
2456162|NCT03199300||Bleomycin-treated with toxicity|Patients with toxicity during/after treatment with bleomycin.
2456165|NCT03199300||Bleomycin-treated without toxicity|Patients without toxicity during/after treatment with bleomycin.
2456230|NCT03198936|Experimental|Cognizin® SynapsaTM|Dose - 2 capsules twice a day with meals
2456231|NCT03198936|Placebo Comparator|Placebo|Matching placebo capsules with microcrystalline cellulose with added colours Dose - 2 capsules twice a day with meals
2456265|NCT03198663|Experimental|POSSE Intervention|
2456268|NCT03198663|Other|Control|Delayed intervention
2456313|NCT03198442|Experimental|Breast PET|PET imaging of breast with patient in prone position.
2456421|NCT03198234|Experimental|Cohort 1|Participants will receive 1 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2456422|NCT03198234|Experimental|Cohort 2|Participants will receive 3 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2456423|NCT03198234|Experimental|Cohort 3|Participants will receive 9 X 10^6/kg (± 10%) T-allo10 cells infused intravenously on Day -1 (day before transplant)
2456509|NCT03197311|Experimental|Mobile app group|In addition to receiving standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions a customized mobile app will be downloaded to the participant's smartphone to application to monitor postoperative analgesic consumption, disposal and pain control and patient satisfaction for one week after surgery.
2456511|NCT03197311|No Intervention|Control group|The control group will receive the standard of care which includes prescription of postoperative narcotic and NSAID analgesics and usual postoperative instructions and a case report form will be used to gather data from the medical record and from a post op telephone survey a week after surgery..
2456672|NCT03196310|Experimental|PRP|Intra-articular injection of platelet rich plasma.
2455561|NCT03202927|Experimental|TPI-120 (PEGFILGRASTIM)|One daily dose of TPI-120 (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
2455568|NCT03202927|Active Comparator|Neulasta (PEGFILGRASTIM)|One daily dose of Neulasta (PEGFILGRASTIM) 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 1) of Cycle 1 followed by one daily dose of 6 mg/0.6 ml administered subcutaneously on Day 1 (Study Day 22) of Cycle 2 with a gap of 21 days between two cycles
2455690|NCT03202368|Experimental|Tocilizumab: GCA Flare or Persistent Disease Activity|Participants who were treated with tocilizumab in Study WA28119 and experienced a new GCA flare within 3 years after completion of Study WA28119 or had persistent active GCA at the time of completion of Study WA28119, will receive SC tocilizumab in this study.
2455738|NCT03201887|Experimental|Sub-optimal Traumatic Brain Injury|Sub-optimal effort
2455739|NCT03201887|Experimental|Sub-optimal effort Chronic pain|Sub-optimal effort
2455740|NCT03201887|No Intervention|Traumatic Brain Injury|optimal effort
2455741|NCT03201887|No Intervention|Chronic pain|optimal effort
2455786|NCT03201536|Active Comparator|sutures|zipLine3 device verses conventional sutures
2455789|NCT03201536|Active Comparator|Zip3 Device|
2455826|NCT03201237|Experimental|30 min AOT|
2455831|NCT03201237|Placebo Comparator|60 min AOT|
2455918|NCT03200951|Experimental|Bolus group|
2455919|NCT03200951|Active Comparator|Infusion group|
2455978|NCT03200496|Experimental|TALION®|
2455979|NCT03200496|Experimental|DA-5206(Fasting)|
2455980|NCT03200496|Experimental|DA-5206(Fed)|
2456021|NCT03200080|Placebo Comparator|Treatment A|Placebo oral tablet and Placebo oral capsule
2456022|NCT03200080|Experimental|Treatment B|Tozadenant 120 mg
2456023|NCT03200080|Experimental|Treatment C|Tozadenant 240 mg
2456024|NCT03200080|Experimental|Treatment D|Tozadenant 480 mg
2456025|NCT03200080|Active Comparator|Treatment E|d-amphetamine 20 mg
2456027|NCT03200080|Active Comparator|Treatment F|d-amphetamine 40 mg
2456098|NCT03199625|Experimental|Cognitive Therapy group|treatment with Cognitive Therapy
2456101|NCT03199625|Experimental|Behavior Therapy group|treatment with Behavior Therapy
2456104|NCT03199625|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
2456213|NCT03199157|Active Comparator|Fentanyl Group|Patients received the fentanyl 12 mcg transdermal patch (FG, n=38) 8 hours preoperatively and until 24 hours after the surgery
2456217|NCT03199157|No Intervention|Control group|
2456316|NCT03198793|Experimental|QGC001|Capsules of QGC001 250 mg
2456429|NCT03197792|Experimental|Pulmonary endarterectomy patients|All patients
2456455|NCT03197493|Experimental|High Dose|carbidopa-levodopa 25-100 mg 2 tablets TID
2456457|NCT03197493|Experimental|Intermediate Dose|carbidopa-levodopa 25-100 mg 1 tablet TID
2456475|NCT03197298||Clopidogrel Period|ACS patients treated by PCI with newer-generation DES before the guideline suggested change in primary DAPT-regimen
2456477|NCT03197298||Ticagrelor Period|ACS patients treated by PCI with newer-generation DES after the guideline suggested change in primary DAPT-regimen
2456553|NCT03196999|Active Comparator|Personalized Attention Bias Training|Personalized version of ABM Training.
2456559|NCT03196999|Placebo Comparator|Neutral Attention Training Condition|Non-active version of ABM training.
2456564|NCT03196999|Active Comparator|Non-Personalized Attention Bias Training|Non-personalized version of ABM training.
2456617|NCT03196557|Experimental|Arm A|Specified dose on specified days
2456619|NCT03196557|Placebo Comparator|Arm B|Specified dose on specified days
2456671|NCT03196180|Experimental|Treatment (topical fluorouracil, imiquimod)|Patients receive topical fluorouracil intravaginally via applicator at weeks 1, 3, 5, 7, 9, 11, 13, and 15 and imiquimod intravaginally via applicator at weeks 2, 4, 6, 8, 10, 12, 14, and 16. Patients who are menstruating will delay application until the end of the menstrual cycle.
3173163|NCT00609050|Active Comparator|1|Self-Regulated Exercise with Telephone Reinforcement
2458963|NCT03180463|Placebo Comparator|Group 2|Core decompression surgery.
3173164|NCT00609050|Active Comparator|2|Attention Control
3173165|NCT00609063|Experimental|1|Participants will receive atorvastatin for 6 months.
3173166|NCT00609063|Placebo Comparator|2|Participants will receive matching placebo for 6 months.
3173167|NCT00609089|Experimental|I|Community Reinforcement and Family Training for Retention in Treatment and Recovery and Reduction of HIV Risk Behavior (CRAFT-T)
3173168|NCT00609089|Active Comparator|II|Treatment As Usual
3173169|NCT00609102|Placebo Comparator|Placebo|
3173170|NCT00609102|Active Comparator|antioxidant drug|n-acetylcysteine
3173171|NCT00609115|Experimental|T|The Test Group will have 18 half hour AMES (Assisted Movement with Enhanced Sensation) treatments per qualified subject limb with the AMES device. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
3173172|NCT00609115|Sham Comparator|C-1|Eighteen treatment sessions for each qualifying subject limb using the AMES device programed to provide placebo therapy. Each treatment session consisting of 30 minutes of placebo therapy. Sessions to be scheduled preferably 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
3173173|NCT00609115|Active Comparator|C-2|Crossover treatment of subjects who received placebo treatment during Phase 1 of the study to provide 18 regular (i.e., non-placebo) AMES (Assisted Movement with Enhanced Sensation) treatment sessions. Sessions to be scheduled preferably 2 to 3 times per week with each session one-half hour in length.
3173174|NCT00609141|Experimental|Treatment (monoclonal antibody therapy)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for up to 2 years in the absence of unacceptable toxicity or disease progression.
3173175|NCT00609154|Experimental|Diabetic Group|Participants with Type 2 diabetes
3173176|NCT00609154|Active Comparator|Non-diabetic Group|Participants who are non-diabetic will serve as control. treatment is matched to experimental group
2455572|NCT03203122|Sham Comparator|Comparator Group|Patients are randomized to treatment in either right or left side. The other side works as control
2455620|NCT03202563|Experimental|Gemigliptin 50mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Gemigliptin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
2455624|NCT03202563|Active Comparator|Dapagliflozin 10mg|"the subjects should visit a study site 4 times during the treatment period for about 12 weeks in total.~Drug: Dapagliflozin Drug: Metformin Procedure: Diet/exercise questionnaire Procedure: Continuous Glucose Monitoring System(CGMS)"
2455687|NCT03202186|Placebo Comparator|Placebo|oral administration of Placebo capsule
2455692|NCT03202186|Experimental|Progesterone 200 mg|oral administration of progesterone 200 mg
2455695|NCT03202186|Experimental|Progesterone 300 mg|oral administration of progesterone 300 mg
2455699|NCT03202186|Experimental|Progesterone 400 mg|oral administration of progesterone 400 mg
2455726|NCT03201822|Experimental|100 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 100 cocoa flavanol/70 kg BW
2455727|NCT03201822|Experimental|200 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 200 cocoa flavanol/70 kg BW
2455729|NCT03201822|Experimental|400 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 400 cocoa flavanol/70 kg BW
2455731|NCT03201822|Experimental|1000 mg of Cocoa Flavanols/70 kg BW|Fruit flavored non-dairy drink containing 1000 cocoa flavanol/70 kg BW
2455777|NCT03201614|Experimental|A-CP HA|Patients randomized in this group will be treated with a combination of platelet-rich plasma plus hyaluronic acid prepared with A-CP HA Kit.
2455779|NCT03201614|Active Comparator|ArthroVisc 40|Patients randomized in this group will be treated with hyaluronic acid only (ArthroVisc 40); hyaluronic acid is the same as the one contained in the A-CP HA Kit.
2455781|NCT03201614|Placebo Comparator|Placebo|Patients randomized in this group will be treated with a saline solution.
2455822|NCT03201276||Drug group|patients taking glucosamine
2455944|NCT03200717|Experimental|pazopanib 800 mg|administered after checkpoint inhibitor treatment
2456026|NCT03200236|Experimental|Intensive Telephone Counseling|This arm provides a multi-faceted, 8-session intensive telephone counseling (ITC) protocol, tailored on lung cancer screening results, with 8-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
2456028|NCT03200236|Active Comparator|Usual Care|This arm provides a multi-faceted, 3-session usual care telephone counseling (UC) protocol, with 2-weeks of free nicotine replacement patches provided (Nicoderm patch, 21mg, 14mg, and 7mg) and primary care engagement.
2456073|NCT03199664|Active Comparator|Group A (NB-UVB)|Intervention: patients will be treated with Narrow band ultra violet rays alone for 6 months
2456077|NCT03199664|Active Comparator|Group B ( combined NB-UVB & Tacrolimus)|Intervention: patients will be treated with NB-UVB & Tacrolimus 0.03 % ointment for 6 months
2456143|NCT03199430|Placebo Comparator|Placebo|1450mg Corn flour
2456148|NCT03199430|Active Comparator|Epigallocatechin gallate|1450mg Epigallocatechin gallate
2456209|NCT03199066||All NHL subtypes|no interventions
2456212|NCT03199066||DLBCL|only patients with diffuse large B-cell lymphoma
2456216|NCT03199066||FL|only patients with follicular lymphoma
2456219|NCT03199066||MCL|only patients with mantle cell lymphoma
2456220|NCT03199066||SLL/CLL|only patients with small lymphocytic lymphoma / chronic lymphocytic leukemia
2456223|NCT03199066||MZL|only patients with marginal zone lymphoma
2456226|NCT03199066||other B-cell lymphomas|only patients with B-lymphomas not described above
2456227|NCT03199066||T-cell lymphomas|only patients with all types of T-cell lymphoma
2456338|NCT03198728|Experimental|SOV2012-F1-treated|200 patients treated with SOV2012-F1, starting dose of 600 mg - (400 mg with morning meal and 200 mg with evening meal). Dose titrated up to a maximum of 600 mg TU in the morning and 400 mg in the evening or down to 200 mg TU in the morning based on plasma T at Days 14 and 42.
2456340|NCT03198728|Active Comparator|Andro-Gel treated|100 patients treated with AndroGel, starting dose of 40.5 mg QD. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 42.
3190783|NCT00791297|Active Comparator|2|Contraceptive Vaginal Ring delivering a daily dose of 2500 μg of CDB-2914
3190784|NCT00791310|Experimental|TEP|Performance of of TEP coupled to scanner X
2456512|NCT03197337|Experimental|Control manipulation first|Patients in this group will first undergo the control manipulation while the study manipulation will follow.
2456513|NCT03197337|Experimental|Study manipulation First|Patients in this group will first undergo the study manipulation while the control manipulation will follow.
2456552|NCT03196895|Active Comparator|WR|Weight reduction training
2456554|NCT03196895|Active Comparator|GE|PPG training
2456558|NCT03196895|Experimental|GEM|PPG training + discrete BG feedback
2456563|NCT03196895|Experimental|GEM+CGM|PPG training + continuous BG feedback
3190785|NCT00791362|Other|improvement programme CVD|
3190786|NCT00791362|Other|improvement programme other conditions|
2456691|NCT03196024|Active Comparator|Individual-focused intervention arm|Individual-focused intervention arm: Educational sessions will be provided to the individual members of the family pairs who are at-risk for type 2 diabetes or CVD.
2456948|NCT03194100||Diabetes Mellitus|
3190787|NCT00791375|Experimental|Physical Activity Intervention|Participants in this arm will be given access to a website designed to help them increase their levels of physical activity
3190788|NCT00791375|Placebo Comparator|Cancer Website Control Group|Participants in this arm will be given information on cancer-related websites (that do not provide information on physical activity)
3190789|NCT00791427||AMD Patients|
3190790|NCT00791440|Experimental|1|Up to 26 sessions (over a 30 week period) of weekly, individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
3190791|NCT00791440|Active Comparator|2|30 weeks of standard psychiatric treatment.
3190792|NCT00791453||I|Established patients at the Clarksdale Diabetes and Metabolism Center
3190793|NCT00791466|Experimental|1|
3190794|NCT00791466|Placebo Comparator|2|
2455574|NCT03203070|Experimental|TAP block|The patients will receive intravenous analgesia with Metamizol iv 2g/8h and intraoperative laparoscopic-guided TAP block for control of postoperative pain.
3190795|NCT00791505|Active Comparator|Ciprofloxacin|750 mg a day during 10 days
2455797|NCT03201952|Active Comparator|Ursodeoxycholic Acid/Placebos|During one of the subjects two randomized visits the subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation during visit #1. During visit #2 subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid.
2455799|NCT03201952|Active Comparator|Placebos/Ursodeoxycholic Acid|Subjects will receive a saline solution of totaling 5cc via their ileostomy that has been prepared by investigational drug services (IDS) in order to mimic the preparation of the medication comparator of ursodeoxycholic acid during visit #1. During visit #2 subject will receive a 300mg elixir solution of ursodeoxycholic acid (UDCA) via their ileostomy that has been prepared by investigational drug services (IDS) in a 5cc elixir formulation.
3154328|NCT00296465|Active Comparator|Clomiphene Citrate / Placebo SC|Oral clomiphene citrate (over encapsulated) for 5 days and Placebo Pulsatile GnRH (Lutrepulse®) administered subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
3154329|NCT00296478|Experimental|1|Endometrin 100mg BID
2455940|NCT03200691|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent anti-PD-1 antibody SHR-1210. Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40Gy/20f.~SHR-1210 200mg fixed dose every 2 weeks delivered concurrent with radiation therapy.~After 2-4 weeks of neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
3154330|NCT00296478|Experimental|2|Endometrin 100mg TID
3154331|NCT00296478|Active Comparator|3|Crinone
3154332|NCT00296595|Placebo Comparator|Placebo|Placebo capsules + 500 mL/day of placebo juice
2456117|NCT03199456|Experimental|Zip Surgical Skin Closure Device group|The subjects randomised to this arm will be treated with the Zip device for 10 days (+/-2) days.
2456122|NCT03199456|Active Comparator|Standard of Care sutures group|The subjects randomised to this arm will be treated with standard of care sutures for 10 days (+/- 2 days).
2456199|NCT03199170|Sham Comparator|Intrathecal morphine|Intrathecal morphine 0.2 mg, 0.9%NSS each side
2456200|NCT03199170|Experimental|Intrathecal morphine with bilateral Quadratus Lumborum Block|Intrathecal morphine 0.2 mg, 0.25%Bupivacaine 25 ml each side
2456201|NCT03199170|Experimental|Bilateral Quadratus Lumborum Block|No intrathecal morphine, 0.25%Bupivacaine 25 ml each side
2456314|NCT03198806|Active Comparator|Control group in supine position|"Intervention:~- Only treadmill aerobic exercise with 60 min recovery in supine position"
2456318|NCT03198806|Experimental|Hydration group in supine position|"Interventions:~Treadmill aerobic exercise with 60 min recovery in supine position~Water intake"
2456323|NCT03198806|Active Comparator|Control group in orthostatic position|"Intervention:~- Only treadmill aerobic exercise with 10 min recovery in orthostatic position"
2456326|NCT03198806|Experimental|Hydration group in orthostatic position|"Interventions:~Treadmill aerobic exercise with 10 min recovery in orthostatic position~Water intake"
2456369|NCT03198117|Experimental|Huaier Granule|Huaier Granule
2456372|NCT03198117|Placebo Comparator|placebo|placebo
2456374|NCT03198117|No Intervention|No-treatment Control|patients refused any treatment
2456432|NCT03197623|Experimental|LLP2A-ALENDRONATE|50, 150, 400, 750 or 1200 μg/kg or placebo given as a one time intravenous administration over 120 minutes.
2456435|NCT03197623|Placebo Comparator|Placebo|Placebo given as a one time intravenous administration over 120 minutes.
2456592|NCT03196596||Computer simulation|Patients in whom a computer simulation model will be obtained based on pre procedural CT
2456594|NCT03196596||Prospective compare group|Patients in whom no computer simulation model will be obtained
2456741|NCT03195621|Experimental|Interventional therapy group|
2456743|NCT03195621|No Intervention|Conservative treatment group|
2456788|NCT03195270|Experimental|Single Arm|[18F]FDG PET/MRI
3154333|NCT00296595|Experimental|Cranberry Juice|Placebo capsules + 500 mL/day of cranberry juice
2456949|NCT03194100||Prediabetes|
2456950|NCT03194100||Normal glucose tolerance|
3154334|NCT00296595|Experimental|Fish Oil|2 g/day of fish oil + 500 mL/day of placebo juice
3154335|NCT00296595|Experimental|Cranberry Juice + Fish Oil|2 g/day of fish oil + 500 mL/day of cranberry juice
3154336|NCT00296608|Active Comparator|Radiotherapy|RT was delivered with photons from a linear accelerator with an energy level of 8MVor above.
3154337|NCT00296608|Experimental|Chemotherapy and radiotherapy|The first CT cycle was administered from days 1 to 5 of the RT treatment. LV 20 mg/m2/d was delivered intravenously immediately before administration of FU. FU 350 mg/m2/d was delivered during 20 minutes in 100 mL of saline infusion, 1 hour before RT. The second cycle was administered from days 29 to 33 of the RT treatment using the same schedule.
3154338|NCT00296621|Experimental|1|
3154339|NCT00296621|Placebo Comparator|2|
3154340|NCT00296634|Experimental|1|45 microgram dose Hemagglutinin (HA), 120 subjects receiving Aluminum hydroxide and 120 not receiving Aluminum hydroxide.
3154341|NCT00296634|Experimental|2|15 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3154342|NCT00296634|Experimental|4|3.75 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3154343|NCT00296634|Experimental|3|7.5 microgram dose HA, 60 subjects receiving Aluminum hydroxide and 60 not receiving Aluminum hydroxide.
3154344|NCT00296660||1|Proven acute HIV-1 infection
3154345|NCT00296660||1A|Sexual partners of members of Group 1
3154346|NCT00296660||2|Established HIV-infection
3154347|NCT00296660||3|HIV-1 uninfected
3154348|NCT00296686|Experimental|tranylcypromine|sequential tranylcypromine (TC) followed by TC + dextroamphetamine followed by TC + T3
2455582|NCT03202888|Experimental|Intervention|After completing enrollment surveys, including measures of patient activation and medical knowledge, participants will be invited to use the novel IT. The technology is a mobile responsive website for survey data collection made by our technology vendor, QuesGen. Patients and family members will be able to access the website from any personal device with internet access: laptop, tablet, or smart phone. QuesGen will send a text message reminder to participants with a link to specific questionnaires at scheduled time intervals. Frequency of text messaging will likely be daily, but will ultimately reflect family and patient feedback in Aim 1. In addition to text reminders, participants will be able to answer questionnaires at-will by accessing the mobile responsive website.
2455631|NCT03202628|Experimental|Treatment (ixazomib, pomalidomide, dexamethasone, ASCT)|"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.~CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2455753|NCT03201744|Experimental|Moderate Neuromuscular Block|Train of four count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
2455755|NCT03201744|Experimental|Deep Neuromuscular Block|Post tetanic count of 1-2. All procedures will start with low-pressure insufflation (8 mm Hg). Surgeon assessment of the conditions will be serially performed during surgery on an established visual scale. If conditions are deemed less than adequate (score 1-2), insufflation pressure will incrementally increase up to 15 mm Hg. Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
2455806|NCT03201458|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455807|NCT03201458|Experimental|Arm B (atezolizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes on days 1 and 15 and cobimetinib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2455949|NCT03200639|Active Comparator|Physical training, CT|Combined Trained with no cancer (CT): Post menopausal women with no cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
2455951|NCT03200639|Active Comparator|Physical training, HIITBW|High intensity interval training with body weight with no cancer (HIITBW): Post menopausal women with no cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
2455956|NCT03200639|Experimental|Physical training, CTc|Combined Trained with gynecological and/or breast cancer (CTc): Post menopausal women with with gynecological and/or breast cancer submitted to 12 weeks of combined training (i.e. aerobic training plus resistance training)
2455957|NCT03200639|Experimental|Physical training, HIITBWc|High intensity interval training with body weight with gynecological and/or breast cancer (HIITBWc): Post menopausal women with gynecological and/or breast cancer submitted to 12 weeks of high intensity interval training with body weight (i.e. step climbing plus squats)
2456052|NCT03199898||34-32 GA|premature infants born <34,6-32,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2456058|NCT03199898||32-28 GA|premature infants born <32-28,1 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2456062|NCT03199898||28-23 GA|premature infants born <28-23,0 weeks of gestational age (GA) receiving different types of non-invasive and invasive respiratory support, and severity of respiratory distress assessed by Silverman-Andersen Retraction Score.
2456174|NCT03199521||Atrial Fibrillation newly diagnosed, starting apixaban|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays before and after stabilisation(4 weeks) of their anticoagulation. This will allow to compare the effect of apixaban on endogenous fibrinolysis before and after treatment.
2456177|NCT03199521||Atrial fibrillation on stable warfarin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against warfarin on endogenous fibrinolysis on stable treatment.
2456179|NCT03199521||Atrial Fibrillation on stable aspirin treatment|Patients will undergo the global thrombosis test (GTT), thromboelastography (TEG) and thrombin generation assays on stable anticoagulation treatment. This will allow to compare the effect of apixaban against aspirin on endogenous fibrinolysis on stable treatment.
2456235|NCT03198975||Preoperative imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo preoperative Gd-EOB-DTPA enhanced magnetic resonance image.
2456287|NCT03198585|Active Comparator|Empagliflozin 10 mg|
2456288|NCT03198585|Placebo Comparator|Placebo|
2456353|NCT03198325|Experimental|Interruption of antiretroviral therapy|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
2456952|NCT03194139|Experimental|Sentinel Cohort|
2455629|NCT03202615|Active Comparator|F (ferrous sulphate with pregnancy)|Pregnant women with IDA, in the 2nd trimester are enrolled and treated for 2 months regularly with oral administration of 150 mg of dried ferrous sulphate capsules (Ferrofol capsules, Eipico, Egypt), one capsule three times daily on an empty stomach, at least 1 hour before or 2 hours after meals, in addition to placebo sachets (starch) twice a day.
2455688|NCT03202238|Active Comparator|Conventional|Venepuncture without the use of any venepuncture assistive device
2455693|NCT03202238|Active Comparator|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
2455698|NCT03202238|Experimental|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
3154349|NCT00296712|Experimental|escitalopram + bupropion|patients begin on escitalopram 10 mg/d, then bupropion 150 mg/d is added and each is alternately increased as tolerated to maximal dose of escitalopram of 40 mg/d and of bupropion of 450 mg/d
3154350|NCT00296777|Experimental|escitalopram|escitalopram 10 mg/d, increasing by 10 mg/week if tolerated and not remitted to maximum dose of 40 mg/d
2455891|NCT03200977||Exposed to nivolumab prior to allogeneic HCT|patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
2455893|NCT03200977||Unexposed to nivolumab prior to allogeneic HCT|patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
2455923|NCT03200704|Experimental|IC2000/SPY-PHI|Per standard of care, each subject will receive an injection of Tc-99m radioactive colloid. Then the periareolar area of the breast(s) identified with breast cancer will be injected (intradermal) twice with 0.05 ml of a 2.5 mg/ml solution of IC2000. Following the injection lymph node mapping will occur based on intraoperative fluorescence visualization using IC2000 and SPY-PHI. Lymph nodes will be excised following identification with IC2000 and SPY-PHI. The Gamma Probe will then be used with Tc-99m for confirmation of the excised lymph nodes as well as in the area of LN excision to ensure all LNs have been identified and excised.
2455973|NCT03200405|Experimental|DynaMeshVisible|the umbilical hernia will be fixed with a mesh, which is incorporated with Fe3O4 particles to become visible in MRI
2455976|NCT03200405|Active Comparator|DynaMeshCICAT|the umbilical hernia will be fixed with a Non-MRI-visible PVDF Mesh
2456013|NCT03200158|Other|Endoscopy biopsy and blood|The healthy volunteers were treated with endoscopy biopsy and blood.The patients were treated with bedside endoscopy biopsy and diagnosed with SRMD due to illness，then collect their blood samples.
2456046|NCT03199794||OBIZUR participants|Participants previously treated with OBIZUR and continue to be treated with OBIZUR during the study.
2456145|NCT03199495|Experimental|electroacupuncture|Participants were randomized divided into experimental and control groups .Acupuncture included Hegu (LI 4), Neiguan (PC6), Zusali (ST 36), Shanjuxu (ST37), Xiajuxu (ST39), Taichong (LR3) and Taibai(SP3) on both hands and legs. Acupuncture included Hegu (LI 4) and Neiguan (PC6), Zusali (ST 36) and Taichong (LR3) with electrical stimulation were conducted. The frequency of electrical stimulation was 2 Hz and the intensities of the stimulation was below 9.8 mA for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
2456147|NCT03199495|Sham Comparator|sham electroacupuncture|Participants were randomized divided into experimental and control groups. The Vaccaria Seeds (scientific name:Vaccaria segetalis) will be applied in control group. Vaccaria Seed is a spherical, smooth and hard seed, which is commonly used on ear acupuncture point. In control group, Vaccaria Seeds will be secured on the acupuncture point the same as experimental group, and coverd by transcutaneous electrical nerve stimulation (TENS), which is actually not turned on. The intervention will last for 15 minutes.After 15 minutes treatment, acupuncture were removed and after 15 minutes the investigators stated to evaluate.
3154351|NCT00296777|Experimental|bupropion|bupropion XL 150 mg/d, increasing by 150 mg/d if tolerated and not remitted to maximum dose of 450 mg/d
3154352|NCT00296777|Experimental|imipramine|imipramine 50 mg/d for 3 days, then 100 mg/d for 4 days, then 150 mg/d for 3 days then 200 mg/d for 4 days then 250 mg/d for a week and then 300 mg/d thereafter, all dose increases if tolerated and not remitted
3154353|NCT00296855|Experimental|Arm 1|
3154354|NCT00296894|Experimental|1|Drug - adalimimab sc
2456472|NCT03197402|Experimental|Leucine-enriched protein group|Leucine-enriched protein gel delivery system supplementation
2456490|NCT03197688||Notapplicable|Not applicable as non-interventional study
3154355|NCT00296894|Placebo Comparator|2|Placebo
3154356|NCT00296907|Experimental|Psychological Intervention|2-session psychological intervention
3154357|NCT00297024|Experimental|MRI for brain mets|
3154358|NCT00297089|Active Comparator|A|Pemetrexed + ABT-751
3154359|NCT00297089|Placebo Comparator|B|Pemetrexed + placebo
3154360|NCT00297128|Active Comparator|1|
3154361|NCT00297141|Experimental|single arm (radiochemotherapy)|single arm study (capecitabine, oxaliplatin)
3154362|NCT00297154|No Intervention|Control|Patients continue receive a single educational session and continue medical managment of heart failure as per their physician
3154363|NCT00297154|Experimental|Lifestyle modification|Patients recieve weekly sessions with dietician, replace 2 meals/day with meal replacement beverage, and initiate a walking program.
2455734|NCT03201861|Experimental|paclitaxel and cisplatin|Drug: paclitaxel, cisplatin, epirubicin and cyclophosphamide Patients will be administered paclitaxel (80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks) and cisplatin (25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 3 cycles) followed by epirubicin and cyclophosphamide (EC) (epirubicin 90mg/m² i.v.d1, cyclophosphamide 600mg/m² i.v.d1) for 4 cycles.
2455736|NCT03201861|Active Comparator|epirubicin and cyclophosphamide|"Drug：epirubicin, cyclophosphamide, paclitaxel and docetaxel~Investigators will declare one of the following regimens:~Patients with hormone receptor (HR) positive breast cancer wil be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles.~Patients with triple-negative breast cancer will be administered epirubicin (90mg/m² i.v.d1 q21d) and cyclophosphamide (600mg/m² i.v.d1 q21d) for 4 cycles followed by weekly paclitaxel (80 mg/m² i.v.d1) for 12 weeks or docetaxel (75mg/m² i.v.d1 q21d) for 4 cycles."
2455785|NCT03201549|Experimental|healthy|healthy volunteers will ingest fructose and have FGF21 levels measured
2455809|NCT03201289||Cardiac surgery|
2455886|NCT03201042||1a:Lyme patients- Erythema Migrans(EM)rash present|Patients with newly diagnosed Lyme disease based on the presence of a physician-documented EM rash. PCR, serology and Tcell based assay.
2455888|NCT03201042||1b:Lyme patients no typical EM|Patients documented symptoms of early Lyme disease, without a typical EM rash present, and the physician's intention to treat for Lyme disease. PCR, serology and Tcell based assay
2455889|NCT03201042||Cohort 2: healthy controls|Patients drawn from Lyme disease non-endemic areas and subjects with known exposure to Lyme disease will be excluded. PCR, serology and Tcell based assay.
2455983|NCT03200509|Experimental|Physical Activity Intervention|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. In addition, the intervention group will receive health coaching sessions and an activity monitor.
2455985|NCT03200509|Sham Comparator|Control group|The participants from both groups will receive a group exercise program, including a combination of general, stabilisation, strengthening and resistance exercises. The participants allocated to the control group will receive sham health coaching and a sham activity monitor, in addition to the exercise program.
2456033|NCT03200067|Experimental|Personalized rehabilitation service group|Breast cancer patients who use mobile healthcare service application and receive personal feedback from clinician
2456034|NCT03200067|No Intervention|Conventional group|Breast cancer patients with conventional care
2456094|NCT03199729|Experimental|Slip-only training|Overground, slip specific perturbation training only delivered in a fixed sequence. After the baseline walking trials, subjects will walk for 30-35 trials, after which training will begin consisting of a first block of 8 repeated slips (S1-S8), a block of 3 regular (non-perturbed) walking trials (W1-W3), another block of 8 slips (S9-16), a second block of 3 regular walking trials (W4-W6), and a final block of 8 slips (S17-S24) mixed with 10 regular walking trials.
2456097|NCT03199729|Experimental|Trip-only training|Trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
2456099|NCT03199729|No Intervention|Control|Walk for about 70-75 trials at the preferred walking pace to match the total trials the other groups receive before the test perturbations.
2456103|NCT03199729|Experimental|Combined slip+trip training|Training consisting of repeated exposure to both slips and trips.
3154364|NCT00297193|Experimental|Transplant Arm|Hematopoietic stem cell mobilisation followed, within 4 weeks, by high dose immunoablation and autologous stem cell transplantation
3154365|NCT00297193|Experimental|Delayed Transplant|Hematopoietic stem cell mobilisation followed, after 59 weeks, by high dose immunoablation and autologous hematopoietic stem cell transplantation
2456242|NCT03198845|Active Comparator|video game|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised video game play therapy 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of video game intervention for patients with knee osteoarthritis were assessed."
2456245|NCT03198845|Sham Comparator|exercise group|"Participants received a total of twelve 40-min sessions of hot pack therapy combined transcutaneous electrical nerve simulation over the knees followed by 20-min supervised therapeutic exercise 20-min per session for 3 times per week for a 4-week duration.~Therapeutic effects of therapeutic exercise for patients with knee osteoarthritis were assessed."
2456436|NCT03197753|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion
2456442|NCT03197753|Active Comparator|Nasotracheal intubation|Nasotracheal tube insertion
2456508|NCT03197428|Experimental|PRP group|15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
2456510|NCT03197428|Placebo Comparator|Control group|15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
2456544|NCT03196921|Experimental|Symptomatic Cryptococcal Meningitis|CAMB (Encochleated Amphotericin B)
2456547|NCT03196921|Experimental|Asymptomatic Cryptococcal Antigenemia|CAMB (Encochleated Amphotericin B)
2456641|NCT03196362|Active Comparator|PIO/MET|one fixed dose pioglitazone/metformin (15mg/500mg) tablet will be orally administrated twice daily
2456646|NCT03196362|Placebo Comparator|placebo|one tablet of placebo will be given twice daily
2456688|NCT03196024|Experimental|Family-focused intervention arm|Family-focused intervention arm: Educational sessions will be provided to family pairs that include participants who are at-risk for type 2 diabetes or CVD and their co-participating family member.
2456700|NCT03195790|Experimental|Home treatment arm|Family-based pediatric obesity treatment delivered in the family's home.
3154366|NCT00297206|Experimental|Cohort 1|Subjects in the age group of 2 to less than 6 years will be included
3154367|NCT00297206|Experimental|Cohort 2|Subjects in the age group of 1 to less than 2 years will be included
3154368|NCT00297206|Experimental|Cohort 3|Subjects in the age group of 6 months to less than 1 year will be included
3154369|NCT00297206|Experimental|Cohort 4|Subjects in the age group of 3 months to less than 6 months will be included
3154370|NCT00297206|Experimental|Cohort 5|Subjects in the age group of 1 month to less than 3 months will be included
3154371|NCT00297219|Active Comparator|2|high dialysate calcium
2455665|NCT03202329|Other|nurse-based care|heart failure nurses visit postoperatively every (working-) day to check fluid balance, medication, rhythm and general condition
2455748|NCT03202082|Experimental|Neuropsychological testing|Participants from this group will be administered a neuropsychological battery in addition to the initial and follow-up surveys
2455749|NCT03202082|No Intervention|Treatment as usual|Participants from this group will be administered the initial and follow-up survey.
3154372|NCT00297219|Active Comparator|1|low dialysate calcium
3154373|NCT00297271||Mild cognitive impairment or dementia|Patients with mild cognitive impairment or dementia.
3154374|NCT00297323||001|
3154375|NCT00297336||001|
3154376|NCT00297349||001|
3154377|NCT00297362||Galantamine hydrobromide|
3154378|NCT00297401|Experimental|1|
3154379|NCT00297401|Placebo Comparator|2|
3154380|NCT00297414||Patients with mild cognitive impairment|Patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
3154381|NCT00297453|Experimental|Internet|Individual counseling + nicotine replacement. 6 sessions across a 3 month period.
2456491|NCT03197207|Experimental|lifting and thrusting|"Dragon and Tiger warring in lifting and thrusting"
2456494|NCT03197207|Experimental|twisting and rotating|"Dragon and Tiger warring in twisting-rotating"
2456546|NCT03196986|Experimental|MIL60|MIL60 (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
2456549|NCT03196986|Active Comparator|Bevacizumab|Bevacizumab (15mg/kg) was co-administered intravenously with 4 to 6-cycle paclitaxel/carboplatin, non-progressive patients are then given with maintenance single-agent MIL60 (7.5mg/kg) until disease progression, intolerable toxicity, or withdrawal.
2456623|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (15μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2456624|NCT03196661|Placebo Comparator|H7N9 split influenza vaccine (30μg/dose)|"This group was divided into three subgroups according ages of subjects, the ages of those subjects are: 3 to 11(36 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines)，12 to 17(36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines)，≥18 (36 subjects got inoculated test vaccines, 12 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2456627|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (7.5μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2456631|NCT03196661|Placebo Comparator|H7N9 whole virus influenza vaccine (15μg/dose)|"This group was divided into two subgroups according ages of subjects, the ages of those subjects are: 12 to 17(54 subjects got inoculated test vaccines,18 subjects got inoculated reference vaccines)，≥18 (54 subjects got inoculated test vaccines, 18 subjects got inoculated reference vaccines).~Immune procedure: 0,21st day; Physical examination: 0,4th, 21st,25th day; Antibody detection: 0,21st,42nd day."
2456643|NCT03196128|Active Comparator|Digital|
2456648|NCT03196128|Active Comparator|Non Digital|
2456717|NCT03195998||Group A|Gestational Age 23 0/7 - 28 6/7 weeks
2456719|NCT03195998||Group B|Gestational Age 29 0/7 weeks - 34 6/7 weeks
2456781|NCT03195439|Experimental|patients in ICU|
2456840|NCT03194919|Experimental|Negotiating quit date|Endre: a digital smoking cessation counsellor
2456842|NCT03194919|Active Comparator|Preset quit date|Endre: a digital smoking cessation counsellor
2456884|NCT03194568|Experimental|Anterior Vertebral Tethering|Subjects receiving Anterior Vertebral Tethering intervention.
3154382|NCT00297453|Experimental|Counseling|Individual counseling plus nicotine replacement treatment.
3154383|NCT00297453|Active Comparator|Self-Help|Self-help Manual plus nicotine replacment treatment.
3154384|NCT00297752|Active Comparator|'ceriumnitrate silversulfadiazine (flammacerium)|facial burns treatment with Cerium nitrate silver sulfadiazine
3154385|NCT00297752|Active Comparator|flammazine|facial burns treatment with silver sulfadiazine
3154386|NCT00297791|Other|1|surgery (open or laparoscopic) and observation
3154387|NCT00297804|Experimental|Arm 1|
3154388|NCT00297804|Active Comparator|Arm 2|
3154389|NCT00297817|Experimental|Arm 1: rMenB|
3154390|NCT00297817|Experimental|Arm 2: rMenB + OMV|
3154391|NCT00297817|Placebo Comparator|Arm 3: Placebo|
3154392|NCT00297856||Boostrix cohort|
3154393|NCT00297856||Historical Td cohort|
3154394|NCT00297869|No Intervention|1|
3154395|NCT00297869|Experimental|2|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
3154396|NCT00297895|Active Comparator|Ultrasound observation + delayed CLND if recurrence detected|
3154397|NCT00297895|Active Comparator|CLND|
3154398|NCT00297947|Experimental|600 mg/day quetiapine (Group B)|Patients qualifying for the Double Blind Phase will be randomly assigned to 600 mg quetiapine (Group B) daily and treated on the assigned dose in a double-blind fashion for 8 weeks
3154399|NCT00297947|Experimental|1200 mg/day quetiapine (Group A)|Patients qualifying for the Double Blind Phase will be randomly assigned to high dose 1200 mg quetiapine daily (Group A) on the assigned dose in a double-blind fashion for 8 weeks
3154400|NCT00297986||1|healthy subjects
3154401|NCT00298025|Experimental|Cetrotide®|
3154402|NCT00298025|Active Comparator|Antagon ™|
3190796|NCT00791505|Active Comparator|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
2455683|NCT03202173|Active Comparator|normal mucosa|Flat and relatively uniform polygonal epithelial cells with alternating dark and light bands were noted in pCLE images of normal mucosa after intravenous injecting 10% fluorescein.
2455686|NCT03202173|Experimental|lymphoid hyperplasia|An unorganized tissue architecture, irregular cells (difference of cell shape, color and size), slightly intensified fluorescein leakage, and vessels not assessable were found in the lymphoid hyperplasia of nasopharyngeal mucosa after intravenous injecting 10% fluorescein..
2455691|NCT03202173|Experimental|nasopharyngeal carcinoma|pCLE images of nasopharyngeal carcinoma, which was associated with crowded unorganized tissue architecture (a dark-gray background without identification of mucosal structures), irregular cells like cell clusters, amplified fluorescein leakage, and irregular vessels changes after intravenous injecting 10% fluorescein.
2455792|NCT03201848|Experimental|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight with treatment duration for 48 weeks
2455794|NCT03201848|Placebo Comparator|Placebo|Placebo given to subject will be adjusted by body weight After 24 weeks of placebo, change to Huaiqihuang Granule for another 24 weeks.
2455868|NCT03201120|Experimental|Outdoor Sun Exposure Behavior|"A convenience sample of white, English-speaking adults ages 18 to 49 will be recruited via online advertisements in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 120 adults to test outdoor UV exposure messages. The investigators will quota sample to ensure representation across age and gender groups.~The inclusion criteria are that adults must be white, must be between 18-49 years old and must speak English."
2455878|NCT03201120|Experimental|Indoor Tanning Behavior|"A convenience sample of white, English-speaking females ages 18 to 25 will be recruited via online advertisements and flyers in Philadelphia and the surrounding region (within a 30 mile radius). The investigators will recruit 60 adults to test indoor tanning messages.~The inclusion criteria are that adults must be white, female, must be between 18-25 years old, must have used an indoor tanning bed at least once in the past 12 months, and must speak English."
2455934|NCT03200808|Experimental|treatment group|"Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.~Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department."
2456016|NCT03200431|Experimental|Test of a new adhesive strip|This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 24 hours. The adhesive strip is not yet part of a marketed ostomy device.
2456108|NCT03199820|Active Comparator|Cook Cervical balloon|Cook cervical double balloon catheter
2456110|NCT03199820|Active Comparator|Prostin E2 Vaginal suppository|Prostaglandin E2 sustained release vaginal insert
2456207|NCT03199196|Experimental|Group 1 - Intervention|"Participants given an activity tracker at the given an accelerometer at each visit. Participants instructed in use of a smartphone application at the baseline visit.~Participant emailed electronic newsletters to read that may help participant be more physically active.~Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
2456214|NCT03199196|Other|Group 2 - Control|"Participants sent electronic newsletters throughout the study that may help participant be more physically active.~Study visits performed 2 times (1 time at the beginning of the study, and 1 time 16 weeks after beginning the study).~Participants complete questionnaires 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.~Participants invited to take part in a final focus group sometime after the 16-week visit."
2456240|NCT03198689|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous use
2456310|NCT03198533|Active Comparator|Triathlon PA|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
2456315|NCT03198533|Active Comparator|Triathlon Pressfit|Triathlon PA (HA-surface) versus Triathlon Pressfit design: The goal with the un-cemented technique is to reach a full integration between the bone and the prosthesis. During the last years the usage of prosthesis with hydroxyapatite surface within tooth-, mandibular-surgery, hips- and knee-joints, have increased significantly. It has been shown that a thin layer of hydroxyapatite stimulates the anchorage of the implant. The goal with this sub study is to compare the stability of the fixation when using two different types of Triathlon un-cemented prosthesis designs. PA (HA-surface) versus Pressfit.
2456355|NCT03198182|Experimental|Module A|BMS-986036 Arm
2456356|NCT03198182|Placebo Comparator|Module B|Placebo Arm
2456428|NCT03197948||Health Services Research (electronic patient reported outcome)|Patients complete questionnaires over 15 minutes once a week over 3 months via a smartphone application. Patients rate urinary function, bowel habits, sexual function, hormonal function, and overall satisfaction. Patients with advanced disease also answer questions related to pain, fatigue/lack of energy, weight loss, and worry domains.
2456458|NCT03197519|Experimental|Experimental group|The experimental group will receive treatment as usual, that is to say, the standard treatment based on CBT principles that is offered by the different ED units in Spain, plus an online intervention using TCApp for a period of 12 weeks.
2456460|NCT03197519|Other|TAU control group|The TAU control group will receive treatment as usual, offered by the different ED units in Spain. Patients from the control group will be offered access to TCApp after a 6-month period.
2456469|NCT03197246|Experimental|IVECG and chest X-ray|The patients in this group will be examined with perioperative IVECG for PICC tip placement, as well as standard postoperative chest X-ray.
2455684|NCT03202342|Experimental|Gluc+EB_cold/water/glucose+EB/glucose/EB|First Glucose + Ethyl butyrate 22 C, then Water 22 C, then Glucose + Ethyl butyrate 0 C, then Glucose 22 C and then Ethyl butyrate 22 C
2455685|NCT03202342|Experimental|Gluc+EB_cold/glucose+EB/water/EB/glucose|First Glucose + Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 0 C, then Water 22 C, then Ethyl butyrate 22 C and then Glucose 22 C
2455689|NCT03202342|Experimental|Gluc+EB_cold/gluc+EB/EB/water/glucose|First Glucose + Ethyl butyrate 0 C, then Glucose + Ethyl butyrate 22 C, then Ethyl butyrate 22 C, then Water 22 C and then Glucose 22 C
2455694|NCT03202342|Experimental|Gluc+EB_cold/EB/gluc+EB/glucose/water|First Glucose + Ethyl butyrate 0 C, then Ethyl butyrate 22 C, then Glucose + Ethyl butyrate 22 C, then Glucose 22 C and then Water 22 C
2455787|NCT03201588|Experimental|Formulaid|Formulaid 2:1 Arachidonic acid/Docosahexaenoic acid (AA/DHA). Enteral supplement of AA (0,1-1ml) (100mg(kg/day) and DHA (50mg/kg/day) from birth to 40 weeks postmenstrual age in addition to conventional parenteral fatty acid treatment with Clinoleic
2455790|NCT03201588|No Intervention|Clinoleic|"Sterile fat emulsion [containing a mixture of refined olive oil (approximately 80%) and refined soya oil (approximately 20%)] 200 g, egg lecithin (purified egg phospholipids) 12 g, glycerol 22.5 g, sodium oleate 0.3 g and Water for Injections to 1,000 mL (final pH between 6.0-8.0).~One of the active ingredients, soya oil, contains ascorbyl palmitate as an antioxidant (free radical scavenger), in the concentration of 0.15 mg/g of oil."
2455808|NCT03201224||Group without image transmission|"Before Group"
2455811|NCT03201224||Group with image transmission|"After Group"
2455926|NCT03200665|Experimental|Ultrasound 35-36 (6 / 7 days weeks)|The patients that are randomized to this group, besides accomplishing the standard of care of national guidelines (third trimester ultrasound at 30-32 (6 / 7 days weeks)) will be submitted to an additional third trimester ultrasound at 35-36 (6 / 7 days weeks).
2455928|NCT03200665|No Intervention|Standard of Care|This is the control group that will be managed in accordance to national guidelines of screening of late fetal growth restriction in low risk pregnancies: third trimester ultrasound at 30-32 (6 / 7 days weeks).
2455982|NCT03200457|Experimental|Patients with hepatic iron overload or steatosis|Each patient (80) will have two MRI exams on the same day: one performed in common practice on a 1.5 Tesla device and the other on a 3 Tesla device.
2456036|NCT03200054|No Intervention|Clinic-based Care|Clinic-based care is the current standard of care and is defined as referral of women on antiretroviral therapy (ART) to general primary care adult ART services.
2456038|NCT03200054|Experimental|Adherence Club Care|Adherence club care involves referral of women on ART to community-based ART services in the form of adherence clubs, which are led by community health workers and supported by ART clinic nurses.
2456086|NCT03199677|Experimental|apatinib with 500mg qd po|Patients administrate apatinib with the dose of 500mg once per day,half an hour after a meal.
2456136|NCT03199417|Experimental|Multiprofen/interventional|"A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel. This topical formulation has been in use commercially under the trade name Multi-profen. This topical cream will be applied by the patient three times per day."
2456141|NCT03199417|Placebo Comparator|Control/Placebo Group|A identically packaged placebo cream treatment will be utilized in the control population.
2456392|NCT03198039|Experimental|Group 1|Meditation twice daily for at least two weeks prior to surgery and for four weeks after surgery
2456393|NCT03198039|Experimental|Group 2|Meditation twice daily for four weeks after surgery
2456394|NCT03198039|No Intervention|Group 3|Control group - will undergo surgery and subsequent hospital stay according to the current standard of care, which does not include meditation
2456480|NCT03197649|No Intervention|Control|No laser phototherapy treatment
2456484|NCT03197649|Experimental|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
3154403|NCT00298051|No Intervention|Early umbilical cord clamping (control)|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
2456555|NCT03196856|Experimental|Yogurt Group|Group will be consuming 200g of Greek Yogurt (Plain, 0%) 3 times daily for 12 weeks
2456560|NCT03196856|Placebo Comparator|Study Designed Supplement Group|Group will consume an isoenergetic, protein void, maltodextrin-based placebo supplement during the same time points for 12 weeks as well. The Placebo contain maltodextrin and pudding powder to mimic the consistency of Greek yogurt.
2456620|NCT03196570|Experimental|Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
2456674|NCT03196310|Active Comparator|Corticosteroid|Intra-articular injection of kenalog.
2456676|NCT03196310|Placebo Comparator|Normal Saline|Intra-articular injection of normal saline
2455737|NCT03202147|Placebo Comparator|Placebo|ALZT-OP1a: placebo capsule for oral inhalation via dry powder inhaler, taken twice per day (morning and evening), 8-12 hours apart.
2455869|NCT03201172||Univation® X|
2455875|NCT03201172||iUni®|
2455950|NCT03200834|Active Comparator|D2 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D2 lymph node dissection
2455955|NCT03200834|Experimental|D3 lymph node dissection for right colon cancer|Hemicolectomy for right colon cancer with D3 lymph node dissection
2456012|NCT03200275||HOSPITALISED PNEUMONIA PATIENTS|"All patients of more than 18 years of age, hospitalized consecutively for pneumonia irrespective of it being community or hospital acquired. All the patients included in this study will need to have acute symptoms of less than 2 weeks and radiological features which are compatible to pneumonia.~They will undergo testing for Legionella pneumophila serogroup 1 urine antigen using a qualitative rapid assay following manufacturer's instructions at baseline. The diagnosis of Legionella pneumonia is made if the Immunocatch™ Legionella Urine Antigen Test is positive."
2456053|NCT03199807|Experimental|NRT + radiotherapy|HCC received NRT and radiotherapy
2456134|NCT03199560|Active Comparator|Tilmanocept|Tc 99m tilmanocept
2456140|NCT03199560|Active Comparator|Sulfur Colloid|Tc 99m filtered sulfur colloid
2456234|NCT03199027|No Intervention|Clinic-based Care|Clinic-based care is the current Standard-of-Care whereby newly initiated ART patients attend the ART clinic.
2456236|NCT03199027|Experimental|Adherence Club Care|Adherence club care involves referral to community-based ART services in the form of Adherence clubs, which are led by community health workers and supported by ART clinic nurses.
2456290|NCT03198598|Experimental|MS patients with EDSS from 0 to 5.5 for yoga|Three months of Iyengar Yoga practice.
2456291|NCT03198598|No Intervention|MS patients with EDSS from 0 to 5.5 for control|
2456293|NCT03198598|Experimental|MS patients with EDSS from 6 to 8 for yoga|Receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips
2456297|NCT03198598|No Intervention|MS patients with EDSS from 6 to 8 for control|
2456301|NCT03198598|No Intervention|Healthy subjects|
2456375|NCT03198299|Active Comparator|study group: MEI BIN insoles|Study group: participants in the study group were prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
2456376|NCT03198299|No Intervention|control group: without MEI BIN insoles|Control group: participants in the control group were not prescribed with customized insoles (MEI BIN insoles) to keep the subtalar joint in neutral position, for 12 weeks.
2456437|NCT03197805|Experimental|Use of PAM 50 test in Her2 equivocal breast cancer patient|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test).
2456487|NCT03197350|Active Comparator|HFpEF|"We intend to recruit consecutive patients admitted for HFPEF in our institution during the next 4 years. Eligible patients include those with age ≥50 years, LVEF ≥45%, symptomatic HF, and either a hospitalization for HF within the prior year or an elevated natriuretic peptide level (BNP ≥100 pg/mL or NT-proBNP ≥360 pg/mL) within the 60 days before inclusion.~Intervention: cMR"
2456489|NCT03197350|Active Comparator|Controls|"We plan to recruit 10 per decade of age. These subjects will allow us to evaluate the effects of age on the parameters of our study. They will have no risk factors, a normal ECG at rest and normal heart ultrasound and no abnormalities on a stress test.~Intervention: cMR"
2456654|NCT03196323||Initial Cohort|"In Aim 1, the investigators will evaluate psychometrically RettBe 1.0 following, in part, previous studies including our examination of anxiety instruments and adaptation of the Anxiety, Depression and Mood Scale (ADAMS) for RTT, and their adaptations of the Aberrant Behavior Checklist-Community (ABC-C) for fragile X syndrome and Down syndrome. In Aim 1, the investigators will also refine RettBe 1.0 by adding new missing items based on parental input or clinician (PIs of sites involved) feedback. The resulting instrument, RettBe 2.0 will be tested in Aim 2."
2456659|NCT03196323||Validation Cohort|Testing of RettBe 2.0 will be carried out with a new (naïve) validation cohort of 300 subjects and two raters (preferentially both parents/caregivers, alternatively one teacher or therapist), to determine inter-rater reliability. One rater, preferentially a parent, will be asked to also complete three other behavioral measures (RSBQ, ADAMS, ABC-C) for comparisons. Scores for RettBe 2.0 will be analyzed in terms of psychometric properties, as performed for RettBe 1.0. However, in addition to structure (construct validity) and content validity, the investigators will also examine convergent and discriminant validity by correlating domain RettBe 2.0 scores with those of comparable and non-comparable domain scores of the RSBQ, ADAMS, and ABC-C, respectively.
2456748|NCT03195452|Experimental|Raltegravir|antiretroviral tritherapy: Raltegravir 600 mg tablet orally (2 tablets QD) and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)
2456796|NCT03195166|Experimental|hemodynamic profile|FloTrac sensor/Vigileo
2456847|NCT03194854|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
2456848|NCT03194854|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
2456875|NCT03194529|Experimental|FMT in children with disease remission|All children (with Crohn's disease in remission) will receive the equivalent of 50 g of stools from a healthy donor (FMT) into the jejunum through upper endoscopy.
3154404|NCT00298051|Experimental|Delayed umbilical cord clamping|Umbilical cord was clamped at 2 minutes after delivery of the infant's shoulder's with the infant held at the level of the mother's uterus.
3154405|NCT00298168|Experimental|1|
3154406|NCT00298168|Experimental|2|
3154407|NCT00298168|Placebo Comparator|3|
3154408|NCT00298220|Active Comparator|training|tailored multi-component implementation program
3154409|NCT00298220|No Intervention|control|
3154410|NCT00298259|Active Comparator|ORIF|open reduction internal fixation of fractured ribs in flail chest patients
3154411|NCT00298259|No Intervention|conservative management|current standard conservative management
2455746|NCT03201913|Experimental|Accelerated dose escalation study|"Dose escalation of TTC-352 administered as an oral capsule, twice a day for 28 days (one cycle).~Patients will receive sequential 28-day cycles of treatment until disease progression, unacceptable toxicity, patient refusal to continue treatment, any other reason to discontinue treatment (e.g., further participation is not in the patient's best interest) or study completion/termination."
2455798|NCT03201497||patients with PJP|PJP patients in ICU with or without HIV infection
2455821|NCT03201263|Active Comparator|PSV group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.).
2455825|NCT03201263|Experimental|PSV+Sigh group|Will be treated by standard of care for patients undergoing assisted mechanical ventilation (e.g., protective PSV settings, protocolized weaning, etc.) + Sigh (short cyclic recruitment breath once every minute) until death or spontaneous breathing trial and extubation.
2455929|NCT03200756|Experimental|Sedentary Group|The experimental group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
2455932|NCT03200756|Active Comparator|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
2455975|NCT03200418|Experimental|Test of new adhesives|"On the peristomal area four different patches are applied to the skin. There is a bag welded on each patch. The bag contains real output.~The difference between the four patches is that they consist of different adhesives.~One patch is made of a standard hydrocolloid adhesive~The primary endpoint is maesured after 8 hours and 24 hours And the three other patches consist of the newly developed adhesives. P-4 P-15 P-16"
2456119|NCT03199469|Experimental|Lower Dose|"1.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~1.3 x10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time."
2456123|NCT03199469|Experimental|Higher Dose|"3.0 x 10^14 vg/kg of AT132 defined with the use of 1st generation vg titer assay delivered intravenously one time.~3.5 x 10^14 vg/kg of AT132 defined with the use of 2nd generation vg titer assay delivered intravenously one time"
2456126|NCT03199469|No Intervention|Delayed-Treatment Control|Delayed-Treatment Control subjects will generally have the same assessments as treated subjects. After the follow up period, eligible delayed-treatment control subjects will be dosed with AT132 and initiate the same post-dose procedures as subjects who received AT132.
2456228|NCT03199092|Experimental|RRT+sat|RRT in combination with specific auditory training (sat) administered for a total of 20 hours over 10 weeks (60 minutes biweekly sessions).
2456229|NCT03199092|Experimental|Abilmente|Abilmente method administered for a total of 10 hours over 5 weeks (60 minutes biweekly sessions).
2456261|NCT03198702|Experimental|Toxin group|The babies receive a botulinum toxin type A injection at the age of 12 months
2456263|NCT03198702|Sham Comparator|Sham group|The babies receive a simulated injection procedure at the age of 12 months
3154412|NCT00298298|Experimental|1|5 million autologous, DNP-modified NSCLC cells
2456351|NCT03198208||Reference group|No fentanyl dose administered during surgery
2456352|NCT03198208||Comparative group|Fentanyl dose administered during surgery
2456626|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:6|K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
2456628|NCT03196479|Active Comparator|ketamine:propofol ratio of 1:4|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
2456653|NCT03196115||Observation|Patients with Hyaline fibromatosis syndrome or high-grade suspicion for Hyaline fibromatosis syndrome
2456713|NCT03195959||PH-Patients|Patients with mean pulmonary artery pressure >25mmHg and a pulmonary arterial wedge pressure <15mmHg during right heart catheterisation, which are diagnosed as having pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension.
2456714|NCT03195959||Control group|Patients with clinically indicated right heart catheterisation (because of dyspnea or other signs of PH), but had no PH (no elevated mean pulmonary artery pressure (mPAP <20mmHg)).
2456749|NCT03195491|Experimental|Monotherapy|Nivolumab administered every two weeks
2456775|NCT03195088|Experimental|Active Treatment|Single rising doses of BI drug
2456776|NCT03195088|Placebo Comparator|Placebo|Matching volumes of drug-free solution
2456805|NCT03194971||TTField at Recurrence|
2456810|NCT03194971||TTField at New Diagnosis|
2456849|NCT03194750|Experimental|Share Data|
2456850|NCT03194750|Active Comparator|Do Not Share Data|
3154413|NCT00298298|Experimental|2|2.5 million autologous, DNP-modified NSCLC cells
3154414|NCT00298298|Experimental|3|0.5 million autologous, DNP-modified NSCLC cells
3154415|NCT00298311|Experimental|mci guidance & peer social support|home visits to promote maternal-child interaction & social support
3154416|NCT00298311|Sham Comparator|peer social support|social support
3154417|NCT00298324|Active Comparator|Myfortic|Patients in this arm will receive Myfortic + Prednisone + Cyclosporine
3154418|NCT00298324|Other|Standard Care/ Placebo|In this arm patients will receive Prednisone + Cyclosporine + Placebo or Prednisone + Cyclosporine
3154419|NCT00298415|Active Comparator|A|Chemotherapy (mono)
3154420|NCT00298415|Experimental|B|Chemotherapy (doublet)
3154421|NCT00298428|Other|SPACE group|
3154422|NCT00298506|Active Comparator|FK506+MMF|
3173177|NCT00609180|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
3173178|NCT00609180|Experimental|2|Participants will receive initial full-calorie enteral feeding and the omega-3 fatty acid and anti-oxidant supplements
3173179|NCT00609180|Experimental|3|Participants will receive initial minimal (trophic) enteral feeding and the placebo supplement
3173180|NCT00609180|Placebo Comparator|4|Participants will receive initial full-calorie enteral feeding and the placebo supplement
3173181|NCT00609193||1|Study subjects receiving lithium
3190797|NCT00791531|Experimental|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
2455866|NCT03201094|No Intervention|Standard of Care|Patients will receive standard of care mobilization and nutritional supplementation throughout the study period.
2455871|NCT03201094|Experimental|HPRO + NMES|Patients will receive high protein supplementation(HPRO) administered within 30 minutes after each NMES session and additionally once at approximately 10 PM.
2455877|NCT03201094|Experimental|NMES only|Patients will undergo two 30 minute NMES sessions per day during study period.
2455883|NCT03201094|Experimental|HPRO only|Patients will receive HPRO three times daily during study period
2455909|NCT03200743||Hpertension|
2455911|NCT03200743||Health|
2455935|NCT03200587|Experimental|Avelumab and cabozantinib, all patients|
2455990|NCT03200392|Experimental|L-DGG/LRB|laser root surface conditioning & laser DGG harvesting
2455991|NCT03200392|Experimental|B-DGG/LRB|laser root surface conditioning & blade DGG harvesting
2455992|NCT03200392|Active Comparator|B-DGG|blade DGG harvesting
2456039|NCT03199989|Active Comparator|adjuvant chemotherapy group|patients enrolled int the adjuvant chemotherapy group will receive adjuvant chemotherapy[CapeOX（Capecitabine+Oxaliplatin）] by the current guidelines
2456040|NCT03199989|Experimental|observation group|patients enrolled int the adjuvant chemotherapy group will not receive adjuvant chemotherapy just for observation
2456111|NCT03199638|Experimental|an exercise group|in which subjects will perform daily 'exercise snacks' within 30 min before breakfast, lunch, and/or dinner or bedtime snack, along with a placebo drink which will be given before breakfast and dinner (twice daily);
2456114|NCT03199638|Experimental|an exercise + glutamine group|in which subjects will receive a glutamine drink (0.25 g/kg per dose) before breakfast and dinner (twice daily), and perform 'exercise snacks' before each meal
2456116|NCT03199638|No Intervention|control group|"in which we will use historic data from previous study (Statins in children with type 1 diabetes: effects on metabolism, inflammation and endothelial function) by choosing 12 children between 13-19 years with type 1 diabetes and meeting the very same inclusion/ exclusion criteria. We have readily available data for their HbA1C, CGM downloads, all labs and anthropometry for 3 months. We will select age, gender, and HbA1c-matched adolescents as these data were prospectively collected."
2456221|NCT03199105|Experimental|preoperative education and tetracaine|
2456224|NCT03199105|Experimental|tetracaine|
2456249|NCT03198741|Active Comparator|Aspirin+clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),continue aspirin + clopidogrel (12-month DAPT group).The treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2456253|NCT03198741|Experimental|Aspirin|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive aspirin + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2456255|NCT03198741|Experimental|Clopidogrel|"Open label clopidogrel (75mg/d) plus aspirin (100mg/d) for first 6 months after enrollment. At 6 months (±2 weeks),receive clopidogrel + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.~Evaluation of gastric and intestinal mucosal lesions by AMCE will be performed at the time of screening, randomization (at 6 months ±2 weeks) and 6 months thereafter (at 12 months ±2 weeks)."
2456285|NCT03198455|Experimental|Andosan|The Agaricus blazei Murill-based mushroom extract, Andosan™, is given as one dosage 60 ml/day orally for 2 months. The intervention solution is given for 1 month's consumption at a time in a neutral plastic container
2456286|NCT03198455|Placebo Comparator|Placebo|The placebo is drinking water with brownish food coloring, given as one dosage 60 ml/day orally for 2 months. The placebo solution is given for 1 month's consumption at a time in a neutral plastic container (same as for intervention/experimental solution).
2456320|NCT03198377|Experimental|TENS: Randomized frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2456325|NCT03198377|Experimental|TENS: Scan 6/6 of frequency modulation|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2456329|NCT03198377|Experimental|TENS: Fixed frequency|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2456332|NCT03198377|Sham Comparator|TENS: Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
2456386|NCT03198104||Liver disease|Paediatric patients (50-60 pts.) with liver disease who are scheduled for an ultrasound-guided liver biopsy as part of their standard care - these patients will be scanned using MRI and fibroscan, then will proceed through standard care pathway to receive blood tests and a liver biopsy. Findings from the fibroscan, blood tests and liver biopsy will be compared to the MRI data to determine it's accuracy in detecting and distinguishing different types of liver disease.
2456390|NCT03198104||Healthy Volunteers|Healthy volunteers (20-30 children) will be scanned using MRI and fibroscan and used as healthy controls.
2456473|NCT03197246|Active Comparator|Standard|Standard method, PICC tip placement confirmed by postoperative chest X-ray .
3190798|NCT00791544|Experimental|Dose Level -1|0.5 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3190799|NCT00791544|Experimental|Dose Level 1|1 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3190800|NCT00791544|Experimental|Dose Level 2|3 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3190801|NCT00791544|Experimental|Dose Level 3|6 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3190802|NCT00791544|Experimental|Dose Level 4|12 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3190803|NCT00791544|Experimental|Dose Level 5|18 mg/kg AVE1642 single agent at cycle 1 with sorafenib at cycle 2
3154423|NCT00298532|No Intervention|standard therapy|"The use of a before-after controlled study design and 36-month time periods will mirror the approach of our Adult OPALS Study. The Control (before) Period represents the 36 months immediately prior to the introduction of ALS programs at each study community. The Intervention (after) Period is comprised of the 36 months immediately after each community has met all standards for a full ALS program, as defined below. Data will be pooled across communities but the start date for the periods will vary for each community as each will require different amounts of time to prepare their ALS program. A 6- to 36-month Run-in period will separate the Control and Intervention Periods and will allow for training and implementation of the ALS program. Data from the Run-in period will not be considered in the primary analysis. The study periods may be summarized as follows: a) Control (Before) Period b) Run-in Period c) Intervention (After) Period."
2456031|NCT03200184|Experimental|Treatment|Subjects will receive sofosbuvir and daclatasvir
2456075|NCT03199690|Experimental|Single arm|"Single arm trial design based on the dosing regimen below:~Day 1 - 7~- Dolutegravir 50 mg once daily with food~Day 8 - 14 - Dolutegravir 100 mg once daily with food~Day 15 - 28~- Rifampicin 600 mg once daily~Day 29 - 35 - Rifampicin 600 mg once daily & Dolutegravir 50 mg once daily~Day 36 - 42~- Rifampicin 600 mg once daily & Dolutegravir 100 mg once daily"
2456181|NCT03199378||Caucasian|English speaking Caucasian individuals
2456184|NCT03199378||African American|English speaking African American individuals
2456188|NCT03199378||Hispanic|Spanish speaking Hispanic individuals
2456378|NCT03198169|Experimental|Active AWC + Active ABFD|Active Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
2456379|NCT03198169|Experimental|Active AWC + Placebo ABFD|Active Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
2456380|NCT03198169|Experimental|Placebo AWC + Active ABFD|Placebo Antimicrobial Wound Cleanser + Active Antimicrobial Barrier Film Dressing + SOC
2456382|NCT03198169|Experimental|Placebo AWC + Placebo ABFD|Placebo Antimicrobial Wound Cleanser + Placebo Antimicrobial Barrier Film Dressing + SOC
2456461|NCT03197506|Experimental|Group 1 (pembrolizumab, surgery, temozolomide, radiation)|"NEOADJUVANT (CYCLE 1): Patients receive pembrolizumab IV over 30 minutes on day 1.~SURGERY (CYCLE 2): Patients undergo standard of care surgery within days 4-7.~CONCURRENT (CYCLE 3): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLE 4-8): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 1-5 every 28 days. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
2456462|NCT03197506|Experimental|Group 2 (pembrolizumab, temozolomide, radiation therapy )|"CONCURRENT (CYCLE 1): Starting 21-35 days after surgery, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 and temozolomide PO daily on days 8-54. Patients also undergo external beam radiation therapy every 5 days per week on days 8-54.~ADJUVANT (CYCLES 2-6): Within 3-5 weeks after completing radiation therapy, patients receive pembrolizumab IV over 30 minutes on days 1, 22, and 43 of cycles 2-5 and 1 and 22 of cycle 6 (up to a total of 17 doses). Patients also receive temozolomide PO daily on days 1-5, 29-33, and 57-61 of cycles 2 and 6, days 22-26 and 50-54 of cycle 3, days 15-19 and 43-47 of cycle 4, days 8-12 and 36-40 of cycle 5. Treatment repeats every 63 days for up to 5 cycles in the absence of disease progression or unexpected toxicity."
3154424|NCT00298545|Placebo Comparator|placebo and Calcitriol|placebo tablets together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
3154425|NCT00298545|Active Comparator|2|calcium together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
2456591|NCT03196739|Experimental|Virtual rehabilitation|Upper limb rehabilitation using virtual reality with a head-mounted display (HTC Vive; HTC Co., New Taipei City, Taiwan)
2456658|NCT03196375|Experimental|Experimental|
2456665|NCT03196375|Placebo Comparator|Placebo Comparator|
2456759|NCT03195348|Experimental|HBF Bed Rest|7 days control period followed by a washout period, then 7 days of HBF.
2456808|NCT03195114||Multimodality Imaging and Biomarkers|Post-TAVR patients who received commercial Medtronic Evolut-R or Evolut PRO bioprosthesis implant and found to have at least mild PVL on 1-month post-TAVR echocardiogram will undergo multimodality imaging and biomarkers evaluation at 1-month and 7-months post-TAVR.
3154426|NCT00298623|Placebo Comparator|Placebo|
3154427|NCT00298623|Experimental|XP13512 (GSK1838262)|
3154428|NCT00298675|Experimental|Iniparib|
3154429|NCT00298675|Experimental|Iniparib/irinotecan|
3154430|NCT00298727|Active Comparator|1|SHIPS: Face-to-Face Workshop
3154431|NCT00298727|Active Comparator|2|ePBL: Online Problem-Based Course
3154432|NCT00298792|Experimental|Individualized Assessment & treatment|Individualized treatment for alcohol dependent persons, based on momentary assessment of high-risk situations and recorded coping abilities.
3154433|NCT00298792|Active Comparator|Packaged Cognitive-Behavioral Treatment|Manualized cognitive-behavioral treatment for alcohol dependent persons.
3154434|NCT00298870|Experimental|PGx-treatment|NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)
3154435|NCT00298870|Active Comparator|STD-treatment|Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)
3154436|NCT00298883|Experimental|Treatment|This is a single arm, interventional trial.
3154437|NCT00298909|Experimental|1|niacin
3154438|NCT00298909|Active Comparator|2|physical exercise
3154439|NCT00298909|Placebo Comparator|3|control
3154440|NCT00298922|Active Comparator|Azithromycin|participants taking 500 mg tablets orally thrice weekly for 24 weeks
3154441|NCT00298922|Placebo Comparator|Placebo|Participants taking 500 mg tablets orally thrice weekly for 24 weeks
3154442|NCT00298974|Experimental|hydrocodone/acetaminophen extended release|
3154443|NCT00298974|Placebo Comparator|Placebo|
3154444|NCT00298987|Experimental|A1|
3154445|NCT00299013|Active Comparator|1|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
3154446|NCT00299013|Experimental|2|COLAL-PRED 40mg oral capsule, once daily for 8 weeks.
2455796|NCT03201835|Active Comparator|Sativex®|spray X 4 actuations, Each 100 μL spray contains 2.7 mg THC and 2.5 mg CBD, total per administration: 10.8 mg THC and 10 mg CBD
3190804|NCT00791544|Experimental|Combination cohort 1|AVE1642 selected dose in combination with sorafenib
3190805|NCT00791544|Experimental|Combination cohort 2|AVE1642 selected dose in combination with erlotinib
3190806|NCT00791570|Experimental|A|
2455963|NCT03200444|Experimental|Testing of 6 adhesive strips|"Each subject tests six adhesive strips on pre-striped skin.~Standard adhesive 1~standard adhesive 2~Standard adhesive 3~P-4~P-15~P-16~The six strips are applied on abdominal skin. The order to which the adhesive strips are located on the skin is randomized. The subjects will change the adhesive strips at home and the adhesion of the adhesive strips will be measured at 5 visits."
2456035|NCT03200223|Experimental|Personalized lifestyle intervention group|Personalized lifestyle intervention group Patients who use mobile healthcare service application and receive personal feedback from clinician
2456037|NCT03200223|No Intervention|Conventional group|Patients with conventional care
2456060|NCT03199716|Experimental|Parent Mentors and Intervention Group|Parent mentors are parents from our UC Davis Pediatrics Endocrinology clinic who have met our parent mentor inclusion criteria; the intervention group are families in our clinic who have met our mentee family inclusion criteria
2456065|NCT03199716|No Intervention|Control Group with no Parent Mentors|The control group is made up of families at our UC Davis Pediatrics Endocrinology clinic who have met the mentee family inclusion criteria but are not matched with a parent mentor
2456150|NCT03199547|Experimental|AZITHROMYCIN|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
2456155|NCT03199547|Placebo Comparator|Placebo oral tablet|A single dose of 2G Azithromycin or Placebo will be administered orally to women in labour
2456232|NCT03199014|Experimental|prolonged deployment strategy group|"in deploying the Drug-eluting Stents with a prolonged time group,the inflation time was more than 30 seconds when the Drug-eluting Stents deploying,unless the patients was unstable."
2456233|NCT03199014|Active Comparator|rapid deployment strategy group|"in deploying the Drug-eluting Stents with a conventional time group, a conventional method was used to deploying drug-eluting stents,the actual inflation time was within 10s determined by interventional cardiologist."
2456237|NCT03198637|Experimental|Monitoring|Neuromuscular Blockade's monitoring
2456239|NCT03198637|Active Comparator|Clinical assessment|No active monitoring of cisatracurium
2456303|NCT03198546|Other|CAR-T cell therapy group|Appropriate patients who could benefit from the GPC3 and TGFβ targeting CAR-T cell therapy against HCC are chosen to be the CAR-T cell therapy group.
2456354|NCT03198286|Experimental|Supportive care (survivor care plan, survey)|Patients receive a customized treatment summary and survivor care plan via the Carevive Survivor Care Planning System and review it during their follow-up visit. Patients also complete a survey on a tablet computer over 10-20 minutes before and after their follow-up visit.
2456426|NCT03197987|Experimental|Endocuff colonoscopy|Endocuff-assisted colonoscopy
2456427|NCT03197987|Active Comparator|Cap colonoscopy|Cap-assisted colonoscopy
2456454|NCT03197532||Group 1|Otherwise healthy, mid-reproductive aged women between the ages of 20 and 35 years previously exposed to high dose alkylating agent therapy (or have an alkylator score of 1 or more), and at least 1 year from cancer treatment.
2456456|NCT03197532||Group 2|Healthy, mid-reproductive aged women between the ages of 20 to 35 who have not been exposed to cancer therapy.
2456459|NCT03197532||Group 3|Reproductive aged women between the ages of 43-50 who have not been exposed to cancer therapy, nor have a history of infertility
3190807|NCT00791596|Experimental|1|The first Arm received the intervention between baseline and the first follow-up, whereas the second Arm was the Control group
3190808|NCT00791596|Experimental|2|The second Arm received the intervention between the third and the fourth follow-up, whereas the first Arm was the Control group
2456566|NCT03196817|Active Comparator|Carpal tunnel injection|Carpal tunnel injection (infiltration) group of patients will be referred to the Hospital Alvorada to carry out steroid injection. The injection in carpal tunnel will be an association of 6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%, totaling 1.5 ml.
2456568|NCT03196817|Active Comparator|Wrist splinting|Wrist splinting will be use in the nigth time, remain the wrist in the 15th degree in extension, until its removal in the morning.
2456655|NCT03196518|Experimental|PET Imaging With 18F-TFB|The intervention is the administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes. This will be followed by a 30 minute dynamic PET/CT study immediately after injection, at 60 minutes (+/- 10 min) and 4 hours (+/- 15 min) post injection. The second and third scan will last up to 30 minutes.
2456696|NCT03195907||PPT group|Those participated in pulmonary rehabilitation program
2456697|NCT03195907||Control group|Those served as control group
3190809|NCT00791635||Observational (questionnaires)|"RETROSPECTIVE PORTION: Patients who have undergone pelvic exenteration complete one set of QOL questionnaires.~PROSPECTIVE PORTION: Patients undergoing pelvic exenteration complete questionnaires over 20-40 minutes within 2 weeks before surgery, and at 4-12 weeks, 6 months, and 1, 2, 3, 4, 5, and 10 years after surgery regarding feelings, abilities, depression, coping, social support, sexual function and body image. Patients with cervical cancer may complete 1 additional questionnaire during each of these visits."
3190810|NCT00791687||PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers received full course of betamethasone before delivery.
3190811|NCT00791687||NON PRENATAL CORTICOSTEROIDS|Extremely low gestational age neonates (<28 weeks gestation) whose mothers did not receive full course of betamethasone before delivery.
2456791|NCT03194984|Other|Young Patient|With 18-25 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
2456793|NCT03194984|Other|Adult Patient|With 40-65 years old. Drug: Hydrogen peroxide 35%. Drug: Hydrogen peroxide 38%
3190812|NCT00791726||1|Patients with noninfectious uveitis and macular edema
3190813|NCT00791739|Experimental|one arm study|
3190814|NCT00791752|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
3190815|NCT00791752|Placebo Comparator|2|Placebo
3190816|NCT00791791|Other|1|increasing remifentanil administration
2455816|NCT03201874|Active Comparator|Education Control|In addition to standard medical care, youth in the education control group will be provided with access to a self-guided education study website, which will contain static education about SCD (no self-management skills, goal-setting, or social support content) to access over 8-weeks.
2455817|NCT03201874|Experimental|Pain Self-Management Intervention|In addition to standard medical SCD care, youth in the pain self-management intervention group will receive the iCanCope with SCD mobile intervention including goal-setting, peer social support, and pain self-management skills over a period of 8 weeks.
3190817|NCT00791791|Other|2|decreasing remifentanil concentration
3190818|NCT00791804|Experimental|Single Arm|
2455972|NCT03200613|Experimental|Apixaban|Apixaban 2.5 mg orally twice daily
2455974|NCT03200613|Active Comparator|Low Molecular Weight Heparin|Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily
2456029|NCT03200119|Experimental|Mobile application user group|In the active group, participants were educated to modify their lifestyle to lose weight by using a smart phone-based lifestyle app which was designed to collect daily activity and dietary information. The app was composed of two main modules: a diet module, and a physical activity module.
2456032|NCT03200119|No Intervention|Control group|Conventional lifestyle modification
2456079|NCT03199742|Active Comparator|PTSD Coach with no Coaching|Participants will receive the PTSD coach mobile app.
2456082|NCT03199742|Experimental|PTSD Coach with Peer Coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a Veteran peer.
2456085|NCT03199742|Experimental|PTSD Coach with Clinician coaching|Participants will receive the PTSD Coach + mobile app which will provide routine, personalized coaching for 8 weeks from a clinical psychologist.
2456090|NCT03199742|Experimental|PTSD Coach with Automated Coaching|Participants will receive the PTSD Coach + mobile app which will provide automated, personalized coaching for 8 weeks.
2456112|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 First Dose - Active|N = 2, 100 mg TBA-7371 or matching placebo
2456115|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 First Dose - Placebo|N = 1, 100 mg TBA-7371 or matching placebo
2456118|NCT03199339|Active Comparator|SAD Part 1 Cohort 1 Second Dose - Active|N = 4, 100 mg TBA-7371 or matching placebo
2456121|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 1 Second Dose -Placebo|N = 1, 100 mg TBA-7371 or matching placebo
2456125|NCT03199339|Active Comparator|SAD Part 1 Cohort 2 - Active|N= 6, 250 mg TBA-7371 or matching placebo
2456127|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 2 - Placebo|N = 2, 250 mg TBA-7371 or matching placebo
2456130|NCT03199339|Active Comparator|SAD Part 1 Cohort 3 - Active|N = 6, 500 mg TBA-7371 or matching placebo
2456131|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 3 - Placebo|N = 2, 500 mg TBA-7371 or matching placebo
2456133|NCT03199339|Active Comparator|SAD Part 1 Cohort 4 - Active|N = 6, 1000 mg TBA-7371 or matching placebo
2456138|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 4 - Placebo|N = 2, 1000 mg TBA-7371 or matching placebo
2456142|NCT03199339|Active Comparator|SAD Part 1 Cohort 5 - Active|N = 6, 1500 mg TBA-7371 or matching placebo
2456149|NCT03199339|Placebo Comparator|SAD Part 1 Cohort 5 - Placebo|N = 2, 1500 mg TBA-7371 or matching placebo
2456152|NCT03199339|Active Comparator|MAD Part 2 Cohort 1 - Active|N = 9, 100 mg TBA-7371 or matching placebo
2456156|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 1 - Placebo|N = 3, 100 mg TBA-7371 or matching placebo for 14 days
2456160|NCT03199339|Active Comparator|MAD Part 2 Cohort 2 - Active|N = 9, 200 mg TBA-7371 or matching placebo for 14 days
2456167|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 2 - Placebo|N = 3, 200 mg TBA-7371 or matching placebo for 14 days
2456171|NCT03199339|Active Comparator|MAD Part 2 Cohort 3 - Active|N = 9, 400 mg TBA-7371 or matching placebo for 14 days
2456172|NCT03199339|Placebo Comparator|MAD Part 2 Cohort 3 - Placebo|N = 3, 400 mg TBA-7371 or matching placebo for 14 days
2456175|NCT03199339|Active Comparator|DDI Part 3 Cohort 1|14 subjects to receive midazolam and bupropion before and after orally giving 200mg of TBA-7371, 1 per day for 14 days
2456238|NCT03198780|Experimental|Breathing Awareness|"In the clinic, once patients are proficient with the proposed tool, they will (1) independently don the pulse oximeter, (2) use the prototype to perform the mindful breathing intervention. The whole session will last no longer than 60 minutes with 30 minutes for the consent and demonstrations, two minutes to don the study devices, 15 minutes to practice mindful breathing, and two minutes to doff the study devices. The mindful breathing portion will be divided into three sessions. Each session will last three minutes and display a different presentation of Heart Rate Coherence biofeedback.~At home, after completing the in-clinic study, five patients will take the mindful breathing tool home for a week to practice pursed-lip breathing at least five times. They will don the study devices, perform the intervention, and doff study devices."
2456439|NCT03197727|Other|GC Saliva-Check BUFFER|Saliva test pH Buffering capacity Flow rate
2456877|NCT03194724||High Vitamin A exposure|There was no intervention
3190819|NCT00791830|Active Comparator|Irbesartan|
3190820|NCT00791830|Placebo Comparator|Placebo|
3190821|NCT00791856|Active Comparator|1|28 cm2 testosterone patch
3190822|NCT00791856|Experimental|2|14 cm2 testosterone patch
3190823|NCT00791882|Experimental|1|"Group of behaviors by which someone express feelings, attitudes, wishes,opinions and rights , in an adequate manner regarding situation and context.~Social skills are the substrate for social competence, which is the ability to find and legitimate relevant and personal goals"
3190824|NCT00791882|No Intervention|2|Control group will attend the same number of sessions, but without intervention of the therapists
3190825|NCT00791895|Experimental|A|
3190826|NCT00791960|Active Comparator|Dimenhydrinate|Dimenhydrinate
3190827|NCT00791960|Placebo Comparator|Placebo|Placebo
3190828|NCT00791986|No Intervention|control|The patients in this control group do not conduct any breathing training.
3190829|NCT00791986|Experimental|ULB|The patients conduct controlled slow breathing training using the WPTB device without inspiratory resistance.
3190830|NCT00791986|Experimental|LB|The patients breath in against resistance using WPTB device.
2455843|NCT03201341|Other|Study in TMS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the brain areas involved in these processes. Before the Transcranial magnetic stimulation (TMS) examination, MRI of the brain will be performed.The TMS review will consist of three distinct sessions separated from one another by at least one week, depending on the protocol, and which will differ simply at the site or type of stimulation.
2455845|NCT03201341|Other|Study in tDCS|To better understand the normal functioning of the brain in the representation of the body and the space of action, to determine the functional role of the cerebral areas involved in these processes. The transcranial Direct Current Stimulation (tDCS) exam will consist of three separate sessions separated from each other by at least one week and will simply differ at the stimulation site. The task accomplished is explained in detail by the experimenter.
2455938|NCT03200730|Experimental|Family Dignity Intervention group|"A standard framework of 12 FDI questions is given to patient-family dyads in the intervention group during baseline to provides them with the opportunity to think about their responses. During the intervention interview scheduled 2-3 days later, the FDI therapist follows that dyad's cues, help them to organize their thoughts, facilitate disclosure of cherished memories, and encourage the expression of appreciation. The interview is be recorded, quickly transcribed verbatim then edited into a coherent narrative. A second review session is arranged to review and finalize the edited transcript with the dyads. Once the legacy documents are ready, a final family sharing session is arranged for the dyads to share and read this document to each other and their loved ones."
2455939|NCT03200730|No Intervention|Control group|Patient-family dyads in the control group have at least four interviews with a designated member of the research team via psychosocial home visits. Completing the assessments and taking part in the interviews provides them with the opportunity to share their feelings and emotions along their illness trajectory. The extent to which they feel sharing is therapeutic is explored in the interview.
3154447|NCT00299013|Experimental|3|COLAL-PRED 60mg oral capsule, once daily for 8 weeks.
3154448|NCT00299013|Experimental|4|COLAL-PRED 80mg oral capsule, once daily for 8 weeks.
3154449|NCT00299039|Active Comparator|1|
3154450|NCT00299039|Active Comparator|2|
2456137|NCT03199482|Active Comparator|Drug dexamethasone|preoperative single dose of dexamethasone 0.5 mg oral tablet given to patients before starting of root canal treatment by 30 minutes.
2456144|NCT03199482|Placebo Comparator|Placebo|Placebo will be administrated to patients before stating of root canal treatment
2456295|NCT03198611||Normal function|No systolic dysfunction No diastolic dysfunction No right ventricular dysfunction
2456298|NCT03198611||Left ventricular systolic dysfunction|Left ventricular ejection fraction < 50%
2456300|NCT03198611||Left ventricular diastolic dysfunction|"Classification according to:~Mitral lateral annulus e' in tissue Doppler < 10 cm/s~American society of echocardiography (ASE) criteria 2009~ASE criteria 2016"
2456304|NCT03198611||Right ventricular dysfunction|Tricuspid annulus plane systolic excursion < 17 cm
2456385|NCT03197961|Experimental|DMPA with tenofovir/emtricitabine PrEP|the drug combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg which is known as Truvada® will be taken orally once daily for 14 days by all participants. Drug concentrations will be measured (blood sampling) and one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection after the first course of tenofovir disoproxil fumarate/emtricitabine is completed. Then, a second round of the combination of tenofovir disoproxil fumarate 300mg and emtricitabine 200mg (Truvada®) will be taken orally once daily for 14 days by all participants.
2456443|NCT03197714|Experimental|OPB-111077|Level 1: 200 mg daily Level 2: 250 mg daily
2456485|NCT03197415|Experimental|PRP group|Intradisc injection of autologous platelet-rich plasma gel
3154451|NCT00299052|Active Comparator|A|Bone reamings with 5cc of DMB putty
3154452|NCT00299052|Active Comparator|B|Bone reamings
2456710|NCT03195647|Experimental|Relaxed control|Those randomised to the 'Relaxed' Group will receive potassium supplementation only if their serum potassium drops below or equals 3.6 mEq/L.
2456711|NCT03195647|Active Comparator|Tight Control|Patients randomised to the 'Tight' group will receive potassium supplementation if their serum potassium falls below 4.5 mEq/L (current practice).
2456747|NCT03195530||Elderly patients|Patients over 65 years, scheduled to general surgery, requiring general anesthesia
2456812|NCT03195218|Experimental|HRME examination|HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
3154453|NCT00299091|No Intervention|Control|Efavirenz capsules 600 mg
3154454|NCT00299091|Experimental|Experimental|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
3154455|NCT00299169|Experimental|1|N of 1 trials of statin therapy
3154456|NCT00299169|Other|2|usual care
3154457|NCT00299234|Placebo Comparator|2|placebo
3154458|NCT00299234|Experimental|1|atomoxetine
3154459|NCT00299260|Active Comparator|vaccine|glycoprotein B plus MF59 adjuvant
3154460|NCT00299260|Placebo Comparator|placebo|normal saline
3154461|NCT00299273|Experimental|Low calorie high fat/protein diet|Low calorie high fat/protein diet
3154462|NCT00299286|Experimental|Lapatinib|lapatinib oral 1500mg daily taken as 6 tablets as one dose 10-14 days presurgery
3154463|NCT00299286|Placebo Comparator|Lapatinib-Placebo|placebo comparator 6 tablets taken as one dose daily
3154464|NCT00299325|Experimental|Rimonabant|Rimonabant 20 mg once daily with mild hypocaloric diet
3154465|NCT00299325|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily with mild hypocaloric diet
3154466|NCT00299390|Experimental|Sagopilone|
3154467|NCT00299403|Active Comparator|1|Right frontal low frequency rTMS
3154468|NCT00299403|Active Comparator|2|electroconvulsive therapy (ECT). Right unilateral ECT 3 time a week in 3 weeks
3154469|NCT00299429|Active Comparator|MIDCAB Surgery|MIDCAB Surgery
3154470|NCT00299429|Experimental|PCI with drug-eluting stent|PCI with DES
3154471|NCT00299442|Experimental|1|Self-help Triple P Behavioural Family Intervention
3154472|NCT00299442|No Intervention|2|Wait-list control
2455941|NCT03200886||Sinovial H-L Group|The patients treated have received one cycle of two injections (at baseline and 15 days apart) of 1 ml of Sinovial H-L® (3.2% - 16mg + 16mg, Ibsa).
2455942|NCT03200886||Control Group|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl).
2455997|NCT03200301|Experimental|Intact Umbilical Cord Milking|Umbilical Cord Milking involves pinching of the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will be then released, allowing for a brief 2-second pause between each milking motion. This will be repeated for a total of 3 times over a duration less than 20 seconds.
2455999|NCT03200301|No Intervention|Early Cord Clamping|Umbilical cord will be clamped immediately after delivery and baby will be handed over to the neonatal team.
2456083|NCT03199950|Experimental|Prophylactic Haloperidol arm|Patients will receive oral haloperidol 2dd1mg (08.00am & 10.00pm)
2456087|NCT03199950|Placebo Comparator|No treatment|Patients will receive oral placebo 2dd (08.00am & 10.00pm)
2456192|NCT03199326|Experimental|Collaborative Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the collaborative practice, the caseworkers will conduct a standard CPS investigation. Additionally, caseworkers will seek parental permission to contact an identified primary health care provider at two points in the CPS investigation for information sharing related to health needs, social risks, and recommended interventions.
2456194|NCT03199326|No Intervention|Comparison Care|CPS caseworkers will be randomized to collaborative or comparison practice. For any infant investigated by a caseworker in the comparison practice, the caseworkers will conduct a standard CPS investigation.
2456328|NCT03198962||Groups A|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-negative participants will be actively offered to visit the clinic for pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP) or STI services and encouraged to visit the clinic outside of the scheduled visits for these services whenever they feel needed. Adherence to PrEP, PEP, STI treatment will be evaluated in those who are prescribed these medications. Among HIV seroconverters, drug use patterns will be longitudinally monitored prior to and after HIV diagnosis. HIV seroconverters at month 6 or month 12 will be transferred to groups C, D dependent on drug use history.
2456330|NCT03198962||Groups C|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
2456333|NCT03198962||Group B|At each visit, a series of self-administered questionnaires will be used to collect demographic, sexual behavioral risk and drug use data. HIV testing, risk reduction counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18.
2456335|NCT03198962||Group D|At each visit, a series of self-administered questionnaires will be used to collect demographic, behavioral risk and drug use data. In addition, data on adherence to antiretroviral therapy (ART) will be collected. Risk reduction counseling, adherence counseling, condoms & lubricants will also be provided at these visits. Syphilis serology, Chlamydia trachomatis/Neisseria gonorrhea testing from anal and urethral compartments will be performed at baseline, month 6,12,18. HIV-positive participants, if they have not yet started ART, will be referred to preferred hospitals to receive ART regardless of CD4 count according to the 2014 National Guidelines. Drug use patterns will be longitudinally monitored prior to and after ART initiation.
3154473|NCT00299455|Experimental|1|Reconstituted amoxicillin-clavulanate at 40/5.7 mg/kg/day in 2 divided doses for 7 days.
3154474|NCT00299455|Placebo Comparator|2|Reconstituted placebo in 2 divided doses for 7 days.
2456395|NCT03197831||Private Option Expansion|This group incorporates data from the state of Arkansas and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
2456396|NCT03197831||Managed Medicaid Expansion|This group incorporates data from the state of Kentucky and is applicable only to aims 1 and 2 where we are determining the impact of difference methods of Medicaid expansion on inpatient and ED utilization.
2456398|NCT03197831||No Medicaid Expansion|This group incorporates data from the state of Florida in aims 1 and 2 and all the states which did not expand Medicaid enrollment in 2014 for aim 3.
2456400|NCT03197831||Medicaid Expansion|This group incorporates data from the state of Arkansas and Kentucky in aims 1 and 2 and all the states which expanded Medicaid enrollment in 2014 (except New Hampshire and Michigan) for aim 3.
2456447|NCT03197675|Sham Comparator|Control group|Participants who are randomized to the control group will not receive any acupuncture. Participants will however be assessed weekly to obtain the same data on their pain scale and other outcome measures as the treatment group. Participants will be evaluated in person during their standard of care clinical follow up appointments at the three month and six month points for in person interviews and data collection .
2456448|NCT03197675|Active Comparator|treatment group|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture, 8 treatments of auricular acupuncture). Pain Numeric Rating Score (NRS) will be evaluated by the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
2456467|NCT03197402|Active Comparator|Comparator group|Milk protein gel delivery system supplementation
3154475|NCT00299507|Experimental|15 mg Anecortave Acetate, 3 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months).
2455958|NCT03200600|Experimental|Dexamethasone and lipid microsphere|"Dexamethasone 10 mg is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2455960|NCT03200600|Experimental|Normal saline and flurbiprofen axetil|"Normal saline 2 ml is administered before anesthesia induction.~Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2455962|NCT03200600|Experimental|Normal saline and lipid microsphere|"Normal saline 2 ml is administered before anesthesia induction.~Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h."
2456003|NCT03200197|Experimental|menthol chewing gum|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection. The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After using the intervention (menthol chewing gum) for 10 minutes, chewing at a natural rhythm and swallowing the saliva produced, the intensity and final discomfort were measured using the same scales.
2456005|NCT03200197|Active Comparator|Usual care (maintenance of fasting)|Allocation concealment was performed through the use of individual opaque envelopes numbered externally in sequence, containing the randomly defined group information.This step was performed by a researcher who did not participate in the data collection.The intensity of the initial thirst was measured by means of the Verbal Numerical Scale (VNS), which ranged from 0 (no thirst) to 10 (very intense thirst) and the discomfort of the initial thirst was measured through the Perioperative Thirst Discomfort Scale (PTDS), which is composed of 7 attributes and ranges from 0 to 14. After maintaining the usual care, that is, reaffirming the need for fasting for 10 minutes, the intensity and final discomfort were measured using the same scales.
2456055|NCT03199833|Experimental|Arms|RETRAINER-S2 & Conventional Therapy 27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S2 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2456059|NCT03199833|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2456107|NCT03199508|Experimental|the 3-day voiding diary group|The 3-day voiding diary group is as the experimental group in which several centers use the 3-day voiding diary by cluster randomization. The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
2456109|NCT03199508|Active Comparator|the 7-day voiding diary group|The 7-day voiding diary group is as the control group in which several centers use the 7-day voiding diary by cluster randomization. The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights. The 3-day voiding diary group is the experimental group in which several centers use the 3-day voiding diary by cluster randomization.
2456205|NCT03199183||Takayasu arteritis|All recruited Takayasu arteritis patients.
2456445|NCT03197766|Experimental|Active BMN 111|Daily subcutaneous injection of 15 micrograms per kilogram BMN111
2456446|NCT03197766|Placebo Comparator|Placebo|Daily subcutaneous injection of placebo
2456535|NCT03197181|Experimental|anodal transcranial direct current stimulation|anodal transcranial direct current stimulation (current strength: 1 mA, duration: 20 min) over the frontopolar cortex
2456536|NCT03197181|Sham Comparator|sham transcranial direct current stimulation|sham transcranial direct current stimulation (current strength: 1 mA, duration: 0.5 min) over the frontopolar cortex
2456545|NCT03196778|Experimental|Low Dose Radiation|
2456599|NCT03196713|Other|Tailored supervision|
2456604|NCT03196713|Other|Regular supervision|
2456666|NCT03196271|Other|Study arm|One single arm, consisting of a 3 day baseline period, a 28 day control period and a 28 day intervention period (Ketocal 2.5:1), in that order.
2456715|NCT03195816|Experimental|computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program.
2456718|NCT03195816|No Intervention|MCI control group|The control group will receive a usual standard care without engagement in intervention
2456881|NCT03194607||Patients|
2456886|NCT03194607||Controls|
3154476|NCT00299507|Experimental|15 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
3154477|NCT00299507|Experimental|30 mg Anecortave Acetate, 6 month intervals|Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months).
3154478|NCT00299507|Sham Comparator|Anecortave Acetate Vehicle|One 0.5 mL sham injection of Anecortave Acetate Vehicle at 6 month intervals (3, 9, 15, 21 months).
3154479|NCT00299559|Other|1|cross over application of both specimen
3154480|NCT00299611|Active Comparator|1|Levetiracetam
3154481|NCT00299611|Placebo Comparator|2|there is no active ingredient in the pills.
3154482|NCT00299650|Placebo Comparator|A|
3154483|NCT00299650|Active Comparator|B|
3154484|NCT00299676||001|Galantamine (Reminyl) Use of Reminyl according to approved NZ data sheet
3154485|NCT00299819|Active Comparator|1|MEDI-545
3154486|NCT00299819|Active Comparator|2|MEDI-545
3154487|NCT00299819|Active Comparator|3|MEDI-545
2455959|NCT03200548|Sham Comparator|Sham acupressure plus usual care|There is a set of unilateral and bilateral acupoints that will be stimulated for 3 minutes per point giving a total treatment time of about 30 minutes daily. None of these points are on meridians nor are they on actual points. They were chosen to be in the same general body quadrant as the true points.
2455961|NCT03200548|Placebo Comparator|Usual care|Participants will be asked to continue following their healthcare providers' instruction for chronic SLE management. We anticipate that most women will be treated per the American College of Rheumatology clinical guidelines. Participants will be asked to continue any current treatment and not to start or stop treatments including acupuncture/acupressure over the course of the study. All treatments for pain will be recorded.
2456004|NCT03200249|Experimental|Treatment|"- Treatment : concomitant preoperative radio-chemotherapy (during 5 weeks)~Chimiotherapy: Capecitabine 1600 mg/m2/j ; 5/7 days during the 5 weeks of radiotherapy~Radiotherapy RT + SIB-IMRT (5 weeks ; 5 sessions/week ; 25 sessions): Pelvic prophylactic dose of 45 Gy (1,8 Gy/session); boost with a dose of 60 Gy on the tumor PTV (2,4 Gy/session) - Total dose: 60 Gy in 25 sessions during 5 weeks.~- TME surgery (8 weeks after the end of treatment)"
3154488|NCT00299819|Active Comparator|4|MEDI-545
3154489|NCT00299819|Active Comparator|5|MEDI-545
2456163|NCT03199352||RYGB: Hand-sewn|This group would receive a Roux-en-y gastric bypass with the anastomosis hand-sewn using a minimally-invasive robotic surgical approach
2456168|NCT03199352||RYGB: linear-staple|This group would receive a Roux-en-y gastric bypass with the anastomosis sewn with a linear stapler using a laparoscopic surgical approach
3154490|NCT00299858|Active Comparator|Study Group|Patients will be given theophylline, titrated to optimal blood levels, for a period of 4 weeks.
3154491|NCT00299858|Placebo Comparator|Placebo group|Patients will receive placebo pills for a period of 4 weeks.
2456305|NCT03198403|Experimental|Popliteal plexus block|Patients with an FTB, reporting postoperative pain (NRS > 3) will have a popliteal plexus block
2456306|NCT03198403|No Intervention|No intervention|Patients with postoperative pain NRS < or = 3
2456348|NCT03198273|Experimental|Clinical pilates exercises|Participants will exercise 3 times a week for 6 weeks (18 sessions in total, 45-60 minutes each session) in accompany with a physiotherapist. Since the chosen model for exercise training is clinical pilates exercises, separate patient training will be needed. First 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase; and Second 3 weeks planned as Warming Phase, Exercise Phase (first 3 weeks), Cooling Phase.
2456350|NCT03198273|Experimental|Physiotherapy Program|Standard physiotherapy program consisting of conservative treatment is applied to both groups. The conservative treatment schedule to be applied to planned as 10 sessions, 3 times a week.
2456441|NCT03198013|Experimental|Module A|Single Ascending Dose
2456444|NCT03198013|Experimental|Module B|Multiple Ascending Dose
2456580|NCT03196804|Experimental|LC28-0126|LC28-0126(IV)
2456582|NCT03196804|Placebo Comparator|Placebo|Placebo of LC28-0126
2456625|NCT03196492||No hormone|Half of the cohort (n=40) will have opted to forgo hormonal contraception (HC).
2456629|NCT03196492||Depo-provera|Half of the cohort (n=40) will have opted to initiate injectable depo-provera (DMPA).
2456675|NCT03196154||Metformin|Patients who are on either metformin 2g per day or metformin extended release 2g per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
2456677|NCT03196154||Metformin + Gliclazide|Patient who are on both metformin 2g per day or metformin extended release 2g per day and gliclazide 320mg per day or gliclazide modified release 120mg per day. Subject will be required to fast overnight. Fasting insulin levels and plasma drug levels will be measured.
2456699|NCT03195790|Active Comparator|Medical center treatment arm|Family-based pediatric obesity treatment delivered at an urban medical center.
3154492|NCT00299884||1|Lipitor 20 mg
3154493|NCT00299884||2|Lipidil Supra 160 mg and Ezetrol 10 mg
3154494|NCT00299962|Experimental|Dose level 4|
3154495|NCT00299962|Experimental|Dose level 5|
3154496|NCT00299962|Experimental|Dose Level 1|on Days 1 and 15
3154497|NCT00299962|Experimental|Dose Level 2|On Days 1 and 15
3154498|NCT00299962|Experimental|Dose Level 3|On Days 1 and 15
3154499|NCT00300040|Experimental|1|Hemoglobin glutamer 250 - bovine
3154500|NCT00300040|Active Comparator|2|6% Hydroxyethylstarch
3154501|NCT00300092|No Intervention|No antibioitcs|Group 1 received no antibiotics
3154502|NCT00300092|Active Comparator|Cephalexin|Group 2 received cephalexin at 50 mg/kg divided 3 times daily for 7 days
3154503|NCT00300118|Experimental|A|
3154504|NCT00300118|Active Comparator|B|
3154505|NCT00300131||1|Bioabsorbable Vascular Solutions (BVS) Everolimus Eluting Coronary Stent System
3154506|NCT00300196|Experimental|Intravenous ancrod|Intravenous ancrod infused at a rate of 0.167 IU/kg/hr (0.6 mL/kg/hr) for 2 or 3 hours depending on the pretreatment fibrinogen level.
3154507|NCT00300196|Placebo Comparator|Intravenous Placebo|Intravenous placebo at a rate of 0.6 mL/kg/hr for 2 or 3 hours depending on the pretreatment fibrinogen level.
3154508|NCT00300261|No Intervention|1|receives home care
3154509|NCT00300261|Experimental|2|receives telehealth monitoring in addition to home care
3154510|NCT00300300|No Intervention|1|applying a patellar graft using conventional surgical technique.
3154511|NCT00300300|No Intervention|2|applying a hamstring graft using conventional surgical technique.
3154512|NCT00300300|Experimental|3|applying a patellar graft using a computer-assisted surgy technique.
3154513|NCT00300300|Experimental|4|hamstring graft CAOS
3154514|NCT00300313|Active Comparator|1|
3154515|NCT00300313|Placebo Comparator|2|
3154516|NCT00300326|No Intervention|1|Using the same knee implant with a conventional surgical technique.
3154517|NCT00300326|Active Comparator|2|Using the same knee implant using a computer-assist surgery group is the comparator
3154518|NCT00300534|No Intervention|Abbott Laboratories Determine test for syphilis|Abbott Laboratories Determine rapid test for syphilis
3154519|NCT00300573|Experimental|Dexelvucitabine (DFC)|200 mg once daily
3154520|NCT00300573|Active Comparator|lamivudine (3TC)|300 mg once daily
3154521|NCT00300586|Sham Comparator|A (supervision)|medical supervision, second line chemotherapy if progression
2456047|NCT03199976|Experimental|Tiotropium Bromide & Salbutamol|Inhaled Tiotropium Bromide 5 µg once a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2456048|NCT03199976|Active Comparator|Fluticasone Propionate & Salbutamol|Inhaled Fluticasone Propionate 125 µg twice a day, beginning at the onset of an upper respiratory tract infection and continuing for 7 to 14 days as needed, and inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2456049|NCT03199976|Active Comparator|Salbutamol|Inhaled Salbutamol 0.2 mg 4 to 6 times a day as needed for wheeze and shortness of breath
2456244|NCT03198624|Active Comparator|HTL0018318 Low dose, Part A.|Part A. 1 single dose on day 1. Discharged on day 4 of Period 1 (following 10 day washout).
2456250|NCT03198624|Active Comparator|HTL0018318 High dose, Part A|1 single dose on day 1. Discharged on day 4 of period 2 (following 10 day washout).
2456254|NCT03198624|Active Comparator|HTL0018318 Low dose, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
2456256|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 1.
2456258|NCT03198624|Active Comparator|HTL0018318 High dose, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
2456259|NCT03198624|Placebo Comparator|Placebo oral capsule, Part B.|1 dose daily for 5 days (5 active doses total). Discharged on day 8 of period 2.
3154522|NCT00300586|Active Comparator|B (gemcitabicine)|Maintenance treatment (gemcitabicine 1250 mg/m² J1, J8 (repeated cycles every 21 days), second line chemotherapy if progression
2456357|NCT03198338|Experimental|TAP group|Drug: 0.25% Bupivacaine, 0.5mL/kg
2456358|NCT03198338|Sham Comparator|Placebo group|Drug: 0.9% Normal Saline, 0.5mL/kg
2456415|NCT03197896|Experimental|Group I (prostate cancer information)|The educator reviews general information about the prostate Cancer
2456419|NCT03197896|Active Comparator|Group II (general health information)|The educator reviews topics about health promotion actions.
2456468|NCT03197597||Strain isolation from the nasopharynx|A group of culture positive whooping cough patients.
2456520|NCT03197142||Out-of-hospital cardiac arrest|All the patients who suffered an out-of-hospital cardiac arrest in the Lombardia Region
2456551|NCT03196830|Experimental|Treatment group|the group of patients who received CAR-T treatment
2456601|NCT03196674|Active Comparator|manipulated feedback|
2456603|NCT03196674|Active Comparator|non-manipulated feedback|
3154523|NCT00300586|Experimental|C (Erlotinib)|Treatment by erlotinib 150 mg/day (sequential treatment), second line chemotherapy if progression
3154524|NCT00300599|Active Comparator|A|Continue positive airway pressure
2456770|NCT03195829|Experimental|Computerized cognitive stimulation|Computerized Cognitive Stimulation was administered to intervention group (IG).
2456772|NCT03195829|Active Comparator|Multimedia-based internet activities|Multimedia-based internet activities was administered to active control group (ACG).
3154525|NCT00300599|Placebo Comparator|B|Placebo
3154526|NCT00300612|Experimental|vaccine group|
3154527|NCT00300638||1- MRI and interviews|In our research, we are trying to understand where in the brain these emotional behaviors take place, and whether or not the brain functions differently for alcoholic and nonalcoholic individuals. We present emotional words and pictures on a computer screen, and using Magnetic Resonance Imaging (MRI) scans, we observe how the brain works when people purposefully respond to the words and pictures. Interviews, cognitive tests, and emotional measurements will also be done. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
3154528|NCT00300729|Active Comparator|Celecoxib|Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
3154529|NCT00300729|Placebo Comparator|Placebo|Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
3154530|NCT00300768|Experimental|2 mg moxidectin|2 mg moxidectin (Dose-escalation 1st step)
3154531|NCT00300768|Active Comparator|Ivermectin 150 mcg/kg|Active comparator arm (ivermectin 150 mcg/kg).
3154532|NCT00300768|Experimental|4 mg moxidectin|4 mg moxidectin (dose escalation second step)
3154533|NCT00300768|Experimental|8 mg moxidectin|8 mg moxidectin (dose escalation third step)
3154534|NCT00300846|Active Comparator|A1|
3154535|NCT00300846|Placebo Comparator|A2|
3154536|NCT00300872|Active Comparator|1|Continuous positive airway pressure (CPAP)
3154537|NCT00300872|Sham Comparator|2|Sham Continuous positive airway pressure (CPAP)
3154538|NCT00300898|Active Comparator|Nucleoplasty|Procedure/Surgery: Nucleoplasty
3154539|NCT00300898|Active Comparator|Percutaneous decompression|Procedure/Surgery: Percutaneous decompression
3154540|NCT00300898|Active Comparator|Electrothermal disc decompression (IDET)|Procedure/Surgery: Intervertebral electrothermal disc decompression (IDET)
3154541|NCT00300898|Experimental|Behavioral:Conservative treatment|Conservative treatment with oral medications, physical therapy, epidural steroid injections
3154542|NCT00300937|Experimental|A|
3154543|NCT00300950|Active Comparator|1|Gencitabine
3154544|NCT00300950|Experimental|2|Gemcitabine with GI-4000
3154545|NCT00300976|Experimental|Intensive therapy|
3154546|NCT00300976|Active Comparator|Conventional therapy|
3154547|NCT00301015|Experimental|1|Malaria diagnosis aided with rapid diagnostic test
3154548|NCT00301015|Active Comparator|2|Malaria diagnosis based on clinical judgement only
3154549|NCT00301106|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
3154550|NCT00301119||lung cancer screening cohort|observational only. no intervention. current, former and never smokers over age 50 without history of cancer, except for non melanoma skin cancer, no previous treatment with chemotherapy.
3173182|NCT00609193||2|Study subjects receiving quetiapine
2456054|NCT03199651|Active Comparator|Arm I (UC)|Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
2456056|NCT03199651|Experimental|Arm II (AGIT/DS)|Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC/DS.
2456120|NCT03199261|Experimental|rE-4 Injection|10µg, rE-4 Injection, 30 minutes prior to the start time of a standard breakfast.
2456124|NCT03199261|Active Comparator|rE-4 Freeze-dried Powder|10µg, rE-4 Freeze-dried Powder, 30 minutes prior to the start time of a standard breakfast.
2456197|NCT03199144|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy delivering 30 Gy in 5 fractions over 9 days
2456252|NCT03198819||Rifampisin group|"Researchers will administer topical Rifampicin and intravenous cefotaxime~For Rifampicin; 10 mg/kg/day, 24 h infusion on defect area during 3 days~For cefotaxime; 50 mg/kg/day, twice a day, intravenous during 5 days."
2456257|NCT03198819||Control group|"Researchers will only administer intravenous cefotaxime~1) Doses; 50 mg/kg/day, twice a day, intravenous during 5 days."
2456296|NCT03198481|Active Comparator|Patient-Centered Counseling Video Group|MUS video utilizing a patient mentor.
2456302|NCT03198481|Active Comparator|Physician Counseling Video Group|MUS video by a physician.
2456366|NCT03198260|Experimental|Fascial Manipulation|fascial manipulation is a manual therapy technique were to apply deep frictional massage to the deep fascial structure or point to increase its pliability
2456371|NCT03198260|Active Comparator|Running kinematics|the change in a range of joint angles during different phases of running
2456498|NCT03197857|Experimental|Control|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456500|NCT03197857|Experimental|Control + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456501|NCT03197857|Experimental|Training in aquabike|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456502|NCT03197857|Experimental|- Training in aquabike + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456505|NCT03197857|Experimental|Bicycle training|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456507|NCT03197857|Experimental|- Bicycle training + protein supplementation|"Physical condition will be evaluated in obese patients before surgery and 1, 4, 6, 12, 18 and 24 months after surgery.~Between 1 and 4 months after surgery, participants will be assigned to one of the postoperative care groups:~Control~Control + protein supplementation~Training in aquabike~Training in aquabike + protein supplementation~Bicycle training~Bicycle training + protein supplementation"
2456574|NCT03196882|Active Comparator|Stratum 1: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
2456576|NCT03196882|Experimental|Stratum 1: 80 mg/day of iron|"Ferrimanitol ovoalbumin. 80mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 1: If the levels of Hb are situated between 110 and 130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 80 mg/d (high supplementation)"
2456577|NCT03196882|Active Comparator|stratum 2: 40 mg/day of iron|"Ferrimanitol ovoalbumin. 40mg of iron in a sachet (powder for oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
2456578|NCT03196882|Experimental|stratum 2: 20 mg/day of iron|"Ferrimanitol ovoalbumin. 20mg of iron in a sachet (oral solution) by mouth, every 24 hours from 12th week of gestation to partum~Stratum 2: If the levels of Hb are >130 g/L, the individual will be randomly assigned to an iron dose supplement of 40 (medium supplementation) or 20 mg/d (low supplementation)"
2456721|NCT03195855|Experimental|Ankle and big toe mobilisations combined with home stretches|"Intervention group (n=29):~This group will undertake talocural and 1st MTP joint mobilisations (x1/week for 6 weeks) and a 6 week home programme of stretching exercises.~Mobilisations: In our study, a traction intervention consisting of two, 2-min sets of Maitland grade II joint traction will precede 2-min sets of Maitland grade III mobilisations with one minute rest in between sets. Four sets will be performed for the ankle and two for the MTP. This protocol has been used previously (19, 43). The direction of mobilisation force will be parallel to the treatment plane and perpendicular to the treatment plane during traction (75).~Home Program: There will be 3 stretches prescribed (gastrocnemius, soleus and plantar fascia). Participants will be recommended to undertake three consecutive static stretches for 20-30s with a 1 minute rest period (76). Stretches will occur in standing."
3154551|NCT00301119||r/o lung cancer|observational only. no intervention. patients with CT findings suspicious for lung cancer who are undergoing bronchoscopy and/or surgery.
3154552|NCT00301184|Experimental|1A|One 0.3 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^7 TCID50 MVA or placebo at Months 4 and 6
3154553|NCT00301184|Experimental|1B|One 3.0 mg dose of DNA HIV vaccine or placebo administered at study entry and Month 2, followed by one dose of 1x10^8 TCID50MVA or placebo administered at Months 4 and 6
3154554|NCT00301184|Experimental|2A|One MTD (determined in Part 1) of DNA HIV vaccine or placebo administered at study entry. One dose of placebo or MTD of MVA at Months 2 and 6
3154555|NCT00301184|Experimental|2B|One dose of placebo or MTD of MVA administered at study entry and Months 2 and 6
3154556|NCT00301210|Experimental|1|tramadol dose 1
3154557|NCT00301210|Experimental|2|tramadol dose 2
3154558|NCT00301249||Family Investigation of Nephropathy and Diabetes (FIND)|Individuals with diabetic nephropathy, their parents, and selected siblings
3154559|NCT00301249||African American MALD|Case-control study of African American patients with nephropathy (cases) and their spouses (controls) unaffected by diabetes and nephropathy; offspring were genotyped when available to provide haplotype data.
3154560|NCT00301249||Mexican American MALD|Case-control study of unrelated individuals of Mexican American heritage in which both cases and controls had diabetes, but only the case had nephropathy
3154561|NCT00301379||1|Patients with unresectable cholangiocarcinoma.
3154562|NCT00301392|Other|Pitavastatin|Administration of Pitavastatin
3154563|NCT00301405|Active Comparator|Thalidomide|Open Label drug
3154564|NCT00301457|Experimental|1|6 years adjuvant anastrozole therapy
3154565|NCT00301457|Experimental|2|3 years adjuvant anastrozole therapy
3154566|NCT00301483|Experimental|1|HBOC-201 followed by standard therapy
3154567|NCT00301483|Active Comparator|2|Standard Therapy
3154568|NCT00301522|Experimental|Arm 1|
3154569|NCT00301522|Active Comparator|Arm 2|
3154570|NCT00301535|Experimental|1|
3154571|NCT00301535|No Intervention|2|
3154572|NCT00301561|Experimental|1|Simplify treatment follow-up
3154573|NCT00301561|Active Comparator|2|Standard treatment follow-up
3154574|NCT00301600|Active Comparator|Mycophenolate mofeti|
3154575|NCT00301613|Active Comparator|Mycophenolate mofetil|
3154576|NCT00301652|Experimental|mycophenolate mofetil|
3154577|NCT00301769|Experimental|Arm I|Patients receive SJG-136 IV over 15 minutes on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of SJG-136 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.
3154578|NCT00301795|Experimental|Treatment (oblimersen sodium and rituximab)|"Induction therapy (month 1): Patients receive oblimersen IV continuously on days 1-7 and 15-21 and rituximab IV on days 3, 10, 17, and 24 in month 1.~Extended induction therapy (months 3, 5, 7, and 9): Patients receive oblimersen IV continuously on days 22-28 and rituximab IV on day 24 in months 3, 5, 7, and 9.~Treatment continues for 9 months in the absence of disease progression or unacceptable toxicity."
3154579|NCT00301847|Experimental|Arm I|Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3154580|NCT00301886|Experimental|zoledronate|zoledronate
3154581|NCT00301886|Experimental|ibandronate|ibandronate
3154582|NCT00301925|Active Comparator|Epi-CMF|
3154583|NCT00301925|Experimental|Accelerated Epi-CMF|
3154584|NCT00301925|Experimental|Epi-Capecitabine|
3154585|NCT00301925|Experimental|Accelerated Epi-Capecitabine|
3154586|NCT00301938|Experimental|Arm I (enzyme inhibitor, chemotherapy)|Patients receive a loading dose of oral perifosine every 6 hours on day 1 followed by a maintenance dose once daily on days 2-28 of course 1 and then once daily on days 1-28 in all subsequent courses. Patients also receive 7-hydroxystaurosporine IV over 3 hours on day 4. Cohorts of 3-6 patients receive escalating doses of 7-hydroxystaurosporine until the MTD is determined.
3154587|NCT00301938|Experimental|Arm 2 (enzyme inhibitor, chemotherapy)|Patients receive 7-hydroxystaurosporine IV over 3 hours on day 1 at the MTD determined in group I. Patients also receive oral perifosine as a loading dose every 6 hours on day 4 followed by a maintenance dose once daily on days 5-28 of course 1 and then once daily on days 1-28 in all subsequent courses.
3154588|NCT00301951|Experimental|cord blood transplant|
3154589|NCT00302029||CMV positive|CMV +, N=500/167
3154590|NCT00302029||CMV negative|CMV -, N=500/167
3154591|NCT00302172|Experimental|ARQ 197|
3154592|NCT00302185|Active Comparator|Nurse-led supportive care|Visit with a Palliative Care nurse once weekly for 4 weeks
3154593|NCT00302185|Experimental|Acupuncture|Patients received acupuncture once a week for 4 weeks.
3154594|NCT00302237||1|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
3154595|NCT00302341|Experimental|1|pafuramidine maleate, oral tablet, 100 mg bid X 14 days
3154596|NCT00302341|Active Comparator|2|TMP/SMX oral tablet, 15 mg/kg, split tid X 21 days
3154597|NCT00302380||un-medicated subjects with ADHD|
3154598|NCT00302380||subjects without ADHD|
3154599|NCT00302393|Active Comparator|IR-MPH|Immediate Release Methylphenidate administered before PET Scan
3154600|NCT00302393|Active Comparator|Concerta|OROS Methylphenidate (Concerta) administered before PET Scan
3154601|NCT00302419|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
3154602|NCT00302419|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
3154603|NCT00302471|Experimental|1600 mg twice a day|MK0429
3154604|NCT00302471|Experimental|200 mg twice a day|MK0429
3154605|NCT00302471|Experimental|800 mg twice a day|MK0429
2456106|NCT03199404||Treated Subjects|Subject experiencing an acute ischemic stroke in which imaging demonstrates a vascular occlusion located in the distal internal carotid artery (ICA) through the distal middle cerebral artery (MCA) and in which the TRAP technique is used for at least the first two thrombectomy passes per occluded vessel and that meet the other inclusion-exclusion criteria.
2456193|NCT03199209|Experimental|Group I (home visit, information about healthy lifestyles)|Participants and their family member meet with a community health worker in their home over 90 minutes to learn about physical activity, healthy eating, and to set goals, once a month for 6 months. Participants also receive 2-5 text messages per week that contain health tips related to healthy lifestyles and information about local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
2456195|NCT03199209|Experimental|Group II (home visit, information about healthy homes)|Participants and their family member meet with a community health worker in their home over 90 minutes to receive information on how to be safe and healthy at home and information about indoor air quality, home safety, CPR/first aid, how to prepare for emergencies, and keeping pests away, once a month for 6 months. Participants also receive 2-5 text messages per week that contain information about healthy homes and local resources. Participants also attend a study visit with a research staff over 90-120 minutes at a community center, MD Anderson, or at home at baseline, 6 months, and 12 months.
2456542|NCT03196869|Experimental|Chrono-chemotherapy group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy;Delivery time is different from the control group
2456543|NCT03196869|Other|Routine intravenous drip|control group:Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
2456608|NCT03196544|Experimental|Social Approach Training (5 sessions)|
2456610|NCT03196544|Experimental|Social Approach Training (10 sessions)|
2456612|NCT03196544|No Intervention|Delayed Treatment (Waitlist)|
2456640|NCT03196206|Experimental|Group A|Normal Renal Function
2456644|NCT03196206|Experimental|Group B|Moderate Renal Impairment
2456649|NCT03196206|Experimental|Group C|Severe Renal Impairment
2456693|NCT03196011|Active Comparator|TKR with mechanical alignment|TKR implanted using traditional alignment methods
2456695|NCT03196011|Experimental|TKR using alternative alignment method|TKR implanted using alternative alignment methods
3154606|NCT00302471|Experimental|400 mg twice a day|MK0429
2456804|NCT03195387|Experimental|D-1/120 mg MMV390048|Treatment of cohort 1: subjects receive a single oral dose of MMV390048 on Day -1, prior to PfSPZ challenge on Day 0.
2456809|NCT03195387|Experimental|D-7/120 mg MMV390048|Treatment of cohort 2: subjects receive a single oral dose of MMV390048 on Day -7, prior to PfSPZ challenge on Day 0.
3154607|NCT00302510|Placebo Comparator|immunoadsorption|
3154608|NCT00302523|Active Comparator|FK506|
3154609|NCT00302536|Experimental|Tacrolimus|
3154610|NCT00302549|Active Comparator|FK506|
3154611|NCT00302601|Other|None relevant|Not relevant
3154612|NCT00302627|Experimental|Pamidronate, Vitamin D, and Calcium|"60mg or 90mg given at baseline, 6,12,18, and 24 months~vitamin D 800 units/day~calcium carbonate 1500 milligrams/day"
3154613|NCT00302640|Active Comparator|Nitazoxanide|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
3154614|NCT00302640|Placebo Comparator|Placebo|7.5mg/kg (age under 12 months), 5 mL (100mg nitazoxanide; age 1-3 years), 10 mL (200mg nitazoxanide; age 4-11 years) twice daily x 3 days
3154615|NCT00302653|Experimental|1|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
3154616|NCT00302666|Sham Comparator|Arm 1|
3154617|NCT00302666|Sham Comparator|Arm 2|
3154618|NCT00302705|Active Comparator|Valsartan|160 mg/day on awakening
3154619|NCT00302705|Active Comparator|Enalapril|10-20 mg/day on awakening
3154620|NCT00302744|Other|1|Each subject functions as their own control (one placebo session/one active drug session)
3154621|NCT00302796|Experimental|Group A, Antibiotic|1 antibiotic tablet 45 patients Group
3154622|NCT00302796|Placebo Comparator|Group B: 1 placebo|1 placebo tablet
3154623|NCT00302796|Experimental|Group C: Antibiotics|2 antibiotic tablets 45 patients
3154624|NCT00302796|Placebo Comparator|Group D, Placebo|2 placebo tablets 36 patients
3154625|NCT00302822|Experimental|Intensification|lopinavir or efavirenz and emtricitabine/tenofovir and intensification with enfuvirtide (week 0 to 24)
3154626|NCT00302822|Active Comparator|Standard|lopinavir or efavirenz and emtricitabine/tenofovir
3154627|NCT00302900|Experimental|1|Pre-donation water and muscle tension during donation
3154628|NCT00302900|Experimental|2|Pre-donation water
3154629|NCT00302900|Sham Comparator|3|Pre-donation muscle tension
3154630|NCT00302900|No Intervention|4|Standard donation
3154631|NCT00303017|Experimental|flavocoxid|medical food
3154632|NCT00303017|Active Comparator|naproxen|NSAID
3154633|NCT00303030|Active Comparator|1. Anal injection|
3154634|NCT00303030|Active Comparator|2. Biofeedback|
3154635|NCT00303043||1|
3154636|NCT00303134|Experimental|Islet Cell Transplantation|
3154637|NCT00303199|Experimental|Single Arm|
3154638|NCT00303212|No Intervention|UC|Usual HF guideline-base care
3154639|NCT00303212|Experimental|TM|Telemonitoring group plus usual guideline-based HF care
3154640|NCT00303251|Experimental|TKI258|
3154641|NCT00303277|Active Comparator|1|simvastatin
3154642|NCT00303277|Active Comparator|2|pravastatin
3154643|NCT00303290|Experimental|PEG-Intron + ARA-C|Peg Interferon Alpha 2b (Peg Intron) 4.5 micrograms/kg once a week. ARA-C 10 mg under the skin daily.
3154644|NCT00303303|Experimental|1|Active initial and maintenance therapy
3154645|NCT00303303|Experimental|2|Active initial therapy; placebo maintenance therapy.
3154646|NCT00303303|Placebo Comparator|3|Placebo initial and maintenance therapy.
3154647|NCT00303342|Experimental|mind body treatment|regulation of attention, respiration and posture
3154648|NCT00303342|Active Comparator|desensitization|mentation on insomnia behaviors and cognitive activity
2456248|NCT03198832|Sham Comparator|Type 2 diabetes mellitus and periodontitis|periodontal debridement in a single session.
2456251|NCT03198832|No Intervention|Type 2 diabetes mellitus and without periodontitis|maintained every three months.
3190831|NCT00792012|Experimental|Glioblastoma Multiforme Patients|Hypofractionated Intensity-Modulated Radiation Therapy (Hypo-IMRT) Combining with Temozolomide (TMZ) Chemotherapy
2456397|NCT03197909||Healthy subjects|Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old
2456399|NCT03197909||COPD patients|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old
2456431|NCT03197636||Malignant melanoma patients|40 patients with metastatic melanoma are included. Patients are admitted to Department of Oncology, Aarhus University Hospital (AUH). The patients are recruited to the study from the outpatient clinic of the Department of Oncology when they are about to begin treatment with pembrolizumab.
2456434|NCT03197636||Healthy controls|20 Healthy volunteers (HV) are included, matched by age and gender.
2456463|NCT03197480|Other|DME treatment group|"All patients will received 4 intravitreal injections of aflibercept.~Based on the OCT outcome they will be classified into 2 groups for assessment of biomarkers:~Less than 20% reduction in CRT on OCT or <5 letter improvement of VA (if VA<6/6 and CRT>=340) Rapid (Mac Dry at M4) Delayed: Persistent fluid at M4, but more than 20% reduction in CRT on OCT"
2456537|NCT03196908|Experimental|Energy Drink Brand 1|Two 16-oz bottles of Energy Drink Brand 1
2456538|NCT03196908|Experimental|Energy Drink Brand 2|Two 16-oz bottles of Energy Drink Brand 2
2456539|NCT03196908|Placebo Comparator|Placebo|Two 16-oz bottles that each contain 390 ml of carbonated water, 20 ml of reconstituted lime juice, and 70 ml of cherry flavoring
2456656|NCT03196388|Experimental|Enzalutamide with External|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingestenzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (25 weeks).
2456729|NCT03195946|Experimental|Lu AF35700 and Cocktail of CYP450 substrates|Day 1 oral midazolam administration, Day 2 Cocktail of CYP450 substrates administration. Daily Lu AF35700 administration from Day 5 to Day 28 with co-administration on Day 27 with oral midazolam and Day 28 with CYP450 substrate cocktail
2456789|NCT03195296||Graves' Orbitopathy|Patients with Graves' Orbitopathy subjected to orbital decompression
2456862|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 1)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Days 1 and 15 in 28-day cycle up to disease progression."
2456864|NCT03194867|Experimental|Isatuximab/cemiplimab (Regimen 2)|"Isatuximab on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression.~Cemiplimab on Day 1 in 28-day cycle up to disease progression."
2456865|NCT03194867|Active Comparator|Isatuximab|Isatuximab on Days 1, 8, 15 and 22, then Day 1 and 15 in 28-day cycles up to disease progression.
3154649|NCT00303381|Experimental|Interferon-beta-1a, 44 microgram|
3154650|NCT00303381|Experimental|Interferon-beta-1a, 66 microgram|
3154651|NCT00303381|Placebo Comparator|Placebo|
3154652|NCT00303420|Active Comparator|1|Alteplase used by normal dwell procedure
3154653|NCT00303420|Experimental|2|"Alteplase given by an new push protocol"
3154654|NCT00303498|Experimental|Sitaxsentan sodium|
3154655|NCT00303498|Placebo Comparator|Placebo|
3154656|NCT00303524|Experimental|1|Zoladex 3-month depot
3154657|NCT00303524|Experimental|2|Zoladex 1-month depot
3154658|NCT00303563|Experimental|1|
3154659|NCT00303563|Experimental|2|
3154660|NCT00303563|Experimental|3|
3154661|NCT00303563|Placebo Comparator|4|
3154662|NCT00303589|Experimental|1|
3154663|NCT00303589|Experimental|2|
3154664|NCT00303589|Active Comparator|3|
3154665|NCT00303732|Experimental|PTK787, RAD001|PTK787 (vatalinib) 1000 mg daily, RAD001 (everolimus) 5 mg daily
3154666|NCT00303758|Active Comparator|LV5FU2 simplifié + cisplatine puis gemcitabine si progression|LV5FU2 simplifié + cisplatine puis gemcitabine si progression
3154667|NCT00303758|Experimental|gemcitabine puis LV5FU2 simplifié + cisplatine si progression|gemcitabine puis LV5FU2 simplifié + cisplatine si progression
3154668|NCT00303771|Active Comparator|LV5FU2 classique|LV5FU2 classique
3154669|NCT00303771|Experimental|LV5FU2 classique + irinotécan|LV5FU2 classique + irinotécan
3154670|NCT00303771|Active Comparator|LV5FU2 simplifié|LV5FU2 simplifié
3154671|NCT00303771|Experimental|LV5FU2 simplifié+ irinotécan|LV5FU2 simplifié + irinotécan
3154672|NCT00303784|Active Comparator|LHRH agonists|"Patients randomised to the control arm will receive continuous treatment with LHRH agonists as per local practice. Treatment should continue for at least 3 years. LHRH antagonists, such as degarelix, are not allowed on the trial. The recommended anti-flare medication is bicalutamide and should be prescribed according to local practice. Control arm medication should be obtained from the hospital pharmacy or GP as per local practice."
3154673|NCT00303784|Experimental|Oestrogen Patches|Patients randomised to the investigational arm will receive transcutaneous oestrogen patches (100 micrograms/24 hours). Treatment should be planned to continue for at least 3 years. For patients prescribed bicalutamide or flutamide prior to randomisation, this treatment should be discontinued before treatment with the patches can commence (no washout period is needed).
3173183|NCT00609219|Experimental|EBV specific CTL|autologous EBV specific CTLs
3173184|NCT00609284|Experimental|1|Radiotherapy 70Gy, Erbitux, Carboplatin-5FU
3173185|NCT00609284|Active Comparator|2|Radiotherapy 70Gy, Erbitux
3173186|NCT00609297||Supportive Care|Alive Hospice Patients with Pain
3173187|NCT00609310|Experimental|I|Flavonoid treatment
3173188|NCT00609323|Experimental|1|
3173189|NCT00609323|Placebo Comparator|2|
3173190|NCT00609349|Other|connective tissue disease|all patients suffer from a connective tissue disease representing a risk for the development of pulmonary hypertension
2456272|NCT03198676|Active Comparator|A - PrEP-001 6.4 mg - 0.8 mg/spray|PrEP-001 Nasal Powder, 0.8 mg/spray (G-006) (Formulation A)
2456273|NCT03198676|Active Comparator|B - PrEP-001 6.4 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
2456274|NCT03198676|Active Comparator|C - PrEP-001 3.2 mg - 1.6 mg/spray|PrEP-001 Nasal Powder, 1.6 mg/spray (F002) (Formulation B)
2456275|NCT03198676|Placebo Comparator|D - Placebo|PrEP-001 Placebo Nasal Powder (matching Formulation B)
2456309|NCT03198390||Subjects with chronic skin conditions|Subjects with chronic skin conditions including but not limited to atopic dermatitis, contact dermatitis, hidradenitis suppurativa, and psoriasis
2456311|NCT03198390||Healthy subjects|
2456361|NCT03198247|Active Comparator|Control Group: Usual Care|"Procedure: Usual care The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
2456362|NCT03198247|Experimental|Experimental: Usual Care + PNE and CST|"Procedure: Usual care + PNE and CST. The PNE and CST program will be divided in 3 individual sessions. This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviours"
2456401|NCT03197870|Experimental|AKB-9778 15mg BID|
2456402|NCT03197870|Experimental|AKB-9778 15mg QD|
2456405|NCT03197870|Placebo Comparator|Placebo BID|
2456481|NCT03197363||Białystok PLUS|Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
2456557|NCT03197103|Experimental|N-Acetylcysteine (NAC)|Breast enlargement with autologous fat graft obtained by liposuction with Pietruski solution (tumescent solution with NAC).
2456561|NCT03197103|No Intervention|Control|Contralateral breast enlargement with autologous fat graft obtained by liposuction with standard tumescent solution.
2456597|NCT03196583|Experimental|Single-arm study|Velo-Lingual Bite (BVL)
2456642|NCT03196336|Other|Intervention|The intervention is the pharmacotherapeutic follow-up care. This service is performed according to the Pharmacotherapy Workup method, which is a protocol for the pharmacotherapeutic follow-up. This service identify, prevent and solve drug-related problems. It consiste of five pharmaceutical consultations (every up to 2-3 months) with the patient.
2456645|NCT03196336|Other|Control|The intervention is the usual procedure of dispensation of drugs. It is performed in five meetings (every up to 2-3 months) between the investigator and the patient.
2456698|NCT03196037|Experimental|Tai Chi|The Tai Chi intervention will be lead by an expert Tai Chi instructor with 15 years of teaching experience, and will take place at a local Yoga studio. The 8-week intervention entails two 75-minute sessions per week for a total of 16 sessions. Each session will begin with a 15- minute warm-up followed by 25 minutes of performing basic stances, footwork, upper-body/arm/hand movement, proper body alignment, mental/visual focus, and balance; 30 minutes of instruction in a choreographed form (first section of the Yang style long-form); and ending with a 5-minute cool-down.
2456732|NCT03195673|Experimental|TZ group|"Treatment:Patients in this group received standard medical therapy and Terazosin (TZ) treatment.~Drug: TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.~Procedure: Carotid Artery Stenting"
2456738|NCT03195673|Other|control group|Treatment: Patients in this group received standard medical therapy alone. Procedure: Carotid Artery Stenting
2456795|NCT03195231|Experimental|Wuling Powder Group|Take Wuling Powder 3 times a day，3 pills each time for 12 weeks
2456800|NCT03195231|Placebo Comparator|Placebo Group|Take placebo drug which cannot be distinguished from the experimental drug 3 times a day，3 pills each time for 12 weeks
2456851|NCT03194815|Active Comparator|Intravenous immunoglobulin and Rituximab|One cycle of intravenous immunoglobulin (IVIG) 2g/kg over 2-5 days (days 1-5) followed by (b) two infusions of 1g rituximab (the first infusion starting between days 28-35, and the second infusion 14 days later), each with 100mg methylprednisolone.
2456852|NCT03194815|Placebo Comparator|Placebo|One cycle of 0.9% saline solution over 2-5 days (days 1-5) followed by (b) two infusions of placebo solution alongside placebo pill - in equal volumes to steroid pre-medication and rituximab.
3154674|NCT00303797|Experimental|Treatment (bortezomib, sorafenib tosylate)|"GROUP I (solid tumors-dose-escalation group): Patients receive oral sorafenib twice daily on days 1-21 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of sorafenib and bortezomib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~GROUP II (multiple myeloma or chronic lymphocytic leukemia-maximum tolerated dose [MTD] group): Patients receive oral sorafenib at the MTD twice daily on days 3-21 of course 1 and on days 1-21 of each subsequent course. Patients also receive bortezomib IV over 3-5 seconds at the MTD on days 1, 4, 8, and 11.~Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3154675|NCT00303836|Experimental|Arm I|Patients undergo apheresis and in-vitro depletion of T-regulatory cells. Patients then receive a nonmyeloablative, lymphocyte-depleting preparative regimen comprising cyclophosphamide IV over 1 hour on days -8 and -7 and fludarabine IV over 15-30 minutes on days -6 to -2 followed by autologous T-regulatory-depleted lymphocytes IV over 20-30 minutes on day 0. Patients receive vaccination with gp100:209-217 (210M) and MART-1:27-35 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on days 0-3, 20-23, 41-44, and 62-65. Patients also receive filgrastim (G-CSF) SC beginning on day 1 and continuing until blood counts recover.
3154676|NCT00303836|Experimental|Arm II|Patients receive treatment as in arm I. Patients also receive high-dose IL-2 IV over 15 minutes every 8 hours on days 0-4, beginning after the lymphocyte infusion. IL-2 treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3173191|NCT00609375|Experimental|I|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
3190832|NCT00792038||1|OCD patients
2456339|NCT03198364|Experimental|START + Mobile Augmentation|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START) with 12 weeks of augmentation by use of automated software to prompt users to engage in personalized adaptive coping
2456341|NCT03198364|Active Comparator|START|4 Sessions of In-Person Psychoeducation called Safety and Recovery Therapy (START)
2456408|NCT03198065|Experimental|Hand-made glove setting|The patients receive Hand-made glove setting
2456411|NCT03198065|Experimental|commercialized multiport setting|The patients receive commercialized single-incision multiport setting
2456450|NCT03197584|Experimental|NANT Ovarian Cancer Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, paclitaxel, omega-3-acid ethyl esters, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6301, and hank®.
2456476|NCT03197220|Experimental|fish|
2456479|NCT03197220|Experimental|walnut|
2456483|NCT03197220|Experimental|fish-walnut|
2456529|NCT03197077|Experimental|Elonva|A single injection of 100 microgram corifollitropin alfa. Oocyte retrieval on day five after corifollitropin alfa injection.
2456532|NCT03197077|Active Comparator|Puregon|Three daily injections of 150 IU follitropin beta. Oocyte retrieval on day five after the first follitropin beta injection.
2456613|NCT03196427|Experimental|Vedolizumab High Dose Group|Participants with UC or CD having baseline weight of greater than or equal to (>=) 30 kilogram (kg) will receive Vedolizumab 300 milligram (mg) and participants with UC or CD having baseline weight of less than (<) 30 kg will receive Vedolizumab 200 mg, intravenous infusion, every 8 weeks for up to 5 years.
2456615|NCT03196427|Experimental|Vedolizumab Low Dose Group|Participants with UC or CD having baseline weight of >= 30 kg will receive Vedolizumab 150 mg and participants with UC or CD having baseline weight of < 30 kg will receive Vedolizumab 100 mg intravenous infusion, every 8 weeks for up to 5 years.
2456679|NCT03196050|Experimental|Telemonitoring using a handheld device|Patients will be euqipped with either an app or a handheld device with a pre-installed app to communicate with the coordinating center.
2456760|NCT03195374||Patients with chronic non-cancer pain|Each addictovigilance centre will contact Pain Clinics in order to enroll patients meeting the inclusion criteria.
2456821|NCT03195062|Experimental|Test meal|The subjects will receive a liquid test meal containing glucose and fructose with 13C fructose.
3154677|NCT00303849|Experimental|Treatment (etoposide, mannitol, melphalan, carboplatin, STS)|Patients receive etoposide phosphate IV over 10 minutes, mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes on days 1 and 2. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Courses repeat every 4 to 6 weeks for up to 12 months.
3154678|NCT00303875|No Intervention|Wait-list control|Wait-list control received diet & exercise counseling during year 2 as a courtesy
3154679|NCT00303875|Experimental|Lifestyle counseling|subjects randomized to receive diet & exercise counseling for one year
3154680|NCT00303888|Experimental|Arm I|Patients receive docetaxel IV over 1 hour on days 1, 8, and 15 and oral placebo three times daily on days 1-21.
3154681|NCT00303888|Experimental|Arm II|Patients receive oral phenoxodiol three times daily on days 1-21 and docetaxel IV over 1 hour on days 1, 8, and 15.
3154682|NCT00303992|Experimental|Trastuzumab and Irinotecan|
3154683|NCT00304018|Experimental|cord blood transplant|
3154684|NCT00304135|Active Comparator|Radio-chimiothérapie|Radio-chimiothérapie
3154685|NCT00304135|Experimental|GEMOX|GEMOX
3154686|NCT00304148||CRIC Cohort|
3154687|NCT00304148||CRIC Subcohort|
3154688|NCT00304174||Subjects with bulimia nervosa|Participants with bulimia nervosa
3154689|NCT00304174||Controls between 80-120% of ideal weight|Controls without bulimia nervosa
3154690|NCT00304200|Experimental|Single arm, Open Label|Single arm, Open Label Temodar and Sutent
3154691|NCT00304304|Active Comparator|Intervention - asthma education|CCC received asthma education in the first 6 months of the study
3154692|NCT00304304|Placebo Comparator|Wait-list control|CCC received asthma education in second 6 months of study
3154693|NCT00304317|Experimental|I|Celecoxib
3154694|NCT00304317|Placebo Comparator|II|Placebo
3154695|NCT00304382|Experimental|PPV-PCV|Patients receive Pneumovax, and 6 months later Prevnar
3154696|NCT00304382|Experimental|PCV-PPV|Patients receive Prevnar, and 6 months later Pneumovax
3154697|NCT00304382|Experimental|PCV-PCV|Patients receive Prevnar, and 6 months later Prevnar again
3154698|NCT00304382|Experimental|PCV only|Patients receive Prevnar only
3154699|NCT00304434|Other|1|
3154700|NCT00304525|Experimental|RAF265 - Arm 1|Patients received 10mg RAF265 as a once weekly dose until progressive disease was confirmed.
3154701|NCT00304525|Experimental|RAF265 - Arm 2|"RAF265 is given as a single PK run-in dose, a single loading dose on day 1 of cycle 1, followed by once daily maintenance doses."
3154702|NCT00304525|Experimental|RAF265 - Arm 3|Patients were treated with once weekly dosing of RAF265
3154703|NCT00304525|Experimental|RAF265 - Arm 4|Patients with locally advanced or metastatic melanoma will utilize a dose close to or at the MTD/RPTD of the liquid formulation that was determined in Arm 2.
3154704|NCT00304525|Experimental|RAF265 - Arm 5|RAF265 was administered as a continuous dose for 2 weeks followed by a dose holiday of 1 week.
3154705|NCT00304551|Experimental|1|
3154706|NCT00304551|Experimental|2|
3154707|NCT00304551|No Intervention|3|
3154708|NCT00304564|Experimental|geriatric community|Subject will stand on a computerized posturography force plate and stability scores are measured
3154709|NCT00304603||Patients from previous topiramate obesity and diabetes studies|The patients from previous topiramate obesity and diabetes studies (PRI/TOP-INT-31 or PRI/TOP-INT-33 or a subset of patients with diabetes mellitus who were randomized within the PRI/TOP-INT-34 study at sites that also participated in the PRI/TOP-INT-31 study.
3154710|NCT00304759|Experimental|1|6000 cGy / 20 fractions in 4 weeks
3154711|NCT00304759|Active Comparator|2|7800 cGy / 39 fractions in 8 weeks
3154712|NCT00304772|Active Comparator|1|
3154713|NCT00304772|Active Comparator|2|
3154714|NCT00304798|Experimental|Admission|Admission
3154715|NCT00304798|No Intervention|Discharge|Discharge
3154716|NCT00304850|Experimental|R+ / K+|
2456404|NCT03198143|Experimental|Healthy Subjects - Ghrelin|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2456407|NCT03198143|Placebo Comparator|Healthy Subjects - Saline|Healthy subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2456409|NCT03198143|Experimental|Obese Subjects - Ghrelin|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of human synthetic Acyl Ghrelin at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2456412|NCT03198143|Placebo Comparator|Obese Subjects - Saline|Obese subjects will arrive after consuming a standard meal 60 minutes prior to study onset. They will receive a single subcutaneous injection of 0.9% saline at the start of the study. 5 minutes post-injection, the subjects will receive written instructions and begin their first decision-making task on a computer.
2456433|NCT03197571|Experimental|Nant Urothelial Cancer Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2456464|NCT03197272|Experimental|PiXL Protocol A|PiXL treatment with UV irradiation in a central 4 mm homogenous zone of the cornea. For myopia of less than 1.0D, 10 J/cm2 will be used, for higher levels of myopia 15J/cm2 will be used.
2456471|NCT03197272|Active Comparator|PiXL Protocol B|PiXL treatment with UV irradiation in a central ring-shaped 4-mm area of the cornea. A central 2-mm zone is left untreated, and the energy is higher towards the periphery of the ring-shaped area, reaching its maximum at 2 mm from the corneal centre. For myopia of less than 1.0D, a maximum of 10 J/cm2 will be used, for higher levels of myopia a maximum of 15J/cm2 will be used.
2456525|NCT03197116|Active Comparator|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
2456526|NCT03197116|Placebo Comparator|No reminder|No additional reminder will be offered
2456586|NCT03196843|Experimental|Raltitrexed plus Radiation|Raltitrexed 2.5mg/m2, iv, every 3 weeks, concurrently with intensity modulated radiotherapy(IMRT)
2456588|NCT03196843|Active Comparator|Radiation|Intensity modulated radiotherapy(IMRT) alone radical radiotherapy:70Gy/2Gy/7 weeks preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 weeks
2456618|NCT03196401|Experimental|Durvalumab Plus Radiation Therapy|Durvalumab (1500mg administered intravenously every 28 days), concurrently with definitive radiation therapy to the solitary bone plasmacytoma to start within 14 days of the first dose of durvalumab.
2456660|NCT03196102|Experimental|BTI + Cigarette smoking military tailored pamphlet|BTI + Cigarette smoking military tailored pamphlet
2456669|NCT03196102|Active Comparator|Cigarette smoking military tailored pamphlet|Cigarette smoking military tailored pamphlet
2456673|NCT03196102|Active Comparator|Standard smoking cessation pamphlet|Standard smoking cessation pamphlet
2456706|NCT03195777|Experimental|Single Arm: Observation after Imaging|This is a single-arm study, where subjects will be monitored for development of PTS after baseline non-invasive imaging with FDG PET/CT. The experimental interventIon is the PET/CT imaging.
2456773|NCT03195556|Experimental|Healthy subjects|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
2456774|NCT03195556|Experimental|Peripheral Artery Disease|Low-power contrast ultrasound perfusion imaging and measurement of ABI and TBI will be performed before and after a 15 min high-power ultrasound cavitation therapy with intermittent ultrasound and intravenous infusion of microbubbles.
2456813|NCT03194958|No Intervention|Standard Quitline|Participants will receive standard Missouri quitline services
2456815|NCT03194958|Experimental|Specialized Quitline|Participants will receive an enhanced version of the standard quitline services
2456819|NCT03194958|Experimental|Standard Quitline with Basic Needs Navigator|Participants receive standard quitline services with navigator
2456825|NCT03194958|Experimental|Specialized Quitline with Basic Needs Navigator|Participants receive enhanced quitline services with navigator
2456888|NCT03194633||Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)|Male and female patients with a diagnosis of CKD and hypertension (age, 18-70 years) was enrolled.
3154717|NCT00304850|Experimental|R+ / K-|
3154718|NCT00304850|Experimental|R- / K+|
3154719|NCT00304850|Placebo Comparator|R- /K-|
3154720|NCT00304863|No Intervention|Arm 1|This are will not receive Lactobacillus
3154721|NCT00304863|Experimental|Arm 2|This arm will receive lactobacillus
3154722|NCT00305032|Experimental|1|
3154723|NCT00305045|Active Comparator|High-frequency Left (HFL)|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 29 - 5 second trains with 30 second inter-train interval."
3154724|NCT00305045|Active Comparator|Bilateral|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Subjects under age 65 will have treatment delivered at 100% of the RMT; those over age 65 will have treatment delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: i) low-frequency right: 4 trains of 100 second duration and one train of 65 second duration, with a 30 second inter-train interval, followed by ii) HFL: 15 - 5 second trains with 30 second inter-train interval."
3173192|NCT00609375|Active Comparator|II|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for at least 7 days and no more than 14 days days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
3190833|NCT00792038||2|Normal Controls
2456324|NCT03198429|Experimental|Embedding mother-child intervention|"Workers in the MIM condition will receive additional training and facilitated referral to MIM for eligible clients. Specifically, workers randomly assigned to this condition will receive:~a one-day training at the beginning of the study on the impact of DV on mothers, mothering, and child development~access to a practice leader and consultant to respond to question and concerns about working with women victims of DV on parenting issues~access to a 30-minute presentation, once a month, on issues of practice specific to working with this population In addition,~cases judged by intake workers as being appropriate referrals to the MIM program (see Methods) and being assigned to these workers for ongoing service will be flagged at the time of transfer as being potentially appropriate referrals to the Mothers in Mind program~clients who are then referred to MIM as part of clinical service will be given access to this program at the earliest possible opportunity."
2456327|NCT03198429|Experimental|Combined intervention|A final group of workers will be randomly assigned to receive all the training, support, and referral opportunities associated with both the Embedded Mothers in Mind condition and the Embedded Caring Dads condition.
2456331|NCT03198429|No Intervention|Treatment as usual|Workers in the service as usual condition will continue to provide in-home support to children and families in accordance with current practice. Workers will receive regular supervision from their supervisors. A review of practice reveals that, in general, workers make referrals to intervention programs in only a small minority of cases. Such referrals will continue under this study protocol - service will proceed as usual. This condition is not a placebo, families are continuing to receive the full child protection service that they would normally have received if this trail were not being run.
3154725|NCT00305045|Sham Comparator|Sham Stimulation|Stimulation will occur over the site of active treatment, but with only the side-edge resting on the scalp. It will be administered as HFL for 17 minutes, with the coil angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
2456493|NCT03197662|Experimental|Experimental: Intranasal Oxytocin (IN-OXT)|Syntocinon (synthetic oxytocin) will be used in this protocol. Each subject will receive a dose of 16 IU QD and will be instructed to inhale 2 puffs per nostril (4 IU each).
2456497|NCT03197662|Placebo Comparator|Placebo Comparator: Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril (4 IU each).
2456593|NCT03196648|Experimental|Gingival health formulation in accelerating device|The interventional gingival health formulation is applied to the participant's mouth by means of an intra-oral accelerating device for a single eight-minute application, daily. Participants were instructed to brush their teeth with an OTC toothpaste twice daily, morning and night.
2456595|NCT03196648|Experimental|Gingival health formulation on a toothbrush|The interventional gingival health formulation is applied to the participant's mouth by means of a toothbrush and OTC toothpaste, together with the formulation in equal amounts, for two-minute applications twice daily, morning and night.
2456596|NCT03196648|Active Comparator|Control group (Split mouth design)|The control group did not receive the interventional gingival health formulation. Participants were instructed to brush their teeth with a toothbrush and OTC toothpaste twice daily, morning and night. In addition, participants were instructed to floss only half of their mouth daily, having the non-flossed half serve as an untreated comparative control of toothbrushing alone.
2456661|NCT03196258|Experimental|intervention - CBT|Participants in this arm will receive 6 weekly one-on-one, 1-hour sessions of Cognitive Behavioural Therapy session (intervention) in addition to receiving standard of care treatment for their fracture(s).
2456667|NCT03196258|No Intervention|control|Participants in the control arm of the study will receive standard of care treatment for their fracture(s) but will not receive any Cognitive Behavioral Therapy.
2456704|NCT03195920|Experimental|Enhanced Lithotripsy System|Treatment for urinary stones with the Enhanced Lithotripsy System
2456720|NCT03195582|Experimental|Test group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the test group, Corsodyl gel 1% Chlorohexidine will be applied on the implant and the healing abutment. Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
2456722|NCT03195582|No Intervention|CONTROL group|"following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant .In the control group, Corsodyl gel 1% Chlorohexidine will not be applied on the implant and the healing abutment). Healing abutment of 4 mm height will be screwed to the implant and flap will be sutured with silk 4-0 sutures.~Parallel radiograph will be taken after the surgery"
2456829|NCT03195426|Experimental|distal nerves blocks group|"This study aims at assessing the effectiveness of combined supra scapular nerve block, infraclavicular block and supraclavicular nerve block as surgical anesthesia for patients scheduled for arthroscopic shoulder surgery.~These blocks are performed for decades in routine care. The originality of this study is to analyze the combination of these different blocks for post-operative pain relief in arthroscopic shoulder surgery. This combination can be considered as an alternative to interscalene block well known to be associated with diaphragmatic paralysis.~Local anesthetics used in this study are used for many years in routine care: Ropivacaine 0.375%. A single injection will be performed under ultrasounds. No continuous injection will be performed."
2456868|NCT03194685|Experimental|Cohort 1: 10 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456869|NCT03194685|Experimental|Cohort 2: 20 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456871|NCT03194685|Experimental|Cohort 3: 35 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456872|NCT03194685|Experimental|Cohort 4: 50 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456873|NCT03194685|Experimental|Cohort 5: 75 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456874|NCT03194685|Experimental|Cohort 6: 100 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456878|NCT03194685|Experimental|Cohort 7: 150 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456882|NCT03194685|Experimental|Cohort 8: 225 mg|Orally once a day (QD) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456889|NCT03194685|Experimental|Cohort 20: 50 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456403|NCT03197974|Other|Mindfulness for Bipolar|Introduction to, and training in the skills of mindfulness, self-compassion, and values-oriented action, and how these can be applied to managing symptoms of bipolar disorder.
2456406|NCT03197974|Other|Psychoeducation for Bipolar|Information about bipolar disorder and the patient's role in managing the condition, including identifying triggers, and responding to early warning signs of episodes, and developing a healthy lifestyle
2456465|NCT03197610|Experimental|SCTG+EMD|TEST GROUP: Langer and Langer technique was used to prepare the recipient side. The vestibule surfaces of adjacent interdental papillae were de-epithelialized. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges. EMD (Emdogain®, Straumann, Basel, Switzerland) was used in the test group in addition to SCTG. Prior to EMD application, the root surface was applied with 24% EDTA (PrefGel, Straumann, Basel, Switzerland) for 2 minutes. The area was washed with saline and then EMD was applied.
2456470|NCT03197610|Experimental|ONLY SCTG|CONTROL GROUP: Langer and Langer technique was used to prepare the recipient side. The anesthetic solution was applied to the donor site in the palatinal region on the same side as the operation site. The dimensions of the recipient area were measured by periodontal probes and four bleeding centers were created in the palatinal region. The graft was placed on the recipient site and fixed with 4.0 silk sutures. Pressure was applied to the operation area for 5 minutes with saline impregnated sponges.
2456540|NCT03197168|Experimental|Intervention|Intervention to reduce self-stigma among people with mental illness + Usual care
2456541|NCT03197168|Placebo Comparator|Control|Usual care
2456575|NCT03196752|Experimental|Only arm|Patient's cricoid membrane is identified using both laryngeal handshake method and simple palpation
2456632|NCT03196531|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2456633|NCT03196531|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2456634|NCT03196531|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2456635|NCT03196531|Experimental|Cohort 2: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2456678|NCT03196089|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
2456680|NCT03196089|Sham Comparator|Sham room air|Room air will be applied similarly to oxygen
2456735|NCT03195803|Experimental|MCI with WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
2456740|NCT03195803|Active Comparator|MCI without WMH|Computerized Cognitive Stimulation was administered to this group, twice a week.
2456830|NCT03195140|Experimental|Intervention Arm|"The intervention arm (use of PLGS feature) will utilize Tandem Diabetes Care's ambulatory insulin infusion pump with integrated Dexcom G5 CGM and predictive low glucose suspend function. This pump is called the t:slim X2 with Basal-IQ Technology and is referred to in the protocol as the Tandem PLGS pump."
2456831|NCT03195140|No Intervention|Control Arm|The control arm (SAP only) will utilize an identical pump in functionality as the Tandem PLGS pump except for the lack of the PLGS feature and the associated user interface. This pump is called the t:slim X2 Dexcom G5 Mobile CGM Enabled pump, and is referred to in the protocol as the Tandem SAP pump.
2456853|NCT03194620|Placebo Comparator|Control|Single oral intake of flavanol-free fruit-flavored non-dairy drink
2456855|NCT03194620|Experimental|Theaflavins|Single oral intake of a fruit-flavored non-dairy drink containing a mixture of theaflavins
2456856|NCT03194620|Experimental|Procyanidin Dimer B2 (DB2)|Single oral intake of a fruit-flavored non-dairy drink containing Procyanidin Dimer B2 (DB2)
2456858|NCT03194620|Experimental|(-)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin-3-O-gallate (EGCG)
2456859|NCT03194620|Experimental|(-)-Epicatechin-3-O-gallate (ECG)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin-3-O-gallate (ECG)
2456860|NCT03194620|Active Comparator|(-)-Epicatechin (EC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epicatechin (EC)
2456861|NCT03194620|Experimental|(-)-Epigallocatechin (EGC)|Single oral intake of a fruit-flavored non-dairy drink containing (-)-Epigallocatechin (EGC)
2456863|NCT03194620|Experimental|Thearubigins|Single oral intake of a fruit-flavored non-dairy drink containing thearubigins
2456879|NCT03194425|Experimental|OAB|Patients with overactive bladder on sacral neuromodulation.
2456887|NCT03194425|Experimental|NOUR|Patients with non-obstructive urinary retention on sacral neuromodulation.
3154726|NCT00305097|Experimental|Caffeinated coffee|Caffeinated coffee
3154727|NCT00305097|Experimental|Decaffeinated coffee|Decaffeinated coffee
3154728|NCT00305097|Active Comparator|No coffee|
3154729|NCT00305123||1|12,000 children 5 to 16 years of age attending the 4 public elementary schools in Djikoroni-para-Sébénikoro, Bamako, Mali.
3154730|NCT00305175||Patients With Prior Hydroxyurea|Patients who have received hydroxyurea therapy before entering the study.
3154731|NCT00305175||Patients Without Prior Hydroxyurea|Patients who have not received hydroxyurea before study entry.
3154732|NCT00305188|Experimental|Xaliproden (SR57746A)|
3154733|NCT00305188|Placebo Comparator|Placebo|
3154734|NCT00305279|Active Comparator|1|
3154735|NCT00305279|Active Comparator|2|
3154736|NCT00305279|Active Comparator|3|
2456430|NCT03198026|Experimental|Treatment (ibrutinib, obinutuzumab)|"Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.~After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then annually for up to 2 years."
2456488|NCT03197441|Experimental|PRP group|Arthroscopic knee surgery plus intraoperative platelet-rich plasma
2456548|NCT03197012|Experimental|Main Study: 90Y-DOTA-TOC|90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.
2456550|NCT03197012|Experimental|Sub-study: 90Y and 68Ga-DOTA-TOC|"90Y-DOTA-TOC will be administered one time over thirty minutes via the hepatic arterial catheter in the outpatient setting. The injected dose will be 85 to 115 mCi.~Patients enrolled in the correlative sub-study will also receive 111-259 MBq (3-7 mCi) of 68Ga-DOTA-TOC concurrent with 90Y-DOTA-TOC"
2456600|NCT03196622|Experimental|Older people|A cross-sectional multicentre study will be performed in hospital and retirement houses on patients ages 75 years old or more.
3154737|NCT00305435|Experimental|romiplostim (AMG-531)|
2456777|NCT03195036|No Intervention|Control|The control group of women/children dyads who consent and are patients at the control clinics will not have any exposure to ECD programming.
2456779|NCT03195036|Experimental|Intervention Arm|The intervention group of women/children dyads who consent and are patients at the intervention clinics will receive regular home-based ECD services focused on positive parenting and early stimulation.
2456832|NCT03194945|Active Comparator|Linagliptin plus metformin|CSII followed by Linagliptin 5 mg Qd + Metformin 0.5 g bid for 48 weeks
2456833|NCT03194945|Active Comparator|Linagliptin|CSII followed by Linagliptin 5mg Qd for 48 weeks
2456834|NCT03194945|Active Comparator|Metformin|CSII followed by Metformin 0.5 bid for 48 weeks
2456835|NCT03194945|Active Comparator|Lifestyle alone|No OHA is given after CSII
3154738|NCT00305461|Active Comparator|1|Ciclesonide 160µg
3154739|NCT00305461|Active Comparator|2|Ciclesonide 320µg
3154740|NCT00305539|Active Comparator|1|
3154741|NCT00305539|Placebo Comparator|2|placebo
3154742|NCT00305552|Experimental|1|THALIDOMIDE
3154743|NCT00305656|Experimental|Arm I|Patients receive oral AZD2171 once daily on days 1-28.
3154744|NCT00305669|Experimental|GM-CSF before surgery|GM-CSF dose prior to surgery- Cohort 1-GM-CSF 250mcg/m2 for 2 weeks Cohort 2-GM-CSF 250mcg/m2 for 3 weeks Cohort 3-GM-CSF 250mcg/m2 for 4 weeks Cohort 4-GM-CSF 125mcg/m2 for 4 weeks
3154745|NCT00305734|Experimental|Treatment (bortezomib, gemcitabine hydrochloride)|"Patients receive bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses of treatment with bortezomib.~Patients who experience disease progression on single-agent bortezomib and did not receive prior gemcitabine hydrochloride may begin combination therapy within 10-28 days of the last dose of bortezomib. Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and bortezomib IV on days 1, 4, 8, 11. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. Patients achieving a CR receive 2 additional courses beyond the confirmed CR."
3154746|NCT00305747|Experimental|BR-DIM|BR-DIM will be administered at a starting dose of 75 mg po twice daily. Patients will be instructed to take tablets twice daily with 8 ozs. of water, with/without food. A study calendar will be provided and patients will be asked to fill the appropriate boxes when they take their study capsules. One treatment cycle is 28 days.
3154747|NCT00305825|Experimental|Study intervention|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral letrozole once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3154748|NCT00305851|Experimental|"Low Dose Control Books on Tape"|Individuals randomly assigned to low-dose control group will have the same amount and timing of contacts as TMV group. A trained music therapist delivers the low-dose intervention (music therapy). Low-dose control group AYA initially choose up to three books-on-CD from a library selection of popular recordings. During the six sessions with the music therapist, AYA listens to the book and/or discusses their impressions and thoughts about he contents. Our rationale for having options of either listening to or discussing is to ensure the intervener has activities that will provide comparable contact time compared to the TMV group. As a parallel activity to the TMV protocol during which participants can work on their music video between sessions, AYA in the low-dose control group are provided with a portable CD player to listen to the books anytime during their hospitalization. As books ar e completed, or if the AYA changes their mind about the choice, the intervener offers other books.
3154749|NCT00305851|Experimental|"Experimental Music Video"|Intervention includes six 1-hour sessions (two sessions per week over 3 weeks) designed specifically for the pre-transplant and acute phase of treatment. The initial TMV session with the therapist occurs within 3 days of hospital admission. The phases of the intervention that require patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout work sheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer. The protocol concentrates many of these cognitive and active components to produce the video at the beginning, when patients experience less fatigue and malaise
3154750|NCT00305890|Experimental|1|Participants will partake in a lifestyle behavioral weight management program for 24 weeks.
3154751|NCT00305890|Experimental|2|Participants will partake in pain-coping skills training for 24 weeks.
3154752|NCT00305890|Experimental|3|Participants will partake in lifestyle behavioral weight management program plus pain-coping skills training for 24 weeks.
3154753|NCT00305890|Active Comparator|4|Participants will receive standard care for 24 weeks.
3154754|NCT00305916|Active Comparator|1|conventional coronary angiography
3154755|NCT00305916|Experimental|2|multislice spiral computed tomography coronary angiography
3154756|NCT00305929|Experimental|1|Treatment with Tookad VTP
3154757|NCT00306007||English prenatal|English speaking women recruited from the general OB/GYN clinic
2456474|NCT03197454|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
2456478|NCT03197454|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 50 treatment sessions, up to 5 sessions per week, 42 minutes per session.
3190834|NCT00792051|Active Comparator|1|Influenza vaccine
3190835|NCT00792051|Placebo Comparator|2|
2456630|NCT03196414|Experimental|CART-138/BCMA/19/more|
2456647|NCT03196141|Active Comparator|Healthy volunteers|"Part#1: 15 healthy volunteers; 2 assessment sessions. Session 1: StO2 vs. EndoPAT Method comparison analysis; both StO2 and EndoPAT will be applied simultaneously & pulse oximeter probes placed bilaterally on fingers. Baseline readings will be taken for 5 minutes. The blood pressure cuff will be inflated to suprasystolic pressure and StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Session 2: This session will occur within 1 week of session 1. This session is to determine the consistency of the response.~All probes will be applied as in session 1 and cycles of 10 minutes for 3 sessions will be done. All the measurements in session 1 will be captured in session 2.~This will determine inter-day variability. (total time is 53 min)."
2456650|NCT03196141|Active Comparator|Pregnant women with normal BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness."
2456651|NCT03196141|Active Comparator|Pregnant women with high BP|"Part #2: 20 participants, 10 normotensive and 10 pre-eclamptic pregnant women during their visit to labor floor.~Session 1: Both StO2 and EndoPAT will be applied simultaneously to the same arm below a BP cuff. Baseline readings will be taken for 5 minutes, the blood pressure cuff will be inflated to suprasystolic pressure StO2 and pulsatile volume changes will be measured by peripheral arterial tonometry, continuous measurement for 3 min and repeated every 10 minutes for 3 sessions.~Additionally, vascular stiffness with be measured by SphygmoCor to measure pulse wave velocity (PWV).~Participants must also agree to participate OB/GYN biobanking protocol HIC# 1601017004 to be in this study.~All participants will have follow-up at 48 hours, including a blood draw, assessment of endothelial function and vascular stiffness.~Participants with hypertension will be followed in conjunction with routine clinical follow-up at 2, 6 and 12 weeks post-partum."
2456707|NCT03195985|Experimental|Mindfulness-based Intervention|Mindfulness intervention of 4 weeks
2456708|NCT03195985|Active Comparator|"Age Well psycho-education course"|4-week active control condition
2456744|NCT03195543||Patients with PAH|Diagnostic tests will be performed on patients with Pulmonary Artery Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
2456746|NCT03195543||Patients with CTEPH|Diagnostic tests will be performed on patients with Chronic Thromboembolic Pulmonary Hypertension in order to assess any blood coagulation disorders. Platelet function, coagulation and fibrinolysis will be evaluated by platelet function analyzer-100 (PFA-100), light transmission aggregometry, rotational thromboelastometry (ROTEM) and endogenous thrombin potential.
3154758|NCT00306007||Spanish prenatal|Spanish speaking (monolingual) women recruited from the general OB/GYN clinic
3154759|NCT00306007||English abortion clinic|English speaking women recruited from the abortion clinic
2456839|NCT03194906|Active Comparator|Memantine|Beginning at least two weeks prior to radiation therapy, participants receive memantine. Treatment continues for 12 weeks with periodic cognitive assessments and lab work.
2456841|NCT03194906|Placebo Comparator|Placebo|Beginning at least two weeks prior to radiation therapy, participants receive a placebo. Treatment and assessment are identical to the memantine group.
3154760|NCT00306007||Spanish abortion clinic|Spanish speaking (monolingual) women recruited from the abortion clinic
3154761|NCT00306059|Experimental|patients having acute kidney injury|
3154762|NCT00306098|Experimental|Islet transplantation|
3154763|NCT00306111|Experimental|Pegfilgrastim|Pegfilgrastim for stem cell mobilization (single arm)
3154764|NCT00306137|Experimental|Arm 1|
3154765|NCT00306137|Placebo Comparator|Arm 2|
3154766|NCT00306150|Experimental|Arm 1|
3154767|NCT00306150|Placebo Comparator|Arm 2|
3154768|NCT00306215|Experimental|1|Blinded study arm
3154769|NCT00306215|Experimental|2|Blinded study arm
3154770|NCT00306215|Experimental|3|Blinded study arm
3154771|NCT00306215|Experimental|4|Blinded study arm
3154772|NCT00306228|Active Comparator|bare-metal stent without tirofiban|implantation of a bare-metal stent with no tirofiban infusion after fibrinolysis
3154773|NCT00306228|Active Comparator|bare-metal stent with tirofiban|implantation of a bare-metal stent with tirofiban infusion after fibrinolysis
3154774|NCT00306228|Active Comparator|paclitaxel-eluting stent without tirofiban|implantation of a paclitaxel eluting-stent with no tirofiban after fibrinolysis
3154775|NCT00306228|Active Comparator|paclitaxel-eluting stent with tirofiban|implantation of a paclitaxel eluting-stent with tirofiban infusion after fibrinolysis
3154776|NCT00306397|Active Comparator|A|Rapamycin - MMF after 3 months
3154777|NCT00306397|Active Comparator|B|Low dose tacrolimus - MMF - Rapamycin after 3 months
3154778|NCT00306462|Active Comparator|1|Intravenous magnesium sulfate or placebo
3154779|NCT00306462|Active Comparator|2|Oral nifedipine or placebo
3154780|NCT00306475|Active Comparator|1|
3154781|NCT00306475|Placebo Comparator|2|
3154782|NCT00306501|Other|Button Press|Training with button press
3154783|NCT00306501|Other|Vibtrotactile|Sensory Stimulation - Vibrotactile device with button press to initiate swallowing during retraining
2456657|NCT03196219|Other|Arm 1|Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.
2456664|NCT03196219|Placebo Comparator|Arm 2|Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 & 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).
2456670|NCT03196219|Other|Arm 3|If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.
2456733|NCT03195842|No Intervention|Usual discharge care|Standard discharge instructions, meaning conversation with physician, usually via interpreter, along with written instructions compiled by the nurse. Written instructions include pre-translated handouts for common languages, and untranslated (English) patient-specific instructions.
2456739|NCT03195842|Experimental|Recordable card|Usual care, as above, plus patient-specific and standard instructions recorded in the patient's preferred language for care and given to them on a card to take home.
2456752|NCT03195361|Experimental|Single-arm|Subjects suffering from anterior POP-Q grade 2 (point Aa and Ba≥ -1) and above, who are scheduled for POP surgery, will be transplanted with the SRS device
2456784|NCT03195153|Experimental|statin only|30 DAYS OF STATIN THERAPY ATORVASTATIN 80 MG)
2456785|NCT03195153|Experimental|allopurinol only|30 DAYS OF ALLOPURINOL (300 MG)
2456786|NCT03195153|Experimental|statin and allopurinol|30 DAYS OF CO-ADMINISTRATION OF ATORVASTATIN AND ALLOPURINOL
2456891|NCT03194399|Experimental|Breast cancer patients|
3154784|NCT00306501|Other|Cortical Stimulation|Training with Cortical stimulation - cortical stimulation during training with button press
3154785|NCT00306501|Other|Combined|Combined vibrotactile and cortical stimulation with button press training
3154786|NCT00306540|Active Comparator|1|Placebo Seroquel + existing therapy
3154787|NCT00306540|Experimental|2|Seroquel + existing therapy
3154788|NCT00306631|Experimental|1|
3154789|NCT00306644|Experimental|Arm 1|study drug
3154790|NCT00306709|Experimental|Teaching|
3154791|NCT00306735|Experimental|Palonosetron|
3154792|NCT00306774|Experimental|1|Participants will receive vitamin D (cholecalciferol)
3154793|NCT00306774|Placebo Comparator|2|Participants will receive a matched placebo
3154794|NCT00306839|Other|1|Tissel group
3154795|NCT00306839|Other|2|Suture group
3154796|NCT00306904|Experimental|1|3.0 mg/eye dose group
3154797|NCT00306904|Experimental|2|1.5 mg/eye dose group
3154798|NCT00306904|Experimental|3|0.2 mg/eye dose group
3154799|NCT00306930|Other|A|Acetabular cup replacement with total hip arthroplasty
3154800|NCT00306956|Experimental|A|Recommendation to offer a pacifier to 15 days old newborn infants with successful breastfeeding
3154801|NCT00306956|Active Comparator|B|Recommendation not to offer a pacifier to normal newborn infant with successful breastfeeding at 15 days of age
3154802|NCT00307008|Experimental|Group A|
3154803|NCT00307021|Active Comparator|Group A|
3154804|NCT00307021|Experimental|Group B|
3154805|NCT00307099|Experimental|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
3154806|NCT00307099|Active Comparator|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
3154807|NCT00307177|Experimental|Arm D|25 subjects receive Recombinant rHA0 vaccine at 135 mcg per rHA0, via IM injection on Day 0
3154808|NCT00307177|Experimental|Arm C|25 subjects receive Recombinant rHA0 vaccine at 45 mcg per rHA0, via IM injection on Day 0
3154809|NCT00307177|Experimental|Arm B|25 subjects receive Recombinant rHA0 vaccine at 15 mcg per rHA0, via IM injection on Day 0
3154810|NCT00307177|Active Comparator|Arm A|25 subjects receive Standard TIV at 15 mcg HA per virus, in a total volume of 0.5 mL, by deep intramuscular (IM) injection on Day 0
3154811|NCT00307190||Binge Eating Disorder|Women with Binge Eating Disorder
3154812|NCT00307190||Controls|Weight, age, and gender-matched control subjects
3154813|NCT00307203|Experimental|I|Experiment group received 300 mgs of bupropion, in addition to weekly CBT and nicotine replacement therapy
3154814|NCT00307203|Placebo Comparator|II|Placebo group received placebo, in addition to weekly CBT and nicotine replacement therapy
3154815|NCT00307216|Experimental|1|Participants will receive Graduated Recovery Intervention Program plus treatment as usual
3154816|NCT00307216|Active Comparator|2|Participants will receive treatment as usual
3154817|NCT00307281||Registry|10 pack year tobacco smoking history required, current or former smokers accepted.
3154818|NCT00307320|No Intervention|1|
3154819|NCT00307320|Experimental|2|Relaxation techniques
3154820|NCT00307398|Experimental|AL-3789|One injection to the study eye by the posterior juxtascleral depot procedure at 6-month intervals for 42 months.
3154821|NCT00307398|Sham Comparator|Anecortave Acetate Vehicle|One sham injection to the study eye at 6-month intervals for 42 months. Syringe containing AA vehicle was not inserted into the eye.
3154822|NCT00307463|Active Comparator|strict volume control policy|strict volume control policy: Antihypertensive medicine will be stopped and strict volume control policy will be applied.
3154823|NCT00307463|Other|antihypertensive drugs administration|antihypertensive drugs administration: Antihypertensive medicine will be continued. Target BP will be 130/80 mmHg in both groups.
3154824|NCT00307502|Experimental|NVP|Nevirapine
3154825|NCT00307502|Experimental|EFV|Efavirenz
3154826|NCT00307502|Experimental|INV|Indinavir/ritonavir
2456587|NCT03197051||Q2|Q2 means a group of lower 25~50% of serum syndecan-1 concentration.
2456589|NCT03197051||Q3|Q3 means a group of higher 50~75% of serum syndecan-1 concentration.
2456590|NCT03197051||Q4|Q4 means a group of highest 75~100% of serum syndecan-1 concentration.
2456607|NCT03196453|Active Comparator|Probiotic|Lactobacillus rhamnosus GG
2456609|NCT03196453|Active Comparator|Probiotic and protein|Lactobacillus rhamnosus GG and whey protein isolate
2456611|NCT03196453|Placebo Comparator|Placebo|Placebo
2456728|NCT03195608|Experimental|Intervention|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, the lane change assistance system will be introduced and participants will be taught how to use it. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world. They will drive this new route with the assistive technology. One to two weeks after the post-test, participants will be invited to participate in a follow-up assessment (battery of tests and simulator assessment).
2456731|NCT03195608|Active Comparator|Control|Participants will complete a standardized battery of paper and pencil and computer tests. Following these tests, participants will complete a baseline simulator driving assessment without any form of assistive technology. We will employ a CDS-200 driving simulator (DriveSafety Inc., Salt Lake City, UT). A trained blinded evaluator will observe the recorded drive and score the drive. After the baseline assessment, participants will engage in 3 intervention sessions (lasting 30 minutes each). During these sessions, participants will drive the scenario and receive feedback from a trained evaluator regarding their live performance. No lane change assistance system will be utilized. After the 3 sessions, participants will participate in a post-test, similar to the baseline assessment but with a different route within the simulated world.
2456792|NCT03195283||Traditional meal service|TMS consists of three meals served by nutritional assistants throughout the day. Preference for dinner can be indicated in the morning by the individual patient from a menu list with predefined choices for meat, potatoes/rice/pasta and vegetables with various portion sizes.
2456799|NCT03195283||FoodforCare|FfC consists of a 6-meals per day service. At bedside, patients are offered one or more small protein-rich dishes from a choice of 3. Nutritional assistants play a key role in recommending and delivering these protein-rich meals and assist patient in choosing the most optimal dish, based on the patient's nutrition order in the electronic patient record.
2456867|NCT03194841|Experimental|Heart Failure Application|A mobile application that allowed for input of physiologic data, qualitative questions about symptoms and education
3154827|NCT00307502|Experimental|NFV|Nelfinavir
3154828|NCT00307502|Experimental|SQV|Saquinavir/ritonavir
3154829|NCT00307502|Experimental|LPV|Lopinavir/ritonavir
3154830|NCT00307502|Experimental|ATV|Atazanavir
3154831|NCT00307502|Experimental|ATV/rtv|Atazanavir/ritonavir
3154832|NCT00307502|Experimental|Fos-APV|Fos-amprenavir/ritonavir
3154833|NCT00307502|Experimental|TPV|Tipranavir/ritonavir
3154834|NCT00307502|Experimental|DRV|Darunavir/ritonavir
3154835|NCT00307515|Experimental|1|Fibrin Sealant 2 (FS2)
3154836|NCT00307515|Active Comparator|2|Oxidized Regenerated Cellulose (Surgicel)
3154837|NCT00307528|Active Comparator|Group A|
3154838|NCT00307528|Experimental|Group B|
3154839|NCT00307528|Experimental|Group C|
3154840|NCT00307528|Experimental|Group D|
3154841|NCT00307528|Experimental|Group E|
3154842|NCT00307528|Experimental|Group F|
3154843|NCT00307593|Active Comparator|1|Rituximab
3154844|NCT00307593|Active Comparator|2|Infliximab
3154845|NCT00307632|Experimental|Norelgestromine (NLGM)/Ethinyl Estradiol (EE)|
3154846|NCT00307671|Other|A|conventional treatment
3154847|NCT00307671|Experimental|B|reduction dose
3154848|NCT00307710|Experimental|A: Trivalent Subvirion Vaccine|Group A: Trivalent subvirion vaccine - standard inactivated influenza vaccine by intramuscular injection.
3154849|NCT00307710|Experimental|B: Vaccine 15 μg|Group B: Trivalent rHA0 vaccine 15 μg per rHA0 (total 45 μg rHA0)
3154850|NCT00307710|Experimental|C: Vaccine 45 μg|Group C: Trivalent rHA0 vaccine 45 μg per rHA0 (total 135 μg rHA0)
3154851|NCT00307710|Experimental|D: Vaccine 135 μg|Group D: Trivalent rHA0 vaccine 135 μg per rHA0 (total 405 μg rHA0)
3154852|NCT00307723|Experimental|Regimen Level 1|Radiation/Oxaliplatin/5-FU
3154853|NCT00307723|Experimental|Regimen Level 2|Radiation/Oxaliplatin/Bevacizumab/5-FU
3154854|NCT00307749|Placebo Comparator|1|
3154855|NCT00307749|Experimental|2|
3154856|NCT00307749|Experimental|3|
3154857|NCT00307749|Experimental|4|
3154858|NCT00307762|Experimental|1|Gait trainer exercise actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
3154859|NCT00307762|Active Comparator|2|Overground walking exercises actively for 20 minutes + 55 minutes other gait-oriented physiotherapy
3154860|NCT00307762|No Intervention|3|Control patients with ordinary therapy
3154861|NCT00307827|Experimental|Arm 1|Visilizumab low dose level
3154862|NCT00307827|Experimental|Arm 2|Visilizumab middle dose level
3154863|NCT00307827|Experimental|Arm 3|Visilizumab high dose level
3154864|NCT00307853|Active Comparator|1|TraumeelS
3154865|NCT00307853|Placebo Comparator|Placebo|
3154866|NCT00307866|Experimental|Arm 1|
3154867|NCT00307892|Active Comparator|A|TRAUMEEL S
3154868|NCT00307892|Placebo Comparator|B|comparable placebo remedy (injection and oral)
3154869|NCT00307905|Active Comparator|A|TRAUMEEL S
3154870|NCT00307905|Placebo Comparator|B|placebo remedy
3154871|NCT00308009|Active Comparator|1|Group I, Prolapse repair and TVT concomitantly
3154872|NCT00308009|Active Comparator|2|Group II, Prolapse repair and TVT 3 months afterwards if necessary
3154873|NCT00308100|Experimental|1|
3154874|NCT00308100|Active Comparator|2|
2456602|NCT03196726|Experimental|Intervention Arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. After session with Medical Officer, participants will be seen by Nurse who additionally manage them using brief Cognitive Behavioral Therapy. Participants will be follow-up at weekly basis for 6 weeks.
2456605|NCT03196726|Placebo Comparator|Control arm|Participants will be seen by Medical Officer and manage using standard management based on Clinical Practice Guideline for management of postnatal depression. Participants will be follow-up at weekly basis for 6 weeks.
2456730|NCT03195725||Year 2013|Participant's notes will be reviewed from the year 2013
2456736|NCT03195725||Year 2015|Participant's notes will be reviewed from the year 2015
2456757|NCT03195335||Children with cerebral palsy|Children who diagnosed as cerebral palsy by a pediatric neurologist
2456818|NCT03195127|Experimental|multimodal physical therapy|Multimodal physical therapy sessions three times a week, for four weeks, lasting one hour. Consist of limb strengthening exercises, endurance training, and balance/coordination drills.
2456824|NCT03195127|No Intervention|Usual care|Subjects will receive the standard therapy program provided by University Specialty Hospital therapy services. To compliment the physical therapy regimen, an optimized nutritional program will be administered according accepted guidelines.
2456870|NCT03194711||Patients with stable CAD|
3154875|NCT00308152|No Intervention|Control|Observation only
3154876|NCT00308152|Active Comparator|Active|Infusion of 1 liter normal saline before sedated colonoscopy
3154877|NCT00308165|Experimental|Topotecan|Once a plastic catheter is placed, within 24 hours of placement, the catheter will be connected to a small pump at the bedside, and the convection-enhanced delivery of the Topotecan will begin. The Topotecan will be infused for 4 to 5 days after which time the catheters will simply be pulled out. Patients will be monitored with blood tests and MRI scans during the treatment and at different time periods during the following months.
3154878|NCT00308204|Experimental|Raptiva|raptiva injection
3154879|NCT00308256|Experimental|Nurse counseling|Phone calls performed by nurse 15 days after each monthly visit
3154880|NCT00308256|No Intervention|Control|Normal monthly follow-up without phone calls
3154881|NCT00308269|Experimental|Vintafolide 1.2 mg IV Bolus|Vintafolide 1.2 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3154882|NCT00308269|Experimental|Vintafolide 2.5 mg IV Bolus|Vintafolide 2.5 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3154883|NCT00308269|Experimental|Vintafolide 4.0 mg IV Bolus|Vintafolide 4.0 mg administered by IV bolus on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3154884|NCT00308269|Experimental|Vintafolide 2.5 mg IV Infusion|Vintafolide 2.5 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3154885|NCT00308269|Experimental|Vintafolide 3.0 mg IV Infusion|Vintafolide 3.0 mg administered by a 1-hour IV infusion on Days 1, 3, 5, 15, 17, and 19 of 4-week treatment cycles
3154886|NCT00308334|Experimental|Domperidone|Domperidone
3154887|NCT00308334|Placebo Comparator|placeob- Sugar pill|
3154888|NCT00308412|Experimental|1|Two 10^5 PFU doses of rHPIV3cp45 vaccine given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
3154889|NCT00308412|Placebo Comparator|2|Two placebo vaccinations given as nose drops to healthy infants and children aged 6 to 36 months of age. The two doses are given 4 to 10 weeks apart.
3154890|NCT00308438|Experimental|1|All subjects in the study dosed at 0.1 mg/kg teduglutide
3154891|NCT00308503|Experimental|1|5 mg/day
3154892|NCT00308503|Placebo Comparator|2|
3154893|NCT00308724|Experimental|1|Cognitive Behavior Therapy
3154894|NCT00308724|Active Comparator|2|Usual Care
3154895|NCT00308763|Active Comparator|1|Nicotine patch plus placebo sustained-release bupropion
3154896|NCT00308763|Active Comparator|2|Placebo nicotine patch plus sustained-release bupropion
3154897|NCT00308763|Active Comparator|3|Nicotine patch plus sustained-release bupropion
3154898|NCT00308776|Experimental|Cholecystokinin|Participants will receive intravenous saline plus cholescystokinin.
3154899|NCT00308776|Placebo Comparator|Saline|Participants will receive intravenous saline only.
3154900|NCT00308789|Experimental|1|Biphasic NCPAP
3154901|NCT00308789|Active Comparator|2|Continuous CPAP
3154902|NCT00308854|Active Comparator|1|PD P 506 A-PDT
3154903|NCT00308854|Placebo Comparator|2|Placebo-PDT
3154904|NCT00308893|Experimental|Escitalopram|Treatment response after 3 and 6 weeks
3154905|NCT00308906||1|Hospitalized, untreated infants and children
3154906|NCT00308906||2|Aminoglycoside treated infants and children without renal injury
3154907|NCT00308906||3|Aminoglycoside treated infants with renal injury
3154908|NCT00308919|Experimental|WST 09|Treatment with WST09 Vascular Photodynamic therapy
3154909|NCT00308945|Experimental|2|cross-over comparison of two substances
3154910|NCT00308945|Experimental|1|
3154911|NCT00308971|Active Comparator|1|
3154912|NCT00308971|Placebo Comparator|2|
3154913|NCT00309023|Experimental|dose escalation|
3154914|NCT00309049|Active Comparator|A1|
3154915|NCT00309049|Active Comparator|A2|
3154916|NCT00309049|Active Comparator|A3|
3154917|NCT00309075|Experimental|Arm 1|
3154918|NCT00309088|Experimental|1|
3154919|NCT00309088|Placebo Comparator|2|
3154920|NCT00309101|Experimental|1. tacrolimus|
3154921|NCT00309114|Experimental|Interventions for Experimental Arm|Bacterial Interference with Escherichia coli 83972. Each bladder inoculation contains the study organism, E. coli 83972, suspended as a clear solution in sterile physiological saline.
3154922|NCT00309114|Placebo Comparator|Interventions for Control Arm|Each bladder inoculation contains sterile physiological saline that does not contain the study organism.
3154923|NCT00309179|Experimental|1|
3154924|NCT00309218|Active Comparator|A|Steroid withdrawal
3154925|NCT00309218|Placebo Comparator|B|continuos Steroid treatment
3154926|NCT00309257|Experimental|ACE inhibitor, ATA II antagonists and Statins|
3154927|NCT00309283|Experimental|somatostatin|
2456606|NCT03196700|Experimental|Short course radiotherapy|The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered
2456662|NCT03196245||Pregnant women|Pregnant women undergoing influenza vaccination or acutely infected with influenza
2456737|NCT03195933|Experimental|Cortisol first, Placebo second|Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during first functional magnetic resonance imaging (fMRI) session; Identically appearing placebo capsule during second fMRI session.
2456742|NCT03195933|Experimental|Placebo first, Cortisol second|Placebo capsule during first fMRI session; Single oral administration of 20 mg cortisol capsule to pharmacologically elevate cortisol levels during second fMRI session.
2456764|NCT03195257|Placebo Comparator|Hypoglycemia-saline|
2456765|NCT03195257|Experimental|Hypoglycemia-GIP|
2456766|NCT03195257|Active Comparator|Hypoglycemia-GLP-1|
2456767|NCT03195257|Experimental|Hyperglycemia-GIP|
2456768|NCT03195257|Placebo Comparator|Hyperglycemia-Saline|
2456836|NCT03195023|Active Comparator|RAS Blockers|Patients in this arm will receive Lisinopril 20mg/day
2456838|NCT03195023|Active Comparator|Non RAS Blockers|Patients in this arm will receive Amlodipine 10mg/day or Lercanidipine 20mg/day +/- diuretics
3154928|NCT00309283|Placebo Comparator|Saline solution|
3154929|NCT00309296|Experimental|Longitudinal Care|One year of combined behavioral and pharamcological tobacco dependence treatment, with interim smoking reduciton for smokers who fail initial quit attempt.
3154930|NCT00309296|Active Comparator|Usual Care|Evidence based, state-of-the-science tobacco treatment; combined behavioral and pharmacological treatment for 8 weeks
3154931|NCT00309348|Experimental|Weekly measurement of graft flow|The surveillance group was measured with the FloMon instrument weekly, and all procedures related to their access-grafts recorded
3154932|NCT00309348|No Intervention|Control|The control group was questioned weekly with regard to their graft status and whether there had been any graft-related procedures
3154933|NCT00309413|Active Comparator|1|Cannabidiol/Placebo
3154934|NCT00309413|Placebo Comparator|2|Placebo/Cannabidiol
3154935|NCT00309478|Experimental|2 (CMF scheme)|6 cycles CMF scheme (cyclophosphamide, methotrexate, fluorouracil)
3154936|NCT00309478|Experimental|1 (Nol + Zol)|Zoladex (3 years) combined with Nolvadex (5 years)
3154937|NCT00309491|Experimental|Group I|Tamoxifen alone
3154938|NCT00309491|Experimental|Group II|Tamoxifen + Aminoglutethimide
3154939|NCT00309556|Active Comparator|A (experimental group)|Epirubicin/Docetaxel/Capecitabine-containing chemotherapy ± trastuzumab in HER-2 positive disease
3154940|NCT00309556|Active Comparator|B (control group)|Epirubicin/Docetaxel-containing chemotherapy ± trastuzumab in HER-2 positive disease
3154941|NCT00309569|Experimental|A (pre- + postoperative chemotherapy)|3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil) followed by surgery. Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
3154942|NCT00309569|Experimental|B (conventional postoperative chemotherapy)|Surgery followed by 3 cycles CMF (cyclophophamide + Methotrexat + 5-Fluorouracil). Subsequently node-positive patients received 3 cycles anthracycline-based chemotherapy regime EC (epirubicin + cyclophosphamide) and node-negative patients another 3 cycles CMF.
3154943|NCT00309595|Experimental|1|Cordis SMART™ nitinol self expandable stent
3154944|NCT00309595|Active Comparator|2|balloon
3154945|NCT00309647|Experimental|H5N1 Formulation 1 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval
3154946|NCT00309647|Experimental|H5N1 Formulation 2 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval
3154947|NCT00309647|Experimental|H5N1 Formulation 3 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval
3154948|NCT00309647|Experimental|H5N1 Formulation 4 Group|Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval
3154949|NCT00309647|Active Comparator|H5N1 Formulation 5 Group|Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval
3154950|NCT00309647|Active Comparator|H5N1 Formulation 6 Group|Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval
3154951|NCT00309647|Active Comparator|H5N1 Formulation 7 Group|Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval
3154952|NCT00309647|Active Comparator|H5N1 Formulation 8 Group|Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval
3154953|NCT00309699|Placebo Comparator|003|Placebo Daily for 3 weeks
3154954|NCT00309699|Active Comparator|002|Quetiapine 400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
3154955|NCT00309699|Experimental|001|Paliperidone ER 3 to 12 mg daily, flexibly dosed, for 12 weeks
3154956|NCT00309855|Placebo Comparator|Double Placebo|(i.m. vehicle 0.5 mL weekly x three injections and oral placebo once daily x 21 days)
3154957|NCT00309855|Other|Testosterone IM and oral placebo|IM injections weekly x three injections and oral placebo once daily x 21 days
3154958|NCT00309855|Other|Testosterone and Oral Anastrozole|IM injections weekly x 3 injections and oral daily x 21 days
3154959|NCT00309855|Other|Testosterone and Dutasteride|IM injections weekly x 3 injections and oral once daily x 21 days
3154960|NCT00309972|Active Comparator|Sequential arm (SEQ)|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
3154961|NCT00309972|Experimental|Experimental arm (CON)|Concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
3173193|NCT00609388|Active Comparator|A|Group A receives an intraportal Tacrolimus-infusion, ATG Induction, Tacrolimus and Steroids.
3173194|NCT00609388|Placebo Comparator|B|Group B receives a placebo-Saline solution (0.9%)-Infusion, ATG induction, Tacrolimus and Steroids.
3173195|NCT00609401|Experimental|1|Sorafenib 400 bid + IL-2 3 MU per 5 day/week for 2 weeks every 4
3173196|NCT00609401|Experimental|2|Sorafenib 400 mg bid
3190836|NCT00792064||1|Kidney-Tx-recipients
2456614|NCT03196466||antiepileptics titration|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
2456616|NCT03196466||antiepileptics titration and available blood samples|Titration of valproic acid, carbamazepine, phenobarbital, phenytoin, levetiracetam, lamotrigine, topiramate, oxcarbazepine, stiripentol, clobazam, brivaracétam, felbamate, lacosamide, rufinamide, gabapentine, pregabaline, sultiame, tiagabine, vigabatrine, mesuximide, primidone, perampanel, ethosuximide, zonisamide and cannabidiol
2456745|NCT03195764|Experimental|T-1101 (Tosylate)|
2456761|NCT03195205|Other|High-Risk Patients|OraQuick HCV screening for HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations
2456790|NCT03195075|Active Comparator|Group 1|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to endoscopic ultrasonography guided biliary drainage
2456794|NCT03195075|Active Comparator|Group 2|20 Patients with malignant biliary obstruction after failed endoscopic retrograde cholangio-pancreaticography will be subjected to percutaneous trans-hepatic biliary drainage.
2456845|NCT03194828|Active Comparator|Monitoring only|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months
2456846|NCT03194828|Experimental|Monitoring and reminder|Patients in this arm will be given a real-time medication use monitor to use in dispensing their topical glaucoma medication for 3 months and will receive an automated reminder (text or voice) when a missed dose is determined by the device's system
3154962|NCT00310024|Experimental|Treatment (vorinostat, bortezomib)|"Patients receive bortezomib IV on days 1, 4, 8, and 11 followed by oral SAHA twice daily on days 4-11. Beginning in course 3, some patients may receive low-dose oral dexamethasone on days 4-8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional cohort of 10 patients receive treatment at the MTD.~Patients undergo blood collection and tumor biopsies periodically during study for pharmacologic and biomarker correlative studies."
3154963|NCT00310063|Experimental|Arm I|Sea Band elastic acupressure wristband
3154964|NCT00310063|Sham Comparator|Arm II|Sham wristband
3154965|NCT00310115||Smoking Prevention Usual Care|Arm I (usual care): Self-help materials and brief relapse prevention advice based on Treating Tobacco Use and Dependence Clinical Practice Guideline.
3154966|NCT00310115||MRP|Arm II (motivational relapse prevention [MRP]): Same intervention as usual care, plus 30 minutes telephone counseling at 34 & 36 weeks gestation then at 2, 4, 7, & 16 weeks postpartum.
3154967|NCT00310115||Enhanced MRP +|Arm III (enhanced MRP [MRP+]): Same intervention as usual care and telephone counseling as MRP, plus 1 hour in-person counseling at 30-33 weeks gestation & 8 weeks postpartum.
3154968|NCT00310141|Active Comparator|Standard Care Group|Written self-help materials, counseling, and 6-week nicotine patch supply
3154969|NCT00310141|Active Comparator|Computer Treatment Group (CDT)|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
3154970|NCT00310141|Experimental|CDT Pilot|Written self-help materials, counseling, 6-week nicotine patch supply and 6 weeks of computer-delivered treatment
3154971|NCT00310167|Experimental|4 Gy|4 Gy in 2 fractions
3154972|NCT00310167|Active Comparator|24 Gy|24 Gy in 12 fractions
3154973|NCT00310206|Experimental|ID injection-9 mcg|25 subjects to receive 9 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
3154974|NCT00310206|Experimental|IM injection-15 mcg|25 subjects to receive 15 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
3154975|NCT00310206|Experimental|IM injection-45 mcg|25 subjects to receive 45 mcg of inactivated influenza A/H5N1 vaccine intramuscularly on Days 0 and 28.
3154976|NCT00310206|Experimental|ID injection-3 mcg|25 subjects to receive 3 mcg of inactivated influenza A/H5N1 vaccine intradermally on Days 0 and 28.
3154977|NCT00310219|Experimental|Arm 1|Two radiation oncologists are randomly assigned to develop either a 3DCRT plan using CT only, or a 3DCRT plan using fused PET/CT
3154978|NCT00310323|Experimental|1|Children with OSAS identified via sleep study
3154979|NCT00310388|Experimental|Retigabine (INN), Ezogabine (USAN)|Retigabine (Ezogabine): all subjects
3154980|NCT00310492|Active Comparator|Subcutaneous immunotherapy|Subcutaneous injections with ALK-depot SQ mites to 100,000 SQ-U
3154981|NCT00310492|Placebo Comparator|Subcutaneous injections|placebo injections
3154982|NCT00310531|Experimental|Arm 1|
3154983|NCT00310531|Active Comparator|Arm 2|
3154984|NCT00310544|Experimental|Arm 2|
3154985|NCT00310544|Experimental|Arm 1|
3154986|NCT00310557|Experimental|Arm 1|
3154987|NCT00310596|Experimental|Arm 1|
3154988|NCT00310596|Experimental|Arm 2|
3154989|NCT00310596|Experimental|Arm 3|
3154990|NCT00310596|Experimental|Arm 4|
3154991|NCT00310596|Active Comparator|Arm 5|
3154992|NCT00310596|Placebo Comparator|Arm 6|
3154993|NCT00310609|Experimental|Arm 1|
3154994|NCT00310661|Placebo Comparator|Placebo|Placebo hard gelatin capsules matching the investigational medication
3154995|NCT00310661|Experimental|Sarizotan HCI|Sarizotan HCI is administered at various doses ranging from 2-7mg.
3154996|NCT00310713|Experimental|Group 1|
3154997|NCT00310713|Experimental|Group 2|
3154998|NCT00310713|Experimental|Group 3|
3154999|NCT00310713|Experimental|Group 4|
3155000|NCT00310713|Experimental|Group 5|
3155001|NCT00310726|Experimental|Abrupt Weaning|Women were counseled to abruptly wean their child at 4 months of age.
3155002|NCT00310726|Active Comparator|Exclusive breastfeeding per WHO guidelines|Women were counseled to adhere to the WHO recommendations for duration of exclusive breastfeeding.
3155003|NCT00310765|Active Comparator|1|75-150 mg of pregabalin po BID
3155004|NCT00310765|Placebo Comparator|2|Placebo 75 or 150 mg po BID
3190837|NCT00792064||2|Liver-Tx-recipients
2456622|NCT03196570|Active Comparator|Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
2456663|NCT03196167|Experimental|Sugammadex|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
2456668|NCT03196167|Placebo Comparator|Placebo|Research pharmacy will provide the Sugammadex (2m/kg) vs. Placebo in a syringe.
2456726|NCT03195569||Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
2456727|NCT03195569||Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles.
2456798|NCT03195244|No Intervention|Observation|
2456801|NCT03195244|Active Comparator|One-on-one Aquatic Therapy|
2456803|NCT03195244|Experimental|Group Aquatic Therapy|
2456876|NCT03194802|Experimental|Sleeping Without Pills Program|Cognitive behavioral therapy; Motivational Interviewing; Scheduled and gradual drug tapering
2456883|NCT03194802|Active Comparator|Self-Monitoring|Daily Self-monitoring of sleep and sleep medication using sleep diary
3155005|NCT00310778|Experimental|1|treatment
3155006|NCT00310830|No Intervention|1|
3155007|NCT00310830|Experimental|2|
3155008|NCT00310843||All study population|
3155009|NCT00310869|Experimental|E|
3155010|NCT00310895|Experimental|Dose escalation|Treatment Schedule 3 will consist of dosing on Days 1, 4, 8, and 11 of each 21 day cycle (3 weeks equals 1 cycle) and Treatment Schedule 4 will consist of dosing on Day 1 of each 28 day cycle (4 weeks equals 1 cycle)
3155011|NCT00311090|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
3155012|NCT00311090|Active Comparator|Idraparinux|"Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)"
3155013|NCT00311103|No Intervention|Care in the Control Group (CG)|Care in the Control Group (CG): was that provided by the General Practitioners, with basic diagnostic and therapeutic procedures without specified protocols.
3155014|NCT00311103|Experimental|Early Intervention Programa (IG)|Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
3155015|NCT00311129|Experimental|Arm 1|
3155016|NCT00311129|Active Comparator|Arm 2|
3155017|NCT00311298|Placebo Comparator|No micronutrients|Biscuit without additional micronutrients
3155018|NCT00311298|Experimental|Micronutrients|Biscuit with additional micronutrients
3155019|NCT00311298|Active Comparator|1 biscuit|1 biscuit with micronutrients
3155020|NCT00311298|Experimental|6 biscuits|1 biscuit with micronutrients, plus 5 biscuits without additional micronutrients
3155021|NCT00311324|Experimental|Special Intervention|One individual counseling visit, twelve group sessions, three postcards, and twelve telephone calls.
3155022|NCT00311324|Experimental|Delayed Intervention|"Direct mailing of two American Dietary Association pamphlets (Healthy Eating and Staying Alive) and three bimonthly newsletters providing general health information and study updates."
3155023|NCT00311389|Experimental|Travoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
3155024|NCT00311389|Active Comparator|Latanoprost/Timolol|1 drop in the affected eye(s) once daily in the morning for 12 months
3155025|NCT00311415|Experimental|Group 1: 2+4 Months (2-doses)|
3155026|NCT00311415|Experimental|Group 2: 2 Months (1-dose)|
3155027|NCT00311415|Experimental|Group 3: 6 Months (1-dose)|
3155028|NCT00311415|Active Comparator|Group 4: 12-16 Months (1 dose in the second year of life)|
3155029|NCT00311467|Active Comparator|Capecitabine and Interferon|Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
3155030|NCT00311467|Active Comparator|Interferon|"Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
3155031|NCT00311545|Experimental|CNTO 328|CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)
3155032|NCT00311558|Experimental|SSG & INF|1 arm study: SSG & interferon
3155033|NCT00311597|Experimental|Single fractionated radiation adjusted for tumor size|Single fractionated radiation adjusted for volume of tumor tissue encompassed by desired isodose line
3173197|NCT00609427|Experimental|EA|Training in external memory aids
3173198|NCT00609427|Experimental|MT|Mnemonic training intervention
3173199|NCT00609427|No Intervention|WL|Wait-list control
2456683|NCT03196063|Active Comparator|Eccentric|"Patients allocated in this group will perform three sets of 15 unipodal squats with the affected limb on an inclined plane. The patient will be instructed to perform only the eccentric phase of the exercise, keeping the torso erect and flexing the knee up to 90 degrees. The return to the initial position will be performed with the unaffected leg. To increase exercise load, the patient will carry a bag with washers. This protocol will last eight weeks, with 24 face-to-face sessions.~Both groups will also receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
2456684|NCT03196063|Experimental|Modified protocol|"Patients allocated in this group will receive treatment based on a protocol published in a clinical practice guide, with modifications to make the protocol more pragmatic. Thus, the use of mechanotherapy devices will be replaced by free weight exercises, so that the protocol can be performed in environments that do not offer this type of machinery. This protocol is composed of four exercise stages, being the first three stages performed in the presence of the physiotherapist, and will last eight weeks with approximately 24 face-to-face sessions.~Both groups will receive a protocol with complementary isotonic exercises, focusing on the strengthening of gluteus maximus, gluteus medius, hamstrings and calves."
2456701|NCT03195751||Manual Goniometer measurements|Measurements of shoulder range of motion using manual goniometer
2456702|NCT03195751||Software development kit measurements|Measurements of shoulder range of motion using a proprietary SDK
2456762|NCT03195595||mitral valve replacement|patients whom underwent Mitral valve replacement through minimal invasive incision
2456763|NCT03195595||conventional mitral valve replacement|patients whom underwent Mitral valve replacement through conventional sternotomy
2456778|NCT03195049|Experimental|blood group|blood is collected for maternal and infant blood group,complete blood count,before, during and after the procedure of exchange transfusion .
2456780|NCT03195049|Experimental|serum bilirubin estimation|estimation of serum bilirubin before, during and after the procedure of exchange transfusion .
2456837|NCT03194932|Experimental|Treatment|"In Part 1, venetoclax with cytarabine will initially be given at dose level 1 and escalated based on tolerability. Idarubicin will be given only at dose level 4.~Note: Part 1 has been completed.~Two expansion cohorts will be enrolled:~Cohort A will be a group of 12 participants receiving the recommended phase 2 doses (RP2D) of venetoclax plus cytarabine.~Cohort B will be a group of 12 participants receiving the RP2D of venetoclax plus cytarabine and idarubicin.~Intrathecal Triple Therapy (ITMHA) will be given prior to cycle 1. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA beginning on day 8 until the cerebrospinal fluid becomes free of leukemia.~Cohort C: Participants will receive venetoclax PO on days 1-21, azacitidine IV on days 1-7, and cytarabine Q12H on days 8-11."
3155034|NCT00311610|Experimental|SN-38 liposome|"Patients receive SN-38 liposome IV over 90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed every 3 months for up to 3 years."
3155035|NCT00311662|Experimental|1|Tonabersat 40mg
3155036|NCT00311662|Placebo Comparator|2|
3155037|NCT00311675|Experimental|1|
3155038|NCT00311688||1|Individuals will follow the schedule of the study they are participating in
3155039|NCT00311727|Experimental|Influenza A/H5N1|232 subjects receiving Influenza A/H5N1 vaccine.
3155040|NCT00311753|Experimental|1|Certoparin
3155041|NCT00311753|Active Comparator|2|Heparin
3155042|NCT00311792|Experimental|1|Simulator training
3155043|NCT00311792|Active Comparator|2|Traditional Clinical education at operating room
3155044|NCT00311805|Active Comparator|1|
3155045|NCT00311805|Active Comparator|2|
3155046|NCT00311805|Placebo Comparator|3|
3155047|NCT00311831|Active Comparator|1|
3155048|NCT00311831|Experimental|2|
3155049|NCT00311896|Experimental|Bemiparin|
3155050|NCT00311896|Placebo Comparator|Placebo|
3155051|NCT00311922|Active Comparator|Control|Active Control Arm receives Comprehensive Diabetes Education
3155052|NCT00311922|Experimental|Intervention Arm|Receives comprehensive education that is literacy/numeracy sensitive
3155053|NCT00311948|Active Comparator|Telephone counseling + interactive website|Teen has access to interactive website and receives tailored telephone counseling
3155054|NCT00311948|Other|Control with interactive website|Teen only has access to interactive website.
3155055|NCT00312000|Active Comparator|1Capecitabine-irinotecan|1st line- 2nd line (3rd line oxaliplatin plus capecitabine)
3155056|NCT00312000|Experimental|2capecitabine plus irinotecan|1st line (2nd line oxaliplatin plus capecitabine)
3155057|NCT00312013|No Intervention|No Nadroparin|Patients will receive all standard anticancer treatment. Patients in this arm will not receive nadroparin
3155058|NCT00312013|Experimental|Nadroparin|Patients will be randomized to receive standard anticancer treatment. Nadroparin patients will be treated with therapeutic doses of subcutaneous (s.c). nadroparin for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2-week periods of therapeutic doses of nadroparin will be given for a total of 6 cycles each separated by a 4-week wash-out. The study treatment period ends at week 46 regardless of number of cycles achieved at that moment.
3155059|NCT00312039|Experimental|A|
3155060|NCT00312039|Active Comparator|B|
3155061|NCT00312052|Experimental|E5555 50 mg|Participants received one 50 mg E5555 and two 100 mg placebo tablets, once orally daily for 24 weeks.
3155062|NCT00312052|Experimental|E5555 100 mg|Participants received one 50 mg placebo, one 100 mg E5555 and one 100 mg placebo tablets, once orally daily for 24 weeks.
3155063|NCT00312052|Active Comparator|E5555 200 mg|Participants received one 50 mg placebo and two 100 mg E5555 tablets were taken orally once daily for 24 weeks.
3155064|NCT00312052|Placebo Comparator|Placebo|Participants received one 50 mg placebo and two 100 mg placebo tablets, once orally daily for 24 weeks.
3173200|NCT00609440|Other|A|A single case study, of a patient that was submitted to a physiotherapeutic treatment.
3173201|NCT00609453|Experimental|1|Individuals with major depressive disorder receiving therapy
3173202|NCT00609479|Experimental|1|Internal fixation with Micronail. 41 patients.
3173203|NCT00609479|Experimental|2|External fixation with Hoffmann-II-non-bridging. 41 patients.
2456712|NCT03195634||HVPG group|"When HVPG > 12 mmHg, patients would be treated with carvedilol at an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day.~After about 8 weeks, the patients treated with carvedilol will received the second HVPG monitoring wether achieved a decrease in HVPG below 12 mm Hg or>20% from baseline."
2456750|NCT03195504|Experimental|HFNC (High Flow Nasal Cannulae)|High Flow Nasal Cannulae providing humidified, high-flow oxygen during induction of anesthesia
2456751|NCT03195504|Active Comparator|CON (control)|Standard flow oxygen during induction of anesthesia
2456814|NCT03195192|Other|Single arm|This is a biomarker study analyzing tissue for baseline biomarkers and collecting tissue at progression for further analysis of biomarkers changes after treatment with CDK 4/6 inhibitors and endocrine therapy
3155065|NCT00312065|Experimental|Patient|Once stabilized, a trimmed reflective shield to cover only the probe itself will be placed over the thermistor probe. Changes in measured skin temperature and warmer power output will be recorded non-invasively, as well as the time taken to reestablish baseline status. A full-sized reflective shield will then be placed over the thermistor probe and the same observations recorded, then repeated 15 minutes later. At the time of a subsequent routine change in thermistor position, the same procedure will be followed, but omitting the intermediate step of using the smaller trimmed shield. Continuous core temperatures will be monitored via a short rectal probe during the study periods.
3155066|NCT00312091|Experimental|A, Stage 1|Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
3155067|NCT00312091|Experimental|A, Stage 2|Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
3155068|NCT00312091|Experimental|B, Stage 1|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
3155069|NCT00312091|Experimental|B, Stage 2|Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
3155070|NCT00312247||Boys taking steroids|Boys who are taking prednisone or deflazacort
3155071|NCT00312247||Boys who are steroid naive|Boys who are not taking steroids for a variety of reasons
3155072|NCT00312260|Experimental|1|
3155073|NCT00312260|Active Comparator|2|
3155074|NCT00312286|Experimental|1|
3155075|NCT00312286|Experimental|2|
3155076|NCT00312286|Experimental|3|
3155077|NCT00312286|Experimental|4|
3155078|NCT00312286|Experimental|5|
3155079|NCT00312286|Experimental|6|
3155080|NCT00312286|Experimental|7|
3155081|NCT00312286|Placebo Comparator|8|
3155082|NCT00312286|Placebo Comparator|9|
3155083|NCT00312286|Placebo Comparator|10|
3155084|NCT00312286|Placebo Comparator|11|
3155085|NCT00312299|Experimental|Arm 1 A - Square edge PMMA IOL|50 patientes will recieve square edge PMMA IOL
3155086|NCT00312299|Active Comparator|1B|In group 1, 50 eyes will receive round edge PMMA IOL
3155087|NCT00312299|Experimental|2A|In group 2, 50 eyes will receive square edge PMMA IOL
3155088|NCT00312299|Active Comparator|2B|In group 2, 50 eyes will receive acrysof IOL
3155089|NCT00312390|Other|Healthy Control Subjects|
3155090|NCT00312390|Other|Subjects with amblyopia|
3155091|NCT00312403|Other|1|Patients with primary open angle glaucoma
3155092|NCT00312403|Other|2|Age- and sex-matched control subjects
3155093|NCT00312442|Experimental|WST 09|Treatment with WST09-mediated VTP
3155094|NCT00312455|Experimental|1|Drug Treatment
3155095|NCT00312455|Placebo Comparator|2|Placebo treatment
3155096|NCT00312481|Experimental|1|MOVIPREP
3155097|NCT00312481|Active Comparator|2|Picolax
3155098|NCT00312546|Experimental|2A|Discontinuation of VPA and enfuvirtide administered for 24 weeks. As of 05/20/08 this step was discontinued.
3155099|NCT00312546|Experimental|2B|Continuation of VPA for up to 96 weeks. As of 05/20/08 this step was discontinued.
3155100|NCT00312546|Experimental|3A|VPA may be added to enfuvirtide for 16 weeks. VPA and enfuvirtide will be continued for up to 96 weeks in responders, and the study will be discontinued in nonresponders.
3155101|NCT00312546|Experimental|3B|Enfuvirtide may be continued for up to 96 weeks. As of 05/20/08 this step was discontinued.
3155102|NCT00312585|Experimental|Acupuncture|
3155103|NCT00312585|Sham Comparator|Sham Acupuncture|
3155104|NCT00312585|No Intervention|Usual care only|
3155105|NCT00312598||aripiprazole|observational measures of metabolic parameters of subjects who are making clinically determined medication switch to aripiprazole
3155106|NCT00312780|Experimental|Arm 1: XL784|
3155107|NCT00312780|Placebo Comparator|Arm 2: Placebo Gel capsules|
3155108|NCT00312936|No Intervention|Wait List|
3155109|NCT00312936|Experimental|MBSR|8 week mindfulness based stress reduction
3155110|NCT00312949|Experimental|1|Participants will use the interactive website
3155111|NCT00312949|Active Comparator|2|Participants will read written materials and watch a video
3155112|NCT00312962|Active Comparator|1|Participants will use commercially available computer games
3155113|NCT00312962|Experimental|2|Participants will receive targeted cognitive training with neuroplasticity-based software created by Posit Science Corporation
3155114|NCT00312975|Experimental|Arm A|
3155115|NCT00312975|Active Comparator|Arm B|
3155116|NCT00313053|Experimental|Human mAb 216|
3155117|NCT00313105|Experimental|Smokeless Tobacco|Smokeless Tobacco and individual visits
3155118|NCT00313105|Active Comparator|Nicotine tablets|Nicotine tablets
3155119|NCT00313105|Placebo Comparator|3|7-mg nicotine patch acts as placebo
3155120|NCT00313157|Active Comparator|Metoprolol|Treatment with Metoprolol 100 mg x 1 for three weeks
3155121|NCT00313157|Active Comparator|Diltiazem|Treatment with Diltiazem 360 mg x 1 for three weeks
3155122|NCT00313157|Active Comparator|Verapamil|Treatment with Verapamil 240 mg x 1 for three weeks
3155123|NCT00313157|Active Comparator|Carvedilol|Treatment with Carvedilol 25 mg x 1 for three weeks
2456716|NCT03195712||Patients with Class II and III Obesity|Patients enrolled in an outpatient weight loss program from 2010-2016.
3155124|NCT00313183|Experimental|1|single doses of pramlintide acetate or placebo, given in three different sequences to three cohorts of subjects
3155125|NCT00313196|No Intervention|1|
3155126|NCT00313196|Experimental|2|
3155127|NCT00313235|Experimental|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
3155128|NCT00313248|Experimental|Arm 1|
3155129|NCT00313248|Experimental|Arm 2|
3155130|NCT00313339|No Intervention|Control Group|A concurrent group meeting eligibility criteria but not receiving CD34+cells will be evaluated similar to the study group to assess the extent, if any, of significant improvement in cardiac perfusion/function without the CD34+cell product infusion.
3155131|NCT00313339|Experimental|Treatment Group|Intra-coronary infusion of an autologous bone marrow derived CD34+ stem cell product.
3155132|NCT00313378|Experimental|ketamine|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
3155133|NCT00313378|Other|placebo|This study compares two groups of patients undergoing thoracotomy for partial pneumonectomy, one receiving intravenous ketamine since the beginning of procedure and then during 48 hours, the other receiving inactive normal saline (placebo).
3155134|NCT00313404|Experimental|Norovirus in groundwater|We dosed volunteers with safety tested infectious norovirus in groundwater (that met EPA standards for drinking water). The length of time norovirus remained in groundwater varied by volunteer.
3155135|NCT00313417|Active Comparator|1|
3155136|NCT00313417|Placebo Comparator|2|
3155137|NCT00313430||Dialysis patients|
3155138|NCT00313430||with or wthout glucose added to dialysis fluid|
3155139|NCT00313508|Experimental|A: Peptide-pulsed DC, ALI and Low Dose Fludarabine|Fludarabine: 5 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
3155140|NCT00313508|Experimental|B: Peptide-pulsed DC, ALI and High Dose Fludarabine|Fludarabine: 25 mg/m^2/day, Auto Lymphocyte Infusion, DC Infusion
3155141|NCT00313599|Experimental|Lapatinib and Paclitaxel|Lapatinib will be self-administered orally on days 1 and 2 of weeks 1, 2, and 3 of a 4-week cycle. Lapatinib is the experimental therapy and is being administered using a dose escalation design guided by careful monitoring of toxicities. Abraxane will be administered IV weekly on day 3 of weeks 1, 2, and 3 of a 4-week cycle. Abraxane is being administered at the well tolerated and effective standard dose and schedule of 100mg/m2 weekly 3 out of 4 weeks as defined by previous phase I and II studies. Patients will continue on therapy as long as they are not experiencing toxicities and there is no evidence of disease progression.
3155142|NCT00313768|Active Comparator|B|Standard of care chemotherapy
3155143|NCT00313768|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
3155144|NCT00313794|Experimental|1|single arm
3155145|NCT00313807|Active Comparator|1|Intravenous saline infusion plus amino acid infusion
3155146|NCT00313807|Placebo Comparator|2|Intravenous saline infusion plus placebo infusion
3155147|NCT00313872|Experimental|FOLFIRI|
3155148|NCT00313872|Experimental|DP|"D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr, D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr~D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan"
3155149|NCT00313885|Experimental|1|1 mg daily
3155150|NCT00313885|Experimental|2|5 mg daily
3155151|NCT00313885|Placebo Comparator|3|
3155152|NCT00313950|Experimental|Group 1|
3155153|NCT00313950|Experimental|Group 2|
3155154|NCT00313950|Experimental|Group 3|
3155155|NCT00313963|Experimental|1|
3155156|NCT00313963|Placebo Comparator|2|
3155157|NCT00313976|Experimental|Arm 1|
3155158|NCT00313976|Experimental|Arm 2|
3155159|NCT00313989|Experimental|Evaluation of implants of patients receiving radiotherapy.|
3155160|NCT00314015|Experimental|Patients with immediately loaded implants.|
3155161|NCT00314028|Active Comparator|1|Standard of care treatment
3155162|NCT00314028|Experimental|2|Educational program designed to motivate and provide information on the correct use of condoms
3155163|NCT00314054|Experimental|1|HCV-796 1000mg single dose
3155164|NCT00314067|Experimental|1|
3155165|NCT00314067|Experimental|2|
3155166|NCT00314067|Active Comparator|3|
3155167|NCT00314158|Experimental|Brinzolamide +Timolol|
3155168|NCT00314158|Active Comparator|Brinzolamide|
3155169|NCT00314158|Active Comparator|Timolol|
3155170|NCT00314171|Experimental|Brinzolamide + Timolol|
3155171|NCT00314171|Active Comparator|Dorzolamide + Timolol|
3155172|NCT00314275|Experimental|ENDEAVOR|Drug Eluting Stent
3155173|NCT00314314|Experimental|1|
2456723|NCT03195855|No Intervention|Control group of usual care including podiatry|"Control group (n=29):~Usual care including regular monitoring of foot health by podiatrists as indicated by NICE (NG19) guidelines (78). A review of current clinical practice within the podiatry clinic indicates that people with moderate/intermediate risk are reviewed every 3 months. Interventions include nail care, callus debridement and foot care advice.~In both groups, interventions delivered by podiatrists in the study period will be determined from the clinic notes."
2456754|NCT03195413|Experimental|Nerve Block Arm|This group of patients will receive an ultrasound-guided forearm block intervention by the study team. The nerve block will be achieved with a solution of 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine (mixed in a 1:1 volume ratio) dosed once. A second dose will be given only in the case of complete block failure.
2456755|NCT03195413|No Intervention|Control Arm|This group will receive the standard of care in our emergency department, as determined by their primary team. If a patient here receives a nerve block from the primary team, they will be handled with intention-to-treat analysis.
2456787|NCT03195101|Experimental|patients with orbital tumors|patients with orbital tumors will be managed by excisional or incisional biopsy via the transconjunctival orbitotomy approach
2456866|NCT03194880||HIV testing|At each visit, the DIC HIV testing algorithm will be performed, and additionally, HIV testing by the Anonymous Clinic Algorithm, the Alere™ HIV Combo and the Alere™ q HIV-1/2 Detect. The latter two tests will be performed at the DICs. In case of an invalid result for the Alere™ HIV Combo or the Alere™ q HIV-1/2 Detect, the test will be repeated. If the repeated test is invalid after the second attempt, it is recorded as 'invalid result'.
3155174|NCT00314314|Placebo Comparator|2|
3155175|NCT00314548|Experimental|Cases|PGE1 drug
3155176|NCT00314548|Placebo Comparator|Placebo|normal saline via same nebulizer
3155177|NCT00314626|Experimental|A|abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h
3155178|NCT00314626|No Intervention|B|efavirenz + 2 NUCS
3155179|NCT00314743|Active Comparator|Control (No aprepitant)|"Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 20 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 20 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 20 mg IV)"
3155180|NCT00314743|Experimental|Experimental (with aprepitant)|"Aprepitant 125 mg PO will be given 30 minutes prior to the first dose of chemotherapy followed by Aprepitant 80 mg PO QD for the remainder of chemotherapy and continuing for a total of 2 days after completing the regimen.~Regimen #1 (BEAM; NHL and HL)~Carmustine 300 mg/m2 IV on day -7 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Etoposide 100 mg/m2 IV Q 12 hours x 8 doses on days -6 to -3 (premedicate first daily dose ondansetron 32 mg IV and dexamethasone 10 mg IV)~Cytarabine 100 mg/m2 IV Q 12 hours x 8 doses on days -6 and -3 (no additional premedication)~Melphalan 140 mg/m2 IV on day -2 (premedicate with ondansetron 32 mg IV and dexamethasone 10 mg IV)~Regimen #2 (MM and Amyloidosis)~Melphalan 100 mg/m2 IV on days -3 and -2 (premedicate each dose with ondansetron 32 mg IV and dexamethasone 10 mg IV)"
3155181|NCT00314782|Experimental|Part A|Part A (dose-finding): ZD4054 (Zibotentan) 10 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3155182|NCT00314782|Experimental|Part A (ZD4054 (Zibotentan) 15 mg + docetaxel)|Part A (dose-finding): ZD4054 (Zibotentan) 15 mg oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3155183|NCT00314782|Experimental|Part B|Part B (randomised, placebo-controlled): ZD4054 (Zibotentan) Maximum Tolerated Dose (MTD), 15mg, oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3155184|NCT00314782|Experimental|Part B (placebo)|Part B (randomised, placebo-controlled): Matching placebo oral tablet once daily, with docetaxel 75mg/m^2 intravenous infusion once per cycle
3155185|NCT00314847|No Intervention|Control|IABP, inotropic drugs, antiplatelet agents according to site habits.
3155186|NCT00314847|Experimental|Experimental|ECLS +/- IABP, inotropic drugs, antiplatelet agents according to site habits.
3155187|NCT00314925|Experimental|1|
3155188|NCT00314977|Experimental|A|Cycles 1-4 q 3 weeks: doxorubicin plus cyclophosphamide Cycles 5-8 q 3 weeks: docetaxel
3155189|NCT00314977|Experimental|B|Cycles 1-6 q 3 weeks: doxorubicin, cyclophosphamide and docetaxel
3155190|NCT00315016|Placebo Comparator|1|placebo (double dummy)
3155191|NCT00315016|Active Comparator|2|eplerenone
3155192|NCT00315016|Active Comparator|3|doubling of fosinopril dose
3155193|NCT00315029|Experimental|1|Receives combined patient centred intervention
3155194|NCT00315029|No Intervention|2|Standard treatment
3155195|NCT00315094|Experimental|1|
3155196|NCT00315094|No Intervention|2|After a control period, this group crosses over to experimental interventions (Arm 1)
3155197|NCT00315133|Experimental|Transplant arm|This is a single arm study. The intervention is immunosuppression and autologous stem cell transplantation.
3155198|NCT00315159|No Intervention|No intervention|Patients with negative SLN will be followed on no intervention arm
3155199|NCT00315198|Active Comparator|Near activities|2 hours of daily patching combined with near visual activities while patching
3155200|NCT00315198|Active Comparator|Distance activities|2 hours of daily patching combined with distance visual activities while patching
3155201|NCT00315211|Other|Arm A|Weekly intravenous topotecan with intravenous docetaxel
3155202|NCT00315237|Experimental|1|
3155203|NCT00315237|No Intervention|2|best supportive care for 18 week duration
3155204|NCT00315250|Experimental|[123I]β-CIT|To assess B-CIT and SPECT imaging
3155205|NCT00315354|Experimental|1|Low glycemic index diet
3155206|NCT00315354|Active Comparator|2|Low fat diet
3155207|NCT00315354|Active Comparator|3|Very low carbohydrate diet
3155208|NCT00315562|Experimental|Early|Early
3155209|NCT00315562|Active Comparator|Delayed|Delayed
3155210|NCT00315575||1|Individuals with high risk for Alzheimer's disease
3155211|NCT00315575||2|Individuals with low risk for Alzheimer's disease
3173204|NCT00609505|Other|TM|Telemedicine genetic counseling group
2456725|NCT03195868|Experimental|Photobiomodulation|All patients will be treated similarly in this study
3155212|NCT00315640|Experimental|Anecortave Acetate 3 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
3155213|NCT00315640|Experimental|Anecortave Acetate 15 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
2456823|NCT03194997|Experimental|Dance|The group randomized to Dance intervention will receive a 3-week intervention with belly dance classes. The classes will be divided in: Warm up and stretching (10 minutes), Main part with belly dance steps and movements (40 minutes) and relaxation (10 minutes).
2456826|NCT03194997|Experimental|Pilates|The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
2456827|NCT03194997|No Intervention|Control|The group randomized to Control group will be invited to maintain routine activities and be contacted by phone every two months and will receive an explanatory booklet on the benefits of physical activity after diagnosis of breast cancer as well as instructions on lymphedema prevention. Also, this group will be invited to three meeting during the 16 weeks of intervention, the first meeting will focus on stretching exercise to develop at home, a second meeting will be about self-esteem and the last meeting will be about prevented of lymphedema. The women in this group will not receive a dance or pilates intervention.
3155214|NCT00315640|Experimental|Anecortave Acetate 30 mg Depot|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
3155215|NCT00315640|Other|Anecortave Acetate Vehicle|
3155216|NCT00315692||Premenopausal women|
3155217|NCT00315692||Postmenopausal women|
3155218|NCT00315744|Experimental|Subjects receiving salmeterol/fluticasone|Eligible subjects will receive 60 individual doses of the salmeterol 50 microgram/ fluticasone 100 microgram combination. Subjects will also receive placebo.
3155219|NCT00315744|Active Comparator|Subjects receiving fluticasone|Eligible subjects will receive 60 individual fluticasone 100 microgram doses each.
3155220|NCT00315757|Active Comparator|A|Bortezomib
3155221|NCT00315757|Experimental|B-10|Bortezomib and Mapatumumab 10 mg/kg
3155222|NCT00315757|Experimental|B-20|Bortezomib and Mapatumumab 20 mg/kg
3155223|NCT00315900|Experimental|Depakote ER|Depakote ER
3155224|NCT00315900|Active Comparator|Seroquel|Seroquel
3155225|NCT00315913|Experimental|IV Propranolol|IV dose propranolol
3155226|NCT00315913|Placebo Comparator|IV Placebo|IV Placebo of saline solution equal to propranolol in volume
3155227|NCT00315926|Experimental|Melatonin|
3155228|NCT00315926|Placebo Comparator|Placebo|
3155229|NCT00315991|Experimental|BGAT Intervention|Blood Glucose Awareness Training for Parents
3155230|NCT00315991|No Intervention|Control|Enter PDA data and complete questionnaires only. No intervention received.
3155231|NCT00316108|Experimental|Arm 1|
3155232|NCT00316134||Pts scheduled to remove pleural fluid|
3155233|NCT00316290|Experimental|1|Participants will receive integrated parent training.
3155234|NCT00316290|Active Comparator|2|Parents will receive behavioral parent training.
3155235|NCT00316316|Active Comparator|1|Participants will receive motivational interviewing plus exposure and response prevention
3155236|NCT00316316|Active Comparator|2|Participants will receive exposure and response prevention only
3155237|NCT00316563|Active Comparator|1|
3155238|NCT00316563|Placebo Comparator|2|
3155239|NCT00316745|Active Comparator|1|mFOLFOX6 （ → IRIS ( Irinotecan and S-1) ）
3155240|NCT00316745|Experimental|2|IRIS ( Irinotecan and S-1 ) → mFOLFOX6
3155241|NCT00316758|Experimental|1|
3155242|NCT00316771|Experimental|P38 Inhibitor (4) 150mg|
3155243|NCT00316771|Experimental|P38 Inhibitor (4) 25mg|
3155244|NCT00316771|Experimental|P38 Inhibitor (4) 300mg|
3155245|NCT00316771|Experimental|P38 Inhibitor (4) 50mg|
3155246|NCT00316771|Experimental|P38 Inhibitor (4) 75mg|
3155247|NCT00316771|Placebo Comparator|Placebo|
3155248|NCT00316797|Experimental|123-I INER|To assess 123-I INER
3155249|NCT00316810|Experimental|Campath|"Day 0: Before revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by Campath 30 mg i.v. infusion over 3-6 hours.~Day 1: No treatment~Day 2: Initial dose of Tacrolimus 0.05 - 0.1 mg/kg/d orally.~till Month 6: Aim at blood level of 12-15 ng/ml (try to prevent the Tacrolimus trough level falling below 12 ng/ml in the first 6 months).~Month 7-12: Maintain the Tacrolimus blood level at 6-12 ng/ml after 6 months."
3155250|NCT00316810|Active Comparator|ATG|"Day 0: Prior to revascularisation patients are given 500 mg of Methylprednisolone i.v. followed by a single shot of a polyclonal antilymphocyte preparation. Tacrolimus will be given immediately after transplantation(0.05-0.1 mg/kg/d) orally. Preoperative loading dose MMF: 2 g orally.~From Day 1: Total initial daily dose of 0.05-0.1 mg/kg administered orally in 2 doses. Blood trough levels 12-15 ng/ml during the first 6 months and maintain blood levels 6-12 ng/ml after 6 months. Total daily dose of MMF is 2 g administered orally in 2 doses. Patients will receive Methylprednisolone 250 mg IV 12h post surgery and 125 mg of Methylprednisolone 24 h post transplantation.~Steroid taper (orally):~Day 2: 100 mg of Prednisolon Day 3: 80 mg of Prednisolon Day 4: 60 mg of Prednisolon Day 5: 40 mg of Prednisolon Day 6: 25 mg of Prednisolon Day 21: 20 mg of Prednisolon~Reduction by 5 mg in two week intervals/complete withdrawal by 3 months post-tx."
3155251|NCT00316836||Group 1|Patients complete a 10-minute questionnaire about factors that might affect changes in breast density at baseline and another questionnaire at 1 year and 2 years post registration. Blood samples are collected at baseline (before initiation of treatment ) and at 1 year post registration for hormone and drug level analysis. Mammograms taken prior to registration (within 12 months prior to enrollment) and at approximately 1 and 2 years post-registration to this study are retrieved and digitized for determination of percent breast density and dense area.
3173205|NCT00609505|Other|FTF|Face-to-face genetic counseling group
3173206|NCT00609531|Experimental|Active|Individuals with an Autism Spectrum Disorder receiving citalopram
3173207|NCT00609531|Placebo Comparator|Placebo|Individuals with an Autistic Spectrum Disorder receiving placebo
3173208|NCT00609544|Experimental|1|
3173209|NCT00609544|Placebo Comparator|2|
3190838|NCT00792064||3|Heart-Tx-recipients
2456734|NCT03195738|Experimental|Intervention arm|"The Cognitive Orientation to Occupational Performance (CO-OP) Approach will be delivered over 10 30-60 minute sessions over a seven week period as follows: 2 sessions/week for 3 weeks, then 1 session per week for 4 weeks. In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which will be the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
2456797|NCT03195309|Active Comparator|Group A|Group A patients received 0.08% ropivacaine plus 4 mcg /mL fentanyl
2456802|NCT03195309|Active Comparator|Group B|Group B patients received 0.08% ropivacaine plus 2mcg /mL fentanyl
2456807|NCT03195309|Active Comparator|Group C|Group C patients received 0.16 % ropivacaine plus 2 mcg /mL fentanyl
3155252|NCT00316849|Experimental|Treatment (temsirolimus, temozolomide, radiation therapy)|GROUP 1: (temsirolimus with radiation and temozolomide) Patients receive temsirolimus IV over 30 minutes once weekly. Beginning 7-10 days later, patients also receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. GROUP 2: (radiation and temozolomide) Patients receive oral temozolomide daily and undergo concurrent 3-D conformal radiotherapy or intensity-modulated radiotherapy once daily, 5 days a week, for 6 weeks. Patients with stable or responding disease proceed to adjuvant therapy. ADJUVANT THERAPY: Beginning 4-6 weeks after the completion of chemoradiotherapy patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3155253|NCT00316875|Experimental|Lapatinib Ditosylate and Doxil|
3155254|NCT00316953|Experimental|Stratum 1 (solid tumors)|Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3155255|NCT00316953|Experimental|Stratum 2 (leukemia)|Patients receive dasatinib as in stratum 1. Cohorts of 3-12 patients receive escalating or de-escalating doses of dasatinib. The MTD is defined as the dose preceding that at which 7 of 12 patients experience DLT.
3155256|NCT00316992|Experimental|Ramelteon 8 mg and Placebo|
3155257|NCT00317018|Other|Arm 1|Implementation Group
3155258|NCT00317018|No Intervention|Arm 2|Control Group
3155259|NCT00317031|Active Comparator|1|Acamprosate
3155260|NCT00317031|Active Comparator|2|Naltrexone
3155261|NCT00317031|Placebo Comparator|3|Placebo
3155262|NCT00317070|Active Comparator|DMSO|Intravesical installation
3155263|NCT00317070|Experimental|Cocktail|
3155264|NCT00317096|Active Comparator|FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The FCM combination comprised:~25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
3155265|NCT00317096|Experimental|R-FCM|"All patients underwent a central randomization procedure. Randomization was done by a Computer program stratified for histology, Response to the preceding chemotherapy, and the number of previous chemotherapies using the method of permutuated blocks.~The R-FCM combination comprised:~375 mg/m2 rituximab on the day before the respective FCM course. 25 mg/m2 fludarabine per day iv over 30 minutes, days 1 to 3 200 mg/m2 cyclophosphamide per day as a 4-hour-infusion, days 1 to 3 8 mg/m2 mitoxantrone per day iv over 30 minutes, day 1 4 treatment Cycles á 4 weeks per cycle In patients with peripheral lymphocyte Counts more than 20.000/mm3 and/or a large Tumor mass (ie, bulky disease more than 10 cm) a cytoreductive pre-phase could be performed, comprising cyclophosphamide at a dose of 200 mg/m2 as a 1-hour-infusion over 3 to 5 days."
3155266|NCT00317096|Other|Observation only|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
3155267|NCT00317096|Other|rituximab maintenance|"Patients achieving a complete or partial remission after FCM or R-FCM underwent a subsequent randomization for 2 courses of rituximab to be given 3 and 6 months after completion of salvage therapy versus observation only.~Courses of rituximab consisted of 4 doses of 375 mg/m2 per day given at 4 consecutive weeks.~This second randomization was stratified for the type of salvage therapy with FCM or R-FCM, the Response to this Treatment (CR or PR), and histology."
3155268|NCT00317135|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3155269|NCT00317135|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3155270|NCT00317135|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3173210|NCT00609557|Experimental|A|All subjects receive placebo for the first two weeks and then duloxetine for the next 10 weeks, but they are blind to what they are receiving.
2456816|NCT03195387|Experimental|D-X/YY mg MMV390048|Treatment of cohort 3: subjects receive a single oral dose of MMV390048 (dose to be determined) on a day (to be determined) prior to PfSPZ challenge on Day 0. Dosage and day of administration will be determined on the basis of data emerging from the first two cohorts.
2456820|NCT03195387|Placebo Comparator|Placebo|MMV390048 placebo
2456892|NCT03194685|Experimental|Cohort 21: 75 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456893|NCT03194659|No Intervention|Placebo|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the placebo arm of the trial, no additional choline chloride will be added to the cocktail.
2456894|NCT03194438|Experimental|UZIT arm|Multi-modal components integrative therapy intervention program, Urban Zen Integrative Therapy.
2456895|NCT03194594|Active Comparator|Group K (n = 31)|will receive a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
2456897|NCT03194594|Active Comparator|Group D (n = 31)|will receive dexamethasone 0.5 mg/kg i.v. plus 2 ml normal saline, at 5 minutes after the induction of anesthesia
2456898|NCT03194685|Experimental|Cohort 22: 100 mg|Orally twice daily (BID) on Days 1-28 of a 28-day cycle. Drug: FF-10101-01
2456899|NCT03194659|Experimental|Supplemental Choline|Administration of the deuterated choline chloride will take place in a grape juice cocktail solution. For individuals in the experimental arm of the trial, supplemental choline chloride will be added to the cocktail.
2456896|NCT03194555|Experimental|Low-Dose Naltrexone and Acetaminophen Combination|
2456900|NCT03194594|Experimental|Group KD (n = 31)|will receive ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v., at 5 minutes after the induction of anesthesia
2456901|NCT03194555|Placebo Comparator|Placebo|
3190839|NCT00792064||4|Lung-Tx-recipients
3190840|NCT00792090|Experimental|1|Fermented milk
3190841|NCT00792090|Active Comparator|2|Standard milk
3190842|NCT00792129||Control|Posterior unilateral interbody fusion using an open approach midline incision (TLIF)
3190843|NCT00792129||Experimental|MiLIF procedure with specialized Atavi instrumentation and minimally invasive visualization capabilities
3190844|NCT00792168|Active Comparator|1. Venlafaxine|
2456908|NCT03194477|Experimental|Mobile-enhanced Engagement Intervention|Mobile-enhanced engagement intervention (MEI) to support HIV-positive and high risk HIV-negative participants achieve sustained engagement and sustained retention in HIV treatment or HIV prevention (PrEP) and substance use services at 18-months.
3190845|NCT00792168|Placebo Comparator|2. Placebo|
2456911|NCT03194412|Experimental|Diet /nutritional|Special diet for elderly. It should be rich in the appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients.
2456912|NCT03194542|Experimental|Luspatercept in subjects with MPN-associated myelofibrosis|Subjects across each of the cohorts (Cohort 1, Cohort 2, Cohort 3A, and Cohort 3B) will receive luspatercept.
2456915|NCT03194477|No Intervention|Control - SOC Case Management|Standard of care (SOC) case management.
2456916|NCT03194412|Experimental|Physical activity|Regular physical activity in everyday life of the elderly - exercises to improve coordination and balance, stretching exercises, strength exercises.
3190846|NCT00792181|Experimental|1|Medical intervention - with benzodiazepines (Midazolam).
2456919|NCT03194412|Experimental|Comprehensive therapy|Special diet for elderly (appropriately amount of protein, carotenoids, vitamins, minerals, macro and micronutrients) and regular physical activity in everyday life of the elderly (exercises to improve coordination and balance, stretching exercises, strength exercises)
2456921|NCT03194412|Experimental|Caregivers of elderly|Education about frailty: prevention and treatment (nutrition, physical activity, dietary supplement diet).
2456922|NCT03194412|No Intervention|Control group|Without intervention
2456932|NCT03194178||Pierre Robin sequence patients|Patients presenting a Pierre Robin sequence, and who have been cared in their early childhood by either the Necker or Trousseau hospitals teams, and who are between 12 and 18 years old at the beginning of the study.
3190847|NCT00792181|Experimental|2|Course intervention - a professional development course for caregivers.
3190848|NCT00792181|Experimental|3|Combination of both medical interventions and a professional development course for caregivers.
3190849|NCT00792181|No Intervention|4|No intervention at all = a control group
3190850|NCT00792194|Experimental|training group|supervised training program 3 times a week with coach.
3190851|NCT00792194|No Intervention|group without training|a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
3190852|NCT00792207|Experimental|Intervention|"Intervention Group:~The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data recorded by an activity monitor."
2456914|NCT03194386|Active Comparator|Reassurance|15 minutes psychologist visit
2456920|NCT03194386|Experimental|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing (R-TEP EMDR) At the end of cares, before ED discharge, a trained psychologist will conduct a single R-TEP EMDR session. Each session may last about 60 minutes
3155271|NCT00317135|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
3155272|NCT00317148|Experimental|Placebo|
3155273|NCT00317148|Experimental|DHEA|
3155274|NCT00317187|Experimental|Hib-MenAC Lot 1 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 1 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
2456931|NCT03194243||Patients admitted for acute dyspnea|Patients admitted for acute dyspnea in the emergency department
2456934|NCT03194191|Experimental|Regular acupuncture needles|"Real acupuncture procedure The real acupuncture will be performed by means of standard stainless-steel needles (0.30-mm diameter, 30-mm length/Gauge 8 x 1.2), located bilaterally in 5 real acupoints."
2456937|NCT03194191|Sham Comparator|Sham acupuncture needles|Sham acupuncture with a no penetrating sham needle (blunt and telescopic), giving the impression of insertion but without penetrating the skin will be placed bilaterally in 5 false acupoints
2456939|NCT03194295|Experimental|Community Support Intervention|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Community Support Intervention Group, which requires methadone maintenance treatment (MMT) participants to attend the group with a drug-free family member or friend (community support person; CSP).
2456940|NCT03194308|Other|HIV-uninfected women|A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
2456943|NCT03194295|Active Comparator|Standard Care|Participants randomized to this condition will be scheduled to attend a 12-week (1x/wk for one hour) manual-guided Substance Use Disorder Educational Group as an attention-control for the intervention described in the experimental condition.
2456963|NCT03194113|Active Comparator|Trauma-Focused Treatment|Weekly sessions of prolonged exposure
2456964|NCT03194113|Active Comparator|Emotion Regulation Treatment|weekly sessions of emotion regulation and skills training.
2456965|NCT03194113|Active Comparator|Intensive Trauma-Focused Treatment|prolonged exposure, 3 sessions per week
2456984|NCT03193840|Experimental|old acetabular fracture|posterior wall osteotomy would be conducted for thr patient with displaced acetabular fracture without surgical treatment over three weeks.
2456988|NCT03193905|Other|Cotton blanket|30 hypothermia patients undergo the standard procedure with a cotton blanket during major spinal surgery
2456992|NCT03193944|Active Comparator|Intervention group|Intervention group will receive 50,000 U vitamin D3 per week (equivalent to 1,250 μg) for 8 weeks
2456993|NCT03193957|Experimental|SB4|SB4 (etanercept) 50 mg/mL
2456994|NCT03193905|Other|Bairhugger Full Access Underbody blanket|30 hypothermia patients undergo the Bairhugger Full Access Underbody blanket procedure during major spinal surgery (new procedure)
2456998|NCT03193944|Placebo Comparator|control group|Control group will receive vitamin D as a placebo. placebo will be identical in appearance taste and odourless.
2457002|NCT03193996|Other|SLIL Injury|Surgical interventions for all subjects will be determined based on combined findings of both 4DCT and standard arthroscopy.
2457008|NCT03193970||Bladder Cancer Patients Undergoing Radical Cystectomy|Prospective registry of bladder cancer patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating centers.
2457010|NCT03193723|Active Comparator|Group A|US guided five step field block will be performed
2457012|NCT03193723|Active Comparator|Group B|Spinal anesthesia will be administered in sitting position
2457019|NCT03193918|Experimental|Crenolanib combined with ramucirumab/paclitaxel|
2457032|NCT03193489|Experimental|Exercise therapy|Parkinson's group takes part in a treadmill treatment that takes place 3 times a week for 2 years.
2457034|NCT03193255|Active Comparator|No daily lens rubbing|Daily lens disinfection with OPHTECS cleadew GP without lens rubbing
2457036|NCT03193502|Experimental|Portal Vein thrombosis|rivaroxaban
2457037|NCT03193255|Active Comparator|Daily rubbing|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with cleadew GP
2457038|NCT03193580|Experimental|Anodal Conventional tDCS|The intervention will be anodal conventional tDCS. Anodal tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0 milliamp. Anode positioned over the right primary motor cortex, and the cathode over the contralateral supraorbital area.
2457040|NCT03193320|Active Comparator|Liberal group protocol|Fluid loading with 500 ml at induction. Baseline fluid infusion - 8 ml/kg/h. Fluid challenge - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
2457041|NCT03193255|Active Comparator|Daily rubbing with separate cleaner|Daily lens disinfection with OPHTECS cleadew GP after lens rubbing with a daily lipid cleaner
2457044|NCT03193320|Active Comparator|Restrictive group protocol|No fluid loading at induction. Baseline fluid infusion - 4 ml/kg/h. Fluid challenges - if mean arterial pressure (MAP) falls to < 65 mmHg, a fluid challenge will be administered.
3173211|NCT00609570|Experimental|Fruit and vegetables|Fruits and vegetables
3173212|NCT00609570|Active Comparator|Whey protein|Whey protein
3173213|NCT00609570|Active Comparator|Ca|Calcium pills
3173214|NCT00609596|Other|Arm 1|
2456942|NCT03194230|No Intervention|Without cervical dilator|Induction of labour by oral of 400µg of misoprostol each 3 hours.
2456944|NCT03194230|Experimental|With cervical dilator|Induction of labour by cervical placement of hygroscopic dilators for 3 hours and oral of 400µg tablets of misoprostol each 3 hours.
2456945|NCT03194282|Experimental|chronic stroke patient with insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
2456946|NCT03194269|Experimental|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
2456947|NCT03194282|Sham Comparator|chronic stroke patient without insole|Poor balance capacity is one of clinical symptoms of stroke patient.Poor balance, or postural stability, is significant predictors the risk of fall.
2456951|NCT03194152|Experimental|Peanut|Daily consumption of 2 servings of roasted peanuts for 12 weeks Intervention: Dietary Supplement: Roasted peanuts
3190853|NCT00792207|Active Comparator|Control|The control group will use an activity monitor and will have access to a website to monitor activity, but will not receive the Virtual Coach program.
2456955|NCT03194152|Experimental|Control|Daily consumption of isocaloric matched snack food for 12 weeks Intervention: Other: High Carbohydrate Snack
3190854|NCT00792220|Experimental|MSU|
2456956|NCT03194204|Active Comparator|RA patients treated with methotrexate|"Disease activity score(DAS28) matrix metalloproteinase-3(MMP-3) and matrix metalloproteinase-9(MMP-9), Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid Rheumatoid factor (RF IgM, U/L) Anti- cyclic citrullinated peptide . Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views .~Cardiac assessment :By electrocardiogram ( ECG ) and echocardiography , Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
3190855|NCT00792220|Active Comparator|OCCM|
2456961|NCT03194204|Active Comparator|RA patients treated with methotrexate plus doxycycline|"Disease activity score(DAS28) Matrix Metalloproteinase-3 (MMP-3) and Matrix Metalloproteinase-9 (MMP-9) Erythrocyte sedimentation rate C- reactive protein Complete blood count Urine analysis Renal and liver function tests Lipid profile, blood glucose level Serum uric acid , Rheumatoid factor (RF IgM(immunoglobulin M), U/L) Anti- cyclic citrullinated peptide. Radiological assessment :Plain radiographs of both hands and feet in the postero-anterior views.~Cardiac assessment :~By electrocardiogram ( ECG ) and echocardiography Carotid artery intima-medial thickness (IMT) will be done by colored doppler ultrasound."
2456978|NCT03193827|Experimental|study group|In this group in-line filters (Pall, Dreieich, Germany) are connected to peripheral vascular access and used during anaesthesia and the following 96 postoperative hours.
2456981|NCT03193827|Active Comparator|control group|Patients randomised to standard care are managed without an in-line filter and according to local routine practice for intravenous drug administration in the adult patient.
2456983|NCT03193684|Experimental|Treatment|dapagliflozin 10 mg per day
2456985|NCT03193879||COPD group|COPD patients
2456986|NCT03193749|Experimental|Amiodarone Hydrochloride|Oral treatment for at least 6 months
2456989|NCT03193879||Asthma group|Asthma patients
2456990|NCT03193749|Placebo Comparator|Placebo|Oral treatment for at least 6 months
2456991|NCT03193684|Placebo Comparator|control|matching placebo 1 pill per day
2456997|NCT03193879||Health group|Healthy volunteers
2457009|NCT03193853|Experimental|Tak + cisplatin and nab paclitaxel|Patients with metastatic TNBC who meet the enrollment criteria will receive TAK-228 and TAK-117 until disease progression followed by nab paclitaxel plus cisplatin for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion.
2457016|NCT03193801|Experimental|Failing mitral transcatheter valve|Patients with a failing bioprosthetic valve in the mitral position demonstrating stenosis and/or insufficiency will be treated with Edwards SAPIEN 3 transcatheter valve.
2457018|NCT03193632||Study group|critically-ill patients who will be admitted to the surgical ICU for ventilatory support and will be expected to continue for more than one day US Muscle layer thickness (MLT) estimation will be used to estimate LBM and REE estimation by indirect calorimetry will be performed
2457022|NCT03193268|Experimental|High intensity agility group|Exercise therapy
2457023|NCT03193268|Experimental|Non-agility cycling group|Parkinson's Bicycle Group, which takes 1 hour of exercise every day for 5 weeks
2457024|NCT03193268|No Intervention|No-exercise control group|Control Parkinson's disease control group thad will not receive exercise treatment
2457027|NCT03193411|Other|microkeratome group|30 eyes were treated by microkeratome
2457030|NCT03193411|Other|femtosecond group|30 eyes were treated by femtosecond laser
2457039|NCT03193294|Active Comparator|Intervention group (coronary function test results disclosed)|In the intervention group, coronary function tests are measured and disclosed to the attending clinician permitting re-evaluation of the initial diagnosis and treatment as compared with initial angiography-guided decisions. The intervention involves measurement of CFR, IMR and RRR in a target, major coronary artery followed by coronary reactivity testing using incremental doses of acetylcholine (10-4M, 10-5M, 10-6M) to assess endothelial function, bolus infusion of ACh (10-4M) for vasospasm provocation testing, followed by administration of a bolus dose (300 micrograms) of glyceryl trinitrate. Endotypes are identified based on established criteria for abnormalities in coronary vasodilator function, vasospasm and microvascular resistance. The endotypes (diagnostic strata) are: obstructive CAD, coronary artery spasm, microvascular angina, endothelial dysfunction (no angina), normal (non-cardiac). A diagnosis may be ruled-in or ruled-out based on the test results.
2457062|NCT03193437|Experimental|Selinexor|Open Label Selinexor 40 mg
2456960|NCT03194126|Experimental|Mifepristone + Misoprostol OR oxytocine + laminaria|
2456962|NCT03194126|Other|Mifepristone + Misoprostol OR oxytocine|
2457011|NCT03193762||Painful hospitalized patient|The anxiety of those patients will be measured with an Anxiety VAS
2457035|NCT03193372||Rosacea Concierge Program|Patients diagnosed with rosacea and currently receiving topical monotherapy with Finacea Foam
2457175|NCT03192709|Experimental|A|Sildenafil vaginal suppositories users
2457178|NCT03192709|Placebo Comparator|B|Daily vaginal placebo users with HMG administration
2457182|NCT03192709|Placebo Comparator|C|Daily vaginal placebo users with HMG administration day until the day of oocyte retrieval.
2457206|NCT03192085|Other|SITA FAST then SITA STANDARD|SITA FAST and SITA STANDARD
2457207|NCT03192085|Active Comparator|SITA STANDARD then SITA FAST|SITA FAST and SITA STANDARD
2457271|NCT03191942|Experimental|Modified ortho-k lenses|Participants wearing ortho-k lens with a modified BOZD of 5mm
2457281|NCT03191942|Active Comparator|Ortho-k lenses|Participants wearing ortho-k lens with a standardized BOZD of 6mm
2457306|NCT03191591|Experimental|First 1,000 Days Program|
2457360|NCT03191357||TBI/no PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) without psychological health (PH) concerns.~no intervention/Observational"
2457361|NCT03191357||TBI with PH|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experienced traumatic brain injury (TBI) and also have psychological health (PH) concerns.~no intervention/Observational"
2457362|NCT03191357||PH only|"Active and reserve component SMs along with others who are eligible for care in the DoD healthcare system, who have experience psychological health (PH) concerns.~no intervention/Observational"
2457363|NCT03191357||Controls|"Control participants may include (i) those with exposure to primary blast without the development of TBI, (ii) those with physical injuries without experiencing head injury, and (iii) healthy participants (non-injured, non-TBI, non-PH).~no intervention/Observational"
3155275|NCT00317187|Experimental|Hib-MenAC Lot 2 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 2 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3173215|NCT00609648|Experimental|CARL|CARL computer program
3173216|NCT00609648|Active Comparator|Pamphlet|Reassuring pamphlet about dental injections
2457519|NCT03190187|Active Comparator|Spinal manipulation|Spinal manipulation to the spine will be applied to participants enrolled in this group.
2457521|NCT03190187|Sham Comparator|Sham manipulation|Sham technique wich mimic the intervention manipulation with less force and different body location will be applied.
2457555|NCT03189836|Experimental|ACTR707 in combination with rituximab|
2457593|NCT03189472|Experimental|active tDCS|
2457602|NCT03189472|Sham Comparator|sham tDCS|
2457853|NCT03187899|Sham Comparator|"Interscalene block plus sham"|"Patients in this group will receive a traditional interscalene block and a sham superficial plexus block with ropivacaine and 5-10cc of normal saline. N = 20"
2457854|NCT03187899|Active Comparator|Interscalene plus superficial plexus block|Patients in this group will receive a traditional interscalene block and a superficial plexus block with ropivacaine . N = 20
2457907|NCT03187509|Experimental|Weight-Based Torsemide Group|Subjects will be randomized to complete a weight-based torsemide dosing regimen for their outpatient heart failure management. These subjects will prescribed a specified dose of torsemide on discharge from the hospital and subsequently have a phone encounter with a physician three times a week where their dose of torsemide will be titrated based on an algorithm which factors in current symptoms and weight. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
2457908|NCT03187509|Active Comparator|Standard Outpatient Management Group|Subjects will be randomized to standard outpatient heart failure management where they will be prescribed a fixed daily dose of a loop diuretic upon discharge from the hospital and have a follow-up appointment within one week of discharge. All medications including loop diuretic type, dose and frequency will be managed at the discretion of the patient's primary care physician or cardiologist. Study subjects will have a final follow-up appointment at the completion of the study to evaluate current symptoms, weight and perform blood work to assess kidney function, electrolytes and brain natriuretic peptide levels.
2458000|NCT03186651|Experimental|Trans Vagina Support|Tension Free Vaginal Support (TVS):The subjects in the TVS Group used pads during week 1 (Baseline), fitted, trained and selected device size week 2 and used the selected device size during week 3 (treatment week).
2458006|NCT03186651|No Intervention|Standard Care|Standard of care (SoC): The subjects in the SoC group continued with conventional treatment i.e. using pads during week 1, 2 and 3. They were offered to use the TVS device for two weeks after completion of week 3.
2458074|NCT03186495|Experimental|Normal renal function|Subjects with normal renal function
3173217|NCT00609661||1|Patients presenting to the Ohio State University Emergency Department or directly admitted to the Ohio State University Burn Unit following thermal burn.
3173218|NCT00609661||2|Healthy volunteers
3173219|NCT00609687|Other|A|Patients with suspected sarcoid-related posterior segment inflammation with inconclusive clinical exam findings, ancillary testing, and laboratory results
3173220|NCT00609700||1|Historical group: patients treated with Ringer's Lactate solution after severe burn injury
3173221|NCT00609700||2|Actual group: patients treated with Ringer's Acetate solution after severe burn injury
3173222|NCT00609713|Experimental|1|Comprehensive 12-month family-based obesity treatment with separate adolescents and parents group sessions
3173223|NCT00609713|Active Comparator|2|Individual 12-month nutrition education program
3173224|NCT00609752|Active Comparator|1|
3173225|NCT00609752|Active Comparator|2|
2456970|NCT03193983|Experimental|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
2456971|NCT03193983|Experimental|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
2457013|NCT03193710||Total intravenous anesthesia group|The anesthesia of patients in the total intravenous anesthesia group will be maintained with propofol and remifentanil.
2457014|NCT03193710||Inhalational anesthesia group|The anesthesia of patients in the inhalational anesthesia group will be maintained with sevoflurane and remifentanil.
2457064|NCT03193281|Other|Dasatinib|"All patients will begin the study on dasatinib treatment (Sprycel® 100mg once daily oral administration). Those who reach MR3.0 at 12 months (end of Study Stage 1) and achieve a confirmed result at 13 months, will switch to imatinib treatment (Imatinib-AFT 400mg once daily oral administration) for the next 24 months (Study Stage 2).~Patients who do not achieve a confirmed MR3.0 result at 13 months will not be eligible to switch to imatinib treatment and will remain on dasatinib treatment, as per Study Stage 1.~Patients will be assessed on a 3-monthly basis throughout the study. Those who discontinue dasatinib treatment during the study for reasons other than the planned treatment switch to imatinib at 13 months, will also be followed up every 3 months."
2457101|NCT03192839|Experimental|Low dose PUFA|
2457104|NCT03192839|Experimental|High dose PUFA|
2457106|NCT03192839|Placebo Comparator|Placebo|
2457148|NCT03192657|Experimental|Basiliximab group|"Basiliximab: 20mg injection each time at day1 and day5, respectively. The first administration should be within 8 weeks after disease onset.~Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
2457160|NCT03192657|Active Comparator|control group|"Calcineurin inhibitors: cyclosporin A 3-5mg/kg/d or tacrolimus 0.05-0.10mg/kg/d.~Steroids: 1mg/kg/d, calculated with prednisone."
2457277|NCT03191968|Experimental|Supervised PA Plus Behavioral Counseling|25 prostate cancer survivors will receive supervised physical activity and behavioral counseling (SPA+BC) based on the M-PAC. In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
2457284|NCT03191968|Active Comparator|Supervised PA Plus Exercise Counseling|25 prostate cancer survivors will supervised physical activity and exercise counseling (SPA+EC).In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
2457303|NCT03191578|Experimental|RUTI® injection|
2457308|NCT03191578|Placebo Comparator|Sodium Chloride 0.9% injection|
2457435|NCT03190876|No Intervention|Suction drain|Conventional body contouring procedure, application of Redon suction drains, drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
2457437|NCT03190876|Active Comparator|Passive drain|Conventional body contouring procedure, application of drains without suction (passive drainage), drain removal when output is less than 30 ml in 24 hours or at the latest on postoperative day 7
2457438|NCT03190876|Active Comparator|No drain|Conventional body contouring procedure, no application of drains
2457501|NCT03190525||Multiple Myeloma patients|
2457554|NCT03189914|Experimental|RX-3117 + Abraxane|"RX-3117: oral, 500 - 700 mg/ day for 5 days on/ 2 days off for 3 weeks. 1 washout week/ cycle.~Abraxane: 75 - 125 mg/m^2, infused once per week for 3 weeks. 1 washout week/ cycle."
2457598|NCT03189485||Normal Controls and MCI|All subjects will receive 18F-AV-1451 PET scan.
2457662|NCT03189316|Other|subjects with ovarian cyst|Peritoneal fluid sample obtained from coelioscopy for exploration of ovarian cysts and blood sample
2457664|NCT03189316|Other|subjects with peritoneal dialysis|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample
2457726|NCT03188744||Group 1|Patients with CC with PFMD.
2457729|NCT03188744||Group 2|Patients with CC without PFMD.
2457732|NCT03188744||Group 3|Patients without CC with PFMD.
2457735|NCT03188744||Group 4|Patients without CC without PFMD.
2457755|NCT03188315|Experimental|cases|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
2457756|NCT03188315|Active Comparator|control|HPV detection HPV Genotyping HPV Oncogenes and oncoproteins
2457773|NCT03188198|Active Comparator|Arm A - R-CHOP|"Patients receive the following treatment:Rituximab 375 mg/m2 IV infusion on Day 1 prior to CHOP chemotherapy.Cyclophosphamide 750 mg/m^2 IV on Day 1.Doxorubicin 50 mg/m^2 IV on Day 1.Vincristine 1.4 mg/m^2 IV (2 mg cap) on Day 1.Prednisone 40 mg/m^2/day PO on Days 1-5.filgrastim or pegfilgrastim as defined in the protocol Required ancillary medications is administered during all cycles as defined in the protocol. Cycles will be repeated every 21 days for 6 treatment cycles. Restaging will occur after Cycles 4 and 6.~Interventions:-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: filgrastim-Drug: pegfilgrastim"
2457775|NCT03188198|Experimental|Arm B - DA-EPOCH-R|"Patients receive the following treatment: Cycle 1 Doses:Rituximab 375 mg/m^2 IV infusion on Day 1 prior to EPOCH chemotherapy. Doxorubicin 10 mg/m^2/day CIVI on Days 1-4.Etoposide 50 mg/m^2/day CIVI on Days 1-4. Vincristine 0.4 mg/m^2/day (no cap) CIVI on Days 1-4 (total 1.6 mg/m2 over 96 hours). Cyclophosphamide 750 mg/m^2 IV on Day 5 (following completion of 96 hour infusions). Prednisone 60 mg/m^2 PO BID on Days 1-5 Administer filgrastim 480 mcg subcutaneous daily from Day 6 until ANC > 5000 after the nadir (nadir usually between Days 10-12) Doses for subsequent cycles will be determined by the absolute neutrophil (ANC) or platelet nadir from the previous cycle. Cycles will be repeated every 21 days for a maximum of 6 cycles. Restaging will occur after Cycles 4 and 6.~Interventions:~-Biological: rituximab-Drug: cyclophosphamide-Drug: doxorubicin-Drug: vincristine-Drug: prednisone-Drug: etoposide-Drug: filgrastim"
2457827|NCT03188003|Experimental|Stabilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic stabilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on stabilization"
2456974|NCT03194061|Experimental|Hypofractionated chemoradiation|20 fractions of 275cGy and concomitant weekly cisplatin 35mg/m2 x 4 cycles
2456987|NCT03193671||Benign|Benign tumors, pre-and postmenopausal
2456995|NCT03193671||Malignant|Malignant tumors, pre-and postmenopausal
2457003|NCT03193671||Borderline|Borderline tumors, pre-and postmenopausal
2457006|NCT03193671||Malignant+borderline|Malignant+borderline tumors, pre-and postmenopausal
2457052|NCT03193424|Experimental|Apatinib|
2457057|NCT03193424|Active Comparator|docetaxel|
2457119|NCT03192969|Experimental|Abatacept Combination Therapy|Abatacept subcutaneous injection (125 mg/mL prefilled syringe weekly) in combination with glucocorticoid therapy (up to 28-week taper of oral prednisone daily)
2457121|NCT03192969|Placebo Comparator|Placebo Monotherapy- 28 Weeks|Glucocorticoid therapy (28-week taper of oral prednisone daily) in combination with placebo subcutaneous injection (1 mL pre-filled syringe weekly)
2457122|NCT03192969|Placebo Comparator|Placebo Monotherapy- 52 Weeks|Glucocorticoid therapy (52 week taper of oral prednisone daily) in combination with subcutaneous placebo weekly
3173226|NCT00609778|Experimental|1:Mechanical CPR with LUCAS|A Mechanical device that provides chest compressions
3190856|NCT00792233|Experimental|1|Participants taking anti-TNF medications will be monitored for signs of their disease for 6 months. If, after 6 months, their disease has become inactive, they will stop taking anti-TNF medications for up to 8 months. If participants who are no longer taking anti-TNF medications have a disease flare-up, they will begin treatment again.
2457305|NCT03191682|Experimental|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression
2457383|NCT03191305|Active Comparator|Coumadin Group|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day.The total duration OFf coumadin would be six months.
2457385|NCT03191305|Active Comparator|Rivoroxaban Group|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, THEN 20 mg PO qDay for 6 months.
2457398|NCT03190850|Experimental|Intervention|"Intervention: Exercises wih load Device: Powerbreathe"
2457400|NCT03190850|Placebo Comparator|Control|Control: Exercises without load
2457456|NCT03190733|Experimental|ATG 10.0mg/kg|ATG 10.0mg/kg group refers to treatment with ATG in the total dose of 10.0mg/kg.
2457459|NCT03190733|Active Comparator|ATG 12.5mg/kg|ATG 12.5mg/kg group refers to treatment with ATG in the total dose of 12.5mg/kg.
2457466|NCT03190356||Primary diagnosis alcohol use disorder (AUD)|Primary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
2457468|NCT03190356||Secondary diagnosis alcohol use disorder (AUD)|Secondary diagnosis of alcohol use disorder (AUD) population enrolled in MAP's System
3190857|NCT00792246|Experimental|graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
2457591|NCT03189420||Glioblastoma|Samples of brain tumor diagnosed as glioblastoma
2457597|NCT03189420||Low grade glioma|Samples of brain tumor diagnosed as low grade glioma
2457652|NCT03189264|Active Comparator|Percutaneous nephrolithotomy with Coaxial Dilatation|Percutaneous nephrolithotomy with Coaxial Dilatation for treatment of kidney stones greater than 2 cm.
2457653|NCT03189264|Placebo Comparator|Percutaneous nephrolithotomy with Pneumatic Balloon|Percutaneous nephrolithotomy with Pneumatic Balloon for treatment of kidney stones greater than 2 cm.
2457704|NCT03188757|Experimental|hyperglycaemic clamp|
3190858|NCT00792246|Experimental|No graft versus host disease|Patients receiving oral voriconazole will be switched to intravenous voriconazole. Pharmacokinetics will be determined after each formulation.
2457894|NCT03187873|Experimental|Chama cha MamaToto|Women attending chamas will meet twice per month, receive social and health education from CHVs and participate in a savings/loans program.
2457897|NCT03187873|No Intervention|Control|The CHVs in the control group will be given refresher training on health roles they are supposed to play according to the standard MOH activities
3190859|NCT00792285|Experimental|Automated Telephone Outreach|Automated Telephone Outreach with Speech Recognition
2457957|NCT03187015|Other|Midazolam|Treatment A: 2 mg of Midazolam administered - Period 1, Day 1 Treatment B: 2 mg of Midazolam with 5 mg Entinostat (after 14 day minimum washout from Period 1, Day 1) - Period 2, Day 1
2458049|NCT03186703|Experimental|Tailored knowledge translation|During the 12-week intervention, intervention group participants will have access to the Portal and will receive targeted weekly email alerts including blog posts and evidence summaries relevant to cancer prevention and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant cancer prevention information.
2458050|NCT03186703|No Intervention|Control|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored intervention.
3190860|NCT00792285|No Intervention|Usual Care|Usual Care
3190861|NCT00792311|Experimental|Tsui test|Tsui test administration.
2458224|NCT03185676|Experimental|Billberry|A bilberry-based probiotic beverage
2458232|NCT03185676|Active Comparator|Control|A control beverage without bilberries or probiotics
2458285|NCT03185156|Experimental|propofol group|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
2458287|NCT03185156|Placebo Comparator|control group|first dose 0.03ml/Kg normal saline, then 0.1ml/Kg/hr micro-pump
2458395|NCT03184766|Experimental|1|Treatment Order: Test, Comparator 1, Comparator 2
2458401|NCT03184766|Experimental|2|Treatment Order: Test, Comparator 2, Comparator 1
2458402|NCT03184766|Experimental|3|Treatment Order: Comparator 1, Test, Comparator 2
2459810|NCT03174496||Children and adolescents aged 8-16 years|
3190862|NCT00792324|Active Comparator|Group 1|Four 100mg Etravirine tablets plus one Efavirenz (EFV) placebo tablet once daily
3190863|NCT00792324|Active Comparator|Group 2|One 600mg EFV tablet plus four Etravirine placebo tablet tablets once daily
2456975|NCT03194074|Experimental|propofol group|Propofol/remifentanil-based general anesthesia.
2456976|NCT03194074|Experimental|desflurane group|Desflurane/remifentanil-based general anesthesia.
2456977|NCT03194048|Experimental|Functional Chewing Training|Children with CP and have tongue thrust included this group.
2456979|NCT03194048|Active Comparator|Control|Children with CP and have tongue thrust included this group.
2456999|NCT03193645||Degarelix|
2457046|NCT03193567|Experimental|HEKT cell|Enrolled patients will receive HEKT cell injection, 10-days interval, totally 3 times.
2457094|NCT03193125|Experimental|Carnitine|500 mg of L-carnitine to be taken 3 times a day 15 minutes before meals for 14 days.
2457096|NCT03193125|Placebo Comparator|Placebo|500 mg of placebo to be taken 3 times a day 15 minutes before meals for 14 days.
2457111|NCT03193073|Active Comparator|CKD patients with different stages|"Full clinical history and through clinical examination.~Full blood count at time of diagnosis and 3 months after initiation of treatment with iron and erythropoietin Stimulating agents.~Iron study at time of diagnosis and 3 months after treatment .~Serum calcium , phosphorus, intact Parathrmone hormone. 5-24- urinary proteins or Albumin Creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~6- Lipid profile . 7-Estimated glomerular filtration rate by MDRD equation ."
2457117|NCT03193073|Active Comparator|Newly renal transplanted patients .|"Full clinical history and through clinical examination.~Pre transplant Serum calcium , phosphorus , I Parathrmone hormone , serial measures every / 3 months for 2 years.~Pre-transplant full blood count serial measures every / 3 months for 2 years.~Pre transplant serum Iron study and annually for 2 years.~24- urinary proteins or albumin-creatinine ratio every month (for 3 months )then every 3 months (1 st year), then annually.~Post-transplant serum FGF-23 (as independent risk factor) at 6months.~Different immunosuppressive protocols.~Pre-transplant panel reactive antibody,donor-specific antibody"
2457134|NCT03192566|Experimental|Tylenol Dosing|"Dosing of Tylenol for postoperative pain relief will include:~children < 16 years; 650 mg every 6 hours, max 2.6 gram per 24 hours and children > or equal to 16 years every 6 hours 1 g of acetaminophen, max 4 gram per 24 hours)."
2457143|NCT03192761|Active Comparator|ACL-reconstruction hamstrings|ACL reconstruction hamstrings
2457150|NCT03192761|Active Comparator|ACL-reconstruction patella tendon|ACL reconstruction patella tendon
2457162|NCT03192761|Active Comparator|ACL-reconstruction iliotibial tract|ACL reconstruction iliotibial tract
2457190|NCT03192384||Before intervention|Data from clusters before educational programme intervention implemented.
2457191|NCT03192384||After intervention|Data from clusters after educational programme intervention implemented
2457222|NCT03192254|Active Comparator|Self-Monitoring Control|Daily tracking of fruit and vegetable consumption
2457224|NCT03192254|Experimental|Daily Incentives|Incentives for fruit and vegetable consumption delivered daily
2457229|NCT03192254|Experimental|Delayed Lump Sum Incentives|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
2457239|NCT03192059|Experimental|experimental arm|Pembrolizumab, immune modulatory cocktail composed of Vitamin D, Lansoprazole Teva, Cyclophosphamide and Aspirine, radiation and Curcumin
2457273|NCT03191825|Active Comparator|Standard web-application|Endre: a digital smoking cessation counsellor
2457282|NCT03191825|Experimental|Web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered from web-page
2457289|NCT03191825|Experimental|SMS & web-based lapse management system|Endre: a digital smoking cessation counsellor + Lapse management system triggered by SMS-textmessage
2457302|NCT03191734|Experimental|AQUABEAM System|AQUABEAM System
2457322|NCT03191461||Cancer Patients|Cancer patients with Stage I-III breast cancer or lymphoma that have received an anthracycline agent during treatment at least 2 years prior to enrollment in this study. Adenosine stress test MRI will be performed.
2457326|NCT03191461||Healthy Controls|Age-matched Healthy Control to cancer survivor with no history of cancer or anthracycline treatment. Adenosine stress test MRI will be performed.
2457389|NCT03191318|Active Comparator|ERAS pathway|Laparoscopic sleeve gastrectomy with ERAS pathway
2457391|NCT03191318|Active Comparator|Standard pathway|Laparoscopic sleeve gastrectomy with standard pathway
2457430|NCT03191136|Experimental|Group1|taking YHD1119 (pregabalin 300mg) in fasted state at Period 1
2457433|NCT03191136|Experimental|Group2|taking YHD1119 (pregabalin 300mg) in fed state at Period 1
2457458|NCT03190785|Experimental|Benzoic acid washout and exposure|All subjects will be in this arm which employs a pre-post exposure design. Subjects will undergo a 2 week washout period where they avoid consumption of benzoate containing beverages. Then there is a 1 week exposure period comprising daily consumption of benzoate containing beverages to result in up to 5 mg/kg per day benzoic acid intake.
2457482|NCT03190551|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2457487|NCT03190551|Active Comparator|costoclavicular approach|Patients in this group will be randomized to receive an costoclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
3190864|NCT00792337|Active Comparator|simvastatin|simvastatin in combination with budesonide
3190865|NCT00792337|Placebo Comparator|B1-6-12|Budesonide in combination with B1-6-12
2457552|NCT03190122|Active Comparator|group with pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Pealing Of The Outer Layer Of The Cavernous Sinus
2457557|NCT03190122|Experimental|group without pealing of the outer layer of cavernous sinus|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision Without Pealing Of The Outer Layer Of The Cavernous Sinus
2457616|NCT03189654||Treatment group|Non-invasive ventilation after pleurocentesis
2457619|NCT03189654||Control group|Oxygen Administration via nasal tube
2457709|NCT03188848|Experimental|BPI-3016|Single-dose subcutaneous injection of BPI-3016 with escalating dose from 0.6 mg
2457714|NCT03188848|Placebo Comparator|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
2460229|NCT03172000|Active Comparator|Colonoscopy and biopsy|IBD patients
3190866|NCT00792350||Group 1|
2456980|NCT03193775|Active Comparator|chronic HBV with persistent HBsAg|"inactive carriers (n=100). Group II: CHB exposed to nucleos(t)ides (n=120) till 6 months after HBe seroconversion and HBV DNA disappearance in HBeAg positive (n=60) or DNA disappearance in HBeAg negative patients (n=60). All showed persistent HBs antigenemia.~they were given 30 µg of HBV vaccine initiated 6 months after HBe seroconversion and disappearance of HBV DNA."
2456982|NCT03193775|No Intervention|control group|A control group (n=100) did not receive HBV vaccine
3190867|NCT00792376|Experimental|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
3190868|NCT00792376|Active Comparator|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
3190869|NCT00792389|Experimental|1|Patients receiving warmed, humidified gas
3190870|NCT00792389|Active Comparator|2|Patients receiving cool, day gas
3190871|NCT00792402||1 control group|Computerized data collection of outcome measures in usual care
3190872|NCT00792402||2 intervention group|Computerized data collection of outcome measures and interviews to clinicians which are using a computerized Heart Failure guideline in their daily practice.
3190873|NCT00792415||1|Limited continuous opioid exposure (at least 120 and less than 156 hours)
2457127|NCT03192813||Symetis ACURATE neo™ transfemoral TAVI system|Patient assigned to this group will be implanted with Symetis ACURATE neo™ transfemoral TAVI system.
2457131|NCT03192813||Medtronic CoreValve Evolut R TAVI System|Patient assigned to this group will be implanted with Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System.
2457152|NCT03192462|Experimental|Group A (Closed to New Patient Enrollment)|"Patients with locally advanced or metastatic pancreatic adenocarcinoma who are responding following 3 cycles of first line chemotherapy will receive 6 infusions with a fixed dose of multiTAA specific T cells beginning on the 4th week of the 4th cycle of chemotherapy. MultiTAA T cell infusions will occur on day 21 (a chemotherapy off week) of each chemotherapy cycle starting on chemotherapy cycle 4."
2457169|NCT03192462|Experimental|Group B (Closed to New Patient Enrollment)|Patients with locally advanced or metastatic pancreatic adenocarcinoma who have failed first line chemotherapy or are intolerant or ineligible to receive standard of care chemotherapy will be evaluated in the clinic and receive 6 infusions (administered at monthly intervals) with a fixed dose of multiTAA specific T cells.
2457172|NCT03192462|Experimental|Group C (Closed to New Patient Enrollment)|Patients with resectable pancreatic adenocarcinoma following completion of neoadjuvant chemotherapy, radiotherapy or combination. These patients will receive 6 infusions with a fixed dose of multiTAA specific T cells. One infusion will occur 4 weeks prior to surgical resection (with an option to infuse up to one week earlier) and after the completion of all pre-operative chemotherapy and/or radiation. The subsequent 5 infusions will occur at monthly intervals beginning 8 weeks post-surgery. Following surgery all patients will additionally receive 3 months of standard of care (SOC) chemotherapy starting week 9 after surgery. Hence, SOC chemo will occur weeks 9-11, 13-15, and 17-19 post-surgery and multiTAA T cell infusions will occur at weeks 8, 12, 16, 20, and 24 post-surgery.
2457254|NCT03192241|Experimental|Pump|Mothers provided with a manual breast pump
2457258|NCT03192241|Active Comparator|book|Mothers provided with a children's book
2457401|NCT03191188|Experimental|Levothyroxine|
2457403|NCT03191188|Placebo Comparator|Placebo|
2457451|NCT03190707|Experimental|Intervention|The intervention consists of three key components aiming at promoting a better attachment between child and mother/parents and through that giving the child the best possible beginning of life. The three components aim at: 1) detecting ill-being in vulnerable pregnant woman and initiation of potential treatment, 2) strengthening knowledge sharing and organizing the course for the families across the sectors, 3) strengthening parenting skills.
2457452|NCT03190707|No Intervention|Control|The existing practice for psychosocial vulnerable pregnant women on Gentofte-Herlev Hospital, Denmark, will be offered for women allocated to the control group. The control group will be measured at the same follow-up periods as the intervention group.
2457471|NCT03190408||Shock|
2457565|NCT03190226|Experimental|L-PRF membranes|"Intra-oral split thickness preparation - apically repositioned to the periosteum.~L-PRF membranes will be used to cover the site. Free Gingival Grafts will be used to cover the site."
2457581|NCT03189563|Placebo Comparator|Placebo|placebo, tid
2457583|NCT03189563|Experimental|DA-9805 low|DA-9805 45mg
2457585|NCT03189563|Experimental|DA-9805 high|DA-9805 90mg
2457697|NCT03188705|Experimental|Overall Cohort|Participants will receive clopidogrel treatment alone (300 mg loading dose followed by 75 mg/d for 6 days), followed by clopidogrel (75 mg) plus aspirin (324 mg) treatment on day 8.
2457764|NCT03188549|Active Comparator|Departments of Branch A|Intervention: AniosGel Respiratory ICU Pediatric Cardiac Surgery, NICU Hemato-Oncology, Oncology Internal A, C, D, E, F Surgery C, Vascular Surgery and Chest Surgery Pediatric B South Imaging Orthopedics B
2457767|NCT03188549|Active Comparator|Departments of Branch B|Intervention: Softaman Neurosurgery ICU Cardiac Surgery, Cardiac ICU, Pediatric ICU Pediatric Hemato-Oncology Internal B and I, Geriatric C and D Surgery B Pediatric B North Emergency Room Orthopedics A and Hand
2457768|NCT03188549|Active Comparator|Branch C|Control Intervention - Septol without any changes All patients hospitalized in the 29 departments in Sheba, including two of the branches, during the year of the study
2457851|NCT03188068|Active Comparator|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
2457852|NCT03188068|Active Comparator|Sirolimus plus prednisolone|"Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.~Prednisolone was administered 2 mg/kg administered once daily. Should satisfactory clinical responses and hematologic stabilization ensue, prednisolone may be tapered and discontinued within the following 4-6 weeks."
2457885|NCT03187574||Group A|group received Elevate Ant™ single-incision mesh
3190874|NCT00792415||2|Extended continuous opioid exposure (156 hours or more)
3190875|NCT00792441|No Intervention|intervention group|Patients with mechanical ventilated who met the criteria for weaning from medical doctor in Srinagarind hospital, Khon Kaen University
2456996|NCT03193814|Experimental|Chemotherapy + Apatinib|chemotherapy regimens include: Folfox (Oxaplatin 85 mg/m2 IV over 2 hours, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks) or Folfiri (Irinotecan 150-180 mg/m2 IV over 30-90 minutes, day 1; Leucovorin 400 mg/m2 over 2 hours, day 1; 5-FU 400 mg/m2 IV bolus on day 1, then 1200mg/m2/day x 2 days; repeat every 2 weeks)； apatinib 500mg po qd
2457161|NCT03192527|Experimental|Arm A|KN015, Triptorelin
2457168|NCT03192527|Placebo Comparator|Arm B|placebo, Triptorelin
3190876|NCT00792454|Experimental|exercise training/renal rehabilitation|Experimental arm will undergo 12 weeks of training in exercise, meditation, and nutrition education.
3190877|NCT00792454|No Intervention|control|Control co-hort will receive usual chronic kidney disease care and no exercise, meditation or dietary education intervention.
3190878|NCT00792480|Experimental|Intensive Counseling Group|
3190879|NCT00792480|No Intervention|Routine care group|"The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics & Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle."
3190880|NCT00792493|Experimental|ORM-12741|
3190881|NCT00792493|Placebo Comparator|Placebo|
3190882|NCT00792506|Experimental|ITF2357|
3190883|NCT00792519|Experimental|CBT|group cognitive behavioral treatment
3190884|NCT00792519|Active Comparator|HIV support group|group support
3190885|NCT00792532||iMRI|
2461113|NCT03166345|Experimental|PRP injection into Uterine Cavity|PRP injection into Uterine Cavity For Treatment of Thin Endometrium
2461114|NCT03166345|Experimental|CSF (colony stimulating factor)|CSF for Treatment of Thin Endometrium
2461116|NCT03166345|No Intervention|No intervention|The control arm.
2461123|NCT03165838|Experimental|Postpartum Visit 3-4 Weeks|Participants will have postpartum visit scheduled 3-4 weeks after birth
2461131|NCT03165838|Experimental|Postpartum Visit 6-8 Weeks|Participants will have postpartum visit scheduled 6-8 weeks after birth
2461198|NCT03165682||Group 1|Twenty-five patients with Systemic Lupus Erythematosus with prominent fatigue symptoms ( inclusion criterion: FSS of at least 4)
2461199|NCT03165682||Group 2|Twenty-five patients with Systemic Lupus Erythematosus without subjectively enhanced fatiguability
2461200|NCT03165682||Group 3|Twenty-five age, sex and educationally matched controls among the health worker.
2461295|NCT03165305|Experimental|Sustained Inflation Group|Includes the infants who administered sustained inflation for 5 seconds with a pressure of 30cm H20 immediately after the delivery.
2461296|NCT03165305|No Intervention|No Intervention group|Includes routine neonatal care in the delivery room
2461313|NCT03164733||<40|patients younger than 40 years
2461317|NCT03164733||40-60|patients younger than 60 years and not older than 40 years
2461319|NCT03164733||60-80|patients younger than 80 years and not older than 80 years
2461324|NCT03164733||>80|patients older than 80 years
2461389|NCT03164447|Experimental|Multi-Drug Resistant|
2461479|NCT03163849|Placebo Comparator|control group|oral tablets
2461487|NCT03163849|Experimental|Study group|sofosbuvir , daclatasvir oral tablets
2461506|NCT03163277|No Intervention|Standard of care|Continue current antiretroviral regimen
2461507|NCT03163277|Experimental|Reduced Neurotoxicity Arm|Emtricitabine plus darunavir/cobicistat plus maraviroc
2461573|NCT03162874|Placebo Comparator|PLACEBO|
2461576|NCT03162874|Experimental|PXT002331 - 10mg|
2461578|NCT03162874|Experimental|PXT002331 - 30mg|
2461696|NCT03162302||Healthy Subjects|Healthy volunteers will undergo 60 minute non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences.
2461703|NCT03162302||Clinical Patients|Patients in whom an MRI is indicated for their disease condition will undergo the clinical scan, followed by up to 30 minutes non-contrast enhanced Magnetic Resonance Imaging (MRI) of the abdomen using novel imaging sequences. Clinical patients may also elect to undergo a research only scan of approximately one hour.
2461772|NCT03161847||OPMD Subjects|The study cohort consists of individuals with genetically confirmed OPMD who will be followed longitudinally using periodic standardized assessments of clinical status in an observational, non-interventional study.
2461809|NCT03161379|Experimental|CY, Nivolumab, GVAX, and SBRT|CY, Nivolumab, GVAX, and SBRT
2461847|NCT03160976|No Intervention|Control Group|Subjects will only receive the Evaluation Protocol and will be followed for 90 days.
2461848|NCT03160976|Active Comparator|Intervention Group|A single 50 minutes session of cold exposure with a cryolipolysis device. The parameters will be: temperature -10°C and vacuum between 60 Kpas (at beginning) and 40 Kpas (until the end).
2461965|NCT03160651|Active Comparator|methylprednisolone|Patients will receive 28 days of methylprednisolone 32 mg/day
2461966|NCT03160651|Placebo Comparator|placebo|Patients will receive 28 days of matching placebo
2462009|NCT03160157||laparoscopic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
2462118|NCT03159390|Experimental|phenylacetate salt of ornithine|There are 4 study days of approximately 10 hours. Amino acid tracers (e.g., OP, PHE, TYR) will be provided via IV. The dosage of OP provided in this study 6 g in a period of 6 hours. 2 muscle biopsies will be completed on 2 of the study days.
3190886|NCT00792558|Experimental|Single Arm|
3190887|NCT00792584|Experimental|1|patients treats with etravirine for 6 weeks
2457001|NCT03193658|Active Comparator|Group T|Will receive bilateral US guided Thoracolumbar Interfascial Plane (TLIP) block at the proposed level of surgery before the start of the surgery
2457005|NCT03193658|Active Comparator|Group O|Will not receive the block and postoperative pain control will be managed by I.V drug based multi-modal approach (Opioid & acetaminophen) only.
2457177|NCT03192436|Active Comparator|Real Ultrasound|The subjects will receive real ultrasound intervention.
2457181|NCT03192436|Sham Comparator|Sham Ultrasound|The subjects will receive sham ultrasound intervention.
2457215|NCT03192163||ResearchMatch Group|
2457220|NCT03192163||Northwestern Center for Ethnic Skin Group|
2457265|NCT03191903|Experimental|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).
2457267|NCT03191903|Active Comparator|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
2457275|NCT03191903|Active Comparator|Triamcinolone Hexacetonide (TH)|A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.
2457298|NCT03191422|Experimental|LSVT BIG intervention recipients|Participants participated in all of the evaluation steps as well as the LSVT BIG protocol which includes 16, 1-hour intervention sessions with a certified therapist performing, targeted exercises and activities to improve participation in occupations - with a focus on large amplitude movement.
2457330|NCT03191383|Experimental|GSK3003891A vaccine formulation 1 mother Group|Subjects in this group will receive a single 30µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2457331|NCT03191383|Experimental|GSK3003891A vaccine formulation 2 mother Group|Subjects in this group will receive a single 60µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2457334|NCT03191383|Experimental|GSK3003891A vaccine formulation 3 mother Group|Subjects in this group will receive a single 120µg dose of the GSK3003891A investigational vaccine, by intramuscular injection into the deltoid region of the non-dominant arm.
2457336|NCT03191383|Placebo Comparator|Control group|Subjects in this group will receive a single placebo injection, intramuscularly into the deltoid region of the non-dominant arm.
2457337|NCT03191383|No Intervention|GSK3003891A vaccine formulation 1 infant Group|Infants born to mothers vaccinated with a single 30µg dose of the investigational GSK3003891A vaccine
2457340|NCT03191383|No Intervention|GSK3003891A vaccine formulation 2 infant Group|Infants born to mothers vaccinated with a single 60µg dose of the investigational GSK3003891A vaccine
2457343|NCT03191383|No Intervention|GSK3003891A vaccine formulation 3 infant Group|Infants born to mothers vaccinated with a single 120µg dose of the investigational GSK3003891A vaccine
2457346|NCT03191383|No Intervention|Control infant Group|Infants born to mothers who received a single placebo injection
2457405|NCT03191032|Experimental|Training Group|Early sensory re-education of the hand protocol with a sensor glove model, after a median and/or ulnar nerve injury repair
2457408|NCT03191032|No Intervention|Control Group|Conventional rehabilitation for peripheral nerve injuries if the hand, without application of any kind of early sensory re-education protocol
2457442|NCT03190746||No SNP|Subjects have two copies of the wild type gene
2457443|NCT03190746||SNP present|Subjects have one or two copies of the SNP
2457489|NCT03190486|Experimental|Men contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2457492|NCT03190486|Experimental|Women contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2457497|NCT03190486|Experimental|Father contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2457499|NCT03190486|Experimental|Mother contact-less with children|functional Magnetic Resonance Imaging (fMRI).
2457538|NCT03190057||Consecutive percutaneous coronary intervention|
2457608|NCT03189550||Historical control|Patients who underwent colorectal surgery with standard perioperative care starting from June 2014 and progressing backward in time.
2457611|NCT03189550||ERAS without SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care (SOC) ERAS perioperative care from July 2014 to February 2015
2457614|NCT03189550||ERAS with SOC noninvasive hemodynamic monitoring|Patients who underwent colorectal surgery after implementation of standard of care ERAS perioperative care with standard of care noninvasive hemodynamic monitoring (with the ClearSight System, Edwards Lifesciences) after February 2015
2457648|NCT03189095|Experimental|Intervention|
2457651|NCT03189095|No Intervention|Wait-List Control|
2457723|NCT03188900||preeclampsia|pregnancy with preeclampsia
2457724|NCT03188900||control|pregnancy without preeclampsia
2457765|NCT03188380||Plain abdominal radiograph (AR)|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
2457766|NCT03188380||Abdominal ultrasound (AUS)|If plain abdominal radiography is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
3190888|NCT00792584|Experimental|2|patients treats with efavirenz for 6 weeks
3190889|NCT00792597||spine or hip surgery|
2457880|NCT03187548|Experimental|CPP-ACP|Casein phosphopeptide amorphous calcium phosphate dental paste
2457925|NCT03187340|Active Comparator|Sleep education and relaxation 1|Behavioral education intervention about sleep and relaxation
2457926|NCT03187340|Experimental|Sleep education and relaxation 2|Behavioral education intervention about sleep and relaxation
2457980|NCT03186950|Active Comparator|Restoration with Stainless Steel Crowns|Restoration of the tooth after endodontic treatment using stainless steel crown.
2457982|NCT03186950|Experimental|Restoration using BulkFill CR|Restoration of the tooth after endodontic treatment using bulkfill composite resin
3190890|NCT00792649||1|screening colonoscopy with HD+ endoscopes
3190891|NCT00792649||2|screening colonoscopy with standardvideoendoscopes
3190892|NCT00792662|Experimental|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
3190893|NCT00792662|Placebo Comparator|Placebo|Standard inactive pill.
3190894|NCT00792675|Experimental|Exercise|
3190895|NCT00792727|Experimental|Ketoprofen Patch|Treatment with experimental drug
2457004|NCT03193788|Experimental|pemetrexed maintenance|"Drug: Pemetrexed Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.~Drug: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment~Drug: vitamin B12 injection 1000 μg IM 7 days prior to treatment initiation and the every then every 3 cycles until the end of treatment~Drug: dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment"
2457007|NCT03193788|No Intervention|observation|observation group will be observed with best supportive care until progressive disease
2457025|NCT03193229|Experimental|MapTrek|Patients in the intervention group receive a Fitbit and MapTrek, an interactive text-messaging platform. The only equipment needed is a Fitbit (we provide) and a smartphone (required prior to enrollment). Each week, patients are assigned to a virtual walking route. Each day, they receive a text message with a link to the current route. The link will take them to a map where they can see their progress and the progress of others. A leaderboard provides information on how many steps each participant has taken. MapTrek also supports Street View on Google Maps, so patients can explore what they would see if they were in that location. Throughout each race, patients will randomly receive challenge text messages. Completing a challenge awards bonus steps to propel their character along the map.
2457026|NCT03193229|Active Comparator|Fitbit Only|Patients randomized to the control group will receive a Fitbit only. This will allow us to determine if changes in physical activity are due to MapTrek or simply by giving the patients a Fitbit.
3155276|NCT00317187|Experimental|Hib-MenAC Lot 3 Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB combined vaccine mixed extemporaneously with Meningitec conjugate vaccine Lot 3 at 2, 4 and 6 months of age as an intramuscular injections in the anterolateral part of the left thigh.
3155277|NCT00317187|Active Comparator|Hiberix Group|Healthy male or female subjects aged 56 to 83 days of age at the time of the first study vaccine dose, with previous hepatitis B vaccine at birth, received Tritanrix-HepB vaccine mixed extemporaneously with conjugate vaccine Hiberix at 2, 4 and 6 months of age as intramuscular injection in the anterolateral part of the thigh.
3155278|NCT00317200|Active Comparator|1|Paclitaxel + Devacizumab in patients with chemosensitive relapsed small cell lung cancer.
3155279|NCT00317252|Experimental|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held >= 24 hours pre-cardiac catheterization and restarted post-catheterization after creatinine measurement (48-96 hours post)
3155280|NCT00317252|Other|Continue ACE1 or ARB|Randomized to continue on prescribed ACE1 or ARB
3155281|NCT00317278|Experimental|A,1|Massage therapy
3155282|NCT00317278|Sham Comparator|A,2|
3155283|NCT00317291|Experimental|Acupuncture/Moxibustion|Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
3155284|NCT00317291|Sham Comparator|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion for Peripheral Neuropathy in HIV
3155285|NCT00317304|Experimental|MBSR|
3155286|NCT00317382|No Intervention|No Ultrasound|Standard LP without ultrasound use
3155287|NCT00317382|Experimental|Ultrasound Use|Ultrasound used to assess spine and best location for lumbar puncture.
3155288|NCT00317395|Experimental|Otamixaban Dose 1|dosage regimen 1
3155289|NCT00317395|Experimental|Otamixaban Dose 2|dosage regimen 2
3155290|NCT00317395|Experimental|Otamixaban Dose 3|dosage regimen 3
3155291|NCT00317395|Experimental|Otamixaban Dose 4|dosage regimen 4
3155292|NCT00317395|Experimental|Otamixaban Dose 5|dosage regimen 5
3155293|NCT00317395|Active Comparator|UFH/Eptifibatide|
3155294|NCT00317460|Active Comparator|1|Physician Management
3155295|NCT00317460|Experimental|2|Physician Management and counseling (drug counseling and medication adherence)
3155296|NCT00317499|Experimental|Etanercept|
3155297|NCT00317499|Placebo Comparator|Placebo|
3155298|NCT00317512|Active Comparator|1|Voluven will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
3155299|NCT00317512|Active Comparator|2|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by Voluven at 7.7 ml/min over 15 minutes
3155300|NCT00317512|Experimental|3|HBOC-201 will be administered at 7.7 ml/min over 15 minutes,followed by HBOC-201 at 7.7 ml/min over 15 minutes
3155301|NCT00317616||Unaffected individuals from families in which the genetic cause of ALS is known|This population would include pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
3155302|NCT00317629|Active Comparator|1|
3155303|NCT00317629|Experimental|2|
3155304|NCT00317694|Experimental|1|
3155305|NCT00317694|Placebo Comparator|2|
3155306|NCT00317707|Experimental|N-3 PUFA|
3155307|NCT00317707|Placebo Comparator|Olive oil|
3155308|NCT00317746|Placebo Comparator|Placebo|Placebo + PEG-interferon-alfa2b + ribavirin
3155309|NCT00317746|Experimental|Citalopram|Citalopram + PEG-interferon-alpha2b + ribavirin
3155310|NCT00317772|Experimental|Topotecan + Gefitinib|"Phase I: Topotecan: 2.0, 3.0, or 4.0 mg/m^2 by vein Days 1, 8 and 15 of 28 day cycle.~Gefitinib: 250 mg by mouth daily.~Phase II: Topotecan starting dose: MTD from Phase I by vein Days 1, 8, and 15 of 28 day cycle.~Gefitinib: 250 by mouth daily for 28 Days."
3155311|NCT00317837|Active Comparator|1|Patients treated with a cemented modular hemiarthroplasty, with a unipolar head
3155312|NCT00317837|Active Comparator|2|Patients treated with a modular cemented hemiarthroplasty with a bipolar head.
3155313|NCT00317889|Experimental|Compaction|Compaction technique for femoral bone preparation prior to cementless femoral stem insertion.
3155314|NCT00317889|Active Comparator|Broaching|Broaching technique for femoral bone preparation prior to cementless femoral stem insertion.
3155315|NCT00317967|Experimental|1|Atorvastatin
3155316|NCT00317967|Placebo Comparator|2|Placebo
3155317|NCT00317980|Experimental|Low dose|Meglumine antimoniate 5 mg/kg/d for 20 days
3155318|NCT00317980|Active Comparator|Standard dose|Meglumine antimoniate 15 mg/kg/d for 20 days
3173227|NCT00609778|Active Comparator|2 Manual CPR|Manual chest compressions
3173228|NCT00609791|Experimental|nab-paclitaxel|
3173229|NCT00609817|Experimental|GCS-100|
2457015|NCT03193697|Experimental|control group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
2457017|NCT03193697|Experimental|trial group|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
2457102|NCT03192852|Experimental|Violet LED (405 nm)+ gel placebo|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier + gel placebo
2457103|NCT03192852|Experimental|Violet LED + CP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with carbamide peroxide 35% ( Whiteform - Fórmula & Ação, São Paulo, Brazil) actived with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier
2457107|NCT03192852|Experimental|HP 35%|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with hydrogen peroxide 35% (Whiteness HP, FGM, Joinvile, SC, Brasil) and gingival barrier
2457113|NCT03192852|Experimental|HP 35% + Violet LED + Gingivoplasty|20 patients will be submitted to dental bleaching involving the teeth 15-25 and 45 - 35 with Violet LED 405 nm (Bright Max Whitening, MMO, São Carlos, SP, Brazil) with gingival barrier split-mouth at first session. After 48 hours will be do Gingivoplasty.
2457133|NCT03192592|Experimental|Body moisturizer Apotech®|Instructions for use: Massage the product in the body twice a day (morning and evening) with gentle movements until completely absorption. Daily use for 28 days.
2457256|NCT03192397|Experimental|Prevention (chemotherapy, TBI, cyclophosphamide)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan hydrochloride IV over 30 minutes on day -2. Patients undergo TBI on day -1.~STEM CELL INFUSION: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS REGIMEN: Patients receive cyclophosphamide IV over 2 hours on days 3-4, mycophenolate mofetil IV over 2 hours on days 5-35, and sirolimus IV and then PO once tolerated on days 5-180 with a taper beginning on day 100."
3190896|NCT00792727|Placebo Comparator|Placebo Patch|Treatment with placebo drug
3190897|NCT00792740|Placebo Comparator|Placebo capsules|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)"
2457513|NCT03190278|Experimental|Part 1: Dose Escalation|"Several tested doses of UCART123v1.2 with different lymphodepletion regimens to establish Maximum Tolerated Dose (MTD) and identify Recommended Phase 2 Dose (RP2D)~Dose Expansion: UCART123v1.2 administered at the selected dose determined from the dose escalation phase"
2457525|NCT03189953|Experimental|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
2457682|NCT03188978|Experimental|Treatment|Atorvastatin 40mg once daily orally for 8 weeks starting 2 weeks before AVF creation
2457683|NCT03188978|Placebo Comparator|Placebo|1 tablet once daily orally for 8 weeks starting 2 weeks before AVF creation
2457728|NCT03188640|Other|Surgery|Participants will be operated using laparoscopic gastric bypass surgery.
2457760|NCT03188471|Experimental|GnRH antagonist|Vitamin C (1 tablet daily) as placebo of aspirin GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days
2457763|NCT03188471|Active Comparator|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days.
2457786|NCT03188094||South Asians with Prediabetes|
2457829|NCT03187951|Experimental|Arm A: Standard of Care (SOC)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants encouraged to remain active during chemotherapy and/or radiation. Participants receive a booklet that contains a stretching guide with full-body stretches and safety."
2457843|NCT03187990|Experimental|PET/MRI before biopsy|Patients with suspected areas on mpMRI will undergo additional [68Ga]PSMA-11 PET/MRI scan with subsequent mpMRI and PET/MRI guided biopsy.
2457844|NCT03187990|Experimental|PET/MRI after biopsy|Patients with unclear areas or a negative finding in the mpMRI for MRI guided biopsy but positive biopsy, which will undergo the additional [68Ga]PSMA-11 PET/MRI scan with [68Ga]PSMA.
2457914|NCT03187483|Active Comparator|Flash-free bracket group|Orthodontic treatment with flash-free bracket system
2457020|NCT03194009|Active Comparator|Lifestyle Intervention|The prediabetic individuals from the primary care centres that belong to this arm, will receive only recommendations for lifestyle modifications (physical activity and diet).
2457021|NCT03194009|Active Comparator|Metformin|The prediabetic individuals from the primary care centres that belong to this arm, will receive metformin treatment and lifestyle modifications recommendations (physical activity and diet).
2457028|NCT03193242|Experimental|Intervention|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
2457031|NCT03193242|No Intervention|Control|"Electronic Asthma Management System: eAMS - Control~At control sites, eligible clinicians will be offered access to the web-based clinician-oriented asthma action plan (AAP) educational module produced by the Lung Association, copies of the Canadian Asthma Guidelines, and standard fillable paper-based AAPs (the eAMS will be offered after study end)."
2457070|NCT03193177||the 21-day fasting-like diet|Participants will be supplied with fasting-like diet containing only 5% of normal calorie intake. Physical examinations will be performed on day 0, 4,7,14,21 and 51 after the clinical trial.
2457126|NCT03192865||diaphragmatic paralysis/paresis group|"Diaphragmatic paralysis can be associated with regional anesthesia procedure in arthroscopic shoulder surgery as phrenic nerve is close to the brachial plexus.~Diaphragmatic paralysis will be defined using ultrasounds."
2457130|NCT03192865||No diaphragmatic paralysis/paresis group|Some strategies of peripheral nerve block are able to spare diaphragmatic paralysis.
2457145|NCT03192553|Experimental|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2457151|NCT03192553|Experimental|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2457164|NCT03192553|Experimental|One-Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2457170|NCT03192553|Other|CDC Procedure (Control)|Participants will doff PPE following the CDC procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
2457194|NCT03192202|Experimental|Cohort 1|1.5 mg/kg of AFM13 once weekly for weeks 1-8.
2457195|NCT03192202|Experimental|Cohort 2|1.5 mg/kg of AFM13 three times per week for weeks 1-8.
2457196|NCT03192202|Experimental|Cohort 3|0.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2457197|NCT03192202|Experimental|Cohort 4|1.5 mg/kg in of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2457198|NCT03192202|Experimental|Cohort 5|7.0 mg/kg of AFM13 once weekly for weeks 1-8.
2457199|NCT03192202|Experimental|Cohort 6|4.5 mg/kg of AFM13 three times per week for weeks 1-2. 7.0 mg/kg of AFM13 once weekly for weeks 3-8.
2457243|NCT03192007||Patients with Stable Renal Function|Patients will be given MRI
2457247|NCT03192007||Patients with Worsening Renal Function due to complications|MRI
2457297|NCT03191760|Experimental|Behavioral Activation and Social Engagement|Participants will attend 6 in-person therapy sessions lasting approximately 45 minutes per session, held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills. We have modified the standard Behavioral Activation intervention by reducing the number and length of sessions to accommodate the Primary Care setting. In addition, there will be a stronger emphasis on social engagement in BASE then in standard BA and social contact and support will be addressed during each treatment session.
2457315|NCT03191539|Experimental|Apremilast|30 mg of Apremilast twice a day during 52 weeks. During the first 6 days will be a dose escalation as the following: Day 1: 10 mg daily Day 2: 10 mg day- 10 mg night Day 3: 10 mg day- 20 mg night Day 4: 20mg day- 20mg night Day 5: 20 mg day- 30 mg night Day 6: 30 mg day- 30 mg night
2457374|NCT03191331|Experimental|Intervention group|Dietary intervention. Intervention group will receive written material on healthy diet during pregnancy, nutritional guidance given by public health nurses at each maternity care clinic visit and group meeting with dietician x2.
2457376|NCT03191331|No Intervention|Control group|The control group will receive written material on healthy diet during pregnancy, otherwise basic care and guidance at maternity care clinics.
3155319|NCT00318006|Active Comparator|Spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
3173230|NCT00609830|Experimental|Tailored Materials|
3173231|NCT00609830|Experimental|Physician Feedback|
2457475|NCT03190512|Active Comparator|Test Group|"Psychological measurements were taken from periodontal disease patients before treatment and after 6 weeks.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions) was performed and the Psychological questionnaires were filled."
2457480|NCT03190512|Placebo Comparator|Control Group|"Psychological measurements were taken from periodontal disease patients at the baseline and after 6 weeks without the periodontal treatment.~Intervention: The Psychological questionnaires were filled."
2457544|NCT03190135|Experimental|BOKS: 2 day per week|
2457546|NCT03190135|Experimental|BOKS: 3 day per week|
2457550|NCT03190135|No Intervention|Non-BOKS|
2457637|NCT03189355|Experimental|Patients With Septic Shock|Blood sampling on D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube and D4 zonulin Bioelectrical impedance vector analysis on D1 + D4 Muscular echography on D1 + D4
3173232|NCT00609830|Active Comparator|Generic Materials|
3173233|NCT00609830|Placebo Comparator|Placebo Comparator|Participants receive no information
3173234|NCT00609843|Experimental|1|
2457029|NCT03193619||PTA-UltraScore Focused Force PTA balloon|Treatment with the UltraScore Focused Force PTA balloon will be per the investigational site's standard of care and adhering to the IFU.
2457092|NCT03192917|Experimental|Active treatment|This group of participant will receive low intensity shock wave treatment accounted on their penile shaft once every week for 5 weeks.
2457093|NCT03192917|Placebo Comparator|Placebo group|this group of participant will meet up for treatment. The treatment given will be the exact same as the active group, but the transducer used for shock wave treat will me capped, meaning that no shock waves are transmitted to their penis.
2457153|NCT03192644|Experimental|Group A (TAI)|
2457167|NCT03192644|Active Comparator|Group B (TACE)|
2457192|NCT03192215|Experimental|Active agent: Apixaban|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Apixaban
2457193|NCT03192215|Active Comparator|Active control: Aspirin|Patients with a recent embolic stroke of undetermined source (ESUS) and evidence of atrial cardiopathy will receive Aspirin
2457461|NCT03190694|Experimental|Dapagliflozin 10mg Tablet|10 mg Green, plain, diamond shaped, film coated tablet (orally)
2457462|NCT03190694|Placebo Comparator|Placebo Matching Dapagliflozin Tablet|Green, plain, diamond shaped, film coated tablet. Does not contain active ingredient
2457486|NCT03190317||HIV-infected Veterans who use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and use MHV.
2457490|NCT03190317||HIV-infected Veterans who do not use MHV|This group represents the population of HIV-infected Veterans active in care at a VA health system, who have been diagnosed with HIV and do not use MHV.
2457494|NCT03190317||Providers and staff of HIV-infected veteran|This groups represents the population of providers and staff who utilize the MHV portal to deliver care for HIV-infected veterans.
2457545|NCT03190031|Experimental|Endurance respiratory muscle training|The intervention consists in performing isocapnic hyperpnea at 70-80% of maximal voluntary ventilation for 20 min, 5 times a week, for 8 weeks
2457547|NCT03190031|Active Comparator|Resistance inspiratory muscle training|The intervention consists in performing inspiratory resistive breathing at 70-80% of maximal inspiratory pressure for 20 min, 5 times a week, for 8 weeks
2457584|NCT03189641|Experimental|Cilostazol eluting stent system (CES-1)|
2457645|NCT03189290|Active Comparator|ropivacaine|"Active Comparator: ropivacaine group~- Before general anaesthesia, ultrasound guided Quadratus Lumborum Block (QLB) will be performed with 30 mL 0.33% Ropivacaine"
2457646|NCT03189290|Placebo Comparator|placebo|"Sham Comparator: saline group~- Before general anaesthesia, ultrasound guided Sham Quadratus Lumborum Block (QLB) will be performed with 30 mL saline."
2457848|NCT03188419||1|Retrospective chart review of patients with inherited immunodeficiency diseases requiring allogeneic hematopoietic stem cell transplant (allo HSCT)
2457878|NCT03187639|Experimental|FFRct default primary investigation|All patients undergo FFRct as the default test assuming they have no pre-specified contraindications to CT angiography. The result of the FFRct will be conveyed to the supervising physician within 24 hours and will be used to determine the subsequent management plan.
2457883|NCT03187639|Active Comparator|Standard care|All patients will be assessed and managed exactly as they are usually treated by the randomising centre and the RACP using the local algorithms interpreted from the NICE Chest Pain of Recent Onset Guidance.
2457955|NCT03187314|Experimental|Experimental Group|Radiation to 60 Gy, 5 x per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
2457999|NCT03186768|Experimental|Intervention arm|Intervention arm receives a training of trainers on the soap on a rope hall pass intervention.
2458005|NCT03186768|No Intervention|Control arm|Control arm delays the training of trainers on the soap on a rope hall pass intervention until endline hand washing data has been collected.
2458051|NCT03186534|Experimental|2GETHER|2GETHER is an HIV prevention and relationship education program designed for young male couples. 2GETHER consists of 4 sessions (2 group sessions, 2 individualized couple session) administered over the course of 1 month (1 session per week). Group sessions focus on developing skills related to sexual health and relationship functioning, including HIV prevention in couples, communication skills, coping skills, problem-solving and acceptance. Individualized couple sessions focus on implementation of skills specific to the needs of each couple.
2458052|NCT03186534|Active Comparator|Positive Affect Enhancement|The control condition is a positive affect enhancement program for couples. This is an active and attention-matched control condition. Group sessions focus on developing various coping skills that aim to enhance positive emotions in couples, and individualized couple sessions focus on skills implementation.
2458099|NCT03186196|Experimental|Group 1|Diet with 191 mcg/day of Folate
2458107|NCT03186196|Active Comparator|Group 2|Diet containing 90 mcg / day of Folate
2458165|NCT03185975|Placebo Comparator|Control arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
2458167|NCT03185975|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online Motivational interviewing/certified testing and referral (MI/CTR).
3190898|NCT00792740|Experimental|ITF2357|"oral ITF2357 50 mg b.i.d.~matching placebo Two parallel groups (1:1)."
3190899|NCT00792753|Experimental|1. DESyne DES|Test arm: Intervention with DESyne Novolimus-Eluting Coronary Stent DESyne Novolimus Stent System
3190900|NCT00792753|Active Comparator|2. Medtronic Endeavor DES|Control arm: Intervention with Medtronic Endeavor Zotarolimus-Eluting Coronary Stent Medtronic Endeavor Coronary Stent System
3190901|NCT00792753|Experimental|3. DESyne BD DES|Test arm: Intervention with DESyne BD Novolimus-Eluting Coronary Stent DESyne BD Novolimus Stent System
2463071|NCT03152240||Men patients|Men patients
3190902|NCT00792766|Experimental|RAD001|
3190903|NCT00792792||Tissue transfer skin flap|Modulated Imaging Spectroscopy
3190904|NCT00792818|Experimental|curcuma domestica|1,500 mg/day (oral) divided into 3 times for 28 days
3190905|NCT00792818|Active Comparator|Ibuprofen|1,200 mg/day (oral) divided into 3 times for 28 days
3190906|NCT00792831|Experimental|ITF2357|
2457042|NCT03193294|Sham Comparator|Usual care group (coronary function results not disclosed)|Coronary function tests are measured but not disclosed to the attending clinician or the participant. The same coronary function tests are undertaken as in the intervention group. Masking is achieved by obscuring the catheter laboratory monitors from the attending clinician and participant. The effectiveness of masking is prospectively monitored.
2457116|NCT03193034|Experimental|ATTUNE Cementless RP TKA|Subjects will receive a cementless, rotating platform total knee arthroplasty.
2457136|NCT03192631|Experimental|with financial incentive|Patients randomized to this arm will start with receiving the financial incentive. Cross-over after 9 months to treatment as usual.
2457138|NCT03192631|No Intervention|treatment as usual|Patients randomized to this arm will start with receiving treatment as usual, cross-over after 9 months to incentive arm.
2457234|NCT03192358||Amyotrophic Lateral Sclerosis|We will be recruiting individuals with confirmed or probably ALS, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
2457238|NCT03192358||Parkinson's Disease|We will be recruiting individuals with a diagnosis of Parkinson's disease, who experience speech or swallowing problems, to attend one data collection session. All participants will undergo the same protocol, including a Videofluoroscopic Swallowing Examination, and Tongue Strength Measurement.
2457296|NCT03191773|Experimental|Anti-CD19 CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen with Fludarabine and Cyclophosphamide followed by anti-CD19 CAR-transduced T cells.
2457300|NCT03191448|Experimental|Ridge preservation in molar sites|"Patient who will need a single molar site extracted as part of their treatment will be screened and consented for this research study.~Ridge preservation will be performed in single molar extraction site. The site will be grafted with freezed dried bone allograft (FDBA) and covered with a collagen wound dressing (Collaplug). This is already part of clinical standard care using FDA approved products in an FDA approved fashion. The study aims at documenting the clinical outcome of such accepted procedure more precisely and compare it existing data using other materials."
2457364|NCT03191253|Experimental|Intervention|The intervention consists of comprehensive, medically-appropriate food support (meals and groceries), individual nutritional counseling, and group-based nutritional education.
2457365|NCT03191253|No Intervention|Control|The control group will continue to receive their regular Project Open Hand services (standard of care) which includes 1-2 food services/day.
2457388|NCT03190980|Experimental|5% glucose|neonates will receive 2 ml of 5% glucose before heel prick
2457390|NCT03190980|Experimental|30% glucose|neonates will receive 2 ml of 30% glucose before heel prick
2457392|NCT03190980|Placebo Comparator|Placebo|neonates will receive 2 ml of sterile water before heel prick
2457445|NCT03190798|Active Comparator|Canagliflozin Group|Assuming a 25% dropout rate, 16 individuals in the canagliflozin group
2457446|NCT03190798|Placebo Comparator|Placebo Group|Assuming a 25% dropout rate, 11 individuals in the placebo group
2457473|NCT03190382|Experimental|Received Decision Tool|Peripheral artery disease patients that received the decision support tool.
2457575|NCT03190161|Experimental|Schizophrenia Patients|Clinician verification diagnosis of Schizophrenia or Schizoaffective Disorder
2457628|NCT03189394|Experimental|PRIDE|The in-person experimental condition, PRIDE, consists of in-person intervention activities that are scheduled over two Saturdays, back to back, approximately 3 hours each (6 hours total). This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements.
2457631|NCT03189394|Experimental|ePRIDE|ePRIDE is an online adaptation of the experimental condition, PRIDE, and consists of online intervention activities that are scheduled to be completed over two weeks, lasting approximately 6 hours total. This intervention consists of relationship-focused activities for couples to take part in together, focusing on relationship communication, dynamics, and sexual agreements, and is designed for couples to take together sitting side by side.
2457632|NCT03189394|Active Comparator|Men's Health|Men's Health is the active comparator group. Participants in this group go through in-person intervention days, scheduled on Saturdays back to back, but differ from the PRIDE arm because this intervention does not focus on relationship dynamics. Instead, these two Saturday intervention days focus on general men's health, including heart health, cancer, and STDs.
2457658|NCT03189069||Patients prescribed apixaban|
2457661|NCT03189069||Patients prescribed dabigatran|
2457665|NCT03189069||Patients prescribed rivaroxaban|
2457667|NCT03189069||Patients prescribed warfarin|
2457695|NCT03188692|Experimental|BK1310|
2457753|NCT03188575|Experimental|iCBT for Depression and Anxiety|SilverCloud Internet-Delivered Cognitive Behavioural Therapy
2457754|NCT03188575|Active Comparator|Waiting List|Waiting list control
2457788|NCT03188237|Experimental|AfyaJamii facility|Facilities using AfyaJamii
2457793|NCT03188237|No Intervention|Referent facility|Facilities using Focused Antenatal Care Individual Model
2457825|NCT03187938||Pregnant women at 24-28 weeks gestation|Pregnant women, aged 18 and older, who are seen for their prenatal care and who are between 24w0d and 28w6d weeks gestation.Their alkaline phosphatase levels will be tested in this study.
2457945|NCT03187184|Experimental|OneOme RightMed® Test|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
2457996|NCT03186885|Experimental|In-Person Family Intervention|Healthy Frio In-Person Family-focused Intervention; In-person group setting at a community center
2458001|NCT03186885|Experimental|Remote Technology Family Intervention|Healthy Frio Remote Technology Family-focused Intervention; Home-based delivered remotely with technology
2458009|NCT03186885|Active Comparator|Control|Control; Participants will receive standard health education materials, a community resource guide, and encouragement to follow up with their primary care provider for office-based counseling.
2457043|NCT03193580|Experimental|Anodal High Definition tDCS|The intervention will be anodal high definition-tDCS. Anodal HD-tDCS: 30 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 30 second ramp down to 0milliamp. Anode entered over the right primary motor cortex, and four cathodes placed in a ring formation surrounding the anode.
2457050|NCT03193580|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same anodal conventional tDCS protocol as outlined above. This includes the initial stimulation sequence of ramp up of 30 seconds, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist after 120 seconds of stimulation to automatically ramp down to 0milliamp over 30 seconds.
2457114|NCT03192943|Experimental|Dose Escalation|monotherapy and combination therapy
2457179|NCT03192670|Sham Comparator|Sham control group|Sham control group received same procedure without LED-T. Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)
2457180|NCT03192670|Experimental|CA(Carotid artery)-stimulation group|"In CA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2457183|NCT03192670|Experimental|VA(Vertebral artery)-stimulation group|"In VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2457185|NCT03192670|Experimental|CA+VA dual stimulation group|"In CA+VA group, total sessions of the LED-T was done for each groups and assessment of parameters was followed that.~Each group subject underwent LED therapy (30 min) once a day for 20 days, commencing at Baseline screening test.~Device: Low-level light therapy device approved by the ethics committees of Pusan National hospital and conformity MSDS as safe treatment device for brain diseases Parameters: Neuroimaging assessment(fMRI, SPECT), Neuropsychological Behavioral Assessment(SNSB, K-MoCA, Corsiblock test, K-MBI, K-ADL, GDS, EQ-5D)"
2457255|NCT03192098|Experimental|Progressive|Patients will be dilated > 3mm and can be dilated up to 6mm in diameter
2457261|NCT03192098|Active Comparator|Conservative (rule-of-3)|Patients will be dilated according to the rule-of-3 (i.e. dilation of no more than 3mm in diameter)
2457367|NCT03191071|Experimental|UltraPro|"General practitioners randomly assigned to the UltraPro arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the UltraPro algorithm.~The UltraPro algorithm combines the result of a procalcitonin point-of-care test with lung ultrasound result to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
2457368|NCT03191071|Experimental|Procalcitonin|"General practitioners randomly assigned to the procalcitonin arm will be responsible to recruit patients fulfilling the inclusion criteria and manage them using the procalcitonin algorithm.~The procalcitonin point-of-care test will be performed, as described above, to decide on antibiotic prescription. Blood sampling will be performed to identify potential novel biomarkers. Naso-pharyngeal swabs as well as sputum culture will allow for microbiologic identification of aetiological agents."
2457370|NCT03191071|Active Comparator|Usual Care|"General practitioners randomly assigned to the usual care arm will be responsible to recruit patients fulfilling the inclusion criteria and will manage and treat these patients as they usually do. Only general practitioners who do not use procalcitonin and lung ultrasonography routinely will be included in the usual care arm.~Naso-pharyngeal swabs as well as sputum culture will be performed to allow for microbiologic identification of aetiological agents."
3155320|NCT00318006|Experimental|Irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
2457572|NCT03189927|Experimental|BD-Covered stent|Device: BD-Covered stent for refractory benign esophageal strictures with of without fistulae
2457617|NCT03189407|Other|Moringa oleifera tea in T2DM patients|The study was a pre/post design for type 2 diabetes mellitus patients on metformin in which each patient acted as his/her control. Intervention of twice daily pre-packed 400g dried Moringa oleifera leaves to be prepared as tea by the patients was done. Evaluation of the effect of the tea on metformin steady state concentrations and blood glucose measurements were done.
2457641|NCT03189238|Placebo Comparator|Placebo|
2457643|NCT03189238|Active Comparator|PRP|
3155321|NCT00318019|Experimental|OPC Factor(TM)|
3155322|NCT00318019|Placebo Comparator|Placebo|
2458036|NCT03186625|Experimental|Compound Panax Notoginseng Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
2458043|NCT03186625|Placebo Comparator|Placebo Granule|On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
3155323|NCT00318032|Other|Intensive Treatment|Frequent specialised diabetes clinician contact. DESMOND self-management programme
3155324|NCT00318071|Experimental|Treatment|Treatment arm patients had at least one Merci Retriever deployed
3155325|NCT00318097||MAS patients|patient with clinical diagnosis of MAS
3155326|NCT00318097||controls|age matched, tanner stage matched controls
3155327|NCT00318110|Experimental|MUD treatment|NST using MUD for metastatic renal cell carcinoma
3155328|NCT00318123|Experimental|A|Abacavir 600mg + lamivudine 300mg in on table QD + efavirenz 600mg QD
3155329|NCT00318123|Experimental|B|Abacavir 600mg + lamivudine 300mg in ine tablet QD * lopinavir/ritonavir 400/100 mg BID
2457045|NCT03193359|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections to head/neck areas at Day 0 and Week 12.
2457109|NCT03193086||Alemtuzumab treated MS patients|Those with Multiple Sclerosis that have commenced therapy with alemtuzumab (60 mg infusion over the course of 5 days) and completed treatment with alemtuzumab (additional 36 mg infusion during the course of 3 days, 12 months later).
2457154|NCT03192683|Active Comparator|Regular sling|
2457166|NCT03192683|Experimental|Cast-sling|
2457221|NCT03192332|Experimental|Direct mechanical thrombectomy|Treatment with direct mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
2457227|NCT03192332|Active Comparator|Combined intravenous thrombolysis and mechanical thrombectomy|Treatment with intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA) followed by mechanical thrombectomy with a commercially available stent-retriever revascularization device of the Solitaire™ type.
2457313|NCT03191409||Control Group|Health adults with no evidence of brain lesions on conventional magnetic resonance imaging(MRI) and no neural developmental disorders.
2457317|NCT03191409||Patients Group|ESRD patients pre-hemodialysis will be collected.The following exclusion criteria were applied in this study: (a)history of drug or alcohol abuse, (b) brain lesions such as a tumor or stroke assessed on the basis of medical history, (c) history of or current psychiatric disorders, and (d) head motion more than 1.0 mm or 1.0°during magnetic resonance imaging. All patients completed laboratory tests to evaluate renal function,serum creatinine, and urea levels within the 12 hours before magnetic resonance imaging.
2457358|NCT03191240|Experimental|Vasopressins|Additional vasopressin 40 IU intravenous injection for 2 times
2457359|NCT03191240|Placebo Comparator|Normal saline|Additional normal saline intravenous injection for 2 times
2457412|NCT03191006|Active Comparator|study group: MEI BIN insoles|Participants in the study group will be prescribed with a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
2457414|NCT03191006|No Intervention|control group: without MEI BIN insoles|Participants in this control group will not receive a pair of customized insoles (MEI BIN) to keep the subtalar joint in neutral position, for 12 weeks.
2457503|NCT03190655|Experimental|Aluminaid|Treatment group: Aluminaid wound dressing
2457505|NCT03190655|Active Comparator|Hydrogel|Hydrogel wound dressing (Trademark: Burnshield)
2457551|NCT03190044|Experimental|Migraineurs (verum)|One pill per day of PACR: magnesium 281,25 mg; partenium 150 mg (partenolides 1200mcg); andrographis 100 mg (andrographolides 10 mg); co-enzyme Q10 20 mg; riboflavin 4,8 mg.
2457553|NCT03190044|Placebo Comparator|Migranineurs (placebo)|One pill per day of placebo: Cellulose
3190907|NCT00792844|Experimental|Bio-K capsule|1 capsule of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for duration of antibiotic therapy and 7 days after or until discharge, whichever comes first
2457670|NCT03189004|Active Comparator|Identification and registration of pregnant women and servic|Pregnant women will receive auto reminder through their mobile for ANC visit prior to their scheduled date for each visit via voice message followed by text message. The schedule visit date will be calculated by the system automatically from the LMP. The reminder will include the date, time, available facilities and services for ANC, and will be sent to the women several times to ensure their ANC visits. The system will also send auto reminder through text message to the concerned service provider to check whether the pregnant woman has received ANC or not. The service provider will provide and update the ANC services and status of the particular pregnant woman. Apart from ANC reminders, the pregnant women will also receive voice message on healthcare during pregnancy, danger signs and birth preparedness.From the LMP, the expected date of delivery (EDD) will be calculated by the system and reminder will be sent to the pregnant women automatically.
2457673|NCT03189004|Active Comparator|Birth notification|The pregnant women will be encouraged and trained to notify immediately after the delivery through SMS by themselves or by anyone on behalf of the delivered women. After receiving birth notification, system will automatically update the particulars of newborns including date of birth, PNC schedule, EPI vaccination due dates for the newborn and location of service centre. The system will also send auto reminder to the mothers with a specific time schedule for PNC visit, newborn care visit and schedule of receiving vaccines for the newborn.
2457676|NCT03189004|Active Comparator|Childhood vaccination services under EPI|After the outcome of the delivery of the registered pregnant women, the system will receive the birth notification as mentioned in the birth notification process. Mothers/caregivers of the newborn will receive auto voice/text messages one day prior to their visit to the vaccination centres. A second reminder will be sent to the parents of all the targeted children through their own phones or their family's numbers collected earlier on the vaccination day at the beginning of the vaccination session for bringing their children for vaccination. A third reminder will be sent to the mothers/caregivers of the children who were not vaccinated after receiving the second reminder as scheduled on that day. The system will also provide auto reminder to the concerned service provider including EPI session wise list of targeted children. The service providers will update the status of vaccination of session using their Smartphone
2457677|NCT03189004|Active Comparator|Newly married couple identification|The Smartphones will contain specific software for newly married couple registration where some necessary information (names of newly married couple, age, address, LMP, current contraceptive use, future fertility plan and mobile phone number) can be updated and sent to the server. A unique ID number will be automatically created. This unique ID will ensure her to get necessary family planning services within the study area. Based on the information gathered through couple registration process, the system will automatically generate the most suitable family planning options for a couple and send the information to the concerned service providers. The service provider will motivate the client for the most suitable FP method option generated by the system and after taking the consent they provide the method accordingly.
2457711|NCT03188887|Active Comparator|CONTROL|Treatment with Renin Angiotensin system (RAS) blockade.
2457716|NCT03188887|Experimental|EXPERIMENTAL|Corticotherapy + RAS blockade treatment. Drug injection (intravenous) + tablets
2457784|NCT03188432|Experimental|Treatment - Carboplatin, CRS, HIPEC|Beginning 4-8 weeks after completion of chemotherapy, patients undergo CRS. Patients then receive carboplatin IP over 90 minutes immediately following CRS.
2457047|NCT03193255|Active Comparator|Daily rubbing and weekly protein removal|Daily lens disinfection with OPHTECS cleadew GP after daily lipid cleaner followed by weekly protein removal treatment
2457140|NCT03192722|Experimental|Immediate exposure to near vision glasses with filters|Participants immediately provided with near vision glasses with colored filters
2457155|NCT03192722|Other|Delayed exposure to near vision glasses with filters|Participants provided with near vision glasses with colored filters after 8 weeks of wearing clear near vision glasses
2457165|NCT03192722|Other|Immediate exposure to LuxIQ/2|Participants are examined with LuxIQ/2 to determine preferred lighting as determined by device followed by examination with OttLite Cobra
2457171|NCT03192722|Other|Immediate exposure to OttLite Cobra|Participants are examined with OttLite Cobra to determine preferred lighting followed by LuxIQ/2
3155330|NCT00318188|Experimental|Intervention group|The patients in this group will do a personalized standardized rehabilitation program on the quality of life.
2457259|NCT03191955||Cancer|Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery
2457263|NCT03191955||Non-cancer|Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions
2457320|NCT03191669||MS patients|Single group of patients with MS attending an outpatient MS clinic or hospitalization
2457369|NCT03191162|Active Comparator|B300/60|Benznidazole 300mg/day p.o. divided in two doses for 60 days
2457371|NCT03191162|Experimental|B150/60|Benznidazole 150mg/day p.o. divided in two doses for 60 days
2457372|NCT03191162|Experimental|B400/15|Benznidazole 400mg/day p.o. divided in two doses for 15 days
2457422|NCT03190902|Experimental|specific computer training (ST) - POMS|
2457425|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - POMS|
2457429|NCT03190902|Experimental|specific computer training (ST) - ADHD|
2457434|NCT03190902|Active Comparator|nonspecific computer training (n-ST) - ADHD|
2457537|NCT03190265|Experimental|CY, Nivolumab, Ipilimumab, GVAX, CRS-207|
2457539|NCT03190265|Experimental|Nivolumab, Ipilimumab, CRS-207|
2457576|NCT03189615|Experimental|Patients with mild hepatic impairment (Group1)|
2457577|NCT03189615|Experimental|Patients with moderate hepatic impairment (Group 2)|
2457579|NCT03189615|Experimental|Healthy subjects (Group 3)|
2457642|NCT03189368||Heart failure patients eligible for CRT|"Adult, consenting patients with any cardiomyopathy type and an existing I/IIa indication for a CRT-D device will receive a device with multi-site pacing capability. Initially, for 6 months, optimal, conventional, resynchronization therapy will be delivered. Following this, all patients will crossover to optimized multi-site pacing, and receive this therapy for 6 more months. Optimization of therapy will be determined based on maximization of cardiac output, i.e. maximization of left ventricular outflow tract velocity-time integral.~Baseline measurements of serum creatinine and ventriculoarterial coupling will also be acquired."
2457692|NCT03188939|Active Comparator|G s|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction, local anesthetic (30 ml bupivacaine) is injected at the point where the subclavian artery meets the first rib
2457693|NCT03188939|Active Comparator|G ic|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
2457694|NCT03188939|Active Comparator|G d|20 guage 10cm block needle inserted in the supraclavicular fossa guided by portable ultrasound machine using in plane method and lateral to medial direction,half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
2457779|NCT03188302|Other|Specimen collection|Collection of stool samples
2457821|NCT03188016|Experimental|Intensive Interaction with music|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker plus music improvised by a music therapist with the aim of enhancing child - support worker interaction
2457822|NCT03188016|Active Comparator|Standard Intensive Interaction|Weekly Intensive Interaction (Nind & Hewett) from a trained support worker
2457860|NCT03187743|Experimental|Pharmacokinetics/dynamics|Blood samples at 3 visits
3190908|NCT00792844|Active Comparator|Bio-K liquid|98 g of lactobacillus acidophilus and lactobacillus casei (50 billion live bacteria) daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever comes first
2457942|NCT03186989|Experimental|IONIS-MAPTRx|IONIS MAPTRx (Study Drug)
2457947|NCT03186989|Placebo Comparator|Placebo|Artificial CSF
2458025|NCT03186664|Experimental|A: Sativex+Lokomat Training|Patients Sativex responders will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
2458041|NCT03186664|Active Comparator|B: other antispastic+Lokomat Training|Patients treated with others antispastic drugs will perform a neurorobotic-assisted gait training (RAGT, each session will last at least 45', 3 times per week, for a total amount of 20 treatment's sessions).
2458071|NCT03186274|No Intervention|Control Group|Those in the control group (CG) will write a pre and post-study reflection essay discussing their experiences with end of life discussions.
2458072|NCT03186274|Experimental|Facilitated Group Session|Participants in Facilitated Group Session (previously called Intervention Group 1) will watch a pre-recorded video describing the SPIKES model and then take part of a facilitated guided group session reviewing the model and group interview of standardized/simulated patient encounter.
2458073|NCT03186274|Experimental|CELA Session|Participants in the CELA Session (previously called Intervention Group 2) will watch a pre-recorded video describing the SPIKES model and then participate in an individualized standardized/simulated patient scenario that will be filmed at the Center for Experiential Learning and Assessment (CELA).
2458140|NCT03186118|Experimental|Cohort A|Participants will receive CD19-targeting CAR T cells. Participants who have a total CD19 antigen load in bone marrow of <15% will be assigned to Cohort A, to receive up to 6 T-APC treatments.
2458404|NCT03184766|Experimental|4|Treatment Order: Comparator 1, Comparator 2, Test
2457048|NCT03193346|Experimental|BOTOX®|BOTOX® (botulinum toxin Type A) 155U to 195U intramuscular (IM) injections in head/neck areas at Day 0 and Week 12.
2457055|NCT03193346|Placebo Comparator|Placebo|Placebo matching BOTOX® [Sodium chloride 0.9 milligrams (mg)] IM injections in head/neck areas at Day 0 and Week 12.
2457108|NCT03192995|Active Comparator|Experimental|lorcaserin, extended release
2457112|NCT03192995|Placebo Comparator|Control|Placebo
2457146|NCT03192605|Experimental|Blueberry|150 grams wild blueberries
2457157|NCT03192605|Placebo Comparator|Placebo|Placebo control
3190909|NCT00792844|No Intervention|no Bio-K|No lactobacillus product - standard infection control procedures (i.e. handwashing, etc.)
2457314|NCT03191500|Experimental|steerable catheter|to study the safety and efficacy of a steerable catheter in the treatment of peripheral vascular disease
2457460|NCT03190824|Experimental|OBP-301|Eligible patients with unresectable Stage III and IV melanoma will receive up to 13 treatments of OBP 301 at a concentration of 1 × 1012 virus particles (VP)/mL for 24 weeks.
2457514|NCT03190148|Other|Pregnant women with RYGB-operation|Pregnant women with a history of RYGB-Operation were investigated.
2457515|NCT03190148|Other|Normal weight pregnant women|Normal weight pregnant women were investigated.
2457516|NCT03190148|Other|Obese Pregnant women|Obese pregnant women were investigated.
2457573|NCT03189901|No Intervention|Regular Management|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline.
2457574|NCT03189901|Experimental|Regular management+Levosimendan|Patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level who treated by regular strategy in guideline and levosimendan.
2457675|NCT03189342|Experimental|Single Task Training|Performed balance and gait exercises
2457678|NCT03189342|Experimental|Dual task training|Performed cognitive activity simultaneously with balance and gait exercises
2457680|NCT03189342|Experimental|Exercise-Cognitive Activity Combined Training|Performed cognitive, balance and gait activity training asynchronously at different times during the same day
2457712|NCT03188653|Active Comparator|CeraVe® Eczema Soothing Body Wash|One of the 7 forearm locations will be selected to receive CeraVe® Eczema Soothing Body Wash one time only.
2457717|NCT03188653|Active Comparator|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 forearm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash one time only.
2457722|NCT03188653|Active Comparator|Dove® Sensitive Skin Body Wash|One of the 7 forearm locations will be selected to receive Dove® Sensitive Skin Body Wash one time only.
2457725|NCT03188653|Active Comparator|Eucerin® Skin Calming Body Wash|One of the 7 forearm locations will be selected to receive Eucerin® Skin Calming Body Wash one time only.
2457730|NCT03188653|Active Comparator|Aveeno® Skin Relief Body Wash|One of the 7 forearm locations will be selected to receive Aveeno® Skin Relief Body Wash one time only.
2457733|NCT03188653|Active Comparator|MooGoo® Milk Wash|One of the 7 forearm locations will be selected to receive MooGoo® Milk Wash one time only.
2457734|NCT03188653|Active Comparator|Free & Clear Liquid Cleanser|One of the 7 forearm locations will be selected to receive Free & Clear Liquid Cleanser
2457780|NCT03188276|Active Comparator|CHC patients|32 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir or Daclatasvir-Sofosbuvir.
2457782|NCT03188276|No Intervention|Healthy controls|20 Healthy controls without any treatment
2457836|NCT03187977|Active Comparator|Cognitive Training|Participants will participate in computer-based cognitive training at the end of therapy.
2457840|NCT03187977|No Intervention|Standard-of-Care|At the end of therapy, participants will participate in the current standard-of-care which does not include computer-based cognitive training.
2457857|NCT03187704|Active Comparator|filtration|Air filtration in homes
2457858|NCT03187704|Sham Comparator|no filtration|Sham air filtration
2457917|NCT03187444|Experimental|Patients with chronic inflammatory rheumatism|All patients over 18 years, with rheumatoid arthritis treated for the first time with conventional anti-TNF therapy, Abatacept, Tocilizumab, Rituximab or patients with spondyloarthritis treated for the first time with NSAIDs that may be associated with conventional background treatments for peripheral or biological (anti-TNF, Usketinumab) may be included.
2457951|NCT03187041|Experimental|Skin surface pressures under tourniquets and sensation|"Phase 1: Each phlebotomist will apply the tourniquet 10 separate times to the right arm of each subject. The tourniquet will remain on the arm for approximately ten seconds, to be able to allot enough time to collect an accurate pressure measurement. All 10 tourniquet skin pressure measurements will take place on the same day for a subject.~Phase 2: 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 1 hour. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use."
2458032|NCT03186807||low risk pregnancy|"Inclusion criteria - Women aged 18-45 years old ,Pregnant women between 14+0 and 34+0 weeks.speaking Hebrew language and eligible for obtaining informed consent.~Gestation who had a singleton fetus in cephalic presentation, with well documented gestational age by first trimester US scan CRL.~Biometric measurement within 10th to 90th percentile.and low risk for fetal brain developmental disorders."
2458060|NCT03186391||Patients with suspected PAD|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
2458119|NCT03186170|Experimental|SSA|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSA versus traditional technique of swin up) as well as embryo development.~In this arm, the sperm selection for IVF will be performed by the new proposed technique of Sperm Selection Assay which consist to expose spermatozoa a progesterone quemoatractant Sperm selection via SSA technique"
2458122|NCT03186365|Active Comparator|12-week arm|patients receiving 12 weeks of elbasvir 50 mg/grazoprevir 100 mg (Zepatier Oral Product) daily
2458123|NCT03186443|Active Comparator|pregabalin|experiment group: pregabalin 300mg,q12h for 6 months
2458127|NCT03186443|Experimental|gabapentin|compared to pregabalin effect on herpetic neuralgia
2458191|NCT03185767|Other|SLE group|
2457049|NCT03193320|Experimental|PVI-guided group protocol|No fluid loading at induction. Baseline fluid infusion - 2 ml/kg/h. PVI will be monitored continuously since anesthesia induction. Fluid challenges - if PVI rises >=13 (or MAP falls < 65 mmHg), a fluid challenge will be administered.
2457051|NCT03193307|Experimental|All subjects|Microgynon alone (run in period) then Microgynon & BI 409306 treatment period
3190910|NCT00792857|Experimental|CTAP201 Injection at dose a|CTAP201 at dose a
3190911|NCT00792857|Experimental|CTAP201 Injection|CTAP201 at dose b or dose c
3190912|NCT00792857|Active Comparator|Doxercalciferol at dose a|Active at dose a
3190913|NCT00792857|Active Comparator|Doxercalciferol|Active at dose b or dose c
3190914|NCT00792870|Experimental|SURI Enhanced|
2457202|NCT03192111|Experimental|Mild Renal Impairment|Subjects with mild renal impairment
2457203|NCT03192111|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment
2457204|NCT03192111|Experimental|Severe Renal Impairment|Subjects with severe renal impairment
2457205|NCT03192111|Experimental|Healthy Subjects|Healthy volunteers mean-matched to the mild, moderate, and severe renal impairment patients
2457232|NCT03192046|Experimental|Carbon Fiber Ankle Foot Orthosis (AFO)|For the bracing group, the participants will wear custom fabricated carbon fiber braces in addition to participating in a daily walking program and 7 visits of PT.
2457236|NCT03192046|Active Comparator|Control Group, Walking Program Only|The participants in this group will be prescribed a daily home walking walking program and 7 visits of PT.
2457262|NCT03191981|Experimental|Treatment|Cyclophosphamide and lenalidomide combined with fixed dose pembrolizumab
3190915|NCT00792870|Active Comparator|SURI Standard|
2457324|NCT03191487|Experimental|ChimioPal|Systematic collection of clinical and laboratory toxicities.
2457328|NCT03191487|Active Comparator|Standard|The usual management and logistic pathways will be respected.
2457394|NCT03191123|Active Comparator|Hepatic resection|Indications for Hepatic resection were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
2457396|NCT03191123|Experimental|Transarterial Chemoembolization(TACE)|Transarterial Chemoembolization is performed in less than one week after clinical diagnosis.
2457444|NCT03190720|Experimental|Mobile Community First|Participants will be registered to a mobile community at first. After 6 weeks, They will leave the mobile community.
2457447|NCT03190681|Experimental|methylphenidate|
2457448|NCT03190720|Experimental|Mobile Community Later|Participants will not be registered to a mobile community at first. After 6 weeks, They will be registered to the mobile community.
2457449|NCT03190681|Placebo Comparator|inactive pill|
2457469|NCT03190434||amniotic fluid|amniotic fluid identification by AL-SENSE product
2457502|NCT03190447|Active Comparator|Conventional dressing|The conventional dressing (sterile gauzes) will be applied
2457504|NCT03190447|Experimental|Aquacel Surgical®|Postoperative sterile dressing composed by non-woven inner pad (in contact with wound) Technology Hydrofiber® formed from sodium carboxymethylcellulose
2457507|NCT03190447|Experimental|Mepilex Border post-op®|Flexible absorbent all-in-one post-op dressing, super-absorbent fibres for high and fast absorption with optimised retention.
2457510|NCT03190447|Experimental|Opsite post-op visible®|Adhesive dressing with absorbent foam in the form of a grid to visualize the wound without lifting the dressing
2457511|NCT03190447|Experimental|Urgotul ABSORB border silicona®|A soft-adherent TLC (Technology Lipido-Colloid) layer (polymers and hydrocolloid particles) combined with an absorbent polyurethane foam pad and a highly absorbent layer. A vapour permeable waterproof outer film with silicone adhesive on the edges.
2457526|NCT03189966|Experimental|Group T|Patients in transversalis fascia plane block group(Group T) will receive ultrasound-guided transversalis fascia plane block using0.3% ropivacaine(0.8 ml/kg) after general anesthesia
2457528|NCT03189966|Experimental|Group Q|Patients in quadratus lumborum block group（Group Q） will receive ultrasound-guided quadratus lumborum block using0.3%ropivacaine(0.8 ml/kg).after general anesthesia.
2457529|NCT03189966|No Intervention|Group C|Patients in the third group as control (Group C)receive no nerve block.Patients will be extubated based on clinical criteria.
2457543|NCT03190239|Experimental|Apatinib|Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd
2457590|NCT03189680|Experimental|Exercise therapy|Parkinson's disease group that receive 3 weeks of intensive exercise therapy in a rehabilitation center.
2457596|NCT03189680|No Intervention|Control|Parkinson's disease control group that will not receive exercise treatment.
2457604|NCT03189680|No Intervention|Healthy|A healthy group whose results will be compared with Parkinson's disease groups.
2457618|NCT03189732|Experimental|Metformin oral +exercise|Metformin, one dose 2000mg, 2.5h before the start of 60 min physical exercise
2457620|NCT03189732|Active Comparator|Metformin local in AT +exercise|Metformin perfused into microdialysis probe inserted in adipose tissue, 0.3ug/min 1.5h before the exercise and during 60min physical exercise
2457621|NCT03189732|Active Comparator|No metformin + exercise|60min physical exercise without pretreatment of metformin
2457647|NCT03189212|Active Comparator|Usual Care Visit|
2457649|NCT03189082|Experimental|Intervention group|
2457650|NCT03189212|Experimental|Telemedicine Visit|
2457702|NCT03188809|Active Comparator|femoral nerve block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
2457707|NCT03188809|Active Comparator|adductor canal block|Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
2457781|NCT03188159|Experimental|IV Vinorelbine|IV Vinorelbine 25mg/m2
3190916|NCT00792883||patients ARDS|142 Patients in respiratory failure with a diagnosis of ARDS hospitalized at the ICU.
3190917|NCT00792883||Patients non ARDS|432 patients in respiratory failure from other causes (ARDS being formally excluded), hospitalized at the same ICU.
3190918|NCT00792883||Healthy controls|626 healthy patients undergoing elective surgery at the Pediatric Surgery Department or recruited from the pediatric ambulatory.
3190919|NCT00792896|Experimental|1|Family conference + education materials
3190920|NCT00792896|No Intervention|2|education materials
2457054|NCT03193450|Experimental|Re-education group|Patients in this arm will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
2457059|NCT03193450|Active Comparator|Non re-education group|Patients in this arm only received an instruction card about the drug administration at the clinic by doctors but no re-education by telephone during treatment
2457257|NCT03191929|Experimental|HIT Intervention Arm|The Health Information Technology Intervention Study Arm consisted of: 1) web-based tutorial on delivering trauma-informed care, 2) Multi-media mental health risk assessment, 3) Immediate provider notification, which included flagging patients' scores that met criteria for symptoms of depression and/or PTSD, 4) subsequent integration into the patient electronic medical record, and 5) Clinical decision support adapted from the Harvard Program in Refugee Trauma.
2457260|NCT03191929|Active Comparator|Minimal Intervention Control Arm|The Minimal Intervention Control Arm consisted of: 1) web-based tutorial on delivering culturally competent health care in general, 2) Multi-media mental health risk assessment, 3) Provider notification only in the event that patients' scores evidenced symptoms of being at risk to harm either themselves or others.
2457386|NCT03191214||No Warming|Patients undergoing brief surgical procedures of >15 minutes for whom no warming devices are being employed.
2457387|NCT03191214||Forced Air Warming|Patients undergoing surgical procedures in which forced air warming, is being used
2457450|NCT03190811|Experimental|Anti-PD-1 plus DC-CIK|
2457453|NCT03190811|Active Comparator|Anti-PD-1 alone|
2457464|NCT03190395|Experimental|CPVI Group|CPVI Group: Pure Circumferential pulmonary vein isolation(CPVI)
2457465|NCT03190395|Active Comparator|CPVI+LARA Group|CPVI+LARA Group: Circumferential pulmonary vein isolation combine with Left Atrium Roofline Ablation
2457540|NCT03190252||Trimix|Exposure to ambient pressure of maximum 11 ATA breathing Trimix. Exposure to oxygen partial pressure of 130 kPa breathing Trimix.
2457615|NCT03189758|Experimental|Intervention|Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
3155331|NCT00318188|No Intervention|Control group|Habitual care
2457700|NCT03188835|Other|Isocaloric Diet|Two weeks of isocaloric diet
2457701|NCT03188835|Other|Fructose diet|Two weeks of hypercaloric diet supplemented with fructose
2457705|NCT03188835|Other|Glucose diet|Two weeks of hypercaloric diet supplemented with glucose
2457789|NCT03188211|Other|Intervention|Clinicians allocated to intervention arm will receive an e-learning educational program based on simulation-based technologies (Dr Sim). Dr Sim provides a powerful editing system that allows to create clinical cases according to the educational need and purposes. It will be distributed on an e-learning platform, allowing the user to act in a highly interactive learning environment. Management of the virtual patients is carried out interactively and each diagnostic and or therapeutic choice will be supported by any scientific data, guidelines recommendations, drug descriptions and literature references useful to address the best choice for that specific patient as it should be in real practice.
2457792|NCT03188211|Other|Control|Clinicians allocated to control arm will not receive the e-learning educational program based on simulation-based technologies (Dr Sim).
2457862|NCT03187808|Experimental|Group A|Group A is a group of performing single thoracic manipulation at zygapophyseal joint of T6-T7.
2457865|NCT03187808|Experimental|Group B|Group B is a group of performing single thoracic manipulation combined with special massage technique (RT technique).
2457905|NCT03187405|No Intervention|EVD alone|In the EVD alone group group, the EVD will be managed as usual - i.e. will only be used to drain CSF.
2457906|NCT03187405|Experimental|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
2457956|NCT03187171|Active Comparator|Allograft Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft.
2457964|NCT03187171|Active Comparator|Cohere PEEK Fusion Group|The anterior approach to the cervical spine for discectomy and fusion by the insertion of a Cohere porous PEEK fusion device.
2458007|NCT03186755|Experimental|Hylo-Dual|Hyaluronic acid 0.05% & Ectoine 2.0% (Hylo-Dual) 1 drop in both eyes 3 times/day for 8 weeks
2458013|NCT03186755|Active Comparator|Patanol|Olopatadine hydrochloride ophthalmic solution 0.1% (Olopatadine) 1 drop in both eyes 2 times/day for 8 weeks
2458077|NCT03186430|Experimental|Comprehensive Vaccine Promotion Package|The pediatric practices randomized to this arm will receive the comprehensive adolescent vaccine promotion package. Practice physicians and staff will be familiarized with each component, and practices will be instructed to implement each vaccine-promotion component to the best of their ability.
2458079|NCT03186430|No Intervention|Standard Vaccination Promotion|The pediatric practices randomized to the control arm will not receive the comprehensive vaccine promotion package and will instead be instructed to continue offering their standard adolescent vaccination promotion practices to adolescent patients.
2458110|NCT03186066|Active Comparator|Standard Therapy|Buried Bumper Syndrome is treated by endoscopically dissecting the overgrown tissue with an endoscopic submucosal dissection knife.
2458118|NCT03186066|Experimental|Flamingo Device|The Flamingo device is used for treatment of Buried Bumper Syndrome.
2458159|NCT03185949|Sham Comparator|Sedation and subcutaneous lidocaine|Lidocaine injected at the femoral artery site. This patients will undergo behavioral therapy for 6 months and will crossover and will receive bariatric embolization.
2458161|NCT03185949|Experimental|interventional: bariatric embolization|• In patients randomized to intervention bariatric embolization will be performed using Endobar Infusion Catheter System. After procedure patients will undergo behavioral therapy
2458292|NCT03185325||Non hodgkin lymphoma patients|bone marrow puncture and venous blood samples
2458297|NCT03185325||healthy voulnteers|venous blood samples
2458437|NCT03183947|Experimental|fMRI Neurofeedback regulation of left PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
2458443|NCT03183947|Experimental|fMRI Neurofeedback of right PFC|Study related procedures included: PANAS, BDI-II, ERQ (questionnaires or evaluations)
3155332|NCT00318201|Experimental|1|Altered efficacy for drug to drug interaction of diltiazam with erythromycin
3155333|NCT00318214|Experimental|1|
3155334|NCT00318214|Placebo Comparator|2|
2457056|NCT03193463|Experimental|Predominantly enhancing mass with volume of 8 cc or less|Only 1 Cleveland Multiport Catheter (CMC) will be placed and CED will be performed intra-operatively only in a magnetic resonance imaging (MRI) equipped Operating Room. Topotecan infusion will be performed over a 4-hour period, with the goal of complete tumor coverage. The initial rate will be 1.20 ml/hour and infusion will be monitored by intermittent MRI imaging. The rate may be adjusted upwards during the infusion, in the event of incomplete tumor coverage, or downwards, if new mass effect is apparent. Following completion of the 4-hour infusion, the CMC will be removed. The initial rate for each subsequent patient may be adjusted upwards in increments of up to 1.20 ml/hour based upon the tumor coverage and safety characteristics of the previously treated patients.
2457060|NCT03193463|Experimental|Predominantly enhancing mass with volume of > 8 cc|2 Cleveland Multiport Catheter (CMCs) will be placed and the total infusion rate of Topotecan per CMC to be used for the first 24 hours for the first patient will be 0.834 ml/hour (3.48 microliters/minute/microcatheter). The rate used for the second 24 hours of the infusion will be 1.668 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.834 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the enhancing tumor by the infused Gadopentetic acid (Gd-DTPA), or 2) rate-limiting toxicity.
2457063|NCT03193463|Experimental|Predominantly non-enhancing mass|The total infusion rate of Topotecan per Cleveland Multiport Catheter (CMC) to be used for the first 24 hours for the first patient will be 0.29 ml/hour. The rate used for the second 24 hours of the infusion will be 0.58 ml/hour. If the first patient does not experience rate-limiting toxicity, then the patient #2's initial infusion rate will start at the highest tolerated rate for patient #1, and the second 24-hour rate for that patient will be increased by 0.29 ml/hour. Each subsequent patient will undergo rate escalation in a similar manner until we observe either: 1) complete coverage of the non-enhancing tumor by the infused Gd-DTPA, or 2) rate-limiting toxicity.
2457095|NCT03192878||Naive patients|Patients with corticosteroid- and/or traditional immunosuppressive drug-resistant Takayasu's arteritis with indication of initiating therapy with anti-TNF-alpha
2457097|NCT03192878||Switch patients|Patients with Takayasu's arteritis already in therapy with infliximab originator (Remicade) in whom the originator therapy will be replaced with infliximab biosimilar therapy
3155335|NCT00318227|Active Comparator|Liberal Red cell transfusion arm|Transfusion if Hgb <100g/L
3155336|NCT00318227|Active Comparator|Restrictive Red Cell transfusion|Transfusion if Hgb <70g/L
2457316|NCT03191513|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
2457319|NCT03191513|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
2457325|NCT03191513|Active Comparator|Control|Rapeseed oil. 50g fat.
2457373|NCT03191110||Colorectal cancer patients|
2457439|NCT03190889|No Intervention|STAN|Patients in the STAN group will participate in twelve sessions of supervised physical therapy over a six week period. Patients will participate in agility and plyometric drills, and continue strength exercises from the previous treatment phase. The clinic program will be performed in conjunction with a home running program. Patients in this group will not receive feedback from the therapist regarding movement quality during activities.
2457440|NCT03190889|Other|HOME|HOME Program is distinguished by patients participating in a home only intervention that consists of running and strengthening exercises performed twice a week for six weeks. No plyometric or agility drills are performed in this study arm. This represents the minimal intervention to prepare for a return to sports. No neuromuscular training or movement training beyond the sagittal plane will be performed.
2457441|NCT03190889|Experimental|TNMT|Patients who are enrolled in the TNMT group will participate in 12 sessions of supervised outpatient physical therapy over a six week period. The TNMT protocol is distinguished by performance of exercises designed to enhance core and hip strength, performance of neuromuscular training exercise that are designed to correct movement flaws associated with second ACL injury25, providing verbal and visual feedback and performance of single leg drills on both legs.
2457496|NCT03190473|Experimental|Svelte|
2457500|NCT03190473|Active Comparator|Control|
2457566|NCT03189797|Experimental|study group|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:~In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions."
2457567|NCT03189797|No Intervention|control group|In the Control group participants assigned to the control condition will be advised to maintain their existing lifestyles. For ethical reasons, if the program shows its effectiveness, it will be made available to all groups at the end of the study.
2457603|NCT03189537|Experimental|Ingavirin|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid) capsules, 90 mg once daily for 7 days
2457609|NCT03189537|Placebo Comparator|Placebo|Placebo oral capsule, once daily for 7 days
2457639|NCT03189173|Experimental|All patients|"Patients will receive all four interventions in randomized order.~Note: Data will not be analyzed separately for the 16 cross-over combinations of intervention order:~Interventions: Oral appliance | Oral appliance plus oxygen | Oxygen | No treatment"
2457847|NCT03188146||PBC patients with liver biopsy|Ursodeoxycholic acid will be given compliance to the treatment guideline.
2457915|NCT03187483|Active Comparator|Control|Orthodontic treatment with conventional adhesive-coated brackets
2457962|NCT03187080|Experimental|Group 1 Arm A|Breast reduction with Paravertebral block using local anesthetic.
3155337|NCT00318240|Experimental|1|High Intensity Focused
3155338|NCT00318266||patients with suerficial transitional cell carcinoma|
3155339|NCT00318331|Active Comparator|A|Will receive enteral glutamine
3155340|NCT00318331|No Intervention|B|No enteral glutamine given
3155341|NCT00318383|Experimental|1|200 mcg NicVAX in each of 4 doses
3155342|NCT00318383|Experimental|2|200 mcg NicVAX in each of 5 doses
2457231|NCT03192930||Saturation|Individuals exposed to prolonged hyperbaric exposure
2457235|NCT03192930||Control|Individuals not exposed to prolonged hyperbaric exposure
2457280|NCT03191838|Experimental|Audiovisual|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
2457288|NCT03191838|No Intervention|Controls|The control group will not be given distraction equipment.
3155343|NCT00318383|Experimental|3|400 mcg NicVAX in each of 4 doses
3155344|NCT00318383|Experimental|4|400 mcg NicVAX in each of 5 doses
2457478|NCT03190616|Experimental|drug,apatinib|apatinib 500mg/qd, 28d/cycle
2457586|NCT03189667|Experimental|Drug coated balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with Drug-coated balloon"
2457587|NCT03189667|Active Comparator|Plain balloon angioplasty|"Vessel preparation with Pre dilatation~Vessel treatment with additional Plain balloon angioplasty:"
2457635|NCT03189043|Experimental|Test|Use of antimicrobial surface
2457636|NCT03189043|No Intervention|Control|No antimicrobial surface
3155345|NCT00318383|Placebo Comparator|5|Placebo in 4 or 5 doses
3155346|NCT00318383|Experimental|6|200 mcg NicVAX formulation 2 in each of 5 doses
3155347|NCT00318396|Experimental|Compaction|The bone is pressed very hard together before implantation of femoral component.
3155348|NCT00318396|Active Comparator|Conventional technique|The bone is broached before implantation of femoral component.
2457794|NCT03188367|Active Comparator|1A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457798|NCT03188367|Active Comparator|1B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457799|NCT03188367|Active Comparator|1C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457801|NCT03188367|Placebo Comparator|2C - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
3155349|NCT00318487|Experimental|Bilateral sinus augmentation|
2457833|NCT03188003|Experimental|Mobilization|"This group will undergo 10 Pilates sessions with a focus on lumbo-pelvic mobilization exercises approach.~Intervention administered: Exercise Movement Techniques (Pilates Exercise) based on mobilization"
3155350|NCT00318630|Experimental|Subjects receiving treatment 1|Eligible subjects will receive rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily administered orally for 28 days followed by placebo oral tablet.
3155351|NCT00318630|Experimental|Subjects receiving treatment 2|Eligible subjects will receive placebo oral tablet followed by rosiglitazone immediate release tablet with a dose of 4 milligrams twice daily for 28 days.
3155352|NCT00318695|Experimental|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
3155353|NCT00318695|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
3155354|NCT00318721|Experimental|Intervention|
3155355|NCT00318721|No Intervention|control|
3155356|NCT00318760|Experimental|ARM 1|
3155357|NCT00318760|Placebo Comparator|ARM 2|
3155358|NCT00318799|Experimental|Arm 1|
3155359|NCT00318799|Active Comparator|Arm 2|
3155360|NCT00318838|Placebo Comparator|1|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
3155361|NCT00318838|Experimental|2|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
3155362|NCT00318851|Experimental|Carotid Artery Stenting|
3155363|NCT00318877|Experimental|After school sports|After school team sports
3155364|NCT00318877|Active Comparator|Health and Nutrition Education|Health and Nutrition Education Active Placebo Control
3155365|NCT00318890|Experimental|Docetaxel + cisplatin followed by radiation|Docetaxel with cisplatin is given for three cycles, followed by concomitant therapy with weekly docetaxel for 4 weeks. Radiation therapy is given 5 days each week on Days 64-106 with a concomitant boost in the last 2 weeks of treatment. Amifostine is given as an injection on a daily basis during radiotherapy.
2457066|NCT03193606|Experimental|nano silver fluoride solution|carious dentin to be treated with partial caries excavation with application of nano silver fluoride solution prior to glass ionomer restoration.
2457067|NCT03193606|No Intervention|no nano silver fluoride|carious dentin to be treated with partial caries excavation without application of nano silver fluoride solution restored directly with glass ionomer.
3190921|NCT00792961|Experimental|Endomicroscopy|Endomicroscopy is performed in addition to the patient's indicated robot-assisted prostate surgery
3190922|NCT00792974||COPD by GOLD-criteria III and IV|
2457142|NCT03192423||Expert|The physicians in the Expert-group will perform a LP following local standard procedure protocol.
2457149|NCT03192423||Intermediate|The physicians in the Intermediate-group will perform a LP following local standard procedure protocol.
2457163|NCT03192423||Novice|The physicians in the novice-group will perform a LP following local standard procedure protocol.
2457208|NCT03192280|Experimental|All study participants|"Each subject will receive single topical induction application of Leukotriene B4 (LTB4) on the inner arm.~Images of the treated area will be captured using multiple medical devices."
2457276|NCT03191812|Sham Comparator|Sham Stimulation|The Sham stimulation intervention will consist of one, twenty-minute session of transcranial direct current stimulation (tDCS) that does not target a cortical area but instead, provides just enough current to create tingling sensations across the scalp to mimic the feeling of receiving the real stimulation. The sham stimulation will use the same number and placement of electrodes as the real stimulation but with a much smaller total current intensity of 0.5 milliamps (mA).
2457283|NCT03191812|Experimental|M1 Stimulation|The M1 stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex at a total current intensity of 1.5 mA.
2457290|NCT03191812|Experimental|DLPFC Stimulation|The DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the dorsolateral prefrontal cortex at a total current intensity of 1.5 mA.
2457294|NCT03191812|Experimental|M1+DLPFC Stimulation|The M1+DLPFC stimulation intervention consists of one, twenty-minute session of transcranial direct current stimulation (tDCS) targeting the primary motor cortex and the dorsolateral prefrontal cortex simultaneously at a total current intensity of 3.0 mA.
2457309|NCT03191474|No Intervention|Standard of Care Arm|Participants will receive standard of care HIV risk assessment, PrEP education, and an appointment for a PrEP evaluation visit at an affiliated clinic.
2457312|NCT03191474|Experimental|T-POWr Intervention Arm|Participants will receive the same HIV risk assessment, PrEP education, and appointment for a PrEP evaluation visit as the Control Arm. Participants in the Intervention Arm will also receive a thorough client-centered case management evaluation that will assess needs including access to health insurance, general health care, assessment of current hormone administration, housing, mental health care, domestic violence care, substance use treatment, and other services.
2457377|NCT03191279||First aid correct|Patient has received first aid according to local guidelines for all indicated first aid measures from bystanders on scene of accident when the first ambulance arrives
2457379|NCT03191279||First aid attempted|Bystanders have attempted first aid for indicated first aid measures, but measures have been incorrectly performed according to local guidelines
2457381|NCT03191279||No first aid|Indicated first aid measures have not been carried out when the first ambulance arrives on scene
2457411|NCT03190928||1|Patients with grades 1-2 or 3a follicular lymphoma (FL)
2457491|NCT03190668|Active Comparator|First Regimen Group|The first regimen will consist of a bolus dose of Cefazolin 30mg/kg up to a maximum of 2000mg IV administered prior to surgical incision. The same pre-operative dose of Cefazolin will be repeated every 3 hours until the completion of surgery. Two will paraspinal muscle microdialysis catheters and two subcutaneous microdialysis catheters will be inserted.
2457495|NCT03190668|Active Comparator|Second Regimen Group|The second regimen will consist of an initial bolus dose of 30 mg/kg up to maximum of 2000 mg. Following the initial bolus dose a continuous Cefazolin drip will start until the end of surgery. Cefazolin drip dose will be 10 mg/(kg*h) up to maximum of 667 mg/h.Two microdialysis catheters will be inserted into a paraspinal muscle and two microdialysis catheters will be inserted subcutaneously.
2457518|NCT03189979|Experimental|Club Fit|Intervention includes exposure to physical activity and healthy eating intervention policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
2457556|NCT03189888|Other|apheresis|leukapheresis in ulcerative colitis
2457589|NCT03189693|Experimental|PVB group|Patients will receive two PVB injections at levels T12-L1 and L1-L2 using anesthetic mixture
2457594|NCT03189693|Placebo Comparator|Placebo|Patients will receive two PVB injections containing placebo at levels T12-L1 and L1-L2
2457657|NCT03189147|Experimental|Biceps Tenodesis|Patients in this group will received biceps tenodesis intervention to address their labral lesion
2457660|NCT03189147|Active Comparator|Debridement|Patients in this group will received debridement intervention to address their labral lesion
2457719|NCT03188770||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
2457787|NCT03188107||Risky Infants|Infants that have risk of developing motor impairment, or infants diagnosed as Spina Bifida, Down Syndrome ect.
2457790|NCT03188107||Healthy Infants|Healthy infants that have normal motor development
2457863|NCT03187717||TIVA (Total intravenous anesthesia)|Group TIVA; patients who used intravenous anesthesia procedure
2457866|NCT03187717||IA (Inhalation anesthesia)|Group IA; patients who used inhalation anesthesia procedure
2458192|NCT03185767|Other|control group|
3190923|NCT00793000|Experimental|Cohort 1|
3190924|NCT00793000|Experimental|Cohort 2|
3190925|NCT00793000|Experimental|Cohort 3|
3190926|NCT00793000|Experimental|Cohort 4|
3190927|NCT00793000|Experimental|Cohort 5|
3190928|NCT00793000|Experimental|Cohort 6|
3190929|NCT00793000|Experimental|Cohort 7|
3190930|NCT00793000|Experimental|Cohort 8|Japanese volunteers, low dose previously tested (based on PK)
3190931|NCT00793000|Experimental|Cohort 9|Japanese volunteers, intermediate dose previously tested (based on PK)
3190932|NCT00793000|Experimental|Cohort 10|Japanese volunteers, high dose previously tested (based on safety)
3190933|NCT00793013|Experimental|ARDS Net Low Tidal Volume|
3190934|NCT00793013|Experimental|APRV Ventilation|
2457147|NCT03192579|Experimental|Standard lipid lowering therapy|Start with only rosuvastatin 2.5mg and up to 20mg/day
2457156|NCT03192579|Active Comparator|Intensive lipid lowering therapy|Start EPA and rosuvastatin 10mg/day and up to 20mg/day
2457228|NCT03192267||No treatment|No treatment
2457307|NCT03191721|Experimental|Test: Triclosan toothpaste|"To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
2457311|NCT03191721|Placebo Comparator|Control: Fluoride toothpaste|"To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.~Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction."
2457406|NCT03191084|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
2457407|NCT03191084|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the five study visits.
2457479|NCT03190642|Active Comparator|1000mg methylprednisolone group|Evaluating effects of 1000mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
2457483|NCT03190642|Active Comparator|125mg methylprednisolone group|Evaluating effects of 125mg of methylpresdnisolone administered immediately preoperatively and its effects on swelling.
2457542|NCT03190070|Experimental|Study group|All study participants are in the same group and will have their kidney function measured twice, before and after ingestion of protein, 1 g/(kg body weight). The protein will be given in the form of the protein drink Liquacel (Global Health Products, Rochester, NY).
2457751|NCT03188562|Experimental|EBUS-TBNA, EUS-NA|"PET/CT~Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA)"
2457752|NCT03188562|Experimental|TEMLA|"PET/CT~Transcervical Extended Mediastinal Lymphadenectomy (TEMLA)"
2457785|NCT03188250|Experimental|Chama cha MamaToto|Pregnant women in communities where chama cha mamatoto is taking place will be invited to join and participate in bi-weekly group meetings for a year
2457791|NCT03188250|No Intervention|Referent|Pregnant women attending at least one prenatal visit in communities where chama cha mamatoto was implemented three months later served as the comparison
2457834|NCT03187964|No Intervention|PLHIV Centralised Xpert Ultra|Patient sputum specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised Xpert Ultra TB testing at the National Health Laboratory Services (NHLS) facility in Greenpoint, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
2457838|NCT03187964|Active Comparator|PLHIV Point of Care Xpert Ultra|Patient sputum specimen collected at KCHC and Xpert Ultra TB testing done on site at point of care (POC).
2457841|NCT03187964|No Intervention|PLHIV Centralised Xpert VL|Patient blood specimen collected at Kraaifontein Community Health Centre (KCHC) and sent for centralised viral load testing at the NHLS facility in Tygerberg Hospital, Cape Town, South Africa. Centralised testing uses the established NHLS transportation, testing and report-back to clinic infrastructure according to the national algorithm.
2457842|NCT03187964|Active Comparator|PLHIV Point of Care Xpert VL|Patient blood specimen collected at KCHC and Xpert HIV-1 viral load testing done on site at point of care (POC).
2457939|NCT03187106|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for a total of 6 doses; 500 mg metronidazole per oral every 8 hours for a total of 6 doses
2457941|NCT03187106|Placebo Comparator|Placebo / standard of care|Placebo pills per oral every 8 hours for a total of 6 doses
2458026|NCT03186794|Experimental|SLE Exercise|We propose to enroll 20 sedentary, adult, women with negligible to mild SLE disease activity (SELENA-SLEDAI less than or equal to 4) in this pilot study. Subjects must also have a Fatigue Severity Scale (FSS) composite score less than or equal to 4.0. We will restrict our recruitment to women with SLE as this is a small pilot study and would like to eliminate possible gender-biased confounders of physical activity (approximately 90% of patients with SLE are women).
2458106|NCT03186339||TAVI patients|patients undergoing TF (transfemoral) TAVI as treatment for the aortic stenosis
2458114|NCT03186339||SAVR patients|patients undergoing isolated surgical valve replacement as treatment for the aortic stenosis
2458117|NCT03186339||MM patients|patients in whom the aortic stenosis is medically managed
3173235|NCT00609856|Active Comparator|1|Pioglitazone
3173236|NCT00609856|Active Comparator|2|Insulin glargine
3173237|NCT00609882|Active Comparator|HHFNC|Infants randomized to the Humidified High Flow Nasal Cannula (HHFNC) treatment group post extubation
3173238|NCT00609882|Active Comparator|nCPAP|Infants randomized to the nasal Continuous Positive Airway Pressure (nCPAP) treatment group
3173239|NCT00609908|Active Comparator|A1|Acute Burn Wounds: Wound debridement and split skin grafting
3173240|NCT00609908|Experimental|A2|Acute Burn Wounds: excision of the burn wound and primary closure, using a skin stretching device
3173241|NCT00609908|Active Comparator|B1|Scar reconstruction: serial excision
3173242|NCT00609908|Experimental|B2|Scar reconstruction: primary closure, using skin stretching device
3173243|NCT00609921|Active Comparator|1|ARQ197
3173244|NCT00609934|Experimental|Sorafenib and palliative radiotherapy|
3173245|NCT00609960|No Intervention|1|no medication or clowns present during the preopertaive phase
3173246|NCT00609960|Active Comparator|2|midazolam a anxiolytic drug was given in the preoperative phase
3173247|NCT00609960|Active Comparator|3|clowns where present during the preoperative phase
3173248|NCT00609999|Experimental|Stratum A|Pts not on EIAEDs
3173249|NCT00609999|Experimental|Stratum B|Pts on EIAEDs
3173250|NCT00610025|Active Comparator|1|10 patients with no previous abdominal surgeries, pre-insufflation of the abdomen using a veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
2457078|NCT03193203|Experimental|Sequence 1|SB4 (etanercept) 50 mg/mL PFS and AI
2457079|NCT03193203|Experimental|Sequence 2|SB4 (etanercept) 50 mg/mL AI and PFS
2457141|NCT03192514|Experimental|Electronic Deprescribing tool|GPs of enrolled patients with access to the electronic Deprescribing tool
2457159|NCT03192514|No Intervention|Usual Care|Usual care By GP´s
3155366|NCT00318903|Experimental|Taxotere/Irinotecan|Taxotere and Irinotecan is given intravenously for 3 consecutive weeks with a one-week break before radiotherapy for 5-6 weeks. A combination of Taxotere and Irinotecan will then be administered simultaneously with the radiotherapy.
3155367|NCT00318942|Active Comparator|1|Crystalloids, any type of Crystalloids including isotonic or hypertonic saline, Ringer Lactates either modified or not
3155368|NCT00318942|Experimental|2|Colloids, including albumin, gelatines, starch any other synthetic colloids
3155369|NCT00318955|Experimental|Dexmedetomidine group|
2457304|NCT03191435|Experimental|Inspiratory muscle training|Patients will perform the inspiratory muscle training using a load moderate of 30% of maximal inspiratory pressure (MIP 30%).
2457310|NCT03191435|Placebo Comparator|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a load of 2% of maximal inspiratory pressure (MIP 2%).
2457382|NCT03191175||HIV patients|
2457384|NCT03191175||Control patients|
2457413|NCT03190863|Experimental|Motor imagery combined with neurofeedback (MINF)|
2457415|NCT03190863|Active Comparator|Motor imagery (MI)|
2457417|NCT03190863|Sham Comparator|Control (C)|
2457477|NCT03190577|Experimental|patients with neuropathy of unknown aetiology|from a blood sample performed at inclusion, a genetic analysis will be performed to research transthyretin mutation
2457541|NCT03190018|Experimental|Single group with CLS PD device|Aim of the intervention is to evaluate the adsorbs of uremic toxins and certain ions with Purcart and the evaluation of the glucose-salt solution ability to achieve stable osmolality. The intervention is during an eight hour study session.
2457570|NCT03189771|Experimental|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
2457571|NCT03189771|Placebo Comparator|no occlusal surface reduction|No occlusal surface reduction after single visit root canal treatment
2457640|NCT03189056||Single cohort|"single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography~If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure."
2457770|NCT03188510|Experimental|LY3074828 Reference|LY3074828 administered subcutaneously (SC) as 3 injections
2457771|NCT03188510|Experimental|LY3074828 Test 1|LY3074828 administered as SC injections in two prefilled syringes
2457772|NCT03188510|Experimental|LY3074828 Test 2|LY3074828 administered as SC injections in four prefilled syringes
2457818|NCT03188029|Experimental|adrenocortical function|repeated general anesthesia with 0.3 mg/kg etomidate, 0.5 mg/kg propofol and 0.5 mg/kg succinylcholine, every 2 days for 3 to 4 weeks for electroconvulsive therapy.
2457877|NCT03187834|Active Comparator|Azithromycin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Azithromycin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm and treated for 5 days.~Children will receive treatment everyday, once a day as is:~Azithromycin: 10 mg/kg once daily on Day 1, then 5 mg/kg once daily Days 2-5"
2457889|NCT03187574||Group B|group received Perigee™ transvaginal mesh
2457936|NCT03187366|Active Comparator|Low risk|Villages shifted to low risk pesticides that don't kill prawns
2457938|NCT03187366|Experimental|No agrochemicals|Villages that eliminate agrochemicals
3155370|NCT00318955|Active Comparator|Propofol group|
3155371|NCT00319124||Case|Patients with hip Osteoarthritis
3155372|NCT00319124||Control|Healthy controls without hip osteoarthritis
3155373|NCT00319150|No Intervention|Standard of Care|Epo dose to remain constant throughout study
3155374|NCT00319150|Active Comparator|Dosage Decrease Arm|Arm 2 is to have an decrease of erythropoietin at regular intervals.
3155375|NCT00319202|Experimental|1|
3155376|NCT00319202|Placebo Comparator|2|
3155377|NCT00319228|Experimental|Antithrombin III|
3155378|NCT00319267|Experimental|Bosentan|The initial dose of bosentan was 2 mg/kg b.i.d. for 4 weeks. After 4 weeks, the initial dose was up-titrated to the maintenance dose of 4 mg/kg b.i.d. up to the end of the study treatment at Week 12. If the maintenance dose was not well tolerated, the dose could be down-titrated to the initial dose.
3155379|NCT00319280|Experimental|1|Minced Iliac Crest autograft in osteotomysite
3155380|NCT00319280|Experimental|2|Injectable calcium phosphate cement in osteotomysite
3155381|NCT00319280|Active Comparator|3|Local autograft in the osteotomysite serves as control
3155382|NCT00319358|Active Comparator|Antioxidants|Intervention was done with antioxidants
3155383|NCT00319358|Placebo Comparator|Placebo|
3155384|NCT00319371||1|women with vasospasm and difficulties of initiating sleep
3155385|NCT00319371||2|women without vasospasm and no difficulties of initiating sleep
3155386|NCT00319423|Active Comparator|Patient education|Patient education according to Klassbo et al 2003
3155387|NCT00319423|Experimental|Patient education and supervised exercise|Patient education according to Klassbo et al 2003. Supervised exercise containing strengthening, functional and flexibility exercises.
2457144|NCT03192501||Study group (A group)|In this group, we perform whole exome or genome sequencing of tumor sample in compared to blood sample, screen tumor-related special mutations by using biomedical informatics analysis procedure and utilized the iCAGES system to rank the most appropriate drugs available and then manually examine this list to select the best therapeutic strategy for the patient based on availability of drug and expert knowledge. The PFS, OS, and quality of life (QOL) will be recorded and compared with that from standard care.
2457158|NCT03192501||Control group (B group)|In this group, patients with advanced cancers (matched with Group A) will be treated under the guidance of NCCN, without performing iCAGES analysis.
2457217|NCT03192293|Experimental|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period:~Metformin: 850mg (one tablet) twice a day~Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle."
2457270|NCT03191877|Experimental|COFFEE|they will start to drink coffee 6 hours postoperative for maximum 3 doses (100ml), 8 hours apart, diet will start after 1st audible bowel sound.
2457287|NCT03191877|Active Comparator|oral fluid|"they will drink plain fluid (water) 6 hours postoperative. Diet will start after 1st audible bowel sound.~Women in this group will not receive either coffee."
2457292|NCT03191877|No Intervention|control|the control group and they will be NPO for 24 hours on IV fluid (3 LITRES/24 HOURS). Diet will start after 1st audible bowel sound
2457321|NCT03191604||Endoscopists familiar with EET|Physicians familiar with conducting endoscopic eradication therapy.
2457397|NCT03191201|Active Comparator|Ferric carboxymaltose arm|Ferric carboxymaltose (FCM), 1000 mg iron element will be administered once by drip infusion (Intravenous route). FCM will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution prior to administration. Infusion time will be 15 minutes.
2457399|NCT03191201|Placebo Comparator|Placebo arm|"A commercially available sterile, 250 mL, 0.9% sodium chloride solution will be administered by drip infusion (Intravenous route). Infusion time will be 15 minutes.~At the end of the randomised part of the study, participants initially randomised to the placebo group will be included in a non-blinded open-label extension part and receive a FCM 1000 mg injection."
2457476|NCT03190421|Experimental|Expanded Urinary Culture (EQUC)|Participants in this arm will receive the expanded urine culture
2457481|NCT03190421|Active Comparator|Standard Urine Culture (SUC)|Participants in this arm will receive the standard urine culture
3190935|NCT00793026|Experimental|1|Dermacyd Breeze Pocket BR (Lactic Acid)
3190936|NCT00793052|Experimental|A|
2457900|NCT03187535|Experimental|Transcutaneous Electrical Acupoint Stimulation|"Subjects in the Transcutaneous Electrical Acupoint Stimulation (TEAS) group will receive 20 minutes of TEAS via ES-130 beginning at the time ondansetron is administered (usually given 30 minutes before the end of surgery), for prevention of PONV."
2457901|NCT03187535|Sham Comparator|No Transcutaneous Electrical Acupoint Stimulation|"Subjects in the No Transcutaneous Electrical Acupoint Stimulation group will not receive any TEAS, although they will have the acupoints identified and ECG patches placed. The device will not be connected to the electrodes of the ES-130 device at the end of surgery, and no TEAS will be delivered."
2457927|NCT03187210|Experimental|Dosis finding (Phase I)|Brentuximab Vedotin at day -8 together with standard BeEAM (Bendamustine, Cytarabine, Etoposide and Melphalan) chemotherapy at days -7 to -1 followed by reinfusion of autologous stem cells at day 0
2457929|NCT03187210|Active Comparator|Arm A (Phase II)|"BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; Etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
2457930|NCT03187210|Experimental|Arm B (Phase II)|"Brentuximab Vedotin 1.8 mg/kg at day -8 together with standard BeEAM chemotherapy at days -7 to -1~BeEAM Regimen:~Bendamustine intravenously once daily on days -7 and -6 at 200 mg/m2/day; Cytarabine (ARA-C) 400 mg/m2/day intravenously once daily from day -5 to day-2; etoposide 200 mg/m2/day intravenously once daily from day -5 to day -2; and Melphalan 140 mg/m2/day intravenously once on day -1, followed by reinfusion of autologous stem cells at day 0"
2457991|NCT03186859|Active Comparator|Roux-en-Y Gastric Bypass (RYGB) surgery|
2457992|NCT03186859|Active Comparator|Sleeve Gastrectomy (SG) surgery|
2458027|NCT03186586|Experimental|Ulipristal acetate 5mg/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Ulipristal acetate at 5mg/day/five days Ulipristal 5mg daily for 5 days at the bleeding episode
2458038|NCT03186586|Placebo Comparator|Placebo 1 pill/day/five days|Women with abnormal bleeding during use of Mirena will allocate to UPA or placebo Placebo at 1pill/day/five days Placebo one pill a day for 5 days at the bleeding episode
2458094|NCT03186313|Experimental|Part A: Arm 1|Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
2458097|NCT03186313|Active Comparator|Part A: Arm 2|"Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.~Treatment assignments will be stratified according to the presence or absence of cirrhosis."
2458109|NCT03186313|Experimental|Part B: Arm 3|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks.
3155388|NCT00319488|Active Comparator|1|Active ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
3155389|NCT00319488|Active Comparator|2|Active LTRA plus placebo ICS plus albuterol inhalation treatment four times daily
3155390|NCT00319488|Placebo Comparator|3|Placebo ICS plus placebo LTRA plus albuterol inhalation treatments four times daily
3155391|NCT00319527||Observation|Living Kidney Donors with controls who have not donated a kidney or had certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
2457105|NCT03192982|Experimental|Foot pump (A-V Impulse, 6000 Series)|In OR before operation starts randomized to foot pump treatment post operative. Pump placed on foot immediately after operation is finished. Foot pump will be left on foot until full mobilization is reached
2457110|NCT03192982|Active Comparator|Standard treatment (compression)|"In OR before operation starts randomized to standart treatment for edema after in situ bypass.~Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg"
2457137|NCT03192618|Experimental|treatment group|
2457139|NCT03192618|No Intervention|control group|
2457211|NCT03192319|Experimental|2years to 5years after HCT|Patients will be vaccinated with Zostavax from 2years to 5years after hematopoietic stem cell transplantation
2457213|NCT03192319|Active Comparator|5years to 10years after HCT|Patients will be vaccinated with Zostavax from 5years to 10years after hematopoietic stem cell transplantation
2457216|NCT03192319|Active Comparator|6 month after chemotherapy for leukemia|Patients will be vaccinated with Zostavax 6 months after the leukemia is cured with chemotherapy
2457219|NCT03192319|Active Comparator|healthy people|Healthy adults over 50 years old will be vaccinated with Zostavax
2457269|NCT03191864|Experimental|APT-1011 1.5 mg HS|Placebo after breakfast, APT-1011 1.5 mg HS
2457278|NCT03191864|Experimental|APT-1011 1.5 mg BID|APT-1011 1.5 mg after breakfast, APT-1011 1.5 mg HS
2457285|NCT03191864|Experimental|APT-1011 3 mg HS|Placebo after breakfast, APT-1011 3 mg HS
2457291|NCT03191864|Experimental|APT-1011 3 mg BID|APT-1011 3 mg after breakfast, APT-1011 3 mg HS
2457293|NCT03191864|Placebo Comparator|Placebo BID|Placebo 30 minutes after breakfast and HS
2457344|NCT03191370|Active Comparator|Local Anaesthetic, no distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) as an active comparator without distraction during the procedure.
2457347|NCT03191370|Experimental|Local Anaesthetic, with distraction|Will receive local (co-phenylcaine) anesthetic spray (Local Anesthetics,Topical) with distraction during the procedure. The simple distraction technique is the experimental intervention.
2457348|NCT03191370|No Intervention|No Local Anaesthetic without distraction|Will receive no local (co-phenylcaine) anaesthetic spray without distraction during the procedure.
2457349|NCT03191370|Experimental|No Local Anaesthetic, with distraction|Will receive no local (co-phenylcaine) anesthetic spray with distraction during the procedure. The simple distraction technique is the experimental intervention.
3173251|NCT00610025|Active Comparator|2|10 patients with history of previous abdominal surgeries, pre-insufflation of the abdomen using veress needle (standard procedure for insufflating the abdomen for laparoscopic surgery)
2457588|NCT03189498|Experimental|Group 1: Participants With Normal Renal Function|Adult participants with normal renal function (estimated glomerular filtration rate [eGFR] greater than or equal to [>=] 90 milliliter per minute [mL/min]) will receive a single oral dose of 1,000 milligram (mg) JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2457595|NCT03189498|Experimental|Group 2: Participants With Mild Renal Impairment|Adult participants with mild impaired renal function (eGFR >=60 to less than [<] 90 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2457601|NCT03189498|Experimental|Group 3: Participants With Moderate Renal Impairment|Adult participants with moderate impaired renal function (eGFR >=30 to <60 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2457610|NCT03189498|Experimental|Group 4: Participants With Severe Renal Impairment|Adult participants with severe impaired renal function (eGFR >= 15 to <30 mL/min) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period.
2457613|NCT03189498|Experimental|Group 5: Participants With ESRD With or Without Hemodialysis|Adult participants with end-stage renal disease (ESRD) (eGFR <15 mL/min if not on hemodialysis or requiring hemodialysis treatment for at least 3 months before screening if on hemodialysis) will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250-mg tablets) on Day 1 of treatment period. Participants with ESRD on hemodialysis will be dosed on an interdialysis day within 24 hours of their last hemodialysis treatment.
2457668|NCT03189160|Experimental|PEG-rhGH low dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
2457671|NCT03189160|Experimental|PEG-rhGH high dose|PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
2457674|NCT03189160|No Intervention|Non-treatment control group|
2457708|NCT03188601||Rambam|Approximately 40 patients in total.No intervention planned.
2457710|NCT03188601||Soroka|Approximately 10 patients in total.No intervention planned.
2457715|NCT03188601||Tel Aviv Souraski|Approximately 40 patients in total.No intervention planned.
2457720|NCT03188601||Jerusalem Hadassah|Approximately 50 patients in total. No intervention planned.
2457759|NCT03188445|Experimental|IV administration|Iron isomaltoside (Monofer) Administered iv
2457761|NCT03188445|Active Comparator|Oral administration|Ferrous fumarate with ascorbic acid Administered oral
2457828|NCT03188133|Experimental|VH|schizophrenia patients with visual hallucinations
2457832|NCT03188133|Active Comparator|AH/NH|schizophrenia patients with auditory hallucinations or no hallucinations
2457839|NCT03188133|Active Comparator|C|healthy controls
2457868|NCT03187691|Experimental|CAMB 200 mg|200 mg CAMB (MAT2203) Oral Amphotericin B
2457871|NCT03187691|Experimental|CAMB 400 mg|400 mg CAMB (MAT2203) Oral Amphotericin B
2457874|NCT03187691|Experimental|CAMB 800mg|800 mg CAMB (MAT2203) Oral Amphotericin B
2457933|NCT03187366|No Intervention|Status quo|Status quo pesticide use
2457115|NCT03193112||Study group|The investigators analyze the intraocular pressure changes on patients who have been using Agomelatine for their primary depressive disorder. For the treatment of depression, patients will have been started routinely Agomelatine tablet of 25 mg orally. The investigators measure the eye pressure for one months in those patients receiving standard depression treatment.
2457173|NCT03192696|Experimental|Treatment Cohort|Atherectomy of in-stent restenosis
2457226|NCT03192072||Subjects with Acute Respiratory Illness|Patients with acute respiratory illness identified in the Emergency Department
3155393|NCT00319657|Experimental|Immune tolerance, kidney transplantation|Intervention: Participants will receive hematopoietic cell transplantation and Total lymphoid irradiation. The intervention is intended to induce immune tolerance in HLA-matched living donor kidney transplantation, to allow withdrawal of the immunosuppressive drugs. Immune tolerance is achieved through the development of donor/recipient mixed chimerism following combined kidney and hematopoietic stem cell transplantation from the living donor.
3155394|NCT00319826||1|Subjects with Staphylococcus Bacteremia
2457454|NCT03190772|Experimental|Positive placebo group|Participants receive a placebo nasal spray. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
2457455|NCT03190772|Placebo Comparator|Placebo control group|Participants receive a placebo nasal spray and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
2457457|NCT03190772|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
3155395|NCT00319826||2|Healthy (Non-infected) Control Subjects in the Nasal Carriage Group
2457517|NCT03189992|Experimental|CC-GSYXZ|Colon cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection
2457520|NCT03189992|Placebo Comparator|CC-WZ|Colon cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
2457522|NCT03189992|Experimental|HCC-GSYXZ|Hepatoma cancer with Chinese medicine syndrome Yin deficiency of liver and kidney and spleen deficiency.Intervented by Bushen-Jianpi Dedoction and cinobufotalin injection.
2457524|NCT03189992|Placebo Comparator|HCC-WZ|Hepatoma cancer with none Chinese medicine syndrome.Intervented by cinobufotalin injection
2457559|NCT03189810|Experimental|Active rTMS (20Hz)|Active rTMS administered with the MagProX100/R30 stimulator equipped with the B65 active coil for dorsolateral prefrontal cortex (DLPFC) stimulator (MagVenture, Farum, Denmark).The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
2457561|NCT03189810|Sham Comparator|Sham rTMS|Sham rTMS administered with the MagProX100/R30 stimulator equipped with the B65 placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark). The randomization order will be determined by a project scientist from Temerty. While the primary aim of this study is not to treat individuals with cannabis dependence, it is imperative that participants attend weekly study visits in an attempt to achieve end of study (Day 28) cannabis abstinence.
2457600|NCT03189511|Experimental|Experimental|Volunteers receive calorimetric tests and FDG PET scans pre and post 2 weeks of Fluvastatine.
2457736|NCT03188952|Active Comparator|ICDAS|International Caries Detection and Assessment System : Caries assessment system which is used to assess Any carious lesions then they are rated in codes from 0,1,2,3,4,5,6
2457737|NCT03188952|Experimental|ICCMS|International Caries Classification and Management System Any carious lesions detected are rated in score as the follow:Code 0 = ICDAS 0 Code A = ICDAS 1,2 Code B = ICDAS 3,4 Code C= ICDAS 4,6
2457762|NCT03188328|Experimental|AvidinOX/177Lu-ST2210|Patients will receive an intralesion injection of AvidinOX followed by two intravenous infusions of 177Lu- ST2210 with a distance of 14 days between them
3190937|NCT00793065||1|Physicians that are using paper-based medical charts and who are not receiving Medical Home redesign incentives.
2457910|NCT03187431|Experimental|IPF patients|autologous bone marrow mesenchymal stem cells
2457954|NCT03187145||diabetic patients|
2457961|NCT03187145||healthy control|
2458035|NCT03186820|Experimental|SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
2458104|NCT03186352|Experimental|after intervention|sample for microbial analysis it taken with sterile a rose bur (size 014) on micro motor after intervention
2458155|NCT03185910|Experimental|MBCP education|The intervention includes 3-hour classes per week during the duration of eight weeks and a 7- hour silent meditation practice as well.
2458158|NCT03185910|Placebo Comparator|Hospital-based antenatal education|Hospital-based antenatal education program will be held 2 hrs once a month for 2 months.
2458201|NCT03185611|Experimental|Rifaximin and Thiopurine|Prescribed Rifaximin (600mg, twice daily) combined with Azathioprine (2.0-2.5mg/kg/day) for 3 months after surgery, and then Azathioprine monotherapy (2.0-2.5mg/kg/day) for the next 3months.
2458210|NCT03185611|Active Comparator|Thiopurine|Prescribed Azathioprine (2.0-2.5mg/kg/day) for 6 months after surgery.
2458311|NCT03185195|Experimental|AQX-1125 Oral Tablet|AQX-1125 - Oral Tablet
2458315|NCT03185195|Experimental|[14C]-AQX-1125 IV|Radiolabelled AQX-1125 - Intravenous
2458318|NCT03185195|Experimental|[14C]-AQX-1125 Oral Solution|Radiolabelled AQX-1125 - Oral Solution
2458370|NCT03184532||D|diabetic patients
2458371|NCT03184532||ND|non-diabetic patients
2458422|NCT03184324|Experimental|DWP14012 20mg|DWP14012 20mg, tablet, orally, once daily
2458424|NCT03184324|Experimental|DWP14012 40mg|DWP14012 40mg, tablet, orally, once daily
2458426|NCT03184324|Experimental|DWP14012 80mg|DWP14012 40mg*2, tablet, orally, once daily
2458429|NCT03184324|Active Comparator|Esomerpazole 40mg|Esomerpazole 40mg, tablet, orally, once daily
2458477|NCT03183726||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-DFU-101
3155396|NCT00319852|Experimental|1|
3155397|NCT00319852|Active Comparator|2|
3190938|NCT00793065||2|Physicians that are using Electronic Health Records (EHRs) and who are not undergoing Medical Home redesign.
3190939|NCT00793065||3|Physicians that are using Electronic Health Records (EHRs) and undergoing Medical Home redesign.
2457184|NCT03192449|Experimental|Albendazole 400mg p.o. single dose|Volunteers receive 1 tablet albendazole 400mg (GSK) fasting.
3173252|NCT00610025|Active Comparator|3|10 patients with no previous history of abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3190940|NCT00793091|Active Comparator|1|
3190941|NCT00793091|Placebo Comparator|2|
3190942|NCT00793117|Experimental|1|poly vinil chloride packing
3190943|NCT00793130|Other|Coltect|Coltect contains natural compounds: curcumin, green tea and selenium which are approved as food supplements by the Ministry of Health in Israel. Curcumin and green tea are widely used in the food industry.
2457474|NCT03190603|Experimental|Celecoxib arm|Axial Spondyloarthritis patients who takes celecoxib 400mg for day
2457548|NCT03190200||MRI|Subjects with healthy knees
3190944|NCT00793143||Sleeve|
2457659|NCT03189121||Healthy Volunteers|20 overweight and obese adult men
2457783|NCT03188172|Experimental|Trial Treatment|"Induction:~Cyclophosphamide 500mg, days 1, 8 Bortezomib 1.3mg/m2, days 1, 4, 8, 11 Lenalidomide 25mg, days 1-14 Daratumumab 16mg/kg, days 1, 8, 15 (cycles 1& 2), day 1 only from cycle 3 Dexamethasone 20-40mg, days 1, 4, 8, 11~ASCT stem cell harvest:~with Bortezomib 1.3mg/m2, (12 hours post melphalan) Bortezomib 1.3mg/m2, day +5, +14, weekly~Consolidation part 1:~Bortezomib 1.3mg/m2 days 1, 8, 15, 22 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1 Dexamethasone 20-40mg days 1, 8, 15, 22~Consolidation part 2:~Bortezomib 1.3mg/m2 days 1, 8, 15 Lenalidomide 25mg days 1-21 Daratumumab 16mg/kg day 1~Maintenance:~Lenalidomide 10mg days 1-21 Daratumumab 16mg/kg day 1"
2457952|NCT03187496|Experimental|Single Arm|
2458034|NCT03186716|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
2458044|NCT03186716|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2458145|NCT03186287|Experimental|Eccentric training group|The participants in this group will actively perform eccentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
2458147|NCT03186287|Experimental|Concentric training group|The participants in this group will actively perform concentric phase of resistive shoulder exercises. Additionally they will receive standard physiotherapy.
2458149|NCT03186287|Active Comparator|Control group|The participants in this group will receive only standard physiotherapy.
2458177|NCT03185650|Other|tPAD, then PARI LC Star Nebulizer|tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then PARI LC delivering 7% HS labeled with technetium-99m sulfur colloid particles.
2458180|NCT03185650|Other|PARI LC Star Nebulizer, then tPAD|PARI LC delivering 7% HS labelled with technetium-99m sulfur colloid particles separated by 2-28 days and then tPAD device delivering 14% HS labelled with technetium-99m sulfur colloid particles
2458245|NCT03185468|Experimental|4SCAR-PSMA|4SCAR PSMA-modified T cells can recognize and kill tumor cells through the recognize of PSMA .This study will evaluate the side effects and effective doses of 4SCAR-PSMA T cells in treating refractory and recurrent solid tumors.
2458249|NCT03185468|Experimental|4SCAR-FRa|4SCAR FRa-modified T cells can recognize and kill tumor cells through the recognize of FRa .This study will evaluate the side effects and effective doses of 4SCAR-FRa T cells in treating refractory and recurrent solid tumors.
2458347|NCT03185078|Experimental|Active Comparator: Low density ESWT Application|ESWT application will be done at energy density of 0.12 mJ/mm2.
2458351|NCT03185078|Experimental|Active Comparator: High density ESWT Application|ESWT application will be done at an energy density of 0.3 mJ/mm2.
2458353|NCT03185078|Sham Comparator|Control|The ESWT application will be executed when the ESWT application is in the off position. During application, pre-recorded sound beats will be played to the treatment group.
2458378|NCT03184415|Experimental|DWC20155/DWC20156 Combination Therapy|
2458385|NCT03184415|Active Comparator|DWC20155 Monotherapy|
2458386|NCT03184415|Active Comparator|DWC20156 Monotherapy|
2458440|NCT03184090|Experimental|Palbociclib + Endocrine Therapy|"Patients will receive palbociclib capsules orally for 21 days every four weeks in combination with endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole).~Treatment will continue until disease progression (with the exception of patients who develop isolated progression in the brain), unacceptable toxicity, death, or discontinuation from the study treatment for any other reason."
2458513|NCT03183635|Experimental|Kinect based Rapid Movement Therapy|Kinect based Rapid Movement Therapy (RMT) training requires participants to move their limbs very rapidly to reach-to-grasp or step towards a virtual target appear suddenly on a screen, which is designed to their range of motion as well as response speed.
2458515|NCT03183635|Placebo Comparator|Conventional balance training|Conventional balance training involves some slow and low-impact muscle strengthening and mobilizing exercises.
2458620|NCT03183102|No Intervention|Estrogen suppression no flax|Control subjects will not consume flaxseed, but will receive GnRH suppression
3190945|NCT00793143||Bypass|
3190946|NCT00793156|Placebo Comparator|Placebo|Patients will be randomized into Placebo group
3190947|NCT00793156|Active Comparator|2|2.5 µg group randomized
3190948|NCT00793156|Active Comparator|3|5.0 µg group randomized
3190949|NCT00793195|Active Comparator|1) Intralipid|Fat Emulsions for Intravenous Nutrition
3190950|NCT00793195|Experimental|2) SMOFlipid|Fat Emulsions for Intravenous Nutrition
3190951|NCT00793208|Experimental|Vaccine|vaccine composed of lethally irradiated semi-allogeneic human fibroblasts transfected with genomic tumor DNA from the patient's own tumor
2457135|NCT03192540|Experimental|Exercise|These are participants who will be undergoing exercise intervention.
2457200|NCT03192371|Experimental|Zagreb 2-1-1 Group|4 doses of Rabipur vaccine, administered intramuscularly according to the Zagreb (2-1-1) regimen (i.e., 2 doses of vaccine administered on Day 1 and 1 dose of vaccine administered on Days 8 and 22).
2457201|NCT03192371|Experimental|Essen 1-1-1-1-1 Group|5 doses of Rabipur vaccine, administered intramuscularly according to the Essen (1-1-1-1-1) regimen (i.e., 1 dose of vaccine administered on Days 1, 4, 8, 15, and 29).
2457250|NCT03192033|Other|Arterial closure device used is Proglide® (Abbott)|
2457252|NCT03192033|Other|Arterial closure device used is Femoseal® (Terumo)|
2457318|NCT03191643||differentiated thyroid cancer|Patients with locally recurrent thyroid cancer, treated with radical radiotherapy after total thyroidectomy +/- central compartment and/or laterocervical lymphadenectomy, previously treated with one or more cycles of 131 Iodine-ablation (RAI) and TSH suppression.
2457378|NCT03191344||with IPSS record/IPSS|the surgoen use the IPSS in all thyroidectomy
2457380|NCT03191344||Traditionaldescription Group/TD|the surgoen without the IPSS，use Traditional description
2457423|NCT03190941|Experimental|1/Phase I|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
2457426|NCT03190941|Experimental|2/Phase II|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-KRAS G12V mTCR PBL + high-dose aldesleukin
3190952|NCT00793221|Other|Sirolimus-eluting stent|Implantation of sirolimus-eluting coronary stent
3190953|NCT00793221|Active Comparator|Everolimus-eluting stent|Implantation of everolimus-eluting coronary stent
2457523|NCT03189940|Active Comparator|App user group|
2457527|NCT03189940|Sham Comparator|Control group|Control participants, the physicians could assess the lifestyle and recommend further lifestyle modification only on the basis of the participants' recalls
2457580|NCT03189628|Experimental|stromal vascular fraction|Transplantation of resuspended SVF
2457582|NCT03189628|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
2457666|NCT03189329|Active Comparator|Group L|Patients undergoing block with 2% lidocaine hydrochloride
2457672|NCT03189329|Active Comparator|Group LB|Patients undergoing block with 0.5% levobupivacaine
2457698|NCT03188666|Experimental|REGN2477|
2457699|NCT03188666|Experimental|Placebo|
2457769|NCT03188458|Other|Second and third trimester Group|This study group will include infants whose mothers have received Boostrix during the second (21-27 weeks) and third trimester (above 28 weeks) of their pregnancy, as per routine practice.
2457795|NCT03188081||Cohort A|Adult RA patients followed up according to local clinical practice only at the hospital wards
2457797|NCT03188081||Cohort B|Adult RA patients followed up according to local clinical practice at the Hospital wards and additionally at their home through a support program
2457845|NCT03187912|Active Comparator|Riboflavin with 20% Dextran|Riboflavin drops with Dextran
2457846|NCT03187912|Active Comparator|Riboflavin with HPMC|Riboflavin drops with HPMC
2457892|NCT03187665||1-6 years|12 subjects in the age range of 1-6 years old.
2457896|NCT03187665||6-10 years|12 subjects in the age range of 6-10 years old.
2457898|NCT03187665||11-17 years|12 subjects in the age range of 11-17 years old.
3190954|NCT00793234|Experimental|1|0.3 mg/kg TB-402
3190955|NCT00793234|Experimental|2|0.6 mg/kg TB-402
3173253|NCT00610025|Active Comparator|4|10 patients with history of previous abdominal surgeries, no veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3190956|NCT00793234|Experimental|3|1.2 mg/kg TB-402
2458238|NCT03185390|Other|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
2458322|NCT03185130|Active Comparator|Standard Treatment Arm|Standard Treatment Arm will receive: normal saline at 5 ml IV given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
2458327|NCT03185130|Experimental|Study Arm|Study arm patients will receive: normal saline at 20 mL/kg (up to 1000 mL) given over 1 hour, prochlorperazine 0.15 mg/kg up to 10 mg IV, diphenhydramine 1mg/kg (up to 50 mg) IV.
2458411|NCT03184506|Sham Comparator|control group|
2458412|NCT03184506|Active Comparator|pre-warming group|
2458450|NCT03184064|Experimental|Treatment arm 1|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), citrus extract (low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2458454|NCT03184064|Experimental|Treatment arm 2|Participants will receive the placebo, citrus extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2458461|NCT03184064|Experimental|Treatment arm 3|Participants will receive the placebo, blackcurrant extract (low dose), blackcurrant extract (high dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2458464|NCT03184064|Experimental|Treatment arm 4|Participants will receive the placebo, blackcurrant extract (low dose), citrus extract (low dose), blackcurrant and citrus extracts (low dose / low dose) at 4 separate study visits, in a random order. Visits will be separated by at least 7 days.
2458558|NCT03183492|Experimental|HAV Group|Subjects who were vaccinated under UMV with 2 doses of Havrix® Junior at infancy and will receive a single challenge dose of Havrix Adult at Visit 1 (Day 1).
3190957|NCT00793234|Active Comparator|4|
2458627|NCT03182647||Non surgery|Patients were not treated with surgery initially
2458629|NCT03182647||Surgery|Patients had an initial surgical treatment
2458704|NCT03182231|Experimental|RYGB patients|Patients who will receive a RYGB surgery
2457245|NCT03192020|Active Comparator|Percutaneous needle fasciotomy|
2457251|NCT03192020|Active Comparator|Collagenase clostridium histolyticum|Generic name of the drug is collagenase clostridium histolyticum. Dosage form is injectable powder, dosage 0.58 mg and frequency is one injection in four weeks up to three times.
2457253|NCT03192020|Active Comparator|Limited fasciectomy|
2457323|NCT03191617|Experimental|Liquid human milk fortifier|Liquid human milk fortifier which has higher protein content and also LCPUFA
2457327|NCT03191617|Active Comparator|Powder human milk fortifier|Powder human milk fortifier with less protein content and no LCPUFA
3173254|NCT00610025|Active Comparator|5|10 patients, all with no previous mid to upper abdominal surgeries, no Veress needle pre-insufflation (insufflating the abdominal cavity through the endoscope, transgastrically)
3173255|NCT00610025|Active Comparator|6|10 patients, all with previous mid-to-upper abdominal surgeries, no Veress needle pre-insufflation, endoscopic take-down of intra-abdominal adhesions (if identified)
2457655|NCT03189225|Other|Capillary And Venous Accuracy|All subjects provided blood sample(s) to be tested on three Blood Glucose Monitoring Systems ( OneTouch Ultra 2, OneTouch Verio (Rice), OneTouch SelectPlus), LifeScan reference instrument ( YSI 2300) and hospitals own biochemistry analysers.
2457713|NCT03188783|Experimental|Cohort 1: GDC-0853 Low Dose|Japanese subjects will receive a single low dose of GDC-0853 or matching placebo by mouth.
2457718|NCT03188783|Experimental|Cohort 2: GDC-0853 Intermediate Dose|Japanese subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
2457721|NCT03188783|Experimental|Cohort 3: GDC-0853 Intermediate Dose|Caucasian subjects will receive a single intermediate dose of GDC-0853 or matching placebo by mouth. Subsequently, participants will receive twice-daily intermediate doses of GDC-0853 or matching placebo by mouth for 4 days followed by a single intermediate dose of GDC-0853 or matching placebo by mouth.
2457727|NCT03188783|Experimental|Cohort 4: GDC-0853 Low Dose|Japanese subjects will receive a single high dose of GDC-0853 or matching placebo by mouth.
2457758|NCT03188341||vascular surgery patients|"clinically concealed repolarization disturbances during vascular surgery procedure~clinically disclosed cardiac complications during and after vascular surgery procedure"
2457887|NCT03187561|Experimental|Family Foundations (FF)|The original Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants assigned to this arm
2457890|NCT03187561|Experimental|Sleep-adapted Family Foundations (FF+)|A sleep-adapted Family Foundations transition-to-parenthood coparenting intervention will be implemented to all participants in this arm. The adaptation will be an emphasis on coparenting in relation to infant sleep concerns and activities.
2457893|NCT03187561|Other|Control|Participants in this arm will not receive either intervention.
2457911|NCT03187275|Experimental|Swedish Massage Therapy|Participants in this arm will receive Swedish massage, which is the most commonly offered and best-known type of massage.
2457912|NCT03187275|Active Comparator|Light Touch Intervention|Participants in this arm will receive light touch only.
2457919|NCT03187093|Active Comparator|Vortioxetine|
2457921|NCT03187093|Active Comparator|Escitalopram|
2457983|NCT03186976|Experimental|Aggressive Risk Factor Control|Multifaceted risk factor management relating to BP, exercise, sleep apnea, alcohol intake and diabetes management
2457985|NCT03186976|Active Comparator|Standard of Care|All patients in the control arm will receive therapies for AF as per the existing guidelines. BP, cholesterol, diabetic management will be administered as per the available guidelines.
2458047|NCT03186612|Active Comparator|OT intervention|Conventional occupational therapy (OT) treatment will consist of 20 sessions in total, during which subjects will perform activities for training manipulative and functional dexterity of the upper limb aimed at activities of daily living. These will be distributed in two OT sessions per week, each lasting 30 minutes.
2458048|NCT03186612|Experimental|OT+VR intervention|The intervention applied to the experimental group will consist of 20 sessions of conventional OT distributed in two sessions per week, each lasting 30 minutes. Additionally, they will receive 20 treatment sessions lasting 20 minutes, twice weekly of virtual reality (VR) via the online and free website motiongamingconsole.com, during which they will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro. All the interventions will consider the level of fatigue experimented by the patient by featuring a progressive increase of the treatment times according to the same.
2458128|NCT03186235||Group I : 18 healthy controls|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2458130|NCT03186235||group II : 16 Hepatitis C infected patients (naïve)|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
3173256|NCT00610038|Experimental|1|Glibenclamide
3173257|NCT00610051|Placebo Comparator|trial arm|6 months central continuous infusion with Papeilin by infusion pump.
3173258|NCT00610051|Active Comparator|Placebo arm|6 months central infusion with NS by infusion pump with exact infusion rat as trial arm.
3173259|NCT00610064|Other|A|Baseline neuroimaging
3173260|NCT00610064|Other|B|Neuroimaging during sacral neuromodulation
3173261|NCT00610077|Experimental|1|Letrozole
3173262|NCT00610077|Active Comparator|2|Clomiphene citrate
3173263|NCT00610090|Experimental|Treatment - UniFit AAA Stent Graft|
3173264|NCT00610103|Active Comparator|KW-6500|Drug: KW-6500 (apomorphine hydrochloride (USAN))
3173265|NCT00610103|Placebo Comparator|Placebo|Placebo
3173266|NCT00610142|Active Comparator|1|
2457186|NCT03192735|Experimental|Apatinib Combined With SOX|In this group,subject will be given ApatinibMesylateTablets 500mg one time a day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 one time a day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
2457241|NCT03191994|Experimental|MDD exercise group|This group will receive eight weeks of moderate exercise in addition to their usual treatment
2457242|NCT03191994|No Intervention|MDD control group|This group will receive usual care with no exercise
2457244|NCT03191994|Experimental|Healthy Exercise|This group will perform an eight week moderate intensity exercise intervention
2457248|NCT03191994|No Intervention|Healthy control|This group will not perform exercise
2457299|NCT03191526|Experimental|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
2457301|NCT03191526|Placebo Comparator|Placebo (saline)|Intravenous injection every 12 weeks. Duration of double-blind treatment is going to be for 24 weeks and be followed by transitional period, which is for maximal 4 weeks. After that, duration of open label treatment is going to be conducted for 24 weeks. And an extension treatment will be continued until the approval or termination.
2457402|NCT03191097|Experimental|Ingavirin|
2457404|NCT03191097|Placebo Comparator|Placebo oral capsule|
2457484|NCT03190629|Active Comparator|High-flux hemodialysis|3 times per week
2457488|NCT03190629|Experimental|On line-hemodiafiltration|3 times per week
3190958|NCT00793260|Active Comparator|Usual Support Group|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
2457592|NCT03189459|Active Comparator|HVP Patient-Subject|"Patients will be asked to participate in four study visits, which will involve in-home clinical assessments, a needs assessment, and completion of some questionnaires. Additional information will be obtained from patients' routine medical records: their medical and medication history, family history, neurological examination findings, and office visit records.~Completion of Home Visit Program intervention."
2457599|NCT03189459|Active Comparator|HVP Caregiver-Subject|"Caregivers enrolling in the study will be asked to participate in the four home visits, which will involve in-home clinical assessments and completion of some questionnaires. After the first home visit, caregivers will be matched with a peer mentor, an individual who was a prior caregiver to someone with PD who is interested in sharing their knowledge, experience, and time to help improve the lives of current caregivers. Once a week, for a period of 4 months between home visits 2 and 3, caregivers will be asked to meet with their peer mentor, who will be trained to serve as a resource and listening ear, in addition to the medical team.~Completion of Home Visit Program and Caregiver Mentorship Program interventions."
2457607|NCT03189459|No Intervention|De-identified Control Subjects|Control subjects will be drawn from the National Parkinson Foundation Parkinson Outcomes Project (POP). Patient-caregiver dyads will be matched on patient gender, age, and HY stage.
2457612|NCT03189459|Active Comparator|HVP Peer Mentors|"Peer mentors enrolled in this study would be asked to complete a five-hour mentor training program. During this training, caregivers will be asked to complete some questionnaires about their background and caregiving experience. After completion of the mentorship training, peer mentors will be paired with a mentee who is a current caregiver enrolled in the home visit study along with their loved one with Parkinson's. Peer mentors will be asked to speak with their mentee once a week for 16 weeks. After a 16 week break, peer mentors will be paired with a second mentee and will repeat the process for another 16-week-long mentoring session.~Completion of Caregiver Mentorship Program intervention."
2457740|NCT03188614|Placebo Comparator|Normal saline group|Shock patients who resuscitated with normal saline were enrolled between June, 2015-June.2016.
2457741|NCT03188614|Experimental|Balanced solution group|Shock patients who resuscitated with balanced solution were enrolled after June, 2016.
2457774|NCT03188289|Placebo Comparator|Placebo gel|The placebo gel is used by all patients on one side of the mouth and serves as a control group.
2457776|NCT03188289|Active Comparator|Clorhexidine gel|Chlorhexidine gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2457777|NCT03188289|Active Comparator|Clorhexidine-Chitosan gel|Clorhexidine-chitosan gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2457778|NCT03188289|Active Comparator|Hyaluronic acid gel|Hialuronic acid gel is one of three gels used to compare the placebo gel and will be used on the contralateral side to the side assigned as placebo in a third of the participants.
2457916|NCT03187457|Other|Treatment group|Metronidazole 400 mg 3 times daily for 5 days for Bacterial Vaginosis (BV) infection
2457918|NCT03187457|Other|Control group|Healthy women without Bacterial Vaginosis and without treatment
2457937|NCT03187054|Active Comparator|POPQ-based surgery|will undergo anterior or posterior colporrhaphy for all of anterior or posterior vaginal prolapse stage 2 or greater (i.e. point Ba or Bp ≥-1 on the POPQ examination)
2457940|NCT03187054|Experimental|Simulated apical support-based surgery|will undergo anterior or posterior colporrhaphy only for the prolapse unresolved under simulated apical support (i.e. point Ba or Bp ≥-1 under simulated apical support)
2458029|NCT03186872|No Intervention|Care as usual|Participants randomized to this group will continue to see the IBD medical home team as usual
2458040|NCT03186872|Experimental|Digital behavioral program app|Participants randomized to this group will see the IBD medical home team and will utilize the cognitive behavioral app as the intervention.
2458121|NCT03186365|Experimental|8-week arm|patients receiving 8 weeks of elbasvir 50 mg/grazoprevir (Zepatier Oral Product)100 mg daily
2457210|NCT03193164|Experimental|group 1|Neuromuscular Electrical Stimulation (NMES) and after decubitus position with the limbs raised without NMES.
2457212|NCT03193164|Sham Comparator|group 2|Decubitus Position with the limbs raised to 20º without NMES and after NMES.
2457264|NCT03191851|Active Comparator|Standard Device|Standard device
2457268|NCT03191851|Experimental|Melody Device|Melody device without Pump
2457274|NCT03191851|Experimental|Melody Device with pump|Melody Catheter device with Andromeda Pump
2457338|NCT03191565|Experimental|App-Condition|In this condition the intervention is that participants enter their skills-use and mood on a smartphone. They can follow their progress on graphs on the smartphone, get reminders to train skills, get psychoeducation about what the different emotion regulation coping skills can do, and how to do the skills. therapists can watch patient progress online, and review skill use together with the patients while in psychotherapy. The intervention is using a smartphone as an adjunct to the treatment.
2457341|NCT03191565|Active Comparator|Paperdiary-condition|Patients are, weekly, given a paper diary sheet to fill out on a daily basis at home No prompting, no accumulative overview of progress. Patients are supposed to bring this paper to the weekly therapysession
2457366|NCT03191045||Healthy participants|A group of 21 healthy adult participants studied twice (test-retest)
3173267|NCT00610142|Active Comparator|2|
3173268|NCT00610181||Breast MRI|Magnetic resonance imaging (MRI) of breast for patients with invasive lobular carcinoma of the breast.
3173269|NCT00610194|Experimental|Arm 1|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
2457463|NCT03190499||Children with childhood cancer|Children with childhood cancer that are having medical treatment will be assessed with family based questionnaires.
2457506|NCT03190304|Active Comparator|Enalapril|Enalapril at a dose of 10 mg twice daily for 6 months
2457512|NCT03190304|Experimental|Neprilysin (LCZ696)|LCZ696 at a dose of 200 mg twice daily for 6 months
2457568|NCT03189784|Experimental|mobilization group|this group will receive mobilization with movement techniques.
2457569|NCT03189784|No Intervention|Control group|The control group will receive no intervention
2457663|NCT03189030|Experimental|Treatment arm|pLADD treatment cycle is once every 3 weeks; starting dose 1×10^8 colony-forming units (CFU) administered IV over 1 hour, and if tolerated increasing to 1×10^9 CFU
2457696|NCT03188731||Pregnant Women|
2457742|NCT03188497|Experimental|Experience group 1|The dose of lobaplatin is 25mg/m2 on d1,d22,d43.
2457743|NCT03188497|Experimental|Experience group 2|The dose of lobaplatin is on d1,d22,d43.
2457744|NCT03188497|Experimental|Experience group 3|The dose of lobaplatin is on d1,d22,d43.
2457747|NCT03188497|Experimental|Experience group 4|The dose of lobaplatin is 40mg/m2 on d1,d22,d43.
2457749|NCT03188497|Experimental|Experience group 5|The dose of lobaplatin is 45mg/m2 on d1,d22,d43.
2457750|NCT03188497|Experimental|Experience group 6|The dose of lobaplatin is 50mg/m2 on d1,d22,d43.
2457849|NCT03188224|Experimental|Intervention|MyTransition app
2457850|NCT03188224|No Intervention|Control|Usual care
2457870|NCT03187600|Active Comparator|Standard of Care|Procedure: a superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out to the level of the prevertebral fascia and be comprised of mucosa and pharyngeal muscle.
2457873|NCT03187600|Experimental|Experimental Group|Procedure: a modified superiorly based pharyngeal flap surgery as per Hogan and Cable and Canady. It is performed trans-orally under general anesthetic. The soft palate is divided midline to visualize the posterior pharyngeal wall. A small flap is dissected via longitudinal incisions with a superior pedicle from the posterior pharyngeal wall at the level of the velum. The flap is then brought anteriorly, the inferior portion is lined with mucosa from the nasal portion of the soft palate and sutured in-place to create an incomplete pharyngeal obstruction that acts as a dynamic valve. Nasal stents are placed in each lateral port to prevent airway compromise and maintain flap integrity. Stents are removed two days post operatively and the patient is discharged after removal of stents and deemed to have a stable airway. Dissection will be carried out only to the level of the superior constrictor muscle and comprised of mucosua/submucosa
2457953|NCT03187379|Experimental|Exparel, Liposomal Bupivacaine|Subjects in this arm will receive Exparel® liposomal bupivacaine injected concurrently with 0.25% bupivacaine at the incisional sites prior to closing
2457960|NCT03187379|Active Comparator|Control|Subjects in this arm will receive 0.25% bupivacaine alone
2458020|NCT03186742|Experimental|Group A|The patients who had Eplerenone 50mg tab once a day added to their standard hypertensive treatment.
2458022|NCT03186742|No Intervention|Group B|The patients who did not receive an additional drug to their standard hypertensive treatment.
2458087|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Teen Only|Only the teen will receive the educational intervention.
2458088|NCT03186469|Active Comparator|Behavioral: Safety Baby shower Dyad|Both the teen and the teens support person will receive the educational intervention.
2458090|NCT03186469|Other|Behavioral: Standard of Care Control|Standard of care.
2465477|NCT03136133|Placebo Comparator|Placebo drink|Placebo drink
3173270|NCT00610220|Active Comparator|1|
3173271|NCT00610220|Experimental|2|
3173272|NCT00610233|Active Comparator|A|Urodynamic investigation with deep brain stimulation ON
3173273|NCT00610233|Experimental|B|Urodynamics with deep brain stimulation OFF
3155398|NCT00319878|Experimental|1|Participants will be treated with sirolimus and cyclosporine. In phase I, each dose cohort will initially enroll three patients. If no dose-limiting toxicity (DLT) is observed by Day 28 in any patient of a cohort, then 3 patients will be treated with the next highest sirolimus dose. If 1 out of 3 patients in any cohort experiences a DLT, then 3 more patients will be enrolled in that cohort. If no more patients have a DLT by Day 28, then sirolimus dose escalation will proceed. If one or more patients experience a DLT then that dose level will be considered to be the maximum tolerated sirolimus dose, and Phase II patients will be treated at the next lowest level. Cyclosporine will be given as a twice daily oral dose.
3155399|NCT00319917|Experimental|1|
2457578|NCT03189576|Other|CRC patients after primary surgery|sequential blood draw taken to monitor residual disease
2457633|NCT03189381|Experimental|Cohort A|Standard PCI dose
2457634|NCT03189381|Experimental|Cohort B|Low PCI dose
2457638|NCT03189017|Experimental|ICP-022|"There are 5 cohorts in the Part 1 phase of the trial. Three quarters of subjects will be randomized to receive ICP-022 in a double-blind fashion. Five dose levels will be evaluated; dose escalation steps may be modified based on the safety from the previous dose. Cohort 4 will return on Day 8 and receive a single dose of ICP-022 under fed conditions.~In Part 2 phase of the trial,three quarters of subjects will be randomized to receive the ICP-022 in a double-blind fashion in 3 cohorts. ICP-022 will be administered once a day for 14 consecutive days."
2457644|NCT03189017|Placebo Comparator|Placebos|"In part 1 phase of the trial, one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Cohort 4 will return on Day 8 and receive a single dose of placebo under fed conditions.~In Part 2 phase of the trial,one quarter of subjects will be randomized to receive placebo in a double-blind fashion. Placebo will be administered once a day for 14 consecutive days."
2457812|NCT03188042|Experimental|rtACS Stimulation Group|
2457813|NCT03188042|Sham Comparator|Sham Intervention Group|Sham stimulation looks like rtACS, but is not active rtACS.
3155400|NCT00319917|Placebo Comparator|2|
2457993|NCT03186924|Experimental|Take a STAND for health|A newly developed personalized intervention focused on replacing sedentary time with light-(or very light-) intensity physical activity
2457994|NCT03186924|No Intervention|Control|The control group will receive all regular medical care and advice on healthy lifestyle, including the promotion of recommended physical activity levels and health nutrition.
2457997|NCT03186573|No Intervention|Control Group|The athletes will not receive any drink and will do the simulations of the fight.
2458002|NCT03186573|Active Comparator|Intervention group|(Intervention, grape juice) - athletes will receive 400 ml per day of grape juice (containing 66g of carbohydrates) for 14 days and will do the fight simulations.
2458012|NCT03186573|Placebo Comparator|Placebo Group|(Placebo, grape-flavored maltodextrin carbohydrate) - athletes will receive400ml of drink daily with 66g of maltodextrin for 14 days and will do the fight simulations; The amount of maltodextrin is equal to the amount of carbohydrate present in grape juice.
2458082|NCT03186482|Active Comparator|Descovy® (TAF/FTC)|"ATC Code J05AR17. Pharmaceutical form (use standard terms): Film-Coated Tablet Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol: 56 days.~Maximum dose allowed 200mg/25mg per day. Total dose 200/25mg. Oral Use."
2458084|NCT03186482|Active Comparator|Viread® (TDF)|"ATC Code J05AF07. Pharmaceutical form (use standard terms): Film-Coated Tablet. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 245mg per day. Total dose: 245mg. Oral Use."
2458086|NCT03186482|Active Comparator|Rifadin® (Rifampicin)|"ATC Code J0AB02 Pharmaceutical form (use standard terms): Capsule, Hard. Specific paediatric formulation?: No. Maximum duration of treatment of a subject according to the protocol 28 days.~Maximum dose allowed: 600mg per day. Total dose: 600mg. Oral Use."
2458101|NCT03186053|Experimental|sodium creatine phosphate|5g creatine phosphate was dissolved in 50ml saline solution. After induction of anesthesia, the patients were first given a load dose of 1g, 20min (30ml / h) , And then pumped at a rate of 1 g / h (10 ml / h).
2458113|NCT03186053|Placebo Comparator|Control|The control group was treated with saline in the same manner.
2458162|NCT03185858|Experimental|SINEMA intervention group|The intervention arm will implement the SINEMA model for one year, which consists of a provider-facing intervention aiming to strengthen the capacity of village doctors in delivering stroke secondary prevention, and a stroke survivor-facing intervention aiming to promote medication adherence and physical activity.
2458163|NCT03185858|No Intervention|Control group|Villages in the control arm continue their usual practice without the introduction of any of the SINEMA activities described above. People who have hypertension or who are at high-risk of hypertension may receive follow-up visits four times per year as part of the basic public health services required by the government.
3155401|NCT00319969|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
3155402|NCT00319969|Active Comparator|2|Topotecan 1.5mg/m<2> IV, days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
3155403|NCT00320008|Active Comparator|Standard Treatment Arm|This arm will at any time during the active intervention period follow treatment guidelines by the Danish Medical Association for the treatment of type 2 diabetes.
3155404|NCT00320008|Experimental|Intensive Treatment Arm|This arm will during the active intervention period be treated according to intensified multiple risk factor intervention following strict guidelines set out by the study protocol.
3155405|NCT00320047|Experimental|1|Participants will take baclofen for 10 weeks.
3155406|NCT00320073|Experimental|Arm A|Pemetrexed, Vinflunine, Folate, B12, Dexamethasone, Ondansetron, Midazolam
2457656|NCT03189186|Experimental|Pembrolizumab|Advanced (stage II and above with multiple tumors or vena cava) and metastatic Renal Cell Carcinoma will be first treated with cryoablation on a large primary tumor and then given 200 mg pembrolizumab every 3-week for 3 cycles, followed by cytoreductive or partial/radical nephrectomy. After the surgery, patients will resume pembrolizumab for additional 5 cycles or up to a total of 2 years if a partial response is observed at the discretion of the treating medical oncologist or urologist until a complete tumor remission, disease progression, unacceptable toxicity, subject refusal, or subject death due to any cause.
2457731|NCT03188679|Other|mRNA sequencing|amniotic fluid for patients with CMV seroconversion during pregnancy will undergo mRNA sequencing
2457814|NCT03188406||Gastric cancer|Patients with clinical or histological diagnosis of stomach cancer
2457815|NCT03188406||Gastric intestinal metaplasia|Patients classified as OLGIM >0
2457817|NCT03188406||Non-atrophic gastritis|Patients classified as OLGA 0
2457859|NCT03187821|Active Comparator|Superior|Laser peripheral iridotomy done at superior part of iris.
2457861|NCT03187821|Active Comparator|Nasal/temporal|Laser peripheral iridotomy done at temporal/nasal part of iris.
2457959|NCT03187067||Mozambique, cases|
2457966|NCT03187067||Mozambique, controls|
2457970|NCT03187067||Pakistan, cases|
2457972|NCT03187067||Pakistan, controls|
2458023|NCT03186690|Experimental|Biodentine|This includes teeth that were treated with Biodntine cement
2458024|NCT03186690|Experimental|Mineral Trioxide Aggregate|This includes teeth that were treated with Mineral Trioxide Aggregate (MTA) cement
3190959|NCT00793260|Experimental|Enhanced Support Group|The Enhanced-Support Group intervention used more sophisticated predictive models, more extensive outreach to engage individuals, and provided tighter feedback loops to inform the care support process.
3190960|NCT00793273||A|
2458205|NCT03185598||non-MACE|no MACE occurred
2458214|NCT03185598||MACE|MACE occurred
2458264|NCT03185338|Experimental|Active commuting to/from school|This intervention will be focused on children and their families following the ecological model proposed by Sallis et al., targeting mainly individual factors such as children's perceptions (safety perception on the way to school) and attitudes (independence or motivation to walk). A total of six 1-hour activities will be conducted at the classroom and two activities in the school neighborhood designed based on previous literature. Taken together, these activities will emphasize the benefits of active commuting to/from school and promote active commuting to/from school.Moreover, supporting information will be sent to families on four occasions during the intervention to encourage families to use active modes of commuting to/from school.
2458265|NCT03185338|Experimental|Active Physical Education lessons|This intervention has been developed by the Spanish Ministry of Health, Social Services and Equality and the Ministry of Education, Culture and Sport to increase the amount of children's PA during PE lessons in primary schools. At the time of this study, any school in Spain could choose to adopt this programme. This intervention includes two sets of eight active PE lessons specifically developed for third grade of primary school. These lessons will replace the original PE lessons in schools assigned to Active PE lesson intervention and integrated intervention.Additionally, this intervention provides some methodological advices to increase the PA time during the PE lesson (i.e. different ways to take attendance or deciding on the most suitable activity given the availability of resources).
2458267|NCT03185338|Experimental|Active school recess|This intervention has been designed based on previous research. The teacher will prepare the school playground offering adequate space and games to encourage children to be active. A sheet placed on the wall as a reminder will help teacher to remind children to participate and motivate them. On this sheet, each child will write the activity completed during the school recess every day during the intervention period.
2458269|NCT03185338|Experimental|Sleep health promotion|"Eight activities will be carried out at home and at school. During the first activity, parents and children will attend a general talk about sleep and health and will sign a contract for a healthy sleep at home. Also, children will complete a diary in which they will keep a record of their activities prior to going to bed and after waking up in the morning. At school, the first classroom-based activity will be based on the educational program I have a dream (Spanish adaptation of the SimplyHealthy@Schools International Program). The remaining classroom-based activities will include with a group art project with questions and answers about sleep, discussion groups about the sleep diary completed at home, and an abbreviated version of the Jacobson's progressive relaxation technique."
2458270|NCT03185338|Experimental|School global intervention|Also, a simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
2458271|NCT03185338|No Intervention|Control school|Control school will be evaluate but will not receive any intervention
2458320|NCT03184922|Active Comparator|Fixed suspensory loop|Non-adjustable femoral cortical fixation device to be used
2458325|NCT03184922|Experimental|Adjustable suspensory loop|Adjustable femoral cortical fixation device to be used
2458375|NCT03184545|Experimental|EMS and PT|Group 1: Electrical Muscle stimulation (EMS) and Physical therapy (PT).
2458376|NCT03184545|Active Comparator|Only PT|Group 2: Only Physical therapy (PT).
2458427|NCT03184181|Experimental|EPTE® group|The intervention for this group consisted of Therapeutic Percutaneous Electrolysis (EPTE®). Patient received EPTE® once week for four weeks associated with eccentric exercises device at home.
2458430|NCT03184181|Active Comparator|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises device at home. Patient received 3 sessions of dry needling a week for four weeks.
2458489|NCT03183830|Experimental|Nitrate-rich Beetroot Juice|Individuals will receive a once daily dose of dietary nitrate in the form of a beetroot juice concentrate (70mL) containing ~5-6mmol inorganic nitrate (James White Drinks, UK) for 12 +/- 2 weeks. This dose has been chosen due to several reports demonstrating efficacy in patients with cardiovascular disease.
3190961|NCT00793286|Other|A|Mesh fixation by staples
3190962|NCT00793286|Other|B|Mesh fixation by glue
3190963|NCT00793299|Experimental|Video Illness Narrative|single arm pilot study
3190964|NCT00793338|Experimental|Sildenafil|All patients will receive open-label treatment with sildenafil.
3190965|NCT00793364|Active Comparator|Stanol ester|Stanol-ester administration group
3190966|NCT00793364|Placebo Comparator|Placebo spread|Placebo spread group
2457679|NCT03189004|Active Comparator|e-Referral|There will be online referral system for the registered women and their children for ANC, PNC, delivery care, neonatal management, IMCI and other complication management in which healthcare providers from lower facilities can refer a patient to the higher facilities. The women will be identified in the higher facilities by their unique ID. The service providers will enter referral data to the system during the referral process and the patients and providers from higher facilities will get system generated reminders about the referral. The service providers in higher facilities will be able to check the health status and cause of referral using patient's unique ID number from the system and will manage accordingly as well as update the given management to the system. If the referred woman does not visit the referral facility, she will receive repeated reminders auto-generated by the system to comply the referral
2457681|NCT03189004|Active Comparator|e-monitoring|There will be web based monitoring system to oversee the progress and status of all the activities under this study for policy makers, programme peoples and other supervisors from national to the union levels. All these data will be available in the central database which will be visualized and accessible at all concerned levels through internet in particular website. They can constantly follow up the progression and healthcare delivery system of the respective area and provide regular feedback, when necessary. There will be provision of auto-generation of reports for each and every activity through the system by area and service provider specific.
2457745|NCT03188627|Experimental|Bronchial basal cells|Transplantation of autologous bronchial basal cells
2457748|NCT03188627|No Intervention|Control|Conventional treatment
2457881|NCT03187587|Experimental|imILT treatment|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2457886|NCT03187587|Active Comparator|Standard chemotherapy treatment|This study arm recieves chemotherapy treatment as standard care at the clinical study site.
2458124|NCT03186144|Experimental|No arm : descriptive study|
3155407|NCT00320073|Experimental|Arm B|Vinflunine, Erlotinib, Ondansetron, Midazolam
3155408|NCT00320099|Active Comparator|1|Hydrocortisone and convention glycemic control
2458206|NCT03185559|Active Comparator|Relievion device- Treatment stimulation|Relievion Device- Treatment combined occipital and supraorbital transcutaneous nerve stimulation
2458215|NCT03185559|Sham Comparator|Relievion device- Sham Stimulation|Relievion Device- Sham combined occipital and supraorbital transcutaneous nerve stimulation
2458296|NCT03185208|Experimental|Lithium carbonate|Lithium carbonate will be initiated at 150 mg per day and increased based on blood levels until a steady blood level between 0.6 and 0.8 meq/L is achieved. Participants will continue at the dose achieved for 2 years with quarterly monitoring.
2458299|NCT03185208|Placebo Comparator|placebo|Matching placebo will be initiated and increased based on pretend blood levels. Participants will take placebo for 2 years with quarterly monitoring.
2458417|NCT03183973|Experimental|PRF group|patients who will receive Platelet Rich Fibrin (PFR) suspension
2458419|NCT03183973|Experimental|placebo group|
2458472|NCT03183921||Cases|All ICU patients with nosocomial lower respiratory tract infection
3155409|NCT00320099|Experimental|2|Hydrocortisone and fludrocortisone and conventional glucose control
3155410|NCT00320099|Experimental|3|Hydrocortisone and intensive insulin therapy
2458571|NCT03183128|Experimental|SER-109|Received oral dose of SER-109
2458575|NCT03183128|Placebo Comparator|Placebo|Received matching placebo
2458656|NCT03182621|Experimental|THINK|The Translational Health in Nutrition and Kinesiology (THINK) program will have education and fitness sessions lasting two hours, five times a week for a total of 10 weeks. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence.
2458658|NCT03182621|Active Comparator|SPARK|This The Sports, Play, and Active Recreation for Kids (SPARK) group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre and post testing protocol as the intervention group, but will not receive the THINK program.
2458750|NCT03182270|Experimental|pancreatic cysts|
2458861|NCT03181178|Active Comparator|KokoPlus and Nutrition Education|Macro-micronutrient complementary food supplement and Nutrition Education
2458862|NCT03181178|Active Comparator|Micronutrient and Nutrition Education|A micronutrient powder and Nutrition Education
2458864|NCT03181178|Active Comparator|Nutrition Education Only|Nutrition Education
2458865|NCT03181178|No Intervention|Growth Monitoring Only|Growth monitoring
2458885|NCT03180814|Active Comparator|Young Group|Healthy young of both sexes between the ages of 18 and 30 years will perform a whole body vibration session
2458886|NCT03180814|Experimental|Elderly Group|Healthy elderly of both sexes between the ages of 60 and 80 years will perform a whole body vibration session
3155411|NCT00320099|Experimental|4|hydrocortisone, fludrocortisone and intensive insulin therapy
2459111|NCT03179358|Experimental|C-REX group|After resection of the disease in colon, the intestinal ends will be anastomosed by the investigational device, i.e. C-REX LapAid and C-REX DMH/DMHC included in the C-REX Ring-locking Procedure.
2459160|NCT03179306||Samples|de-identified images and clinical data from NCI studies.
2459176|NCT03179254|Experimental|Oral hypoglycemic agent continue|Metformin continue on the day of surgery
3155412|NCT00320125|No Intervention|1|Usual diet
3155413|NCT00320125|Active Comparator|2|Orange juice fortified with calcium
3155414|NCT00320125|Active Comparator|3|Dairy products
3155415|NCT00320138|Active Comparator|Acupuncture|
3155416|NCT00320138|No Intervention|Wait List|Usual Care
3155417|NCT00320164||Group A: Leukapheresis|Subject's peripheral blood mononuclear cells are collected via leukapheresis.
3155418|NCT00320164||Group B: Buffy Coats Collection|Subject's peripheral blood mononuclear cells are collected via the buffy coats from blood.
3155419|NCT00320203|Experimental|Anecortave Acetate 3 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3155420|NCT00320203|Experimental|Anecortave Acetate 15 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3155421|NCT00320203|Experimental|Anecortave Acetate 30 mg Depot|Single injection, anterior juxtascleral depot (AJD)
3155422|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
2457802|NCT03188367|Placebo Comparator|2B - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 10 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457803|NCT03188367|Placebo Comparator|2A - NCGS|Seventy subjects with nonceliac gluten sensitivity will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457805|NCT03188367|Active Comparator|1A - HV|Seventy healthy volunteers will be given 14 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457807|NCT03188367|Active Comparator|1B - HV|Seventy healthy volunteers will be given 10 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 6.0 grams for five days. In order to maintain the double-blind, patients will be also given 4 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457808|NCT03188367|Active Comparator|1C - HV|Seventy healthy volunteers will be given 7 gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457809|NCT03188367|Placebo Comparator|2C- HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457810|NCT03188367|Placebo Comparator|2B - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 7 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 4.2 grams for five days. In order to maintain the double-blind, patients will be also given 7 capsules of placebo (rice starch) per day. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457811|NCT03188367|Placebo Comparator|2A - HV|Seventy healthy volunteers will be given 14 daily gastrosoluble capsules containing placebo (rice starch) for five days. At the end of the first five day-long treatment, subjects will continue only their wash-out from gluten for two weeks, without taking any capsule. At T3, individuals will be given 14 daily gastrosoluble capsules containing purified wheat gluten corresponding to a daily gluten intake of 8.4 grams for five days. In both first and second five day-long treatment the 14 capsules will be ingested in no more than two times using a glass of water over the day.
2457891|NCT03187769|Experimental|ALKS 3831|Coated bilayer tablet
2457895|NCT03187769|Active Comparator|Olanzapine|Coated bilayer tablet
3155423|NCT00320359|Active Comparator|Arm A|Cisplatin 75 mg/m2 i.v., day 1, Etoposide 100 mg/m2 i.v., days 1-3
3155424|NCT00320359|Experimental|Arm B|Topotecan 1 mg/ m2, i.v., days 1-5 Cisplatin 75 mg/m2 i.v., days 5
3155425|NCT00320567|Experimental|001|norgestimate/ethinyl estradiol
3155426|NCT00320580|Experimental|001|norelgestromin/ethinyl estradiol
3155427|NCT00320619|Experimental|1|Participants will receive either EACA.
3155428|NCT00320619|Placebo Comparator|2|Participants will receive placebo.
3155429|NCT00320658|Experimental|A|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm B.
3155430|NCT00320658|Experimental|B|3 vaccinations with a dose of 40 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm A.
3155431|NCT00320658|Experimental|C|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm D after review of the results from Arms A and B.
3155432|NCT00320658|Experimental|D|3 vaccinations with a dose of 160 mcg MSP1 42-C1/Alhydrogel and CPG7909 given into the deltoid muscle of either arm. Each vaccination will be given 1 month apart. This arm will enroll concurrently with Arm C after review of the results from Arms A and B.
3155433|NCT00320684||1|Women who have had anorexia nervosa but are now maintaining a healthy weight
3155434|NCT00320684||2|Women who have never had anorexia nervosa and are maintaining a healthy weight
2457835|NCT03187951|Experimental|Arm B: Multi-Modal Exercise and Nutrition Program (MMENP)|"After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, then 3-7 months after surgery: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life. Participant's hand grip strength measured. Participants arm strength measured. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes. Participants complete a nutritional questionnaire and receive nutritional counseling. Participants receive educational materials and personalized counseling based on participant's answers.~Participants complete moderate-intensity aerobic exercise 5 days each week. Participants complete strength training exercises 2 times per week.~Participants contacted by phone by member of study staff 1 time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing."
2457902|NCT03187522|Experimental|TREO Stent-Graft|Patients who receive a TREO Abdominal Stent-Graft System
2457943|NCT03187158||Pune Maternal Nutrition Cohort|Study has been planned on the F1 generation of the mothers recruited under the PMNS study at Diabetes Unit, KEM-Pune. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation. This study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
2457946|NCT03187158||New Delhi Birth Cohort|Study has been planned on the F1 generation of the mothers recruited under the New Delhi Birth Cohort in New Delhi, India. Data on maternal nutrition, exposures and anthropometry have been collected, in the F1 generation, the study will be adding cross sectional lung function measurement, biochemical analyses for nutritional, immunological and inflammatory biomarkers.
2458008|NCT03186833||Group A|males or females aged > 70 years without major systemic comorbidities (resting blood pressure <140/90 mmHg, no history diabetes mellitus according to WHO criteria).
2458014|NCT03186833||Group B|males or females aged >70 years with hypertension, defined as a documented blood pressure of Systolic Blood Pressure (SP >140 mmHg or >90mmHg Diastolic Blood Pressure) without diabetes mellitus and HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria b) need for diuretic therapy.
2458017|NCT03186833||Group C|male or female aged > 70 years with diabetes mellitus (defined according to the World Health Organization (WHO)) AND hypertension, without HF defined as: a) relevant symptoms/signs/radiographic findings as indicated by Boston criteria38 b) need for diuretic therapy.
2458019|NCT03186833||Group D|male or female aged >70 years with HFPEF, defined as signs and symptoms of HF with LVEF>50% and raised natriuretic peptides (BNP>35pg/ml or NT-proBNP>125pg/ml) along with one other criteria: i) structural heart disease (left atrial enlargement or left ventricular hypertrophy) on TTE, ii) evidence of LV diastolic dysfunction based on ESC Guidelines 2016, or iii) hospitalization with heart failure within 12 months prior to study entry.
2458021|NCT03186833||Group E|male or female aged >70 years with HFREF, defined as HF with LVEF <40% on TTE)
2458069|NCT03186404|Placebo Comparator|Placebos|Placebos
2458070|NCT03186404|Experimental|Statin|Atorvastatin 40mg
2458092|NCT03186105|Experimental|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days.
2458170|NCT03185988|Experimental|GI tumor beyond CRC, ESCC, BTC,GC&GEJA|HER2 positive GI tumor beyond CRC, ESCC, BTC,GC&GEJA
2458171|NCT03185988|Experimental|Esophageal squamous cell carcinoma|HER2 positive Esophageal squamous cell carcinoma
2458173|NCT03185988|Experimental|Biliary tract cancer|HER2 positive Biliary tract cancer
2458174|NCT03185988|Experimental|Colorectal cancer|HER2 positive and RAS/BRAF wild type colorectal cancer
2458209|NCT03185442|Experimental|PRF-fMRI|
2458302|NCT03184883|Experimental|single conventional denture|patients with mandibular edentulous arch by using acrylic resin denture with soft linner
2458305|NCT03184883|Active Comparator|single flexible denture|patients with mandibular edentulous arch by using flexible lower denture
2458381|NCT03184688|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2458388|NCT03184688|Placebo Comparator|Normal saline|Normal saline for hydrodissection
2458456|NCT03184155|Experimental|Intracoronary Nicardipine|200 mcg intracoronary injection of nicardipine prior to PCI, with potential for additional 100 mcg nicardipine before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
2458459|NCT03184155|Placebo Comparator|Sterile Saline|Injection of sterile saline prior to PCI, with potential for additional saline injections before stent placement, balloon post-dilation, and before post-PCI IMR measurement.
2458514|NCT03183622||ALLO-ASC-DFU treatment|Subjects with ALLO-ASC-DFU treatment in phase 1 clinical trial of ALLO-ASC-BI-101
2458540|NCT03183297|Experimental|JMI-001|JMI-001 is a combination product of naproxen 220mg and fexofenadine 60mg (Dose Level one) then a combination product of naproxen 440mg and fexofenadine 120mg (Dose Level Two).
2458541|NCT03183297|Active Comparator|Naproxen|Naproxen 220mg or 440mg
2458543|NCT03183297|Active Comparator|Fexofenadine|fexofenadine 60mg or 120mg
2458546|NCT03183297|Placebo Comparator|Placebo|
2458591|NCT03182972|Experimental|Intervention arm|"Seminar presentation will be done using the followings:~Power point presentation on the following topics as it relates to medication reconciliation:~Communication skill (with patients and also with other members of the healthcare team)~Documentation of pharmaceutical care activities~Medication history taking~Drug therapy problems~Medication reconciliation practice~Case studies on medication reconciliation~Role plays on medication reconciliation"
2458592|NCT03182972|No Intervention|Control arm|Control group
2458624|NCT03182686|Experimental|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA)), solution, 4 mL, single intra-articular injection
2458630|NCT03182686|Other|Saline|Saline, solution, 4 mL, single intra-articular injection
2458803|NCT03181295|No Intervention|Usual care|Standard periodic health review (PHR) appointment. [As patients will get a survey about PA levels prior to their PHR, this may affect their likelihood of addressing PA during their PHR.]
2458808|NCT03181295|Experimental|Usual care plus intervention|Standard PHR appointment plus personalized exercise Rx and resources
2458875|NCT03181152||ACOS group|Impulse Oscillometry Bronchial Dilation Test if needed
2457855|NCT03187795|Experimental|Oxybutynin chloride IR then Mirabegron|Subjects randomized to this group will receive oxybutynin IR (5 mg three times daily) for 6 weeks. After the initial 6 weeks, subjects in this group will then be switched to an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily).
2457856|NCT03187795|Experimental|Mirabegron then Oxybutynin chloride IR|Subjects randomized to this group will receive an escalating dose of mirabegron for 6 weeks (25 mg once daily for 2 weeks, followed by 50 mg once daily for 4 weeks; Note: two placebo daily will be included with mirabegron once daily to match the frequency of dosing to oxybutynin IR three times daily). After the initial 6 weeks, subjects in this group will then be switched to receive oxybutynin IR (5 mg three times daily) for 6 weeks
2457932|NCT03187392|Active Comparator|lidocaine injection|
2457935|NCT03187392|Experimental|lidocaine-prilocaine cream|
2458031|NCT03186911|Other|E-liquid Group|Participants will sample two different e-liquids.
2458080|NCT03186417|Experimental|Cohort 1|2 million human MSC (hMSC)/kg infusion versus placebo infusion
2458083|NCT03186417|Experimental|Cohort 2|4 million hMSC/kg infusion versus placebo infusion
2458085|NCT03186417|Experimental|Cohort 3|6 million hMSC/kg infusion versus placebo infusion
2458142|NCT03186040|Other|Lacosamide|
2458183|NCT03185741|Experimental|UMS Strategy|"Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record.~Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose.~Single-page, plain language medication information sheets with important medication-related information following health literacy best practices."
2458185|NCT03185741|Experimental|UMS Strategy + SMS Text Messaging|In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.
2458187|NCT03185741|No Intervention|Usual Care|Patients of providers randomized to the usual care arm will receive their standard care
3190967|NCT00793364|Other|Mediterranean diet group|Mediterranean diet group
3190968|NCT00793377|Experimental|ADOC x 4 + Tam 20|Adriamycin will be given at a dose of 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles. Adriamycin will be administered as a short i.v. infusion over 15 minutes, followed immediately by a 1-hour infusion of docetaxel diluted in 250 mL NaCl. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
2458324|NCT03185000|Experimental|Immediate ATIMP (AP)|Patients randomised to AP will receive Treg immunotherapy (TR004) infusion at Week 0 and Placebo infusion at Week 8.
2458329|NCT03185000|Experimental|Delayed ATIMP (PA)|Patients randomised to PA will receive Placebo infusion at Week 0 and Treg immunotherapy (TR004) infusion at Week 8.
3190969|NCT00793377|Experimental|AC x 4 - Doc x 4 + Tam 20|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy
2458421|NCT03184038|Other|Assessment of neurocognitive function|Patients undergo assessment of neurocognitive function at baseline and at 2, 4, 6, and 12 months after undergoing standard of care Stereotactic Radiosurgery (SRS) or Stereotactic Body Radiation Therapy (SBRT)
2458499|NCT03183804||ALLO-ASC-DFU|Subjects with ALLO-ASC-DFU treatment in phase 2 clinical trial of ALLO-ASC-DFU-201
2458504|NCT03183804||Standard therapy|Subjects with Standard therapy in phase 2 clinical trial of ALLO-ASC-DFU-201
2458554|NCT03183323|Experimental|Telerehabilitation|In addition to optimal medical treatment: 3 months of twice weekly group-based telerehabilitation through a video-conferencing on a tablet platform. In addition access to instruction videos for further self-training through the same platform and throughout the whole 2-year periode. Electronic devices to trace activity.
2458556|NCT03183323|No Intervention|Standard care|In addition to optimal medical treatment: Advice on physical activity. Electronic devices to trace activity.
3190970|NCT00793390||inflammatory breast cancer cases|inflammatory breast cancer cases
3190971|NCT00793390||non-inflammotory breast cancer cases|non-inflammatory breast cancer cases
2458778|NCT03182205|Experimental|Inspiratory muscle exercise (IME)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure.
2458783|NCT03182205|Sham Comparator|Sham IME|Participants will be submitted to inspiratory muscle exercise with the same equipment as the intervention group, but without a load generating resistance.
2458818|NCT03181269|Experimental|Intervention education|Participants will receive the intervention education and data recording package.
2458826|NCT03181269|Placebo Comparator|Placebo education|Participants will receive the placebo educational and data recording package.
2459137|NCT03179514|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
2459148|NCT03179514|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
3190972|NCT00793390||visitor controls without cancer|visitor controls without breast cancer- those visiting cancer patients
3190973|NCT00793416|Experimental|ShuntCheck measure|All patients will have ShuntCheck measurements along with radionuclide shunt patency testing.
2457876|NCT03187626|Experimental|Intra-articular botulinum toxin A and splinting|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
2457879|NCT03187626|Active Comparator|Intra-articular saline and splinting|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
2457944|NCT03187249|Experimental|Cognitive Behavioral Therapy|receive cognitive-behavioral therapy for 12 weeks
2457948|NCT03187249|Experimental|Pulmonary Rehabilitation Therapy|receive pulmonary rehabilitation therapy for 12 weeks
2457949|NCT03187249|Experimental|Combined Therapy|receive both cognitive-behavioral therapy and pulmonary rehabilitation therapy for 12 weeks
2457950|NCT03187249|No Intervention|Regular Therapy|receive regular therapy for chronic obstructive pulmonary disease
3190974|NCT00793442||Novel Endothelial Markers Derivation|"Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants.~From the ProCESS subjects, the researchers will include those who were: 1) recruited by participating centers who participated in other components of this ancillary study or 2) who were sequentially enrolled from periods derived from the beginning, middle, and end of the ProCESS study."
3190975|NCT00793442||Novel Endothelial Marker Validation|Our study participants will come from the Protocolized Care for Early Severe Sepsis (ProCESS) trial will be eligible participants; the researchers will recruit a sequential 300 patient validation set.
3190976|NCT00793468|Placebo Comparator|Placebo Arm|Subjects in placebo arm will be taking placebo once daily for 12 weeks from week 5 to 16.
3190977|NCT00793468|Experimental|GSK598809 Arm|Subjects in GSK598809 arm will be taking GSK598809 once daily for 12 weeks from weeks 5 to 16.
3190978|NCT00793481||Diagnostic tool|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
3190979|NCT00793494|Experimental|Probaclac|Administration of Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™) b.i.d.
2458237|NCT03185793|Placebo Comparator|Placebo|placebo for 5 weeks
2458239|NCT03185793|Experimental|2.5mg SHR4640|SHR4640 for 5 weeks
2458240|NCT03185793|Experimental|5mg SHR4640|SHR4640 for 5 weeks
2458243|NCT03185793|Experimental|10mg SHR4640|SHR4640 for 5 weeks
2458246|NCT03185793|Active Comparator|50mg benzbromarone|Benzbromarone for 5 weeks
2458289|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
3190980|NCT00793494|Placebo Comparator|Placebo|
2458451|NCT03184051||Ultrasound assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a total arthroplasty. Diagnostic performance of ultrasonography is evaluated on ex vivo cartilage samples (2 samples per patient are selected with different stage of OA : 1 with early stage and 1 with advanced stage).
2458502|NCT03183661||ALLO-ASC-CD injection|Subjects with ALLO-ASC-CD injection in phase 1 clinical trial of ALLOASC-CD-101
2458553|NCT03183440|Experimental|PREBIOTICS|188 pregnant women
2458555|NCT03183440|Placebo Comparator|PLACEBO|188 pregnant women
3190981|NCT00793507|Experimental|1: Intervention Group|All participants in the intervention group will be receiving standard preventive dental care received by children in their dental providers' office. These intervention children will receive dental scaling, cleaning and fluoride varnish at visits every three to six months. All participants in the intervention group will receive active reminder/recall from the hygienist, encouraging the participants to return every three to six months for the oral exam, cleaning, scaling and fluoride application.
3190982|NCT00793507|Active Comparator|2: Control Group|The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist.
3190983|NCT00793559|Active Comparator|terlipressin bolus|1 mg of terlipressin received one time only
3190984|NCT00793559|Experimental|terlipressin drip|
3190985|NCT00793637||Surgical|Patients with proximal and/or distal tibial, femoral and/or humeral fractures treated with intramedullary nails and the Angular Stable Locking System(ASLS)
2458717|NCT03182036|Experimental|Study group|Portable pulsed oxygen
2458843|NCT03181802|Experimental|botulinum toxin A|
2458845|NCT03181802|Placebo Comparator|Placebo|
2458905|NCT03180944|Experimental|1.2% Lugol's solution|This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
2458911|NCT03180944|Experimental|1.0% Lugol's solution|This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
2458918|NCT03180944|Experimental|0.8% Lugol's solution|This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
2458921|NCT03180944|Experimental|0.6% Lugol's solution|This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
2458926|NCT03180944|Experimental|0.4% Lugol's solution|This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.
2458961|NCT03180463|Experimental|Group 1|Core decompression surgery; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#).
3190986|NCT00793663|Experimental|1|The effect of xenon as an anaesthetic on the depth of hypnosis.
3190987|NCT00793663|Active Comparator|2|The effect of sevoflurane as an anesthetic on the depth of hypnosis
3190988|NCT00793663|Experimental|3|Dexamethasone as prevention of postoperative nausea and vomiting after xenon or sevoflurane anesthesia
3190989|NCT00793663|Placebo Comparator|4|
3190990|NCT00793663|Experimental|5|Ondansetron, to determine the onset-time of ondansetron when used as rescue medication for postoperative nausea and vomiting
3190991|NCT00793663|Placebo Comparator|6|
3190992|NCT00793676|Other|A= Asthma|
3190993|NCT00793676|Other|B= COPD|
3190994|NCT00793676|Other|C= Control|
3190995|NCT00793689||total thyroidectomy|patients undergoing total thyroidectomy
3190996|NCT00793702|Experimental|A|two injections 0.01 µg rdESAT-6 + rCFP-10 (6 weeks interval)
2457882|NCT03187834|Active Comparator|Amoxicillin|"Comparison of nasopharyngeal and rectal microbiome in children receiving Amoxicillin versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, twice a day as is:~Amoxicillin: 25 mg/kg/day, divided into twice daily doses for Days 1-5"
2457884|NCT03187834|Active Comparator|Cotrimoxazole|"Comparison of nasopharyngeal and rectal microbiome in children receiving Cotri-moxazole versus children receiving placebo Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive treatment everyday, once a day as is:~Co-trimoxazole: 240 mg daily for Days 1-5"
2457888|NCT03187834|Placebo Comparator|Placebo|"Comparison of nasopharyngeal and rectal microbiome in children receiving placebo versus children receiving antibiotics Children aged 6 months to 59 months will be measured and weighed then, they will be randomized to one of the study arm.~Children will receive Placebo everyday, once a day."
2457920|NCT03187223|Active Comparator|Arm A (Mel)|Melphalan 100mg/m2/day iv days -2 and -1
2457922|NCT03187223|Experimental|Arm B (BenMel)|Melphalan 100mg/m2/day iv days -2 and -1 Bendamustine 200mg/m2/day iv days -4 and -3
2457979|NCT03186963|Experimental|No immobilization|Patients receive a conventional dressing made with gauze, cotton padding and inelastic bandage after the surgery. They are instructed to start light wrist movements on the first postoperative day and progress as tolerated, beginning rehabilitation with physiotherapy after 2 weeks postoperatively.
2457981|NCT03186963|Active Comparator|Volar splint|Patients receive a volar plaster splint with inelastic bandage after the surgery, and are instructed not to remove the immobilization for 2 weeks. After this period, the immobilization is removed and patients begin rehabilitation with physiotherapy.
3190997|NCT00793702|Experimental|B|two injections 0.01 µg rdESAT-6 + rCFP-10 (12 weeks interval)
3190998|NCT00793702|Experimental|C|two injections 0.1 µg rdESAT-6 + rCFP-10 (6 weeks interval)
2458307|NCT03184857|Active Comparator|two stage sinus lifting using bovine bone particles|Open maxillary sinus lifting will be done with sinus augmentation using bovine bone particles
2458308|NCT03184857|Experimental|two sage sinus lifting using Nano HA bone particles|Open maxillary sinus lifting will be done with sinus augmentation using Nano HA bone particles
2458398|NCT03184662|Experimental|HIPA group|"Twice weekly physical activity session in a dedicated structure, supervised by a graduated coach, alternating sessions of strengthening and intermittent HIPA, allowing a mixed stimulation of neuro-muscular and cardiovascular systems, and regular (every 3 months) adjustment of the intensity of the program.~The sessions will be preferably performed in sports gyms but if required can also be performed online with supervised coaches, trained for the study."
2458400|NCT03184662|Active Comparator|Control group|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD (French Language Diabetes Society).
2458494|NCT03183674|Experimental|oxytocin spray|oxytocin nose spray dose 0,4IU/kg, once unique dose
2458497|NCT03183674|Placebo Comparator|placebo|saline nose spray, 0,9 %, once unique dose
2458534|NCT03183375|Experimental|Hydroxyurea arm|This arm will be given investigational drug that is Hydroxyurea .This intervention will be given along with the standard treatment that is blood transfusion and iron chelation.
2458535|NCT03183375|No Intervention|Standard arm|this arm will only receive the standard treatment which is blood transfusion and iron chelation
2458561|NCT03183089|Experimental|Active|
2458562|NCT03183089|Active Comparator|Active Comparator|
2458618|NCT03182881|Experimental|Miofascial-reléase|Myofascial Release (MR), with the purpose of releasing fascial restriction zones and major fibrosis (thoraco-brachial) caused by restriction after CM tto. IM therapy was applied to the affected area. The position of the patient was identical during both treatment sessions.
2458619|NCT03182881|Active Comparator|Manual Lymphatic Drainage (MLD)|It was applied following the Leduc method with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, in the chest region and in the arm with the same sequence as Guerero et al. The objective of the application in our study is to obtain a beneficial treatment for the patient since it produces an increase of blood and lymphatic circulation, with positive effects on the peripheral vegetative nervous system.
2458690|NCT03182465|Other|the predictive value of ProCalcitonin|Patients with solid tumors admitted at the emergency care presenting a febrile neutropenia due to chemotherapy
2458780|NCT03182049||GPA (Wegener's granulomatosis) patients|
2458889|NCT03180853||Relapsed Multiple Myeloma Participants|The participants in the United States with a confirmed diagnosis of relapsed multiple myeloma following 1 to 3 prior lines of therapy who initiate treatment with a proteasome inhibitor (PI) and/or immunomodulatory drug (IMiD) used either as monotherapy or combination therapy with other treatments as per routine clinical practice within 90 days prior to study enrollment. These participants will be observed for the sequence of systemic myeloma treatments used during routine clinical practice, considering the life expectancy of patients with myeloma in the registry.
2459035|NCT03180203|Experimental|INTELLiVENT-ASV|INTELLiVENT-ASV is a full closed-loop ventilation mode,available on the mechanical ventilator S1 of Hamilton.
2459038|NCT03180203|Active Comparator|Conventional modes|Volume controlled continuous mandatory ventilation (CMV) mode with pressure support mode on the Hamilton S1 Device.
2459078|NCT03179878|Experimental|SYNB1020|SYNB1020
2459080|NCT03179878|Placebo Comparator|Placebo|100 mL masking solution
2459144|NCT03179579|Experimental|Experimental group|"HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~HIPEC with paclitaxel 135 mg/m^2+HIPEC with cisplatin 75 mg/m^2±HIPEC with Raltitrexed 3 mg/m^2 intraperitoneally in succession~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
2459151|NCT03179579|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks~Cytoreductive surgery~4-6 cycles of adjuvant chemotherapy: S-1 40-60 mg/m^2, d1-d14, Bid p.o.+ oxaliplatin 130 mg/m^2, d1, IV, every 3 weeks"
2459409|NCT03177538|Active Comparator|Follitropin alfa and lutropin alfa|Pergoveris 300 IU
3155435|NCT00320697|Other|Bupropion + Nicotine patch + Nicotine gum or lozenges|Open label phase All enrolled subjects received weekly CBT group sessions, bupropion 300 mg/daily (if medically eligible), nicotine patch 21 mg/day, and up to 20 mg/day of nicotine gum or lozenge for prn use. Subjects set a quit date between weeks 3 and 4; a ½ hour individual CBT session to help prepare them for the quit date. The open phase groups consisted of 8 weekly CBT meetings.
3155436|NCT00320697|Active Comparator|Bupropion + Nicotine Patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial.Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
2457998|NCT03186729|Experimental|Antithrombotic treatment|For patients with vascular disease and indication for antiplatelet drugs: Antiplatelet drugs; For patients with atrial fibrillation and indication for anticoagulant drugs: Anticoagulant drugs
2458004|NCT03186729|No Intervention|No antithrombotic treatment|For patients with indication for antiplatelet drugs: No antithrombotic drugs For patients with atrial fibrillation and indication for anticoagulant drugs: No anticoagulant drugs.
2458061|NCT03186456|Experimental|Group 1|Aspirin Tablet, 100mg/d; Allogeneic umbilical cord mesenchymal stem cells, 0.5-1*10^6/kg
2458062|NCT03186456|Placebo Comparator|Group 2|Aspirin Tablet, 100mg/d; Placebo
2458126|NCT03186157||Decompressive craniectomy patients|All of the patients that undergo decompressive craniectomy due to intracranial mass lesion and are transferred to neuro-rehabilitation unit in our university hospital.
2458175|NCT03185832||CRT-D Cohort|Composite rate of first appropriately treated ventricular arrhythmia
2458176|NCT03185832||ICD Cohort|Composite rate of first appropriately treated ventricular arrhythmia
2458179|NCT03185832||PM / CRT-P Cohort|All cause mortality
2458181|NCT03185832||Non-device Cohort|All-cause mortality in the subject cohort with 2 to 5 predefined SCD driving risk factors
2458312|NCT03184831|Active Comparator|sinus lift, implant placement, sole bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a deproteinized bovine bone solely.
2458316|NCT03184831|Experimental|sinus lift, implant placement, injectable PRF + bovine bone|sinus floor elevation with simultaneous implant placement together with grafting the sinus with a mixture of injectable platelet rich fibrin with a deproteinized bovine bone.
2458393|NCT03184610||OCT-scanning|Patients with Keratoconus are scanned with an OCT-Prototype
2458396|NCT03184610||OCT-scanning for volunteers|Volunteers with healthy eyes are scanned with an OCT-Prototype
2458467|NCT03184194|Experimental|Nivolumab-daratumumab|daratumumab 16 mg/kg: 8 times once weekly, then 8 times every 2 weeks; then every 4 weeks; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks
2458470|NCT03184194|Experimental|Nivolumab-daratumumab with cylclophosphamide|daratumumab 16 mg/kg: weekly for 8 weeks, then Q2W for 16 weeks, ten Q4W thereafter; nivolumab: 240 mg every 2 weeks during first 6 cycles, followed by 480 mg every 4 weeks; low-dose cyclophosphamide 50mg daily on days 1-28 of each 28-day cycle;
2458621|NCT03182790|Experimental|Group A|Instant Messaging IM + regular messages +AWARD advice + warning leaflet + referral card
2458622|NCT03182790|Experimental|Group B|COSH booklet + general brief advices +Placebo Messages
2458756|NCT03181854|Experimental|Intervention group|Consultation with PCT doctor every 3 weeks. Telephone coaching once a week for 3 months and once in 2 weeks for another 3 months.
2458757|NCT03181854|No Intervention|Control Group|Usual palliative care can be provided if desired.
2458806|NCT03181321|Experimental|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
2458809|NCT03181321|No Intervention|Control|Participants in this arm will not be asked to change anything in their lifestyle during the 6 month period.
2458867|NCT03181139||pre-ERAS|Patients cared for prior to the implementation of the Enhanced Recovery after surgery for total mastectomy pathway
2458869|NCT03181139||post-ERAS|patients cared for after the implementation of the Enhanced Recovery after surgery for total mastectomy pathway. Pathway included preoperative acetaminophen and gabapentin, Pec blocks, multimodal analgesia postoperatively and aggressive PONV treatment.
2459073|NCT03179774|Experimental|Clinical registry-ER and OMT|In clinical registry setting, participants who selected Endovascular revascularization and optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
2459178|NCT03179254|Active Comparator|Oral hypoglycemic agent discontinue|Metformin discontinue on the day of surgery
3174518|NCT00624390|Experimental|Sepraspray|Sepraspray applied directly to both sides of the uterus, Fallopian tubes, and ovaries (or opposing sites if not possible to apply directly). Sepraspray was applied via a sterile cannula at a tissue concentration of approximately 5 mg/cm^2.
3174519|NCT00624390|No Intervention|Control|No anti-adhesion treatment was used.
3174520|NCT00624403|Active Comparator|1|LMA ProSeal
3174521|NCT00624403|Experimental|2|I-Gel
3174522|NCT00624455|Active Comparator|1|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
3174523|NCT00624455|Placebo Comparator|2|Placebo
3174524|NCT00624481|Active Comparator|1|
3174525|NCT00624481|Experimental|2|
3174526|NCT00624481|Experimental|3|
3174527|NCT00624481|Experimental|4|
3174528|NCT00624481|Experimental|5|
3174529|NCT00624494|Active Comparator|Conventional monitoring|hemodynamic monitoring - conventional monitoring
3174530|NCT00624494|Active Comparator|Advanced monitoring|hemodynamic monitoring - advanced monitoring
3174531|NCT00624533|Active Comparator|A|Primary Health Care Conventional Physiotherapy Treatment (based in electrotherapy)
3190999|NCT00793702|Experimental|D|two injections 0.1 µg rdESAT-6 + rCFP-10 (12 weeks interval)
3191000|NCT00793702|Experimental|E|one injection 1.0 µg rdESAT-6 + rCFP-10
2458033|NCT03186547|Experimental|Botulinum Toxin A Injection|this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
2458037|NCT03186547|Experimental|Modified Lip Repositioning Surgery|this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
2458112|NCT03186326|Active Comparator|Arm A Chemotherapy (standard treatment)|FOLFOX or FOLFIRI +/- targeted therapy
2458116|NCT03186326|Experimental|Arm B - Immunotherapy (experimental arm)|Avelumab
2458251|NCT03185351|Active Comparator|BUPIVACAINE|"patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB.~."
2458253|NCT03185351|Active Comparator|BUPIVACAINE and midazolam|patients will receive 20 ml of 0.5% bupivacaine + midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB.
2458254|NCT03185351|Active Comparator|BUPIVACAINE and i.v midazolam|patients will receive 20 ml of 0.5% bupivacaine + 5 ml normal saline (0.9%) using supraclavicular BPB + 0.03 mg/kg of midazolam by I.V. route at the same time of the block
2458380|NCT03184350|Other|Adjuvant pelvic proton radiation|
2458434|NCT03184220|Experimental|EXPERIMENTAL GROUP|"Patients who are pregnant, have pacemaker and those surgically operated cervical spine patients who have been treated with myofascial therapy a month earlier.~Multimodal physical therapy program includes:~Myofascial syndrome cervical therapy treatment."
2458441|NCT03184220|Experimental|CONTROL GROUP|"Multimodal physical therapy program includes:~ultrasound therapy (US),~transcutaneous electric nerve stimulation (TENS)~massage."
2458488|NCT03183765|Experimental|MMR vaccine|Measles-Mumps-Rubella Vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments
2458490|NCT03183765|Active Comparator|Cryotherapy|patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions
2458577|NCT03183115|Experimental|RFA group|Balloon type RFA (12J/cm2, 1 application) will be applied for the entire speckled esophageal mucosa at the 3 months after complete ESD
2458580|NCT03183115|No Intervention|Control group|No intervention; surveillance endoscopy alone
2458599|NCT03182712|Experimental|n-3 PUFA Group|Subjects receiving n-3 PUFA (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks.
2458601|NCT03182712|Placebo Comparator|Placebo Group|Subjects receiving gelatin capsules (500mg). Three capsules were ingested daily for eight weeks.
2458665|NCT03182595|Experimental|open---label|An open---label, single centre, nonrandomized clinical study in healthy volunteers, with intervention over a 13---week period.
2458696|NCT03182257|Experimental|ONO-7579 Part A|Single Ascending doses of ONO-7579
2458697|NCT03182257|Experimental|ONO-7579 Part B|Expansion phase of ONO-7579
3191001|NCT00793715|Active Comparator|1|Decompressive laparotomy with temporary abdominal closure
3191002|NCT00793715|Active Comparator|2|Patients who will receive percutaneous puncture with placement of abdominal catheter
3191003|NCT00793728|Active Comparator|Antrectomy|
3191004|NCT00793728|Active Comparator|Without antrectomy|
3191005|NCT00793741||1|Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate
3191006|NCT00793741||2|Healthy control subjects
2459040|NCT03180255|Experimental|EGP-437|40 mg/ml dexamethasone phosphate solution delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
2459043|NCT03180255|Placebo Comparator|Placebo|100 mM sodium citrate buffer solution (placebo) delivered by iontophoresis treatment consisting of 4.5 mA-min at 3.0 mA
2459072|NCT03179826||Study population|Adults consulting with one of the participating general practitioners and requiring long term inhaled corticoids and monitoring.
2459122|NCT03179644|Experimental|Bi-pulmonary transplantation|Adult patient admitted in the Respiratory Distress and Severe Infections Intensive Care Unit in the postoperative period following a double lung transplant after written informed consent.
2459171|NCT03179228|Experimental|Prostate Embolization|Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
2459643|NCT03176017|Placebo Comparator|Conventional TUIP|regular non ejaculatory sparing TUIP
3191007|NCT00793754|No Intervention|1|
3191008|NCT00793754|Experimental|2|Aspirin 100 mg / day
3191009|NCT00793754|Experimental|3|Atorvastatin 40 mg / day
3191010|NCT00793754|Experimental|4|Aspirin 100 mg / day + Atorvastatin 40 mg / day
3191011|NCT00793767|Placebo Comparator|placebo|placebo
3191012|NCT00793767|Experimental|Erythropoietin|acute administration of erythropoietin
3191013|NCT00793806||Medical Tool|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
3191014|NCT00793832|Active Comparator|1|Supervised exercise.
3191015|NCT00793832|Active Comparator|2|Diet Advice
3191016|NCT00793845|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (total body irradiation, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
3191017|NCT00793858|Active Comparator|1|placebo in left nostril, isotonic ciclesonide in right
3191018|NCT00793858|Active Comparator|2|hypotonic ciclesonide in left nostril, placebo in right
3191019|NCT00793858|Active Comparator|3|hypotonic ciclesonide in right and left nostrils
3191020|NCT00793858|Active Comparator|4|isotonic ciclesonide in both right and left nostrils
3191021|NCT00793858|Placebo Comparator|6|placebo in both right and left nostrils
2457968|NCT03187080|Sham Comparator|Group 1 Arm B|Breast reduction with Sham paravertebral block using saline.
2457971|NCT03187080|Experimental|Group 2 Arm A|Breast augmentation with Paravertebral block using local anesthetic.
2457973|NCT03187080|Sham Comparator|Group 2 Arm B|Breast augmentation with Sham paravertebral block using saline.
2457974|NCT03187080|Experimental|Group 3 Arm A|Breast reduction with Enhanced recovery after breast surgery (ERABS) strategies.
2457976|NCT03187080|No Intervention|Group 3 Arm B|Breast reduction, standard perioperative management.
2457977|NCT03187080|Experimental|Group 4 Arm A|Breast augmentation with Enhanced recovery after breast surgery (ERABS) strategies.
2457978|NCT03187080|No Intervention|Group 4 Arm B|Breast augmentation, standard perioperative management.
2458028|NCT03186560|Active Comparator|Group A: Arterial Leg Ulcer|Defined as healing/non-healing Healing defined as reduction in wound area of greater than 20% over a 2-week period
2458039|NCT03186560|Active Comparator|Group B: Mixed Leg Ulcer|only to be done once Arterial leg ulcers show change in flux ABPI of <0.8-0.6
2458045|NCT03186560|Active Comparator|Group C: Diabetic Foot Ulcer - neuropathic|On clinical inspection present as neuropathic
2458046|NCT03186560|Active Comparator|Group D: Diabetic Foot Ulcer - neuroischemic|On clinical inspection present as neuroischemic
2458089|NCT03186222||cases with acne vulgaris|A group of 100 patients with acne vulgaris. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
2458091|NCT03186222||control group|control group of 100 age and sex matched healthy volunteers. blood sample are taken in the morning hours, between 08:00 and 10:00 am.
2458151|NCT03186014|Experimental|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
2458199|NCT03185689|Experimental|Intervention group|Effectiveness of an intensified DSME in T2D adult patients
2458208|NCT03185689|No Intervention|Comparison group|The comparison group have got the usual traditional way of education, which is given occasionally for all of diabetes patients at waiting area. Other than this, the comparison group didn't get an organized and intensified DSME.
2458321|NCT03185299|Experimental|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
2458328|NCT03185299|Experimental|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
3155437|NCT00320697|Placebo Comparator|Placebo pill + placebo patch|Randomized phase: Subjects who achieved 2 weeks continuous abstinence at the end of the open intervention and who are medically eligible for bupropion were eligible for the double blind, relapse prevention trial. Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
2458439|NCT03184012|Experimental|NuSmile Zirconia crowns|NuSmile Zirconia crowns is an esthetic primary anterior crown used to restore carious primary anterior teeth.
2458445|NCT03184012|Experimental|Composite resin strip crowns|Composite resin strip crowns is an esthetic conventional primary anterior crown used to restore carious primary anterior teeth.
2458501|NCT03183791|Experimental|RELAX group|
2458503|NCT03183791|Active Comparator|Monitored Usual Care (MUC) group|
3155438|NCT00320775|Experimental|Part A|Part A: An open label study in which six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye. The total volume of each injection will be 100 μL. Enrollment in new dose levels will not begin until all patients in the preceding dose level have completed Visit 5 (Day 15).
2458635|NCT03182634|Experimental|Cohort A - Extended-dose fulvestrant|Fulvestrant 500mg IM on Cycle 1 Days 1, 8 and 15 and Cycle 2 onwards Days 1 and 15
2458636|NCT03182634|Experimental|Cohort B - Neratinib|Neratinib 240mg PO on a continuous schedule starting on Cycle 1 Day 1 AND in ER positive breast cancer, fulvestrant 500mg IM on Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
2458639|NCT03182634|Experimental|Cohort C - AZD5363 and fulvestrant|AZD5363 400mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment AND fulvestrant 500mg IM Cycle 1 Days 1 and 15 and Cycle 2 onwards Day 1
2458642|NCT03182634|Experimental|Cohort D - AZD5363|AZD5363 480mg PO BID on a 7 day schedule of 4 days on treatment followed by 3 days off treatment
2458643|NCT03182634|Experimental|Cohort E - olaparib and AZD6738|AZD6738 160mg to be administered once daily on Days 1-7 of each cycle and olaparib 300mg to be administered twice daily on a continuous schedule starting on Cycle 1 Day 1.
2458738|NCT03182127|Other|one Group|Magnetic resonance imaging and ultrasound will be done for all patient
2458802|NCT03181698||first group|patients with more than one episodes of mania
2458807|NCT03181698||second group|sex-matched and age- matched healthy controls
2458870|NCT03181165|Experimental|Low-carbohydrate Therapeutic Nutrition|A 12-week low-carbohydrate, energy-restricted diet will be administered using a combination of pre-packaged foods and whole foods from pre-specified lists.
2458872|NCT03181165|No Intervention|Treatment-as-usual waitlist control|Participants will receive standard lifestyle advice to follow a low-fat, low-sugar, high fibre diet and aim to accumulate 150 minutes of moderate activity per week.
2458887|NCT03180788|Active Comparator|Traditional ESD|The patients in this Group will undergo traditional ESD.
2458891|NCT03180788|Experimental|Traction assisted ESD|The patients in this Group will undergo traction assisted ESD
2459005|NCT03180294|Experimental|Arm A (bupropion hydrochloride, placebo)|Patients receive bupropion hydrochloride PO QD on days 1-63 and placebo PO QD on days 8-71.
3155439|NCT00320775|Active Comparator|Part B|Part B: A controlled, prospective, randomized, double-masked study in which up to 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive a single ITV injection of2.0 mg/eye VEGF Trap (or the MTD if reached prior to 2.0 mg) followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later. Enrollment into Part B will begin 2 weeks after the last subject to receive the 2.0 mg/eye dose in Part A has been observed for 15 days and it has been determined that the safety profile of VEGF Trap at this dose level is adequate to support expansion of dosing at this dose level. The dose of pegaptanib sodium will be 0.3 mg, according to the package insert.
2457984|NCT03186937|Experimental|Hominex-2|"Participants will receive an individualized dietary prescription that incorporates a methionine-free amino acid-modified medical food (Hominex-2, Abbott Nutrition) supplemented with low-methionine foods. Hominex-2 contains a mixture of L-amino acids but lacks methionine.~Participants will be asked to have an optional non-contrast MRI to assess body composition prior to and at completion of the methionine-restricted (MR) diet. Not completing a scheduled MRI is not considered a protocol deviation.~Participants will be followed for 30 days after surgery or biopsy date. Subjects removed from study for unacceptable adverse events (AEs) will be followed until resolution or stabilization of the AE."
2457995|NCT03186599|No Intervention|high adherence control group|-Patients on continuous MEMS monitoring with usual care.
2458003|NCT03186599|No Intervention|low adherence control group|-Patients on continuous MEMS monitoring with usual care.
2458011|NCT03186599|Experimental|low adherence intervention group|"Patient with the WALKON mobile application.~Patient with monthly feedback call~Patients on continuous MEMS monitoring."
2458053|NCT03186508|Active Comparator|Optimize Sleep (OS)|Optimize Sleep will focus exclusively on enhancing sleep by using effective behavioral strategies. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
2458054|NCT03186508|Active Comparator|Optimize Sleep-Plus (OS-Plus)|OS-Plus will focus on enhancing sleep and targeted eating (decreasing sugar-sweetened beverages and sweet and salty snack foods) and activity (increasing physical activity and decreasing TV viewing) behaviors. Specific strategies to be used include: goal setting and self-monitoring, positive bedtime routines, stimulus control/sleep hygiene strategies, problem-solving regarding challenges, and review of effective strategies for relapse prevention.
2458105|NCT03186183|Experimental|GPS program|"The individual GPS motivational interviewing counseling program has 4-6 sessions.~Week 1: information on sexually transmitted infections and HIV disclosure laws is reviewed. Participants are introduced to the sex diary, stress exercise, and stages of change model.~Week 2: a decisional balance exercise about the participant's current sexual behavior is completed and a behavioral goal is chosen.~Week 3: participants explore their greatest fears and hopes about the goal, and the importance of and their confidence in achieving it.~Week 4: the facilitator and participant identify triggers, automatic thoughts, counters, strategies, supports, and rewards pertaining to the pursuit of the goal and role play the new goal.~1-2 supplemental sessions may be added as needed."
2458197|NCT03185884|Active Comparator|Control|- 237 ml beverage; consumed once per test visit
2458198|NCT03185884|Experimental|Experimental|- 237 ml beverage; consumed once per test visit
2458229|NCT03185364|Experimental|Interventional group|Sildenafil Citrate, 20mg, tid for 12 weeks
2458236|NCT03185364|Placebo Comparator|Control group|placebo oral tablet, 12 weeks
2458280|NCT03185104|Experimental|Silver diamine fluoride|38% silver diamine fluoride solution (Saforide, Toyo Seiyaku Kasei Co. Ltd., Osaka, Japan) is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
2458283|NCT03185104|Placebo Comparator|Distilled water|Distilled water is professionally applied to exposed coronal and root surfaces of all teeth every 6 months for 36 months.
2458346|NCT03184805|Active Comparator|Continuing aspirin|Patients in the group may continue the administration of aspirin during perioperative period.
2458350|NCT03184805|Experimental|Stopping aspirin|Patients in the group may stop medication of antiplatelet drugs during perioperative period.
2458420|NCT03184168|Experimental|treatment|[14C]lorlatinib
2458473|NCT03183882|Experimental|Normative Peer Comparison|One-time summary report of 14-month individual history of opioid prescribing WITH comparisons to (a) other providers at their site and (2) other providers at 15 ED sites with similar prescribing
2458474|NCT03183882|Active Comparator|Control Feedback|One-time summary report of their individual history of opioid prescribing
2458518|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in IPF Patients, Recovered COVID19 Patients, and Healthy Volunteers|"Arm1: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the lungs in the FOV is followed by two vertex-to-thigh PET/CT scans.~NOTE: If the patient cannot tolerate lying down for an extended period of time at the time of imaging, the patient may be switched to scanning protocol Option B, which does not include an initial 60-minute dynamic PET/CT scan.~IPF Patients will have a repeat [18F]FP-R01-MG-F2 PET/CT scan performed within 3-8 weeks post initial scan (within 12-24 months post initial scan for previously scanned IPF patients if they are willing to be re-consented)."
2458520|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in PSC Patients|"Arm 2: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. A 60-minute dynamic PET/CT scan to the center of the liver in the FOV is followed by two vertex-to-thigh PET/CT scans.~A repeat [18F]FP-R01-MG-F2 PET/CT scan will be performed within 3-8 weeks post initial scan if a signal is present in the first scan."
2458522|NCT03183570|Experimental|[18F]FP-R01-MG-F2 PET/CT in actively infected COVID19 Patients|Arm 3: 7mCi (range 6-9 mCi) [18F]FP-R01-MG-F2 will be administered to the study participant. One vertex-to-thigh PET/CT scans to the center of the lung in the FOV will follow approximately 60 min post-injection.
3191022|NCT00793858|Active Comparator|5|isotonic ciclesonide in left nostril and hypotonic ciclesonide in right
2458010|NCT03186898|Experimental|Proton Therapy (Radiation Therapy)|Patients undergo proton therapy over 15-24 days for 5 or 15 fractions.
2458016|NCT03186898|Experimental|Photon Therapy (Radiation Therapy)|Patients undergo photon therapy over 15-24 days for 5 or 15 fractions.
2458137|NCT03186131|Active Comparator|Oral Ibandronate alone|Monthly Oral Intake of Ibandronate
2458139|NCT03186131|Active Comparator|Oral Ibandronate and Vitamin D|Monthly oral intake of Ibandronate and daily oral intake of Vitamin D
2458186|NCT03185780|Experimental|Treatment|Patients will be treated with acupuncture and/or touch therapies, this in parallel to their chemo-radiation regimen. These treatments will be administered twice-weekly during active chemo-radiation treatment (6 weeks), followed by once-weekly treatment throughout the remainder of the study period (6 months)
2458200|NCT03185494|Experimental|anti-CD19/22 CAR T cells|Patients receive anti-CD19/22-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
2458313|NCT03184870|Experimental|Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI|FOLFIRI: FOL (folinic acid [leucovorin]) F (fluorouracil [5-fluorouracil]) IRI (irinotecan [CAMPTOSAR])
2458319|NCT03184870|Experimental|Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel|
2458323|NCT03184870|Experimental|Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab|2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable
2458326|NCT03184870|Experimental|Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI|
2458330|NCT03184870|Experimental|Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI|
2458331|NCT03184870|Experimental|Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI|
2458333|NCT03184870|Experimental|Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel|
2458335|NCT03184870|Experimental|Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel|
2458336|NCT03184870|Experimental|Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel|
2458337|NCT03184870|Experimental|Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab|
2458338|NCT03184870|Experimental|Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab|
2458339|NCT03184870|Experimental|Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy|
2458340|NCT03184870|Experimental|Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy|
2458431|NCT03183986|Active Comparator|Phototherapy 478 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 478 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
2458432|NCT03183986|Active Comparator|Phototherapy 459 nm|The jaundiced neonates receives phototherapy with blue light from above at wavelength 459 nm. They are treated for 24 hours, which is standard treatment for neonatal jaundice.
3155440|NCT00320775|Active Comparator|Part C|Part C: A controlled, prospective, randomized, double-masked study in which approximately 30 subjects meeting eligibility criteria will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap. Initiation of Part C is contingent upon the 4.0 mg dose being adequately tolerated in Part A.
3155441|NCT00320814|Experimental|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
2458557|NCT03183310|Active Comparator|Chlorpromazine|Administration of an intravenous bolus injection of 10 mg Chlorpromazine to investigate the effect on esophageal sensitivity.
2458559|NCT03183310|Placebo Comparator|Placebo (Saline)|Administration of an intravenous bolus injection of saline (placebo) as the control condition of chlorpromazine in this cross-over study.
2458626|NCT03182855|Active Comparator|Prehospital ticagrelor|"Ticagrelor 180 mg orally administered in the ambulance as soon as possible after inclusion and before coronary angiography. The two pills are chewed and swallowed with a glass of water.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
2458628|NCT03182855|Active Comparator|Inhospital cangrelor tetrasodium|"Ticagrelor 180 mg orally in combination with cangrelor intravenously (bolus 30 μg/kg within 1 minute followed by infusion (4 μg/kg/minute) for two hours) both administered immediately after coronary angiography, when PPCI is indicated.~In both groups heparin and bivalirudin will be administered as part of routine therapy. In hemodynamically compromised patients with a high thrombus load a glycoprotein IIb/IIIa inhibitor may be used as bail-out therapy (these patients will be excluded). These drugs are not deemed to be study medication."
2458700|NCT03182361|Experimental|Study group|Everybody enrolled in the study will receive BioComp Industries cranio-maxillo-facial (CMF) screw implants
2458727|NCT03181945|Active Comparator|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
2458732|NCT03181945|Active Comparator|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
2458764|NCT03181776|Experimental|left lateral tilting arm|all patients will be put in three angles of left lateral tilt in randomized order (supine position - left lateral tilting in 15 degrees - and left lateral tilting in 30 degrees) and the hemodynamic data will be compared in the three angles.
2458810|NCT03181425||Imaging assessment|All subject of the study have a knee osteoarthritis (OA) and are going to have a knee prosthetic surgery with cartilage excision. Imaging measurements are conducted on human cartilage samples (2 samples per patient are selected : healthy and severely degraded).
2458868|NCT03181113||peginterferon alfa 2b|
2458871|NCT03181113||peginterferon alfa 2a|
2458940|NCT03180723|Experimental|study group|Rituximab is given in 2 doses (1 gm each dose) to a group of15 patients with primary membranoproliferative glomerulonephritis at (0 - after 2 weeks)
2458945|NCT03180723|Active Comparator|control group|Cyclosporine is given orally in a dose of 2mg/kg/d for 3 months to another group of patients with primary membranoproliferative glomerulonephritis.
2459017|NCT03180346|Active Comparator|Standard of Care|
3155442|NCT00321074|Active Comparator|1|
3155443|NCT00321074|Experimental|2|
3155444|NCT00321087|Experimental|1|T2000 dose escalation
2458030|NCT03186846|Active Comparator|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
2458042|NCT03186846|Active Comparator|placebo|No multimodal monitoring will be applied in control group.
2458100|NCT03186248|Experimental|Short myotomy|Per oral endoscopic myotomy extending from 3 cm cephalad to 3 cm distal to EGJ
2458108|NCT03186248|Active Comparator|Long myotomy|Per oral endoscopic myotomy extending from 6-8cm cephalad to and 3 cm distal to EGJ.
2458169|NCT03185923|Experimental|TCM plus conventional drug|The experimental group will receive three type of TCM inaddition conventional drug according to china CAP guidline 2016.
2458172|NCT03185923|Placebo Comparator|TCM placebo plus conventional drug|The control group will receive three type of placebo TCM inaddition conventional drug according to china CAP guidline 2016.
2458230|NCT03185507|Experimental|Cryotherapy|Participants received superficial cryotherapy using the Cryohelmet(TM)
2458234|NCT03185507|No Intervention|Control|Participants sat quietly for 20 minutes
2458300|NCT03185143|Experimental|Naltrexone and Acetaminophen Combination|
2458303|NCT03185143|Active Comparator|Sumatriptan 100 mg|
2458306|NCT03185143|Placebo Comparator|Placebo|
2458436|NCT03184233|Other|Cerebral aneurysm surgery with RVP|Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored. During surgery subjects allocated in this study arm will undergo RVP.
2458446|NCT03184233|Active Comparator|Craniotomy without RVP|"Subjects receive a Magnetic Resonance Imaging of the brain pre-and postoperatively as standard of care. To screen for rapid ventricular pacing induced micro-infarcts, the contralateral hemisphere (contralateral to the hemisphere operated on) and fossa posterior will be evaluated. Troponin levels will be determinated preoperatively, peroperative and at 6, 12 and 24 hours postoperative by blood sample. Maximum cTnl level and cTnl level 24 hours will be compared. Brain oxygenation (Sct O₂) by near-infrared spectroscopy will be monitored.~No rapid ventricular pacing is applied perioperatively."
2458492|NCT03183752|Experimental|Metformin|patients randomized to Metformin group
2458496|NCT03183752|Placebo Comparator|Placebo|patients randomized to placebo group
2458524|NCT03183336|Experimental|Interpositional block graft|ridge split interpositional block graft
2458525|NCT03183336|Active Comparator|Onlay block graft|decortication onlay block graft
2458542|NCT03183193|Placebo Comparator|Control diet|A conventional and balanced diet based on American Heart Association (AHA) guidelines and lifestyle advice to achieve the objective of American Association for the Study of Liver Diseases (AASLD): loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
2458544|NCT03183193|Experimental|FLiO diet|A mediterranean dietary strategy based on macronutrient distribution (quantity and quality), antioxidant capacity, meal frequency, dietary behaviour and lifestyle advice to achieve the objective of AASLD: loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation.
2458611|NCT03182959|Experimental|Lower dose, higher dose|"During the first cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
2458614|NCT03182959|Experimental|Higher dose, lower dose|"During the first cycle, the patient will self-administer Avmacol® (140 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer eight tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary.~During the second cycle, the patient will self-administer Avmacol® (70 μmol/day SF equivalent) starting on the evening of Day 1 of the cycle. Participants will self-administer four tablets of Avmacol® every evening, ideally between 4 pm and 8 pm, through the evening of Day 28. Participants will record the date and time of each Avmacol® administration on the provided diary."
2458684|NCT03182504|Experimental|Nacubactam Plus Meropenem|Participants will receive a single dose of nacubactam co-administered with meropenem.
2458731|NCT03182101|Experimental|Exposure Therapy with fidelity checklist|Therapist and parent/child participants will complete an Exposure Guide after each session.
3155445|NCT00321087|Experimental|2|Placebo followed by T2000 dose escalation
3155446|NCT00321087|Experimental|3|Placebo followed by T2000 dose escalation
3155447|NCT00321100|Active Comparator|A|Cetuximab 250mg/m2 IVweekly of each 21 day cycle; Oxaliplatin 130mg/m2 IVday 1 of each 21 day cycle; Capecitabine 850mg/m2 PO days 1-14 of each 21 day cycle; Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
3155448|NCT00321100|Active Comparator|B|Cetuximab 250mg/m2 IV weekly for each 21 day cycle
2458917|NCT03180775|Sham Comparator|Control|Other: Cellulose (control): cellulose, water soluble powder, 2 g in one daily dose, during 30 days
2458923|NCT03180775|Experimental|Glycine (Trade name: Glycine)|Dietary Supplement: Glycine, water soluble powder, 7.8 g daily in one dose, during 30 days.
3155449|NCT00321113|Active Comparator|1|oral
3155450|NCT00321113|Experimental|2|oral
3174532|NCT00624533|Experimental|B|Group B was treated with the GDS Method (muscular and articular chains physiotherapy method)
2458075|NCT03186495|Experimental|Mild renal impairment|Subjects with mild renal impairment
2458076|NCT03186495|Experimental|Moderate renal impairment|Subjects with moderate renal impairment
2458078|NCT03186495|Experimental|Severe renal impairment|Subjects with severe renal impairment
2458081|NCT03186495|Experimental|Requiring haemodialysis treatment|Subjects requiring haemodialysis treatment
2458102|NCT03186079|Active Comparator|Xiaojidaozhi Decoction|Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
2458111|NCT03186079|Placebo Comparator|non-Xiaojidaozhi Decoction|Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation
2458182|NCT03185806|Experimental|Puncture and Drainage|The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.
2458184|NCT03185806|No Intervention|Conservative therapy|The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.
2458295|NCT03184844|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
2458377|NCT03184675|Experimental|Functional action observation training|
2458382|NCT03184675|Other|General action observation training group|
2458447|NCT03184246|Experimental|GlideScope|intubation with GlideScope
2458448|NCT03184246|Active Comparator|Direct laryngoscopy|intubation with laryngoscope
2458479|NCT03183739|Experimental|ASP8062 lower dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2458482|NCT03183739|Experimental|ASP8062 middle dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2458485|NCT03183739|Experimental|ASP8062 higher dose|Subjects will receive a single dose of ASP8062 on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2458487|NCT03183739|Placebo Comparator|Placebo|Subjects will receive a single dose of Placebo on Day 1, followed by 5 days of washout (Days 2-6) and once daily dosing for 14 consecutive days (Days 7-20) at the same dose level.
2458579|NCT03183453|Experimental|Neuropsychological treatment|The tested treatment is a combination of neuropsychological rehabilitation procedures: learning, episodic memory recall after a delay, selective attention, inhibition of predominant responses and awareness of deficits.
2458582|NCT03183453|No Intervention|Non-confabulators control group|Non-confabulators (brain injured patients but without confabulations) in this control group only performed the pre- and post-measurements without treatment.
2458583|NCT03183453|No Intervention|Healthy control group|Healthy participants in this control group only performed the pre- and post-measurements without treatment.
2458765|NCT03181633|Experimental|ACH-0144471|All participants will receive ACH-0144471 during the treatment period.
3155451|NCT00321152|Experimental|1|Deplin/Deplin = participants will receive 7.5 mg/day of Deplin (6(S)-5-MTHF)for the first 4 weeks, and then 15 mg/day of Deplin for the next 4 weeks.
2458895|NCT03181074||CHC patients in Mexico|patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
2458974|NCT03180606||Predicted and personalized primary care|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives personalized primary care
2458976|NCT03180606||Predicted but with treatment as usual|Elderly 75 years of age and older in primary care with high risk of being fragile and future risk of needing hospital care that receives treatment as usual
2459037|NCT03180281|Experimental|DPP4 group|DPP4 inhibitor,1 pill qd
2459041|NCT03180281|Experimental|insulin group|insulin,glargine or detemir，0.2U/Kg,qd
2459042|NCT03180281|Placebo Comparator|SU group|SU,Glimepiride，1-2mg qd
2459094|NCT03179761|Experimental|Group I (HD-TIV)|Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.
2459101|NCT03179761|Active Comparator|Group 2(SD-QIV)|Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.
2459116|NCT03179371||1|Mothers whose fetus has CDH
2459184|NCT03179267|Experimental|SNAP40 monitor|All participants in the study will be fitted with the SNAP40 ambulatory monitoring device as well as usual monitoring as standard care
2459227|NCT03178734|Other|Indwelling Foley Catheter|These patients will have a traditional foley catheter with attached drainage bag (Indwelling Foley Catheter).
2459230|NCT03178734|Other|Self-Contained Valved Catheter|These patients will have a BARD Flip Flo Catheter Valve attached to the original foley catheter (Self-Contained Valved Catheter).
2459285|NCT03178461|No Intervention|Room temperature parenteral fluids|"This group will receive IV room temperature fluids, which is the standard of care.~The composition of the fluids given will be normal saline with 5% dextrose."
2459289|NCT03178461|Experimental|Body temperature parenteral fluids|"This group will receive IV warmed fluids, body temperature, which is the experimental intervention.~The composition of the fluids given will be normal saline with 5% dextrose."
3174533|NCT00624546||1|gerd patients
3174534|NCT00624546||2|non gerd controls
3174535|NCT00624598|Experimental|SMART Group|The experimental group will have a nutrition program based solely on measured resting metabolic rate. The nutrition plan will be a specific calorie level that will promote a 1-2.5 lb per week weight reduction. No experimental participants' nutrition plan will be below 1200 Kcal/day for women or 1600 Kcal/day for men. Second, the experimental group will receive a downloadable copy of a computerized nutrition software program (BalanceLog: Microlife USA, Inc. Golden, CO) that functions s on a Windows 2000-XP or Palm operating system.
3174536|NCT00624598|Active Comparator|Usual Care|Standard 1200 kcal/day diet (women) 1600 kcal/day diet (men) using a sample 3-day menu program. The diet will be follow current government based recommendations for carbohydrates (i.e. 55%), fat (30%), and protein (15%). Study participants will receive a standard paper-based food and exercise journal
3174537|NCT00624611|Active Comparator|1|Residual pump blood management post aortic cannula removal
3174538|NCT00624611|Experimental|2|Residual pump blood management post aortic cannula removal
3174539|NCT00624624||1|"Eugonadal men with Lapband"
3174540|NCT00624624||2|"Hypogonadal men with Lapband"
2458095|NCT03186092|Active Comparator|Intervention Group|inspiratory muscle training with load
2458096|NCT03186092|Sham Comparator|Control Group|unloaded inspiratory muscle training
2458190|NCT03185936|Experimental|Optic disc pit maculopathy|pars plana vitrectomy with internal limiting membrane (ILM) peeling, endolaser
2458223|NCT03185416|No Intervention|Control group|The first prospective group -the control group- will consist of 30 patients receiving treatment by the Interventional Radiology team- along with their 30 primary caregivers. Neither the patient nor the caregiver will receive the palliative care training intervention. Patients and their caregivers will receive questionnaires regarding their health status (physical and psychosocial) and health services utilization at 1, 2, and 3 months post-procedure- during their follow-up visits.
2458231|NCT03185416|Experimental|Intervention Group|The second prospective component of the study -the intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
2458309|NCT03185169|Other|Replens and coconut oil|Commercially available Replens applied via prefilled applicator into the vagina and coconut oil applied at the vaginal introitus and vulva. Both are to be administered by the patient 2 times per week, interval between dosing to be approximately 2 days. Patients will be encouraged to apply Preseed, coconut oil, or patient's personal lubricant of choice into the vagina prior to sexual activity.
2458361|NCT03184597|Experimental|Group with two strong risk factors|When HLA screening before commencing aromatic AEDs shows positive for both HLA-A*24:02 and HLA-B*15:02 in a patient, aromatic AEDs were not administrated for this patient.
2458362|NCT03184597|Experimental|Group with one strong risk factors|"When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:02, carbamazepine (CBZ) was not administrated, and other aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.~When HLA screening before commencing aromatic AEDs shows positive for HLA-B*15:01 or HLA-A*24:02, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead."
2458363|NCT03184597|Experimental|Group with one potential risk factors|When HLA screening before commencing aromatic AEDs shows positive for any potential risk allele such as HLA-B*15:11, HLA-A*02:01and HLA-DRB1*01:01, aromatic AEDs were prescribed with caution or avoided if alternative non-aromatic AEDs can be prescribed instead.
2458364|NCT03184597|Experimental|Group without known risk factors|When HLA screening before commencing aromatic AEDs shows negative for any known HLA risk allele , aromatic AEDs was administrated to these patients.
2458407|NCT03184376|Experimental|Prebiotic|Prebiotic oligofructose (Orafti P95, Beneo-Orafti Inc., Tienen, Belgium) taken 8g orally per day for 12 weeks followed by 16g per day for 24 weeks.
2458409|NCT03184376|Placebo Comparator|Placebo|Placebo maltodextrin (isocaloric to prebiotic) taken 3.3g orally per day for 12 weeks followed by 6.6g per day for 24 weeks.
2458539|NCT03183271|Experimental|Experimental: External beam radiotherapy|A total of 20 patients will be irradiated with protons after photon IMRT
2458594|NCT03183050|Experimental|Question Prompt List|This is a single-arm study. Therefore, all participants will receive the prompt list.
2458646|NCT03182608|Experimental|Group 1|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tuffier's line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tenth rib line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
2458647|NCT03182608|Experimental|Group 2|In the lateral decubitus position, an investigator evaluate the L4-5 interspinous level using an anatomic landmark (Tenth rib line), and then evaluate the L4-5 interspinous level using another anatomic landmark (Tuffier's line). Another investigator evaluate the actual L4-5 interspinous level by noninvasive ultrasonography.
2458698|NCT03182335||Mechanical Ventilation (MV) with vasoactive infusions|adult ICU patients who are mechanically ventilated with sedative infusion and/or analgesic infusion and also requiring vasoactive drug infusions for the treatment of shock. Patients will be excluded if receiving dexmedetomidine as sedative.
3155452|NCT00321152|Experimental|2|placebo/Deplin = participants will receive placebo for the first 4 weeks, and then 7.5 mg/day of Deplin (6(S)-5-MTHF) for the next 4 weeks.
3155453|NCT00321152|Placebo Comparator|3|placebo/placebo = both tablets of study medication will be placebo during both phases of the study.
2458758|NCT03181672|Active Comparator|Stellate ganglion block|Stellate ganglion block
2458760|NCT03181672|Placebo Comparator|control group|Deltoid muscle injection
2458948|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.6 U/kg|Single subcutaneous injection of 0.6 U/kg
2458950|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
2458952|NCT03180710|Experimental|BioChaperone® Combo 75/25 at 1.0 U/kg|Single subcutaneous dose of 1.0 U/kg
2458953|NCT03180710|Active Comparator|Humalog® Mix25 at 0.8 U/kg|Single subcutaneous dose of 0.8 U/kg
2458989|NCT03180424|Active Comparator|L Carnitine + Exercise at home|Patients who will receive L Carnitine, in liquid form, at a dosage of 2g per day, in a single intake, in addition to physical exercise advice at home for which a manual will be delivered in the consultation, for 12 weeks.
2458992|NCT03180424|Experimental|L Carnitine + supervised exercise|Patients receiving L Carnitine, in liquid form, at doses of 2g per day, in a single intake, in addition to a supervised physical exercise plan, for 12 weeks.
2459092|NCT03180021||Patients with Lupus Nephritis|
3155454|NCT00321178|Experimental|SR4/CR4|after 4 weeks of standard treatment with streptomycin and rifampicin, patients in the experimental arm switch to oral treatment consisting of rifampicin and clarithromycin
3155455|NCT00321178|Active Comparator|SR8|standard treatment consisting of 8 weeks of streptomycin and rifampicin
3155456|NCT00321191|Experimental|N2O|
3155457|NCT00321191|Placebo Comparator|No N2O|
3155458|NCT00321308|Active Comparator|B|Standard of care chemotherapy
3155459|NCT00321308|Experimental|A|Standard of care chemotherapy plus experimental intervention (PF-3512676)
3155460|NCT00321334|Active Comparator|Docetexel|Chemotherapy+Surgery
2458103|NCT03186300|Other|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
2458156|NCT03185962||Successful extubation|extubated successfully
2458157|NCT03185962||Extubation failure|reintubated within 48 hours
2458160|NCT03185962||NPPV/NHF|use of non-invasive positive pressure ventilation (NPPV) or nasal high flow (NHF) within 48 hours after extubation
2458204|NCT03185624|Experimental|Rifaximin|Prescribed Rifaximin (600mg, twice daily) for 3 months after surgery
2458213|NCT03185624|No Intervention|Blank control|No intervention after surgery
2458255|NCT03185286|Experimental|3D-printed personalized metal implant|3D-printed personalized metal implant will be used in bone defect surgeries.
2458293|NCT03184896||Hip Fracture|
2458349|NCT03184740|Experimental|Active-tDCS|A constant current (anodic) of 2mA will be applied for 20 minutes over the Primary motor cortex (M1).
2458352|NCT03184740|Sham Comparator|Sham-tDCS|A constant current (sham) of 2mA will be applied on the Primary motor cortex, but the stimulator will be turned off after 30 seconds .
2458373|NCT03184480||SUBJECTS RECEIVING ARNUITY ELLIPTA|Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.
2458462|NCT03184285|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
2458569|NCT03183037|Experimental|Acupuncture Treatment Group|Ten acupuncture treatments over the course of eight weeks, with twice weekly acupuncture treatments for the first two weeks, and then weekly treatment thereafter.
2458573|NCT03183037|Placebo Comparator|Sham Acupuncture Treatment Group|Ten sham acupuncture treatments over the course of eight weeks, with twice weekly sham acupuncture treatments for the first two weeks, and then weekly sham acupuncture treatment thereafter.
2458576|NCT03183037|Active Comparator|Usual Care Group|Twelve weeks of usual care.
3155461|NCT00321412|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
3155462|NCT00321412|Experimental|1|AST-120, 2 gram sachets
2458661|NCT03182543|Experimental|AM1|Mango pulp beverage
2458663|NCT03182543|Experimental|AM2|Mango pulp and peel beverage
2458666|NCT03182543|Placebo Comparator|Control|Control beverage
2458724|NCT03182166|Experimental|Patients treated with golimumab|"The optimization procedure is:~For patients treated at 50 mg of golimumab every 4 weeks (less than 80 kg) will have an increase dose of golimumab: 100 mg every 4 weeks for 8 weeks. They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies.~For patients treated at 100 mg of golimumab every four weeks (more than 80 kg) will have an increase dose of golimumab: treated at 100 mg every 2 weeks for 4 weeks.~They will have rectosigmoidoscopy for measured mayo score and blood samples for measured the concentration of golimumab antibodies."
2458831|NCT03181620|No Intervention|Continuous Infusion Arm|Patients receive typical continuous infusions (drips) of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on RASS and CPOT.
2458837|NCT03181620|Experimental|Intermittent Sliding Scale Arm|Patients receive hourly boluses of both sedative agent and narcotic agent for sedation/pain control while mechanically ventilated based on a sliding scale of RASS and CPOT.
2458941|NCT03180736|Experimental|Daratumumab+Pomalidomide+Dexamethasone|Daratumumab at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
2458946|NCT03180736|Active Comparator|Pomalidomide + Dexamethasone|Pomalidomide 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle Dexamethasone 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle
2459047|NCT03180177|Experimental|Experimental group|"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with paclitaxel 175 mg/m^2 and cisplatin 75 mg/m^2 intraperitoneally in succession~2 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2459050|NCT03180177|Active Comparator|Control group|"3 cycles of neoadjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks~Interval debulking surgery~3 cycles of adjuvant chemotherapy: paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks"
2459102|NCT03179683|Active Comparator|Diode laser application|An 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side (treatment group)
3155463|NCT00321451|Experimental|1|
3155464|NCT00321451|Sham Comparator|2|
3155465|NCT00321451|Active Comparator|3|
3155466|NCT00321516|Experimental|1|
3155467|NCT00321659|Experimental|Aerobic and flexibility exercise|16 weeks of aerobic and flexibility exercise. Three days per week for 1 hour of walking and cycling.
3155468|NCT00321659|Experimental|Strength, aerobic, and flexibility|16 weeks of strength training, aerobic, and flexibility exercise (ST) intervention;
2458115|NCT03186313|Active Comparator|Part B: Arm 4|Daily dose including Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks.
2458188|NCT03185845|Experimental|Prolonged anticoagulation|3 months longer anticoagulation after regular treatment
2458189|NCT03185845|No Intervention|Regular anticoagulation|stop anticoagulation after regular treatment
2458227|NCT03185429|Experimental|Experimental|"Drug:Cyclophosphamide~Biological/Vaccine:Tumor Specific Antigen-loaded Dendritic Cells"
2458268|NCT03185091|Other|rapid ventricular pacing|Safety of rapid ventricular pacing during neurosurgical procedures
2458278|NCT03184948|Active Comparator|Phase 1|"This is the first set of randomly selected hospitals to receive the intervention (Brilliance device). The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
2458281|NCT03184948|Active Comparator|Phase 2|"This is the second set of hospitals to receive the device. For the first three months, they receive no intervention, after which they become part of the active comparator arm. The intervention to be provided is the phototherapy device, Brilliance.~*No individual participants are recruited for this study."
2458284|NCT03184948|No Intervention|Phase 3|"This is the last set of hospitals to receive the device. For the first six months, they receive no intervention, after which the study is completed and they are given the device Brilliance.~*No individual participants are recruited for this study."
2458345|NCT03184818||No antibacterial from other provider (Arm 1)|Patients with symptomatic, uncomplicated urinary tract infection presenting without a prescription for an antibacterial from another health care practitioner.
2458348|NCT03184818||Antibacterial from other provider (Arm 2)|Patients with symptomatic, uncomplicated urinary tract infection or asymptomatic bacteriuria presenting with a prescription for an antibacterial from another health care practitioner.
2458383|NCT03184493|Experimental|Celebrex|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.
2458390|NCT03184493|Experimental|Metformin|Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
2458391|NCT03184493|Active Comparator|Celebrex plus Metformin|Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.
2458394|NCT03184493|No Intervention|Empty control group|This group patients will not receive any postoperative adjuvant therapy.
2458452|NCT03184129|Experimental|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd., Wuhan, China (newly developed).
2458457|NCT03184129|Experimental|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
2458607|NCT03183011|Other|Post-CRT MRI|This study has a single arm. Enrolled patients will follow the protocol as described, including evaluation with MRI, echocardiography, and cardiopulmonary exercise testing.
2458650|NCT03182556|Placebo Comparator|Stretching|Stretching sessions was held twice a week in the University of Almería facilities, lasting approximately one hour and they included different muscle areas exercises as well as stretching across the board.
2458652|NCT03182556|Experimental|Aquatic Exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
2458653|NCT03182556|Experimental|Electromyography-Biofeedback training|The whole treatment will last about 12 sessions. Each one lasts about 30 and 40 minutes and will be performed continuously once a week. The frequency may be increased if the level of tonic muscle tension becomes too high.
2458710|NCT03181919|Experimental|Step Up group|includes females taking Letrozole 5 mg tablets in a step-up protocol 5 mg in day one, 7.5 in day 2, 10 mg in days 3, 12.5 mg in day 4 and 15 in day 5 started in day 3 to day 7 of menstrual cycle.
2458714|NCT03181919|No Intervention|Control group|includes females taking Letrozole 5 mg tab orally once daily started in day 3 to day 7 of menstrual cycle.
2458805|NCT03181477|Other|radiotherapy + chimiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
2458883|NCT03181087|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
2458966|NCT03180658|Experimental|experimental|GTR+CGF+bone graft, CGF
2458971|NCT03180658|Active Comparator|controlled|CGF+bone graft
2459015|NCT03180307|Sham Comparator|no fluorescent imaging|Patient injected with OTL38, but does not undergo fluorescent imaging
2459019|NCT03180307|Experimental|near infrared imaging arm|Patient injected with OTL38 and undergoes near infrared imaging
2459084|NCT03179904|Experimental|Cohort A (FASN inhibitor TVB-2640, paclitaxel, trastuzumab)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28, paclitaxel IV over 1-96 hours on days 1, 8, and 15, and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
2459085|NCT03179904|Experimental|Cohort B (TVB-2640, trastuzumab, endocrine therapy)|Patients receive FASN inhibitor TVB-2640 PO QD on days 1-28 and trastuzumab IV over 30-90 minutes on days 1, 8, 15, and 22. Patients also continue endocrine therapy of either anastrozole PO QD, exemestane PO QD, fulvestrant IM on days 1 and 14 of cycle 1 and day 1 of subsequent cycles, or letrozole PO QD. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
2459217|NCT03178929|Experimental|S-Adenosyl Methionine Treatment|"Patients will be treated with S-Adenosyl Methionine treatment after radical treatment.~2000mg, po"
2458120|NCT03186170|Active Comparator|control|"The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up for sperm selection) as well as embryo development.~In this arm, the sperm selection for IVF will be the traditional swin up technique with different Percoll gradient Sperm selection via traditional swin-up"
2458153|NCT03185871|Experimental|Celecoxib|"The participants will be scheduled for the two quantitative breast MRI exams. Following the first MRI exam, participants will start taking celecoxib 200mg twice a day with food. Subjects will take a minimum of 26 doses and no more than 32 doses of celecoxib during the study.~Participants will intake 200mg of celecoxib two times a day (400mg/day total) for 2 weeks after biopsy. Histologic tissue samples will be obtained for evaluation at time of biopsy of the tumor and at time of surgery removal of the tumor."
2458242|NCT03185637||Gastroschisis|All patients presenting primarily to the institution with gastroschisis during the data collection period will be included in the study.
2458247|NCT03185637||Anorectal malformation|All patients presenting primarily to the institution with anorectal malformation during the data collection period will be included in the study.
2458248|NCT03185637||Appendicitis|All patients under 16-years of age presenting primarily to the institution with appendicitis during the data collection period will be included in the study.
2458250|NCT03185637||Intussusception|All patients under 16-years of age presenting primarily to the institution with intussusception during the data collection period will be included in the study.
2458252|NCT03185637||Inguinal hernia|All patients under 16-years of age undergoing surgery for an inguinal hernia at the institution during the data collection period will be included in the study.
2458310|NCT03185039|Experimental|kidney cancer|Localized, oligometastatic or metastatic
2458389|NCT03184584|Experimental|PBI-4050|
2458475|NCT03183817|Experimental|Person-centred care at distance|Person-centred care at distance through an eHealth platform, used both by professionals, patients and relatives
2458476|NCT03183817|No Intervention|Usual Care|Evidence-based care
2458516|NCT03183557|Active Comparator|ZA alone|
2458517|NCT03183557|Active Comparator|ZA plus VD|
2458548|NCT03183232|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
2458549|NCT03183232|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
2458550|NCT03183232|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
2458670|NCT03182439|Active Comparator|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
2458671|NCT03182439|Active Comparator|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
2458673|NCT03182439|Active Comparator|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
2458675|NCT03182439|Active Comparator|Apple Watch|Apple Watch Heart Rate Monitoring Device
2458708|NCT03182075|Experimental|Active Training|OCD participants will receive active emotional reactivity training (14 sessions) via computer.
2458713|NCT03182075|Sham Comparator|Passive Training|OCD participants will receive passive computerized training (14 sessions) via computer.
2458835|NCT03181815|Experimental|treatment arm|The patients in this arm will receive C-CAG regimen for salvage treatment,detailed as following: Cladribine 5mg/㎡，d1-5；G-CSF 300ug,d0-9; aclarubicin 10mg,d3-6;cytarabine 10mg/㎡ q12h, SC, d3-9;4 weeks a cycle
2458906|NCT03180931||Scaffold thrombosis|Any patients who suffered from scaffold thrombosis occurring beyond 1 year after implantation of a Absorb BVS 1.1 and investigated by OCT with sufficient image quality allowing for CoreLab analysis at the timepoint of thrombosis.
2458987|NCT03180437|Active Comparator|Group A|In this group, the patients will receive IRE surgery to control the local tumor under CT .
2458988|NCT03180437|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and IRE surgery
2459029|NCT03180125|Experimental|sodium hyaluorinate ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by low molecular weight sodium hyaluronate (Hyalgan) injection ultrasonographically guided
2459031|NCT03180125|Placebo Comparator|corticosteroid with ultrasound guided|median nerve hydro-dissection using 1% lidocain followed by injection of corticosteroid Ultrasonographically guided
2459087|NCT03179813|Experimental|Hydrocortisone group|Intraoperative topical use of hydrocortisone as a irrigation solution in third molar surgery.
2459093|NCT03179813|Placebo Comparator|Control Group|Intraoperative irrigation with saline solution.
2459128|NCT03179423|Experimental|GNbAC1|Monthly IV repeated dose
2459131|NCT03179423|Placebo Comparator|Placebo|Monthly IV repeated dose
2459174|NCT03178994|Experimental|2% ketoconazole cream|2% ketoconazole cream apply on face twice daily for 10 weeks.
2459177|NCT03178994|Placebo Comparator|Placebo|Hydrophilic cream (in-house preparation) apply on face twice daily for 10 weeks.
2459210|NCT03178864|Experimental|Rivaroxaban|Rivaroxaban
2459211|NCT03178864|Active Comparator|Standard of care|Unfractionated heparin Low-molecular weight heparin (dalteparin, enoxaparin, tinzaparin) Warfarin
2459264|NCT03178292|Active Comparator|Levofloxacin|Levofloxacin 500 mg daily for 5 days
2459266|NCT03178292|Placebo Comparator|Placebo|Placebo tab daily for 5 days
3155469|NCT00321659|Experimental|Fibromyalgia Self-Help Course|7 weeks of FSHC behavior change education
3155470|NCT00321659|Experimental|a Combination of ST and FSHC|16 wks of a combination of ST and FSHC (ST-FSHC) exercise and behavior change education
3155471|NCT00321724|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3155472|NCT00321802|Experimental|1|Patients randomized to active drug, then AF burden and CRP values will be compared to those in placebo arm.
3155473|NCT00321802|Placebo Comparator|2|Patients take placebo once daily for 6 Months, then AF burden and CRP values will be compared to those in experimental arm.
2458131|NCT03186235||group III:18 HCV-infected patients complicated with cirrhosis|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2458133|NCT03186235||group IV: 18 HCV-infected patients with Hepatocellular cancer|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2458134|NCT03186235||Group V:18 patients with sustained viral response (SVR).|Two milliliter of heparinized whole blood samples will be used for the Flow cytometry analysis to quantify percentages of circulating regulatory T cells in human peripheral blood in chronic hepatitis C patients in comparison with that of controls by four-colour flow cytometry analysis using a set of fluorochrome-labeled monoclonal antibodies against regulatory T cell surface markers and estimation of the level of IL35 by ElISA.
2458211|NCT03185754|Experimental|early phase lung cancer|sublobar resection and lobectomy
2458279|NCT03185234|Active Comparator|Real tDCS|Anodal tDCS at an intensity of 2 mA is applied for 10 minutes at a time on 5 consecutive days. The anodal electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere, the cathodal electrode is located supraorbital on the right side. Motor tasks are performed before and after the stimulation.
2458282|NCT03185234|Sham Comparator|Sham tDCS|Sham stimulation is applied for 10 minutes at a time on 5 consecutive days. One electrode is placed over the left parietal cortex (P3 in 10/20 EEG) of the lesioned hemisphere and a second electrode supraorbital on the right side. Motor tasks are performed before and after the stimulation.
2458355|NCT03184792|Active Comparator|Transcutaneous spinal stimulation & Physical therapy|Transcutaneous cervical electrical stimulation combined with physical therapy that targets rehabilitation of upper extremity functions
2458358|NCT03184792|Active Comparator|Physical therapy only|Physical therapy that targets rehabilitation of upper extremity functions
2458379|NCT03184402|Experimental|DWJ1252|
2458384|NCT03184402|Active Comparator|Gasmotin|
2458423|NCT03184142|Experimental|Simulation|During a suturing class at the simulation center, the students enter a classroom. Although the students are not aware of this, among them is an actor playing the role of a student. One of the two professors is also an actor. As the activity progresses, the professor targets the student played by an actor. The intimidation intensifies until the end. At the end of the activity, there is a debriefing explaining to the students that the bullying professor and the victim were actors.
2458425|NCT03184142|Experimental|Video|During a suturing class at the simulation center, after 55 minutes of suturing, the students will be exposed to a 15-minute video on workplace and hospital intimidation and how to manage it.
2458428|NCT03184142|Placebo Comparator|Control|During a suturing class at the simulation center, the students suture for the entire 70-minute duration of the activity. They are not exposed to intimidation (control group).
2458495|NCT03183856|Experimental|Morning walk|200 steps of gait rehabilitation using an end-effector typed gait robot with 5 minute break, 3 times a day for 10 weekdays: the end-effector type gait robot (Morning Walk®, Hyundai Heavy Industry, Republic of Korea)
2458500|NCT03183856|Active Comparator|No Morning walk|200 steps by themselves or with a help of a walker on a even floor at a comfortable pace with 5 minute break, three times a day for 10 weekdays
2458560|NCT03183414||cardiac surgery patients|cardiac surgery patients with a significant peroperative aortic valve stenosis (gradient>40mmHg and/or aortic valve area <1cm2). During cardiac surgery measurements of right ventricular dysfunction were taken by echocardiography
2458584|NCT03182894|Experimental|Epacadostat + Pembrolizumab + Azacitidine|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
2458692|NCT03182296|Experimental|Gestational diabetes|Women with a history of gestational diabetes
2458693|NCT03182296|Active Comparator|Control|Women without a history of gestational diabetes
2458749|NCT03182010|Experimental|Cesarean section incision closure using barbed sutures|Cesarean section incision is closed using barbed sutures
2458752|NCT03182010|Active Comparator|Cesarean section incision closure using conventional sutures|Cesarean section incision is closed using conventional sutures
2458822|NCT03181282|Experimental|Physical Therapy|Participants assigned to Physical Therapy (PT) will attend a 1-hour visit with a physical therapist twice weekly for 8 weeks. The PT intervention, which will mirror traditional PT for those with PD, will include exercises designed to improve balance and gait.
2458825|NCT03181282|No Intervention|Control|Participants in the control group will receive the current standard of care following STN-DBS. As such, STN-DBS settings and anti-PD medications will be optimized according to the determination of their neurologist in the same fashion as they will be in the experimental group. Those in the control group will not receive prescribed exercise from a physical therapist.
3155474|NCT00321815|Experimental|A|Standard of Care chemotherapy plus experimental intervention (PF-3512676)
2458884|NCT03180840|Experimental|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg intravenous infusion every 4 weeks
2458967|NCT03180476|Experimental|apatinib|apatinib,500mg,qd，28 day/cycle until the emergence of PD, death, intolerable toxicity
2459095|NCT03180021||Patients with IgA Neuropathy|
3155475|NCT00321815|Active Comparator|B|Standard of Care chemotherapy
3155476|NCT00321867|Active Comparator|1|Native tissue repair
3155477|NCT00321867|Experimental|2|Posterior repair with graft
3155478|NCT00322010|Experimental|Early PT OT|Early PT/OT Therapy assessments to begin on the first day that consent is obtained. Therapy is delivered by a team consisting of a physical and occupational therapist and coordinated with daily sedative interruption.
3155479|NCT00322010|No Intervention|Standard Care|PT/OT delivered as ordered by the primary ICU team
3155480|NCT00322036|Experimental|1|Oral 800 mg BID dosing
2458132|NCT03186027|Active Comparator|Active supplement (CoQ10 plus NADH)|"CFS/ME patients will be randomized to evaluate the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH: 20 mg/day) taking 4 tablets/day during 8-weeks in term.~Active supplement based on Coenzyme Q10 plus NADH"
2458135|NCT03186027|Placebo Comparator|Phosphoserine plus vitamin C|"CFS/ME patients will be randomized to assess the effect of placebo (phospho-serine plus vitamin C) taking 4 tablets/day for 8-weeks in term.~Placebo: phosphoserine plus vitamin C"
2458164|NCT03185728|Experimental|iLookOut|Online, interactive learning program developed by study team.
2458166|NCT03185728|Active Comparator|Standard|Online mandated reporter training developed by the state of Maine during Y1, then recruited to complete iLookOut during Y2 and Y3.
2458168|NCT03185728|No Intervention|Control|No active recruitment or incentivizing of participants to complete any training on mandated reporting during Y1 and Y2, then recruited to complete iLookOut during Y3.
2458203|NCT03185533||to reduce ED length of stay|to reduce ED length of stay to lessen ED crowding by using Lean-sigma management and quality improvement interventions including reducing boarding time and medical decision time.
2458298|NCT03185312||patients with acne vulgaris|Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
2458301|NCT03185312||patients with vitiligo|Clinical evaluation including full history taking and dermatological examination will be done . Assessment of disease severity will be performed using VASI score Skin biopsies will be taken from lesional and non-lesional skin .immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3..
2458304|NCT03185312||control|"Skin biopsies will be taken from skin of controls.~. Five micron thick sections will be cut from paraffin blocks for immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3."
2458356|NCT03184649|Experimental|intervention arm|Ibuprofen suspension (Ibufen®, 100 mg/5 mL; fruit flavored, orange colour, Abbott) will be given 30 min before injection of local anesthesia. Then pain scores will be recorded from 0-4.
2458359|NCT03184649|Experimental|intervention|Paracetamol (Calpol™, 250 mg/5 mL; fruit flavored, orange color, GlaxoSmithKline) will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
2458360|NCT03184649|Placebo Comparator|comparator|A fruit-flavored orange color placebo solution will be given 60 min before injection of local anesthesia.Then pain scores will be recorded from 0-4.
2458410|NCT03184389|Other|Within-participant micro-randomization|Each minute when participant is available is randomly assigned to either intervention (to practice a stress management exercise) vs. no intervention prompt. When intervention occurs, participant's smartphone vibrates and relaxation app opens, prompting performance of a relaxation exercise.
2458570|NCT03183505|Experimental|Anyu Peibo|Anyu Peibo Capsule, oral, 0.8g twice per day
2458574|NCT03183505|Placebo Comparator|Placebo|Placebo,oral, twice per day
2458625|NCT03182764||never smokers|Never smokers are those who have never consumed cigarettes in their lifetime.
2458631|NCT03182764||Ex-smokers|Ex-smokers are those who consumed cigarettes previously but do not smoke at the time of the survey.
2458632|NCT03182764||Current smokers|Current smokers are those who, at the time of the survey, consume cigarettes daily or occasionally.
2458678|NCT03182426|Experimental|Treated arm|"For participants assigned to the treated arm, they will follow study regime below: Intervention treatment will last from Day 0 up to Month 24.~Day 0: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Day 1: Subjects will receive plerixafor (0.24 mg/kg/day) sc. to mobilize CD34+ stem cells to peripheral blood.~Day 1: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 24 months."
2458680|NCT03182426|Experimental|Control arm|"For participant assigned to the control arm, they will be monitored and tested for the first 12 months, and receive intervention treatment from Month 12 up to Month 24.~Month 12: Subjects will receive alemtuzumab (30mg iv single dose); anakinra (100 mg sc.); etanercept (50 mg sc.) and liraglutide (0.6 mg sc.).~Month 12 + 1 day: Subjects will receive plerixafor (0.24 mg/kg/day) sc.. Month 12 + 1 day: Continuing with anakinra 100mg sc. daily for 12 month; etanercept 50mg sc. twice weekly for first 3 months, and 50mg sc. weekly for another 9 months; liraglutide 0.6 mg sc. daily for 7 days, then 1.2 mg sc. daily (or up to 1.8mg daily) as tolerated for 12 months."
2458712|NCT03182023||ECMO mode|ECMO mode includes Venovenous- ECMO and Venoarterial- ECMO
2458773|NCT03181841|Experimental|Active dose 1|Single dose of PF-06412562 in low dosage strength
2458774|NCT03181841|Experimental|Active dose 2|Single dose of PF-06412562 in medium dosage strength
2458775|NCT03181841|Experimental|Active dose 3|Single dose of PF-06412562 in higher dosage strength
2458776|NCT03181841|Placebo Comparator|Placebo|Single dose of placebo
2458815|NCT03181347|Experimental|Roux-en-Y Gastric Bypass (RYGB)|Severely obese patients scheduled for Roux-en-Y Gastric Bypass surgery
2458819|NCT03181347|Experimental|Sleeve Gastrectomy (SG)|Severely obese patients scheduled for Sleeve Gastrectomy surgery
2458827|NCT03181347|Active Comparator|Non-surgical|Severely obese controls with dietary and activity modifications and excludes meal replacement or pharmacologic interventions
2459082|NCT03179982|Experimental|Intervention|"Male adolescents (15-17 years) will be randomly allocated to an intervention arm based on permuted blocked randomization. The intervention arm will receive the HIV-IPV intervention called Safe South Africa.~Safe South Africa is a group-based, facilitated behavioral intervention for prevention of HIV risk and IPV perpetration specifically tailored for male adolescents. The behavioral intervention is comprised of 2-hour sessions, held once a week for a total of two weeks."
2459103|NCT03179683|No Intervention|No application|no treatment were aplied
2458141|NCT03186118|Experimental|Cohort B|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing on Study Day 14 indicates they are at risk for early loss of CAR T cells will be assigned to Cohort B to receive up to 6 T-APC treatments. If laboratory testing prior to planned T-APC treatment indicates loss of CAR-T cells, participants may move to Cohort C.
2458143|NCT03186118|Experimental|Cohort C|Participants will receive CD19-targeting CAR T cells. Participants for whom laboratory testing shows loss of CAR T cells within 6 months will be assigned to Cohort C. They will receive another CAR T cell infusion followed by up to 6 T-APC treatments.
2458144|NCT03186118|Experimental|Cohort D|Participants will receive CD19-targeting CAR T cells. Participants who do not meet assignment rules for Cohorts A, B, or C will be followed after CAR T cell infusion in Cohort D.
2458221|NCT03185702||Patients with Turner Syndrome|Chromosomal diagnosis and typical features
2458225|NCT03185702||Unaffected controls|Normal females and unaffected family members
3155481|NCT00322036|Placebo Comparator|2|Oral BID dosing
2458433|NCT03184025|Other|patients have class I caries|patients have received four restorations which included HEMA containing and HEMA-free dentin adhesive with or without surface sealing
2458493|NCT03183843|Active Comparator|Dabigatran|Dabigatran etexilate 150 mg by mouth every 12 hours for a year
2458498|NCT03183843|Active Comparator|Warfarin|Warfarin by mouth every 24 hours in a dose providing international normalized ratio (INR) 2.5-3.5 for a year
2458532|NCT03183362|Experimental|Barbed suture ( STRATAFIX™ )|Cesarean section incision is closed using barbed sutures
2458533|NCT03183362|Active Comparator|Conventional suture (VICRYL™)|Cesarean section incision is closed using conventional sutures
2458578|NCT03183076|Active Comparator|modified adkins diet|modified adkins diet. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis.
2458581|NCT03183076|Active Comparator|Pharmacotherapy without diet|It consists in administer only pharmacological treatment withot a special diet, Drug-resistant epilepsy is characterized by the use of antiepileptic drugs and in optimal doses, depending on the type of epilepsy, at least on two consecutive occasions without response to management.
2458598|NCT03182699|Experimental|Etelcalcetide|Patients will receive Etelcalcetide i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
2458600|NCT03182699|Active Comparator|Alfacalcidol|Patients will receive Alfacalcidol i.v. 3 times per week after dialysis Dose titration will take plac every 4 weeks in the first 16 weeks Dose adaptation is based on PTH, SerumCa++, SerumPhosphate, T-50-time
2458672|NCT03182413|Placebo Comparator|PBO|Placebo
2458674|NCT03182413|Active Comparator|MOD|Modafinil 100mg
2458676|NCT03182413|Experimental|THN102 100/1|modafinil 100 mg + 1 mg flecainide
2458677|NCT03182413|Experimental|THN102 100/3|modafinil 100 mg + 3 mg flecainide
2458679|NCT03182413|Experimental|THN102 100/9|modafinil 100 mg + 9 mg flecainide
2458736|NCT03182114|Placebo Comparator|supine position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in supine position
2458740|NCT03182114|Experimental|Left lateral tilted position|the patient will receive spinal anesthesia by Bupivacaine; then she will be placed in left lateral tilted position
2458781|NCT03181659|Experimental|Group 1: patients with NSCLBP who do not seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
2458787|NCT03181659|Experimental|Group 2: patients with NSCLBP who do not seek care|Therapeutic Education, Therapeutic Exercice
2458791|NCT03181659|Experimental|Group 3: patients with NSCLBP who seek care|Manual Therapy, Therapeutic Education, Therapeutic Exercice
2458793|NCT03181659|Experimental|Group 4: patients with NSCLBP who seek care|Therapeutic Education, Therapeutic Exercice
2458821|NCT03181256||Screening|Patients are followed up at 1, 2, 3, 4, and 5 years and undergo collection of sputum, nasal epithelium, buccal epithelium, blood, and urine samples. Patients also undergo pulmonary function tests, chest CT, and review of medical records
2458888|NCT03180918|Experimental|testicular tissue cryopreservation|
2458964|NCT03180632|Active Comparator|Group A|Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
2458969|NCT03180632|Placebo Comparator|Group B|Patient will receive a placebo similar in color, form and size.
2458973|NCT03180632|No Intervention|Group 3|Patient will receive no intervention.
2459034|NCT03180242|Experimental|EG12014|EG12014
2459036|NCT03180242|Active Comparator|EU-sourced Herceptin|EU-sourced Herceptin
2459039|NCT03180242|Active Comparator|US-sourced Herceptin|US-sourced Herceptin
2459168|NCT03179293|Active Comparator|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
2459169|NCT03179293|Placebo Comparator|Control|Normal saline will be administered IV over the next 3 min prior to the patient leaving the OR
2459303|NCT03178240|Experimental|Intervention|45 minutes seminar on skin cancer prevention and UV-protection in general.
2459840|NCT03174678|Experimental|Dexmedetomidine|Group administered 1µg/kg dexmedetomidine oral
3155482|NCT00322062|Experimental|1|"1 pack (contains 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets)= 2L NRL994 . 2 sachets (one of each) will be dissolved in 1L of water. Each litre will be drunk within 1 hour. Furthermore, at least 1000ml (or more) of any additional clear fluid (except milk) has to be drunk after the 2L of NRL994."
3155483|NCT00322062|Active Comparator|2|1 pack consists of 2 flasks of 45ml. Each flask has to be dissolved within 125ml of water. Each intake of NaP solution has to be preceded and followed by 250ml (or more if necessary)of clear liquids(excluding milk)and a delay of at least 12 hours between the intake of the 2 x 45ml of NaP solution has to be completed. In addition, 750ml more of clear liquids (excluding milk)or more if needed must be drunk between the 2 intakes.
3155484|NCT00322114|Experimental|Arm I|Participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks.
3155485|NCT00322114|Experimental|Arm II|Participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks.
3155486|NCT00322114|Placebo Comparator|Arm III|Participants receive oral placebo twice daily for 3 weeks.
2458146|NCT03186001|Experimental|v shape|Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
2458148|NCT03186001|Experimental|middle frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a straight pattern will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
2458150|NCT03186001|Experimental|high frontalis|: Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally.Then 5 equally spaced injections, in a straight pattern 1 cm below the hairline will be placed in the frontalis. One injection in the middle of the forehead, one on the same level of the lateral canthus and one between them.
2458272|NCT03185221|Experimental|Cordimax|Rapamycin Eluting Coronary Stent
2458273|NCT03185221|Active Comparator|XIENCE V|Everolimus Eluting Coronary Stent
2458294|NCT03184961|Experimental|lung recruitment maneuver|"Heart rate, mean arterial pressure, stroke volume, pulse pressure variations, pleth variability index, and photoplethysmographic waveform were recorded before lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s), during lung recruitment maneuver when stroke volume reached its minimal value.~Cardiac index measured before and after volume expansion (10ml/kg saline, 0.9%, infused during 10 min). Patients were considered as responders to fluid administration if cardiac index increased greater than or equal to 15%."
2458374|NCT03184753|Experimental|Single arm|OC-IgT cells to treat ovarian cancer.
2458460|NCT03184259|Experimental|Robotic ankle system|Subjects will wear the Ankle Robot during 20-session gait training, power assistance will be provided from the motor to the ankle joint.
2458463|NCT03184259|Experimental|Robotic knee system|Subjects will wear the Knee Robot during 20-session gait training, power assistance will be provided from the motor to the knee joint.
2458465|NCT03184259|Placebo Comparator|Ankle Sham group|Subjects will wear the Ankle Robot during 20-session gait training, but no power assistance will be provided from the motor to the ankle joint.
2458466|NCT03184259|Placebo Comparator|Knee Sham group|Subjects will wear the Knee Robot during 20-session gait training, but no power assistance will be provided from the motor to the knee joint.
2458468|NCT03184259|No Intervention|Health Control|Healthy subjects will wear the Ankle Robot and/or Knee Robot during walking tasks (with or without power assistance), to collect control data for investigating if there are any effects of the robotic assistance on normal gait pattern.
2458547|NCT03183544|Experimental|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|Single injection for diagnostic use only
2458595|NCT03182998|Experimental|Arm A (Knowing Your Options)|"Arm A (Knowing your Options) Patients receive Knowing your Options decision aid before their consultation visit."
2458596|NCT03182998|Experimental|Arm B (Prostate Choice)|"Patients receive Prostate Choice decision aid during their consultation visit."
2458597|NCT03182998|Active Comparator|Arm C (Usual Care)|Patients undergo usual care.
2458699|NCT03182374|Active Comparator|nSTRIDE APS|The nSTRIDE APS Kit is designed to be used for the safe and rapid preparation of APS from a small sample of blood at the patient's point of care. The APS is to be injected intra-articularly for the treatment of knee osteoarthritis and associated symptoms.
2458701|NCT03182374|Active Comparator|Synvisc-One|Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee
2458733|NCT03181880|Active Comparator|Aclidinium/formoterol|Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination
2458739|NCT03181880|Active Comparator|Bronchodilators|The comparator arm consists of SOC.
2458777|NCT03181737|Experimental|Covivio|"Covivio is an internet intervention for people with diabetes mellitus type 2. Content is continuously adapted to patients´ concerns and needs. Techniques to promote the disease self-management (i.e. nutrition, exercise), the motivation for health behavior (i.e. discussing pros and cons) conveying goal setting, mediating knowledge about diabetes (i.e. basics, symptoms & complications, diagnosis, therapy) , and reducing depressive symptoms (i.e. increasing activation, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets.~Patients are also prompted complete brief adherence self-monitoring questionnaires (adherence index) regularly. Optional text messages with motivational content accompany the program daily. The program can be accessed for 56 days after registration."
2458785|NCT03181737|Active Comparator|Relaxio|Relaxio is a psychological online-relaxation-training. The purpose of the program is to improve the self-management of diabetes by relaxation and stress reduction. The program consist of three types of exercises (1) imagination (i.e. sunset, mountain lake), (2) breathing techniques (i.e. balancing, calm breathing), and (3) body exercises (i.e. relaxing body journey, progressive muscle relaxation (PMR)). The exercises are supported by audio files (optionally also for reading). Optional weekly text messages with motivational content accompany the program. The program can be accessed for 56 days after registration.
2458788|NCT03181737|No Intervention|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Covivio six months post-baseline (i.e., wait list with respect to Covivio access).
2458876|NCT03181152||Asthma group|Impulse Oscillometry Bronchial Dilation Test if needed
2458877|NCT03181152||COPD group|Impulse Oscillometry Bronchial Dilation Test if needed
2458178|NCT03185715|Other|Counseling policy embryo transfer|All recipients completed a validated self-report questionnaire on the preference on the number of embryos to be transferred and the relevance for the decision-making process attributed to certain factors. The questionnaire also included questions on sociodemographic characteristics, medical-reproductive background and cycle's results and risks perception. All recipients received oral and written counselling. After counselling, during the treatment, the recipients completed a second questionnaire in order to check if their decision had changed.
2458314|NCT03184935|Experimental|Experimental group|Basic medication: Decitabine; Allogeneic umbilical cord mesenchymal stem cells.
2458317|NCT03184935|Placebo Comparator|Control group|Basic medication: Decitabine; placebo: saline.
3155487|NCT00322127|Experimental|1|AMD3100 given as a single 240 g/kg dose followed 14-90 days later by a single 320 g/kg dose
2458449|NCT03184116|Experimental|Individual intervention|Individual intervention using cognitive-behavioral principles
2458453|NCT03184116|No Intervention|Control|No additional intervention
2458519|NCT03183466|Experimental|Patients included in inclusion criteria|
2458563|NCT03183219|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor.
2458565|NCT03183219|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2458567|NCT03183219|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery or IRE surgery
2458610|NCT03182816|Experimental|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
2458648|NCT03182517||chronic kidney diseases|patients with chronic renal failure on dialysis since 3-5 years
2458702|NCT03182322|Experimental|intranasal insulin|rH-insulin formulation and for a dose of 440 IU insulin to the nasal mucosa. Treatment will be administered daily for the first 7 intervention days, and one day per week thereafter for 6 months.
2458703|NCT03182322|Placebo Comparator|intranasal placebo|Treatment with placebo nasal spray daily for the first 7 intervention days and one day per week thereafter for 6 months.
3155488|NCT00322127|Experimental|2|AMD3100 given as a single 320 g/kg dose followed 14-90 days later by a single 400 g/kg dose
3155489|NCT00322127|Experimental|3|AMD3100 given as a single 400 g/kg dose followed 14-90 days later by a single 480 g/kg dose.
3155490|NCT00322127|Experimental|4|randomized to either receive 240 g/kg first followed by 480 g/kg after a washout period or 480 g/kg first followed by 240 g/kg after a washout period.
2458817|NCT03181243|Experimental|MadaJet|Jet injector (Madajet medical Urology) preloaded as manufacturer's instruction
2458828|NCT03181243|Experimental|Needle injection|01 sterile 10-mL syringe with small gauge needle (25 ga), solution for sterile preparation, 10 - 15 mL Lidocaine 2%
2458897|NCT03180970|Experimental|group 1|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.
2458902|NCT03180970|Experimental|group 2|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.
2458914|NCT03180970|Experimental|group 3|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.
2458919|NCT03180970|Experimental|group 4|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.
2458925|NCT03180970|Experimental|group 5|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.
2458985|NCT03180450|Experimental|Treatment group|conventional treatment; Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) by i.v.
2458986|NCT03180450|Placebo Comparator|Control group|Conventional treatment
2459104|NCT03179696|Experimental|Mobile-assisted CBT|Psychosocial intervention combining in-person and smartphone-based cognitive-behavioral therapy (CBT) for experiential negative symptoms in schizophrenia called, Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
3155491|NCT00322166|Active Comparator|Group A, Sunlight|Participants in this arm are required to sit in the sun most days of the week for 15 minutes
3155492|NCT00322166|Active Comparator|Group B, sunlight and calcium|Participants in this group receive sunlight and a calcium supplement
2459194|NCT03178981|Active Comparator|Conventional cigarette|Commercially-available combustible cigarette
2459196|NCT03178981|Experimental|Second-generation e-cigarette A|Prototype second-generation (closed-tank) e-cigarette
2459197|NCT03178981|Experimental|Second-generation e-cigarette B|Prototype second-generation (closed-tank) e-cigarette
2459199|NCT03178981|Experimental|Second-generation e-cigarette C|Prototype second-generation (closed-tank) e-cigarette
2459200|NCT03178981|Experimental|Second-generation e-cigarette D|Prototype second-generation (closed-tank) e-cigarette
2459201|NCT03178981|Active Comparator|Second-generation e-cigarette E|Commercially-available second-generation (closed-tank) e-cigarette
2459240|NCT03178617|Active Comparator|Arm I (standard of care LIP)|Parents or caregivers attend standard of care LIP consisting of a meeting to review results of a neurocognitive evaluation and to discuss recommendations for optimal learning and school performance for 1 session.
2459241|NCT03178617|Experimental|Arm II (HIP)|Parents or caregivers attend HIP consisting of individual parental skill training sessions with a bilingual therapist over 60-90 minutes every 2 weeks for a total of 8 sessions.
2459304|NCT03178279|Experimental|Use of the Physical Health Plan|Use of the Physical Health Plan
2459357|NCT03178032|Experimental|single arm treatment DNX-2401|Single arm receiving virus DNX-2401 infusion after tumor biopsy
2459362|NCT03177863|Experimental|Study cohort|"Healthy women 25 - 30 years of age with CIN2 who consent to inclusion and with no former history of CIN (any grade). The intervention is expectancy with clinical visits every 6 months. Women will leave study cohort if found with total regression (no CIN) or CIN3"
3155493|NCT00322166|No Intervention|Group C|Control group
3155494|NCT00322179||Obese|
3155495|NCT00322179||Non-Obese|
3174541|NCT00624624||3|Eugonadal men with gastric bypass procedure
3155496|NCT00322218|Experimental|1|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
3155497|NCT00322218|Other|2|Observation
3155498|NCT00322257|Experimental|A|
2458354|NCT03184714|No Intervention|Control|
2458357|NCT03184714|Experimental|Interventional group|NIPPV as treatment of OS
2458367|NCT03184467|Placebo Comparator|Control group|Normal saline 0.9%
2458368|NCT03184467|Experimental|Study group 1|GV1001 0.56 mg
2458369|NCT03184467|Experimental|Study group 2|GV1001 1.12 mg
2458418|NCT03184298|Other|Group|Participants receive three interventions: Surveys, Interviews, and Group Workshops
2458649|NCT03182530|Active Comparator|ULTRA method group|
2458651|NCT03182530|Active Comparator|standard patent hemostasis group|
2458654|NCT03182530|Experimental|control group|
2458742|NCT03182283|No Intervention|Pre-intervention|All patients at the psychosis wards receive care as usual before staff goes through educational intervention.
2458743|NCT03182283|Other|Post-intervention|After staff attended educational intervention and implemented Person-centered psychosis care in the wards all patients admitted will receive person-centered care.
2458790|NCT03181685|Active Comparator|Treatment S (Subcutaneous)|Progesterone 25 mg subcutaneous (a single administration per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
2458792|NCT03181685|Active Comparator|Treatment V (Vaginal)|Micronized progesterone 200 mg (3 vaginal administrations per day) from the day of oocyte retrieval. Controlled ovarian stimulation (COS) will be performed with recombinant FSH and cetrorelix acetate.
2458834|NCT03181230||Adolescents|Adolescents and young adults with Turner syndrome will undergo studies of cardiometabolism, fitness, quality of life questionnaires, and a brief interview.
2458838|NCT03181230||Parents|One parent of a participant will complete parent-report quality of life questionnaires and a brief interview.
2458901|NCT03180983|Other|INTERVENTIONAL GROUP|The intervention group will receive a blended-learning intervention.
2458909|NCT03180983|No Intervention|CONTROL GROUP|No intervention
2458984|NCT03180580|Experimental|HEAL guideline+ Healthy Tiffin box|"HEAL guideline+ Healthy Tiffin box intervention arm will receive a culturally appropriate healthy eating and active living messages including a specially designed healthy tiffin box to practice healthy eating. HEAL guideline+ Healthy Tiffin box is a combination of intervention to promote healthy eating and physical activity behavior as well as improve the practice.~HEAL guideline-Healthy Eating and Active Living (HEAL) Guideline. A complete intervention guideline for promoting healthy dietary pattern and physical activity.~Healthy Tiffin box- A five chamber snack box that will help to contain food stuffs from all 5 major food groups eg; grain, meat/fish foods, vegetables, fruits and milk or milk products. This box will help to practice healthy eating behaviors."
2459009|NCT03180229|Active Comparator|Granisetron|Five minutes before the induction 1 ml (1 mg / ml) iv granisetron will use. .Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
2459011|NCT03180229|No Intervention|Control|Five minutes before the induction 1 ml saline iv use.Then blood pressure (systolic, diastolic, mean) and heart rate will record per 5 minute during surgery.
2459056|NCT03180060||SPECT|SPECT compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2459057|NCT03180060||Stress Echo|Stress Echo compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2459058|NCT03180060||CMR perfusion|CMR perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2459059|NCT03180060||CT perfusion|CT perfusion compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2459060|NCT03180060||Positron Emission Tomography|PET compared versus four reference standards (two anatomic cutoffs: angiographic lesions >50% and >70% and two functional cutoffs: FFRi <0.80 and <0.75).
2459129|NCT03179540|Experimental|non-operative management|Patients with low rectal cancer who have achieved a complete clinical response following chemoradiotherapy will undergo active follow-up with regular clinical visits, physical exam, endoscopy and imaging assessments at regular intervals for 2 years to assess for tumour re-growth or spread to the liver and lungs
2459202|NCT03179163|No Intervention|Normotensive|Blood Pressure <120/80 mmHg
2459205|NCT03179163|Experimental|Hypertensive - ACEi +SH|Captopril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2459208|NCT03179163|Experimental|Hypertensive - ACE inhibitor (ACEi)|Enalapril Pill intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2459209|NCT03179163|Active Comparator|Hypertensive - Diuretic|Hydrochlorothiazide intervention Blood Pressure ≥140/90 mmHg and <160/110 mmHg
2459295|NCT03178474|Active Comparator|Breast-Fed Group|The infants will be fed with human breast milk by their mother
2459297|NCT03178474|Experimental|TOFER Formula Group|TOFER Infant formula,TOFER®: Infants will be fed by using TOFER® infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
2459299|NCT03178474|Experimental|JINLINGGUAN Formula Group|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: Infants will be fed by using JINLINGGUAN (PRO-KIDO™ I-PROTECH®) infant formula (Phase I baby formula) from baseline (about 5-14 days) to 13 weeks of age.
2459842|NCT03174678|Other|Control|Apple juice
3155499|NCT00322257|Active Comparator|B|
3155500|NCT00322283|Experimental|Oglemilast|
3155501|NCT00322283|Placebo Comparator|Placebo|
3155502|NCT00322322|Experimental|1|L-Carnitine
3155503|NCT00322361|Experimental|1|Modified Process Hepatitis B Vaccine
3155504|NCT00322361|Active Comparator|2|Recombivax HB™
3155505|NCT00322400|Experimental|B1|AMG 706 50 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
3155506|NCT00322400|Experimental|A4|75 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8 and D15 every 28 days)
3155507|NCT00322400|Experimental|A1|AMG 706 50 mg daily + Paclitaxel (90 mg/m2 D1, D8, D15 every 28 days)
3155508|NCT00322400|Experimental|B4|75 mg AMG 706 daily + Docetaxel (100 mg/m2, D1 every 21 days)
2458207|NCT03185585||Adults 60 yrs and older|Participants will be asked to take the full MNA and COAST tools, separately .They will take a hand grip strength test to evaluate their functional status and five times Sit to Stand test as part of the COAST screening tool. Moreover, their weight, height, mid-arm circumference and calf circumference, will be measured as part of the MNA screening tool.
2458276|NCT03185247|Experimental|Group Intervention|10-week parent-child multi-family group
2458286|NCT03184909|Experimental|Tulsi active|
2458288|NCT03184909|Placebo Comparator|Tulsi placebo|
2458365|NCT03184779|Experimental|Intervention|The intervention group will receive an educational video containing safety messages and an injury prevention component with the intent of reducing behaviours and actions on the hill than can potentially lead to injury.
2458366|NCT03184779|No Intervention|Control|The control group will receive the usual procedures associated with school outings where students have the opportunity to watch the standard welcome video (~8 minutes) with information on how their day will go and how to use and put on safety equipment. The information given in the control procedure emphasizes preparation and how to use and put on equipment rather than safety messages oriented towards preventing injury and collisions. Students in the control group will watch the video prior to participating in the ski area school program.
2458387|NCT03184363|Experimental|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
2458416|NCT03184272|Experimental|bariatric surgery|baseline alert 1; Anti-Trendelenburg-position (ATB); Anti-Trendelenburg-position (ATB) in narcosis; baseline in narcosis 1; passive leg raising; volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); baseline in narcosis 2; start capnoperitoneum; Anti-Trendelenburg-position (ATB) plus capnoperitoneum; ATB plus capnoperitoneum plus volume bolus substitution (15 ml/kgKG Sterofundin balanced solution); ATB loss of capnoperitoneum; baseline in narcosis; baseline alert 2; torso position rising 30° at the beginning; torso position rising 30° at the end
3155509|NCT00322400|Experimental|B5|MTD of AMG 706 + Docetaxel (75mg/m2 D1 every 21 days)
3155510|NCT00322400|Experimental|B3|100 mg AMG 706 daily + Docetaxel (100 mg/m2 on D1 every 21 days)
2458753|NCT03181906|Experimental|Pre-Consultation Medication Reconciliation|Participants underwent medication reconciliation service before their consultation with the attending doctor. A best possible medication history (BPMH) was created and saved as an electronic draft in the electronic medical record system.
2458755|NCT03181906|No Intervention|Control|Participants in the control group proceeded with usual care, where the doctor reviewed the patient's condition and ordered an electronic prescription
2458779|NCT03181646|No Intervention|control group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive only supportive care
2458782|NCT03181646|Experimental|study group|newborns with hypoxic ischemic encephalopathy grade 2/3 who will receive citicoline along with supportive care
2458836|NCT03181360|Active Comparator|Tenecteplase|Tenecteplase + Best standard treatment
2458840|NCT03181360|Other|Control|No tenecteplase + Best standard treatment
2459046|NCT03180099|Active Comparator|Thoracolumbar Interfascial Plane Block|Bilateral ultrasound guided thoracolumbar interfascial plane block
2459048|NCT03180099|Active Comparator|Epidural Block|Epidural Block
2459086|NCT03179722|Experimental|Intervention group: Frenchspeaking patients|Intervention: Medication review
2459088|NCT03179722|Experimental|Intervention group: Dutchspeaking patients|Intervention: Medication review Intervention: Dutchspeaking patients are also invited to participate to Additional data collection: questionnaires
2459133|NCT03179449|Experimental|Diagnostic (ferumoxytol-enhanced MRI)|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
2459206|NCT03179020|Experimental|Checklist ICUs|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
2459207|NCT03179020|Active Comparator|Usual Care ICUs|Management of the potential donor according usual care.
2459308|NCT03178175|Experimental|"acupuncture with De Qi"|all participants in this group will receive the standard procedure of acupuncture.
2459309|NCT03178175|Sham Comparator|Sham acupuncture|In this group, all participants will receive acupuncture needle insertion but not exact acupoint's location and depth.
2459337|NCT03177889|Sham Comparator|Usual treatment|oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid]
2459343|NCT03177889|Active Comparator|TCM treatment|"Traditional Chinese Medicine plus oral mucolytics (described above);~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g"
3155511|NCT00322400|Experimental|B2|AMG 706 125 mg daily + Docetaxel (100 mg/m2 D1 every 21 days)
3155512|NCT00322400|Experimental|A2|AMG 706 125 mg daily + paclitaxel 90 mg/m2 D1, D8, D15 every 28 days
2459404|NCT03177538|Active Comparator|Corifollitropin alfa and menotropin|Elonva 150 mcg, Merional 150-300 IU
3155513|NCT00322400|Experimental|A3|100 mg AMG 706 daily + Paclitaxel (90 mg/m2 on D1, D8, and D15 every 28 days)
3155514|NCT00322478|Other|GlucoMON-ADMS enabled|Patients who are equipped with the automated technology vs. standard/conventional care
3155515|NCT00322517|Experimental|SU014813|
3155516|NCT00322530|Active Comparator|SLED|
3155517|NCT00322530|Active Comparator|CVVHD|
3155518|NCT00322543|Experimental|Drug eluting stent|Corio™ Pimecrolimus-eluting stent
3155519|NCT00322569|Experimental|1|Corio™ Pimecrolimus-Eluting Cobalt Chromium Coronary Stent System
2458226|NCT03185403|Active Comparator|continous paravertebral block|"echoguided thoracic continous paravertebral block was placed before the surgery.~A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required."
2458235|NCT03185403|Active Comparator|continous Thoracic epidural block|thoracic epidural catheter was inserted before the surgery. A bolus of 5 ml of ropivacaine 0.2% and 10µg of Sufentanil was injected in the catheter at the end of the abdominal time. A continuous infusion of ropivacaine 0.2% at 4ml/h was then initiated at the thoracic time. Postoperative patient-controlled analgesia consisted on an infusion of ropivacaine 0.2% at 6ml/h and a permitted bolus of 4ml every 15min as required.
2458438|NCT03184311|Experimental|High-intensity interval training (HIT)|A 12-week HIT will be performed 3 times per week on a bicycle ergometer according to the protocol of Wisløff et al. In the first 4 weeks of the program, all sessions will consist of moderate continuous training (MCT) at 60-80% of peak heart rate (HRpeak) for 40 minutes in order that patients get used to exercising. For weeks 4-12, the following HIT protocol is intended: Patients will warm up for 10 minutes at moderate intensity (60-70% of HRpeak, Borg 11-13) before cycling four 4-minute intervals at high intensity (85-95% of HRpeak, Borg 15-17). Each interval will be separated by a 3-minute active pause at 60-70% of HRpeak (Borg 11-13). The training session will end with a 5-minute cool-down at moderate intensity (60-70% of HRpeak). Total exercise time will be 40 minutes.
2458442|NCT03184311|Placebo Comparator|Moderate-intensity continuous training (MCT)|A 12-week MCT will be performed 3 times per week on a bicycle ergometer. All sessions will consist of moderate continuous training (MCT) at 60-70% of peak heart rate (HRpeak) for 47 minutes.
2458478|NCT03183713|Active Comparator|Comparison Group|Patients with a zero risk score will serve as a comparison group (N=20).
2458480|NCT03183713|Active Comparator|Sham Treatment|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
2458483|NCT03183713|Active Comparator|CBT|All patients at risk will be stratified by risk rating and randomly assigned to 2 groups; sham treatment (N=20) or CBT (N=20).
2458521|NCT03183479|Experimental|Treatment group|The patients in treatment group will receive Fibrinogen Concentrate Human administration.
2458523|NCT03183479|Placebo Comparator|Control group|The patients in control group will be administered with normal saline solution as placebo.
2458612|NCT03182777|Active Comparator|Lidocaine with epinephrine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% with epinephrine 1:100.000 for dental restorative procedures in patients with cardiac channelopathies.
2458615|NCT03182777|Active Comparator|Lidocaine|Application of local dental anesthesia with two cartridges (3,6 mL) of lidocaine 2% without vasoconstrictor for dental restorative procedures in patients with cardiac channelopathies.
2458685|NCT03182491||Anaphylaxis|
2458686|NCT03182491||Febrile transfusion reactions|
2458687|NCT03182491||Mild allergic reactions|
2458688|NCT03182491||Healthy controls|
2458709|NCT03182062|Active Comparator|OLA-iHFNC|"Intraoperatively ventilated patients with a tidal volume (VT) of 5-6ml / kg of ideal body weight and respiratory rate to maintain normal carbon dioxide. After intubation, in all patients will be performed an alveolar recruitment maneuver (MRA) and a PEEP titration trial (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively, high flow oxygen therapy will be individually indicated by evaluating peripheral oxygen saturation."
2458711|NCT03182062|Active Comparator|STD-O2|"Intraoperatively ventilated patients with a tidal volume of 5-6 ml / kg of ideal body weightand respiratory rate to maintain normal carbon dioxide, PEEP 5 cmH2O. In this group no recruitment maneuvers or optimal PEEP setting will be performed.~Postoperatively, standard oxygen therapy."
2458759|NCT03181763|Experimental|MDMA|Participants receive 100 mg MDMA
2458761|NCT03181763|Placebo Comparator|Placebo|Participants receive inactive placebo
2458798|NCT03181464|Experimental|experimental - lidocaine 4%|Continuous infusion lidocaine at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx.
2458799|NCT03181464|Placebo Comparator|placebo comparator|Continuous infusion saline at 3ml/hr for 1 hour bilaterally onto the posterior wall of the nasopharynx
3155520|NCT00322569|Experimental|2|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System
3155521|NCT00322569|Active Comparator|Control Arm|Costar ™ Paclitaxel-Eluting Coronary Stent System
2458890|NCT03180866|No Intervention|Non-treatment Control|Control arm will not have any intervention
2458893|NCT03180866|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
2458981|NCT03180593|Active Comparator|Valsartan Arm|Valsartan 80mg randomly assigned for 8 weeks to asses BP control with office and 24-hour ABPM and reduction of LVH
2458982|NCT03180593|Active Comparator|Nebivolol/Valsartan|Nebivolol/Valsartan 5/80mg randomly assigned for 8 weeks to asses Blood Pressure control with office and 24-hour Ambulatory Blood Pressure Monitoring and reduction of Left Ventricular Hypertrophy
3155522|NCT00322608|Experimental|Dose escalation|
2459112|NCT03179501|Experimental|NP001|NP001
2459113|NCT03179501|Placebo Comparator|Placebo|Normal saline
3155523|NCT00322686|Experimental|Oglemilast followed by placebo|
3155524|NCT00322686|Experimental|Placebo followed by Oglemilast|
3155525|NCT00322699|Experimental|A single arm, non-randomized Phase II Study|Non-Randomized Phase II,Single Arm Study evaluating the efficacy of whole bladder photodynamic therapy as an alternative to radical cystectomy.
3155526|NCT00322946|Experimental|1|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^5 PFU dose) into the deltoid region of either arm.
3155527|NCT00322946|Experimental|2|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^3 PFU dose) into the deltoid region of either arm. This arm will enroll after Arm 1.
3155528|NCT00322946|Experimental|3|One subcutaneous vaccination with rDEN4delta30-4995 vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm will enroll after Arms 1 and 2.
3155529|NCT00322946|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3191023|NCT00793884||Diabetes Education|Latino individuals with diabetes who are attending the Emory Latino Diabetes Education Program (ELDEP) will be followed in order to collect outcomes on clinical measurements. The class curriculum follows the American Association of Diabetes Educators (AADE) seven self-care behaviors: healthy eating, being active, monitoring, medication use, problem-solving and healthy coping. Program participants attend an initial 3 hour diabetes education class conducted in Spanish and then are invited to return to monthly follow-up sessions covering topics of meal planning, exercise, medications and complications. The follow-up sessions include activities such as dance lessons, cooking demonstrations, and sharing.
3191024|NCT00793897|Experimental|Sequential allocation of patients in two dosing schedules|
3191025|NCT00793923|Experimental|Combination Therapy|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
2458414|NCT03184337|Active Comparator|Active Control|Participants in the active control group will receive 8 group sessions of the CDC's PreventT2 program.
2458415|NCT03184337|Experimental|Experimental|Participants in the experimental group will receive 8 group sessions of the CDC's PreventT2 Program with Added Sleep Content designed to extend and improve sleep.
2458435|NCT03183999|Experimental|GINST group|Experimental group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Fermented ginseng (GINST) was supplied.
2458444|NCT03183999|Placebo Comparator|Control group|Control group was randomly assigned among the volunteers who met the inclusion criteria: men between the ages of 18 and 60 who had sperm motility of less than 32%. Placebo was supplied.
2458481|NCT03183700|Other|Control arm 1|The women will receive the usual recall with a new invitation letter with a prefixed appointment.
2458484|NCT03183700|Experimental|Intervention arm 2|Dry one, where FloqSwab, with which perform the sampling is contained and will be preserved after sampling in a tube without preservation solutions
2458486|NCT03183700|Experimental|Intervention arm 3|Wet one in which, after sampling, the FloqSwab, will be dissolved in preservation solutions.
2458551|NCT03183427||Group of patients with pineal cyst|Group of patients with pineal cyst
2458552|NCT03183427||Control group|Group of subjects without pineal cyst
2458593|NCT03182985|Experimental|Time Restricted Feeding|Patients will reduce daily oral intake to 10 hours per day
2458617|NCT03182673|Experimental|SHR7390, SHR-1210 and SHR3162|"Total 60-100 subjects with advanced solid tumors~In the two-drug combination therapy,subjects were received single oral doses of SHR7390，then accepted two drug combination therapy, SHR7390 is administered multiple daily oral doses of SHR7390 for 28 days for a treatment cycle. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose.~In the second study part, subjects accepted three drug combination therapy, SHR7390 is administered orally for 21 days and discontinued for 7 days in a 28-day treatment cycle,SHR3162 was administered orally twice a day for 28 days at a fixed dose of 100 mg. At the same time, SHR-1210 was given intravenously per 2 weeks at the 200mg fixed dose"
2458682|NCT03182400|Experimental|Healthy volunteer|Neurophysiological assessment Neuropsychological assessment
2458726|NCT03182140||Kyleena|Non-interventional, observational, uncontrolled study in women that have chosen Kyleena as their contraceptive method before entering the study
2458786|NCT03181555|Other|Pregnant Obese African American Women|Exploratory
2458813|NCT03181334|Active Comparator|Branch I|"Condition 1: (Standard Intervention)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation letter to complete free colorectal cancer (CRC) screening."
2458814|NCT03181334|Experimental|Branch II and Branch III|"Condition 2: (Time Guideline)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal cancer (CRC) screening within a specified time frame:~Branch II - Brief Time (1-week)~Branch III - Extended Time (3-weeks)"
2458823|NCT03181334|Experimental|Branch IV and Branch V|"Condition 3: (Time Guideline + Incentive)~Mailed fecal immunochemical test (FIT) kit including the following:~Invitation to complete free colorectal (CRC) screening within a specified time frame with a monetary incentive:~Branch IV - High Incentive~Branch V - Low Incentive"
2458954|NCT03180697||APT MR imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will be asked to participate in this study. The routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy.
2458990|NCT03180411||Cognitive Testing Phase Group|Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease.
2458993|NCT03180411||Pilot Testing Phase Group|"After Cognitive Testing Phase interview, participants may be asked to have a second one-on-one interview with research staff.~Participants may also be asked to complete a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant also asked to give participant's opinion about colorectal cancer follow-up materials."
2459028|NCT03180112||case group|Children suffering from Autism Spectrum disorders of variable grades attending to assiut University Children Hospital aged between six months and five years.
2459030|NCT03180112||control group|Healthy children of matching age and sex.
3155530|NCT00322972|Other|A|Annual mass treatment
3191026|NCT00793923|Active Comparator|Monotherapy|intravitreal injection of 0.5 mg ranibizumab
2459185|NCT03178916||Low risk pregnant women|evaluation of the efficacy of breastfeeding Low risk pregnant women
2459186|NCT03178916||high risk pregnant women|evaluation of the efficacy of breastfeeding high risk pregnant women
2459245|NCT03178747|Active Comparator|Case|Patients who clinically diagnosed as herpes simplex, herpes zoster or varicella zoster skin infection.
2459246|NCT03178747|Sham Comparator|Negative control|Patients who develops vesicular lesion but not typically considered as herpesviral skin infection, such as acute eczema, Paederus dermatitis
2459263|NCT03178318|Other|cricothyroid membrane|ultrasound of the neck will identify the position of the upper and lower border of the cricothyroid membrane in extended position.
2459323|NCT03178188|Experimental|laser treated DLE lesions|DLE which received the pulsed-dye laser
2459326|NCT03178188|Sham Comparator|sham treated DLE lesions|DLE which received the sham
2458406|NCT03184766|Experimental|5|Treatment Order: Comparator 2, Test, Comparator 1
2458408|NCT03184766|Experimental|6|Treatment Order: Comparator 2, Comparator 1, Test
2458469|NCT03183960|Experimental|Mentor|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
2458471|NCT03183960|Active Comparator|Traditional rehabilitation|An independent centralized randomization database will provide allocation concealed to the involved clinicians and assessors. A stratified block randomization of severity of impairment will be performed within each rehabilitation hospital
2458564|NCT03183206|Experimental|Group A|In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor
2458566|NCT03183206|Experimental|Group B|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
2458568|NCT03183206|Experimental|Group C|In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery
2458604|NCT03182803|Experimental|Anti-CTLA-4/PD-1 expressing meso-CAR-T|This study have only one arm that is the CTLA-4/PD-1 antibodies expressing mesoCAR-T cells group. All patients with advanced solid tumors will take part in the screening, who matching all the conditions will be chosen for the treatment.New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
3155531|NCT00322972|Other|B|Biannual mass treatment
3155532|NCT00322972|Experimental|C|Mass administration of antibiotic; treatment of children (1-10 years of age) only
3155533|NCT00322972|No Intervention|D|Delayed initiation of mass administration of antibiotic
2458816|NCT03181399|Experimental|Triheptanoin|This is a single arm study.
2458896|NCT03181022|No Intervention|Phase 1a|To develop a measure of MI fidelity to ensure methodological rigor, acceptability and feasibility of administration, and clinical usefulness (Phase 1a). Ratings of 200 recordings of full patient-provider interactions with ratings of thin slices (recording 1 minute every 5 minutes) will be compared.
2458898|NCT03181022|No Intervention|Phase 1b|To conduct evidence-based tailoring of MI training for adolescent HIV care settings (Phase 1b). Coding via sequential analysis will be conducted of the 200 recordings to identify those specific provider communication behaviors that predict subsequent youth motivational statements.
2458903|NCT03181022|No Intervention|Phase 2|To collaboratively develop the implementation intervention with 2 clinic teams associated with the ATN (Phase 2). A formative evaluation will be done to provide local diagnostic data regarding barriers and facilitators to adoption and create development panels - local development teams made up of clinicians and administrators from the site, and study staff to address barriers and facilitators from formative evaluation and draft locally-customized clinical care and multi-level implementation strategies with initial sustainability plans.
2458910|NCT03181022|Experimental|Phase 3|To pilot test the implementation intervention and process/outcome evaluation protocols at two ATN sites in preparation for a full-scale trial.
2459013|NCT03180346|Active Comparator|Single-Use Negative Pressure Wound Therapy|
3155534|NCT00322972|Other|F|One-time mass administration only
3155535|NCT00322972|Experimental|G|One-time mass administration of antibiotics, plus intensive latrine construction
3155536|NCT00323011|Active Comparator|Arm A: 5-FU/LV/CPT-11/Bevacizumab|5-FU 400 mg/m2, days 1, 15, & 29 Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29
3155537|NCT00323011|Experimental|Arm B: 5-FU/LV/CPT-11/Bevacizumab + Dalteparin|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, days 1, 15, & 29
3155538|NCT00323011|Experimental|5-FU/LV/CPT-11/Bevacizumab+Dalteparin daily|5-FU 400 mg/m2, days 1, 15, & 29 5-FU 2400 continuous infusion days 1-2, 15-16, 29-30. Leucovorin Calcium 200 mg/m2, days 1, 15, & 29 CPT-11 180 mg/m2, days 1, 15 & 29 Bevacizumab 5mg/kg, days 1, 15, & 29 Dalteparin 5000 IU subcutaneous starting cycle 2, daily
3155539|NCT00323076|Experimental|1|18F-FAZA PET Imaging
3155540|NCT00323089|Experimental|Surgical Arm|Preoperative CT-Guided Microcoil Localization (CTML) and Fluoroscopic-Guided Video-Assisted Thoracoscopic (VATS) Wedge Resection of Small Peripheral Pulmonary Nodules (SPPN)
3155541|NCT00323141|Active Comparator|Ventralex|
3155542|NCT00323141|Active Comparator|Leight Weight Vypro II prothesis|
3155543|NCT00323206|Experimental|Intra-tumoral Electroporation of pIL-12|Participants will receive intra-tumoral injection of pIL-12 followed immediately by electrical discharge around the tumor site resulting in electroporation of plasmid DNA into tumor cells. For each lesion selected for therapy, a total of three electroporation treatments will be performed.
3174542|NCT00624624||4|Hypogonadal men with gastric bypass procedure
2458491|NCT03183830|Placebo Comparator|Nitrate-deplete Beetroot Juice|The placebo control is an identical juice from which the nitrate anion has been removed using a standard anion exchange resin. Visually there is no detectable difference between the juices and previous spectral, ion concentration, sugar levels, ascorbate analysis and taste testing has confirmed no differences in colour and constituents. The process to extract nitrate from the juice is the same technique used to remove inorganic nitrate from general drinking water supplies, and has been approved for use by Ethics Committees. The nitrate-free juice is not considered a drug or medicine, and is classified as a foodstuff.
2458527|NCT03183349|Experimental|platelet rich fibrin|immediate implant grafting
2458529|NCT03183349|Active Comparator|deprotienized bovine bone (tutogen)|immediate implant grafting
2458737|NCT03182179|Experimental|O-P sequence|Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.
2458741|NCT03182179|Experimental|P-O sequence|Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.
2458767|NCT03181568|Other|Control|This arm group (control) will receive standard wound care of chronic wounds
2458768|NCT03181568|Other|Treatment|The treatment arm of the study will utilize the MolecuLight i:X Imaging Device to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present
2458842|NCT03181386|Experimental|Rivaroxaban|As the rivaroxaban is ingested 1x/day, the interval between a maximum peak concentration and the other peak is 24 hours. Therefore, the surgery will be performed between two peaks of maximum drug concentration, knowing that the maximum peak concentration is an average of two hours after ingestion. So the surgical procedure should be scheduled 14 hours (2 hours+ 12 hours) after the last medication intake.
2458846|NCT03181386|Experimental|Dabigatran and Apixaban|As dabigatran and apixaban are taken 2x/day, the interval between two peak concentration is 12 hours.Taking into account the first two hours of maximum peak concentration and half the interval between two peaks (2 hours + 6 hours = 8 hours), the surgical procedure must be programmed eight hours after the last intake of medication.
2458847|NCT03181386|Active Comparator|Warfarin|The control group will consist of patients on chronic use of warfarin. The operation will be scheduled at any time, provided that the patient has INR value between 2.0 and 3.0 and test performed in maximum 15 days before surgery.
2458904|NCT03180905|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
2458912|NCT03180905|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points
2459044|NCT03180190||patients with ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
2459045|NCT03180190||patients without ocular toxicity|"Screening for ophthalmic exclusion criteria by slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT) genotyping using real time PCR (Taqman discrimination assay) for study frequency of single nucleotide polymorphisms (SNPs) of CYP2C19, CYP1A2, and ABCG2."
2459071|NCT03179839|Experimental|Mindfulness-based Cognitive Therapy|MBCT group is a treatment group used mindfulness-based cognitive therapy, and guided by two therapists for 10 sessions. Every collection of about 6-8 patients is a closed structural group. Each session lasts 2.5 hours once a week, and has daily homework assignments.
2459074|NCT03179839|Placebo Comparator|Psycho-education Program|The program is consists of the information and principle of treatment for OCD, group sharing, supporting and discussion.
2459077|NCT03179839|Active Comparator|SSRIs Therapy|This is a control group that can choose to use SSRI drugs which the SFDA approved for the treatment of OCD (Sertraline, Fluvoxamine, initial dose of 50 mg).
2459141|NCT03179553||HIE|Babies admitted to the neonatal unit with suspected mild, moderate or severe hypoxic ischaemic encephalopathy .
2459150|NCT03179553||Healthy|Babies who are inpatients in the postnatal ward, born following uncomplicated pregnancy and delivery.
2459203|NCT03178708|Active Comparator|Group A amantadine sulfate|the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
2459204|NCT03178708|Placebo Comparator|Group B ringer lactate|the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
2459269|NCT03178565|Experimental|Intervention Group|Respiratory physiotherapy using a mechanical insufflation-exsufflation device (CoughAssist)
2459272|NCT03178565|Active Comparator|Control Group|Respiratory physiotherapy according standard of care - without the use of a mechanical insufflation-exsufflation device.
2459332|NCT03178136||case group|There is no intervention in case group.
2459335|NCT03178136||control group|The control group as the contrast for case group.
2459496|NCT03177018|Experimental|Patients with Cardiomyocytes collection|Patients suffering from arrhythmogenic right ventricular cardiomyopathy/dysplasia cardiac and needing endocardial voltage mapping for disease diagnosis and/or prognosis assessment
2459599|NCT03176537|Placebo Comparator|Placebo|Gel, daily
2459601|NCT03176537|Experimental|TRT|Testosterone Replacement Therapy
2459653|NCT03175900|Experimental|Naoan dripping pills for migraine|Drug: Naoan dripping pills, Chinese patent medicine，pill. Patients will receive treatment with Naoan dripping pills for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning（fMRI and DTI）
2459692|NCT03175874|Other|osteoporosis and alzheimer|patient with osteoporosis and alzheimer hospitalized for total hip prosthesis.
2458511|NCT03183596|Active Comparator|Deep Serratus Anterior Block|"Patients in the deep Serratus Anterior Block (DSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone deposited deep to the serratus. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
2458512|NCT03183596|Active Comparator|Superficial Serratus Anterior Block|"Patients in the superficial Serratus Anterior Block (SSAB) group will have 20-60cc of 0.25% bupivacaine and 2-4mg of dexamethasone placed between serratus and latissimus dorsi. The investigator will then evaluate the difference based on pain scores, opiate consumption, length of hospital stay, as well as nausea and vomiting."
2458545|NCT03183258|Experimental|Sentinel Skin Flap|
2458605|NCT03183024|Placebo Comparator|placebo|placebo for benralizumab sc given during run-in phase
2458606|NCT03183024|Experimental|benralizumab|benralizumab sc once a month for 3 months for subjects who meet inclusion/exclusion criteria after run-in phase
2458655|NCT03182569|Experimental|flexible catheter|The flexible Subcutaneous catheter for insulin administration
2458659|NCT03182569|Active Comparator|hourly rigid needle puncture|Hourly rigid needle puncture for Subcutaneous insulin administration
3155544|NCT00323323|Experimental|Alemtuzumab/CHOP|For all patients enrolled, the study will begin with a stepped-up schedule of single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5. Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose
3155545|NCT00323375|Experimental|AQ-13 (Investigational 4-Aminoquinoline)|Arm: Experimental: AQ-13 AQ-13 capsules with 350 mg AQ-13 base per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
3155546|NCT00323375|Active Comparator|CQ (Chloroquine)|Arm: Active Comparator: CQ CQ Capsules with 300 mg CQ base per capsule per capsule. Two capsules orally on days 1 and 2, one capsule orally on day 3.
2458801|NCT03181438|Experimental|TAP Block|"The TAP block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of 0.375% ropivacaine"
2458804|NCT03181438|Sham Comparator|Saline Group|"The block will be performed under general anesthesia, according to the technique described below:~The patient will be placed supine with the abdomen exposed between the iliac crest and the costal margin~After skin antisepsis, a high-frequency ultrasound transducer will be placed transversely across the anterior axillary line above the iliac crest~In this region, the abdominal musculature (external oblique, internal oblique and transverse abdomen) is identified, and the transverse abdominal plane of the abdomen~The needle (BD-A-50mm) will be inserted in the technique in plane to the region of the transverse plane of the abdomen, where the solution will be administered.~In this group, will be administered 20 mL of Saline"
3155547|NCT00323401|Experimental|Interventon|Antenatal classes for the parents
2458916|NCT03180762|Experimental|Part 1: Cohort 1 (JNJ-64140284 or Placebo)|Participants will receive 0.1 milligram (mg) JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458922|NCT03180762|Experimental|Part 1: Cohort 2 (JNJ-64140284 or Placebo)|Participants will receive 0.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458928|NCT03180762|Experimental|Part 1: Cohort 3 (JNJ-64140284 or Placebo)|Participants will receive 2.5 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458930|NCT03180762|Experimental|Part 1: Cohort 4 (JNJ-64140284 or Placebo)|Participants will receive 10 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458933|NCT03180762|Experimental|Part 1: Cohort 5 (JNJ-64140284 or Placebo)|Participants will receive 50 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458934|NCT03180762|Experimental|Part 1: Cohort 6 (JNJ-64140284 or Placebo)|Participants will receive 150 mg JNJ-64140284 or matching placebo under fasted condition on Day 1.
2458937|NCT03180762|Experimental|Part 2: Cohort 7 (JNJ-64140284)|Participants will receive JNJ-64140284 (dose to be determined - the dose of JNJ-64140284 will be determined on the basis of acceptable safety, tolerability and pharmacokinetics [PK] of preceding dose levels; no more than 50 percent (%) of the highest dose tested [though as high as possible within this restriction] and considered well tolerated in Part 1) under fed conditions on Day 1.
2458944|NCT03180762|Experimental|Part 3: Cohort 8 (JNJ-64140284 or Placebo)|Participants will receive JNJ-64140284 or matching placebo (dose to be determined - dose will be determined based on PK data from previous cohorts and which will be well-tolerated in Part 1) under fasted condition on Day 1.
2459165|NCT03179202|Experimental|Peripheral Nerve Stimulation|All study subjects will have up to 4 Leads placed in their low back, will use the SPRINT Peripheral Nerve Stimulation (PNS) System, and will receive electrical stimulation.
2459231|NCT03178890|Experimental|Osseointegrated Human Machine Gateway (OHMG)|"Patients will be upgraded to the OHMG if already users of the OPRA Implant System, or implanted with the OPRA Implant System plus OHMG. Each patient will work as his/her own control before and after implantation of the OHMG.~A single surgery is required to upgrade OPRA Implant System users to the OHMG, and no additional surgeries are required if the OHMG is implanted at the same time as the OPRA Implant System."
3155548|NCT00323401|No Intervention|Control|No programme are offered
3155549|NCT00323440||Group 1|FMF patients in remission
3155550|NCT00323440||Group 2|FMF patients during attack
3155551|NCT00323440||Group 3|FMF patients without colchicine in remission
3155552|NCT00323440||Group 4|FMF patients without colchicine in attack
3155553|NCT00323466|Experimental|IMRT|
3155554|NCT00323518|Placebo Comparator|1|placebo
3155555|NCT00323518|Experimental|2|30 mcg/kg velafermin
3155556|NCT00323518|Experimental|3|10 mcg/kg velafermin
2458613|NCT03182842|Experimental|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM glucose values
2458616|NCT03182842|Active Comparator|SMBG - Blinded Sensor - Control|Insulin dosing based on SMBG, FreeStyle Libre FGM will be blinded.
2458681|NCT03182452||Pre Phase (no Alarm Advisor)|No Software installed
2458683|NCT03182452||Post Phase (Alarm Advisor installed)|Software implemented and staff trained (Interventional Phase)
2458695|NCT03182153||Enrolled subjects|Subjects who are diagnosed with HCM and require routine extended cardiac monitoring for risk stratification of sudden cardiac death. All subjects will receive 28 days of external cardiac monitoring.
2458719|NCT03181984|Experimental|Hemoporfin|
2458841|NCT03181750|No Intervention|Control|Patients and caregivers randomized to this arm will receive a packet of educational materials in English or Spanish. These materials are written at 5-6th grade reading level. The materials focus on advance care planning, pain and symptom management, and hospice care.
2458844|NCT03181750|Experimental|Patient Navigator Intervention Group|Patient and caregivers randomized to this arm will receive the same packet of educational materials. They will also receive at least 5 visits from a bicultural bilingual patient navigator. The navigator will utilize a annualized visit guide manual to lead discussions on advance care planning, pain and symptom management, and hospice care.
2458892|NCT03180957|Experimental|Anti-TNF|adalimumab
2458894|NCT03180957|Placebo Comparator|Placebo|saline
2458968|NCT03180567|Experimental|Warfarin resistant patients|Genetic Mutations
2458972|NCT03180567|Placebo Comparator|Control|Genetic Mutations
2459010|NCT03180320|Experimental|BESMILE-HF group|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines. In addition, patients will receive the BESMILE-HF program.
2459012|NCT03180320|Other|Control|Patients in the control group will receive only the usual medications, since patients typically do not receive exercise-based cardiac rehabilitation in this kind of setting.
2459054|NCT03179995|Experimental|Octreotide treatment arm|Octreotide will be administered post-operatively until day 5
2459055|NCT03179995|Placebo Comparator|Placebo Arm|Normal saline will be administered post-operatively until day 5
2459069|NCT03179709||Intervention|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the active treatment arm of ROSE.
2459070|NCT03179709||Control|The investigators will interview physicians, nurses, respiratory therapists and other clinicians who have cared for patients enrolled in the control treatment arm of ROSE.
2459075|NCT03179709||Refusal|The investigators will interview physicians who have refused to allow their patients to be enrolled in ROSE.
2459125|NCT03179618|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
2459127|NCT03179618|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2459242|NCT03178799||FLS|Fracture Liaison Service (Care managers based coordination service for fragility fracture patients with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.)
2459243|NCT03178799||UC|usual care (Care managers will perform baseline assessments and follow them by telephone annually for up to 10 years. )
2459283|NCT03178357|Other|HCM patients with CR|30 HCM patients treated as standard subjected to 4-week hospital cardiac rehabilitation (CR) including psychological care (counseling and / or psychoeducation) and physical training followed by 8 weeks of telerehabilitation in the patient's home (cardiac rehabilitation + standard therapy)
2459284|NCT03178357|Other|HCM patients without CR (control group)|30 HCM patients in control group - standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling (standard therapy)
2459336|NCT03178019||Euglycemia group|Normoglycemic/normotolerant subjects
2459340|NCT03178019||Prediabetes group|Subjects with prediabetes
2459345|NCT03178019||Diabetes group|Subjects with type 2 diabetes mellitus
2459381|NCT03177720|Active Comparator|Ciprofloxacin|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
2459386|NCT03177720|Active Comparator|Imipenem|Half of patients and healthy volunteers are receiving ciprofloxacin, the other half imipenem.
2459453|NCT03177356|Experimental|extraction,implant placement,PRF|Extraction of Mandibular first molar and Implant placement followed by Placement of placement of Platelet rich fibrin as space filling material
2459455|NCT03177356|Active Comparator|Exctraction,Implant placement,Bone graft|Extraction of mandibular first molar followed by implant placement and xenogenic bone graft as space filling material
3155557|NCT00323518|Experimental|4|60 mcg/kg velafermin
3155558|NCT00323531|Active Comparator|1|Video assisted thoracoscopic decortication
3155559|NCT00323531|Experimental|2|Fibrinolysis through the chest tube
3155560|NCT00323648|Experimental|postoperatively antibiotics|
3155561|NCT00323661|Experimental|1|Rate-adaptation by Closed Loop Stimulation
2459566|NCT03176394|Experimental|BLASTX Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with BLASTX. This gel lubricates with the same viscosity as McKesson Jelly and has a biofilm disruptive active ingredient.
2459568|NCT03176394|Placebo Comparator|McKesson Jelly Lubricated Catheter|Subjects for which catheterization is prescribed will be catheterized with a Foley lubricated with McKesson Jelly. This jelly lubricates with the same viscosity as BLASTX but has no biofilm disruptive active ingredient.
2459607|NCT03176199|Experimental|Control-released oxycodone|Control-released oxycodone Q12H, initial daily dose is 20 mg + immediate-released oxycodone for PRN
2459609|NCT03176199|Active Comparator|Immediate-released oxycodone|Immediate-released oxycodone Q6H, initial daily dose is 20mg + immediate-released oxycodone for PRN
3155562|NCT00323661|Active Comparator|2|Accelerometer based pacing rate adaptation
3155563|NCT00323674|Active Comparator|Light Weight Mesh|
3155564|NCT00323674|Active Comparator|Polysoft Mesh|
3155565|NCT00323713|Experimental|VLPD diet|Adavnced CKD patients (stage 4-5) on a very low protein diet
3155566|NCT00323713|Active Comparator|LPD diet|Adavnced CKD patients (stage 4-5) on a low protein diet
2458623|NCT03183102|Experimental|Estrogen suppression with flax|Flax subjects will consume flaxseed for 2 months in addition to GnRH suppression
2458668|NCT03182478|Active Comparator|Individual Treatment|Intervention with the Rothbaum Protocol in individual format, with eight weekly sessions each one of 45 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
2458669|NCT03182478|Active Comparator|Group Treatment|Intervention with the Rothbaum Protocol in group format up to 10 patients, with eight weekly sessions each one of 90 minutes, applied by a trained investigator. Session 1: Psychoeducation and self-monitoring. Session 2: habit reversal techniques. Session 3: muscle relaxation and diaphragmatic breathing. Session 4: stop the thought. Session 5: oriented internal dialogue. Session 6: cognitive techniques. Session 7: role-play. Session 8: relapse prevention
2458730|NCT03182192|Experimental|Hypoglycemia|Patients with hypoglycemia after gastric bypass
2458735|NCT03182192|Active Comparator|Control|Patients without hypoglycemia after gastric bypass
3191027|NCT00793962|Experimental|hypofractionation radiotherapy|breast cancer women with mastectomy high-risk: T3-4 and/or 4 or more axillary nodes involvement postmastectomy hypofractionation radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
3191028|NCT00793962|Active Comparator|conventional fractionation radiotherapy|breast cancer women with mastectomy high-risk with T3-4 and/or 4 or more axillary nodes postmastectomy conventional fractionation radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
2458878|NCT03181100|Experimental|Cohort I (vemurafenib, cobimetinib, atezolizumab)|Patients receive vemurafenib PO BID on days 1-21, cobimetinib PO QD on days 1-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
2458879|NCT03181100|Experimental|Cohort II (atezolizumab, cobimetinib)|Patients receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression and unacceptable toxicity.
2458880|NCT03181100|Experimental|Cohort III (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 60-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
2458881|NCT03181100|Experimental|Cohort IV (nab-paclitaxel, atezolizumab, paclitaxel,)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 and atezolizumab IV on day 1 over 30-60 minutes. Patients may receive paclitaxel IV over 30 minutes on day 1 as a substitute for nab-paclitaxel. Cycles repeat every 21 days in the absence of disease progression and unacceptable toxicity.
2459022|NCT03180333|Experimental|PNA 1|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 7 days;
2459023|NCT03180333|Placebo Comparator|PNA placebo|Multiple dosing tolerance test:Metacavir Enteric-coated Capsules placebo 160mg/320mg,once a day,continuous administration for 7 days
2459024|NCT03180333|Experimental|PNA 2|Single dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 80mg/160mg/320mg,single-dose;
2459025|NCT03180333|Experimental|PNA 3|Multiple dosing pharmacokinetic test:Metacavir Enteric-coated Capsules 160mg/320mg,once a day,continuous administration for 6 days;
2459027|NCT03180333|Experimental|PNA 4|The effect of diet:Metacavir Enteric-coated Capsules 160mg,before and after meal.
2459097|NCT03179930|Experimental|Entinostat and Pembrolizumab|patients will be assigned to receive therapy with entinostat given by mouth once weekly and pembrolizumab given intravenously every 3 weeks
2459134|NCT03179332|Experimental|BioChaperone® insulin lispro|Single subcutaneous administration of BioChaperone® insulin lispro
2459143|NCT03179332|Active Comparator|Fiasp®|Single subcutaneous administration of Fiasp® (insulin aspart)
2459152|NCT03179332|Active Comparator|Novorapid®|Single subcutaneous administration of Novorapid® (insulin aspart)
2459187|NCT03179124||Hemiparetic cerebral palsy|Unilateral paresis in which upper extremities are more severely affected than lower extremities.
2459188|NCT03179124||Diparetic cerebral palsy|Lower extremities were more affected than upper extremities
2459224|NCT03178721||1|Systemic lupus erythematosus with atherosclerosis
2459228|NCT03178721||2|Systemic lupus erythematosus without atherosclerosis
2459457|NCT03177135|Experimental|AmnioSense diagnostic pantyliner|AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods
2459503|NCT03176940|Experimental|2-HOBA first dose|Dose escalation studies in humans: 50mg dose
2459506|NCT03176940|Experimental|2-HOBA second dose|Dose escalation studies in humans: 100mg dose
2459514|NCT03176940|Experimental|2-HOBA third dose|Dose escalation studies in humans: 200mg dose
2459519|NCT03176940|Experimental|2-HOBA fourth dose|Dose escalation studies in humans: 330mg dose
2459526|NCT03176940|Experimental|2-HOBA fifth dose|Dose escalation studies in humans: 550mg dose
2459528|NCT03176940|Experimental|2-HOBA sixth dose|Dose escalation studies in humans: 825mg dose
2459616|NCT03175978|Experimental|IGF/MTX|This arm will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, as assessed after 2 cycles, unacceptable toxicity, or patient refusal.
2459695|NCT03175809|Active Comparator|PFM training|4 sessions (40 minutes approximately), Twice a week for 2 weeks of pelvic floor training with electromyographic biofeedback.
2459703|NCT03175809|Experimental|PFM training plus dry needling|PFM training associated with the use of dry needling over abdominal, gluteal and lombar miofascial trigger points.
2459746|NCT03175133|Experimental|Strength training|Strength exercises for ankle PF, hip abduction, and trunk muscles. Exercises will be done in three standard positions of supine, sidelying, prone, seated, and standing. Exercises during the initial 4 weeks will be completed 2x week with supervision of a physical therapist and 2x week at home, for a total of 4x week. For the final 4 weeks of the intervention will be completed 1x week with supervision and 3x week at home.
2458723|NCT03182088|Experimental|0.025 mcg /Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.05 mcg/Kg/min) equivalent to norepinephrine infusion (0.025 mcg/Kg/min).
2458728|NCT03182088|Experimental|0.050 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.1 mcg/Kg/min) equivalent to norepinephrine infusion (0.050 mcg/Kg/min).
2458734|NCT03182088|Experimental|0.075 mcg/Kg/min group|The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine bitartrate infusion (0.15 mcg/Kg/min) equivalent to norepinephrine infusion (0.075 mcg/Kg/min)
2458769|NCT03181581|Experimental|High grade gliomas stage 1 ACF|In the first stage 12-15 patients with high-grade gliomas will be included in the trial (acoustic coupling fluid) group.
2458770|NCT03181581|Experimental|Low-high grade gliomas stage 2 ACF|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the trial (acoustic coupling fluid) group of 22-25 patients with both low-grade and high-grade glioma
2458771|NCT03181581|Active Comparator|High grade gliomas stage 1 control|In the first stage 12-15 patients with high-grade gliomas will be included in the Ringer's acetate (control) group.
2458772|NCT03181581|Active Comparator|Low-high grade gliomas stage 2 control|If the interim safety assessments validate that the study can continue, the second stage involves inclusion in the Ringer's acetate (control) group of 22-25 patients with both low-grade and high-grade glioma
2458800|NCT03181373||Traumatic brain injury population|Defined population : traumatic brain injury population
2458858|NCT03181191|Active Comparator|Totally pancreatectomised patients|Oral glucose tolerance test and biopsies
2458859|NCT03181191|Active Comparator|Type 2 diabetes patients|Oral glucose tolerance test and biopsies
2458860|NCT03181191|Active Comparator|Healthy control subjects|Oral glucose tolerance test and biopsies
2458900|NCT03180879|Experimental|1|Treatment Order: Test, Reference, Comparator
2458908|NCT03180879|Experimental|2|Treatment Order: Test, Comparator, Reference
2458913|NCT03180879|Experimental|3|Treatment Order: Reference, Test, Comparator
2458920|NCT03180879|Experimental|4|Treatment Order: Reference, Comparator, Test
2458924|NCT03180879|Experimental|5|Treatment Order: Comparator, Test, Reference
2458927|NCT03180879|Experimental|6|Treatment Order: Comparator, Reference, Test
2458991|NCT03180398|Experimental|Multi-parametric MRI for Prostate Cancer|MRI will be acquired for prostate cancer patients undergoing radiation treatment.
2459032|NCT03180164|Other|chronic lung diseases|bronchiectasis , bronchial asthma and chronic obstructive pulmonary disease assess anxiety and depression by hospital anxiety and depression scale
2459105|NCT03179956|Experimental|Ribociclib|
2459145|NCT03179384|Experimental|ceftriaxone treatment|
2459219|NCT03178656|Active Comparator|PVTT WITH SORAFENIB|"AASLD recommend therapy:~sorafenib tablet, 400mg, bid."
2459221|NCT03178656|Experimental|PVTT WITH OPERATION|patients suitable for surgery
2459274|NCT03178409||cHCC-MFCCC|Patients affected by combined HCC-MFCCC
2459275|NCT03178409||HCC|Patients affected by classical HCC
2459277|NCT03178409||MFCCC|Patients affected by classical MFCCC
2459442|NCT03177460|Experimental|Arm A (daratumumab)|Patients receive daratumumab IV over 4-8 hours once weekly for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo radical prostatectomy during week 6.
2459449|NCT03177460|Experimental|Arm B (FMS inhibitor JNJ-40346527)|Patients receive FMS inhibitor JNJ-40346527 PO BID for 4-5 weeks in the absence of disease progression or unacceptable toxicity. After a 3 day wash-out period, patients undergo radical prostatectomy.
2459536|NCT03176758|Active Comparator|Spinal block|"Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
2459539|NCT03176758|Active Comparator|General anesthesia|"1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg ideal body weight diluted with 100cc Normal Saline~+ Total Knee Replacement ( which will not be the intervention of interest)"
2459574|NCT03176355|Other|Chronic dacryocystitis patients|
2459626|NCT03176160||Patients receiving palliative regimen consisting of LITT|Patients with WHO grade IV malignant glioma who are approved for and receive the LITT (Laser Interstitial Thermal Therapy) procedure
2459670|NCT03175744|Experimental|Stellarex DCB|Spectranetics Stellarex Drug Coated Balloon
2459671|NCT03175744|Active Comparator|PTA Catheter|Standard Uncoated Balloon Angioplasty Catheter
3155567|NCT00323804|Experimental|Randomised PegIFN alfa 2b + ribavirin (RBV) arm|Combination of ribavirin capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
2459742|NCT03175016|Experimental|DEBIRI|Transcatheter arterial chemoembolization(TACE) with Irinotecan eluting-bead(DEBIRI)
2459803|NCT03174795|Experimental|RO7079901 and Meropenem|Participants will receive RO7079901 and meropenem. The duration of study drug treatment will be determined by the investigator after evaluation of the participant's response to study drug treatment. Participants should receive a minimum treatment period of 3 days and up to 14 days of intravenous (IV) study drug treatment.
2459849|NCT03174444|Experimental|Small Media|Participants receive bilingual brochures and access to bilingual website about colorectal cancer screening.
2459850|NCT03174444|No Intervention|Control|Participants receive no information about colorectal cancer screening from the study during the intervention period, but may receive usual care from health care provider.
2460235|NCT03172000|No Intervention|Colonoscopic biopsy|Non IBD patients colonoscopic biopsy
2458694|NCT03182348||Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
2458721|NCT03181997||TAVI Patients with active cancer|Patients with active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
2458725|NCT03181997||TAVI patients without cancer|Patients with no active cancer undergoing transcatheter aortic valve implantation (TAVI) with native aortic valves.
3174543|NCT00624637|Other|A|infants after craniofacial surgery receive one massage with aromatherapy three hours postoperatively
3174544|NCT00624637|Other|B|infants after craniofacial surgery receive one massage with carrier oil three hours postoperatively
2458848|NCT03181217|Experimental|water 22, water 0, glucose 0, glucose 22|Subjects consume 300 ml water at 22 ºC, 300 ml water at 0 ºC, 300 ml water at 0 ºC containing 75 grams glucose and 300 ml water at 22 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
2458849|NCT03181217|Experimental|water 0, glucose 22, water 22, glucose 0|Subjects consume 300 ml water at 0 ºC, 300 ml water at 22 ºC containing 75 grams glucose, 300 ml water at 22 ºC and 300 ml water at 0 ºC containing 75 grams glucose sequentially with a one-week washout between consumptions
2458850|NCT03181217|Experimental|glucose 22, glucose 0, water 0, water 22|Subjects consume 300 ml water at 22ºC containing 75 grams glucose, 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 0 ºC and 300 ml water at 22 ºC sequentially with a one-week washout between consumptions
2458851|NCT03181217|Experimental|glucose 0, water 22, glucose 22, water 0|Subjects consume 300 ml water at 0 ºC containing 75 grams glucose, 300 ml water at 22 ºC, 300 ml water at 22 ºC containing 75 grams glucose and 300 ml water at 0 ºC sequentially with a one-week washout between consumptions
2458882|NCT03180827|Experimental|ovarian tissue cryopreservation|
2458975|NCT03180671|No Intervention|Group 1 Control|Counselling with explanation of preventive procedures.
2458978|NCT03180671|Active Comparator|Group 2 deprogramer Sliding Guide|Intervention using the Deprogrammer Sliding Guide for 12-15 minutes.
2458979|NCT03180671|Active Comparator|Group 3 deprogrammer Dawson B-Splint|Intervention using the Dawson B-Splint for 7 days with breaks for eating/drinking and oral hygiene procedures.
2458983|NCT03180671|Active Comparator|Group 4 deprogrammer Kois|Intervention using the Kois deprogrammer for 14 days with breaks for eating/drinking and oral hygiene procedures.
2459016|NCT03180151|No Intervention|Orthodontic tooth movement group|This is the control group in which pateints will be treated by conventional orthodontic treatment and extraction of premolars without piezotome
2459020|NCT03180151|Experimental|Corticotomy assisted orthodontic group|This is the study group in which patients will be treated by conventional orthodontic treatment aided by corticotomy procedure perfumed by using a piezotome.(piezotome assisted orthodontic tooth movement)
2459140|NCT03179592||Low-volume contrast media injection protocol|Patients will receive a low-volume contrast media (Ultravist 370Mg I/Ml Solution for Injection) injection protocol that is tailored to a specific tube voltage. Tube voltages will be automatically selected by the scanner to be used for the CCTA acquisition.
2459193|NCT03179176|Experimental|HFUD utilisation|
3191029|NCT00793975|Experimental|IMC-1121B|"All patients will receive intravenous infusions of IMC-1121B with the dose depending on which cohort they are enrolled into. A minimum of three patients will be enrolled in each cohort.~A completed patient will be either a patient who completes the 4-week treatment cycle and 2-week observation period (for a total of 6 weeks), or a patient who discontinues therapy for an IMC-1121B-related toxicity. Toxicity data for each cohort will be reviewed prior to dose escalation.~When all patients complete a cohort, dose escalation to the next cohort will occur."
2459444|NCT03177226|Experimental|Functional TENS stimulation|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
2459447|NCT03177226|Sham Comparator|Non-stimulation treatment|Short stimulation to identifying Sensory Threshold and Motor Threshold, followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase [from full erection to ejaculation]
2459505|NCT03176875|Experimental|PEN group|Partial enteral nutrition (PEN) group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and a limited (25% of dietary needs = 1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
2459507|NCT03176875|Active Comparator|EEN group|Exclusive enteral nutrition (EEN) group will receive 100 % of their daily caloric requirements from a poymeric formula (Alicalm, Nutricia) for 6 weeks.
2459579|NCT03176485|Experimental|ArmA: With Solar Simulated Light Exposure|
2459587|NCT03176485|Experimental|ArmB: With Solar Simulated Light Exposure (Vemurafenib/Dabraf)|Subjects in this study arm undergo the same procedures as Arm A, with the addition of a blood test for the presence of porphyrins
2459588|NCT03176485|No Intervention|ArmC: Without Solar Simulated Light Exposure|
2459641|NCT03176017|Active Comparator|Ejaculatory sparing TUIP|Ejaculatory sparing TUIP
2458907|NCT03181048|Experimental|Periacetabular osteotomy|Standard periacetabular osteotomy on the day of surgery.
2458915|NCT03181048|Active Comparator|Periacetabular osteotomy with hip arthroscopy|Hip arthroscopy on the day of surgery, followed by a standard periacetabular osteotomy.
3155568|NCT00323804|Placebo Comparator|Randomised PegIFN alfa 2b + ribavirin-placebo arm|Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36
3155569|NCT00323830|Experimental|capecitabine/cisplatin/radiotherapy|postoperative XP/RT
2459089|NCT03179800|Experimental|MobiusHD Implantation|MobiusHD Implantation
2459096|NCT03179800|Sham Comparator|Sham Implantation|Sham Implantation
2459189|NCT03178903|Active Comparator|tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
2459190|NCT03178903|Sham Comparator|Sham tDCS and Aerobic Exercise|Each participant will undergo a 20-minute session of sham transcranial direct current stimulation (tDCS) delivered to the dorsolateral prefrontal cortex (DLPFC). Each session of tDCS will be immediately followed by a supervised 30-minute, moderate-intensity bout of exercise. These procedures will occur 3x/week for 8 weeks.
2459232|NCT03178695|Experimental|Treatment Group|PRP is freshly isolated from patients with diminished ovarian reserve as determined by at least one prior IVF cycle canceled for poor follicular recruitment response, or estimated by serum AMH and/or FSH, no menses for ≥1 year. Immediately following substrate isolation and activation with calcium gluconate, approximately 5 mL of autologous PRP is injected into each ovary under direct transvaginal sonogram guidance. AMH, FSH, and serum estradiol data will be recorded at 2wk intervals post-PRP and compared to baseline (pre-PRP) values.
2459235|NCT03178695|No Intervention|Comparison Group|Data collected from all patients in the Treatment Group will be compared to a dataset compiled from 25 - 50 women of similar age having received like treatment via IVF and gonadotropin stimulation for positive fertility outcomes in past clinical work at the Center for Advanced Genetics, as a comparison model and substitute control group. The purpose of this comparison will be to determine overall efficacy of the Inovium Ovarian Rejuvenation Treatment as separated from the standard efficacy rates of CAG-established IVF processes and gonadotropins used in the trial.
2459259|NCT03178383|Experimental|Integrated Approach|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
2459260|NCT03178383|Active Comparator|Standard Comparison|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
2459302|NCT03178227|Experimental|Intervention|The intervention is a school-based intervention involving photoaging of the students selfies which takes 45 minutes total.
2459306|NCT03178227|No Intervention|Control|No intervention.
2459391|NCT03177915|Active Comparator|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
2459394|NCT03177915|Active Comparator|Saline|Injection 10 cc saline injection as a median nerve hydro-dissection
2459468|NCT03176797|Experimental|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
2459545|NCT03176719||Children of 1 years old|200 healthy volunteers aged between 12 and 23 months
2459546|NCT03176719||Children aged 2-4|200 healthy volunteers aged between 24 and 59 months
2459547|NCT03176719||Children aged 5 - 9|200 healthy volunteers aged between 60 and 119 months
2459549|NCT03176719||Children aged 10 - 14|200 healthy volunteers aged between 120 and 179 months
2459551|NCT03176719||Adults of 15 years and older|200 healthy volunteers of 180 months or older
2459617|NCT03175952||PCI|
2459663|NCT03175835|Experimental|Rosuvastatin 20 mg & CKD-519 200 mg|"Period 1: Treatment A(Rosuvastatin 20 mg(20 mg X 1 tablet))~Period 2: Treatment B(CKD-519 200 mg(100 mg X 2 tablets))~Period 3: Treatment C(Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets))"
2459791|NCT03174834|Other|Bladder Stimulation Technique|Single arm study, where urine collection will be done via bladder stimulation and subsequently catheterization if they meet the eligibility criteria.
2459813|NCT03174561|Other|Inuline, Choline and Silymarin + Diet|"Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions together with a dietary supplement.~Intervention: Dietary Supplement, a combination of Inuline, Silymarin and Choline The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days"
2459814|NCT03174561|Other|Diet restriction|Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
2459912|NCT03174015|Experimental|Intervention|"Landlords on selected plots will receive the Bauleni Secret intervention. Landlords and selected tenants will be surveyed in baseline/end-line data collection."
3155570|NCT00323830|Active Comparator|capecitabine/cisplatin|postoperative XP
3155571|NCT00323856|Experimental|Coagulation factor VIII (Human)|Anti-Hemophilic coagulation factor VIII (Human) Alphanate SD/HT
3155572|NCT00323895|Experimental|1|group with intra-Cypher™ restenosis
3155573|NCT00323895|Active Comparator|2|group with intra-Taxus™ restenosis
3155574|NCT00323895|Active Comparator|3|group with intra-BMS restenosis
3155575|NCT00323908||1|Women at high risk for developing breast cancer
3155576|NCT00323934|Experimental|1|MGCD0103 Oral 2 times weekly
3155577|NCT00323947|Active Comparator|1|Participants will take OROS-MPH then switch to placebo
2458929|NCT03180775|Experimental|Alanine (Trade name: L-Alanine)|Dietary Supplement: Alanine, water soluble powder, 8.5 g daily in one dose, during 30 days.
2458931|NCT03180775|Experimental|Leucine (Trade name: L-Leucine)|Dietary Supplement: Leucine, water soluble powder, 14 g daily in one dose, during 30 days.
2458932|NCT03180775|Experimental|Isoleucine (Trade name: L-Isoleucine)|Dietary Supplement: Isoleucine, water soluble powder, 8.2 g daily in one dose, during 30 days.
2458936|NCT03180775|Experimental|Valine (Trade name: L-Valine)|Dietary Supplement: Valine, water soluble powder, 9 g daily in one dose, during 30 days.
2458938|NCT03180775|Experimental|Cysteine (Trade name: L-Cysteine)|Dietary Supplement: Cysteine, water soluble powder, 2.2 g daily in one dose, during 30 days.
2458943|NCT03180775|Experimental|Arginine (Trade name: L-Arginine)|Dietary Supplement: Arginine, water soluble powder, 10 g daily in one dose, during 30 days.
2458947|NCT03180775|Experimental|Methionine (Trade name: DL-Methionine)|Dietary Supplement: Methionine, water soluble powder, 4 g daily in one dose, during 30 days.
2458949|NCT03180775|Experimental|Glutamate (Trade name: L-Glutamic acid)|Dietary Supplement: Glutamate, water soluble powder, 33 g daily in one dose, during 30 days.
2458951|NCT03180775|Experimental|Glutamine (Trade name: L-Glutamine)|Dietary Supplement: Glutamine, water soluble powder, 30 g daily in one dose, during 30 days.
3155578|NCT00323947|Placebo Comparator|2|Participants will take placebo then switch to OROS-MPH
3155579|NCT00323973|Experimental|1|
2459268|NCT03178396|Experimental|Young, intervention|patients ages 18-45, taking melatonin
2459270|NCT03178396|No Intervention|Young, control|patients ages 18-45, usual care
2459271|NCT03178396|Experimental|Older, intervention|patients ages 60 and older, taking melatonin
2459273|NCT03178396|No Intervention|Older, control|patients ages 60 and older, usual care
2459329|NCT03178110|Experimental|Physical therapy and dynasplint|Participants with trismus will receive a manual therapy protocol plus exercises and the use of the dynasplint (DTS) device for a duration of 8 weeks. The first two weeks of treatment will include 2 days per week of manual therapy and active jaw opening exercises. Following this initial treatment phase, the DTS will be introduced and the frequency of manual therapy will remain at two times per week.
2459423|NCT03177174|Active Comparator|Docetaxel|
2459427|NCT03177174|Active Comparator|Cisplatin|
2459434|NCT03177174|Active Comparator|DocetaxelCisplatin|Cisplatin combined with Docetaxel
3155580|NCT00323973|Placebo Comparator|2|Placebo
2459619|NCT03176108|Experimental|CBT Group|"The CBT group benefits of an intervention based on the program Better manage its anger and its frustrations of 15 sessions for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
2459622|NCT03176108|Sham Comparator|Control Group|"The control group participates in an intervention of body mediation (theatre) of 15 session for the children.~Parents participate in an CBT intervention of 8 sessions every 15 days. The session allow to develop adapted behaviors, to manage the disruptive behaviors and to improve the relations parents/children."
2459660|NCT03175757|Experimental|Cholesterol Health Formulation|Turmeric and black cumin seed preparation
2459661|NCT03175757|Placebo Comparator|Placebo|Placebo
2459717|NCT03175471||Patients with autoimmune liver disease|"Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
2459766|NCT03175068|Active Comparator|CBT|The clinical psychologist will use a manualized CBT approach tailored to MDD or gSAD. Over a 12-week period sessions will include core CBT strategies -- psychoeducation, cognitive intervention (e.g., cognitive restructuring), behavioral changes (i.e., fear exposure, behavioral activation strategies) and relapse prevention.
2459770|NCT03175068|Placebo Comparator|ST|The clinical psychologist will use an ST approach that resembles client-centered therapy of Carl Rogers (1951) which has been used as a control psychotherapy. The manual is based on supportive psychotherapy principles. Over a 12-week period sessions will emphasize reflective listening and elicitation of affect. In contrast to CBT, therapists allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathetic comments. Therapists will refrain from delineating any CBT theoretical framework and avoided cognitive and behavioral techniques that might overlap with CBT.
2459900|NCT03174314|Experimental|50 visually impaired|50 visually impaired subjects will provide continuity across iterations of the testing, allowing for direct comparisons of responses within an individual for a single behavioral measure across different iterations of the device architecture and output configuration.
3155581|NCT00324012|Experimental|treatment|taxotere and cisplatin day one every three weeks
3155582|NCT00324025|Experimental|1|Mycograb
3155583|NCT00324025|Active Comparator|2|biological
3155584|NCT00324129|Experimental|1|
3155585|NCT00324194|Experimental|1|MGCD0103 oral dose 2 times per week.
3155586|NCT00324220|Experimental|1|MGCD0103 oral administration 3 times per week.
3155587|NCT00324311|Experimental|DGD|
3155588|NCT00324311|Active Comparator|SOC|
3155589|NCT00324324|Active Comparator|moxifloxacin hydrochloride|Moxifloxacin 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
3155590|NCT00324324|Placebo Comparator|Sugar pill|Placebo 1 capsule orally once a day through D+100 after bone marrow transplant, then discontinue
3155591|NCT00324363|Experimental|Exenatide|Placebo lead-in; exenatide 5 mcg for 4 weeks; exenatide 10 mcg for 12 weeks
3155592|NCT00324363|Placebo Comparator|Placebo|Placebo in volume equal to exenatide
3155593|NCT00324402||1|Healthy pregnant women, 18-40
3155594|NCT00324428|Experimental|Transcranial Magnetic Stimulation (TMS)|This arm provides active 1Hz repetitive TMS (rTMS) applied to SII
3155595|NCT00324428|Sham Comparator|Transcranial Magnetic Stimulation Sham|This arm provides sham 1Hz repetitive TMS (rTMS) applied to SII
2458965|NCT03180541|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation"
2458970|NCT03180541|No Intervention|Treatment-As-Usual|"The Treatment-As-Usual arm will include individuals who:~live in areas where no DBT intervention is currently available OR~were offered a place on the DBT programme but decided not to partake at that time"
2459014|NCT03180359|Experimental|Patient already transplanted or waiting for a transplantation|
2459067|NCT03180008|Active Comparator|Fit and Strong!|
2459068|NCT03180008|Experimental|Fit and Strong! Plus|
3174545|NCT00624637|No Intervention|C|no intervention, standard postoperative care
3174546|NCT00624663|Active Comparator|1|(1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule) X 2 per day, total of 5 intakes
2459237|NCT03178786|Experimental|Parkinson's Disease|
2459239|NCT03178786|Sham Comparator|Healthy Control Subjects|
2459341|NCT03177928|Active Comparator|study group|patients with myeloproliferative neoplasms and reveal cardiac complications by using echocardiogram, intervention by using transthorathic echocardiography for all patients.
2459346|NCT03177928|Active Comparator|control group|patients with hematological disorders including myeloproliferative neoplasms without cardiac affection by using echocardiogram. Intervention will be in the form of using transthorath echocardiography with all patients to reveal any cardiac abnormalities.
2459347|NCT03177928|Active Comparator|control group 2|healthy people from the same age and sex will be investigated using echocardiogram. Intervention will be in the form of using transthorathic echocardiography.
2459443|NCT03177421|Experimental|Bedtime media use and sleep problems|This arm will receive screening for and associated clinical decision support on sleep problems and bedtime media use.
2459451|NCT03177421|Other|Sleep problems only|This arm will receive screening for and associated clinical decision support on sleep problems only.
2459471|NCT03176849|Experimental|Single, high dose oral vitamin D3|Patients will take a single oral dose of vitamin D3 based on age and initial vitamin D level. A patient will be classified as sufficient, insufficient, or deficient at the start of therapy. Following this dose, patients will also be given standard vitamin D3 supplementation according to current Endocrine Society Guidelines.
2459472|NCT03176849|Active Comparator|Standard Vitamin D Supplementation|Patients will be given standard vitamin D3 supplementation during transplant in accordance with standard of care per Endocrine Society Guidelines. This supplementation is based on a patient's initial vitamin D level.
2459492|NCT03176680|Experimental|Fluid therapy optimization|Fluid loading to optimize stroke volume after induction.
2459494|NCT03176680|No Intervention|Fluid therapy normalization|No fluid loading after induction.
2459580|NCT03176589|Sham Comparator|sham PEP|3 cycles of 10 deep inspiration and expiration in a sham tube without expiratory resistance
2459585|NCT03176589|Active Comparator|PEP|3 cycles of 10 deep inspiration followed by expiration with positive expiratory pressure (PEP) device or PEP bottle of 10-15 cm of water pressure
2459589|NCT03176589|Experimental|deep breathing maneuvers|3 cycled of 10 deep breathing maneuvers without PEP or sham PEP
2459782|NCT03174990||Aspirin responsive|The participant is shown to be responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
2459786|NCT03174990||Aspirin non-responsive|The participant is shown to be non-responsive to platelet activity inhibition by aspirin, as determined by testing with VerifyNow
2459793|NCT03174990||Clopidogrel responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
2459795|NCT03174990||Clopidogrel non-responsive|The participant is shown to be responsive to platelet activity inhibition by clopidogrel, as determined by testing with VerifyNow
2459819|NCT03174626|Experimental|WLSCC Intervention|Williams LifeSkills framework on stress management and cancer care
2459821|NCT03174626|Other|Usual Care|No intervention is provided
2459877|NCT03174262|Experimental|Ergonomic Computer Workstation Training|
2459882|NCT03174262|No Intervention|Control Group|
2459962|NCT03173950|Experimental|1/Experimental Therapy|Participants will receive nivolumab at standard dose of240mg IV every 2 weeks for cycles 1 through 2, thendoses of 480mg every 4 weeks for a total of 14 additional doses
2460021|NCT03173339|Active Comparator|Low remifentanil and high sevoflurane|Remifentanil was administered as 0.1 mcg/kg/min. Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
2460026|NCT03173339|Experimental|High remifentanil and low sevoflurane|Sevoflurane was administered as 0.5 MAC. Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
2460067|NCT03172910|Experimental|Cohort 1|ciraparantag (60 mg)
2460073|NCT03172910|Experimental|Cohort 2|ciraparantag (120 mg)
2460081|NCT03172910|Experimental|Cohort 3|ciraparantag (180 mg)
2460084|NCT03172910|Experimental|Cohort 4|ciraparantag (30 mg)
2460090|NCT03172910|Placebo Comparator|Placebo|placebo (saline for injection)
2460155|NCT03172559|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy (SBRT) treatment will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues. The recommended dose will be 30 gray (Gy) in 5 fractions. The treatment will be administered in 5 alternative days. Patients will come every other day to the hospital to be treated and will not need to be admitted. Patients will not receive further SBRT on the treated tumor.
3174547|NCT00624663|Active Comparator|2|(2 x 1.5 mg Exelon® Capsules) X 2 per day, total of 5 intakes
2458994|NCT03180424|Placebo Comparator|Placebos + supervised exercise|Patients receiving placebo and supervised exercise plan.
2459051|NCT03180086|Experimental|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
2459090|NCT03179735|Experimental|Essential oils mouthwash|Essential-oils group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing a fixed combination of four essential oils (eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%)
2459098|NCT03179735|Experimental|Cetylpyridinium mouthwash|Cetylpyridinium chloride group will rinse with an alcohol-free mouthwash (twice daily use; 20 ml/30 s) containing cetylpyridinium chloride 0.7 mg/ml
2459100|NCT03179735|Placebo Comparator|Placebos mouthwash|Placebo group will rinse with an alcohol-free placebo solution (twice daily use; 20 ml/30 s)
2459170|NCT03179150||Oncological patients with extra-thoracic cancer|Patients enrolled into the study performed CT either for staging, restaging or follow-up of extrathoracic malignancies.
2459212|NCT03178968|Experimental|15 minutes' erosion|Orange juice is administered ex vivo and in vivo for 5 minutes and repeated a total of 3 times
2459213|NCT03178968|Experimental|30 minutes' erosion|Orange juice is administered ex vivo and in vivo for 10 minutes and repeated a total of 3 times
2459214|NCT03178968|Experimental|45 minutes' erosion|Orange juice is administered ex vivo and in vivo for 15 minutes and repeated a total of 3 times
3155596|NCT00324467|Active Comparator|R-CHOP (Negative Mid-Treatment PET Scan)|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a negative mid-treatment PET scan (no evidence of abnormal 18F-FDG uptake) will complete therapy with two additional cycles of R-CHOP for a total of 6 cycles of chemotherapy. Patients with a mid-treatment PET scan interpreted to be indeterminate or equivocal will be recorded as such, but should be considered negative for the purpose of treatment planning and should not prompt a change in therapy."
3155597|NCT00324467|Active Comparator|R-ICE (Positive Mid-Treatment PET Scan|"All participants will receive 4 cycles of standard dose R-CHOP chemotherapy administered at 3-weekly intervals. Non-progressing participants will undergo a mid-treatment PET scan along with routine restaging investigations after 4 cycles of R-CHOP. Patients with a mid-treatment PET scan (abnormal 18F-FDG uptake) will be switched to R-ICE chemotherapy and receive 4 cycles of R-ICE for a total of 8 cycles of chemotherapy.~Following completion of R-ICE chemotherapy, patients will undergo a post-treatment PET scan along with routine restaging investigations. The post-treatment PET scan will be performed between days 28 and 35 following the final cycle of R-ICE. Patients with a negative post-treatment PET scan will undergo no further therapy. Patients with a positive post-treatment PET scan corresponding to persistent abnormalities on CT scan will be considered for radiation therapy to PET positive sites."
3155598|NCT00324480|Experimental|Treatment (chemotherapy, enzyme inhibitor)|Before beginning course 1 of study therapy, patients receive oral SAHA on days 1-3 in order to ensure tolerability of the drug. Beginning 1 week later, patients receive oral SAHA once daily on days 1-3 and 8-10 and fixed-dose alvocidib IV over 1 hour on days 2 and 9. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3155599|NCT00324506|Active Comparator|Cellcept and Avonex|
3155600|NCT00324519|Active Comparator|Misoprostol Drug|This is the misoprostol drug.
3155601|NCT00324519|Experimental|The Foley Bulb|This is the experimental portion to test the Foley Bulb.
3155602|NCT00324558|Experimental|1|Bemiparin 3,500 IU
3155603|NCT00324558|No Intervention|Control|
3155604|NCT00324623|Experimental|Lymphodepletion, vaccine, IMP321 adjuvant|
2459498|NCT03176823|Sham Comparator|Control Arm|"Control-arm patients will be treated with standard Best Practice management of traumatic brain injury, with the addition of sham-RIC. The sham intervention will use a purpose-built device which will visually and audibly mimic a functional RIC device, with the key distinction being non-inflation of the arm cuff with resultant non-occlusion and no induced ischemia. To mask patient enrollment, all patients in both study arms will have the arm and RIC device draped in an opaque sheet so that the extremity distal to the RIC device are not visible to medical staff during the period of intervention."
2459502|NCT03176823|Experimental|RIC Arm|The RIC treatment will be applied with a purpose-built commercial RIC device which will aid in standardizing dose and delivery. Therapeutic RIC will be provided by the CellAegis Technologies autoRIC device on an upper extremity. As with the control cohort, this cohort will undergo complete extremity draping.
2460127|NCT03172767||Term Preschoolers|Term children who haven't attend school.
3155605|NCT00324727|Experimental|Arm I|"Patients undergo an isolated hepatic arterial infusion of melphalan over 30 minutes on day 1. Treatment repeats every 4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response undergo 2 additional courses~in the absence of ongoing or increasing toxicity."
3155606|NCT00324727|Active Comparator|Arm II|"Patients receive the best alternative therapy comprising supportive care, systemic or regional chemotherapy, hepatic artery (chemo)-embolization, or any other appropriate therapy at the National Cancer Institute or therapy at the discretion of their physician.~Patients may cross over to arm I if they have evidence of disease progression."
3155607|NCT00324766|Active Comparator|1|levosimendan
3155608|NCT00324766|Placebo Comparator|2|Placebo, 1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
3155609|NCT00324922|Active Comparator|1|trimethoprim-sulfamethoxazole
3155610|NCT00324922|Active Comparator|2|vancomycin
3155611|NCT00324974|Experimental|Lansoprazole QD|
3155612|NCT00324974|Placebo Comparator|Placebo QD|
3155613|NCT00325013|Experimental|II|
3155614|NCT00325182|Experimental|Intervention: Levetiracetam|Levetiracetam dose schedule Days 1-4 250 mg bid Days 5- 19 500 mg bid Days 20 -70 1000 mg bid Days 71-78 500 mg bid Days 79-85 250 mg bid Days 86-91
3155615|NCT00325182|Placebo Comparator|Historical controls|Historical controls from COMBINE study who receive a placebo
3191030|NCT00793988|Active Comparator|1|Group receiving vibration-assisted anaesthesia
3191031|NCT00793988|Placebo Comparator|2|Group receiving switched-off vibrating device
3191032|NCT00794001|Experimental|Data Feedback|The intervention is systematic feedback on performance (using predefined quality indicators) to cardiology, ED, and EMS-stakeholders and staff.
2459172|NCT03179280|Active Comparator|Adolescents with T1D on CSII|3 standard meals with varying composition were consumed and combined with alternative types of D/WB and S/WB All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
2459173|NCT03179280|No Intervention|Healthy adolescents|3 standard meals with varying composition were consumed
2459223|NCT03178877||IBS|IBS group is medical student who filled Rome IV criteria for IBS
2459225|NCT03178877||Non IBS|Non-IBS group is non IBS medical student based on Rome IV criteria
2459287|NCT03178513|Experimental|Home visit|A participant in this arm will receive a home visit after discharge from the hospital.
2459291|NCT03178513|No Intervention|Usual Care|A participant in this arm will not receive a home visit after discharge from the hospital.
2459373|NCT03178006||obese plus diabetes,|BMI 30-40kg/m2 and diabetes or pre-diabetes
2459379|NCT03178006||obese|BMI 30-40kg/m2
2459388|NCT03178006||control|BMI 20-27,5kg/m2
2459417|NCT03177434|Active Comparator|Dicopeg Junior|"Polyethylene glycols (PEG) - 3350 Dosage form: oral solution sachets Frequency: 2 doses~Dosage:~weight up to 8 kg - 1 sachet per day~weight 8 - 12 kg - 2 sachets a day~weight 12 - 20 kg - 3 sachets a day~weight> 20 kg - 4 sachets per day, Duration: 12 weeks vs Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks"
2459418|NCT03177434|Active Comparator|Lactulose|Lactulose Dosage form: oral solution Dosage: 2 ml / kg / day Frequency: 2 doses Duration: 12 weeks
2459452|NCT03177161|Experimental|Postal Questionnaire|
2459454|NCT03177161|Experimental|Online Questionnaire|
2459458|NCT03177161|Experimental|Face-to-face Questionnaire|
2459459|NCT03177161|Experimental|Telephone Questionnaire|
3191033|NCT00794014|Experimental|Conservative strategy|
3191034|NCT00794014|Experimental|Aggressive strategy|
3191035|NCT00794027|Other|Yoga group|Patients with heart failure
3191036|NCT00794053|Experimental|study group|The members in this group will undergo intervention by having surgery and lymph node detection by dye staining
2459654|NCT03176030||Fortified foods|Fortified foods will be delivered to this group for 3 consecutive days mainly on a mid-meal trolley three times a day (between breakfast and lunch around 10am, between lunch and dinner around 3 pm, and in the evening). However, fortified foods will be available 24 hours and patients will be encouraged to order as many as they like anytime during the day.
2459656|NCT03176030||Baseline|Prior to implementing the intervention, dietary intake among eligible patients offered the standard hospital menu will be measured on the study wards for 24 hours during three days in each of the study wards to estimate the energy and protein intake.
3191037|NCT00794066||1|TIA
3191038|NCT00794066||2|Ischemic stroke
2459754|NCT03174938|Other|COHORT A: Cognitively healthy younger individuals (40-65 y)|"We will recruit 300 cognitively healthy individuals from the Malmö Offspring study, which is an epidemiological study. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline.~An auxiliary cohort (termed Cohort A2) of 40 healthy individuals aged 20-40 years of age will also be included."
2459759|NCT03175263||Patients with chronic migraine|Patients with chronic migraine refractory to conventional treatments
3155616|NCT00325221|Experimental|Home Monitoring On|Home Monitoring activated after implantation (Intervention HM On)
2459788|NCT03174847||Medical Treatment|Patients who undergo medical treatment, in view of bilateral PA, or unilateral PA not keen for surgery, or indeterminate (lack of localisation on tests)
3191039|NCT00794066||3|Hemorrhagic stroke
3191040|NCT00794079|Experimental|A|omega-3 fatty acids
3191041|NCT00794079|Placebo Comparator|B|corn oil
3191042|NCT00794092|Experimental|Sinerem|MRI scanning of patients with AAA before and 24hrs +/- 4hrs after administration of Sinerem
3191043|NCT00794105||Normal ears|
3191044|NCT00794105||Otitis media ears.|
3191045|NCT00794183|Active Comparator|1|AVD set by taking the larger of 0.50ms or A-V interval 0.30
3191046|NCT00794183|Active Comparator|2|AVD set by taking the larger of 0.50ms or A-V interval 0.50
3191047|NCT00794183|Active Comparator|3|AVD set by taking the larger of 0.50ms or A-V interval 0.70
3191048|NCT00794209|Experimental|1|
3191049|NCT00794222|Experimental|Mood monitoring|The mobiletype monitoring intervention group will monitor their current activities, current mood, responses to negative mood, any recent stressors and coping strategies. Other activities monitored include eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.
3191050|NCT00794222|No Intervention|Comparison monitoring program|"The mobiletype monitoring comparison group will monitor their current activities, eating patterns, exercise patterns, quantity and quality of sleep and alcohol and cannabis use.~This program excludes questions about mood, stress and coping strategies."
3191051|NCT00794235|Other|Sorafenib and Dacarbacine|
3191052|NCT00794248|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191053|NCT00794248|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191054|NCT00794261|Experimental|Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
2459007|NCT03180294|Experimental|Arm B (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO QD on days 1-7 and 64-71, and BID on days 8-63.
2459008|NCT03180294|Placebo Comparator|Arm C (placebo)|Patients receive placebo PO QD on days 1-7 and 64-71, and BID on days 8-63.
2459310|NCT03178214|Experimental|Infacort - Yoghurt|One single 5mg dose of Infacort will be sprinkled onto 5mL of yoghurt and swallowed within three minutes. This will be taken with 240mL of water.
2459316|NCT03178214|Experimental|Infacort - Soft Food|One single 5mg dose of Infacort will be sprinkled onto 5mL of soft food (such as applesauce) and swallowed within three minutes. This will be taken with 240mL of water.
2459319|NCT03178214|Active Comparator|Infacort - Dry Granules|One single 5mg dose of Infacort will be administered as dry granules to the back of the tongue and swallowed. This will be taken with 240mL of water.
2459390|NCT03177902||Observational group|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy
2459392|NCT03177902||Control group|Healthy Volunteers
2459462|NCT03177057|Experimental|Arm I (self-monitoring)|ARM I (SELF-MONITORING): Patients complete tanning and sun protection usage entries daily for 14 days.
2459463|NCT03177057|Experimental|Arm II (text messages)|ARM II (TEXT MESSAGES): Patients receive individualized text messages based on baseline assessment of tanning motives (appearance, enjoyment, social) daily for 14 days.
2459464|NCT03177057|Experimental|Arm III (self-monitoring, text messages)|ARM III (COMBINED GROUP): Patients complete tanning and sun protection usage entries and also receive individualized text messages daily for 14 days.
2459465|NCT03177057|Sham Comparator|Arm IV (questionnaire administration)|ARM IV (CONTROL GROUP): Patients complete study assessments.
2459561|NCT03176524|Experimental|BioChaperone® glucagon formulation 1|Single subcutaneous fixed doses (50 µg and 1.0 mg)
2459562|NCT03176524|Experimental|BioChaperone® glucagon formulation 2|Single subcutaneous fixed doses (50 µg and 1.0 mg)
2459563|NCT03176524|Active Comparator|GlucaGen® HypoKit®|Single subcutaneous fixed doses (50 µg and 1.0 mg)
3191055|NCT00794261|Active Comparator|Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
2459689|NCT03175367|Experimental|Group A: dosing regimen 1|SC Evinacumab QW for 16 weeks
2459694|NCT03175367|Experimental|Group A: dosing regimen 2|SC Evinacumab Q2W for 16 weeks (alternating with matching placebo on opposite weeks)
2459699|NCT03175367|Experimental|Group A: dosing regimen 3|SC Evinacumab QW for 16 weeks
2459706|NCT03175367|Experimental|Group A: matching placebo|Placebo SC QW for 16 weeks
2459709|NCT03175367|Experimental|Group B: dosing regimen 1|Intravenous (IV) Evinacumab Q4W for 24 weeks
2459711|NCT03175367|Experimental|Group B: dosing regimen 2|IV Evinacumab Q4W for 24 weeks
2459712|NCT03175367|Experimental|Group B: matching placebo|Placebo IV Q4W for 24 weeks
2459804|NCT03174548|Experimental|Fed Tablet period (Test, T)|Sotagliflozin oral in fed conditions
2459805|NCT03174548|Experimental|Fasted Tablet period (Reference, R)|Sotagliflozin oral in fasting conditions
2459806|NCT03174548|Experimental|Oral Solution period (S)|Sotagliflozin oral solution in fasting conditions
2459852|NCT03174418||Cohort A|Patients with bifurcated coronary lesions treated by percutaneous coronary interventions.
2459853|NCT03174418||Cohort B|Patients with untreated bifurcated coronary lesions.
2459895|NCT03174054||Patients with no clear lesion in PET or MRI|If the clinical suspicion of cancer is low, there will be no biopsy, only follow-up. If the decision is to perform a biopsy on the prostate, it will be performed with transrectal sonar guidance and systematic biopsies will be performed (12 samples will be taken from different areas of the prostate)
2459896|NCT03174054||Patients with MRI lesions and overlapping mapping lesions|If MRI and PET are matched, a US FUSION MRI biopsy will be taken between 4-8 samples directly from the lesion as well as other systemic prostate samples according to the surgeon's decision. Will be taken and sent separately to pathology.
2459897|NCT03174054||Patients with a discrepancy between the PET and MRI|A FUSION approach will be biopsy. Four to eight samples for each lesion, as well as other systemic prostate samples will be taken according to the surgeon's decision, and the samples will be marked and sent separately to the pathology.
2459938|NCT03173859|Experimental|Rotational|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 for 3 cycles, followed by apalutamide 240mg qD orally for 3 cycles. The duration of each cycle is 28 days
2459942|NCT03173859|Active Comparator|Sequential|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally starting on Day 1 of Cycle 1 until disease progression, followed by apalutamide 240mg qD orally until second disease progression.
2460012|NCT03173495|Experimental|FRUCTOSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2460019|NCT03173495|Placebo Comparator|DEXTROSE|Day 0, 45 min in rest position. Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2460023|NCT03173495|Active Comparator|FRUCTEX|Day 0, 45 min of 60%VO2peak aerobic exercise . Day 1, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a fructose-rich beverage (0.5 g / kg). Day 2, High Fat Meal (HFM) consisted of macronutrients (50% fat, 40% carbohydrate and 10% protein) with a dextrose-rich beverage (0.5 g / kg).
2460124|NCT03172767||Preterm Preschoolers|Preterm children who haven't attend school.
2459033|NCT03180372|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
3155617|NCT00325221|Experimental|Home Monitoring Off|Home Monitoring activated 9 months after implantation (Intervention HM Off)
2459286|NCT03178253||3|
2459445|NCT03177148|Active Comparator|Usual Care|"1-2 pediatric clinicians per practice will be trained in study procedures, current obesity treatment guidelines, and obesity billing and coding via telephone and webinar~NO active enrollment of parents~Secure extraction of HIPAA limited Electronic Health Record (EHR) and billing data from practices for outcomes analyses~At the end of the intervention period, 1-2 pediatric clinicians will be offered the in-person MI training and DVD materials"
2459448|NCT03177148|Experimental|Intervention by Clinicians|"Clinicians complete surveys during enrollment and end of the intervention~1-2 clinicians from each practice will receive 2.5 days of in-person MI training, two scored encounters with a standardized patient, and an interactive DVD MI booster training system focusing on pediatric obesity.~Enroll 35 eligible parents per practice~Clinicians give up to 4 in-person, MI sessions to enrolled parents over 2 years.~Dietitians will provide up to 6 telephone counseling sessions.~•Parents will complete surveys after enrollment and at the end of intervention"
2459509|NCT03176888|Experimental|Exercise|Patients in the Exercise group will follow a fully-supervised exercise routine (Reduced-exertion, high-intensity interval training (REHIT)) with 3 weekly 10-minute training sessions consisting of easy cycling interspersed with 2 brief 'all-out' cycle sprints. Patients in this group will also be offered up to 6 sessions of cognitive behavioral therapy. The duration of the intervention will be the weeks between enrolling in the study and surgery (~1-4 weeks), as well as an additional period of up to 6 weeks following surgery.
2459513|NCT03176888|No Intervention|Standard care|Patients allocated to the Standard Care group will receive the care they would have also received if they would not have participated in the study. They will however undergo the same testing sessions as patients in the Exercise group.
2459573|NCT03176498|Experimental|Experimental group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium； Allogeneic umbilical cord mesenchymal stem cells
2459576|NCT03176498|Placebo Comparator|Control group|Basic medication：Aspirin Enteric-coated Tablets & Atorvastatin Calcium; Placebo：saline
3155618|NCT00325273|Experimental|probiotics & allergy|"To understand the preventive effect of probiotics in neonatal peroid~To investate the possible mechanism"
3155619|NCT00325286|Experimental|1|Treatment with lithium and extended release carbamazepine
2459684|NCT03175640|Experimental|Implementation intervention|
2459727|NCT03175211|Experimental|BI 456906|
2459728|NCT03175211|Placebo Comparator|Placebo|
2459756|NCT03175003|Active Comparator|Food Product 1|Macronutrient similar to experimental, micronutrient lower than experimental
2459760|NCT03175003|Active Comparator|Food Product 2|Macronutrient lower than experimental, micronutrient similar to experimental
2459763|NCT03175003|Experimental|Food Product 3|Experimental 1
2459765|NCT03175003|Experimental|Food Product 4|Experimental 2
2459828|NCT03174691|Experimental|Hormonal levels|Collect blood samples Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
2459872|NCT03174210|Experimental|COPD patients with delivery order 1, 2|Patients will use two different Oxygen devices at rest (1.liquid oxygen device (Companion R), 2. portable Oxygen concentrator (Activox TM 4L))
2459878|NCT03174210|Experimental|COPD patients with delivery order 2,1|Patients will use two different Oxygen devices at rest (1. portable Oxygen concentrator (Activox TM 4L), 2. liquid oxygen device (Companion R))
2459928|NCT03173872|Experimental|One Group Study Arm|One group study arm assesses pre Reiki and post Reiki intervention measures
2460208|NCT03172208|Placebo Comparator|Group 2: White - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to White participants
2467710|NCT03119961|Experimental|SONOCLOUD®|BBB opening by ultrasound
3155620|NCT00325351|Experimental|Arm 1|
3155621|NCT00325364|Experimental|1|
3155622|NCT00325364|Active Comparator|2|
3155623|NCT00325494|Experimental|Cohort 1|MORAb-009 weekly dose of 12.5 mg/m^2
3155624|NCT00325494|Experimental|Cohort 2|MORAb-009 weekly dose of 25 mg/m^2
3155625|NCT00325494|Experimental|Cohort 3|MORAb-009 weekly dose of 50 mg/m^2
3155626|NCT00325494|Experimental|Cohort 4|MORAb-009 weekly dose of 100 mg/m^2
3155627|NCT00325494|Experimental|Cohort 5|MORAb-009 weekly dose of 200 mg/m^2
3155628|NCT00325494|Experimental|Cohort 6|MORAb-009 weekly dose of 400 mg/m^2
3155629|NCT00325507|Experimental|TroVax|TroVax given as first or second line treatment in conjuntion with low dose IL-2.
3155630|NCT00325520||Anorexia nervosa|Individuals with anorexia nervosa receiving inpatient treatment
3155631|NCT00325520||Healthy controls|
3155632|NCT00325533|Experimental|Screening & Enhanced Intervention|After an intensive 10-week baselne screening, the enhanced intervention group barbers will be trained to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit.
3155633|NCT00325533|Active Comparator|Screening|After the intensive 10-week baseline BP screening (an intervention in itself), the barbershops in the comparison arm received a continual supply of American Heart Association pamphlets on Hypertension in African Americans.
3155634|NCT00325637|Active Comparator|A,1,III|To compare the effect of cilnidipine (calcium channel blocker) and losartan (angiotension II receptor blocker) on CBF in patients with ischemic stroke
3155635|NCT00325650|Experimental|Rimonabant|Rimonabant 20 mg once daily
3155636|NCT00325650|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3155637|NCT00325689|Active Comparator|Quetiapine or Risperidone + Aripiprazole|
3155638|NCT00325689|Placebo Comparator|Quetiapine or Risperidone + placebo|
3155639|NCT00325715|Experimental|1|
3155640|NCT00325715|Active Comparator|2|
3155641|NCT00325728|Experimental|Ramelteon 8 mg QD|
3155642|NCT00325728|Placebo Comparator|Placebo|
3155643|NCT00325936|Active Comparator|Nifedipine|parrallel design
3155644|NCT00325936|Experimental|Cilnidipine|
3155645|NCT00325949|Experimental|arm label (1) hydrocodone/acetaminophen extended release|
2459076|NCT03179774|No Intervention|Clinical registry-OMT|In clinical registry setting, participants who selected optimal medical therapy as the treatment for carotid artery occlusion are enrolled.
2459079|NCT03179774|Experimental|RCT-ER and OMT|In randomized control trial setting, participants who are randomized to received endovascular revascularization and optimal medical therapy for carotid artery occlusion are enrolled.
2459081|NCT03179774|No Intervention|RCT-OMT|In randomized control trial setting, participants who are randomized to received optimal medical therapy for carotid artery occlusion are enrolled.
2459136|NCT03179527|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
2459147|NCT03179527|Other|Conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2459348|NCT03177876|Experimental|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles [Nanostreams] with simultaneous implant placement
2459351|NCT03177876|Active Comparator|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
2459387|NCT03177668|Experimental|YS110|"Phase 1 part: Administration of 3 different dose cohort~Phase 2 part: Administration of recommended dose determined from result of Phase 1 part"
2459433|NCT03177382|Experimental|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w. The TME operation will be given 3-4 weeks after the end of the total neoadjuvant treatment.
2459438|NCT03177382|Active Comparator|concurrent chemoradiotherapy group|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
3155646|NCT00325949|Experimental|arm label (2) hydrocodone/acetaminophen extended release|
2459556|NCT03176576|Experimental|Patient Navigator (PN)|Patient Navigator (PN) Intervention Group. In addition to the Baseline Questionnaire and the Follow-up Questionnaire, PN intervention participants will complete a brief Patient Navigator Satisfaction Survey.
2459558|NCT03176576|Other|Usual Care (UC)|Usual Care (UC) Control Group. Control sample of patients not receiving PN intervention will complete a Baseline Questionnaire and the six-week Follow-up Questionnaire. Participants under UC will have access to all services typically provided to Moffitt Cancer Center (MCC) patients. Any baseline distress score greater than three will be reported to the patient's primary oncologist and clinic nurse.
2459613|NCT03176225|Experimental|Test Arm|In Test Arm, the subjects will be implanted with test article - XenoSure patch. The interventions include: Open heart surgery to address the heart disease; Close the defects with XenoSure Patch
2459614|NCT03176225|Active Comparator|Control Arm|In Control Arm, the subjects will be implanted with comparator device - Polyester patch by Shanghai Chest Medical Technology Co. The interventions include: Open heart surgery to address the heart disease; Close the defects with Chest Polyester Patch
3155647|NCT00325949|Placebo Comparator|Arm label (3) placebo|
3155648|NCT00326014|Experimental|A|
2459796|NCT03175432|Experimental|Arm I (atezolizumab, bevacizumab)|Participants receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2459798|NCT03175432|Experimental|Arm II (atezolizumab, bevacizumab, cobimetinib)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles with atezolizumab and bevacizumab repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients also receive cobimetinib PO TID on days 1-21. Cycles with cobimetinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3155649|NCT00326027|Active Comparator|1|Pantoprazole 20 mg
2459902|NCT03174093|Experimental|MATCh AFib|Participants assigned to the intervention group will have the support of the MATCh AFib application during the consultations with their physician and receive individual text messaging targeting knowledge about atrial fibrillation, medication adherence and monitoring during months 1-3.
2459906|NCT03174093|No Intervention|Standard Care|Participants assigned to the control group will complete measures at each time point and maintain care as usual (i.e., medical treatment, INR monitoring and consultations with their physician without mHealth support)
2459965|NCT03173807|Active Comparator|dietary and exercise counseling|The duration of study in Arm A will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 3 months, 6 months, 12 months and 24 months.
2460209|NCT03172208|Experimental|Group 3: Japanese - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
3155650|NCT00326027|Active Comparator|2|Pantoprazole 40 mg
3155651|NCT00326040|Experimental|A|
3155652|NCT00326066|Active Comparator|1|
3155653|NCT00326066|Placebo Comparator|2|
3155654|NCT00326079|Active Comparator|1|
3155655|NCT00326079|Active Comparator|2|
3155656|NCT00326157|Experimental|1|AmBisome® will be administered for a duration of 8 weeks
3155657|NCT00326222|Experimental|1|Lifestyle counseling
3155658|NCT00326222|No Intervention|2|Usual care
3155659|NCT00326248|Experimental|Arm 1|
3155660|NCT00326287|Experimental|Ceftobiprole medocaril|Ceftobiprole medocaril 500mg q8h as 2h infusions, 7-14d
3155661|NCT00326287|Active Comparator|Ceftriaxone with or without Linezolid|Ceftriaxone 2g qd as 0.5h infusions with or without Linezolid 600mg q12h as 1h infusions, 7-14d
3155662|NCT00326339|Experimental|1|R788 50 mg PO bid
3155663|NCT00326339|Experimental|2|R788 100 mg PO bid
2459083|NCT03179982|No Intervention|Control|Male adolescents (15-17 years) will be randomly allocated to a control arm based on permuted blocked randomization. The control arm will consist of ordinary usual care. The ordinary usual care condition will consist of a packet of existing available brochures on HIV and other sexually transmitted diseases including testing, prevention, and treatment; IPV prevention and intervention; and places to access prevention, care, and support for these outcomes and related health outcomes.
2459139|NCT03179605|Experimental|DFD-06 Cream|This is a single arm, open label study and there will be no reference or control product used in this study
2459179|NCT03179059|Experimental|Pregnancy tests at baseline & follow-up|We offer free pregnancy test service at baseline and at follow-up survey.
2459180|NCT03179059|Experimental|Pregnancy tests only at baseline|We offer free pregnancy test service at baseline
2459181|NCT03179059|No Intervention|Do Not Offer Pregnancy Test|Control group. No intervention is implemented.
2459218|NCT03178825|Experimental|Hybrid Fractional Laser|Hybrid fractional 2940 nm and 1470 nm laser treatment
2459265|NCT03178422|Experimental|CQSS2 System (nicotine 21 mg)|Active CQSS2 System (nicotine 21 mg) with Digital Coach. One active Drug Cartridge will be used to transdermally administer 21 mg nicotine via a 5.4% w/v solution in an aqueous EtOH mixture per day. Metered pulses of 125 µL of solution will automatically be delivered by the assembled CQSS2 (containing the Control Unit and Drug Cartridge) at Time = 0, 0.5, 1, 7, 7.5, and 13 hours.
2459267|NCT03178422|Active Comparator|NicoDerm® CQ® patch (21 mg)|NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
2459330|NCT03178123|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs for 1 year (27 treatments)
2459331|NCT03178123|Active Comparator|high-dose recombinant interferon a-2B|Patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5. Treatment repeats weekly for 4 weeks in the absence of disease progression or unacceptable toxicity.Then patients receive 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
2459376|NCT03177707|Experimental|Immediate start|Patients begin the Mindfulness-based Therapy Group for Couples treatment group immediately after enrollment
2459384|NCT03177707|Other|Delayed start|Patients begin the Mindfulness-based Therapy Group for Couples after a delay post-study enrollment (approximately 6 months)
2459475|NCT03177109|Active Comparator|Fluoride Varnish Group|5% fluoride varnish (Acclean) applied topically
2459476|NCT03177109|Active Comparator|Arginine paste Group|8% arginine containing paste (Colgate® Sensitive Pro-Relief™) applied topically
2459477|NCT03177109|Active Comparator|Adhesive Resin Group|Self-adhesive resin (Seal and Protect, Dentsply) applied topically
2459555|NCT03176641|Active Comparator|PRP group|30 patients will receive autologous platelet-rich plasma gel during meniscus repair surgery.
2459557|NCT03176641|Placebo Comparator|Control group|30 patients will receive meniscus repair surgery only.
2459598|NCT03176303||Pulsed Electromagnetic Field|one group all of whom will be treated with the PEMF device
2459769|NCT03175510||patients group|Patients with low back pain (18-65 years)
2459825|NCT03174717|Experimental|Music intervention|LTC residents will participate in an individualized music performance with a musician
2459876|NCT03174249|Experimental|Exposure therapy|Graded exposure therapy in vivo in combination with methods targeting cortical reorganisation.
2459941|NCT03173898|Experimental|primary periodontal ligament anesthesia|PDL anesthesia versus local infiltration
2459945|NCT03173898|Active Comparator|local infiltration|PDL anesthesia versus local infiltration
3155664|NCT00326339|Experimental|3|R788 150 mg PO bid
3155665|NCT00326339|Placebo Comparator|4|Placebo PO bid
2460214|NCT03172169||Healthy control group|no intervention
2460216|NCT03172169||Difficult withdrawal group|The mechanical ventilation time was >48 hours and the first SBT failure
2460219|NCT03172169||Mechanical ventilation control group|Elective and expected postoperative control of mechanical ventilation time greater than 12h after cardiothoracic surgery
3155666|NCT00326378|Active Comparator|CCRT arm without consolidation chemotherapy|Docetaxel 20mg/m2 & Cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy
3155667|NCT00326378|Experimental|CCRT arm with consolidation chemotherapy|docetaxel 20mg/m2 & cisplatin 20mg/m2 (D1,8,15,22,29,36) during radiotherapy, and followed by consolidation chemotherapy with 3-weekly docetaxel 35mg/m2 & cisplatin 35mg/m2 (D1,8) every 3 weeks (#3).
2460293|NCT03171519|Active Comparator|Exercise|
2460295|NCT03171519|Experimental|Exercise + acupuncture|
2460374|NCT03171194|Experimental|Drug: Low Dose Mesenchymal Stem Cells ( MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
2460453|NCT03170687|Experimental|foot cast|
2460457|NCT03170687|Active Comparator|short leg cast|
2460472|NCT03170310|Experimental|Apatinib|
2460603|NCT03169712|Experimental|Imagery Rehearsal Therapy + CBT for PTSD|5 sessions of IRT + 15 sessions of trauma-focused CBT
3155668|NCT00326404|Experimental|1|
3155669|NCT00326404|Active Comparator|2|
3155670|NCT00326443|Experimental|1|14 subjects Oral CVD 909 with buffer on Day 0. Parental Vi polysaccharide vaccine on Day 21.
3155671|NCT00326443|Placebo Comparator|2|14 subjects oral buffer placebo. Parental Vi polysaccharide vaccine on Day 21.
3155672|NCT00326456|Experimental|carboplatin and liposomal doxorubicin|
3155673|NCT00326456|Active Comparator|carboplatin and paclitaxel|
3155674|NCT00326469|Experimental|1|
3155675|NCT00326534||Controls|Patients without sarcoidosis, but requiring a fiberoptic bronchoscopy
3155676|NCT00326534||Sarcoidosis patients|Patients with newly diagnosed sarcoidosis
3155677|NCT00326586|Experimental|1|
3174548|NCT00624663|Placebo Comparator|3|(2 x Placebo Capsules) X 2 per days, total of 5 intakes
3174549|NCT00624676|Experimental|A|LHA formulation
3174550|NCT00624676|Active Comparator|B|5% benzoyl peroxide
3155678|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"Intervention: Standard radiation treatment for high risk prostate cancer. Once daily Monday to Friday for 8 weeks.~3DCRT 7800 cGY/39 Fractions/ STD Technique*~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
3155679|NCT00326638|Experimental|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"Intervention: Helical Tomotherapy Intensity Modulated Radiotherapy (IMRT) once daily Monday to Friday for 8 weeks.~IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions Boost IMRT to Prostate 3,200 cGy/16"
3155680|NCT00326664|Experimental|Treatment (cediranib maleate)|Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3155681|NCT00326820|Experimental|Ibandronic Acid|50mg tablet once daily over 96 weeks
3155682|NCT00326820|Active Comparator|Zoledronic Acid|4 mg via intravenous infusion (iv) over a minimum of 15 minutes in at least 100mls of saline every 4 weeks over 96 weeks
3155683|NCT00326976|Experimental|1|400 mg injected in 2 divided boluses
3155684|NCT00326976|Placebo Comparator|2|Matching placebo
3155685|NCT00326989|Active Comparator|Low-dose shock wave treatment & Placebo|
3155686|NCT00326989|Active Comparator|low-dose shock-wave treatment & Cell therapy|
3155687|NCT00326989|Active Comparator|High-dose shock-wave treatment & Placebo|
3155688|NCT00326989|Active Comparator|High-dose shock-wave treatment & cell therapy|
3155689|NCT00326989|Active Comparator|Placebo shock-wave treatment & cell therapy|
3155690|NCT00327054|Experimental|Nigella sativa seed|
2459294|NCT03178526|Active Comparator|levostatin gel|levostatin gel 1.2% topical gel was put into teh periodontal pocket using an insulin syringe
2459296|NCT03178526|Placebo Comparator|placebo gel|placebo gel 1.2% topical gel was put into the periodontal pocket using an insulin syringe
2459334|NCT03177967|Experimental|Treatment groups spring (1,2)|"Seven sessions CBT-I treatment for two different groups of eight participants (n=16)~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
2459338|NCT03177967|Experimental|Waiting list - Treatment groups fall|"This group (n=22) receives no treatment during the spring and summer, and is measured three times as a waiting list control in this period of time. The same group will receive treatment i three different groups during sept/oct.~Interventions: Sleep restriction/Stimulus Control Discussion of adverse cognitions about sleep"
2459344|NCT03177967|Active Comparator|Psychoeducative course in Nesodden|"This group (expected to be n=16) will receive a four session psychoeducative learning based course on how to manage insomnia~Interventions: Psychoeducative advice to improve sleep"
3155691|NCT00327054|No Intervention|Control|
3155692|NCT00327093|Experimental|1|Bevacizumab
3155693|NCT00327093|Experimental|2|Cetuximab
3155694|NCT00327106|Active Comparator|1|Exacyl
3155695|NCT00327106|Placebo Comparator|2|Physiologic serum
3155696|NCT00327132|Experimental|Experimental Arm|
3155697|NCT00327184|Experimental|Group Hib-MenC|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
3155698|NCT00327184|Active Comparator|Group NeisVac-C|Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.
3155699|NCT00327197|Experimental|Intermittent mild steroid-naïve asthmatic group|Asymptomatic subjects receiving only beta-agonist inhaler with predicted FEV1 >=80% and normal peak expiratory flow between attacks will be included.
3155700|NCT00327197|Experimental|Mild to moderate persistent asthmatic group|Subjects with mild to moderate persistent asthma on low to moderate dose of inhaled corticosteroid (200-500 microgram fluticasone propionate daily or equivalent), an FEV1 >= 80% predicted (post-bronchodilator), and less than 20% variability in peak expiratory flow.
3155701|NCT00327197|Experimental|Severe asthma group|Subjects with severe persistent asthma. They will be on either: high inhaled corticosteroid (CS >=1000 microgram fluticasone daily or equivalent) or on high dose inhaled CS plus oral CS (no more than 20 milligrams predisolone a day). The subjects should have at least one ( if on oral steroids) or two (if only on inhaled steroids) of the following: 1) FEV1<80% and FEV1/FVC ratio <70% 2) more than 25% variability in peak expiratory flow 3) daily symptoms ± nocturnal symptoms 4) severe exacerbations of >= twice a year in at least one of the last two years.
3155702|NCT00327197|Placebo Comparator|Healthy subjects group|Non-asthmatic and non-smokers with FEV1 > 85% predicted, on no regular medication.
3155703|NCT00327210|Experimental|BGATHome|Blood Glucose Awareness Training at Home Internet Intervention
3155704|NCT00327210|No Intervention|Control|No intervention
3155705|NCT00327223|Experimental|imexon|Dose escalation of imexon
3155706|NCT00327288|Experimental|A|Docetaxel plus imexon
3155707|NCT00327379|Experimental|Arm 1|
3155708|NCT00327379|Placebo Comparator|Arm 2|
3155709|NCT00327509||1-HTG|high tension glaucoma highest IOP > 21 mmHg
3155710|NCT00327509||2-NTG|normal tension glaucoma highest measured IOP < 21 mmHg
3155711|NCT00327509||3-PEX|pseudoexfoliation glaucoma PEX material visible
3155712|NCT00327509||4-Juvenile|juvenile glaucoma
3155713|NCT00327509||5-Control1|healthy subjects (age group 1)
3155714|NCT00327509||6-Control2|healthy subjects (age group 2)
3155715|NCT00327535|Experimental|Mircera 6.3 micrograms/kg|
3155716|NCT00327535|Experimental|Mircera 9 micrograms/kg|
3155717|NCT00327535|Experimental|Mircera 12 micrograms/kg|
3155718|NCT00327535|Active Comparator|Darbepoetin alfa|
3155719|NCT00327600|Experimental|imexon + DTIC|
3155720|NCT00327665|Experimental|Group A|
3155721|NCT00327665|Experimental|Group B|
3155722|NCT00327665|Experimental|Group C|
3155723|NCT00327665|Active Comparator|Group D|
3155724|NCT00327665|Active Comparator|Group E|
3155725|NCT00327704|Active Comparator|Albumin|
3155726|NCT00327704|Placebo Comparator|Saline|
3155727|NCT00327743|Experimental|larotaxel + Capecitabine|
3155728|NCT00327769|Active Comparator|1|Anastrozole
3155729|NCT00327769|Experimental|2|Anastrozole + Fulvestrant
3155730|NCT00327808|Experimental|Inhaler|TPI 1020
2459118|NCT03179488|Experimental|Spinal TENS stimulation|"Spinal TENS stimulation: A constant voltage and a symmetric biphasic current of 200 microseg pulse-width at a frequency of 100Hz. The intensity will increase until participants report a strong but comfortable sensation, just below motor threshold."
2459120|NCT03179488|Sham Comparator|Sham stimulation|The same procedures as experimental group, but but will be applied a sham electrical stimulation increasing the current intensity until sensory perception of the stimulus, and then decreased to zero where it will fix until the end of the stimulation.
2459249|NCT03178591|Active Comparator|vildagliptin|Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.
2459250|NCT03178591|Active Comparator|Dapagliflozin|Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.
2459280|NCT03178305|Experimental|Intervention|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
2459282|NCT03178305|No Intervention|Care as usual|Patients in this arm will receive care as usual with no restrictions.
2459399|NCT03177551||Developement Cohort|Development the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
2459403|NCT03177551||Validation Cohort|Validation the Predictive Nomogram for mCRPC in Patients with Prostate Cancer
2459426|NCT03177252|Experimental|Scalp block with lidocaine and bupivacaine|"Scalp block with a mixture of 2% lidocaine and 0.5% bupivacaine~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
2459432|NCT03177252|Placebo Comparator|Scalp block with saline|"Scalp block with saline~Once the surgery is completed, patients will be awaken and extubated following a basic neurological exam. If the extubation is delayed or if the patient is taken to ICU intubated, those patients will be excluded from the study."
2459478|NCT03176966|Active Comparator|Vitamin E then Ropinirole|Patients will be provided with vitamin E, 400 international units (IU), at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to Ropinirole. Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
2459479|NCT03176966|Active Comparator|Ropinirole then Vitamin E|Patients will be prescribed ropinirole at baseline. Patient demographics will be collected along with baseline lab data including magnesium, potassium, albumin, and total bilirubin levels. After 3 months, patients will be switched to vitamin E, 400 international units (IU). Surveys measuring muscle cramp frequency and intensity will be collected at baseline, 3 months, and 6 months.
3155731|NCT00327808|Active Comparator|Inhaler cortico.|Budesonide inhaler
3155732|NCT00327860||Cohort 1|"Age between 1 and 16 years (before 17th birthday) and estimated (based on SCr) Schwartz GFR between 30 and 90 ml/min|1.73m2"
3155733|NCT00327860||Cohort 2|"Age between 1 and 16 years (before 17th birthday), estimated GFR between 45 and 90 ml/min|1.73m2 based on the updated Schwartz formula, and an equal distribution of children with glomerular and non-glomerular causes of disease were enrolled (i.e., 150 within each) and the study placed an upper limit of 60% for the percent of enrolled with non-glomerular disease."
3155734|NCT00327860||Cohort 3|Age between 6 months and 16 years (before 17th birthday) with non-glomerular diagnosis and duration of kidney disease less than 5 years will be enrolled.
3155735|NCT00327873|Experimental|A|Oxygen
3155736|NCT00327873|Active Comparator|B|Medical Air
3155737|NCT00327912|Experimental|1|Laparoscopic Biliopancreatic diversion with Duodenal switch
3155738|NCT00327912|Active Comparator|2|Laparoscopic Roux-en-Y Gastric Bypass
3155739|NCT00327964||study population|601 children enrolled in an on-going longitudinal antimalarial treatment efficacy trial in Kampala, Uganda.
3155740|NCT00328068||Back pain / peripheral arthritis|Patients with chronic back pain of unknown origin and onset of back pain <45 years of age or patients with peripheral arthritis / enthesitis / dactylitis of unknown origin and onset <45 years of age
2459721|NCT03175380|Experimental|bacillus Calmette-Guérin|All participants will receive a total of two doses of bacillus Calmette-Guérin (BCG), by intradermal injection, approximately 6 months apart. They will be observed for 284 days
2459730|NCT03175042||Pregnant patients with anemia|Pregnant patients meeting Center for Disease Control (CDC) guidelines for anemia during pregnancy will be screened for participation in the study. In the outpatient setting at our institution it is standard of care that these women have complete blood counts (CBCs) drawn every 4-6 weeks. At the time of the routine blood draw, we will place the non invasive monitor on their finger to record the hemoglobin value. We will be comparing the hemoglobin values obtained from the CBC to that obtained from the non-invasive monitor.
3155741|NCT00328107|Experimental|Low Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2) and 15μg from A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
3155742|NCT00328107|Experimental|Full Dose|Recombinant Trivalent Hemagglutinin Influenza Vaccine, 2004/05 formulation containing 45μg of each hemagglutinin derived from A/Wyoming/3/03(H3N2), A/New Caledonia/20/99(H1N1) and B/Jiangsu/10/03
3155743|NCT00328107|Placebo Comparator|Placebo|0.9% Sodium Chloride
3155744|NCT00328146||Observation of Sternal Re-entry|All subjects.
3155745|NCT00328211|Experimental|Bile Acid|To assess the role of bile acid pool size changes on cholesterol absorption, synthesis and intralumenal cholesterol solubilization.
3155746|NCT00328211|Experimental|Cholesterol Absorption|To determine whether cholesterol absorption, synthesis and solubilization will be significantly altered by changes in phospholipid content, specifically sphingolipids and phosphatidylcholine in the intestinal lumen.
3174551|NCT00624689|Experimental|1|Modified formula
2459142|NCT03179566|No Intervention|Usual Care|For the first two weeks, there will be no intervention or changes to the usual discharge instructions
2459153|NCT03179566|Active Comparator|Information Sheet|At discharge, patients will receive an informational sheet detailing options for safe drug disposal
2459155|NCT03179566|Active Comparator|Deterra Drug Deactivation System|At discharge, patients will receive a Deterra Drug Deactivation System.
2459182|NCT03179085|Active Comparator|Usual Care / Delayed Intervention|Participants randomized to the control group will receive usual care by their provider for 12 months. They will also attend one group class taught by CHRs in which they will learn basic information about diabetes prevention. DI participants will receive publicly-available literature that reinforces the information given in class, and they will have no other contact with study staff aside from during study data collection visits at baseline and 12 months. After 12 months of usual care, patients will enter into the delayed intervention where they will complete 12 months of Home-Based Kidney Care (HBKC).
2459183|NCT03179085|Experimental|Home-Based Kidney Care Intervention|All subjects randomized to the HBKC arm will be visited by a CHR in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and participant preference will be incorporated into the HBKC intervention arm by allowing participants to prioritize the order in which curriculum topic areas will be emphasized by the CHRs. Topics from currently available NIDDK and IHS kidney education materials will include: (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
2459229|NCT03178812|Active Comparator|Patients with pancreatic cysts|Fine-needle aspiration (FNA) by Endoscopic Ultrasound (EUS) will collect liquid from patients' pancreatic cysts to measure their Interleukin and TNF levels
2459234|NCT03178812|Active Comparator|Healthy volunteers|Laboratory blood test to measure Interleukin and TNF levels
2459261|NCT03178435|No Intervention|Observational|patients will be recruited to this arm to observe prospectively the incidence of AKI among critically ill patients.patients will receive the standard care.No other intervention will be delivered
2459262|NCT03178435|Active Comparator|Interventional|Patients in this arm will be subject to AKI risk score. This risk score was recently developed and validated in Mayo clinic the intervention will be Measures to prevent AKI among critically ill patients
2459358|NCT03177824|Experimental|S|Sildenafil citrate (25mg)
2459359|NCT03177824|Placebo Comparator|P|placebo oral tablet
2459397|NCT03177590|Experimental|Recordings of facial and vocal emotional|Recordings of facial and vocal emotional productions during Children are performing three tasks
2459450|NCT03177278|Experimental|Arm 1|
2459501|NCT03176953|Experimental|prolonged exposure + topiramate|psychotherapy plus active medication
2459508|NCT03176953|Active Comparator|prolonged exposure + placebo|psychotherapy plus placebo medication
2459632|NCT03176069|Active Comparator|Group A - women diagnosed with vaginismus|"All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.~The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy Manual therapy Electrotherapy (electric electrostimulation, ultrasound) Behavioral therapy"
2459634|NCT03176069|Active Comparator|Group B - women without a diagnosis of vaginismus|All patients will be submitted to anamnesis, physical examination, examination of the pelvic floor. The algometry will be performed with patient will be lying in a supine position (belly up), with the pelvis in a neutral position, back at 45º and feet supported in stirrups, for the verification the perineal pain threshold.
2459662|NCT03175705|Experimental|Autologous T cell therapy+Tegafur+Interleukin-2 (IL-2)|Autologous in vitro expanded HCC antigens-specific CD8+ T lymphocytes in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with relapsed/advanced HCC.
2459783|NCT03175458|Experimental|sinus lift,implant placement,tenting|elevation of the sinus membrane with simultaneous implant placement without the use of any bone graft material(tenting technique)
2459787|NCT03175458|Active Comparator|sinus lift,implant placement,bovine bone|elevation of the sinus membrane with simultaneous implant placement together with deproteinized bovine bone graft substitute for augmentation
2459898|NCT03174353|Experimental|Lanreotide arm|Single arm study. A single deep subcutaneous dose of lanreotide (Somatuline Depot 120 Mg/0.5Ml) will be administered prior to planned resection on the day of surgery.
2459918|NCT03173820|Placebo Comparator|Conventional|no genotype of CYP3A5 investigated to adjust tacrolimus dosage regimen
2459920|NCT03173820|Active Comparator|Genotype guided|Use CYP3A5 genotype to adjust dosage regimen for tacrolimus
2459986|NCT03173612|Experimental|AML-CAMS-2016 trial|AML-CAMS-2016 regimen includes risk-stratified therapy and the use of Dasatinib in CBF-AML.The induction regimen includes MAE (etoposide 150mg/㎡/d d1-5, cytarabine 200mg/㎡/d d6-12 , mitoxantrone 5 mg/㎡/d d6-10), CAG (aclacinomycin 6mg/㎡/d d1-8, Ara-C 10mg/㎡ q12h d1-14 , G-CSF 200ug/㎡/d d1-14),IAE (idarubicin 8 mg/㎡/d d1-3, Ara-C 500mg/㎡/d d1-3 d8-10, VP-16 200mg/㎡/d d8-10).Consolidation regimen includes IA (Ara-C 1g/㎡ q12h d1-4, IDA 10mg/㎡/d d1), MA (Ara-C 1g/㎡ q12h d1-4, MTZ 5mg/㎡/d d1-3), IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5), MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),IAE (IDA 10mg/㎡/d d1, Ara-C 3g/㎡ q12h d1-3, VP-16 100mg/㎡/d d1-5),EA (Ara-C 2g/㎡ q12h d1-5, VP-16 100mg/㎡/d d1-5),MAE (Ara-C 200mg/㎡ d4-8, VP-16 150mg/㎡/d d1-3, MTZ 5mg/㎡/d d4-6). Dasatinib (60-80mg/㎡) is used in CBF-AML as a part of consolidation therapy.
2460063|NCT03172988|Experimental|Dexamethasone and flurbiprofen axetil|Dexamethasone 10 mg is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2460268|NCT03171753|Active Comparator|Control|patients wear headphones for 30 minuts without any sound
2459175|NCT03179007|Experimental|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|This study have only one arm that is anti-CTLA-4/PD-1 expressing MUC1-CAR-T group. All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing MUC1-targeted CAR-T cells. New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
3155747|NCT00328211|Experimental|Intralumenal|To assess intralumenal solubilization and absorption of biliary and dietary cholesterol.
3155748|NCT00328250|Experimental|1|Participants will receive the online CBT intervention immediately and will use the online program for 8 weeks
3155749|NCT00328250|Active Comparator|2|Participants will receive the online CBT intervention after a 4-month waiting period
2459401|NCT03177564|Active Comparator|Protective Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
2459406|NCT03177564|Active Comparator|Protective Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
2459411|NCT03177564|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
2459510|NCT03177031|Active Comparator|Stay Safe (STS)|CAPD system produced by Fresenius Medical Care in Germany
2459516|NCT03177031|Experimental|Stay Safe Link (SSL)|CAPD system produced by Fresenius Medical Care in Malaysia
2459596|NCT03176511|Experimental|MOB+DTBC Group|A Matter of Balance plus Dual-Task Balance Challenge Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of DTBC each class. Each class is 2 hours 15 minutes.
2459597|NCT03176511|Active Comparator|MOB Group|A Matter of Balance Group. Standardized MOB classes twice/week for 4 weeks, plus 15 minutes of social time each class. Each class is 2 hours 15 minutes.
2459635|NCT03175939|Experimental|CCRT alone|External beam radiotherapy > 66 Gy Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-5 at week 1 and 5 of radiotherapy Modified for IMRT: Cisplatin 60 mg/m2 IV D1, 5-FU 600 mg/m2 IV D1-3 at week 1, 4 and 7 of radiotherapy
2459659|NCT03175666|Experimental|Nant TNBC|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2459687|NCT03175354|Experimental|ALX-101 Gel 1.5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 1.5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
2459691|NCT03175354|Experimental|ALX-101 Gel 5% vs. ALX-101 Gel Vehicle|ALX-101 Gel 5% applied twice daily for 42 days to one treatment area and ALX-101 Gel Vehicle applied twice daily for 42 days to a second treatment area. Treatments will be randomly assigned to bilateral target areas.
2459737|NCT03174977|Experimental|18F-Raltegravir|
2459776|NCT03174873|Other|Laparoscopy for unexplained infertile couples|
2459861|NCT03174340|Experimental|Exercise + diet|"Exercise intervention:~During the first session a standardized exercise prescription will be discussed with the participant. The exercise program will be of a moderate intensity, at less than 140 heart beats/min (which corresponds to 60% of the calculated maximum heart rate (HRmax) or 50% maximum oxygen volume (VO2max) ). A session of 30 to 60 minutes/week will be organised.~Participants will be instructed to conduct a nonsedentary lifestyle. They will be encouraged to increase their number of steps on a daily basis and perform not more that 45 minutes of continuous exercise per day. Pedometers will be used to measure the compliance and as a positive feedback for motivation.~The participants will return to the exercise laboratory once per week for Actiheart data downloading, number of steps recording, exercise support and counselling, and to perform the supervised group exercise intervention.~This is in addition to the diet (see below, control group)"
2459865|NCT03174340|No Intervention|Diet only|Participants will receive diet counselling according to their characteristics. The usual recommendation is to have a fractioned normocaloric diet (unless the dietician identify a grossly hypercaloric diet), with low fat and increase in fibers content.
2459934|NCT03173989|Experimental|Orthosis Exercises Orientation|Patients used orthosis, made exercises and received orientation for home.
2459935|NCT03173989|Active Comparator|Orientation|Patients received orientation for home.
2460046|NCT03173209|Other|school professional development|Professional development in Calm Moments Cards program. Occupational therapists used lecture and coaching to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
2460105|NCT03172832|Active Comparator|Percutaneous Transhepatic Drainage|Subjects randomized to this arm will undergo PTBD as the first drainage intervention.
2460107|NCT03172832|Active Comparator|Endoscopic Retrograde Cholangiography|Subjects randomized to this arm will undergo ERC as the first drainage intervention.
2460195|NCT03172208|Experimental|Group 1: Japanese - Caplacizumab Dose 1 iv (SD)|Single dose (SD) of Caplacizumab Dose 1 administered intravenously (iv) to Japanese participants
2460197|NCT03172208|Placebo Comparator|Group 1: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
2460200|NCT03172208|Experimental|Group 2: Japanese - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to Japanese participants
2460203|NCT03172208|Experimental|Group 2: Japanese - Placebo iv (SD)|Single dose (SD) of Placebo administered intravenously (iv) to Japanese participants
2460206|NCT03172208|Experimental|Group 2: White - Caplacizumab Dose 2 iv (SD)|Single dose (SD) of Caplacizumab Dose 2 administered intravenously (iv) to White participants
2468288|NCT03116087|Placebo Comparator|Placebo|Placebo patches
3155750|NCT00328367|Experimental|A|clozapine plus aripiprazole
3155751|NCT00328367|Placebo Comparator|B|clozapine plus placebo
3155752|NCT00328393|Active Comparator|Pioglitazone|Pioglitazone 45 mg, 8 weeks
3155753|NCT00328393|Placebo Comparator|Placebo|Placebo
3155754|NCT00328419|Experimental|1|photoprotected parenteral nutrition
3155755|NCT00328419|Active Comparator|2|Non-photoprotected parenteral nutrition
3155756|NCT00328445|No Intervention|Control|Business as usual
2459191|NCT03179098|Active Comparator|Control group (GC)|The control group (GC) that will perform the 10 'sustained stretching tractioned by a load proportional to the force captured during a maximal voluntary isometric contraction (MVIC)
2459192|NCT03179098|Active Comparator|GWM|The modified Weeks Group (GWM) that will carry out the modified Weeks protocol
2459233|NCT03178643|Active Comparator|Proguanil Oral Tablet|Proguanil is the current standard of care for chemoprevention of malaria in children with SCA in Kenya. This medication will be taken on a daily basis
2459236|NCT03178643|Active Comparator|Sulfadoxine/Pyrimethanine-Amodiaquine|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ) is a combination therapy comprised of sulfadoxine and pyrimethamine (two antifolate antimicrobials) co-administered with amodiaquine. This medication is taken on a monthly basis.
2459238|NCT03178643|Active Comparator|Dihydroartemisinin-Piperaquine (DP)|DP is an artemisinin-combination therapy consisting of the artemisinin derivative dihydroartemisinin and the bisquinoline piperaquine. This medication is taken on a monthly basis.
2459372|NCT03177785|Experimental|Intervention|6-weeks of telephone-delivered sessions, moderated by a trained clinician offering EverydayMatters MS.
2459380|NCT03177785|No Intervention|Control|Wait-list control
2459581|NCT03176472|Experimental|ricolinostat|Ricolinostat 120 mg, taken once daily (QD) by mouth; each dose in 12 mL liquid formulation (10 mg ricolinostat per mL)
2459592|NCT03176472|Placebo Comparator|placebo|Placebo, 12 mL of liquid formulation with no active ingredient (i.e., ricolinostat), taken once daily (QD) by mouth
2459657|NCT03175679|Experimental|Autologous iNKT Cells + Tegafur +Interleukin-2(IL-2)|Autologous in vitro expanded iNKT cells in conjunction with IL-2 and along with lymphodepleting chemotherapy (Tegafur) will be administered to patients with advanced HCC.
2459686|NCT03175497|Experimental|Telatinib mesylate treatment arm|"Open label, single arm trial. For the 1st phase: three cohorts, and each with 3-6 solid tumor patients who will be treated with telatinib at predetermined dose: 600 mg bid, 900 mg bid, or 1200 mg bid, respectively.~For the 2nd phase, one cohort with 12 GC patients who will be treated with telatinib at 900 mg bid"
3155757|NCT00328445|Experimental|Treatment|Positive Action
2459988|NCT03173456|Active Comparator|oxycodone/APAP|5 mg oxycodone + 325 mg acetaminophen
2460001|NCT03173456|Active Comparator|hydrocodone/APAP|5 mg hydrocodone + 300 mg acetaminophen
2460009|NCT03173456|Active Comparator|codeine/APAP|30 mg codeine + 300 mg acetaminophen
2460015|NCT03173456|Active Comparator|400 ibuprofen/APAP|400 mg ibuprofen + 1000 mg acetaminophen
2460025|NCT03173456|Active Comparator|800 ibuprofen/APAP|800 mg ibuprofen + 1000 mg acetaminophen
2460060|NCT03172897|Experimental|Dexmedetomidine group|Dexmedetomidine is infused at a rate of 0.1 ug/kg/h for a maximum of 3 days.
2460068|NCT03172897|Placebo Comparator|Placebo group|Placebo (normal saline) is infused at a same rate as in the dexmedetomidine group for a maximum of 3 days.
2460116|NCT03172663|Experimental|group 1|
2460120|NCT03172663|Active Comparator|group 2|
2460143|NCT03172442|Experimental|orthodontic removable traction appliance|"Patients in this group will be treated using the orthodontic removable traction appliance (vacuum plate with two hooks between lateral incisor and canine in each side). An rapid maxillary expander will be applied to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.~Class III elastic traction from upper first molar to the hook in both side. This appliance will be used full-time with Class III elastics (6- to 8-ounce) traction."
2460145|NCT03172442|No Intervention|Control group|without intervention
3155758|NCT00328458|Experimental|Cohort 1 Brain Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
2460231|NCT03171870|Other|Idiopathic Pulmonary Fibrosis|Idiopathic pulmonary fibrosis patients on high resolution computed tomography characterized by presence of reticular opacities often associated with traction bronchiectasis
2460270|NCT03171727|Experimental|study group|After TIPS procedure was performed, low molecular weight heparin was given for three days.
2460271|NCT03171727|No Intervention|control group|After TIPS procedure was performed, no low molecular weight heparin was given.
2460291|NCT03171350|Experimental|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test
2460357|NCT03171142|Active Comparator|Heliox group|receive Helium oxygen mixture 21:79 via nasal cannula 2L/min
2460359|NCT03171142|Active Comparator|Air group|receive oxygen 21%via nasal cannula 2L/min
3155759|NCT00328458|Experimental|Cohort 2 Head and Neck Tumors|The investigational drug - EPO906 will be administered as an intravenous infusion over five to ten minutes on weeks 1, 3 and 6, for the duration of radiation therapy up to a maximum of 7 weeks. Duration of therapy will be determined by disease cohort.
2460608|NCT03169920|Active Comparator|Test Group|Modified-Minimally Invasive Surgical Technique + PRF
3155760|NCT00328484|Experimental|1|Eleven month lifestyle activity program
3155761|NCT00328484|Active Comparator|2|Three month exercise program
3155762|NCT00328497|Experimental|1|Panzem NCD will be dosed orally at a level of 1,000 mg, four times daily for 28 consecutive days and bevacizumab will be administered at a dose of 5 mg/kg as an intravenous bolus on Day 1 and Day 15 of the Treatment Period
3155763|NCT00328575|Experimental|Intensity-Modulated Radiotherapy (IMRT)|Patients with brain metastases will be enrolled in one of three dose levels based on tumor size. For tumor size of 3 cm or less (maximum diameter in any dimension), doses of 47.5Gy, 52.5Gy, and 54.5Gy will be tested. For tumor size of greater than 3 cm (maximum diameter in any dimension), doses of 42.5Gy, 47.5Gy, and 52.5Gy will be tested.
3155764|NCT00328588|Experimental|1|7 days continuous infusion
3155765|NCT00328679|Experimental|A|
3155766|NCT00328692|Experimental|2|
3155767|NCT00328692|Placebo Comparator|1|
3155768|NCT00328744|Experimental|1|Behavioral: Behavioral weight loss (Standard)
3155769|NCT00328744|Experimental|2|Behavioral: Behavioral weight loss (Limited Variety)
3155770|NCT00328809|Experimental|Spirnolactone|
3155771|NCT00328822|Experimental|A|Quetiapine
3155772|NCT00328822|Placebo Comparator|B|Placebo
3174552|NCT00624689|No Intervention|2|Standard formula
3174553|NCT00624689|No Intervention|3|Breastfed
2459195|NCT03179111|Experimental|Low Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 8-10mmHg. The number of subjects anticipated for this arm will be 47. Participants in this low pressure group are expected to encounter lesser shoulder tip pain and abdominal pain. Operating field for surgeons also expected to be better.
2459198|NCT03179111|Experimental|Standard Pressure Group|Participants will undergo elective bariatric surgery. Participants under this group will be given intra-abdominal pressure of 12-15mmHg. The number of subjects anticipated for this arm will be 47. Participants in this group are expected to have an increased amount of shoulder tip pain and higher pain score postoperatively compared to low pressure group. Operating fields for surgeons are expected to be less clear.
2459244|NCT03178630||Patients with autoimmune liver disease|"Patients with autoimmune liver disease~Patients (6-23 y.o.) with established clinical diagnosis of AIH or suspected diagnosis of AIH based on elevated serum AST or ALT, elevated IgG level >1.1 ULN, elevated titer of autoantibodies, including ANA, SMA, LKM, LC-1 or SLA, which is consistent with the simplified criteria for the diagnosis of AIH in children will be enrolled.~Patients (6-23 y.o.) with established clinical diagnosis of PSC or Suspected diagnosis of PSC supported by abnormal cholangiogram (ERCP or MRCP) or elevated GGT>1.5 ULN and dilated bile ducts by liver ultrasound will be enrolled."
2459349|NCT03178084|Experimental|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|"Maraviroc (UK-427,857) 300 mg once daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily).~Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz"
2459353|NCT03178084|Active Comparator|Efavirenz QD + Zidovudine/Lamivudine BID|Efavirenz (600 mg once daily) added to Zidovudine/Lamivudine (300 mg/150 mg twice daily
2459354|NCT03178084|Experimental|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine BID|Maraviroc (UK-427,857) 300 mg twice daily added to Zidovudine/Lamivudine (300 mg/150 mg twice daily)
2459393|NCT03177629|Experimental|Treatment arm: H. pylori eradication|treatment arm: H. pylori eradication at visit 1(0 month)
2459395|NCT03177629|No Intervention|Control arm -1st stage|At visit 1(0 month) no intervention, observation only from visit 1 to visit 3
2459396|NCT03177629|Active Comparator|Control arm - 2nd stage|Same patients group with control arm 1st stage. After observation for 3 months during stage 1, the patients of control arm will be treated with same regimen for H. pylori eradication at visit 4 (2nd stage).
3155773|NCT00328848|Experimental|Intervention care management|post dischsrge care management by a nurse care manager who performs in-home vistis and reports to a interdisciplinary team. Team generates care recommendations based on patient goals. PCP and care manager implement the care plan that is based on patient goals. Includes education, behavioral interventions, and coaching.
3155774|NCT00328874|Placebo Comparator|Placebo|
3155775|NCT00328874|Active Comparator|Coenzyme Q10|
3155776|NCT00328887|Experimental|CD40 Gene Transfer|Recruitment will be random from the referral base of the investigators from the popula¬tion of individuals with esophageal cancer defined by the protocol inclu¬sion/exclusion criteria.
2459473|NCT03176914|Experimental|Intervention arm|Eleven clusters (Villages) will be randomly selected. A cluster will comprises of 10-15 volunteers selected from a cohort 10-15 households. Educative sessions will be held in each cluster once every fortnight using a participatory methods by a trained Village Health Worker (VHW). A session will focus on one thematic area running for 1-2 hours. Trained volunteers will in turn replicate the session(s) in their cohorts and do home visits to monitor care practices and screen children for various ailment. Health information is collated from each cluster and consolidated by the VHW who reports monthly at the clinic.
2459474|NCT03176914|Active Comparator|Conventional Intervention arm|In the conventional mobilization system, a Village Health Worker facilitates community health programs as the sole source of health education for the entire villages. She does home visits, child growth monitoring and the various components primary health care at village level inclusive of disease surveillance and community case management using the 'supermarket approach' , whereby 3 or more themes are covered in a space of 10- 30 minutes in functions like funerals, village gatherings and other opportune moments. The Village Health worker prepares village monthly reports on all the indicators on community health and submits to the local health centre.
2459542|NCT03176693|Active Comparator|Phenoxybenzamine|3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
2459544|NCT03176693|Experimental|Doxazosin|3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
2459586|NCT03176316|Experimental|Naloxone|1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours
2459637|NCT03176043|Experimental|Thirst Driven infusion|Subjects who are self administering fluid will be instructed when (at any point in the experiment) they are experiencing thirst to request a fluid bolus with an electronic trigger. In response to this trigger the researcher will then deliver a 200ml bolus of IV fluid. After delivery of the fluid bolus, a lockout period is set for 15mins within which the researcher will not deliver another bolus in response to the trigger.
2459638|NCT03176043|Active Comparator|NICE infusion|Subjects receiving standard fluid maintenance will receive a baseline infusion rate of 30 mL/kg/24hr (1.25 mL/kg/hr). In addition to this a 500 mL bolus will be delivered if any of the following clinical signs, indicating hypovolaemia, are observed on regular examination: low peripheral perfusion, heart rate >90 /min, systolic BP <100 mmHg, respiratory rate >20, peripheral capillary refill >2sec. A maximum of 2000 mL of fluid will be delivered by additional boluses.
2459673|NCT03175692||critical illness in infants and children|Those infants and children who has congenital metabolism disorder or acute disorder.
2459683|NCT03175393||postprandial dyslipidemia|
2459738|NCT03175198||Prazaxa Capsules Group|
2459220|NCT03178929|No Intervention|control group|Patients will be treated without S-Adenosyl Methionine treatment after radical treatment.
2459276|NCT03178539|Active Comparator|diclofenac|patients will receive intra-operative diclofenac sodium at dose of 0.3 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
2459278|NCT03178539|Active Comparator|ketorolac|patients will receive intra-operative ketorolac tromethamine at dose of 0.5 mg/kg intravenously then will continue postoperatively on the same drug received intra-operative.
2459356|NCT03178058||Parturients for CS|"Parturients presenting for Cesarean section will be enrolled preoperatively. Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
2459367|NCT03177616|No Intervention|Usual Care|Subjects randomized to the usual care control group will continue using their usual medical care as prescribed by their physician. They are not to use any chiropractic treatment or begin new therapies.
2459370|NCT03177616|Experimental|Chiropractic Treatment + Usual Care|Patients will receive a course of 10 chiropractic treatments over a 14 week period. They are to also maintain their usual medical care as prescribed by their physician, but are not to begin any new therapies.
2459419|NCT03177499|Experimental|Single arm study|"Patients will receive CT angiography, Doppler ultrasound, invasive PPG, and vePPG per protocol.~Intervention: Procedure: Invasive PPG"
2459460|NCT03177122|Experimental|Myo-Inositol|1g Myo-inositol per day, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) + 400 ug of Folic acid
2459461|NCT03177122|No Intervention|No intervention|Standard care: 400 ug of Folic acid
2459483|NCT03176745||healthy controls|"no history of pulmonary disease~absence of symptoms, smoking history < 10 pack years~normal lung function testing"
2459484|NCT03176745||chronic obstructive pulmonary disease|"clinical history and/or specialist diagnosis of COPD and risk factor(s)~persistent bronchial obstruction and/or hyperinflation and/or radiological sign of emphysema, each without alternative explanation~dyspnea, cough and/or sputum production"
2459485|NCT03176745||bronchial asthma|"clinical history and/or specialist diagnosis of bronchial asthma~respiratory symptoms compatible with asthma varying over time~variable and/or reversible obstructive ventilation disorder and/or airway hyperresponsiveness~exclusion of alternative explanation"
2459486|NCT03176745||sarcoidosis|"clinical history and/or specialist diagnosis of sarcoidosis~lymphocytic alveolitis and CD4/CD8 > 3.5 in bronchoalveolar lavage and/or noncaseating epithelioid granuloma~exclusion of alternative explanation"
2459559|NCT03176628|Experimental|Basis|Nicotinamide riboside (NR) and pterostilbene oral capsules 250mg/50mg (Step 1) twice daily for 2 days. If the study progresses to Steps 2, 3, and 4, then 2x, 3x, and 4x the doses in Step 1 will be administered.
2459560|NCT03176628|Placebo Comparator|Placebo|Capsules identical in appearance and number to the agent used in Steps 1-4.
2459583|NCT03176251|Active Comparator|Control Group: Conventional Training Group|This group will receive 4 hours of didactic and hands-on sessions on colonoscopy theory and non-technical skills. Participants will also watch a video that demonstrates an ideal endoscopic procedure. After each didactic session, a short multiple-choice questionnaire based on the topics covered in that session will be administered. In addition to didactic training, the control group will be given six hours of expert-assisted instruction on low-fidelity (1 hour) and high-fidelity (5 hours) colonoscopy simulators. Six modules of increasing difficulty in colonoscopy will be taught using one-on-one feedback from an expert academic endoscopist. The endoscopy instructor will demonstrate techniques and provide feedback. During training on the high-fidelity simulator, the last two hours will take the form of the integrated scenario, which will feature a standardized patient (SP) and standardized nurse (SN). Feedback will be given after each integrated scenario by the instructor.
2459590|NCT03176251|Experimental|Intervention Group: Gamified-Integrated Curriculum (GIC)|The intervention group will receive the same core training as the control group with additional elements of gamification: leaderboards and badges. First, leaderboards will be used to track and rank participants' performances. This will be done through an anonymized ID tag that allows a participant to identify only their position on the leaderboard. This leaderboard will include 4 components: non-technical skills, technical skills, cognitive skills, and overall ranking. Scores will be aggregated only from participants training on the same days. The leaderboard will be displayed on a central laptop and/or TV screen and will be accessible at any time throughout the day. Second, participants in the GIC group will have the opportunity to be rewarded for their performances using achievement badges which are visual cues to the player that he or she has achieved something. Awards will be given to participants at the top of the leaderboard and with the most badges.
2459618|NCT03176082|Experimental|Intervention Group|"Intervention group will receive:~A reminder letter indicating need for screening~A FIT kit with completion instructions~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the Mecklenburg County Public Health Department (MCPHD)~A pre-paid return mailer for FIT Kit"
2459620|NCT03176082|Active Comparator|Comparison Group|"Comparison group will receive:~A reminder letter indicating need for screening~Instructions for obtaining a FIT kit~A health information card including the ability to update records for current screening and opt out from colon cancer screening communication from the MCPHD"
2459675|NCT03175822|Experimental|Visual Arts Training|Visual Arts Training
2459676|NCT03175822|No Intervention|Waitlist Control|Waitlist Control
3174554|NCT00624702|Active Comparator|1|Active Comparator 1 different salt formulation of Indacaterol.
2459794|NCT03174847||Surgical Treatment|Patients with unilateral PA who underwent adrenalectomy
2459247|NCT03178604|Active Comparator|Classic massage|Classic massage (CM) treatment based on petrissage. It applies: 1 minute of mild effleurage, 5 minutes of deep effleurage with the thumbs, 5 minutes of firm kneading and 1 minute of tapotement (20 minutes in total). This procedure was repeated for each muscle group.
2459248|NCT03178604|Active Comparator|Sham massage|Sham massage (SM). 20 minutes in total soft effleurage was performed. This procedure was repeated for each muscle group.
2459290|NCT03178331||Grade 1 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
2459293|NCT03178331||Grade 5 children|Areas of concern in study questionnaires: growth, physical symptom, hearing, school absenteeism, learning, concentration, behavior, emotions, getting on with others, eating, sleeping, wellbeing of family, free description of concern, wish to talk about concerns with the school doctor
2459377|NCT03177980||Fentanyl|All infants in need of analgesia according to an algorithm based on pain assessment results will receive fentanyl as the first analgesic drug.
2459382|NCT03177980||Fentanyl and Clonidine|Infants in need of further analgesia according to an algorithm based on pain assessment results will receive fentanyl and clonidine as the analgesic drugs.
2459436|NCT03177304|Experimental|Web based IPT Training|All subjects (trainees) received the web based training, consisting of an on-line tutorial, remote live training via videoconferencing, and access to a post-training web portal
2459518|NCT03177083|Active Comparator|peginterferon beta-1a|
2459527|NCT03177083|Active Comparator|Current Therapy|
2459664|NCT03175783|Experimental|Treatment Group|Treatment group will receive intervention by putting on Fitbit Zip activity tracker with automatic step counts feedback throughout the study.
2459666|NCT03175783|Sham Comparator|Control Group|Control group will be put on intervention with same Fitbit Zip activity tracker but without automatic feedback for same duration of intervention.
2459718|NCT03175445||mandible CBCT scans in males|74 males CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size.
2459719|NCT03175445||mandible CBCT scans in female|74 females CBCT scan by planmeca promax 3D Mid machine using 90 kVp, 10 mA, 14 seconds and 200×60 mm FOV with a 0.2 mm voxel size
2459731|NCT03175055|Experimental|Phoenix|Phoenix
2459773|NCT03174886|Experimental|AADvac1 40 µg|The intervention consists of Axon Peptide 108 coupled to keyhole limpet haemocyanin (KLH) 40 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
2459774|NCT03174886|Experimental|AADvac1 160 µg|The intervention consists of Axon Peptide 108 coupled to KLH 160 µg/0.30 mL suspension for injection; and aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg Al3+/0.30 mL), administered subcutaneously. The basic immunisation regimen consists of 6 doses administered subcutaneously in 6-week intervals. Subsequently, 5 booster doses are applied in 13-week intervals, for a total of 11 administrations.
2459940|NCT03173833|No Intervention|Control group|Participants will not receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) after the first time they fill in the questionnaire. And they will be able to discuss their care needs with their health care practitioners.
2459943|NCT03173833|Experimental|Experimental group|"Participants will receive the outcome of their questionnaire in the form of computerized assessment with graphic outcome (CAGO) every time after the first time they fill in the questionnaire.~And they will be able to discuss their care needs with their health care practitioners."
2459979|NCT03173534|Active Comparator|TAVR + Medical Therapy|n=175 will undergo Transcatheter Aortic Valve Replacement (TAVR) alone with medical management for atrial fibrillation
2459981|NCT03173534|Experimental|TAVR + WATCHMAN|n=175 will undergo simultaneous Transcatheter Aortic Valve Replacement (TAVR) with a WATCHMAN device.
2460047|NCT03173183|Experimental|genuine regional Rhizoma Atractylodis|"Granules of genuine regional Rhizoma Atractylodis:~Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
2460048|NCT03173183|Active Comparator|non-genuine regional Rhizoma Atractylodis|"Granules of non-genuine regional Rhizoma Atractylodis (Luotian, Hubei province) :~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd., orally administration, 9g per time, 3 times a day."
2460049|NCT03173183|Placebo Comparator|placebo|placebo granules: Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd., orally administration, 9g per time, 3 times a day.
2460112|NCT03172819|Experimental|OBP-301+Pembrolizumab|OBP-301+Pembrolizumab
2460452|NCT03170869|Experimental|DEB-TACE Procedure with Surefire Precision Infusion System|"The study duration for each patient is 24 months and includes a baseline visit, procedure visit and follow-up visits at 1 week, 1 month, 3 months, 6 months and every 3 months until liver transplant or death.~The following evaluations/activities will be performed at baseline: Informed consent, history, physical exam, data collection of CT/ MRI within 1 month of the visit date, data collection of lab values and quality of life questionnaire.~The treatment visit includes the DEB-TACE procedure with the Surefire Precision Infusion System. After the procedure, a Cone Beam CT of the liver will be performed to determine distribution and density of the beads in the tumor and adverse events monitoring.~The following evaluations / activities will be performed during the follow-up period: physical exam, data collection of contrast enhanced CT/MRI to evaluate tumor response, data collection of lab values, adverse event monitoring and quality of life questionnaire."
2460498|NCT03170336|Experimental|amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks
2460610|NCT03169920|Active Comparator|Control Group|Modified-Minimally Invasive Surgical Technique alone.
2459288|NCT03178500|Experimental|Traditional|Clomiphene citrate (50mg) will be given for 5 days (days 3-7). Transvaginal ultrasound from 9th-20th every other day if ovulation occur the patient will be excluded. If no ovulation, we will wait for the next menses and increase the dose to (100mg). if no ovulation occurred increase the dose to (150mg) in the next cycle if no ovulation increase the dose to (200mg) TVUS from 9th-20th ovary other day. If no ovulation we will wait for next cycle and increase the dose to (250mg) and so till 6 cycles.
2459292|NCT03178500|Experimental|Stair step protocol|If there is no response (no follicle >10mm), so, (100mg) clomiphene will be initiated immediately for 5 days and ultrasound will be repeated 1 week after the first ultrasound. If there is no response, (150mg) clomiphene will be initiated immediately for another 5 days and TV/US will be performed 1 week after the second TV/US
2459333|NCT03177993|Experimental|IDA 1|"ivermectin, diethylcarbamazine and albendazole Day 0,~permethrin Day 0 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
2459339|NCT03177993|Experimental|IDA 2|"ivermectin, diethylcarbamazine and albendazole Day 0, ivermectin Day 8~permethrin Day 0 and Day 8 if excluded from ivermectin~Details of dosing:~ivermectin: 200 mcg/kg oral~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash o after 4hrs when less than 2 months; apply to whole body and wash off after 8hrs when 2 months and older."
2459342|NCT03177993|Active Comparator|DA|"diethylcarbamazine and albendazole Day 0~permethrin Day 8 if scabies present in participant or household member~Details of dosing:~diethylcarbazine: 6mg/kg oral~albendazole 400mg oral~permethrin 5% cream topical: apply to whole body and wash off after 4hrs when less than 2 months; apply to whole body and wash o after 8hrs when 2 months and older."
2459374|NCT03177681|Experimental|Group 1 - Antibiotics Taken During Past 2 Weeks|"Group 1: Participant was on antibiotics anytime during the past 2 weeks prior to the time of enrollment.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
2459383|NCT03177681|Experimental|Group 2 - No Antibiotics Taken During Past 2 Weeks|"Group 2: Participant has not been on antibiotics in the past 2 weeks.~Tongue assessment, stool sample, and questionnaires done at baseline and once during Days 3-7 and once during Days 8-12.~Participants wear a Holter monitor for 20-24 hours at baseline and once during Days 3-7 and once during Days 8-12.~Participants given 2 tablespoons (33 cc) of yogurt each day for 12 days."
2459422|NCT03177187|Experimental|Phase I|Increasing doses of AZD5069 in combination with a fixed dose of enzalutamide to establish the recommended phase II dose.
2459429|NCT03177187|Experimental|Phase II|"The Phase II part of the study will evaluate the recommended phase II dose identified in Phase I of the study in patients with metastatic castration resistant prostate cancer.~RECRUITING"
2459469|NCT03176901|Experimental|Mindfulness-Based Stress Reduction|8 week manualized, standardized mindfulness-based stress reduction program taught by a certified Mindfulness-Based Stress Reduction instructor
2459470|NCT03176901|Active Comparator|Health Enhancement Program|8 week manualized, standardized health enhancement program, taught by a certified health education specialist
2459520|NCT03176706||Lebanese pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in the Lebanon.
2459525|NCT03176706||Thai pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Thailand.
2459531|NCT03176706||South African pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in South Africa.
2459532|NCT03176706||New Zealand pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in New Zealand.
2459537|NCT03176706||Swedish Pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Sweden.
2459540|NCT03176706||Peruvian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Peru.
2459541|NCT03176706||Russian pregnant women|Pregnant women which are suspected to have mild to moderate iodine deficiency but are otherwise health and living in Russia.
2459567|NCT03176342|Experimental|patch test arm|Patch test by selected allergens and drawing blood for ELIspot and LTT
2459602|NCT03176212|Active Comparator|Beverage with milk fat globule membrane|In this arm, subjects consumed a beverage
2459604|NCT03176212|Placebo Comparator|Control|In this arm, subjects consumed a beverage with identical macronutrients
2459697|NCT03175913|Experimental|Vapocoolant spray group|vapocoolant spray was applied for 10 second
2459702|NCT03175913|Active Comparator|Local infiltration group|3 ml of 2% lidocaine infiltrated subcutaneously
2459735|NCT03175185||Parents of children with ADHD|100 parents of 50 children who were diagnosed with ADHD and
2459736|NCT03175185||Parent of children without ADHD|100 parents of 50 children who are ADHD free as a control group
2459739|NCT03174912|Active Comparator|Group 1|Whole patient group (patients not treated with BCG and patients treated with BCG)
2459740|NCT03174912|No Intervention|Group 2|Patients not treated with BCG
2459741|NCT03174912|Active Comparator|Group 3|Patients treated with BCG
2459801|NCT03174821|Experimental|Insulin pump therapy|The total requisite amount=0.44×weight (Kg); The preprandial and basal amount respectively took up 50% of integral dose.15 minutes before meal the preprandial insulin was equally given by 3 times. The basal insulin was pumped at 00:00-3:00，3:00-8:00，8:00-14:00，14:00-20:00，20:00-24:00.
2459802|NCT03174821|No Intervention|Normal control|The subjects were asked to maintain normal diet and lifestyle until the end of the observation period.
2459808|NCT03174470|Experimental|TENS stimulator|Single day Transcutaneous electrical nerve stimulations utilizing a commercial TENS stimulator (TensMed S82 ENRAF-NONIUS)
2459854|NCT03174379|Placebo Comparator|Control Group|Standard of Care (SOC) treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
2459855|NCT03174379|Active Comparator|Treatment Group|60-minute treatment session twice a week for three weeks
2459307|NCT03178240|No Intervention|Control|The control croup takes part in the survey but does not receive an intervention.
2459355|NCT03177954|Experimental|Patient Oriented Discharge Summary|A one hour patient oriented discharge summary meeting will take place with participants.
2459363|NCT03177655|Experimental|Guided Imagery|Guided Imagery meditation
2459365|NCT03177655|Active Comparator|Journaling|Keeping a journal
2459515|NCT03176810|Active Comparator|OCT-guided PCI|PCI is performed by OCT guidance.
2459523|NCT03176810|Active Comparator|Angiography-guided PCI|PCI is performed by angiography guidance alone.
2459593|NCT03176446|Active Comparator|Control Group|The children anesthesia will be traditional technique
2459594|NCT03176446|Active Comparator|Computerized Group|The children anesthesia will be computerized technique
2459595|NCT03176446|Active Comparator|DentalVibe Group|The children anesthesia will be DentalVibe technique
2459650|NCT03175887|Experimental|Intervention Arm|Participants will receive TMS. They will be randomized to either the left dorsolateral prefrontal cortex or the medial prefrontal cortex.
2459652|NCT03175887|Other|Treatment Arm|"After the experimental arm, if a patient was randomized to the medial prefrontal cortex during the experimental arm and it did not work for them, they have the option of returning for a session of TMS to the FDA-approved dorsolateral prefrontal cortex.~If they were assigned to the dorsolateral prefrontal cortex, they are not eligible to return for another set of treatment."
2459815|NCT03174730|Experimental|Growth mindset|In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.
2459817|NCT03174730|Other|Control|Participants will get SmartQuit, but not the growth mindset intervention.
2459873|NCT03174288|Experimental|Exercise alone|24 weeks of exercise treatment
2459880|NCT03174288|Experimental|spironolactone alone|24 weeks of Spironolactone treatment
2459884|NCT03174288|Experimental|Exercise + Spironolactone|24 weeks of exercise + Spironolactone treatment
2459961|NCT03173846||Adult children of AD patients|
2460057|NCT03172936|Experimental|Dosing Schedule A|Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
2460058|NCT03172936|Experimental|Dosing Schedule B|Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
2460123|NCT03172572||Indication for surgery|Solid neoplasms
2460159|NCT03172377|Experimental|Intervention group|Lengthening adalimumab dosing interval: The adalimumab injection interval during maintenance therapy (40 mg sc / 2 weeks) will be extended through a stepwise disease activity guided manner to 3 weeks and subsequently - after 24 weeks - to 4 weeks. If a step-down leads to recurrence of disease activity patients will return to the preceding effective dosing interval.
2460165|NCT03172377|No Intervention|Control group|Standard care: patients will continue adalimumab maintenance treatment of 40mg per 2 weeks. Treatment decisions are made at the discretion of the treating physician.
2460436|NCT03170713|Active Comparator|arveles|800 mg ibuprofen and 50 mg arveles in 150 cc normal saline before operation will be given in 30 minutes.
2460437|NCT03170713|Active Comparator|intrafen|intrafen 800 mg in 150 cc normal saline before operation will be given in 30 minutes.
2460439|NCT03170713|Placebo Comparator|placebos|Pre-operative 150 cc normal saline will be delivered in 30 minutes
3155777|NCT00328965|Other|Lacidipine|All subjects who meet eligiblity criteria receive 2mg for the first 4 weeks in an open manner. If target systolic blood pressure is not ahcieved, subject can increase the dose to 4mg and then 6mg consequently.
3155778|NCT00329004|Experimental|1|
3155779|NCT00329017||1|Post-menopausal women who are at increased risk for development of breast cancer on the basis of family or personal history.
3155780|NCT00329043|Experimental|Sunitinib + Hormonal Ablation Before Prostatectomy|Sunitinib Malate 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles. LHRH Agonist intramuscular injection either monthly for 3 months or in a single 3-month dose. Radical prostatectomy after completion of Sunitinib and LHRH agonist.
3155781|NCT00329056|Experimental|1|40 mg MitoQ OD
3155782|NCT00329056|Experimental|2|80 mg MitoQ OD
3155783|NCT00329056|Placebo Comparator|3|Placebo
2460790|NCT03168256|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
2460792|NCT03168256|Experimental|CF101 3mg|CF101 3mg, orally q12 hours
2460794|NCT03168256|Active Comparator|Apremilast 30mg|Apremilast 30mg, orally q12 hours
2460796|NCT03168256|Placebo Comparator|Placebo|Placebo control , orally q12 hours
2460867|NCT03167775|Experimental|Elemene + the best supportive treatment|the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .
2460944|NCT03167567|Experimental|intervention|These women will have a medical clown present in the room during their labor
2460961|NCT03167567|No Intervention|Control|These women will not have a medical clown in the room during their labor
2461005|NCT03167047|Active Comparator|Caudal block|"Caudal epidural given for post-operative pain relief. Dose used is 1.5ml/kg of weak Levo-Bupivacaine solution (0.125%).~Patients will also receive standardised pain relief of paracetamol and fentanyl"
2461008|NCT03167047|Active Comparator|Nerve block|"Peripheral nerve block given for post operative pain relief. Levo-Bupivacaine 0.25% 2mg/Kg given under ultrasound guidance.~Patients will also receive standardised pain relief of paracetamol and fentanyl"
3155784|NCT00329082|Experimental|1|
3155785|NCT00329082|Experimental|2|
3155786|NCT00329082|Experimental|3|
3155787|NCT00329082|Experimental|4|
3155788|NCT00329082|Placebo Comparator|5|
3155789|NCT00329342|Experimental|1|
3155790|NCT00329342|No Intervention|2|
3155791|NCT00329381|Placebo Comparator|1|Placebo will be compared to Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3155792|NCT00329381|Experimental|2|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
3155793|NCT00329459|Experimental|arm 1|Treximet (sumatriptan/naproxen sodium)
3191056|NCT00794274|Experimental|Open label drug|"Drug: CC-100004~After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis"
3191057|NCT00794287||1|Hymenoptera allergic patients before allergen specific immunotherapy
2459366|NCT03177811|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2459369|NCT03177811|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2459543|NCT03177070|Experimental|Methylene Blue|Intravenous administration of methylene blue and assessment of ureteric fluorescence intraoperatively.
2459571|NCT03176420|Experimental|Symptomayic chronically occluded cervical ICA|
2459639|NCT03176173|Experimental|Arm I (image guided radiation therapy)|Patients undergo radical-dose image guided radiation therapy daily for up to 10 days (within 2 weeks) while undergoing standard of care immunotherapy.
2459640|NCT03176173|Active Comparator|Arm II (standard of care immunotherapy)|Patients who decline to undergo radiation therapy receive standard of care immunotherapy.
2459665|NCT03175614|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and nutrition.
2459667|NCT03175614|Experimental|Intervention group|Add for three months a Smartphone with an app (EVIDENT III) and a Smartband to lose weight and improve physical activity.
2459732|NCT03175081|Experimental|Test group|Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure.
2459734|NCT03175081|Experimental|Control group|Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure.
2459790|NCT03174860|Experimental|Diclofenac Potassium 50mg tab|Diclofenac Potassium 50mg (Cataflam) tablet to be administered one hour before treatment.
2459792|NCT03174860|Placebo Comparator|Placebo|Placebo to be administered one hour before treatment.
2459809|NCT03174522|Experimental|REX-001|REX-001 is a cell suspension of autologous bone marrow mononuclear cells (BM-MNCs) composed of several mature cell types.
2459811|NCT03174522|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
2459903|NCT03174041|Experimental|Part 1|Participants will receive a single dose of midazolam followed by multiple doses of GDC-0853 coadministered with a single dose of midazolam.
2459908|NCT03174041|Experimental|Part 2|Participants will receive a single dose of rosuvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of rosuvastatin.
2459910|NCT03174041|Experimental|Part 3|Participants will receive a single dose of simvastatin followed by multiple doses of GDC-0853 coadministered with a single dose of simvastatin.
2459911|NCT03174041|Experimental|Part 4|Participants will receive a single dose of GDC-0853 followed by multiple doses of itraconazole coadministered with a single dose of GDC-0853.
2459972|NCT03173651|Experimental|Group W|This group was intubated by Fiberoptic bronchoscope assisted by Modified Williams airway as a conduit
2459975|NCT03173651|Experimental|Group G|This group was intubated by Fiberoptic bronchoscope assisted by Modified Guedle's airway as a conduit
2459976|NCT03173651|Experimental|Group M|This group was intubated by Fiberoptic bronchoscope assisted by LMA MADgic airway as a conduit
2460020|NCT03173261|Other|tuberculous pleural effusion|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
2460102|NCT03173105|Active Comparator|Group 1 (G1)|active tDCS + dynamic proprioceptive exercises
2460104|NCT03173105|Sham Comparator|Group 2 (G2)|sham tDCS + dynamic proprioceptive exercises
2460106|NCT03173105|Active Comparator|Group 3 (G3)|active tDCS + static proprioceptive exercises
2460108|NCT03173105|Sham Comparator|Group 4 (4)|sham tDCS + static proprioceptive exercises
2460177|NCT03172533|Active Comparator|verum group|approved oral contraceptive: ethinyl estradiol 0.03mg and dienogest 2mg (combination drug) daily intake over 10 weeks
2460182|NCT03172533|Placebo Comparator|placebo group|placebo
2460223|NCT03172013||Cirrhotic ascitic patients with SBP,|Cirrhotic ascitic patients with SBP,
2460225|NCT03172013||cirrhotic ascitic patients without SBP,|cirrhotic ascitic patients without SBP,
2460226|NCT03172013||Healthy volunteers|Healthy individuals
2460292|NCT03171688||Modeling|It is the cohort that will be used for selecting risk factors and models for predicting postoperative nausea and vomiting.
2460297|NCT03171688||Validation|It is the cohort that will be used for validation of risk factors and models selected in the modeling group.
2460376|NCT03171233|Active Comparator|Group mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient does the movement actively, but is assisted by the therapist to mobilize.
2460377|NCT03171233|Active Comparator|Group Self mobilization with movement|Techniques to improve ankle mobility that possibily will to cause changes in the biomechanical motion of the lower limb. The patient performs the movement and the mobilization in an independently way without receiving help from the therapist
3191058|NCT00794287||2|Hymenoptera allergic patients after allergen specific immunotherapy
2460822|NCT03168243|Experimental|High Energy High Protein Tube Feed|As study is a single arm design, all patients will be in the intervention group. The will act as their own control by means of a 3 day baseline period. All patients in the study will receive the same intervention, the high energy high protein tube feed, in quantities specified by their dietitian based on their nutritional requirements.
2460869|NCT03167892|Experimental|Intervention|Oral screen
2460872|NCT03167892|No Intervention|Control|No intervention
2460951|NCT03167502|Active Comparator|concentric work|patient suffering from knee osteoarthritis will follow a concentric work. This training is 2 sessions per week for 6 weeks
2460963|NCT03167502|Experimental|eccentric work|patient suffering from knee osteoarthritis will follow an eccentric work. This training is 2 sessions per week for 6 weeks
3155794|NCT00329459|Placebo Comparator|arm 2|placebo to match
2459360|NCT03177837|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2459361|NCT03177837|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2459402|NCT03177577|Placebo Comparator|Splint Only|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb.
2459408|NCT03177577|Active Comparator|Splint with first dorsal interosseous (FDI) strengthening|Subjects with carpometacarpal (CMC) osteoarthritis treated by splinting of their thumb combined with first dorsal interosseous (FDI) strengthening stabilization exercises.
2459437|NCT03177239|Experimental|Nivolumab and Ipilimumab|"Part 1: nivolumab 240mg IV q2w for a maximum of 12 months.~Part 2; nivolumab 240mg IV q3w in addition to ipilimumab 1mg/kg q3w x 4 cycles Then nivolumab 240mg q2w for a maximum of 12 months."
2459521|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Placebo-Controlled Period)|MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.
2459524|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Placebo-Controlled Period)|Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.
2459530|NCT03176771|Experimental|Placebo (Double-Blind Placebo-Controlled Period)|Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.
2459533|NCT03176771|Experimental|MT-5199 40 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.
2459538|NCT03176771|Experimental|MT-5199 80 mg (Double-Blind Extension Period)|At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.
2459647|NCT03175926|Experimental|Group 1|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2459648|NCT03175926|Experimental|Group 2|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2459649|NCT03175926|Experimental|Group 3|placebo Diskus® placebo Ellipta® Pulmicort® Turbuhaler®
2459708|NCT03175549|Active Comparator|Otezla (apremilast)|100 mg (50 mg/bid) taken orally for 5 days after a 9 day titration to recommended dose
2459710|NCT03175549|Placebo Comparator|Placebo|Placebo pill taken orally for 14 days
2459784|NCT03175094|Experimental|Holistic Health Recovery Program for HIV+ Intervention|
2459785|NCT03175094|No Intervention|Control|
2459843|NCT03174613|Experimental|LC51-0255|tablets, PO
2459845|NCT03174613|Placebo Comparator|Placebo|tablets, PO
2459858|NCT03174145|Active Comparator|Active group|
2459860|NCT03174145|Sham Comparator|Control group|
2459954|NCT03173911|Active Comparator|Ankle|composed by 12 participants who will receive the application of the bandage for the ankle strategy in both lower limbs, being determined the application of the technique in I without fixed point, from medial malleolus to lateral malleolus passing under the hindfoot, finally a cleavage technique passing over the malleoli and ending in the anterior region of the ankle joint. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2459957|NCT03173911|Active Comparator|Hamstrings|composed by 12 participants who will receive the application of the bandage for the posterior thigh (hamstrings) strategy in both lower limbs. The technique will be determined in I with fixed point of the skin of the ischial tuberosity and moving point until the Lateral tibia (near the head of the fibula) and medial tibia (goose-foot insertion). The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2459959|NCT03173911|Active Comparator|Lumbar|composed by 12 participants who will receive the application of the bandage for the hip (lumbar) strategy, being determined the application of the technique in I with fixed point in the ischial tuberosity and moving point until the height of the last ribs, making a cleavage in the Height of the superior iliac spine. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2460156|NCT03172559|No Intervention|No intervention|Follow-up will be carried out every 3 months and a computed tomography (CT) scan of the chest and abdomen or an magnetic resonance imaging (MRI), and blood work with liver function test and alpha-fetoprotein (AFP) value will be done until the patient is transplanted or drops-out of the waiting list.
3155795|NCT00329472|Experimental|Gem/Cis|neoadjuvant chemotherapy: gemcitabine 1250mg/m2 D1,D8 & cisplatin 70mg/m2 , 2 cycles
3155796|NCT00329472|No Intervention|no neoadjuvant chemotherapy|
3155797|NCT00329511|Active Comparator|A|methyldopa
3155798|NCT00329511|Active Comparator|B|clonidine patch
3155799|NCT00329537|Experimental|Arm 1|
3155800|NCT00329537|Placebo Comparator|Arm 2|
3155801|NCT00329563|Experimental|Cold fluid|
3155802|NCT00329563|No Intervention|control, standard of care|
3155803|NCT00329589|Experimental|CNS|Velcade (bortezomib)
2459350|NCT03177941|Experimental|Skin Self-Examination|"Melanoma patients (n=300) and their first-degree relatives (n=300) that are between 16-70 years old will participate in the study. Participants will be randomized to receive the intervention or the control group. Participants randomized to the control group will have access to the app later.~Assigned Interventions Behavioral: Skin self-examination structure training First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle."
2459352|NCT03177941|Active Comparator|Active Control|"Participants (n=150) will complete web-based surveys at baseline and 4-months. Control participants do not initially receive training; however, after completing the 4-month survey they will be given access to the training.~Assigned Interventions~Behavioral: Skin self-examination structured training Training will be provided via a mobile application. After completing the 4-month survey, the control participants may request the link to download the application."
2459389|NCT03177642||Data Repository Group|All adults presenting to the hand and upper extremity service at Massachusetts General Hospital.
2459535|NCT03177096|Experimental|Peds QL questionnaire and diabetes modulate|Routine practice of a continuous measure sensor of the glycemia with insulin pump for children aged 2 to 13 years followed at Mulhouse Hospital for type 1 diabetes : 5 sessions after enrollment visit(V1) (1 session 2 months, 4 months, 6 months, 8 months and 10 months) This study will be proposed to patients treated for type 1 diabetes enrolled in kindergarten, primary school, attending a nursery or a childcare center (patient's participation = 10 months) and will evaluate the child quality of life and the parents and staffs in preschool and school felt too.
2459582|NCT03176368|Experimental|Coconut Oil|Through a interventional/cohort design, we propose to study the experience of coconut oil over a three month period, allowing patients to use Biotene© oral lubricant (or another product of their choice) as an alternative to coconut oil if they so prefer.
2459642|NCT03176056|Experimental|Low carbohydrate diet|Low carbohydrate diet limits carbohydrate <=90g/day
2459644|NCT03176056|Active Comparator|Calori restricted diet|Traditional diabetic diet
2459672|NCT03175653|Experimental|Arm A - Oxycodone Pill A|Participants in this study arm will receive a prescription for a lower number oxycodone (oxycodone A) pills for post-cesarean pain control.
2459674|NCT03175653|Active Comparator|Arm B - Oxycodone Pill B|Participants in this study arm will receive a prescription for a higher number of oxycodone (oxycodone B) pills for post-cesarean pain control.
2459688|NCT03175341|Experimental|Vitamin C Supplement|"Ascorbic Acid (AA) with neoadjuvant chemotherapy. Participants received an initial loading dose of 1,5 g Ascorbic Acid (i.v in 100 ml sterile water) on Day 1 followed by 0,75g Ascorbic Acid (i.v in 100 ml sterile water) on Day 2-4 at each chemotherapy cycle and concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician.~Ascorbic Acid is administered intravenously before neoadjuvant therapy in D1"
2459693|NCT03175341|Active Comparator|Placebo|"Placebos (normal saline (0.9%) with neoadjuvant chemotherapy. 100 ml normal saline 0.9% (placebo) will be administered (i.v) by the same scheme as Ascorbic Acid on Day 1 and respectively Day 2-4 at each chemotherapy cycle.~Concomitant neoadjuvant chemotherapy regimens administered at the choice of treating physician."
2459729|NCT03175107|Experimental|PD_patients|Patients with Parkinson disease or Parkinsonism (characteristic symptoms such as rigidity, extrapyramidal symptoms), with functional disorders in upper extremities and minor problems at daily activities, with the level 2-3 in the Hoehn and Yahr Scale. They will perform exergaming at home for up to 4 weeks.
2459777|NCT03174951|Experimental|Treatment group|IVIg group
2459781|NCT03174951|No Intervention|control group|Patients who do not receive any treatment despite a history of Recurrent Pregnancy Loss problem as controls
2459812|NCT03174587|Experimental|CS20AT04|Test group : CS20AT04 (allogenic bone marrow derived mesenchymal stem cells.)
3191059|NCT00794300||Acute myocardial infarction patients|
2459977|NCT03173794|No Intervention|Usual Care Only|The control group will receive usual care, no CommunityRx-H intervention
2459978|NCT03173794|Experimental|Usual Care and Intervention|The intervention arm will receive the CommunityRx-H intervention, an information-based intervention that provides referrals to community resources
2459998|NCT03173274|Experimental|Contingency Management (CM)|Those in the CM condition will continue to provide CO values twice-daily, and will receive escalating reinforcement values for CO values indicating continuous smoking abstinence (CO < 6 ppm).
2460007|NCT03173274|Active Comparator|Non-Contingent Reinforcement|Participants in the NC condition will also provide CO levels twice-daily. However, their reinforcement will not be contingent upon their CO level but will be yoked to someone in the CM condition so that average reinforcer values are equivalent across the 2 conditions.
3191060|NCT00794326|Experimental|PDsol 12|Treatment with a peritoneal dialysis solution containing a low concentration of sodium.
2460313|NCT03171571|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one year follow-up, plus connected coaching.
2460494|NCT03170648|Experimental|Acupuncture|Patients will receive a 30-minute session of a standardized ear acupuncture treatment Acupuncture needles will be gently manipulated to increase stimulation For each ear acupuncture session, the patient will have ear acupuncture therapy administered to each ear
2460534|NCT03170128|Active Comparator|Outpatient Physical Therapy|
2460536|NCT03170128|Active Comparator|Home Exercises|
2460583|NCT03169855||Refractive media opacities: present|Refractive media opacities: present
2460584|NCT03169855||Refractive media opacities: absent|Refractive media opacities: absent
2460607|NCT03169621||Patients with RIF|Patients with repeated implantation failure (RIF) with indication of hysteroscopy within normal clinical practice, who will undergo FIV or ICSI and embryo transfer within their assisted reproduction treatment (ART).
2469945|NCT03104946||Neonatal Necrotizing Enterocolitis|
3191061|NCT00794326|Active Comparator|Gambrosol trio 40|Treatment with the peritoneal dialysis solution Gambrosol trio 40 isotonic bag (1.5%)
3191062|NCT00794378|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
3155804|NCT00329589|Experimental|Head and Neck|Velcade (bortezomib)
3155805|NCT00329589|Experimental|Cervix|Velcade (bortezomib)
2459553|NCT03176602||All patients admitted to the ICU|All patients ≥ 18 years old who had ≥ 24 hours length of stay in the ICU
2459584|NCT03176329|Other|INTELLIVENT-ASV / Conventional mode|Full closed-loop ventilation control (INTELLIVENT-ASV) is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to conventional ventilation 30 minutes before Nursing 2
2459591|NCT03176329|Other|Conventional mode / INTELLIVENT-ASV|Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
2459651|NCT03175991||ovarian masses patients|women of different age groups diagnosed as having an ovarian mass or accidentally discovered ovarian mass in non-complaining female by ultrasonography or Patients known to have primary that may give metastasis to the ovaries.
2459767|NCT03175588|Experimental|virtual rehabilitation|video based exercise
2459771|NCT03175588|No Intervention|physical Activity|different type of physical Activity
2459871|NCT03174223||Deep neuromuscular block|patients received a continuous rocuronium dose to maintain a depth of neuromuscular block of 1-2 twitches post tetanic count
2459879|NCT03174223||moderate neuromuscular block|patients received neuromuscular block aimed at > 0 twitches train of four
3155806|NCT00329628|Experimental|Arm 1|
2460027|NCT03173508|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2460031|NCT03173508|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2460069|NCT03172975|Experimental|Na-GST-1/Alhydrogel|100 µg ˆNaˆ-GST-1/Alhydrogel administered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2460077|NCT03172975|Experimental|Na-GST-1/Alhydrogel + CPG 10104|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 500 µg CPG 10104 delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2460082|NCT03172975|Experimental|Na-GST-1/Alhydrogel + GLA-AF|100 µg ˆNaˆ-GST-1/Alhydrogel co-administered with 5 µg GLA-AF delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2460088|NCT03172975|Placebo Comparator|Saline Placebo|Sterile saline placebo delivered intramuscularly in the deltoid on study days 0, 56 and 112 followed by controlled human hookworm infection with 50 infectious Necator americanus larvae on study day 140.
2460168|NCT03172507||Atherosclerosis group|Patients with significant coronary artery disease.
2460170|NCT03172507||Control group|Healthy controls without confirmed coronary artery disease.
2460217|NCT03172104||Very preterm group|"Preterm infants <30 weeks' GA at birth admitted to one of the neonatal nurseries at the Royal Women's Hospital in Melbourne, Australia.~Inclusion criteria: Infants admitted to the Royal Women's Hospital, Melbourne, Australia, neonatal nurseries, born <30 weeks' GA. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment and (ii) infants with non-English speaking parents."
2460218|NCT03172104||Term control group|Inclusion criteria: Infants admitted to the Royal Women's Hospital Melbourne, Australia, born >36 completed weeks' GA and weighing >2500 g. Exclusion criteria: (i) infants with congenital abnormalities known to affect neurodevelopment (ii) infants requiring admission to neonatal intensive or special care nursery and (iii) infants with non-English speaking parents.
2460261|NCT03171831|Experimental|Haploidentical HSCT|"Procedure: Haploidentical hematopoietic stem cell transplantation from a related donor (partially matched sibling, father or mother).~Conditioning: Busulfan （4 mg/kg/day,4 days） + Cyclophosphamide （50 mg/kg/day,4 days）+ Fludarabine （50 mg/m2/day,3 days）~GVHD Prophylaxis：Mycophenolate mofetil（0.25g/day）+ Tacrolimus（0.03mg/kg/day）+ Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）+ Thymoglobulin（2.5 mg/kg/day,4 days）+Basiliximab（10mg on day 0 and +4）"
2460342|NCT03171337|Experimental|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory, twice 1 week for 4 weeks，fMRI will be used to detect the cerebral function changes
2460343|NCT03171337|Active Comparator|Fu's subcutaneous needling (FSN)|FSN at the points related with CTTH, twice 1 week for 4 weeks, fMRI will be used to detect the cerebral function changes.
2460344|NCT03171337|Sham Comparator|Sham acupuncture|Streitberger placebo needles at nonacupoint for CTTH, twice 1 week for 4 weeks,fMRI will be used to detect the cerebral function changes.
2460355|NCT03170908||Phase I Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
2460358|NCT03170908||Phase II Patients|Patients with depression receiving community-based services will receive Interpersonal Psychotherapy
2469946|NCT03104946||Brain injury|
3155807|NCT00329628|Active Comparator|Arm 2|
3155808|NCT00329654|Experimental|Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation.
3155809|NCT00329680|Experimental|1|Experimental arm will receive an enteral diet enriched with EPA, GLA and Antioxidant vitamins
3155810|NCT00329680|Placebo Comparator|2|"This arm will receive an enteral diet considered as a standard ICU diet, isocaloric to the control diet but not enhanced with EPA, GLA and antioxidant vitamins"
3155811|NCT00329693|Placebo Comparator|1|Daily Tablets Dosing
3155812|NCT00329693|Experimental|2|Daily Tablets Dose
3155813|NCT00329693|Experimental|3|Daily Tablets Dosing
3155814|NCT00329693|Experimental|4|Daily Tablets Dosing
3155815|NCT00329706|Experimental|1|Experimental arm will have an immediate release of the PET report
3155816|NCT00329706|Active Comparator|2|Active Comparator arm will have a delayed release of 2 years
3155817|NCT00329758|Active Comparator|1|
3155818|NCT00329758|Placebo Comparator|2|
3155819|NCT00329810|Experimental|Switch|
3155820|NCT00329914|Placebo Comparator|Placebo|
3155821|NCT00329914|Active Comparator|Progesterone|
2459378|NCT03177850|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2459385|NCT03177850|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2459431|NCT03177317|Experimental|Elderly patients (>= 70 years of age)|Dexamethasone 8mg intravenously before chemotherapy
2459499|NCT03177044|Experimental|Behavioural treatment|2 to 6 sessions of bowel behavioural training with a pelvic floor physiotherapist
2459577|NCT03176563||Women treated with the herbal drug Uva Ursi|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the Uva Ursi arm.
2459578|NCT03176563||Women treated with antibiotics|Patients of the clinical trial REGATTA (NCT03151603) who have been randomized in the fosfomycin arm.
2459681|NCT03175718|Experimental|VAC Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of Incisional Negative pressure wound therapy.
2459682|NCT03175718|Active Comparator|Control Wound Dressing|Limb salvage surgery is performed on sarcoma patients 4-6 week post radiotherapy. These patients will be randomized to receive 2 weeks of standard gauze dressing with no negative pressure application.
2459748|NCT03175250|Active Comparator|Health Education|This condition included live health education followed by health education videos on HIV risks, testing, and condom use. The videos were presented over laptop.
2459751|NCT03175250|Active Comparator|Action Plan|This condition included live health education followed by computerized procedures focusing on action plans for HIV testing and condom use and some of the same health education videos in the Health Education condition.
2459753|NCT03175250|Experimental|Memory Practice|This condition included live health education followed by computerized action plan procedures (as in the Action Plan condition), followed by several memory practice procedures also delivered over laptop. The memory practice procedures were designed to help participants more readily retrieve and use action plans in critical situations.
2459838|NCT03174743|Placebo Comparator|Convential Ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of 60%.
2459841|NCT03174743|Placebo Comparator|Convential Ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
2459844|NCT03174743|Active Comparator|Protective ventilation 1|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
2459846|NCT03174743|Active Comparator|Protective ventilation 2|Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 6 cmH2O and a FiO2 of 100% with lung recruitment maneuvers.
3155822|NCT00329940|Experimental|Letrozole|to evaluate the rheumatological tolerability of Femara
3155823|NCT00329979||1|Radial access
2459997|NCT03173248|Experimental|AG-120 (ivosidenib) with Azacitidine|
2460008|NCT03173248|Placebo Comparator|Placebo with Azacitidine|
2460142|NCT03172429||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2460144|NCT03172429||High altitude control|Healthy highlanders living above 2500 m.
2460147|NCT03172429||Low altitude control|Healthy lowlanders living below 1000 m.
2460252|NCT03171961|Experimental|online visit group|in online visit group , subjects has online visit with dietitian every 2 weeks
2460254|NCT03171961|Experimental|clinic visit group|clinic visit group ,subject has every 2 weeks in person visit at clinic
2460256|NCT03171961|Experimental|self-directed group|self-directed group ,subjects receive nutritional information via web and their energy needs for weight loss
2460328|NCT03171298|Experimental|transanal TME|Laparoscopic Assisted Transanal Total Mesorectal Excision
2460356|NCT03170999||Subjects included in Focus groups|Approximately 45 subjects with COPD will participate in the focus group interviews for item identification. The group may contain subjects who are functionally illiterate and at least one third women will be recruited.
2460360|NCT03170999||Subjects included in cognitive interviews|Approximately 9 subjects with COPD will be involved in cognitive interviews and will be asked to respond to all of the items in the draft item set.
2460362|NCT03170999||Subjects included in candidate item set|Approximately 150 subjects with COPD will respond to the questions in candidate item set.
2460463|NCT03170739|Experimental|Dexmedetomidine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump at the beginning of surgery.
2460464|NCT03170739|Experimental|Dopamine|Dopamine 3ug/kg/min ivpump at the beginning of surgery.
2460466|NCT03170739|Experimental|Dexmedetomidine+dopamine|Dexmedetomidine 0.5ug/kg iv follow by 0.2ug/kg/h ivpump, combined with dopamine 3ug/kg/min ivpump at the beginning of surgery.
2460467|NCT03170739|No Intervention|Control group|No intervention
2460508|NCT03170258|Experimental|Reward-related Brain Region Feedback|Participants in this group will receive neurofeedback from a reward-related brain area (e.g., VTA, PFC) using EEG and/or fMRI during the experiment.
2460509|NCT03170258|Sham Comparator|Noise Control|Participants in this group will receive sham neurofeedback. Both groups will be debriefed at the end of the study.
2460550|NCT03170011|Experimental|Intervention|The training protocol will be include 12 sessions completed over six weeks following a periodization training format. Each session will last approximately 40 minutes. At first, training will focus on high volume, low intensity, self-selected velocity with a progression to high intensity, low volume, self-selected velocity ending with a focus on power training (moderate intensity, moderate volume, high velocity movement) over the six weeks of training.
2469947|NCT03104946||sepsis|
3155824|NCT00329979||2|Femoral access
3191063|NCT00794391|Experimental|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
3191064|NCT00794391|Active Comparator|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
3191065|NCT00794430|Experimental|V3381|V3381: titrated from 100 mg bid to maximum 400 mg bid over 4 weeks followed by maintenance phase at highest tolerated dose. Total duration of treatment 13 weeks.
3191066|NCT00794430|Placebo Comparator|Placebo|Placebo to match V3381, 100 mg, given according to the same regimen.
2459495|NCT03176667|Experimental|ESP for VATS|Erector Spinae plane (ESP) block
2459497|NCT03176667|Active Comparator|ICB for VATS|Intercostal block (ICB)
2459615|NCT03176147||Pregnant women|Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice.
2459680|NCT03175848|Experimental|Chemotherapy,radiotherapy|Lymphatic metastasis patients undergoing 2 cycles of chemotherapy(TP/TC), blood metastasis patients receiving 4 cycles of chemotherapy, then patients with therapeutic evaluation for (CR+PR+SD) will undergo the radiotherapy (external irradiation plus brachytherapy) for primary lesion area , all patients completed total 6 cycles of chemotherapy (TP/TC), and finally will determine the of treatment plans of metastasis areas based on tolerance and discuss results by MDT.
2459723|NCT03175289|Active Comparator|Arm I (standard of care, home exercises)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients also perform prescribed exercises at home daily for 3 sets of 10 repetitions.
2459726|NCT03175289|Experimental|Arm II (standard of care, home exercises, EMST)|Patients receive standard of care comprising of written patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus. Patients participate in a therapy session conducted by a speech pathologist over 30 minutes once per week for 6 weeks during chemoradiation therapy. Patients perform prescribed exercises at home daily for 3 sets of 10 repetitions. Patients also participate in an EMST session over 30 minutes comprising of 5 sets of 5 repetitions daily for 5 days per week for 6 weeks during chemoradiation therapy
2459778|NCT03174964|Experimental|Treatment group|IVIg group
2459780|NCT03174964|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem as controls
2459820|NCT03174639|Experimental|Inverted and free ILM insertion|Both inverted and free ILM flaps were inserted into the macular hole
2459905|NCT03174327|Other|Hepatic Transplantation|
2459933|NCT03173755||People with normal weight|
2459937|NCT03173755||people with overweight and obesity|
2459995|NCT03173573|Experimental|Part 1 SAD FDL176 level 1 to 6|Part 1: Single dose of FDL176 test formulation Level 1 to 6 on healthy males.
2460003|NCT03173573|Placebo Comparator|Part 1 SAD Placebo|Part 1: Single dose of Placebo for FDL176.
2460013|NCT03173573|Experimental|Part 2 SAD FDL176 at fasted state|Part 2: single dose of FDL176 test formulation, fasted state.
2460022|NCT03173573|Experimental|Part 2 SAD FDL176 at fed state|Part 2: single dose of FDL176 test formulation, fed state
2460030|NCT03173573|Experimental|Part 3 SAD FDL176 test formulation|Part 3: Single dose of FDL176 test formulation on healthy females.
2460033|NCT03173573|Placebo Comparator|Part 3 SAD placebo|Part 3: Single dose of Placebo for FDL176.
2460035|NCT03173573|Experimental|Part 4 MAD FDL176 Level 1 to 3|Part 4: Dose escalation of FDL176 test formulation Level 1 to 3.
2460036|NCT03173573|Placebo Comparator|Part 4 MAD Placebo|Part 4: Dose escalation of Placebo for FDL176 Level 1 to 3.
2460037|NCT03173573|Experimental|Part 5 SAD FDL176 test formulation|Part 5: Single dose of FDL176 test formulation.
3191067|NCT00794443|Experimental|1. Monthly - Dose 1|Monthly intermittent administration, dose 1
3191068|NCT00794443|Experimental|2. Monthly - Dose 2|Monthly intermittent administration, dose 2
3191069|NCT00794443|Active Comparator|3. Daily|Daily administration
3191070|NCT00794456|Experimental|1|Association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L.
2460183|NCT03172351|Experimental|EDoF1|
2460185|NCT03172351|Active Comparator|Monofocal|
2460186|NCT03172351|Active Comparator|EDoF2|
2460236|NCT03171922|Experimental|Internet Diet|Internet Diet group have online dietary coach every 2 weeks
2460239|NCT03171922|Experimental|Clinic Diet|clinic visit based weight loss diet program group who have every 2 weeks visit at clinic.
2460327|NCT03171454|Experimental|Delayed Intrauterine Balloon therapy|In the delayed balloon group,a Foley catheter will be inserted into the uterine cavity 2 weeks after the surgery, the balloon will be inflated with normal saline (from 3ml to 5ml) then deflated, and the procedure repeated three time over 3 minutes or so, then the cavity will be flushed with 10 mls of normal saline solution after via the irrigating channel of the Foley catheter before removal. The whole procedure will be repeated a further 2 weeks later.
2460329|NCT03171454|Experimental|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
2460383|NCT03170986|Experimental|Multisectoral Agriculture and Microfinance Arm|
2460386|NCT03170986|No Intervention|Control Arm|
2460501|NCT03170336|Active Comparator|hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
3191071|NCT00794456|Active Comparator|2|Valeriana officinalis 50 mg
3191072|NCT00794495|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191073|NCT00794495|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
2459441|NCT03177213||pemphigus vulgaris patients|20 pemphigus vulgaris patients will be included in the study, either newly diagnosed or recurrent. Patients will be recruited on admission from Dermatology department and Outpatient Clinic, Assiut University Hospitals
2459446|NCT03177213||Healthy controls|10 healthy age and sex matched subjects will be included as controls.
2459480|NCT03176992|Active Comparator|Surgicel group|80 patients underwent formal curettage followed by insertion of 4 pieces of Surgicel inside the uterine cavity
2459481|NCT03176992|No Intervention|Thermal balloon ablation group|80 patients underwent thermal balloon ablation using bipolar radiofrequency electrical energy (Novasure)
2459482|NCT03176992|No Intervention|Endometrial resection group|80 patients underwent transcervical Hysteroscopic endometrial resection
3191074|NCT00794586|Experimental|FTI 80mg/20mg BID|Fosfomycin/Tobramycin combination 80mg/20 mg inhaled twice daily
3191075|NCT00794586|Experimental|FTI 160mg/40mg BID|Fosfomycin/Tobramycin combination 160 mg/40 mg inhaled twice daily
2459610|NCT03176186|No Intervention|TH/TTM|Protocol-directed standard of care (including TH/TTM) dictated by the 2015 guidelines for Post-Cardiac Arrest Care from the American Heart Association and the European Resuscitation Council. Mechanical Ventilation delivered by individual site-sanctioned ventilator.
2459611|NCT03176186|Active Comparator|TH/TTM plus Xenon|50% xenon gas in addition to standard of care, including therapeutic hypothermia/targeted temperature management (TH/TTM).
2459658|NCT03175770||Patients with benign or malign tumor in the oropharynx|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
2459701|NCT03175484||Observation TLX|surgical specialty ( including anesthesia) residents and nurses undergoing High Fidelity Simulation scenarios.
2459775|NCT03175237|Experimental|Group of Motor Patterns|For the mirror therapy protocol applied to the Motor Standard, each patient was treated with 15 mirror therapy sessions, 3 times a week for a total duration of 50 minutes. There were 4 exercises of voluntary range of motion involving the extension and mass flexion of the fingers, adduction and abduction of the fingers, pronation and supination of the forearm and elbow extension with associated shoulder elevation.
2459779|NCT03175237|Experimental|Group of Functional Activities|For the mirror therapy protocol applied to functional activities, four functional exercises were performed: fitting of pieces stimulating fine and thick gripping, stacking of cubes / cups and transfer of objects of different shapes and sizes. Each patient was treated with 15 mirror therapy sessions, 3 times a week with a total duration of 50 minutes
2459823|NCT03174600||Stroke patients|Stroke patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months
2459870|NCT03174236|Experimental|Ceftriaxone|Arm 1 IV Ceftriaxone: Participants in this group receive 80mg/kg IV ceftriaxone once a day for a minimum of 48 hours and a usual maximum of seven days.
2459875|NCT03174236|Active Comparator|Benzyl penicillin plus gentamicin|Arm 2 IV Benzyl penicillin plus gentamicin (usual care): Participants in this group receive 50 000 U/kg IV benzyl penicillin every six hours for a minimum of two days and a maximum of seven days.
2459883|NCT03174236|Experimental|Metronidazole|Arm 1 Metronidazole: Participants receive 10 to 16 mg/kg oral metronidazole twice a day for seven days.
2459886|NCT03174236|Placebo Comparator|Placebo|Arm 2 Placebo: Participants receive an oral placebo dose to match that for Metronidazole twice a day for seven days.
2459960|NCT03173703|Experimental|Test Arm|Test Arm are subjects to be implanted with test article -XenoSure patch. The interventions include: Repair/reconstruction of the diseased vessel; Implant the XenoSure patch
2459963|NCT03173703|Active Comparator|Control Arm|Test Arm are subjects to be implanted with B. Braun's Vascular-Patch.The interventions include: Repair/reconstruction of the diseased vessel; Implant the Vascular-Patch.
2460011|NCT03173391|Experimental|HMS5552|75mg BID
2460018|NCT03173391|Placebo Comparator|Placebo|BID
2460059|NCT03173040|Experimental|NiuBangZi pill group|Drug: NiuBangZi pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi pill and methotrexate
2460061|NCT03173040|Placebo Comparator|Placeo group|Drug: NiuBangZi placebo pill (4g, twice a day, 3 months, oral) Drug: methotrexate (5mg, once a week, 3 months, oral) participants should administrate both NiuBangZi placebo pill and methotrexate
2460117|NCT03172689|Other|CardioQ|CardioQ will be used as CO monitor simultaneously with the standard of care PiCCO CO monitor
2460173|NCT03172416|Other|Oxaliplatin|"3+3 dose escalation of oxaliplatin~This is a single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3),120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level.~Oxaliplatin every 6 weeks with IV nivolumab every 2 weeks~PIPAC oxaliplatin at 90mg/m2 every 6 weeks with IV nivolumab at 240mg every 2 weeks"
2460220|NCT03171974|Experimental|treatment group|The treatment group will be injected with dexamethasone instracapsular under US according to our built protocol.
2460267|NCT03171753|Experimental|Music therapy|Listening prerecorded music through an individual headset for 30 min in before the induction of anesthesia
3191076|NCT00794586|Placebo Comparator|Placebo A BID|Placebo A inhaled twice daily
3191077|NCT00794586|Placebo Comparator|Placebo B BID|Placebo B inhaled twice daily
3191078|NCT00794599|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191079|NCT00794599|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191080|NCT00794612|Experimental|1|Dermacyd Femina Pocket BR (Lactic Acid)
2459456|NCT03177447|Other|Summative evaluation trial of ENABLE CHF-PC|Single arm summative evaluation study was selected for several reasons: 1) to continue to determine recruitment feasibility; 2) retention- our prior work has demonstrated fairly equal dropouts in the intervention and control conditions, hence we believe we will be able to judge retention in a single arm design; 3) using a small randomized controlled trial (RCT) for power estimates runs a high risk of either overestimating or underestimating treatment effects; and 4) most importantly, the primary purpose of this study is to determine intervention efficacy. Therefore delivering the intervention to the maximum number of participants given the limitations of 2-year pilot funding allows the investigators to obtain the maximal input and experience with the intervention that is needed to achieve the study's Aim 1.
2459500|NCT03176862||CKD|40 patients per group of CKD from stage 2 to stage 5.
2459504|NCT03176862||Kidney transplant recipients|20 live-donor recipients will be studied pre-operatively and then followed up at 6 weeks and 1 years post-operatively.
2459512|NCT03176862||Controls|40 healthy controls and 40 hypertensive controls.
2459570|NCT03176264|Experimental|PDR001|
2459606|NCT03176121|Experimental|Oxycodone treatment|"Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate his/her background dose.~After regular time assessment of the pain score (NRS), if the pain control is inadequate (NRS ≥ 4), a total daily dose in 24hrs will be summed up for the next dose titration until reach a stable dose (as defined as total daily dose is fixed for at least two weeks)."
2459700|NCT03175523|Active Comparator|Imaging guided Bioresorbable scaffold|
2459707|NCT03175523|Experimental|QCA-guided Bioresorbable scaffold|quantitative coronary angiography guided Bioresorbable scaffold
3191081|NCT00794625|Experimental|1|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add valproate and behavioral family counseling to their treatment during Phase 2. If they do not respond to valproate, they will be switched to risperidone.
2459847|NCT03174431|Active Comparator|Continence Pessary|Participants randomized to the continence pessary will be fitted for a pessary by a clinician at enrollment and they will be taught how to remove and reinsert the device. Per usual clinical practice they will be instructed to call with any concerns and scheduled for a return visit in 2 weeks for a follow-up to assess fit and comfort and undergo refitting if necessary.
2459848|NCT03174431|Active Comparator|Disposable Intravaginal Device|Participants randomized to the intravaginal device will be given a sizing kit in the office, asked to select a size and provided with a 2-week supply of the appropriately sized devices. In accordance with manufacturer guidelines, participants will be instructed that the device is to be used for no more than 8 hours per 24-hour period and that each device is single use only. Participants will return in 2 weeks for a follow-up visit to assess fit and comfort, undergo resizing as necessary and receive an additional 2 week supply of the appropriately sized devices.
3191082|NCT00794625|Experimental|2|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add risperidone and behavioral family counseling to their treatment during Phase 2. If they do not respond to risperidone, they will switch to valproate.
3191083|NCT00794625|Placebo Comparator|3|During Phase 1, participants will receive a stimulant medication. If they do not respond to the stimulant, they will add placebo and behavioral family counseling to their treatment during Phase 2.
2459936|NCT03173729||Phase 1 Cohort 1|CRC (n = 150)
2459939|NCT03173729||Phase 1 Cohort 2|Precancerous polyps (n = 150)
2459944|NCT03173729||Phase 1 Cohort 3|Normal controls (n = 150)
2459946|NCT03173729||Phase 2 Field Test|75 patients who are high risk for CRC as described in the eligibility
2459949|NCT03173729||Phase 2 Validation Study Cohort 1|Family history of CRC (n = 330)
2459951|NCT03173729||Phase 2 Validation Study Cohort 2|LGI bleeding (n = 240)
2459955|NCT03173729||Phase 2 Validation Study Cohort 3|Patients with history of CRC (n = 75)
2459992|NCT03173352||Infant hemangioma(IH)|Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear. So, We designed the study to collect data about both epidemiology related risk ractors of infantile hemangioma in China.
3191084|NCT00794651||OA|moderate to severe osteoarthritis of the knee
3191085|NCT00794690|Experimental|black cohosh extract, liver|100 postmenopausal women
3191086|NCT00794703|Experimental|1. Micafungin|
2460221|NCT03171935|Experimental|High-Flow Nasal Cannula Oxygenation|
2460222|NCT03171935|Experimental|Noninvasive Positive Pressure Ventilation|
2460224|NCT03171935|Active Comparator|Conventional Weaning|
2460262|NCT03171714|Experimental|Derma-Stent|The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.
2460264|NCT03171714|Active Comparator|Usual Care, cotton gauze packing|Standard of care to pack a drained abscess for healing.
2460330|NCT03171389|Experimental|Cohort A|patients with primary c-KIT mutations and with either no detectable or non-exon13-secondary mutations (as measured by plasma sequencing); failure of imatinib treatment (only) Treatment with oral ponatinib 30MG (milligram) daily until progression or intolerable side effects.
2460332|NCT03171389|Experimental|Cohort B|GIST patients with primary c-KIT mutations and secondary c-KIT mutations in Exon 13; failure of imatinib treatment (only) Treatment with oral ponatinib 30MG daily until progression or intolerable side effects.
2460335|NCT03171389|Experimental|Cohort C|"GIST patients with KIT-mutations and treatment failure of imatinib, sunitinib and regorafenib.~Treatment with oral ponatinib 30MG daily until progression or intolerable side effects."
2460429|NCT03170856|Experimental|Exercise Intervention Group|Thse patients will undergo a sub-maximal exercise training as treatment for concussion.
2460595|NCT03169712|Active Comparator|CBT for PTSD|15 sessions of trauma-focused CBT
3191087|NCT00794703|Active Comparator|2. Itraconazole|
3191088|NCT00794716|Experimental|NRL972|
3191089|NCT00794742||Burn Wounds|Patients with burn wounds
3191090|NCT00794755|Active Comparator|Vitamin K|
3191091|NCT00794755|Placebo Comparator|Placebo|
3191092|NCT00794768|Experimental|Clarinex followed by Allegra|Clarinex 5 mg by mouth daily for 7 days followed by Allegra 180 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
2459655|NCT03175900|Placebo Comparator|Placebo|Drug: Placebo, pill. Patients will receive treatment with placebo for 12 weeks, Fenbid can be taken if headache is unbearable Procedure: MRI scanning （fMRI and DTI）
2459677|NCT03175536||HDHP with PDL|Enrollees switched from a high-deductible health plan (HDHP) to a HDHP with a preventive drug list (PDL)
2459678|NCT03175536||HDHP without PDL|Enrollees switched from a traditional plan to a high-deductible health plan (HDHP) without a preventive drug list (PDL). Enrollees who stayed in a HDHP without a PDL will also serve as controls for the study group who switch from HDHPs without PDLs to HDHPs with PDLs.
2459679|NCT03175536||traditional plan|Enrollees who remained in a traditional health plan with a deductible < $500
2459722|NCT03175315|Experimental|FLASH|"Intervention: Conduct of the newly developed treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH).~FLASH consists of 4 lessons focusing on empowering patients to autonomously use flash glucose monitoring (FGM) in their daily routine. Patients learn to effectively interpret the different information provided by FGM in order to improve not only glycemic control but also to improve the implementation of insulin therapy in daily life. Psychological and motivational aspects of living with diabetes and handling of the FGM are addressed as well."
2459725|NCT03175315|No Intervention|Waiting List|Diabetic patients using FGM receive treatment as usual until the last measurement point. After completion of the study, they are offered participation in the FLASH program.
2459745|NCT03175029|Experimental|TAC-302|
2459750|NCT03175029|Placebo Comparator|Placebo|
2459831|NCT03174769|Active Comparator|Normal Protein with weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~5 oz eq of protein foods for 12 wk"
2459837|NCT03174769|Experimental|High protein and weight loss|"weight loss subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age~Meal Pattern USDA Healthy U.S.-Style Eating Pattern with ~12.5 oz eq of protein foods for 12 wk"
3191093|NCT00794768|Experimental|Allegra followed by Clarinex|Allegra 180 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191094|NCT00794781|Experimental|1|
3191095|NCT00794794|Experimental|Desloratadine and Cetirizine Crossover|To compare the preference in taste between desloratadine and cetirizine.
3191096|NCT00794807|Experimental|Alefacept|
2459989|NCT03173417|Experimental|IM19 CART|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
2460078|NCT03173027|Experimental|Experimental group|Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
2460087|NCT03173027|Placebo Comparator|Placebo group|Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
2460113|NCT03172676|No Intervention|Helicobacter pylori negative patients|chronic immune thrombocytopenic purpura patients who will be diagnosed negative for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients.
2460114|NCT03172676|Active Comparator|Helicobacter pylori positive patients with intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will receive treatment of Helicobacter pylori: Amoxicillin for 14 days, Clarithromycin for 14 days and Proton pump inhibitor for one month).
2460115|NCT03172676|No Intervention|Helicobacter pylori positive patients without intervention|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for Helicobacter pylori infection using detection of Helicobacter pylori antigen in stool of these patients will not receive treatment of Helicobacter pylori during the study,these patient group will receive treatment of Helicobacter pylori after the end of the study
2460161|NCT03172390|Experimental|Cohort of patients : ascending aorta dilatation|measure of ascending aorta quality and quantity parameters by 4D Cardiac magnetic resonance
2460243|NCT03172143|Active Comparator|Mesenteric sparing ileocolic resection|Ileocolic resection without removal of the lymph nodes in the mesentery.
2460245|NCT03172143|Active Comparator|High ligation ileocolic resection|Ileocolic resection with removal of lymph nodes in the mesentery
2460298|NCT03171584|Experimental|Terbinafine group|Arm (1) will receive Terbinafine (250mg/day for 6 weeks).
2460302|NCT03171584|Experimental|Fluconazole group|Arm (2) will receive Fluconazole (300mg once weekly for 3monthes).
2460308|NCT03171584|Experimental|Itraconazole group|Arm (3) will receive Itraconazole (400mg/day for one week per month followed by 3 free weeks ,, 2 pulses for finger nail)
2460389|NCT03171116||CKD-CT|subjects with CKD stages II-V under conservative treatment
2460392|NCT03171116||CKD-HD|subjects with CKD stage V on hemodialysis
2460397|NCT03171116||RTx renal transplant|renal transplant recipients
2460399|NCT03171116||Controls|control subjects
2460461|NCT03170570|Experimental|treatment|retreatment using intensity-modulated radiotherapy for cervical cancer patients with in-field recurrence
2469948|NCT03104946||Patent Ductus Arteriosus|
3191097|NCT00794846|Experimental|Clarinex followed by Zyrtec|Clarinex 5 mg by mouth daily for 7 days followed by Zyrtec 10 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191098|NCT00794846|Experimental|Zyrtec followed by Clarinex|Zyrtec 10 mg by mouth daily for 7 days followed by Clarinex 5 mg by mouth daily for 7 days, with 5-28 days washout between treatments.
3191099|NCT00794872||1|Patients with stage 3 CKD
3191100|NCT00794872||2|Patients with stage 4 CKD
3191101|NCT00794872||3|Patients without evidence for CDK
3191102|NCT00794885|Experimental|Enalapril/folic acid|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
3191103|NCT00794885|Active Comparator|Enalapril|Enalapril maleate 10 mg per day is given
3191104|NCT00794898|Experimental|Arm 1|Remicade in the treatment of patients with active RA despite treatment with MTX.
3191105|NCT00794911|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions.
3191106|NCT00794911|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
2459696|NCT03175627|Active Comparator|Filtek One|Bulk fill composite material used for posterior tooth fillings.
2459704|NCT03175627|Active Comparator|Filtek Z250|Composite material used for incremental filling of posterior teeth.
2459733|NCT03175146|Experimental|Experimental|Stereotactic Body Radiation Therapy
2459743|NCT03174899|Experimental|Stage1:eGFR; ≥90 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. . ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2459744|NCT03174899|Experimental|Stage 2: eGFR; 60-89 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2459747|NCT03174899|Experimental|Stage 3:eGFR; 30-59 mL/min/1.73 m2|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2459749|NCT03174899|Experimental|Stage 4:eGFR; 15-29 mL/min/1.73 m2 .|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaginggradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2459752|NCT03174899|Experimental|Stage 5:eGFR; < 15 mL/min/1.73 m2.|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys-and 6 total ROIs from bilateral kidneys will be averaged for each patient. The mean ADC values will be recorded for each patient and the relationship of ADC values with CKD stage will be evaluated.
2459826|NCT03174756|Experimental|HOCl 0.025%|15 ml of Hypochlorous acid mouthwash at 0.025%
2459830|NCT03174756|Experimental|HOCl 0.05%|15 ml of Hypochlorous acid mouthwash at 0.05%
2459834|NCT03174756|Active Comparator|CHX 0.2%|15 ml of chlorhexidine mouthwash at 0.2%
2459835|NCT03174756|Active Comparator|CHX 0.025%|15 ml of chlorhexidine at mouthwash0.025%
2459839|NCT03174756|Placebo Comparator|Placebo|15 ml of Sterile water
2459899|NCT03174067|Experimental|Buprenorphine|Patient receives buprenorphine in the emergency room based on a clinical trial protocol as well as a take home prescription for buprenorphine
2459901|NCT03174067|Active Comparator|Clonidine|Patient receives clonidine in the emergency room based on a clinical trial protocol and also receives a take home prescription for clonidine
2459924|NCT03173742|Experimental|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2459925|NCT03173742|Experimental|T1, T3, T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2459926|NCT03173742|Experimental|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2459929|NCT03173742|Experimental|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2459931|NCT03173742|Experimental|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2459698|NCT03175874|Other|osteoporosis without alzheimer|Patient with osteoporosis without alzheimer hospitalized for total hip prosthesis.
2459705|NCT03175874|Other|Patient with arthrosis without alzheimer|Patient with arthrosis without alzheimer hospitalized for total hip prosthesis.
3191107|NCT00794911|No Intervention|Standard Care|
2459999|NCT03173638|Experimental|Mesenchymal stem from valladolid (MSV)|Allogenic mesenchymal stem cells from bone marrow
2460054|NCT03173157|Experimental|Value Feedback Arm|A weekly email will be sent to all inpatient, resident-staffed cardiology teams outlining best use practices from AHA/ACC statements on trans-thoracic echoacardiography and data feedback on in-hospital charges, running 13 week average usage and previous week usage of full and limited trans thoracic echocardiograms
2460126|NCT03172793|Experimental|Telavancin injection Dose 1 (7.5mg/kg)|The pharmacokinetics and tolerability of telavancin 7.5mg/kg q24h will be measured in 6 participants.
2460128|NCT03172793|Experimental|Telavancin injection Dose 2 (10mg/kg)|After completion and analysis of 7.5mg/kg group, the next 6 participants will receive 10mg/kg q24h, and pharmacokinetics and tolerability will be measured.
2460131|NCT03172793|Experimental|Telavancin injection Dose 3 (TBD)|The third arm will enroll 6 participants to receive the following dose of telavancin q24h: 7.5, 10, 12.5, or 15 mg/kg. The final dose will be selected based on pharmacokinetic studies from first 12 participants, tolerability, and pharmacodynamic modeling.
2460174|NCT03172299|Active Comparator|Injection of anti-VEGF|
2460179|NCT03172299|Placebo Comparator|false injection of anti-VEGF|
2460289|NCT03171740|Active Comparator|Dexmedetomidine|Children will receive 1mcg/kg intranasal dexmedetomidine and oral saline, 30 minutes before going to operation theater.
2460296|NCT03171740|Active Comparator|Midazolam oral solution|Children will receive 0,5mg/kg oral midazolam and intranasal saline, 30 minutes before going to operation theater.
2460361|NCT03171077|Active Comparator|Virtual Rehabilitation|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
2460363|NCT03171077|Experimental|PNF Method|A program of therapeutic exercises (G1) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes diagonal exercise scapula (anterior and posterior elevation); b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training;
2460365|NCT03171077|Active Comparator|Virtual Rehabilitation and PNF Method|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
2460458|NCT03170726|Active Comparator|arveles|Ibuprofen 800 mg in normal saline 150 cc and dexketoprofen (50 mg) before operation will be given in 30 minutes
2460459|NCT03170726|Active Comparator|intrafen|intrafen 800 mg in normal saline 150 cc before operation will be given in 30 minutes
2460460|NCT03170726|Placebo Comparator|plasebos|150 cc normal saline will be given in 30 minutes during preoperative period
3155825|NCT00329992|Experimental|Treatment group|16 sessions Brief Eclectic Psychotherapy
3155826|NCT00329992|Placebo Comparator|Control group|Minimal attention waitlist group
2460715|NCT03168958|Active Comparator|Methadone Group|Patients in this group will receive 0.4 mg/kg of methadone at induction of anesthesia
2460716|NCT03168958|Sham Comparator|Saline-Control Group|Patients in this group will receive an equal volume of saline as the active comparator group at induction of anesthesia
2460761|NCT03168685|Experimental|Experimental|"Multiple device intervention~SureSource Engage mobile application~ActiGraph Link~weight scale"
2460947|NCT03167606|Experimental|Immediate Intervention|Study participants randomized to the intervention arm will have access to the MyPEEPS Mobile for the next three months.
2460960|NCT03167606|Experimental|Delayed Intervention|Participants randomized to the delayed intervention arm will not have access to MyPEEPS Mobile and will be asked to complete their surveys every 3 months and return to the study site in 9 months for a follow-up visit (at which time they will receive the MyPEEPS Mobile intervention).
2461027|NCT03166670||study group|children with acute secretory diarrhea
2461030|NCT03166670||Control group|normal healthy children
2461093|NCT03166371|Experimental|Liposomal Glutathione (GSH)|Participants will be randomized to receive two teaspoons containing 840 mg GSH (420 mg/tsp) twice daily for 90 days after discharge from Emory University Hospital (EUH).
2461102|NCT03166371|Placebo Comparator|Placebo|Participants will be randomized to receive a placebo product identical to liposomal glutathione (GSH) twice daily for 90 days after discharge from Emory University Hospital (EUH).
2461136|NCT03165877|Experimental|Low-glycemic index|Low-glycemic index lunches and dinners (<55%)
3155827|NCT00330018|Experimental|1|PO Valganciclovir
3155828|NCT00330018|Active Comparator|2|PO Acyclovir
3155829|NCT00330044|Experimental|Drug|Carboplatin and Pemetrexed
3155830|NCT00330096|Experimental|Hesperidin-rich food|
3155831|NCT00330096|Placebo Comparator|No intervention: Placebo|
3155832|NCT00330135|Experimental|1|Sodium hyaluronate 2.5 ml - 1 injection
3155833|NCT00330135|Placebo Comparator|2|Placebo injection - 1 injection
3155834|NCT00330226||Psychopharmacotherapy|patients under antipsychotic or mood stabilizer treatment
2459755|NCT03174938|Other|COHORT B: Cognitively healthy elderly individuals (66-100 y)|"We will recruit 300 cognitively healthy individuals from the Malmö/Lund region, where we will aim to include as many individuals as possible that did participate in the Malmö Diet and Cancer study during the early 1990's. The participants will be stratified according to a) family history of dementia in first degree relatives (with onset before 80 years of age) and b) APOE 4 genotype; i.e. 25% will have no family history and no APOE 4 allele, 25% will have a family history and no APOE 4 allele, 25% will have no family history and at least one APOE 4 allele, 25% will have a family history and at least one APOE 4 allele.~FOLLOW-UP FOR 8 YEARS Every 2 years new clinical, cognitive, neurological, and psychiatric assessments will be performed as well as CSF/blood sampling.~MRI, Tau PET and Amyloid PET will be done every 4 years in all cases, and Tau PET and MRI every two years if the subject is amyloid positive at baseline."
2459757|NCT03174938|Other|COHORT C: SCD and MCI|"550 patients with either subjective cognitive decline or mild cognitive impairment will be recruited in a consecutive fashion from the Skåne University Hospital and Ängelholm Hospital. We will only include cases where the medical doctor believes that the cognitive symptoms are caused by an incipient neurocognitive disorder. For example, all cases with evidence of brain amyloid pathology (i.e. an abnormal CSF Aβ42/40 ratio) will be included.~FOLLOW-UP FOR 6 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done every 2 years. Amyloid PET will be performed at baseline and after 4 years.~A auxiliary cohort (Cohort C2) 150 cases with SCD/MCI where the doctor does not suspect incipient neurocognitive disorder, will undergo the same baseline investigations, but they will be followed up clinically only after 2, 4 and 8 y."
2459762|NCT03174938|Other|COHORT D: Dementia due to Alzheimer's disease|"300 patients with mild to moderate dementia due to Alzheimer's disease (AD) will be recruited from the Skåne University Hospital and Ängelholm Hospital in southern Sweden. We will include 50 cases aged 40-65 years of age, 200 cases aged 66-79 years of age and 50 cases aged 80-100 years of age.~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
2459764|NCT03174938|Other|COHORT E: Other dementias|"Patients with primary neurodegenerative disorders other than Alzheimer's disease will be recruited:~160 cases with Frontotemporal dementia (FTD)-related disorders, including behavioral variant of FTD (bvFTD), Progressive nonfluent aphasia (PNFA), semantic dementia (SD), Progressive supranuclear palsy (PSP), Corticobasal degeneration (CBD).~50 cases with subcortical Vascular dementia (VaD).~200 cases with either Parkinson's disease (PD), Parkinson's disease with dementia (PDD), Dementia with Lewy Bodies (DLB), Multiple system atrophy (MSA).~FOLLOW-UP FOR 2 YEARS Every 12 months new clinical, cognitive, neurological, and psychiatric assessments will be performed.~CSF/blood sampling, Tau PET (depends on further funding) and MRI will be done at baseline and after 2 years. No Amyloid PET in this group."
2459833|NCT03174457||Treatment: micafungin|Participants receive once daily by intravenous infusion.
2459904|NCT03174028|Active Comparator|laparoscopic group|laparoscopic pull-through
2459909|NCT03174028|Sham Comparator|posterior sagittal group|posterior sagittal anorectoplasty
2459950|NCT03173781|Experimental|droxidopa|"Droxidopa will be supplied in 100 and 200 mg pill sizes. The subject should administer the three doses 4 hours apart with the last dose prior to 4:00 pm (example: 8:00 am, 12:00 pm, and 4:00 pm). The proposed dosing is 100mg TID at baseline, then titrate slowly up to 600 mg TID. During titration, droxidopa or placebo, initiated at 100 mg TID was titrated upward in 100-mg TID increments every 48 hours until the subject:~Reaches the maximum permitted dosage of 600 mg TID;~Has a systolic blood pressure≥160mmHg or diastolic blood pressure ≥100mmHg after 10 minutes supine on 3 consecutive measurements; or~Experiences intolerable adverse events (AEs)."
2459953|NCT03173781|Placebo Comparator|placebo|sugar pill
2460010|NCT03173443|Experimental|single lumen tube|fiberoptic intubation with single lumen tube with bronchial blocker.
2460016|NCT03173443|Experimental|double lumen tube|fiberoptic intubation with double lumen tube.
2460070|NCT03173066|Experimental|Single Arm|Patients with a clinical concern for pulmonary embolus but not able to receive iodinated contrast will be enrolled. Ferumoxytol will be administered as a contrast agent in coordination with magnetic resonance angiography to identify patency of the cardiopulmonary vasculature.
2460118|NCT03172715|Active Comparator|ORIF (open reduction-internal fixation)|"Osteosynthesis with locking plate(s) will be performed using medial and/or lateral incision, according to morphology of the fracture. Additional osteosynthesis material will be used when necessary. The articular surface will be reduced and bone transplantation or bone substitute used if required.~Postoperatively, touch-down weight bearing will be allowed for 6 weeks, followed by 2 weeks of half-weight-bearing period. A walker or wheelchair will be used when necessary."
2460119|NCT03172715|Experimental|TKR (total knee replacement)|Arthroplasty of the knee will be performed within two weeks after the fracture. Medial parapatellar approach will be used. The minimal possible constraint of the prosthesis (cruciate retaining, posterior cruciate sacrificing or semi-constrained) will be used. A possible insufficient bone stock may be rebuilt with augments. Hinged prosthesis will be used only if stability of the medial collateral ligament is insufficient. A cemented or uncemented tibial stem extender (minimum length 50mm) will be used in all cases. Additional osteosynthesis will be used when necessary. Postoperatively, the patients will be allowed full weight bearing as tolerated.
2460157|NCT03172312||Total thyroidectomy|Patients need to do total thyroidectomy According to guidelines
2460160|NCT03172312||Hemithyroidectomy|Patients need to do Hemithyroidectomy According to guidelines
3191108|NCT00794976|Experimental|1|Dexamethasone Iontophoretic Patch (low dose)
3191109|NCT00794976|Experimental|2|Dexamethasone Iontophoretic Patch (high dose)
2460334|NCT03171311|Active Comparator|Angiographic guided PCI|Angiographic guided PCI is revascularization by percutaneous coronary intervention (PCI) and optional use of intravascular ultrasound (IVUS).
2460336|NCT03171311|Experimental|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by systematic use of intravascular optical coherence tomography (OCT)
3191110|NCT00794976|Experimental|3|Dexamethasone Passive Patch
3191111|NCT00794976|Placebo Comparator|4|Placebo Patch
3191112|NCT00794989|Experimental|Arm 1: Intervention|Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
3191113|NCT00794989|Other|Arm 2: Observational|Patients do not receive ground flaxseed.
2459800|NCT03174808|Experimental|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend group sessions led by an instructor experienced in MBSR in an academic setting.
2459827|NCT03174483|Experimental|hypertonic saline|nasal spray will be used twice daily
2459829|NCT03174483|Active Comparator|fluticasone|nasal spray will be used once daily
3155835|NCT00330252|Experimental|Alemtuzumab & Rituximab|"Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)"
3155836|NCT00330265|Experimental|1|KC-002
3155837|NCT00330265|Other|2|Conventional Wound Therapy
3155838|NCT00330304|Experimental|Isoniazid preventive therapy|HIV infected children living in a high TB prevalence area receive isonaizid prophylaxis daily, together with cotrimoxazole prohpylaxis either 3 times a week or daily.
3155839|NCT00330304|Placebo Comparator|Placebo|HIV infected children living in a high TB prevalence area receive placebo once daily
3155840|NCT00330317|Experimental|Letrozole|
2459968|NCT03173677|Active Comparator|Lipid intake|12 subjects had 300 Calories of lipids or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2459971|NCT03173677|Active Comparator|Glucose intake|12 subjects had 300 Calories of glucose or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2459974|NCT03173677|Active Comparator|Protein intake|12 subjects had 300 Calories Whey protein intake or 300 mL of water. Blood samples were drawn at 0, 1, 2, and 3 hrs post intake. There was a one week period between the 2 intakes.
2459990|NCT03173287|Experimental|Patients with hepatic biopsy|The patients having benefited from a hepatic biopsy for evaluation of the hepatic fibrosis, will benefit in 10 days of a MRI in the service of radiology of the hospital Gabriel Montpied.
2460097|NCT03173118|Other|suspected chronic pancreatitis patients|Patients with suspected chronic pancreatitis will undergo Endoscopic ultrasound elastography to assess whether this detects chronic pancreatitis.
2460101|NCT03173118|Other|Assessment of abdominal pain patients|Patients who are referred for assessment of abdominal pain without risk factors or any other tests suggesting chronic pancreatitis will undergo Endoscopic ultrasound elastography
2460150|NCT03172624|Experimental|R/M adenoid cystic carcinoma (ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
2460153|NCT03172624|Experimental|R/M SGC of any histology, except ACC (Non ACC)|Enrolled patients will be treated with nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks).
2460244|NCT03172091|Experimental|Acute rejection|Pulmonary transplant patients with acute rejection
2460247|NCT03172091|Other|Control group|Pulmonary transplant patients without acute rejection
2460312|NCT03171558|Experimental|Gastric Pull Up|Patients randomized to undergo gastric pull up surgical reconstruction of pharyngoesophageal defect.
2460315|NCT03171558|Active Comparator|Free Flap|Patients randomized to undergo free flap (anterolateral thigh or radial forearm) surgical reconstruction of pharyngoesophageal defect.
2460373|NCT03171064|Experimental|Experimental intervention arm (EX)|The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
2460375|NCT03171064|No Intervention|Wait list - control group (UC)|Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.
2460445|NCT03170700|No Intervention|Control|Participants will receive a nutrition program without parental feeding content. They will attend the nutrition program (Eating Smart • Being Active).
2460447|NCT03170700|Experimental|In-person|Nutrition program with in-person parental feeding content.
2460448|NCT03170700|Experimental|Online|Nutrition program with online parental feeding content.
2460484|NCT03170375|Experimental|Motivational Interviewing + WHEELS-I|In addition to motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan., participants in this arm will also receive an electronically-delivered tailored messaging intervention called Women's and Men's Hypertension Experiences and Emerging Lifestyle Intervention (WHEELS-I).
2460489|NCT03170375|Active Comparator|Motivational Interviewing|Participants in this arm will receive motivational interviewing-based counseling with a registered dietitian to promote adoption of the sodium-restricted Dietary Approaches to Stop Hypertension (DASH/SRD) eating plan.
2460490|NCT03170375|Experimental|DASH/SRD Diet|Participants in this arm will receive prepared, pre-packaged meals containing 1150mg of sodium.
2460492|NCT03170375|Placebo Comparator|Control Diet|Participants in this arm will receive prepared, pre-packaged meals containing 5750mg of sodium.
3155841|NCT00330369|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
3155842|NCT00330369|Experimental|Darusentan 50 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
3155843|NCT00330369|Experimental|Darusentan 100 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
3155844|NCT00330369|Experimental|Darusentan 300 mg|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks
2459816|NCT03174509|Active Comparator|Positive Pressure Extubation|Positive pressure extubation is used for patients in this group.
2459818|NCT03174509|Active Comparator|Traditional Extubation|Traditional extubation is used for patients in this group.
2459922|NCT03173716|Active Comparator|Intervention Group|DEFINITY contrast will be prepared according to package insert instructions. A dose of 1.5 mL activated DEFINITY diluted in 28.5 of preservative free saline to constitute a total volume of 30 mL will be infused at a rate of 90-120 mL/hr (1.5-2.0 mL/min). RTMPE will be performed.
2459923|NCT03173716|No Intervention|Control Arm|Echocardiograms will be performed without the use of DEFINITY contrast/RTMPE.
2459984|NCT03173625|Experimental|AC-076 sc administration - single ascending dose|On Day 1, 48 subjects will receive AC-076 at different single dose levels in a sequential manner and in a maximum of 6 dose levels, starting from 1 mg. Subjects will be followed by an observation period of 48 h. Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
2459985|NCT03173625|Placebo Comparator|Placebo|For each AC-076 dose level tested, 2 healthy male subjects will receive matching placebo in the same condition
2460043|NCT03173222|Active Comparator|EA1|
2460044|NCT03173222|Active Comparator|EA2|
2460045|NCT03173222|No Intervention|Control|
2460109|NCT03172845|Experimental|Vulnerable plaque|Thin-cap fibro atheroma (TCFA) was defined as a lipid-rich plaque with the thinnest fibrous cap thickness<65um. Plaque rupture was identified by the presence of fibrous cap discontinuity with a clear cavity formation inside the plaque. Plaque erosion is characterized by luminal thrombus and absence of the endothelium or without evidence of fibrous cap disruption. Fibro calcific plaque contains OCT evidence of fibrous tissue along with calcium that appears as a signal-poor or heterogeneous region with a sharply delineated border which is applied to larger calcifications. Calcified nodule is characterized as a signal or multiple regions of calcium protruding into the lumen, superficial calcification accompanied by substantive calcium proximal and or distal to the lesion. Thrombus is defined as a mass attached to luminal surface or floating within the lumen. It is seen as a protrusion inside the lumen of the artery with signal attenuation.
2460110|NCT03172845|Active Comparator|Without any vulnerable plaqueStable plaque|patient with bifurcation lesion undergoing baseline coronary angiography and baseline OCT.
2460158|NCT03172598|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered twice daily low dose of MT-8554 during the treatment period.
2460163|NCT03172598|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered twice daily middle dose of MT-8554 during the treatment period.
2460166|NCT03172598|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered twice daily high dose of MT-8554 during the treatment period.
2460169|NCT03172598|Experimental|MT-8554, then placebo|The study participants will receive MT-8554 (TBD mg) in the first phase, followed by placebo in the second phase
2460171|NCT03172598|Experimental|Placebo, then MT-8554|The study participants will receive placebo in the first phase, followed by MT-8554 (TBD mg) in the second phase
2460274|NCT03171467|Experimental|Salpingectomy|Opportunistic salpingectomy at the time of laparoscopic cholecystectomy
2460331|NCT03171285||Less than 35 years old|Clinical and laboratory evaluations
2460333|NCT03171285||Greater than or equal to 35 years|Clinical and laboratory evaluations
2460350|NCT03171012|Experimental|Lower limbs CRT+ PNF|Lower Limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
2460351|NCT03171012|Active Comparator|Lower limbs CRT + respiration|Lower limbs Cardiorespiratory training associated with respiration
2460352|NCT03171012|Experimental|Upper limbs CRT + PNF|Upper limbs Cardiorespiratory training associated with Proprioceptive Neuromuscular Facilitation
2460353|NCT03171012|Active Comparator|Upper limbs CRT + respiration|Upper limbs Cardiorespiratory training associated with respiration
2460414|NCT03170791|Experimental|vagal nerve stimulation intervention|All participants consented to the study will undergo an exercise session using equipment such as pedals and cylinders to facilitate activity. During the exercise session the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. Patients will be videoed during the therapy sessions to allow researchers to retrospectively count the number and type of repetitive movements successfully performed. At the end of the exercises, the stimulator clip will be removed from the patient's ear and cleaned with an alcohol disinfectant wipe ready for next use.
2460475|NCT03170531||Custom MR spine coil|
3191114|NCT00795015|Active Comparator|leuven|these patients had their IV insulin controlled by using the protocol adapted from van den Berghe et al. University of Leuven, Belgium, NEJM Nov. 2001
2459822|NCT03174782|Active Comparator|Treatment|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
2459824|NCT03174782|Placebo Comparator|Control|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
2459863|NCT03174171|Experimental|Intervention|Everolimus 0.75 mg b.i.d. orally for 14 days.
2459967|NCT03173963|Active Comparator|Drug|Empagliflozin 10mg once a day
2459969|NCT03173963|Placebo Comparator|Placebo|1 placebo tablet a day
2460017|NCT03173326|Experimental|Subarachnoid block|
2460028|NCT03173326|Active Comparator|General anesthesia|
2460066|NCT03173001||Patients with colorectal cancer|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2460072|NCT03173001||Population|The control group includes residents of Tashkent city without any complaints from gastrointestinal tract matched by gender and age to the patients with colorectal cancer.
2460080|NCT03173001||Patients with CRC without metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2460086|NCT03173001||Patients with CRC with metastases|Patients hospitalized with colorectal cancer at the Department of Coloproctology of Republican Oncology Research Center.
2460091|NCT03173001||Patients with CRC before operation|Patients hospitalized with colorectal cancer before operation at the Department of Coloproctology of Republican Oncology Research Center.
2460093|NCT03173001||Patients with CRC after operation|Patients hospitalized with colorectal cancer after operation at the Department of Coloproctology of Republican Oncology Research Center.
2460095|NCT03173001||Patients with CRC before chemotherapy|Patients hospitalized with colorectal cancer before operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
2460099|NCT03173001||Patients with CRC after chemotherapy|Patients hospitalized with colorectal cancer after operation and chemotherapy at the Department of Chemotherapy of Republican Oncology Research Center.
2460162|NCT03172585|Other|High Resolution computed tomography|Patients will be included in the study when High resolution chest computed tomography without contrast enhancement is ordered by the primary physician. Before the High resolution chest computed tomography scan, a Trans thoracic ultrasonography will be performed.
2460201|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
2460205|NCT03172117|Experimental|NEUROSTEM® (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
2460207|NCT03172117|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
2460250|NCT03171818|Experimental|Darbepoetin|Darbepoetin alfa (Aranesp, Amgen)
2460251|NCT03171818|Placebo Comparator|Placebo|Saline
3155845|NCT00330434|Other|Trial Withdrawn 2|Trial Withdrawn 2
3155846|NCT00330434|Other|Trial Withdrawn 1|Trial Withdrawn 1
3155847|NCT00330447||Studygroup|Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy
3155848|NCT00330447||Control group|Children from the general population
2460430|NCT03171207|Experimental|Start with Lite Run Gait Trainer|Patients start therapy with the Lite Run Gait Trainer device, followed by a Current Harness System in an ABAB design.
2460432|NCT03171207|Experimental|Start with Current Harness System|Patients start therapy with a Current Harness System, followed by the Lite Run Gait Trainer in an ABAB design.
2460474|NCT03170453|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
2460478|NCT03170453|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
2460510|NCT03170167||Patients|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 patient enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
2460511|NCT03170167||Parents|This is a pre-post survey study of Communitas, a pre-existing integrative medicine and mind-body skills group visit for adolescents living with chronic illness and their parents. Approximately 50-100 parent enrollees of the Communitas group visits will be recruited to participate in this survey study optionally.
2460542|NCT03169998||GDFT group|The fluid infusion is to be performed, in accordance with GDFT protocol, on the basis of cardiac index (CI), stroke volume index(SVI) and stroke volume (SV) in addition to invasively measured arterial pressure by Vigilio / FloTrac Monitor.
2460543|NCT03169998||Control group|Patients in whom the surgery was conducted without the use of EV1000/ FloTrac monitoring among those who had undergone laparoscopic hepatobiliary or pancreatic surgery in the past.
2460704|NCT03169257|Experimental|OB|Obese subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years. OB subjects will undergo for 12 months an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes.
3155849|NCT00330473|Experimental|1|Treatment options available on the market plus the option of taking Human Insulin Inhalation Powder.
3155850|NCT00330473|Active Comparator|2|Treatment Options available on the market.
3155851|NCT00330499|Experimental|A|Synchronous chemo / radiation therapy
3155852|NCT00330499|Active Comparator|B|Radiation Alone
2459832|NCT03174665||Patients with Pain|"Patients who had upper limb surgery or other trauma with a history of persistent spontaneous and/or evoked pain with duration of at least 3 months.~Patients will be recruited to the study by using a postal follow up questionnaire. Patients who judge their pain at least moderate and/or affecting daily life by will be eligible and asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed."
2459836|NCT03174665||Patients with no pain|Patients operated with nerve suture surgery after a lesion of the nerves of upper extremity will be recruited to the study by using a postal follow up questionnaire. Patients with no pain will be asked to participate. Patients will visit the Pain Clinic once. Oral and written information about the study will be provided, informed consent obtained. The affected nerve will be identified and the anatomy verified by ultrasound when needed.
2459890|NCT03174197|Experimental|Adjuvant phase (temozolomide, atezolizumab)|Patients receive temozolomide PO on days 1-5 and atezolizumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2459893|NCT03174197|Experimental|Concurrent phase (temozolomide, atezolizumab, RT)|Patients receive temozolomide PO daily on days 1-42 and atezolizumab IV over 30-60 minutes on day 1, 15, 29, and 42. Patients undergo RT 5 days per week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
3191115|NCT00795015|Active Comparator|glucommander|these subjects had IV insulin controlled by a computer program called the glucommander described by Davidson, P et al Diabetes Care Oct. 2005
3191116|NCT00795028|Active Comparator|1|Standard Care for people after a hip fracture
2460055|NCT03172858|Experimental|Intracervical Balloon Catheter Group|"The intracervical balloon catheter will be passed through the cervix either with a speculum exam or by a digital exam. Then the catheter balloon will be filled with 80 cc of sterile fluid. The catheter will be pulled to tension and taped to the patient's leg.~Patients will have the option to IV pain medication at the time of intracervical balloon placement. The intracervical balloon will remain in place for 6 hours unless it falls out spontaneously. At the 6 hour mark, a vaginal exam will assess if the intracervical balloon has pulled through the cervix or if it needs further tension. The intracervical balloon will remain in place a maximum of 12 hours. After a maximum of 12 hours in place the intracervical balloon will be removed and oxytocin will be started per protocol."
2460056|NCT03172858|Active Comparator|Immediate low-dose oxytocin infusion group|At our institution the policy for oxytocin infusion is to start at a low dose of 2mu/min and to increase by 2mu/min at 15 to 20 minute intervals based on how often uterine contractions are occuring. A specific order from a physician is required to increase the oxytocin dose above 20 mu/min. Oxytocin will be titrated per usual protocol.
2460130|NCT03172741|Placebo Comparator|Placebo group: THC (0%) / CBD (0%)|The matching dose for high THC, high CBD or mixed CBD/THC is a 1 gram placebo cigarette (THC (0%) / CBD (0%)) smoked once per day of for 3 months.
2460133|NCT03172741|Experimental|CBD group:THC (<1%) / CBD (>10%)|The dose for the CBD group (THC (<1%) / CBD (>10%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2460135|NCT03172741|Experimental|THC group: THC (>10%) / CBD (<1%) THC group|The dose for the THC group (THC (>10%) / CBD (<1%)) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2460137|NCT03172741|Experimental|Mixed group:THC (5-10%) / CBD (5-10%)|The dose for the mixed group THC (5-10%) / CBD (5-10%) ) is 1 gram medical marijuana cigarette smoked once per day for 3 months.
2460172|NCT03172286|Active Comparator|Patient treated with fake radiofrequencer|
2460176|NCT03172286|Experimental|Patient treated with radiofrequencer|
2460257|NCT03172078|Active Comparator|Target-control infusion without bispectral index monitoring|Target-control infusion (TCI) with propofol during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
2460260|NCT03172078|Active Comparator|Target-control infusion with bispectral index monitoring|Target-control infusion (TCI) with propofol and BIS monitoring during advanced endoscopic procedure e.g. endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP)
2460301|NCT03171506|Experimental|Usual care plus ketogenic diet|
2460306|NCT03171506|Placebo Comparator|Usual care plus AND diet|
2460364|NCT03171168|Active Comparator|Traditional Physical Therapy|Participants will have traditional physical therapy up to 20 sessions, up to two sessions per week. This will involve exercise and modalities as decided by the therapists and medical providers. Participants will have a home exercise program for the remainder of the year.
2460367|NCT03171168|Experimental|AposTherapy|Participants will have AposTherapy instead of traditional physical therapy over the course of one year. This will include 7 sessions of gait assessment and re-calibration with daily at home exercise with the device over the year.
2460450|NCT03170752|Experimental|Intervention group|"The screening intervention Cardiovascular Assessment Screening Program (CASP) to be implemented by NPs in the intervention group has three steps:~Identification of patients (using Eligibility for Heart Health Screening Form, Heart Health Assessment Pamphlet, Tracking Form for Heart Health Screening, Algorithm for NP to Screen);~Screening utilizing appropriate tools (Cardiovascular Screening Checklist, Heart Health Screening Website/App);~Actions to follow up on the screening results (Heart Health Screening Website/App, CV Decision Tree Algorithm)."
2460455|NCT03170752|No Intervention|Control group|The NPs in the control group will be instructed to follow usual practice to screen patients for cardiovascular disease.
2460497|NCT03170323|Experimental|Mycophenolate mofetil|Drug: Mycophenolate mofetil, high dose steroid Duration: 1 year
2460500|NCT03170323|Active Comparator|Cyclosporin|Drug: Cyclosporin, low dose steroid Duration: 1 year
2460530|NCT03170089|Active Comparator|Intervention|Professional tooth cleaning (scaling) Oral Health educational program
2460531|NCT03170089|No Intervention|Control|NO program or scaling done
2460575|NCT03169881|Experimental|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC)
2460576|NCT03169881|Placebo Comparator|Placebo|Equal volume normal saline for IV administration, or sham dosing
3191117|NCT00795028|Experimental|2|Standard Care + exercise intervention
3191118|NCT00795041||1|10 women with indication for ART with ICSI or IVF
3191119|NCT00795054||allogeneic stem cell recipients|Pediatric and adult allogeneic stem cell transplant recipients and their care givers.
2459862|NCT03174106|Experimental|Smartphone-Application|"Patients in Smartphone-Application-arm will get Access to the Application Vett, they will be learned how to use it. They will receive feedback based on their goals and tasks in the Application for one year, and they will also receive motivational Notifications through the Application, atleast once a week in the follow-up period. Patients in this arm will also have the possibility to send questions to their supervisor through the Application, in that case they will receive answer within two working days. In addition they will receive usual care which is described below."
2459864|NCT03174106|No Intervention|Control-group|Patients in the control-group will receive usual care consisting of general advice according to a heart-friendly lifestyle and follow-up by their general practitioner.
2460065|NCT03173196||Sepsis group|Patients with a septic shock or a severe sepsis (surgical and non-surgical patients), staying on Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
2460074|NCT03173196||Non-septic group|Patients without sepsis (surgical and non-surgical patients), staying at least 24 hours on an Intensive Care Unit, Non-invasive Multispectral Sonography - measurement
2460139|NCT03172728|Experimental|Therapeutic intervention- psycho-education pamphlet|"Psycho-education information (appendix 1) will be provided by research assistant in a pamphlet and audio recording, with a written referral to the women's mental health services in case symptoms arise. This psycho-education information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond within a week will be contacted by a research assistant and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
2460140|NCT03172728|No Intervention|Control group|"Control group will receive general psychoeducation about the emotional after effects of childbirth in a pamphlet and audio recording and the phone number for the women's mental health services. This psychoeducation information will be sent again by Qualtrics 4 weeks later and women will be prompted to read it again. Women who do not respond will be contacted by a research assistant within a week and reminded to respond.~In the end of the reading material, there will be a reading confirmation question. In the case that a participant will not answer this question or if the answer will suggest that the participant did not read the material, the research assistant will contact her by phone to confirm the reading."
3191120|NCT00795067||Carotid atherosclerosis group|Patients who undergo carotid ultrasound examination for carotid atherosclerosis screening
3191121|NCT00795080||1|Normal volunteers who do not have malformations in their cerebral spinal fluid (CSF)
2460314|NCT03171597|Other|conventional western medicine|Patients in this group will be treated by conventional western medicine, including anti-platelet drugss，lipid regulating drugs, coronary vasodilator, etc.
2460316|NCT03171597|Experimental|Qi deficiency and blood stasis|Patients in this group will be treated by Shuanghe Decoction at the base of conventional western medicine.
2460317|NCT03171597|Experimental|Qi stagnation and blood stasis|Patients in this group will be treated by Xuefu Zhuyu Decoction at the base of conventional western medicine.
2460318|NCT03171597|Experimental|Phlegm and blood stasis|Patients in this group will be treated by Gualou Xiebai Banxia Decoction & Danshen Decoction at the base of conventional western medicine.
2460407|NCT03170843|Experimental|O-Trac|The experimental group will use the plastic ring wound retractor for wound protection during the surgery.
2460409|NCT03170843|No Intervention|Surgical pad|The control group will use a conventional surgical pad for wound protection during the surgery.
2460499|NCT03170440|Experimental|Noninvasive nerve stimulation type I|This group will receive one type of nerve stimulation
2460502|NCT03170440|Active Comparator|Noninvasive nerve stimulation type II|This group will receive second type of nerve stimulation
2460538|NCT03170050|Experimental|YYD701-2|YYD701-2 Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2460540|NCT03170050|Active Comparator|Restylane Perlane Lidocaine|Restylane Perlane Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2460582|NCT03169829|Experimental|Hemodialysis Patients|Phosphorus and potassium homeostasis will be assessed based on the concentrations of phosphorus and potassium in blood samples collected in fasting, post-prandial, mid-afternoon, pre-dialysis states, as well as the concentrations of phosphorus-regulatory factors, calcitriol, parathyroid hormone and fibroblast growth factor-23. The participants will be transitioned gradually to a plant-rich diet
2460626|NCT03169400||Theranova treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
2460629|NCT03169400||Standard treated|We will collect pool of human sera from HD patients treated with regular bicarbonate dialysis membrane (baseline). Then, patients will be treated for 3 months with Theranove dialyzer, and sera will be collected at 1, 2, and 3 months. We will create a serum pool.
2460660|NCT03169205||preexisting Diabetes mellitus type 1|
2460663|NCT03169205||preexisting Diabetes mellitus type 2|
2460666|NCT03169205||Gestational Diabetes mellitus|
3191122|NCT00795080||2|Patients with incidentally discovered Chiari 1 DVS malformation of the cerebral spinal fluid (CSF)
3191123|NCT00795080||3|Patients with known Chiari or any other CVJ malformations undergoing a workup prior to surgery. Research images will be added to the clinically ordered exams ordered at 3 months and 1 year after surgery.
2460807|NCT03168165|No Intervention|Usual Care|Usual care, no intervention
2460812|NCT03168165|Experimental|Pain Neuroscience Education Training|The region of clinics randomized to this arm will receive PNE education, which consists of 6 weeks online training followed by an on-site training day.
2460879|NCT03167710|Experimental|dry needling, manipulation stretching|
2460885|NCT03167710|Active Comparator|manual therapy, exercise, ultrasound|
2469949|NCT03104946||Respiratory Distress Syndrome|
3191124|NCT00795093||1|552 GERD patients, partial responders to PPI treatment
3191125|NCT00795106|Active Comparator|Capsaicin patch|Patches will contain capsaicin 0.1% (500 mcg)
2459866|NCT03174119|Active Comparator|Real light exposition by the mean of Luminette®|All patients will be exposed to a real light (1500 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo ligh. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
2459868|NCT03174119|Placebo Comparator|Placebo light exposition by the mean of Luminette®|All patients will also be exposed to a placebo light (80 lux, 470 nm) during the treatment phase, 3 times per day (morning, afternoon and evening) for 60 minutes each via goggles providing light at the eyes level. Meanwhile, different assessments will be performed in order evaluating the potential effects of provided light in comparison to placebo light. Patients will be given behavioral assessments (Coma Recovery Scale-Revised, Nociception Coma Scale-Revised, brainstem reflexes,...), physiological (body core temperature, saliva, urine, heart rate, blood sample), neuroimaging and neurophysiological tools (PET, fMRI, TMS-EEG, resting-state and auditory paradigm EEG) before, during and after treatment.
3174555|NCT00624702|Active Comparator|2|Active Comparator 2 different salt formulation of Indacaterol.
2460039|NCT03173430|Experimental|Arm 1|An evaluable subject is any subject who completes two 28-day cycles of blinatumomab or discontinues blinatumomab after completion of less than one cycle due to toxicity.
2460052|NCT03172923|Active Comparator|sliding hip screw|fixation of fracture with a sliding hip screw
2460053|NCT03172923|Experimental|intramedullary nail|fixation of the fracture with an intramedullary nail
2460111|NCT03172806||Study Group|All patients included in the study. First: clinical scores were collected in all patients. Second: all patients underwent a polysomnography in order to compare this results with these of the clinical scores.
3191126|NCT00795106|Placebo Comparator|Placebo patch|Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing.
2460241|NCT03172065|Other|control group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml saline
2460242|NCT03172065|Other|Dexmedetomidine group|will receive 3.5 ml (17.5 mg) hyperbaric Bupivacaine + 0.5 ml dexmedetomidine (0.5 mic)
2460299|NCT03171649|Experimental|RETRAINER-S1 & Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session consists of 30-minute training with the RETRAINER-S1 system plus 60 minutes of conventional therapy. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2460307|NCT03171649|Active Comparator|Conventional Therapy|27 sessions, 3 sessions per week for a total of 9 weeks. Each session lasts about 90 minutes and consists of different training modalities typically used in the rehabilitation of the arm after stroke. The training session is customized on the patients' need and can be adapted to their improvement during the intervention.
2460369|NCT03171090|Active Comparator|sphenopalatine block using local anasthetic|
2460371|NCT03171090|Placebo Comparator|sphenopalatine block using saline|
2460433|NCT03170765|Experimental|GROUP A|measles vaccine at 6 months and 9 months of age
2460434|NCT03170765|Experimental|GROUP B|measles vaccine at 7.5 months and 9 months of age
2460435|NCT03170765|Active Comparator|GROUP C|measles vaccine at 9 months of age (current practice)
2460485|NCT03170427|Sham Comparator|8 mg (2 mL) levobupivacaine|8mg (2ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
2460488|NCT03170427|Active Comparator|6 mg (1.6 mL) levobupivacaine|6mg (1.6ml) levobupivacaine plus 20 µg fentanyl will be given intrathecally by spinal anesthesia. The impendance cardiography, the sensory and motor block will be monitored
2460539|NCT03170115|Experimental|Aspirin|Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
2460541|NCT03170115|Placebo Comparator|Placebo Oral Tablet|Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy
2460586|NCT03169803|Experimental|Single arm, NeuroTronik CANS Therapy System|
2460649|NCT03169413||cases|Fifty diabetic children diagnosed under the age of one year subjected to genetic analysis to study human leucocytic antigen haplotype class two (DR-DQ) and detection of mutations in the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel also possible risk factors associated with the disease.
2460650|NCT03169413||control one|Twenty five diabetic children diagnosed after the age of one year subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and possible risk factors associated with disease .
2460651|NCT03169413||control two|Twenty five healthy children matched by age subjected to genetic study to study human leucocytic antigen and possible of presence of gene mutation of the potassium channel, inwardly rectifying subfamily J member 11 gene encoding the Kir6.2 subunit of adenosine triphosphate sensitive potassium channel and exposure to similar risk factors associated with disease .
2460693|NCT03169049|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2460697|NCT03169049|Sham Comparator|Sham stimulation|Electrodes are placed over the arm for a 20 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
2460722|NCT03168776|Experimental|BuMA Supreme Coronary Stent System|
2460725|NCT03168776|Active Comparator|Xience or Promus Everolimus Stent System|
2460802|NCT03168191|Experimental|E-cigarette flavor|In this arm, subjects will receive an experimental flavor. Participants will be randomly assigned to low or high dose of nicotine.
2460803|NCT03168191|Experimental|Menthol Flavor|In this arm, subjects will receive a menthol flavor. Participants will be randomly assigned to low or high dose of nicotine.
2470002|NCT03104595|Experimental|Cohort 1|EC-18 500 mg
3191127|NCT00795119|Experimental|NIRS|Children who undergo NIRS
2459889|NCT03174392|Experimental|Resistance based training study:|Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
2459892|NCT03174392|Active Comparator|Speed based training study:|Each training session will begin by determining the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
2459927|NCT03173885|Experimental|PGS (genetic screening)|Intent to transfer single cryopreserved embryo, selection based on euploid status (after preimplantation genetic screening) and standard morphological assessment
2459930|NCT03173885|No Intervention|no PGS (no genetic screening)|Intent to transfer single cryopreserved embryo, selection based on standard morphological assessment
2459987|NCT03173599|Experimental|PNA 40mg|"Metacavir Enteric-coated Capsules,oral before meal~The beginning dose is 40mg,If no adverse effects were observed in 40 mg, the next dose group was started of 80mg."
2459993|NCT03173599|Experimental|PNA 80mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 80mg,If no adverse effects were observed in 80 mg, the next dose group was started of 160mg."
2460006|NCT03173599|Experimental|PNA 160mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 160mg,If no adverse effects were observed in 160 mg, the next dose group was started of 240mg."
2460014|NCT03173599|Experimental|PNA 240mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 240mg,If no adverse effects were observed in 240 mg, the next dose group was started of 360mg."
2460024|NCT03173599|Experimental|PNA 360mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 360mg,If no adverse effects were observed in 360 mg, the next dose group was started of 480mg."
2460029|NCT03173599|Experimental|PNA 480mg|"Metacavir Enteric-coated Capsules,oral before meal~The single dose is 480mg."
2460034|NCT03173599|Placebo Comparator|PNA Placebo|"Metacavir Enteric-coated Capsules Placebo,oral before meal~The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg"
2460062|NCT03172871|Experimental|Aripiprazole IM Depot|"Aripiprazole IM depot group (Aripiprazole IM Depot):~The first 2 weeks of the acute treatment phase IM Injection 400 mg every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase IM Injection 400/300 mg every 4 weeks + placebo（tablets）(once a day)"
2460075|NCT03172871|Active Comparator|Aripiprazole tablet|"Oral aripiprazole group (Aripiprazole tablet):~The first 2 weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day After the first two weeks of the acute treatment phase Placebo (Injection) every 4 weeks + Aripiprazole tablets 10-20 mg per day"
2460148|NCT03172637||Group A|50 female end stage renal disease patients
2460151|NCT03172637||Group B|50 normal female patients
2460198|NCT03172234|Active Comparator|amantadine group (Group A)|the patients will receive oral amantadine sulfate using the dose 100 mg 120 minutes prior to the surgery, 5 ml saline IV 5 minutes before intubation.
2460202|NCT03172234|Active Comparator|gabapentin group(Group B)|the patients will receive oral gabapentin using the dose 800 mg 120 minutes prior to surgery,5 ml saline IV 5 minutes before intubation.
2460204|NCT03172234|Placebo Comparator|control group (group C)|the patients will receive placebo oral tablet 120 minutes prior to surgery, IV fentanyl 2µ/kg in 5 ml saline 5 minutes before intubation.
2460249|NCT03171844|Experimental|Skin to skin|Implement of skin to skin
2460304|NCT03171610|Experimental|Sufentanil group|Arm Description: PCA with sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
2460309|NCT03171610|Active Comparator|Fentanyl group|PCA with fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml
2460411|NCT03171155|Experimental|XPro System|Implantation of XPro System during percutaneous vascular closure
2460468|NCT03170505||Acellular Dermal Matrix|
2460471|NCT03170505||Conchal Cartilage|
3191128|NCT00795158|Experimental|Arm 1|
2460614|NCT03169777|Experimental|Nant CRC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2460706|NCT03169101||HIV+|HIV-infected smokers: diagnosed with HIV infection and exhibiting viral load of less than or equal to 1000 copies/mL and CD4+ counts of greater than or equal to 200 cells/mm3 within 6 months prior to enrollment
2460712|NCT03169101||HIV-|HIV-uninfected smokers: negative HIV status will be confirmed by an on-site rapid HIV blood test
3174556|NCT00624702|Active Comparator|3|Active Comparator 3 different salt formulation of Indacaterol.
2460921|NCT03167424||BVS restenosis|Patients with a Bioresorbable Vascular Scaffold Restenosis
3174557|NCT00624702|Placebo Comparator|4|
3174558|NCT00624715|Active Comparator|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint"
3174559|NCT00624715|Placebo Comparator|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
3174560|NCT00624728|Experimental|A|
2459907|NCT03174314|Active Comparator|50 healthy controls|50 healthy (naive) subjects invaluable insights as well as a range of body types, cognitive abilities, and other idiosyncrasies that will keep our design and testing process from tailoring the device to a small set of individuals rather than the broader population.
2459956|NCT03173768|No Intervention|pre-intervention period|The charts of patients who were prescribed intravenous antibiotics at hospital discharge were reviewed. Appropriateness of intravenous antibiotics was assessed by ID specialists.
2459958|NCT03173768|Experimental|post-intervention period|The intervention is the charts of patients who were prescribed intravenous antibiotics at hospital discharge by the primary team were prospectively reviewed and intervened by ID team (ID specialist approval)
2460146|NCT03172611|Experimental|Plant-based diet|A defined, plant-based diet was prescribed for 4 weeks.
2460287|NCT03171402||Low fruit and vegetable consumers|Participants with low F&V consumption, as defined by 24-hr dietary recall
2460288|NCT03171402||High fruit and vegetable consumers|Participants with high F&V consumption, as defined by 24-hr dietary recall
2460394|NCT03170895|Experimental|sorafenib and Omacetaxine Mepesuccinate|"The starting dose of sorafenib will be 400 mg twice daily. Sorafenib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~OM will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with sorafenib) in 28-day cycle.~Sorafenib and OM will be continued until leukemia progression or allogeneic HSCT. Thereafter, patients will be followed up and information about disease status and survival will be collected."
2460449|NCT03170596|Experimental|Tazarotene gel arm|The treatment protocol in this arm will consist of night time application of Tazarotene 0.1% gel during the entire study period. (3 months)
2460451|NCT03170596|Active Comparator|Microneedling arm|The treatment protocol in this arm will consist of four sessions of microneedling at monthly intervals. (0, 1, 2, 3 months)
3191129|NCT00795171|Experimental|Docetaxel + Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
2460727|NCT03168945|Active Comparator|Novel diagnostics arm|The intervention is to screen a sputum specimen collected on a participant with suspected TB in the community at the point-of-contact in a mobile van using an on-site GeneXpert MTB/RIF machine
2460729|NCT03168945|Placebo Comparator|Routine screening arm|The control arm is to send a sputum specimen collected on a participant with suspected TB at the mobile van for routine smear microscopy at a laboratory
2460832|NCT03168503|Experimental|LGG+Promitor™|LGG:10^12 CFU/g Lactobacillus rhamnosus GG (commercialised as LGG) combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2460835|NCT03168503|Experimental|Promitor™|Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2460837|NCT03168503|Experimental|LGG-PB12+Promitor™|LGG-PB12:10^12 CFU/g of a pilus-less derivative L. rhamnosus GG combined with Promitor™:12g fibres/delivered of Soluble Corn Fibre (SCF) as dry powders to be consumed as 250 ml beverages at breakfast.
2460839|NCT03168503|Placebo Comparator|Maltodextrin|Maltodextrin (an oligosaccharide without prebiotic effect) 12g delivered and served as dry powders to be consumed as 250 ml beverages at breakfast.
2460862|NCT03167762|Experimental|Study group|
2460938|NCT03167580|Experimental|Ventilation with restricted PEEP level|Use of the restricted PEEP level (0 - 5 cm H2O, the lowest possible PEEP level) after intubation and during all mechanical ventilation.
2460946|NCT03167580|Active Comparator|Ventilation with liberal PEEP Level|Use of the liberal PEEP level (8 cm H2O) after intubation and during all mechanical ventilation.
2461098|NCT03166579|Experimental|Dialectical Behaviour Therapy|"Participants receive the standard 12 month DBT programme where all four modes of treatment are delivered including: individual therapy, group skills training, telephone coaching and DBT team consultation."
2461146|NCT03166020|Experimental|Rehabilitation with Interactive Table|Included patients will be invited to participate in 10 sessions, focused on the movement and manipulation of instrumented objects on interactive table with serious game, during 30 minutes per day, 5 days a week, for 14 days. An occupational therapist will be required only for patient installation in front of the table.
2461156|NCT03166020|Active Comparator|Self Rehabilitation|Included patients will be instructed to perform 10 self-rehabilitation sessions with 9 exercises (3 stretching, 3 reinforcement, 3 spot-oriented work) during 30 minutes per day, 5 days a week, for 14 days.
2461216|NCT03165578|Experimental|Neurofeedback|Neurofeedback training.
2461219|NCT03165578|Sham Comparator|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
2461258|NCT03165149|Active Comparator|Group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % )
2461262|NCT03165149|Active Comparator|Group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) a
2461267|NCT03165149|Active Comparator|Group (C)|patients will receive 3 mg / kg of Ketamine diluted by 20 ml saline (0.9 %)
2461300|NCT03164837|Experimental|68Ga-NOTA-RM26 PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-RM26 in one dose intravenously and underwent PET/CT scan 15-30 min later.
2461336|NCT03164577|Active Comparator|DARTNA|DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
2461338|NCT03164577|Placebo Comparator|Usual care plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
3191130|NCT00795171|Active Comparator|Taxotere|docetaxel 75mg/m2 day1 q 21d x 4 cycles
2461642|NCT03162601||Neurovascular|Patients to receive percutaneous neurovascular intervention
2459913|NCT03174015|No Intervention|Control|Landlords and selected tenants will be surveyed in baseline/end-line data collection only.
2459970|NCT03173690|Experimental|Intervention group|Receive medication reconciliation at the ICU, pluss medication reconciliation at the ward
2459973|NCT03173690|Other|Control group|No intervention at the ICU, medication reconciliation at the ward
2460050|NCT03172962|Experimental|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
2460051|NCT03172962|Active Comparator|Usual care (control)|Will receive the usual care at the hospital
3191131|NCT00795197||Screening Group|Screening Group
3191132|NCT00795223|Active Comparator|1|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
3191133|NCT00795223|Active Comparator|2|Injection of 0.3 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
2460228|NCT03171987|Experimental|Lidocaine patch|Lidocaine patch local application 1 piece per day for 28 days at back pain area.
2460234|NCT03171987|Active Comparator|Flurbiprofen patch|Flurbiprofen patch local application 1 piece per day for 28 days at back pain area.
2460278|NCT03171623|Experimental|SY-004 2mg|SY-004 (globalagliatin hydrochloride) 2mg by mouth, single dose
2460279|NCT03171623|Placebo Comparator|SY-004 20mg&placebo|SY-004 (globalagliatin hydrochloride) 20mg or placebo by mouth, single dose
2460280|NCT03171623|Placebo Comparator|SY-004 40mg&placebo|SY-004 (globalagliatin hydrochloride) 40mg or placebo by mouth, single dose
2460281|NCT03171623|Placebo Comparator|SY-004 80mg&placebo|SY-004 (globalagliatin hydrochloride) 80mg or placebo by mouth, single dose
2460282|NCT03171623|Placebo Comparator|SY-004 120mg&placebo|SY-004(globalagliatin hydrochloride) 120mg or placebo by mouth, single dose
2460366|NCT03171181|Experimental|UPVD non compensated|Intervention group: 30 participants with unilateral peripheral vestibular disorders. Exposed to vestibular reeducation.
2460368|NCT03171181|No Intervention|control group|Control group, to obtain reference values.
2460370|NCT03171181|No Intervention|UPVD compensated|Registered spatial orientation in a group of 30 participants with compensated lesion.
3191134|NCT00795223|Active Comparator|3|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.5% bupivacaine
3191135|NCT00795223|Active Comparator|4|Injection of 0.2 mg morphine with spinal block and perform femoral nerve block with 0.25% bupivacaine
2460679|NCT03169270|Experimental|COPD training group|COPD were required to be clinically stable at the time of study without episodes of exacerbation or oral steroid treatment in the previous four months. All COPD patients were on bronchodilators and inhaled corticosteroids. No patient presented severe co-morbidities. The intervention consists in an 8-week programe of exercise training.
2460682|NCT03169270|Active Comparator|Healthy training group|Healthy sedentary age-matched subjects were recruited from the outpatients' clinics of our hospital. The intervention consists in an 8-week programe of exercise training.
2460739|NCT03168854|Experimental|GAP Arm 1|10 subjects will receive 5 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 0, 4, 8, 12, and 20 for a maximum cumulative dose of 1000 GAP3KO bites per subject
2460749|NCT03168854|Experimental|GAP Arm 2|6 subjects will receive 3 vaccinations: the GAP3KO vaccine administered by the bite of approximately 200 infected A. Stephensi mosquitoes at weeks 8, 12, and 20 for a maximum cumulative dose of 600 GAP3KO bites per subject
2460753|NCT03168854|Active Comparator|Malaria-naive Infectivity Control Arm|6 healthy volunteers will receive challenge with wild type Plasmodium falciparum NF54 sporozoites through the bites of five infectious A. stephensi moquitoes using standard CHMI procedures
2460791|NCT03168386|Experimental|Intensive motor rehabilitation group|
2460840|NCT03168113||AD and Peanut Food Allergy|"Participants with active Atopic Dermatitis (AD) and food allergy to peanut.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Peanut skin prick test wheal ≥ 8 mm."
2460843|NCT03168113||AD and No Food Allergy|"Participants with active Atopic Dermatitis (AD) and no food allergy.* Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative skin prick test (wheal < 3 mm) to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed."
2460845|NCT03168113||Non-Atopic Health Control|"Participants that are non-atopic, healthy controls*. Twenty participants ages 4 to 17 years of age will be enrolled in this group.~*Negative for Atopic Dermatitis (AD), asthma, or allergic rhinitis; negative for food allergy; and negative by skin prick test to peanut, milk, egg, wheat, soy, shellfish mix, tree nuts, and sesame seed, and negative to environmental allergens - cat, dog, dust mite, cockroach, and local trees/grasses/weeds/molds."
2460909|NCT03167814|Active Comparator|Diet group|Diet group will be on no-fat diet including MCT-oil supplement starting right after surgery according to our pancreas ERAS-protocol.
2460911|NCT03167814|No Intervention|Normal food-group|This study group will follow normal ERAS-protocol after pancreas surgery and start normal diet after surgery. If chyle-leak is diagnosed then it will be treated with the same no-fat diet as the intervention group.
2460942|NCT03167294|Other|Single Arm|AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH
2461017|NCT03167099|Experimental|Full Weight Bearing|Participants assigned to full weight bearing after fixation of distal femur fracture.
2461022|NCT03167099|No Intervention|Partial Weight Bearing|Participants assigned to partial weight bearing, standard of care, after fixation of distal femur fracture.
2461095|NCT03166527|Other|Open Label study|open label study using Panzyga immune globulin 10% intravenous solution with no placebo.
3191136|NCT00795249|Experimental|smoker|Individuals who have a habit of chronic smoking without any coronary risk factors
3191137|NCT00795249|No Intervention|non-smoker|the age-matched healthy volunteers
2461260|NCT03165227|Experimental|BI 685509 Dose 1|
2461265|NCT03165227|Experimental|BI 685509 Dose 2|
2461269|NCT03165227|Experimental|BI 685509 Dose 3|
2459932|NCT03173742|Experimental|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
2460002|NCT03173365|Experimental|Brimonidine Tartrate|The respective palm to be treated with Brimonidine will be randomly assessed and will be matched for handedness to include equal numbers of dominant and non-dominant treated palms.
2460064|NCT03173053|Active Comparator|Search and destroy (SD) strategy|"A quick and, short topical decolonization treatment combined with systemic antibiotics for S. aureus.~Drug: Doxycycline 200mg once daily during one week Drug: Trimethoprim 200mg twice daily during one week Drug: Co-trimoxazol (Sulfamethoxazole/trimethoprim) 960mg twice daily during one week Drug: Clindamycin 600mg thrice daily during one week Drug: Clarithromycin 500mg twice daily during one week Drug: Ciprofloxacin 750mg twice daily during one week Drug: Fusidic acid (tablet) 500mg thrice daily during one week Drug: Rifampin 600mg twice daily during one week Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
2460071|NCT03173053|Active Comparator|Continuous suppression (CS) strategy|"A repeated, continuous, topical decolonization treatment of S. aureus~Drug: Mupirocin nasal ointment 20mg/g thrice daily during one week Drug: Fusidic acid ointment 20mg/g thrice daily during during five days Drug: Chlorhexidine body wash 40 mg/ml once daily during five days Drug: Betadine shampoo 75 mg/ml once daily during five days Drug: Chlorhexidine oropharyngeal rinse 2mg/ml thrice daily during five days"
2460180|NCT03172468||Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who achieve sustained return of spontaneous circulation (ROSC) following prehospital cardiopulmonary resuscitation.
2460184|NCT03172468||Non-Survivors|Patients suffering from out-of-hospital cardiac arrest (OHCA), who are declared dead after prehospital cardiopulmonary resuscitation.
2460232|NCT03172052|Experimental|streptokinase instillation|Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred and if drained fluid through the tube was <100 cc in 24 h provided that tube is patent and properly positioned.
2460233|NCT03172052|Experimental|instillation of MESNA|Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
2460238|NCT03172052|Experimental|Medical thoracoscopy procedure|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope
2460240|NCT03172052|Experimental|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
2460300|NCT03171493|Experimental|Intravesical MV-NIS therapy prior to radical cystectomy|MV-NIS will be administered via intravesical instillation as a single dose on Day 1 (7, 14, 21 or 28 days before cystectomy) or two doses on Day 1 and 15 (14 and 28 days before cystectomy).
3155853|NCT00330629|Active Comparator|Standard Behavioral Treatment|"Goal setting: daily/weekly goals for calorie and fat consumption, exercise time, and behavior change.~Self-monitoring: systematically observing and recording one's behavior,45,46 which will be reviewed by the therapists, and written feedback will be provided to reinforce positive behaviors.~Feedback: therapists monitor the recorded behavior changes and provide feedback/encouragement."
3191138|NCT00795262|Placebo Comparator|placebo comparator|Quinapril 40 mg (Accupril)plus placebo will be given for 8 weeks.
2460546|NCT03169959|Experimental|Cohort 1: Sequence 1 (ABC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2460547|NCT03169959|Experimental|Cohort 1: Sequence 2 (ACB)|"Subjects were randomized to treatment sequence 1 ACB:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2460548|NCT03169959|Experimental|Cohort 1: Sequence 3 (BAC)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2460549|NCT03169959|Experimental|Cohort 1: Sequence 4 (BCA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2460551|NCT03169959|Experimental|Cohort 1: Sequence 5 (CAB)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR without food."
2460623|NCT03169348|Experimental|study group|Hepatitis- C virus with thrombocytopenia
2459964|NCT03173911|Active Comparator|Total|composed by 12 participants who will receive the application of the bandage for all strategies in both lower limbs, being determined the application of the technique in I with fixed point in the II and III toes and moving point until the height of the last ribs , Passing through the entire posterior region. The balance of each individual will be evaluated in the force platform at four different times, before, immediately after, after 24 and 48 hours after the application of the bandage, in three different tasks of postural control in the force platform, being: unipedal right, unipedal left and task Of bipedal support in the semi-tandem position. Will be performed three evaluations of 30s each, with 30s of interval between each evaluation.
2459996|NCT03173378||Narcoleptic Patients|Type 1 and Type 2 narcoleptic adult patients usually followed at the Lyon Sleep Medicine and Respiratory Disease center
2460004|NCT03173378||Control|Adult age-matched family members of the patients
2460098|NCT03173092|Experimental|Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg|Ixazomib 4 milligram (mg), capsules, orally, once, on Days 1, 8 and 15 and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21; and dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22 of a 28-day cycle for a maximum of 39 cycles until PD or unacceptable toxicity, whichever occurs for up to 3 years.
2460326|NCT03171363|Experimental|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
2460438|NCT03170830|Experimental|Healthy control group|Age:45-75 years.Pepole who have normal ECG without the history of cardiovascular disease can be included in the healthy control group.
2460440|NCT03170830|Experimental|unstable angina disease control group|Age:>18 years.Unstable angina patients meet the diagnostic criteria.
2460441|NCT03170830|Experimental|acute myocardial infarction group|Age:>18 years.Acute myocardial infarction patients meet the diagnostic criteria.
2460487|NCT03170414||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
2460580|NCT03169764|Experimental|Nant HNSCC Vaccine|avelumab, bevacizumab, capecitabine, cetuximab, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab-paclitaxel, nivolumab, lovaza, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2460652|NCT03169439|Other|hepatic focal lesions and pancreatic masses|
2460735|NCT03168646|Active Comparator|group 1|wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur.
2460737|NCT03168646|Active Comparator|group 2|ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner.
2460882|NCT03167866|Placebo Comparator|control group|DM patients who receive a weekly informational Short Message Service (SMS) by phone for 26 weeks. informational SMS
2460888|NCT03167866|Experimental|test group|DM patients who receive a weekly motivational Short Message Service (SMS) for 26 weeks. motivational SMS
2460939|NCT03167476||RLH|This group includes subjects diagnosed with reactive lymphoid hyperplasia.
2460953|NCT03167476||Lymphoma|This group includes subjects diagnosed with lymphoma.
2461104|NCT03166410|Experimental|Cell Treatment|
3155854|NCT00330629|Active Comparator|SBT+LOV Group|In addition to SBT, participants will aim to eliminate all meat, poultry, and fish from their diet over the first 6 weeks, and will be taught how to select appropriate substitutes for these foods, such as low- or no-fat dairy products (cheeses, milk), and protein-containing vegetable sources (soy products, legumes). .
2461290|NCT03165318|Active Comparator|Pulsed Electromagnetic Field Therapy|Active Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
2461292|NCT03165318|Sham Comparator|Sham Therapy|Inactive Pulsed Electromagnetic Field therapy device; exposed once weekly for 10 minutes.
2461360|NCT03164460|Experimental|Group I (SBRT)|Patients undergo SBRT every other day for a total of 5 treatments.
2461361|NCT03164460|Experimental|Group II (IMRT/IMPT)|Patients undergo IMRT/IMPT once daily (Monday-Friday) for up to 30-35 treatments.
2461477|NCT03164044||Patients with drug allergy|Patients with drug allergy to antibiotics or NSAIDs
2461523|NCT03163407|Active Comparator|Norepinephrine group|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
2470004|NCT03104595|Experimental|Cohort 2|EC-18 1000 mg
3155855|NCT00330694|Experimental|I|Implementation of ParkNet within 8 regions
3155856|NCT00330694|Other|II|Usual Care in 8 regions
3155857|NCT00330746|Experimental|A|cetuximab and gemcitabine combination
3155858|NCT00330746|Experimental|B|gemcitabine followed by cetuximab (sequential)
3155859|NCT00330798|Experimental|Nevanac|One drop, three times daily, in the assigned eye for the first three postoperative days
3155860|NCT00330798|Placebo Comparator|Acular LS|One drop, three times daily, in the assigned eye for the first three postoperative days
3155861|NCT00330824|Experimental|antibiotic steroid (single vial)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
3155862|NCT00330824|Active Comparator|antibiotic / steroid (2 vials)|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having LASIK surgery
3155863|NCT00330902|Active Comparator|1|Sulfadoxine pyrimethamine plus three daily doses of artesunate
3155864|NCT00330902|Experimental|2|Sulfadoxine pyrimethamine plus artesunate plus primaquine
3155865|NCT00330980|Experimental|1|Participants will receive 20 mg of simvastatin for 6 months.
3155866|NCT00330980|Experimental|2|Participants will receive 40 mg of pravastatin for 6 months.
3155867|NCT00330980|Placebo Comparator|3|Participants will receive placebo for 6 months.
3155868|NCT00331032|Experimental|1: 3% w/w SPL7013 Gel|40 subjects VivaGel™.
3155869|NCT00331032|Placebo Comparator|2: Placebo|20 subjects placebo.
3155870|NCT00331045|Placebo Comparator|Placebo|
3155871|NCT00331045|Experimental|Alvimopan 0.25 mg/yday|
3155872|NCT00331045|Experimental|Alviompan 0.5 mg/day|
3155873|NCT00331045|Experimental|Alvimopan 1 mg/day|
2459966|NCT03173807|Active Comparator|standard of care|The duration of study in Arm B will be 24 months, with study assessments and interventions (review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer) done at baseline, 12 months, 15 months, 18 months and 24 months. At 12 months, participants in Arm B will be offered the same intervention that Arm A received during months 1-12.
2459991|NCT03173404|Experimental|Group I|Patients underwent hysteroscopy examination before IVF cycle.
2460000|NCT03173404|No Intervention|Group II|Patients underwent direct IVF cycle without previous hysteroscopy.
2460096|NCT03173131|Experimental|Opioid counseling group|Counseling provided to patients prior to surgery regarding opioid usage, side effect, long term effect and risks of opioids.
2460100|NCT03173131|No Intervention|No Counseling|No preoperative counseling will be provided to this group. Standard medication information will be provided only.
2460121|NCT03172650||study group|non alcoholic fatty liver disease patients
2460122|NCT03172650||Control group|fatty liver patients
3155874|NCT00331058|Other|healthy volunteers|control group not receiving prednisolone
2460253|NCT03171948|Experimental|Almond group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
2460255|NCT03171948|Experimental|Nut Free group|Nut Free group (NFG), as control group, who continue their diet without any nut consumption.
2460290|NCT03171532|Active Comparator|4 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus and Gracilis tendons will be measured after clearing all adherent muscle tissue. The ends will be prepared and folded in middle to prepare4-strand graft.
2460294|NCT03171532|Active Comparator|5 strand hamstring ACL reconstruction|The hamstring tendons will be harvested by standard technique and the lengths of the Semitendinosus (ST) and Gracilis (GR) tendons will be measured after clearing all adherent muscle tissue. For 5-strand graft, minimum length of ST and GR in consideration would be 24 cm and 16 cm respectively. For 5-strand group the ST tendon will be be folded twice and sutured on itself to make a three strand graft and then GR tendon will be folded once along with it to make a final 5-strand graft.
2460372|NCT03171246|Experimental|CD-TREAT (Solid food-based intervention)|"Solid food-based dietary intervention replicating composition of exclusive enteral nutrition (EEN).~Daily for up to 12 weeks."
2460442|NCT03170674|Experimental|FT21039 Product Use Group|Subjects will use the electronic cigarette product (FT21039).
2460443|NCT03170674|Experimental|FT21092 Product Use Group|Subjects will use the electronic cigarette product (FT21092).
2460444|NCT03170674|Experimental|FT21018 Product Use Group|Subjects will use the electronic cigarette product (FT21018).
2460446|NCT03170674|No Intervention|Abstinence Group|Subjects in the Abstinence Group will not be assigned any products.
2460647|NCT03170037|Active Comparator|Standard V-E ventilation technique|After induction of anesthesia subject will be ventilated using the standard V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
2460648|NCT03170037|Experimental|Reversal V-E ventilation technique|After induction of anesthesia subject will be ventilated using the reversal V-E ventilation technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute, I:E ratio of 1:2, peak inspiratory pressure of 20cmH2O and no PEEP. If the subjects can be adequately ventilated, as defined by perceivable chest movement and end tidal CO2 during the first three breaths, ventilation will continue for total ten breaths.
2460667|NCT03169114|Active Comparator|Amikacin injection|Antibiotic Non-Operative Management Strategy
2460669|NCT03169114|Active Comparator|Appendicectomy|Surgery Management Strategy
2460841|NCT03168230||PVE|Patients who required PVE prior to the attempt of liver resection.
2460844|NCT03168230||No-PVE|Patients who received upfront surgery (no PVE prior to the intervention)
2460894|NCT03167853|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg per 2 weeks until disease progresses or unacceptable tolerability occurs.
3155875|NCT00331058|Other|asthmatic volunteers|receive prednisolone for 14-16 days
3155876|NCT00331071||001|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE worn for 1 week and replaced for 3 consecutive weeks fourth week is patch free
3155877|NCT00331071||002|Monophasic or triphasic Oral contraceptive tablet 35 mcg EE for 21 consecutive days followed by no or drug-free tablet for 7 days
2460980|NCT03166969|Experimental|Patients taken care in neurovascular unit|
2461049|NCT03166800|Placebo Comparator|Placebo|20 subjects will receive placebo.
2461051|NCT03166800|Active Comparator|20mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 20mg of MitoQ will be administered to 20 subjects in this trial.
2461054|NCT03166800|Active Comparator|40mg oral MitoQ|MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. 40mg of MitoQ will be administered to 20 subjects in this trial.
2461137|NCT03165877|Active Comparator|Control|Medium/high glycemic index lunches and dinners (>60%)
2461689|NCT03162237|Active Comparator|AutologousTreg|Autologous Treg:2x10^6/Kg
3155878|NCT00331084|Experimental|antibiotic steroid drops/single vial|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
3155879|NCT00331084|Active Comparator|antibiotic steroids drops|efficacy of antibiotic steroid combination compared with individual administration in prevention of postoperative inflammation in patients having cataract surgery
2459980|NCT03173586||NHS|"Least-squares mean (95% CI) concentrations of biomarkers by frequency of sugar sweetened beverage (SSB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of artificially sweetened beverage (ASB) intake among participants free of diabetes and cardiovascular disease in the NHS.~Least-squares mean (95% CI) concentrations of biomarkers by frequency of fruit juice intake among participants free of diabetes and cardiovascular disease in the NHS."
2459994|NCT03173235||Infertile women|Women which desire to have children but are probable infertile between 18 and 45 year old
2460005|NCT03173235||healthy women|Healthy women without systemic diseases in the age of 18 to 45 years
3155880|NCT00331097|Active Comparator|A|Standard chemotherapy with CMF
3155881|NCT00331097|Experimental|B|Weekly docetaxel
3155882|NCT00331123|Placebo Comparator|Placebo|Placebo patch
2460178|NCT03172273|Experimental|TIPS with PTFE|Transjugular Intrahepatic portosystemic shunt with PTFE covered stents
2460181|NCT03172273|Active Comparator|paracentesis|Paracentesis with albumine invision
2460319|NCT03171376|Active Comparator|Intraorifice Group|After root canal treatment intraorifice barrier of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) placed 3mm inside canals from root canal orifice.
2460320|NCT03171376|Active Comparator|Base Group|2mm thick base of glass-ionomer cement (Ketac™ Molar, 3M ESPE ) applied uniformly on the floor of the pulp chamber after completion root canal treatment.
2460322|NCT03171376|Active Comparator|Control Group|Neither intraorifice barrier nor base applied after completion of root canal treatment.
3155883|NCT00331123|Experimental|Testosterone Patch|
3155884|NCT00331214|Sham Comparator|Placebo|placebo patch for 6 months
2460532|NCT03170063||Parkinson's Disease Subjects|Up to 30 Parkinson's Disease patients will be enrolled.
2460533|NCT03170063||Healthy Controls|Up to 20 healthy controls will be enrolled.
2460585|NCT03169842|Experimental|Cyst fluid glucose|Single arm- cyst fluid glucose will be measured from pancreatic cyst fluid aspirate
2460618|NCT03169647|Experimental|Intervention|listening-based protocol (type A)
2460620|NCT03169647|Placebo Comparator|Control|listening-based protocol (type B)
2460656|NCT03169309|Experimental|Pre and Post Intervention|One Study Arm - Quantitative and qualitative sleep quality measure will be captured at baseline (Phase I/Week 1-2), while using Brain Entrainment Technology (Phase II/Week3-4), and after using the technology.
2460662|NCT03168997|Other|Mild AD|Memantine Hydrochloride 20mg tablet per day by mouth on mild AD
2460664|NCT03168997|Other|Moderate AD|Memantine Hydrochloride 20mg tablet per day by mouth on moderate AD
2460668|NCT03168997|Other|Severe AD|Memantine Hydrochloride 20mg tablet per day by mouth on severe AD
2460741|NCT03168880|Active Comparator|A|weekly Paclitaxel chemotherapy at the dose of 100 mg/m2/week for 8 weeks as a 1-hour infusion and AC/EC (60/600 or 90/600) / 3 weekly.
2460747|NCT03168880|Experimental|B|weekly Paclitaxel at 100mg /m2/week + weekly Carboplatin AUC-2 as an infusion over 60 minutes and AC/EC (60/600 or 90/600)/ 3 weekly.
2460801|NCT03168464|Experimental|Immunotherapy + Radiation|Non-ablative radiotherapy (6GyX5) is directed to one lesion during a first immunotherapy treatment with Ipilimumab 3 mg/kg (± 24hrs from first RT dose). On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
2460889|NCT03167996|Experimental|Group B/ HealthPals|"Group B have access to HealthPals app where they will coordinate with a trained health coach Group B patients will only come into SSATHI clinic to see their doctor for an initial visit and 6 month follow up, and they will have a telephone visit with their doctor at 3 months instead of an in-clinic visit~Lab testing is the same for both Group A/ control and Group B patients"
2460895|NCT03167996|No Intervention|Group A/ Control|"Group B will not have access to HealthPals app~Group A patients will come into SSATHI clinic to see their doctor for an initial visit, a 3 month follow up, and a 6 month follow up~Lab testing is the same for both Group A/ control and Group B patients"
2460959|NCT03167463|Experimental|choanoplasty with flap|flap surgery
2460997|NCT03167034|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2460998|NCT03167034|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2461021|NCT03166644|Experimental|Control Group|Patients with major abdominal surgery
3155885|NCT00331214|Experimental|Testosterone|Testosterone patch
3155886|NCT00331279|Active Comparator|Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
3155887|NCT00331279|Placebo Comparator|Placebo|
3155889|NCT00331435|Active Comparator|1|FA-guided PDT
3155890|NCT00331435|Experimental|2|ICG-guided PDT
3155891|NCT00331487|Experimental|Pioglitazone QD|
3155892|NCT00331487|Active Comparator|Rosiglitazone QD|
3155893|NCT00331500|Experimental|Olopatadine Hydrochloride 0.2%|Olopatadine hydrochloride ophthalmic solution, 0.2%, 1 drop in each eye, once-daily in the morning for 6 weeks
3155894|NCT00331500|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop in each eye, once-daily in the morning for 6 weeks
3155895|NCT00331513|Active Comparator|Arm I (vorinostat, idarubicin)|Patients receive oral SAHA three times daily on days 1-14 and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
2460076|NCT03172988|Experimental|Dexamethasone and lipid microsphere|Dexamethasone 10 mg is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2460079|NCT03172988|Experimental|Normal saline and flurbiprofen axetil|Normal saline 2 ml is administered before anesthesia induction. Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2460085|NCT03172988|Placebo Comparator|Normal saline and lipid microsphere|Normal saline 2 ml is administered before anesthesia induction. Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
2460149|NCT03172546||Anti-IIa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti IIa anticoagulant including analysis of PK-PD genetic polymorphisms
2460152|NCT03172546||Anti-Xa users|Determination of predictors of anticoagulant activity in a prospective cohort of patients using oral anti Xa anticoagulant including analysis of PK-PD genetic polymorphisms
2460196|NCT03172182|Experimental|Virtual reality (VR) group|Immersive education using a 360-degree VR video tour at operation day
2460199|NCT03172182|No Intervention|Control Group|Conventional verbal education of preoperative proceudres
2460227|NCT03171896|Experimental|Intervention|Medical clown
2460230|NCT03171896|Sham Comparator|No Intervention|No clown in the room
2460269|NCT03171701||maturation of arteriovenous fistula|
2460339|NCT03171428||TAA|Thoraco-Abdominal Approach: those patients with liver tumors operated with the thoracic-abdominal approach
2460341|NCT03171428||AA|Abdominal Approach: those patients with liver tumors operated with the abdominal approach (without the thoracotomy)
2460378|NCT03170973|Experimental|Comparison of fatty acids before and after exercise|
2460379|NCT03170973|No Intervention|Comparison of fatty acids at baseline and 24 hours after|
2460469|NCT03170635|Other|6 week Refreshing Recess program|Education and coaching for recess supervisors to learn about how to promote positive social interaction and active play with all students during recess. Provision of play activities for students during recess that foster active play, teamwork, and inclusion of students with disabilities and/or social challenges.
2460506|NCT03170245||B thalassemia group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
2460507|NCT03170245||Control group|"Laboratory investigations :~complete blood count~renal and liver function tests~serum ferritin~lipid profile~Interleukin -6~HsC-RP~Adiponectin level~Imaging :~Abdominal ultrasound~Echocardiography~Carotid intima media thickness"
2460617|NCT03169582|Active Comparator|Avanafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil).
2460619|NCT03169582|Active Comparator|Sildenafil|Clinical evaluation of the two pharmacological interventions (Sildenafil vs Avanafil)
2460665|NCT03169010||Idiopathic Pulmonary Artery Hypertension|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to idiopathic pulmonary artery hypertension (PAH).
2460670|NCT03169010||Hereditary PAH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary PAH.
2460674|NCT03169010||Hereditary Hemorrhagic Telangiectasia|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to hereditary hemorrhagic telangiectasia associated PAH.
2460676|NCT03169010||Pulmonary Veno-Occlusive Disease (PVOD)|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to PVOD.
2460678|NCT03169010||Pulmonary Capillary Hemangiomatosis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to pulmonary capillary hemangiomatosis associated PAH
2460681|NCT03169010||Cavernous Transformation of Portal Vein|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to cavernous transformation of portal vein associated PAH
2460686|NCT03169010||CTEPH|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to chronic thromboembolism pulmonary hypertension (CTEPH).
2460687|NCT03169010||Pulmonary Takaysu Arteritis|Investigators will conduct laboratory biomarker analysis and genetic analysis to identify pathogenesis or factors related to Pulmonary Takaysu Arteritis.
2460759|NCT03168633|Experimental|patients receiving emails|"Diagnosed DM2 patients who meet inclusion criteria. the patients will receive emails containing information about DM2 as a method of reminding patients of the importance of adjusting post diagnosis life-style changes.~web-based DM2 information pages"
3191139|NCT00795262|Active Comparator|Active comparator|Quinapril 40 mg plus Alpha Lipoic Acid (ALA)on vascular effects of patients with diabetes and hypertension
3191140|NCT00795314|Active Comparator|1|Propofol-fentanyl combined anesthesia
2460877|NCT03167905|Experimental|Epidural group|Patients are assigned to receive epidural delivery system (fentanyl and ropivacaine) for labour as pain relief option.
2460883|NCT03167905|Active Comparator|Non-epidural group|Patients are assigned to receive entonox (laughing gas), meperidine (pethidine) or remifentanil (Ultiva) for labour as pain relief option.
2460933|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg once daily (QD) for 1 day|Cohort 1
2460934|NCT03167242|Experimental|KAF156 800 mg and LUM-SDF 960 mg QD for 1 day|Cohort 2
3191141|NCT00795314|Experimental|2|Propofol-butorphanol combined anesthesia
2460210|NCT03172208|Placebo Comparator|Group 3: Japanese - Placebo sc (SD)|Single dose (SD) of Placebo administered subcutaneously (sc) to Japanese participants
2460211|NCT03172208|Experimental|Group 3: White - Caplacizumab Dose 2 sc (SD)|Single dose (SD) of Caplacizumab Dose 2 administered subcutaneously (sc) to White participants
2460212|NCT03172208|Placebo Comparator|Group 3: White - Placebo sc (SD)|Single dose (SD) Placebo administered subcutaneously (sc) to White participants
2460213|NCT03172208|Experimental|Group 4: Japanese - Caplacizumab Dose 2 sc (MD)|Multiple doses (MD) of Caplacizumab Dose 2 administered subcutaneously (sc) to Japanese participants
2460215|NCT03172208|Placebo Comparator|Group 4: Japanese - Placebo sc (MD)|Multiple doses (MD) of Placebo administered subcutaneously (sc) to Japanese participants
2460275|NCT03171779||Usual practice|
2460276|NCT03171779||IPEM|Interprofessional Training in Early Identification and Multidimensional Evaluation (IPEM) of patients' palliative needs
2460277|NCT03171779||IPEM and PAS|Interprofessional Early Identification Training and Multidimensional Assessment (IPEM) of patients' palliative needs, and to the Early Care Planning (SAP)
2460345|NCT03171272|Experimental|Experimental Group|
2460346|NCT03171272|Sham Comparator|Control Group|
2460423|NCT03170921|Experimental|Angola|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2460425|NCT03170921|Experimental|Benguela|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2460427|NCT03170921|Experimental|São Bento|The rhythm performance had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
2460594|NCT03170492|Experimental|Computerized Cognitive Training|RehaCom for 480 minutes over 12 weeks.
2460598|NCT03170492|Active Comparator|Pencil-and-Paper Cognitive Training|Table-top based activities for 480 minutes over 12 weeks.
2460627|NCT03169478|No Intervention|multiple myoma control group|The control group will not have any balloon therapy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
2460630|NCT03169478|Experimental|multiple myoma IUB dilatation group|The multiple myoma study group will have Foley-catheter intrauterine balloon dilatation therapy 2 weeks and 4 weeks after hysteroscopic myomectomy. A second-look hysteroscopy will be carried out 6 weeks after the surgery.
2460657|NCT03169179|Experimental|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
2460774|NCT03168568|Experimental|Valsartan/Sacubitril|Valsartan-Sacubitril 50mg/100mg twice daily, titrated to 200mg twice daily p.o. Duration of product administration: 3 months
2460775|NCT03168568|Active Comparator|Valsartan|Valsartan 40mg/80mg twice daily, titrated to 160mg twice daily p.o Duration of product administration: 3 months
2460777|NCT03168204|Experimental|Risk of being frail experimental group|
2460780|NCT03168204|No Intervention|Risk of being frail control group|
2460782|NCT03168204|No Intervention|No/low risk of being frail|
2460788|NCT03168204|No Intervention|Risk of being frail care avoiders|
2460849|NCT03168087||0% dilution|Blood specimen which was diluted with 0% level using a plasmalyte-148 solution
2460850|NCT03168087||20% dilution|Blood specimen which was diluted with 20% level using a plasmalyte-148 solution
2460851|NCT03168087||40% dilution|Blood specimen which was diluted with 40% level using a plasmalyte-148 solution
2460852|NCT03168087||60% dilution|Blood specimen which was diluted with 60% level using a plasmalyte-148 solution
2460892|NCT03167697|Experimental|Synergy|This group will receive the new phenylalanine-free protein substitute daily for 28 days. Patients in this group intervention will be directed to consume one powder sachet (33 g) of daily made up with 100mL of water. The new substitute delivers 414 kJ, 20g protein equivalent and a combination of essential and non-essential amino acids as well a combination of vitamins and minerals.
2460899|NCT03167697|Active Comparator|Routine|This group will continue their usual dietary and/or protein substitute regimen (maximum of 1 protein substitute per day (equal to 20g protein equivalent) control) for 28 days.
2460948|NCT03167307|Experimental|Omega-3 fatty acid oil|A daily dose of 500mg EPA/ 250mg DHA in the 8 to <13 year olds, and 1000mg EPA / 500mg DHA in the 13 to <18 years olds, respectively, will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
2460958|NCT03167307|Placebo Comparator|Placebo oil|Placebo capsules will contain mostly medium chain triglycerides (MCT) and also a small amount of fish oil to mimic the fishy flavour and taste. Placebo will be added to standardized treatment according to the German S3 Guidelines for the treatment of depression in children and adolescents
2460994|NCT03166891|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
3155896|NCT00331513|Active Comparator|Arm II (vorinostat, idarubicin)|Patients receive oral SAHA three times daily and idarubicin IV over 15 minutes once daily on days 1-3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy or who reach the maximum cumulative dose of idarubicin or an equivalent anthracycline and achieve clinical benefit may continue treatment with SAHA alone 3 times daily on days 1-14 of each course, in the absence of disease progression or unacceptable toxicity.
3155897|NCT00331565|Experimental|Surgery|Bariatric surgery
2461273|NCT03165227|Placebo Comparator|Placebo|
2470011|NCT03104595|Experimental|Cohort 3|EC-18 1500 mg
3155898|NCT00331604|Experimental|A|
3155899|NCT00331604|Active Comparator|B|
3155900|NCT00331604|Active Comparator|C|
3155901|NCT00331643|Experimental|Treatment (ixabepilone)|Patients receive ixabepilone IV over 1 hour on days 1-5. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression.
3155902|NCT00331669|Placebo Comparator|1|device
3155903|NCT00331695|Experimental|1|17 alpha-hydroxyprogesterones caproate
3155904|NCT00331708|Experimental|Artesunate plus sulphadoxine-pyrimethamine|
2460237|NCT03172156||Stage I NSCLC patients after surgery with ctDNA detection|Stage I NSCLC patients;ctDNA detection
2460266|NCT03171662|Experimental|group study|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
2460337|NCT03171441||Controls|eutrophic children
2460338|NCT03171441||Overweight|Overweight children
2460340|NCT03171441||Obese|Obese children
2460381|NCT03170947|Experimental|Custom insoles|Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. Custom insoles will make with direct adaptation technique (TAD) being of pvc resin.
2460385|NCT03170947|Active Comparator|Standardized insoles|Standardized insoles will be done by Ethylene-vinyl acetate (EVA) material.
3191142|NCT00795327|Experimental|1|single arm study
3191143|NCT00795353||1. Amevive Exposure|Canadian subjects with moderate to severe chronic plaque psoriasis
3191144|NCT00795379|Experimental|IE|Participants will complete an at home four-week, intervention targeting their negative cognitions triggered by physical sensations. The goal of IE is to purposefully induce bodily sensations related to autonomic arousal so that participants can learn that those sensations are not harmful. IE and Cognitive restructuring have been found to be superior to progressive muscle relaxation as a way to avoid aversive autonomic sensations.
3191145|NCT00795379|No Intervention|2|waitlist control
3191146|NCT00795392||1|Patients assessed with ASA physical status scale
3191147|NCT00795392||2|Patients assessed with full-scale psychological factors
3191148|NCT00795405|Sham Comparator|1|No exposure to sporting events
2460590|NCT03169725|Experimental|Test group 1|Low dose (Stage2: Lot A) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2460591|NCT03169725|Experimental|Test group 2|Middle dose (Stage2: Lot B) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2460592|NCT03169725|Experimental|Test group 3|High dose (Stage2: Lot C) of investigational inactivated poliomyelitis vaccine based on Sabin strains (LBVC)
2460593|NCT03169725|Active Comparator|Comparator|Cormmercialized inactivated poliomyelitis vaccine based on Sabin strains (Imovax Polio)
2460638|NCT03169543|Experimental|Sleep deprivation|36-hours of total sleep deprivation
2460658|NCT03169192||Repeated fractures group|detection of gene mutations of osteogenesis imperfecta in single group of patients with repeated fractures then start treatment with zoledronic acid in doses children less than 5 years ( 0.025 milligram for each kilogram every 3 months for 18 months duration) children more than 5 years ( 0.05 milligram for each kilogram every 6 months for 18 months duration)
3191149|NCT00795405|Experimental|2|Exposure to sporting events
2460826|NCT03168152|Experimental|MWA|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
2460828|NCT03168152|Experimental|SBRT|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
2460876|NCT03167918|Experimental|Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate 0.5 g bid, PO
2460880|NCT03167918|Experimental|Xuefuzhuyu Decoction|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Xuefuzhuyu Decoction 100 ml bid，po
2460887|NCT03167918|Experimental|Xuefuzhuyu Decoction &Calcium dobesilate|gave each patient metformin (1000 mg, bid, PO), Mecobalamin Tablets, (0.5 mg bid, PO) and Calcium dobesilate (0.5 g bid, PO)& Xuefuzhuyu Decoction（100 ml bid，po)
2460940|NCT03167268|Experimental|Lycopene 20mg cpr/die|Lycopene is a compound belonging to carotenoid group, largely contained in tomatoes and their derivatives, which has an extreme antioxidant activity. In Dermatology, prolonged use of β-carotenoids in general and of lycopene in particular in the diet showed to be effective in skin protection from ageing, sunlight and radiotherapy damages because these compounds may accumulate in skin and thus contribute to reduce free radicals and inflammation effects.
2460954|NCT03167268|Placebo Comparator|Placebo|"Containing same excipients than the experimental Lycopene 20 mg but not active principle (Lycopene)"
2461040|NCT03166982|Experimental|laparoscopy|the tubo-ovarian abscess should be drained by interventional radiology, preferably by transvaginal or laparoscopic
2461042|NCT03166982|Experimental|ultrasound-guided puncture|The transvaginal echo guided puncture to replace the first laparoscopy because of its less invasive nature, this is a simple act, fast, possible under mild sedation, the cost is still lower than laparoscopy
2461068|NCT03166332|Active Comparator|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and mixed nuts.
2461078|NCT03166332|Active Comparator|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
2461084|NCT03166332|No Intervention|No intervention|No intervention strategy
2461246|NCT03165604|Active Comparator|Normal weight|30 normal weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
2461247|NCT03165604|Active Comparator|Over weight|30 over weight children will receive 2 types of information: standard information and positive information regarding a water drink before physical exercise
2461386|NCT03164317|Active Comparator|Intervention|Trained NCC together with electronic decision support system
2461387|NCT03164317|Other|Control|No trained NCC and electronic decision support system
3191150|NCT00795418|Experimental|CAD106|
3191151|NCT00795418|Placebo Comparator|Placebo|
2461552|NCT03163212|Experimental|Lactoferrin/FOS 100mg/kg|100 mg/kg enteral administration daily for 30 days
3191152|NCT00795444|Experimental|Maraviroc|Adult patients with HIV infection and a viral load that has been suppressed for a long period (less than 50 copies/mL for at least 2 years) while on antiretroviral therapy.The treatment group will maintain the habitual antiretroviral therapy combined with maraviroc.
2460303|NCT03171675||Preterm/Chronic Periodontitis|Included ten female patients who underwent spontaneous preterm birth and were diagnosed with chronic periodontitis upon clinical examination
2460305|NCT03171675||Preterm/Healthy Periodontium|Included ten female patients who underwent spontaneous preterm birth and who had a healthy periodontium upon clinical examination
2460310|NCT03171675||Term/Chronic Periodontitis|Included ten female patients who underwent spontaneous normal term birth and were diagnosed with chronic periodontitis upon clinical examination
2460311|NCT03171675||Term/Healthy Periodontium|Included ten female patients who underwent spontaneous normal term birth and who had a healthy periodontium upon clinical examination (Armitage1999)
2460426|NCT03171220|Experimental|Neoantigen Reactive T Cells + SHR-1210|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory;Both Fludarabine 30mg/m2/D and Cyclophosphamide 300mg/m2/D will be i.v. for 3 days before cell infusion; NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4 doses;programmed cell death-1（PD1） inhibitor SHR-1210,200mg,will be i.v. Q3 weeks for total 4 doses,2 day2 prior to each NRTs infusion;Interleukin-2 (IL-2) will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.All Patients will receive a total of 4 cycles of treatment.
2460476|NCT03170401|No Intervention|no protein supplementation|trauma subjects receiving enteral nutrition without any protein supplementation
2460480|NCT03170401|Active Comparator|protein supplementation|trauma subjects receiving enteral nutrition with additional protein supplementation
2460606|NCT03170180|Experimental|sunitinib|
2460609|NCT03170180|Experimental|gefitinib|
2460611|NCT03170180|Experimental|imatinib|
2460653|NCT03169335|Experimental|Experimental group|QL1101 + paclitaxel/carboplatin:subjects are given 15 mg/kg QL1101 on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
2460654|NCT03169335|Active Comparator|Control group|Avastin® + paclitaxel/carboplatin:subjects are given 15 mg/kg Avastin® on Day 1 of each cycle with every 3 weeks as a cycle, respectively combined with paclitaxel/carboplatin for 6 cycles (at least 4 cycles).
2460695|NCT03168984|Experimental|UCB0942|Cohort 1 (Japanese subjects): Single dose of UCB0942 (dosage regimen 1) Cohort 2 (Japanese subjects): Single dose of UCB0942 (dosage regimen 2) Cohort 3 (Japanese subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2) Cohort 4 (Caucasian subjects): Single dose of UCB0942 (dosage regimen 3) followed, after maximum 21 days, by multiple doses of UCB0942 (dosage regimen 2)
2460698|NCT03168984|Placebo Comparator|Placebo|Cohort 1 and Cohort 2: Single dose of Placebo Cohort 3 and Cohort 4: Single dose of Placebo followed, after maximum 21 days, by multiple doses of Placebo
2460742|NCT03168789|Experimental|Tension Tamer (TT)|Breathing Awareness Mediation delivered by smartphone app.
2460750|NCT03168789|Active Comparator|Lifestyle education program (SPCTL)|Healthy lifestyle education provided by text messages and links to media. Runkeeper app to log physical activity.
2460793|NCT03168477|Experimental|dry needling and spinal manipulation|
2460795|NCT03168477|Active Comparator|mobilization, exercise, modalities|
2460847|NCT03168048|Experimental|Mobile application|Patients undergoing radiotherapy will receive additional therapy support by an application installed on a mobile device
2460893|NCT03167749||Patients group|Male patients with liver cirrhosis of any etiology and severity. Laboratory tests will be done
2460902|NCT03167749||Control group|Healthy males without history or features of liver disease. Laboratory tests will be done
2460923|NCT03167450||Adults|Adults have sickle cell disease
2460925|NCT03167450||Parents|Parents with children/adults who have sickle cell disease
2460926|NCT03167450||Physicians|Physicians who have delivered healthcare to individuals living with sickle cell disease for at least a year
2460985|NCT03167164|Experimental|NANT MCC Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-051, ETBX-061, GI-6301, and haNK."
3191153|NCT00795457|Experimental|1|Patients must have undergone surgery or biopsy alone ≤16 weeks prior to study entry (no postoperative radiation or chemotherapy).
2461069|NCT03166228|Active Comparator|normal saline0.9%|0.9% saline distension media is used as long as diathermy is not in use
2461077|NCT03166228|Placebo Comparator|1.5% GLYCINE|1.5% GLYCINE DURING OPERATIVE HYSTEROSCOPY as long as diathermy is in use
2461150|NCT03166150|Experimental|Multi-modal rehabilitation program|12 weeks of various exercises
2461158|NCT03166150|Active Comparator|Pelvic Floor Physical therapy|12 weeks of standard pelvic floor physical therapy
2461238|NCT03165513|Experimental|Experimental arm|mhGAP-IG psychosocial intervention
2461279|NCT03165084|Experimental|Intervention arm|Participants in the intervention group will receive usual care, and also use a diabetesapp and a homepage and advice personally tailored according to the personal needs to provide support for them to manage e.g. food choices, exercise, medicine, blood sugars and emotional adaptation.
2461282|NCT03165084|Other|Control arm|Participants in the control group will receive usual care and also take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
2461284|NCT03165084|Other|External comparison group|An external comparison group will be recruited from two other primary health care centers in order to analyse possible Hawthorne effects.
2461327|NCT03164785|Experimental|Treatment Group|"Treatment：subjects receive Jinshuibao Capsule. ARB will be continued as a routine therapy.~Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling"
2461328|NCT03164785|No Intervention|Control Group|Patients receive a standard dose of ARB drug as a routine therapy. Counseling: subjects will follow through regular check-up and receive lifestyle and other diabetes treatment counseling
2461374|NCT03164421|Experimental|N-Acetylcysteine|N-Acetylcysteine used by clomiphene resistant pcos women
2461375|NCT03164421|Active Comparator|L-carnitine|L-carnitine used by clomiphene resistant pcos women
2470016|NCT03104595|Experimental|Cohort 4|EC-18 2000 mg
2460321|NCT03171324|Experimental|AGA 6 weeks|Iron supplementation will be started at 2mg/kg from 6 weeks of age to 1 year
2460323|NCT03171324|Experimental|AGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
2460324|NCT03171324|Experimental|SGA 6 weeks|Iron supplementation will be started from 6 weeks of age to 1 year
2460325|NCT03171324|Experimental|SGA 6 months|Iron supplementation will be started from 6 months of age to 1 year
2460390|NCT03171038|Experimental|Telemonitoring group|6 months of telemonitoring (t0-t1), followed by usual care up until common long-term stopping date (t1-t2).
2460395|NCT03171038|No Intervention|Usual care group|Usual care from t0 up until the common stopping date (t2).
2460470|NCT03170622||IBD|Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
2460516|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 1|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2460518|NCT03170206|Experimental|Binimetinib Combine with Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle~Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2460521|NCT03170206|Experimental|Binimetinib Phase 2|"Binimetinib will be administered orally twice daily~Patients will be dosed with Binimetinib continuously through the four weeks per cycle"
2460525|NCT03170206|Experimental|Palbociclib Phase 2|"Palbociclib will be administered orally once daily~Patients will be dosed with palbociclib for three weeks out of every four weeks per cycle"
2460581|NCT03169894|Experimental|MDGN-002|MDGN-002 will be supplied in vials of 150 mg/mL. MDGN-002 will be administered by SQ injection in the abdomen every 14 days at 1 of 2 dose levels: 1.0 mg/kg or 3.0 mg/kg.
2460641|NCT03169556|Experimental|video-laryngoscope guided lightwand|
2460645|NCT03169556|Active Comparator|lightwand|
2460700|NCT03169127|Experimental|Experimental Group Ibuprofen 600mg|Two Hundred healthy volunteers underwent removal of one lower third molar, will be treated to control pain, swelling and trismus with ibuprofen 600mg. Therefore, these 200 patients will be genotyped and phenotyped for these genes and their postoperative records with all data collected will be compared with the haplotypes found in the Brazilian population.
3155905|NCT00331721|Active Comparator|1|Enecadin
2460810|NCT03168529|Active Comparator|Ivabradine (Corlanor)|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving active drug for study duration.
2460813|NCT03168529|Placebo Comparator|Placebo|All subjects will complete the same number of follow-ups, dose titrations (if necessary) and study procedures however, subjects in this arm will be receiving placebo for study duration.
2460890|NCT03167970||Pill cam and EGD|Patients in this arm is requested to swallow the esophageal capsule and then undergo standard EGD.
2461038|NCT03166774||patient consulting in oncology ervice|Program of support of the sexual health in oncology by questionnaire
2461096|NCT03166501|Experimental|Treatment|Lanicemine 100mg Intravenous
2461107|NCT03166501|Placebo Comparator|Placebo|Normal saline Intravenous
2461127|NCT03165851||CAMS-2005 trial|The induction course was Daunorubicin(DNR) + Cytarabine(Ara-C) or Homoharringtonine(HHT) + Ara-C or HHT + DNR + Ara-C. There are 5 consolidation course after complete remission (CR).
2461133|NCT03165851||CAMS-2009 trial|The induction course was MAE(Mitoxantrone + Cytarabine + Etoposide) or IAE(Idamycin + Cytarabine + Etoposide). Risk-stratified therapy and dose-dense intensive chemotherapy were adopted in the consolidation therapy. After the second course of therapy, patients in remission were stratified into three risk groups: low-risk children were defined as those with t(8;21) and a white blood cell count lower than 50,000/L, inv(16), or an age younger than 2 years without any high-risk factors; high-risk children were those with CR after consolidation course 1 or induction C , or with abnormalities of monosomy 7, 5q-, t(16;21), t(9;22)(Philadelphia chromosome [Ph1]); intermediate-risk children were those who were not in either a low-risk or high-risk group. Hematopoietic stem cell transplantation (HSCT) was indicated for only relapsed patients in the second CR.
2461367|NCT03164330|No Intervention|Control|The control group takes a baseline survey, and thereafter has minimal interaction with the project, until a follow-up biometric screening is conducted during the one-year follow-up.
2461368|NCT03164330|Experimental|A25|"Group A25 is offered no compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - low compensation"
2461369|NCT03164330|Experimental|A75|"Group A75 is offered no compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - No compensation, Wellness Activities - high compensation"
2461370|NCT03164330|Experimental|B25|"Group B25 is offered moderate compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
2461475|NCT03163602|Active Comparator|Control Group 1|Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
2461866|NCT03161028|Experimental|Arm 1: Lipoic Acid|59 subjects receive oral lipoic acid 1200mg daily
3155906|NCT00331721|Placebo Comparator|2|Placebo
2460384|NCT03170960|Experimental|Dose Escalation|"Subjects will accrue in cohorts of 3-6 subjects for evaluation of cabozantinib tablet dose of either 20 mg, 40 mg, and 60 mg orally qd in combination with standard dosing regimen of atezolizumab (1200 mg infusion q3w). A standard 3 plus 3 design will be utilized to determine a recommended combination dosing regimen for the Expansion Stage."
2460388|NCT03170960|Experimental|Expansion Cohort 1|RCC subjects with clear cell histology who have not received prior systemic anticancer therapy.
2460391|NCT03170960|Experimental|Expansion Cohort 2|UC subjects (including bladder, renal pelvis, ureter, urethra) who have progressed on or after platinum-containing chemotherapy.
2460396|NCT03170960|Experimental|Expansion Cohort 3|UC subjects (including bladder, renal pelvis, ureter, urethra) who are ineligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
2460398|NCT03170960|Experimental|Expansion Cohort 4|UC subjects (including bladder, renal pelvis, ureter, urethra) eligible for cisplatin-based chemotherapy and have not received prior systemic chemotherapy.
2460400|NCT03170960|Experimental|Expansion Cohort 5|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior immune check-point inhibitor (ICI) (anti-PD1 or anti-PD-L1) therapy.
2460401|NCT03170960|Experimental|Expansion Cohort 6|CRPC subjects who have radiographically progressed in soft tissue on or after enzalutamide and/or abiraterone acetate for metastatic disease.
2460402|NCT03170960|Experimental|Expansion Cohort 7|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior immune checkpoint inhibitor (ICI) (anti-PD-1 or anti-PD-L1) therapy.
2460403|NCT03170960|Experimental|Expansion Cohort 8|Stage IV non-squamous NSCLC subjects with positive PD-L1 expression and without prior systemic anticancer therapy.
2460404|NCT03170960|Experimental|Expansion Cohort 9|Stage IV nonsquamous NSCLC subjects with sensitizing EGFR mutation who have radiographically progressed during or following prior treatment with an EGFR-targeting TKI. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
2460405|NCT03170960|Experimental|Expansion Cohort 10|RCC subjects with non-clear cell histology who have had up to one prior VEGFR-targeting TKI therapy.
2460406|NCT03170960|Experimental|Expansion Cohort 11|TNBC subjects who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
2460408|NCT03170960|Experimental|Expansion Cohort 12|OC subjects (including primary peritoneal cancer and fallopian tube cancer) who have platinum-resistant or refractory disease who have had up to two lines of prior systemic anticancer therapy.
2460410|NCT03170960|Experimental|Expansion Cohort 13|EC subjects (serous or endometrioid histology) who have radiographically progressed during or following treatment with at least one prior systemic anticancer therapy.
2460412|NCT03170960|Experimental|Expansion Cohort 14|HCC subjects (Child-Pugh score A) who have not received prior systemic anticancer therapy.
2460413|NCT03170960|Experimental|Expansion Cohort 15|GC/GEJC/LEC subjects who have radiographically progressed during or following platinum-containing or fluoropyrimidine-containing chemotherapy.
2460415|NCT03170960|Experimental|Expansion Cohort 16|CRC subjects who have radiographically progressed during or following systemic chemotherapy that contained fluoropyrimidine in combination with oxaliplatin or irinotecan.
2460416|NCT03170960|Experimental|Expansion Cohort 17|H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
2460417|NCT03170960|Experimental|Expansion Cohort 18|DTC subjects (follicular, papillary, and poorly differentiated histologies) who are radioactive iodine (RAI) refractory or deemed ineligible for treatment with RAI.
2460418|NCT03170960|Experimental|Expansion Cohort 19 (SAC)|UC subjects (including renal pelvis, ureter, urinary bladder, urethra) who have radiographically progressed on or after one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
2460419|NCT03170960|Experimental|Expansion Cohort 20 (SAC)|Stage IV non-squamous NSCLC subjects who have radiographically progressed on or after treatment with one prior ICI (anti-PD-1 or anti-PD-L1). Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
2460420|NCT03170960|Experimental|Expansion Cohort 21 (SAC)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
2460421|NCT03170960|Experimental|Expansion Cohort 22 (SAA)|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC. Subjects may be allowed to receive combination therapy at the Cohort Review Committee recommended dose following radiographic disease progression.
2460422|NCT03170960|Experimental|Expansion Cohort 23|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with one, and only one, novel hormonal therapy (NHT) (eg, abiraterone, enzalutamide, apalutamide, daralutamide) for CSPC, mCRPC, or non-metastatic CRPC
2460424|NCT03170960|Experimental|Expansion Cohort 24|Metastatic CRPC (mCRPC) subjects who have histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features who have had prior treatment with at least one NHT and have received docetaxel for mCRPC
2460588|NCT03169738|Experimental|Nant NSCLC Vaccine|avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.
2460639|NCT03169426|Experimental|Beta Blockers Carvedilol Phosphate|"Subjects are going to take beta-blocker (carvedilol, 12.5 mg once) before undergoing remote ischemic conditioning.~Intervention: taking beta-blocker"
2460431|NCT03170856|No Intervention|Usual Care Group|These patients will not undergo a sub-maximal exercise training. They will follow the exercise instructions given to them by their physician.
2460599|NCT03170479|Experimental|RUTF with Vitamin D|Two groups (arms) of malnourished children will be made, one study and one control group; Experimental arm will use RUTF and two mega doses of 200,000 IU vitamin D randomly first after 15 days of enrollment and second after 15 days of first dose.
2460604|NCT03170479|Placebo Comparator|RUTF with Placebo|Placebo arm will receive Ready to Use Therapeutic Food (RUTF) and extra virgin olive oil as Placebo.
2460624|NCT03169465|Experimental|open group|patients with posterior calcaneal deformity
2460628|NCT03169465|Active Comparator|endoscopic group|patients with posterior calcaneal deformity
2460659|NCT03169218|Experimental|Mirror therapy group|Mirror therapy group: exercises looking at the reflection in the mirror of the hand moving
2460661|NCT03169218|Placebo Comparator|Placebo group|Placebo group: exercises performed with the mirror turned to avoid the reflection of the hand and looking at the hand that did not remain hidden.
2460751|NCT03168867|No Intervention|Standard Educational Control|Participants in the standard educational control group will be provided with standard care regarding type 1 diabetes management during their routine clinic visits as usual. The standard care will be consistent with diabetes education provided by each of the study sites.
2460754|NCT03168867|Experimental|The 3Ms Intervention + Standard Care|Parents will complete the first intervention session in the diabetes clinic immediately after baseline data collection and randomization. The subsequent two intervention sessions will also be conducted during regularly scheduled diabetes clinic visits.
3155907|NCT00331838|Experimental|Semuloparin 5 mg|Semuloparin sodium 5 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3155908|NCT00331838|Experimental|Semuloparin 10 mg|Semuloparin sodium 10 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3191154|NCT00795457|Experimental|2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥6 months prior to enrollment, and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression.
2460853|NCT03168061|Experimental|NC-6300|"In Part 1, patients will receive an intravenous infusion of NC-6300 at escalating doses starting at a fixed dose on Day 1 of a 21-day cycle. After enrollment of the initial patient, the first patient in each cohort will not be enrolled until all patients at the immediately lower cohort have completed at least 1 full 21-day cycle. In Part 1, patients will continue to receive treatment until they experience disease progression, experience unacceptable toxicity, or withdraw voluntarily.~Part 2 will begin after the RPII dose of NC-6300 is identified. All patients in Part 2 will receive NC-6300 at the RPII dose."
2460870|NCT03167658|Experimental|Treatment|Employees at treatment worksites will be given access to workplace wellness programming. Participation by employees will be voluntary, but all employees at treatment sites will be considered as part of the treatment group. Employees will also be invited to complete on-site biometric assessments and questionnaires. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2460871|NCT03167658|No Intervention|Primary Control|Employees at primary control worksites will be invited to complete on-site biometric assessments and questionnaires, but will not have access to the workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2460873|NCT03167658|No Intervention|Secondary Control|Employees at secondary control worksites will not participate in in-person screenings or questionnaires, and will not have access to workplace wellness programming. Data from secondary data sources (including employment records and health insurance claims) will be collected for employees at all BJ's worksites.
2460945|NCT03167528|Experimental|Lung transplant|"Patients who must undergo a lung transplant at the FOCH hospital.~Before and after transplantation, patients benefits of learning and realization sessions of complementary techniques:~Relaxation,~Hypnosis,~Holistic gymnastics,~Transcutaneous electrical nerve stimulation (TENS),~Sophrology."
2461018|NCT03166852|Experimental|Home-training group|High-intensity training at home 3 times/week for 5 weeks
2461066|NCT03166566|Other|laminar drainage implant surgery|patients included and operated
2461145|NCT03166163|Experimental|Azadirachta indica (Neem extract)|its herbal mouthwash that will be given to a group a Egyptian children twice a day(10 ml each) for 3 weeks
2461153|NCT03166163|Active Comparator|chlorhexidine mouthwash|its an antimoicrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily(10 ml each) for 3 weeks
2461224|NCT03165500|Active Comparator|Diazepam|Sedation of the anxious patient with diazepam 5 mg for measuring vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2461227|NCT03165500|Active Comparator|Midazolam|Sedation of the anxious patient with midazolam 7.5 mg for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2461230|NCT03165500|Active Comparator|Nitrous Oxide + Oxygen Gas|Inhaled sedation of the mixture of 40% of nitrous oxide and 60% of oxygen gas for measurement of vital signs (blood pressure, heart rate, oxygen saturation) in the pre, trans and postoperative periods of third molar extraction.
2461381|NCT03164187||Diabeton MR 60|
2461419|NCT03163901|Active Comparator|Treatment groups|To recruit and organize patients with TBI enrolled in a standard rehabilitation program into three groups ((a) treatment group receiving OMT; (b) control group A receiving sham treatment; and (c) control group B receiving neither OMT nor sham treatment) in order to assess the feasibility and adherence to the protocol and determine participation and attrition rates in preparation for a larger study.
2461481|NCT03163602|Active Comparator|Test Group 2|Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)
2471864|NCT03092440||"Nursing students group"|nursing students
3155909|NCT00331838|Experimental|Semuloparin 20 mg|Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3155910|NCT00331838|Experimental|Semuloparin 40 mg|Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
2460578|NCT03169751||PNES Cohort|Participants who experience a non-epileptic event with upper extremity motor involvement, while enrolled in the trial
2460579|NCT03169751||Epileptic Cohort|Participants who experience an epileptic event with upper extremity motor involvement, while enrolled in the trial
2460613|NCT03169660|Experimental|Treatment group|Eyes with submacular hemorrhage secondary to exudative age-related macular degeneration and were treated with vascular endothelial growth factor trap-eye.
2460634|NCT03169322|Active Comparator|Test Group|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing (SRP)
2460637|NCT03169322|Active Comparator|Control Group|Nose breathers having chronic periodontitis will receive scaling and root planing (SRP)
2460717|NCT03169140|Active Comparator|Group 1|Receive a combination of products (TheraBand Kinesiology Tape and Biofreeze) to use for one week for at home pain management.
2460718|NCT03169140|Active Comparator|Group 2|Receive TheraBand Kinesiology Tape product to use for one week for at home pain management.
2460719|NCT03169140|Active Comparator|Group 3|Receive a topical product, Biofreeze, to use for one week for at home pain management
2460720|NCT03169140|Active Comparator|Group 4|Receive advice sheet outlining at home pain management strategies to use for one week.
2460743|NCT03168620|Active Comparator|ITR group|In ITR group after partial caries removal(PCR), interim therapeutic restoration of glass ionomer cement (GIC) Ketac molar was placed for one month before definitive adhesive restoration
2460746|NCT03168620|Active Comparator|Non ITR group|In NON-ITR group, cavity preparation was similar to ITR group, but definitive restoration was done in the same visit
2460827|NCT03168490|Active Comparator|1.5g low gluten friendly bread|1.5g low gluten friendly bread as15g bun/day to be consumed as 250 ml beverages at breakfast for 14 days
2460829|NCT03168490|Active Comparator|3g medium gluten friendly bread|3g medium gluten friendly bread as 30g bun to be consumed as 250 ml beverages at breakfast for 14days
2460830|NCT03168490|Active Comparator|6g high gluten friendly bread|6g high gluten friendly bread as 60g bun to be consumed as 250 ml beverages at breakfast for 14 days
2460831|NCT03168490|Placebo Comparator|Control bread|Placebo control bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
2460833|NCT03168490|Placebo Comparator|Gluten free bread|Gluten bread as 15g bun to be consumed as 250 ml beverages at breakfast for 14 days
2460874|NCT03167840|Experimental|Physical training alone (PT)|Physical Training (flexibility, endurance, strengthening, and balance training) for 60-90 minutes 3x/week over 12 weeks of moderate intensity.
2460875|NCT03167840|Experimental|Cognitive training alone (CT)|Cognitive training with a focus on orientation, memory, attention and executive functioning for 60-90 minutes per session, once per week for 12 weeks.
2460881|NCT03167840|Experimental|Physical and cognitive training (PACT)|Integrated cognitive training in physical exercise for 60-90 minutes per session, 3x/week over 12 weeks.
2460886|NCT03167840|No Intervention|Wait-list group (WG)|The control group on wait-list. They will be instructed to go on with their usual activities and will receive the intervention, combined physical and cognitive training, at a later date.
2460922|NCT03167333|Experimental|PRP group|the patients received PRP(platelet-rich-plasma) injection twice at 2-week intervals
2460924|NCT03167333|Active Comparator|HA group|the patients received HA(hyaluronic acid) injection twice at 2-week intervals
2461043|NCT03167138|Experimental|Autologous micro-fragmented adipose tissue|Injection (under ultrasound guidance) of autologous micro-fragmented adipose tissue obtained from abdominal region or thighs using the Lipogems® system.
2461067|NCT03166293|Experimental|Immediate Group|Children will participate in intensive leg training with a physical therapist 1 hour/day, 4 days/week for 12 weeks. Children will continue to receive standard physical therapy care. Children will be followed for one year from the time of enrollment in the study.
2461076|NCT03166293|Experimental|Delay Group|Children will be monitored for 3 months with no intervention. Children will participate in intensive leg training with a physical therapist after the 3 month delay period. Training will be 1 hour/day, 4 days/week for 12 weeks. They will continue to receive standard care throughout. Children will be followed for one year from the time of enrollment in the study.
2461126|NCT03166137|Experimental|Carbon dioxide laser group|(group A): thirty patients will be treated by application of carbon dioxide laser.
2461130|NCT03166137|Active Comparator|Cryotherapy group|(group B): thirty patients will be treated by cryotherapy application.
2461189|NCT03165708||anesthesiologist|The active comparators for this study will be expert anaesthesiologists (operator). The operators will be blinded to all visual and audible CompuFlo® real-time pressure feedbacks.Inter-rater agreement, or concordance, between an expert anaesthesiologist and the CompuFlo® Epidural Computer Controlled System for the epidural space verification will be assessed by blinded tagging of the operator's feeling of the ligamenta and epidural space on the screen of the Compuflo to be eventually compared with the pressure's variations
2461225|NCT03165396|Experimental|Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 2.0~2.5μg/ml ）for maintaining
2461226|NCT03165396|Experimental|1.2 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 1.2 μg/ml ）combined with appropriate sevoflurane for maintaining
2461229|NCT03165396|Experimental|0.6 μg/ml Propofol|administrated Target Controlled Infusion （TCI）of propofol （Cp 0.6 μg/ml ）combined with appropriate sevoflurane for maintaining
2461231|NCT03165396|Experimental|Sevoflurane|administrated 1.3 minimum alveolar concentration（MAC ） sevoflurane for maintaining
2461497|NCT03163966|Experimental|Placebo|CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
2471867|NCT03092440||"New nurses group"|Nurses with < 2 years experience
3191155|NCT00795470|No Intervention|No catheter change no antimicrobial|Urinary catheter will not be changed and no antimicrobials will be prescribed
2460491|NCT03170466|Experimental|Primary Palliative Care|The intervention will be delivered through four primary mechanisms. First, an existing HF nurse will deliver the intervention to patients during regularly scheduled visits. Second, telephone calls will reinforce topics. Third, patients will regularly report symptoms through the MyUPMC patient portal. Fourth, the nurse will act as a liaison to communicate concerns to the patient's cardiologist and primary care physician, as well as facilitating other resources (e.g., home health). In addition, follow-up assessments will be completed via phone or email at least 2 weeks post-intervention delivery. Caregivers will complete surveys during the first in-person visit and then during the follow-up assessments.
2460493|NCT03170466|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality HF care provided to all patients. Control patients may still receive palliative care outside of the study.
3155911|NCT00331838|Experimental|Semuloparin 60 mg|Semuloparin sodium 60 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
2460605|NCT03169933|Other|intensified and modulated adjuvant RT|All patients underwent combined, intensified and modulated adjuvant radiotherapy for 5 days a week with the following doses: 1) pelvic node irradiation (45 Gy; 1.8 Gy/fraction) followed by boost on the prostate bed (19.8-25.2 Gy; 1.8 Gy/fraction; total dose: 64.8-70.2 Gy) or 2) exclusive prostate bed irradiation (64.8 -70.2 Gy; 1.8 Gy/fraction).
2460672|NCT03169387|Experimental|Virtual Reality|Microsoft's Xbox 360® will be used with Kinect™,
2460675|NCT03169387|Active Comparator|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training
2460744|NCT03168828|Experimental|TAR-302-5018|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
2460805|NCT03168451|Experimental|Intervention|Members of the intervention group will receive culturally tailored text messages encouraging them to quit smoking. They will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
2460809|NCT03168451|No Intervention|Control|Members of the control group will receive data collection text messages at 6, 12, 18, and 26 weeks post target quit date, assessing their current tobacco smoking behavior.
3191156|NCT00795470|Active Comparator|Antimicrobial and catheter change|
3191157|NCT00795470|Active Comparator|Catheter change and NO antimicrobial|
2460919|NCT03167593|Placebo Comparator|Control|Capsules containing 300 mg of maltodextrin.
2460920|NCT03167593|Experimental|Probiotic|Capsules containing 3x10(9) colon-forming units of the strain L. coryniformis K8 CECT5711 in a matrix of maltodextrin.
2460967|NCT03167190|Other|Control|Traditional landmark-based lumbar puncture technique by palpation
2460972|NCT03167190|Experimental|Experimental (ultrasound)|Use of point-of-care ultrasound to identify bony landmarks.
2461011|NCT03166917|Experimental|3D printing implant|3D printing implant in bone defect
2461015|NCT03166917|Placebo Comparator|Autogenous bone grafting|autogenous bone grafting in bone defect
2461112|NCT03166488|Experimental|Tricuspid Valvular Repair Patients|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE) within 1 month preoperatively and as close to 6 months postoperatively as reasonably achievable.
2461139|NCT03165942|Experimental|Alcoholic Beverage|Participants will complete an MRI and oral alcohol session.
2461144|NCT03165942|Placebo Comparator|Non-Alcoholic Beverage|Participants will complete an MRI and oral non-alcoholic session.
2461257|NCT03165552|Experimental|Educational Arm|This group will receive an acute kidney injury educational intervention
2461305|NCT03164902|Experimental|Digital Medicine Arm|Subjects enrolled in this single arm study will be directed to use digital medicine versions of their hepatitis C therapy for the duration of therapy.
2461354|NCT03164512|Placebo Comparator|Placebo|Placebo oral and vapor
2461356|NCT03164512|Experimental|Vaporized High Cannabidiol Cannabis|Cannabis containing approximately 100mg cannabidiol and 5mg delta-9-THC
2461358|NCT03164512|Experimental|Vaporized Cannabidiol|100mg cannabidiol in vapor
2461359|NCT03164512|Experimental|Oral Cannabidiol|100mg oral cannabidiol
2461411|NCT03164109|Experimental|GC4419 IV|
2461412|NCT03164109|Placebo Comparator|Placebo|
2461414|NCT03164109|Active Comparator|Oral moxifloxacin|
2461444|NCT03163654|Active Comparator|Experimental group|Surgery 1: The tunnel technique for covering multiple gingival recessions. Graft: porcine-derived acellular dermal collagen matrix (PADM, mucoderm® ).
2461445|NCT03163654|Active Comparator|Control group|Surgery 2: The tunnel technique for covering multiple gingival recessions. Graft: connective tissue graft
2461511|NCT03163563||Easywarm|Self warming blanket to prevent perioperative hypothermia
2461515|NCT03163563||BairHugger|Forced-air warming blanket to prevent perioperative hypothermia
2461562|NCT03163108|No Intervention|RMC only|routine manual control (RMC) of the fraction of inspired oxygen (FIO2)
2461563|NCT03163108|Active Comparator|CLAC slow|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 180sec WAIT-Interval (slow algorithm) of the fraction of inspired oxygen (FIO2)"
2461564|NCT03163108|Experimental|CLAC fast|"routine manual control (RMC) + Closed-loop automatic oxygen control (CLAC) with 30sec WAIT-Interval (fast algorithm) of the fraction of inspired oxygen (FIO2)"
2461649|NCT03162484|Experimental|Physical activity intervention group|"The intervention consisted in doing physical activities two to four times per week, each session last 60 minutes. The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.~Each session starts with a warm up. The main part of the session is divided into two sections. The first section includes different exercises to improve balance, mobility and coordination. The second section is comprised of communicative and cooperative games. The session finishes with a cool-down."
2461658|NCT03162484|No Intervention|Control group|People in control group did not receive any physical activity program.
3191158|NCT00795470|Active Comparator|Antimicrobial and NO catheter change|
3191159|NCT00795483|Experimental|1-ANNUAL|1. Zoledronic acid + Lifestyle modifications (experimental)
2460503|NCT03170284||Bevacizumab|Participants with advanced (stage IIIB/IV) NSCLC other than predominantly squamous cell histology receiving Bevacizumab in accordance with the summary product characteristics (SPC) is observed.
2460535|NCT03169946|Active Comparator|Test Group|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement (RCT with CHX-MTZ,OFD).
2460537|NCT03169946|Active Comparator|Positive Control Group :|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement(RCT with CHX,OFD).
2460587|NCT03169868|Experimental|Enhanced Medication reconciliation|Medication reconciliation with pharmacist using electronic health records, pharmacy dispensing data and Sano Patient Medication Profile(TM)
2460589|NCT03169868|No Intervention|Standard Medication reconciliation|Medication reconciliation with pharmacist using electronic health records and pharmacy dispensing data only
2460671|NCT03169634|Experimental|short or long stemmed rTKR cemented|
2460673|NCT03169634|Experimental|Cone with short stem|
2460677|NCT03169634|Experimental|Cone with long stem|
2460731|NCT03168815|Experimental|High Flow Nasal Cannula (HFNC)|Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
2460734|NCT03168815|Active Comparator|Low Flow Nasal Cannula (LFNC)|Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
2460785|NCT03168516|Experimental|Experimental intervention|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
2460786|NCT03168516|No Intervention|Control intervention|Standard care, i.e. manual adjustments of the FiO2 only
2460854|NCT03168035|Experimental|NC-4016|"Dose Escalation Group: NC-4016 will be administered as 2-hour intravenous infusion once every 3 weeks. Initial dose level 15 mg/m2. The dose level of NC-4016 in subsequent cohorts determined by the toxicity profile of the previous cohort, and dose level increased to 25, 30, 40, 60, and 80 mg/m2 or higher at each subsequent cycle until the highest dose level is reached or DLT prohibits further dose-level escalation. Dose level 1 will be the starting dose level (DL). If 2 out of the first 3 patients enrolled at DL1 experience a DLT during Cycle 1 or Cycle 2,then the next cohort of patients will be enrolled at DL0 (10 mg/m2).~Dose Expansion Group: Maximum tolerated dose from Dose Escalation Group"
2460910|NCT03167684|Experimental|Oral appliance therapy|Oral appliance (SomnoMed) worn nightly
2460915|NCT03167684|No Intervention|Control|Sham oral appliance device
3155912|NCT00331838|Active Comparator|Enoxaparin 40 mg|Enoxaparin sodium 40 mg + Placebo (for Semuloparin sodium) once daily for 4-10 days with an initial dose given 12 hours before or 8 hours after surgery depending on the willingness of the investigator
3155913|NCT00331838|Experimental|Placebo pre-op / Semuloparin 20 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 20 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
2461016|NCT03166878|Experimental|Treatment (UCART019)|"The UCART019 will be administered by i.v. injection over 20-30 minutes as a using a split dose approach to dosing: Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose"
2461094|NCT03166514|Experimental|Commercially Available Food Bar|62 g. Fitjoy Bar
2461100|NCT03166514|Placebo Comparator|Placebo|25 g. Dextrose
2461138|NCT03165890|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2461142|NCT03165890|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
3191160|NCT00795483|Other|2-CONTROL|2. Lifestyle modifications (control)
3191161|NCT00795483|Experimental|3-BIENNIAL|3. Zoledronic acid + Lifestyle modifications (experimental)
2461378|NCT03164213|Experimental|Experimental tDCS|TDCS stimulation at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
2461382|NCT03164213|Sham Comparator|sham tDCS|Sham tDCS at the left M1 region followed by naming therapy. The intervention will be given daily for duration of two weeks (5 days/week).
2461474|NCT03163888||Navigation TKR group|TKR performed under computer navigation without violating distal femur bone marrow.
2461480|NCT03163888||Conventional TKR group|TKR performed under conventional distal femur cutting juts with violation of distal femur bone marrow.
2461537|NCT03163459|Active Comparator|mechanical thrombectomy group|Conventional mechanical thrombectomy
2461538|NCT03163459|Experimental|mechanical thrombectomy plus selective brain cooling group|A microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
2461583|NCT03162887|Experimental|Screening (education module, counseling)|"Participants receive a research team member-led breast cancer and mammogram educational module and undergo a web-based decision counseling session over 2 hours. Participants then receive a next steps document and may undergo an interview to discuss their decision-making process and relevant experiences during the course of the study."
2461663|NCT03162562|Experimental|Oregovomab plus Poly ICLC (Hiltonol)|Oregovomab Solution, 2 mg IV, every three weeks (weeks 0, 3, 6, and 9) and then once at week 16 plus poly ICLC Suspension, 2 mg IM, 30 minutes post-oregovomab infusion and 48 hours post-oregovomab infusion (total 10 doses)
2461724|NCT03162250|Experimental|DSTA4637S low dose level + SOC|DSTA4637S low dose level intravenous (IV) infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
3191162|NCT00795496||AD patients|AD patients who fulfill the inclusion criteria for the study
2460596|NCT03169686|Experimental|Intervention Group|"Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team. One to six messages will be sent per day for the time leading up to the quit date and 12 weeks after quit data.~One to three messages will be sent per week until the end of the 24 weeks follow up after quit data. They will also be encouraged to send self-help, peer support messages in their group. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points."
2460601|NCT03169686|No Intervention|Control Group|Control group participants will not receive any smoking cessation messages by professional team. They will receive messages of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 4, 8, 12, 16, 20 and 24 points.
2460625|NCT03169517||Peripheral nerve block group|patients scheduled for elective upper or lower limb surgery with peripheral nerve block will receive LSCI measurements and pinprick sensory tests at 5 min before the block and at 5-min intervals till 30 min after the block.
3191163|NCT00795522|Experimental|Arm 1|Desloratadine
3191164|NCT00795548|Experimental|5-Azacitidine|5-Azacitidine in addition to standard donor lymphocyte infusions.
2460762|NCT03168607|Experimental|FOLFIRI|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
3191165|NCT00795561|Experimental|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
3191166|NCT00795561|Active Comparator|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
2460896|NCT03167645|Experimental|Human albumin|Substitution of human albumin until serum albumin >30g/l; dosage: (30 g/l - serum albumin [g/l] ) x 0,04 l/kg x body weight [kg] x 2
2460900|NCT03167645|No Intervention|Control|Standard clinical care
2460935|NCT03167398|Experimental|CRE carriers|Fecal Microbiota Transplantation
2460987|NCT03167086|Experimental|Single Session Skills-Based Pain Psychology Class|"Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention for chronic pain."
2460991|NCT03167086|Active Comparator|Cognitive Behavioral Therapy (CBT)|8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total).
2460995|NCT03167086|Active Comparator|Health Education (HE)|The active control treatment arm consists only of Health Education and has no psychological treatment components. It is a 2-hour HE class matched to the single-session psychological experimental arm (ER) on 4 important factors: duration, structure, format and site.
2461073|NCT03166605|No Intervention|Control|"First group: Control~Follow the current standard protocol used at Albany Medical Center that includes:~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period"
2461082|NCT03166605|Sham Comparator|Sham|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing~Do not drink anything for an additional 2 hours after swallowing pill cam. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
2461089|NCT03166605|Experimental|Experiment|"Receive 3 ml simethicone 20 minutes prior to capsule swallowing.~Receive 3 ml simethicone 1 hours after capsule swallowing~Receive 1.5 ml simethicone 2 hours after capsule swallowing~Do not drink anything for an additional 1 hour after taking last simethicone dose. After which patient may drink clear liquids~Do not eat solid food until 4 hours after swallowing. After which patient may eat light that includes soup, toast.~Return to clinic (RTC) 8 hours after to remove equipment~Avoid carbonated beverages and gas forming foods for the completion of the 8-hours study period."
3191167|NCT00795574|Experimental|infliximab|Double blind placebo cross-over
3191168|NCT00795574|Placebo Comparator|Placebo|Double blind placebo controlled cross-over
3191169|NCT00795587|Active Comparator|mannitol high dose|mannitol 20% 0,8 g/ kg on minutes
3191170|NCT00795587|Active Comparator|mannitol low dose|mannitol 20% 0,4 g/ kg on minutes
2461210|NCT03165331|Other|Intervention group|The intervention group will go through the intervention programme (Ung Face IT) after T1 and randomisation. Programme takes 7 weeks to complete + Treatment as usual (local health care services). Questionnaires after the 7 weeks (T2) and after three months (T3) and 6 months (T4).
2461211|NCT03165331|Other|Control group|Treatment as usual for three months after T1 and randomisation, with local health care support if needed. Questionnaires at T2 and T3 before participants are given access to the intervention (Ung Face IT) after three months. Questionnaire at T4 (post-intervention).
2461303|NCT03164889|Experimental|ETV+GM-CSF|Entecavir (ETV) plus Granulocyte Macrophage-colony Stimulating Factor (GM-CSF). ETV was given 0.5mg/d, oral; GM-CSF was given 100ug, the 3th, 4th, 5th day at week1, 4, 12, 24, 48, subcutaneous injection.
2461304|NCT03164889|Active Comparator|ETV monotherapy|As standard antiviral therapy, Entecavir was given 0.5mg/d, oral.
2461491|NCT03163966|Experimental|CR6086 30 mg|CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
2461493|NCT03163966|Experimental|CR6086 90 mg|CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
2461495|NCT03163966|Experimental|CR6086 180 mg|CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
3191171|NCT00795613|Experimental|PET pos|Patients With Interim Pet Positive Proceed To Escalated Beacopp Regimen
2460529|NCT03170102|Other|Building capacity through education|Building capacity process through education - Occupational therapy students participate in online webinars and discussions following completion of readings.
2460577|NCT03169907|Experimental|Rh isoimmunized patients|Patients will be selected from Rh isoimmunized patients (positive titre of indirect coomb's test) who are scheduled to have intrauterine blood transfusion. This intrauterine blood transfusion is due to fetal anemia, and it is detected when the measurement of PSV (peak systolic velocity) of middle cerebral artery is more than 1.5 MoM (multiple of the median) according to Fetal Medicine unit of Cairo University protocol. All fetuses are free of structural and functional Fetal and echocardiographic anomaly scan.
2460597|NCT03169699||Cough Arm|Children age 16 years old and below with cough at presentation - Patients presenting with active or chronic or residual cough
2460602|NCT03169699||Well Arm|Children age 16 years old and below and Well with no presentation of cough
2460631|NCT03169504|Experimental|Acupuncture|Patients in this arm will receive acupuncture.
2460633|NCT03169504|Experimental|Conventional drug|Patients will be individually divided into Group A, Group B, Group C and Group D according to GOLD 2017. For Group A, Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd) will be used. For Group B and Group C, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) will be used. As for Group D, Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH) or Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline) will be used.
2460635|NCT03169504|Experimental|Acupuncture plus conventional drug|Patients in this arm will receive both acupuncture and conventional drug.
2460752|NCT03168893|Experimental|Deep brain stimulation ON|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation continue 3 months more activated, patient and psychiatrist don´t know
2460755|NCT03168893|Experimental|Deep brain stimulation OFF|Surgical procedure is necessary.In surgery, two cerebral electrodes (either in the Subgenual cingulate or in the Accumbens Nucleus) are connected to a subcutaneous generator at abdominal fat level, under general anesthesia. The patient will initiate the stimulation prior to discharge . At 6 months follow up, Deep brain stimulation is stopped during 3 months , patient and psychiatrist don´t know
2460784|NCT03168373|Experimental|Intensive group|language rehabilitation therapy by language therapist for 1 hours on every working day for 4 weeks
2460787|NCT03168373|Active Comparator|Conventional group|language rehabilitation therapy by language therapist for 30 minutes on every working day for 4 weeks
2460846|NCT03168074|Experimental|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).
2460863|NCT03167736|Experimental|Electric dry needling, manipulation|
2460866|NCT03167736|Active Comparator|conventional physical therapy|
3191172|NCT00795613|Other|PET negative|Patients With Interim-Pet Negative Continue The Conventional ABVD Regimen
3191173|NCT00795626|Experimental|Lifestyle counseling|"Two groups:~control - conventional care~intervention - systematic education in the reduction of the risk estimate to cardiovascular events"
2461046|NCT03166787|Experimental|Myocardial Blood Flow|Myocardial contrast echocardiography will be used to measure regional myocardial perfusion .
2461047|NCT03166787|Experimental|Assess Coronary Endothelial Function|young hookah smokers will be randomized to have coronary endothelial function assessed before and after inhaling Carbon Monoxide or room air from a Douglas bag.
2461048|NCT03166787|Experimental|Test coronary endothelial function|Test coronary endothelial function before after hookah smokers smoke charcoal-heated hookah and before and after age-matched cigarette smokers smoke 2 cigarettes. In the same subjects, we will test for acute smoking-induced changes in LV wall strain by speckle tracking. Finally, in a subset of subjects we will repeat the MCE and speckle tracking studies after pretreatment with either i.v. vitamin C or one dose of oral tadalafil.
2461061|NCT03166241|Experimental|study group|measure serum interleukin 21 level in patients with severe adverse drug reaction who show change in serum interleukin 21 before and after therapy the following investigation will be done at the begning of the study to patients: Complete Blood Picture Erythrocyte Sedimentation Rate Random blood sugar Liver function tests Kidney function tests
2461062|NCT03166241|Placebo Comparator|control group|compare serum interleukin 21 level in patients with severe adverse drug reaction and healthy control subjects
2461181|NCT03165773|Experimental|Oatmeal|87 grams oatmeal
2461183|NCT03165773|Active Comparator|Corn grits|67 grams corn grits
2461256|NCT03165422||Adult patients with melanoma|Adult patients with melanoma at participating centers in Japan
2461306|NCT03164915|Experimental|LIV-GAMMA SN Inj.|
3191174|NCT00795652|Experimental|Distance Treatment|50% randomized to receive Distance Treatment for postpartum depression
3191175|NCT00795652|No Intervention|Usual Care Services|50% randomized to receive usual care services for postpartum depression
2461407|NCT03163953|Experimental|TPAG with long break|PA coaching based on TPAG and long break or break 15 minutes for every 2 hours (TPAG with LB)
2461408|NCT03163953|Experimental|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
2461409|NCT03163953|Other|Control|No intervention
2461484|NCT03163706|Experimental|Schizophrenia patients|Patients with DSM-5 criteria of schizophrenia
2461489|NCT03163706|Other|Control group|Control, no schizophrenia
2461518|NCT03163355|Active Comparator|pureed rice with a gelling agent|3 ml of pureed rice containing a gelling agent is attempted to swallow under endoscopic examination of swallowing
2461521|NCT03163355|Placebo Comparator|standard pureed rice|3 ml of standard pureed rice is attempted to swallow under endoscopic examination of swallowing
2460553|NCT03169959|Experimental|Cohort 1: Sequence 6 (CBA)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~A= Reference product - 2.5mg ONGLYZA (2.5mg saxagliptin) and 5/1000mg XIGDUO XR (5 mg dapagliflozin / 1000mg Metformin XR) after food.~B = Test product - Triple FCDP consisting of 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR after food.~C = Test product - Triple FCDP tablet consisting of 2.5mg saxagliptin / 5mg dapagliflozin / 1000 mg metformin XR without food."
2460555|NCT03169959|Experimental|Cohort 2: Sequence 1 (DEF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460556|NCT03169959|Experimental|Cohort 2: Sequence 2 (DFE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460557|NCT03169959|Experimental|Cohort 2: Sequence 3 (EDF)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460558|NCT03169959|Experimental|Cohort 2: Sequence 4 (EFD)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460559|NCT03169959|Experimental|Cohort 2: Sequence 5 (FDE)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460561|NCT03169959|Experimental|COhort 2: Sequence 6 (FED)|"Subjects were randomized to treatment sequence 1 ABC:~On Day 1, each subjects will receive orally single-dose of the treatment assigned to that treatment period.~D= Reference product - 5mg ONGLYZA (5mg saxagliptin) and 10/1000mg XIGDUO XR (10 mg dapagliflozin / 1000mg Metformin XR) after food.~E = Test product - Triple FCDP consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR after food.~F = Test product - Triple FCDP tablet consisting of 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR without food."
2460643|NCT03169569|Experimental|Hemostatic powder group (Endo-clot™ group)|Patients who will undergo ESD with Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) after hemostasis on the post-resection ulcer using conventional method and removal of specimen.
2460646|NCT03169569|Active Comparator|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|For patients in the control group, hemostasis with conventional method (electrical coagulation and/or clip, Coagrasper®, Olympus, Japan) will be done.
2460766|NCT03168594|Experimental|A:Irinotecan combined with cisplatin (IP regimen)|patients in arm A will receive chemotherapy of IP regimen: Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
2460770|NCT03168594|Experimental|B:Etoposide combined with cisplatin (EP regimen)|patients in arm B will receive chemotherapy of EP regimen: Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
2460842|NCT03168139|Experimental|Olaptesed pegol + Pembrolizumab|
2460861|NCT03167723|Experimental|28 French chest tube for hemothorax|28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
2460864|NCT03167723|Experimental|14 French chest tube for hemothorax|14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax
2460955|NCT03167554|Sham Comparator|Sham group|Simulating of the electrolysis application.he electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
2460964|NCT03167554|Experimental|Experimental group 1|Electrolysis application with monopolar needle.
2460966|NCT03167554|Experimental|Experimental group 2|Electrolysis application with bipolar needle.
2461029|NCT03166839||Region 1: Africa|Women living in and experiencing PPH in countries located in Africa.
2461033|NCT03166839||Region 2: Asia|Women living in and experiencing PPH in countries located in Africa.
2461036|NCT03166839||Region 3: Europe, NA, SA, Aus|Women living in and experiencing PPH in countries located in Africa.
2461088|NCT03166397|Experimental|ACT TIL|"Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d..~Preparation and administration of TIL~Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient."
2461154|NCT03166046|Active Comparator|Study Group|Subjects will use the active pulsed shortwave therapy device (ActiPatch) as a prophylactic treatment for episodic migraine
2461160|NCT03166046|Placebo Comparator|Control Group|Subjects will use the placebo pulsed shortwave therapy device (Placebo ActiPatch) as a prophylactic treatment for episodic migraine
2460726|NCT03168763|Experimental|Video 1A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2460728|NCT03168763|Experimental|Video 1B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2460732|NCT03168763|Experimental|Video 2A|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2460736|NCT03168763|Experimental|Video 2B|"Questionnaires completed at baseline, after each video viewing, and at completion.~Participants shown Video 1A or 1B, then shown Video 2A or 2B."
2460836|NCT03168412|Experimental|the Accelerated Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,7,21 day.
2460838|NCT03168412|Active Comparator|the Standard Vaccination Schedule Group|Participants in this arm are aged over 18 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at 0,1,6 month.
2460878|NCT03167801||spinal cord injury|spinal cord injury all scores AIS
2460884|NCT03167801||Healthy volunteers|Healthy volunteers for whom melatonin profiles have been taken and stored in the Lyon endocrinology laboratory's database. No healthy volunteers will be directly recruited for the study.
3155914|NCT00331838|Experimental|Placebo pre-op / Semuloparin 40 mg|"Placebo (for Semuloparin sodium) + Placebo (for Enoxaparin sodium) 12 hours before surgery then,~Semuloparin sodium 40 mg + Placebo (for Enoxaparin sodium) once daily for 4-10 days with an initial dose given 8 hours after surgery"
2461010|NCT03167060|Active Comparator|Active Rhinochill|Intranasal cooling device , using nasal cannula
2461014|NCT03167060|Sham Comparator|Control Rhinochill|Intranasal cooling device , using nasal cannula (difference with active device not disclosed to maintain blindness)
2461091|NCT03166423|Experimental|MU001 patches (Investigational)|"Patches MU001 (snail slime, calendula extract and propolis extract) more standard of care. Two or three application for week. Treatment until 60 days.~Patches MU001 (snail slime, calendula extract and propolis extract) on health zone. Three days of treatment."
2461092|NCT03166423|Experimental|Conventional patches (Control)|Conventional patches approved for diabetic foot ulcers more standard of care. Two or three application for week. Treatment until 60 days.
2461169|NCT03165903|Experimental|Cue and Implementation-Intention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption.
2461173|NCT03165903|Other|Control Arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message.
2461212|NCT03165474|Active Comparator|Control Arm|In the control group, children and parents will receive didactic health information and resources by email and/or text. The delivery mode of the health messages will be based on based on personal preference.
2461214|NCT03165474|Experimental|Intervention Arm|In the intervention group, children will have access to a web-based interactive nutrition comic and receive health messages from comic characters by email and/or text, while parents will receive weekly newsletters related to nutrition and health by email and/or text.
3155915|NCT00331890|Experimental|Active|Receives active drug
3155916|NCT00331890|Placebo Comparator|Placebo|Receives a placebo
2461390|NCT03164122|Experimental|Intra-articular injection|
3155917|NCT00331929|Experimental|A|Cohort of school children that evaluated with questionnaire and spirometry with MINATO 500 JAPAN spirometer
3155918|NCT00331955|Experimental|Treatment (vorinostat, doxorubicin hydrochloride)|Patients receive oral vorinostat twice daily for 5 doses on days 1-3, 8-10, and 15-17 and doxorubicin hydrochloride IV on days 3, 10, and 17. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease after 6 courses of treatment may continue to receive vorinostat alone in the absence of disease progression.
3155919|NCT00331994|Experimental|1|
3155920|NCT00331994|Active Comparator|2|
3155921|NCT00332007|Experimental|1|Tonabersat 40 mg daily
3155922|NCT00332007|Placebo Comparator|2|
3155923|NCT00332020|Experimental|Arm 1|
3155924|NCT00332020|Active Comparator|Arm 2|
3155925|NCT00332098|Experimental|1|Family-Focused Treatment Plus Pharmacotherapy
3155926|NCT00332098|Active Comparator|2|Enhanced Care Plus Pharmacotherapy
3155927|NCT00332124|Placebo Comparator|1|Participants will take placebo
3155928|NCT00332124|Active Comparator|2|Participants will take choline
3155929|NCT00332176|Experimental|1|
3155930|NCT00332176|Experimental|2|
3155931|NCT00332176|Active Comparator|3|
3155932|NCT00332228|Active Comparator|CE plus oral +depot naltrexone|Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;
3155933|NCT00332228|Placebo Comparator|CE plus oral naltrexone+ placebo|CE with oral naltrexone plus two placebo injections
3155934|NCT00332228|Experimental|BNT plus Depot naltrexone|BNT plus two doses of depot naltrexone prior to hospital discharge
3155935|NCT00332228|Placebo Comparator|BNT plus PBO injection|BNT plus two placebo injections
3155936|NCT00332254|Experimental|1|Intra-articular IL-1Ra
3155937|NCT00332254|Placebo Comparator|2|Intra-articular saline
3155938|NCT00332280|Experimental|AMT2003|
3155939|NCT00332293|Experimental|Moxifloxacin|
3155940|NCT00332293|Active Comparator|VIGAMOX|
2460612|NCT03169790|Experimental|Nant NHL Vaccine|avelumab, bevacizumab, capecitabine, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, lovaza, oxaliplatin, rituximab, stereotactic body radiation therapy, ALT-803,ETBX-061, and haNK.
2460707|NCT03169283|Experimental|Cereal 1|A cereal high in viscous dietary fiber B glucan
2460711|NCT03169283|Active Comparator|Cereal 2|A cereal without B glucan
2460823|NCT03168178|Active Comparator|Standard Antibiotic Treatment|Standard antibiotic treatment provided to patient. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
2460825|NCT03168178|Experimental|No Antibiotic Treatment|No Antibiotic treatment given. Placenta submitted for pathologic exam. Maternal and neonatal outcomes collected.
2460907|NCT03167931|Experimental|18-49 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
2460908|NCT03167931|Experimental|50-85 years group|Participants undergo 2 sessions of MRI + transcranial Magnetic Stimulation or transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
2460943|NCT03167281|No Intervention|tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily 24-48 hours after chest tube placed.
2460956|NCT03167281|Experimental|Early tPA and DNase|10mg of t-PA and 5 mg of DNase in a 30 mL solution of water/saline administered via chest tube over three days twice daily with initial administration occurring at chest tube placement.
2460981|NCT03167021||Students|Students of the Auvergne Rhone Alpes region will be contacted by email thanks to the student associations and scholarity departments. Answer to the survey will be done online.
2461024|NCT03166748|Active Comparator|MTA pulpotomy|mineral trioxide aggregates (MTA) is accepted as an optimum material for use in vital pulp therapy of permanent teeth
2461028|NCT03166748|Experimental|Potassium Nitrate in Polycarboxylate cement|Potassium nitrate (KNO3) is a superior desensitizer for hypersensitive teeth. Used with polycarboxylate cement, it serves as an effective liner for deep carious lesions. Also when placed under deep restorations with less than 1 mm of protective dentin remaining, it was effective in preserving pulpal vitality and it diminished the incidence and severity of post-restoration pain. As temporary cement (Kno3/zinc oxide eugenol [ZOE]) It reduced pain following full crown preparation.
2461071|NCT03166462|No Intervention|Control|"Patients in this arm will proceed through the current standard of care for pre-operative screening performed by either the patient's primary care physician or the pre-operative anesthesia clinic which screens patients prior to total knee or total hip arthroplasty."
2461079|NCT03166462|Experimental|Intervention|Patients in this arm will be referred to the Sleep Medicine clinic at the University of Miami Hospital for additional testing and evaluation for obstructive sleep apnea. If they are successfully diagnosed, they will receive appropriate treatment and any interventions for the peri-operative period as recommended by the pulmonary medicine team.
2461121|NCT03166189|Experimental|bone marrow-derived MSC and HRT|endometrial injection of autologous cell product of MSC with hormonal replacement therapy before frozen/thawed ET
2461122|NCT03166189|Active Comparator|hormonal replacement therapy|standard endometrial preparation for frozen/thawed ET
2461291|NCT03165279||Patient with AAA|Patient will receive a 'Zenith Alpha Abdominal stentgraft' as intervention to eliminate the abdominal aortic aneurysm.
3155941|NCT00332306|Experimental|2|Didanosine + Lamivudine + Nevirapine
3155942|NCT00332306|Active Comparator|1|Didanosine + Lamivudine + Efavirenz
3155943|NCT00332371|Experimental|1|
2461384|NCT03164070||Patients with osteoarthritis|Patients with medium and large joint osteoarthritis
2461385|NCT03164070||Control group|Control group of healthy persons
2461494|NCT03163940|Experimental|Laughter Yoga (LY) Group|The LY session will be offered twice weekly, for 45 minutes each time. Each participant will be asked to attend a total of 8 groups (over 4 weeks).
2461498|NCT03163940|No Intervention|Treatment-as-usual (TAU)|The TAU will receive their usual routine community mental health care (including medications) and attend medical outpatient appointments as determined by their individual needs.
2461510|NCT03163264|Experimental|PAL Intervention|"Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity~Receiving Peer Assisted Lifestyle intervention (PAL tool, health coaching at baseline, follow-up health coaching calls, potential support of goals from primary care provider)"
2461514|NCT03163264|Active Comparator|Enhanced Usual Care (EUC)|Body mass index of =30kg/m2 OR Body mass index of =25 kg/m2 with an obesity associated co-morbidity
2461592|NCT03163030|Experimental|Therapy|Right Cervical Vagus Nerve Stimulation (VNS)
3155944|NCT00332371|No Intervention|2|
2461718|NCT03162263|Experimental|Ekso training|All patients underwent twenty-four Ekso sessions, scheduled 3 times a week. Each session lasted about 1h, and included transferring into the device arranged on an office chair; donning, standing, walking, sitting, doffing; and transferring out of the exoskeleton.The user can stand up, sit down, and walk with help of a front-wheeled walker and with the exoskeleton attached to a ceiling rail tether. A physical therapist initially provides assistance to maintain the user's center of mass over the base of support to prevent falling.
3155945|NCT00332397|Active Comparator|A|Rapamycin-eluting Stent (Cypher)
3155946|NCT00332397|Active Comparator|B|Zotarolimus-eluting Stent (Endeavor)
3155947|NCT00332397|Active Comparator|C|Rapamycin-eluting Stent
3155948|NCT00332514|Other|Patients offered follow-up phone call|Patients offered follow-up telephone call
3155949|NCT00332566|Experimental|Group A|
3155950|NCT00332566|Active Comparator|Group B|
3155951|NCT00332657|Experimental|Anecortave Acetate, 15 mg|One 0.5 mL injection of 30 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
3155952|NCT00332657|Experimental|Anecortave Acetate, 30 mg|One 0.5 mL injection of 60 mg/mL Anecortave Acetate Sterile Suspension into the posterior juxtascleral depot (PJD) at 6-month intervals for 42 months.
3155953|NCT00332657|Sham Comparator|Anecortave Acetate Vehicle|One sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
3155954|NCT00332670|Active Comparator|1|10.000lux bright blue light 1hour every morning 1 hour after wake-up time during three weeks
2460632|NCT03169361||Ixazomib 4 mg|The usual adult dosage for oral administration is 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle will be repeated for 6 cycles. The dose may be reduced appropriately according to the patient's condition. Participants will receive interventions as part of routine medical care.
2460696|NCT03169166|Experimental|"Repeated 3-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart (0.3/0.2/0.2mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
2460701|NCT03169166|No Intervention|"Conventional 1-dose GnRHa  Triptorelin"|Triptorelin pre-filled syringes will be administered subcutaneously in a single dose (0.3 mg) when at least three follicles 18 mm in diameter have been observed by ultrasound examination.
2460730|NCT03168724|Experimental|GMT Intervention|Over the course of 9 weeks, there are 2h-group sessions with a therapist.
2460733|NCT03168724|No Intervention|Control|Group not getting the intervention
2460824|NCT03168555|Experimental|Intervention|chenodeoxycholic acid 1250mg po.
2460904|NCT03167944|Experimental|Conventional electrocautery|
2460906|NCT03167944|Experimental|Low thermal electrosurgery system|
2460930|NCT03167372|Experimental|Bright white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of bright white light and dim red light; alternating bright white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 bright white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
2460931|NCT03167372|Active Comparator|Dim white light vs dim red light|"A balanced sequence (ABBA) over a 12 week period of dim white light and dim red light; alternating dim white and dim red light every 3 weeks.~Subjects will receive 2 Litebook® Advantage lightboxes - 1 dim white and 1 dim red. Information such as mood, fatigue, sleep and light therapy side effects will be self-reported using a smartphone diary; physical activity and sleep will also be reported using a Fitbit Flex2 TM. Data visualization at 12 weeks."
2460986|NCT03166943|Experimental|study group|Systolic function by echocardiography to100 Hepatitis C virus infected patients on continuous regimen ( sofosbuvir and daclatasvir )
2460992|NCT03166943|Active Comparator|Control group|Diastolic function by echocardiography age and sex matched group of 30 patients with Hepatitis C virus who did not receive antiviral treatment ( sofosbuvir and daclatasvir )
2461006|NCT03166709|Active Comparator|Treatment As Usual|Intensive Outpatient Program (IOP) addiction treatment
2461012|NCT03166709|Experimental|Experimental|Secondary Prevention Intervention (PARS) plus Treatment as Usual
2461103|NCT03166319|Experimental|Suspected CNS Vasculitis|Patients with suspected CNS vasculitis will undergo an MRI, including intracranial vessel wall imaging.
2461165|NCT03165929|Active Comparator|flurbiprofen-free gingival graft|
2461166|NCT03165929|Placebo Comparator|placebo-free gingival graft|
2461170|NCT03165929|Active Comparator|flurbiprofen-connective tissue graft|
2461174|NCT03165929|Placebo Comparator|placebo-connective tissue graft|
2461248|NCT03165448||Self-reported questions|All the participants will enroll the same study protocol, without any exceptions: pre-operative patient's self-reported questioning, post-operative doctor's questioning, 4-6 weeks patients retesting.
2461310|NCT03164980|Experimental|Arm A|PLD followed by Trabectedin. Treatment is repeated every 3 weeks for 6 cycles or until disease progression.
2461311|NCT03164980|Experimental|Arm B|"Carboplatin/PLD~Carboplatin/Gemcitabine~Carboplatin/Paclitaxel Patients will be treated for 6 cycles or until PD, unacceptable toxicity or patient's wish to discontinue, whichever occurs first."
2461404|NCT03164252|Active Comparator|Grupo I- Lower laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 10 J / cm2 fluency, in the immediate period after surgical period of the third molar third molar extraction / impacted by the intraoral region
2461405|NCT03164252|Active Comparator|Grupo II- Greater laser fluency|20 patients received 660 nm red laser diode laser therapy, 30 mW power and 30J / cm2 fluency, in the immediate period after surgical of the third molar third molar extraction / impacted by the intraoral region
2461406|NCT03164252|Placebo Comparator|Grupo III- Laser sham|Application of laser sham, the handpiece of the device will be positioned intraorally and activated. However, the tip of the applicator will be covered by an opaque material that prevents radiation from passing through.
2461451|NCT03163680||Low Dose PPI|patients with upper upper gastrointestinal bleeding were treated in low dose of proton Bump inhibitor meaning 40 mg twice daily
2461531|NCT03163576|Experimental|study group|patients received niacin 750 mg twice daily up to 2000 mg in addition to usual phosphate binders .
2461535|NCT03163576|Active Comparator|control group|patients received usual phosphate binders .
2461643|NCT03162900|Experimental|Glasdegib QT Therapeutic Exposure|Randomized sequence of Glasdegib clinical exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
2461651|NCT03162900|Experimental|Glasdegib QT Supra-therapeutic Exposure|Randomized sequence of glasdegib supra-therapeutic exposure, Placebo and moxifloxacin active control administration. This treatment will be in four separate sequences with four periods per sequence. Each period will be separated by a washout of atleast 6 days.
2461719|NCT03162068||Control group|Cases are recruited thanks to advertisement within CHU.
2461728|NCT03162068||Post menopausal women|Post-menopausal women are recruited within rheumatology service.
2461733|NCT03162068||Cushing' syndrome group|Cushing' syndrome patients are recruited during hospitalisation in endocrinology service
2461777|NCT03161639|No Intervention|Operator 1|Perform the pulpectomies except the working length measurement
2461778|NCT03161639|No Intervention|Operator 2|Perform the electronic length measurement of the pulpectomies
2461779|NCT03161639|Active Comparator|Operator 3|Perform radiographic length measurement and final evaluation of the pulpectomies
2461821|NCT03161288|Experimental|Cohorts 1-3|Healthy volunteers will receive single rising doses of KY1005 or placebo
2461823|NCT03161288|Experimental|Cohorts 4-8|Healthy volunteers will receive multiple rising doses of KY1005 or placebo
2460636|NCT03169491|Experimental|Therapeutic|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
2460640|NCT03169491|Sham Comparator|Suboptimal|Continuous positive airway pressure (CPAP) every night for two weeks at fixed pressure of 4 cmH2O, via oronasal interface.
2460642|NCT03169491|Other|Severe OSAS|Continuous positive airway pressure (CPAP) with automatic pressure from 4 to 15 cmH2O every night for one week, afterwards use of CPAP at the P90 of pressure determinated during automatic use for one week, via oronasal interface.
2460694|NCT03169088|Experimental|Coaching procedure|Volunteers will received Updated National Dietary Guidelines about food and physical activity with a one-year follow-up, plus connected coaching.
2460738|NCT03168802|Experimental|MRgFUS facet treatment|MRgFUS ablation for facet joint pain once at Lumbar spine
2460748|NCT03168802|Active Comparator|Radiofrequency ablation facet treatment|Radiofrequency ablation for facet joint pain once at Lumbar spine
2460798|NCT03168438|Experimental|Arm 1: Letetresgene autoleucel (GSK3377794)|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.
2460800|NCT03168438|Experimental|Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab|Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.
2460859|NCT03167983||dementia|patients with dementia
2460860|NCT03167983||control|healthy control
2460914|NCT03167619|Experimental|A - olaparib alone|Twice daily oral Olaparib 300mg alone as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
2460917|NCT03167619|Experimental|B - olaparib plus durvalumab|Twice daily oral olaparib plus intravenous Durvalumab every 4 weeks as maintenance therapy until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
2460957|NCT03167216|Experimental|Treatment arm|Treated arm with cromolyn sodium and cetirizine hydrochloride
2461031|NCT03166865|Experimental|Intervention group|Intraarticular injection of 2×10~7 Umbilical-cord mesenchimal stem cells with plateler Rich Plasma(5ml)
2461034|NCT03166865|Other|Control group|Intraarticular injection of hyaluronic acid
2461074|NCT03166384|Active Comparator|control group|"For the patients in the control group, surgeon dose not use electrosurgical bipolar sealing device at all and use conventional tie and ligation methods during tissue dissection and vessel ligation.~interventions: 'conventional suture and tie'"
2461083|NCT03166384|Experimental|study group|"For the patients in the study group, the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.~interventions: electrosurgical bipolar sealing devices"
2461141|NCT03166098||Diagnosis of Schizophrenia|
2461149|NCT03166098||Diagnosis of Bipolar Disorder|
2461152|NCT03166098||Unaffected siblings of the SZ groups|
2461159|NCT03166098||Unaffected siblings of the BP group|
2461162|NCT03166098||Healthy control (HC) comparison group|
2461237|NCT03165487||Luminal A Breast Cancer|Luminal A Breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
2461240|NCT03165487||Triple Negative Breast Cancer|triple Negative breast cancer subjects will have tissue specimens and blood collected before and after IORT during the Breast conserving surgery.
3155955|NCT00332670|Placebo Comparator|2|50lux dim red light 1 hour every morning 1 hr after wake-up time during 3 weeks
3155956|NCT00332683|Active Comparator|Control|Patients randomly assigned to this group will have no changes in the ETT during surgery
2461459|NCT03163979|Active Comparator|PET/CT and Comet assay guided IMRT|18F-FDG PET/CT and Comet assay guide IMRT Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
2461462|NCT03163979|Active Comparator|PET/CT and Comet assay guided RapidArc|"18F-FDG PET/CT and Comet assay guide RapidArc:~1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment."
2461465|NCT03163979|Active Comparator|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
2461468|NCT03163979|Sham Comparator|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
2461513|NCT03163420|Placebo Comparator|Placebo|placebo
2461519|NCT03163420|Experimental|Diclofenac potassium|Diclofenac potassium 50 mg
2461687|NCT03162237|Experimental|Porcine islets and autologous treg|Porcine islets:10000 islet equivalent（IEQ）/Kg; Treg:2x10^6/Kg
3155957|NCT00332683|Experimental|Treatment group|Patients in this group will undergo same surgery as control group but with a monitoring and manipulation of ETT pressure
3155958|NCT00332774|Experimental|Nevanac|
3155959|NCT00332774|Active Comparator|Acular|
3155960|NCT00332774|Placebo Comparator|Vehicle|
3155961|NCT00332852|Experimental|Letrozole|
3155962|NCT00332878|Experimental|1|Stepping Stones
3155963|NCT00332878|Active Comparator|2|A 3 hour intervention on HIV and safer sex
3155964|NCT00332904|Active Comparator|beta|patients with liver cirrhosis, treated with betablocker
3155965|NCT00332904|Active Comparator|spiron|patients with liver cirrhosis, treated with aldosterone antagonist
3155966|NCT00332904|No Intervention|control|patients with liver cirrhosis, no treatment
3155967|NCT00332917|Experimental|1|
2460644|NCT03169426|No Intervention|Control|Subjects are going to undergo remote ischemic conditioning without taking any drug.
2460740|NCT03168659|Other|Treatment|Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System
2460834|NCT03168399|Experimental|Consumption of PKU Explore|Daily feed, substituting the participant's normal phe-free protein substitute for PKU Explore.
2460865|NCT03167827|Experimental|Group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
2460868|NCT03167827|Placebo Comparator|Group placebo and exercise|The placebo group received 100mg containing starch of corn.
2460949|NCT03167515|Experimental|074-6751 Lotion|
2461004|NCT03166995|Experimental|Experimental group 1|Low impact aerobic exercise group. 1hour, twice a week
2461009|NCT03166995|Experimental|Experimental group 2|Postural exercises group. 1hour, twice a week
2461013|NCT03166995|No Intervention|Control propriocepcion|No exercise, just proprioceptive control.
2461072|NCT03166540|Experimental|low consumers|1 cup of espresso coffee/day at 9.00 A.M. for 1 month
2461081|NCT03166540|Experimental|high consumers|3 cup of espresso coffee/day at 9.00 A.M. 12.00 P.M. and 3.00 P.M. for 1 month
2461087|NCT03166540|Experimental|medium consumers|1 cup of espresso coffee at 9.00 A.M. + cocoa-based products containing coffee at 12.00 P.M. and 3.00 P.M. for 1 month
2461128|NCT03166059|Experimental|Single arm|CaveoVasc® Thrombolysis Protection System
2461190|NCT03165760|No Intervention|control group|Vt = 8 ml/kg of PBW and PEEP = 4 cm H2O
2461194|NCT03165760|Experimental|protective ventilation group|Vt = 6ml/kg of PBW, PEEP = 10 and RM if disconnected
2461203|NCT03165370||Insomnia|those with unsatisfactory sleep quantity and/or quality (difficulty with sleep induction, awakenings during the night, early morning awakening, total sleep time, and overall quality of sleep), complaint of a minimum frequency (at least three times a week) and duration (1 month), marked distress caused by the sleep problem and/or interference with ordinary activities of daily living
2461339|NCT03164486|Experimental|18F-αvβ6-BP|Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.
2461396|NCT03164291|Experimental|Rifabutin|Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections or other NTM disease who fail therapy with other drugs ( i.e., rifampin)
2461454|NCT03163784|Placebo Comparator|Arm A|Weekly placebo (for Fecal Inoculum Capsule) treatment with placebo pre-treatment.
2461460|NCT03163784|Experimental|Arm B|Weekly Fecal Inoculum Capsule treatment with placebo pre-treatment.
2461464|NCT03163784|Experimental|Arm C|Weekly Fecal Inoculum Capsule treatment with antibiotic pre-treatment.
2461533|NCT03163433|Experimental|Feedback in the consultation|Feedback in the consultation is the intervention. Patients complete PROM before each consultation and take part in a dialogue about the results with their physician.
2461536|NCT03163433|No Intervention|Control|Usual consultations
2461590|NCT03162965|Active Comparator|Choice|Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
2461593|NCT03162965|Active Comparator|HIV Counseling and Testing|Clinic Based HIV Counseling and Testing (HCT)
2461625|NCT03162510|Experimental|SOLAR|Albumin-Bound Paclitaxel /nab-Paclitaxel (Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60~ 85 mg/m2 IVD 2hr at D1, plus Tegafur,oral S-1 35mg/m2 and Folinic acid/LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
2461691|NCT03162224|Experimental|HPV associated recurrent/metastatic HNSCC|Approximately 50 patients with HPV associated recurrent/metastatic HNSCC
2461776|NCT03161613||Cancer patients in Mexico|lung cancer, melanoma cancer, renal cancer, Squamous Cell Carcinoma of the Head and Neck, and chronic Hodgkin Lymphoma patients in Mexico who have failed at least one treatment before being treated with nivolumab
2461850|NCT03161002||wild genotype|Through next generation sequencing, distinguish wild genotype of ticagrelor
2461851|NCT03161002||mutant genotype|Through next generation sequencing, distinguish mutant genotype of ticagrelor
2461900|NCT03160664|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2461902|NCT03160664|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2461948|NCT03160404|Experimental|EXERCISE|Aerobic exercise (50% Reserve heart hate), 50 minutes, 3 times/week, during 6 weeks.
2461949|NCT03160404|Active Comparator|ZOLPIDEM|10 mg/night during 6 weeks
2461997|NCT03160261|Experimental|Exenatide|Single injection of 10 μg Exenatide subcutaneously.
2462140|NCT03159871|Experimental|Stratafix suture|
2462143|NCT03159871|Active Comparator|Vicryl suture|
3155968|NCT00332956|Active Comparator|Group 1|Volunteers will be vaccinated with 80 mcg rF1V vaccine on Study Days 0 , 28, 182
2462260|NCT03158259|Experimental|Intervention group MSU|Patient will be diagnosed (NIHSS, CT and conventional blood-measures) and given thrombolytic treatment (when indicated) prehospitally by anesthesiologist in Mobile Stroke Unit (MSU)
3155969|NCT00332956|Active Comparator|Group 2|Volunteers will be vaccinated with 80 mcg of rF1V vaccine at Study Days 0, 56, 182
3155970|NCT00332956|Active Comparator|Group 3|Volunteers will be vaccinated with 160 mcg rF1V vaccine given on Study Days 0, 28, 182
3155971|NCT00332956|Active Comparator|Group 4|Volunteers will be vaccinated with 160 mcg rf1V vaccine on Study Days 0, 56, 182
3155972|NCT00332969|Experimental|Sandostatin|
3155973|NCT00333073|Experimental|Bulkamid|Submucosal injection of Bulkamid into urethra
3155974|NCT00333099|Placebo Comparator|nutrition|study of immuno-modulating enteral nutrition
3155975|NCT00333112|Experimental|1|
3155976|NCT00333112|Placebo Comparator|2|
3155977|NCT00333125|Experimental|Travoprost/Timolol|
3155978|NCT00333125|Active Comparator|Dorzolamide/Timolol|
3155979|NCT00333203|Experimental|NGOIS|
3155980|NCT00333203|Active Comparator|BSS Plus|
3155981|NCT00333216|Experimental|15 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 30 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
2460655|NCT03169374|Experimental|Virtual Reality Technology|Virtual Reality Therapy
2460699|NCT03169023|Experimental|Arm 1: ScaleDown (only first 16 patients)|"Baseline quality of life and image surveys~Weigh themselves every day on the provided Wi-Fi Scale~Personalized feedback with text message comes as soon as participants step on the scale~At the 6 month time period, quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~Only 16 participants were in this arm because ScaleDown went out of business~At 12 month follow-up weight will be abstracted from medical record"
2460702|NCT03169023|Active Comparator|Arm 2: Enhanced Usual Care|"Baseline quality of life and image surveys~Brief in-person counseling session by a research assistant using the Enhanced Usual Care Handouts from the American Cancer Society website which provides guidelines on healthy eating and exercise~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At 12 month follow-up weight will be abstracted from medical record"
2460705|NCT03169023|Experimental|Arm 3: iOTA|"Baseline quality of life and image surveys~Weigh themselves everyday using the provided Balance High Accuracy Digital Body Fat Scale~Health coach will meet one-on-one with each participant (in-person or phone) to review health risk assessment and to choose 3 behavior goals related to healthy eating and physical activity at enrollment, 3 months, and 6 months~Self-monitoring via SMS text messaging. Weekly check-ins by text providing data about weight and goals~At the 6 month time period quality of life and body image surveys will be completed and in-office anthropometric assessments will be completed~At the end of 6 months, the participants will also receive the Enhanced Usual Care Packet which provides printed material from the American Cancer Society Website~At 12 month follow-up weight will be abstracted from medical record"
2460767|NCT03168581|Experimental|CN-105|All eligible subjects will receive study drug, CN-105
2460848|NCT03168126||Pro-AQT-Monitoting|Patients with OSCC of the jaws and tumor resection + primary free flap reconstruction
2460897|NCT03167788|Experimental|Intervention|Cross-matched allogeneic stored red cells will be rejuvenated using rejuvesol® Red Blood Cell Processing Solution (Citra Labs, MA, a Zimmer Biomet Company, IN, USA) with washing and re-suspension in an additive solution prior to transfusion. The rejuvenated red cells will then be administered to the patient as per standard practice and according to established institutional protocols. A maximum of 6 rejuvenated red cell units will be transfused within any 24 hour period.
2460901|NCT03167788|Active Comparator|Control|Standard care i.e. Cross-matched allogeneic stored non-rejuvenated, unwashed red cells will be administered to the patient as per standard practice and according to established institutional protocols.
2460936|NCT03167385|Experimental|Experitmental|Continuous oral intake of Apatinib Mesylate (500mg), once a day, until progression of disease or severe adverse effect.
2460978|NCT03167008||idiopathic male infertility|"total of 30 male patients with idiopathic male infertility.~Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
2460979|NCT03167008||fertile male group|"total of 30 fertile male (as control)~Semen samples will be collected,Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010).~blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured."
3155982|NCT00333216|Experimental|30 mg Anecortave Acetate|Anecortave Acetate Sterile Suspension, 60 mg/mL, one injection of 0.5 mL in the study eye every 6 months for 48 months
2461105|NCT03166358|Experimental|hatha yoga intervention|Participants randomized to the intervention are asked to attend 8 hatha yoga classes delivered in a group format.
2461110|NCT03166358|No Intervention|waitlist control|Participants randomized to the waitlist control condition complete assessments while the intervention group completes the yoga intervention. They are given the option to complete 8 hatha yoga classes delivered in group format once the waitlist period is finished.
2461208|NCT03165383|Active Comparator|Transversus Abdominis Plane (TAP) Block Group|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly upto 24 hours.
2461209|NCT03165383|Placebo Comparator|Control Group (No TAP Block)|The Transversus Abdominis Plane Block was not performed. Intravenous PCA Morphine was given as rescue analgesic upto 24 hours.
2461249|NCT03165214|Active Comparator|coil group|micro coils
2461251|NCT03165214|Experimental|glue group|hystoacryl mixed with lipidol
2461309|NCT03164967|Other|Active Drug|All subjects will receive Bivigam based on their prior dosing to be adjusted as clinically necessary.
2461364|NCT03164473|Experimental|Rituximab|"pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)~plus orally placebo-azathioprine for 24 months"
2461366|NCT03164473|Active Comparator|Azathioprine|"standard maintenance oral azathioprine therapy (2 mg/kg/day) for 24 months~plus 4 placebo-rituximab infusions given every 6 months for 18 months"
2461394|NCT03164031|Experimental|Close-fitting orthotic shorts condition|Orthotic shorts will be made to measure for each participant, designed to provide some compression to the hips, pelvis and thighs and to provide support. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
2461398|NCT03164031|Active Comparator|Looser fitting shorts condition|Looser shorts will be made to measure for each participant, designed to look similar to the orthotic shorts but provide minimal support or compression. Shorts will be worn during objective testing of walking ability and then taken home. Wear will be increased gradually over 5 days but then worn every day during normal daily activity.
2461554|NCT03163212|Experimental|Lactoferrin/FOS 200mg/kg|200 mg/kg enteral administration daily for 30 days
2460680|NCT03169231|Experimental|Study Group A|Single peripheral IV infusion of 25 million Longeveron Mesenchymal Stem Cells (LMSCs)
2460683|NCT03169231|Experimental|Study Group B|Single peripheral IV infusion of 50 million Longeveron Mesenchymal Stem Cells (LMSCs)
2460690|NCT03169231|Experimental|Study Group C|Single peripheral IV infusion of 100 million Longeveron Mesenchymal Stem Cells (LMSCs)
2460691|NCT03169231|Experimental|Study Group D|Single peripheral IV infusion of 200 million Longeveron Mesenchymal Stem Cells (LMSCs)
2460692|NCT03169231|Placebo Comparator|Study Group E|Single peripheral IV infusion of placebo.
2460756|NCT03168698|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2460757|NCT03168698|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2460758|NCT03168698|Active Comparator|Oxytocin 0.5IU|Oxytocin 0.5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2460760|NCT03168698|Active Comparator|Oxytocin 5IU|Oxytocin 5IU, administered intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
2460913|NCT03167879|Experimental|SCC1--high intensity supervision|Integration of safer conception counseling into family planning services, with intensive training and supervision
2460916|NCT03167879|Experimental|SCC2-- low intensity supervision|Integration of safer conception counseling into family planning services, with less intensive training and supervision that mimics Ministry of Health approach
2460918|NCT03167879|No Intervention|Usual care family planning services|Family planning services that are currently available as part of usual care, which focus almost solely on contraception and pregnancy prevention
2461007|NCT03166904|Experimental|AZD2014|Vistusertib(AZD2014) 50mg BD continuous schedule of a 28 day cycle
2461119|NCT03166033||Case Group|"age between 41 and 70years. People in the case group with the symptom numbness and then were clinical and neural-electrophysiological diagnosed CTS. People in the control group would be exclude the symptom numbness. The case group included clinical diagnosed carpal tunnel syndrome which was divided into 4 parts every 10 years old age. The gender of the patients of the control group was matched to the case group and divided into 4 parts by age."
2461120|NCT03166033||Control Group|The present case-control study was based on the single medical center in Shanghai, China, in which more than 5000 CTS patients per year are treated. The hospital involved in the study is a university teaching hospital. Cases were recruited from the surgical wards and appropriate outpatient clinics, while the controls were recruited from the outpatient clinics. Both groups filled out a standardized questionnaire, and a standardized patient record was filled out by a hand surgeon. In addition, participants with jobs involving lifting and carrying of loads were interviewed.
2461177|NCT03165786|Experimental|FREE Group|Cognitive behavioral therapy intervention with real-time continuous glucose monitoring.
2461178|NCT03165786|No Intervention|Control Group|Real-time continuous glucose monitoring
2461206|NCT03165435|Experimental|CV-MG01|The active targeted immunotherapy candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
2461207|NCT03165435|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
3155983|NCT00333216|Sham Comparator|Anecortave Acetate Vehicle|Anecortave Acetate Vehicle, one sham injection in the study eye every 6 months for 48 months
3155984|NCT00333268|Experimental|NGOIS|
3155985|NCT00333268|Active Comparator|BSS Plus|
2461596|NCT03163004|Experimental|Intervention group|Implementation of standing desks in the classroom
2461599|NCT03163004|No Intervention|Control group|
2461644|NCT03162575|Experimental|Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2.5 hours
2461652|NCT03162575|No Intervention|Waiting List Control|Patients assigned to the waiting list condition will receive no intervention for three months and afterwards will receive MBCT
2461710|NCT03162198||Cirrhosis with HCC|
2461716|NCT03162198||Cirrhosis without HCC|
2461757|NCT03161717|Experimental|Epidural electrical stimulation (EES)|n=20
2461761|NCT03161717|Active Comparator|Loss of resistance (LOR)|n=20
2461807|NCT03161470|Active Comparator|Standard Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) without the mechanical chair.
2461808|NCT03161470|Experimental|Mechanical Chair Repositioning|Participants randomly selected for this treatment arm will undergo standard BPPV treatments (canalith repositioning procedure) with the mechanical chair.
2461811|NCT03161470|Sham Comparator|Sham Treatment|Participants randomly selected for the sham arm will undergo be strapped into the mechanical chair as for the treatment arm but will only undergo the test positions for BPPV-the Dix-Hallpike maneuver. No BPPV repositioning treatment will be completed at the first encounter. At the follow-up visit, standard BPPV treatments (canalith repositioning procedure) will be completed.
2461862|NCT03161015|Experimental|GBT440 Dose 1: Severe Renal Impairment|eGFR < 30 mL/min/1.73m2, not on dialysis
2461871|NCT03161015|Experimental|GBT440 Dose 1: Moderate Renal Impairment|30 mL/min/1.73m2 = or < eGFR < 60 mL/min/1.73m2
2461878|NCT03161015|Experimental|GBT440 Dose 1: Mild Renal Impairment|60 mL/min/1.73m2 = or < eGFR < 90 mL/min/1.73m2
2461882|NCT03161015|Experimental|GBT440 Dose 1: Normal Renal function|eGFR > or = 90 mL/min/1.73m2
2461942|NCT03160586|Active Comparator|Stutter|Children who stuttering
2461944|NCT03160586|Active Comparator|Control|Children who non stuttering
2461981|NCT03160248|Experimental|Apremilast|Patients randomized to this arm will start Apremilast with a titration phase of 5 days, followed by 30 mg Apremilast tablets twice daily (BID) by mouth (PO) for a total of 32 weeks (including titration phase).
3155986|NCT00333320|Placebo Comparator|- Control|
3155987|NCT00333320|Experimental|-postconditioning group|
3155988|NCT00333333||SGA infants|Infants who are thought to be small for gestational age (SGA)
2460708|NCT03169257|No Intervention|NW|Normal weight subjects according to the International Obesity Task Force (IOTF) criteria aged 6 to 16 years and age, sex and pubertal status matched with the OB group
2460721|NCT03168737|Experimental|Group A (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 PET-CT scans at 60, 90, 120, 150, and 180 minutes on days 1 and 2.
2460723|NCT03168737|Experimental|Group B (18F-fluoroazomycin arabinoside, PET-CT scans)|Patients receive 18F-fluoroazomycin arabinoside IV and after 60 minutes undergo 5 or less PET-CT scans on day 1 and 5 or less PET-CT scans >= 24 hours later up to 10 days.
3191176|NCT00795691|Experimental|Low-carbohydrate diet|The low-carbohydrate diet was based on the Atkins weight loss diet. The daily intake goals were to restrict intake of carbohydrate to 20-25 grams for the first 2-week phase. If body weight decreased, the daily goal for carbohydrate was increased by 5 grams. If body weight increased, the daily goal for carbohydrate intake was decreased by 5 grams. The minimum goal for carbohydrate intake was 20 grams per day and the maximum goal was 50 grams per day.
3191177|NCT00795691|Active Comparator|Low-fat diet|The low-fat diet was based on the algorithm used to restrict fat and calorie intake in the Diabetes Prevention Program. The daily goals for fat intake was based on an algorithm to reduce total calorie intake to achieve a one pound weight loss per week with 25% of calories from fat.
3191178|NCT00795730|Placebo Comparator|placebo|
2460891|NCT03167957|Experimental|CAMB 200 mg|200 mg CAMB Oral Amphotericin B
2460898|NCT03167957|Experimental|CAMB 400 mg|400 mg CAMB Oral Amphotericin B
3191179|NCT00795730|Experimental|NSA-789|
2461019|NCT03166683|Experimental|Hemopatch|Use of hemopatch like a control of bile leakage/sealant during liver resection surgery.
2461025|NCT03166683|Active Comparator|Standard of care|Application of standards of care, may include other sealant / hemostatic devices as patches or liquid/gels, during liver resection surgery.
2461097|NCT03166449|Experimental|Neomune|18 patients with traumatic brain injury were given Neomune as enteral nutrition.
2461106|NCT03166449|Active Comparator|Fresubin® HP energy|18 patients with traumatic brain injury were given Fresubin® HP energy as enteral nutrition.
2461124|NCT03165864|Experimental|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
2461132|NCT03165864|Placebo Comparator|Placebo|Saline .9%
3191180|NCT00795756|Experimental|Intrathecal DepoCyte|I.t. DepoCyte 50 mg admninistered x6-8 (depending on immunophenotypic disease subset) during induction/consolidation/eraly maintenance phases
3191181|NCT00795756|Active Comparator|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg injected intrathecally x12 during indiction/consolidation phases
3191182|NCT00795782|Experimental|UniCND|Limited/ipsilateral central lymph node dissection
2461280|NCT03165019||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2461283|NCT03165019||High altitude control|Healthy highlanders living above 2500 m.
2461285|NCT03165019||Low altitude control|Healthy lowlanders living below 1000 m.
2461416|NCT03164135|Experimental|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 before transplantation into the patient.
2461476|NCT03163641|Experimental|Treatment 1|Ocular Bandage Gel
2461483|NCT03163641|Experimental|Treatment 2|Ocular Bandage Gel
2461488|NCT03163641|Active Comparator|Control Group|Artificial tears with Acuvue Oasys
2461530|NCT03163251|Experimental|READ-SG Cohort|Each post-graduate year (PGY) will receive the intervention of a monthly peer-facilitated small group sessions (READ-SG Sessions) based on topics that are common to residency training and based on themes regarding humanism in medicine.
2461666|NCT03162718|Other|single arm|exercise
2461709|NCT03162159||cohort for model computing|patients with CAH, born between 1970 and 1993, with genetically proven CAH, available growth and bone maturation data.
2461713|NCT03162159||cohort for model validation|patients with CAH, born between 1994 and 1998, with genetically proven CAH, available growth and bone maturation data.
2461763|NCT03161756|Experimental|Arm A|Patients in Arm A will receive nivolumab 3 mg/kg intravenously (IV) every 2 weeks for 4 doses and denosumab 120 mg subcutaneously (SC) given D1, D8, D15, D29 (induction phase). Thereafter, nivolumab 480 mg IV and denosumab 120 mg SC every 4 weeks for a total of 24 months (maintenance phase).
2461766|NCT03161756|Experimental|Arm B|Patients in Arm B will receive ipilimumab at 3 mg/kg combined with nivolumab at 1 mg/kg IV every 3 weeks for 4 doses with denosumab 120 mg SC given D1, D8, D15, D29, D57 (induction phase). This will be followed by nivolumab 480 mg IV and denosumab 120 mg SC ever 4 weeks for a total of 24 months (maintenance phase).
2461797|NCT03161249|Experimental|Experimental group|Mobile psychotherapy (5 modules) plus treatment as usual
2461799|NCT03161249|Other|Control group|"Control group: Treatment as usual~The description of this group, the control group, corresponds to the treatment to receive the usual treatment that is received on a regular basis, we will not perform any additional intervention"
2461865|NCT03161197|Experimental|Intervention|The intervention consists of 8-10 sessions consisting of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation exercises, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, during every point of contact subjects will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
3191183|NCT00795782|Active Comparator|BiCND|Comprehensive/bilateral central lymph node dissection
3191184|NCT00795782|No Intervention|NoCND|No central lymph node dissection
2460778|NCT03168360|Experimental|Intensive group|cognitive rehabilitation therapy for 1 hour by cognitive therapist on every working day for 4 weeks
2460779|NCT03168360|Active Comparator|Conventional group|cognitive rehabilitation therapy for 30 minutes by cognitive therapist on every working day for 4 weeks
2460856|NCT03168100|Experimental|Study Treatment|Elotuzumab (10 mg Days 1 and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg days 1, 8, 15, and 22) administered in 28-day cycles which will be alternated every 8 weeks with bortezomib (1.0 mg Days 1, 8, and 15), lenalidomide (15 mg Days 1-21), and dexamethasone (20 mg Days 1, 8, 15, and 22)
2460912|NCT03167632||dental patients|
2460983|NCT03167125|Active Comparator|Automated Prompts|Patients randomized to this arm will receive automated prompts to complete and return the FIT kit.
2460988|NCT03167125|Active Comparator|Automated Plus Live Prompts|Patients randomized to this arm will receive automated prompts plus linguistically and culturally tailored live prompts to complete and return the FIT kit.
2460993|NCT03167125|No Intervention|Usual Care|Patients randomized to this arm will receive usual care screening opportunities per recommended colorectal cancer screening guidelines.
2461020|NCT03166696||acute cerebral infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute cerebral infarction
2461026|NCT03166696||acute myocardial infarction|the registry and follow up of consecutive patients who were admitted and diagnosed with acute myocardial infarction
2461080|NCT03166553|Experimental|Elemene +Oxaliplatin|the group treated with the Elemene Injection/Elemene Oral Emulsion in Combination with Systematic Chemotherapy including Oxaliplatin
2461086|NCT03166553|No Intervention|Oxaliplatin|the group treated with Systematic Chemotherapy including Oxaliplatin
3191185|NCT00795795|Active Comparator|with PGS|IVF cycles with Preimplantation Genetic Screening (PGS)
2461288|NCT03165292|Experimental|Arm A: High administered activity 131I-mIBG radiolabelled with iodine-131 and Topotecan|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
2461289|NCT03165292|Experimental|Arm B: High dose Thiotepa|"The trial will evaluate two randomised arms. Each arm includes~three cycles of Temozolomide-Irinotecan, similar in both arms,~a specific consolidation course detailed hereinafter,~a BuMel sequence, followed by an ASCT, similar in both arms,~external radiotherapy as appropriate, and/or local surgery of the tumour residues as appropriate."
2461388|NCT03164382|Experimental|HAIF group|FOLFOX regimen: oxaliplatin 130 mg/m2 on day 1 from hour 0 to 3; leucovorin 200 mg/m2 from hour 3 to 5, fluorouracil 400 mg/m2 bolus at hour 5, and then fluorouracil 2,400 mg/m2 over 46 hours, via hepatic artery, once every 3 weeks.
2461392|NCT03164382|Active Comparator|Sorafenib group|Sorafenib 200mg Tab, 400 mg twice per day orally. Treatment was given in 4-week cycles.
2461448|NCT03163823|Placebo Comparator|Standard Communication|Standard of Care communication styles will be used. Patients will receive the standard communication protocol identified by the hospital.
2461457|NCT03163823|Experimental|iPad with Speech App|Use of application Proloquo2Go on iPad device. The application being used is called Proloquo2Go which is the intervention portion. The iPad is the device used to access the application.
2461532|NCT03163511|Experimental|Cohort 1|VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants
2461534|NCT03163511|Experimental|Cohort 2|VC-02 Combination Product; Up to twelve units implanted of which up to ten (10) are VC-02-300 implants and the rest are VC-02-20 implants.
2461616|NCT03162653|Active Comparator|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
2461617|NCT03162653|Placebo Comparator|Placebo|mannitol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
2461682|NCT03162315|No Intervention|Fresh embryo transfer|fresh embryo transfer (standard of care)
2461683|NCT03162315|Experimental|Freeze all|Vitrification of all embryos and replacement of a thawed embryo in a subsequent cycle
2461688|NCT03162016|Experimental|Transplants of acellular matrix|
2461690|NCT03162016|Active Comparator|Transplants of connective tissue|
3191186|NCT00795795|Active Comparator|Without PGS|IVF cycle without Preimplantation Genetic Screening
3191187|NCT00795808|Experimental|BMI > 32|Women with BMI > 32
2461955|NCT03160378|Experimental|Intervention|The participants in the intervention group will receive treatment as usual + 10 sessions of organizational skills training
2461959|NCT03160378|Other|Control|Control participants will receive treatment as usual.
3191188|NCT00795808|Experimental|BMI </= 32|Women with BMI </= 32
3191189|NCT00795834|Placebo Comparator|Beverage|
3191190|NCT00795834|Active Comparator|High Polyphenol Beverage|
3191191|NCT00795847|Experimental|1. Preminent|Patients with blood pressure self-measurement-proven morning hypertension are treated with Preminent 1T qd for 3 months.
3191192|NCT00795847|Active Comparator|2. High-dose losartan|Patients with blood pressure self-measurement-proven morning hypertension are treated with losartan 100 mg qd for 3 months.
3191193|NCT00795860|Active Comparator|Weight loss - diet only|
3191194|NCT00795860|Experimental|Weight loss plus exercise|
3191195|NCT00795899|Experimental|1|Epirubicin/Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab in patients with HER-2 overexpression
2460804|NCT03168191|Placebo Comparator|No Flavor|In this arm, subjects will receive no flavor. Participants will be randomly assigned to low or high dose of nicotine.
2460855|NCT03168009|Experimental|Bariatric Surgery|Patients will undergo either Omega Loop Gastric Bypass or Sleeve Gastrectomy. The decision which type of surgery will be performed, will by made by the surgeon and the patient based on clinical considerations and the patient's wishes.
3155989|NCT00333333||Pre-eclampsia exposed|Infants who are born to mothers who had pre-eclampsia
3155990|NCT00333398|Experimental|1|250 subjects-Lot #1 multiple-dose vial (thimerosal-containing).
2460932|NCT03167320||LOVIC|Irish patients with low Von Willebrand levels will be have both venous blood sampling and a bleeding score administered at study entry. A DDAVP (1-desamino-8-D-arginine vasopressin) fall off study was organised for those patients in the cohort with no previous fall offs available and no contraindications to DDAVP.
2460996|NCT03167112|Experimental|FOLFIRINOX|Oxaliplatin, Irinotecan, Leucovorin, Fluorouracil
3155991|NCT00333398|Experimental|2|250 subjects-Lot #2 multiple-dose vial (thimerosal-containing).
3155992|NCT00333398|Experimental|3|250 subjects-Lot #3 multiple-dose vial (thimerosal-containing).
3155993|NCT00333398|Placebo Comparator|4|250 subjects-multiple-dose vial placebo (thimerosal-containing).
2461065|NCT03166306|Experimental|Patients with idiopathic or familial PAH|Ten patients with severe idiopathic or familial PAH will undergo PET-CT imaging with [89Zr]-bevacizumab.
2461070|NCT03166306|Experimental|Patients with exercise associated PAH|Ten patients with exercise associated PAH (EPAH) will undergo PET-CT imaging with [89Zr]-bevacizumab.
2461075|NCT03166306|Active Comparator|Healthy volunteers|Ten individuals with no known cardiopulmonary disease will undergo PET-CT imaging with [89Zr]-bevacizumab.
2461125|NCT03166111|Experimental|lidocaine group|lidocaine in-situ gel inserted vaginally
2461129|NCT03166111|Placebo Comparator|placebo group|placebo gel inserted vaginally
2461191|NCT03165695|Experimental|Ramelteon Arm|Ramelteon tablet 8 mg orally at 21:00 for 7 days or until discharge whichever comes first.
2461193|NCT03165695|Placebo Comparator|Placebo Arm|Sugar pill manufactured to mimic Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first.
2461201|NCT03165344|Experimental|hydrocortisone group|
2461202|NCT03165344|Placebo Comparator|prednisone grope|
2461234|NCT03165253|Active Comparator|Synbiotic Group|The patients will be treated with the standard triple therapy that consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month, and the synbiotic Bifidobacterium animalis oral product (5000000000 colony forming units/dose) plus inulin (900 mg) given a single dose for 14 days, concurrently.
2461236|NCT03165253|Other|Standard Therapy Group|The patients in this group will be treated with standard triple therapy only. The standard triple therapy consists of amoxicillin oral tablet 50 mg/kg/d and clarithromycin oral tablet 15 mg/kg/d twice daily for 14 days, and omeprazole 1 mg/kg/d once daily for a month.
2461259|NCT03165032||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2461263|NCT03165032||High altitude control|Healthy highlanders living above 2500 m.
2461270|NCT03165032||Low altitude control|Healthy lowlanders living below 1000 m.
2461301|NCT03164876|Experimental|Dose AUT00206 800 mg BD|AUT00206 800mg twice daily for 28 days
2461302|NCT03164876|Placebo Comparator|Placebo|Placebo to match AUT00206 twice daily for 28 days
3155994|NCT00333398|Experimental|5|250 subjects-Prefilled Lot #1, #2, or #3 (TBD) (thimerosal-free).
3155995|NCT00333411|Experimental|BIRT 2584 XX high dose|
3155996|NCT00333411|Experimental|BIRT 2584 XX medium dose|
3155997|NCT00333411|Experimental|BIRT 2584 XX low dose|
3155998|NCT00333411|Placebo Comparator|Placebo|
3155999|NCT00333424|Placebo Comparator|Placebo|placebo containing diluent alone
2461526|NCT03163407|Active Comparator|Ephedrine group|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
2461555|NCT03163212|Experimental|Lactoferrin/FOS 300mg/kg|300 mg/kg enteral administration daily for 30 days
3156000|NCT00333463||Intervention group|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
3156001|NCT00333463||Non-Intervention Group|The control group was told to take drops as prescribed and received no additional intervention.
3156002|NCT00333502|Experimental|CRLX101 (formerly known as IT-101)|CRLX101 dosing per protocol dose escalation cohorts to MTD, then expansion cohort treated at MTD of CRLX101 15mg/m2
3156003|NCT00333515|Experimental|1|Administration of one of 3 doses (dose escalation) of the active drug (HuBChE). (Dose-escalation proceeds only after safety evaluation and after the previous dosage has been found to be acceptable by an independent Data Safety Monitoring Board.)
3156004|NCT00333515|Placebo Comparator|2|Administration of placebo
3156005|NCT00333528|Experimental|1|Administration of one dose of the active drug (6 volunteers)
3156006|NCT00333528|Placebo Comparator|2|Administration of placebo (2 volunteers)
3156007|NCT00333541|Experimental|Treatment|follow-up via e-mail link to survey
3156008|NCT00333541|No Intervention|Control|standard follow-up by phone and in-person interview
3156009|NCT00333554|Experimental|DHA Treatment Group|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
3156010|NCT00333554|Placebo Comparator|Control Group|Placebo for DHA given to nursing mother (breast milk), study formula, or capsules (removing content and mixing with food)depending on age of child.
3156011|NCT00333580||Group 1|
3156012|NCT00333658|Experimental|1|Intervention
3156013|NCT00333658|No Intervention|2|Work Services
3156014|NCT00333684|Active Comparator|receive bioalcamid at baseline|half subjects received bioalcamid at baseline
3156015|NCT00333684|Active Comparator|Receive bioalcamid at 24 weeks|other half of subjets received bioalcamid at 24 weeks
3156016|NCT00333749|Experimental|1|55 children < 5 years with acute oral ulcer disease.
3156017|NCT00333749|Placebo Comparator|2|55 Children < 5 years with acute oral ulcer disease.
2460941|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 2 days|Cohort 3
2460952|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 480 mg QD for 3 days|Cohort 4
2460962|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 480 mg QD for 3 days|Cohort 5
2460965|NCT03167242|Experimental|KAF156 400 mg and LUM-SDF 960 mg QD for 3 days|Cohort 6
2460969|NCT03167242|Active Comparator|Coartem twice a day (BID) for 3 days|Cohort 7
2460973|NCT03167242|Experimental|KAF156 200 mg and LUM-SDF 960 mg once daily for 1 day|PK Run-in Cohort
2461044|NCT03166813|Experimental|Intervention RIPC|The intervention RIPC protocol will be induced by three cycles of inflation of a blood pressure cuff placed over the upper or lower limb, where deemed to cause minimal discomfort to patient, to 15 mmHg above the systolic blood pressure for five minutes followed by five minutes of cuff deflation to 0 mmHg.
2461045|NCT03166813|Placebo Comparator|Control|The control protocol involves only placement of blood pressure cuff but without inflation for 30 minutes.
2461140|NCT03166007|Experimental|Optimised bowel care + abdominal massage|In addition to optimised bowel care as described below for the control group, the Intervention Nurse will teach the participant and/or their carer in the intervention arm how to deliver the abdominal massage. This will include viewing the massage DVD and the abdominal massage training booklet, as well as the demonstration of the technique on the participant by the Intervention Nurse.
2461143|NCT03166007|Active Comparator|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated.
2461217|NCT03165565|Experimental|MI and ACT|Participants will receive behavioral therapy including Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
2461220|NCT03165565|Active Comparator|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
2461255|NCT03165162|Experimental|Study Arm|Food Order: Randomly assigned orders of 7 bowls of granola, each with a different food label.
2461307|NCT03164941||Nasal SLT|This cohort will have 180 degree SLT completed on the nasal quadrants of the trabecular meshwork.
2461308|NCT03164941||Temporal SLT|This cohort will have 180 degree SLT completed on the temporal quadrants of the trabecular meshwork.
2461344|NCT03164499|Active Comparator|Control group|Individual counselling on lifestyles.
2461347|NCT03164499|Experimental|Intervention group|Individual counselling on lifestyles and additional group counselling on lifestyles.
2461446|NCT03163693|Experimental|Group dexmedetomidine|20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
2461450|NCT03163693|Placebo Comparator|Group control|20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
3191196|NCT00795912|Active Comparator|1|Atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
3191197|NCT00795912|No Intervention|2|Usual medical care of heart failure
2461582|NCT03162757|Experimental|Subclavian vein access|
2461587|NCT03162757|Experimental|Internal jugular vein access|
2461640|NCT03162588|Experimental|multiple burrhole therapy and erythropoietin|pretreatment with IV erythropoietin for 3 days, 120000IU#3 then multiple burrhole procedure on the hemisphere effected is performed
2461737|NCT03162211|Experimental|Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the experimental group will receive automated reminders (by text message, phone and/or email) to complete outcome measures each week. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals. The intervention will last 6-months, with feedback forms being generated once per week for the first three month and then each month for a total of fifteen feedback time points. Patients in the feedback group will be encouraged to meet with their clinician each month to discuss the feedback.
2461740|NCT03162211|No Intervention|No Feedback Arm|A registry platform including access to all self-report rating scales and the feedback mechanism will be made available to all patients. Patients in the control group will not receive regular reminders or be sent feedback reports on an automatic regular basis.
2461769|NCT03161665|Experimental|BMT Roadmap|The BMT Roadmap information system will be tested in 20 caregivers of patients undergoing autologous or allogeneic BMT and in 20 patients undergoing autologous or allogeneic BMT.
2461801|NCT03161444|Other|Elective patient|Patient who has patricipated to the study CHIKVIH (NCT02553369) will have a blood collection during a follow up visit for HIV infection.
2461879|NCT03161132|Experimental|Olaparib 300mg|Olaparib bid orally at 300 mg (tablet formulation) continuously, combined with chemotherapy with Pegylated Liposomal Doxorubicin (up to 6 cycles), then, as monotherapy at the same dose and frequency (300mg bid orally) until progression of disease or unaccepted toxicity.
2461885|NCT03161132|Other|Pegylated Liposomal Doxorubicin (PLD)|PLD 40mg/m2 every 28 days intravenous for up to 6 cycles. This treatment will be combined with Olaparib (as described earlier).
2461964|NCT03160521|Experimental|Risperidone ISM 75 mg|Patients assigned to this arm will received 75 mg of Risperidone ISM during double-blind treatment period.
2461968|NCT03160521|Experimental|Risperidone ISM 100 mg|Patients assigned to this arm will received 100 mg of Risperidone ISM during double-blind treatment period.
2461969|NCT03160521|Placebo Comparator|Placebo|Patients assigned to this arm will received placebo of Risperidone ISM during double-blind treatment period.
2462013|NCT03159988|Experimental|Non-randomized treatment group|12 weeks of daily does subcutaneous injection of Angiotensin-(1-7) 100 mcg/kg/day
2462046|NCT03159715|Experimental|Internet-based Global Protocol|Intervention group that carries out the Internet-based Global Protocol and receives therapist support.
2462047|NCT03159715|Experimental|Internet-based Behavioral Activation Protocol|Intervention group that carries out the Internet-based Behavioral Activation Protocol and receives therapist support.
3191198|NCT00795925|Experimental|propiverine hydrochloride|
3191199|NCT00795938|Active Comparator|Conventional Oral Tablet With Water|
2460982|NCT03166956|Experimental|GA (glutamine and vitamin C) group|"Interventions of glutamine and vitamin C enteral supplementations were given to surgical intensive care unit (ICU) patients.~Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan)."
2460990|NCT03166956|Placebo Comparator|Control (C) group|"Placebo:~Subjects in the C group received isocaloric maltodextrin as placebo."
3191200|NCT00795938|Experimental|Experimental Tablet With Water|
2461164|NCT03165799|Experimental|Mindfulness Education|"Participants viewed an informational video titled, All it Takes is 10 Mindful Minutes by mindfulness expert, Andy Puddicombe. Following the video, a guided discussion was provided that focused on how the principles of mindfulness can be used to influence a physician's state of mental presence, allowing for moments of clarity, insight, and reflection, and potentially enhance provider and patient safety."
2461167|NCT03165799|No Intervention|No Intervention|Participants did not receive mindfulness education.
2461221|NCT03165591|Experimental|Experimental|Daily tablet of V3-P given orally for 2 months
3156018|NCT00333827|Active Comparator|Optimal Therapy|Optimal therapy for cardiac failure
3156019|NCT00333827|Experimental|cell therapy|stem cell
2461417|NCT03164395|Experimental|Internal Cardioversion|Patients randomized to external cardioversion will undergo external synchronized cardioversion per institutional protocol.
2461418|NCT03164395|Active Comparator|External Cardioversion|Patients randomized to internal cardioversion will have a maximum energy shock delivered from the device between the RV coil and can. If cardioversion is not successful they will then undergo external cardioversion per institutional protocol.
2461485|NCT03163628|Experimental|7 biomarkers combination|
2461665|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
2461667|NCT03162783|Experimental|ADX-102 Ophthalmic Solution (0.1%)|
2461669|NCT03162783|Experimental|ADX-102 Ophthalmic Lipid Solution (0.5%)|
2461714|NCT03162042||Squamous cell carcinoma|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
2461717|NCT03162042||Control group|55 patients were included in the study : 32 in the cancer group (only squamous cell carcinoma) and 23 in the control group.
2461756|NCT03161730|Experimental|McGrath videolaryngoscopy|Participants attempt to perform three intubation using McGrath videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2461760|NCT03161730|Experimental|Pentax videolaryngoscopy|Participants attempt to perform three intubation using Pentax videolaryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2461764|NCT03161730|Active Comparator|Macintosh laryngoscopy|Participants attempt to perform three intubation using Macintosh laryngoscope in the manikin with the normal airway and difficult airway scenario, respectively.
2462036|NCT03159910|Experimental|Shoulder-Café (intervention)|A Shoulder-Café intervention consists of three café-meetings.
2462037|NCT03159910|Active Comparator|Shoulder-Guidance (control)|The Shoulder-Guidance intervention consists of an initial individual appointment and two e-mail contacts.
2462087|NCT03159572||Ovarian cancer group|Patients who are diagnosed with ovarian cancer and have a plan of surgery.
2462144|NCT03159182|Experimental|Pressure garment and silicone insert|Custom measured pressure garment with a textile bonded silicone insert in either the distal or proximal portion of the pressure garment, to be worn 23 hours per day.
2462149|NCT03159182|Active Comparator|Pressure Garment|Custom measured pressure garment, to be worn 23 hours per day.
2462483|NCT03156673|Experimental|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2462529|NCT03156322|Active Comparator|Group 5|5 mL epidural initiation volume (bupivacaine + fentanyl)
2462531|NCT03156322|Active Comparator|Group 10|10 mL epidural initiation volume (bupivacaine + fentanyl)
2462533|NCT03156322|Active Comparator|Group 20|20 mL epidural initiation volume (bupivacaine + fentanyl)
3156020|NCT00333918|Experimental|1-bromfenac ophthalmic solution|sterile ophthalmic solution
3156021|NCT00333918|Placebo Comparator|2-placebo comparator|sterile ophthalmic solution
3156022|NCT00334022|Placebo Comparator|Did not receive enfuvirtide|patients were randomized to either receive enfuviratide or not receive it
3156023|NCT00334022|Active Comparator|enfuvirtide|enfuvirtide 1ml BID
3156024|NCT00334100|Other|Arm 1|
3156025|NCT00334139|Experimental|zoledronic acid|
3156026|NCT00334217|Experimental|1|PSS CogRehab exercises
3156027|NCT00334217|No Intervention|2|On-line computer games
3156028|NCT00334321|Experimental|IMRT with chemotherapy|"IMRT (upper third of vagina & para-vaginal tissue and the common, external and internal iliac nodal regions) 160-180 cGy daily fractions for a total dose of 4500-5120 cGy. Once a day treatment four to five days a week for approximately 6 weeks.~Intracavitary vaginal brachytherapy - some patients will be given this and it will be decided by the treating physician.~Carboplatin - AUC 6, IV over 30-60 minutes following completion of paclitaxel, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles~Paclitaxel - 175 mg/m2, 3 hour continuous IV infusion, administered prior to carboplatin, given once every 3 weeks (3 weeks=1 cycles) for a total of 6 cycles"
3156029|NCT00334347|Active Comparator|Depakote ER|
3156030|NCT00334347|Active Comparator|Depakote DR|
3156031|NCT00334360|Experimental|1|dexmedetomidine
3156032|NCT00334360|Experimental|2|Buspirone
3156033|NCT00334360|Experimental|3|Buspirone and dexmedetomidine
3156034|NCT00334360|Placebo Comparator|Control|No drug
3156035|NCT00334373|Experimental|Post conditioning|Balloon inflations-deflations
3156036|NCT00334373|Placebo Comparator|Standard care|No balloon inflations
3156037|NCT00334438|Other|Zevalin + Velcade Single Arm Study|Zevalin (Ibritumomab Tiuxetan) and Velcade (Bortezomib)
3156038|NCT00334490|Active Comparator|1|Oral Sildenafil 12.5 mg
3156039|NCT00334490|Placebo Comparator|2|Placebo in 5 mls distilled water
3156040|NCT00334555|Active Comparator|usual care|patient told to refer her partner for treatment
3156041|NCT00334555|Active Comparator|partner delivered|patient given medication to deliver to her partners
2461001|NCT03167177|Experimental|NANT Melanoma Vaccine|"A combination of agents will be administered to subjects in this study:~avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel, nivolumab, omega-3-acid ethyl esters, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-6207, GI-6301, and haNK."
2461085|NCT03166280||hepatitisC-pre-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis before receiving their treatment
2461090|NCT03166280||hepatitis C-ttt|Naïve HCV Patients (>18Y) coming to National Committee for control of viral hepatitis- 12 weeks after stoppage their treatment of sofosbuvir 400 mg/day plus Daclatasvir 60 mg/day for 12 weeks.
2461147|NCT03166072|Active Comparator|Low-vision rehabilitation program|Participants and their care givers in Low-vision rehabilitation program will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and after Low-vision rehabilitation program.
2461155|NCT03166072|Placebo Comparator|No Intervention|Participants and their care givers will undergo a standardized interview to measure HRQoL using the time trade-off method (TTO), depression using the Patient Health Questionnaire (PHQ-9), anxiety using Generalized Anxiety Disorder (GAD-7) and Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48) at the first study visit and will continue to receive treatment as usual.
3156042|NCT00334555|Active Comparator|field intervention|field intervention to find partners
3156043|NCT00334568|Experimental|Rosi XR|Rosi XR
2461318|NCT03164746|Active Comparator|DRY group|Dry sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
2461323|NCT03164746|Experimental|WET Group|Wet sheet therapeutic body wraps will be conducted through twice-a-week sessions for a 3-month duration. Sessions take place in the same quiet room and they usually last 45 minutes each up to 1 hour depending on the patient's response. During sessions, the patient wearied a bathing suit. Sessions were conducted under the supervision of an occupational therapist and involved at least two members of the patient's care team.
2461376|NCT03164343|Experimental|Pain Neuroscience Education for children|All participants within this study will receive Pain Neuroscience Education
2461399|NCT03164005||Group 1|subjects without metabolic diseases
2461401|NCT03164005||Group 2|subjects with metabolic diseases
2461453|NCT03163810|Experimental|Erchonia Verju and EVRL Laser|"The Erchonia Verju Laser has 6 diodes that each emit 17 milliwatts (mW) 532 nanometers (nm) of green laser light.~The Erchonia EVRL Laser emits 635 nanometers (nm) red light and 405 nm blue light simultaneously"
2461502|NCT03163524|Experimental|Treatment group (modified text)|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
2461504|NCT03163524|Sham Comparator|Control group (standard text)|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
2461597|NCT03163082|Active Comparator|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
2461600|NCT03163082|Active Comparator|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
2461603|NCT03163082|Active Comparator|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
2461606|NCT03163082|Active Comparator|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
2461662|NCT03162432|Experimental|Vitamin D3 Treatment|Subjects receiving Remicade will be treated with oral Vitamin D3
2461800|NCT03161366|Experimental|Single arm|Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10^7 PFU)
2461877|NCT03161184|Active Comparator|Control (paper based)|"Women received prenatal household visits from CHWs who were trained on the Tanzania Ministry of Health and Social Welfare's National integrated Maternal, Newborn and Child Health (i-MNCH) paper-based protocols, i.e. received intervention SUSTAIN Paperbased training of CHW (SOC)"
2461883|NCT03161184|Experimental|Intervention (Smart phone assisted)|"Women received prenatal household visits from CHWs trained on the following:~A) National i-MNCH programme; and B) Smartphone-assisted counseling protocol: a smartphone application designed to assist with identification of danger signs during pregnancy, referral to health facilities, and MNCH counseling~, i.e. received intervention SUSTAIN Smartphone training of CHW (SP+)"
2461932|NCT03160625|Active Comparator|Rate Adaptive Pacing ON|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age
2462129|NCT03158922||Stage 1|Caucasian men aged 55-69 to undergo genetic profiling.
3156044|NCT00334568|Placebo Comparator|Placebo|Placebo (matched)
3156045|NCT00334581|Experimental|1|Irbesartan 150mg
3156046|NCT00334581|Experimental|2|Irbesartan 300mg
3156047|NCT00334594|Active Comparator|No radiotherapy|
3156048|NCT00334594|Experimental|Radiotherapy|
3156049|NCT00334646|Experimental|Arm A|cyclophosphamide + dexamethasone + ondansetron
3156050|NCT00334646|Experimental|Arm B|cyclophosphamide + dexamethasone + ondansetron + GW679769
3156051|NCT00334685|Experimental|[S,S]-Reboxetine + Pregabalin|
3156052|NCT00334685|Active Comparator|Pregabalin|
2461023|NCT03166644|Experimental|Intervention Group|Patients with standard practice
2461099|NCT03166436|Experimental|RFA plus stenting|Endoluminal radiofrequency ablation followed by biliary stenting
2461108|NCT03166436|Active Comparator|Stenting alone|Biliary stenting alone
2461171|NCT03165825|Experimental|Tranforaminal|will receive cervical epidural injection via a transforaminal route with dexamethasone steroid
2461175|NCT03165825|Active Comparator|Interlaminar|will receive cervical epidural injection via an interlaminar route with betamethasone steroid
2461410|NCT03164096|Experimental|intrathecal bupivacaine|intrathecal bupivacaine hydrochloride 0.5%,12.5mg
2461452|NCT03163719||Patients with generalized convulsive seizure|All adult patients (aged at least 18 years old) presenting to the CHU Clermont-Ferrand adult emergencies with a strong suspicion of generalized tonic-clonic seizure beginning less than 4 hours will be included. Each eligible patient will be proposed by a doctor, to participate to the study. The emergency doctor will verify the patient's inclusion and non-inclusion criteria.
2461517|NCT03163537||Kidney transplantation, postmortal, day|
2461520|NCT03163537||Kidney transplantation, postmortal, night|
2461522|NCT03163537||Kidney transplantation, living donor|
2461610|NCT03162744||Suicide attempt or ideas|Elderly patients who attempted suicide or who emitted suicidal ideas
2461647|NCT03162497|Experimental|Azithromycin|Preservative-free azithromycin 15mg/g (Azyter® Augentropfen im Einzeldosisbehältnis, Thea, Clermont-Ferrand, France) one drop twice daily for two days then once daily for 26 days
2461657|NCT03162497|Active Comparator|Doxycycline|"Doxycycline 100mg (Doxycycline Genericon, Genericon Pharma GmbH, Graz, Austria) twice daily for 6 weeks"
2461731|NCT03162146||Patient admitted to intensive care unit|All patients requiring intensive care unit stay
2461837|NCT03161574|Experimental|FOLFOXIRI|patients with CRM positive who received FOLFOXIRI alone for 6 cycles before surgery
2462040|NCT03159884|Experimental|3+Q12W|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, followed by every 12 weeks. If the subject meets the additional medication criteria in 12 weeks during treatment, additional injection can be given;"
2462041|NCT03159884|Experimental|3+TAE|"The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the treatment-extended dosing criteria. When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the extra dosing criteria."
2462124|NCT03158948|Experimental|MOTREM 1|0.3 mg/kg/h
2462125|NCT03158948|Experimental|MOTREM 2|1.0 mg/kg/h
2462126|NCT03158948|Experimental|MOTREM 3|3.0 mg/kg/h
2462127|NCT03158948|Placebo Comparator|Placebo|
2462221|NCT03158779|Experimental|SBRT and chemotherapy|"Participants received 4 months of FOLFIRINOX or Gemcitabine-Abraxane before SBRT was administered. A 3-weeks break from chemotherapy and restaging with thorax-abdominal CT scan to confirm the absence of distant metastases was required before SBRT delivery.~Before SBRT simulation, patients may will have implanted fiducial into the pancreatic tumor.~The SBRT schedule will be [6 x 9 Gy = 54 Gy] delivered in consecutive days."
2462377|NCT03157765|Experimental|EMB intervention|These patients receive and endometrial biopsy
2462379|NCT03157765|No Intervention|Routine care|These patient receive routine care
2462389|NCT03157180||Test group|general anesthesia There is allergic reaction during anesthesia Sign informed consent
2462390|NCT03157180||Control group|general anesthesia There is no allergic reaction during anesthesia Sign informed consent
2462514|NCT03156361|Experimental|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
2462517|NCT03156361|Active Comparator|Insulin Lispro 100 UNIT/mL|Sterile Water for Injection (SWFI) is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
2462997|NCT03152916|Experimental|3D printing personalized plate|3D printing personalized plate will be used to guide the Kirschner wires in the joint fusion surgery.
3156053|NCT00334724|Active Comparator|1|Home blood pressure group
3156054|NCT00334724|Active Comparator|2|Office blood pressure group
3156055|NCT00334750||There is no intervention in this study|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
2464119|NCT03145129||POAG group|Patients diagnosed with POAG and OSA who require treatment with CPAP
3156056|NCT00334789|Experimental|Treatment (belinostat, isotretinoin)|"Patients receive belinostat IV over 30 minutes on days 1-5 and isotretinoin PO QD on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of belinostat until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.~Once the MTD is determined, an expanded cohort of 10 patients are enrolled and treated at the MTD. These patients also undergo blood collection periodically during treatment for pharmacokinetic studies.~All patients undergo blood collection, buccal scrapings, and tumor biopsies periodically for biomarker, pharmacodynamic, gene expression, and laboratory studies."
3156057|NCT00334828|Experimental|1|
3156058|NCT00334828|Placebo Comparator|2|
3156059|NCT00334867|Active Comparator|Arm I|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-15; doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 1, 7, and 13; cyclophosphamide IV over 1 hour on day 1 in weeks 1, 7, and 13; and ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4, 10, and 16. Patients undergo local therapy comprising conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19.
3174561|NCT00624754|Experimental|1|Patients with OAD will receive Symbicort® at the dose of two puffs morning and evening, each delivering 400/12 µg of budesonide/formoterol. Symbicort® will be administered by inhalation using the Turbuhaler (TH) system
2461063|NCT03166254|Experimental|Cohort A: Stage IV squamous NSCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
2461064|NCT03166254|Experimental|Cohort B: Extensive stage SCLC|"4 cycles of standard of care (SOC) platinum doublet chemotherapy (investigator's choice)~Pembrolizumab (200 mg every 3 weeks (Q3W) for 4 cycles while patient is receiving SOC chemo). Pembrolizumab may continue to be administered Q3W for a maximum of 35 total administrations~All patients will begin the NEO-PV-01 vaccination at Week 12, 3 weeks following the 4th cycle of pembrolizumab / chemotherapy. At Week 12 (Cycle 5), NEO-PV-01 vaccinations will be administered in a prime-boost schedule with 5 priming vaccinations over a 3 week period followed by booster vaccinations at 1 month and 2 months after the last priming vaccination~Up to 20 personalized vaccine peptides will be administered for each patient. Vaccine administration will occur on Days 1, 4, 8, 15 during Cycle 5 of pembrolizumab administration and Day 1 of Cycle 6 of pembrolizumab administration, on Day 8 during Cycle 7 of pembrolizumab administration, and on Day 15 during Cycle 8 of pembrolizumab administration"
2461188|NCT03165630|No Intervention|Group 1|Education or Control group.
2461192|NCT03165630|Experimental|Group 2|Transportation incentives
2461195|NCT03165630|Experimental|Group 3|Transportation and rehabilitation services incentives
2461204|NCT03165357|Experimental|Sodium bicarbonate|"Group taking oral NaHCO3 supplementation in a progressive-dose regimen.~Interventions:~The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 37.5 to 150 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
2461205|NCT03165357|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin).~Interventions:~The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.~Between the 10-day NaHCO3 and PLA or a PLA and NaHCO3 treatments, a 14-day washout period was introduced."
2461264|NCT03165240|Experimental|BI 690517 Dose 1|
2461268|NCT03165240|Experimental|BI 690517 Dose 2|
2461272|NCT03165240|Experimental|BI 690517 Dose 3|
2461275|NCT03165240|Experimental|Eplerenone|
2461277|NCT03165240|Placebo Comparator|Placebo|
2461348|NCT03164603|Experimental|NLG8021 Dose Escalation|Approximately 6 to 36 participants will be enrolled and treated at escalating doses of NLG802. Treatment may continue until unacceptable toxicity or disease progression. Successive groups of at least 3 participants will be evaluated during a 28-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage.
2461379|NCT03164200|Experimental|High fat breakfast|45% fat 35% Carbohydrate 20% protein
2461383|NCT03164200|Experimental|Higher carbohydrate breakfast|60% carbohydrate 20% fat 20% protein
2461449|NCT03163927|Experimental|Intervention|Participants receive a 1.5-hour standardized simulation-based training course, with mastery learning.
2461458|NCT03163927|No Intervention|Control|Participants observe a procedure performed by a senior.
2461503|NCT03163498||ACTIVE|Participating in this group will be 30 active hypertension patients who exercise at least 3 times a week for at least 30 minutes
2461505|NCT03163498||INACTIVE|Participating in this group will be 30 inactive hypertension patients who do not exercise.
2461570|NCT03162861|Experimental|the observation group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
2461574|NCT03162861|Experimental|the control group|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
3191201|NCT00795938|Experimental|Experimental Tablet Without Water|
3191202|NCT00795964|Experimental|1|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
3191203|NCT00795964|Active Comparator|2|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
3191204|NCT00795977|Experimental|dendritic cells|
3191205|NCT00796042|Active Comparator|1|Usual Care
3191206|NCT00796042|Experimental|2|Individualized, Community-based, Pressure management and Mobility program:
3191207|NCT00796055|Experimental|1|MEDI-547
3191208|NCT00796068|Experimental|Arm I (low risk for graft failure)|"Patients receive a conditioning regimen comprising fludarabine phosphate IV over 1 hour QD on days -6 to -2 and treosulfan IV over 120 minutes on days - 6 to -4. Patients undergo TBI on day -1. Patients then undergo donor UCBT on day 0.~Patients receive GVHD prophylaxis comprising cyclosporine IV over 1 hour or PO 2-3 times daily on days -3 to 100, followed by a taper in the absence of GVHD. Patients also receive mycophenolate mofetil IV 3 times daily on days 0 to 40, followed by a taper in the absence of GVHD."
3191209|NCT00796068|Experimental|Arm II (high risk for graft failure)|Patients receive a conditioning regimen, TBI, donor UCBT, GVHD prophylaxis, and mycophenolate mofetil as in Arm I.
2461228|NCT03165656||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension living above 2500 m.
2461232|NCT03165656||High altitude control|Healthy highlanders living above 2500 m.
2461233|NCT03165656||Low altitude control|Healthy lowlanders living below 1000 m.
2461244|NCT03165123|Placebo Comparator|placebo group|The patients will receive oral placebo tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
2461245|NCT03165123|Active Comparator|Azithromycin group|The patients will receive 250 mg oral Azithromycin tablet, one hour before induction of anesthesia and 5 mg Intra-venous dexamethasone within 1-2 minutes after the umbilical cord is clamped.
2461293|NCT03164993|Placebo Comparator|Arm Chemotherapy + Placebo|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + placebo
2461294|NCT03164993|Active Comparator|Arm Chemotherapy + Atezolizumab|Chemo (pegylated liposomal doxorubicin + cyclophosphamide) + Atezolizumab
2461463|NCT03164161|Active Comparator|Cold Pressor Test Results|Participants, enrolling the healthy participants high and low pain perception groups, will undergo cold pressor test. According to the results patients will be assigned according to time (min:s) until first pain felt (pain threshold) and time (min:s) until unbearable pain and test withdraw (pain tolerance). Also, pain ratings (1-10) at same points will be used as participants alignment tool.
2461466|NCT03164161|Active Comparator|β-endorphins level in saliva|Participants will be sorted according to β-endorphin levels in saliva., therefore the β-endorphins evaluation in saliva intervention will be performed.
2461469|NCT03164161|Active Comparator|β-endorphin level in blood plasma|Participants will be sorted according to β-endorphin levels in blood plasma, therefore β-endorphins evaluation in blood plasma will be performed.
2461471|NCT03164161|No Intervention|Pain perception rating|Healthy participants will be sorted in to groups: high and low pain perception groups, according to the results of questionnaires, containing various oral surgery procedures pain ranking.
2461828|NCT03161262|Experimental|SMS-based reminders|This group will receive consistent medication reminders, as per the patient's prescribed frequency, and weekly surveys prompting them to report their pain level and an image of their surgical site. They will also receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
2461831|NCT03161262|No Intervention|Control group|The control group will not receive medication reminders or questions regarding their pain or surgical site. This group will receive a monthly questionnaire via SMS to assess patient satisfaction with the intervention and changes in medication adherence behaviors.
2461854|NCT03160950|Experimental|LuxaCrown|
2461933|NCT03160482||Papillary carcinoma, classical variant|
2461936|NCT03160482||Follicular carcinoma|
2461937|NCT03160482||Colloid nodule|
2461938|NCT03160482||Hyperplastic nodule|
2461939|NCT03160482||Adenomatoid nodule|
2461940|NCT03160482||Follicular adenoma|
2461941|NCT03160482||Papillary carcinoma, follicular variant|
2461943|NCT03160482||Medullary carcinoma|
2461945|NCT03160482||Lymphocytic thyroiditis|
2461989|NCT03160131|Active Comparator|Intervention|All participants receive NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
2461990|NCT03160131|No Intervention|Control|All participants receive no NVT course training and are tested at baseline and at the end of the study for primary and secondary endpoints.
2462131|NCT03158922||Stage 2|Men from Stage 1 identified as having a higher genetic risk score (top 10%) for prostate cancer.
3174562|NCT00624754|Placebo Comparator|2|Patients with OAD will receive lactose as a placebo, administered by inhalation using the Turbuhaler (TH) system
2462208|NCT03158766||Microdiscectomy|Patients with lumbar disc herniation who failed conservative treatment undergoing surgical treatment through microdiscectomy.
3174563|NCT00624767|Experimental|1|Insulin Nasal Spray
3174564|NCT00624767|Active Comparator|2|NovoLog
3174565|NCT00624793|Experimental|I. Standard|Standard - Formula Acup Protocol
3174566|NCT00624793|Experimental|2. Individualized|Individualized Acup protocol based on TCM diagnosis
3174567|NCT00624793|Sham Comparator|3|(Control Group) Sham acupuncture
3174568|NCT00624845|Experimental|Drug|
3174569|NCT00624845|Placebo Comparator|Vehicle|
3174570|NCT00624858|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/ day
3174571|NCT00624871|Active Comparator|A|Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days
3174572|NCT00624871|Placebo Comparator|B|Infants will receive equivalent amount of placebo
3174573|NCT00624884||A|Patients with moderate-to-severe aortic regurgitation having normal left ventricular ejection fraction
3174574|NCT00624884||B|Age, sex and bodymass index matched healthy subjects
3174575|NCT00624936|Experimental|Vidaza and Velcade|Vidaza 75mg/m2 IV over 30 min daily on days 1-7 This dose is the same for all dose levels. Velcade will be given immediately after Vidaza is completed at one of the following dose levels: 1, 2, 3, 4
3174576|NCT00624949||1|women with Turner syndrome
3174577|NCT00624949||2.|Control women
3174578|NCT00624962|Other|Correlative/Supportive Care|
3174579|NCT00624975|Experimental|Vaccine|
3174580|NCT00624975|Placebo Comparator|Placebo|
3174581|NCT00624988|Experimental|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
3174582|NCT00625001||1|Women with Turner syndrome
3174583|NCT00625001||2|Healthy control women
3174584|NCT00625014|Experimental|1|Healthy men
3174585|NCT00625027||Group 1|Children presenting to the Emergency Department under the care of a parent or guardian, between 0600 and 2400 during the study period.
3174586|NCT00625040||A|Obese patients without diabetes with a Body Mass Index > 37 kg/m2
3174587|NCT00625053|Experimental|1|Laparoscopic repair
2461115|NCT03166475|Experimental|Palatal pedicle flap (Group 1)|On patients of this group were performed the palatal pedicle subepithelial connective tissue flap after the extraction, following the technique described by Khoury & Happe (2000), which consists of total detachment of the palatal flap followed by division of the flap to release the connective tissue, maintain a pedicle and sliding it to cover the fresh socket by primary intention. The sutures were removed seven to ten days of postoperative.
2461117|NCT03166475|Experimental|Graft + palatal pedicle flap (Group 2)|On patients of this group were performed the palatal pedicle flap like the group 1, however, the sockets were previously filled with a graft of synthetic bone substitute (Bone Ceramic®, Straumann, Switzerland) and then recovered with the connective flap and sutured by primary intention. The sutures were removed seven to ten days of postoperative.
2461118|NCT03166475|Experimental|Provisional ovoid pontic (Group 3)|On patients of this group, after the extraction of the tooth, were made a provisional ovoid pontic with acrylic resin or with the crown of the removed tooth itself, cut and sealed with composite resin. The pontics were placed to seal the entire gingival margin of the socket and penetrating 2 to 3 mm into it, stabilized laterally by the adjacent teeth with orthodontic and composite resin or acrylic resin. No sutures were made.
2461134|NCT03165812|Experimental|SADJB-SG group|Patients in this group will undergo bariatric surgery. There are two parts to this procedure. One is the restrictive type of weight loss surgery, which reduces the stomach size. The other type prevents the body from absorbing fats and sugar properly, as the small intestine will be attached to the small stomach, bypassing most of the stomach and upper part of the small intestine. This surgery will be performed using a minimally invasive technique known as laparoscopic keyhole surgery.
2461135|NCT03165812|Experimental|IMT group|Patients in this group will be subjected to strict adherence to diet, optimisation of diabetic medications and close monitoring of blood glucose and HbA1c.
2461184|NCT03165643||NGT-normal birth weight|
2461185|NCT03165643||NGT-macrosomia|
2461186|NCT03165643||GDM-normal birth weight|
2461187|NCT03165643||GDM-macrosomia|
2461312|NCT03164694|Experimental|Apatinib|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5) plus apatinib. Apatinib was given 850 mg per day orally at day one of chemotherapy.
2461314|NCT03164694|Active Comparator|Control|Patients were given pemetrexed (500 mg/m2) plus carboplatin (AUC =5).
2461391|NCT03164148|Experimental|Case Evaluation by T-REX TRI00A|Case evaluation consists of confirmation of hospital visit dates, any side effects of device, T-REX TRI00A
2461467|NCT03163836||double valve replacement group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) but did not received concomitant AF ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months. Exclusion criteria for consideration for concomitant AF ablation includes >70 years old, left atrium (LA) diameter >7 cm, or preoperative left ventricle (LV) ejection fraction < 40% and patients falls in these criteria were excluded from this group.
2461470|NCT03163836||surgical ablation group|Patients received aortic+mitral valve replacement at Guangzhou General Hospital of Guangzhou Military Command with persistent or long-standing atrial fibrillation(AF) and received concomitant surgical ablation. Persistent AF was defined as AF lasting more than 7 days and long-standing persistent AF as continuous AF for more than 12 months.
2461529|NCT03163381|Experimental|Apatinib|Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .
2461586|NCT03162991|Experimental|12-Week Aerobic Exercise Intervention|
2461588|NCT03162991|No Intervention|12-Week Control Period|
2461621|NCT03162640||P|for cannabis
2461623|NCT03162640||C|for the control group
3191210|NCT00796094||Evaluation of tissue elasticity|Evaluate the potential importance of tissue elasticity in the assessment soft tissue structures.
3191211|NCT00796133|Active Comparator|1|0.5 ml of NES/E2 equaling 0.45 g and contains 1.5 mg NES/0.5 mg E2
2461827|NCT03161223|Other|A: Oral 5-azacitidine, durvalumab, romidepsin|Arm A: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase), durvalumab will be administered intravenously on day 8 and romidepsin intravenously on days 8 and 15 of a 28-day treatment cycle
2461832|NCT03161223|Other|B: durvalumab, pralatrexate, romidepsin|Arm B: Durvalumab will be administered intravenously on day 1, pralatrexate will be administered intravenously on days 1 and 15, and romidepsin will be administered intravenously on days 1 and 15. Each treatment cycle will last 28 days. All patients receiving pralatrexate will receive folic acid and vitamin B12 supplementation according to the drug package insert. Leucovorin rescue is also allowed at the dose of 15 mg orally twice daily on days 3 to 6 and 17 to 20.
2461834|NCT03161223|Other|C: durvalumab, romidepsin|Arm C: Durvalumab will be administered intravenously on day 1 and romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day treatment cycle
2461835|NCT03161223|Other|D: durvalumab, 5-azacitidine|Arm D: Patients will first undergo a 7-day lead-in phase of 5-azacitidine. 5-azacitidine will be administered orally from day 1 to day 14 (including the lead-in phase) and durvalumab will be administered intravenously on day 8 of a 28-day treatment cycle
3191212|NCT00796133|Active Comparator|2|1.0 ml of NES/E2 gel equaling 0.9 g and contains 3.0 mg NES/1.0 mg E2
3191213|NCT00796133|Active Comparator|3|1.5 ml of NES/E2 gel equaling 4.5 mg NES/1.5 mg E2
3191214|NCT00796159||Olmesartan medoxomil + HCTZ|
3191215|NCT00796172|Experimental|1|Medication adherence system (MAS) plus counseling from doctors
2462213|NCT03158610|Experimental|Capecitabine metronomic chemotherapy|Capecitabine 500mg/m2 bid po qd
3191216|NCT00796172|Active Comparator|2|Usual care
3191217|NCT00796198|Active Comparator|Xalatan+Cosopt|Cosopt will be added to Xalatan when Xalatan is effective but not sufficient to reach the target pressure (Add group) (n = 25)
3191218|NCT00796198|Active Comparator|Xalatan|when Xalatan is effective and sufficient to reach the target pressure no other medication will be added (control group) (n = 25)
3191219|NCT00796211|Experimental|1|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
3191220|NCT00796211|Experimental|2|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
3191221|NCT00796211|Active Comparator|3|0.1% nortriptyline HCl topical cream
3191222|NCT00796211|Active Comparator|4|0.005% calcipotriol topical cream
2461235|NCT03165669|Experimental|Cervical pillow|"The cervical pillow is known as the Viscospring PostuRite - medium model, made by SOFF-ART S.r.l. - Via Maestri del Lavoro 49 - 05100 Terni, Italy. The Viscospring PostuRite pillow is externally made of viscoelastic polyurethane and internally 60 independent, individually coated harmonic phosphate-coated steel springs, are thought to promote correct posture of the cervical spine, due to the adaptation of the pillow to the shape and movements of the head.~Each intervention will be supported by a 30-minutes informative session delivered by a physical therapist, and will be completed by the delivery of an informative brochure."
2461239|NCT03165669|Active Comparator|Education|The educational intervention will be conducted by a physical therapist and will consist of a advice on positions, movements and activities recommended or not recommended for people with chronic neck pain, both in the workplace and in leisure time, including nighttime postures. Each educational intervention will be carried out individually, will last half an hour and will be supported by the delivery of an informative brochure.
2461261|NCT03165071|Experimental|ACT-132577 (50 mg)|8 healthy subjects and 8 subjects with severe renal function impairment will receive a single oral dose of 50 mg ACT-132577 administered as capsule following an overnight fast
2461335|NCT03164590|Active Comparator|ketamine|
2461337|NCT03164590|Active Comparator|dexmedetomidine|
2461341|NCT03164590|Placebo Comparator|bupivacaine|
2461524|NCT03163485|Experimental|Dialytrode|Multimodal neuro-monitoring by dialytrode (investigational medical device)
2461525|NCT03163485|Other|Standard treatment|Either EVD and/or micro-dialysis according to standard treatment
2461561|NCT03162926|Experimental|Single-group|Up to six (6) VC-02-20 implants
2461694|NCT03162276|Experimental|Intervention|Inquiry Based Stress Reduction
2461695|NCT03162276|Placebo Comparator|Control|The placebo group participants will receive a modified form of the intervention at the close of the study
2461767|NCT03161886|Experimental|Pan-enteric capsule endoscopy (PCE)|Evidence of active disease by PCE prompted a change in therapy at the discretion of the treating clinician and according to current available pediatric guidelines. The definition of medical treatment adjustment after evidence of inflammation was: the introduction of steroids or enteral nutrition, the introduction or optimization of immunosuppressives; the introduction, optimization of biologics; or the introduction of both immunosuppressive agents and biologics. In case of a negative PCE and presence of symptoms, the magnetic resonance enterography (MRE) could help in guiding therapeutic decisions.
2461793|NCT03161457|Experimental|JHL1101|Each subject will receive 2 intravenous infusions of 1000 mg JHL1101: the first infusion on Baseline and the second on Day 15.
2461795|NCT03161457|Active Comparator|MabThera|Each subject will receive 2 intravenous infusions of 1000 mg MabThera: the first infusion on Baseline and the second on Day 15 (Visit 5).
2461856|NCT03160924|Active Comparator|Enhanced Recovery After Surgery (ERAS)|"In this arm, the ERAS perioperative care program will be applied.~Preoperative counselling by surgeon, dietician and physiotherapist~Preoperative carbohydrate-loaded drink 800ml 12.5% Carbohydrate drink 8h before surgery 400ml 12.5% Carbohydrate drink 4h before surgery (Omit 4h drink if patient has DM)~Fluid restriction, avoid opioids, use of Cox-II inhibitors as analgesics~Avoid use of drains~Early resumption of diet~Early mobilisation with physiotherapist~Dietary counselling by dietician~Early discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be called by doctors every day after discharge to monitor their clinical status. There will be a low threshold for readmitting patients. Patients will also be given a hotline to call if they feel unwell. They will be seen in clinic on post-operative D7 and D14."
2461858|NCT03160924|No Intervention|Conventional perioperative program|"In this arm, the conventional preoperative program will be applied.~No preoperative counselling~No Preoperative carbohydrate-loaded drink~Routine anaesthesia, no specific protocol on fluid restriction, opioids will be used as usual. Tramadol would be used as postoperative pain control.~Routine use of drains~Diet will be resumed when there is flatus clinically~Mobilisation as per patient's wish~Dietary counselling by dietician~Discharge if fulfil discharge criteria.~Discharge criteria:~Adequate pain control with oral analgesics Ability to tolerate soft diet Passage of flatus Mobilization~Patients will be seen in clinic on post-operative D14."
2461930|NCT03160742||Non-invasive monitoring|In addition to standard monitoring, the Mespere VENUS 200CVP system will be used to record central venous pressures.
2461973|NCT03160339|Experimental|PXVX0047 treatment group|Subjects will receive PXVX0047 vaccine and Teva Placebo-to-Match
2461974|NCT03160339|Active Comparator|Teva Ad4/Ad7 treatment group|Subjects will receive Teva Ad4/Ad7 vaccine and PXVX0047 Placebo-to-Match
2462014|NCT03160066|Active Comparator|Active|Capsules containing 1x10^9 colony forming units of Lactobacillus Rhamnosus (JB-1) will be given once per day for 4 weeks.
2462020|NCT03160066|Placebo Comparator|Placebo|Placebo capsules identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients (corn starch, magnesium stearate and silicon dioxide) in the probiotic supplement will be given once per day for 4 weeks.
2462055|NCT03159728|Experimental|Educative intervention|"Who wish to participate in the program Caring for Caregivers will be the intervention group. The intervention or program Caring for Caregivers to develop was proposed by the Group of Chronic Care Patient and Family School of Nursing at the National University of Colombia. This program includes four sessions or meetings with the caretaker, induction and three modules, the first is geared to strengthen the knowledge; the second, to strengthen the value and the third, to strengthen patience."
2462057|NCT03159728|No Intervention|Control group|"The control group will receive training about knowledge of chronic disease and care.~In addition, once it confirmed the effectiveness of the intervention participants in the control group will be contacted to contemplate the possibility of receiving the benefits of the intervention."
2462145|NCT03159351|Experimental|active rTMS treatment|received active rTMS treatment 20 times for 20 days
2462153|NCT03159351|Sham Comparator|sham rTMS treatment|received sham rTMS treatment 20 times for 20 days
3191223|NCT00796211|Placebo Comparator|5|Vehicle of CRx-197 topical cream (placebo)
2461241|NCT03165539||Thoracic surgery patient|Pre-operatively, patients will have baseline cognitive assessment done using the Mini-mental status test and MOCA test. Intra-operatively patients' baseline cerebral saturation (%) will be measured, and continuously monitored throughout the procedure. Post-operatively, patients will be assessed for delirium using the CAM score.
2461299|NCT03165006||Screened women with breast cancer|
2461333|NCT03164642|Experimental|LENA with Feedback|Mothers who will run the LENA system with their young children, AND who will receive feedback from their service providers on how to enhance the language the home language environment.
2461334|NCT03164642|Placebo Comparator|LENA no feedback|Mothers who will only run the LENA system with their young children. These mothers will NOT receive feedback from their service providers on how to enhance the language the home language environment.
2461377|NCT03164304|Active Comparator|One gram magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 1 g of mgso4 to prevent and control of convulsions
2461380|NCT03164304|Experimental|Two grams magnesium sulfate|Pregnant women with a diagnosis of severe pre-eclampsia will receive 2 g of mgso4 to prevent and control of convulsions
2461428|NCT03163914|Active Comparator|Epinephrine|Epinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
2461430|NCT03163914|Active Comparator|Norepinephrine|Norepinephrine will prepare as 5µg/ ml and epinephrine infusion rate will adjust 30 ml/h.
2461432|NCT03163914|Active Comparator|Phenylephrine|Phenylephrine will prepare as 100 µg/ ml and phenylephrine infusion rate will adjust 30 ml/h.
2461434|NCT03163914|Placebo Comparator|Control|Saline infusion will apply at equivalent volume till the surgical operation
2461547|NCT03163550|Experimental|Cohort 1|Healthy volunteers
2461549|NCT03163550|Experimental|Cohort 2|Healthy volunteers
2461551|NCT03163550|Experimental|Cohort 3|Healthy volunteers
2461553|NCT03163550|Experimental|Cohort 4|Healthy volunteers
2461556|NCT03163550|Experimental|Cohort 5|Healthy volunteers
2461614|NCT03162770|Experimental|Intervention Group|This group will receive the Mindfulness meditation practice and after that patients will not receive any other intervention.
2461615|NCT03162770|No Intervention|No Control Group|Initially this control group will wait and after 12 weeks this group will receive the intervention
3191224|NCT00796237|Experimental|WBV|In their regular physiotherapy sessions, the subjects in the experimental group will receive whole body vibration therapy for a duration of 4 weeks during their stay in the Tung Wah Hospital.
3191225|NCT00796237|Active Comparator|CON|The subjects in this group will not receive whole body vibration therapy.
2461722|NCT03161951||Neuroinfections|Patients with acute neuroinfections of bacterial and viral ethology.
2461725|NCT03161951||Intestinal Infectious Diseases|Patients with acute intestinal infectious diseases of bacterial and viral ethology.
2461735|NCT03161951||Control group|Control group of healthy persons
2461765|NCT03161769||Percutaneous neurovascular treatment|Procedure: Percutaneous neurovascular treatment of intracranial aneurysms
2461829|NCT03161418|Experimental|KSP-910638G 0.4 mg subjects 1-3|The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject.
2461833|NCT03161418|Experimental|KSP-910638G 1.2 mg subjects 4-25|Following a safety review of the first three subjects receiving 0.4 mg dose, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.
2461864|NCT03160963||Ages 18-29|Power testing 18-29 year old men and women
2461867|NCT03160963||Ages 30-39|Power testing 30-39 year old men and women
2461873|NCT03160963||Ages 40-49|Power testing 40-49 year old men and women
2461884|NCT03160963||Ages 50-59|Power testing 50-59 year old men and women
2461886|NCT03160963||Ages 60-69|Power testing 60-69 year old men and women
2461888|NCT03160963||Ages 70-79|Power testing 70-79 year old men and women
2461889|NCT03160963||Ages 80+|Power testing men and women 80 years of age and above
2462007|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
2462068|NCT03159806||Outpatients|Attendees at the nephrology outpatient clinic at Hammersmith Hospital will be invited to take part in microdialysis sampling
2462103|NCT03159325|No Intervention|Usual Care|The usual care group will receive all standard treatment, instructions and information for patients with cardiovascular disease, but no Healing Circles program.
2462104|NCT03159325|Experimental|Healing Circles|Healing Circles is an evidence-based and patient-informed novel self-management platform designed to support patients with CVD. It uses a private, secure social network that helps connect patients to one another, to personalized, disease management information , and provides functions to assist patients in self-management via evidence-based principles of behaviour change.
2462167|NCT03159052|Experimental|SHR3824 Placebo|once daily, 24 weeks
2462169|NCT03159052|Experimental|SHR3824 5 mg|once daily, 52 weeks
2462172|NCT03159052|Experimental|SHR3824 10 mg|once daily, 52 weeks
3191226|NCT00796250|Experimental|Group A|
3191227|NCT00796250|Active Comparator|Group B|
3191228|NCT00796263|Other|HAART|"The proposed HAART regimen consists of:~2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications~Dolutegravir(DTG) 50 mg orally once daily"
2462655|NCT03155451||Epithelial ovarian cancer|patients receive the ctDNA methylation markers screening
2462702|NCT03155217||patients between 65 and 75 years|Patients aged 65-75 years with MM treated with single or dual therapy
3191229|NCT00796289|Experimental|GnRH High Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
2461266|NCT03165097|Experimental|ACT-709478|"40 subjects will receive multiple doses of ACT-709478 at the planned dose levels of 30, 60, 100, and 200 mg.~Each dose level will be investigated in a new cohort of 10 healthy male and female subjects (4 male subjects on active drug and 1 on placebo, 4 female subjects on active drug and 1 on placebo) undergoing one treatment period with a once daily dosing scheme."
2461271|NCT03165097|Placebo Comparator|Placebo|Matched placebo administered accordingly
2461274|NCT03165097|Other|Midazolam|4 mg taken by mouth on Day 1 of the corresponding cohort
2461276|NCT03165097|Experimental|ACT-709478 combined with Midazolam|On Day 22 and Day 30, midazolam (4 mg) and ACT-709478 (60 mg or 100 mg) to be co-administered.
2461322|NCT03164811|Experimental|GDFT group|The GDFT group will receive 400 ml of 12.5% carbohydrate drink after 6 pm until the bed time in the day before surgery and 200 ml in the morning of the surgery day. Acetate ringer solution will be start at 7:00. After induction PPV will be measure and fluid bolus 200 ml in 10 minutes will be given if PPV >13 before prone position. During the operation, the patient in GDFT group will receipt fluid therapy according to acceptable PPV
2461325|NCT03164811|Other|controlled group|The carbohydrate drink will not be given. Fluid, blood and blood product administration will be under attending anesthesiologist order.
2461393|NCT03164239|Experimental|Intervention group - telephone and print exercise intervention|The intervention group (IG) received a total of three intervention packages, one every second month, during the intervention period. The first intervention package was distributed at intervention start. The intervention package consisted of a tailored exercise program, national recommendations for physical activity, prompts and reminders. Additionally the IG received fortnightly supportive motivational contact every two weeks, alternately by telephone og email
2461395|NCT03164239|No Intervention|Control group|The control group (CG) were encouraged to continue previous lifestyle.
2461478|NCT03163862|Placebo Comparator|Placebo|Patients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
2461486|NCT03163862|Experimental|G-CSF group|"Patients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before.~The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer"
2461490|NCT03163862|Sham Comparator|Comparative group|patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
2461512|NCT03163290|Experimental|Posterolateral Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip abductors, lateral rotators and extensors. Posterolateral Hip Complex Exercises add extension knee in open kinetic chain, squat , abduction exercise, Clam exercise and external rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
2461516|NCT03163290|Active Comparator|Anteromedial Hip Complex Exercises|The intervention protocol will be composed of: Heating, lower limb stretching, strengthening the quadriceps, and hip aductors, medial rotators and flexors. Anteromedial Hip Complex Exercises add extension knee in open kinetic chain, squat ,hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise. Physiotherapy treatment sessions will last for an average of one hour, twice a week, for a period of six weeks.
2461567|NCT03163121|Experimental|Group 1 - PfSPZ-GA1 Vaccine|"Group 1 will comprise of 3 volunteers who will receive one immunization of 1.35 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2461569|NCT03163121|Experimental|Group 2 - PfSPZ-GA1 Vaccine|"Group 2 will comprise of 3 volunteers who will receive one immunization of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2461571|NCT03163121|Experimental|Group 3 - PfSPZ-GA1 Vaccine|"Group 3 will comprise of 13 volunteers who will receive one immunization of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine via DVI.~Volunteers will be followed closely for monitoring of adverse events and possible breakthrough blood infections by testing for the presence of parasitemia by qPCR. All volunteers will be treated with a curative regimen of atovaquone/proguanil (A/P) should break-through parasites be detected in the peripheral blood, or at the end of the follow-up period (28 days) if they are not qPCR positive. Six months after the inoculation, a final visit will take place to assess adverse events."
2461575|NCT03163121|Experimental|Group 4 - PfSPZ-GA1 Vaccine|"Group 4 will comprise of 13 volunteers who will receive 3 immunizations of 9.0 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2461577|NCT03163121|Experimental|Group 5 - PfSPZ-GA1 Vaccine|"Group 5 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ-GA1 Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2461595|NCT03163043|Experimental|Active, Male and Female Children|Participants will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2461350|NCT03164668|Other|Usual cigs; menthol e-cig then tobacco e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
2461352|NCT03164668|Other|Usual cigs; tobacco e-cig then menthol e-cigs|Participants can continue to smoke their usual cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
2461355|NCT03164668|Other|avoid menthol cigs; menthol e-cig then tobacco e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive menthol flavored e-cigarettes and for the second month they receive tobacco flavored e-cigarettes
2461357|NCT03164668|Other|avoid menthol cigs; tobacco e-cig then menthol e-cigs|Participants avoid smoking menthol cigarettes. For the first month of study they receive tobacco flavored e-cigarettes and for the second month they receive menthol flavored e-cigarettes
2461413|NCT03164083|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection
2461415|NCT03164083|Experimental|placebo|The patients who are in control group and underwent placebo injection
2461447|NCT03163667|Active Comparator|CB-839 plus everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
2461455|NCT03163667|Placebo Comparator|Placebo plus everolimus|Placebo is administered as oral tablets BID in combination with standard QD everolimus in 28 day cycles.
2461550|NCT03163173|Experimental|Single Arm - Treatment Group|30 mg (~100 μCi) dose of [14C]GC4419 administered as an IV infusion over 15 minutes on Day 1 following an overnight fast
2461605|NCT03162822|Active Comparator|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
2461607|NCT03162822|Active Comparator|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
2461608|NCT03162822|Active Comparator|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
2461611|NCT03162822|Active Comparator|Evaluative Conditioning Intervention|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
2461646|NCT03162406|Experimental|Vitamin D|Procedure: SRP Dietary Supplement: Vitamin D3 Oral supplementation 25000 IU once per week for 6 months Other Name: Cholecalciferol
2461656|NCT03162406|Placebo Comparator|Placebo|Procedure: SRP Dietary Supplement: Placebo Oral supplementation once per week for 6 months
2461806|NCT03161392||Ductal lesion|Subjects with a ductal lesion detected on ultrasonography.
2461810|NCT03161392||No ductal lesion|Subjects without a ductal lesion detected on ultrasonography
2461910|NCT03161093|Experimental|Fasinumab dosing regimen 1|Fasinumab Subcutaneous (SC) dosing regimen 1 and naproxen-matching placebo oral
2461912|NCT03161093|Experimental|Fasinumab dosing regimen 2|Fasinumab SC dosing regimen 2 and naproxen-matching placebo oral
2461914|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen|
2461915|NCT03161093|Experimental|Fasinumab-matching placebo and naproxen-matching placebo|
2462139|NCT03159065|Experimental|Bilberry|A bilberry-based beverage with fermented oatmeal
2462141|NCT03159065|Experimental|Blackcurrant|A blackcurrant-based beverage with fermented oatmeal
2462147|NCT03159065|Experimental|Mango|A mango-based based beverage with fermented oatmeal
2462152|NCT03159065|Experimental|Beetroot|A beetroot-based based beverage with fermented oatmeal
2462156|NCT03159065|Experimental|Rose hip|A rose hip-based based beverage with fermented oatmeal
2462160|NCT03159065|Active Comparator|Glucose drink|A reference glucose drink
2462220|NCT03158558|Experimental|AM-CBCT for PTSD|Accelerated, Multi-Couple Group Cognitive-Behavioral Conjoint Therapy delivered in a single weekend retreat
2462279|NCT03158155||Patients with vitamin D deficiency|1. children with vitamin D deficiency with age group from 2-5 years old
2462352|NCT03157830||Ocrelizumab, OCREVUS|Patients eligible for this study will be receiving OCREVUS as part of their routine care for MS treatment, and undergo the standard monitoring tests and procedures for MS patients receiving treatment. In addition, they will complete the EDSS scale on 6 occasions over a 12-month period, and the MSIS-29 on three occasions during the 12 month period for research.
2462393|NCT03157271|No Intervention|PFPS Treatment|This arm (group of patients) will receive typical/pragmatically designed treatment for patellofemoral pain syndrome.
2462396|NCT03157271|Experimental|PFPS Plus Dry Needling Treatment|This group will receive the same typical/pragmatically designed treatment for patellofemoral pain syndrome but with the addition of a dry needling intervention.
2462431|NCT03156972|Active Comparator|Group a|
2462432|NCT03156972|Active Comparator|Group b|
2462490|NCT03156465|Experimental|Hybrid L24 and Standard CI|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
2462545|NCT03156218|Experimental|Without ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
2462550|NCT03156218|Experimental|With mild to moderate ARDS|"Patients admitted to the ICU after cardiac surgery with a PaO2/FiO2 ratio > 100 and < 300.~Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%."
2462697|NCT03155256|Experimental|Coils + Cyanoacrylate Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils with cyanoacrylate
2464121|NCT03145129||Control group|Patients with OSA and without POAG who require treatment with CPAP
2461371|NCT03164330|Experimental|B75|"Group B75 is offered moderate compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - moderate compensation, Wellness Activities - high compensation"
2461372|NCT03164330|Experimental|C25|"Group C25 is offered high compensation for completing a biometric screening and HRA, and low compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation, Wellness Activities - high compensation"
2461373|NCT03164330|Experimental|C75|"Group C75 is offered high compensation for completing a biometric screening and HRA, and high compensation for each completed wellness course in the fall or spring of the study.~Interventions: Workplace Wellness Program, Biometric Screening/HRA - high compensation Wellness Activities - high compensation"
2461424|NCT03163992|Experimental|pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
2461496|NCT03163589|Experimental|study group|Within 4 to 6 hours after birth all cases with moderate to severe hypoxic ischemic encephalopathy will be enrolled in therapeutic hypothermia using total body cooling and temperature and Receive erythropoietin (1000 U/kg intravenously) on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
2461499|NCT03163589|Placebo Comparator|control group|Within 4 to 6 hours after birth cases with moderate to severe hypoxic ischemic encephalopathy enrolled in therapeutic hypothermia using total body cooling and temperature and Receive normal saline on days 1, 2, 3, 5 ,7 and 9 (six doses,first two doses will be daily from the first day and last 4 doses will be every 2 days)
2461508|NCT03163238|Active Comparator|Group D|One syringe contain dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
2461509|NCT03163238|Placebo Comparator|Group S|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
2461598|NCT03163056|Other|Cognitive-behavioral treatment (CBT)|The CBT treatment condition is implemented in group-based sessions carried out during 8 weeks. Components included: information about tobacco, behavioral contract whereby patients committed to attend sessions, self-monitoring and graphical representation of cigarette smoking, nicotine fading (a weekly reduction of 30% of nicotine intake from the first to the four week, and abstinence from the fifth week onwards), physiological feedback (CO in expired air and cotinine analyses) on cigarette intake, stimulus control, strategies for managing nicotine withdrawal symptoms, training in alternative behaviors, and relapse prevention strategies (e.g., problem solving techniques).
2461601|NCT03163056|Active Comparator|CBT+Behavioral Activation (BA)|This intervention includes both CBT and BA strategies for smoking cessation and depression management. Participants allocated to this condition received 8 therapy sessions. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
2461604|NCT03163056|Active Comparator|CBT+BA+ Contingency Management (CM)|This intervention is provided in the same manner as the above treatment protocols but with the addition of a CM procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
2461645|NCT03162419|Active Comparator|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
2461653|NCT03162419|Experimental|Standard Medical Therapy + Plasma exchange + GCSF|The patients in group B shall be given GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28 along with alternate day high volume plasma exchange sessions till a maximum of ten sessions.
2461660|NCT03162419|Experimental|Standard Medical Therapy + GCSF|"The patients in this will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.~The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28"
3191230|NCT00796289|Experimental|GnRH Medium Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3191231|NCT00796289|Experimental|GnRH Low Target Delivery|10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
2461892|NCT03160820|Other|one dose of MMR|Subjects are vaccinated with MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 months old.
2461893|NCT03160820|Other|30 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 4 years old, sequentially.
2461896|NCT03160820|Other|42 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 5 years old, sequentially.
2461897|NCT03160820|Other|54 months after two doses of MMR|Subjects are vaccinated two doses of MMR(Measles, mumps and rubella Combined Vaccine, Live) on 18 month and 6 years old, sequentially.
2461951|NCT03160456|Experimental|Transcutaneous electrical stimulation|The group of participants receiving continuous transcutaneous electrical stimulation will be trained on the device and settings will be recorded. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At each visit comfort, compliance and adverse reactions will be recorded. At 12-weeks, the patients will be invited for a repeat assessment including polysomnography during a night of electrical stimulation. Usage time of the device will be discussed with the patients and recorded.
2461400|NCT03164278|Experimental|Immediate Training (no follow up)|Individuals may decide to participate in the research study training program, but not in any follow up questionnaires. This group will have immediate access to the independent transfer training materials. They will complete data collection measures embedded in the transfer training program, including demographics, Online Learning Readiness Scale (OLRS), Moorong Self Efficacy Scale (MSES), Patient Reported Outcome Measurement Information System (PROMIS), Transfer Assessment Instrument Questionnaire (TAI-Q), and the Wheelchair User Shoulder Pain Index (WUSPI).
2461402|NCT03164278|Experimental|Immediate Training (with follow up)|Individuals may decide to participate in the research study, but do not want to be randomized. After consent is obtained, these individuals will be directed immediately to the baseline questionnaires (see above) before and after the independent transfer training. Participants may also be asked to complete a user satisfaction survey.
2461403|NCT03164278|Experimental|Randomized Training|Individuals may decide to participate in the research study and agree to be randomized. These individuals will be immediately randomized into an immediate or a wait list control group. The immediate will receive the independent transfer training program after completing the baseline questionnaires. The wait list control group will wait approximately 6 months before receiving the independent transfer training program.
2461456|NCT03163732|Other|Large molecular profiling panel|This panel is FOne Panel with a 324 cancer-related gene.
2461461|NCT03163732|Other|Limited molecular profiling panel|This panel is CONTROL Panel with a 87 cancer-related gene.
2461527|NCT03163316||Breast cancer patients|Patients will undergo unenhanced magnetic resonance imaging on both axillae.
2461591|NCT03162978|Experimental|HIIT + POE|High-intensity interval training (HIIT) plus positive outcome expectations (POE) from participating in the exercise program.
2461594|NCT03162978|Experimental|HIIT only|High-intensity interval training (HIIT) only.
2461641|NCT03162523||Scandinavian Prostate Cancer Group (SPCG), study number 7|Patients included in hallmark study of SPCG-7 receiving EBRT to 70 Gy in combination with lifelong anti-androgen treatment
2461654|NCT03162523||Norwegian Urologic Cancer Group (NUCG) study number 7|Patients receiving EBRT to 74 Gy in combination with hormonal therapy. Approved by ethical comittee. Questionnaires already been completed during a different study (NUCG-7). These patients will therefore not be contacted again.
2461692|NCT03162185|Experimental|Interventional group|Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.
2461693|NCT03162185|Placebo Comparator|Control group|Half of the participants ( n= 30) will receive the placebo.
3174588|NCT00625053|Active Comparator|2|Open repair
3174589|NCT00625079|Placebo Comparator|Pre-transplant placebo|There are two placebo comparators.... one for the group of patients with resting PAH and another for the group of patients with exercise PAH
2461814|NCT03161275||nirs|The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
2461816|NCT03161275||cognitive function|Upon the day preceding the actual surgery, and again at 5 days after the surgery, the Mini Mental State Examination test was completed, with a view to assessing the chang-es in the patients' cognitive function. The difference between score in Mini Mental State Examination higher than 2 points defined a diagnosis of cognitive dysfunction.
2461891|NCT03161145||Unresectable or metastatic renal cell carcinoma (mRCC)|Medical records will be reviewed for treatment patterns and outcomes
2461956|NCT03160612|Other|Case|Transfer Training Subjects will be randomized to receive the transfer training either after baseline measures are collected (case) during visit 1.
2461961|NCT03160612|Other|Control|Transfer Training Subjects will be randomized to receive the transfer training during the follow-up testing at visit 2.
2462073|NCT03159819|Experimental|CAR-CLD18 T cells|"Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion."
2462151|NCT03159247|Experimental|eyeGuide|Two personalized eHealth interventions aimed to improve glaucoma medication adherence.
2462219|NCT03158675|Experimental|Fractional co2 laser&topical steroid|"participant will be compared with one side of the body to the ather side.~Intervention:~-Procedure: Fractional carbon dioxide laser.~-Drug: Topical corticosteroid.~-Radiation: Ultraviolet B narrow band."
2462258|NCT03158090||Surgical treatment|The subject was received transnasal butterfly surgery.
2462262|NCT03158090||Drug therapy|The subject was received drug treatment including somatostatin analogues such as sandostatin and lanreotide, dopamine receptor agonists and GH receptor antagonists.
2462269|NCT03158090||Radiotherapeutics|he subject was received radiotherapy methods including radiotherapy, linear accelerator X knife, gamma knife and so on.
2462326|NCT03157804|Experimental|Autologous CD34+ cells transducted with PGK-FANCA-Wpre *|CD34 + cells from patients with Fanconi subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the gene FANCA, PGK-FANCA-Wpre*The product to be infused consist of a suspension of transduced CD34^+ cells.
2462429|NCT03157388|Experimental|Intervention|Combined Vancomycin and Gentamycin and Meropenem
2462470|NCT03156790|Experimental|Spectrila®|recombinant L-Asparaginase
2462494|NCT03156400|Active Comparator|Parkinson's disease|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Individual with PD who has recently had a diagnosis of Stage 1 or 2 on the Hoehn and Yahr scale."
2462571|NCT03155919|Placebo Comparator|PLAchoc|Treatment composed by placebo (starch powder) and chocolate milk
2462626|NCT03155633|Experimental|Running Group|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
2461420|NCT03163901|Other|Effect of OMT on clinical outcome measures|Clinical outcome measures including Neurocom Balance Manager assessments (Modified Clinical Test of Sensory Interaction and Balance; Stability Evaluation Test; Rhythmic Weight Shift; Limits of Stability), Vestibular Oculomotor Screen, Motion Sensitivity Test, as well as questionnaires such as the Headache Impact Test (HIT-6), Dizziness Handicap Inventory, and the more general quality of life measures (dressing; bathing; medication management, etc. as assessed by the SF 36 QOL questionnaire).
2461421|NCT03163901|No Intervention|Anti-inflammatory Biomarkers|to analyze urine and plasma samples collected from the three groups of participants: urine and plasma samples one hour before, plasma samples one hour after and 48 hours after treatment for alterations in the levels of low molecular weight compounds or protein components to identify potential biomarkers that may correlate with the TBI condition and/or the OMT.
2461422|NCT03163901|No Intervention|Infrastructure development|to establish the infrastructure for the recording, management, and extraction of clinical data and to estimate effect sizes and variability in key outcome measures so that a larger, longer term study can be planned with sufficient statistical power to identify significant results.
2461472|NCT03163615|Experimental|Tibet Rhodiola Capsule|
2461473|NCT03163615|Placebo Comparator|Placebo oral capsule|
2461609|NCT03163069|Experimental|Conventional Whitening dentifrice|in-office bleaching with the conventional whitening dentifrice
2461612|NCT03163069|Experimental|Whitening dentifrice containing blue covarine|in-office bleaching with the whitening dentifrice containing blue covarine
2461613|NCT03163069|Experimental|Regular dentifrice|in-office bleaching with the regular dentifrice
2461655|NCT03162445||Typically developing controls|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
2461661|NCT03162445||Autism spectrum disorder|Boys between ages 7 and 14 years old at study onset without medications or diseases impairing bone development
2461698|NCT03162289|Active Comparator|Fasting|60-72 h-modified fasting (36-48 h before and 24 h after chemotherapy)
2461702|NCT03162289|Active Comparator|Vegan|60-72 h-vegan diet (36-48 h before and 24 h after chemotherapy)
2461759|NCT03161691||Ischemic Stroke|Percutaneous neurovascular treatment of acute ischemic stroke patients.
2461790|NCT03161509|Experimental|paracetamol|10 participants will undergo measurement of paracetamol levels before and after sleeve gastrectomy
2461792|NCT03161509|Experimental|antiepileptic drug|Up to 10 participants in each drug (up to 4 medications, total of up to 40 participants) will undergo measurement of levels of their chronic medication after a dose before and after sleeve gastrectomy
2461838|NCT03161210|Experimental|Dextrose Prolotherapy|
2461841|NCT03161210|Active Comparator|Local Anaesthetic|
2461843|NCT03161210|Placebo Comparator|Saline|
2461874|NCT03160911|Experimental|Over-the-scope clip|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. The endoscopist can decided whether to pre inject the ulcer with adrenaline. Then the OTSC is used for haemostasis.
2461881|NCT03160911|Active Comparator|Conventional endoscopic haemostasis|The patient would receive an esophagogastroduodenoscope to identify the bleeding source. Haemostasis will be performed in the conventional way, either using heater probe, endoscopic clips and/or injection of adrenaline
2462006|NCT03159962|Active Comparator|Treated Group 1|Patient treated with bonded RME (Rapid Maxillary Expander) with a 13-mm screw. The acrylic splints of the bonded expander extended from the first deciduous molars through the first permanent molars.
2462012|NCT03159962|Active Comparator|Treated Group 2|Patients treated with banded RME (Rapid Maxillary Expander) in the form of a butterfly palatal expander with a 13-mm screw cemented through bands on the second deciduous upper molars.
2462019|NCT03159962|No Intervention|Untreated Control Group|Matched untreated Class II control group prospectively evaluated after one year
2462066|NCT03159702|Experimental|MEL/FLU and Total-Body Irradiation (TBI)|"For patients who are < 60 years.~Melphalan: 140 mg/m2/day IV on Day: -6~Fludarabine: 40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance (CrCl) may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].)~TBI: 200 cGy Day: -1.~For patients who are ≥60 years and/or Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI) score of >3 (at the discretion of treating physician will have an option to receive):~Melphalan: 70 mg/m2/day IV on Day -6.~Fludarabine: 40 mg/m2/day IV Days -5, -4, -3, -2.~TBI: 200 cGy; Days -1."
3174590|NCT00625079|Experimental|Pre-transplant sildenafil|There are two active comparators, one group with resting PAH and another with exercise PAH, both receiving drug.
2462216|NCT03158610|Active Comparator|Capecitabine standard dosage chemotherapy|Capecitabine 1000mg/m2 bid po d1-d14,q3w
3174591|NCT00625079|No Intervention|Pre-transplant no PAH-specific therapy|this group of patients has no evidence for either resting or exercise PAH but will be followed without specific drug intervention
3174592|NCT00625092|Experimental|Hyperthermic Treatment|Patients receiving combination of hyperthermic intraperitoneal chemotherapy (HIPC) with oxaliplatin plus intraperitoneal 5-Fu and intraperitoneal leucovorin with peritoneal metastases.
3174593|NCT00625105|Active Comparator|Biofeedback|HRV coherence biofeedback procedure
3174594|NCT00625105|Sham Comparator|Sham intervention|Passive monitor viewing
3174595|NCT00625118||1|Children in receipt of a Hib containing vaccine at pre-school booster (3.5-6 years old).
3174596|NCT00625157|Experimental|1|
3174597|NCT00625157|Placebo Comparator|2|
3174598|NCT00625170|Active Comparator|1|Healthy men
3174599|NCT00625170|Active Comparator|2|Healthy men with a positive family anamneses of schizophrenia
3174600|NCT00625196|Experimental|Subjects receiving fluticasone foroate/ vilanterol|Eligible subjects will receive single dose of fluticasone foroate/ vilanterol combination treatment 800 micrograms/ 50 micrograms administered using a novel powder inhaler. There will be a washout period of 7 to 10 days between treatments.
3174601|NCT00625196|Active Comparator|Subjects receiving fluticasone foroate|Eligible subjects will receive single dose of fluticasone foroate 800 micrograms administered using a novel powder inhaler.
3174602|NCT00625196|Active Comparator|Subjects receiving vilanterol|Eligible subjects will receive single dose of vilanterol 50 micrograms administered using a novel powder inhaler.
3174603|NCT00625196|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of placebo administered using a novel powder inhaler.
3156060|NCT00334867|Experimental|Arm II|Patients receive vincristine sulfate IV over 1 minute once a week on day 1 in weeks 1-3, 7-9, and 13-16; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 13; cyclophosphamide IV over 30 minutes on days 1-5 in weeks 1 and 13 and IV over 1 hour on day 1 in weeks 7 and 16; ifosfamide IV over 1 hour and etoposide IV over 1 hour on days 1-5 in weeks 4 and 10; and doxorubicin hydrochloride IV over 15 minutes on days 1 and 2 in weeks 7 and 16. Patients also undergo local therapy comprising of conventional surgery (surgical resection) in approximately week 18 and/or radiation therapy beginning in approximately week 19. Patients then proceed to combination chemotherapy.
3156061|NCT00334945||Growth Hormone|Patient ages 3-14 years receiving growth hormone for growth hormone deficiency or short stature
3156062|NCT00334945||Healthy Children|Children with normal stature ages 3-18 years.
3156063|NCT00334971|Other|1|Healthy Caucasian women 18-35 years old
3156064|NCT00334971|Other|2|Healthy African-American women 18-35 years old
3156065|NCT00334971|Other|3|Healthy Caucasian women 36-45 years old
3156066|NCT00334971|Other|4|Female fragile X premutation carriers 18-45 years old
3156067|NCT00335023|Active Comparator|Red blood cell transfusion|At least one unit of red blood cells will be administered.
3156068|NCT00335023|No Intervention|Control|No red blood cell transfusion. Iron suppletion is allowed and can be administered according to local protocol. If suppletion is prescribed, the type and duration will be registered
3156069|NCT00335036|Active Comparator|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
2461741|NCT03161977||Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
2461781|NCT03161652|Placebo Comparator|DME lactose pill|Patients with DME will be randomized to take a lactose pill (placebo).
2461782|NCT03161652|Experimental|DME levosulpiride|Patients with DME will be randomized to take levosulpiride.
2461783|NCT03161652|Placebo Comparator|DR lactose pill|Patients with non-proliferative DR will be randomized to take a lactose pill (placebo)
2461784|NCT03161652|Experimental|DR levosulpiride|Patients with non-proliferative DR will be randomized to take levosulpiride
2461785|NCT03161652|Placebo Comparator|DR, vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take a lactose pill (placebo).
2461786|NCT03161652|Experimental|DR, vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study) will be randomized to take levosulpiride.
3156070|NCT00335036|Active Comparator|Gore PTFE-coated|ICD lead with PTFE-coated coils
3156071|NCT00335049|Experimental|PAL|Progressive Addition Spectacle Lenses (PALs) with a +2.00 D add worn for first year off study. Single Vision Lenses worn for second year of study.
3156072|NCT00335049|Active Comparator|SVL|Single Vision Lenses (SVLs) worn both years of the study.
3156073|NCT00335075|Experimental|Temodal group|Subjects treated with temozolomide.
3156074|NCT00335075|Active Comparator|Semustine group|Subjects treated with semustine.
3156075|NCT00335166|Experimental|1|
3156076|NCT00335166|Active Comparator|2|
3156077|NCT00335166|Placebo Comparator|3|
3156078|NCT00335179|Active Comparator|Imiquimod cream|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream Applied 3 times per week for 4 weeks
3156079|NCT00335179|Placebo Comparator|Vehicle cream|Vehicle cream 250 mg Applied 3 times per week for 4 weeks
3156080|NCT00335192|Experimental|1|"Phase I: 3TC + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + LPV/rtv"
3156081|NCT00335192|Experimental|2|"Phase I: ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: ABV + LPV/rtv"
3156082|NCT00335192|Experimental|3|"Phase I: 3TC + ABV + TDF + NVP or LPV/rtv~Phase II: patients on treatment with LPV/rtv, stop TDF during 4 weeks: 3TC + ABV + LPV/rtv"
3156083|NCT00335218|Experimental|Arm 1|
3156084|NCT00335218|Placebo Comparator|Arm 2|
3156085|NCT00335231|Experimental|gatifloxacin|one group will receive topical application of gatifloxacin prior to surgery,
3156086|NCT00335231|No Intervention|no eye drops|this group will receive no eye drops.
3156087|NCT00335244|Experimental|1|Intravenous L-citrulline
3156088|NCT00335244|Placebo Comparator|2|Placebo of intravenous L-citrulline
3156089|NCT00335309|Experimental|1|The Investigational arm is treated with sinus irrigation with normal saline 0.9% and intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
3156090|NCT00335309|Active Comparator|2|The control arm is treated with the same intravenous antibiotics of Augmentin 1 gram 3 times a day for 4 days, and then per os (PO) Augmentin 875mg twice a day (BID) for another 10 days. There is no sinus irrigation with normal saline for this arm. The treatment is done while the patient is admitted to the otolaryngology - head and neck surgery department.
3156091|NCT00335335|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
3156092|NCT00335348|Experimental|Bortezomib and Dexamethasone|
3156093|NCT00335374|Experimental|1|
3156094|NCT00335595|Active Comparator|1|XELOXA
3156095|NCT00335595|Experimental|2|XELOXA-A
3156096|NCT00335686|No Intervention|1|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
3156097|NCT00335686|No Intervention|2|Nevirapine (Viramune): 1 comp (200mg)/12h
3156098|NCT00335751|Experimental|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
3156099|NCT00335816|Experimental|Group 1 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil intravenously continuously over 24 hours 7 days a week for 6 weeks. Patients undergo standard surgical resection after completion of chemoradiation therapy..
2461482|NCT03163745||Asymptomatic spontaneous bacterial peritonitis|"All the included patients will be subjected to:~Full medical History and physical examination~Laboratory investigations: Complete blood picture , kidney function tests, liver function tests ,prothrombin time and concentration~Abdominal Ultrasound~Ascitic fluid paracentesis will be done to test for total leucocyte count and polymorphonuclear count , total protein and albumin levels. Testing for cytological analysis and culture will be done."
2461528|NCT03163368|Experimental|Neoadjuvant stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to neurosurgical resection of the indexed brain metastasis. The dose of radiation to be administered to the indexed lesion will be established as a function of tumor size.
2461585|NCT03162913|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry powder.
2461589|NCT03162913|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo powder.
3156100|NCT00335816|Experimental|Group 2 (Closed to Enrollment)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1-2. Treatment repeats every 14 days for 2 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
3156101|NCT00335816|Experimental|Group 3 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 4 courses. After the last week of post-radiation chemotherapy, patients undergo standard surgical resection.
3156102|NCT00335816|Experimental|Group 4 (chemotherapy, FOLFOX, conventional surgery)|All patients undergo chemoradiation therapy comprising radiation therapy once daily 5 days a week for 5 weeks and fluorouracil IV continuously over 24 hours 7 days a week for 6 weeks. Beginning 4 weeks after completion of chemoradiation therapy, patients receive modified FOLFOX-6 chemotherapy as in group II. Treatment repeats every 14 days for 6 courses. After the last week of post- radiation chemotherapy, patients undergo standard surgical resection. Patients then receive 3 additional courses of FOLFOX-6 chemotherapy or other chemotherapy off study as directed by the physician.
3156103|NCT00335985|Experimental|1|
3156104|NCT00335985|Placebo Comparator|2|
3156105|NCT00335998|Experimental|Treatment (triapine)|"Group 1: Patients undergo external-beam pelvic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33. Patients also receive 3-AP IV over 2 hours on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33 and cisplatin IV over 1½ hours on day 2, 9, 16, 23, and 30.~Group 2: Patients undergo external-beam pelvic radiotherapy and receive 3-AP as in group 1.~In both groups, patients undergo intracavitary or interstitial brachytherapy at least once weekly for 3-5 weeks during or after external-beam radiotherapy as per standard of care."
3156106|NCT00336076||Participants evaluated for mastocytosis|Observational study of all patients referred for suspected mast cell disease. Collection of blood or bone marrow for analysis during diagnostic procedures.
3156107|NCT00336102||Group 1 Breast Cancer Patient Cases|"Patients between the ages of 25 and 75, diagnosed with primary, operable, stage I-III B breast cancer with planned chemotherapy regimen Adriamycin / Cytoxan (AC) plus a taxane are trial candidates.~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
3156108|NCT00336102||Group 2 Healthy Controls|"Controls will be women from the same general demographic area as Group 1 Cases, have no prior history of cancer and be within 5 years of the Group 1 case's age (+/- 5 years).~Will have physiologic testing at baseline to assess thyroid function and fatigue assessment and management inventory. Will follow-up on management of therapy complications for thyroid disorder if one identified or until off study."
3156109|NCT00336141|Experimental|Vorinostat|
2461721|NCT03162003||Cohort 1|Patient with visceral disease and/or bone lesions (excluding patients who only have nodal disease), who have commenced or are about to commence ADT and whose disease has not shown any evidence of castration resistance.
2461727|NCT03162003||Cohort 2|Patient with castrate-resistant disease at time of treatment change
3156110|NCT00336180|Experimental|HW|The experimental group (HW) receives 18 classroom-based lessons on leisure motivation, life skills, and skills to avoid substance use and sexual risk.
2461796|NCT03161431|Experimental|Monotherapy: SX-682 dose escalation|Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.
2461798|NCT03161431|Experimental|Combination therapy: SX-682 dose escalation with pembrolizumab|SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
2461972|NCT03160430|Experimental|Part A PK Arm|a single 100 mg dose of RVX000222 (apabetalone) on the day of dialysis, followed by a one (1) week washout period, and a second dose of RVX000222 (apabetalone) administered on a non-dialysis day (total of two (2) 100 mg RVX000222 doses)
2461975|NCT03160430|Placebo Comparator|Part B Sequence A|RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); Placebo b.i.d for 6 weeks
2461976|NCT03160430|Placebo Comparator|Part B Sequence B|Placebo b.i.d for 6 weeks; 4 Week Washout (No RVX000222/placebo administration); RVX000222 (apabetalone) 100 mg b.i.d (total 200 mg/day) for 6 weeks
2462049|NCT03159715|Experimental|IInternet-based Positive Psychology Protocol|Intervention group that carries out the Internet-based Positive Psychology Protocol and receives therapist support.
3156111|NCT00336193|Experimental|Home visitation|In the intervention condition, nurse home visitors receive enhanced training to improve delivery of parenting interventions to mothers
3156112|NCT00336219|Active Comparator|1|Pantoprazole 40 mg
3156113|NCT00336245|Experimental|Copper T Intrauterine Contraceptive Device|
2461492|NCT03163797||Oropharyngeal cancer|A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level >200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
2461544|NCT03163329|Experimental|TAVR group|
2461546|NCT03163329|Active Comparator|SAVR group|
2461568|NCT03162848|Experimental|SystemCHANGE intervention|The SystemCHANGE™ intervention utilizes the Socioecological Model and Plan-Do-Check Act model as its framework and focuses on changing the individual's environment to change behavior using small experiments with feedback.
2461572|NCT03162848|No Intervention|Attention Control|The attention control group will receive education at baseline, 1 month, and 2 months following America Heart Association brochures.
2461701|NCT03162029||study group|CBCT imaging of patients with end stage renal failure, undergoing hemo-dialysis
2461705|NCT03162029||control group|CBCT imaging of medically-free participants
2461768|NCT03161873||avaOnly|Participants will measure with Ava bracelet and determine ovulation with a home (luteinizing hormone) LH urine test
2461770|NCT03161873||avaSaliva|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone.
2461773|NCT03161873||avaSalivaUS|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition participants will collect saliva for the measurements of estrogen and progesterone. Moreover ultrasound will be used to observe the day at which the ovum is released.
2461775|NCT03161873||avaBBT|Participants will measure with Ava bracelet and determine ovulation with a home LH urine test. In addition, participants will measure their basal body temperature (BBT) daily.
2461802|NCT03161314|Experimental|(Sub-project 1)PHP / (Sub-project 3)Strengthening|
2461804|NCT03161314|Active Comparator|(Sub-project 1)Normal healthy / (Sub-project 3)Stretching|(Sub-project 3) Conservative physical therapy treatment with stretching exercise
2461855|NCT03161119|Experimental|Catheter Cook K-Jets-551910-S|Catheter Cook K-Jets-551910-S consists of an outer firm and an inner ultrasoft catheter. The outer guiding catheter (17 cm long) is slightly stiff, with a preshaped curve and a rounded bulb tip to help negotiate the cervical canal. It has a depth marker at 4 cm from the tip, which can be pulled back to a second marker at 5 cm. The inner catheter (23 cm long) is made of a soft material with a rounded bullet tip. In general, the inner catheter does not negotiate the cervical canal directly but rather is introduced into the uterine cavity through the outer catheter.
2461857|NCT03161119|Active Comparator|Catheter Cook k-soft-5000 (or K-J-SP-681710, K-J-SPPE-68171)|This catheter system consists of an outer firm and inner soft catheter. The outer guiding catheter (15,4 cm long) is straight and made of flexible material. The inner catheter (23 cm long) is made of a very soft and flexible polyurethan. The inner catheter is introduced directly through the cervix.
2462023|NCT03160053|Experimental|Treatment Group|Keloids that were randomized to the treatment group, were exposed to Narrowband-UVB (NB-UVB). Targeted UVB will be delivered to the keloid for up to 16 weeks using the Lumera UVB light phototherapy device (Daavlin, Bryan Ohio, USA).The affected skin will be irradiated using a hand-held fiber optic cable with an adjustable aperture.
2462030|NCT03160053|No Intervention|Control Group|Keloids that were randomized to a non treatment group, were not exposed to the NB-UVB light.
2462063|NCT03159754|Experimental|Early Appendectomy|
2462064|NCT03159754|Experimental|Interval Appendectomy|
2462071|NCT03159754|Experimental|No Appendectomy|
2462122|NCT03159013|Other|Pesticide toxicokinetics- oral|Exposure type: ORAL Toxicokinetics
2462123|NCT03159013|Other|Pesticide toxicokinetics- dermal|Exposure type: DERMAL Toxicokinetics
2462210|NCT03158545|Placebo Comparator|Olive oil Placebo|3 x 1 g capsules daily Placebo: olive oil
2462211|NCT03158545|Active Comparator|EPA-rich|3 x 1 g capsules daily containing EPA-enriched oil
2462212|NCT03158545|Active Comparator|DHA-rich|3 x 1 g capsules daily containing DHA-enriched oil
2462259|NCT03158168|Experimental|study group|"The first group will receive Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by insulin syringe in the largest wart at the first visit.( Only those patients who showed a positive response to the Candida test antigen).I njections will be repeated for all patients into the same lesion every 3 weeks for three treatment sessions. Follow up for next six months for any recurrences.~Storage: A 1ml multidose vial of candidal antigen (Candin) which is an intradermal test antigen, stored between 2c-8c."
2462264|NCT03158168|Active Comparator|control group|"The second group will receive an IL injection of 2%Zn sulfate with a dose of (0.1ml-0.3ml) by insulin syringe ,in the largest one .the wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis [19]. Injections will be repeated for all patients into the same lesion every 2 weeks for three treatment sessions.Follow up for next six months for any recurrences.~Preparation of 2% zinc sulfate: A measure of 2g. of zinc sulfate powder is to be dissolved in 100 ml of sterile distilled water and autoclaved at 95c for 20 min(20)."
2462316|NCT03157856||Experimental: fluorescence assessment|Medical device: Use of the FEMTO-ST institute medical device to detect prostatic and non prostatic tissue.
2462320|NCT03157609|Experimental|Thermometry with SpotOn|Application of SpotOn sensor on forehead.
2462321|NCT03157609|Active Comparator|Thermometry with oesophageal probe|Nasal insertion of oesophageal temperature probe in the lower fourth of the oesophagus.
2462469|NCT03156933||Splicing variants|Sample of acute myeloid leukaemia primary cells
2461541|NCT03163160|Experimental|Pelvic floor manual therapy group|Pelvic floor manual therapy is a clinical approach utilizing specifics hands-on mobilizing techniques to treat soft tissues. The technique require mobilization of soft-tissue by myofascial stretching maneuvers intended to improve bio-mechanical elasticity. The therapeutic protocol will be applied for 4 weeks.
2461542|NCT03163160|Experimental|Pelvic floor electrolysis group|Pelvic floor electrolysis technique consists in an ultrasound-guided application of a galvanic electrolytic current that causes a controlled local inflammatory process in the target tissue. This allows for phagocytosis and the subsequent regeneration of the affected tissue. The therapeutic protocol will be applied for 4 weeks.
2461581|NCT03162835||Educated group|Children within this group will receive Pain Neuroscience Education.
2461584|NCT03162835||Non-educated group|Children within this group will not receive Pain Neuroscience Education
2461706|NCT03162120|Active Comparator|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
2461707|NCT03162120|Active Comparator|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
2461819|NCT03161548|Experimental|Induction chemotherapy|Induction chemotherapy will be given every 21 days, with the DCU regimen, followed by tongue conservation surgery, and postoperative CCRT as indicated.
3156114|NCT00336245|Active Comparator|Hormonal Contraception|
3156115|NCT00336336|Experimental|1|N-3PUFA
3156116|NCT00336336|Placebo Comparator|2|
2462111|NCT03159273|Experimental|Beetroot Juice Group|Subjects in this group are given 7 daily doses of a dietary nitrate supplement (Beet-it Sport beetroot juice shots) and asked to drink one dose daily during the week of their final academic examinations of that term in college.
2462113|NCT03159273|No Intervention|Control|Subjects in this group are not given a dietary nitrate supplement but are assessed at the same time points as those in the experimental group.
2462132|NCT03158974|Experimental|VIR007|Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
2462222|NCT03158792|Active Comparator|Enoxaparin 20 mg|
2462223|NCT03158792|Active Comparator|Enoxaparin 30 mg|
2462267|NCT03158103|Experimental|MEK162 in combination with Pexidartinib|Pexidartinib will be administered orally by the patients on a twice daily basis throughout the treatment cycle. Pexidartinib is available in 200mg tablets. MEK162 wiIl be administered orally on a twice daily basis throughout the treatment cycle. MEK162 is available in 15mg tablets. In this phase I study all patients will have a 2-week lead in of pexidartinib therapy alone. Thereafter, pexidartinib will be administered in combination with MEK162 on a consecutive daily basis. A treatment cycle consists of 28 days. In the dose escalation portion the dose of pexidartinib and MEK 162 will depend on the dose level cohort onto which the patient is enrolled.
2462313|NCT03157882||Study Population|Pediatric patients presenting to the emergency department with acute painful conditions (please see inclusion and exclusion criteria)
2462349|NCT03157622|Active Comparator|Exposure in vivo|In the Exposure in vivo (EXP) condition, patients are given a careful explanation of the fear-avoidance model. Patients are encouraged to adopt the model to their individual situation. Factors for the maintenance of chronic pain (such as pain cognitions and pain-related fear) are discussed. Especially, negative consequences of avoidance behavior are highlighted. In preparation of the exposure sessions, patients develop an individual fear hierarchy using the Photo Series of Daily Actives. Subsequently, patients are encouraged to test their fear-avoidance beliefs during behavioral experiments and to reduce avoidance behaviors during individually tailored exposure exercises.
2462350|NCT03157622|Active Comparator|Cognitive Behavioral Psychotherapy|In the Cognitive Behavioral Psychotherapy (CBT) condition, patients are introduced to several strategies to improve their pain management. The principle of graded activity encourages patients to re-engage in former activities by dividing these activities into smaller steps. Predetermined resting periods are offered as a form to prevent patients from phases of excessive demands followed by long terms of recovery. Progressive muscle relaxation is introduced as a technique to improve the experience of pain. The strategy of attention shifting is presented to change their perception of pain. Maladaptive pain-related cognitions are identified and challenged by cognitive interventions.
2462401|NCT03157310|Experimental|Gefitinib|Gefitinib is an selective small molecule epidermal growth factor receptors (EGFRs) tyrosine kinase inhibitors (EGFR-TKI) for non-small cell lung cancer.
3156117|NCT00336336|Experimental|3|Rosuvastatin
3156118|NCT00336336|Placebo Comparator|4|
2461565|NCT03163095|Active Comparator|Open Abdomen Management with ANPPT dressing|The abdominal fascia will not be closed, but a temporally abdomenal closure (TAC) dressing (such as AbThera dressing) will be placed to protect the viscera with active Negative Pressure Peritoneal drain. Formal abdominal closure or dressing change at 24-72 hours from placement should be performed.
2461566|NCT03163095|Sham Comparator|Closed Abdomen Management|Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain). Any decision to perform a re-laparotomy will be at the discretion of the treating surgical team.
2461618|NCT03162679|Experimental|Emotion Regulation Group Therapy|Participants assigned to this condition will receive treatment immediately after assignment.
2461619|NCT03162679|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment directly after the treatment phase of the intervention group.
2461685|NCT03162367|Experimental|Autologous epidermal cell suspension group|
2461686|NCT03162367|Active Comparator|Silver sulfadiazine ointment group|
2461803|NCT03161522|Experimental|Group I (maintenance chemotherapy)|Participants receive fluorouracil and capecitabine per instructions of the treating physician in the absence of disease progression or unacceptable toxicity.
2461805|NCT03161522|Experimental|Group II (local therapy)|Participants receive fluorouracil and capecitabine and undergo RT per instructions of the treating physician in the absence of disease progression or unacceptable toxicity. Participants may also undergo surgery to some or all of the remaining sites of disease as is clinically prudent and indicated by treating physician.
2461861|NCT03160859|Other|Control Method|One arm of the study will include unsedated colonoscopy with water exchange (WE) as the control method. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
2461868|NCT03160859|Other|Study Method|The other arm will include unsedated colonoscopy with water exchange (WE) and the addition of a simple commercially available accessory to the colonoscopy device: a cap (Disposable Distal Attachment, Olympus Medical Systems Corp., Tokyo, Japan) fitted to the colonoscope per manufacturer instruction. Residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water will be removed predominantly during insertion.
2461986|NCT03160300|Experimental|Binaural Beats|Music with Binaural Beats: Binaural beat signals embedded in relaxing music, in a crossover design
2461988|NCT03160300|Sham Comparator|Placebo|Music: Relaxing music without the binaural beat component, in a crossover design
2462056|NCT03159494|Experimental|Intervention group|10 patients with type 2 diabetes enrolled to perform 8 times of High-Intensity Training. The subjects were tested before and after the training period.
2462059|NCT03159494|Experimental|Pilot study|6 patients with type 2 diabetes enrolled to perform 6 times of High-Intensity Training. The subjects were tested before and after the training period
3156119|NCT00336362|Active Comparator|1|Participants will receive hydroxyurea pretreatment.
3156120|NCT00336362|No Intervention|2|Participants will not receive hydroxyurea pretreatment.
2462228|NCT03158415|Experimental|Parents of Young Adults with T1D|Parents of young adults ages 18 to 25 years with type 1 diabetes who are transitioning to independence. During six weeks, participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
2462327|NCT03157726|Active Comparator|TUKEP(enucleation of prostate)|"Patients accept TUKEP (transurethral plasmakinetic enucleation of prostate). The TUKEP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running, the beak of resectoscope was used to enucleation of prostate and the bipolar loop was used to cutting and coagulation, There are many manufacturers of Bipolar TURP systems. Any bipolar plasmakinetic system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
2462328|NCT03157726|Active Comparator|TURP(resection of prostate)|"Patients accept TURP (transurethral resection of prostate). The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system approved by the CFDA (Chinese food and drug administration) may be used for the study.~The bipolar plasmakinetic system was set at 160 W for cutting and 100 W for coagulation."
2462572|NCT03155971|Experimental|PCB group|Prospective, single center, single-group clinical study. Interventions: Patients in the PCB group will be treated (angioplasted) with Paclitaxel-Coated Balloon (SeQuent ® Please; B.Braun, Melsungen, Germany)
3156121|NCT00336375|Experimental|1|All treatment doses accompanied with intake of fatty food
3156122|NCT00336375|Active Comparator|2|All treatment doses not-accompanied with intake of fatty food.
3156123|NCT00336453|Experimental|FluBlok-22.5 μg, 6-35 months old|6-35 months old, FluBlok-22.5 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
3156124|NCT00336453|Experimental|FluBlok-45 μg, 6-35 months old|6-35 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
3156125|NCT00336453|Active Comparator|TIV-7.5 μg, 6-35 months old|6-35 months old, 2006-2007 formulation of Fluzone, (sanofi-pasteur, Swiftwater, PA)-7.5 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
3174604|NCT00625209|Placebo Comparator|1|placebo of hydrocortisone, placebo of fludrocortisone and placebo of activated protein C
2461579|NCT03163121|Experimental|Group 6 - PfSPZ Vaccine|"Group 6 will comprise of 13 volunteers who will receive 3 immunizations of 4.5 x 10^5 PfSPZ of PfSPZ Vaccine 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2461580|NCT03163121|Placebo Comparator|Group 7 - Normal Saline Placebo control|"Group 7 will comprise of 9 volunteers who will receive 3 injections of normal saline placebo 8 weeks apart via DVI.~3 weeks after the last injection, volunteers will undergo mosquito-bite CHMI with five NF54-infected mosquitoes. After CHMI, volunteers will be followed closely for monitoring of adverse events and blood stage infections, and will be seen once daily from day 6 until day 21 after infection and on day 28. All volunteers will be treated with a curative regimen of antimalarials, which may be A/P or artemether/lumefantrine, at the time of detection of blood stage parasitemia by qPCR or 28 days after CHMI. Adverse events will be assessed up to 6 months after the CHMI."
2461639|NCT03162393||group 1|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve
2461648|NCT03162393||group 2|phrenic nerve transfer to musculocutaneous nerve; spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve
2461659|NCT03162393||group 3|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
2461664|NCT03162393||group 4|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to triceps branch and radial nerve; contralateral C7 nerve transfer to median nerve and musculocutaneous nerve
2461668|NCT03162393||group 5|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve, radial nerve and axillary nerve; contralateral C7 nerve transfer to median nerve and triceps branch
2461670|NCT03162393||group 6|spinal accessory transfer to suprascapular nerve; intercostal nerve transfer to musculocutaneous nerve and radial nerve; contralateral C7 nerve transfer to median nerve and triceps branch
2461723|NCT03162094|Experimental|AVX-012 Opthalmic Solution Low dose|"Phase I: AVX-012 ophthalmic solution Low dose administration three times per day (TID) for 7 days~Phase II: If the low dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution Low dose administration three times per day (TID) and two times per day (BID) for 28 days"
2461732|NCT03162094|Experimental|AVX-012 Opthalmic Solution High dose|"Phase I: AVX-012 ophthalmic solution High dose administration three times per day (TID) for 7 days~Phase II: If the high dose of AVX012 is selected on phase I, AVX-012 ophthalmic solution High dose administration three times per day (TID) and two times per day (BID) for 28 days"
2461738|NCT03162094|Placebo Comparator|Placebo (Vehicle) Opthalmic Solution|"Phase I: Placebo ophthalmic solution administration three times per day (TID) for 7 days~Phase II: Placebo ophthalmic solution administration three times per day (TID) and two times per day (BID) for 28 days"
2461822|NCT03161561|Other|capacity of primary phagocytes|capacity of primary phagocytes isolated from COPD patients' blood to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
2461880|NCT03161041|Experimental|Bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
2461953|NCT03160677|Experimental|Intensive blood pressure management|
2461962|NCT03160677|Active Comparator|Standard blood pressure management|
2462028|NCT03160092|Experimental|Intervention|"Clinical Participants will receive a 4 session individual intervention, which will be delivered by Assistant Practitioners and Assistant Psychologists (who will have received specific training in the delivering of the intervention).~The intervention will target the participant's attenuated positive psychotic symptoms, which will be referred to as: 'unusual' experiences (unless the participant prefers an alternative).~The therapist will focus on creating a therapeutic relationship in which the participant experiences them as warm, accepting and empathic. The aim is for the participant to feel listened to and understood.~The intervention will focus on taking a normalising and non-catastrophising approach to the individual's unusual experiences. The participants will be provided with psychoeducation to support this aim."
2462082|NCT03159767|Experimental|Spinal Mobility Measurement: Rater A|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
2462086|NCT03159767|Experimental|Spinal Mobility Measurement: Rater B|All patients will undergo the same ViMove Spinal Sensor measurement protocol with independent raters.
2462146|NCT03159156|No Intervention|Blood Donation As Usual|Volunteer blood donors complete assessment materials, including assessment of respiratory activity, but otherwise undergo the typical blood donation procedure.
2462150|NCT03159156|Experimental|Applied Tension|Participants are taught a simple muscle tensing technique with a brief video presented on a notebook computer before giving blood. They are asked to engage in repeated gentle 5-sec on, 5-sec off cycles of whole body isometric muscle tension before and while giving blood.
2462154|NCT03159156|Experimental|Respiration Control|Participants are taught a simple respiration control technique with a brief video presented on a notebook computer before giving blood. They are asked to breathe in a gentle shallow but regular fashion aimed at reducing risk for hyperventilation before and while giving blood.
2462159|NCT03159156|Experimental|Applied Tension/Respiration Control|Participants are asked to practice both Applied Tension and Respiration Control before and while giving blood.
2462195|NCT03158623|Experimental|Platelet Rich Plasma|30cc of PRP was administered at closure of wound
2462197|NCT03158623|Experimental|Cellerate (Activated Collegen)|1gm of Cellerate was administered at closure of wound
2462229|NCT03158350|Experimental|Stationary Bristle Technique (SBT)|Instructed brushing method. Participants are asked to brush twice daily, for 2 minutes at a time, following instructions for the Stationary Bristle Technique.
2462233|NCT03158350|No Intervention|Non-Stationary Bristle Technique (NSBT)|The control group will be asked to brush twice daily, for 2 minutes at a time, following their normal toothbrushing technique.
2461684|NCT03162341|Experimental|UltraSonography and DECT|"UltraSonography and DECT will be used in patient monitoring after 6, 12 and 24 months of treatment in order to evaluate the correlation between the 2 explorations for the measurement in tophus volume change.~Those are interventions that are not part of the standard care of the patients."
2461699|NCT03161990||Transgluteal approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a transgluteal approach.
2461704|NCT03161990||Posterior approach to the hip joint|Patients who have been revised once for an infected total hip replacement with debridement and implant retention and in whom both the primary hip arthroplasty and the revision procedure were performed through a posterior approach.
2461836|NCT03161496||wild genotype|Through next generation sequencing, distinguish wild genotype of NOACs
2461840|NCT03161496||mutant genotype|Through next generation sequencing, distinguish mutant genotype of NOACs
2461859|NCT03160872||Women who undergo donor sperm insemination|Non infertile women who undergo donor sperm insemination cycle
2461927|NCT03160729|Active Comparator|High dose|Dexamethasone 24 mg
2461928|NCT03160729|Active Comparator|Low dose|Dexamethasone 8 mg
2462027|NCT03160079|Experimental|Blinatumomab + Pembrolizumab|
2462136|NCT03159221|Experimental|BFST for Teens with Type 2 Diabetes|Psychological intervention: Families randomized to the intervention group will receive 12 sessions of Behavioral Family Systems Therapy for Teens with type 2 diabetes (BFST-DM2) over 6 months.
2462138|NCT03159221|No Intervention|Control group (Standard Care)|The participants assigned to the control group will receive their standard medical care for diabetes.
2462244|NCT03158376|Experimental|gabapentin group|"the day before surgery : gabapentin 400 mg orally~preoperatively (2 hours before surgery) : 3 capsules each containing 400 mg gabapentin (total gabapentin dose 1200 mg) and intravenous infusion of 50 ml of normal saline solution~postoperative day 1 to 10 : 400 mg x 3 ( gabapentin 1200 mg daily)"
2462247|NCT03158376|Placebo Comparator|placebo group|"The day before surgery: 1 placebo capsule orally~preoperatively (2 hours before surgery) : 3 placebo capsules and intravenous infusion of 75 mg hydroxyzine~postoperative day 1 to 10: 1 placebo capsule x 3"
2462287|NCT03157960|Experimental|Blueberry drink|Participant will receive a blueberry drink containing 18 g of fructose and 14 g of glucose.
2462293|NCT03157960|Experimental|Blueberry and pizza|Participant will receive a blueberry drink and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
2462298|NCT03157960|Experimental|Soft beverage|Participant will receive a Soft beverage (Coca-cola containing 17,5 g fructose and 17,5 g glucose)
2462299|NCT03157960|Experimental|Soft beverage and pizza|Participant will receive a Soft beverage and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
2462303|NCT03157960|Experimental|Fructose|Participant will receive a drink containing 35 g of fructose
2462305|NCT03157960|Experimental|Fructose and pizza|Participant will receive a drink containing 35 g of fructose and a slice of pizza (170 grams; 22 g protein, 20 g fat and 50 g carbohydrate; 425 kCal)
3156126|NCT00336453|Active Comparator|TIV-15 μg, 36-59 months old|36-59 months old, 2006-2007 formulation of Fluzone (sanofi-pasteur, Swiftwater, PA)-15 μg of each hemagglutinin antigen: A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Malaysia/2506/2004 like viruses
3156127|NCT00336453|Experimental|FluBlok-45 μg, 36-59 months old|36-59 months old, FluBlok-45 μg of each recombinant hemagglutinin antigen: 2006-2007 formulation containing A/New Caledonia/20/99 (H1N1), A/Wisconsin/67/05 (H3N2), and B/Ohio/01/05 like viruses
2462558|NCT03156153|Experimental|Bumetanide group|Double-blind phase: in the first 3 months, patients will receive the experimental treatment - bumetanide, oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, all the patients will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
2462562|NCT03156153|Placebo Comparator|Control group|Double-blind phase: in the first 3 months, patients will receive the placebo - oral intake, 0.5mg/time, twice a day; Open-label phase: after 3 month double-blined treatment, patients in this group will receive 3-month bumetanide treatment - oral intake, 0.5mg/time, twice a day.
2462614|NCT03155698|Experimental|microneedling,NB-UVB with & without PRP|"Each participant will be compared with one side of the body to the other side~Intervention:~Combination Product: microneedling and Platelet rich plasma.~radiation : NB-UVB phototherapy"
2462671|NCT03155152|Experimental|DECT Group|"The DECT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is progressively decreased throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
2462676|NCT03155152|Active Comparator|HIIT Group|"The HIIT session consists of four bouts of 4 min high-intensity decremental exercise with 3 min of active recovery between bouts. Load is kept constant throughout each exercise bout. The training period will last for a total of 4 weeks, with three weekly sessions of supervised training"
2462837|NCT03154177|Experimental|Group Care + Ultrasound+Pregnancy Testing|Group ANC and PNC care, in combination with early pregnancy testing and ultrasound.
2462859|NCT03153787|Experimental|Not pregnancy|Vaginal probiotic administration
2463037|NCT03152786|Experimental|Group I (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO 2 hours prior to standard of care prostatectomy.
2464512|NCT03142191|Experimental|CC-90001 200 mg PO QD|55 subjects will be randomized to CC-90001 200mg
3156128|NCT00336557||Regularly Scheduled NAb Testing Arm|Subjects will be scheduled for 5 study visits over the course of 12 months and any NAbs test results will be available to the investigator during the study.
3156129|NCT00336557||Usual Care Arm|Subjects will be scheduled for 2 study visits over the course of 12 months and any NAbs test results will be unknown by the investigator until the conclusion of the subject's study participation.
3156130|NCT00336622|Experimental|Experimental|Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
3156131|NCT00336622|Active Comparator|Control|Off-the-shelf splint
2461620|NCT03162731|Experimental|Treatment ( nivolumab, ipilimumab, radiation therapy)|Patients receive nivolumab IV over at least 30 minutes every 2 weeks and ipilimumab IV over at least 90 minutes every 6 weeks. Beginning week 3, patients undergo simultaneous integrated boost intensity modulated radiation therapy or volumetric modulated arc therapy for 5 days per week over 7 weeks. Patients continue nivolumab every 2 weeks for 12 doses and ipilimumab every 6 weeks for 4 doses. Courses repeat for up to 23 weeks in the absence of disease progression or unacceptable toxicity.
2461720|NCT03162081||Users|"Elderly patients who use prescription benzodiazepines/Z-hypnotics or opiates~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
2461726|NCT03162081||Non-users|"Age and gender matched controls not using the above~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Cognistat Neurobehavioural cognitive status examination (Cognistat), Neuropsychological profiling, Medication use, Comorbidity"
2461736|NCT03162081||Screening group|"Patients over 65 admitted to hospital as in-patients~Clinical interview, Substance misuse screening, EuroQol five dimensional health-related quality of life questionnaires (EQ-5D), Impulsivity screening, Cognitive screening, Functional tests, Medication use, Comorbidity"
3191232|NCT00796289|Active Comparator|Clomiphene Citrate|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
2461906|NCT03160807|Experimental|Levofloxacin 5 days|Levolet 500 mg given for 5 days
2461907|NCT03160807|Active Comparator|Levofloxacin 10 days|Levolet 500 mg given for 10 days
2461946|NCT03160391|Experimental|Music Training|Music Training
2461947|NCT03160391|Active Comparator|Dance Training|Dance Training
2461950|NCT03160391|No Intervention|Passive control group|Passive control group
2462076|NCT03159585|Experimental|TAEST16001|Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.
3191233|NCT00796289|Placebo Comparator|Placebo|Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
3191234|NCT00796341|Experimental|1|
2462165|NCT03158909|Experimental|Interventional|Patients in this group will receive eyemask and earplugs, for use during the night, and orientations about space and time, every night.
2462168|NCT03158909|Active Comparator|Orientation about space and time|This group will receive orientations about space and time olny, every night.
2462188|NCT03158532|Placebo Comparator|Placebo I/Placebo II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2462189|NCT03158532|Experimental|Nitroglycerin I/Placebo II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 0,9% Saline 10 mL was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2462190|NCT03158532|Active Comparator|Placebo I /Nitroglycerin II|0,9% Saline 10 mL was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2462192|NCT03158532|Experimental|Nitroglycerin I /Nitroglycerin II|500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the start of a transradial procedure (right after sheath placement) and 500 microgram of Nitroglycerin (in 10 mL saline) was given intra-arterially through the sheath at the end of procedure (just before sheath removal).
2462273|NCT03158207|Experimental|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask.. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2462276|NCT03158207|Active Comparator|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
2462315|NCT03157843||Medical Patients|Medical patients who received, at admission and during all the length of recovery, antithrombotic drugs (low-molecular-weight heparin at prophylactic dosage ).
2462318|NCT03157843||Control Group|Medical patients not treated with antithrombotic drugs during the recovery. Subjects age, sex and comorbidities matched.
3191235|NCT00796341|No Intervention|2|
3191236|NCT00796354|Active Comparator|NRL920|
3191237|NCT00796354|Placebo Comparator|Placebo|
3191238|NCT00796393|Experimental|2|Subject with active product, not vaccinated against influenza.
3191239|NCT00796393|Placebo Comparator|3|Subject with placebo, vaccinated against influenza.
3191240|NCT00796393|Placebo Comparator|4|Subject with placebo, not vaccinated against influenza.
3191241|NCT00796393|Experimental|1|Subject with active product, vaccinated against influenza
3191242|NCT00796458|Active Comparator|Arm I|Patients continue to receive LHRH-A therapy until disease progression.
3191243|NCT00796458|Experimental|Arm II|Patients receive LHRH-A therapy as in arm I. Patients also receive docetaxel IV on day 1. Treatment with docetaxel repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3191244|NCT00796484|Experimental|1|
3191245|NCT00796497|Experimental|ondansetron|
3191246|NCT00796536|Experimental|1|Participants will undergo 12 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
3191247|NCT00796536|Active Comparator|2|Participants will received 12 weeks of pain education and a pre- and post-intervention MRI brain scan.
3191248|NCT00796575|Experimental|CS-8080|3 mg CS-8080, 10mg CS-8080, 20 mg CS-8080
3191249|NCT00796575|Placebo Comparator|placebo|placebo
3191250|NCT00796588|No Intervention|Control group|Patients undergoing liver surgery without the designated intervention
3191251|NCT00796588|Other|RIPC|application of pneumatic tourniquet in patients undergoing liver surgery
3191252|NCT00796601|Experimental|Esreboxetine|
2462033|NCT03159949|Experimental|PR- REHIIT|"PR-REHIIT participants (Sprint Snacks) will participate in 3 separate training session per day on 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
2462034|NCT03159949|Experimental|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second sprints with three minutes rest in between, and a one-minute cool-down.
3191253|NCT00796601|Placebo Comparator|Placebo|
3191254|NCT00796679|Experimental|1|paricalcitol
2462162|NCT03159039|Experimental|Conventional Physiotherapy (PT)|Postural drainage + manual vibration
2462164|NCT03159039|Active Comparator|Prolonged slow exhalation technique|Prolonged exhalation + Conventional PT
2462202|NCT03158597||AMI|
2462204|NCT03158597||Control|
2462255|NCT03158324|Experimental|Advanced refractory solid tumors|Patients with advanced refractory solid tumors will be enrolled.
2462378|NCT03157908|Experimental|Smartphone app|All participants in this pilot study will install the smartphone app for testing
2462441|NCT03157141||Control group, CG|For the purpose of the study, forty subjects for each group will be recruited. The control group (CG group) (so-called healthy subjects) CG will be recruited following the recruitment of the AA group and of the TAR group, as a sex, age and BMI matched design will be pursued. Inclusion criteria for the CG group are no history of orthopaedic lower limb surgery and absence of any known neurological or systematic disease.
2462443|NCT03157141||Total ankle replacement group (TAR group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects.
2462445|NCT03157141||Ankle arthrodesis group (AA group)|The number of AA and TAR subjects used in a majority of studies to analyze the functional repercussion of an ankle arthrodesis or a total ankle replacement varied between 10 and 35 subjects
2462519|NCT03156634|Experimental|PALS|Participants will view materials about the antihypertensive, chlorthalidone on the Patient Activated Learning System (PALS).
2462522|NCT03156634|Active Comparator|WedMD|Participants will view materials about the antihypertensive, chlorthalidone on WebMD.
2462576|NCT03156023|Active Comparator|Active|Receive active investigational product (AMG 570).
2462579|NCT03156023|Placebo Comparator|Placebo|Receive placebo investigational product
2462606|NCT03155568|Active Comparator|sciatic nerve block|ultrasound guided sciatic nerve block by injecting 30ml of 0.5% bupivacaine and visualized circumferentially spreading around the sciatic nerve
2462608|NCT03155568|Active Comparator|ankle block|ankle block performed by injecting 20 ml of 0.5% bupivacaine in equal amounts around the five major nerves supplying the foot
2462610|NCT03155568|Active Comparator|combined popliteal and ankle block|combined block performed by the use of 20 ml of 0.25% bupivacaine for sciatic nerve block followed by the ankle block with use of 20 ml of 0.5% bupivacaine both in the same manner as other two groups.
2462715|NCT03155282||Cirrhotic group|30 patients with cirrhosis will be evaluated by EUS-E to measure liver and spleen stiffness. Different cirrhosis etiologies will be included like cirrhosis induces by alcohol, virus, autoimmune, nonalcoholic steatohepatitis (NASH), cryptogenic, primary sclerosing cholangitis and primary biliary cirrhosis. The cirrhotic status will be determinate by clinical, biochemical and/or imaging methods (abdominal ultrasound or CT scan).
2462716|NCT03155282||Control group|30 normal patients with no history of liver disease (negative hepatitis B virus and hepatitis C virus serology, insignificant alcohol intake, normal ultrasound and laboratory), in whom a EUS has to be performed to evaluate a esophageal or gastric subepithelial lesion, chronic pancreatitis, will be evaluated by EUS-E to measure liver and spleen stiffness.
2462825|NCT03154606|Experimental|HP-Beverage Breakfast|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will vary in protein source. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
2462830|NCT03154606|Active Comparator|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will primarily as carbohydrates as a control. All ingredients are GRAS listed and approved. All participants will complete all 12 interventions.
2462908|NCT03153293|Experimental|rAAV2-ND4|A Single IVT Injection of recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4)（0.05ml).The dose is 1 × 10^10 vg/0.05 mL for test groups.
2462995|NCT03152864|Experimental|Full Package|
2462996|NCT03152864|No Intervention|Sensing Only|
3191255|NCT00796679|Placebo Comparator|2|placebo
3191256|NCT00796692|Experimental|Group 2|Low molecular weight heparin
3191257|NCT00796692|Active Comparator|Group 1|Unfractionated heparin(UFH)
3191258|NCT00796770|Experimental|Dendritic Cell Vaccine|Autologous dendritic cells generated using GM-CSF and interferon alpha, loaded with HIV lipopeptides and activated with lipopolysaccharide
2463393|NCT03150420|Placebo Comparator|Placebo-Normal Saline|0.9% sodium chloride injection, USP (normal saline)
3191259|NCT00796783||1|Patients with presumed Cushing's disease who have failed pituitary surgery and/or radiation and require medical treatment for recurrent or persistent Cushing's syndrome.
3191260|NCT00796796|Experimental|Cohort 1 (Starting Dose)|"Temsirolimus 20 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
3191261|NCT00796796|Experimental|Cohort 2|"Temsirolimus 25 mg IV weekly for 4 weeks~Radiation therapy will begin on Day 2, one day after the initial dose of temsirolimus. Treatment will consist of daily fractions of 250 cGy, 5 days per week to a total cumulative dose of 3500 cGy for a total of 14 days."
2461697|NCT03162133|Experimental|Exercise group|After completing the baseline tests, participants in exercise group were instructed to attend 90-minute, supervised Baduanjin exercise 2 times per week. The Baduanjin intervention used the standardized Baduanjin training program, designed by the General Administration of Sports of China. Two senior Baduanjin teachers from Guangzhou Sports University conducted the training.
2461700|NCT03162133|Experimental|Waiting list Control group|"Participants assigned to the wait-list control were told to continue performing their usual care and daily activities, and to refrain from doing any Baduanjin exercise.~After their post-assessment they were able to attend the Baduanjin classes."
2461771|NCT03161860|Experimental|Personalised citizen assistance|The experimental group will receive the Personalised citizen assistance for social participation (APIC), i.e. weekly 3-hour personalised stimulation sessions by a trained volunteer over 12 months. Sessions will encourage empowerment, gradual mobilisation of personal and environmental resources, and community integration.
2461774|NCT03161860|No Intervention|Control group|The control group will receive the publicly-funded universal healthcare services available to all Quebecers.
2461812|NCT03161301||Group 1|IL-37 genotype 1.1
2461815|NCT03161301||Group 2|IL-37 genotype 1.2
2461820|NCT03161301||Group 3|IL-37 genotype 2.2
2461905|NCT03161106|Experimental|Nutrional Therapy Group|Nutritional group- Protein of 1.5 gm/kg thrice daily for 6 months
2461908|NCT03161106|Active Comparator|Lactulose Group|Lactulose - 20 mL thrice daily (maximum) for 6 months
2461993|NCT03160144|Experimental|open lung approach ventilation strategy|Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
2461995|NCT03160144|No Intervention|conventional ventilation strategy|Procedure: conventional ventilation strategy (NOLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, no PEEP and no recruitment maneuver.
2462050|NCT03159845|Active Comparator|Control|patients undergone autologous stem cell transplantation. They take levofloxacin 500 mg/d, aciclovir 400 mg bid, fluconazole 200 mg bid from day +10 until day +30 after stem cell transplantation
2462052|NCT03159845|Experimental|Zinc|patients undergone autologous stem cell transplantation. They take the same antimicrobial prophylaxis of patients of the Control group, and, in addition, a daily oral supplementation of Zinc Sulfate, 600 mg/die, uncoated tabs, from day +5 until day +100 after transplant
2462119|NCT03159338|Active Comparator|treatment group|One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation
2462121|NCT03159338|Placebo Comparator|Control group|In control site , placebo gel will be placed before rigid fixation
2462158|NCT03158870||Pheochromocytoma|Patient who underwent surgical procedure for pheochromocytoma
3191262|NCT00796809||Biologics|Patients receiving TNF inhibitors or biologic agents
3191263|NCT00796809||DMARD|Patients receiving methotrexate without any biologic
3191264|NCT00796887|Experimental|Niaspan® 500mg|
2462353|NCT03157739|Experimental|Evaluation of Optimized Prototype|Patients and parents will use MigraineManager to complete assessment measures at baseline and post-treatment (i.e., 2 months after baseline). Answers to these measures will determine what interventions each participant will receive. Data obtained in this phase will be used to make final modifications to MigraineManager for large scale testing.
2462450|NCT03157323|Other|Low Glycemic Index Diet|Following a low glycemic index diet verses a standard american diet.
2462504|NCT03156504|Experimental|Ketamine|Subjects will receive three IV Ketamine Hydrochloride infusions (0.5 mg/kg, infused over 100 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers) and following ketamine treatment (change biomarkers).
2462564|NCT03156062|Experimental|study group|
2462567|NCT03156062|Active Comparator|control group|
3191265|NCT00796887|Experimental|Niaspan® 1000mg|
2462734|NCT03154814|Experimental|ulinastatin treatment|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
2462739|NCT03154814|Placebo Comparator|control|conventional CPB was applied without ulinastatin treatment
2462815|NCT03154372|Other|deliberate practice|expert supervised practice with validated metrics
2462819|NCT03154372|Other|self-guided practice|self guided practice with validated metrics
2462861|NCT03153943|Experimental|Workbook support group|Printed educational workbook and pedometer.
2462871|NCT03153943|Experimental|HIP Mobile e-Monitoring support group|Remote monitoring via smart shoe insoles and a coaching with enabling educational electronic program accessed through a tablet.
2462953|NCT03153072|Other|A child with supraventricular tachycardia|
2463002|NCT03152838||Autism Cases|"20 confirmed autism cases will be involved in this study.~The autism patients will be diagnosed according to:Gilliam Autism Rating Scale Arabic version: An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score.~Fasting blood samples will be collected from autism children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
2463039|NCT03152786|Active Comparator|Group II (no treatment)|Patients receive no treatment prior to standard of care prostatectomy.
3191266|NCT00796887|Placebo Comparator|Placebo|
3191267|NCT00796900|Experimental|Dantrolene|
3191268|NCT00796900|Placebo Comparator|Placebo|
2461729|NCT03162250|Experimental|DSTA4637S intermediate dose level+ SOC|DSTA4637S intermediate dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2461734|NCT03162250|Experimental|DSTA4637S high dose level+ SOC|DSTA4637S high dose level IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2461739|NCT03162250|Placebo Comparator|Placebo + SOC|Placebo matched to DSTA4637S IV infusion will be administered within 24 hours of randomization on Day 1 and then every 7 days up to 6 doses of study drug in addition to anti-staphylococcal SOC antibiotics.
2461780|NCT03161587||Subjects with COPD|Subjects with diagnosis of COPD at least one year, visiting outpatient clinics in tertiary hospitals in China and in stable state at enrolment.
2461824|NCT03161236|Experimental|home exercise program|• The exercise group will follow a home exercise protocol for eight weeks: that involves standing on one foot, walking, and doing wall squats.
2461826|NCT03161236|Active Comparator|non exercise group|• The non-exercise group will continue with their usual life style
2461849|NCT03160989|Experimental|Postmenopausal and hypertensive women|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
2461890|NCT03160833|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE (high-density polyethylene) bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, until disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 50, 100, 200, 300, 400, and 500 mg/day
2461954|NCT03160534|Experimental|Intervention|Preoperative exercise intervention
2461960|NCT03160534|No Intervention|Control|Only measurements
2462000|NCT03160196|Experimental|Experimental practices|The decision support tool is a Web-based software program accessed via a GP computer desktop icon. Clicking the icon opens a single page of tick boxes asking for relevant aspects of the presenting illness. Most fields for relevant medical history and patient demographics are automatically populated from data in the electronic health record. Depending on diagnosis and risk estimation, the tool recommends a guideline-based management strategy. Override options exist but require a justification from the GP. The tool also provides relevant prescriptions, radiology access, and referral forms, and a variety of patient information leaflets. GPs in practices randomized to the intervention group will have to initiate the tool but will not have to follow the tool's advice.
2462002|NCT03160196|Active Comparator|Control practices|Control practices will be aware of the tool but will be unable to access it and managed patients by usual care, which could include care aligned with the Guidelines. Prior to randomization, GPs from all participating practices (control and intervention) will attend a 1-hour face-to-face didactic education session on diabetes mellitus 2 management and the Colombia diabetes mellitus 2 Guidelines. The intervention pertains to the cluster level.
2462069|NCT03159429|Experimental|Experimental arm|"Patients randomized to this arm will participate in the new rehabilitation programme.~Intervention: Nasal breathing rehabilitation"
2462075|NCT03159429|Active Comparator|Comparator arm|"Patients randomized to this arm will participate in the usual rehabilitation programme.~Intervention: Standard rehabilitation"
3191269|NCT00796913|Active Comparator|Stop of medication after remission|"After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:~Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487."
2462171|NCT03158935|Experimental|Advanced metastatic melanoma (Cohort 1)|Cyclophosphamide and fludarabine followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
2462173|NCT03158935|Experimental|Advanced ovarian cancer (Cohort 2):|Cyclophosphamide followed by Tumor-Infiltrating Lymphocytes (TILs), Interleukin-2 (IL-2), and pembrolizumab
2462198|NCT03158467||Phase 1|
2462200|NCT03158467||Phase 2|
2462230|NCT03158363|Experimental|"LPS, 36 hour immobilization and fast"|"Interventions:~Test subjects undergo 48 hour exercise restriction and overnight fast.~Study day 1:~- LPS (1 ng/kg) will be administered. Test subjects will fast and bedrest for the rest of the study period.~Study day 2:~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies.~Study day 3:~- Blood sample."
2462235|NCT03158363|No Intervention|"Control"|"Test subjects undergo overnight fast. No exercise restrictions.~3 hour Basal period: Continued fast and bedrest. Phenylalanine, tyrosine, carbamide, glucose and palmitate tracers are infused. Muscle and fat biopsies are taken from m. vastus lateralis and stomach.~3 hour hyperinsulinemic euglycemic clamp period with muscle and fat biopsies."
2462257|NCT03157986|Active Comparator|Whole Body Vibration training|Balance Training on a Vibration platform
2462263|NCT03157986|Active Comparator|Conventional Balance training|Balance Training on a Balance board
2462317|NCT03157895|Experimental|Program group|This group receives the Connecting program with telephone support. It's anticipated the program will take up to 14 weeks to complete.
2462319|NCT03157895|No Intervention|Comparison group|This group receives Children's Administration services as usual.
2462372|NCT03157557|Experimental|Lifestyle treatment|Lifestyle treatment
2462375|NCT03157557|No Intervention|Treatment as Usual|Treatment as Usual
2462395|NCT03157154||First group|Haemophilia patients with history of either cardiovascular disease or atrial fibrillation undergoing an antiplatelet or anticoagulant prophylaxis
2462488|NCT03156491||Recurrent miscarriage group|Women with unexplained recurrent miscarriages (three or more first trimester miscarriages).
2461730|NCT03162263|Active Comparator|Overground training|Conventional gait training overground; before the training 10 min lower limb muscular exercises and stretching were performed by the physiotherapist. The overground training had the same duration of the Ekso training.
2461752|NCT03161678|Active Comparator|Wild-Type Genotype|Research subjects with wild type CES1 genotypes will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2461754|NCT03161678|Experimental|Carriers of the CES1 G143E Mutation|Research subjects who carry the CES1 G143E allele (rs71647871) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2461758|NCT03161678|Experimental|Carriers of CES1 Functional Mutation|Research subjects who carry a CES1 mutation of potential functional impact (to be determined...studies ongoing) will be studied before and after oral ingestion of clopidogrel (75 mg/d for 8 days) and ticagrelor (90 mg twice daily for 8 days) treatment.
2461813|NCT03161340|Experimental|Treatment group|Rapamycin group
2461817|NCT03161340|No Intervention|Control group|Patients who do not receive any treatment despite a history of Recurrent Implantation Failure problem
2461887|NCT03161067|Experimental|Surgical implantation of BiCNS|
2461931|NCT03160638|Experimental|Azithromycin arm|Patients in this arm will be treated with azithromycin 250 mg once daily on top of standard HRZE treatment.
2461934|NCT03160638|No Intervention|Standard of care arm|Patients in this arm will receive no additional treatment on top of standard HRZE treatment
2461984|NCT03160313|Experimental|InFuSE|Experimental group which will receive health education, group discussion, and supervised exercise.
2461985|NCT03160313|Active Comparator|Patient Education/Group Discussion|Active control group which will receive health education and group discussion.
2462016|NCT03159975|Experimental|Dose level 1 (GX-70 0.26mg)|Administrating GX-70 0.26mg
2462021|NCT03159975|Experimental|Dose level 2 (GX-70 1mg)|Administrating GX-70 1mg
2462025|NCT03159975|Experimental|Dose level 3 (GX-70 4mg)|Administrating GX-70 4mg
2462201|NCT03158805|Active Comparator|Active drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
2462205|NCT03158805|Placebo Comparator|Placebo|Placebo (no active drug)
2462275|NCT03158194|Experimental|CBT for anxiety-related asthma|Ten to twelve weekly sessions of CBT targeting enhanced function and decreased symptoms of anxiety.
2462332|NCT03157817||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of Chronic Obstructive Pulmonary Disease
2462333|NCT03157817||Healthy Volunteers|Volunteers without any respiratory condition or symptoms
2462418|NCT03157193|Experimental|Test Group|Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
2462423|NCT03157193|Sham Comparator|Control 1 Group|Hydroxypropyl guar based gel, without any biological effect.
2462425|NCT03157193|No Intervention|Control 2 Group|No gel application, only standard perimplantitis treatment.
2462485|NCT03156478|No Intervention|Control group|At baseline, individuals in the control group receive digital information package about lifestyle risk factors of type 2 diabetes with recommendations on healthy diet and physical activity in accordance with the Finnish Nutrition Recommendations and the national recommendation for health enhancing physical activity.
2462486|NCT03156478|Experimental|Digital lifestyle intervention group|Participants are instructed to use a digital self-help tool for 12 months. This tool is developed in the StopDia-study to enact positive changes in participant's health behaviour. The digital intervention consists of 2 components which motivate, enable and trigger the participants to improve their health behaviours. B.J. Fogg's Tiny Habits -ideology. The digital intervention is based on the Fogg Behaviour Model (FBM) and the Behaviour Wizard.
2462487|NCT03156478|Experimental|Combined digital and face-to-face lifestyle intervention group|Participants are using the StopDia digital solution tool as described above. In addition, they have six face-to-face group coaching (6-15 participants/group) sessions at local health centers facilitated by trained nurses. The face-to-face group intervention is based on the Self-Determination Theory and theories of self-regulation, and delivered using intrinsic motivational coaching approach designed and tested in the GOAL lifestyle intervention, and further developed in several other studies in Finland and internationally.
2462557|NCT03156257||Self-reported healthy males and females|The investigators are interested in sampling a wide variety of individuals from varying ethnic groups, sex, and age range.
2462619|NCT03155750|Experimental|Zero Time Exercise training|Subjects in this group will attend two 2-hour ZTEx training lessons. Each subject will receive a handout and an exercise log. The handout includes a picture-illustrating ZTEx step-by-step protocol. The exercise log is for them to record their time spending on performing the ZTEx every day during the 8-week study period.
2462624|NCT03155750|Active Comparator|sleep hygiene education|Subjects in this group will receive two 2-hour lessons of sleep hygiene education delivered by a registered nurse.
3191270|NCT00796913|No Intervention|Medication for 2 yrs after remission|See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
2462766|NCT03154593||Stage 1|Stage 1 will determine the prevalence of chronic oedema among patients attending weight management services at the Royal Derby Hospital and how it impacts on every day life.
2462769|NCT03154593||Stage 2|Stage 2 will determine whether bariatric surgery improves the oedema.
2462828|NCT03154281|Experimental|Cohort 1|(each cycle is 28 days long) Everolimus 5mg daily on Mondays, Wednesdays, and Fridays Niraparib 100mg daily
2462831|NCT03154281|Experimental|Cohort 2|(each cycle is 28 days long) Everolimus 5 mg daily on Mondays, Wednesdays, and Fridays Niraparib 200 mg daily
2462832|NCT03154281|Experimental|Cohort 3|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 200 mg daily
2462833|NCT03154281|Experimental|Cohort 4|(each cycle is 28 days long) Everolimus 5 mg daily Niraparib 300 mg daily
2462909|NCT03153358|Experimental|icotinib+SBRT|icotinib 125 milligram,three times a day for 28 days oral administration,12weeks later given the SBRT treatment depended on the outcome of icotinib
2461753|NCT03161782|Experimental|PNF Stretching group|Each subject in PNF Stretching group will receive a treatment protocol consisting of PNF stretching, cold therapy and exercise.
2461755|NCT03161782|Experimental|Static Stretching group|Each subject in Static Stretching group will receive a treatment protocol consisting of static stretching, cold therapy and exercise.
2461789|NCT03161353|Experimental|Cohort A|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel (during 4 cycles):~PET responders or not responders after surgery: Continue with Perjeta+Herceptin+ Endocrine therapy (tamoxifen or letrozole) during 12 cycles~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
2461791|NCT03161353|Experimental|Cohort B|"Cohorts A/B if there is no evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening. Interventional: Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) during 2 cycles.~PET responders: Perjeta+Herceptin+Endocrine therapy during 6 cycles. -Complete response: continue with Perjeta+Herceptin+ Endocrine therapy during 10 cycles -Non-complete response: Perjeta+Herceptin+ Carboplatin+ Docetaxel during 6 cycles and Perjeta+Herceptin+Endocrine therapy during 4 cycles.~PET non-responders: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients with or without complete response will continue with Perjeta+Herceptin+Endocrine therapy during 10 cycles.~A sub-set of 42 patients (35 patients from cohort A and 7 patients from cohort B) from 5 sites in Spain are participating in the LINGain sub-study Prospective evaluation of predictive/prognostic immunogenicity biomarkers for target therapy in HER2-positive early breast cancer within the PHERGain study."
2461794|NCT03161353|Experimental|Cohort C|cohorts C if there is evidence of subclinic M1 assessed by 18F-FDG PET/CT at screening Interventional: Perjeta+Herceptin+Carboplatin+Docetaxel during 6 cycles. Patients will continue with Perjeta+Herceptin+Endocrine therapy (tamoxifen or letrozole) after surgery or no surgery.
2461898|NCT03160755||Qualitative Interviews|Adult outpatients with metabolic syndrome.
2461983|NCT03160352|Experimental|Exergame|The Senso is a training system (dividat, Schindellegi, Switzerland) for improving physical and cognitive function was used as exergame. With foot pushes participants triggered on a pressure-sensitive plate. The Senso game was projected with a beamer at white wall. To promote head movement during training the direction of the beamer was vertical tilted (± 15°) and horizontal turned (90°) with a remote controlled power panner.
2462015|NCT03160014|Experimental|healthy volunteers|Drug: SHR3824 20mg/day, oral tablet, single dose
2462022|NCT03160014|Experimental|Mild Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2462024|NCT03160014|Experimental|Moderate Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2462029|NCT03160014|Experimental|Severe Hepatic Impairment|Drug: SHR3824 20mg/day, oral tablet, single dose
2462067|NCT03159689|Experimental|Mixed Tree Nuts|a hypo caloric weight loss dietary plan with mixed tree nuts
2462070|NCT03159689|Active Comparator|Pretzels|a hypo caloric weight loss dietary plan with pretzels
2462109|NCT03159312|Experimental|Assigned Interventions|20 individuals undergoing bariatric surgery and post surgery normal indications with moderate exercise program
2462110|NCT03159312|No Intervention|Control group|Control group: 23 individuals undergoing bariatric surgery and post surgery normal indications without exercise program
3156132|NCT00336648|Experimental|Gemcitabine + Avastin + Surgery|Gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy
3156133|NCT00336674|Active Comparator|DV001|Recombinant human intranasal insulin formulation in a buffered solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product is formulated at a dose strength of 1100 IU / mL (40mg/mL) manufacturing formulation. The product will be self administered by eligible participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
2462232|NCT03158441||cases|The patients enrolled for the study will be women scheduled for breast MRI due to high risk screening or pretreatment evaluation. The patients will fill in a form regarding: age, hormonal status, risk factors, prior breast surgery or treatment (a form which is routinely filled out in our institution). They will then undergo a breast MRI scan, using the routine protocol in our institution. This will be directly followed by a DTI sequence, which takes about 10 minutes in addition to the regular examination. The DTI sequence is routinely used in other imaging institutions, as part of the breast MRI protocol.
2462234|NCT03158441||control|same patients , dynamic scan
3191271|NCT00796913|Experimental|Se-yeast 200 Microgr/day + arm A|Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.
3191272|NCT00796939|Active Comparator|Green Light Mask|
2462323|NCT03157596|Experimental|intervention group|"selected randomly from a list of all the 105 special education centers registered at the State Ministry of Education, and randomly allocated into intervention group.~all the children with developmental disabilities in enrolled in the school who met the eligibility criteria were examined and all their parents were interviewed.~Caregivers' baseline knowledge and attitudes towards the oral healthcare of their children was assessed by an interview questionnaire.~examination for the children with developmental disabilities was carried out to assess caregivers' practice by assessing the oral hygiene level and amount of unmet treatment needs.~educational intervention by an Oral Health Education Program for Caregivers of Children with developmental disabilities about the oral health care of Children with DD, in the form of a short video, accompanied by demonstration & followed by an interactive discussion .~the same evaluation was carried out again 3 months after the intervention."
2462568|NCT03155919|Experimental|TAUchoc|Treatment composed by taurine powder and chocolate milk
3191273|NCT00796939|Placebo Comparator|Red light mask|
3191274|NCT00796952|Active Comparator|Usual Care|"Patient management by the attending Radiation oncologist as usual."
2461787|NCT03161652|Placebo Comparator|DME plus ranibizumab lactose pill|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take a lactose pill (placebo)
2461788|NCT03161652|Experimental|DME plus ranibizumab levosulpiride|Patients with DME that will receive intravitreal antiangiogenic therapy with ranibizumab will be randomized to take levosulpiride
2461863|NCT03161080|Experimental|Dry Eye Neovis|20 Patients with dry eye syndrome receiving Neovis Total Multi Eyedrops
2461869|NCT03161080|Experimental|Dry Eye Vismed|20 Patients with dry eye syndrome receiving Vismed Multi Eyedrops
2461875|NCT03161080|Experimental|Dry Eye Hydrabak|20 Patients with dry eye syndrome receiving Hydrabak Eyedrops
2461952|NCT03160599|Experimental|Restricted Calorie Ketogenic Diet|"Calorie restriction: The basis of dietary design is 70-85% of individual's total calories. The total calorie is based on patient's activity level and their basal metabolism values, which is obtained from indirect calorimetry or harris-benedict formula.~Treatment will consist of ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard."
2462005|NCT03160209||300 esophageal cases|diagnosed with histologically confirmed ESCC
2462010|NCT03160209||300 patient controls|without a history of esophageal cancer or esophageal squamous dysplasia, a history of other cancer, or upper gastrointestinal diseases
2462074|NCT03159793|Active Comparator|Group A|Live Modelling
2462077|NCT03159793|Active Comparator|Group B|Filmed Modelling
2462078|NCT03159793|No Intervention|Group C|No Modelling
2462161|NCT03159234|Other|Diabetic pregnant women|
2462214|NCT03158649|Experimental|Positive Psychology Internet-based Intervention condition|Internet-based positive psychology training
2462217|NCT03158649|No Intervention|Waiting List condition|Waiting List control condition
2462256|NCT03158142|Experimental|Atropine group|One drop of Atropine Sulfate 1% Oph Soln will be administered either in the morning or at night in each eye. Study measurements will be taken approximately after 1, 12, 24 and 96 hours after drop instillation. After a 2 week wash out period with no eye drops, another drop of 1% atropine sulfate ophthalmic eye drops will be administered either in the morning or night (the visit that was not taken before) and study measurements will be scheduled approximately after 1, 12 24 and 96 hours after drop instillation
3191275|NCT00796952|Experimental|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their chemo-radiation treatment (up to a maximum of 6 weeks)
3191276|NCT00796952|Sham Comparator|Valchuff|"Standardised sham swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of chemo-radiation treatment."
3191277|NCT00796965|Experimental|1|
2462705|NCT03155074|Experimental|High-Intensity Training|
2462707|NCT03155074|No Intervention|Usual Care|
2462720|NCT03154840|Experimental|Eutropin 4IU|
2462721|NCT03154840|Experimental|Eutropin AQ 12IU|
2462723|NCT03154840|Experimental|Eutropin Pen 36IU|
2462760|NCT03154671|Experimental|Intervention group|At study enrollment participants allocated to the intervention arm will complete a comprehensive geriatric assessment with the study intervention team (nurse and physician). Based on these findings a care plan tailored to the needs of the older adult with cancer will be developed and implemented. The study intervention nurse will call the participant at least monthly to follow up and evaluate the care (e.g. whether adjustments are required) and more if needed. All participants will receive a monthly healthy aging newsletter.
2462762|NCT03154671|No Intervention|Control group|The participant will receive usual care from their treating oncology team. All participants will receive a monthly healthy aging newsletter.
3191278|NCT00796965|Placebo Comparator|2|
3191279|NCT00797004||endoscopic sinus procedure candidates|
2462848|NCT03153722|Experimental|Pediatric discharge process intervention|All patients hospitalized on the pediatric ward under the pediatric hospitalist service will participate in pediatric discharge process interventions.
2462884|NCT03153644||Patients|Women with chronic medical conditions
2462888|NCT03153644||Primary Care Providers and Medical Staff|"Primary care providers can include doctors and advanced practice professionals, including midwives, nurse practitioners, and physician assistants.~Medical staff can include social workers, nurses, medical assistants, and administrative staff"
2462891|NCT03153644||Primary Practice|Primary care practices (family medicine, internal medicine, medicine-pediatric, or any combination of these) that at a practice-level already provide contraceptive counseling and services to reproductive-age women
2462957|NCT03153306|Experimental|"the bolus group"|10ml/kg of the natural colloid 5% albumin was given at 1 hrs.
2462965|NCT03153306|Experimental|"thecontinuous group"|10ml/kg of the natural colloid 5% albumin was given over 6 hrs
2463008|NCT03152747||A|"Group A with pre-operative complete posterior vitreous detachment Group A will be invited for one follow-up visit (two months post-operatively) followed up by telephone interviews at one, two, three and five years after surgery to determine occurrence of pseudophakic retinal detachment.~Examinations: Best corrected Visual Acuity (BCVA) , SD-OCT (spectral domain optical coherence tomography), Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
2463011|NCT03152747||B|"Group B with no/partial PVD~Group B will be invited for follow-up examinations at two months, six months and one year after surgery to document occurrence of PVD (if a PVD is present at one of the follow-ups, no more visits are necessary). Two, three and five years after surgery, all patients from group B will be interviewed by telephone, as in group A, to document the occurrence of pseudophakic retinal detachment.~Examinations: BCVA, SD-OCT, Ultrasound B-scan (substudy only), Slit lamp examination, telephone interview"
2463067|NCT03152409|Active Comparator|Aspirin augmentation to treatment|Participants who meet inclusion criteria for the study and are randomized to the active treatment arm will be given pills for the ensuing 8 weeks, consisting of a daily dose of aspirin 325 mg to be taken every evening before bed.
2464514|NCT03142191|Placebo Comparator|Placebo PO QD|55 subjects will be randomized to placebo
2461852|NCT03160937|Experimental|Manual therapy Foam|The subjects included rolled the foam roller down their quadriceps using short kneading-like motions until it was just above their patellae, and then rolled it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
2461853|NCT03160937|Active Comparator|Manual therapy Nerve|The subjects was positioned lying on his/her side with a pillow underside leg (without fully flexing it) and the cervical and thoracic spines flexed. The investigator flex the knee and the hip extended and then put it back to its initial position in one fluid motion. The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets
2461895|NCT03160781|Experimental|Platelet Rich Plasma|Combination of Intraarticular and Intraosseous Administraion of Platelet Rich Plasma
2461957|NCT03160547|Active Comparator|Usual Protein/Amino Acid Group|Patients will receive a usual protein/amino acid dose (≤1.2 g/kg/d)
2461963|NCT03160547|Active Comparator|Higher Protein/Amino Acid Group|Patients will receive a higher protein/amino acid dose (≥2.2 g/kg/d).
2462065|NCT03159481|Experimental|Usual Care + Health Promotion Intervention|Usual glaucoma care along with telehealth-based brief culturally informed health promotion intervention
2462072|NCT03159481|No Intervention|Usual Care Only|Usual glaucoma management only, no intervention.
2462114|NCT03159286|Experimental|Abstainer|Participants view social networking site profiles with alcohol content that references abstaining from alcohol use.
2462115|NCT03159286|Experimental|Abstainer + User|Participants view social networking site profiles with alcohol content that references both abstaining from alcohol use and using alcohol.
2462116|NCT03159286|Experimental|Control|Participants view social networking site profiles with no alcohol content.
2462187|NCT03158961|Experimental|TOETVA|a new approach in surgery which can treat the thyroid disease
2462226|NCT03158454|Other|Capsula Closure|
2462227|NCT03158454|Other|Non-Capsula Closure|
3156134|NCT00336674|Placebo Comparator|Placebo|Placebo insulin carrier solution of benzalkonium chloride and glycerol presented in multi-dose nasal spray devices with actuators (Pfeiffer) designed to deliver 100ul spray doses to nasal mucosa. The product will be self administered by participants as two 100 microlitre spray doses per nostril. Treatment will be administered daily for 7 consecutive days then on one day each week for 12 months. Participants will be followed until they develop diabetes or until 5 years after the last participant has been randomised (maximum period of follow up is expected to be 10 years.
2462354|NCT03157713|Experimental|Goal-Directed|Patients will receive enhanced usual care and also be informed that they will receive goal-directed financial incentives.
2462358|NCT03157713|Experimental|Outcome-Based|Patients will receive enhanced usual care and be informed that they will receive outcome-based financial incentives for significant weight losses.
2462361|NCT03157713|Other|Control-Enhanced Usual Care|Patients will only receive enhanced usual care.
2462385|NCT03157206||DME patients treated with aflibercept|angiography by ultrawide field
2462442|NCT03157063||Inactive, normal weight|Less than 30 minutes per day of moderate to vigorous physical activity (MVPA), and body mass index percentile (BMI%) between 5th to 75th percentile.
2462444|NCT03157063||Inactive, overweight/obese|Less than 30 minutes per day MVPA, BMI% between 85th and 99th.
2462446|NCT03157063||Active, normal weight|More than 60 minutes per day MVPA, BMI% between 5th and 75th.
2462447|NCT03157063||Active, overweight/obese|More than 60 minutes per day MVPA, BMI% between 85th and 99th.
2462524|NCT03156608|Experimental|Novii Device ECG/EMG System|These patients will have the Novii ECG/EMG system placed throughout labor and delivery, unless a provider or investigator determines that a different device (internal or external) is necessary for a better signal.
2462528|NCT03156608|Active Comparator|Standard of Care External Monitor|A standard external monitor will be placed throughout labor and delivery, unless a provider or investigator determines that an internal device is necessary for a better signal.
3156135|NCT00336713|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 64 weeks
3156136|NCT00336713|Placebo Comparator|Placebo|Placebo for Saredutant once daily in the morning during the maintenance phase for a maximum of 52 weeks
2462601|NCT03155516|Experimental|GPM Ward|Good Pain management ward
2462605|NCT03155516|Active Comparator|Control Ward|Current practice controlled ward
3156137|NCT00336752|Active Comparator|1|Non operative treatment of Weber B ankle fracture. Use of cast, with no surgical intervention
3156138|NCT00336752|Active Comparator|2|Operative treatment of Weber B ankle fracture. Open reduction and internal fixation to repair a broken bones.
3156139|NCT00336791|Experimental|Paclitaxel + Additional FAC/FEC|"12 weekly Paclitaxel treatments 80 mg/m^2 by vein (IVPB) over 1 hour + 4 additional FAC or FEC combination chemotherapy treatments; FAC or FEC treatments given once every 3 weeks.~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
2462751|NCT03154684|Active Comparator|STARK intervention|New care concept for hip fracture patients
2462758|NCT03154684|Other|Standard Care|Swiss standard of care for hip fracture patients
2462802|NCT03154398||1|case control
2462840|NCT03154060|Experimental|Intervention|Using 3 Abbott FreeStyle Libre Flash Glucose Monitoring sensors in parallel and measure 7 times a day BG by capillary finger stick testing.
2462846|NCT03153800|Experimental|Bronchial basal cells|
2462886|NCT03153670||Deep brain stimulation (DBS) patients|We will observe brain activation changes in patient's who have received DBS as part of their standard of care
2462952|NCT03152994||COPD patients with T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who will develope T2DM during the follow-up will be divided into the groupCOPD patients with T2DM."
3156140|NCT00336791|Active Comparator|FAC/FEC|"6 courses FAC or FEC Combination Chemotherapy~FAC Chemotherapy: 5-Fluorouracil 500 mg/m^2 intravenous (IV) day 1 & 4 + Doxorubicin 50 mg/m^2 IV day 1 over 72 hour continuous infusion or IV bolus + Cyclophosphamide 500 mg/m^2 IV day 1.~FEC Chemotherapy: 5-Fluorouracil 500 mg/m^2 IV day 1 + Epirubicin 100 mg/m^2 IV day 1 + Cyclophosphamide 500 mg/m^2 IV day 1."
3191280|NCT00797017||001|
3191281|NCT00797017||002|
2461872|NCT03161028|Placebo Comparator|Arm 2: Placebo|59 subjects receive placebo daily
2461970|NCT03160469|Experimental|Elipse capsule insertion group|All patient who inserted elipse capsule in single clinic
2461987|NCT03160118|Other|Seasonal,quadrivalent,influenza vaccine|1 vaccine will be administered to all participants, namely Alfa-Rix Tetra 2016-2017
2462035|NCT03159936|Experimental|Tofacitinib citrate|All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.
2462058|NCT03159598|Active Comparator|Tissue Glu with drains|This is standard of care to use Tissue Glu in addition to a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2462060|NCT03159598|Experimental|Tissue Glu without drains|This group utilizes Tissue Glu without the presence of a drain. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2462062|NCT03159598|Active Comparator|Drains|This is standard of care to use traditional closed-suction drains. Pre-operatively, as well as on post-operative patients will be asked to complete a questionnaire that addresses their pain, impact of drains on activities of daily living, social and physical activities. Patients will also be asked to provide information regarding who is caring for the drains, the impact of drains on the caregiver, the amount of anxiety the patient has related to drain removal and the amount of pain associated with drain removal
2462157|NCT03159169|Experimental|study patients|Single arm study. Patients will receive Spinal Cord Stimulation (SCS) according to standard clinical procedures.
2462329|NCT03157934||Primary CSC admission|Patients with primary admission to endovascular-ready hospital (comprehensive stroke center)
2462330|NCT03157934||Primary non-CSC SU admission|Patients with primary admission to non-endovascular-ready hospital with (regional/local) stroke unit
2462331|NCT03157934||Non-acute stroke hospital admission|Patients with primary admission to non-acute stroke-ready hospital
2462383|NCT03157427|Experimental|CRYOBEAUTY MAINS|Cryotherapy medical device designed to treat solar lentigo on the randomized hand.
2462384|NCT03157427|No Intervention|Control|The non randomized hand is not teated.
2462414|NCT03157102|Experimental|HFNC group|
2462421|NCT03157102|Other|Standard Oxygen Therapy group (STO group)|
2462472|NCT03156725|Experimental|Ferrous Sulfate|The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.
2462476|NCT03156725|Experimental|Aspiron|The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.
2462505|NCT03156426||Study population|Adults with a histological, clinical or radiological diagnosis of cirrhosis who are admitted to RIE over a 4-month period will be approached by a member of their clinical care team for potential participation. Eligible patients may be recruited from accident and emergency, the acute medical unit, hepatology ward, high dependency or intensive care units. Recurrent admissions are common, so only the first admission for each recruited patient will be included. Patients will be monitored to identify acute kidney injury (AKI) during admission.
2462560|NCT03156192|Experimental|Caregivers of ICU patients|Caregivers (family member) aged over 20 who provides care to ICU patients
2462704|NCT03155321||Polish General Surgeons|The group is formed by active polish general surgeons, both specialists and in training
2462719|NCT03154827|Experimental|Combination Treatment Single Arm|Combination Treatment of BL-8040 with Atezolizumab
2462777|NCT03154632|Active Comparator|US Group|Ultrasound Therapy
2462778|NCT03154632|Active Comparator|DCD Group|Digital Capacitive Diathermy Therapy
2462793|NCT03154216|Experimental|Exercise only|90 minutes of exercise
2462795|NCT03154216|Experimental|Exercise and high glycemic index drink|90 minutes of exercise followed by consumption of high-glycemic index Gatorade drink matched for calories expended during the exercise
2462798|NCT03154216|Experimental|Exercise and low glycemic index drink|90 minutes of exercise followed by consumption of low-glycemic index milk drink matched for calories expended during the exercise
2462800|NCT03154216|No Intervention|No exercise and no beverage|No exercise and no beverage
2462863|NCT03153930|Placebo Comparator|Sitting Only (SIT)|In-Lab (full sample): children will sit continuously for 3 hours during an OGTT Free-living (sub-sample; N=12): children will complete their habitual sedentary behaviors over 4 days; they will also wear a continuous glucose monitor
2462870|NCT03153930|Experimental|Walking Breaks (WALK)|In-Lab (full sample): children will be asked to walk on a treadmill every 30 minutes for 3 minute bouts during a 3 hour OGTT Free-living (sub-sample; N=12): children will be prompted with an ActivPAL vtap monitor on the right thigh to perform 3-minute walking bouts whenever sedentary time has lasted longer than 30 minutes over 4 days; they will also wear a continuous glucose monitor
2462983|NCT03153410|Experimental|Cyclophosphamide, GVAX, Pembrolizumab and IMC-CS4|
3191282|NCT00797017||003|
3191283|NCT00797017||004|
2463252|NCT03151252|Other|Food allergy|Patients with confirmed foodspecific- IgE antibodies in blood
2463255|NCT03151252|Other|healthy controls|participants without foodspecific- IgE antibodies in blood and other gastrointestinal symptoms
2463257|NCT03151252|Other|gastointestinal symptoms without foodallergy in blood|Patients without foodspecific- IgE antibodies in blood, but with gastrointestinal symptoms
2463303|NCT03150771|Experimental|Cohort 1|Aripiprazole; single; gluteal
3191284|NCT00797017||005|
3191285|NCT00797017||006|
3191286|NCT00797017||007|
3191287|NCT00797030|Active Comparator|1|Ten HIV-positive-patients with dry eye diagnosis received sodium carboxymethylcellulose 0.5% drops (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) for six months.
3191288|NCT00797030|Other|2|Ten HIV-positive-patients with dry eye received sodium carboximethylcelullose 0.5% (1 drop 4 times per day) during six months
3191289|NCT00797043||Photon/Proton Radiation Therapy|Data consolidation and analysis
3191290|NCT00797056|Experimental|G-CSF|
2462094|NCT03159416|Experimental|Inclisiran (normal renal function)|Participants will receive a single dose of 300 milligram (mg) inclisiran administered by SC injection on Day 1. Normal renal function is defined as estimated creatinine clearance (CrCl) of ≥90 milliliter (mL)/minute (min).
2462097|NCT03159416|Experimental|Inclisiran (mild renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Mild renal impairment is defined as CrCl ranging from 60 to 89 mL/min.
2462099|NCT03159416|Experimental|Inclisiran (moderate renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Moderate renal impairment is defined as CrCl ranging from 30 to 59 mL/min.
2462100|NCT03159416|Experimental|Inclisiran (severe renal impairment)|Participants will receive a single dose of 300 mg inclisiran administered by SC injection on Day 1. Severe renal impairment is defined as CrCl ranging from 15 to 29 mL/min.
2462133|NCT03159078|Other|Polymyxin B monotherapy|Intravenous piggyback with Polymyxin B and control(Normal saline)
2462134|NCT03159078|Experimental|Polymyxin B plus Carbapenem|Intravenous piggyback with Polymyxin B plus Carbapenem
2462215|NCT03158727|Experimental|Cx611|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Cx611 at a fixed dose of 160 million expanded allogeneic adipose-derived stem cells (eASCs) each
2462218|NCT03158727|Placebo Comparator|Placebo|Subjects treated in an intensive care unit for sCABP, but that may be screened at the emergency department, will receive SoC therapy according to local guidelines plus two intravenous central line infusions of Ringer Lactate
3191291|NCT00797056|Placebo Comparator|Placebo|
2462357|NCT03157687||Healthy controls|"Blood sampling for nutrition and inflammatory status~Stool sampling before preventive gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2462360|NCT03157687||Inflammatory bowel disease (IBD)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2462362|NCT03157687||Liver transplantation recipient (LTX)|"Blood sampling for nutrition and inflammatory status~Stool sampling before indicated gastroscopy and colonoscopy for evaluation of liver transplantation (LTX)~Questionnaires about general health, gastrointestinal symptoms and 3-day food record~Collection of biopsies in duodenum during gastroscopy~Collection of biopsies in terminal ileum, cecum, colon ascendens, sigma"
2462400|NCT03157297|Experimental|Enrolled|Subjects enrolled in the MARVEL study. Enrolled subjects will have the MARVEL algorithm downloaded into their implanted market released Micra device.
2462459|NCT03156842|Experimental|Fimasartan/Amlodipine, Rosuvastatin|Co-administration of a fixed dose combination of Fimasartan/Amlodipine and Rosuvastatin
2462461|NCT03156842|Active Comparator|Fimasartan/Amlodipine|a fixed dose combination of Fimasartan/Amlodipine
2462465|NCT03156842|Active Comparator|Fimasartan, Rosuvastatin|Co-administration of Fimasartan and Rosuvastatin
2462509|NCT03156452|Experimental|Steroid & Mycophenolate mofetil 1st line|Mycophenolate mofetil: 1 gm bd Non-IMP Steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
2462511|NCT03156452|Active Comparator|Prednisolone (Steroid) alone 1st line|Non-IMP steroid: 1mg/kg od 4 days (maximum of 100mg), 40mg od 2 weeks, 20mg od 2 weeks, 10mg od 2 weeks, 5mg od 2 weeks then 5mg alternate days 2 weeks.
2462546|NCT03156036|Experimental|MGMT hypermethylated Cohort A|MGMT hypermethylated Cohort A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=86)
2462549|NCT03156036|Active Comparator|MGMT hypermethylated Cohort B|MGMT hypermethylated B Cohort patients will be randomised into preoperative CRT with capecitabine arms. (n=86)
2462552|NCT03156036|Active Comparator|MGMT unmethylated Cohort A|MGMT unmethylated A patients will be randomised into preoperative CRT with temozolomide plus capecitabine arms. (n=37)
2462554|NCT03156036|Active Comparator|MGMT unmethylated Cohort B|"MGMT unmethylated B patients will be randomised into preoperative CRT with capecitabine arms.~(n=37)"
2462620|NCT03155737|Experimental|Self-acupressure Training|Subjects in the self-administered acupressure exercise group will receive two 1.5 hours acupressure training sessions. The training will be conducted in a group format with 4-7 subjects per group. Each subject will then receive a handout and an acupressure log. The handout includes a picture-illustrating acupressure step-by-step protocol. They will be told to perform the self-acupressure twice per day for 6 weeks.
2462630|NCT03155737|Active Comparator|Knee Health Education|Subjects in the health education control group will receive knowledge related to knee OA. The health education will be conducted in a talk format for 1.5 hours for two sessions.
2462701|NCT03155217||patients over 75 years|Patients with MM treated with single or combination therapy over 75 years of age.
3191292|NCT00797069|Active Comparator|standard nutritional product|Standard nutritional product not specific for diabetes
3191293|NCT00797069|Active Comparator|diabetes specific product|Diabetes specific nutritional product
3191294|NCT00797069|Experimental|Experimental diabetes specific product|Diabetes specific experimental nutritional product
3191295|NCT00797082|Experimental|1|"MRI = Myocardial Perfusion Stress and MPS = Myocardial Perfusion Scintigraphy~Diabetic patients~Coronary insufficiency"
3191296|NCT00797121|Experimental|Preoperative biliary drainage|
3191297|NCT00797121|No Intervention|Controlled group|
3191298|NCT00797134||DR|Diabetic Retinopathy
2461992|NCT03160040||Minocycline IV|Participants who received 2 doses over 48 hours if given once daily or 4 doses over 48 hours if given twice daily of minocycline intravenous (IV) as monotherapy, with or without transition to oral minocycline.
2462084|NCT03159832|Active Comparator|Normal renal function|All subjects were given SHR3824 20mg only one time.
2462090|NCT03159832|Active Comparator|Mild renal dysfunction|All subjects were given SHR3824 20mg only one time.
2462093|NCT03159832|Active Comparator|Moderate renal dysfunction|All subjects were given SHR3824 20mg only one time.
2462148|NCT03159104|Experimental|Tenoten for children|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
2462155|NCT03159104|Placebo Comparator|Placebo|Oral administration. Single dose: 1 tablets (to be held in the mouth until dissolution is complete - outside of meals). 1 tablet three times daily.
2462193|NCT03158584|Active Comparator|morphine 2 μg/kg|Children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
2462194|NCT03158584|Active Comparator|morphine 5 μg/kg|Children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
2462196|NCT03158584|Active Comparator|morphine 10 μg/kg|Children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
2462237|NCT03158337|Experimental|Aerobic exercise|Participants took part in a supervised 6-month long aerobic (walk/jog) training program held 3 days/week. Each session included a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cooldown, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise increased from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity is based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity builds from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
2462289|NCT03157999|Experimental|Intervention group (CAST)|Participants in the intervention group will receive the CAST hospital-to-home transition intervention in addition to usual care.
2462295|NCT03157999|No Intervention|Control group (usual care)|Participants assigned to the control group will receive usual care at discharge from hospital to home.
2462351|NCT03157700|Experimental|REAL media|Participants in this group will be assigned to use the REAL media curriculum.
2462356|NCT03157700|No Intervention|Programming as usual|Participants in this group will participate in 4-H programming as usual. They will have the opportunity to use the REAL media curriculum at the conclusion of the study.
2462399|NCT03157284|Placebo Comparator|Placebo|Placebo Group will receive 7gr Maltodextrin
2462402|NCT03157284|Experimental|Intervention Rice Flour|The Intervention Group will receive 7gr of the experimental ingredient fermented Rice Flour
2462451|NCT03156920|Active Comparator|Sumatriptan|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of sumatriptan 50 mg
2462453|NCT03156920|Placebo Comparator|Placebo|Headache is induced with Cilostazol. This headache is pre-treated double-blinded with 2 tablets of placebo
2462496|NCT03156556|Experimental|Mood Mechanic|"The Mood Mechanic Course is comprised of five online lessons completed over an 8-week period.~Lesson 1 presents information on anxiety and depression as well as on the cycle of symptoms.~Lesson 2 presents different strategies to generate helpful cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors and graded exposure.~Lesson 5 is about problem solving and relapse prevention.~For each lesson, a Do It Yourself guide is included containing homework as well as case stories. Additional material on different topics is also included such as structured problem solving."
2462555|NCT03156179||Girls with type 1 diabetes|
2462635|NCT03155789||Low Back Pain emanating from L4-5|"S TLIF at L4-5 (n=10)~MI TLIF at L4-5 (n=10)~XLIF at L4-5 (n=10)"
2462642|NCT03155789||Low Back Pain emanating from L5-S1|"S TLIF at L5-S1 (n=10)~MI TLIF at L5-S1 (n=10)~XLIF at L5-S1 (n=10)"
2462644|NCT03155789||Low Back Pain emanating from L4-5 and L5-S1|"S TLIF at L4-5 and L5-S1 (n=10)~MI TLIF at L4-5 and L5-S1 (n=10)~XLIF at L4-5 and L5-S1 (n=10)"
2462680|NCT03155191|Experimental|Dose Level -1 to 2|"0.3 to 3 x 10^6 autologous CD19-CAR-T cells/kg per patient will be administered intravenously after a conditioning chemotherapy with cyclophosphamide.~cohort -1: 3×10^5 cells/kg cohort 1: 1×10^6 cells/kg cohort 2: 3×10^6 cells/kg."
2462779|NCT03154645|Active Comparator|Ibuprofen|ibuprofen, 600mg, three times a day, through to ascent to high altitude
2462780|NCT03154645|Active Comparator|acetazolamide|acetazolamide, 125mg, two times a day, through to ascent to high altitude
3156141|NCT00336830|Active Comparator|Usual Care|Comparator without MD endorsement of Cardiac Rehabilitation
3156142|NCT00336830|Experimental|MD Endorsment of CR|Provided with MD endorsement of participation in Cardiac Rehabilitation
2462938|NCT03153553|Active Comparator|Ischaemic Preconditioning Group|The participant will rest in a sitting position for 10 minutes before measuring resting blood pressure. Blood pressure will be measured on the arm. IPC will be administered to the upper arm using cuff inflation pressures of 30mm Hg above the systolic BP using a manual BP. The IPC cycles comprised of three cycles of cuff inflation each lasting 5 min in duration followed by 5-min period of cuff deflation
2462940|NCT03153553|Sham Comparator|Control group|The participant will rest in a sitting position for 10 min before measuring resting blood pressure. Blood pressure will be measured on the upper arm. Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
3156143|NCT00336843|Experimental|Zevalin-BuCyE|histologically confirmed, relapsed or refractory CD20 positive B-cell NHL including diffuse large B-cell, follicular, mantle cell, and Burkitt lymphomas.
3156144|NCT00336882|Active Comparator|1|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
3156145|NCT00336882|Experimental|2|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
3156146|NCT00336921|Active Comparator|1|Alfuzosin 10mg
3156147|NCT00336921|Placebo Comparator|2|Placebo
2461935|NCT03160625|Active Comparator|Rate Adaptive Pacing OFF|The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.
3191299|NCT00797186|Other|Intensive therapy|There is one arm in this trial. All patients receive the same therapy. The goal is to compare a noninvasive and invasive imaging technique in the same population.
2462088|NCT03159559|Experimental|Treatment group|In the treatment group ,patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days ;
2462092|NCT03159559|No Intervention|Control group|In the control group, patients received conventional therapy only.
2462128|NCT03159130||receiving lidocaine|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of 1% lidocaine.
2462130|NCT03159130||receiving injectable saline|Each patient will receive an OnQ pain pump intra-operatively, with attachment to two OnQ catheters inserted on the lateral sides of the abdomen. Each catheter will be infused with 15 cc of injectable saline.
2462203|NCT03158818||HBV mono-infected (Standard of Care)|500 patients in Zambia
2462282|NCT03158246|Experimental|Yigu Group|"a single 15-minute infusion of Generic Zoledronic Acid (Yigu®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
2462285|NCT03158246|Active Comparator|Aclasta Group|"a single 15-minute infusion of Original Zoledronic Acid (Aclasta®) (5 mg/100ml)~600mg/d calcium and 925IU/d vitamin D for oral daily, 12 months"
2462340|NCT03157674||HNC patients|"HNC patients who have been diagnosed with HNC between~01-Jan-2013 and 30-Sep-2016."
2462380|NCT03157401||intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
2462381|NCT03157401||intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
2462382|NCT03157401||control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
3191300|NCT00797199||1-Treatment Group 1|Women receiving HRT treatment of Premarin.
2462513|NCT03156660|Experimental|Weight gain prevention (Group 1)|Small Changes weight stability intervention
2462516|NCT03156660|Experimental|Weight loss intervention (Group 2)|Look AHEAD weight loss intervention
2462520|NCT03156660|Active Comparator|Self-guided intervention (Group 3)|Self-guided weight management with the EatingWell Diet book
2462686|NCT03155360||Infant with colics|"Infants with colics according to Wessel definition :~Recurrent episodes of irritability, fussing or crying from birth to 4 months of age~Episodes last for 3 hours per day ; on 3 days per week ; for 3 weeks~Episodes can not be attributed to another disorder"
2462693|NCT03155360||Infant without colics|
2462726|NCT03154892|Experimental|Intracameral injection|Intracameral injection of conbercept for the treatment of NVG
2462728|NCT03154892|Active Comparator|Intravitreal injection|Intravitreal injection of conbercept for the treatment of NVG
2462860|NCT03153813|Experimental|Drug|Up to 4 patches to cover a surface of 1200 cm2 will be applied to the painful area depending on the surface of pain during 60 minutes : capsaicin 8% patches (Qutenza)
2462869|NCT03153813|Placebo Comparator|Placebo|Up to 4 patches will be applied to the painful area depending on the surface of pain during 60 minutes : placebo
2462907|NCT03153488|Experimental|Methylphenidate|Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
2462914|NCT03153488|Experimental|Amphetamine|Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
2462984|NCT03153202|Experimental|Participants with CLL|Participants with relapsed/ refractory Chronic Lymphocytic Leukemia (CLL) or 17p- CLL
2462988|NCT03153202|Experimental|Participants with MCL|Participants with relapsed/ refractory Mantle Cell Lymphoma (MCL)
2463075|NCT03152487|Active Comparator|Celiac Plexus Neurolysis|CPN will be undertaken at the celiac space which is located between the aorta and the celiac artery origin. A 22 or 19-gauge Fine Needle Aspiration (FNA) needle is used, and its tip is placed slightly anterior and cephalic to the origin of the celiac artery. Aspiration is first performed using a syringe to ensure that vascular puncture has not occurred. 10 mL Bupivacaine is injected first, followed by 20 mL of 98% alcohol.
2463076|NCT03152487|Active Comparator|Radiofrequency Ablation|Once the celiac ganglia are identified on EUS, a 19-gauge FNA needle is inserted into the center of the ganglion or area of celiac plexus under EUS guidance. The radiofrequency (RF) probe (EMcision, Montreal, Canada) is advanced through the FNA needle. Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest and repeated as required.
2463127|NCT03151915||Patients who underwent fetoscopic laser coagulation with TTTS|This is an retrospektive trial. We use data of patients who underwent fetoscopic laser coagulation with TTTS retrospectively. All patients meet eligibility criteria and give written informed consent before therapy. As part of the ongoing quality control we were able to safely store patient data relating to fetoscopic laser coagulation with TTTS.
2463167|NCT03151655|Experimental|MATTeRS Video|
2463169|NCT03151655|Active Comparator|Didactic Video|
2463197|NCT03151317||With therapeutic education|Patients assigned to this group will have participated in a therapeutic education program.
2463201|NCT03151317||Without therapeutic education (control)|Patients assigned to this (control) group have not had any kind of therapeutic education.
2463254|NCT03151096|Experimental|treatment arm|5mg Riboflavin pills
2463256|NCT03151096|Placebo Comparator|Placebo arm|Placebo pills
2463277|NCT03150810|Experimental|Arm A (Dose Escalation) TMZ Pulse Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 7 of a 28-day cycle.
2463278|NCT03150810|Experimental|Arm B (Dose Escalation) TMZ Continuous Dosing|Participants receive continuous BGB-290 and escalating flat doses of 40mg, 80mg, 100mg, 120mg (as 20 mg capsules) daily administered orally up to the maximum tolerated dose (MTD) of TMZ on Days 1 - 28 of a 28-day cycle.
2461958|NCT03160456|Active Comparator|Continuous positive airway pressure|Participants who will be randomized to the usual care group will be given their own CPAP device, as previously prescribed. Weekly phone calls and follow up visits at 6- and 12-weeks will be organized. At the last visit, the patients will be studied during a repeat inpatient polysomnography and the initial assessment will be repeated.
2461994|NCT03160105|No Intervention|Continuing cART + Standard monitoring|Patients randomized to this arm will continue their current standard ART regimen (cART) and will continue a standard 3-monthly routine safety biological monitoring (including CD4 cell count, fasting lipids and glucose, renal and hepatic function tests) at their SHCS site.
2461998|NCT03160105|Experimental|Continuing cART + Patient-centered monitoring|Patients randomized to this arm will continue their current cART and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
2461999|NCT03160105|Experimental|Switch to DTG+FTC + Standard monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed once per year and at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
2462001|NCT03160105|Experimental|Switch to DTG+FTC + Patient-centered monitoring|Patients randomized to this arm will be switched to DTG + FTC dual maintenance therapy and will have immunological and safety blood examinations performed at screening and at week 48. In addition, patients will be ask to choose at least one of the following alternative options for weeks 6, 12 and 36: decentralised venipuncture and blood tests, delivery of ARV drugs by mail and Assessment and clinical interview by phone or skype call
2462048|NCT03159650|Experimental|intravascular ultrasonography guided|
2462051|NCT03159650|Active Comparator|Angiography guided|
2462095|NCT03159403||Oritavancin|Participants who received at least one dose (at least one for 3 hours per dose) of oritavancin intravenous (IV) as monotherapy or part of a broader regimen. The maximum number of doses to be received by a participant is not known at this time.
2462176|NCT03158844||HIV+ patients (Standard of care)|300 HIV-infected and hospitalized adult patients at the University Teaching Hospital (UTH) will be recruited.
2462179|NCT03158844||Health systems informants|15 key Zambian health systems informants and leaders who can discuss inpatient care and the process of linking hospitalized patients to HIV care.
2462206|NCT03158519|Experimental|iMETX intervention|Individualized exercise recommendation
2462342|NCT03157778|Experimental|Obese men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in obese men.
2462345|NCT03157778|Active Comparator|Normal-weight men|Measured plasmatic concentration of pregnenolone and endocannabinoid in fasting conditions and over a meal in normal-weight men.
2462412|NCT03157362|Active Comparator|Time 1|Participant will be randomly assigned to one of the four interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2462419|NCT03157362|Active Comparator|Time 2|Participant will be randomly assigned to one of the remaining three interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2462424|NCT03157362|Active Comparator|Time 3|Participant will be randomly assigned to one of the remaining two interventions; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2462426|NCT03157362|Active Comparator|Time 4|Participant will complete the remaining intervention; either Near Non-Social, Near Social, Far Non-Social, or Far Social
2462455|NCT03156738|Experimental|Dose 1|MT-2990 or Placebo
2462457|NCT03156738|Experimental|Dose 2|MT-2990 or Placebo
2462460|NCT03156738|Experimental|Dose 3|MT-2990 or Placebo
2462462|NCT03156738|Experimental|Dose 4|MT-2990 or Placebo
2462466|NCT03156738|Experimental|Dose 5|MT-2990 or Placebo
2462492|NCT03156413|Experimental|F&P Nasal Mask|Trial nasal pillows CPAP mask
2462569|NCT03156231|Active Comparator|ACETAZOLAMIDE oral capsule|Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m
2462570|NCT03156231|Placebo Comparator|PLACEBO oral capsule|Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3200m until the morning after the second night at 3200m.
2462633|NCT03155659||CHNS|
2462639|NCT03155659||NHANES|
2462670|NCT03155308||Polyp group|Consecutive adult patients between 18 and 80 years of age, referred for elective outpatient colonoscopy and in whom polypectomy or biopsy is perform will be enrolled to be evaluated using Pentax chromoendoscopy (i-scan and Optical Enhancement)
2462744|NCT03154996|Experimental|Long term CED of Topotecan|An additional 5 patients will be treated with TPT by CED maintained for 32 days. TPT infusions will be carried out for 32 days using Synchromed II infusion pumps with the same infusion parameters and experimental conditions used in the short term studies.
2462806|NCT03154346||General Population|An unlimited number of participants will be accepted into a Baseline registry. From the Baseline registry, approximately 10,000 participants will be selected for the Baseline Study. Participant enrollment for the Baseline Study will be stratified by age, sex and risk factors and will aim to reflect the race and ethnicity distribution within the U.S.. The population includes a broad range of participants across the health spectrum, including exceptionally healthy participants, participants at risk of disease, and participants with current disease. The study population will be enriched for participants with an elevated risk of primary cardiovascular disease, lung cancer, and/or breast/ovarian cancers.
2462878|NCT03154021|Experimental|Gingivitis Test|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and Next Science Over the Counter (OTC) Oral Rinse with Essential Oils.
2462880|NCT03154021|Placebo Comparator|Gingivitis Placebo|All subjects will have oral examination, dental cleaning, plaque samples taken, given Colgate Total Toothpaste, Oral B Manual Toothbrush and OTC Oral Rinse Control.
2462934|NCT03153397|Experimental|Nutraflora scFOS|prebiotic fiber-containing formula (Nutraflora scFOS)
2462936|NCT03153397|Active Comparator|Osmolite|non-prebiotic fiber containing formula (Osmolite)
2463692|NCT03148145|Experimental|Averaged Steps Goals and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2461982|NCT03160248|Experimental|Placebo + Apremilast|Patients randomized to this arm will receive identically matching placebo (including the titration phase) by mouth for first 16 weeks. Placebo participants will be switched to receive Apremilast 30 mg BID from beginning of Week 17 for another 16 weeks. In this arm Apremilast will be started without titration.
2461991|NCT03160001|Placebo Comparator|Placebo and etanercept|Placebo lactose 500mg cap twice daily with etanercept 50mg weekly for 8 weeks
2461996|NCT03160001|Experimental|Niclosamide and etanercept|Niclosamide cap 500 mg twice daily with Etanercept 50mg weekly for 8 weeks
2462042|NCT03159741|Experimental|Inhibitor + GLP-2|
2462043|NCT03159741|Experimental|Placebo + GLP-2|
2462044|NCT03159741|Active Comparator|Placebo + GIP|
2462045|NCT03159741|Placebo Comparator|Placebo + Saline|
2462061|NCT03159507|Experimental|MAG-EPA|MAG-EPA softgel (500mg), daily dose between 1g and 3.5g
2462120|NCT03159364|Experimental|Infusion of pathogen-specific CTLs|Repetitive CTL infusions to treat microbial infections
2462175|NCT03158896|Experimental|MSCTC-0010 Dose Escalation|"Cohort 1: First 5 participants will receive a lower dose of cord-blood derived Wharton's jelly mesenchymal stem cells (MSCTC-0010) and they will be observed for 42 days after the dose for treatment-related serious adverse events (TRSAE) and response.~Cohort 2: Second 5 participants will receive an increased dose of MSCTC-0010 and will be observed for 42 days after the dose for TRSAE and response."
2462199|NCT03158506|Experimental|[C14]-labelled HMS5552|
2462239|NCT03158389|Experimental|Subtrial A: APG101|"weekly application of 800 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462241|NCT03158389|Experimental|Subtrial B: Alectinib|"600 mg orally twice daily (bid) for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462243|NCT03158389|Experimental|Subtrial C: Idasanutlin|"at escalating doses from 100 mg until maximum tolerated dose daily administered (orally) on five consecutive days of a 28-day cycle for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462246|NCT03158389|Experimental|Subtrial D: Atezolizumab|"application of 1200 mg i.v. every three weeks for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462249|NCT03158389|Experimental|Subtrial E: Vismodegib|"daily application of 150 mg orally for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462250|NCT03158389|Experimental|Subtrial F: Palbociclib|"75/100/125 mg orally once daily on 21/28 days~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks~followed by a 4 weeks break (after last dose of 2nd cycle)~and with maintenance therapy with palbociclib at 125 mg daily for 6 months or until progression"
2462252|NCT03158389|Experimental|Subtrial G: Temsirolimus|"weekly application of 25 mg i.v. for 6 months or until progression~in conjunction with radiotherapy (at 60 Gy in 2 Gy fractions) for the first 6 weeks"
2462339|NCT03157791|Experimental|Simethicone with Bowel Prep|Group A will receive 2 simethicone tablets (180mg each) so that one tablet is taken at the same time as each bowel preparation dose.
2462341|NCT03157791|No Intervention|Control|Group B will receive no simethicone tablets.
2462391|NCT03157375|Other|0°|Implantation of the intraocular lens Vivinex p261 on axis 0°
2462392|NCT03157375|Other|45°|Implantation of the intraocular lens Vivinex p261 on axis 45°
2462394|NCT03157375|Other|90°|Implantation of the intraocular lens Vivinex p261 on axis 90°
2462397|NCT03157375|Other|135°|Implantation of the intraocular lens Vivinex p261 on axis 135°
2462435|NCT03156946|Experimental|Breastfeeding support program|
2462436|NCT03156946|Other|Usual or routine care|
2462482|NCT03156686|No Intervention|Control|Patients will be randomly assigned to conventional hospital care
2462484|NCT03156686|Experimental|Home care treatment|Patients will be randomly assigned to the HOME-based hospitalization and treated with intravenous diuretics. Following discharge within 48 hours from the hospital, patients in the HC group will be treated at home.
2462498|NCT03156335|Experimental|Focused Ultrasound|
2462559|NCT03156101|Experimental|BinD19|BinD19 (autologous T cells transduced with CD19 TCR-ζ/4-1BB vector) administered as an IV infusion on days 0, 1 and 2 in the absence of disease progression or unacceptable toxicity. Minimum/maximum dose: 1x10^6/kg / 1x10^7/kg administered to patients with R/R B cell Acute Lymphoblastic Leukemia (ALL) or Lymphoma.
2462625|NCT03155776||GUS_infants|Infants patient undergoing general anesthesia for abdominal surgery
2462763|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (neutral)|
2462765|NCT03154567|Placebo Comparator|Yohimbine 0mg X Cue Condition (marijuana)|
2462768|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (neutral)|
2462771|NCT03154567|Active Comparator|Yohimbine 20mg X Cue Condition (marijuana)|
2462773|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (neutral)|
2462774|NCT03154567|Active Comparator|Yohimbine 40mg X Cue Condition (marijuana)|
3156148|NCT00336934|Experimental|Arm I|Patients receive oral pomegranate extract daily.
3156149|NCT00336934|Placebo Comparator|Arm II|Patients receive oral placebo daily.
3156150|NCT00336960|Experimental|treatment intervention|
3156151|NCT00337051|Experimental|S|General Anesthesia with sevoflurane (inhalation) as hypnotic
3156152|NCT00337051|Active Comparator|P|General Anesthesia With Propofol TCI
3156153|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 1|25 kBq/kg b.w., 3 times at 6 week intervals
3156154|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 2|50 kBq/kg b.w., 3 times at 6 week intervals
3156155|NCT00337155|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223) Dose group 3|80 kBq/kg b.w., 3 times at 6 week intervals
3156156|NCT00337259|Experimental|Gemcitabine|"histologically confirmed marginal zone lymphoma~gemcitabine 1,250 mg/m2 on days 1 and 8 of each cycle, repeated every 3 weeks and continued for 6 cycles, until disease progression, withdrawal due to toxicity, or withdrawal of consent."
3156157|NCT00337298|Experimental|1|Crossover design. Arm is same all the way
3156158|NCT00337376|Experimental|1|
3156159|NCT00337389|Experimental|1|CoFactor, 5-FU, Avastin
3191301|NCT00797199||2-Treatment Group 2|Women receiving combination HRT treatment of Premarin + Provera.
2462083|NCT03159533|Active Comparator|CHW Intervention|CHW lead Sessions Session1: BP and the Cardiovascular System Session 2: Nutrition and food labels Session 3: Physical Activity and Stress Management Session 4: CVD Risk factors: cholesterol, blood sugar, & Smoking Session 5: Health Communication, Healthcare access & Review
2462089|NCT03159533|Placebo Comparator|Control Group|Wait-list
2462142|NCT03159117|Experimental|PF 06688992|This clinical study will be a dose-finding phase I study in which patients will be treated with various doses of Pfizer PF-06688992 using a Bayesian dose escalation scheme.
2462207|NCT03158740|Active Comparator|DII-Based Counseling System|The DII-based counseling group will utilize our 12-week IMAGINE Counseling System curriculum.The DII-based counseling group will meet once a week for 12 weeks to cook, and to engage in exercise and stress-reduction activities. Along with the initial clinic, participants will meet one-on-one for a nutrition counseling session with a registered dietitian. Participants will have access to online material through our Imagine Healthy Online Portal and will be given take-home activities, referred to as IMAGINE actions. These homework assignments will focus on goal setting for nutrition, physical activity, and stress reduction. The nutrition components of this intervention will be based on the DII and will focus on anti-inflammatory foods and components.
2462209|NCT03158740|Active Comparator|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC.
3191302|NCT00797199||3- Treatment Group 3|Women receiving combination HRT treatment of Premarin + Prometrium.
3191303|NCT00797199||4- Controls|Women not on HRT or healthy controls.
2462373|NCT03157518|Experimental|Treatment Arm|Patients enrolled will receive probiotic supplementation following the first bronchoscopy for four weeks. A second bronchoscopy will be performed following probiotic administration.
2462411|NCT03157245||participant|
2462433|NCT03156855|Experimental|sequential therapy for 14 days (S14)|14 day sequential therapy
2462434|NCT03156855|Active Comparator|bismuth quadruple therapy (Q10)|Bismuth quadruple therapy
2462480|NCT03156699||STEMI patients treated with primary PCI|Database analysis only
2462495|NCT03156387|Experimental|Diode laser|A 2.8 W, 980 nm diode laser(Sirona Advanced) in continuous wave mode with an air cooling handpiece was used in the alternative frenectomy technique. The frenulum was held with a hemostat, and a repeated continuous wave mode was applied for the excision. It was also used to remove the periosteal adhesion. The remnants of the ablated tissue were removed with saline, and no sutures were placed after the diode laser treatment.
2462501|NCT03156387|Active Comparator|Scalpel|(1) topical anesthesia (20% benzocaine), (2) local anesthesia using the bilateral vestibular infiltration technique, with 0.6 ml (1/3 of the carpule contents) of 4% articaine and 1:200,000 epinephrine, (3) hemostatic clamping of the frenulum, (4) excision of the whole band of tissue, together with its alveolar attachment, with a 15C scalpel blade, (5) relaxation and unbending of any fibrous adhesions to the underlying periosteum, and (6) simple suturing with 5-0 silk thread
2462541|NCT03156088||Overactive Bladder Patients|"Overactive bladder patients treated with sacral neuromodulator InterStim"
2462607|NCT03155555||Experimental|Children aged 1-12 years undergoing major surgeries under general endotracheal anaesthesia with mechanical ventilation under neuromuscular blockade
2462669|NCT03155412||Offspring of type 2 diabetic patients|Group 1: 25 healthy lean men (age 30-45, BMI <28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.
2462685|NCT03155412||Control subjects|Group 2: 25 healthy lean men (age 30-45, BMI <28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.
2462743|NCT03155009|Experimental|Alectinib|600 mg orally twice daily (BID) for up to 2 years
2462801|NCT03154307|Experimental|Group 1: Weekly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days) , LF-rTMS 1 session/week for 1 month (4 days), and LF-rTMS 1 session/month for 11 months
2462804|NCT03154307|Experimental|Group 2: Monthly TMS|LF-rTMS intervention for 2 weeks (5 days per week for total of 10 days), LF-rTMS 1 session/month for 12 months
2462809|NCT03154307|Sham Comparator|Group 3: Sham TMS|Sham LF-rTMS for 2 weeks (5 days per week for a total of 10 days), sham LF-rTMS 1 session/week for 1 month (4 days), and sham LF-rTMS 1 session/month for 1 month. After the sham stimulation real LF-rTMS intervention sessions will be delivered as follows: 50% of placebo group will follow group 1 protocol and the other 50% will follow group 2 protocol
2462813|NCT03154307|Experimental|Short-term protocol|LF-rTMS intervention daily for up to 5 days in medically refractory status epilepticus participants only
2462868|NCT03153917|Experimental|melatonin and cortisol sampling|14 healthy volunteer nurses working on 12 hours night/day schedules in the Sleep Medicine Center of Lyon.
2462896|NCT03153527|Placebo Comparator|Placebo arm (intervention arm)|Stop glucocorticoid treatment; administer placebo matching the verum preparation in weekly intervals.
2462900|NCT03153527|Active Comparator|Verum group (control/standard arm)|If patient is on > 7.5 mg prednisone-equivalent daily: administer 7.5 mg q.d. for 7 days, then 5 mg q.d. for 7 days, then 2.5 mg q.d. for 7 days, then 2.5 mg q.d. every second day, then stop. If patient on 7.5 mg q.d.: maintain for 7 days, then taper as above.
2463089|NCT03152175|Experimental|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride administered as a capsule 60 minutes prior to memory reactivation
3191304|NCT00797238||NSCLC stage III|Taiwanese NSCLC patients with stage III
3191305|NCT00797251||Right posterior section group|Patients with tumors in the right posterior section of the liver (segments 6-7)
3191306|NCT00797264|Experimental|A|Ketamine pre and per operative, and morphine postoperative
3191307|NCT00797264|Active Comparator|B|NaCl pre and per operative, and morphine postoperative
2462017|NCT03160157||robotic surgical group|"Patients suitable for elective cholecystectomy with minimally invasive approach will be consented and randomized into either the robotic or laparoscopic group and both the patient and the operating physician will be notified which technique will be performed. Patients will be randomized to a 1:1 ratio. In order to eliminate bias in randomization, the investigators will be using an online resource available at: https://www.randomizer.org.~After randomization, the investigators will complete a chart review that will follow the patients for a total of 30 days. The patient participation will be limited to the consent discussion and potential sign off. There will be no other clinic visits in regards to this research."
2462085|NCT03159520|Active Comparator|Advice on acupressure|Advice sheet on use of acupressure for post orthodontic pain
2462091|NCT03159520|Active Comparator|Advice on analgesics|Advice sheet on use of NSAID analgesics for post orthodontic pain
2462224|NCT03158480|Experimental|DC-CIK+interferon Group|dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
2462225|NCT03158480|Placebo Comparator|Placebo+interferon Group|saline as placebo plus interferon intervention
2462254|NCT03158077||Raltegravir + ABC/3TC|Switching or switching strategy with RAL and ABC / 3TC guidelines, 48 weeks before the start of the study
2462314|NCT03157947|Experimental|Decision Aid|Subjects will be asked to complete baseline surveys. Once the surveys are completed, subjects will review the Decision Aid tool with a study team member. Once the subjects have gone through the tool, study team members will answer any additional questions he may have regarding the tool. The subjects will then discuss with the investigator various cancer management options, quality of life implications, and any questions the subjects may have regarding cancer management options. Subjects that are ready may make a cancer management decision at this time, or choose to wait until their next scheduled visit. Subjects will be followed at subsequent urology clinic visits for up to 6 months. Subjects will complete follow-up surveys at the 3, 6, 9 and 12 month visits.
2462322|NCT03157570|Experimental|Exercise intervention group|The exercise group will participate in a 6-month home exercise along with demonstration videos. The exercise training program is an online 7-minute high-intensity interval training (HIIT) exercise through the integrated application of an exercise provision website and mobile Apps. The program will comprise of a broad range of exercises, applied at varying speeds and directions in order to increase heart rate, and to load a variety of muscle groups and skeletal regions in the upper and lower body. The exercise will be performed 5 days per week with the remaining 2 days as rest days.
2462324|NCT03157570|No Intervention|Control group|The control group have no intervention and receives only standard care.
3156160|NCT00337389|Active Comparator|2|Leucovorin, 5-FU, Avastin
3156161|NCT00337454|Experimental|A1|
2462437|NCT03157011|Experimental|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary.
2462478|NCT03156712|Experimental|FeSO4|Ferrou sulfate: Each participant was given a one time oral dose of the 10 mg iron as ferrous sulfate with the test meal (described in study design) and serum iron was measured every 30 min for 4 hours.
2462479|NCT03156712|Experimental|ASP Fe (10 mg)|ASP (10 mg Fe): Each participants was given a one time oral dose of ASP containing 10 mg iron. The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
2462481|NCT03156712|Experimental|ASP Fe (20 mg)|ASP (20 mg Fe): Each participant was given a one time oral dose ASP containing of 20 mg iron The capsule was consumed with the test meal and serum iron was measured every 30 min for 4 hours.
2462503|NCT03156283|Experimental|SleepWell24 Application|A mobile health smartphone application based on evidence-based health behavior change theory and interventions to promote adherence to positive airway pressure therapy
2462508|NCT03156283|Other|Usual Care Plus Activity Monitor|Per usual clinical care standards within the Center for Sleep Medicine at Mayo Clinic Arizona, all patients will receive instructions/education on positive airway pressure (PAP) use, multiple mask fittings, encouragement to use PAP every night, and staff is available in the event of problems. Control patients will also receive a wearable activity monitor to use during the study. The wearable sensor will be used to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
2462537|NCT03156075|Experimental|Intervention group|"This group will receive the nutrition and exercise program intervention. Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn.~and the first one will start before discharge. The patients will receive a leaflet to describe the instructions."
2462539|NCT03156075|No Intervention|Control group|This group will be selected from the previous three months, they didn't receive any intervention and received the usual care postoperative.
2462578|NCT03155893|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 15 and 16 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 2 orally under fed conditions.
2462581|NCT03155893|Experimental|Panel 1: Treatment B|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily from Day 1 to 16 along with single dose of AL-335 placebo (matching 1200 milligram [mg] AL-335 [3*400 mg tablets]) on Day 15 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2 and 15 along with moxifloxacin 400 mg (1*400 mg capsule) single dose on Day 16 orally under fed conditions.
2462613|NCT03155633|No Intervention|Rest Group|Rest during the 9 days after the race
3156162|NCT00337454|Experimental|A2|
3156163|NCT00337454|Experimental|A3|
3156164|NCT00337454|Experimental|B1|
3156165|NCT00337454|Experimental|B2|
3156166|NCT00337454|Experimental|B3|
3156167|NCT00337480|No Intervention|conventional|This arm is the conventional way of taking care of patients after an acute coronary syndrome
3174605|NCT00625209|Active Comparator|2|Hydrocortisone plus fludrocortisone and a placebo of activated protein C
3156168|NCT00337480|Active Comparator|structured|This arm is an active way to monitor and educate patients after their acute coronary syndrome, with the intervention of health members in a House of Education
3156169|NCT00337493|Experimental|1|
2462079|NCT03159442|Experimental|Cohort 1|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 300 μg AZD8871 or placebo. This dose will be given as 1 inhalation from the 300 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16."
2462080|NCT03159442|Experimental|Cohort 2|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 600 μg AZD8871 as 1 inhalation from the 600 μg AZD8871 or placebo inhaler.~Single inhaled dose of AZD8871 or placebo will be administered on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to 600 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
2462081|NCT03159442|Experimental|Cohort 3|"Multiple inhaled doses of AZD8871 will be administered via single dose DPI. Each subject will receive 900 μg AZD8871 as 1 inhalation from the 300 μg AZD8871 inhaler and 1 inhalation from the 600 μg AZD8871 inhaler, or placebo as 2 inhalations from 2 different placebo inhalers.~Single inhaled dose of AZD8871 or placebo on Day 1 and then single once daily inhalations of AZD8871 or placebo will be administered for 12 days from Day 5 until Day 16.~Dose escalation to the 900 μg dose will be done only after the SRC has determined the adequacy of the dose to be given."
3191308|NCT00797264|Experimental|C|Ketamine and morphine postoperative
2462231|NCT03158402|Sham Comparator|sham IMT|Preoperative Inspiratory muscle training at low intensity (15% Pimax) which is considered as a no effect training.
2462236|NCT03158402|Experimental|Hi Intensity IMT|High intensity muscle training in the preoperative period at 80% of the maximal inspiratory muscle pressure.
2462283|NCT03158025|Experimental|Placebo, LEM 10 mg, SUV 40 mg, LEM 20 mg, ZOL 30 mg, LEM 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: Placebo (3 × placebo lemborexant [LEM] tablets; 3 × placebo zolpidem [ZOL] tablets; 2 × placebo suvorexant [SUV], over-encapsulated); LEM 10 milligrams (mg) (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2462288|NCT03158025|Experimental|LEM 10 mg, LEM 20 mg, Placebo, LEM 30 mg, SUV 40 mg, ZOL 30 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2462292|NCT03158025|Experimental|LEM 20 mg, LEM 30 mg, LEM 10 mg, ZOL 30 mg, Placebo, SUV 40 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets). Each treatment period will be separated by a washout interval of at least 14 days.
2462325|NCT03157596|No Intervention|control group|Evaluation of the knowledge, attitude and practice of caregivers of children with developmental disabilities towards the oral health of their children at baseline and 3 months after without any intervention.
2462344|NCT03157505|Active Comparator|Purethal Birch immunotherapy|Purethat Birch intervention and symptomatic treatment for 24 months
2463311|NCT03150771|Experimental|Cohort 2|Aripiprazole; single; gluteal
3156170|NCT00337493|Experimental|2|
3156171|NCT00337493|Experimental|3|
3156172|NCT00337519|Experimental|1|see detailed description
3156173|NCT00337532|Active Comparator|paclitaxel-cisplatin combination regimen|
3156174|NCT00337558|Experimental|1|Solifenacin succinate
3156175|NCT00337558|Experimental|2|Solifenacin succinate and simplified bladder training
3156176|NCT00337636|Experimental|HuCNS-SC|human central nervous system stem cells
3156177|NCT00337649|Experimental|1|
3156178|NCT00337701|Experimental|1|
3156179|NCT00337701|Experimental|2|
3156180|NCT00337714|Placebo Comparator|A|in this arm conventional CVCs will be inserted
3156181|NCT00337714|Active Comparator|B|group B will receive medicated silver nanoparticles CVC
3156182|NCT00337753|Active Comparator|Cognitive Behavioral Therapy|Weekly Cognitive Behavior therapy
3156183|NCT00337753|Other|Wait-list|Subjects in wait-list for six-weeks
3156184|NCT00337766|Active Comparator|Desmopressin (DDAVP)|
3156185|NCT00337766|Placebo Comparator|Placebo|
3156186|NCT00337805|Active Comparator|1 colloid|Boluses of fluids are a pentastarch (up to 1000 ml)
3156187|NCT00337805|Active Comparator|2. Crytalloid|Boluses are given as normal saline
3156188|NCT00337870|Experimental|Treatment|50% randomized to receive distraction intervention during painful procedure
3156189|NCT00337870|No Intervention|Control|50% RANDOMIZED TO RECEIVE NO INTERVENITON
3156190|NCT00337896||observation|healthy adults ages 18-64 years, enrolled at Stanford University Hospital and participating in another clinical trial (DMID Protocol 04-062)
2462238|NCT03158428|Experimental|CSD170202AA, CSD170202AB Use Group|Use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2462240|NCT03158428|Experimental|CSD170202AB, CSD170202AA Use Group|Use of product CSD170202AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170202AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2462280|NCT03157973|Experimental|Education intervention|
2462284|NCT03157973|No Intervention|Standard of Care|
2462404|NCT03157336|Experimental|Peer-led Intervention|Peers (community women in leading roles) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial.
2462407|NCT03157336|Experimental|Specialist-led Intervention|Specialists (nutritionists) training other women in the wetting method for safe processing of cassava in a non-inferiority intervention trial..
3156191|NCT00337909|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3156192|NCT00337909|Active Comparator|Active Control|Educational DVDs
2462561|NCT03156010|Other|TBI Group|Subjects with history of TBI will undergo testing with all three devices.
2462565|NCT03156010|Other|Control Group|Subjects with no history of TBI will undergo testing with all three devices.
3156193|NCT00337909|No Intervention|No Contact Control|
3156194|NCT00337974|Experimental|Experimental Treatment|Computerized Plasticity-Based Adaptive Cognitive Training
3156195|NCT00337974|Active Comparator|Active Control|Educational DVDs
3156196|NCT00337974|No Intervention|No Contact Control|
3156197|NCT00338026|Experimental|ECO-4601|
3156198|NCT00338065|Experimental|Subjects with autonomic dysfunction|"Subjects with known autonomic dysfunction diagnoses as defined by the General Clinical Research Center (GCRC) such as pure autonomic failure, Postural orthostatic tachycardia syndrome (POTS), and Multiple System Atrophy( MSA).~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3156199|NCT00338065|Experimental|Primary open-angle glaucoma subjects|"Subjects diagnosed with primary open-angle glaucoma following a glaucoma specialist's examination.~Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3156200|NCT00338065|Experimental|Subjects with normal-pressure glaucoma|"Subjects with open-angle glaucoma damage following a glaucoma specialist's examination without ever an intraocular pressure recording greater than 21 mm Hg.~.1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3156201|NCT00338065|Active Comparator|Normal subjects|"Subjects without evidence of glaucoma or autonomic dysfunction.~..1. Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes~2. Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking."
3156202|NCT00338130|Active Comparator|1|Temozolomide
3156203|NCT00338130|Experimental|2|AZD6244
3156204|NCT00338182|Experimental|AZD1152|AZD1152 treatment given for 2 days every 14 days (2 treatment days followed by 12 days off treatment)
2462960|NCT03153254|Experimental|Healthy persons|Test upper limb robot assisted therapy device. During 1 session of 1/2 hour.
2462967|NCT03153254|Experimental|Stroke patients|Training with new upper limb robot assisted therapy device. During 2 to 5 sessions of 1/2 hour.
2463025|NCT03152643|Experimental|blastocyst-stage embryo transfer group|For subjects assigned to blastocyst-stage (D5/D6) embryo transfer group, all embryos will be cultured to D5 or D6. 1 blastocysts of the best quality will be transferred in fresh cycle on D5 or D6 after oocyte retrieval (D5 embryo will be the prior choice). The surplus embryos, if any, will be vitrified for future FET in case the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on D5 or D6 can be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
2463370|NCT03150394|Placebo Comparator|Treatment of quadruple eradication therapy with PLACEBO|
3156205|NCT00338195|No Intervention|Delayed intervention control|
3156206|NCT00338208|No Intervention|No training|Subjects will be fitted with low vision devices; no extra training will be provided.
3156207|NCT00338208|Experimental|Training in the Use of Low Vision Devices|Subjects will be fitted with low vision devices and will receive 6 training sessions with prescribed devices for up to 1 hour each time
3156208|NCT00338234||Cardiac surgery|Successive cardiac surgery patients
3156209|NCT00338234||Surgical ICU|Successive patients admitted to the surgical ICU for more than 7 days, and experiencing anemia
3156210|NCT00338273|Active Comparator|A1|
3156211|NCT00338273|Placebo Comparator|A2|
3156212|NCT00338312|Placebo Comparator|1|Placebo patch
3156213|NCT00338312|Experimental|2|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
3156214|NCT00338325|Experimental|Treatment|50% randomized to receive treatment: reading pre-operatively
3156215|NCT00338325|No Intervention|Control|50% randomized to receive no intervention pre-operatively: no reading
3156216|NCT00338364|Experimental|Treatment|50% randomized to receive distraction during painful procedure
3156217|NCT00338364|No Intervention|Control|50% randomized to receive no distraction during painful procedure
3156218|NCT00338377|Experimental|Group A: Chemotherapy + IL-2 plus T-cells|"Cyclophosphamide 60 mg/kg/d by vein (IV) over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.~Group A has been closed to new patient entry as of January 14, 2016."
3174606|NCT00625209|Active Comparator|3|placebo of hydrocortisone, placebo of fludrocortisone and activated protein C
3174607|NCT00625209|Active Comparator|4|hydrocortisone plus fludrocortisone plus activated protein C
3174608|NCT00625222|Experimental|1|
3156219|NCT00338377|Experimental|Group B: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
2462430|NCT03157037|Experimental|Treatment HMed-IdeS|IdeS intravenous infusion 0.25 mg/kg BW intravenous infusion
2462464|NCT03156764||Qp/Qs ratio monitoring|Qp/Qs ratio monitoring
2462497|NCT03156530|Experimental|Auricular acupuncture|Stimulated with needles at three joint points of the lower limb, knee and ankle. Balance assessments will be performed prior to (initial) pacing, 20 minutes after the initiation of the pacing protocol (second evaluation) and after 5 minutes the final evaluation.
2462506|NCT03156530|Placebo Comparator|Control|Not receive stimulation.
2462556|NCT03156166|Experimental|Ambu AuraGain|Ambu AuraGain is inserted in children undergoing general anesthesia. The size of AuraGain is as follows: size 1 for children <5 kg, size 1.5 for 5-10kg, size 2 for 10-20kg, size 2.5 for 20-30kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2462563|NCT03156166|Experimental|I-gel|I-gel is inserted in children undergoing general anesthesia. The size of I-gel is as follows: size 1 for children weighing 2-5kg, size 1.5 for 5-12kg, size 2 for 10-25kg, size 2.5 for 25-35kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2462566|NCT03156166|Experimental|Air-Q intubating laryngeal airway (ILA)|Air-Q ILA is inserted in children undergoing general anesthesia. The size of Air-Q ILA is as follows: size 1 for children between 4-7 kg, size 1.5 for 7-17kg, size 2 for 17-30kg, size 2.5 for 30-50kg. Fiberoptic bronchoscope will be performed to measure the distance between the grill and vocal cord.
2462617|NCT03155711|Experimental|HFNC|HFNC with a 60 liters per minute flow will be given to the patients before anesthesia induction and before extubation at the end of the surgery
2462629|NCT03155711|Active Comparator|Standard|This patients will be managed as usual care. Pre-oxygenation before induction will be performed with supplemental oxygen but without positive pressure. After extubation patients will be oxygenated through a ventury mask.
2462746|NCT03155022|Experimental|RIC+ ICIC +|Patients with remote ischemic conditioning and intracoronary ischemic conditioning
2462753|NCT03155022|Other|RCI - ICIC -|Control group with no remote ischemic conditioning and no intracoronary ischemic conditioning
2462784|NCT03154320|Active Comparator|Standard Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and provide a sputum specimen for spot Xpert Ultra testing (48-hour results). Those with high clinical/radiographic suspicion for TB will start same-day TB treatment. On Day 2, participants will return for results of Xpert Ultra testing (spot specimen) and to provide a specimen for early morning Xpert Ultra testing. Those who are Xpert Ultra positive will start TB treatment. Those who are not diagnosed with TB will start ART on Day 9, after testing and treatment for other opportunistic infections. A liquid TB culture will be performed on both the spot and early morning specimens.
2462785|NCT03154320|Experimental|Same-Day Treatment Group|On Day 0 (day of HIV diagnosis and study enrollment) participants will receive a chest x-ray and Xpert Ultra testing with same-day results. Based on clinical symptoms, Xpert Ultra results, and chest x-ray, physician will determine whether or not the participant has tuberculosis. Those who are diagnosed with TB will start same-day TB treatment. Those who are not diagnosed with TB will start same-day ART.
3191309|NCT00797290||Photon/Proton Radiation Therapy|Photon/Proton Radiation Therapy
2462955|NCT03152994||COPD patients without T2DM|"For it's an observational study, fasting blood glucose(FBG) will be checked every six months. The patients who won't develope T2DM during the follow-up will be divided into the groupCOPD patients without T2DM."
3174609|NCT00625235|Other|1|High Carbohydrate diet
3174610|NCT00625235|Other|2|High Protein diet
3174611|NCT00625248||no anthithrombotic|procedures where there were no antithrombotics
3174612|NCT00625248||Antithrombotic - continued|patients who are on antithrombotics
3174613|NCT00625248||Discontinued Antithrombotic|Patients who were on antithrombotics but have been discontinued
3174614|NCT00625261|Experimental|1|The mothers of the two-years old children in the intervention group took part at the Heidelberg Parent-based Language Intervention HPLI
3174615|NCT00625261|No Intervention|2|Waiting group, no intervention until children were three years of age
3174616|NCT00625274|Experimental|1|Oral
3174617|NCT00625274|Experimental|2|Oral
3174618|NCT00625274|Experimental|3|Oral
3174619|NCT00625300|Active Comparator|1|Active treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
3174620|NCT00625300|Sham Comparator|Placebo|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (sham) over the motor cortex and the prefrontal cortex.
3174621|NCT00625313|Experimental|HMY Model YA-60BB IOL|Patients receiving a Hoya HMY Acrylic Foldable Intraocular Lens.
3174622|NCT00625326|Experimental|75 µg/g COL-121 Ointment|75 µg/g COL-121 Ointment
3174623|NCT00625326|Experimental|150 µg/g COL-121 Ointment|150 µg/g COL-121 Ointment
3174624|NCT00625326|Experimental|300 µg/g COL-121 Ointment|300 µg/g COL-121 Ointment
3174625|NCT00625326|Active Comparator|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment (active control)
3174626|NCT00625326|Placebo Comparator|Placebo Ointment|Placebo Ointment
3174627|NCT00625339|Experimental|A|entecavir 0.5 mg QD
3174628|NCT00625339|Active Comparator|B|lamivudine 100 mg QD
3174629|NCT00625378|Experimental|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial
3174631|NCT00625430|Experimental|1|Six Cohorts with escalating vector dose
2462261|NCT03158129|Experimental|Arm A (nivolumab)|Participants receive nivolumab IV over 60 minutes on days 1, 15, and 29 in the absence of disease progression or unacceptable toxicity.
2462268|NCT03158129|Experimental|Arm B (nivolumab, ipilimumab)|Participants receive nivolumab as in Arm A and receive ipilimumab IV over 90 minutes on day 1 in the absence of disease progression or unacceptable toxicity.
2462270|NCT03158129|Experimental|Arm C (nivolumab, cisplatin, docetaxel, pemetrexed)|Patients receive nivolumab IV over 30 minutes and cisplatin IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
2462271|NCT03158129|Experimental|Arm D (ipilimumab, nivolumab, chemotherapy)|Patients receive ipilimumab IV over 90 minutes on day 1, nivolumab IV over 30 minutes on days 1, 22, and 43, and cisplatin (or carboplatin) IV over 2 hours on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity. Patients also receive docetaxel IV over 1 hour or pemetrexed IV over 10 minutes on days 1, 22, and 43 in the absence of disease progression or unacceptable toxicity.
2462413|NCT03157414|Active Comparator|Empagliflozin|10 mg once daily for 24 weeks
2462417|NCT03157414|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
2462456|NCT03156803|Experimental|Healthy eating blog (HEB)|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
2462458|NCT03156803|No Intervention|Control|Mothers randomised to the control group will not have access to the healthy eating blog.
2462500|NCT03156582||"all participants included Milan criteria  and AFP score"|"The first arm is made of liver recipients or dropped off list patients at the time of the Milan criteria (fixed until 2013/06/01 for transplanted patients because mandatory three months reevaluation of patients obliged the various teams to respect the criteria at this time, but until 2013/03/01 for dropped off patients because we did not want to count dropped of because of the AFP score in this arm).~The second arm is made of liver recipients or dropped off list patients at the time of the AFP score (fixed after 2013/06/01)for transplanted patients and after 2013/03/01 for dropped off patients)"
3174632|NCT00625456|Experimental|Single Arm, dose escalation|dose escalation starting dose 1e5 pfu/kg bw to 3e7 pfu/kg bw; Recombinant Vaccinia GM-CSF (JX-594)
3174633|NCT00625469|Experimental|treatment with bosentan|patients with resting or exercise induced PAH receive bosentan in a randomized open label fashion
2462661|NCT03155373||A|Asymptomatic/mild symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction >60%)
2462662|NCT03155373||B|Symptomatic patients with normal pre-operative left ventricular function (defined as left ventricular ejection fraction greater than or equal to 60%)
2462663|NCT03155373||C|Patients with impaired pre-operative left ventricular function (defined as left ventricular ejection fraction <60%)
2462725|NCT03154736|Experimental|Interview|Individual interview an in a group interview. Socio-economic questionnaire
2462817|NCT03154294|Experimental|Cohort 1|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 100mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2462821|NCT03154294|Experimental|Cohort 2|Paclitaxel 60mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2462823|NCT03154294|Experimental|Cohort 3|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 2mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2462826|NCT03154294|Experimental|Cohort 4|Paclitaxel 80mg/m Day 1, Day 8, Day 15 TAK-228 3mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2462829|NCT03154294|Experimental|Cohort 5|Paclitaxel 80mg/m2 Day 1, Day 8, Day 15 TAK-228 4mg Days 2-4, Days 9-11, Days 16-18, Days 23-25 TAK-117 200mg Days 2-4, Days 9-11, Days 16-18, Days 23-25
2462853|NCT03153774|Experimental|Heart failure patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
2462858|NCT03153774|Experimental|TAVI patients|The main objective was to assess the prevalence of sarcopenia in chronic heart failure patients and in patients before the trans aortic valvular implantation.
3174634|NCT00625469|No Intervention|PAH group with no therapy|patients with resting or exercise PAH get randomized to receive no specific therapy
2462992|NCT03152929|Active Comparator|Paravertebral Block|The Paravertebral Block is performed along the spine utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
2462994|NCT03152929|Active Comparator|Pectoral Nerve Block|The Pectoral Nerve Block is performed anteriorly, at the level of the axillary line, also utilizing ultrasound guided technique (20-30 mL 0.5% Ropivacaine)
2463077|NCT03152474|Active Comparator|Solumedrol 20mg|Solumedrol injection will be given in the vein every 8 hrs. for 7 days.
2463078|NCT03152474|Active Comparator|Vitamin A 100,000 IU|Vitamin A injection will be given in the arm muscle for 7 days.
2463080|NCT03152474|Placebo Comparator|Placebo|Placebo will be given in the vein every 8 hrs. for 7 days or given in the arm muscle for 7 days.
2463152|NCT03151850||ulcerative colitis|We analysed the diversity of the fungal and bacterial in patients with Ulcerative Colitis (UC). We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
2463154|NCT03151850||Control|Analysing the diversity of the fungal and bacterial in patients without ulcerative colitis. We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
2463283|NCT03150628|Experimental|Study population|
2463387|NCT03150537|Active Comparator|Jet injector|40 participants will receive Fluviral influenza vaccine using the Med-Jet H4
3174635|NCT00625469|No Intervention|No PAH and no therapy|patients with no evidence of either resting or exercise PAH receive no intervention but are followed until lung transplantation
3174636|NCT00625482|Active Comparator|Boys 1|OPV as usual
3174637|NCT00625482|Experimental|Boys 2|OPV plus BCG
3174638|NCT00625482|Active Comparator|Girls 1|OPV as usual
3174639|NCT00625482|Experimental|Girls 2|OPV plus BCG
2462266|NCT03158259|Active Comparator|Conventional ambulance|Patient will be brought to hospital by normal ambulance according to existing procedures. Diagnosis (NIHSS, CT and conventional blood-measures) and thrombolytic treatment (when indicated) will be given in hospital.
2462311|NCT03157869|Experimental|Transcranial Direct Current Stimulation|"Intervention: anodic tDCS (20 minutes ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
2462312|NCT03157869|Sham Comparator|Control|"Intervention: simulated anodic tDCS (30 seconds ON, intensity 2milliamps) on the primary motor cortex contralateral of the trained hand (right) simultaneously to the motor training and supraorbital cathode ipsilateral~Motor training will consist of 8 blocks with 300 repetitions of sequential finger movements performed with the right hand."
2462363|NCT03157635|Experimental|Part 1 (Healthy Volunteers): Crovalimab|Healthy participants will receive a single dose of crovalimab in each dose-escalation cohort of Part 1. Crovalimab will be administered at a starting dose of 75 milligrams (mg). Doses are planned to be escalated up to Cohort 5.
2462364|NCT03157635|Placebo Comparator|Part 1 (Healthy Volunteers): Placebo|Healthy participants will receive a single dose of crovalimab matching placebo in each dose-escalation cohort of Part 1.
2462365|NCT03157635|Experimental|Part 2 (PNH Participants): Crovalimab|PNH participants will receive 3 single ascending doses (375 mg IV, 500 mg IV, 1000 mg of crovalimab) on Days 1, 8, and 22 followed by weekly crovalimab administrations up to a maximum of 5 months. Weekly crovalimab administrations will start no earlier than Day 36. The starting dose of Part 2 is based on data from Part 1 of the study.
2462366|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab QW|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 170 mg QW on Day 8 for a maximum treatment duration of 5 months.
2462367|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q2W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 340 mg Q2W for a maximum treatment duration of 5 months.
2462368|NCT03157635|Experimental|Part 3 (PNH Participants): Crovalimab Q4W|Participants will receive crovalimab at a dose of 1000 mg on Day 1 and 680 mg Q4W starting on Day 8 for a maximum treatment duration of 5 months.
2462369|NCT03157635|Experimental|Part 4 (eculizumab pretreated PNH Participants): Crovalimab|"PNH Participants pretreated with eculizumab will receive crovalimab:~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
2462371|NCT03157635|Experimental|Part 4 (treatment naïve PNH Participants): Crovalimab|"Treatment naïve PNH Participants will receive:~Participants >/= 100 kg: loading dose of 1500 mg IV on day 1; Participants < 100 kg: loading dose of 1000 mg IV on day 1. In all Participants, the remainder of the loading series schedule will be 340 mg SC on Days 2, 8, 15, and 22. For Participants >/= 100 kg, maintenance dosing will be 1020 mg SC on week 5 and then Q4W thereafter. Patients < 100 kg will receive a maintenance dose of 680 mg SC on the same schedule."
2462374|NCT03157635|Experimental|OLE (PNH Participants): Crovalimab|PNH Participants who participated in Parts 2, 3 and 4 and who derive clinical benefit from crovalimab may enroll into OLE. Participants will either receive 680 mg SC Q4W (body weight >/= 40 kg to < 100 kg) or 1020 mg SC Q4W (body weight >/= 100 kg) for up to a maximum treatment duration of five years from entry into OLE.
2462416|NCT03157076|Active Comparator|Pacing mode with CLS|
2462420|NCT03157076|Active Comparator|Intrinsic mode|
2462471|NCT03156829|Experimental|Splint alone|
2462474|NCT03156829|Experimental|Cortico-steroid alone|
2462475|NCT03156829|Experimental|Splint and cortico-steroid combined|
2462493|NCT03156374|Experimental|Ovulation test use|Use of both ovulation tests and standardised care
2462597|NCT03156244||Caucasian|This cohort will consist of 40 white patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
2462598|NCT03156244||African American|This cohort will consist of 40 African American patients who are receiving either radiation or surgery for treatment of their prostate or bladder cancer.
2462602|NCT03155490|Experimental|Leadership Training|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
2462604|NCT03155490|No Intervention|Control|Subjects are resident trainees with a role in the emergency department evaluation and management of trauma patients.
3174640|NCT00625495|Experimental|1|IV Nexium
2462732|NCT03154931|Active Comparator|CBT-SG|This CBT-Supportive group will focus on the interaction here-and-now, realizing that the group acts as a secure place, driven by interactions among its participants and therapist and co-therapist. The main objective is to welcome and support the participation of all patients and stimulate the group's initiatives, encouraging interpersonal interactions and mutual aid. There will be no specific therapeutic intervention in relation to any PTSD related content.
2462737|NCT03154931|Experimental|CFT-G|This CFT-group will focus on activities using specific therapeutic strategies, to learn and training compassionate skills - psychoeducation and exercises developed for use in session and at home.They will learn What is compassion and shame? Steps to the training of compassion and how Building a compassionate image. Will use Thoughts Daily Record - self critical and self compassionate. Explanation of Formulation of Strategy Threats and Security, The Three Emotional regulation systems and PTSD formulation - based on shame and guilt. They will learn how to incorporate these skills to everyday situations. At the end, will write an Autobiography writing about this experience and share with the group.
2462852|NCT03153735|Experimental|CMDHA0101|Maximum injection dose : 22 ml It is a product containing 0.3% lidocaine hydrochloride, a topical anesthetic ingredient, in a crosslinked hyaluronic acid gel
2462855|NCT03153735|Active Comparator|PowerFill®|Maximum injection dose : 22 ml A white solid that was lyophilized with mixed spherical PLA (Poly-D, L-lactide) microparticles and CMC (sodium carboxymethylcellulose)
2463005|NCT03152890|Experimental|Study group|The study group receives a linear mixed effects model-proposed dose of insulin when hyperglycemia is noticed after reperfusion of liver graft.
2463053|NCT03152435|Experimental|anti-tumor response of CART-EGFR|
3174641|NCT00625495|Experimental|2|Oral Nexium
2462296|NCT03158025|Experimental|LEM 30 mg, ZOL 30 mg, LEM 20 mg, SUV 40 mg, LEM 10 mg, Placebo|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2462300|NCT03158025|Experimental|ZOL 30 mg, SUV 40 mg, LEM 30 mg, Placebo, LEM 20 mg, LEM 10 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2462301|NCT03158025|Experimental|SUV 40 mg, Placebo, ZOL 30 mg, LEM 10 mg, LEM 30 mg, LEM 20 mg|Participants will receive the following treatments (orally) in Treatments Periods 1 through 6, respectively: SUV 40 mg (2 × 20 mg SUV tablets, over-encapsulated; 3 × placebo ZOL tablets; 3 × placebo LEM tablets); placebo (3 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); ZOL 30 mg (3 × 10 mg ZOL tablets; 3 × placebo LEM tablets; 2 × placebo SUV, over-encapsulated); LEM 10 mg (1 × 10 mg LEM tablet; 2 × placebo LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 30 mg (3 × 10 mg LEM tablets; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated); LEM 20 mg (2 × 10 mg LEM tablets; 1 × placebo LEM tablet; 3 × placebo ZOL tablets; 2 × placebo SUV, over-encapsulated). Each treatment period will be separated by a washout interval of at least 14 days.
2462370|NCT03157544|Experimental|Pain Relief Kit|Immediately following baseline data collection participants will be given the Pain Relief Kit and instructed about the contents. From this kit, a sample of Biofreeze® and TheraBand® Kinesiology Tape will be applied to the participant. The contents of the Pain Relief Kit will include four modes of non-pharmacological interventions that have been previously demonstrated to relieve musculoskeletal pain. Following Baseline data collection, participants will review the content of the Pain Relief Kit with a member of the research staff. During this review the subject will be informed about the recommended use of all the four modes of the non-pharmacological interventions included in the kit. This information will also be included in written form in the Pain Relief Kit.
3191310|NCT00797303|Experimental|1|A single intraoperative subconjunctival application of bevacizumab and 2 months follow-up
2462438|NCT03157024|Experimental|Sham Press Needle - Ring Sham (RS)|A sterilised stainless steel press needle that only has the ring-shaped head of needle without needle body has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. RS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2462439|NCT03157024|Active Comparator|Real Needle (RN)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body and the third layer is attached to skin. RN will be placed on acupoint LI11 and ear shenmen of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2462440|NCT03157024|Sham Comparator|Kim Sham (KS)|A sterilised stainless steel press needle (diameter 0.18 mm X length 1.5 mm, Dongbang Acupuncture Inc., Boryeong, Chungcheongnam-do, Korea) with a blunted tip has three layers of adhesive tape. Between the first and second layer is the head of needle to support needle body while maintaining identical appearance and the third layer is attached to skin. KS will be placed on 1 cm medial to acupoint LI11 and ear wrist, a non-specific control auricular acupoint used in the previous literature of the non-dominant side. An acupoint detector (personal TENS electronic acupuncture, Hammtek Korea, Seoul, Korea) will be used to locate points with lower skin impedance than those nearby.
2462526|NCT03156647||idiopathic Parkinson disease|
2462530|NCT03156647||iatrogenic parkinsonian syndrome|
2462532|NCT03156647||healthy volunteers|
2462592|NCT03155932|Experimental|APD334|APD334 active treatment for 24 weeks.
2462645|NCT03155503|Active Comparator|Single ascending dose|Single dose of SUVN-911 or placebo in healthy male subjects
2462647|NCT03155503|Active Comparator|Multiple ascending dose|Multiple doses of SUVN-911 or placebo in healthy male subjects
2462681|NCT03155113|Other|patients with chronic HCV infection|"Patients with chronic HCV infection to be treated with any of the available DAA (without associated PEG-IFN) in daily clinical practice.~Intervention: Blood Drawing.Before starting therapy a blood sample will be collected from any subject."
2462752|NCT03154983|Experimental|First-line treatment|First-line treatment：treatment including Mesylate Apatinib Combined With Docetaxel and S-1(DS).DS Docetaxel 75mg/m2 d1 iv.drop 1h（one hour）， S-1(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid), Q21d(21 days a cycle); Mesylate Apatinib 500mg Po QD(once a day) continuous use; until disease deterioration.
2462783|NCT03154411|Experimental|ABY-029|ABY-029 will be administered prior to surgery and tissue will be examined ex vivo to determine binding with EGFR positive tumor tissue.
2462834|NCT03154177|No Intervention|Standard ANC and PNC care only|Standard care offered following national guidelines of ANC and PNC.
2462835|NCT03154177|Other|Standard Care + Ultrasound+Pregnancy Testing|Standard care in combination with early pregnancy testing and ultrasound.
2462836|NCT03154177|Experimental|Group ANC and PNC only|Health facilities randomized to provide group ANC/PNC.
2462346|NCT03157505|Placebo Comparator|placebo and symptomatic treatment|placebo intervention and symtomatic treatment during 24 months
2462405|NCT03157349|Experimental|Experimental|The experimental group will receive the active product (Biofreeze) over the course of 1 week.
2462408|NCT03157349|Sham Comparator|Placebo|The placebo will use a product created to mimic the topical analgesic Biofreeze over the course of one week. All active ingredients have been removed.
2462463|NCT03156907|Experimental|Chronic pain patients|The primary objective of this study is to assess the success rate at 6 months of opioid temporary rotation by High Dosage Buprenorphine (HDB) taper dose in chronic non cancer pain patients (CNCP) with physical withdrawal symptoms making opioid withdrawal impossible.
2462510|NCT03156517|Active Comparator|Deep Brain Stimulation in VIM|Patients receive stimulation in the VIM-nucleus of the thalamus
2462512|NCT03156517|Active Comparator|Deep Brain Stimulation in PSA|Patients receive stimulation in the posterior subthalamic area
2462540|NCT03156049|Active Comparator|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
2462542|NCT03156049|Active Comparator|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
2462599|NCT03155841|Experimental|Life Skills Coaching|Participants in the experimental arm will receive access to HIV prevention and life skills content, including opportunities for goal setting, a directory of local resources in their community, and the ability to discuss their goals with Youth Navigators through a video-chat function.
2462600|NCT03155841|Active Comparator|Community Resources|Participants in the control arm will receive access to a directory of local resources in their community.
2462616|NCT03155477|Experimental|"Cholecalciferol and C. Xanthorrhiza"|Subjects received Cholecalciferol 400 IU 3 times daily and C. Xanthorrhiza 20 mg 3 times daily per oral for 3 months (group II, n=19)
2462623|NCT03155477|Placebo Comparator|"Cholecalciferol and placebo"|Subjects received cholecalciferol 3×400 IU and placebo 3×1 tablet for 3 months (group I, n=20).
2462668|NCT03155139||Patients without primary aldosteronism (PA)|PA case detection or confirmatory tests was negative.
2462675|NCT03155139||Patients with primary aldosteronism (PA)|PA case detection and confirmatory tests were positive.
2462748|NCT03154879||Comatose cardiac arrest survivors|
2462882|NCT03153982|Experimental|Head and neck squamous cell carcinoma|"Participants will take 15 mg or 20 mg of ruxolitinib by mouth twice daily for up to 4 weeks during the pre-operative window. Dose will be assigned based on participant platelet count at baseline. The last dose will be taken the morning of planned surgery.~Ruxolitinib will be dispensed in 5 mg tablets. Participants will either take three tables (15 mg) in the morning and evening, or four tablets in the morning and evening (20 mg)."
2462917|NCT03153371||Early-onset Alzheimer's disease|This group will include 90 patients who have been diagnosed with clinically probable early-onset Alzheimer's disease by the UCLA Neurology Clinic (60 variant phenotypes; 30 typical amnestic).
2462921|NCT03153371||Alzheimer's disease|This group will include 30 patients who have been diagnosed with clinically probable Alzheimer's disease (typical late-onset AD)
2462923|NCT03153371||Controls|Healthy age-matched individuals without clinically significant cognitive impairments will be enrolled into this study.
2462973|NCT03153137|Experimental|Macitentan|Macitentan 10 mg per day; film-coated tablet; oral use
2462980|NCT03153137|Placebo Comparator|Placebo|film-coated tablet; oral use
2463083|NCT03152188|Experimental|FMT|Fecal Microbiota Transplantation (FMT) capsules
2463085|NCT03152188|Placebo Comparator|Placebo|Placebo capsules
2463144|NCT03151876|Experimental|ChiCGB|"Experimental: ChiCGB~Chidamide administered orally on D-7, -4, 0,+3~Cladribine administered at 10mg on D-6 to D-2~Gemcitabine administered at 2500 mg/m2 on days -6 and -2.~Busulfan administered at 3.2 mg/kg (adjusted ideal body weight) on days -6 to -3.~Dexamethasone 10 mg by vein daily from day -6 to day -1. Caphosol oral rinses 30 mL four times a day used from day -8.~Interventions:~Drug: Chidamide Drug: Cladribine Drug: Gemcitabine Drug: Busulfan Drug: Dexamethasone Procedure: Stem Cell Transplant"
2463267|NCT03151239|Placebo Comparator|Placebo|
2463269|NCT03151239|Experimental|NMN supplementation|
2463302|NCT03150654|Experimental|Laser pan-retinal photocoagulation|Conventional laser pan-retinal photocoagulations were performed by using green laser photocoagulator, every month for 3 months
2463364|NCT03150446|Experimental|The group using flexible cystoscopy|50 patients with large upper ureteral stones underwent laparoscopic ureterolithotomy with flexible cystoscopy to confirm the correct positioning of the double-J stent. After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy.
2463423|NCT03150069||Morquio A / Biological Mothers|Women with Morquio A who have biological children
2463432|NCT03150069||Morquio A / No Biological Children|Women with Morquio A who do not have biological children (both adoptive mothers and non-mothers)
2463436|NCT03150069||Morquio B / Biological Mothers|Women with Morquio B who have biological children
2463437|NCT03150069||Morquio B / No Biological Children|Women with Morquio B who do not have biological children (both adoptive mothers and non-mothers)
2463484|NCT03149614|Active Comparator|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000.
2463493|NCT03149614|Experimental|Vertebral Resonant Oscillation (POLD method)|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
2463610|NCT03148704||palonosetron palonosetron hydrochloride|A continuous sequence of patients using palonosetron palonosetron hydrochloride capsules(Ruo Shan®)
2463789|NCT03147365|No Intervention|Control group|Twenty five children who will not receive any physical therapy treatment.
3174642|NCT00625521|Experimental|1|Drug: ASF 1096 0.5 % cream applied twice daily
2462615|NCT03155815||Derivation Cohort|Eligible respondents to the combined 2001, 2003, 2005 and 2007 Canadian Community Health Surveys, conducted by Statistics Canada.
2462632|NCT03155815||Validation Cohort|Eligible respondents to the 2008/2009 Canadian Community Health Survey.
2462678|NCT03155334|Other|Prevalence of CCSVI in MS|Subjects with prevalence of CCSVI in Multiple Sclerosis and in Other Neurodegenerative Diseases - PIS User Testing
2462687|NCT03155334|Other|BVD Exploited Against MS|Subjects suffering from Brain venous drainage exploited against Multiple Sclerosis - PIS User Testing
2462730|NCT03154853|No Intervention|normal foot|no intervention
2462733|NCT03154853|Experimental|functional flatfoot|Behavioral: short foot exercise
2462764|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (neutral)|
2462767|NCT03154580|Placebo Comparator|N-acetylcysteine 0mg X Cue Exposure (marijuana)|
2462770|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (neutral)|
2462772|NCT03154580|Active Comparator|N-acetylcysteine 2400mg X Cue Exposure (marijuana)|
2462787|NCT03154255|Experimental|Mediterranean Style-Diet Group|"These subjects will receive a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
2462788|NCT03154255|No Intervention|Standard Diet Group|These subjects will receive Standard Diet according to routine care and practice. The standard diet will be distributed with 55-60% of carbohydrates (45-50% complex and no more than 10% refined and processed sugars), 25-30% lipids and 15% proteins, and will be performedin accordance with the calories of an isocaloric balanced diet calculated throughout the Italian LARN Guidelines for age and gender (Società Italiana di Nutrizione Umana, 2014), inspired to Mediterranean pyramid.
2462877|NCT03154073|Experimental|Moderate Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of moderate intensity exercise per week. Exercise will be supervised by trained staff.
2462879|NCT03154073|Experimental|Vigorous Exercise Training|Exercise training program that will focus on engaging in ~150 minutes of vigorous intensity exercise per week. Exercise will be supervised by trained staff.
2462935|NCT03153423|Other|Basic intermittent exotropia patients|
2463020|NCT03152812||free skin flaps|
2463021|NCT03152812||free muscle flaps|
2463055|NCT03152383|Experimental|Autism Spectrum Disorder|Children diagnosed as having autism spectrum disorder
2463059|NCT03152383|Active Comparator|Typically developing|Children who are typically developing
2463062|NCT03152383|Active Comparator|Other Developmental Delay|Children diagnosed with a developmental delay other than autism spectrum disorder
2463113|NCT03151980|Active Comparator|Hamam treated skin and sun exposure|
2463117|NCT03151980|Other|Untreated skin and sun exposure|
2463482|NCT03149588|Experimental|propofol|
2463490|NCT03149588|Experimental|sevoflurane|
2463520|NCT03149263||Toxin-clown|"Botulinum toxin injections are carried out according to the usual injection protocol.~40 children will be included into the arm toxin with clown distraction. During injections, clowns take information with the doctor before the procedure on the child's pathology, the cognitive level, the number of injections. During injections, clowns fit and distraction can change depending on the reaction of the child to their intervention."
2463521|NCT03149263||Toxin-usual distraction|"40 children will be included into the arm toxin with usual distraction The usual distraction involves discussion with the child, and its accompanying its interests, to define the use of music, songs, television, video games or other distraction during the session. If the first distraction doesn't work, it's possible to switch to another distraction during injections"
2463581|NCT03149016|Experimental|Corticotomy-assisted Retraction|Corticotomy-assisted retraction will be performed in order to help in accelerating upper incisors' retraction
2463584|NCT03149016|No Intervention|Conventional Retraction|Conventional retraction will be used in this group of patients by sliding mechanisms
2463625|NCT03148574|Experimental|misoprostol|intrauterine 400 microgram
2463628|NCT03148574|Active Comparator|oxytocin|intravenous infusion 10 units
3174643|NCT00625521|Placebo Comparator|2|Cream vehicle for ASF 1096 cream applied twice daily
2463726|NCT03147625|Experimental|SHAPE Intervention|Participants in this group will receive a 12-week SHAPE intervention, comprising of 2 home visits, 10 weekly group-based activity sessions and a SHAPE health-promotion booklet.
2463730|NCT03147625|No Intervention|Control group|Participants in the control group will continue to participate in activities offered in the senior activity centre, community centres and voluntary welfare organisations.
2463862|NCT03146858|Experimental|Enoxaparin|The patients will receive a 3-6 hour infusion of enoxaparin. The effects of the infusion will be assess when used on patients will acute heart attacks and undergoing emergency treatment with PPCI.
3174644|NCT00625534|Experimental|1|Laparoscopic repair
3174645|NCT00625534|Active Comparator|2|Open tension free inguinal hernia mesh repair
3174646|NCT00625547|Experimental|1|
3174647|NCT00625547|Experimental|2|
3174648|NCT00625560|Experimental|A|entecavir 1.0 mg QD
3174649|NCT00625560|Active Comparator|B|lamivudine 100 mg QD
3174650|NCT00625599||1|Salvadorian students at the Evangelical University in non-health track studies over the age of 18. The students must accept the invitation to participate along with signing the informed consent to be eligible.
3174651|NCT00625599||2|Patients over the age of 45 presenting to Hospital Zacamil with an acute fracture. Patients must accept the invitation to the study and sign the informed consent to be eligible.
3174652|NCT00625612|Placebo Comparator|2|
3174653|NCT00625612|Experimental|1|Denufosol Tetrasodium (INS37217) Inhalation Solution
3174654|NCT00625638|Experimental|Standard Care Only|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
3174655|NCT00625638|Experimental|Standard Care + IVR System|Standard Care + Interactive Voice Response (IVR) System Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes. Phone calls made once daily, each taking about 3-5 minutes to complete.
2462355|NCT03157479|Experimental|Protective ventilation|Volume controlled ventilation with tidal volume 6-7 ml/kg of predicted body weight (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 10 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8 seconds and an inspiratory pause of 0.3 seconds and FiO2 will be kept unchanged during the whole study period. In patients in this group, recruiting maneuvers will be performed throughout a stepwise 5 cmH2O PEEP increase every 30 seconds to achieve a PEEP of 35 cmH2O during Pressure Controlled Ventilation (10 cmH2O of inspiratory pressure while keeping respiratory rate unmodified), followed by a stepwise 5 cmH2O PEEP reduction every 30 seconds until the baseline set peep is reached.
2462359|NCT03157479|Active Comparator|Standard Ventilation|Volume controlled ventilation with tidal volume 10 ml/kg of PBW (45.5 + 0.91 (height [cm] -152.4)), FiO2 0.4 and PEEP 5 cmH2O during the whole study period. Respiratory rate will be titrated to keep end-tidal CO2 values between 30 mmHg and 40 mmHg. I:E ratio will be set in order to obtain an inspiratory time of 0.8-1 seconds and an inspiratory pause of 0.3 second
2462403|NCT03157167|Experimental|100 mcg/5 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
2462406|NCT03157167|Experimental|100 mcg/10 mCi Tc99m-Tilmanocept|Four subjects will receive a single IV injection of 100 micrograms of Tc99m tilmanocept radiolabeled with 10 mCi.
2462409|NCT03157167|Experimental|200 mcg/5 mCi Tc99m-Tilmanocept|Up to six subjects will receive a single subcutaneous injection and a single IV injection of 200 micrograms of Tc99m tilmanocept radiolabeled with 5 mCi.
2462499|NCT03156348|Experimental|Intervented|The intervention group will receive in addition to the usual care, it will receive the Clinical Pharmacist Care during hospitalization, discharge and during 2 months post-discharge, through a home visit at 30 ± 5 days post-discharge and a telephone call at 60 ± 5 days.
2462507|NCT03156348|No Intervention|Control|"The control group will receive hospital care and discharge from a clinical team previously trained in geriatric clinical pharmacology, which includes epicrisis, indications that the physician deems pertinent to the discharge and prescriptions if necessary and a medical control at 15 days post-discharge.~Information will be collected that allows the characterization:~Sociodemographic~Morbid~Pharmaco-therapeutic~Functionality before (baseline), during and after hospitalization~A physician, a pharmacist and an occupational therapist, blind to the treatment assignment, will collect the records using a specially designed record. Post-discharge evaluations will be conducted through telephone interviews at 30, 60 and 90 days after hospital discharge."
2462544|NCT03156140|Experimental|motion|Right hand performs three different motion types
2462577|NCT03155867|Active Comparator|Meal replacement A|
2462582|NCT03155867|Active Comparator|Meal replacement B|
2462586|NCT03155867|Active Comparator|Meal replacement C|
2462591|NCT03155867|Active Comparator|Meal replacement D|
2462593|NCT03155867|Active Comparator|Meal replacement E|
2462596|NCT03155867|Active Comparator|Meal replacement F|
2462603|NCT03155529||radical hysterectomy group|"Using dynamic MRI and 3D reconstruction to assess the effect of RH on pelvic floor muscles and pelvic organs (location and mobility of bladder neck and urethral).~Inclusion Criteria： ①Patients diagnosed as FIGO stage IA2、IB1、IIA1 cervical cancer ; ②Patients diagnosed as FIGO stage IB2、IIA2 cervical cancer, eligible for RH after neoadjuvant chemotherapy; ③Patients diagnosed as FIGO stage IIA endometrial carcinoma; ④Patients didn't have pelvic organ prolapse and urinary incontinence; ⑤Ability to hold Valsalva for dynamic MRI; ⑥Patients aged 20-70 years; ⑦Patients undergone RH surgery; ⑧Informed consent was signed.~Exclusion Criteria：~①With MRI or urodynamic examination contraindication; ②Previously undergone POP or SUI surgery; ③BMI>30 ④With serious postoperative complications."
2462658|NCT03155438||Low responder|"Low responder : women aged 25-49 years old with less than 5 oocytes (1-4 oocytes) retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
2462659|NCT03155438||Normal responder|"Normal responder women aged 25-49 years old with 5-15 oocytes retrieved during controlled ovarian hyperstimulation~Oxidative stress-related gene expression and oocyte competence biomarkers will be performed to access the difference between low and normal responders."
2462706|NCT03155048|Active Comparator|oral estradiol group|patients with the usage of 6 milligrams/day oral estradiol
2462709|NCT03155048|Active Comparator|estradiol transdermal patch group|patients with the usage of 3.9 milligrams estradiol transdermal patch
3174656|NCT00625651|Experimental|AMG 655 Low Dose|AMG 655 (low dose) + mFOLFOX6 + Bevacizumab
3174657|NCT00625651|Placebo Comparator|Placebo|Placebo + mFOLFOX6 + Bevacizumab
2462862|NCT03154008|Experimental|Active Treatment|Group cognitive behavioral therapy (CBT) for 8 weeks.
2462982|NCT03153566|Experimental|study group|include (15) patients will be injected with Tuberculin vaccine 0.3 ml every 2 weeks, vaccine will be injected in the largest wart, 4 sessions will be done then patients will be followed for 2 months
2462987|NCT03153566|Active Comparator|control group|include (15) patients will be treated with cryotherapy every 2 weeks ,4 sessions will be done then patients will be followed for 2 months
2462990|NCT03153566|Experimental|combined group|include (15) patients will be treated with combined cryotherapy and Tuberculin vaccine , one week cryotherapy and the other week Tuberculin vaccine , then patients will be followed for 2 weeks
2463032|NCT03152682|Experimental|Consume GoodIdea at Visit 2 and Placebo at Visit 3|
2463035|NCT03152682|Experimental|Consume Placebo at Visit 2 and GoodIdea at Visit 3|
2463070|NCT03152240||Women patients|Women patients
3174658|NCT00625651|Experimental|AMG 655 High Dose|AMG 655 (high dose) + mFOLFOX6 + Bevacizumab
3174659|NCT00625664|Experimental|1|
3174660|NCT00625664|Active Comparator|2|
3174661|NCT00625677|Experimental|1|"Pediacel - 2,3,4 months Prevenar - 2,4 months Menjugate - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
3174662|NCT00625677|Experimental|2|"Pediacel - 2,3,4 months Prevenar - 2,4 months Neis-vacC - 3 months Hib/ pneumo conjugate/ Men C conjugate - 12 months~Blood collected - 4,5,12,13 months"
3174663|NCT00625781|Experimental|B2|IGT randomized to treatment
3174664|NCT00625781|No Intervention|B1|"IGT randomized to no treatment"
2462376|NCT03157661||Single group study|"The study population will involve patients presenting for elective surgery, who fulfil inclusion criteria, in all surgical disciplines with elective surgical slates in the main theatre complex, during the period of the study.~Inclusion Criteria:~Patients included in the study will be:~> 18 years of age~Non-cardiac patients~Non-obstetric patients~Patients receiving general, neuraxial, regional or local/topical anaesthesia for elective surgical intervention"
2462415|NCT03157115|Experimental|HFrEF: Heart failure - reduced ejection fraction|Patients with heart failure and reduced ejection fraction (around 35%).
2462422|NCT03157115|Active Comparator|Control|Patients with a cardiac condition but a normal ejection fraction (>45%), without heart failure. The patients from the HFrEF group will be matched with patients from the control group for sex, age, BMI and cardiovascular treatment.
2462467|NCT03156816|Experimental|Colchicine|The patients will receive an oral bolus of colchicine of 2 mg followed by 0.5 mg b.i.d. during 5 days.
2462468|NCT03156816|Placebo Comparator|Control arm|The patients will receive an oral bolus of placebo of 2 mg followed by 0.5 mg b.i.d. during 5 days.
2462525|NCT03156296|Active Comparator|BUPIVACAINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
2462527|NCT03156296|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
2462590|NCT03155984||Anti-CD20 antibody|Patients with hematological malignancies receiving anti-CD20 antibody therapy
2462611|NCT03155594|Experimental|Single arm|Patients in this trial will receive a FreeStyle Libre patch that continuously measures glucose in addition to their standard glucose monitoring.
2462692|NCT03155386||Standard Angiomammography (SenoBright®)|
2462696|NCT03155386||Optimized angiomammography|
2462781|NCT03154619|Active Comparator|TR987|This group will receive twice-weekly applications of 0.1% TR 987 in a gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
2462782|NCT03154619|Placebo Comparator|Placebo|This group will receive twice-weekly applications of placebo gel base plus SoC for the first 4 weeks, then once weekly applications for the remaining 8 weeks of the trial.
2462842|NCT03154151|Experimental|Online Cognitive-Behavioral Therapy|Through guided writing, Internet-based cognitive therapy aims to help WTC responders and survivors process any traumatic experiences they lived through during their WTC recovery work and exposure.
2462843|NCT03154151|Active Comparator|Online Supportive Therapy|Through guided writing, Internet-based supportive therapy aims to help WTC responders and survivors work through any life problems they might currently be experiencing.
2462951|NCT03153007||Subjects with DFU|Adult male or female subjects, 18 years of age or over and currently receiving treatment for a diagnosis of DFU or have received treatment for a past foot ulcer within the last 6 months, will be recruited from up to three clinical sites. They will undergo concept elicitation interviews over the telephone or in-person by trained and experienced interviewers.
2463036|NCT03152877|Experimental|Liposomal bupivacaine treatment group|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the experimental arm, following completion of the surgical repair.
2463038|NCT03152877|Active Comparator|0.25% plain bupivacaine treatment group|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, in subjects in the active comparator arm, following completion of the surgical repair.
2463063|NCT03152214|Experimental|Team RWB + Vigorous Intensity Aerobic Exercise|"Participants assigned to the integrated arm will be prescribed the following for the course of 8 weeks:~1 session of exercise counseling~3 weekly 25-minute sessions of vigorous intensity aerobic exercise~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2463066|NCT03152214|Active Comparator|Team RWB|"Participants assigned to the Team RWB arm will be prescribed the following for the course of 8 weeks:~1 weekly Team RWB event~4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2463068|NCT03152214|No Intervention|Waitlist|"Participants assigned to the waitlist arm will be prescribed the following for the course of 8 weeks:~• 4 biweekly assessments~Participants will also complete an online assessment at week 9 to provide follow-up data."
2463096|NCT03152058|Experimental|Certolizumab Pegol|"All participants are administered certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter.~1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
2463136|NCT03151772|Experimental|Disulfiram|Disulfiram 200 mg twice daily and copper 2,5 mg once daily. For bioavailability purpose only, treatment is withdrawn postoperatively
2463140|NCT03151772|Experimental|Metformin|Metformin 850 mg x 3 daily. For bioavailability purpose only, treatment is withdrawn postoperatively
2463164|NCT03151564|Experimental|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
2463166|NCT03151564|Experimental|Computed tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
2463207|NCT03151291|No Intervention|Control group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
2463212|NCT03151291|Experimental|EMS group|"physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
2463215|NCT03151291|Experimental|HMB group|HMB supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)
2462398|NCT03157154||Control group|Haemophilia patient without such history or treatment matched on age and disease status (haemophilia A or B and the severity of the disease : severe, mild, minor).
2462473|NCT03156881|Experimental|Treatment group|"The participants in the treatment group (anticipating 24) will be receiving four global osteopathic treatments in a six week period alongside their standard care. Their standard care is to improve diet and increase exercise.Blood work done about every 3 months to check liver enzyme levels to observe improvements or monitor severity of the disease.~This group will also complete questionnaires evaluating their quality of life (CLDQ) and their readiness to change before and after the treatment series."
2462477|NCT03156881|No Intervention|Control Group|This group will have an anticipated 24 participants and will continue their standard care as explained above along with completing two questionnaires evaluating their quality of life and readiness to change. This group will not be receiving any osteopathic treatment.
2462491|NCT03156439|Experimental|BIS-001 ER|The subjects will be dosed twice daily (BID); in an on-site setting at dose initiation and at times of dose escalation to evaluate safety, and for specimen collection for routine laboratory and pharmacokinetic analysis. Subjects will be discharged and compliance of BID dosing will be monitored via twice daily phone calls by site staff. The initial dose will be 0.5mg BID with a dose escalation every 2-3 days until a maximum tolerated dose is observed or a maximum of 2.5mg BID dose is obtained.
2462548|NCT03156205|Experimental|Interactive Music Therapy|
2462551|NCT03156205|Other|passive music listening|
2462553|NCT03156205|Other|passive earphone-use|
2462660|NCT03155243||Participants receiving adalimumab (Humira®)|Participants with active non- infectious intermediate, posterior or panuveitis receiving adalimumab (Humira®).
2462741|NCT03154866|Experimental|Lactobacillus kefiri LKF01 DSM32079|
2462749|NCT03154866|Placebo Comparator|Placebo|
2462789|NCT03154450|Experimental|Data available to team|Encore Anywhere will be installed and available for review by the clinical team
2462792|NCT03154450|Active Comparator|No Data available to team|Encore Anywhere will be installed but the data collected will not be available to the clinical team
2462970|NCT03153046|Experimental|Prebiotics|12 week ingestion of prebiotics, Bimuno galacto-oligosaccharide (B-GOS).
2462979|NCT03153046|Placebo Comparator|Maltodextrin|12 week ingestion of maltodextrin
3174665|NCT00625794|Experimental|1|8 weeks or counseling plus 6 weeks of nicotine nasal spray
3174666|NCT00625794|Active Comparator|2|8 weeks or counseling only.
2463376|NCT03150251|Experimental|Overnight Oats|40 g of overnight oats
2463378|NCT03150251|Placebo Comparator|Soaked Cream of Rice|28.8 cream of rice
2463379|NCT03150251|Placebo Comparator|Cooked Cream of Rice|28.8 cooked cream of rice
2463510|NCT03149575|Experimental|VAL-083, Dianhydrogalactitol|Up to 120 eligible patients will be randomized to receive VAL-083.
2463515|NCT03149575|Active Comparator|Physician's Choice of Salvage Therapy|"Up to 60 patients will be randomized to receive Investigator's choice of salvage therapy temozolomide, lomustine, or carboplatin"
3174667|NCT00625833|Placebo Comparator|Placebo|
3174668|NCT00625833|Experimental|2|
2463621|NCT03148548||Patients with iliofermoral thrombosis without rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did not undergo recanalisation
2463626|NCT03148548||Patients with ilifermoral thrombosis with rekanalisation|subjects with proven iliofemoral thrombosis (V. cava-aplasia, pelvic vein thrombosis, VTE) which was proven by objective methods such as Duplex sonography, CT/MRT, phlebography and who did undergo recanalisation
2463703|NCT03148288|Experimental|Vitamin D supplementation|4000IU Vitamin D qd
2463704|NCT03148288|Placebo Comparator|placebo|
2463722|NCT03147755||Dysphagia|Patients with stroke associated dysphagia
2463729|NCT03147755||No dysphagia|Patients without stroke associated dysphagia
2463784|NCT03147521|Experimental|Accidental falls care bundle|Care Bundle Implementation Arm
2463796|NCT03147521|Active Comparator|Accidental falls standard care|Standard Care Implementation Arm (Universal strategy application for the environmental and patient)
2463875|NCT03147157|Experimental|research group,low MR group|tacrolimus regimen guided by HLA matching rate
2463878|NCT03147157|No Intervention|observation group,low MR group|tacrolimus regimen is applied according to clinical experience
2463879|NCT03147157|Experimental|research group,middle MR group|tacrolimus regimen guided by HLA matching rate
2463880|NCT03147157|No Intervention|observation group,middle MR group|tacrolimus regimen is applied according to clinical experience
2463883|NCT03147157|Experimental|research group,high MR group|tacrolimus regimen guided by HLA matching rate
2463886|NCT03147157|No Intervention|observation group,high MR group|tacrolimus regimen is applied according to clinical experience
2463934|NCT03146377|Experimental|Xeloxiri|
2463964|NCT03145974||Hypoxemic Acute Respiratory Failure|Consecutive intubated patients receiving invasive mechanical ventilation, with a PaO2/FiO2 ≤300 mmHg under a PEEP of 5 cmH2O or more, and with a FiO2 of 0.3 or more.
2464101|NCT03145584|Active Comparator|Continuous Adductor Canal Saphenous Catheter|Participants in this group were randomly allocated to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A PERINEURAL CATHETER WAS INSERTED IMMEDIATELY AFTER INJECTION OF THE INITIAL BOLUS OF LOCAL ANAESTHETIC. THE CATHETER WAS CONNECTED TO A PAJUNK FUSERPUMP CONTAINING 350 ML OF 0.15625% BUPIVACAINE AND INFUSED AT 8ML/HR.
2464146|NCT03144791||elderly , young adults|Participants are in 9 light conditions, 5 minute for each condition.
2464195|NCT03144544||Pediatric specialist hospitals|Free-standing hospitals providing tertiary pediatric referral services and performing pediatric surgical procedures
2464196|NCT03144544||Non-pediatric specialist hospitals|Other hospitals performing pediatric surgical procedures
2464246|NCT03144245|Experimental|AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels
3174669|NCT00625859|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
2462448|NCT03156959|Experimental|EMDR plus CBT-Eb|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5. In the EMDR plus CBT-Eb arm, 16 EMDR sessions will be mandatory in adjunction to the CBT-Eb sessions, irrespectively of the BMI. EMDR will use an eight-phase approach that will include having the patient recall distressing images while receiving one of several types of bilateral sensory input, such as side to side eye movements.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
2462449|NCT03156959|Active Comparator|CBT-Eb alone|"20 CBT-Eb sessions will be mandatory for patients with BMI>17.5 and 40 CBT-Eb sessions will be mandatory for patients with BMI≤17.5.~Patients will follow psychopharmacological treatment for anxiety and depression symptoms if needed, and their parents will be invited to participate to a cycle of eight family meetings on eating disorders and psychological support following ECHO approach (Rhind et al., 2014)."
3191311|NCT00797329||observation|adult men with alcohol and polydrug use according to DSM-IV criteria, hospitalized in maximum security department between 2002 - 2008
3191312|NCT00797342|Other|first of three dosing cohorts|
2462573|NCT03155906|Experimental|Integrated treatment|Patients randomised to receive integrated treatment will be counselled on treatment by physician working at MAR outpatient clinic where patient receive OST care, and will receive medication and follow-up at the same MAR outpatient clinic. Treatment medication will be given in line with national guidelines with a close and integrated follow-up.
2462574|NCT03155906|Active Comparator|Standard treatment|Those randomised to receive standard treatment will be offered referral for standard HCV treatment at a medical ward hospital clinic. Treatment medication will be given in line with national guidelines.
2462634|NCT03155607|No Intervention|Standard Care|
2462641|NCT03155607|Experimental|Virtual Reality Distraction|
2462679|NCT03155204|Experimental|Test Product 1|tiotropium pMDI 2 inhalations
2462691|NCT03155204|Experimental|Test Product 2|tiotropium pMDI 2 inhalations
2462695|NCT03155204|Experimental|Test Product 3|tiotropium pMDI 2 inhalations
2462698|NCT03155204|Experimental|Test Product 4|tiotropium pMDI 2 inhalations
2462699|NCT03155204|Active Comparator|Commercial Product|tiotropium Respimat 2 inhalations
2462740|NCT03154801|Experimental|Paramedical care|paramedical early detection of sexual dysfunction and sexual health counseling
2462807|NCT03154528||healthy control group|serum level of Vitamin D is going to be checked by ELISA in 30 healthy control volunteers
2462811|NCT03154528||case study group|serum level of Vitamin D is going to be checked by ELISA in 60 Androgenetic Alopecia patients.
3191313|NCT00797342|Other|second of three dosing cohorts|
3191314|NCT00797342|Other|third of three dosing cohorts|
2462894|NCT03153605|Experimental|SATISI_7|
2462942|NCT03153228||Smokers of traditional cigarettes|29 healthy smokers of traditional cigarettes (min. 1 packyear)
2462943|NCT03153228||Smokers of e-cigarettes|29 healthy smokers of e-cigarettes (min. 1 packyear)
2462944|NCT03153228||Control|29 healthy volunteers.
2462985|NCT03152955|Experimental|Group A|Patients in Group A will receive scalp nerve block and patient-controlled analgesia which contains sufentanil and ondansetron.
2462989|NCT03152955|Experimental|Group B|In Group B, patient-controlled analgesia which contains sufentanil、ondansetron and ketamine will be applied.
2462993|NCT03152955|Sham Comparator|Group C|In Group C, patient-controlled analgesia which contains sufentanil and ondansetron will be applied.
2463000|NCT03152565|Experimental|Avelumab in combination ADC vaccine|Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.
2463052|NCT03152305||Women with menstrual migraine|Womens presenting with regular menstrual migraine treated with triptans will be included in the study.
2463058|NCT03152305||Matched control|The potential variations will be compared to the measures done on matched healthy women outside and during menses.
3191315|NCT00797368|Experimental|Manual Therapy and Exercise|Manual Therapy and Exercise
3191316|NCT00797368|Active Comparator|Home Exercise|Home Exercise
3191317|NCT00797381||1|
2463222|NCT03151278|Experimental|Zero-fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of Ensite NavX without fluoroscopy.
2463224|NCT03151278|Active Comparator|Conventional fluoroscopy ablation|Atrial arrhythmias will be mapped and ablated under the guidance of X-ray plus any tree dimensional mapping system.
2463260|NCT03151005|Experimental|Metformin-GLP-1 Receptor Agonist|Metformin-GLP-1 Receptor Agonist Therapy: metformin 0.5 g/time by mouth, 3 times per day, with 5 ug exenatide subcutaneous injection twice per day, for 4 weeks, then change to 10ug exenatide subcutaneous injection twice per day for 8 weeks; or metformin 0.5 g/time by mouth, 3 times per day, with 0.6mg liraglutide subcutaneous injection once per day, for 1 weeks, then change to 1.2-1.8 mg liraglutide subcutaneous injection according to patient's blood glucose condition, twice per day for 8 weeks.
2463261|NCT03151005|Active Comparator|Metformin-Oral Contraceptive(OC)|Metformin-Oral Contraceptive(OC) Therapy: metformin 0.5 g/ time by mouth, 3 times per day, with Diane 35(OC) 1 piece per day by mouth, for 12 weeks.
2463305|NCT03150667|Active Comparator|Ticagrelor Arm|Eligible patients randomized to the Ticagrelor arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records.
2463391|NCT03150420|Experimental|Sodium Thiosulfate|Sodium Thiosulfate Injection (25 grams sodium thiosulfate)
2464414|NCT03143153|Active Comparator|Cisplatin + Fluorouracil|
3191318|NCT00797381||2|
3191319|NCT00797394|Experimental|Treated|
3191320|NCT00797394|Active Comparator|Control|
3191321|NCT00797420|Other|Loading Dose|Loading Dose
3191322|NCT00797420|Other|Loading & high dose|Loading dose & high dose Fluconazole
3191323|NCT00797433||Mechanical ventilation|All male patients with acute respiratory failure requiring mechanical ventilation
2462489|NCT03156491||Control group|Proven fertile women (at least 1 successful pregnancy and no more than 1 miscarriage).
3191324|NCT00797446||Photon/Proton Radiation Therapy|Data collection will be obtained from the patient's medical records including initial evaluation, pathology report, dosimetry information, radiotherapy completion records and follow-up.
2462618|NCT03155542||colorectal cancer patient case group|Histologically confirmed colorectal adenocarcinoma
2462628|NCT03155542||family member control group|without the diagnosis of CRC and accompanied the patient to the primary care clinic visit
2462666|NCT03155295||Physical reality simulation (rehearsal)|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. Participants with patients assigned to preoperative rehearsal will undergo pre-operative simulation only once.
2462683|NCT03155295||Virtual reality simulation|The DaVinci surgical skills simulator (DVSSS) uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. Participants with patients assigned to preoperative simulation will complete a refresher module on the Virtual reality simulator.
2462747|NCT03154944|Experimental|Ostomy device 1|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
2462754|NCT03154944|Experimental|Ostomy device 2|In this arm the subjects test a new ostomy device consisting of a new adhesive and a known top film
2462757|NCT03154944|Experimental|Ostomy device 3|In this arm the subjects test a new ostomy device consisting of a known adhesive and a new top film
2462786|NCT03154385|Experimental|arm 1|"Two intravenous perfusions of 1 g of Rituximab (Mabthera ®) at W0 and W2 coupled with 100 mg intravenous methylprednisone to avoid potential allergic reactions.~Five belimumab (Benlysta ®) injections will be administered (W0 + 2days, W2 + 2 days, W4, W8, W12) at 10mg/kg doses. The first two injections are administered 2 days after Rituximab perfusions. The adopted experimental scheme was once used to show use of belimumab in systemic lupus erythematosus in accordance with AMM regulation"
2462838|NCT03154125|Experimental|Abdomen|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2462839|NCT03154125|Experimental|Upper thigh|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2462841|NCT03154125|Experimental|Back of the upper arm|Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) injected subcutaneously every 4 months (17-18 weeks) for 3 treatment cycles (12 months).
2462854|NCT03153761|Experimental|CSD170201AA, CSD170201AB Use Group|Use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2462857|NCT03153761|Experimental|CSD170201AB, CSD170201AA Use Group|Use of product CSD170201AB exclusively for approximately one week (seven days +1/-2 day) prior to a test visit, followed by use of product CSD170201AA exclusively for approximately one week (seven days +1/-2 day) prior to a test visit.
2462904|NCT03153501|Other|Diagnostic arm|Patients with pleural diseases; malignant pleural diseases, tuberculous pleurisy, and other exudate required CT-guided Abrams needle biopsy, US-guided cutting needle biopsy, and medical thoracoscopy.
2462966|NCT03153176|Experimental|intervention|Training program for Physical Education teacher. Individual level: moderate to vigorous physical activity. Organizational level: school health policy for healthy lifestyle
2462974|NCT03153176|No Intervention|no intervention|Physical Education and school curriculum as usual
2463028|NCT03152669||Chronic obstructive pulmonary disease|Subjects with COPD who were randomised to treatment in the original SLS
2463029|NCT03152669||Asthma|Subjects with asthma who were randomised to treatment in the original SLS.
2463049|NCT03152357||Patients implanted with a ConforMIS device|Previously underwent surgical implantation of a ConforMIS iUni, iDuo or iTotal knee replacement
3191325|NCT00797472|Active Comparator|Arm I: R-mabHD|Anti-hodgkin disease agent
3191326|NCT00797472|Active Comparator|Arm II: ABVD|
3191327|NCT00797485|Active Comparator|Arm I|Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFIRI chemotherapy comprising irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 2 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2463234|NCT03151187|Experimental|Curriculum administered prior to OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) prior to the OSCE.
2463238|NCT03151187|Active Comparator|Curriculum administered after OSCE|Programs randomized to this arm will receive the teaching intervention (two 2 hour lectures) after the OSCE.
2463291|NCT03150862|Experimental|Arm A (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
2463293|NCT03150862|Experimental|Arm B (Dose Escalation)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
2463295|NCT03150862|Experimental|Arm A (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib and radiation therapy.
2463297|NCT03150862|Experimental|Arm B (Dose Expansion)|Participants with newly diagnosed unmethylated GBM will receive Pamiparib, radiation therapy (RT) and temozolomide (TMZ).
2463298|NCT03150862|Experimental|Arm C (Dose Escalation)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
2463301|NCT03150862|Experimental|Arm C (Dose Expansion-Cohorts C1 and C2)|Participants with recurrent/refractory methylated or unmethylated GBM will receive Pamiparib and TMZ.
2463345|NCT03150238||Post-operative Crohn Disease patients|Adult patients, with a defined diagnosis of CD, who underwent a surgery for CD in the previous 6 months
2462502|NCT03156400|Active Comparator|Healthy Control|"Men and women can be included in the study if they are between 50 and 85 years of age and meet the following criteria:~Have received clearance from a primary physician to perform a exercise stress test.~Will be able to walk on a motorized treadmill with supporting harness system. Healthy individual with no unresolved cardiovascular, neuromuscular, and/or musculoskeletal disease."
2462543|NCT03156127|Experimental|BR-UPS 5 mg tablet|
2462547|NCT03156127|Active Comparator|Inisia 5 mg tablet|
2462583|NCT03155854|Active Comparator|Pretendinous cord excision|Patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be excised
2462587|NCT03155854|Active Comparator|Division/manipulation of the cord|patients will undergo either a targeted palmar fasciectomy procedure in which the involved Dupuytren's fascia will be incised.
2462609|NCT03155581|Other|User intervention|Bilingual key women from Somalia and Pakistan trained as peer educators for their respective communities will meet the women to increase awareness regarding the importance of cervical cancer prevention and to help peers overcome detected barriers and increase attendance to screening during meetings with the women organised according to their practical needs, using videos and interactive material
2462612|NCT03155581|Other|Health professional intervention|"General practitioners working in the intervention areas are contacted by letter and an appointment is made for a short meeting to increase awareness of the health professionals involved in screening working in the chosen areas. Material is given(posters and reminding objects) to remind practitioners of the intervention and invite women attending to the center to make an appointment with their GP. No change in screening as usual will be implemented for health professionals working in the control areas."
3174670|NCT00625859|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3174671|NCT00625859|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3191328|NCT00797485|Experimental|Arm II|Patients receive bevacizumab and FOLFIRI chemotherapy (B-FOLFIRI) as in arm I. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes on day 1 and oral capecitabine once every 12 hours on days 1-14. Treatment repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2462816|NCT03154229|Active Comparator|Paper-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use paper-based decision support at the 5 hospitals designated.
2462818|NCT03154229|Active Comparator|Smartphone-based decision-support|Prior to starting the study, 10 hospitals will be made into 5 pairs. The paper versus smartphone intervention will be randomized to one member of each pair. The study arm will consist of a pre-interventional (6 weeks) followed by an interventional period (12 weeks); this arms will use smartphon-based decision support at the 5 hospitals designated.
2462866|NCT03153904|Experimental|MATCH Training plus MATCH Consultation|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists participate in weekly consultation meetings that are led by a MATCH Consultant from the study team. MATCH Consultants review sessions and the clinical monitoring and feedback system, provide recommendations for upcoming sessions, and review MATCH modules via role-plays and models.
2462874|NCT03153904|Active Comparator|MATCH Training only|Therapists at local, community clinics attend a 6-day training on the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems (MATCH; Chorpita & Weisz, 2009). After the training, therapists use MATCH as they think best and receive supervision from supervisors at the clinic.
2462961|NCT03153124|Experimental|Respiratory muscle training|- three months of intradialytic training of a physical therapy protocol with PowerBreath.
2462972|NCT03153124|No Intervention|Control|No intervention
2463141|NCT03151954|Experimental|nasal polyps|"Explore the degree of abnormal proliferation in NESCs,and analyze the relationship between the proliferation and the activation of hippo-YAP pathway,then explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence （P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.~Explore if the LPS and LPS and Th2/17 cytokines, as well as the epidermal growth factors can effect the hippo-YAP pathway of NESCs through cell culture, Western Blot and Real time PCR,and test the YAP expression and location through Immunohistochemistry.~Explore that how the hippo-YAP effect the proliferation and differentiation of NESCs through cell transfection;~Explore the regulation of hippo-YAP pathway in NESCs."
2463142|NCT03151954|Placebo Comparator|inferior turbinate|Compared with nasal polyps,explore the levels of LPS and Th2/17 cytokines in nasal polyps,and the relation between cytokines and the activation of hippo-YAP pathway through Immunohistochemistry and Immunofluorescence（P63、Ki67、YAP、LATS1/2 and MST1/2），as well as Western Blot and the Flow cytometry.
2463186|NCT03151460|Experimental|Parkinson|Patients with Parkinson's disease assuming or not Dopamine Agents
2463187|NCT03151460|No Intervention|Normal Controls|Age and education comparable healthy subjects
2463307|NCT03150784|Experimental|Motor coordination difficulties|"Type: Experimental main~EPIC club: 60min session / 2 times weekly / 7 weeks"
2463315|NCT03150784|Other|Non motor coordination difficulties|"Type: Experimental comparator~EPIC club: 60min session / 2 times weekly / 7 weeks"
2463358|NCT03150394|Experimental|Treatment of quadruple eradication therapy with GASTRUS|
2464693|NCT03141164|Experimental|Training|Computerized vision training
2462585|NCT03155893|Experimental|Panel 1: Treatment C|Participants will receive odalasvir (ODV) placebo (matching 25 milligram [mg] ODV [1*25 mg tablet]) and simeprevir (SMV) placebo (matching 150 mg SMV [2*75 mg capsules]) once daily on Day 1 and moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) as a single dose on Day 1, 2, 15 and 16 along with ODV 25 mg (1*25 mg tablet) and SMV 150 mg (2*75 mg capsule) once daily on Day 2 to 16 and AL-335 1200 mg (3*400 mg tablet) single dose on Day 15 orally under fed conditions.
2462588|NCT03155893|Placebo Comparator|Panel 2: Treatment E|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2; ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) on Days 3 to 7; and ODV placebo (matching 100 mg ODV [2*50 mg tablets] on Days 8 to 14, orally once daily under fed conditions.
2462595|NCT03155893|Experimental|Panel 2: Treatment F|Participants will receive ODV 200 mg (4*50 mg tablets) on Days 1 and 2; ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) on Days 3 to 7, and ODV 100 mg (2*50 mg tablets) on Days 8 to 14, orally once daily under fed conditions.
2462656|NCT03155464|Other|Group 1|"Order of two elements of surgical procedure: patients in group 1 will receive sympathectomy prior to bypass during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
2462657|NCT03155464|Other|Group 2|"Order of two elements of surgical procedure: Patients in group 2 will receive bypass prior to sympathectomy during the surgical procedure.~Indocyanine Green (ICG) will be used in both groups."
2462664|NCT03155087||T2DM patients|Metformin dosages ranged from 500 to 2000 mg per day
2462665|NCT03155087||healthy subjects|the healthy subjects was not intervened
2462727|NCT03155035|Experimental|Intervention|Albendazole 200 mg 2 tablets single dose
2462729|NCT03155035|Placebo Comparator|Placebo|Calcium 400 mg + vitamin D 2.5 mcg 2 tablets single dose
2462805|NCT03154515|Experimental|Ingavirin|Imidazolyl ethanamide pentandioic acid 90 mg once daily for 5 days
2462810|NCT03154515|Placebo Comparator|Placebo|Placebo capsule identical in appearance to Ingavirin capsule
2462856|NCT03153891|Experimental|Natural Environment|Participants experience a virtual reality natural environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
2462865|NCT03153891|Experimental|Built Environment|Participants experience a virtual reality built environment intervention (using VR goggles with Smartphone) for 10 minutes on two occasions, 1 week apart.
2462875|NCT03153891|No Intervention|Control|Participants do not experience a VR intervention. Instead they visit with research assistants for 10 minutes on two occasions, 1 week apart.
2462945|NCT03153436|Active Comparator|Normal S.A group|Infertile men with normal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
2462946|NCT03153436|Active Comparator|Abnormal S.A group|Infertile men with abnormal semen analysis. each sample is divided into 2 identical aliquots: one aliquot (Myo aliquot) is supplied with myoinositol, The other aliquot is left as it is (control aliquot).
2462998|NCT03152903|Experimental|VPM1002 (Recombinant BCG vaccine)|
2462999|NCT03152903|Placebo Comparator|Placebo|
2463091|NCT03152097|Placebo Comparator|Placebo|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
2463092|NCT03152097|Experimental|Commercially available Diindolylmethane|This crossover design will include 4 weeks of diindolylmethane and 4 weeks of matching placebo assignment.
3156220|NCT00338377|Experimental|Group C: Prior Treatment with BRAF Inhibitor|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
3156221|NCT00338377|Experimental|Group D: Leptomeningeal Disease|"T-cells: 5.0x109 TIL administered on Day 1 and 10x109 TIL on Day 15.~IL-2: 1.2 MIU of IL- 2 on Days 2, 4, 9, 11, 16 and 18 as tolerated. After this period, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks, patients switched to IL-2."
3156222|NCT00338377|Experimental|Group E: Chemotherapy + IL-2 plus T-Cells + Vaccine|Chemotherapy and IL-2 plus T-cells and the vaccine of dendritic cells received by vein (IV) about 4 hours after T-cells and again on Day 21 (+/- 7 days). Cyclophosphamide 60 mg/kg/d IV over 2 hours Days -7 and -6 (with Mesna) and Fludarabine 25 mg/m^2 IV daily Days -5 to -1 before T cell infusion. On Day 0, up to 1.5 x 10^11 T cells IV infusion over 30-60 minutes. Interleukin-2 12-16 hours after T cell infusion at standard dose of 720,000 IU/kg as intravenous bolus over 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26.
2463442|NCT03149796||RA patients|"designated to be treated with tocilizumab and followed in rheumatology clinics.~Laboratory blood tests will be collected and analyzed"
2463449|NCT03149796||healthy controls|control Laboratory blood tests will be collected and analyzed
2463487|NCT03149562||plasma transfusions|The critical ill neonates with plasma transfusions
2463496|NCT03149562||non-plasma transfusions|The critical ill neonates without plasma transfusions
3156223|NCT00338390|No Intervention|1|Maintain antiretroviral treatment
3156224|NCT00338390|Experimental|2|Change tenofovir to abacavir and increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
2463700|NCT03148171|No Intervention|Routine PrEP Care|Routine PrEP Care at each clinical site.
2463798|NCT03147365|Experimental|Study group A|Twenty five children who will receive physical therapy treatment which include aerobic exercises.
3156225|NCT00338390|Experimental|3|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
3156226|NCT00338429|Experimental|Treatment: FHP Sleep Program|Stratified with or without behavior Disorder Diagnosis (ADHD): 50% randomized to receive Better Days, Better Nights- sleep distance intervention
3156227|NCT00338429|No Intervention|Control: Usual Care|Stratified with/without behavior diagnosis (ADHD): 50% randomized to receive usual care for sleep disorder
3156228|NCT00338481|Active Comparator|1|
3156229|NCT00338481|Active Comparator|2|
3156230|NCT00338494|Experimental|1|
2462621|NCT03155646|Active Comparator|DEXMEDETOMIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%).
2462631|NCT03155646|Active Comparator|CLONIDINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%).
2462638|NCT03155646|Active Comparator|LEVOBUPIVACAINE|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
2462708|NCT03155126||Saline group|Patients resuscitated with saline
2462712|NCT03155126||Acetated Ringer's sodium group|Patients resuscitated with Acetated Ringer's sodium
2462736|NCT03154775|Experimental|C-CAR011|Lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene
2462797|NCT03154489|Other|Acenocoumarol|
2462799|NCT03154489|Other|control group|
2462845|NCT03154034||Severe mitral regurgitation|
2462883|NCT03153683||Acute Ischemic Stroke Patients|This is a registry. No above standard of care interventions will take place. Participants must have an acute thromboembolus within an intracranial artery in the anterior circulation (internal carotid, anterior cerebral, middle cerebral), which undergoes mechanical thrombectomy per standard of care.
2462959|NCT03153384||one both experimental and control arm|Each patient experiences two methods of blood cultures.
2463057|NCT03152370|Experimental|E7046 in combination with Long Course Chemoradiotherapy (LCRT)|Participants will receive once daily (QD) doses of E7046 (recommended Phase 2 dose [RP2D] determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. LCRT will be initiated on Day 15 and will consist of a total of 45 Grays (GY) radiation administered in 1.8 GY daily doses delivered for 5 days (Monday to Friday) every week for 5 weeks. Capecitabine (825 milligrams per meters squared [mg/m^2]) will be administered twice daily on the days of radiotherapy. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
2463060|NCT03152370|Experimental|E7046 in combination with SCRT followed by chemotherapy|Participants will receive QD doses of E7046 (RP2D determined in the Dose-Escalation part of the study) for 10 weeks, starting on Day 1, 14 days prior to initiation of the radiotherapy. Short course radiotherapy (SCRT) will be initiated on Day 15 and will consist of a total of 25 Gy radiation administered in 5 Gy daily doses for 5 days (Monday to Friday) for 1 week. Ten days after the end of radiotherapy, 3 cycles of the modified folinic acid/5-FU/oxaliplatin (mFOLFOX-6) regimen will be administered every 2 weeks for 2 consecutive days. Surgery will be performed 14 to 16 weeks from the first day of E7046 treatment.
2463138|NCT03151928||women presenting with vaginitis symptoms|"Women with vaginitis seeking routine care will be approached to have five additional swabs collected during their pelvic exam~vaginal swab for qualitative PCR using the BD Max Vaginal Panel on the automated BDMAX System~Vaginal smear for evaluation with Gram's stain and Nuget's criteria~Vaginal swab for yeast culture~Vaginal swab for Trichomonas vaginalis NAAT~Vaginal swab for discrepant analysis testing"
2463175|NCT03151525|Experimental|Azathioprine|Azathioprine 2-2.5 mg/kg/day, according to approved indication
2463176|NCT03151525|Active Comparator|Infliximab|Infliximab 5 mg/kg every 8 weeks
2463245|NCT03151161|Experimental|Experimental Group|"Chemotherapy regime: Pemetrexed (500mg/m2) + Carboplatin (AUC=5), 1 cycle every 3 weeks, maximum 4 cycles;~Intermittent regime: Icotinib 125mg, three times a day, d2-15 in each cycle; maintenance regime: icotinib 125mg, three times a day, since the last cycle until disease progression."
2463249|NCT03151161|Active Comparator|Control Group|Single drug: Icotinib 125mg, three times a day, continous until disease progression
2463312|NCT03150797|Experimental|Melatonin 3mg|Melatonin 3mg
2463322|NCT03150797|Experimental|Melatonin 6mg|Melatonin 6mg
2463328|NCT03150797|Placebo Comparator|Placebo oral capsule|Placebo
2463360|NCT03150355||open reduction and internal fixation|outcome of open reduction and internal fixation of fractures of proximal femur and acetabulum in patients aged 65 years and older
2463368|NCT03150355||Arthroplasty|outcome of arthroplasty of fractures of proximal femur and acetabulum in patients aged 65 years and older
2463375|NCT03150355||conservative management|outcome of conservative management of fractures of proximal femur and acetabulum in patients aged 65 years and older
3156231|NCT00338520||Healthy Controls (HC)|Healthy control children will be enrolled from out-patient well-baby visits.
2463460|NCT03149653|Experimental|1 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
2463461|NCT03149653|Active Comparator|2 Home Parenteral Nutrition, Cross-over|Random Cycle Sequence - Cycle 1: Clinoleic (baseline), 50g/per day, 42 days Clinoleic + Omegaven, 40g + 10g/per day, 28 days. Cycle 2: Lipoplus (baseline), 50g/per day, 42 days Lipoplus + Omegaven, 40g + 10g/per day, 28 days. Cycle 3: SMOFlipid (baseline), 50g/per day, 42 days SMOFlipid + Omegaven, 40g + 10g/per day, 28 days.
2463462|NCT03149653|No Intervention|Comparator3|Healthy Control
2463517|NCT03149393|Experimental|Qizhi Weitong Granules Group|Patients in this group will take Qizhi Weitong Granules for 8 weeks.
2463518|NCT03149393|Active Comparator|Mosapride Citrate Tablets Group|Patients in this group will take mosapride citrate tablets for 8 weeks.
2463590|NCT03149068||75 patient|Seventy five (75) CKD patients in different stages will be included in our study from Nephrology unit, Internal Medicine department, Assuit University Hospital
2463593|NCT03149068||25 healthy control|twenty five (25) age and sex matched apparently healthy individuals will be enrolled as controls
2463651|NCT03148522|Experimental|escitalopram|Eligible patients were assigned to escitalopram treatment based on investigators' clinical practice.
2463652|NCT03148522|Experimental|duloxetine|Eligible patients were assigned to duloxetine treatment based on investigators' clinical practice.
2463653|NCT03148522|Experimental|mirtazapine|Eligible patients were assigned to mirtazapine treatment based on investigators' clinical practice.
2463868|NCT03146780|Active Comparator|Digital 1|
2462636|NCT03155633|Experimental|Elliptical Group|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
2462674|NCT03155165||Group A Retroview™ colonoscope|Patients that have a polyp already seen in a previous colonoscopy and the colonoscopy is indicated for polypectomy will be submitted to a Retroview™ colonoscope
2462684|NCT03155165||Group B Retroview™ colonoscope|The rest of colonoscopies indicated will be submitted to a Retroview™ colonoscope
2462755|NCT03154918|Experimental|GLIDE|Treated with GLIDE regiment chemotherapy for 4 cycles.
2462790|NCT03154424|Placebo Comparator|Bridging (control group)|External fixation in treatment the distal radius fracture
2462794|NCT03154424|Active Comparator|Nonbridging (tested group)|External fixation in treatment the distal radius fracture improve grip strength?
2462864|NCT03153852|Experimental|Combined peeling agents|Modified Jessner's solution will be applied on the right side and glycolic acid 70% on the other side of the face.trichloroacetic acid 20% will be applied in one uniform coat to both sides
2462947|NCT03153345|Experimental|Intervention group|The intervention group participated in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks. During the same period, the intervention group also took part in bedside respiratory muscle training twice a day for 7 days a week over a 3-week period.
2462948|NCT03153345|Active Comparator|Control group|The control group participated only in a conventional stroke rehabilitation program, which consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training. This program was performed for 30 minutes twice a day 5 days a week, over for at least 3 weeks.
2463017|NCT03152851|Experimental|Pressure stimulus group by ultrasound probe|A pressure stimulus would be applied once using a device (ultrasound probe) to the anteroposterior wall of the bladder until the anterior & posterior wall meet if the measured diameters (AP x T) is 2 X 2 or more by ultrasound
2463024|NCT03152851|No Intervention|Non-pressure stimulus group|No pressure stimulus would be given
2463048|NCT03152344||COPD patients without chronic respiratory failure|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
2463051|NCT03152344||COPD patients with home oxygen therapy|"We will recruit COPD patients in stable condition (free of exacerbation of the disease for a month), 40 without chronic respiratory failure and 40 with home oxygen therapy.~The patients will be proposed to perform the following tests and to fill in questionnaires"
2463149|NCT03151746|Placebo Comparator|Placebo|Placebo pill administered 1 hour before planned surgical procedure
2463153|NCT03151746|Experimental|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
2463205|NCT03151421|Experimental|Home air quality monitoring and feedback|Home air quality monitoring and feedback
2463228|NCT03151070||Zone 1|"Zone 1 includes the following communities from Huehuentenango Distric:~San Rafael Petzal~San Sebastian Huehuetenango~San Gaspar Ixchil~Santa Bárbara~Colotenango~Aguacatán"
2463230|NCT03151070||Zone 2|"Zone 2 includes the following communities from Alta Verapaz district:~Tamahú~San Miguel Tucurú~Panzós~Senahú~Telemán"
2463233|NCT03151070||Zone 3|"Zone 3 includes the following communities from Huehuetenango district:~San Idelfonso Ixtahuacán~La Democracia~San Juan Atitán~Tectitán~Santiago Chimaltenango"
2463236|NCT03151070||Zona 4|"Zone 4 includes the following communities from Alta Verapaz district:~Lanquín~Santa María Cahabón~Chisec~Chahal~Raxruhá~Campur"
2463237|NCT03151070||Zona 5|"Zone 5 includes the following communities from Huehuetenango district:~Nenton~Jacaltenango~Todos Santos Cuchumatán~Santa Eulalia~San Mateo Ixtatán~San Juan Ixcoy"
2463239|NCT03151070||Zona 6|"Zone 6 includes the following communities from Alta Verapaz district:~Santa Cruz Verapaz~Tactic~San Pedro Carchá~San Juan Chamelco"
2463308|NCT03150849||patient group|patient with chronic lymphocytic leukemia
2463310|NCT03150849||control group|healthy control group
2463366|NCT03150459|Experimental|Simvastatin 20 mg + Rifaximin 400 mg (group 1)|Simvastatin 20 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
2463374|NCT03150459|Experimental|Simvastatin 40 mg + Rifaximin 400 mg (group 2)|Simvastatin 40 mg/day and rifaximin 400 mg/8 hours orally for 12 weeks
2463377|NCT03150459|Placebo Comparator|Placebo of Simvastatin + Placebo of Rifaximin (group 3)|Placebo simvastatin and placebo rifaximin orally for 12 weeks
3191329|NCT00797498||Xerostomia Questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
3191330|NCT00797524||DR|Diabetic Retinopathy
2463511|NCT03149406||Symptomatic patients|in the department with carotid plaque Comparing the expression of miRNAs
2463514|NCT03149406||Asymptomatic patients|in consultation with carotid plaque Comparing the expression of miRNAs
2463559|NCT03149107|Experimental|IPPI + NAC|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
2463562|NCT03149107|Experimental|PSM + NAC|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention. Double-blinded."
2463566|NCT03149107|Experimental|IPPI + Placebo|"IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater).~Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
3191331|NCT00797524||ARMD|Age-Related Macular Degeneration
2463872|NCT03146780|Active Comparator|Digital 2|
2463873|NCT03146780|Active Comparator|Digital 3|
3191332|NCT00797524||ME|Macular Edema
2462673|NCT03155100|Experimental|Carfilzomib, elotuzumab, dexamethasone|Carfilzomib 70 milligram(mg)/m2 iv (56 mg/m2 for first five patients for cycles 1-2) once weekly, on days 1, 8 and 15 (cycles 1-8), from cycle 9 on days 1 and 15 until progression or toxicity; elotuzumab 10 mg/kg iv on days 1,8,15 for cycles 1-2, on days 1and 15 from cycle 3 until progression or toxicity; dexamethasone 40 mg weekly (shared to po and iv)
2462745|NCT03154723|Experimental|Vitamin A Group|In vitamin A group, The extremely preterm infants will be given the daily dose 1500 IU/day in drop form added to their enteral feeds as soon as minimal feeding is introduced.The duration of vitamin A supplementation was 28 days.
2462803|NCT03154463|Active Comparator|TAP blocks|TAP group was received TAP block using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
2462808|NCT03154463|Active Comparator|continuous epidural infusion|Epidural group received epidural regional anesthesia in sitting position, with epidural regimen of 0.25% bupivacaine without any adjuvant
2462872|NCT03153995|Experimental|sub-periosteal soft tissue expansion|Eight patients will receive osmotic hydrogel expanders prior to bone augmentation procedures. All expanders will be placed in sub-periosteal positions using the tunnel technique.
2462876|NCT03153995|Active Comparator|periosteal releasing incision|periosteal releasing incision will be performed for Eight patients during ridge augmentation surgery .
2462910|NCT03153514|Experimental|Obinutuzumab|"Obinutuzumab i.v.~Cycle 1: in the peri-transplant and transplantation phase~Cycle 2: if active disease and/or MRD positivity on day +60, +90, +180 or +270"
2462968|NCT03153059||group 1|a large number of defecation group (≥ 2-3 times/day) - 20 subjects
2462976|NCT03153059||group 2|normal defecation group (1 time/day or 1 time/2 days) - 20 subjects
2462978|NCT03153059||group 3|a small number of defecation group (≤ 2 times/week) - 20 subjects
2463015|NCT03152734||Elderly patient|Elderly patient undergoing surgical and non-surgical intervention with the use of anesthesia provided by an anesthetist
3191333|NCT00797550|Active Comparator|Control|The Control arm of the study will receive bone autograft.
3191334|NCT00797550|Experimental|Treatment|The Treatment arm of the study will receive single level posterolateral spinal fusion between L1 to S1 levels with implantation of BRC product.
2463304|NCT03150576|Active Comparator|Control|4 cycles of: Paclitaxel 80mg/m2 Day 1, 8 & 15, every 3 weeks, Carboplatin area under the curve (AUC) 5 Day 1, every 3 weeks
2463314|NCT03150576|Experimental|Research 1|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day -2 to Day 10 every 3 weeks
2463321|NCT03150576|Experimental|Research 2|4 cycles of: Paclitaxel 80mg/m2 on Days 1, 8 & 15 every 3 weeks, Carboplatin AUC 5 Day 1, every 3 weeks, Olaparib oral 150mg twice daily, Day 3 to Day 14 every 3 weeks
2463346|NCT03150316|Experimental|Treat Regimen|CKD-581(investigational Drug) Lenalidomide Dexamethasone
2463420|NCT03150147|Experimental|Non-ischemic preservation.|Non-ischemic hypothermic perfusion (NIHP): The device, a portable heart-lung machine, is continous/intermittent perfused the heart with a new preservation solution at a temperature of 8°C.
2463428|NCT03150147|Other|Standard ischemic storage.|Ischemic cold static storage: a crystalloid solution (cardioplegia) is used to stop and preserve the heart. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
2463498|NCT03149627||Individuals from selected households|Individuals residing in selected households in Lusaka Province, Zambia.
2463522|NCT03149211|Active Comparator|Cohort 1|Subjects will receive current standard HAART treatment as the active control group.
2463523|NCT03149211|Experimental|Cohort 2|Subjects will receive UB-421 without HAART treatment by intravenous infusion at 25 mg/kg bi-weekly. After 26-week treatment period, subjects will enter 22-week follow-up period with current standard HAART treatment.
2463574|NCT03148977||Patients admitted to the burn center|Patients admitted to the Burn Service with acute burn injuries requiring at least one surgical excision and grafting operation.
2463632|NCT03148626|Experimental|MINDI mindfulness curriculum|The intervention is a seven-session mindfulness curriculum to be delivered over six months to pediatric interns.
2463634|NCT03148626|Placebo Comparator|Control|Usual education.
2463746|NCT03147898||Group 1: Toddlers|Non-intervention observational study. Toddlers will receive wP-containing combination vaccine as part of the national immunization schedule
2463749|NCT03147898||Group 2: Toddlers|Non-intervention observational study. Toddlers will receive an aP-containing combination vaccine as part of the national immunization schedule.
2463753|NCT03147898||Group 3: Preschooler|Non-intervention observational study. Preschoolers will receive a wP-containing combination vaccine as part of the national immunization schedule.
2463756|NCT03147898||Group 4: Preschooler|Non-intervention observational study. Preschoolers will receive an aP-containing combination vaccine as part of the national immunization schedule.
2463848|NCT03147196|Experimental|Arm A (raloxifene hydrochloride)|Patients receive low dose raloxifene hydrochloride PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2463851|NCT03147196|Experimental|Arm B (bicalutamide)|Patients receive low dose bicalutamide PO daily on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2463854|NCT03147196|Experimental|Arm C (raloxifene hydrochloride, bicalutamide)|Patients receive low dose raloxifene hydrochloride PO daily and low dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2463855|NCT03147196|Experimental|Arm D (raloxifene hydrochloride, bicalutamide)|Patients receive high dose raloxifene hydrochloride PO daily and high dose bicalutamide PO on days 1-30. Treatment repeats every 30 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2464695|NCT03141164|Sham Comparator|Control|Sham
3191335|NCT00797576||1/Cases|Subjects whom had cardioversion aborted due to LAA thrombus or suspicion of LAA thrombus on TEE.
3191336|NCT00797576||2/Controls|Subjects with underlying atrial fibrillation undergoing elective TEE as clinically indicated for any reason.
3191337|NCT00797589|Experimental|Ringer lactate|Crystalloid solution
3191338|NCT00797589|Experimental|HES solution (Tetraspan®)|Balanced colloid solution
2462700|NCT03155256|Experimental|Coils Group|Patients with Gastric Varices GOV II or IGV I and with active bleeding, history of previous bleeding due to GV (secondary prophylaxis) or high-risk GV according to Baveno VI consensus for primary prophylaxis will be treated using EUS-guided injection of coils
2462731|NCT03154762|Experimental|NIPPV|Patients will receive NIPPV with an S bilevel device during 4 nights, the equipment will be placed ad libitum, a 12 cmH2O inspiratory pressure and a 4 cmH2O expiratory pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after intervention.
2462735|NCT03154762|Sham Comparator|CPAP|Patients will receive a 4 cmH2O continuous positive airway pressure device during 4 nights; this is the minimum pressure necessary to avoid death space with no effect on minute ventilation. The equipment will be placed ad libitum. Pressure will be administered through a nasal mask. CRP, FEV1, exhaled fraction of nitric oxide, IL-4, IL-5, IL-13, IL-17, IgE, cell count will be measured before and after sham intervention.
2462913|NCT03153618|Experimental|VALIDATE subjects|Will be invited to interact with VALIDATE to determine if they meet referral indications for cancer predisposition assessment.
2462918|NCT03153618|No Intervention|Control|Current standard of care will be followed
2462977|NCT03153215|Active Comparator|Intervention group|women with severe IUGR
2462981|NCT03153215|Active Comparator|Control group|women with severe IUGR
2463001|NCT03152721|Placebo Comparator|Control|Treating physician will in advance of upcoming visit be provided with the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
2463003|NCT03152721|Experimental|Intervention|Treating physician will in advance of upcoming visit be provided with a Parkinson KinetiGraph recording report and interpretation in addition to the self assessment scales PDQ8 and NMS-Questionnaire to aid clinical assessment
2463056|NCT03152292||Group 1: Parkinson Disease Psychosis (PDP) patients|PDP patients not treated with an antipsychotic at the time of enrollment
2463061|NCT03152292||Group 2: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with an antipsychotic (other than NUPLAZID®) at the time of enrollment
2463065|NCT03152292||Group 3: Parkinson Disease Psychosis (PDP) patients|PDP patients treated with NUPLAZID® at the time of enrollment
2463151|NCT03151720|Experimental|Cohort 1: Sequence 1 (ABAB)|Participants will receive 10 milligram (mg) loratadine (1*10 mg oral tablet) as Xisimin (Treatment A) on Day 1 of Period 1 and Period 3 and 10 mg loratadine (1*10 mg oral tablet) administered as Clarityne (Treatment B) on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2463155|NCT03151720|Experimental|Cohort 1: Sequence 2 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fasted condition. A washout period of at least 7 days will be maintained between each treatment administration.
2463156|NCT03151720|Experimental|Cohort 2: Sequence 1 (ABAB)|Participants will receive Treatment A on Day 1 of Period 1 and Period 3 and Treatment B on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2463157|NCT03151720|Experimental|Cohort 2: Sequence 1 (BABA)|Participants will receive Treatment B on Day 1 of Period 1 and Period 3 and Treatment A on Day 1 of Period 2 and Period 4 under fed condition. A washout period of at least 7 days will be maintained between each treatment administration.
2463185|NCT03151356||Patients|Patients addressed for prostate biopsies because of clinical and/or biological suspicion of prostate cancer.
3191339|NCT00797602||Proton Radiation|
3191340|NCT00797615|Placebo Comparator|Alternative Intervention|12-week alternate intervention program focused on building self-esteem and social self-efficacy
3191341|NCT00797615|Active Comparator|Active Intervention|12-week intervention program focused on dietary intake and physical activity
2463388|NCT03150264|Experimental|PCV-VG+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation volume-guaranteed mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
2463394|NCT03150264|Active Comparator|PCV+PEEP5cmH₂O|Patients in this group are ventilated with pressure-controlled ventilation mode. And we use PEEP of 5cmH₂O to open the collapsed alveoli.
2463410|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 40mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 40 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
3191342|NCT00797628|Experimental|Information Prescription|"Providers will give usual care to patients who smoke and a paper prescription with the name and url of the Smoking Coach website. The smoking coach website is a tailored, public health intervention for smoking cessation."
3191343|NCT00797628|Experimental|QUIT-PRIMO|Providers will give usual care to patients who smoke and then refer patients to the online smoking cessation system electronically.
3191344|NCT00797641||1|Patients admitted to the hospital, or inpatients admitted for another reason, presenting with overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical or laboratory evidence of acute blood loss from the upper gastrointestinal tract
3191345|NCT00797654|Experimental|1|Participants will receive pre and post HIV-test counseling and an information-motivation-behavior skills training combined with cognitive processing therapy
3191346|NCT00797654|Active Comparator|2|Participants will receive pre and post HIV-test counseling
3191347|NCT00797680|Experimental|72 hours hypothermia|72 hours hypothermia
3191348|NCT00797680|Experimental|24 hours hypothermia|24 hours hypothermia
3191349|NCT00797693|Experimental|Vaginal Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
3191350|NCT00797693|Experimental|Oral Misoprostol|A drug is given vaginally and to compare this with an oral administration of the same drug to find it is effect on it is effect on the cervix
3191351|NCT00797706|Placebo Comparator|Vehicle|
3191352|NCT00797706|Experimental|Low dose|
3191353|NCT00797706|Experimental|High dose|
3191354|NCT00797719|Experimental|All|This is a single arm study. All patients enrolled will be in this arm.
2462703|NCT03155217||patients less than 65 years|patients less than 65 years with MM treated with single or dual therapy
2462750|NCT03154905||Control|Healthy controls
2462756|NCT03154905||Study group|Patient diagnosed with any disorder of the digestive system (including the alimentary tract, hepatobiliary tree, pancreas, insulin resistance or diabetes, obesity or malnutrition)
2462812|NCT03154541|Experimental|Non Cystic Fibrosis (CF) cohort|"The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. No prescription is necessary. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline."
2462814|NCT03154541|Experimental|Cystic Fibrosis (CF) cohort|The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
2462905|NCT03153267|Active Comparator|EM-7 days doxycycline|
2462911|NCT03153267|Active Comparator|EM-14 days doxycycline|
2462919|NCT03153267|Placebo Comparator|Controls|
2462986|NCT03153111|Active Comparator|Macitentan|Subjects randomized to the macitentan arm receives one tablet of macitentan 10 mg every day for at least 24 to maximum 52 weeks.
2462991|NCT03153111|Placebo Comparator|Placebo|Subjects randomized to the placebo arm received one tablet of placebo every day for at least 24 to maximum 52 weeks.
2463110|NCT03152071|Experimental|Robot assisted thoracic surgery|RATS
2463111|NCT03152071|Active Comparator|Video assisted thoracic surgery|VATS
2463158|NCT03151681|Experimental|Propranolol pill + mismatch memory reactivation|Prediction-error will be incorporated into each treatment sessions.
2463160|NCT03151681|Experimental|Propranolol pill + standard memory reactivation|
2463162|NCT03151681|No Intervention|Waitlist|
2463208|NCT03151304|Experimental|Stage 1a and 1b open-label pracinostat plus azacitidine|"open-label single arm pracinostat plus azacitidine. Pracinostat: 45 mg administered orally 3 days each week for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.~In later cycles (i.e., after Cycle 4), pracinostat dose reduction to 45 mg orally 3 days each week × 2 weeks (instead of 3 weeks) or dose interruption is allowed to manage toxicity such as fatigue, gastrointestinal toxicity, or myelosuppression.~Azacitine: 75 mg/m2 for 7 days of each 28-day cycle. Administration will occur by subcutaneous (SC) injection, or IV infusion if SC injections are not tolerated, on one of two schedules:~Schedule 1 - daily therapy on Days 1 through 7~Schedule 2 - 5-2-2 schedule in which subjects receive azacitidine for 5 consecutive days (Days 1 through 5) with rest on Days 6 and 7, and resume azacitidine dosing the first two days of the next week (Days 8 and 9) of each 28-day cycle"
2463268|NCT03150940||Duke University Athletes|"Division 1 Athletes, participating in obligatory screening prior to athletic competition every summer. The investigators are observing required study outcomes (ECGs, history and physicals, and ultrasounds) to see what is useful in the screening.~ECG: 12 lead electrocardiogram that visualizes cardiac activity~history and physical: background information about athlete's and their family history~ultrasound: bedside cardiac ultrasound to visualize 2D imaging of structural cardiac function"
2463285|NCT03150680||SYNTAX score = 0|Patients with nonobstructive CAD (≤50 % diameter stenosis)
2463287|NCT03150680||0 < SYNTAX score <23|Low SYNTAX group
2463289|NCT03150680||SYNTAX score >= 23|Intermediate-High SYNTAX group
2463361|NCT03150472|Experimental|Ivory Dentin Graft (Ivory Graft Ltd.)|"Ivory Dentin Graft is a bone graft material for the repair or augmentation of bone defects in dental procedures. It consists of sterile 300 - 1200 μm porous particles or granules of hydroxyapatite which retain the natural form of the source porcine dentin and also the natural protein matrix which consists largely of porcine collagen.~This type of Graft Matrix will be administered as the intervention."
2463371|NCT03150472|Active Comparator|OsteoBiol Gen-Os ® (Tecnoss)|"A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures (matrix and porous form) and presents a highly osteoconductive properties.~It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.~This type of Graft Matrix will be administered as the intervention."
2463601|NCT03148808|Experimental|NVS Therapy|NVS Therapy will be delivered to de novo lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA) during PTA in patients with symptomatic peripheral artery disease.
2463644|NCT03148431|Experimental|LY3002815|Escalating doses of LY3002815 administered intravenously (IV) once in healthy participants
2463649|NCT03148431|Placebo Comparator|Placebo|Placebo administered IV once in healthy participants
2463668|NCT03148119|Experimental|Topical QRH Heptapeptide Administration|
2463713|NCT03147976|Experimental|AMG 337|AMG 337 in subjects with advanced or metastatic solid tumors that overexpress MET or harbor METex14del mutations
2463718|NCT03147664||Pediatric Pompe patients|"Visit 1: Patients arrived at that hospital at 7:00 am, vital signs were collected and a complete neuromuscular evaluation was carried out (gross motor function measure score sheet (GMFM-88), 6MWT, pre-CPET questionnaire (demographics, physical activity level, risk assessment, asthma/atopy/smoking history, family history), pulmonary function tests and CPET. Following the evaluation, at approximately 9 am, the patient started infusion of ERT.~Visit 2: Two days following visit 1, the patient arrived at the hospital at 2:00 pm, vital signs were assessed and GMFM-88, 6MWT, pulmonary function tests, and CPET were performed."
2463772|NCT03147573|Experimental|Blood pressure monitoring|
2463832|NCT03147014|Other|Maternal Hyperoxygenation|Maternal hyperoxygenation will be offered by administering 10 liters nasal cannula by face-mask (approximately 60% fiO2) for a minimum of 10 minutes.
2463866|NCT03146780|Placebo Comparator|Conventional|
2462738|NCT03154970|Experimental|Obstructive sleep apnea group (G OSA)|The cervical stabilization will be performed with craniocervical flexion training aiming to strength the deep cervical flexors. For this purpose a pressure biofeedback device (stabilizer) that allows progressive levels of pressure during exercise(22-30 mmHg) will be used, which will be increased according to the capacity of the individuals (avoiding compensations or pain). The participant will be instructed to perform the craniocervical flexion in the supine position, the duration of the contraction will be 10 seconds followed by 10 seconds of rest (3 sets of 10 repetitions). The sessions will be held 2 times in weeks, for 6 weeks.
2462742|NCT03154970|No Intervention|Control group (GC)|The GC will be reassessed after six weeks and the same G OSA treatment will be offered after this period.
3191355|NCT00797745|Active Comparator|Standard of Care|"PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily for 48 weeks.~Subjects with >= 1 log decrease from baseline in HCV-RNA levels after 12 weeks, but still above the lower limit of quantitation, have the option of crossing over to PegIntron, ribavirin plus SCH 900518 400 mg and ritonavir 100 mg daily for 12 weeks. This is followed by standard of care, PegIntron and ribavirin, for a total treatment duration of up to 48 weeks."
3191356|NCT00797745|Experimental|2|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
2462847|NCT03153839|Experimental|Study group|74 infants who will practice with their parents a programme of aquatic physical activity in a swimming pool for one year. They will be evaluated before and after the programme.
2462849|NCT03153839|No Intervention|Control group|71 infants who will not practice the programme. They only will be evaluated.
2462885|NCT03153657|Experimental|Piroxicam-beta-Cyclodextrin|Intervention: Drug Piroxicam-beta-Cyclodextrin
2462889|NCT03153657|Placebo Comparator|Placebo|Intervention: Drug Placebo
2462937|NCT03153280|Experimental|Lithium, Oxaliplatin & Capecitabine|Target serum concentrations of escalating doses of lithium (0.6, 0.9, 1.26 or 1.4 mmol/L) in combination standard chemotherapy - oxaliplatin and capecitabine.
2462954|NCT03152981|Active Comparator|Desflurane group|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure
2462958|NCT03152981|Active Comparator|Propofol group|In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
2463073|NCT03152500|Experimental|FEMTIS IOL|The FEMTIS-IOL has a special haptic system that allows the lens to clamp into the capsulorrhexis.
2463074|NCT03152500|Active Comparator|Acrysof IOL|The Acrysof IOL has a flexible haptic design that keeps the IOL stable and centered in the capsular bag
2463159|NCT03151707|Experimental|Nicotinamide riboside 2g/day|
2463211|NCT03151369|Other|Morphine|patients with the visual analog scale over 3 will receive morphine
3156232|NCT00338520||Uncomplicated Malaria (UM)|Febrile children admitted to the hospital with Plasmodium falciparum parasitemia, no other cause of fever identified, no evidence of severe malaria (as listed in Study Protocol, Section 5.2 under exclusion criteria for UM), and no co-infection with other malaria species will be enrolled in the UM group.
2463309|NCT03150745|Other|Colposcopic group|
2463316|NCT03150745|Other|office hysteroscopic group|
2463404|NCT03150173|Experimental|O-BMT (onsite treatment)|Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment
2463405|NCT03150173|Active Comparator|Enhanced Referral|In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment
2463445|NCT03149809|Active Comparator|Behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
2463450|NCT03149809|Active Comparator|Drug Therapy|Daily solifenacin drug therapy
2463471|NCT03149471||Normal endothelial function|patients diagnosed with PE and have normal endothelial function test- RHI score >=1.67
2463477|NCT03149471||Endothelial dysfunction group|patients diagnosed with PE and have endothelial function- RHI<1.67
2463527|NCT03149315|Experimental|Open Label Administration|Allergic subjects will be given ibrutinib 420mg daily for 2-7 doses to determine the shortest amount of time and fewest ibrutinib doses required to suppress food skin prick testing and basophil activation test reactivity.
2463553|NCT03148951||Group 1|Group 1: patients receiving general anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2463554|NCT03148951||Group 2|Group 2: patients receiving general anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2463556|NCT03148951||Group 3|Group 3: patients receiving regional (spinal) anesthesia and having a postoperative pain VAS score equal to or below 50 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2463561|NCT03148951||Group 4|Group 4: patients receiving spinal anesthesia and having a postoperative pain VAS score equal to or above 60 at 1st, 6th, 12th nd 24th hours the pain sores will be evaluated at 4 time intervals and so the number of patients in every group may change at every time interval.
2463607|NCT03148717|Active Comparator|Preoperative|"Group no.1 will receive preoperative rectal 400 microgram of misoprostol (Sigma) 2 tablets and postoperative rectal placebo2 tablets."
2463608|NCT03148717|Active Comparator|Postoperative|"Group no.2 will receive preoperative rectal placebo 2 tablets and postoperative rectal 400 microgram of misoprostol (Sigma)  2 tablets ."
2463635|NCT03148340||VIPS monitoring group|The study population will consist of adult patients presenting for evaluation of acute brain pathology,
2463690|NCT03148145|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
2463960|NCT03146247|Other|One arm|all patients receive same dose and dosing regimen with Apremilast
2462887|NCT03153696|Experimental|Cellie Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention immediately following the completion of the T1 measures.
2462890|NCT03153696|Other|Cellie Wait-list Control|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support. In this condition, children and parents will be introduced to the Cellie Intervention via phone and mail following the completion of the T3 measures.
2462899|NCT03153332||MDCT group|The MDCT images of seven hepatic tumors were loaded on software to uniform study conditions, allowing both axial and coronal scans visualization.
2462902|NCT03153332||3D visualization system group|The 3D virtual reconstructions of seven hepatic tumors were loaded on the visualization software which enables the rotation of the virtual model.
2462906|NCT03153332||3D printing group|3D-printed models of seven hepatic tumors were created based on MDCT images, participants were allowed to freely handle them.
2462962|NCT03153163|Experimental|Trastuzumab Emtansine|Participants with HER2-positive LA/MBC who received prior trastuzumab and taxane therapy will receive trastuzumab emtansine.
2463010|NCT03152799|Experimental|Remote Ischaemic Pre-Conditioning (RIPC) Intervention|Remote Ischaemic Pre-Conditioning intervention to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
2463016|NCT03152799|Sham Comparator|Sham Control|Sham Control to be applied via peripheral blood pressure cuff inflation/deflations to upper lower limb contra-lateral to affected side of hemiparesis
2463050|NCT03152331|Experimental|Receptive Awareness Training|
2463102|NCT03152149|Active Comparator|1. Spiolto Respimat|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
2463104|NCT03152149|Active Comparator|2. Relvar Ellipta|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
2463146|NCT03151733|Experimental|single incision laparoscopic surgery|patients with colorectal cancer and undergo single incision laparoscopic surgery
2463150|NCT03151733|Placebo Comparator|Conventional laparoscopic surgery|patients with colorectal cancer and undergo conventional laparoscopic surgery
2463274|NCT03150927|Experimental|Probiotic Microbial Composite|Probiotic Microbial Composite is a safe, 100% natural material containing all Generally Recognized as Safe (GRAS) Probiotics, combined with FDA approved food grade excipient materials. The probiotics contained within are also all 100% natural and non-Genetically Modified Organisms (non-GMO).
2463275|NCT03150927|Placebo Comparator|Placebo|Placebo is a mixture of inactive ingredients found in Probiotic Microbial Composite. These ingredients are FDA approved food grade materials, 100% natural and palatable.
2463306|NCT03150615|Experimental|Early enteral nutrition|Nasojejunal tube insertion was done intraopratively. Early enteral nutrition with standard enteral formulas administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2463317|NCT03150615|Placebo Comparator|Saline Group|Nasojejunal tube insertion was done intraopratively. Saline was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2463324|NCT03150615|Other|ERAS Group|Nasojejunal tube insertion was done intraopratively. None was administered through the nasojejunal tube. Oral intake was encouraged as long as the patient can tolerate.
2463350|NCT03150329|Experimental|Treatment (vorinostat, pembrolizumab)|Patients receive vorinostat PO BID on days 1-5 and 8-12 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for 24 months in the absence of disease progression or unacceptable toxicity.
2463406|NCT03149952|Other|Patient hospitalized for allogeneic haematopoietic stem cells|
2463444|NCT03149770|Experimental|1|Naloxone, intranasal 4mg
2463448|NCT03149770|Placebo Comparator|2|Placebo
2463489|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Escalation|Dose escalation and determination
2463495|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Determination|Additional enrollment into previously cleared monotherapy dose levels
2463500|NCT03149549|Experimental|CX-2009 Monotherapy: 21-Day Dosing Regimen-Expansion|Dose expansion
2463503|NCT03149549|Experimental|CX-2009 Monotherapy: 14-Day Dosing Regimen-Expansion|Dose escalation and determination in selected tumor types
2463540|NCT03148990|Experimental|Measles and Rubella vaccine|Biological/Vaccine: Administration of the experimental vaccine (Measles and Rubella).
2463541|NCT03148990|Active Comparator|Measles, Mumps and Rubella vaccine|Biological/Vaccine: Administration of the comparator vaccine (Measles, Mumps and Rubella).
2463589|NCT03148847||Baseline care|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
2463592|NCT03148847||Referential's dissemination|Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
2464014|NCT03146091|Experimental|Outpatient nonantibiotic treatment|
3156233|NCT00338520||Cerebral Malaria (CM)|Comatose children admitted to the hospitals will be evaluated by the house physician and/or member of the study team. If lumbar puncture is obtained, the parent or guardian will be approached for permission to enroll the child into the study. Parasitemic children with no other cause of coma identified will included in the CM group.
2462949|NCT03152942|Experimental|Progesterone alone|Progesterone 400 mg once daily until 34 weeks.
2462950|NCT03152942|Active Comparator|Progesterone and aminophylline.|Progesterone 400 mg and aminophylline 225 mg once daily until 34 weeks.
2463064|NCT03152448||Early Stage Prostate Cancer|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer
2463137|NCT03151967|Active Comparator|applicator containing active drug|Vaginal applicator containing Lactobacillus crispatus CTV-05
2463139|NCT03151967|Placebo Comparator|placebo vaginal applicator|Inactive vaginal applicator without any drug
2463173|NCT03151499|Experimental|All Subjects|Reference Treatment (BI 409306) given alone followed by Test Treatment (BI 409306 + Rifampicin)
2463231|NCT03151200|Active Comparator|binocular treatment|Active treatment group will receive five days of one hour visual binocular training by playing a specifically designed falling blocks video game on a computer screen that will be individually calibrated for each person with red-green glasses with treatment effect.
2463235|NCT03151200|Sham Comparator|sham treatment|Sham treatment group will receive five days of one hour sham visual binocular training by playing a specially designed falling blocks video game on a computer screen with polarized glasses with no treatment effect.
3191357|NCT00797745|Experimental|3|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3191358|NCT00797745|Experimental|4|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 200 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
2463386|NCT03150225|Experimental|Exercise group + supplementation|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily."
2463390|NCT03150225|Active Comparator|Control group + supplementation|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive supplementation of Eurycoma longifolia in 200mg capsules with standardized extract in aqueous-soluble extract and should be taken daily.
2463392|NCT03150225|Experimental|Exercise group + placebo|"It will be composed of participants randomly assigned to this group, reinforcing the importance of attendance in classes (minimum of 75% of frequency) for significant health benefits. The evaluation measures will be made through a self-administered questionnaire and physical evaluations (cardiorespiratory fitness, body mass index, percentage of fat, waist circumference and muscular strength). The intervention with the concurrent training will be carried out in a gymnasium in Florianópolis, Santa Catarina. After all the evaluation procedures have been performed, the intervention period will begin, being three times a week, lasting 60 minutes, according to the study protocol.~In addition participants will receive starch capsules to be taken daily."
2463396|NCT03150225|No Intervention|Control group + placebo|Will be reinforced to the participants of this group the importance of maintaining their daily activities. In addition participants will receive starch capsules to be taken daily.
2463416|NCT03149861|Experimental|No focal biopsy needed|Patients in which PET/MR have found no focal findings, will undergo a systemic biopsy as per standard of care, without specific cores for study purposes (Systemic TRUS guided biopsy)
2463425|NCT03149861|Experimental|Focal biopsy|Patients with a suspicious focal finding on PET/MR, will undergo systemic+focal or focal fusion biopsy (PET/MR-ultrasound guided Fusion biopsy)
2463509|NCT03149640|Experimental|Inhaled amikacin|Inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
2463513|NCT03149640|Placebo Comparator|Placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
2463579|NCT03148925|Experimental|SELA-070|
2463585|NCT03148925|Placebo Comparator|Saline|
2463616|NCT03148561|Other|Misoprostol group|The women received misoprostol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical, Egypt) once dose placed in the posterior vaginal fornix
2463618|NCT03148561|No Intervention|Expectant group|Women did not receive any medication.
2463667|NCT03148366|Experimental|Levofloxacin based sequential therapy|"Levofloxacin based sequential therapy~: sequential therapy containing levofloxacin for 14 days D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days"
2463670|NCT03148366|Active Comparator|bismuth quadruple therapy (BQ)|bismuth quadruple therapy for 10 days (BQ) D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
2463709|NCT03147924|Experimental|Attending Improvisation Group|Attended 3 or more Improvisation Group sessions
2463809|NCT03147235|Experimental|vitrectomy with music listening|Patients undergoing vitrectomy surgery will listen to a designed playlist of music during the entire duration of surgery
2464015|NCT03146091|Active Comparator|Outpatient antibiotic treatment|
2462912|NCT03153540|Active Comparator|Active iTBS|"Device: MagPro X100 stimulator equipped with the B65 fluid-cooled coil for dominant Inferior Frontal Gyrus (IFG) stimulation (MagPro, Medtronic).~Intervention: 10 sessions daily of iTBS over 2 weeks. Active-iTBS consists of intermittent Theta Burst Stimulation to the dominant IFG (120% of resting motor threshold, bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total over 3 min)."
2462915|NCT03153540|Sham Comparator|Sham iTBS|"Device: MagPro X100 stimulator applied to dominant inferior frontal lobe.~Intervention: 10 sessions daily of sham iTBS over 2 weeks. Sham sessions involve a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered."
2462969|NCT03153085|Experimental|TBI-1401(HF10) + Ipilimumab|1x10^7 TCID50/mL TBI-1401(HF10) administered to a single or multiple eligible tumors in a total volume up to 5.0 mL (injection volume will be adjusted based on the size of tumor mass) by intratumoral injection and 3 mg/kg ipilimumab administered by intravenous infusions.
2463012|NCT03152578|Active Comparator|BetaC + Capsacian|1-3 mls BetaC + Capsacian applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2463018|NCT03152578|Active Comparator|BetaC Only|1-3 mls BetaC applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2463022|NCT03152578|Placebo Comparator|Placebo|1-3 mls Placebo applied to the painful areas, once upon awakening, once mid day and once before bed-time, each day for two (2) weeks.
2463087|NCT03152318|Experimental|Arm A- rQNestin|"Arm A is rQNestin34.5v.2 treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
2463088|NCT03152318|Experimental|Arm B- rQNestin+CPA|"Arm B is rQNestin34.5v.2 treatment with Cyclophosphamide (CPA) pre-treatment This study follows a standard 3+3 dose escalation design. Participants will not enroll to Arm B until the MTD or HTD has been met for Arm A.~Cyclophosphamide one intravenous injection 2 days prior to procedure.~Subjects with presumed radiologic evidence of recurrent malignant glioma will undergo stereotactic biopsy under monitored general or local anesthesia. Evidence of recurrent high grade or malignant must be found on frozen section for the person to receive administration of the agent.~rQNestin34.5v.2 Indicated dose as per cohort, Intratumor administration during surgery, single dose"
2463122|NCT03151785|Active Comparator|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
2463130|NCT03151785|Active Comparator|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
2463135|NCT03151785|Active Comparator|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
2463174|NCT03151538|Experimental|Pes Planus Group|This group of patients received children with pes planus. It will be applied exercise training mixed with play
2463177|NCT03151538|Other|Controlled Group|This group of patients received healthy children.
2463227|NCT03151174|Experimental|Vitamin D - 10000IU|These individuals have been categorized as Vitamin D deficient and will receive 10000IU of Vitamin D per day.
2463229|NCT03151174|Experimental|Vitamin D - 5000IU|These individuals have been categorized as Vitamin D insufficient and will receive 5000IU of Vitamin D per day.
2463232|NCT03151174|No Intervention|Placebo|These individuals have been categorized as Vitamin D sufficient and will receive placebo.
2463276|NCT03150901||diabetic patients|"In a prospective study, we will collect wound edge tissue specimens from 75 patients with DF during surgical debridement. From each patient, 1-4 specimens will be obtained per debridement. To evaluate debrided tissue, each specimen will be processed for paraffin embedding and stained with haematoxylin and eosin. Histopathology analysis of multiple specimens acquired from the same wound will be analysed. Full-thickness epidermis biopsies will be followed by biomarker assessment such as:~Expression of insulin-like growth factor 1 receptor (IGF-1R)~Adiponectin~Leptin~Resistin~Osteocalcin~Osteoprotegerin~Insulin, c-peptid~HOMA-IR"
2463282|NCT03150602|Experimental|Pralatrexate treatment|Pralatrexate will initially be administered at a dose of 30 mg/m2/week on days 1, 8, 15, 22, 29 and 36 for 6 weeks in a 7-week cycle (cycle: 6 weeks + 1 week rest). The scheduled date can be done within a window time of plus or minus 1 day
2463362|NCT03150550|Experimental|Relapse Prevention|Each patient will perform 12 classic psychotherapeutic sessions over a period of 6 weeks.
2463373|NCT03150550|Experimental|Mindfulness Practice|Each patient will perform 12 mindfulness psychotherapeutic sessions over a period of 6 weeks.
2463426|NCT03150030||Patients with type 2 diabetes|Insulin-treated type 2 diabetes with diabetic complications
2463434|NCT03150030||Healthy controls|Healthy control subjects
2463481|NCT03149601||Healthy Weight|Participants with BMI < 95th percentile
2463488|NCT03149601||Obese|Participants with BMI > or = 95th percentile
3191359|NCT00797745|Experimental|5|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 400 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
2463671|NCT03148197||Admitted for allogeneic HSCT|Patients admitted for performance of an allogeneic HSCT after high dosis chemotherapy.
2463673|NCT03148197||First diagnosis AML|Patients admitted with a first diagnosis of an acute myeloid leukemia for chemotherapy. Depending on factors like age or molecular risk profile some of these patients will proceed to allogeneic HSCT.
2463706|NCT03147950|Active Comparator|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
2463708|NCT03147950|Active Comparator|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
2463758|NCT03147677|Experimental|Alfacalcidol and Irbesartan|The subjects in this group orally take Alfacalcidol Soft Capsules at 0.25ug/day and Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2462922|NCT03153592|Active Comparator|conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O.
2462926|NCT03153592|Experimental|transpulmonary pressure strategy|13 patients will undergo volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, and with a inspiratory transpulmonary pressure less than 20 cmH2O and an expiratory transpulmonary pressure and inspired oxygen set accordingly to predefined criteria.
2462963|NCT03153098||Standard delivery|Participants will receive a behaviour change technique booklet, consultations (baseline, and optional at 3, 6, and 12 months), a booster phone call (week 2), motivational text messages (weeks 3, 6, and 12), and signposting to 12 weeks of exercise classes.
2462971|NCT03153098||Enhanced delivery|Participants will receive the same as intervention but the 12 weeks of exercise will be free and tailored to their needs, and there will be optional exercise 'buddies' available.
2463033|NCT03152695|Experimental|High-intensity focused ultrasound therapy|Abdominal MRI will be used to target the tumor, and the tumor will be divided into slices with 5mm separation using MR images. By scanning the HIFU beam in successive sweeps from the deep to the shallow regions of the tumor.
2463097|NCT03152253|Experimental|Text Message for Smoking Cessation|smoking cessation promotion messages and medication reminders sent via text messages for up to 30 days before quit day and 8 weeks following quit day, along with access to a social support chat room
2463098|NCT03152253|Placebo Comparator|Non-Interventional Text Messages|General motivational text messages sent on the same schedule at TMQ arm of the study with access to a social support chat room.
2463116|NCT03151759||No radiotherapy|Surgery only
2463120|NCT03151759||25 Gray radiotherapy|Surgery after short term radiotherapy
2463126|NCT03151759||50 Gray radiotherapy|Surgery after long term radiotherapy
2463198|NCT03151603|Experimental|Uva Ursi|"placebo to fosfomycin: 3 g granules orally 1x1 (day 0)~and~Uva Ursi: 105 mg (Arctuvan®) 3x2 tablets orally from day 0 for 5 days"
2463203|NCT03151603|Active Comparator|fosfomycin|"fosfomycin (Monuril®): 3 g granules orally 1x1 (day 0),~and~placebo to Uva Ursi: 3x2 tablets orally from day 0 for 5 days~If the patient returns with persistent/recurrent symptoms, antibiotic therapy according to the sensitivity test."
2463296|NCT03150732|Active Comparator|Systemic nalbuphine group|53 patients will receive nalbuphine systemically
2463299|NCT03150732|Active Comparator|Local nalbuphine group|53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
2463351|NCT03150498|Experimental|BTD-001 (fed)|
2463354|NCT03150498|Experimental|BTD-001 (fasted)|
3191360|NCT00797745|Experimental|6|PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily plus SCH 900518 100 mg twice daily plus ritonavir 100 mg twice daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 12 or 36 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
2463549|NCT03149120|Experimental|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
2463552|NCT03149120|Experimental|Nivolumab with Pazopanib|Pazopanib at a dose of 800mg by mouth daily.
2463602|NCT03148730|No Intervention|manual group|This group will have a standard of care anesthesia. All the drugs, fluid and adjustement of ventilation settings will be done manually by the supervising anesthesiologist using the same drugs and fluids as the closed-loop group
2463603|NCT03148730|Experimental|automated closed-loop group|This group will have a fully automated anesthesia, analgesia , ventilation and fluid management using 3 indenpendent closed-loop systems same drugs used in both groups ( propofol and remifentanil, Plasmalyte and /or Voluven)
3156234|NCT00338520||Non-malaria CNS disease (NMC)|Children without parasitemia and diagnosed with a non-malaria cause of coma or CNS disease will be enrolled in the non-malaria CNS disease group.
2463813|NCT03147222|Experimental|Fracture Care at Home|A trained FFC coach will visit each caregiver and fracture participant in the home for a 1-2 hour session once a week for 8 weeks.
2463850|NCT03146923|Active Comparator|Standard Care Arm|Patients randomised to the standard care arm will be re educated using the current low phosphorus diet prescription.
2463853|NCT03146923|Experimental|Modified Intervention Arm|Patients randomised to the intervention arm will be educated using a modified low phosphorus diet prescription.
2463897|NCT03146624|Experimental|attachment|attachment retained obturator
2463899|NCT03146624|Active Comparator|clasp|clasp retained obturator
2463953|NCT03146312|Experimental|MVM/phytochemical supplement|a multi-vitamin, multi-mineral, phytochemical supplement
2463955|NCT03146312|Placebo Comparator|Placebo|a placebo tablet (microcrystalline cellulose) identical in size, shape and color to the treatment
2463988|NCT03145883|No Intervention|Control group|Control group
2463989|NCT03145883|Experimental|Home-based Aerobic Exercise|Participants will be prescribed weekly exercise goals starting with 75 minutes a week (e.g., 15 minutes per day, 5 days a week) and progressed to 200 minutes a week (e.g., 40 minutes per day, 5 days a week) by week 12. Exercise will consist of participant preference of mobility exercises, most likely walking. Aerobic exercise, similar to a brisk walk, will be recommended as the primary mode of exercise.
2464032|NCT03145636|Other|Observational arm|Subjects will receive the device implant and use the vBloc Achieve Weight Management Program.
2464034|NCT03145636|Other|Randomized sub-study -Treatment|Subjects will be randomly assigned (1:1) either to treatment or control. Treatment arm will receive the device and use of vBloc Achieve Weight Management Program.
2464037|NCT03145636|Other|Randomized sub-study - Control|Subjects will be randomly assigned (1:1) either to treatment or control. Control will participate in a Control Weight Management (CWM) program for 6 months prior to receiving the device implant and using the vBloc Achieve program.
2464071|NCT03145246||tooth loss|regeneration treated teeth loss
3156235|NCT00338559||LMA group|Patients in which laryngeal mask airway (LMA) is used.
3156236|NCT00338559||ET group|Patients in which endotracheal tube (ET) is used.
3156237|NCT00338572|Active Comparator|1|12-week exercise program
2463180|NCT03151616||No anticholinergic exposure|People with an anticholinergic risk scale score of 0
2463182|NCT03151616||Moderate anticholinergic exposure|People with an anticholinergic risk scale score of 1-2
2463184|NCT03151616||High anticholinergic exposure|People with an anticholinergic risk scale score of >=3
2463246|NCT03151122|Experimental|continuous care group|continuous care group (CCG): This is the experimental group where continuous care supported would be offered by the nurse coordinated integrative health care team. which is, parents in this group receive support during infant hospitalization. The support covers both hospitalization phase and after-discharge phase. In-hospital support include educational support and promoting mother-infant attachment. Nurses will be responsible for home visits after infant discharge.
2463253|NCT03151122|Active Comparator|routine care group|Routine Care Group (RCG): This is the comparison group of preterm infants. the routine care interventions generally include telephone reminding about follow-up care of the infants and hotline for parents to call when needed.
2463288|NCT03150823|Experimental|Upward Direct Current (Ascending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the anode is placed at the distal level and the cathode at the proximal level. This would be an excitatory effect of the nervous system.
2463290|NCT03150823|Experimental|Downward Direct Current (Descending Effect)|Group subjected to a direct current application (Longitudinal Galvanization) in which the cathode is placed at the distal level and the anode at the proximal level. This would be an inhibitory effect of the nervous system.
2463292|NCT03150823|Sham Comparator|Sham Direct Current|Group to which an electrical installation will be carried out without emission of part of the electrotherapy equipment. The electrodes will be applied longitudinally to the participants with the equipment switched off.
2463453|NCT03150004|Experimental|CLAG-M regimen|Patients' treatment cycle is 30 days.
2463512|NCT03149445|Experimental|Tesofensine/Metoprolol|Tesofensine + metoprolol administered once a day, in the morning with a meal
2463516|NCT03149445|Placebo Comparator|Tesofensine/Metoprolol placebo|Placebo tablets matching tesofensine + metoprolol administered once a day, in the morning with meal
3156238|NCT00338572|Experimental|2|12-week combined exercise and diet program
2463658|NCT03148392||Cryo Balloon Ablation|Arctic Front Advance Cryo Balloon: Mode of ablation determined based on patient and physician preference
2463660|NCT03148392||Radiofrequency Ablation|Contact Force Sensing Radiofrequency Catheter Ablation: Mode of ablation determined based on patient and physician preference
2463681|NCT03148028||PID IBD patients|patients with an immunodeficiency and inflammatory bowel disease phenotype
2463744|NCT03147885|Experimental|Treatment (selinexor, RCHOP)|Patients will receive selinexor PO on days 1, 8, and 15 of a 21 week cycle. RCHOP will be given at standard dosing every 21 days. In the phase 1 part there is dose escalation for Selinexor in a 3+3 design. Treatment will be given for 6 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or better will receive maintenance selinexor PO on days 1, 8, 15, and 22 every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2463788|NCT03147313|Sham Comparator|Sham|
2463800|NCT03147313|Active Comparator|Shockwave 300 pulses|300 pulses of extracorporeal shock wave will be applied
2463803|NCT03147313|Active Comparator|Shockwave 500 pulses|500 pulses of extracorporeal shock wave will be applied
2463827|NCT03146962|Experimental|All Subjects|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B). Cohort C will receive high dose vitamin C for 1-3 weeks. During week 1 vitamin C infusion and Y90 radioembolization of hepatic metastases will occur same day.
2463856|NCT03146819||iTotal PS KRS|Patients who have had an iTotal (posterior stabilized) knee replacement at least 6 months prior to testing.
2463857|NCT03146819||Off-the-Shelf KRS|Patients who have had an off-the-shelf (posterior stabilized) knee replacement at least 6 months prior to testing.
2464010|NCT03145909|Experimental|Dose Escalation Cohort|ABBV-176 will be administered via intravenous infusion at escalating dose levels until the maximum tolerated dose is reached.
2464011|NCT03145909|Experimental|Expanded RPTD Cohort|ABBV-176 via intravenous administration in participants with breast cancer at the Recommended Phase Two Dose (RPTD) determined during the Dose Escalation Cohort
2464058|NCT03145337|Active Comparator|Cohort A|FlexHD ADM
2464060|NCT03145337|Active Comparator|Cohort B|AlloDerm RTU ADM
3156239|NCT00338572|No Intervention|3|Non-intervention group
3156240|NCT00338689|Experimental|Lower protein formula|"Intervention: Infant formula with relatively low protein content (1.25 g/ 100 ml) during the first year of life; described as Lower protein formula"
3156241|NCT00338689|Placebo Comparator|Higher protein formula|"Intervention: Infant formula with a relatively high protein content (2.05 g/ 100 ml) during the first year of life; described as Higher protein formula"
3156242|NCT00338689|No Intervention|Breastfed reference group|Non-randomized breastfed group of infants at least 3 months exclusively breastfed
3156243|NCT00338715|Experimental|A|Prophylactic Pulmonary Vein Isolation in Addition to CABG for the prevention of postoperative Atrial Fibrillation
3156244|NCT00338767|Experimental|Treatment|Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
3156245|NCT00338767|No Intervention|Control|Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project
3156246|NCT00338832|Experimental|1|Participants will receive the Physically Ready for Invigorating Movement Every Day program
3156247|NCT00338832|Active Comparator|2|Participants will receive the Program for Activity, Leisure Skills, and Socialization
3156248|NCT00338845|Experimental|1|Participants will receive the Share Safer Sex counseling program
3156249|NCT00338845|Active Comparator|2|Participants will receive a standard didactic safer-sex counseling session
3156250|NCT00338858|Active Comparator|1|TD
3156251|NCT00338858|Experimental|2|TBI
3156252|NCT00338858|Experimental|a|Cerebral palsy
3156253|NCT00338871|Experimental|study|home exercise
3156254|NCT00338871|No Intervention|control|regular therapy
3156255|NCT00338923|Active Comparator|Treatment arm|One Arm - Active Compound (HO/03/03)
2463013|NCT03152825||Viable myocardium Group|"At least ONE of the following:~Late gadolinium enhancement <75%.~Improvement in segmental function ≥1 grade during low dose dobutamine"
2463019|NCT03152825||Non-viable myocardium group|"At least ONE of the following:~Late gadolinium enhancement ≥75%.~No improvement in segmental function during low dose dobutamine"
2463023|NCT03152825||Inducible ischaemia group|"At least ONE of the following:~perfusion defect (≥ 1,5 segments) assessed during peak infusion of adenosine or dobutamine~new wall motion abnormalities or worsening ≥1 grade during peak infusion of dobutamine"
2463026|NCT03152825||Non-inducible ischaemia group|"None of conditions qualifying for the Inducible ischemia group"
2463079|NCT03152279||Celiac Disease|Patients with suspected Celiac Disease who plan to undergo duodenal biopsy as part of routine clinical care
2463082|NCT03152279||Control|Patients scheduled for an upper endoscopy for indication other than evaluation of Celiac Disease or concern for CeD as part of routine clinical care
2463145|NCT03151889|Experimental|TENS Group|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
2463148|NCT03151889|No Intervention|Control Group|Control Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux) and Post-test evaluations.
2463250|NCT03151135||AN patients|Patients with Anorexia Nervosa (AN). No intervention, observation at end of inpatient treatment
2463325|NCT03150836|Experimental|Safety Lead-In, Regimen A1 Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (33Gy delivered as 6.6Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463330|NCT03150836|Experimental|Safety Lead-In, Regimen A2 Durvalumab + RT|In cohort A2 the dose of radiation will be decreased to a total dose of 30 Gy administered in 5 fractions of 6 Gy. Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (30 Gy delivered as 6.0Gy x 5 fractions) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463331|NCT03150836|Experimental|Safety Lead-In, Regimen B1 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 2 cycles with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After two doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463332|NCT03150836|Experimental|Safety Lead-In, Regimen B2 Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 cycle with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After one dose of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463333|NCT03150836|Experimental|Expansion Cohort, Regimen A: Durvalumab + RT|Durvalumab 1500 mg will be delivered via IV infusion q4wk. Radiation Therapy (RT) will be delivered beginning on day 8 ± 3 of durvalumab. RT (either 33Gy delivered as 6.6Gy x 5 fractions or 30 Gy delivered as 6.0 Gy x 5 fractions, as determined during the safety lead-in for Regimen B) should be completed within 14 days from the start of RT ideally over 5 consecutive days. Durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463334|NCT03150836|Experimental|Expansion Cohort Regimen B: Durvalumab + Tremelimumab + RT|Tremelimumab 75 mg will be administered via IV infusion q4wk for 1 or 2 cycles (as determined during the safety lead-in for Regimen B) with durvalumab 1500 mg via IV infusion. Radiation Therapy (RT), at the optimal dose determined in the safety lead-in from Regimen A, will be delivered beginning on day 8 ± 3 of durvalumab. After 1 or 2 doses of tremelimumab and durvalumab, durvalumab 1500 mg q4wk will be continued to complete either 13 total cycles of durvalumab OR until disease progression, unacceptable toxicity, or patient withdrawal from study, whichever comes first.
2463380|NCT03150277|Experimental|Plyometric-Resistance|This group will perform plyometric exercise first and then heavy resistance exercise
2463382|NCT03150277|Experimental|Resistance-Plyometric|This group will perform resistance exercise first and then plyometric exercise
2463491|NCT03149757|Experimental|YouTHrive|YouTHrive is a five-month technology-based intervention that uses peer-to-peer interaction, daily self-monitoring, and tailored content to address barriers to HIV medication adherence.
2463497|NCT03149757|Active Comparator|Thrive Tips|Participants randomized to the control condition will receive a weekly email with static informational content about living with HIV and general well being.
2463719|NCT03147638|Experimental|1 month|patient treated with Anti coagulation for one month
2463720|NCT03147638|Active Comparator|3 months|standard of care , treatment for 3 months
3156256|NCT00338975|Experimental|1|Cognitive Behavioral Social Skills Training (CBSST)
2463876|NCT03146767|Experimental|Tetanic Group|A Tetanic stimulation (Tetanus stabilization of baseline) is administered to the monitorized arm before calibrating the neuromuscular block monitor. Then Train-of-four (TOF) stimuli are administered every 20 seconds for 20 minutes.
2475071|NCT03070132|Experimental|Placebo|Administered orally TID
3156257|NCT00338975|Active Comparator|2|Goal-Focused Supportive Contact (GFSC)
3156258|NCT00339014|Active Comparator|Group 1|Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day
3156259|NCT00339014|Active Comparator|Group 2|Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day
3156260|NCT00339014|Active Comparator|Group 3|Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day
3156261|NCT00339014|Active Comparator|Group 4|Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day
2462964|NCT03153150|Experimental|Start oral anticoagulant (OAC)|"If the patient is randomized in this arm, an oral anticoagulant:~Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or~Direct thrombin inhibitor: Dabigatran or~Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (≥1 year) to the patient."
2462975|NCT03153150|No Intervention|Do not start oral anticoagulant (OAC)|"If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:~antiplatelet drug(s) or~no antithrombotic drugs."
2463072|NCT03152461||Surgical patients|Patients undergoing elective cardiac or vascular surgery involving bypass, or major spine surgery, or surgical patients presenting with acute bleeding in a post-surgical unit.
2463143|NCT03152006|No Intervention|Control|The control arm does not receive the ACT intervention.
2463147|NCT03152006|Experimental|ACT Intervention|Intervention activities include the three components of the ACT intervention: (1) alternating pediatric and adult clinic visits in the 12 month pre-transfer period (2) peer facilitated organized support group during the 24-month graduated transition period and (3) patient advocate and case management team to coordinate transfer process.
2463178|NCT03151408|Experimental|Pracinostat plus AZA|60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
2463179|NCT03151408|Placebo Comparator|Placebo plus AZA|1 capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.
2463365|NCT03150433|Experimental|Behavioral symptom management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, feedback and goals for improving sleep and pain management, and addressing cognitive and emotional strategies for managing sleep and pain.
2463372|NCT03150433|Other|Sickle cell disease management|Five sessions working one-on-one with a study interventionist, either in person or by telephone. Includes monitoring of the individual's sleep pattern, information about sickle cell disease and its management, and information about improving sleep and managing pain.
2463419|NCT03150017|Experimental|Online programme|SPIRE The programme consists of six modules over six weeks and is based on cognitive behavioural principles. It comprises psychology sessions using cognitive techniques to identify unhelpful and unrealistic thoughts and beliefs related to pain and to challenge and change them and weekly relaxation audios and a home exercise session. Goal setting by participants is used encouraged throughout the programme to aid the implementation of learned CBT techniques into daily life. Educational sessions are delivered across a range of topics including mechanisms of pain after SCI, explanations of the pain gate control theory and how CBT strategies employed can impact on the perception of pain, discussion of medication use, stress management and pacing strategies for activities of daily living.
2463427|NCT03150017|No Intervention|Usual Care|Continue to manage pain using usual care.
2463483|NCT03149380|Experimental|Intervention|Subjects will be given access to educational content on AD using interactive learning strategies
2463492|NCT03149380|Sham Comparator|Time-neutral control|Subjects will be given access to time-neutral general educational content on AD
2463572|NCT03149276||Limited English Proficiency Group|"LEP persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered limited English proficient when a non-English language was preferred. Interventions included professional interpreter services and occupational therapy."
2463575|NCT03149276||English Speaking Group|"English speaking persons were identified by asking, What language would you like to receive medical information and services in? Patients were considered English speaking when the English language was preferred. Intervention included occupational therapy."
2463611|NCT03148652|Experimental|Enhanced Intervention (CBT+working memory training)|A standard, manualized cognitive behavioral therapy-based intervention for individuals interested in quitting smoking plus computerized working memory training
2463614|NCT03148652|Placebo Comparator|Control Intervention Condition|Participants will receive a manualized cognitive behavioral therapy-based intervention
2463665|NCT03148353|Experimental|Modified subacromial injection|"Intervention procedure: corticosteroid injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa and biceps tendon~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
2463666|NCT03148353|Placebo Comparator|Standardized subacromial injection|"Intervention procedure: corticoseroid injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 40 mg triamcinolone acetonide (a kind of corticosteroid)~Intervention procedure: lidocaine injection into the subacromial bursa only~Device for guidance: high-resolution ultrasound~Drug: 3 mL of lidocaine (the medication will be mixed with 40 mg triamcinolone acetonide)"
2463714|NCT03147963|Experimental|Docetaxel 2-Weeks regimen group|Docetaxel injection 50mg/m2,iv,d1,every 2 weeks
2463715|NCT03147963|Active Comparator|Docetaxel 3-Weeks regimen group|Docetaxel injection 75mg/m2,iv,d1,every 3 weeks
2463759|NCT03147599|Active Comparator|Mebeverine|Coloverin (Mebeverine hydrochloride 135 mg)
2463760|NCT03147599|Placebo Comparator|Placebo|Placebo
2463781|NCT03147300|Active Comparator|Östergötland region - Control group|
2463793|NCT03147300|Experimental|Östergötland region - Intervention group|
2463842|NCT03147027||VT ablation group|
2463846|NCT03147027||medication group|
2463904|NCT03146689|Experimental|Topical NSAID and topical capsaicin|"Within each participant:~Topical NSAID (A) or capsaicin (B) are taken for a treatment period of four weeks. This is followed by another four week treatment period with the other treatment. These two treatment periods comprise one treatment cycle. The order of treatments within a treatment cycle is determined randomly (AB or BA).~This treatment cycle is repeated so that all participants undergo a maximum of three topical NSAID treatment periods and three topical capsaicin treatment periods (i.e., three treatment cycles). This is reduced to two cycles if they are found to meet the criteria for response at the interim analysis (after cycle two)."
2463007|NCT03152838||Control|"20 age-gender matched typical development children that will be assigned to the normal control group.~Control children will be examined by a psychiatrist to exclude any sub-clinical autistic features.~Fasting blood samples will be collected from control children for DNA Methylation-and quantitative Real-time Polymerase Chain Reaction Analysis"
2463054|NCT03152396|Other|Patients with inflammatory arthritis|All patients enrolled have a form of inflammatory arthritis and at least one uncontrolled CV risk factor (i.e. blood pressure, LDL-cholesterol, HbA1C, or current tobacco use). Pharmacist will assess each participants CV risk score using the validated RxEACH CV risk calculator. Over the 6 month intervention period, pharmacists will assist patients to modify a contributing risk factor thru treatment recommendations, prescription adaptation, and prescribing where necessary to meet treatment targets.
2463093|NCT03152032|Experimental|In-House Vocational Training Programs|The In-House Vocational Training Programs were government-funded services offered to newly discharged inpatients or current outpatients with chronic psychiatric disorders in four regional psychiatric hospitals of Taiwan. The programs emphasized the utilization of the hospitals' existing spaces, facilities and manpower alongside the community sources to train participants in various job options including bakery training, culinary skill, barista training, computer data processing, auto wash and detailing, janitorial training, and wash and fold laundry service. Each program was staffed with occupational therapists and paid or volunteer job coaches, along with cross-disciplinary support from psychiatrists, psychologists, social workers, nurses, vocational specialists or others.
2463119|NCT03151837|Experimental|Momordica charantia|Subjects will take the capsule of Greenyn Momordica charantia extracts 600 mg/day orally for three months.
2463129|NCT03151837|Placebo Comparator|Placebo control|Subjects will take the capsule of Placebo 600 mg/day orally for three months.
2463168|NCT03151577|Other|Evolution of IOP after XEN® Gel Stent implantation|To study the efficacy of the XEN® Gel Stent in lowering the IOP.
3156262|NCT00339014|Active Comparator|Group 5|Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day
2463242|NCT03151044|Experimental|EPI-90|"Participants in this arm shall be given high-dose Epirubicin Combined with CVP ± Rituximab for six 21-day cycles:~High-dose Epirubicin 90mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
2463244|NCT03151044|Active Comparator|EPI-75|"Participants in this arm shall be given standard-dose Epirubicin, Combined with CVP ± Rituximab for six 21-day cycles:~Standard-dose Epirubicin 75mg/m2, i.v., Day 1; Cyclophosphamide 750mg/m2, i.v., Day 1; Vincristine 1.4mg/m2, i.v., Day 1; Prednisolone 100mg/m2, p.o., Day 1-5;~Plus/not plus:~Rituximab 375mg/m2, i.v., Day 0"
2463280|NCT03150641|Other|Immediate cord clamping|Umbilical cord clamped within 15 seconds of delivery of baby
2463284|NCT03150641|Experimental|Delayed cord clamping|Umbilical cord clamped 60 seconds after delivery of baby
2463341|NCT03150563|No Intervention|Control Group|The subjects of the CG will receive the same orientations of the other groups in relation to the importance of the routines of stretching activities, but during the study period, they will not be able to perform stretches during their day to day life.
2463342|NCT03150563|Experimental|Experimental Group 1|"The experimental group 1 will have the sensation of SENSATION SENSING WITHOUT DESCONFORT as an intensity for the application of the passive stretch protocol."
2463343|NCT03150563|Experimental|Experimental Group 2|"The GE2 will have the feeling of MAXIMUM DISORDER WITHOUT PAIN as the as an intensity for the application of the passive stretch protocol."
2463344|NCT03150563|Experimental|Experimental Group 3|"GE3 will have the sensation of MAXIMUM TOLERABLE PAIN as the as an intensity for the application of the passive stretch protocol."
2463389|NCT03150212|Experimental|Saccharomyces cerevisiae CNCM I-3856|
2463397|NCT03150212|Placebo Comparator|Placebo|
2463413|NCT03149874|Active Comparator|Hepatitis B recombinant DNA vaccine|Each Hepatitis B recombinant DNA vaccine vial contained 20 microgram of vaccine dose. Two vials will be intramuscularly injected one vial in each deltoid muscle on months zero, one, two and six.
2463417|NCT03149874|Active Comparator|Combined hepatitis A and B vaccine|Each one-milliliter dose of vaccine contains 720 ELISA units of inactivated hepatitis A virus and 20 mcg of recombinant HBsAg protein. One dose of vaccine also contains 0.45 mg of aluminum. Two vials will be intramuscularly injected one vial in each deltoid muscle on on days zero, seven, and 21.
2463525|NCT03149367|Experimental|Fixed suture|
2463526|NCT03149367|Experimental|Adjustable suture|
2463542|NCT03148964||Follow-up Arm|Blood sampling only
2463639|NCT03148860|Active Comparator|Methotrexate naive - Ustekinumab and Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2463642|NCT03148860|Placebo Comparator|Methotrexate naive - Ustekinumab and Placebo to Methotrexate|Methotrexate naive subjects will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2463647|NCT03148860|Active Comparator|Methotrexate pre-treated subjects-Ustekinumab and Methotrexate|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2463648|NCT03148860|Placebo Comparator|Methotrexate pre-treated subjects-Ustekinumab and PLC|subjects pretreated with Methotrexate will be randomised to receive Methotrexate or Placebo, Ustekinumab will be given open-label
2463676|NCT03148054||Study group|Patients undergoing elective left sided colon surgery
2463733|NCT03147911||Stroke or systemic embolism : Positive|- 583 patients
2463739|NCT03147911||Stroke or systemic embolism : Negative|- 598 patients
2463779|NCT03147339|Experimental|AGEs restricted diet|Low calorie diet + AGEs restricted diet
2463786|NCT03147339|No Intervention|control|Low calorie diet
2463830|NCT03147131|Active Comparator|Fitmore short stem|"Intervention: Total hip arthroplasty with an uncemented femoral short stem, the Fitmore short stem (Zimmer, Warsaw, USA). Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: Fitmore Short Stem"
2463831|NCT03147131|Active Comparator|CLS straight stem|"Intervention: Total hip arthroplasty with an uncemented femoral straight stem, the CLS short stem (Zimmer, Warsaw, USA).Furthermore, an uncemented cup (Allofit, Zimmer, Warzaw, USA).~Device: CLS Straight Stem"
2475830|NCT03064594||wedge resection|wedge resection
3156263|NCT00339014|Active Comparator|Group 6|Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day
3156264|NCT00339014|Placebo Comparator|Group 7|
2463027|NCT03152643|Experimental|cleavage-stage embryo transfer group|For subjects assigned to the cleavage-stage (D2/3) embryo transfer group, 1 cleavage embryos of the best quality will be transferred in fresh cycle on Day 2/3 after oocyte retrieval. The surplus embryos, if any, will be vitrified for future FET if the fresh cycle does not result in a live birth. If a patient is at a high risk of OHSS, all embryos on Day 2/3 are allowed to be cryopreserved with vitrification for patient's safety. The FET cycle will be initiated on the second menstrual cycle after oocyte retrieval.
2463081|NCT03152227|Experimental|ACGG & ATONU|ACGG high-producing chicks to households along with provision of technical input on production and ATONU Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
2463084|NCT03152227|Active Comparator|ACGG only|ACGG high-producing chicks to households along with provision of technical input on production
2463086|NCT03152227|No Intervention|Control|ACGG eligible households in non-ACGG villages receiving standard of care agricultural and health services as provided in Ethiopia
2463124|NCT03151863|Active Comparator|Opioids, placebo|One single dose of subcutaneous opioids and intranasal placebo (NaCl0.9%).
2463132|NCT03151863|Experimental|Placebo, Dexmedetomidine|One single dose of subcutaneous placebo (NaCl0.9%) and intranasal Dexmedetomidine 1.25ug/Kg
2463172|NCT03151447|Experimental|SBRT in combined with anti-PD-1 antibody|Patients will receive stereotactic body radiation therapy to metastatic lesions of liver, lung, bone, brain or lymph nodes and concurrent anti-PD-1 antibody treatment.
2463263|NCT03150953|No Intervention|Standard of Care|Patients will receive standard of care which is 1-2 warm blankets.
2463264|NCT03150953|Experimental|MRI-safe warming device|The MRI-safe bore covering consists of a clear covering sheet positioned over the openings of the MRI scanner.
2463266|NCT03150953|Experimental|MRI-safe warming device and Bair hugger|IN addition to positioning the MRI-safe bore covering over the opening of the MRI scanner, the opening of the covering sheet will be connected to a device which blows warm air called a Bair Hugger. The Bair Hugger is an approved device, and MRI safe.
3156265|NCT00339027||Preschool children|Children aged 3-5 years who are enrolled in federally-subsidized early care and education centers in underserved communities in Miami-Dade County
3156266|NCT00339092|Experimental|Treatment|Participants who receive storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals
2464077|NCT03145792|Experimental|Seeking Safety|Behavioral therapy for trauma and addiction.
2464078|NCT03145792|Active Comparator|CBT for Pathological Gambling|Behavioral therapy for gambling problems.
2464192|NCT03144934|Experimental|Administraion of investigational product|"0.25mg, 1mg, 3mg, 6mg, or 9mg (optional) of GX-I7~6 subjects per each cohort~twice administration with 4-week intervals"
2464194|NCT03144934|Placebo Comparator|Administraion of placebo|"GX-I7 vehicle (formulation buffer)~2 subjects per each cohort~twice administration with 4-week intervals"
2464318|NCT03143868|Experimental|Aerobic Exercise|
2464322|NCT03143868|Experimental|Resistance Exercise|
2464327|NCT03143868|Placebo Comparator|No Exercise|
2464364|NCT03143231|Experimental|Normal saline|Sodium Chloride 0.9% will be provided
2464371|NCT03143231|Experimental|Hypertonic saline|500 ml Sodium Chloride 0.9% with 60 ml Sodium Chloride 20% will be provided
2464469|NCT03142971|Experimental|Intervention:f-ESWT (focused shock wave therapy)|In the study-group, a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf) was used . At the beginning of each treatment session, the enthesis of the gluteal tendons at the greater trochanter (at the anterior half of its lateral facet) was targeted through a non-inline sonographic focusing, using a linear probe (7.5-12 MHz) connected to an ultrasound scanner (ESAOTE MYLAB FIVE, Genova and Florence, Italy). All patients received 1800 pulses (frequency=4Hz) of an energy flux density of 0.15 mJ/mm2 once a week for three consecutive weeks. At the first treatment session, the energy flux density was gradually increased from 0.05 to 0.15 mJ/mm2 during the first 500 pulses.
2464473|NCT03142971|Active Comparator|Intervention:UST (ultrasound therapy)|In the control-group, we used a mono-frequency device (ROLAND, RT-20 series, frequency=1MHz). We treated an area of 5cm2, softly moving the US-probe around the most painful point of the greater trochanter at the clinical palpation. UST was supplied in a continuous modality, with an intensity of 1.5 W/cm2, for ten consecutive daily sessions of ten minutes each.
2464571|NCT03142061|Experimental|ECT|
2464636|NCT03141463|Experimental|Vvax001 therapeutic cancer vaccine|Patients will receive three consecutive doses of Vvax001, with an interval of 3 weeks
2464797|NCT03140709||Induced vaginal delivery|Saliva samples will be obtained both during induction and infusion, every 15 minutes after each change in dose. An estimated total of 5 saliva samples will be collected from each patient. Therefore, the last collection point (sample 5) will be during the oxytocin infusion after the 4th dose change. In addition, 2 blood samples will be collected from 5 patients - one baseline sample and another sample at same time as last saliva sample.
2464800|NCT03140709||Cesarian delivery|A total of 3 saliva samples will be collected from each patient - one at baseline preoperative, one intrapartum at least 15 min after starting the standard 250 ml/h oxytocin infusion, and one postpartum in post-anesthesia care unit (PACU) at least 15 min after starting the standard 125 ml/h oxytocin infusion. Therefore, the last collection point (sample 3) will be during the oxytocin infusion in PACU. In addition, 1 blood sample will be collected from each patient in this cohort - at same time as last saliva sample.
3156267|NCT00339092|Active Comparator|Control|Participants who receive standard care
3156268|NCT00339170|Experimental|1|Participants receive a 12-month cognitive enhancement training program plus a 12-month work therapy program.
3156269|NCT00339170|Active Comparator|2|Participants receive a 12-month work therapy program alone.
3156270|NCT00339196|Experimental|1|5-azacytidine VALPROIC acid and ATRA
3156271|NCT00339222||1|Melanoma-prone families from dermatology clinics.
3156275|NCT00339326||Cases with Kaposi's Sarcoma|Cases with Kaposi's Sarcoma from Southern Italy.
3156276|NCT00339326||Controls without KS|Controls from Southern Italy.
3156277|NCT00339352||1|Cases
3156278|NCT00339352||2|Controls
2463069|NCT03152409|Placebo Comparator|Placebo augmentation to treatment|Participants randomized to the placebo arm will receive a placebo oral tablet of the same size, shape, and color as the aspirin tablet. Participants will be instructed to take their pills in the evening before bed.
2463128|NCT03151993|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
2463134|NCT03151993|Active Comparator|Actilyse|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
2463209|NCT03151343|Experimental|Empagliflozin|Empagliflozin, coated tablets, 25mg, once daily, for 13 weeks
2463213|NCT03151343|Placebo Comparator|Placebo|Placebo, coated tablets, once daily, for 13 weeks
2463286|NCT03151018||Onyx|The patients who received PCI with Resolute Onyx stent(s)
2463347|NCT03150290|Other|ALS patients without weight loss.|18-FDG-PET. Indirect Calorimetry.
2463348|NCT03150290|Other|ALS patients with weight loss.|18-FDG-PET. Indirect Calorimetry.
3191361|NCT00797745|Experimental|7|4 week lead-in with PegIntron 1.5 mcg/kg SC weekly plus ribavirin 600 to 1400 mg daily (weight-based) by mouth twice daily followed by PegIntron plus ribavirin plus SCH 900518 600 mg daily plus ritonavir 100 mg daily for 12 weeks. Depending on HCV-RNA levels after 4 weeks of SCH 900518, patients will receive an additional 8 or 32 weeks of PegIntron/ribavirin. Total treatment duration will be 24 or 48 weeks.
3191362|NCT00797758|Experimental|1|Umbilical cord blood transplantation after reduced intensity conditioning
2463548|NCT03149159|Experimental|Nivolumab + Ipilimumab + SRT|
3191363|NCT00797771|Experimental|A|"Adi insulin pump users"
3191364|NCT00797810|Experimental|therapy|
2463751|NCT03147859|Experimental|Group A-150mg dose of vedolizumab per infusion followed by ATI - Low Dose|* Please note that the previous low dose arm was 75mg of vedolizumab per infusion, but no participant was ever given this dose. The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 150 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 doses as tolerated. ATI will begin between weeks 6 and 7, and infusions continued at weeks 8, 12, 16 and 20.
2463754|NCT03147859|Experimental|Group B-300mg dose of vedolizumab per infusion followed by ATI - Mid Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 300 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
2463757|NCT03147859|Experimental|Group C-600mg dose of vedolizumab per infusion followed by ATI - High Dose|The study will have a 20-week treatment phase and a 28-week follow-up phase over one year. Intravenous infusion of 600 mg of vedolizumab per infusion per visit schedule will be administered to 4 participants. The visit schedule will be the same for each group - Infusion at weeks 0, 2, 5, 8 and every 4 weeks thereafter up to 40 weeks for at least 7 (and up to 12) doses as tolerated. ATI will begin between week 10, and infusions continued at weeks 12, 16 and 20. Infusions may also be given at weeks 24, 28, 32, 36 and 40 depending on tolerance and pVL response.
2463780|NCT03147287|Active Comparator|Fulvestrant|-Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly
2463787|NCT03147287|Experimental|Fulvestrant with Palbociclib|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly"
2463797|NCT03147287|Experimental|Fulvestrant with Palbociclib and Avelumab|"Palbociclib should be taken orally, once per day for 21 days on a 28 days cyclye~Fulvestrant will be administered in the clinic as two IM injections on Cycle 1 Days 1, 15, then monthly~Avelumab will be administered intravebously once every 2 weeks"
2463881|NCT03146832|Experimental|Habituation|The habituation instruction focuses on changes of the initial physical fear-responses during exposure sessions. It is explained that the level of anxiety will gradually decrease, or habituate, each time someone faces a feared situation. Participants are then instructed to observe their own level of fear during the three practice trials with the thermode. Together with the experimenter, participants have to indicate their level of arousal on an 11-point scale (0= neutral, 10 = very high) in-between and after the three practice trials. After the practice trial, participants are instructed to reconsider their own development of physical responses. Participants are encouraged to remember the development of their level of arousal during the test trail with the thermode.
2463884|NCT03146832|Experimental|Expectation Violation|"The expectation violation instruction focuses on the verification of negative expectancies during exposures sessions. It is explained that exposure exercises help to create own experiences which allow to directly test negative predicted outcomes. Together with the experimenter, participants are then encouraged to formulate concrete concerns in regard to the practice trail with the thermode. Before the practice trails, participants have to indicate the likelihood of their concerns on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are instructed to evaluate their own concerns by some guided questions (e.g. What did you learn?). Participants are encouraged to keep their own experience in mind during the test trail with the thermode."
2463887|NCT03146832|No Intervention|Control|"Participants in the control group are not provided with information about exposure therapy. Instead, participants listen to a newspaper article which reports on the daily work in a botanical garden. Together with the experimenter, participants are then asked to name the most interesting aspect in the article. Before the practice trails, participants have to rate how likely it is that they would further inform themselves about botanical gardens on an 11-point scale (0= not likely, 10 = very likely). After the practice trails, participants are provided with some further questions about the newspaper article (e.g. Did you find the newspaper article interesting?). This cognitive exercise does not cover any pain-related topics and, therefore, does not serve as a distraction instruction."
3191365|NCT00797836|Experimental|Quantiferon Gold|
3191366|NCT00797849|Active Comparator|1|Wear prosthetics laminated with Farabloc surrounding the liner. If not wearing prosthetics, subject needs to wear Farabloc sock or glove over shrinker.
2463090|NCT03152175|Placebo Comparator|Placebo|Placebo manufactured as a capsule to mimic 1mg/kg of propranolol hydrochloride administered 60 minutes prior to memory reactivation
3156279|NCT00339352||3|first-degree relatives of cases/controls
3156280|NCT00339365|Experimental|1|Promoting first relationships group
2463399|NCT03150186||SHS exposure in homes|Measurement of nicotine level in private homes
2463401|NCT03150186||SHS exposure in private cars|Measurement of nicotine level in private cars
2463403|NCT03150186||SHS exposure in outdoor settings|Measurement of nicotine level in outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings)
2463674|NCT03148249|Experimental|interview with an ophthalmologist|Patients get an interview with an ophthalmologist
2463675|NCT03148249|Experimental|interview/treatment by a psychiatrist|patients get an interview and a possible treatment by a psychiatrist
2463721|NCT03147703|Experimental|Early Eating (EE)|The intervention is Food Timing, Early Eating is defined at 13:00 hours for lunch
2463725|NCT03147703|Experimental|Late Eating (LE)|The intervention is Food Timing, Late Eating is defined for 17:30 hours for lunch
2463774|NCT03147469|No Intervention|Neutral|After insertion of Ambu AuraGain™, the variables will be assessed at each positions including neutral, flexion, extension, right rotation under random order.
2463778|NCT03147469|Experimental|Flexion|After positioning the subjects' neck to flexion, the variables will be assessed.
2463783|NCT03147469|Experimental|Extension|After positioning the subjects' neck to extension, the variables will be assessed.
2463795|NCT03147469|Experimental|Right rotation|After positioning the subjects' head to right rotation, the variables will be assessed.
3156281|NCT00339365|Active Comparator|2|Early education support group
2463931|NCT03146637|Experimental|Activated CIK armed with bispecific antibody treatment group|CIK cells were activated by bispecific antibody of anti-CD3-MUC1/CEA/EpCAM/GPC3
2463941|NCT03146637|Active Comparator|Traditional CIK treatment group|CIK cells were not activated
2464057|NCT03145506||Mohs Surgery Patients|Adult patients undergoing Mohs surgery for treatment of BCC or SCC
2464150|NCT03144765|Experimental|taTME|Enrolled subjects will undergo the study procedure, laparoscopically-assisted Transanal Total Mesorectal Excision (taTME).
2464250|NCT03144193|Experimental|Experimental|Topical anti-aging cosmetic cream (active)
2464253|NCT03144193|Placebo Comparator|Placebo|Basic formulation without active ingredients (vehicle)
3156282|NCT00339469|Other|2|Controlled feeding study.
3156284|NCT00339495||Non-Screening|Participants received their usual care
2464433|NCT03142698|Experimental|Hepatic steatosis|Evaluation of different techniques in quantification of hepatic steatosis by MRImaging (PDFF 3, 6 and 11 gradient echoes and Spectroscopy) compared to the histological method (reference)
2464488|NCT03142529|No Intervention|Integrated Therapy|This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
2464491|NCT03142529|Experimental|Integrated Therapy and colonic dialysis|This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
2464510|NCT03142191|Experimental|CC-90001 400 mg PO QD|55 subjects will be randomized to CC-90001 400mg
3156285|NCT00339495||Screening|Participants received trial-provided screening examinations for prostate, lung, colorectal, and ovarian cancer
3156286|NCT00339521||Case-Parent Triad|Childhood Asthmatics (aged 4-17) are Cases; biologic parents of cases are genetic Controls.
3156287|NCT00339534||Cases|Cases were recruited at Korle Bu Teaching Hospital in Accra, Ghana, between 2008 and 2012.
3156288|NCT00339534||Controls|Controls were selected in a population-based component using a probability sample designed with the 2000 Ghana Population and Housing Census data between 2004 and 2006.
3156289|NCT00339560||Cases will bile duct CA|Patients with bile duct cancer
3156290|NCT00339560||Cases with Gallbladder CA|Patients with gallbladder cancer
3156291|NCT00339560||Controls with gall stones|Patients undergoing cholecystectomy for gall stones
3156292|NCT00339560||Controls without cancer|Hospital controls with cancer
3156293|NCT00339573||National Housing Stock|The target population of this study was the national housing stock (1998-1999) ofapproximately 95 million housing units.
3156294|NCT00339612||HIV-infected children who acquired HIV infection through mothe|HIV-infected children in who acquired HIV infection through mother-to-child transmission (MTCT).
3156295|NCT00339625|Experimental|1|low fat, high fiber, high fruit and vegetable eating plan
3156296|NCT00339625|No Intervention|2|Usual Diet
3156297|NCT00339651||Cases|Women in one large U.S. health care plan. Cases will consist of women who developed endometrial carcinoma or censored complex atypical hyperplasia at least 1 year after receiving a diagnosis of endometrial hyperplasia.
3156298|NCT00339651||Controls|Women in one large U.S. health care plan. Controls will consist of individually matched women who received a diagnosis of endometrial hyperplasia at the same age and date as the cases and were cancer-free and hysterectomy-free until the date at which the index cases were diagnosed with endometrial carcinoma or censored complex atypical hyperplasia.
3156299|NCT00339664||1/ patients|Patients on approved clinical trials
3156300|NCT00339677||Volunteers|Volunteers
3156301|NCT00339690|Experimental|Test Kit Homes|Households assigned to use the in-home test kit.
3156302|NCT00339703||Control|Subjects between the ages of 18 and 65 without a diagnosis of asthma or other inflammatory disease were enrolled from the patient population at Wilford Hall Medical Center. Subjects underwent a single blood draw and spirometer.
3174672|NCT00625859|Experimental|Subjects receiving treatment sequence 4|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
2463094|NCT03152045|Experimental|Communication Intervention|Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
2463095|NCT03152045|No Intervention|Standard Of Care|Investigators will compare patients randomized into the intervention group to those who receive standard of care.
2463170|NCT03151668|Experimental|Dexmedetomidin|
2463171|NCT03151668|No Intervention|Midazolam|
2463214|NCT03151213|Active Comparator|Pregabalin|Pregabalin 150 mg before intervention
2463216|NCT03151213|Placebo Comparator|Placebo|Placebo before intervention
2463240|NCT03151031|Experimental|Experimental Group|In the experimental group, the participants will be asked to perform star excursion balance test (SEBT) under two conditions, before and after the application of cryotherapy
2463241|NCT03151031|No Intervention|Control Group|In the control group, the participants will be asked asked to perform star excursion balance test (SEBT) under two conditions, before and after 10 minutes rest
2463313|NCT03150888||Hospital based hypertension cohort|
2463320|NCT03150888||Community based hypertension cohort|
2463415|NCT03149965|Active Comparator|Body mass index 18.5-24.9|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
2463424|NCT03149965|Experimental|body mass index ≥30|The anovaginal distance was measured with transperineal ultrasound. The standardized method consisted of placing the vaginal probe at a right angle to the posterior vaginal distal wall, and in a transversal scanning plane. The internal anal sphincter was detected as a low-echogenic ring when the probe was moved cranially from the distal anal canal to the mid anal canal. The anovaginal distance was defined as the distance between the anal mucosa and the vaginal wall at the middle level of the anal.
2463508|NCT03149679|Experimental|Cyclophosphamide arm|Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.
2463547|NCT03149146|Experimental|Clinical Decision Making (CDM) Workshop|Series of CDM educational workshop will be conducted for one group of participants and they will be guided the CDM process through the two clinical practice models; Therapeutic process (TP) and International Classification of Functioning, Disability and Health (ICF).
2463550|NCT03149146|Active Comparator|Clinical Decision Making Workbook|Participants will receive Clinical Decision Making (CDM) workbook which will be used to teach the Clinical Decision Making process in the four days workshop.
2463599|NCT03148782|Experimental|OST Intervention|12 weekly in-person sessions, each lasting approximately 1 hour, targeting 3 core organizational skills domains-Tracking Assignments, Managing Materials and Time Management
2463819|NCT03147209|Experimental|Health Coaching|This group will undergo coaching and activities to improve strength and balance.
3156303|NCT00339703||Mild to Moderate Asthma|Subjects between the ages of 18 and 65, who were previously diagnosed with moderate to severe persistent asthma as defined by the National Asthma Education and Prevention Program (NAEPP), were enrolled from the Allergy and Immunology clinic at Wilford Hall Medical Center. Subjects on inhaled corticosteroids or other controller medications were allowed in the study, but subjects on oral corticosteroids were excluded. Subjects underwent a single blood draw and spirometer.
3156304|NCT00339716||Belarus in utero|subjects exposed to I131 in utero
3156305|NCT00339716||Main BelAm|subjects exposed to I131 at age less than 18 year
2464000|NCT03145948|Experimental|Arm A|Participants, who are healthy volunteers, receiving ABBV-553 dose A or placebo
2464001|NCT03145948|Experimental|Arm B|Participants, who are healthy volunteers, receiving ABBV-553 dose B or placebo
2464003|NCT03145948|Experimental|Arm C|Participants, who are healthy volunteers, receiving ABBV-553 dose C or placebo
2464004|NCT03145948|Experimental|Arm D|Participants, who are healthy volunteers, receiving ABBV-553 dose D or placebo
2464006|NCT03145948|Experimental|Arm E|Participants with psoriasis receiving ABBV-553 dose B or placebo
2464008|NCT03145948|Experimental|Arm F|Participants with psoriasis receiving ABBV-553 dose C or placebo
3156306|NCT00339742||Clinic Referral controls|Controls referred by the endoscopy clinic
3156307|NCT00339742||Esophageal Cancer cases|Histologically confirmed squamous cell cancer of the esophagus
2464278|NCT03143816|Active Comparator|Technosphere insulin (TI, Afrezza) -Treatment arm|
2464279|NCT03143816|No Intervention|Insulin Aspart ( Novolog) -Control arm|
2464419|NCT03143023|Experimental|arginine toothpaste|
2464420|NCT03143023|Active Comparator|fluoride toothpaste|
2464456|NCT03142737|Experimental|Peanut butter intake|Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
3156308|NCT00339742||Neighborhood controls|Controls recruited from the neighborhood
3156309|NCT00339768|Experimental|Amox/omepr|2 weeks; placebo controlled
3156310|NCT00339768|Experimental|Garlic|Supplement for 7 years; placebo controlled
3156311|NCT00339768|Experimental|Vitamins|Supplement for 7 years; placebo controlled
3156312|NCT00339859||1|The population controls are collected from DMV records in the Baltimore region of MD. The cases are patients at the University of Maryland Medical System, including the associated Veterans' Association Hospital.
3156313|NCT00339885||AADM|Family and Population based individuals
3156314|NCT00339885||Action-LADA|Population based individuals
3156315|NCT00339885||D2D 2004|Population based individuals
3156316|NCT00339885||DIAGEN (Dresden Biobank)|Population based individuals
3156317|NCT00339885||FINRISK 1987|Population based individuals
3156318|NCT00339885||FINRISK 2002|Population based individuals; Test DNA
3156319|NCT00339885||Fusion 1|Affected-sib pair (ASP) families and elderly controls
3156320|NCT00339885||Fusion 2|275 Replication ASP Families; Trios
3156321|NCT00339885||Fusion 3|Siblings of FUSION1 families; Spouses, Offspring of 291 FUSION 1 families; Spouses, Offspring of Elderly Controls; Other F1 relatives
3191367|NCT00797849|Sham Comparator|2|Wear prosthetics laminated with sham material surrounding the liner. If not wearing prosthetics, subject needs to wear sock or glove over shrinker.
2463161|NCT03151694||DRD4 and DRD2 Polymorphism Detection|The genetic component of endophenotype for responsiveness to environment (ERE) will be characterized with reference to Taq1A allele in dopamine-2 receptor (DRD2) gene and the exon 3 7-repeat allele of the dopamine-4 receptor (DRD4) gene. This will assist in understanding the role of DRD2 and DRD4 in shaping the neurocognitive functions and link to the eating behaviors of the children and other primary outcome variables.
2463223|NCT03151382|Experimental|Experimental group|
2463225|NCT03151382|Other|Control group|
2463281|NCT03150992|Experimental|Elemental 028 Extra Liquid|All patients will be assessed and given an individual plan for Elemental Diet (ED) introduction. The actual amount of ED prescribed will depend on the tolerance and palatability and not nutritional status. The recommendation of a minimum of 2 cartons of ED will be drunk orally by patients, along with other clear fluids only. Following introduction of ED, patients will be discharged from hospital (if applicable) and followed up for 2 weeks. They will have a telephone follow-up assessment once a week for 2 weeks. All other assessments will follow the standard of care. During the follow-up patients will be assessed using the Memorial Symptom Assessment Scale (MSAS) and will be asked to complete a nutritional diary every day and a quality of life questionnaire at several time points.
2463363|NCT03150524|Active Comparator|Nimodipine|Patients in group one will receive short-acting nimodipine every 4 hours.
2463367|NCT03150524|Active Comparator|Verapamil ER|Patients in group two will receive long-acting verapamil every 12 hours.
2463451|NCT03149926||Patients with Borderline Personality Disorder|
2463452|NCT03149926||Healthy controls|
2463470|NCT03149523||Colorectal cancer|Patient with stage III colon carcinoma
2463474|NCT03149523||Kidney cancer|Patient with clear cell kidney carcinoma more than 4 cm surgically removed
2463478|NCT03149523||Liver cancer|Patient with advanced hepatocellular carcinoma : biopsy or resected BCLC (Barcelona Clinic Liver Cancer) stage B or C for diagnostic and/or therapeutic purposes
2463528|NCT03149302|Experimental|Local neck treatment (LNT)|Cervical mobilization and specific therapeutic exercises
2463529|NCT03149302|Experimental|LNT plus sensorimotor exercises|Local neck treatment plus a tailored sensorimotor exercise program.
2463531|NCT03149302|Experimental|LNT plus balance exercises|Local neck treatment plus balance training program.
2463532|NCT03149302|Experimental|LNT plus sensorimotor/balance exercises|A combination of local neck treatment, sensorimotor control exercise, and balance exercise.
2463587|NCT03148912|Experimental|diagnostic algorithm|Optimizing the interpretation of the more readily available anti-PF4 assay would reduce the reliance on functional testing/ confirmatory testing (Serotonin Release Assay, SRA) and the number of patients exposed to unnecessary changes in anticoagulation therapy while awaiting the timely functional test results
3156322|NCT00339885||Fusion 4/5|Spouses, Offspring of FUSION 1 and 2 Families
3156323|NCT00339885||FUSION Finnish Groups|Family and Population based (including METSIM and DR's EXTRA): Tissue samples
3156324|NCT00339885||Health-2000|Population based individuals
3156325|NCT00339885||HUNT 2|Population based individuals
2463959|NCT03146221|Other|Person to be surgically treated for arteritis|
2464031|NCT03145870|Other|Patient with multiple symptomatic myeloma|
2464059|NCT03145298|Experimental|Biological: Allogeneic Human Cardiosphere-Derived Cells (CDCs)|The Phase 1a portion (N=6 subjects) consists of an open-label, single-arm, study design - dose escalation. The potentially conducted Phase 1b portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design.
2464061|NCT03145298|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=6 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=20 subjects) consists of a double-blind, randomized, placebo-controlled study design with a 1:1 ratio.
2464155|NCT03144583|Experimental|Adult differentiated autologous T-cells|Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z. Such cells will be administered in a single infusion intravenously at a total ARI-0001 cell dose of 0.5-10 x 106 / kg body weight.
2464205|NCT03144466|Experimental|Part A - Starting dose|100mg of pembrolizumab in n=3 patients, administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
2464206|NCT03144466|Experimental|Part A - Escalation dose|Escalation of dose to 200mg of pembrolizumab in a further n=3 patients provided no more than 1/6 patients at starting dose experience a DLT. Increase in cohort by three patients to n=6 patients provided no more than 1/3 patients experience a Dose Limiting Toxicity (DLT).
2464208|NCT03144466|Experimental|Part B - Expansion phase|Recruitment of expansion cohort of n=14 patients using Maximum Tolerated Dose (MTD) of Pembrolizumab as determined in the dose escalation phase. MTD to be administered in 8 cycles every 3 weeks for a total of 18 weeks commencing two weeks prior to first fraction of radiotherapy and given in combination with Radical Radiotherapy, Brachytherapy and Cisplatin Chemotherapy.
2464267|NCT03144063||Toronto Lupus Cohort|"Objective 1 and 3 Cohort:~≥4 American College of Rheumatology (ACR) criteria or 3 ACR criteria plus a typical histological lesion of SLE on renal or skin biopsy~Clinician's diagnosis based on his/her assessment~Patients from the Toronto Lupus Clinic with regular follow-up, defined as having follow up visits at 3 and 6 months from the baseline visit (1st study visit)."
3156326|NCT00339885||METSIM|Population based individuals
3156327|NCT00339885||Savitaipale|Population based individuals
3191368|NCT00797875|Experimental|1|PNF stretching x 5 repetitions for 3 days
2463118|NCT03152123|Experimental|Pitolisant HCl, 40 mg|Pitolisant HCl, 40 mg administered as 2 capsules, each containing 1 × 20 mg pitolisant HCl tablet (over-encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2463123|NCT03152123|Experimental|Pitolisant HCl, 240 mg|Pitolisant HCl, 240 mg administered as 4 capsules, each containing 60 mg pitolisant HCl (3 x 20 mg pitolisant HCl tablets, encapsulated in 1 capsule)
2463131|NCT03152123|Active Comparator|Phentermine HCl, 60 mg|Phentermine HCl, 60 mg administered as 2 capsules, each containing 1 × 30 mg phentermine HCl capsule (over- encapsulated), and 2 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2463133|NCT03152123|Placebo Comparator|Placebo|Placebo administered as 4 capsules, each containing 1 × 100 mg lactose tablet (over-encapsulated)
2463188|NCT03151486|Experimental|Cohort 1:JNJ-55308942 0.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 0.5 milligrams (mg) or matching placebo as an oral solution after an overnight fast on Day 1 of Cohort 1 after single ascending dose (SAD).
2463189|NCT03151486|Experimental|Cohort 2: JNJ-55308942 1.5 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 1.5 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2463190|NCT03151486|Experimental|Cohort 3: JNJ-55308942 4 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 4 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2463191|NCT03151486|Experimental|Cohort 4: (JNJ-55308942 12 mg or Placebo (SAD Part))|Participants will be randomized to receive a single dose of JNJ-55308942 12 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2463195|NCT03151486|Experimental|Cohort 5: JNJ-55308942 36 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 36 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2463196|NCT03151486|Experimental|Cohort 6: JNJ-55308942 100 mg or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 100 mg or matching placebo as an oral solution after an overnight fast on Day 1.
2463200|NCT03151486|Experimental|Cohort 7: JNJ-55308942 or Placebo (SAD Part)|Participants will be randomized to receive a single dose of JNJ-55308942 or matching placebo as an oral solution in a fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
2463202|NCT03151486|Experimental|Cohort 1: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the multiple ascending doses (MAD) will be determined based on the data from the SAD part.
2463204|NCT03151486|Experimental|Cohort 2: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
2463206|NCT03151486|Experimental|Cohort 3: JNJ-55308942 or Placebo (MAD Part)|Participants will be randomized to receive JNJ-55308942 or matching placebo once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
2463271|NCT03150914|Placebo Comparator|Placebo|Overencapsulated matrix
2463273|NCT03150914|Active Comparator|Treatment|Over-encapsulated 1 mg sirolimus tablet
3191369|NCT00797875|Active Comparator|2|passive stretching
3191370|NCT00797888|Experimental|Telephonic|Tailored telephonic intervention to improve HbA1c for participants in the diabetes registry
3191371|NCT00797888|Active Comparator|Standard registry|People with diabetes who are in the A1c registry may receive letters from the DOHMH to promote improved A1c and also give lists of bronx resources for healther foof and activites
2463519|NCT03149666||Evaluation of bitter taste|Participants will be evaluated as to the intensity of bitter taste when performing watery mouthwash with quinine.
2463551|NCT03149081|Experimental|Boswellia|Boswellia will be given at 800mg by mouth three times a day, immediately after each meal. Boswellia will be given from the time surgical resection is scheduled until the night before surgical resection.
2463806|NCT03147560|Experimental|Group 1|The sequential immunization strategy for group 1 on polio was Sabin IPV+ bOPV + bOPV.
2463807|NCT03147560|Experimental|Group 2|The sequential immunization strategy for group 2 on polio was Sabin IPV + Sabin IPV + bOPV.
2463811|NCT03147560|Experimental|Group 3|The sequential immunization strategy for group 3 on polio was Sabin IPV + Sabin IPV + Sabin IPV.
2463930|NCT03146364|Experimental|Hospitalization patients|patients in psychiatric hospitalization will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
2463943|NCT03146364|Experimental|Ambulatory patients|patients being treated in a clinic will take part in tests at Virtual Reality - Virtual Interactive Supermarket environment (diagnosis)
2463990|NCT03146013||HTLV Repeat Reactive (RR) / Non Reactive (NR)|Blood donor specimens that tested repeat reactive on the first FDA licensed HTLV screening assay and non-reactive on the second FDA licensed HTLV screening assay
2464012|NCT03145610|Placebo Comparator|Placebo toothpaste|Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
2464013|NCT03145610|Experimental|triclosan/copolymer/fluoride toothpaste|triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.
2464066|NCT03145454|Experimental|Pain detection|Electroencephalographical responses will be collected during surgical gesture by different intervention: electroencephalography helmet, dermal electrode, blood pressure sensors, pupillometry glasses and Holter.
2464093|NCT03145051|Experimental|Respimer Netiflow mineral salts solution|Nasal irrigation with Respimer Netiflow mineral salts solution, 4 times/day during 8 weeks using Respimer Netiflow class I medical device
2464095|NCT03145051|Active Comparator|Saline solution|Nasal irrigation with saline solution , 4 times/day during 8 weeks using Respimer Netiflow class I medical device
2464149|NCT03144895|Other|Arterial catheter|by anatomical placement alone
2464151|NCT03144895|Other|Placement|of an arterial catheter by ultrasound tracking
2464213|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fluoroscopy|positioning of the right-sided double lumen tube with a wire guide and fluoroscopy
2463217|NCT03151291|Experimental|HMB+EMS group|"HMB supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with HMB (3 g/d)"
2463218|NCT03151291|Experimental|LC group|LC supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)
2463219|NCT03151291|Experimental|LC+EMS group|"LC supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with LC (4 g/d)"
2463220|NCT03151291|Experimental|EPA group|EPA supplemented group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)
2463221|NCT03151291|Experimental|EPA+EMS group|"EPA supplemented physical exercise group performing a regular WB-EMS Training (two WB-EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight) + specific dietary supplementation with EPA (2.2 g/d)"
2463258|NCT03150966|Experimental|Patients who received nanocurcumin|Patients who received nanocurcumin
2463259|NCT03150966|Placebo Comparator|Patients who received placebo|Patients who received placebo
2463300|NCT03150706|Experimental|Avelumab|"The mismatch repair deficient or microsatellite instable, or POLE mutated metastatic colorectal cancer patients who were progressed after at least one prior systemic treatment for metastatic setting.~After checking the eligibility for the study entry, patients will be entered into the study treatment with avelumab monotherapy."
3191372|NCT00797901|Experimental|Collaborative Care, Treatment as Usual|
2463439|NCT03149783|Experimental|Ropivacaine|Participants will have bilateral TAP catheters placed along with continuous infusion of ropivacaine.
2463446|NCT03149783|Placebo Comparator|Placebo|Participants will have bilateral TAP catheters placed along with continuous infusion of placebo.
2463480|NCT03149536|Active Comparator|Group 1|recombinant FSH starting dose: 100 IU to develop a pharmacogenetic test
2463486|NCT03149536|Active Comparator|Group 2|recombinant FSH starting dose: 125 IU to develop a pharmacogenetic test
2463494|NCT03149536|Active Comparator|Group 3|recombinant FSH starting dose: 150 IU to develop a pharmacogenetic test
2463499|NCT03149536|Active Comparator|Group 4|recombinant FSH starting dose: 175 IU to develop a pharmacogenetic test
2463501|NCT03149536|Active Comparator|Group 5|recombinant FSH starting dose: 200 IU to develop a pharmacogenetic test
2463504|NCT03149536|Active Comparator|Group 6|recombinant FSH starting dose: 225 IU to develop a pharmacogenetic test
2463543|NCT03149133|Experimental|Classical Hypertrophy|The classical hypertrophy group performs strength training with 75-80% of 1-Repetition Maximum.
2463544|NCT03149133|Experimental|Occlusive Training|The occlusive hypertrophy group performs strength training with %35-50 of 1-Repetition Maximum.
2463577|NCT03148834|Experimental|Control Reperfusion Primary Angioplasty|Patients admitted with acute myocardial infarction and TIMI flow 0/1, will be treated with the use of an intracoronary venous blood solution and dextran to protect the myocardium during reperfusion.
2463583|NCT03148834|No Intervention|Standard Primary Coronary Angioplasty|Patients admitted with an acute myocardial infarction and TIMI flow 0/1, will be treated with primary angioplasty according to norms described in the international guidelines of treatment.
2463629|NCT03148600|Active Comparator|Intervention arm|Pelvic floor and bowel behavioural training programme provided by physiotherapists over 2- 6 sessions within the 6 months following ileostomy closure for patients with an ileo-anal pouch
2463630|NCT03148600|Placebo Comparator|Standard arm|Standard post-operative nursing and medical care provided in hospital clinic
2463684|NCT03148210|Active Comparator|Enhanced Care|Treatment strategy using evidence-based guidelines for asthma or COPD
2463686|NCT03148210|Placebo Comparator|Standard of Care|Spirometry result sent to family MD
2463724|NCT03147716|Active Comparator|Enrollment Flyer|Participants in this condition received one of the strategies in the Parent Engagement Package: an enrollment flyer that provided information about the Triple P Positive Parenting Program being offered at their child's school, including the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form. Parents who returned the enrollment form received automated text, email and/or phone reminders and a confirmation letter prior to each parenting program session.
2463731|NCT03147716|Experimental|Enrollment Flyer & Testimonial Booklet|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a two-page, testimonial booklet that included photos and quotes from parents and children describing benefits other parents reported after participating in the Triple P Positive Parenting Program and fun activities children reported about the childcare. The booklet also contained the location of meetings, free childcare, choice of days/times and English or Spanish groups, and an enrollment form.
2463738|NCT03147716|Experimental|Enrollment Flyer & Teacher Endorsement|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus a teacher endorsement of the Triple P Positive Parenting Program. The teacher also gave the participant a colorful brochure that included information about the location of meetings, free childcare, topics covered, choice of days/times and English or Spanish groups, and an enrollment form.
2463741|NCT03147716|Experimental|Enrollment Flyer & Engagement Call|Participants in this condition received two of the strategies in the Parent Engagement Package: the enrollment flyer plus an engagement call from a Triple P provider. Providers followed a manualized protocol for implementing the engagement call, which included strategies to increase parental motivation to participate in Triple P and reduce barriers to participation.
2463745|NCT03147716|Experimental|All Engagement Strategies|Participants in this condition received all engagement strategies in the Parent Engagement Package: enrollment flyer, testimonial booklet, teacher endorsement, and provider engagement call.
2463816|NCT03147274|Experimental|Intervention Group|Participants in this group will receive 3 group education sessions led by a diabetes nurse educator in addition to standard care.
2476118|NCT03062644|Experimental|MR308 200 mg bid|Tramadol/Celecoxib
2463247|NCT03150979|Experimental|Provision of a cane|The experimental group will receive a single-point cane, with ergonomic handgrip, which will be individually adjusted to the participant's height. A physiotherapist will provide instructions on how to walk with the cane and the participants will practice for about 15 minutes or until they feel comfortable with the device. Then, they will take the cane home and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
2463251|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
3191373|NCT00797914||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
2463353|NCT03150381|Active Comparator|Weight Loss Only|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight).
2463355|NCT03150381|Experimental|Weight Loss Plus|Group-based behavioral weight loss intervention designed to reach clinically significant weight loss (~5-10% of baseline weight) plus community-level strategies to support healthy weight. Strategies are based on CDC's recommended community strategies and are developed by local contractors. They include expanded farmers markets/gardens, improvement to walking trails, etc.
2463359|NCT03150381|Active Comparator|Control|Educational materials and optional participation in community-wide cancer awareness activities.
3191374|NCT00797927|Experimental|1. quetiapine|quetiapine would replace the original conventional antipsychotic agent
2463472|NCT03149484||Pediatric Group|Children with unilateral conductive hearing loss who are treated with bone conductive devices
2463476|NCT03149484||Parent/Guardian Group|The parent or guardian of a child with unilateral conductive hearing loss who are treated with bone conductive devices
2463524|NCT03149289||HCV RNA positive|hemoglobinopathies with hepatites C treated with antiviral drugs
3156328|NCT00339885||UEF - Laakso|Monogenic disease individuals and family members
3156329|NCT00339937||Cases|Adults in Italy with Kaposi's sarcoma
2463810|NCT03147534|Active Comparator|Children Age 1 month to 2 years|"Collecting temperatures on patients using the ARC InstaTemp MD and a Welch Allyn rectal thermometer."
2463815|NCT03147534|Active Comparator|Children > 2 to 5 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn rectal and Covidien tympanic thermometer."
2463817|NCT03147534|Active Comparator|Children > 5 to ≤ 10 years|"Collecting temperatures on patients using the ARC InstaTemp MD, the Welch Allyn oral and the Covidien tympanic thermometer."
2463889|NCT03146871|Experimental|Treatment (sEphB4-HSA, azacitidine, decitabine)|Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2463956|NCT03146286|Placebo Comparator|Control|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
2463957|NCT03146286|Experimental|Saturated Fat|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.7 g/kg bodyweight palm stearin. 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
2463958|NCT03146286|Experimental|Fish Oil|Chocolate flavoured drink spiked with 15mg/kg [2H31]palmitate (D31palmitate) and singly-labelled water (H218O) containing 0.45 g/kg bodyweight palm stearin and 0.25 g/kg bodyweight fish oil (n3PUFA). 4 hours post test meal a bolus of milk protein (30 g), which has been intrinsically labelled with [13C]phenylalanine, along with 75 g of glucose in 250 ml of water will be given.
2464026|NCT03145857|Experimental|[68]Ga-HA-DOTATATE|All participants will be imaged with [68]Ga-HA-DOTATATE PET/CT or PET/MRI for uptake by somatostatin receptor positive tumours. Up to seven [68]Ga-HA-DOTATATE scans may be performed per participant, as clinically indicated.
2464075|NCT03145311|Active Comparator|Real rTMS|Each patient received real repititive transcranial magnetic stimulation (rTMS) 20 HZ at 100% RMT (a total of 2000 pulses to each hand area consisting of 10 trains of 200 pulses with intertrain interval 30 s), over the hand motor area area for 10 consecutive days
2464076|NCT03145311|Sham Comparator|Sham rTMS|Each patient received repetitive transcranial magnetic stimulation (rTMS) with the same pulse delivery as the 1st group but with the coil placed perpendicular to the scalp.
2464143|NCT03144960|Other|mechanical thrombectomy|The study will be performed involving ischemic stroke patients with proximal occlusion within 4.5 hours from stroke onset, mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption.
3191375|NCT00797927|No Intervention|2. conventional antipsychotics|
2464254|NCT03144167|Other|Patients, aged 18-88, with glioblastoma|
2464334|NCT03143790|Active Comparator|ESWT|500 shockwave 3 different points on penis bilateral
2464337|NCT03143790|Placebo Comparator|Placebo|500 shockwave 3 different points on penis bilateral
3191376|NCT00797940|Experimental|Single Arm|Up to 42 subjects with first recurrence or progression of GBM
2464475|NCT03142633||Women with Polycystic Ovary Syndrome|"Participants of the PICOLO study~Inclusion criteria:~Women aged 18-40 years when included in the PICOLO-cohort, PCOS based on the Rotterdam 2003 consensus criteria Exclusion criteria: Contraceptive pills within 6 weeks from examination, endocrinological disease (i.e. diabetes, thyroid dysfunction), endometriosis and premature ovarian insufficiency, breastfeeding women and pregnancy."
3191377|NCT00797953|Experimental|Low dose|2 capsules of T89 with 1 placebo capsule each time, twice daily. The daily dose is 250 mg.
3191378|NCT00797953|Experimental|High dose|3 capsules of T89 each time, twice daily. The daily dose is 375 mg
3191379|NCT00797953|Placebo Comparator|Placebo|3 placebo capsules (PC) each time, twice per day. The daily dose is 0 mg.
3191380|NCT00797979|Experimental|1|Skull Grip bone fixation
2463279|NCT03150810|Experimental|Dose Expansion, 6 cohorts|Participants receive continuous BGB-290 and TMZ at the recommended phase 2 dose (RP2D) and schedule in 28 day cycles
2463352|NCT03150303||Vitamin K Antagonists (VKA)|Patients on VKA
2463356|NCT03150303||Direct Oral Anticoagulant (DOAC)|Patients on OAD
2463400|NCT03150134|Experimental|early reduction|Usually in the absence of GvHD, immunosuppressive drugs(Cyclosporine) were gradually reduced by 6 weeks and discontinued in three months after transplant in the advanced patients while immunosuppressive agents were gradually reduced by 2 months and discontinued in four months after transplant in the advanced patients in haploidentical SCT even if complete donor chimerism (CDC) achieved. If donor chimerism had not achieved CDC with no significant acute GVHD at four weeks after HSCT, immunosuppressive agents were gradually reduced. If GvHD was present during the time of immunosuppressive agents reduction, CsA was added again and tapering was done over longer periods.
2463402|NCT03150134|Placebo Comparator|routine reduction|Arm/Group Descriptions.Immunosuppressive drugs(cyclosporine) were routine reduced by 3 months and discontinued in the 5 months without GvHD in the CR group. We used the result of chimerism as the reference.
2463414|NCT03149835|Experimental|COPD|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination. Before initiating the protocol, patients were asked about discomfort related to NIV or any aspect of the experiment.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
2463421|NCT03149835|Experimental|Healthy Control|"After study enrollment, 15 days before the performance of the experimental protocol, patients performed neurocognitive tests (Digit Span Test, Digit Symbol-Coding, Corsi Block-tapping, Trail Making Test A and B and Stroop Test) and NIV adaptation. Pulmonary function (spirometry) was measured in all subjects after a thorough medical history and physical examination.~CBF was measured by transcranial Doppler by mean of LMCAFV immediately before NIV, during NIV at 5, 30 and 60 minutes and after NIV removal at 5 and 30 minutes. ABG were collected immediately before the experiment, after one hour of NIV breathing and 30 minutes after NIV discontinuation."
2463463|NCT03149692|Experimental|Penile allograft|Penile human allografts transplanted
2463479|NCT03149419|Active Comparator|Paroxetine|Paroxetine 7,5 mg - 1 pill/day for 12 weeks
2463485|NCT03149419|Placebo Comparator|Placebo|Placebo oral capsule (corn starch) - 1 pill/day for 12 weeks
2463555|NCT03149250||Pregnant Preeclampsia|"Pregnant between 35th and 40th week of pregnancy Preeclampisa~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling"
2463558|NCT03149250||Pregnant No-Preeclampsia|Control Group 1 Pregnant between 35th and 40th week of pregnancy No Preeclampsia Healthy Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling in the context of routinely performed blood sampling
2463564|NCT03149250||Not Pregnant|"Control group 2 Healthy and not pregnant control group~Intervention: Aggregometry, Monitoring of plasmatic hemostasis: Aggregometry and conventional coagulation testing after blood sampling."
2463591|NCT03148678|Experimental|Mindfulness first; Contingent RT-fMRI-NF|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
2463594|NCT03148678|Sham Comparator|Mindfulness first; Non-Contingent Neurofeedback|"Participants start with the mindfulness intervention followed by the mind wandering intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
2463595|NCT03148678|Experimental|Mind wandering first; Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type experimental refers to contingent RT-fMRI-NF, during which participants are provided with contingent RT-fMRI-NF of their own brain activity."
2463598|NCT03148678|Sham Comparator|Mind wandering first; Non-Contingent Neurofeedback|"Participants start with the mind wandering intervention followed by the mindfulness intervention. The arm type sham comparator refers to non-contingent RT-fMRI-NF, during which participants are provided with sham RT-fMRI-NF of brain activity of previously recorded subject."
2463646|NCT03148301||Patients with Spina Bifida|Adults with and parents of children with Spina Bifida followed by the team in UZ Leuven will be asked to complete a survey
2463685|NCT03148132|Active Comparator|Bevacizumab injection|Application of Intravitreal Bevacizumab (0.50mg/0.02mL), unique dosis
2463689|NCT03148132|Experimental|Ranibizumab Ophthalmic|Application of Intravitreal Ranibizumab (0.25mg/0.025mL), unique dosis
2463743|NCT03147833|Experimental|Sport beverages Protein|Intervention group ingesting PROTEIN
2463747|NCT03147833|Active Comparator|Sports beverage Carbohydrate|Placebo group ingesting carbohydrate
2463782|NCT03147430||Invasive Cancer|Invasive cancer confirmed by biopsy
2463794|NCT03147430||Benign or pre-invasive lesion|Benign or pre-invasive lesion confirmed by biopsy
2463835|NCT03147105|Experimental|arm ergometry|Home-based treatment after education in center, training following interval training plan on chip cards for 12 weeks at least 4-5 times/week
2463837|NCT03147105|Active Comparator|waiting group|training after 12 weeks.
2463871|NCT03146728||tetraplegia, paraplegia|motor complete spinal cord injured individuals with tetraplegia or paraplegia
2463874|NCT03146728||able-bodied|age height and weight matched able bodied
2463928|NCT03146481|Experimental|Aceclofenac|Aceclofenac 100 mg tablet
2463938|NCT03146481|Placebo Comparator|placebo|Placebo
2464020|NCT03145961|No Intervention|Observation|Patient will have blood samples collected for ctDNA analysis every 3 months for up to 2 years from starting ctDNA screening.
2464055|NCT03145402|Experimental|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells injection in patients with Heart Failure
2464056|NCT03145402|Placebo Comparator|Placebo|Placebo injection via coronary arteries in patients with Heart Failure
2463318|NCT03150667|Active Comparator|Clopidogrel|Eligible patients randomized to the Clopidogrel arm will receive open label drug at a dose selected by their providers along with 81mg aspirin. These patients will be followed for 1 year through chart review for events. For event free patients, a phone follow-up will be done at the end of 1 year to record events These events be documented in the medical records
3156330|NCT00339937||Controls|Adults in Italy without Kaposi's sarcoma
2463418|NCT03150121|Experimental|Ovarian cancer patients|High grade ovarian/fallopian tube/primary peritoneal carcinoma patients with current active disease, at any stage and histological type, who have not yet undergone debulking surgery.
2463429|NCT03150121|Active Comparator|Non-malignant controls|Patients with non-malignant gynecological conditions indicating surgical procedure, either salpingo-oophorectomy, hysterectomy or hysteroscopy.
2463435|NCT03150121|Experimental|High risk population|Healthy women with genetically high risk for developing ovarian cancer, who have not undergone risk reducing procedure.
2463466|NCT03149458|Experimental|Dance group|dance program for 8 one-hour sessions.
2463467|NCT03149458|Active Comparator|control group|upper limb rehabilitation for 8 one-hour sessions.
2463530|NCT03149354|Other|Patients with HIV|Patients with HIV
2463538|NCT03148938|Experimental|Patients with Multiple Sclerosis|Patients will perform one or two visits at 15 days interval. Patients will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B), followed by a crossover to the other group at day 15 for patients who will do two visits.
2463539|NCT03148938|Active Comparator|Healthy volunteer|Healthy volunteers will only perform one visit. Healthy volunteers will be randomly assigned to either traditional/digital group (Group A) or digital/traditional group (Group B).
2463588|NCT03148821||Healthy volunteer participants|The investigators propose a snap shot study in a group of healthy volunteers of varying BMIs, laying on surfaces a patient would be exposed to during their hospital stay. Participants will lie on a variety of surfaces they may find themselves on during an emergency admission to hospital, including an operating table, in a variety of positions. Participants pressure distributions in each scenario will be measured with a pressure sensing mattress.
2463637|NCT03148509|Experimental|bupropion|receive bupropion
2463640|NCT03148509|Experimental|risperidone|receive risperidone
2463643|NCT03148509|Experimental|aripiprazole|receive aripiprazole
2463707|NCT03148002|Active Comparator|Current Bowel Protocol|Patients will receive the Current Bowel Protocol with senna. Lactulose will be used for rescue therapy.
2463710|NCT03148002|Active Comparator|PEG Bowel Protocol|Patients will receive the Protocol with Polyethylene Glycol 3350. Lactulose will be used for rescue therapy.
2463763|NCT03147612|Experimental|Treatment (chemotherapy, ponatinib, blinatumomab)|See Detailed Description.
3156331|NCT00339950||1|Asymptomatic women between the ages of 40 and 75 referred to regional military medical centers for routine colorectal screening
3156332|NCT00339989||Women undergoing colposcopy|women attending the University of Oklahoma Colposcopy Clinic
2463993|NCT03145844||Direct Acting Agents|No Intervention
2464098|NCT03145571|Other|Continuity of midwifery care|Clinics where the continuity of midwifery care program was implemented during 2013
2464103|NCT03145571|No Intervention|Control|Clinics where no structured changes had been made to the ante- and post- natal care during the period 2013-2015
2464185|NCT03144921|Experimental|EPIC A|Group A will start the EPIC intervention immediately after assessment 1. The EPIC program consists of a 7-session, psychoeducational skills training intervention designed to provide education and skills on how to prepare for the future and reduce stress regarding memory changes and loss for both the person with early-stage dementia and their care partner. Following the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
2464188|NCT03144921|Active Comparator|EPIC B (WLC)|Group B - the wait list comparison (WLC) group - will have a 75-minute group education session (comparator intervention) about 3 weeks after baseline assessment. The WLC session is an overview of memory loss/dementia and its related impact for EPs and CPs and an overview of aging network services in the community. They will receive a brief telephone check-in call approximately 3 weeks before the T2 assessment. The WLC group will start the complete EPIC psychoeducational skills training intervention immediately after Assessment 2. Following completion of the 7 EPIC sessions, participants will attend monthly booster sessions up to 12 months to reinforce the skills/lessons.
2464216|NCT03144336|Experimental|Intervention group|"Participants in the intervention group will be able to accumulate rewards points for correctly answering weekly quizzes regarding the HIV prevention information; these reward incentives aim to encourage retention in the study and improve HIV prevention knowledge engagement and recollection.~Intervention 'Rewards for testing HIV-negative' Every three months those in the intervention group can win a prize based on testing HIV-negative at least once during that time period. The chance of winning will increase based on the number of reward points a participant accumulates by correctly answering questions on the weekly quizzes."
2464220|NCT03144336|Active Comparator|Control group|Intervention: Information provision: Participants in the control group will receive weekly information by SMS to encourage retention in the study and improve HIV prevention knowledge engagement and recollection. They are encouraged to come to the clinic every three months to test for HIV but do not receive any incentives for answering messages or for the HIV tests.
2464305|NCT03143907|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
2464308|NCT03143907|Other|Group-B - Delayed Intervention|6 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
2464361|NCT03143335|Active Comparator|Retropectoral immediate breast reconstruction|Participants are randomized to immediate breast reconstruction with the implant placed retropectoral.
2464367|NCT03143335|Active Comparator|Prepectoral immediate breast reconstruction|Participants are randomized to direct to immediate breast reconstruction with the implant placed prepectoral using acellular dermal matrix for support.
3191381|NCT00797979|Active Comparator|2|Standard skull bon flap fixation, sutures
3156333|NCT00340210||Serum Bank Participants|The Columbia MO Serum Bank recruited 6915 women living in and around Columbia MO between 1977-1987 who were cancer-free except for non-melanoma skin cancer and at least 18 years of age.
3191382|NCT00797992|Experimental|1|Myopic eyes with retinal neovascularization
3191383|NCT00798031|Other|1|a minimum of two dental implants, but up to 3 dental implants, will be placed in each of 20 subjects. All surgical procedures will be performed as outpatient procedures at the College of Dentistry and implant placement will follow a one-stage procedure under local anesthesia. Placement of the 2-3 dental implants is the only intervention.
2463506|NCT03149718|Active Comparator|SMC (n=23)|Standard Medication Counseling.
2463507|NCT03149718|Experimental|BI-MTM (n=23)|Brief Intervention Medication Therapy Management.
2463557|NCT03149094|Experimental|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
2463560|NCT03149094|Active Comparator|CBSM-SMI control|The control group will receive an app called LifeSum, which focuses on healthy lifestyles.
2463609|NCT03148665||Control population|Control population (n=150): absence of current or prior oropharyngeal carcinoma, no active cancer diagnosis. Control population includes at least 50 subjects who have smoked at least 100 cigarettes during lifetime OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as a one-time test for control subjects
2463612|NCT03148665||Cancer population|Cancer population (n=150): patients with previously untreated oral cavity or oropharynx squamous cell carcinoma with absence of distant metastasis OncAlert saliva-based screening, a noninvasive point of care salivary rinse test performed as at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
3156334|NCT00340262||FIT Participants|
3156335|NCT00340288||Premenopausal fibroid cases|Premenopausal women (18 years or older) with at least one uterine leiomyoma diagnosis confirmed by ultrasound
3156336|NCT00340340||Cases|Newly diagnosed lung cancer cases
2463691|NCT03148041|Active Comparator|intensive health education program|Participants in the intervention group will have an intensive health education program of the introductory lecture and brochures about stroke as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
2463694|NCT03148041|Placebo Comparator|routine care|Participants in the control group will have a routine care of different lecture and brochures than the intervention group as well as they fill up the questionnaire at baseline. At week 6 and 12 of the study the participants will only fill up the questionnaire.
2463748|NCT03147872|No Intervention|5% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will continue to have their embryos cultured at 5% oxygen until they are deemed to be clinically usable or not clinically usable (as per standard protocol).
2463750|NCT03147872|Experimental|2% Oxygen|All patients' embryos will be cultured in 5% oxygen from day 1 through 3 of development. After day 3 of development, patients randomized to this arm will have their embryos cultured at 2% oxygen until they are deemed to be clinically usable or not clinically usable (per standard criteria).
3156337|NCT00340340||Controls|Population-based controls
3156338|NCT00340457||Cases|African American patients with renal cancer from two geographic areas of the US
2463839|NCT03147066|Experimental|Dezocine|0.1 mg/kg of intravenous dezocine 30 min before the end of surgery
2463844|NCT03147066|Active Comparator|Flurbiprofen axetil|1 mg/kg of intravenous flurbiprofen axetil 30 min before the end of surgery
2463917|NCT03146546||Septic Shock|Patients with septic shock as defined by the Sepsis-3 criteria(9)
2463918|NCT03146546||Septic Shock with AKI|Patients with septic shock as defined by the Sepsis-3 criteria(9) with concomitant AKI
2463982|NCT03146182|No Intervention|Control|Patients are treated according to current local guidelines on antibiotic treatment for CAP.
2463985|NCT03146182|Experimental|CRP|Patients are treated according to the CRP-algorithm. CRP is measured daily. Antibiotic treatment is stopped when CRP reach threshold value.
2463987|NCT03146182|Experimental|PCT|Patients are treated according to the PCT-algorithm. PCT is measured daily. Antibiotic treatment is stopped when PCT reach threshold value.
2463998|NCT03145649||Gestational diabetes mellitus|Women with gestational diabetes mellitus and their infants. The blood glucose of women with gestational diabetes mellitus was controlled by dietary therapy or insulin injection.
2463999|NCT03145649||Healthy|Healthy mother-infant dyads
2464046|NCT03145480|Experimental|Fit arm|ibrutinib and obinutuzumab in combination with the CHOP regimen
2464047|NCT03145480|Experimental|Frail arm|ibrutinib and obinutuzumab
2464111|NCT03145194|Experimental|Ticagrelor|Patients will receive Ticagrelor 180mg (2 x 90mg tablets)
2464114|NCT03145194|Placebo Comparator|Placebo|Patients will receive Placebo (2 matching tablets)
2464157|NCT03144778|Experimental|Cohort I (durvalumab)|Participants receive durvalumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
2464165|NCT03144778|Experimental|Cohort II (durvalumab, tremelimumab)|Participants receive durvalumab IV over 1 hour and tremelimumab IV over 1 hour on days 1 and 29 in the absence of disease progression or unaccepted toxicity. Between days 52 and 72, participants undergo standard of care surgery.
2464239|NCT03144128|Placebo Comparator|Control (Ctl)|Standard of Care resistance exercise and timed protein supplementation with placebo capsule daily for 12 weeks
2464241|NCT03144128|Experimental|Vitamin D|Standard of Care resistance exercise and timed protein supplementation with 5,000IU vitamin D supplementation daily for 12 weeks
2464280|NCT03143842|Other|Vagus Nerve Stimulation|VNS paired with word pairs, VNS unpaired with word pairs, no VNS
2464408|NCT03143153|Experimental|Nivolumab + Ipilimumab|
2464413|NCT03143153|Experimental|Nivolumab + Cisplatin + Fluorouacil|
3156339|NCT00340457||Controls|African American participants without renal cancer from two geographic areas of the US
3156340|NCT00340535||Individuals|Individuals recruited at U of Pittsburgh
2463395|NCT03150537|Active Comparator|IM injection (pre-filled syringe)|20 participants will receive Fluviral influenza vaccine using pre-filled syringes for time-motion comparison to Med-Jet H4
2463398|NCT03150537|Active Comparator|IM injection (multi-dose vial)|20 participants will receive Fluviral influenza vaccine using a multi-dose vial for time-motion comparison to Med-Jet H4
2463422|NCT03149913|Experimental|Drug coated balloon|SeQuentPlease OTW paclitaxel coated balloon catheter
2463430|NCT03149913|Active Comparator|uncoated PTA balloon catheter|Standard of care uncoated BTK balloon catheter
2463473|NCT03149497|Active Comparator|improved anterior approach only in traumatic cervical spine|
2463475|NCT03149497|Active Comparator|failed anterior approach only in traumatic cervical spine|
2463536|NCT03149341||Study|Congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
2463537|NCT03149341||Normal Volunteers|No congenital heart disease or acquired cardiopulmonary disease who will get (or have gotten) and MRI
2463576|NCT03148886|Experimental|PA intervention|The intervention consisted in a home-based adapted PA program defined at the inclusion, according to patient's capacities.
2463619|NCT03148587|Experimental|Multi-level pregnancy test (MLPT)|Patients randomized to multi-level pregnancy test (MLPT) arm will receive MLPTs to perform at home one and two weeks after taking mifepristone. They will be asked to interpret the results of the MLPT as it relates to their pregnancy termination status.
2463622|NCT03148587|Experimental|Low sensitivity pregnancy test (LSPT)|Patients randomized to low sensitivity pregnancy test (LSPT) arm will receive LSPTs to perform at home at one and two weeks after taking mifepristone. They will be asked to interpret the results of the LSPT as it relates to their pregnancy termination status.
2463697|NCT03148314|Other|hospital- based standard dose of vaginal misoprostol|
2463701|NCT03148314|Other|Home-based extended low dose of buccal/sublingual misoprostol|
2463736|NCT03147768|Experimental|Distal Pancreatectomy Sealing using LTW|At the completion of pancreatic resection, the cut surface of the pancreas is covered with two layers of Albu-Green solder and one layer of D-Albumin lamina, all welded with the laser. The 60 Watt custom 810nm diode laser, is set to deliver continuous energy with laser irradiation power of approximately 150 W/cm2 with a Fluence of 90 J/cm2. During soldering the tip of the custom hand piece with top hat beam profile is held 1-2 cm from the wound surface to generate a 5mm spot size. Albu-Green Solder is observed to convert from a liquid green state to a solid white crust when the laser is activated indicating the completion of welding and providing a visual cue to the operator. The amount of Albu-Green solder and size of the denatured albumin lamina used is documented. The total laser tissue welding time for the three layers and the laser tissue welding time in seconds per cm2 is documented.
2463785|NCT03147404|Experimental|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
2463882|NCT03146754|Experimental|Stable ADHF patients|Lung ultrasound to access b lines
2463885|NCT03146754|Active Comparator|Control Patients|Patients without any cardiopulmonary disease will be control patients for the active subjects, age-matched accordingly.
2463908|NCT03146416|Experimental|Cohort 1|Evinacumab SC or placebo SC
2463909|NCT03146416|Experimental|Cohort 2|Low dose regimen: evinacumab IV or placebo IV
2463910|NCT03146416|Experimental|Cohort 3|High dose regimen: evinacumab IV or placebo IV
2463911|NCT03146416|Experimental|Cohort 4|Evinacumab or placebo SC every week (QW) x 8 doses
2463912|NCT03146416|Experimental|Cohort 5|Evinacumab or placebo SC x 1 dose
2463977|NCT03146169|Experimental|Training group|Four two-hour training sessions were conducted at baseline, and one week, one month and three months after the first session.
3191384|NCT00798044|Experimental|Feedback to counselors|substance abuse counselors received feedback reports on their average performance and on the average performance of the clinic as a whole. Feedback reports contained information on average alliance, treatment satisfaction, and drug/alcohol use.
3191385|NCT00798044|No Intervention|Treatment as Usual|No feedback reports were provided in this arm.
3191386|NCT00798057||Proton Radiation|
3191387|NCT00798070|Experimental|Arm A: dtEC→dtT|Individually tailored and two weekly dosed epirubicin + cyclophosphamide followed by a three weeks break followed by biweekly and tailored docetaxel (dtEC→dtT) given every second week
3191388|NCT00798070|Active Comparator|Arm B: FEC→T|Fixed dosed and three weekly epirubicin, cyclophosphamide and 5-fluorouracil, followed by fixed dosed and three weekly docetaxel
2464255|NCT03144154|Experimental|Experimental group : Hypnosis-based intervention|Groupal intervention combining self-care techniques and self-hypnosis exercises
2464258|NCT03144154|No Intervention|Control group : Usual care|Control group receiving usual care but not the intervention
2464301|NCT03143777|No Intervention|Baseline|Standard physiotherapy and mobilisation
2464303|NCT03143777|Experimental|Sara Combilizer group|Ongoing care with the sara combilizer available for use
2464358|NCT03143426|Experimental|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualisation.
2464362|NCT03143426|No Intervention|2D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 2D visualisation, the standard viewing method used during all laparoscopic surgeries currently.
2464425|NCT03142997||group S|anesthetized children on spontaneous ventilation.
2464426|NCT03142997||group C|anesthetized children on controlled ventilation.
2464788|NCT03140384|Active Comparator|Administration of oral Misoprostol|
2464790|NCT03140384|Active Comparator|Administration of Misoprostol vaginally|
2464792|NCT03140384|Active Comparator|Administration of buccal Misoprostol|
2464846|NCT03140280|Experimental|Dietary Intervention|Freeze-dried black raspberry powder administration.
2464874|NCT03139955||Bodytrak|This is a single group study. 8 participants will be recruited and will receive the same intervention of physiological data collection using Bodytrak.
2464933|NCT03139487|Active Comparator|Low molecular weight heparin|Dalteparin, 200 IU/kg subcutaneously once daily for 4 weeks followed by 150 IU/kg once daily for 20 weeks
2463409|NCT03149900||Secukinumab|"Patients will be recruited in the Comprehensive Center for Inflammation Medicine. The study population will consist of 40 subjects (both male and female), aged 18 years and older, in whom treatment with Secukinumab is clinically indicated and according to the licensed product specifications. The study drug will be prescribed by a doctor who is independent of this study. Visit 1 will be carried out prior to the first injection of Secukinumab.~All patients will receive a number and the data will be recorded in a pseudo-anonymised form. No blinding is necessary for investigators or patients (open study), as all patients receive the same treatment (marketed product)."
2463468|NCT03149432|Active Comparator|Reference analgesic|Gabapentin Rehabilitation Local care
2463469|NCT03149432|Experimental|reference analgesic and mirror therapy|Mirror Therapy Gabapentin Rehabilitation Local care
2463569|NCT03149198|Experimental|Interventional group|Mat pilates exercises
2463571|NCT03149198|Active Comparator|Control group|Aquatic aerobic exercises
2463620|NCT03148639|Experimental|Avatar therapy|Immediate Avatar therapy.
2463624|NCT03148639|Other|Treatment-as-usual|Treatment-as-usual then delayed Avatar therapy.
3191389|NCT00798109|Experimental|Motivational Therapy|Four motivational interview for cannabis abuse in schizophrenia population during one month
3191390|NCT00798109|Other|Usual Care|Usual care with intensive psychotherapy
2463742|NCT03147729|Other|Radiofrequency in anal incontinence: a pilot study|It will be a single arm study with a group of anal incontinence with 10 women with anal incontinence
2463768|NCT03147456|Experimental|Intervention group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies.Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day, over 3-5 intervals). Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient (Cubitan Protein, Nutricia, Netherlands).
2463770|NCT03147456|Placebo Comparator|Control group|Patients will receive nutritional counseling by a bariatric dietitian in a routine round, aiming that they will know the post-surgery diet stages and to not develop any nutritional deficiencies. Before discharge from the hospital, patients will receive supplement and will be advised by the dietitian regarding its use (one can per day over 3-5 intervals).Following hospital discharge, Control patients will receive supplement contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes (preOp, Nutricia, Netherlands).
2463826|NCT03147183||candidates for renal transplant|
2463867|NCT03146845|Experimental|Allevyn Life Non-Bordered|Foam Dressing
2463869|NCT03146845|Other|Standard care|Standard care dressing
2463932|NCT03146468|Experimental|Nivolumab treatment arm|Nivolumab injection 3mg/kg intravenously every 2 weeks
2463976|NCT03146052|Experimental|Asymmetric split dose preparation|75% of the dose is given on the day before of the procedure and 25% of the dose is given on the day of the procedure
2463984|NCT03146052|Active Comparator|Symmetric split dose preparation|50% of the dose is given on the day before of the procedure and 50% of the dose is given on the day of the procedure
2464048|NCT03145688|No Intervention|Control|The control group package will consist of the Canadian 24 Hour Movement Guidelines recommending 60 minutes of moderate to vigorous physical activity per day for children. The guide also contains arguments & information about the benefits of physical activity.
2464049|NCT03145688|Experimental|Family physical activity Planning|Behavoural: Family Physical Activity Planning. The physical activity planning intervention condition will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include workbook on how to plan for family physical activity; brainstorming exercises for parents & children where they list physical activities that they have found fun in the past, as well as some new activities they would like to try & skill training content to help with goal setting & tracking of physical activity.
2464050|NCT03145688|Experimental|Family Physical Activity Habit Formation|Behavioural: Family Physical Activity Habit formation. The Habit formation intervention condition will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. The material includes a brief discussion of what habits are with some very straightforward examples such as preparing for sleep routines or initiating to drive a car to work. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms.
2464108|NCT03145168|Experimental|High Target Mean Arterial Pressure|
2464112|NCT03145168|Active Comparator|Low target Mean Arterial Pressure|
2464172|NCT03144856|Experimental|Apatinib group|Apatinib 500mg, po, QD, every 4 weeks.
2464201|NCT03144375|Active Comparator|Medical Optimization|Medical treatment and education x 4 months, re- eval at 4 months and possible cross-over to surgery
2464202|NCT03144375|Active Comparator|Surgical treatment|Surgical treatment up front
2464265|NCT03144141|Other|Patients with the diagnosis of threat of uterine delivery|
2464299|NCT03143699|Experimental|Immediate feedback|Submitted to a training on blood pressure measurement skills and an immediate feedback after their encounter with an standardized patient - SP
2464304|NCT03143699|No Intervention|Students with no immediate feedback|Submitted to a training on blood pressure measurement skills, but without an immediate feedback after their encounter with an standardized patient - SP
2464405|NCT03143413||Systemic sclerosis|Systemic sclerosis is an autoimmune connective tissue disease with undefined etiology and characterized by progressive fibrosis of the skin and major organs. Dry eyes and / or buccal syndrome is commonly reported in patients with systemic sclerosis.
2464409|NCT03143413||Gougerot-Sjogren syndrome|Goujerot-Sjogren syndrome is a chronic autoimmune disorder that is characterized by dryness of the eyes (xerophthalmia) and / or mouth (xerostomia).
2464411|NCT03143413||Sicca-Asthenia-Polyalgia syndrome|It may be primary or secondary to another connective tissue disease (such as lupus, rheumatoid arthritis or other).
2464445|NCT03142737|Experimental|Red kidney bean intake|Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
2464449|NCT03142737|Experimental|Eggs intake|Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
2476119|NCT03062644|Active Comparator|Tramadol 100 mg qid|Tramadol
2463411|NCT03149822|Experimental|Phase 1: Pembrolizumab 200 mg plus Cabozantinib 60mg|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib 60 mg orally once daily until disease progression, unacceptable toxicity, or consent withdrawal.
2463412|NCT03149822|Experimental|Phase 2: Pembrolizumab 200 mg plus Cabozantinib at the RP2D|Pembrolizumab 200 mg intravenous (IV) infusion on day 1 of each 21-day cycle in combination with cabozantinib at the RP2D orally once daily for up to 35 cycles, until disease progression, unacceptable toxicity, or consent withdrawal. All participants who stop pembrolizumab after 35 cycles with SD or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping pembrolizumab from the initial treatment phase.
2463502|NCT03149510|Experimental|Mobile Application|Participants will be using a mobile application, activity monitor and scale.
2463505|NCT03149510|No Intervention|Control Group|Participants will receive standard of care.
2463545|NCT03149185|Active Comparator|T-CBSM|Technology based cognitive behavioral stress management.
2463546|NCT03149185|Active Comparator|T-HP|Technology based health promotion (control condition)
2463623|NCT03148535|Experimental|lithium carbonate|recieve lithium carbonate
2463627|NCT03148535|Experimental|lithium carbonate combined with SSRI antidepressant treatment|recieve lithium carbonate combined with SSRI antidepressant treatment
2463683|NCT03148223|Experimental|Intervention|Auriculotherapy with application of mustard seeds fixed with adhesive tape at specific points in the auricle during one session per week lasting 20 minutes for 3 consecutive months.
2463688|NCT03148223|Placebo Comparator|Control|Auriculotherapy with tape-only fixation in the auricle, without mustard seeds, following the same stitch protocol used with the intervention group, during a session per week lasting 20 minutes, for three consecutive months.
2463752|NCT03147846|Experimental|delayed cord clamping|"Keep the baby at the level or below the placenta for 45-60 seconds before clamping the cord.~Keep the room temperature at 23-25˚C and wrap the baby if possible"
2463755|NCT03147846|Active Comparator|cord milking|Do 4-5 strips from proximal (maternal) end of the cord (as proximal as possible) towards the baby abdomen with thumb and forefinger Wait for 2 seconds between each stripping Keep the baby at the level of placenta
2463790|NCT03147352||NSTI patients|NSTI is an infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and that spreads along tissue structures.
2463799|NCT03147352||Orthopaedic control patients|Elective orthopaedic control patients.
2463828|NCT03147053|Experimental|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules .
2463829|NCT03147053|Placebo Comparator|Placebo|Patients in this group were administered the placebo .
3191391|NCT00798122|Experimental|Women|IVUS and MRI performed in women with no obstructive CAD at angiography
2464016|NCT03146104|Active Comparator|Group P|Maintenance of anesthesia with 100-150mcg/kg/min propofol, O2 and air and FiO2 of 40%
2464019|NCT03146104|Active Comparator|Group I|Maintenance of anesthesia with 1 MAC of isoflurane,O2 and air and FiO2 of 40%
2464067|NCT03145376||patients before and after TAVI/MitraClip|geriatric assessment of patients before and after TAVI/Mitraclip
3191392|NCT00798148|Experimental|MIBG|
3191393|NCT00798187||Homogeneous Support Group|
2464363|NCT03143543|Experimental|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
2464369|NCT03143543|Placebo Comparator|Group B Parallel Placebo|Placebo orally for 7 days vs Group A
2464375|NCT03143543|Experimental|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
2464380|NCT03143543|Placebo Comparator|Group B2Parallel Placebo|Placebo orally for 7 days vs Group A2
2464561|NCT03141970|Experimental|Intervention: Prednisolone|Drug: 12- Weeks of Prednisolone Therapy Subjects will add an additional 12 weeks of Prednisolone to follow pre-randomization standard of care prednisolone. Post randomization Prednisolone therapy of 30 mg/m2 on alternate days for 4 weeks, 20 mg/m2 on alternate days for 4 weeks, and 10 mg/m2 on alternate days for 4 weeks
2464563|NCT03141970|No Intervention|No intervention|Subjects will NOT receive 12-weeks of additional Prednisolone therapy following randomization
2464615|NCT03141671|Experimental|GnRH + Bicalutamide|"GnRH agonist injection monthly or every 3 months for 6 months~Bicalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
2464620|NCT03141671|Experimental|GnRH+Abiraterone+Apalutamide+Prednisone|"GnRH agonist injection monthly or every 3 months for 6 months~Abiraterone acetate by mouth once/day for 6 months~Prednisone by mouth once/day for 6 months~Apalutamide by mouth once/day for 6 months~Salvage radiation (starting 4-10 weeks after initiation of ADT)"
3191394|NCT00798187||Heterogeneous Support Group One|
3191395|NCT00798187||Heterogeneous Support Group Two|
2464764|NCT03140813|Experimental|Placebo - Low-Dose - High-Dose|Placebo AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules
2464767|NCT03140813|Experimental|Placebo - High-Dose - Low-Dose|Placebo AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules
2464770|NCT03140813|Experimental|Low-Dose - Placebo - High-Dose|AZD7325 5mg BID in gelatin capsules Placebo AZD7325 15mg BID in gelatin capsules
2464771|NCT03140813|Experimental|Low-Dose - High-Dose - Placebo|AZD7325 5mg BID in gelatin capsules AZD7325 15mg BID in gelatin capsules Placebo
2464772|NCT03140813|Experimental|High-Dose - Low-Dose - Placebo|AZD7325 15mg BID in gelatin capsules AZD7325 5mg BID in gelatin capsules Placebo
3191396|NCT00798200|Other|Exercise|All participants will take part in a supervised, structured, exercise program
3191397|NCT00798213|Experimental|Participants with AML randomized to SCH 727965|
3191398|NCT00798213|Active Comparator|Participants with AML randomized to gemtuzumab ozogamicin|
3191399|NCT00798213|Experimental|AML treated w/ SCH 727965 after prog. on gemtuzumab ozogamicin|
3191400|NCT00798213|Experimental|Participants with ALL treated with SCH 727965|
3191401|NCT00798226|Active Comparator|1|n-3 fatty acid
3191402|NCT00798226|Placebo Comparator|2|Olive oil
3191403|NCT00798239|Active Comparator|Control|The control arm is Iliac Crest Autograft
3191404|NCT00798239|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
3191405|NCT00798239|Experimental|Prefix 750|Prefix (AMPLEX) B2A Enhanced Ceramic Granules
3191406|NCT00798252|Experimental|Arm A (Capecitabine + Brivanib alaninate)|
2463661|NCT03148483|Experimental|Early PT plus Fortified Milk|early periodontal therapy (during pregnancy) plus fortified milk
2463662|NCT03148483|Experimental|Early PT plus Plain Milk|early periodontal therapy (during pregnancy) plus plain milk
2463663|NCT03148483|Experimental|Delayed PT plus Fortified Milk|delayed periodontal therapy (after delivery) plus fortified milk
2463664|NCT03148483|Placebo Comparator|Delayed PT plus Plain Milk|delayed periodontal therapy (after delivery) plus plain milk
2463711|NCT03147989||Group 1, 0.10 mmol/kg|For patients having received MULTIHANCE at a standard dose of 0.10 mmol/kg for their clinically indicated MRI examination.
2463712|NCT03147989||Group 2, 0.05 mmol/kg|For patients having received MULTIHANCE at a dose of 0.05 mmol/kg for their clinically indicated MRI examination.
2463716|NCT03147651||Cystic Fibrosis (CF) bronchiectasis|Diagnosis of Cystic Fibrosis (CF), follow up in a CF center, evidence of bronchiectasis on computed tomography (CT).
2463717|NCT03147651||non-Cystic Fibrosis (CF) bronchiectasis|Negative evaluation for of Cystic Fibrosis (CF), evidence of bronchiectasis on computed tomography (CT).
2463791|NCT03147547|Active Comparator|Promotional Brochure|Participants in this condition received one of the strategies in the Parent Engagement Package: a promotional brochure with information about the parenting intervention being offered at their child's school, the Triple P Positive Parenting Program. This information included the location of meetings, free childcare, topics covered, choice of English or Spanish groups, meeting day and time, and an enrollment form. Parents who returned the enrollment form received a confirmation letter prior to the first parenting program session.
2463801|NCT03147547|Experimental|Parent Engagement Package|Participants in this condition received all engagement strategies in the Parent Engagement Package, which included: 1) the promotional brochure; 2) family testimonial flyer that included photos and quotes from prior participants; 3) teacher endorsement of the Triple P program; 4) provider engagement call to motivate parents to attend; and 5) phone reminders prior to each Triple P session.
2463833|NCT03146975|No Intervention|Healthy|
2463834|NCT03146975|Experimental|Periodontitis without diabetes|
2463836|NCT03146975|Experimental|Periodontitis compensated diabetes|
2463838|NCT03146975|Experimental|Periodontitis decompensated diabetes|
2463840|NCT03146975|No Intervention|Compensated diabetes non periodontitis|
2463843|NCT03146975|No Intervention|Decompensated diabetes non periodontitis|
2463865|NCT03146715|Active Comparator|High-carotenoid food feeding trial|Twenty-three children were randomly assigned to a treatment with a high carotenoid baked food (4.3mg carotenoids/120g, 360 kcal)
2463870|NCT03146715|Placebo Comparator|No-carotenoid food feeding trial|Twenty-five children were randomly assigned to consume a baked food with no carotenoids (300 kcals/73g)
2463896|NCT03146520||Colorectal (CRC)|stage I-IV CRC subjects
2463898|NCT03146520||Polyps|subjects with adenoma or polyps
2463900|NCT03146520||Other cancers|subjects with other cancers
2463901|NCT03146520||Healthy|subjects with no evidence of CRC
2463929|NCT03146299|Active Comparator|Group A: TLH|
2463942|NCT03146299|Active Comparator|Group B: LAVH|
2463962|NCT03146026|No Intervention|No Exercise (CON)|Fifteen obese adolescent girls. This arm did not perform any exercise training for 12 weeks. Caloric intake was 1921.7 kcal/day.
2463963|NCT03146026|Experimental|Combined Exercise Training (CET)|Fifteen obese adolescent girls. This arm performed combined exercise training 3 times per a week for 12 weeks. Caloric intake was 1921.7 kcal/day.
2464083|NCT03145805||liver resection patients|Liver resection patients sited with an epidural catheter for bupivacaine infusion for 3-5 days postoperatively to manage postoperative pain
2464144|NCT03144947|Experimental|Group A|"Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~After surgery, study patients will receive trastuzumab IV x 14 cycles"
2464145|NCT03144947|Experimental|Group B|Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles
2464191|NCT03144557|Experimental|Intervention|Education protocol to correct inhalation technique
2464315|NCT03143881|Experimental|Intervention|Intervention patients will receive personalized education regarding their condition, pre- and post-testing of their HF knowledge base, and ED standard of care during the enrollment (index) visit. Patients will then be contacted via telephone 30 days post-index visit for re-testing and reinforcement of previously learned material.
2464316|NCT03143881|No Intervention|Control|Control patients will receive ED standard of care.
2464393|NCT03143322|Experimental|Systemic treatment + SBRT|Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.
2464395|NCT03143322|No Intervention|Systemic treatment|Palliative radiotherapy on bone metastases is allowed if necessary (pain, fracture, spinal cord compression…)
2464441|NCT03142685|Experimental|Arm B: Kub + Bowel US|Subjects clinical suspected of NEC whom are randomized into Arm B at time of consent will receive a bowel ultrasound q24 for 48 hours and a KUB q12 for 48 hours.
2464463|NCT03142737|Experimental|Ground beef intake|Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
3191407|NCT00798252|Experimental|Arm B (Doxorubicin + Brivanib alaninate)|
3191408|NCT00798252|Experimental|Arm C (Ixabepilone + Brivanib alaninate)|
3191409|NCT00798252|Experimental|Arm D (Docetaxel + Brivanib alaninate)|
3191410|NCT00798252|Experimental|Arm E (Paclitaxel + Brivanib alaninate)|
2463568|NCT03149107|Active Comparator|PSM + Placebo|"PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).~N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Placebo will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM)."
2463657|NCT03148444|Experimental|Antibiotics treated|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with recommendations to take antibiotic treatment for 5 days following the procedure (cefalexin 500 mg qid, or in the presence of beta-lactam sensitivity roxithromycin 150 mg bid)
2463659|NCT03148444|No Intervention|without Antibiotics Treatment|Patients undergoing de novo implantation or replacement of cardiac implantable devices (single-chamber, dual-chamber and biventricular pacemakers and defibrillators) in our institution will be discharged home with no recommendations regarding antibiotic treatment.
2463698|NCT03148015||ADH/LCIS|Atypical Ductal Hyperplasia or Lobular carcinoma in situ with DCIS
2463699|NCT03148015||DCIS|Pure Ductal Carcinoma in Situ
2463702|NCT03148015||Invasive|invasive ductal carcinoma with DCIS
2463735|NCT03147807|Experimental|betaLACTA® result given to physician|In the experimental group, betaLACTA® rapid diagnostic test guided de-escalation result will be given to physician at Day 0 and empirical carbapenems will be de-escalated to Cefepime or Ceftazidime +/- Amikacin since the second dose.
2463740|NCT03147807|No Intervention|betaLACTA® result NOT given to physician|In the control group, betaLACTA® result will not be given to physician and patients will receive empirical carbapenem during the time required to obtain final results of antibiotic susceptibility test
2463776|NCT03147391||LAA closure with LAmbre|The patients with atrial fibrillation who received left atrial appendage (LAA) closure using the LAmbre device in our center from April 2014 to November 2015.
3156341|NCT00340600||DES Exposed|DES-exposed mothers, daughters and sons, and identified subjects
2463924|NCT03146208||Coronary artery disease patients with type 2 DM|Coronary artery disease patients with type 2 diabetes (age 20-55 years). The present study will be carried on 25 patients attending to cardiology department with coronary artery disease with type 2 diabetes
2463935|NCT03146208||Coronary artery disease patients without type 2 DM|The present study will be carried on 29 patients attending to cardiology department with coronary artery disease without type 2 diabetes (age 20-55 years).
2463944|NCT03146208||Healthy control group|we will include 54 age-matched patients with normal angiogram
2463965|NCT03146000|Experimental|lidocaine-prilocaine|women will receive 5 mg lidocaine-prilocaine cream topically on the episiotomy line
2463967|NCT03146000|Active Comparator|meloxicam|women will receive one 15 mg meloxicam rectal suppository
2463994|NCT03145740|Experimental|Intensive F.O.T.T.®|Intensive F.O.T.T.® intervention was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Before and after the intervention, the patient was positioned in a standardized way in side lying for 10 minutes to rest. Here, the Electromyographic Bioimpedance Measuring device (EMBI) measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. In the intervention itself, the patient was facilitated with specific handling and interventions to swallow, according to F.O.T.T.®. The faciltation was embedded into a meaningful context for the patient, e.g. tooth brushing or eating small amounts of apple sauce, if safe.
2463995|NCT03145740|Placebo Comparator|Unspecific stimulation of face and mouth|The intervention in the control group was given twice a day, approximately 20 minutes per intervention, exclusive time to position the patient. Patients in the control group were before and after the intervention, positioned in a standardized way in side lying for 10 minutes to rest. The EMBI measured the spontaneous swallowing frequency and -quality during both, the resting period and the intervention. The intervention included unspecific stimulation of the hands and the face, without therapeutic interventions directed towards facilitation of swallowing.
2464053|NCT03145532|Experimental|Real tDCS plus robotic training|Children will receive 20 min of real tDCS stimulation per session, followed by robotic training for 1 hr.
2464054|NCT03145532|Sham Comparator|Sham tDCS plus robotic training|Children will receive 20 min of sham tDCS stimulation per session, followed by robotic training for 1 hr.
2464140|NCT03145155|Experimental|Intervention|Pregnant women in intervention arm will receive CoC card and health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will include CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given three times during pregnancy and one time during postpartum period.
2464142|NCT03145155|Placebo Comparator|Control|Pregnant women in control arm will receive ordinary health education on pregnancy care
2464152|NCT03144596|Experimental|Alfuzosin Hydrochloride|Alfuzosin hydrochloride 10 mg tablet by mouth, every 24 hours for 3 months
2464156|NCT03144596|Active Comparator|Tamsulosin Hydrochloride|Tamsulosin hydrochloride 0.4 mg tablet by mouth, every 24 hours for 3 months
2464209|NCT03144388|Experimental|Variable Stepping Training|High intensity stepping training in multiple environments, including overground, on a treadmill and on stairs.
2464210|NCT03144388|Active Comparator|Variable Non-specific Training|High intensity non-stepping training, including balance, strength, and cycling tasks
2464236|NCT03144050||0|Control - no diabetes
2464238|NCT03144050||1|Diabetes
2464240|NCT03144050||2|Diabetes w/neuropathy
2464242|NCT03144050||3|Diabetes with vascular disease
2464245|NCT03144050||4|Diabetes w/healed ulcer
2464248|NCT03144050||5|Diabetes with current ulcer
2464330|NCT03143738|Experimental|continuous anesthesia of adductor canal|
2464332|NCT03143738|Experimental|continuous anesthesia of femoral nerve|
3156342|NCT00340600||DES Unexposed|DES-unexposed mothers, daughters and sons, and identified subjects
2464516|NCT03142191|Experimental|CC-90001 400 mg PO QD- Sub-Study|30 subjects will be randomized to CC-90001 400mg
2464519|NCT03142191|Placebo Comparator|Placebo PO QD- Sub-Study|15 subjects will be randomized to placebo
3156343|NCT00340626||Control|healthy individuals with no history of oral cleftsto serve as controls
2463695|NCT03148145|Experimental|Algorithm Steps Goal and Random Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2463696|NCT03148145|Experimental|Algorithm Steps Goal and Messages|Step Goal Delivery by Smartphone Message Delivery by Smartphone
2463723|NCT03147781|No Intervention|Standard care|Participants in this group only receive standard post-cesarean care of the study hospital. It includes mobility restraint, foley retention, IV fluid infusion, oral intake instructions, oral pain medications routine, and breastfeeding practice.
2463727|NCT03147781|Sham Comparator|Sham AT with Medulla Junci|Participants in this group receive auricular tape with Medulla Junci in addition to standard post-cesarean care during the early 96 postpartum hours.
2463732|NCT03147781|Experimental|True AT with magnetic pellets|Participants in this group receive auricular tape with magnetic pellets in addition to standard post-cesarean care during the early 96 postpartum hours.
2463767|NCT03147443|Experimental|Individualized Decoction|"It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.~The Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2463769|NCT03147443|Placebo Comparator|placebo|"Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The placebo and test drug have no differences in dosage form, appearance, color, specification, label, and so forth.~The placebo is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2463771|NCT03147443|Active Comparator|Tested drug minus heat-clearing herbs|"It is the decoction of the Individualized Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.~This control Chinese herbal decoction is taken by one decoction a day and divided into 2 doses, for 3 weeks in each observation period."
2463845|NCT03147092|Experimental|Hypertension group|Hypertensive patients will be counseled to initiate life style changes as weight loss, salt reduction, exercise, reduced alcohol consumption, smoking cessation and fresh fruits and vegetables in their diets. Drug treatment will be started for subjects that are not responding to nonpharmacological treatment. The anti-hypertensive medications will be Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet, atenolol and Losartan potassium 50 mg. All of these anti-hypertensive drugs are available in the PPP. If BP control is not yet obtained, other antihypertensive drugs will be requested: clonidine, spironolactone, hydralazine and amlodipine.
3191411|NCT00798265|Experimental|1|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
3191412|NCT00798265|Experimental|2|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
2463971|NCT03146195||POP|Female patients with pelvic organ prolapse,such as: cystocele, uterine prolapse, the vault prolapse, rectal prolapse ,undergo pelvic floor reconstruction surgery.Before and after sugery,take dynamic magnetic resonance imaging scan.
2463979|NCT03146195||Non-POP|Females with normal pelvic floor support,don't need pelvic floor reconstruction surgery,only take once dynamic magnetic resonance imaging scan.
2464035|NCT03145727|Placebo Comparator|Placebo Group|Placebo Group: In this group the participants received TENS with frequency of 75Hz, pulse duration of 200 microseconds. The stimulation time will be for only 10s.
2464039|NCT03145727|Experimental|Low Frequency Group|Low Frequency Group: In this group the TENS will be adjusted with frequency of 10Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
2464041|NCT03145727|Experimental|High Frequency Group|High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
3191413|NCT00798265|Active Comparator|3|.5 mL dose injected IM at 0, 2 and 6 months (+/- 2 weeks) and knowledge survey at week 0
3191414|NCT00798278|Experimental|Urokinase|urokinase infusion for 3 days
3191415|NCT00798278|Active Comparator|Thoracoscopic|Video-Assisted Thoracoscopic
2464147|NCT03144739|Active Comparator|Control|Children enrolled during the control phase will receive care under the Current collaborative care protocol. Participating general practitioners are currently trained to recognize child mental health problems and refer them to partner community mental health centers for treatment.
2464148|NCT03144739|Experimental|Intervention|Children enrolled during the intervention phase will receive Training in management of children's mental health problems. This will involve treatment by their general practitioner in collaboration with a partner community mental health center; children meeting certain criteria for severity, or whose parents prefer center treatment, will be immediately referred.
2464214|NCT03144531|Experimental|SKIP Intervention|
2464317|NCT03143634|Experimental|The Modular Protocol for Mental Health|"The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include:~M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation"
2464321|NCT03143634|Placebo Comparator|Treatment-as-usual|For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.
2464466|NCT03142737|Experimental|Intact beef intake|Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
3191416|NCT00798291|Placebo Comparator|Ad lib diet/placebo|Ad lib diet and control product placebo
2463705|NCT03148171|Active Comparator|WERK Supportive Contact|Support contact will provide emotional support and practical support in order to help their friend/family member to stay engaged in PrEP Care.
2463734|NCT03147794|Experimental|FES using MyndMove Technology|This is the only arm of the study. Participants will be provided with the FES intervention as part of the protocol.
2463847|NCT03147079|Experimental|Intervention|Lifestyle intervention
2463849|NCT03147079|Experimental|Internal controls|
2463852|NCT03147079|Experimental|External controls|
2463902|NCT03146650|Experimental|Treatment (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, 43, 57, and 71 of course 1 and on days 1 and 15 of course 2, over 60 minutes on days 29 and 57 of course 2 and on days 1, 29, and 57 of subsequent courses. Patients also receive ipilimumab over 90 minutes on days 1 and 43. Courses repeat every 84 days in the absence of disease progression or unexpected toxicity.
2463925|NCT03146273|Experimental|A|The tablet/capsule will be administered as a single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs.
2463936|NCT03146273|Experimental|B|The gel will be administrated to the same group of patients in the single dose after 12 hours of fasting. The participants will be monitored during 6 hours for the level of minerals and Multivitamin minerals in the blood, adverse events and vital signs
2463991|NCT03146078||Primary Cohort|"Participants with baseline visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and stable fixation and clinically determined [on Octopus 900 Pro] kinetic visual field III4e area 10° or more in the study eye (primary cohort) will be enrolled into the longitudinal natural history study"
2463992|NCT03146078||Secondary Cohort|"Participants with baseline visual acuity ETDRS letter score of 53 or less [approximate Snellen equivalent 20/100 or worse] or unstable fixation or clinically determined [on Octopus 900 Pro] kinetic visual field III4e area less than 10°in the study eye (secondary cohort) will be enrolled in the cross-sectional baseline study"
2464062|NCT03145519|Experimental|OptiVein|Placement of IV-catheter and administration of treatment using OptiVein catheter.
2464064|NCT03145519|Active Comparator|Vasofix Certo|Placement of IV-catheter and administration of treatment using Vasofix Certo catheter.
2464116|NCT03145116|Experimental|509|
2464163|NCT03144648||Cases|Incident primary invasive breast cancer cases aged 20-45 years are recruited from major cancer hospitals in four large Latin American cities (Mexico City, San Jose, Medellin, and Santiago) prior to any treatments. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses. Highly standardized immunohistochemical and molecular analyses are performed to identify cancer subtypes
2464170|NCT03144648||Controls|Women with no cancer recruited from the population residing in the same cities for at least 3 years and matched to cases on age (+/- 5 years) and health care institution. For each subject, complete questionnaire data on socio-demographic factors, health and reproductive history, early risk factors, physical activity, diet, occupation, environmental risk factors, ethnicity, and family history of cancer are collected. Validated and standardized food frequency questionnaires are administered to gather information on diet. Anthropometry is measured according to standardized protocols. Blood and urine samples are also collected for biomarker analyses.
2464203|NCT03144271|Experimental|NNC 0113-0217|Dose-escalation trial
2464204|NCT03144271|Placebo Comparator|Placebo|Dose-escalation trial
3191417|NCT00798291|Experimental|Ad lib diet/AN 777|Ad lib diet and AN 777
3191418|NCT00798291|Active Comparator|Ad lib diet/placebo/exercise|Diet ad lib; exercise; and placebo
2464289|NCT03143621|Experimental|Coffee|100 cc's of coffee administered three times per day until return to bowel function has been established.
2464290|NCT03143621|Placebo Comparator|Water|100 cc's of warm water administered three times per day until return to bowel function has been established.
2464347|NCT03143452|Active Comparator|lidocaine gel|Lidocaine gel group: received 2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
2464348|NCT03143452|Active Comparator|tetracaine eye drop|Tetracaine eye drop group: received 0.5% tetracaine eye drop 5 minutes before phacoemulsification
3191419|NCT00798291|Experimental|Ad lib diet/ AN 777/ exercise|Diet ad lib; AN 777; exercise
3191420|NCT00798343|Active Comparator|Seasonal vaccine|Seasonal influenza vaccination
3191421|NCT00798343|Experimental|Pandemic vaccine|MF59-adjuvanted H5N1 monovalent vaccine
2464542|NCT03142308||Surgeons|Young surgeons in all surgical specialities
2464627|NCT03141593|Active Comparator|Vitamin D: liquid form, start weekly|5'600 IU weekly (1.4 ml oily drops) start for 3 months, will cross-over to 24'000 IU monthly (5 ml alcoholic drops) for the following 3 months.
3191422|NCT00798356|Other|1|Yoga training
3191423|NCT00798382|Experimental|1: Soy formula|experimental soy formula #1
3191424|NCT00798382|Active Comparator|2: Soy Formula|Commercially available soy formula
3191425|NCT00798382|Experimental|3: Soy formula|experimental soy formula #2
3191426|NCT00798395|Experimental|Treatment 1|
3191427|NCT00798395|Experimental|Treatment 2|
3191428|NCT00798395|Placebo Comparator|Treatment 3|
3191429|NCT00798395|Active Comparator|Treatment 4|
3191430|NCT00798408|Experimental|1|Participants will maintain current physical activity and take a fluid supplement.
3191431|NCT00798408|Experimental|2|Participants will maintain current physical activity and take a solid supplement.
3191432|NCT00798421||Heathcare worker|health care worker exposed to patient with influenza
3191433|NCT00798447|Experimental|lipid emulsion with n-3 FA|
3191434|NCT00798447|Active Comparator|lipid emulsion without n-3 FA|
3191435|NCT00798460|Active Comparator|Lamivudine plus adefovir|
3191436|NCT00798460|Active Comparator|Clevudine plus adefovir|
3191437|NCT00798473|Experimental|1|Zoledronic acid, 0.06 mg/kg IV in a single infusion, maximum of 4 mg
3191438|NCT00798473|Placebo Comparator|2|IV saline infusion
3191439|NCT00798499||1|Laboratory variables
3156344|NCT00340626||Oral Cleft Family Members|individuals with unilateral or bilateral cleft lip with or without cleft palate and their unaffected relatives
3156345|NCT00340808||endometrial cancer cases|endometrial cancer cases
2463792|NCT03147326|Other|FDG-NaF-MRI|"All participants will undergo three project scans/the following interventions:~FDG-PET-CT NaF-PET-CT Whole-body MRI All participants will undergo a whole-body x-ray as part of clinical routine practice."
2463858|NCT03147001|Experimental|Protein ingestion|Subjects ingested protein drinks
2463861|NCT03147001|Placebo Comparator|Placebo|Subjects ingested a non-caloric placebo drink
2463919|NCT03146572|Experimental|Intervention|Parent of child to receive intervention, Sit Down and Play
2463920|NCT03146572|Active Comparator|Control|Parent will receive handout to promote positive behavior
2463966|NCT03146143|Experimental|ultrafiltration group|ultrafiltration after cardiopulmonary bypass in congenital cardiac surgery
2463975|NCT03146143|No Intervention|non ultrafiltration control group|no ultrafiltration will be applied in this group
2464042|NCT03145558|Experimental|Trans-Arterial Tirapazamine Embolization (TATE)|Patients will receive a fixed dose of Tirapazamine combined with embolization using Lipiodol and Gelfoam.
2464043|NCT03145558|Active Comparator|Trans-Arterial ChemoEmbolization (TACE)|Patients will receive a mixture of doxorubicin and Lipiodol into the tumor feeding artery followed by injection of Gelfoam to induce embolization per standard procedure.
2464136|NCT03145233|Experimental|Isometric exercise|12 week Isometric exercise programme - two exercises (one side-lying and the other standing); six repetitions of each with muscle contraction sustained for 30 seconds. Exercises performed once daily with each session lasting no longer than 10 minutes.
2464137|NCT03145233|Experimental|Isotonic exercise|12 week Isotonic exercise programme - two exercises (one side-lying and the other standing); each exercise - 3 sets of 10 repetitions, each repetition 6 seconds duration. Exercises performed once daily with each session lasting no longer than 10 minutes.
2464180|NCT03144609|Active Comparator|PEEP 4|Active Comparator low PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with Positive endexpiratory pressure (PEEP) 4 cm H2O(water)
2464183|NCT03144609|Experimental|PEEP 7 & ARM|Experimental ARM & Experimental high PEEP: obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 7 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
2464187|NCT03144609|Experimental|PEEP 10 & ARM|Experimental ARM & Experimental high PEEP:obese patient during oral-surgical procedures under general anesthesia ventilated with PEEP( positive endexpiratory pressure) 10 cm H2O with ARM(alveolar recruitment maneuver) provided every 30 min
2464223|NCT03144232|Experimental|Active rTMS|10 Hz rTMS applied to the left DLPFC
2464226|NCT03144232|Sham Comparator|Sham rTMS|Sham rTMS applied to the left DLPFC
2464282|NCT03143933|Active Comparator|propofol|this arm will receive propofol in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
2464283|NCT03143933|Active Comparator|propofol and fentanyl|this arm will receive propofol and fentanyl in induction of anesthesia and blood sample will be withdrawn before induction and another sample will be withdrawn after induction with 3 mins
2464349|NCT03143504|Other|Single arm.|All participants in the same arm.
2464406|NCT03143075|Active Comparator|Inflammation group|Subjects with CRP≥3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
2464410|NCT03143075|Active Comparator|Non-inflammation group|Subjects with CRP<3, will receive eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, for 8 weeks, added to their pre-stabilized antidepressant medication
2464499|NCT03142217|Other|Patient with Huntington's Disease|
2464554|NCT03142100||Hebrew speaking participants|Hebrew speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
2464556|NCT03142100||Arabic speaking participants|Arabic speaking bilateral-bimodal users will be assessed using cochlear implants and hearing aids
3156346|NCT00340860||Norweigian Population-Based Pregnancy Cohort|Norwegian-speaking pregnant women, their children born post enrollment, and enrolled children's fathers
3156347|NCT00340873||Cases|Individuals exposed to digoxin
3156348|NCT00340873||Controls|Individuals not exposed to digoxin
2464838|NCT03140293|Active Comparator|Lidocaine Injection|Injection of lidocaine which is given prior to chorionic villus sampling
2464840|NCT03140293|Experimental|Gebauer Ethyl Chloride Spray|Topical anesthesia will be Gebauer Ethyl Chloride sprayed continuously from 3 - 7 seconds from a distance of 3-9 inches until the skin turns white (not frosting the skin) as per Gebauer package insert instructions.
2464861|NCT03140007|Other|Control arm - ERCP arm|Control arm- If a patient is randomized to the Control arm, then the procedure will consist of the following: ERC with recording of ERC-based impression of malignancy .ERC-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The biopsy forceps / brush will be selected per investigator preference. ERC-guided brushing will be performed, consisting of 10 through-and-fro passes through the target lesion. After this a biliary stent will be placed under ERC-guidance if needed. A biliary sphincterotomy will be performed as needed
2464862|NCT03140007|Active Comparator|Study arm - cholangioscopy arm|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
2464964|NCT03139318|Experimental|GRID Radiotherapy|Patients will be treated with GRID Radiotherapy
3156349|NCT00340977||Case-Control Parent-Triad|Norwegian infants born with cleft lip or palate over a 5 year period
2463761|NCT03147677|Active Comparator|Irbesartan|The subjects in this group orally take Irbesartan Pills at 150mg/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2463762|NCT03147677|Active Comparator|Alfacalcidol|The subjects in this group orally takeAlfacalcidol Soft Capsules at 0.25ug/day for 16 consecutive weeks.All subjects will be followed up for 4 weeks after medication is over. A total of 4 visits have been scheduled for this study at week 0, week 8, week 16, week 20.
2463808|NCT03147261|Experimental|lifestyle intervention|Intensive follow up in lifestyle factors with a reduced calorie DM , physical activity and behavioural therapy.
2463812|NCT03147261|No Intervention|No intervention|Healthy diet recommendations following the usual pediatric advice
2463906|NCT03146351|Experimental|Early and moderate preterm group|Infants born before 34 weeks included in this group
2463907|NCT03146351|Experimental|Late preterm group|Infants born between 34 and 37 weeks included in this group
2463926|NCT03146234|Experimental|CAR-GPC3 T cells|"Autologous T Cells with a GPC3-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.~Lymphodepletion conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -6 to Day -3 prior to CAR-GPC3 T cells infusion."
2463961|NCT03146039|Other|Radiation Therapy|The patient will receive Whole Pelvis Radiation Therapy 40 - 50.4 Gy in 1.8 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks followed by Stereotactic Body Radiotherapy 5.5 - 8.0 Gy per fraction x 5 fractions using arc therapy.
3191440|NCT00798512|Experimental|1|Single arm Study in which 120 patients fulfilling eligibility criteria will be screened and undergo carotid stenting with the Cristallo ideale™ carotid stent after placement of the Mo.Ma device as cerebral protection system. The technique of diffusion-weighted magnetic resonance imaging (DW-MRI) will be used to identify new ischemic lesions.
3191441|NCT00798525|Active Comparator|PR1|Patients treated with Argatroban (Argatra®), a direct thrombin inhibitor
3191442|NCT00798525|Active Comparator|PR2|Patients treated with Lepirudin (Refludan®), a direct thrombin inhibitor
3191443|NCT00798538|Active Comparator|Integrated|Provision of buprenorphine induction and management, substance abuse counseling and HIV care at one clinic.
3191444|NCT00798538|Placebo Comparator|Non-integrated|Buprenorphine induction, substance abuse counseling and HIV care will be managed at multiple locations, respectively: the Community Health Care Van, the Yale AIDS Program, and individuals' HIV clinics.
3191445|NCT00798551|Other|Risk counseling|Risk counseling regarding elevated blood pressure
3191446|NCT00798616|Placebo Comparator|Responders/Placebo|Albuterol responders being given placebo
3191447|NCT00798616|Active Comparator|Responders/Steroids|albuterol responders being given steroids
3191448|NCT00798616|Placebo Comparator|Non-responders/placebo|non-albuterol responders being given placebo
3191449|NCT00798616|Active Comparator|non-responders/steroids|non-albuterol responders being given steroids
3191450|NCT00798629|Experimental|Vaccine Dose Escalation|Dose Escalation: Intradermal DC Injection. Level 1: Cell Dose: 2 x 10^6 Level 2: Cell Dose: 1 x 10^7 Level 3: Cell Dose: 2 x 10^7
3191451|NCT00798642|Active Comparator|Hypnotherapy|
3191452|NCT00798642|Placebo Comparator|Standard care|
2464331|NCT03143517||Inflammatory Bowel Disease (IBD)|A stool sample will be collected from adult subjects with Inflammatory Bowel Disease (IBD), confirmed by endoscopy and histologic examination.
2464335|NCT03143517||Irritable Bowel Syndrome (IBS)|A stool sample will be collected from adult subjects with adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria.
2464338|NCT03143517||Other GastroIntestinal (GI) Disorders|A stool sample will be collected from adult subjects with adult subjects with gastrointestinal disorders other than IBD or IBS.
2464399|NCT03143062||Cases|150 patients that suffered an in-hospital cardiac arrest in a hospital ward.
2464403|NCT03143062||Controls|300 patients that did not suffer an in-hospital cardiac arrest but was treated in a hospital ward.
2464443|NCT03142828|Active Comparator|Test (clorhexidine gel)|The healing abutments were covered by a chlorhexidine gel after the first week of the second surgery (2-stage implants).
2464448|NCT03142828|Placebo Comparator|Placebo|The healing abutments were covered without any antiseptic gel after the first week of the second surgery (2-stage implants).
2464533|NCT03142386|Experimental|OMT group|Osteopathic manipulative treatment
2464535|NCT03142386|Active Comparator|Control Group|Physiotherapy
2464565|NCT03141853|Experimental|Equine-assisted Therapy Group|This group will interact and ride horses for 1 hour each week for 6 weeks. Horses will remain at a walk and an standard Therapeutic Riding curriculum will be used including safety, mounting, riding, tasks while riding, dismount, bonding with the horse.
2464567|NCT03141853|Placebo Comparator|Arthritis Exercise Education Group|This group will receive exercise education that targets arthritis symptoms for 1 hour each week for 6 weeks. This will be based on the exercise education from the Arthritis foundation How-to Exercise With Arthritis. (n.d.).
2464604|NCT03141632|Active Comparator|Dulaglutide|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
2464610|NCT03141632|Placebo Comparator|Placebo|0.5 ml normal saline (0.9% sodium chloride), sc once weekly for 3 weeks.
2464763|NCT03140865||Cognitively Normal|This group will include 300 healthy volunteers with no apparent memory problems. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
2464974|NCT03139305|Active Comparator|Glucagon Low Dose|
2464976|NCT03139305|Active Comparator|Glucagon High Dose|
3191453|NCT00798642|Placebo Comparator|Mind Body Therapy|
3191454|NCT00798668|Experimental|1|participants continue current exercise and take liquid supplement
2463765|NCT03147586|Active Comparator|Bio-tech and omega-3 plus|Bio-tech (Biopharm pharmaceutical) powder 30 mg t.d.s. (contains multivitamins and essential amino acids) plus omega-3 plus (SEDICO pharmaceutical) capsules t.d.s (source for omega-3 fatty acids) 1 week before and 2 week after surgery
2463766|NCT03147586|Placebo Comparator|placebo|placebo powder 30 mg t.d.s plus placebo capsules t.d.s for 1 week before and 2 week after surgery
3191455|NCT00798668|Experimental|2|Participants continue current exercise and take solid supplement
3191456|NCT00798668|Experimental|3|Participants continue current sedentary behavior and take liquid supplements
3191457|NCT00798668|Experimental|4|Participants continue current sedentary behavior and take solid supplements
3191458|NCT00798681|Experimental|1|Patients will receive RTU TPN with olive-oil as the primary source of lipids
3191459|NCT00798681|Active Comparator|2|CNF parenteral nutrition made with olive oil as the primary source of lipids
3191460|NCT00798681|Active Comparator|3|CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
2463915|NCT03146611||COPD patients|A diagnosis of COPD was made by a clinical history, examination and spirometer (forced expiratory volume in 1st second/forced vital capacity (FEV1/FVC)ratio of <0.7). The severity of COPD was graded according to the Global Initiative for Chronic Obstructive Lung Disease guidelines. [9] (Stage I, mild COPD: FEV1≥80.0% predicted; Stage II, moderate COPD: FEV1 80-50.0%; Stage III, severe COPD: FEV1 50- 30.0%; Stage IV, very severe COPD: FEV1< 30.0%). The exacerbation of COPD was defined as the patient being diagnosed with COPD with two or more of the following three symptoms of exacerbations: new or worsening cough, worsened dyspnea, and worsened sputum volume and/or change in its color.
2463916|NCT03146611||control|healthy sex and age matched group
3156350|NCT00341016||Cohort of Chernobyl cleanup workers (liquidators) in Ukraine|Cases with leukemia and related diseases, and matched controls in the cohort
3156351|NCT00341068||Cleft|children and adults with a cleft lip and/or cleft palate and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
2464099|NCT03145467|Experimental|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
2464106|NCT03145467|Experimental|Zolmitriptan|Second Group: Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients.
2464174|NCT03144817|No Intervention|Control Group|
2464178|NCT03144817|Experimental|Intervention Group|Intervention group will dialyze with dialysate Na 135 mEq/L.
2464215|NCT03144414|Active Comparator|LAVH|Laparoscopic Assisted Vaginal Hysterectomy
2464222|NCT03144414|Active Comparator|LADH|Laparoscopic Assisted Doderlin Vaginal Hysterectomy
3156352|NCT00341068||NTD|children and adults with an NTD (neural tube defects) and their parents residing in the Republic of Ireland, Northern Ireland and the United Kingdom
2464350|NCT03143465|Experimental|CGRP|
2464351|NCT03143465|Experimental|Sildenafil|
2464352|NCT03143465|Placebo Comparator|Placebo|
2464397|NCT03143049|Experimental|Pomalidomide, Cyclophosphamide, Dex (PCD)|
2464401|NCT03143049|Active Comparator|Pomalidomide, Dex (PD)|
2464546|NCT03142542|Experimental|Udenafil 75mg|Drug: Udenafil 75mg by mouth, once daily, for 32 weeks
2464549|NCT03142542|Placebo Comparator|Placebo|Drug: placebo by mouth, once daily, for 32 weeks
2464570|NCT03141775||Treatment of CDI|Treatment of CDI for hospitalized patients with Clostridium difficile associated diarrhea
2464607|NCT03141619||Respiratory failure and/or shock|All enrolled patients will undergo 72 hours of monitoring of cerebral oxygenation with near-infrared spectroscopy.
2464640|NCT03141437|Active Comparator|Arm I (standard of care)|Participants receive standard of care including education materials about fertility preservation from the Livestrong organization and a referral for fertility preservation, if requested.
2464642|NCT03141437|Experimental|Arm II (standard of care, decision-making website)|Participants receive standard of care as in Arm I. Participants also use the decision-making the website.
2464711|NCT03140956|Experimental|Levodopa formulation D|Levodopa formulation D
2464716|NCT03140956|Experimental|Levodopa formulation E|Levodopa formulation E
2464718|NCT03140956|Experimental|Levodopa formulation F|Levodopa formulation F
2464722|NCT03140956|Active Comparator|Sinemet IR 100/25mg|Sinemet IR 100/25MG
2464725|NCT03140956|Active Comparator|Sinemet CR 100/25mg|Sinemet IR 100/25MG
2464727|NCT03140956|Experimental|ODM-104 100mg|ODM-104 100MG
2464728|NCT03140956|Active Comparator|Carbidopa 20mg|Carbidopa 20MG
2464730|NCT03140956|Active Comparator|Carbidopa 65mg|Carbidopa 65MG
2464803|NCT03140657|Experimental|Nanocurcumin Arm|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months.
2464809|NCT03140657|Placebo Comparator|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months.
2464856|NCT03140124|Other|Group 1|First session: worry stone, second session: exercise peddler
2464857|NCT03140124|Other|Group 2|First session: exercise peddler, second session: worry stone
2464916|NCT03139812|Other|30-day SiH CW, No Daily Irrigation|Control group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines with no daily morning irrigation of the eyes with sterile saline solution
3156353|NCT00341094||Main UkrArm|Subjects exposed to I131 before the age of 18 years
3156354|NCT00341094||Ukraine in utero|Subjects exposed to I131 in utero
3156356|NCT00341263||Cases - twin pregnancies|Maternal and cord hormones in twins
3156357|NCT00341263||Controls - singleton pregnancies|Maternal and cord hormones in singletons
3156359|NCT00341302||Cohort 1|HIV Infected Pregnant Women
3191461|NCT00798733||Non-Operative|Surgeon treated the patient non-operatively
3191462|NCT00798733||Operative|Surgeon treated the patient operatively
3191463|NCT00798746||Pyloric Drainage Procedure|Esophagectomy with pyloric drainage procedure
2463802|NCT03147365|Experimental|Study group B|Twenty five children who will receive physical therapy treatment which include modified strength training program.
2463859|NCT03146988|Experimental|RGB-02 6 mg SC (test product)|
2463863|NCT03146988|Active Comparator|Neulasta®|
2463945|NCT03146559|Experimental|EMG and TENS|"Wireless Bluetooth EMG (Myo) bracelet will be placed on the healthy forearm. A voluntary dorsi flexion of the healthy wrist produces data that will be transmitted to a PC and will be used to activate (via Arduino controller) a Transcutaneous Electric Nerve Stimulator (TENS), placed on the paretic forearm, that will stimulate wrist dorsi flexors.~5 days per week, for 3 weeks, 15 minutes per day."
2463949|NCT03146559|Active Comparator|TENS only|"Custom-built software & hardware: PC + Arduino controller and Transcutaneous Electric Nerve Stimulator (TENS) device, will be used to stimulate wrist dorsi flexors of the paretic forearm.~5 days per week, for 3 weeks, 15 minutes per day."
2464022|NCT03145922||Sarcoidosis|
2464023|NCT03145922||Healthy Controls|
2464044|NCT03145363|Experimental|Intervention|receive interactive text messages
2464045|NCT03145363|Active Comparator|Control|Receive informational text messages
2464123|NCT03145220|Active Comparator|EA-230|Intravenous infusion of EA-230, 90 mg/kg/hour. Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
2464124|NCT03145220|Placebo Comparator|Placebo|Intravenous infusion of NaCl (equivalent osmolarity with active intervention EA-230). Administered from start of surgical incision until stoppage of the cardio-pulmonary bypass pump, for a maximum of 4 hours.
2464164|NCT03144713|Experimental|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
2464171|NCT03144713|Active Comparator|Midodrine|Midodrine 7.5 mg thrice daily for 3 days.
2464179|NCT03144713|Active Comparator|Standard Medical Therapy|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
2464325|NCT03143712|Experimental|Treatment A|GLPG1690 oral capsules after breakfast
2464328|NCT03143712|Experimental|Treatment B|GLPG1690 oral tablets after breakfast
2464329|NCT03143712|Experimental|Treatment C|GLPG1690 oral tablets after overnight fast
2464365|NCT03143218|Active Comparator|SMC with SP+AQ|Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
2464370|NCT03143218|Active Comparator|RTS,S/AS01|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
2464376|NCT03143218|Active Comparator|RTS,S/AS01 PLUS SMC with SP+AQ|Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
2464431|NCT03142776|Placebo Comparator|Periodontal debridement|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).
2464437|NCT03142776|Active Comparator|Periodontal debridement + CLM|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours) for 3 days.
2464440|NCT03142776|Active Comparator|Periodontal debridement + PDT|Periodontal pockets that received periodontal debridement associated with placebo (members took with placebo 500 mg b.i.d. for 3 days) and a single application of PDT (Photodynamic Therapy).
2464447|NCT03142776|Active Comparator|Periodontal debridement + CLM + PDT|Periodontal pockets that received periodontal debridement associated with systemic clarithromycin (500 mg - 12/12 hours for 3 days) and single application of PDT.
2464504|NCT03142269|Active Comparator|polished group|360°anterior capsule polishing was performed with double-ended capsule polisher randomly in one eye
2464506|NCT03142269|Placebo Comparator|unpolished group|the opposite unpolished was used as the control
2464578|NCT03142087|Active Comparator|virtual reality exercises|Nintendo Wii Fit Plus Game Console is used in these group. The one session included:warm-up exercises in 5-10 minutes, games (soccer heading, ski jump, ski slalom, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
2464583|NCT03142087|Active Comparator|conventional exercises|Physiotherapy and rehabilitation session included: warm-up exercises in 5-10 minutes, balance exercises (balance board, balance ball, two and one leg stand exercises, weight bearing exercises, balance in different type of surfaces, etc.) in 30-40 minutes, and cooling exercises in 5 minutes.
2464649|NCT03141515|Active Comparator|Control group|After anesthesia induction patients received lung recruitment maneuver using pressure-control ventilation with a patient in supine position with 10 cmH2O level of positive end-expiratory pressure PEEP during 180 seconds. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
2464651|NCT03141515|Experimental|Recruitment maneuver group|Patients received lung recruitment maneuver with postural changes of lateral decubitus using pressure-control ventilation, 10 cmH2O level of PEEP in left and in right lateral decubitus during 90 seconds in each one. Lung ultrasound examination will be performed at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
3156360|NCT00341302||Pediatric Cohort 2|HIV exposed , uninfected children born to HIV infected women
2464805|NCT03140618|Experimental|LEPPIC|The light and environment project in psychiatric inpatient care
2464868|NCT03140202|Experimental|Guide then blind|This group use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible) first, then have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask).
2464869|NCT03140202|Experimental|Blind then guide|This group have no access to the CPRmeter visual feedback during cardiopulmonary resuscitation (screen mask) first then use the CPRmeter visual feedback during cardiopulmonary resuscitation (screen visible).
2464897|NCT03139708|Experimental|Alphagan plus|Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
2464899|NCT03139708|Experimental|Tropicamide and Phenylephrine plus|Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
2464901|NCT03139708|Active Comparator|Tropicamide and Phenylephrine only|Tropicamide and Phenylephrine only arm is given one drop of each times one.
2476122|NCT03062644|Active Comparator|Celecoxib 100 mg bid|Celecoxib
2463814|NCT03147235|No Intervention|vitrectomy without music listening|Patients undergoing vitrectomy surgery will not be exposed to music listening.
2463860|NCT03146949|Active Comparator|Sorin Inspire Oxygenator|Sorin Inspire Oxygenator is used on the cardiopulmonary bypass machine
2463864|NCT03146949|Active Comparator|Medtronic Affinity Fusion Oxygenator|Medtronic Affinity Fusion Oxygenator is used on the cardiopulmonary bypass machine
2463969|NCT03146130|Active Comparator|Patient treated with N-acetylcysteine|Patients randomise in the drug group
2463974|NCT03146130|Placebo Comparator|Patient treated with placebo|Patients randomise in the placebo group
2464007|NCT03145714|Experimental|Propofol/Sevoflurane (Group P)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous (IV) Propofol Infusion at rate 100-150 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery. Intervention is to titrate dosage of Propofol and Sevoflurane to maintain Bispectral Index between 40-60.~Total dosage of IV Propofol and Sevoflurane uptake will be calculated at the end of surgery."
2464009|NCT03145714|Active Comparator|Dexmedetomidine/Sevoflurane (Group D)|"Standard technique of induction of anaesthesia .~Maintenance of anesthesia with intravenous Dexmedetomidine Infusion at rate 1- 4 mcg/kilogram/hour and Inhalational Anesthetic Sevoflurane during the surgery.~Intervention is to titrate dosage of Dexmedetomidine and Sevoflurane to maintain Bispectral Index between 40 - 60.~Total dosage of IV Dexmedetomidine and Sevoflurane uptake will be calculated at the end of surgery."
2464102|NCT03145415|Experimental|Bilateral Pudendal block|0.25 cc per kg of 0.2% ropivacaine will be injected once for right pudendal N block and the same volume for the left pudendal N block before the start of the surgery
2464109|NCT03145415|Active Comparator|Caudal block|1 cc per kg of 0.2% ropivacaine in the caudal space given before the start of surgery
2464175|NCT03144882|Active Comparator|intervention|the trial group (n =35 )
2464181|NCT03144882|Placebo Comparator|placebo|control group
2464218|NCT03144401|Active Comparator|Preoperative|"• Group no.1 will receive preoperative sublingual 400 microgram of misoprostol (Sigma) 2 tablets and postoperative sublingual placebo2 tablets."
2464224|NCT03144401|Active Comparator|Postoperative|"• Group no.2 will receive preoperative sublingual placebo 2 tablets and postoperative sublingual 400 microgram of misoprostol (Sigma)  2 tablets ."
2464281|NCT03143920|Experimental|Hyperbaric Oxygen|Hyperbaric oxygen therapy-2.4 atmosphere absolute for 90 minutes with 2-five minute air breaks administered daily, 5 days per week for 8 weeks total treatment.
2464302|NCT03143530|Active Comparator|Pectoralis Block with Ropivacaine|General anesthesia + pectoralis block with ropivacaine injection 30ml of 0.25% (75mg)
2464306|NCT03143530|Placebo Comparator|Pectoralis Block with normal saline|General anesthesia + Pectoralis block with 30ml of normal saline injection
2464372|NCT03143348||Control/Nonsurgical|Infants with postnatally confirmed acyanotic congenital heart disease not expected to require surgery in the first six months of life.
2464379|NCT03143348||Surgery w/o bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery without cardiopulmonary bypass.
2464381|NCT03143348||Surgery w/ bypass|Infants with postnatally confirmed congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
2464436|NCT03142880|Active Comparator|commonly hyperbaric ropivacaine group|This group will receive spinal anesthesia with commonly hyperbaric ropivacaine solution,which was made by adding 50% glucose to the plain ropivacaine commercially availablethe to make it's density is close to commonly hyperbaric bupivacaine.
2464442|NCT03142880|Experimental|marginally hyperbaric ropivacaine group|This group will receive spinal anesthesia with marginally hyperbaric ropivacaine,which was made by adding 5% glucose to the plain ropivacaine commercially availablethe to make it's density is slightly denser than cerebrospinal fluid but much less denser than commonly hyperbaric bupivacaine/ropivacaine.
2464493|NCT03142503|Placebo Comparator|Placebo|Soybean supplementation
2464494|NCT03142503|Active Comparator|Diet + placebo|Soybean supplementation and diet intervention
2464495|NCT03142503|Experimental|Diet + Supplementation|Omega 3 and diet intervention
2464539|NCT03142178|Experimental|Experimental 3VM1001 2g X 3 daily|3VM1001 active cream administered 2g cream three times daily for seven days
2464543|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 2g X 3 daily|3VM1001 placebo vehicle administered 2g cream three times daily for seven days
2464547|NCT03142178|Experimental|Experimental 3VM1001 3g X 3 daily|3VM1001 active cream administered 3g cream three times daily for seven days
2464548|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X3 daily|3VM1001 placebo vehicle administered 3g cream three times daily for seven day
2464551|NCT03142178|Experimental|Experimental 3VM1001 3g x 4 daily|3VM1001 active cream administered 3g cream four times daily for seven days
2464552|NCT03142178|Placebo Comparator|Placebo; 3VM1001 vehicle 3g X 4 daily|3VM1001 placebo vehicle administered 3g cream four times daily for seven days
2464632|NCT03141580|Experimental|Study group|Subjects with carotid stent who consented to undergo near-infrared spectroscopy and intravascular ultrasound imaging.
2464680|NCT03141229|Experimental|Intervention|One school semester MBSR training for teacher; followed by one school semester mindfulness training for children and one school semester follow-up period.
2464688|NCT03141229|Other|Waitlist|One school semester waitlist; followed by one school semester MBSR training for teacher and one school semester MBSR training for children.
2464828|NCT03140501|Experimental|Immediate Intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), immediately after baseline data are collected."
2464830|NCT03140501|Other|Delayed intervention|"Participants randomized to this group will receive the intervention, the mobile application (app), after a three month delay."
2464854|NCT03140059|Active Comparator|Open flap debridement|In this group (n = 22), patients will receive open flap debridement will be performed to treat residual pockets.
2464855|NCT03140059|Active Comparator|Repeated application of aPDT|In this group (n=22), patients will receive 5 applications of antimicrobial photodynamic therapy after the scaling and root planing.
2464922|NCT03139812|Other|30-day SiH CW, Daily Irrigation|Treatment group subjects wore SiH lenses for 30-day CW under normal clinical practice guidelines, and also irrigated the eyes with sterile saline solution every morning upon awakening
2476123|NCT03062644|Placebo Comparator|Placebo|Placebo
2463818|NCT03147274|No Intervention|Control Group|These participants will receive no intervention. They will have clinic care as usual and will receive three diabetes newsletters to match for attention.
2463890|NCT03146897|Active Comparator|Super Cereal Plus with amylase|
2463891|NCT03146897|Active Comparator|Corn-soy Blend Plus and Vegetable Oil|
2463892|NCT03146897|Active Comparator|Corn-soy Whey Blend and Vegetable Oil|
2463893|NCT03146897|Active Comparator|Ready-to-Use-Supplementary Food|
2463970|NCT03146325|Experimental|PYLERA AND OMEPRAZOLE|14-DAY COURSE OF 3-1 PYLERA (3 CAPSULES QID) PLUS OMEPRAZOLE (BID)
2463980|NCT03146325|Placebo Comparator|PLACEBO|MATCHING PLACEBOS
2464017|NCT03145662|Active Comparator|high pressure balloon|randomized to have dialysis fistula or AV graft treated with high pressure balloon
2464018|NCT03145662|Active Comparator|cutting balloon|randomized to have dialysis fistula or AV graft treated with cutting balloon
2464051|NCT03145389||With epidural catheter placement|In this group of patients, after explaining about the procedure an 18 Gauge epidural catheter was placed in thoracic 11-12 inter vertebral space under strict asepsis.
2464052|NCT03145389||Without epidural catheter placement|In this group of patients epidural catheter was not inserted and post operative pain was managed by using intravenous drugs.
3156361|NCT00341302||Pediatric Cohort 3|HIV exposed, uninfected children 6 months to 5 years of age
3156362|NCT00341315||Cohort|A primarily African-American population living in the vicinity of a DDT production plant inAlabama.
3156363|NCT00341328|Experimental|1|In one arm the patient will receive intradermal Mycobacterium W Vaccine along with Category I ATT drugs according to RNTCP guidelines
3191464|NCT00798746||No Pyloric Drainage Procedure|Esophagectomy without pyloric drainage procedure
2464154|NCT03144726|Experimental|Negative pressure wound therapy|A vacuum assisted closure device will be applied in this arm
2464161|NCT03144726|Other|Standard dressing|Standard dressing will be applied to this arm
2464211|NCT03144453|Experimental|Sugammadex|The patients received sugammadex as neuromuscular blockade reversal
2464212|NCT03144453|Active Comparator|Standard|The patients received neostigmine + atropine as neuromuscular blockade reversal
2464293|NCT03143673|Experimental|ACURATE TA™|Patient implanted with ACURATE TA™ Bioprosthesis
2464382|NCT03143400|Active Comparator|Healthy volunteers|Healthy volunteers will test each of the 3 galenic forms of Lactobacillus salivarius on 3 periods of 7 days. Each period will be separated from another with a 14-day wash-out period at least.
2464384|NCT03143400|Active Comparator|Ileostomized patients|Ileostomized patients will only take a unique dose of each probiotic. Each intake of a different probiotic will be separated from another by a 14-day wash-out period at least.
2464444|NCT03142867||Control|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The control group will be made of individuals who do not meet the qualifications for a liver biopsy."
2464451|NCT03142867||NAFLD|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NAFLD group will be made of individuals who qualify for a liver biopsy and have histologically proven NAFLD."
2464458|NCT03142867||NASH|"The target population for this study is male and female patients (age 18 to 80) and will consist of retired and active military personnel and their dependents. There will be no race, ethnic, or gender limitations to enrollment.~The NASH group will be made of individuals who qualify for a liver biopsy and have histologically proven NASH."
2464529|NCT03142373|Experimental|CV4 group|CV4 technique
2464532|NCT03142373|Experimental|RR group|Rib Raising technique
2464534|NCT03142373|Placebo Comparator|Placebo group|Light touch
2464580|NCT03141866|Experimental|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
2464589|NCT03141866|Experimental|Exercise Intervention 2: Machine-based resistance training|Specialised, chair-based resistance training equipment for older adults.
2464697|NCT03141138|Experimental|Group 1: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2464698|NCT03141138|Experimental|Group 1: TDENV-LAV F17 on Day 180|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2464700|NCT03141138|Experimental|Group 2: TDENV-PIV on Day 0|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2464702|NCT03141138|Experimental|Group 2:TDENV-LAV F17 on Day 90|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
2464823|NCT03140358|Active Comparator|Premyopia atropine|On Atropine 0.01%
2464827|NCT03140358|Placebo Comparator|Premyopia placebo|On placebo
2464832|NCT03140358|Active Comparator|Low myopia atropine|On Atropine 0.01% daily or every other day
2464835|NCT03140358|Placebo Comparator|Low myopia placebo|On placebo
2465037|NCT03139097||Healthy Volunteers|Blood samples from healthy volunteers analyzed on the Quantra System.
2465137|NCT03138434||Optimization phase|The first five patients will be included for the optimization of the MRI sequences. This is to ensure that a standard protocol will work for different sizes of AAA. These patients will only be scanned once.
2465153|NCT03138044|Experimental|Combined Treatment|The Combined Treatment: patients undergo a surgical operation of ipsilateral liver lobe devascularization and four weeks later after the operation percutaneous alcohol injection sessions.
2463877|NCT03146767|No Intervention|Control Group|Conventional monitor baseline stabilization: Train-of-four stimuli are administered every 20 seconds for 20 minutes
2463948|NCT03146494||STAAD|
2463950|NCT03146494||Normal|
2463972|NCT03146065|Experimental|PF-06730512|Study Drug being used in the study
2463981|NCT03146065|Placebo Comparator|Placebo|Placebo for IV/SC administration
2464027|NCT03145675|Experimental|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and additional enoxaparin 0.25 mg/kg at the beginning of PCI (i.e., insertion of guiding catheter).
2464028|NCT03145675|Active Comparator|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter) and NO additional enoxaparin at the beginning of PCI (i.e., insertion of guiding catheter).
2464029|NCT03145675|Experimental|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
2464030|NCT03145675|Active Comparator|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg at the beginning of coronary angiography (i.e., insertion of angiographic catheter).
2464068|NCT03145272|Experimental|Age group|"An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines.~This arm can be divided into 2 subgroups; (1)12 months - 1.9 years age group. (2) 2 - 5.9 years age group."
2464251|NCT03144024|Experimental|band|
2464256|NCT03144024|Active Comparator|Rigid ring|
2464319|NCT03143751|Experimental|Continuous hyperosmolar therapy|Standard cares plus continuous hyperosmolar therapy (NaCl20%)
2464324|NCT03143751|No Intervention|Control|Standard cares alone.
2464374|NCT03143192|Experimental|Aflibercept with Micropulse Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Micropulse Laser at initial visit and reassessed every 12 weeks.
2464377|NCT03143192|Sham Comparator|Aflibercept with Sham Laser|Aflibercept 2mg (0.05mL) injected intravitreally every 4 weeks or as needed Sham Laser at initial visit and reassessed every 12 weeks.
2464471|NCT03142919|Experimental|High CRP LPS Intervention|High CRP Individuals with Major Depressive Disorder receiving LPS intervention
2464474|NCT03142919|Active Comparator|Low CRP LPS Intervention|Low CRP Individuals with Major Depressive Disorder receiving LPS intervention
2464476|NCT03142919|Placebo Comparator|High CRP LPS Placebo|High CRP Individuals with Major Depressive Disorder receiving placebo
2464477|NCT03142919|Placebo Comparator|Low CRP LPS Placebo|Low CRP Individuals with Major Depressive Disorder receiving placebo
2464526|NCT03142256|Active Comparator|Incentivised - Conditional Cash Transfer|Cash incentive for good drug levels assed by Dried Blood Spot
2464530|NCT03142256|No Intervention|No incentive|Truvada 200Mg-300Mg Tablet
2464575|NCT03141814||asthma|20 patients with ongoing ashma
2464584|NCT03141814||complete asthma remission|20 subjects with complete asthma remission
2464588|NCT03141814||clinical asthma remission|20 subjects with clinical asthma remission
2464592|NCT03141814||non-asthmatic healthy controls|20 subjects without respiratory symptoms and normal lung function and no bronchial hyperresponsiveness to methacholine and/or AMP
2464659|NCT03141541|No Intervention|Usual care|All patients receive a thorough physical examination by a rheumatologist or a chiropractor with a subsequent examination by a physiotherapist.The patients receive general information about the nature back pain, adjustment of analgesic treatment and clarification of any need of further diagnosing or assessment by a surgeon. The physiotherapist furthermore makes an assessment of the patients' physical capacity and function and provides guidelines for any exercise programme. Based on the physiotherapist's judgement, the patient may be referred to rehabilitation in the local community
2464663|NCT03141541|Experimental|Group based pain management intervention|In addition to usual care as described for the control group, the patients in the intervention group will participate in a cognitive group-based pain management intervention. The aim of the intervention is to improve the patients' understanding of their back pain problem, and that they learn different pain coping strategies. The intervention is based on cognitive behavioural therapy including elements of acceptance and commitment therapy, and furthermore uses different relaxation and breathing exercises.
3156364|NCT00341328|Placebo Comparator|2|In this Arm patient will receive Placebo along with Category I ATT drugs according to RNTCP guidelines
3156365|NCT00341380||Patients|Undergoing resection of lung tumor
2464882|NCT03140215|Active Comparator|Baska Device ventilation group|Device: laryngeal mask insertion (Baska)
2464883|NCT03140215|Active Comparator|I-Gel device ventilation group|Device: laryngeal mask insertion ( I-gel )
2464968|NCT03139513||Metastatic Melanoma|Participants with BRAF V600 mutation-positive unresectable or metastatic melanoma, having started treatment with cobimetinib in combination with vemurafenib as per local guidelines and/or routine clinical practice in context of TAU program, will be observed.
3156366|NCT00341406||Healthy volunteers|healthy, non-overweight or other medical conditions
3156367|NCT00341406||Patients overweight|Those who are generally healthy but overweight
3156368|NCT00341406||Patients with health conditions|Those with diabetes and cardiovascular disease.
2463903|NCT03146533|Experimental|CD19 CART|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CD19 CART cells. The CD19 CART cells are to be administered on day0,day1,day2.
2463927|NCT03146260|Experimental|Conventional TESE|Conventional testicular sperm extraction (TESE) will be done under anesthesia through small vertical incision in the median raphe, skin, dartos and tunica vaginalis is opened to expose tunica albuginea. The tunica albuginea is incised for about 4mm at the upper pole near the head of epididymis.
2463937|NCT03146260|Experimental|Microdissection TESE|Microdissection testicular sperm extraction (TESE)will be carried under anesthesia micro TESE will be through a transverse incision of the testis covering three-quarters of its circumference, according to a line preserving as much as possible the predominantly transversal sub albugineal vessels. The testis will be opened like a book by gently separating the lobular tissue of both sides. Then, the tissue will be examined under the microscope at ×10-24 magnification to search for areas with dilated whitish tubules, from which numerous microretrievals will be performed.
2463968|NCT03145987|Experimental|Vitis vinifera extract|Vitis vinifera extract 250 mg/day orally administered for 12 weeks.
2463973|NCT03145987|Placebo Comparator|Placebo|Placebo orally administered once a day for 12 weeks.
3191465|NCT00798772|Experimental|A: Broad spectrum micronutrients|"The experimental treatment medications (micronutrients and antioxidants) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
2464160|NCT03144843|Experimental|Experimental group|Apatinib: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
2464166|NCT03144843|Placebo Comparator|Placebo group|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
2464199|NCT03144323|Experimental|Study group|This group will receive 4 daily electronic reminders via the Calendar app on their mobile phones, reminding them to wear their elastics.
2464200|NCT03144323|No Intervention|Control group|This group will receive their orthodontic treatment and elastics instructions as normal, without reminders.
2464233|NCT03144115|Experimental|oxytocin fertility|intranasal oxytocin administration (24IU) in women's fertility phase (LH>40 mIU/ml)
2464234|NCT03144115|Placebo Comparator|placebos fertility|intranasal placebo administration (24IU) in women's fertility phase (LH>40 mIU/ml)
2464235|NCT03144115|Experimental|oxytocin luteal|intranasal oxytocin administration (24IU) in women's luteal phase (LH<30 mIU/ml)
2464237|NCT03144115|Placebo Comparator|placebos luteal|intranasal placebos administration (24IU) in women's luteal phase (LH<30 mIU/ml)
2464373|NCT03143205|Experimental|AWARENESS for sexual minorities|Group receives new CBT-based intervention
2464378|NCT03143205|Active Comparator|Writing tasks|Group receives writing-based sessions
2464467|NCT03142958|Other|Integra® Cadence™ Total Ankle System|
2464520|NCT03142282|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Xeloda
2464525|NCT03142282|Experimental|Radiotherapy|consolidative radiotherapy plus maintenance chemotherapy
2464644|NCT03141294|Placebo Comparator|sd-PDT group|The investigators applied the traditional standard dilation technique when operating tracheostomy on the standard group.
2464646|NCT03141294|Experimental|re-PDT group|The investigators applied the reformative dilation technique when operating tracheostomy on the re-PDT group.
2464794|NCT03140449|Experimental|Rapamycin|Rapamycin(0.1%)
2464796|NCT03140449|Experimental|Calcitriol|Calcitriol(3mcg/g)
2464798|NCT03140449|Experimental|Rapamycin-calcitriol combination|Rapamycin(0.1%) with Calcitriol(3mcg/g)
2464877|NCT03140085|Active Comparator|Anbiotica|
2464878|NCT03140085|Active Comparator|Bacteriophages|
2464879|NCT03140085|Placebo Comparator|Placebo|
2464920|NCT03139643|Experimental|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
2464924|NCT03139643|Experimental|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
2464926|NCT03139643|Placebo Comparator|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
2464941|NCT03139253|Experimental|clarithromycin susceptible|"Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and clarithromycin.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI)."
2464942|NCT03139253|Experimental|metronidazole susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tinidazole.
2464946|NCT03139253|Experimental|levofloxacin susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and levofloxacin.
2464949|NCT03139253|Experimental|furazolidone susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and furazolidone.
2463933|NCT03146390|Active Comparator|Essential oils (Listerine Mentol)|"a single mouthwash with 20 ml of essential oils for 30 seconds~20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1)."
2463940|NCT03146390|Placebo Comparator|Water|"a single mouthwash with 20 ml of sterile water for 30 seconds~20 ml rinses for 30 seconds with sterile water/2 times daily (1/0/1)."
2463946|NCT03146390|Experimental|Alcohol free essential oils|"a single mouthwash with 20 ml of alcohol free essential oils for 30 seconds~20 ml rinses for 30 seconds with alcohol free essential oils/2 times daily (1/0/1)."
2464024|NCT03145896|Active Comparator|IBD patients with Vitamin D treatment|
2464025|NCT03145896|No Intervention|IBD patients with no Vitamin D treatment|
2464100|NCT03145350|Active Comparator|High-fat, low-carbohydrate diet|Dietary intervention: Participants will consume a diet that is rich in saturated fat (20% total energy) and low in free sugars for 4 weeks. This diet will include commonly eaten foods such as butter, cheese, and fatty meat products. Total fat intake in this intervention will be 40-45% total energy.
2464107|NCT03145350|Active Comparator|Low-fat, high-carbohydrate diet|Dietary intervention: Participants will consume a diet that is low in saturated fat (~5% total energy) and rich in free sugars (20% total energy).The diet will include commonly eaten food and drink such as sugar sweetened beverages, confectionery (e.g. fruit gums) and table sugar.
2464173|NCT03144830|Experimental|Overground walking program|Study participant will be involved in an indoor, overground walking program using an exoskeleton wearable walking device under the supervision of a physiotherapist.
2464243|NCT03144206|Experimental|Hyperbaric Oxygen Group|Patients will receive Hyperbaric Oxygen treatments in the immediate postoperative period
2464244|NCT03144206|No Intervention|Standard of Care Group|Patients will not receive Hyperbaric Oxygen treatments in the immediate postoperative period
2464398|NCT03143088||Medical clown|Medical clown will be present in the pediatric emergency department while assessing blood pressure during triage of patients.
2464402|NCT03143088||Blood pressure assessment|Blood pressure will be measured by the medical center protocols.
2464434|NCT03142802|Experimental|Patients with testicular germ cell cancer|Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
2464502|NCT03142555|Experimental|Health talk plus intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 minutes);~Social media (intensive reminders);~Regular personalized what's app interaction ( up to 2 months duration)"
2464508|NCT03142555|Placebo Comparator|Health talk plus less intensive social media intervention|"Subjects in this group will receive:~General health talk;~Phone follow-up/counselling service (15 - 30 mintues);~Social media ( less intensive reminders)"
2464568|NCT03141983|Active Comparator|Anakinra|"Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1 alpha and IL-1 beta by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra).~Anakinra will be supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe will contain 100 mg in 0.67 ml solution (pH 6.5) containing disodium EDTA (0.12 mg), sodium chloride (5.48 mg), sodium citrate (1.29 mg), and polysorbate 80 (0.70 mg) in Water for Injection, USP."
2464569|NCT03141983|Placebo Comparator|Placebo|Saline (0.9%) will be used as the placebo, supplied in pre-filled syringes as a sterile, clear, colorless-to-white, preservative free solution.
2464596|NCT03141645|Experimental|Fluid loading group|Patients will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation
2464597|NCT03141645|Active Comparator|Ondansetron group|Patients will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation.
2464599|NCT03141645|No Intervention|Control group|Patients will receive neither preoperative intravenous fluid loading nor intravenous ondansetron.
2464641|NCT03141398||High-Risk Group|The objective of the study to compare the efficiency of detecting glycemic abnormalities using Continuous Glucose Monitoring (CGMs) versus Oral Glucose Tolerance Test (OGTT) and HbA1C. versus T2* MRI of the pancreas (T2* MRI of the Pancreas) in high-risk patients due to insulin deficiency (potential beta cell injury) and those with insulin resistance and to study the different factors that may affect the glycemic control in these patients in relation to their results like the Dose of corticosteroids and chemotherapy in ALL and Hemoglobinopathies,Liver function in ALL and Hemoglobinopathies, and Serum ferritin in Hemoglobinopathies and their transfusion status.
2464733|NCT03141099|Active Comparator|Low normal MAP and low normal PaO2|MAP 63 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
2464734|NCT03141099|Active Comparator|High normal MAP and low normal PaO2|MAP 77 mmHg and PaO2 9-10 kPa during targeted temperature management (36 hours) after OHCA.
2464735|NCT03141099|Active Comparator|Low normal MAP and high normal PaO2|MAP 63 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
2464736|NCT03141099|Active Comparator|High normal MAP and high normal PaO2|MAP 77 mmHg and PaO2 13-14 kPa during targeted temperature management (36 hours) after OHCA.
2464755|NCT03140553|Experimental|TCH|docetaxel/carboplatin/trastuzumab
2464756|NCT03140553|Active Comparator|EC-TH|epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab
2464824|NCT03140436|Experimental|sodium bicarbonate powders (65 µm)|sodium bicarbonate powders with grain size 65 µm
2464826|NCT03140436|Experimental|sodium bicarbonate powders (40 µm)|sodium bicarbonate powders with grain size 40 µm
2464871|NCT03140020||Clipping|Clipping of an aneurysm of the anterior communicating artery - A titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after microsurgical aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from microsurgical treatment.
2464925|NCT03139630||HIV-infected patients|HIV-infected adult male or female patients who are HIV treatment naive and initiate antiretroviral therapy including a protease inhibitor during the follow up period.
2464002|NCT03145597|Experimental|Laminate veneer of composite|Laminate veneer of composite (Estenia, Kuraray Dental), composite laminate veneer, 2-4-6 veneers per patient will be made.
2464005|NCT03145597|Experimental|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
2464063|NCT03145441|Experimental|CytoSorb®|The CytoSorb® filter will be installed into the cardiopulmonary bypass circle during cardiac transplantation in this study group (30 patients)
2464065|NCT03145441|No Intervention|Control|No filter will be installed into the cardiopulmonary bypass circle in this group (30 patients).
2464117|NCT03145103|Experimental|409M|CT ASPHINA 409M IOL
2464182|NCT03144869|Experimental|physical activity monitor only|"Children will wear a Runscribe accelerometer for two weeks. Runscribe is a small inertial sensor (weight 15g, size 35x25x7.5 mm). It can be attached to the body in several positions (wrist, waist, sacrum, chest, thigh, foot) and is used for monitoring movement. Runscribe does not beep, flash or have a visual display. It will not provide PA feedback to the individuals in real-time, only via a researcher after the data has been downloaded. In this study, we are not wishing to influence children's behaviour by providing PA feedback in real-time. We are trying to establish whether PA monitoring is feasible and acceptable - and further research could go on to explore the use of real-time PA feedback as an educational technique.~Phase 1 findings will help to determine: i) method of monitor distribution to participants (post, clinic or in-person), ii) preferred wear position."
2464184|NCT03144869|Experimental|physical activity monitor plus constant glucose monitor|Children using a personal constant glucose monitor (CGM) or CGM on loan from clinic as part of clinical care will be approached for Arm 2. These children will wear Runscribe at the same time as a CGM. Runscribe and CGM worn over the same 2 week period.
2464221|NCT03144362|Active Comparator|Bilateral Sliding Technique|
2464225|NCT03144362|Active Comparator|Unilateral Sliding Techniques|
2464228|NCT03144362|No Intervention|Standard care|
2464266|NCT03143946|Experimental|Vitamin supplement and diet advice|Single arm. Patient be prescribed vitamin supplement if vitamin deficiencies are diagnosed and will get diet advice
2464291|NCT03143647||Control|"Female~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1~Not pregnant"
2464292|NCT03143647||Case|"Female~Pregnant with possible pre-eclampsia~Over 18 years of age~American Society of Anesthesiologists physical fitness scale 1"
2464357|NCT03143439||Program group|The program group will be comprised of all individuals who enrolled in the FACT program from July 2016 through September 2019 and have active child support cases with the Contra Costa County Department of Child Support Services.
2464359|NCT03143439||Comparison group|The comparison group will be comprised of individuals with active child support cases with the Contra Costa County Department of Child Support Services who are demographically comparable to the treatment group (i.e., FACT fathers with active child support cases), yet did not participate in or receive FACT services.
2464430|NCT03143010|Placebo Comparator|control group|intrathecal Dexmedetomidine received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline .
2464432|NCT03143010|Experimental|1.5 DEX|Dexmedetomidine 1.5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (1.5μg) dexmedetomidine
2464438|NCT03143010|Experimental|3 DEX|Dexmedetomidine 3 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (3μg) dexmedetomidine
2464446|NCT03143010|Experimental|5 DEX|Dexmedetomidine 5 micrograms received 3mL (15mg) of 0.5% levobupivacaine +0.5ml (5μg) dexmedetomidine
2464500|NCT03142295|Experimental|Urine transfusion|Intervention: Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
2464572|NCT03142035|Experimental|Dienogest|patients will receive daily dienogest (2mg) for a total of 3 months (84 days)
2464573|NCT03142035|Active Comparator|GnRH agonist|patients will receive a single GnRH-a injection (3.25mg) every 28 days for three months.
2464574|NCT03142035|Other|Control Group|patients will not receive any medical intervention and will proceed with their IFV/ICSI cycles.
2464666|NCT03141554|Active Comparator|Treatment Sequence Group 1|"Treatment Sequence Group 1 = A -> B -> C~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm)."
2464667|NCT03141554|Active Comparator|Treatment Sequence Group 2|"Treatment Sequence Group 2 = B -> C -> A~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle"
2464670|NCT03141554|Active Comparator|Treatment Sequence Group 3|"Treatment Sequence Group 3 = C -> A -> B~Treatment C = Normal saline gargle (lukewarm).~Treatment A = 1% Betadine® PVP-I based mouth wash and gargle~Treatment B = 0.2% Chlor-Rinse™ Chlorhexidine based mouth wash (no alcohol)"
2464745|NCT03140930|Experimental|Duodenal tastants, ileal placebo|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of placebo (tap water)
2464746|NCT03140930|Experimental|Duodenal placebo, ileal tastants|Duodenal infusion of placebo (tap water), ileal infusion of combination of tastants (sweet, bitter and umami)
2464748|NCT03140930|Experimental|Duodenal tastants, ileal tastants|Duodenal infusion of combination of tastants (sweet, bitter and umami), ileal infusion of combination of tastants (sweet, bitter and umami)
2464749|NCT03140930|Placebo Comparator|Duodenal placebo, ileal placebo|Duodenal infusion of placebo (tap water), ileal infusion of placebo (tap water)
2464804|NCT03140488|No Intervention|Lean-Control|"1) Control group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2464927|NCT03139630||HIV-uninfected patients|HIV-uninfected adult male or female patients.
2463978|NCT03146455||Health adults|(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.
2463996|NCT03145753|Experimental|HIV/HCV Education plus Testing|In this arm education should be provided and also resources for testing, HIV/HCV rapid tests and Testing staff different from clinical practice resources
2463997|NCT03145753|Active Comparator|HIV/HCV Education|In this arm only education should be provided
2464070|NCT03145493|Experimental|Usage of suction drains|Usage of suction drains
2464073|NCT03145493|No Intervention|No usage of suction drains|No usage of suction drains
2464130|NCT03144999|Experimental|Low Dose|AAVCAGsCD59
2464131|NCT03144999|Experimental|Mid Dose|AAVCAGsCD59
2464133|NCT03144999|Experimental|High Dose|AAVCAGsCD59
2464158|NCT03144661|Experimental|Part 1|Subjects with HCC, cholangiocarcinoma, or esophageal, nasopharyngeal, or serous ovarian cancers, regardless of FGF/FGFR alteration status.
2464162|NCT03144661|Experimental|Part 2 Cohort A|Subjects with HCC with FGF19 amplification.
2464168|NCT03144661|Experimental|Part 2 Cohort B|Subjects with HCC without FGF19 amplification.
2464177|NCT03144661|Experimental|Part 2 Cohort C|Subjects with cholangiocarcinoma or esophageal, nasopharyngeal, or serous ovarian cancers (regardless of FGF/FGFR status), or other solid tumor malignancies with documented FGF19/FGFR4 alteration.
2464252|NCT03144102|Experimental|VR-based motor rehabilitation with tDCS|
2464257|NCT03144102|Active Comparator|Occupational Therapy with tDCS|
2464261|NCT03144102|Sham Comparator|VR-based motor rehabilitation with sham tDCS|
2464262|NCT03144102|Sham Comparator|Occupational Therapy with sham tDCS|
2464295|NCT03143686||ACURATE TA™ Transapical Aortic Bioprosthesis|The first two hundred and fifty (250) patients in whom the commercial, or CE Mark, ACURATE TATM Transapical Aortic Bioprosthesis is implanted.
2464366|NCT03143257||Subjects|Diagnosed with CHL, SSD and mixed HL who currently have or have had the Sophono implant
2464421|NCT03142945|Active Comparator|Traditional Physical Therapy Group|Traditional Physical Therapy Group Physical therapy-based interventions: home exercises (not repeated motions), stretching, modalities, and posture instruction.
2464422|NCT03142945|Experimental|MDT based physical therapy|MDT based physical therapy Physical therapy-based interventions: home exercises (including repeated motions), stretching, modalities, and posture instruction.
2464478|NCT03142620|Active Comparator|Triple Therapy 10 days|Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days
2464479|NCT03142620|Active Comparator|Triple Therapy 10 days+ vitamin D for 10|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 10 days"
2464480|NCT03142620|Active Comparator|Triple Therapy 10 days+vitamin D for 28|"Esomeprazole 40mg, Amoxicillin-Potassium Clavulanate Combination 1000mg and clarithromycin 500mg for 10 days~+ vitamin D3 IU for 28 days"
2464590|NCT03142074||Ascending thoracic aortic aneurysm|"Biomechanical and microstructural analysis of ATAA~ECG-gated CT"
2464653|NCT03141502|Experimental|Skin Stretching Device (SSD)|the wound is primarily closed by aid of the SSD after necessary surgical debridement.
2464654|NCT03141502|Active Comparator|Skin Grafting (SG)|the wound is primarily closed by the technique of skin grafting after necessary surgical debridement.
2464795|NCT03140644|Experimental|Patients with thoracic sarcoidosis|Patients routinely followed-up for thoracic sarcoidosis with a CT scan indicated in the follow-up
2464866|NCT03140228|Experimental|I-Gel group|I-gel will be used for maintenance of airway during general anaesthesia
2464867|NCT03140228|Active Comparator|LMA ambu auraonce group|LMA ambu auraonce will be used for maintenance of airway during general anaesthesia
3191466|NCT00798772|Active Comparator|B: Identical appearing multivitamins|"The active comparator/control medications (identical appearing RDA multivitamins and minerals) will be taken as one packet (8 capsules) twice a day with meals. Because of the presence of calcium, iron and zinc in the study medication, any other medication must be taken at least two hours before or after taking it. Participants may initiate the intervention at half dose (one packet of 8 capsules once a day) and increase to full dose after one week.~The intervention will last for two years."
2464969|NCT03139565|Experimental|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
2464972|NCT03139565|Active Comparator|Standard 2016-2017 Flu vaccine|This will be the Standard 2016-2017 influenza vaccine made available by public health. It will contain 15 microgram of each strain and will be delivered in the deltoid muscle of non-dominant arm.
2465033|NCT03139019|Experimental|Process incentives|Process incentives participants will receive incentives based on visit attendance in the YMCA DPP session. This incentive will be $ 15 for attending each session.
2465036|NCT03139019|Experimental|Outcome incentives|Outcome incentives participants will be weighed at 8 and 16 weeks after the program starts and if they have lost 2.5% of their body weight at each time point then they will receive $100 and $140 respectively.
2465039|NCT03139019|Experimental|Process and Outcome incentives|If assigned to the Process and Outcome arm participants will be informed that they can earn additional incentives for attending DPP classes and losing weight. Participants in this arm can earn $7.50 per DPP class (max 16) and $50 and $70 for achieving 2.5% weight loss at 8 and 16 weeks respectively.
2465042|NCT03139019|No Intervention|Control arm|If assigned to the Control arm participants will not be eligible for any additional incentives and will just learn the goals of the DPP program itself.
2465277|NCT03137147|Other|Cognitive-Behavioral Therapy|Intervention for Sleep and Pain in Youth, a 7-session cognitive-behavioral therapy intervention for co-morbid insomnia and headache
2465359|NCT03136900|Experimental|Study Diet|Enteral diet made of Nutrilon without lactose® fortified by concentration
2465362|NCT03136900|Active Comparator|Control Diet|Enteral diet made of Nutrilon without lactose® fortified by Maltodextrin and oil supplementation.
2465560|NCT03135314|Active Comparator|Hypoxia Cocoa flavanol|Exercise or cognitive test in (acute) hypoxic condition after 7 days of cocoa flavanol intake
2464021|NCT03145961|Experimental|Pembrolizumab Treatment|Patients will be given pembrolizumab every 3 weeks for up to a maximum of 12 months, with blood samples collected prior to each cycle for continued ctDNA analysis. Following treatment discontinuation, blood samples will be collected for ctDNA analysis every 3 months for a further 12 months.
2464120|NCT03145285|Experimental|Cohort 1|"Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy.~Treatment with single agent Abiraterone Acetate (AA) until progression"
2464122|NCT03145285|Experimental|Cohort 2|"Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection.~Treatment with single agent Abiraterone Acetate (AA) for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month, then Mitotane +/- chemotherapy can be started upon the clinician's decision."
2464186|NCT03144752||Cohort 1: Participants between 8 to 14 weeks gestation|Cohort 1 will include female participants who present for the first prenatal visit which takes place between Weeks 8 and 14 at maternity practices associated with University of North Carolina (UNC) Women's Care. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
2464189|NCT03144752||Cohort 2: Participants between 15 to 36 weeks gestation|Cohort 2 will include female participants enrolled at various points in their pregnancy from Week 15 up through 36 weeks gestation. Biomarkers, medical and psychiatric history, and psychosocial measures will be evaluated and utilized in developing a predictive risk algorithm for perinatal depression.
2464217|NCT03144427||Burns|Patients with burns to 20% or more of their BSA (body surface area) require resuscitation with intravenous crystalloid fluids in order to avoid organ failure and death
2464285|NCT03143998|Experimental|HCV GT1a TN|Participants with HCV GT1a infection who are TN will take MK-5172A for 12 weeks.
2464286|NCT03143998|Experimental|HCV GT1a TE|Participants with HCV GT1a infection who are TE will take MK-5172A for 12 weeks.
2464287|NCT03143998|Experimental|HCV GT1b TN|Participants with HCV GT1b infection who are TN will take MK-5172A for 12 weeks.
2464288|NCT03143998|Experimental|HCV GT1b TE|Participants with HCV GT1b infection who are TE will take MK-5172A for 12 weeks.
2464353|NCT03143491|Experimental|SOR007 0.15%|1 mL of 0.15% SOR007 Ointment
2464354|NCT03143491|Experimental|SOR007 1.0%|1 mL of 1.0% SOR007 Ointment
2464355|NCT03143491|Experimental|SOR007 2.0%|1 mL of 2.0% SOR007 Ointment
2464415|NCT03143036|Experimental|Daratumumab, thalidomide and dexamethasone|
3156369|NCT00341458||Cancer Cases|Women 20-74 years old, residents of Warsaw and Lodz that were newly diagnosed with confirmed in situ or invasive breast cancer or ovarian or endometrial cancer
3156372|NCT00341549||Myopia|The subject population will be adult individuals and their children, in good health with the exception of myopia.
3156373|NCT00341588||Cases|Male U.S. serviceman, age 18-45 years old with TGCT
3156374|NCT00341588||Controls|Male U.S. serviceman, age 18-45 years old without TGCT
3156375|NCT00341627||1|Population-based sampling of individuals affected with Chordoma
2464837|NCT03140332|Other|Patient with CHC|
2464950|NCT03139253|Experimental|tetracycline susceptible|Patients will receive a 14-day triple therapy to eradicate H. pylori. The regimen is consist of Ilaprazole, amoxicillin and tetracycline.
3156379|NCT00341692||Samples of normal breast tissue|Samples of normal breast tissue from organ donors for assessment of histology.
3156380|NCT00341835||High risk lung cancer families|Individuals from families with a high risk of lung cancer, both affected and unaffected family members
3156381|NCT00341900||Case|Male pilots with high cosmic radiation exposure
3156383|NCT00341952||Cases|individuals diagnosed with incident, first primary non-Hodgkin lymphoma
3156384|NCT00341952||Controls|individuals identified in the same geographical areas without non-Hodgkin lymphoma or othercancers
3156385|NCT00341991||1|Cases from hospitals
3156386|NCT00341991||2|Controls from the general populations
3156387|NCT00341991||3|Biological Samples
3156388|NCT00342004||Healthy Volunteers|Healthy female urban residents in Shanghai between ages of 40-70.
3156389|NCT00342108|Experimental|1|Diagnosis: CP, moderate to severe MR and CVI
3156390|NCT00342108|Experimental|2|Diagnosis: CP, Moderate to severe MR, no visual impairment
3156391|NCT00342121||1|Corn farmers enrolled in the Agricultural Health Study who are non-smokers, and who plan to apply specific pesticides.
3156392|NCT00342121||2|Control subjects selected from agricultural extension workers in Iowa who are non-smokers
3156393|NCT00342147||1|This is a high risk population of families for NPC
3156394|NCT00342173||Women in Costa Rica|Examining the natural history of HPV and cervical neoplasia in Costa Rican women.
3156397|NCT00342316|Experimental|Stem cell transplant (RICT)|Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation
3156398|NCT00342316|No Intervention|Control arm|Treatment according to standard of care, i.e. not undergoing RICT
2464069|NCT03145831|Experimental|Somavaratan|fusion protein, subcutaneous bolus injection, 3.5 mg/kg twice monthly
2464153|NCT03145012|Experimental|Treatment Group|"This is a one arm study in which all individuals receive the treatment; therefore there is no allocation or randomization.~Thirty subjects will receive ranitidine to a maximum of 900 mg/day in 2 daily doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets. The ranitidine will be taken orally."
2464227|NCT03144505|No Intervention|Control|The control group will be invited to an orientation session, where it will be provided detailed information concerning their home base exercise program. Additionally, once in every 4 weeks, the control group will meet for thematic sessions regarding diabetes topics, such as, nutrition, physical activity, and clinical complications. Due to ethical reasons, the control group needs to be provided with a standard counseling approach, as suggested in this research project.
2464229|NCT03144505|Experimental|MCT combined with RT Group|"MCT Group is designed to have equal energy expenditure when compared with HIIT Group. We standardized the exercise prescription according to body weight (kg), predicting that physical activity guidelines of 150 min peer week moderate intensity is equivalent to 10 kcal/kg of a combined session of RT and MCT. The MCT group will perform continuous cycling 3 days per week, with an exercise intensity of 40 to 59% of the heart rate reserve (HRR).~Participants will also perform an RT circuit: 1 set of two pull upper body exercises (seated row and lat pulldown); 1 set of two push upper body exercises (chest press and shoulder press); 1 set of two leg exercises (leg press and one leg lunge); and 1 set of two core exercises (dead bug and regular plank). Each set consisting in 10 to 12 repetitions."
2464230|NCT03144505|Experimental|HIIT combined with RT Group|"The HIIT program will perform cycle ergometer 3 days a week, and it will be divided into three phases: preparation phase (weeks 1-4), where the participants perform MCT (40-59% of the HRR); transition phase (weeks 5-8), in which the HIIT program is introduced progressively, starting with bouts of 2 minutes at 70% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 5-6), and finishing with bouts of 80% of the HRR, followed by 1 minute at 40-59% of the HRR (weeks 7-8); training phase (weeks 9-42), where the participants perform 1 minute of exercise at 90% of the HRR, followed by 1 minute resting at 40-59% of the HRR.~The HIIT session will have the same energy expenditure as the MCT group, using the 10kcal/kg week target. Participants will also fulfill the same RT as the MCT group."
3191467|NCT00798785|Experimental|group I ATG-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=30"
3191468|NCT00798785|Experimental|group II ATG-Rituximab-MMF-TAC|"Two clinical implants in the liver:~First Implant: ATG fresenium + Rituximab Maintained immunosuppression: MMF-TAC n=5"
2464323|NCT03143478|Experimental|M-MARK|Participants self administer rehabilitation exercises using the M-MARK device for 20 days.
2464407|NCT03143283|No Intervention|Usual care|Hospital EDs are observed under usual care conditions (families receive usual care at the ED).
2464412|NCT03143283|Experimental|Safety Study Lethal Means Counseling|During the intervention phase, mental health clinicians at EDs of participating hospitals are trained in lethal means counseling and implement the new protocol uniformly with eligible families.
2464423|NCT03142672|Experimental|Experimental group|Pulpotomy and tooth filling
2464424|NCT03142672|Active Comparator|Control group|Tooth filling
2464481|NCT03142607|Active Comparator|Group A|subjects will be instructed to apply a standard 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva for the next 14 days, twice a day for 30 minutes, after morning and evening tooth brushing
2464483|NCT03142607|Active Comparator|Group B|Subjects will be instructed to apply 0.8 % Metronidazole gel (anaerobic gel) twice daily for 30 minutes after morning and evening tooth brushing for two weeks
2464486|NCT03142607|Active Comparator|Group C|subjects will be instructed to apply 0.2 % Chlorhexidine gel (clinica gel) on the marginal gingiva after morning tooth brushing for 30 minutes and 0.8 % metronidazole gel (anaerobic gel) after evening tooth brushing for 30 minutes for two weeks. Subjects in these groups will receive the detailed and precise instruction and demonstrations on the diurnal alternate application of the two gels
2464522|NCT03142230|Experimental|non-nutritive suction with holed baby bottle nipple|A group using the holed baby bottle nipple
2464527|NCT03142230|Active Comparator|Simple non-nutritive suction with personal pacifier|A group using personal pacifier
2464601|NCT03141918|Experimental|Curcumin group 1|Intervention will be with intake of curcumin, 1000mg per 30 days
2464602|NCT03141918|Placebo Comparator|Curcumin group 2|Intervention will be with placebo intake of curcumin, 1000mg per 30 days
2464650|NCT03141385|Experimental|RIPC intervention|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
2464652|NCT03141385|Sham Comparator|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
2464721|NCT03141073|Experimental|HMS5552|75mg BID
2464726|NCT03141073|Placebo Comparator|Placebo|BID
2464836|NCT03140735|Other|Control group of 150 heart disease-free individuals|
2464839|NCT03140735|Other|Patients with aortic sclerosis|
2464841|NCT03140735|Other|Patients with moderate aortic stenting (RA)|
2464843|NCT03140735|Other|Patients with Serious Aortic Retention|
2464884|NCT03139981|Experimental|ASN002 40 mg|40 mg ASN002
2464886|NCT03139981|Experimental|ASN002 80 mg|80 mg ASN002
2464889|NCT03139981|Experimental|ASN002 20 mg|20 mg ASN002
2464893|NCT03139981|Experimental|ASN002 120 mg|120 mg ASN002
3191469|NCT00798785|Experimental|group III ATG-Basilixumab-MMF-TAC|"Two clinical implants in the liver:~First implant: ATG-fresenium Second implant: basilixumab Maintained immunosuppression: MMF-TAC n=5"
2465028|NCT03138772||Healthy Controls|No intervention. Only monitoring LCI
2465029|NCT03138772||Cystic Fibrosis Patients|No intervention. Only monitoring LCI
2465070|NCT03138499|Experimental|Module A|Nivolumab combined with Brentuximab
2465071|NCT03138499|Experimental|Module B|Brentuximab alone
2464072|NCT03145246||clinical attachment loss ≥ 2 mm|regenerated treated teeth with clinical attachment loss ≥ 2 mm
2464074|NCT03145246||clinical attachment loss loss < 2 mm|regenerated treated teeth with clinical attachment loss < 2 mm
2464193|NCT03144986|Experimental|Deep insula-coil rTMS|"Active treatment phase consists of deep rTMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase.~Maintaince treatment phase includes two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks."
2464207|NCT03144284||dental interns|dental interns in pediatric dentistry department, faculty of dentistry, Cairo University.
2464272|NCT03144076|Experimental|Group A|[Other: RSBY Health Insurance] The households in this group were offered RSBY for free. They did not have to pay the fee amount or premium amount and simply had to present their chit at the enrollment station and were enrolled. The entire premium amount including fee (Rs. 173 in Mysore, Rs. 163 in Gulbarga) has to be borne by the study. These households were automatically re-enrolled in RSBY for free for the second year of the study.
2464274|NCT03144076|Experimental|Group B|[Other: RSBY Health Insurance] The households in this treatment group were first given a cash transfer equivalent to the fee and premium for RSBY during the first visit to their household. In addition, they were offered the opportunity to purchase RSBY during a second visit to their household and get their household enrolled during that time. At that time, payment would be collected from the respondents who wanted to get enrolled and then these respondents would be taken to the enrollment stations to get them enrolled. For those households that chose to purchase RSBY for the first year of the study, their coverage was automatically extended to the second year of the study at no additional cost to them.
2464276|NCT03144076|Experimental|Group C|[Other: RSBY Health Insurance] The households in this group were simply offered an opportunity to purchase RSBY if they wished to. They were informed about this during the first visit to their household and for the households who wanted to get enrolled, the fee and premuim amount was collected and enrolment was done during the second visit to their household.
2464277|NCT03144076|No Intervention|Group D|[No intervention] The households in this group were not offered anything and were informed that they had been randomly selected to not receive anything beyond the participation incentive that all survey participants received. In addition, a short survey was administered to them at this time.
2464307|NCT03143582|Experimental|Running group|13 week, bi-weekly running group
2464345|NCT03143387|Active Comparator|Atraumatic Restorative Treatment|Partial removal of carious tissue using manual instruments.
2464346|NCT03143387|Experimental|Chemo-mechanical Removal|Partial removal of carious tissue using manual instruments and the material Chemo-mechanical removal group using Papacarie™gel.
2464392|NCT03143114|Experimental|Myomectomy|Women will be subjected to laparotomy to remove the myomas
2464394|NCT03143114|No Intervention|Conservative management|Women will not be subjected to surgery (conservative management)
2464427|NCT03142789|Active Comparator|Certa Catheter|"A Certa-catheter (suture method) is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
2464428|NCT03142789|Active Comparator|Standard Catheter|"A Standard-catheter is inserted under ultrasound guidance at the midthigh level in the adductor canal, using an in plane technique, short/oblique axis view.~A bolus of ropivacaine will be administered during real time US imaging to ensure correct placement of the catheter (initial bolus). An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses every 8 hours until 12 pm on POD2.~2 dressings will be applied (medial and lateral) to obscure which catheter has been placed."
2464429|NCT03142789|Active Comparator|Single Bolus|"A bolus of ropivacaine will be injected into the adductor canal, at the midthigh level, using a 80 mm x 22G Pajunk needle during real time US imaging (initial bolus).~A sham catheter (25 Certa and 25 standard catheters according to randomi-zation) will be fixed externally and covered by dressings as in the catheter groups groups (Certa and standard). Care will be taken to use approximately the same amount of time as used in the catheter groups (Certa and standard) An infusion pump will be connected immediately following catheter insertion, delivering intermittent boluses into the dressing every 8 hour until 12 PM on POD2."
3191470|NCT00798785|Experimental|group IV omentum|"Two clinical implants: first in the omentum followed by a clinical implant in the liver:~First implant: ATG-fresenium Maintained immunosuppression: MMF-TAC n=10"
2464647|NCT03141567||Outpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
2464648|NCT03141567||Inpatient|Individuals undergoing clinically indicated Right Heart Catheterization.
2464703|NCT03141125|Experimental|Physalis angulata ethanol extract|"Physalis angulata ethanol extract was given with dosage 3 x 250 mg/day, orally, for 3 months.~In addition, patients also received standard therapy for scleroderma."
2464704|NCT03141125|Placebo Comparator|Placebo|Patients received standard therapy and placebo (amylum powder) for comparator at dosage 3 x 250 mg/day, orally, for 3 months.
2464844|NCT03140306|Experimental|Low dose CT abdomen and pelvis|Low dose computed tomography
2464848|NCT03140306|Experimental|Control dose CT abdomen and pelvis|Control dose CT abdomen and pelvis
2464898|NCT03139942|Experimental|Imaging using OPTIC probe|Single arm study to test the feasibility of a new device - the OPTIC imaging probe. All participants enrolled in the study may be imaged using optical spectral reflectance and autofluorescence imaging during their endoscopy procedure.
2464931|NCT03139474|Active Comparator|agonist group|Triptorelin at a dose 1 milligram per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
2464932|NCT03139474|Active Comparator|antagonist group|•Multiple dose Gonadotrophin releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .
2464981|NCT03139201|Experimental|OxyAqua|OxyAqua (olifilcon D) daily disposable
2464096|NCT03145077|Experimental|Cohort 1 (DCE-MRI)|Patients with newly diagnosed tumors undergo DCE-MRI within 4 weeks prior to the first radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation. Patients who were previously irradiated and are at various stages of oncologic follow-up undergo DCE-MRI for a total of 2-5 times at baseline and at 6, 12, 24, 36, and/or 48 months post radiation. Patients in the third or subsequent years post treatment may undergo subsequent yearly imaging studies.
2464104|NCT03145077|Experimental|Cohort 2 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to the first re-radiation fraction, within 3-5 weeks after radiation start, and at 2, 6, 12, 24, and 36 months post radiation.
2464110|NCT03145077|Experimental|Cohort 3 (DCE-MRI)|Patients undergo DCE-MRI before and at 2 and 6 months post ORN treatment. Patients may undergo DCE-MRI during the mid-ORN treatment.
2464113|NCT03145077|Experimental|Cohort 4 (DCE-MRI)|Patients undergo DCE-MRI within 4 weeks prior to and at 5-10 weeks and 12 months post surgery.
3156399|NCT00342342||Beaver Dam Eye Study|Individuals over 45 years of age enrolled in Beaver Dam Wisconsin
2464249|NCT03144492||self-reported healthy individuals|"Self-reported healthy individuals avoiding blood draw on the days participants are feeling under the weatheror sick. In that case, study team can delay the blood draw until the subject feels better, but this would not preclude anyone from participating."
2464273|NCT03143803|Active Comparator|Polyherbal|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
2464275|NCT03143803|Placebo Comparator|Placebo|Placebo will contain an inert substance
2464340|NCT03143595||Control group|Patients in this group have normal cognition as assessed by the validated Mini-Cog test before the elective operation.
2464342|NCT03143595||Impaired group|Patients in this group have impaired cognition as assessed by the validated Mini-Cog test before the elective operation.
2464459|NCT03142893|Experimental|Control Condition|"8 am - Saline Solution for Injection 10 am - Placebo oral capsule~1 pm - Saline Solution for Injection 4 pm - Placebo oral capsule & start hourly blood sampling 7 pm - Gonadorelin (GnRH) and Corticorelin (CRH) injections 9 pm - Saline Solution for Injection & last blood sample"
2464465|NCT03142893|Experimental|Hypothalamic Condition|"8 am - Ganirelix 10 am - Placebo oral capsule~1 pm - Dexamethasone injection 4 pm - Placebo oral capsule and start of hourly blood sampling 7 pm - GnRH and CRH injections 9 pm - Saline Solution for Injection and last sample of blood taken"
2464470|NCT03142893|Experimental|Pituitary Condition|"8am - Saline Solution for Injection 10am - Ketoconazole Pill~1pm - Saline Solution for Injection 4pm - Ketoconazole Pill & start of hourly blood sampling 7pm - GnRH and CRH 9pm - Hydrocortisone Injection & last blood sample"
2464472|NCT03142893|Experimental|Adrenal/Testis Condition|"10pm - Ganirelix Injection & Dexamethasone Pills (night before) 8am - start of hourly blood sampling 10am - Dexamethasone Pills 11am - last hourly blood sample taken 11:30am - start of blood sampling every 10 minutes~1pm - Recombinant Human Luteinizing Hormone (rhLH) Injection 3pm - rhLH Injection 5pm - rhLH Injection 5pm - Cosyntropin Injectable product 7pm - GnRH and CRH Injections 9pm - last blood sample taken"
2464531|NCT03142139||Danish Birth Cohorts 1997-2012|"RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib~RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib among children who received a timely first dose of DTaP-IPV-Hib~RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated on development of Atopic Dermatitis."
2464576|NCT03141840|Experimental|Experimental|Experimental group: ABL01 is to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
2464579|NCT03141840|Placebo Comparator|Control|Control group: Placebo solution to be applied topically to the infected nail once a week during the study period to counter onychomycosis.
3156400|NCT00342342||Framingham Eye Study|Subset of individuals from the Framingham Heart Study who received eye examinations
2464959|NCT03139422|Active Comparator|Tranexamic Acid|Tranexamic Acid oral tablets 500 mg every six hour with the onset of the first day of menstrual cycle till the end of bleeding for 3 cycles
2464963|NCT03139422|Experimental|Calcium Dobesilate|Calcium Dobesilate oral tablets 500 mg (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.
2465015|NCT03139045|Active Comparator|Venous puncture using VVV at the beginning of the procedure|
2465016|NCT03139045|Active Comparator|Venous puncture without VVV|
2465052|NCT03138668|Experimental|Low dose Ropivacaine|Perineural injection of 8 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve
2465054|NCT03138668|Experimental|High dose Ropivacaine|Perineural injection of 16 ml of Ropivacaine 0.75% at the lateral femoral cutaneous nerve.
2465084|NCT03138278|No Intervention|Usual care|ICU with ordinary care for elderly ICU survivors and their care-givers
2465086|NCT03138278|Active Comparator|Telephone support|ICU with day-time telephone support to care-givers
2465132|NCT03138174||Diabetes|One group consisting of diabetic subjects
3156401|NCT00342368|Active Comparator|1|CPAP through an helmet
3156402|NCT00342368|No Intervention|2|O2 therapy with conventional face mask
3156403|NCT00342381|Active Comparator|3.4 diaminopyridine|Single dose 3,4 diaminopyridine
3156404|NCT00342381|Placebo Comparator|Placebo|Two tablets identical to active treatment
3156405|NCT00342407||Cohort|Female flight attendants
3156406|NCT00342433||Localized Prostate Cancer cases|Cases enrolled between Jan 2000 and Apr 2004 at five locations. Study subject eligibility: Age >=18; scheduled for radical prostatectomy; and newly diagnosed with localized prostate cancer.
3156407|NCT00342472||1|Two of the oldest individuals (a male and a female greater than 18 years of age) from each of 10-15 nonsmoking households from the high-risk region of Linxian, China
2464105|NCT03145584|Sham Comparator|Single Shot Adductor Canal Saphenous Block|Participants in this group were randomly allocated NOT to receive a perineural catheter placed at the time of adductor canal block (ACB). The ACB was performed under ultrasound guidance and a 10ml injection of 0.5% bupivacaine was administered adjacent to the saphenous nerve. A SHAM CATHETER WAS PLACED ON THE SURFACE OF THE LEG AND COVERED BY AN OPAQUE DRESSING TO CONCEAL THE INSERTION SITE. ALL PATIENTS HAD THE PROXIMAL END OF THEIR CATHETER ATTACHED TO PORTABLE ELASTOMERIC PUMPS (PAJUNK FUSERPUMP 350 ML) CONCEALED IN OPAQUE BAGS TO PREVENT PATIENTS AND ASSESSORS FROM DETERMINING WHICH PUMPS WERE ACTUALLY FUNCTIONING. THESE PUMPS FUNCTION WITHOUT A MOTOR AND SO MAKE NO SOUND.
3191471|NCT00798798|Experimental|Implantable Tissue Expansion Device|Will apply externally implantable tissue expansion device for 2 days
3191472|NCT00798811|Other|KSPNO-S-081|Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor
3191473|NCT00798811|Other|KSPNO-S-082|High-dose Chemotherapy and Autologous Stem Cell Rescue in Infants and Young Children with Newly Diagnosed High-risk Brain Tumor To Avoid or Reduce Craniospinal Radiation
2464310|NCT03143608||Indiana group|50 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
2464312|NCT03143608||Wisconsin group|49 adult patients males and females with GERD and 2-5 cm hiatal hernias. Each had laparoscopic hiatal hernia repair followed by transoral incisionless fundoplication
2464387|NCT03143296|Experimental|Current recipient of a Med-El cochlear implant|Participants who have received a MED-EL cochlear implant as a standard of care for treatment of hearing loss. Participants are tested at one time point with a simulated reverberant environment.
2464389|NCT03143296|Active Comparator|Future Med-El Recipient|Cochlear implant candidates not yet implanted and chose Med-El device as standard of care for treatment of hearing loss. Participants are tested at 3 time points over 6 months in a simulated reverberant environment.
2464452|NCT03142906|Experimental|Scan group|Patients randomized to the scan group (intervention arm) will receive a preoperative point-of-care ultrasound (POCUS) exam as an adjunct to their preoperative assessment, the results of which will be disclosed to the anesthesiologist and the patient care team. This POCUS exam will include a focused cardiac ultrasound, a lung and pleural ultrasound, and a gastric volume and content ultrasound assessment. Patients randomized to this arm may also receive repeat POCUS exams as needed and as clinical conditions change. These repeat exams may be requested by the anesthesiologist or patient care team.
2464457|NCT03142906|No Intervention|No scan group|Patients randomized to no scan (control arm) will not receive a preoperative point-of-care ultrasound exam. Patients in this arm will receive the standard-of-care; a routine preoperative assessment and physical examination by their attending anesthesiologist.
2464537|NCT03142360|Experimental|Treatment group|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
2464541|NCT03142360|No Intervention|Non-Treatment group|On the other hand, the control group does not take anything.
2464559|NCT03141827|Experimental|Insulin|Nasal spray, insulin 40 IU, single dose
2464560|NCT03141827|Placebo Comparator|Placebo|Nasal spray, placebo, single dose
2464608|NCT03141697|Experimental|Carbon Dioxide|Colonoscopy with Insufflation of Carbon Dioxide
2464617|NCT03141697|Placebo Comparator|Room Air|Colonoscopy with Insufflatioin of Room Air
2464712|NCT03140982|Active Comparator|GR fast induction|propofol TCI effect site mode infusion using the PK Marsh model ke0 1,21 min-1 target 5.4 ug/ml (LOC EC95) util loss of consciousness (LOC) After LOC we maintain initial target during 10 min without intervention, except respiratory support if required.
2464713|NCT03140982|Active Comparator|GL slow induction|propofol infused at 10 mg/kg/h with CeCALC PK Marsh model ke0 1,21 min-1 same PK model After LOC we maintain the CeCALC observed al LOC during 10 min without intervention, except respiratory support if it was required.
2464761|NCT03140748|Other|Patients with fungal peritonitis|
2464762|NCT03140748|Other|Patients with peritonitis without yeast|
2464845|NCT03140397|Placebo Comparator|Placebo|Capsules filled with mannitol and silicon dioxide
2464847|NCT03140397|Experimental|6-prenylnaringenin|500 mg 6-PN plus mannitol and silicon dioxide
2464849|NCT03140397|Experimental|8-prenylnaringenin|500 mg 8-PN plus mannitol and silicon dioxide
2464913|NCT03139890|Experimental|High-fat milkshake|
2464914|NCT03139890|Experimental|High-carbohydrate milkshake|
2464917|NCT03139890|Experimental|High-protein milkshake|
2464943|NCT03139292|Experimental|ProSeal Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for PLMA insertion
2464947|NCT03139292|Experimental|AmbuAuraGain Laryngeal Mask Airway|Intravenous (0.02mg/kg Midazolam and 2 microgram/kg Fentanyl) and oxygen via a face mask will be administered. Two minutes later, general anesthesia will be induced using 2 mg/kg intravenous Propofol mixed with 25 mg Lidocaine Injected over 30 seconds, Mask ventilation commence and continue for at least 30 seconds until conditions are suitable for AmbuAuraGain Laryngeal Mask Airway insertion
2464998|NCT03139136|Active Comparator|MBS2320|
2465000|NCT03139136|Placebo Comparator|Placebo|
3191474|NCT00798811|Other|KSPNO-S-083|High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Recurrent Brain Tumor or Non-germinomatous Germ Cell Tumor with Inadequate Response to Conventional Treatment
3191475|NCT00798824|Active Comparator|Indwelling nasogastric tube placement|
3191476|NCT00798824|Active Comparator|Intermittent orogastric tube placement|
3191477|NCT00798837|Other|IMAX|"There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions.~A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
3191478|NCT00798850|Active Comparator|PTA|
3191479|NCT00798850|Active Comparator|SEP|
2464219|NCT03144479|Experimental|Positioning of right-sided double lumen tube with fibroscope|positioning of the right sided double lumen tube in the same patient but with a fibroscope
2464296|NCT03143972|Experimental|Dexmedetomidine only|"Dexmedetomidine will be administered by effect-site TCI according to the Hannivoort model extended with an effect-site rate constant of 0.0428min-1.~A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (40 min), 3 ng/ml (50 min), 4 ng/ml (40 min), 5 ng/ml (40 min) and 8 ng/ml (70 min)."
2464297|NCT03143972|Experimental|Remifentanil only|Remifentanil will be administered by effect-site TCI according to the Eleveld model. A stepwise increasing dosing regimen will be given, with concentrations targeting an effect site concentration of 1 ng/ml (12 min), 2 ng/ml (12 min), 3 ng/ml (12 min), 5 ng/ml (12 min) and 7 ng/ml (12 min).
2464300|NCT03143972|Experimental|Dexmedetomidine-Remifentanil interaction|"A fixed background dose of dexmedetomidine will be given, this will be calculated after the first 5 subjects completed the dexmedetomidine only session. It will be set to 50% of the observed mean EC50TOL (Tolerance of Laryngoscopy).~Remifentanil infusion will be administered by effect site TCI with stepwise increasing targets of 0.5 - 1.0 - 1.5 - 2.0 - 2.5 - 3.0 - 4.0 ng/ml, each lasting for 15 minutes."
2464396|NCT03143361||Aortic valve replacement patients|All the patients operated on aortic valve replacement in the study period at all the centers participating in the study
2464454|NCT03142763|Experimental|Egg intake|Consumption of 3 eggs per day for breakfast, 4 weeks
2464462|NCT03142763|Experimental|Choline Supplement intake|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
2464536|NCT03142464|No Intervention|IV fluids|Regular IV fluids (Glucose 5% and Sodium Chloride 10% or Ringer) at the surgeon description
2464538|NCT03142464|Experimental|No IV fluids|No IV fluids after the termination of the operation. T
2464585|NCT03141892||Diabetes Mellitus, Type 1 and Type 2|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
2464660|NCT03141489|Experimental|NICE guidelines for refeeding syndrome|High protein enteral tubefeeding solution. NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
2464662|NCT03141489|Experimental|Diakonhjemmet Hospital Protocol(DS)|High protein enteral tubefeeding solution. The intervention group, Diakonhjemmets feeding protocol, will start at 20 calories a kg a day, and increasing until estimated needs are met within 3days
2464710|NCT03141008||Ketogenic diet exposed group|"Fibroscan changes with different diets:~Patients in a weight loss program using a ketogenic diet. Will compare differences in Fibroscan and metabolic changes."
2464715|NCT03141008||NAFLD diet exposed group|"Fibroscan changes with different diets:~Patients in a NAFLD clinic using low calorie, low fat diet. Will compare differences in Fibroscan and metabolic changes."
2464831|NCT03140774||Cohort 1: Phase 1 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo.
2464833|NCT03140774||Cohort 2: Received r-VSV-ZEBOV vaccine|Previously exposed to Ebola vaccine rVSV-EBOV.
2464834|NCT03140774||Cohort 3: Phase 2 participants|Previously exposed to Ebola vaccine Ad26-ZEBOV and MVA-BN-Filo
2464858|NCT03139968|Experimental|Radiation absorbing drape|Conventional protection measurements. Additionally, a lead-free protective, disposable drape containing bismuth and antimony (RADPAD®) is placed onto the sterile drape on the patient between the operator and the image intensifier.
2464859|NCT03139968|Active Comparator|Dummy group|Conventional protection measurements. Additionally, a dummy, silicone, disposable drape (appearing identical to the experimental arm) is placed onto the sterile drape on the patient between the operator and the image intensifier.
2464860|NCT03139968|No Intervention|Control goup|Only conventional protection measurements.
2464915|NCT03139825|Other|Adolescent with suicidal behavior and personality disorder|
2464958|NCT03139357||Primary care patients|Patients ages 20-65 who score 5 or greater on the GAD-7 will be given the SF12, GAD7, medial utilization, and helpfulness questionnaires at 6 month intervals for a 2 year period.
3191480|NCT00798850|Active Comparator|PTA+SEP|
3191481|NCT00798863|Experimental|operative group|The patients of the group will have the operation of two step video assisted submandibular sialadenectomy.
3191482|NCT00798876|Placebo Comparator|Standard Western Diet|Subjects will be asked to consume a standard Western Diet for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
3191483|NCT00798876|Experimental|Low-Fat Diet|Subjects will be asked to consume a low fat diet with fish oil and vitamin E supplements for 4 weeks. For the 4-week period, subjects will be provided with all food and beverages. Subjects will also undergo a medical examination, dietary interview, blood draw, and radical prostatectomy(as part of standard of care).
3191484|NCT00798902|Active Comparator|Control|Iliac Crest Autograft
3191485|NCT00798902|Experimental|Prefix 150|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
3191486|NCT00798915|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
3191487|NCT00798915|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3191488|NCT00798915|Experimental|Type 2 diabetes mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3191489|NCT00798941|Experimental|pain intervention|music and massage for 30 minutes
2465338|NCT03136679||Group 1 Normal|Spouse or Subject's caregiver. Blood and urine samples will be collected.
2465339|NCT03136679||Mild Cognitive Impairment|Subjects with MCI: Blood and urine samples will be collected.
3191490|NCT00798941|Experimental|thirst intervention|sterile water mouth spray, lip moisturizer,mouth swab
3191491|NCT00798941|No Intervention|control|
3191492|NCT00798954|Active Comparator|TAXUS|
3191493|NCT00798954|Active Comparator|Cypher|
3191494|NCT00798980||Arm 1|
2464247|NCT03144245|Experimental|Combination AMV564|Continuous infusion or subcutaneous dosing of AMV564 at increasing dose levels in combination with pembrolizumab
2464309|NCT03143725|Experimental|Treatment A|GLPG1972 oral solution after overnight fast
2464311|NCT03143725|Experimental|Treatment B|GLPG1972 oral DC tablet after breakfast
2464313|NCT03143725|Experimental|Treatment C|GLPG1972 oral WG tablet after overnight fast
2464314|NCT03143725|Experimental|Treatment D|GLPG1972 oral WG tablet after breakfast
2464390|NCT03143309|Experimental|Walking + WhatsApp|The participants assigned to the intervention group will be given a brief (15-minute) orientation where they learn about the importance of exercise, diet, and the benefits of weight reduction. They will be given further instruction on the regular use of the pedometer. They will be enrolled into a WhatsApp group. They will receive 2-3 health-promotional (walking and diet) messages per week via WhatsApp.
2464391|NCT03143309|Active Comparator|WhatsApp Only|The control participants will be enrolled into a WhatsApp group. They will receive 2-3 non-health related messages per week via WhatsApp.
2464455|NCT03142854|Active Comparator|Group A: standard group|Participants are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
2464460|NCT03142854|Experimental|Group B: tailored group|"Participants are given personalized regimens for bowel preparation according to the the predictive model( a model which grades patients as low or high risk according to risk factors such as age, body mass index≧ 30 kg/m2, diabetes, constipation, pelvic surgery and tricyclic antidepressants usage).~Low risk patients are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen; High risk patients are given standard regimen: 4 L Polyethylene Glycol (PEG) regimen."
3191495|NCT00798993|Active Comparator|Structured exercise program|Participants will be randomised at 3 months into either this group or the comparator of usual exercise.
3191496|NCT00798993|Experimental|Vitamin D|Cholecalciferol 2000U per day will be given to all participants for the duration of the study
3191497|NCT00798993|Placebo Comparator|Usual exercise|Participants randomised to this arm, at 3 months, will continue on their usual exercise routine
2464672|NCT03141190|Experimental|Mental Training for Surgeons|Mindfulness-Based Stress Reduction (MBSR, as published elsewhere extensively) slightly modified by shortening the eight weekly classes to 2 hours each and the home practice requirement to 20 minutes. Taught by a veteran MBSR teacher with greater than 10,000 hours of personal practice and nearly 10 years of formal MBSR teaching experience.
2464674|NCT03141190|Active Comparator|The Mind of a Surgeon|8 weekly classes of 2 hours each with group reading and discussion of selected articles and stories about the ethos and experience of becoming a surgeon. Designed and administered by a surgical faculty member with extensive experience in surgical education and scholarly work in the area of the 'surgical personality'.
2464737|NCT03140943|Experimental|Carfilzomib, Thalidomide and Dexamethasone|
2464812|NCT03140540|Active Comparator|Group A (stroke volume variation) guided fluid|Stroke volume variation guided intraoperative intravenous fluid will be administered.
2464815|NCT03140540|Active Comparator|Group B(Study group) TEE guided fluid|Transesophageal echocardiography will be used to guide the fluid therapy.
3191498|NCT00799006|Placebo Comparator|Placebo|
3191499|NCT00799006|Experimental|PF-04620110|
3191500|NCT00799032|Other|Stent|Catania Stent
3191501|NCT00799045|Experimental|Aspirin + clopidogrel|Aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
2465069|NCT03138642|Experimental|RT|The patients are prescribed a EQD2of 65-70Gy to CTV1(high-risk regions including tumor bed), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT). The Prophylactic irradiation to upper neck is is decided by radiation physicians and given a EQD2 of 70-77Gy to CTVnd (clinically negative lymph nodes), 50-55Gy to CTVn2（neck nodal regions). If there is residual tumor, a EQD2 of 70-77Gy is prescribed to GTV.
2465227|NCT03137485|Active Comparator|Conventional|Patients in this arm will have conventional open lumbar discectomy operation.
2465228|NCT03137485|Active Comparator|Endoscopic|Patients in this arm will have Percutaneous Endoscopic Translaminar lumbar discectomy operation using Easy Go system Endoscopy
2465248|NCT03137212|Experimental|A group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 3-6 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
2465252|NCT03137212|Experimental|B group|STEMI patients first are given thrombolysis and then transfer to PCI center to be treated by PCI 6-24 hours after thrombolysis if the thrombolysis is successful. if the thrombolysis is not successful, patients will be treated by PCI immediately.
2465314|NCT03137056|Active Comparator|Hemodialysis with Theranova|This arm is represented by the period during which the patients will undergo dialysis with the Theranova membrane.
2465315|NCT03137056|Active Comparator|Hemodialysis with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
2465316|NCT03137056|Active Comparator|Hemodiafiltration with FX1000|This arm is represented by the period during which the patients will undergo dialysis with the FX1000 membrane.
3156412|NCT00342771||NCI Maryland pop-based controls|population-based controls
3156413|NCT00342771||NCI-Maryland Prostate Cancer Cases|prostate cancer cases
3191502|NCT00799045|Active Comparator|Aspirin|Aspirin (80 mg/day) for 3 months following ASD closure.
2465562|NCT03135314|Placebo Comparator|Hypoxia Placebo|Exercise or cognitive test in (acute) hypoxic condition after 7 days of placebo intake
3156415|NCT00342849|Experimental|1|Scuccimer Treatment Group
3191503|NCT00799058|Active Comparator|dapivirine gel 4789|will be applied by participants once daily for 12-weeks treatment period
3191504|NCT00799058|Active Comparator|dapivirine gel 4759|Will be applied by participants once daily for12-weeks treatment period
3191505|NCT00799058|Placebo Comparator|HEC-based placebo gel, 2.5g containing no Dapivirine|Will be applied once daily for 12-weeks treatment period
3191506|NCT00799071|Experimental|posaconazole|posaconazole as antifungal prophylaxis
3191507|NCT00799084|Experimental|Nurse|Receives symptom management assistance from an oncology nurse via the telephone
2464268|NCT03144063||BLISS-52 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-52 trial data. The extracted trial data consists of data on all patients that participated in the trial."
2464269|NCT03144063||BLISS-76 Cohort|"Objective 2 Cohort:~Validation of the SLEDAI-2KG will be completed on BLISS-76 trial data. The extracted trial data consists of data on all patients that participated in the trial."
3156416|NCT00342849|Placebo Comparator|2|In order to provide placebo with an odor comparable to that of succimer, the Drug Distribution Center will place a small canister containing 200 mg of active drug into each bottle of placebo drug. A canister containing 200 mg of placebo will be placed inside each bottle of succimer so that all bottles will appear the same.
3156417|NCT00342862||1. Amevive Exposure|Pregnant women with psoriasis exposed to AMEVIVE® at any point within 8 weeks prior to conception, or at any time during pregnancy, where the outcome of the pregnancy is unknown prospectively
2464400|NCT03143140|Experimental|PAFA and tumor ablation|first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor
2464404|NCT03143140|Other|tumor ablation|ablation of tumor directly
2464439|NCT03142724|Experimental|[18F]MNI-968|To assess the safety and tolerability and to determine the radiation dosimetry of [18F]MNI-968.
2464489|NCT03142516|Experimental|FOLFIRI + panitumumab|"All patients will receive panitumumab plus FOLFIRI for disease control in 14-day cycles until disease progression, unacceptable toxicity, investigator's decision or patient withdrawal of consent, at the following doses:~Panitumumab: 6 mg/kg administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy~FOLFIRI~Irinotecan: 150 mg/m2 as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle.~Folinic acid: (leucovorin) 200-400 mg/m2 IV over 2 hours on day 1~5-FU: 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2"
2464501|NCT03142126|Experimental|Early Ambulation|To affirm the safety and efficacy of ambulation of 20 minutes after diagnostic left heart catheterization.
2464613|NCT03142048|Experimental|Schools of Health for the Elderly|"Participants receiving the community intervention (explained in the section Intervention)"
2464618|NCT03142048|No Intervention|Comparison Group|Participants in the study that do not receive the intervention
2464720|NCT03141047|Experimental|Lifespan Integration|This arm is given one session of Lifespan Integration. Differences on Impact of Event Scale from the first measurement at inclusion and the second measurement 20 +/- 3 days after the first measurement, and after treatment, is analyzed and compared with the results from the Group on waiting list. A third measurement and comparison is being made 6 months +/- 6 weeks after the first measurement at inclusion.
2464724|NCT03141047|No Intervention|Waiting list|This arm gets no treatment, and differences on Impact of Event Scale from the first measurement at inclusion at the second measurement 20 +/- 3 days after, without treatment, is analyzed and compared with the results from the treatment Group. A third measurement and comparison is being made 6 months +/- 6 week after the first measurement at inclusion.
3156418|NCT00342875||Population Controls|Control subjects were selected randomly from state Department of Motor Vehicle and Centers for Medicare and Medicaid Services (CMS) beneficiary records.
2464996|NCT03139617|Active Comparator|Fascia Iliaca Compartment Block (FICB)|fascia iliaca compartment block is done using a blind technique with a blunt size 24 Gauge (G) needle. The technique is based upon the anatomical landmark and once located the space local anaesthetic ropivacaine 0.375% will be given based on the body weight.
2464997|NCT03139617|Experimental|3 in 1 femoral block (FNB)|Ultrasound guided femoral 3 in 1 block using insulated stimulating needle 22 Gauge (G). Ropivacaine 0.375% as per ideal body weight.
2465048|NCT03138824|Experimental|SPIES assisted TURBT|Storz Professional Image Enhancement System (SPIES) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
2465049|NCT03138824|Experimental|WLI assisted TURBT|White Light Imaging (WLI) assisted transurethral resection of bladder tumour for Non-muscle invasive bladder cancer
2465120|NCT03138317|Experimental|PRP|Goup 1: knee injection of Platelet Rich Plasma (PRP)
2465123|NCT03138317|Experimental|Plasma|Group 2: knee injection of Plasma
2465126|NCT03138317|Placebo Comparator|Placebo|Group 3: knee injection of placebo (saline solution)
2465163|NCT03137823|Other|patients|each patient will be reviewed twice - first time culture from the tonsills and the second culture from the bucal surface.
2465229|NCT03137524|Experimental|Hand Held Fan Therapy|
2465230|NCT03137524|No Intervention|No Intervention|
3191508|NCT00799084|Experimental|AVR|Receives symptom management assistance from an Automated telephone system
2465431|NCT03136406|Experimental|NANT Pancreatic Cancer Vaccine|"A combination of agents will be administered to subjects in this study:~cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011."
2465504|NCT03135821|Placebo Comparator|10% active Placebo|"Placebo will constitute granules with 10% active core ingredients as below:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g~- 2 packets of sachets once before breakfast and once before dinner."
3156419|NCT00342875||Urinary Bladder Cases|patients with histologically confirmed carcinoma of the urinary bladder
3156422|NCT00342927||Volunteers|Volunteers for a genetic study of diabetes and nephropathy
3156423|NCT00342953||Cohort|Women receiving implants and other plastic surgery.
3156424|NCT00342992||Healthy Volunteers|Male smokers in Southwestern Finland
3156425|NCT00343031||Pregnant women delivering male infants|Male newborns and their mothers living in Tapachula (Chiapas, Mexico) and surrounding areas exposed to DDT through house spraying programs to control malaria, grouped by level of DDT exposure.
3156426|NCT00343109|Experimental|Arm I|Patients receive HER-2/neu intracellular domain peptide-based vaccine mixed with GM-CSF intradermally once monthly for 6 months in the absence of disease progression or unacceptable toxicity.
3156427|NCT00343135|Experimental|ARM 1|
3156428|NCT00343200|Placebo Comparator|Placebo|
3156429|NCT00343200|Experimental|Sildenafil|
2464383|NCT03143244|Active Comparator|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
2464386|NCT03143244|Active Comparator|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
2464388|NCT03143244|Placebo Comparator|Control group (Normal Saline) (C)|Patients received same volume of normal slaine in two sets.
2464453|NCT03142841|No Intervention|Standard Care|Study participants will receive the usual standard care they would receive had they not been enrolled in this study
2464461|NCT03142841|Experimental|Problem Solving Intervention|The intervention consists of a problem-solving intervention and information/tools on the previously developed, evidenced-based Spanish-version of the RESCUE stroke caregiver website to improve stroke caregiver outcomes. The intervention will be conducted via telephone by a trained rehabilitation counselor. The intervention consists of four components: 1. Introduction to the RESCUE website and the problem-solving method; 2. Illustrative example on how to use the problem-solving approach and the RESCUE website to address caregiving problems; 3. Individualized practice exercise to develop a personalized problem-solving plan; and 4. Summary of the problem-solving method.
2464505|NCT03142321|Experimental|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab will be initiated at 300 mg intravenous (IV) dosing at 0, 2 and 6 weeks followed by the 1st maintenance with 300 mg IV at week 14. Patients who have not achieved clinical response at week 14 will be eligible to undergo dose escalation to 4 weekly dosing of vedolizumab depending on the judgement of the treating gastroenterologist.
2464564|NCT03141996|Experimental|Vibration to upper posterior neck muscles|Treatment will be performed by occupational therapist practitioners prior to regular occupational therapy session using a vibration tool.
2464566|NCT03141996|Active Comparator|Standard of care|Regular occupational therapy session
2464595|NCT03141658|Experimental|TS-134 20 mg|
2464598|NCT03141658|Experimental|TS-134 60 mg|
2464600|NCT03141658|Experimental|Placebo|
2464668|NCT03141333|Experimental|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
2464673|NCT03141333|No Intervention|No intervention|Participants of this group will have access to the following section of the web plate-form: information, which is consistent with the standard of care for many families of children with DCD, who only have access to online information but do not have access to any type of intervention.
2464739|NCT03140969|Experimental|QR-110|Administered every 3 months
2464757|NCT03140566|Experimental|Clinical assessment plus IVC diameter|Decongesting treatment guided by clinical assessment and ultrasound evaluation of the inferior vena cava diameter
2464758|NCT03140566|Sham Comparator|Clinical assessment only|Decongesting treatment guided by clinical assessment alone
2464811|NCT03140423|Active Comparator|Arm 1: Routine Care (Mupirocin/CHG)|ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing
2464814|NCT03140423|Active Comparator|Arm 2: Iodophor/CHG Decolonization|ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing
2464945|NCT03139591|Active Comparator|lidocaine inhalation|Lidocaine inhalation group: 1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection
2464948|NCT03139591|Active Comparator|intravenous dexamethasone|Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone
2465006|NCT03139110||Control|Patients treated in emergency departments without the presence of a mediator.
2465008|NCT03139110||Mediation|Patients treated in emergency departments with the presence of a mediator.
2465102|NCT03138200|Other|Blood transfusion based on central venous oxygen saturation|
2465176|NCT03138005|Active Comparator|target SpO2 98-100%|Post ROSC oxygen titrated to maintain SpO2 between 98-100%
2465182|NCT03138005|Experimental|target SpO2 90-94%|Post ROSC oxygen titrated to maintain SpO2 between 90-94%
2465276|NCT03137238||Early_PD|People with Parkinson's disease in the early stages with low doses of antiparkinsonian medication and no motor fluctuations.
2465282|NCT03137238||Advanced_PD|People with advanced Parkinson's disease with motor fluctuations.
2465286|NCT03137238||Early_controls|Healthy participants matched for age and gender to the 'Early_PD' group.
2465292|NCT03137238||Advanced_controls|Healthy participants matched for age and gender to the 'Advanced_PD' group.
2465421|NCT03136419|Placebo Comparator|Control|Placebo capsules bis in die for 8 weeks
2465428|NCT03136419|Experimental|Experimental|Lactobacillus casei DG capsules bis in die for 8 weeks
2465482|NCT03135886|Experimental|HIV Testing Practice Coaching Intervention Group|The HIV Testing Practice Coaching (PC) Intervention is designed to improve the provision and sustained implementation of on-site HIV testing and linkage to care among OTP patients.
2465483|NCT03135886|Experimental|HIV and HCV Testing Practice Coaching Intervention Group|The HIV and HCV Testing Practice Coaching (PC) Intervention will leverage the HIV PC intervention and follow the same interventional steps described above, and, in addition, provide information and training to support joint HIV/HCV testing and linkage to care among OTP patients.
2465484|NCT03135886|Other|Information Control Group|The administrators of OTPs assigned to the control condition will receive a website link to and hard copy of the NIDA/SAMHSA Blending Initiative product for HIV rapid testing.
2465535|NCT03135561|Experimental|pedometer-plus-email|
2465538|NCT03135561|Active Comparator|pedometer-only|
3191509|NCT00799097||Endoscopic Sinus Surgery|Subjects who have failed maximum medical management and have elected for endoscopic sinus surgery
3191510|NCT00799110|Experimental|Group 2|Vaccine, GM-CSF and imiquimod,
2465617|NCT03134807||Admission of elderly ICU patients (≥80)|All consecutibve admission in 3 month period or 20 pateints
3191511|NCT00799110|Experimental|Group 1|Vaccination plus GM-CSF
2464435|NCT03142646|Experimental|IM19 CART|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of IM19CART cells administered intravenously.
2464487|NCT03142477|Other|Control|Control group patients will not receive any interventions with therapeutic touch. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
2464490|NCT03142477|Placebo Comparator|Placebo|Placebo patients group patients will receive the therapeutic touch intervention by a graduate student without any therapeutic touch training. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
2464492|NCT03142477|Experimental|Treatment|Treatment patients group patients will receive the therapeutic touch interventions with a trained therapeutic touch professional. Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. Levels of cortisol, salivary IgA, hematological index results and telomerase activity before and after the use of therapeutic touch will be measured.
3156430|NCT00343239|Experimental|Docetaxel/Cisplatin/Fluorouracil (DCF)|DCF combination for three 21-day cycles unless a disease progression is observed at the tumor assessment scheduled after the second cycle or due to patient intolerability
2464623|NCT03141710|Experimental|12 type 2 diabetes patients|Long-term dietary (12 weeks) intervention of 20ml of prebiotic per day
2464676|NCT03141216|Experimental|VCV+PSV|volume controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
2464682|NCT03141216|Experimental|PCV+PSV|pressure controlled cycled, assisted-controlled cycled ventilation mode + pressure support ventilation mode. Progression of invasive ventilatory assistance as the patient recovers during post-surgery.
2464738|NCT03140878|Experimental|LGG|Lactobacillus rhamnosous (LGG) 450 billion CFU dissolved in water
2464740|NCT03140878|Placebo Comparator|Placebo|The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics
2464918|NCT03139760|Experimental|POWERSforID|POWERSforID intervention group
2464921|NCT03139760|No Intervention|Control|Usual clinical care
2464982|NCT03139331|Experimental|Pazopanib, irinotecan, temozolomide (PAZIT)|Patients will receive daily oral pazopanib on days 1-21 in a 21-day cycle. This will be combined with intravenous or oral irinotecan and oral temozolomide on days 1-5. Dosing of irinotecan will be from 25 to 37.5 mg/m2/day for IV dosing or from 45 to 67.5 mg/m2/dose for oral dosing and oral temozolomide will be 100 mg/m2/day for dose levels at each assigned dose level. In the absence of disease progression or unacceptable toxicity, patients will receive cycles of therapy repeating every 21 days for a maximum of 12 months on study.
2465024|NCT03138863|Experimental|Fetuses with Left CDH|Performance of fetal endoscopic tracheal occlusion (FETO) surgery by insertion of the BALT GoldbBAL2 Detachable Balloon with the BALT catheter system.
2465065|NCT03138564|Experimental|SPIRIT Clinic|Patients at clinics that have been randomized to the SPIRIT arm will be given the option to participate in the intervention. SPIRIT is a two-session, 60-minute, structured psychoeducational intervention, targeting both patient and surrogate. Using a provider manual, the care provider follows six steps: 1) assessing illness presentation, 2) identifying gaps and concerns, 3) creating conditions for conceptual change, 4) introducing replacement information, 5) summarizing, and 6) setting goals and planning.
2465066|NCT03138564|Active Comparator|Comparison Condition Clinic|Patients at clinics that have been randomized to the control arm will be given the option to participate as a study control. The control clinics will have delayed implementation of the SPIRIT intervention.
2465108|NCT03138109||grade1&2 diastolic dysfunction|lower diastolic dysfunction exposure
2465112|NCT03138109||grade 3 diastolic dysfunction|higher diastolic dysfunction exposure
2465174|NCT03137966|Active Comparator|Deferoxamine|Patients will be randomised to treatment with Deferoxamine (n=87). Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
2465179|NCT03137966|Placebo Comparator|Placebo|Patients will be randomised to treatment with placebo (n=87). Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
2465231|NCT03137498|Experimental|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes (active experimental) and normal saline 1ml intravenous push injection (placebo)
2465232|NCT03137498|Active Comparator|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection (active intervention) and Normal saline 50ml IVPB over 10 minutes (placebo)
2465278|NCT03137199|Experimental|Group receiving 20 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
2465283|NCT03137199|Experimental|Group receiving 100 million hMSCs|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
2465346|NCT03136848|Experimental|Normothermic perfusion|Kidneys retrieved from deceased donors will undergo the study intervention consisting of 4-10 hours of Normothermic ex-vivo perfusion using a blood-based solution, prior to implantation in the transplant recipient
2465378|NCT03136510|Other|Newly diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients new diagnosis of NVAF (VKA treatment ≤1 week) initiated with apixaban 5 mg
2465380|NCT03136510|Other|Previously diagnosed NVAF: apixaban 5 mg|blood collection for biological analyses of 30 patients previously treated by VKA for more than 3 months switched to apixaban 5 mg
2465414|NCT03136471||EMR data extraction|"EMR Data extraction from the Louisiana Clinical Data Research Network (LaCDRN). The Louisiana Clinical Data Research Network (LaCDRN) data will be requested, including patients' records of pharmacy, inpatient, outpatient and lab results from January 01, 2016 to December 31, 2021. It is a retrospective data analysis without interaction with any participants. All data is de-identified and the study participants will not be contacted in any way.~Inclusion criteria: Patients with type 2 diabetes, whose age>=18 years old will be extracted from database of LaCDRN.~Exclusion criteria: Patients without type 2 diabetes or age<18 years old."
2464450|NCT03142685|No Intervention|Arm A: KUB Only|Subjects clinical suspected of NEC whom are randomized into Arm A at time of consent will receive a KUB q12 for 48 hours. This is the current standard-of-care procedures.
2464517|NCT03142490|Experimental|Treatment|In vitro fertilization patients submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
2464521|NCT03142490|Active Comparator|Control|In vitro fertilization patients not submitted to acupuncture as a complementary therapy. Patients in both groups will be evaluated by 4 different questionnaires.
2464586|NCT03141879|Experimental|Physical Activity Intervention|HUR resistance training intervention
2464591|NCT03141879|No Intervention|Regular care|(Wait-list control)
2464656|NCT03141476|Other|Cefuroxime 1,5g|BMI <30kg/m*m
2464657|NCT03141476|Other|Cefuroxime 3g|BMI 30-50kg/m*m
2464661|NCT03141476|Other|Cefuroxime 4,5g|BMI >50kg/m*m
2464731|NCT03140995|Active Comparator|Exercise Intervention|The walking programme will consist of a total of 21 aerobic walking sessions, with 1 per week being supervised by a trained physiotherapist, spread over a maximum of eight weeks (2-3 times/week). During the first 4 weeks the intention is to increase frequency and the final 4 weeks the intensity, using the Borg Rate of Perceived exertion 6-20 or distance from 2km to 6km. The participants will attend the University of Limerick for a final assessment at week 9.
2464732|NCT03140995|No Intervention|Control Group|The control group will be given verbal and written instructions regarding the benefits of exercise in RA.
3156431|NCT00343265|Active Comparator|1|Progesterone gel
3156432|NCT00343265|Placebo Comparator|2|Vaginal gel with no medication
3156433|NCT00343395|Active Comparator|Avandamet|AVANDAMET 2/500 mg
2464806|NCT03140475||Individuals with schizophrenia|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates)~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response)~Clinical variables:~Positive and Negative Syndrome Scale / Birchwood Insight Scale / Beck Cognitive Insight Scale / Personal and Social Performance Scale / Calgary Depression Scale / Chlorpromazine equivalents~Neuropsychological variables:~National Adult Reading Test (French) / Wechsler Adult Intelligence Scale version IV (WAIS-IV) subtests (matrix reasoning, vocabulary, letter-number sequencing)"
2464810|NCT03140475||Controls|"Behavioral variables:~Type 1 task (motion discrimination) accuracy (binary: correct/incorrect) / Type 1 reaction time (continuous: time to respond to the type 1 task in ms) / Confidence (continuous: visual analog scale) / Type 2 reaction time (continuous: time to report confidence in ms) / Mouse trajectory (pixel coordinates) /~Physiological variables:~Electroencephalogram (continuous: 64ch. time-locked to type 1 response) / Heart rate (continuous: time-locked to type 1 response) / Galvanic skin response (continuous: time-locked to type 1 response) /~Clinical variables:~Calgary Depression Scale~Neuropsychological variables:~National Adult Reading Test (French) / WAIS-IV subtests (matrix reasoning, vocabulary, letter-number sequencing)"
2464902|NCT03140150|Experimental|Active Group|A single visit 1 to 3 months after implantation then followed by the attending cardiologist.
2464904|NCT03140150|Other|Control Group|A first visit 1 to 3 months after implantation and then every 6 months or every year according to the recommendations of pacemaker follow-up (ie 2 or 4 systematic visits during the follow-up of 2 years).
2464955|NCT03139409|Active Comparator|conventonal adhesive|peak lc bond
2464960|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate ,6 months later and 1 year
2465003|NCT03139058|Other|prevalence of cirrhosis|Study the prevalence of cirrhosis in patients with VADS cancer
2465017|NCT03138759|Experimental|Pexidartinib then Probenecid|Participants receive Sequence AB: Treatment A (pexidartinib) first, then Treatment B (probenecid), with a washout period between them
2465018|NCT03138759|Experimental|Probenecid then Pexidartinib|Participants receive Sequence BA: Treatment B (probenecid) first, then Treatment A (pexidartinib), with a washout period between them
2465209|NCT03137667|No Intervention|Control|No school-located influenza vaccination clinic
2465214|NCT03137667|Experimental|School-located Influenza Vaccination|Children in intervention schools were offered a chance to receive influenza vaccination at a school-located influenza vaccination clinic, if their parent or legal guardian provided permission
2465267|NCT03137342|Experimental|Pepped on PrEP|"Using an efficient stepped care (adaptive) model, all participants will receive three sessions of PrEP-STEPS counseling for PrEP adherence delivered by a Masters-level or above therapist. Some individuals may require a more intensive approach. These participants will receive an additional seven counseling sessions of behavioral activation with integrated cognitive behavioral therapy (CBT) designed to reduce stimulant use and promote positive behaviors."
2465271|NCT03137342|No Intervention|Standard of Care|PrEP adherence counseling from the Miriam Hospital PrEP Clinic.
2465319|NCT03136965|Experimental|Platelet-Rich Plasma (PRP)|Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous PRP.
2465320|NCT03136965|Placebo Comparator|Dry Needling Procedure|Group 2 (dry needling) will undergo US-guided dry needling procedure similar to PRP injection.
2465321|NCT03136965|Sham Comparator|Sham Procedure|Group 3 (sham) will undergo US-guided sham dry needling procedure.
2465422|NCT03136471||Healthcare Professionals|"Healthcare professionals (physician, nurse) will be randomly selected from LaCDRN partner health system. An email will be distributed to the registered clinicians at partner health systems.~Inclusion criteria: physicians and nurses who treat diabetes patients and work at clinic settings within LaCDRN network and consent to participate the study.~Exclusion criteria: physicians and nurses who do not treat diabetes patients or not work at clinic settings within LaCDRN network; refuse to participate the study."
3156434|NCT00343395|Placebo Comparator|Placebo|
3156435|NCT00343421|Experimental|Group 1|PEDIACEL co-administered with Prevenar
3156436|NCT00343421|Active Comparator|Group 2|Infanrix-IPV+Hib co-administered with Prevenar
3156437|NCT00343616|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomization.
3156438|NCT00343616|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomization.
3156439|NCT00343616|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
2464557|NCT03142009|Experimental|Program group|Tribal Research Team members recruit participants by sending letters home with the fourth and fifth grade children. This letter provides an overview of the FL/CP and invite interested parents and children to learn more. TRT and UNM team members follow-up with interested parents individually. If families are committed to being a part of FL/CP, a meeting is set to conduct the informed consent process and complete pretest. Families in the program group then attend FL/CP sessions which covers the intergenerational culturally adapted curriculum. Program families also participate in various aspects of the program including completing a Community Action Project.
2464558|NCT03142009|No Intervention|Comparison group|Upon receiving the letter families that selected not to participate or who decline to participate will be invited to take part in the research study as comparison participants. Comparison participants do not attend the FL/CP sessions and only complete the pre, post and 1 year post tests.
2464581|NCT03141723|Active Comparator|KMC & WHO protocol (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2464587|NCT03141723|Active Comparator|KMC & WHO protocol (1-24 hours)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2464593|NCT03141723|Experimental|KMC, WHO protocol & bag (0-1 hour)|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2464594|NCT03141723|Experimental|KMC, WHO protocol & bag (1-24 hours|The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
2464743|NCT03140839|Experimental|Imaginal Rescripting|"Imaginal Rescripting (IR) targets imagery-based mental representations embedded within patients negative autobiographical memories related to social anxiety. In IR, patients progress through 3 distinct phases: (1) They relive a past negative event in their imagination, (2) are guided to actively change the original memory in their imagination to create more satisfying outcomes, and (3) relive the memory again while incorporating the new information. The IR intervention will be administered in one 90 minute session."
2464744|NCT03140839|Active Comparator|Imaginal Exposure|"Imaginal Exposure (IE) involves repeatedly reliving a negative autobiographical memory related to social anxiety from a first-person perspective and actively considering alternative meanings of the memory, but differs from IR in that the original memory itself is never explicitly modified in any way. The IE intervention will be administered in one 90 minute session."
2464747|NCT03140839|Placebo Comparator|Supportive Counselling|Supportive counselling (SC) provides patients with empathic support regarding a negative autobiographical memory related to social anxiety. The SC condition controls for non-specific clinical factors such as therapeutic attention and alliance. SC will be administered in one 60-90 minute session.
2464819|NCT03140514|Experimental|Intervention|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care
2464820|NCT03140514|No Intervention|Control|Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.
2464870|NCT03140072|Experimental|AZD9898|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where AZD9898 will be administered. Eight subjects will participate in each cohort. Within each cohort, 6 (alternatively 8 or 10) subjects will be randomized to receive a single dose of AZD9898. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, 4 (alternatively 6 or 8) patients will be randomized to receive a single dose of AZD9898. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 6 (alternatively 8, 10 or 12) subjects will be randomized to receive AZD9898. The subjects taking part in one of the MAD cohorts under fasted conditions will also take part in Part 3B in order to explore the influence of food on the PK of AZD9898.
2464872|NCT03140072|Placebo Comparator|Placebo|In Part 1 of the study, 5 single dose cohorts are planned to be evaluated, where matching placebo will be administered. Eight subjects will participate in each cohort. Within each cohort, 2 (alternatively 3) subjects will be randomized to receive a single dose of matching placebo. Fifteen asthma patients are planned to participate in 3 cohorts in Part 2. Five patients will participate in each cohort. Within each cohort, one patient (alternatively 2 or 3 patients) will be randomized to receive a single dose of matching placebo. In Part 3, 3 dose cohorts are planned. Nine healthy subjects will participate in each cohort. Within each cohort, 3 (alternatively 4) subjects will be randomized to receive matching placebo.
2464900|NCT03139695||Critically ill patients|High resolution ultrasound of the diaphragm and intercostal muscle
2464978|NCT03139305|Placebo Comparator|Placebo|
3156440|NCT00343616|Experimental|Letrozole for 2 years plus tamoxifen for 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
3156441|NCT00343681|Experimental|1|
3156442|NCT00343798|Experimental|Treatment (umbilical cord blood transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI BID on days -4 to -1.~TRANSPLANTATION : Patients undergo double-unit umbilical cord blood transplantation comprising unmanipulated umbilical cord blood unit IV over 20-30 minutes, and 4-6 hours later patients receive ex vivo-expanded umbilical cord blood cells IV over 30 minutes on day 0.~GRAFT-VERSUS-HOST-DISEASE PROPHYLAXIS: Patients receive cyclosporine IV every 8 or 12 hours on days -3 to 100, followed by a taper to at least day 180. Patients also receive MMF IV every 8 hours on days -3 to 5 and then PO, if tolerated, on days 6-30."
3156443|NCT00343824|Experimental|aquacel AG hydrofiber|
3191512|NCT00799136|Other|One|Rituxan with EPOCH and Antiretrovirals
2464497|NCT03142165|Experimental|BMS-986263|
2464498|NCT03142165|Placebo Comparator|Placebo|
2464562|NCT03142022||SDB and lung transplantation|Polysomnography at 1 year after lung transplantation.
3156444|NCT00343824|Experimental|Acticoat burn dressing|
3156445|NCT00343928|Experimental|1|
2464876|NCT03139851|Other|Cyclophosphamide and Pembrolizumab|"The treatments received are:~cyclophosphamide (50 mg/day, daily, per os)~pembrolizumab (200 mg every 3 weeks, intravenously [IV]). On days 1, cyclophosphamide should be taken first and pembrolizumab infusion initiated within 1 hour after cyclophosphamide intake."
2464928|NCT03139656|Experimental|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
2464929|NCT03139656|Experimental|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
2464930|NCT03139656|Experimental|Combined (Values Clarification & Planning)|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
2464983|NCT03139214|Experimental|Intervention|Parenting intervention, 7 weekly sessions, each session 2 hours in length.
2464988|NCT03139214|No Intervention|Control|3 mailings about child development and stress management.
2465098|NCT03138187|No Intervention|control|without physical exercise sessions
2465100|NCT03138187|Experimental|Moderate exercise group|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
2465101|NCT03138187|Experimental|Vigorous exercise group|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
2465155|NCT03138018|Active Comparator|Standard instruction|
2465156|NCT03138018|Experimental|Reduced threat instruction|
2465210|NCT03137680|No Intervention|Control Arm|No specific exercise regime for the control group. Usual hospital SOP will be adhered to
2465219|NCT03137680|Experimental|Exercise Arm|The exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of 6 weeks. This will be performed at least 6 weeks prior to the creation of the AV fistula
2465260|NCT03137355||Leigh syndrome|All people diagnosed with Leigh syndrome.
2465322|NCT03137004|Experimental|biweekly DS|The biweekly DS regimen consisted of Docetaxel (50mg/m2) and S-1 (40mg/m2)
3156446|NCT00343980|Experimental|A|
3156447|NCT00343980|Active Comparator|B|
3156448|NCT00344006|Experimental|Arm 1|
3156449|NCT00344045|Active Comparator|A|
3156450|NCT00344045|Placebo Comparator|B|
3156451|NCT00344123|Other|Tipranavir/ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin.~Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
3156452|NCT00344149|Experimental|Rituximab|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
3156453|NCT00344149|Placebo Comparator|Placebo|I.V infusion of NaCl 0.9%
3156455|NCT00344214|Experimental|1|Participants will receive the tri-focal cognitive behavioral therapy - social skills training counseling program
3156456|NCT00344214|Active Comparator|2|Participants will receive the standard care comparison condition
3156457|NCT00344253|Experimental|1|Interferon beta 3x weekly
3156458|NCT00344253|Active Comparator|2|Methotrexate sc 20 mg weekly
3156460|NCT00344474|Experimental|learning to cope with your impulsivity|cognitive behavioural intervention teaching high impulsive youth how to manage their impulsive thinking and behaviours
3156461|NCT00344474|Experimental|learning to cope with your sensation seeking|cognitive-behavioural intervention teaching high sensation seeking youth how to manage their need for stimulation and excitement
2464524|NCT03142399|Experimental|whey protein|The whey protein group will receive whey protein supplementation 30g/day of whey protein during three months (12 weeks)
2464528|NCT03142399|Placebo Comparator|placebo group|The placebo group (maltodextrin) will receive 30g/day of maltodextrin during three months (12 weeks)
2464603|NCT03141944||Apathetic patients|"De novo Parkinson's Disease patients with Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
2464609|NCT03141944||Non-apathetic patients|"De novo Parkinson's Disease patients without Apathy which participated in a former study and are under dopaminergic treatment at inclusion.~All patients will be evaluated with regard to apathy, depression, pain, behavior and personality. Primary outcome measure is the degree of Apathy by the Starkstein scale of apathy"
3191513|NCT00799149|Active Comparator|Gabapentin|Gabapentin (1200 mg) administered 30-90 min before the patient entered the operating room; Subsequent doses of Gabapentin (1200 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
3191514|NCT00799149|Active Comparator|Etoricoxib|Etoricoxib (120 mg)administered 30-90 min before the patient entered the operating room; Subsequent doses of etoricoxib (120 mg)were administered on the mornings (08H00) of the first, second, and third postoperative days.
2464759|NCT03140826||Meropenem arm|Patients receiving meropenem to treat an infection.
2464760|NCT03140826||Pip-Tazo arm|Patients receiving piperacillin-meropenem to treat an infection.
2464822|NCT03140410||Linezolid-resistant S. epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidermidis strains, tested resistant to linezolid
2464829|NCT03140410||Linezolid-susceptible S.epidermidis|Patients affected by blood stream infections caused by meticillin-resistant S.epidemridis strains, tested susceptible to linezolid
2464908|NCT03140033|Active Comparator|Misoprostol oral tablets|79 women will recieve 400 micrograms of misoprostol ( misotac) sublingually and 20 IU of oxytocin at cord clamping
2464911|NCT03140033|Placebo Comparator|Ranitidine oral tablets|79 women will recieve ranitidine oral tablets sublingually and 20 IU of oxytocin at cord clamping
2464957|NCT03139344|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session low-frequency exercise or high-frequency exercise.
2464962|NCT03139344|Experimental|Training study|Adaptations in gene regulation, systemic metabolic markers, and patient-report metrics in response to training with high-frequency exercise.
2465058|NCT03138616|Experimental|vitamin D intervention group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
2465060|NCT03138616|No Intervention|control group(NGR)|"normal glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
2465062|NCT03138616|Experimental|vitamin D intervention group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~took 1600 units of vitamin D daily for nine months and meanwhile receive lifestyle intervention."
2465064|NCT03138616|No Intervention|control group(IGR)|"impaired glucose regulation group according to the oral glucose tolerance test (OGTT) around 42 days postpartum.~only receive lifestyle intervention."
2465133|NCT03138252|Active Comparator|Cervical Ripening Balloon Alone|Multiparous women will begin cervical ripening with a cervical ripening balloon alone. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
2465144|NCT03138252|Active Comparator|Cervical Ripening Balloon + Oxytocin|Multiparous women will begin cervical ripening with a cervical ripening balloon and simultaneous oxytocin. After the balloon is expelled or removed, induction of labor will proceed with pitocin per standard protocol at MacDonald Women's Hospital.
2465168|NCT03137849|Active Comparator|Yoga Poses + Breath control|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas with specific muscles contractions) combined with ujjayi pranayama technique as breath control
2465175|NCT03137849|Active Comparator|Yoga Poses|Twice a week 75 minutes video class of yoga poses routine ( including yoga bandhas/ specific muscles contractions)
2465180|NCT03137849|Active Comparator|Stretching Exercises + Breath control|Twice a week 75 minutes video class of stretching exercises routine combined with ujjayi pranayama technique as breath control
2465183|NCT03137849|Active Comparator|Stretching Exercises|Twice a week 75 minutes video class of stretching exercises routine
2465225|NCT03137472|Experimental|Active Treatment|Participants will receive active TMS in the target area once daily for two days
2465226|NCT03137472|Sham Comparator|Sham Treatment|Participants will receive active TMS in a non-target area once daily for two days
2465261|NCT03137264||T790M positive|Patients determined to be T790M positive on cobas tissue and/or cobas plasma testing during Part 1 may be followed for clinical outcomes in Part 2, and will be treated in accordance with standard of care, which may include osimertinib.
2465269|NCT03137264||T790M negative|Patients determined to be T790M negative during Part 1 will not be followed for clinical outcomes in Part 2.
2465334|NCT03136770|Experimental|A|CK-30 600 mg -> red ginseng extracts 2.94 g
2465336|NCT03136770|Experimental|B|red ginseng extracts 2.94 g -> CK-30 600 mg
3156462|NCT00344474|Experimental|learning to cope with your anxiety sensitivity|cognitive behavioural intervention targeting catastrophic thinking in high anxiety sensitive youth
2465473|NCT03135912|Experimental|Experimental Treatment|Patients supplied with Experimental Drug SESC 01 for daily topical therapy for 4 weeks.
2465474|NCT03135912|Placebo Comparator|Vehicle Control|Patients supplied with inactive vehicle (placebo), identical to experimental treatment but without active ingredients, to be applied daily for 4 weeks.
2465475|NCT03135912|Active Comparator|Active Comparator|Terbinafine hydrochloride cream, to be applied twice daily for 4 weeks.
2465508|NCT03135665|Other|ScoE|This is a cross-sectional study on screened school children recommended for radiographic assessment in the scoliosis screening program of SHS in Hong Kong. Both x-ray, ultrasound and ATR measurement of the spine will be performed on the same day at Prince of Wales Hospital.
2464540|NCT03142347|Active Comparator|Remote endarterectomy|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
2464545|NCT03142347|Experimental|Remote endarterectomy + DCB balloon|Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.
2464614|NCT03141801|Experimental|Eccentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the eccentric exercise + blood flow restriction training group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
2464619|NCT03141801|Experimental|Concentric Exercise with Delfi Blood Flow Restriction Training|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions.
2464622|NCT03141801|Active Comparator|Eccentric Exercise|Patients randomized to the eccentric exercise group will receive eccentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their eccentric 1-repetition maximum for 4 sets of 10 repetitions.
2464624|NCT03141801|Active Comparator|Concentric Exercise|Patients randomized to the concentric exercise group will receive concentric exercise two times per week for 8 weeks, beginning 8-12 weeks after anterior cruciate ligament reconstruction. Patients will completed the exercise with knee range of motion limited to 20-60 degrees of knee flexion and will train at an intensity equal to 70% of their concentric 1-repetition maximum for 4 sets of 10 repetitions. During exercise, patients will have the DELFI personalized tourniquet system applied over the quadriceps to restrict blood flow. The tourniquet will be set to a limb occlusion pressure of 80%.
2464639|NCT03141268||Healthy volunteers|Normal subjects aged 18-80 years. No chronic diseases.
2464643|NCT03141268||IBS patients, lactose intolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose intolerant. No concomitant diseases.
2464645|NCT03141268||IBS patients, lactose tolerant|Subjects 18-80 years diagnosed with IBS for more than 6 months ago; lactose tolerant. No concomitant diseases.
2464709|NCT03141112||early CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy up to 48 hours after reaching criteria of severe sepsis.
2464714|NCT03141112||late CRRT initiation|Patients in ICU with severe sepsis, both gender, adult, over 18 years od age. Initiation of renal replacement therapy after 48 hours after reaching criteria of severe sepsis.
2464774|NCT03140787|Experimental|Nasal Spray of Lidocaine HCL|This group will receive treatment with an application of nasal spray for anesthetization.
2464776|NCT03140787|Active Comparator|Infiltration injection of Lidocaine HCL|Each patient in this group will receive an infiltration injection for anesthetization
2464801|NCT03140319|Experimental|Fibroblast|Injection of Fibroblast
2464807|NCT03140319|Placebo Comparator|Placebo|the patient receive placebo injection
2464864|NCT03140111|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 28 days, followed by Treatment B for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2464865|NCT03140111|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 28 days, followed by Treatment A for 28 days. There will be a minimum 7 day washout between Treatments. LAMELLEYE Dry Eye Drops and OPTIVE FUSION will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2464903|NCT03139734|Other|Sacral neuromodulation|The purpose of this study is to find out if Sacral Neuromodulation is an effective treatment for pelvic pain associated with endometriosis.
2464987|NCT03139396|Active Comparator|inlay shaped inlay bridge design|The inlay shaped inlay bridge design preparation show three types of preparation, the inlay shaped, the tub shaped inlay bridge design and the proximal box shaped designs. Intracoronal preparation of the inlay retained prosthesis for the abutments (inlay shaped and tub shaped) should show the following criteria: The inlay shaped preparation should show an occlusal-proximal box preparation and to be designed with the line angles should be rounded, smooth and rounded corners, and rectangular flat floor with no beveling for the occlusal and gingival margins. The occlusal inlay preparation should have preparation depth allowed for a thickness of 2.0 mm for the material of the bridge. The occlusal reduction show 4 mm width with extension of 4 or 6 mm mesio distally for the posterior teeth.
2464990|NCT03139396|Experimental|tub shaped inlay bridge design|The tub-shaped reduction consist of an occlusal proximal inlay and prepared as the same geometry as the inlay shaped preparation, except that for the proximal box preparation which is not present in this preparation design.
3156463|NCT00344474|Experimental|learning to manage your negative thinking|cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3156464|NCT00344539|Experimental|B|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum and 500 mg CPG 7909.
3156465|NCT00344539|Experimental|C|80 mcg AMA1-C1/Alhydrogel® with 368 mcg Aluminum alone.
3156466|NCT00344539|Experimental|A|20 mcg AMA1-C1/Alhydrogel® with 377 mcg Aluminum and 500 mg CPG 7909.
2464629|NCT03141593|Active Comparator|Vitamin D: solid form, start weekly|5'600 IU weekly (1 soft capsule) start for 3 months, will cross-over to 20'000 IU monthly (1 tablet) for the following 3 months.
2464630|NCT03141593|Active Comparator|Vitamin D: liquid form, start monthly|24'000 IU monthly (5 ml alcoholic drops) start for 3 months, will cross-over to 5'600 IU weekly (1.4 ml oily drops) for the following 3 months.
2464631|NCT03141593|Active Comparator|Vitamin D: solid form, start monthly|20'000 IU monthly (1 tablet) start for 3 months, will cross-over to 5'600 IU weekly (1 soft capsule) for the following 3 months.
2464677|NCT03141255|No Intervention|Control Group|Patients will receive only standard of care treatment for cardiogenic shock.
2464681|NCT03141255|Experimental|Therapeutic Hypothermia|Patients will be cooled to between 32°C and 34°C using the IVTM™ System and the Quattro® Catheter in addition to receiving standard of care treatment for cardiogenic shock.
2464741|NCT03140904|Other|Standard weekly visits|Standard weekly visits at the outpatient therapeutic feeding center until discharge
2464742|NCT03140904|Other|Monthly visits|Monthly visits at the outpatient therapeutic feeding center with caregiver support for home-based surveillance, with visits scheduled at weeks 4, 8, 10 and 12 until discharge
2464775|NCT03140527|Active Comparator|SAD HV PTI-801 Active - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
2464777|NCT03140527|Placebo Comparator|SAD HV PTI-801 Placebo - Complete|The safety, tolerability, and pharmacokinetic profile of PTI-801 will be evaluated following a single dose of PTI-801. Three cohorts are planned for evaluation where subjects will be randomized to PTI-801 or placebo.The subjects will be followed for 7 days post dose.
2464778|NCT03140527|Active Comparator|MAD HV PTI-801 Active - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
2464779|NCT03140527|Placebo Comparator|MAD HV PTI-801 Placebo - Complete|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-801 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 10, 12 and 14.
2464780|NCT03140527|Active Comparator|FE HV PTI-801 Active - Complete|Following the conclusion of SAD groups and after sufficient review of study data and approval by the SRC, a third set of healthy adult subjects will participate in the Food Effect cohort. Subjects will be randomized to Fed or Fasted on Days 1 and 12. Follow up visits will occur 7 days post Day 12 dose.
2464781|NCT03140527|Active Comparator|DDI HV PTI-801 Active - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
2464782|NCT03140527|Placebo Comparator|DDI HV PTI-801 Placebo - Complete|Following the conclusion of HV MAD Cohort 2 and after sufficient review of study data and approval by the SRC, a fourth set of healthy adult subjects will participate in the Drug-Drug Interactions cohort. Subjects will receive a 3-drug cocktail consisting of caffeine, bupropion, and midazolam on Day 1. On Day 4, subjects will be randomized to receive either PTI-801 or placebo QD for a total of 12 days. On Day 17, subjects will receive the 3-drug cocktail in combination with PTI-801 or placebo. Subjects will remain in clinic until Day 20. A follow up visit will occur on Day 24.
2464783|NCT03140527|Active Comparator|MAD Cohort 1-3 CF PTI-801 Active - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
2464784|NCT03140527|Placebo Comparator|MAD Cohort 1-3 CF PTI-801 Placebo - Complete|Adult subjects diagnosed with CF currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months will participate in the Part 2 complementary CF MAD cohort. The CF MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to receive either PTI-801 or placebo QD for a total of 14 days. A follow up visit will occur on Day 21.
2464785|NCT03140527|Active Comparator|Cohort 4 CF PTI-801 Active co-admin PTI-808 Active - Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
2464786|NCT03140527|Placebo Comparator|Cohort 4 CF PTI-801 Placebo co-admin PTI-808 Placebo- Complete|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 4. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
2464787|NCT03140527|Active Comparator|Cohort 5 CF PTI-801 Active co-admin with PTI-808 Active|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
2464789|NCT03140527|Placebo Comparator|Cohort 5 CF PTI-801 Placebo co-admin with PTI-808 Placebo|Adult subjects diagnosed with CF not currently receiving a CFTR modulator therapy within 30 days prior to Day 1 will participate in the Part 2 CF Cohort 5. Subjects will be randomized to receive either PTI-801 co-administered with PTI-808 or placebos QD.
2464791|NCT03140527|Active Comparator|Cohort 6 CF PTI-801 Active|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
3156467|NCT00344552|Experimental|1|
2464633|NCT03141957||Young patients|Patients with non-small cell lung carcinoma younger than 75y
2464634|NCT03141957||Elderly patients|Patients with non-small cell lung carcinoma aged 75 or more
2464684|NCT03141203|Experimental|Dose Level 1|"8mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2464687|NCT03141203|Experimental|Dose Level 2 (starting dose)|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/36mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2464690|NCT03141203|Experimental|Dose Level 3|"10mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2464692|NCT03141203|Experimental|Dose Level 4|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/45mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2464694|NCT03141203|Experimental|Dose Level 5|"12mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
2464696|NCT03141203|Experimental|Dose Level 6|"14mg/m2 Romidepsin (administered on days 1, 8, 15) and 20/56mg/m2 Carfilzomib (administered days 1, 2, 8, 9, 15, 16) over 8 cycles of treatment.~Carfilzomib dose will be 20mg/m2 for the first 2 doses (i.e. day 1 and 2 of cycle 1), rising to the target dose for subsequent doses and cycles."
3191515|NCT00799149|Placebo Comparator|Sugar pill|Sugar pill administered 30-90 min before the patient entered the operating room. Subsequent doses of Sugar pill were administered on the mornings (08H00) of the first, second, and third postoperative days.
2464885|NCT03139838|Active Comparator|EHR-Based Intervention A|Intervention A (Prognostication) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2464887|NCT03139838|Active Comparator|EHR-Based Intervention B|Intervention B (Accountable Justification) will be an EHR-based screen prompt triggered for eligible patients. The intervention will consist of no more than two questions that can be completed in two minutes or less. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2464891|NCT03139838|Active Comparator|Combined EHR-Based Intervention (A+B)|Intervention A and B prompts will be combined and triggered for eligible patients simultaneously. Completion of the prompt will be encouraged but not required, and adherence will be assessed in a minimally intrusive manner.
2464895|NCT03139838|No Intervention|Pre-Intervention (Control)|There is no trial-driven approach to care. All hospitals contribute a minimum of 5 months of outcomes data prior to adopting the intervention. Pre-specified outcomes data will be electronically extracted for patients meeting eligibility criteria but there will be no attempt to influence delivery of usual care within the hospital. The length of the control phase will differ at each hospital, dependent on the sequence in which hospitals are assigned to switch to the intervention phase.
2464940|NCT03139266|Experimental|UPLIFT|The Project UPLIFT intervention was designed for delivery to groups of six to eight people by telephone or Internet, though for this study the intervention will be web based only. The telephone intervention comprised eight hour-long sessions, each including check-in, instruction, skill building, and discussion, with homework between sessions. The Web intervention contains the same elements: check-in, video instruction, skill building, a discussion board, and homework between sessions. Instruction focuses on increasing knowledge about depression, cystic fibrosis (CF), cognitive behavioral therapy (CBT), and mindfulness and skills related to CBT and mindfulness.
2464944|NCT03139266|Other|Control Group|Treatment-as-usual
2465004|NCT03139123||Patients with acute kidney injury|Intensive care unit patients with acute kidney injury. Patients under continuous renal replacement therapy and hemodynamic monitoring.
2465056|NCT03138785|Experimental|conventional treatment|In this arm, patients with documented fungal keratitis undergo conventional medical treatment.
2465059|NCT03138785|Active Comparator|conventional treatment +CXL|In this arm, patients with documented fungal keratitis undergo conventional medical treatment plus CXL, beginning on the first day
2465090|NCT03138291|Experimental|Somnodent|SomnoDent is a custom-made oral appliance for the treatment of mild to moderate obstructive sleep apnea. SomnoDent is worn during sleep to provide Continuous Open Airway Therapy by moving the lower jaw slightly forward. This movement tightens the soft tissue and muscles of the upper airway, which prevents obstructive apneas while sleeping.
2465154|NCT03138161|Experimental|Phase 1|"Phase 1: 3-6 will be treated with escalating doses of Trabectedin every 3 weeks up to 18 doses. Dose Level 1 is 1.0 mg/m2; Dose Level 2,1.2 mg/m2; Dose Level 3,1.5 mg/m2. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses.~Phase 2: All patients will be treated with the maximum tolerated dose of Trabectedin every 3 weeks. Beginning 2 weeks after the first dose of Trabectedin, all patients will be treated with Ipilimumab at 1 mg/kg every 12 weeks up to 5 doses, and Nivolumab at 3 mg/kg every 2 weeks up to 26 doses."
2465208|NCT03137654|Active Comparator|Affective Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using emotionally-laden stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2465213|NCT03137654|Active Comparator|Neutral Training|Subjects complete baseline assessment, 3 wks of training with versions of the tasks using neutral stimuli, and a post-training assessment. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2465217|NCT03137654|No Intervention|Control (Non-active)|Subjects complete a baseline assessment and a secondary assessment approximately three weeks later. No active intervention is delivered. Subjects will be contacted monthly for 3 months after discharge for follow-up interviews.
2464753|NCT03140891|Experimental|NHFOV|NHFOV is used as the supporting mode after extubation
2464754|NCT03140891|Active Comparator|NCPAP|NCPAP is used as the supporting mode after extubation
2464802|NCT03140462||liver transplant patients and donors|To study clinical and genetic factors on tacrolimus dose normalized trough concentration.
2464909|NCT03140241|Experimental|PDR measurement|Two measurements of PDR perioperatively before and after opioid administration
2464970|NCT03139435|Experimental|Diagnostic (ultrasound)|Patients undergo peripheral nerve ultrasound. Patients also undergo skin biopsy.
2465061|NCT03138993|Active Comparator|Patient decision aid|
2465063|NCT03138993|Sham Comparator|General sleep education|
2465139|NCT03138265|Experimental|High intensity exercise training|HIT training protocol.
3156468|NCT00344565|Placebo Comparator|Placebo|Placebo, was matched to modafinil up to 400 mg/day. Patients also receive motivational interviewing and Cognitive Behavioral Therapy-Relapse Prevention (CBT-RP)
3156469|NCT00344565|Active Comparator|Modafinil|Modafinil (Active comparator). Patients received motivational interviewing and Cognitive Behavioral Therapy--relapse prevention (CBT-RP)
2465678|NCT03134547|Active Comparator|low volume volatile anesthetics|1.0 % sevoflurane sedation via face mask , low dose sevoflurane group
2465684|NCT03134547|Active Comparator|high volume volatile anesthetics|2.5 % sevoflurane sedation via face mask, high dose sevoflurane group
2465728|NCT03134170|No Intervention|No intervention|The no intervention group will serve as control group. This group will receive standard care and will be an active comparator. At the end of the study they may join the intervention group
2465729|NCT03134170|Other|Intervention group|The intervention group will be seen by a pharmacist iin addition to their normal provider. The pharmacist will provide medication therapy review of the patient's therapy. The pharmacist will make recommendations to make revisions in the patient's therapy.
2465808|NCT03133663|Active Comparator|Control group|Pulse oximeter and auscultation to determine heart rate during neonatal resuscitation. Pulse oximeter will be used to determine oxygen saturation.
2465814|NCT03133663|Experimental|Electrocardiogram group|Electrocardiogram to determine heart rate during neonatal resuscitation. Pulse oximeter will still be used per Neonatal Resuscitation Program guidelines for oxygen saturation.
2465883|NCT03133221|Experimental|Oral Zydelig 150 mg BID|Zydelig given orally at 150 mg twice daily continuously on 28-day cycles starting 30 to 120 days after autologous stem cell transplantation for patients with indolent or transformed indolent B-cell NHL, for up to 1 year maintenance duration. Dose withhold/modification is allowed according to tolerability/toxicity.
2465923|NCT03132779|Experimental|One armed|One group of patient will take Intralipid for all
2465991|NCT03132506||paper-based patient-reported-outcomes|
2466002|NCT03132506||on web-based patient-reported-outcomes|
2466063|NCT03131973|Experimental|Methotrexate|Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
2466066|NCT03131973|Experimental|Cytochrome P450 and Transporter Substrates|Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.
2466105|NCT03131284|No Intervention|Control|Families of newborns whose paediatrician is assigned to the control arm, receive usual education about nutrition and lifestyle, during their child's first two years of life.
2466106|NCT03131284|Experimental|Intensive education.|Families of newborns whose paediatrician is assigned to the intervention arm, receive standardized lifestyle counseling along with educational written material about their child's first two years of life, which corresponds to the experimental treatment.
2466223|NCT03131154|Experimental|ADX-102 Ophthalmic Solution (0.5%)|
2466225|NCT03131154|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Solution|
2466289|NCT03130426|Experimental|Intervention|Drug: iGlarLixi - sc injection; Drug: metformin - oral administration; Drug: insulin glargine - sc injection; Behavioral: lifestyle therapy, diet and exercise
2466294|NCT03130426|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
2466389|NCT03130062|Experimental|Exercise|Volunteers underwent a supervised resistance exercise program for 16 weeks. The subjects performed 10 exercises with 3 sets of 10 maximum repetitions in each. The training sessions were held twice a week.
2466392|NCT03130062|No Intervention|Control|Volunteers in this group were instructed not to perform systematic physical exercises for 16 weeks (the same period of the GEX group training program), and only the SSP medication treatment was maintained, and they were followed up during the study period.
2466512|NCT03128996|Experimental|RIC Prep Regimen & GVHD Prophylaxis|Single arm study. All patients receive the same Reduced Intensity Conditioning (RIC) regimen and GVHD prophylaxis regimen
2466618|NCT03128346|Experimental|The nerve block group|TTP block under dynamic ultrasound guidance plus the standard care (hydromorphone, fentanyl, aspirin, acetaminophen)
2466621|NCT03128346|Active Comparator|The standard of care group|Patients in the standard care group will receive pain medications, such as hydromorphone, fentanyl, aspirin and acetaminophen.
2466685|NCT03127696|Experimental|FMT + LMP|FMT and lifestyle modification program
2466689|NCT03127696|Experimental|FMT alone|Fecal Microbiota Transplantation
2466691|NCT03127696|Sham Comparator|Sham + LMP|Sham and lifestyle modification program
3191516|NCT00799162||Women with a scheduled cesarean section|
3191517|NCT00799175|Active Comparator|1 Group A(Active)|Group A (Active) receives a multimodal injection intra- and postoperatively
2466789|NCT03126669|Active Comparator|Treratment|100% oxygen at 2 ATA at the hyperbaric chamber
3156470|NCT00344591|Experimental|Tailored SET program|tailored SET program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
3156471|NCT00344591|Active Comparator|Individually focused therapy|Individually focused therapy program for reducing sexual and drug-related HIV transmission risk factors and increasing HIV treatment adherence in HIV infected men who have recently been released from prison
3156472|NCT00344656||Subjects and Controls|Patients with DSM-IV Anorexia Nervosa
2464765|NCT03140865||Mild Cognitive Impairment|This group will include 400 volunteers who have mild memory problems that are observed during cognitive testing. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend the visits or be available via telephone to complete study interviews.
2464768|NCT03140865||Alzheimer's disease|This group will include 150 volunteers with mild stage Alzheimer's disease dementia. Participants will complete an assessment at enrollment and once per year for the following 5 years. In addition to memory assessments at baseline and year 4, participants will have a brain MRI, OGTT A reliable study partner will need to attend visits to complete study interviews.
2464842|NCT03140371|Experimental|High energy high protein peptide feed|"This is a one-arm study. Each patient recruited onto the study will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
2465255|NCT03137537|Experimental|Ivabradine|"Ivabradine will be administered for a total of 6 weeks~Ivabradine is taken orally twice daily~Dosage will be adjusted according to physician determination"
2465263|NCT03137537|Placebo Comparator|Placebo Oral Tablet|"Placebo will be administered for a total of 6 weeks~Placebo is taken orally twice daily~Dosage will be adjusted according to physician determination"
2465332|NCT03136939||type 1 diabetes|
2465333|NCT03136939||type 2 diabetes|
2465337|NCT03136939||healthy people|
3156473|NCT00344721|Active Comparator|EPA/DHA/flaxseed|Study patients in the active comparator arm will take four soft-gel capsules containing omega-3 fatty acids (a nutritional supplement) orally daily for 3 months. Each daily dose contains eicosapentaenoic acid (450 mg), docosahexaenoic acid (300 mg) and flaxseed oil (1000 mg).
3156474|NCT00344721|Placebo Comparator|Wheat germ oil|Study patients in the placebo arm will take four doses of soft-gel capsules containing wheat germ oil orally daily for 3 months.
2465512|NCT03135704|Active Comparator|"Re Spine Mattress"|"Adults suffering low back pain will treat their low back pain using the Re Spine mattress"
2465513|NCT03135704|Active Comparator|Physiotherapy|Adults suffering low back pain will treat their low back pain using conventional physiotherapy protocols
2465559|NCT03135340|Experimental|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
2465561|NCT03135340|Active Comparator|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
2465606|NCT03135054|Experimental|Combination|"Quizartinib is a second generation FLT3 inhibitors.The starting dose of quizartinib will be 30 mg/day oral unless the patients are taking a strong CYP3A4 inhibitor in which case the dose will be 20 mg /day. Quizartinib should be taken continuously throughout the treatment period unless there is no evidence of response at first assessment on day 28 or progressive disease at any time during the treatment.~Omacetaxine Mepesuccinate will be given at 1.5 mg/m2/day (maximum dose 3 mg) for 7 days (concurrently with quizartinib) in 28-day cycle."
2465645|NCT03134651|Active Comparator|Monitoring brain function-low-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
2465648|NCT03134651|Active Comparator|monitoring brain function-high-anxiety|Anxiety has determined a cutoff score of 17. Patients were divided into two groups according to the recorded BAI score: a low-anxiety group and a high-anxiety group.The monitoring brain function values were recorded at baseline, 5 minutes, 15 minutes, and after anesthesia. Propofol was performed by ventilation with face mask. Monitoring brain function was keep value between 40 and 60.
2465690|NCT03134417|Experimental|Vitamin D and magnesium|Daily oral vitamin D (1000 IU) and magnesium (360 mg) supplement
2465694|NCT03134417|Active Comparator|Vitamin D|Daily oral vitamin D (1000 IU) supplement
2465702|NCT03134417|Placebo Comparator|Placebo|Daily oral placebo (cellulose)
3156475|NCT00344760|Active Comparator|Standard Treatment|Efavirenz 600mg once daily, Lamivudine 300mg once daily and Tenofovir 300mg once daily
3156476|NCT00344760|Experimental|Standard Treatment Plus Enfuvirtide|Efavirenz 600mg once daily, Lamivudine 300mg once daily, Tenofovir 300mg once daily and enfuvirtide 90mg subcutaneously twice a day until the viral load is less than 50copies for 2 consecutive visits or 12 weeks (whichever comes first).
3156477|NCT00344786|Experimental|CNF2024|
3156478|NCT00344825||Group 1|
3156479|NCT00344890|Experimental|Preservon|
3156480|NCT00344890|Active Comparator|Control|
3156481|NCT00344942|Experimental|1|
3156482|NCT00344942|Placebo Comparator|2|
3156483|NCT00345059|Active Comparator|docetaxel|single agent docetaxel
3156484|NCT00345059|Experimental|docetaxel + vinorelbine OR gemcitabine|docetaxel in combination with either vinorelbine or with gemcitabine
3156485|NCT00345059|Experimental|docetaxel + capecitabine|docetaxel in combination with capecitabine
3156486|NCT00345163|Experimental|1|
3156487|NCT00345163|Experimental|2|
3156488|NCT00345189|Other|Dosing Schedule 1|Starting dose of 25 mg, with dosing twice a week for 3 weeks out of a 4-week course (Schedule 1). Dosing for schedule 1 is currently closed.
3156489|NCT00345189|Other|Dosing Schedule 2|Starting dose of 600 mg, with dosing twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
3156490|NCT00345319|Active Comparator|Group 1|
3156491|NCT00345319|Active Comparator|Group 2|
2464773|NCT03140813|Experimental|High-Dose - Placebo - Low-Dose|AZD7325 15mg BID in gelatin capsules Placebo AZD7325 5mg BID in gelatin capsules
2464850|NCT03140267|Experimental|Difficult to wean patients|Maximal Inspiratory Pressure and Peak Pressure from the inclusion day to the extubation day will be measure.
3191518|NCT00799175|Placebo Comparator|2 Group P (Placebo)|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
3191519|NCT00799188|No Intervention|1|reduction of immunosuppression
2465186|NCT03137979|Experimental|Group A: GMSCs and collagen scaffolds|Patients in group A will receive GMSCs seeded into collagen scaffolds at the local periodontal defects immediately after open flap debridement.
2465189|NCT03137979|Experimental|Group B: collagen scaffolds|Patients in group B will receive collagen scaffolds implantation at the local periodontal defects immediately after open flap debridement.
2465190|NCT03137979|Other|Group C: comparator|Patients in comparator group will only undergo an open flap debridement.
2465259|NCT03137394||Spinal Cord Injury|Participants with SCI in the acute, in-patient rehabilitation phase.Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury;
2465265|NCT03137394||Able-bodied control|Age- and gender-matched able-bodied individuals (matched to SCI group). Control group data will be collected at baseline and at the 1-year follow-up.
2465348|NCT03136952||Pediatric children under 1 yrs old|Observation study of two measurement points of cerebral oxygenation
3191520|NCT00799188|Experimental|2|switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)
2465509|NCT03135691||Patients at High Risk for OSA|Patients at High Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery; retrospective study, no intervention administered.
2465542|NCT03135366|Active Comparator|Standard of Care (Control)|
2465549|NCT03135366|Experimental|Keheala Intervention (Treatment)|The intervention consisted of a daily request for self-verification of medication adherence, access to a supporter via a chat client, and information about TB.
2465614|NCT03135145|Active Comparator|Lite Run Gait Trainer|Participants will be using the Lite Run Gait Trainer to assist them in weightbearing and walking after SDR or SEMLS surgery.
2465616|NCT03135145|Placebo Comparator|Usual Treatments|Participants will be using current treatments used in clinical practice to assist them in weightbearing and walking after SDR or SEMLS surgery.
2465679|NCT03134612|Active Comparator|Ondansetron|Ondansetron 8mg (2mg/cc) was given intravenously via a 20 G vein canula
2465685|NCT03134612|Active Comparator|Lidocain|Lidocain 40mg (20mg/cc + 2cc of normal saline) was given intravenously via a 20 G vein canula
3191521|NCT00799201|Experimental|Control|Sennosides liquid 5mL (8.8mg) every 6 hours plus docusate sodium liquid 10mL (100mg) every 12 hours
3191522|NCT00799214|Placebo Comparator|1|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
2465790|NCT03133793|Placebo Comparator|Placebo Only|Participants in this group will receive placebo pills and placebo powder.
2465792|NCT03133793|Active Comparator|CoQ10 Only|Participants in this group will receive CoQ10 pills and placebo powder
2465795|NCT03133793|Active Comparator|D-ribose Only|Participants in this group will receive placebo pills and D-ribose oral powder.
2465796|NCT03133793|Experimental|CoQ10 + D-ribose|Participants in this group will receive CoQ10 pills and D-ribose oral powder.
2465811|NCT03133377|Experimental|Early activity and Mobilisation intervention|Patients will be assessed daily by an ICU physiotherapist using the ICU Mobility Scale (IMS) to determine the dosage and type of active exercises the patient will receive, using the early activity and mobilisation protocol. This protocol is hierarchical, with the objective of each intervention session beginning with the highest level of activity possible for the longest time possible, which then steps down to lower levels of activity if the patient fatigues. The intervention will be administered on all days in which the patient is admitted to ICU during the index hospitalisation, censored at 28days after.
2465817|NCT03133377|No Intervention|Standard of care|The control group will receive standard care from physiotherapy staff not involved in delivering the intervention. We have previously established that standard care in Australia for a patient receiving prolonged IMV (control group intervention) frequently involves no active exercise out of bed.
2465949|NCT03132701|Active Comparator|Magnesium group|Mg is administered with dose of 30 mg/kg for 10 minutes and then 10 mg/kg/hr until 5 minutes before surgery ends
2465953|NCT03132701|Placebo Comparator|Control group|Saline is administered with same volume of Mg of magnesium group until 5 minutes before surgery ends
2465975|NCT03132272|Experimental|Immunoadsorption with Globaffin for Alzheimer Dementia|Immunoadsorption with Globaffin
2466043|NCT03131856|Experimental|Nutritional intervention programme|An individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks).
2466045|NCT03131856|No Intervention|Usual care|Usual care which means no individual dietary plan and no nutrition follow-up visits after discharge.
2466116|NCT03131609||A: Container + Castile-soap wipe|Sterile urine collection container and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen - Control group represents usual care in the Emergency Department.
2466122|NCT03131609||B: Container + Silver impregnated wipe|Sterile urine collection container and silver-impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2466128|NCT03131609||C: Funnel + Castile-soap wipe|Sterile urine collection funnel and Castile-soap wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2466138|NCT03131518|Other|Traditional bicycle|Access to a traditional bicycle will be provided.
2464793|NCT03140527|Placebo Comparator|Cohort 6 CF PTI-801 Placebo|Adult subjects diagnosed with CF currently on stable tezacaftor/ivacaftor background therapy for a minimum of one month will participate in the Part 2 complementary CF MAD cohort. Subjects will be randomized to receive either PTI-801 or placebo QD.
2464919|NCT03139864|Experimental|type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
2464923|NCT03139864|Active Comparator|without type 1 diabetes|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
2464967|NCT03139227|Experimental|Supportive Care (celery-banana bread)|Patients consume one serving of lower dose apigenin celery-banana bread daily on days 1-7, and then consume one serving of higher dose apigenin celery-banana bread on days 8-14. Patients undergo blood sample collection on day 1 prior to and 6 hours after bread ingestion, on day 8 prior to and 6 hours after ingestion of bread, and on day 15 (or endpoint). Patients also provide a baseline urine sample and then 24-hour urine samples on days 1, 7, 8, and 14.
2465040|NCT03138603|Experimental|Metoprolol|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg prior to extubation, and subsequently an oral doser 25mg metoprolol tartrate) in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
2465043|NCT03138603|Placebo Comparator|Placebo|Patients will receive up to 3 IV doses of placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
2465093|NCT03138395||Experimental: Specimen Collection|Collection of peripheral blood and bone marrow samples will occur during routine care procedures. Collection of finger stick and saliva specimens will occur on the same day as the peripheral blood and bone marrow procedure, or during routine clinical procedures.
2465134|NCT03138148||Severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is superior to the entire cohort's 75th percentile
2465143|NCT03138148||less severe patient-ventilator asynchrony|Patients in whom the total percentage of time spent in asynchrony is inferior to the entire cohort's 75th percentile
2465165|NCT03137836|Experimental|Intervention|Sit-to-stand desks (Ergotron LearnFit®) will replace standard desks. In addition, meeting with parents and teacher's training will be conducted in order to support behavior change.
2465171|NCT03137836|No Intervention|Control|Control classroom will maintain their routine in sitting desks.
2465237|NCT03137563||Women eligible for cervical cancer screening|French women aged 25 to 65 years living in the Department of Hérault or Aude (France), attending one of the 8 centers where the questionnaire will be distributed
2465253|NCT03137134|Active Comparator|Treatment A|(reference) Crizotinib cMS 300 mg in fasted state
2465256|NCT03137134|Experimental|Treatment B|(test) Crizotinib cMS 300 mg in fed state
2465264|NCT03137134|Experimental|Treatment C|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg in fasted state
2465272|NCT03137134|Experimental|Treatment D|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with apple sauce.
2465274|NCT03137134|Experimental|Treatment E|(test) 5 days of esomeprazole 40 mg followed by crizotinib cMS 300 mg with orange juice
2465353|NCT03136835|Experimental|Pilot|Maternal Hyperoxygenation (4L/min via nasal prongs)
2465394|NCT03136393|Active Comparator|Control|Community based antenatal counselling
2465401|NCT03136393|Experimental|Intervention|Community based dietary counselling
2465456|NCT03136042|Experimental|physiotherapists maneuvers|physiotherapy techniques
2465459|NCT03136042|Active Comparator|hypertonic saline 3%|four nebulizations with 3% hypertonic saline.
2465462|NCT03136042|Active Comparator|saline + physiotherapy maneuvers|1 nebulizations + physiotherapy techniques
2465545|NCT03135600|Experimental|Normal|The participants from this group are healthy people.
2465550|NCT03135600|Experimental|ACLD|The participants from this group suffer from anterior cruciate ligament injury.
2465584|NCT03135158||Women in labor|All participants who have a vaginal delivery
3191523|NCT00799214|Experimental|2|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
2465768|NCT03134066||Treatment-resistant depression patients|Subjects with TRD who have been deemed appropriate for (and have decided to receive) clinical, non-research ketamine treatment at the ketamine clinic at Massachusetts General Hospital. As this is an assessment-only observational study, no treatment assignment or randomization procedures will be used.
2465803|NCT03133637||Ceftriaxone Arm|
2465874|NCT03133312|Experimental|Chlorhexidine Gluconate|Pre-operative vagina preparation with Chlorhexidine Gluconate Intervention: Drug: Chlorhexidine Gluconate Other Name: Chlora-Prep
2465878|NCT03133312|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative vagina preparation with Povidone-Iodine Scrub and Paint Intervention: Drug: Povidone-Iodine Scrub and Paint Other Name: Betadine
2465945|NCT03132805|No Intervention|Control|Schools which receive no intervention
2465952|NCT03132805|Experimental|PATHS to PAX|Universal classroom-based preventive intervention designed to reduce aggression.
2465956|NCT03132805|Experimental|PATHS to PAX and the IncredibleYears|The combination of PATHS to PAX with the Incredible Years child and parent groups.
2466013|NCT03132285|Other|PrePex Day 0 foreskin removal|Day 0 foreskin removal
2466065|NCT03131947||Union|Radiological union on RUST score (figure 2) (score of 3 on at least 3 cortices in AP, lateral, medial or posterior cortex - total of 9 or more) within 6 months of surgery
2466067|NCT03131947||Delayed union|Impaired bone healing at six months (RUST score < 9)
2466200|NCT03131050|Experimental|High-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
2466206|NCT03131050|Experimental|Low-dose scopolamine add-on therapy|Scopolamine (0.3 mg/1 ml, i.m.) QD; placebo (1 ml saline, i.m.) QD; escitalopram （10 mg/d p.o.）QD
2466211|NCT03131050|Placebo Comparator|Placebo add-on therapy|Placebo (1 ml saline, i.m.) Bid; escitalopram （10 mg/d p.o.）QD
2466278|NCT03130621||Adenocarcinoma of upper digestive tract|Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;
2466282|NCT03130621||Esophageal squamous cell carcinoma|Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;
2464808|NCT03140488|Experimental|Lean-Intervention|"2) Intervention group: Lean cohort: BMI ≤25, at <20 weeks gestation or BMI ≤28 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2464813|NCT03140488|No Intervention|Obese-Control|"3) Control group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, low dose oxytocin protocol~Low dose oxytocin regimen (the standard at Banner University Labor and Delivery, as well as across the United States): 30 units in 500cc 0.9% normal saline bag (60 milliunit/cc). Starting rate would be 2 milliunit/minute, or 2cc/hour. The medication will be increased by 2 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 20 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2464816|NCT03140488|Experimental|Obese-Intervention|"4) Intervention group: Obese cohort: BMI ≥30, at <20 weeks gestation or BMI ≥35 at a term gestation, high dose oxytocin protocol~High dose oxytocin regimen (endorsed by American College of Obstetricians and Gynecologists): 90 units in 500cc 0.9% normal saline bag (180 milliunit/cc). Starting rate would be 6 milliunit/minute, or 2cc/hour. The medication will be increased by 6 milliunit/minute = 2cc/hr every 30 minutes until adequacy of contraction or cervical change. At 60 milliunit/minute = 20cc/hr, provider will assess patient for eligibility to continue to increase oxytocin dosage."
2464892|NCT03140163|Experimental|Subjects suffering from pneumonia|CXR ULD-CT
2464934|NCT03139461|Experimental|Intervention|Receives PT-REFER Capacity-building toolkit to facilitate partnership building with physical therapists
2464935|NCT03139461|No Intervention|Control|Does not receive PT-REFER Capacity-building toolkit to guide partnership building, instead conducting business as usual.
2465007|NCT03138902|Experimental|Glucose Tolerance Beverage|75 g. of a fruit punch flavored oral glucose solution
2465031|NCT03138720|Experimental|Open Label|All patients will receive open label medication at set dosages unless the dosage needs to be adjusted to treat an adverse event or dose toxicity.
2465096|NCT03138447|Experimental|Prospective Cohort|
2465097|NCT03138447|No Intervention|Retrospective Cohort|
2465138|NCT03138083|Experimental|Module 1 Monotherapy Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) monotherapy in all comer patients up to a maximally tolerated or maximally feasible dose
2465145|NCT03138083|Experimental|Module 1 Monotherapy Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at minimally biologically active doses and above
2465147|NCT03138083|Experimental|Module 1 Monotherapy Expansion Cohort(s)|Expansion cohort(s) dosing OMO-1 (bid) monotherapy in patients selected for MET dependent tumours at recommended phase 2 dose (RP2D)
2465149|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Multiple Ascending Dose|Multiple ascending dose cohorts dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients up to a maximally tolerated or maximally feasible dose
2465151|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Paired Biopsy|Paired biopsy cohort(s) dosing OMO-1 (bid) in combination with EGFR-TKI in MET amplified patients at minimally biologically active doses and above
2465152|NCT03138083|Experimental|Module 2 Combination with EGFR-TKI Expansion Cohort|Expansion cohort dosing OMO-1 (bid) monotherapy in combination with EGFR-TKI in MET amplified patients at recommended phase 2 (combination) dose (RP2D)
2465233|NCT03137641||Nurses in contact with chemotherapies|"It is a nurses cohort, who administer chemotherapies or are in charge of patients treated by chemotherapie. Three urine samples are collected:~first : between 0 to 3h before the beginning of the workday second : between 0 to 2h after the end of the workday third : between 7 to 10h after the end of the workday"
2465280|NCT03137186|Active Comparator|Investigational arm|Metformin will be added to standard of care
2465287|NCT03137186|No Intervention|Control arm|Patients will treated according to Standard of care only
3191524|NCT00799214|Active Comparator|3|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
3191525|NCT00799240|Active Comparator|Arm A Pemetrexed Cisplatin|Arm A: Pemetrexed, cisplatin: pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days. Patients will be treated for a maximum of 6 cycles.
3191526|NCT00799240|Experimental|Arm B Permetrexed, Cisplatin, MK-0646|Pemetrexed and cisplatin chemotherapy at standard doses given IV every 21 days in combination with MK-0646 given IV, 10 mg/Kg, Days 1, 8 and 15 weekly
3191527|NCT00799266|Experimental|Zoledronic acid|Twice yearly 0.05 mg/kg (max 5 mg) i.v infusion (at least 30 minutes) of zoledronic acid
3191528|NCT00799266|Placebo Comparator|Placebo|Twice yearly i.v of infusion of Placebo (similar dosing as active drug)
3191529|NCT00799279|Experimental|Follow-up Counseling Arm|smoking cessation training for providers,practice tools for providers, patient quit plan, and follow-up telephone counselling for smokers
3191530|NCT00799279|Active Comparator|Practice Support Arm|smoking cessation training for providers,practice tools for providers, patient quit plan for smokers.
3156492|NCT00345358|Active Comparator|Synflorix <6M Group|This group consisted of subjects up to 6 months of age at first vaccination who received 3 doses of Synflorix™ vaccine co-administered with Infanrix™ IPV/Hib at 3, 4 and 5 months of age and a booster dose of the same vaccines at 12-15 months of age. Vaccines were administrated intramuscularly in the right (Synflorix™) or the left (Infanrix™ IPV/Hib ) thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
2465770|NCT03133897|Active Comparator|Prednisone|Prednisone group: Children will receive four doses (days) of prednisone 1 mg/kg/dose once daily (maximum dose 50 mg) following the initial dose of corticosteroid received in the ED under the Nursing Medical Directive or Pre-Printed Order form.
2465777|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), low|Biological/Vaccine: ≥3.0logCCID50/ml but <3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)[ ≥3.0logCCID50/ml but <3.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
2466050|NCT03131700|Experimental|RPH-001|A single dose of RPH-001 will be administered (IV) 5 mg/kg dose .
2464863|NCT03140046|Experimental|Corneal Topography|we will do Corneal Topography for every patient before doing photorefractive keratectomy (PRK) and also after it , to measure the change in the quality of vision and measure the change in the quality of vision
2464910|NCT03139773|Experimental|Normal Weight|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
2464912|NCT03139773|Experimental|Overweight/Obese|Received control breakfast beverage and breakfast beverage supplemented with omega-3 fatty acids.
2464986|NCT03139383|Placebo Comparator|normal saline solution|The patients received normal saline solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
2464991|NCT03139383|Active Comparator|dextrose solution|The patients received dextrose solution as a maintenance fluid during surgery in dose of 2 ml/kg/hour.
2465019|NCT03138850|Experimental|Olympus standard bite block|Standard of care using standard bite block and nasal cannula
2465020|NCT03138850|Experimental|YX Mandibular advancement bite block|Mandibular advancement bite block group
2465021|NCT03138850|Experimental|Optiflow High flow nasal cannula|High flow nasal cannula group
2465053|NCT03138538|Experimental|Part 1: M8891|
2465055|NCT03138538|Experimental|Part 2A: Dose Escalation Cohort: M8891 and Cabozantinib|
2465057|NCT03138538|Experimental|Part 2B: Dose Expansion Cohort: M8891 and Cabozantinib|
2465109|NCT03138213|Experimental|TLPD|Ttotal laparoscopic pancreaticoduodenectomy
2465111|NCT03138213|Experimental|OPD|Open pancreaticoduodenectomy
2465187|NCT03137940|Experimental|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator. The anode electrode is placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode is placed in the supraorbital region (SO) of the contralateral hemisphere.
2465188|NCT03137940|Sham Comparator|Sham tDCS|one-shot of sham tDCS session with BrainStim Stimulator (20 minutes). The montage of the electrodes will be placed as in the experimental session i.e.the anode electrode will be placed in a primary motor cortex (M1) of ipsilesional hemisphere (EEG 10/20 system), while cathode in the supraorbital region (SO) of the contralateral hemisphere.
2465284|NCT03137446|No Intervention|Usual Care|Participants randomized to the usual care resuscitation strategy will receive an initial 30 ml/kg bolus and then IV fluids as needed and without limit as well as IV vasopressors to maintain a MAP>65, determined by the primary care team for the duration of the study.
2465289|NCT03137446|Experimental|Restrictive Care|Participants randomized to the restrictive fluid resuscitation strategy will be LIMITED to 60 ml/kg (up to 6000 ml) of IV fluids as initial resuscitation followed by administration of IV vasopressors to maintain a MAP>65 mm Hg for the first 72 hours of care. The intervention is defined as capping the total allowed IVF administered. After 72 hours the participants are eligible for IV fluids as determined by the primary care team.
2465366|NCT03136887||JOURNEY II XR TKA|This is a single arm study, all subjects will receive JOURNEY II XR TKA
3191531|NCT00799305||COPD patients|
3191532|NCT00799331|Experimental|A|AZD5985
3191533|NCT00799331|Experimental|B|placebo
2465530|NCT03135457|Other|Group A|Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min
2465532|NCT03135457|Other|Group B|Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min
2465597|NCT03135184|Experimental|HDL Therapeutics PDS-2™ System|Serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
2465703|NCT03134755||Study cohort (all children with asthma)|300 children with asthma will receive the same inhaled corticosteroid (ICS) for six weeks, in order to assess response to ICS.Bronchodilator response will be measured before and after ICS therapy. Stress levels (the exposure of interest) will be assessed with a validated questionnaire, before ICS administration (thus, it is an observational study of whether stress is related to treatment response)
2465779|NCT03134040|Experimental|Incentives (Rebate)|On a weekly basis, participants receive a small monetary incentive to exercise each time they attend the YMCA.
2465782|NCT03134040|Experimental|Incentives (Donation)|On a weekly basis, a small monetary incentive to exercise is provided in the form of a donation to a charity of the participant's choice for attendance at the YMCA.
2465785|NCT03134040|Active Comparator|Control|Participants receive feedback on their exercise attendance on a weekly basis.
2465824|NCT03133468|Experimental|Part 1: AJM347|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of AJM347, respectively, administered in the fasted state on Day 1.
2465825|NCT03133468|Placebo Comparator|Part 1: Placebo|Caucasian and Japanese participants will be randomized to receive one of eight and four single oral doses of matching placebo, respectively, administered in the fasted state on Day 1.
2465827|NCT03133468|Experimental|Part 2: Low-dose AJM347|"Caucasian and Japanese participants will receive a low dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 6 sequential treatment periods."
2465828|NCT03133468|Experimental|Part 2: High-dose AJM347|"Caucasian and Japanese participants will receive a high dose of AJM347 (at different frequencies and in either a fed or fasted state) on Day 1 of each of 2 sequential treatment periods (the frequency and timing with respect to meals will be determined after review of the data from the low-dose AJM347 groups)."
2465829|NCT03133468|Experimental|Part 3: AJM347|Caucasian and Japanese participants will be randomized to receive one of three single doses of AJM347 on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
2465938|NCT03132961||Block 5|Participants in the cohort will undergo testing in the order of: cVEMP, ECoG, oVEMP
2465940|NCT03132961||Block 6|Participants in the cohort will undergo testing in the order of: cVEMP, oVEMP, ECoG
3191534|NCT00799344||Stent|Catania Stent
3191535|NCT00799370|Experimental|1|Early weight bearing: immediate in postoperative
3191536|NCT00799370|Experimental|2|Delayed weight bearing: 2 months after surgery
2464873|NCT03140020||Coiling|Coiling of an aneurysm of the anterior communicating artery - Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage. Patients will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after endovascular aneurysm treatment. Furthermore the patients will undergo additional neuropsychological examinations 12 months after long-term recovery from endovascular treatment.
2464875|NCT03140020||Healthy Controls|Healthy controls will undergo baseline structural MRI, task fMRI, rsfMRI, and baseline neuropsychological examinations prior as well as 2 months after baseline examinations. Furthermore all subjects will undergo additional neuropsychological examinations 12 months after baseline examination.
2464906|NCT03139669|Experimental|HPV home testing kit|The procedures will be recruitment of under-screened women in Health Districts 1, 2 and 3 of Southwest Virginia to complete HPV home testing using self-collection kits distributed by lay navigators. Regardless of HPV positivity, all women will be provided with information about cervical cancer screening (locations, cost, etc.), and will be encouraged to complete Pap screening by a clinician.
2465041|NCT03138681|Placebo Comparator|Placebo|
2465045|NCT03138681|Experimental|ATP|
2465047|NCT03138681|Experimental|phosphocreatine|
2465161|NCT03137810|Experimental|placental cord drainage|In 90 women after vaginal delivery of the baby, the placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
2465162|NCT03137810|Active Comparator|Non placental cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
2465216|NCT03137628||patients undergoing colectomy, GA and MV|venous blood samples collected from colorectal cancer patients undergoing selective colectomy with general anesthesia(GA) and mechanical ventilation(MV) before general anethesia and the third hour after
2465221|NCT03137628||healthy controls|donated venous blood samples from healthy people undergoing physical examination but not general anesthesia or mechanical ventilation.
2465304|NCT03137017|Experimental|GRT7014 fasted|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the Investigational medicinal product (IMP)."
2465306|NCT03137017|Experimental|GRT7014 fed|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (GRT7014 - Abuse Deterrent Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
2465309|NCT03137017|Active Comparator|Norco fasted|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fasted conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until 4 hours after the administration of the IMP."
2465311|NCT03137017|Active Comparator|Norco fed|"Norco fixed dose combination Hydrocodone bitartrate 5 mg/acetaminophen 325 mg tablet (Norco 5Mg-325Mg Tablet) under fed conditions.~Participant must fast from approximately 10:00 pm pre-dosing day until they consume a high-calorie and high-fat breakfast the following morning.~The IMP must be administered as soon as the meal has been eaten."
2465335|NCT03136744|Experimental|Sit Less with MS|The Sit Less with MS program is based on Social Cognitive Theory (SCT) and consists of strategies that will enable people with MS to 'sit less' by frequently interrupting sitting and 'move more' by replacing sitting with light-intensity activity during waking hours.
2465416|NCT03136575|Active Comparator|Qigong|Patients in the Qigong group receive Qigong,a mind-body exercise, 3 times a week, for 6 weeks during radiotherapy course. The participants are given a DVD contains Qigong program, and they attend the Qigong class in a health education room at the radiation oncology department to assure their attendance.
2465419|NCT03136575|Placebo Comparator|wait-list control|Patients who are assigned to the wait-list control are told to have some exercise by their own but no actually attend the the class in fact.
2465489|NCT03135951|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6 mg G-CSF per cycle)~Supplied in 1 mL prefilled, single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle after TC administration"
2465539|NCT03135587|Experimental|Weight 0|The participants will not carry any loading to walk on treadmill.
2465543|NCT03135587|Experimental|Weight 10|The participants will wear 10kg loading suit to walk on treadmill.
2465547|NCT03135587|Experimental|Weight 20|The participants will wear 20kg loading suit to walk on treadmill.
2465552|NCT03135587|Experimental|Weight 30|The participants will wear 30kg loading suit to walk on treadmill.
2465554|NCT03135587|Experimental|Weight 40|The participants will wear 40kg loading suit to walk on treadmill.
2465556|NCT03135587|Experimental|Weight 50|The participants will wear 50kg loading suit to walk on treadmill.
2465615|NCT03135106|Experimental|Treatment A: Erdafitinib alone|Participants will receive single 4 milligram (mg) oral dose of erdafitinib on Day 1 in a fasted state.
2465618|NCT03135106|Experimental|Treatment B: Erdafitinib + Fluconazole|Participants will receive 400 mg fluconazole once daily orally from Day 1 to Day 11 in a fasted state and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 400 mg fluconazole dose.
2465619|NCT03135106|Experimental|Treatment C: Erdafitinib + Itraconazole|Participants will receive 200 mg itraconazole once daily orally from Day 1 to Day 11 and on Day 5, a single 4-mg oral dose of erdafitinib will be administered 30+/-10 minutes after the intake of 200 mg itraconazole dose.
2465669|NCT03134534|Other|VATS group|Surgical procedure: VATS lobectomy
2465670|NCT03134534|Other|RATS group|Surgical procedure: RATS lobectomy
2467478|NCT03121755||Sangre Por Salud cohort members|Subjects entered in the Sangre Por Salud Biobank
2464888|NCT03139877||HLP|"Intervention Cohorts:The intended target population is the adolescent with a BMI ≥ 95th percentile.~Healthy Lifestyles Program(HLP) will serve as the primary recruitment site for the intervention cohort. A prospective, longitudinal observational case control study will be performed. All participants will receive HLP standard of care (intensive lifestyle modification and access to Bull City Fit.) Groups: (1) HL-only, (2) HL + Low carbohydrate diet, (3) HL + weight loss medication(s) and (4) HL + Bariatric surgery.~Participants will be assigned to groups as per usual HLP clinical care, based on established standards and guidelines, expert medical provider recommendations, and family preference."
2464890|NCT03139877||Healthy Weight Siblings|Healthy weight siblings of HLP participants who meet age and BMI criteria will be offered enrollment at the time their overweight sibling is consented to provide comparative data. This group will be asked to provide a fecal and blood sample at one time point.
2464894|NCT03139877||Healthy Weight age/sex matched controls|"Healthy weight, age and gender matched patients will be recruited from the Duke Children's primary care practice Participants will be recruited at the time of their annual physical to provide comparative data.~This group will be asked to provide a fecal and blood sample at one time point."
2464936|NCT03139539|Active Comparator|Ioban|In this arm patients will be operated using Ioban as incisional drape.
2464938|NCT03139539|No Intervention|Control|In this arm patients will be operated using no incisional drape.
2464971|NCT03139175|Experimental|temporomandibular disorder group|subjects with TMD and CLBP symptoms undergo balance assessment with Biodex balance system
2464973|NCT03139175|Active Comparator|chronic low back pain group|subjects only with LBP symptoms undergo balance assessment with Biodex balance system
2464975|NCT03139175|Other|Normal|subjects without temporomandibular disorder and low back pain symptoms undergo balance assessment with Biodex balance system
3191537|NCT00799461|Experimental|Arm I (full website access w/ PST; first study only)|Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
3191538|NCT00799461|Experimental|Arm II (full website access without PST)|Patients receive full access to INSPIRE website for 6 months as in arm I.
3191539|NCT00799461|Sham Comparator|Arm III (delayed website access)|Patients do not have access to INSPIRE website for 6 months. After 6 months, patients receive full access to INSPIRE website for 3 months.
3191540|NCT00799500|Experimental|Weekly screening|Screening and treatment of bacterial vaginosis during pregnancy through self-administered weekly vaginal pH determination.
3191541|NCT00799500|No Intervention|Observation|Usual care
3191542|NCT00799513|Experimental|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
3191543|NCT00799526|Experimental|Ex Vivo Transplantation|Autologous Ex Vivo Conjunctival Epithelial Cell Expansion for Symblepharon Transplantation
2465169|NCT03137888|Experimental|sMRI-Guided RT with TMZ|Patients undergo spectroscopic magnetic resonance imaging-guided dose-escalated radiation therapy daily for the first 5 days of every week (Monday - Friday) over 6 weeks. Patients also receive standard of care temozolomide PO daily during radiation therapy for up to 42 days.
2465242|NCT03137407|Experimental|DaxibotulinumtoxinA 240 units|Botulinum Toxins, Type A Intramuscular Injection
2465245|NCT03137407|Placebo Comparator|Placebo|Placebo Intramuscular Injection
2465300|NCT03137030|Experimental|GRT7014 - 1 Tablet (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2465301|NCT03137030|Experimental|GRT7014 - 10 Tablets (Part 1)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2465303|NCT03137030|Active Comparator|Norco - 1 Tablet (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2465307|NCT03137030|Active Comparator|Norco - 10 Tablets (Part 1)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2465310|NCT03137030|Experimental|GRT7014 - 5 Tablets (Optional Part 2)|"Abuse deterrent formulation of a fixed dose combination of hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet.~(GRT7014 - Abuse Deterrend Tablet)"
2465312|NCT03137030|Active Comparator|Norco - 5 Tablets (Optional Part 2)|Norco fixed dose combination hydrocodone bitartrate 5 mg/acetaminophen 325 mg immediate release (IR) tablet (Norco 5Mg-325Mg Tablet).
2465360|NCT03136705|Active Comparator|Lanthanum + Nicotinamide|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
2465363|NCT03136705|Active Comparator|Lanthanum + Nicotinamide Placebo|Lanthanum Carbonate 1000mg orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
2465365|NCT03136705|Active Comparator|Lanthanum Placebo + Nicotinamide|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide 750mg orally twice daily for 2 weeks
2465367|NCT03136705|Placebo Comparator|Lanthanum Placebo + Nicotinamide Placebo|Lanthanum Carbonate Placebo orally three times daily with meals for 2 weeks and Nicotinamide Placebo orally twice daily for 2 weeks
2465412|NCT03136250|Active Comparator|Group A (Control Group - Static Stretching)|(Control Group - Static Stretching + Standard Treatment)
2465418|NCT03136250|Experimental|Group B (Autogenic Inhibition MET)|(Autogenic Inhibition - PIR + Standard treatment)
2465425|NCT03136250|Experimental|Group C (Reciprocal Inhibition MET)|(Reciprocal Inhibition - RI + Standard treatment)
3191544|NCT00799552|Placebo Comparator|Placebo|
2465591|NCT03135197||Migalastat|Migalastat administered according to SmPC
2465720|NCT03134287|Active Comparator|two-finger method|Those who received nasogastric tube placement by two-finger method
2465721|NCT03134287|Active Comparator|reverse sellick's method|Those who received nasogastric tube placement by reverse sellick's method
2464905|NCT03139799|Experimental|Puzzle Video Game Intervention|Group T will first receive the experimental and then the control intervention (T-C) In phase I both groups take a baseline measurement (pre-test), then group T is given the casual puzzle game task (experimental intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the the experimental intervention group T now serves as control. After phase II (16 weeks) both groups are post-tested again.
2464907|NCT03139799|Active Comparator|Tablet Newspaper Reading Intervention|Group C will first receive the the control intervention and then experimental and (C-T). In phase I both groups take a baseline measurement (pre-test), then group C is performing the newspaper reading task (control intervention). After phase I (8 weeks) both groups are post-tested (mid-test). In phase II, groups are switched and the control group C is given the experimental intervention (casual puzzle game task). After phase II (16 weeks) both groups are post-tested again.
2464985|NCT03139149|Active Comparator|Early surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 12 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast in 3 h after admission. In case of of clinical and radiologic signs of obstruction in 12 h after admission, surgery is performed. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
2464989|NCT03139149|Active Comparator|Late surgery|After exclusion of indications for an emergency operation, conservative treatment is performed up to 48 hours from the moment of admission. Each patient receive blood test, blood lactate investigation, blood biochemistry, X-ray of the abdomen, ultrasound and CT on the admission. Each patient receive water-soluble contrast 3 h after admission. In case of present of obstruction and absence of contrast in colon in 36 h after intake (48 h after admission) a surgery is perform. On the first stage of surgical treatment laparoscopic adhesiolysis is performed. If it is impossible to eliminate the cause of obstruction by laparoscopic technique laparotomy is performed.
2465034|NCT03138811|Experimental|CSJ117|low dose, medium dose, or high dose administered as a once daily inhaled dose
2465038|NCT03138811|Placebo Comparator|Placebo|placebo comparator administered as once daily inhaled dose
2465131|NCT03138304|Experimental|Adventure video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
2465140|NCT03138304|Active Comparator|Educational Program|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
2465205|NCT03137758|Experimental|Level 1 (50 mg) PCUR-101|Starting Dose, 3+3 Cohort Design
2465207|NCT03137758|Experimental|Level 2 (100 mg) PCUR-101|
2465212|NCT03137758|Experimental|Level 3 (150 mg) PCUR-101|
2465218|NCT03137758|Experimental|Level 4 (200 mg) PCUR-101|
2465222|NCT03137758|Experimental|Level 5 (250 mg) PCUR-101|
2465224|NCT03137758|Experimental|Level 6 (300 mg) PCUR-101|
2465279|NCT03137277||Olympus 190|Olympus colonoscope 190 C (intervention group), screening colonoscopy examination with the latest generation colonoscope (190 series CF or PCF colonoscopies, Olympus Corp, Hamburg, Germany).
2465285|NCT03137277||Olympus 160/165|Olympus colonoscope 165 C (control group), screening colonoscopy examination with the 160/5 generation colonoscope (Olympus Corp, Hamburg, Germany),
2465355|NCT03136783|Other|Patient with stage IV melanoma|
2465398|NCT03136458|Experimental|Real ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 50 mmHg above the systolic arterial pressure of the patient.
2465403|NCT03136458|Active Comparator|Dummy ischemic preconditioning|Insufflation of an arterial pressure cuff located in one upper extremity, during 4 cycles, each with a duration of 5 minutes insufflation and 5 minutes of disinflation. The cuff will be insufflated to reach 10 mmHg above the diastolic arterial pressure of the patient.
2465485|NCT03136003|Experimental|Arm A: DDAVP followed by exercise|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: Exercise"
2465486|NCT03136003|Active Comparator|Arm B: DDAVP alone|"Intervention #1: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril).~Intervention #2: no further intervention (rest)"
2465488|NCT03136003|Experimental|Arm C: Exercise alone|"Intervention #1: Exercise~Intervention #2: no further intervention (rest)"
2465493|NCT03136003|Experimental|ARM D: Exercise followed by DDAVP|"Intervention #1: Exercise~Intervention #2: DDAVP. The participant will take either 1 or 2 nasal sprays of IN DDAVP. For patients weighing <50 kg: 150 ug (i.e. 1 spray into one nostril) and patients weighing ≥50 kg: 300 ug (i.e. 2 sprays - one into each nostril)."
2465514|NCT03135496||Surgery with CEC|
2465516|NCT03135496||Without CEC|
2464937|NCT03139487|Experimental|Direct oral anticoagulant|"Rivaroxaban, 15 mg orally twice daily for 3 weeks followed by 20mg once daily for 21 weeks~Apixaban, 10 mg orally twice daily for 7days followed by 5mg twice daily for 21 weeks"
2465014|NCT03138980|Experimental|Mobile application|
2465032|NCT03138694||Methotrexate injection|Patients with Ectopic pregnancy treated with Methotrexate injection.
2465035|NCT03138694||Self resolution|"Patients with Ectopic pregnancy that had signs of self resolution with our Watchful waiting protocol."
2465196|NCT03137732|Active Comparator|Surgeon-inserted|Rectus sheath catheter will be inserted under direct vision / palpation of the space at the end of the operation.
2465199|NCT03137732|Active Comparator|Anaesthetist-inserted|Rectus sheath catheter will be inserted under ultrasound guidance by the anaethetist.
2465244|NCT03137433|Experimental|Meal-Replacements|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data).
2465249|NCT03137433|Experimental|Meal-Replacements Plus|Participants will be asked to strictly follow the individually-prescribed eating regimen, which will include shakes (breakfast and lunch) and pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables per day. Daily caloric allotment will be tailored for each individual (number of shakes and frozen meals) by calculating the average daily caloric deficit necessary to achieve negative energy balance (using the metabolic rate/energy expenditure data). This group will be provided additional information to go along with meal-replacements.
2465308|NCT03137082|Experimental|Guanfacine XR 3mgs/daily|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
2465313|NCT03137082|Placebo Comparator|Placebo (for guanfacine)|"Guanfacine XR tablet by mouth every 24 hours for 12 weeks~21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~Full dose: 3mgs/d (day 21- day 70)~2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)"
2465364|NCT03136718||First-time hearing aid users|Individuals using hearing aids for the first-time (or if previous users, have not having worn hearing aids for more than 3 years) will have access to the mobile-enabled RLOs (mRLOs) intervention, which will be given to the participants shortly after their hearing aid is fitted.
2465388|NCT03136354|Active Comparator|ESD Group|Endoscopic Submucosal Dissection
2465389|NCT03136354|Active Comparator|LAG Group|Laparoscopic Assisted Gastrectomy
2465448|NCT03136146|Experimental|Treatment (combination chemotherapy)|See detailed description
3174673|NCT00625859|Experimental|Subjects receiving treatment sequence 5|Eligible subjects will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
3191545|NCT00799552|Experimental|RX-10045|
2465671|NCT03134482|Experimental|In vitro maturation (IVM)|"hCG primed in vitro maturation (IVM) procedure Gonadotropin is not used in this patient group If the endometrial thickness in 6mm or more and the mean diameter of largest follicle is 11 mm or less on menstrual cycle day 9 to 12 on ultrasonography, oocyte retrieval is planned two days later.~Recombinant hCG injection (priming) is given 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization.~The biochemical pregnancy is confirmed by serum beta hCG 15 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
2465674|NCT03134482|Active Comparator|Minimal stimulation IVF|"minimal stimulation IVF procedure These patients are stimulated with 150 or less IU of recombinant Follicle-stimulating hormone (FSH) from menstrual cycle day 3 in GnRH antagonist protocol.~If the mean diameters of two or more follicles are 17mm or more, oocyte retrieval is planned two days later.~Recombinant hCG is triggered 36 hour before oocyte retrieval, followed by intracytoplasmic sperm injection (ICSI) for oocyte fertilization if needed.~The biochemical pregnancy is confirmed by serum beta hCG 14 days later oocyte retrieval.~The clinical pregnancy is confirmed when gestational sac is detected by transvaginal ultrasonography 3 weeks later oocyte retrieval."
2465730|NCT03134235|Experimental|Raw, plant-based diet|A raw, plant-based diet was prescribed for 4 weeks.
2465761|NCT03133845|Active Comparator|General anesthesia|In this group patients will receive general anesthesia. Anesthetic induction will occur with propofol (generally 1-2 mg/kg), maintenance with a volatile anesthetic, muscle paralysis with a muscle relaxant, and pain control with fentanyl (generally 2-5 mcg/kg titrated). Patients on baseline opioids may receive additional opioids (such as dilaudid) based on clinical criteria. The anesthetic provider will be blinded to BIS values. Discretionary use of intrathecal morphine may be used.
2465762|NCT03133845|Experimental|Spinal anesthesia with light sedation|In this group patients will receive light sedation with propofol and a spinal anesthetic. Spinal anesthesia will be obtained by injecting approximately 10-15 mg of bupivacaine into the subarachnoid space. Up to 2 mg of midazolam may be given during spinal needle insertion. Although spinal anesthesia is sufficient for surgery, sedation is routinely administered using a propofol infusion, titrated to a BIS>60-70. Discretionary use of intrathecal morphine may be used.
2465849|NCT03133429|Experimental|Patients with MER stent|Patients eligible for Carotid Artery Stenting
2465884|NCT03133052|Active Comparator|training group|Intervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
2465885|NCT03133052|Placebo Comparator|control group|Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
3191546|NCT00799565|Experimental|1|Subject with a Mitral Valvular Prolapse
3191547|NCT00799565|Experimental|2|Healthy Volunteers
3191548|NCT00799656|Experimental|1|First period: Ataciguat - Second period: Placebo
3191549|NCT00799656|Experimental|2|First period: Placebo - Second period: Ataciguat
3191550|NCT00799669||MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
2465091|NCT03138473||Main Group|Acute Coronary Syndrome Patients With Multi-Vessel Disease. The Residual SYNTAX score (rSS) and the SYNTAX Revascularization Index (SRI) will be calculated in this group and its relationship with patient outcomes either in hospital or in 6 months to 1 year follow-up will be evaluated.
2465141|NCT03138135|Experimental|Intervention|The Intervention group will receive the HOME Study intervention.
2465146|NCT03138135|Active Comparator|Control|The Control group will receive standard of care.
2465166|NCT03137745||all patients undergoing CRS with HIPEC|thromboelastography was done in 60 patients undergoing CRS with HIPEC in RGCI FROM MARCH2015- MARCH 2016
2465234|NCT03137576|Active Comparator|Paravertebral block (PVB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Paravertebral Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2465235|NCT03137576|Experimental|Erector Spinae Plane Block (ESPB)|"Intraoperative pain management~Sedation~Continuous monitoring of sedation with bispectral index. Sedation is achieved with propofol 1% (target bispectral index: 50-70), plus on-demand remifentanyl (50 mcg/ml in TCI, dose target Cet 2-8 ng/ml).~Erector Spinae Plane Block~Post operative pain management~Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2465239|NCT03137160|Experimental|Ixekizumab (Taltz)|We have received funding for only a small pilot study to prove a benefit from Interleukin-17 inhibition in Pyoderma Gangranosum . Therefore, there is only one treatment arm. The primary outcome will be a comparison of week 12 to baseline regarding a two-point improvement in the Investigator Global Assessment.
2465290|NCT03137108|Experimental|Incomplete Spinal cord injury|
3191551|NCT00799669||MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
3191552|NCT00799682|Active Comparator|Xalatan®|
3191553|NCT00799682|Active Comparator|Travatan Z®|
3191554|NCT00799721||1|VLBW infants with erythropoietin therapy
2465536|NCT03135626|Experimental|Biodentine|Biodentine pulpotomy agent
2465540|NCT03135626|Experimental|ProRoot MTA|ProRoot MTA pulpotomy agent
2465544|NCT03135626|Experimental|MTA Plus|MTA Plus pulpotomy agent
2465548|NCT03135626|Active Comparator|Ferric Sulfate 20% Dental Gel|Ferric Sulfate %20 Dental Gel pulpotomy agent
2465581|NCT03135119|Active Comparator|TF-CBT|Youth will receive standard Trauma-Focused Cognitive-Behavioral Therapy
2465583|NCT03135119|Experimental|TF-CBT+AAT|Youth will received Trauma-Focused Cognitive-Behavioral Therapy with Animal-Assisted Therapy as an adjunct.
2465630|NCT03134885||VigilanS Nord-Pas de Calais cohort|All patients leaving in the Nord-Pas de Calais region and entering in the VigilanS program after a suicide attempt
2465715|NCT03134365|Experimental|Mixed meal|
2465718|NCT03134365|Active Comparator|Combined meal|
2465760|NCT03134014|No Intervention|Breakfast Skipping (BS)|The BS group will continue to skip breakfast.
2465765|NCT03134014|Active Comparator|Normal Protein Breakfast (NP)|The NP groups will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The NP breakfasts will be 11% protein (10 g protein), 63% CHO, and 26% fat
2465767|NCT03134014|Active Comparator|High Protein Breakfast (HP)|The HP group will be provided with the respective breakfast meals to consume, at home, between 6:00-8:00 am each day over the 4-mo intervention. The energy content of the breakfast meals will be standardized to 350 kcal. The HP breakfasts will be 34% protein (30 g protein), 40% CHO, and 26% fat.
2465905|NCT03133013|Experimental|Individuals with Untreated Depression|32 participants diagnosed with Major Depressive Disorder by a psychiatric specialist of this research according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and defined as a score of 15 or higher on the clinician-administered Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
2465906|NCT03133013|Other|Healthy Participants|32 healthy participants with absence of mental disorders, including but not limited to depression and sleep disorders, by a psychiatric specialist according to MINI screening and Diagnostic and Statistical Manual (DSM-5) criteria, and negative Hamilton Rating Scale for Depression, Beck Depression Inventory, and Patient Health Questionnaire for Depression (PHQ-9). The participants will be attached to the SLEEPSCOPE device.
2465947|NCT03132610|Active Comparator|Experimental group|Conventional Therapy + Xiyanping injection(andrographolide sulfonate)
2465954|NCT03132610|Placebo Comparator|control group|Conventional Therapy + Xiyanping injection simulation/andrographolide sulfonate simulation(0.9% normal saline)
2465995|NCT03132259|Experimental|High dose dexmedethomidine|High dose is 0.5 microgram/kg/hr
2466005|NCT03132259|Experimental|Low dose dexmedethomidine|Low dose is 0.2 microgram/kg/hr
2468522|NCT03114579|Other|Measurement of cardiac output obtained by NEXFIN HD.|
3191555|NCT00799721||2|VLBW infants without erythropoietin therapy.
3191556|NCT00799734|Active Comparator|alternative medicine|Intake of prepacked Chinese herbal medicine (EXD), one sachet of granules (15g extracted granules) twice a day
3191557|NCT00799734|Placebo Comparator|placebo|placebo therapy of 15g granules with similar colour and taste.
3191558|NCT00799747|Experimental|1|AZD4017 in ascending doses (start dose 2mg)
3191559|NCT00799747|Placebo Comparator|2|Placebo
3191560|NCT00799760|Experimental|1|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
3191561|NCT00799760|Active Comparator|2|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 days
3191562|NCT00799760|Active Comparator|3|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
2464977|NCT03139500|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive single oral doses of JNJ-61803534 or placebo in the fasted or fed state.
2464979|NCT03139500|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-61803534 or placebo over a 14-day period.
2464980|NCT03139500|Experimental|Part 3: Drug-drug Interaction (DDI)|Participants will receive single oral doses of midazolam on Day 1 and Day 16 and will receive JNJ-61803534 daily from Day 3 through Day 16 for 14 days at a dose based on the data from the SAD and MAD part.
2465103|NCT03138356|Experimental|Cohort 1 Treatment A|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR (Extended-release) FDC (Fixed-dose combination) tablet administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2465104|NCT03138356|Experimental|Cohort 1 Treatment B|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2465105|NCT03138356|Active Comparator|Cohort 1 Treatment C (Reference product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin XR) co-administered under fasted condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (ABC), (ACB), (BAC), (BCA), (CAB) or (CBA)."
2465106|NCT03138356|Experimental|Cohort 2 Treatment D|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2465107|NCT03138356|Experimental|Cohort 2 Treatment E|"Single-dose of saxagliptin (2.5 mg), dapagliflozin (5 mg), metformin (850 mg) XR FDC tablet, administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2465110|NCT03138356|Active Comparator|Cohort 2 Treatment F (Reference Product)|"Single-dose of Onglyza® (2.5 mg saxagliptin), Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (DEF), (DFE), (EDF), (EFD), (FDE) or (FED)."
2465113|NCT03138356|Experimental|Cohort 3 Treatment G|"Single-dose dapagliflozin (5 mg) / metformin (1000 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
2465115|NCT03138356|Experimental|Cohort 3 Treatment H|"Single-dose dapagliflozin (5 mg) / metformin (850 mg) XR FDC tablet administered orally under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
2465119|NCT03138356|Active Comparator|Cohort 3 Treatment I (Reference Product)|"Single-dose Forxiga® (5 mg dapagliflozin) and Glucophage XR® (2 x 500 mg metformin) co-administered under fed condition. Within each cohort, subjects will be randomized to 1 of 6 treatment sequences, each subject will receive 3 single-dose treatments in either a fasted or fed-state.~The treatment sequences are (GHI), (GIH), (HGI), (HIG), (IHG) or (IGH)."
3174674|NCT00625859|Experimental|Subjects receiving treatment sequence 6|Eligible subjects will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. A= Bupropion SR + GSK189075 placebo, B= Bupropion SR placebo + GSK189075 and C= Bupropion SR + GSK189075
2465331|NCT03136666|Experimental|Nifedipine + Candesartan cilexetil|Coadministration of single doses of nifedipine and candesartan tablets
2465368|NCT03136588|Experimental|ICT based monitoring group|Intervention: In the ICT-based centralized monitoring group, both subjects and medical staff receive feedbacks regarding a missed dose, misuse, and overuse of the medication in the form of text messages and pill box alarms.
2465369|NCT03136588|No Intervention|Control group|Use standard questionnaire to gather information for drug adherence
2465400|NCT03136315|Experimental|INFERNAL Arm|The INFERNAL Arm will have serum and urinary dosage for creatinine and cystanin C at the beginning and at the end of the 110 km race.
2465476|NCT03136133|Active Comparator|Active protein drink|Active protein drink
3174675|NCT00625898|Active Comparator|1A: TCH-H|Docetaxel (T), Carboplatin (C), and Trastuzumab (H) followed by Trastuzumab (H)
3174676|NCT00625898|Experimental|1B: TCHB-HB|Docetaxel (T), Carboplatin (C), Trastuzumab (H), Bevacizumab (B) followed by Trastuzumab (T) and Bevacizumab (B)
3174677|NCT00625898|Active Comparator|2A: TH-FEC-H|Docetaxel (T) and Trastuzumab (H) followed by 5-fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H)
3174678|NCT00625898|Experimental|2B: THB-FEC-HB|Docetaxel (T), Trastuzumab (H), and Bevacizumab (B) followed by 5-Fluorouracil (F), Epirubicin (E), and Cyclophosphamide (C) followed by Trastuzumab (H) and Bevacizumab (B)
3174679|NCT00625911|Active Comparator|morphine only|standard analgesia protocol
3174680|NCT00625911|Experimental|morphine ketamine|alterantive regimen for intravenous patient controlled analgesia
3174681|NCT00625924||1|autogenous tissue breast reconstruction
3174682|NCT00625924||2|tissue expander/implant breast reconstruction
3174683|NCT00625924||3|mastectomy alone
3174684|NCT00625963||I,A|I=Pulmonary Hypertension Patients A=ILD patients with Pulmonary Hypertension Patients
3174685|NCT00625976|Experimental|1|
3174686|NCT00625976|Experimental|2|
3174687|NCT00626002|Experimental|1|
3174688|NCT00626015|Experimental|Arm I|Temozolomide, PEP-3-KLH conjugate vaccine, and daclizumab
3174689|NCT00626015|Experimental|Arm II|Temozolomide, PEP-3-KLH conjugate vaccine, and normal saline
2464984|NCT03139201|Active Comparator|Si-Hy|Si-Hy (olifilcon B) daily disposable
2465030|NCT03138915|Experimental|Single arm study|Patients will receive CTA, HVPG measurement, and rHVPG per protocol. Intervention: Procedure: HVPG measurement
2465089|NCT03138408|Experimental|SC-004|
2465092|NCT03138408|Experimental|SC-004 and ABBV-181|
2465194|NCT03137953|Experimental|Clinical and Imaging|Subjects in this arm would undergo clinical evaluation of skin involvement followed by Radiological Imaging (CT/MRI) based evaluation of the distance between the base of the tumor and the skin. Based on this distance, the skin would either be conserved or not during tumor resection.
2465247|NCT03137420||Severely injured patients and their relatives|Severely injured patients (ISS > 16) and their relatives. Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
2465251|NCT03137420||Monotrauma patients and theri relatives|Patients with isolated non-life threatening musculo-skeletal injuries and their relatives (control). Relatives are defined as on of the following: spouse/partner, son/daughter, parent, sibling, cousin.
2465317|NCT03137043||Severe Asthmatic Subjects|Subjects requiring high dose inhaled corticosteroids (ICS) plus a second controller (and/or systemic glucocorticosteroids) to prevent it from becoming 'uncontrolled' or which remains 'uncontrolled' despite the therapy.
2465318|NCT03137043||Non-Severe Asthmatic Subjects|Subjects with intermittent, persistent mild or moderate asthma.
2465349|NCT03136601|Active Comparator|PTNS monthly|Patients return for PTNS maintenance monthly.
2465352|NCT03136601|Experimental|PTNS as needed|Patients return for PTNS as needed (2-12 weeks).
2465397|NCT03136445|Experimental|Intervention Arm|Tranexamic acid (TXA). Dose schedule TXA 1g every eight hours IV or 1.5g every eight hours PO.
2465405|NCT03136445|Placebo Comparator|Control Arm|Placebo (saline) if administration is IV. Placebo tablet matched for appearance to TXA if oral.
2465495|NCT03135795|Experimental|patients undergoing pancreatectomy|patients undergoing pancreatectomy received dexmedetomidine 1μg/Kg，sufentanil 0.5μg/Kg， propofol 2mg/Kg，rocuronium 0.6mg/Kg for induction.And received sevoflurane(1-2%), remifentanil(0.1-0.2ug/kg/min) and propofol(0.3-0.6mg/kg/h) for maintenance. Parecoxib 40mg was given single intravenously before incision. And PCA with sufentanil 1ug/ml was started immediately after surgery.
2465527|NCT03135405|No Intervention|Usual care|
2465528|NCT03135405|Experimental|Intervention|
2465589|NCT03135236|Experimental|Parent training|All registered participants will participate in a series of trainings (3 separate) on sexuality education.
2465652|NCT03134638|Experimental|Dose Escalation|Dose escalation phase to explore maximum tolerated dose across two dosing schedules. SY-1365 will be administered intravenously weekly and twice-weekly for 3 weeks of each 4-week cycle
2465655|NCT03134638|Experimental|Advanced Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 3 prior lines of therapy (SY-1365 single agent)
2465657|NCT03134638|Experimental|Relapsed Ovarian Cancer|Patients with ovarian cancer previously treated with ≥ 1 prior line of therapy including a platinum-based regimen (SY-1365 + carboplatin)
2465659|NCT03134638|Experimental|Clear Cell Ovarian Cancer|Patients with clear cell ovarian cancer previously treated with ≥ 1 prior line of therapy (SY-1365 single agent)
2465661|NCT03134638|Experimental|Advanced Solid Tumors|Biopsy cohort of approximately 20-30 patients with advanced solid tumors from whom pre- and post-treatment biopsies will be obtained (SY-1365 single agent)
2465663|NCT03134638|Experimental|HR+ breast cancer|Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy (SY-1365 + fulvestrant)
2465699|NCT03134300|Active Comparator|Low SES|
2465705|NCT03134300|Placebo Comparator|Normal/high SES|
2465787|NCT03134079|Active Comparator|full sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2465788|NCT03134079|Experimental|reduced sugar recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2465789|NCT03134079|Experimental|reduced sugar plus spice recipe|"Each subject was randomly assigned to one of six possible sequences to taste three recipes of each test item. Oatmeal and tea were served together and tastings occurred over three weeks; tasting of apple crisp occurred over three different weeks. Tastings of the three recipes occurred one week apart. The three recipes were full sugar recipe (FS), reduced sugar recipe (RS) and reduced sugar plus spice recipe (RSS). Each subject was randomly assigned to one of the below sequence schedules for each taste test whereby A, B, and C refer to one of the three recipes (FS, RS, or RSS):~Sequence 1: A, B, C Sequence 2: A, C, B Sequence 3: B, A, C Sequence 4: B, C, A Sequence 5: C, A, B Sequence 6: C, B, A"
2465840|NCT03133442|No Intervention|Baseline Nights|No vestibular stimulation is applied. However, the sound of the moving bed will be played back to the participant at the right sound intensity level.
2465842|NCT03133442|Experimental|Movement Nights|Vestibular stimulation, in the form of gentle rocking movements, is provided using the Somnomat V4 rocking bed. Stimulation is provided for the entire 7 hours of the night from lights off to lights on. The stimulation frequency is in the range of 0.1-0.3 Hz, with an amplitude in the range of 0.05 to 0.1m
2466044|NCT03131921||Colorectal cancer|No intervention. Patients with newly diagnosed stage II-IV colorectal cancer will be enrolled.
3156493|NCT00345358|Experimental|Synflorix 7-11M Group|This group consisted of subjects 7 to 11 months of age at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose one month later, and a booster dose at 12-15 months of age. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
3174690|NCT00626015|Experimental|Basiliximab|Patients will receive basiliximab 20 mg IV with vaccine # 1 only and continue with PEP-3-KLH, temozolomide.
2465116|NCT03138421|Experimental|ABX-1431 HCl|
2465122|NCT03138421|Placebo Comparator|Placebo|
2465170|NCT03137875||Patient with sputum smear positive 2+|patient who will have a positive diagnostic of tuberculosis using microscopy with a 2+ grade
2465173|NCT03137875||patient smear positive scanty or 1+|patient who will have a positive diagnostic of tuberculosis using microscopy with a scanty or 1+ grade
2465178|NCT03137875||patient smear negative|patient with a negative TB microscopy result
2465275|NCT03137251|Experimental|TENS 1|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 1: Biphasic asymmetric pulse, pulse width of 100 µs and a frequency of 100 Hz. The intensity is individually titrated according to the sensitivity of the parturient."
2465281|NCT03137251|Experimental|TENS 2|"This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour.~Dose TENS 2: Biphasic asymmetric pulse, pulse width of 350 µs and a variable frequency between 80 and 100Hz. The intensity is individually titrated according to the sensitivity of the parturient."
2465288|NCT03137251|Sham Comparator|Placebo TENS|This group will receive TENS continuously for 30 minutes starting at the beginning of the active phase of labour. However, TENS has been modified, so that it emits light and sound but does not transmit electrical current.
2465351|NCT03136809|Experimental|Cu(II)ATSM|Cu(II)ATSM administered once daily
2465399|NCT03136432||Children with cerebral palsy|Children with cerebral palsy, who can walking dependently and continuously for 6 minutes.
2465447|NCT03136081||Septic shock and candidiasis|"The realized analyses will be two types:~1/an immunological analysis that is the characterization of the capacities of defense against germs and 2/a search(research) of Candida by microscopic examination and culture on circles of growth but also the research for the genome of the mushroom by a state-of-the-art technique of the laboratory of mycology ( PCR). Usual takings of research for bacteria."
2465479|NCT03135847|Experimental|Amputee and Able Bodied Subjects|Map the locations in the skin or deeper muscle where limb movement perceptions occur. Use tactors (small robots providing touch and vibration) to mechanically provide sensation to the residual muscles in amputees and the intact muscles in able-bodied. The functional experiments will occur concurrently with development and application of new prosthetic socket designs to incorporate control and feedback.
2465570|NCT03135470||Current practice group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period
2465571|NCT03135470||Standard operating protocol group|All plenipotentiary ambulatory surgery patients, with informed consent, during the three month study period after creating and informing standardized operating protocol
2465573|NCT03135470||Mobile phone app group|All plenipotentiary ambulatory surgery patients during the three month study period with informed consent to use mobile phone app in assesment of pain and pain medication
2465633|NCT03134729|Experimental|Serratus Plane Loco-regional block|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours, and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours~plus~Ropivacaine (30 ml, 0.3%), for Serratus Plane Block"
2465635|NCT03134729|No Intervention|Standard of Care|"Continuous infusion of Tramadol 200 mg or Ketorolac 60 mg~Rescue analgesia with Morphine (0.1 mg/kg) a single time every 24 hours and/or Tramadol 100 mg up to three times every 24 hours and/ or Ketorolac 30 mg up to three times every 24 hours"
2465665|NCT03134495||PPI exposed children|all children with at least one prescription of PPI
2465666|NCT03134495||non-exposed children|all children with no prescription of PPI
2465731|NCT03134339|Experimental|saline 0.00mcg/kg/s|0.00 mcg/kg/s The day order will be randomized per day
2465732|NCT03134339|Experimental|0.24mcg/kg/s|0.24 mcg/kg/s The day order will be randomized per day
2465733|NCT03134339|Experimental|0.048mcg/kg/s|0.048 mcg/kg/s The day order will be randomized per day
2465734|NCT03134339|Experimental|0.024 mcg/kg/s|0.024 mcg/kg/s The day order will be randomized per day
2465786|NCT03133819|Other|Q-Sense_QST (TSA II)|"QST measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.~Using the method of limits, a threshold will determine as the average of four successive stimuli for cold and warmth sensation and two for heat pain."
2465806|NCT03133533|Active Comparator|laparoscopic|laparoscopic inguinal hernia repair
2465813|NCT03133533|Active Comparator|robot-assisted|robot-assisted inguinal hernia repair
2465857|NCT03133234||EGFR T790M Patients|Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
2465909|NCT03132987|Experimental|Progressive strengthening program|Subjects identified as having a clinically relevant strength deficit will be asked to participate in physical therapy sessions 3 times per week for 3 weeks. The strengthening program will consist of an individualized, progressive exercise program with an emphasis on increasing lower extremity strength, power, and biomechanics.
2465960|NCT03132584|Experimental|Cyclophosphamide and Alemtuzumab|"After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have CD52 positive aggressive lymphoma. Not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Cyclophosphamide~Alemtuzumab"
2466003|NCT03132207||Pregnant women|Pregnant women attending hospital during pregnancy monitoring and / or being hospitalized in one of the maternity wards associated with the project.
2466011|NCT03132207||Professional|health professionals in charge of the follow-up of these pregnant women and their childbirth.
3174691|NCT00626041|Other|1|referral to primary care network for management of blood pressure, lipids and diabetes.
2465022|NCT03138746||HBO|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing 100% oxygen
2465023|NCT03138746||Hyperbaric air|On day 2, the participant will undergo a 2-hour hyperbaric exposure breathing air
2465099|NCT03138551|Experimental|Mealtime PREP|"Every participant enrolled in this single-case experimental design trial with multiple replications progressed through three phases.~A: Baseline - typical mealtimes in the home.~B: Parent-Training - parents trained in Mealtime PREP (Promoting Routines of Exploration and Play) intervention.~B-prime: Family Autonomy - parents continue to deliver treatment strategies. Therapist support withdrawn."
2465157|NCT03138031|Experimental|Percutaneous Ethanol Injection (PEI)|"Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of 8 during the procedure. Postprocedure analgesia may be required."
2465192|NCT03137706||Ancillary-correlative (tissue stiffness analysis)|Patients undergo fresh tumor tissue collection at the time of surgery. The fresh tumor tissue samples are analyzed for tissue stiffness measurements using optical polarimeter device and cell viability using automated cell counter.
2465241|NCT03137381|Experimental|CTP-543, 4 mg|Oral tablet, dosed twice-daily
2465243|NCT03137381|Experimental|CTP-543, 8 mg|Oral tablet, dosed twice-daily
2465246|NCT03137381|Experimental|CTP-543, 12 mg|Oral tablet, dosed twice-daily
2465250|NCT03137381|Placebo Comparator|Placebo|Oral tablet, dosed twice daily
2465329|NCT03136978||Endometriosis|Patients affected by endometriosis (histologically confirmed) at different stages, who will undergo laparoscopic surgery.
2465330|NCT03136978||Ovarian functional cysts|Patients affected by ovarian functional cysts, who will undergo laparoscopic surgery.
2465371|NCT03136614|Active Comparator|Preoperative|A single measurement with an Arteriograph is performed a day before an elective surgical intervention.
2465372|NCT03136614|Active Comparator|Intraoperative|An arteriograph is put on the patient for the time of operation. The device is set to measure in every 5 minutes.
2465373|NCT03136614|Active Comparator|Intensive Care Unit|Three separate measurements are performed on the subject with an Arteriograph throughout every dayshift for 3 days.
2465406|NCT03136302||Subthalamic Nucleus (STN)|Patients with Parkinson's disease
2465408|NCT03136302||Globus Pallidus (Gpi)|Patients with Dystonia
2465410|NCT03136302||Ventral intermediate nucleus of the thalamus (VIM)|Patients with Tremor
2465454|NCT03136029|Experimental|Oral AOx|8 week oral antioxidant treatment
2465458|NCT03136029|Placebo Comparator|Oral AOx (placebo)|Placebo for arm 1
2465461|NCT03136029|Experimental|Oral BH4|8 week oral tetrahydrobiopterin treatment
2465464|NCT03136029|Placebo Comparator|Oral BH4 (placebo)|Placebo for arm 3
2465465|NCT03136029|Experimental|Ex training|8-week knee-extensor exercise training program
2465468|NCT03136029|Sham Comparator|Ex training (attn con)|Attention control for arm 5
2465525|NCT03135652|Experimental|chemoradiotherapy|radiotherapy: adjuvant SBRT of liver lesions; chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
2465526|NCT03135652|Active Comparator|chemotherapy|chemotherapy: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
2465586|NCT03135249|Other|Alemtuzumab treatment.|"Patients with relapsing-remitting multiple sclerosis previously treated with natalizumab, the following treatment arms with alemtuzumab will be implemented:~Year One: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for five days to be given within eight hours after dilution.~Year Two: Alemtuzumab 12 mg (1.2 ml) IV Infusion via pump over a minimum of four hours daily for three days to be given within eight hours after dilution."
2465620|NCT03134872|Experimental|SHR-1210+Chemotherapy|Subjects receive SHR-1210 200mg and pemetrexed 500 mg/m^2 and carboplatin AUC 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional SHR-1210 200mg and pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
2465621|NCT03134872|Active Comparator|Chemotherapy|Subjects receive pemetrexed 500 mg/m^2 and carboplatin Area Under the Curve (AUC) 5, administered as IV infusion on Day 1 of each 21-day cycle for 4-6 cycles followed by optional pemetrexed 500 mg/m^2 every three weeks (Q3W) maintenance for the remainder of the study or until documented PD. If PD occurs, Subjects may be able to receive SHR-1210 Q3W for the remainder of the study or until documented PD.
3191563|NCT00799799|Experimental|NK|patient treated as per protocol
3191564|NCT00799838|Experimental|Ketoprofen + Amoxicillin|Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
3191565|NCT00799838|Placebo Comparator|Amoxicillin|Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days
2465914|NCT03133299|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
2465919|NCT03133299|Experimental|Vitamin D plus Glucocorticoid group|Oral vitamin D3 tablet, 60,000 IU weekly for 2 months (8 doses) along with Oral prednisolone 0.5 mg/kg/day for four weeks, 0.25 mg/kg/day for four weeks followed by 0.125 mg/kg/day for four weeks. Prednisolone will then be tapered by 5 mg every two weeks and discontinued. The total duration of glucocorticoids will be four months
2465977|NCT03132441|Experimental|Cardiac Rehabilitation|"Strength Training for Frailty:~All patients enrolled will be enrolled in 6 weeks of cardiac rehabilitation for the pilot study."
2466041|NCT03132051|Experimental|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
2466126|NCT03131544|Experimental|FLA for BPH Active Treatment|
2466203|NCT03130933|Active Comparator|The second tested subgroup|The tested subgroup from the main group with prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery .
2465067|NCT03138525||Multiple Sclerosis|Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab
2465068|NCT03138525||Healthy|Healthy individuals serving as controls to the subjects with MS
2465135|NCT03138239|Experimental|16 patients diagnosed with HCC|"12 patients will be tested at the stage of diagnosis (staging)~4 patients who have tested at staging, will be tested again after treatment.~4 patients with treatment failure or recurrence."
2465177|NCT03137914|Experimental|autologous chondrocyte transplantation|Autologous transplant of chondrocytes diluted in hyaluronic acid after orthognathic surgery. The transplantation will be performed through an intra-articular injection into the TMJ (arthrocentesis). Hyaluronic acid is used only as a soluble medium to dilute the chondrocytes, so it is not considered as another experimental group, or as part of interest in this investigation.
2465262|NCT03137511|Experimental|Intervention group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~The MG collects relevant clinical information~The MG takes 2 photographs of the lesion with his smartphone.~The MG sends to the dermatologist by e-mail the 2 photographs of the lesion accompanied by relevant clinical information~The MG calls the secretariat of the dermatologist to record the admissibility of the mail, to give the identity and the coordinates of the patient whose photos have just been sent and to obtain an appointment.~The dermatologist proposes an appointment to the patient."
2465270|NCT03137511|No Intervention|Control group|"General practitioners will be invited to screen for melanoma as part of their regular consultations.~General practitioners and dermatologists continue their practice in the usual way."
2465341|NCT03136991|Active Comparator|Cohort 1|Participants will receive AZD4831 5 mg/placebo oral suspension.
2465342|NCT03136991|Active Comparator|Cohort 2|Participants will receive AZD4831 (Additional dose 1)/placebo oral suspension.
2465344|NCT03136991|Active Comparator|Cohort 3|Participants will receive AZD4831 (Additional dose 2)/placebo oral suspension.
2465345|NCT03136991|Active Comparator|Cohort 4|Participants will receive AZD4831 (Additional dose 3)/placebo oral suspension.
3191566|NCT00799851|Active Comparator|Variceal band ligation|VBL was performed with a multiband ligation device (Euroligator System®). The first band was placed at or close to the gastroesophageal junction, with subsequent bands being placed proximally in a slightly spiral pattern. All visible varices within the distal esophagus were treated, with a maximum of 10 bands being placed in each session. There was a 3-week interval between each treatment session. When VBL was technically impossible due to scarring, sclerotherapy with ethanolamine oleate was performed on thin vessels.
2465492|NCT03135873|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at a daily dosage of 2.1 g for a 6 month period.
2465494|NCT03135873|Placebo Comparator|Placebo|This arm of patients will receive placebo for a 6 month period.
3191567|NCT00799851|Active Comparator|cyanoacrylate injection|"CI group received intravariceal injections of 0.5 ml of N-butyl-2-cyanoacrylate (Histoacryl®) diluted in 0.5 ml of Lipiodol (Lipiodol®). Before injection of the Histoacryl-Lipiodol mixture, the catheter was filled up with 1 ml of Lipiodol. After puncturing the EV, the mixture was injected inside it and followed by injection of 1 ml of distilled water. Finally the catheter was retracted. To minimize the risk of embolism, a maximum of two medium or large vessels, in opposite walls, were treated in each session and not more than 0.5 ml of Histoacryl® was injected into each vessel.~A second injection was performed in any EV that maintained blood flow (medium or large size, blue, depressive at palpation with the catheter), in a bi-weekly interval basis. A chest x-ray was performed to evaluate the location of the Histoacryl-Lipiodol solution. Small vessels were treated with ethanolamine oleate sclerotherapy."
3191568|NCT00799864|Experimental|Rilpivirine (TMC278)|The patients received rilpivirine with 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as a background regimen in cohort 1 [aged greater than or equal to (> =) 12 to less than (<) 18 years] for up to 240 weeks which is already completed and recruitment closed and will receive this treatment in cohort 2 (children aged > = 6 to < 12 years) for up to 48 weeks. The NRTIs include zidovudine, abacavir, or tenofovir disoproxil fumarate in combination with lamivudine or emtricitabine.
2465675|NCT03134586|Other|trial participant|All participants undergoes the same diagnostic imaging
2465740|NCT03134196|Placebo Comparator|Placebo|Encapsulated masked placebo
2465741|NCT03134196|Active Comparator|Masked Oral Valacyclovir 1000 mg daily|Valacyclovir, 500 mg, oral pill, two 500mg pills daily
2465916|NCT03132922|Experimental|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|
2465925|NCT03132922|Experimental|Radiation Sub-Study: Autologous genetically modified MAGE-A4c1|
2466118|NCT03131518|Other|E-bicycle|Access to an e-bicycle will be provided.
2466127|NCT03131518|Other|Longtail bicycle|Access to a longtail bicycle will be provided.
2465117|NCT03138070|Experimental|Arm 1|14 days of BYL719 treatment, open label
2465164|NCT03137927|Experimental|Group 1 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 2,5*10*8 bacteria cells (CFU)
2465167|NCT03137927|Placebo Comparator|Group 1 placebo|3 individuals will get placebo
2465172|NCT03137927|Experimental|Group 2 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 10*9 bacteria cells(CFU)
2465181|NCT03137927|Placebo Comparator|Group 2 placebo|3 individuals will get placebo
2465184|NCT03137927|Experimental|Group 3 Vaccine GamLPV|9 individuals will be vaccinated intranasally with 4*10*9 bacteria cells(CFU)
2465185|NCT03137927|Placebo Comparator|Group 3 placebo|3 individuals will get placebo
3191570|NCT00799890|Experimental|Sunphenon|
2465402|NCT03136224|Experimental|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medikal, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
2465407|NCT03136224|Active Comparator|Plastic Clamping|Alisklamp (Alisklamp, Abagrup Health Services Ltd, Ankara, Turkey) was used in the plastic clamp technique. The clamp size was chosen according to the diameter of the penis of the patient. The clamp was inserted into the glans and then the skin and the mucosa were pulled to the appropriate size and clamped. The skin and mucosa were excised from the distal part of the clamp with the aid of a lancet. After the operation, the clamp was removed on the 4th day
2465409|NCT03136224|Sham Comparator|Surgical Circumcision|In classical surgical circumcision, foreskin was hung up with the clamp. The outer skin and secondly the mucosa was cut by using scissors. Following the hemorrhage intervention, the skin-mucosa integrity was sutured by using the 5/0 absorbable suture. Medical dressing was done.
2465460|NCT03135925|Other|Intervention|Exercise program
2465503|NCT03135769|Experimental|Avelumab|Avelumab administration at 10 mg/kg every 14 days during 6 months maximum
3191571|NCT00799890|Placebo Comparator|Placebo|
3191572|NCT00799916|Active Comparator|Voluven|Resuscitation fluid: Voluven (R)
3191573|NCT00799916|Active Comparator|Saline|Resuscitation fluid: Saline solution
3191574|NCT00799929|Active Comparator|ARM A - Mini IVF|The Mini IVF method entails pre-treatment with oral contraceptive pills. Ovarian stimulation is achieved using an oral anti-estrogen in conjunction with injections of gonadotropin (225IU-600IU per cycle), with initial dose of 75IU-150IU per injection. Ovulation is induced by a GnRH (gonadotropin-releasing hormone) agonist nasal spray/hCG (human chorionic gonadotropin) injection. Retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. Blastocyst stage embryos are vitrified using the CryoTop method. No fresh embryo transfer is conducted. Subsequently, SET of a thawed blastocyst is performed in a natural cycle/HRT that does not involve ovarian stimulation. SETs are conducted until pregnancy is achieved or all vitrified blastocysts have been used.
2465810|NCT03133741|Placebo Comparator|Placebo|Saline
2465815|NCT03133741|Other|GIP-A|Infusion of GIP-A alone as study tool.
2465818|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
2465821|NCT03133741|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
2465886|NCT03133156|Experimental|Moderate Intensity Training-Healthy Lean|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2465887|NCT03133156|Experimental|Moderate Intensity Training-Healthy Overweight/Obese|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2465888|NCT03133156|Experimental|Moderate Intensity Training-Overweight/Obese Type 2 Diabetes|Eligible subjects will undergo a 10-week moderate intensity exercise program.
2465890|NCT03133156|Experimental|High Intensity Training-Healthy Lean.|Eligible subjects will undergo a 10-week high intensity exercise program
2465958|NCT03132727||Pharyngo laryngeal MRI|Patient with a laryngeal or hypopharyngeal cancer at any stage, with a doubt about cartilage invasion and eligible for surgical treatment for which there is an indication for performing an MRI in addition to CT at the discretion of the investigator
2465993|NCT03132311|Experimental|HIV positive subjects|"300 HIV positive adults with CD4 > 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, >500 cells/mm3).~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
2465997|NCT03132311|Active Comparator|HIV negative subjects|"100 HIV negative adults.~Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)"
2466186|NCT03131128|Experimental|Mindfulness-based Intervention|2 sessions of diet nutrition education and 6 sessions of Mindfulness-based intervention, 1.5 hours each session.
2466190|NCT03131128|Active Comparator|Health Education Intervention|2 sessions of diet nutrition education and 6 sessions of Health Education, 1.5 hours each session.
2466237|NCT03130842|Active Comparator|Sublingual alprazolam|
2466244|NCT03130842|Active Comparator|Oral midazolam|
2466259|NCT03130504|Active Comparator|17α hydroxy progesterone caproate group|
2466261|NCT03130504|No Intervention|No intervention group|
2466300|NCT03130400||Normal|This group is control group. Participants in this group do not have knee diseases or any other bad injuries in lower limbs.
2466301|NCT03130400||KOA|Participants in this group have knee osteoarthritis and have no other bad injuries in lower limbs.
2466302|NCT03130400||ACLD|Participants in this group have anterior cruciate ligament deficiency with or without meniscus deficiency and have no other bad injuries in lower limbs.
2466303|NCT03130400||MD|Participants in this group have meniscus deficiency and have no other bad injuries in lower limbs.
3156494|NCT00345358|Experimental|Synflorix 12-23M Group|This group consisted of subjects 12 to 23 months inclusive at first vaccination who received 2 doses of Synflorix™, one first dose at enrolment followed by a second dose 2 months later. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
3174692|NCT00626054|Active Comparator|1|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
2465413|NCT03136172||Premature infant|premature infants with 32 weeks or less gestational age or 1,500 g or less birth weight, who born in the Inha university hospital and admit to the neonatal intensive care unit of the Inha university hospital
2465481|NCT03135990|Experimental|CBT + VR|Cognitive Behavioral Therapy with Virtual Reality technology.
2465522|NCT03135613|Experimental|Normal|Participants of this group are as controls.
2465524|NCT03135613|Experimental|MF|Participants of this group are patients with tumor around knee after microwave ablation with plate internal fixation.
2465577|NCT03135275|Active Comparator|Staged complete PCI|Patients randomized to staged complete PCI will have treated during the index admission only the culprit lesion and they will be hospitalized after 19-45 days, to complete the coronary revascularization on all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
2465578|NCT03135275|Experimental|Immediate complete PCI|Patients randomized to immediate complete PCI will have treated immediately after the revascularization of the culprit lesion during the index procedure all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
2465695|NCT03134846|Experimental|Phase 1: 10mg Cetuximab-IRDye800CW|Three patients will receive 10mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2465697|NCT03134846|Experimental|Phase 1: 25mg Cetuximab-IRDye800CW|Patients will receive 25mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2465707|NCT03134846|Experimental|Phase 1: 50 mg Cetuximab-IRDye800CW|Patients will receive 50mg Cetuximab-IRDye800cv I.V. four days prior to surgery.
2465711|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 15 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 15 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
2465712|NCT03134846|Experimental|Phase 1: 75mg cetuximab + 25 mg Cetuximab-IRDye800CW|Patients will receive 75mg cetuximab + 25 mg Cetuximab-IRDye800CW I.V. four days prior to surgery.
2465713|NCT03134846|Experimental|After having established the optimal cetuximab-IRDye800CW dose|After having established the optimal cetuximab-IRDye800CW dose we will extent the study by including up to 70 patients for this specific dose (as determined in phase 1).
2465804|NCT03133754|Experimental|DP-PEEP|recruitment maneuver + individualized PEEP
2465807|NCT03133754|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
2465854|NCT03133260||Non cardiac surgery|Determine perioperative troponin to diagnose perioperative MINS. In case of MINS acetylsalicylic acid and statins will be started if no contraindication. We will follow-up these patients for a year (including cardiologic evaluation after discharge)
2465902|NCT03132974|Experimental|SGHH|Admission to Sogyeonghwalhyeol-tang granule
2465903|NCT03132974|Experimental|SGHH with manipulation therapy|Admission to Sogyeonghwalhyeol-tang granule and manipulation therapy
2465904|NCT03132974|Placebo Comparator|Placebo with manipulation therapy|
2465950|NCT03132636|Experimental|Group 1- metastatic BCC|Administration of cemiplimab in accordance with protocol dosing regimen
2465955|NCT03132636|Experimental|Group 2 - unresectable locally advanced BCC|Administration of cemiplimab in accordance with protocol dosing regimen
2466023|NCT03132103|Experimental|Solar simulated radiation (SSR)|Solar simulated radiation (SSR)
2466026|NCT03132103|Placebo Comparator|Placebo SSR|Placebo SSR
2466027|NCT03132103|Experimental|Oral Vitamin D3|Oral Vitamin D3
2466031|NCT03132103|Placebo Comparator|Placebo Oral Vitamin D3|Placebo Oral Vitamin D3
2466109|NCT03131583|Experimental|Cohort 1|Colchicine 0.5 mg Oral Tablet Day-14~Day16 qd, Febuxostat 80 mg Oral Tablet Day1 and Day8 qd, SHR4640 10 mg Oral Tablet Day3~Day8 qd.
2466193|NCT03131102||Patients with epithelial ovarian cancer (EOC)|Patients undergoing cytoreductive surgery due to epithelial ovarian cancer
2466198|NCT03131102||Subgroup - Metabolomics in EOC patients without ascites|In a subgroup (n=10), patients without preoperative ascites will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
2466202|NCT03131102||Subgroup - Metabolomics in EOC patients with ascites >500ml|In a subgroup (n=10), patients with preoperative ascites >500ml will undergo extended metabolic measures to investigate mitochondrial dysfunction during the preoperative period.
2466240|NCT03130790|Experimental|Varlititib+mFOLFOX6|
2466246|NCT03130790|Placebo Comparator|Placebo+mFOLFOX6|
2466291|NCT03130413|Experimental|Ambu Aura Gain|Ambu Aura Gain supraglottic airway size 2 or 2.5 will be inserted once patients are paralyzed
2466296|NCT03130413|Active Comparator|Air-Q|Air-Q supraglottic airway size 1.5 and 2.0will be inserted once the patients are paralyzed
2466336|NCT03130127|Experimental|Continuous infusion of terlipressin|In our clinical practice, continuous infusion of terlipressin is being employed.
2466340|NCT03130127|Active Comparator|Bolus infusion of terlipressin|Traditionally, a bolus infusion of terlipressin is recommended.
2466436|NCT03129217||Patients weaning from mechanical ventilation|
2466522|NCT03128736|Experimental|dexlansoprazole group|dexlansoprazole 60mg
2466526|NCT03128736|Experimental|esomeprazole group|esomeprazole 40mg
2466592|NCT03128294||long-term survivors of ovarian cancer|long-term survivors of ovarian cancer
2466614|NCT03127995|Experimental|HYPOFRACTIONATED|"40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 40 Gy to CTV breast in 15 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 42.3 Gy on CTV breast and 52.2 Gy on CTV boost in 18 fractions"
2466620|NCT03127995|Other|NORMOFRACTIONATED|"50 Gy / 25 fractions, 2.0 Gy per fraction, 5 fractions per week.~If the patient is candidate for a boost it will be provided as follows:~sequential boost with 50 Gy to CTV breast in 25 fractions and 16 Gy to CTV boost in 8 fractions~or simultaneous integrated boost (SIB) with 51.52 Gy on CTV breast and 63 Gy on CTV boost in 28 fractions"
2465142|NCT03138434||Study phase|"This phase will commence after the optimization phase. This phase is where we want to assess the feasibility, reproducibility and association with disease severity between MRI parameters and AAA.~These twenty patients will be scanned twice, with an interval of 1 week ± 5 days.~The study will be completed when we have 20 patients with 2 scans for each sequence, or when a maximum number of 30 patients in the study phase have been scanned."
2465158|NCT03137862|Placebo Comparator|Arm A comparator|Arm A: patients will maintain a commercially available gluten free diet and receive bread containing 3 gr of cornstarch daily for 12 weeks; these patients will serve as controls.
2465159|NCT03137862|Experimental|Arm B|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 3 gr of gluten friendly bread daily for 12 weeks."
2465160|NCT03137862|Experimental|Arm C|"Dietary supplement: patients will be have to continue the gluten free diet supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
2465236|NCT03137602|Other|ATOMIC mobile app|The proposed ATOMIC intervention consists of four primary components: (a) one-on-one chats with a PA coach, (b) informational posts, (c) PA self-monitoring through an activity tracker and (d) educational modules regarding different aspects of becoming PA delivered through our MS specific PA app.
3156495|NCT00345358|Experimental|Synflorix >=24M Group|This group consisted of subjects aged between 24 months (inclusive) to 5 years (inclusive) at vaccination who received one dose of Synflorix™. The Synflorix™ vaccine was administrated intramuscularly in the right thigh or deltoid region (deltoid region only for children >12 months of age if muscle size was adequate).
2465688|NCT03134378|Experimental|14 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
2465693|NCT03134378|Placebo Comparator|10 days triple therapy|Rabeprazole Clarithromycin Amoxicillin
2465781|NCT03134001|Experimental|Test Group|Patients receiving oral analgesics via the PCoA™ Acute device
2465783|NCT03134001|No Intervention|Control Group|Patients receiving oral analgesics by nurse, upon request
2465822|NCT03133559||Cohort 1|Patients infected with HIV off antiretroviral therapy
2465823|NCT03133559||Cohort 2|Patients infected with HIV experiencing virologic control, but with blunted immunologic recovery
2465826|NCT03133559||Cohort 3|Matched healthy volunteers
2465920|NCT03133182||Polypharmacy|People taking >=5 unique prescription drugs in the 3 months prior to surgery
2465927|NCT03133182||No polypharmacy|People taking <5 unique prescription drugs in the 3 months prior to surgery
3156496|NCT00345475||AED treatment|Women being treated with UCB AEDs while pregnant.
3156497|NCT00345501|Experimental|1|Iloprost
3156498|NCT00345501|Placebo Comparator|2|Placebo
2466047|NCT03131752|Experimental|Intervention Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~The intervention will last 7 days for all the patients. Three phases will be performed: warm up, knee muscle strengthening with elastic bands and stretch/relax."
2466051|NCT03131752|No Intervention|Control Group|"The patients will be evaluated on 4 phases: at the first contact (at least 24 hours after drug therapy and at most 48 hours), 7 days, 30 days and 3 months after the first contact. They will be submitted to an anamnesis, assessment of muscular strength, physical activity level, functional capacity, dyspnea on activity daily living and quality of life.~Patients will be not receive intervention."
2466187|NCT03131115|Active Comparator|Lateral Crural Strut Graft|Lateral crura strut graft is a well described and universally used technique involves strengthening lateral crus of lower lateral cartilage of the nose with piece of cartilage.
2466189|NCT03131115|Active Comparator|Bone-Anchored suspension|Bone- Anchored suspension is a well described surgical technique which involves anchoring the nasal sidewall to the bony rim below the eye.
2466236|NCT03130803|No Intervention|Baseline|9 hour sleep opportunity at habitual sleep/wake times for 14 days at home and 1 day in lab repeated for visit 1 and visit 2
2466242|NCT03130803|Experimental|Insufficient Sleep|2 days with 5 hour sleep opportunities immediately following baseline on both visit 1 and visit 2.
2466295|NCT03130517|Other|Intervention group|Use of single dose of intravenous immunoglobulin in a dose 0.5_1gm /kg to intervention group
2466298|NCT03130517|Other|Control group|Control group will recieve phototherapy only
2466313|NCT03130140|Active Comparator|Macroscopic on-site evaluation|EUS-FNA perform with a 19-gauge needle with macroscopic on-site evaluation.
2466314|NCT03130140|Sham Comparator|Control|EUS-FNA perform with a 19-gauge needle with conventional techniques.
2466364|NCT03129932|Active Comparator|gluten phase|volunteers will receive 2 corn muffins containing12g of gluten/muffin to be consumed daily for 4 weeks
2466368|NCT03129932|Placebo Comparator|Placebo phase|volunteers will receive 2 corn muffins without gluten/muffin to be consumed daily for 4 weeks
2466417|NCT03129490|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466421|NCT03129490|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466425|NCT03129490|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
3156499|NCT00345514|No Intervention|1|
3156500|NCT00345514|Active Comparator|2|
3156501|NCT00345514|Active Comparator|3|
3156502|NCT00345553||1|Biliary atresia subjects who have their native liver
3156503|NCT00345553||2|Biliary atresia subjects who have had a liver transplant
3156504|NCT00345618|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 3 or 6 months depending on the stratum, after enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
3191575|NCT00799929|Active Comparator|Arm B - Conventional IVF|The standard IVF method entails pre-treatment with a GnRH analog injections in the midluteal phase. Controlled ovarian hyperstimulation is achieved with injections of gonadotropin (150IU-300IU/day). Ovulation is induced by hCG injection and retrieved oocytes following in vitro fertilization (IVF/ICSI) are cultured to the blastocyst stage. If this occurs on day 5, then fresh SET/DET (single embryo transfer/double embryo transfer) is performed. Remaining blastocysts are cryopreserved and transferred in subsequent natural cycles/HRT (hormone replacement therapy) that does not involve ovarian stimulation.
3191576|NCT00799955|Placebo Comparator|1|Subjects will receive 100 micrograms of spinal morphine, at the time of spinal needle insertion (standard care at BCW). At the end of the case, one of two investigators, using ultrasound, will visualize the transversus abdominis plane. A capped needle will be pushed against the skin to mimic the pressure sensation of the TAP block. The needle will not break the skin and nothing will be injected in this control group. The procedure will then be repeated on the other side. A dressing will be applied on each side to blind the subject and researcher to which group she is in.
2465404|NCT03136185|Experimental|IMG-7289|Single starting dose with individualized dose titrations throughout
2465451|NCT03135977|Experimental|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
2465567|NCT03135444|Experimental|Provider Field Test|15 providers will be given an initial version of the PSA TOOL, over a 4 week period, they will be able to provide feedback on the tool. This will be used to revise the screening decision aid. Informal interviews with providers will also be conducted by a member of the study team to obtain feedback about ease of use and usefulness of the tool.
2465568|NCT03135444|Experimental|Patient test of revised PSA TOOL|150 patients will be asked to use the revised PSA TOOL. Pre- and Post-tests will be given to see if the tool changed the knowledge that patients have an option to be screened for prostate cancer and of specific factors to be considered in the screening decision. Informal interviews with patients who are exposed to the tool will also be conducted by a member of the study team to obtain feedback on issues addressed by the survey questions.
2465601|NCT03134950|Experimental|ADAPT|Aim to Decrease Anxiety and Pain Treatment (ADAPT) is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions are in person with a trained psychologist and the following 2-4 sessions are web-based. Each web-based session is followed by phone support.
2465605|NCT03134950|No Intervention|Medical Treatment as Usual|Medical treatment as usual
2465831|NCT03133689||EPIC-Norfolk|This cohort comprises 25,636 residents of a predefined English healthcare region (11,606 men and 14,030 women). Participants in this cohort study were originally recruited from 35 general practices in Norfolk, England as part of an investigation into diet and cancer, but the study's scope was subsequently widened to include additional outcomes including cardiovascular diseases.
2465836|NCT03133689||GAZEL|This cohort comprises 20,625 employees of French gas and electricity companies (15,011 men and 5,614 women). The cohort commenced data collection in 1989 and follow-up assessments were subsequently completed on an annual basis. The data have undergone linkage to national health administrative datasets.
2465839|NCT03133689||NSHD|This dataset comes from the 1946 National Birth Cohort study, which comprises all persons born in England, Scotland and Wales in one week in March 1946. The cohort comprises 5,362 individuals (2,815 men and 2,547 women). Data have been collected from participants on a regular basis throughout their life, including information on lifestyle and, in combination with administrative datasets, on health outcomes.
2465841|NCT03133689||Twenty-07-1930s|This cohort comprises 1,551 Scottish participants (702 men and 849 women) born around 1932 who were recruited in 1986 as part of a study of health inequalities. The repeated nature of the data collection will enable identification of longitudinal alcohol intake patterns, while linkage to Scottish health system records will enable identification of coronary heart disease onset.
2465843|NCT03133689||Twenty-07-1950s|This cohort comprises 1,444 Scottish participants (656 men and 788 women) born around 1952 who were recruited in 1986, alongside the T-07-1930s' cohort, as part of a study of health inequalities. Participant health was tracked through linkage with national health records.
2465846|NCT03133689||Whitehall II|This cohort comprises 10,308 British civil servants (6,895 men and 3,413 women). The cohort study commenced data collection in 1985 and participants have since undergone questionnaire and clinical assessments across regular intervals. Additional tracking of health outcomes has been performed through linkage with administrative databases. Demographic, behavioural and clinical data will be sourced from this cohort for the purposes of the current study.
2465872|NCT03133091|Active Comparator|PIEB (Patient Intermittent Epidural Bolus)|"PIEB: The boluses are programmed every 30 minutes. The patient can ask for another extra bolus in between if she wishes.~The dosis per hour are equivalent to the PCEA. We make a comparison between PCEA vs PIEB."
2465877|NCT03133091|Active Comparator|PCEA (Patient continuous Epidural Analgesia)|"PCEA: There is a continuous infusion and the patient can order extra boluses every 15 minutes.~The dosis per hour are equivalent to the other arm to the PIEB. We make a comparison between PCEA vs PIEB."
2466035|NCT03132064||post total knee arthroplasty|The measurements will made for patients before and after total knee arthroplasty to explore the improvements and possible correlation with preoperative pain psychology and hypersensitivity
2466070|NCT03131661||SpA with DMARDs|Participants with first diagnosis or confirmed diagnosis of Spondyloarthritis (SpA) and naïve to conventional, targeted or biological Disease modifying anti-rheumatic drugs (DMARDs) will be observed in order to describe SpA characteristics and pattern of clinical presentation.
2466120|NCT03131297|Experimental|Anal fistula treated by radiofrequency|treatment by radiofrequency: patient with anal fistula treated by radiofrequency
2466230|NCT03130985||Cardiac surgery patients|The study cohort will comprise of patients without a history of AF that undergo cardiac surgery (CABG or mitral valve surgery) with increased CHADSVASC scores of ≥2.
2466325|NCT03130231||POD group|POD group refers to the patients who were diagnosed to be delirious by the Confusion Assessment Method.
2465204|NCT03137589|No Intervention|Control|Patients of this group are routinely treated without telemedical support.
2465206|NCT03137589|Active Comparator|Telemedical support|Patients of this group are routinely treated with telemedical support.
2465258|NCT03137368|Experimental|treatment group|Exemestane Tablets combined with ovarian function suppression/ablation
2465266|NCT03137368|Active Comparator|control group|Tamoxifen Tablets combined with ovarian function suppression/ablation
2465347|NCT03136874||Donors who procreated|
2465350|NCT03136874||Donors who don't procreated|
2465390|NCT03136276|Active Comparator|IPS Empress CAD|Leucite Based glass Ceramics which is etchable ceramics and proved to have good success rate if used for laminate veneers
2465393|NCT03136276|Experimental|polished Celtra Duo|Zirconia reinforced lithium silicate, it is a recent material with glass ceramics enriched with 10% zirconia that offers high strength properties
2465498|NCT03136120||Subjects with suspected fibrotic ILD|Eligible subjects will receive nebulized ipratropium bromide 500 mcg for 10 minutes. The subjects will be sedated for bronchoscopic procedure as per routine practice for subjects having bronchoscopy. Cryobiopsy samples for this study will be taken after samples required for diagnosis has been taken and it is safe to do so. One to three endobronchial forceps biopsy samples will be taken from up to 5 subjects to allow comparison of proximal and distal drug distribution.
2465582|NCT03135093||Stroke subjects|
2465585|NCT03135093||Healthy subjects|
2465775|NCT03133949||Patients with idiopathic inflammatory aortitis|
2465778|NCT03133949||a group of witnesses|
2465862|NCT03133546|Experimental|Osimertinib plus Bevacizumab|Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
2465863|NCT03133546|Active Comparator|Osimertinib alone|Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.
2465948|NCT03132792|Experimental|Autologous genetically modified AFPᶜ³³²T cells|
3156505|NCT00345618|Active Comparator|Warfarin|"Warfarin, INR-adjusted dose, started 24 hours after the start of enoxaparin, 1.0 mg/kg, every 12 hours for at least 5 days, and continued for 3 or 6 months depending on the stratum.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or over-dosage)."
2466039|NCT03131804|Experimental|Interventional Participants|Patients will represent their own controls (pre and post intervention), in the HD unit of Al Qassimi Hospital, Sharjah, United Arab Emirates.
3156506|NCT00345644|Experimental|1|
3156507|NCT00345644|Placebo Comparator|2|
2466107|NCT03131271|Experimental|Experimental Group|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter. Immediately after its removal, the responsible nurse removed the catheter. A neutral instruction set was used on each patient prior to application of the ice pack. Patients in the experimental group were told that they may or may not experience pain during the catheter removal. The patients were also told that the aim of the study was to measure the effect of ice bag application upon pain during catheter removal, and that ice pack application may or may not be effective in terms of their own pain.
2466108|NCT03131271|No Intervention|Control Group|The control group received the standard clinic procedure in that the catheter was removed by the assigned nurse without any cold application to the femoral region. Each control patient was informed that some patients may experience pain during catheter removal, and that they may or may not experience pain. Patients were also told that their pain levels would be measured during catheter removal.
2466205|NCT03131180|Experimental|RLHS dashboard|Patients randomized to RLHS website access are given instructions on how the RLHS dashboard works both by phone and by email and are given open access to the RLHS dashboard website immediately after enrollment and before meeting with the CCPR clinical team for their consultation. Each user has an access code, which allows them to track their access. They maintain access to the website throughout their care in the CCPR. Patients in the RLHS access group complete the System Usability Scale (SUS; a 10 item questionnaire to evaluate software, websites, and applications) after use of the RLHS at consultation. Those in the RLHS access group also complete a 7-item exit interview either via phone or on REDCap.
2466210|NCT03131180|No Intervention|Standard consultation alone|Those not randomized to RLHS access undergo standard consultation only.
2466429|NCT03129399|Experimental|King Vision video laryngoscope|
2466434|NCT03129399|Active Comparator|McGrath MAC video laryngoscope|
2466497|NCT03128970|No Intervention|frozen/thawed|blastocysts with three or less grade of expansion will be thawed and then subsequently transferred into women uterus three hours post-thawing.
2466498|NCT03128970|Experimental|synchronized frozen/thawed hatching blastocysts|blastocyst thawing (with three or less grade of expansion) will take place the day before embryo transfer in order to reach hatching stage
3156508|NCT00345670|Experimental|1|MEDI-534
3156509|NCT00345670|Experimental|2|MEDI-534
3156510|NCT00345670|Experimental|3|MEDI-534
3156511|NCT00345709||National Research Registry Enrollment|Patient, living or deceased, with a pathologically-confirmed diagnosis of Ovarian Cancer.
3156512|NCT00345748|Active Comparator|Abatacept 2 mg/kg|
3156513|NCT00345748|Active Comparator|Abatacept 10 mg/kg|
3156514|NCT00345748|Placebo Comparator|Placebo|
3156515|NCT00345761|Experimental|Step 1|
3156516|NCT00345761|Experimental|Step 2|
3156517|NCT00345761|Experimental|Step 3|
3156518|NCT00345787|Placebo Comparator|0|
3156519|NCT00345787|Experimental|1|
3156520|NCT00345800|Experimental|Sodium Oxybate|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
3156521|NCT00345813|Experimental|Arm I|Patients receive oral soy supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of soy supplementation.
2465223|NCT03137615||Pituitary Surgery|"Patients having pituitary gland surgery~Inclusion criteria - Any adult patient undergoing trans-sphenoidal pituitary surgery.~Exclusion criteria - Under 16 years of age, pregnancy, uncontrolled hypertension, allergy to any local anaesthetic, patient refusal or revision pituitary surgery"
2465238|NCT03137329|Other|Weight Loss Surgery (WLS) Arm|Subjects enrolled in the WLS arm will undergo WLS as part of the routine care provided by the respective WLS centers. During routine care patients typically meet with their dietician at least twice prior to WLS and are placed on a higher protein meal replacement supplement and calorie controlled diet. For weeks 1-52, the investigators will ensure that patients are receiving 1500mg of elemental calcium and 3000 IU of vitamin D based on recent best practice guidelines. In addition, participants will complete an individualized pragmatic exercise program for the first 52 weeks after surgery. Patients will begin the program after receiving clearance from their surgeon. Patients will meet with a physical therapist at BIDMC for individual sessions.
2465240|NCT03137329|Other|Lifestyle Arm|Subjects enrolled in the lifestyle group will be prescribed a balanced high protein diet (1g high quality protein/kg body weight/day) that provides an energy deficit of 500 to 750 kcal /day from their daily energy requirements[58] and prescribed a weight loss goal of 10% over the course of 6 months. Participants will meet with a trained dietician/nutritionist at the BIDMC General Clinical Research Unit. The investigators will incorporate the HMR (Health Management Resources) high protein meal replacement supplements into participants' diet regimen for the first 24 weeks. In addition, participants will complete a comparable 52-week exercise program consisting of an individualized pragmatic exercise program.
2465294|NCT03137095||Breast Cancer Patient Participants|Female breast cancer patients receiving chemotherapy
2465297|NCT03137095||Healthy, age-matched, female participants|Healthy, female, age-matched participants
2465358|NCT03136822|Other|Control|Standard dressing
2465361|NCT03136822|Experimental|Treatment|Standard dressing + Wound dressing (DERMALIX)
2465392|NCT03136341|Active Comparator|Abobotulinum toxin A|
2465396|NCT03136341|Placebo Comparator|Placebo|
2465587|NCT03135288|Experimental|Cell-phone assisted|will be advised that they are going to receive a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits. They will be also provided with a cell phone number working 7 days a week to answer any query or questions regarding her family planning program.
2465588|NCT03135288|No Intervention|control group|will receive the same above adequate counseling with referral card but without any phone assistance
2465607|NCT03134859|Experimental|0 to 30 min/day tummy time|Group tasked to engage in an accumulation of 0 to 30 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2465609|NCT03134859|Experimental|31-60 min/day tummy time|Group tasked to engage in an accumulation of 31 to 60 minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2465611|NCT03134859|Experimental|>61 min/day tummy time|Group tasked to engage in an accumulation of 61 or more minutes of deliberate tummy time activities daily from study entry until the time at which the infant can independently transition in and out of sitting
2465642|NCT03134664|Experimental|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
2465647|NCT03134664|Experimental|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
2465681|NCT03134443|Active Comparator|Experimental group|Xiyanping injection(andrographolide sulfonate) 10-20ml/d, with 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
2465686|NCT03134443|Placebo Comparator|control group|Xiyanping injection simulation(andrographolide sulfonate simulation) 10-20ml/d, The treatment method is the same as the experimental group.
2465725|NCT03134157|Experimental|Simvastatin and vaginal placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ vaginal placebo will be given every day for 3 months.
2465726|NCT03134157|Experimental|Simvastatin and oral placebo|The patients with leiomyoma receive simvastatin 40 mg orally+ oral placebo will be given every day for 3 months.
2465727|NCT03134157|Experimental|Vaginal placebo+ oral placebo|The patients with leiomyoma receive Vaginal placebo+ oral placebo every day for 3 months.
2465758|NCT03133832|Experimental|The cure rate between the two treatment|Compare the cure rate between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2465759|NCT03133832|Experimental|The amount of eggs produced|Compare the amount of eggs produced between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2465764|NCT03133832|Experimental|The economic benefit|Compare the economic benefit between the Chinese-made praziquantel and companion tablet at one dose of 40 mg/kg
2465858|NCT03133364|Active Comparator|Sensory optimized meals|"Intervention group is receiving:~Popular dishes selected from hospital and meal service menus optimized by sensory experts. Optimization is done with respect to taste, texture and appereance and on nutritional composition of the meals with focus on protein content."
2465859|NCT03133364|Placebo Comparator|Control|"Control group is receiving:~Popular dishes selected from hospital and meal service menus, NOT optimized by sensory experts."
2465915|NCT03132961||Block 1|Participants in the cohort will undergo testing in the order of: ECoG, oVEMP, cVEMP
2465921|NCT03132961||Block 2|Participants in the cohort will undergo testing in the order of: ECoG, cVEMP, oVEMP
2465930|NCT03132961||Block 3|Participants in the cohort will undergo testing in the order of: oVEMP, cVEMP, ECoG
2465935|NCT03132961||Block 4|Participants in the cohort will undergo testing in the order of: oVEMP, ECoG, cVEMP
2465268|NCT03137290|Active Comparator|Neostigmine|1 mg of Atropine (1ml) was mixed with 2.5mg of Neostigmine (1ml) and diluted into 10mls with Normal Saline 0.9% in a 10ml standard syringe.
2465273|NCT03137290|Experimental|Sugammadex sodium|100mg Sugammadex (1ml) is diluted into 10mls in a standard 10mls syringe with Normal Saline 0.9%.
2465411|NCT03136549|Placebo Comparator|Room temperature|The nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
2465417|NCT03136549|Experimental|Thermo-softening|The naso tracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L) at warm cabinet set to 45°C (approximately 117°F).
2465453|NCT03136016|No Intervention|control|without any activity
2465455|NCT03136016|Experimental|educational activities|The students will receive educational activities in the classroom.
2465457|NCT03136016|Experimental|nudging|The students will receive changes in the school environment (nudge strategies);
2465463|NCT03136016|Experimental|nudging + educational activities|The students will receive educational activities and changes in the school environment.
2465534|NCT03135756||Depression and anxiety symptoms|
2465537|NCT03135756||Healthy controls|
2465574|NCT03135223|Experimental|Intervention group|Co-created, school-based intervention to promote physical activity
2465576|NCT03135223|No Intervention|Control group|
2465714|NCT03134352|Experimental|ZL-3101(Fugan) bid group|Fugan AM + Fugan PM
2465717|NCT03134352|Experimental|ZL-3101(Fugan) qd group|Fugan AM + Placebo PM
2465719|NCT03134352|Placebo Comparator|placebo group|Placebo AM + Placebo PM
2465763|NCT03133884|Experimental|Acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 20 seconds.
2465766|NCT03133884|Other|Superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
2465845|NCT03133611|Other|Parkinson's disease|Speech assessment. Routine clinical assessment.
2465847|NCT03133611|Other|REM sleep behaviour disorder|Speech assessment. Routine clinical assessment.
2465850|NCT03133611|Other|Healthy controls|Speech assessment. Routine clinical assessment.
2465985|NCT03132142|Experimental|Capsaicin|Capsacin (8%) patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
2465988|NCT03132142|Experimental|Trans-cinnamaldehyde|Trans-cinnamaldehyde (10%, dissolved in 90% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
2465996|NCT03132142|Experimental|L-menthol|L-menthol (40%, dissolved in 96% ethanol) applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms on a cotton ball placed in a plastic chamber to limit evaporation.
2466009|NCT03132142|Placebo Comparator|Vehicle patch|Inert vehicle patches applied topically 4 times for 1 hour to a 4x4 cm predefined area on the skin of the volar forearms.
2466216|NCT03131024|Experimental|Aerobic exercise|The exercise arm includes a single bout of supervised treadmill walking scheduled such that it would end approximately 24 hours prior to each of the participant's scheduled anthracycline treatment time.
2466217|NCT03131024|Experimental|50% caloric restriction|The caloric restriction arm will restrict their total caloric intake by 50% for 48 hours prior to each anthracycline treatment.
2466219|NCT03131024|No Intervention|Usual care|The usual care arm will be asked to maintain their typical exercise and diet throughout treatment.
2466330|NCT03130283|Active Comparator|Home Hospitalization|Visit every day at home
2466332|NCT03130283|Placebo Comparator|Conventional Hospitalization|Review Clinical History
3156522|NCT00345813|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for 4 weeks. Patients undergo radical prostatectomy within 21 days after completion of placebo supplementation.
3156523|NCT00345826|Experimental|Dasatinib|
3156524|NCT00345930||2|Individuals without drug induced liver disease
3156525|NCT00345930||1|Individuals with drug induced liver disease
3156526|NCT00345982|Experimental|A|Sertindole 16 mg
3156527|NCT00345982|Placebo Comparator|B|Placebo
3156528|NCT00346021|Experimental|Sun Protection Intervention|School based sun protection education, provision of free hats.
3156529|NCT00346021|No Intervention|Control arm|Usual sun protection practices
3156530|NCT00346047|Placebo Comparator|0|
3156531|NCT00346047|Experimental|1|
3156532|NCT00346125|Active Comparator|Preferred Standard Regimen|Subjects with soft tissue sarcoma who are receiving pegylated liposomal doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
3156533|NCT00346125|Active Comparator|Alternative Treatment Regimen|Subjects with soft tissue sarcoma who are receiving Doxorubicin hydrochloride, Ifosfamide with mesna and pegfilgrastim - Repeat every 28 days for 4 cycles total
3156534|NCT00346177|Active Comparator|1|Stem Cells
3156535|NCT00346177|Placebo Comparator|2|Placebo
3156536|NCT00346229|Experimental|Thermodox|ThermoDox20-40mg/m2 every 21-35 days followed by Chest Wall Hyperthermia
3156537|NCT00346294|Other|Single-Arm|Open-lable Single Arm Study
3156538|NCT00346320|Experimental|Radiotherapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
3156539|NCT00346437|Experimental|1|Ad5FGF-4
3156540|NCT00346437|Experimental|2|Ad5FGF-4
3156541|NCT00346437|Placebo Comparator|3|Placebo
3156542|NCT00346502|Experimental|Ointment|Treatment will consist of four weeks of daily application of 20% BA ointment to the dysplastic nevi, after which it will be removed surgically and examined. A similar dysplastic nevi will be removed as a control. Four groups of patients will be enrolled. The first group will apply the ointment once a day, the second twice a day, the third three times a day, and the fourth four times a day.
2465340|NCT03136679||Alzheimer's disease|Subjects with Alzheimer's disease A. Mild B. Moderate C. Severe Blood and urine samples will be collected from these three sub-groups.
2465415|NCT03136562||Kidney transplanted patients|Kidney transplanted patients in prednisolone treatment. Adrenal function is assessed by a synacthen test.
2465420|NCT03136562||Control group|Patients in dialysis not in prednisolone treatment. Adrenal function is assessed by a synacthen test.
2465467|NCT03135938|Active Comparator|Grading Inferior Oblique Anterior Transposition|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
2465469|NCT03135938|Active Comparator|Classic Inferior Oblique Anterior Transposition|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes
3156543|NCT00346528|Experimental|NGOIS|
3156544|NCT00346528|Active Comparator|BSS Plus|
3156545|NCT00346567|Active Comparator|1|AZT from week 28 or asap thereafter. Intrapartum AZT and 3TC + Single dose NVP Postpartum Combivir tail for 7 days twice daily
3156546|NCT00346567|Experimental|2|AZT from week 28 or asap thereafter. Intrapartum Single dose Truvada + Single dose NVP
2465866|NCT03133325|Other|All subjects|Treatment with both GP0045 and Restylane Lyft Lidocaine
2465992|NCT03132376|Experimental|Breakfast Preload Drink|"Participants were given isovolumetric drinks, to consume in the morning after an overnight fast, followed by questionnaires asking throughout the day asking participants of their perceived hunger, fullness, desire to eat, and prospective food consumption, and if they would like to eat again. Four hours following consumption, they were given an ad libitum pasta meal to consume.~The drinks consisted of the following:~Water Preload Drink, Whey Protein Isolate Drink, Micellar Casein Protein Drink, Egg White Isolate Protein Drink, and Egg White Concentrate Protein Drink"
2466048|NCT03131908|Experimental|GSK2636771 + Pembrolizumab|"Phase I: Participants receive the lowest dose level of GSK2636771. Each new group receives a higher dose of GSK2636771 than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of GSK2636771 is found. Participants receive the same dose level of Pembrolizumab.~Phase II: Participants receive GSK2636771 at the highest dose that was tolerated in Phase 1. Participants receive the same dose level of Pembrolizumab."
2466131|NCT03131427||Wilson's Disease|Patients who were diagnosed or possibly diagnosed with Wilson's disease. The diagnosis can be made or possibly made on the basis of Wilson's disease scoring system proposed by the Working Party at the 8th International Meeting on Wilson's disease, Leipzig 2001.
2466139|NCT03131427||Hereditary Hemochromatosis|Hereditary hemochromatosis can be clinically diagnosed if: ① transferrin saturation≥45% and/or elevated ferritin; ② iron overload in liver and/or spleen on magnetic resonance imaging (MRI) of liver or on liver histology; ③ exclude causes of secondary iron overload, such as alcoholic or other chronic liver disease, iron-overloading anemia, and parenteral iron overload.
2466142|NCT03131427||Hereditary Hyperbilirubinemias|Hereditary hyperbilirubinemias involve four syndromes: Gilbert, Crigler-Najjar, Dubin-Johnson and Rotor, among which the first two are characterized by unconjugated hyperbilirubinemia and the second two by conjugated hyperbilirubinemia. Diagnosis of hereditary hyperbilirubinemia should exclude other causes of hyperbilirubinemia, such as obstructive bile duct (slerosing cholangitis, calculi, parasites), intrahepatic cholestasis(drugs, hepatitis, immune-mediated, infectious), acute or chronic hepatocellular injury(sepsis, parenteral nutrition, severe blood loss/hypotension, trauma, conjestive heart failure), increased bilirubin production(hemolysis, hematological disease), decreased bilirubin uptake (drugs, portosystemic shunting ), reduced conjugation activity (neonatal, thyroid disease, chronic hepatitis/inflammation, wilson's disease).
2466207|NCT03130933|Placebo Comparator|The second control subgroup|The control subgroup from the main group with prior inflammation received a placebo one hour prior the lower third molar surgery .
3156547|NCT00346671|Placebo Comparator|Supine Rest|30min supine rest listening to soft music
3156548|NCT00346671|Sham Comparator|Sham Reiki|30 min intervention by sham practitioner
3156549|NCT00346671|Experimental|Reiki|30 min session with Reiki practitioner
3156550|NCT00346749|Experimental|Arm 1|
3156551|NCT00346762||1|HIV infected former commercial blood donors (FBDs) in Fuyang, Anhui Province
3156552|NCT00346788|Experimental|MIS|minimally invasive incision
3156553|NCT00346788|Active Comparator|Standard|Standard incision length
3156554|NCT00346801|Experimental|CPT-11 + Celecoxib/Cisplatin with RT|CPT-11 + Celecoxib + Cisplatin + Radiation Therapy (RT)
3156555|NCT00346840|Experimental|MVI 25|Misoprostol vaginal insert 25 mcg
3156556|NCT00346840|Experimental|MVI 50|Misoprostol vaginal insert 50 mcg
3156557|NCT00346840|Experimental|MVI 100|Misoprostol vaginal insert 100 mcg
3156558|NCT00346840|Experimental|MVI 200|Misoprostol vaginal insert 200 mcg
3156559|NCT00346853|Experimental|1|
3156560|NCT00346853|Placebo Comparator|2|saline
3156561|NCT00346918|Active Comparator|1|Treatment of hypertension, cyst infections and flank pain
3156562|NCT00346918|Active Comparator|2|Sirolimus plus Standard Treatment
3156563|NCT00346944|Experimental|Treatment group|
3156564|NCT00346944|No Intervention|Reference group|
3156565|NCT00346957|Experimental|Anecortave Acetate 30|
3156566|NCT00346957|Experimental|Anecortave Acetate 15|
3156567|NCT00346957|Experimental|Anecortave Acetate 3|
3156568|NCT00346957|Placebo Comparator|Anecortave Acetate Vehicle|
3156569|NCT00346970|Experimental|1|Extended-release Niacin
3156570|NCT00346970|Placebo Comparator|2|Placebo
3156571|NCT00346983|Experimental|A|
3156572|NCT00346983|Placebo Comparator|B|
3156573|NCT00346996|Active Comparator|1|HUman Insulin
3156574|NCT00346996|Experimental|2|Analogue insulin
3156575|NCT00347048|Experimental|1|
3156576|NCT00347048|Placebo Comparator|2|
3156577|NCT00347100|Experimental|1|Administration of Insulin Glargine and Sulfonylurea or Metformin
3156578|NCT00347100|Active Comparator|2|Administration of Sulfonylurea or Metformin + a second Oral Anti Diabetic (OAD) among Glyburide, Glyclazide,Glimiperide,Glipizide or Metformin
2465357|NCT03136653|Experimental|Single arm Study MP0250 plus BOR + DEX|Single arm study of MP0250 plus bortezomib + dexamethasone
2465424|NCT03136237|Experimental|Cohort 1|Day 1: Digoxin 0.25 mg oral dose Day 11-18: BCX7353 350 mg oral dose Day 19: Digoxin 0.25 mg oral dose and BCX7353 350 mg oral dose Day 20-21: BCX7353 350 mg oral dose
2465429|NCT03136237|Experimental|Cohort 2|Day 1: Rosuvastatin 10 mg oral dose Day 7-14: BCX7353 350 mg oral dose Day 15: Rosuvastatin 10 mg oral dose and BCX7353 350 mg oral dose Day 16: BCX7353 350 mg oral dose
2465434|NCT03136237|Experimental|Cohort 3|Day 1: BCX7353 350 mg oral dose Day 14: single oral dose of Cyclosporine 600 mg and BCX7353 350 mg
2465496|NCT03135860|Experimental|Inhaled Nitric Oxide 30mcg/kg/IBW/hr|Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
3156579|NCT00347139|Experimental|GW642444|
2465692|NCT03135041|Experimental|Fiber-containing dietary supplement|2 x 200 ml of fiber-enriched UHT milk during 12 weeks of energy restriction
2465701|NCT03135041|Placebo Comparator|Placebo|2 x 200 ml of UHT milk with maltodextrin during 12 weeks of energy restriction
2465907|NCT03133039|Active Comparator|bioabsorbable screw|
2465908|NCT03133039|Active Comparator|titanium screw|
2465922|NCT03132597|Experimental|Early Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the beginning of the first semester
2465932|NCT03132597|Experimental|Late Mindfulness exposure|six weeks of 2 hours class of mindfulness training and orientations for home training at the second half of the first semester
2465936|NCT03132597|No Intervention|Control (not exposed)|Students not exposed to the mindfulness mandatory course (not exposed to the intervention)
3156580|NCT00347139|Active Comparator|Salmeterol|
3156581|NCT00347152|Active Comparator|2|Slow Progressive Divalproex DR to Divalproex ER switch
3156582|NCT00347152|Active Comparator|1|Immediate, Progressive Divalproex DR to Divalproex ER switch
2466040|NCT03132025|Experimental|"A: apatinib and capecitabine"|"Arm A: apatinib and capecitabine apatinib 250mg qdpo; capecitabine 1000mg/m2 qdpo d1-14 q3w"
2466042|NCT03132025|Active Comparator|"B: capecitabine single drug"|"Arm B: capecitabine single drug capecitabine 1000mg/m2 qdpo d1-14 q3w"
2466124|NCT03131557|Experimental|Line extension of the Phonak Audéo B hearing aid|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
2466133|NCT03131557|Active Comparator|Phonak Audéo B hearing aid|Phonak Audéo B will be fitted to the participants individual hearing loss.
2466208|NCT03131037|Experimental|Study Arm|AdV-tk (aglatimagene besadenovec) + valacyclovir
2466247|NCT03130725|Experimental|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
2466248|NCT03130725|Active Comparator|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
2466263|NCT03130465||Aripiprazole Once Monthly (AOM)|Schizophrenia patients who initiated maintenance treatment with AOM during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
2466267|NCT03130465||Daily oral atypical AP|Schizophrenia patients who initiated maintenance treatment with any daily oral atypical AP during a schizophrenia-related hospitalisation or during the first three months after this hospitalisation.
2466345|NCT03129997|Active Comparator|Gluten test food|volunteers will receive 2 corn based muffins containing 7,5g of gluten/muffin to be consumed daily for 3 weeks
2466348|NCT03129997|Placebo Comparator|Placebo test food|volunteers will receive 2 corn based muffins to be consumed daily in any meal for 3 weeks
2466379|NCT03129711|Experimental|glazed Celtra Duo|zirconia reinforced lithium silicate glass ceramic is infiltrated with 10% zirconia by weight, producing zirconia reinforced lithium silicate ceramic
2466579|NCT03128489|Experimental|DTPa-IPV/Hib Group|All subjects will receive three doses of primary vaccination at 6, 10 and 14 weeks of age.
3156583|NCT00347321|Experimental|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
3156584|NCT00347386|Experimental|Zinc|Administration of zinc sulphate every day during illness
3156585|NCT00347386|Placebo Comparator|Placebo|Placebo tablet
3156586|NCT00347412|Experimental|A|NOV-002 Injection in combination with Carboplatin and Paclitaxel
3156587|NCT00347412|Active Comparator|B|Paclitaxel and Carboplatin Alone
3156588|NCT00347425|Other|A|
3156589|NCT00347425|Other|B|
3156590|NCT00347555|Experimental|Group D|18 subjects 160 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3156591|NCT00347555|Experimental|Group A|18 subjects 5 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3156592|NCT00347555|Experimental|Group B|18 subjects 20 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3156593|NCT00347555|Experimental|Group C|18 subjects 80 micrograms EBA-175+500 micrograms aluminum adjuvant; 2 subjects placebo.
3156594|NCT00347594|Experimental|Next Generation Diagnostic Instrument|Next Generation Diagnostic Instrument (NGDI)
3156595|NCT00347594|Active Comparator|Zyoptix Diagnostic Workstation|Zyoptix Diagnostic Workstation (ZDW)
3156596|NCT00347646|Experimental|Plasmin|Human-derived plasmin reconstituted with sterile sodium chloride for intravitreal injection.
3156597|NCT00347659|Experimental|Single Treatment|Experimental Treatment
3156598|NCT00347672|Experimental|1|Two vaccinations of H5N1 VN 2004/AA vaccine at the highest dose
3156599|NCT00347672|Experimental|2|One vaccination of H5N1 VN 2004/AA vaccine at a dose in-between the lowest and highest doses
3156600|NCT00347672|Experimental|3|One vaccination of H5N1 VN 2004/AA vaccine at the lowest dose
3156601|NCT00347737|Experimental|1|Teriparatide
3156602|NCT00347763|No Intervention|control|no active fly spray intervention
3156603|NCT00347763|Active Comparator|intervention|aerial spray of permethrin daily for two weeks and weekly as needed by assessment of fly density
3156604|NCT00347854|Experimental|FID 105783|
3156605|NCT00347854|Active Comparator|Visine|
3156606|NCT00347854|Active Comparator|Refresh Liquigel|
3156607|NCT00347854|Active Comparator|Refresh Plus|
3156608|NCT00347997|Experimental|LASIK|LASIK correction of myopia and myopic astigmatism
2465391|NCT03136211|Experimental|EIRA intervention|"EIRA intervention It is based on the Transtheoretical Model (TTM) and States of Change and it is made by physicians and nurses in routine care of primary care practices according to the conceptual framework of the 5A: Ask, Advise, Assess, Assist, and Arrange. It consists of a first visit of screening (Ask). Subsequently, the professional develops a personalized plan that is negotiated with the participant (Advise and Assess). This plan is reviewed during successive visits and positive changes are reinforced and new objectives are negotiated (Assist and Arrange). The motivational interview is the essential tool of the intervention. The intervention is carried out to different levels: individual, group and community."
2465395|NCT03136211|No Intervention|Usual care|"Health providers of this group integrate in their practice the recommendations of the Program of Preventive Activities and Health Promotion (PAPPS). These guidelines are based on systematic screening and brief advice for the prevention of cardiovascular and mental diseases and cancer as well as vaccine recommendations."
2465471|NCT03136055|Experimental|Part A: Pembrolizumab only|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion.
2465472|NCT03136055|Experimental|Part B: Pembrolizumab + Chemotherapy|Participants will receive 200 mg of pembrolizumab will be given every three weeks via IV infusion and, either 125 mg/m2 of irinotecan given via IV infusion in a two week (on for one week, off for one week format in 3 week cycles) or 80 mg/m2 of paclitaxel given every week via IV infusion depending on physician assessment
2465510|NCT03135639|Experimental|Sham Stim followed by Alpha Stim|"20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS."
2465511|NCT03135639|Experimental|Alpha Stim followed by Sham Stim|"20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.~Participants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.~Sham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham."
3156609|NCT00348036|Experimental|Group therapy|Participants will receive interpersonal group therapy.
3156610|NCT00348036|Active Comparator|Control|Participants will receive information only on PTSD.
3156611|NCT00348075|Experimental|Neurovision|
3156612|NCT00348153|Experimental|Adalimumab + corticosteroids + immunosuppressive treatments|Adalimumab 40 mg eow, stable immunosuppression, corticosteroids in 1 mg/kg/Bodyweight (max. 80 mg) and taper
3156613|NCT00348153|Active Comparator|immunosuppressive treatment + corticosteroids|corticosteroids upped to 1mg/kg/Bodyweight and taper, stable immunosuppressive treatment
2465689|NCT03134456|Experimental|single arm: pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
2465742|NCT03134118|Experimental|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
2465879|NCT03133195|Experimental|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks
2465882|NCT03133195|Placebo Comparator|Placebo|Placebo subcutaneous once daily for 12 weeks
2465983|NCT03132337||Stem Cell Transplant|Serial Blood Draws
2466053|NCT03132012|Experimental|Indoor tanning intervention|Web-based intervention modules to discourage tanning.
2466057|NCT03132012|Active Comparator|standard of care control|General information regarding UV protection measures through an online Qualtrics interface. Content will mirror information provided in brochures typically available in a dermatology office or through skin cancer prevention websites.
2466238|NCT03130829|Experimental|Oligo Fucoidan|Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
2466243|NCT03130829|Placebo Comparator|Placebo|Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.
2466262|NCT03130491|Other|TAVR + Embolic protection|subjects with severe native aortic valve stenosis who meet the commercially approved indications for transcatheter aortic valve replacement
2466308|NCT03130361|Experimental|Noninvasive ventilation|Participants will use the device at home by intermittence during or after physical activities for reducing dyspnea or for shortening dyspnea-recovery time over a 4-week period.
2466354|NCT03129971|Experimental|control group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
2466356|NCT03129971|Experimental|experimental group|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
2466370|NCT03129607||POPF group|Patients who had POPF will be included into POPF group.
2466373|NCT03129607||Observation group|Patients without POPF will be included into observation group.
2466402|NCT03129412|Experimental|Arm 1|4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.
2466461|NCT03129139|Experimental|Regimen A (monotherapy)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day off schedule. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
2466462|NCT03129139|Experimental|Regimen B (combination)|MinnelideTM Capsules will be given orally once daily x 21 days in combination with protein-bound paclitaxel given intravenously on days 1, 8 and 15 in patients with pancreas and breast cancer. One cycle will equal 28 days. MinnelideTM Capsules should be given with the patient in a fasting state.
2466599|NCT03128645||Group 1|Standard method group
2466600|NCT03128645||Group 2|Abdominal corset group
3156614|NCT00348335|Active Comparator|1: Restasis|
3156615|NCT00348335|Active Comparator|2: Refresh Endura|
3156616|NCT00348387|Experimental|Group 1|
2465426|NCT03136471||Patients for Qualitative Study|"Patients with diabetes who are a members of Diabetes Advisory Group or partner LaCDRN health system will be contacted via email, letter or phone call.~Inclusion criteria:~Diabetes patients who consent to participate the study.~Age 65+;~Diagnosis code for diabetes in the last 2 years;~Diagnosis code for at least one additional chronic condition in the last 2 years.~Exclusion criteria: age<65; patient with diabetes without other chronic conditions."
2465430|NCT03136471||LaCDRN partner health system's medical directors|Face-to-face semi-structured interviews will be used to explore organizational cultures, their social architecture, resources, capacity, communication networks, assess barriers, and refine the data collection for the assessing the RE-AIM framework. The one time interview will take 1 hour. A 10 minutes questionnaire of Diabetes care coordination readiness assessment (DCCRA) will be emailed to them annually during entire 5 years of study period.
2465435|NCT03136471||PROMIS® survey|"Patients for PROMIS® survey (National Institutes of Health's Patient-Reported Outcome Measurement Information System Global Health Measures). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or age<18 years old."
2465437|NCT03136471||PACIC+ survey|"Patients for PACIC+ survey (Group Health Research Institute's Patient Assessment of Care for Chronic Conditions+). Patients will be administered the surveys at the point-of-care visit (in exam rooms) using REACHnet's tablet-based application.~Inclusion criteria:~All patients age 18+ with a Diabetes diagnosis and who registered at REACHnet.~Able to provide informed consent~Exclusion criteria: patients who do not provide inform consent or without diabetes diagnosis or age<18 years old"
2465439|NCT03136471||Telehealth Services using HCPCS/CPT for COVID-19 Patients|Study population with versus without telehealth services. Telehealth services using the HCPCS/CPT codes will be defined in the following categories: Medicare telehealth visits (CPT codes: 99201-99215; HCPCS codes: G0425-G0427, G0406-G0408), virtual check-in (HCPCS codes: G2010, G2012), and e-visits (CPT codes: 99421-99423, HCPCS codes: G2061-G2063). Propensity score-matching will be used to ensure comparison groups are comparable at baseline.
2465450|NCT03135964|Active Comparator|foam|PU foam dressing from KCI
2465452|NCT03135964|Active Comparator|gauze|Polyhexamethylene biguamide (PHMB) impregnated gauze (Kerlix AMD, Covidien)
2465497|NCT03135782|Experimental|Health Services Research (Chart review, training, coaching)|"MEDICAL CHART REVIEW: Medical charts from patients with diagnoses of head and neck cancer, lung cancer, prostate cancer, or breast cancer are reviewed at months 1-12 to determine the frequency of tobacco assessments and documentation of discussions with patients regarding tobacco use and utilization of cessation resources as before and after the proposed training.~PROVIDER TRAINING: Providers undergo training to use patient coaching such as the 5A's (Ask, Advise, Assess, Assist, and Arrange), to conduct regular tobacco intake assessment using motivational interviewing techniques. Providers also undergo training to use public/community tobacco cessation resources for patients ready to quit within six weeks, and have access to pharmacy residents for ad-hoc prescribing questions.~PATIENT COACHING: Patients attend 4 phone or in-person motivational interviewing coaching sessions over 30-45 minutes for 6-8 weeks or longer as needed."
2465553|NCT03135509|Experimental|Treatment A (Reference)- CC-220 gelatin capsules|A single dose of 0.6 mg CC-220, administered as two 0.3-mg formulated CC-220 gelatin capsules.
2465555|NCT03135509|Experimental|Treatment B (Test)- CC-220 HPMC capsule|A single dose of 0.6 mg CC-220, administered as one 0.6-mg formulated CC-220 hydroxypropyl methylcellulose (HPMC) capsule.
2465696|NCT03135132|Placebo Comparator|Control group|Usual dietary intake group
2465704|NCT03135132|Experimental|LCD group|Low calorie diet (LCD) group (300kcal/day intake reduction)
2465771|NCT03134053|Experimental|extracorporeal shock-wave|
2465776|NCT03134053|Sham Comparator|massage|
2465809|NCT03133507|Experimental|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
2465812|NCT03133507|Experimental|Reassurance Condition|Children will receive empathic support from the experimenter.
2465819|NCT03133507|Experimental|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
2465880|NCT03133247|Experimental|SHR-1316 dose-escalation|SHR-1316 doses will be escalated sequentially in 5 cohorts.
2465966|NCT03132545||PCOS|
2465967|NCT03132545||controls|
2465981|NCT03132233|Active Comparator|Verum|Receives the investigational medicine product (IMP; Beta-hydroxybutyrate calcium and magnesium salt).
2465986|NCT03132233|Placebo Comparator|Placebo|Receives a matched placebo powder to the IMP.
2466103|NCT03131622|Experimental|Digital Therapeutics|Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services.
2466104|NCT03131622|No Intervention|Control|
2466316|NCT03130179|Experimental|Nicorette Strongmint lozenge 4mg|A single dose of one nicotine 4 mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
2466317|NCT03130179|Active Comparator|Niquitin Minimint lozenge 4mg|A single dose of one nicotine 4mg lozenge will be administrated orally to slowly dissolve in the mouth for nicotine absorption via the buccal mucosa.
2466358|NCT03129841|Experimental|early dinner+Diet|
2466359|NCT03129841|Experimental|late dinner+Diet|
2466387|NCT03129581|Active Comparator|Time Restricted|This group will receive dietary counseling.
2466388|NCT03129581|No Intervention|Time Unrestricted|This group will not receive dietary counseling.
2466403|NCT03129308||HIV infected patients|4.5 ml of blood will be collected during a routine medical check-up.
2466404|NCT03129308||HIV negative control patients|4.5 ml of blood will be collected during a routine medical check-up.
2466474|NCT03129087|Experimental|Vocal activity|The vocal activity arm will require the participant to remain in the clinic and read aloud continuously for a period of one hour after a botulinum toxin injection
2465680|NCT03134573||Multiple Sclerosis|Women and men in Germany with the diagnosis of MS that are treated with Betaferon and use the myBETAapp
3156617|NCT00348387|Active Comparator|Group 2|
3156618|NCT00348439|Experimental|Plasmin Injection|human-derived plasmin
2465978|NCT03132519|Experimental|Sevo-2.0|This group will maintain remifentanil infusion by TCI to 2 ng/ml during emergence and extubation after have received sevoflurane during procedure.
2465980|NCT03132519|Experimental|Sevo-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
2465984|NCT03132519|Experimental|Des-2.0|This group will maintain the remifentanil infusion by TCI to 2.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2465989|NCT03132519|Experimental|Des-2.5|This group will maintain the remifentanil infusion by TCI to 2.5 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2466000|NCT03132519|Active Comparator|Sevo-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received sevoflurane during surgical procedure.
2466006|NCT03132519|Active Comparator|Des-Control|This group will maintain the remifentanil infusion by TCI to 1.0 ng/ml during emergence and tracheal extubation after have received desflurane during surgical procedure.
2466060|NCT03131843|Experimental|Alcohol|Alcohol will be wiped on the vaccine injection site immediately before vaccine injection.
2466062|NCT03131843|Placebo Comparator|No alcohol|Alcohol will be wiped adjacent to the vaccine injection site immediately before vaccine injection.
2466226|NCT03130946|Experimental|Cryo-assisted core needle biopsy|Eligible patients undergo lymph node biopsy with FNA and crpo-assisted stick freeze device sequentially.
2466228|NCT03130946|Active Comparator|Fine needle aspiration alone|Patients undergo lymph node biopsy with FNA alone.
2466271|NCT03130556|Experimental|Glasdegib BE and Food|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet after a high fat, high calorie meal.
2466274|NCT03130556|Experimental|Glasdegib BE and PPI Effect|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects receive a 100 mg single dose ICH tablet in the fasted state after repeated daily dosing with rabeprazole.
2466337|NCT03130270|Experimental|Apatinib group|Apatinib mesylate tablet：the starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd).
2466394|NCT03129698|Other|Formerly Arm Label|Apatinib 250mg daily
2466442|NCT03129230|Experimental|Free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck.
3156619|NCT00348439|Placebo Comparator|Vehicle|Plasmin formulation, without active ingredient.
3156620|NCT00348517|Experimental|Systane|
2466607|NCT03128281|Experimental|Conventional Insufflation System (CIS)|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Conventional Insufflation System (CIS) used for pneumoperitoneum during laparoscopic/robotic surgery."
2466613|NCT03128281|Experimental|ConMed AirSeal Insufflation System (AIS) at Low Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Low Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
2466617|NCT03128281|Active Comparator|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~ConMed AirSeal Insufflation System (AIS) at Higher Pressure used for pneumoperitoneum during laparoscopic/robotic surgery."
2466686|NCT03127761||Allogeneic HCT|Prospectively enrolled cohort of patients receiving allogeneic hematopoietic cell transplantation for multiple myeloma
2466690|NCT03127761||Historical autoHCT|Historical cohort of patients with autologous hematopoietic cell transplantation between 2010 and 2016
3156621|NCT00348517|Active Comparator|Refresh|
3156622|NCT00348569|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed 2 to 21 days later by catheter coronary angiography (CATH).
3156623|NCT00348608|Experimental|Visipaque Injection|All participants will receive intravenous (IV) administration of 80 mL Visipaque (iodixanol) 320 mg-I/mL at a rate of 4-5 mL per second via power injector followed by a saline injection of 40-50 mL 0.9% sodium chloride solution at a rate of 4-5 mL per second.
3156624|NCT00348621|Active Comparator|Visual impairment intervention program|enhanced access to eye care services
3156625|NCT00348621|No Intervention|Usual care|family and nursing home was apprised of ocular exam results; eye care services left to family/nursing home arrangements
3156626|NCT00348699|Experimental|Treatment (AFP464)|Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3156627|NCT00348712|Active Comparator|A|
3156628|NCT00348712|Active Comparator|B|
3156629|NCT00348738|Experimental|1|Patients assigned to this group are receiving Erythropoietin medication
3156630|NCT00348738|No Intervention|2|control group receiving no treatment
3156631|NCT00348777|Active Comparator|1|group with 18 days thermal cure
3156632|NCT00348777|Sham Comparator|2|group with no thermal cure but only access 3 days to watering place 6 months after inclusion
3156633|NCT00348829|Active Comparator|1|Surgical mitral valve reconstruction
3156634|NCT00348829|No Intervention|2|conservative treatment
3174693|NCT00626054|Active Comparator|2|Group 2 will receive half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test.
3191577|NCT00799955|Active Comparator|2|No additional spinal medications will be given. At the end of the case, one of the two investigators, under sterile conditions, and using ultrasound, will visualize the tip of a blunt regional anaesthesia needle entering the transversus abdominis plane. After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected, under vision, into the transversus abdominis plane, on each side. The subjects will still have spinal anesthesia of the abdomen and therefore will not feel needle insertion as sharp although most will have a sensation of pressure. A dressing will be applied over the needle's entry points.
2465557|NCT03135353|Experimental|3D saline infusion sonohysterography|participants presenting with abnormal uterine bleeding will undergo 3D saline infusion sonohysterography
2465558|NCT03135353|Experimental|Office hysteroscopy|after undergoing 3D SIS, cases would undergo office hysteroscopy and the investigator would be blinded to the results of SIS
2465595|NCT03135080|Experimental|Long-term HEAD START Training|Fifteen surgeons will participate in long-term HEAD START practice once live surgical training is complete. Each week the participant will complete 2 surgeries on the HEAD START device and mark the surgery number on the cartridge. Monthly, the participant will send the accumulated cartridges to Addis for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his/her impression of the surgeries with the participant during a regular monthly call. He/she will also note the findings on a standardized form. Practice will continue for approximately 4-6 months, depending on the length of the rainy season and time of enrollment.
2465596|NCT03135080|Active Comparator|Standard of Care|Once live surgical training is complete, fifteen surgeons will commence live surgery without supervision until the rainy season begins. Then they will break for the rainy season, per the typical practice. The trainer will assess their skill levels on live surgery at the end of training and again at the start of the surgical season in the fall.
2465641|NCT03134742||Control Group|Subjects will not have any additional scans only those that are standard of care. Their data will be used for comparison
2465644|NCT03134742||CT Scan only|Three CT Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment.
2465650|NCT03134742||DEXA Scans only|Three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
2465653|NCT03134742||CT and DEXA Scans|Three CT Scans and three DEXA Scans will be done of the affected extremity as well as the contralateral extremity at Baseline (pre-radiotherapy), and 6 months and 1 year post-radiotherapy treatment
2465672|NCT03134391|Active Comparator|vapocoolant spray|Subjects received Vapocoolant spray before spinal anesthesia
2465673|NCT03134391|Active Comparator|EMLA|Subjects received EMLA before spinal anesthesia
2465700|NCT03134261|Other|SPECT-CT|The participants will undergo two project scans: WB-MRI and SPECT-CT
2465708|NCT03134261|Other|Cholin-PET-CT|The participants will undergo two project scans: WB-MRI and Cholin-PET-CT
2465710|NCT03134261|Other|PSMA-PET-CT|The participants will undergo two project scans: WB-MRI and PSMA-PET-CT
2465743|NCT03133962|Other|Patients applying for CAP or long-term central catheter|
2465772|NCT03133806|Experimental|Ultrasept LAA Closure System|Interventional percutaneous transcatheter device.
2465834|NCT03133520|No Intervention|Standard oxygen group|This patient groups will receive only routine oxygen therapy. Routine oxygen therapy involves administering low-to-medium oxygen flows through a nasal cannula or mask to achieve SpO2≥95%.
2465837|NCT03133520|Experimental|High flow oxygen therapy group|This patients group will receive high flow oxygen therapy. High flow nasal oxygen therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, it allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
2465889|NCT03133143|Experimental|Cognifit|Participants are instructed to play CogniFit 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
2465892|NCT03133143|Active Comparator|SIMS 4 (Maxis, Inc)|Participants are instructed to play SIMS 4 45-60 minutes, 5 days/week. A minimum of 50 gaming hours will be acquired to ensure observable neuroplasticity in the brain after gaming.
2465894|NCT03133143|No Intervention|Treatment as usual|No specific intervention will be offered to those who receive treatment as usual according to their treatment schedule. The participants are encouraged not to play video games during the study period.
2465962|NCT03132675|Experimental|tavo-EP plus IV pembrolizumab|Intratumoral Tavokinogene Telseplasmid (tavo, pIL 12) plus Electroporation (ImmunoPulse) in Combination with Intravenous Pembrolizumab
2466024|NCT03132116|Experimental|Gentamicin|intra-nodal injection of gentamicin
2466029|NCT03132116|Placebo Comparator|Placebo|intra-nodal injection of placebo
2466075|NCT03131674|Experimental|Direct treatment|
2466077|NCT03131674|Experimental|Delayed treatment|
2466123|NCT03131375|Active Comparator|Group A|In Group A: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group A receives a 50 ml NS infusion containing the drug Dexmedetomidine 1 mcg kg-1 slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.16 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
2466132|NCT03131375|Placebo Comparator|Group B|In Group B: Anesthesia induction drugs: propofol , fentanyl , rocuronium iv. After induction, Group B receives a volume matched normal saline infusion slowly. Anesthesia maintainance drugs: propofol and remifentanil. Reversal of neuromuscular block drugs: Sugammadex according to TOF measurements. Postoperative analgesia drugs: nalbuphine 0.2 mg kg-1 . Monitoring devices: ECG, NIBP , ETCO2, SpO2, Bispectral index, Train of four ratio.
2466194|NCT03130933|Active Comparator|The first tested subgroup|The tested subgroup from the main group without prior inflammation received a prophylactic single dose of 4 x Amoxicillin 500 Mg one hour prior the lower third molar surgery.
2466197|NCT03130933|Placebo Comparator|The first control subgroup|The control subgroup from the main group without prior inflammation received a placebo one hour prior the lower third molar surgery .
2466304|NCT03130400||Plica|Participants in this group have plica syndrome and have no other bad injuries in lower limbs.
2465505|NCT03135821|Active Comparator|Traditional Chinese Medication (TCM) Drug A,B,C,D|"Traditional Chinese Medication (TCM) Drug A,B,C,D.~TCM Drug A:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome15g~TCM Drug B:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Liver stagnation with heaty transformation: add Scutellaria Root 5g、Prunella Spike 5g~TCM Drug C:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Prominent abdominal pain: White Peony Root to increase to 15g add Bupleurum Root 5g~TCM Drug D:~White Peony Root 10g Processed Liquorice 3g Immature Bitter Orange 8g White Atractylodes Rhizome 15g Hard stools: add Peach Kernel 5g、Areca Seed 5g"
2465529|NCT03135392|Active Comparator|Breast Reconstruction with Artificial Implant|Participants undergoing unilateral reconstruction: patient will serve as internal control with contralateral breast and reconstructed breast will be compared to all other reconstructed breasts. Participants undergoing bilateral reconstruction: reconstructed breasts will be compared to all other reconstructed breasts
2465531|NCT03135392|Active Comparator|Autologous Breast Reconstruction without Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which do not have their nerves reconstructed during surgery
2465533|NCT03135392|Experimental|Autologous Breast Reconstruction with Neurotization|Participants undergoing autologous tissue (her own tissue from other areas of the body) reconstruction which have a nerve connected (neurotized) during surgery.
2465575|NCT03135171|Experimental|Trastuzumab, Pertuzumab and Tocilizumab|
2465600|NCT03134924|Experimental|Experimental condition|The WASH (Women's and Sexual Health) intervention included the elements of the enhanced standard of care condition and in addition, a group-based, culturally-tailored intervention to enhance the uptake of the recommendations. Facilitators covered an intervention manual on risks associated with IVP, symptoms of vaginal infections, vaginal health, women's experience with alternative methods for vaginal care, and communication with partners about vaginal health and the risks associated with IVP.
2465603|NCT03134924|Other|Enhanced Standard of Care|"This study provided an enhanced standard of care (SOC+) comparison condition, consisting of a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV using the Nugent criteria and provision of medication (oral metronidazole) within 48 hours of the examination in women with Nugent score of 7-10, regardless of the presence of symptoms. In addition, at baseline, participants received an individual education session on the risk of engaging in IVP, advice to discontinue IVP, and tips for healthy vaginal hygiene, emphasizing avoiding IVP and suggesting replacing IVP by external vaginal cleansing."
2465643|NCT03134690|Experimental|delayed start antagonist|30 women with f poor ovarian responses undergo ovarian stimulation with delayed start antagonist.
2465649|NCT03134690|Experimental|conventional antagonist|30 women with diagnose of poor ovarian response will have undergone ovarian stimulation with conventional antagonist protocol.
2465687|NCT03134430|Placebo Comparator|Normal saline|equal volume of normal saline as treatment group
2465691|NCT03134430|Active Comparator|peripheral Nerve block|0.35% ropivacaine and 0.5% lidocaine in normal saline
2465769|NCT03134105|Experimental|Monthly Feedback|Sites will receive monthly reports of their patients enrolled in the study with data for each of their patients participating in the study along with summary data for their practice and all patients participating in the study.
2465774|NCT03134105|Active Comparator|End-of-study Feedback|Sites will only receive the report of their patients at the end of the 6 month follow-up period.
2465832|NCT03133572|Experimental|Supraglottic airway|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
2465835|NCT03133572|Active Comparator|Face-mask|All newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
2465873|NCT03133078|Experimental|Exercise: step-down test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
2465881|NCT03133078|Experimental|Exercise: side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
2465982|NCT03132428||P Neonates|Premature (P) neonates [at least 27 weeks but less than 34 weeks of gestational age]
2465987|NCT03132428||TNT Neonates|Term-Near-Term (TNT) neonates at least 34 weeks of gestational age
3191578|NCT00799968|Active Comparator|Group 1|UK-12h group
3191579|NCT00799968|Experimental|Group 2|UK-2h group
2466112|NCT03131258|Other|Donor Nephrectomy|Donor Nephrectomy
3191580|NCT00799994||1|Patients that have medical intervention in an attempt to lower intraocular pressure (oral or topical)
3191581|NCT00799994||2|Patients who have received no intervention
2466605|NCT03128216|Active Comparator|Blind Local Anesthetic Infiltration|
2466611|NCT03128216|Active Comparator|Transversals Fascia Block|
3191582|NCT00800007|Active Comparator|ANZ-521|
3191583|NCT00800007|Placebo Comparator|Placebo|
3191584|NCT00800033|Experimental|Aerobic exercise training|
3191585|NCT00800033|Placebo Comparator|Resistance exercise training|
3191586|NCT00800033|Experimental|pulse diet|Pulse based diet containing peas, lentils, and beans
3191587|NCT00800033|No Intervention|Regular diet|
3191588|NCT00800046|Experimental|AccuCinch® Ventriculoplasty System|Patients meeting the enrollment criteria will be treated with the AccuCinch® Ventriculoplasty System.
3191589|NCT00800059|Experimental|Treatment|Treatment with TMI and autologous Stem Cell transplant
3191590|NCT00800072|Experimental|oxygen therapy|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
2465515|NCT03135418|Experimental|Intervention|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift and Leap motion will be used to create an immersive interactive environment. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire,Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
2465517|NCT03135418|Sham Comparator|Control|25 stroke patients between the ages of 18-80, stroke duration of less than 2 months and not more than 2 years whose MMSE scores equal or above the 25 will be included in this study. Oculus Rift a will be used to create an immersive visual environment.Patient will be watching the premade scenarios without interaction. Modified Ashworth Scale (MAS), Functional independence scale, self-care questionnaire, Action Research Arm Test, Fugl meyer upper extremity motor evaluations will be applied just before the rehabilitation program, after the application and at the end of 6 weeks.
2465569|NCT03135301|Experimental|letrozole plus metformin|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued
2465572|NCT03135301|Active Comparator|letrozole|5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding
2465602|NCT03134976||Salvage Larynx|The first group includes subjects with cancer of the voice box (laryngeal squamous cell carcinoma) that has already been treated by either chemotherapy or radiation. This group will be treated using the standard of care, which includes starting thyroid hormone replacement therapy (levothyroxine) after surgery.
2465604|NCT03134976||Non-Salvage Larynx|The second group of subjects will consist of patients who have head and neck cancer of sites other than the voice box (larynx) without prior exposure to radiation or chemotherapy who are undergoing flap reconstruction surgery. This group will not be treated with levothyroxine so long as the subject has normal thyroid function. If a subject is hypothyroid, then thyroid hormone replacement will be given as a part of routine clinical care.
2465632|NCT03134677|Experimental|Bupivacaine|We were performed spinal anesthesia sitting position by midline. After confirming the free flow of cerebrospinal fluid, bupivacaine was administered without aspiration.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
2465636|NCT03134677|Experimental|Sevoflurane|We were performed general anesthesia with sevoflurane. Anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
2465667|NCT03134469|Experimental|Probiotics|Intake of a probiotic capsule once daily
2465668|NCT03134469|Placebo Comparator|Placebo|Intake of a placebo capsule once daily
3191591|NCT00800085|No Intervention|FDR of type 1 diabetes patients receiving glucose 20%|First Degree Relatives of diabetes type 1 patient with a high, intermedian or low risk (accoring to the criteria of the protocol), for developing diabetes type 1.
2465944|NCT03132948|Experimental|Physical Activity|Single arm study where patients choose from physical activities after baseline assessment by PT. Activities include the following: Nintendo WII fit console, Xbox Kinect fit console and other sport activities.
2466001|NCT03132324|Experimental|INCB059872 0.5 mg|INCB059872 0.5 mg tablet administered orally every other day (QOD) for 28 days on an empty stomach. If dose was well tolerated, once daily (QD) administration was evaluated independently and in parallel with QOD administration.
2466007|NCT03132324|Experimental|INCB059872 1 mg|INCB059872 1 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
2466014|NCT03132324|Experimental|INCB059872 2 mg|INCB059872 2 mg tablet administered orally QOD for 28 days on an empty stomach. If dose was well tolerated, QD administration was evaluated independently and in parallel with QOD administration.
2466046|NCT03131830||Staff of the University Clinic of Tuebingen|Online-based questionnaire
2466052|NCT03131830||Participants of the 9th German Urogynecological Congress|Online-based questionnaire
2466058|NCT03131830||All members of the German Society of Obsetrics and Gynecology|Online-based questionnaire
2466061|NCT03131830||Pregnant women from Tübingen and Heidelberg|Online-based questionnaire
3191592|NCT00800098|Placebo Comparator|Placebo|Placebo cream matched on consistency, color, and smell
3191593|NCT00800098|Active Comparator|Active|AARP active arthritis cream
3191594|NCT00800111|Other|Treatment|Endothelial keratoplasty procedure is performed.
2466438|NCT03129542|Active Comparator|Midodrine Hydrochloride 10 milligrams|Three doses of oral midodrine every 8 hours will be administered in addition to usual care for sepsis. Participants randomized to the intervention group will receive a total of 3 doses of midodrine 10 milligrams every 8 hours by mouth in the form of a tablet encapsulated in order to be identical to placebo. Participants will receive treatment for a total of 16 hours, beginning with the first dose.
2466441|NCT03129542|Placebo Comparator|Placebo oral capsule|For participants randomized to the placebo arm, an identical appearing capsule containing only Lactose Monohydrate powder will be administered every 8 hours for a total of 3 doses.
3191595|NCT00800124|No Intervention|1|Cemented hemiprosthesis
2466531|NCT03128450|Experimental|h-NSC arm|"human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel，produced by Shanghai Angecon Biotechology Cooperate.~One enrolled PD patient was given 2 vessels h-NSC througth nasal cavity weekly for 4 weeks。Total cell number will be over ≥4×10 6cells for one time."
2466633|NCT03128268|Experimental|All Enrollees|"Intervention: Diagnostic test~All enrollees will receive a 4D MRI as a research intervention using imaging software for 4 dimensional images for Cardiac MRI"
2466733|NCT03127319|Experimental|apatinib and docetaxel zoledronic|apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
2466734|NCT03127319|Active Comparator|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
2466785|NCT03126929||Vegetative state|patients lack awareness of self and environment even in the presence for eye-opening and sleep-wake cycles using CRS-R and GCS
2465563|NCT03135314|Active Comparator|Normoxia Cocoa flavanol|Exercise or cognitive test in normoxic condition after 7 days of cocoa flavanol intake
2465564|NCT03135314|Placebo Comparator|normoxia placebo|Exercise or cognitive test in normoxic condition after 7 days of placebo intake
2465592|NCT03135067|Experimental|Provision of multiple self-tests|Participants in intervention clusters will be given multiple HIV self-test kits, testing instructions, and advice to use their discretion when offering self-tests to selected sexual partners. Participants will be encouraged to offer self-tests primarily to current and potential partners with whom unprotected sex is likely. All participants will be encouraged to use condoms with sexual partners. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering self-tests to partners. Participants will have opportunities to obtain additional HIV self-test kits on a monthly basis.
2465594|NCT03135067|No Intervention|Referral vouchers for VCT|Participants will be given a multiple referral vouchers for HIV testing to distribute to their sexual partners. All participants will be encouraged to use condoms with sexual partners. These referral vouchers will encourage the partners to seek HIV counseling & testing services in local clinics. Participants will also be advised to assess the risk of intimate partner violence (IPV) as a result of offering referral vouchers to partners. Participants will have opportunities to obtain additional referral vouchers on a monthly basis.
2465722|NCT03134274|Experimental|Pregnant women|Pregnant women above the age of 18 years, undergoing routine pre-natal care, who own and are familiar with use of a smartphone receive a Dip HBDA kit for home use.
2465750|NCT03133975|Experimental|Treatment|Single high dose IM VIT D
2465752|NCT03133975|Active Comparator|Control|Usual diet mix of carbohydrates - lipid - protein - minerals & vitamins
2465801|NCT03133728||Pre-Intervention Group|The Investigators will visit each of the selected 3 clusters (i.e. 6 primary health clinics) to construct a retrospective cohort of high-risk HIV-infected women who entered the national PMTCT program and received the SOC between June 1, 2017 and May 31, 2018. Using existing data through the electronic health record information (SmartCare and LIMS), the investigators will gather individual-level retrospective data on high-risk Mother-Infant Pairs (MIPs) from PMTCT enrolment through the child's ART enrolment, initiation, and retention rate at 3 months.
2465802|NCT03133728||Post-Intervention Group|Study Research Assistants (RA) will review routine patient files and registers, augmented by existing electronic health record information, to identify a new cohort of high-risk Mother-Infant Pairs (MIPs) at each study site between the dates of June 1, 2019 and May 31, 2020. The outreach team will include, at a minimum, the study RA, a study peer, and an HIV counselor from the health facility, who will carry the Alere™ q HIV-1/2 Detect with them. When the outreach team contacts a high-risk MIP at community level, the team will approach the MIP for study screening, consent, and enrolment procedures. Study staff will ask the parent/guardian if the parent/guardian would like the IYC to be tested at their home, at a community health post, or other private space in the community. The IYC will be tested using both the Alere™ q HIV-1/2 Detect platform and a reflex DBS PCR test to evaluate performance of the POC platform in a mobile setting against the gold standard.
2465844|NCT03133351||PCM|All enrolled subjects will have a blood sample tested using PCM.
2465867|NCT03133117|Experimental|Cerebral Bases of Central and Peripheral Visual Integration|
2465943|NCT03132896||Patients with moderate or severe ARDS|
2466032|NCT03132077||satisfaction post total knee arthroplasty|The focus of this project is exploring outcomes post-primary total knee arthroplasty (TKA) using the available pre/post-operative Oxford Knee Score (OKS), University of California Los Angeles (UCLA) Activity Score, EQ-5D General Health Questionnaire, Visual Analogue (VAS) for pain, age and smoking status data, and correlations between these data and post operation patient satisfaction.
2466049|NCT03131739||Community Level Assessment|65 communities will undergo assessment of community / structural variables through review of public records and 3-5 key community interviewees per community.
2466054|NCT03131739||Individual Level Assessment|A subset of 6 communities will be elected through a stratification process. Youth will complete a set of protective factors measures and outcomes. Adults will complete a section of the Neighborhood Matters survey.
3191596|NCT00800124|Active Comparator|2|Non-cemented hemiprosthesis
3191597|NCT00800137|Active Comparator|Bridging anti-coagulation|Low Molecular Weight Heparin or IV unfractionated Heparin
2466227|NCT03130881|Experimental|PLB1003|ALK-positive (ALK+) advanced NSCLC
2466266|NCT03130634|Experimental|prescription of silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
2466269|NCT03130634|No Intervention|control|During six cycles of FOLFIRI chemotherapy, the patients will not take silymarin during chemotherapy
2466320|NCT03130335|Experimental|Bone Marrow Aspirate (BMA) Injection|
2466465|NCT03129464|Experimental|Cold Therapy|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. Intervention will include the patient being asked to use a reusable cold gel pack to deliver cold therapy to their abdominal incisions every 6 hours for the first 72 hours.
2466467|NCT03129464|No Intervention|Control|Patients undergoing total laparoscopic hysterectomy will receive routine pre-operative multi-modal analgesia regimen and well as routine post-operative analgesia with instructions for dosing. They will not receive any additional intervention.
2466487|NCT03128710||Survey Group|Approximately 300 patients with prostate cancer will be provided a survey investigating their treatment preferences and side effects faced during and after receiving radiation treatment.
2466489|NCT03128710||Focus Group|Approximately 75 participants will participate in a focus group. All participants will have completed radiation treatment and will discuss side effects after having received radiation, as well as their quality of life while receiving radiation.
2466616|NCT03128216|Active Comparator|Spinal Anesthesia|
2466679|NCT03127787||CMV infected|CMV infected observational study testing using DxN CMV Assay. Study is observational and results not used to manage patient care.
3191598|NCT00800137|Experimental|Continued oral anti-coagulation|Coumadin
3191599|NCT00800163|Experimental|ED Physician Activation/Immediate Transfer|
3191600|NCT00800215|Experimental|1|
3191601|NCT00800215|Placebo Comparator|2|
3191602|NCT00800215|Experimental|3|
3191603|NCT00800215|Placebo Comparator|4|
3191604|NCT00800228||1|Eight men and eight women to define the time course of changes in MBG \ and OLC accompanying sodium loading
2465626|NCT03134937|Other|Study Arm|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
2465677|NCT03134560|Active Comparator|With vein display instrument|Vein cannulation was done after the vein display instrument displays the veins using infrared
2465683|NCT03134560|No Intervention|Without vein display instrument|vein cannulation was done without any vein display instrument
2465816|NCT03133715|Active Comparator|laparoscopic ventral hernia|laparoscopic ventral hernia repair
2465820|NCT03133715|Active Comparator|robot-assisted ventral hernia|robot-assisted ventral hernia repair
2465897|NCT03133208||Sepsis with AMS|Patients presenting to the ED with suspected sepsis who develop altered mental status
2465899|NCT03133208||Sepsis without AMS|Patients presenting to the ED with suspected sepsis without change in mental status
2465901|NCT03133208||Control|Patients presenting to the ED with no suspicion of systemic inflammation that need hospitalization (control category)
2465924|NCT03132688||children < 2 years old|Children under 2 years of age who received intravenous propofol during general anesthesia.
2466056|NCT03131791|Experimental|shock wave|The interventions were focused in the hypertonic muscles of the upper limb of 3000 impulses, a pressure of 1.5 bar and frequency of 5Hz were used to treat the biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
2466059|NCT03131791|Experimental|Botulinum toxin A|We performed BoNT-A 500 unit in 2cc 0.9% normal saline at biceps brachii, flexor carpi ulnaris and flexor carpi radialis, mainly in the middle of the belly.
2466121|NCT03131440|Experimental|Experimental Condition #1|core, support calls
2466129|NCT03131440|Experimental|Experimental Condition #2|core, support calls, app+
2466136|NCT03131440|Experimental|Experimental Condition #3|core, support calls, buddy
2466141|NCT03131440|Experimental|Experimental Condition #4|core, support calls, online gym
2466145|NCT03131440|Experimental|Experimental Condition #5|core, support calls, app notifications
2466146|NCT03131440|Experimental|Experimental Condition #6|core, app+
2466148|NCT03131440|Experimental|Experimental Condition #7|core, app+, buddy
2466149|NCT03131440|Experimental|Experimental Condition #8|core, app+, online gym
2466150|NCT03131440|Experimental|Experimental Condition #9|core, app+, app notifications
2466151|NCT03131440|Experimental|Experimental Condition #10|core, buddy
2466152|NCT03131440|Experimental|Experimental Condition #11|core, buddy, online gym
2466153|NCT03131440|Experimental|Experimental Condition #12|core, buddy, app notifications
2466156|NCT03131440|Experimental|Experimental Condition #13|core, online gym
2466158|NCT03131440|Experimental|Experimental Condition #14|core, online gym, app notifications
2466160|NCT03131440|Experimental|Experimental Condition #15|core, app notifications
2466162|NCT03131440|Experimental|Experimental Condition #16|core, support calls, app+, buddy
2466163|NCT03131440|Experimental|Experimental Condition #17|core, support calls, app+, online gym
2466164|NCT03131440|Experimental|Experimental Condition #18|core, support calls, app+, app notifications
2466165|NCT03131440|Experimental|Experimental Condition #19|core, support calls, buddy, online gym
2466166|NCT03131440|Experimental|Experimental Condition #20|core, support calls, buddy, app notifications
2466167|NCT03131440|Experimental|Experimental Condition #21|core, support calls, online gym, app notifications
2466168|NCT03131440|Experimental|Experimental Condition #22|core, app+, buddy, online gym
2466169|NCT03131440|Experimental|Experimental Condition #23|core, app+, buddy, online gym, app notifications
2466170|NCT03131440|Experimental|Experimental Condition #24|core, support calls, buddy, online gym, app notifications
2466171|NCT03131440|Experimental|Experimental Condition #25|core, buddy, online gym, app notifications
2466172|NCT03131440|Experimental|Experimental Condition #26|core, app+, online gym, app notifications
2466173|NCT03131440|Experimental|Experimental Condition #27|core, support calls, app+, buddy, online gym
2466174|NCT03131440|Experimental|Experimental Condition #28|core, support calls, app+, buddy, app notifications
2466175|NCT03131440|Experimental|Experimental Condition #29|core, support calls, app+, online gym, app notifications
2466177|NCT03131440|Experimental|Experimental Condition #30|core
2466179|NCT03131440|Experimental|Experimental Condition #31|core, app+, buddy, app notifications
2466181|NCT03131440|Experimental|Experimental Condition #32|core, support calls, app+, buddy, online gym, app notifications
2466338|NCT03130049|Experimental|Patients with postoperative pain, NRS >3|Patients reporting postoperative pain (NRS >3) localized to the center of the knee (10 patients) will receive a popliteal plexus block
2466342|NCT03130049|No Intervention|Patients with postoperative pain, NRS ≤ 3|(approx. 90 patients)
2466408|NCT03129425|Experimental|Intervention group|Sessions in groups
2466411|NCT03129425|Sham Comparator|Control group|Sessions in groups
2466455|NCT03129074|Experimental|Varlitinib given in combination with capecitabine|"PO varlitinib 300 mg BID~PO capecitabine 1000 mg/m2 BID"
2466476|NCT03128801|Experimental|Global Stretching Program (GSP)|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active).
2466477|NCT03128801|Active Comparator|Stabilization Exercises|A exercise protocol will be administered and the criteria to increase exercise progression was previously described by Hicks et al (2005).
2466540|NCT03128541||Ultrasound Spine in sitting position|Participants will be assigned to a sitting decubitus position to identify the Tuffier's Line
2466546|NCT03128541||Ultrasound Spine in lateral position|Participants will be assigned to a lateral decubitus position to identify the Tuffier's Line
2465629|NCT03134794|Experimental|Educational Intervention|"Education intervention using the TLS. The active group will received an educational intervention applying proven concepts in medical education (cognitive reflection/checklist, traffic light system (TLS). Previous research showed that TL food labels prompted individuals to consider their health and to make healthier choices. A color-coded system influences the valuation process in favor of healthier choices by interfering with automatic decisions and triggering the re-evaluation process (Ena, Krajbich et al Judgement and DM 2016).~The TLS is being implemented to facilitate the identification of patients at risk of developing a clinical and radiological progression that could result in escalation of therapy."
2465631|NCT03134794|No Intervention|Control|Usual Care. The control group will make therapeutic decisions without being exposed to the educational intervention as part of the current standard practice.
2465676|NCT03134508||pregnant IBD women treated|pregnant IBD women treated by antiTNFα
2465682|NCT03134508||pregnant IBD women not treated|pregnant IBD women not treated by antiTNFα
2465957|NCT03132766|Experimental|New Hope + Elders' Resilience + CM|Participants will receive case management plus the New Hope curriculum and subsequently the Elders' Resilience curriculum.
2465959|NCT03132766|Experimental|New Hope + CM|Participants will receive case management plus the New Hope curriculum.
2465961|NCT03132766|Experimental|Elders' Resilience + CM|Participants will receive case management plus the Elders' Resilience curriculum.
2465963|NCT03132766|Active Comparator|CM alone|Participants will receive case management only.
2466344|NCT03130023|Experimental|Test group|All subjects will be enrolled in the test group and will receive Pulse Oximeter with ORI.
2466378|NCT03129737|Experimental|Tricuspid valve annuloplasty|Concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm /m2) with or without TR≤ moderate in pts undergoing mitral valve surgery
2466385|NCT03129737|Active Comparator|Mitral valve repair|No concomitant tricuspid valve annuloplasty in patients with tricuspid annulus dilatation (>21mm/m2) with or without TR ≤ moderate in pts undergoing mitral valve surgery
2466426|NCT03129191|Active Comparator|AB arm|"Sequence:~Aided with non-invasive bone conduction hearing aid A~Aided with non-invasive bone conduction hearing aid B"
2466430|NCT03129191|Active Comparator|BA arm|"Sequence:~Aided with non-invasive bone conduction hearing aid B~Aided with non-invasive bone conduction hearing aid A"
3174694|NCT00626067|Active Comparator|1 Fully functional monitoring device|Fully functional monitoring device
2466577|NCT03128593|Experimental|Experimental: JR-141|
2466598|NCT03128060|Experimental|Home-based Palliative Care|Home-based palliative care features home visits by an interdisciplinary PC team (physician, nurse, social worker, and chaplain) that provides pain and symptom management, psychosocial support, advance care planning, disease management education, spiritual and grief counseling, and other services as needed.
2466601|NCT03128060|Active Comparator|Enhanced Usual Care|Enhanced usual care refers to: 1) usual primary care provided by a primary care physician who has been offered special training in the core elements of palliative care; 2) case management services; and 3) provider support through palliative care consultation.
2466660|NCT03127878|Active Comparator|Active-control|High-intensity endurance exercise of lower-limb with strengthening exercise of upper- and lower-limb
2466661|NCT03127878|Experimental|Upper-limb additional training|High-intensity endurance exercise of upper- and lower-limb with strengthening exercise of upper- and lower-limb
2466688|NCT03127475|Sham Comparator|sham tDCS|Device: Sham tDCS Sham stimulation will be 30s stimulation with ramp up and ramp off for 10s at 2.0 mA.
2466708|NCT03127709||Participants with a histiocytic disorder diagnosis|Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
3174695|NCT00626067|Active Comparator|2 Partially functional monitoring device|Partially functional monitoring device
3174696|NCT00626067|Sham Comparator|3 Non-functional monitoring device|Non-functional monitoring device
3174697|NCT00626106|Placebo Comparator|Placebo|
3174698|NCT00626106|Active Comparator|Investigational Product|
3174699|NCT00626106|Other|Roll-over|
3174700|NCT00626119||Control|
3174701|NCT00626119||diseased|
3174702|NCT00626132|Experimental|Eucommia|Eucommia capsules two orally three times a day for 2 weeks
3174703|NCT00626132|Placebo Comparator|1|
3174704|NCT00626145|Placebo Comparator|1|Patients receive intracoronary injections of saline 7 days after PCI.
3174705|NCT00626145|Experimental|2|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
3174706|NCT00626158|Experimental|Gem/Cape|
3174707|NCT00626171|Other|1|Allergen challenge
3174708|NCT00626184|Placebo Comparator|A|Placebo
3174709|NCT00626184|Active Comparator|B|Active study Drug: ALV003
3174710|NCT00626223|Experimental|A|patients treated with intravenous 5-MTHF (Prefolic®, Knoll, Milan, Italy) 50 mg at the end of each hemodialysis session; The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week
3174711|NCT00626223|Active Comparator|B|"treated with 5 mg per day of oral folic acid (Folina® Schwarz Pharma, Milan, Italy).~The group will receive supplementation with vitamin B6 300 mg (Benadon®, Roche, Milan, Italy) and vitamin B12 1000 mcg (Dobetin®, A.C.R.A.F, Rome, Italy) administered by intravenous injection at the end of the hemodialysis session three times per week"
3174712|NCT00626236|Experimental|Treatment 1|
3174713|NCT00626236|Experimental|Treatment 2|
3174714|NCT00626236|Experimental|Treatment 3|
3174715|NCT00626236|Experimental|Treatment 4|
3174716|NCT00626249|Experimental|T Inhalation powder in diabetic subjs w/ normal renal func|T inhalation powder in diabetic subjects with normal renal function, Single dose, 30 units
3174717|NCT00626249|Experimental|T Inhalation powder diabetic subj w/mild or moderate nephrop|T Inhalation powder in diabetic subjects w/mild or moderate nephropathy - Single dose, 30 units
3174718|NCT00626262|Experimental|1|20mg oral
3174719|NCT00626262|Experimental|2|20mg IV
3174720|NCT00626288|Experimental|A|Mesalazine cpr 800 mg t.i.d. for 12 weeks
2465799|NCT03133780|Active Comparator|Ketamine|Patients will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
2465800|NCT03133780|Active Comparator|Midazolam|Patients will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
2465851|NCT03133416|Active Comparator|PRP preparation|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval.
2465852|NCT03133416|Active Comparator|Physiotherapy|Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
2465853|NCT03133416|Active Comparator|PRP and physiotherapy|PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. Then about 2ml PRP will be extracted, and will be infiltrated to the lesion site under ultrasound guidance. The injection technique is similar to that described by Kesikburun .21 Patients in group 1 or group 3 will receive 2 injections of PRP, with 1 month interval;Physiotherapy includes hot pack, electric therapy and therapeutic exercise, which will be supervised by a senior physical therapist. The therapeutic exercise consists of active and passive stretch, and strengthening exercise of the rotator cuff, the shoulder girdle, and the pectoral muscles, 3 times a week, and will continue for 1.5 months. After 1.5 months' supervised training, home program exercise follows and will be continued for another 1.5 months.
2465871|NCT03133026|Active Comparator|Sludge group|If Single operator cholangioscopy reveals only sludge then sludge will be cleared using conventional technique during ERCP.
2465876|NCT03133026|Active Comparator|Ingrowth / Overgrowth|If Single operator cholangioscopy reveals tumour ingrowth or overgrowth then to evaluate the role of biliary RFA for occluded stent due to tumour ingrowth or overgrowth
2465913|NCT03132818||Patients undergoing AMP with oocyte donation|
2465917|NCT03132818||Couples supported in AMP with sperm donation|
2465929|NCT03132818||Couples supported in AMP intra torque|
2465971|NCT03132467|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo a biopsy and receive standard of care neoadjuvant chemotherapy before undergoing surgery.
2466028|NCT03132168|Other|Subjects undergoing radical cystectomy|Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
2466071|NCT03131778|Active Comparator|Open Liver Resection|Conventional open liver resection trough subcostal incision
2466073|NCT03131778|Experimental|Laparoscopic Liver Resection|Pure laparoscopic liver resection without hand assistance
2466119|NCT03131414||Irritable bowel syndrome|"A total of 2000 patients with IBS who have met Rome IV criteria are 13 years of age or older will be consented and recruited for this study.~IBS patients will be categorized into diarrhea predominant IBS (IBS-D), constipation predominant IBS (IBS-C) or alternating constipation and diarrhea (IBS-A) or unclassified IBS (IBS-U). A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2466130|NCT03131414||Ulcerative colitis|"2000 CD and 2000 UC cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult UC patients, and the Paris classification for pediatric UC. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2466135|NCT03131414||Crohn's disease|"2000 CD cases over the age of 4 years will be enrolled.~Montreal Classification will be used for adult CD patients, and the Paris classification for pediatric CD. The research coordinator will conduct a chart review to confirm date of diagnosis and maximal phenotype at time of enrolment. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2466143|NCT03131414||Healthy control|"A total of 2000 healthy family members, relative or friends of cohort participants over the age of 4 will be consented and recruited for this study.~Each control that agrees to participate will undergo an initial screening questionnaire to confirm that they are healthy and have no gastrointestinal symptoms using the ROME IV Questionnaire. A detailed diet history will be obtained and gastrointestinal microbiome will be evaluated."
2466192|NCT03130920|No Intervention|Control|
2466195|NCT03130920|Active Comparator|Remote ischemic preconditioning|
2466196|NCT03130920|Active Comparator|Local ischemic preconditioning|
2466231|NCT03130751|Experimental|Mobile application|
2466265|NCT03130569|No Intervention|Control Group|Will simply complete surveys at baseline and at the three-month follow-up.
2466270|NCT03130569|Experimental|Web-based Module Group|Participants will complete surveys at baseline. Participants in this arm will be provided with information to access and complete a web-based educational module (AKA the intervention), at the end of which will be given the opportunity to request and complete genetic testing for skin cancer. Participants who elect to complete the genetic testing will receive their genetic testing results along with a two-week follow-up call. All participants will also complete the survey at the three month follow-up.
2466362|NCT03129854|Experimental|experimental group|Prostate cryotherapy plus ADT
2466365|NCT03129854|No Intervention|control group|standard of care ADT continually
2466475|NCT03129087|Experimental|Vocal rest|The vocal rest arm will require the participant to remain in the clinic and remain on complete vocal rest for a period of one hour after a botulinum toxin injection
3174721|NCT00626288|Placebo Comparator|B|Placebo cpr t.i.d. for 12 weeks
2465848|NCT03133650|Experimental|Vascular-targeted photodynamic therapy (VTP) using WST11|Participants will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes, during an endoscopy procedure, followed by immediate laser light application.
2465868|NCT03133065|Active Comparator|Group 1: treatment after 6 months post transplantation|53 patients received Sofosbuvir+ribavirin standard of care for treatment of HCV post liver transplantation for 6 months
2465869|NCT03133065|Active Comparator|Group 2: early treatment afer 3 months post transplantation|36 patients received other DAAs regiment for treatment of HCV post liver transplantation for 3- 6 months
2465998|NCT03132415|Experimental|Get Connected|Get Connected is a brief intervention focused on resolving ambivalence about HIV prevention behaviors, increasing self-efficacy for change, and enhancing motivation moving toward action.
2466010|NCT03132415|Active Comparator|Non-tailored HIV Test Locator|Participants randomized to the control condition will be directed to a website that includes information on the AIDSVU.org testing site locator. Given the availability of search engines to locate HIV/STI testing sites, the test locator condition may be considered usual care.
2466188|NCT03131011|Experimental|Arm 1 - UV ink|Radiotherapy tattoos will be applied using an invisible UV fluorescent ink that can only be detected while illuminated with a special ultraviolet flashlight.
2466191|NCT03131011|No Intervention|Arm 2 - Black ink|Radiotherapy tattoos will be applied using standard black ink.
2466233|NCT03130855|Experimental|inferior alveolar nerve block with 4% articaine|inferior alveolar nerve block using 4% articaine anesthetic solution
2466234|NCT03130855|Active Comparator|buccal infiltration with 4% articaine|buccal infiltration using 4% articaine anesthetic solution
2466275|NCT03130543|No Intervention|Standard Formula|This is the group of subjects randomized to receive their standard formula
2466277|NCT03130543|Experimental|Standard Formula with Rice Cereal|This is the group of subjects randomized to receive their standard formula with rice cereal added
2466281|NCT03130543|Experimental|Enfamil AR|This is the group of subjects randomized to receive Enfamil AR
2466355|NCT03129919|Experimental|Orthodontic patients treated with brackets Carriere SLX®|Subjects requiring orthodontic treatment and will be treated with passive self-ligating braces Carriere SLX®
2466357|NCT03129919|Active Comparator|Orthodontic patients treated with brackets Empower®|Subjects requiring orthodontic treatment and will be treated with interactive self-ligating braces Empower®
2466375|NCT03129633|Experimental|Promotores Network|Promotores will engage participants using the materials A Page of My Life and the Success Plan. Promotores will ask participants to rank their satisfaction with each of the domains included in the A Page of My Life and ask them what domain they want to change. Using non-directive questions, promotores will guide the participant to draft a plan for success. The promotor/a will follow up with participants within a week of enrollment and at least monthly via phone/text during six months. During the intervention period, promotores will meet with participants (child and parent together, if applicable) at least three times in-person during which they will deliver the short (15-minutes) educational components of the intervention.
2466380|NCT03129633|No Intervention|Wait-list Control|The community liaison will deliver a short (15-minute) educational session on the benefits of a healthy lifestyle and preventive use of health care, and give participants a pamphlet with relevant local health care and social service resources.
2466414|NCT03129373|Experimental|Pixie group|"Cryogenic treatment of wart (liquified nitrous oxide)~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2466418|NCT03129373|Active Comparator|Wartner group|"Cryogenic treatment of wart (dimethylether propane-based):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2466422|NCT03129373|Active Comparator|Wortie group|"Cryogenic treatment of wart (dimethylether-based product):~Maximum 3 application by the technician in charge of the study.~Apply between 15 to 20 sec on hand and 40 sec on feet."
2466471|NCT03129009|Active Comparator|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
2466473|NCT03129009|Experimental|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
2466521|NCT03128658||Trauma patients|Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.
2466647|NCT03127930|Experimental|Intervention|Intervention: Participants receive both usual care including a standard brochure on patient management provided by the Alzheimer's Association plus a tailored problem-solving intervention to improve caregiver's management of medications for their family or friend care recipient who has memory deficit.
3174722|NCT00626301|Experimental|1|Children who have completed HIV-NAT 017. Children treated with other double boosted PIs such as indinavir plus lopinavir/ ritonavir are also included.
3174723|NCT00626314|Experimental|1|myoblast
3174724|NCT00626314|Sham Comparator|2|sham injection procedure
3174725|NCT00626353|Experimental|Intervention|Patients treated by an interdisciplinary, intersectoral and interventional team responsible for providing home-based rehabilitation.
3174726|NCT00626353|Active Comparator|Control|Control patients treated following standard care procedures in our department with no interference from the interventional team.
3174727|NCT00626418|Placebo Comparator|1|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
3174728|NCT00626418|Active Comparator|2|This will be a crossover study. Ascending doses of active drug will be administered on study nights 3-5 with an option of 3 additional nights in an attempt to identify a tolerable efficacious dose. Night 1 will be an adaptation night and night two will be a placebo night.
3174729|NCT00626457|Experimental|Maintenance First|
3174730|NCT00626457|Active Comparator|Weight Loss First|
3174731|NCT00626470|Active Comparator|-TSP|Patients operated without TSP
2465773|NCT03133897|Experimental|Dexamethasone|"Dexamethasone group: Children will receive the approximate pharmacologic equivalent of two doses (days) of dexamethasone 0.6 mg/kg/dose (maximum dose 16 mg per dose) once daily as follows. The standard dose of prednisone/prednisolone provided in the emergency department is 2 mg/kg/dose (maximum dose 50 mg), which is approximately equivalent to 0.3 mg/kg/dose of dexamethasone. Therefore, patients who received prednisone/prednisolone in emergency department as per the current Nursing Medical Directive and Pre-Printed Order form will receive a top-up These patients will then receive a dose of dexamethasone 0.6 mg/kg (maximum dose 16 mg) 24 hours after the initial corticosteroid dose received in the Emergency Department of dexamethasone 0.3 mg/kg (maximum dose 8 mg) upon enrollment."
2465833|NCT03133494|Active Comparator|Laparoscopic cholecystectomy in smokers|ABG analysis of patients with history of smoking posted for laparoscopic cholecystectomy was collected
2465838|NCT03133494|Placebo Comparator|Laparoscopic cholecystectomy nonsmokers|ABG analysis of patients without history of smoking posted for laparoscopic cholecystectomy was collected
2465898|NCT03133130|Experimental|BMT101|cp-lasiRNA
2465900|NCT03133130|Placebo Comparator|Placebo|Normal Saline
2465928|NCT03132714|Active Comparator|PD + (AMX + MET)|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg
2465934|NCT03132714|Active Comparator|PD + CLM|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic clarithromycin 500 mg
2465937|NCT03132714|Active Comparator|PD + (AMX + MET) + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and single application of PDT
2465939|NCT03132714|Active Comparator|PD + CLM + sPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and single application of PDT
2465941|NCT03132714|Active Comparator|PD + (AMX + MET) + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Amoxicillin 500 mg + Metronidazole 400 mg and repeated application of PDT
2465942|NCT03132714|Active Comparator|PD + CLM + rPDT|periodontal pockets that will receive full-mouth ultrasonic debridement associated with systemic Clarithromycin 500 mg and repeated application of PDT
2466018|NCT03132181|Experimental|Empagliofizin|Patients will receive empagliflozin 10 mg qd for a period of 3 months.
2466019|NCT03132181|Placebo Comparator|Placebo|Patients of the placebo arm will receive placebo tablets qd for a period of 3 months.
2466036|NCT03131817|Experimental|PD with mood disorder or impulsivity|This is a single-center study of the neurophysiology of non-motor symptoms such as anxiety, depression, and impulsivity that are comorbid in Parkinson's Disease.
2466080|NCT03131635|Experimental|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
2466082|NCT03131635|No Intervention|Delayed Treatment Group (DTG)|
2466113|NCT03131336|Experimental|PeproStat|PeproStat 2.5mg/mL soaked into haemostatic gelatin sponge, applied to a target bleeding site
2466114|NCT03131336|Placebo Comparator|Saline|Saline soaked into haemostatic gelatin sponge, applied to a target bleeding site
2466229|NCT03130972||developmental delay|Children who visited tertiary rehabilitation clinic for delayed motor development were all included.
3156635|NCT00348855|Experimental|1|"Intervention with one day training, electronic device to measure bood pressure, leaflet with goals and drug strategies according to guidelines, six specific cardiovascular consultations during two years, feed back on results of the intervention group at inclusion, year 1 and year 2.~Specific consultations will be focused on goals to be reach, compliance, exercise and diet."
3156636|NCT00348855|No Intervention|2|
3156637|NCT00348868|Experimental|1|enhanced behavioral motivation counseling
2466305|NCT03130374|Experimental|Mesenchymal stem cell treated group|Patients treated according to current clinical protocols plus autologous olfactory mucosa-derived mesenchymal stem cells
2466306|NCT03130374|No Intervention|Control group|Patients treated according to current clinical protocols
2466346|NCT03130036|Experimental|No risk of disease|Subjects with no identifiable risk of Alzheimer's Disease
2466347|NCT03130036|Experimental|Asymptomatic|Asymptomatic subjects with increased risk of Alzheimer's disease
2466349|NCT03130036|Experimental|Early Alzheimer's or Mild Cognitive Impairment|Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)
2466371|NCT03129646|Experimental|Arm 1 - MF/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 14 days
2466374|NCT03129646|Experimental|Arm 2 - MF 28d/PM 14d|Paromomycin 20 mg/kg/d IM for 14 days combined with oral miltefosine allometric dosing for 28 days
2466377|NCT03129646|Active Comparator|Arm 3 - SSG/PM 17d|Sodium Stibogluconate 20 mg/kg/day IM/IV combined with Paromomycin 15 mg/kg/day IM for 17 days
2466460|NCT03129165|Experimental|Screening and prevention of CVD|
2466507|NCT03128762||Cases|"Patients in this group are asthmatic (see inclusion/exclusion) criteria.~Intervention: ILC2 levels in blood"
2466508|NCT03128762||Controls|"Controls are non-asthmatic subjects that are age and gender matched to asthma cases.~Intervention: ILC2 levels in blood"
2466536|NCT03128437|Experimental|Aerobic Exercise Condition|6 aerobic exercise exposures will be completed over the course of 2 weeks.
2466537|NCT03128437|No Intervention|Assessment Only Condition|"Participants randomly assigned to the control condition will complete assessments at the same time intervals as the active condition, but will not participate in exercise sessions.~Assessments will take place at baseline, week 2, week 4, and week 8."
2466630|NCT03128203|Experimental|Oxytocin|
2466637|NCT03128203|Placebo Comparator|Placebo|
3156638|NCT00348868|Active Comparator|2|
3156639|NCT00348894|Experimental|Open Treatment|[S,S]-reboxetine
3156640|NCT00348894|Other|Standard Care|Standard Care
3156641|NCT00348907|Active Comparator|1|immediate thermal cure (1st year)
3156642|NCT00348907|Sham Comparator|2|late thermal cure (2 years)
3156643|NCT00348920|No Intervention|1- General Anesthesia|General Anesthesia includes administration of a routine cardiac anesthetic as per institutional norms.
3174732|NCT00626470|Active Comparator|+TSP|Patients operated with TSP
2465780|NCT03133923|Experimental|Attenuated Mumps vaccine (KMB-17), high|Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)[≥4.5 logCCID50/ml] in 360 infants (8-24 months old) on 0 day
2465784|NCT03133923|Active Comparator|Measles and Mumps Combined Vaccine，Live|manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
2465805|NCT03133455|Other|Patient with Fibromyalgia|
2465855|NCT03133273|No Intervention|Usual care|Patient is followed within the usual care for stage 4 colorectal cancer
2465856|NCT03133273|Experimental|Oncogramme®|For patients in the Oncogramme® group, chemotherapy will be adapted to Oncogramme® results.
2465918|NCT03132935||Telemedicine group|Telemedical care of acute coronary syndromes in the prehospital phase. Paramedics were supported by a physician in a tele consultation centre.
2465926|NCT03132935||Control group|Conventional on-scene care of acute coronary syndromes by a physician. No telemedicine system was available during this control period.
2465970|NCT03132480|Experimental|hypovolemia|
2465994|NCT03132194|Experimental|DPSG 7.5%|"DPSG 7.5% (Taro Pharmaceuticals USA)~Topical, twice daily on the face for 84 days."
2465999|NCT03132194|Placebo Comparator|Vehicle Gel|"Placebo product (Taro Pharmaceuticals Inc.)~Topical, twice daily on the face for 84 days."
2466012|NCT03132194|Active Comparator|Aczone|"dapsone 7.5~Topical, twice daily on the face for 84 days."
2466068|NCT03131882|Experimental|Hyaluronic acid|Hyaluronic acid
2466069|NCT03131882|Active Comparator|Triamcinolone acetonide|10mg/ml Triamcinolone acetonide
2466213|NCT03131193|No Intervention|No provider - No cash transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2466214|NCT03131193|Experimental|No Provider - Cash Transfer|Study primary health centers (PHC) will carry out business-as-usual, with no additional staffing or changes to usual clinic operations. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2466215|NCT03131193|Experimental|Physician - No Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2466218|NCT03131193|Experimental|Physician - Cash Transfer|Study PHCs will receive an additional health provider - a physician. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2466220|NCT03131193|Experimental|Mid-level Provider - No Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the PHC will not receive any incentives (conditional cash transfer) to encourage them to seek care at the study clinic.
2466221|NCT03131193|Experimental|Mid-level Provider - Cash Transfer|Study PHCs will receive an additional health provider - a mid-level provider. Study participants who live in the community served by the study PHC will receive a conditional cash transfer if they use services provided by the study PHC.
2466292|NCT03130582||Disease status at mobilization PR|
2466297|NCT03130582||Disease status at mobilization PD|
2466310|NCT03130166|Experimental|Intracorporeal anastomosis|Patients undergo robotic right colectomy with intracorporeal anastomosis.
2466311|NCT03130166|Active Comparator|Extracorporeal anastomosis|Patients undergo robotic right colectomy with extracorporeal anastomosis.
3156644|NCT00348920|Experimental|2- High Spinal and General Anesthesia|High Spinal and General Anesthesia includes a high dose intrathecal anesthetic administered prior to the induction of a standardized cardiac general anesthetic.
2466437|NCT03129204|Experimental|SAF-T Intervention Group|The SĀF-T intervention includes coaching from SĀF-T trained research staff on awareness of biological sensations associated with events in the ICU that are perceived stressful. The research staff member will sit across from the participant and ask them to use their eyes to follow hand movements that will induce lateral left-right (saccadic) eye movements to elicit an orienting response that activates an investigatory reflex in which first, an alert response occurs and then, a reflexive pause produces decreased arousal in the face of no threat, which elicits a calming response that rapidly eliminates negative biological sensations of stress.
2466440|NCT03129204|No Intervention|Control Group|The control group will not receive the SAF-T intervention.
2466656|NCT03127917|Experimental|CitrullinePlacebo|Subjects allocated to the CitrullinePlacebo study arm received L-citrulline first, followed by placebo.
2466657|NCT03127917|Experimental|PlaceboCitrulline|Subjects allocated to the PlaceboCitrulline study arm received placebo first, followed by L-citrulline.
2466711|NCT03127449|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
2466736|NCT03127111||Adjuvant chemotherapy|Samples from patients with stage III colorectal cancer who are going to receive fluorouracil-based adjuvant chemotherapy will be used for gene mutations analysis, gene methylation analysis, gene expression analysis, SNP analysis, and protein expression analysis.
2466812|NCT03126838||diaphragmatic dysfunction|diaphragmatic displacement < 10 ml, and / OR diaphragmatic thickening fraction < 36 %.
2466827|NCT03126838||non diaphragmatic dysfunction|diaphragmatic displacement > 10 ml, and / OR diaphragmatic thickening fraction > 36 %.
2466863|NCT03126409|Experimental|No-Touch vein harvesting technique|During saphenous vein harvesting, surrounding tissue of the vein is preserved, and manual distension of the vein graft is avoided
2466865|NCT03126409|Active Comparator|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
2466936|NCT03126071|Experimental|Raltitrexed and Irinotecan（RALIRI） plus Bevacizumab(AVASTIN)|Irinotecan:250mg/m2 iv,90min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
2466937|NCT03126071|Experimental|Raltitrexed and Oxaliplatin（RALOX） plus Bevacizumab(AVASTIN)|Oxaliplatin:130mg/m2 iv,120min,d1, Raltitrexed:3.0mg/m2,iv,15min,d1, Bevacizumab:7.5mg/kg iv,30min,d1,q3w. Maintenance: Raltitrexed(3.0mg/m2,iv,15min,d1,q3w)+Bevacizumab(7.5 mg/kg q3w)
2465830|NCT03133468|Placebo Comparator|Part 3: Placebo|Caucasian and Japanese participants will be randomized to receive one of three single doses of matching placebo on the morning of Day 1 and multiple daily doses beginning on the morning of Day 3, with the last dose received on the evening of Day 9. The actual doses, dosing frequencies, and timings with respect to meals to be employed in Part 3 of the study will be determined after review of the data from dose groups in Parts 1 and 2 of the study.
2465870|NCT03133104||antenatal corticosteroids|Women who received a rescue dose of steroids
2465875|NCT03133104||No antenatal corticosteroids|Women who did not received a rescue dose of steroids
2465931|NCT03132623|Active Comparator|Experimental group|andrographolide sulfonate(Xiyanping injection) 10-20ml/d, With 0.9% normal saline 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
2465933|NCT03132623|Placebo Comparator|control group|andrographolide sulfonate simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
2465990|NCT03132389||Patients attending after a sexual assault|Patients attending and examined after sexual assault at the Sexual Assault Centre in Oslo, who have given informed consent to inclusion in the study.
2466076|NCT03132038|Experimental|Nivolumab|Nivolumab will be given every two weeks for a maximum of one year (12 cycles) at a dose of 3 mg/kg to be administered as a 60 minute IV infusion
2466321|NCT03130322|Experimental|NightPP|Participants of the NightPP will be subjected to one MRI session and two MEG recording sessions: the first one before a physical practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
2466322|NCT03130322|Experimental|NightMI|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
2466324|NCT03130322|Experimental|NightCtrl|Participants of the NightCtrl will be subjected to one MRI session and two MEG recording sessions: the first one before a mental rotation practice session, a second MEG session right after practice,and second MEG session right after practice.
2466327|NCT03130322|Experimental|Day|Participants of the NightMI will be subjected to one MRI session and two MEG recording sessions: the first one before a motor imagery practice session of the two motor tasks investigated in the study, and second MEG session right after practice.
3156645|NCT00348985|Experimental|PXD101 in Combination with Bortezomib (PS-341)|Patients receive PXD101 IV over 30 minutes on days 1-5 and bortezomib IV on days 1, 4, 8, and 11 (2, 5, 8, and 11 during course 1).
3156646|NCT00349050|Active Comparator|1|laboratory pain assessment
3156647|NCT00349050|Active Comparator|2|transcranial magnetic stimulation
2466555|NCT03128528|Placebo Comparator|Placebo Oral Tablet|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
2466557|NCT03128528|Active Comparator|Empagliflozin|Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
2466608|NCT03128125|Experimental|High intellectual potential|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in children with high intellectual potential.
2466612|NCT03128125|Other|Control|Participation in the study involves the conduct of a clinical examination in neurology, the collection of anamnestic elements and a neuropsychological examination in control children with no particularities.
2466667|NCT03127839|Active Comparator|Eccentric Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing eccentric strengthening exercises of the rotator cuff to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the eccentric strengthening exercises daily at home.
2466668|NCT03127839|Active Comparator|Traditional Strengthening Exercise|Patients will be asked to complete at least 6 outpatient PT sessions over a 4-week period. This will include an individualized impairment-focused approach, utilizing traditional rotator cuff strengthening exercises to address any impairments or reinforce any standard of care manual treatment. Patients will also be given a home exercise program with instructions so that they can perform the traditional rotator cuff strengthening exercises daily at home.
2466683|NCT03127475|Experimental|real tDCS|Device: Transcranial direct current stimulation In tDCS,the anodal pad was tapped over the primary motor cortex and the cathode pad was adhered of the contralateral frontal region. A constant current of 2.0 mA will be apply for up to 20 min, with a linear fade in /fade out of 10 s in anodal and cathodal conditions resulting in a current density of 0.8A/M2 which is 177 times below the lesion effect of tDCS in the rats study(142.9A/m2)
3156648|NCT00349076|Experimental|1|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil und Oxaliplatin:~Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours; repeat day 15, 8 cycles"
3156649|NCT00349076|Active Comparator|2|"Preoperative simultaneous radiochemotherapy: 5-Fluorouracil Radiotherapy starts on day 1 of chemotherapy; 28 fractions; single dose: 1,8 Gy once per day, monday through friday; Total dose: 50,4 Gy; 5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
3156650|NCT00349089|Active Comparator|1|Cisplatin/Vinorelbine
3156651|NCT00349089|Experimental|2|Cisplatin/Pemetrexed
3156652|NCT00349102|Active Comparator|A|Free breathing during conformal radiation
3156653|NCT00349102|Experimental|B|Breath holding during conformal radiation
3156654|NCT00349167|Experimental|PR-104|PR104 was administered as a 1-hr IV infusion every 21 days at doses ranging from 135 to 1400 mg/m2
3156655|NCT00349193|Active Comparator|Laquinimod 0.3 mg|Laquinimod 0.3 mg
3156656|NCT00349193|Active Comparator|Laquinimod 0.6 mg|Laquinimod 0.6 mg
3156657|NCT00349193|Placebo Comparator|Placebo|Blinded Placebo
2465891|NCT03133169||on chelation|"patients with B-thalassemia major samples of which will be examined for renal and liver function, Erythrocyte Glutamine level, ferritin level and complete blood picture. Also Echo will be done for measuring the Tricuspid regurge velocity.~group 1: cases on chelation: deferasirox 500mg oral tablet with initial dose 20 mg/kg guided by ferritin level~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
2465893|NCT03133169||No chelation|"group 2: cases without chelation~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
2465895|NCT03133169||splenectomy|"group 3: cases with splenectomy~Diagnostic Test: blood sample~Diagnostic Test: Tricuspid regurge velocity"
2465896|NCT03133169||no splenectomy|group 4: cases without splenectomy Diagnostic Test: blood sample Diagnostic Test: Tricuspid regurge velocity
2465910|NCT03132662|Active Comparator|Very Low Calorie Diet|The first group will continue according to the standard bariatric preoperative protocol and will be assigned a VLCLD of 900 cal/day (Optifast ® 4 servings/day each containing: 225 cal + 0.35 g linolenic acid) for 2-3 weeks prior to surgery according to the surgeon's preferences.
2465911|NCT03132662|Experimental|Omega-3|The second group will be assigned to 3 gr. daily oral intake of Ω-3 PUFAs ((Oceano3 ® 1000 mg Krill Oil tabs (150 mg EPA + 90 mg DHA) 3 times a day) for 4 weeks with only regular dietary suggestions before surgery.
2465912|NCT03132662|No Intervention|No-treatment|The third group will not receive treatment for liver size reduction prior to surgery.
2465964|NCT03132558||CTA|Patients with AIS only receieved cerebral CTA exam.
2465965|NCT03132558||CTA+DSA|Patients with AIS receieved cerebral CTA, followed by endovascular treatment with the guidence of digital substration angiography (DSA).
3191605|NCT00800228||2|32 additional women to determine whether breathing pattern is predictive of sodium sensitivity in that gender. Women are being studied in the second experiment because they, but not men, have been shown to have an association of breathing pattern with high perceived stress11 and an association of high resting end tidal CO2 with high resting blood pressure.
3191606|NCT00800267|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
2466078|NCT03131765|Experimental|YS-ON-001|"Phase 1- Dose escalation based on YS-ON-001 safety and tolerability obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur.~Phase 1b- recommended dose determined in Phase 1. Enrollment of two expansion cohorts will be restricted to the tumour types, breast cancer and liver cancer"
2466110|NCT03131349||column heading in tables|history examinations investigation:serum zinc and iron
2466111|NCT03131349||row heading in tables|history examinations investigation:serum zinc and iron
2466209|NCT03131141|Experimental|Cohort A|Cohort A will receive a single IV administration of 14C-BC-3781 containing 150 mg BC-3781 and NMT 4.3 MBq (117 µCi) 14C, administered as an infusion over 60 min after a light breakfast
2466212|NCT03131141|Experimental|Cohort B|Cohort B will receive a single oral administration of 14C-BC-3781 containing 600 mg BC-3781 and NMT 4.1 MBq (112 µCi) 14C, in the fasted state
2466249|NCT03130712|Experimental|GPC3-CART cells|
3191607|NCT00800267|Active Comparator|latanoprost 0.005%|
2466334|NCT03130114|Placebo Comparator|Control|Placebo mixture, 0.25 ml / kg / day
2466335|NCT03130114|Experimental|Azithromycin|Azithromycin mixture (40 mg / ml), 0.25 ml / kg / day
3191608|NCT00800267|Active Comparator|Timolol - 0.5%|
3191609|NCT00800280|Experimental|Single dose PD 0332334|
3191610|NCT00800280|Experimental|Single dose PD 0332334 with steady-state cimetidine|
2466552|NCT03128515|Experimental|MTD Dose Escalation|Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
2466553|NCT03128515|Active Comparator|Fixed Dose|Fixed dose of Hydroxyurea, 20 mg/kg/day
2466625|NCT03128151||Study group|Intraoperative neuromuscular monitoring and pharmacological reversion according to data sheet
2466631|NCT03128151||Control group|Treated according to usual clinical practice
2466680|NCT03127800|Experimental|Morphine sulphate|Participants will be given a first dose of morphine sulphate (intravenously) before bedtime and a second dose four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness
2466740|NCT03127293||Hyperemesis Gravidarum group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
2466741|NCT03127293||control group|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
2466767|NCT03126903|Experimental|Single-Arm|KeraKlear Non-Penetrating Keratoprosthesis
3191611|NCT00800293||Cohort Group 1|Subject Numbers 1 to 29
3191612|NCT00800293||Cohort Group 2|Subject Numbers 20 to 59
2466959|NCT03125577|Experimental|4SCAR19 and 4SCAR20/CD22/CD30/CD38/CD70/CD123|Patients who have relapsed and refractory B cell malignancies after chemotherapy will be treated with CD19 and CD20/CD22/CD30/CD38/CD70/CD123-specific gene-engineered T cells.
3191613|NCT00800293||Cohort Group 3|Subject Numbers 60 to 89
3191614|NCT00800293||Cohort Group 4|Subject Numbers 90 to 116
3191615|NCT00800306|Experimental|levosimendan|
3191616|NCT00800306|Active Comparator|Control|
3191617|NCT00800319|Experimental|RDC-0313, 5mg|5 mg of RDC-0313; single dose
3191618|NCT00800319|Experimental|RDC-0313, 15 mg|15 mg RDC-0313; single dose
3191619|NCT00800319|Experimental|RDC-0313, 25mg|25 mg RDC-0313; single dose
3191620|NCT00800319|Experimental|RDC-0313, 50 mg|50 mg RDC-0313; single dose
3191621|NCT00800319|Experimental|RDC-0313, 75 mg|75 mg RDC-0313; single dose
3191622|NCT00800319|Placebo Comparator|Placebo|volume-match placebo; single dose
3191623|NCT00800332|Experimental|1|
3191624|NCT00800332|Experimental|2|
3191625|NCT00800332|Placebo Comparator|3|
3191626|NCT00800358|Experimental|1|Oral Paricalcitol in varying doses
3191627|NCT00800358|Active Comparator|2|Calcitriol
3191628|NCT00800371||JIA|Patients with JIA
3191629|NCT00800410|No Intervention|Information on community resources|Participants received information about free and publicly available community resources on healthy lifestyle activities
3191630|NCT00800410|Experimental|Community Health Worker services|
2466055|NCT03131700|Active Comparator|EU sourced Avastin®|A single dose of Avastin® will be administered (IV) 5 mg/kg dose .
2466290|NCT03130660|Experimental|Short Axis Ultrasonography|one person does both ultrasound and line insertion
2466293|NCT03130660|Experimental|Long Axis Ultrasonography|one person does ultrasound and another inserts the central line
2466328|NCT03130153|Experimental|hypertensives on Aspirin mouthwash|
2466331|NCT03130153|Active Comparator|non-hypertensives on Aspirin mouthwash|
2466333|NCT03130153|Active Comparator|hypertensives on Saline mouthwash|
2466390|NCT03129763|Experimental|60mmHg Group|60mmHg capsule pressure expansion. This pressure depends on the ideal capsule pressure that previous study given.
2466393|NCT03129763|Experimental|70mmHg Group|70mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2466395|NCT03129763|Experimental|80mmHg Group|80mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2466396|NCT03129763|Experimental|90mmHg Group|90mmHg capsule pressure expansion. This pressure gradient depends on the ideal capsule pressure that previous study given, and the regular expansion pressure in recent studies.
2466397|NCT03129763|Experimental|100mmHg Group|100mmHg capsule pressure expansion. This pressure gradient depends on the regular expansion pressure in recent studies.
2466562|NCT03128554|Experimental|Intervention with Training and Materials|Clinics randomized to the intervention group will receive a one time, 2-hour Continuing Medical Education/Group Learning training session on the smoking reduction intervention model, along with provider and patient handouts.
2466568|NCT03128554|No Intervention|Usual Care|Clinics randomized to the control group will not be exposed to the intervention program.
3156658|NCT00349206|Experimental|Arm 1|Patients receive temsirolimus IV over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
3156659|NCT00349219|Experimental|1|erlotinib followed at progression by gemcitabine and cisplatin
3156660|NCT00349219|Active Comparator|2|cisplatin and gemcitabine chemotherapy for 6 cycles, followed at progression by erlotinib
3156661|NCT00349271|Experimental|Stem Cell therapy|Stem Cell therapy
3156662|NCT00349271|Active Comparator|Standart therapy|Standart therapy
3156663|NCT00349362|Experimental|Testosterone|Testosterone injections- 200mg- every 2 weeks
2466677|NCT03127670|Experimental|Solanum melongena peel extract 0.05%|25 Patients Solanum melongena peel extract 0.05% Twice daily applied topically for 12 weeks
2466737|NCT03127345|Experimental|Omegaven|15 infants with esophageal atresia undergoing surgical repair will receive Omegaven 1 g/kg/day IV infused over 8-24 hours for 28 days
2466739|NCT03127345|Active Comparator|Intralipid|15 infants with esophageal atresia undergoing surgical repair will receive the standard of care lipid formulation (Intralipid) as per hospital protocol for 28 days
2466777|NCT03126890||Linezolid TDM (prospective)|Adult patients received linezolid at NTUH. This prospective cohort study will draw blood from every patient to measure the linezolid blood concentration. After blood concentration analysis by high pressure liquid chromatography (HPLC), the investigator will report the concentration to clinicians and dose adjustment is judged by clinician (not the investigators).
2466780|NCT03126890||Linezolid observation (retrospective)|Adult patients received linezolid at NTUH.
2466877|NCT03126032||Patients with suspected sepsis|"Patients presenting in the Emergency Room (ER) with the clinical suspicion of infection/sepsis.~Evaluation of the glycocalyx damage with the use of GlycoCheck™-System, as well as blood sample at presentation, day 1 and day 7 of their hospital stay."
2466881|NCT03126032||Non-Sepsis Patients|"Patients presenting in the Emergency Room with other conditions apart from infection/sepsis.~Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation."
2466883|NCT03126032||Healthy Individuals|Evaluation of their sublingual glycocalyx and blood sample for further microbiologic and laboratory analysis at presentation.
2466943|NCT03125928|Experimental|Investigational Arm|
2476468|NCT03060434|Active Comparator|Control|Ibuprofen
3156664|NCT00349362|Placebo Comparator|Placebo|Normal saline injections- every two weeks
3156665|NCT00349375|Experimental|1|
3156666|NCT00349375|Experimental|2|
3156667|NCT00349375|Active Comparator|3|
3156668|NCT00349427|Experimental|Rosiglitazone|4mg
3156669|NCT00349427|Placebo Comparator|Rosiglitazone placebo|4mg
3156670|NCT00349440|Active Comparator|1|
3156671|NCT00349440|Placebo Comparator|2|
3156672|NCT00349453|Experimental|Deferiprone (L1) monotherapy|Deferiprone (L1) monotherapy
3156673|NCT00349453|Experimental|Combination therapy|Deferiprone (L1) and desferrioxamine combination treatment
3156674|NCT00349479|Active Comparator|Intervention|
3156675|NCT00349479|No Intervention|Control|
3156676|NCT00349492|Active Comparator|EP|etoposide + cisplatin
3156677|NCT00349596|Experimental|Decitabine|Decitabine administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
3156678|NCT00349726|Experimental|Inositol low volume|Single dose of intravenous inositol 5%, 60 mg/kg (1.2ml/kg) given over 20 minutes
3156679|NCT00349726|Experimental|Inositol high volume|Single dose of intravenous inositol 5%, 120 mg/kg (2.4ml/kg) given over 20 minutes
3156680|NCT00349726|Placebo Comparator|Placebo low volume|Placebo (5% glucose) at a volume equal to 60 mg/kg (1.2 ml/kg) given via IV over 20 minutes.
3156681|NCT00349726|Placebo Comparator|Placebo high volume|Placebo (5% glucose) at a volume equal to 120 mg/kg (2.4 ml/kg) given via IV over 20 minutes
3156682|NCT00349791|Placebo Comparator|1|placebo patch replaced twice a week for two years
3156683|NCT00349791|Experimental|2|testosterone patch replaced twice a week for two years
3156684|NCT00349804|Other|Air cooled (COOL)|Subjects will complete the intermitent exercise protocol with cool dry air blown under the shoulder pads during the rest periods and recovery session
3156685|NCT00349856|Active Comparator|1|
3156686|NCT00349869|Experimental|1|8-week yoga program
3156687|NCT00349869|No Intervention|2|Usual care control
3156688|NCT00349934|Experimental|A|IMP321
2466064|NCT03131934|Experimental|Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8|"All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12~Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8~An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.~While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels."
2466235|NCT03130816|Experimental|allogeneic cord blood transplantation|"Intravenous(IV) infusion will be done by the following method A. After 4 hours of fasting, subjects will be sedated with chloral hydrate (Pocral®) syrup B. Intravenous infusion will be conducted in stem cell center, CHA Bundang Medical Center and the therapy will be performed by the Principal Investigator or a physician delegated from the Principal Investigator. The physician conducting the infusion will not participate in the efficacy and result analysis of this study.~C. Oxygen saturation will be monitored during therapy."
2466273|NCT03130530||ALF-X|all patient underwent robotic colorectal surgery using ALF-X system
2466307|NCT03130387|Other|Office hysteroscopy|Examinatin with Office hysteroscope for women with abnormal uterine bleeding who had a history of previous cesarean section
2466318|NCT03130010|Placebo Comparator|The control group|One hour before the end of the operation, the control group was received 20 ml of saline.
2466319|NCT03130010|Active Comparator|The Nefopam group|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam.
2466360|NCT03129880|Placebo Comparator|Weekly Voice Therapy|Participants are randomized to receiving weekly voice therapy sessions
2466361|NCT03129880|Active Comparator|Intensive Voice Therapy|Participants are randomized to receiving multiple sessions of voice therapy in one day
2466419|NCT03129555|Active Comparator|Dabigatran|After randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466423|NCT03129555|Active Comparator|Rivaroxaban|After randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466427|NCT03129555|Active Comparator|Edoxaban|After randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466432|NCT03129555|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466520|NCT03128814||Elite (pre)adolescent tennis players|
2466523|NCT03128814||Age- and gender-matched controls|
2466573|NCT03128333|Experimental|RunKeeper app + physiotherapy coaching|Group A will use the RunKeeper app for half a year to self-monitor leisure-time PA. Besides, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is all explained in a brief user's manual. In addition, patients will be educated about the health risks of a sedentary lifestyle, inactivity and (when applicable) other unhealthy lifestyle behaviors (e.g. unhealthy diet, overweight or obesity, sun exposure, alcohol intake). Benefits of a behavior change, becoming physically active and pursuing a healthy lifestyle will be explained by a trained physiotherapist who will also coach the patient during the PA program.
2466580|NCT03128333|Other|usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
3191631|NCT00800423|Experimental|brimonidine|"50 patients receiving Brimonidine Tartrate drops in the operated eye: 1 drop X2 a day for 1 month.~they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
3191632|NCT00800423|Active Comparator|2 tmolol|"50 patients receiving timolol maleate 0.5% drops in the operated eye~1 drop X2 a day for 1 month. they will also be administered the usual medications after cataract surgery (corticosteroids and antibiotics drops)"
3191633|NCT00800423|No Intervention|3|50 patients will not receive any additional drug to the usual medications after cataract surgery (corticosteroids and antibiotics drops)
2466662|NCT03127579|Experimental|Longer meal duration|Families eat longer as they usually do
2466663|NCT03127579|No Intervention|Usual meal duration|Families eat as long as they usually do
2466695|NCT03127462|Experimental|Individualized Education|
2466696|NCT03127462|No Intervention|Control group|
2466721|NCT03127202|Experimental|Cardiac Resynchronization Therapy-Defibrillator|Eligible patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator
2466803|NCT03126916|Experimental|Arm A (chemotherapy, HSCT, EBRT)|See Arm A in detailed description.
2466811|NCT03126916|Experimental|Arm B (Iobenguane I-131, chemotherapy, HSCT, EBRT)|See Arm B in detailed description.
2466828|NCT03126916|Experimental|Arm C (Iobenguane I-131, chemotherapy, BuMel, HSCT, EBRT)|See Arm C in detailed description. Closed to accrual as of 12/17/20.
2466830|NCT03126916|Experimental|Arm D (chemotherapy, HSCT, EBRT)|See Arm D in detailed description.
2466831|NCT03126916|Experimental|Arm E (crizotinib, chemotherapy, HSCT, EBRT)|See Arm E in detailed description.
2467316|NCT03122938|Experimental|Lactoferrin Group|lactoferrin-supplemented formula
2467321|NCT03122938|Placebo Comparator|Control Group|formula without lactoferrin supplementation
2467361|NCT03122756|Placebo Comparator|Group (C)|will include 50 women who will receive intravenous normal saline (0.9 %).
2467387|NCT03122769|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
2476475|NCT03060434|Experimental|Pentoxifylline|Pentoxifylline oral tablets
3191634|NCT00800462|Active Comparator|Oxybutynin Cl|
3191635|NCT00800462|Active Comparator|Trospium Cl|
3156689|NCT00349947|Active Comparator|1|Participants will take part in an exercise program.
3156690|NCT00349947|No Intervention|2|Participants will take part in a usual activity group.
2466459|NCT03129269|Experimental|neuroimaging amyloid diagnosis by MRI and PET scan|"There is only one arm. The procedure consists in neuroimaging to diagnose the presence of amyloid plaques in the brains and permit earlier detection of Alzheimer's disease. MRI and PET Scan.~Visits will be scheduled at baseline, 1 and 2 years for a full neuropsychological, functional and physical evaluation.~In addition, at 6 and 18 months patients will be seen in consultation by a Geriatrician and research assistant for a medical check.~PET-Scan will be scheduled in the 2 months following inclusion for amyloid measurements. The MRI will be proposed, depending on the clinical relevance~A blood sample for biobank will be taken at visit 2 and at the end of the study (visit 5)."
2466482|NCT03128788|Active Comparator|Active Comparator: supine position|Active Comparator: supine position thoracic epidural catheterization with supine position
2466484|NCT03128788|Active Comparator|Active Comparator: flexed lateral position|Active Comparator: flexed lateral position thoracic epidural catheterization with flexed lateral position
2466541|NCT03128606|Experimental|GLPG3067 single dose|Single dose of GLPG3067 oral suspension at up to 6 dose levels in ascending order.
2466544|NCT03128606|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension.
2466548|NCT03128606|Experimental|GLPG3067 oral suspension fed 1|Single dose 1 of GLPG3067 oral suspension after a standardized breakfast.
2466551|NCT03128606|Experimental|GLPG3067 oral tablet fed 1|Single dose 1 of GLPG3067 oral tablet after a standardized breakfast.
2466554|NCT03128606|Experimental|GLPG3067 oral tablet fasted 1|Single dose 1 of GLPG3067 oral tablet after an overnight fast.
2466556|NCT03128606|Experimental|GLPG3067 oral tablet fed 2|Single dose 2 of GLPG3067 oral tablet after a standardized breakfast.
2466558|NCT03128606|Experimental|GLPG3067 oral tablet fed 2 high-fat high-calorie|Single dose 2 of GLPG3067 oral tablet after a high-fat high-calorie breakfast
2466559|NCT03128606|Experimental|GLPG3067 multiple dose|Multiple doses of GLPG3067 oral suspension at up to 5 dose levels in ascending order.
2466560|NCT03128606|Placebo Comparator|Placebo multiple dose|Multiple doses of Placebo oral suspension.
2466561|NCT03128606|Experimental|GLPG3067/GLPG2222 multiple dose|Multiple doses of GLPG3067 oral suspension combined with GLPG2222 oral tablet up to 2 dose levels in ascending order.
2466565|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral suspension combined with GLPG2222 matching placebo oral tablet.
2466571|NCT03128606|Experimental|GLPG3067/GLPG2222/GLPG2737 multiple dose|Multiple doses of GLPG3067 oral tablet combined with GLPG2222 oral tablet and GLPG2737 oral capsule at up to 2 dose levels in ascending order.
2466574|NCT03128606|Placebo Comparator|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|Multiple doses of GLPG3067 matching placebo oral tablet combined with GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule.
2466641|NCT03128021|Active Comparator|Escitalopram Pill|Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
2466644|NCT03128021|Placebo Comparator|Placebo|"Participants will be given a sugar pill (placebo) to be taken by mouth once daily for the 6 week duration of Phase I. As this arm is also double-blinded, participants will receive an initial dose of 5 mg and further titrations (maximum dose of 20 mg) will be decided based on clinical response and tolerability.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima."
2466645|NCT03128021|Other|Escitalopram Pill (Phase II)|"Participants who were in the placebo arm for Phase I who do not show signs of response to treatment by week 6 (defined as either a MADRS score of greater than 12 or less than a 30% reduction in MADRS score to be deemed a non-responder) will be given the option to have an open-label trial of escitalopram in Phase II.~Participants in this arm will receive an initial dose of 5 mg. Further titrations throughout the 6 week duration of Phase 2 (maximum dose of 20 mg) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.~Note: This arm no longer applies as of 5/16/18. Participants are now randomly assigned to Lexapro or Fetzima and the assignment does not change throughout the study."
2466793|NCT03126669|Placebo Comparator|Placebo|normal air, in the hyperbaric chamber
3156691|NCT00349999||1|18 males and non pregnant females, ages 18-45, with acute cholera.
3156692|NCT00350012||1|Persons who have had a stroke and either have, or do not have, a pathological asymmetry of perception, attention and action causing functional disability (spatial neglect; Barrett and Burkholder, 2006).
3156693|NCT00350012||2|Healthy age- and education-matched volunteers
3156694|NCT00350051|Experimental|Arm 1|
3156695|NCT00350129||1|healthy vasospastic subjects
3156696|NCT00350129||2|healthy non-vasospastic subjects
3156697|NCT00350181|Experimental|Regimen Treatment 1|For subjects 18-60 years old with lymphoma: (BCNU+ VP-16 +CY) BCNU 15 mg / kg (maximum dose 550 mg/m² actual body weight) on day -6. VP 60 mg / kg on day 4 and CY 100 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
3156698|NCT00350181|Experimental|Regimen Treatment 2|For subjects 18-50 years old with AML, ALL or CML: (VP-16 +CY+ FBI) Patients aged 18-50 years with AML, ALL or CML: FTBI 1320 cGy delivered in 11 120 cGy fractions over 4 days on days -8 through -5. VP 60 mg / kg on day -4 and CY 60 mg / kg on day -2. Followed by Sirolimus and MMF as prophylaxis
3156699|NCT00350181|Experimental|Regimen Treatment 3|For subjects 51-60 years with MDS, AML or ALL or 18-60 with MDS, secondary AML pr non-CML myeloproliferative disease: (BU+ VP-16 +CY) BU 1 mg/kg every 6 hours X 14 doses on days -9 through -6 with target concentration at steady state of X 800 ng / ml based on first dose pharmacokinetics. VP 60 mg / kg on day -5 and CY 45 mg / kg per day -2 days on day -3 and day -2. Followed by Sirolimus and MMF as prophylaxis
3156700|NCT00350194|Placebo Comparator|1|Omega-3 fatty acid vs. placebo comparator
3156701|NCT00350233|Experimental|ExAblate MRgFUS|
3156702|NCT00350285|Experimental|1|Motivational enhancement therapy
3156703|NCT00350285|Active Comparator|2|Marijuana education
3156704|NCT00350285|No Intervention|3|Delayed treatment control condition
3156705|NCT00350350||elderly people|elderly people over 70 years residents of old's people homes with symptoms of dry mouth
2466137|NCT03131609||D: Funnel + Silver-impregnated wipe|Urine collection funnel and sliver impregnated cloth-wipe given to patient to self-obtain a clean catch mid-stream urine specimen
2466222|NCT03130907|Active Comparator|Stent|
2466224|NCT03130907|Experimental|No stent|
2466286|NCT03130673||hip fracture|fracture of proximal femur
2466409|NCT03129438|Experimental|continuous EEG (cEEG)|Patients randomized to continuous EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last a minimum of 30 and a maximum of 48 hours. During this time, one interruption to a maximum of two hours for diagnostic purposes will be allowed. Reactivity testing using auditory and nociceptive stimuli will be performed at least twice during the recording time. Recordings will be visually interpreted by certified electroencephalographers (i.e., interpretation of the automated algorithm only won't be allowed) using the 2013 American Clinical neurophysiology nomenclature; interpretations will be communicated within two hours of their completion to the treating team.
2466412|NCT03129438|Active Comparator|routine EEG (rEEG)|Patients randomized to routine EEG will be recorded with at least 21 electrodes placed according to the international 10-20 system; occasionally, a reduced montage will be allowed in patients with extensive neurosurgical scars, according to good common practice. Recordings will last between 20 and 30 minutes; two recordings will take place over a period of 24 to 48 hours. Reactivity testing using auditory and nociceptive stimuli will be performed once per recording. Recordings will be visually interpreted by certified electroencephalographers using the 2013 American Clinical neurophysiology nomenclature, as for the experimental intervention, and the interpretation will be communicated within two hours of its completion to the treating team.
2466444|NCT03129061|Experimental|Cohort 1 Patients with M/R SCCHN|"Patients with unresectable and metastatic SCCHN cancer who will receive anti-PD-1 treatment under SOC. SOC treatments currently include nivolumab and pembrolizumab (anti-PD-1 treatment). The protocol may be amended to include other agents should they become SOC. Patients will receive a baseline [18F]F-AraG PET/CT scan and another [18F]F-AraG PET/CT scan 6 to 12 weeks after anti-PD-1 dose."
2466445|NCT03129061|Experimental|Cohort 2 Patients with de novo SCCHN|Patients with de novo SCCHN prior to initiation of anti-cancer treatment (e.g., radiation, chemoradiation, or surgery). Patients will receive ONE DOSE of the anti-PD-1 treatment, after the baseline [18F]F-AraG PET/CT scan, baseline blood and tumor tissue collection. Patients will receive a second [18F]F-AraG PET/CT scan 2 - 3 weeks after the one dose of anti-PD-1 treatment.
2466505|NCT03128853|Experimental|Test subjects|Each subject receives the Rad-67 and DCI Mini sensor that will measure hemoglobin repeatedly in order to compare those measurements against a blood sample reference.
2466532|NCT03128463||significantly effective group|visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
2466533|NCT03128463||effective group|visual improvement ≥5 letters and <15 letters in EDTRS table after intravitreal injection of conbercept
2466534|NCT03128463||invalid group|visual improvement <5 letters and visual reduction<5 letters in EDTRS table after intravitreal injection of Combercept
2466535|NCT03128463||deterioration group|visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
2466604|NCT03128177|Experimental|High sodium diet|High sodium diet is 6 g sodium per day for 10 days
2466606|NCT03128177|Experimental|Low sodium diet|Low sodium diet is 1.5 g sodium per day for 10 days
2466673|NCT03127657|Experimental|Cock's comb extract 0.01%|25 Patients Cock's comb extract 0.01% Applied topically twice daily for 12 weeks
2466718|NCT03127397|No Intervention|Standard of Care|
2466720|NCT03127397|Experimental|Praise Message|Receives up to two praise message phone calls after each completed ART appointment.
2466768|NCT03126981|Experimental|Whole, natural almonds|1.5 oz of whole, natural almonds
2466769|NCT03126981|Placebo Comparator|Low-fat, high refined starches/sugars|Low-fat foods,high in refined starches and added sugars
2466875|NCT03126461|Experimental|SAbR plus ipilimumab plus nivolumab|SAbR/GRID plus ipilimumab 3mg/kg IV q3wk x 4 plus nivolumab 1 mg/kg IV q3wk x 4, followed by nivolumab 240 mg IV q 2wk until progression or intolerable toxicity
2466925|NCT03126006|Experimental|NSPT plus oral hygiene|It includes pregnant women (with periodontal disease) who will be subjected to one episode of non-surgical periodontal therapy under local anesthesia during pregnancy. they will receive oral hygiene instruction also.
2466928|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
2467011|NCT03125161|Experimental|Arm A|HAI plus chemotherapy ± target therapy
2467016|NCT03125161|Active Comparator|Arm B|chemotherapy ± target therapy
3156706|NCT00350389|Experimental|1|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
3156707|NCT00350389|No Intervention|2|Usual care, updated multifocal glasses if required
3156708|NCT00350415|Experimental|1|Asacol 2.4 g/day (400 mg tablet)
2467183|NCT03123822|Experimental|Single vision glasses|Typical glasses prescribed for children to correct only distance refractive error and to be worn all waking hours.
2467186|NCT03123822|Experimental|Single vision glasses with anti-glare coating|Typical glasses prescribed for children to correct only distance prescription with anti-glare coating and to be worn all waking hours.
2467188|NCT03123822|Experimental|Eyezen|Commercially available, low-powered, progressive addition lenses glasses with anti-glare coating to be worn all waking hours
2467220|NCT03123562|Experimental|Stem cell transplantation|Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
3156709|NCT00350415|Active Comparator|2|Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
3156710|NCT00350454|Active Comparator|A|Drug eluting stent using biodegradable polymer BP stent
3156711|NCT00350454|Active Comparator|B|polymer-free drug eluting stent PF stent
3156712|NCT00350454|Active Comparator|C|permanent polymer using stents PP stent
3156713|NCT00350506|Experimental|64 Channel VCT|All subjects underwent Coronary Computed Tomographic Angiography (CCTA) after receiving an intravenous (IV) administration of Visipaque (320 mgI/mL), to be followed by catheter coronary angiography (CATH).
3156714|NCT00350571|Active Comparator|Standard care follow up|Standard care counselor follow up care phone calls or letters.
3156715|NCT00350571|Experimental|Drop out reengagement motivational intervention|Single session office based or phone based motivational counseling session designed to promote participant re-engagement in standard treatment.
3156716|NCT00350584|Experimental|Mindfulness Telehealth for PTSD|Participants receive two in-person sessions and 6 sessions over the phone. Participants are introduced to mindfulness concepts. CDs with guided meditation exercises are given to participants and they are asked to practice between sessions.
2466538|NCT03128567||Stimulation of the subthalamic nucleus|25 patients with Parkinson's disease
2466547|NCT03128567||Best medical treatment|25 patients with Parkinson's disease
2466593|NCT03128255||Regular Thyroid Work-up|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics. Data and images of patient characteristics, laboratory results, ultrasonography loops and planar 99mTcO4 scintigraphy are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
2466595|NCT03128255||Regular Thyroid Work-up and I-124 PET/US|Nuclear Medicine physicians evaluate up to 34 cases of patients who have received regular thyroid diagnostics and additional I-124 PET/CT, followed by I-124 PET/US (administration of I-124 was not subject of this study). Data and images of patient characteristics, laboratory results, ultrasonography loops, planar 99mTcO4 scintigraphy as well as I-124 PET/US loops are provided and the physicians are asked to assign the function (hypo-, iso-, hyperfunctional) to predefined thyroid nodules visible on ultrasonography.
2466602|NCT03127982|Experimental|Group 1|Immediately following randomization, participants in this condition attend 12-13 biweekly face-to face individual sessions that last approximately 1.5 hrs each of the cultural adaptation of the Unified Protocol trans diagnostic treatment comprising the following modules: motivation enhancement, psycho-education of emotion, emotion awareness training, cognitive reappraisal, emotion avoidance and emotion-driven behavior, tolerance training for physical sensations, emotion exposure, and relapse prevention. Treatment is provided by graduate students in clinical psychology who have been trained in the UP and receive weekly supervision by experienced clinicians and use a Workbook for homework assigned between sessions.
2466603|NCT03127982|Active Comparator|Group 2|Participants randomly assigned to this condition do not receive any active intervention during a six-week wait period after randomization, while completing assessment evaluation at the beginning and end of wait list period, after which they receive the same intervention (Unified Protocol) provided to the treatment condition (Group 1).
2466674|NCT03127891|Experimental|pranayama yoga|yoga breathing exercise
2466676|NCT03127891|Placebo Comparator|control group|no intervention
2466806|NCT03126812|Experimental|Carboplatin, paclitaxel, pembrolizumab|Carboplatin AUC= 6 paclitaxel 80 mg/m2 Pembrolizumab 200 mg starting cycle 2
2466856|NCT03126279||Preoperative Chronic Knee OA Patients|Patients will be recruited from orthopaedic preoperative clinics from those awaiting total knee replacement surgery.
2466858|NCT03126279||Healthy Volunteers|Healthy volunteers will be recruited that are aged match to our OA patient cohort so meaningful comparisons regarding brain activity and pain sensitisation characteristics can be assessed.
2466915|NCT03126084|Active Comparator|TAP|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive transversus abdominis plane block with 20 ml of 0.25% bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2466919|NCT03126084|Active Comparator|QLB2|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive quadratus lumborum type 2 block with 20 ml of %0.25 bupivacaine preoperatively, in addition to intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2466923|NCT03126084|Active Comparator|CONT|"Patients will undergo inguinal hernia repair under subarachnoid block with 0.5% bupivacaine+glucose.~Patients will receive intravenous acetaminophen 1000mg twice a day for postoperative analgesia.~Tramadol HCl 50mg intramuscular will be provided for salvage analgesia postoperatively."
2466994|NCT03125603||NSCLC's patients|"Patients with NSCLC treated in Cliniques Universitaires Saint-Luc with immunotherapy.~Consultation of the patient's medical files at the hospital."
2467005|NCT03125239|Experimental|Merestinib and LY2874455|"Patients who fulfill eligibility criteria will be entered into the trial to receive Merestinib and LY2874455.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have AML, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Merestinib~LY2874455"
2467037|NCT03125083|Experimental|skin-restricted lupus (SRL) patients|Role of inflammation in psychiatric disorders in patients with cutaneous lupus
2467200|NCT03123796||Only PPI|Kidney transplant recipients who used only proton pump inhibitors and did not use histamine H2 receptor antagonists.
2467201|NCT03123796||Only H2RA|Kidney transplant recipients who used only histamine H2 receptor antagonists and did not use proton pump inhibitors.
2467203|NCT03123796||PPI and H2RA|Kidney transplant recipients who used both proton pump inhibitors and histamine H2 receptor antagonists.
2467430|NCT03122028|Experimental|LAmbre closure system|
3156717|NCT00350584|Active Comparator|Psychoeducation Telehealth for PTSD|Participants receive two in-person sessions and six telehealth sessions with education about symptoms of PTSD and coping strategies. In addition, participants are asked to read short homework assignments and think about them during the week; these are discussed in weekly sessions.
3156718|NCT00350610|Active Comparator|1|Standard treatment as usual (TAU) in a community based clinic consisting of individual and group therapy sessions and regular urine monitoring.
3156719|NCT00350610|Experimental|2|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping cocaine use and increasing coping skills twice weekly for 8 weeks.
2466144|NCT03131427||Inherited Cholestatic Liver Disease|Patients who were diagnosed or possibly diagnosed with Inherited cholestatic liver disease, including progressive familial intrahepatic cholestasis(PFIC) and benign recurrent intrahepatic cholestasis(BRIC).
2466147|NCT03131427||Other genetic/metabolic liver diseases|Patients who were diagnosed or possibly diagnosed with genetic/metabolic liver diseases except for Wilson's disease, hereditary hemochromatosis, hereditary hyperbilirubinemias or inherited cholestatic liver disease.
2466199|NCT03130894||Healthy control|A FPG concentration < 6.1 mmol/l, and a 2-h oral glucose tolerance test (OGTT) plasma glucose concentration < 7.8 mmol/l was considered normal glucose tolerance.
2466204|NCT03130894||Type 2 diabetes|Type 2 diabetes was diagnosed when fasting plasma glucose (FPG) ≥ 7.0 mmol/l, and/or 2-h post-glucose load ≥ 11.1 mmol/l.
2466241|NCT03130764|Experimental|Durvalumab/Tremelimumab|Patients with resected stage IB-IIIA NSCLC who have completed standard adjuvant therapy (as recommended by the treating physician) to receive durvalumab-tremelimumab will be enrolled. Patients will receive durvalumab (20 mg/kg) intravenously every 4 weeks for 1 year and tremelimumab (1 mg/kg) intravenously every 4 weeks for 4 doses.
2466312|NCT03130244|Active Comparator|Device Placement|The patients in this arm will receive the Magnet Anastomosis System and an anastomosis will be created.
2466315|NCT03130244|No Intervention|Control|The patients in this arm will receive the best medical management.
2466363|NCT03129906|Active Comparator|Gluten|Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
2466366|NCT03129906|Placebo Comparator|Rice protein|Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
2466446|NCT03129451||Tremor-dominant|Tremor-dominant Parkinson's disease
2466447|NCT03129451||Akinetic-Rigid|Akinetic-Rigid type Parkinson's disease
2466448|NCT03129451||Multiple systems atrophy|Multiple systems atrophy PD
2466450|NCT03129451||Levodopa-naïve|Levodopa-naïve Parkinson's disease
2466452|NCT03129451||Tremor-dominant / app|Tremor-dominant Parkinson's disease with an appendectomy
2466453|NCT03129451||Akinetic-Rigid / app|Akinetic-Rigid Parkinson's disease with an appendectomy
2466454|NCT03129451||Levodopa-naïve w/app|Levodopa-naïve Parkinson's disease with an appendectomy
2466493|NCT03128827|Experimental|Test Subjects|All test subjects were pediatric patients following general anesthesia who received the RAM sensor which measures respiration rate.
2466542|NCT03128580||Natural Cycle|The patient will not undergo hyperstimulation rather a natural cycle
2466545|NCT03128580||Stimulated Cycle|The 80 patients will undergo hyperstimulation cycle as per the clinical practice planned for the patient.
2466615|NCT03128190|No Intervention|Control group|In the control period, patients were given intravenous fluids at the discretion of the anesthesiologist based on institutional protocol using 250ml of crystalloids or 100ml of colloids based on central venous pressure (CVP) and mean arterial pressure (MAP) measurements. The aim was to keep the CVP ≥ 8mmHg and MAP ≥ 65mmHg. Fluid boluses were administered up to a total of 1000ml, if patients did not attain a MAP of >65 mmHg, a vasopressor drug was administered.
2466619|NCT03128190|Experimental|PPV group|intraoperative fluid management was titrated to maintain PPV< 10%. fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
2466654|NCT03127852|Experimental|Telemonitoring (Medly)|The telemonitoring technology will enable patients with complex chronic illnesses, to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the mobile phone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
2466655|NCT03127852|No Intervention|Control|Standard of care: Patients are followed in a specialty care clinic treating their primary conditions. Patients typically have scheduled appointments every six months.
3191636|NCT00800462|Active Comparator|Darifenacin Hydrogren Bromide (HBr)|
3191637|NCT00800475|Active Comparator|Test Drug|
3191638|NCT00800475|Active Comparator|Reference Drug|
3191639|NCT00800501|Experimental|sNN0029|
2466879|NCT03126058|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally. B: Remove catheter early.~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation for right hemicolectomy, Miles rectectomy and Hartman rectectomy, simple cleansing enema for left hemicolectomy,sigmoidectomy and Dixon rectectomy; C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
2467028|NCT03125460||Initial Enrollment|Initial enrollment of patients with history of bladder cancer
2467036|NCT03125460||Longitudinal Cohort|Longitudinal Cohort - patients considered anticipatory positive at the time of enrollment and one random disease negative patient per anticipatory positive patient
3191640|NCT00800501|Placebo Comparator|Placebo|
3191641|NCT00800514|Experimental|active|
3191642|NCT00800527|Active Comparator|1|Gabapentin
2467251|NCT03123302||Group 2|Epileptic patients who are sedated with a total dose of pentothal 4 mg/kg and midazolam 0.1 mg/kg.
2467256|NCT03123302||Group 3|Non-epileptic patients who are sedated with a total dose of propofol 1 mg/kg and ketamine 1 mg/kg.
2467258|NCT03123302||Group 4|Non-epileptic patients who are sedated with a total dose of midazolame 0.1 mg/kg and ketamine 1 mg/kg.
2467295|NCT03122951|Other|ovulation test use|All voluteers will receive device for use according to instructions
2469316|NCT03109132|Active Comparator|Model 4|Device - Experimental sample line Model 4
3191643|NCT00800527|Active Comparator|2|Diclofenac
3191644|NCT00800553|Experimental|donepezil|donepezil, 5 mg p.o. for approx 2 weeks
3191645|NCT00800553|Placebo Comparator|placebo|placebo
3191646|NCT00800566|Experimental|Oral Clofarabine|
2466184|NCT03130998|Active Comparator|Control - Group A|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
2466185|NCT03130998|Experimental|Intervention - Group B|When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive individualized support through a remote knowledge broker (rKB) communicating via interactive technology. The rKB will be certified in tobacco cessation counseling through CAMH's TEACH program and will have completed a specialty course on tobacco addiction treatment in those with mental illness. The rKB will have access to the CAMH network of KBs (e.g. Evidence Exchange Network ) for guidance and support, as this has been shown to be important for KB success.
2466279|NCT03130647|Experimental|Focused ultrasound|Repeated measures sham control
2466400|NCT03129529|Experimental|focused shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz. The intensities of FSWT were 0.10 mJ/mm2.
2466401|NCT03129529|Experimental|radial shock wave|Treatment was administered directly to the middle of muscle bellies of the spastic triceps surae muscle in three sessions, with one week interval. During each session, 3000 pulses (1500 shots in the gastrocnemius and 1500 shots in the soleus muscle) were delivered at 5 Hz.The intensities of RSWT were 2.0 bar.
3156720|NCT00350649|Experimental|1|manualized delivery of CBT by trained clinicians
3156721|NCT00350649|Active Comparator|2|CBT with Contingency Management reinforcement for attendance and completing homework (CBT+CM/adherence)
3156722|NCT00350649|Experimental|3|Contingency Management for abstinence alone (CM/abstinence)
3156723|NCT00350649|Active Comparator|4|Contingency Management integrated with CBT (CM/abstinence+CBT)
2466581|NCT03128476|Active Comparator|1 bottle|
2466582|NCT03128476|Active Comparator|2 bottles|
2466585|NCT03128476|Placebo Comparator|Placebo|
2466623|NCT03128073|Experimental|Single group|The intervention is with the Carry Life system ultrafiltration (CLS UF) device, which administers a Glucose-salt solution intermittently to a volume of the intraperitoneal fluid in the device.
2466678|NCT03127813|Experimental|Treated glaucoma|POAG patients established on treatment
2466681|NCT03127813|Experimental|Untreated|Newly diagnosed treatment naïve POAG patients
2466682|NCT03127813|Active Comparator|Control|Control subjects without glaucoma
2466709|NCT03127267|Experimental|Masitinib (4.5) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d
2466710|NCT03127267|Experimental|Masitinib (6.0) & Riluzole|Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control. Masitinib will be administered as an add-on to riluzole at 50 mg b.i.d.
2466712|NCT03127267|Placebo Comparator|Placebo & Riluzole|Participants receive a matched dose placebo, given orally twice daily, in combination with riluzole at 50 mg b.i.d.
2466770|NCT03126994|Experimental|PhysioWave Cardiovascular Analyzer|The Experimental Device is the PhysioWave Cardiovascular Analyzer, which will be used to measure Pulse Wave Velocity, Pulse Rate, Body Weight, and BMI. This will be compared to FDA-cleared devices to determine equivalence: AtCor XCEL PWA & PWV to measure Pulse Wave Velocity and Pulse rate, and Detecto SOLO to measure Body Weight and BMI.
2466859|NCT03126435|Experimental|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly plus gemcitabine 1000mg/m² once weekly for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
2466862|NCT03126435|Other|Gemcitabine|Gemcitabine 1000mg/m² once weekly, for 1 cycle (8 weeks) consisting of 3 weeks of treatment and 1 week rest followed by 3 weeks of treatment and 1 week rest until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.
2466949|NCT03125811|Active Comparator|Inhaled Isopropyl Alcohol (IPA)|Inhaled Isopropyl Alcohol (alcohol prep pad)
2466952|NCT03125811|Other|Oral Dissolvable Tablet Zofran (OZ)|4 mg Oral Dissolvable Tablet Zofran (ondansetron)
3156724|NCT00350662|Experimental|Deferiprone + Desferrioxamine|
3156725|NCT00350662|Experimental|Deferiprone single agent|
2467187|NCT03124134|Experimental|B) Gelesis200, 100 g carbs|4.20 g of Gelesis200 before a 100 g carbohydrate breakfast
2467189|NCT03124134|Placebo Comparator|C) Water, 50 g carbs|300 mL water before a 50 g carbohydrate breakfast
2467190|NCT03124134|Placebo Comparator|D) Water, 100 g carbs|300 mL water before a 100 g carbohydrate breakfast
3156726|NCT00350662|Active Comparator|Desferrioxamine single agent|
3156727|NCT00350688|Other|Helical tomotherapy IMRT|Helical tomotherapy IMRT
3156728|NCT00350701|Experimental|androgel 5g|androgel 5g
3156729|NCT00350701|Experimental|androgel 10g|androgel 10g
3156730|NCT00350701|Placebo Comparator|placebo|placebo
3156731|NCT00350714|Experimental|MBT|C13 methacetin dissolved in water to be ingested after breath baseline collected. Metabolism to measured in real time.
3156732|NCT00350753|Experimental|Erlotinib and bevacizumab|
3156733|NCT00350766|Experimental|Treated Group|Intracoronary injection in the infarcted-related artery of 100 million bone marrow mononuclear cells resuspended in a 10 ml solution of saline with autologous serum.
3156734|NCT00350766|Placebo Comparator|Control Group|Intracoronary injection in the infarcted-related artery of placebo solution consisting of a saline containing autologous blood serum.
2466201|NCT03131063||Septic patient under ECMO treatment|Every adult patient admitted to ICU, under ECMO treatment, with known or suspected sepsis and receiving antibiotic therapy, was eligible for inclusion. The concentration of the studied antibiotics was determined by a combination of liquid chromatography and mass spectrometry from blood samples. For intermittent administration of antibiotic, two successive samples were performed both at 50% (Cmax) and 100% (Cmin) of the dosing interval.
3156735|NCT00350805||Healthy volunteers|
3156736|NCT00350805||Patients|
2466276|NCT03130452|Active Comparator|concomitant group|lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.
2466280|NCT03130452|Experimental|tailored treatment group I|23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.
2466284|NCT03130452|Experimental|tailored treatment group II|23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.
2466339|NCT03130101|Other|80% basal insulin reduction|
2466341|NCT03130101|Other|50% basal insulin reduction|
2466343|NCT03130101|Other|100% basal insulin reduction|
2466382|NCT03129685|Experimental|Devascularization|Patients undergoing ipsilateral hepatic artery ligation with extrahepatic collaterals division (HALED)
2466415|NCT03129282|No Intervention|Control|"Participants allocated to the control group will receive treatment as usual for cardiac rehabilitation"
2466416|NCT03129282|Active Comparator|Intervention|"Participants allocated to the intervention group will receive treatment as usual for cardiac rehabilitation plus the home-based metacognitive therapy (Home-MCT)"
2466466|NCT03129022|Active Comparator|Successful epidural anaesthesia|It is defined as VAS score <5, 30 min after a loading dose, given after the last attempt.
2466468|NCT03129022|Active Comparator|Failed epidural anaesthesia|It is defined as VAS score ≥5, 30 min after a loading dose, given after the last attempt.
2466519|NCT03128684|Experimental|Small Green Lentil Muffin|
2466524|NCT03128684|Experimental|Split Red Lentil Muffin|
2466527|NCT03128684|Placebo Comparator|Wheat Muffin|
2466528|NCT03128684|Experimental|Small Green Lentil Chili|
2466529|NCT03128684|Experimental|Split Red Lentil Chili|
2466530|NCT03128684|Placebo Comparator|Rice Chili|
2466587|NCT03128242|Experimental|oxytocin group|oxytocin treatment
2466588|NCT03128242|Placebo Comparator|placebo group|placebo treatment
2467085|NCT03124589|No Intervention|No Intervention|A questionnaire that asks individuals what components of an online intervention they might find useful.
2467086|NCT03124589|Experimental|Online Gambling Internet Intervention|An online gambling Internet intervention (housed at CAMH and developed based on the self-help materials created by Professor David Hodgins)
2467137|NCT03124186|Experimental|Active stimulation with motor training|2 hours of active peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2467138|NCT03124186|Active Comparator|Sham stimulation with motor training|2 hours of sham peripheral nerve stimulation (intervention) paired with 4 hours of intensive task-oriented upper extremity training. Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy. Peripheral nerve stimulation will be delivered using a S88 Dual Output Stimulator by Grass Technologies.
2467279|NCT03123185|Experimental|Single rising dose part|Groups of healthy volunteers receive rising single doses of BI 705564
2467280|NCT03123185|Experimental|Food effect part|Groups of healthy volunteers receive single doses of BI 705564 with and without food
2467327|NCT03122795|Experimental|Microbiome transplant|The only arm of the study. Patients suffering from CRSsNP gets microbiome transplants from donors without any sinonasal health problems.
2467339|NCT03122483||OSA|Blood biomarker results in subjects with obstructive sleep apnea.
2467340|NCT03122483||Non-OSA|Blood biomarker results in subjects without obstructive sleep apnea
2467443|NCT03122054|Other|Group L (n:88)|patients treated surgically with laparoscopic cholecystectomy immediately
2467446|NCT03122054|Other|Group D (n:88)|patients first treated medically and than treated surgically with delayed (4-8 weeks later) laparoscopic cholecystectomy
2467483|NCT03121625|Experimental|Autologous CAR-T cells|Patients will be be treated with autologous CAR-T cells.
2467535|NCT03121339|Active Comparator|Treatment A - Fasting Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to fasted subjects.
3156737|NCT00350818|Experimental|Azacitidine|Azacitidine after Allogeneic Transplantation
3156738|NCT00350857|Active Comparator|Equetro active|
3156739|NCT00350883|Other|Treatment as Usual|
3156740|NCT00350883|Experimental|Cognitive Therapy|
3156741|NCT00350909|Experimental|1|One arm was a 2-session brief intervention with both sessions involving only the adolescent. Each session was a 60 minute individual session with the counselor.
3156742|NCT00350909|Active Comparator|2|The other arm was a 3-session brief intervention, with 2 sessions involving the adolescent and one session with the parent. Each of these individual sessions were 60 minutes.
3156743|NCT00350935||Healthy volunteers|Healthy controls
3156744|NCT00350935||Patients|Patients with schizophrenia
3156745|NCT00350948|Experimental|Telcyta + Liposomal Doxorubicin|Telcyta at 1000 mg/m2 followed by Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
3156746|NCT00350948|Active Comparator|Liposomal Doxorubicin|Liposomal Doxorubicin at 50 mg/m2 on Day 1 of each four-week treatment cycle
3156747|NCT00350974||End-stage Renal Disease|on maintenance hemodialysis 3 x per week for more than 12 months
3156748|NCT00350974||No kidney disease|eGFR greater than 60 ml/Min
3156749|NCT00350974||Hypertensive group|Blood pressure greater than 130/80
3156750|NCT00350987|Experimental|PCT|PCT guidance
2466272|NCT03130595||PD outpatients in West Sweden|Cross-sectional random sample of patients with PD that have visited outpatient clinics in West Sweden in the last 6+6 months
2466309|NCT03130348|Experimental|Treatment (ibrutinib, bortezomib, dexamethasone)|Patients receive ibrutinib PO QD on days 1-28. After 3 courses, patients who achieve partial response repeat treatment every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve partial response after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4, patients who do not achieve partial response also receive bortezomib SC and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
2466405|NCT03129503||Acute coronary syndrome (ACS)|Patients with STE- or NSTE-ACS (acute coronary syndrome)
2466844|NCT03126487|Experimental|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND
2466906|NCT03126175|Active Comparator|Above elbow immobilization|Above elbow immobililization with short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow. Additional splint with a 15cm width splint on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
2466913|NCT03126175|Experimental|Below elbow immobilization|Below elbow immobilization with exclusively short radial splint that will be performed with 20cm wide gypsum cut to fit the thumb. The splint will be applied to the radial aspect of the wrist covering the volar and dorsal portion of the radius to the elbow.
2466975|NCT03125746|Experimental|LXI-15029|
2466981|NCT03125746|Experimental|LXI-15029+Exemestane|
2467041|NCT03125382|Active Comparator|In office standard visit-New|Patients with new implants who do not perform device data transmission through Carelink system
2467046|NCT03125382|Active Comparator|In office standard visit-Previous|Patients with previous implants who do not perform device data transmission through Carelink system
2467048|NCT03125382|Experimental|Carelink - New Implants|Patients with new implants who perform device data transmission through Carelink system
2467051|NCT03125382|Experimental|Carelink - Previous Implants|Patients with previous implants who perform device data transmission through Carelink system
2467080|NCT03124615|Experimental|Enzalutamide|Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
2467156|NCT03124160|Experimental|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini containing 380mm2 of copper surface inserted into the uterine cavity.
2467162|NCT03124160|Active Comparator|ParaGard® CuT380A|ParaGard® CuT380A containing 380mm2 of copper surface inserted into the uterine cavity.
3156751|NCT00350987|Active Comparator|Guidelines|enforced guidelines
3156752|NCT00351013|Experimental|1|
2467300|NCT03123081|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involves milking 30 cm length of cord at birth, after initiation of ventilation.
2467301|NCT03123081|No Intervention|Immediate Umbilical Cord Clamping|Procedure: No Intervention: Immediate Umbilical Cord Clamping or Immediate Cord Clamping.
2467374|NCT03122665|Active Comparator|Nefopam low dose|Nefopam continuous intravenous infusion at 0.5 mg/ml for three hours.
2467376|NCT03122665|Active Comparator|Nefopam high dose|Nefopam continuous intravenous infusion at 1.0 mg/ml for three hours.
2467521|NCT03121560|Active Comparator|Hysteroscopy|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
2467524|NCT03121560|Experimental|Hysterosonography|Women with ≥ 18 with abnormal bleeding (post-menopausal menorrhagia or metrorrhagia), managed at bleeding clinic. Each women will undergo an hysteroscopy and a hysterosonography and will be her own control.
2467569|NCT03121014|Experimental|Patient Treatment|Patients will receive fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). In addition to the above conditioning regimen all patients will receive TMI at a dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of administration of tacrolimus and methotrexate. Post-transplant evaluation will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2 years.
2467608|NCT03120455|Experimental|Almond group (AG)|Obese or overweight female adults will be randomly allocated to have have almond as afternoon snack while they have a hypoenergetic diet.
2467610|NCT03120455|Active Comparator|Pistachio group (PG)|Obese or overweight female adults will be randomly allocated to have have Pistachio as afternoon snack while they have a hypoenergetic diet.
2467611|NCT03120455|Placebo Comparator|Nut Free (NFG, CG)|Obese or overweight female adults are asked to avoid all nuts, seeds, and nut products while they have a hypoenergetic diet. , as the control group.
2467643|NCT03120338|Experimental|The Development and Wellbeing Assessment|"The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.~The DAWBA will be administered in addition to care as usual."
2467646|NCT03120338|No Intervention|Care as Usual|Care as usual
2467693|NCT03120104|Active Comparator|Pre-intervention group|Pre-intervention group interventions:pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
2467696|NCT03120104|Active Comparator|Post-intervention group|Post-intervention group: pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) two weeks after the stoma closure
3156753|NCT00351026|Active Comparator|1|25 HIV negative opiate dependent patients all treated with methadone
3156754|NCT00351026|Active Comparator|2|25 HIV positive opiate dependent patients all treated with methadone
3156755|NCT00351052|Experimental|1|Pimecrolimus
3156756|NCT00351052|Placebo Comparator|2|Vehicle
3156757|NCT00351078|Experimental|PTC124 PO|4-, 4-, and 8-mg/kg TID first 14 days of cycle 10-, 10-, and 20-mg/kg TID second 14 days of cycle 28 day study
3156758|NCT00351117|Experimental|1|St. John's wort 300mg PO TID
2466283|NCT03130608|Experimental|Inspiratory Muscle Training|"The experimental group will perform Inspiratory Muscle Training (IMT) using a THRESHOLD device, a simple hand held one way valve.~In addition, the experimental group will gradually increase their activity as part of their usual care post-transplant."
2466285|NCT03130608|No Intervention|Usual Care|Receive the usual post-liver transplant care of gradually increase their activity.
2466323|NCT03130218|No Intervention|Control|Patients in the control group will not receive peppermint oil aromatherapy as a primary intervention for postoperative nausea and vomiting. Primary therapy for postoperative nausea and vomiting would entail standard antiemetic drug therapies. Patient monitoring and documentation would include the following: Patients in the control group will be assessed every 4 hours and as needed for nausea. All aspects of care from physician, nursing and all disciplines will be consistent with current practices in care of postoperative bariatric surgical patients.
2466326|NCT03130218|Experimental|Intervention|Patients in the intervention group will receive peppermint oil aromatherapy as primary treatment for postoperative nausea. Pharmacological therapy with anti-nausea drug therapies will be available as needed. All other aspects of medical, surgical and nursing care will be standard practice for pre and post-operative care related to the bariatric surgical patient. Patients in the intervention group will be assessed every 4 hours and as needed for nausea. Post-intervention, the patient will be re-assessed for level of nausea after one hour. In the event the patient refuses peppermint oil aromatherapy and requests anti-emetic drug therapies, they are able to do so.
2466510|NCT03129035|Active Comparator|internal iliac artery ligation|women undergo bilateral internal iliac artery ligation after fetal extraction and before proceeding in cesarean hysterectomy
2466511|NCT03129035|Active Comparator|No internal iliac artery ligation|Women undergo cesarean hysterectomy after fetal extraction
2466583|NCT03128359|Experimental|Regimen A (fludarabine, melphalan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -3 and melphalan hydrochloride IV over 20 minutes on day -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2466584|NCT03128359|Experimental|Regimen B (fludarabine, busulfan, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 1-3 hours and busulfan IV over 3 hour on days -5 to -2.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2466586|NCT03128359|Experimental|Regimen C (fludarabine, TBI, PBSC HCT, GVHD prophylaxis)|"Patients receive fludarabine phosphate IV over 60 minutes on days -7 to -5 and TBI BID on days -4 to -1.~Patients undergo PBSC HCT on day 0.~Patients receive cyclophosphamide IV over 1-2 hours on days 3-4, mycophenolate mofetil IV or PO TID beginning on days 5 and stopping on day 35 if no severe GVHD is present-35, and tacrolimus IV continuously on days 5-180 with a taper beginning on day 90 in the absence of disease progression or unacceptable toxicity."
2466742|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment B|Participants will receive single dose of 25 milligram (mg) rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment B containing a single intramuscular (IM) injection of 600 mg rilpivirine long-acting parenteral formulation (RPV LA) [with different particle size distribution (PSD) as compared to Treatment A, D, C and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2466743|NCT03127189|Experimental|Cohort 1-RPV LA: Treatment D|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment D containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and E) on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2466745|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment A|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment A containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment B, C, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2466747|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment C|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment C containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, D and E] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2466749|NCT03127189|Experimental|Cohort 2-RPV LA: Treatment E|Participants will receive single dose of 25 mg rilpivirine (RPV) as an oral solution on Day 1 in Session 1 and Treatment E containing a single IM injection of 600 mg RPV LA [with different PSD as compared to Treatment A, B, C and D] on Day 1 of session 2. Both the sessions are separated by a wash-out Period of at least 14 days.
2466804|NCT03126734|Experimental|Experimental Group|The parents of this group will receive 5 sessions of infant massage course (1 per week) between two measurements of the variables
2466817|NCT03126734|No Intervention|Control Group|The parents of this group will not receive infant massage course (1 per week) between two measurements of the variables. They will receive it after two measurements.
2466921|NCT03126396|Experimental|Urgo 310 3166 dressing|Urgo 310 3166 dressing
2466942|NCT03125824|Other|Tattoos previously treated in Soliton 2016-001 trial|Identical tattoos treated by Laser + AWD in Soliton's previous trial
2466984|NCT03125616|Active Comparator|Standard UK 4CMenB vaccine|4CMenB (Bexsero®) vaccination at 2 and 4 months and a booster at 12 months .
2466985|NCT03125616|Experimental|Additional 4CMenB Vaccine|4CMenB (Bexsero®) vaccination at 2, 3 and 4 months and a booster at 12 months.
2467012|NCT03125174||control|healthy individuals with no history of lung disease
2467017|NCT03125174||bronchiectasis patients|individuals with a diagnoses of bronchiectasis
3191647|NCT00800579|Experimental|1|GS-9411 0.6 mg
3191648|NCT00800579|Experimental|2|GS-9411 1.2 mg
2467225|NCT03123510|Experimental|Synbiotic supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides
3191649|NCT00800579|Experimental|3|GS-9411 2.4 mg
3191650|NCT00800579|Placebo Comparator|4|Inhaled volume-matched sterile saline placebo
2466329|NCT03130231||Non-POD group|Non-POD refered to the patients who did not become delirious by the Confusion Assessment Method.
2466372|NCT03129828|Experimental|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
2466449|NCT03129334|Experimental|LST Middle School Online|Students will participate in a series of e-learning modules plus classroom sessions related to drug abuse prevention, including prescription drug abuse
2466451|NCT03129334|No Intervention|Treatment as Usual (Control)|Students will not participate in the e-learning modules. They will receive any standard classroom instruction on drug abuse/health education.
2466494|NCT03128866|Experimental|Arm I (tranexamic acid)|Patients receive tranexamic acid IV over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity.
2466496|NCT03128866|Experimental|Arm II (no tranexamic acid)|Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity.
2466697|NCT03127553|No Intervention|A - control|Free diet with standard bread
2466698|NCT03127553|Active Comparator|B - low-salt diet with normal bread|Low-sodium diet with standard bread
2466701|NCT03127553|Experimental|C - low-salt diet with low-salt bread|Low-sodium diet with low-sodium bread
2466744|NCT03127176||BD with cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) and cognitive impairment.~Intervention: Genome sequencing of fecal samples"
2466746|NCT03127176||BD without cognitive impairment|"This group will include euthymic patients with bipolar disorder type I or II (YMRS<6 and HMDRS<8) without cognitive impairment.~Intervention: Genome sequencing of fecal samples"
2466748|NCT03127176||Control group|This group will include healthy volunteers. Intervention: Genome sequencing of fecal samples
2466807|NCT03126825|Other|Conventional CI|The conventional CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
2466820|NCT03126825|Other|Hybrid CI|The Hybrid CI group will receive the noise reduction on and off signal processing test programs. This is a within subject repeated measures design, so all subjects will receive the same testing but in a counterbalanced order.
2466852|NCT03126292|Experimental|Sit Down and Play|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visits.
2466853|NCT03126292|Active Comparator|Handout|Families in the control group will receive handouts regarding child safety
2467026|NCT03125291|No Intervention|Bridges Workshop|Participants will receive a one-time, 90-minute workshop.
2467031|NCT03125291|Experimental|Bridges 4-week Program|Parents and adolescents will attend separate 1.25-hour groups simultaneously and then meet together for 45 minutes. Group meetings will be conducted at the school once per week for four weeks. Each week will cover a different topic. The parent program will focus on positive parenting and goal setting, parent-adolescent relationship strengthening, behavior management, and monitoring. The adolescent program will focus on personal goals and motivation, emotion regulation, cognitive control, and adaptive coping.
2467061|NCT03124862|Experimental|Test group|The subjects will be enrolled into the test group and will receive ARM sensor.
3156759|NCT00351117|Placebo Comparator|2|Lactose in capsule matching the St. John's wort. 300mg PO TID
2467318|NCT03122925||Control|Healthy subjects
2467324|NCT03122925||Friedreich's Ataxia|Diagnosed for Friedreich's Ataxia
2467439|NCT03122119|Experimental|Platelet Rich Plasma Joint Injection|Venous blood will be drawn from the patient receiving injection treatment. It will be spun down to form PRP and reinjected back into the SI joint.
2467496|NCT03121703|Experimental|lumbar stabilization exercises group|diverse lumbar stabilization exercises
2467500|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
2467549|NCT03121261|Experimental|0.5% levobupivacaine with 0.015% clonidine|0.5% levobupivacaine 15 mg with 0.015% clonidine 50 mcg and 40% glucose 0.5 ml will be preformed as subarachnoid block
2467551|NCT03121261|Active Comparator|0.5% levobupivacaine with 0.9% saline|0.5% levobupivacaine 15 mg with 0.33 ml of 0.9% saline and 40% glucose 0.5 ml will be preformed as subarachnoid block
2467585|NCT03120845|Experimental|Post operative Pain in one visit RCT|One visit RCT Ibuprofen for Post operative pain. Take 400 mg every 6 hours, a week after.
2467588|NCT03120845|Experimental|Post operative pain in two-visits RCT|Two visits RCT Ibuprofen for Post operative pain. Take 400 mg every 6-8 hours, a week after.
2467677|NCT03120221||First trimester pregnant women|
2467692|NCT03119922||SCD french new born|New-borns diagnosed by NBS from 01/01/2006 to 31/12/2010 (AFDPHE data, France)
3156760|NCT00351143|Experimental|Interventional group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training in Period 2
3156761|NCT00351143|Active Comparator|Control group: Period 2|Randomized subjects will receive salmeterol/fluticasone propionate 50/250 µg in treatment Period 2
3156762|NCT00351143|Experimental|Subjects receiving salmeterol/fluticasone propionate: Period 1|All subjects treated with salmeterol/fluticasone propionate 50/250 µg b.i.d without any other intervention will be included in Period 1
3156763|NCT00351325|Experimental|dose escalation|
3156764|NCT00351364|Active Comparator|Montelukast sodium|Drug arm - Montelukast as a single dose 100 mg. To test the hypothesis of leukotriene inhibition.
2466352|NCT03129984||The study population|The study population is comprised of all patients included in the Brizzy register, Belgium.
2466391|NCT03129659|Experimental|CT-group|Coronary CT angiography
2466443|NCT03129256|Experimental|Apatinib & S-1|Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
2466525|NCT03128879|Experimental|Treatment (venetoclax, ibrutinib)|Participants receive venetoclax PO QD and ibrutinib PO QD. Courses repeat every 4 weeks for up to 24 courses in the absence of disease progression or unaccepted toxicity.
2466609|NCT03128034|Experimental|Treatment (211^At-BC8-B10, PBSC)|Patients receive 211^At-BC8-B10 IV over 6-8 hours on day -7 and fludarabine phosphate IV over 30 minutes on days -4, -3 and -2. Patients undergo TBI and PBSC transplant on day 0. Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 and then tapered to day 180, or continuing to day 96 and then tapered to day 150. Patients receive mycophenolate mofetil PO or IV (first dose to occur 4-6 hours after PBSC infusion) every 12 hours on days 0-27, or every 8 hours on day 0 and then reduced to every 12 hours on days 30-40. Patients with HLA-matched unrelated donors receive sirolimus PO QD on days -3 to 150 and then tapered to day 180.
2466756|NCT03127124|Experimental|NANT-008 in combination with other agents|NANT-008 will be administered in combination with 5-fluorouracil, bevacizumab, leucovorin, and oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
2466802|NCT03126721|Experimental|oral midazolam alone|single dose of oral midazolam administered alone in period 1
2466809|NCT03126721|Experimental|oral midazolam administered with multiple doses of PF-06751979|single dose of midazolam on day 10 with multiple doses of PF-06751979 once a day on Days 1-11 in period 2
2466851|NCT03126305||OC-Go|Approximately 10-20 9-17 year-olds receiving exposure based cognitive behavior therapy for OCD through the UCLA Division of Child and Adolescent Psychiatry OCD treatment programs
3156765|NCT00351364|Placebo Comparator|2|No drug given - no placebo available. To compare with active drug.
2466988|NCT03125720|Experimental|GUIDED group|Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
2466989|NCT03125720|No Intervention|Control group|No Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.
2467082|NCT03124628|Experimental|Flywheel resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform flywheel leg press resistance exercise twice per week.
2467083|NCT03124628|Active Comparator|Weight-stack resistance exercise|During 8 weeks, all the subjects will follow a standard resistance exercise training program within the Stockholm Habilitation Center system. In addition, patients in this arm will perform conventional, weight-stack leg press resistance exercise twice per week.
2467119|NCT03124225||Ultrasound|Early Arthritis Patients seeing a Rheumatologist who uses US for assessment routinely in clinic
2467123|NCT03124225||Non-Ultrasound|Early Arthritis Patients seeing a Rheumatologist who does not uses US for assessment routinely in clinic
2467153|NCT03124082|Active Comparator|opioid|remifentanil 0,15-0,25 mcg/kg/h
2467154|NCT03124082|Experimental|opioid free|ketamine bolus 0,5 mg/kg + infusion 0,25 mg/kg/h lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h clonidine 4 mcg/kg
2467219|NCT03123718|Other|Intrathecal Methotrexate|
2467224|NCT03123718|Active Comparator|High-dose Intravenous Methotrexate|
2467270|NCT03123276|Experimental|gemcitabine + pembrolizumab|First cohort of 6 patients may receive Gemcitabine 800 mg/m2 + Pembrolizumab 200 mg. After safety data review, if no DLTs then dose for Gemcitabine will be increased to 1000 and further 1200 mg/m2.
2467313|NCT03122834||Cohort A|Newly diagnosed Heart Failure patients who will be treated with beta blockers (BB) and Angiotensin converting enzyme inhibitors (ACEIs)/or Angiotensin receptor blockers (ARBs) for the first time.
2467314|NCT03122834||Cohort B|Heart Failure patients who are candidate for add-on treatment with Spironolactone / Eplerenone.
3156766|NCT00351390|Placebo Comparator|SOC|Standard of care HF therapy without NT-proBNP guidance
2467492|NCT03121378||Hip arthroplasty with bone cement|Patients undergoing hip replacement surgery with bone cement use: blood samples taken before cement use and after cement prosthesis fixation.
2467498|NCT03121378||Non cement hip arthroplasty|Patients undergoing hip replacement surgery without bone cement. Blood samples taken before bone reaming and after implantation of femoral prosthesis.
2467556|NCT03121183||Patients who have undergone an extraction of implantable pace|
2467587|NCT03120871||All subjects|Female sex, obese, aged 9-17 years, Tanner stages 1-5.
2467704|NCT03120130|Experimental|Cohort 4|This cohort will include 3 patients with the fourth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
3156767|NCT00351390|Active Comparator|NT-proBNP arm|NT-proBNP plus standard HF management
3156768|NCT00351403|Experimental|Individualized therapy|Lengh of therapy depends on time point when no HCV RNA is detectable in blood with Versant HCV Qualitative assay.
3156769|NCT00351403|Other|Historical control|48 week standard therapy
3156770|NCT00351429|Experimental|1|
3156771|NCT00351442||1|Inidividuals who have been exposed to HIV but remain uninfected.
3156772|NCT00351442||2|HIV infected regular sexual partners of Group 1 participants.
3156773|NCT00351442||3|HIV uninfected individuals or couples who have not been exposed to HIV.
3156774|NCT00351598||1|Patients with loco-regional, NSCLC treated by definitive radiotherapy.
3156775|NCT00351624|Active Comparator|DHA|
3156776|NCT00351624|Placebo Comparator|placebo|
3156777|NCT00351663|Active Comparator|IV by weight|intravenous dose of 0.5 mg/kg enoxaparin once daily
3156778|NCT00351663|Active Comparator|SC fixed dose|subcutaneous fixed dose of 40 mg enoxaparin once daily
3156779|NCT00351663|Active Comparator|SC by weight|subcutaneous dose of 0.5 mg/kg enoxaparin once daily
3156780|NCT00351702|Active Comparator|Isoniazid|Isoniazid (300mg) daily for 36 months
3174733|NCT00626483|Experimental|CMV pp65-LAMP mRNA-loaded DC vaccination|Basiliximab will be safe in combination with CMV pp65-LAMP mRNA-loaded DC vaccination and GM-CSF
2466376|NCT03129893||Patients intubated with uncuffed tracheal tubes|Portex uncuffed TT sizes selected according to local institutional guidelines. Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to institutional guidelines in uncuffed TTs.
2466383|NCT03129893||Patients intubated with cuffed tracheal tubes|Cuffed TT sizes selected as follows: ID 3.0 mm for birth (>3 kg body weight) to < 8 months; ID 3.5 mm for 8 to < 12 months (Salgo, Schmitz et al. 2006). Tracheal intubation performed under direct laryngoscopy by the oral or nasal route, without or with the use of bougies or stylets. TT insertion depth managed according to the depth marking in cuffed TTs.
3173274|NCT00610246|Experimental|Sorafenib and Radiation|Eligible patients (not candidates for curative treatment) will have measurable lesions in the anatomic thorax, abdomen or pelvis (any histology) amenable to palliative radiation treatment (30 Gy in 10 fractions). Patients receive sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. If full oral dose (400 mg po bid) is reached in a given cohort (dose level three) then an additional dose level will open where sorafenib treatment (400 mg bid) is extended following radiation for a total of eight weeks.
3173275|NCT00610259|Experimental|1|brief behavioral therapy for insomnia (bBT-I) in addition to treatment as usual (TAU)
3173276|NCT00610259|Active Comparator|2|Treatment as usual (TAU)
2466503|NCT03128775|Experimental|Nudge|This group will receive changes in the school environment (nudge strategies). Interventions regarding food consumption were based on nudge strategies to led students to eat more fruits and vegetables. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) are available for use in the school sports court.
2466504|NCT03128775|Experimental|Primary prevention|This group will receive educational activities in the classroom. Classroom-based educational activities will be based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans.
2466506|NCT03128775|Experimental|Primary prevention + nudge|This group will receive educational activities and in the classroomchanges in the school environment (nudge).
2466509|NCT03128775|No Intervention|Control|without any activity
2466754|NCT03127215|Experimental|Arm E: Olaparib / Trabectedin|Olaparib / Trabectedin
2466757|NCT03127215|Other|Arm C: Physician's choice|Physician's choice
2466818|NCT03126695|Experimental|Treatment Sequence 1 (ADBC)|"Subjects were randomized to treatment sequence ADBC:~On Day 1, following an overnight fast of at least 10 hours, each subject will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2466823|NCT03126695|Experimental|Treatment Sequence 2 (BACD)|"Subjects were randomized to treatment sequence BACD:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2466829|NCT03126695|Experimental|Treatment Sequence 3 (CBDA)|"Subjects were randomized to treatment sequence CBDA:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2466832|NCT03126695|Active Comparator|Treatment Sequence 4 (DCAB)|"Subjects were randomized to treatment sequence DCAB:~On Day 1, following an overnight fast of at least 10 hours, each subjects will receive single dose of the treatment assigned to that treatment period.~A =Ticagrelor granule for oral suspension equal to 90 mg. B = Ticagrelor pediatric tablets equal to 90 mg. C= Ticagrelor pediatric tablets suspended in water equal to 90 mg. D = Ticagrelor commercial IR (1 x 90 mg) tablet"
2466880|NCT03126149|Experimental|Cohort 1_Period 1_Active|Single ascending dose of PF-06667272
2466882|NCT03126149|Placebo Comparator|Cohort 1_Period 1_Placebo|Single dose of placebo
2466884|NCT03126149|Experimental|Cohort 1_Period 2_Active|Single ascending dose of PF-06667272
2466885|NCT03126149|Placebo Comparator|Cohort 1_Period 2_Placebo|Single dose of placebo
2466886|NCT03126149|Experimental|Cohort 1_Period 3_Active|Single ascending dose of PF-06667272
2466887|NCT03126149|Placebo Comparator|Cohort 1_Period 3_Placebo|Single dose of placebo
2466888|NCT03126149|Experimental|Cohrot 1_Period 4_Active|Single ascending dose of PF-06667272
2466889|NCT03126149|Placebo Comparator|Cohort 1_Period 4_Placebo|Single dose of placebo
2466890|NCT03126149|Experimental|Cohort 2_Period 1_Active|Single ascending dose of PF-06667272
2466892|NCT03126149|Placebo Comparator|Cohort 2_Period 1_Placebo|Single dose of placebo
2466894|NCT03126149|Experimental|Cohort 2_Period 2_Active|Single ascending dose of PF-06667272
2466895|NCT03126149|Placebo Comparator|Cohort 2_Period 2_Placebo|Single dose of placebo
2466896|NCT03126149|Experimental|Cohort 2_Period 3_Active|Single ascending dose of PF-06667272
2466897|NCT03126149|Placebo Comparator|Cohort 2_Period 3_Placebo|Single dose of placebo
2466898|NCT03126149|Experimental|Cohort 2_Period 4_Active|Single ascending dose of PF-06667272
2466899|NCT03126149|Placebo Comparator|Cohort 2_Period 4_Placebo|Single dose of placebo
2466958|NCT03125681|Experimental|Remote ischemic conditioning|Applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times) before and after coronary anastomoses.
2466960|NCT03125681|Placebo Comparator|Control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
2467227|NCT03123510|Placebo Comparator|placebo|sugar pills
3174734|NCT00626535|Experimental|1|20mg once daily
3174735|NCT00626535|Placebo Comparator|2|Oral once daily
2466384|NCT03129711|Active Comparator|Glazed IPS Empress CAD|glazed Leucite based glass ceramics ,Its a glass ceramic which is etchable and proved to have good esthetics if used for laminate veneers
2466406|NCT03129347|Experimental|Nalmefene (high dose)|Nalmefene (high dose) intranasal one time during the 17 day inpatient treatment period
2466407|NCT03129347|Experimental|Nalmefene and Intravail|Nalmefene (high dose) with Intravail intranasal one time during the 17 day inpatient treatment period
2466410|NCT03129347|Experimental|Nalmefene (low dose)|Nalmefene (low dose) intranasal one time during the 17 day inpatient treatment period
2466413|NCT03129347|Experimental|Nalmefene Intramuscular|Nalmefene intramuscular one time during the 17 day inpatient treatment period
2466491|NCT03129048|Experimental|MedDiet-WL|MedDiet-WL group, advice and exchange lists will be designed to promote a 1-2 lb. per week weight loss (approximately 30% caloric restriction or a reduction of about 600 calories per day) for an end goal of a 7% weight loss from baseline.
2466492|NCT03129048|Experimental|MedDiet-A|For the MedDiet-A group, dietary advice and corresponding exchange lists will be given within the context of promoting weight stability.
2466495|NCT03129048|Other|Typical Diet Control (TDC)|Typical Diet Control (TDC) will maintain current eating and activity patterns and weight over 14 months.
2466563|NCT03128502||healthy control|Ten healthy control subjects presented with clinically healthy periodontium. Control subjects had to meet the following criteria for inclusion: probing depth less than 3mm, no clinical attachment loss, no bleeding on probing, with Gingival and Plaque index 0-1.
2466564|NCT03128502||plaque induced gingivitis|Ten patients who had plaque induced gingivitis characterized by the presence of any of the following clinical signs: redness and edema of the gingival tissue, bleeding upon provocation, changes in contour and consistency, presence of calculus and/or plaque, with no clinical attachment loss nor radiographic evidence of bone loss.
2466569|NCT03128502||chronic periodontitis|Ten chronic moderate to severe periodontitis patients selected according to the criteria currently adopted by Armitage 1999. Moderate destruction is generally characterized by periodontal probing depths up to 6 mm with clinical attachment loss of up to 4 mm. Advanced destruction is generally characterized by periodontal probing depths greater than 6 mm with attachment loss greater than 4 mm. Radiographic evidence of bone loss is apparent, Increased tooth mobility may be present.
2466575|NCT03128502||aggressive periodontitis|Ten patients suffering generalized aggressive periodontitis, patients were less than 35 years of age and had generalized interproximal attachment loss affecting at least 3 permanent teeth other than the first molars and incisors with at least one site each with PD and CAL >5 mm, Attachment loss occurs in pronounced episodic periods of destruction, and there is familial aggregation (subjects were asked if they had at least one other member of the family presenting or with a history of periodontal diseases).
2466627|NCT03128164|Experimental|HMPL-689|HMPL-689, oral, BID, doses should be taken at ~12-hour intervals (eg, at ~8 AM and at ~8 PM)
3173277|NCT00610272|Experimental|Single Site Radiation 4Gy Fraction|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
3173278|NCT00610272|Active Comparator|Single Site Radiation 8Gy Fraction|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
2466774|NCT03127020|Experimental|PQR309|PQR309 being taken continuously on daily basis (60,80mg) or intermittent (120mg, 140mg, 160mg) dosing
2466814|NCT03126565|Experimental|Group A|This group will include a cohort of 185 participants who will be monitored by the CareSage risk assessment platform. Tailored interventions, using a Stepped-Care Approach, will be targeted to patients flagged as high risk for emergency transport during the 6-month intervention period.
2466821|NCT03126565|No Intervention|Group B|This group will include a cohort of 185 participants where study staff will not see if patients are flagged by the CareSage risk assessment platform as being at high or low risk for emergency transport during the 6-month intervention period. Patients will continue to receive care as usual.
3191651|NCT00800592|Active Comparator|10 mg sildenafil bolus|10 mg sildenafil bolus
3191652|NCT00800605|Experimental|1|Vero cell-derived, trivalent, seasonal influenza vaccine
3191653|NCT00800605|Placebo Comparator|2|Phosphate-buffered saline
3191654|NCT00800618|Experimental|PF-02413873|PF-2413873 active treatment
3191655|NCT00800618|Placebo Comparator|Placebo|Placebo
3191656|NCT00800644||Evaluation Group|Bone Mineral Density Test + MRI or CT + Blood Test
2467097|NCT03124485|Experimental|Endoscopic Sleeve Gastroplasty|A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
2467101|NCT03124485|Active Comparator|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
2467191|NCT03124134|Experimental|E) Gelesis200, TBD carbs|up to 4.20 g Gelesis200 before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
2467248|NCT03123302||Group 1|Epileptic patients who are sedated with a total dose of propofol 2 mg/kg and midazolam 0.1 mg/kg.
3191657|NCT00800670|Experimental|Lower dose|Lower dose of Ad5Ag85A: 10^8pfu
3191658|NCT00800670|Experimental|Higher dose|Higher dose of vaccine Ad5Ag85A: 10^9pfu
3174736|NCT00626587|Placebo Comparator|A|Conventional diagnostic procedures (transbronchial biopsy and bronchial washing) for peripheral pulmonary lesions
2466428|NCT03129295|Experimental|MPC-SHRC|oral tablet four times a day for 3 days
2466433|NCT03129295|Placebo Comparator|Placebo|oral tablet four times a day for 3 days
2466515|NCT03128697|Experimental|Satiating diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
2466516|NCT03128697|Experimental|Satiating diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the experimental diet (satiating diet) for a 16-week period.
2466517|NCT03128697|Active Comparator|Control diet-Low satiety phenotype|Low satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
2466518|NCT03128697|Active Comparator|Control diet-High satiety phenotype|High satiety phenotype subjects who were submitted to the control diet (based on the Canadian Food Guide) for a 16-week period.
2466567|NCT03128320|Experimental|BAY1193397/Placebo (sequence A-B-C)|Subjects with type II diabetes who follow treatment sequence A-B-C. Single oral dose of a placebo tablet in the first intervention period (Treatment A); followed by single oral dose of 1 mg BAY1193397 (Treatment B); then single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2466572|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-C-A)|Subjects with type II diabetes who follow treatment sequence B-C-A. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of 5 mg BAY1193397 IR tablet under fasted state in the second intervention period (Treatment C), then single oral dose of a placebo tablet under fasted conditions in the third intervention period (Treatment A). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2466576|NCT03128320|Experimental|BAY1193397/Placebo (sequence B-A-C)|Subjects with type II diabetes who follow treatment sequence B-A-C. Single oral dose of 1 mg BAY1193397 in the first intervention period (Treatment B); followed by single oral dose of a placebo tablet in the second intervention period (Treatment A), then 5 mg BAY1193397 IR tablet under fasted conditions in the third intervention period (Treatment C). A wash-out phase of approximately 120 - 360 hours was maintained between each treatment.
2466624|NCT03128047|Experimental|Recurrent high grade gliomas and ependymomas|"Recurrent high-grade glioma and ependamoma patients will receive treatment with the Optune NovoTTF-200A system as monotherapy.~Interventions: Device: Optune NovoTTF-200A System Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles combined with Temozolomide and Bevacizumab."
2466707|NCT03127735|Experimental|BAY1436032|"Dose escalation:~Various doses of study drug will be tested on a small number of patients/dose with the goal of identifying the most appropriate dose(s) for further evaluation in dose expansion. The MTD of the study drug may or may not be identified. It is anticipated that 3-4 patients will be treated at each dose of study drug to be tested and that 15-20 total patients will be treated in this part of the trial.~Dose expansion:~Up to 2 different doses of study drug will be tested on up to 30 patients/dose with the goal of identifying the most appropriate RP2D for further clinical development. The doses to be evaluated in this part of the trial will be selected based on information obtained during dose escalation."
2466750|NCT03127072|Experimental|Arm A|RFA plus chemotherapy ± target therapy
2466751|NCT03127072|Active Comparator|Arm B|chemotherapy ± target therapy
2466778|NCT03126799|Active Comparator|A: Erlotinib only|"Standard therapy arm:~Erlotinib 150mg. po, qd, daily, q 3weeks"
2466779|NCT03126799|Experimental|B: Erlotinib plus Bevacizumab|Study treatment arm; Erlotinib 150mg, po. qd, daily, q 3weeks plus Bevacizumab 15mg/kg, iv, on D1, q 3weeks.
2466870|NCT03126500||Malnourished|malnourished, geriatrics patients at hospital discharge
2466903|NCT03126045|Active Comparator|Standard needle|Patients perform a spinal punction according to the usual practice, with a standard needle.
2466912|NCT03126045|Experimental|Atraumatic needle|Patients perform a spinal punction according to the usual practice, with an atraumatic needle.
2466963|NCT03125772|Experimental|TAXUS Element™ Paclitaxel-Eluting System|The TAXUS® Element™ stent system is a multifunctional device providing a mechanical structure for vascular lumen support and a pharmacological agent targeted toward reducing or preventing the incidence of restenosis. The TAXUS Element™ stent is a balloon expandable, stainless steel platinum alloy stent, coated with paclitaxel in a slow-release system, pre-mounted on a high-pressure Monorail delivery catheter and is intended for use in the treatment of coronary artery disease. The pharmacological agent, paclitaxel, is incorporated into a triblock polymer matrix and applied to the surface of the stent. The polymer matrix provides controlled release of available paclitaxel. The TAXUS Element™ stent design is built upon the TAXUS Express and TAXUS Liberte design experience, but incorporates several improved stent design characteristics. The TAXUS Element™ stent also has a smaller tip profile, designed to enhance the ability to cross tighter and/or more complex lesions.
2466969|NCT03125772|Active Comparator|XIENCE PRIME™ ™ Everolimus-Eluting Stent System|The everolimus-eluting stent (EES, manufactured and distributed by Abbott Vascular, Santa Clara, CA, as XIENCE PRIME™ ) is a balloon expandable stent manufactured from a flexible cobalt chromium alloy with a multicellular design and 0.0032-in strut thickness which is coated with a thin (7.8 μm) nonadhesive, durable, biocompatible acrylic polymer and fluorinated copolymer releasing everolimus. Everolimus [40-O-(2-hydroxyethyl)- rapamycin], a semisynthetic macrolide immunosuppressant, inhibits growth factor-stimulated cell proliferation by causing cell-cycle arrest in the late G1 stage, thereby suppressing neointimal formation. Comparative analysis in an in vivo rabbit aortoiliac model has shown more rapid endothelialization with the EES compared to SES, PES, and ZES.
2467029|NCT03125369|Experimental|Duodenojejunal bypass|patients receive sleeve gastrectomy plus duodeno-jejunal bypass
2467038|NCT03125369|Active Comparator|Roux-en-Y gastric bypass|patients receive roux-Y gastric bypass
2467094|NCT03124394||CRS and intraoperative chemotherapy|Patients receiving cytoreductive surgery and intraoperative chemotherapy (HIPEC/PIPAC)
2467184|NCT03124134|Experimental|A) Gelesis200, 50 g carbs|4.20 g of Gelesis200 before a 50 g carbohydrate breakfast
2467260|NCT03123250|Experimental|Aquablation procedure|
3174737|NCT00626652|Experimental|1|
3174738|NCT00626665|Placebo Comparator|Placebo|One placebo tablet every alternate day for 6 weeks
2466431|NCT03129490|Active Comparator|Apixaban|After randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time.
2466500|NCT03128749|Experimental|Mindfulness Based Intervention|"Mindfulness-based cognitive therapy (MBCT), adjusted to OCD patients, will be applied in 10 weekly sessions of 2 hours followed by an extra session 4 weeks later. The treatment will be applied in a group format of 10 to 12 patients.~These patients will be also attending to their regular psychiatric visits for medication control."
2466502|NCT03128749|Active Comparator|Treatment as Usual (TAU)|Patients will be attending to their regular psychiatric visits during the whole trial period.
2466570|NCT03128385|Experimental|Intensive CIT Model Program|"In day camp model, the therapist will monitor and modify the activities to fit each child's ability and need (e.g. implementing task analysis, grading the challenge for each individual with varying capabilities) to make sure the intervention quality is equivalence to the individualized treatment.The day camp model will be arranged as Adventure Camp that decorating the treatment place as the adventure world and the participants take role as a warrior. This novel design is mean to enhance and motivate the engagement of participation."
2466578|NCT03128385|Experimental|Distributed CIT Model Program|All treatment activities will be focused on the training of the more affected upper limbs with contextual restraint. Investigators choose this child-friendly way to restraint children's non or less impaired hand without any devices. Investigators will provide a unilateral activities and verbal cues to restraint participants' non or less affected side. All tailored activities will be designed as fun and age-appropriated based on the child's preference and parents' concerns. In order to help children to generalize the therapeutic gains to the real world environment, the intervention will take place in the natural environment such as home or school where it may be easier to identify real practical problems and makes the family or caregivers involved more closely and directly.
3191659|NCT00800696|Experimental|oral care|intervention: The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx.
3191660|NCT00800696|No Intervention|control|continue to receive oral care as performed today.
2466664|NCT03127592|Experimental|Group 1|1 active treatment (Fixed Dose Combination) + 2 placebos
2466665|NCT03127592|Active Comparator|Group 2|1 active treatment (Cyclobenzaprine) + 2 placebos
2466666|NCT03127592|Active Comparator|Group 3|1 active treatment (Etodolac) + 2 placebos
2466713|NCT03127423|Experimental|Hybrid ablation group|Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.
2466714|NCT03127423|Active Comparator|Thoracoscopic surgical ablation group|Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.
2466816|NCT03127059|Experimental|Breathing Exercises|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Three physiotherapist-sessions of Breathing Exercises (BrEX) with duration of 60 minutes (the initial) and 30 minutes (other sessions) at week 1, 4, and 9. The participant is expected to do 10 minutes of home exercise twice daily. The entire intervention combines elements of the Papworth method, and the Buteyko technique."
2466824|NCT03127059|Other|Usual care|"Individual instruction from a nurse at baseline aimed at knowledge on pharmacological treatment and optimized inhalation techniques. The participants will be encouraged to use online video instruction.~Besides the individual instruction described above, patients will receive only short information given initially at recruitment. They are allowed to receive instruction in positive expiratory pressure-treatment and physiotherapy targeting other problems than dysfunctional breathing (DB)."
2466920|NCT03126214|Experimental|Active Pharmacist Arm|OAC therapy will be initiated/adjusted by the community pharmacist in accordance to the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.
2466924|NCT03126214|Active Comparator|Enhanced Usual Care Arm|Pharmacist will be refer participants to their physician in regards to OAC therapy for atrial fibrillation. The pharmacist will provide a current medication list to the physician as well as notification of a new diagnosis of atrial fibrillation
2466982|NCT03125733|Experimental|STESD|Submucosal tunneling endoscopic septum division
2467024|NCT03125356|Experimental|Diet Soda|Subjects will be asked to consume a diet soda three times daily for eight weeks.
3191661|NCT00800709|Experimental|Memantine|
2467240|NCT03123640|Experimental|Intervention group|Pharmacist conducts medication reconciliation and medication review while the patient is admitted to the emergency Department. The pharmacist present results from medication reconciliation to physicians at the emergency Department before the Medical history is obtained. Further the pharmacist will discuss drug related problems obtained during the medication review with the physicians to customize and optimize the medication treatment for each patient.
2467241|NCT03123640|No Intervention|Control group|Standard treatment without pharmacist intervention in the emergency department
2467277|NCT03123159||HBV Infected patients|chronic HBV patients who will undergo standard of care FDA approved antiviral therapy to treat HBV infections. Will have blood drawn to be tested using the DxN HBV Assay. Study is observational and results will not be used to manage patient care.
2467334|NCT03122782|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
2467354|NCT03122756|Experimental|Group (D)|will include 50 women who will receive intravenous dexamethasone.
3191662|NCT00800722|Experimental|Treatment of Port Wine Stain|Rapamycin Treatment of Port Wine Stain
3191663|NCT00800748|Experimental|Group A|Participants with genotype 1, 4, 5 or 6 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 1000-1200 mg PO daily (dependent on body weight) for 48 weeks.
3191664|NCT00800748|Experimental|Group B|Participants with genotype 2 or 3 received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 24 weeks.
3191665|NCT00800748|Experimental|Group C|Participants with HIV co-infection received peginterferon alfa-2a 180 mcg SC qw + ribavirin 800 mg PO daily for 48 weeks.
2466435|NCT03129477|Experimental|Telemonitoring in NonInvasiveVentilation|"Tele-monitoring in noninvasive ventilation with Lumis 150 and others Resmed equipments with AirView monitoring system, in COPD patients.~• Education and adaptation of the patient to NIV."
2466439|NCT03129477|No Intervention|2- conventional monitoring group|"Conventional monitoring group~• Education and adaptation of the patient to NIV."
2466632|NCT03128424|Experimental|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is intended for patients with atherosclerotic lesions of the SFA
3173279|NCT00610272|Active Comparator|Multiple Sites Radiation 8Gy Fraction|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
3173280|NCT00610272|Experimental|Multiple Sites Radiation 12Gy Fraction|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
2466699|NCT03127371|Experimental|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
2466700|NCT03127371|Experimental|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess using lidocaine local anesthesia administered subcutaneously. The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
2466724|NCT03127137|Other|Control cohort Group|Control cohort group will receive medications not predetermined by the set protocol.
2466727|NCT03127137|Active Comparator|Experimental Group 1|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
2466730|NCT03127137|Placebo Comparator|Experimental Group 2|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
2466775|NCT03126877|Experimental|Optimized Ocular Surface|For patients enrolled into the treatment group for preoperative optimization of the ocular surface, utilize the LipiFlow® vectored thermal pulsating eyepieces (Activators) to gently apply heat and massage, thus evacuating the Meibomian glands. Omega-3 vitamin supplements should also be provided, initiated and dosed according to standard clinical practice, to maximize ocular surface health.
2466776|NCT03126877|Active Comparator|Non-Optimized Ocular Surface|Patients enrolled into the non-treatment group will not be optimized preoperatively for ocular surface health. No LipiFlow® Activators and no Omega-3 vitamin supplements will be provided, initiated, nor dosed.
2466971|NCT03125694|Active Comparator|Sitagliptin|
2466977|NCT03125694|Active Comparator|Pioglitazone|
2467099|NCT03124667|Experimental|Gaming Condition|The games group will visit the lab on 5 separate occasions, for 2 hours each, to complete training sessions (playing seated and standing computerized games), and then complete 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
2467192|NCT03124134|Placebo Comparator|F) Water, TBD carbs|300 mL of water before a meal of either 50 g or 100 g carbohydrate breakfast (to be determined after interim analysis)
3173281|NCT00610285||non-invasive immobilization system|This is a feasibility study to evaluate the accuracy of an alternative, non-invasive immobilization system in combination with image guided patient setup for SRS treatments. The aim is to determine whether or not the non-invasive system can provide comparable accuracy as the conventional invasive head ring system. If successful, patient discomfort can be significantly reduced for such treatments.
3173282|NCT00610298|Experimental|I|Subjects who receive whole body vibration
3173283|NCT00610298|No Intervention|N|Subjects do not receive whole body vibration intervention
3173284|NCT00610324|Experimental|1|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
3173285|NCT00610324|Active Comparator|2|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
3173286|NCT00610337|Placebo Comparator|1|
3173287|NCT00610337|Experimental|2|1mg Cethrin®
3173288|NCT00610337|Experimental|3|3mg Cethrin®
3173289|NCT00610337|Experimental|4|6mg Cethrin®
3173290|NCT00610337|Experimental|5|12mg Cethrin®. Administration of this dose is dependent on data from lower doses.
3173291|NCT00610337|Experimental|6|18mg Cethrin®. Administration of this dose is dependent on data from lower doses.
2466463|NCT03129139|Experimental|Regimen C (monotherapy in Gastric Cancer)|Minnelide™ Capsules will be given as a single agent orally once daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days. Minnelide™ Capsules should be given with the patient in a fasting state.
2466759|NCT03127163|Other|Mild Keratoconus|"A group of 65 patients with keratoconus who were implanted with an intrastromal corneal ring; the group was composed of 40 males (61.50%) and 25 females (38.50%), with a mean age of 27.88 ± 7.38 years (range, 17-47 years). The patients were fully informed about the study and signed a consent form previously approved by the ethics committee of our institution.~We used the Amsler-Krumeich classification and included only patients classified as grade I or II. The investigators performed the intraestromal corneal ring surgery in the selected group."
2466781|NCT03126773||BAY86-4891|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Angeliq Micro is indicated are fit for participation in this non-interventional study.
2466839|NCT03126526|Experimental|Food specific inhibitory control training|The stimuli in this task will involve pictures of food.
2466841|NCT03126526|Active Comparator|General inhibitory control training|The stimuli in this task will not involve pictures of food, but pictures of stationary and household items.
2466843|NCT03126526|No Intervention|Baseline brain activation assessment (healthy controls)|This arm is included to assess brain activation using EEG among healthy controls at baseline in order to compare responses to participants with eating disorders.
2466904|NCT03126188||Sertraline group|Mild and Moderate depressive episode without somatic syndrome who are treated with Sertraline. Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
2466911|NCT03126188||Dosulepin group|Mild and Moderate depressive episode with somatic syndrome who were treated with Dosulepin. Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks
2466916|NCT03126188||Venlafaxine group|Severe depressive episode without psychotic symptoms who were treated with Venlafaxine. Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
2466972|NCT03125759||Control|patients without any history of stroke
2466979|NCT03125759||Ischemic Stroke|patients with an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction within 72 hours.
2467027|NCT03125408||chronic HCV Infected patients|chronic HCV patients who will undergo standard of care FDA approved antiviral therapy to treat genotype 1,2, or 3 infections and will have blood drawn at various time points and tested using the DxN HCV Assay. Study is observational and results will not be used to manage patient care.
2467093|NCT03124316|No Intervention|Email #1: FULLY TURNED OFF|No behavioural change techniques (BCTs) 'turned on' in the email. The email would contain only standardized content.
2467104|NCT03124316|Experimental|Email #2: ANTICIPATED REGRET|Anticipated regret content + standardized content
2467109|NCT03124316|Experimental|Email #3: MATERIAL INCENTIVE|Material incentive content + standardized content
2467111|NCT03124316|Experimental|Email #4: PROBLEM SOLVING|Problem solving content + standardized content
2467114|NCT03124316|Experimental|Email #5: REGRET + INCENTIVE|Anticipated regret content + Material incentive content + standardized content
2467116|NCT03124316|Experimental|Email #6: REGRET + PROBLEM SOLVING|Anticipated regret content + Problem solving content + standardized content
2467120|NCT03124316|Experimental|Email #7: INCENTIVE + PROBLEM SOLVING|Material incentive content + Problem solving content + standardized content
2467124|NCT03124316|Experimental|Email #8: ALL BCTs|Anticipated regret content + Material incentive content + Problem solving content + standardized content
2467247|NCT03123419|Other|Vaccine|All patients who consent to be in the study will receive Appointment reminders.
2467417|NCT03122327||Newly diagnosed MM patients|newly diagnosed MM patients who fulfilled the inclusion criteria for this study
2467453|NCT03121859|Active Comparator|Neck stabilization exercise|The patients who had only neck stabilization exercise
2467458|NCT03121859|Active Comparator|TENS+ neck stabilization exercise|The patients who had both TENS and neck stabilization exercise
2467462|NCT03121859|Active Comparator|IFC+ neck stabilization exercise|The patients who had both interferential current therapy and neck stabilization exercise
2467526|NCT03121547|Placebo Comparator|Placebo oral tablet|One inert calcium tablet is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
2467528|NCT03121547|Experimental|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|One tablet containing 100 milligrams (mg) Mandolgin Retard, Sandoz is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
2467529|NCT03121547|Experimental|Tapentadol 50 mg Oral Tablet|One tablet containing 50 milligrams (mg) Palexia Depot, Grünenthal is administered after a set of baseline measurements are performed. Subsequently outcomes are assessed every hour for 6 hours, yielding a total of 7 hourly measurements.
3173292|NCT00610350|Experimental|L|
3173293|NCT00610350|Experimental|P|
2468150|NCT03117153|Experimental|DA-5502 liquid toothpaste|"SMFP 760mg, CPC 50mg, tocopherol acetate 10mg, panthenol 100mg, Dipotassium glycyrrhizinate 20mg.~everyday 3 times for 6 weeks"
3173294|NCT00610376|Experimental|1A|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home intervention component.
3173295|NCT00610376|Active Comparator|2|This group did not receive any special treatment during the study, but did receive the intervention at the close of the study
3174739|NCT00626678|Experimental|1|Oral administration of prednisone and azathioprine throughout study
3174740|NCT00626678|Placebo Comparator|2|Oral administration of prednisone and placebo throughout study
3174741|NCT00626704|Experimental|Arm 1|AMG 655 + Doxorubicin
3174742|NCT00626704|Placebo Comparator|Arm 2|Placebo + Doxorubicin
3174743|NCT00626717|Experimental|1|
3174744|NCT00626717|Sham Comparator|2|
3156781|NCT00351715|Experimental|Pharmacokinetic|One episode of breakthrough pain was to be evaluated per patient. Clinical status and bloodwork was evaluated prior to entering into this phase of the trial, and patients were eligible if bloodwork demonstrated a HgB of >90 g/L with no concurrent bleeding. A peripheral intravenous catheter was inserted and saline locked. When breakthrough pain was experienced, methadone was administered, and the patient completed a pain intensity numeric rating scale at time 0 and every 10 minutes for one hour. A 10 cc specimen of blood was collected prior to administration of methadone, and again every 10 minutes for one hour. Blood was collected without anticoagulant, allowed to clot, separated by centrifugation, and serum samples flash frozen. Serum methadone levels were quantified by LC/MS/MS with comparison to isotopically labeled internal standards
3156782|NCT00351767|Experimental|1|
3156783|NCT00351767|Experimental|2|
3156784|NCT00351767|Experimental|3|
2466629|NCT03127969|Other|Fluidotherapy treatment|Patients who received fluidotherapy and joint protection and exercise
2466635|NCT03127969|Other|Joint protection and exercise|Patients who received joint protection and exercise
2466675|NCT03127774|Experimental|Surgery with HIPEC|Cytoreductive surgery followed by HIPEC with cisplatin and sodium thiosulfate
2466702|NCT03127241|Active Comparator|Armon Ayura|Upper limb assistive device with active solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
2466703|NCT03127241|Active Comparator|Jaeco Wrex|Upper limb assistive device with passive solutions for gravity compensation. Intervention: The upper limb exoskeleton is worn by the patient on the preferred arm, and it is used during daily life activities to support arm movements, particularly getting rid of gravity arm weight.
2466772|NCT03127150||CL group|Subjects who had CL after pancreatic operation will be observed.
2466773|NCT03127150||Observation group|Subjects without CL after pancreatic operation will be observed.
3156785|NCT00351767|Placebo Comparator|4|
3156786|NCT00351793||Combined Deformity <30 degrees|
2466907|NCT03125993|Experimental|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week. For individual follow-up, body components and metabolic risk factors will be tested before and after the study.
2466947|NCT03125863|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove enlarged prostatic tissue. Following the aquablation intervention, a urinary catheter will be inserted to apply pressure on treated tissue for hemostasis.
2466961|NCT03125551|Active Comparator|Ginger|Ginger ( Zingiber officinale) 4 grams po dly for 14 days
2466962|NCT03125551|Active Comparator|Garlic|Garlic (Allium sativum) 4-12 mg alliin po dly for 14 days
2466966|NCT03125551|Active Comparator|Ginkgo Biloba|Ginkgo Biloba 40mg po tds for 14 days
2466974|NCT03125551|Active Comparator|Ginseng|Ginseng 400mg po dly for 14 days
2466980|NCT03125551|Placebo Comparator|Placebo|Placebo po dly for 14 days
2467018|NCT03125317||The music group|Participant will allow to listen any kind of music which they wish
2467020|NCT03125317||valsalva maneuver|participants will be asked to take a deep breath and exhale the air out in 15 seconds
2467021|NCT03125317||The control group|no intervention
2467062|NCT03124914|Active Comparator|Patients considered physically active|Measures of strength and determination of neuromuscular fatigue
2467064|NCT03124914|Active Comparator|Patients considered physically inactive|Measures of strength and determination of neuromuscular fatigue
2467400|NCT03122158|Active Comparator|Major depressive disorder|In this group, adolescents with major depressive disorder will be recruited. It was planned to include 30 participants.Escitalopram treatment will be given to those with Major Depressive Disorder with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
2467402|NCT03122158|Active Comparator|Anxiety disorders|In this group, adolescents with anxiety disorders will be recruited. It was planned to include 30 participants. Additionally, the specification of which anxiety disorders are assigned to the participants will also be provided. Escitalopram treatment will be given to participants with anxiety disorders with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
3156787|NCT00351793||Combined Deformity >30 degrees|
3156788|NCT00351806|Experimental|Chinese herbal medicine|
3156789|NCT00351806|Placebo Comparator|placebo|
3156790|NCT00351884|Experimental|vildagliptin am|
3156791|NCT00351884|Experimental|vildagliptin pm|
3156792|NCT00351884|Placebo Comparator|placebo|
3156793|NCT00351962|Experimental|Schedule I (10 fractions)|Subjects will receive a total of 10 stereotactic radiation treatments, given over 3 weeks.
3156794|NCT00351962|Experimental|Schedule II (4 fractions)|Subjects will receive a total of 4 stereotactic radiation treatments, given over 2 weeks.
3156795|NCT00351975|Experimental|Arm I (chemotherapy)|Patients receive azacitidine SC on days 1-5.
3156796|NCT00351975|Experimental|Arm II (chemotherapy, enzyme inhibitor therapy)|Patients receive azacitidine as in arm I and belinostat at the MTD IV over 30 minutes on days 1-5.
3156797|NCT00351988||African American caregivers|African American caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3156798|NCT00351988||Latino caregivers|Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3156799|NCT00351988||White non-Latino caregivers|White non-Latino caregivers for patients with advanced non-small cell lung cancer or breast cancer.
3156800|NCT00352079|Active Comparator|Intravesicle BCG|"Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months postrandomization (cycles 2 - 8)"
3156801|NCT00352079|Active Comparator|Iressa and Intravesicle BCG|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)~Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)"
3156802|NCT00352144|Experimental|1|eszopiclone 3 mg tablet
3156803|NCT00352144|Placebo Comparator|2|Placebo tablet
2466596|NCT03128112|No Intervention|Exam room without poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms without posters will be ask to fill out a second short questionnaire after seeing their physician that will ask parents whether they discussed their child's weight status with their physician and whether they believe their own child is: very overweight, overweight, healthy weight, underweight, or very underweight.
2466597|NCT03128112|Active Comparator|Exam room with poster|All parents will be asked to fill out a questionnaire detailing basic demographic information as well as their perception of their child's weight. Parents who are in exam rooms with posters will be directed to read the poster on the exam room wall. After viewing the poster and after seeing their physician, parents will be ask to fill out a second short questionnaire that will ask parents whether they discussed their child's weight status with their physician, whether this conversation was prompted by the poster, and whether they believe their own child is very overweight, overweight, healthy weight, underweight, or very underweight.
2466715|NCT03127436||Acarovac Hausstaubmilbe|"This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients (children and adults) in routine medical care.~During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.~Data on tolerability are documented by the physicians."
3156804|NCT00352170|Experimental|1|calcium supplementation
3156805|NCT00352170|Experimental|2|calcium and vitamin D3 supplementation
3156806|NCT00352170|Experimental|3|placebo
3156807|NCT00352183|Experimental|1|
2466902|NCT03126318|Active Comparator|COR-001|COR-001 5, 15, 50, or 100 mg dose (depending on dose cohort assigned to patient) given by subcutaneous injection one time only
2466910|NCT03126318|Placebo Comparator|Placebo|Placebo at pH 6.0will be given in a volume to match the volume of COR-001 being given for the dose cohort by subcutaneous injection one time only
3156808|NCT00352183|Active Comparator|2|
3156809|NCT00352196|Experimental|Magnetic Resonance Spectroscopy|Subjects will receive a baseline MRS prior to and within 7 day of completing 12 weeks of standard treatment with.
2466991|NCT03125525||Active treatment patients|Patients using Cefaly device on routine daily basis
2467112|NCT03124524|No Intervention|Control group|33 healthy controls
2467115|NCT03124524|Active Comparator|Qlarista Group|group who were administered estradiol valerate/dienogest
2467117|NCT03124524|Active Comparator|Yasmin Group|group who were administered ethinylestradiol and drospirenone
2467160|NCT03124043|Experimental|Intervention First|Participants in Intervention First were enrolled in the intervention for the first 6 months of study participation followed by a return to usual care for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc.
2467166|NCT03124043|Experimental|Intervention Second|"Participants in the 'Intervention Second received usual care for the first 6 months of study participation followed by enrollment in the intervention for the following 6 months. The intervention included provision of a cellular-enable glucose meter and enrollment in the Livongo for Diabetes support program that provided both in-the-moment and scheduled support, both provided by Livongo Health Inc."
2467228|NCT03123731|Active Comparator|Control Arm|Participants will wear a Fitbit but will not receive any additional elements of the iSTEP intervention.
2467229|NCT03123731|Experimental|iSTEP PA intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA) and reduce sedentary behavior, including setting weekly goals to increase average daily step counts.
2467230|NCT03123731|Experimental|iSTEP PA and diet intervention|Participants will wear a Fitbit and receive interactive daily text messages that are designed to motivate moderate physical activity (PA), reduce sedentary behavior, and promote adherence to a Mediterranean-style diet. Participants will also be administered diet counseling from a registered dietitian and receive weekly feedback on both physical activity and diet behaviors.
2467328|NCT03122912|Experimental|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
2467329|NCT03122912|Active Comparator|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
2467878|NCT03118791|Active Comparator|320 mg ACN|Capsules containing 320 mg anthocyanins
3156810|NCT00352196|Other|NO-MRS|Subjects will receive 12 weeks of standard treatment of risperidone 0.25 to 11 mg per day, or early termination. Dose titration will based on response and tolerability.
3156811|NCT00352300|Experimental|Treatment (carboplatin, paclitaxel, pegfilgrastim)|Patients receive carboplatin IV and paclitaxel IV over 3 hours on day 1. Patients also receive pegfilgrastim subcutaneously on day 2.
3156812|NCT00352313|Experimental|Phase I|Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
3156813|NCT00352313|Experimental|Phase II|Patients receive carboplatin IV in week 1 and ATN-161 IV, at the MTD determined in phase I, 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3173296|NCT00610376|Experimental|1B|Preschools randomized to this group received a multicomponent intervention to improve handwashing behavior of the children. Children within the preschool intervention group were individually randomized to a home intervention or a home control intervention program. The children in this arm received the home control component.
3173297|NCT00610389|Experimental|1|
3173298|NCT00610402||blood sample tear drop sample|blood sample tear drop sample
3174745|NCT00626756|Experimental|LI|arm controled by LIDCO technology
2466646|NCT03128021|Active Comparator|Levomilnacipran Pill|Participants will receive an initial dose of 20 mg blinded levomilnacipran. At day 7, the doses will be titrated to 40 mg of levomilnacipran. Further titrations (maximum dose of 120 mg of levomilnacipran) will be decided based on clinical response and tolerability. The medication will be taken by mouth in pill form, once daily.
2466716|NCT03127410|Experimental|Traction|Intermittent lumbar traction will be performed in the prone position for 3 x 15-minute sessions at 40% of the participants body weight and will be adjusted based on the participants response.
2466760|NCT03127046|Experimental|Group 1|Aceclofenac → Esomeprazole → Concomitant of Aceclofenac and esomeprazole
2466761|NCT03127046|Experimental|Group 2|Concomitant of Aceclofenac and esomeprazole→Aceclofenac→ Esomeprazole
2466762|NCT03127046|Experimental|Group 3|Esomeprazole →Concomitant of Aceclofenac and esomeprazole→ Aceclofenac
2466763|NCT03127046|Experimental|Group 4|Concomitant of Aceclofenac and esomeprazole→Esomeprazole→Aceclofenac
2466764|NCT03127046|Experimental|Group 5|Esomeprazole→Aceclofenac→ Concomitant of Aceclofenac and esomeprazole
2466765|NCT03127046|Experimental|Group 6|Aceclofenac→Concomitant of Aceclofenac and esomeprazole→Esomeprazole
2466835|NCT03126591|Experimental|Olaratumab Dose Level 1 + Pembrolizumab|Olaratumab given intravenously (IV) and pembrolizumab given IV.
2466836|NCT03126591|Experimental|Olaratumab Dose Level 2 + Pembrolizumab|Olaratumab given IV and pembrolizumab given IV.
2466837|NCT03126591|Experimental|Olaratumab + Pembrolizumab Expansion|Olaratumab given IV and pembrolizumab given IV.
2466901|NCT03126162|Experimental|Bladder Backfilled group|Subjects randomized to the bladder backfilled group (Group A) will have 200 mL of normal saline instilled into their bladders prior to removal of the foley catheter. The foley catheter will subsequently be removed
2466909|NCT03126162|Placebo Comparator|Control group|Subjects randomized to the control group (Group B) will just have their foley catheters removed at the end of the surgery. This is routinely done post-operatively after routine gynecologic surgery.
2466965|NCT03125785||contact lens and eye drops|Contact lenses collected from patients that have used eye drops containing dexamethasone and benzalkonium chloride for a set period of time and set dosage after surgery
2466973|NCT03125785||contact lens and no eye drops|Contact lenses used for the same period of time collected from a control group that has had no surgery and no eye drops in combination with their contact lenses.
2467040|NCT03125421|Other|control period|standard preventive methods of pressure sores in each center
2467045|NCT03125421|Experimental|experimental period|experimental multifaceted preventive methods of pressure sores
2467139|NCT03124420|Active Comparator|Group A (Drug: 7-day triple therapy)|Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
2467141|NCT03124420|Sham Comparator|Group B (Drug: 14-day triple therapy)|Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).
2467379|NCT03122444|Experimental|Imipramine|Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.
2467425|NCT03122132||Spanish cohort with HCV treated with DAA|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ritonavir 8 weeks and dasabuvir 8 weeks
2467503|NCT03121742|Placebo Comparator|Treatment as usual [TAU] plus assessment|Patients will receive standard care plus assessment.
2467504|NCT03121742|Experimental|Treatment as usual [TAU] plus intervention|Patients will receive standard care plus an ecological momentary intervention.
2467553|NCT03121170|Experimental|ESWT during PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2bar and total 5000 frequencies approximately. The time is menstrual cycle first one and third day, and the therapy divide into two times.
2467555|NCT03121170|Experimental|ESWT before PD|For women with primary dysmenorrhea, they have new devise Extracorporeal Shock Wave Therapy to treat. The dose is 15 hertz, 1.8-2.2 bar and total 5000 frequencies approximately. The time start from the 5th and 7th day before the estimated first day of menstrual cycle and all therapy time consuming need 15 minutes.
2467559|NCT03121170|Placebo Comparator|hot compress paste|In hot compress paste group , the women with primary dysmenorrhea stick the hot compress paste on their belly autonomously.
3174746|NCT00626756|No Intervention|CA|standard approach
2467650|NCT03120637|Experimental|Methylene Blue|Methylene Blue intravenous route, 2 mg/kg Loading Dose over 30 minutes, followed by 0.5 mg/kg/hr for 6 hours
2467655|NCT03120637|No Intervention|Standard Treatment|
2467733|NCT03120091||Enrolled Patients|A total of 20 patients were enrolled for the place of CGMS. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
2467753|NCT03119623|Active Comparator|Sacubitril/Valsartan|Sacubitril/valsartan 100mg (Dose Level 1) titrated up if tolerated to 200 mg twice daily (Dose Level 2)
2476690|NCT03058900|Experimental|Fecal microbiota transplantation (FMT)|
3174747|NCT00626769||1|Postmenopausal women with established osteopenia receiving aglycone genistein 54 mg/day for 3 years
3174748|NCT00626769||2|Postmenopausal women with established osteopenia receiving placebo (Calcium and vitD) for 3 years
3174749|NCT00626834|Experimental|Vigabatrin Dose 1|
3174750|NCT00626834|Experimental|Vigabatrin Dose 2|
3174751|NCT00626834|Experimental|Vigabatrin Dose 3|
3174752|NCT00626834|Placebo Comparator|Matching placebo|
3174753|NCT00626847||1|Primary Open Angle Glaucoma (POAG)
3174754|NCT00626847||2|Controls (Normals, patients without glaucoma)
3174755|NCT00626873|Experimental|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
3174756|NCT00626938||sarcoidosis|sarcoidosis patients
2466650|NCT03127930|No Intervention|Usual Care|No Intervention: Participants do not receive the problem solving intervention and are followed as a Usual Care condition including receiving a standard brochure on patient management provided by the Alzheimer's Association. .
2466706|NCT03127683|Experimental|AuraGain group|"An AuraGain will be placed in all patients, and mechanical ventilation will be performed using a volume-controlled mode with a tidal volume of 10 ml/kg.~The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed first for the neutral head position and then for the extended, flexed, and rotated head positions in a random order."
2466766|NCT03127098|Experimental|ETBX-011 in combination with ALT-803|A combination of agents will be administered to subjects in this dose-escalation study
2466805|NCT03126656|Experimental|Hypogonadic with chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II), and hypogonadism (plasma testosterone levels <11.4 nmol / L);
2466813|NCT03126656|Experimental|Hypogonadic|patients just with hypogonadism (testosterone <11.4 nmol / L) in the absence of documented cardiovascular disease
2466822|NCT03126656|No Intervention|chronic heart failure|patients suffering from mild to moderate heart failure (LVEF ≥ 40%, NYHA I-II) with normal testosterone levels(plasma testosterone levels > 11.4 nmol / L), in optimized standard therapy for heart failure
2466854|NCT03126357|Experimental|Product usage order ABECD|Subjects will use each of the 5 products (ABECD) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466855|NCT03126357|Experimental|Product usage order BCADE|Subjects will use each of the 5 products (BCADE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466857|NCT03126357|Experimental|Product usage order CDBEA|Subjects will use each of the 5 products (CDBEA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466860|NCT03126357|Experimental|Product usage order DECAB|Subjects will use each of the 5 products (DECAB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466861|NCT03126357|Experimental|Product usage order EADBC|Subjects will use each of the 5 products (EADBC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466864|NCT03126357|Experimental|Product usage order DCEBA|Subjects will use each of the 5 products (DCEBA) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466866|NCT03126357|Experimental|Product usage order EDACB|Subjects will use each of the 5 products (EDACB) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466867|NCT03126357|Experimental|Product usage order AEBDC|Subjects will use each of the 5 products (AEBDC) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466868|NCT03126357|Experimental|Product usage order BACED|Subjects will use each of the 5 products (BACED) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466869|NCT03126357|Experimental|Product usage order CBDAE|Subjects will use each of the 5 products (CBDAE) sequentially for 1 and 1/2 days during an 11 day confinement, followed by a 4 hour Test Session.
2466956|NCT03125889|Experimental|Treatment Arm|Subjects will receive treatment with the AquaBeam System to remove prostatic tissue.
2467001|NCT03125473|Experimental|Dose Group 1|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 8
2467002|NCT03125473|Experimental|Dose Group 2|Multiple doses of low doseVXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1, 3, and 5
2467003|NCT03125473|Experimental|Dose Group 3|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 1 tablet of VXA-G1.1-NN on Days 1 and 29.
2467004|NCT03125473|Experimental|Dose Group 4|Multiple doses of low dose VXA-G1.1-NN Oral Vaccine Tablets will be orally administered. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk. Subjects will receive 6 tablets of VXA-G1.1-NN on Days 1 and 29
2467008|NCT03125148|Other|Enteral stenting intraduodenal|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
2467009|NCT03125148|Other|Enteral stenting transpyloric|Enteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
2467053|NCT03125057|Experimental|low light dose|PDT is applied to the patients at low light dose : power density of 60mW/cm2 for 20 minutes
2467054|NCT03125057|Experimental|high light dose|PDT is applied to the patients at high light dose : power density of 75mW/cm2 for 20 minutes
3191666|NCT00800761|Active Comparator|Deferoxamine alone|comparison of deferoxamine subcutaneous 40mg/kg/die alone versus combined therapy deferoxamine-deferiprone
2467165|NCT03124173|Other|Behavioral Tasks|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
2467211|NCT03123692|Experimental|Treatment|14 days treatment with NBMI 300 mg/day
2467214|NCT03123692|Placebo Comparator|Placebo|14 days treatment with Placebo
2467252|NCT03123445|Experimental|Endostar + Gemcitabine and Cisplatin|Patients in this group will be given endostar combined with gemcitabine and cisplatine.
2467255|NCT03123445|Active Comparator|Gemcitabine and Cisplatin|Patients in this group will be given gemcitabine and cisplatine.
3156814|NCT00352326|Experimental|Children (with dystonia and controls)|"Participants sat in a chair or their own wheelchair in front of a table whose surface height was adjusted at the midpoint between the hip and the Xiphoid process. They placed the hand that was not used for the task on their lap.~An iPad® (Apple Inc, Cupertino, California) was located on the table in portrait mode in front of the participants at a distance that ranged between 40 and 55 cm. An adjustable metal bookstand supported the iPad® to allow the participants a comfortable screen view. The size of the screen was 19.5 × 14.6 cm. Custom software was developed for the experimental task (XCode 3.2 development environment, iOS 4.2 operating system; Apple Inc, Cupertino, California)."
3156815|NCT00352339|Experimental|Aripiprazole|switching group (from risperidone to aripiprazole)
2466795|NCT03126578|Experimental|All subjects|"Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12.~Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731."
2466845|NCT03126422|Experimental|Dexmedetomidine 0 μg/kg/min|
2466846|NCT03126422|Experimental|Dexmedetomidine 0.03 μg/kg/min|
2466847|NCT03126422|Experimental|Dexmedetomidine 0.06 μg/kg/min|
2466848|NCT03126422|Experimental|Dexmedetomidine 0.09 μg/kg/min|
2466908|NCT03126123|Other|acetic acid test|Patients will receive surgical treatment for anal condylomatosis and acetic acid on the mucosa of the anal canal before the surgical procedure
2466990|NCT03125876|Experimental|CT053PTSA|60mg-100mg
2467006|NCT03125252|Experimental|Bundle|Specific action plan : ABCDE, complemented with care related to the nursing and paramedical role concerning the patient's environmental factors
2467007|NCT03125252|Other|Control|Standard paramedical and medical practices
3156816|NCT00352339|Active Comparator|Risperidone|Start with risperidone and keep it through the end of study
2467121|NCT03124472|Active Comparator|uterine artery ligation|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
2467125|NCT03124472|Active Comparator|Traditional lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta."
2467167|NCT03123978|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO BID and enzalutamide PO QD on weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2467231|NCT03123653|Experimental|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks.
2467284|NCT03123237|Placebo Comparator|Control|"control will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2467287|NCT03123237|Active Comparator|Diabetic|"diabetic cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2467290|NCT03123237|Active Comparator|Hypertensive|"hypertesive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2467293|NCT03123237|Active Comparator|Diabetic & Hypertensive|"Diabetic & Hypertensive cases will be subjected to:~• Quantitative Tc99m DMSA renal scan using SPECT technique."
2467356|NCT03122730|Experimental|VentaProst|VentaProst (epoprostenol solution for inhalation via custom drug delivery system)
3156817|NCT00352339|Active Comparator|Abilify|Start with aripiprazole and keep it through the end of study
3156818|NCT00352378|Experimental|Adriamycin plus Cyclophosphamide|Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1.
2467468|NCT03121794||Low BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 18.5 - 25 kg/m2
2467472|NCT03121794||Moderate BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI 30-35 kg/m2 will receive ultrasound exam.
2467476|NCT03121794||High BMI|Ultrasonographic identification of proximal humerus landmarks for patients with BMI > 40 kg/m2 will receive ultrasound exam.
3156819|NCT00352378|Experimental|Taxotere plus Xeloda|Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14
2467560|NCT03121222|Placebo Comparator|Lactose|The placebo group received orally two lactose tablets per day for 30 days. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
2467707|NCT03120130|Experimental|Cohort 5|This cohort will include 3 patients with the fifth calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
3156820|NCT00352391||Vanguard Study|Patients with Head and Neck or Non-Small Cell Lung Cancer who are Current or Former Smokers.
3156821|NCT00352443|Experimental|everolimus/lapatinib|Part 1, dose finding: everolimus and lapatinib at assigned dose daily Part 2, cohort A: Everolimus MTD from Part I: 5 mg PO 1-28 Daily Lapatinib MTD from Part I: 1,250 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28 Part 2, cohort B: Lapatinib MTD from Part I: 1,250 mg PO 1-28 Daily Everolimus MTD from Part I: 5 mg PO Cycle 1, Daily Days 8-28** Subsequent Cycles, Days 1-28
3156822|NCT00352469|Placebo Comparator|2|Subjects will be randomized to receive either Seroquel SR or placebo
3173299|NCT00610493|Experimental|Bevacizumab + Temsirolimus|Bevacizumab 5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle. Temsirolimus 5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle. First tumor biopsy during screening visit and Second at the end of Cycle 1. DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1.
3173300|NCT00610506|Experimental|A|Lexapro
2466669|NCT03127839|Active Comparator|Eccentric Exercise + pain education|"In addition to the treatment provided in the Eccentric Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
2466670|NCT03127839|Active Comparator|Traditional Exercise + pain education|"In addition to the treatment provided in the Traditional Exercise Arm patients will receive additional self-management training education focused on neuroscience of pain principles.~This will include e a 5-minute video called Understanding pain in less than 5 minutes, and what to do about it!, or aka explain pain video. The patients will also receive an interactive education booklet and review session with their PT, a series of weekly e-mails that reinforce key components of the booklet and video; and reinforcing messages when in the clinic doing their exercises."
2466752|NCT03127007|Experimental|Arm A|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV. Rectal surgery is planned during week 15"
2466753|NCT03127007|Active Comparator|Arm B|"Protracted IV 5-FU 225 mg/m2 is given from day 1 to 5 in parallel with radiotherapy 1.8 to 2 Gy from day 1 to 5 during 5 consecutive weeks.~Rectal surgery is planned during week 15"
3156823|NCT00352495|Experimental|Vinblastine sulfate and carboplatin|The MTD of vinblastine in combination with a monthly dose of carboplatin will be determined during the first cycle of therapy. Each 4-week cycle will consist of carboplatin once every 4 weeks on day 1. Vinblastine will be given once a week for 3 weeks followed by a one week break. Doses of carboplatin and vinblastine sulfate will be assigned at study enrollment. Patients may receive eleven additional four week cycles, barring tumor progression or unacceptable toxicity. The total duration of therapy will be approximately 48 weeks.
2466842|NCT03126513|Experimental|G-POEM in refractory gastroparesis|Participants with refractory gastroparesis will be confirmed by endoscopy, clinical and scintigraphy studies.
2466900|NCT03126201||Study Group|Patients with biopsy-proven primary focal segmental glomerulosclerosis.
3156824|NCT00352521|Experimental|Bevacizumab and irinotecan|The bevacizumab will be dosed at 10 mg/kg every 14 days (days 1, 15 and 29) and the irinotecan on days 2, 15, and 29 of the first six week schedule. The irinotecan dose will depend on whether the patient is on an enzyme-inducing antiepileptic drug (EIAED). If the patient is on an EIAED, the patient will receive 340 mg/m2 on days 2, 15, and 29 of the first six week schedule. If the patient is not on an EIAED, the dose of irinotecan will be 125 mg/m2 on days 2, 15, and 29 of the first six week schedule. After the first cycle, the irinotecan and bevacizumab will be given on days 1, 15 and 29.
3156825|NCT00352560|Active Comparator|A|
2467232|NCT03123406|Experimental|Severe SHPT|Administer Cinacalcet HCL to subjects whose iPTH>900 pg/ml from 1st to 32nd week.
2467234|NCT03123406|Experimental|Moderate SHPT|Administer Cinacalcet HCL to subjects whose 600≤iPTH<900 pg/ml from 1st to 32nd week.
2467236|NCT03123406|Experimental|Mild SHPT|Administer Cinacalcet HCL to subjects whose 300≤iPTH<600 pg/ml from 1st to 32nd week.
2467272|NCT03123146|Experimental|Fb-Cognitive Behavioral Therapy|Functional Behavior-Based Cognitive Behavioral Therapy: Group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
2467273|NCT03123146|No Intervention|Treatment as Usual (TAU)|"Children assigned to this condition received usual care, meaning that they could continue with any services. This group acted as a control group whereby access to intervention was patient-directed."
2467306|NCT03122847||Patients|30 patients with Graves' ophthalmopathy in which treatment with intravenous methylprednisolone is indicated
2467355|NCT03122639|Active Comparator|Treatment|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
2467359|NCT03122639|Placebo Comparator|Control|OSA patients who adhered or did not adhere with CPAP will be randomized 1:1 to treatment (atorvastatin 10 mg daily) or control group (placebo).
2467407|NCT03122275|Experimental|Stepwise intervention|"Stepwise approach, with increasing complexity and cost, to improve adherence to organized cervical cancer screening, implemented through three steps:~step 1a - customized text message invitation; step 1b - customized automatic phone call invitation; step 2 - secretary phone call; step 3 - health professional phone call and face-to-face appointment.~Intervention stops whenever the participant adheres to organized screening or after undergoing the complete stepwise intervention."
2467410|NCT03122275|Active Comparator|Written Letter|Comparator will be the standard of care of invitation to cervical cancer screening: written letter
2467451|NCT03121846|Experimental|apatinib group|apatinib 500mg po qd, 28 days for a cycle.
3156826|NCT00352560|Placebo Comparator|B|
2467635|NCT03120325|Experimental|Vagal Nerve Stimulation|All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
2467699|NCT03120169|Active Comparator|treadmill endurance training|
2467702|NCT03120169|Active Comparator|cycling endurance training|
2467861|NCT03118960|Active Comparator|Freedom Bed|Bed turns and positions subjects automatically for the healing and prevention of pressure injury
2467879|NCT03118791|Active Comparator|480 mg ACN|Capsules containing 480 mg anthocyanins
3156827|NCT00352599|Active Comparator|Lovastatin|Lovastatin
3156828|NCT00352599|Placebo Comparator|Placebo pill|Placebo pill
3156829|NCT00352703|Experimental|Kepivance (palifermin) 60 μg/kg/day IV|60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
3156830|NCT00352729|Active Comparator|A|
3156831|NCT00352742|Experimental|1|ATN-224 + bortezomib
3156832|NCT00352768|Experimental|F|
3156833|NCT00352768|Placebo Comparator|P|
3156834|NCT00352820||Interview + Questionnaire|
3156835|NCT00352859|Experimental|Arm 1|
3156836|NCT00352859|Experimental|Arm 2|
2466717|NCT03127254|Experimental|Video Narrative with surveys|Participants will be asked to create a 10-15 minute video narrative on their experiences after being diagnosed with cancer. Participants will also be asked to complete surveys including pediatric quality of life (PedsQL), Ten Item Personality Inventory (TIPI), Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test, and The Cognitive Log (Cog-Log)
2466819|NCT03126942|Experimental|Novaloc, then Locator|Participants will receive the Novaloc attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Locator attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
2466825|NCT03126942|Active Comparator|Locator, then Novaloc|Participants will receive the Locator attachment on a single implant inserted in the mandibular midline. This attachment will be used for 3 months and then changed by the Novaloc attachment. The second attachment will be used for another 3-month period. Participants will keep preferred attachment for further 12 months
2466905|NCT03126266|Experimental|Patients receiving re-irradiation|Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
2466948|NCT03125850|Experimental|day-ward group|
2466951|NCT03125850|Active Comparator|inpatient group|
2466998|NCT03125538|Experimental|Motor Imagery|Participants from the experimental group will perform MIP concomitantly with usual physical rehabilitation program.
2467000|NCT03125538|Active Comparator|Control task|Concomitantly with usual physical rehabilitation program, participants from the control group will perform a cognitive task that has no impact on motor rehabilitation (word scramble game).
2467181|NCT03123835|Other|Treatment|Patients meeting inclusion criteria for possible surgical therapies for their current condition (IE Achelasia, Enlarged Gastric Pouch and/or Gastrogastric Fistula after primary weight loss surgery, etc) will be educated on the different therapy options including traditional laparoscopic surgery and/or Endoscopic Interventions including POEM (Percutaneous Oral Endoscopic Myomectomy for the treatment of Achelasia) or Endoscoscopic Pouch/GastroJejunostomy repair or closure of the Gastrogastric Fistula as examples.
3156838|NCT00353015|Experimental|Irinotecan plus Cisplatin|Irinotecan 65 mg/m2 and Cisplatin 25 mg/m2 intravenous (IV) days 1, 8 of a 21-day cycle
3156839|NCT00353028|Experimental|F|
2467433|NCT03121911|Experimental|Group 1 - Interval Training (IT)|"All participants will be submitted to several exams of cardiac and pulmonary functions. Then, group 1 (IT) will participate in a physical training program for 12 weeks and will be re-evaluated after this period. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure (accelerometer). At the end of this period all the tests will be repeated.~Each exercise session will last for 60 minutes and will be divided into three parts as follows: warm up (10 minutes); interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold found in CPET (70%, 80%, 100% and 110%); cooling down (10 minutes)."
2467435|NCT03121911|Experimental|Group 2 - IT + IMT|"All participants will be submitted to the same evaluations before and after training, and 6 months after discharge. Group 2 (IT + inspiratory muscle training (IMT)) will participate in a 12 week physical training program. After discharge, they will be monitored for an aditional period of 6 months, with returns every two months to measure the energy expenditure.~The group 2 will perform the IMT session at the end of the warm-up exercises, prior to the beginning of the IT on a cycloergometer. IMT session consists of 2 series of 12 inspirations with a 60% of MIP. Participant will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minutes interval between series. All the others exercises will be identical between group 1 and 2."
3156840|NCT00353028|Placebo Comparator|P|
3156841|NCT00353106||Patients|Patients with chronic GVHD
3156842|NCT00353106||Content Expert Panel|Content expert panel with 5 years experience caring for patients with cGVHD.
3156843|NCT00353106||Caregivers|Caregivers of patients with cGVHD
3156844|NCT00353145|Experimental|Gemcitabine + Oxaliplatin|Gemcitabine 1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 and Oxaliplatin 100 mg/m^2 by vein infused on Day 2 over two hours. Repeated every 14 days (one cycle).
3156845|NCT00353223|Experimental|A|Participants will receive combined interpersonal and behavioral psychotherapy aimed at reducing depression in patients with heart failure.
3156846|NCT00353223|Active Comparator|B|Participants will receive the attention control condition.
3156847|NCT00353249|Experimental|1|Participants will receive adapted cognitive behavioral therapy treatment
3156848|NCT00353249|No Intervention|2|Participants will receive no treatment for the course of the study; they will be offered courtesy PTSD 5 weeks after the experimental intervention.
3156849|NCT00353379|Experimental|guanfacine|Participants will take guanfacine.
3156850|NCT00353379|Placebo Comparator|placebo|Participants will take placebo.
3156851|NCT00353405|Experimental|1|Participants receiving social skills training and mass media messages
3156852|NCT00353405|Experimental|2|Participants receiving social skills training and no mass media messages
3156853|NCT00353405|Experimental|3|Participants receiving mass media messages and no social skills training
3156854|NCT00353405|Experimental|4|Participants receiving no social skills training and no mass media messages
3156855|NCT00353457|Experimental|Arm 1|Capecitabine, Oxaliplatin and Cetuximab
3156856|NCT00353470|Experimental|1|Participants will receive panic focused psychodynamic psychotherapy for 12 weeks
3156857|NCT00353470|Active Comparator|2|Participants will receive cognitive behavioral therapy-panic control treatment for 12 weeks
3156858|NCT00353470|Active Comparator|3|Participants will receive applied relaxation training for 12 weeks
3173301|NCT00610519|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
3173302|NCT00610519|Placebo Comparator|2|spray containing placebo.
3173303|NCT00610545|Active Comparator|1|Use Atorvastatin 80mg for 60 days , and the vascular surgery will be made between day-7 and day-60
3173304|NCT00610545|Active Comparator|2|Use Atorvastatin 20 mg for 60 days , and the vascular surgery will be made between day-7 and day-60
3174757|NCT00626938||controls|healthy volunteers and other interstitial lung disease (ILD) patients
3174758|NCT00626951|Experimental|1|LMA Supreme
3174759|NCT00626951|Experimental|2|LMA ProSeal
2466719|NCT03127631|Active Comparator|Randomized - Intervention|The intervention will consist of a systematic cardiovascular and lifestyle risk factor modification strategy, including dietary and exercise advice, advice to quit smoking, and the prescription of open-label antiplatelet agents, statins, ACE-I, and other antihypertensive medications where appropriate.
2466722|NCT03127631|No Intervention|Randomized - Control|The control will consist of usual clinical care, which may include a referral to a cardiologist or internist, or the use of treatments included in the intervention as clinically indicated, if part of the treating physician's standard practice.
2466815|NCT03126708|Experimental|chemotherapy (cisplatin plus paclitaxel) and cetuximab|
2466826|NCT03126708|Active Comparator|chemotherapy (cisplatin plus paclitaxel)|
2466932|NCT03126097|Experimental|JNJ-64155806+COCP+JNJ-64155806 with COCP|Participants will receive JNJ-64155806 150 milligram (mg) twice daily (BID) under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] followed by a 10-day washout phase; followed by Ethinylestradiol/drospirenone 0.02 mg/3 mg given as a combined oral contraceptive pill (COCP) once daily (QD) on Days 18 to 41 and COCP placebo QD on Days 42 to 45 [COCP Lead-in Phase]; further followed by COCP QD on Days 46 to 69 (on Days 59 to 66 under fed condition), JNJ-64155806 150 mg BID (under fed conditions) on Days 60 to 66, and COCP placebo QD on Days 70 to 73 [JNJ-64155806 + COCP Co-administration Phase].
2466978|NCT03125668|Experimental|Intervention Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive a telephone follow-up (five calls) and two Face to face counseling.
2466983|NCT03125668|Active Comparator|Control Group|At the hospitalization, patients receive the educational program (Power Point®Slides, booklets and orientation) about the use of warfarin. After hospital discharge they receive two face to face counseling.
2467030|NCT03125330|Experimental|One-to-One Coaching|"Participants randomized to One-to-One Coaching meet for an initial 2-hour coaching session, followed by seven 1-hour coaching sessions every 3-weeks. These eight sessions take place over the course of 6 months.~Additional requirements for One-to-One Coaching:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to One-to-One Coaching.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
2467039|NCT03125330|Active Comparator|Group Coaching|"Participants meet for 90-minutes each month for 6 months for facilitated professional coaching with a group of colleagues.~Additional requirements:~Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment, (b) at 6-months after study enrollment, and (c) 12-months following study enrollment.~Complete a 15-minute VIA Character Strengths Test online prior to Group Coaching.~Prior to your initial group coaching session, participate in a 75-minute private phone interview with the primary investigator to discuss the how you make decisions and make sense of the world.~Following the completion of the final coaching session, participants are interviewed by a con-investigator by phone call to assess the experience of coaching.~Each coaching session will be recorded, transcribed, anonymized, and analyzed to identify common themes."
2467044|NCT03125330|No Intervention|Group Coaching Waitlist|"Participants are offered group coaching at the completion of the 12-month study period. Six 90-minute group coaching sessions will occur over the course of six months.~Additional requirements:~• Complete a 30-minute online assessment of goal attainment, well-being, burnout, and leadership strengths (a) at study enrollment (b) and at 6-months after study enrollment."
2467092|NCT03124329|Experimental|Coronally Advanced Flap|
2467100|NCT03124329|Experimental|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|
2467107|NCT03124329|Experimental|Intrasulcular tunneling|
2467110|NCT03124329|Experimental|VISTA + Leukocyte-Platelet Rich Fibrin|
2467157|NCT03124017|Experimental|Alert Group|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart
2467161|NCT03124017|No Intervention|Control Group|No electronic alert and no Geneva Risk Score calculation tool issued in the electronic patient chart
2467215|NCT03123744|Experimental|Palbociclib 125 mg|Palbociclib is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study measurements will be obtained at baseline and about every 8 weeks thereafter. Subjects will continue study drug until disease progression or unacceptable toxicity.
2467259|NCT03123367|Active Comparator|Group 1: Nella VuSleeve|Sleeve
2467261|NCT03123367|Active Comparator|Group 2: Nella NuSpec|Speculum
2467262|NCT03123367|Active Comparator|Group 3: NellaSpec|Speculum
2467263|NCT03123367|Active Comparator|Group 4: Nella Insert|Sleeve
2467307|NCT03122977|Experimental|Full mouth scaling and root planing|FM-SRP Non surgical periodontal treatment will be performed in all dentition within 24 hours
2467308|NCT03122977|Active Comparator|Quadrant scaling and root planing|"Q-SRP Non surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2467341|NCT03122600||vascular surgery group|Elderly patients undergoing vascular surgery in the lower half of the body
2467389|NCT03122392|Experimental|AMS 800 Artificial Urinary Sphincter|"The AMS 800™ Urinary Control System is an implantable, fluid-filled, solid silicone elastomer prosthesis used to treat urinary incontinence due to reduced outlet resistance (intrinsic sphincter deficiency) following prostate surgery. The AMS 800 Urinary Control System simulates normal sphincter function by opening and closing the urethra, under patient control. When the cuff is closed, urine stays in the bladder.~When the patient wishes to void, he simply squeezes and releases the pump several times. This causes the fluid in the cuff to move into the pressure-regulating balloon . The cuff opens and urine passes through the urethra. The balloon then automatically re-pressurizes the cuff through the pump, within several minutes, the cuff again closes the urethra.~The control pump, which in implanted in the scrotum, is also designed to allow the clinician or patient to deactivate and activate the system without additional surgery."
2466723|NCT03127280|No Intervention|Conventional Foley Care|Following surgery, the patient's Foley catheter is removed on the morning of post-operative day one.
2466725|NCT03127280|Experimental|Fast Tract Foley care|Following surgery, the patient's Foley catheter is removed on post-operative day zero, four hours after the completion of surgery.
3156859|NCT00353483||Tissue, blood, and bone marrow (optional) collection|"Undergo neoadjuvant systemic therapy~initial surgery for sentinel lymph node biopsy/portacath placement~definitive cancer surgery (if applicable)~when portacath is removed (1 year, if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis~Undergo Adjuvant Systemic Therapy~initial surgery for a sentinel lymph node biopsy/portacath placement~when portacath is removed (1 year, if available)~If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.~Undergone neoadjuvant systemic therapy~during definitive cancer surgery/portacath removal (if available)~if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis"
3156860|NCT00353548||1-Anorexia Nervosa|Women ages 16-50 who meet DSM-IV criteria for anorexia nervosa
3156861|NCT00353548||2-Bulimia Nervosa|Women age 16-50 who meet DSM-IV criteria for bulimia nervosa
3156862|NCT00353548||3-Binge Eating Disorder|Women with binge eating disorder
2466941|NCT03125837||general anesthesia|Digital photographs of the face of each patient undergoing general anesthesia with endotracheal intubation
2467013|NCT03125434|Experimental|healthy volunteers|EOS full-spine, MRI, gait analysis
2467079|NCT03124641|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of Hypothermic machine perfusion (HOPE) for 1-2 hours
2467081|NCT03124641|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
2467150|NCT03124238|Experimental|Massage|Massage therapy of the lumbar muscles in a prone position during 30 minutes
2467151|NCT03124238|No Intervention|Control|Rest during 5 minutes in a prone position
2467152|NCT03123887||R/r B-precursor ALL|This study selected patients with Relapsed or Refractory (R/r) B-precursor Acute Lymphoblastic Leukemia
2467195|NCT03123770|Experimental|DC Follow T|Participants receive pegylated liposomal doxorubicin plus cyclophosphamide followed by docetaxel before surgery.
2467196|NCT03123770|Active Comparator|EC Follow T|Participants receive epirubicin plus cyclophosphamide followed by docetaxel before surgery.
3156863|NCT00353548||4-Healthy Controls|Healthy control subjects ages 16-50 of normal weight
2467320|NCT03122821|Experimental|Group 1|Trans-cranial direct stimulation + Mental Imagery
2467323|NCT03122821|Active Comparator|Group 2|Trans-cranial direct stimulation only
3156864|NCT00353548||5-Obese Controls|Healthy obese control subjects
2467460|NCT03122067|Experimental|oxytocin group|male participants with oxytocin treatment
2467463|NCT03122067|Placebo Comparator|placebo group|male participants with placebo treatment
2467518|NCT03121313|Experimental|Maintenance|"Eligible patient will be given maintenance tegafur-uracil for one year.~Dose of tegafur-uracil will be based on patient's body surface area (BSA):~BSA < 1.5 m2: tegafur-uracil 300 mg/day (1 capsule three times a day)~BSA ≥ 1.5 m2: tegafur-uracil 400 mg/day (2 capsules twice a day) Tegafur-uracil will be started after patient has complete the adjuvant radiotherapy and been enrolled into the study."
2467649|NCT03120611|Experimental|Virtural reality exercise|Virtual reality exercise performed during the hemodialysis session, using the Kinect, specially adapted for patients undertaking hemodialysis
2467656|NCT03120611|Active Comparator|Conventional exercise intradialysis|Exercise combining both aerobic (cycling) and strengthening exercise of lower limbs for patients during the hemodialysis session
2467720|NCT03120039||Healthy adults|Healthy adults without any limitations in upper extremity movement or function.
2467773|NCT03119714|Active Comparator|Pemirolast|Pemirolast 200mg bid 14-16 days
2467780|NCT03119714|Placebo Comparator|Placebo Oral Tablet|Matching placebo bid 14-16 days
2467918|NCT03118570|Experimental|BPS804 Dose 1|BPS804 IV Infusion
2467919|NCT03118570|Experimental|BPS804 Dose 2|BPS804 IV Infusion
3156865|NCT00353561|Active Comparator|1, Boric acid|600 mg vaginal pessaries for 14 days
3156866|NCT00353561|Other|2, Fluconazole|
3156867|NCT00353574|Experimental|Darusentan 50 mg|Darusentan 50 mg administered orally once daily
3156868|NCT00353574|Experimental|Darusentan 100 mg|Darusentan 100 mg administered orally once daily
3156869|NCT00353574|Experimental|Darusentan 300 mg|Darusentan 300 mg administered orally once daily
3156870|NCT00353587|Experimental|MBX-102 200 mg|MBX-102 200 mg once daily for 16 weeks
3156871|NCT00353587|Experimental|MBX-102 400 mg|MBX-102 400 mg once daily for 16 weeks
3156872|NCT00353587|Experimental|MBX-102 600 mg|MBX-102 600 mg once daily for 16 weeks
3156873|NCT00353587|Placebo Comparator|Sugar Pill|Placebo comparator once daily for 16 weeks
3156874|NCT00353587|Active Comparator|Actos|Actos 30 mg once daily for 16 weeks
3156875|NCT00353613|Other|1|LBJ Hospital
3156876|NCT00353613|Other|2|Ben Taub Hospital
3156877|NCT00353639||IBD subjects|Subjects with Inflammatory Bowell Disease
3156878|NCT00353665|Experimental|1 - active|memantine + riluzole
3156879|NCT00353665|Placebo Comparator|2|riluzole + placebo
3156880|NCT00353717|Experimental|1|
3156881|NCT00353743|Active Comparator|1|Patients that receive up to 10 days of doxycycline 200mg/day and metronidazole 500mg/day
2466726|NCT03127306||CAM-ICU (+) Delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
2466729|NCT03127306||CAM-ICU (-) Non-delirious patients.|"Behavioral: BPS assessment~Polish version of BPS tool validation.~Other Names:~Pain assessment in non-verbal patients"
2466771|NCT03126955||HELPS Syndrome unable to lateralize contractions|Each patient will have the following 3 diagnostic pre-operative tests: i) MRI (CISS sequence), ii) video laryngoscopy, and iii) sequential Botox injections in their throat (left side and then 3 months later on the right side).
2466801|NCT03126604||vaginal delivery|Women underwent non complicated non instumental normal vaginal delivery
2466808|NCT03126604||Cesarean section|Women underwent elective Cesarean section
3191667|NCT00800761|Active Comparator|Deferoxamine plus Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
3191668|NCT00800774|Experimental|1|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
3191669|NCT00800787|Experimental|Arm One: Nabi-HB|All subjects will be administered Nabi HB Subcutaneously
2466929|NCT03125980|Experimental|Perioperative chemotherapy with CapOX regimen|
2466933|NCT03125980|Active Comparator|Postoperative chemotherapy with CapOX regimen|
3191670|NCT00800800|Active Comparator|1|Rosuvastatin 40 mg
2467090|NCT03124576||control group|Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
2467091|NCT03124576||group B|Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder
2467096|NCT03124576||group C|Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
2467102|NCT03124576||group D|Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring
2467179|NCT03124004||Direct Oral Anticoagulants|assuming Pradaxa or Eliquis or Apixaban or Xarelto; undergoing periodontal debridement
2467180|NCT03124004||oral anticoagulant therapy|assuming Coumadin or Sintrom; undergoing periodontal debridement
2467239|NCT03123601|Experimental|Risk sign displays|At baseline patients will undertake a screening risk assessment and it will be attributed a correspondent risk display. Study duration will be a minimum of 3 months per participant, including daily record of events and monthly interview assessments. Events data will be compared with historical data extracted retrospectively from medical and nursing charts.
2467294|NCT03123172|Other|co2 gap|arterial and central venous blood gases to measure Co2 gap
2467388|NCT03122743||Ancillary-Correlative (collection of samples, questionnaires)|Patients undergo collection of serum samples for epinephrine and cortisol levels at baseline and 4 clinical visits. Patients also receive the Self-Perceived Stress questionnaire and the Distress Thermometer questionnaire to measure perceived stress.
2467427|NCT03122002||Patients With Ischemic Stroke|The patients with all types of ischemic stroke including TIA, small vessle diseases, MCAO, and ect. These patients will be recorded their emergency treatment, medical history, details about their drug therapy, results of their routine blood test and image scan, and whether they receive intravascular therapy in time or not.
2467432|NCT03122002||Healthy Control|The patients admitted to hospital for symptoms like dizzness and headache, which later proved to be not related to cerebral vascular diseases, would be treated as control. Their medical history and the results of their routine blood test and image scan will be recorded.
2467509|NCT03121573|Other|intervention|medication: duloxetine 30 to 60 mg tablets by mouth, QD to BID.
2467545|NCT03121157|Experimental|Intervention|The intervention group will receive two sessions of computer-delivered motivational interviewing via CIAS software programmed to target adherence to medications. The intervention group will also receive text messaged adherence reminders between sessions. Both the computer-delivered sessions and text messages will be tailored to the participant using ecological momentary assessment.
2467547|NCT03121157|No Intervention|Control|Control participants complete CIAS-delivered asthma education modules matched for length, location, and method of delivery of the intervention session. Control participants complete each module at their own pace and then complete a short quiz to assess their knowledge. Control participants also receive text messages between intervention sessions. Message content is the same for all control participants and contains general facts about asthma (not tailored). Message timing is not tailored and is sent at the same time every day (4:00 PM--time chosen to avoid AM and PM medication times but to not interfere with sleep and school activities).
2467565|NCT03120910|Experimental|Test Subjects|All subjects are enrolled into this arm and will receive an investigational pulse CO-Oximeter sensor, including nasal sensors, with the same or similar technology and materials as the Masimo FDA cleared devices and sensors.
2467636|NCT03120754|Experimental|Experimental Group|Placement of peritoneal drainage
2467639|NCT03120754|Active Comparator|Control group|No peritoneal drainage
2467695|NCT03120130|Experimental|Cohort 1|This cohort will include 3 patients with the first calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity (DLT) in this group the study continues including the next cohort. However, if If only one patient in a given cohort develops DLT, three more patients will be included at that dose level, up to a maximum total of six patients per dose level. If two or more of the three patients of a certain dose level develop DLT, this dose level is considered very toxic, and the study does not proceed. If this occurs at the first dose level, the study will be finalized. If only one in six patients at a dose level develops DLTs, escalation proceeds until Tolerated Maximum Dose.
2467698|NCT03120130|Experimental|Cohort 2|This cohort will include 3 patients with the second calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2467701|NCT03120130|Experimental|Cohort 3|This cohort will include 3 patients with the third calculated dose of Amblyomin-X drug. The patient will receive the intravenous drug. If no Dose-limiting toxicity in this group the study continues including the next cohort
2466786|NCT03126929||Minimally conscious state|Patients display inconsistent, but reproducible and discernible signs of awareness using CRS-R and GCS
2466787|NCT03126929||Emergence from MCS|Patients regain accurate communication and/or functional use of objects using CRS-R and GCS
2466876|NCT03126474||Delphi panel|Group of expert surgeons who have experience dealing with distal radius fractures No intervention will be performed on a patient. Participants will discuss and aim to obtain agreement about best treatment options for a variety of cases
2466930|NCT03125967|Active Comparator|Blue Light|Blue light exposure (Philips GoLite Blu HF3429/60) administered daily for 25 minutes between 8:00AM and 9:00AM
2466935|NCT03125967|Placebo Comparator|Red Light|Red light exposure (Philips LivingColor Aura 70998/60/48) administered daily for 25 minutes between 8:00AM and 9:00AM
2466967|NCT03125642|Experimental|BEAM: NHL & HL|BCNU, etoposide, Ara-C and melphalan (BEAM) for all NHL and those HL patients who are unable to receive CBV
2466970|NCT03125642|Experimental|CBV: HL|Cyclophosphamide, BCNU and VP-16 (CBV) for HL patients
2466976|NCT03125642|Experimental|CY/TBI|Cyclophosphamide/Total Body Irradiation (CY/TBI) for patients with recent history of CNS lymphoma or those with allergies/contra-indications to agents used in BEAM
2467015|NCT03125135|Experimental|Test Subject|All subjects are enrolled into the test group and all subjects receive the MightySat RX Pulse Oximeter Sensor.
3156882|NCT00353743|Placebo Comparator|2|Patients that do not receive antibiotics, only placebo
2467182|NCT03123809|Active Comparator|Gastric Electrical Stimulation (GES) ON|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned ON for 3 months during a double-blind phase of the study. This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol.Therefore all subjects in this arm will receive overall 6 months of intervention, which will be provided by the active stimulation of GES System (GES turned ON for 6 months)."
2467185|NCT03123809|Placebo Comparator|Gastric Electrical Stimulation (GES) OFF|"Gastric Electrical Stimulation (GES) system involves surgical implantation of a pulse generator in the abdominal wall and 2 electrodes into the muscularis propria of the stomach.~After surgery this group of GP patients will have their GES programed and system will be turned OFF for 3 months.This step will be followed with additional 3 months of active stimulation (GES System will be turned ON) as it is described in the protocol. Therefore all subjects in this arm will receive first 3 months of non GES intervention (GES System OFF), and 3 following months of active intervention which will be provided by the stimulation of GES System (GES turned ON for 3 months)."
2467217|NCT03123549|Experimental|Simplify Disc|Simplify Disc at two levels of the cervical spine
2467218|NCT03123549|No Intervention|Historical Control|This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=188) of a previously completed two level cervical disc trial.
2467269|NCT03123224|Experimental|Combined Aerobic and Resistance Exercise|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry. Exercises will focus on increasing the heart rate to a point at which participants will breathe more heavily and may sweat.
2467271|NCT03123224|Active Comparator|Balance and Flexibility|Participants will work with study staff to develop an individualized physical training program based on their level of functioning at study entry.
2467530|NCT03121300||High Risk Lung Cancer Patients|
2467567|NCT03120897|Experimental|Test group|The subjects will be enrolled into the test group and will receive RAM sensor.
2467604|NCT03120728|Experimental|12-14mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 12-14mm on transvaginal ultrasound.
2467605|NCT03120728|Experimental|15-17mm leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 15-17mm on transvaginal ultrasound.
2467606|NCT03120728|Experimental|18mm or greater leading follicle size|Placement of the etonogestrel/ethinyl estradiol contraceptive vaginal ring when leading follicle measures 18mm or greater on transvaginal ultrasound.
2467645|NCT03120377|Active Comparator|Platform group|Group submitted to the whole body vibration training program
2467651|NCT03120377|Sham Comparator|Platform sham group|Group that will receive the whole body vibration simulation treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display on and a sound device coupled with vibration-generated noise recording, but without therapeutic purposes.
2467754|NCT03119792|Experimental|Investigational|An education intervention will be implemented for 600 children from the original cohort (300) and comparable cohort (300) over a four month period at community centers. These sessions will occur twice a month on the weekends. The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles.
2467771|NCT03119636|Experimental|NPC transplantation|The patients will receive Levodopa combined with a regular neural precursor cell (NPC) transplantation
2467778|NCT03119636|Experimental|HLA-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-matched neural precursor cell (NPC) transplantation
3156884|NCT00353808|Experimental|s, s reboxetine|
3156885|NCT00354081|Active Comparator|1|folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg)
3156886|NCT00354081|Active Comparator|2|folic acid (0.8 mg) plus vitamin B12 (0.4 mg)
3156887|NCT00354081|Active Comparator|3|vitamin B6 (40 mg)
3156888|NCT00354081|Placebo Comparator|4|placebo
3156889|NCT00354120|Experimental|1|Alentuzumab
3156890|NCT00354120|Active Comparator|2|Globulina antilinfocitaria
3156891|NCT00354133|Active Comparator|DBS treatment|Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment
3156892|NCT00354133|Active Comparator|BMT treatment|Patients in this arm get best medical treatment only.
3174760|NCT00626964||Lifestyle or bariatric surgery|Morbid Obesity with BMI >= 40 kg/m2 or BMI >= 35 with Comorbidity
2466791|NCT03126864|Experimental|CD33-CAR-T cells - Adult Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
2466797|NCT03126864|Experimental|CD33-CAR-T cells - Pediatric Group|"After enrollment, steady state leukapheresis performed to collect apheresis material.~Fludarabine administered by vein on Days -5 to -3.~Cyclophosphamide administered by vein on Day -3.~CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found."
3156893|NCT00354185|Experimental|Treatment (tanespimycin, belinostat)|"Patients receive 17-AAG IV over 2 hours on days 1, 4, 8, and 11 and PXD101 IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of 17-AAG and PDX101 until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 12 patients are treated at the MTD.~Patients undergo blood collection on days 1 and 4 of course 1 for pharmacokinetic studies."
3156894|NCT00354198|Active Comparator|corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
3156895|NCT00354198|Experimental|pentoxifylline + corticosteroids|[intravenous pulse methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses + intravenous infusion of pentoxifylline (0.33-0.66 mg/kg/h) x 7 days + oral pentoxifylline (400-800 mg/day) from days 8 to 90
3156896|NCT00354211||1|FLOTRAC™ SYSTEM
2467075|NCT03124680|Active Comparator|opioid free group|Opioid free group using dexmedetomidine, ketamine, lidocaine, MgSO4
2467076|NCT03124680|Placebo Comparator|Opioid group|Opioid group using sufentanil, lidocaine, clonidine
2467095|NCT03124290|Other|CPR with attention distraction first|First, they perform two-minute chest compressions with conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions without conducting the PASAT.
2467105|NCT03124290|Other|CPR without attention distraction first|First, they perform two-minute chest compressions without conducting the PASAT. After 20 mins' rest, they perform two-minute chest compressions with conducting the PASAT.
2467315|NCT03122873||Myelopathy of any cause|Male or female 18 years or older with myelopathy and detectable finger extension weakness due to 1) prototypic multiple sclerosis (N=50) 2) other etiologies of myelopathy (N=50), including other inflammatory conditions (e.g. idiopathic transverse myelitis, neuromyelitis optica, acute disseminated encephalomyelitis, sarcoidosis) or other etiologies (compression, vascular disorders, degenerative disorders, neoplasms).
2467319|NCT03122873||Peripheral neuropathy|Male or female 18 years or older with C7 radiculopathy, radial neuropathy, plexopathy, peripheral neuropathy, who have detectable finger extension weakness.
2467322|NCT03122873||Healthy Controls|Male and female 18 year or older with no finger extension weakness and no known neurological conditions.
2467342|NCT03122561|Other|Paracetamol 500 mg tablet at Morning|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at morning
2467343|NCT03122561|Other|Paracetamol 500 mg tablet at Midday|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at midday
2467348|NCT03122561|Other|Paracetamol 500 mg tablet at Night|Urinary paracetamol of 41 healthy volunteers will be measured after oral administration at night
2467395|NCT03122301|Active Comparator|Bupivicaine|Stellate Ganglion Block Injection with bupivicaine
2467397|NCT03122301|Sham Comparator|Saline|Saline injection
2467464|NCT03121976|Experimental|Ultrasound|Femoral catheters inserted using ultrasound only
2467465|NCT03121976|Active Comparator|Ultrasound + Nerve Stimulation|Femoral catheters inserted using ultrasound with nerve stimulation
2467484|NCT03121521|Experimental|melatonin|Melatonin 10mg/d p.o.
2467485|NCT03121521|Placebo Comparator|placebo|placebo 10mg/d p.o.
2467579|NCT03121092|No Intervention|Discontinue ACEI or ARB|Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
2467580|NCT03121092|Active Comparator|Continue ACEI or ARB|Patients in this group will take an ACE or ARB on the day of surgery.
2467641|NCT03120650|Experimental|Scalp acupuncture|number:58 The needle will be maintained in place for 30 minutes. Patients in both groups will receive rehabilitation five times per week (Monday through Friday) for 8 consecutive weeks.
2467644|NCT03120650|Active Comparator|Conventional rehabilitation|number:58 Rehabilitation will be conducted for 1 hour five times per week (Monday through Friday) for 8 weeks.
2467774|NCT03119753|Experimental|Group R|Rapid Prototyping method of fabrication of complete denture: the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
2467783|NCT03119753|Active Comparator|Group C|Conventional method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
2467852|NCT03119246|Experimental|HD patients|
2467858|NCT03119246|Experimental|Controls|
2468154|NCT03117153|Placebo Comparator|placebo|"no active ingredients~everyday 3 times for 6 weeks"
2468212|NCT03116672|Experimental|ketorolac 10 mg|Administration of one dose Ketorolac 10 mg 15 minutes before treatment
3156897|NCT00354211||2|Control Group
3156898|NCT00354237|Other|B|No intensive treatment
3156899|NCT00354237|Experimental|A|Intensive insulin treatment
3174761|NCT00626977||R|R group:15 mL of 0.125% ropivacaine (18.75 mg)
2466878|NCT03126240||sleeve Gastrectomy|This is a five-trocar technique. The abdominal cavity is accessed through a 1cm supraumbilical incision using an optical trocar. The operating ports are inserted under direct vision. The gastroesophageal (GE) junction is exposed. A point on the greater curvature approximately 3-6cm to the pylorus is identified as the distal extent of the resection. Ultrasonic shears are used to divide the vessels long the greater curve up to the angle of His. Linear cutting staplers are used to vertically transect the stomach, creating a narrow gastric tube with. A 19Fr drain is placed in the subhepatic space near the staple line. The resected portion of the stomach is extracted through one of the working ports.
2467023|NCT03125187|Experimental|Sodium heparin UQ First|The participants will receive the Sodium heparin UQ intravenous drug administration at first period and the Sodium heparin FK intravenous drug administration at second period
2467035|NCT03125187|Experimental|Sodium Heparin FK First|The participants will receive the Sodium heparin FK intravenous drug administration at first period and the Sodium heparin UQ intravenous drug administration at second period
2467177|NCT03124030||Direct Oral Anticoagulants|assuming Pradaxa or Apixaban or Eliquis; undergo simple dental extraction
2467178|NCT03124030||Oral Anticoagulant therapy|assuming Coumadin or Sintrom; undergo simple dental extraction
2467244|NCT03123289|Experimental|68Gallium-citrate|"This arm, undergoing the 68-Gallium citrate PET/CT scan intervention, includes the PET/CT scans performed with 68Gallium-citrate radiotracer. Note that same patients scanned with different radiotracers serve in both arms."
2467246|NCT03123289|Experimental|18F-FDG|"This arm, undergoing the 18F FDG PET/CT scan intervention, includes the PET/CT scans performed with 18F-FDG tracer.~Note that same patients scanned with different radiotracers serve in both arms."
2467299|NCT03123107|Experimental|Ascorbic Acid|4 patients will receive 15 mg/kg of ascorbic acid IV the day before and after CABG surgery; 4 patients will receive 30 mg/kg of ascorbic acid IV the day before and after CABG surgery. The maximum dose of ascorbic acid will be 2 g.
2467370|NCT03122691|Placebo Comparator|Placebo Oral Cannabis|Single acute administration of placebo cannabis baked into a brownie
2467371|NCT03122691|Experimental|Low-Dose Oral Cannabis|Single acute administration of cannabis containing 10mg THC baked into a brownie
2467373|NCT03122691|Experimental|High-Dose Oral Cannabis|Single acute administration of cannabis containing 25mg THC baked into a brownie
2467375|NCT03122691|Placebo Comparator|Placebo Vaporized Cannabis|Single acute administration of placebo cannabis via commercial vaporizer
2467377|NCT03122691|Experimental|Low-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 5mg THC via commercial vaporizer
2467378|NCT03122691|Experimental|High-Dose Vaporized Cannabis|Single acute administration of placebo cannabis containing 20mg THC via commercial vaporizer
2467411|NCT03122093||CD-DIET Gluten-Free Diet Group|This former randomized control trial (RCT) group received a gluten-free education and continued support from a dietitian for a 1-year period via the CD-DIET Study (NCT01566110)
2467414|NCT03122093||CD-DIET Gluten-Containing Diet Group|This former RCT group did not receive a gluten-free education and 1-year support from a dietitian via the CD-DIET Study (NCT01566110), but rather a single gluten-free education session upon exiting the study.
2467416|NCT03122093||CD-DIET Ineligibles/Refusals|This group contains T1D/CD individuals who were not eligible or refused to join the CD-DIET RCT (e.g. already self-selected their diet or had no interest in being randomized). These individuals were instead redirected to the clinical route.
2467456|NCT03121872|Experimental|Root Coverage Surgery with T-PRF|"Multiple gingival recessions were treated by Titanium prepared PRF (T-PRF) in 16 patients.~The T-PRF membrane that was procured was placed in the defect area 1 mm beyond the enamel-cement border.. The T-PRF was fixed in the receiver area by a mattress stitch through the apical aspect using 5-0 monofilament absorbable sutures. The flap was stitched in a manner that completely covered the graft in the coronal aspect. Thereafter, the graft was fixed to the flap on the coronal aspect with horizontal mattress sutures. Compression was applied to the receiver area with serum-impregnated sterile gauze for approximately 5 minutes, and then periodontal paste was placed onto the surgery site."
2467461|NCT03121872|Active Comparator|Root Coverage Surgery with CTG|"Multiple gingival recessions were treated by Connective Tissue Graft (CTG)in 18 patients.The CTG width was measured to include 1 mm beyond the root surface defects in the receiver area. Following anaesthesia of the palate, the borders of the start and finish incisions were marked. Subepithelial connective tissue that was 1.5-2 mm thick and excluded the periosteum was removed and maintained in physiological saline. The palate was stitched with 4-0 absorbable sutures (Pegalak, Doğsan, Turkey) and covered with a periodontal paste.~Before placing the connective tissue in the receiver area, the fat and glandular tissues and the band-shaped epithelium on the connective tissue were removed using scissors."
2467523|NCT03121599|Experimental|18F-FLT PET/CT|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
3156900|NCT00354250|Experimental|Treatment (ispinesib)|Patients receive ispinesib (SB-715992) IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3156901|NCT00354263|Placebo Comparator|A|PBS injected alone in step 1 or mixed with Aggripal in step 2
3156902|NCT00354263|Experimental|B|
3156903|NCT00354315|Experimental|1|Immediate Continuous medical education (CME)
3156904|NCT00354315|No Intervention|2|control, 6 months delay CME intervention
3156905|NCT00354354|Experimental|1|Combivent
3156906|NCT00354354|Placebo Comparator|2|Saline Solution (0.9% NaCl)
3156907|NCT00354406|Experimental|A|Patients in Arm A (Early abciximab arm) will receive abciximab at time of STEMI diagnosis, before transfer to the Cath Lab to undergo primary angioplasty.
3156908|NCT00354406|Active Comparator|B|Patients in Arm B (Late abciximab arm) will receive abciximab at time of primary angioplasty, directly in the Cath Lab.
3156909|NCT00354419|Experimental|Arm I|See Detailed Description
3191671|NCT00800800|Placebo Comparator|2|placebo
3191672|NCT00800813||open, laparoscopic, or robotic-assisted lap|Patients will also be assessed for penile length and the presence of Peyronie's Disease at these specified times.
3191673|NCT00800930|Active Comparator|1|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
2466993|NCT03125512|Experimental|Night Shift positional device|Randomized to Night shift positional therapy first for 8 weeks, followed by CPAP for 8 weeks, with a 1 week washout period.
2466996|NCT03125512|Active Comparator|Continuous positive airway pressure|Randomized to CPAP first for 8 weeks, followed by positional therapy for 8 weeks, with a 1 week washout period.
2467032|NCT03125213|Active Comparator|Peg-IFN plus AL-3778|
2467043|NCT03125213|Placebo Comparator|Peg-IFN plus matching placebo|
3191674|NCT00800930|Placebo Comparator|2|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
2467089|NCT03124498|Experimental|CIK Cell|"Phase I - Three dose levels escalated according to 3+3 rule~Phase II - The recommended dose level according to the results from Phase I"
2467202|NCT03124147|Active Comparator|Anodal tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2467204|NCT03124147|Active Comparator|Cathodal tDCS with motor training|20 minutes of cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2467208|NCT03124147|Active Comparator|Dual tDCS with motor training|20 minutes of anodal transcranial direct current stimulation applied to the ipsilesional hemisphere and cathodal transcranial direct current stimulation applied to the contralesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2467212|NCT03124147|Sham Comparator|Sham tDCS with motor training|20 minutes of sham transcranial direct current stimulation applied to the ipsilesional hemisphere (intervention) paired with 3 hours of intensive, task-oriented upper extremity motor training. Transcranial direct current stimulation will be delivered using the Neuroconn Eldith stimulator by Magstim.
2467268|NCT03123458|Experimental|Single arm, cfMSC to treat immune disorders|cfMSCs treatment
2467351|NCT03122613|Active Comparator|Curcumin|Dietary supplements of Curcumin capsules
2467358|NCT03122613|Placebo Comparator|Curcumin Placebo|Identical looking placebo of the active arm
3191675|NCT00800943|Experimental|Campath-1H|
3191676|NCT00800956|Experimental|Single oral dose of [14C]-esreboxetine|
3191677|NCT00800969|Other|all patients|all patients with Adenocarcinoma
3191678|NCT00800995|Sham Comparator|Control|
2467578|NCT03121118||Scan opportunity|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
2467581|NCT03121118||Comparison group|40 dyads comprised of individuals with Mild Cognitive Impairment and a study partner who is either a family member or kin-like friend.
2467725|NCT03120000|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
2467750|NCT03119506||Long Recess Duration/Before Lunch|
2467751|NCT03119506||Short Recess Duration/Before Lunch|
2467757|NCT03119506||Long Recess Duration/After Lunch|
2467768|NCT03119506||Short Recess Duration/After Lunch|
2467866|NCT03119324|Experimental|B-Cure® diode laser|"Thirty patients receiving LLLT by the B-Cure® diode laser (Good Energies, Haifa, Israel) 808nm low power device at 5 Joules/min, 250 milliWatts 15 KiloHertz for 8', (40 Joules each) in contact mode directly over the painful area, twice a day for 7 consecutive days.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
2467922|NCT03118570|Experimental|BPS804 Dose 3|BPS804 IV Infusion
3191679|NCT00800995|Experimental|SOD|
3191680|NCT00801008|Experimental|Exercise and Relaxation Intervention|Participants in this arm will receive a 12 week exercise and relaxation intervention
3191681|NCT00801008|No Intervention|Wait List Control Condition|Participants in this arm will be offered the exercise and relaxation intervention after a 12 week delay.
3191682|NCT00801021|Experimental|Frio Oral Rinse|Prescription Mouth Rinse
3191683|NCT00801034|Placebo Comparator|1|Calcium tablets
3191684|NCT00801034|Active Comparator|2|Potassium tablets
3191685|NCT00801047|Experimental|1|Epidural group
3191686|NCT00801047|Active Comparator|2|Remifentanil iv PCA
3156910|NCT00354458|Placebo Comparator|1|
2467033|NCT03125343|Experimental|No surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation.
2467042|NCT03125343|Active Comparator|Surgery|Patients with indication of complete response on follow-up MRI will undergo endoscopy, and digital rectal examination to ascertain complete response. MRI together with documentation from endoscopy will be reviewed at the Regional University Hospital to establish agreement regarding interpretation. Patients with complete response will be offered watch and wait strategy, but the patients that want surgery will be operated according to the multi disciplinary conference decision.
2467073|NCT03124654||Education|
2467084|NCT03124433|Experimental|Neoadjuvant apalutamide|Oral apaluatmide 240mg daily for 12 weeks followed by standard of care robotic radical prostatectomy and pelvic node dissection
2467163|NCT03123913|Experimental|Combination therapy|Testosterone Enanthate and Somatropin
2467249|NCT03123627|Experimental|New profilaxis|Prophylaxis is discontinued when the patient developed CMV-specific cellular immunity.
2467254|NCT03123627|Active Comparator|Profilaxis recommended by TTS|Valganciclovir prophylaxis until day +90 as recommended by the International Consensus document of the TTS.
2467278|NCT03123016|Experimental|Vitiligo with Apremilast and NB-UVB phototherapy|Each participant will be compared with one side of the body to the other side
2467325|NCT03122808||Neonatal encephalopathy|"The inclusion criteria will be:~Moderate or severe neonatal encephalopathy~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~Non-hypoxic-ischaemic aetiology or postnatal hypoxic-ischaemia~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
2467326|NCT03122808||Control|"The inclusion criteria will be:~Gestational age of 35+0 weeks or greater~Singleton pregnancy~Inborn~The exclusion criteria will be:~APGAR score of less than 5 at 1 minute or less than 7 at 5 or 10 minutes~Admission to the neonatal unit~Major congenital abnormalities~Less than 15 minutes of digital CTG recording from labour available"
2467447|NCT03121989|Active Comparator|Hyperpolarized Pyruvate (13C) Injection|"The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.~After the injection research, MRI will be done and images evaluated."
2467450|NCT03121989|Placebo Comparator|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that acts as test object. It provides a signal that is used to ensure that the MRI system is functioning properly.
2467527|NCT03121508|Other|TODAY Project|All participants will attend individualized self-management sessions led by an occupational therapist. The classes will focus on promoting modifying daily activities, habits, roles, and routines to promote healthy lifestyles for individuals with type 2 diabetes.
2467586|NCT03121066|Active Comparator|Experimental group|Transcranial Magnetic Stimulation + Conventional intervention
2467589|NCT03121066|Sham Comparator|Sham control group|Sham Transcranial Magnetic Stimulation + Conventional intervention
2467592|NCT03121066|No Intervention|Non TMS Control group|Conventional intervention alone
2467629|NCT03120494|Experimental|Subjects at risk of HIV|25 high risk MSM and 50 negative partners in a sero-discordant couple will be recruited and emtricitabine and tenofovir (Truvada) for PrEP will be provided, per guidelines, for one year
2467687|NCT03120195|Experimental|EndoRotor® ablation|Prospective pilot study, to be performed in 30 patients with Barrett's esophagus that have an indication for ablation treatment. Barrett's ablation will be performed using the EndoRotor®.
2467787|NCT03119415|Experimental|Cooperative Learning|Teachers in intervention schools are training in cooperative learning (CL).
2467788|NCT03119415|No Intervention|Business as Usual|Schools continue with business as usual.
2467876|NCT03118882|Active Comparator|Diet Group|
2467877|NCT03118882|Active Comparator|Physical activity group|
2467880|NCT03118882|Active Comparator|Physical activity and diet group|
2467881|NCT03118882|No Intervention|Control group|
2467940|NCT03118479|Experimental|Androgen only addback|Anastrozole 10 mg orally once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
2467942|NCT03118479|Experimental|Combined sex steroid addback|Placebo (sugar pill) tablet once daily for 3 months Testosterone gel 7.5 g transdermally daily for 3 months.
2468117|NCT03118089|Experimental|Biscuit style oral nutritional supplement treatment|Participants will take the biscuit style oral nutritional supplement at an intervention level equivalent to their current oral nutritional supplement prescription
2468120|NCT03118089|No Intervention|Standard Care|Participants will remain on their current oral nutritional supplement
2468161|NCT03117036||Lymphoma|Patients are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphoma. All patients should receive systemic chemotherapy. Newly diagnosed or relapsed/refractory patients can be enrolled.
2468191|NCT03116620|Experimental|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
2468237|NCT03116347|Experimental|EPOCH 1|Ramp up period for participants who were not treated with HyQvia prior to this study
2468244|NCT03116425|Active Comparator|Placebo|Stimulation of a region with normal rCBF and putatively unrelated to catatonic symptoms (parietal cortex).
2468258|NCT03116516|Other|ARM1|"In ARM1, 30 subjects will be assigned and the subjects will be administered telmisartan/amlodipine and rosuvastatin at Day1 and YHP1604 at Day22."
3156911|NCT00354458|Experimental|2|
3156912|NCT00354523|Experimental|Capecitabine + Dacarbazine + Imatinib|Capecitabine starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle. Dacarbazine starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle. Imatinib starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
3156913|NCT00354536|Active Comparator|albiglutide|albiglutide injection
3156914|NCT00354536|Placebo Comparator|albiglutide placebo|placebo injection
3156915|NCT00354562|Active Comparator|A|Docetaxel + ABT-751
2467010|NCT03125447|Experimental|Prematurely born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
2467014|NCT03125447|Active Comparator|Term born children|Speed and accuracy answer to visual stimuli evaluated in 3 distinct posture/mobility situations
3191687|NCT00801060|Experimental|Treatment Group A|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
2467118|NCT03124277|Experimental|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
2467122|NCT03124277|Other|Control group|Best local diet
2467170|NCT03123991|Experimental|Experimental Group|UP-A adapted as a preventive intervention. Specifically, the Spanish version of The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a 9 sessions school-based preventive intervention. The intervention is delivered in nine weekly sessions (each session lasting around 55 minutes).
2467171|NCT03123991|Other|Wait-list Control Group|Same than experimental group (EG), after EG finishes. Specifically, classes in waitlist condition will be offered the same intervention than experimental group after EG finishes the three months follow-up.Before that, waitlist means that the classess work as usual with issues of mental health.
2467245|NCT03123497||Idiopathic Thrombocytopenic Purpura|completion of questionnaire
2467372|NCT03122717|Experimental|Gefitinib + Osimertinib|"Gerfitinib will administered orally at a pre determine dose daily~Osimertinib will administered orally at a pre determine dose daily"
2467398|NCT03122197|Experimental|Letrozole|"The treatment starting dose will be 2.5mg administered orally once daily. Daily doses up to 10mg and single doses of 30mg have been shown to be safe in prior studies and therefore we expect that letrozole doses up to 20mg in this study will be safe.~The recommended phase II dose (RP2D) will be considered the dose that results in ≥ 2uM letrozole concentration in the tumor or the highest dose achieved (20mg daily for cohort level 7) with < 2/6 patients with DLTs. This dose will be planned for future phase II studies to determine potential efficacy."
2467422|NCT03121963|Experimental|Treatment Group|A combination regimen of oxycodone 5 mg Q6hr PRN, acetaminophen 650 mg Q6hr, celecoxib 400 mg BID post-operatively x 2 weeks, and gabapentin 400 mg loading dose, 300 mg TID to be started 1 week pre-operatively then continued post-operatively x 2 weeks.
2467423|NCT03121963|Active Comparator|Control Group|A single medication regimen of hydrocodone-acetaminophen 7.5 mg Q6hr PRN post-operatively x 2 weeks.
2467494|NCT03121716|Experimental|SHR-1210, gemcitabine and cis-platinum|Subjects receive SHR-1210 200mg (Day 1) and gemcitabine 1000mg/m2 (Day 1 and Day 8)and cis-platinum 80mg/m2 (Day 1) of each 21-day cycle for at most 6 cycles, followed by SHR-1210 200mg every three weeks (Q3W) maintenance for the remainder of the study or until documented PD.
3191688|NCT00801060|Active Comparator|Treatment Group B|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
2467776|NCT03119428|Experimental|OMP-313M32|Intravenous (in the vein) infusions of OMP-313M32 as a single agent
2467786|NCT03119428|Experimental|OMP-313M32 and Nivolumab|Intravenous (in the vein) infusions of OMP-313M32 in combination with nivolumab
2467853|NCT03119103|Other|Intervention of Functional Bed Sheet|Interventions will be non-invasive where healthy adults (over the age of 17, 10 male and 10 female) sleeps on the functional bed sheet overnight.
2467874|NCT03118817|Experimental|HM95573|Single arm
2467916|NCT03118557|Experimental|Pilates pelvic floor strengthening exercise|
2467977|NCT03118245|Experimental|AuraGain group|AuraGain is inserted for maintenance of general anesthesia. The size 1 is for children <5kg, size 2 for 5-10kg, size 2 for 10-20kg, and size 2.5 for 20-30kg.
2467978|NCT03118245|Experimental|I-gel group|I-gel is s inserted for maintenance of general anesthesia. The size 1 is for children weighted 2-5kg, size 2 for 5-12kg, size 2 for 10-25kg, and size 2.5 for 25-35kg.
2468035|NCT03117920|Experimental|Minnelide|0.67 mg/m2 Minnelide daily as a 30min iv infusion on days 1-21 of each 28 day cycle, followed by a 7 day rest period (D 22-28).
2468095|NCT03117504||First trimester|women during first trimester(less than 14 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
2468101|NCT03117504||Third trimester|women during third trimester(more than 28 weeks of pregnancy) will complete self-reported questionnaires and undergo clinical examination to confirm the stress incontinence.
2468179|NCT03117088|Active Comparator|Checklist ISBAR 3|online-based checklist for standardized handovers
2468182|NCT03117088|Placebo Comparator|Checklist VICUR|comparator Checklist
2468234|NCT03116412|No Intervention|Routine follow up|Follow up according to national guidelines.
2468235|NCT03116412|Experimental|Radiological assessments|Radiological assessments (CT or PET scans) at 5 occasions during 3 years.
2468335|NCT03115866|Experimental|FRUVED|Individuals that are at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet with 50% fruit and vegetables.
2468337|NCT03115866|Experimental|FRUVED + LRC|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low refined carbohydrates.
2468359|NCT03115437|Experimental|Hard cushioned running shoes|Running shoes with cushioned properties among the hardest of the market benchmark (Stiffness: +/- 90 N/mm)
2467047|NCT03125278||Medication indication on the label|Patients discharged from Regions Hospital (St. Paul, MN) where we have implemented a standard process of printing the indication for all new medications on the prescription bottle.
2467049|NCT03125278||No medication indication given|Patients discharged from Brigham and Women's Hospital (Boston, MA) where there is no requirement for providing information on medication indications to patients at discharge.
2467242|NCT03123484|Experimental|β-elemene+EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) and β-elemene
2467243|NCT03123484|Active Comparator|EGFR TKI|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)
3156916|NCT00354562|Placebo Comparator|B|Docetaxel + placebo
3156917|NCT00354575|Experimental|A|Chinese Herb (CCH1)
2467338|NCT03122470|Experimental|MRI guided biopsy + TRUS biopsy|Patients will undergo an MRI guided biopsy and standard trans-rectal ultrasonography-guided (TRUS) biopsy. Results will be compared to see which can more accurately diagnose and manage prostate cancer
2467390|NCT03122353|Experimental|Calcipotriene Hydrate and Betamethasone|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
2467391|NCT03122353|Active Comparator|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
2467393|NCT03122353|Placebo Comparator|Placebo|Topical suspension without active ingredient
2467470|NCT03121781|Active Comparator|CPAP with binasal prongs|Edi will be recorded while the infant is on nasal CPAP with the binasal prongs, with a PEEP of 5-8 cm H2O, for 2 hours. Then, the infant will be switched the interface to the RAM cannula, with a PEEP 2 cmH2O higher, during 2 hours.
2467473|NCT03121781|Active Comparator|CPAP with RAM cannula|Edi will be recorded while the infant is on nasal CPAP with the RAM cannula with a PEEP 2 cmH20 higher than the levels the infant was receiving before starting the study protocol, for 2 hours. Then, the infant will be switched the interface to the binasal prongs with a PEEP between 5-8 cmH2O, during 2 hours.
2467510|NCT03121482|Active Comparator|HFNC alone|Control group
2467512|NCT03121482|Experimental|HFNC and NIV|
2467632|NCT03120767|Experimental|Condition 1|enrolled in the Risk and Resilience course during Fall 2017 and directly encouraged to participate in the Founders Living and Learning Community wellness activities for the Fall of 2017 (Coordinated Wellness Programming)
2467634|NCT03120767|Active Comparator|Condition 2|enrolled in the Risk and Resilience course in Spring 2018, and not directly encouraged to participate in the WIN Living and Learning Community wellness activities
2467637|NCT03120767|No Intervention|Condition 3|a control group that receives none of the interventions during the first year. This group will instead receive an online pamphlet that contains a number of wellness tips and advice for first-year students. Condition 3 participants have access to the WIN Living and Learning Community wellness activities in Fall of 2017 and Spring of 2018, but are not directly encouraged to participate.
2467719|NCT03120143|Experimental|Team sport and high protein group|This group participated in team sport based small-sided ball games with supplementation of a drink with a high content of protein after the training sessions
2467727|NCT03120143|Experimental|Team sport and low protein group|This group participated in team sport based small-sided ball games with supplementation of a drink low in protein content after the training sessions
2467734|NCT03120143|No Intervention|Control group|This group continued their usual life style without intervention
3156918|NCT00354575|Placebo Comparator|B|Starch powder as placebo
3156919|NCT00354627|Experimental|TMC125|TMC125 200 mg b.i.d. till commercially available.
2467894|NCT03118999|Experimental|OM3-FFA|Omega3 linked to free fatty acids
2467896|NCT03118999|Experimental|OM3 -MAG|Omega3 linked to Monoacylglycerol
2467897|NCT03118999|Experimental|OM3-EE|Omega3 linked to ethylester
2467946|NCT03118414|Experimental|Physical Exercise Group|Physical Exercise (PE) is an intervention that aim to improve balance and muscle strength of the elders. It composed of 3 steps; warming up exercise, core content of the exercise (strength and balance training) and cool down exercise program.
2467947|NCT03118414|Experimental|Virtual Reality|Virtual Reality (VR) VR is an intervention that aim to improve balance of the elders. It stimulates the auditory and visual function and concentration of the participants throughout the training. It composed of 10 games that included weight shifting from side to side, stepping into different directions, trunk flexion, extension and side bending, movements of the upper and lower limbs, and trunk twisting in this study.
2467949|NCT03118414|Experimental|Brain Exercise|"Brain Exercise (BE) BE is an intervention that aim to stimulate the cognitive function of the elders.~It stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training"
2467951|NCT03118414|No Intervention|Control Group|No Intervention: Healthy control No intervention was given to this group of participants. The control group was reminded not to participate in any other exercise or intervention program except their routine daily activities.
2467998|NCT03118063|Experimental|Active trigger point|Evaluation of the dynamometry of the maximum and medium gluteus muscles and correlate with the presence or not of trigger point
2468001|NCT03118063|Active Comparator|Latent trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
2468004|NCT03118063|Active Comparator|No trigger point|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
2476695|NCT03058900|Sham Comparator|Placebo (saline)|
3156920|NCT00354692|Experimental|Experimental|
3156921|NCT00354705||Colon Cancer Patients|Patients with colon cancer recently removed by surgery.
3156922|NCT00354731|Active Comparator|corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
3156923|NCT00354731|Experimental|Pentoxifylline + corticosteroid|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M + oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
3156924|NCT00354757|Active Comparator|2 arms|PPI 1
3156925|NCT00354757|Active Comparator|PPI|PPI 2
3156926|NCT00354861|Experimental|A|IMP321
2467087|NCT03124446|Experimental|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
2467088|NCT03124446|Active Comparator|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
3156927|NCT00354861|Placebo Comparator|B|Saline
2467408|NCT03122210|Other|Control group|In this group, the nursing staff administed oxygen supply if necessary with the usual pratice in care unit for 24 hours after myocard infarction. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
2467413|NCT03122210|Other|FreeO2 with SpO2 target = 92%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 92%.
2467415|NCT03122210|Other|FreeO2 with SpO2 target =97%|In this group oxygen flow was automatically adjusted with the FreeO2 device (automatic titration of oxygen flow) to achived SpO2 target set by clinicial for 24 hours after myocard infarction. In this group, the SpO2 target was set at 97%.
2467444|NCT03121924|Experimental|Immediately oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~The first arm is the immediately denudation and immediately ICSI of the oocytes, and in the second arm the oocyte are denuded and injected after 4 hours from the pick up ."
2467449|NCT03121924|Experimental|Delayed oocyte denudation|"After the retrieval , sybling oocytes were assigned to one o more recipient and then ,the oocytes were randomized in two arms .~In this arm, the oocyte are denuded and injected after 4 hours from the pick up ."
2467620|NCT03120533|Experimental|Treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site, each day the same site.
2467621|NCT03120533|Placebo Comparator|Placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil
2467688|NCT03120234|Experimental|Dexmedetomidine and ketamine|The group will receive loading dose of dexmedetomidine 1mcg/kg over 10 Min followed by a maintenance of 0.5 mcg/ kg/ hr.ketamine 0.5 mg/kg will be given as bolus at the time of induction.
2467689|NCT03120234|Experimental|fentanyl and placebo|pts will receive fentanyl 2mcg/kg as bolus over 10 Mon followed by 1 mcg/ kg/hr as maintenance, instead of ketamine placebo(0.9%saline ) will be given in control group
2467765|NCT03119779|Experimental|TheraCal vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of incremental layers of TheraCal using the tip of the syringe container of the material and each layer should not exceed 1 mm then light curing each increment. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
2467775|NCT03119779|Active Comparator|MTA vital pulp therapy|Using rubber dam isolation we will remove the caries using large round but under copious amount of coolant and if carious exposure occur, part of the pulp chamber will be removed using sharp spoon excavator. After complete removal of the caries and control of bleeding, then direct application of freshly mixed MTA-Anglus on sterile glass slap. MTA application then gentle condensation over wet cotton till MTA thickness is about 2-3 mm thickness and removal of excess material from walls of pulp chamber. Application of wet cotton for 15 min. to achieve initial setting of MTA. Then Riva self-cure glass-ionomer base and composite resin final restoration. We will take immediate standardized postoperative periapical radiographs.
2467863|NCT03118960|Active Comparator|Group II Low Air Loss/Alternating Pressure Mattress|Bed provides subjects with alternating pressure with low air loss mattress for the healing and prevention of pressure injury
2467925|NCT03118570|Experimental|BPS804 Dose 4|BPS804 IV Infusion
3156928|NCT00354861|Active Comparator|C|Engerix B
3156929|NCT00354874|Experimental|GW642444 50mcg|
3156930|NCT00354874|Experimental|GW642444 100mcg|
3156931|NCT00354874|Experimental|GW642444 200mcg|
3156932|NCT00354874|Active Comparator|salmeterol 50mcg|
3156933|NCT00354874|Placebo Comparator|placebo|
3156934|NCT00354926|Experimental|AME 133v|All subjects will receive weekly intravenous infusions of AME-133v. Each subject will receive a total of 4 infusions administered once a week for 3 consecutive weeks.
3156935|NCT00354965|Experimental|ARM 1|
3156936|NCT00354991|Experimental|1|Losartan/HCTZ
3156937|NCT00355069|Experimental|1|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt AND family education
3156938|NCT00355069|Experimental|2|Received the Basic Pediatric Chronic Care Model AND the Medication Assessment Prompt but NOT family education
3156939|NCT00355069|Experimental|3|Received the Basic Pediatric Chronic Care Model AND family education but NOT the Medication Assessment Prompt
3156940|NCT00355069|Placebo Comparator|4|Received the Basic Pediatric Chronic Care Model only (NO Medication Assessment Prompt and NO family education)
3156941|NCT00355095|Active Comparator|1|erythropoietin
3156942|NCT00355095|No Intervention|2|Placebo
3156943|NCT00355186|No Intervention|Control|
3156944|NCT00355186|Experimental|Early|
3156945|NCT00355186|Experimental|Late|
3156946|NCT00355238|Experimental|1|no comparator to brivanib
2467106|NCT03124667|Active Comparator|Video Condition|The videos group will visit the lab on 5 separate occasions, for 2 hours each, to view health and educational YouTube videos, and then view 5 similar sessions at home (lasting 2 hours, but may be split into 1-hour sessions at their convenience), at the onset of the exercise program. The training sessions will be scheduled concurrently with exercise classes in the first month. This group will also be asked to accumulate 150 minutes of exercise by attending weekly supervised and unsupervised, group-based aerobic and resistance exercise classes, by visiting the fitness facility alone, and by walking or strength training at home when necessary to supplement fitness facility activities to fully meet public health recommendations, for a period of 12 months.
3191689|NCT00801073|Experimental|Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
2467221|NCT03123536||Point-of-care ultrasound group|High risk patients received point-of-care ultrasound assessment perioperatively, treatment was oriented by the findings of point-of-care ultrasound.
2467223|NCT03123536||Control group|High risk patients received management by the experience of the clinical team.
2467253|NCT03123315|Experimental|Cook Bush DL™ Ureteral Illuminating Catheter|As part of this study an additional tool will be used during the hysterectomy. This tool is called a Cook Bush DL™ Ureteral Illuminating Catheter, which is a lighted ureteral stent. This is a very thin tube that goes into the ureter. A urologist, who is an expert at placing these devices, will insert a stent into each ureter during surgery. The lighted stents will help effectively find the ureters and keep track of them during the surgery. This same procedure is already being done in many other forms of abdominal surgery to help find the ureter. The stents will be removed before the surgery is complete and treatment will not differ in any other way.
2467291|NCT03123042|Experimental|Sentinel basin dissection|Intervention: Sentinel basin dissection
2467363|NCT03122626|Experimental|Experimental Group|The intervention is a group, task-oriented exercise program involving two 1-hour exercise classes per week for 12 weeks. The class involves a seated warm-up, repetitive, progressive practice of functional balance and mobility tasks, and a seated cool down. The warm-up consists of active range-of-motion exercises, aerobic exercise, leg loading, stretching, and sit-to-stand training. The cool-down involves exercises with an emphasis on stretching and relaxation. Tasks are organized in a 3-station circuit completed by participants grouped by overall ability: Superstation 1: walking, aerobic training, and wall work (standing and reaching, wall push-ups); Superstation 2: standing weight shifts, coordinated with stepping and lunging; and Superstation 3: tap-ups, step-ups, and heel/toe raises, hamstring curls, marching-on-the-spot, and mini-squats. Participants are instructed to be physically active by walking in their neighbourhood, practicing the program exercises, or using the stairs.
2467366|NCT03122626|No Intervention|Wait-listed Control Group|The control group will receive usual care which will be monitored and is expected to consist of provision of a home exercise program and information on community resources according to current best practices. At the end of the study period, participants in the control group will be offered to participate in the 3-month exercise program.
2467418|NCT03122340|Placebo Comparator|Placebo Group|Oil: 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
2467419|NCT03122340|Experimental|Polyprenol Group|Polyprenols (ROPREN): 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
2467474|NCT03121807|Experimental|Home parenteral nutrition|"Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.~Patients received 85 mg/m2 oxaliplatin and 200 mg/m2 leucovorin as a 2-h intravenous infusion on day 1, followed by 2400 mg/m2 5Fluorouracil as a 46-h continuous infusion. This regimen is repeated every 14 days as a cycle."
2467493|NCT03121430|Experimental|Group A|subjects using the drug eluting peripheral vascular stent system
2467497|NCT03121430|Active Comparator|Group B|subjects using the Nitinol Stent System (Cordis Corporation)
2467712|NCT03120117|Experimental|Cough Test following Sling Surgery|All subjects enrolled will undergo sling surgery for treatment of stress urinary incontinence and subsequently asked to do a standing cough test.
3191690|NCT00801086|Experimental|1|MTS-01 (7% Tempol gel)
3191691|NCT00801086|Placebo Comparator|2|Vehicle
2467820|NCT03118986|Active Comparator|Olanzapine|Standard antiemetics plus olanzapine
2467821|NCT03118986|Placebo Comparator|Placebo Oral Tablet|Standard antiemetics plus placebo
2467939|NCT03118323||Patients in need of endodontic treatment|n = 200
2467995|NCT03118115|Experimental|Impedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
2468093|NCT03117400||Bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is blue without any other defect features (as described in the second group, 'non bland blue defect'). The blue is the result of the submucosal injection of dye (indigo carmine), used to lift lesions before starting the resection.
2468099|NCT03117400||Non bland blue defect|The defect after endoscopic mucosal resection of the colonic large laterally spreading lesion (20mm or more) is not just blue, but contains other defect features, such as visible vessels, herniation of vessels, submucosal fat, exposed muscle, fibrous bands, submucosal haemorrhage or non stained submucosa.
2468165|NCT03117114|Other|Standard Arm|Standard colonoscopy without mounted Endocuff Vision device. Therefore standard polypectomy in case of polyp resection.
2468169|NCT03117114|Active Comparator|Endocuff Vision Arm|Endocuff Vision device mounted to the endoscope prior to the beginning of the procedure. Therefore EVD assisted polypectomy in case of polyp resection.
2468231|NCT03116594|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2478205|NCT03048877|Placebo Comparator|Placebo|Placebo Tablets
3191692|NCT00801112||1|PD patients with residual renal function >200ml with BIA monitor.
3191693|NCT00801112||2|PD patients with residual renal function <200ml with BIA monitor.
3191694|NCT00801112||3|PD patients with residual renal function >200ml without BIA monitor
3191695|NCT00801112||4|PD patients with residual renal function <200ml without BIA monitor
3191696|NCT00801151|Experimental|Vorinostat, vinorelbine|Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
2467158|NCT03123900|Experimental|Physical exercise (n= 40)|Walking program up to 45 minutes, 5 times a week for 3 months.
2467164|NCT03123900|Experimental|Cognitive training (n=40)|Computerized cognitive training up to 45 minutes, 5 times a week for 3 months.
2467168|NCT03123900|Experimental|Combined training (n=40)|Exercise and cognitive training up to 90 minutes, 5 times a week for 3 months.
2467169|NCT03123900|No Intervention|Control group (n=20)|Waiting list group.They receive no intervention during this waiting period. At the end of this period our training programs are available to them.
2467205|NCT03123666|Experimental|Granulocyte/macrophage colony-stimulating factor (GM-CSF)|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer OR Placebo for 7 days. Both the groups will receive standard medical care
2467209|NCT03123666|Placebo Comparator|Placebo|Placebo will be given identical to the interventional
3191697|NCT00801164|Experimental|Frio Oral Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
3191698|NCT00801164|Experimental|Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
2467382|NCT03122405|Experimental|Test group|The subjects will be enrolled in the test group and will simultaneously receive both RAM sensors.
3191699|NCT00801177|Experimental|IMC-11F8 (Every week)|Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.
3191700|NCT00801177|Experimental|IMC-11F8 (Every other week)|Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.
2467520|NCT03121352|Experimental|Carboplatin + Nab-paclitaxel + Pembrolizumab|Combination therapy of Carboplatin, Nab-paclitaxel, and Pembrolizumab
2467566|NCT03120988|Experimental|Lavage with Platelet Poor Plasma (PPP)|"Lavage using 50 cc of PPP in the knee joint. Using visual guidance, the PPP lavage will be conducted, introducing a solution of platelet poor plasma into the knee joint with subsequent removal of the fluid, in effect washing out the joint space."
2467622|NCT03120416|Experimental|Resistance exercise training program|Eight exercises will be used to include large upper and lower body muscle groups. The baseline 1 repetition maximum (RM) will be used to set initial training loads. All exercise sessions will be performed under the supervision of an exercise physiologist. Vital signs and body weight will be recorded before each session. The workload during training will be adjusted to reflect 80% of the most recent 1 RM (approximately 8-12 RM set). In addition, patients' workloads will be progressively increased if the patients can lift the weight more than 12 repetitions. Participants will perform three sets of 8-12 repetitions on each machine per session.
2467624|NCT03120416|No Intervention|Control|Participants randomized to the control group will be offered an educational brochure regarding exercise published by the NKF.
2467666|NCT03120273|Experimental|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd in dexlansoprazole treatment arm for 5 days
2467668|NCT03120273|Active Comparator|Lansoprazole Injection|30 mg q12h in lansoprazole treatment arm for 5 days.
2467716|NCT03119935|Experimental|Amflow assist ambu bag ventiation|Newely developed method (Amflow assist ambu bag ventilation)
2467723|NCT03119935|Experimental|Ambu bag ventilation|Ordinary method (ambu bag ventilation
2467747|NCT03119597|Placebo Comparator|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
2467748|NCT03119597|Experimental|Wild Blueberry Power-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
2467814|NCT03119337|Experimental|Text-based VMMC follow-up|Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits.
2467815|NCT03119337|No Intervention|Routine VMMC follow-up care|Routine VMMC follow up care with in person visits according to national guidelines.
2467818|NCT03119012|Active Comparator|P2Y12 receptor inhibitor monotherapy arm|In patients who do not occur a MACCE until 12-month after BRS implantation, P2Y12 receptor inhibitor monotherapy arm will be received clopidogrel 75mg qd or ticagrelor 60mg bid during follow-up period (24 months after randomization).
2467819|NCT03119012|Active Comparator|Extended DAPT arm|In patients who do not occur a MACCE until 12-month after BRS implantation, Extended DAPT arm will be received aspirin 100mg qd plus P2Y12 receptor inhibitor (clopidogrel 75mg qd or ticagrelor 60mg bid) during follow-up period (24 months after randomization).
2467915|NCT03118726||NM Perinatal Collaborative|Hospitals working with the New Mexico Perinatal Collaborative (NMPC) on implementing immediate postpartum long-acting reversible contraception programs.
2467960|NCT03118310|Placebo Comparator|Placebo|Placebo diet
2467965|NCT03118310|Experimental|5:2|5:2 diet
2467968|NCT03118310|Experimental|LCHF|LCHF diet
2468028|NCT03117959|Placebo Comparator|Stryker Triathlon Custom Fit Knee|implanted in standard fashion
2468029|NCT03117959|Experimental|Stryker shape match|no longer RCT
2468172|NCT03117127|Active Comparator|Whole eggs|After resistance exercise, participants will ingest whole eggs (18 g protein, 17 g fat) cooked in scrambled form.
2468173|NCT03117127|Experimental|Egg Whites|After resistance exercise, participants will ingest egg whites (18 g protein, 0 g fat) cooked in scrambled form.
2468285|NCT03116087|Active Comparator|Testosterone patch|Testosterone patches
3191701|NCT00801190|Active Comparator|HES (130/0.4)|33 ml/kg i.v. HES (130/0.4)
3191702|NCT00801190|Placebo Comparator|Ringer's Lactate|33 ml/kg i.v. Rigner's Lactate
3191703|NCT00801203|Experimental|1|Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)
3191704|NCT00801203|Experimental|2|Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)
3208585|NCT00976144|Experimental|GSK573719, GW642444, GSK573719+GW642444, placebo|This is a four-way cross-over study. Subjects, healthy volunteers, will receive a single dose of GSK573719 (500ug), GW642444 (50ug), GSK573719 (500ug)+GW642444 (50ug) administered concurrently, or placebo at each of the four treatment periods. There is a minimum wash-out period of seven days between doses. On enrolment into the study, subjects will be assigned to one of four treatment sequences which are based on a Williams design in accordance with the randomization schedule generated by GSK prior to study start.
2467155|NCT03124095|Experimental|Combined Exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
2467159|NCT03124095|No Intervention|Control Group|The control group will be advised not to change their health habits. After the intervention they will be invited to participate in a physical exercise program.
2467216|NCT03123757|Other|Intervention|Patients performed the 6-minute walk test and completed the EQ-5D quality of life questionnaire.
3208586|NCT00976157||Ventilator-associated pneumonia|
2467317|NCT03122964||Patients with gross or microscopic hematuria|This study aims to prospectively enroll a minimum of 700 subjects, with gross or microscopic hematuria. Each site will target enrollment of 100 subjects and patient samples will be collected from consecutive patients meeting the inclusion criteria outlined below. The total study duration is expected to be 24 months.
2467381|NCT03122574|Experimental|Treatment|Pure (100%) lavender aromatherapy
2467383|NCT03122574|Placebo Comparator|Placebo Control|Pure (100%) jojoba aromatherapy
2467384|NCT03122574|No Intervention|Standard of care Control|No aromatherapy control group
2467424|NCT03122080|Active Comparator|Electroacupuncture group|electroacupuncture+standard care
2467429|NCT03122080|Placebo Comparator|Control A group|placebo acupuncture+standard care
2467436|NCT03122080|Other|Control B group|standard care
2467522|NCT03121690|Experimental|prednisone|prednisone 40 mg/day for 7 days
2467525|NCT03121690|Experimental|placebo|5ml saline /day for 7 days
2467600|NCT03120975|Experimental|Computerized decision support|
2467601|NCT03120975|Active Comparator|Standard antibiotic stewardship|
2467657|NCT03120390|Experimental|Group I (PCT)|Patients undergo supervised exercise sessions comprising of AE over 30 minutes and RE over 25 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
2467661|NCT03120390|Experimental|Group II (PAT)|Patients undergo supervised exercise sessions comprising of AE over 45-60 minutes 3 days per week for 24 weeks. Patients are encouraged to complete AE at home over 20 minutes 1 day per week. Patients receive a Polar heart rate monitor to monitor heart rate during the AE sessions.
2467665|NCT03120390|Active Comparator|Group III (usual care)|Patients undergo usual care. Beginning 24 weeks, patients may undergo supervised exercise sessions comprising of AE and RE as in Group I.
2467690|NCT03119883|Other|MGUS group|MGUS patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
2467691|NCT03119883|Other|Multiple Myeloma group|Multiple Myeloma patients will undergo an intervention which includes an intravenous infusion of 13-Carbon labeled glutamine prior to undergoing a bone marrow aspiration to acquire their bone marrow plasma cells. The glutamine utilization by these bone marrow plasma cells will be assessed by gas-chromatography mass spectrometry by measuring the 13C isotopomer enrichment in the plasma cells.
2467772|NCT03119740||open appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open appendectomy (AE)
2467781|NCT03119740||laparoscopic appendectomy|Patients were selected retrospectively on the basis of the documented MEL code (medical service code) of open laparoscopic appendectomy (LSK AE)
2467805|NCT03119311|Experimental|VOG group|Video-oculography
2467810|NCT03119311|Active Comparator|APCT group|alternative prism cover test
2467840|NCT03119064|Experimental|Dose 1|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 1 50mg/m2 IV every 2 weeks"
2467844|NCT03119064|Experimental|Dose 2|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 2 70 mg/m2 IV every 2 weeks"
2467857|NCT03119064|Experimental|Dose 3|"Temozolomide: 50mg/m2/day until disease progression.~Nanoliposomal irinotecan :~Dose Level 3 80mg/m2 IV every 2 weeks"
2467912|NCT03118635|Experimental|Intervention|Daily, four-hour physical activity intervention
2467914|NCT03118635|No Intervention|Control|No treatment control
3208587|NCT00976170|Experimental|1|
3208588|NCT00976222|Other|1 Arm Ranibizumab|
2468038|NCT03117855|Experimental|Treatment (capecitabine, yttrium Y-90 radioembolization)|Patients undergo yttrium Y 90 resin microspheres radioembolization over 60-90 minutes on day 1. Patients receive capecitabine PO BID on days 1-14.
2468116|NCT03117426|Experimental|SYMFONY IOL|"The unique design of this IOL merges two complementary enabling technologies: (1) its diffractive echelette design feature extends the range of vision, and (2) achromatic technology corrects chromatic aberration for enhanced contrast sensitivity. Theoretically, combining these two mechanism of action results in a continuous range of high-quality vision for far, intermediate, and near distances with the same low incidence of halos and glare associated with monofocal IOLs (see figure 2).~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
2468155|NCT03116971|Experimental|M3814 (HME Tablet + PiC) with Etoposide and Cisplatin|Participants received M3814 100 mg hot melt extrusion (HME) tablet orally 5 days prior to Day 1 and M3814 100 mg PiC, orally once daily from Day 1 in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 mg/m^2 over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until PD.
3208589|NCT00976235|Experimental|IMT|
3208590|NCT00976261|Experimental|GSK1614235|Glucose lowering agent under investigation.
3208591|NCT00976261|Active Comparator|Sitagliptin|Glucose lowering comparator
2467206|NCT03123796||No Acid Suppressive Treatment|Kidney transplant recipients who used neither proton pump inhibitors nor histamine H2 receptor antagonists.
2467237|NCT03123523||Patients group|35 patients
2467238|NCT03123523||Healthy volunteers|20 healthy volunteers
2467283|NCT03123094|Experimental|BI 655130 dose group 1 (Intravenous)|
2467285|NCT03123094|Experimental|BI 655130 dose group 2 (Intravenous)|
2467289|NCT03123094|Experimental|BI 655130 dose group 3 (Intravenous)|
2467292|NCT03123094|Experimental|BI 655130 dose group 4 (Subcutaneous)|
2467296|NCT03123094|Placebo Comparator|Matching placebo for each dose group (Intravenous)|
2467297|NCT03123094|Placebo Comparator|Matching placebo (Subcutaneous)|
2467362|NCT03122678|Experimental|Thiamine Supplementation Group|Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
2467365|NCT03122678|Placebo Comparator|Placebo Group|Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
2467412|NCT03122249|Other|OASIS|Patients that meet the eligibility criteria will be enrolled in the study and will receive the advanced cancer symptom management intervention
2467448|NCT03121937|Experimental|Mobile App|Participants will receive a mobile app to be used during psychotherapy that syncs information with the participant's therapist from sessions.
2467452|NCT03121937|No Intervention|Treatment as Usual|Participants will receive treatment as usual with aspects of the mobile app available through paper-based worksheets.
2467487|NCT03121638|Active Comparator|VARIVAX|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm
2467488|NCT03121638|Active Comparator|ZOSTAVAX|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
2467489|NCT03121638|Experimental|NBP6081|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2467490|NCT03121638|Experimental|NBP6082|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2467491|NCT03121638|Experimental|NBP6083|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2467531|NCT03121274|Active Comparator|Early pushing during vaginal delivery|patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not
2467534|NCT03121274|Active Comparator|Delayed pushingduring vaginal delivery|patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible
2467570|NCT03120962|Experimental|oxycodone|Oxycodone 20mg/day, for 4 weeks and famciclovir 500mg three-times daily for 7 days.
2467572|NCT03120962|Active Comparator|standard treatment|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day (whichever is lower), for 4-12 weeks and famciclovir 500mg three-times daily for 7 days.
2467623|NCT03120585|Experimental|Fluid Management Intervention|Restricting IV fluids to infants with respiratory distress to mimic fluid intake of normal healthy breast fed infants (less fluid that current standard of care)
2467625|NCT03120585|No Intervention|Control Group|Infants with respiratory distress will receive standard of care fluid management.
2467667|NCT03120247|Active Comparator|DEX I|OTM Dexmetetomidine 1µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2467669|NCT03120247|Active Comparator|DEX II|OTM Dexmetetomidine0.75µg/kg Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2467671|NCT03120247|Active Comparator|DEX III|OTM Dexmetetomidine 0.5µg/kg. Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
2467703|NCT03119896|Experimental|Intervention Group (using Navigator Tool)|The participants will receive a copy of the Navigator Tool Intervention, a paper-based information pack including the My Pain Concerns Form, suggested questions to ask your healthcare professional, a goal setting sheet and information on common self-management strategies. They will be encouraged to fill in some of the forms before the consultation, and some during the consultation. They will have consultations with a healthcare professional who has undergone a Self-management Awareness Training with the Thistle Foundation.
2467705|NCT03119896|No Intervention|Control Group (not using Navigator Tool)|These participants will not have access to the Navigator Tool Intervention, and will have consultations with a healthcare professional who has not undergone the Self-management Awareness Training.
2467745|NCT03119584|Active Comparator|1)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
2467746|NCT03119584|Active Comparator|2)28days of linaclotide or placebo|patient will be randomized and allocated to one of the treatment arms using computerized generated simple random number in a double-blinded fashion for 28 days of therapy with the study drug, linaclotide or placebo. Patients, and trial personnel involve (other than biostatistician) in this study will not be aware of the group assignments. Patients, treatment providers and staffs will be kept blinded in this study.
2467871|NCT03118791|Placebo Comparator|Placebo|Capsules containing maltodextrin
2467872|NCT03118791|Active Comparator|80 mg ACN|Capsules containing 80 mg anthocyanins
2467873|NCT03118791|Active Comparator|160 mg ACN|Capsules containing 160 mg anthocyanins
2467875|NCT03118791|Active Comparator|240 mg ACN|Capsules containing 240 mg anthocyanins
2467250|NCT03123432|Experimental|immunomodulating nutrients enriched diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, enteral nutrition (EN) was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the immunomodulating nutrients enriched diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the interventional diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
2467257|NCT03123432|Active Comparator|standard diet|Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.
2467298|NCT03123003|Experimental|SonicBone Ultrasound|Assessment of bone age by SonicBone Ultrasound will compared to wrist X-ray assessment
2467369|NCT03122704|Experimental|Group B Streptococcus (GBS) screening|Vaginal and anal swab of patients will be screened for GBS screening
2467455|NCT03122314|Experimental|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solution Bristol-Myers Squibb_UK) intravenous (IV) was given 100 patients
2467459|NCT03122314|Experimental|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
2467507|NCT03121495|Active Comparator|Second forward view exam|During withdrawal, the colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed.
2467508|NCT03121495|No Intervention|Conventional withdrawal exam|No intervention additional to the conventional withdrawal examination during withdrawal
2467552|NCT03121131|Other|Accurate Clinical Exam Findings|Radiologists will be provided with accurate clinical exam data.
2467554|NCT03121131|Other|Inaccurate Clinical Exam Findings|Radiologists will be provided with purposefully incorrect clinical exam data
2467557|NCT03121131|Other|No Clinical Exam Findings|Radiologists will be not be provided with any clinical exam data
2467593|NCT03120884|Experimental|IVF|embryos are cultured using conventional in vitro fertilization.A maximum of 2 embryos will be transferred for each treatment cycle.
2467597|NCT03120884|Experimental|ICSI|embryos are fertilized using ICSI.A maximum of 2 embryos will be transferred for each treatment cycle.
2467616|NCT03120468|Experimental|Topiramate and N-Acetyl Cysteine|Drug: Topiramate and N-Acetyl Cysteine Other Name for Topiramate: Topamax
2467617|NCT03120468|Experimental|Topiramate and Placebo|Drug: Topiramate and Placebo Other Name for Topiramate: Topamax Other Name for Placebo: Sugar Pill
2467638|NCT03120299|Experimental|Group A Drug|"Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks~Other Names:~Omega-3 Fatty Acid fish oil Omega 3 Treasure"
2467640|NCT03120299|Placebo Comparator|Group B Drug|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
2467715|NCT03120065|Other|MEMS follow up|Approximately 25% of the enrolled study population will have their adherence to medicines monitored by research personnel through the use of electronic dose monitoring caps (MEMS) for a period of 3 months. The participant's ART medication regimen will be dispensed in a bottle with a cap that monitors the time and date in which the cap is opened. Each month, the participant will bring the bottle with them on their clinic day for three months and the research personnel will extract the timing information from the cap.
2467758|NCT03119675|Other|Photorefraction of ages 1 to 6 years|Clinical Validation of GoCheck Kids Smartphone App
2467836|NCT03119298||High-fear-of-physical-activity group|Group members with high fear of physical activity
2467845|NCT03119298||Low-fear-of-physical-activity group|Group members with low fear of physical activity
2467854|NCT03119298||Control group|Healthy subjects matched for age and sex
2467891|NCT03118908|Experimental|Amberen and Smart B|"Amberen - a dietary supplement: 2 capsules (one while capsule 200 mg and one orange capsule 200 mg) are taken once a day with a meal, preferably after breakfast, for 3 months.~SMART В - a dietary supplement: 1 capsule per day (166 mg) is taken once a day with a meal, preferably after breakfast, for 3 months, concurrently with Amberen."
2467892|NCT03118908|Placebo Comparator|Placebo|Placebo is taken as follows: 3 capsules (one while capsule 200 mg, one orange capsule 200 mg, one capsule 166mg) are taken once a day with a meal, preferably after breakfast, for 3 months.
2467937|NCT03118440|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
2467938|NCT03118440|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
2468008|NCT03118128|Active Comparator|metformin|Metformin 850mg PO three times a day, during the pre-induction with steroids, induction remission, consolidation and maintenance
2468009|NCT03118128|No Intervention|No metformin|
2468019|NCT03117699|Experimental|Hemiplegic subjects|"Testing of a new device for seated-standing passages after undergoing medical evaluation included Fugl Meyer scale, Berg scale and Bergego scale.~Phase 1 :~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
2468022|NCT03117699|Experimental|Healthy volunteers|"Testing of a new device for seated-standing passages .~Phase 1 :~3 seated-standing passages without help~3 seated-standing passages with a handle equipped with 6 force captors~3 seated-standing passages with the device"
2468071|NCT03117582||Patients with C.diff infection|Patients with C.diff infection not responding to antibiotics who are now scheduled for the FMT procedure for routine care of their condition.
2468151|NCT03116971|Experimental|M3814 PiC with Etoposide and Cisplatin|Participants received M3814 100 milligram (mg) powder in capsule (PiC) orally once daily in combination with Etoposide 100 mg/m^2 over a 60 minute intravenous infusion on Days 1-3 and Cisplatin 75 milligram per square meter (mg/m^2) over a 60-minute intravenous infusion on Day 1 for 6 cycles with each cycle lasting 3 weeks (21 days) until progressive disease (PD).
2467302|NCT03122990|Experimental|Full mouth scaling and root planing|FM-SRP No surgical periodontal treatment will be performed in all dentition within 24 hours
2467304|NCT03122990|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP No surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2467350|NCT03122652|Experimental|Terifunomide|
2467357|NCT03122652|Placebo Comparator|Placebo|
2467426|NCT03122015|Experimental|Therapeutic clown distraction|The child will interact with the therapeutic clown throughout the painful procedure. The types of distraction interventions will be determined by the clown according to the child's age, culture and behavior. The clown can use different distraction activities such as magic, humor, visualization and play. According to various writings, the presence of the clown before the procedure varied between two to 20 minutes. In our study, the presence of the clown with parents and children will be about 10 minutes before the procedure and while the nurse performs the procedure until the child leaves the room. The distraction performed by a therapeutic clown is used in St. Justine' Hospital. Indeed, a team of therapeutic clowns is present in the hospital four times a week to distract the children. However, this procedure is not applied routinely in painful procedures and no study has evaluated its usefulness or effect.
2467431|NCT03122015|No Intervention|Standard care|
2467514|NCT03121391|No Intervention|Control|The medical intensive care unit in four hospitals will comprise the clusters. All four clusters begin the study under the control condition. Ventilator withdrawal is conducted by the usual personnel in those units. Data is collected through observation of the process and the respiratory comfort of the enrolled patients. Each cluster is randomly selected to sequentially cross over to the intervention. The remaining clusters continue with usual care (control) until selected for crossover.
2467516|NCT03121391|Active Comparator|Intervention|Each cluster is randomly selected to sequentially crossover to the intervention. When crossed over to the intervention the assigned intensive care nurse conducts the ventilator withdrawal according to the algorithm. The algorithm is informed by an objective measure of patient respiratory comfort. Data is collected through observation of the process and the respiratory comfort of the enrolled patients.
2467575|NCT03121053|Active Comparator|sodium bicarbonate|250ml 1.4% sodium bicarbonate 1 h before TAVR
2467577|NCT03121053|Active Comparator|hypotone saline|0.65% sodiumchloride 1 ml/kg/h for 12 h before and 12 h after TAVR
2467658|NCT03120624|Experimental|Arm A (VSV-hIFNbeta-NIS, SPECT/CT, TFB-PET, biopsy)|Patients receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
2467662|NCT03120624|Experimental|Arm B (ruxolitinib, VSV-hIFNbeta-NIS, SPECT/CT,TFB-PET,biopsy)|Patients receive ruxolitinib phosphate PO BID on days -3 to 9. Patients also receive VSV-hIFNbeta-NIS IV over 60-90 minutes on day 1. After 2 days, patients receive technetium Tc-99m sodium pertechnetate IV, and about 30 minutes later, undergo whole body planar imaging and SPECT/CT imaging or receive fluorine F18 tetrafluoroborate IV and undergo TFB-PET imaging. If previous imaging data are positive, patients receive technetium Tc-99m sodium pertechnetate IV and undergo another planar and SPECT/CT imaging or fluorine F18 tetrafluoroborate IV and undergo another TFB-PET imaging between 7-10 days and on 15 days if needed after VSV-hIFNbeta-NIS infusion. Biopsy of accessible NIS image-positive tumors may occur after any imaging. Patients also undergo image-guided biopsy of accessible tumor on day 29.
2467738|NCT03119818|Experimental|Patients suffering from ESRD treated by chronic hemodialysis|Patients aged from 18 to 80 years old, suffering from ESRD, treated by chronic hemodialysis since at least 6 months and whose phosphatemia at the beginning of HD sessions ranged from 1.5 to 3 mmol/L. Phosphorus (31P) magnetic resonance spectroscopy will be performed in these patients during hemodialysis in order to measure intracellular phosphate and ATP concentrations and intracellular pH evolution during hemodialysis.
2467756|NCT03119454||Patients receiving diprospan|Patients who are receiving diprospan in standard therapy of their existing disease, or multiple times, but following the introduction of diprospan is planned no earlier than 28 days after the first administration.
2467767|NCT03119454||Control subjects|Patients or healthy volunteers who had not received systemic or local corticosteroids in the last 12 weeks before the screening visit.
2467829|NCT03119259|Active Comparator|ABC Clinical Program Only and Usual Care|Patients and informal caregivers randomized to the comparison group will receive care provided by the ABC Clinical Program and IUHP. The ABC Clinical Program is the standard of ADRD care at Eskenazi Health and Primary Care Visits at Indiana University Health is the usual care.
2467834|NCT03119259|Experimental|BCN Mobile App Plus ABC and BCN Mobile app only|Patients and caregivers randomized to the intervention group will continue to receive care in ABC clinical program and IUHP, and have the BCN software installed on either the caregiver's personal mobile device (assuming it meets minimal technical requirements) or a device provided by the study, per participant preference. A research assistant will orient participants to the device, provide training on the BCN software, and troubleshoot technical issues. Participants will receive daytime technical support by phone, electronic support request through a separate app, or printed and in-app help manuals. Hardware, software, and connectivity check-ups will be provided by study research personnel.
2467909|NCT03118700|No Intervention|Non-exercise Control|Subjects will come to the laboratory for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow. During this time, subjects will remain seated with their body posture maintained constant
3208592|NCT00976261|Placebo Comparator|Placebo|Placebo to match GSK1614235 and placebo to match Sitagliptin
2467989|NCT03118050|Experimental|RT in T2DM|Type 2 diabetes subjects will undergo 3 months of resistance exercise training. Muscle size, strength and response to a low dose amino acids will be measured before and after training. Results of this arm will be compared to those previously obtained in healthy older subjects who participated in NCT02999802 (same training protocol) after 1:1 matching for age and sex.
2467337|NCT03122782|Placebo Comparator|Normal Saline (control group)|Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
2467380|NCT03122418|Experimental|Exercise Study Group|All subjects in this study will receive a personal fitness device and be asked to participate in some routine exercise. Each participant will be compared to their own initial CFQ-R score (to measure quality of life) before and after use of the personal fitness device.
2467511|NCT03121417|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity
2467568|NCT03121040|Experimental|Subjects ingested VAAM® for 10 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 10 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
2467571|NCT03121040|Experimental|Subjects ingested VAAM® for 6 weeks|Ten young athletes ingested Vespa amino acid mixture (VAAM®) for 6 weeks, divided into different meter race including 1500-, 800- and 400-meter races.
2467573|NCT03121040|No Intervention|Subjects ingested nothing|Ten young athletes before ingesting Vespa amino acid mixture (VAAM®) , divided into different meter race including 1500-, 800- and 400-meter races.
2467612|NCT03120702|Experimental|Neonatal Test Subjects|All test subjects in this group are neonatal patients who will receive a investigational Rainbow SpHb sensor.
2467694|NCT03119857|Active Comparator|Antiandrogen|Antiandrogen (bicalutamide 150 mg x 1) p.o. alone,
2467697|NCT03119857|Experimental|Antiandrogen + docetaxel|Antiandrogen (bicalutamide 150 mg x 1) p.o. + Docetaxel 75 mg/m2 (maximum 2.0 m2 ) i.v. q 3 weeks x up to 8-10 cycles.
2467841|NCT03119038|Active Comparator|Combination Medication Injection|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine, 30 mg ketorolac, 200 mcg epinephrine, and 100 mcg clonidine in a 100 mL 0.9% saline solution
2467847|NCT03119038|Active Comparator|Single Medication Injection|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine and 30 mL 0.25% bupivacaine without epinephrine
2467904|NCT03118648||stroke|"Patients over 18 years old leaving the correctional institution with orientation back home~First stroke deficit with non-regressive clinical expression in 24 hours~Independent in activities of daily living and living at home before stroke. This earlier independence is confirmed by the absence of professional carers in personal care activities~Proper oral understanding as measured by score 7 in the Language Screening Test (LAST) (Flamand-Roze et al, 2011)~No psychiatric history that led to hospitalization for more than six months~Written informed consent after reading the briefing note~Patient affiliated or beneficiary of a social security scheme."
2467958|NCT03118362|Experimental|Plasmalyte®|Plasmalyte® is a balanced solution containing a low chloride concentration (i.e. 98 mmol/L), it also contains acetate (27 mmol/L) and gluconate (23 mmol/L) as buffer solutions.
2467959|NCT03118362|Experimental|Ringer Lactate®|Ringer Lactate® is a balanced solution containing a low chloride concentration (i.e. 111mmol/L), it also contains lactate (29 mmol/L) as buffer solutions.
2468034|NCT03117972|Experimental|Arm A : FOLFOXIRI - bevacizumab|FOLFOXIRI + bevacizumab, 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 or bevacizumab-capecitabine) until disease progression or limiting toxicities
2468040|NCT03117972|Active Comparator|Arm B: FOLFOX or FOLFIRI - bevacizumab|FOLFOX or FOLFIRI + bevacizumab 12 cures following by maintenance chemotherapy (bevacizumab + LV5FU2 ou bevacizumab capecitabine) until disease progression or limiting toxicities
3156947|NCT00355251|Experimental|A|4 semanas manteniendo el tratamiento antirretroviral e iniciar atorvastatina 40 mg/día. A la semana 4 interrupción HAART y aumentar a 80 mg/día de atorvastatina hasta la semana 32 de seguimiento
3156948|NCT00355251|No Intervention|B|4 semanas manteniendo el tratamiento antirretroviral. A la semana 4 interrupción HAART hasta la semana 32 de seguimiento
2468187|NCT03116789|Active Comparator|VGA-1(Probiotics)|Lactobacillus rhamnosus and Lactobacillus acidophilus.
2468190|NCT03116789|Active Comparator|VGA-2(Probiotics)|Lactobacillus rhamnosus and Lactobacillus plantarum.
2468242|NCT03116425|Experimental|Verum 1 - Premotor|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the premotor region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
2468243|NCT03116425|Experimental|Verum 2 - Prefrontal|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The network including the prefrontal region will be targeted. The therapeutic protocol will be design to correct the rCBF anomaly."
3156949|NCT00355303|Active Comparator|Misoprostol tablet, PGE2 gel|participants are assigned to one of two arms for the duration of the study In one group induction of labour is done by intravaginal misoprostol tablets at 4 hrly interval with maximum of five doses.In other group PGE2 gel is applied in poaterior fornix at six hourly interval.
3156950|NCT00355316|Experimental|Stage IV Breast Cancer|Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.
3156951|NCT00355316|Other|Healthy Volunteers|Baseline blood draw.
3156952|NCT00355355|Experimental|Litx|Drug: Talaporfin Sodium (1 mg/kg iv), Device: Interstitial Light Emitting Diodes (200 J/cm) 3 treatments within 6 months
3156953|NCT00355355|Active Comparator|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
3156954|NCT00355485|Experimental|Microdermabrasion Treatment|Bilateral, split-face comparison in which one half of the face will be randomly assigned to receive the microdermabrasion treatment(s) while the other half of the face will not. Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart. In all cases, microdermabrasion treatment parameters will be within those accepted in cosmetic work.
3156955|NCT00355498||1|Controls
3156956|NCT00355498||2|Mild Cognitive Impairment
3156957|NCT00355498||3|Alzheimer's disease
3156958|NCT00355498||4|FTD
3174762|NCT00626977||RC|RC group:0.0625% ropivacaine (9.375 mg) plus 75 ug clonidine
2467345|NCT03122509|Experimental|durvalumab and tremelimumab plus Radiotherapy (RT)|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice. RT will be initiated within 7 days after the first of durvalumab and tremelimumab.
2467347|NCT03122509|Experimental|durvalumab and tremelimumab plus ablation|Patients will receive 1500 mg durvalumab via IV infusion q4w for up to 4 doses/cycles and 75 mg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 1500 mg durvalumab q4w starting on Week 16. Tremelimumab will be administered first. Durvalumab infusion will start approximately 1 hour after the end of tremelimumab infusion. The duration will be approximately 1 hour for each infusion. The ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice. Ablation will be performed within 7 days after the first of durvalumab and tremelimumab.
2467404|NCT03122236|Active Comparator|Standard walking with tDCS dosage A|Neurorehabilitation of Standard Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
2467405|NCT03122236|Active Comparator|Complex walking with tDCS dosage A|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage A
2467409|NCT03122236|Active Comparator|Complex walking with tDCS dosage B|Neurorehabilitation of Complex Walking and Transcranial Direct Current Stimulation (tDCS) dosage B
3208593|NCT00976287|Active Comparator|Conserved Therapy|Conserved Therapy
2467532|NCT03121287||Lung or Esophageal Patients|Patients with lung or esophageal cancer undergoing conventionally-fractionated radiation therapy. Interventions to be administered include: Imaging Biomarkers using Volumetric CT Scans, Pulmonary using Pulmonary Function Test & 6Minute Hall Walk, Imaging using Cardiac MRI, Specimen Collection using Blood Draws.
2467576|NCT03120936|Other|Main|Emtricitabine / Tenofovir Disoproxil Oral Tablet and PrEP support.
2467711|NCT03120156|Active Comparator|No insoles|Control group of people with poor postural control that won't use insoles
2467714|NCT03120156|Active Comparator|Normal insoles|Control group of people with poor postural control that will get normal standard insoles.
2467717|NCT03120156|Active Comparator|Sensomotoric insoles|Control group of people with poor postural control that will get normal standard insoles.
2467749|NCT03119558|Experimental|18F-Florbetaben (Neuraceq®) PET/MRI|Participants with known or suspected cardiac amyloidosis will be injected with 8 mCi of 18F-Florbetaben (Neuraceq®) and undergo the PET/MRI image acquisition 45-60 minute post-injection. PET and MRI data will be acquired simultaneously to ensure optimal timing and spatial correspondence between MRI and PET data. Total scan time will take approximately 60 minutes.
2467832|NCT03119350|Other|Physical Training|"There was concurrent physical training intervention: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation and learning to exercise, 8 weeks of physical training.~Frequency: 3 times per week Duration: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
2467869|NCT03118830|Active Comparator|Long GnRH agonist|daily SC injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium < 5 mm and low E2 < 50 and LH < 5IU/l with either HMG or rFSH in a starting dose of 150-300 IU/day
2467870|NCT03118830|Active Comparator|GnRH antagonist|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l. Daily sc rFSH injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done
2467902|NCT03118583|Experimental|Dietary supplement with carrageenan|300 mg/day of dietary supplement containing carrageenan
2467948|NCT03118388|Experimental|36 SEI youth|36 homeless youth (ages 16-24) randomized to the SEI intervention
2467950|NCT03118388|Experimental|36 IPS youth|36 homeless youth (ages 16-24) randomized to the IPS intervention
2468003|NCT03118076|Placebo Comparator|Group R|Nerve blocks were administered with 0.3% ropivacaine without dexmedetomidine.
2468005|NCT03118076|Experimental|Group RD|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
2468073|NCT03117283|Experimental|LTG with Bursectomy|laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach
2468076|NCT03117283|Sham Comparator|LTG without Bursectomy|laparoscopic D2 radical total gastrectomy without bursectomy
2468138|NCT03117179|Other|Patient with an interview|
2468139|NCT03117179|Other|Patient without an interview|
2468177|NCT03116867||patients receiving hysteroscopic tubal occlusion|This group will have sonosalpingography done for them one month after the tubal occlusion.
2468240|NCT03116555|Experimental|Irinotecan plus apatinib|"Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day).~Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities."
3156959|NCT00355524|Experimental|Group A with >= 20 kg to < 30 kg body weight|300 milligram (mg) of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
3156960|NCT00355524|Experimental|Group A with >= 30 kg to < 40 kg body weight|300 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 milliliter [mL]) of ritonavir liquid (80 milligram/milliliter [mg/ml]) will be administered orally twice daily.
2478257|NCT03048526|Experimental|NovaTears®|
3156961|NCT00355524|Experimental|Group A with >= 40 kg to < 50 kg body weight|450 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
2467406|NCT03122106|Experimental|Personalized neoantigen DNA vaccine|"Vaccines will be weeks 1, 5, 9, 13, 17, and 21. Vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. All study injections will be given intramuscularly using TDS-IM system. At each vaccination time point, patients will receive 2 injections of the neoantigen DNA vaccine, 1 injection into each deltoid or lateralis.~Minimum observation of 30 minutes. Vital signs will be taken at 30-45 minutes post-immunization. The injection sites will be inspected for evidence of local reaction. Follow up on subject well-being will be performed by telephone on the 1st or 2nd day following each injection. -Post-vaccination follow-up visits are at Week 25 ± 7 days and Week 77 ± 14 days. Additional follow-up visits or telephone contact will be scheduled at Week 129 and annually thereafter if the patient is alive and available for follow-up.~At intervals throughout the study (both before and after vaccination) subjects will have blood drawn for immunologic assays."
2467506|NCT03121651|Experimental|RL-adaptive application|"Dyad is comprised of individual with disability (spina bifida or cerebral palsy) and the respective parent/legal guardian (also referred to as caregivers).~Young adult will use the RL-adaptive support application that the investigators are developing to help manage medications."
2467591|NCT03120793||Esophageal balloon catheter placement|This is the primary and only arm of the study in which acute respiratory distress syndrome patients will have an esophageal balloon catheter placed with pressures recorded in the supine, upright and prone positions
2467675|NCT03120546|Experimental|Group A|rigid video stylet intubation - video laryngoscope intubation
2467676|NCT03120546|Experimental|Group B|video laryngoscope intubation - rigid video stylet intubation
2467728|NCT03119909|Other|Learning of actions-events associations|Each subject will conduct 4 sessions, i.e. a training session and three fMRI sessions. The first session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
2467735|NCT03119909|Other|Learning of action-event associations not linked to action|"This study is divided into two parts: a pilot behavioral study to determine the learning characteristics of non-action events and an fMRI study to study the neural networks involved in this type of learning.~30 subjects will participate in the behavioral study and 60 will participate in the fMRI study)"
2467779|NCT03119467|Experimental|Single arm|RP4010 to be administered
2467833|NCT03119129|Experimental|Cohort 1|Four middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, Academic Year (AY) 2016-2017
2467839|NCT03119129|Experimental|Cohort 2|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2016-2017
2467843|NCT03119129|Experimental|Cohort 3|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 2, AY 2017-2018
2467851|NCT03119129|Experimental|Cohort 4|Three middle or intermediate schools receiving the Ho'ouna Pono curriculum in Quarter 3, AY 2017-2018
2467980|NCT03118258|Experimental|Pap smear|'Pap smear' arm: women are invited to participate in a preventive consultation. This consultation is followed by direct patient referral for Pap smear testing in a partner health facility.
2467983|NCT03118258|Experimental|Self-collected vaginal swab for HPV testing + pap smear triage|"'Self-collected vaginal swab for HPV testing + pap smear triage' arm : women are invited to participate in a preventive consultation. This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
2468025|NCT03117894|Active Comparator|GA with RA|Regional Anesthesia and General Anesthesia.
2468026|NCT03117894|Active Comparator|GA without RA|Only General Anesthesia (without a supplemental Regional Anesthesia).
3156962|NCT00355524|Experimental|Group B with >= 20 kg to < 30 kg body weight|375 mg of TMC114 tablet with 50 mg (which is equivalent to 0.625 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
3174763|NCT00626990|Active Comparator|RT alone|radiation therapy alone
2468264|NCT03116269|Experimental|cilostazol group|aspirin placebo daily and 100 mg cilostazol twice daily
2468265|NCT03116269|Active Comparator|aspirin group|100 mg aspirin daily and cilostazol placebo twice daily
2468375|NCT03115515|Experimental|Adjustment in number of doses of thyroid hormone per week|"Patients in this group will increase pre-pregnancy thyroid hormone dose by 2 doses/week (extra dose on Wednesday and Saturday). Further dose adjustment are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase by 3 doses/week~TSH 5.0-9.9mIU/L, increase by 2 doses/week~TSH 2.0-4.9mIU/L, increase by 1 dose/week~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease by 1 dose/week~TSH<0.1mIU/L, decrease by 2 doses/week~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
2468412|NCT03115242|Experimental|Acute ischemic carotid stroke|"Patients hospitalized in the neurovascular intensive care unit for an acute ischemic stroke with a carotid plaque responding to inclusion criteria.~These patients receive a contrast injection Sonovue® will be performed during the neck vessels doppler ultrasound."
2468457|NCT03114826||Renal cell carcinoma in renal transplant patients|
3174764|NCT00626990|Active Comparator|RT & Concurrent CT|Radiotherapy and concurrent temozolomide chemotherapy
3174765|NCT00626990|Active Comparator|RT + Adjuvant CT|Radiotherapy plus adjuvant temozolomide chemotherapy
3174766|NCT00626990|Active Comparator|RT & Concurrent CT + adjuvant CT|Radiotherapy and concurrent chemotherapy plus adjuvant temozolomide chemotherapy
2467399|NCT03122262|Active Comparator|Tenofovir Alafenamide|Descovy: Tenofivir alafenamide tablets 25mg daily, Emtricitabine 200mg daily
2467401|NCT03122262|Active Comparator|Dolutegravir|Dolutegravir 50mg daily, Truvada 500mg daily
2467403|NCT03122262|Active Comparator|Atripla|Atripla: Efavirenz 600mg daily, Tenofovir Disoproxil Fumarate 300mg daily, Emtricitabine 200mg daily
2467469|NCT03121833|Experimental|Endostar & AIM regimen / GT regimen|Endostar & AIM regimen / GT regimen; Endostar 15mg, into 500ml 0.9% sodium chloride intravenous infusion of 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; AIM regimen is Pirarubicin (THP) + Ifosfamide (IFO), the specific dose is IFO 8-12g / m2, given 4-5 days; THP 75mg / m2, given 1-2 days; 21-28 days for a cycle; GT regimen is Docetaxel (TXT) + Gemcitabine (GEM), specific dose of Gemcitabine 1000mg / m2 (D1, D8) and Docetaxel 75mg / m2 (D8); 21-28 days for a cycle; Preferred AIM regimen, AIM regimen chemotherapy failure or can not tolerate anthracycline chemotherapy in patients with GT regimen.
2467471|NCT03121833|Placebo Comparator|Placebo & AIM regimen / GT regimen|Placebo + AIM regimen / GT regimen; Placebo is 500ml 0.9% sodium chloride, Intravenous 3 ~ 4h, d1 ~ d14, 21-28 days for a cycle; The chemotherapy regimen is the same as the experimental group.
2467502|NCT03121443||Patient position|Perfusion index
2467533|NCT03121248|Experimental|WBI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed
2467536|NCT03121248|Active Comparator|WBI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed
2467538|NCT03121248|Experimental|WBI - observational - 5|WBI 5 fractions SIB 5 fractions if needed
2467539|NCT03121248|Active Comparator|WBI - observational - 15|WBI 15 fractions SIB 15 fractions if needed
2467540|NCT03121248|Experimental|WBI + LNI - randomized - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2467543|NCT03121248|Active Comparator|WBI + LNI - randomized - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2467544|NCT03121248|Experimental|WBI with LNI - observational - 5|WBI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2467546|NCT03121248|Active Comparator|WBI with LNI - observational - 15|WBI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2467548|NCT03121248|Experimental|thoracic wall irradiation (TWI) +/- LNI - observational - 5|TWI 5 fractions SIB 5 fractions if needed LNI 5 fractions
2467550|NCT03121248|Active Comparator|TWI +/- LNI - observational - 15|TWI 15 fractions SIB 15 fractions if needed LNI 15 fractions
2467647|NCT03120689|Active Comparator|Live Surgery with VITOM|Learner will not assist during the surgery, but watch the live surgery that is projected on a screen via the VITOM camera followed by a short questionnaire.
2467654|NCT03120689|Active Comparator|Live Surgery without VITOM|Learner will assist in the traditional manner without the use of the VITOM camera followed by a short questionnaire.
2467660|NCT03120689|Active Comparator|Video viewing with VITOM|Learner will watch a video taped using the VITOM camera followed by a short questionnaire.
2467664|NCT03120689|Active Comparator|Video viewing with standard camera|Learner will watch a video taped using the standard hand-held high definition camera followed by a short questionnaire.
2467700|NCT03119974|Other|Tpo-RA discontinuation|
2467782|NCT03119727|Other|Automated oxygen adjustment|All patient in this study have automatic oxygen titration and automatic oxygen weanning
2467837|NCT03119207|Experimental|Naptime Participants|The participants will undergo the Naptime Protocol. The study team will provide a 4 hour period nightly during which patient room activity, light levels and noise levels will be decreased. The team will monitor the changes in the number and quality of these disruptions and to monitor the changes in patient sleep and outcome following our intervention.
2467846|NCT03119207|No Intervention|Control Participants|Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored. Standard care will be provided. During the intervention period patients are randomized to either control or naptime.
2467855|NCT03119207|No Intervention|Baseline Participants|Prior to the intervention period, baseline patients under usual care are monitored. Naptime will not be enforced. Patient room activity, light levels and noise levels are monitored.
2467900|NCT03118856||HD-WLE|Intervention: Prediction of polyp histology with HD-WLE
2467901|NCT03118856||EC|Intervention: Prediction of polyp histology with EC
2467941|NCT03118401|Experimental|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
2467943|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
2468006|NCT03118141|Active Comparator|PGS group|Subjects in the PGS group will have blastocyst biopsy and sequencing done with 3 good-quality embryos on Day 5. Principle of freeze-all and single thawed blastocyst transfer will be applied. The transfer order of euploid embryos will be determined by blastocyst morphologic score. The outcome of all euploids transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2468007|NCT03118141|Active Comparator|IVF group|Subjects in the IVF group will also comply with the principle of freeze-all and single thawed blastocyst transfer. The order of transfer will be determined by blastocyst morphologic score. The outcome of up to 3 transfers within 1 year after randomization will be followed up. During study, every subject will have at most one live birth.
2468042|NCT03117673||group 1|Patients with mild to moderate TI and normal RVSP (< 40mmHg) and mean PAP (< 25mmHg)
2468046|NCT03117673||group 2|Patients with mild to moderate TI and elevated RVSP (> 40mmHg) and mean PAP (> 25mmHg)
2468051|NCT03117673||group 3|Patients with severe TI (defined as Vena contracta > or equal 7mm, reversed systolic hepatic vein flow, proximal isovelocity surface area (PISA) radius > 9 mm, and very large central jet or eccentric wall impinging jet)
2468084|NCT03117374|Experimental|Team Nutriathlon intervention|Participants were invited to participate in the Team Nutriathlon for an 8-week period
2468085|NCT03117374|No Intervention|Control|Participants were invited to follow the regular school curricular for an 8-week period
3174767|NCT00627003|Experimental|1|
2467428|NCT03122041|Experimental|SITA|Sitagliptin (SITA) Lifestyle intervention and sitagliptin 100mg per day for 12 weeks
2467434|NCT03122041|Experimental|CON|Controls (CON) Lifestyle intervention
2467499|NCT03121729|Experimental|enhanced recovery after surgery|"enhanced recovery after surgery includes:~Multimodal analgesia~Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet~Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early~Early activity~Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken"
2467618|NCT03120715|Placebo Comparator|NLMWH-A|non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
2467619|NCT03120715|Experimental|LMWH-B|low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
2467672|NCT03120260|Experimental|Short Sleep|Diet+ have 5 hour sleep at night (SS)
2467674|NCT03120260|Experimental|Normal Sleep|Diet+ have 7-8 hour sleep at night (NS)
2467721|NCT03119948|Placebo Comparator|Group 1|Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2467729|NCT03119948|Active Comparator|Group 2|Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2467731|NCT03119948|Active Comparator|Group 3|Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
2467755|NCT03119480||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
2467822|NCT03119272||Anorexia Nervosa Patients|Inpatient population at Eating Disorders Unit (EDU) at the University of North Carolina Neurosciences Hospital. Recruited upon intake into the unit.
2467827|NCT03119272||Age and Sex Matched Healthy Controls|University of North Carolina Psychiatry email listserv.
2467906|NCT03118895|Experimental|Treatment Arm|Patients with coronary artery disease at high risk of bleeding receiving the BioFreedom™ BA9™ drug-coated stent
2467975|NCT03118375||Cohort|Hearing and speech tests will be performed on the subject and repeated to compare results obtained using their current BAHA processor against results using super-power BAHA processor.
3156963|NCT00355524|Experimental|Group B with >= 30 kg to < 40 kg body weight|450 mg of TMC114 tablet with 60 mg (which is equivalent to 0.75 mL) of ritonavir liquid (80 mg/mL) will be administered orally twice daily.
2468176|NCT03116815|Other|Intervention|Intervention is the use of the MyChart web-application whereby participants record their home blood pressure readings directly into their electronic medical record. Their physicians are then alerted of these blood pressure readings.
2468236|NCT03116542|Experimental|Diagnostic (18F-FLT PET/CT)|"Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-L-thymidine) PET/CT (Positron Emission Tomography/Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. [18F] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) [18F] FLT by intravenous infusion."
3156964|NCT00355524|Experimental|Group B with >= 40 kg to < 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
3156965|NCT00355524|Experimental|Participants with >= 50 kg body weight|600 mg of TMC114 tablet with 100 mg of ritonavir capsule will be administered orally twice daily.
3156966|NCT00355537|Experimental|Active|
3156967|NCT00355537|Placebo Comparator|Placebo|
3156968|NCT00355550|Active Comparator|AC-1202|Tricaprilin formulation, once daily. Administered orally
3156969|NCT00355550|Placebo Comparator|Matching Placebo to AC-1202|Placebo formulation, once daily. Administered orally
3156970|NCT00355576|Experimental|Minocycline + Creatine|Minocycline 100 mg BID and Creatine 10 g BID
3156971|NCT00355576|Experimental|Celecoxib + Creatine|Celecoxib 400 mg BID and Creatine 10 g BID
3156972|NCT00355628|Experimental|1|KW-2246 (fentanyl citrate)
2468334|NCT03115645|Experimental|Intervention group|Participants in the intervention group will receive the Dynamic Working Intervention program, as described in the next section.
2468336|NCT03115645|No Intervention|Control group|Participants in the control group will not receive any intervention and will perform their work in the same manner as before.
3156973|NCT00355641|Experimental|Open Label|All subjects will receive ropinirole XR in this study. The total daily dose range of ropinirole XR will be 0.5mg to 6.0mg daily
3156974|NCT00355654|Experimental|Group 1|Participants will receive PEDIACEL with Prevenar at Visit 1 and ENGERIX-B Kinder at Visit 2
3156975|NCT00355654|Active Comparator|Group 2|Participants will receive Infanrix hexa with Prevenar at Visit 1
2467437|NCT03121911|No Intervention|Group 3 - Absence of rehabilitation|Group 3 (absence of rehabilitation) will be made up of those patients who for any reason do not agree to participate in the rehabilitation program, such as those who do not live in the city, and will remain without intervention. All participants in this group will perform all the evaluations procedures, comprised of: heart rate variability, hematological and biochemical profile, erythrocytes membrane deformability and stability, inflammatory markers, respiratory pressures, plethysmography, spirometry, carbon monoxide diffusion capacity, ankle brachial index, electrical bioimpedance, echocardiogram, quality of life questionnaires (SF-36 and MacNew QLMI), cardiopulmonary exercise testing and constant load tests.
2467505|NCT03121664|Experimental|Cohort 1|
2467562|NCT03121196||deprived women|Two groups of women will be compared deprived women and non-deprived women
2467563|NCT03121196||non-deprived women|Two groups of women will be compared deprived women and non-deprived women
2467602|NCT03120780|Active Comparator|Low Dose Fentanyl|Low dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 20 mcg fentanyl (Fentanyl 20 mcg)
2467603|NCT03120780|Experimental|High Dose Fentanyl|High dose epidural fentanyl combined with local anesthetic as 10mL of 0.125% bupivacaine with 100 mcg fentanyl (Fentanyl 100 mcg)
2467626|NCT03120403|Active Comparator|intrathecal morphine 2 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 2 μg/kg in 2 ml volume normal saline.
2467627|NCT03120403|Active Comparator|intrathecal morphine 5 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique. children will receive intrathecal morphine 5 μg/kg in 2 ml volume normal saline.
2467628|NCT03120403|Active Comparator|intrathecal morphine 10 μg/kg|After G A and securing the tube in place , the patients will be placed in the lateral decubtious position and a single dose of intrathecal morphine will be performed using a 25 gauge needle (Brown ®,Germany) and free flow of CSF technique.children will receive intrathecal morphine 10 μg/kg in 2 ml volume normal saline.
2467684|NCT03120208|Experimental|women in the nonexposed group without a hemorrhage|
2467685|NCT03120208|Experimental|women in the exposed group with a hemorrhage|
2467686|NCT03120208|Experimental|Partners|
2467718|NCT03119844|Experimental|Exercise and placebo phototherapy|Placebo phototherapy and Cycle ergometer exercise rehabilitation protocol
2467726|NCT03119844|Experimental|Exercise and active phototherapy|Active phototherapy and Cycle ergometer exercise rehabilitation protocol
2467743|NCT03119545|Experimental|Beardslee family centered intervention|This Group will have the family centered program.
2467744|NCT03119545|No Intervention|Comparison group|This Group will have standard care
2467798|NCT03119376|No Intervention|USUAL PEER REVIEWER|Two researchers will read all the peer-review reports and editors' comments for the first round. The researchers will determine whether the peer-reviewers and/or editors raised some concern on the completeness of reporting of the 10 CONSORT items considered and identified a switch primary outcome(s) between the manuscript and the register. The assessment of all peer-review reports and editors' comments for each manuscript will be combined (i.e., the item will be rated as incompletely reported if at least one peer reviewer rated it as such). The 2 researchers will be blinded to the gold standard assessment.
2467800|NCT03119376|Experimental|COBPeer|Junior peer reviewers will be invited to participate in an online training course on peer review (COBPeer).
2467801|NCT03119376|No Intervention|GOLD STANDARD|Pairs of systematic reviewers will independently extract data from eligible reports. Reviewers involved in the data extraction will have expertise in the conduct of systematic reviews and will assess the completeness of reporting from the systematic reviewer perspective. They will not have access to the tool to avoid being influenced by the tool. The systematic reviewers will also systematically compare the primary outcome(s) reported in the manuscript and the primary outcome(s) reported in the registry and will document any discrepancies.
2467825|NCT03119077|Experimental|BAY1161116|Dose steps 1 to 6 of BAY1161116 (increasing dose levels)
2467830|NCT03119077|Placebo Comparator|Placebo|Placebo Dose 1 to 6 of BAY 1161116
3208594|NCT00976287|Experimental|Interventional Therapy|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
2468124|NCT03117231|Experimental|Active tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
2468127|NCT03117231|Sham Comparator|Sham tDCS|Subjects will undergo low-intensity transcranial electrical stimulation for 20 minutes.
2468149|NCT03116945|Experimental|Drug; 68Gallium Citrate|Procedure: PET/CT Imaging
2468194|NCT03116633||Arm A|1st line setting-approx. 150 patients. collect tissue biopsy per standard of care & one blood draw (40ml)
2468197|NCT03116633||Arm B|1st line setting- approx. 100 patients one blood draw (40ml)
2468199|NCT03116633||Arm C|Approx. 10 patients tissue collection optional 3 blood draws (40ml) over 5 days
2468309|NCT03116009|Active Comparator|Screening for diabetes with 1-hour GCT and HbA1|Participants in this group will do 1-hour GCT before 20 weeks of gestation. Those with positive test will undergo 3-hours OGTT. Diabetes will be diagnosed if they have two or more abnormal values out of the 4 values and they will be treated accordingly based on the institutional protocol. They will also have HbA1C done.
2468310|NCT03116009|Experimental|Early screening with only HbA1C|Participants in this group will only have HbA1C done before 20 weeks but will do the standard diabetes screening at 24 - 28 weeks. Those who have abnormal values will also be treated based on the institutional protocol.
2468355|NCT03115606|Active Comparator|Videolaryngoscope|Patients intubated with C-Mac D Blade Videolaryngoscope
2468358|NCT03115606|Active Comparator|Fastrach LMA|Patients intubated with Fastrach LMA
2468512|NCT03114709|Experimental|Mindful Movement|8, 90-minute, in-person, group sessions over 8 weeks
2479495|NCT03039842|Experimental|5 mg MM|5mg memantine+valproate
2467480|NCT03121469|Experimental|Per-Operative Radiotherapy|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
3191705|NCT00801216|Experimental|High-dose sequential chemoimmunotherapy|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
3191706|NCT00801255|Experimental|Cohort A|
2467607|NCT03120429|Experimental|Fish group|subjects will have 3 x 150 g lean fish/ week at main meal
2467609|NCT03120429|Experimental|Control group|subjects will have no seafood.
2467648|NCT03120364|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2467653|NCT03120364|Active Comparator|Zostavax|Single dose 0.65mL of Zostavax by subcutaneous injection into the outer aspect of the upper arm
2467722|NCT03120026|Experimental|Experimental Product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
2467730|NCT03120026|Placebo Comparator|Isocaloric Placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
2467752|NCT03119493|Experimental|Periodized aerobic interval training|The experimental groups will participate in a 16 week, three times a week based-program of periodized aerobic interval training that consist in warming [5 minutes of general stretching and 5 minutes of walking on treadmill with heart rate less than 20 percent of heart rate reserve (HHR)], followed by periodized aerobic interval training on treadmill, and cooling down [5 minutes of walk in treadmill with a heart rate less than 20 percent of HRR and 5 minutes of rest]
2467760|NCT03119493|No Intervention|Control group|Participants in the control group will be instructed not to take part in any regular exercise programs during the study period.
2467920|NCT03118505|Experimental|Group 1|Infuse Bone Graft [4.2 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2467923|NCT03118505|Experimental|Group 2|Infuse Bone Graft [6 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2467926|NCT03118505|Experimental|Group 3|Infuse Bone Graft [12 mg per operative level] + Mastergraft Strip + local bone autograft + posterior fixation
2467927|NCT03118505|Active Comparator|Control|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation.
2468010|NCT03118102||anesthetist group|anesthetist doctor who subjected to noise in operating rooms
2468011|NCT03118102||control group|doctors in the same hospital who are not subjected to noise in operating rooms
2468020|NCT03117712||Delirium|patients who develop postoperative delirium after surgery with cardiopulmonary bypass measured by Delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
2468023|NCT03117712||No delirium|patients who develop no postoperative delirium after surgery with cardiopulmonary bypass measured by delirium scores (CAM-ICU, ICDSC), TCD for detection of HITS and carotis duplex sonography
2468077|NCT03117465|Experimental|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
2468080|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
2468133|NCT03117205|Experimental|Kinesio Taping® group|
2468135|NCT03117205|Placebo Comparator|placebo group|
2468142|NCT03116919|Other|Potato arm|One group will be fed an extra serving of boiled, baked or mashed potatoes daily for 1 week
2468143|NCT03116919|Other|Non-starchy vegetable|Then crossover to an extra serving of a non-starchy vegetable
2468186|NCT03116737|Experimental|Benzocaine Otic Solution|
2468189|NCT03116737|Placebo Comparator|Placebo|
2468228|NCT03116386|Other|run-in period|"In order to improve the precision of data, the run-in period is dedicated to sensitize the caregivers about the importance of~reporting all the falls occurring during the night~tracking in each resident's file, all informations about the estimate length of time spent on floor after a fall occurring during the night~and also reporting every other events occuring at night as wandering. All the beds will progressively equipped with the Etolya-F ® devices but the Etolya-F ® ddevices will stay off."
2468229|NCT03116386|Sham Comparator|control period|We expect 30 falls will occurr at night during this 6 months period. Etolya-F ® devices will be installed on the bed of all participant residents but with limited fonctionnalities i.e. only the length of absence in the bed will be recorded (difference between time of detection of the beginning of absence in the bed and time where the resident will be found by the caregivers out of his bed).
2468230|NCT03116386|Experimental|Etolya-F ® devices|We also expect 30 falls will occur at night during this 6-month period. Etolya-F ® devices will be used with all their functionalities i.e. permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
3191707|NCT00801255|Experimental|Cohort B|
2468521|NCT03114579|Other|Measure of the cardiac output obtained by a reference methode|
3191708|NCT00801255|Experimental|Cohort C|
2467513|NCT03121404||Cirrhosis Patient|Patients will be identified from the transplant list. Inclusion criteria will be all subjects with cirrhosis of any etiology who will undergo liver transplantation. . Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery. For the cirrhotic patients this includes hand grip test and dual energy x-ray absorption (DEXA).
2467515|NCT03121404||Healthy Controls|Controls will be identified from the abdominal surgery operating room lists at Cleveland Clinic. Rectus abdominis muscle biopsy will be obtained directly after induction of anesthesia for the procedure. In addition patients will have anthropometric measurements taken within 2 weeks of surgery which will not include DEXA or hand grip test.
2467584|NCT03121079|Experimental|Interferon alpha group|The patients in arm will be receive interferon alpha injection (3 million U/time)twice a week, as the intervention since the third month after HLA-identical transplantation.
2467630|NCT03120598|Active Comparator|ATTC strategy|Behavioral: Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
2467631|NCT03120598|Experimental|ISF strategy|Behavioral: Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change) and Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
2467708|NCT03119870|Experimental|1|Each subject will conduct 3 sessions, i.e. a training session, an anatomical MRI session and an EEG session. The first session will be to train the subject to carry out the different behavioral tasks that he will then have to perform during the session of EEG.
3191709|NCT00801255|Experimental|Cohort D|
3191710|NCT00801255|Experimental|Cohort E|
3191711|NCT00801255|Experimental|Cohort F|
3191712|NCT00801255|Experimental|Cohort G|
3191713|NCT00801268|Active Comparator|emodin|
3191714|NCT00801268|Experimental|Triptolide Woldifii|TW60mg/d
2467893|NCT03118609|Experimental|"Caregivers for Understanding Needs"|"5-8 informal caregiver participants in focus group will discuss current perceived needs.~Up to 150 participants will complete the Understanding Needs survey"
3191715|NCT00801281|Active Comparator|R-CVP|Standard arm 1. R-CVP - Rituximab, Cyclophosphamide, Vincristine, Prednisone 2
2468027|NCT03117842|Experimental|Intervention Group|Participants in the intervention group will receive the 3 text or voice messages weekly. The messages will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support.
2468030|NCT03117842|No Intervention|Control Group|"Those in the control group will get one check-in text or voice message between baseline and midline and another between midline and endline."
3191716|NCT00801281|Experimental|R-CHOP|Study arm 2. R-CHOP - Rituximab, Cyclophosphamide, Hydroxyldaunorubicine (doxorubicin), Oncovin (vincristine), Prednisone 1
3191717|NCT00801307|Experimental|1|He/O2 78:22
2468252|NCT03116503|Experimental|bipolar disorder and comorbid depression|number of diagnosis of bipolar disorder and comorbid depression of suicidal behaviors in the pediatric population.
2468317|NCT03116048|Other|Pecs group (study group)|Chronic pain assessment with study questionnaire
2468319|NCT03116048|Other|Control group (placebo group)|Chronic pain assessment with study questionnaire
2468432|NCT03115034|Active Comparator|CEA with melatonin|Patients under CEA with melatonin taken during perioperative period.
2468435|NCT03115034|Placebo Comparator|CEA with placebo|Patients under CEA with placebo taken during perioperative period.
2468439|NCT03115034|Sham Comparator|CEA with blank control|Patients under CEA with nothing unnecessary taken during perioperative period.
2468524|NCT03114644|Other|Babies born prematurely between 27 and 37 SA|
2468575|NCT03114202|Experimental|Intervention group|Intensive nutritional counseling: once they are admitted to the study and once a week during radiotherapy
2468576|NCT03114202|Other|Control group|Standard care: when there is demand, usually 1 to 2 times during radiotherapy
2468624|NCT03113760|Experimental|Tadekinig alfa|Patients that have completed the SAOL phase without a flare will receive Tadekinig alfa for addition 8 weeks.
2468625|NCT03113760|Placebo Comparator|0.9% sodium chloride|Patients that have completed the SAOL phase without a flare will receive placebo comparator for addition 8 weeks.
2468669|NCT03113383|Experimental|Primary Arm|Use of the thoracic bifurcation and the visceral manifold to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy.
2468675|NCT03113383|Experimental|Expanded Selection Arm|Patient that meets the criteria for inclusion in the primary study arm but has one or more of the inclusion criteria which would exclude them from the primary study arm.
2468720|NCT03113097|Active Comparator|Good-quality embryo transfer|Women who had only good-quality embryo transfer
2468728|NCT03113097|Active Comparator|good- and poor-quality embryo transfer|Women who had both good- and poor-quality embryo transfer
3191718|NCT00801307|Experimental|2|He/O2 65:35
3191719|NCT00801307|Active Comparator|3|Medical Air
3191720|NCT00801320|Experimental|Cohort 1|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF
3191721|NCT00801320|Experimental|Cohort 2|Patients with either primary ovarian carcinoma or ovarian carcinoma in first relapse treated with DC/Ovarian tumor cells + GM-CSF and topical Imiquimod at site of vaccination
3191722|NCT00801359|Active Comparator|BSSplus|
3191723|NCT00801359|Experimental|Ringer|
3191724|NCT00801372||Pre-existing Fibroblast MCB|Pre-existing fibroblast donors for hESC derivation project
3191725|NCT00801411|Experimental|Arm I|Patients receive cyclophosphamide IV and docetaxel IV over 1 hour on day 1.
3191726|NCT00801411|Active Comparator|Arm II|Patients receive cyclophosphamide IV and doxorubicin hydrochloride IV on day 1.
3191727|NCT00801424|Experimental|standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
2467537|NCT03121339|Active Comparator|Treatment B - Fed Condition|Radio-labeled VXA-A1.1 H1 Tablet Vaccine (small) and VXA-A1.1 H1 Tablet Vaccine (large) will be administered to subjects with a small snack.
2467596|NCT03120923|Experimental|Lidocaine 3 cc & Triamcinolone Acetonide|
2467598|NCT03120923|Active Comparator|Lidocaine 9cc & Triamcinolone Acetonide|
2467613|NCT03120442|Experimental|Propofol-fentanyl|Fentanyl 0.5 mcg/kg Propofol Target-controlled infusion to achieve MOAA/S 3-4 as end point of sedation Bispectral index (BIS) monitoring
2467614|NCT03120442|Experimental|Dexmedetomidine|Fentanyl 0.5 mcg/kg Dexmedetomidine in incremental titrated dose for moderate sedation to achieve MOAA/S 3-4 as end-point of titration Bispectral index (BIS) monitoring
2467615|NCT03120442|Experimental|Fentanyl|Fentanyl 0.5 mcg/kg Supplemental dosage of fentanyl for intraoperative anxiolysis
2467670|NCT03120286||Overweight and obesity|Women with BMI >25
2467673|NCT03120286||Normal weight group|Women with BMI =18-24
2467740|NCT03119987||UGIB|Those who was diagnosed as UGI bleeding at emergency department during the study periods. Red cell distribution widths wers checked at all patients.
2467759|NCT03119441|Experimental|Dental water jet|Dental water jet (Jetpik JP210)
2467766|NCT03119441|Active Comparator|Dental floss|Dental floss
2467850|NCT03119233|Experimental|Single-Arm|The PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
2467895|NCT03118544||Patients undergoing CTO PCI|Evaluates the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated CTO PCI. The system allows monitoring and display of contrast volumes that are manually injected during the procedure which will be compared to physician entered contrast usage thresholds during angiographic procedures.
2467921|NCT03118453|Experimental|Active implementation clinics|Patients recruited by physical therapists who underwent an implementation period with active implementations strategies, such as supervision, web lectures, peer learning in groups consisting of colleagues. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these active implementation strategies.
2467924|NCT03118453|Active Comparator|Passive implementation clinics|Patients recruited by physical therapists who underwent an implementation period with passive implementations strategies, such as written material and a short web lecture. A behavioral medicine approach in physical therapy for patients with musculoskeletal pain was encouraged with these passive implementation strategies
2467986|NCT03118167|Experimental|Tea polyphenols & Acrylamide|TP 0.05g, 0.1g, 0.2g (starches filled, up to 0.35g) capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2467987|NCT03118167|Experimental|AOB-w & Acrylamide|AOB-w 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2467988|NCT03118167|Active Comparator|Placebo & Acrylamide|Placebo (Starches) 0.35g capsule by mouth, Acrylamide (Potato Chips) 12.6μg/kg b.w. by mouth, for one single oral dose
2468013|NCT03117790|Experimental|Dexmedetomidine group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
2468014|NCT03117790|Placebo Comparator|Placebo group|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. Patient-controlled analgesia is provided during the first 3 days after surgery.
3174768|NCT00627003|Experimental|2|
2468293|NCT03116074|No Intervention|Study 1: Pre-intervention 1|"Usual care.~Patients/caregivers do not have access to patient portal. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
2468295|NCT03116074|Experimental|Study 1: Post-intervention|"Patient-Centered Discharge Toolkit: patient portal and provider safety dashboard PLUS patient pre-discharge checklist, provider discharge preparation indicator, secure patient-provider messaging~Patients/caregivers have access to patient portal with discharge module (pre-discharge preparation checklist) and secure patient-provider messaging tools activated. Providers have access to discharge preparation indicator on safety dashboard and secure patient-provider messaging tools."
2468297|NCT03116074|No Intervention|Study 1: Pre-intervention 2|"Usual care PLUS patient portal and provider safety dashboard.~Patients/caregivers have access to patient portal but not discharge module or secure patient-provider messaging tools. Providers have access to safety dashboard without discharge preparation indicator. Providers do not have access to secure patient-provider messaging tools."
2468298|NCT03116074|No Intervention|Study 2: Pre-intervention|"Usual care on three general medicine units.~Patients/caregivers do not have access to the discharge preparation checklist. Providers do not have access to the safety dashboard."
2468299|NCT03116074|Experimental|Study 2: Post-intervention|Patients/caregivers have access to the discharge preparation checklist. Providers have access to safety dashboard.
2468425|NCT03114917|Experimental|CARMS therapy + TAU|Participants allocated to the CARMS therapy + TAU arm will receive their usual care and treatment from mental health services along with CARMS (Cognitive AppRoaches to coMbatting Suicidality) therapy. The CARMS therapy comprises of 24 sessions, each up to 50 minutes long over a 6 month period.
2468431|NCT03114917|No Intervention|TAU|Participants allocated to treatment as usual (TAU) will receive their usual care and treatment from mental health services.
3174769|NCT00627029|Experimental|Intervention|Care coordination, consisting variously (depending on the demonstration site)--nurse telephonic counseling, nurse in-person home visits, home telemonitoring equipment, and physician education and feedback.
3174770|NCT00627029|No Intervention|Control|Usual care in Medicare fee-for-service from beneficiaries' physicians and other health care providers
3174771|NCT00627055|Experimental|1|LPV/r monotherapy
3174772|NCT00627055|Active Comparator|2|LPV/r + 2NRTIs (TDF/FTC or TDF/3TC)
3174773|NCT00627068||1|High cardiovascular risk age over 61 years.
3174774|NCT00627068||2|Low Cardiovascular risk age over 61.
3174775|NCT00627068||3|High cardiovascular risk age over 25 but under 61.
2467561|NCT03121222|Experimental|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption.
2467595|NCT03120819|Active Comparator|Oncologist Recommendation only|Medical providers in this study provide a standardized brief recommendation for exercise to a consenting patient during a clinical visit. Patients randomized to this arm receive a packet that contained a study information sheet and standard published exercise information materials. The standard materials consisted of publicly available exercise recommendations for cancer survivors from the American Cancer Society (ACS). The packet of exercise information intended to represent general information about exercise and cancer that would be readily available to patients through the internet, a medical clinic, or cancer support services.
2467599|NCT03120819|Experimental|Oncologist Recommendation + DVD|Participants in this arm receive the same oncologist's recommendation and written materials as the comparator group and also received an instructional yoga DVD. Inclusion of the video is intended to provide patients with a tool for following the oncologist's exercise recommendation. The instructional video contains a brief introduction from a breast cancer survivor, who was also featured in the exercise portion of the DVD, and safety information about lymphedema from a lymphedema therapist. The exercise program is a 30-minute, low intensity, restorative yoga program to improve whole body flexibility and to be safe for participants who were in active treatment for cancer and/or who had metastatic disease. Women are encouraged to use the DVD at least 3 times per week.
2467633|NCT03120481||Normal control|
2467706|NCT03120182|Active Comparator|Aspirin Arm|The patients will receive acetylsalicylic acid (100mg once a day, orally) for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
2467709|NCT03120182|Placebo Comparator|Placebo Arm|The patients will receive placebo oral tablets for 12 days whereas the normal ASA treatment will be resumed 12 days after randomization
2467741|NCT03119532|Experimental|Receive feedback email|Anesthesia care providers who receive monthly feedback emails on the participants specific quality measures
2467742|NCT03119532|No Intervention|Did not receive feedback email|Anesthesia care providers who did NOT receive monthly feedback emails on the participants specific quality measures
2467789|NCT03119402|Experimental|RRT + active tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of active tDCS (1.5 mA, 5x5cm anodal electrode on left parieto-temporal regions and 5x5cm cathodal electrode on right parieto-temporal regions).
2467792|NCT03119402|Sham Comparator|RRT + sham tDCS|Rhythmic Reading Training, administered for 5 hours over 10 days consecutive (30-minute training sessions per day) + simultaneous 20 minutes of sham tDCS (with the same active tDCS setup, current applied for 30 seconds,
3191728|NCT00801437||Xalacom treatment|patients with primary glaucoma
2467973|NCT03118349|Experimental|Escalation Cohorts|MVT-5873 blocking dose and MVT-1075 dose escalation Initial to maximum tolerated dose
2467976|NCT03118349|Experimental|Expansion Cohort|MVT-5873 blocking dose and MVT-1075 Maximum tolerated dose
2468021|NCT03117907||Infants with low infectious status|
2468024|NCT03117907||Infants with high infectious status|
2468069|NCT03117608|Experimental|AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT)|injection of aMAT obtained with Lipogems® technology.
2468070|NCT03117608|Active Comparator|platelet-rich plasma (PRP)|single injection of platelet-rich plasma
2468113|NCT03117244|Experimental|Exercise Group|
2468118|NCT03117244|Active Comparator|Exercise and NMES Group|
2468123|NCT03117244|No Intervention|Control Group|
2468145|NCT03116997|Experimental|Neuromuscular blockade reversed with neostigmine/gly|
2468147|NCT03116997|Active Comparator|Neuromuscular blockade reversed with sugammadex|
2468195|NCT03116711|Active Comparator|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
2468198|NCT03116711|Active Comparator|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
2468200|NCT03116711|Active Comparator|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 30% carbohydrate, 45% protein, 25% fat diet
2468203|NCT03116711|Active Comparator|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire (CIQ) plus 20% carbohydrate, 45% protein, 35% fat diet
2468284|NCT03116308|Experimental|50 mg OPC|Subjects received 50 mg OPC once-daily in the evening for 12 days. On D9 subjects were to receive 50 mg OPC in the evening after a minimum 6 hours fast. On D10 subjects were to receive the QD dose of 50 mg OPC thirty minutes after the start of moderate meal (with a previous 6 hours fast)
2468382|NCT03115619||Participants With IPF|Observational data of participants with IPF under treatment with pirfenidone will be collected from the medical records as a part of their routine clinical visits at 12-week interval until study completion or early withdrawal (up to Week 52).
2468438|NCT03115008|Experimental|Video-based terminal feedback|
2468440|NCT03115008|No Intervention|Conventional concurrent feedback|
2468508|NCT03114748|Experimental|EEG|2 scalp electroencephalographic (EEG) recording will be acquired in ON and OFF DBS conditions
2468509|NCT03114748|Experimental|DBS ON and OFF|DBS is turned ON and OFF in the 2 EEG sections
2468564|NCT03114306|Experimental|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee to achieve maximal distal block of nerve fibres. Infiltration is performed directly after knee replacement and during weaning of general anaesthesia.
2468566|NCT03114306|Active Comparator|Regional anaesthesia|Patients receive a combined anaesthesia with a regional-anaesthesiological catheter placed close to the distal Nervus saphenus and a single shot anaesthesia of Nervus ischiadicus using local anaesthetics (regional-anaesthesiological catheter analgesia).
2468585|NCT03113825|Experimental|AVB-620 & Investigational Imaging Device|Eligible subjects will receive a single dose of AVB-620 as intravenous infusion before the surgical procedure. During the surgical procedure, fluorescent imaging will be undertaken to distinguish between malignant and nonmalignant tissues.
2480950|NCT03030092|No Intervention|Control group|Today's standard care
2467652|NCT03120559|No Intervention|Control|"The dental consultation was the same for all the groups.~- Examination and diagnosis (15 min).~- Motivation, discussion about desired outcomes and treatment needs followed by instrumentation (scaling, polishing) (30 min).~- Therapeutic goals, therapeutic strategies, teaching skills (brushing and interproximal control with regular waxed floss at the Control group) and scheduling of the follow-up appointment (15 min).~They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback."
2467659|NCT03120559|Other|NFH - New Floss Holder|The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The consultation time was 60 minutes and also included specific behavior change techniques, such as reinforcement, goal-setting, and feedback. New Floss Holder - Gum Chucks
2467663|NCT03120559|Other|New Floss Holder and Short Messages|"The dental consultation was the same for all the groups. They were properly organized in accordance with the features of each patient, such as their gingival condition, gingivitis perception, habits and expectancies concerning the treatment. The Intervention time was 60 minutes and also included behavior change techniques, such as reinforcement, goal-setting, and feedback. Participants in the NFH/SMS group further received a total of 16 messages (SMS).~New Floss Holder - Gum Chucks/SMS"
3191729|NCT00801450|Experimental|Intravitreal (IVI)|
3191730|NCT00801450|Experimental|SubTenon´s (STI)|
3191731|NCT00801463|Experimental|Large pred|Prednisone 60mg/d*8 wks
3191732|NCT00801463|Experimental|small pred|Pred 30mg/d*8wks
3191733|NCT00801489|Experimental|Treatment (filgrastim, fludara, cytara, gemtuzu, idarubicin)|See Detailed Description
2467930|NCT03118622||Pentax group|Intubation using Pentax
2467931|NCT03118622||Macintosh group|Intubation using Macintosh
2467992|NCT03118180|Experimental|CART19 group|All patients were included for CART19 therapy
2468012|NCT03117829|Experimental|Improve Brain Blood Flow|12 week diet and exercise program to improve brain blood flow
2468088|NCT03117413|Other|Asymmetric hearing loss|Asymmetric hearing loss treated with a cochlear implant will undergo positron emission tomography scan.
2468092|NCT03117413|Other|Normal hearing subjects|Normal hearing subjects will undergo positron emission tomography scan.
2468162|NCT03117075|Experimental|Experimental|"using device for scoring pain scale, named ANAPA®"
2468192|NCT03116646|Experimental|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
2468255|NCT03116373|Active Comparator|maxilla fixing then mandible fixing|The tracheal tube is first fixed on the maxilla. After the measures of the outcomes, its site of fixation is changed for the mandible for the outcome measurement in the second site of fixation.
2468257|NCT03116373|Active Comparator|mandible fixing then maxilla fixing|The tracheal tube is first fixed on the mandible. After the measures of the outcomes, its site of fixation is changed for the maxilla for the outcome measurement in the second site of fixation.
2468392|NCT03115970||Trauma patients|All patients having / suspected to have severe trauma injuries
3191734|NCT00801502|Other|Control|No change in diet
3191735|NCT00801502|Active Comparator|Oily fish|Two portions of salmon per week from week 20 of pregnancy until giving birth
2468529|NCT03114384|Experimental|Healthy volunteers|
2468580|NCT03114215|Active Comparator|MD1003|The investigational drug will consist in capsules of 100 mg biotin and excipients (lactose, magnesium stearate, croscarmellose sodium, Silica) tid during 12 months
2468583|NCT03114215|Placebo Comparator|PLACEBO|This formulation consists in lactose powder and other excipients (magnesium stearate, croscarmellose sodium, Silica) as placebo, tid during 6 months and then switch to MD1003 tid during 6 additional months.
2468776|NCT03112551|Active Comparator|group 1|group one will be treated with 24 hours maintenance dose of magnesium sulphate
2468780|NCT03112551|Experimental|group 2|group 2 will be treated with 12 hours maintenance dose of magnesium sulphate
2468833|NCT03112408|Experimental|FORWARD (Axe 1)|
2468838|NCT03112408|Experimental|BACKWARD (Axe 1)|
2468843|NCT03112408|Experimental|CONTROL (Axe 1)|
2468848|NCT03112408|Experimental|ADAPTATION (Axe 2)|
2468856|NCT03112408|Experimental|CONTROL (Axe 2)|
2468896|NCT03111758|Active Comparator|Geko Device|Neuromuscular Stimulator
2468901|NCT03111758|Active Comparator|IPCS|Intermittent Pneumotic Compression Stocking
3191736|NCT00801528|Active Comparator|Ropivacaine|Continuous wound instillation of ropivacaine 0.2 % at a rate set of 10 mL/hr
3191737|NCT00801528|Active Comparator|Diclofenac|Continuous wound instillation of diclofenac (300 mg/240 ml water for injection) at a rate set of 10 mL/hr
3191738|NCT00801528|Placebo Comparator|Water for injection|Continuous wound instillation of water for injection at a rate set of 10 mL/hr
3191739|NCT00801541||AMD|Patients with wet AMD in one eye and dry AMD in the other eye (study eye).
3191740|NCT00801554||ASD|Children and adults with Autism Spectrum Disorders.
3191741|NCT00801554||Non-ASD|Healthy volunteers who have never been diagnosed with an Autism Spectrum Disorder in their lifetime.
3191742|NCT00801567|Experimental|1|All subjects will receive the intervention (MRS scan).
3191743|NCT00801580|Experimental|1|The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).
3191744|NCT00801593||Children with JIA|
2467713|NCT03120130|Experimental|Cohort 6|This cohort will include 3 patients with the sixth calculated dose of Amblyomin-X drug, the last dose calculated. The patient will receive the intravenous drug.
2467762|NCT03119519|Experimental|Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) followed by 3D-CRT (three-dimensional conformal radiotherapy) or IMRT (intensity modulated radiotherapy) to primary thoracic foci or remediable oligometastatic focus.
2467770|NCT03119519|Active Comparator|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
2467955|NCT03118219|Experimental|Positive adjustment coping intervention|All persons allocated to the intervention group will receive daily text messages (SMS) to their smartphones with sentences for positive adjustment over two weeks starting from the day of the egg-cell punctuation.
2467956|NCT03118219|Other|Brainteaser|All persons allocated to the comparison intervention group will receive daily text messages (SMS) to their smartphones with brainteasers over two weeks starting from the day of the egg-cell punctuation.
2467997|NCT03118037||Sonata|Women who undergo transcervical radiofrequency(RF) ablation with the Sonata System for treatment of their fibroids
2468041|NCT03117686||healthy volunteers|10 healthy volunteers climbing Mount Kilimanjaro receiving lung ultrasound
2468045|NCT03117686||patients after lung transplantation|10 patients > 2years after lung transplantation climbing Mount Kilimanjaro receiving lung ultrasound
2468075|NCT03117387||moderate neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
2468079|NCT03117387||deep neuromuscular block, normal body mass index|Patients with normal BMI (< 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
2468082|NCT03117387||moderate neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a moderate neuromuscular block (train of four 1-3 twitches)
2468083|NCT03117387||deep neuromuscular block, high body mass index|Patients with high BMI (> 30) who will receive a deep neuromuscular block (post tetanic count of 1-2 twitches)
2468148|NCT03117166|Experimental|Lidocaine|treatment arm
2468152|NCT03117166|Placebo Comparator|Saline|placebo arm
2468305|NCT03116022|Active Comparator|proximal estriol group (PEG )|This arm is composed of women using estriol 1 mg / 1g in the proximal third of vagina every other night
2468307|NCT03116022|Experimental|distal estriol group (DEG)|This arm is composed of women using estriol 1 mg / 1g in the distal third of the vagina every other night
2468308|NCT03116022|Placebo Comparator|Control group (CG)|This arm is composed of women using vaginal gel lubricant base water during intercourse
2468478|NCT03114839|Experimental|Dietary Supplement: Lactobacillus casei strain Shirota (LcS)|
2468523|NCT03114527|Experimental|Dedifferentiated Liposarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
2468525|NCT03114527|Experimental|Leiomyosarcoma Arm|Patients receive ribociclib orally at 300mg/day for 21 days of each 28 day cycle and everolimus 2.5mg orally on a continuous 28 day cycle.
3174776|NCT00627068||4|Low cardiovascular risk age over 25 under 61.
3174777|NCT00627081|Placebo Comparator|1|general anesthesia and thoracic epidural administration of saline
2468646|NCT03113396|Experimental|baclofen|Patients will receive baclofen (10mg t.i.d) for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is placebo (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
2468651|NCT03113396|Placebo Comparator|placebo|Patients will receive placebo for 2 weeks, thereafter they will be crossed over to the alternative treatment, which is baclofen (10mg t.i.d) (identically looking capsules). After 2 weeks of treatment, patients will undergo a High Resolution Impedance Manometry (HRiM) measurement, with meal. We will record for in total 2 hours. Patients are asked to fill out questionnaires concerning their overall wellbeing.
2468724|NCT03113162|Experimental|Autologous Hematopoietic Stem Cell with BEAM Regimen|Autologous HSCT following Reduced-Intensity BEAM Regimen
2468758|NCT03112616||Left-brain damaged chronic patients|
2468762|NCT03112616||Right-brain damaged chronic patients|
2468851|NCT03112447|Experimental|absorbable cartilage nail Group|10 males and 7 females, ages 7-15 years (average, 11.8), and 3 patients with elbow dislocation, the fractures were fixed by absorbable cartilage nail
2468858|NCT03112447|Active Comparator|traditional Kirschner wire Group|10 males and 5 females, ages 8-14 years (average, 12.6), and 4 patients with elbow dislocation, the fractures were fixed by traditional Kirschner wires
2468902|NCT03111953|Active Comparator|RYGB|Subjects received Roux-en-Y Gastric Bypass surgery.
2468910|NCT03111953|Experimental|BPD|Subjects received Biliopancreatic Diversion Surgery
2468945|NCT03111576||Normotensive|This group will include 50 pregnant women with normal blood pressure between 28 and 34 weeks.
2468947|NCT03111576||Pre-eclamptic|This group will include 50 pregnant women with diagnosis of pre-eclampsia between 28 and 34 weeks.
2468969|NCT03111277|Experimental|Experimental: ExAblate Transcranial treatment|The ExAblate Transcranial system will be used to destroy a small cluster of cells that may be causing the study participant's pain . The ExAblate uses ultrasound to heat a small spot in the brain. Ultrasound passes through the skin and skull and into the brain to focus on a spot the study investigator wants to treat.
2469032|NCT03111095|Experimental|Mobile Health Participants|Subjects will use the mobile health device to record their blood pressure and weight measurements everyday for 6 weeks postpartum.
2469033|NCT03111095|No Intervention|Standard of Care|This arm is a chart review done on hypertensive women who do not participate in using the mobile health device.
3174778|NCT00627081|Active Comparator|2|general anesthesia and thoracic epidural administration of chirocaine
3174779|NCT00627107|Experimental|A|A group of paraplegics.
3174780|NCT00627120|Experimental|1|1mg dose group
3174781|NCT00627120|Experimental|2|10mg dose group
3174782|NCT00627120|Experimental|3|100mg dose group
3174783|NCT00627120|Experimental|4|200mg dose group
3174784|NCT00627120|Experimental|5|400mg dose group
2467761|NCT03119766|Experimental|Kolofort|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
2467769|NCT03119766|Placebo Comparator|Placebo|Oral. Single dose: 2 tablets. Dose regimen: 2 tablets twice daily (4 tablets a day). Tablets should be held in the mouth until dissolution is complete; not to be taken concomitantly with food.
2467835|NCT03119051|Experimental|online cognitive training|Patients will receive 3-4 times of 20-30 minutes' training game every week
2467842|NCT03119051|No Intervention|no training|Patients will not undergo preoperative cognitive training.
2467849|NCT03119051|Experimental|Cognitive training and physical exercise|Patients will receive 3-4 times of 20-30 minutes' training game every week and 2 times of 60 minutes' Tai Chi Training
2467907|NCT03118713|Experimental|ipragliflozin and metformin|Subjects will receive daily dosage of ipragliflozin and metformin as single tablets
2467908|NCT03118713|Experimental|glimepiride and metformin|Subjects will receive daily dosage of glimepiride and metformin as single tablets
2467962|NCT03118154||Manual Physical Therapy, retrospective|Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
2467963|NCT03118154||Control, prospective|Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.
2467999|NCT03118011|Active Comparator|No smoking|The ward where the patients can not go out to smoke
2468002|NCT03118011|Placebo Comparator|Smoking|The ward where the patients can go out to smoke.
2468112|NCT03117725|Experimental|melatonin administration group|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. After randomization, participants are to under go melatonin administration intervention from the time of controlled ovarian hyperstimulation(COH) to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
2468115|NCT03117725|Placebo Comparator|placebo comparator|"Total 50 patients are to be randomized into this group, 25 of which are poor responder and the others are normal responders. Participants for placebo comparator are advised to take the drug (placebo) from the time of COH to the date of oocyte retrieval. If pregnancy is not confirmed in the first cycle, all subjects are to enter the second cycle after 1-2 months of recovery period.~For the second cycle, the procedure will be repeated same as the first cycle with doubling of the drug dosage . It should also be administered for 2 weeks until the date of oocyte retrieval."
2468171|NCT03116958|Active Comparator|Standard care|"Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit as per usual care.~Patients will be fitted with a mask and given a CPAP and instructed on how to use the device. Each CPAP machine will be provided with a modem sending daily compliance and adherence information to MyOSA web site but no intervention based on these data is planned in this group. All patients will be visited at 1,3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine. Information will be downloaded from their machines (CPAP adherence, applied CPAP pressure, mask leak, and residual respiratory events…)."
2468174|NCT03116958|Experimental|Telemedicine|"Patients diagnosed as OSA and treated with CPAP, followed up in sleep unit, adding a telemedicine integrated system.~Patients will be fitted with a mask , given a CPAP, and instructed on how to use the device. Using patients' baseline and initial follow-up data a software will provide a prediction of CPAP compliance at 6 months, and propose personalized interventions to increase compliance (smartphone app). All patients will be visited at 3 and 6 months at sleep unit. Patients will be checked about progress and adherence to therapy and any problems with their machine."
2468215|NCT03116529|Experimental|Treatment|Neoadjuvant Radiation plus Durvalumab and Tremelimumab Wide Surgical Resection Adjuvant Durvalumab
2468241|NCT03116243||MSHS children and families|"Cohort includes:~children (1272)~parents (1272)~teachers (159)~teaching assistants (159)~program and center directors (253)"
2468266|NCT03116126|Active Comparator|Guanfacine|
2468267|NCT03116126|Placebo Comparator|Placebo|
2468323|NCT03115879|Placebo Comparator|Placebo Group|Hip manipulation simulation
2468324|NCT03115879|Experimental|Manipulation Group|Hip manipulation
2468354|NCT03115372|Experimental|Group I (CRC education)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
2468356|NCT03115372|Active Comparator|Group II (CRC brochure)|LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
2468423|NCT03115047|Experimental|dexmedetomidine|"Unique dose of dexmedetomidine injection:~intravenous injection~0.35 mcg/kg~in two minutes~if shivering 5 minutes after delivery"
2468427|NCT03115047|Active Comparator|meperidine|"Unique dose of meperidine injection:~intravenous injection~0.35 mg/kg~in two minutes~if shivering 5 minutes after delivery"
2468494|NCT03114696|Experimental|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
2468495|NCT03114696|Placebo Comparator|Placebo|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
2468547|NCT03114371|Experimental|Oxytocin|Daily intranasal administrations of oxytocin for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be 8 International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
2468548|NCT03114371|Placebo Comparator|Placebo|Daily intranasal administrations of placebo for 12 weeks, followed by an open-label period of 12 weeks of oxytocin. Oxytocin dose will be International Unit for patients aged from 3 to 6 years and 16 International Unit for patients aged from 7 to 12 years.
3191745|NCT00801606|Experimental|Study drug containing zinc alone|Zinc 20 mg daily
2467763|NCT03119623|Active Comparator|Enalapril|Enalapril 5mg (Dose Level 1) titrated up if tolerated to 10mg twice daily (Dose Level 2)
2467838|NCT03119194|Experimental|Reguimen A - [14C]-BIA 9-1067|"100 mg [14C]-BIA 9-1067 Capsule containing not more than 3.3 MBq (89.2 µCi) 14C; will be administered with 240 mL water.~Single dose administration on a single occasion."
2467984|NCT03118427|Experimental|Zero-fluoroscopy implantation|Pacemaker implantation performed for all patients in this group with zero-fluoroscopy 3D navigation.
2467985|NCT03118427|Active Comparator|Conventional fluoroscopy implantation|Pacemaker implantation performed for all patients with conventional x-ray navigation.
2468087|NCT03117478|Other|1. Participants without meditation experience|Novices. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
2468090|NCT03117478|Other|2. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. Note that there is no meditation intervention in this study but that the two groups differ in their lifetime meditation experience.
2468097|NCT03117478|Other|3. Participants without meditation experience|Novices. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
2468100|NCT03117478|Other|4. Participant with a significant meditation experience|Experts : > 5000 hours of practice during their life. There is no meditation intervention during the study but the investigators investigate the effects of meditation by comparing 2 groups who differ in their life time meditation experience (i.e., novices vs. experts).
2468201|NCT03116763|Experimental|iPeer2Peer Mentorship|In addition to standard care, youth in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with JIA aged 18-22 years who have learned to function successfully with their disease). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
2468204|NCT03116763|Active Comparator|Control Group|The control group will receive standard care but without the iPeer2Peer program.
2468292|NCT03116282|Experimental|Intervention|Conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of therapy where participants are not required to show up at a clinic.
2468294|NCT03116282|No Intervention|Control|Treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic.
3191746|NCT00801606|Experimental|Study drug Micronutrient without zinc|micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc.
3191747|NCT00801606|Experimental|Study drug Micronutrient with zinc|micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc).
3191748|NCT00801606|Placebo Comparator|Placebo|Placebo only
2468540|NCT03114410|Experimental|Re:MIX|In the experimental arm, the Re:MIX curriculum was implemented. The Re:MIX curriculum is a comprehensive teen pregnancy prevention consisting of ten hour-long sessions, delivered approximately once per week. The Re:MIX curriculum is taught by a professional health educator, partnered with a young parent educator who is a young parent (aged 18-25).
2468541|NCT03114410|No Intervention|Comparison|"In the comparison arm, teachers were given the option of implementing the Healthy Youth, Healthy You curriculum (focusing on nutrition, mental health, and fitness) or proceed with business as usual (no curriculum)."
3191749|NCT00801619||Intervention|Receive decision support when reviewing bilirubin results in the clinical information systems/electronic health record
3191750|NCT00801619||Control|No decision support
2468622|NCT03113773|Experimental|Part A|Proleukin/Placebo in patients with stable ischaemic heart disease
2468623|NCT03113773|Experimental|Part B|Proleukin/Placebo in patients with cute coronary syndromes
2468652|NCT03113409|Experimental|Procedure 1|Procedure 1: 5-day induction with increasing doses of oral naltrexone. Participants will receive XR-NTX on day five together with buprenorphine, and will continue receiving buprenorphine for 4 weeks until they receive 2nd XR-NTX dose.
2468656|NCT03113409|Experimental|Procedure 2|Procedure 2: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. No buprenorphine will be given beyond day 10.
2468662|NCT03113409|Experimental|Procedure 3|Procedure 3: 10-day induction with buprenorphine administered daily and increasing daily doses of oral naltrexone beginning on day 2 . On day 10 participants will receive XR-NTX dose, and another one 4 weeks later. Buprenorphine will continue for 4 weeks until the 2nd XR-NTX dose.
3191751|NCT00801645|Experimental|Obese exercise|
3191752|NCT00801645|No Intervention|Obese Control|
2468800|NCT03112499|Active Comparator|PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who percutaneous nephrolithotomy (PCNL) will be conducted
2468801|NCT03112499|Active Comparator|mini-PCNL Group|Patients with renal calculi 10-30mm in maximal diameter in who mini- percutaneous nephrolithotomy (mini-PCNL) will be conducted
2468802|NCT03112499|Active Comparator|RIRS Group|Patients with renal calculi 10-30mm in maximal diameter in who retrograde intrarenal surgery (RIRS) will be conducted
2468815|NCT03112122|Active Comparator|core decompression technique|The standard surgical technique is the subchondral anterograde drilling, which permit a revascularization of the Bone Marrow Edema (BME) and a reduction of the intramedullary pressure (core decompression).
2468832|NCT03112356|Experimental|99mTc-Leukoscan® scintigraphy|Patients presenting a suspicions of infectious endocarditis on surgical materials and undergoing the 99mTc-Leukoscan® scintigraphy
3191753|NCT00801645|Experimental|Lean Exercise|
3191754|NCT00801645|No Intervention|Lean Control|
3191755|NCT00801671|Active Comparator|1|
3191756|NCT00801671|Sham Comparator|2|
3191757|NCT00801697|Experimental|1A|rAD5-naive participants will receive rAd35 intramuscularly at study entry and rAd5 intramuscularly at Month 6
3191758|NCT00801697|Placebo Comparator|1B|Participants will receive rAd35 placebo intramuscularly at study entry and rAd5 placebo intramuscularly at Month 6
2467764|NCT03119792|Active Comparator|Control|The control group will consist of 600 children from the original cohort (300) and comparable cohort (300). The control group will meet twice a month for four months at community centers. During these sessions, investigators will teach a curriculum that is not related to knowledge, attitudes, and habits towards healthy lifestyles.
2467848|NCT03119220|Other|Low informational support|After the first week, informational support will be manipulated by providing one group with information in the form of physical activity monitoring only.
2467856|NCT03119220|Other|high informational support|The second group will additionally receive individualized information on how to change behavior by providing maps of a participant's neighborhood with distances depicted in steps, lists with age- and health-status appropriate suggestions as to how to increase numbers of steps, as well as medical information linking changes in physical activity to change in health outcomes; and information on health effects of behavior change by monitoring changes in sleep in conjunction with physical activity changes.
2467883|NCT03118804||Weaning Guide by EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT
3174785|NCT00627120|Experimental|6|800mg dose group
2467966|NCT03118206|Active Comparator|Lumbar spinal manipulation|Lumbar spinal manipulation will be performed up to 8 times within 1 month (no more than 2 times per week) by Dr. WangTso-Liang, who is a well-trained and experienced manual therapy doctor. If the symptoms subside before the end of 1 month' treatment, the manipulation is discontinued.
2467967|NCT03118206|Active Comparator|Physical therapy|Physical therapy will include treatment with therapeutic exercise and modalities (lumbar traction, heattherapy, electric stimulation, and therapeutic exercise) for 2 month with frequency 3 times per week.
2467970|NCT03118206|Active Comparator|Surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
2468033|NCT03117946|Experimental|Biological samples|"Blood samples will be collected at baseline, at J15/J20 after RTCT initiation, and then 1 month, 3 months and 12 months after the end of RTCT treatment, and at disease progression if applicable.~Tumor tissues will be collected if available."
2468109|NCT03117439|No Intervention|Control Group|Patients undergoing empirical anti fungal therapy. Interruption of anti fungal treatment will be decided on the basis of standard clinically and microbiologically criteria.
2468110|NCT03117439|Experimental|1-3 Beta-D-Glucan Group|Patients undergoing anti fungal de-escalation according to 1-3 Beta-D-Glucan results
2468158|NCT03117062|Experimental|Occlusal Reduction|performing occlusal reduction on functional cusps until abscence of contact was confirmed
2468159|NCT03117062|No Intervention|non-occlusal reduction|occlusal surface left intact
2468357|NCT03115840||Adults (≥18 years old) with critical illness|
2468403|NCT03115268|Experimental|Immediate|Participants allocated to the immediate arm will receive 6 months of Social support groups delivered in EVA Park immediately after randomisation. They will be re-assessed in Month 7, then receive 6 months of usual care, followed by reassessment in month 14.
2468404|NCT03115268|Active Comparator|Wait list control|Participants allocated to the wait list control arm will receive 6 months of usual care after randomisation. They will be re-assessed in month 7, and will then receive 6 months of social support groups delivered in EVA Park, with reassessment in month 14.
2468433|NCT03114943|Experimental|NBP608|Single dose 0.5mL of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468434|NCT03114943|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468526|NCT03114722|Active Comparator|heparin 10U/ml|Heparinised saline (10U/ml) lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
2468535|NCT03114722|Experimental|citrate 4%|4% citrate lock in between each catheter use (with standard twice weekly normal saline flushing if catheter not being used)
2468560|NCT03114098|Experimental|CYP2D6 gene abnormalities|"A salivary sample (2 ml sample) which will allow the investigation of an anomaly of the metabolism of psychotropic drug.~Blood sampling will be performed to assess treatment tolerance (6 ml). A sample (4 ml) will be kept for possible future analyzes in relation to the objectives of this study for the recruiting center of Nice.~Electrocardiogram~Clinical exam~Clinical Global Impression Scale (CGI-S)~Children's Global Assessment Scale (CGAS)~Sheehan Disability Scale (SDS)~Wechsler Preschool and Primary Scale of Intelligence III (WPPSI-III )~Wechsler Intelligence Scale for Children - 4 (WISC-4)~Wechsler Adult Intelligence Scale 4 (WAIS 4)~Diagnostic and Statistical Manual of Mental Disorders (DSM)~Autism Diagnostic Interview (ADI)"
2468586|NCT03113877||Clinical Testing for Autonomic Dysfunction|COMPASS-31 Survey completion. Autonomic Reflex Screen. Thermoregulatory Swear Test.
3174786|NCT00627133|Experimental|1|
3174787|NCT00627146|Placebo Comparator|B|
3174788|NCT00627146|Active Comparator|A|ChAgly CD3
3174789|NCT00627159|Other|1|high risk
3174790|NCT00627159|Other|2|low to moderate risk
3174791|NCT00627185|Experimental|1|Intervention group (dental practices) that received the interactive motivational website for patient tobacco cessation
3174792|NCT00627185|Placebo Comparator|2|Control group (dental practices) that did not receive any materials or resources on tobacco cessation. This is a wait-list control.
3174793|NCT00627211|No Intervention|Room air insufflation|Air used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is current standard procedure, i.e. no experimental intervention.
2467785|NCT03119636|Experimental|HLA-non-matched NPC transplantation|The patients will receive Levodopa combined with a HLA-non-matched neural precursor cell (NPC) transplantation
2467824|NCT03119116||Stroke Prevention with Rivaroxaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Rivaroxaban during the study period
2467826|NCT03119116||Stroke Prevention with Dabigatran in NVAF Patients|All NVAF patients above 18 years for age prescribed with Dabigatran during the study period
2467831|NCT03119116||Stroke Prevention with Apixaban in NVAF Patients|All NVAF patients above 18 years for age prescribed with Apixaban during the study period
2467882|NCT03118752|Experimental|Collaborative Care|Participants randomized to collaborative care (CC) will receive a 26-week, telephone based CC intervention. Care managers will monitor participants' psychiatric symptoms, review current treatments for their psychiatric and cardiac illnesses, deliver psychotherapeutic interventions, provide education about self-monitoring for cardiac symptoms, perform motivational interviewing to encourage health behavior adherence, and coordinate care between psychiatric/cardiac specialists and participants' primary care physicians. CC will utilize a treat-to-target approach, with a goal of remission of psychiatric and cardiac symptoms.
2467886|NCT03118752|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care (eUC) arm will not receive any specific intervention, though they will be free to receive any treatment for psychiatric or cardiac illness. Participants' outpatient providers will be informed of their psychiatric diagnosis, which may lead to higher-than-usual treatment for psychiatric illness.
2467903|NCT03118492|Experimental|Treatment (combination chemotherapy, TBI, HCT)|Patients receive melphalan IV over 30 minutes on day -5, fludarabine IV over 30-60 minutes on days -5 to -2. Patients undergo TBI on day -1 and HCT on day 0. Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Starting on day 5, patients receive tacrolimus IV then PO for 6 months followed by a taper, mycophenolate mofetil PO TID until day 35, and G-CSF IV daily until absolute neutrophil count > 1,500/mm^3 for 3 consecutive days. Treatment continues in the absence of disease progression or unexpected toxicity.
2468015|NCT03117764|Active Comparator|Acute IV AB for exacerbation at hospital|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
2468018|NCT03117764|Experimental|Acute IV AB for exacerbation at home|"The study will compare muscular strength of hospitalised patients who receive specific exercise training, with patients who follow their antibiotherapy at home without specific exercise training.~Interventions: microfet dynamometer, 1 minute sit to stand test, accelerometer."
2468086|NCT03117556|Experimental|BTS Intervention|Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
2468089|NCT03117556|No Intervention|No BTS Intervention|Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
2468163|NCT03117101|Experimental|Dose escalation/ Dose extension of Lucitanib|"Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.~Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity."
2468193|NCT03116607|No Intervention|Control|The control group will receive the usual hospital care. In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.
2468196|NCT03116607|Experimental|Intervened|"The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge.~In addition, an interview that allows the characterization of the sample and the measurement of variables such as adherence, problems related to medication and user satisfaction.~patient education/ recommendations to the health team"
2468268|NCT03116360|Experimental|Single Arm|All patients will undergo traditional xray screening as well as experimental screening with diagnostic ultrasound. All subjects will undergo confirmatory MRI.
2468321|NCT03115918|Active Comparator|Pancreatic Duct Stent Placement|Subject will have placement of either the Advanix or Cook Pancreatic Stent placed.
2468322|NCT03115918|Active Comparator|No Pancreatic Duct Stent Placement|Subject will not have a pancreatic Duct stent placed.
2468360|NCT03115489|Placebo Comparator|Traditional Treatment (Group T)|Group T patients will be placed into burst suppression with the traditional drug infusions which include any single or combination of drugs; usually benzodiazepines, barbiturates and or propofol.
2468362|NCT03115489|Active Comparator|Ketamine Infusion (Group K)|Patients in the group K arm will receive a loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached. After 48 hours of burst suppression the ketamine dosage will be reduced by 2mg/kg/hr in a stepwise fashion to evaluated for EEG or clinical evidence of seizure recurrence.
2468413|NCT03115216|Active Comparator|FLA-CEIOL|Femtosecond laser assisted cataract extraction and intraocular lens placement
2468414|NCT03115216|Active Comparator|CEIOL|Clear corneal incision with manual cataract extraction and intraocular lens placement
2468466|NCT03114813||Clinically indicated primary prophylaxis|"Approach all those who have had a portal pressure measurement (HVPG) as part of their routine clinical care.~At baseline participants will consent to have an additional MRI scan before undergoing clinical screening Endoscopy.~All participants found to have oesophgeal varices that require primary prophylaxis, will be started on Carvedilol 6.25mg.~After 1 week, participants will return for dose optimisation~After 4-12 weeks of treatment, participants will have:~repeat one hour MRI scan~repeat HVPG to evaluate treatment response"
2468545|NCT03114293|No Intervention|Waiting group|Waiting group
2468549|NCT03114293|Experimental|Smartphone intervention|Smartphone bases behavioural intervention
2468584|NCT03114046|Experimental|Baseline Phase|This project will conduct a single-subject pre-experimental AB mixed methods design, considering A phase as the baseline strand. During this phase multiple assessments will be administered. This phase will last 2 consecutive weeks, with 5 visits total.
2469027|NCT03111134|No Intervention|Routine Abdominal Closure|
3191759|NCT00801697|Experimental|2A|rAD5-naive participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd5 intramuscularly at Month 6
3191760|NCT00801697|Placebo Comparator|2B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd5 placebo intramuscularly at Month 6
3191761|NCT00801697|Experimental|3A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
3191762|NCT00801697|Placebo Comparator|3B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
3191763|NCT00801697|Experimental|4A|Participants will receive DNA vaccine intramuscularly at study entry and Months 1 and 2 and rAd35 intramuscularly at Month 6
2467961|NCT03118232|Active Comparator|Decolonization|Nursing homes assigned to this arm will perform decolonization using topical antiseptic products.
2467964|NCT03118232|No Intervention|Routine Bathing|Routine bathing per facility protocol.
2468067|NCT03117595|Active Comparator|BF|Interventions: Intrathecal administration -Bupivacaine 2.5mg (0.5ml) + Fentanyl 25mcg (0.5ml) + 1ml sterile water in one shot Ephedrine 3-5mg in aliquots in the event of hypotension Promethazine 12.5 - 25mg in the event of vomiting or significant pruritus naloxone 2mcg/kg in the event of respiratory distress
2468068|NCT03117595|Active Comparator|BFM|Interventions: Intrathecal administration - Bupivacaine 2.5mg (0.5ml) + fentanyl 25mcg (0.5ml) + 0.25mg morphine (0.25ml) + 0.75ml sterile water in one shot ephedrine 3-5mg in aliquots for hypotension Promethazine 12.5 - 25mg for vomiting or significant pruritus Naloxone 2mcg/kg in the event of respiratory distress
2468125|NCT03117257|Experimental|the treatment group|docetaxel plus lobaplatin induction chemotherapy combined with lopoplatin chemoradiotherapy
2468129|NCT03117257|Active Comparator|the control group|TPF induction chemotherapy combined with cisplatin chemoradiotherapy
2468144|NCT03116906|Experimental|BI 685509|multiple rising doses of BI 685509
2468146|NCT03116906|Placebo Comparator|Placebo|matching placebo
2468269|NCT03116321|Experimental|Test 1 - TBM (Treatment A - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
2468270|NCT03116321|Experimental|Test 2 - TBM (Treatment B - 2 × 200 mg tablet)|"single oral dose of 800 mg (4 × 200 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
2468271|NCT03116321|Active Comparator|Reference Product - MF (Treatment C - 1 × 800 mg tablet)|"single oral dose of 800 mg (1 × 800 mg tablet) of Eslicarbazepine acetate (ESL) as tablets, on each of three separate occasions, under fasting conditions.~Route of administration:Oral."
3191764|NCT00801697|Placebo Comparator|4B|Participants will receive DNA vaccine placebo intramuscularly at study entry and Months 1 and 2 and rAd35 placebo intramuscularly at Month 6
3191765|NCT00801710|Experimental|BridgePoint Medial System|
2468419|NCT03114865|Experimental|Post-alloHSCT Maintenance|Blinatumomab will be administered as a continuous intravenous (IV) infusion over four weeks followed by a two-week treatment free interval. It is recommended that patients are hospitalized at least during the first three days of the first cycle and the first two days of the second cycles.
2468501|NCT03114670|Experimental|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|Patients will receive a full dose CART infusion at day 0.
2468600|NCT03113981|Experimental|ACTISURF-CERAFIT|Total hip arthroplasty (CERAFIT) grafted by PolyNass
2468607|NCT03113981|Active Comparator|CERAFIT|Total hip arthroplasty (CERAFIT) with HydroxyApatite (HA) no grafted by PolyNass
2468635|NCT03113591|Experimental|Osteo introducer group|undergo minimal invasive total hip arthroplasty surgery
2468636|NCT03113591|Active Comparator|Control group|undergo common total hip arthroplasty surgery
2468690|NCT03113279||Obese older individuals|Obese older individuals
2468692|NCT03113279||Lean older individuals|Lean older individuals
2468693|NCT03113279||Young lean individuals|Young lean individuals
2468803|NCT03112876||Young Age - Healthy|These subjects are between the age of 12 and 35 years. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2468804|NCT03112876||Old Age -Healthy|These subjects are 55 years of age and older. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2468806|NCT03112876||Active Smoker|These subjects are active smokers who smoke often. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2468808|NCT03112876||Dermatological skin condition: Acne vulgaris|These subjects have acne vulgaris. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2468810|NCT03112876||Dermatological skin condition: Atopic dermatitis|These subjects have atopic dermatitis. This group will undergo the following intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
2468865|NCT03112109||Intervention Group|Patients receiving 'new care'
2468867|NCT03112109||Control group|Patients receiving 'old / usual care'
2468903|NCT03111771||Group K +|Group K +: cancer of the upper aerodigestive tract with or without cachexia
2468909|NCT03111771||Group K-|Group K-: absence of cancer and absence of cachexia
2468912|NCT03111771||Control group|The MYOMEC study includes the inclusion of healthy patients (to form a control group
2469011|NCT03111446|Active Comparator|Spinal Anesthesia|Spinal anesthesia will be used to anesthetize patients in this group for caesarian section
2469015|NCT03111446|Active Comparator|General Anesthesia|Standardized General Anesthesia will be used to anesthetize patients in this group for caesarian section
3191766|NCT00801736|Experimental|Platinum Arm|Cisplatin (IMP) / Pemetrexed (IMP)
3191767|NCT00801736|Experimental|Non Platinum Arm|Paclitaxel (IMP) / Pemetrexed (IMP)
3191768|NCT00801788|Experimental|Egalet® oxycodone Treatment A|Single Dose Administration
2467860|NCT03118973|Experimental|Goff|For patients in whom biliary cannulation is difficult to achieve, Goff trans-pancreatic septotomy will be performed to facilitate biliary cannulation.
2467862|NCT03118973|Experimental|Double wire|For patients in whom biliary cannulation is difficult to achieve, double wire technique will be used to facilitate biliary cannulation.
2467905|NCT03118674|Experimental|Harvoni|1 tablet per day, oral, taken with or without food. 8 weeks for patients without cirrhosis, not previously treated with HCV GT1 and HCV rNA < 6 million IU/mL; 12 weeks for patients without cirrhosis; 24 weeks for patients with compensated cirrhosis
2467969|NCT03118336|Placebo Comparator|placebo group|
2467971|NCT03118336|Experimental|empaglifozine group|
2468050|NCT03117998|Experimental|REMD-477 Treatment A|Administered as a repeated subcutaneous (SC) doses in subjects with Type 1 Diabetes
2468052|NCT03117998|Experimental|REMD-477 Treatment B|Administered as a repeated SC doses in subjects with Type 1 Diabetes
2468054|NCT03117998|Placebo Comparator|Matching placebo|Administered as a repeated SC doses in subjects with Type 1 Diabetes
2468072|NCT03117335|Active Comparator|Vinorelbine plus Cisplatin With placebos|The control group
2468074|NCT03117335|Experimental|Vinorelbine plus Cisplatin With Sulijia|The treatment group
3191769|NCT00801788|Experimental|Egalet® oxycodone Treatment B|Single Dose Administration
2468286|NCT03116165|Experimental|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
2468289|NCT03116165|Placebo Comparator|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
2468350|NCT03115775|Active Comparator|Conjugated linoleic acid (Tonalin)|Conjugated linoleic acid (4000 mg Tonalin FFA 80 per day)
2468351|NCT03115775|Active Comparator|Vitamin D|Vitamin D3 (2000 IU per day)
2468352|NCT03115775|Active Comparator|Conjugated linoleic acid and Vitamin D|Conjugated linoleic acid (4000 mg Tonalin FFA 80) and Vitamin D (2000 IU) per day
2468353|NCT03115775|Placebo Comparator|Placebo|Corn oil (4000 mg per day)
3191770|NCT00801788|Experimental|Egalet® oxycodone Treatment C|Single Dose Administration
3191771|NCT00801788|Active Comparator|Active comparator|Single Dose Administration
3191772|NCT00801814|Placebo Comparator|1|White Bread
3191773|NCT00801814|Placebo Comparator|2|White Bread and Margarine Control
3191774|NCT00801814|Placebo Comparator|3|Glucose drink control
3191775|NCT00801814|Experimental|4|"White bread and margarine~or~Glucose drink"
3191776|NCT00801814|Experimental|5|"White bread and margarine~or~Glucose drink"
3191777|NCT00801814|Experimental|6|"White bread and margarine~or~Glucose drink"
3191778|NCT00801853|Experimental|Aerovant 1|Aerovant 1mg bid
2468679|NCT03113344||Children with the usage of anti-infective drugs|
2468736|NCT03112915|Active Comparator|QLB: Quadratus lumborum block|"QLB: Quadratus lumborum block :Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.25 %"
2468738|NCT03112915|Active Comparator|TAP: transversus abdominis plan block|"TAP: Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.25%"
2468812|NCT03112304|Experimental|MATCH-ADTC Wave 1|Wave 1 clinicians received MATCH training at the beginning of the project and used MATCH to treat participating children from their clinic for two years, with weekly case consultation from MATCH experts who were part of the study team, and then received consultation from their own clinic supervisors who had been trained as MATCH Associate Consultants (ACs), supported by the TRAC system.
2468813|NCT03112304|Experimental|MATCH-ADTC Wave 2|Wave 2 clinicians provided treatment as usual (e.g., usual care) with the children they treated during the initial two years of the project. Afterwards, they trained in MATCH and used it to treat children in their clinics with weekly case consultation from our study team of MATCH experts, supported by the TRAC system.
2468913|NCT03112083|Active Comparator|Krill oil|Krill powder capsules, 4 g
2468914|NCT03112083|Placebo Comparator|Placebo|Placebo capsules, maize strach, 4 g
2469321|NCT03109132|Active Comparator|Model 5|Device - Experimental sample line Model 5
3191779|NCT00801853|Experimental|Aerovant 2|Aerovant 3mg bid
3191780|NCT00801853|Experimental|Aerovant 3|Aerovant 10mg bid
3191781|NCT00801853|Placebo Comparator|Placebo Control|Placebo Control
3191782|NCT00801866|Experimental|Group 1|Panretinal Photocoagulation + Bevacizumab
3191783|NCT00801866|Experimental|Group 2|Panretinal Photocoagulation
3191784|NCT00801879|Active Comparator|Mupirocin ointment|0.25g mupirocin calcium ointment, 2% in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
3191785|NCT00801879|Placebo Comparator|Placebo ointment|0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
3191786|NCT00801905|Active Comparator|1: Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
3191787|NCT00801905|Placebo Comparator|2: placebo|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
3191788|NCT00801918|Other|DD Alone|Patients will get Denileukin Diftitox for 5 days every 3 weeks for a total of 4 cycles.
2467867|NCT03119324|Placebo Comparator|B-Cure® diode laser sham device|"Thirty patients that follows the same protocol of the SG but receive a B-Cure laser® sham device, seemingly identical to the effective one but devoid of main diode source.~The laser must be placed directly over the painful area, after having cleaned it with a soft cotton socket to remove skin impurities that could interfere with therapeutic light absorption.~The first application is performed at the Department of Oral Sciences of Sapienza University of Rome by a laser expert investigator and serves as instruction. The remnants must be performed by the patients themselves at home, once on the first day and twice a day in the following 6 days.~Patients were instructed to perform the applications always at the same time."
2467868|NCT03119324|Active Comparator|Nimesulide Ratiopharm® and Flexiban®|"Thirty patients follows the conventional drug therapy protocol, of two non-consecutive cycles of 5 days of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® (100 mg a day), interspersed with one 5 days cycle of Myorelaxant, Flexiban® (10 mg a day).~From day 1 to 5, patients assumed 50mg of Nimesulide Ratiopharm®, twice a day; from 6th to 10th day they assumed 10mg of Flexiban® in single dose, from day 11 to 15 they assumed 50mg of Nimesulide Ratiopharm® twice a day.~Patients were instructed to assume the therapy always at the same time"
3191789|NCT00801918|Experimental|DD with ICE Chemotherapy|For patients who show a response to DD alone after 4 cycles or for patients who show progressive disease after 2 cycles, DD will be given with ICE chemotherapy for 2 cycles.
2467957|NCT03118193|Experimental|Depressive patient|olfactive tests ; blood test ; optional: Tissue Pulsatility imaging ; optional: Collection of faeces
2468031|NCT03118024|Active Comparator|Fluid restriction|Crystalloid fluid max. 2.0 ml/kg/h, no administration of colloids, noradrenaline max. 0.15 µg/kg/min
2468037|NCT03118024|Active Comparator|Catecholamine restriction|Noradrenaline max. 0.04 µg/kg/min, fluids max. 8.0 ml/kg/h
2468094|NCT03117491|Active Comparator|GGNB injection technique|In GGNB group, every patient received two1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
2468102|NCT03117491|Active Comparator|IANB injection technique|In IANB group, every patient received two 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique
2468105|NCT03117491|Active Comparator|GGNB + IANB injection technique|In IANB + GGNB group, every patient received one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the IANB technique and one 1.8-mL cartridges of 2% lidocaine with 1:80,000 epinephrine using the GGNB technique
2468153|NCT03117023|Experimental|dexmedetomidine group|sufentanil + dexmedetomidine
2468156|NCT03117023|No Intervention|control group|sufentanil + saline
2468181|NCT03116724|Experimental|CVC catheterization through Rt. IJV|"The depth of central venous catheter during central venous catheterization through Rt. IJV will be decided by using real-time TEE.~The position of tip of CVC will be guided by TEE to fit the tip at 2 cm away from the junction between right atrium and superior vena cava."
2468217|NCT03116490||group RA|the anesthesia type for patients with hip fracture surgery is regional anesthesia
2468219|NCT03116490||group GA|the anesthesia type for patients with hip fracture surgery is general anesthesia
2468246|NCT03116204||Patients hospitalized in a FRC department|
2468311|NCT03115996|Experimental|REGN3918 (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918
2468312|NCT03115996|Experimental|Placebo (Cohorts 1-4 & 6a)|Cohorts 1-4 and 6a will receive placebo
2468313|NCT03115996|Experimental|REGN3918 (Cohort 5 & 6b)|Cohort 5 and 6b will receive multiple doses of REGN3918
2468314|NCT03115996|Experimental|Placebo (Cohort 5 & 6b)|Cohort 5 and 6b will receive placebo
2468389|NCT03115593|Experimental|postmenopausal patients with metrorrhagia|"Postmenopausal patients with metrorrhagia and endometrial hypertrophy defined by an endometrium ticker than 3 mm (ultrasound result).~The threshold choice of 3 mm was chosen according to a recent review of the literature to limit the risk of false negatives for cancer."
2468421|NCT03115060|Experimental|normal saline|Intravenous fluid used in these patients would be normal saline which would be given intravenously during intraoperative and postoperative period
2468429|NCT03115060|Experimental|ringer lactate|Intravenous fluid used in these patients would be ringer lactate which would be given intravenously during intraoperative and postoperative period
2468436|NCT03115060|Experimental|plasmalyte A|Intravenous fluid used in this arm in patients would be plasmalyte A which would be given intravenously during intraoperative and postoperative period
2468598|NCT03113968|Active Comparator|electroconvulsive therapy (ECT)|Treatments will be given 3 times a week up to a total of 9 treatments over 3 - 5 weeks. Initial ECT treatment is Right Unilateral (RUL) ultra-brief pulse at 6X seizure threshold. Seizure threshold and dose can be increased per investigator and patient discretion.
2468608|NCT03113968|Active Comparator|ketamine infusion|Treatments will be given 2 times a week up to a total of 6 treatment over 3 - 5 weeks. Initial standard dose will be 0.5 mg/kg infusion over 40 min. The dose can be modified if clinically warranted per investigator and patient discretion.
2468628|NCT03113448|Active Comparator|0.075% Capsaicin Lotion|0.075% Capsaicin Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
2468629|NCT03113448|Placebo Comparator|Placebo Lotion|Placebo Lotion is used for application at skin area involved with symptomatic neuropathic pain (both feet or/and hands), 3-4 times a day, everyday for 8 weeks then stop
2468658|NCT03113357|Experimental|Myofascial release technique|Subjects lied down in supine with knee flexion. Therapist seated on a stool at the head of the table. Elbows and supinated forearms on the table. Asked the client to lift their head off the table. Position the tips of the first three fingers into the soft tissue immediately inferior to the arc of atlas. The fingers are stabilized in a flexed position - around 45° at the MP and PIP joints. The subject is asked to rest their head back down so the fingertips are in the sub-occipital soft tissues and the finger pads rest firmly against the inferior aspect of the atlas. Once the position is perceived to be comfortable, a series of soft tissue responses will occur, characterized by local softening sensations followed by an increase in the weight of the head.
2468667|NCT03113461|Experimental|CPAP adherent|Study participants in this arm are using the CPAP intervention consistently
2468676|NCT03113461|Active Comparator|CPAP non-adherent|Study participants in this arm are not using the CPAP intervention consistently
2468678|NCT03113461|No Intervention|No OSA|Study participants who do not have OSA
2467910|NCT03118700|Experimental|Aerobic Interval Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
2467911|NCT03118700|Experimental|Continuous Exercise|Subjects will be equipped with a heart rate (HR) monitor and perform an interval exercise bout on a cycle ergometer. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will perform a 30-minute exercise bout at a HR that elicits 75%-80% of their measured HRmax. Work rate will be adjusted, if needed, to keep HR within this value. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax. After the exercise, subjects will remain seated in the lab for 4 hours and their blood pressure will be measured every 10 minutes using the Oscar 2 with SphygmoCor ambulatory blood pressure system, and cardiac output will be measured with 10-second averages using the PhysioFlow.
2467979|NCT03118271|Active Comparator|lumbar traction|Treatment with lumbar traction is via an OPD base. It comprised a 20 min. treatment session over a period of 2 months. If the symptoms subside before the end of 2 months' treatment, lumbar traction will be discontinued, and the treatment duration and number of treatment session will be recorded. The frequency of treatment is 3 times per week. Treatment method is according to the common clinical guidelines, starting from 25% of the subject's body weight and steadily increasing to 50% of body weight. Before traction, heat therapy will be applied to the low back of the subject, and electric therapy will also be given to the painful areas. The treatment will be conducted by the same physiotherapist.
2467981|NCT03118271|Active Comparator|spinal manipulation|Spinal manipulation will be performed by a spinal manipulator (Dr. Tso-Liang Wang) who was graduated from Los Angeles College of Chiropractic. Before performing spinal manipulation, he will exam the patient's whole body throughly, especially focusing on the lumbo-pelvic-hip region. What he exams includes pelvic and spinal alignment, tension of soft tissues, tissue texture, joint mobility, movement patterns, and muscle power. The manipulation is started with release of the hypertonic myofascial structures and thus normalize the myofascial tension of the lumbo-pelvic-hip region. Then he will align the lumbar spine, pelvis and hip joint three-dimensionally according to the findings of his examination on the same day. The manipulation will be performed up to 8 times within one month (no more than 2 manipulations a week). If the symptoms subside before the end of one-month' treatment, the manipulation is discontinued and the number of treatment session will be recorded.
2467982|NCT03118271|Active Comparator|surgery|General anesthesia, the patient will be put in the prone and abdomen-free position. A 4-cm midline longitudinal incision will be made over the spinous processes of the L3-5 levels. It will be deepened through the fat and fascia in line with the skin incision to reach the spinous processes.The paraspinous muscles will be dissected subperiosteally down the spinous processes and along the lamina to the facet joints. Laminectomy will be done carefully at the herniated disc level for posterior decompression. The ligamentum flavum will be excised to expose the dural sac.Using blunt dissection, the investigators carefully continue down the lateral side of the dura to the floor of the spinal canal; the investigators retract the dura and its nerve root medially. After the posterior aspect of the disc space is revealed, the affected disc will be removed and discotomy will be performed.The wound will be closed in the routine fashion after meticulous hemostasis and normal saline irrigation.
2468091|NCT03117270|Experimental|oral filgotinib tablets|
2468096|NCT03117270|Placebo Comparator|placebo tablets|
3191790|NCT00801944|Experimental|I|Solifenacin succinate 5/10mg
3191791|NCT00801944|Experimental|II|Placebo
2468329|NCT03115697|Active Comparator|Lactulose with Rifaximin|
2468330|NCT03115697|Experimental|Plasmapheresis|Plasmapheresis will be added to the standard medical care therapy.(Maximum of 3 sessions once in 24 hours/or alternate days with an follow up for 5 days)
2468407|NCT03115255|Experimental|serum VEGF level|Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
2468420|NCT03114930|Other|Standard output|
2468426|NCT03114930|Other|Non standard output|
2468502|NCT03114761|Experimental|CTA-IH|
2468542|NCT03114358|Experimental|Early carbapenems de-escalation|De-escalation carbapenems within 24 hours or no later than 72 hours of prescription by Infectious disease specialist (early de-escalation).
2468543|NCT03114358|No Intervention|Late carbapenems de-escalation|De-escalation followed the hospital policy in which carbapenems were evaluated by ID specialist at 72 hours of admission (late de-escalation). De-escalation may occurred earlier depends upon the decision of the primary care team
2468573|NCT03114072|Active Comparator|Blue-blocking glasses|N=30 The Blue-blocking glasses (orange-tinted), which remove more than 99% of the blue wavelengths (wavelengths within the visible spectrum shorter than 530 nm). Luminous transmittance: 50%.
2468574|NCT03114072|Active Comparator|Light grey control glasses|N=30 Partially blue blocking light grey glasses, blocking only about 50% of blue wavelengths (wavelengths within the visible spectra shorter than 530 nm). Luminous transmittance: 55%.
2468620|NCT03113747|Experimental|ALLO-ASCs|The patients receive ALLO-ADSCs. Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging
3191792|NCT00801957|Experimental|1|tacrolimus ointment 0.03%
3191793|NCT00801957|Active Comparator|2|hydrocortisone acetate 1% and butyrate 0.1%
2467913|NCT03118661|Experimental|Maraviroc after allo-HCT|"Step 1: participants who have received at least 30 days of maraviroc immediately post allo-HCT can be enrolled. Blood will be drawn at 2 time points at least 2 weeks apart, but within 4 weeks, and assessed for HIV-1 reservoir using both DNA assays and cell-associated reactivation by infectivity after stimulation. If any biopsies post allo-HCT are performed as part of standard of care and available, these will also be assessed for HIV-1~Step 2: If HIV-1 reservoir is undetecable, antiretrovirals (ART) will be stopped in a structured treatment interruption (STI). HIV-1 VLs and CD4+ T-cells check weekly. Week 16, participants will have a large volume blood draw if remain suppressed. If confirmed return of viremia, ART will be reinitiated and he/she will be followed until HIV VL is <50 copies/ml. If he/she remains suppressed at Week 16 and repeat assays confirm no detectable HIV-1, HIV-1 VLs and CD4+ T-cell counts will be checked monthly until Week 52, and then quarterly until Year 5"
2467972|NCT03118284||Foley catheter group|Urine collection and blood collection and NRS for pain in patients having surgery for which their surgeon has ordered placement of a Foley catheter.
2467974|NCT03118284||Healthy control group|Blood collection in healthy volunteers from the Research Participant Registry or recruited from posters around the Washington University campus
2468053|NCT03117933|Active Comparator|A: Paclitaxel|Paclitaxel, IV weekly, 80mg/m2; until progression
2468055|NCT03117933|Experimental|B: Olaparib|Olaparib, oral, 300mg twice daily; until progression
2468057|NCT03117933|Experimental|C: Olaparib and Cediranib|Olaparib, oral, 300mg twice daily and Cediranib, tablet, 20mg once daily; until progression
2468104|NCT03117322|Experimental|Synbiotic|"Each participant will receive the next:~agave inulin (4 g) in powder~Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops daily, once a day for four weeks."
2468106|NCT03117322|Experimental|Probiotic|Lactobacillus reuteri DSM 17938 (1 x 10^8 cfu) in 5 drops and maltodextrin (4 g) in powder daily, once a day for four weeks.
2468107|NCT03117322|Experimental|Prebiotic|agave inulin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
2468108|NCT03117322|Placebo Comparator|Placebo|maltodextrin (4 g) in powder and an oil mix (sunflower oil and medium chain triglyceride oil) in 5 drops daily, once a day for four weeks.
2468160|NCT03116893|Experimental|Reference Treatment|BI 685509 given alone, fasted
2468166|NCT03116893|Experimental|Treatment 1|BI 685509, given alone, after a high fat, high calorie breakfast
2468168|NCT03116893|Experimental|Treatment 2|BI 685509, given together with itraconazole, fasted
2468170|NCT03116893|Experimental|Treatment 3|BI 685509, given together with rifampicin, fasted
2468210|NCT03116581|Other|Vicarious reward|"If a decision influences the well-being of another (through monetary payoff), the decision making processes should differ from a decision that would influences only oneself. The difference will be reflected in the reaction-times and in the accuracy of the response to the task. The drift diffusion models care then used to estimate le decision parameter in each condition and understand which parameter is influenced by the beneficiary of the payoff associated with a decision.~Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the influence of others on the decision making process, by assessing the neural activity related to the decision making processes. Also, the research compares how the brain responses for payoff for others and payoffs for oneself, specially to confirm that these responses are located in different areas of the Anterior cingulate Cortex."
2468213|NCT03116581|Other|Audience effect|In order to clarify the complex changes in the decision-making processes induced by simple observation by others (audience) , the experiment have two levels of difficulty . These levels of difficulty will be determined in such a way as to achieve better 'public' performance than 'private' when the task is easy (high level of consistency) and poor performance when the task is difficult (low level of coherence) As described in the literature in psychology. Drift diffusion models will be used to better understand the variations in performance, to decipher between a modulation of the diffusion velocity and or of the decision threshold. This study will help characterize how observation by others modulates performance. Once the decision parameter characterized with behavioral experiment, the study aims to better understand the neural network sustaining the impact of observation by others on the decision making process.
2468256|NCT03116256|Other|VLCD only|Very low calorie diet (VLCD) only group- participants in this group will receive complete meal replacement for 6 weeks.
2468259|NCT03116256|Active Comparator|VLCD+RET|VLCD+RET group- participants in this group will receive complete meal replacement for 6 weeks and resistance exercise training 3 times every week for 6 weeks.
2468261|NCT03116256|Active Comparator|VLCD+HIIT|VLCD+HIIT group- participants in this group will receive complete meal replacement for 6 weeks and High intensity interval training 3 times every week for 6 weeks.
2468315|NCT03115892|Experimental|intervention arm|Green Tea With Aloe Vera mouthwash twice daily for one week
2468316|NCT03115892|Active Comparator|control arm|Chlorhexidine Mouthwash twice daily for one week
2468366|NCT03115528||Medical Oncology Physicians|Medical oncology physicians are sent the Estimation of Prognosis questionnaire by email.
2468376|NCT03115528||Palliative Care Physicians|Palliative care physicians are sent the Estimation of Prognosis questionnaire by email.
2468455|NCT03115099|Placebo Comparator|Placebo (Part A)|Single oral dose of placebo (sugar pill) administered to healthy participants in up to 1 study period in Part A
2468462|NCT03115099|Experimental|LY3325656 (Part A)|Single ascending dose of LY3325656 administered orally to healthy participants in up to 3 study periods in Part A
2468469|NCT03115099|Placebo Comparator|Placebo (Part B)|Single oral dose of placebo (sugar pill) administered to participants with T2DM in 1 study period in Part B
2468475|NCT03115099|Experimental|LY3325656 (Part B)|Single oral dose of LY3325656 administered to participants with T2DM in 1 study period in Part B
2468477|NCT03115099|Active Comparator|Liraglutide (Part B)|Single subcutaneous dose of liraglutide administered to participants with T2DM in 1 study period in Part B
2468479|NCT03115099|Experimental|LY3325656 + Sitagliptin (Part B)|Single oral dose of LY3325656 and sitagliptin administered to participants with T2DM in 1 study period in Part B
2468527|NCT03114423|Experimental|Treatment As Usual + Treatment with EMDR|
2468533|NCT03114423|Sham Comparator|Treatment As Usual + Cognitive Training|
3191794|NCT00801957|Other|3|Control group vaccination and challenge dose only
2467990|NCT03118050|Experimental|BR in healthy subjects, LAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2467991|NCT03118050|Experimental|BR in healthy subjects, HAA|Healthy subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
2467993|NCT03118050|Experimental|BR in T2DM, LAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2467994|NCT03118050|Experimental|BR in T2DM, HAA|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with standard of care physical therapy. Muscle size, strength and response to a high dose amino acids (HAA) will be measured before and after bed rest.
2467996|NCT03118050|Experimental|BR in healthy subjects, PT|Healthy subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2468000|NCT03118050|Experimental|BR in T2DM, PT|Type 2 diabetes (T2DM) subjects will undergo short term bed rest with intensive physical therapy (PT). Muscle size, strength and response to a low dose amino acids (LAA) will be measured before and after bed rest.
2468032|NCT03117660|Experimental|Vitamin A|Subjects will receive 3-4weeks of vitamin A
2468036|NCT03117660|No Intervention|Control|Subjects will receive no treatment
2468111|NCT03117530|Experimental|Minocycline|
2468164|NCT03117049|Experimental|ONO-4538 group|"ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
2468167|NCT03117049|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.~Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent."
2468331|NCT03115658|Experimental|Exercise Intervention|"Participants met with a PhD level psychologist experienced with health behavior change, to set a personalized exercise goal and plan. Participants were told the studies' goal to engage in 150 minutes of moderate intensity or greater physical activity each week, based on the ACSM recommendations, but participants were allowed to set any personal goal. Participants were also instructed on how to self-monitor their physical activity.~After the initial meeting all other intervention components were sent through the mail. The intervention consists of three types of print material that were mailed: stage-matched manuals, tailored feedback report, and tip sheets."
3191795|NCT00801970|Experimental|1 - Pregnant - Tokophobic|Psychoanalysis treatment.
3191796|NCT00801970|Experimental|2 - Pregnant - Tokophobic|Cognitive-Behavioral treatment.
3191797|NCT00801970|Experimental|3 - Non-pregnant - Tokophobic|Group Therapy
2468483|NCT03114787|Other|Patient receiving respiratory physiotherapy|
2468485|NCT03114787|Other|Patient not receiving respiratory physiotherapy|
2468531|NCT03114436||Consented deceased organ donors|Includes neurological determination of death (DND) and by circulatory determination of death (DCD).
2468597|NCT03113903|Experimental|scheduled surgery|
2468605|NCT03113903|Other|healthy volunteers|
2468632|NCT03113604||Patients with untreated CHC not sorafenib|
2468633|NCT03113604||Patients with non-sorafenib CHC|
2468634|NCT03113604||Patients with CHCs responding to sorafenib|
2468680|NCT03113292|Experimental|Pilates Method|Mat Pilates Program, 2x/week, for 6 weeks, supervised by a Physiotherapist. Sessions will last forty five min, with 4 individuals per session. On average, 10 to 15 exercises will be performed per session, with repetitions ranging from 10 to 20 times, according subject's limitations. If necessary, the exercises will be adapted individually for the three levels of difficulty: basic, intermediate and advanced. Progress will be dependent on the absence of postural compensations when performing the repetitions of the exercises.
2468682|NCT03113292|Active Comparator|Home Exercise Prescription|Composed by two familiarization sessions, supervised by a Physiotherapist. The protocol include postural reeducation exercises, stretching and muscle strengthening, stabilization and mobilization of the spine. Subsequently, participants will receive an educational booklet containing information on low back pain, anatomy of the spine and its relation to the muscular chain, care during daily life activities and the importance of regular physical exercises. Also, it will include a booklet with the prescription of therapeutic home exercises to be performed during the next 6 weeks. It will be recommended that the participants perform the exercises 2x/week. Participants will also be contacted weekly by email and/or telephone, for remote supervision and for checking the prescribed exercises.
2468716|NCT03113006|Active Comparator|Standard Panretinal Photocoagulation|Localized to all four retinal quadrants.
2468727|NCT03113006|Experimental|Individ. Panretinal Photocoagulation|Localized to only the affected quadrants.
2468792|NCT03112655|Experimental|Human african trypanosomiasis patient|RNA, neopterin and 5-hydroxytryptophan detection
2468864|NCT03112226|Active Comparator|GnRHant + E2|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal estradiol add-back; Climara patch, 0.075mg/day, weekly for 12 weeks
2468866|NCT03112226|Placebo Comparator|GnRHant + Placebo|Single dose of GnRH antagonist degarelix acetate for depot injection (80mg) Transdermal placebo patch, weekly for 12 weeks
2468925|NCT03111706||dehiscencd scar|women who are discovered with scar dehiscence during cesarean section
2468927|NCT03111706||Intact scar|women with intact scar detected during cesarean section
2468977|NCT03111355|Experimental|Brazil Nut supplementation|Consumption of one Brazil nut a day for 2 months followed by 2 months without intervention
3173305|NCT00610571|Experimental|Oral Topotecan and Temodar|Two separate strata to accrue independently. Stratum 1: Patients taking receiving Dilantin, Tegretol, Trileptal or Phenobarbital. Stratum 2: Patients on anti-convulsants other than Dilantin, Tegretol, Trileptal or Phenobarbital or patients not on any anti-convulsants
3173306|NCT00610584|Experimental|1|verum acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
2468114|NCT03117348|Experimental|Gradual goal-dose EN|Patients in Gradual Goal-dose EN group will receive increased calories gradually by enteral nutrition and will reach the 80% of target energy by enteral nutrition at day 8.
2468119|NCT03117348|Experimental|Immediate goal-dose EN|Patients in immediate Goal-dose EN group will reach the 100% of target energy by enteral nutrition at day 3 after abdominal surgery.
2468175|NCT03116984|Active Comparator|Transcatheter arterial chemoembolization|TACE group: The frequency of treatment is determined based on the disease condition for patients who are randomly assigned to group of TACE treatment.TACE is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery, and micro-embolization superselective catheterization is preferred.Adriamycin(30 to 60mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.The dose of ultra fluid lipiodol was determined by diameter and blood supply type of HCC,generally 5-20ml, and no more than 30ml once.The boundary is considered whether there are large amounts of lipiodol to deposit in the tumor and tiny branches shadow of portal veins in paracarcinoma under fluoroscopic guidance. Embolizing agents(gelatin sponge particles 350um-560um) are added after lipiodol emulsion embolization.It has a possibility of observeation alone if tumor achieves a complete response after two times TACE.
2468178|NCT03116984|Experimental|External-beam radiotherapy|EBRT group: Patients who were randomized to the external- beam radiotherapy (EBRT) 3-5 weeks after the completion 2 times TACE.Radiotherapy equipment is based on the conditions of the cooperative units. 3-DCRT, IMRT or IGRT will be opted based on hospital. IGRT can also be used via helical tomotherapy, Rapid Arc or VMAT. The target volume should include the visible tumor.
2468222|NCT03116464|Experimental|Intervention Group|Caregiver and patient with dementia dyads who receive the family intervention.
2468278|NCT03116178|Active Comparator|Group B|"Group B- intervention -Body weight guided Intraoperative fluid administered @ 6-8 ml/kg and blood loss replacement with colloid.~hourly urine output if less than 0.5ml/hr 100-200ml bolus of plasmalyte was administered."
2468279|NCT03116178|Active Comparator|Group G|Group G- intervention - PVI( Masimo co oximeter) guided fluid therapy.
2468391|NCT03115346|Experimental|decision aid|the experimental group will receive the decision aid
2468394|NCT03115346|No Intervention|control|the control group will only receive the survey
2468446|NCT03114904|Other|"Usual weaning management"|
2468450|NCT03114904|Other|Introduction to H2 for the discontinuation of therapeutics|
2468561|NCT03114592|No Intervention|Standard Care|"Complete a survey asking about kidney function and participant demographics.~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
2468563|NCT03114592|Experimental|mHealth Tool|"Complete a survey asking about kidney function and participant demographics.~Review a 15-20 minute educational tool on a tablet about kidney health~Receive a one-month follow-up call (one month after hospital discharge date) and complete a phone survey about patient kidney function after discharge"
2468602|NCT03113864|Placebo Comparator|Placebo|Will be identical looking to treatment
2468610|NCT03113864|Experimental|Lutein|10 mg of FloraGLO Lutein
2468700|NCT03113240|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
2468708|NCT03113240|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2468757|NCT03112707|Experimental|Study arm|1023 real world high-bleeding risk (HBR) patients with coronary artery disease (stable as well as acute coronary syndromes) who qualify for percutaneous coronary interventions will be included in the study.
2468853|NCT03112486||Cardiac Arrest cohort|adult patients (≥ 18 years of age) with non-traumatic out of hospital cardiac arrest
2468859|NCT03112486||Control cohort|matched control population will include hemodynamically stable patients who present to the ED with chest pain that is not of cardiac etiology (non-traumatic chief complaints).
2468994|NCT03111615|Experimental|Aromatase Inhibitor group|Female patients of 50 and above y.o. shall initiate hormone therapy (Letrozol 2.5 mg or Anastrazol 1 mg) immediately after the diagnosis until surgery.
2468995|NCT03111615|No Intervention|Control group|Female patients of 50 and above y.o. that follow standard protocol (no pre-surgery (Letrozol 2.5 mg or Anastrazol 1 mg))
2468996|NCT03111615|Other|Aromatase Inhibitor Active surveillance|Female patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
2468997|NCT03111615|Other|Aromatase Inhibitor Active surveillance + aas|emale patients of 50 and above y.o. that refuse surgery and therefor follow standard protocol (only Letrozol 2.5mg or Anastrazol 1 mg plus acetilsalicilic acid) until disease progression, death or will of surgery In this subgroup we are going to include, under HT, female patients with CDis,that refuse the standard treatment with surgery plus eventual rt and/or ht
2469065|NCT03110887||Preterm neonate with thrombocytopenia|Preterm neonates (GA<34 weeks) with severe thrombocytopenia
2469094|NCT03110731|Experimental|Intervention group|Physical training (2x / week) was performed for 12 weeks
2469097|NCT03110731|No Intervention|Control Group|no intervention
3173307|NCT00610584|Placebo Comparator|2|minimal (sham) acupuncture plus rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
3173308|NCT00610584|Active Comparator|3|rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))alone
3173309|NCT00610597||1|alcoholic liver disease
3173310|NCT00610597||2|chronic hepatitis C virus infection
3173311|NCT00610610|Experimental|A|Paroxetine - Controlled Release
3173312|NCT00610610|Placebo Comparator|B|Same colour, shape placebo
2468056|NCT03117751|Experimental|B-ALL and B-LLy, Low-risk|"Patients with low-risk B ALL and LLy will have Induction (6 weeks), Consolidation (8 weeks), and Continuation (120 weeks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 1-2 doses of daunorubicin (based on day 8 peripheral blood MRD in patients with ETV6-RUNX1 or hyperdiploid) are given. Dasatinib is given for patients with ABL1-class fusion. Blinatumomab will be given to patients with certain genetic subtypes and those with Down syndrome.~Interventions: Prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, thioguanine, methotrexate, dexamethasone, blinatumomab."
2468058|NCT03117751|Experimental|B-ALL and B-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5%, LLy patients who don't qualify for complete response at end of Remission Induction and all patients with ETP and T/M MPAL. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD >5%. Blinatumomab will be given to patients with residual disease at the end of induction (≥0.01% and <1%), certain genetic subtypes and Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, thioguanine, methotrexate, dexamethasone, doxorubicin."
2468059|NCT03117751|Experimental|B-ALL and B-LLy, High-risk|"Induction (6 weeks), Early Intensification (4 weeks), Consolidation (8 weeks), and Immunotherapy (chimeric antigen receptor [CAR] T cells). Patients who do not respond to Immunotherapy will receive Reintensification therapy. During Remission Induction therapy, prednisone dose is 40mg/m^2 and 2 doses of daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib are given as done for patients with standard-risk B-ALL but are discontinued in Immunotherapy and Reintensification therapy. Blinatumomab will be given to patients who are not able to receive CAR T cell therapy and patients with certain genetic subtypes and those with Down syndrome.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, blinatumomab, etoposide, dexamethasone, clofarabine, thioguanine, methotrexate."
2468061|NCT03117751|Experimental|T-ALL and T-LLy, Standard-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Continuation (120 wks). During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib is given for patients with Ph+ and those with ABL1-class fusion. Ruxolitinib is given for patients with activation of JAK-STAT signaling; ALL patients with Day 15 or Day 22 MRD ≥5% and all patients with ETP and T/M MPAL and LLy patients who don't qualify for complete response at end of Remission Induction. Bortezomib is given to patients without targetable lesions and Day 15 or Day 22 MRD ≥ 5%.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, dexamethasone, doxorubicin, nelarabine, thioguanine."
2468063|NCT03117751|Experimental|T-ALL and T-LLy, High-risk|"Induction (6 wks), Early Intensification (4 wks), Consolidation (8 wks), and Reintensification. During Remission Induction therapy, prednisone dose is 60mg/m^2 and 3 doses daunorubicin are given. Dasatinib, ruxolitinib, and bortezomib given as done for patients with standard-risk T-ALL but are discontinued in Reintensification therapy.~Interventions: prednisone, vincristine, daunorubicin, pegaspargase (or Erwinase®), cyclophosphamide, cytarabine, mercaptopurine, dasatinib, bortezomib, ruxolitinib, methotrexate, etoposide, dexamethasone, clofarabine, vorinostat, idarubicin, nelarabine, thioguanine.."
2468064|NCT03117751|Experimental|ALL, CEP72 T/T, Vincristine|"Patients with the CEP72 rs904627T/T genotype (~16% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive either 1.5 mg/m^2 or 1 mg/m^2 of vincristine beginning with Continuation Week 1.~Intervention: vincristine."
2468065|NCT03117751|Experimental|ALL, CEP72 C/T or C/C, Vincristine|"Patients with either a CEP72 rs904627 C/T or C/C genotype (~84% of patients) will be randomized (unblinded design, only those who evaluate neuropathy are blinded) to receive vincristine (2 mg/m^2 per dose except during Reinduction I and Reinduction II when 3 weekly doses of 1.5 mg/m^2 will be given) and dexamethasone pulses through Week 49 of Continuation Treatment or through Week 101 of Continuation Treatment.~Interventions: vincristine, dexamethasone, methotrexate, mercaptopurine."
3191798|NCT00801970|No Intervention|4 - Control|Pregnant and non-pregnant non-tokophobic women will answer questionnaires. Won't receive therapy.
2468452|NCT03114891|Experimental|fMRI-guided target|This site of stimulation will be created from participants' individualized resting connectivity data to guide stimulation that we show is especially effective in influencing downstream brain areas of interest. We will focus on a target region of the lateral prefrontal cortex (LPFC) that our data suggest is particularly effective at influencing the sgACC. Theta-burst stimulation will be administered to this target.
2468461|NCT03114891|Active Comparator|Standard brain target|As an alternative brain target, we will also test the efficacy of the dorsolateral prefrontal cortex as a target given its precedence as an FDA-approved stimulation site for remediating depressive symptoms. Theta-burst stimulation will be administered to this target.
2468595|NCT03114020|Experimental|Hyaluronic Acid inhalation solution|3mL of 0.03% Hyaluronic Acid inhalation solution BID for 28 days
2468603|NCT03114020|Placebo Comparator|Placebo Inhalation Solution|3mL matching placebo inhalation solution BID for 28 days
2468630|NCT03113500|Experimental|Treatment (CHEP-BV)|"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity."
2468768|NCT03112525||Patient under Rivaroxaban|
2468773|NCT03112525||Patient under Apixaban|
2469030|NCT03111134|Experimental|New Abdominal Closure|modified component separation technique is used to abdomen closing.
3208595|NCT00976300|Experimental|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months.
2468098|NCT03117296||Post procedure routine PT and or OT|Routine PT and or OT
2468103|NCT03117296||Post Procedure PT and OT pathway|Post procedure day zero nursing mobilization; post procedure day one PT and OT assessment and intervention, daily PT and OT intervention
2468140|NCT03117010||Hemophagocytosis|"Subjects should fulfill the following criteria~Subjects should have at least one of the following problems~Presence of hemophagocytosis in tissue or bone marrow~Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria~Age > 18 years~Written informed consents~Subjects receive steroids and etoposide"
2468180|NCT03116776|Experimental|Walnut Shell Glasses Moxibustion|Use wire to make a glass frame which can fix two walnut shells and moxa roll in front of the eyes, the walnut shell should be soaked in medlar chrysanthemum water and use the moxibustion to treat eye disease.
2468183|NCT03116776|Active Comparator|Sodium hyaluronate eye drops|Commonly used artificial tears in clinical.
2468262|NCT03116399|Experimental|PRISM 2.0 Condition|Exposing participants to the PRISM 2.0 interface.
2468263|NCT03116399|Placebo Comparator|Tablet Condition|Exposing participants to the regular computer/tablet
2468296|NCT03115944|Experimental|UltraSpeed Treatment|UltraSpeed ultrasound treatments
2468339|NCT03115736|Experimental|Switch|Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen
2468381|NCT03115385|Placebo Comparator|Placebo|Inactive ingredients include maltose, lemon flavoring (or corn starch if unflavored), and silicon dioxide.
2468390|NCT03115385|Active Comparator|VSL#3|VSL#3 is classified as a medical food that is specially formulated and processed to provide a precise mixture of 8 strains of bacterial species with potential synergistic relationships. These strains include Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii subsp. bulgaricus.
2468448|NCT03115073|Experimental|0,2% Candiplus|Candiplus® 0.2%
2468458|NCT03115073|Experimental|0,3% Candiplus|Candiplus® 0.3%
2468463|NCT03115073|Experimental|0,4% Candiplus|Candiplus® 0.4%
2468472|NCT03115073|Active Comparator|Clotri mono|Clotrimazole mono
2468568|NCT03114462|Experimental|Stereotactic Hypofractionated Radioablation (HYDRA)|"Participants receive HYDRA radiation on up to 5 days over the course of about 2 weeks, and for a total of 5 times.~Questionnaires completed at Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years."
2468582|NCT03113799|Other|Single Arm study|Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
2468648|NCT03113630|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2468650|NCT03113630|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2468654|NCT03113630|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2468657|NCT03113630|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2468664|NCT03113630|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2468674|NCT03113630|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2468696|NCT03112954|Experimental|Buccal-relaxant formula|The buccal-relaxant formula used in this study contained 8 floral essences from native and non-native plants commonly grown in Brazil, developed at the Mater Gaia Institute. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days.
2468698|NCT03112954|Experimental|Placebo|Each patient received a small amber glass bottle containing the placebo, and was instructed to use four drops sublingually 4 times a day for 22 days.
2468796|NCT03112811|Experimental|Intubated infant|
2468799|NCT03112811|Experimental|Extubated infant|
2468837|NCT03112187|Experimental|Intervention|Ferfer is a food supplement in liposomal form, with essential, vitamins including Vitamin C and Vitamin B12. Ferfer directly dissolves in the mouth without the need for water. The technology of liposomal microencapsulation, allows daily iron supplementation without any of the typical side effects of conventional oral iron supplements, such as heartburn, diarrhea, constipation, nausea and coloring of the mucous membranes and of the stools, which increases patient compliance. It has no metallic taste or smell, does not color mucous membrane and has excellent tolerability
2468990|NCT03111680|Experimental|intervention|this arm received an environmental intervention to make healthy eating and activity easier for residents
2468993|NCT03111680|No Intervention|control|the control participants received no interventions
2469034|NCT03111082||Lean|BMI less than or equal to 29.9
2469035|NCT03111082||Obese|BMI between 30.0 and 39.9
2469037|NCT03111082||Morbidly Obese|BMI greater than or equal to 40.0
2469132|NCT03110679|Experimental|autologous bone marrow concentrate|concentration of bone marrow taken from the patient's right tibia using Bio-MAC® suction catheter, company Biologic Therapies, Inc., and concentrated by centrifuge Bio.SPINTM Magellan®, company Biologic Therapies , Inc., and its injection in the intra-articular.
2469139|NCT03110679|Experimental|hyaluronic acid.|single injection of intra-articular hyaluronic acid 60mg (4 cc), and serve as a control.
2469235|NCT03109691|Active Comparator|group 1|30 patients will receive bupivacaine
2469236|NCT03109691|Active Comparator|group 2|30 patients will receive bupivacaine and Dexamethasone. .
2469304|NCT03109132|Active Comparator|Model 1|Device - O2/CO2 Oral/Nasal cannula sample line - Oridion smart CapnoLine® H Plus with Wedge cannula
2468078|NCT03117452|Experimental|visual training condition|Participants in the visual training condition will participate in the visual training (VT) group, during which they will complete computerized visual training that targets low- and mid-level visual processes. Each group will include a maximum of 3 participants and will meet 3 times a week over a period of 12-14 weeks.
2468081|NCT03117452|No Intervention|control condition|Participants assigned to the control condition will receive standard Partial Hospital care without visual training.
2468136|NCT03117192|Experimental|Zinc sulfate|Zinc sulfate is provided in the form of syrup at a dose of 1.5 mg/kg/day, maximum 50 mg/day.
2468137|NCT03117192|Placebo Comparator|Sucrose syrup|Sucrose syrup is used as placebo, its provided in the form of syrup with similar appearance and taste.
2468157|NCT03116880||Image registration|
2468209|NCT03116659|Experimental|Single Arm|Doxycycline 100 mg PO BID x 14 days, then Imiquimod up to 2 packs 3/ week x 28 days
2468300|NCT03116295|Experimental|Group 1 - 25 mg OPC|In Group 1, subjects will receive randomly in Period 1 and 2, either a single 25 mg dose of OPC [AF] or a single 25 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
2468301|NCT03116295|Experimental|Group 2 - 50 mg OPC|In Group 2, subjects will receive randomly on Period 1 and 2, either a single 50 mg dose of OPC [AF], or a single 50 mg dose of OPC [NF]. Treatments will be administered in the fasting state, the subjects having fasted for at least 10 hours
2468347|NCT03115671|Experimental|Intervention|Each child participant in the Intervention group will be taking 4 capsules of Vayarin per day for 3 months. Each capsule contains 167mg Lipirinen, providing 75mg Phosphatidylserine (PS), 21.5mg EPA and 8.5mg DHA. This gives a daily dosage of 300mg PS and 120mg EPA/DHA. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
2468349|NCT03115671|No Intervention|Control|Participants in the Control group will not be given Vayarin. They may continue their treatment as usual provided there is no change in medication and intervention during the trial.
2468371|NCT03115320|Experimental|Pregnyl (Human chorionic gonadotropin)|In this group, patients have natural cycle in frozen-thawed embryo transfer and the ovulation is confirmed by administration of hCG (Pregnyl® 5000 IU). The day of transferring embryo is depending on the day of administration of hCG and the age of the embryo. The day zero day is defined by ovulation triggered by hCG.
2468380|NCT03115320|Other|Home ovulation test|The patients randomized to the LH surge group perform the ovulation home test daily from the urine. Thus, the ovulation in this group is corfimed by the urine test. The day of transferring embryo is depending on the positive ovulation test and the age of the embryo. The day zero day is defined by positive ovulation test.
2468424|NCT03115086||Existing User|Patients who have been using Cholbam for at least 30 days
2468430|NCT03115086||New User|First-time initiators of Cholbam
2468553|NCT03114397|Active Comparator|anodal stimulation|Patients will receive anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
2468556|NCT03114397|Placebo Comparator|sham stimulation|Patients will receive sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes) for a total of 20 sessions.
3191799|NCT00801996||1. Prostate Cancer|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males ages 40 years or older~Individuals from the Qatari Peninsula whose ancestors up to three generations back were natives of Qatar.~Individuals undergoing Trans Rectal Ultrasound (TRUS) biopsy as dictated by their standard clinical care~Ultrasound OR digital rectal examination consistent with prostate disease OR A level of PSA (Prostatic Specific Antigen) greater than 3.0~Exclusion Criteria:~• Patient refuses consent"
3191800|NCT00801996||2. Normal Healthy Controls|"Inclusion Criteria:~All study subjects should be able to provide informed consent~Males or females ages 40 years or older (see section A8 for the rationale for the inclusion of females)~Individuals of Arab descent from Qatari peninsula without any personal or family history of prostate cancer~Exclusion Criteria:~Individuals with family history of prostate cancer~Individuals not deemed in good overall health by the investigator will not be accepted into the study"
3191801|NCT00802009|Experimental|1|Dexamethasone 8mg added to routine local anesthetic during brachial plexus blockade.
2468805|NCT03112512|Experimental|EIT|PEEP titration is performed where EIT is measured at the same time. After PEEP titration, EIT data is analyzed. Global inhomogeneity index and regional compliance based on EIT are calculated. PEEP level is selected when ventilation distribution is most homogeneous.
2468807|NCT03112512|Experimental|G5 VENTILATOR|Protective Ventilation Tool by G5(MV) to determine the optimal PEEP on ARDS patients. The results are delivered by the ventilator automatically.
2468834|NCT03112135|Active Comparator|Systemic TXA|TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr
2468842|NCT03112135|Active Comparator|Topical TXA|Topical TXA 1 gm diluted in 200 ml saline
2468847|NCT03112135|Active Comparator|Topical adrenaline|Topical adrenaline 1 mg diluted in 200 ml saline
2468938|NCT03111511|Experimental|Drospirenone/Ethinylestradiol + Midazolam + JNJ-56136379|Participants will receive single dose of drospirenone/ethinylestradiol 3 milligram (mg)/0.02 mg (oral contraceptive [OC]) and single dose of midazolam 2 mg under fasted conditions on Day 1. JNJ-56136379 250 mg twice daily will be administered on Days 6, 7 and JNJ-56136379 170 mg once daily on Days 8 to 25 under fed conditions, except on Day 21 on which Single dose of JNJ-56136379 170 mg + single dose of OC and single dose of midazolam 2 mg will be administered on fasted state. A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg and midazolam 2 mg on Day 21 under fasted conditions.
2469003|NCT03111264|Experimental|CHAMP group|Childcare centers randomly assigned the CHAMP group will receive an intervention that promotes physical activity in the classroom by developing gross motor skills through movement and enhances the nutritional environment in the centers by exposing preschoolers to new foods.
2469005|NCT03111264|Experimental|CHAMP+ group|These childcare centers, also randomly assigned, will have the same intervention as the CHAMP group in addition to a parenting intervention that promotes wellness and healthy behaviors within families.
2469008|NCT03111264|No Intervention|Control|This group will not receive theCHAMP intervention at the childcare center nor will this group receive the CHAMP+ parenting intervention.
2469047|NCT03110835||15 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
2468122|NCT03117426|Active Comparator|AT LISA tri 839MP IOL|"This trifocal IOL provides three useful focal distances, far, intermediate, and near, and therefore aims to provide functional visual restoration after cataract surgery.~Primary indication is implantation for the visual correction in adult patients in whom a cataractous lens has been removed, who desire useful vision over a continuous range of distances including far, intermediate, and near, resulting in spectacle independency. This device is intended to be placed in the capsular bag."
2468141|NCT03116932||Part A - high risk MSM|"Part A will consist of a descriptive analysis of the acceptability and knowledge on the topic of PrEP of the individuals that undergo routine HIV testing and counseling in study facilities or through outreach activities.~Part A will be focused only on high risk MSM. For this part of the study, 225 high risk will be interviewed to understand the knowledge and acceptability of PrEP in this population in Puerto Rico."
2468185|NCT03116802|Experimental|Statin Group|A total of 35 healthy adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, pre-screened to be receiving long term statin therapy of ≥ 6 months and negative for diabetes (defined as HbA1c <6.5%) will be enrolled upon written informed consent. They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
2468188|NCT03116802|Active Comparator|Control Group|"Another 35 healthy non-diabetic adult subjects, 30-50 years old with a range of BMI from 18 to 30 kg/m2, not receiving long-term statins will serve as controls will be enrolled upon written informed consent.~They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)"
2468245|NCT03116451|Experimental|Foot Health Promoting Program|The experimental group will receive an electronic intervention (Foot Health Promotion Program, FHPP) for 8 weeks consisting of foot self-care guidance (skin and nail self-care), foot exercises, foot stretching and professional footwear guidance. Each topic includes lectures (delivered via Adobe Presenter) and self-directed learning where participant will go through a list of links to websites and watch videos about foot self-care. In addition, the learning will be evaluated using four individual tasks related to foot self-care.
2468248|NCT03116451|No Intervention|Comparison group|The comparison group will not receive any instructions or guidance for foot self-care but participant in the comparison group will complete the same measurement points than experimental group. After the study, the comparison group will also receive the same intervention than experimental group (if effective).
2468291|NCT03116061||Multimorbidity cohort|The study population included a random sample of multimorbid patients (according to the EGPRN definition of multimorbidity). Patients were selected by 19 FPs in their offices in the county of Finistere (in north-west France) from July 2014 to December 2014. Randomization was achieved by including the first four multimorbid patients (according to the inclusion criteria) encountered during their second working day of each week. As patients were booking their appointments with the practice without the FPs' clearance, the FPs were not able to select them
2468368|NCT03115762|Experimental|ASKB1202|Subject to receive one intravenous (i.v.) infusion of ASKB1202
2468379|NCT03115762|Active Comparator|bevacizumab A|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in China
2468387|NCT03115762|Active Comparator|bevacizumab B|Subject to receive one intravenous (i.v.) infusion of bevacizumab sold in Europe
2468411|NCT03115138|Other|Patients with glial tumor|
2468417|NCT03114852||CKD patients|"'blood collection'~Patients with chronic kidney disease in renal replacement therapy living in the sanitary administrative region of Niteroi/Rio de Janeiro. They will be interviewed about past history of familiar renal disease. They will have blood functional renal biochemistry analysed."
2468418|NCT03114852||Renal Familiar Disease|'blood collection' They will have blood tested to renal genetic diseases
2468482|NCT03114774||grup 1|Ramsay Sedation Scale (RSS) Score monitoring
2468484|NCT03114774||Grup 2|The bispectral index (BIS) monitoring
2468536|NCT03114449|Experimental|Auricular acupuncture|Auricular acupuncture (AA) with indwelling fixed needles at specific AA points
2468538|NCT03114449|Sham Comparator|Sham auricular acupuncture|Sham auricular acupuncture with indwelling fixed needles at non- AA points
2468557|NCT03114137||sickle cell patients|"age: five-year-old or more~major sickle cell syndrome confirmed by hemoglobin phenotype: SS, SC, SBeta+ or Sbeta0~steady state defined as the absence of vaso-occlusive crisis for the previous 15 days, absence of fever or infectious disease for the previous 8 days and absence of transfusion for the previous 2 months"
2468558|NCT03114137||control patients|"volunteer parents or siblings of sickle cell patients~hospital staff or their children matched on country and age +/- 3 ans with the patients"
2468591|NCT03113786|No Intervention|Standard of Care|Subjects randomized to standard of care will undergo a traditional lumbar discectomy procedure without any additional interventions
2468596|NCT03113786|Active Comparator|CLARIX™100|Subjects randomized to the CLARIX™100 arm will undergo a traditional lumbar discectomy, after which CLARIX™100 will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
2468606|NCT03113786|Active Comparator|CLARIX CORD 1K|Subjects randomized to the CLARIX CORD 1K arm will undergo a traditional lumbar discectomy, after which CLARIX CORD 1K will be applied to the affected site. The tissue will be applied to the annulus at the defect site as a patch just prior to wound closure.
2468653|NCT03113305||Gastric bypass patients|Patients planned to undergo Gastric bypass procedure. Patients will be assessed -1 month, 3 month, 24 month and 48 months post surgery.
2468655|NCT03113305||Healthy controls|Healthy controls with no planned weight loss/gain. Control participant assessments will be time-matched with patients.
2468711|NCT03113214|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 57.2 Gy.
2468721|NCT03113214|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 64.4 Gy.
2468729|NCT03113214|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 71.6 Gy.
2468734|NCT03113214|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 78.8 Gy.
2468737|NCT03113214|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 86 Gy.
2468739|NCT03113214|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 93.2 Gy.
2468765|NCT03112538|Active Comparator|Insulin pump|Medtronic Minimed Paradigm Veo Insulin Pump utilising rapid acting insulin Glulisine or Aspart
2469063|NCT03110835||30 mCi radioiodine|6 patients with low risk differentiated thyroid cancer, as determined by histology
2468214|NCT03116672|Experimental|Diclofenac|Administration of one dose Diclofenac 15 minutes before treatment
2468216|NCT03116672|Experimental|Placebo oral capsule|Administration of Placebo capsule 15 minutes before treatment
2468247|NCT03116191|Experimental|SK-1404 high dose|
2468249|NCT03116191|Experimental|SK-1404 middle dose|
2468250|NCT03116191|Experimental|SK-1404 low dose|
2468251|NCT03116191|Placebo Comparator|Placebo|
2468318|NCT03116035|Active Comparator|Web-based decision aid|A commercially available web-based breast cancer surgery decision aid
2468320|NCT03116035|Active Comparator|Standard websites|selected, high-quality standard web-sites
2468365|NCT03115554|Active Comparator|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
2468370|NCT03115554|Active Comparator|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
2468441|NCT03115190|Other|General practitioner diagnosis with Heart score|Patients with chest pain who are reviewed by the general practitioner (GP) at the GP cooperation will be evaluated with the Heart score to support the GP with the diagnosis.
2468442|NCT03115190|No Intervention|Triage Nurse education|The general practitioner cooperation employs nurses for (telephone) triage. They are aided by a computer based triage system, the Netherlands triage system (NTS), a 6-level urgency triage system. With this study we aim to educate the nurses in the signs and symptoms of chest pain patients. The training program will aim to educate the triage nurses in acute coronary syndrome, including pathophysiology, symptoms and risk factors. The NTS will be incorporated within the training. The triage nurses will receive a training session by Cardiologists with information about acute coronary syndrome, the symptoms and the risks.
2468443|NCT03115190|No Intervention|Baseline registry as comparison|"All patients referred to the emergency department (ED) with suspected acute coronary syndrome (ACS) will be evaluated. They will receive a questionnaire to evaluate the accuracy of referral and the delays of ACS patients. This will be compared to the registry at baseline. Some patients will either have not contacted the general practitioner cooperation (GPC) at all, or will have been referred to the ED directly through the GPC nurse triage.~The 30 day, 6 months and one year follow-up of all patients will be via medical records, or in case of no or not enough information, by telephone."
2468577|NCT03114059||standalone CyPass implantation|patients who have undergone a standalone cypass implantation without cataract surgery more than 3 years ago
3173313|NCT00610623|Experimental|1|azithromycin iv 300 mg/day
3173314|NCT00610623|Placebo Comparator|2|Placebo
2468731|NCT03113058|Experimental|study group|
2468754|NCT03112681|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
2468755|NCT03112681|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
2468756|NCT03112681|Placebo Comparator|Placebo|Placebo tablet Once daily for 16 weeks
2468852|NCT03112278|Active Comparator|Ceramic restorations|Ceramic ultrathin occlusal veneers
2468855|NCT03112278|Active Comparator|Composite resin restorations|Composite resin ultrathin occlusal veneers
2468895|NCT03111914|Other|Dual Energy Computed Tomography (DECT)|This is a single-arm study. Each patient will receive an unenhanced dual energy CT scan followed by a contrast-enhanced scan as part of clinical routine work up. No change in the contrast material injection protocol will be performed for this this study.
2468972|NCT03111654|Other|Patients with pericardial closure of the auricle|
2468980|NCT03111654|Other|Patients without closure of the auricle|
2469158|NCT03110289|Experimental|Superdonor FMT|Fecal microbiota transplantation from a healthy donor that was selected based on a fecal/blood screening, medical interview and on abundance of taxa of the investigators their interest
2469161|NCT03110289|Sham Comparator|Autologous FMT|Fecal microbiota transplantation derived from feces from the patient her/himself.
2469210|NCT03110042||Observational Cohort|All patients will receive usual standard of care with the heart failure management including the routine supplemental oxygen therapy.
2469249|NCT03109756|Experimental|Single-dose 5 mg OV101|
2469261|NCT03109366|Other|Online self-management support|Access to online self-management support tool for six months
2469319|NCT03109236|Experimental|Treatment|"Patient will undergo CD133+ cells transplantation at stable compensated state.~5 dose GCSF will be administered 5 days consecutively before bone marrow harvesting.~Approximately 250ml of bone marrow will be harvested and subjected to CD133 isolation using clinimacs (Miltenyi Biotec) in a closed system.~Under ultrasound guidance, 50 mls of 50-100 million CD133 cells will be infused directly through transhepatic route into portal venous circulation of the liver over 5 mins."
2469323|NCT03109236|Active Comparator|Control|"Non-Transplant Arm:~Patients will receive 5 doses of GCSF"
2469358|NCT03108846|Experimental|Escitalopram|Escitalopram up to 15mg/day taken as 1-3 capsules each containing 5mg escitalopram once per day in the morning
2469359|NCT03108846|Placebo Comparator|Placebo|1-3 capsules each containing placebo only once per day in the morning
2469451|NCT03108326||Group 1a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with biologics is not allowed.
2469453|NCT03108326||Group 1b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with 1 biologics is allowed
2469455|NCT03108326||Group 2|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced Ustekinumab therapy (n=150). A prior therapy with ≥2 biologic is allowed.
3173315|NCT00610636|Experimental|1|The patients with secondary resectable colorectal hepatic metastasis undergoing surgery
3173316|NCT00610636|Active Comparator|2|The patients with secondary resectable colorectal hepatic metastasis who underwent continuous chemotherapy
3173317|NCT00610753|Experimental|Family Behavioral Therapy|This intervention focuses on counseling the parents (and other family members) on refeeding their child. When weight is being steadily regained the focus of therapy shifts to allow the child more independence.
3173318|NCT00610753|Active Comparator|Systems Family Therapy|This therapy focuses primarily on clarifying psychological processes within the family.
3173319|NCT00610766||1|
3173320|NCT00610779|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
2468232|NCT03116594|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm
2468233|NCT03116594|Active Comparator|Zostavax|Single dose 0.65mL Zostavax by subcutaneous injection into the outer aspect of the upper arm
2468276|NCT03116139|No Intervention|Low risk for kidney injury with use of CT|No randomization due to low risk for kidney injury. 100 patients undergoing CTPA with an estimated risk of CIN <10% (CINRisk Score <2)
2468280|NCT03116139|Active Comparator|Randomized to V/Q|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to VQ imaging (unexposed control)
2468283|NCT03116139|Active Comparator|Randomized to CT|150 patients with > 25% estimated risk of CIN (CINRisk Score ≥ 2), randomized to CT (exposure to iodinated contrast media)
2468373|NCT03115359|Experimental|Mindfulness Meditation|Mindfulness Meditation intervention, adjunctive to usual care for opioid-treated chronic low back pain.
2468386|NCT03115359|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy intervention, adjunctive to usual care for opioid-treated chronic low back pain.
2468447|NCT03114956|Experimental|Group A|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
2468454|NCT03114956|Experimental|Group B|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
2468467|NCT03114956|Experimental|Group C|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
2468470|NCT03114956|Experimental|Group D|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
2468516|NCT03114540|Experimental|GBT440 Dose 1:Mild hepatic impairment|Child Pugh A
2468517|NCT03114540|Experimental|GBT440 Dose 1:Moderate hep. impairment|Child Pugh B
2468519|NCT03114540|Experimental|GBT440 Dose 1:Severe hepatic impairment|Child Pugh C
2468520|NCT03114540|Experimental|GBT440 Dose 1:Normal hepatic function|Healthy subjects
2468601|NCT03114163||Cohort 1: Nivolumab|≥2nd line treatment for recurrent/ metastatic (R/M) Squamous cell carcinoma of the head and neck (SCCHN), prior platinum-based therapy was administered for locally advanced, metastatic or recurrent disease
2468612|NCT03114163||Cohort 2: Nivolumab|1st line treatment for R/M SCCHN, prior platinum-based therapy was administered for locally advanced disease in the adjuvant or primary setting
2468659|NCT03113669|Other|Intervention (CBT-GSH)|Participants will receive a clinical intake (1 hour) and 6-sessions (approximately 25 minutes each) over 12 weeks of individual guided self-help CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn to use his self-help book Overcoming Binge Eating with the therapeutic guidance of clinician. Participants will be provided with a copy of Overcoming Binge Eating. The treatment is a largely behavioral treatment that focuses on helping patients engage in more regular eating, reduce dieting behaviors, and eliminate behaviors that contribute to binge eating. All participants in the study will receive the same treatment.
2468718|NCT03113136|Active Comparator|Low wattage E cigarette device|
2468723|NCT03113136|Active Comparator|High wattage E cigarette device|
2468732|NCT03113136|Active Comparator|Usual brand cigarette|
2468809|NCT03112603|Experimental|Ruxolitinib|Ruxolitinib for the treatment period and extension period.
2468811|NCT03112603|Active Comparator|Best Available Therapy|Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.
2469020|NCT03111225|Experimental|CRPS patients|CRPS patients that will be examined for trigger points in the thoracic muscles. 10 out of the 23 will also be included in the intervention stage and will recieve a month of conventional physiotherapy, and a month of conventional physiotherapy with addition of massage to the thoracic area.
2469021|NCT03111225|No Intervention|healthy controls|healthy controls that will be examined for trigger points in the thoracic muscles (and will be compared to the CRPS patients)
2469072|NCT03110848|Experimental|Statins|Atorvastatin 20 mg daily associated with intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
2469077|NCT03110848|Active Comparator|No statins|Intravenous glucocorticoids, namely 500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
2469119|NCT03110497|Experimental|Single application brachytherapy|After external beam radiotherapy with or without chemotherapy as per standard, each study patient will undergo single application brachytherapy to deliver 3 High Dose Rate (HDR) fractions [1st, 2nd and 3rd fractions of doses 9 Gy, 7 Gy and 7 Gy respectively] keeping 6-12 hours of interval. All patients will undergo an inter-fraction Computed Tomography (CT) scan before delivery of second fraction. Plan will be re-optimized to reduce the dose to Organs at Risk (OAR's), only if the dose exceeds the dose constraints. Dose constraints being exceedingly hard in 1st fraction or before 2nd fraction even after re-planning will deem patient non-feasible but optimization will be done to give preference to OAR's while accepting some compromise in target doses.
2469255|NCT03109574|Other|Standard of Care Device|Current standard of care polyurethane catheter used at the hospital
2469256|NCT03109574|Other|Study Device|BioFlo DuraMax Chronic Hemodialysis Catheter
2469328|NCT03109327||Urgent Excision|Subjects with moles suspicious of melanoma and are scheduled for an urgent excision.
2469334|NCT03109327||Non-urgent Excision|Subjects with moles not-suspicious of melanoma and are scheduled for a non urgent excision.
2469366|NCT03108833|Experimental|Low Dose Experimental Group|Recombinant Human Prourokinase:40mg
2469367|NCT03108833|Experimental|High Dose Experimental Group|Recombinant Human Prourokinase:50mg
2469460|NCT03108365|Active Comparator|Cotton Gauze|Size: 1 x 1 cm
2468238|NCT03116347|Experimental|EPOCH 2|Participants who were treated with HyQvia prior to this study, and those who completed the ramp up period (Epoch 1). After one year in Epoch 2, participants with anti-rHuPH20 antibody titer <160 at all time-points during the study will complete the study termination/completion visit at the next possible occasion. Participants with anti-rHuPH20 antibody titer ≥160 during the study and/or at the last measurement will continue for an additional two years of HyQvia treatment and observation.
2468239|NCT03116347|Active Comparator|Epoch 3|Safety follow-up for participants whose anti-rHuPH20 antibody titer was ≥ 160 during Epoch 1 or Epoch 2 and who experience either a related serious adverse event (SAE) or a related severe adverse event (AE)
2468304|NCT03115957|Experimental|Early PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 after abdominal surgery.
2468306|NCT03115957|Experimental|Delayed PN|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 8 after abdominal surgery.
3191802|NCT00802009|Active Comparator|2|Routine anesthetic solution (30 cc 1.5% mepivicaine) used during brachial plexus blockade.
2468552|NCT03114241|Active Comparator|Intervention|An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient during 3 months.
2468555|NCT03114241|No Intervention|Control|Usual care.
2468661|NCT03113708|Sham Comparator|Heparinisation,actual body weight|In 'Heparinisation,actual body weight' group , heparin sodium; will be done according to actual body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
2468670|NCT03113708|Experimental|Heparinisation, lean body weight|In 'Heparinisation, lean body weight' group heparin sodium will be done according to lean body weight and ACT will be recorded prior to CPB. Before coming out CPB, protamine will be done according to heparin dose. And then ACT will be recorded.
2468686|NCT03113123|Other|PrEP with Truvada®|"On demand PrEP (only for MSM - with the possibility of dosing schedule switching): 2 pills of Truvada within 24 to 2 hours prior first sexual intercourse, then 1 pill every 24 hours during the period of sexual activity with one pill after the last sexual intercourse, and one last pill 24 hours later~Continuous PrEP: 1 pill every 24 hours, at least 7 days before the first sexual intercourse. When PrEP is to be discontinued, 2 pills 24 hours apart after the last sexual intercourse then stop PrEP. If PrEP is to be resumed, 1 pill every 24 hours, started at least 7 days before the first sexual intercourse or 2 pills at least 2 hours before the first sexual intercourse and then 1 pill every 24 hours."
2468786|NCT03112798||Macintosh group|The patients will be intubated by using Macintosh blades and the outcomes will be compared with Miller blades.
2468789|NCT03112798||Miller group|The patients will be intubated by using Miller blades and the outcomes will be compared with Macintosh blades.
2468827|NCT03112369|Experimental|Narrative Exposure Therapy (NET)|Counseling program
2468830|NCT03112369|Experimental|Motivational Interviewing w/Skills Training (MIST)|Counseling program
2468898|NCT03111901|Experimental|Level 1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 12 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
2468904|NCT03111901|Experimental|Level -1|Pembrolizumab (200 mg) administered intravenously (day 2 of cycle 1; day 1 of cycles 2 and beyond); Low dose-interleukin 2 (LD-IL2) 5 MIU/m2 administered subcutaneously (days 1-5 and 8-12 of each cycle); each cycle is 21 days.
2468940|NCT03111472|Experimental|Self-management guide for falls in Parkinson's|A guide for people with Parkinson's and their caregivers to self-manage falls.
2469010|NCT03111303||HAP patients|Mechanical ventilation, patients fulfilled HAP criteria
2469014|NCT03111303||non HAP patients|Mechanical ventilation, patients without HAP
3173321|NCT00610779|Placebo Comparator|2|spray containing placebo.
2469171|NCT03110484|Experimental|Pemetrexed+Tarceva|D1 Pemetrexed 500 mg/m2 IV+ D1-21 Erlotinib 100mg once daily
2469260|NCT03109665||Glaucoma within NICOLA|NICOLA study Participants Eligible for GwNICOLA by meeting inclusion criteria
2469337|NCT03109223|Active Comparator|Commercially availabel infant formula|
2469342|NCT03109223|Experimental|Test formula with 2-FL|
2469346|NCT03109223|Active Comparator|Breast Fed|
2469390|NCT03108703|Experimental|SBRT|RCC patients
2469476|NCT03108352|Experimental|Conbercept ophthalmic injection|Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
2469480|NCT03108352|Sham Comparator|sham/Conbercept ophthalmic injection|Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)
2469510|NCT03107806|Other|Glucose monitoring by OptiScanner®|Glucose monitoring and intervention guided by OptiScanner®
2469513|NCT03107806|Other|Blinded continuous glucose monitoring|Blinded continuous glucose monitoring by OptiScanner® and glucose lowering intervention guided by routine glucose measurements
2469581|NCT03107442|No Intervention|Control|Usual care, with recommendations for a healthy lifestyle.
2470430|NCT03101423|Active Comparator|interleukin-2|interleukin-2 treatment per month
3173322|NCT00610792|Experimental|1|
3173323|NCT00610805|Experimental|1|Participants randomized to this arm (n=15) will be followed by Preventive Cardiology and will have appropriate goal oriented interventions on their risk factor levels for 2 years.
3173324|NCT00610805|Other|2|Participants randomized to this arm (n=15) will receive usual care. The PI will send a letter of all testing results to their primary care physician. No standard care will be withheld.
3173325|NCT00610818||A|Patients receiving palifermin to prevent mucositis from bone marrow transplant.
2468260|NCT03116516|Other|ARM2|"In ARM2, 30 subjects will be assigned and the subjects will be administered YHP1604 at Day1 and telmisartan/amlodipine and rosuvastatin at Day22."
2468396|NCT03115567|No Intervention|Control|Patients in Control group will be instructed to follow a daily moisturizer and sunscreen regimen. Erlotinib, cetuximab, panitumumab, or afatinib will be administered as standard of care treatment.
2468399|NCT03115567|Experimental|Triamcinolone|Patients in the Triamcinolone group will be applying Triamcinolone 0.1% cream daily to their face, chest, and upper back, in addition to adhering to the same daily moisturizer and sunscreen regimen of the Control group. Erlotinib, cetuximab, panitumumab, or afatinib will be administered concomitantly as standard of care treatment.
3156976|NCT00355667|Active Comparator|A|Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
3156977|NCT00355667|Active Comparator|B|Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
3156978|NCT00355680|Experimental|1|Aurolab Green Laser
2468740|NCT03112889|Experimental|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
2468761|NCT03112577|Experimental|REGN3500|REGN3500: masked and randomized dosing regimen per protocol (part 1 only)
2468766|NCT03112577|Experimental|Dupilumab|Dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
2468771|NCT03112577|Experimental|REGN3500 plus dupilumab|REGN3500 plus dupilumab: masked and randomized dosing regimen per protocol (part 1 only)
2468775|NCT03112577|Experimental|Placebo|Placebo: masked and randomized dosing regimen per protocol (part 1 only)
2468779|NCT03112577|Active Comparator|Fluticasone propionate|Fluticasone propionate: open label dosing regimen per protocol (part 2 only)
3156979|NCT00355680|Active Comparator|2|Available Green Laser
3156980|NCT00355719|Experimental|Nevirapine-atazanavir|Atazanavir/ritonavir 300/100 mg once daily for ≥2 weeks. Nevirapine was added at a dose of 200 mg once daily from days 0 to 14, and 200 mg twice daily from days 14 to 28.
3156981|NCT00355771|Experimental|Treatment Group 1|
3156982|NCT00355771|Placebo Comparator|Treatment Group 2|
2469043|NCT03111056|Experimental|Web-Based Intervention|In an effort to reduce heavy drinking, participants will be asked to complete a daily monitoring assessment each morning for 14 days. Based on their responses, they will be provided a coping skill to either directly address their alcohol use or attempt to improve their emotion regulation and distress tolerance skills.
2469062|NCT03111056|No Intervention|Assessment Only Control|Participants will be asked to complete only the daily monitoring assessment each morning for 14 days.
2469197|NCT03110016|Experimental|Smartphone Application|SPSRS is a smartphone application system designed to improve self-confidence in individuals with subthreshold depression. The application presents a motion picture that displays words every 5 s for improving self-confidence of the user.
2469251|NCT03109795|Experimental|Clonidine|To test the magnitude by which short-term (4 weeks) sympathetic nerve activity blockade (clonidine) improves large elastic artery stiffness, vascular inflammation and baroreflex function in subjects with moderate-to-high levels of anxiety
2469253|NCT03109795|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide is a blood pressure-lowering control condition to compare to the effects of clonidine
2469280|NCT03109340|Active Comparator|Supervised treadmill group|a. Supervised treadmill group (Group I): The participants were instructed walking exercise at their target heart rate on a treadmill in Sports Rehabilitation Unit of Pamukkale University.
2469281|NCT03109340|Experimental|ECE PEDO pedometer group|b. ECE PEDO® pedometer group (Group II): Participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from their target range of steps per minute.
2469324|NCT03109106|Experimental|PCT Arm|"oAntibiotic management includes use of a validated PCT algorithm in addition to clinical judgment, other laboratory values, and microbiological pathogen identification. Subjects will be enrolled and data collected prospectively in 2017.~Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge."
2469330|NCT03109106|No Intervention|Control Group|Patients enrolled during the control blocks will receive antibiotics for respiratory infection at the provider's discretion in keeping with current standards of care. Patient records will be reviewed for outcomes data and the patients will receive a phone call for outcomes assessment at 30 days post discharge.
2469419|NCT03108612|Experimental|Study group|Intervention: Análisis de carga de trabajo (ACT)
2469471|NCT03108209|Experimental|single arm|Signle arm study. Every subjects apply Photoderm Max lait SPF50+ and Photoderm stick SPF50+
2469542|NCT03107923||Preoperative myocardial reserve yes/no|Patients with extensive myocardial fibrosis typically presents with limited myocardial contractile reserve that can be assessed by a dobutamine stress test. The patients will be allocated to a responder and non-responder group according to the results from this test.
2469580|NCT03107442|Experimental|Exercise|12-weeks aerobic exercise intervention
3156983|NCT00355810|Experimental|placebo followed by probiotic|placebo, then washout period, then Lactobacillus plantarum MF1298
3156984|NCT00355810|Experimental|probiotic followed by placebo|Lactobacillus plantarum MF1298, then washout period, then placebo
3156985|NCT00355849|Experimental|1|Intensified Glargine
3156986|NCT00355849|Experimental|2|HIIP
3191803|NCT00802035|Active Comparator|IR am|30 mg, single dose, morning administration (immediate release [IR])
2468345|NCT03115463|Experimental|OX25|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 10th to 25th percentile saturations observed in healthy term newborns.
2468346|NCT03115463|No Intervention|OX50|Resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines
2468348|NCT03115463|Active Comparator|OX75|Resuscitation will be initiated at 30% O2. Titration of oxygen during neonatal resuscitation: Intervention is target goal saturations which will be the 75th percentile saturations observed in healthy term newborns.
2468374|NCT03115307|Experimental|Gonapeptyl|In the intervention group the patient will get the advice to using triptorelin (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.
2468383|NCT03115307|No Intervention|Control group|In the control group, there are no luteal phase medications in the insemination cycle.
2468445|NCT03115164||Patients with DIA / DIG treated at the French SFCE pediatric|
2468532|NCT03114631|Experimental|Dendritic cells lysate-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with tumor lysate
2468537|NCT03114631|No Intervention|Control group|Patients treated according to clinical protocols
2468539|NCT03114631|Experimental|Dendritic cells peptide-pulsed group|Patients treated according to clinical protocols plus autologous dendritic cells, pulsed with MUC-1/WT-1 peptides
2468559|NCT03114111|Active Comparator|Application of ALA|The treatment will consist of split-face comparisons of no application of aminolevulinic acid (ALA) vs ALA application to either half of the face. Prior to ALA application, the face will be swabbed for microbiome analysis. After the ALA application, the subjects will incubate with the ALA on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
2468562|NCT03114111|Placebo Comparator|No Application of ALA|For the placebo, Demo Levulan Kerastick, which contains no active ingredient and is enclosed in same cardboard sleeve and cap, will be applied to the other side of the face to mimic the surface of the ALA application stick. After the placebo application, the subjects will incubate with the placebo on their face per the standard PDT protocol used at UC Davis Dermatology clinic for facial PDT treatments. The side of the face being treated will remain the same during all treatments.
2468613|NCT03113851|Experimental|Radiotherapy and rhGM-CSF|Patients with metastatic non-small cell lung cancer received 3.5 Gy per fraction to a total dose of 35 Gy/ 10 fractions over 2 weeks, combined with rhGM-CSF (125 μg/m2).
2468640|NCT03113513|Active Comparator|McCall culdoplasty|The McCall culdoplasty will be performed in a modified version as described by McCall in 1957. Specifically, two long acting bioresorbable sutures are put through the specific anatomic landmarks.
2468641|NCT03113513|Active Comparator|Sacrospinous ligament fixation|The SLF technique will be performed as described by Richter et al (Amreich, 1951). Two long acting bioresorbable sutures are passed through the right sacrospinous ligament and then fixed to the vaginal cuff.
2468715|NCT03113201|Experimental|Collabri Flex|Collaborative care
2468726|NCT03113201|Experimental|Consultation-Liaison|Consultations with general practitioner
2468784|NCT03112629||symptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who display one or more of the following symptoms: exertional shortness of breath, chest pain, exertional dizziness or syncope.
2468788|NCT03112629||asymptomatic AS|Patients diagnosed with severe aortic stenosis in echocardiography who do not display symptoms
2468818|NCT03112317||Hypothermia|Patients with mild hypothermia at start of the surgery
2468822|NCT03112317||Normothermia|Patients with normal core temperature at start of surgery.
2468918|NCT03112057|Experimental|Healthy subjects|Healthy subjects of different ages (20 persons), Interventions: harmonic generation microscopy
2468920|NCT03112057|Experimental|peripheral neuropathy|the participant have symptoms and diagnosed with peripheral neuropathy (90 persons), Interventions:harmonic generation microscopy
2468921|NCT03112057|Experimental|diabetic neuropathy|the participant have symptoms and diagnosed with diabetic neuropathy (20 persons), Interventions:harmonic generation microscopy
2468922|NCT03112057|Experimental|chemotherapy induced neuropathy|before chemotherapy, during chemotherapy, after peripheral nerve lesions were cured (30 persons). Interventions:harmonic generation microscopy
2468923|NCT03112057|Experimental|Polydactyly|Abandoned extra digit specimen of polydactyly(10 persons): the normal skin and nerve endings in extra digit: Interventions: harmonic generation microscopy
2468974|NCT03111368|Active Comparator|EUS- FNA Slow-pull|Endoscopic ultrasound-guided fine needle aspiration using a stylet slow-pull technique of solid pancreatic mass
2468984|NCT03111368|Active Comparator|EUS-FNA Negative Pressure|Endoscopic ultrasound-guided fine needle aspiration using negative pressure technique of solid pancreatic mass
2469054|NCT03111069|Experimental|Resectable Intra-Abdominal/Pelvic Tumors|Participants receive complete surgical tumor resection with no gross residual disease, followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) using Doxorubicin.
2469069|NCT03111069|Experimental|Unresectable Intra-Abdominal/Pelvic Tumors|"Participants receive debulking surgery followed by intra-operative radiation (IORT) in the form of brachytherapy to the gross residual pelvic tumor sites.~Participants have the option of returning for HIPEC 4 weeks (or more) after IORT, if active disease remains."
2469106|NCT03110419|Experimental|Intervention|The training group will perform a Physical Exercise as multicomponent training.
2469107|NCT03110419|No Intervention|Control|The control group will only be evaluated, without any intervention.
2469211|NCT03109925|Experimental|Radio-opaque embolic arm|"Patients will undergo intervention in the form of prostate artery embolization with the new radio-opaque embolic Lumi-Bead developed by BTG plc."
2469265|NCT03109704|Experimental|Supine thrust manipulation|The supine upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
2469267|NCT03109704|Experimental|Seated thrust manipulation|The seated upper thoracic spine thrust manipulation will be performed two times, regardless of joint cavitation.
2469269|NCT03109704|Sham Comparator|Sham manipulation|The sham manipulation will be performed two times.
2468327|NCT03115983|Experimental|LimiFlex|Posterior dynamic stabilization with the LimiFlex Paraspinous Tension Band
2468328|NCT03115983|Active Comparator|Fusion|Transforaminal lumbar interbody fusion with concomitant posterolateral fusion with pedicle screw instrumentation
3156987|NCT00355849|Experimental|3|Intensified Glargine plus HIIP
2468554|NCT03114280|Experimental|TPF2|docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days followed by radiotherapy (RT) combined with carboplatin
2468593|NCT03113890|Experimental|Assay Guided Group (AGG)|These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report prior to patient discharge and use it to guide psychoeducation and medication management.
2468599|NCT03113890|Other|Treatment as Usual (TAU)|Thus this group will serve as the control group for the outcomes related to Genecept-guided decision making. These patients will undergo a cheek swab to collect DNA for the Genecept assay. Study doctors will receive the Genecept report at the 12-week follow up visit (12 weeks after patient discharge) and will use it to guide psychoeducation. The Study Doctors will not receive the report during the patient's inpatient stay (treatment as usual, TAU). Clinicians will receive the assay report for patients in the treatment-as-usual group at the 3-month followup period.
2468671|NCT03113487|Experimental|Treatment (pembrolizumab, p53MVA)|Patients receive pembrolizumab IV over 30 minutes every 3 weeks and modified vaccinia virus ankara vaccine expressing p53 SC every 3 weeks for up to 3 vaccines. Cycles with pembrolizumab repeat every 3 weeks for up to 49 weeks in the absence of disease progression or unacceptable toxicity.
2468719|NCT03112941|Experimental|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
2468730|NCT03112941|Experimental|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
2468778|NCT03112733||Patients with ovarian carcinoma|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.
2468781|NCT03112733||Control group|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.
2468783|NCT03112733||Benign adnexal mass|Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.
2468829|NCT03112343|Active Comparator|ICT-based intervention|Subjects in the ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
2468836|NCT03112343|Placebo Comparator|Conventional intervention group|Subjects in the conventional intervention group will only save and send their health information to the server via the personal health record app
2468888|NCT03111875|Active Comparator|Routine thermal management|Patients assigned to routine thermal management will not be pre-warmed and ambient intraoperative temperature will be maintained near 20°C per routine. Only transfused blood will be warmed. An Multi-Position Upper Body Warming Blanket forced-air cover will be positioned over an appropriate non-operative site, but will not initially be activated. Should core temperature decrease to 35.5°C, the warmer will be activated as necessary to prevent core temperature from decreasing further.
2468892|NCT03111875|Experimental|Aggressive thermal management|"Patients assigned to aggressive warming will be pre-warmed with a full-body Bair Hugger or Bair Paws cover for ≈30 minutes before induction of anesthesia. The warmer will initially be set to high which corresponds to ≈43°C. It will be subsequently adjusted to make patients feel warm, but not uncomfortably so. Patients will be aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C, using an Multi-Position Upper Body and Full Access Underbody Warming Blankets forced-air covers when clinically practical. All intravenous fluids will be warmed to body temperature."
2468970|NCT03111342|Experimental|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
2468983|NCT03111342|Sham Comparator|Dry-needling|A placement of thin needle into the cervix without substance injection
2468989|NCT03111342|No Intervention|No intervention|No intervention for pain relief prior to LNG-IUS insertion
2469041|NCT03111004||Study Group|The Study Group receives 'new care' (integrated health and social care)
2469056|NCT03111004||Comparator Group|The comparator group receives usual care
2469126|NCT03110588|Experimental|PACE with Cabazitaxel @ 15 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 15 mg/m2 every 3 weeks.
2469129|NCT03110588|Experimental|PACE with Cabazitaxel @ 20 mg/m2|The drugs to be administered are: prednisone 5 mg orally twice daily, abiraterone 1000 mg orally once daily, enzalutamide 160 mg orally once daily, and cabazitaxel intravenous infusion at 20 mg/m2 every 3 weeks.
2469212|NCT03110198|Experimental|Mesalazine with hydrocortisone sodium succinate|Mesalazine（4g） with hydrocortisone sodium succinate (100mg ) enema
2469216|NCT03110198|Active Comparator|Mesalazine|Mesalazine （4g）enema
2469222|NCT03110198|Active Comparator|Hydrocortisone sodium succinate|Hydrocortisone sodium succinate (100mg ) enema
2469456|NCT03108365|Experimental|Axiostat|"Size: 1 x 1 cm~Chitosan based haemostatic dressing"
3156988|NCT00355862|Active Comparator|1|Center specific immunosuppressive regimen (mTOR inhibitor free)
3156989|NCT00355862|Experimental|2|Sirolimus containing regimen
3156990|NCT00355888|Experimental|Open label study of MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
3156991|NCT00355940|Experimental|1|
3156992|NCT00355940|Active Comparator|2|
2468332|NCT03115723||Group 1 : Percutaneous coronary intervention|All the patients who underwent percutaneous coronary intervention, in 9 invasive cardiology centers in the Aquitaine Region, France.
2468333|NCT03115723||Group 2 : Coronary angiography|All the patients who underwent coronary angiography, in 9 invasive cardiology centers in the Aquitaine Region, France
3191804|NCT00802035|Experimental|ER am|30 mg; single dose; morning administration (extended release [ER])
2468453|NCT03115203|Other|Facial paralysis|
2468460|NCT03115203|Other|Healthy subject|
2468518|NCT03114566||Consenting healthy donor|Transplant and healthy HLA typed donors
2468590|NCT03113942|Experimental|Pomalidomide group|Open label - all participants will receive pomalidomide 2mg orally once a day for 6 cycles (21 days on treatment and a 7 day rest period constitutes a cycle).
2468668|NCT03113617|Experimental|Diagnostic (68Ga-RM2 PET/CT)|Patients receive 68Ga-RM2 IV. Within 45-60 minutes, patients undergo a PET/CT scan. Patients may undergo a second PET/CT scan immediately after the first scan for attenuation correction. Patients may undergo also a repeat 68Ga-RM2 PET/CT scan after the completion of their treatment to evaluate response to therapy, if requested by the treating physician.
3191805|NCT00802035|Experimental|ER pm|30 mg; single dose; evening administration
3191806|NCT00802035|Active Comparator|IR pm|30 mg; single dose; evening administration
3191807|NCT00802048|Experimental|1|48h postoperative infusion of ropivacaine
3191808|NCT00802048|Placebo Comparator|2|48h postoperative infusion of NaCl.
3191809|NCT00802087|Experimental|Egalet® hydrocodone treatment A|Single Dose administration
3191810|NCT00802087|Experimental|Egalet® hydrocodone Treatment B|Single Dose Administration
3191811|NCT00802087|Experimental|Egalet® hydrocodone Treatment C|Single Dose Administration
3191812|NCT00802087|Experimental|Egalet® hydrocodone Treatment D|Single Dose Administration
3191813|NCT00802087|Active Comparator|Active Comparator|Single Dose Administration
3191814|NCT00802126|Experimental|Bevacizumab and verteporfin|
2468885|NCT03111966||Spanish cohort with HCV treated with DAA|
3191815|NCT00802139|Experimental|venoferrum group|
2469025|NCT03111160|Experimental|lower energy|SMILE procedure using lower energy (100, 105, and 110 nJ)
2469026|NCT03111160|Active Comparator|conventional energy (115 to 150 nJ)|SMILE procedure using conventional energy (115 to 150 nJ)
2469086|NCT03110796|Experimental|LU3103209 Dose 1|Dressing with LU3103209 Dose 1
2469087|NCT03110796|Experimental|LU3103209 Dose 2|Dressing with LU3103209 Dose 2
2469088|NCT03110796|Placebo Comparator|No LU3103209|Dressing without LU3103209
2469128|NCT03110341|Experimental|Erythropoietin|Erythropoietin is administered 750U/kg intravenously every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections regardless of gestational age), starting with the first dose within 72 hours after birth. A single dose consisted of 750U EPO per kg of birth weight dissolved in 3mL/kg normal saline was administered intravenously during a period of 5 minutes.
2469135|NCT03110341|Placebo Comparator|Normal saline|Normal saline is administered 3ml/kg intravenously every other day for 2 weeks, starting with the first dose within 72 hours after birth. Similarly, the placebo dose consisted of 3mL of normal saline per kilogram birth weight was administered intravenously during a period of 5 minutes.
2469174|NCT03110094|Other|Rheumatoid arthritis - Adalimumab|
2469176|NCT03110094|Other|Healthy volunteer|
3191816|NCT00802139|Active Comparator|Bolgre group|
3191817|NCT00802152|Experimental|Home Monitoring|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
2469285|NCT03109457||Oral squamous cell carcinoma|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
2469286|NCT03109457||Control|"Sections (4-5 microns thick) will be cut for the immunohistochemical procedure, from each paraffin block and placed on positively charged (Opti-plus) slides by the technicians in the Oral and Maxillofacial laboratory setting.~Hep C cAg : sc-58144, santa cruz biotechnology, USA) a mouse monoclonal antibody raised against Hepatitis C virus will be purchased and used for immunohistochemical staining."
2469348|NCT03109054||Low Anxiety Level|The patients had low anxiety levels. Anxiety levels will determine with S-Anxiety TX-1 (State-Trait Anxiety Inventory Test:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
2469349|NCT03109054||High Anxiety Level|The patients had high anxiety levels. Anxiety levels will determine with S-Anxiety (State-Trait Anxiety Inventory Test: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3879951/)
2469420|NCT03108729|Experimental|eslicarbazepine acetate|elicarbazepine acetate, once daily flexible dosing
2469502|NCT03107858|Active Comparator|Norepinephrine|
2469503|NCT03107858|Active Comparator|Dopamine|
2469612|NCT03107403|Experimental|Healthy subjects|
3191818|NCT00802152|No Intervention|Usual Care|100 eligible subjects identified as (HbA1c >= 8% OR SBP > 130 mm Hg)
3191819|NCT00802165|Experimental|Electroacupuncture Treatment Group|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
3191820|NCT00802165|Sham Comparator|Sham Treatment Group|Sham electroacupuncture treatment gives comparison to the experimental group
3191821|NCT00802191||Control Group|Participants with no movement disorders.
3191822|NCT00802191||Movement Disorders Participants|Participants have a movement disorder
3191823|NCT00802217|Active Comparator|Cohort 1|Civamide liquid filled softgel capsule 5 mg
3191824|NCT00802217|Active Comparator|Cohort 2|Civamide liquid filled soft gel capsules 2 x 5 mg
3191825|NCT00802230|Active Comparator|1|Carvedilol IR
3191826|NCT00802230|Active Comparator|2|Metoprolol Succinate
3191827|NCT00802256|Experimental|A|teeth which are treated with Mineral Trioxide Aggregate (MTA) material
3191828|NCT00802256|Experimental|B|teeth which are treated with new Endodontic Cement (NEC) material
3191829|NCT00802269|Experimental|Reduced Fluence Parameters|Eyes receiving retinal photocoagulation with reduced fluence parameters (time 20-50 msec, power 400-700 mW)
2468338|NCT03115866|Experimental|FRUVED + LF|Individuals at risk for metS and those with metS went through an 8-week dietary intervention called FRUVEDomics to increase fruit and vegetable consumption measuring metabolome and microbiome markers with health-related behaviors. In this arm, individuals were assigned to a diet of 50% fruit and vegetables plus low fat.
2468451|NCT03114982|Experimental|Low potency of NBP608|Single dose 0.5mL of low potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468456|NCT03114982|Experimental|Middle potency of NBP608|Single dose 0.5mL of middle potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468464|NCT03114982|Experimental|High potency of NBP608|Single dose 0.5mL of high potency of NBP608 by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468471|NCT03114982|Active Comparator|Varivax|Single dose 0.5mL of Varivax by subcutaneous injection into the outer aspect of the upper arm or the anterolateral thigh
2468528|NCT03114514|Experimental|PRP injection|A PRP-injection will be performed three times during the course of treatment
2468581|NCT03114176|Experimental|Divers group|Throughout each dive, subjects performed a 20-minute long mild exercise on an underwater bike. The depth of dive was set at 15 meters, where the subjects performed an activity guided by Borg CR-10 scale at intensity level 3 (25 rpm). The ascent rate was set at 10 m/min, with a decompression stop at 5 meters for 3 min, according to the US Navy Manual Diving Table. 48 h prior to the immersions, none of the participants consumed medications or dived or flew. In the first part of the experiment, all subjects performed a dive breathing Enriched Air Nitrox (EAN, 32% ppO2). Baseline clinical measurements were collected before and after this first dive in order to have a reference [CTRL] and to measure physiological modifications due to immersion [NTRX]. After twenty days of no diving activity, subjects were engaged in a KD for seven days. At the end of this period, subjects performed a single immersion breathing EAN. The measures were performed after this single dive [KETO-NTRX]
2468704|NCT03112928|Experimental|Phantom Motor Execution (PME)|Phantom motor execution is decoded via myoelectric pattern recognition and promoted via serious gaming in virtual and augmented reality.
2468712|NCT03112928|Active Comparator|Phantom Motor Imagery (PMI)|Use the same device and visual stimulation as PME, with the difference that participants imagine to perform, rather than execute phantom movements. Myoelectric activity is used to monitor that the subjects do not produce muscular contractions but only imagine the movements.
2468790|NCT03112564|Other|Sevoflurane 8% + Intravenous fentanyl|Avoidance of rocuronium/cisatracurium
2468839|NCT03112239|Active Comparator|photobiomodulation by active LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with active photobiomodulation by LEDT to increase peripheral muscle function post resistance training.
2468845|NCT03112239|Placebo Comparator|photobiomodulation by Placebo LEDT|The subjects will be initially pre-evaluated by performing pulmonary function tests, peripheral muscle strength tests, functional capacity tests, physical activity questionnaires and clinical control of asthma, and cardiopulmonary exercise test. After the evaluation, patients will be randomized into two resistance training groups, one of them being associated to the intervention with placebo LEDT photobiomodulation to increase peripheral muscle function post resistance training.
3191830|NCT00802269|Active Comparator|Traditional parameters|Eyes receiving retinal photocoagulation with traditional parameters (time 100-200 msec, power 200-400 mW)
3191831|NCT00802282|Experimental|1|First of 5 groups, as described in the protocol and to which volunteers are blinded
2469013|NCT03111329|Experimental|GRASS - Intervention group|"The intervention group (GRASS) will receive 3 hourly feeds, with no gastric residuals being aspirated. Solely opening of the nasogastric tube once every 6 hours to relieve possible backflow of gastric content will be allowed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.~Intervention = NO aspiration of gastric residuals"
2469017|NCT03111329|No Intervention|Standard Approach group|Standard Approach group serving as control group will be treated as per standard approach - participants will be fed 3 hourly and gastric residuals checked via nasogastric tube prior to each feed. Amount of enteral feeds given and increase in dose will be specified in an enteral feeding plan prior to start of the study. Amount of enteral feeds given will increase every six hours with a calculated overall increase of 20 ml/kg of birth weight in the total amount given every 24 hours.
3191832|NCT00802282|Experimental|2|Second of 5 groups, as described in the protocol and to which volunteers are blinded
2469202|NCT03109886|Experimental|Milciclib maleate|milciclib maleate ,10, 50 and 100 mg hard gelatine capsules , 100 mg once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles)
2469308|NCT03109132|Active Comparator|Model 2|Device -O2/CO2 Oral/Nasal cannula sample line- Oridion smart CapnoLine® Plus with Non-Wedge cannula
2468361|NCT03115437|Experimental|Soft cushioned running shoes|Running shoes with cushioned properties among the softest of the market benchmark (Stiffness: +/- 57 N/mm)
2468415|NCT03115229|No Intervention|Control Group|The control group of the RCT was composed of 35 students randomly assigned to the control group who are BMI was between 25.0-29.9 or BMI was between 18.5-24.9 and they were in the risk group in terms of obesity according to the risk rating scales.
2468416|NCT03115229|Experimental|Intervention Group|The selected students were associated with obesity risk factors about obesity (owerveight or normal weight and they were in the risk group in terms of obesity according to the risk rating scales, and between 19-24 years old) and randomly assigned to the experimental group to Protective Nursing Interventions for Reduction Obesity Risk
2468444|NCT03114800|Experimental|E-Scale|Weight monitoring
2468503|NCT03114605|Experimental|Mindfulness|Mindfulness-based Intervention (8 sessions - 2 hours each- 1 session/week)
2468504|NCT03114605|No Intervention|Control|Waiting List
2468510|NCT03114332|Experimental|Study Group|Patients for whom a subcutaneous drain was used
2468511|NCT03114332|No Intervention|Control group|No drain group
2468565|NCT03114267||Patient with chronic lymphocytic thyroiditis|
2468567|NCT03114267||Healthy subjects|
2468589|NCT03113838||Taking YXSF Capsule Group|The overall individuals taking YXSF Capsule and achieving the inclusion criteria.
3156993|NCT00355966|Active Comparator|A|In group A, immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
3156994|NCT00355966|Active Comparator|B|In Group B immediate induction of labour will be done by application of vaginal PGE2 gel 0.5 gm at an interval of 6 hours , a maximum of 2 doses.
2468705|NCT03113019|Experimental|Immunotherapy based on dendritic cells|Intravenous administration dendritic cell and activated mononuclear cells at least 3 times 20-30 million cells / injection
2468844|NCT03112759|Experimental|Cognitive Behavioral Therapy|Patients randomly selected for CBT will attend 8 weekly one-on-one therapy sessions. Patients will be prescribed conventional narcotic therapy as needed.
2468850|NCT03112759|No Intervention|No Cognitive Behavioral Therapy|Patients randomly selected for no CBT will be treated with conventional narcotic therapy alone.
2468886|NCT03112031|Experimental|Tamoxifen augmented antifungal therapy|Tamoxifen 300mg/day for 2 weeks, combined with standard antifungal therapy (amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks)
2468889|NCT03112031|Active Comparator|Standard antifungal therapy|Amphotericin B 1mg/kg/day combined with fluconazole 800mg/day for the first 2 weeks followed by fluconazole 800mg/day for 8 weeks.
3156995|NCT00356005|Experimental|Azithromycin + Artesunate|Azithromycin + Artesunate treatment
3156996|NCT00356005|Active Comparator|Artesunate|Artesunate treatment controls
2469046|NCT03110965|Experimental|Experimental arm|Patients will have an X-ray before beginning to do one or two yoga poses daily for 4 - 10 months. After that period, they will have a second X-ray.
2469179|NCT03110575|Experimental|TNX-102 SL|2 x TNX-102 SL, 2.8 mg tablets taken daily at bedtime for 12 weeks
2469258|NCT03109587|Active Comparator|Vivomixx (Visbiome)|2 packets of probiotics by mouth/day for 12 weeks
2469259|NCT03109587|Placebo Comparator|Placebo|identical in appearance, but without probiotics.
2469339|NCT03109249|Experimental|SPARC1613|Intravenous administration of SPARC1613
2469345|NCT03109249|Active Comparator|Reference 1613|Intravenous administration of Reference1613
2469397|NCT03108599|Experimental|Intervention|All participants in the intervention arm will receive two interventions: an enhanced cab intervention alone, and then the enhanced cab conditions combined with a behavioral sleep intervention.
2469398|NCT03108599|No Intervention|Control|Usual practices with regards to cab conditions and access to workplace programs for preventing sleep and fatigue problems.
2469489|NCT03108274|Experimental|Part 1: Danicopan and Midazolam|"Period 1: Participants received a single dose of midazolam.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of midazolam.~Scheduled pharmacokinetics (PK) blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
2469490|NCT03108274|Experimental|Part 2: Danicopan and Fexofenadine|"Period 1: Participants received a single dose of fexofenadine.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of fexofenadine.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
2469491|NCT03108274|Experimental|Part 3: Danicopan and MMF|"Period 1: Participants received a single dose of MMF.~Period 2: Participants received multiple doses of danicopan, in addition to coadministration with a single dose of MMF.~Scheduled PK blood samples were collected, with a washout period of at least 3 days between the dose in Period 1 and the first dose in Period 2."
2469607|NCT03107286|Other|Tc-99m MAG3|Children ages 1-6 years old will be eligible to participate. Routine imaging is performed immediately as a dynamic acquisition with 80 frames over 20 min. (15 s per frame). Subjects in each age group will be additionally imaged 2-3 h post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2470431|NCT03101423|Active Comparator|DLI|donor lymphocyte infusion (DLI) treatment per month
3156997|NCT00356083|Experimental|switch from morphine to methadon|
3156998|NCT00356109|Experimental|1|
3156999|NCT00356109|Active Comparator|2|
3157000|NCT00356174||Children with food allergy|340 longitudinally followed children with egg and/or milk allergy without elevated peanut specific Immunoglobulin E (IgE), less than 5 kUA/L
3157001|NCT00356174||Full sibling controls for genetic studies|Approximately 250 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for genetic studies.
3157002|NCT00356174||Full sibling controls for mechanistic studies|Approximately 50 not age matched full siblings (i.e., non-step siblings, non-half siblings) will be recruited as an additional control group for mechanistic studies. A subset of this cohort will be without food allergy,
3157003|NCT00356213|Experimental|A|laparoscopic sleeve gastrectomy
3157004|NCT00356213|Active Comparator|B|laparoscopic gastric bypass
2468369|NCT03115398|No Intervention|Activity Monitoring with Routine Care|Subjects randomized to the control arm will wear activity trackers but will have no specific instructions to increase their activity levels.
2468377|NCT03115398|Experimental|Pedometer-based Walking Program|Subjects randomized to the experimental arm will be instructed to meet the customized daily step count goals that are displayed on their fitness trackers. Patients who fail to meet their step count goal for three consecutive days will be contacted by a study coordinator and reminded to try to meet the activity goals. If the patient reports that his or her activity is limited by treatment-related toxicities, the patient's treating physicians will be notified to ensure that supportive care needs are being met.
2468449|NCT03115151|Experimental|Patient-Controlled Epidural Analgesia|Bupivacaine and fentanyl infusion via Continuous Lumbar Epidural Analgesia during postoperative 72 hours
2468459|NCT03115151|Sham Comparator|Intravenous patient-controlled analgesia|Postoperative intravenous patient-controlled analgesia (IV PCA) with Hydromorphone
2468499|NCT03114475|Experimental|CO2 Laser Irradiation|This group of patients will be treated by splitting the dental arches into four quadrants: upper right, upper left, lower right and lower left. Two quadrants will receive the CO2 laser irradiation whereas the remaining two quadrants will receive no treatment (i.e. the placebo light).
2468500|NCT03114475|Placebo Comparator|Placebo|A placebo light will be used as if the patient is irradiated with the laser beam.
2468609|NCT03114033|Experimental|Targeted therapeutic mild hypercapnia|Target arterial carbon dioxide range of 50-55 mmHg for 24 hours following randomisation
2468614|NCT03114033|Active Comparator|Targeted normocapnia (Standard care)|Target arterial carbon dioxide range of 35-45 mmHg for 24 hours following randomisation
2468699|NCT03113266|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2468774|NCT03112746|Experimental|Cognitive Orientation to daily Occupational Performance|One group was submitted to the CO-OP approach to learn cognitive strategies to perform the chosen tasks.
2468899|NCT03112096|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
2468907|NCT03112096|Experimental|Alzheimer's Disease Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 injection
3191833|NCT00802282|Experimental|3|Third of 5 groups, as described in the protocol and to which volunteers are blinded
3191834|NCT00802282|Experimental|4|Fourth of 5 groups, as described in the protocol and to which volunteers are blinded
3191835|NCT00802282|Experimental|5|Fifth of 5 groups as described in the protocol and to which volunteers are blinded
2469040|NCT03110822|Experimental|Rux Len and Steroid|Ruxolitinib Oral Tablet [Jakafi] at 5mg, 10mg or 15mg BID, Lenalidomide Oral at 5mg or 10mg QD and Methylprednisolone Oral at 40mg QOD. (Dose varies during dose escalation portion of the study)
2469055|NCT03110822|Experimental|Rux and Steroid until progression, then add Len|Subject will receive Ruxolitinib Oral Tablet [Jakafi] at 15mg BID, and Methylprednisolone at 40mg QOD until disease progression. Lenalidomide at 10mg QD will be added to the treatment (Ruxolitinib, Methylprednisolone) once disease progression was confirmed.
2469131|NCT03110315|Experimental|Suvorexant|Suvorexant - 10 mg (one tablet) taken by mouth once daily at bedtime with option to up-titrate to 20 mg (two tablets) taken by mouth once daily at bedtime.
2469140|NCT03110315|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth once daily at bedtime and two tablets taken by mouth daily at bedtime if subject up-titrates.
2469169|NCT03110081|Experimental|Quadratus lumborum block|Quadratus lumborum (QL) block group will receive a single shot injection of 25 ml 0.25% bupivacaine pre-operatively, followed post-operatively by infusion of ropivacaine 0.2% continuously administered via the QL catheter for at least 48 hours.
2469170|NCT03110081|Active Comparator|Epidural analgesia|Midthoracic catheters will be inserted preoperatively. A bupivacaine 0.1% infusion will be started before the surgical incision, and continuously administered for at least 48 hr at an infusion rate of 5 ml/hr.
2469218|NCT03109964|Active Comparator|Hemostasis with bipolar coagulation|Patients undergoing laparoscopic ovarian cystectomy with bipolar coagulation hemostasis.
2469223|NCT03109964|Experimental|Hemostasis with SURGIFLO|Patients undergoing laparoscopic ovarian cystectomy with SURGIFLO hemostasis.
2469297|NCT03109613|Experimental|Positive end-expiratory pressure (PEEP) level changes|Sequential changes in PEEP level within range of 4-8 cm H2O followed by measurement of V/Q mismatch at each level.
2469373|NCT03108963|Experimental|L-carnitine and Metformin|L-carnitine and Metformin in Obese PCOS Women trying induction of ovulation with clomiphene citrate.
2469375|NCT03108963|Active Comparator|placebo|placebo was given toObese PCOS Women trying induction of ovulation with clomiphene citrate.
3191836|NCT00802295|Active Comparator|standard dosis protocol|Administration of standard dosis of gonadotrophins for ovarian stimulation.
3191837|NCT00802295|Experimental|2|Administration of low dosis of Gonadotrophins for ovarian stimulation
2469515|NCT03107728|Experimental|Advanced orthotic brace|
2469516|NCT03107728|Active Comparator|Conventional orthotic brace|
2469659|NCT03107585|Experimental|bilateral cervical plexus block (GP1)|arm intervention GP1 : after skin disinfection and oral premedication , ultrasound guided cervical bilateral bloc ,with10 ml of bupivacaine 0.25 was realized in each side of deep cervical space; then general anesthesia was performed with local protocol
2469661|NCT03107585|Placebo Comparator|control(GP2)|GP2 control no specific intervention only general anesthesia was performed with local protocol
2469713|NCT03106584|Active Comparator|Glucosamine sulphate|"Glucosamine sulphate will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Glucosamine will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Aquamin-plus), after a washout period of not less than 1 month between the intervention arms of the study."
2469774|NCT03106324||TNE NDMM patients treated with lenalidomide regimen|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
3191838|NCT00802308|Experimental|Treatment A|Single dose administration of Egalet® morphine with alcohol
2468385|NCT03115515|Experimental|Adjustment in micrograms per day of thyroid hormone|"Patients in this group adjust thyroid hormone dose based on Visit 1 TSH and pre-pregnancy thyroid hormone dose. Further dose adjustments are made every 2-4 weeks based on serum TSH, as shown below:~TSH>10mIU/L, increase dose by 50mcg/day if dose <125mcg/day or increase by 75mcg/day if dose >125mcg~TSH 5.0-9.9mIU/L, increase dose by 25mcg/day if dose <125mcg/day or increase by 50mcg/day if dose >125mcg~TSH 2.0-4.9mIU/L, increase dose by 12.5mcg/day if dose <125mcg/day or increase by 25mcg/day if dose >125mcg~TSH 0.4-1.9mIU/L, no change~TSH<0.4mIU/L, decrease dose by 12.5mcg/day if dose <125mcg/day or decrease by 25mcg/day if dose >125mcg/day~TSH<0.1mIU/L, decrease dose by 25mcg/day if dose <125mcg/day or decrease by 50mcg/day if dose >125mcg/day~Thyroid hormone dose will NOT be decreased due to TSH<0.4mIU/L during the 1st trimester unless patient also has elevated circulating T4 and/or T3 levels, indicate of true hyperthyroidism."
2468410|NCT03115125|Other|Adult patients with severe sepsis|
2468473|NCT03114878|Active Comparator|TRT / EMDR|Tinnitus Retraining Therapy / Eye Movement Desensitization Reprocessing
2468476|NCT03114878|Active Comparator|TRT / CBT|Tinnitus Retraining Therapy / Cognitive Behavioral Therapy
2468514|NCT03114501|Experimental|Yoga Program Group|"Participants take part in the partner-based yoga program.~Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later)."
2468515|NCT03114501|Experimental|Waitlist Control Group (WLC)|"Participants receive standard of care.~Questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).~After the study has been completed, participant and caregiver/alternative caregiver offered the opportunity to take part in the partner-based yoga program."
2468578|NCT03114150|Experimental|Cardiorespiratory fitness training|Cardiorespiratory fitness training will be a 24-week supervised cycling program designed to improve cardiorespiratory fitness, with supervision directly from the research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes light intensity cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, 6 minutes of moderate intensity cycling per session will be added, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
2468579|NCT03114150|Active Comparator|Functional fitness training|Functional fitness training will be a 24-week supervised exercise program designed to focus on functional flexibility and mobility, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes of light intensity cycling and 20 minutes of dynamic stretching to increase range of motion and functional fitness, for 3 sessions/week. In each additional week, additional stretches will be added to maintain variety and improve flexibility of all major muscle groups.
2468631|NCT03113695|Experimental|obinutuzumab, lenalidomide, and HDMP|
2468681|NCT03113318|Experimental|Lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection and pulmonary metastasectomy from colorectal cancer
2468683|NCT03113318|Active Comparator|Pulmonary metastasectomy only|Only pulmonary metastasectomy from colorectal cancer
2468689|NCT03112967|Experimental|OSS(Suprep)|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
2468691|NCT03112967|Active Comparator|4L PEG solution(Colyte)|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
3157005|NCT00356291|Experimental|1|Participants will receive Skill-Building and Motivational Interviewing.
2468819|NCT03112200|Active Comparator|Subchondroplasty with Arthroscopy|After randomization to the study group, subjects assigned to the Subchondroplasty + Arthroscopy group will undergo the Subchondroplasty portion of the procedure before or after the Arthroscopy portion per the surgeon's discretion. All operative procedures are to be performed under aseptic conditions according to the institution's standards.
2468823|NCT03112200|Sham Comparator|Arthroscopy Alone|"After randomization, subjects assigned to the Arthroscopy control group will undergo arthroscopy of the study knee with one or more of the following procedures:~Partial meniscectomy~Lavage~Debridement~Loose body removal~Synovectomy~Removal of osteophytes in the notch or locations other than those adjacent to BML(s)~Superficial skin incision(s) should be created at the typical AccuPort® access point(s) as if the subject had undergone Subchondroplasty. The incisions should be closed in the typical fashion."
2468900|NCT03111797||video-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a video-assisted surgical procedure
2468905|NCT03111797||robot-assisted lobectomy group|patients operated of lung lobectomy for an early stage cancer using a robot-assisted surgical procedure
2468934|NCT03111524|Active Comparator|Intervention school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2468936|NCT03111524|Active Comparator|Intervention school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher.The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2469309|NCT03109132|Active Comparator|Model 3|Device - Experimental sample line Model 3
2468513|NCT03114709|Active Comparator|10 Keys to Health & Wellbeing|8, 90-minute, in-person, group sessions over 8 weeks
2468546|NCT03114254|Experimental|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days"
2468594|NCT03114007|Experimental|Preventure, Equipe and Inter-Action|Preventure program, Equipe program and Inter-Action services: Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program), parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program) and integrated services for youth with significant internalizing and externalizing problems (Inter-Action services).
2468604|NCT03114007|Experimental|Preventure program and Equipe program|Early personality-targeted interventions for students most at risk of mental health problems and substance misuse (Preventure program) and parent program mainly for parents of high risk youth, especially those reporting discord at home (Equipe program)
2468611|NCT03114007|No Intervention|Control|Treatment as usual
2468665|NCT03113474|Experimental|Palatable-neutral|Participants are exposed to palatable food in the first test session, and to the neutral food in the second test session.
2468673|NCT03113474|Experimental|Neutral-palatable|Participants are exposed to neutral food in the first test session, and to the palatable food in the second test session.
2468709|NCT03113149||knee osteoarthritis|Patients with knee osteoarthritis after having started physical therapy
2468769|NCT03112837|Experimental|drug group|live Lactobacillus, Bifidobacterium and Enterococcus ( two pills two times a day)with radiotherapy and Chemotherapy
2468772|NCT03112837|No Intervention|non-drug group|only receiving radiotherapy and chemotherapy
2468777|NCT03112837|No Intervention|healthy control group|
2468849|NCT03112382|Active Comparator|zinc supplement plus vitamin A and E|patients will be receiving zinc supplement plus vitamin A and E for 3 months.
2468857|NCT03112382|Active Comparator|vitamin A and E|patients will be receiving equivalent dose of vitamin A and E only for 3 months
2468861|NCT03112382|No Intervention|no vitamins|patients will be observed for 3 months
2468908|NCT03111888|Experimental|Patient-Specific Tracheobronchial Stent|Observe and document the ability of a patient-specific tracheobronchial stent to improve a patient's quality of life and symptoms associated with airway stenosis.
2469004|NCT03111602|Experimental|interventional group|The interventional group was submitted to dietary orientation to restrict polyphenol-rich foods
2469007|NCT03111602|No Intervention|control group|healthy group as comparator
2469048|NCT03110939|Experimental|hyperthermic perfusion group|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)
2469059|NCT03110939|No Intervention|control group|standard surgery of advanced lung cancer/esophageal cancer
2469108|NCT03110653|Active Comparator|Remifentanil|Remifentanil TCI: gradual withdrawal: reduction of 30% / 15 mins (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
2469109|NCT03110653|Placebo Comparator|NaCl 0.9%|Remifentanil abrupt discontinuation / NaCl 0.9% (control group with a reduction of 30% /15 mins) (2 -> 1.4 -> 1 -> 0.7-> 0.5 -> 0.35 -> 0.25 -> 0 ng/ml)
2469220|NCT03110237|Active Comparator|Control Balance Training (BT) class|Group based circuit training class, 30 minute session, twice a week for three weeks
2469226|NCT03110237|Experimental|Fallproof Balance Training (BT) class|Group based balance training class based on the FallProof(TM) approach, 30 minute session , twice a week for three weeks
2469284|NCT03109444||Hip Ultrasound of Newborn infants|Newborns born at CRMC (term newborns and pre-mature newborns over 32 weeks gestational age). This will include newborns cared for in the neonatal intensive care unit (NICU) over 32 weeks gestational age, and newborns cared for on the normal labor and delivery floor. the newborn will receive an ultrasound of their hips while in the hospital (done by a trained sonographer). This will happen in the patient's room with the LAR present. An ultrasound of the hip takes approximately 15 minutes and is non-invasive, non-painful and does not utilize any ionizing radiation. Newborns will be scheduled to return once a week until the newborn's hips reach criteria for normal hip morphology or the newborn reaches 6 weeks of corrected age.
2469341|NCT03109067|Experimental|Standardized meal|"Standardized meal for :~50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism"
2469364|NCT03108768|Experimental|Successor of Phonak Virto V|The successor of Phonak's Virto V will be fitted to the participants individual hearing loss.
2469365|NCT03108768|Active Comparator|Phonak Virto V|Phonak Virto V will be fitted to the participants individual hearing loss.
2469447|NCT03108417|Experimental|cNEP|continuous negative external pressure will be used nightly by all participants
2469525|NCT03108053|Active Comparator|Guidewire used|Patients whose semirigid ureteroscopy procedure is conducted with the use of safety guidewire
2469527|NCT03108053|Experimental|No guide wire used|Patients whose semirigid ureteroscopy procedure is conducted without the use of safety guidewire
2469569|NCT03107494|Experimental|Treatment with GATS|Gala Airway Treatment System (GATS) / RheOx
2469590|NCT03107234||Patient with breast cancer requiring surgery to|
2469630|NCT03107065|Experimental|single treatment|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands
3191839|NCT00802308|Experimental|Treatment B|Single dose administration of Egalet® morphine with alcohol
2469700|NCT03106818|Active Comparator|group A|( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
2469705|NCT03106818|Active Comparator|group B|bupivacaine 0.125% infusion in the presternum , for 48 hours
2481266|NCT03028181||1|Control group non-exposed to tobacco smoking
3191840|NCT00802308|Experimental|Treatment C|Single dose administration of Egalet® morphine with alcohol
3191841|NCT00802308|Placebo Comparator|Treatment D|Single dose administration of Egalet® morphine with water
3191842|NCT00802321|Experimental|dutasteride|
3191843|NCT00802334|Experimental|1|
3191844|NCT00802347|Experimental|I5NP|
3191845|NCT00802347|Placebo Comparator|Saline|
3191846|NCT00802373|Experimental|I|Solifenacin succinate 5/10mg
3191847|NCT00802373|Experimental|II|Tolterodine 4mg
3191848|NCT00802399|Other|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
2468569|NCT03114085|Experimental|Apatinib Combined with Capecitabine|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group; Capecitabine,1000mg/m2,twice a day (at intervals of 12 hours,equivalent to a total daily dose of 2000 mg / m2),orally,sustained 14 days, off for 7 days, every 21 days for a cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group.
2468570|NCT03114085|Active Comparator|Apatinib|Apatinib,500mg,once a day, orally (after breakfast),from day 1 to day 21 (including day 21) for continuous administration, every 21 days for one cycle. If after two dose adjustments, the subject still can not tolerate toxicity, he or she should be out of group;
2468615|NCT03113812|Experimental|ABvac40|
2468618|NCT03113812|Placebo Comparator|Placebo|
2468639|NCT03113539|Experimental|Subjects awaiting for an aortic evaluation|"Subjects already waiting for an aortic evaluation, either a first diagnostic scan or follow-up of a known aneurysm.~Each subjects will have the two CT-scans on the same day."
2468710|NCT03113227|Active Comparator|Successful Induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
2468722|NCT03113227|Active Comparator|Failed induction of labor group|Both transvaginal ultrasound and vaginal examination will be done for that group
2468787|NCT03112668|Experimental|Supportive Care (ACT)|Patients and their partners attend 6 weekly ACT sessions over 60-75 minutes. Couples learn skills of acceptance, avoidance, awareness, values and committed action, mindfulness and values in relationships, and handling persistent worries and concerns. Patients and their partners also do homework assignment after each session.
2468816|NCT03112161|Experimental|Eucaloric|Participants will consume a eucaloric diet with a macronutrient composition of 20% protein, 30% fat and 50% carbohydrate for 4 days (Eucaloric Feeding Period). The caloric value of the diet will be calculated based on lean body mass plus an activity factor to ensure energy and macronutrient balance.
2468821|NCT03112161|Experimental|Overfed|Following 3 days of eucaloric feeding, participants will complete a 1-day overfeeding period (Overfeeding Feeding Period), during which their diet will have a daily energy value of 40% greater than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
2468825|NCT03112161|Experimental|Underfed|Following 3 days of eucaloric feeding, participants will complete a 1-day underfeeding period (Underfeeding Feeding Period), during which their diet will have a daily energy value of 40% less than the eucaloric diet (Eucaloric Arm), although the macronutrient composition will remain the same (20% protein, 30% fat, 50% carbohydrate).
2468911|NCT03112044|Experimental|HCV+ lung transplant to HCV- recipients|HCV+ donor lungs will be treated with Normothermic Ex Vivo Lung Perfusion (EVLP) in order to reduce viral load and minimize risk of HCV transmission. Patients who become viremic defined as at least two consecutive positive samples will receive sofosbuvir/velpatasvir 400 mg/100 mg (Epclusa) for 12 weeks.
2468978|NCT03111459|Experimental|Primary Study Arm|Patients meeting primary inclusion/exclusion criteria will be enrolled in this arm and treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
2468987|NCT03111459|Experimental|Expanded Selection Arm|Patients who fail to meet the inclusion criteria of the Primary Study Arm may be enrolled under the Expanded Selection Arm and be treated with the Medtronic Valiant Thoracoabdominal Stent Graft System.
2469038|NCT03111030|Experimental|ProacTive SCI|Individualized physical activity coaching sessions
2469050|NCT03111030|No Intervention|Wait-list control|Standard care, receiving physical activity coaching sessions after completing post-testing
3157006|NCT00356291|Active Comparator|2|Participants will receive Skill-Building.
3157007|NCT00356317|Experimental|1|Participants will receive a 15-week family therapy
2469374|NCT03108989|Experimental|Sugammadex group|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
2469376|NCT03108989|Active Comparator|Neostigmine group|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
2469413|NCT03108534|Experimental|CHF1535 NEXThaler|CHF1535 100/6 NEXThaler (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
2469414|NCT03108534|Active Comparator|CHF1535 pMDI|CHF1535 100/6 pMDI (Beclometasone dipropionate 100 µg + formoterol fumarate 6 µg)
2469417|NCT03108534|Placebo Comparator|Placebo|Double dummy study: placebo is for both CHF1535 pMDI and CHF1535 NEXThaler
2469500|NCT03108079|Other|Arm 1|"Women who agree to participate will undergo a standard high resolution, thin slice pelvic floor static/dynamic MRI study, first with a full bladder, and after the bladder is emptied. Bladder filling and drainage will be performed sequentially, using each of the 2 catheter types (Cystosure Urinary Access Catheter and Foley Catheter). During bladder emptying, a cine video scan will be taken at the midsagittal plane to show the dynamics of the bladder fluid and walls during emptying. Each subject will serve as their own control.~Interventions are listed in the Interventions Section."
2469563|NCT03107676|Active Comparator|trunk endurance with hands above head|participants had to practice trunk extensors endurance training with having hands above head.
2469564|NCT03107676|Active Comparator|trunk endurance with hands behind head|participants had to practice trunk extensors endurance training with having hands behind head.
2469565|NCT03107676|Active Comparator|trunk endurance with hands parallel|participants had to practice trunk extensors endurance training with having hands parallel to the trunk.
2469566|NCT03107676|No Intervention|trunk endurance with no intervention|participants will be tested for trunk extensors endurance with having hands on chest but no intervention.
2469608|NCT03107312||Known vaccination history|Single blood sample collection from subjects with verified records of vaccination or recent booster immunization against measles, mumps, rubella, varicella, tetanus, pertussis, poliomyelitis, diphtheria, meningococcal infection
3157008|NCT00356317|Active Comparator|2|Participants will receive a 3-week family therapy (treatment as usual)
3157009|NCT00356343|Experimental|NMES Strengthening Group|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
3157010|NCT00356343|No Intervention|Control Group|No Intervention Control Group
3157011|NCT00356343|Active Comparator|Volitional Strengthening|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
2468616|NCT03114189|Active Comparator|Footbath, care of sleep|"Warm water (37°C) filled up to the level of the ankle. Water has to be heated up to 42°C and increased to the calf 's half height within 15 minutes.~Information about wrong and correct behaviour."
2468619|NCT03114189|Active Comparator|Care of sleep|Information about wrong and correct behaviour.
2468643|NCT03113526|Active Comparator|Less than 30ml per 24-hour|Drain removed as early as day one as long as output less than 30ml per 24-hour
2468645|NCT03113526|Active Comparator|Less than 100ml per 24-hour|Drain removed as early as day one as long as output less than 100ml per 24-hour
2468694|NCT03113188|Experimental|CBP501, CDDP, Nivolumab|CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients with Advanced Refractory Tumors
2468795|NCT03112850|Active Comparator|Group A|Participants who will be fitted with hearing aids for the first 3 months of 6 months auditory training program
2468797|NCT03112850|Active Comparator|Group B|Participants who will be fitted with hearing aids for the second 3 months of 6 months auditory training program
2468828|NCT03112148|Experimental|Treatment A|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fed state.
2468831|NCT03112148|Experimental|Treatment B:|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fed state.
2468840|NCT03112148|Experimental|Treatment C|Single oral 10 mg dose of tofacitinib MR-FAST administered in the fasted state.
2468846|NCT03112148|Experimental|Treatment D|Single oral 10 mg dose of tofacitinib MR-SLOW administered in the fasted state.
2468854|NCT03112148|Experimental|Treatment E|Single oral 10 mg dose of tofacitinib MR-MODERATE administered in the fasted state
2468860|NCT03112148|Experimental|Treatment F|Single oral 10 mg dose of tofacitinib IR Solution (10 mL of the 1 mg/mL solution) administered in the fasted state
2468915|NCT03111810|Active Comparator|Active|Prednisolone 20mg once daily and AZD4017 400mg twice daily for 7 days.
2468916|NCT03111810|Placebo Comparator|Placebo Oral Tablet|Prednisolone 20mg once daily and placebo twice daily for 7 days.
3157012|NCT00356356|Experimental|All subjects|257 subjects
3157013|NCT00356447|Active Comparator|Arm 1|
2469190|NCT03109912|No Intervention|Control|At the baseline fitness assessment, the FitBit daily step goal is set at the manufacturer standard 10,000 steps. Throughout the study, these 30 participants will receive generic, non-personalized encouragement and recommendations (if requested by the participant) for PA at routine clinic visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, exercise is reinforced with generic encouragement, export FitBit data and review any missing data concerning for equipment failure or user error.
2469194|NCT03109912|Experimental|Exercise Intervention|The baseline fitness assessment includes an additional 30-minutes for exercise prescriptions; participant FitBit daily step goal is set based on a collaborative review between the participant and PT and participants receive individualized exercise prescriptions based on their assessment. Throughout the study, these 30 participants will receive customized encouragement and personalized fitness recommendations for PA at routine visits, baseline and follow-up assessments at 3 and 6 month clinic visits. At the 3-month and 6-month visits, study team members meet again with the participant for an additional 30-45 minutes to reinforce exercise through exercise prescriptions and individualized encouragement, export FitBit data and review any missing data concerning for equipment failure or user error and address any specific exercise concerns. FitBit daily step goals may be adjusted based on collaborative review between the participant and PT.
2469313|NCT03109275|Active Comparator|Single MRI examination|40 subjects will benefit from a full MRI
2469318|NCT03109275|Sham Comparator|Reproducibility study|10 subjects will benefit from the realization of 3 MRI. An MRI examination performed at the time of inclusion and then an examination, at 3 months and at 9 months (ie 3 examinations per subject).
2469362|NCT03108937|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
2469363|NCT03108937|Placebo Comparator|saline|Same amount of saline will be administrated.
2469381|NCT03108560|Experimental|Sublobar group|Patients receive sublobar resection, including wedge resection and segmentectomy.
2469382|NCT03108560|Active Comparator|Lobectomy group|Patients receive lobectomy.
2469474|NCT03108391|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 3 to size 5 based on manufacturer guidelines
2469477|NCT03108391|Active Comparator|LMA Supreme|Subjects will receive the LMA Supreme size 3 to size 5 based on manufacturer guidelines
2469511|NCT03107910|Other|Experimental Stigma Counseling|Single session, stigma focused, anticipated HIV stigma counseling will be provided. Intervention will include a focus on barriers to testing.
2469514|NCT03107910|Other|Control Health Information|Single session, online health information seeking and evaluation. HIV/STI testing appointments are provided online. Stigma and Structural Interventions
3157014|NCT00356447|Placebo Comparator|Arm 2|
3157015|NCT00356460|Experimental|1 - Part 1|Dose Group
3157016|NCT00356460|Experimental|2 - Part 1|Dose Group
3157017|NCT00356460|Experimental|3 - Part 1|Dose Group
3157018|NCT00356460|Experimental|4 - Part 1|Dose Group
3157019|NCT00356460|Experimental|5 - Part 1|Dose Group
3157020|NCT00356460|Experimental|6 - Part 1|Dose Group
3157021|NCT00356460|Experimental|1 (Part 2)|
3157022|NCT00356460|Experimental|2 (part 2)|
3157023|NCT00356473|Placebo Comparator|Placebo|Placebo
3157024|NCT00356473|Experimental|Atorvastatin|Atorvastatin
3157025|NCT00356486|Experimental|A|Peginterferon alfa-2a (40 KD) (270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (40 KD) (180 µg/week) + Ribavirin (1000-1200 mg/day) for 8 weeks
3157026|NCT00356486|Experimental|B|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
3157027|NCT00356616|Experimental|A|Trizivir+ Tenofovir 2/day
3157028|NCT00356616|No Intervention|B|antiretroviral treatment optimizated by genotyp
3157029|NCT00356642|Experimental|Single dose 1 cohort|Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
3157030|NCT00356642|Experimental|Repeat dose 1 cohort|Subjects with BSA disease involvement between 10 and 15% will be included. Subjects will receive either 100-150 mg GW842470X or placebo in a ratio of 3:1
2468684|NCT03113370|Experimental|Fish Oil|4 grams of fish oil per day
2468685|NCT03113370|Placebo Comparator|Placebo|4 grams of olive oil capsules per day
2468707|NCT03113032|Experimental|Exercise group 1|This group of patients will receive the P-SEC exercise intervention protocol on their 'surgical' leg in addition to their normal pre-surgical care.
2468714|NCT03113032|Experimental|Exercise group 2|This group of patients will receive the P-SEC exercise intervention protocol on their 'non-surgical' leg in addition to their normal pre-surgical care.
2468725|NCT03113032|Active Comparator|Control group|This group of patients will not receive the P-SEC protocol but will follow normal pre-surgical care along with the other two groups of patients.
2468760|NCT03112642|Active Comparator|Standard Group|In the Standard Group, in the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered into the brachial plexus of the upper limb being operated on, at the supraclavicular level.
2468763|NCT03112642|Experimental|Test Group|"In this group, the ultrasound guided local anesthetic block into the brachial plexus at the supraclavicular level of the upper limb being operated on will be supplemented by use of a blockade monitor (Nerve stimulator device) to direct final placement of the needle for the nerve block.~Only this group of the patients will receive this intervention with sufficient detail so that it can be distinguished from the Test Group"
2468835|NCT03112330|Experimental|platelet rich plasma injection group|To evaluate the safety and efficacy of plasma rich platelet injection on inferior turbinate mucosa in patients with atrophic rhinitis
2468876|NCT03111927|No Intervention|Reference Arm: Breastfed|Epidemiological reference group of breastfed infants.
2468879|NCT03111927|Experimental|Investigational|Infant Formula: enriched level of myelin-relevant nutrients
2468882|NCT03111927|Active Comparator|Control|Infant formula: standard level of myelin-relevant nutrients
2468956|NCT03111667|Experimental|Student Participants: Teen Marijuana Check Up|2 Session Motivational Enhancement Therapy intervention for adolescents who use marijuana.
2468958|NCT03111667|Other|Student Participants: Treatment As Usual|Students will receive referrals to local agencies and other resources as typically done by school based staff. At the end of research follow-up period, students in this condition will be eligible to receive the active intervention.
2468960|NCT03111667|Experimental|Interventionist Participants: Gold Standard Coaching|Interventionists will receive weekly coaching and feedback about sessions and skills from the project PI.
2468961|NCT03111667|Active Comparator|Interventionist Participants: As Needed Coaching|Interventionists will receive coaching and feedback about sessions and skills from the project PI only when sessions fall below adherent skill levels.
2468963|NCT03111667|No Intervention|Administrator Participants: Environment|School Administrators will provide data about the school environment.
2468964|NCT03111667|No Intervention|School Staff Participants: Environment|Staff will provide data about the school environment
3157031|NCT00356642|Experimental|Repeat dose 2 cohort|Subjects with BSA disease involvement between 30 and 40% will be included. Subjects will receive either 300-400 mg GW842470X or placebo in a ratio of 3:1
2469095|NCT03110718|Experimental|ArmeoP+real MV|The patients underwent forty 1h Armeo-P training sessions (i.e. five times a week for eight consecutive weeks). During the first session, the device was adjusted to the patient's arm size and the angle of suspension. The working space and the exercises were selected once the UL had been fitted with the system. All the subjects in the arm received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air, wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude so that it was just below the threshold for perceiving an illusory movement. The investigators chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
2469098|NCT03110718|Active Comparator|ArmeoP+ Sham MV|"The patients underwent the same Armeo-P trainingas the experimental group. Only the vibration protocol was didderent. Indeed, in the control group a sham vibration was used, while in the experimental group, patients underwent a real one.~Sham vibration was delivered to the control group using the same procedure of the experimental group;however, vibration intensity was subthreshold (i.e. 50mBar below the threshold)."
2469147|NCT03110406|Experimental|whole-body vibration|The whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, semi-squat with knees at 15º flexion and upper limbs slightly flexed and supported on the platform. The exercises will be performed, in the first two weeks, for 10 minutes consisting of 60 seconds of low intensity with 30 seconds of rest standing in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. °
2469151|NCT03110406|Sham Comparator|Simulated whole-body vibration|The simulated whole-body vibration training will be performed with the patients in the static position, feet apart at 20 cm, in semi-squat with knees at 15º of flexion and upper limbs slightly flexed and supported on the platform that presents a motor that simulates the noise of the platform But does not produce any therapeutic effect
3157032|NCT00356642|Experimental|Repeat dose 3 cohort|Subjects with BSA disease involvement >=50% will be included. Subjects will receive either 500-1000 mg GW842470X or placebo in a ratio of 2:1
3157033|NCT00356681|Placebo Comparator|Arm A Placebo|Blinded AMG 706 placebo plus paclitaxel
3157034|NCT00356681|Experimental|Arm B Experimental|Blinded AMG 706 plus paclitaxel
3191849|NCT00802425|Experimental|2|AM-111 low dose
2469392|NCT03108716|Experimental|hamate hook removal|The patients were assigned to hamate hook removal(n=13).
2469393|NCT03108716|Experimental|microscrew internal fixation|The patients were assigned to the microscrew internal fixation after open reduction (n=11).
2468621|NCT03113747|No Intervention|The standard treatment|"All patients will be subjected to standard stepped treatment of burn wounds:~Infusion therapy aimed to eliminate disorders of homeostasis during burn shock and burn toxemia;~Systemic antibiotic therapy for preventing infectious complications;~Adequate analgesia and sedation;~Decompression necrotomy in the first 24 hours following the burn trauma;~Necrectomy simultaneously with imposition of lyophilized xenografts performed in the first 1-5 days after applying burn;~Autologous skin grafting 3-5 days after performed xenografts with the perforation coefficient 1:3"
2468663|NCT03113435|No Intervention|Standard|In this group standard care will be provided to patients undergoing major abdominal surgery, regarding hemodynamic optimization
2468672|NCT03113435|Active Comparator|NICE group|In this arm patients will be treated according to stroke volume optimization described in NICE program
2468677|NCT03113435|Experimental|Oxygen consumption group|In this arm patients will receive hemodynamic optimization based on their oxygen consumption need
2468717|NCT03113110|Other|Empagliflozin Arm|Posttransplant Diabetes Mellitus (PTDM) patients after kidney transplantation receiving Empagliflozin 10 MG [Jardiance]
2468782|NCT03112720|Active Comparator|Epidural blood patch|20ml of sterile blood is obtained from the patients arm and placed in the epidural space using standard sterile epidural access.
2468785|NCT03112720|Experimental|Sphenopalatine Ganglion Block|Cotton tip applicators are used to deliver lidocaine to the posterior nares in the area of skin overlying the Sphenopalatine gangion
2468917|NCT03112070|Experimental|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
2468919|NCT03112070|No Intervention|Control session (CONTROL)|A 45-min session with no exercise. During this session, participants will remain seated or standing as desired. They will read, talk, and drink water, but do nothing else.
2468973|NCT03111485|Experimental|A (drug-placebo)|Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg) followed by a washout period and placebo oral capsule, each taken at bedtime for 2 weeks
2468981|NCT03111485|Experimental|B (placebo-drug)|Placebo oral capsule followed by a washout period and Sinemet CR (Long-acting levodopa: levodopa 200mg/ carbidopa 50mg), taken at bedtime for 2 weeks
3157035|NCT00356681|Active Comparator|Arm C Comparator|Open-label bevacizumab plus paclitaxel
3157036|NCT00356707||1|This cohort comprises women from the Black Women's Health Study, a prospective study of African American women, who lived in the Los Angeles, New York, or Chicago metropolitan areas at the time of completion of the 1995, 1997, or 1999 questionnaires.
2469184|NCT03110367|Active Comparator|Pain Reframing Intervention|"Participants will be randomized into this group:~- Memory reframe with parent facilitated by researcher:~Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways."
2469187|NCT03110367|Sham Comparator|Attention Control Group|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Attention control (watch video [Planet Earth] for same amount of time): Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience."
2469188|NCT03110367|No Intervention|Normal Reminiscing|"Participants will include 90 youth scheduled for a pectus repair or a spinal fusion surgery, surgeries associated with high levels of post-surgical pain, and their parents. They will be recruited at the Alberta Children's Hospital. The timelines and measures to be administered to parents and children are listed below. The timelines will include a baseline assessment (1-3 weeks pre-op), in hospital assessment for several days, 1-2 weeks post-op (acute recovery phase), the 2-4 week post-op clinic visit (memory reframing intervention) and 6 weeks post-op.~Participants will be randomized into this group:~- Normal Reminiscing: Parents and youth in the normal reminiscing group will be instructed to reminisce with their children about the in-hospital and post-surgery periods as they normally would."
2469250|NCT03109821||THA patients|
2469306|NCT03109379|Experimental|TAR-302-5018 (42-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.
2469311|NCT03109379|Experimental|TAR-302-5018 (84-day Indwelling)|Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 84. TAR-302-5018 releases trospium gradually during the 84 day indwelling time.
2469399|NCT03108794||Immune tolerance phase|Immune tolerance phase is diagnosed based on the presence of high serum levels of HBV-DNA, hepatitis B e antigen (HBeAg), but normal or minimally elevated serum alanine aminotransferase (ALT), and normal liver or only minimal histological activity and scant fibrosis.
2469400|NCT03108794||HBeAg positive CHB|HBeAg positive CHB is defined as those with HBsAg positive for more 6 months, HBeAg positive, high HBV DNA, elevated serum levels of ALT and histological activity.
2469402|NCT03108794||HBeAg negative CHB|HBeAg negative CHB is defined as those with HBeAg negative, anti-HBe positive, lower serum HBV DNA levels and histological necroinflammation and fibrosis.
3157037|NCT00356733|Experimental|EPO rise|EPO administration
3157038|NCT00356733|Experimental|EPO stable|EPO and stable Hemoglobin
3157039|NCT00356733|No Intervention|control|standard treatment
2468660|NCT03113682|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
2468701|NCT03113175|Experimental|Collabri Flex|Collaborative care
2468706|NCT03113175|Experimental|Consultation-Liaison|Consultations with general practitioner
2468841|NCT03112395|Experimental|Combined SOC/Pio treatment|Prospective trial (1 month SOC, 2 month SOC + Pio Medical Device, 1 month SOC follow-up) month, with collection of endpoints every second week
2468887|NCT03112018|Active Comparator|Standard care|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation"
2468890|NCT03112018|Experimental|Enhanced care (intervention)|"Data strengthening~modified Safe Childbirth Checklist (mSCC) implementation~Health provider training (PRONTO)~Quality Improvement (QI) Cycles"
3191850|NCT00802425|Placebo Comparator|1|
2469044|NCT03110757|Experimental|Group A|10mcg Sm-TSP-2/Alhydrogel® (n=8)
2469060|NCT03110757|Experimental|Group B|10mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2469070|NCT03110757|Experimental|Group D|30mcg Sm-TSP-2/Alhydrogel® (n=8)
2469075|NCT03110757|Experimental|Group E|30mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2469081|NCT03110757|Experimental|Group G|100mcg Sm-TSP-2/Alhydrogel® (n=8)
2469083|NCT03110757|Experimental|Group H|100mcg Sm-TSP-2/Alhydrogel®/+ AP 10-701 (n=8)
2469085|NCT03110757|Active Comparator|Pooled Active Comparator Group|Euvax B Hepatitis B vaccine (n=12)
2469127|NCT03110354|Experimental|DS-3201b in AML or ALL|DS-3201b is administered orally to participants with AML or ALL at a starting dose of 100 mg once a day, and then possibly at higher doses depending on safety observations
2469213|NCT03110159|Experimental|Levulan® Kerastick® and blue light illumination|"Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light using the standard FDA approved treatment time for the BLU-U device of 16 minutes 40 seconds.~Each subject will be randomized to undergo treatment to one side face and one dorsal forearm/hand treatment, while the other side will serve as untreated control. Treatments will be conducted at the beginning of study Day 1 (Initial Treatment), Day 30 after the initial treatment (+ 3 days), Day 180 after initial treatment (+ 30 days), 1 year after the initial treatment (+ 30 days), and every 6 months (+ 30 days) thereafter for 2 additional years."
2469288|NCT03109652|Active Comparator|IV TXA alone|One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
2469291|NCT03109652|Experimental|IV TXA and Oral TXA 5 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5."
2469294|NCT03109652|Experimental|IV TXA and Oral TXA 2 days|"One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.~Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2."
2469439|NCT03108443||Glaucoma|Subjects identified as having glaucoma. No interventions will be performed.
2469440|NCT03108443||Healthy controls|Subjects identified as having healthy eyes with no disease.
2469452|NCT03108131|Experimental|Treatment (cobimetinib, atezolizumab)|Participants receive cobimetinib PO QD on days 1-21 and atezolizumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2469539|NCT03107845|Active Comparator|Cognitive Behavior Therapy|Cognitive Behavioral Therapy without psychometric Feedback.
2469541|NCT03107845|Experimental|CBT plus Feedback|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback
2469544|NCT03107845|Experimental|CBT plus Feedback plus CST|Cognitive Behavioral Therapy (CBT) with Psychometric Feedback and Clinical Support Tools (CST)
2469585|NCT03107429|Active Comparator|Placebo and Trendelenburg Position|"Volunteers received placebo medication and placed in Trendelenburg.~IOP will be measured. Participants will then be administered with a placebo and after 2.5 hours will be placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
2469586|NCT03107429|Experimental|Acetazolamide and Trendelenburg Position|"Volunteer given acetazolomide and placed in Trendelenburg position and IOP measured.~IOP will be measured. Participants will then be administered with acetazolamide and after 2.5 hours placed in 17 degrees head-down position for a minimum of 1 hour and maximum 4 hours. Repeat IOP measure will be taken whilst still in the Trendelenburg position after 5 mins and then every 30 minutes."
2469623|NCT03107117|Experimental|Computer counseling|a computer-assisted adolescent motivational intervention called e-toke plus an online parenting program - Parenting Wisely
2469627|NCT03107117|Active Comparator|Standard care|Standard care is typically referral to counseling for substance use
3157040|NCT00356746||1|elective CABG only patients
3157041|NCT00356746||2|elective ICD replacement surgical patients requiring general anesthesia
2469806|NCT03105739|Experimental|Anesthetised|LMA removal once the halogenated anesthetic turned off
2469808|NCT03105739|Active Comparator|Awake|LMA removal once the patient fully regained consciousness
2469859|NCT03105505|Active Comparator|Permethrin 5%|Contains permethrin 5% w/w (equivalent to 50 mg/g), formaldehyde solution 0.278% w/w and butylated hydroxytoluene (E321) 0.02% w/w.
3157042|NCT00356824||1|HIV-infected children in Uganda
3157043|NCT00356837|Experimental|A|Those with extremity fractures.
3157044|NCT00356928|Experimental|Cyclophosphamide + T cells|Conditioning regimen with cyclophosphamide followed by donor T cells on Day 0.
3157045|NCT00356941|Experimental|Chemoradiation Treated Patients|Patients receiving Docetaxel, Oxaliplatin and radiotherapy.
3157046|NCT00357149|Active Comparator|A|Cisplatin from day 1 to day 4 and 5-FU for 4 days starting immediately after the end of cisplatin infusion on day 1. Both drugs were administered during week 1 and 6 of irradiation, starting from day 1 of weekly radiotherapy.
2468666|NCT03113357|Experimental|conventional exercise therapy|Craniocervical flexion exercises, performed in supine lying, aimed to target the deep neck flexor muscles. Then they trained to be able to hold progressively increasing ranges of craniocervical flexion using feedback from an airfilled pressure sensor placed behind the neck. The muscles of the scapula, particularly the serratus anterior and lower trapezius, were trained using inner range holding exercises of scapular adduction and retraction, practiced initially in the prone lying position. The subjects were trained to sit with a natural lumbar lordosis while gently adducting and retracting their scapulas and gently flexed their cranio-cervical spine to facilitate the deep neck flexors.
2468687|NCT03113084|Experimental|Group Sodium Heparin UQ First|The participants will receive the Sodium heparin UQ subcutaneous drug administration at first period and the Sodium heparin FK subcutaneous drug administration at second period
2468688|NCT03113084|Experimental|Group Sodium Heparin FK First|The participants will receive the Sodium heparin FK subcutaneous drug administration at first period and the Sodium heparin UQ subcutaneous drug administration at second period
3174794|NCT00627211|Experimental|CO2 insufflation|CO2 used for insufflation during gastroscopy to expand the lumen for inspection of the mucosal lining. This is not standard procedure and therefore experimental intervention.
3174795|NCT00627237|Experimental|Immediate start|Starts the 12 week intervention immediately after enrollment
2468826|NCT03112213||Participants With RA|Participants with RA who are being treated with tocilizumab and NSAIDs will be observed for approximately 6 months to evaluate the quantitative pattern of NSAID use and the impact of treatment with tocilizumab on NSAID use.
3191851|NCT00802425|Experimental|3|AM-111 high dose
2468965|NCT03111251|Experimental|Provider-only intervention|New provider- and system-level evidence-based strategies for increasing HPV vaccination rates are being implemented throughout the entire clinic network. This includes provider assessment and feedback, provider reminders, provider education, and patient reminders.
2468968|NCT03111251|Experimental|Provider plus parent intervention|Clinics randomized to the provider plus parent intervention will receive both the provider intervention and the parent education intervention.
2469036|NCT03110952|Experimental|TDENV-PIV x2|2 doses of TDENV-PIV on Day 0 and Day 28
2469039|NCT03110952|Experimental|TDENV-F17/TDENV-PIV|1 dose TDENV-F17 on Day 0 and 1 dose TDENV-PIV on Day 28
2469049|NCT03110952|Experimental|TDENV-PIV/TDENV-F17|1 dose TDENV-PIV on Day 0 and 1 dose TDENV-F17 on Day 28
2469068|NCT03110952|Placebo Comparator|Placebo|2 doses placebo (phosphate buffered saline) Day 0 and Day 28
2469340|NCT03109041|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a whipple procedure for pancreatic cancer will receive an implant at the time of surgery of the new CivaSheet directional brachytherapy device. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
2469421|NCT03108755|Experimental|ASP7713 Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will be started on a fixed single dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2469423|NCT03108755|Placebo Comparator|Placebo Single Ascending Dose|Successive cohorts of 8 non-Japanese participants (6 ASP7713/ 2 Placebo / 1-7 cohorts) will each be started on a single fixed dose of ASP7713 or matching Placebo. The first two participants will receive either ASP7713 or matching placebo. If no safety issues are observed in the first 24 hours in the first two participants, then the remaining six participants will be dosed. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2469427|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2469431|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Adults: 18-55 years)|Successive cohorts of 16 participants consisting of 8 non-Japanese and 8 Japanese (12 ASP7713/ 4 Placebo /1-3 cohorts) will each be started on a fixed multiple dose of ASP7713 or matching Placebo twice or three times daily for 14 days. Safety, tolerability and available Pharmacokinetic data from proceeding cohorts will be assessed for dose escalation.
2469434|NCT03108755|Experimental|ASP7713 Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
2469436|NCT03108755|Placebo Comparator|Placebo Multiple Ascending Dose (Elderly: 65 years or older)|Dosing of the non-Japanese elderly cohort will commence after having established the safety and tolerability of corresponding dose in adults male and female participants.
2469495|NCT03108118||Acute respiratory failure|We are enrolling patients who are intubated because of acute respiratory distress syndrome, pneumonia, septic shock, or severe acute brain injury (GCS ≤ 8 prior to intubation). This population is targeted for study because they are at relatively high risk of requiring prolonged mechanical ventilation.
2469562|NCT03107702||Melatonin and bariatric surgery|the relationship between melatonin level and analgesia requirement.
3174796|NCT00627237|Experimental|Waitlist group|Starts the 12 week intervention 12 weeks after initial enrollment
3174797|NCT00627250|Experimental|A|Amantadine 100 mg every morning and 12 noon
3174798|NCT00627250|Placebo Comparator|B|Placebo tablet every morning and 12 noon
3174799|NCT00627263|No Intervention|1|Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
3174800|NCT00627263|Experimental|2|In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
3174801|NCT00627276|Experimental|Arm I|Patients receive oral omega-3 fatty acid capsules 3 times daily for up to 8 weeks.
3174802|NCT00627276|Placebo Comparator|Arm II|Patients receive oral placebo olive oil capsules 3 times daily for up to 8 weeks.
2468695|NCT03112980|Experimental|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI) using the most appropriate CE (Conformité Européene)-marked device available, with a minimum demand of experience of 30 implanted devices/type per center.
2468697|NCT03112980|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement (SAVR) with free choice of surgical bioprosthesis and free choice of surgical access according to the surgeon's preference.
2468863|NCT03112291|Experimental|permanent teeth apexification|They should have one permanent tooth with traumatic necrosis, which in turns should show color alteration, fistulae, periapical lesion, and/or internal or external root resorption, pain, or absence of pulp response to sensitivity tests at a clinical examination to be considered necrotic. Male and female patients who had not undergone antibiotic therapy 3 months before the treatment were included and clinical and radiographic examinations confirmed pulp necrosis. This study analyzed the clinical and microbiological results of the endodontic treatment performed on permanent teeth with necrosis caused by traumatic injury and treated using revascularization technique, double antibiotic paste, intra-canal medication, and an MTA cervical plug.
2468891|NCT03111823|Experimental|Supportive Care (aerobic exercise)|Patients undergo aerobic exercise sessions consisting of cycling or walking at a low-moderate intensity and progressing to moderate intensity for 30 minutes 2 times a week for up to 8 weeks.
2468929|NCT03111537|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered alternative nicotine products and instructed for partial or complete substitution of cigarettes (subject's choice);
2468930|NCT03111537|Experimental|Complete Substitution E-Cigarette|Complete substitution (i.e., no smoking) with e-cigarette use
2468931|NCT03111537|Experimental|Partial Substitution E-Cigarette|Partial substitution, encouraged to use e-cigarettes instead of smoking usual cigarettes
2468932|NCT03111537|Experimental|Complete Substitution Nic Gum or Lozenge|Complete substitution (i.e., no smoking) to nicotine gum or lozenge use
2468975|NCT03111290|Sham Comparator|Sham|Device: Direct Cortical Stimulation Sham. Trials in which stimulation is not applied. These trials are initiated using a generic trigger generator.
2468988|NCT03111290|Active Comparator|Stimulation|Device: Direct Cortical Stimulation. 150 stimulations with stimulations lasting 5 seconds at different target electrodes at two target frequencies (e.g. 5 Hz and 10 Hz) 2 milliampere in amplitude (Pulse shape - Biphasic square pulse 200 microsecond in duration per phase). Stimulation will be applied concurrently with the task and stimulation trials will be randomly interleaved with sham trials.
2469080|NCT03111017|Experimental|Exercise Training|Subjects will perform continuous endurance exercise (arm and leg cycle on Schwinn AD6 Airdyne ergometer, treadmill walking) 3 days per week. During the first 4-weeks, the exercise intensity will be set at 60%-70% of heart rate reserve and will increase by 5% per month. The initial exercise duration be 30 minutes and will gradually increase by 10 minutes every month. A 5-minute warm up and cool-down will precede and follow the aerobic conditioning phase. After the aerobic training phase is completed, patients will also perform unilateral handgrip exercise at an initial intensity of 50% maximal voluntary contraction for 1 set of 10 repetitions, and the intensity and sets will increase by 5% and 1 set, respectively each month.
2469084|NCT03111017|No Intervention|Attention Control|These subjects will be asked to continue with normal activity and will not be given any exercise training. The subjects will be contacted by the study coordinator at pre-arranged times and dates once a month and involve inquiry regarding overall well-being of the subject.
2469155|NCT03110510|Experimental|FOLFIRI|D1 Irinotecan 180 mg/m2 IV D1-2 5-FU 400mg/m2 bolus and then 2400mg/m2 continuous infusion D1 Leucovorin 200 mg/m2 Until disease progression, patient's refusal or unacceptable toxicities
3191852|NCT00802451|Active Comparator|Test Drug|
3191853|NCT00802451|Active Comparator|Reference Drug|
2469264|NCT03109509|Active Comparator|Fitbit-only Group|Participants randomized to the FB group were provided a Fitbit Zip activity monitor and were instructed on how to wear the monitor, how to pair the activity monitor to their smartphone, and asked to provide our team consent to access their Fitbit data through Fitbit's Application Programming Interface (API)
2469266|NCT03109509|Experimental|Fitbit + Pokémon Go Group|Participants randomized to the FB+P group received the same Fitbit Zip activity monitor and text message reminders as the FB group. This group was also shown how to download the Pokémon Go application to their smartphone and were provided brief instructions on how to play the game. Participants were instructed to simply explore the game and play it at their leisure. Participants were not provided any specific goals related to game play or physical activity in general.
2469290|NCT03109197||Retrospective SUDC cases|All child biospecimens (including mucosal swab or blood samples for DNA analysis, pathology slides, tissue blocks, tissue samples or organs retained at autopsy) will be transferred to NYU Biorepository
2469293|NCT03109197||Prospective SUDC cases|Heart and brain tissue will undergo full cardiac pathology consultation or neuropathology consultation will be transferred to pathologists at NYU or Mayo (based on pathologist availability). The PHI will remain intact in these cases since they will need to know how to identify the deceased with the medical records they receive and to complete the entire investigation thoroughly. A full consultation report will be sent back to Dr. Orrin Devinsky and tissue will be returned to the NYU biorepository upon completion of the cardiac or neuropathology consultation.
2469350|NCT03109028|Active Comparator|Treatment as Usual|Regular standard psychiatric health care including all feasible interventions including medication, psychotherapy and social work.
2469352|NCT03109028|Experimental|Stepped and Collaborative Care Modell|A stepped and collaborative treatment model with varying stepped psychotherapeutic interventions for adult and adolescent refugees.
2469478|NCT03108222||Healthy Subjects|Healthy subjects, free of CKD
2469483|NCT03108222||Moderate CKD Subjects|Subjects with moderate-stage CKD
3191854|NCT00802477|Experimental|1|Application of Autologous Blood Products to surgical site during mastectomy.
2468702|NCT03113045|Experimental|Seated Time|Pts will be seated for the allocated time depending on the previous patients hypotensive response
2468759|NCT03112772|Experimental|Group I|Participants who are receiving socket preservation using allograft (Puros® Allograft, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, Zimmer dental, Zimmer, USA).
2468764|NCT03112772|Experimental|Group II|Participants who are receiving socket preservation cancellous particulate bovine bone xenograft (CopiOs® Cancellous Particulate, Zimmer dental, Zimmer, USA) covered by membrane (size: 15x20mm) made of type I collagen fibers purified from bovine tendon (BioMend® Membrane, 15x20mm, Zimmer dental, Zimmer, USA).
2468767|NCT03112772|No Intervention|Group III|No grafting materials will be inserted, so it serves as a negative control group.
2468862|NCT03112460||all patients|all of patients who went through basic and advanced cardiopulmonary resuscitations would be analyzed
2468894|NCT03111836|Sham Comparator|Control group|The Control group received limited to general information on blood pressure management
2468897|NCT03111836|Active Comparator|Expert-driven group|The intervention will consisted of pre-determined exercise and dietary goals (e.g. increase daily steps by 1000 steps, consuming 2-3 servings of fruit and vegetables per day).
2468906|NCT03111836|Active Comparator|User-driven group|The User-driven group received an intervention that enabled participants to select their areas of lifestyle change using text and video web links embedded in the email. The trans-theoretical model was used to inform the design of the User-driven program.
2468950|NCT03111563|Other|warm saline|case group ,
2468952|NCT03111563|Other|room temperature|control group
2468966|NCT03111238|Experimental|REX-001|REX-001 is a cell suspension of autologous BM-MNCs composed of several mature cell types.
2468976|NCT03111238|Placebo Comparator|Placebo|The final formulation of the placebo will be a diluted suspension of red blood cells.
2469051|NCT03110874|Experimental|Experimental group (one-way education)|"Experimental group (one-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~video based education"
2469058|NCT03110874|Active Comparator|Control group(two-way education)|"Control group(two-way education)~Fluterol Inhalation Capsule (fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg)~direct education"
2469134|NCT03110536||2h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 2 hours.
2469137|NCT03110536||4h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 4 hours.
2469145|NCT03110536||6h assessment|The assessment of the burnout syndrome will be carried out at the beginning of the triage shift and after 6 hours.
2469214|NCT03110055|Experimental|HCV patients with un-resectable HCC|"HCV genotype 1 (a and b) cirrhotic patients (child pugh A compensated cirrhosis) with advanced and un-resectable HCC who are eligible for TACE . The patients will receive Grazoprevir/Elbasvir and Transarterial Chemoembolization.~Their outcomes will be compared to the medical records of patients who underwent Transarterial Chemoembolization only, in the past."
2469287|NCT03109678|Experimental|Aura-i / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with Rüsch Super Safety Silk™ tracheal tube
2469289|NCT03109678|Experimental|Aura-i / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Ambu Aura-i™ with LMA ETT™ tracheal tube
2469292|NCT03109678|Experimental|Fastrach / Rüsch|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with Rüsch Super Safety Silk™ tracheal tube
2469295|NCT03109678|Experimental|Fastrach / LMA ETT|Blind tracheal intubation: Combination of laryngeal mask Fastrach™ with LMA ETT™ tracheal tube
2469351|NCT03109002||Cohort: Pharmacologically Treated Depression (PTD) Cases|This study is based on anonymized health services data, study population include US residents with medical insurance between 1 Jan, 2010 and 31 Dec, 2014 as described by the Truven MarketScan Medicaid (MDCD), Truven MarketScan Medicare Supplemental (MCDR), and Truven MarketScan Commercial Claims and Encounters (CCAE) databases. Within each database, pharmacologically treated depression (PTD) cases incident during 2011 will be followed for up to 4 years to ascertain their TRD status and 1-year incidence rates for PTD and TRD. Participants will not receive any intervention as a part of this study. To assure they are incident rather than prevalent cases, study participants are required to have 1 year without a dispensing of an antidepressant medication before they can join the cohort.
2469360|NCT03108781|Active Comparator|Lavender Oil|
2469361|NCT03108781|Placebo Comparator|sunflower oil|
2469401|NCT03108547||Sarcoidosis - fatigued|Men and women with sarcoidosis and a score of ≥ 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
2469405|NCT03108547||Sarcoidosis - non-fatigued|Men and women with sarcoidosis and a score of < 22 on the Fatigue Assessment Scale. A small hair sample will be cut and the participants will be asked to complete questionnaires on fatigue, anxiety, depression, stress and quality of life.
2469409|NCT03108547||Healthy controls|Hair steroid values of a previously collected normal values study in adults will be used as healthy controls
2469454|NCT03108235|Experimental|Intervention group A|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP)
2469458|NCT03108235|Experimental|Intervention group B|HOM-HEMP with the smartphone app.
2469462|NCT03108235|Active Comparator|control group|Participants will receive the standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
2469538|NCT03107936|Experimental|smokeSCREEN game play|Participants are instructed to access the web-based videogame intervention, smokeSCREEN, through a secured website and play the game using their unique User ID and password.
2469587|NCT03107468|Experimental|Mokhuri intensive treatment group|Patients in this arm will be treated with 35-week of Mokhuri intensive treatment program which compromise 10 sessions of acupuncture, Chuna and patient consultation during 5 weeks.
2469588|NCT03107468|Active Comparator|Non-surgical conventional treatment group|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment during 5 weeks.
2469660|NCT03106883|Experimental|Affective training|"One happy and three sad faces selected from the NimStim Set of Facial Expressions~Five five-minute blocks separate by 90-second rest periods"
2468770|NCT03112538|Active Comparator|Multiple daily injections of insulin|Multiple daily injections consisting of a single basal insulin injection(Glargine) and 3 bolus insulin injections (rapid acting insulin Glulisine or Aspart) before each meal
2468814|NCT03112265|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC), and (2) a youth monitoring and feedback system (MFS).
2468817|NCT03112265|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
2468893|NCT03111849||hospitalized chronic obstructive patients|
2469001|NCT03111641|Experimental|Lung ultrasonography|
2469057|NCT03110991|Experimental|Cognitive-behavioral intervention via App|The participants of the two experimental groups will receive a cognitive-behavioral intervention for depression prevention via a smartphone App, adapted from an indicated depression prevention program for caregivers in face-to-face group format developed by our research team, based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger (1985), which has proven to be efficacious in the prevention of the onset of new major depressive episodes and the decrease of depressive symptoms both short- and long-term (Vázquez et a., 2014, 2016). In both groups the intervention administered via App will consist of 5 modules.
2469067|NCT03110991|Experimental|Cognitive-behavioral intervention via App + multiconference|Additionally, this experimental group will receive phone group conference calls during four 30 minute-sessions.
2469073|NCT03110991|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms.The use of such treatments will be recorded.
3157047|NCT00357149|Experimental|B|Docetaxel followed by cisplatin and 5-FU from day 1 to day 4 starting after the end of cisplatin infusion. The cycle was repeated every 3 weeks up to a total of 3 cycles. After 3-6 weeks from the end of neoadjuvant chemotherapy, patients will receive with the same modality of arm A (reference arm).
3157048|NCT00357188|Active Comparator|A|
2469229|NCT03109834|Active Comparator|Meal replacement (MR) group|"Energy-restricted modified diet with MR for weight control dietary supplement: MR shakes, soups or bars. Duration: 3-month weight loss phase (phase 1)~During weight stabilization phase (phase 2) MR counted to food choice option."
2469230|NCT03109834|Other|Control (C) group|"Energy-restricted modified diet without MR for weight control. Duration: 3-month weight loss phase (phase 1)~During 3-month weight stabilization phase (phase 2) MR counted to food choice option."
2469233|NCT03109834|Active Comparator|Verum group|"Specific micronutrient composition with omega-3 fatty acids (capsules)~Duration: 6-month weight maintenance phase (phase 3)"
2469234|NCT03109834|Placebo Comparator|Placebo group|"Placebo capsules~Duration: 6-month weight maintenance phase (phase 3)"
2469247|NCT03109522|Experimental|axillary reverse mapping|Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
2469248|NCT03109522|Active Comparator|standard axillary surgery|The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
3157049|NCT00357188|Active Comparator|B|
2469300|NCT03109093|Experimental|Blinatumomab|"Patients will receive four cycles of treatment, unless criteria for treatment discontinuation apply. The duration of one cycle is 6 weeks, including a four week continuous intravenous infusion and a two week infusion free interval, which may be extended by a maximum of 7 days.~Patients entered with MRD level <10-4 (non quantifiable/MolNE1, quantifiable/MolNE2) or positive MRD, non quantifiable (MolNE3) will receive up to two cycles of Blinatumomab.~Transfer of patients to alloHSCT after one cycle or after subsequent cycles is considered as per protocol discontinuation and as premature treatment discontinuation In case of hematological or extramedullary relapse, the study treatment will be permanently discontinued."
2469433|NCT03108664|Experimental|11.25 mg/mL SYL1001 ophthalmic solution|1 drop of 11.25 mg/mL SYL1001 ophthalmic solution in the affected eye(s) q.d
2469437|NCT03108664|Experimental|Vehicle ophthalmic solution|1 drop of vehicle ophthalmic solution in the affected eye(s) q.d
2469493|NCT03108092|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
2469494|NCT03108092|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
2469602|NCT03107247|Other|Tc-99m MDP|Patients ages 1-16 years old will be included. Routine SPECT imaging will be collected 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ for 10-15 s per view using a 1282 matrix. Half of the subjects will also be imaged between 30 and 90 min, PA. The 2nd half will be at 4-6 h, PA. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2469638|NCT03106948|Placebo Comparator|Low frequency angioplasty|Subjects who have had 0-1 angioplasty during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty but will not have insertion of the ACT drug delivery catheter
2469640|NCT03106948|Active Comparator|Moderate frequency angioplasty|Subjects who have had 2-3 angioplasties during the 12 months prior to randomization. Subjects will have endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
3157050|NCT00357240|Active Comparator|A1|
3157051|NCT00357240|Active Comparator|A2|
3157052|NCT00357240|Experimental|A3 I|
3157053|NCT00357240|Experimental|A3 II|
3157054|NCT00357240|Active Comparator|B1|
3157055|NCT00357240|Active Comparator|B2|
3157056|NCT00357240|Experimental|B3 I|
3157057|NCT00357240|Experimental|B3 II|
3157058|NCT00357279|Placebo Comparator|1|Placebo
3157059|NCT00357279|Experimental|2|
2468820|NCT03112122|Experimental|bone substitution (i-FactorTM)|i-FactorTM is a combination of the mineral component of bone (Anorganic Bone Mineral) with a peptide replicating the cell-binding domain of Type-I collagen (P-15). It has been used in bone defects and in spine fusion providing good clinical results. Thus, i-FactorTM could be a valid and efficient bone substitute to treat BMLs with subchondral injections.
2468824|NCT03112122|Experimental|injections of autologous Bone Marrow Concentrate (BMC)|injections of autologous BMC.
2468878|NCT03111992|Experimental|Arm A|Dose escalation of single agent CJM112
2468881|NCT03111992|Experimental|Arm B|Dose escalation of CJM112 in combination with a fixed dose of PDR001
2468884|NCT03111992|Experimental|Arm C|Dose escalation of LCL161 in combination with a fixed dose of PDR001
2468933|NCT03111498|Other|theory-based training programme|theory-based training programme (oral presentation including a step-by-step guidance saying)
2468935|NCT03111498|Other|practice-based training|practice-based training programme (one-to-one teaching)
2469116|NCT03110549|Experimental|Cohort 1 Arm A|Subcutaneous 200 mg of TMB-607 on Day 0 or Placebo
2469118|NCT03110549|Experimental|Cohort 1 Arm B|Subcutaneous 500 mg of TMB-607 on Day 0 or Placebo
2469122|NCT03110549|Experimental|Cohort 1 Arm C|Subcutaneous 1000 mg of TMB-607 on Day 0 or Placebo
2469124|NCT03110549|Experimental|Cohort 2 Arm A|Subcutaneous 100 mg of TMB-607 on Day 0 or Placebo
2469133|NCT03110549|Experimental|Cohort 2 Arm B|Subcutaneous 400 mg of TMB-607 on Day 0 or Placebo
2469136|NCT03110549|Experimental|Cohort 2 Arm C|Subcutaneous 800 mg of TMB-607 on Day 0 or Placebo
2469141|NCT03110549|Experimental|Cohort 2 Arm D|Subcutaneous 1500 mg of TMB-607 on Day 0 or Placebo
2469221|NCT03109990|Experimental|Dexmedetomidine|Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.
2469224|NCT03109990|Placebo Comparator|saline|Same amount of saline will be administrated.
2469275|NCT03109600|Experimental|Vi-DT (Bio Farma)|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
2469276|NCT03109600|Active Comparator|Vi polysaccharide vaccine|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine
2469277|NCT03109600|Experimental|Vi-DT (Bio Farma) ~ Children|2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine
2469278|NCT03109600|Active Comparator|Vi polysaccharide vaccine ~ Children|1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine
2469310|NCT03109080|Experimental|Olaparib + radiation therapy|One week of Olaparib alone followed by 5 weeks of Olaparib and concurrent loco-regional radiotherapy. Five levels of dose of Olaparib are expected.
2469518|NCT03107650||High risk patients|Patients with high risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
2469521|NCT03107650||Low risk patients|Patients with low risk of suboptimal mesorectum quality and/or positive circumferential margin after the application of the preoperative prediction model developed
2469613|NCT03107260|Other|Occurrence of postoperative cognitive dysfunction|
2469639|NCT03106935|Active Comparator|Obstet Gynecol,SecondSoochowU|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
2469642|NCT03106935|No Intervention|reproductive center,SecondSoochowU|For the control group ,women with subclinical hypothyroidism are not given any drugs .
3157060|NCT00357305|Experimental|Treatment (enzyme inhibitor, chemotherapy)|Patients receive oral SAHA two or three times daily on days 1-7 and cytarabine IV over 3 hours twice daily and etoposide IV over 1 hour once daily on days 11-14. Treatment repeats approximately every 6-7 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3157061|NCT00357318|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2469825|NCT03105947|Active Comparator|Coconut oil|50g extra virgin coconut oil to be consumed daily for four weeks
2469830|NCT03105947|Active Comparator|Butter|50g butter to be consumed daily for four weeks
2469833|NCT03105947|Active Comparator|Olive Oil|50g extra virgin olive oil to be consumed daily for four weeks
2469996|NCT03104426|Active Comparator|Darbepoetin alfa group|Group treated with darbepoetin alfa (Aranesp) 10microg/kg once a week for a period of 8 weeks.
2470000|NCT03104426|No Intervention|Control group|"Standard care which involves close monitoring of hemoglobin levels and if necessary, top-up red cell transfusion."
2470033|NCT03104231|Experimental|study group|All the patients will be shown three-dimensional (3D) movie.
2470075|NCT03104088||SPG4 patients|
3157062|NCT00357357|Placebo Comparator|Group1|4x 7 day rising dose
3157063|NCT00357357|Placebo Comparator|Group2|4x, 7 day rising dose
3157064|NCT00357357|Placebo Comparator|Group3|28 day fixed lower dose
3157065|NCT00357357|Placebo Comparator|Group4|28 day fixed upper dose
3157066|NCT00357422|Active Comparator|surgery|
3157067|NCT00357422|Active Comparator|local therapy|
3157068|NCT00357448|Experimental|Arm I|Patients receive intraperitoneal denileukin diftitox over at least 15 minutes on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3157069|NCT00357474|Active Comparator|chemotherapy|Transarterial chemoembolization (TACE)
3157070|NCT00357474|Active Comparator|ethanol|Percutaneous ethanol injection therapy (PEIT)
3157071|NCT00357565|Experimental|Double Unit UCB Transplantation|Patients that receive 2 units of umbilical cord blood transplantation (UCBT).
3157072|NCT00357565|Experimental|Single Unit UCB Transplantation|Patients that receive one unit of umbilical cord blood transplantation (only if 2 adequate size and matched units are not available).
3157073|NCT00357591|Active Comparator|Control|
3191855|NCT00802477|Active Comparator|2|Standard Modified Radical Mastectomy
3191856|NCT00802490|Active Comparator|Intervention|20 sessions of EEG biofeedback training
3191857|NCT00802490|Placebo Comparator|Control|Only 1 session of EEG biofeedback training
2468979|NCT03111420|Experimental|Clopidogrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
2468986|NCT03111420|Experimental|Prasugrel|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
2468991|NCT03111420|Experimental|Ticagrelor|"Platelet function test before and after administration of P2Y12 inhibitor antiplatelet therapy after ASA 81 mg.~Loading dose day 1. Maintenance dose over subsequent 7 days."
3191858|NCT00802516|Placebo Comparator|1. placebo|placebo margarine
3191859|NCT00802516|Experimental|2. stanol ester|margarine with plant stanol ester
2469143|NCT03110328|Experimental|mk3475 200mg|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W) Open-label
2469191|NCT03110133|Experimental|CP101|Full Spectrum Microbiota Capsule
2469195|NCT03110133|Placebo Comparator|Placebo|Matching Placebo Capsule
2469268|NCT03109431|Experimental|Enhanced Standard Care|"Youth randomized to the Enhanced Standard Care arm will receive an Automated Messaging and Monitoring Intervention (AMMI), which involves receiving 1-5 texts per day to motivate, inform and refer to HIV care and health services. Message banks will focus on the HIV Treatment Continuum, with libraries dedicated to healthcare, wellness, sexual health, drug use and ARV adherence for YLH.~Youth will also receive a weekly monitoring survey that covers six domains related to the HIV Treatment Continuum, including: ARV adherence, condomless sex, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
2469270|NCT03109431|Experimental|Stepped Care|Youth randomized to the Stepped Care arm will receive up to three levels of intervention, depending on whether or not they have achieved viral suppression at each four-month assessment point. All youth will begin at Level 1 which is the same as the Enhanced Standard Care arm. If they fail to achieve viral suppression at a reassessment in four months, they will be moved to Level 2, which includes both Level 1 and enrollment in private, online peer support groups. If they fail to achieve viral suppression at another four-month assessment point, they will be moved to Level 3, which includes both Levels 1-2 and Coaching. Coaches will provide support using a strengths-based coaching approach.
2469325|NCT03109119|Active Comparator|Group S|These patients will be induced and maintained with sevoflurane during anaesthesia.
2469329|NCT03109119|Sham Comparator|Group P|These patients will be induced and maintained with propofol during anaesthesia.
2469501|NCT03108066|Experimental|PT2385 Tablets|Twenty-five patients will be enrolled in each stage of a two-stage design
2469560|NCT03107663|Experimental|⁸⁹Zr-Df-IAB22M2C Infusion|3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes
2469606|NCT03107338|Active Comparator|DEXKETOPROFEN TROMETAMOL|Patients received a dose of 25 mg DKT in an oral suspension 15 minutes before surgery
2469611|NCT03107338|Placebo Comparator|Placebo|Patients received a dose of 500 mg Vitamin C in an oral suspension 15 minutes before surgery
3191860|NCT00802516|Experimental|3. sterol ester|margarine with plant sterol ester
3191861|NCT00802542||1|Adult patients with mild or moderate essential hypertension who do not tolerate ACE inhibitors because of cough, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal and the doctor has decided to increase the Atacand dose to 16mg as per SmPC.
2469736|NCT03106467|Experimental|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy is performed through single-port which is installed in umbilicus.
2469738|NCT03106467|Active Comparator|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy is performed using conventional three-port technique which needs two additional ports outside umbilicus in addition to trans-umbilical port
2469767|NCT03106168|Experimental|With periapical granuloma|Patients presenting periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
2469769|NCT03106168|Experimental|Without periapical granuloma|Patients without periapical granuloma in mandibular molar teeth, diagnosed by periapical radiography
2469896|NCT03105453||Study arm|Women in the study arm will undergo microbiome samplings described in the interventions section (3 sampling points)
2469937|NCT03104881|Experimental|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
2469938|NCT03104881|Experimental|2D end-effector type robot|2 dimension end-effector type upper extremity robot
2469978|NCT03104621|Experimental|Group 1|Group 1, for the first 6 months, the subjects of group 1 used non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) and then changed to 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product (Taflotan®)for 6 months.
2469980|NCT03104621|Experimental|Group 2|Group 2, for the first 6 months, the subjects of group 2 used 0.001% Benzalkonium chloride (BAK), 0.0015% tafluprost product(Taflotan®) and then changed to non-preservative disposable 0.0015% tafluprost product(Taflotan-S®) for 6 months.
2470035|NCT03104400|Experimental|ABT-494 Dose A + Placebo Adalimumab|It is administered once daily.
2470036|NCT03104400|Experimental|ABT-494 Dose B + Placebo Adalimumab|It is administered once daily.
2470038|NCT03104400|Active Comparator|Adalimumab + Placebo ABT-494|It is administered subcutaneously once every two weeks.
2470040|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose A|It is administered once daily.
2470043|NCT03104400|Experimental|Placebo ABT-494 + Placebo Adalimumab Then ABT-494 Dose B|It is administered once daily.
2470423|NCT03101774|Experimental|threshold-IMT group|Using inspiratory muscle training using threshold load device for 8 weeks
2470424|NCT03101774|Experimental|resisive-IMT group|Using inspiratory muscle training using resistive device for 8 weeks
2470425|NCT03101774|Sham Comparator|control group|not conduct inspiratory muscle training for 8 weeks
3191862|NCT00802555|Experimental|ARQ 197|
3191863|NCT00802581|Experimental|1|Ensuring circumferential spread of local anesthetic around the sciatic nerve.
3191864|NCT00802581|Active Comparator|2|Single shot injection of local anesthetic near the sciatic nerve will be performed, without ensuring circumferential spread.
2468880|NCT03111979|Experimental|Beta-alanine supplementation|Participants will be supplemented with 4.8g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
2468883|NCT03111979|Placebo Comparator|Placebo|Participants will be supplemented with 4.8 g·d-1 placebo (maltodextrin; NAI, USA). The regimen will consist of two 800 mg tablets three times per day at 3-4 hour intervals the same regimen for beta-alanine tablets
2468967|NCT03111693||obese patients|obese patients of our clinical nutrition service, hospitalized for nutrional assessement, are included.
2469029|NCT03111121|Active Comparator|Group 1|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes:Group 1 will receive reversal with neostigmine (0.04 mg/kg and glycopyrrolate (0.01 mg/kg)
2469031|NCT03111121|Active Comparator|Group 2|Reversal of Paralysis in Microlaryngoscopy procedures: Inhaled anesthetics: sevoflurane at 1 MAC, remifentanil and intubation with rocuronium at 0.6-1.2 mg/kg (vitals maintained within 20% of baseline). Standard anti-nausea prophylaxis - Ondansetran and Decadran intraoperative.After induction; amount of inhaled anesthetic and remifentanil used will be titrated based on hemodynamic parameters (maintained within 20% from baseline) and a BIS monitor.TOF testing done every 5 minutes: Group2 will receive reversal with sugammadex 4mg/kg
2469090|NCT03110705||recreational diving group|middle-class populations registered at a leisure sports club
2469093|NCT03110705||recrational multisport course|middle-class populations registered at a leisure sports club
2469111|NCT03110445|Experimental|rVV-740CTA vaccine|
2469167|NCT03110276|Experimental|EYP001a|
2469168|NCT03110276|Placebo Comparator|Placebo|
2469215|NCT03109977|Experimental|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT|Zr-DFO-pertuzumab (89Zr-DFO-pertuzumab) PET/CT will be performed in patients with known HER2-positive malignancy. Patients with multifocal disease, as demonstrated on cross-sectional imaging studies, will be preferentially recruited.
2469237|NCT03109730|Experimental|Cohort B1|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2469238|NCT03109730|Experimental|Cohort B2|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2469239|NCT03109730|Experimental|Cohort B3|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2469240|NCT03109730|Experimental|Cohort B4|ABI-H0731 or Placebo in varying doses by mouth for 28 days
2469241|NCT03109730|Experimental|Cohort B5|ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days
2469242|NCT03109730|Experimental|Cohort B6|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
2469331|NCT03109314|Active Comparator|Single-letter training group|Subjects will be trained on a low-contrast single-letter task. The task is to identify a faint letter (low-contrast). Performance will be measured as correct or incorrect. Training will consist of identifying these low-contrast letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
2469335|NCT03109314|Active Comparator|Uncrowd training group|Subjects will be trained on an uncrowd task (identifying the middle letter of groups of three letters presented). Performance will be measured as correct or incorrect. Training will consist of identifying these letters for 1000 trials per day (10 blocks of 100 trials each, subjects can take breaks in-between blocks), for a total of 10 days. During training, subjects will be administered a daily dosage of 5 mg of donepezil. Immediately before and after training (the day before and the day after), subjects' performance on (1) visual acuity; (2) contrast for identifying letters and (3) crowding extent will be measured.
2469379|NCT03108742|Experimental|dermal stapler|
2469380|NCT03108742|Active Comparator|classic intradermal suture|
2469536|NCT03107975|Experimental|Cell Therapy|intrathecal injection of human amniotic epithelial cells
3157074|NCT00357604|Active Comparator|A1|
2469596|NCT03107208|Experimental|Early glargine (Lantus)|A dose of glargine (Lantus®) is given subcutaneously early in the management of DKA (i.e. while the participant is still receiving intravenous insulin). Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
2469599|NCT03107208|Other|Control group|A dose of glargine (Lantus®) is given subcutaneously after resolution of the DKA (i.e. when the intravenous insulin is stopped). This is currently the standard-of-care practice for children in DKA. Participants will also be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA.
2469673|NCT03106831|Experimental|Pituitrin arm|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
2469676|NCT03106831|Experimental|Norepinephrine arm|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
2469710|NCT03106506|Experimental|Test-implant with graft|Patients who received a connective tissue graft around implants
2469716|NCT03106506|Active Comparator|Control-Implant without graft|Implant installation surgery with cone morse system without the placement of connective tissue graft.
2469860|NCT03105505|Active Comparator|Synthomycine 5%,|Contains chloramphenicol 5%.
2481267|NCT03028181||2|Control group exposed to tobacco smoking
3157075|NCT00357604|Experimental|A2|
3157076|NCT00357669|Placebo Comparator|Placebo|
3157077|NCT00357669|Experimental|Brivaracetam 50 mg/day|BRV 50 mg/day
3157078|NCT00357669|Experimental|Brivaracetam 150 mg/day|BRV 150 mg/day
2468937|NCT03111524|Active Comparator|Intervention school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2468939|NCT03111524|Active Comparator|Intervention school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2468941|NCT03111524|Active Comparator|Intervention school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is administered by the teacher. The participants observe the intervention which is a social story (read by the teacher), the class performs a role-play (same plot as the story) and then the teacher facilitates and leads a semi-structured discussion. The intervention takes place in 1 classroom lesson only. No further intervention is completed.
2468942|NCT03111524|Placebo Comparator|control school 1|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2468943|NCT03111524|Placebo Comparator|control school 2|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2468944|NCT03111524|Placebo Comparator|control school 3|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2468946|NCT03111524|Placebo Comparator|control school 4|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2468948|NCT03111524|Placebo Comparator|control school 5|All participants complete the questionnaire at baseline. The Classroom Communication Resource Intervention is not administered by the teacher.
2469006|NCT03111199|Placebo Comparator|Control Placebo Group|The subjects of this group will be submitted to TENS bound in placebo mode in the lumbar spine.
2469009|NCT03111199|Experimental|Cryotherapy Group|The subjects of this group will be submitted to Cryotherapy in the lumbar spine.
2469012|NCT03111199|Experimental|TENS Burst Group|The subjects of this group will be submitted to TENS Burst in the lumbar spine.
2469016|NCT03111199|Experimental|TENS Burst and Cryotherapy Group|The subjects of this group will be submitted to TENS Burst and Cryotherapy in the lumbar spine.
2469078|NCT03110783|No Intervention|suture (control)|Subjects randomized to control will receive additional dural sutures as deemed necessary by the surgeon. CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
2469082|NCT03110783|Experimental|Bioseal|Subjects randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds. Up to two applications (one application includes applying up to two layers of Bioseal product followed by the CSF leakage re-evaluation with Valsalva maneuver) per subject are allowed. Closure of the remaining layers of the surgical site will be performed according to the surgeon's standard of practice.
2469120|NCT03110393|Experimental|Ambu® AuraGain™|Intervention with Ambu® AuraGain™Laryngeal Mask
2469123|NCT03110393|Active Comparator|Intersurgical i-gel®|Intervention with Intersurgical i-gel® Laryngeal Mask
3191865|NCT00802594|Experimental|DB289|
3191866|NCT00802646|Experimental|1|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of preservative-free normal saline will be administered through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
2469227|NCT03109847|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment.
2469228|NCT03109847|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily for 3 days and then PO BID for up to 2 weeks after completing radioactive iodine treatment
2469257|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
2469332|NCT03109301|Experimental|Arm 1|Patients > 18 years of age
2469336|NCT03109301|Experimental|Arm 2|Patients < 18 years of age
2469356|NCT03108820|Experimental|TMH Intervention|The multidisciplinary team which develops and carries out the intervention includes a care coordinator who will organize and align recovery resources, a Trauma Surgeon (Dr. Zarzaur), a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), and an ICU collaborative care nurse (Dr. Lasiter). Using the Healthy Aging Brain Care monitor, care protocols, specialized software, and specific care protocols, the multidisciplinary team will modulate the intensity and the type of intervention the patient's receive based on the patient's needs. The intervention will last from the time of discharge to 6 months after injury.
2469357|NCT03108820|Active Comparator|Usual Care|Review hospital discharge and rehabilitation plan, identify the primary care physician responsible for the patient care. Patients will receive education on communication skills; caregiver coping skills; and legal and financial advice. Patients randomized to usual care will receive no further interventions.
2469383|NCT03108586|Active Comparator|FDI|Diagnosis and dental treatment decision based on the criteria of the International Dental Federation (FDI).
2469384|NCT03108586|Experimental|CARS|Diagnosis and dental treatment decision according to CARS (Caries Associated with Restorations or Sealants) detection criteria.
2469424|NCT03108378||MultiHance Single Dose|Subjects who received a single dose of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
2469430|NCT03108378||MultiHance Multiple Dose|Subjects who received multiple doses of MultiHance and no other Gd agent and who are also scheduled for orthopedic surgery
2469942|NCT03104946||Retinopathy|
2468949|NCT03111589|Experimental|SCD patients under regular chronic exchange transfusion|Sickle cell disease patients (SCD) under regular chronic exchange transfusions. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2468951|NCT03111589|Experimental|SCD patients under HU treatment alone|Sickle cell disease patients (SCD) under hydroxyurea (HU) alone. Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2468953|NCT03111589|Experimental|SCD patients under HU treatment+sporadic transfusion|Sickle cell disease patients (SCD) under hydroxyurea (HU) and receiving sporadic transfusions.Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2468954|NCT03111589|Active Comparator|Control group|Pediatric and adult patients from the HUDERF and CHU-Brugmann Hospitals.
2469019|NCT03111186|Active Comparator|Opiate group|Group receiving oxycodone alone (oxycodone HCl 5 mg up to six times daily as needed for pain)
2469023|NCT03111186|Active Comparator|Non-opiate group|Group receiving ibuprofen and acetaminophen (acetaminophen 650 mg up to four times daily and ibuprofen 400 mg up to six times daily as need for pain)
2469301|NCT03109535|Active Comparator|Fitbit-only Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks.
2469303|NCT03109535|Experimental|Fitbit + MapTrek Group|Participants received a Fitbit Zip activity monitor to wear daily for 10 weeks. Participants also received access to an mHealth game called MapTrek for 10 weeks. MapTrek places users in weekly walking races and sends automated text messages to participants on a daily basis. Messages include a link to the online game as well as motivational messages designed to increase physical activity.
2469371|NCT03108976|Sham Comparator|Control group|Children with a typical development.
2469372|NCT03108976|Active Comparator|Case group|Children with Autism Spectrum Disorders.
2469444|NCT03108508|Experimental|Prod1|G5 Siliplant
2469445|NCT03108508|Experimental|Prod2|Orgono Powder®
2469448|NCT03108508|Experimental|Prod3|G7 ALOE
2469504|NCT03108001||Lean mothers|Participants that were in Glowing born from Lean mothers.
2469505|NCT03108001||Overweight mothers|Participants that were in Glowing born from Overweight mothers.
2469506|NCT03108001||Obese mothers|Participants that were in Glowing born from Obese mothers.
2469507|NCT03108001||Exercise group mothers|Participants that were in Expecting born from mothers that were in the exercise group.
2469508|NCT03108001||Non Exercise group mothers|Participants that were in Expecting born from mothers that were in the non- exercise group.
3157079|NCT00357682|Experimental|Arm A|20mg Esomeprazole
2469743|NCT03106428|Experimental|acute myeloid leukemia|Patients with R/R AML by World Health Organization (WHO) classification (Arber et al, 2016) who have failed prior standard therapy and for whom no standard therapies are available
2469748|NCT03106428|Experimental|Multiple Myeloma|Patients with R/R MM who have failed prior standard therapy(ies) which should include immunomodulatory agents and proteasome inhibitors and for whom there is no standard salvage regimen.
2469752|NCT03106428|Experimental|Diffuse Large B-cell Lymphoma|Patients with R/R DLBCL who have failed prior standard therapy(ies) and for whom there is no standard salvage regimen.
2469798|NCT03105934|Experimental|Pulmonary Arterial Hypertension|Patients with Pulmonary Arterial Hypertension
2469863|NCT03105596|Experimental|Chidamide plus DICE regimen|Chidamide combined with DICE (Dexamethasone, Ifosfamide, Cisplatin and Etoposide) regimen
2469931|NCT03105050||Countries in Europe|All 51 countries will fill out their unique data on access to bariatric surgery in Europe
2469966|NCT03104764|Active Comparator|Scalpel|Frenotomy performed with conventional scalpel
2469967|NCT03104764|Experimental|Er:YAG laser|Frenotomy performed with Er:YAG laser
2470009|NCT03104465|Experimental|Mindfulness training|6 90-minute sessions interactive, web-based mindfulness training complemented with mobile application
2470063|NCT03104179|Experimental|Treatment|CPB with Cytosorb
2470066|NCT03104179|No Intervention|Control|CPB without Cytosorb (Control)
2470122|NCT03103880|Experimental|Medication Adherence and Pulmonary Function Tests|
2470125|NCT03103880|Experimental|Medication Adherence and Peak Flow Measurements|
2470296|NCT03102749||Normal weight|Included patients with a BMI < 25 will be part of this group.
2470299|NCT03102749||Overweight|Included patients with a BMI >= 25 and <30 will be part of this group.
2470302|NCT03102749||Obese|Included patients with a BMI >= 30 will be part of this group.
2470387|NCT03102307||CNB biopsy/clip placement not done|Clinically affected lymph nodes cannot be biopsied or clip labeled. Patients are not suitable for TAD
2470571|NCT03100630|Active Comparator|Treatment C: RO7239361|RO7239361 subcutaneous injections on specified days; thigh
3157080|NCT00357682|Experimental|Arm B|80mg Esomeprazole
3157081|NCT00357682|Experimental|Arm C|20mg Esomeprazole + 300mg Aspirin
3157082|NCT00357682|Experimental|Arm D|80mg Esomeprazole + 300mg Aspirin
3157083|NCT00357708|Experimental|Treatment (decitabine, vorinostat)|"Patients receive decitabine IV over 1 hour on days 1-5 and oral vorinostat (SAHA) three times daily on days 6-19. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 6 patients receive escalating doses of decitabine and SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose."
3157084|NCT00357721|Active Comparator|A1|
3157085|NCT00357721|Active Comparator|A2|
3157086|NCT00357721|Active Comparator|A3|
3157087|NCT00357747|Experimental|AEG35156 plus docetaxel|
3157088|NCT00357786|Experimental|A|Enzyme replacement for Fabry's Disease
3157089|NCT00357799|Active Comparator|VeinViewer Arm|Attempts at IV placement will be made with use of the VeinViewer Machine
3157090|NCT00357799|No Intervention|Conventional Method|IV attempted with conventional method
3157091|NCT00357890|Experimental|Pump therapy (CSII)|Use of pump therapy
3157092|NCT00357890|Active Comparator|Multiple daily injections (MDI)|Use of MDI (basal bolus therapy with glargine)
3157093|NCT00357942|Experimental|C group I|Morphine mouthwash and placebo i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
2468985|NCT03111433|Experimental|Group I|this group of patients will receive their standard insulin treatment in addition to 100 mg of coenzyme Q10 soft gelatin capsule once daily for three month
2468992|NCT03111433|Active Comparator|Group II|this group of patients will receive their standard insulin treatment only
2469114|NCT03110640|Experimental|CD9CAR-T transfer|All subjects will receive allogeneic stem cell transplantation after infusion of αCD19-TCRz-CD28 CAR-T
2469199|NCT03110172|Active Comparator|KSS scale|Knee Society Score with Duloxetine Hydrochloride
2469201|NCT03110172|Active Comparator|HAMD-17 scale|Hamilton Depression Score with Duloxetine Hydrochloride
2469204|NCT03110172|Active Comparator|SF-36 scale|Medical Outcomes Study Short Form-36 score with Duloxetine Hydrochloride
2469206|NCT03110172|Active Comparator|WOMAC scale|Western Ontario and McMaster Universities Index with Duloxetine Hydrochloride
2469244|NCT03109743|Experimental|Sisters-GPS: Group Clinical Visits|Those randomized to the Sisters-GPS arm will be expected to attend a total of seven group clinical visits, once a week for ~1.5 hours. Groups visits will include education, self-management skills development, and a clinical assessment by a medical provider with a focus on HIV treatment and adherence. Additionally, Sisters-GPS participants will be encouraged to participate in a private social media site specifically designed for the study, where participants will be able communicate with one another and with research staff. Group size will be 8-10 participants.
2469246|NCT03109743|Active Comparator|Control: One-on-one Adherence Counseling|Those randomized to the control condition will receive an appointment with a HIV treatment adherence counselor and will be expected to attend a minimum of three adherence counseling visits. .
2469314|NCT03109405|Experimental|stimulation-assisted|All subjects received treatment (stimulation-assisted) with the Veinplicity Device per the Instructions for Use. The subject underwent standard IV cannulation using a 20 gauge cannula into the available vein immediately after completion of device stimulation. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
2469320|NCT03109405|Other|standard IV cannulation|The subject underwent standard IV cannulation using a 20 gauge cannula into the best available vein. Use of a tourniquet was at the discretion of the nurse performing the IV cannulation.
2469368|NCT03108911|Experimental|Group I (GFD)|Patients receive GFD prepared by the hospital per dietary/nutrition pharmacy standards from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
2469370|NCT03108911|Experimental|Group II (standard diet)|Patients receive a standard diet for from the initiation of induction chemotherapy until hospital discharge (approximately 30 days). Patients also complete a daily food intake diary. A stool sample is collected from patients at baseline, day 14, and on the day of hospital discharge for gut microbiome analysis.
3191867|NCT00802646|Active Comparator|2|When it is time for the epidural catheter, the mother will receive 2.5 mcg fentanyl spinally and then a bag of combined spinal epidural anesthetic through the epidural pump. When additional pain medication is requested, the mother will receive a known combined spinal epidural solution.
3191868|NCT00802698|Experimental|Group 1|
2469531|NCT03107741|No Intervention|Passive Control|Subjects in this group will not receive any intervention.
2469534|NCT03107741|Placebo Comparator|Conventional Exercise|Subjects in this group will receive three 1-hour conventional exercise training sections per week for 12 weeks
2469540|NCT03107741|Active Comparator|Tai Chi|Subjects in this group will receive three 1-hour tai chi training sections per week for 12 weeks
2469663|NCT03107013|Experimental|[14C]-BTD-001|
2469694|NCT03106558|Active Comparator|Manual instrument total knee replacement|
2469697|NCT03106558|Active Comparator|Robitic arm total knee replacement|
2469760|NCT03106389|Active Comparator|Misoprostol|This group will receive 400 micrograms of misoprostol administered vaginally for the first dose, followed after 6 hours by 400 micrograms administered orally, repeated every 6 hours.
2469761|NCT03106389|Experimental|Misoprostol/Transcervical catheter|This group will receive the same regimen, but will have in addition a transcervical balloon (Foleys') catheter that is inflated with 30 ml. of fluid; with weighted traction using a 1000 ml fluid-filled bag applying continuous pressure to the cervix
2469827|NCT03105869|Experimental|fluorocholine PET/CT|all patients will undergo a second PET/CT with fluorocholine
2469843|NCT03105401||Patients affected by Parkinson's disease|Outpatients affected by Parkinson's Disease consulting in neurology can be included if volunteer
2469862|NCT03105193|Experimental|Intraperitoneal Lignocaine|IP Lignocaine
2469864|NCT03105193|Experimental|Intravenous lignocaine|IV lignocaine
2469952|NCT03104972|Experimental|tDCS - placebo|tDCS-placebo (sham) group to receive either transcranial direct stimulation (tDCS) or matching placebo (sham( during 5 following days (one session each day). After a one week break, there will be a crossover between the control group and the sham group: those we received tDCS in the 1st week will get sham, while those who received sham in the 1st week will received tDCS at the 3rd week.
2469953|NCT03104972|Experimental|tRNS - placebo|trans cranial random stimulation (tRNS)-sham group, who will receive the same type of intervention with the same intervals as above but with tRNS instead of tDCS.
2469954|NCT03104972|Experimental|tDCS-tRNS|tDCS-tRNS group. Here the same intervention as above will be provided with the same intervals, but real tDCS and real tRNS will be provided in a counterbalanced fashion. This would allow to compare the different treatment in a within-subject design, as well as to compare the effect of those to sham stimulation in the first two groups in a between-subject design.
2470130|NCT03104023|Active Comparator|Staple line inversion|Patients will undergo a staple line inversion with a a running suture of Polypropylene 2/0.
2470131|NCT03104023|Experimental|Staple line buttressing|The gastric section will be performed with preloaded buttress material .
2470179|NCT03103490|Other|18F-FSPG PET/MRI|Patients undergoing 18F-FSPG PET/MRI scan
2470181|NCT03103490|Other|18F-FSPG PET/CT|Patients undergoing 18F-FSPG PET/CT scan
3191869|NCT00802711|Experimental|Arm I|Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
2470634|NCT03100305||Very preterm infants|
2470638|NCT03100305||Moderately preterm infants|
2469064|NCT03110913|Experimental|Methionine bioavailability in lentils|"Participants will be seen initially for pre-study assessment (3 hour). They will then be studied for up to 10 times. levels of phenylalanine intake (7 Study periods).~You could be expected to participate in up to 10 different sets of experiments which will take 11 weeks to 6 months. Each set of experiment consists of a 3 day period. During the first 2 days (Adaptation Days) you will be expected to consume 4 meals per day consisting of a protein liquid drink and protein free-cookies and/or a lentil stew with or without rice, which will be provided by the investigators"
2469112|NCT03110627|Experimental|VDD ICD|VDD ICD - A single-lead ICD system with the ability to sense atrial rhythm from the floating electrode (a VDD-ICD known as the DX) - Experimental group
2469113|NCT03110627|Active Comparator|VVI ICD|VVI ICD - Single chamber ICD system - Control group
2469189|NCT03110120|Active Comparator|serratus|Serratus plane block and local control
2469193|NCT03110120|Sham Comparator|local|serratus control and local anesthesia
2469271|NCT03109717||Treatment Resistant Depression|Screened for eligibility using several psychiatric assessments. If qualifies to participate in the study, will have to stop any antidepressants that they are taking to prepare for the use of Monoamine Oxidase Inhibitor(MAOI). After a two week washout period, subjects will have an fMRI and will be started on a MAOI. Then be followed for 8 weeks, part of routine care.
2469272|NCT03109717||Healthy Control|Screen for eligibility, then MRI.
2469317|NCT03109145|Experimental|Menopause educational secure messaging|Secure messages that provide information about menopause and treatment option for menopause symptoms.
2469322|NCT03109145|No Intervention|Usual care: Control|Control group of eligible women patients between 45-60 years who do not receive the intervention at the West Palm Beach and Orlando Veterans Healthcare System. Usual care participants did not receive the educational secure messages.
3191870|NCT00802711|Experimental|Arm II|Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
3191871|NCT00802724|Experimental|1 Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
3191872|NCT00802724|Active Comparator|2 Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
3191873|NCT00802750|Experimental|A|
2469559|NCT03107767|Active Comparator|Prospective Cohort|The prospective cohort following introduction of the evidence based algorithm for ankle fractures.
2469561|NCT03107767|No Intervention|Historical Cohort|Patients treated before introduction of algorithm. Matched to prospective cohort for comparison
2469604|NCT03107364||Colorectal surgery|Patient who underwent elective colorectal surgery
2469605|NCT03107364||Hip fracture|Patient who underwent urgent surgical procedure for hip fracture
2469727|NCT03106532|Experimental|PHP-201 0.25% ophthalmic solution|PHP-201 0.25% ophthalmic solution, TID
2469728|NCT03106532|Experimental|PHP-201 0.5% ophthalmic solution|PHP-201 0.5% ophthalmic solution, TID
2469729|NCT03106532|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic solution, TID
2469781|NCT03106142|Other|Academic detailing visit arm|The GPs will receive an academic detailing visit by a medical visitor. GPs will receive information on the conservative evidence-based management of knee osteoarthritis with physiotherapy. The information will be summarized on a flyer for the GPs.
2469783|NCT03106142|No Intervention|control group|The two case vignettes will also be presented to GP who did not received the intervention.
2469840|NCT03105765|Active Comparator|Ketamine|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Ketamine 0,2 mg/kg ideal Body weight per hour for 24 hours."
2469842|NCT03105765|Placebo Comparator|Placebo|"The patients in this Group underwent General anaesthesia with total intravenous anaesthesia containing remifentanil (0,02-0,04 mg/kg ideal Body weight), propofol (4-6 mg/kg ideal Body weight) and atracurium.~Placebo (normal Saline) for 24 hours."
2469866|NCT03105232||Group A|Morphin, Hydromorfon, Oxycodon
2469870|NCT03105232||Group B|Buprenorfin
2469874|NCT03105232||Group C|Fentanyl
2469877|NCT03105232||Group D|Opioid rotation
2469934|NCT03105024|Experimental|Exposure + self-efficacy enhancement|After the virtual exposure session, participants will receive instructions to recall the exposure session with a focus on the personal mastery experiences/achievements made during exposure.
2469935|NCT03105024|Active Comparator|Exposure + control intervention|After the virtual exposure session, participants will receive instructions to recall the exposure session
2469936|NCT03105024|No Intervention|Exposure only|Treatment as usual: no intervention after the exposure session will be given.
2469983|NCT03104634|Experimental|Active arm|Aclidinium bromide/formoterol fumarate dihydrate 400 mcg/12 mcg Twice daily (once in the morning, once in the evening) 7-days
2469984|NCT03104634|Placebo Comparator|Placebo arm|Placebo Twice daily (once in the morning, once in the evening) 7-days
2470003|NCT03104348|Other|COPD screening|
3191874|NCT00802750|Experimental|B|
2470169|NCT03103451|Experimental|Cohort 1|"This cohort includes 3 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
3191875|NCT00802763||vaginitis|
2469160|NCT03110302|Active Comparator|Office-based telehealth (OBT)|Veterans come to a VA clinic and meet with a therapist via telehealth, using videoconferencing technology
2469163|NCT03110302|Active Comparator|Home-based telehealth (HBT)|Veterans stay at home and meet with the therapist via telehealth, using videoconferencing technology
2469164|NCT03110302|Experimental|In home, in person (IHIP)|Therapist goes to the Veterans' homes to provide the psychotherapy
2469273|NCT03109496||OME Patients|Suffer from chronic Otitis Media with Effusion (OME) for at least 3 months and undergo ventilation tube placement.
2469274|NCT03109496||Healthy Control|Undergo surgery that gives access to the middle ear space (e.g. cochlear implant surgery) or adenoids, in absence of upper respiratory tract infections.
2469315|NCT03109158|Experimental|NC-6004 and 5-FU|"Phase I, continual reassessment method, dose-escalation study to determine the maximum tolerated dose (MTD) and an RPII dose of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.~In Part 1, patients will be assigned to receive cetuximab followed by NC-6004 and 5-FU.~Phase II, adaptive, open-label expansion study evaluating the activity, safety, and tolerability of NC-6004 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck at the RPII dose identified in Part 1.~In Part 2, all patients will receive NC-6004 at the RPII dose established in Part 1, in combination with cetuximab and 5-FU according to the same schedule as used in Part 1."
2469425|NCT03108651|Active Comparator|Case|Motivational message will be administrated.
2469429|NCT03108651|No Intervention|Control|Motivational message will not be administrated.
2469449|NCT03108196|Experimental|sigmoid|"Use 15 cm detaenial sigmoid colon to reconstructed a U shape neobladder after radical cystectomy."
2469450|NCT03108196|Experimental|ileal|"Use 70 cm distal ileal segment to reconstructed a spherical shape neobladder after radical cystectomy."
2469529|NCT03108014||Breast milk fed|Fed primarily breast fed as an infant
2469532|NCT03108014||Milk based formula fed|Fed primarily milk based formula as an infant
2469535|NCT03108014||Soy based formula fed|Fed primarily soy based formula as an infant
2469570|NCT03107546|Other|Skin graft|full thickness skin graft
2469571|NCT03107546|Experimental|Hyalomatrix|skin graft substitute
3157094|NCT00357942|Active Comparator|C group II|Placebo mouthwash and morphine i.v.(24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
3157095|NCT00357942|Placebo Comparator|C group III|Placebo mouthwash and placebo i.v. (24 hours) Added on standard analgesic treatment (paracetamol and patient controlled analgesia, morphine)
3157096|NCT00357981|Experimental|ORTHO EVRA|"The approximate first two months of women's participation will be spent documenting baseline information about their health and well-being, work patterns and performance, and the economic impact of their menstruation. Subjects will then initiate two, two month intervals of continuous use of ORTHO EVRA.~Over this four month treatment period, subjects will document their health and well-being, work patterns and performance, and the economic impact of their menstruation while being treated with ORTHO EVRA. This will allow us to compare subjects' experiences pre- and post-treatment. The study's instruments will focus on eliciting information on the personal and economic costs of menstruation such as measuring time missed from work, changes in productivity and work satisfaction, and impact on quality of life."
3157097|NCT00358033|Experimental|group intervention|pharmacist-led group intervention in behavioral and pharmacologic therapy
2469739|NCT03106480||HIV and Diabetes Cohort|Participants recruited in the study will have diverse characteristics. Participants will either be HIV infected or HIV negative and among those HIV-infected there will be those on ART and those not on ART. In addition, participants will have other background characteristics like having history of tuberculosis treatment, being malnourished while starting ART, having diabetes at ART initiation etc. Investigators will also be able to examine the effect of immune activation, body composition changes, and other related factors on the risk of diabetes. This diversity of characteristics will help provide adequate data to address study outcomes.
2469796|NCT03106116|Experimental|Enhanced External Counterpulsation|Experimental: Enhanced External Counterpulsation (EECP) intervention on top of guideline- driven standard medical therapy for coronary heart disease
2469802|NCT03106116|Active Comparator|Control|Guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention
2469853|NCT03105492||Pregnant women|Women who are pregnant
2469895|NCT03105115|Active Comparator|intrathecal fentanyl|heavy bupivacaine 14mg and fentanyl 20mcg will be injected intrathecally during spinal anesthesia
3157098|NCT00358033|Active Comparator|individual|pharmacist-based individual clinic visits with behavioral and pharmacologic intervention for cardiac risk reduction
3157099|NCT00358033|No Intervention|usual care|usual care
3157100|NCT00358072|Experimental|1|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
3157101|NCT00358202|Active Comparator|1 cefepime|
3157102|NCT00358202|Active Comparator|2 ceftriaxone|
3157103|NCT00358267|Active Comparator|RFA|Radiofrequency Ablation (RFA) involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
3157104|NCT00358267|Active Comparator|PRIT|Partial Resection of Inferior Turbinate (PRIT) involves surgically removing a small piece off the turbinate, which also reduces its size.
3157105|NCT00358306||a|those with previous history of Acute kidney injury
3157106|NCT00358319|Experimental|Phase I|Dose escalation phase
3157107|NCT00358319|Experimental|Phase II|All patients enrolled in the Phase II will be treated with Valproic Acid (VPA) and Karenitecin using the dosing schedule determined to be the Maximum Tolerated Dose (MTD) in Phase I.
3157108|NCT00358345||1|Intermediate AMD
3157109|NCT00358345||2|Newly diagnosed CNV
3174803|NCT00627289||1|patients with chronic postherniotomy pain (>1 year), affecting everyday activities severely
2469110|NCT03110666|Experimental|Autologous concentrated bone marrow aspirate|autologous concentrated bone marrow aspirate obtained from the BioCUE Concentration System
2469175|NCT03110263|Experimental|Multicomponent internet-based self-help|Multicomponent internet-based self-help
2469177|NCT03110263|Experimental|Internet-based sleep restriction|Internet-based sleep restriction
2469178|NCT03110263|No Intervention|Waiting control group|Access to internet-based intervention after 8-weeks
2469192|NCT03109899|Experimental|Intervention|Participants in this arm will have access to the Sex Pro mobile app and support for HIV/STI testing and PrEP uptake.
2469196|NCT03109899|No Intervention|Control|Participants in this arm will be given the local standard of care for HIV/STI testing and PrEP access.
3191876|NCT00802776|Active Comparator|FLAK|Femtosecond laser assisted keratoplasty
2469475|NCT03108495|Experimental|Cohort 1 LN-145 monotherapy|Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
2469479|NCT03108495|Experimental|Cohort 2 LN-145 monotherapy|Patients previously treated with an antiprogrammed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) checkpoint inhibitor: Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
2469482|NCT03108495|Experimental|Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only|Patients will be administered with pembrolizumab, followed by NMA lymphodepletion, then infused with their autologous TIL (LN-145) followed by pembrolizumab every 3 or 6 weeks post IL-2 administration up to 24 months.
2469484|NCT03108495|Experimental|Cohort 4 - Non-enrolling Cohort|Cohort includes patient population not meeting inclusion criteria in cohort 1 and 2. Post-NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
2469488|NCT03108495|Experimental|Cohort 5 Retreatment Cohort|Patients who have been previously treated with LN-145 may be given a second treatment with TIL.
2469610|NCT03107390|Other|Patients with CD or RCH|
2469614|NCT03107390|Other|The control population|
2469712|NCT03106610|Experimental|Nivolumab|"Participants receive Nivolumab by vein over about 60 minutes on Day 1 of Cycles 1-3 before scheduled surgery. Each study cycle is 14 days (2 weeks).~Questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery."
2469771|NCT03106233||LTP flap breast reconstruction|All consecutive patients who underwent LTP flap breast reconstructions (unilateral, bilateral or stacked unilateral) between September 2012 and November 2016 at three centers in Maastricht, the Netherlands, and New York and New Orleans, the United States, were included. Autologous breast reconstruction was performed by using the upper lateral thigh region as a donor site.
2469791|NCT03105921|Experimental|Electrodes|Electrodes
2469836|NCT03105635|Other|Patients|"Participating primary care providers will be encouraged to refer their patients who could benefit from community resources to these services. They will complete the study referral form for all patients referred to a resource. They will briefly mention the study to patients who are referred to a community resource, and ask for their verbal consent to be contacted by a member of the research team to learn more about the study, and leave a patient recruitment package with them."
2469838|NCT03105635|Other|Practice and Provider|"Four to six practices will be recruited to participate in this feasibility study. Primary care members working in a participating practice will be invited to participate in the study.~All primary care providers will be encouraged to participate and at least one primary care provider is required to participate to include the practice in the study.~After the obtaining an interest from a practice member to whom the invitation email was sent, we will offer all practice members eligible for the study an information session during which the study is described and participation offered. The practice manager or lead will be provided with the Practice Information and Consent Form"
2469894|NCT03105336|Experimental|axicabtagene ciloleucel|
2469962|NCT03104660|Experimental|CE certified mitral valve repair systems|CE certified transcatheter mitral valve repair systems
2470039|NCT03104543|Experimental|Education|Educational materials
2470042|NCT03104543|Active Comparator|Test results|Test results only; with delayed access to the experimental materials
2470115|NCT03103971|Experimental|Treatment (leukapheresis, chemotherapy, huJCAR014)|Patients undergo leukapheresis. Beginning 14-16 days after leukapheresis, patients undergo lymphodepleting chemotherapy comprising either cyclophosphamide IV daily for 1 day and fludarabine IV daily for 3 days or cyclophosphamide and fludarabine IV daily for 3 days. Within 36-96 hours after completion of lymphodepleting chemotherapy, patients receive huJCAR014 IV over 20-30 minutes on day 0.
2470182|NCT03103295|Experimental|3D-Tissue Engineered Bone Equivalent|"Patients with bone defects of critical size of long bones~3D Tissue Engineered Bone Equivalent: allogeneic or xenogeneic partially demineralized bone matrix (DBM) and plasma-derived fibrin gel seeded with autologous cultured bone marrow-derived multipotent mesenchymal stromal cells (BM-MSCs), periosteal progenitor cells (PPCs), peripheral blood-derived endothelial progenitor cells (PB-EPCs)."
2470246|NCT03102892|Active Comparator|Scaling Root Planing|Treatment by scaling and root planing. Repetition after 7 and 14 days.
2470249|NCT03102892|Experimental|Antimicrobial Photodynamic Therapy|Scaling and root planing and Antimicrobial photodynamic therapy with red laser (658 nm, 0.1 Watts, 2229 J/cm², 10s per point) and methylene blue dye (10mg/ml). Repetition after 7 and 14 days.
2470301|NCT03102658|Experimental|Obese subjects 100mg|8 subjects with a BMI>40kg/m2 will receive 100mg Micafungin
2470304|NCT03102658|Active Comparator|Obese subjects 200mg|8 subjects with a BMI>40kg/m2 will receive 200mg Micafungin
2470306|NCT03102658|Active Comparator|non-obese subjects|8 non obese subjects with a BMI >18.5 and <25 kg/m2 will receive 100mg Micafungin
2470352|NCT03102216|No Intervention|Current workflow pathway|In the Current (normal) Workflow Pathway, after a patient is triaged, they are reviewed by the doctor. It is routine for the doctor to then order diagnostic tests/investigations that include blood tests, which are analysed at the laboratory, x-rays, which are performed in the Radiology department, and an ECG, which is performed by an ECG technician. Once the results of those tests are ready, the doctor will then review the patient a second time with all the results. The decision for patient disposition will then be made
2470353|NCT03102216|Experimental|Enhanced workflow pathway iSTAT|Patients will receive i-STAT point-of-care troponin, INR (International Normalised Ratio), CG4(blood gas analysis) and chem8 tests prior to seeing the doctor.
3191877|NCT00802776|Active Comparator|PKP|Penetrating Keratoplasty
2469148|NCT03110432||Standard lipid lowering therapy|Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids (and any combinations of these agents)
2469152|NCT03110432||PCSK9 Inhibitor [EPC]|Evolocumab or alirocumab.
2469219|NCT03110068||Preoperative clinical/imaging features|In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo contrast-enhanced computed tomography (CECT) and contrast-enhanced ultrasound (CEUS).
2469262|NCT03109626|Active Comparator|DHA administration|DHA 600 mg/day will be administered for 16 weeks to 5 patients in double blind
2469263|NCT03109626|Placebo Comparator|placebo administration|placebo will be made with the same colour and taste, in softgel as DHA, and will be administered for 16 weeks to 5 patients in double blind.
2469344|NCT03109210|No Intervention|Standard Care|Participants randomized to standard care will receive normal follow-up care with their health care provider. This will include routine assessment and adjustment of PAP therapy, and instruction in proper sleep hygiene.
2469347|NCT03109210|Experimental|Intervention|In addition to standard care procedures, participants randomized to the intervention arm will receive up to two sequential treatments. First, participants will receive Online Cognitive Behavioral Therapy (OCBT). Those who meet criteria for remission after this first treatment will continue through follow-up without further treatment. Those who do not will be randomized again to either extended OCBT, or Therapist-directed Cognitive Behavioral Therapy (TCBT).
2469394|NCT03108677||metastatic|For osteosarcoma patients with metastasis, collecting blood samples.
2469396|NCT03108677||non-metastatic|For osteosarcoma patients without metastasis, collecting blood samples.
2469470|NCT03108287|Active Comparator|RAK therapy|rabeprazole+amoxicillin+clarithromycin
2469473|NCT03108287|Active Comparator|RBAK therapy|rabeprazole+amoxicillin+clarithromycin+bismuth subcitrate
3157110|NCT00358371|Experimental|Subjects receiving flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
3157111|NCT00358371|Experimental|Subjects receiving flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
2469591|NCT03107130||SUI Surgery Patients in 2015|All women 18 years of age or older, who underwent surgery for SUI between January 2015 and December 2015
3157112|NCT00358384|Experimental|Subjects receiving treatment A|Eligible subjects will receive 0.1 percent pazopanib ointment.
3157113|NCT00358384|Experimental|Subjects receiving treatment B|Eligible subjects will receive 0.5 percent pazopanib ointment.
3157114|NCT00358384|Experimental|Subjects receiving treatment C|Eligible subjects will receive 1 percent pazopanib ointment.
2469819|NCT03105804|Experimental|FT21039 Group|7 day at-home use of electronic cigarette FT21039 followed by a 2 day in-clinic period.
2469821|NCT03105804|Experimental|FT21041 Group|7 day at-home use of electronic cigarette FT21041 followed by a 2 day in-clinic period.
2469828|NCT03105804|Experimental|FT21044 Group|7 day at-home use of electronic cigarette FT21044 followed by a 2 day in-clinic period.
2469829|NCT03105804|Experimental|FT21042 Group|7 day at-home use of electronic cigarette FT21042 followed by a 2 day in-clinic period.
2469889|NCT03105284|Active Comparator|Liposuction of fat|The intervention examined is the extraction method by liposuction.
2469902|NCT03105284|No Intervention|Excision of fat|Control group
2470006|NCT03104894|Experimental|Study Group|The study group will receive meibomian glands massage and artificial drops PRN
2470010|NCT03104894|Sham Comparator|Control Group|The control group will receive sham meibomian glands massage and artificial drops PRN.
2470068|NCT03104153|No Intervention|Output-based|
2470070|NCT03104153|Active Comparator|Early-removal|
2470086|NCT03103828|Active Comparator|Computer-tailored intervention|
2470089|NCT03103828|Active Comparator|Motivational Interviewing|
2470090|NCT03103828|Active Comparator|Motivational Enhancement Therapy|
2470092|NCT03103828|No Intervention|Control Group|
2470143|NCT03103698|Other|Monitoring of perioperative analgesia by the ANI device|
2470146|NCT03103698|Other|conventional monitoring based on hemodynamic variations.|
2470241|NCT03103386|Experimental|Fermented Rye Bran group|Intake of food product with a patented fermented rye bran: A patented fermented rye bran ingredient for food purpose has been produced through a process where a specific Lactobacillus curvatis strain was incubated with rye bran by Kampffmayer Food Innovation GmbH, Germany. The dried fermented rye bran was incorporated into a whole grain rye crisp bread product (25% on weight basis) commercially available in Sweden and in a novel extruded whole grain rye product (20%) developed by Lantmännen.Two crisp rye bread pieces (2 x 12g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily. Rye puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily. Total energy: 518 kcal/day.
2470288|NCT03102567|Placebo Comparator|placebo|oral hard gelatin capsules containing placebo for q.d. administration
3157115|NCT00358384|Placebo Comparator|Subjects receiving treatment D|Eligible subjects will receive pazopanib vehicle as negative control.
3157116|NCT00358384|Placebo Comparator|Subjects receiving treatment E|Eligible subjects will receive 0.1 percent betamethasone valerate ointment as steroid positive control.
3157117|NCT00358384|Placebo Comparator|Subjects receiving treatment F|Eligible subjects will receive 0.005 percent calcipotriol ointment as vitamin D agonist positive control.
3157118|NCT00358397|Experimental|Treatment arm|
3157119|NCT00358410|Experimental|GW679769|120mg once a day
3157120|NCT00358410|Placebo Comparator|Placebo|Placebo once a day
3157121|NCT00358423|Experimental|A|
3157122|NCT00358423|Placebo Comparator|B|
3157123|NCT00358488|Experimental|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
3157124|NCT00358488|Experimental|salbutamol|salbutamol
3157125|NCT00358488|Experimental|salmeterol 50mcg|salmeterol 50mcg
3157126|NCT00358488|Placebo Comparator|placebo|placebo
3157127|NCT00358540|Experimental|Group B|Group B is a dose escalation phase designed to determine the optimal biological dose of eltrombopag in subjects with sarcoma who received chemotherapy treatment with Adriamycin and Ifosfamide
3174804|NCT00627302|Active Comparator|2|Systane
3174805|NCT00627302|Active Comparator|1|PEG-400
2469182|NCT03110211|Experimental|Physical Therapist Evaluation|Patients are randomized to have an initial appointment with a physical therapist for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a physical therapist.
2469185|NCT03110211|Experimental|Primary Care Physician Evaluation|Patients are randomized to have an initial appointment with a primary care physician for a musculoskeletal complaint. The intervention is an initial evaluation and treatment recommendations by a primary care physician.
2469243|NCT03109808|Experimental|e-health strategy|Assigned intervention: e-health strategy
2469245|NCT03109808|Active Comparator|Traditional Oral Hygiene Education|Assigned intervention: traditional oral hygiene education
2469305|NCT03109392|Experimental|Nebulized lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
2469307|NCT03109392|Experimental|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
2469312|NCT03109392|Active Comparator|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
2469377|NCT03108872||LAAO group|One-hundred consecutive patients who underwent left atrial appendage occlusion from October 2010 to March 2015 in 5 Korean tertiary cardiovascular centers will be retrospectively registered.
2469378|NCT03108872||NOAC group|Two-hundred age-, sex-, CHA2DS2-VASc score- and HAS-BLED score- matched control will be selected with a 1:2 ratio among all patients treated with new oral anticoagulants to prevent ischemic events from 5 centers during same periods
2469618|NCT03107299|Other|Control|
2469621|NCT03107299|Other|Send sms to patients|
2469626|NCT03107299|Other|pharmaceutical maintenance following medical consultation|
2469671|NCT03106792|Experimental|Hairfinity #1|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2469672|NCT03106792|Experimental|Hairfinity #2|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2469675|NCT03106792|Experimental|Hairfinity #3|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2469678|NCT03106792|Placebo Comparator|Placebo|Dosage form: Capsule Frequency: Take 2 capsules by mouth in the morning with a meal. Duration: 90 days
2469711|NCT03106493||Primary|Singletons and 1 twin of each pair
2469718|NCT03106493||Secondary|Twin sibling of children enrolled in primary cohort
2469723|NCT03106493||Tertiary|Higher order multiples and siblings
2469770|NCT03106298||Iron Sucrose Treatment|All patients with iron deficiency anemia (those without CKD or HF, those with CKD only, those with HF only, and those with CKD/HF) will be given 5 weekly doses of 200 mg of intravenous iron sucrose.
2469799|NCT03105882|Experimental|Neuro-Spinal Scaffold|
2469875|NCT03105583||Pregnant women visiting the obstetrics department|
2469959|NCT03104998|Other|coenzyme Q10|Dose of 200 mg of CoQ10 taken daily by mouth from day 1 till 26 weeks
3157128|NCT00358540|Experimental|Group A|Group A will be used for further exploration of the optimal biological dose (as initially established by completion of Group B), by using 2 different dosing schedules of eltrombopag.
3157129|NCT00358566|Active Comparator|Gemcitabine|Gemcitabine alone treatment.
2470111|NCT03104036|Active Comparator|Mesalazine enema|Will be treated with 4 g mesalazine enema 1x daily for 2 weeks, then every other day until the end of the 6th week.
2470117|NCT03104036|Experimental|Faecal bacterial transplantation enema|Will be applied enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline, the 1st week 5 times, than one time a week until the end of the 6th week.
2470162|NCT03103581|Experimental|BLI4700|BLI4700 Bowel Preparation (Investigational Regimen)
2470244|NCT03103243|Other|Intervention|This is a single arm trial. All participants will be administered two baseline fMRIs and blood analysis prior to participation in a mindfulness group and individual mindfulness intervention sessions. A post intervention fMRI and blood analysis will complete the trial participation.
2470309|NCT03102723|Experimental|Cangrelor|Cangrelor (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
2470314|NCT03102723|Placebo Comparator|Placebo|Matching normal saline placebo (single intravenous bolus followed by a 120-minute infusion) initiated prior to PPCI.
2470357|NCT03102177|Experimental|Stable isotope arm|Measurement of blood levels of labelled levothyroxine after administration of single oral dose of stable isotope levothyroxine
2470412|NCT03101904|Experimental|Nitrate then Placebo|"Participants will consume a daily a beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
2470416|NCT03101904|Placebo Comparator|Placebo then Nitrate|"Participants will consume a daily Nitrate-depleted beetroot shot for six days. Each shot will consist of 1x70ml nitrate-depleted beetroot Placebo shot (~0.003mmol of nitrate; Beet It, James White Drinks Ltd, Ipswich, UK).~Following a minimum of ten days wash out, participants will then consume a daily beetroot shot for six days. Each shot will consist of: 1x70ml concentrated NO-3 shot of rich Beetroot juice (~7mmol nitrate; Beet It, James White Drinks Ltd, Ipswich, UK)."
2470518|NCT03101124|Experimental|abdominoplasty moistening|Tranexamic Acid 25 mg/ml for wound surface moistening prior to wound closure
2470524|NCT03101124|Experimental|abdominoplasty bolus|Tranexamic Acid 5 mg/ml as bolus in wound cavity after wound closure
2470530|NCT03101124|Active Comparator|preoperative intravenous administration|Tranexamic Acid Injectable Solution administered before hip replacement surgery
2469296|NCT03109639|Active Comparator|Group A|This group will undergo tissue acquisition using the conventional EUS-FNA needle followed by the experimental Acquire EUS- FNB needle
2469299|NCT03109639|Active Comparator|Group B|This group will undergo tissue acquisition using the experimental Acquire EUS- FNB needle followed by the conventional EUS-FNA needle
2469428|NCT03108950|Experimental|Home-Based Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
2469467|NCT03108170|Active Comparator|3 programs group|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her duo date
2469469|NCT03108170|Active Comparator|one program group|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her duo date.
3157130|NCT00358566|Experimental|GV1001|GV1001 in sequential combination with Gemcitabine
3157131|NCT00358722|Experimental|Fermagate|
2469631|NCT03107078|Experimental|Group Ia|"I:The increase of fat volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
2469632|NCT03107078|Experimental|Group Ib|"I:The increase of fat volume dominates. b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
2469633|NCT03107078|Experimental|Group IIa|"II:The increase of extraocular muscles volume dominates .~a:The weekly protocol was as follows: 0.5 g glucocorticoids weekly for 6 weeks, followed by 0.25 g weekly for 6 weeks."
2469634|NCT03107078|Experimental|Group IIb|"II:The increase of extraocular muscles volume dominates . b:The qod protocol was as follows: 0.5 g glucocorticoids qod. for 3 interval days per month for 3 months."
2469688|NCT03106727|Active Comparator|Zalewa|Household Model Intervention introduced first - March 2017
2469691|NCT03106727|Active Comparator|Ligowe and Magaleta|Household Model Intervention to be introduced in June 2017
2469695|NCT03106727|Active Comparator|Neno District Hospital and Neno Parish|Household Model Intervention to be introduced in September 2017
2469701|NCT03106727|Active Comparator|Matope|Household Model Intervention to be introduced in December 2017
2469704|NCT03106727|Active Comparator|Matandani and Nsambe|Household Model Intervention to be introduced in March 2018
2469708|NCT03106727|Active Comparator|Luwani, Nkula, and Midzemba|Household Model Intervention to be introduced in June 2018
2469793|NCT03106025|Experimental|Patients Receiving Ultrasound|Enrolled participants will receive a bedside ocular ultrasound of the affected eye and the ultrasound will be compared with the ophthalmologist diagnosis. The participant's medical record will also be reviewed for information regarding demographics, complications, and outcomes.
2469858|NCT03105570|Experimental|Areola sparing mastectomy.|Eligible patients undergo areola sparing mastectomy.
2469897|NCT03105076|Experimental|DAs group|Shared decision making using decision aids
2469910|NCT03105076|No Intervention|Control group|Standard oral explanation guided with booklets
2469972|NCT03104842|Experimental|Arm A Transplantation|Patients ≤ 70 years of age and eligible for stem cell transplantation will enter study arm A They will undergo 6 cycles of Induction Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd), after intensification another 4 cycles of I-KRd as consolidation will be followed by IKR maintenance until PD or Toxicity
2469974|NCT03104842|Experimental|Arm B No-Transplantation|Patients > 70 years or ineligible for stem cell transplantation will enter study arm B They will undergo 12 cycles of Treatment : Carfilzomib, Lenalidomid, Isatuximab (I-KRd) (6 Cycles Induction, 2 Cycles Intensification, 4 Cycles Consolidation),to be followed by I-KR maintenance util PD or Toxicity
2470037|NCT03104335|Experimental|Study arm|every participant will recieve 750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
2470088|NCT03103997|Active Comparator|New Needle|EUS-guided liver biopsy with needle and suction, no preparation
2470091|NCT03103997|Experimental|Dry Heparin|EUS-guided liver biopsy with needle flushed with heparin, then flushed with air, suction then attached
2470093|NCT03103997|Experimental|Wet Heparin|EUS-guided liver biopsy with needle flushed with heparin, 2 cc of liquid added to suction then attached.
2470145|NCT03103685|Placebo Comparator|ASA alone|The patient in this arm will be ask to stop P2Y12 inhibitor before dental procedure, 5 days for clopidogrel and ticagrelol and 7 days for prasugrel.
2470148|NCT03103685|Experimental|Uninterrupted DAPT|The patient in this arm will continue dual anti platelet until the date of dental procedure.
2470221|NCT03103074|Experimental|Botulinum B Toxin|Botulinum toxin B (Neurobloc(R)) 50 Units (U)/ml 0,05-0,1 ml/injection intradermally in a grid with 1- 1 1/2 cm between every injection in affected areas A maximum of 4000 U/patient/treatment Treatment every three months
2470222|NCT03103074|Placebo Comparator|Placebo|Saline (NaCl 0,9%) 0,05-0,1 ml/injection intradermally in a grid With 1- 1 1/2 cm between every injection in affected areas Treatment in placebo group (n=10) only at first intervention
2470264|NCT03102853|Active Comparator|Nordic diet|
2470266|NCT03102853|Other|Control diet|
2470285|NCT03102567|Experimental|GLPG1205 50mg q.d.|oral hard gelatin capsules with 50 mg GLPG1205 for q.d. administration - compared to placebo
2470640|NCT03100305||Late preterm infants|
3157132|NCT00358787|Active Comparator|1|Crossed K wire orientation for surgical management of a type III Supracondylar fracture.
3157133|NCT00358787|Active Comparator|2|Lateral K wire orientation for surgical management of a type III Supracondylar fracture.
3157134|NCT00358813|Experimental|Subjects receiving casopitant|Eligible subjects will receive a 100 milligrams oral dose of casopitant once daily for five consecutive days.
3157135|NCT00358852||Patients with Schizophrenia|
3157136|NCT00358878|Experimental|Satavaptan|
3157137|NCT00358878|Placebo Comparator|Placebo|
2469298|NCT03109171|Other|Expert rater|Pulmonologist or Otolaryngologist with experience in laryngopharyngeal sensory evaluation: who has made more than 50 laryngopharyngeal sensory tests.
2469302|NCT03109171|Other|Non-expert rater|"Pulmonologist or Otolaryngologist inexperienced in laryngopharyngeal sensory evaluation: who has made minimum 5 and maximum 50 laryngopharyngeal sensory tests.~Pulmonologist fellow who has completed the training provided for a Pulmonologist Fellow in bronchoscopy and who has performed minimum 5 and maximum 50 laryngopharyngeal sensory testing."
2469443|NCT03108625|Experimental|Vortioxetine|Once daily dosing of vortioxetine (oral tablets) for 78 weeks.
2469523|NCT03107832|Active Comparator|general anesthesia|In general anesthesia group (Group G), and induction was managed using 1.5 mg/kg fentanyl and 2 mg/kg propofol; 0.5 mg/kg rocuronium and sevoflurane in a 50% oxygen /air mixture was used. Blood gas analysis monitoring was performed in the 30th minute before and after pneumoperitoneum
2469526|NCT03107832|Experimental|thoracic epidural anesthesia|In epidural anesthesia group(Group E), a catheter was installed and received 20 mg lidocaine hydrochloride, 15 mg bupivacaine, and 25 mg fentanyl citrate adjusted to 10 cc with normal saline to be injected by the epidural catheter. Bi-spectral index -controlled sedation was provided
2469625|NCT03107507|Active Comparator|Levetiracetam|"Levetiracetam given in oral form via oro-gastric tube, first a bolus dose 40-50mg/kg then maintenance dose 10-30 mg/kg/day divided every 12 hours.~Duration: until seizure free"
2469628|NCT03107507|Active Comparator|Phenobarbital|"Phenobarbital given in IV form, loading dose 20mg/kg that can be repeated after a 20 minute interval not to exceed 40mg/kg then maintenance dose 2-4 mg/kg/day divided every 12 hours.~Duration: until seizure free"
2469674|NCT03106766|Experimental|Acne cream 1x|Twice-daily facial applications of the 1X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
2469677|NCT03106766|Experimental|Acne cream 2x|Twice-daily facial applications of the 2X product (avoiding contact with eyes and all mucous membranes) to the entire face for 6 months.
2469744|NCT03106519|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the median and ulnar nerves
2469749|NCT03106519|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the median and ulnar nerves
2469778|NCT03106064|Placebo Comparator|Usual Care Group|Intervention: Usual care
2469779|NCT03106064|Experimental|Intervention Group|Intervention:Promoting independence in self-care
2469820|NCT03105791|No Intervention|Normal pre-operative education|• Control group received normal pre-operative education regarding surgery
2469823|NCT03105791|Active Comparator|Opioid usage education|• The study group received formal education detailing recommended post-operative opioid usage, side effects, dependence, and addiction
2469904|NCT03105206||Low Pole Renal Calculus|patients with low pole renal calculus who are suitable to treat by flexible ureteroscopy
2469969|NCT03104829|Active Comparator|DSME|participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later
2469971|NCT03104829|Experimental|DSME+MI|participants in this arm will receive standard care for diabetes plus motivation interviewing (MI) sessions at the beginning of the study and 3 months later, will also receive motivation interviewing sessions by phone at 1, 2, 4, 5 month after the beginning of the study
2469994|NCT03104452||Pregnant Smokers|Participants are pregnant women who smoked in the six months prior to their pregnancy.
2470044|NCT03104257||Cannabis Dependent Subjects|Subjects who are frequent cannabis users
2470045|NCT03104257||Healthy Controls|Subjects with no current cannabis use
2470110|NCT03103958|Active Comparator|probiotic|Probiotic consists of Lactobacillus acidophilus NCFM, Lactobacillus rhamnosus HN001, Lactobacillus paracasei LPC-37 and Bifidobacterium lactis HN019 (Probiatop), Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
2470116|NCT03103958|Placebo Comparator|Placebo|Placebo consists of maltodextrin. Subjects will take two sachets per day after diluting them in 100 ml of water for 28 days.
2470178|NCT03103633|Experimental|Individualized Goal-Directed Therapy|The goal of intervention:mean artery pressure declined with less than 20% of baseline, BIS 45-60 before and after CPB; and BIS 40-45 during CPB, Brain oxygen saturation declined with less than 20% of baseline.
2470180|NCT03103633|Sham Comparator|Controlled|no intervention beside the same monitoring with MAP, BIS and brain oxygen saturation and receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
3191878|NCT00802789||1|Mild to moderate adult asthmatics (≥18years of age) insufficiently treated with ICS or ICS + LABA.
2470268|NCT03102840||Children nasal swab only|Pneumococcal nasopharyngeal carriage in children aged 6-48 months who have previously received PCV13
2470269|NCT03102840||Children nasal swab + serum|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
2470293|NCT03102541||Cardiac Surgery|214 adult patients with estimated GFR ≥60 ml/min/1.73 m2 (CKD-Epidemiology Collaboration equation) undergoing elective cardiac surgery (coronary artery bypass, valve replacements, combined or other surgery, with cardiopulmonary bypass) between November 2014 and October 2015 at the San Bortolo Hospital, Vicenza, Italy
2470362|NCT03102398|Experimental|Single-arm and Open-label Study|
2470426|NCT03101852|Experimental|Nutritional therapy|Children included in the study with severe acute malnutrition receive Plumpy Nut: WHO recommends a Plumpy Nut® prescription of 75 to 100 kcal/kg/d in children aged 5 to 10 years and 60 to 90 kcal/kg/d above that age. The lowest value was used and maximum energy intake provided by RUF was limited to 2,000 kcal/d i.e. 4 sachets in order to preserve habitual diet and prevent appetite saturation
2470427|NCT03101852|Experimental|Nutritional supplementation|Children included in the study with moderate acute malnutrition receive Plumpy Sup: 60kcal/kg/day, limited to 4 doses/day.
2470437|NCT03101410|Experimental|gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
2470439|NCT03101410|Experimental|gluten fee|Selected participants will be randomly allocated to treatment group (gluten or gluten free)
2470773|NCT03099850||Chronic Pancreatitis|
3191879|NCT00802802|Experimental|Cohort I, Step 1|HIV-infected children 3 months to 36 months of age, receiving EFV and two NRTIs
2469326|NCT03109132|Active Comparator|Model 6|Device - O2/CO2 cannula w/female luer (Westmed comfort plus #0504)
2469385|NCT03108690|Experimental|TDM and CI.|Continuous infusion of beta-lactam antibiotics. Therapeutic drug monitoring of beta-lactam antibiotics.
2469388|NCT03108690|No Intervention|Control|Beta-lactam antibiotics given as intermittent infusion. Samples of serum concentration of beta-lactam will be collected for comparison, but blinded during the study.
2469441|NCT03108313|Experimental|aloe vera toothpaste|aloe vera toothpaste isa will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
2469442|NCT03108313|Active Comparator|fluoride toothpaste|fluoride toothpaste isa herbal toothpaste will be administrated 2 times per day for 30 days and salivary bacterial count will be tested before the use of toothpaste the after 15 days and 30 days
2469492|NCT03108105|Experimental|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
2469537|NCT03107819||Pediatric patients undergoing EGD|Subjects ages 2-18 years undergoing upper endoscopy (EGD) will submit a blood and urine specimen for plasma and urine metabolomics profiling.
2469572|NCT03107481|Active Comparator|Acetaminophen|
2469574|NCT03107481|Active Comparator|Hydromorphone|
2469655|NCT03107169|Active Comparator|Vancomycin|Patients in this arm received vancomycin 250mg every 6 hrs for 10-14 days
2469658|NCT03107169|Experimental|FMT-FURM|Patients in this arm receive FMT-FURM
3191880|NCT00802802|Experimental|Cohort II|HIV/TB-coinfected children 3 months to 36 months of age, receiving EFV, two NRTIs, and rifampin-containing anti-tuberculosis (anti-TB) therapy
3191881|NCT00802802|Experimental|Cohort I, Step 2|HIV-infected children from Cohort I who become coinfected with TB during the study. They will receive EFV, two NRTIs, and rifampin-containing anti-TB therapy
2469811|NCT03105960|Experimental|garlic with lime juice mouthwash|"garlic with lime juice mouthwash is herbal antimicrobial .children were instructed to rinse for 14 days, twice daily, ,10 ml (undiluted) for 30 second and then expectorate .~To prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract."
2469813|NCT03105960|Active Comparator|chlorhexidine mouthwash|"chlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days. it is commercial mouthwash~."
2469887|NCT03105180||0% dilution|Blood specimen which was diluted with 0% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2469899|NCT03105180||10% dilution|Blood specimen which was diluted with 10% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2469914|NCT03105180||20% dilution|Blood specimen which was diluted with 20% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
2469919|NCT03105180||40% dilution|Blood specimen which was diluted with 40% level using a mixture of 2.7% sorbitol-0.54% mannitol solution
3191882|NCT00802815|Experimental|Etanercept|
3191883|NCT00802828|Active Comparator|Test Product|
3191884|NCT00802828|Active Comparator|Reference Product|
3191885|NCT00802906|Active Comparator|1|1.5 mg bevacizumab single injection and on demand if leakage is persistent or recurs
3191886|NCT00802906|Active Comparator|2|initial selective subthreshold micropulselasercoagulation and on demand if leakage is persistent or recurs
2470252|NCT03103009|Experimental|pasireotide|Interventions - One patient will be given a drug, pasireotide (Signifor), on a compassionate use basis for treatment of post-gastric bypass hypoglycemia. The minimal dose will be 0.3 mg subcutaneous daily and the maximal dose will be 0.6 mg subcutaneous twice daily. The patient may continue treatment with pasireotide indefinitely unless the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued at the discretion of the treating physician or Novartis or withdrawal of consent.
2470290|NCT03102697||Obese individuals|Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
2470338|NCT03102359|Experimental|Selective Head Cooling|Participants received a cooling helmet filled with ice water mixture after an-esthesia induction until the end of the surgery.
2470340|NCT03102359|Experimental|Dexmedetomidine|Giving dexmedetomidine1μg/kg i.v for 10 minutes, then use computerized infusion pump at 0.5μg/kg.h until the end of the surgery.
2470342|NCT03102359|Experimental|Selective Head Cooling and Dexmedetomidine|Using selective head cooling combined with dexmedetomidine as described before
2470343|NCT03102359|No Intervention|Control|No intervention in this group
2470451|NCT03101436|Experimental|Lean Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
2470476|NCT03101332|Experimental|VR-CBT|Virtual Reality cognitive behavior therapy. 10-12 sessions of individual Cognitive Behavior Therapy with exposure tasks carried out through Virtual Reality.
3191887|NCT00802906|No Intervention|3|control
3191888|NCT00802932||Partial Breast Radiation|1. Patients receiving Partial breast radiation
3191889|NCT00802932||Whole Breast Radiation|2. Patients receiving whole breast radiation
3191890|NCT00802958||Cohort Group 1|Subjects number 1 to 30
3191891|NCT00802958||Cohort Group 2|Subjects number 31 to 56
3191892|NCT00802958||Cohort Group 3|Subject Numbers 57 to 76
3191893|NCT00802971|Experimental|1: FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
3191894|NCT00802971|No Intervention|2: Control|
3191895|NCT00803088|Experimental|1|Treatment of airways with the Alair System
3191896|NCT00803127||no treament|
3191897|NCT00803140|Active Comparator|Cautery Arm|Cautery to make skin incision
3191898|NCT00803140|Active Comparator|Scalpel Incision|Scalpel to make skin incision
3191899|NCT00803166||Cohort Group 1|Subjects number 1 to 30
2469369|NCT03108833|Active Comparator|Active Comparator Controlled Group|Alteplase:100mg if weight>=65kg, 1.5mg/kg if weight<65kg
2469403|NCT03108430||Inhalation pneumonia|
2469406|NCT03108430||Proven inhalations|
2469410|NCT03108430||Suspected inhalations (coma + anamnesis)|
2469461|NCT03108248||ISP-TACE group|During the study period, a total of 44 patients with HCC with PVTT underwent the irradiation stent placement and TACE were included in the ISP-TACE group.
2469465|NCT03108248||TACE group|During the study period, a total of 82 patients with HCC with PVTT underwent TACE monotherapy were included in the ISP-TACE group.
2469520|NCT03107962|Experimental|PD-1 Blocking Antibody|Pembrolizumab
2469568|NCT03107533||Video recording of clinical visit|Investigators will enroll patients from the Department of Orthopedic Surgery for enrollment. The shared decision group will provide staff for data analysis.
2469595|NCT03107273||Diagnostic patient|
2469598|NCT03107273||Control|
2469679|NCT03107000|Active Comparator|Trabeculectomy group|Patients with Open Angle Glaucoma requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
2469681|NCT03107000|Active Comparator|Phako-trabeculectomy group|Patients with Open Angle Glaucoma and cataract requiring incisional surgery in whom specular microscopy can be performed without any delay in their treatment
2469732|NCT03106454|Active Comparator|Combination oral contraceptive pill|Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg Taken cyclically as 24 tablets containing EE 10mcg/NET acetate 1mg 2 tablets of EE 10mcg only 2 tablets of ferrous fumarate 75mg
2469733|NCT03106454|Experimental|Progestin only pill|Norethindrone 0.35mg Marketed use for 1 tablet per day. For study dosing, patients will take 3 tablets daily for a total of 1.05mg daily.
2469810|NCT03105726||Group I|Group managed by ventricular assist devices in first intention in Bad-Oeynhausen, Germany
2469815|NCT03105726||Group II|Group managed with medical therapy, heart transplantation, or both, in first intention,in Paris, France
2469844|NCT03105544|Experimental|Intervention|Simulation-based training: Virtual-reality simulation training on the Medaphor Scantrainer Transabdominal Simulator until expert level is reached. Then training on a physical mannikin until an average OSAUS-score of 3 or more is attained.
2469845|NCT03105544|No Intervention|Control|No intervention.
2469901|NCT03105154|Experimental|Prevena Dressing|Groin dressed with Prevena
2469911|NCT03105154|Active Comparator|Conventional Dressing|Groin dressed with conventional bandage
2469968|NCT03104803|Experimental|Long-term PAS|The intervention is given to one hand only
2469970|NCT03104803|No Intervention|No intervention|Contralateral hand of the same patient
3157138|NCT00358943||Patients in ICGG Gaucher Registry|No experimental intervention is given. A patient with Gaucher Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
3157139|NCT00358943||Pregnant women with confirmed diagnosis of Gaucher disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Gaucher disease who are participating in the ICGG Gaucher Registry and consented to participate in the Gaucher Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy and irrespective of the commercial product with which she may be treated.
3157140|NCT00358982|Experimental|1|
3157141|NCT00358995|Active Comparator|1|Cognitive Behavior Therapy (CBT) may include keeping a diary of significant events and associated feelings, thoughts and behaviors; questioning and testing cognitions, assumptions, evaluations and beliefs that might be unhelpful and unrealistic; gradually facing activities which may have been avoided; and trying out new ways of behaving and reacting and using relaxation and distraction techniques.
2470255|NCT03103048|Active Comparator|Group 1|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages (start); 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage.
2470256|NCT03103048|Placebo Comparator|Group 2|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo (start); 3 - With bandage; 4 - With tensioned bandage.
2470258|NCT03103048|Active Comparator|Group 3|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage (start); 4 - With tensioned bandage.
2470261|NCT03103048|Active Comparator|Group 4|The tests will be performed in thirty days, session with lasting 15 minutes each, when all volunteers will be submitted in four measure tests: 1- Without bandages; 2 - With placebo; 3 - With bandage; 4 - With tensioned bandage (start).
2470307|NCT03102489|Experimental|BP101|Treatment with BP101
2470315|NCT03102489|Placebo Comparator|Placebo|Treatment with placebo
2470375|NCT03102281||recurrent group|Patients who had recurrent common bile duct stones.
2470379|NCT03102281||control group|Patients who had not recurrent common bile duct stones.
2470410|NCT03101800|Experimental|Azathioprine and Allopurinol|
2470415|NCT03101800|Active Comparator|Azathioprine|
2470482|NCT03101527|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
2470525|NCT03101046|Other|Group1: Arm A (standard arm) + Arm B (experimental arm)|"Arm A: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks) after randomization.~Arm B: Patients with docetaxel resistant mCRPC (defined as having ≥5 CTCs / 7.5 mL) will receive up to 10 cycles of cabazitaxel (20 mg/m² every 3 weeks) after randomization."
2470534|NCT03101046|Other|Group 2: Cohort|Patients with docetaxel sensitive mCRPC (defined as having <5 CTCs / 7.5 mL) will receive up to 8 additional cycles of docetaxel (75 mg/m² every 3 weeks)
2470786|NCT03099668|Experimental|OSAC|Single visit to a multidisciplinary clinic (the One Stop Arthritis Clinic, OSAC), followed by routine care
2470789|NCT03099668|No Intervention|Routine care|Routine care
3157142|NCT00358995|Active Comparator|2|Stress Management Therapy (SMT) includes relaxation, interaction, biofeedback, exercises, such as muscle stretching exercises, yoga, meditation, time management techniques, and many more.
3157143|NCT00359008||1|Intermediate AMD
3157144|NCT00359008||2|New untreated CNV subject
2469395|NCT03108716|Experimental|short-arm tube-type plaster fixation|The patients were assigned to the short-arm tube-type plaster fixation (conservative treatment) (n=4).
2469446|NCT03108300|Experimental|propranolol hydrochloride with Doxorubicin|The patients suffering from metastatic soft tissue sarcoma will receive doxorubicin 60mg per square meter of body surface area every 21 days combined with propranolol hydrochloride 40mg twice daily
3191900|NCT00803166||Cohort Group 2|Subjects number 31 to 60
3191901|NCT00803192|Active Comparator|Test Drug|
3191902|NCT00803192|Active Comparator|Reference Drug|
3191903|NCT00803218||Cohort Group 1|Subjects number 1 to 26
2469745|NCT03106363|Active Comparator|Alcohol/Placebo Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
2469750|NCT03106363|Active Comparator|Placebo Alcohol/Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
2469754|NCT03106363|Active Comparator|Alcohol/Cannabis|Participant will drink an alcoholic beverage to obtain a target blood alcohol content of 0.08mg% and will smoke a delta 9 tetrahydrocannabinol (potency 12.5%) cigarette.
2469756|NCT03106363|Placebo Comparator|Placebo Alcohol/Placebo Cannabis|Participant will drink tonic water (capped with a minimal amount of alcohol to enhance alcohol cues) and will smoke a placebo delta 9 tetrahydrocannabinol (< 0.03%) cigarette.
2469797|NCT03105856|Active Comparator|CERVARIX|hrHPV-based screening and HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 months)
2469801|NCT03105856|Active Comparator|GARDASIL|hrHPV-based screening and Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) vaccine group according to a two-dose schedule (0-12 months)
2469803|NCT03105856|No Intervention|CONTROL GROUP|Control group who will receive only hrHPV-based screening.
3191904|NCT00803218||Cohort Group 2|Subjects number 27 to 56
3191905|NCT00803231||Retrospective cohort|Patient treated with Xigris between January 2006 and November 2008.
3191906|NCT00803231||Prospective cohort|Patient treated with Xigris between November 2008 and November 2009.
3191907|NCT00803257|Experimental|1|Lumbrical splint and lumbrical stretches
3191908|NCT00803257|Active Comparator|2|Lumbrical Splint and regular exercises
3191909|NCT00803257|Active Comparator|3|Regular splint and lumbrical exercises
3191910|NCT00803257|Active Comparator|4|Regular splint and regular exercises
2469939|NCT03104946||Bronchopulmonary Dysplasia|
3191911|NCT00803296||Obese patients with type 2 diabetes|Patients with type 2 diabetes and BMI>33
3191912|NCT00803296||Obese subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BMI>33
3191913|NCT00803296||Lean subjects with type 2 diabetes|Patients with type 2 diabetes and BM<25
3191914|NCT00803296||Lean subjects with normal glucose tolerance|Subjects with normal glucose tolerance and BM<25
3191915|NCT00803309|Active Comparator|A|PegIntron® 1.5 µg/kg once weekly (QW) subcutaneous (sc) plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 24 weeks beyond standard treatment with 24 weeks follow-up
3191916|NCT00803309|Active Comparator|B|PegIntron® 1.5 µg/kg QW sc plus Rebetol® 800-1400 mg per os divided in 2 daily doses for additional 12 weeks beyond standard treatment with 24 weeks follow-up
3191917|NCT00803322||1|communities where tuberculosis patients followed the conventional health facility based tuberculosis case finding and treatment
3191918|NCT00803322||2|community where suspects of pulmonary tuberculosis were identified by community health workers and received treatment in the community
3191919|NCT00803335|Active Comparator|Premarin cream 0.5gm|Application of 0.5gm of vaginal estrogen cream nightly until surgery.
3191920|NCT00803335|Active Comparator|Premarin cream 1.0gm|Application of 1.0gm of vaginal estrogen cream nightly until surgery.
3191921|NCT00803335|No Intervention|No intervention|Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.
3191922|NCT00803348|Active Comparator|1|Initial Bolus dose of 0.2% ropivicaine followed by 0.2% ropivicaine infusion until day 2 post-op
3191923|NCT00803348|Experimental|2|Initial Bolus dose of 0.2% ropivicaine followed by 0.1% ropivicaine infusion until day 2 post-op
3191924|NCT00803348|Placebo Comparator|3|Initial Bolus dose of 0.375% ropivicaine followed by saline infusion until day 2 post-op
3191925|NCT00803374|Experimental|0.1 mg/kg|
3191926|NCT00803374|Experimental|0.3 mg/kg|
3191927|NCT00803374|Experimental|1.0 mg/kg|
3191928|NCT00803374|Experimental|3.0 mg/kg|
3191929|NCT00803374|Experimental|10 mg/kg|
3191930|NCT00803387||Patients taking Xalatan with ocular dryness or irritation|"patient must already be using xalatan for at least 1 month prior to study enrollment in both eyes and have complaints of dry eye and/or irritation.~any race and of either sex, diagnosed with open angle glaucoma (OAG) (with or without pseudoexfoliation or pigment dispersion components) or ocular hypertension (OHT)"
3191931|NCT00803426|Active Comparator|1|Local anesthetic will be injected above the division of the sciatic nerve.
3191932|NCT00803426|Experimental|2|Local anesthetic will be injected below the division of the sciatic nerve, around the common peroneal and tibial nerves.
3191933|NCT00803439||Cohort Group 1|Subjects number 1 to 20
3191934|NCT00803439||Cohort Group 2|Subjects number 21 to 40
3191935|NCT00803439||Cohort Group 3|Subjects number 41 to 60
3191936|NCT00803439||Cohort Group 4|Subjects number 61 to 80
3191937|NCT00803465||Cohort Group 1|Subjects number 1 to 24
3191938|NCT00803465||Cohort Group 2|Subjects number 25 to 44
3191939|NCT00803465||Cohort Group 3|Subjects number 45 to 68
3191940|NCT00803465||Cohort Group 4|Subjects number 69 to 91
3191941|NCT00803465||Cohort Group 5|Subjects Number 92 to 115
3191942|NCT00803478|Active Comparator|Hinge position|superior vs. temporal
3191943|NCT00803478|Active Comparator|Hinge width|45 vs 90 degrees
3191944|NCT00803478|Active Comparator|Flap Thickness|110 vs 130 microns
3191945|NCT00803491|Experimental|Problem based learning program|PBL intervention - a self-promoting PBL program for patients with rheumatic diseases.
3191946|NCT00803491|Active Comparator|Control group|Traditional rheumatological care.
2469404|NCT03108794||Inactive HBsAg carriers|Inactive HBsAg carriers was defined as those with HBsAg positive than 6 months, with low HBV DNA and persistently normal ALT, without evidence of cirrhosis.
2469408|NCT03108794||Compensated cirrhosis|"Diagnosis of compensated cirrhosis can be made if one of the following criteria was met:~by liver histology: Ishak fibrosis stage 5-6 or METAVIR F4.~endoscopy-proven gastroesophageal varices, afrter excluding non-cirrhotic portal hypertension.~at least 2 features of cirrhosis:~irregular liver surface, granular or nodular liver parenchyma, with or without splenomegaly (spleen thickness > 4.0cm or > 5 rib units) on ultrasound ,CT or MRI;~PLT<100×109/L without other causes;~Serum album in<35 g/L or INR>1.3 or PT prolongs>3s;~LSM>13 kpa (ALT<5×ULN)."
2469411|NCT03108794||Decompensated cirrhosis|Decompensated cirrhosis was diagnosed based on the presence of ascites, bleeding esophageal varices and/or hepatic encephalopathy in cirrhotic patients.
2469415|NCT03108794||Hepatocellular carcinoma|Diagnosis of hepatocellular carcinoma（HCC）can be established when one of the following one of the following 2 criteria:（1）in cirrhotic patients with nodules of 1cm or larger with typical features of HCC ( arterial enhancement with washout in venous or delay phase) on 2 radiological studies or with 1 radiological study and elevation of serum AFP; or（2）histological evidence of HCC.
3191947|NCT00803530|Experimental|1|"Loading phase (week 1): ATO 0.3 mg/Kg/die for 5 consecutive days.~Subsequent phase (from week 2 to week 16): ATO 0.25 mg/kg twice a week (day 2 and 5 of every week).~Ascorbic acid 1000 mg IV within 30 minutes after each arsenic trioxide infusion for 16 consecutive weeks."
3191948|NCT00803556|Experimental|Arm 1|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of alvespimycin"
2469643|NCT03106805|Experimental|insertion by the end of the 4th week postpartum|
2469651|NCT03106805|Active Comparator|insertion by the end of the 6th week postpartum|
2469699|NCT03106662|Experimental|Mesenchymal Stem Cell in Haplo-SCT|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
2469763|NCT03106402||Treated with topical NSAID|197 eyes of - patients were treated with topical bromfenac sodium hydrate (Bronuck®, Taejoon Pharm. LTD.) 2times a day starting 1 day before surgery and continued for 2 weeks after surgery.
2469768|NCT03106402||Treated without topical NSAID|147 eyes did not receive topical NSAID after cataract surgery
2469822|NCT03106012|Experimental|Hsyterolaparoscopy|Subjected to bath diagnostic hystroscopy and laparoscopy
2469891|NCT03105375|Experimental|Single ascending dose of X842|Single ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
2469909|NCT03105375|Experimental|Multiple ascending dose of X842|Multiple ascending oral dose of X842 administered to subjects in cohorts. Cohorts are administered in sequence.
2469916|NCT03105375|Active Comparator|Losec|Standard oral dose of omeprazole administered to subjects in one cohort.
2470007|NCT03104712|Other|Glucose #1|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2470014|NCT03104712|Active Comparator|Spaghetti|50 grams of available carbohydrate from spaghetti will be cooked according to package instructions and consumed as a test meal
2470017|NCT03104712|Active Comparator|Rice|50 grams of available carbohydrate from white rice will be cooked according to package instructions and consumed as a test meal
2470019|NCT03104712|Active Comparator|Spaghetti + tomato sauce|50 grams of available carbohydrate from spaghetti plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
2470021|NCT03104712|Active Comparator|Rice + tomato sauce|50 grams of available carbohydrate from white rice plus tomato sauce (1:1 ratio) will be cooked according to package instructions and consumed as a test meal
2470023|NCT03104712|Active Comparator|Spaghetti + Pesto|50 grams of available carbohydrate from spaghetti plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
2470025|NCT03104712|Active Comparator|Rice + Pesto|50 grams of available carbohydrate from white rice plus pesto sauce (1:0.5 ratio) will be cooked according to package instructions and consumed as a test meal
2470026|NCT03104712|Other|Glucose #2|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2470027|NCT03104712|Other|Glucose #3|50 grams of available carbohydrate from glucose monohydrate will be dissolved in 250mL water and consumed as a test meal
2470114|NCT03103932|No Intervention|Usual care|Participants will be treated as is usual at each institution. Biomarkers will be measured on Day 2-3 and again prior to discharge from hospital. NTproBNP levels will not be revealed to care providers.
2470119|NCT03103932|Experimental|Biomarker guided discharge pathway|Admission NTproBNP levels will be used to stratify participants into lower and medium-higher risk care pathways. NTproBNP levels will be repeated on Day 2-3 and again prior to discharge. Each care pathway is designed to optimize discharge time according to NTproBNP levels. All NTproBNP results will be displayed on the front of the participant's chart along with the care pathway that the participant has been randomized to. The care providers will be reminded daily by the study team that the participant is in the biomarker guided discharge pathway arm of the study and that the designated care pathway should be followed as closely as possible.
2470202|NCT03103334|Experimental|Experimental A|Zeneo® - Methotrexate thigh to Methotrexate Biodim® thigh
2470203|NCT03103334|Experimental|Experimental B|Methotrexate Biodim® thigh to Zeneo® - Methotrexate thigh
2470204|NCT03103334|Experimental|Experimental C|Zeneo® - Methotrexate abdomen to Methotrexate Biodim® abdomen
2470205|NCT03103334|Experimental|Experimental D|Methotrexate Biodim® abdomen to Zeneo® - Methotrexate abdomen
2470514|NCT03101085|Experimental|S-equol|Participants will receive S-equol 50mg twice daily for one month
2469432|NCT03108378||ProHance Single Dose|Subjects who received a single dose of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
2469435|NCT03108378||ProHance Multiple Dose|Subjects who received multiple doses of ProHance and no other Gd agent and who are also scheduled for orthopedic surgery
2469438|NCT03108378||Control Subgroup|Subjects who have not received any Gd agent and who are also scheduled for orthopedic surgery
2469486|NCT03108144|No Intervention|Control - Group A|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group A will not receive computer alerts but will still have access to the alcohol consumption data as part of the baseline assessment (Screening). Healthcare providers will have access to all the same resources available as the intervention clinic (Treatment as usual).
2469487|NCT03108144|Experimental|Intervention - Group B|When a patient is identified as consuming alcohol above CCS guidelines (based on mandatory baseline questionnaire) the practitioner in Group B will receive computer alerts (Screening). The alert will provide a 5 minute script (Brief Intervention) for the health care providers to relay to patients and the ability to print or email a self-help resource to the patient each time the patient visits (Referral to Treatment).
2469524|NCT03107884|Experimental|Metformin (Bed Rest)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). During bed rest, participants will be given 1 gram of metformin two times a day (morning and evening). This dosage and frequency will occur during four consecutive days of bed rest.
2469528|NCT03107884|Placebo Comparator|Placebo (Bed Rest)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. During bed rest, participants will be given the same amount of pills and given at the same time of day (morning and evening) as the experimental group. This strategy will occur during four consecutive days of bed rest.
2469530|NCT03107884|Experimental|Metformin (2 week run-in only)|Metformin will be given to participants incrementally during a 2 week run in period such that they will receive the clinical dose (2 grams per day). These participants will not participate in the bed rest portion of the protocol.
2469533|NCT03107884|Placebo Comparator|Placebo (2 week run-in only)|Placebo will be given to participants incrementally during a 2 week run in period such that they will receive the same amount of pills as the experimental group. These participants will not participate in the bed rest portion of the protocol.
2469589|NCT03107325|Other|F-18 FDG|Only patients scheduled for a whole body PET scan will be eligible. Subjects of all ages will be imaged after 4 h. The CT image from the routine scan will be used for the 2nd scan to avoid additional CT exposure. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2469653|NCT03107039|Experimental|Exercise|This arm will use a resistance exercise curriculum.
2469657|NCT03107039|Active Comparator|Health Education|This arm will use health education curriculum.
2469702|NCT03106649|Experimental|Gr (E)|The group in which the proposed algorithm for prevention and treatment of spinal hypotension will be tested with regard to fluid and vasopressor use, by means of echocardiography.
2469706|NCT03106649|No Intervention|Gr (S)|The control group in which the anesthesia (fluid and vasopressor) management will be decided by the attending anesthesiologist
2469759|NCT03106376|Experimental|Healthy subjects|16% O2 gas in breathed air for 30 minutes 26% O2 gas in breathed air for 30 minutes
2469834|NCT03105687|No Intervention|Control|"Participants in the Control group will receive standard Pharmaceutical Care according to the principles of Good Pharmaceutical Practice and national Slovak legislation requirements only.~Participants in the control group will also receive a welcome SMS one day after enrollment and an end-of-trial SMS three months after the enrollment. Additionally, prior to their scheduled follow-up visit (Visit 2), three months following the enrollment, trial pharmacists will call the participants to remind them of their follow-up visit."
2469835|NCT03105687|Experimental|Intervention|Participants in the intervention group will also receive standard Pharmaceutical Care provided by the trial pharmacist, the welcome SMS and the end-of-trial SMS. Additionally, they will receive daily SMS reminders of their blood pressure-lowering medication intake from a trial pharmacist for a period of 3 months after the enrollment. The structure of the SMS reminder will follow the information provided as a part of the usual drug dispensation and counselling process as described in the Slovak national Decree No. 129/2012 Coll. Thus, most of the data are available on the prescription and all of the collected data are already a well-established and required part of the standard Pharmaceutical Care in Slovakia. The simple structure of the SMS reminder will allow for future reproducibility.
2469867|NCT03105167|Experimental|CBT-TLIF group|Patients who are randomised to the CBT-TLIF group will have cortical bone trajectory screws instead of pedicle screws During the opreation. After preventive use of antibliotics,A small skin incision was made at the fused segment, an entry point for insertion of the CBT screws was drilled in the junction of the center of the superior articular process and 1 mm inferior to the inferior border of the transverse process according to Matsukawa et al.A straight probe was used to create a trajectory for the CBT screws from the entry point to the opposite corner of the pedicle and vertebral body under anteroposterior fluoroscopic guidance.nilateral facetectomy is performed to gain access to the intervertebral disc.Afterwards, interbody fusion was performed.Device: CBT screws.
2469872|NCT03105167|Experimental|PS-TLIF group|Patients who are randomised to the PS-TLIF group will have pedicle screws During the opreation. A posterior midline incision, about 6 cm, was performed at the level of interest level under fluoroscopic guidance. Pedicle screws were inserted into the vertebral body by using freehand, and the inferior and superior articular processes and part pf the lamina were removed by using an osteotome. To expose the lateral border of the ipsilateral nerve root, the ligamentum flavum was removed. Afterwards, interbody fusion was performed.Device:traditional pedicle screws.
2470073|NCT03104114|Placebo Comparator|Historical Control|Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
2470074|NCT03104114|Experimental|Pharmacist-intervention|In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
2470522|NCT03101085|Placebo Comparator|Placebo|Participants will receive matched placebo pill to take twice daily for one month
2469457|NCT03108326||Group 3a|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with biologic is not allowed.
2469463|NCT03108326||Group 3b|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with 1 biologic is allowed.
2469466|NCT03108326||Group 4|CD-patients (age at enrollment: 18-80 years) receiving a newly introduced biologics therapy other than Ustekinumab (n=150). A prior therapy with ≥2 biologics is allowed.
2469552|NCT03107949|Experimental|Lungpacer Diaphragm Pacing Therapy (DPTS)|The LIVE Catheter will be temporarily inserted (LIVE Catheter will be inserted into every patient enrolled and can stay in place for up to 30 days) into the left subclavian vein and connected to the Lungpacer Control Unit in order to perform diaphragm pacing to stimulate the phrenic nerves and activate the diaphragm 3 x a day on all patients until extubated/removed from mechanical ventilation or until day 30 whichever comes first.
3208596|NCT00976300|Active Comparator|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals).
3208597|NCT00976313||1|male patients
2469787|NCT03106259||Non-Interventional Study|Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.[NCT02221258]
2469804|NCT03105713|Experimental|Patient Safety Checklist Intervention|The intervention to be administered is three patient safety checklists for patients to be performed: a) before admission to hospital; b) under hospital stay (discharge); c) after discharge from hospital.
2469805|NCT03105713|No Intervention|Controls|Patients do not receive the safety checklist intervention. Care as usual.
2469884|NCT03105219|Experimental|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
2469890|NCT03105219|Sham Comparator|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
2469977|NCT03104855|Experimental|Single pharmacokinetics arm|
2469999|NCT03104439|Experimental|Nivolumab+Ipilimumab|"Nivolumab will be administered intravenously 3 times per cycle~Ipilimumab will be administered intravenously once per cycle~Radiation Therapy will be administered per hospital standard"
2470062|NCT03104218|Experimental|tDCS group|tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training). The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles), contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
2470065|NCT03104218|Sham Comparator|Placebo group|"The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition. The parameters on the tDCS will be set-up by a research assistant before each session. The treating physiotherapist will not have access to the control board of the tDCS."
2470096|NCT03103841||Children and young people with epilepsy|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
2470097|NCT03103841||Healthy controls|Sleep studies [Polysomnography] to assess presence and severity of obstructive sleep apnoea in children with epilepsy compared with a healthy control group
2470151|NCT03103659|Experimental|Elderly patient with cancer living in a nursing home|
2470190|NCT03103399|Experimental|50 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 50 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2470191|NCT03103399|Experimental|100 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 100 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2470194|NCT03103399|Experimental|150 mg nebicapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 150 mg of the study treatment in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2470196|NCT03103399|Active Comparator|200 mg entacapone|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive 200 mg of entacapone (Comtan®) in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2470197|NCT03103399|Placebo Comparator|Placebo|At Visit V2, patients received a supply of a placebo to take concomitantly with each levodopa/DDCI dose for the duration of the run-in period (Period 1). At the end of Period 1, patients were randomised to receive study treatment matching placebo tablets in addition to their levodopa/DDCI therapy for the duration of the double-blind (Period 2)
2470265|NCT03102866|Active Comparator|Arm I (usual care)|Patients receive usual care for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
2470267|NCT03102866|Experimental|Arm II (aerobic and strength training exercise)|Patients undergo a supervised aerobic and strength training exercise session over 40-60 minutes 3 times weekly for 6 weeks during radiation therapy and for 12 weeks after completion of radiation therapy.
2470289|NCT03102502|Experimental|Enhanced External Counterpulsation|Patients receive a total of 35-36 hours of EECP treatment on top of guideline- driven standard medical therapy for coronary heart disease, 1-hour sessions every day over a 7-week period.
3208598|NCT00976313||2|female patients
3208599|NCT00976326|Experimental|A: Healthy volunteers|
3157145|NCT00359047|Experimental|Documentation|Written educational material on osteoporosis for the participant and the physician.
2469654|NCT03107195|Other|Tc-99m DMSA|Patients aged 1-6 years old will be enrolled. Routine SPECT imaging will be performed 3-4 h post-administration (PA) with a dual-detector rotating gamma camera over a 360˚ rotation for 8 s per view using a 1282 matrix. In each age group, half of the subjects will also be imaged between 30 and 90 min, post-administration. The 2nd half will be imaged at 4-6 h, post-administration. It is important to note that the patient volunteers will not receive any additional radiation exposure for inclusion in this study. They are only being ask to allow imaging at one additional time point.
2469740|NCT03106246||New onset T1DM|Newly diagnosed Type I diabetic patients who are hyperglycemic but still C-peptide positive
2469742|NCT03106246||T1DM|Patients with established type I diabetes. they are hyperglycemic but C-peptide negative
2469746|NCT03106246||T2DM|Patients with established type II diabetes.
2469751|NCT03106246||Islet Transplant|Patients who received an islet transplantation for type I diabetes
2469753|NCT03106246||Healthy Volunteers|Normoglycemic healthy volunteers
2469826|NCT03105674|Active Comparator|Standard Therapy|Patients will receive a combination of Marcaine and Lidocaine injection (standard local anesthetics) as a part of their peri-anal block prior to the surgery.
2469831|NCT03105674|Experimental|Multi-drug local anaesthetics|"Patients will receive a combination [Multi-drug local anesthetics (Combination)] of following drugs as a part of their peri-anal block prior to the surgery (multi-drug local anesthetics)~Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
2470018|NCT03104374|Experimental|ABT-494 Dose A|It is administered once daily.
2470020|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose B|It is administered once daily.
2470022|NCT03104374|Experimental|ABT-494 Dose B|It is administered once daily.
2470024|NCT03104374|Placebo Comparator|Placebo followed by ABT-494 Dose A|It is administered once daily.
2470272|NCT03102827|Active Comparator|Oxygen - ambient air|high-flow oxygen therapy administered during first night, ambient air without high-flow therapy (placebo) administered during second night
2470273|NCT03102827|Placebo Comparator|Ambient air - oxygen|Ambient air without high-flow therapy (placebo) administered during first night , high-flow oxygen therapy administered during second night
2470286|NCT03102528||Cardiac Surgery Patients|All adult patients undergoing cardiac surgery (elective/emergent) at San Bortolo Hospital, Vicenza, Italy during November 2014 - October 2015
2470461|NCT03101488|Experimental|KN035|KN035 is to be injected subcutaneously 0.1mg/kg or 0.3mg/kg or 1mg/kg or 2.5mg/kg or 5mg/kg or 10mg/kg weekly until disease progresses or unacceptable tolerability occurs.
2470531|NCT03101163|Experimental|Intervention|Subjects randomized to the intervention group will undergo subchondral drilling surgery according to standard protocol, and will also receive a regimen of PBSC and HA intra-articular injections and postoperative physiotherapy.
2470539|NCT03101163|Active Comparator|Standard treatment|Subjects randomized to the standard treatment-controlled parallel group will receive intra-articular HA injections and a physiotherapy regimen.
2470570|NCT03100695|No Intervention|Control|Patients will undergo operative procedure with no additional intervention.
2470573|NCT03100695|Experimental|Study|Patients will undergo usual operative procedure with the addition of an injection of autologous, concentrated PRP-BMA at the site of fixation.
2470628|NCT03100409|Experimental|Dietary modification|Personalized dietary intervention, low residue diet
2470632|NCT03100409|No Intervention|Control|Dietary recommendations currently used in the INCan
2470734|NCT03099603|Placebo Comparator|0.5g|single dose of placebo to 2 healthy subjects or 0.5g HTD1801 to 6 healthy subjects
2470738|NCT03099603|Placebo Comparator|1.0g|single dose of placebo to 2 healthy subjects or 1.0g HTD1801 to 6 healthy subjects
2470744|NCT03099603|Placebo Comparator|2.0g|single dose of placebo to 2 healthy subjects or 2.0g HTD1801 to 6 healthy subjects
2470746|NCT03099603|Placebo Comparator|4.0g|single dose of placebo to 2 healthy subjects or 4.0g HTD1801 to 6 healthy subjects
3157146|NCT00359047|Experimental|Video|A 15-minute educational video on osteoporosis as well as written documentation on osteoporosis for the participant and the physician.
3157147|NCT00359086|Experimental|1|
3157148|NCT00359125|Active Comparator|1|RU-486, 600 mg/day for 1 week.
3157149|NCT00359125|Placebo Comparator|2|Placebo, 600 mg/day for 1 week
3157150|NCT00359151|Experimental|Celecoxib|Celecoxib
3157151|NCT00359151|Placebo Comparator|Placebo|Placebo
3157152|NCT00359164|Active Comparator|1|Bevacizumab with verteporfin at Low Fluence Photodynamic Therapy.
3157153|NCT00359164|Active Comparator|2|Bevacizumab with verteporfin at Very Low Photodynamic Therapy.
3157154|NCT00359164|Sham Comparator|3|Bevacizumab with verteporfin with Sham Photodynamic Therapy.
3157155|NCT00359177|Experimental|Healthy subjects receiving GW679769|Healthy Subjects will receive single 100 milligram (mg) oral doses of GW679769 for five consecutive days.
3157156|NCT00359177|Experimental|Subjects with hepatic impairment receiving GW679769|Subjects with hepatic impairment will receive single 100 mg oral doses of GW679769 for five consecutive days.
3157157|NCT00359190|Experimental|Lapatinib receivers|Subjects with treatment-naïve breast tumors will be administered lapatinib 1500 mg once daily, 1000 mg once daily, or 500 mg twice daily for a minimum of 9 days and maximum of 15 days prior to surgical resection..
3157158|NCT00359229|Experimental|1|For 3 weeks
3157159|NCT00359242|Experimental|1|Soothing and Calming instructions given at 2 weeks of life
3157160|NCT00359242|Experimental|2|Repeated food exposure instructions given between 4 and 6 months of life
3157161|NCT00359242|Experimental|3|Receive both interventions: Soothing and Calming and Repeated food exposure
3157162|NCT00359242|No Intervention|4|Group receiving neither of the interventions.
3157163|NCT00359255|Active Comparator|1|
3157164|NCT00359255|Experimental|2|
2469543|NCT03107988|Experimental|Cohort A1 (Dose-finding)|Lorlatinib will be given orally once daily continuously for 28 days. The dose level of lorlatinib will be assigned at the time of study registration. The starting dose for cohort A1 is 45 mg/m2/dose
2469545|NCT03107988|Experimental|Cohort A2 (Adult and large BSA)|Lorlatinib will be given at the adult recommended phase 2 dose (RP2D) of 100 mg orally once daily continuously for 28 days.
2469546|NCT03107988|Experimental|Cohort B1 (Expansion)|Lorlatinib will be given orally once daily continuously for 28 days at the RP2D defined by cohort A1. This cohort will not begin enrollment until the recommended phase 2 dose is established from the dose escalation cohort A1.
2469547|NCT03107988|Experimental|Cohort B2 (Combined w/ chemotherapy)|Lorlatinib will be given orally once daily continuously for 28 days, at the RP2D defined by cohort A1. Lorlatinib should be administered at least one hour prior to conventional chemotherapy (Cyclophosphamide and Topotecan) on days 1-5 of each cycle.
2469652|NCT03106974|Active Comparator|Macintosh Laryngoscope|orotracheal intubation (OTI) with Macintosh Laryngoscope Direct laryngoscopy
2469656|NCT03106974|Active Comparator|Totaltrack VLM|orotracheal intubation (OTI) with Totaltrack VlM Indirect laryngoscopy
2469709|NCT03106623|Experimental|ONO-8577 Arm|Oral administration of ONO-8577 once a daily for 4 weeks
2469717|NCT03106623|Active Comparator|Active Comparator Arm|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
2469721|NCT03106623|Placebo Comparator|Placebo Arm|Oral administration of Placebo once a daily for 4 weeks
2469795|NCT03106051||Patients with active psoriatic arthritis|Patients who suffer from active psoriatic arthritis with at least moderate disease corresponding to a PGA of ≥2
2469846|NCT03105609||Naive wet age-related macular degeneration|Patients recruited to the study will be patients who meet the Australian MBS criteria for treatment of exudative CNV with Lucentis. For the duration of the study, the patients will have standard induction and monthly dosing of Lucentis (Ranibizumab; intravitreal; 0.5 mg) to allow comparison with published studies. The only extra intervention for the study is the acquisition of hyperspectral mages with the hyperspectral camera and the acquisition of additional fundus autofluorescence images to the clinical norm.
2469888|NCT03105141|Experimental|RIC substudy 1|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg or 40 mmHg above systolic pressure) twice daily for 12 months.
2469898|NCT03105141|Experimental|RIC substudy 2|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
2469913|NCT03105141|Experimental|RIC substudy 3|A total of 180 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) twice daily for 12 months.
2469918|NCT03105141|Experimental|RIC substudy 4|A total of 120 patients in this substudy will receive standard medical therapy and bilateral upper limb remote ischemic conditioning intervention (Doctormate®) (200 mmHg) once or twice daily for 12 months.
3157165|NCT00359268||1|Any patient with a condition or disease whose etiology is unknown.
2470104|NCT03104049|Active Comparator|the PD NMT Group|the NMT Group were treated with NMT
2470109|NCT03104049|No Intervention|The PD Group without NMT|The patients received only their usual pharmacological PD therapy
2470176|NCT03103646|Experimental|Lu AF35700|Day 1: Single dose of Lu AF35700. Extensive metabolisers (EMs): 10mg. Poor metabolisers (PMs): 5 mg
2470177|NCT03103646|Experimental|Lu AF35700 AND itraconazole|Days 29 to 31: once-daily dosage of 200 mg itraconazole. Day 32: Single dose of Lu AF35700 (EMs: 10 mg, PMs: 5 mg) and 300 mg itraconazole Days 33 to 42: once-daily dosage of 200 mg itraconazole
2470245|NCT03103126|No Intervention|Control|Standard care.
2470248|NCT03103126|Experimental|Combined resistance exercise and walking|Combined resistance exercise and walking.
3208600|NCT00976326|Experimental|B: Subjects with mild liver impairment|
2470438|NCT03101826|Experimental|Filtered Music Intervention|All participants will participate in pre-intervention assessments (6 months, 1 week prior) and post-intervention assessments (1 week, 1 month post). The Filtered Music Intervention (i.e., Listening Project Protocol) will last for 1 hour per day, for 5 consecutive days.
2470549|NCT03100877|Experimental|Treatment (mel/TMI, ASCT)|"MOBILIZATION AND APHERESIS: Patients receive cyclophosphamide IV over 2 hours. Beginning 24 hours after cyclophosphamide administration, patients receive filgrastim SC or IV. Patients also undergo apheresis over 4 hours on day 10.~CONDITIONING REGIMEN: Patients receive palifermin IV on days -8, to -6, undergo TMI on days -5 to -2, and receive melphalan IV over 30 minutes on day -1. Patients then undergo ASCT IV on day 0, receive palifermin IV on days 1-3, and receive filgrastim SC or IV on day 5.~MAINTENANCE THERAPY: Beginning 30 days after ASCT, patients receive lenalidomide PO daily."
3157166|NCT00359320|Experimental|Mucosa-to-jejunal mucosa technique of pancreaticojejunosto|Determine whether a duct mucosa-to-jejunal mucosa technique of pancreaticojejunostomy will improve the pancreatic fistula rate
3157167|NCT00359333|Experimental|Single Group|
3157168|NCT00359359|Experimental|Sagopilone and cisplatin|The study drug sagopilone was administered in combination with a fixed dose of cisplatin
3157169|NCT00359385|Active Comparator|Alendronate 70mg weekly|Alendronate 70mg weekly
3157170|NCT00359385|Placebo Comparator|placebo of alendronate 70mg weekly|placebo of Alendronate 70mg weekly
3157171|NCT00359398|Experimental|Platelet sequestration|Sequestration of platelet rich plasma before cardiopulmonary bypass
3157172|NCT00359398|No Intervention|Standard care|No platelet rich plasma sequestration undertaken before cardiopulmonary bypass (usual practice)
3157173|NCT00359437|Experimental|Satavaptan|
3157174|NCT00359437|Placebo Comparator|Placebo|
3157175|NCT00359463|Active Comparator|Healthy subjects|Subjects will receive a single 50 mg oral dose of eltrombopag.
3157176|NCT00359463|Experimental|Subjects with hepatic impairment|Subjects with mild, moderate or severe hepatic impairment will receive a single 50 mg oral dose of eltrombopag.
3157177|NCT00359476|Experimental|1|
3157178|NCT00359567|Experimental|1|palonosetron
3157179|NCT00359567|Active Comparator|2|granisetron hydrochloride
2469573|NCT03107598|Experimental|colloid preload|Group CoP: group with colloid preload The preload group received rapid infusion of 15ml/kg of 6% hydroxyethyl starch (6% HES) administered by gravity at a wide-open rate over a period of 15-30min before induction of spinal anesthesia.
2469575|NCT03107598|Placebo Comparator|crystalloid coload|Group CrC: group with crystalloid coload The coload group received a sodium chloride 0.9% perfusion as rapidly as possible starting at the time of intrathecal injection for spinal anesthesia.
2469592|NCT03107221|Experimental|Intervention|"Access to online self-help programme Smart Eating along with usual treatment from a specialist eating disorder service"
2469593|NCT03107221|No Intervention|Control|Usual treatment from a specialist eating disorder service
3208601|NCT00976326|Experimental|C: Subjects with moderate liver impairment|
3208602|NCT00976326|Experimental|D: Subjects with severe liver impairment|
3208603|NCT00976365|Experimental|THL-P|Solution for study only.
2469809|NCT03105752|Experimental|Research participants|"Each participant of a clinical trial completed the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) about its understanding of the information received. This questionnaire was retrieved immediately on the day of consent, with no possibility of referring to the content of information letter."
3208604|NCT00976365|Placebo Comparator|Sugar pill|THL-p
2469985|NCT03104686|Active Comparator|Bread|Bread (50g available carbohydrate, 109 g) eaten with 500 mL of water
2469986|NCT03104686|Experimental|Short pasta (dry)|Cooked penne (142 g; 71 g uncooked) eaten with 500 mL of water
2469987|NCT03104686|Experimental|Long pasta (dry)|Cooked spaghetti (142 g; 71 g uncooked) eaten with 500 mL of water
2469989|NCT03104686|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
2470047|NCT03104309|Other|Levonorgestrel intrauterine system|
2470078|NCT03104010|Experimental|PEG-rhGH-1|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The first stage, 1-2mg/2-4mg, subcutaneous injection,weekly, 26 weeks.
2470080|NCT03104010|Experimental|PEG-rhGH-2|Pegylated recombinant human growth hormone injection, 12IU/2.0mg/1.0ml/bottle. The second stage (extension period study), maximum ≤4mg/w (24IU/w), 52 weeks.
2470127|NCT03103737|Experimental|Intervention|Psychological intervention composed by four sessions along 1 week. Participants can interact with virtual environments and a multimedia system for reminiscence purposes.
2470128|NCT03103737|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. After one week, they have the possibility to receive the psychological intervention.
2470159|NCT03103516|Experimental|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
2470160|NCT03103516|Experimental|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
2470186|NCT03103204|Experimental|Normal weight full-mouth disinfection|"Normal weight (body mass index 18.5 - 24.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2470188|NCT03103204|Experimental|Overweight full-mouth disinfection|"Overweight (body mass index 25.0 - 29.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2470189|NCT03103204|Experimental|Obesity I full-mouth disinfection|"Obesity I (body mass index 30.0 - 34.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2470192|NCT03103204|Experimental|Obesity II full-mouth disinfection|"Obesity II (body mass index 35.0 - 39.9 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2470195|NCT03103204|Experimental|Obesity III full-mouth disinfection|"Obesity III (body mass index ≥ 40.0 kg/m2) individuals with chronic periodontitis~Full-mouth manual scaling and root planing within 24 hours~tongue cleaning with chlorhexidine gel 1% for 1 minute~tonsils disinfection with chlorhexidine spray 0.2%~rinsing with 15mL of 0.2% chlorhexidine solution for 30 seconds before and after dental scaling~subgingival irrigation of all periodontal pockets with with 1% chlorhexidine solution~daily rinsing with 0.2% chlorhexidine solution (15mL/30 seconds/2 times a day"
2470243|NCT03102996|Experimental|Verum|Patients will receive Nephrotrans.
2470251|NCT03102996|Placebo Comparator|Placebo|Patients will receive Placebo.
2470305|NCT03102684|No Intervention|No exposure|No exposure to secondhand exposure to aerosols produced by e-cigarettes
2470308|NCT03102684|Experimental|Low exposure|Secondhand exposure to e-cigarette aerosols (low)
2470311|NCT03102684|Experimental|High exposure|Secondhand exposure to e-cigarette aerosols (high)
2470390|NCT03102307||CNB/clip placement done - benign|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals no axillary tumor spread. Patients are suitable for TAD
2470566|NCT03100630|Active Comparator|Treatment A: RO7239361|RO7239361 subcutaneous injections on specified days; abdomen
3208605|NCT00976378|Experimental|0.05 mg/kg NOX-A12|
3208606|NCT00976378|Experimental|0.15 mg/kg NOX-A12|
3208607|NCT00976378|Experimental|0.45 mg/kg NOX-A12|
2469594|NCT03107351|Sham Comparator|repeatability measures|In this arm, healthy subjects will undergo repeated measures at different times of the day.
2469597|NCT03107351|Experimental|Contractility changes measures|In this arm, healthy subjects will have their cardiac contractility increased in a controlled way and assessed with both HK and echocardiography.
2469841|NCT03105973|Experimental|Open-Label Trial Arm|Will receive 4 weeks of technology-enabled CBT treatment.
2469976|NCT03104868|No Intervention|Usual Care|Patients in this group will receive the usual standard of care.
2469979|NCT03104868|Experimental|Intervention|Patients in this group will receive the TAKE IT strategy components.
2470050|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 1)|Participants randomized to receive risankizumab dose 1 in Induction Period 1.
2470051|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 1)|Participants randomized to receive risankizumab dose 2 in Induction Period 1.
2470052|NCT03104413|Placebo Comparator|Placebo (Induction Period 1)|Participants randomized to receive placebo for risankizumab in Induction Period 1.
2470053|NCT03104413|Experimental|Risankizumab Dose 1 (Induction Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
2470054|NCT03104413|Experimental|Risankizumab Dose 2 (Induction Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
2470055|NCT03104413|Experimental|Risankizumab Dose 3 (Induction period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
2470372|NCT03101995|Experimental|Gemcitabine|Gemcitabine doses: 300 mg/m2/week for 6 weeks.
2470513|NCT03101176|Experimental|Experimental: Single Arm|All consenting patients will undergo mpUS imaging prior to surgery with the ultrasound contrast agent Sonovue for the CEUS specific mode.
2470582|NCT03100747|Active Comparator|Bilamellar 3 mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 3 mm from the eyelid margin.
2470585|NCT03100747|Active Comparator|Bilamellar 5mm|Bilamellar tarsal rotation trichiasis surgery involves a full-thickness incision through the upper eyelid. For this arm, the height of the incision will be assigned at 5 mm from the eyelid margin.
2470588|NCT03100747|Active Comparator|Trabut 3mm|Trabut surgery involves a partial-thickness incision through the upper eyelid parallel to the eyelid margin. For this surgery, the height of the incision will be assigned at 3 mm from the eyelid margin.
2470620|NCT03100227|Active Comparator|PET [18F] FDG|Each subject will have a PET scan at [18F] FDG.The raw imaging data obtained from these controls will be post-processed using the Statistical Parametric Mapping software. Schematically, the data of each control will be normalized in the same anatomical space, then smoothed and averaged between the different controls. This will make it possible to constitute the normative database.
2470621|NCT03100227|Sham Comparator|Review test-retest|Of the 40 volunteers included, 10 will have test-retest exams (2 separate exams every 15 days).
2470664|NCT03099993|Other|A: Healthy volunteers|
2470668|NCT03099993|Other|B: Patient with heamiplegia|
2470675|NCT03099993|Other|C: Patient with heamiplegia and constraint induced therapy|arm with constraint induced therapy (done before the protocol)
3191949|NCT00803556|Experimental|Arm 2|"Patients whose last dose is > 21 days prior to first dose of Trastuzumab on study. First infusion: 90 mins for 4 mg/kg loading dose of trastuzumab followed by 60 min infusion of paclitaxel and 60 min of infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin~Patients whose last dose is < 21 days prior to first dose of Trastuzumab on study. All infusions: 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin. Subsequent infusions weekly 30 mins for 2 mg/kg trastuzumab followed by 60 min infusion of paclitaxel and 60 min infusion of alvespimycin"
3191950|NCT00803582|Experimental|Experimental|Traditional acupuncture
3191951|NCT00803582|Sham Comparator|Placebo|Placebo acupuncture
3191952|NCT00803582|No Intervention|No-treatment|no treatment
3191953|NCT00803608|Active Comparator|02|Current standard of care insole
3191954|NCT00803608|Experimental|01|TrueContour® insole
3191955|NCT00803673|Experimental|Active|100mcg 719
2471013|NCT03097939|Experimental|Nivolumab and Ipilimumab|
2471028|NCT03097627|Experimental|ICG Intervention|The intervention to be administered is intravenous indocyanine green for intra-thoracic lesion localization and use of a near infrared camera to detect the ICG. All study subjects will receive this same intervention; there is only one arm.
2471076|NCT03097445|Experimental|Nicotine Replacement Therapy|mailed 5 week course of transdermal nicotine patches
2471078|NCT03097445|No Intervention|Control|No intervention control group
2471108|NCT03097068|Experimental|0.3 mg Lucentis|Aqueous Humor sample post injection of 0.3 mg Lucentis
3191956|NCT00803673|Experimental|Active 2|500mcg '719
2471223|NCT03096340|Experimental|IT-141|
2471257|NCT03096145|Experimental|Behavioral Intervention|Behavioral: telephone counseling 1 sessions, mobile texting, and health incentive
2471319|NCT03095833|Other|Influence of cognitive biases on food intake|Determine how high-level cognitive control can affect the price to pay for a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
2471323|NCT03095833|Other|Modulation of the floral flavor of a wine|Highlight the brain regions involved in the visual bias related to the intensity of a wine's dress combined with the floral character evaluation of its flavor.
2471411|NCT03095092|Experimental|BIA 6-512 fed|BIA 6-512 400 mg following a standard meal
2471413|NCT03095092|Experimental|BIA 6-512 fasting|BIA 6-512 400 mg following at least 8 h of fasting
2471470|NCT03094949|Active Comparator|Partial Nephrectomy|a kind of operation for renal tumor
2469609|NCT03107312||Migrants|Single blood sample collection from recent migrants to Germany without verified vaccination records
2469645|NCT03106922|Experimental|PMF104|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6~500 ml in 1-1.5 hours <= to 18 kg~625 ml in 1-1.5 hours >18 kg 6<=Age<12:~750 ml in 1-2 hours <=25 kg~1000 ml in 1-2 hours 25-35 kg~1250 ml in 1-2 hours >35 kg 12>=Age<18 :~1500 ml in 2-3 hours <= 45 kg~1750 ml in 2-3 hours>45 kg.~Rescue dose (if no clear watery stools 3 hours after the entire solution):~250 ml 2 Age <=6;~500 ml 6 <=Age<12; up to a cumulative maximum volume of 2000 ml 12<=Age<18."
2469650|NCT03106922|Active Comparator|Klean- prep|"The day before the colonoscopy, starting in the mid-late afternoon (4-6 p.m.), by oral route:~2<=Age<6:~90 ml/kg in 1-1.5 hours 2<=Age<6~80 ml/kg in 1-1.5 hours 5<=Age<6~2<=Age<6:~80 ml/kg in 1-2 hours 6<=Age<10~70 ml/kg in 1-2 hours 10<=Age<12~12<=Age<18:~70 ml/kg in 2-3 hours. Rescue dose (if no clear watery stools 3 hours after the entire Klean-Prep solution): 50% of the initial dose."
2469730|NCT03106545|Experimental|Single mixture LB & bupivacaine|A single mixture of liposome bupivacaine 1.3% (5 mL) + bupivacaine 0.5% (2.5 mL) injected into the distal tibial and deep peroneal nerves
2469731|NCT03106545|Active Comparator|Bupivacaine alone|Bupivacaine 0.5% (7.5 mL) injected into the distal tibial and deep peroneal nerves
2469734|NCT03106545|Sham Comparator|General anesthesia|General anesthesia
2469776|NCT03106194|Other|history of injection drug use|"Men and women ≥ 18 years old with a history of injection drug use, enrolled in the opiate substitution program of CAD Limburg.~Case management"
2469892|NCT03105466|Experimental|Acellular porcine cornea group|Participants with corneal diseases not involving the endothelial layer undergo deep anterior lamellar keratoplasty using acellular porcine cornea
2470032|NCT03104751||Infants with Complex Congenital Heart Defect|Infants diagnosed a Complex Congenital Heart Defect
2470034|NCT03104751||Comparison/Healthy Infants|Infants born without genetic syndromes or cardiac condition.
2470084|NCT03104101|Active Comparator|TPTNS|Those who received Transcutaneous posterior tibial nerve stimulation sessions only
2470087|NCT03104101|Active Comparator|TPTNS+Drug|Those who received Transcutaneous posterior tibial nerve stimulation sessions plus 20 mg Trospium chloride
2470139|NCT03103711|Experimental|Intervention|"The entire intervention is composed by four 30 minutes sessions along 1 week. Its focus is on the promotion of well-being by the use of two virtual environments (Emotional Parks and Walk through Nature). These environments allow participants to involve in different exercises (working with self statements, videos, images, slow breathing, focus on the present exercises) with the purpose of increase positive emotional states."
2470142|NCT03103711|No Intervention|Control|Participants receive the medical treatment deliver by the hospital. They fulfill several questionnaires at two moments (pre and post 1 week after). After this, they have the possibility to receive the psychological intervention.
3191957|NCT00803673|Experimental|Active 3|1000mcg '719
3191958|NCT00803673|Placebo Comparator|Placebo|Placebo '719
3191959|NCT00803699|Placebo Comparator|Placebo|Capsule contains no selenium
3191960|NCT00803699|Active Comparator|Selenium as L-selenomethionine|50, 100, or 200 micrograms of selenium
3191961|NCT00803725|Active Comparator|1|Mepivicaine for spinal anesthesia
3191962|NCT00803725|Experimental|2|Mepivacaine with Fentanyl for spinal anesthesia
3191963|NCT00803764|Active Comparator|Test Product|
2470292|NCT03102632|No Intervention|Usual Water Intake|For the first 6 months of the study, the participants will continue their usual water intake.
3191964|NCT00803764|Active Comparator|Reference Product|
3191965|NCT00803803|Experimental|Pilocarpine Concentration|Varying concentration 0.5 to 8% - 22 patients were examined regarding: visual acuity, iris color, pupil size, chamber angle, C/D ratio, visual field (VF), coefficient of aqueous outflow and Goldmann tonometry. After a one month washout period, pilocarpine was used 4 times daily, in concentrations from 0.5 to 8%. The amount of IOP change was compared with various clinical findings
3191966|NCT00803803|Experimental|Pilocarpine Frequency|Varying frequency, once to four times daily - 15 patients were included in a crossover study: IOP was checked daily for 3 days and for 9 hours on fourth day. Pilocarpine was started on day 5 once daily OD and BID OS; on day 9 once daily OD and QID OS; on day 12 QID OD and once daily OS; on day 16 once daily OD and QID OS; and on day 19 QID OD and once daily OS. No medications were used on days 23-25. IOP was measured on days 4, 8, 11, 15, 18, 22 and 25.
3191967|NCT00803816|Other|Addition of everolimus to standard care|refractive to cyclosporine A (CsA) received additional everolimus.
3191968|NCT00803855|Experimental|AZD1446 Oral or placebo|Single oral administration of AZD1446 or placebo
3191969|NCT00803855|Experimental|AZD1446 Oral, with or without food|Single oral administration of AZD1446 with or without food
3191970|NCT00803868|Experimental|1|Varenicline
3191971|NCT00803868|Placebo Comparator|2|Placebo
3191972|NCT00803881||CF patients of all age groups|Longitudinal prospective assessment of upper and lower airway colonization in all patients attended in the Jena University CF centre
3191973|NCT00803894|Active Comparator|A|MK0752 1000 mg
3191974|NCT00803894|Active Comparator|B|MK0752 350 mg
3191975|NCT00803894|Placebo Comparator|C|Placebo
3191976|NCT00803907|Experimental|nodular BCC of the eyelid|Patients with nodular BCC of the eyelid
3191977|NCT00803920||Exenatide|
3191978|NCT00803920||Exenatide LAR|
3191979|NCT00803933|Experimental|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
3191980|NCT00803933|Active Comparator|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
3191981|NCT00803946|Active Comparator|Test Product|
3191982|NCT00803946|Active Comparator|Reference Product|
3191983|NCT00803972|Experimental|Stage 1: 3 U insulin plus rHuPH20|Participants will receive 3 Units (U) of regular insulin (100 U/milliliter [mL]), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 micrograms (μg)/mL recombinant human hyaluronidase (rHuPH20).
3191984|NCT00803972|Experimental|Stage 1: 12 U insulin plus rHuPH20|Participants will receive 12 U of regular insulin (100 U/mL), coadministered with sequential concentrations of 0, 1.25, 5, 10, 20, and 80 μg/mL rHuPH20.
3191985|NCT00803972|Experimental|Stage 2: insulin plus rHuPH20|Participants will receive 6, 12, and 24 U regular insulin (100 U/mL) in a randomly assigned order, with each insulin dose administered once with and once without 5 μg/mL rHuPH20.
2469619|NCT03107143|Experimental|Treatment Group|Trial subjects have Q2 System installed on their beds in addition to receiving standard care of pressure ulcer prevention according to study hospital's policy and protocol.
2469622|NCT03107143|No Intervention|Control Group|Control subjects receive only standard care of pressure ulcer prevention according to study hospital's policy and protocol without Q2 System
2469646|NCT03106857|Placebo Comparator|Group A|Physical activity, a low caloric diet, and the routine standard care for constipation
2469649|NCT03106857|No Intervention|Group B|No intervention
2469682|NCT03106675|Experimental|HIFU-treatment|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
2469683|NCT03106675|Active Comparator|Radiation therapy|"Pre-treatment imaging~Pre-treatment questionnaires and laboratory blood samples~Intervention (Varian Truebeam Radiotherapy System)~Follow-up (imaging, questionnaires, laboratory)~Follow-up pain medication usage"
2469735|NCT03106441|Experimental|High flow oxygen therapy by nasal cannula|Experimental Device : High flow oxygen therapy by nasal cannula.
2469737|NCT03106441|Active Comparator|Facial mask oxygenation in BIPAP ventilation|Active Comparator: Facial mask oxygenation in BIPAP ventilation
2469764|NCT03106181|Active Comparator|Cataract surgery|Conventional phacoemulsification cataract surgery and intraocular lens implantation
2469766|NCT03106181|Experimental|Cataract surgery plus iStent inject®|Conventional phacoemulsification cataract surgery and lens implantation plus insertion of iStent inject®
2469789|NCT03105908|Other|Treatment|Internet delivered Acceptance and Commitment therapy, supported by a psychologist/psychology student under supervision.
2469790|NCT03105908|Other|Waiting list control condition|Participants receive no treatment for ten weeks, i.e. waiting list condition. Following post-assessment, the control condition receive unguided iACT (i.e. the same content and structure as iACT but without systematic therapist communication).
2469837|NCT03105648||thyroid cancer|
2469839|NCT03105648||benign thyroid nodules|
2469903|NCT03105349|Experimental|Single arm|16 weeks treatment with elbasvir/grazoprevir plus sofosbuvir and ribavirina
3157181|NCT00359606|Experimental|Treatment (5-fluoro-2-deoxycytidine, tetrahydrouridine)|Patients receive tetrahydrouridine PO on day 1; 5-fluoro-2-deoxycytidine PO on days 1 and 8; tetrahydrouridine IV over 3 hours on days 2-5, 8, and 9-12; and 5-fluoro-2-deoxycytidine IV over 3 hours on days 2-5 and 9-12 of course 1. For all subsequent courses, patients receive tetrahydrouridine IV over 3 hours and 5-fluoro-2-deoxycytidine IV over 3 hours on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2469995|NCT03104387|Experimental|Diesel train - exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The exposure scenario is defined as a workday (6 hours) on the diesel ME-driven model regional train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
2469998|NCT03104387|Sham Comparator|Electric train - low exposure scenario|"The same study person will be exposed to two different scenarios, at different times and for three consecutive days. It will be a lag time of 2 weeks between each exposure scenario. The low exposure scenario is defined as a workday (6 hours) on the electric train. The Diesel Train Scenario is performed twice. After the scenario completion (on the third day in defined train routes) the vascular function, lung function, blood and urine samplings are performed."
2470071|NCT03104244||Youth Football|5th and 6th grade tackle football players will be enrolled in 2016. They will be followed as a cohort, participating in the study each year they play tackle football, through 8th grade. Total enrollment is expected to reach 70 players.
2470072|NCT03104244||High School Football|Varsity football players from Brighton High School are eligible for the study in each year of the study. The varsity team consists of approximately 80 players. Total enrollment in this group is expected to reach 200 subjects; 80 the first year with 40 additional enrolled each subsequent year of the study.
2470098|NCT03103802|Experimental|Intra-oral scanning|
2470101|NCT03103802|Experimental|extra-oral scanning of the plaster model obtained via alginate|
2470108|NCT03103802|Experimental|extra-oral scanning of plaster model obtained via rubber base|
2470112|NCT03103802|Experimental|extra-oral scanning of the rubber base impression|
2470118|NCT03103802|Experimental|extra-oral scanning of the alginate impression|
2470137|NCT03103594|Active Comparator|DMSO alone|Half of the patients will undergo DMSO instillation
2470140|NCT03103594|Experimental|DMSO with Botox|The other half will be randomized to DMSO mixed with 200U of botulinum toxin instillation
2470163|NCT03103412|Experimental|TD-3504 Low-Dose|6 healthy subjects and 6 ulcerative colitis subjects will be randomized to receive low-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2470164|NCT03103412|Experimental|TD-3504 Mid-Dose|6 healthy subjects will be randomized to receive mid-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2470166|NCT03103412|Experimental|TD-3504 High-Dose|6 healthy subjects will be randomized to receive high-dose TD-3504 and low-dose of 15N2-tofacitinib orally single dose.
2470168|NCT03103412|Placebo Comparator|Placebo|6 healthy subjects and 2 ulcerative colitis subjects to receive placebo orally single dose.
2470206|NCT03103191||Case|"50 subjects with fibrosing interstitial lung disease.~50 subjects with pulmonary fibrosis secondary to collagen diseases."
2470209|NCT03103191||Control|"75 subjects without pulmonary fibrosis but with other common respiratory diseases like asthma, COPD or bronchiectasis.~75 subjects with collagen disease without pulmonary fibrosis."
2470270|NCT03102957|Experimental|epileptic patients|2 functional MRI (pre and post resective surgery) with memory and language tasks
2470271|NCT03102957|Other|Healthy volunteers|1 functional MRI with memory and language tasks
2470282|NCT03102788|Active Comparator|Control|Patients in the control group will receive their first consultation in specialist health care by a rheumatologist. Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid. The rheumatologist may also refer participants to occupational therapy if needed.
2469714|NCT03106714||Detectable RT-PCR ZIKV|Men and women aged 18 years and above with diagnosis of ZIKV infection
2469757|NCT03106285|Experimental|Lactobacillus reuteri DSM17938|Oil drops
2469758|NCT03106285|Placebo Comparator|Placebo|Oils drops
2469816|NCT03106038|Experimental|Nerindocianine for Injection|One Arm: Nerindocianine for Injection (Initial dosing cohort: 0.06 mg/kg body weight); solution, intravenous, one time administration during surgery. the study has only one arm.
2469865|NCT03105440|Experimental|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
2469869|NCT03105440|Experimental|Virtual reality|"The software used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation Together with Federal University of Uberlândia. This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
2469873|NCT03105440|Experimental|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
2469876|NCT03105440|Experimental|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
2469878|NCT03105440|Experimental|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
2469880|NCT03105440|Experimental|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
2469941|NCT03104920|Experimental|ERAS program|We give an ERAS pathway, which comprises of optimized management of diet, mobilization, analgesia and GI function recovery for patients with HCC.
2469943|NCT03104920|Active Comparator|Traditional treatment|We give routine clinic practices for the treatment of HCC.
2469991|NCT03104608|Active Comparator|Automatic Self Transcending Meditation|Participants in the ASTM group will undergo training in groups of 10 by certified teachers. Further, the following self-rated scales will be administered by a trained rater at the fourth ASTM session (week 0) as well as at weeks 4, 8, 12, and 24: Time Trade-off (TTO), Visual Function Questionnaire (VFQ-25), the Patient Health Questionnaire (PHQ-9), and Generalized Anxiety Disorder (GAD-7).
2469993|NCT03104608|Placebo Comparator|Treatment as Usual|Participants will continue to receive their treatment as usual. The following self-rated scales will be administered by a trained rater at weeks 0, 4, 8, 12 and 24: TTO, VFQ-25, PHQ-9, and GAD-7.
2470064|NCT03104270|Experimental|Elo Pom Car and Dex|"Drug dosing and administration:~All drugs are administered on a 28-day cycle.~Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond.~Pomalidomide: 3 mg PO on days 1-21~Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles.~Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ."
2470124|NCT03103776|Other|Patients who have Graves disease|
2470126|NCT03103776|Other|Patients having a goiter|
3157182|NCT00359645|No Intervention|Control|Annual auto questionnaire
2470247|NCT03103256|Experimental|YHP1701|PO, Once daily (QD), 8 weeks
2470250|NCT03103256|Active Comparator|YHR1703|PO, Once daily (QD), 8 weeks
2470253|NCT03103256|Active Comparator|YHR1704|PO, Once daily (QD), 8 weeks
2470312|NCT03102671|Experimental|AB sequence|Usual care followed by use of HeartHab application: Treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle), followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence.
2470318|NCT03102671|Experimental|BA sequence|Use of HeartHab application followed by usual care: patients will be followed by telemonitoring during treatment B. The tele-intervention will consist of two months telerehabilitation and telecoaching concerning physical activity, healthy lifestyle and medication adherence, followed by treatment A comprises the usual care (i.e. one information session on the importance of medication adherence, risk factor control and healthy lifestyle)
2470334|NCT03102229|Experimental|Activity Monitoring|"Enhanced Supportive Care - Status Checks Would occur everyday during treatment when a patient is deemed high-risk based on activity level. Other Names: •Daily Status Checks~Enhanced Supportive Care - Referrals On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor. Other Names: •Referrals"
2470376|NCT03102047|Experimental|durvalumab|IV infusion once every 2 weeks for 4 total doses
3157183|NCT00359645|Experimental|Screening|Annual screening of Head and Neck cancer
3157184|NCT00359658|Experimental|1|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal; Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily; Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 mg/ml
3157185|NCT00359671|Experimental|1|Arm 1: study drug
3157186|NCT00359671|Other|2|Arm 2: study drug + comparator
2469635|NCT03106896||postherpetic neuralgia (PHN group)|"persist more than 3 months after the resolution of the acute shingles episode and have pain intensity greater than 4 on the visual analog scale (VAS 0, no pain; 10, worst pain imaginable)."
2469636|NCT03106896||acute herpetic pain (AHP group)|have pain (VAS≧4 ) duration of within 7 days after zoster onset at initial interview
2469637|NCT03106896||healthy control (CON group)|healthy population
2469690|NCT03106740|Experimental|Minocycline Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
2469692|NCT03106740|Placebo Comparator|Placebo Arm|Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
2469762|NCT03106311|Active Comparator|Rupture of membranes group|Pregnant women with definite rupture of membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
2469765|NCT03106311|Active Comparator|Intact membranes group|Pregnant women with intact membranes will undergo speculum examination. Vaginal washing will be done. The washing fluid will be taken for quantitative and qualitative assessment of beta subunit of human chorionic gonadotropin.
2469794|NCT03105986|Experimental|Treatment sequence AB|Participants will receive Treatment A (1000 milligram (mg) oral dose of JNJ-64041575 on Day 1) in Period 1, followed by Treatment B (1000 mg oral dose of JNJ-64041575 on Day 22 along with probenecid 500 mg on Day 21 to Day 28) in Period 2. A washout Period of 21 days will be maintained between each Period.
2469800|NCT03105986|Experimental|Treatment sequence BA|Participants will receive Treatment B (1000 mg oral dose of JNJ-64041575 on Day 1 along with probenecid 500 mg on Day -1 to Day 7) in Period 1, followed by Treatment A (1000 mg oral dose of JNJ-64041575 on Day 22) in Period 2. A washout Period of 21 days will be maintained between each Period.
2469906|NCT03105102|Placebo Comparator|Double-blind Placebo for Risankizumab (Sub-Study 1)|Participants randomized to receive double-blind placebo for risankizumab for 52 weeks.
2469912|NCT03105102|Experimental|Double-blind Risankizumab Dose 1 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 1 for 52 weeks.
2469917|NCT03105102|Experimental|Double-blind Risankizumab Dose 2 (Sub-Study 1)|Participants randomized to receive double-blind risankizumab dose 2 for 52 weeks.
2469920|NCT03105102|Experimental|Maintenance Risankizumab Dose 1 (Sub-Study 2)|Participants will receive double-blind subcutaneous (SC)risankizumab dose 1 and intravenous placebo at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
2469923|NCT03105102|Experimental|Maintenance Risankizumab Dose 2 (Sub-Study 2)|Participants will receive double-blind subcutaneous placebo and intravenous risankizumab dose 3 at Week 0 followed by open-label SC risankizumab dose 1 from Week 8 through Week 52.
2469925|NCT03105102|Experimental|Open-label Risankizumab (Sub-Study 3)|Participants who completed Sub-study 1 or Sub-study 2 or other AbbVie risankizumab Crohn's disease study or M16-006 or M15-991 without endoscopy will receive open-label risankizumab dose 1 or dose 2 depending on their preceding study beginning at Week 56.
2469927|NCT03105102|Experimental|Risankizumab On-Body Injector and Open Label (Sub-Study 4)|Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
3157188|NCT00359723|Experimental|Methylphenidate 0.4 mg/kg TID followed by placebo TID|As above
3157189|NCT00359723|Experimental|Placebo TID followed by methylphenidate 0.4 mg/kg TID|As above
3157190|NCT00359814|Experimental|1|Azathioprine administration: was stopped at day 0; Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily; Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
3157191|NCT00359866|Experimental|Pelvic IMRT with Tomotherapy|"Helical tomotherapy will be used to plan and deliver the radiation treatment.~Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common, external and internal iliac nodal regions.~External beam radiation will be delivered in 160-180 cGy daily fractions to a total dose of 4500-5120 cGY.~Receive treatment once a day for five days a week for approximately 6 weeks.~Treating physician will make determination if patient is to receive intracavitary brachytherapy.~Treating physician will make determination if patient is to receive chemotherapy (allowed but not mandated)."
2470448|NCT03101670|Experimental|filgotinib|
2470454|NCT03101670|Placebo Comparator|placebo|
3157192|NCT00359879|Experimental|1 - exenatide before breakfast and dinner|
3157193|NCT00359879|Active Comparator|2 - exenatide before lunch and dinner|
3157194|NCT00359892|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 60mg
3157195|NCT00359905|Experimental|Silodosin|
3157196|NCT00359905|Active Comparator|Tamsulosin|
3157197|NCT00359905|Placebo Comparator|Placebo|
3157198|NCT00359918|Experimental|Prehospital facilitated PCI|
3157199|NCT00359918|Active Comparator|Primary PCI|
3157200|NCT00359957|Experimental|1|ADDED condition - behavioral intervention for modifying diet and physical activity, with greater emphasis on physical activity than the STANDARD condition
3157201|NCT00359957|Active Comparator|2|STANDARD condition - behavioral intervention for modifying diet, with little emphasis on physical activity
3157202|NCT00359970|Active Comparator|Azithromycin 500 mg plus Placebo|a single 500 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
3157203|NCT00359970|Active Comparator|Azithromycin 1000 mg plus Placebo|a single 1000 mg dose of Azitrhomycin at the start of treatment; a single loading dose of placebo at the start of treatment and then a dose of placebo after each loose stool
3157204|NCT00359970|Experimental|Azithromycin 500 mg plus Loperamide|a single 500 mg dose of Azitrhomycin at the start of treatment; a single 4 mg loading dose of Loperamide at the start of treatment and then 2 mg Loperamide after each loose stool
3174806|NCT00627315||Surgery|Obese adult men and women who are undergoing bariatric surgery (gastric bypass or gastric banding).
3174807|NCT00627328||1|pacemaker patients with previously diagnosed AT.
2469647|NCT03106948|Active Comparator|High frequency angioplasty|High frequency angioplasty defined by 4 or more angioplasties 12 months prior to randomization. Subjects will receive ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
2469693|NCT03106597|Experimental|Manidipine 20mg|50 patients will be administered orally manidipine 20mg/day after 1~2 week run-in period
2469696|NCT03106597|Active Comparator|Amlodipine 10mg|50 patients will be administered orally amlodipine 10mg/day after 1~2 week run-in period
2469741|NCT03106350||questionnaire|EORTC-QLQ-30 questionnaire
2469780|NCT03106090|No Intervention|No SCP Control|Patients returning for early follow-up who did not receive SCP.
2469782|NCT03106090|No Intervention|SOC SCP Control|Patients returning for early follow-up who received a standard of care SCP.
2469784|NCT03106090|Experimental|eSCP Intervention|"Patients currently receiving treatment who will be enrolled to receive an enhanced SCP (eSCP) with additional information beyond ASCO guidelines tailored to patient concerns and preferences."
2469817|NCT03105661|Active Comparator|Treatment Arm|"Patients will be randomized to treatment with antihypertensive medications used with pregnancy for thirty years.~Labetalol Hydrochloride 200 mg orally every 12 hours Nifedipine 60 mg orally daily Atenolol 25 mg daily"
2469818|NCT03105661|No Intervention|Non-treatment Arm|Patients who are randomized to the non-treatment arm will not receive antihypertensive medications.
2469868|NCT03105310|Active Comparator|Pegylated interferon|Pegylated interferon alfa alone 180 microgram subcutaneous weekly for 24 weeks
2469871|NCT03105310|Experimental|Pegylated interferon with ezetimibe|Pegylated interferon alfa 180 micro-gram subcutaneous weekly for 24 weeks and Ezetimibe 10 mg orally for 24 weeks
2469957|NCT03105011|Experimental|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes).
3174808|NCT00627328||2|pacemaker patients without previously diagnosed AT.
3174809|NCT00627341|Experimental|Exposure and Response Prevention|Participants will receive Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa for 6 months.
2470056|NCT03104140|Experimental|Ketamine group|This group of patients will receive: 1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2470058|NCT03104140|Active Comparator|Thiopental group|2 mg/Kg thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia. Endotracheal tube will be inserted aided by 1 mg/Kg succinyl choline. Patients will undergo surgical procedure to eliminate the source of sepsis e.g. abdominal exploration. Invasive blood pressure monitor will be connected to the patient through an arterial catheter. Electrical velocimetry (cardiometry) device will be connected to the patient to measure cardiac output, stroke volume, and systemic vascular resistance.
2470083|NCT03103893|Experimental|Rapamycin|Rapamycin
2470198|NCT03103321|Experimental|"Arm A (Knowing your Options, Prostate Choice)"|"Patients receive decision aids Knowing your Options before and Prostate Choice during their consultation visit."
2470199|NCT03103321|Experimental|"Arm B (Knowing your Options)"|"Patients receive Knowing your Options decision aid before their consultation visit."
2470200|NCT03103321|Experimental|"Arm C (Prostate Choice)"|"Patients receive Prostate Choice decision aid during their consultation visit."
2470201|NCT03103321|Active Comparator|Arm D (usual care)|Patients undergo usual care.
3191986|NCT00803972|Experimental|Stage 3: 1.5 U insulin lispro plus rHuPH20|Participants will receive 1.5 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
2470359|NCT03102112||Patients with glioma|Consecutive patients with privious MRI scans or symptoms that suggested a cerebral mass, not yet receive treatment.
2470417|NCT03101878|Experimental|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously.
2470421|NCT03101878|Placebo Comparator|Placebo|Saline .9%
2470460|NCT03101553|Experimental|Interpretation Bias Modification|"Treatment consists of eight brief sessions consisting of two tasks. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive feedback based on their response."
2470463|NCT03101553|Active Comparator|Progressive Muscle Relaxation|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release different muscle groups.
2470515|NCT03101189|Experimental|ACT-541468 (25 mg)|8 Japanese and 8 Caucasian subjects will receive 25 mg (1 capsule) of ACT-541468 once daily for 5 days
2470523|NCT03101189|Experimental|ACT-541468 (50 mg)|8 Japanese and 8 Caucasian subjects will receive 50 mg (2 capsules) of ACT-541468 once daily for 5 days
2470569|NCT03100630|Active Comparator|Treatment B: RO7239361|RO7239361 subcutaneous injections on specified days; arm
2481307|NCT03027830|Active Comparator|Conventional|
2469662|NCT03106883|Sham Comparator|Sham training|"Neutral, non-affective, non-social photos of objects (i.e., cars)~Five five-minute blocks separate by 90-second rest periods"
2469722|NCT03106571|Experimental|Pomaglumetad methionil Low + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 9 days with intravenous methamphetamine challenges
2469724|NCT03106571|Experimental|Pomaglumetad methionil Mid + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 80 mg orally twice daily x 8 days with intravenous methamphetamine challenges
2469725|NCT03106571|Experimental|Pomaglumetad methionil High + Methamphetamine|Pomaglumetad 40 mg orally twice daily x 1 day then pomaglumetad 160 mg orally twice daily x 8 days with intravenous methamphetamine challenges
2469726|NCT03106571|Placebo Comparator|Control + Methamphetamine|1-4 placebo tabs orally twice daily x 9 days (to match pomaglumetad dosing in each cohort) with intravenous methamphetamine challenges
2469824|NCT03106155|Experimental|vistusertib (AZD2014)|vistusertib (AZD2014), 50 mg,BID, per os, every 12 hours
2469933|NCT03105037||Study group|CTM assessed with supraglottic airway in situ and without
2469950|NCT03104777|No Intervention|Control Group|No intervention materials will be distributed in the control schools during the intervention period.
2469951|NCT03104777|Experimental|Intervention Group|Intervention materials will be distributed to parents of children in years 3 - 6.
2469981|NCT03104582|Experimental|Biliary drainage 1|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed Endoscopic Retrograde Cholangiopancreatography (ERCP) drainage
2469982|NCT03104582|Active Comparator|Biliary drainage 2|Patients with advanced hilar cholangiocarcinoma need biliary drainage performed percutaneous transhepatic biliary drainage(PTBD) drainage
2470015|NCT03104361|Experimental|Platelet-rich plasma treatment arm|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
2470067|NCT03104166|Experimental|MCO|Patients will be treated thrice weekly with Medium Cut-Off Dialysis membranes.
2470069|NCT03104166|Active Comparator|High-Flux|Patients will be treated thrice weekly with High-Flux Dialysis membranes.
2470123|NCT03103815|Experimental|experimental group|Experimental group will receive Amivita.
2470153|NCT03103529|Experimental|Early Rehab|Children will begin active rehabilitation 2 weeks post-injury
2470155|NCT03103529|Active Comparator|late rehab|Children will begin active rehabilitation 4 weeks post-injury
2470237|NCT03103308|Experimental|Walk training and transplant|Multidirectional walk training with activity monitoring after bone marrow transplant
2470238|NCT03103308|Experimental|Activity Monitoring and transplant|Activity monitoring alone after bone marrow transplant.
3174810|NCT00627341|Active Comparator|Cognitive Behavior Therapy|Participants will receive cognitive behavioral therapy for anorexia nervosa for 6 months.
3174811|NCT00627380|Placebo Comparator|STOC|Standard of care arm continues to receive standard of care treatment for HIV, but does not receive any new treatment/intervention or change in anti-HIV medications. Runs parallel to experimental group. At the end of this 16-wk control period, participants are invited to crossover into the experimental group
2470520|NCT03100929|Experimental|Elective cesarean section|Any patient undergoing elective cesarean section. Ultrasound
2470596|NCT03100786|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
2470597|NCT03100786|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
2470646|NCT03100214|Active Comparator|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions.
2470650|NCT03100214|Experimental|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
2470726|NCT03099785|Active Comparator|Treatment group 1: dose regimen 1|Rifamycin SV-MMX® 600 mg modified release tablets, three times daily (t.i.d.)
2470729|NCT03099785|Active Comparator|Treatment group 2: dose regimen 2|Rifamycin SV-MMX® 600 mg modified release tablets, two times daily (b.i.d.) + matching placebo daily (q.d.)
2470732|NCT03099785|Placebo Comparator|Treatment group 3: matching placebo|Rifamycin SV-MMX® matching placebo tablets, t.i.d.
2470850|NCT03099213|Experimental|Ramipril|Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily.
2470886|NCT03098771|Experimental|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
2470891|NCT03098771|Experimental|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
2470922|NCT03098485|Experimental|Levofloxacin|1 750mg tab of levofloxacin by mouth for 5 days
2470923|NCT03098485|Experimental|Azithromycin|1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)
2482580|NCT03018990|Active Comparator|Healthy control|
3174812|NCT00627380|Experimental|YOGA|Yoga lifestyle intervention administered by certified yoga instructor.
3174813|NCT00627419|Experimental|1|IPI-504
3174814|NCT00627471|Active Comparator|A|This group must follow a defined algorithm. Only the physicians assigned to this group will know the algorithm.
3174815|NCT00627471|Active Comparator|B|This is the control group, following the physician's standard practice.
3174816|NCT00627484||Group 1: GBP non-diabetic|Non-diabetic subjects scheduled to receive gastric bypass
2469788|NCT03106207|Other|Upper gastric endoscopy (UGE)|Patients will be submitted to a UGE before the gastric bypass surgery without a ring and at two, six and 12 months after the surgical procedure .
2469885|NCT03105323||infertile women|All patients were pretreated with Gonadotropin releasing hormone agonist (decapeptyl®) 0.05 mg/day from 10 days prior to the start of menstruation. The patients'ovaries were stimulated with a recombinant follicle-stimulating hormone (FSH, subcutaneous) from day 2 of the menstrual cycle. human chorionic gonadotropin was administered when at least two follicles vary 18-22mm were observed on ultrasonography.Blood samples were collected on the day of final Human chorionic gonadotropin maturation, and serum P levels were measured.Pregnancy was defined by titers within 11 days following Embryo transfer,Clinical pregnancy was defined by the observation of intrauterine embryo heart motion by 7 weeks gestation.
2469958|NCT03104959|Placebo Comparator|Placebo|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take placebo capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
2469960|NCT03104959|Experimental|N-acetyl cysteine|Healthy volunteers consume alcohol independently and estimate number of drinks then apply Vick's vapor rub under nose and take N-Acetyl Cysteine capsules based on number of drinks consumed and fill out a Hangover Symptom Scale the next morning
2470048|NCT03104530||Brown crabmeat consumers|Those habitually consuming 40 grams or more of brown crab meat each week.
2470049|NCT03104530||Control|Those consuming less than 40 grams of brown crabmeat a year, or no brown crabmeat.
2470085|NCT03103945||Patients with cardiac arrhythmias undergoing RF ablation|Patients with cardiac arrhythmias will be undergoing RF ablation using the Niobe Remote Magnetic Navigation System with CDS as their standard of care. System performance data will only be collected during the RF ablation procedure. Outcome measures will be evaluated with the CDS connected and without the CDS connected within all patients.
2470149|NCT03103724|Experimental|Enzalutamide|All subjects will receive open label enzalutamide 160 mg (4 x 40 mg capsules), orally once daily.
2470214|NCT03103373|Active Comparator|Conventional monitor group|Patients will be monitoring with invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography Echocardiography group: Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnogrphy and electrocardiography
2470216|NCT03103373|Active Comparator|Echocardiography group|Patients will be monitoring with echocardiography, invasive blood pressure, central venus catheter, plasma lactate, urinary output, oximeter, capnography and electrocardiography
2470320|NCT03102476|Other|Patients with Type 1 Diabetes|Using euglycaemic clamp, the effect of different temperatures and humidity levels will be assessed on the pharmacokinetic and pharmacodynamic profiles of short-acting insulin Humalog.
2470428|NCT03101787|No Intervention|CCPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and rapid transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical Upon the patient's arrival, the standard of care (CCPR) will be continued according to ERC guidelines.~No special preparations for the trial are needed before the patient's arrival."
2470429|NCT03101787|Experimental|ECPR protocol|"Preclinical Cardiopulmonary resuscitation (CPR) by emergency medical services (EMS) and transport to the emergency department with ongoing mechanical CPR and advanced cardiac life support (ACLS).~Clinical The ECPR team is mobilized while the patient is transported to the hospital. Initiation of extracorporeal cardiopulmonary resuscitation (ECPR).~Time from arrest to start of cannulation is < 60 minutes."
3157205|NCT00359996|Active Comparator|Health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
3157206|NCT00359996|Active Comparator|Control|No additional educational sessions added to usual care of patients.
3157207|NCT00360022|Experimental|Joint Visits|Transition patients will have 2 joint visits performed with the pediatric GI specialist and the adult GI specialist as they transfer care to an adult GI provider.
2470497|NCT03101072|Active Comparator|"Fixed long antibiotic course"|"Patients randomized to this group will receive a fixed long antibiotic course of 14 days."
2470498|NCT03101072|Experimental|"Fixed short antibiotic course"|"Patients randomized to this group will receive a fixed short antibiotic course of 7 days."
2470500|NCT03101072|Experimental|"Individualized antibiotic course"|"Individualized antibiotic course: starting on day 5, therapy will be discontinued after the patient has been afebrile for 48 hours and the CRP level has decreased from its peak by at least 75%"
3157208|NCT00360022|No Intervention|Control|Transition patients in the control group will transfer care to adult GI provider in typical manner.
3157209|NCT00360035|Experimental|GX15-070MS|Obatoclax mesylate 60mg
3157210|NCT00360152|Active Comparator|Positive Axillary Ultrasound|Positive Axillary Ultrasound -> Fine Needle Aspiration Biopsy -> Cytopathology and Reverse Transcription-Polymerase Chain Reaction (RT-PCR) -> Positive Cyto=Axillary Lymph Node Dissection, Negative Cyto=Sentinel Lymph Node Biopsy -> Pathology
3157211|NCT00360152|Active Comparator|Negative Axillary Ultrasound|Negative Axillary Ultrasound -> Sentinel Lymph Node Biopsy/Fine Needle Aspiration Biopsy -> Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and Pathology
3157212|NCT00360256||Control|
3157213|NCT00360256||Case group|
3157214|NCT00360438|Experimental|Rasburicase|
3157215|NCT00360451|Experimental|1|Adolescent only Penn Resiliency Program
3157216|NCT00360451|Experimental|2|Adolescent plus parent Penn Resiliency Program
3157217|NCT00360451|No Intervention|3|Control
3157218|NCT00360477|Active Comparator|1|Floseal
3157219|NCT00360477|Active Comparator|2|Cope-Loop/Nephrostomy Tube
3157220|NCT00360477|Active Comparator|3|Fascial Stitch
3157221|NCT00360594|Experimental|1|Acamprosate
3157222|NCT00360594|Placebo Comparator|2|Placebo
3157223|NCT00360646||Subjects with liver injury|
3157224|NCT00360646||Subjects without liver injury|
2469707|NCT03106818|Active Comparator|Group C|will be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
2469777|NCT03106103||Women with urinary incontinence|The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.
2469792|NCT03105830|Experimental|intervention and data collection|pain management by iv paracetamol
2469848|NCT03105622|Experimental|Running+screen|Running on a treadmill at 60% VO2peak for 30 minutes while watching television.
2469850|NCT03105622|Experimental|Running+music|Running on a treadmill at 60% VO2peak for 30 minutes while listening to music.
2469852|NCT03105622|Experimental|Running without stimulus (control condition)|Running on a treadmill at 60% VO2peak for 30 minutes with no other stimuli.
2469886|NCT03105089|Active Comparator|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
2469900|NCT03105089|No Intervention|control|no intervention will be done
2469940|NCT03104933||Patients with septic shock|patients in septic shock admitted to the ICU
3191987|NCT00803972|Experimental|Stage 3: 6 U insulin lispro plus rHuPH20|Participants will receive 6 U of insulin lispro (50 U/mL), coadministered with sequential concentrations of 0, 0.0625, 0.3125, 1.25, 5, and 20 μg/mL rHuPH20.
2470028|NCT03104283|Experimental|Apatinib Group|take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
2470259|NCT03102983|Experimental|Healthy Volonteers|
2470300|NCT03102606|Active Comparator|Docetaxel (75 mg/m2) + pegfilgrastim (6 mg) + placebo matching plinabulin|
2470303|NCT03102606|Experimental|Docetaxel (75 mg/m2) + plinabulin (40 mg) + placebo matching pegfilgrastim|
2470335|NCT03102138||observation|subjects treated in B4711001 with PF-05206388 will be assessed
2470380|NCT03102021|Active Comparator|1|erythropoeitin
2470385|NCT03102021|Placebo Comparator|2|saline placebo
2470443|NCT03101449|Experimental|Group 1|"20 individuals of Coral UFCSPA without voice problems carry out the exercise with Finnish tube before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
2470447|NCT03101449|Experimental|Group 2|"20 individuals of Coral UFCSPA without voice problems carry out the exercise straw phonation before choir practice once a week for a period of 14 weeks. The exercise will be carried out with blowing set to sound at regular frequency, with frequency variation and with the melody of Happy Birthday; each sequence will be held for 2 minutes with 1 minute interval between them."
2470452|NCT03101449|No Intervention|Group 3|10 individuals of Coral UFCSPA without voice problems. Untreated group.
2470506|NCT03101215|Placebo Comparator|Placebo|glucose drink (100g) with placebo tablets
2470509|NCT03101215|Active Comparator|phosphorus|Glucose drink (100g) with phosphorus tablets (400 mg of phosphorus)
2470589|NCT03100773|Experimental|Group control|Caries-free children submitted to four consecutive sessions of oral health educational strategy (once a week).
2470593|NCT03100773|Experimental|Group of strategy + ART|Children with at least one decayed primary molar in dentin submitted to four consecutive sessions of oral health educational strategy (once a week) followed by Atraumatic Restorative Treatment (ART)
2470595|NCT03100773|Experimental|Group of ART|Children with at least one decayed primary molar in dentin submitted to Atraumatic Restorative Treatment (ART)
2470622|NCT03100240|Experimental|Experimental group|Modified Supper Long Protocol
2470624|NCT03100240|No Intervention|control group|long protocol
2470679|NCT03099980|Experimental|Secukinumab|All participants will be assigned to receive secukinumab 300 mg (2 x 150 mg PFS subcutaneous injections) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 more weeks.
3191988|NCT00803972|Experimental|Stage 4: 95 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 95 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3191989|NCT00803972|Experimental|Stage 4: 50 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 50 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3191990|NCT00803972|Experimental|Stage 4: 25 U/mL insulin lispro plus 5 μg/mL rHuPH20|Participants will receive 25 U/mL insulin lispro, administered once with and once without 5 μg/mL rHuPH20. At each insulin lispro concentration, participants will receive 2, 6, and 20 U lispro.
3191991|NCT00803985|Active Comparator|Lichtenstein|Open operation with onlay light weight polypropylene mesh
3191992|NCT00803985|Active Comparator|Total Extraperitoneal repair (TEP)|Laparoscopic operation with preperitoneal nonfixated mesh
2471089|NCT03097523|Experimental|Study Arm|"Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures:~Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed~Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM)~Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events"
2471137|NCT03097003||Use of Apremilast in patient with plaque psoriasis|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
2471400|NCT03095222|Active Comparator|Group 1: Daily|Daily ketamine infusions of 5 hours in length. Duration of participation will last 4 days.
2471405|NCT03095222|Active Comparator|Group 2: Continuous|Continuous ketamine infusions (24 hours/day). Duration of participation will last 4 days.
2483096|NCT03015337|Experimental|New Physical Education Instructions|
2469720|NCT03106584|Experimental|Aquamin-plus|"Aquamin-plus will be consumed as either supplement A or B (i.e. blinded) for a period of 12-weeks. Aquamin-plus will be taken 2 times daily with food.~After 12 weeks of supplementation, participants will begin taking the alternative supplement (Glucosamine sulphate), after a washout period of not less than 1 month between the intervention arms of the study."
2469772|NCT03106220|Active Comparator|home exercise|participate in home exercise program
2469773|NCT03106220|Placebo Comparator|standard care|encouraged to join physical therapy and walking goals
2469807|NCT03105843|Experimental|Cough Variant Asthma|Individuals diagnosed with Cough variant asthma
2469812|NCT03105843|Experimental|Methacholine-induced cough|Individuals with chronic cough and negative methacholine challenge
2469814|NCT03105843|Experimental|Control|Individuals with no history of asthma or chronic cough
2469893|NCT03105245|Active Comparator|Short time interval + Normal ventilation|
2469908|NCT03105245|Active Comparator|Short time interval + Hyperventilation|
2469915|NCT03105245|Active Comparator|Long time interval + Normal ventilation|
2469921|NCT03105245|Active Comparator|Long time interval + Hyperventilation|
3191993|NCT00804011|Experimental|1|Automatic tube compensation plus pressure support
3191994|NCT00804011|Active Comparator|2|Pressure support alone
3191995|NCT00804024||ClearWay™ RX|
2470133|NCT03103867|Experimental|CGM augmented pump with PLGS (A)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with integrated continuous glucose monitoring and predicted low glucose suspense (PLGS) Randomised cross over treatment during 5 weeks
2470135|NCT03103867|Active Comparator|Insulin pump with CGM (B)|Administration of Subcutaneous administration of Continuous subcutaneous insulin infusion with second device measuring continuous glucose Randomised cross over treatment during 5 weeks
2470157|NCT03103464|Experimental|Intervention Group|Patients to receive standard-of-care physical therapy + sit-to-stand therapy using the Movi chair 3x/wk.
2470158|NCT03103464|Active Comparator|Control Group|Patients to receive standard-of-care physical therapy 3x/wk.
2470183|NCT03103269|Experimental|Challenge! Small Group Intervention only|"This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~This group is in schools that were randomly assigned to NOT receive the Environmental Intervention."
2470184|NCT03103269|Experimental|Challenge! Small Group and Environmental Intervention|"This group consists of participants who receive the Challenge! Small Group Intervention AND attend a school that is randomly assigned to receive an environmental intervention.~This group receives the Challenge! Small Group intervention consisting of curriculum related to health behavior goal setting, healthy eating, and staying active, works out with their Health Educators, and receives a year-long membership to the YMCA.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
2470185|NCT03103269|Experimental|Environmental Intervention Only|"This group consists of participants who do not receive the Challenge! Small Group Intervention but attend a school that is randomly assigned to receive an environmental intervention.~This group does not receive the Challenge! Small Group Intervention.~The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier."
2470187|NCT03103269|No Intervention|Control Group|This group does not receive the Challenge! Small Group intervention and is in a school that is randomly assigned to NOT have the Environmental Intervention.
2470239|NCT03103035|Experimental|Exposition to a healthy eating blog|Participants randomised to this arm are exposed to one blog post each week for a period of 6 months.
2470240|NCT03103035|No Intervention|No exposition to a healthy eating blog|Participants randomised to this arm do not have exposure to the blog.
2470283|NCT03102814|Active Comparator|Current rehabilitation program|The control group will receive the rehabilitation program currently provided at each participating centre at the start of the study.
2470287|NCT03102814|Experimental|BRIDGE rehabilitation program|In intervention phase, the BRIDGE program will be added to the current program.
2470370|NCT03102268||cholangiocarcinoma patients|cholangiocarcinoma patients without any anti-cancer therapy
2470373|NCT03102268||benign biliary stricture patients|benign biliary stricture patients without any therapy targeting the stricture
2470473|NCT03101319|Experimental|Antipsychotic and Vitamin D3|Subjects randomised to vitamin D3 arm will receive a tablet containing 60,000 IU vitamin D3 starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
2470478|NCT03101319|Placebo Comparator|Antipsychotic and B Complex|Subjects randomised to the B Complex arm will receive a tablet of identical size, shape, colour and weight starting from the first day of visit and then be taken by mouth on fixed days every week amounting to a total duration of 08 weeks. The subjects will continue to receive antipsychotics as per the decision of the treating team
2470494|NCT03101059|Experimental|MKS pax|Munier-Kuhn Syndrome patients
2470550|NCT03100890|No Intervention|Control|Non-active comparator
2470552|NCT03100890|Active Comparator|Balance-Proprioception (Hospital)|Preoperative training (hospital)
2470554|NCT03100890|Experimental|Balance-Proprioception (Home)|Preoperative training (home)
2470579|NCT03100604|Experimental|sevoflurane 2%, 1 MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
2470583|NCT03100604|Experimental|Desfluran 6-9% 1MAC|Maintenance of anesthesia was provided with 2% sevoflurane in S Group, and 6-9% desflurane in D Group, with 50% air /oxygen mixture and fresh gas flow at 4 l/min in both groups.
2470630|NCT03100305||Extremely preterm infants|
3191996|NCT00804037|Active Comparator|Ethanol|
3191997|NCT00804037|Active Comparator|Ethanolamine Oleate|
3191998|NCT00804050|Experimental|Infusion A: rEPO|rEPO for 4 mounths consequently
2469775|NCT03106324||TNE NDMM patients treated with non-lenalidomide|Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
2469922|NCT03105128|Experimental|Risankizumab Dose 1 (Period 1)|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
2469924|NCT03105128|Experimental|Risankizumab Dose 2 (Period 1)|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
2469926|NCT03105128|Placebo Comparator|Placebo (Period 1)|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
2469929|NCT03105128|Experimental|Risankizumab Dose 1 (Period 2)|Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
2469930|NCT03105128|Experimental|Risankizumab Dose 2 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
2469932|NCT03105128|Experimental|Risankizumab Dose 3 (Period 2)|Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.
2470329|NCT03102463|Sham Comparator|Water Control|
2470331|NCT03102463|Active Comparator|Milk derived hydrolysate|
2470333|NCT03102463|Active Comparator|Parent Protein|
2470360|NCT03102073||Radner test|reading speed evaluation
2470408|NCT03101865|Experimental|Closed loop with diluted insulin|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using DILUTED insulin aspart over 3 weeks.
2470409|NCT03101865|Active Comparator|Closed loop with standard insulin strength|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature using STANDARD strength insulin aspart over 3 weeks.
2470449|NCT03101475|Experimental|immunotherapy + local tumor ablation|Patients with unresectable colorectal liver metastases which show at least stable disease or partial remission after 4-6 months will receive treatment with durvalumab and tremelimumab plus local tumor ablation (Radiofrequency ablation RFA or Sterotactic body radiation therapy SBRT) of selected liver lesions, followed by maintenance treatment with durvalumab.
3157225|NCT00360737|Active Comparator|NP-018|Subjects received one or two vials of NP-018 administered intravenously.
3157226|NCT00360776|Experimental|Arm I|"Patients will receive tipifarnib by mouth twice a day for 3 weeks. Treatment may repeat every 4 weeks for up to eight courses.~Patients will undergo blood collection periodically for laboratory studies. After finishing treatment, patients will be evaluated every 6 months for 5 years."
2471121|NCT03096860|Experimental|Alcohol consumption and hookah|
2471122|NCT03096860|Placebo Comparator|Placebo consumption and hookah|
2471171|NCT03096769|Other|Study Arm|
2471325|NCT03095846|Experimental|Winter Swimmers|Individualized cooling protocol
2471327|NCT03095846|Experimental|Not-winter Swimmers|Individualized cooling protocol
2471383|NCT03095274|Experimental|Durvalumab|"Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) for 12 months in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: durvalumab 20 mg/kg."
2471384|NCT03095274|Experimental|Tremelimumab|"Tremelimumab 75 mg Q4W (equivalent to 1 mg/kg Q4W) for up to 4 doses/cycles in patients ≥ 30kg.~Weight-based dosing should be used for patients <30 kg: tremelimumab 1 mg/kg Q4."
2471469|NCT03094676|No Intervention|Control|Only the HRV will be followed for two hours without intervention.
2471472|NCT03094676|Experimental|Only Massage|Only the massage, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
2471475|NCT03094676|Experimental|Only Exercise|Only the exercise, and will have the monitoring of the HRV on the techniques and accompanied for two hours.
2471477|NCT03094676|Experimental|Exercise and Massage immediately|Performing the exercise and massage immediately after, will be accompanied by the HRV during the techniques and two hours after.
2471479|NCT03094676|Experimental|Exercise and Massage after recovery|Performing the exercise and massage will be applicated after recovery of HRV, will be accompanied by the HRV during the techniques and two hours afte
2471514|NCT03094312|Experimental|Dynamic Spectral Imaging (ISD)|Evaluation of cognitive functions by ISD
2471568|NCT03094039|Experimental|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
2471570|NCT03094039|Active Comparator|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
2471762|NCT03092921|Experimental|F&P Mask Seal|Participants to use trial seal in-home for 1 week
3157227|NCT00360802|Active Comparator|CBT|Cognitive Behavioral Treatment
3157228|NCT00360802|Active Comparator|MBSR|Mindfulness Based Stress Reduction
3157229|NCT00360841|Experimental|A|The subjects in arms A and B will receive auricular acupuncture. The subjects in arms A will receive auricular acupuncture (at 2nd and 4th chemotherapy courses) as well as the sham auricular acupuncture (at the 3rd chemotherapy course).
3157230|NCT00360841|Sham Comparator|B|The subjects in arms A and B will receive auricular acupuncture. The subjects in arm B will receive the sham auricular acupuncture (at the 2nd and 4th chemotherapy courses) and auricular acupuncture (at the 3rd chemotherapy course).
3157231|NCT00360841|No Intervention|C|No treatment received.
3157232|NCT00360867|Other|1|Single Arm
3157233|NCT00360919|Experimental|A|Cheese
3157234|NCT00360919|Placebo Comparator|B|Fruits and vegetables
3157235|NCT00360958|Experimental|Ultrafiltration|Ultrafiltration treatment
3157236|NCT00360958|Active Comparator|Usual treatment|Usual HF treatment
3157237|NCT00360997|Other|Behavioural|Conventional UK physical therapy (Con UK PT)
3157238|NCT00360997|Experimental|Con UK PT + MTS|Con UK PT + 30/60 or 120 minutes MTS
3157239|NCT00361036|Experimental|1|BeadBlock treatment arm
3157240|NCT00361036|Active Comparator|2|Embospheres control arm
3157241|NCT00361088|Experimental|Phase I|
2469861|NCT03105505|Active Comparator|Fusidic Acid 1%|Contains 1% w/w fusidic acid anhydrous (as the hemihydrates) and 0.011% w/w.
2469905|NCT03105063|Experimental|US GROUP|All patients will first undergo ultrasound scan of the hip in attempt to recognize the AIIS, on the same day , the true morphology of the AIIS will be evaluated using 3d imaging
2470041|NCT03104907|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
2470120|NCT03104062|Other|Ticagrelor|Patients will be randomized to have Ticagrelor 90mg BID
2470121|NCT03104062|Other|Clopidogrel|Patientes will be randomized to have Clopidogrel 75mg once a day
2470161|NCT03103555|Experimental|Bortezomib and cyclophosphamide|Two cycles of bortezomib administered subcutaneously, followed by 4 months of low dose oral cyclophosphamide.
2470193|NCT03103217|Experimental|Brief CBT intervention|
2470254|NCT03103022|Experimental|Interventional Group|Preterm infants who met the eligibility criteria will receive both oral acetaminophen and ibuprofen. Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses and oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
2470349|NCT03102372|Experimental|Protein group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program. Whey protein supplementation 0.4g/kg before sleep.
2470351|NCT03102372|Placebo Comparator|Placebo group|4 weeks of a Very Low Calorie Diet (VLCD) + walking program
3157242|NCT00361088|Experimental|Phase II|
3157243|NCT00361114|Active Comparator|A|SP in symptomatic children aged 6-59 months
2470432|NCT03101397||improved group|defined by two or more of the following: A decrease in symptoms, specifically an increase in the level of exertion required before the patient must stop because of breathlessness or a decline in the frequency or severity of cough Reduction of parenchymal abnormalities on chest CT scan Physiologic improvement defined by > 10% increase in FVC (or at least > 200-ml change) or > 15% increase in single-breath DLCO (or at least > 3 ml/min/mm Hg)
2470434|NCT03101397||deteriorated group|defined by two or more of the following: An increase in symptoms, especially dyspnea or cough; An increase in opacities on chest CT scan, especially the development of honeycombing ; deterioration in lung function with > 10% decrease in FVC ( or > 200ml change) or > 15% decrease in DLCO (or at least > 3ml/min/mm Hg change).
2470436|NCT03101397||stable group|not included in improved group or deteriorated group
2470475|NCT03101345|Other|nutrition product|Peptamen® 1.5 Vanilla, orally administration
2470495|NCT03101098|Experimental|Retroperitoneal hysterectomy|In subjects allocated to the experimental group, which the uterine vessels were ligated where it originates from the internal iliac artery,
2470496|NCT03101098|Active Comparator|Classical hysterectomy|The operative technique of classical total laparoscopic hysterectomy (TLH) performed in the control group was comparable to that of retroperitoneal TLH, except for one that coagulation and transection of uterine artery was achieved using an energy device alongside the cervix
2470590|NCT03100513|Active Comparator|Lactulose|(20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate.
2470594|NCT03100513|Active Comparator|Polyeyhylene Glychol|Polyethylene Glycol 3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water)
2470619|NCT03100279|Experimental|CBT for Anxiety or Depression|If a youth meets criteria for a primary diagnosis of clinical or subclinical depressive disorder she or he will be assigned to Primary and Secondary Control Enhancement Therapy (PASCET; Weisz et al., 1987). If a youth meets criteria for a primary diagnosis for a clinical or subclinical anxiety disorder, she or he will be assigned to the Coping Cat (Kendall, 2000). Both CBT treatments include a therapist manual and companion workbooks for the youth. CBT teaches coping skills that help anxious and depressed youth challenge anxious and depressive thinking. It also helps the child habituate to negative physiological feelings and learn skills to cope with emotional distress.
2470669|NCT03100006|Experimental|Nivolumab and Oregovomab|
2470707|NCT03099642|Experimental|Ultrasound assisted lumbar puncture|The intervention of interest will be the ultrasound-assisted lumbar puncture (UALP). To do this, the treating physician will perform a bedside ultrasound of the spine to identify and mark the level of the conus medullaris and preferred puncture site prior to LP
2470710|NCT03099642|No Intervention|Standard lumbar puncture|The control group will have a standard landmark-based lumbar puncture
2470800|NCT03099486|Experimental|Regorafenib + 5FU/LV Treatment Arm|
2470872|NCT03099005|Active Comparator|Low CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.6% THC + 0.09 CBD. They will then undergo experimental testing as described below under Outcome Measures.
2470877|NCT03099005|Active Comparator|Medium CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis 4 puffs will contain 1.6% THC + 0.09 CBD and 4 puffs will contain 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
2470881|NCT03099005|Active Comparator|High CBD session|In the morning, participants will inhale 8 puffs of vaporized cannabis containing 1.73% THC + 5.4% CBD. They will then undergo experimental testing as described below under Outcome Measures.
2470949|NCT03098589||Patients with T-cell leukemia lymphoma treated with Revlimid|Among patients with relapsed or refractory adult T-cell leukemia lymphoma, patients who received Revlimid will be targeted in this surveillance
2471003|NCT03098186|Active Comparator|Intervention SMS|"SMS aimed to improved adherence to medications used in secondary prevention of cardiovascular disease.~Control SMS: SMS to thanks for participation in the trial and reminders of trial appointments."
2471007|NCT03098186|Placebo Comparator|Control SMS|SMS to thanks for participation in the trial and reminders of trial appointments.
2471048|NCT03097718||Non-specific low back pain|Individuals with recurrent non-specific low back pain
2471050|NCT03097718||Healthy control subjects|Healthy individuals without low back pain
3157244|NCT00361114|Experimental|B|SP to asymptomatic infected children aged 2-10 months
3157245|NCT00361114|Experimental|C|Chlorproguanil/dapsone in symptomatic 6-59 month old children
3157246|NCT00361127|Experimental|CMPD patients|Patients with CMPD with evaluation of ACE I/D polymorphism
3157247|NCT00361153|Active Comparator|1|Colesevelam hydrochloride
2469907|NCT03105115|Experimental|bupivacaine only|heavy bupivacaine 14mg will be injected intrathecally during spinal anesthesia
2469964|NCT03104790|Experimental|naive|Children who have never received any influenza vaccine (The two groups are defined by immunisation history, all receive the same intervention in the study)
2469965|NCT03104790|Experimental|prior vaccinees|Children who have received at least two doses of Fluenz Tetra previously (The two groups are defined by immunisation history, all receive the same intervention in the study)
2469990|NCT03104491|Experimental|Inotuzumab Ozogamicin|"Phase I:~A maximum of 12 cycles will be allowed and doses will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels for ALL participants is 0.1-0.6mg/m^2 and for NHL participants 0.2-0.8mg/m^2~Dosing in the NHL cohort will start at Dose Level 0 (0.3mg/m^2) or one dose level below the ALL cohort maximum tolerated dose (MTD), whichever is higher.~Phase II:~ALL and NHL participants: Will be enrolled until all Phase I ALL/NHL participants (respectively) have been followed and assessed for toxicity for at least 4 weeks after the fourth treatment dose of inotuzumab ozogamicin or 4 weeks after the participant goes off treatment, whichever comes first. Doses to be administered will be determined in the phase I portion of the study. Repeat cycles every 28 days for up to 12 cycles"
2470094|NCT03103984|Experimental|Control|The volunteers (overweight and obese) will receive nutritional counseling and a weight loss diet.
2470095|NCT03103984|Experimental|Immunosuppressed patients|The volunteers (liver transplantation) will receive nutritional counseling and a weight loss diet.
2470138|NCT03103672||Groupe I|Patients who will receive inhalation anesthesia
2470141|NCT03103672||Groupe 2|Patients who will receive total intravenous anesthesia
2470224|NCT03103087|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
2470225|NCT03103087|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
2470226|NCT03103087|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
2470346|NCT03102164||cardiac rehabilitation|patients undergoing cardiologic rehabilitation according to the protocol used routinely at the Military Hospital in Wroclaw.The protocol of rehabilitation, adjusted to clinical status, individual needs and physical capability of the patient, includes gradually increasing level of physical exercise. Upon achieving relative stabilization of clinical status and excluding absolute contraindications to physical exercise, usually on the 2nd or 3rd day of hospitalization, the cardiologic rehabilitation is ordered by a physician in charge. The rehabilitation protocol comprises respiratory, assisted, active dynamic,and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase;they are conducted in a lying, sitting, or standing position.
2470347|NCT03102164||Controls|patients treated using standard pharmacotherapy within Center for Heart Disease, Military Clinical Hospital in Wroclaw.
2470411|NCT03101930|Experimental|liraglutide|Subjects in the liraglutide group will receive subcutaneous liraglutide (0.6 mg/d for one week, 1.2 mg/d for one week, and then 1.8 mg/d for 12 weeks) and oral placebo.
2470414|NCT03101930|Active Comparator|sitagliptin|Subjects in the sitagliptin group will receive subcutaneous placebo daily and sitagliptin 100 mg/d orally for 14 weeks.
2470420|NCT03101930|Active Comparator|hypocaloric diet|Subjects in the hypocaloric diet group will be given a caloric goal designed to achieve a weight loss similar to that expected in the liraglutide treatment arm based on his or her resting energy expenditure. Subjects will be provided counseling and written instructions on how to achieve their daily caloric goal, including use of their own mobile phone applications to monitor caloric intake. To assure compliance with the prescribed caloric goal, subjects will meet with the study dietitian every other week for problem solving and review of diet intake logs.
3157248|NCT00361153|Placebo Comparator|2|placebo
3157249|NCT00361309|Experimental|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks). Patients will be continued on treatment until disease progression, limiting toxicity, or patient withdrawal of consent.
2470643|NCT03100136|Experimental|[11C]PF-06809247|A dose intravenous injection of [11C]PF-06809247 followed by PET scanning.
2470720|NCT03099837||Pregnant mothers|
2470723|NCT03099837||infants|
2470727|NCT03099837||children|
2470825|NCT03099408|Active Comparator|Metronidazole Oral|Metronidazole Oral
2470826|NCT03099408|Active Comparator|"Metronidazole and Lactobacillus"|"Metronidazole and Lactobacillus"
2470864|NCT03098849|Experimental|Buteyko Training|Breathing exercises according to the Buteyko Breathing Technique
2470866|NCT03098849|No Intervention|Control Group|Standard care as usual
2470914|NCT03098667|Experimental|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated
2470916|NCT03098667|Active Comparator|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
2470995|NCT03098264|Active Comparator|Staged surgery|to perform surgery on biliary stone and portal hypertension by staged surgery
2471025|NCT03097796|Experimental|PUL-042|PUL-042 Inhalation Solution
2471107|NCT03097120|Active Comparator|unopposed estrogen|0.625 mg of conjugated equine estrogen
3157250|NCT00361348|Active Comparator|Palifermin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period
3157251|NCT00361348|Experimental|Palifermin + Heparin|A single 60µg/kg IV bolus dose of palifermin on Day 1 of the treatment period + unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
3174817|NCT00627484||Group 2: BND non-diabetic|Non-diabetic subjects scheduled to receive gastric banding
3191999|NCT00804050|Experimental|Infusion B combined r-EPO|rEPO in association with acid 13-cis-retinoic acid and Dihydroxyvitamin D3 for 4 mounths consequently
3192000|NCT00804063||1|glaucoma patients
2470008|NCT03104504|No Intervention|No Intervention|Baseline Retrospective Chart Reviews that are conducted on subjects for the one year period prior to the implementation of the study will serve as the control.
2470013|NCT03104504|Other|Intervention|"The intervention targets will be the following suicide-related clinician behaviors.~suicide risk screening~safety planning~means restriction counseling~Post-acute care follow-up calls A Lean Implementation Strategy: The Implementation of the intervention targets guided by Lean; is expected to increase suicide-related clinician behaviors"
2470057|NCT03104127|Experimental|Alter G Bionic Leg|Participants randomised to a group including normal therapy (physiotherapy) and the use of a Alter G robotic bionic leg. All participants have previously completed normal NHS therapy.
2470059|NCT03104127|Active Comparator|Normal therapy|Participants randomised to a group including normal therapy (physiotherapy) only. All participants have previously completed normal NHS therapy.
2470061|NCT03104127|No Intervention|Usual care|Have completed normal NHS therapy and no longer (> 6 months) receive active physiotherapy.
2470099|NCT03103854|Active Comparator|Control|"Patients in the Control arm of the study performed Moderate Intensity Continuous Training (MICT) and did not receive text message reminders."
2470102|NCT03103854|Experimental|BURST|"Patients in the BURST arm of the study performed BURST physical activity and did not receive text message reminders"
2470106|NCT03103854|Experimental|Text Message Reminders|"Patients in the Text Message Reminders arm of the study performed Moderate Intensity Continuous Training and received text message reminders."
2470113|NCT03103854|Experimental|BURST and Text Message Reminders|"Patients in the BURST and Text Message Reminders arm of the study performed Burst physical activity and received text message reminders"
2470165|NCT03103568|Experimental|Arm A - CYP substrates|"In Arm A of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances tolbutamide, metoprolol and chlorzoxazone will be investigated. These substances are metabolized by CYP2C9, CYP2D6 and CYP2E, respectively.~A cocktail of the substances tolbutamide, metoprolol and chlorzoxazone will be given as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic serum concentrations level is reached. Serum and urine concentrations of nitisinone will then be investigated for 24 hours, followed by giving the substances tolbutamide, metoprolol and chlorzoxazone as a single dose together with nitisinone to investigate the PK during interaction."
2470167|NCT03103568|Experimental|Arm B - OAT substrates|"In Arm B of the clinical study the potential effect of multiple doses of nitisinone on the blood concentration of the active substances furosemide in the blood, which is transported by the transporter proteins OAT 1 and OAT 3, will be investigated.~Furosemide will be given intravenously as a single dose at the beginning of the study and PK will be investigated. The participants will then administer nitisinone for two weeks until therapeutic dose is reached. Furosemide will then be given as a single dose together with nitisinone to investigate the PK during interaction."
2470213|NCT03103152|Experimental|High dose Aspirin & Vitamin D|Aspirin high dose (300mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
2470215|NCT03103152|Experimental|High dose Aspirin, Vitamin D placebo|high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
2470217|NCT03103152|Experimental|Low dose Aspirin , Vitamin D|Low dose aspirin (100mgs) daily & Vitamin D 4,000 IU (0.1mg) per day
2470218|NCT03103152|Placebo Comparator|Low dose Aspirin, Vitamin D placebo|Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)
2470219|NCT03103152|Experimental|Aspirin Placebo, Vitamin D|Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil
2470220|NCT03103152|Experimental|Aspirin placebo, Vitamin D placebo|Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil
2470313|NCT03102801|Active Comparator|Type 2 diabetes arm|Both arms will be subjected to Hypoglycaemia and compare results
2470317|NCT03102801|Active Comparator|Non diabetics arm|Both arms will be subjected to Hypoglycaemia and compare results
2470336|NCT03102255|Active Comparator|Conventional|Performed nasotracheal intubation as usual. Sniffing position but doesn't lift a nasal tip.
2470337|NCT03102255|Experimental|Nasal tip lifting|Performed sniffing position and nasal tip lifting while the endotracheal tube insert patient's nasal cavity.
2470388|NCT03102008|No Intervention|2 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2470393|NCT03102008|No Intervention|3 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2485828|NCT02997488||Pentax|Pentax Airwayscope
3192001|NCT00804063||2|non-glaucoma controls
3192002|NCT00804076|Experimental|NP2|Intradermal injection
3192003|NCT00804089|Experimental|1|Traditional needle acupuncture
3192004|NCT00804089|Active Comparator|2|Myofascial trigger point dry needling
3192005|NCT00804089|Active Comparator|3|Myofascial trigger point acupressure
3192006|NCT00804102|Active Comparator|Retinitis pigmentosa|
3192007|NCT00804102|Active Comparator|Macula off|condition after treatment of retinal detachment
3192008|NCT00804102|Active Comparator|Primary open angle Glaucoma|
3192009|NCT00804102|Active Comparator|Hereditary Macular Degeneration|
3192010|NCT00804102|Active Comparator|Treated Retina detachment|
3192011|NCT00804102|Active Comparator|Retinal Artery Occlusion|
3192012|NCT00804102|Active Comparator|Retinal Vein Occlusion|
3192013|NCT00804102|Active Comparator|Non-Arteriitic-Anterior-Ischemic Optic-Neuropathy|
3192014|NCT00804102|Active Comparator|Hereditary autosomal dominant Optic atrophy|
3192015|NCT00804102|Active Comparator|dry Age-related Macular Degeneration|
3192016|NCT00804102|Active Comparator|Ischemic Macula edema|
3192017|NCT00804102|Sham Comparator|Non-stimulated|
2470129|NCT03103789||GERD patients|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement and have been diagnosed with GERD will have mucosal impedance measured by single catheter and balloon assembly.
2470134|NCT03103789||control|Patients who are undergoing standard of care EGD with or without BRAVO pH capsule placement will have mucosal impedance measured by single catheter and balloon assembly.
2470207|NCT03103477||Office|"Patients presenting for a routine office visit will be asked to donate at least 50 ml of urine. The urine specimen will be aliquoted in containers, one with and one without a PAF-AH inhibitor and kept at room temperature.~The aliquots (2mL) will be frozen at predetermined intervals of 5, 10, 20, 40 and 60 min from time of collection in liquid nitrogen and then later stored in -80 freezer."
2470211|NCT03103477||Surgery|A separate group of patients undergoing surgery lasting more than 60 min operating time, will be consented as well. These patients have Foley catheters in place during the surgery. Five cc's of urine will be collected from the catheter at pre-determined intervals 5, 10, 20, 40 and 60 minutes, aliquoted (2mL) and frozen in liquid nitrogen and later stored in the -80 freezer.
2470262|NCT03102931|Experimental|Reduced ROS/RNS content products|Participants will be given and asked to smoke research cigarettes for the first 4 weeks. For the final 4 weeks of the study they will be given and asked to smoke low ROS content cigarettes.
2470297|NCT03102580|Experimental|OA Care Plan Intervention|For intervention sites, the patient and surgeon will receive the OA Care Plan (currently under development). The OA Care plan with have Patient Reported Outcomes, feedback reports, and risk factors for shared decision making.
2470298|NCT03102580|No Intervention|Usual care|As collection of Patient Reported Outcomes (PROs) is considered standard of care in orthopedics (CMS mandate, Bundled Payment requirements, and reporting for Qualified Clinical Data Registry requirement for example), usual care patients and surgeons will have the ability to see PRO scores.
2470378|NCT03102320|Experimental|Cholangiocarcinoma|"Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with cisplatin. Please note the study is no longer recruiting for the cholangiocarcinoma safety lead-in phase.~During the main study phase anetumab ravtansine will be administered at the determined MTD in combination with cisplatin. Please note the main study phase for cholangiocarcinoma will no longer be going ahead."
2470381|NCT03102320|Experimental|Adenocarcinoma of the pancreas|Safety lead-in phase will determine the MTD of anetumab ravtansine administered in combination with gemcitabine During the main study phase, anetumab ravtansine will be administered at the determined MTD in combination with gemcitabine
2470386|NCT03102320|Experimental|Other solid tumors|(Non-small cell adenocarcinoma of the lung (NSCLC adenocarcinoma), Adenocarcinoma of the breast - triple negative (TNBC), Gastric adenocarcinoma including gastroesophageal junction (GEJ Cancer, Thymic carcinoma) During the main study phase, anetumab ravtansine will be administered at dose of 6.5 mg/kg in solid tumors
2470465|NCT03101384||Patient with a diagnostic error|"Defined by one of :~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm in the next 48h00 after the firts contact with a physician~Absence of prescribed test included in an accepted pulmonary diagnosis algorithm by the first contacted physician but the diagnostic is done before 48h00 because the patient went at the emergency room on his own initiative.~More than one doctor consulted before the diagnostic of pulmonary embolism (excluding the emergency physician if the patient was referred by the 1st contact doctor)"
2470466|NCT03101384||Patient without a diagnostic error|Any patient that did not meet the criteria to define the diagnostic error
3208608|NCT00976378|Experimental|1.35 mg/kg NOX-A12|
2470602|NCT03100526|Experimental|Intervention--PACT Intensive Management|The intervention is the PACT Intensive Management Program (PIM) which provides intensive interdisciplinary care planning, care coordination, patient self-management support, and tailored goal setting based on patient needs and preferences, and additional care management services.
2470606|NCT03100526|No Intervention|Usual care|High-Risk patients receiving care in PACT.
2470614|NCT03100188|Experimental|modified PD|Patients with residual renal kt/v were placed in intervention group
2470716|NCT03099720|Experimental|intervention group|Participants are given ropivacaine (0.5%) at a total dose of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation as pre-emptive analgesia.
2470717|NCT03099720|Placebo Comparator|control group|Participants are given a placebo in the form of fluid injection of saline (0.9%) at total of 50 ml, 30 ml of which is injected locally and 20 ml into the peritoneum once before the end of operation
3157252|NCT00361348|Active Comparator|Heparin|unfractionated heparin for a 2 to 3 day heparin titation/maintenance period and continuing through a 3 day treatment period
3157253|NCT00361413|Experimental|1|Alefacept
3157254|NCT00361413|Placebo Comparator|2|
2470830|NCT03099109|Experimental|LY3321367 Dose Escalation|LY3321367 given intravenously (IV).
3157255|NCT00361465||Parkinsonian patients presenting of the dystonia|15 Parkinsonian patients presenting of the dystonia of ONE or OFF at the time of the phases of driving fluctuations. These patients must present a dystonia of the upper limb, mainly localised than the level of the segment brachial or in distality.
3157256|NCT00361465||patients carrying a primary education dystonia affecting|15 patients carrying a primary education dystonia affecting at least one of the two upper limbs, without excessive involuntary movements
3157257|NCT00361465||patients carrying a secondary dystonia|15 patients carrying a secondary dystonia (consecutive with a perinatal suffering) affecting at least one of the two upper limbs, without excessive involuntary movements
3157258|NCT00361465||pilot subjects|30 healthy pilot subjects paired in sex, age (± 5 years), dominant laterality and level of schooling (15 subjects paired with the Parkinsonian patients and 15 subjects paired with the patients dystonic
3157259|NCT00361478|Experimental|1|"Mother and Baby Program comprising exercise and education."
3157260|NCT00361478|Active Comparator|2|Education only
3157261|NCT00361517|Experimental|GM test|Twice weekly blood draws from the patients in this arm for serial GM monitoring. They will be given standard antifungal prophylaxis but no antifungal therapy unless two consecutive GM readings are positive.
3157262|NCT00361517|No Intervention|no GM monitoring|in this arm the patients will not have any GM monitoring and they will be given standard antifungal prophylaxis and treatment according to the published guidelines.
3174818|NCT00627484||Group 3: GBP diabetic|Diabetic subjects scheduled to receive gastric bypass
3208609|NCT00976378|Experimental|2.7 mg/kg NOX-A12|
2470210|NCT03103230|Experimental|Motor Evoked Potentials|Patients with aphasia after a stroke
2470263|NCT03102944||healthy volunteers|no intervention, extra blood tube taken with blood donation at bloodbank and blood is tested on IVD away from patient.
2470326|NCT03102593|Experimental|ARGX-113 Dose A + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2470327|NCT03102593|Experimental|ARGX-113 Dose B +SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2470328|NCT03102593|Placebo Comparator|Placebo + SoC|Patients will be randomized in a 1:1:1 ratio to ARGX-113 (Dose A or Dose B) or placebo
2470356|NCT03102060|Experimental|Prevention (gluten free diet)|Patients undergo a gluten free diet for 30 days during initial hospitalization for allo-SCT, from the time of admission to discharge.
2470405|NCT03101839|Experimental|AZD4785|This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met.
2470529|NCT03100916|Experimental|Dose Ranging Arm|
2470536|NCT03100916|Experimental|Food Effect arm|
2470649|NCT03100422|Experimental|ARMin|Therapy with the arm therapy robot ARMin
2470654|NCT03100422|Active Comparator|Arm+ occupational therapy|a form of conventional occupational therapy that involves both arms
2470775|NCT03099772|Experimental|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
2470806|NCT03099226|Experimental|Group 1 - BIA 5-453 50 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2470807|NCT03099226|Experimental|Group 2 - BIA 5-453 100 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2470808|NCT03099226|Experimental|Group 3 - BIA 5-453 200 mg or placebo|"This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions.~On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration.~On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast.~The patients were administered between 7:00 and 9:00 o'clock a.m"
2470883|NCT03098927|Active Comparator|Early intervention|Early intervention patients will undergo 3 weeks of motor imagery training immediately upon enrolling in the study between 3 and 6 months post spinal cord injury.
2470885|NCT03098927|Active Comparator|Late intervention|Late intervention patients will undergo 3 weeks of motor imagery training after 6 weeks of standard of care physical rehabilitation following enrollment.
3157263|NCT00361530|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
3157264|NCT00361530|No Intervention|No intervention|Patient has no intervention.
2470925|NCT03098485|Experimental|Cefpodoxime|200mg tab by mouth twice per day for 5 days
2485921|NCT02996708||Group without teleconsultation - after period|
3157265|NCT00361543|Active Comparator|1|Raloxifene Hydrochloride
3157266|NCT00361543|Placebo Comparator|2|placebo tablet
3157267|NCT00361556|Active Comparator|1|The Back Book
3157268|NCT00361556|Active Comparator|2|The Back Guide
3157269|NCT00361556|Active Comparator|3|General health book
3157270|NCT00361660|Experimental|1|Therapy is provided every other day 3 days per week (Monday, Wednesday, Friday).
3157271|NCT00361660|Active Comparator|2|The same therapy is provided daily Monday through Friday
3157272|NCT00361699|Active Comparator|Pravastatin|Patient has 10mg oral administration of Pravastatin per day. It starts within one month from their entry and continues every day until the end of the study or its endpoints.
3157273|NCT00361699|No Intervention|No intervention|Patient has no intervention.
3157274|NCT00361777||Possible Cushing's|Patients with possible cushion's syndrome
3157275|NCT00361790|Other|1|
3157276|NCT00361803|Experimental|All treated subjects|All subjects received Topotecan, administered intravenously over 30 minutes at 4 milligrams per meter^2 weekly for 3 weeks every 28 days.
3157277|NCT00361868|Experimental|1|
3157278|NCT00361868|Active Comparator|2|
3157279|NCT00361881|Experimental|1|ME-609
3157280|NCT00361881|Active Comparator|2|Acyclovir in ME-609 vehicle
3157281|NCT00361881|Placebo Comparator|3|Vehicle
3157282|NCT00361894|Experimental|Arm 1|
3157283|NCT00361894|Active Comparator|Arm 2|
3157284|NCT00361907|Active Comparator|2|Diabetic patients who meet inclusion criteria will be enrolled to start Pulsatile Intravenous Insulin Therapy on a weekly basis. Baseline testing will be performed and measured against continued testing every twelve months.
2470170|NCT03103451|Experimental|Cohort 2|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2470171|NCT03103451|Experimental|Cohort 3|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2470172|NCT03103451|Experimental|Cohort 4|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2470173|NCT03103451|Experimental|Cohort 5|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2470174|NCT03103451|Experimental|Cohort 6|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
2470175|NCT03103451|Experimental|Cohort 7|"This cohort includes up to 6 subjects in BCD-121 group and 1 subject in placebo group.~Intervention: BCD-121/ placebo"
3192018|NCT00804115|No Intervention|1|Latanoprost in combination with Pilocarpine
3192019|NCT00804115|No Intervention|2|Timolol or Cosopt
2470280|NCT03102515|Other|Spinal-anesthesia|Caesarean section performed under spinal anaesthesia and receiving either USG-TAP block or CIC
2470281|NCT03102515|Other|Epidural-anesthesia|Caesarean section performed under epidural anaesthesia and receiving either USG-TAP block or CIC
2470377|NCT03102450|Experimental|Benzalkonium Chloride Spermicide Cream|Pharmatex 1,2% vaginal cream (benzalkonium chloride 1,2g per 100g of vaginal cream)
2470444|NCT03101618||Allergic LAR|Laboratory animal researchers who experienced allergic symptom during exposure to laboratory or pet animals
2470446|NCT03101618||Non-allergic LAR|Laboratory animal researchers who did not experience allergic symptom during exposure to laboratory or pet animals
2470453|NCT03101618||Allergic PO|Pet owners who experienced allergic symptom during exposure to pet animals
2470457|NCT03101618||Non-allergic PO|Pet owners who did not experience allergic symptom during exposure to pet animals
2470458|NCT03101618||Allergic PIW|Allergic pet-related industry workers who experienced allergic symptom during exposure to pet animals
2470459|NCT03101618||Non-allergic PIW|Allergic pet-related industry workers who did not experience allergic symptom during exposure to pet animals
2470512|NCT03101137|Active Comparator|Caudal block with dexmedetomedine|Caudal Dexmedetomidine block group (DEXM) (n= 16) will receive caudal block using the bupivacaine 0.25% and Dexmedetomidine 1 μg/kg with the conventional general anesthesia,
2470521|NCT03101137|Active Comparator|Caudal block with dexamethasone|caudal Dexamethasone Block group (DEXA) (n =16) will receive caudal block using the bupivacaine 0.25% and Dexamethasone 0.1 mg/kg with the conventional general anesthesia,
2470527|NCT03101137|Placebo Comparator|Control (caudal block with bupivacaine)|caudal with bubivacaine (CONTROL) group (n = 16) will receive caudal block using the bupivacaine 0.25% and general anesthesia.
2470560|NCT03100656|Other|Anorexia nervosa I|Anorexia nervosa with BMI <=17.5 kg/m² or BMI >17.5 kg/m² with regular binge-purge episodes
2470561|NCT03100656|Other|Anorexia nervosa II|Anorexia nervosa with BMI > 18.5 kg/m² for at least 12 months.
2470562|NCT03100656|Other|Controls|Healthy control women
2470603|NCT03100461|Active Comparator|HE + HE|Participants receive up to two interventions. Participants receive HE initially and then a second time if not screened after 6 months.
2470607|NCT03100461|Active Comparator|HE + I2|Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
2470608|NCT03100461|Experimental|I2 + I2|Participants receive up to two interventions. Participants receive I2 initially and then a second time if not screened after 6 months.
2470609|NCT03100461|Active Comparator|I2 + HE|Participants receive up to two interventions. Participants receive I2 initially and then HE if not screened after 6 months.
3192021|NCT00804180|Other|Coping skills intervention|Self-Injection Anxiety Counseling: Evaluation of a group treatment for injection-related anxiety. The intention of the study is to obtain basic evaluation of a clinical treatment offered in a natural clinic setting, and does not include a control group, or procedure for random assignment of participants.
2470778|NCT03099512|Experimental|Ex+SFE Group|Individuals in this group who will perform exercises for knee and also short foot exercise
2470780|NCT03099512|Active Comparator|Ex Group|Individuals in this group who will perform exercises for knee only
3192022|NCT00804206|Experimental|Group A|Bevacizumab before panretinal photocoagulation.
3192023|NCT00804206|Experimental|Group B|Bevacizumab after panretinal photocoagulation
3192024|NCT00804219|Experimental|TBE low responder|
2471090|NCT03097237|Experimental|Wholegrain rye|Wholegrain rye products with a high content of dietary fiber
2471093|NCT03097237|Active Comparator|Refined wheat|Refined wheat products with a low content of dietary fiber
2471123|NCT03096977|Experimental|CHUB-TST02 patients|All patients who participated in the NCT02805634 (CHUB-TST02) study.
2471184|NCT03096574||Pregnant women|"Over the age of 16~Under the care of staff working in: University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
2471185|NCT03096574||Maternity healthcare professionals|"Over the age of 18~Working in obstetrics or midwifery who regularly care for women in pregnancy at University Hospital Southampton NHS Foundation Trust, St Georges Healthcare NHS Trust, Oxford University Hospitals NHS Foundation Trust or University Hospitals Bristol NHS Foundation Trust~Able to read and write in English and give fully informed consent"
2471186|NCT03096574||UK General Practitioners|"Fully-qualified general practitioners practicing in the UK~Able to read and write in English and give fully informed consent"
2471360|NCT03095391||Cohort 1|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: none Comparator dose: none
3192025|NCT00804219|Experimental|FSME responder|
3192026|NCT00804219|Experimental|hepatitis B non-responder|
3192027|NCT00804232|Experimental|1|effects on child health of family-based home care compared to traditional hospital-based care,
2470310|NCT03102775|Experimental|Comprehensive follow-up program|15 offices have been randomized to experimental group. Experimental group offices implement the HOLF model developed by the Labor and Welfare Administration
2470316|NCT03102775|Active Comparator|Local family projects|14 offices have been randomized to control group. these implement local family projects. These are developed based on local practice needs
2470348|NCT03102099||contrast-enhanced ultrasound group|The contrast-enhanced ultrasound(CEUS)patients will undergo biopsy with contrast-enhanced ultrasound guidance.
2470350|NCT03102099||conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
3157285|NCT00361907|Placebo Comparator|1|Circulating blood markers will be performed on diabetic control patients at baseline and every twelve months to compare and measure against patients treated with Pulsatile intravenous insulin therapy
3157286|NCT00361933|Experimental|1|
2470541|NCT03100903|Experimental|BI 655130|
2470572|NCT03100799|Other|Patients with osteoarthritis of the knee|This is an exploratory non-drug, interventional biomarker study, however, there are study related procedures which are interventional such as arthroscopy, arthrocentesis and MRI assessment with infusion of a gadolinium-contrast agent.
2470645|NCT03100318|Experimental|FYU-981|
2470648|NCT03100318|Active Comparator|Benzbromarone|
2470784|NCT03099798||Non-Operative Management (NOM)/Observational|"Patients treated observationally for (traumatic) spleen injury."
2470787|NCT03099798||Splenic Artery Embolization|Patients treated with splenic artery embolization for (traumatic) spleen injury.
2470792|NCT03099798||Surgery|Patients treated surgically for (traumatic) spleen injury.
2470869|NCT03098992|Active Comparator|Fotona Dynamis Er:YAG Laser System|Active treatment with Fotona Dynamis Er:YAG Laser System
2470874|NCT03098992|Sham Comparator|Fotona Dynamis Er:YAG Laser System with Sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
2470945|NCT03098524|Experimental|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with 5 acts/minute, tidal volume = 3 ml/kg (ideal body weight) with positive end-expiratory pressure = 5 cmH2O
2470946|NCT03098524|Placebo Comparator|No ventilation (noV arm)|No mechanical ventilation during cardiopulmonary bypass.
2471018|NCT03097913||video-stylet tube assembly|patients who undergo oxo-maxillofacial surgery with nasotracheal intubation general anesthesia are recruited
2471156|NCT03097016|Experimental|Single oral dose of 3 mg CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
2471265|NCT03096171|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
2471266|NCT03096171|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program for 16 weeks.
2471303|NCT03095768|Experimental|Intervention|Lifestyle Education and Cooking Demonstration
2471428|NCT03095040|Experimental|CM082 combined with everolimus|
2471431|NCT03095040|Experimental|CM082|
2471433|NCT03095040|Active Comparator|Everolimus|
3157287|NCT00361946||lean subjects|BMI <85th for age, normal glucose tolerance
2471545|NCT03094169|Experimental|Dose escalation|Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
2471547|NCT03094169|Experimental|Phase 2a Triple Negative Breast Cancer|Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
2471549|NCT03094169|Experimental|Phase 2a Head and Neck Carcinoma|Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
2471551|NCT03094169|Experimental|Phase 2a Non-Small Cell Lung Carcinoma|Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
2471571|NCT03093805|Experimental|Calcipotriene|Patients will apply Calcipotriene cream 2 times per day for 7 days.
2471695|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 1)|Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects
2471696|NCT03093714|Experimental|FDL 169 test formulation (Dose Level 2)|Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects
2471698|NCT03093714|Experimental|FDL 169 test formulation ( Dose Level 3)|Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects
3157288|NCT00361946||obese subjects|BMI> 95th for age normal glucose tolerance
3157289|NCT00361946||Type diabetes|BMI > 85th for age , history of Type 2 diabetes as per ADA criteria
3157290|NCT00361985|Experimental|1|Nexium group
3157291|NCT00362063|Experimental|growth hormone|children with proven growth hormone deficiency
3157292|NCT00362063|No Intervention|healthy controls|No growth hormone is given
3157293|NCT00362089|Active Comparator|Marinol|Intervention group with Marinol D40 fish oil capsules
3157294|NCT00362089|No Intervention|Nutrition counseling|Control group
3157295|NCT00362206|Experimental|1|
3157296|NCT00362206|Experimental|2|
3157297|NCT00362206|Active Comparator|3|
3157298|NCT00362219|Placebo Comparator|Placebo|Gel with no active ingredient
3157299|NCT00362219|Active Comparator|Morphine .25 mg|Gel with 0.25 mg morphine per 100cm2 square of wound
3157300|NCT00362219|Active Comparator|Morphine - .75 mg.|Gel with 0.75 mg morphine per 100cm2 square of wound.
3157301|NCT00362219|Active Comparator|Morphine 1.25 mg.|Gel with 1.25 mg morphine per 100cm2 square of wound.
3157302|NCT00362271|Other|1|
3157303|NCT00362284|Experimental|NYUCI-AC group|Adult children in this arm received the NYUCI-AC intervention, which consisted of 6 individual and family counseling sessions, the offering of an adult child specific support group, and the provision of ad hoc, or ongoing, consultation throughout the duration of participation.
3157304|NCT00362284|No Intervention|Usual care control|Adult children randomly assigned to the usual care control did not receive the NYUCI-AC intervention. If they were in crisis or required support, the NYUCI-AC counselors provided information and referral on an as-needed basis.
3157305|NCT00362323|Experimental|1|
2470242|NCT03103386|Placebo Comparator|Refined Wheat group|Intake of food product with common refined wheat: Corresponding crisp bread and extruded product will be produced using refined wheat flour. Two crisp bread pieces (2 x 12 g) were packed into moisture and air tight portion package. Participants are advised to consume 4 pieces daily.Wheat puff was packed into 2 moisture and air tight portion bags. Participants are advised to consume 2 bags daily.Total energy: 513 kcal/day.
3157306|NCT00362323|Active Comparator|2|
2470491|NCT03101605|Experimental|e-learning|The intervention for this study will be the completion of an original E-learning module on AOM designed by a team of pediatric residents, pediatricians, a pediatric otolaryngologist, a pediatric emergency physician and a pediatric infectious diseases specialist. The module includes interactive sections on anatomy, epidemiology, pathophysiology, microbiology, diagnostic criteria, treatment options and prognosis. A 5 minute video demonstrating appropriate pediatric ear examination techniques is also included in the module. Throughout the module, many examples of ear pathologies captured on video during a previous study. The E-learning module should take 0.5 hr to complete.
2470492|NCT03101605|Other|Standard teaching|"The control group will receive a 2h lecture on AOM, which is the standard teaching method. Given by a pediatrician or a senior pediatric resident, this lecture, using a PowerPoint© presentation support, encompasses clinical cases, notions of anatomy, epidemiology, pathophysiology, diagnostic criteria, treatment options, and prognosis, describes different ear examination techniques, and shows examples of different pathologies."
2470499|NCT03100981|Experimental|Internet-delivered MBCT|The intervention group will immediately receive 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy.
2470502|NCT03100981|Other|Waitlist control|The control group will be on a waiting list to participate in Internet-delivered MBCT after the 6-months follow-up time has passed.
3157307|NCT00362349|Experimental|1|IVIg
3157308|NCT00362427|Experimental|Group A|
3157309|NCT00362427|Experimental|Group B|
3157310|NCT00362427|Active Comparator|Group C|
3157311|NCT00362479|Experimental|1|
3157312|NCT00362518|Placebo Comparator|1|Study Arm A - Control: no vitamins (placebo only).
2470736|NCT03099590|Experimental|Active Treatment, Alkontrol-herbal|Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
2470741|NCT03099590|Placebo Comparator|Placebo Control|Matched dextran containing capsules will serve as placebo.
2470803|NCT03099343|Experimental|Location-based Tailored Messaging|Participants receive location-based tailored messaging via a mobile application throughout the 8-week research study.
2470805|NCT03099343|No Intervention|Control Group|Participants follow their usual eating pattern and will not have access to the application throughout the 8-week research study.
2470938|NCT03098706|Other|NT normothermia|After information for donation and research has been explained, organ donors in the normothermia (NT) group will either be maintained to spontaneously reach a body temperature of 36,5 °C-37,5°, until transfer to the operating room.
2470941|NCT03098706|Experimental|HT mild hypothermia|The intervention will take place after information for donation and research has been explained . Organ donors in the intervention group will either be actively warmed or allowed to reach a body temperature of 34 °C-35°C, until transfer to the operating room.
2471030|NCT03097601||sunitinib cohort|independent cohorts of patients who received sunitinib for metastic kidney cancer, on who we intend to demonstrate that ELR+CXCL cytokines levels are of sunitinib response
2471072|NCT03097497|Experimental|Physiotherapy re-education program|Physiotherapy re-education program based on the pre-activation of the transverse abdominal muscle, performed with progressive difficulty and supervised at all times by an expert physiotherapist. The intervention will last 4 weeks, with two weekly sessions of 30-35 minutes each. Sessions will be held individually.
2471074|NCT03097497|Active Comparator|Conventional treatment by GP|"Will follow conventional treatment prescribed by the general practitioner in a primary care consultation. This conventional treatment is based on the clinical guidlines of the Institut Català de la Salut~http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf"
2471138|NCT03097094|Active Comparator|Male dog|Male dog extract used for skin prick test and conjunctival provocation
2471146|NCT03097094|Active Comparator|Female dog|Female dog extract used for skin prick test and conjunctival provocation
2471211|NCT03096678||LBBB without LV dysfunction|LVEDD>55mm or LVEF<55%
2471212|NCT03096678||LBBB with LV dysfunction|LVEDD<55mm and LVEF>55%
2471244|NCT03096223|Experimental|KHK4083|
2471277|NCT03095963|Active Comparator|Probiotics|The study group took a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®) in addition to levothyroxine
2471279|NCT03095963|Active Comparator|Levothyroxine|The control group took levothyroxine only
2471307|NCT03095612|Experimental|Selinexor in Combination with Docetaxel|Selinexor will be administered once weekly starting one week before chemotherapy initiation in combination with docetaxel. Docetaxel will be given once every 3 weeks. Treatment will be administered in 21-day cycles. Selinexor dose escalation: 60, 80, 100, 40 mg once weekly. Docetaxel 75 mg/m2 IV, 60 every 3 weeks.
2471603|NCT03093779||Hearing|Individuals with no hearing loss and who communicate in spoken English.
3157313|NCT00362518|Active Comparator|2|Study Arm B - Low Dose: Vitamin C 250 mg, Vitamin E 200 IU
3157314|NCT00362518|Active Comparator|3|Study Arm C - Medium Dose: Vitamin C 500 mg, Vitamin E 400 IU
3157315|NCT00362518|Active Comparator|4|Study Arm D - High Dose: Vitamin C 1000 mg, Vitamin E 800 IU.
3157316|NCT00362687|Experimental|1|Truvada 1 tablet once a day.
3157317|NCT00362687|Experimental|2|Emtricitabine 1 capsule once a day
3157318|NCT00362713|Experimental|A|3 mg/kg or 10 mg/kg
3157319|NCT00362726|Active Comparator|A|
3157320|NCT00362726|Active Comparator|B|
3157321|NCT00362726|Active Comparator|C|
3157322|NCT00362726|Active Comparator|D|
3157323|NCT00362726|Active Comparator|E|
3173326|NCT00610831|Experimental|DirectView CR Mammography|Each subject will have routine clinical care imaging obtained and 4 standard mammogram views (RMLO, RCC, LMLO, LCC) using CR mammography. If routine mammograms were obtained on a day previous to enrollment in the study, those images (4 views; 2 views for mastectomy patients) will not be repeated for this study; only the CR images will be obtained.
2470279|NCT03102554|Experimental|Genetic Testing|Subjects will provide a DNA sample, which will be screened for variants in genes related to DSD/hypospadias. Probands/parents who wish to receive results of genetic testing related to DSD/hypospadias will receive these results directly from the research study. Parents who receive results of genetic testing for probands 17 years old or younger will complete questionnaires at the time of enrollment, right after receiving genetic results, and 3 months after receiving genetic results.
2470383|NCT03102424|Experimental|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
2470389|NCT03102424|Placebo Comparator|Sham DW1330 device|The 20 weeks of treatment of the Sham DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
2470487|NCT03101644|Other|Darunavir|All patients treated with darunavir
2470501|NCT03101007|Experimental|ATTUNE|Total Knee Replacement Surgery with cementless ATTUNE Rotating Platform Knee Prosthesis by DePuy
2470503|NCT03101007|Active Comparator|LCS|Total Knee Replacement Surgery with cementless LCS Rotating Platform Knee Prosthesis by DePuy
2470563|NCT03100851|Experimental|LcS intervention|Patients with constipation received dietary supplement with Lactobacaiilus casei strain Shirota.
2470611|NCT03100487|Experimental|Audio Record Guided Imagery (ARGI)|The audio recorded guided imagery sessions (treatment) will be delivered through a digital audio player (Apple iPod Shuffle).
2470612|NCT03100487|Experimental|Deep Breathing Exercises|The deep breathing exercises (control) will be delivered through a digital audio player (Apple iPod Shuffle).
2470637|NCT03100110|Experimental|NeuroCognitive Communicator|
2470698|NCT03099876||7 days treament group|7 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
2470699|NCT03099876||10 days treatment group|10 days of triple therapy (Ilaprazole 10mg, Clarithromycin 500mg Amoxicillin 1000mg B.I.D)
2470750|NCT03099525||RA-ILD|Patients who are diagnosed with ILD. No intervention in this study.
2470752|NCT03099525||RA-non ILD|Patients who are not diagnosed with ILD. No intervention in this study.
2470793|NCT03099291|Experimental|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|Participants will receive a single dose of the RSV D46/NS2/N/ΔM2-2-HindIII vaccine at study entry (Day 0).
2470795|NCT03099291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2470828|NCT03099070|No Intervention|Control, Not-Fasting|Participants will experience the control intervention and will not fast prior to the lab visit.
2470829|NCT03099070|Experimental|Control, Fasting|Participants will experience the control intervention and will fast prior to the lab visit.
2470831|NCT03099070|Experimental|Stress, Not-Fasting|Participants will experience the stress intervention and will not fast prior to the lab visit.
2470833|NCT03099070|Experimental|Stress, Fasting|Participants will experience the stress intervention and will fast prior to the lab visit.
3157324|NCT00362739||1: Lung Disease|Individuals with at least one of the following: (1)symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; (7) individuals suspected of history of lung diseased based on history and/or physical examination
3157325|NCT00362739||2: Normal Controls|Individuals without a history of lung disease
3157326|NCT00362752|Placebo Comparator|Placebo|
2470967|NCT03098160|Experimental|Evofosfamide plus Ipilimumab|Ipilimumab to be administered at same dose. Evofosfamide dose to be determined during duration of trial
2471009|NCT03097991|Experimental|Intervention: Treatment as Usual + Focused Coparenting Consult|Receipt of Treatment As Usual/Resource and Referral supports, plus opportunity to complete six 90-minute Focused Coparenting Consultation (FCC) sessions followed by one postnatal booster session designed to strengthen the mother-father coparenting alliance
2471010|NCT03097991|No Intervention|Control: Treatment as Usual|Receipt of TAU/Resource and Referral supports
2471062|NCT03097575|Experimental|ICG Intervention|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
2471111|NCT03097224|Experimental|Prehabilitation group|Tele-supervised prehabilitation
2471112|NCT03097224|No Intervention|Control group|Usual care
2471157|NCT03096821||ngFDS selected treatment|Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).
2471203|NCT03096535|Experimental|Cooling|Individualized cooling protocol.
2471204|NCT03096535|Experimental|Thermoneutral|Thermoneutral condition day.
2471242|NCT03096249|Experimental|Oxytocin|Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716) will be used for intranasal administration of a single intranasal dose of 24 international units (IU; 3 puffs of 4 IU per nostril)
2471243|NCT03096249|Placebo Comparator|Placebo|Physiological water (sodium chloride (NaCl) solution) Administration via nasal spray
2471330|NCT03095820|Active Comparator|Supportive therapy|The control group received supportive therapy for 12 weeks. In addition to a telephone call once a week and a home visit once a month, this program consisted of identification of physical problems, encouragement of general exercise, encouragement of pleasant activities, and so forth. The control program did not feature any specific goal setting by the participants, specific education about the benefits of achievement of such goals, or symbolic prizes.
2471362|NCT03095391||Cohort 2|GFR: ≥ 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 2 Comparator: Iohexol 5 mL Comparator dose: 1
2471365|NCT03095391||Cohort 3|GFR: ≥ 30 and < 60 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
2471367|NCT03095391||Cohort 4|GFR: ≥ 15 and < 30 mL/min/1.73 m2 VFI dose: 47 mg/3 mL Number of doses: 1 Comparator: Iohexol 5 mL Comparator dose: 1
2471419|NCT03095079|Experimental|EDP|Dacarbazine,DTIC： 250 mg/m2/d，IV, d1-5 Cisplatin PDD：75 mg/m2，IV Endostar ENDO：15 mg/m2/d，CIV,d1~14
2471429|NCT03094936|Other|Group A|This group own twenty patients who met all the inclusion criteria. These will be treated with APC.
2471490|NCT03094598|No Intervention|Control|No intervention
3157327|NCT00362752|Experimental|Norfloxacin 400 mg bid|
2470284|NCT03102788|Experimental|Intervention|Patients in the intervention group will receive their first consultation in specialist health care by an occupational therapy specialist. Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
2470344|NCT03102333|Active Comparator|Constant-rate Infusion|INTERVENTION : Constant-rate Infusion mode : The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
2470345|NCT03102333|Active Comparator|Variable-rate Feedback Infusion|INTERVENTION : Variable-rate Feedback Infusion mode :The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
2470484|NCT03101748|Experimental|Group A (Cohort 1 Phase Ib)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
2470485|NCT03101748|Experimental|Group B (Cohort 1 Phase II)|Patients receive neratinib, paclitaxel, pertuzumab, and trastuzumab as in Group A. Patients then receive doxorubicin IV and cyclophosphamide IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery.
2470486|NCT03101748|Experimental|Group C (Cohort 2)|Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery/ Patients then receive doxorubicin and cyclophosphamide as in Group B. Patients then undergo standard of care surgery.
2470623|NCT03100162|Placebo Comparator|Placebo|Individuals receive a placebo daily, for 3 months.
2470625|NCT03100162|Active Comparator|Probiotic 2g|Individuals receive 2 g of probiotic daily, for 3 months.
2470626|NCT03100162|Active Comparator|Probiotic 4g|Individuals receive 4 g of probiotic daily, for 3 months.
2470690|NCT03099902||Cases|Children with asthma/wheezing whose mothers were active smokers during pregnancy
2470691|NCT03099902||Controls|Children without asthma/wheezing whose mothers were active smokers during pregnancy
2470747|NCT03099551|Active Comparator|Manual Toothbrush users|Group using manual toothbrush Curaprox 5460 Ultra Soft
2470748|NCT03099551|Active Comparator|Sonic Toothbrush users|Group using sonic toothbrush Edel White
3192028|NCT00804232|Experimental|2|effects on child health of family-based psychological treatment compared to traditional hospital-based treatment
3192029|NCT00804245|Experimental|radiolabeled choline tracer scans|PET-CT scans supplemented with Choline 11 tracer
2471095|NCT03097250||PKU Subjects|Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
2471098|NCT03097250||Controls|Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.
2471129|NCT03096925|Experimental|Intervention group|The intervention group will receive guided self-help comprising six web-based sessions, comprising information, exposure to physical activity, how worry can excess pain, physical reactions to pain and worry, consequences of avoidance, and specific panic treatment. The first session will be done at the hospital before discharge, the others at home. Between sessions there will be a brief telephone contact with a project worker.
2471143|NCT03096925|No Intervention|Control group|This group will receive treatment as usual, which is no specific treatment. They can however use the general health system as they like.
2471213|NCT03096301|Experimental|Low-intensity laser|Twelve laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2, in accordance with the protocol suggested by Venezian et al. (2010) and Carvalho et al. (2010). The laser will be applied to 3 points of the masseter muscle (upper, middle, and lower bundles) and 1 point in the anterior temporalis on each side of the face
2471292|NCT03095755|Experimental|Ischemic Conditioning|The investigators will perform ischemic conditioning on the paretic leg by inflating a blood pressure cuff to 225 mmHg to occlude blood flow to the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
3192030|NCT00804271|Other|Memantine|
2470291|NCT03102567|Experimental|GLPG1205 250 mg loading and 50mg q.d. maintenance|open label - oral hard gelatin capsules with 50 mg GLPG1205 for one time 250 mg loading dose and subsequent 50mg q.d. administration
2470339|NCT03102346|Experimental|Home-based Cardiac Rehabilitation group|remote instructed exercise training at home
2470341|NCT03102346|No Intervention|routine group|no instructed exercise training
2470392|NCT03101956|Experimental|L/S Manipulation Study Group|
2470397|NCT03101956|Active Comparator|Control Group|
2470442|NCT03101709|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
2470508|NCT03101202|Experimental|SSD Arm|In the SSD arm, the patients will be intubated with an endotracheal tube with suglottic suction drainage (SSD tube)
2470517|NCT03101202|No Intervention|Standard Arm|In the standard arm, the patients will be intubated with the standard endotracheal tube which does not have subglottic suction.
2470586|NCT03100812|Experimental|Group A|
2470591|NCT03100812|Experimental|Group B|
2470644|NCT03100292|Experimental|bariatric surgery|"This trial is a single-arm study and the enrolled patients are going to undergo sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB).~If the patient has Barrett's esophagus on the preoperative endoscopy, SG is not permitted. Inflammatory bowel disease and Helicobacter pylori infection on a rapid urease test are contraindications of RYGB."
2470794|NCT03099811|Experimental|Intervention: Financial incentives + Smoking cessation program|Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
2470796|NCT03099811|Other|Intervention: Smoking cessation program|Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
2470893|NCT03098810|Placebo Comparator|Normal children|Placebo
2470895|NCT03098810|Experimental|Malnourished children|Oral zinc sulphate syrup
3157328|NCT00362765|Experimental|1|
2471016|NCT03097926|Active Comparator|Standard BPD-DS|Standard BPD-DS with a 250-cm alimentary limb and 100-cm common channel
2471017|NCT03097926|Experimental|Long alimentary limb BPD-DS|BPD-DS with a 100-cm common channel, a 100-cm biliary limb, the remaining bowel as the strict alimentary channel
2471049|NCT03097640|Experimental|CHAMP|Participants enrolled in CHAMP are followed by a team of a social worker and physician across the care continuum. CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
2471051|NCT03097640|No Intervention|Standard Care|Individuals in the standard care arm will receive care as they do normally when hospitalized, including medical and inpatient social work services, as well as outpatient care from their providers.
2471131|NCT03096886|Experimental|Early CCBT|"Intervention: Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to receive 8 weeks of Computer-Augmented Cognitive Behavior Therapy (CCBT) immediately after completing pre-treatment assessments; imaging data will be collected pre- and post-treatment."
2471141|NCT03096886|Experimental|Late CCBT|"Intervention: Waitlist followed by Computer-Augmented Cognitive Behavioral Therapy~Half of participants presenting with MDD will be randomized to be waitlisted for up to 4 weeks and will receive CCBT within 4 weeks; imaging data will also be collected pre--treatment, following waitlist, and post-treatment of CCBT.~This arm will serve as the equivalent of a placebo comparator arm during the waitlist; and then as an experimental arm when receiving 8 weeks of CCBT treatment."
2471150|NCT03096886|No Intervention|Matched Comparison|"No Intervention: Matched Comparison~Healthy controls will act as a matched comparator. Participants will complete pre-treatment assessments and imaging."
2471189|NCT03096561|Other|Hypothermia related cardiac arrest|blood draw from three different vessels punctured in the emergency room (central vein, peripheral vein, artery) and comparison of potassium rate and other biological values between the different sites of blood draw and two different measuring techniques (laboratory vs. blood gas analyser)
2471263|NCT03096418|Experimental|Weekly Paclitaxel|"Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle.~Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery."
2471407|NCT03095235|Experimental|Treatment with riboflavin|Patients will take 400 mg dietary riboflavin per day and go outside without sunglasses for 15 minutes per day to evaluate the effects of riboflavin B2 and natural UV light from sun exposure on cornea cross linking and stabilization of ectatic disease.
2471462|NCT03094923|Experimental|Inspiratory muscle training|Inspiratory muscle training with threshold device and workloud 30% of the peak inpiratory preassure, during two weeks prior to surgery, seven days a week, twice a day, three sets of ten repetitions with supervision.
2471466|NCT03094923|No Intervention|Control group|Control group will receive a supportive educational component in the preoperative period.
2471604|NCT03094429|Active Comparator|NaBen® - 2000 mg/day|Two NaBen® ( 500 mg) will be taken twice daily at a total dose of 2000 mg/day during this study.
2471606|NCT03094429|Active Comparator|NaBen® - 1000 mg/day|One NaBen® (500 mg) and one placebo will be taken twice daily at a total dose of 1000 mg/day during this study.
3157329|NCT00362765|Active Comparator|2|
3157330|NCT00362765|Active Comparator|3|
3157331|NCT00362765|Placebo Comparator|4|
3157332|NCT00362778|Sham Comparator|Serum saline|
3157333|NCT00362830|Experimental|1|
3157334|NCT00362856|Placebo Comparator|Placebo + Gluten|placebo TID + gluten 800 mg TID administered orally in capsules
3157335|NCT00362856|Placebo Comparator|Placebo + Gluten placebo|placebo TID + gluten placebo TID administered orally in capsules
3173327|NCT00610844|Experimental|1|pulmonary radiofrequency ablation
2470294|NCT03102502|Active Comparator|Control|Patients receive guideline- driven standard medical therapy for 7 weeks without Enhanced External Counterpulsation intervention.
2470394|NCT03102294|Active Comparator|Experimental: IMT|inspiratory muscle training (PowerBREATHE) with ~50% of maximum inspiratory pressure
2470399|NCT03102294|Placebo Comparator|Placebo: SHAM|inspiratory muscle training (PowerBREATHE) without inspiratory load
3192031|NCT00804284||Pentacel Group|Infants initiated on PENTACEL® vaccine
3192032|NCT00804284||Other DTap vaccines Group|Infants initiated on other DTaP vaccines
2470599|NCT03100565|Placebo Comparator|colposcopic biopsy under local anesthetic sp|
2470600|NCT03100565|Placebo Comparator|Patients underwent colposcopic biopsy under forced coughing|
2470647|NCT03100201|Active Comparator|Intervention Armeo®Spring|The intervention group will receive conventional occupational- and physiotherapy and an additive robotic-assisted training using the Armeo®Spring robot for three weeks.
2470651|NCT03100201|Active Comparator|Control group|The control group will receive conventional occupational- and physiotherapy.
2470731|NCT03099733|Experimental|concussion|patients who present to ED with concussion
2470799|NCT03099395||No re-MI, one re-MI, > one re-MI|From a population with MI surviving one year (78 468 pts) the number of pts with no re-MI, one re-MI or > re-MI will be described.
2470817|NCT03099122|Experimental|Thymoglobuline|"A cumulative dose of Thymoglobuline will be given intravenously, with a variable interval dose. Methylprednisolone will be given as induction therapy, according to institutional practice.~Tacrolimus, mycophenolate, and prednisone will be given as maintenance therapies."
2470871|NCT03098901|Other|no other arm|
2470924|NCT03098680|Experimental|Group A (Placebo, Salbutamol, Nicardipine, Dobutamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage infusion with dose increasing at each stage. Each stage will be 30 minutes in duration.~Placebo; Salbutamol(Albuterol) Sulfate (Dose: 2mcg/min, 5mcg/min, 10mcg/min); Nicardipine Hydrochloride (Dose: 1mg/hr, 2.5mg/hr, 5mg/hr); Dobutamine Hydrochloride (Dose: 1mcg/kg/min, 2.5mcg/kg/min, 5mcg/kg/min)"
2470926|NCT03098680|Experimental|Group B (Placebo, Phenylephrine, Verapamil, Phentolamine)|"Participants will receive each drug, to be given on separate study days. The drugs will be given as a 3 stage bolus with dose increasing at each stage. Each stage will be 30 minutes apart.~Placebo; Phenylephrine Hydrochloride (Dose: 100mcg, 200mcg, 300mcg); Verapamil Hydrochloride (Dose: 1mg, 2.5mg, 5mg); Phentolamine Mesylate (Dose: 1mg, 2mg, 3mg)"
2470988|NCT03098121|Experimental|Genotype 1 HCV and HIV co-infection|Patients with chronic Genotype 1 HCV and HIV co-infection, with or without resistance-associated substitution (RAS) of NS5A, received grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and patients with chronic genotype 1b received grazoprevir and elbasvir once daily for 12 weeks.
2471057|NCT03097809||Epilepsy Subjects|Subjects will be recruited from the epilepsy-monitoring unit. These subjects would have been already assessed by the Epilepsy Center at the Cleveland Clinic for surgical treatment of medically refractory epilepsy and would have already had SEEG electrodes placed in cortical and limbic areas for clinical diagnostic purposes.
2471100|NCT03097276|Other|Patients who underwent open decompression surgery|
2471135|NCT03096912|Experimental|Ribociclib|Oral, ribociclib 600 mg x 1 a day, 21 days on 7 days off
2471193|NCT03096665||Blood test group|All patients receive the three types of blood test (venous blood test, skin puncture blood (capillary blood) test and arterial blood gas analysis
2471229|NCT03096392|Experimental|HDV insulin lispro 100 UNT/mL|insulin lispro with 0.8 ml HDV added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
2471232|NCT03096392|Active Comparator|insulin lispro 100 UNT/ML|insulin lispro with 0.8 ml sterile water for injection added to a 10 ml vial of insulin lispro, injected subcutaneous before meals as needed. Study duration of 7 weeks (6 weeks of treatment)
3192033|NCT00804310|Experimental|Lapatinib and Ixabepilone|
2471320|NCT03095547|Experimental|F901318 & cyclosporine A & tacrolimus|Interaction between cyclosporine A and tacrolimus with F901318
2471324|NCT03095547|Experimental|F901318 & posaconazole|Interaction between posaconazole and F901318
2471326|NCT03095547|Experimental|F901318 & pantoprazole|Interaction between pantoprazole and F901318
2471328|NCT03095547|Experimental|F901318|F901318 alone
2471386|NCT03095144||Spinal anesthesia|Lumbar puncture was performed with a midline approach through either the fourth or fifth lumbar space using a 22 or 25 -gauge 4 cm disposable styletted needle. Spinal isobaric Bupivacaine 0.5%, 0.8-1 mg.kg-1 without epinephrine was injected using a 1ml tuberculin syringe.
2471389|NCT03095144||General anesthesia|The General anesthesia is preformed by intravenous Propofol (2-4 mg.kg-1) and Fentanyl (1-2 µg.kg-1) and Rocuronium bromide (0.5mg.kg-1) administration to facilitate endotracheal intubation, assisted by Sellick manoeuvre. Anaesthesia maintenance with Sevoflurane (2-3%) in an air/oxygen mixture, intravenous Fentanyl as required.
2471446|NCT03095014|Experimental|Cesarean Myomectomy|Myomectomy plus Cesarean section
2471450|NCT03095014|Active Comparator|Cesarean section|Cesarean section only
2471509|NCT03094520|Experimental|Anodal tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with anodal stimulation
2471511|NCT03094520|Sham Comparator|Sham tDCS + semantic, motor, attentional tasks|Combination of gestural (subjects have to indicate if the gesture is related to the word), attentional and motor tasks with sham stimulation
2471607|NCT03094091|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2471610|NCT03094091|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2471682|NCT03093532|No Intervention|Usual Care|The Usual Care group arm will received pre-printed discharge instructions and an outpatient referral. (This group represents standard of care.)
2471693|NCT03093298|Experimental|Obesity|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling
3192034|NCT00804323|Experimental|Group 1|Patients with open-angle glaucoma
3208610|NCT00976378|Experimental|5.4 mg/kg NOX-A12|
3208611|NCT00976378|Experimental|10.8 mg/kg NOX-A12|
3208612|NCT00976378|Experimental|5.4 mg/kg NOX-A12 plus apheresis|
3208613|NCT00976417||1. Patients in the control group|
2470295|NCT03102632|Experimental|High Water Intake|After a 6 month period of usual water intake, a high water intake daily amount will be prescribed for 1 year.
2470330|NCT03102385|Experimental|Motivational Interview|Complete an on-line motivational interview regarding participants' blood donation experience.
2470332|NCT03102385|Placebo Comparator|Knowledge Interview|Complete an on-line interview regarding participants' general knowledge about blood donation.
2470403|NCT03101982|Active Comparator|test|HBO, ASIA score, blood taking
2470404|NCT03101982|No Intervention|control|ASIA score, blood taking
2470450|NCT03101631|Experimental|CASE ARM|"This is a three cohorts arm with intervention (CGA):~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~Creatinine Clearance (CrCl)~Presence of Geriatric Syndromes"
2470455|NCT03101631|No Intervention|CONTROL ARM|This is a three cohorts arm with no intervention
2470533|NCT03101228|Experimental|Reduced sitting|Objectively measured daily inactive time will be reduced by one hour compared to the baseline.
2470538|NCT03101228|No Intervention|Control|Subjects will be guided to maintain their normal sedentary behaviour and physical activity habits.
2470613|NCT03100448|Other|On1 Concept|On1 Concept & NobelActive implants
2470657|NCT03100084||I. Post Dates|"Pregnant women referred for clinical post term evaluation and/or labour induction.~Blood sampling."
2470660|NCT03100084||II. Induction of Labour|"Pregnant women ≥37+0 GW (gestational week) referred for labour induction (any cause).~Blood sampling."
2470663|NCT03100084||III. All Outpatients|"Pregnant women ≥37+0 GW presenting for any medical reason at OUH outpatient clinic.~Blood sampling"
2470670|NCT03100084||IV. Diabetes in Pregnancy|Pregnant women ≥36+0 GW with pregestational or gestational diabetes. Blood sampling.
2470676|NCT03100084||V. Reduced Fetal Movements|"Pregnant women ≥37+0 GW with reduced fetal movements and/or referred due to reduced symphysis-fundal height.~Blood sampling."
2470681|NCT03100084||VI. Hypertensive Disorders in Pregnancy|"Pregnant women referred for preeclampsia (or other pregnancy induced hypertensive disorders) and/or suspected fetal growth restriction; longitudinal cohorts.~Blood sampling."
2470685|NCT03100084||VII. All Labour Admissions|All pregnant women ≥37+0 GW admitted for labour. Blood sampling.
2470701|NCT03099577|Experimental|radiochemotherapy 1|Patients will be treated with radiation therapy 64.8 Gy
2470704|NCT03099577|Experimental|radiochemotherapy 2|Patients will be treated with radiation therapy 69.6 Gy
2470705|NCT03099577|Experimental|radiochemotherapy 3|Patients will be treated with radiation therapy 74.4 Gy
2470706|NCT03099577|Experimental|radiochemotherapy 4|Patients will be treated with radiation therapy 79.2 Gy
2470709|NCT03099577|Experimental|radiochemotherapy 5|Patients will be treated with radiation therapy 84 Gy
2470711|NCT03099577|Experimental|radiochemotherapy 6|Patients will be treated with radiation therapy 88.8 Gy
2470712|NCT03099577|Experimental|radiochemotherapy 7|Patients will be treated with radiation therapy 93.6 Gy
2470798|NCT03099421|Experimental|Prostatic Artery Embolization|Embolization of the prostatic arteries to induce necrosis and a reduction of the prostate volume.
2470870|NCT03099083||Participants receiving adalimumab|Participants with Psoriasis receiving adalimumab
2470971|NCT03098238|Other|Patients without humoral rejection or DSA|Renal transplant patients with systematic kidney biopsy at 3 months and 12 months Patients without humoral rejection or DSA (Donor Specific Antibodies)
2470975|NCT03098238|Other|Patient without humoral rejection with a DSA|Patient without humoral rejection with a DSA (Donor Specific Antibodies)Patients with a graft biopsy for a donor-specific anti-HLA antibody
2470977|NCT03098238|Other|Patients with humoral rejection|Patients with humoral rejection
2471029|NCT03097900|Active Comparator|Treatment (Caffeine Citrate) group|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
2471033|NCT03097900|Placebo Comparator|Placebo (Water) group|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
2471068|NCT03097419|Experimental|Intervention|Remote post-ischemic conditioning
2471070|NCT03097419|No Intervention|Control|Standard medical care by the primary treatment team.
2471106|NCT03097146|Other|comprehensive multidisciplinary stroke care|
2471253|NCT03096210|Other|Titanium-Prepared Platelet Rich Fibrin|After careful elevation of the schneiderian membrane without perforation,T-PRFs were only used in the test group.
2471254|NCT03096210|Other|Allograft (CTBA Allograft)|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
2471280|NCT03095898|Experimental|True Acupuncture|
2471281|NCT03095898|Sham Comparator|Sham Acupuncture|
2471284|NCT03095898|No Intervention|Control Group|
3208614|NCT00976417||2. Patients in the intervention group|
2471463|NCT03094858|Active Comparator|Comparison group|Equipment only comparison group will use Smartphone and Wristband to monitor sedentary behavior
2471465|NCT03094858|Experimental|Intervention group|Intervention group will receive prompts from Smartphone to reduce sedentary behavior using information from Wristband
2471593|NCT03094104|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2470354|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as a CBC prior to seeing the doctor.
2470355|NCT03102216|Experimental|Enhanced workflow pathway ECG|Patients will receive a 12lead, v1R-v6R(right sided ECG leads) and V7-V9 ECG prior to seeing the doctor.
2470358|NCT03102216|Experimental|Enhanced workflow pathway Lodox|Patients will receive a supine AP and lateral lodox (low dose x-ray) of their chest and abdomen prior to seeing the doctor.
2470361|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests as well as 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2470363|NCT03102216|Experimental|Enhanced workflow pathway iSTAT, CBC ECG|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests, CBC and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2470364|NCT03102216|Experimental|Enhanced workflow pathway iSTAT lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests and Lodox prior to seeing the doctor.
2470365|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC and Lodox prior to seeing the doctor.
2470366|NCT03102216|Experimental|Enhanced workflow pathway ECG Lodox|Patients will receive LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2470368|NCT03102216|Experimental|Enhanced workflow pathway iSTAT ECG Lodox|iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor
2470369|NCT03102216|Experimental|Enhanced workflow pathway iSTAT CBC ECG Lodox|Patients will receive iSTAT point-of-care troponin, INR, CG4+ and chem8 tests; CBC, LODOX and 12lead, v1R-v6R and V7-V9 ECG prior to seeing the doctor.
2470441|NCT03101579|Experimental|Intra-pemetrexed|Patients were treated with intrathecal pemetrexed at dose escalation. The regimen of intrathecal pemetrexed is 10/15/20 mg, plus dexamethasone 5 mg, twice per week for 2 weeks, followed by once per week for 2-4 weeks. Pemetrexed is administrated by intrathecal injection via lumbar puncture. Folic acid 200-400 μg is administered orally once daily, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed. A single dose of vitamin B12 1000 μg is administered by intramuscular injection before the first intrathecal pemetrexed，once per 3 weeks. To detect the pharmacokinetics of intrathecal pemetrexed, the serum and cerebrospinal fluid samples are collected. These samples would be analyzed by spectrometer for drug concentration.
3192035|NCT00804336|Experimental|Pasireotide and RAD001|RAD001 was administered orally as a once-daily dose. Pasireotide s.c. was self-administered s.c. twice daily for 4 weeks. If pasireotide s.c. was tolerated, patients received pasireotide LAR i.m. at the corresponding dose level. Pasireotide s.c. was continued for an additional 2 weeks after administration of pasireotide LAR until anticipated steady-state levels of pasireotide LAR were achieved. Pasireotide LAR was administered every 28 days. Cycles for everolimus and pasireotide LAR were repeated every 28 days.
3192036|NCT00804375|Experimental|2PX|Pain medication
3192037|NCT00804375|Placebo Comparator|placebo|placebo
2470687|NCT03099941|Experimental|Biofeedback group|The biofeedback application which helps patient to understand neutral position and how to maintain it in exercises that are prescribed by the physical therapist
2470689|NCT03099941|Active Comparator|Physical therapist feedback group|In physical therapist feedback group feedback applied by oral and tactile stimulation of physical therapist to helps patient to understand neutral position and how to maintain it in exercises that are prescribed
2470782|NCT03099616|Active Comparator|CLADS group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia. Thereafter anaesthesia maintenance will be done with Propofol, with the dosing based on adjusted body weight (ABW), and administration controlled with CLADS tuned to consistent anaesthetic depth (BIS-50) feedback from the patients.
2470783|NCT03099616|Active Comparator|Desflurane group|Anesthesia will be induced with Propofol administered by CLADSwhich will be set to deliver Propofol according to lean body weight (LBW). A BIS-value of 50 will be used as the target for induction of anesthesia.Thereafter anaesthesia maintenance will be done with desflurane using an agent specific vaporiser, whose dial concentration will be adjusted to maintain a BIS of 50-55 in all the patients
2470851|NCT03099148|Experimental|LY3337641 (R-fasted)|A single dose of LY3337641 reference formulation (R) given orally with water after an overnight fast in one of four periods.
2470852|NCT03099148|Experimental|LY3337641 (T1-fasted)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
2470853|NCT03099148|Experimental|LY3337641 (T1-fed)|A single dose of LY3337641 test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
2470854|NCT03099148|Experimental|LY3337641 (T2-fasted)|A single dose of LY3337641 test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
3192038|NCT00804388|Active Comparator|1|Uncemented total hip replacement, 32 mm caput
3192039|NCT00804388|Active Comparator|2|Uncemented total hip replacement, 36 mm caput
3192040|NCT00804401|Active Comparator|Test Product|
2470956|NCT03098316||POAG|Primary open angle glaucoma patients
2470958|NCT03098316||NTG|Normal/Low tension glaucoma patients
2470960|NCT03098316||Control|Patients with cataract and without glaucoma or other eye diseases
2470989|NCT03098056|Experimental|PROG2|All subjects will be participating in a lifestyle change program - specifically a high protein, limited carbohydrate food plan (High Phyto-PRO food plan), physical activity and a cognitive behavioral program consisting of 11 group visit. Participants will be recieving nutritional Supplements.
2471026|NCT03097848|Experimental|Sorafenib+RFA group|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
2471027|NCT03097848|Active Comparator|RFA group|for eligible cases, RFA will be given only.
3192041|NCT00804401|Active Comparator|Reference Product|
3192042|NCT00804414|Experimental|1|
3192043|NCT00804414|Placebo Comparator|2|
3192044|NCT00804427|Experimental|Fish oil (90% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 90% triglyceride formulation, taken in two divided doses with main meals.
2470371|NCT03102242|Experimental|Treatment|"Induction immunotherapy: atezolizumab 1200 mg IV q 21 days x 4 cycles. Restaging after cycle 2 and cycle 4 induction: patients with progression of disease (PD) at the post-cycle 2 assessment will stop atezolizumab and go immediately to chemoradiotherapy if still stage III and eligible for curative intent therapy.~Chemoradiotherapy: carboplatin AUC = 2 + paclitaxel 50 mg/m2 IV weekly x 6 weeks concurrent with radiation to a total dose of 60 Gy given in 2 Gy fractions daily M-F x 30 fractions~Consolidation chemotherapy: Carboplatin AUC = 6 + paclitaxel 200 mg/m2 IV q 21 days x 2 cycles beginning 3-5 weeks after completion of radiation.~Adjuvant immunotherapy: atezolizumab 1200 mg IV q 21 days to complete one year of therapy (from start of induction)."
2470445|NCT03101683|Experimental|PCWRT Group|Patients with diagnosis of in situ ductal carcinoma (pTis) or invasive breast carcinoma (pT1 and pT2), submitted to NAC sparing mastectomy with prosthetic-based breast reconstruction who have some additional risk factors will receive a partial chest wall radiotherapy
2470516|NCT03101254|Experimental|LY3022855 + Vemurafenib + Cobimetinib|LY3022855 administered intravenously every week Vemurafenib administered by mouth twice daily Cobimetinib administered by mouth once daily on days 1-21of each cycle
2470576|NCT03100669||Pectus surgery|Single arm study: patient undergoing pectus repair surgery
3157336|NCT00362856|Other|Larazotide acetate 8 mg + Gluten placebo|Safety Control Arm. Larazotide acetate 8 mg TID + gluten placebo TID administered orally in capsules
3157337|NCT00362856|Active Comparator|Larazotide acetate 0.25 mg + Gluten|Larazotide acetate 0.25 mg TID + gluten 800 mg TID administered orally in capsules
3157338|NCT00362856|Active Comparator|Larazotide acetate 1 mg + Gluten|Larazotide acetate 1 mg TID + gluten 800 mg TID administered orally in capsules
2470718|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units|100,000 units Vitamin D2 one time only.
2470721|NCT03099759|Active Comparator|Vitamin Dose Group 100,000 Units D2|100,000 units vitamin D2 weekly for three months.
2470724|NCT03099759|Active Comparator|Vitamin Dose Group 50,000/2,000 D2/D3|50,000 units Vitamin D2 for 10 days followed by 2,000 units Vitamin D3 daily the remainder of the three month study period.
2470801|NCT03099382|Experimental|SHR-1210|
2470802|NCT03099382|Active Comparator|Investigator's Choice Standard Therapy|Docetaxel or Irinotecan
2470873|NCT03098836|Experimental|Caucasian|
2470876|NCT03098836|Experimental|African American|
2470983|NCT03097978|Experimental|RIC arm system with pattern recognition|Subject will be fit with a custom socket and receive training on pattern recognition with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2470984|NCT03097978|Experimental|RIC arm system with direct control|Subject will be fit with a custom socket and receive training on direct control with the RIC arm prosthesis. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2470986|NCT03097978|Experimental|Commercial system with PR control|Subject will be fit with a custom socket and receive training on pattern recognition with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2470993|NCT03097978|Experimental|Commercial system with Direct Control|Subject will be fit with a custom socket and receive training on direct control with a conventional, commercial prosthesis system. Once appropriate training has occurred, outcome measures will be completed followed by a home trial for at least 6 weeks with the device. Outcome measures will be collected at the conclusion of the 6 week home trial.
2471174|NCT03096756|Other|Part 1: Single Ascending Dose Escalation GC4702|Serially increase dose escalation of orally formulated GC4702 or placebo (6:2 ratio), preceded by single dose of active comparator, GC4419 IV.
2471177|NCT03096756|Experimental|Part 2: Food Effect Study|Following Part 1 dose find, single dose level of GC4702 administered under fasting for and fed condition.
3157339|NCT00362856|Active Comparator|Larazotide acetate 4 mg + Gluten|Larazotide acetate 4 mg TID + gluten 800 mg TID administered orally in capsules
3157340|NCT00362856|Active Comparator|Larazotide acetate 8 mg + Gluten|Larazotide acetate 8 mg TID + gluten 800 mg TID administered orally in capsules
3157341|NCT00362869|Experimental|1|Dosage 1X10^9 given orally in a sodium bicarbonate solution
3157342|NCT00362869|Experimental|2|Dosage 5X10^9 given orally in a sodium bicarbonate solution
3157343|NCT00362869|Placebo Comparator|5|Sodium bicarbonate placebo solution
3157344|NCT00362869|Experimental|4|Dosage 5X10^10 given orally in a sodium bicarbonate solution
3157345|NCT00362869|Experimental|3|Dosage 1X10^10 given orally in a sodium bicarbonate solution
3157346|NCT00362895|Experimental|Tobradex AF|
3157347|NCT00362895|Active Comparator|TOBRADEX|
3157348|NCT00362908|Active Comparator|Group 1|"Subjects consume study diets in the following order:~Diet 1 (20% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 2 (40% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
3157349|NCT00362908|Active Comparator|Group 2|"Subjects consume study diets in the following order:~Diet 2 (40% fat diet) for 1 month with all food provided,~American Heart Association Step I Diet for 1 month at home, and~Diet 1 (20% fat diet) for 1 month with all food provided and then continue to follow this diet for an additional 4 months at home."
3157350|NCT00362921|Experimental|Gliadel wafers in combination with O6-benzylguanine|
3157351|NCT00362934|Experimental|1|
3157352|NCT00362934|Active Comparator|2|
3157353|NCT00362947|Placebo Comparator|A|A - Parnaparin 8.500 UI aXa od (therapeutic doses) for 10 days followed by placebo for 20 days
3157354|NCT00362947|Active Comparator|B|B - Parnaparin 8.500 UI aXa od for 10 days followed by 6.400 UI aXa once daily (intermediate therapeutic doses) for 20 days
3157355|NCT00362947|Active Comparator|C|C - Parnaparin 4.250 UI aXa od (prophylactic doses) for 30 days
3173328|NCT00610870|Experimental|1|Atorvastatin group
3173329|NCT00610870|No Intervention|2|Control group
3174819|NCT00627484||Group 4: VLCD diabetic|Diabetic subjects scheduled to receive very low calorie diet
2470396|NCT03102307||CNB/clip placement done - malignant|Clinically affected lymph nodes can be biopsied and clip labeled. Needle biopsy reveals axillary tumor spread. Patients are suitable for TAD
2470511|NCT03100955|Active Comparator|EP chemotherapy|Standard treatment or active comparator group contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide.
2470519|NCT03100955|Experimental|EP chemotherapy plus apatinib|Apatinib treatment or experimental group contains standard chemotherapy and apatinib, a VEGF tyrosine kinase inhibitor. It contains a platinum drug, a topoisomerase inhibitor and a VEGF-TKI. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatinum and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI=apatinib, 500 mg, oral daily after chemotherapy, until disease progression or death or un-tolerated toxicites. Used drugs=cisplatinum and etoposide and apatinib.
2470567|NCT03100708||Patient with peritoneal carcinomatosis|Patient with peritoneal carcinomatosis and the Indication for local therapy. The Clinics tumor-board advice is needed.
2470700|NCT03099889|Experimental|Physical Activity intervention arm|Receive a tailored behavioral interventions for exercise and strength training via multiple channels including frequent mailings, integrated voice response and outreach phone calls, interactive website, and referral to local community exercise resources.
2470703|NCT03099889|No Intervention|Control arm|Receive general health mailings
2470745|NCT03099499|Experimental|ONC201 treatment Arm|
2470875|NCT03098875|Active Comparator|Sevoflurane|"General anesthesia using sevoflurane as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
2470878|NCT03098875|Active Comparator|Propofol|"General anesthesia using propofol as a hypnotic agent, and remifentanil as an analgesic.~Two steady state periods of 10 minutes each, one with a steady bispectral index at 25 +/- 5, the other with a steady bispectral index at 55 +/- 5. Continuous recording of heart rate during the last minute of each steady-state. Off-line spectral analysis of heart rate variability."
2471001|NCT03097965|Active Comparator|DIET|"High Phyto-PRO food plan~Physical activity~Cognitive behavioral program"
2471004|NCT03097965|Experimental|PROGRAM|"High Phyto-PRO food plan~Physical activity~Cognitive Behavioral Program~Protein Shakes~Phytosterols supplement~Berberine supplement~Anti-oxidant supplement~Probiotic supplement~Fish Oil supplement~Multiple Vitamin/Multiple Mineral supplement"
2471039|NCT03097770|Experimental|anti-CD19/20 CAR T cells|Patients receive anti-CD19/20-CAR retroviral vector-transduced autologous or donor-derived T cells on day 1 in the absence of disease progression or unacceptable toxicity.
2471079|NCT03097432||ORALVAC COMPACT BÄUME|This non-interventional study was initiated to document the up-dosing period of children and adults with allergic rhinoconjunctivitis and/or allergic asthma treated with a SLIT containing purified, aqueous extracts of birch, alder, and hazel pollen. The following up-dosing schemes were freely selectable: scheme A consists of an up-dosing period of 12 days at the patient´s home using the standardized pollen extract in three different solution strengths to reach the maximum dose; scheme B performed only with the highest solution strength at the physician's office within 2 hours; and the new scheme C which is a regimen for initiation at the physician's office and continuation at the patient's home also exclusively using the highest solution strength and takes 4 days.
3157356|NCT00362973||Hormone Receptor Positive Breast Cancer|Patients with hormone receptor positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of aromatase inhibitor and ovarian suppression (if premenopausal).
3157357|NCT00362973||HER-2/neu Positive Breast Cancer|Patients with HER-2/neu positive primary, recurrent or metastatic breast cancer with a treatment plan that involves (neoadjuvant) administration of trastuzumab.
3157358|NCT00362986|Experimental|sunscreen|"Patients apply sunscreen generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
3157359|NCT00362986|Placebo Comparator|placebo|"Patients apply placebo generously to the entire body twice daily for 4 weeks.~Patients complete self-reported questionnaires regarding their rash status at baseline and then weekly for 8 weeks.~After completion of study treatment, patients are followed for 8 weeks."
2471285|NCT03096080|Experimental|Cohort 1|Single 0.25 mg/kg dose of tesevatinib
2471287|NCT03096080|Experimental|Cohort 2|Single 0.50 mg/kg dose of tesevatinib
2471288|NCT03096080|Experimental|Cohort 3|Single 1.00 mg/kg dose of tesevatinib
2471333|NCT03095560|Experimental|Semi-immersive virtual training with shadow (S-IVTS)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVTS group the projector is located behind the patient, thus the shadow of the patient is projected on the screen.
2471338|NCT03095560|Experimental|Semi-immersive virtual training without shadow (S-IVT)|All the participants underwent a neurocognitive-rehabilitative training consisting of 24 sessions of BTsN. Each treatment session lasted 45 minutes, and was repeated three times a week for 8 weeks. in the BTsN device used in the S-IVT group the projector is located in front of the patient and the shadow is not visible.
3157360|NCT00363116|Active Comparator|5 Dose Daclizbumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
2471444|NCT03094715|Active Comparator|Thrombectomy|Endovascular thrombectomy and best medical care
2471445|NCT03094715|Other|Best medical care|Best medical treatment
2471572|NCT03094026|Experimental|Intervention|The arm will begin the Lumosity program at enrollment in the study.
2471609|NCT03094429|Placebo Comparator|Placebo - 0 mg/day|The control treatment is placebo.
3157361|NCT00363116|Active Comparator|2 Dose Daclizaumab|daclizumab 2 mg/kg/dose every 14 days for 2 doses
3157362|NCT00363116|Active Comparator|Control|no antibody induction
3157363|NCT00363194|Experimental|Lead-In cohort|In Part 1 of Lead-In cohort, subjects will be dosed with a single dose of pazopanib with a high-fat breakfast to establish safety and tolerability.
2470398|NCT03102008|No Intervention|4 Week Waitlist|Participants assessed weekly (via self- and parent-report questionnaires administered on the internet) for symptom change during waitlist (baseline) period. At the end of waitlist and prior to treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2470400|NCT03102008|Experimental|16 Sessions of Therapeutic Intervention|Participants receive 50 minute sessions weekly of therapeutic intervention (Unified Protocol for the Treatment of Emotional Disorders in Adolescents). Symptom change assessed weekly on the internet or before each session (via self- and parent-report questionnaires). At the end of treatment phase, symptom/disorder change assessed via clinical interview conducted by independent evaluator.
2470433|NCT03101722|Experimental|Huperzine A intervention|Huperzine A intervention: Huperzine A with a dose 0.1~0.2 mg/time, 2 times/day. BTHE：basic treatment and health education
2470435|NCT03101722|Sham Comparator|control|Participants in the BTHE group will receive advice regarding lifestyle modification, avoiding alcohol and cigarette consumption.
2470479|NCT03101280|Experimental|Dose-Finding Phase (Part 1): Rucaparib and Atezolizumab|Approximately 6-18 participants with advanced gynecological cancers will receive different doses of rucaparib administered orally (PO) twice daily (BID) with a fixed dose of atezolizumab (1200 milligrams [mg] intravenously [IV], every 21 days) in 21-day cycles, starting with 400 mg rucaparib BID. The recommended Phase II dose (RP2D), determined by the highest dose level with an acceptable safety profile and with a minimum of 6 participants at which fewer than one-third of participants experience a DLT, was identified as 600 mg rucaparib twice a day (BID).
2470481|NCT03101280|Experimental|Dose-Expansion Phase (Part 2): Rucaparib and Atezolizumab|"Two tumor-specific expansion cohorts will begin treatment with a 21-day run-in period of rucaparib monotherapy at the specified dose for rucaparib in the potential RP2D identified in Part 1 for the combination. Cohort 1 will have approximately 30 participants with advanced, platinum-sensitive ovarian cancer with tumors harboring a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)].~Cohort 2 will have approximately 20 participants with previously treated triple-negative breast cancer (TNBC) with a tBRCA mutation [tBCRA(mut)] or BRCA-like molecular signature [tBRCA(wt)/LOH(high)] and have not been exposed to cancer immunotherapies. Following the run in period, participants will receive the combination of rucaparib (specified dose, BID) and atezolizumab (1200 mg IV, every 21 days) in 21-day cycles."
3192045|NCT00804427|Experimental|Fish oil (60% triglycerides)|Fish oil (4 grams/day of combined EPA and DHA) as 60% triglyceride formulation, taken in two divided doses with main meals.
2470605|NCT03100552||Study population|Patients referred to a tertiary endoscopic resection practice found to have an SSP >= 8mm. Endoscopic imaging applied to the sessile serrated polyp (SSP) to determine the presence or absence of dysplasia.
2470631|NCT03100175|Experimental|intervention|"the patient will be scheduled for another appointment and taught a set of exercises including strength training for upper and lower limbs (with elastic bands and weights, rising up from chair and climbing stairs), fitness work out (brisk walking) and balance exercises, as recommended by senior sport programs.~Patients will be provided with printed instructions explaining the recommended exercises, and with a diary to fill in, with days and number of repetitions of specific training elements to be checked in according to their compliance. Patients will also be equipped with a pedometer and will be asked to record the counts regularly~Patients will be met again by a physiotherapist for follow up at the start of every chemotherapy course (once in 3-4 weeks) and will be contacted by phone twice weekly to assure they stick to the training recommendations"
2470635|NCT03100175|No Intervention|control|The control group will receive standard treatment and follow-up with no special emphasis on physical activity
2470763|NCT03099447|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
2470765|NCT03099447|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve.
2470767|NCT03099447|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by oculomotor nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2470855|NCT03099239|Experimental|Single hCT-MSC infusion|Subjects 1-3 will receive a single infusion of hCT-MSCs.
2470856|NCT03099239|Experimental|Two hCT-MSC infusions|Subjects 4-6 will receive two infusions of hCT-MSCs.
2470857|NCT03099239|Experimental|Three hCT-MSC infusions|Subjects 6-12 will receive three infusions of hCT-MSCs.
2470929|NCT03098446|Experimental|Prolonged sitting with exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. On the evening of day 4, they will be asked to run at 65% of VO2max for 1-hour.
2470932|NCT03098446|Experimental|Prolonged sitting without exercise|Subjects will be asked to undergo prolonged sitting (~14-hours/day) for 4 days. Subjects will not be asked to complete the acute bout of exercise to serve as a control.
2470991|NCT03098264|Experimental|Simultaneous surgery|to perform surgery both on biliary stone and portal hypertension
2470406|NCT03101943|Experimental|Family Spirit Nurture (FSN)|The intervention group (n=68) will receive the Family Spirit Nurture (FSN) home-visiting module, consisting of six 45-minute lessons delivered biweekly by trained local American Indian Family Health Coaches (FHCs), from 3 to 6 months postpartum. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices. Lessons are highly visual and interactive, and will incorporate cultural teachings related to infant feeding and nutrition that support aims. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
2470407|NCT03101943|Other|Control Program|The control group (n=68) will receive three home-based lessons with home safety information (injury prevention is a priority identified by Navajo leadership that does not interfere with study questions). Mothers randomized to the control group will receive 3 educational lessons on home safety and child safety proofing. These meaningful topics were selected so as not to dilute measurement on key FSN outcomes and to provide benefit to all study participants. Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing. All families will receive water delivery of drinking water from 6 to 9 months postpartum.
2470493|NCT03101540|Experimental|Supplementation|Subjects received Omega-3 PUFA supplementation
3192046|NCT00804427|Experimental|Fish oil (ethyl esters)|Fish oil (4 grams/day of combined EPA and DHA) as ethyl esters formulation (0% triglycerides), taken in two divided doses with main meals.
3192047|NCT00804427|Placebo Comparator|Soy oil|Soy oil supplement with identical total fat content, taken in two divided doses with main meals.
3192048|NCT00804440|Active Comparator|Test Product|
3192049|NCT00804440|Active Comparator|Reference Product|
2470666|NCT03100019|Experimental|Resveratrol Hypoxia|500mg of trans-resveratrol, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
2470673|NCT03100019|Placebo Comparator|Placebo Hypoxia|Pharmaceutical grade fumed silica, tested at a 16% atmospheric oxygen level; the equivalent to 2134m above sea level.
2470678|NCT03100019|Experimental|Resveratrol Normoxia|500mg of trans-resveratrol, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2470682|NCT03100019|Placebo Comparator|Placebo Normoixa|Pharmaceutical grade fumed silica, tested at a 20.9% atmospheric oxygen level; the equivalent to sea level.
2470708|NCT03099629|Experimental|IMT|inspiratory muscle training
2470751|NCT03099473|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
2470754|NCT03099473|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve.
2470755|NCT03099473|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by trochlear nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2470809|NCT03099278|Experimental|Ezetimibe|
2470880|NCT03098940|Experimental|Chewing gum|Chewing gum with various doses of dronabinol
2470882|NCT03098940|Active Comparator|Capsule (Marinol)|Marinol is a product manufactured by AbbVie Capsule with various strengths of Marinol
2471064|NCT03097536|Experimental|Luna Bar Intervention|Participants will be asked to monitor their blood sugar during migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. This information will be recorded at times when a Luna bar is not consumed, and at times when a Luna Bar is consumed. Participants will serve as their own controls.
2471066|NCT03097536|No Intervention|Morning Migraine|Participants will be asked to monitor their blood sugar on headache free days as well as during migraine. This arm is only for participants who identify as having morning migraine. Study data will also include blood glucose levels, pain severity, 24-hour food diary, 24-hour exercise diary, duration of sleep, perception of quality of sleep, and last menstrual period. Participants will serve as their own controls.
2471118|NCT03097198|Experimental|PbN-TED|Treated with plum-blossom needle first for 10 times during 20 days, followed with a one-month wash-out period and a 10-day period with Tropicamide Eye Drops.
2471120|NCT03097198|Experimental|TED-PbN|Treated with Tropicamide Eye Drops for 10 days first, followed with a one-month wash-out period and 10 times of plum-blossom needle treatment for 20 days.
2471182|NCT03096743|Experimental|Patients with increased intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, Optic nerve B-scan ultrasound and Lumbar puncture.
2471183|NCT03096743|Experimental|Patient without raised intracranial hypertension|Patients will receive the MR elastography, MRI structural brain imaging, Optical Coherence Tomography (OCT) imaging, and Optic nerve B-scan ultrasound. Some patients will receive lumbar punctures.
2471233|NCT03096379||Magnetic resonance imaging|Patients with new-onset of lower gastrointestinal symptoms and ileocecal mucosal lesions of uncertain diagnosis as evidenced by the presence of inflammation, ulceration, strictures or nodules on colonoscopy.
2471260|NCT03096132|Active Comparator|Family Based Behavioral Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a weekly group setting.
2471261|NCT03096132|Experimental|Guided Self-Help Fam. Based Bx Treatment|The program includes information about diet and physical activity education, in addition to parent management skills and behavior therapy strategies in a guided self-help manual.
2471348|NCT03095443|Active Comparator|Attention Control|Receives audio-book twice a day.
2471424|NCT03095131|Experimental|12-lead ECG|
2471781|NCT03092648|Experimental|Bronchial basal cells|
3192050|NCT00804453|Active Comparator|1|Standard blood line
3192051|NCT00804453|Experimental|2|Cartridge blood line
3192052|NCT00804466|Experimental|Women referred to colposcopy clinic|Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
2470456|NCT03101436|Experimental|Obese Subjects|"Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month)~Washout 15 days~Part 2: Mediterranean diet with added Red Wine (270 ml per day) (1 month)"
3173330|NCT00610896||Observation|30 Patients with dualchamber pacemakers or implantable cardioverter-defibrillators (ICDs)
3192053|NCT00804479||no treatment|Available 301 subjects enrolled in CALM-PD Available 82 subjects enrolled in CALM-PD imaging substudy
2470564|NCT03100591|Experimental|14C-radiolabelled ACT-132577|On Day 1, subjects will receive a single oral dose of 25 mg 14C-radiolabeled ACT-132577, administered as an oral formulation in the fasted state
2470615|NCT03100435|Experimental|Er:YAG Laser|Er:YAG Laser only
2470616|NCT03100435|Active Comparator|Carbon Fiber Curette|Carbon fiber curette only
2470617|NCT03100435|Experimental|Er:YAG Laser + Carbon Fiber Curette|Combination of Er:YAG Laser and carbon fiber curette
2470618|NCT03100435|No Intervention|No Treatment|No treatment (control)
2470671|NCT03100032|Experimental|NVD-001|Autologous osteogenic cells in ECM with DBM
2470677|NCT03100032|Active Comparator|Standard of Care|Best standard of care in surgical practice
2470702|NCT03099564|Experimental|pembrolizumab + Y90 radioembolization|Pembrolizumab 200mg IV every 3 weeks in conjunction with Y90 radioembolization (performed one week after the first dose of pembrolizumab)
2470756|NCT03099460|Experimental|ocular electroacupuncture|Patients will receive electroacupuncture for 40 mins with certain parameter at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
2470757|NCT03099460|Experimental|ocular acupuncture|Patients will receive acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve.
2470758|NCT03099460|Sham Comparator|sham acupuncture|Patients will receive sham acupuncture for 40 mins at ocular area, once daily, 5 times a week and 6 weeks in all. The acupoints are selected based on the anatomy of extraocular muscles innervated by abducens nerve. When the care provider performed operating acupuncture, the needles of sham acupuncture set will not be inserted into the skin of patient.
2470820|NCT03099252||Enrolled|"Participating hospitals will offer the video to all parents on their MBU during the 6 month intervention period (using the preferred delivery methods of the hospital and the parents). The video will be available via multiple means to facilitate optimal parental exposure in diverse settings. This will ensure flexibility of the delivery of the intervention, based on preferences of the nominated nurse leaders and their HCP team, families and available resources.~All participating maternal/newborn centres will receive the following tools via the designated nurse unit leader of enrolled sites:~Parent-targeted BSweet2Babies video~Parent cards- Reminder for parents of video, with Quick Response (QR) code of the video~BSweet2Babies Poster-visual reminder for parents and HCP's on the enrolled units~Monthly support calls for the nursing leaders of the Mother Baby Units (MBU)~Bi-monthly community of practice teleconferences for the nursing leaders of the MBU"
2470842|NCT03098914||Beijing Haidian Hospital|
2470845|NCT03098914||Chinese PLA General Hospital|
2470849|NCT03098914||Beijing Tsinghua Chang gung Hospital|
2470884|NCT03098784||Air France employees working near runways|"Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports.~Intervention: Exposure to aircraft exhaust"
2470890|NCT03098784||Air France employees working inside|"Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports.~Intervention: Non exposure to aircraft exhaust"
2470972|NCT03098498|Experimental|Two-Stage Subgingival Debridement|Initially soft subgingival bacterial biofilms are removed from periodontal lesions by an airpolishing device and erythritol cleaning powder. 6 weeks later subgingival calculus is mechanically removed in a second step by mechanical scaling and root planing
2470974|NCT03098498|Active Comparator|One-Stage Subgingival Debridement|Soft subgingival bacterial biofilms, as well as subgingival calculus are concomitantly removed from periodontal lesions by mechanical scaling and root planing
2471034|NCT03097887|Active Comparator|Anti-reflux sutures|Omega Loop Gastric Bypass with anti-reflux sutures using V-Loc sewing device. Biliary reflux measured using Bilitec 2000™.
2471037|NCT03097887|Active Comparator|No anti-reflux sutures|Omega Loop Gastric Bypass without anti-reflux sutures. Biliary reflux measured using Bilitec 2000™.
2471087|NCT03097393||AKI GROUP|measure Procalcitonin among Patient developed Acute kidney injury during ICU stay
2471088|NCT03097393||Non-AKI group|measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay
2471238|NCT03096457|Experimental|Group 1 - Paromomycin cream|40 subjects will be included to receive 15% paromomycin in aquafilm base twice a day during 20 consecutive days. The lesion will be cleaned , then, a generous amount of the study drug (an amount sufficient to cover the area of the ulcer and the lesion border) will be applied to the lesion and rubbed into the ulcer using a gloved finger by a member of the clinical study staff. After application of the study drug, the patient will be observed for 15 minutes for signs of adverse events. If there are no signs of local toxicity, the area of the ulcer will be covered with extra study drug. For Days 2-20, the study drug will be applied and the lesion covered with a sterile gauze and tape dressing as on Day 1.
2471239|NCT03096457|Active Comparator|Group 2. Local Injectable Pentamidine|"20 subjects will be included to receive IL pentamidine [Pentacarinat® Sanofi-Aventis: 30 mg/ml] will administered at a dose of 120 ug (4 ul) per mm2 of lesion area 3 times (on days 1, 3, and 5) as per our previous experience.~A small button of Xylocaine® will be applied by means of a thin needle at the four cardinal points of the lesion and then a small gauge (23g) needle will introduce the drug in each cardinal point. The needle will be moved in all directions to infiltrate of whole lesion and surrounding infiltrated area."
2471241|NCT03096457|Placebo Comparator|Group 3. Vehicle control|10% Urea en parafilm cream will be used in similar ways as paromomycin cream in group 1
2471301|NCT03095924|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2471302|NCT03095924|Experimental|News without spin|News items reporting results of RCTs without spin
2471343|NCT03095443|Experimental|Personalized Music|Receives personalized playlist twice a day.
2471346|NCT03095443|Active Comparator|Non Personalized Music|Receives standardized low beats per minute playlist twice a day.
2471785|NCT03092648|No Intervention|Control|
2470490|NCT03101306|Experimental|MR scans|As part of the study patients will undergo 3 additional MR scans during radiotherapy treatment. These will take place in the 1st, 2nd and 5th weeks of treatment.
2470526|NCT03100994|No Intervention|Group A|without nerve block
2470535|NCT03100994|Active Comparator|Group B|Ultrasound guided transmuscular quadratus lumborum block with 0.125% bupivacaine 30ml
2470537|NCT03100994|Active Comparator|Group C|Ultrasound guided quadratus lumborum type 2 block with 0.125% bupivacaine 30ml
2470652|NCT03100266|Experimental|probiotic|Lactobacillus rhamnosis GG
2470656|NCT03100266|Placebo Comparator|placebo|Inactive capsules
2470804|NCT03099330|Experimental|TQ-B3139|TQ-B3139 p.o. qd
2470879|NCT03099031||Tinzaparin|Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
2470908|NCT03098628|Active Comparator|V - PCV10 vaccine, 0+1|PCV10, 0+1 schedule. PCV vaccine at 12 months of age
2470910|NCT03098628|Active Comparator|W - PCV13 vaccine, 0+1|PCV13 in 0+1 schedule. PCV vaccine at 12 months of age
2470911|NCT03098628|Active Comparator|X - PCV10 vaccine, 1+1|PCV10, 1+1 schedule. PCV vaccine given at 2 and 12 months of age
2470912|NCT03098628|Active Comparator|Y - PCV13 vaccine, 1+1|PCV13, 1+1 schedule. PCV vaccine at 2 and 12 months of age
2470913|NCT03098628|Other|Z - Control|Control group. PCV vaccine given at end of study (24 months)
2470952|NCT03098368|Active Comparator|Patient (active) group|"Rotigotine titration up to 16 mg/24 hr~Starting dose 2 mg/24 hr up titrate 2 mg weekly to optimal/maximum dose~Duration up to 12 weeks~The treatment was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
2470953|NCT03098368|Placebo Comparator|Control (placebo) group|"Placebo transdermal patch were titration with the same protocol as active group.~Duration up to 12 weeks~The treatment (placebo patch) was titrated until optimal dosage~(that which patient/ caregiver felt that nocturnal hypokinesia and/or early morning akinesia was adequately controlled)~(or patient can not tolerated the side effects such as dyskinesia)~All previous dopaminergic medications were not allowed to adjusted during the study period."
2471006|NCT03098108|Experimental|CCPT|
2471031|NCT03097757|No Intervention|(standard of care fracture reduction|Fracture reduction as per standard of care involves closed fracture reduction without real-time imaging, or with c-arm or portable x-ray.
2471035|NCT03097757|Experimental|ultrasound guided fracture reduction|Ultrasound guided Fracture reduction involves closed fracture reduction with the use of real-time ultrasound imaging, prior to, during and after the reduction procedure. C-arm or portable x-ray may also be used as an adjunct.
2471127|NCT03097172||Group 1|"Stable elective patients Stenotic coronary artery 10 x LAD 10 x RCA 10 x Cx~30 patients total"
2471140|NCT03097172||Group 2|"Stable elective patients Chronic total occlusion of one artery~10 x LAD 10 x RCA~20 patients total"
3157364|NCT00363272|Experimental|Arm I|Patients receive ispinesib IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
3157365|NCT00363363|Experimental|1|
2471332|NCT03095703|Experimental|Sirolimus|All patients will receive sirolimus for the duration of the study, with a trough level target range of 5-8 ng/ml.
2471401|NCT03095196||T2DM, treated by multipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by multipolar CRT-d, plus maximal drug therapy.
2471404|NCT03095196||T2DM, treated by bipolar CRT-d|Type 2 diabetes (T2DM) affected by heart failure (HF), treated by bipolar CRT-d, plus maximal drug therapy.
2471458|NCT03094910|Other|123I-MIBG|Only the group of participants with primary Raynaud's phenomenon (Raynaud's disease) is also scheduled for this intervention, the 123I-MIBG.
2471460|NCT03094910|Other|All participants|Examination of vibration perception threshold in fingertips, thermography, Ewing's test, tilt table test, blood samples.
2471508|NCT03094286|Experimental|Arm 1|Durvalumab (MEDI4736) monotherapy at the recommended dose of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients
2471564|NCT03093974|Experimental|treatment|Inhaled colistimethate sodium twice daily
2471565|NCT03093974|Placebo Comparator|Saline solution|inhaled placebo twice daily
2471715|NCT03093389|Experimental|BIA 6-512 25 mg or Placebo|1 capsule of BIA 6-512 25 mg or 1 capsule of placebo.
3157366|NCT00363363|Active Comparator|2|
3157367|NCT00363376|Experimental|Sugar pill|"olanzapine and placebo (sugar pill)"
3157368|NCT00363376|Experimental|Zonisamide|olanzapine and zonisamide (active drug)
3157369|NCT00363428|Placebo Comparator|Control|Receive standard care and educational material on exercise and lifestyle choices of well-being
3157370|NCT00363428|Experimental|Lifestyle intervention|
3157371|NCT00363454|Experimental|Dose Escalation|Phase I: Triciribine Phosphate Monohydrate
3157372|NCT00363519|Placebo Comparator|P|
3157373|NCT00363519|Experimental|E|
3157374|NCT00363636|Experimental|1|
3157375|NCT00363636|Active Comparator|2|
3157376|NCT00363714|Experimental|1|Single intravitreal injection
3157377|NCT00363714|Experimental|2|Single intravitreal injection
3157378|NCT00363714|Experimental|3|Single intravitreal injection
3157379|NCT00363714|Experimental|4|Single intravitreal injection
3157380|NCT00363714|Experimental|5|Single intravitreal injection
2470528|NCT03101189|Placebo Comparator|Placebo|2 Japanese / 2 Caucasian subjects will receive 1 placebo capsule to match subjects in the ACT-541468 (25 mg) group and 2 other Japanese / 2 Caucasian subjects will receive 2 placebo capsules to match subjects in the ACT-541468 (50 mg) group
2470578|NCT03100721|Experimental|PNE+Physiotherapy|Pain neuroscience education (PNE) can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied one time (at baseline). Physiotherapy includes kinesitherapy and exercises.
2470580|NCT03100721|Active Comparator|Physiotherapy|Physiotherapy includes kinesitherapy and exercises.
2470653|NCT03100331|Experimental|Single Arm; all receive neuropsychological testing & follow-up|
2470719|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (82mg)|
2470722|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (164mg)|
2470725|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-101 (246mg)|
2470728|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-111 (175mg)|
2470730|NCT03099824|Experimental|GC4419 IV + GC4711 Oral G-112 (145mg)|
2470735|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-119 (233mg)|
2470739|NCT03099824|Experimental|GC4711 IV + GC4711 Oral G-125 (233mg)|
2470827|NCT03099265|Experimental|patients with borderline resectable pancreatic adenocarcinoma|Borderline resectable disease will be defined by NCCN criteria, and determined centrally by review of a diagnostic pancreas protocol CT scan and/or MRI scan with contrast by a dedicated surgical oncologist and radiologist.
2470889|NCT03098823|Experimental|RAYOS®|
2470894|NCT03098823|Active Comparator|IR prednisone|
3157381|NCT00363714|Experimental|6|Single intravitreal injection
3157382|NCT00363831|Experimental|1|Oxaliplatin
2471000|NCT03098017|Active Comparator|Couscous (dry)|Cooked couscous (50g available carbohydrate, 70g uncooked) eaten with 500 mL of water
2471002|NCT03098017|Experimental|Short pasta (dry)|Cooked penne (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
2471005|NCT03098017|Experimental|Long pasta (dry)|Cooked spaghetti (50g available carbohydrate, 71g uncooked) eaten with 500 mL of water
2471008|NCT03098017|Active Comparator|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
2471038|NCT03097666|Other|C2 Cryoballoon Swipe Ablation System|C2 Cryoballoon Swipe Ablation System
2471081|NCT03097458|Experimental|Counselling|short-term counselling for families
2471085|NCT03097458|No Intervention|Wait-list control group|Wait-list control group
2471149|NCT03097055|Experimental|Traditional Acupuncture|"Traditional acupoints and traditional deqi manipulation"
2471153|NCT03097055|Sham Comparator|Minimal Acupuncture|To avoid traditional acupoints and minimal manipulation
2471191|NCT03096587|Experimental|XP Endo Finisher file|XP Endo Finisher file is used to activate irrigation as a final step in irrigation protocol
2471192|NCT03096587|Active Comparator|ultrasonic activated irrigation|ultrasonic activated irrigation as a final step in irrigation protocol
2471329|NCT03095742|Placebo Comparator|Low MAP|Low mean arterial pressure. 30 patients were blindly randomized to normal range (MAP 65 mmHg) during the peri-cardiac arrest period.
2471334|NCT03095742|Active Comparator|High MAP|High mean arterial pressure. 30 patients were blindly randomized to intervention group (MAP 75 mmHg) during the peri-cardiac arrest period.
2471414|NCT03095183|Placebo Comparator|Traditional Tongue Depressor|The posterior oropharynx exam was performed with a traditional, unflavored Puritan Regular tongue depressor.
2471415|NCT03095183|Active Comparator|Flavored Tongue Depressor|The posterior oropharynx exam was performed with a grape flavored, commercially available, Puritan Junior tongue depressor.
3157383|NCT00363844|Experimental|E|
3157384|NCT00363909|Experimental|low-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
2471576|NCT03094026|Active Comparator|Wait List Control|The arm will begin the Lumosity program 3 months after enrollment in the study.
2471602|NCT03094104|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2471646|NCT03093558|Experimental|Intervention arm|Receive the ECA/Kardia for 30-day use.
2471650|NCT03093558|No Intervention|Usual care arm|Receive a journal for observation of adherence and symptoms.
3157385|NCT00363909|Experimental|medium-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3157386|NCT00363909|Experimental|high-dose citalopram hydrobromide|"Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3157387|NCT00363909|Placebo Comparator|placebo|"Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies."
3157388|NCT00363922|Experimental|1|Rehabilitation in institution
3157389|NCT00363922|Active Comparator|2|Rehabilitation at home
3157390|NCT00363948|Placebo Comparator|P|
3157391|NCT00363948|Experimental|E|
3157392|NCT00363961|Experimental|1|resistance exercise
3157393|NCT00363961|Sham Comparator|2|flexibility exercises
3157394|NCT00363987|Experimental|1|
3157395|NCT00363987|Other|2|
3157396|NCT00364000|Active Comparator|I|Calcium acetate 670 mg tablets
3157397|NCT00364000|Experimental|II|label sevelamer (RenagelR) 800 mg tablets
3157398|NCT00364104|Experimental|A|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
3157399|NCT00364104|Experimental|B|The 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
3157400|NCT00364104|Experimental|C|6-weeks of iron supplementation only plus 10-days of matching placebo of Hp infection eradication therapy
2470633|NCT03100097|Experimental|Intervention (Aspen Horizon 627 LSO)|Patients receive a lumbar brace, Aspen Horizon 627 LSO, in addition to normal medical management
2470636|NCT03100097|No Intervention|Medical Management|Normal medical management
2470688|NCT03099928||Qualitative Interviews|
3157401|NCT00364104|Placebo Comparator|D|
2470822|NCT03099044|Active Comparator|Single Active Dose|Subjects are assigned to receive a single Active beverage and a single placebo beverage.
2470823|NCT03099044|Active Comparator|Double Active Dose|Subjects are assigned to receive 2 doses of Active beverage.
2470824|NCT03099044|Placebo Comparator|Placebo comparator|Subjects are assigned to receive 2 doses of a placebo beverage.
2470939|NCT03098459||Critically Ill Trauma Patients|Non-intervention observational prospective cohort study
2470979|NCT03098251|Experimental|3D typing|typing the patient with 3D typing system and give treatment according preestablished algorism in our center.
2470982|NCT03098251|Active Comparator|routine typing|typing the patient with routine typing system and give treatment according preestablished algorism in our center.
2471060|NCT03097874|Experimental|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
2471061|NCT03097874|Experimental|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment plus Intensive Parental Coaching if weight milestones are not met by session 4.
2471113|NCT03097211|Experimental|Group 1: BIA 6-512 25 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2471114|NCT03097211|Experimental|Group 2: BIA 6-512 50 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2471115|NCT03097211|Experimental|Group 3: BIA 6-512 75 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2471116|NCT03097211|Experimental|Group 4: BIA 6-512 100 mg or placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512/Placebo morning dose, one tablet of Madopar® 250 and one tablet of nebicapone 150 mg were administered
2471218|NCT03096548|Experimental|Sun Safety Ink! Program|A program to (1) increase full-body sun comprehensive sun protection practices, (2) decrease sunburning and tanning and (3) decrease positive attitudes regarding tanning and tanning attractiveness of tattoo studio clients. The program is comprised of a video based communication strategy training presented by research staff to artists of tattoo studios.
2471220|NCT03096548|Active Comparator|Attention Control|The attention control group will provide standard tattoo aftercare instructions to their clients.
2471294|NCT03096158|Experimental|Ventilatory Muscle Training (TREMVEN)|The enrolled participants will perform inspiratory muscle training (IMT) for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit.
2471296|NCT03096158|Experimental|Aerobic Training (AERO)|It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, oxygen saturation (SpO2) and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit.
2471297|NCT03096158|Experimental|Isometric Handgrip Training (ISO)|Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit.
2471331|NCT03095495|Experimental|Early use of HHHFNC|Heated Humidified High Flow Nasal Cannula
2471336|NCT03095495|Active Comparator|Standard Therapy and Rescue HHHFNC|Low Flow Nasal Cannula only if the patient needs oxygenation and Rescue HHHFNC if the patient needs PICU
2471396|NCT03095209||Standard of care concurrent chemo-radiation therapy|
2471427|NCT03094988|Other|Control|The active attention control group will receive a binder with information about personal health including sleep hygiene, nutritional changes, and stress reduction. In addition, they will participate in a control version of the cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
2471432|NCT03094936|Active Comparator|Group B|This group own twenty patients who met all the inclusion criteria. These will be treated with APC plus Endoscopic Suture Technique (OverStitch TM).
2471599|NCT03093779||Deaf|Individuals who are deaf and use sign language to communicate.
3157402|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 1|Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3157403|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3174820|NCT00627484||Group 5: SG diabetic|Diabetic subjects scheduled to receive sleeve gastrectomy
2470587|NCT03100734||With RA|Participants with RA previously treated with Enbrel and transitioned to Benepali
2470592|NCT03100734||With axSpA|Participants with axSpA previously treated with Enbrel and transitioned to Benepali
2470627|NCT03100253|Experimental|"Switching strategy"|Tocilizumab [RoActemra®] [ATC: L04AC07] 8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
2470629|NCT03100253|Active Comparator|"Cycling strategy"|"Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab OR~Infliximab, adalimumab, golimumab or certolizumab if initial failure to the receptor fusion protein, etanercept."
3192054|NCT00804492|Experimental|1|To establish an integrated intervention model for prevention of elderly fall
2470888|NCT03098953|Experimental|Loteprednol Etabonate Ophthalmic Gel|one drop per eye for each eye
2470937|NCT03098537|Active Comparator|Enteral nutrion only|
2470942|NCT03098537|Other|Enteral nutrion + proton pump inhibitor|
2470964|NCT03098225|Experimental|Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy
2470966|NCT03098225|Active Comparator|No Radiotherapy|Patients with moderately severe GO treated with Intravenous glucocorticoids alone
2470990|NCT03098004|Experimental|Sweet-Flavored e-Cigarette|Participants will self-administer a sweet-flavored e-cigarette containing 3 mg/mL of nicotine.
2470994|NCT03098004|Active Comparator|Tobacco-Flavored e-Cigarette|Participants will self-administer a tobacco-flavored e-cigarette containing 3 mg/mL of nicotine.
2471056|NCT03097562|Experimental|CT1|"FLACS- Initial Wound parameters (CT1)~Sample size calculation based on woundleak incidence estimated from preliminary results:~For CT1 vs MT, we will only need 10 per group to have 80% power assuming a 1:1 ratio of CT to MT and 5% type 1 error.~For CT1 vs CT2, we will need 22 per group to have 80% power (assuming 60% wound leakage in CT1 and 20% wound leakage in CT2, a 1:1 ratio, and a 5% type 1 error rate)~A total of 253 patients are eligible for this study, 101 with FLACS and 152 with Manual Cataract Surgery. We thus expect that our study population will allow adequate analysis of the main outcome parameters proposed herein."
2471058|NCT03097562|Experimental|CT2|"The revised profile CT2, consists of a wider anterior side cut angle (beveled corneal undercut) and a narrower posterior side cut angle compared to the initial CT1 profile. This new corneal incision profile is constructed to ensure a tigher wound closure and a better corneal wound reapposition.~The traditional manual wound performed with a standard keratome wil be used as a reference."
2471059|NCT03097562|Active Comparator|MT control group|Standard manual technique (MT)
2471099|NCT03097263||Patients|Patients included for rehabilitation program
2471134|NCT03096938|Placebo Comparator|Normal screening group|patients receive the routine screening examination
2471142|NCT03096938|Experimental|methylation markers screening group|patients receive the methylation markers screening
2471201|NCT03096691|Active Comparator|short cervix group|cervical pessary in group with first pregnancy or no preterm labor
2471202|NCT03096691|Active Comparator|group with cervical insufficiency|cervical pessary in group with multiple preterm labor
2471235|NCT03096262|Experimental|Stroke Patients|
2471236|NCT03096262|Active Comparator|Healthy Controls|
2471289|NCT03095989|Experimental|Mindfulness|Subjects in the intervention group will participate in an online mindfulness program developed in the first phase of the study, in addition to standard clinical care.
2471290|NCT03095989|No Intervention|Waiting list|Participants from the control group will be placed on a waiting list and will receive the standard care, that they would receive if not in the study. They will be assessed according to the assessment schedule, exactly as subjects in the intervention group. After the last assessment (six months after recruitment), they will receive the option to enter the mindfulness program.
2471304|NCT03095573|Experimental|Lateral-viewing capsule|Examination of the small bowel by means of the lateral-viewing CapsoCam device
2471305|NCT03095573|Active Comparator|Axial-viewing capsule|Examination of the small bowel by means of the axial-viewing capsule
2471353|NCT03095404|Experimental|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
2471355|NCT03095404|Experimental|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
2471418|NCT03095105|Experimental|Young group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
2471422|NCT03095105|Experimental|Elderly group|"The study was performed in two consecutive phases: single-dose and multiple-dose.~Subjects were institutionalised on Day 0, the day prior to the single-dose administration (Day 1). Single dose (dose 1) of BIA 6-512 200 mg was administered on Day 1 and subjects remained confined in the Unit until the 24 h post-dose procedures (Day 2). Then, subjects started being administered BIA 6-512 200 mg thrice-daily until the morning of Day 4 (Dose 8). Blood samples were taken at pre-determined time-points for the assay of BIA 6-512"
2471447|NCT03094767|Experimental|Control Group|Patients will be submitted only to the initial protocol of rehabilitation, i. e., they will have only one session on the initial day and one session on the final day, after 12 weeks.
2471451|NCT03094767|Experimental|Interventional Group|Patients will participate in the cardiovascular rehabilitation program during 12 weeks.
2471540|NCT03094442|Active Comparator|Dexamethasone|"Dexamethasone is a potent corticosteroid that has been widely used for chemotherapy induced nausea and vomiting. The mechanism of action is not completely understood. It has been proposed that a single dose may hinder the production and release of anti-inflammatory mediators. Dexamethasone also has a central antiemetic effect by inhibition of prostaglandin and/or release of endogenous opioids. A recent metanalysis concluded that Dexamethasone administration at induction is safe.~We will be using a 8mg dose of Dexamethasone, that is equivalent to 2ml of injectable drug."
2471543|NCT03094442|Placebo Comparator|Saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
3157404|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms.
3157405|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms.
3157406|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 1|Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo.
3157407|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 2|Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD).
3157408|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 2|Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD.
2470915|NCT03098654|Experimental|Enhanced Intervention|"Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:~Community mobilization activities to inform community members of available services~Support at the local health center to aid clinicians in managing uncontrolled cases of DM and HTN, including training for clinical staff, glucometers/test strips, and BP monitors.~HIV counseling and serial rapid HIV testing~Blood glucose and blood pressure testing~DM/HTN medications as needed~Personalized diet and lifestyle counseling for all participants with elevated glucose or BP that includes education, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose/BP."
2470917|NCT03098654|No Intervention|Control|Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care. HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing. Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
2470957|NCT03098342|Experimental|MB-PDT for Onychomycosis|
2470959|NCT03098342|Active Comparator|Amorolfine for Onychomycosis|
2471073|NCT03097354||Non-students|Ad-hoc sample of German adults, not currently enrolled at a university, lifetime alcohol users, no intervention/observational survey study design
2471077|NCT03097354||University students|Ad-hoc sample of German adults, currently enrolled at a university (most likely in Dresden, Germany), lifetime alcohol users, no intervention/observational survey study design
2471151|NCT03097081|Experimental|No orthosis|The intervention consists of a deviation of the standard protocol; patients post-operatively do not receive an orthosis.
2471155|NCT03097081|Active Comparator|Orthosis|As in correspondence with local and international guidelines, patients receive an orthosis as standard post-operative care. This is considered the control group.
2471224|NCT03096613|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
2471228|NCT03096613|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
2471272|NCT03096093|Experimental|Immunotherapy - pancreatic cancer|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with pancreatic or haematological cancer. Treatment will run concurrently with standard chemotherapy.
2471273|NCT03096093|Experimental|Immunotherapy - other late stage cancers|Intradermal injection of ACIT-1 cellular immunotherapy, a total of 2 doses, 4 weeks apart of either 10e5, 10e6, 10e7 or 3x10e7 cells. For patients with other late stage cancers, not receiving any other standard treatment.
2471337|NCT03095664|Experimental|Intervention group|6 months after surgical treatment, women in the experimental group will attend a counseling program to promote healthy eating and physical activity.
2471340|NCT03095664|No Intervention|Control group|Control group will receive usual care (verbal nutritional counseling after surgical treatment, at discharge).
2471409|NCT03095248|Experimental|Stratum 1 - NF2 related vestibular schwannomas|Stratum 1 will include patients with NF2 with vestibular schwannomas who exhibit hearing loss. Participants will receive continuous twice daily dosing of selumetinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
2471412|NCT03095248|Experimental|Stratum 2: other NF2 related tumors (meningiomas and ependymom|Stratum 2 will include patients who have progressive lesions other than VS (including non-vestibular schwannomas, meningiomas, and spinal cord lesions). Participants will receive continuous twice daily dosing of selumentinib. Dosing for children (less than 18 is 25 mg/m2/dose) and dosing for adults is fixed 75 mg/dose.
2471454|NCT03094884|Experimental|Pulsed Low dose radiation with Carboplatin/Paclitaxel|Pulsed Low Dose Radiation concurrent with Carboplatin and Paclitaxel
2471506|NCT03094416|Experimental|levothyroxine sodium capsules|levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months
2471575|NCT03093987|No Intervention|control group|usual care
2471585|NCT03093987|Experimental|critical care ultrasound|Circulation management will be adjusted according to the results of critical ultrasound combined with clearance of lactic acid in patients with shock.
2471636|NCT03093740|Experimental|HCV treatment - no viral resistance|Based on the genotype and negative viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier
2471637|NCT03093740|Experimental|HCV treatment - viral resistance|Based on the genotype and positive viral resistance testing of the donor, (determined within the first week) we will initiate a genotype specific regimen of Zepatier plus Sofosbuvir
2471683|NCT03093311|Experimental|Arm A|Brain tissue oxygenation is measured by NIRS. In time of desaturation the interventions according to NIRS based protocol start.
2471686|NCT03093311|No Intervention|Arm B|Brain tissue oxygenation is not measured.
2471782|NCT03093051|Experimental|UPT Treatment|Investigational therapy (UPT)
2471881|NCT03092271|Active Comparator|Zero Suicide Quality Improvement (ZSQI)|Zero suicide best practices as implemented through a health system zero suicide quality improvement initiative
2471884|NCT03092271|Experimental|Stepped Care for Suicide Prevention|ZSQI plus a stepped care intervention that matches intensity of services to youth risk level.
2489854|NCT02969642|Active Comparator|Treatment|Treatment laser.
2470779|NCT03099317|Experimental|Sinew acupuncture|Subject in the arm will receive real acupuncture intervention.
2470781|NCT03099317|Sham Comparator|Sham acupuncture|Subject in the arm will receive sham acupuncture intervention.
3192055|NCT00804492|Experimental|2|To perform a RCT to investigate the effectiveness of the multicenter, multifaceted intervention program
3192056|NCT00804505|Experimental|1|Test arm daily wear hybrid contact lens.
3192057|NCT00804505|Other|2|Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
3192058|NCT00804518|Experimental|Exercise intervention|
3192059|NCT00804531|Experimental|Visipaque - Hydrocortancyl|Administration of two treatments for the experimental arm
3192060|NCT00804531|Placebo Comparator|Visipaque|Administration of only one treatment in intra discal of visipaque
2470985|NCT03098134|Experimental|VR-Video-Exposure|
2470987|NCT03098134|Active Comparator|Education-Video-|
2471032|NCT03097835|Other|Group A|Group A will be treated with Hyper-Diluted Botox on day 1 and on day 30 they will be treated with 0.9% saline solution.
2471036|NCT03097835|Other|Group B|Group B will be treated with 0.9% saline solution on day 1 and on day 30 they will be treated with Hyper-Diluted Botox.
2471080|NCT03097406||Osteoarthritis group|Patients with osteoarthritis (2017-2019) at Herlev Hospital treated with Global Unite total shoulder arthroplasty
2471082|NCT03097406||Osteoarthritis control group|Patients with osteoarthritis (2013-2016) at Herlev Hospital treated with a Global Advantage
2471084|NCT03097406||Fracture group|Patients with a fracture of the proximal humerus (2017-2019) at Køge and Herlev Hospital treated with Global Unite hemiarthroplasty
2471086|NCT03097406||Fracture control group|Patients with a fracture of the proximal humerus (2013-2016) at Køge and Herlev Hospital treated with Global FX hemiarthroplasty
2471117|NCT03096964|Experimental|Nordic walking|Experimental: Nordic walking Training The total period of training was composed by 8-week of walking with poles, three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Nordic walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
2471119|NCT03096964|Experimental|Free Walking|Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
2471170|NCT03096782|Experimental|Group I (chemotherapy, TBI, cord blood)|"Patients receive rituximab IV on day -11, ATG IV over 4 hours on days -9 and -8, fludarabine IV over 1 hour, clofarabine IV over 1 hour, busulfan IV over 3 hours on days -7 through -4, and TBI on day -3. Patients then receive a cord blood transfusion IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
2471173|NCT03096782|Experimental|Group II (chemotherapy, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -5 to -2, and melphalan IV over 30 minutes on day -2. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
2471176|NCT03096782|Experimental|Group III (chemotherapy, TBI, cord blood)|"Patients receive ATG IV over 4 hours on days -8 and -7, fludarabine IV over 30 minutes on days -6 to -3, cyclophosphamide IV over 1 hour on day -6, and one low-dose treatment of TBI on day -1. Patients then receive a cord blood transplant IV on day 0.~GVHD PROPHYLAXIS: All patients also receive mycofenolate mofetil IV over 2 hours or PO BID on days -3 with a taper beginning on day 100 in the absence of GVHD, tacrolimus IV or PO starting on day -2 for 6 months in the absence of GVHD, and filgrastim-sndz SC QD starting on day 0 until white blood count begins to recover."
2471316|NCT03095716||elderly patients|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
2471402|NCT03095326|Experimental|Zinc Syrup 1.5 mg/kgbw/day|Patient were given zinc formula in the form of syrup with dosage of 1.5 mg/kg body weight/day with a maximum dose of 50 mg/day. The amount of syrup given is estimated to be enough for 4 weeks.
2471406|NCT03095326|Placebo Comparator|Sucrose syrup|Patient were given sucrose syrup as placebo. The syrup was made in the same flavor and consistency as the zinc syrup.
2471440|NCT03094793|Experimental|abnormal EEGs|
3192061|NCT00804544|Experimental|1|Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.
3192062|NCT00804557||Uro-Ease Spirus Catheter|10 patients randomized to the Uro-Ease Catheter group for 1 week. In clinic, patients will be instructed in the use of the Uro-Ease Catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to a standard, non-helical urinary catheter. Patients will be followed up to 1 month.
3208615|NCT00976430|Experimental|Therapy for Parkinson's disease|Stem cell derived from the bone marrow of the patient will be stereotactically transplanted in the striatum.These stem cell are the expected to grow up into dopamine secreting neural cells.
3208616|NCT00976443|Placebo Comparator|Placebo (normal saline)|Gastric injections of normal saline
3208617|NCT00976443|Active Comparator|BTA 100 U|Gastric injections of botulinum toxin A, 100 Units
3208618|NCT00976443|Active Comparator|BTA 300 U|BTA 300 U, gastric injections under EUS guidance
3157409|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 2|Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol.
2471210|NCT03096496||GIMEMA APL0406 patients|APL survivors previously enrolled in GIMEMA APL0406 clinical trial and in 1st molecular CR after third consolidation treatment.
2471267|NCT03096197|Experimental|EAW + TLS|The EAW+TLS training group will receive 60 minutes of exoskeleton-assisted walking overground per session, for a total of 80 sessions (3x/week, 28 wks.) with simultaneous transcutaneous lumbosacral stimulation (TLS) intervention followed by 15 minutes of over ground training without the exoskeleton. component is added to the exoskeleton assisted walking component in this group. TLS will involve placing self-adhesive stimulating electrodes bilaterally over the T11/T12 lumbar region. Correct placement will be confirmed by the elicitation of posterior root muscle reflexes in the lower limb muscles. A constant-voltage stimulator (RT 50 Sage stimulator) will deliver pulses of 2 ms width. TLS will be applied while the participant walks in the Exo-skeleton-assisted walking (EAW).
2471268|NCT03096197|Experimental|EAW without TLS|EAW, exoskeleton-assisted walking, an activity based therapy is a training which involves using the same exoskeleton device for all the participants. Each participant will undergo, 60 minutes of EAW as above. Each participant will undergo a stand evaluation and be instructed in proper use of the device. During the initial 3 sessions of training, the exoskeleton device will be tethered to an overhead pulley system during training to allow subjects to safely adapt to trunk, balance gait activities while walking in the exoskeleton. EAW overground walking will follow each training session with the 6-minute walk test, 10 meter walk test .
2471306|NCT03095677|Experimental|Apnea Group (GApn)|Program of training with exercises including apneas
2471308|NCT03095677|Other|Control Group (GC)|Program of training with exercises without apnea
2471364|NCT03095417|Experimental|Physical Exercise and Cognitive Training|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory."
2471368|NCT03095417|Active Comparator|Physical Exercise and Cognitive Control|"Physical Exercise Intervention: The physical exercise portion of the combined intervention consists of 45 minutes of multi-modal physical exercise focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength and endurance consistent with current exercise recommendations. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
2471370|NCT03095417|Active Comparator|Cognitive Training and Stretching Control|"Stretching Control: This consists of up to 10 minutes of gentle stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Intervention: The cognitive portion of the combined intervention consists of a suite of 24 programs called Brain HQ developed by Posit Science Inc., organized into six categories: attention, speed, memory, people skills, intelligence, and navigation. The DDD-ECT trial will use 45-minute sessions of Brain HQ exercises. The modules are designed to improve time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory. ly directing one session per week and available as needed for rest of the sessions."
2471372|NCT03095417|Sham Comparator|Cognitive Control and Stretching Control|"Stretching Control: This consists of up to 10 minutes of stretching. The study team will deliver 3 sessions per week for 3 months.~Cognitive Control: This consists of up to 20 minutes of puzzles and games, 2 days per week for 3 months. The participants will use on-line Brain HQ Control Games hosted by Posit Science, Inc. as an attention control."
2471471|NCT03094572|No Intervention|visual motor tasks with dominant arm (1)|experimental arm for the first sub-study healthy volunteer
2471473|NCT03094572|No Intervention|control tasks with dominant arm|control arm for the first sub-study healthy volunteer
2471476|NCT03094572|No Intervention|visual motor tasks with non-dominant arm|control arm for the second sub-study healthy volunteer
2471478|NCT03094572|No Intervention|visual motor tasks on dominant arm, flexion movement|experimental arm for the third sub-study healthy volunteer
2471481|NCT03094572|No Intervention|visual motor tasks on dominant arm, extension movement|experimental arm for the third sub-study healthy volunteer
2471483|NCT03094572|Experimental|visual motor tasks|fourth sub-study with hemiplegic patient
3157410|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 2|Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo.
3157411|NCT00364273|Experimental|Subjects receiving treatment sequence 1 : Cohort 3|Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms.
3174821|NCT00627510||A|all patients consecutively admitted to psychiatric inpatient treatment (naturalistic sample from routine psychiatric hospital intake)
3174822|NCT00627536|Experimental|1|Avotermin 5ng/100μL/linear cm wound margin
3174823|NCT00627536|Placebo Comparator|2|Placebo
3174824|NCT00627536|Experimental|3|Avotermin 50ng/100μL/linear cm wound margin
3174825|NCT00627536|Placebo Comparator|4|Placebo matched to avotermin 50ng/100μL/linear cm
3174826|NCT00627536|Experimental|5|Avotermin 200ng/100μL/linear cm
3174827|NCT00627536|Placebo Comparator|6|Placebo matched to avotermin 200ng/100μL/linear cm
3174828|NCT00627536|Experimental|7|Avotermin 500ng/100μL/linear cm wound margin
3174829|NCT00627536|Placebo Comparator|8|Placebo matched to avotermin 500ng/100μL/linear cm
3174830|NCT00627549|Active Comparator|1|
3174831|NCT00627549|Active Comparator|2|
3174832|NCT00627562|Experimental|1|robot assisted endoscopic head and neck surgery
2470859|NCT03099135|Other|Odalasvir and AL-335 With or Without Simeprevir|Participants who completed the LPVPS (Phase 2 or Phase 3 study), in which they received a regimen containing Odalasvir and AL-335 With or Without Simeprevir for the treatment of HCV infection, and who agree to participate in this follow-up study will be assessed for durability of SVR, incidence of late viral relapse, presence and long term-persistence of resistance associated substitutions (RAS) and liver disease status.
2470980|NCT03098693||Sero-discordant Couple Cohort|We will enroll and track a cohort of 60 serodiscordant couples (120 individuals). The HIV-positive couple members will be offered anti-retroviral therapy (ART) and the HIV-negative couple members will be offered pre-exposure prophylaxis (PrEP). We will monitor monthly clinic visits for the couple and will conduct in-depth behavioral surveys at baseline, 6-, 12-, and 18-months.
3192063|NCT00804557||Standard Urinary Catheter|10 patients randomized to a Standard Urinary Catheter group for 1 week. In clinic, patients will be instructed in the use of the catheter. A QOL form will be filled out measuring comfort and ease of use and subsequently after each catheterization. Patients will also record time per catheterization and bladder drainage. Patients will return to Clinic in 1 week to check progress and will then change to the UroEase Spirus Catheter. All patients will be followed up to 1 month.
3192064|NCT00804622|Active Comparator|1|tenofovir disproxil fumarate 300 mg monotherapy
3192065|NCT00804622|Active Comparator|2|telbivudine 600 mg monotherapy
2471161|NCT03096795|Placebo Comparator|Part 1: Placebo|Healthy participants with a history of mild atopy and proven sensitivity to house dust mite (HDM) will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously.
2471163|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 1|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 subcutaneously.
2471164|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 2|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 2 subcutaneously.
2471165|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 3|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 3 subcutaneously.
2471166|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 4|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 4 subcutaneously.
2471167|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 5|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 5 subcutaneously.
2471168|NCT03096795|Experimental|Part 1: MEDI3506 SC Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 subcutaneously.
2471169|NCT03096795|Experimental|Part 1: MEDI3506 IV Dose 6|Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 6 intravenously.
2471172|NCT03096795|Placebo Comparator|Part 2: Placebo|Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
2471175|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 4|Participants with COPD will receive 3 administration of MEDI3506 Dose 4 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
2471178|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 5|Participants with COPD will receive 3 administration of MEDI3506 Dose 5 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
2471179|NCT03096795|Experimental|Part 2: MEDI3506 SC Dose 6|Participants with COPD will receive 3 administration of MEDI3506 Dose 6 subcutaneously two weeks apart over a 4-week dosing period (doses on Days 1, 15, and 29).
2471180|NCT03096795|Placebo Comparator|Part 3: Placebo|Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously.
2471181|NCT03096795|Experimental|Part 3: MEDI3506 IV Dose 6|Healthy Japanese participants will receive a single MEDI3506 Dose 6 intravenously.
2471222|NCT03096366|Experimental|Physical therapy (PT) plus blood flow restriction (BFR)|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion. With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
2471225|NCT03096366|Active Comparator|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
2471258|NCT03096054|Experimental|Part 1 a dose escalation|Phase where groups of patients will receive increasing doses of LY3143921 hydrate to find a safe dose and a dose that best targets the cancer cells.
2471259|NCT03096054|Experimental|Part 2 an expansion|Phase where a larger group of patients will receive the highest dose of LY3143921 hydrate considered to be safe from Part 1, to find out more about how the drug is working.
2471317|NCT03095807|Experimental|NNC9204-1706 A|
2471321|NCT03095807|Placebo Comparator|Placebo|
2471417|NCT03095339|Active Comparator|Educational package|The educational package included the offering of the Self-Esteem , Associative strengths, Resourcefulness, Action-planning and Responsibility (SARAR) Participatory Hygiene and Sanitation Transformation (PHAST) approach, a 52 minutes educational movie and accompanying cartoon booklet. The package was developed using the PRECEDE approach.
2471421|NCT03095339|No Intervention|Control|The control group did not receive any intervention
2471456|NCT03094780|Other|Quality of Life Counseling|
2471500|NCT03094455|Experimental|Experimental group|AOT is based on the observation of meaningful actions followed by their execution
2471501|NCT03094455|Other|Control group|Children will continue standard care for 3 weeks and then will receive the AOT as the Experimental group
2471613|NCT03094221||Arrhythmia Mapping|The study sample includes patients referred for three different types of cardiac arrhythmias, which will be the studied categories: 1) atrial flutter/fibrillation, 2) atrial tachycardia, 3) ventricular tachycardia. Patients will undergo standard of care mapping and ablation procedures.
2471638|NCT03093545|Other|Normal BMI or underweight (< 24 Kg/m2)|
2471642|NCT03093545|Experimental|Obese (BMI > 30 Kg/m2)|
3192066|NCT00804622|Active Comparator|3|telbivudine 600 mg and tenofovir disproxil fumarate 300 mg
2470832|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Escalation|LY3321367 and LY3300054 given IV.
2470834|NCT03099109|Experimental|LY3321367 Dose Expansion|LY3321367 given IV.
2470835|NCT03099109|Experimental|LY3321367 + LY3300054 Dose Expansion|LY3321367 and LY3300054 given IV.
2470836|NCT03099109|Experimental|Japanese Arm D LY3321367|LY3321367 given IV.
2470837|NCT03099109|Experimental|Japanese Arm E LY3300054|LY3300054 given IV.
2470839|NCT03099109|Experimental|Japanese Arm F LY3321367 + LY3300054|LY3321367 and LY3300054 given IV.
2470927|NCT03098719|Experimental|Intervention|
2470931|NCT03098719|No Intervention|Control|
2470992|NCT03098290||Intermittent Claudication|Mild to severe claudication
2470997|NCT03098290||Ischaemic Rest Pain|
2470999|NCT03098290||Critical Limb Threatening Ischaemia|Ulcers, Necrosis, Gangrene
2471075|NCT03097328|Experimental|TAK-228|"TAK-228 will be taken orally on a weekly basis for 4 weeks per cycle~Dosage will be determined by the study team"
2471130|NCT03096951|Experimental|Prehabilitation group|Preoperative and postoperative telerehabilitation
2471144|NCT03096951|Active Comparator|Rehabilitation group|Postoperative telerehabilitation
2471199|NCT03096652|Active Comparator|Midline approach|Standard midline incision, then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
2471200|NCT03096652|Active Comparator|Modified approach|Panniculectomy with vertical incision of the rectus sheath then optimal debulking (hysterectomy + lymphadenectomy +/- omentectomy).
2471215|NCT03096275|Experimental|MMF+MTX+Glucocorticoids|Patients were treated with Glucocorticoids combined with mycphenolate mofetil(MMF) as well as methotrexate(MTX) treatment for 52 weeks and were followed for 52 weeks.
2471217|NCT03096275|Active Comparator|CYC/AZA+Glucocoticoids|Patients were treated with Glucocorticoids combined with cyclophosphamide(CYC)/azathioprine(AZA) for 52 weeks and were followed for 52 weeks
2471274|NCT03095872|Experimental|Bepanthen/Vaseline|One half of the wound occuring after CO2 laser therapy of photo-damaged skin is treated with Bepanthen and the other half with Vaseline.
2471398|NCT03095378|Active Comparator|Control|Root treatment with scaling and root planing.
2471403|NCT03095378|Experimental|Citric acid plus tetracycline|Root treatment with 50% citric acid plus 10% tetracycline, pH1, passive application for 90s.
2471408|NCT03095378|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy with toluidine blue O (100ug/ml - 60s pre-irradiation - pH4) and red laser (660nm, 30 milliwatts, 45 joules per square centimeter, sweeping mode, 90s)
2471455|NCT03094897|Experimental|18F-Al-NOTA-MATBBN PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT
2471510|NCT03094481|Active Comparator|US guided SCPB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
2471512|NCT03094481|Active Comparator|US guided ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2471513|NCT03094481|Active Comparator|US guided SCPB + ISB medial fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2471518|NCT03094481|Active Comparator|US guided SCPB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5.
2471521|NCT03094481|Active Comparator|US guided ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2471525|NCT03094481|Active Comparator|US guided SCPB + ISB lateral fracture|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine. 10ml injected for ultrasound guided Superficial Cervical Plexus Block at C4 or C5. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
2471569|NCT03093831|Experimental|Ibrutinib|
2471663|NCT03093636|Experimental|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App, study insulin, and study CGM at home for 12 weeks.
2471665|NCT03093636|Placebo Comparator|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use study insulin and the study CGM alone at home for 12 weeks.
3192067|NCT00804661||1|Children and adults with cystic fibrosis
3192068|NCT00804674|Active Comparator|1 bupivacain|
3192069|NCT00804674|Placebo Comparator|2 placebo|
2471919|NCT03092102|Experimental|A single dose HEC585（A1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471924|NCT03092102|Experimental|A single dose HEC585（A2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471929|NCT03092102|Experimental|A single dose HEC585/FE（A3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule~Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing"
2471931|NCT03092102|Experimental|A single dose HEC585（A4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471933|NCT03092102|Experimental|A single dose HEC585（A5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471934|NCT03092102|Experimental|A single dose HEC585（A6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471935|NCT03092102|Experimental|A single dose HEC585（A7）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
3192070|NCT00804700|Active Comparator|Control Group|Subjects will be given a 60 minute lecture on the benefits of regular exercise and how music can enhance the exercise experience. Subjects will be individually instructed how to use the Precor elliptical trainer at the Yates fitness center while listening to music. Subjects are instructed to exercise using the elliptical trainer for periods of 45 -55 minutes at a time as frequently as they like with a minimum frequency of once per week. Subjects will also be encouraged to exercise regularly by walking, jogging or engaging in other forms of physical activity during the intervention period. A fitness attendant will be on hand to supervise their exercise activity, but will not give specific advice how to exercise, other than to make sure they are exercising safely.
2470841|NCT03099200||Cohort 1|Participants with early breast cancer currently undergoing treatment (either chemotherapy and targeted HER2 therapy OR targeted HER2 therapy alone) will be observed.
2470844|NCT03099200||Cohort 2|Participants with early breast cancer who have completed treatment and are in disease-free survival (i.e. no longer receiving loco-regional treatment, chemotherapy or targeted HER2 therapy; participants may still be receiving hormone therapy) will be observed.
2470847|NCT03099200||Cohort 3|Participants receiving treatment for metastatic breast cancer will be observed.
2470898|NCT03098732|Experimental|Magnetically Enhanced Diffusion (MED)|The Experimental Treatment will receive the complete MED System Procedure consisting of MED MicroBeads and the MED Workstation magnet procedure for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
2470899|NCT03098732|Sham Comparator|MED Workstation Magnet Sham Control|The MED Workstation Magnet Sham Comparator will not receive MED MicroBeads while the MED Workstation Magnet will be activated as a Sham control for 60 minutes in addition to IV tissue plasminogen activator (tPA or Alteplase).
2470943|NCT03098407|Other|Buprenorphine Maintenance Treatment|Buprenorphine Maintenance Treatment patients will receive instructions regarding a follow-up, outpatient appointment with the Pregnancy Recovery Center at Magee-Womens Hospital, which specializes in Opioid maintenance treatment for pregnant patients, for the next day following enrollment in the study for induction onto buprenorphine maintenance treatment.
2470944|NCT03098407|Other|Methadone Maintenance Treatment|Methadone Maintenance Treatment patients will be immediately admitted to Magee-Womens Hospital for an inpatient induction onto methadone maintenance treatment.
2470963|NCT03098212|Experimental|Aromatherapy|Receive essential oil diffuse by Aroma diffuser during labor. Pain score and dose of analgesics drug are recorded
2470965|NCT03098212|No Intervention|Non-aromatherapy|This group receive pain control by standard of care without essential oil (aromatherapy)
3192071|NCT00804700|Experimental|Intervention Arm|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
3192072|NCT00804726|Experimental|Akreos MI Five-O|Accommodating intraocular lens
3192073|NCT00804739|Experimental|MITT|Mothers will be assigned to the Mother-Infant Treatment Team (MITT)and will receive either psychotherapy or sertraline or both as well as outreach.
3192074|NCT00804752|Experimental|Vitamin D|An addition of Vitamin D to the standard treatment
2471291|NCT03096184|Experimental|Study Group|Apatinib Mesylate Tablets and Tegafur Gimeracil Oteracil Potassium Capsules administered as a daily oral treatment
2471312|NCT03095534|Experimental|3-Step Workout for Life|Participants will exercise at the moderate intensity three times a week for 10 weeks. The total of 30 workout sessions will consist of 18 sessions of group single-joint resistance exercise, 6 sessions of one-on-one multiple-joint resistance exercise, and 6 sessions of one-on-one activities of daily living exercise. During the resistance exercise sessions, participants will use resistance tubing to strengthen major muscle groups of the upper extremity and lower extremity. During the activities of daily living exercise, participants will practice daily tasks around the home. The community fitness staff will modify the task demand to increase the physical challenge of the task to each participant, for example, increasing travel distance.
2471392|NCT03095352|Experimental|Arm A: Pembrolizumab + Carboplatin|Patients receive carboplatin intravenously (IV) and pembrolizumab IV over 30 minutes on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Treatment repeats every 3 weeks for a least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of 6 cycles of carboplatin and pembrolizumab, patients then receive pembrolizumab alone on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity
2471393|NCT03095352|Experimental|Arm B: Carboplatin Monotherapy, then Pembrolizumab for participants who progress only|Patients receive carboplatin IV on day 1. Patients who are HER2+ also receive trastuzumab IV every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression then receive pembrolizumab IV over 30 minutes on day 1 in the cross over (Arm Bx). Carboplatin may be continued or added back into the treatment regimen at the investigator's discretion. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2471468|NCT03094728||Liver transplantation receipients|All patients underwent Living donor liver transplantation at Ain Shams center for organ transplantation (ASCOT) during the designed study period
2471527|NCT03094403|Experimental|Azelaic Acid 15% topical gel|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
2471532|NCT03094403|Active Comparator|Finacea® (azelaic acid) Gel, 15%|Topical, twice daily, for 84 days A thin layer of study treatment was gently massaged into the affected areas on the face
2471535|NCT03094403|Placebo Comparator|Placebo|Topically to the face, twice a day A thin layer of study treatment was gently massaged into the affected areas on the face
2471584|NCT03093909|Experimental|Aerosol Gemcitabine (GCB)|"Dose Escalation Cohort: Participants take Gemcitabine by mist 2 times each week for 4 weeks (28 days).~Expansion Cohort: Participants with OS lung metastases receive study drug at the maximum tolerated dose from Dose Escalation Cohort.~Participants may continue to receive the study drug for up to 12 cycles per decision of doctor."
2471664|NCT03093571|Experimental|Auricular stimulation|Auricular stimulation using indwelling auricular acupuncture needles
2471667|NCT03093571|Experimental|Muscle relaxation|Progressive muscle relaxation according to Jacobsen
2471668|NCT03093571|No Intervention|No intervention|No intervention, just monitoring of outcome parameters
2471684|NCT03093220||community-acquired pneumonia|all adult patients (aged > 16 years) admit to the 4 hospitals between March 2017 and March 2018 with CAP will be enrolled
3157412|NCT00364273|Experimental|Subjects receiving treatment sequence 2 : Cohort 3|Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms.
3157413|NCT00364273|Experimental|Subjects receiving treatment sequence 3 : Cohort 3|Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol.
3192075|NCT00804765|Experimental|1|Therapeutic education
3192076|NCT00804765|Placebo Comparator|2|
3192077|NCT00804778||CABG,general anesthesia|their CO and CI was measured with USCOM and Swan-ganz cco respectively.
3157414|NCT00364273|Experimental|Subjects receiving treatment sequence 4 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo.
3157415|NCT00364273|Experimental|Subjects receiving treatment sequence 5 : Cohort 3|Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo.
3157416|NCT00364325||001|
2471011|NCT03098082|Other|Actim Pancreatitis Dipstick Test|All enrolled subjects who meet inclusion/exclusion criteria will have the Urine Trypsinogen 2 Dipstick test done.
2471023|NCT03097692|Active Comparator|Ischemic preconditioing|50 patients ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
2471024|NCT03097692|Active Comparator|Pharmacologic preconditioing|by sevoflurane anesthesia
2471063|NCT03097549|Experimental|Tät®II Treatment app|Comprehensive treatment programme with information and exercises. Individual advices.
2471065|NCT03097549|Other|Tät®II Information app|"Information only.~."
2471275|NCT03095911|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2471276|NCT03095911|Experimental|News without spin|News items reporting results of RCTs without spin
2471493|NCT03094559|Experimental|FlowMet device|This is a feasibility study
2471590|NCT03094078|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin
2471598|NCT03094078|Experimental|News without spin|News items reporting results of pre-clinical studies without spin
2471645|NCT03093610|Active Comparator|Traditional|The chest tube in the traditional Group will be managed according to the current Guidelines of the investigators' department.
2471649|NCT03093610|Active Comparator|Test group|"The chest tube in the Test Group will constitute the experimental Group. The chest tube will be removed when the fluid production over 24h has reached a weight related threshold."
2471786|NCT03092674|Active Comparator|Arm A (azacitidine)|Patients receive azacitidine SC or IV daily on days 1-7 or on an interrupted schedule which ensures that all 7 days of therapy are received within a 12 day period. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2471788|NCT03092674|Experimental|Arm B (azacitidine, nivolumab)|Patients receive azacitidine as in Arm A and nivolumab IV over 30-60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2471790|NCT03092674|Experimental|Arm C (azacitidine, midostaurin)|Patients receive azacitidine as in Arm A and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2471792|NCT03092674|Experimental|Arm D (decitabine, cytarabine)|"INDUCTION: Patients receive decitabine IV over 2 hours on days 1-5 and cytarabine IV continuously on days 6-11. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients deemed stable at the discretion of the treating physician receive decitabine as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2472277|NCT03089281|Other|SmartDelay™ algorithm|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
2472278|NCT03089281|Other|Fixed AV Delay with BiV pacing|For those subjects implanted with a Boston Scientific CRT-D identified with an RV-LV ≥70ms, 1:1 randomization will occur via the electronic data capture (EDC) system. Subjects will be randomized to have either an AV Delay and pacing chamber determined by SmartDelay or a Fixed AV Delay of 120ms with BiV pacing.
2472551|NCT03087487||NVAF patients on Warfarin|NVAF patients newly initiated with Warfarin. Non-Interventional.
3157417|NCT00364403|Experimental|1|Low glycemic load diet
3157418|NCT00364403|Active Comparator|2|Low fat diet
3157419|NCT00364416||001|
3157420|NCT00364442|Experimental|Arm 1|investigational drug
3157421|NCT00364520||Shanghai Workers|Shanghai Workers
3157422|NCT00364559|Experimental|B|A, Active B, Historical Register
3157423|NCT00364572|Placebo Comparator|1|Two injections of epidural saline 2 weeks apart
3157424|NCT00364572|Experimental|Epidural injection of etanercept|Two injections of epidural etanercept 2 weeks apart
3157427|NCT00364650|Placebo Comparator|I|Placebo
3157428|NCT00364650|Experimental|II|Probiotic supplement
3157429|NCT00364676|Experimental|1|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
3157430|NCT00364676|Experimental|2|Patients are dosed on Day 1 of a 21-day cycle.
3157431|NCT00364741|Active Comparator|A|Fraction of inspired oxygen (FiO2) = 0.30
3157432|NCT00364741|Active Comparator|B|FiO2 = 0.80
3157433|NCT00364767|Experimental|A|Whiskey (32 gram of alcohol/day)
3157434|NCT00364767|Placebo Comparator|B|Water (0 gram alcohol/day)
3157435|NCT00364780|Experimental|1|Patients received XL647 at an intermittent dosing schedule receiving drug for 5 days followed by 9 days without drug.
3157436|NCT00364780|Experimental|2|Patients received drug at a daily dosing schedule
3157437|NCT00364871|Experimental|1|Bupropion SR (400 mg/day) plus Naltrexone (48 mg/day)
3157438|NCT00364871|Experimental|2|Bupropion SR (400 mg/day) plus Naltrexone (16 mg/day)
3157439|NCT00364871|Active Comparator|3|Bupropion SR (400 mg/day)
3157440|NCT00364871|Active Comparator|4|Naltrexone (48 mg/day)
3157441|NCT00364871|Placebo Comparator|5|B-Placebo plus N-Placebo
3157442|NCT00364871|Placebo Comparator|6|B-Placebo plus N-Placebo
3157443|NCT00364871|Experimental|7|Bupropion SR (400 mg/day) plus Naltrexone (32 mg/day)
3157444|NCT00364910|Experimental|Cognitive behavioral therapy (CBT)|Participants will receive cognitive behavioral therapy
3157445|NCT00364910|Active Comparator|Educational session and treatment as usual|Participants will receive an educational session and treatment as usual
3157446|NCT00365001|Experimental|1|
3157447|NCT00365001|Active Comparator|2|
2470928|NCT03098485|Experimental|Azithromycin and cefpodoxime|"Azithromycin: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)~Cefpodoxime: 200mg tab by mouth twice per day for 5 days"
2470973|NCT03098199|Experimental|AMH<1.5, 300IU Gonal-F + 150 IU Menopur|dosage at 300IU Gonal-F + 150IU Menopur
2470976|NCT03098199|Experimental|AMH 1.6-2.5, 225IU Gonal-F+75IU Menopur|dosage of 225IU Gonal-F + 75IU Menopur
2470978|NCT03098199|Experimental|AMH 2.6-6.9, 150IU Gonal-F+75IU Menopur|start dosage of 150IU Gonal-F and 75IU Menopur
2470981|NCT03098199|Experimental|AMH >=7.0, 75IU Gonal-F+75U Menopur|start dosage of 75IU Gonal-F and 75U Menopur
2471052|NCT03097679|Active Comparator|low COF-group|The low COF-group receives a thin-strut stent (Pulsar, Biotronik AG, Bülach, Switzerland) with minimal oversizing (according to manufacturer's Instructions For Use)
2471053|NCT03097679|Active Comparator|high COF-group|The high COF-group receives a stiffer-stent (Lifestent Flexstar, Bard Peripheral Vascular Inc., Tempe, AZ, USA) with maximal oversizing (according to manufacturer's Instructions For Use).
2471126|NCT03097159||Costoclavicular block|For anesthesia, this group of patients will be received ultrasound guided costoclavicular block
2471139|NCT03097159||Supraclavicular block|For anesthesia, this group of patients will be received ultrasound guided supraclavicular block
2471194|NCT03096704||slow transit time constipation|
2471219|NCT03096327|Experimental|Intervention (Montelukast)|Aireez contains Montelukast which is a potent and selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
2471221|NCT03096327|Placebo Comparator|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured.
2471298|NCT03095859|Active Comparator|Control|Standard care (once daily physical rehabilitation, approx. 30 minutes). Standard care will consist of physical exercise, such as early mobility, endurance training, upper limb, lower limb and trunk activity. This will involve non-physical interventions including respiratory therapy, airway clearance and patient and carer education.
2471299|NCT03095859|Experimental|Experimental|Early intensive physical rehabilitation, which will consist of standard care plus one additional treatment per day. The additional early intensive physical rehabilitation session provided to the experimental group will allow for progression of aerobic, strength and flexibility exercise and / or completion of a more comprehensive physical rehabilitation program.
2471339|NCT03095482|Active Comparator|Active tDCS + In Vivo Exposure|Participants assigned to this condition will receive excitatory transcranial direct current stimulation (tDCS) of the left medial prefrontal cortex (lmPFC) and inhibitory tDCS of right dorsolateral prefrontal cortex (rdlPFC). tDCS will be administered for 20 minutes at 1.7 mA, followed by 30 minutes of in vivo exposure therapy.
2471341|NCT03095482|Sham Comparator|sham tDCS + In Vivo Exposure|Participants assigned to this condition will receive sham transcranial direct current stimulation (tDCS), which will consist of 30 seconds of stimulation at the beginning and end of tDCS administration. Electrode positioning will be counterbalanced across participants (i.e., either mPFC+ or mPFC-, with same electrode positioning as the active comparators). Sham tDCS will be administered for 20 minutes, followed by 30 minutes of in vivo exposure therapy.
2471385|NCT03095170|Experimental|Computerized brain fitness training|"Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Calendar Training and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue the computerized brain fitness for another 24 weeks.Participants are encouraged to do at least two hours per week."
2471387|NCT03095170|Experimental|Yoga|"Will receive a 10 day intervention program (over 2 weeks) consisting of Yoga, Calendar Training, and Support Group.~After the initial two week intervention, there will be an extended period during which participants will continue yoga for 24 weeks. Participants assigned to the yoga intervention will continue to meet with their group and their yoga instructor for one hour per week and will be expected to do at least an additional hour of yoga by themselves every week."
2471391|NCT03095170|Active Comparator|Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Wellness Education, Calendar Training and Support Group.
3192078|NCT00804778||group 1|co measured with swan-ganz cco combined with vigilance
3192079|NCT00804791|Active Comparator|Systane|One drop dispensed into each eye
3192080|NCT00804791|Active Comparator|Unisol|One drop dispensed into each eye
3192081|NCT00804804|Experimental|Y1|young volunteers (20-30 years), morningness chronotype
3192082|NCT00804804|Experimental|Y2|young volunteers (20-30 years), eveningness chronotype
2471672|NCT03093376|Experimental|Effortful Control Camp|"Children will participate in an interactive, child-friendly camp comprised of short, game-like exercises to teach inhibitory and attentional control, as well as visuospatial and working memory skills."
2471730|NCT03093168|Experimental|anti-BCMA CAR-T|Administration of anti-BCMA:TCRζ-4-1-BB CAR-T cells to patients with multiple myeloma
2471774|NCT03092817|Active Comparator|Dexamethasone|standard anti-tuberculosis drugs plus dexamethasone for 6-8 weeks
2471775|NCT03092817|Placebo Comparator|Identical placebo|standard anti-tuberculosis drugs plus placebo for 6-8 weeks
2471837|NCT03092453|Experimental|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide given day 1, every six weeks for 2 doses followed by standard of care anti PD-1 therapy
2471874|NCT03092167|Active Comparator|Case|Patients: this group will be submitted to 12-weeks, twice/week, physical exercises.
2471876|NCT03092167|No Intervention|Control|Patients: this group will not be submitted to 12-weeks, twice/week, physical exercises.
2471878|NCT03092167|No Intervention|Healthy control|Volunteers: this group will not be submitted to 12-weeks, twice/week, physical exercises.
3192083|NCT00804804|Experimental|O1|Aged volunteers (65-75 years), morningness chronotype
3192084|NCT00804804|Experimental|O 2|aged volunteers (65-75 years), eveningness chronotype
3192085|NCT00804817|Active Comparator|Care as usual|Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
2470968|NCT03098095|Experimental|Experimental group|Device smartphone. Participants will be trained with a supervised physical activity for 3 days a week for 16 weeks with the use of a smartphone application
2470969|NCT03098095|Experimental|Control Group|Participants will train alone with an exercise program for 16 weeks without the use of a smartphone application
2471067|NCT03097380|Experimental|AZD2115|
2471069|NCT03097380|Active Comparator|Spiriva (Tiotropium)|
2471071|NCT03097380|Experimental|[11C]AZ13754366|
2471128|NCT03097042|Active Comparator|Study group|The catheter will be pulled back slowly and without rotation
2471145|NCT03097042|Active Comparator|Control Group|The catheter will be pulled back by rotating 360 degrees round itself
2471195|NCT03096639|Active Comparator|Diaphragm Pacing Therapy DPTS|Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.
2471197|NCT03096639|No Intervention|Control Group|Standard of care treatment of weaning failure, no intervention is involved in this control group.
2471295|NCT03096028||PMNS cohort|The Pune Maternal Nutrition Study (PMNS) is a preconceptional birth cohort established in 1993 at Diabetes unit KEM hospital research center, Pune. 700 offsprings of the cohort are being followed every 6 years. Maternal vitamin B12 folate level during pregnancy were measured at 18 & 28 weeks.
2471448|NCT03094962|Other|Motion capture, MR scan, CT scan|All volunteers will go through the same data collection process
2471524|NCT03094494||Double Carbapenem Group|Patients underwent Double carbapenem treatment
2471530|NCT03094494||Standard Treatment Group|Patients who were not treated with the double carbapenem
2471580|NCT03094065|Active Comparator|News with Spin|News items reporting results of pre-clinical studies with spin.
2471586|NCT03094065|Experimental|News without spin|News items reporting results of pre-clinical studies without spin.
2471658|NCT03093649|Experimental|patient reported group|Patients reported adverse events using patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) through Application (APP) during the treatment. The summary report was transferred to their clinician immediately. Oncologists would be alarmed if patients reports exceeding the pre-defined threshold.
2471662|NCT03093649|Active Comparator|non-reported group|Patients in this group received normal care during the treatment without completing patient reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE)
2471694|NCT03093233||VKA- and NOAC-related ICH|"Analysis of hematoma enlargement: prevalence, risk factor, associations with therapeutic interventions (in patients with cranial follow-up imaging)~Association of hematoma evacuation surgery with clinical outcomes~Associations of antithrombotic management with ischemic and hemorrhagic complications~Safety of intraventricular fibrinolysis (in patients with severe intraventricular hemorrhage)"
2471745|NCT03092999|Experimental|Healthy subjects|healthy subjects
2471746|NCT03092999|Experimental|Subjects with mild hepatic impairment|hepatically impaired patients (classified as Child Pugh A)
2471747|NCT03092999|Experimental|Subjects with moderate hepatic impairment|hepatically impaired patients (classified as Child Pugh B)
3157448|NCT00365014||Blood disease patients|People with blood diseases presenting at Shanghai hospitals
3157449|NCT00365157|Experimental|Treatment (eribulin mesylate)|Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3157450|NCT00365183|Experimental|Xcytrin® (motexafin gadolinium)|
2471985|NCT03091413||case group|diaphragm ultrasounds during weaning and Pimax measures
2472079|NCT03090828|No Intervention|control|treatment as usual will be provided to patients
2472081|NCT03090828|Active Comparator|app-based therapeutic education|patients will have access to the app providing information of the disease as well as educational guidelines
2472083|NCT03090828|Experimental|enhanced app-based therapeutic education|patients will also have access to a chat room and discussion forum
2472134|NCT03090581|Active Comparator|Biopsies CP 1|Obtain transbronchial lung biopsies with cryoprobe (CP) 1
2472137|NCT03090581|Active Comparator|Biopsies CP 2|Obtain transbronchial lung biopsies with cryoprobe (CP) 2
2472140|NCT03090581|Active Comparator|Biopsies FC|Obtain transbronchial lung biopsies with forceps (FC).
2472151|NCT03090204|Other|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle during a sharp decline of right ventricle preload induced during a session of Intermittent hemodialysis.
3157451|NCT00365222|Experimental|1|
3157452|NCT00365339|Active Comparator|A|
2472752|NCT03086070|Experimental|Treatment arm|omeprazole 20 mg capsule once daily for 8 weeks
3157453|NCT00365339|Experimental|B|
3157454|NCT00365339|Experimental|C|
3157455|NCT00365339|Experimental|D|
3157456|NCT00365339|Experimental|E|
3157457|NCT00365469|Experimental|Probiotic|Commercially available cow's milk based infant formula with Bifidobacterium longum [BL999} and Lactobacillus rhamnosus [LPR]
3157458|NCT00365469|Placebo Comparator|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
3157459|NCT00365677|Experimental|Zyoptix Tissue Saving Aspheric|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
3157460|NCT00365677|Active Comparator|Zyoptix Tissue Saving|The Bausch & Lomb Zyoptix Tissue Saving algorithm is used for treatment with LASIK for the correction of myopia and myopic astigmatism.
3157461|NCT00365690|Active Comparator|1|Participants will receive individual therapy upon request
3157462|NCT00365690|Active Comparator|2|Participants will receive telephone-administered supportive-expressive group therapy
3157463|NCT00365690|Experimental|3|Participants will receive telephone-administered coping improvement group therapy
3157464|NCT00365703|Experimental|1|Orogastric feeding tube.
3157465|NCT00365703|Experimental|2|Nasogastric feeding tube.
2470954|NCT03098355|Experimental|4SCAR19/22 T cells and interleukin-2|Patients with resistant or refractory B cell acute lymphoblastic leukemia (ALL) or non-hodgkin's lymphoma (NHL) will receive CAR-T cells at a total dose of 0.5-5x10^6/kg and regular subcutaneous injection of interleukin-2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months after their serum interleukin-6 levels returned to normal range from day 28 after CAR-T cell infusion.
2471012|NCT03098069||KMC Scale up in a district|This is an implementation research project on scaling up KMC in selected government and private health facilities in an entire district, aiming to cover newborns weighing less than 2000gms at birth.
2471047|NCT03097705|Other|IOP and OCT RNFL measurements|all subjects will undergo ophthalmological exams including IOP and RNFL OCT measurements
3208619|NCT00976469|Experimental|Dose A (3.75 µg HA antigen, 0.25 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5 µg) of H1N1 pandemic influenza vaccine at a 21-day interval.
3208620|NCT00976469|Experimental|Dose B (7.5µg HA antigen, 0.5 mL)|Within each age stratum (4 age strata) subjects will be randomized 1:1 to receive two vaccinations of either Dose A (3.75 µg) or Dose B (7.5µg) of H1N1 pandemic influenza vaccine at a 21-day interval. A booster vaccination with a licensed seasonal trivalent influenza vaccine for the season 2010/2011 will be administered to at least 30 subjects in each age stratum (who have received Dose B) at 360 days after the first vaccination.
3208621|NCT00976534|Experimental|1|
2471226|NCT03096522|Active Comparator|Phenytoin 2% spray|Patients undergoing anal fistulotomy with postoperative topical phenytoin therapy
2471230|NCT03096522|Active Comparator|Anal fistulotomy|Patients undergoing anal fistulotomy without postoperative topical therapy
2471270|NCT03096015|Experimental|Intensive Treatment for Aphasia|
2471314|NCT03095729||Healthy|40 healthy subjects, during quiet breathing and under an inspiratory load (inspiratory threshold loading)
2471318|NCT03095729||Ondine syndrome|12 patients presenting with central hypoventilation syndrome or Ondine's curse syndrome, during spontaneous breathing and with Non Invasive Ventilation
2471322|NCT03095729||Amyotrophic Lateral Sclerosis|30 patients presenting with Amyotrophic Lateral Sclerosis during spontaneous breathing and with Non Invasive Ventilation
2471434|NCT03095001|Experimental|Intraperitoneal bevacizumab+ carboplatin|"Intraperitoneal administration: intraperitoneal bevacizumab plus carboplatin every 3 weeks for 4-6 cycles~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
2471435|NCT03095001|Active Comparator|Intraperitoneal carboplatin|"Intraperitoneal administration: intraperitoneal carboplatin every 3 weeks~Systemic chemotherapy: paclitaxel, iv. every 3 weeks for 4-6 cycles"
2471488|NCT03094624|Experimental|Amusia|Since 2006, recruitment of amusia participants has been organized in the Lyon region, and some 20 participants (and their matched controls in terms of age, sex, laterality, musical practice, number of years of study) have already taken part various studies conducted at the CRNL. The recruitment of amusia participants and controls is continued in order to maintain a sufficient number of participants and compensate for the withdrawals within the cohort already constituted (lack of availability, geographical distance, etc.).
2471491|NCT03094624|Sham Comparator|Matched controls|Matched controls of age, sex, laterality, musical practice, number of years of studies.
2471523|NCT03094208|Experimental|study group|muscle strengthening, weight transfer, dual task balance exercises, dual task gait exercises.
2471531|NCT03094208|Active Comparator|control group|muscle strengthening, weight transfer, balance exercises, gait exercises.
2471588|NCT03094000|Experimental|Experimental group (CBTE-MIND)|Adding a mindfulness skills intervention to group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008)
2471597|NCT03094000|Active Comparator|Control group (CBTE)|Group psychotherapy according to the principles of the Enhanced Cognitive-Behavioral Therapy (CBT-E) for eating disorders (Fairburn, 2008), without a mindfulness skills intervention
2471647|NCT03093597|Active Comparator|virgin coconut oil|All subjects will apply virgin coconut oil to a previously randomize section of the skin on the left or right forearm.
2471652|NCT03093597|Active Comparator|virgin jojoba oil|All subjects will apply virgin jojoba oil to a previously randomize section of the skin on the left or right forearm
2471655|NCT03093597|Active Comparator|virgin almond oil|All subjects will apply virgin almond oil to a previously randomize section of the skin on the left or right forearm
2471659|NCT03093597|Active Comparator|white petrolatum ointment|All subjects will apply white petrolatum ointment to a previously randomize section of the skin on the left or right forearm.
2471680|NCT03093194|Active Comparator|Women going CS without vaginal preparation before surgery|Women going CS without vaginal preparation before surgery. No vaginal preparation before CS with Septal soap and septol.
2471681|NCT03093194|Placebo Comparator|Women going CS with vaginal preparation before surgery|Women going CS with vaginal preparation before surgery. vaginal preparation before CS with Septal soap and septol.
2471751|NCT03093077|Experimental|Anatomic alignment|The aim of anatomic alignment is to recreate an individual's pre-operative alignment using the DePuy ATTUNE total knee arthroplasty system.
2471754|NCT03093077|Active Comparator|Mechanical alignment|The aim of mechanical alignment is to achieve a neutral mechanical alignment regardless of pre-operative status, using the DePuy ATTUNE total knee arthroplasty system.
2471798|NCT03092622|Experimental|exercise training|Outpatients treadmill interval training, 4x4 minutes with 3 minutes in between at lower intensity. 3 sessions weekly for 10 weeks to a total of 30 sessions.
2471889|NCT03092388|Experimental|Study Group Basic|Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.
2471891|NCT03092388|Experimental|Study Group Extended|"Patients receive Multi Frequency Bioimpedance Analysis (mfBIA) before and after sleep recording by Polysomnography/Polygraphy (PSG/PG) in hospital. Capillary Blood Gas Analysis (CBGA) is performed before and after sleep according to mfBIA.~Additionally, during daytime a special test with random parts of the study group basic is performed:~A tilting table with hemodynamic monitoring is used to induce an artificial LFS by moving patients from vertical into horizontal position. Bodyfluid changes are monitored by mfBIA during this procedure."
2472554|NCT03087487||NVAF patients on Apixaban|NVAF patients newly initiated on Apixaban. Non-Interventional.
2471091|NCT03097510|Experimental|Transcendental Meditation|The TM technique is a simple, natural, effortless technique that allows the mind to experience finer levels of the thinking process until the mind transcends and experiences the source of thought, a state of deep, integrated relaxation. During the meditation session, the active mind settles down to a silent yet fully awake state of awareness. TM was taught to study participants by certified instructors, using standardized procedures for teaching.
2471092|NCT03097510|No Intervention|Wait list control|This wait list group served as the control group. After the study was completed, the wait-list controls were given the option to learn the TM technique as their reward for participating as controls during the 4 month study.
2471148|NCT03096990||Use of apremilast in patients with active PsA|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
2471196|NCT03096470||anesthesia|The children were treated with closed reduction with anesthesia after prolonged traction
2471198|NCT03096470||No anesthesia|The children were treated with closed reduction with no anesthesia after prolonged traction
2471237|NCT03096288|Experimental|Evolocumab|Evolocumab (Repatha) 420 mg s.c. single injection
2471240|NCT03096288|Placebo Comparator|Placebo|0.9% sodium chloride s.c. single injection
2471278|NCT03096002||Lifestyle change (one-treatment group)|The lifestyle change program is a 3-week program that will introduce participants to a regular healthy lifestyle that includes exercising at least three times per week and the program will highlight simple dietary strategies. There is no randomization to this program - all individuals enrolled will partake in the same program and will be followed up for 12 months after the program has concluded.
3192086|NCT00804817|Experimental|SCION-HSCT program|"Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
3192087|NCT00804830|Experimental|chemotherapy|Treatment with Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w for 6 months.
3192088|NCT00804856|Experimental|Schedule A|BI 6727 (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c.
3192089|NCT00804856|Experimental|Schedule B|BI 6727 (d1 and 15 - one hour iv.)
3192090|NCT00804856|Active Comparator|Schedule C|LD-ARA C monotherapy (2 x 20 mg/d s.c.)
3192091|NCT00804869||1|PalmScan biometric group
3192092|NCT00804869||2|A-mode ultrasonography biometric group
3192093|NCT00804882||1|Mexican Americans with heart failure and metabolic syndrome
2471548|NCT03094156|Experimental|Placebo|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the Placebo morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2471550|NCT03094156|Experimental|BIA 6-512 25 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 25 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2471552|NCT03094156|Experimental|BIA 6-512 50 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 50 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2471553|NCT03094156|Experimental|BIA 6-512 75 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 75 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
2471554|NCT03094156|Experimental|BIA 6-512 100 mg|Subjects were administered with those investigational products at approximately 8-h intervals, starting in the morning (approximately at 8h00) of Day 1 and finishing in the morning of Day 5 (last dose). On Day 4, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 was administered. On Day 5, concomitantly with the BIA 6-512 100 mg morning dose, one tablet of Madopar® 250 and one tablet of Comtan® were administered.
3192094|NCT00804882||2|Mexican Americans with heart failure without metabolic syndrome
3192095|NCT00804882||3|Non-Hispanic White Americans with heart failure and metabolic syndrome
3192096|NCT00804882||4|Non-Hispanic White Americans with heart failure without metabolic syndrome
3192097|NCT00804895|Experimental|1|subcutaneous injection of Cortivazol ALTIM, 3,375mg
3192098|NCT00804895|Placebo Comparator|2|PROAMP, subcutaneous serum physiological saline
3192099|NCT00804934||0|
3192100|NCT00804947|Experimental|Intravenous busulfan and melphalan|
3192101|NCT00804960|Experimental|Letrozole|1) Letrozole/ Recombinant FSH
3192102|NCT00804960|Active Comparator|Standard IVF|luteal phase GnRHa suppression/gonadotropin
3192103|NCT00805012|Active Comparator|1|docetaxel+CDDP
3192104|NCT00805012|Experimental|2|docetaxel+S-1
3192105|NCT00805051||Severe aortic stenosis|Patients undergoing aortic valve replacement because of severe aortic stenosis
3192106|NCT00805064|Active Comparator|ischemic CRVO|treatment was applied to this entity
3192107|NCT00805064|Active Comparator|non ischemic CRVO|treatment was applied to this entity
3192108|NCT00805064|Active Comparator|BRVO|treatment was applied to this entity
2471109|NCT03097120|Active Comparator|estrogen-plus-medroxyprogesterone|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate
2471110|NCT03097120|Placebo Comparator|placebo|placebo
3192109|NCT00805077|Experimental|1|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
3192110|NCT00805077|Other|2|tidal volume of 10 ml/kg of ideal body weight without PEEP
3192111|NCT00805090|Active Comparator|Sporanox|Active arm approved as an anti-fungal being used to compare HPβCD when administered in DIC075V compared to Sporanox.
2471347|NCT03095430||ESPI Group|General Anesthesia using Entropy and Surgical Pleth Index Monitoring
2471350|NCT03095430||Control Group|General Anesthesia without Entropy and Surgical Pleth Index (Control Group)
2471420|NCT03095157|Placebo Comparator|Placebo|
2471423|NCT03095157|Experimental|Treatment|
2471464|NCT03094845|Placebo Comparator|Placebo|
2471467|NCT03094845|Experimental|hdmASIT+TM|
2471611|NCT03094117|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2471615|NCT03094117|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2471635|NCT03093441|Experimental|Multimodal|Multimodal High-Intensity Interval Training Intervention. This group will train using multimodal exercises for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest. Each session will have the same exercises within each set, but every session will be different than the others for movements utilized. There will be three movements used in each set. The first movement will be a strength movement for 4-6 repetitions. The second movement follows the first immediately and is a faster body weight or light implement power movement for 6-8 repetitions. The third movement follows the second immediately and is a very fast, sprint-like movement for the remainder of the 60 seconds. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
2471640|NCT03093441|Active Comparator|Rowing|Multimodal High-Intensity Interval Training Intervention. This group will train using a rowing ergometer for 5 sets of 60 seconds of all out work, followed by 3 minutes of rest (a total of 20 minutes each session). Each training session will be the same across the 12 weeks. The intent of each set is to be completed with as much effort as possible across the full 60 seconds.
2471641|NCT03093441|No Intervention|Control|Multimodal High-Intensity Interval Training Intervention. This group will be instructed to continue with any activity they were involved in prior to the study and to not begin any new exercise programs during the course of the study. To incentive participation in this group, the control group will be offered the MM-HIIT intervention the following semester at no cost.
3192112|NCT00805090|Experimental|Dyloject|Diclofenac Sodium
3192113|NCT00805103|Experimental|(HFA-SRT) in Large-Volume Brain Metastases|
2471892|NCT03092128||sensitive group; non-sensitive group|sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration. non-sensitive patients were defined as patients reached PD after first month administration and first three months administration.
2471951|NCT03091842|Experimental|Group I (CARE program)|Patients undergo supervised CARE program over 50 minutes comprising of warm up over 5 minutes, moderate to vigorous aerobic and resistance exercises over 40 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
2471955|NCT03091842|Experimental|Group II (TARE program)|Patients undergo supervised TARE program over 80 minutes comprising of warm up over 5 minutes, aerobic exercise over 15 minutes, resistance exercise over 55 minutes, and cool down over 5 minutes 3 days per week for 16 weeks.
2471958|NCT03091842|Active Comparator|Group III (home-based stretching program)|Patients undergo home-based stretching program comprising of one set of 3-4 static stretching exercises held for 30 seconds 3 days per week for 16 weeks. Patients receive instructional DVD and booklet of the flexibility exercises. Patients also complete a weekly activity log. After completion of the stretching program, patients may optionally undergo the CARE program as in group I.
2472006|NCT03091465||Metastatic Renal Cell Carcinoma patients|This is a nation-wide retrospective observational study with patients treated with first-line pazopanib for mRCC in daily clinical practice since April 2011 (date of approval of pazopanib in Spain), January 2016.
2472075|NCT03090906|Experimental|Control group: SCTG from palate|Soft tissue augmentation palate
2472076|NCT03090906|Experimental|Test group: SCTG from tuberosity|Soft tissue augmentation tuberosity
2472119|NCT03090568|Experimental|BIA 5-453 Fasting|BIA 5-453 200 mg in fasting conditions
2472122|NCT03090568|Experimental|BIA 5-453 Fed|BIA 5-453 200 mg in fed conditions
2472183|NCT03090347|Experimental|High-sugar diet|Participants will be asked to consume a relatively low-fat, high-carbohydrate eucaloric diet enriched in free-sugars (20% total energy).
3192114|NCT00805116|Experimental|1|Whale blubber oil
3192115|NCT00805116|Active Comparator|2|Cod liver oil
2472376|NCT03088735|Experimental|Blastocyst-stage embryo transfer strategy|
2472378|NCT03088735|Active Comparator|Cleavage-stage embryo transfer strategy|
2472493|NCT03088150|Active Comparator|Surgical resection|Patients included will undergo resection of hepatic metastases, allowing thermal ablation for additional unresectable lesions.
2472499|NCT03088150|Experimental|Thermal ablation|Patients included will undergo ultrasound guided thermal ablation of hepatic metastases, allowing resection for additional unablatable lesions.
2472509|NCT03087578|Experimental|EA|Patients undergoing electroacupuncture weekly for 6 weeks for 30 minutes/session.
3192117|NCT00805155||Cohort Group 1|Subjects number 1 to 20
3192118|NCT00805155||Cohort Group 2|Subjects number 21 to 50
3192119|NCT00805155||Cohort Group 3|Subject Numbers 51 to 80
3192120|NCT00805181||Acute uncomplicated pyelonephritis|
3192121|NCT00805220|Active Comparator|1|Regular overground walking without poles
3192122|NCT00805220|Experimental|2|Nordic Walking
3192123|NCT00805233|Experimental|1|Combination Ranibizumab intravitreal injection plus bromfenac ophthalmic drops
3192124|NCT00805233|Active Comparator|2|ranibizumab injection alone.
3192125|NCT00805246||Pulmonary Embolism (PE)|Subjects diagnosed with PE by CT will be recruited.
3192126|NCT00805259|Active Comparator|1. Atomistic|payment for own work
3208622|NCT00976534|Placebo Comparator|2|
3157466|NCT00365807|Active Comparator|Brief Family Intervention (Primarily education)|Behaviorally based family group intervention using standard education and nutrition counseling. Three hours of client contact
3157467|NCT00365807|Experimental|Positively Fit|12 week (90 minute per session) behavioral group intervention for children and their parents. Children and parent attend parallel group with identical (but developmentally appropriate) information presented.
2471502|NCT03094377|Experimental|Multisensory therapy group|The Multisensory therapy (MT) group received a 12-weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session began with 15 minutes of sensory stimulation (cold and vibration), 45 minutes of motor training and 30 minutes of self-care training.
2471503|NCT03094377|Active Comparator|Conventional training group|The conventional training (CT) group included 12 weeks (two sessions/ week; 90 minutes/session) training conducted by an occupational therapist. Each session included 60 minutes of upper extremity motor practice (same as in MT group) and 30 minutes of self-care training (same as in MT group).
2471555|NCT03094143|Experimental|Group A: Early intervention|Patients will be referred immediately for aortic valve intervention.
2471556|NCT03094143|No Intervention|Group B: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the participant's clinical team (cardiologist and cardiac surgeon).
2471557|NCT03094143|No Intervention|Group C: Routine care|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). Group C will appear identical to Group B
2471558|NCT03094143|No Intervention|Group D: No further study follow up|Patients will be invited back for clinical follow up according to local policy. Decision making regarding future aortic valve intervention will be taken by the patient's clinical team (cardiologist and cardiac surgeon). No further study follow up will take place but personal data will be retained for future data linkage.
2471566|NCT03093818|Experimental|Pharmacogenomic testing arm|"4,050 patients will provide a DNA sample. A pharmacogenomic test is performed. Results of this test are incorporated in the (electronic) medical record and combined with a clinical decision support system. Physicians and pharmacists may choose to use these results to guide drug and dose selection as per the Dutch Pharmacogenomics Working Group guidelines. Patients will receive a Safety-Code card containing their personal pharmacogenomics results, which can be used by other physicians or pharmacists during subsequent prescriptions."
2471567|NCT03093818|No Intervention|Standard of care arm|"4,050 patients will provide a DNA sample. However, no pharmacogenomic test is performed until the study is completed. Physicians and pharmacists will prescribe and dispense drugs routinely, without using pharmacogenomic test results to guide drug and dose selection. Patients will receive a mock Safety-Code card, which does not contain personal pharmacogenomics results."
2471697|NCT03093584|Active Comparator|Auricular stimulation|Auricular acupuncture with indwelling fixed auricular acupuncture needles
2471700|NCT03093584|Experimental|Expressive writing|Expressive writing - sharing the emotional expectations in front of forthcoming exam
2471703|NCT03093584|No Intervention|No intervention|No intervention, just observation and monitoring of outcome measures
2471756|NCT03092973||Epistaxis Group|
2471758|NCT03092973||Control Group|
2471794|NCT03092596|Experimental|Patient-administered screening tool|Patients will complete a screener for alcohol and drug misuse.
2471801|NCT03092596|Experimental|Patient health navigator-administered screening tool|Patient health navigators will administer a screener for alcohol and drug misuse to patients.
2471806|NCT03092596|Experimental|Patient health navigator-assisted linkage to treatment|Patient health navigators will be trained in motivational interviewing to engage patients about linkage to substance abuse treatment.
2471809|NCT03092596|No Intervention|Treatment as usual|Patients will receive standard care.
2471854|NCT03092310|Experimental|Artificial Pancreas|The artificial pancreas device will employ its enhanced Model Predictive Control (MPC) algorithm with a target glucose level of 110 mg/dL with a trust index for MPC-predicted glucose values, weighing future glucose predictions and only acting on predictions with higher weight in the trust index. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
2472066|NCT03090984|Active Comparator|PMMA (BKU)|"Patients included in the study will undergo 3 hemodialysis treatments. During the PMMA Arm, patient will be dialyzed using a BKU 1.6 (Toray) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.~During each study treatment, blood samples will be taken at specified time points (T0, T5, T15, T30, T90, T240) to assess overall coagulation activation (TAT, PF1+2, d-dimers), contact phase activation (kallikrein, fXIa, fXIIa), and activation of the extrinsic coagulation pathway (TF)."
2472071|NCT03090984|Active Comparator|PS (Phylter)|Patients included in the study will undergo 3 hemodialysis treatments. During the PS Arm, patient will be dialyzed using a Phylter 1.7 (Bellco) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
2472074|NCT03090984|Active Comparator|AN69ST (Evodial)|Patients included in the study will undergo 3 hemodialysis treatments. During the AN69ST Arm, patient will be dialyzed using a Evodial 1.6 (Gambro) dialyzer. All study treatments will be standardized for dialysis access, priming procedure, blood and dialysate flows, anticoagulation therapy and duration of the hemodialysis session.
2472096|NCT03090594|Other|Biopsy|Transbronchial biopsies with cryoprobe.
2489880|NCT02969330|Experimental|Glucose|Glucose ingestion
3157468|NCT00365833||Recipients of Kidney Transplant|Patients Transplanted with Live or Deceased Donor's Kidney. Standard of Care treatment pre- and post-transplant.
3157469|NCT00365885|Experimental|1|electronic mail notifications to care managers about sentinel health events
3157470|NCT00365885|Experimental|2|feedback reports with notifications to clinic managers about sentinel health events
2471214|NCT03096301|Active Comparator|Occlusal Plate|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
2471216|NCT03096301|Placebo Comparator|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
2471283|NCT03096067|Active Comparator|Heavy slow resistance group|Heavy slow resistance training. Three times weekly for 12 weeks.
2471286|NCT03096067|Experimental|Moderate slow resistance group|Moderate slow resistance training. Three times weekly for 12 weeks.
2471313|NCT03095586|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2471315|NCT03095586|Experimental|News without spin|News items reporting results of RCTs without spin
2471416|NCT03095313|Experimental|18F-NaF PET and CT scanning|18F-NaF PET-CT scan (at Baseline visit only) Contrast-enhanced CT Scan (at Baseline and Year 2 only) with possible beta-blocker and nitroglycerin, if medically safe.
2471453|NCT03094741|Experimental|CancerLife Feasibility Group|Participants will be recruited through advertisements targeted to a specific audience using the keywords cancer and cancer survivors
2471537|NCT03094507|Experimental|Group One|Tivicay (Dolutegravir 50 mg) for 14 days OD (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 43-56)
2471538|NCT03094507|Experimental|Group Two|Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 1-14) WASH OUT for 7 days (days 15-21) Tivicay (Dolutegravir 50 mg) OD plus Rezolsta (darunavir/cobicistat 800/150 mg) OD for 14 days (days 22-35) WASH OUT for 7 days (days 36-42) Tivicay (Dolutegravir 50 mg) for 14 days OD (days 43-56)
2471583|NCT03093896|Placebo Comparator|snack mix|snack mix, 3 ounces: dried coconut, meat jerky, butter, cereal party mix
2471589|NCT03093896|Active Comparator|almonds, 1.5 ounces|almonds, 1.5 ounces/day
2471595|NCT03093896|Active Comparator|almonds, 3 ounces|almonds, 3 ounces/day
2471678|NCT03093519|Experimental|KHK6640|Intravenous administration
2471679|NCT03093519|Placebo Comparator|Placebo|Intravenous administration
2471721|NCT03093090|Active Comparator|Water First|20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2471727|NCT03093090|Active Comparator|Milk First|Parmalat™ Whole Milk 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2471731|NCT03093090|Active Comparator|Baby formula first|Similac Pro-Advance™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2471734|NCT03093090|Active Comparator|Ensure Plus first|Ensure Plus™ 20mg furosemide administered PO with 6 oz of randomly-assigned study liquid
2471882|NCT03092232|Experimental|Cohort 1_Active and Matching Placebo|
2471883|NCT03092232|Experimental|Cohort 2_Active and Matching Placebo|
2471886|NCT03092232|Experimental|Cohort 3_Active and Matching Placebo|
3192127|NCT00805259|Active Comparator|2. Altruistic|payment for partner's work
3192128|NCT00805259|Active Comparator|3. Team-based|payment for relative performance of combined effort of each team
3192129|NCT00805259|No Intervention|4. Control|access to software but no financial incentives
2472044|NCT03091075|Experimental|Treatment Group|receiving oral Oxandrolone 24 mg (12mg tablets) per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
2472047|NCT03091075|Placebo Comparator|Placebo Group|receiving placebo medication (Placebo Oral Tablet), oral tablet, with dosing beginning at time of surgery and continuing for 12 weeks postoperative
2472117|NCT03090724|Experimental|BIA 5-453 (Young)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
2472118|NCT03090724|Experimental|BIA 5-453 (Elderly)|"Each subject participated in the study for approximately 7 weeks. Participation included the screening evaluations within 28 days before the first administration, phase A (single dose, a 2-day inpatient period followed by 4 ambulatory visits), phase B (multiple-dose during 7 days, 6 ambulatory visits, followed by a 2-day inpatient period and by 5 ambulatory visits) and a follow-up visit 7 to 10 days after the last administration.~Phase A: single-dose on Day 1, followed by a wash out period Phase B: repeated dose from Day 6 to Day 12 (7 days, steady-state)"
2472185|NCT03090360|Placebo Comparator|Placebo comparator (Control)|Starter infant formula with a probiotic and without a prebiotic. Volumes of feed depend on age, weight and appetite.
2472187|NCT03090360|Experimental|Experimental Formula (Test)|Starter infant formula with a probiotic and prebiotic. Volumes of feed depend on age, weight and appetite.
2472189|NCT03090360|No Intervention|Breastfed reference group|Breastfed reference group
2472258|NCT03089762|Experimental|SVF and PRP|
2472301|NCT03089320|No Intervention|Treatment As Usual (TAU)|"We have elected to compare the CM plus stepped care condition to TAU to test its efficacy against a real world control and because CM plus stepped care is a comprehensive stand alone intervention that would substitute for TAU. While annual AUDIT-C screening is mandatory at the 7 sites, providing interventions for patients with unhealthy alcohol use is a matter of physician judgment and individual clinical practice with wide practice variation. HIV clinicians will not receive knowledge of the results of follow-up research assessments. We will conduct a Treatment Services Review at each follow-up to assess for receipt of addiction treatment services received since the last assessment and assess for contamination."
2472556|NCT03087487||NVAF patients on Dabigatran|NVAF patients newly initiated with Dabigatran. Non-Interventional.
2471227|NCT03096431|Active Comparator|Arm 1: Physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 1: intervention of physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2471231|NCT03096431|Active Comparator|Arm 2:Physical activity and cognitive intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 2: intervention of both cognitive rehabilitation and physical activity begins. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2471234|NCT03096431|Active Comparator|Arm 3: Cognitive and begin physical activity intervention|Undergo baseline testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: Intervention of cognitive rehabilitation begins prior to and is concurrent with WBRT/SRS treatment. 14 days (± 2 days) following WBRT/SRS: all arms undergo testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities. Arm 3: continue intervention of cognitive rehabilitation; add intervention of physical activity. 60 days (± 5 days) post testing after WBRT/SRS: all arms undergo final testing of physical (lower body strength, endurance) and cognitive (executive functioning) abilities.
2471269|NCT03095950|Active Comparator|News with Spin|News items reporting results of RCTs with spin
2471271|NCT03095950|Experimental|News without spin|News items reporting results of RCTs without spin
2471311|NCT03095690|Other|Idiopathic Parkinson's Disease patients|High resolution peripheral scanner (HRpQCT).
2471388|NCT03095365|Active Comparator|Dry needling|Received Dry needling in the neck muscles.
2471390|NCT03095365|Active Comparator|Conventional treatment|the participants received the conventional treatment for non-specific neck pain.
2471394|NCT03095365|Experimental|Dry needling and pain neuroscience education|Received the same treatment as dry needling group and pain education.
2471528|NCT03094546|Experimental|Polyamine supplementation|Intervention: Dietary Supplement (Polyamine supplementation): 750 mg wheat germ extract
2471534|NCT03094546|Placebo Comparator|Placebo|Intervention: Dietary Supplement Placebo: 750 mg cellulose
2471574|NCT03093961|Experimental|Intervention|IASD Implantation
3192130|NCT00805272|Experimental|1|
3192131|NCT00805298|Active Comparator|methylprednisolone|
2471879|NCT03092154|Experimental|Exposed|Patients will receive lipid-lowering agents (Artovastatin) for at least 12-weeks
2471880|NCT03092154|No Intervention|No intervention|Patients will not receive artovastatin (lipid-lowering agents)
2471939|NCT03091881|Active Comparator|Granisetron group|patients in this group will receive intravenous Granisetron 0.1 MG/ML 10 minutes before spinal anesthesia
2471941|NCT03091881|Placebo Comparator|Placebo group|Patients in this group will receive 10 ml normal saline as placebos considering the same timing and color of solution
2471991|NCT03091530|Experimental|Sleeper Stretch THEN Balloon Blow|Sleeper Stretch CROSSOVER TO 90/90 Hip Lift with Balloon Blow Exercise
2471997|NCT03091530|Experimental|Balloon Blow THEN Sleeper Stretch|90/90 Hip Lift with Balloon Blow Exercise CROSSOVER TO Sleeper Stretch
2472063|NCT03091153|No Intervention|Control|Standard care. Annual medication review
2472064|NCT03091153|Experimental|Intervention|In depth medication review with a focus on deprescribing
2472120|NCT03090711|Experimental|TMS|Real transcranial magnetic stimulation (TMS).
2472123|NCT03090711|Sham Comparator|sham TMS|Sham transcranial magnetic stimulation (TMS) as a comparison.
2472125|NCT03090711|Experimental|TMS and tACS|Real transcranial magnetic stimulation (TMS) and real transcranial alternating current stimulation (tACS).
2472126|NCT03090711|Sham Comparator|TMS and sham tACS|Real transcranial magnetic stimulation (TMS) and sham transcranial alternating current stimulation (tACS) as a comparison.
2472147|NCT03090217|Experimental|Pelvic physiotherapy (PP)|Pelvic Physiotherapy include daily pelvic floor muscle training (PFMT). PFMT starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
2472149|NCT03090217|Active Comparator|Stander Care (SC)|The stander care (SC) includes a guideline for gynecological cancer patients under radiotherapy/brachytherapy: 1) daily vaginal dilator therapy (10 to 15 minutes); and 2) usual care management. This SC starts at first session of the brachytherapy and will be conduced during the twelve weeks treatment.
2472294|NCT03089619|Active Comparator|Human-Spongiosa (IMP: drug)|Product Name: Human-Spongiosa,gefriergetrocknet, CHB / Pharmaceutical form: Granules / Routes of Administration: Dental use / Marketing authorisation number : 3004134.00.00 / Marketing Authorisation Holder: Institute of Transfusion Medicine, Tissue bank, Charité university of medicine Berlin / Used by socket preservation
2472295|NCT03089619|Active Comparator|collacone® (IMP: medical device)|Product Name: Collacone / Pharmaceutical form: Absorbable, local Hemostat, porcine collagen / Routes of Administration: Dental use / Medical device with a CE mark / Used by socket preservation
2472341|NCT03088969||patient with a chronic back pain|
2472444|NCT03088618|Experimental|Patients with septal deformity|To evaluate the safety and efficacy of surgical material for nasal septoplasty in septal deformity patients with nasal obstruction
2472492|NCT03087890|Active Comparator|Cotrimoxazole|Patients in the Cotrimoxazole study arm will receive 2 tablets daily of Cotrimoxazole (trimethoprim 80mg + sulfamethoxazole 400mg), these tablets are purchased locally in Tanzania, and are the same as used for pneumocystis preventive therapy under the National AIDS control programme.
3192132|NCT00805298|Placebo Comparator|placebo|
3192133|NCT00805298|Active Comparator|lidocaine|
3192134|NCT00805298|Active Comparator|bupivacaine|
3192135|NCT00805311|Experimental|CEA Group|Patients will undergo carotid endarterectomy (CEA) and receive medical treatment including medical therapy with statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
3208623|NCT00976547||Tinnitus patients|Group of 48 tinnitus patients
2471300|NCT03095794|Experimental|neural mechanisms of decision making|Previous studies on how brain manages a value-based decision have been bounded to individual decisions. The current study will extend the understanding of social dimensions by answering four questions.
2471342|NCT03095469|Experimental|study group|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24 h after PCI.
2471344|NCT03095469|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h when the operation begin and stopped until 24 h after PCI.
3208624|NCT00976586||Patients wiht Incontinentia Pigmenti|Patients wiht Incontinentia Pigmenti
2471489|NCT03094650|Experimental|MindMotion PRO|The training sessions consist of virtual reality based rehabilitation exercises using the MindMotion PRO device.
2471799|NCT03092739||Cytological and Histological Samples|Cytological and histological specimens that meet the eligibility criteria will be analyzed only from those participants who have consented to biomarker research, according to local regulations and ethical guidelines. Cytological samples may originate from fine needle aspirations. Pleural effusions or bronchial cytology samples (brushings and washings) may be allowed. Histological samples may originate from core needle biopsies, bronchial biopsies (thoracoscopy or mediastinoscopy) or surgical tissue resections.
2471850|NCT03092284|Active Comparator|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Allogeneic adipose derived stromal cells
2471851|NCT03092284|Placebo Comparator|Placebo|Saline
2471893|NCT03092115|Experimental|HIV medication adherence app|Youth in this arm will receive a medication adherence application to help them remember to take their HIV treatment medication (antiretroviral therapy) as a supplement to current HIV standard of care.
3157471|NCT00365885|Experimental|3|letters to patients with notifications about sentinel health events
2471986|NCT03091517|Other|GlycoLeap|Since this is a single arm study, all participants will receive the GlycoLeap intervention.
2472052|NCT03091257|Experimental|Dabrafenib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated~Treat cohort with Dabrafenib~Analysis~Treat cohort with Dabrafenib"
2472055|NCT03091257|Experimental|Dabrafenib and Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~BRAF V600 mutated, BRAF/KRAS mutated, or BRAF/NRAS mutated, or BRAF non-V600 mutated~Treat cohort with Dabrafenib and Trametinib~Analysis~Treat cohort with Dabrafenib and Trametinib"
2472057|NCT03091257|Experimental|Trametinib|"Determine if mutation in BRAF, KRAS, NRAS~KRAS or NRAS mutated~Treat cohort with Trametinib~Analysis~Treat cohort with Trametinib"
2472093|NCT03090685|Experimental|True auriculotherapy with seeds|Auriculotherapy complementary to the usual drug treatment. At each ear, selected points edible seeds of roasted mustard with a size of approximately 2 mm will be used, since it is natural and non-toxic. The seeds will be stored in ear plate and applied with the use of micropore clamp and tape in 4 to 5 specific points to control for musculoskeletal pain.
2472097|NCT03090685|Placebo Comparator|Placebo Auriculotherapy with seeds|Placebo Auriculotherapy complementary to usual drug treatment. Seeds will be used in 4 auricular points in the lobe of the ear that have no specific relation to the musculoskeletal pain in the lower limbs and with the innervation of the vagus nerve.
2472174|NCT03090412|Experimental|Arm I (surgery)|Patients undergo standard of care surgery on day 1.
2472176|NCT03090412|Experimental|Arm II (HPPH, PDT)|Patients receive HPPH IV over 1 hour on day 0 and undergo PDT on day 1.
2472196|NCT03089814|Active Comparator|Healthy volunteers|Healthy male volunteers will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
2472197|NCT03089814|Active Comparator|Cardiac surgery patients|Patients scheduled for cardiac surgery will receive ischemic conditioning (4 cycles of 5-min ischemia followed by 5-min reperfusion on upper extremity) while measuring changes in tissue microcirculation at the thenar muscle.
2472266|NCT03089476|Other|High Risk Atopic Infants|Infants, who are at high risk of atopy, which will be determined by a validated questionnaire, will be enrolled. Infants will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), bacterial swabs, and parental questionnaires at each visit (3 visits total). At the latter 2 visits, infants will also undergo skin prick testing to evaluate for food sensitization.
2472267|NCT03089476|Other|Atopic Adults|Parents of infants enrolled in the study will undergo skin tape stripping (STS), transepidermal water loss assessment (TEWL), and complete questionnaires at the first visit.
2472282|NCT03089190|Active Comparator|DC7-2 alone|Administration of DC7-2, a meat-derived octapeptide.
2472286|NCT03089190|Active Comparator|DC7-2 + potato protein isolate|Administration of DC7-2, a meat-derived octapeptide, combined with potato protein isolate that protects DC7-2 from degradation in the GI tract.
2472288|NCT03089190|Active Comparator|Potato protein isolate + placebo|Administration of potato protein isolate combined with inactive whey protein as placebo.
2472289|NCT03089190|Placebo Comparator|Placebo|administration of inactive whey protein
2472398|NCT03088644|Experimental|Part A: 18F-JNJ-64413739|Subjects will receive an intravenous (IV) bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 megaBecquerel (MBq) on Day 1 of Part A to investigate the total body biodistribution and measure the radiation dosimetry.
3157472|NCT00365885|No Intervention|4|electronic mail notifications to care managers about sentinel health events -- generated but withheld
3157473|NCT00365885|No Intervention|5|feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
3208625|NCT00976612||Nilotinib|Patients who receive nilotinib with failure to both imatinib and sunitinib
3208626|NCT00976625|No Intervention|1|Control group without intervention. Treatment group with aortic valve replacement.
2471293|NCT03095755|Sham Comparator|Sham|The investigators will perform sham ischemic conditioning on the paretic leg by inflating a blood pressure cuff to only 25 mmHg on the leg for 5 minutes. This will be repeated for 5 cycles, with 5 minutes of rest between each cycle. The intervention will be performed for a maximum of 12 times within a 4 week period.
2471539|NCT03094182|Experimental|iron group|Patients in the iron group are given Intravenous iron isomaltoside during operation.
2471542|NCT03094182|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
2471687|NCT03093363|Other|Intervention group|Asthmatic patients with the pharmacist's intervention
2471690|NCT03093363|Other|Control group|Asthmatic patients without the pharmacist's intervention (only questionnaires)
2471768|NCT03093064|Experimental|Patient Group: Natalizumab|Natalizumab 300mg, intravenous, once monthly, total of 3 doses
2471770|NCT03093064|Placebo Comparator|Patient Group: Placebo|Saline, intravenous, once monthly, total of 3 doses
2471822|NCT03092531|Experimental|Positive STEPS|"Step 1) all participants randomized to the experimental condition will receive low-intensity, daily two-way SMS texts of personalized reminders to take medications as prescribed (social-cognitive cues). If a participants demonstrates >90% adherence they will remain on step one. Participants who continue to have difficulty adhering to their HIV medications at one month after baseline or anytime up to the end of month three (weeks five through twelve) will progress to Step 2) Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes."
2471827|NCT03092531|No Intervention|Standard of Care|The standard health services offered at each site (e.g., mental health services, case management) and a brief adherence educational session. This will consist of a review of medications and recommended dosing (i.e., to understand regimen), adherence expectations, toxicity expectations and medication misperceptions.The participant will then view a 20-minute animated tutorial which explains the importance of adherence to antiretroviral medication effectiveness.
2471885|NCT03092141|Active Comparator|Patients|Patients will be submitted to physical training (12-weeks, twice/week)
2471887|NCT03092141|Active Comparator|Control group|Healthy individuals will be submitted to physical training (12-weeks, twice/week)
2471943|NCT03091855||PLUG Dementia Trial|Patients with atrial fibrillation that undergo a standard of care, clinically approved, left atrial appendage closure will be considered for study. All patients will be followed for 24 months, and will be assessed at the 3-, 6-, 12-, 18- and 24-months post-left atrial appendage closure as well as other visits deemed necessary for clinical care. All subjects will undergo protocol-specified laboratory tests and will complete 6 standard, validated questionnaires at each follow-up visit, except at the 3-month visit when only one questionnaire will be administered.
2471947|NCT03091855||MRI PLUG Dementia Sub-Study|20 of the 60 subjects who are selected for participation in this sub-study will receive a cranial MRI at baseline and at the 2-year (24 months) follow-up visit.
2471990|NCT03091556||The individuals taking XLGB Pill|The overall individuals taking XLGB Pill with recommended dosage and achieving the inclusion criteria.
3157474|NCT00365885|No Intervention|6|letters to patients with notifications about sentinel health events -- generated but withheld
3157475|NCT00365924|Other|Forteo|
3157476|NCT00365937|Experimental|Group A|The eight HLA-A2 peptides
2472498|NCT03087903|Experimental|150 mg of Grape Seed Extract (GSE)|150 mg of GSE twice daily in the form of 75 mg capsule of Leucoselect Phytosome preparation.
2472513|NCT03087630|Experimental|Reasoned-Based Intervention|Receives reason-based intervention.
2472521|NCT03087630|Experimental|Social-Based Intervention|Receives social-based intervention.
2472531|NCT03087630|Experimental|Integrated Intervention|Receives integrated intervention.
2472534|NCT03087630|Experimental|Attention Control|Receives attention control feedback.
2472734|NCT03086031|Experimental|Program-based vocational rehabilitation|Combined intervention with a neuropsychological, social and community intervention followed by a vocational rehabilitation programme with a total length of 6-9 months.
2472759|NCT03086070|Placebo Comparator|Placebo arm|matching placebo capsules ones daily for 8 weeks
2472775|NCT03085654|Experimental|High anxiety group (single dose)|Oxytocin nasal spray or placebo nasal of one dose in subjects with high trait anxiety.
2473381|NCT03082105|Experimental|Winter snow|First test series breathing in dry snow in winter
3157477|NCT00365937|Experimental|Group B|The eight HLA-A2 peptides + immunological adjuvant Montanide ISA51
3157478|NCT00365937|Experimental|Group C|the eight peptides HLA-A2 + IMP321
3157479|NCT00365937|Experimental|Group D|The eight HLA-A2 peptides + the 2 immunological adjuvants (Montanides ISA 51 and IMP321)
3157480|NCT00366002|Experimental|1|Darifenacin
3157481|NCT00366041|Experimental|Cellularised LG002|Cellularised LG002
3157482|NCT00366041|Experimental|UnCellularised LG002|UnCellularised LG002
3157483|NCT00366093|Experimental|1|eszopiclone 3 mg
3157484|NCT00366093|Placebo Comparator|2|Placebo tablet
3157485|NCT00366145|Active Comparator|Prochymal|Patients who receive standard of care plus treatment with ex vivo cultured adult human Mesenchymal Stem Cells
3157486|NCT00366145|Placebo Comparator|Placebo|Patients who receive standard of care and do not receive treatment with ex vivo cultured adult human mesenchymal stem cells.
3157487|NCT00366158|Experimental|1|Ventricular Instrinsic Preference (VIP) turned ON
3157488|NCT00366158|Active Comparator|2|Ventricular Instrinsic Preference (VIP) turned OFF
3157489|NCT00366210|Experimental|Expanded CI therapy|3.5 hours of training for the more-affected arm set in the laboratory for 15 consecutive weekdays
3157490|NCT00366210|Placebo Comparator|Placebo Control|Stretching, movement exercises, and EMG biofeedback for the same duration as the experimental intervention.
3157491|NCT00366210|No Intervention|Usual & Customary Care Control|Treatments available to participants as part of their regular medical care, such as conventional physical or occupational therapy. For some participants, this would involve no treatment, since all participants were more than one year post stroke.f standard clinical care.
3157492|NCT00366288||1|
3157493|NCT00366288||2|
3157494|NCT00366288||3|
3157495|NCT00366288||4|
3157496|NCT00366288||5|
3157497|NCT00366288||6|
3157498|NCT00366288||7|
2471335|NCT03095820|Experimental|Multidomain intervention|"As a multidomain intervention, four evidence-based therapeutic approaches (physical activity, healthy diet, social activity, and emotional regulation) were incorporated into the program.~In terms of the healthy diet intervention, we encouraged participants to perform at least 30 min of above-moderate physical activity, three times per week. In terms of the healthy diet intervention, the intervention consisted of encouraging participants to consume high quantities of fish, olive oil, legumes, vegetables, and fruit, at a frequency of at least twice a week. In terms of the social activity intervention, we encouraged participants to participate in social organizations, such as the senior center, the hall of the elderly, a fraternity, a reunion, and a clan gathering, at least once a week. In terms of the emotional regulation intervention, we a performed brief cognitive restructuring task for 20 min per visit."
2471397|NCT03095261|Experimental|Self-monitoring (financial incentives then virtual rewards)|Participants will be asked to track their exercise daily, using an online tool called ExTracker.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked. In the second six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked.
2471399|NCT03095261|Active Comparator|Self-monitoring (virtual rewards then financial incentives)|Participants will be asked to track their exercise daily, using an online tool called ExTrack.ca, for 52 weeks. Date, type of exercise, time spent exercising, and distance covered will be self-reported, as will steps per day and 10-minute bouts of MVPA per day (measured by an accelerometer). In the first six months, participants will earn virtual rewards (i.e. heart badges) each day exercise is tracked. In the second six months, participants will earn financial incentive (ex. grocery vouchers) each day exercise is tracked.
3157499|NCT00366327|Experimental|A|
3157500|NCT00366353|Other|1|Sedation suring a spontaneous breathing trial.
3157501|NCT00366353|Other|2|No sedation during spontaneous breathing trial
3157502|NCT00366379|Experimental|1|
3157503|NCT00366379|Experimental|2|
2471639|NCT03093428|Experimental|Radium-223|-Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose
2471643|NCT03093428|Experimental|Pembrolizumab Plus Radium-223|"Radium-223 will be administered intravenously every 4 weeks at a pre-determined dose~Pembrolizumab will be administered intravenously every 3 weeks at a pre-determined dose"
2471733|NCT03093259|Experimental|ABX464 Treatment Arm|Subjects will receive 50 mg of ABX464 orally once daily for 56 days.
2471735|NCT03093259|Placebo Comparator|ABX464 matching placebo Treatment Arm|Subjects will receive 50 mg of ABX464 matching Placebo orally once daily for 56 days.
2471780|NCT03092830||1-arm, 500 participates|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
2471875|NCT03092466|Active Comparator|femoral group|Group 1: placement of a femoral nerve catheter plus femoral block with 15 ml of a Ropivacaine 0,75% solution through the femoral catheter
2471877|NCT03092466|Placebo Comparator|control group|Group 2: placement of a femoral nerve catheter plus the administration of an equivalent volume (15 ml) of a saline solution through the femoral catheter
2471945|NCT03091868|Experimental|Group 1 (BIA 6-512 25 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 25 mg dose = 1 capsule of 25 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2471950|NCT03091868|Experimental|Group 2 (BIA 6-512 50 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 50 mg dose = 2 capsules of 25 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2471954|NCT03091868|Experimental|Group 3 (BIA 6-512 100 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 100 mg dose = 1 capsule of 100 mg plus 1 capsule of placebo In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2471956|NCT03091868|Experimental|Group 4 (BIA 6-512 200 mg + Placebo)|"Single-doses were prepared as follows:~BIA 6-512 200 mg dose = 2 capsules of 100 mg In all groups, placebo recipients received 2 capsules of placebo. BIA 6-512/Placebo capsules and Sinemet® 100/25 and Comtan® tablets were administered simultaneously, by oral route, in fasting conditions."
2472038|NCT03091218||The individuals taking RZZY Capsule|The overall individuals taking RZZY Capsule with recommended dosage and achieving the inclusion criteria.
2472077|NCT03090919|Placebo Comparator|Saline|Subjects randomized to the Saline arm will receive 250cc of physiological saline.
2472078|NCT03090919|Experimental|Platelet transfusion|Subjects randomized to platelet transfusion will receive a unit of platelets (~250cc in volume).
2490093|NCT02967939|Active Comparator|Viread®|Viread® 300mg tablet qd
3157504|NCT00366379|Experimental|3|
3157505|NCT00366379|Experimental|4|
3157506|NCT00366379|Experimental|5|
3157507|NCT00366470|Experimental|A|Vitamin D in doses of 100,000 IU
3157508|NCT00366470|Placebo Comparator|B|
3157509|NCT00366509||1|Lung Disease
3157510|NCT00366509||2|Healthy volunteer
3157511|NCT00366639||001|
3157512|NCT00366704|Experimental|A|
3157513|NCT00366704|Active Comparator|B|
3157514|NCT00366782|Experimental|1|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age
3157515|NCT00366782|Experimental|2|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to HPIV3-seropositive children 15 to 59 months of age). This arm may enroll after Arm 1 depending on the effect of the vaccine on Arm 1.
3157516|NCT00366782|Experimental|3|One vaccination with rB/HPIV3 vaccine (at lower dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
3157517|NCT00366782|Experimental|4|One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to seronegative children or infants 6 to 36 months of age. This arm may enroll after Arm 2.
3157518|NCT00366782|Placebo Comparator|5|One vaccination with placebo vaccine given as nose drops to adults, HPIV3-seropositive children, or seronegative children or infants
3157519|NCT00366795|Experimental|Satavaptan|
2471430|NCT03094988|Experimental|Cognitive and physical prehabilitation|The intervention group will receive the prehabilitation program consisting of a guided progressive program of home-based aerobic and resistance training exercise, which will be adapted based on kinesiologist recommendation for each individual and the individual's perceived exertion. In addition, they will have access to the full cognitive training program. They will receive weekly phone calls by cognitive and physical therapy teams to address issues with any aspects of the program.
2471457|NCT03094689|No Intervention|Control group|
2471459|NCT03094689|Experimental|Immersion group|They will be immersed in a barrel of 200 liters of water (without ice) at room temperature, according to local conditions of temperature and humidity (Natal county - RN). They will be immersed to the height of the iliac crests for 10 minutes.
2471461|NCT03094689|Experimental|Cold water immersion group|They will be immersed in a barrel of 200 liters of ice water at an average temperature of 10 ° C for 10 minutes. They will be immersed to the height of the iliac crests.
2471529|NCT03094468|Experimental|P-3058|
2471536|NCT03094468|Placebo Comparator|Vehicle|
2471577|NCT03093792|Placebo Comparator|Control|(no diet or exercise intervention)
2471587|NCT03093792|Experimental|American Heart Association|(AHA: 55% carbohydrate, 15% protein, 30% fat - diet plus exercise)
2471594|NCT03093792|Active Comparator|Curves Complete - I|(CC - I: 30% carbohydrate, 45% protein, 25% fat - diet plus exercise)
2471600|NCT03093792|Active Comparator|Curves Complete - II|(CC - II: 20% carbohydrate, 45% protein, 35% fat - diet plus exercise)
2471654|NCT03093506|Active Comparator|Low-dose rhEpo|RhEpo 60IU/kg/week
2471657|NCT03093506|Active Comparator|Micro-dose rhEpo|RhEpo 20IU/kg/week
2471661|NCT03093506|Placebo Comparator|Placebo Control|Saline
3192136|NCT00805311|Active Comparator|OMT Group|Patients will receive conservative therapy - optimal medical treatment (OMT) including statins (at least 10 mg atorvastatin irrespective of the baseline cholesterol level), aspirin (100 mg daily) and antihypertensive therapy (at least 50 mg losartan and 5 mg amlodipine 75 mg daily irrespective of the baseline arterial pressure level). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations.
2471783|NCT03092778|Experimental|Cryoablation Group|Participants with mild to moderate obesity will undergo a cryoablation procedure to the vagal nerve.
2471868|NCT03092414|Experimental|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
2471871|NCT03092414|Experimental|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
2471922|NCT03091933|Experimental|GLIDE|GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
2472051|NCT03091270||BOLD-fMRI|Identifying the motor functional cortex in glioma patients with BOLD-fMRI.
2472056|NCT03091270||ZOOMit-fMRI|Identifying the motor functional cortex in glioma patients with ZOOMit-fMRI.
2472112|NCT03090776|Other|unenriched|all eligible women for partial or total mastectomy intervention will be ketamine or placebo saline
2472114|NCT03090776|Other|enriched for PPMP risk|women at high risk for persistent pain after partial or total mastectomy intervention will be ketamine or placebo saline
2472159|NCT03090321|Active Comparator|Stand Prompt|Behavioral Intervention Prompt- Participant will receive a notification asking them to stand and walk if they have been sitting for longer than 60 minutes.
2472161|NCT03090321|Active Comparator|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
2472168|NCT03090321|Active Comparator|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study.
2472173|NCT03090321|Placebo Comparator|Read AHA website|Daily reminder to read the American Heart Association (AHA) website.
2472177|NCT03090321|No Intervention|Baseline monitoring|No feedback is provided to the users. This is the control arm.
2472198|NCT03089840|Experimental|Normothermic Machine Perfusion (OrganOx metra)|Donor livers will be placed on the OrganOx metra device for normothermic perfusion before transplantation.
2472318|NCT03089151|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden, including seeds and transplants, tools, new garden classes and access to master community gardeners in Denver.
2472319|NCT03089151|No Intervention|Wait List Control Group|The non-gardening group will remain on the DUG wait lists and will not receive the garden intervention.
2472349|NCT03088826|Active Comparator|MSIR and Acetaminophen Group|The patients in this group will receive 1 tablet 15mg PO morphine sulfate immediate release combined with 650mg of Acetaminophen
2472354|NCT03088826|Active Comparator|Oxycodone and Acetaminophen Group|The patients in this group will receive 1 tablet 10mg Oxycodone combined with 650mg of Acetaminophen
2472481|NCT03088124|No Intervention|active surveillance|Active surveillance without androgen deprivation
2472484|NCT03088124|Experimental|active surveillance with Apalutamide|Active surveillance during and after 6 months treatment with Apalutamide
2472537|NCT03087539|Experimental|Clotinab (Abciximab)|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
2472539|NCT03087539|Placebo Comparator|Placebo|0.25 mg/kg bolus prior to PCI and then 10 ug/kg/min continuous infusion for 12 hours
2472561|NCT03087240|Experimental|Test|Dental Prophylaxis at fist visit (T0), after 2 weeks (T1) and after 3 months (T2)
2472562|NCT03087240|Other|Control|Wait & Control Study Design: Dental Prophylaxis after 3 months (T2) only
2472579|NCT03087084|Experimental|Cardiac Pacing and Impedance Measurement system|
2472652|NCT03086837|Experimental|Mobile phone based intervention|Participants in the intervention group will receive a 12 week mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to increase active transportation. Feedback will be provided on personal goals.
2472656|NCT03086837|No Intervention|Control|No information
2472671|NCT03086317|Active Comparator|Standard Catheter-Directed Thrombolysis|Participants randomized to this arm will receive standard catheter-directed thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
2471441|NCT03094819|No Intervention|Group 1|Participants randomized to Group 1 will be the control group. They will be observed while they receive usual eye care without any study intervention.
2471442|NCT03094819|Experimental|Financial Incentive|Participants randomized to the Financial Incentive group will be offered a financial incentive in conjunction with their usual eye care. They will receive usual care and a $25 payment if they obtain a confirmed eye examination.
2471443|NCT03094819|Experimental|Retinal Care DR|Participants randomized to the Retinal Care DR Service group will receive: (1) point of care risk assessment for vision-threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision-threatening diabetic retinopathy.
2471516|NCT03094533|Active Comparator|Total intravenous anesthesia|In the total intravenous anesthesia(TIVA) group, target controlled infusion (TCI) I was performed with propofol 4 mcg / ml. When the consciousness of the patient is lost, Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
2471522|NCT03094533|Active Comparator|volatileinduction maintenance anesthesia|In the volatile induction and maintenance anesthesia(VIMA) group, when 8% sevoflurane is inhaled with 100% oxygen at 6 L / min and the consciousness is lost, the concentration of sevoflurane is reduced to 2-3% and then the mask is ventilated.Remifentanil is administered as TCI with a target concentration of 1 ng / ml as an analgesic agent, and rocuronium 0.5 mg / kg is administered intravenously for intubation.
2471578|NCT03093935|Experimental|StimRouter Neuromodulation System|"All eligible patients who are enrolled in this study will be treated with StimRouter stimulation therapy as part of standard of care for the entire duration of the study (6 months) and observed for post-market population-specific data.~Standard recommended stimulation parameters for post-stroke shoulder pain include settings to elicit sensory response (paresthesia) as well as motor response (muscle contraction)."
2471732|NCT03093675|Experimental|TELELAP ALF-X Robotic Surgical System|The patients will undergo surgical procedures using the innovative TELELAP ALF-X robotic system.
2471761|NCT03092882|Experimental|Intervention|Diabetes Self-Management Program
2471765|NCT03092882|No Intervention|Control|
2471823|NCT03092609|Experimental|Attention Bias Modification|
2471826|NCT03092609|Active Comparator|Attention Control|
3157520|NCT00366795|Placebo Comparator|Placebo|
2471921|NCT03092076|Experimental|Pharmacokinetics|The pharmacokinetics characteristic of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
2471926|NCT03092076|Experimental|Antiplatelet effects|The antiplatelet effects of ticagrelor in healthy Chinese is investigated to provide the basis for its efficacy and safety of clinical treatment.
2471928|NCT03092076|No Intervention|The impact of genotype|The recovery time of platelet function following the administration of ticagrelor is widely varied that genetic variants maybe an underlying factor.The impact of genotype on pharmacokinetic parameters and ADP of ticagrelor is compared among different genotypes.
2472004|NCT03091608||The individuals taking XLGB Granule|The overall individuals taking XLGB Granule with recommended dosage and achieving the inclusion criteria.
2472127|NCT03090880|No Intervention|Control|usual care,
2472131|NCT03090880|Experimental|Experimental|tinzaparin sodium
3192137|NCT00805324|Experimental|Arm 1|
2472395|NCT03088670|Experimental|Gosogliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
2472396|NCT03088670|Active Comparator|Vildagliptin treatment group|12 weeks of monotherapy and 24 weeks of combination with Metformin
2472488|NCT03088072|Other|Edoxaban Arm|All patients enrolled in the study will receive 6 weeks of edoxaban therapy, at which time a TEE will be performed. If the result is acceptable, edoxaban will be discontinued, and the patient will be treated with dual antiplatelet therapy (aspirin and clopidogrel) until 6 month follow-up. If device thrombus is present at 6 week TEE, patient will be transitioned to aspirin and adjusted-dose warfarin and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference. Subjects will have a 6 month follow-up visit prior to study completion. After study completion, patients may be treated with aspirin monotherapy according to the FDA instructions for use for the WATCHMAN device, or according to operator discretion.
2472524|NCT03087617|Active Comparator|Usual Care|Usual Care includes a lung cancer screening CT exam. Following the screen, a radiologist will analyze the CT scan image and send the results to the patient's Primary Care Physician (PCP). If the scan is read as a category 1 or 2 in the Lung Reporting and Data System (Lung-RADS), patients are provided a letter in the mail with their results. If the scan is read as a category 3, 4A, 4B, or 4X in Lung-RADS the patient will be contacted by their primary care physician's office and told to schedule a follow up appointment. Either in the letter or at the follow up appointment, patients will be given a Quitline number created specifically for this trial and maintained for the duration.
2472530|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report|In this arm, patients will receive the Usual Care described above and will additionally be provided with the Report. In this arm, the Report will provide the Quitline number.
2472558|NCT03087487||NVAF patients on Rivaroxaban|NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
2472568|NCT03087201|Experimental|nabiximols, oromucosal spray|1-12 puffs nabiximols / day, Duration of treatment: 13 weeks
3157521|NCT00366821||1|Examine the outcomes following cardiac surgery in those newborns with genetic abnormalities.
3157522|NCT00366821||2|Examine the outcomes following cardiac surgery in newborns without genetic abnormalities.
3157523|NCT00366834|Placebo Comparator|Control|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + placebo
3157524|NCT00366834|Experimental|Single dose oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1
3157525|NCT00366834|Experimental|3-day oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV + casopitant 150 mg on Day 1 + 50 mg on days 2 & 3
3157526|NCT00366834|Experimental|3-day IV/oral|ondansetron 8 mg oral twice daily on Day 1-3 and dexamethasone 8 mg IV on Day 1 + 90 mg IV casopitant on day 1 and 50 mg oral casopitant on days 2 & 3
2471449|NCT03094663|Active Comparator|Peri-Articular Injections only|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.5% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~20cc 0.25% bupivacaine~2 mg IV dexamethasone."
2471452|NCT03094663|Experimental|Peri-Articular Injections, Adductor Canal Block, and IPACK|"Combined spinal epidural anesthetic with 1.5% Mepivacaine (60mg)~Injection prior to cementation~bupivacaine 0.25% with epinephrine 30cc;~methylprednisolone, 40 mg/ml, 1 ml~cefazolin, 500 mg in 10 ml~normal saline, 22cc~Superficial injection prior to closure.~a. 20cc 0.25% bupivacaine~Adductor canal block technique (supine position, post IV sedation)~a. Mid-thigh injection of 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone~IPACK technique (supine position) a. 25 cc 0.25% bupivacaine"
2471541|NCT03094247|Active Comparator|Conventional RUTF (S-RUTF)|This is the control group for the study, which will receive the international standard of care therapeutic food. S-RUTF is made with conventional peanuts, which are inherently high in omega-6 linoleic acid.
2471544|NCT03094247|Experimental|High oleic RUTF (HO-RUTF)|The treatment provided to children randomized to this arm of the study includes nutritional content comparable to S-RUTF with the exception of a low lineoleic acid/high oleic acid ratio formulated with high oleic content peanuts.
2471546|NCT03094247|Experimental|DHA-supplemented HO-RUTF (D-HO-RUTF)|The treatment provided to children randomized to this arm of the study mirrors that provided by HO-RUTF with that addition of supplemental DHA at a level higher than attainable with optimal precursors.
2471579|NCT03093844|Experimental|Miltenyi CliniMACS® CD34 Reagent System|"The haploidentical donor will be mobilized by G-CSF and undergo one apheresis to collect CD34+ selected stem cell product after Miltenyi CliniMACS® CD34+ selection. The products will be cryopreserved until the time of transplantation.~Recipients will receive a standard conditioning regimen. After the conditioning regimen, the subjects will receive an allograft on day 0 containing donor CD34+ cells that have been positively selected and T-cell depleted following G-CSF mobilization combined with a single UCB unit. UCB unit will not be manipulated, and will be prepared and infused separately following standard of care procedure."
2471724|NCT03093688|Experimental|treatment|The eligible patient receive the experimental infusion of iNKT cells and CD8+T cells .
2471750|NCT03092908|Placebo Comparator|Control group|Administer 5 ml placebo (purified water) three times a day.
2471753|NCT03092908|Experimental|Intervention group|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
2471797|NCT03092583|Experimental|Patient group|Subjects must meet the modified New York criteria for AS, or the ASAS criteria for Ax-SpA, and must be naïve of biologic therapy (anti-TNF-α agents) at the time of inclusion, or have received but subsequently discontinued anti-TNF-α therapy at least 3 months before inclusion. A blood sample will be drawn (35 mL) to these patients.
2471804|NCT03092583|Other|Control group|Subjects must be free from any inflammatory or auto-immune disease. A blood sample will be drawn (35 mL) to these controls subjects.
3192138|NCT00805350|Experimental|Eplivanserin|Eplivanserin 5 mg/day
3192139|NCT00805350|Placebo Comparator|Placebo|Placebo of Eplivanserin 5 mg/day
3192140|NCT00805376|Experimental|Group A: DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
3192141|NCT00805376|Experimental|Group B: DNX-2401 + Surgery|DNX-2401 injection + Tumor removal
2472017|NCT03091309|Experimental|Intervention|Patients randomized to the intervention group will receive a multi-faceted intervention consisting of: (1) Interactive educational video; (2) Initial in-person counseling with an IBD nurse; (3) Motivational interviewing; (4) Telemedicine-based follow-up; (5) Monthly follow-up questionnaires; and (6) Comprehensive questionnaires.
2472019|NCT03091309|Active Comparator|Control|Patients randomized to the control group will complete the comprehensive questionnaires and will continue to receive the standard of care consistent with their condition, at their respective institution.
2472106|NCT03090737|Experimental|Nivolumab|Specified Dose on Specified Days
2472186|NCT03090152|Active Comparator|Periarticular Injection (PAI)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Peri-articular injection in the operating room~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that includes EPCA (saline) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
2472188|NCT03090152|Active Comparator|Epidural Patient-Controlled Analg (EPCA)|"Aspirin and nerve pain medications including duloxetine and clonidine patch prior to surgery.~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~A pain regimen while in the hospital that consists of Epidural PCA (EPCA) with 0.06% bupivacaine. Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
2472190|NCT03090152|Experimental|PAI + EPCA|"Aspirin and nerve pain medications including duloxetine and clonidine~Combined Spinal Epidural with 1.5% Mepivacaine 4cc~Anesthetic, Antiemetic and peri-articular injection in the operating room~A pain regimen while in the hospital that consists of EPCA (with 0.06% bupivacaine) Duloxetine (Cymbalta) - by mouth Ketorolac (Toradol) - IV Celecoxib (Celebrex) - by mouth Acetaminophen (Tylenol) - IV The EPCA will be removed when pain is well-controlled. Other medications, including opioids, will be available.~Acetaminophen and celecoxib for pain control once out of the hospital. Patients will also receive a prescription for an opioid medication in case they need it."
3192142|NCT00805402|Experimental|1 flow cytometry|flow cytometry
3192143|NCT00805415|Experimental|Arm 1|
3192144|NCT00805415|Experimental|Arm 2|
3192145|NCT00805428||2|control group
3192146|NCT00805428||patients with UC|patients with UC, without corticosteroid or immunosuppressive therapy
3192147|NCT00805506||Diabetes Insulin Treated|People with type 1 or type 2 diabetes on insulin.
2471474|NCT03094949|Experimental|microwave ablation|a kind of minimally invasive therapy by using microwave device for renal tumors
2471517|NCT03094351|Experimental|Robot assisted esophagectomy|Robot-assisted esophagectomy with gastric conduit formation.
2471520|NCT03094351|Active Comparator|Thoracoscopic esophagectomy|Conventional thoracoscopic esophagectomy with gastric conduit formation.
2471573|NCT03093883|Experimental|Test product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose for injection).
2471581|NCT03093883|Active Comparator|Reference product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose for injection).
2471712|NCT03093142|Experimental|tDCS & neurofeedback|30 minutes tDCS & 30 minutes neurofeedback
2471716|NCT03093142|Active Comparator|real neurofeedback|30 minutes real neurofeedback.
2471720|NCT03093142|Sham Comparator|sham neurofeedback|30 minutes sham neurofeedback.
2471776|NCT03092856|Experimental|Arm I (axitinib, anti-OX40 antibody PF-04518600)|Patients receive axitinib PO BID on days 1-14 and anti-OX40 antibody PF-04518600 IV over 60 minutes on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2471778|NCT03092856|Active Comparator|Arm II (axitinib, placebo)|Patients receive axitinib as in Arm I and placebo IV on day 1 beginning with course 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2471858|NCT03092245|Active Comparator|OctaplasLG|OctaplasLG® is an industrial donor plasma product pooled from 630 -1520 single donor units. It possesses unique features when compared to standard FFP, such as having a standardized concentration of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen-free.12 Most importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration. The manufacturing process also inactivates viral, bacterial and prion pathogen by immune neutralization, solvent-detergent treatment and a prion specific ligand affinity chromatography step.
2471859|NCT03092245|Placebo Comparator|Ringer-Acetate|standard of care resuscitation fluid Ringer-acetate is a mixture of electrolytes in water to a slightly hypotonic solution.
2471904|NCT03091972|Experimental|Contact force assisted linear ablation|Left atrial linear ablation performed using the contact force sensing catheter after pulmonary vein isolation
2471909|NCT03091972|Active Comparator|control|Left atrial linear ablation performed using the catheter without contact force sensing after pulmonary vein isolation
2471994|NCT03091660|Active Comparator|Arm I (BCG solution)|INDUCTION: Patients receive TICE BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive TICE BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
2471998|NCT03091660|Experimental|Arm II (Tokyo-172 strain BCG solution)|INDUCTION: Patients receive Tokyo-172 strain BCG solution intravesically once a week for 6 weeks. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution once a week for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 for up to 7 doses.
2472001|NCT03091660|Experimental|Arm III (Tokyo-172 strain BCG solution with priming)|PRIME: Patients receive Tokyo-172 strain BCG vaccine once ID. INDUCTION: Within 21 days, patients receive Tokyo-172 strain BCG solution as in Arm II. MAINTENANCE: Patients receive Tokyo-172 strain BCG solution as in Arm II.
2472179|NCT03090126||Alveolar hypoventilation|
2472204|NCT03089892||Gynecologic cancer patients|Gynecologic cancer patients under chemotherapy
3192148|NCT00805519|Active Comparator|Glucosamine and chondroitin sulfate|in this group patients will receive Glucosamine and chondroitin sulfate oral dietary supplementation
3192149|NCT00805519|Experimental|P :glucosa, chondroitin, Prednis|in this group patients will receive glucosamine and chondroitin sulfate plus Prednisolone oral administration
2472356|NCT03089112|Experimental|Seguence 1|Period 1 : HGP1607 Period 2 : HGP1501 Period 3 : HGP1607+HGP1501
2472358|NCT03089112|Experimental|Seguence 2|Period 1 : HGP1607 Period 2 : HGP1607+HGP1501 Period 3 : HGP1501
2472359|NCT03089112|Experimental|Seguence 3|Period 1 : HGP1501 Period 2 : HGP1607 Period 3 : HGP1607+HGP1501
2472360|NCT03089112|Experimental|Seguence 4|Period 1 : HGP1501 Period 2 : HGP1607+HGP1501 Period 3 : HGP1607
2472361|NCT03089112|Experimental|Seguence 5|Period 1 : HGP1607+HGP1501 Period 2 : HGP1607 Period 3 : HGP1501
2472362|NCT03089112|Experimental|Seguence 6|Period 1 : HGP1607+HGP1501 Period 2 : HGP1501 Period 3 : HGP1607
2472416|NCT03088397|Experimental|Patient decision aid|Group receives the patient decision aid, POCO (POstpartum Contraceptive Options), a grid with various contraceptive options across the columns and characteristics of each option in rows. Group receives Shared Decision Making counseling afterwards.
2472419|NCT03088397|Active Comparator|Website information|Group receives directions on how to get to bedsider.org information pages regarding contraceptive choices. Group receives Shared Decision Making counseling afterwards.
2472422|NCT03088397|Active Comparator|Standard of care|Group receives standard brochure on contraception in their postpartum packet. Group receives Shared Decision Making counseling afterwards.
2472451|NCT03088085|Experimental|Self-mobilization|Use of foam roller to mobilize thoracic spine and ribs every night before going to bed
2472457|NCT03088085|Active Comparator|Sleep Education|Education on sleep hygiene with tips for improving sleep.
3192150|NCT00805519|Experimental|Glucosa, Chondroitin, Chloroquine|in this group pateints will orally receive Glucosamine and Chondroitin sulfate plus Chloroquine.
3192151|NCT00805519|Experimental|Glucosa, Chondro, Prednis,Chloroq|in this group patients will receive Glucosamine and Chondroitin sulfate plus Prednisolone and Chloroquine
2472703|NCT03086915||Patients with neuromuscular block|Neuromuscular blocking agent administrated during surgery to the paediatric patient
2472776|NCT03085654|Experimental|High anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with high trait anxiety.
3192152|NCT00805558|Experimental|Moxifloxacin|Scaling and root planing plus 400 mg moxifloxacin once daily for 7 days.
2471484|NCT03094572|No Intervention|visual motor tasks with dominant arm (2)|experimental arm for the second sub-study healthy volunteer
3157527|NCT00366860|Experimental|Soy bread|Soy bread (75-100 mg isoflavone/day) for 12 weeks
3157528|NCT00366860|Active Comparator|Wheat bread|Wheat bread for 12 weeks
2471860|NCT03092323|Experimental|Treatment|Neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab.
2471861|NCT03092323|No Intervention|Standard of Care|Neoadjuvant radiotherapy followed by surgical resection.
2471946|NCT03091803||Arm I (QSM, T1WI, gadobenate dimeglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadobenate dimeglumine IV and undergo GOCART DCE MRI over 60 minutes.
2471952|NCT03091803||Arm II (QSM, T1WI, gadoterate meglumine, GOCART DCE MRI)|Patients undergo standard of care QSM and T1WI. Patients then receive gadoterate meglumine IV and undergo GOCART DCE MRI over 60 minutes.
2472010|NCT03091426|Experimental|Omiganan 1%|
2472012|NCT03091426|Experimental|Omiganan 1.75%|
2472014|NCT03091426|Experimental|Omiganan 2.5%|
2472015|NCT03091426|Placebo Comparator|Vehicle|
2472048|NCT03091062|Experimental|Study Group|Study subjects will serve as their own control and all will receive treatment with two different Airway Clearance Systems- the Vest® Airway Clearance System and the Monarch™ System. Subjects will be randomized to which treatment is received first.
2472113|NCT03090815||Patient receiving TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive TKI
2472115|NCT03090815||Patient receiving ALK-TKI|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive ALK-TKI
2472116|NCT03090815||Patient receiving chemotherapy|Patients are diagnosed with primary adenocarcinoma and have no concurrent cancers and are going to receive chemotherapy
2472202|NCT03089866||ASA Patients I or II|Participants are healthy (BMI <35), 55years and older, and have the ability to follow instructions. In this population we will quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
2472242|NCT03089632|Experimental|Gluten-free diet|All patients will follow a strict gluten-free diet for 1 month. Measurement will be conducted at baseline and after the intervention.
2472300|NCT03089437|Experimental|Prolonged Standing|Subject stand for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
2472306|NCT03089437|Experimental|Prolonged Sitting|Subject sit for 12 hours. The following day the subject will undergo a high fat tolerance test. Order of sitting/standing will be random and each subject will perform both interventions.
2472351|NCT03088956||bvFTD|Participants with behavioral variant frontotemporal dementia (bvFTD) (n=37)
2472355|NCT03088956||Healthy|Healthy Participants (n=10)
2472428|NCT03088488||Periodontally healthy subjects|
2472430|NCT03088488||Chronic periodontitis patients|
2472479|NCT03088098|Active Comparator|Treatment|Patient receiving LAAO
2472483|NCT03088098|No Intervention|Control|Patient undergoing medical therapy for stroke prevention
2472604|NCT03087422|Experimental|intervention|"The patients in this group will receive daily a text message (SMS) with some orientation about Homecare as an attempt to minimize the side effects of chemotherapy.~The text messages are based on oncology guidelines.The text messages contain information about water intake, emotional support, hygiene, immunity, nutrition, and physical activity. In addition, text messages about prevention and management of symptoms were also developed: nausea and vomiting, diarrhea, constipation, gas, changes in the skin and taste.~Also, the patients allocated in this group will receive the standard care."
2472605|NCT03087422|No Intervention|control|The patients allocated in this group will receive the standard care.
3157529|NCT00366873|Active Comparator|1|cow-milk based infant formula
3157530|NCT00366873|Experimental|2|cow-milk based infant formula with prebiotics
3157531|NCT00366964|No Intervention|Device|
3157532|NCT00366990|Active Comparator|weight loss and sodium intake reduction|Behavioral and weight loss intervention, including a low sodium diet. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking, and a 50% reduction in sodium intake.
3157533|NCT00366990|Placebo Comparator|weight loss and normal sodium intake|Behavioral and weight loss intervention, with regular sodium intake. Study goals are a 10% weight loss, 200 minutes of moderate physical activity a week, such as walking.
3157534|NCT00367029|Active Comparator|1|Print-based, individually tailored motivational program
3157535|NCT00367029|Experimental|2|Enhanced version of the print-based, individually tailored motivational program
3157536|NCT00367042|No Intervention|1|
3157537|NCT00367198|Active Comparator|1|30 ml per serving
3157538|NCT00367198|Active Comparator|2|60 ml per serving
3157539|NCT00367198|No Intervention|3|chronic hemodialysis patients
2471487|NCT03094585|No Intervention|No information|The nurses in this group are offered no booklet or oral information
2471492|NCT03094585|Experimental|Written and oral information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects. Furthermore, they are offered oral information which consisted of group sessions focusing on active feedback
2471495|NCT03094585|Experimental|Written information|The nurses in this group are offered written information which consisted of a booklet describing basic aspects of clinical research including aim, background, formalities, ethics, informed consent, randomisation, blinding, placebo, drug development, and financial aspects.
2471526|NCT03094260|Experimental|High intensity light therapy|Treatment with light therapy in high intensity (10,000 lux)
2471533|NCT03094260|Placebo Comparator|Low intensity light therapy|Treatment with light therapy in low intensity (<500 lux)
2471669|NCT03093402|Experimental|JBT-101: 5 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 5 mg administered twice daily.
2471670|NCT03093402|Experimental|JBT-101: 20 mg & Placebo|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and 20 mg Placebo (P.M. Study Product).
2471673|NCT03093402|Experimental|JBT-101: 20 mg Twice Daily|Eligible subjects will receive assigned study treatment of JBT-101 20 mg (A.M. Study Product) and JBT-101 20 mg (P.M. Study Product).
2471675|NCT03093402|Placebo Comparator|Placebo + Placebo|Eligible subjects will receive assigned study treatment of Placebo (A.M.) and Placebo (P.M.) for (JBT-101).
2471736|NCT03093103|Active Comparator|empagliflozin 10mg|Empagliflozin (Jardiance) 10mg is an SGLT-2inhibitor. The drug will be taken qd for 4 weeks.
2471737|NCT03093103|Placebo Comparator|Placebo|Placebo will be taken qd for 4 weeks.
3192153|NCT00805558|Active Comparator|Ciprofloxacin plus metronidazole|Scaling and root planing plus ciprofloxacin 1000 mg once daily for 7 days and metronidazole 500 mg twice daily for 7 days
3192154|NCT00805571||Adult|Adult patients with end-stage kidney disease awaiting kidney transplantation.
3192155|NCT00805571||Pediatric|Children with end-stage kidney disease awaiting kidney transplantation.
3192156|NCT00805584|Experimental|Arm 1|
3192157|NCT00805597|Experimental|radiotherapy|radiotherapy of 50Gy/25/f/5w to the ipsilateral chest wall and supraclavicular region
3192158|NCT00805597|Active Comparator|no radiotherapy|no radiotherapy
3192159|NCT00805610|Experimental|Hepatocyte Transplantation|Hepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
3192160|NCT00805623|No Intervention|AW|no pacifier , no sucrose
3192161|NCT00805623|Active Comparator|AS|sucrose without pacifier
3192162|NCT00805623|No Intervention|PW|
2472099|NCT03090607|Experimental|Aluvra™|Endoscopic injection of bulking agent (Aluvra) to the lower esophageal sphincter
2472108|NCT03090607|Sham Comparator|Saline|Endoscopic injection of saline
2472158|NCT03090295|Experimental|Palpation and Accuro|The placement site for the spinal anesthesia will be identified using both palpation and Accuro.
2472217|NCT03090009|Active Comparator|Flurbiprofen|Flurbiprofen 100 mg bid.
2472220|NCT03090009|Placebo Comparator|Placebo|Placebo taken bid
2472281|NCT03089502|Experimental|Exercise Rehabilitation|The intervention group will participate in the exercise rehabilitation program for a total of 12 weeks. This includes performing aerobic training five times per week and resistance training two to three times per week. Participants will also be expected to attend the education sessions following their supervised exercise rehabilitation sessions each week.
2472283|NCT03089502|No Intervention|Usual Care|Participants in the control group will be encouraged to continue with their regular physical activity routine and will receive regular standard of care by their Cardiologist and Oncologist.
2472320|NCT03089086|Active Comparator|Group A|Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
2472321|NCT03089086|No Intervention|Group B|Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.
2472367|NCT03088787||Patients for TAVR|Patients for TAVR
2472393|NCT03088527|Experimental|RAD140 Part A and Part B|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of RAD140.~Part B, Safety Expansion: Once the maximum tolerated dose (MTD) has been identified and/or a recommended dose escalation (RDE) has been determined, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary clinical activity of the recommended dose."
2472445|NCT03088306|Active Comparator|Standard analgesia use|A strategy to manage pain in the peri-operative period that is in common clinical use.
2472446|NCT03088306|Active Comparator|Multi-modal pain management|A strategy to manage pain in the peri-operative period that is in common clinical use that is designed to reduce the need for post-operative opioid medication.
2472507|NCT03087838||delirium group|CAM-ICU is positive within the first 24 hours after operation
2472508|NCT03087838||non-delirium group|CAM-ICU is negative within the first 24 hours after operation
2472599|NCT03087227|No Intervention|CONTROL Group|The control group will monitor daily its temperature and the occurrence of other symptoms on a paper surveillance diary and will have to contact the health team in case of fever as done in the usual care.
2472647|NCT03086798|Experimental|Magill forceps|experimental Magill forceps group: Magill forceps technique to facilitate nasotracheal tube advancement into trachea
3192163|NCT00805623|Experimental|PS|Pacifier and sucrose interventional
3192164|NCT00805649|Experimental|1|eyes with predominately classic lesions
3192165|NCT00805649|Experimental|2|eyes with occult lesions
3192166|NCT00805662|Experimental|Oxytocin|Intranasal oxytocin during IUI
3192167|NCT00805688||Symptom Study|Questionnaires + Blood Draw + Pedometer used to learn about symptoms related to chemotherapy and the disease, in patients with advanced pancreatic cancer.
3192168|NCT00805701|Active Comparator|0.5mg Avodart|.5mg avodart capsule orally once a day during 13 months
3192169|NCT00805701|Placebo Comparator|Placebo|placebo capsule orally daily for 13 months
2471494|NCT03094598|Experimental|Leaflet|The leaflet is based on information and journalism theories, paying attention primarily to reader appeal and readability.
2471497|NCT03094598|Experimental|Brochure|The brochure is based on practical communication experience, focusing primarily on logical composition and presentation of condensed information.
2471498|NCT03094598|Experimental|Booklet|The booklet is also based on practical communication experience, but give more elaborate explanations.
3157540|NCT00367198|No Intervention|4|healthy subjects
3157541|NCT00367276|Experimental|Arm 1|
2471596|NCT03093948|Experimental|Remote Ischemic post-conditioning|
2471601|NCT03093948|No Intervention|standard of care|
3192170|NCT00805714||Acute myocardial infarction|AMI patients who are in need to be treated by statins
2471710|NCT03093129|Active Comparator|artesunate|Patients will receive 200 mg artesunate (Arinate®) per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
2471711|NCT03093129|Placebo Comparator|placebo|Patients will receive matching placebo tablets per oral (PO) once daily (OD) for fourteen days prior to their planned surgery and then be followed up for 5 years following surgery.
2471757|NCT03092869|Experimental|Experimental Group|Feet and Ankle Mobilization
2471759|NCT03092869|Active Comparator|Control Group|Proprioceptive Training
2471815|NCT03092570|Experimental|tDCS Post-CVA|The participants will get a 20min stimulation at a maximal intensity of 2mA
2471817|NCT03092570|Sham Comparator|Sham Post-CVA|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2471819|NCT03092570|Experimental|tDCS Young Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
2471820|NCT03092570|Sham Comparator|Sham Young Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2471824|NCT03092570|Experimental|tDCS Older Healthy|The participants will get a 20min stimulation at a maximal intensity of 2mA
2471828|NCT03092570|Sham Comparator|Sham Older Healthy|The tDCS will be placed as for the Experimental group and will last 30 seconds at the beginning of task
2472021|NCT03091322||SR-T group|single chamber pacemaker
2472022|NCT03091322||DR-T group|dual chamber pacemaker
2472023|NCT03091322||HF-T group|triple chamber pacemaker (IS-1 connector)
2472025|NCT03091322||HF-T QP group|triple chamber pacemaker (with IS4 connector) and a lead of the Sentus QP lead family
2472068|NCT03091010|Experimental|Fecal Microbiota Transplantation|
2472072|NCT03091010|Active Comparator|Steroid|
2472129|NCT03090633|Experimental|Fetoscopy|All participants will undergo fetoscopic repair of fetal spina bifida.
2472157|NCT03090243||Study Group|measurements of IOP before and after virtual colonoscopy
2472200|NCT03090061|Experimental|Light induced fluorescence intraoral camera|
2472203|NCT03090061|Active Comparator|Visual-tactile assessment method according to FDI criteria|
2472250|NCT03089645|Experimental|Part 1|MEDI5083 monotherapy followed by Durvalumab monotherapy in subjects with advanced solid tumors
2472255|NCT03089645|Experimental|Part 2|Sequential MEDI5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab in subjects with advanced solid tumors.
2472257|NCT03089645|Experimental|Part 3|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel in subjects with IO refractory/relapsed 2/3L in NSCLC
2472329|NCT03089125|Active Comparator|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians.
2472330|NCT03089125|Experimental|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
2472382|NCT03088722|Experimental|Community health extension workers|Community health extension workers providing contraceptive implants
2472383|NCT03088722|No Intervention|Nurses and midwives|Nurses and midwives providing contraceptive implants (existing care)
2472427|NCT03088410|Experimental|Nevirapine|150 HIV-Exposed Uninfected (HEU) infants on Nevirapine (NVP) Prophylaxis
2472429|NCT03088410|Active Comparator|Zidovudine|150 HIV-Exposed Uninfected (HEU) infants on Zidovudine (AZT) Prophylaxis
2472431|NCT03088410|No Intervention|HIV- unexposed Uninfected (HUU) Infants|150 HIV- unexposed Uninfected (HUU) Infants
2472449|NCT03087994|Experimental|girls with obesity attending a dietary intervention|Participants in this group will attend 12 meetings of dietary interventions that will be guided by a dietician.
2472450|NCT03087994|Active Comparator|girls with obesity|participants in this group will only receive nutrition guidance once during the study
2472454|NCT03087994|Active Comparator|girls with normal weight|participants in this group will only receive nutrition guidance once during the study
2472505|NCT03087734|Active Comparator|Perpendicular stabilizer|Implantation of regular bar with perpendicular stabilizers
2472506|NCT03087734|Experimental|Oblique stabilizer|Implantation of new model of bar with oblique stabilizers
2472609|NCT03086993|Active Comparator|Cisplatin and Gemcitabine|Each Cis/Gem treatment cycle will comprise cisplatin, dosed at 25 mg per square meter of body surface area, and gemcitabine, dosed at 1000 mg per square meter of body surface area. Each will be administered on Days 1 and 8 every 3 weeks.
2472638|NCT03086616|Experimental|Newly Diagnosed DIPG|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI): Nal-IRI given directly into the tumor using a method called CED to newly diagnosed DIPG subjects after completion of radiotherapy. CED will be performed every 4-8 weeks. Drug concentration will start at 20mg/ml and escalate up to 40 mg/ml concentration.
3157542|NCT00367302|Experimental|1|Buprenorphine maintenance
3157543|NCT00367302|Active Comparator|2|Methadone maintenance
3157544|NCT00367328|Active Comparator|A|Oral Antibiotics in standard care vs. Laser treatment
3157545|NCT00367393|Experimental|1|Pimecrolimus cream 1%
3157546|NCT00367406|Experimental|Treatment with a Gamma 3 nail.|
3174833|NCT00627575|Active Comparator|Lamotrigine|Subjects will receive 40 milligram (mg) of Atrovastatin from Days 1-7, from Days 8-56 subjects will receive Lamotrigine and Subjects will receive 300 mg/day of Lamotrigine and 40 mg/day of atorvastatin each morning on Days 57-77.
2471504|NCT03094364|Active Comparator|Immediate Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
2471505|NCT03094364|Active Comparator|Delayed Treatment|"Patients will receive an in-home consultation with an occupational/physical therapist in which they are educated about the intervention, the system is set up, and they are guided through use of the system. After initial contact, therapist support will be available via telephone to address specific difficulties with operating the system, as well as three additional home visits throughout the 3 week intervention.~The rehabilitation program requires use of the rehabilitation gaming system for 1.5 hours daily for 21 consecutive days (equivalent dosage to standard CI therapy), limb activation device worn for 90% of waking hours, and completion of the automated transfer package to facilitate real-world arm use (e.g., problem-solving modules, daily monitoring of arm use). After completing the intervention, the patient will receive additional consultation with the therapist to formulate goals for follow-up. Follow-up assessments will be conducted to assess long-term retention of motor gains."
2471562|NCT03094130|Active Comparator|News with Spin|News items reporting results of phase I/II (non-randomized) trials with spin
2471563|NCT03094130|Experimental|News without spin|News items reporting results of phase I/II (non-randomized) trials without spin
2471619|NCT03093753|Placebo Comparator|Control (study 1)|Control will be 50g glucose dissolved in 200 mL water
2471621|NCT03093753|Experimental|Test (study 1)|The test meals will comprise 50 g glucose plus 50 mg oleuropein from olives dissolved in 200 mL water
2471623|NCT03093753|Placebo Comparator|Control (study 2)|Control will be white bread (109 g) to give 50 g available carbohydrates with 200 mL water
2471624|NCT03093753|Experimental|Test (study 2)|The test meals will comprise 109 g white bread plus 50 mg oleuropein from olives
2471625|NCT03093753|Placebo Comparator|Control (study 3)|Control will be whole-meal bread (132 g) to give 50 g available carbohydrates with 200 mL water
2471626|NCT03093753|Experimental|Test (study 3)|The test meals will comprise whole-meal bread (132 g) with 50 mg oleuropein dissolved in 200 mL water
2471627|NCT03093753|Placebo Comparator|Control (study 4)|Control will be 50 g sucrose dissolved in 200 mL water
2471628|NCT03093753|Experimental|Test (study 4)|The test meals will comprise 50 mg oleuropein and 50 g sucrose dissolved in 200 ml water
2471629|NCT03093753|Placebo Comparator|Control (study 5)|Control will be 25 g sucrose dissolved in 200 mL water
2471630|NCT03093753|Experimental|Test (study 5)|The test meals will comprise 160 mg oleuropein and 25 g sucrose dissolved in 200 ml water
2471631|NCT03093753|Placebo Comparator|Control (study 6)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2471632|NCT03093753|Experimental|Test (study 6)|High carbohydrate diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2471633|NCT03093753|Placebo Comparator|Control (study 7)|Normal diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2471634|NCT03093753|Experimental|Test (study 7)|High fat diet 3 days prior to study visit with 109 g bread with 200 ml water on study visit
2471689|NCT03093155|Active Comparator|Ixabepilone|Ixabepilone 20 mg/m2 days 1, 8, 15 Q 28 days
2471692|NCT03093155|Experimental|Ixabepilone + Bevacizumab|"Ixabepilone 20 mg/m2 days 1, 8, 15~+ Bevacizumab 10 mg/kg days 1, 15 Q 28 days"
3174834|NCT00627575|Active Comparator|phenytoin|Subjects will receive 40 mg of Atrovastatin from Days 1-7, from Days 8-28, subjects will receive 4mg/kg/day of phenytoin in the morning and will continue to take 40 mg/day of atorvastatin each morning. Subjects will receive taper dose of phenytoin from Days 29-30.
3174835|NCT00627588|Experimental|Dose Evaluation|To assess the safety and efficacy of up to three dose levels of ProSavin
2471796|NCT03092544|Active Comparator|RRMS on therapy|18 subjects with a diagnosis of Relapsing Remitting (RRMS) ages 18-55, that are scheduled to begin on dimethyl fumarate
2471802|NCT03092544|Active Comparator|SPMS on therapy|18 subjects with a diagnosis of Secondary Progressive (SPMS) ages 25-65 without clinical or MRI evidence of relapse in two years that are scheduled to begin on dimethyl fumarate
2471808|NCT03092544|No Intervention|SPMS not on therapy|18 subjects with a diagnosis of SPMS ages 25-65 without clinical or MRI evidence of relapse in two years, that are NOT scheduled to begin on dimethyl fumarate
2471814|NCT03092544|No Intervention|Normal Control 1|10 normal controls (younger cohort, mean age 38)
2471816|NCT03092544|No Intervention|Normal Control 2|10 normal controls (younger cohort, mean age 58)
2471888|NCT03092336|Experimental|Electrical Stimulation|"The training with electrostimulation will be performed with the following intensity:~Medium frequency current: 2.500Hz Modulation frequency: up to 50Hz Time on / off: 1: 2 Average session time 10 to 15 min Being applied in the same muscle groups that will be trained in the group that will perform strength training."
2471890|NCT03092336|Experimental|Strength training|There will be 10 exercises: upper limbs: Supine with dumbbells; High pulley pull; Alternating thread with dumbbells; Triceps dumbbell test; Lower limbs: knee extensor, squatting with body weight, plantar flexion, knee flexion and plantar dorsiflexion. The session time will be from 45 minutes to one hour 2 times weekly totaling at the end of the 12 weeks, 24 strength training sessions.
2471937|NCT03091790|Active Comparator|Synthetic Mesh|Synthetic mesh (mid-density polypropylene (generic) Bard soft mesh) will be used in open ventral hernia repair
2471940|NCT03091790|Active Comparator|Biologic Mesh|Biologic mesh (non cross linked porcine acellular dermal matrix: Strattice) will be used in open ventral hernia repair
2472003|NCT03091582|Experimental|Cognitive behavioral therapy|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive factors and behavioral factors on affective distress.
3208627|NCT00976625|Other|2|
2471620|NCT03093467|Experimental|Experimental|Participants receive psychiatric treatment and psychotherapy as usual. In addition, participants have access to the internet-based program ASCENSO: an adjunct support and monitoring system for the treatment of depression.
2471622|NCT03093467|Active Comparator|Control|Patients receive psychiatric treatment and psychotherapy as usual.
2471699|NCT03093337|Experimental|Psychomotor therapy|Early post hospital discharge psychomotor therapy.
2471702|NCT03093337|No Intervention|Control|No specific support.
3192171|NCT00805753|Active Comparator|Arm 1 ACTH 40 units|Receive ACTH at the dose of 40 units sub-cutaneously for up to 12 weeks. If at day 91 no response has been shown, you will have the option to increase the dose of ACTH to 80 units for up to an additional 120 days.
3192172|NCT00805753|Active Comparator|Arm 2 ACTH 80 units|Receive ACTH at the dose of 80 units sub-cutaneously for up to 12 weeks.
3192173|NCT00805805|Experimental|1|Tetrathiomolybdate with ursodiol
3192174|NCT00805805|Placebo Comparator|2|Placebo with ursodiol
2471905|NCT03092037||All participants|All participants will have their blood drawn. DNA will be extracted from whole blood, and serum will be analyzed for ENG concentrations. Genotyping data will be analyzed for associations with serum ENG concentrations.
2471908|NCT03092037||All participants (side-effects)|All participants will have their blood drawn and complete a brief questionnaire regarding bleeding patterns and side-effects. DNA will be extracted from whole blood and genotyping data will be analyzed for associations with specific bleeding patterns and side-effects.
3192175|NCT00805818|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1 mg/kg/h (Cohort 1, n=20), 3 mg/kg/h (Cohort 2, n=20) or 6 mg/kg/h (Cohort 3, n=133) intravenous infusion for a total of 72 consecutive hours.
2472065|NCT03091244||The individuals taking XLGB Capsule|The overall individuals taking XLGB Capsule with recommended dosage and achieving the inclusion criteria.
2472095|NCT03090698|Active Comparator|Hylan|Intra-articular (knee) 6ml Hylan GF20 administration (single shot)
2472100|NCT03090698|Active Comparator|Hylan + Corticosteroid|Intra-articular (knee) 6ml Hylan GF20 and 1ml Triamcinolone 20mg/ml administration (single shot)
2472105|NCT03090698|Active Comparator|Corticosteroid|Intra-articular (knee) 1ml Triamcinolone administration (single shot)
2472164|NCT03090334|Experimental|De-escalation|"In this group, investigators will manage the antifungal therapy according to the BG levels as follows:~antifungal therapy will be stopped immediately after the BG response in case of serum BG <80 pg/ml in presence of clinical stability (CS);~antifungal therapy will be continued until further BG determination, both for BG levels between 80-200 pg/ml and for BG <80 pg/ml in patients without CS. In these cases, if the following BG value is <80 pg/ml antifungal therapy will be stopped independently from the CS achievement.~antifungal therapy will be continued until day 10 for BG levels >200 pg/ml"
2472169|NCT03090334|No Intervention|Standard of care|"In this group antifungal treatment will be continued until clinician's decision.~Investigators will be blinded to the BG levels of patients enrolled in this arm, The BG results will be faxed directly to the coordinating center."
2472199|NCT03089970||Healthy asthma|Asthmatic patients not with an exacerbation, i.e., stable asthmatics
2472201|NCT03089970||Rhinovirus-infected asthmatics|Asthmatics with an exacerbation and associated rhinovirus infection
2472205|NCT03089970||Influenza A-infected asthmatics|Asthmatics with an exacerbation and associated influenza A infection
2472239|NCT03089671|Experimental|Vitamin B|Vitamin B: Patients in this arm will receive 100mg of riboflavin (vitamin B2) 60 to 120 minutes prior to surgery for the purpose of turning the urine bright yellow to see if this helps with detection of ureteric jets during cystoscopy which will be done using normal saline.
2472240|NCT03089671|Active Comparator|D5W (5% dextrose in water)|5% Dextrose in Water: Patients in this arm will receive a placebo in the pre-operative area (for the purpose of blinding the surgical team) 60 to 120 minutes prior to surgery. Intraoperative cystoscopy will then be performed using D5W to see if this helps with detection of ureteric jets.
2472271|NCT03089398|Active Comparator|Hybrid Coronary Revascularization Group|HCR is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization, combined with percutaneous revascularization of at least one non-LAD target.
2472272|NCT03089398|Active Comparator|Percutaneous Coronary Intervention|PCI will be performed using standard techniques at the discretion of the operator. Only Food and Drug Administration (FDA) and Health Canada approved commercially available metallic drug-eluting stents may be used in this protocol.
2472336|NCT03088865|Experimental|Initial Specimen Diversion|Aspirating first blood volume into a regular blood collection tube
2472337|NCT03088865|Active Comparator|Standard practice|Aspirating first blood into blood culture bottles (Standard practice)
2472397|NCT03088709|Experimental|All patients will receive Haploidentical|"The choice of the chemotherapy treatment for transplantation will be up to the investigator. Post-transplant cyclophosphamide will serve as the backbone of the immunosuppression treatment to prevent GVHD. All patients will receive a Haplo-identical stem cell transplantation.~GVHD Prevention Treatment:~Cyclophosphamide 50mg/kg will be administered IV on Day 3 and Day 5 post transplant.~Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth starting on day of transplant and continue approximately 100 days post-transplant.~Mycophenolate mofetil 15mg/kg will be administered twice a day IV until patient can take it by mouth starting on Day 1 post transplant until 28 days."
2472478|NCT03088241|Experimental|Intervention|switch to second-line ART
2472482|NCT03088241|No Intervention|Control|Standard of care: no switch to second-line ART
2472565|NCT03087188||Utilization of inhalator|Film sequences will be shown to patients using incorrect application technique in order to improve technique. Learning success will be assessed subsequently and at a follow-up visit after 2-8 weeks
2472607|NCT03086993|Experimental|Melphalan/PHP|Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
2472851|NCT03085485|Active Comparator|Ivacaftor|Ivacaftor, 150 mg PO every 12 hrs for 84 days
2471644|NCT03093623|Experimental|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
2471651|NCT03093623|No Intervention|Non-Physical activity|the non-physical activity group,investigators do not give them any physical interventions
2471691|NCT03093285||dysthyoidic female|sexually active, hypothyroidic or hyperthyroidic women of childbearing age
2471784|NCT03092765|Experimental|low-dose, high-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471787|NCT03092765|Experimental|low-dose, high-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively higher frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471789|NCT03092765|Experimental|high-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471791|NCT03092765|Experimental|high-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive high-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471793|NCT03092765|Experimental|low-dose, low-frequency E6011; high-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471800|NCT03092765|Experimental|low-dose, low-frequency E6011; low-dose, low-frequency E6011|Participants will receive low-dose E6011 at a relatively lower frequency up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471807|NCT03092765|Experimental|Placebo; high-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive high-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471812|NCT03092765|Experimental|Placebo; low-dose, low-frequency E6011|Participants will receive placebo up to approximately Week 12. Participants will then receive low-dose E6011 at a relatively lower frequency from Week 12 to Week 64.
2471914|NCT03092063|Experimental|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families.
2471915|NCT03092063|Experimental|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by community health workers (promotoras) working with individual patients and families.
2471916|NCT03092063|Experimental|Enhanced Engagement-Nurse|Tomando Control de su Diabetes-Nurse is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
2471917|NCT03092063|Experimental|Enhanced Engagement-Promotora|Tomando Control de su Diabetes-Promotora is a culturally tailored, community-based, Diabetes Self-Management program delivered in a group format by licensed nurses working with individual patients and families. If subjects do not benefit sufficiently, the subject may be randomized to receive three home visits to facilitate engagement with treatment.
2471918|NCT03092063|Experimental|Multifamily Group-Promotora|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the promotoras, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
2471923|NCT03092063|Experimental|Multifamily Group-Nurses|"If subjects do not benefit sufficiently from the initial Tomando Control intervention offered by the nurses, they may be randomized to receive a multifamily group intervention consisting of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
2471982|NCT03091543|Experimental|Sequence A (25 mg - 50 mg - 100 mg - 200 mg - Placebo)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2471984|NCT03091543|Experimental|Sequence B (Placebo - 25 mg - 50 mg - 100 mg - 200 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2471987|NCT03091543|Experimental|Sequence C (200 mg - Placebo - 25 mg - 50 mg - 100 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2471993|NCT03091543|Experimental|Sequence D (100 mg - 200 mg - Placebo - 25 mg - 50 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
3173331|NCT00610909|Experimental|1|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
2471927|NCT03091894|Active Comparator|propofol|patients will receive only propofol intravenous infusion for sedation
2471930|NCT03091894|Active Comparator|propofol-dex.|patients will receive dexmedetomidine in addition to propofol intravenous infusion for sedation
2471999|NCT03091569|Active Comparator|Vitamin K|
2472002|NCT03091569|Placebo Comparator|Control|
2472133|NCT03090503|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
2472136|NCT03090503|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
2472165|NCT03090178|Experimental|Patients|"Wear a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
2472170|NCT03090178|Active Comparator|Healthy Volunteers|"Wear of a wristband actigraph while sleeping and answer to quality of questionnaires on a smartphone application:~sleep diary~Pruritus~dermatology life quality index"
2472218|NCT03089983|Active Comparator|No medication-assisted treatment (control group)|The control group will choose to receive no opioid agonist treatment upon release from prison.
2472225|NCT03089983|Active Comparator|Methadone maintenance treatment (MMT)|Methadone maintenance treatment (MMT) is the standard of care in Malaysia, and participants who choose this arm will receive MMT upon release from prison.
2472227|NCT03089983|Experimental|Buprenorphine/Naloxone|Participants who choose buprenorphine/naloxone will receive an induction phase for 10 days and then move on to receiving it in the community for 6 months. Buprenorphine/naloxone has been authorized and is available for use in Malaysia.
2472229|NCT03089983|Active Comparator|Standard Isoniazid (INH) for 26 weeks|Participants will be randomized to receive INH, the standard of care in Malaysia, for 26 weeks while in prison.
2472231|NCT03089983|Experimental|Short-course isoniazid + rifapentine (INH + RIF) for 12 weeks|Participants will be randomized to receive INH + RIF as TB treatment while in prison.
2472268|NCT03089463||Observation group|The entire participants in this study will be included in this group.
2472487|NCT03088228||healthy pregnants|
2472490|NCT03088228||mild preeclampsia|
2472496|NCT03088228||severe preeclampsia|
2472544|NCT03087708|Active Comparator|Group I (lower dose naloxegol, placebo)|Patients receive lower dose naloxegol PO QD and placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2472547|NCT03087708|Active Comparator|Group II (placebo, higher dose naloxegol)|Patients receive placebo PO QD and higher dose naloxegol PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2472548|NCT03087708|Placebo Comparator|Group III (placebo)|Patients receive placebo PO QD. Courses repeat every 3 weeks in year 1 and then every 3 months in year 2 in the absence of unacceptable toxicity.
2473050|NCT03084003|Experimental|Almond group|2 oz. of almonds everyday for 8 weeks
2473053|NCT03084003|Active Comparator|Control group|Isoenergetic control group 5 graham cracker sheets everyday for 8 weeks
2473108|NCT03083691|Other|Cohort 1, NSCLC|During Treatment Part A nivolumab 240 mg IV q2w as monotherapy is administered. At the time of disease progression a re-biopsy is performed before initiation of combination therapy (Treatment Part B). Within Treatment Part B, nivolumab is given in a dose of 3 mg/kg q2w together with ipilimumab 1 mg/kg IV q6w.
2473111|NCT03083691|Other|Cohort 2, SCLC|Within Treatment Part A, nivolumab 1 mg/kg q3w together with ipilimumab 3 mg/kg q3w for a total of four doses is administered. After the four combined doses have been administered, a re-biopsy is performed before initiation of Treatment Part B. In Treatment Part B, nivolumab 240 mg q2w monotherapy is administered until disease progression or unacceptable toxicity
2473215|NCT03082872|Experimental|Cemented K-wire Fixation|Fractures were transverse (n=32), short oblique or spiral (n=5), and comminuted (n=14) fractures.
2473216|NCT03082872|Experimental|Open Transfixion Pinning|Fractures were transverse (n=28), short oblique or spiral (n=4), and comminuted (n=15) fractures.
2473265|NCT03082781|Experimental|Study group I|Study group I (57 participants) received the NCD with exercise (NCDsport).This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2473307|NCT03082508|Experimental|Algisyl|Algisyl device (implants) administered during a surgical procedure.
3173332|NCT00610909|Placebo Comparator|2|Same shape placebo
3173333|NCT00610922|No Intervention|1|
3173334|NCT00610922|Experimental|2|
3173335|NCT00610948|Experimental|Group 1|Patients receive oral everolimus once daily on days 1-28. Patients also receive leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3173336|NCT00610948|Experimental|Group 2|Patients receive oral everolimus once daily on days 1-28 and panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3173337|NCT00610948|Experimental|Group 3|Patients receive oral everolimus once daily on days 1-28, leucovorin calcium IV followed by fluorouracil IV continuously over 46 hours beginning on day 1, and oxaliplatin IV over 2-4 hours on day 1. Some patients may also receive panitumumab IV over 30-90 minutes on day 1. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3173338|NCT00610961||Basiliximab (Simulect) Induction|Prospective group: patients are scheduled to receive a kidney transplant; and will receive Simulect®, Myfortic® and Prograf® with or without steroids according to routine care (Standard of Care).
3173339|NCT00610961||Thymoglobulin Induction|Retrospective (historical or control) group: patients have already received a kidney transplant and were treated with Thymoglobulin®, Myfortic®, and Prograf® with or without steroids. This treatment was Standard of Care at a time of transplant.
2471685|NCT03093532|Active Comparator|ED SBIRT-HTN|"The ED SBIRT-HTN (The Emergency Department Screening Brief Intervention and Referral for Treatment) arm consists of a series of risk assessment tools (surveys, video, and noninvasive bedside assessments) designed to be efficient, patient-centered and educational for participants in an emergency department setting. Through the intervention, participants will learn more about hypertension management and complications associated with uncontrolled BP. Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
2471688|NCT03093532|Active Comparator|E SBIRT-HTN + PACTH-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
2471743|NCT03092986|Active Comparator|chemotherapy with paclitaxel and carboplatin|Intervention: paclitaxel 200 mg/m2 AUC and carboplatin AUC 6 on day 1 every 3 wks for 2 cycles followed by three dimensional conformal radiotherapy on day 42
2471744|NCT03092986|Experimental|chemotherapy with cisplatin and vinblastine|Intervention : cisplatin 100 mg/m2 on day 1 and 29 and vinblastine 5mg/m2 on days 1,8,15,22 and 29 followed by three dimensional conformal radiotherapy on day 50
2472050|NCT03091088|Active Comparator|Control|walking at an intense pace
2472054|NCT03091088|Experimental|Experimental|osteoporosis specific-oriented training
2472089|NCT03090750|Experimental|Lavender|Lavender oil
2472091|NCT03090750|Experimental|Bergamot|Bergamot oil
2472092|NCT03090750|Placebo Comparator|Water|Water
2472146|NCT03090373|Sham Comparator|Control Group|"At catheter replacement subjects will have a sham UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
2472150|NCT03090373|Active Comparator|Treatment Group|"At catheter replacement subjects will have an active UroShield device attached to the external portion of the catheter and have it activated for 30 days.~Standard of care for the upkeep and cleanliness of the catheter will be adhered to.~At both the baseline and at the conclusion of 30 days, the distal end of the catheter will be collected as well as a sample of retained urine from the bladder and these samples will be evaluated for bacterial colonization."
2472208|NCT03090048|Experimental|Vitamin A|retinyl palmitate USP
2472209|NCT03090048|Experimental|Azithromycin with Vitamin A|USP grade ingredients
2472210|NCT03090048|Active Comparator|Azithromycin|azithromycin monohydrate
2472252|NCT03089515|Active Comparator|Healthy Controls|
2472256|NCT03089515|Experimental|Survivors|
2472273|NCT03089294|Active Comparator|Group A|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)
2472274|NCT03089294|Active Comparator|Group B|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)
2472275|NCT03089294|Active Comparator|Group C|Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)
2472276|NCT03089294|Active Comparator|Group D|Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)
2472326|NCT03089138|Experimental|Regan Tangjiang，Simulation Shufengjiere Capsules|
2472327|NCT03089138|Active Comparator|Simulation Regan Tangjiang，Shufengjiere Capsules|
2472328|NCT03089138|Placebo Comparator|Simulation Regan Tangjiang and Shufengjiere Capsules|
2472365|NCT03088774|Experimental|New web-application|Information material developed in a participatory design together with patients.
2472368|NCT03088774|Experimental|Patient Handbook|Public available information.
2472406|NCT03088514|Experimental|NITRATE-LVH intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 months
2472407|NCT03088514|Placebo Comparator|NITRATE-LVH placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
2472408|NCT03088514|Experimental|NITRATE-CBP intervention|70ml of beetroot juice (approximately 6-8 mmol of inorganic nitrate) once a day for 4 month
2472409|NCT03088514|Placebo Comparator|NITRATE-CBP placebo|70ml of beetroot juice (no inorganic nitrate) once a day for 4 months
2472489|NCT03088176|Experimental|Combination|"Talimogene laherperepvec intratumoral injection up to 4ml of 10^6 PFU/mL on Day 1, followed by up to 4mL of 10^8 PFU/mL 3 weeks later, followed by every 2 weeks thereafter for up to two years.~Dabrafenib 150mg orally twice daily for up to two years Trametinib 2mg orally once daily for up to two years"
3173340|NCT00610974|Active Comparator|1|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
2472576|NCT03087279|Experimental|Texas I-CAN Active Math Lessons|Texas I-CAN Active math lesson in academic classroom
2472583|NCT03087279|Experimental|Texas I-CAN Active Language Arts Lessons|Texas I-CAN Active language arts lessons in academic classroom
2472596|NCT03087279|No Intervention|Control|Regular, Sedentary academic lessons in math and language arts
2472858|NCT03085485|Placebo Comparator|Placebo|matching placebo
3173341|NCT00610974|Experimental|2|One of 2 types of body-weight supported treadmill training (BWSTT) with the Lokomat, which differ only in the level of assistance that the Lokomat provides to leg movements while walking.
3173342|NCT00611039|Experimental|1|Darunavir 900mg + ritonavir 100 mg once a day
3173343|NCT00611039|Active Comparator|2|Darunavir 600mg + ritonavir 100mg twice day
3173344|NCT00611052|Experimental|1|Group cognitive intervention (the Adolescent Coping with Stress)
3173345|NCT00611052|Active Comparator|2|Treatment as usual
3173346|NCT00611052|Active Comparator|3|Healthy controls, receive usual health education in school health care
3174836|NCT00627588|Sham Comparator|Sham element|The potential use of sham comparator to confirm efficacy
3174837|NCT00627614|Experimental|breast imaging study|
2471701|NCT03093714|Placebo Comparator|Placebo|Multiple dose placebo as repeat doses in CF subjects
2471795|NCT03092687||psychiatric disorders|decedents with and without psychiatric use disorders
2471803|NCT03092687||substance disorders|decedents with and without substance use disorders
2471872|NCT03092401||hepatic transplant patients with hepatopulmonary syndrome|
2471873|NCT03092401||hepatic transplant patients without hepatopulmonary syndrome|
2471902|NCT03091998|Active Comparator|Study Drug (CD-NP)|Participants will receive a single subcutaneous injection of CD-NP (5 ug/kg) for 3 days running
2471906|NCT03091998|Placebo Comparator|Placebo (saline)|Participants will receive a single subcutaneous injection (~1 mL) of normal saline for 3 days running
2471976|NCT03091699|Experimental|Moderate intensity exercise|The Exercise intervention will persist of a 20-minute bout of moderate intensity aerobic exercise which by definition is 40-65% of Maximum Heart Rate. Exercise consisted of a 2-minute warm-up, followed by 15 min of walking at a rate, which will allow you to reach 2/3 of your max heart rate, and then a 3-minute cool down on a treadmill equaling 20 minutes. Heart Rate will be examined with Polar Wearlink coded Heart Rate monitors to attain the specific exercise intensity.
2471977|NCT03091699|Active Comparator|Nicotine Inhalation|The nicotine inhalation group will smoke a cigarette to completion of their choice, in the 20 minute time period allocated in the Exercise and Health Psychology Lab psychological assessment room (the room will be equipped with windows that allow for ventilation and an air purifier. During this time the participant will refrain from conversation.
2472026|NCT03091335|Experimental|Music-listening group|Patients in this group will listen to music of their choosing during the entirety of the awake portion of deep brain stimulation surgery
2472029|NCT03091335|No Intervention|Head-phone only group|Patients in this group will receive the same noise-canceling headphones as the patients in the music-listening group. However, they will remain without music per standard of care for awake deep brain stimulation procedures
2472069|NCT03091049||EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse
2472073|NCT03091049||Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
2472101|NCT03090659|Experimental|LCAR-B38M treatment group|r/r multiple myeloma patients be treated with a split doses of LCAR-B38M cells. Total dose of 0.5-5 millions /kg cells will be administered at day 0, day 2 and day 6 by split dose (20%, 30% and 50% respectively).
2472172|NCT03090438|Active Comparator|Varicocele embolization before IVF|Participants will have catheterization and embolization of varicoceles six months before beginning IVF
2472175|NCT03090438|No Intervention|IVF without varicocele embolization|Participants will proceed from enrollment directly to IVF
2472346|NCT03088813|Experimental|Experimental Arm|Irinotecan liposome injection
2472352|NCT03088813|Active Comparator|Control Arm|Topotecan
2472477|NCT03088046|Other|Micronized Progesterone|Administration of 200 mg of vaginal Micronized Progesterone (100 mg every 12 hours) for a 7-day course
2472520|NCT03087721|Experimental|1x2 HIIT-LV, 3 times a week, 24 min|
2472526|NCT03087721|Active Comparator|CAE, moderate intensity, 3 times a week, 36 min|
2472570|NCT03087305||1|All patients age 20yrs or greater referred for EBUS-TBNA with suspicion for primary lung cancer
2472612|NCT03086954|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
2472624|NCT03086642|Experimental|T-Vec|All enrolled patients will receive a test dose of talimogene laherparepvec (10^6 plaque forming units (PFU)/ml) on day 1, followed by treatment doses at escalating concentrations weeks 4, 7, and 10. A biopsy will be obtained during each scheduled endoscopy prior to talimogene laherparepvec injection.
2472680|NCT03086525||Musculoskeletal pain|Participants Healthy male and female students, students of the University of Málaga, will be recruited. . The inclusion criteria are as follows: (i) men / women over 18 years; (ii) students of the University of Málaga.
3173347|NCT00611091|Experimental|I|Intervention Group - (receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
2473055|NCT03084159|Experimental|Participatory design and intervention|Patients in this arm will receive the intervention of using an education worksheet during their appointment with their provider. They will be asked to complete post intervention surveys (for feasibility and feedback prior to actual trial enrollment). Providers and staff at this site have been involved in the design of the intervention process, to make it streamlined and efficient for application in practice.
2473058|NCT03084159|Experimental|Intervention Only|This arm include new patients at the initial site that also received the intervention of using an education worksheet during their appointment and filled out post intervention surveys. Some of these providers/staff were not involved in the initial design of the intervention.
2473063|NCT03084159|No Intervention|Usual Care|A second site included usual care, which did not include the intervention. Participants were given post visit surveys similar to those in the two other study / intervention arms. This site served as a usual care comparison.
2473120|NCT03083652|Sham Comparator|Control|Conventional physiotherapy with NMEs device not activated
2473125|NCT03083652|Experimental|Intervention|Conventional physiotherapy with daily 30-minutes NMEs (5 days/week)
2473208|NCT03083314|Experimental|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
2473209|NCT03083314|Active Comparator|COMPLETE AXILLARY DISSECTION (ALND)|
2473248|NCT03082885|Experimental|Thymosin-α1 group|Patients receive treatment based on standard Therapy with additional Thymosin-α1
2473251|NCT03082885|No Intervention|control group|Patients receive treatment based on standard Therapy
3174838|NCT00627627|Experimental|1|IPI-504
3174839|NCT00627640|Experimental|1|1 active (50 - 100 mg/day)
3174840|NCT00627640|Placebo Comparator|2|
2471714|NCT03093493||EDS patients|Medical records from other institutions and clinical notes for visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints Hypermobility Syndrome (JHS), and other metabolic or genetic disorders and laboratory results, radiology reports and images, and genetic testing that supports EDS diagnoses. Genotyping will be done.
2471717|NCT03093493||EDS family members with or without EDS|Family members of EDS patients with or without EDS. Genotyping will be done.
2471752|NCT03092895|Experimental|SHR-1210+Apatinib(Arm A）|
2471755|NCT03092895|Experimental|SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）|
3157547|NCT00367471|Active Comparator|Group A|Subjects in Treatment Group A (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by an IV infusion of carboplatin over not less than 15 minutes. Carboplatin will be followed by an initial loading dose of trastuzumab by 90 minute IV infusion (first dose only) with subsequent IV doses of trastuzumab to be given weekly over 30 minute infusion. Doses of paclitaxel and carboplatin will be administered weekly (Day 1, 8, and 15). Trastuzumab is administered on Day 1, 8, 15, and 22. Treatment cycles are repeated every four weeks.
2471862|NCT03092206|Experimental|Group 1|F/TAF ; oral; Dose: 25/200 mg; Frequency: QD
2471866|NCT03092206|Experimental|Group 2|Group 2: E/C/F/TAF; oral; Dose: 150/150/200/10 mg; Frequency: QD
2471869|NCT03092206|Experimental|Group 3|Group 3: R/F/TAF; oral; Dose: 25/200/25 mg; Frequency: QD
2471903|NCT03091907||Case|Children with a history of necrotizing enterocolitis
2471907|NCT03091907||control|Children with no history of necrotizing enterocolitis
2471966|NCT03091725|Experimental|RYGB group|Subjects in this group are scheduled to undergo Roux-en-Y gastric bypass surgery and will be assessed after 16-18% weight-loss
2471968|NCT03091725|Active Comparator|VLCD Group|Subjects in this group will participate in a very low-calorie diet intervention to obtain a 16-18% weight loss.
2472024|NCT03091504|Experimental|Albuterol via High flow nasal cannula|Enrolled patients inhale bronchodilator (Albuterol Sulfate) with different concentration via High flow nasal cannula, prepared albuterol concentrations are 0.5mg, 1.0mg, 2.0mg and 4.0mg, patients will be assessed by spirometry after each concentration until bronchodilator response is positive and does not improve after the next dose.
2472036|NCT03091023|Active Comparator|Natural cycle|"Endometrial biopsies and endometrial fluid obtained from healthy females throughout the menstrual cycle at each of these stages:~Early proliferative (EP; days 0-8), late proliferative (LP; days 9-14), early secretory (ES; days 15-18), mid-secretory or receptive (MS; days 19-23), and late secretory (LS; days 24-30)"
2472037|NCT03091023|Active Comparator|ERA in HRT cycle|Endometrial biopsy and endometrial fluid obtained from woman undergoing to Endometrial Receptivity Analysis (ERA) in a hormonal replacement therapy (HRT) cycle.
2472067|NCT03090893|Experimental|Infusion group|Subjects will receive ATryn continuous infusion for maintaining serum antithrombin III levels between 80 - 100
2472094|NCT03090672|Experimental|tSVF + PRP Arm1|Stromal Vascular Fraction tSVF + Platelet Rich Plasma (PRP) concentrate
2472098|NCT03090672|Experimental|tSVF + PRP + cSVF Enrichment Arm 2|tissue Stromal Vascular Fraction (tSVF) + Platelet-Rich Plasma (PRP) concentration + (cSVF)
2472102|NCT03090672|Experimental|Normal Saline IV + cSVF Arm 3|Cellular Stromal Vascular Fraction (cSVF); Normal Saline IV introduction
2472214|NCT03089788|Other|Home-based test and skin test|
3174841|NCT00627653|Experimental|1|
2472338|NCT03088982||Lanmeur multimorbid patients|All multimorbid patients who met 12 FPs in the Lanmeur residential care home in the county of Finistere (in north-west France) from July 2014 to December 2014. These FPs were drawn from those physicians associated with the Lanmeur residential care home.
2472404|NCT03088696|Active Comparator|stimulation of the acupuncture point|"a acupuncture needle and bandage will be applied at pericardium channel 6, point Neiguan"
2472405|NCT03088696|Placebo Comparator|no stimulation of the acupuncture point|"only a bandage will be applied at pericardium channel 6, point Neiguan"
2472464|NCT03088189||Vitamin B12 group|Mothers in the group are receiving vitamin B12 2µg supplements daily
2472467|NCT03088189||Multiple micronutrient group|mothers in this group are receiving vitamin B12 2µg plus multiple micronutrients (MMN) plus 20g of milk powder
2472470|NCT03088189||Placebo|Mothers are receiving placebo
3174842|NCT00627692|Active Comparator|1|Prucalopride
3174843|NCT00627692|Active Comparator|2|Prucalopride
2472593|NCT03087149|Experimental|monitored group|The monitored group will received monitored vit D supplementation
2472598|NCT03087149|Active Comparator|standard group|The standard group will receive standard vit D supplementation
2472689|NCT03086434|Experimental|Culturally tailored intervention|The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
2472690|NCT03086434|Active Comparator|Standard Substance Abuse Education|The control condition participants are assigned to the standard substance abuse education program which is delivered in a classroom format format. They will meet for 10 weekly 50 minute classroom sessions.
2472740|NCT03086083|Experimental|EMDR standard protocol|Standard EMDR protocol, once.
2472743|NCT03086083|Active Comparator|protocol without brain stimulation|Standard EMDR protocol without brain stimulation, once
2472846|NCT03085368|Experimental|EC→PL(Epirubicin+Cyclophosphamide--Docetaxel+lapatinib)|Epirubicin 80 mg/ IV day M2 Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles sequential Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of docetaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
2472850|NCT03085368|Experimental|PEL(Paclitaxel+epirubicin+Lapatinib)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles (intensive chemotherapy), with a total of 6 cycles Also given Lapatinib 1000mg/d Po (fasting) every 30 days for a cycle Note: lapatinib in the first injection of paclitaxel drug taking, once a day, oral dose of 1000mg, a total of over 1 years;
2472923|NCT03084835|Active Comparator|WEB+TXT+TTS|Digital plus Counseling Intervention
2472968|NCT03084562||Dipyridamole|stress test impossible or contraindicated (first intention)
2471719|NCT03093389|Experimental|BIA 6-512 50 mg or Placebo|1 capsule of BIA 6-512 50 mg or 1 capsule of placebo.
2471723|NCT03093389|Experimental|BIA 6-512 100 mg or Placebo|1 capsule of BIA 6-512 100 mg or 1 capsule of placebo.
2471726|NCT03093389|Experimental|BIA 6-512 150 mg or Placebo|1 capsule of BIA 6-512 150 mg or 1 capsule of placebo.
2471777|NCT03092804||normal pressure hydrocephalus|"Included will be subjects with a probable diagnosis of NPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both~The NPH patients will undergo the CSF tap test and then receive the ventriculo-peritoneal shunting surgery. They will have the examination of brain constructure neuroimaging and functional MRI prior to and posterior to the shunting."
2471779|NCT03092804||normal control|Healthy volunteers will undergo the examination of brain constructure and functional MRI.
2471920|NCT03092050|Active Comparator|Facilitated Discussion|Weekly facilitated discussion for 4 weeks
2471925|NCT03092050|Experimental|Guided Imagery and mindfulness|Weekly guided imagery and mindfulness for 4 weeks
2471983|NCT03091634|Experimental|test group|the patients in this group take 6 xue-fu-zhu-yu capsules once, twice a day, for 7weeks.
2471989|NCT03091634|Placebo Comparator|control group|the patients in this group take 6 xue-fu-zhu-yu capsule simulated agents once, twice a day, for 7weeks..
2472034|NCT03091166|Active Comparator|Dexmedetomidine|
2472035|NCT03091166|No Intervention|No Dexmedetomidine|
2472087|NCT03090646|No Intervention|Standard of Care|Participants in the control arm will be instructed to attend required follow-up as is standard of care, but will not receive a financial incentive.
2472088|NCT03090646|Experimental|Financial Incentive|Up to three gift cards to a major online retailer will be mailed to participants assigned to the intervention arm after complete (i.e. all components addressed) and timely (i.e. within the policy-defined follow-up period) submission of follow-up data at each 6-month, 1-year, and 2-year follow-up visit.
2472152|NCT03090464||Standard of Care (SOC)|Participants have standard of care with no access to digital disease management tool
2472155|NCT03090464||SOC + digital disease management|Participants have access to the digital disease management tool in addition to standard of care
2472245|NCT03089775|Experimental|BBI-2000|Cohort A
2472247|NCT03089775|Placebo Comparator|Vehicle|Cohort A
2472248|NCT03089775|Other|Multiple treatments|Cohort B
2472314|NCT03089307|Active Comparator|Group A|Patients will receive one session of low intensity extracorporeal shock wave treatment (LI-ESWT) per week for 6 weeks (6 sessions totally).
2472315|NCT03089307|Active Comparator|Group B|Patients will receive two sessions of low intensity extracorporeal wave treatment (LI-ESWT) per week for 6 weeks (12 sessions totally).
2472331|NCT03088878|Experimental|Part 1|Cirmtuzumab followed by Cirmtuzumab plus ibrutinib
2472332|NCT03088878|Experimental|Part 2|Cirmtuzumab plus ibrutinib
2472333|NCT03088878|Experimental|Part 3 - Arm A|Cirmtuzumab plus ibrutinib
2472334|NCT03088878|Active Comparator|Part 3 - Arm B|Ibrutinib only
2472335|NCT03088878|Active Comparator|Part 4|Cirmtuzumab plus ibrutinib
2472442|NCT03088280|Experimental|3mg/kg Group|Patients will received Thymoglobuline 3mg/Kg (reduced dose)
2472443|NCT03088280|Active Comparator|6mg/kg Group|Patients will received Thymoglobuline 6mg/Kg (standard dose)
2472466|NCT03087942|Experimental|Group 1|ESRD patients
2472469|NCT03087942|Experimental|Group 2|healthy volunteers
2472472|NCT03087942|Experimental|Group 3|severe and moderate renal impaired patients
2472473|NCT03087942|Experimental|Group 4|mild renal impaired patients
2472585|NCT03087097|Experimental|Fecal Microbiota Transplant|FMT by enema: 10mL/kg (maximum 150mL) of healthy donor human intestinal microbiota will be infused.
2472594|NCT03087097|No Intervention|Standard of Care|Standard of care treatment for malnutrition as prescribed by local and national Department of Health Guidelines
2472699|NCT03086863|Experimental|verum electroacupuncture|"Electroacupuncture on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle insertion by 10-15 mm and de qi sensation~Park sham guide tubes~Low frequency electronic stimulation (30 Hz)~Retention for 20 minutes."
2472701|NCT03086863|Sham Comparator|sham electroacupuncture|"Park sham device on on LI4, LI15, TE14, SI9, SI11, and GB21, unilaterally~Needle installation without penetration~Park sham guide tubes~Low frequency electronic stimulation (30 Hz) for a fake noise without conduction~Retention for 20 minutes."
2472741|NCT03085979|Experimental|Burch|Burch Colposuspension
2472745|NCT03085979|Experimental|Trans Obturator Tape|Trans Obturator Tape sling
2472746|NCT03085979|Experimental|Tension free vaginal tape|Tension free vaginal tape sling
3173348|NCT00611091|No Intervention|C|Control Group - (do not receive intervention) randomized at patient level - includes all health plan members, aged 65+, hospitalized at the study site hospital and discharged to an outpatient health plan clinic provider.
3173349|NCT00611117|Experimental|1|High intensity exercise and high fat diet
2472844|NCT03085342|Experimental|Liver MRI|Liver MRI including noncontrast (precontrast) flow measurement, DCE, DWI using multiple b-values, MRE and MR fat quantification.
2472869|NCT03085056|Experimental|Trametinib in Combination With Paclitaxel|Patients will receive paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks, which is a standard regimen in the treatment of anaplastic thyroid cancer, in combination with trametinib 2mg daily during each 4 week cycle.
2472917|NCT03084835|Active Comparator|UC|Usual Care
2472920|NCT03084835|Active Comparator|WEB+TXT|Digital Intervention
2494125|NCT02941679|Active Comparator|HGP1011|Control
3173350|NCT00611117|Experimental|2|Low intensity exercise and high fat diet
3173351|NCT00611143|Experimental|1|Atorvastatin group
3173352|NCT00611143|No Intervention|2|Control group
3173353|NCT00611156|Experimental|A|Spice
3173354|NCT00611156|Experimental|B|Spice
3173355|NCT00611156|Experimental|C|Spice
3173356|NCT00611156|Experimental|D|Spice
3173357|NCT00611156|Placebo Comparator|E|Placebo
3173358|NCT00611169|Experimental|1|Aspirin, clopidogrel, unfractionated heparin plus tirofiban infusion at high bolus dose
3173359|NCT00611169|No Intervention|2|Aspirin, clopidogrel, unfractionated heparin
3173360|NCT00611182||1|Patients with Pulmonary Fibrosis
2471766|NCT03092921|Experimental|F&P Mask|Participants to use trial mask in-home for 2 weeks
2471810|NCT03092557|Experimental|Determination of local pleural strain|Patients will receive four different tidal volumes in random order (6 mL/kg, 8 mL/kg, 10 mL/kg, 12 mL/kg).
2472130|NCT03090867|Active Comparator|Conventional arm|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
2472135|NCT03090867|Experimental|The relative/surrogate will be encouraged to perform care|"The relative or surrogate will perform at least two cares a week . A manual will be given to the relative or surrogate, explaining the different care he can choose to perform on the patient.~The care proposed are: feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~Each care is written down on a collecting sheet."
2472178|NCT03090269|Experimental|Methylphenidate pill|"18 mg tablets with a 3-week titration phase to a maximum dose of 108 mg per day, orally~Associated with phone interviews every month, urine drug toxicologies and blood sampling (PK/PD)"
2472312|NCT03089346|Other|Asthma|"Patients with diagnosis of asthma according to 2016 Global Strategy for Asthma Management and Prevention (GINA) definition"
2472459|NCT03088111|Other|Obiltoxaximab|"This is an open label, 24-week, single arm field study that will be implemented for subjects who receive FDA-approved obiltoxaximab as part of their medical treatment for inhalational anthrax infection in the United States. Adult subjects will be administered a single, intravenous (IV) dose of 16 mg/kg obiltoxaximab given as part of their medical care. Children will receive a weight-adjusted dose.~The primary purpose of the study is to collect data from subjects who have been treated with obiltoxaximab as part of their medical care for inhalational anthrax and to collect additional blood samples for measurement of obiltoxaximab concentrations and presence of anti-therapeutic antibodies (ATA)."
3173361|NCT00611195|Other|1|Larynx assessment under stimulation
2472625|NCT03086668|Experimental|Conventional Jaw thrust Group|an assembly of video-stylet and double curve endotracheal tube with conventional jaw thrust technique to facilitate nasotracheal intubation
2472626|NCT03086668|Experimental|Fingers hook Group|an assembly of video-stylet and double curve endotracheal tube with fingers-hook technique to facilitate nasotracheal intubation
2472663|NCT03086512|Active Comparator|Group I|Group I consists of 45 patients receiving a subtalar fusion with the Acutrak 2® - Fully Threaded Screw.
2472665|NCT03086512|Sham Comparator|Group II|Group II consists of 45 patients receiving a subtalar fusion with the Partially Threaded Synthes® 7.3 Cannulated Screw.
2472705|NCT03086239|Experimental|Part A: Rovalpituzumab tesirine|Part A Dose Escalation: Rovalpituzumab tesirine intravenous (IV) (various doses and dose regimens) on Day 1 of each 6-week cycle
2472708|NCT03086239|Experimental|Part B: Rovalpituzumab tesirine|Part B Dose Expansion: Rovalpituzumab tesirine dosed at regimen(s) previously demonstrated in Part A to not to exceed the maximum tolerated dose (MTD).
2472737|NCT03085953|Experimental|Experimental: Supervisor Intervention|Supervisors in the intervention group will go through the Veteran Supervisor Supportiveness Training.
2472738|NCT03085953|Other|Waitlist Control Group|Supervisors will receive intervention following all measurement points, to serve as a waitlist control comparison group
2472990|NCT03084484|Experimental|Test Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the test group were instructed to eat two kiwifruit per day during the whole study period."
2472993|NCT03084484|Active Comparator|Control Group|"Subjects affected by periodontitis were examined and included in the study. After 2 months subjects also received non-surgical periodontal treatment and then followed for additional 3 months.~Subjects in the control group didi not receive any dietary advice."
2473041|NCT03084133|Experimental|Therapeutic Education Strategy|"Means a screening information and education system in which the particularities of the index cases likely to require adaptation of the device will be collected, analyzed and taken into account.~Intervention 'Therapeutic Education Strategy'"
2473042|NCT03084133|No Intervention|Control group|Provision of information on the need for screening colonoscopy in first-degree relatives of case-index patients by the practitioner taking charge of the index case according to its usual practice
2473309|NCT03082508|Active Comparator|Standard Medical Therapy|as per protocol
3173362|NCT00611208|Experimental|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diptheria toxin)
3173363|NCT00611221|Active Comparator|1|Massage therapy by a regulated massage therapist
3173364|NCT00611221|Active Comparator|2|Massage by anyone else, eg. husband, nurse, doula
3173365|NCT00611260|Experimental|Meditation Cohort|25 patients will be given instruction in vipassana meditation. Vipassana meditation is thought to reduce the incidence of atrial and ventricular arrhythmias in patients with congestive heart failure, and improve their overall psychological profile.
3173366|NCT00611260|Active Comparator|Standard Care|25 patients will receive current standard of care to manage their congestive heart failure, implanted cardiac devices, and psychological health.
3173367|NCT00611273|Experimental|1|Patients who have presented to the investigator for correction of glabellar furrows, as classified per the Rated Numeric Kinetic Line Scale Score for Facial Wrinkles Secondary to Hyperkinetic Function (Note: Class 1 or Higher)7 (Appendix R) are candidates for this study.
3173368|NCT00611286|Experimental|1|treatment with Aspirin and clopidogrel for 24 months after coronary intervention with stents. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent.
3173369|NCT00611286|Active Comparator|2|Treatment with aspirin and clopidogrel for minimum 1 or 6 month(s) after BMS or DES implantation, respectively. This group of patients will be randomized in a 1:1:1:1 ratio to receive bare metal stent, Zotarolimus-eluting stent, paclitaxel-eluting stent or everolimus-eluting stent
3173370|NCT00611312|Experimental|1|Cognitive Training
3174844|NCT00627692|Active Comparator|3|Prucalopride
3174845|NCT00627692|Placebo Comparator|5|Placebo
3174846|NCT00627692|Active Comparator|4|Prucalopride
3174847|NCT00627718|Other|A|All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
2471856|NCT03092180||Idiopathic inflammatory myopathies 1|Intravenous infusion with methyprednisolone / human intravenous immunoglobulin at disease onset
2471857|NCT03092180||Idiopathic inflammatory myopathies 2|Intravenous infusion with methyprednisolone at disease onset
2471910|NCT03092011|Experimental|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours
2471913|NCT03092011|Active Comparator|Morphine|Morphine Sulfate at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours
2471980|NCT03091647|Experimental|acupressure intervention|Practice acupressure at home and complete daily logs
2471981|NCT03091647|Placebo Comparator|usual care|Receive usual care and complete daily logs
2472030|NCT03091296||Men with testosterone deficiency|Screening testosterone concentration of less than 350 ng/dL
2472031|NCT03091296||Men without testosterone deficiency|Screening testosterone concentration of greater than 350 ng/dL
2472053|NCT03091036|Other|Proactive healthcare intervention|Participants who were included before (single-arm pre-post study), now a proactive and integrated intervention program for the health is performed of the complex chronic patient, based in an improvement of the care process.
2472084|NCT03090763||Study population|100 Subjects followed in our department for the diagnosis of aortic aneurysm. On admission, the demographic data (see Appendix 1) will be recorded. Furthermore, within the routine clinically indicated laboratory samples, the levels of selected biochemical markers will be recorded (see Appendix 1). Follow up control laboratory will be performed one year, again within the routine samples.
2472085|NCT03090763||Control population|The control population also includes 100 subjects in total. These will be chosen from aged and sex matched individuals seen in our clinic without disease of the aorta. All subjects included in trial must be at least 18 years old and must sign the informed consent to participation in the study. In the control population, also demographic data will be obtained and the levels of selected biochemical markers will be recorded within the routine clinically indicated laboratory samples.
2472139|NCT03090516|Experimental|Arm A ：Donepezil|A：People are randomly divided into three groups according to the educational conditiono，gender and age.
2472142|NCT03090516|Experimental|Arm B ：Donepezil and Ginkgo biloba dispersible tablets|B：People are randomly divided into three groups according to the educational conditiono，gender and age.
2472143|NCT03090516|Experimental|Arm C：Ginkgo biloba dispersible tablets|C：People are randomly divided into three groups according to the educational conditiono，gender and age.
2472154|NCT03090139||All Participants|All participants with diagnosis of UC and CD, who initiated treatment with anti-TNF therapy from 01 March 2010 up to 01 March 2015 will be observed. Retrospective data extraction will be done for eligible participants from March 2017 up to approximately February 2018.
2472243|NCT03089541|Experimental|Survey Arm|Will receive incentives for completing surveys and evidence of tobacco use status daily for 1 week
2472290|NCT03089450|Experimental|CGBIO stent (DES)|The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
2472292|NCT03089450|Active Comparator|Biomatrix flex(DES)|The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
2472415|NCT03088358|Experimental|TeaRx 50 mg|TeaRx: 50 mg per day PO (active 25 mg + placebo 50 mg every 12 hours) during 12 days (±2 days)
2472418|NCT03088358|Experimental|TeaRx 100 mg|TeaRx: 100 mg per day PO (placebo 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
2472421|NCT03088358|Experimental|TeaRx 150 mg|TeaRx: 150 mg per day PO (active 25 mg + active 50 mg every 12 hours) during 12 days (±2 days)
2472424|NCT03088358|Active Comparator|Enoxaparin|Enoxaparin 40 mg subcutaneous per day (24 hours interval) during 12 days (±2 days)
2472455|NCT03087968|Experimental|GS-4997 + Prednisolone|"GS-4997 + Prednisolone for 28 days~HepQuant SHUNT Test"
2472460|NCT03087968|Placebo Comparator|Prednisolone + Placebo|"Placebo + Prednisolone for 28 days~HepQuant SHUNT Test"
2472532|NCT03087552||Transradial balloon aortic valvuloplasty|Consecutive patients with severe aortic stenosis and receiving as first attempt balloon aortic valvuloplasty by transradial access.
2472563|NCT03087175|Experimental|MGuard stent|MGuard stent is a novel thin-strut metal stent with a polyethylene terephthalate micronet covering designed to trap and exclude thrombus and friable atheromatous debris to prevent distal embolization
2472564|NCT03087175|Active Comparator|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent
2472580|NCT03087006|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) may help with depression, anxiety, stress, PTSD, and may have a positive impact on quality of life of participants diagnosed with dry eye disease. ASTM is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.
2472590|NCT03087006|Placebo Comparator|Treatment as Usual (TAU)|Participants continue to receive treatment as usual including dry eye disease medications.
2472654|NCT03086785|Experimental|apatinib|apatinib 500mg qd po or combined Capecitabine 1000mg/m2 bid d1-d14 q3w
2472685|NCT03086291|Experimental|simvastatin|One arm Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days Cohort 1: 7.5 mg/kg bid for 7 days 14 days off Cohort 2: 10 mg/kg bid for 7 days 14 days off Cohort 3: ( ) mg/kg bid for 7 days 14 days off (to be determined based on PK data of cohort 1 and 2) Q 3 weeks
3174848|NCT00627731|Active Comparator|1|mPSL 240 mg per day for 5 days
2494127|NCT02941679|Active Comparator|HCP0910|Control
3174849|NCT00627731|Experimental|2|PSL 40mg per day for 10 days
3174850|NCT00627744|Placebo Comparator|BE 1|Patients in this arm are randomly assigned to treatment with placebo
3174851|NCT00627744|Active Comparator|BE 2|Patients in this arm are randomly assigned to treatment with Sitagliptin
3174852|NCT00627757||Food challenge test|"Patients~51 patients included"
3174853|NCT00627757||C|Controls 93 healthy controls are included
2471853|NCT03092193|Experimental|Naproxen|20 patients will receive naproxen (one tablet 500 mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
2471855|NCT03092193|Experimental|Naproxen-esomeprazole|20 patients will receive after one month of first collection (with naproxen 500 mg), naproxen-esomeprazole (one tablet 500mg+20mg) to collected saliva samples for pharmacokinetic and pharmacogenetic studies
2471899|NCT03091985|Experimental|Group A|"Drainage of the lactating breast using:~PersonalFit - Breast shield & Brownie - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
2471900|NCT03091985|Experimental|Group B|"Drainage of the lactating breast using:~Brownie - Breast shield & PersonalFit - Breast shield~Breast shields are each to be used for 15 min pumping with the symphony breastpump"
2471974|NCT03091712|Experimental|Paper Titration Tool and Glooko MIDS|"Glooko mobile insulin dosing system(MIDS), using the STEP WISE degludec titration algorithm.~The eligible subjects will be started on insulin degludec (Tresiba® U-200 FlexTouch®). Subjects will use MIDS for insulin degludec titration management. The clinician will configure MIDS Prescription Instruction Form(PIF) using pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program. The Clinician can alter this as appropriate based on medical judgment. Subjects will be started on MIDS and trained on use of Glooko MIDS mobile app. Subjects will get dose adjustment check up on the app and also alert to contact physician if subject experiences hyperglycemia or hypoglycemia."
2471975|NCT03091712|No Intervention|Paper Titration tool|"Usual care for insulin degludec (Tresiba® U-200 FlexTouch® pens) titration using the STEP WISE degludec titration algorithm.The eligible subjects will be started on insulin degludec(Tresiba® U-200 FlexTouch®).~Subjects in this group will be provided with a one-page description of the pre-configured Novo Nordisk, Tresiba Protocol Dosing Treatment Plan which is based on the Novo Tresiba degludec Stepwise Program and how to follow it. The Clinician can alter this as appropriate based on medical judgment. This document will also include instructions to contact the HCP if the subject experiences hyperglycemia or hypoglycemia."
2471995|NCT03091374|Experimental|Growth Hormone|
3208628|NCT00976638|Active Comparator|Chromogenic Arm|Active surveillance of colonization with MRSA or VRE by chromogenic agar with isolation of positive patients.
2472144|NCT03090477|Experimental|Pharmaceutical care and adherence aids|
2472145|NCT03090477|No Intervention|Control (dispensing of TKI & instruction about administration)|
2472181|NCT03090087|Experimental|Healthy person|The purpose is to investigate the effect of A2A adrenoceptor stimulation using the drug regadenoson (Rapiscan) on the diameter of retinal arterioles during hypoxia in vivo.
2472279|NCT03089749||Control|Participants with no history of Traumatic Brain Injury, Traumatic Spinal Cord Injury or Intracranial Neoplasm. A single draw of 5 mL of blood will be obtained as well as demographic information and a brief medical history to act as comparison data to the other groups.
2472280|NCT03089749||Traumatic Brain Injury (TBI)|"Patients with Acute Severe TBI (post-resuscitation GCS of 8 or less). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained from the participant. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, post-resuscitation Glasgow Coma Scale (GCS) scores for brain injury patients~Radiographic indicators of severity including volume of intracranial hemorrhage, effacement of basal cisterns, amount of midline shift as well as Marshall and Rotterdam CT head scores for TBI.~Outcome data including discharge, 3-, 6-, and 12-month extended Glasgow Outcome Scale (GOS) scores"
2472284|NCT03089749||Spinal Cord Injury (SCI)|"Patients with acute spinal cord injury (SCI) (post-resuscitation ASIA score of C, B or A). Participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline post-resuscitation American Spinal Injury Association (ASIA) score and ASIA impairment scale (AIS) grade for patients with spinal cord injury (SCI)~Radiographic indicators of severity including the degree of cord compression, area of cord signal change and the SFGH MRI scale will be employed.~Outcome data including discharge, 3-, 6-, and 12-month ASIA scores for SCI patients"
2472287|NCT03089749||Intracranial Neoplasm|"Patients undergoing resection of intra-axial brain tumors (commonly gliomas such as glioblastoma multiforme, astrocytomas and oligodendrogliomas). All participants will have blood draws at the time points identified below:~At 24h from the time of CNS insult~At 3, 5, 7, 10, 14, 18, 21, 30 days from the time of CNS insult~At 3, 6, and 12 months from the time of CNS insult~Annually for the next four years Total of up to 16 blood draws.~In all cases, 5 mL of blood will be obtained. Demographic data will be collected, including:~Age~Sex~History of prior CNS insult~Clinical indicators of severity including baseline, Karnofsky and Modified Rankin performance status scores for oncology patients.~Radiographic indicators of severity including the pre- and postoperative tumor volumes that will be quantitated.~Outcome data including discharge, 3-, 6-, and 12-month Karnofsky and Modified Rankin scores for oncology patients."
2472350|NCT03088839||30 ALS patients|
2472353|NCT03088839||30 healthy controls|
2472392|NCT03088631|Active Comparator|Metformin group|
2472394|NCT03088631|Placebo Comparator|Placebo group|
2472435|NCT03088332|Experimental|Endoscopic gastroplasty|Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures.
2472486|NCT03088033|Experimental|Treatment|Patients randomized to the treatment arm will undergo a fluoroscopically and intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) guided trans-septal puncture and IASD System II implant procedure.
2472491|NCT03088033|Sham Comparator|Control|Patients randomized to the control arm will undergo ICE from the femoral vein or TEE for examination of the atrial septum and left atrium.
2472592|NCT03087227|Experimental|NEUTROSIS Intervention Group|The NEUTROSIS Intervention group captures daily its temperature and the occurrence of other symptoms on the smartphone application. This information is then transmitted instantly to the hospital care team through the NEUTROSIS shared information system. The medical oncologist will be alerted in case of fever and will contact the patient.
2471870|NCT03092440||"Expert nurses group"|Intensive nurses (with ≥ 4 years experience post graduate)
2471911|NCT03091946|Placebo Comparator|Cooked cream of rice|Cream of rice with additional dried fruits, nuts and seeds cooked just prior to its consumption and served with skim milk as a beverage
2471912|NCT03091946|Experimental|Overnight oats|Oats with additional dried fruits, nuts and seeds soaked overnight in skim milk
2472009|NCT03091686|Experimental|Experimental Group (HAPA SB)|"Experimental (same outcome questionnaire but with informational slideshow focusing on sedentary behaviour and diabetes risk)~HAPA SB Intervention Slideshow"
2472011|NCT03091686|Active Comparator|Attention-Control Group (HAPA MVPA)|"Attention-Control (same outcome questionnaire but with slideshow focusing on benefits of moderate-vigorous physical activity)~HAPA MVPA Intervention Slideshow"
2472013|NCT03091686|No Intervention|Control Group|"Control (outcome questionnaire without any slideshow)~Participants randomly assigned to the control group will receive no information or intervention of any kind and will only be asked to complete the outcome questionnaire."
2472148|NCT03090165|Experimental|Arm A - Phase I|"Dose Escalation Cohort 1 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-21 of a 28 day cycle.~Cohort 2 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 400mg PO daily on days 1-28 of a 28 day cycle.~Cohort 3 will consist of 3-6 patients who will receive bicalutamide 150mg PO daily on days 1-28 of a 28 day cycle and ribociclib 600mg PO daily on days 1-21 of a 28 day cycle.~Experimental: Arm B - Phase II Investigational Treatment The maximum safe dose of ribociclib in combination with bicalutamide will be given to up to 25 patients."
2472215|NCT03089905|Experimental|Sevoflurane/dexmedetomidine/remifentanil|"Dexmedetomidine: loading dose of 1mcg/kg over 10 minutes followed by an infusion of at 1 mcg/kg/hr.~Remifentanil: loading dose 1 mcg/kg over 2 minutes followed by an infusion starting at 0.1 mcg/kg/min or greater.~Sevoflurane: end tidal concentration of 0.6 -0.8% or less."
2472224|NCT03089905|Active Comparator|Sevoflurane|End tidal concentration of 2.5-3.0% or greater.
2472302|NCT03089333|Experimental|Dapagliflozin|Dapagliflozin 10mg daily for 12 weeks.
2472310|NCT03089333|Active Comparator|Glibenclamide|Glibenclamide 5mg daily for 12 weeks.
2472344|NCT03088891|Experimental|Antioxidant-rich snacks|The participants received antioxidant-rich snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included fruits and vegetable smoothies, dark chocolate, walnuts, dried fruits and berries.
2472347|NCT03088891|Placebo Comparator|Control snacks|The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
2472476|NCT03088384||Combat Veterans|Eligible participants must be military veterans who have served in a combat zone as evidenced by documentation on the subject's DD214 (or equivalent if he/she served in a foreign military). Participants must have a diagnosis of post traumatic stress disorder that was as a result of their military combat experience.
2472582|NCT03087357||Low Risk|The Low Risk group will consist of 2,400 pregnancies with no high risk findings (e.g., abnormal ultrasound, positive serum screen) who are undergoing initial clinical cfDNA screening. To simulate a general pregnancy population, approximately 20% of these women will be age 35 and older. An estimated 2% (48) of these LR women will have a failed/no call cfDNA test. Consenting women will provide samples for SmartNIPT testing.
2472589|NCT03087357||High Risk|The High Risk group will consist of 250 women with a positive cfDNA screen reported by a Clinical Laboratory Improvement Amendments (CLIA)-approved commercial laboratory, and who present for consideration of a confirmatory diagnostic test, (i.e., CVS or amniocentesis). Consenting women will provide samples for SmartNIPT testing.
2472632|NCT03086694||group surgery|using medications to maintain low stable blood pressure
3192176|NCT00805818|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion (Cohort 1, n=10), (Cohort 2, n=10) or (Cohort 3, n=67) intravenous infusion for a total of 72 consecutive hours.
3192177|NCT00805831|Experimental|A|Aortic anastomosis surgery will be conducted using HDH device.
3192178|NCT00805844||1|Spine surgery with Motor Evoked Potential monitoring without SedLine monitoring visible.
3192179|NCT00805844||2|Spine surgery with Motor Evoked Potential Monitoring with SedLine monitoring visible.
3192180|NCT00805883|Experimental|1|
3192181|NCT00805896|Experimental|1|Songyou Granule
2473110|NCT03083704|Experimental|Cohort 1|
2473112|NCT03083704|Experimental|Cohort 2|
2473113|NCT03083704|Experimental|Cohort 3|
2473114|NCT03083704|Experimental|Cohort 4|
2473115|NCT03083704|Experimental|Cohort 5|
2473116|NCT03083704|Experimental|Cohort 6|
2473121|NCT03083704|Experimental|Cohort 7|
2473126|NCT03083704|Experimental|Cohort 8|
2473131|NCT03083704|Experimental|Cohort 9|
2473138|NCT03083704|Experimental|Cohort 10|
2473144|NCT03083704|Experimental|Cohort 11|
2473222|NCT03083015|Experimental|Revascularization|Blood clot initiation and grey MTA ( Mineral Tri-oxide Aggregate) cervically compacted.
2473229|NCT03083015|Active Comparator|Apexfication|Apexification using grey MTA apically compacted without mechanical preparation.
2473270|NCT03082690|Experimental|DuoGel|IQP-0528 1% gel administered rectally one time
2473417|NCT03082066||Children|Younger 18 years: Newborns, infants, small child, school child, teens
2473420|NCT03082066||Adults|Even or older 18 years
2473454|NCT03081520|Experimental|Affective response MIT|Moderate intensity continuous training 50 min with walking or running on approximately 75% of HRmax
2473456|NCT03081520|Experimental|Affective response HAIT|High-Intensity Aerobic Interval Training 4x4 min with walking or running on 85-95% of HRmax 3 min active recovery between sets, intensity of approximately 70% of HRmax
2473790|NCT03078933|Active Comparator|Standard of Care|Standard of care for diabetic foot ulcer wound care
3192182|NCT00805896|Placebo Comparator|2|
3192183|NCT00805909|Experimental|NI-0401|5 daily infusions of escalating doses of NI-0401
3192184|NCT00805922||A|
3192185|NCT00806000||Athletes|
3192186|NCT00806013||1|CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
2471936|NCT03092102|Experimental|A single dose HEC585（A8）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471938|NCT03092102|Experimental|Multiple doses HEC585（B1）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471942|NCT03092102|Experimental|Multiple doses HEC585（B2）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471944|NCT03092102|Experimental|Multiple doses HEC585（B3）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471949|NCT03092102|Experimental|Multiple doses HEC585（B4）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471953|NCT03092102|Experimental|Multiple doses HEC585（B5）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471957|NCT03092102|Experimental|Multiple doses HEC585（B6）|"Drug: HEC585 Capsule~Drug: HEC585-matching placebo Capsule"
2471988|NCT03091491|Experimental|Nivolumab|
2471992|NCT03091491|Experimental|Nivolumab and Ipilimumab|
2472080|NCT03090802|Experimental|Intervention|The participants of the program arm will have 15 group sessions with mentor mother and up to 2 home visits from 3 weeks-6 months postpartum, which is package as the Mentoring Adolescent Mothers at School (MAMAS) program. Further, adolescent mothers in the intervention arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
2472082|NCT03090802|No Intervention|Control|Adolescent mothers in the control arm will receive adolescent-friendly clinical care from 2 weeks-9 months postpartum.
2472103|NCT03090529|Experimental|Exercise group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
2472111|NCT03090529|No Intervention|Control group|The control group will receive usual medical care
2472163|NCT03090399|No Intervention|control group|patients in which standard fluid administration was applied
2472167|NCT03090399|Active Comparator|case group|patients in which fluids were administered according to FloTrac parameters
2472211|NCT03089996|Experimental|Piezocision|Piezocision-assisted canine retraction x Control (split mouth design)
2472213|NCT03089996|Experimental|Corticotomy|Corticotomy-assisted canine retraction x Control (split mouth design)
2472221|NCT03089996|Experimental|Piezocision x Corticotomy|Piezocision-assisted retraction x Corticotomy-assisted retraction (split mouth design)
2472259|NCT03089489||Lung recipients with PGD|in the first 72 hours following lung transplantation, the lung recipients have blood gases and chest X-Ray to assess the occurrence of primary graft dysfunction. Chest X-Ray infiltrate and pathological PaO2/FiO2 ratio describe PGD occurence
2472261|NCT03089489||Lung recipients PGD Free|In the first 72 hoours following lung transplantation, if the Cest X-ray is normal, the patient is considered PGD-free
2472342|NCT03089021|Experimental|mulligan mobilization|mobilization for spinous process or facet with neck movement 10 repetetions for 3 times.
2472348|NCT03089021|Experimental|maitland mobilization|maitland mobilization for spinous process or facet joint for 2 min and repeated 3 times.
2472385|NCT03088592|Other|Deep Brain Stimulation|After informed consent is obtained, the patients will undergo routine DBS pre-operative evaluation and diagnostic testing. This includes a pre-operative 3T-MRI with and without gadolinium as well as pre-operative medical clearance by the patient's PCP or general practitioner and/or other medical specialist if necessary. They will also receive a baseline clinical evaluation including both motor function (Unified Parkinson's Disease Rating Scale on and off anti-parkinsonian medication) quality of life assessment (Parkinson's disease Questionnaire-39) and a full neuropsychological evaluation, if not already completed as part of the routine DBS candidacy evaluation within 2 months of surgery. Subjects will have medical clearance from their specialists and be be evaluated by an internal medicine physician prior to surgery and cleared to proceed.
2472425|NCT03088371|Other|Psoas Sciatic blockade|Psoas Sciatic blockade with 20 ml lidocaine 1% and 20 ml bupivacaine 0.25% pajunk needle used for the block and 5 ml Lidocaine 2% used for post-operative pain.
2472426|NCT03088371|Other|Combined spinal epidural|Spinal anaesthesia with 2.5 ml (12.5 mg) of heavy Bupivacaine 0.5%. Epidural for post-operative pain with Bupivacaine 0.125 %in a rate of 7-10 ml/hour Portex combined spinal epidural kit needle through needle.
2472452|NCT03087929||Treatment Arm|Patients who had previously undergone high dose therapy with stem cell support followed by consolidation with Rituximab and alpha-interferon as part of the trial Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon. The patients in this arm have consented to long-term follow up.
2472515|NCT03087825|Sham Comparator|spontaneous breathing|preoxygenation through spontaneous breathing of 100% oxygen gas flow with or without an inward air leak
2472525|NCT03087825|Active Comparator|pressure support ventilation|preoxygenation through non invasive pressure support ventilation of 100% oxygen gas flow (inspiratory trigger sensitivity set at -2 l.min-1, the positive inspiratory support set at +6 cmH2O, the PEEP set at +5 cmH2O and the maximal airway pressure was limited at 15 cmH2O.) with or without an inward air leak
2472586|NCT03087292|Active Comparator|Resistance training group|"Patients to be randomly assigned to the resistance training group will have resistance training with vascular occlusion 2 times per week for a period of 8 weeks on unilateral leg extension machine. During each training, they will performed 3 sets of 15 repetitions at the intensity of 30% 1 RM (repetition maximum). Each training set will separated by a 30 second rest period."
2472595|NCT03087292|No Intervention|Control group|Patients to be randomly assigned to the control group (normal physical activity) will continue with their usual physical activity regime.
2472649|NCT03086811|Experimental|intervention group|First time mothers, when infants were ages 4-6 months old, took part in a training program in small group setting (10-12 mother-infants). the program continued for a month, with 4 weekly meetings. group coordinators were a highly experienced pediatric dietitian, and a social worker. Training topics addressed were infant healthy nutrition and growth, feeding skills, obesity and emotional feeding prevention, parenting. Thereafter, mothers were encouraged to stay in contact with the trainers, till infants reached age 12 months and data was collected using video taping of mealtime feeding interactions at home setting environment. Mother Infant Feeding Interaction very early training
2472651|NCT03086811|No Intervention|control group|Control group first time mothers were recruited when infants were around 11-12 months of age for data collection of mealtime feeding interactions taping at home setting environment. They received during this year the official support and training given in municipality care centers.
2471996|NCT03091543|Experimental|Sequence E (50 mg - 100 mg - 200 mg - Placebo - 25 mg)|Concomitantly with the BIA 6-512/Placebo dose, subjects will be administered levodopa/benserazide 100/25 mg. All subjects attended to each 5 treatment periods and received a different dose of BIA 6-512 or placebo in combination with a single-dose of controlled release levodopa/benserazide 100/25 mg in each of these treatment periods. The washout period between periods was 5 days or more.
2472070|NCT03090971|Experimental|Cutaneous neurofibromas|Each subject will have two treatment neurofibromas and two control neurofibromas. Following microporation, the two treatment neurofibromas will be treated with topical diclofenac while the two control neurofibromas will be treated with topical saline.
2472166|NCT03090113|Experimental|Shuxuetong Injection|Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;
2472171|NCT03090113|Placebo Comparator|Placebo Injection|Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;
2472244|NCT03089710|Experimental|Mini-Fluid Challenge arm|"Fluid challenge test will be presented after induction of anesthesia at a steady state. Fluid challenge test includes 2 components: 100 ml colloid infusion in 1 min followed by 400 ml colloid infusion in 14 mins. Hemodynamic parameter after 1 minute of the end of the 1st and 2nd colloid infusion bolus will be collected.~Applied colloid: hydroxyethyl starch"
2472305|NCT03089424|Placebo Comparator|Placebo PBMT|Application of PBMT (Photobiomodulation Therapy) without any dose (0 Joule) and The Back Book (educational information booklet).
2472308|NCT03089424|Active Comparator|PBMT active|Application of PBMT (Photobiomodulation Therapy) active and The Back Book (educational information booklet).
2472343|NCT03088930|Experimental|Neoadjuvant treatment with Crizotinib|Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.
2472387|NCT03088605|Experimental|Active|TOP1630 Ophthalmic Solution
2472390|NCT03088605|Placebo Comparator|Placebo|Placebo (Vehicle) Ophthalmic Solution
2472501|NCT03087864|Experimental|Atezolizumab and Chemoradiation|Atezolizumab 1200 mg i.v. day 1-22-43-64-85 Carboplatin AUC = 2 i.v day 1-8-15-22-29 Paclitaxel 50 mg/m2 i.v day 1-8-15-22-29 Radiotherapy 23 x 1.8 Gy
2472516|NCT03087526|Experimental|Couple at risk of transmitting a triplet-repeat disease|Expectant couple (pregnant woman between 9 and 34 weeks of gestation and her spouse) at risk of transmitting a triplet-repeat related genetic disease among Huntington disease, Myotonic Dystrophy type 1, Fragile X syndrome, Spinocerebellar Ataxia type 1, Spinocerebellar Ataxia type 2, Spinocerebellar Ataxia type 3
2472566|NCT03087266|Experimental|Full- Mouth Scaling and Root Planing|FM-SRP Non-surgical periodontal treatment will be performed in all dentition within 24 hours.
2472567|NCT03087266|Active Comparator|Quadrant Scaling and Root Planing|"Q-SRP Non-surgical periodontal treatment will be performed in all dentition subdivided in four appointments. Each appointment will be performed with one week interval. In each appointment only a quadrant of the dentition will be instrumented."
2472620|NCT03086980|Active Comparator|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness.Research suggests that ASTM may help reduce depression and anxiety.
2472622|NCT03086980|Placebo Comparator|Treatment as Usual (TAU)|The usual standard of care for patients with glaucoma includes starting them on first line of drugs. Participants will be initiated and maintained on appropriate dosages of such medications as part of standard of care. The usual standard of care also includes an ophthalmic examination measuring best-corrected Snellen VA and pinhole acuities and a follow-up visit once a year.
2472695|NCT03086499||The study population|Patients with pectus excavatum having consulted at the Montpellier University Hospital and who have had corrective surgery.
3157548|NCT00367471|Active Comparator|Group B|Subjects in Treatment Group B (in cohorts of three) will receive oral lapatinib QD (Days 1 to 28). Following lapatinib administration on Day 1, paclitaxel will be administered intravenously over one hour followed immediately by a ≥15 minute intravenous infusion of carboplatin. Doses of paclitaxel, and carboplatin will be administered weekly (Day 1, 8, and 15) for three weeks with cycles repeated every four weeks.
3157549|NCT00367653|Experimental|1|
3157550|NCT00367653|Experimental|2|
2472985|NCT03084289|Experimental|Group 1|Group 1 will receive ChAd63-METRAP at the dose of 5x10^8 vp i.v.
2472988|NCT03084289|Experimental|Group 2|Group 2 will receive ChAd63-METRAP at the dose of 5x10^9 vp i.v.
2472992|NCT03084289|Experimental|Group 3|Group 3 will receive ChAd63-METRAP at the dose of 5x10^10 vp i.v.
2472994|NCT03084289|Experimental|Group 4|Group 4 will receive ChAd63-METRAP at the dose of 5x10^10 vp s.c.
2472995|NCT03084289|Experimental|Group 5|Group 5 will receive ChAd63-METRAP at the dose of 2x10^11 vp s.c.
2472996|NCT03084289|Experimental|Group 6|Group 6 will receive MVA METRAP at the dose of 2 x 10^6 pfu i.v.
2472998|NCT03084289|Experimental|Group 7|Group 7 will receive MVA METRAP at the dose of 2 x 10^7 pfu i.v.
2472999|NCT03084289|Experimental|Group 8|Group 8 will receive MVA METRAP at the dose of 2 x 10^8 pfu i.v.
3157551|NCT00367666|Experimental|Patients Diagnosed with Breast Cancer|
3157552|NCT00367705|Active Comparator|T|VSL-#3
3157553|NCT00367705|Placebo Comparator|P|
3157554|NCT00367757|Other|PVI group|Trigger-based ablation guided by pulmonary vein antrum isolation
3157555|NCT00367757|Other|CFAE group|Substrate-based ablation using an approach targeting CFAEs
3157556|NCT00367757|Other|Combined group|Combined trigger and substrate based approach
3157557|NCT00367809|Experimental|1|
3157558|NCT00367809|Active Comparator|2|
3157559|NCT00367809|No Intervention|3|
3157560|NCT00367861|Experimental|interruption of Glivec®|
3157561|NCT00367887|Active Comparator|1|
3157562|NCT00367887|Active Comparator|2|
3157563|NCT00367887|Active Comparator|3|
3157564|NCT00367900||NIH-AARP Diet and Health Study sub study: PAGE|Diet and Health Study members who self-reported a Parkinson's disease (PD) diagnosis on a follow-up questionnaire, and randomly selected controls, will participate in the PAGE sub study.
3157565|NCT00367952|Experimental|ATC 800mg BID|800mg ATC BID
2472000|NCT03091595|Experimental|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
2472005|NCT03091595|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4-day regimen. One tablet per day orally for 3 treatment cycles.
2472040|NCT03091140||Group A|patients with primary hyperparathyroidism, undergoing parathyroidectomy, as a therapeutic intervention
2472041|NCT03091140||Group B|patients with primary hyperparathyroidism, not undergoing parathyroidectomy and receiving conservative treatment. This group will be considered as control group.
2472043|NCT03091140||Group C|patients undergoing thyroid surgery due to nontoxic multinodular goiter or solitary nontoxic thyroid adenoma. This group will be considered as control group.
2472046|NCT03091140||Group D|healthy subjects. This group will be considered as control group.
2472104|NCT03090841||CMV cases|bio-specimen collected for pregnant women with CMV infection
2472109|NCT03090841||Control cases|bio-specimen collected for pregnant women carrying a fetus with aneuploidy-dysgonosomy
2472216|NCT03090035|Experimental|chronic hepatitis C genotype 2 or 3|In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
2472291|NCT03089528|Experimental|Videolaryngoscopy|the trachea will be intubated using a videolaringoscope
2472293|NCT03089528|Active Comparator|Direct laringoscopy|the trachea will be intubated using a laringoscope
2472366|NCT03089060|Experimental|Silicone Finger Cap|Patients randomized to this arm will be treated with the novel silicone finger cap for the first two weeks of treatment.
2472370|NCT03089060|Active Comparator|Film dressing|Patients randomized to this arm will be treated with conventional film dressings for the first two weeks of treatment.
2472432|NCT03088462|Active Comparator|Treatment As Usual|Any treatment for bipolar disorder participant is involved in.
2472433|NCT03088462|Experimental|Treatment As Usual + LiveWell Program|Treatment as usual combined with the LiveWell program.
3192187|NCT00806013||2|CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
3192188|NCT00806013||3|CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier
3192189|NCT00806039|Other|1|Early renal involvement
2472613|NCT03087123|Active Comparator|2-Week Baseline|Families will be randomized to a 2-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2472615|NCT03087123|Active Comparator|4-Week Baseline|Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2472617|NCT03087123|Active Comparator|6-Week Baseline|Families will be randomized to a 6-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
2472633|NCT03086590||Group 1|COPD mild. The individuals allocated to this group have FEV1 ≥ 80% predicted.
2472636|NCT03086590||Group 2|COPD Moderate. The individuals allocated to this group have 50% ≤ FEV1 < 80% predicted.
2472640|NCT03086590||Group 3|COPD Severe. The individuals allocated to this group have 30% ≤ FEV1 < 50% predicted.
2472644|NCT03086590||Group 4|COPD Very severe. The individuals allocated to this group have FEV1 < 30% predicted.
2472706|NCT03086421||Brain Tumor Participants|Participants with a diagnosis of brain tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
2472710|NCT03086421||Solid Tumor Participants|Participants with a diagnosis of non-Central Nervous System (non-CNS) solid tumor who are between the ages of 4 and 6 years old and are 6 to 12 months post-completion of treatment. They will complete several standard questionnaires.
2472747|NCT03085966|Experimental|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
2472794|NCT03085706|Experimental|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
2472825|NCT03085446|Experimental|PDM nutritional intervention|
2472826|NCT03085446|Experimental|control|General information on nutrition and health
2472833|NCT03085225|Experimental|Combination of trabectedin with durvalumab|"Trabectedin will be administered intraveinously, on day 1 of each cycle, every three weeks, as appropriate for assigned dose level.~Durvalumab will be administered intraveinously, at fixed doses of 1120 mg (equivalent to 15 mg/kg), on day 2 of each cycle, every three weeks."
2472932|NCT03084757|Experimental|research of druggable molecular alterations on tumor biopsy|
3192190|NCT00806039|No Intervention|2|control
3192191|NCT00806065|Experimental|1|
3192192|NCT00806091||COPD subjects|healthy subjects
3192193|NCT00806104|Experimental|1|Fructo-oligosaccharides
3192194|NCT00806104|Placebo Comparator|2|Maltodextrins
3192195|NCT00806117|Active Comparator|Radiotherapy (RT)|Radiotherapy
3192196|NCT00806117|Experimental|Concurrent chemoirradiation (CCRT)|"Concurrent chemoirradiation:~External beam radiation with concurrent weekly platinum chemotherapy"
3192197|NCT00806117|Experimental|Sequence chemo and radiation (SCRT)|"Sequence chemotherapy and radiotherapy:~2 cycles chemotherapy of Paclitaxel and Cisplatin before and after the irradiation"
2472008|NCT03091582|Experimental|Behavioral Activation|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
2472039|NCT03091101|Experimental|Scleral lens wearing keratoconics|Newly diagnosed keratoconics with no previous rigid lens wear fitted with Sceral contact lenses
2472086|NCT03090854||Alzheimer disease patients|
2472138|NCT03090490|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
2472141|NCT03090490|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
2472182|NCT03090230|Experimental|Relay Pro Thoracic Stent-Graft System|The Relay Pro arm includes subjects who receive the device to treat traumatic injury of the descending thoracic aorta with the RelayPro Thoracic Stent-Graft System
2472219|NCT03089801||Tablet Recipients|Veteran patients who have received a VA-issued tablet for tablet-enabled video telehealth.
2472223|NCT03089801||Usual Care|Veteran patients who match tablet recipients based on sociodemographic/clinical characteristics but have not received a VA-issued tablet.
2472251|NCT03089593|Experimental|Extract of ginger|Healthy and eutrophic women will receive two capsules of 200 mg of ginger extract (5% gingerols) to be taken along with a standardized breakfast.
2472254|NCT03089593|Placebo Comparator|Cellulose|Healthy and eutrophic women will receive two capsules of 200 mg of placebo (cellulose) to be taken along with a standardized breakfast.
2472285|NCT03089268||Group 1|"Individuals scheduled for colonoscopy at Hospital Universitari i Politècnic La Fe, participating in the Valencian CRC screening program, will be recruited.~Polypectomy or biopsy will be performed if necessary (following current guidelines).~Specific molecular analysis of serrated lesions and CRC will be carried out."
3192198|NCT00806143|Active Comparator|1|patients will undergo sequential bilateral rTMS treatment
3192199|NCT00806143|Active Comparator|2|patients will undergo unilateral low frequency right sided DLPFC rTMS
2472559|NCT03087474||VKA patients|Vitamin K antagonist (VKA) patients
2472560|NCT03087474||NOAC patients|nonvitamin K antagonist oral anticoagulants (NOAC) patients
2472587|NCT03087162|Experimental|Once daily dose dexlansoprazole|Group 1 Dexlansoprazole 60 mg by oral once daily for 14 days (Levofloxacin 500 mg by oral once daily for 14 days Amoxicillin 1000 mg by oral bid for 14 days Bismuth 1048 mg by oral bid for 14 days)
2472597|NCT03087162|Active Comparator|Twice daily dose dexlansoprazole|Group 2 Dexlansoprazole 60 mg oral bid 14 Days (Levofloxacin 500 mg od oral 14 Days Amoxicillin 1000 mg bid oral 14 Days Bismuth 1048 mg bid oral 14 Days)
2472648|NCT03086824|Experimental|MRgFUS|Patients with painful bone metastases receiving magnetic resonance-guided focused ultrasound treatment.
3192200|NCT00806169|Experimental|1|group I (n=17) nonproliferative DR and ischemic maculopathy
3192201|NCT00806169|Experimental|2|group II (n=38) nonproliferative DR without ischemic maculopathy
2472879|NCT03085160|Experimental|Learning to Breathe|Six-week mindfulness-based group program for adolescents
2472881|NCT03085160|Active Comparator|Health Education|Six-week health education group program for adolescents
2472933|NCT03084770||Active surveillance group|Advised surveillance strategy consists of imaging studies (MR or EUS or US), every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. During surveillance, a high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making.
2472935|NCT03084770||Surgical resection group|Timing and type of resection will be established by the treating physician. Follow up strategy after surgery consists of imaging studies (MR or CT), every 6 months for the first two years and yearly thereafter for five years. An high-quality imaging technique (MRI or CT) is mandatory at least every 12 months. Determination of CgA during follow-up is at physician's discretion. During follow-up, the treating physician is responsible for patient management and decision-making. Date of surgery does not change the timing of follow up which starts from the date of enrolment.
2473000|NCT03084432||caffeine group|22 preterm infants received caffeine (starting from day 2 of life and received for more than 7 days) for apnea prophylaxis or treatment according to protocol of Ain Shams University neonatal intensive care unit [apnea prophylaxis for preterm ≤32 weeks gestation and apnea treatment for those 33 or 34 weeks gestation]. Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
2473002|NCT03084432||control group|20 preterm infants for whom caffeine was not given, either it was not indicated, not available or parents refused its use.Dual Energy X-ray Absorptiometry was done 5th-6th week post-natal age
2473025|NCT03084094|Experimental|M1|Transcranial direct current Stimulation in primary motor cortex
2473027|NCT03084094|Experimental|DLPFC|Transcranial direct current Stimulation in the dorsolateral pre-frontal cortex
2473029|NCT03084094|Sham Comparator|Sham|sham stimulation
3192202|NCT00806169|Experimental|3|group III (n=18) proliferative DR with or without ischemic maculopathy
3192203|NCT00806182||Pediatric case-controls|These are children who underwent lumbar puncture and blood drawing for diagnostic testing for non-inflammatory neurological or non-neurological disorders, and whose samples were retrieved from the clinical lab under a linked Institutional Review Board (IRB) protocol.
3192204|NCT00806182||Pediatric OMS|These are patients treated by the P.I. based on clinical decision making, not a clinical trial (this is an observational study). The types of treatments are varied, and, on the initial evaluation, the patients may be untreated or already tried on various immunotherapies. They range from monotherapy with steroids, ACTH, or IVIg, to disease modifying agents, such as rituximab, cyclophosphamide, and other chemotherapy, typically adjunctively or as combination therapy.
3192205|NCT00806208|Active Comparator|1|MEDI 507 and Methylprednisolone
3192206|NCT00806208|Active Comparator|2|MEDI-507 and Methylprednisolone
3192207|NCT00806208|Active Comparator|3|MEDI-507 and Methylprednisolone
3192208|NCT00806208|Active Comparator|4|MEDI-507 and Methylprednisolone
3192209|NCT00806208|Placebo Comparator|5|Placebo
2472107|NCT03090542|No Intervention|Control|
2472110|NCT03090542|Active Comparator|Product|
2472153|NCT03090451|Experimental|Moderate Aerobic Exercise|Subjects will undergo moderate aerobic physical exercise (40-45% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
2472156|NCT03090451|Experimental|Intense Aerobic Exercise|Subjects will undergo intense aerobic physical exercise (60-65% of VO2-max) on three separate days at i) low insulin levels, ii) medium insulin levels, and iii) high insulin levels.
2472206|NCT03089957|Experimental|Ulinastatin group|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
2472207|NCT03089957|Placebo Comparator|Control group|Control group will be in usual care without any intervention.
2472246|NCT03089554|Experimental|Therapeutic Intervention|Therapeutic Intervention
2472297|NCT03089385|Experimental|Implementation group|This group will have the hypertension tool implemented on them.
2472299|NCT03089385|No Intervention|Control group|This group will not have the tool implemented.
2472402|NCT03088683|Active Comparator|Nathanson Retractor|Nathanson retractor will be used
2472403|NCT03088683|Active Comparator|Reveel Retractor|Reveel retractor will be used
2472456|NCT03088215|Experimental|A / Shock-waves|Will receive shock-waves
2472461|NCT03088215|No Intervention|B / Nothing|Will not receive shock-waves
2472627|NCT03086629|Other|PCI Group|Participants who are patients of consultants randomized to this group will use the PCI during clinics.
2472629|NCT03086629|Other|Non PCI Group|Participants who are patients of consultants randomized to this group will not use the PCI during clinics.
2472791|NCT03085771|Active Comparator|Desferal treatment|Patients will be randomized (by block randomization) to Desferal (DFO) treatment.
2472796|NCT03085771|Placebo Comparator|Isotonic saline treatment|Patients will be randomized (by block randomization) to isotonic saline treatment.
2472848|NCT03085355|Active Comparator|Exercises and PNE|Individuals with neck pain will receive a exercises program and pain neuroscience education. Participants will receive treatments during 4 weeks, 1 treatment per week
2472853|NCT03085355|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and pain neuroscience education and the participants will receive treatments during 4 weeks, 1 treatment per week associated with Osteopathic Manipulative Treatment (OMT)
2473038|NCT03084614||Controls|non exposed controls
2473040|NCT03084614||donors with naturally enriched antimicrobial blood samples and|Donors with naturally enriched antimicrobial blood samples an breast milk, Comparisons will be made with non exposed controls.
2473089|NCT03083834|Experimental|healthy subjects|low-dose cosyntropin stimulation test
2473091|NCT03083834|Experimental|hypoadrenal mitotane treated patients|low-dose cosyntropin stimulation test
2473097|NCT03083834|Experimental|hypoadrenal no-mitotane treated patients|low-dose cosyntropin stimulation test
2473170|NCT03083418|Experimental|Control group|No EDP treatment.
2473173|NCT03083418|Experimental|EDP therapy group|30 minutes continuous stimulation each time, two times a day, a total of one weeks of treatment .Parameters: 30min stimulation time, pacing frequency of 9 beats / min, pulse frequency is 40 hertz, the stimulus intensity (output pulse amplitude) is in the range of 0~30 units, which should be adjusted according to the daily maximum tolerance (patients with no pain and tension).
2473242|NCT03083106|Other|Elevoplasty treatment|Single Group Compared to Baseline, Non-Randomized, Multi-Center, Prospective
3157566|NCT00367965|Experimental|1|eszopiclone 3 mg
3157567|NCT00367965|Placebo Comparator|2|placebo tablet
3157568|NCT00368017|Active Comparator|1|
3157569|NCT00368017|Placebo Comparator|2|
3157570|NCT00368030|Experimental|A|Eszopiclone 3 mg QD
3157571|NCT00368030|Placebo Comparator|B|Placebo tablet
3157572|NCT00368056|Experimental|1|eszopiclone 3 mg
3157573|NCT00368056|Placebo Comparator|2|Placebo tablet
3157575|NCT00368121|Experimental|Cetuximab + Dexamethasone|
3157576|NCT00368160|Experimental|1|eszopiclone 3 mg
3157577|NCT00368160|Placebo Comparator|2|Placebo tablet
3157578|NCT00368212|Experimental|1|"Participants will receive psychoeducational counseling (termed health care counseling)"
3157579|NCT00368212|Active Comparator|2|Participants will receive relaxation response training
3157580|NCT00368264|Experimental|1|azathioprine plus 4 infusions of infliximab (5 mg/kg)
3157581|NCT00368264|Placebo Comparator|2|azathioprine plus 4 placebo infusions
3157582|NCT00368368|Experimental|1|
3157583|NCT00368368|Experimental|2|
3157584|NCT00368368|Experimental|3|
3157585|NCT00368381|Active Comparator|Hydrocortision and fludrocortisone|Study is comparing hydrocortisone alone versus the combination of hydrocortisone and fludrocortisone in the treatment of adrenal insufficiency of septic patients.
3157588|NCT00368511|No Intervention|1|Listening to music and posture changes
3157589|NCT00368602|Experimental|1|This group receives topical beta adrenergic antagonists (Timoptic) plus standard of care.
3157590|NCT00368602|Placebo Comparator|2|The group will be given standard of care with placebo medication.
3157591|NCT00368706|Experimental|1|
3157592|NCT00368706|Active Comparator|2|
2472128|NCT03090555|Experimental|Translational Manipulation|"Participants received an interscalene block on the affected side. Then, a physical therapist performed thrust manipulations on the affected shoulder until full passive physiologic motion was restored. These participants returned to the clinic approximately 3 days later for the first of 6 manual therapy (MT) sessions.~The first clinic treatment session included instruction in a home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program."
2472132|NCT03090555|Active Comparator|Comparison Group|Participants in the comparison group did not undergo a session of translational manipulation. In order to equalize the number of intervention sessions, members of this group underwent 7 in-clinic sessions of manual therapy (MT). The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and MT by a physical therapist that included all indicated grades of non-thrust manipulation. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
2472260|NCT03089567|No Intervention|CONTROL GROUP|Patients waiting for treatment under general Anesthesia without any intervention
2472262|NCT03089567|Active Comparator|Sodium Fluoride Varnish|Sodium Fluoride Varnish will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
2472263|NCT03089567|Experimental|Silver Diamine Fluoride|Silver Diamine Fluoride will be applied at 0,1,3 months Follow ups while waiting to receive dental treatment under general anesthesia
2472307|NCT03089229|Experimental|HAT01H cream|HAT01H medicated cream will come in a blinded tube. This topical medicated cream will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2472311|NCT03089229|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. This topical medicated vehicle will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2472339|NCT03088904|Experimental|Group A: MZ twins (IIV4)|Group A: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2472340|NCT03088904|Experimental|Group B: DZ twins (IIV4)|Group B: Up to 40 healthy dizygotic (DZ) individual twin volunteers, 12-49 years old, will be given inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), and Day 6-8 and Day 28+ 7 (post-immunization). All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).
2472345|NCT03088904|Experimental|Group C: MZ twins (IIV4 or LAIV4)|"Group C: Up to 40 healthy monozygotic (MZ) individual twin volunteers, 12-49 years old, will be randomized within the twin pair to receive either inactivated influenza vaccine quadrivalent (IIV4) Fluzone® Quadrivalent vaccine or live, attenuated influenza vaccine quadrivalent (LAIV4) FluMist® Quadrivalent. Each volunteer will complete a total of 3 visits: Day 0 (pre-immunization), Day 6-8 and Day 28+7 post-immunization. All visits will consist of drawing blood for study assays and monitoring for serious adverse events (SAEs).~This group was terminated in 2016 due to ACIP recommendations against the use of LAIV but may be reopened in 2018 pending LAIV4 availability."
2472389|NCT03088566|Experimental|The D-Foot method|The patients are being foot screened following the routine that is programmed in the D-Foot.
2472391|NCT03088566|Active Comparator|Conventional foot screening|The patients are being foot screened according to conventional methods.
2472447|NCT03088293|Experimental|infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
2472448|NCT03088293|Experimental|cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
2472500|NCT03087877|Other|CGM Users|Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.
3192210|NCT00806273|Active Comparator|Group 2|For Group II, the ultrasonic irrigation system involves using an initial irrigation with a conventional syringe followed by ultrasonic irrigation.
3192211|NCT00806273|Active Comparator|Group 1|For Group I, needle irrigation will be delivered into the pulp chamber using a syringe tip placed above the access opening and removed with high volume suction.
2472704|NCT03086473|Other|Caffeine|Participant will receive caffeine citrate 20mg/kg IV within 2 hours of life and placebo (normal saline IV) at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
2472709|NCT03086473|Other|Placebo|Participant will receive placebo (normal saline IV) within 2 hours of life and caffeine citrate 20mg/kg IV at 12 hours of life. Both infusions will be of identical volumes and appearance, and will be administered over 30 minutes.
2472758|NCT03085940|Experimental|Hydroxychloroquine|
2472761|NCT03085940|Placebo Comparator|Placebo|
2472970|NCT03084562||Regadenoson|stress test and dipyridamole impossible or contraindicated. In particular, patients with severe COPD or asthmatic patient. (second intention)
3192212|NCT00806299|Experimental|1|Drug (including placebo)
3192213|NCT00806299|Experimental|2|Drug (including placebo)
3192214|NCT00806299|Experimental|3|Drug (including placebo)
3192215|NCT00806312||1 PAH|Patients who are ≥ 18 years of age, not pregnant, and undergoing right heart catheterization for PAH diagnosis as part of their clinical care will be approached for consent and participation in this study.
2472184|NCT03090074|Active Comparator|Moderate carbohydrate restriction and traditional support|Moderate carbohydrate restriction and traditional support with group meetings
2472191|NCT03090074|Active Comparator|Extreme low carbohydrate diet and traditional support|Extreme carbohydrate restriction and traditional support with group meetings
2472192|NCT03090074|Active Comparator|Moderate carbohydrate restriction and ACT support|Moderate carbohydrate restriction and psychological support based on acceptance and commitment therapy
2472193|NCT03090074|Active Comparator|Extreme carbohydrate restriction and ACT support|Extreme carbohydrate restriction and psychological support based on acceptance and commitment therapy
2472264|NCT03089736|Experimental|TAU + Education and self care|Treatment as usual (TAU; i.e. pharmacological treatments and advices) + structured education + instructions on self care
2472265|NCT03089736|Other|Treatment as usual (TAU)|Treatment as usual (TAU; i.e. pharmacological treatments and advices)
2472417|NCT03088254|Experimental|Group I|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin 20 mg for 8 weeks
2472420|NCT03088254|Active Comparator|Group II|Treatment of Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo for 8 weeks
2472423|NCT03088254|Active Comparator|Group III|Treatment of Telmisartan 80 mg, Amodipine placebo, Rosuvastatin 20 mg for 8 weeks
2472511|NCT03087747||Group 1|Patients older than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
2472517|NCT03087747||Group 2|Patients younger than 80 yr. Clinical parameters after percutaneous transhepatic cholangiography (PTHC).
2472634|NCT03086902|Experimental|Cryo Ablation|PVCs will be mapped and ablated with a Cryo Ablation catheter
2472637|NCT03086902|Active Comparator|Radiofrequency Ablation|In this arm PVCs will be mapped and ablated with a Radiofrequency Ablation catheter
2472959|NCT03084653||Survey|Close-ended survey questions were formed and will be sent to general surgeons by e-mail containing the web address of the survey.
2473019|NCT03084367||iFR post angiographically successful PCI|
2473105|NCT03083678|Experimental|Afatinib|Afatinib active treatment.
3157593|NCT00368719|No Intervention|1|
3157594|NCT00368771|Active Comparator|1|IBS Stress Management
2473240|NCT03083054|Experimental|Patients|High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia
2473271|NCT03082703|Experimental|Text Messaging|
2473272|NCT03082703|No Intervention|Control|
2473279|NCT03082339||Neurology|Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (>=40mg/d)
2473280|NCT03082339||Pulmonology|Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (>=40mg/d)
2473568|NCT03080857|Experimental|Virtual Platform|Patients will be provided with a computer simulated tool to assist with education and support relating to atrial fibrillation.
2473610|NCT03080506|Experimental|Binder|Each woman will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
2473615|NCT03080506|No Intervention|No binder|The women will not be given a chance to wear abdominal binder or the likes.
2473662|NCT03080168||Actigraph|"All participants will wear an Actigraph (monitoring device) for the duration of their inpatient stay.~NOTE: In clarification, for both this section and Section 4, this devices is an FDA-regulated monitoring device, but NOT an Intervention in this study."
2473754|NCT03079505|Active Comparator|Dasatinib|Dasatinib 100mg, once daily (QD), will be given to 25 patients, orally
2473760|NCT03079505|Experimental|Nilotinib|Nilotinib 300mg, twice daily (BID), will be given to 25 patients, orally
2473815|NCT03079050|Experimental|1|34 patients will be assigned to take Dexlansoprazole 60mg over the 2nd, 3rd, and 4th weeks of the month of Ramadan.
2473903|NCT03078686|Active Comparator|Control ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Platelet Rich Plasma Concentrate)
2473905|NCT03078686|Experimental|Emulsification tSVF + PRP ARM 2|HD-PRP + Emulsified AD-tSVF; Intervention: Platelet Rich Plasma Concentrate
2473908|NCT03078686|Experimental|Emulsification tSVF + PRP + cSVF ARM 3|tSVF; PRP; cSVF cell enriched biocellular therapeutic mix
2473911|NCT03078686|Experimental|cSVF in Normal Saline IV ARM 4|cSVF + Normal Saline IV (500 cc) Infusion
2473971|NCT03077880||thin soft tissue|full thickness thin mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
2473972|NCT03077880||thick soft tissue|full thickness thick mucosal soft tissue at the periodontal probe measured intra-operatory measurement during implant placement
3157595|NCT00368771|Active Comparator|2|IBS Symptom Management
3157596|NCT00368771|Active Comparator|3|IBS Educational Training
3157597|NCT00368784||1|Individuals ages 12-85 with an immune mediated skin disease, such as psoriasis, scleroderma, or mycosis fungoides. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
3157598|NCT00368784||2|Age-Matched Controls without immune mediated skin diseases. Peripheral blood and/or check swabs will be collected from participants ages 12- 85 years old. These samples will then be used to characterize the inflammatory cells as described above.
3157599|NCT00368901|Experimental|Single arm|Every other week dosing of Aranesp SC
3157600|NCT00368953|Experimental|1|
3157601|NCT00368953|Active Comparator|2|
3157602|NCT00369018|Active Comparator|MAL 3|
3157603|NCT00369018|Active Comparator|MAL 12|
3157604|NCT00369018|Active Comparator|HAL 10, 3|
3157605|NCT00369018|Active Comparator|HAL 10, 12|
3157606|NCT00369018|Active Comparator|HAL 40, 3|
3157607|NCT00369018|Active Comparator|HAL 40, 12|
2472235|NCT03089723|Experimental|Lavage with Saline (LS)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to joint lavage with physiologic saline solution 2 to 5 mL (injection with a 30x8 needle and drained with the same needle after removal of the syringe. After emptying of the joint, 1mL saline solution will be injected.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
2472236|NCT03089723|Experimental|Lavage with Osteonil® Mini (LO)|"Under sterile conditions, the 1st carpometacarpal (CMC) will be locally anesthetized with ropivacaine and will be submitted to lavage with physiologic saline solution and Osteonil® Mini 1mL of 10mg will be injected in the 1st CMC joint.~Patients will ask to answer Visual Analog Scale (VAS) questionnaire, Range of Motion (ROM), Quick DASH, Sollerman Test, and functional grip strength (palmar grip strength, lateral grip strength and pulp-pulp pinch strength) evaluations immediately prior to the procedure and after 1, 3 and 6 months of each joint."
2472303|NCT03089372|Active Comparator|Group A|Patients will receive two sessions of LI-ESWT per week for a 3 week period (6 sessions totally)
2472309|NCT03089372|Active Comparator|Group B|Patients will receive one session of LI-ESWT per week for a 6 week period (6 sessions totally)
2472364|NCT03088943|Other|TTE Apical 4 Chamber View|Patients will receive TTE apical 4chamber echo examinations prior to induction and after induction
2472369|NCT03088943|Other|TEE dTG View|Patients will receive TEE deep transgastric echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
2472373|NCT03088943|Other|TEE ME 4C View|Patients will receive TEE midesophageal 4chamber echo examinations after induction and after cardiopulmonary bypass induction (paced at 80, 100, and 120 bpm)
2472541|NCT03087500||Down Syndrome (DS)|120 clinically confirmed full trisomy 21, age 3-50 years of both sexes will be recruited as the target study population. Half of the individuals (n=60) will be children (3-17 years of age) while half (n=60) will be adults (18-50 years of age)
2472543|NCT03087500||Typically Developing Controls|60 typically developing individuals age 3-50, age and gender matched to at least one participant with DS. Half of the controls (n=30) will be age and gender match to children with DS and half (n=30) will be age and gender matched to adults with DS.
2472573|NCT03087318|Experimental|Rehabilitation medical center|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2472574|NCT03087318|Experimental|Private sport club|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2472575|NCT03087318|Experimental|Sport association|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal HR(heart rate) measured during the exercise stress testing (from the screening)~during 3 months."
2472645|NCT03086928|Experimental|lava ultimate|lava ultimate is Resin nano-ceramic which is a mixture of a resin composite matrix and nano-ceramic fillers of approximately 80% by weight. The main advantages of this material over the glass ceramics are the stress absorbing action or stress distribution by having modulus of elasticity near to the tooth dentin and can be individualized intra-orally or extra-orally, either before or after definitive cementation.
2472646|NCT03086928|Active Comparator|E.max cad|E.max is lithium disilicate glass ceramic, composed of quartz, lithium dioxide, phosphor oxide, alumina oxide, and potassium oxide with superior mechanical and optical properties if used for laminate veneers
2472677|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Dose Escalation)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given intravenously (IV).
2472682|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Cohort Expansion)|(Open Label) Olaratumab, nab-paclitaxel and gemcitabine given IV.
2472686|NCT03086369|Experimental|Olaratumab + Nab-paclitaxel + Gemcitabine (Treatment)|(Double Blind) Olaratumab, nab-paclitaxel and gemcitabine given IV.
2472691|NCT03086369|Placebo Comparator|Placebo + Nab-paclitaxel + Gemcitabine|(Double Blind) Placebo, nab-paclitaxel and gemcitabine given IV.
2472790|NCT03085862||Lung ultrasound and EVLW|This prospective study involved 60 patients without known cardiac or pulmonary diseases admitted to the intensive care unit at our hospital after elective abdominal or vascular surgery. The inferior vena cava collapsibility index (IVCcl), PaO2/FiO2 ratio, and appearance of B-lines ≤7 mm were determined upon admission to the intensive care unit and at 6, 12, and 24 h later. Fluid overload was defined as IVCcl ≤ 40% and the presence of B-lines ≤7 mm. Tissue oxygenation impairment was defined as a PaO2/FiO2 ratio < 200.
3192216|NCT00806312||2. Control|Patients who present with symptoms of PAH and whose clinical right heart catheterization doesn't support this diagnosis will be enrolled as control subjects.
3192217|NCT00806325||AML|Adult patients with AML admitted for treatment of the same
2472296|NCT03089177|Experimental|Community Garden Intervention Group|Participants randomized to the Community Garden Intervention Group will receive the garden intervention. Participants will be assigned a plot for one season and will receive a standard package of services and amenities to support participation in the community garden.
2472298|NCT03089177|No Intervention|Wait List Control Group|Participants randomized to the Wait List Control Group will remain on community gardening waiting lists and will not receive the garden intervention.
2472371|NCT03089008|Experimental|Eccentric exercises|The patients were instructed to stand with straight legs on a small step, lift up on the toes, hereafter put the weight on the injured leg and slowly lower the heel as far as possible until they felt a maximal stretch of the calf muscles and/or the Achilles tendon. The exercises were repeated 15 times. Then the patients were told to repeat the exercises with semi-flexed knee. If possible the series should be repeated twice increasing to three times at each session. If pain decreased they should increase the load on the Achilles tendons by wearing a rug sack and increasing the weight of the rug sack by adding weights (5kg each). The patients were told that some pain was to be expected from the tendon during exercise, but that increasing daily pain or morning stiffness indicated that the exercises had been progressed too fast.
2472375|NCT03089008|Other|Control treatment, stretching exercises|The patients were instructed in standing stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee). The stretch was slowly increased and maintained for 30s. This stretch was to be repeated five times during each session. The patients were instructed that the stretching should be pain free, although a small degree of unpleasantness was allowed.
2472410|NCT03088501|Experimental|Interactive Voice Response System|Through IVRS, women will receive a 2-3 minute call that informs them about their lab test, next follow-up visit, breastfeeding, introduction of solid foods, immunization, motor development, and sleep.
2472411|NCT03088501|Experimental|Mother and Baby Affairs (MBA) workshops|"This will involve antenatal workshop and counselling for parents.~Brief talk by health professionals.~Role-plays"
2472412|NCT03088501|No Intervention|Control Arm|The participants in this group do not get any specific interventions but would receive standard instructions to attend follow-up.
2472439|NCT03088163|Experimental|DWI-MRI|
2472475|NCT03087955|Experimental|Acoziborole (SCYX-7158)|Acoziborole (SCYX-7158), in 320-mg tablets, administered by the oral route to patients in the fasting state according to the following dosing regimen: 960 mg (3 tablets) in a single intake on Day 1.
2472504|NCT03087669|Experimental|Observation of hemodynamic parameters|"LVAD flow velocity setting-Rounds Per Minute(RPM) intervention: Change of LVAD RPM while observing Central hemodynamic, echocardiographic and CBFV effects.~MAP intervention: Stepwise Change of MAP from 60-70-80 to 90 mmHg with a fixed set of LVAD RPM. After a 5 minute steady state for each level of MAP, the observations of central hemodynamics, echocardiographic measures and CBFV measurements will be repeated."
2472578|NCT03087032|Experimental|Liraglutide-bolus|'Liraglutide-bolus'(Liraglutide once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
2472591|NCT03087032|Active Comparator|Basal-bolus|'Basal-bolus' (insulin glargine once-daily plus thrice-daily prandial insulin lispro). Patients will receive adding insulin Glargine to prandial insulin Lispro.Dose of insulin will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
2472628|NCT03086720|Experimental|Sodium hypochlorite|Dentin pre-treatment with a experimental solution (sodium hupochlorite), after the dentin acid etching
2472630|NCT03086720|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching
2472679|NCT03086486|Experimental|1200mg L x 26 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 26 weeks plus 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2472683|NCT03086486|Experimental|1200 mg L x 9 weeks + Pa + B|"2 linezolid 600 mg active tablets once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2472697|NCT03086395|Experimental|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab.
2472732|NCT03086044|Experimental|HCV NAT Positive Donor|"Intervention: 4 week treatment course with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily~Participants who receive either heart or lung allografts from a donor who is HCV NAT positive will receive treatment with a direct acting antiviral, sofosbuvir 400mg / velpatasvir 100mg daily, beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation."
3192218|NCT00806338|Experimental|Trodusquemine (MSI-1436) 3mg/m2|
3192219|NCT00806338|Experimental|Trodusquemine (MSI-1436) 6mg/m2|
3192220|NCT00806338|Experimental|Trodusquemine (MSI-1436) 10mg/m2|
3192221|NCT00806338|Placebo Comparator|Placebo|
3192222|NCT00806364||1|Blood, skin, stool/rectal swabs, buccal mucosa and bone marrow aspirate samples from approximately 250 healthy volunteer donors
3192223|NCT00806429|Experimental|1|transvaginal appendectomy
3192224|NCT00806429|No Intervention|2|
2472304|NCT03089320|Experimental|Contingency Management plus Stepped Care (Step 2)|"Step 1: Contingency management; Step 2: Addiction physician management and motivational enhancement therapy~Consistent with tenets of stepped care designs we provide a priori intervals and criteria (drinking targets) that dictate increasing the intensity of treatment (stepping up) based on research and standards in the field. All CM plus stepped care subjects will undergo PEth testing at 3 months to determine the efficacy of Step 1. Patients with a PEth > 8 ng/ml will continue on to Step 2."
2472372|NCT03088852|Active Comparator|Experimental group|After initial intravenous treatment, participants (those with magnesium level ≥1 mg/dL) will be randomized, and oral magnesium therapy ( or no treatment) will be started. The experimental group will receive 400mg magnesium daily in two divided doses. Patients in the experimental group will be discharged with one month's supply of magnesium and continued for at least three months.
2472374|NCT03088852|No Intervention|Control group|control group will receive standard care (no treatment). Patient will have their blood tested and will come for follow up visit every month for 3 months after discharge.
2472437|NCT03088475|Experimental|Experimental Group|A six-month nurse-led smartphone-based self-management programme (i.e. NSSMP) will be provided to the participants in the experimental group.
2472438|NCT03088475|Active Comparator|Control Group|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
2472453|NCT03088007||IME attending ID children|Children with mild to moderate Intellectual Deficiency attending school at IME (Instituts Médico-Educatifs, which are special schools mandated to accommodate children and young people with Intellectual Disability at any level of disability).
2472458|NCT03088007||ULIS attending ID children|Children with mild to moderate Intellectual Deficiency attending school at ULIS (Unités Localisées pour l'Inclusion Scolaire, which enables disabled children to attend regular schools)
2472522|NCT03087799|Experimental|Brief Behavioral Treatment for Sleep|
2472529|NCT03087799|No Intervention|Wait List Control|
2472601|NCT03087383||Prospective Cohort|In adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm, investigator will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
2472603|NCT03087383||Retrospective Cohort|In previous study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm (NCT02700126, 4-2015-1195), investigator enrolled patients and collected data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions.
2472642|NCT03086733|Experimental|Metformin|14 to 21 days of pre-operative Metformin tablets First 5 days 850 mg OD v/o 850 mg BID thereafter until 21 days are completed.
2472668|NCT03086382|Experimental|Treatment A - B|Single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions
2472669|NCT03086382|Experimental|Treatment B - A|Single administration of Treatment B (single dose of LCM 200 mg given as syrup) under fasting conditions, followed by a Wash-Out Period of at least 7 days and a single administration of Treatment A (single dose of Lacosamide (LCM) 200 mg, given as 2 tablets of LCM 100 mg) under fasting conditions
2472720|NCT03086187|Other|Hephaistos unloading orthosis|Hephaistos unloading orthosis: Calf muscle unloading: The 11 male subjects had to wear a novel orthosis for 8 weeks, which greatly reduces plantarflexor forces during gait.
3157608|NCT00369031|Experimental|1|Human Immunodeficiency Virus glycoprotein 140 (vaccine)
3157609|NCT00369031|Active Comparator|2|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant
2472864|NCT03085459||Nurse level N0|who got college degree or above, nurse qualification certificate and working time less than one year
2472865|NCT03085459||Nurse level N1|who got nurse qualification certificate and working time between 1~3 years
2472866|NCT03085459||Nurse level N2|who got nurse qualification certificate and working time between 3~5 years
2472867|NCT03085459||Nurse level N3|who got nurse qualification certificate and working time more than 5 years
2472903|NCT03084926|Experimental|MP0274|
2472940|NCT03084731|Experimental|Goup 1:Children with moderate stunting and wasting|Test 3 prototype MDCFs and the current rice-lentil RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week 2x /day intervention, with a 2 week post-intervention phase to assess durability of MDCF-induced changes in the microbiota.
2472942|NCT03084731|Experimental|Goup 2:Children with moderate stunting and wasting|Select most efficacious MDCF from study 1 and compare with 2 additional MDCF prototypes using the same design used in study 1.
2472944|NCT03084731|Experimental|Goup3:Children with moderate stunting and wasting|Select lead MDCF from studies 1, 2 and conduct final 'bake-off' vs current RUSF and also examine the impact of 1x vs 2x per day administration with a 4 week post-intervention period to provide additional information on the durability of MDCF-sponsored changes in the microbiota.
2472986|NCT03084276|Experimental|High-fat meal|
2472989|NCT03084276|Active Comparator|Low-fat meal|
2475618|NCT03066427|Experimental|Sunitinib|Sunitinib 50 mg/day, 4 weeks on/2weeks off
3157610|NCT00369031|Active Comparator|3|Labile Toxin mutant LTK63 adjuvant
3157611|NCT00369070|Experimental|A|AMG 706 125 mg once daily (QD) and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
3157612|NCT00369070|Experimental|B|AMG 706 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
3192225|NCT00806468|Experimental|Desmopressin|Desmopressin 0,2 mg once daily and Desmopressin 0,2 mg bid for one week each.
2472363|NCT03088761||cuffed tube pressure group|"The pressures of cuffed tracheal tubes will be monitored simultaneously with a cuff manometer and pressure transducer. The measurements will be observed continuously. When the cuff pressure is noted to exceed 15 cmH2O, the cuff will be deflated immediately to less than 15 cmH2O. The time when the correction occurred, the time interval between corrections and the number of corrections during surgery will be recorded.~The baseline cuff pressure will be assessed in the supine position after which time a second measurement will be made in the prone position. A blind investigator will check and record the findings of cuffed tracheal tube."
2472434|NCT03088540|Active Comparator|Standard-of-care chemotherapy|"Standard-of-care chemotherapy will administered from these options:~Doses of Paclitaxel + cisplatin OR Doses Paclitaxel + carboplatin OR Doses Gemcitabine + cisplatin or Doses Gemcitabine + carboplatin OR Doses Pemetrexed + cisplatin followed by optional pemetrexed maintenance OR Doses Pemetrexed + carboplatin followed by optional pemetrexed maintenance"
2472436|NCT03088540|Experimental|cemiplimab|cemiplimab regimen as monotherapy as per study protocol
2472614|NCT03087058|Experimental|Cohort 1|Patiromer for age 12 - < 18 years
2472616|NCT03087058|Experimental|Cohort 2|Patiromer for age 6 - < 12 years
2472619|NCT03087058|Experimental|Cohort 3|Patiromer for age 2 - < 6 years
2472674|NCT03086538|Experimental|Pemetrexed+Tarceva|Pemetrexed 500 mg/m2 IV Q 3 weeks Tarceva 100mg once daily, continous
2472724|NCT03086174|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg Q2w PLUS axitinib 5 mg orally Q2w until disease progresses or unacceptable tolerability occurs
2472744|NCT03085888||Prospective Cohort|This is a prospectively enrolling cohort study with a pre-specified molecular analysis plan. A stratified case-cohort design will be employed to select cancer cases and non-cancer subjects who will be assayed. All cases of cancer (breast and non-breast cancer) will be selected. A random subset of the overall study cohort will also be selected.
2472810|NCT03085563|Active Comparator|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method.
2472813|NCT03085563|Active Comparator|Intranasal Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'.
2472831|NCT03085251|Experimental|Blood glucose measurement|
2472871|NCT03084874|Experimental|Intervention group|Patients in the intervention group will receive an individualized coaching program to increase physical activity and reduce sedentary behavior during 12 weeks
2472872|NCT03084874|No Intervention|Control group|Patients in the control group will receive the standard care for patients with COPD during 12 weeks.
2472910|NCT03084822|Experimental|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
2472943|NCT03084705|Experimental|Manumeter with interactive feedback|Study participants will receive an experimental manumeter and interactive feedback from the manumeter to monitor and motivate their upper extremity functional activities.
2472945|NCT03084705|Experimental|Manumeter without interactive feedback|Study participants will receive an experimental manumeter but receive no feedback from the manumeter, and will be given the current standard-of-care for increasing upper extremity exercise booklet to perform at home.
2473023|NCT03084081|Active Comparator|CO2 standard therapy|Double freeze treatment consists of three-minute freeze, five-minute thaw, three-minute freeze
2473024|NCT03084081|Experimental|CryoPen|Single freeze treatment consists of one five-minute freeze
2473026|NCT03084081|Experimental|Thermocoagulator|Thermoablation for 60-seconds at 100 degrees Celsius
3157613|NCT00369070|Active Comparator|C|Bevacizumab 15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks and paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200 mg/m2 and carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3 week cycle for a maximum of 6 cycles.
2473159|NCT03083431|Experimental|Propranolol|Oral propranolol (1.6 mg propranolol-HCl/kg·d in 3-4 divided dosages) given for 4 10 weeks (depending on postmenstrual gestational age at birth)
2473162|NCT03083431|Placebo Comparator|Placebo|Placebo (same duration as oral propranolol solution)
2473196|NCT03083145|Active Comparator|Educational Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
2473199|NCT03083145|Active Comparator|No Messaging|Whey protein beverage and pea protein beverages administered in a randomized order with a one- to two-week washout period between beverages.
2473217|NCT03082898|Experimental|AIS A or B using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) A or B (non- ambulatory) will receive regular dosing of exoskeleton walking.
2473218|NCT03082898|Experimental|AIS C or D using Indego Exoskeleton|Patients with American Spinal Injury Association Injury Scale (AIS) C or D (Poorly ambulatory) will receive regular dosing of exoskeleton walking.
2473267|NCT03082716|Active Comparator|blood cardioplegia group|patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
2473268|NCT03082716|Experimental|custodiol group|patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
2473331|NCT03082365||pre-dialysis|
2473333|NCT03082365||end stage renal disease|
2473388|NCT03082001|Active Comparator|24% Sucrose|"The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~24% sucrose was prepared by mixing 2.4gm of sucrose in 10ml distilled water."
3157614|NCT00369174|Experimental|Treatment (rosiglitazone maleate)|Patients receive oral rosiglitazone once daily. Treatment continues for 12 weeks in the absence of unacceptable toxicity.
3192226|NCT00806481|Active Comparator|1|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
2472399|NCT03088644|Experimental|Part B: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 at a dose between 150 and 185 MBq on Day 1 of Part B to measure the uptake, distribution, and clearance in brain.
2472400|NCT03088644|Experimental|Part C: 18F-JNJ-64413739|Subjects will receive an IV bolus injection of 18F-JNJ-64413739 for a PET/MR scan on Day 1 and a repeat 18F-JNJ-64413739 PET/magnetic resonance (MR) scan at least 1 week later to determine the test-retest variability in V[t]. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
2472401|NCT03088644|Experimental|Part D: JNJ-54175446 + 18F-JNJ-64413739|Subjects will have a baseline 18F-JNJ-64413739 PET/MR scan on Day 1. On Day 2 they will receive JNJ-54175446 (maximum 600 milligram [mg]) orally (after light breakfast) and then an IV injection of 18F-JNJ-64413739 four hours after dosing for a PET/MR scan. At least 1 week later, they will receive another dose of JNJ-54175446, and then an IV injection of 18F-JNJ-64413739 four hours later for a second post-treatment PET/MR scan. 18F-JNJ-64413739 doses will be between 150 and 185 MBq.
3192227|NCT00806481|Placebo Comparator|2|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
3192228|NCT00806507||Echocardiogram + Blood Test|Additional Echocardiogram views performed in 5-10 minutes of regularly scheduled echocardiograms plus blood tests measuring of hormones and metabolic proteins (such as sugars and acids).
3192229|NCT00806533||HES 130 / 0.42|paediatric patients aged up to 12 years requiring non-emergency volume replacement therapy with HES 130/0.42
3192230|NCT00806559|Active Comparator|Usual room|Patients in this arm will see their clinician in the usual clinical exam room
2472584|NCT03087110|Experimental|Cord blood infusion|Matched sibling donor cord blood cell infusion
2472698|NCT03086850|Experimental|Pedometer|Standard recommendations on healthy habits and lifestyle plus daily recording of steeps with a pedometer
2472700|NCT03086850|Active Comparator|Conventional management|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
2472731|NCT03085992|Experimental|Single Arm|INDUCTION TREATMENT WITH FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY PLUS BEVACIZUMAB
3192231|NCT00806559|Experimental|Re-designed room|Patients assigned to this arm will see the physician in a redesigned clinical exam room
3192232|NCT00806572|Experimental|Treatment|
3192233|NCT00806572|No Intervention|Control|
2472868|NCT03085199|Other|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, laparoscopic reinforcement suture commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
2472885|NCT03084861|Experimental|cord blood eye drops|Experimental drug: cord blood eye drops Description: eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 19 vials of 1 mL per vial Route of administration: ophthalmic/ocular
2472892|NCT03084861|Active Comparator|Conventional treatment|"Conventional treatment:~Artificial tears Description: Lubristil ® (single dose) Dosage regimen: 1 drop every 2 hours Pharmaceutical form: ophthalmic preparation eye drops Presentation: batch of 20 or 30 vials of 0.3 mL per vial Route of administration: ophthalmic~Therapeutic Contact lens Description: Air Optix Night&Day Dosage regimen: 1 contact lens per visit Pharmaceutical form: contact lens Presentation: 1 unit per case Route of administration: ophthalmic/ocular"
2472962|NCT03084627|No Intervention|Generic dietary advice for pregnancy|
2472964|NCT03084627|Experimental|Generic dietary advice for pregnancy + Tailored dietary advice|
3192234|NCT00806611|Experimental|50% Ethanol|Operating surgeon injects 20 ml of 50% ethanol on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
3192235|NCT00806611|Placebo Comparator|Placebo|Operating surgeon injects 20 ml of saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
2473045|NCT03083964|Active Comparator|Usual Care|Usual care involves a lifestyle coaching intervention delivered in primary care sites.
2473046|NCT03083964|Experimental|Priming|Priming involves usual care plus just in time reminder messages related to mindful eating and physical activity.
2473085|NCT03083730|Experimental|Atopic Dermatitis Cohort|"Narrow band UVB treatment (NB-UVB) NB-UVB light treatment 3x/week for 12 weeks (36 visits)~Healthy Control Cohort will be obtained to take baseline blood work as a reference value for baseline expression of blood markers."
2473137|NCT03083522|Experimental|OJS group|admission to Ojeok-san granule
2473143|NCT03083522|Placebo Comparator|Placebo Group|admission to placebo
2473254|NCT03083275|Experimental|Resistance Training|
2473258|NCT03083275|No Intervention|Control|
2473312|NCT03082534|Experimental|Cohort 1|"PD-1/PD-L1 inhibitor-naïve, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2473318|NCT03082534|Experimental|Cohort 2|"PD-1/PD-L1 inhibitor-refractory, cetuximab-naïve~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
3208629|NCT00976638|Active Comparator|Molecular Arm|Active surveillance of colonization with MRSA and VRE by PCR; and of ESBL by chromogenic agar with isolation of positive patients
2473423|NCT03081780|Experimental|FATE NK-100|
3208630|NCT00976651|Active Comparator|Recombinant FSH|Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins. Histology and gene expression is studied on the endometrium.
2472495|NCT03087890|Placebo Comparator|Placebo|Participants in the Placebo arm will receive 2 placebo tablets daily. These tablets have been manufactured by Kragero Tablettproduksjon AS, Norway, and care has been taken to make them look as similar as possible to the locally purchased cotrimoxazole tablets from Tanzania. Neither study participants, care providers, investigators or outcome assessors will know which patients receive cotrimoxazole or placebo
2472510|NCT03087565|Active Comparator|subtotal hystrectomy|"Careful examination under anesthesia. Catheterization by N. 18 Foley's catheter . A transverse lower abdominal incision (Pfannenstiel incision) . the corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination ."
2472512|NCT03087565|Active Comparator|Total hyterectomy|examination under anesthesia. Catheterization by N. 18 Foley's catheter A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Blunt dissection is done . Sharp dissection using Metzenbaum scissors is performed in patients with previous cesarean sections Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics The abdomen is closed in layers; the wound is covered with a sterile dressing. All specimens were sent for pathological examination .
2472588|NCT03087344|Experimental|Chronic liver disease|patient who will undergo liver biopsy will undergo liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
2472639|NCT03086759|Experimental|Platelet rich plasm group|
2472641|NCT03086759|Active Comparator|Triamcinolone Hexacetonide group|
2472643|NCT03086759|Placebo Comparator|Isotonic Saline Solution group|
2472748|NCT03085901|Active Comparator|Precizon toric intraocular lens|Cataract surgery and implantation of Precizon toric intraocular lens
2472753|NCT03085901|Active Comparator|Tecnis toric intraocular lens|Cataract surgery and implantation of Tecnis toric intraocular lens
2472783|NCT03085680|Experimental|Curcumin|Participants will be given identical capsules containing curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
2472784|NCT03085680|Placebo Comparator|Placebo|Participants will be given identical capsules containing placebo (microcrystalline cellulose) and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
2472832|NCT03085212|Experimental|Online stress management program|Participants will receive free access to Stress Free Now, which is an online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavior therapy to help individuals learn to manage their stress.
2472836|NCT03085212|Active Comparator|Wait list control|Participants in this arm will receive free access to the Stress Free Now program at the end of the study.
2472884|NCT03085121|Experimental|Male Extramedullary|In this group, patients are male and femoral extramedullary resection would be used.
2472887|NCT03085121|Experimental|Female Extramedullary|In this group, patients are female and femoral extramedullary resection would be used.
2472891|NCT03085121|Active Comparator|Male Intramedullary|In this group, patients are male and femoral Intramedullary resection would be used.
2472898|NCT03085121|Active Comparator|Female Intramedullary|In this group, patients are female and femoral Intramedullary resection would be used.
2473163|NCT03083535|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice and standardized tooth brush
2473164|NCT03083535|Experimental|Aloe vera massaging|Tooth brushing with dentifrice and standardized tooth brush followed by massaging with aloe vera gel
2473167|NCT03083535|Experimental|SRP with aloe vera massaging|Scaling and root planning was done with ultrasonic scalar. It was followed by aloe vera massaging on half arch for 3 minutes daily
2473244|NCT03083080|Experimental|VATS block (ropivacaine + epinephrine)|VATS block is the peripheral nerve block for video-assisted thoracic surgery, whose injection is administered at the site of chest wall incision.
2473315|NCT03082573|Active Comparator|Group A|"Will be receiving the same background medications and H.P. Acthar gel 40 units twice weekly for 12 weeks.~Patients in group A, can be cross over to group B on week 13 if disease is uncontrolled for continuation until week 24. If their disease is under control then they will continue with the same dosage until week 24.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
2473319|NCT03082573|Active Comparator|Group B|"Will be receiving the same background medications and H.P. Acthar gel 80 units twice weekly for 12 weeks.~if the disease is not under control, will continue with same dosage until week 24. If the disease is under control, will be given the option to reduce the dosage to 40 units twice weekly only if patient is suffering from H.P. Acthar gel related adverse effects.~If the disease is under control, then tapering the steroid dosage can be attempted at the principal investigation's discretion."
2475664|NCT03065946||Case series|Early wakening
2472514|NCT03087578|Active Comparator|Medication|Patients will receive 50 mg of mirabegron daily for 6 weeks. Patients may continue to take this medication after the study if they have improvement in symptoms.
2472581|NCT03087331|Experimental|Pharmacist intervention|Within the pharmacist intervention arm, pharmacists will do medication reviews, assessment, recommendations, education.
2472655|NCT03086889|Experimental|The intervention group|The intervention group will participate in immersion virtual reality based rehabilitation training for 3 weeks.
2472659|NCT03086889|Other|The control group|The control group will receive for traditional rehabilitation training for 3 weeks.
2472835|NCT03085277|Active Comparator|Preterm Formula|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive preterm formula, as the supplementary diets following the standard feeding guidelines in the participating hospitals.
2472840|NCT03085277|Experimental|Bovine Colostrum|MM is always the first priority, when available. When MM is not available, or the available amounts do not fulfill the needs, infants in this group will receive Bovine Colostrum (BC), as the supplementary diets. BC feeding follows the same guideline as the control group in terms of initiation time (within 24-48h of age) and volume (5-10 ml/kg) and advancing rate (5-20 ml/kg/d). BC intervention should not exceed postnatal day 14.
2472911|NCT03084978|Active Comparator|General Anesthesia|Subjects will undergo general anesthesia with endotracheal intubation.
2472914|NCT03084978|Experimental|Conscious Sedation|Subjects will undergo conscious sedation anesthesia.
3157615|NCT00369200|Experimental|Arm I|"Patients receive AFP464 IV over 3 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression.~Cohorts of 2-6 patients receive escalating doses of AFP464 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which ≤ 1 of 6 patients experience dose-limiting toxicity. An additional 10 patients whose tumor is amenable to biopsy are treated at the MTD.~Patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies. Patients treated at the MTD also undergo tumor tissue biopsies periodically for additional pharmacodynamic and correlative biomarker studies.~After completion of study treatment, patients are followed for 4 weeks."
3157616|NCT00369291|Experimental|CpG 7909|Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
3157617|NCT00369356|Sham Comparator|1|Bare Metal Stenting
2473013|NCT03084211|No Intervention|Control Group|The control group will be instructed to gradually return to activities.
2473014|NCT03084211|Experimental|Prescribed Light Exercise Group|Intervention: Prescribed Light Exercise Group will receive discharge instructions prescribing 30 minutes of light exercise (ie: walking).
2473073|NCT03083912||Fortimel Complete|All of the residents included receive ONS
2473100|NCT03083587|Active Comparator|No intervention|Normal lifestyle. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
2473104|NCT03083587|Experimental|Exercise intervention|Followed by a 1 week normal run in period subjects will undergo a 3 min bout, every half hour between 8 am and 6 pm comprises of simple low-intensity exercise such as moderate walking about or climbing a flight of stairs over a 3-week period. Subjects will undergo a muscle and fat biopsy at the start of the 4 w period and after. An oral glucose test at the start and after completion of the 4 week period. Physical activity and glucose will be monitored during the study period.
2473257|NCT03082950||1|human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
2473260|NCT03082950||2|non-human papilloma Virus (hpv) associated vulvar cancer incl. preinvasive lesions
2473316|NCT03082456|Other|Three breast screening modalities|Subjects who have had mammography less than two years ago will receive MBI and breast ultrasound only. Other participants will receive three interventions including molecular breast imaging, mammography and breast ultrasound. The interval between each examination will be less than 6 months.
2473411|NCT03081949|Active Comparator|Treatment|Oral Sodium Selenite 200 µg/day for 3 months
2473415|NCT03081949|No Intervention|Control|No treatment
2473448|NCT03081546||Mild Cognitive Impairment (MCI)|"Persons with age-related Mild Cognitive Impairment (MCI) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria.~Must be concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376)."
2473450|NCT03081546||Healthy Controls|Community dwelling controls older than 55 years of age that are concurrently enrolled in the Rocky Mountain Alzheimer's Disease Center Bio-AD study (clinicaltrials.gov identifier: NCT02612376).
3157618|NCT00369356|Active Comparator|2|Stenting with DES
3157619|NCT00369356|Experimental|3|Bare metal stenting and administration of prednisone
2473632|NCT03080311|Experimental|APG-1252|An accelerated dose escalation scheme will be utilized initially with one patient enrolled per cohort. If at 10 mg or 20 mg dose level, any occurrence in cycle 1 of one ≥ Grade 2 adverse event related or possibly related to APG-1252 (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) is the trigger for converting to a standard 3+3 design at that dose level.
2473685|NCT03079973|Experimental|P-3073|
2473688|NCT03079973|Placebo Comparator|Vehicle|
2473788|NCT03079297|Experimental|L-leucine|4 gm L-leucine by mouth twice daily for two weeks
2473789|NCT03079297|Placebo Comparator|Maltodextrin|4 gm maltodextrin by mouth twice daily for two weeks
2473887|NCT03078400|Experimental|Exploratory Expansion Phase|"Up to 12 subjects~• Cohort 3: SPL-108 daily dose (to be determined in Arm I) + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles."
3157620|NCT00369395|Experimental|Volociximab|Volociximab 15 mg/kg
3157621|NCT00369408|Experimental|1|naltrexone (50 mg orally) for 12-week treatment period
3157622|NCT00369408|Placebo Comparator|2|placebo for 12-week treatment period
3157623|NCT00369447|Experimental|1|200 mg dose
3157624|NCT00369447|Placebo Comparator|2|
3157625|NCT00369473|Experimental|1|350
3157626|NCT00369473|Experimental|2|350
3157627|NCT00369538|Active Comparator|1|losartan, hydrochlorothiazide
3157628|NCT00369538|Active Comparator|2|hydrochlorothiazide, losartan
2472533|NCT03087617|Active Comparator|Usual Care + Counseling|In addition to the Usual Care described above, patients in this arm will participate in a 45 minute smoking cessation counseling session. Approximately three Tobacco Treatment Specialists will be trained to ensure consistent counseling methodology. Counselors will utilize a patient centered approach grounded in Motivational Interviewing skills to elicit perceived benefits for stopping smoking and to enhance self-efficacy for stopping. A major emphasis of a call is to enroll the caller in formal cessation programs and/or convince them to use FDA approved medication as part of a quit attempt. Study participants who desire further smoking cessation support after their session will be connected with the appropriate organization.
2472536|NCT03087617|Experimental|Usual Care + Imbio Smoking Cessation Report + Counseling|In addition to the Usual Care and Counseling described above, patients in this arm will also receive the Report.
2472618|NCT03087071|Experimental|Cohort 1 (panitumumab)|Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
2472621|NCT03087071|Experimental|Cohort 2 (panitumumab, trametinib)|Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2472623|NCT03087071|Experimental|Cohort 3 (panitumumab)|Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
2472694|NCT03086564|Experimental|ADCC & TACE|"The first course :~Patients in the first day of a clinical course will be performed TACE solely and keep 40ml blood sample as baseline sample for scientific research;in the 17th day, 10ml blood will be taken to culture activated dendritic cells;in 29th day, cyclophosphamide(CY) 250mg/m2 is used through an intravenous drip;in 31th day,patients are going to be performed TACE,1-2*10^8 activated dendritic cells are dripped through peripheral vein, 40ml blood sample will be taken for clinical research, simultaneously.~The 31th day in the first course is the same as the first day of the second course, then we come to next therapy course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
2472696|NCT03086564|Active Comparator|TACE|"Every course:~In the first day,patients are performed TACE solely and taken 40ml blood as baseline sample for scientific research;in the 29th day,patients are needed to reach hospital to check related indicators. In the 31th day, patients are performed TACE again.~The 31th day is the same as the first day in the second course.~31 days are a course of treatment, health conditions of patients who participate in will be monitored closely in the process. After previous 3-courses followed-up period, one course will be changed into 93 days."
2472751|NCT03086005|Experimental|Metformin|Metformin 500mg tablet by mouth, every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
2472757|NCT03086005|Placebo Comparator|Placebo|Placebo(identical in appearance to metformin), every 12 hours, from the first day of oral contraceptive pills taken to the day of oocyte retrieval
2472793|NCT03085615|Experimental|100%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 25-30kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
2472797|NCT03085615|Active Comparator|40%NRG|Patient will receive the enteral nutrition product Jevity 1.5 starting at 20mL per hour and increasing by 20mL every four hours until a goal rate delivering 12-14 kcals/kg is achieved. If feeding is interrupted, flow rate will be adjusted to compensate for nutritional loss.
2472852|NCT03085420|Experimental|≥30% TBSA burn injury|For patients in Group 1 with ≥30% TBSA, a baseline Echocardiogram (ECHO) will be obtained approximately one week from admission and monthly (+/- 1 week) or at an interval determined by cardiology during the acute inpatient stay. ECHO tests will be discontinued after 3 negative exams or when discontinued by cardiology, whichever comes first.
2472860|NCT03085420|No Intervention|<30% TBSA burn injury|For patients in Group 2 with <30% TBSA and presence of a cardiac abnormality standard clinical care appropriate for the type of arrhythmia will be followed.
2472921|NCT03084991||OCT group|1500 AMI patients with OCT imaging guidance during PCI
2472924|NCT03084991||CAG group|3000 AMI patients without OCT imaging guidance during PPCI
2473018|NCT03084393||study group|215 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. The investigators do the Mini-Mental score examination (MMSE) and neuropsychological tests 1 day before (baseline) and 1 week after surgery without safety issue. Patients will be divided into POCD and non-POCD groups according to the two times tests.
2473021|NCT03084393||non-surgical group|The investigators enroll 30 healthy volunteers and do the Mini-Mental score examination (MMSE) and neuropsychological tests at 1 day (baseline) and1 week without safety issue. The exclusive purpose of the non-surgical group is to aid in the POCD calculation according to the ISPOCD 1 study definition.
2473049|NCT03083951|Experimental|Complete Mesocolon Excision|A high tie of the inferior mesenteric artery (IMA) should be attempted. The inferior mesenteric vein section at the Treitz angle should be performed. The lymphatic tissue that accompanies the inferior mesenteric vein should be added.
2473052|NCT03083951|Active Comparator|Conventional Locoregional Lymphadenectomy|A high tie of the inferior mesenteric artery (IMA) should be attempted. Lymphadenectomy of the lymphatic tissue that accompanies the IMA will be performed. The inferior mesenteric vein section could be performed at the discretion of the surgeon.
2473119|NCT03083717||Patients with compensated heart failure|
2473124|NCT03083717||Patients with decompensated heart failure|
2473130|NCT03083717||Healthy subjects|
2473179|NCT03083301||Cardiac insufficiency|Patients with cardiac insufficiency (i.e in NYHA class III or IV) or refractory to optimal medical treatment (155 patients since 2003) in the Brugmann University Hospital, in the cardiac surgery department
2473227|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 250mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
2473231|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 500mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
2473236|NCT03083041|Experimental|SHR-1210，200mg,q2w plus apatinib 375mg/d|SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
2472569|NCT03087201|Placebo Comparator|placebo, oromucosal spray|1-12 puffs placebo / day, Duration of treatment: 13 weeks
2472608|NCT03086967|Active Comparator|Six Hour|Placement of foley catheter and extrusion after 6 hours followed by induction.
2472611|NCT03086967|Active Comparator|Twelve Hour|Placement of foley catheter and extrusion after 12 hours followed by induction.
2472653|NCT03086655|Experimental|Tel-me-box with reminder features|Participants randomly assigned to the intervention reminder condition will choose from the reminders available and convey their preferences regarding when reminders should be sent for the tel-me-box device.
2472657|NCT03086655|Other|Tel-me-box with no reminder features|The control arm will include tel-me-box monitoring only. No reminder features will be included with the device.
2472667|NCT03086252|Experimental|Supportive care (patient-driven RBCT)|Patients undergo red blood cell transfusions (RBCT) based on their perception and/or the presence of anemia symptoms for up to 6 months.
2472721|NCT03086200|No Intervention|iTAB + SOC Control Arm|Participants will receive PrEP and standard of care (SOC) including health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psychosocial barriers, and adherence counseling. In addition to SOC, participants will receive daily text messages (iTAB) as reminders for medication adherence. Text messages will be setup during the Baseline visit in coordination with the participant's preferences.
2472723|NCT03086200|Experimental|iTAB + MI-b Intervention Arm|Participants will receive the same PrEP, SOC procedures, and iTAB support as that of the Control Arm. Participants in the Intervention Arm will also receive brief motivational interviewing counseling sessions if adherence becomes suboptimal. Adherence will be monitored by responses to the iTAB system; if Intervention Arm participants reply with 3 consecutive negative or non-responses, MI-b counselors will perform 15-minute over-the-phone motivational interviewing counseling sessions with the participant.
3192236|NCT00806637|Experimental|1|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
2472889|NCT03085108||SIBAT, the S-STS CMCM, and the C-SSRS + CGI-SS-R|Participants randomized to Cohort A will be consented for video-recorded interviews on 3 distinct suicide assessment instruments (the Suicide Ideation and Behavior Assessment Tool [SIBAT], the Sheehan-Suicidality Tracking Scale Clinically Meaningful Change Measure [S-STS CMCM] and the Columbia-Suicide Severity Rating Scale [C-SSRS] + Clinical Global Impression of Severity of Suicidality (Revised) [CGI SS-R]). These participants will be interviewed 3 times within the single study visit by 3 different trained clinical raters, using semi-structured interviews that have been developed for each of the 3 suicide assessment instruments.
2472895|NCT03085108||SIBAT|Participants who are not videotaped for the 3 interviews will only be assessed by SIBAT.
2472928|NCT03084744|Experimental|Schema therapy|Schema therapy in an individual format will be implemented by clinical psychologists. The treatment period will be 2 years with biweekly 50-minute sessions (up to 48 sessions).
2472930|NCT03084744|Placebo Comparator|Active monitoring|Active monitoring by telephone will be implemented by clinical psychologists. The treatment period will be 2 years with monthly 10-minute sessions (up to 24 sessions).
2472971|NCT03084510|Experimental|Lotus Edge™ Valve System|The Lotus Edge™ Valve System is intended to improve the aortic valve function for symptomatic patients with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
2472987|NCT03084250|Experimental|Combination|The subjects will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a
2472991|NCT03084250|Active Comparator|nucleotide analogue|The subjects will be treated by nucleotide analogue (NA) only
2473056|NCT03084120|Other|Gastric bypass surgery|"Pregnant women having undergone a Gastric bypass surgery before the pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2473059|NCT03084120|Other|Reference group|"Pregnant women having a body mass index <25 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2473062|NCT03084120|Other|Overweight|"Pregnant women having a body mass index 25-30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2473067|NCT03084120|Other|Obesity|"Pregnant women having a body mass index > 30 kg/m2 at the early pregnancy.~Collection of bloods samples for the mother.~Retrieval of umbilical cord blood.~Retrieval of placenta.~Collection of newborn's and mother's lock of hair.~Dietetic patient outcomes questionnaires for the mother.~Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire)."
2473154|NCT03083509|Other|Group1 (Resistance trained individuals)|Resistance trained individuals (>3 sessions per weeks for ≥2 years with a minimum of 1 session per week including leg-based exercises)
2473155|NCT03083509|Other|Group 2 (Trained cyclists)|Trained cyclists (competing at a minimum of Category 3 road racing/estimated 10 mile TT of <25 minutes and a training history of ≥5 hours per week for ≥2 years)
2473156|NCT03083509|Other|Group 3 (Team sports players)|Team sports players (minimum of University 1st team level e.g. soccer, rugby union, rugby league, hockey and basketball, playing competitively ≥1x per week for ≥2 years)
2473250|NCT03083223||lung disease|Patients with lung disease
2472571|NCT03087461|Experimental|Intervention Group|"The intervention group will receive a multi-component KT intervention. This will include exercise and self-management components.~The exercise intervention will involve a moderate intensity aerobic exercise program, using recumbent bikes, delivered within the cancer institution. Participants will take part in the 30-minute sessions 8 times. The intervention will be supervised by a physiotherapist (PT) educated in cancer rehabilitation.~The SM component will include educational modules created by a PT. Participants will view these 30 minute modules prior to each exercise intervention, over the same 8 sessions."
2472572|NCT03087461|No Intervention|Usual Care|Control group receiving usual care (no exercise or self-management education within the institution).
2472606|NCT03086941|Active Comparator|Group B(blibd)|group B (blind); an appropriate size endotracheal tube will be introduced through I-gel blindly. Only smooth intubation without force together with manoeuvres necessary to correct the position of tracheal tube will be allowed. Only one attempt of blind intubation is allowed to avoid airway injury. Any resistance to first attempt tube insertion will indicate failure of blind tube insertion.
2472610|NCT03086941|Active Comparator|Group C(control)|group C (control), a paediatric fibrescope will be primed with an appropriate size tracheal tube. The fibrescope will be introduced through I-gel and guide tracheal intubation. After insertion of tube and confirmation of position, the fiberscope will be removed
2472631|NCT03086681|Experimental|concurrent chemoradiotherapy + endostar|4 cycles of Endostar and 5 cycles of DDP concurrent with radiotherapy
2472635|NCT03086681|Active Comparator|concurrent chemoradiotherapy|5 cycles of DDP concurrent with radiotherapy
2472670|NCT03086304|Experimental|TEAS group|Choose several acupoints,give 2/10 hz dilatational wave stimulation.Complete the 30 minutes intervention after extubation and 1-3 days after surgery.Give a health education on the first postoperative day.
2472672|NCT03086304|Experimental|no TEAS group|The choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation,the others steps are same with TEAS group.
2472750|NCT03086122|No Intervention|Obstructive Sleep Apnea (OSA)|OSA patients without erectile dysfunction (ED).
2472756|NCT03086122|No Intervention|OSA + ED|OSA patients with erectile dysfunction diagnosis who are randomly allocated to not receive continuous positive airway pressure (CPAP).
2472762|NCT03086122|Experimental|OSA + ED + CPAP|OSA patients with erectile dysfunction diagnosis who are randomly allocated to receive CPAP.
2472789|NCT03085628|Experimental|Oxytocin|Oxytoxin nasal spray
2472792|NCT03085628|Placebo Comparator|Placebo|Placebo nasal spray
2472862|NCT03085394|Active Comparator|Treatment arm|Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
2472863|NCT03085394|Placebo Comparator|Control Arm|Preoperative intravenous administration of 10ml normal saline.
2472875|NCT03084887|Experimental|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
2472876|NCT03084887|No Intervention|controlled group|no intervention until secondary hospital
3192237|NCT00806637|Active Comparator|2|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
3192238|NCT00806650||Blood draw for diagnosis testing|
3192239|NCT00806663|Experimental|Sunitinib Arm|Sutent sunitinib 37 mg once daily (4 weeks on/2 weeks off)
2473709|NCT03080103||Patients submitted to appendectomy as first-line treatment|"Open or Laparoscopic Appendectomy The assignment of each patient to either the antibiotic-first management arm or the immediate surgery arm, will be non-randomized and decided independently by the Staff Specialist Surgeon on Call, upon careful assessment of AIR score, laboratory findings and imaging. The decision of the management pathway will not be influenced in any case by the participation of the patient in the study, and the assignment of the treatment will be decided by the consultant surgeon according to current good surgical practice and standard practice patterns in Italy."
2473711|NCT03080103||Patients treated with antibiotic-first strategy|Antibiotic therapy.maging. Patients managed conservatively will receive one of the following parenteral antibiotic treatments: Piperacillin/Tazobactam (4.5 g) three intravenous administration per day; Ceftriaxone (2 g) once per day or Ciprofloxacin (500 mg) twice per day plus Metronidazole (500 mg) three times per day; Amoxicillin/Clavulanic acid (2 g) four times per day for a length depending on the clinical conditions; Ertapenem (1 g) one administration per day for three days. Patients were discharged with oral antibiotics (amoxicillin/clavulanic acid or ciprofloxacin) for at least four days.
2473763|NCT03079362||Children|Children who underwent selective dorsal rhizotomy (SDR) including intraoperative neuromonitoring (IOM)
2473818|NCT03079141|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
2473829|NCT03079141|Active Comparator|Oral eplerenone treatment|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
2473918|NCT03078218|No Intervention|Before period group|Strictly observational in order to assess the current screening strategy as it is conducted in real life
2474336|NCT03075228||Obese subjects|Obese is defined as having a BMI of 30-35 kg/m2, waist circumference >88 cm and fasting glucose levels >=6.1 and <7.5 mmol/L
2472577|NCT03087448|Experimental|Ceritinib + Trametinib|"PHASE 1 Standard 3+3 dose escalation starting at dose level 1. Patients with ALK-rearranged, or ROS-1 rearranged NSCLC. 6-18 patients will be enrolled.~Ceritinib dose: 300-450mg orally, once daily over 28 day cycles. Trametinib dose: 1.5mg-2.0mg orally, once daily over 28 day cycles.~PHASE II Cohort A (ALKi Naïve): those who have had no prior ALK inhibitor therapy (prior chemotherapy or immunotherapy is allowed). Aim 20 evaluable patients.~Cohort B (Post-crizotinib PD): those who have received prior treatment with crizotinib and documented disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Aim 21 evaluable patients.~Cohort C (PD on 2nd generation ALKi): those who have received prior treatment with 2nd generation ALKi (e.g. ceritinib, alectinib, loratinib, or brigatinib) and documented disease progression by RECIST 1.1 criteria. Aim 10 evaluable patients.~The Phase II doses will be determined by Phase I dose escalation study"
2472664|NCT03086772|Experimental|Tai Chi|Individuals in the Tai Chi intervention group participated in a 12-week Tai Chi program.
2472666|NCT03086772|Active Comparator|Light Exercise|Individuals in the exercise control group performed a 12-week light exercise program.
2472675|NCT03086226|Experimental|Fosravuconazole 300 mg|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
2472676|NCT03086226|Experimental|Fosravuconazole 200 mg weekly|"Given throughout the study for 12 months as the experimental arm.~Both experimental arms will be evaluated at 3 months. At this time-point, one of the study arms will be dropped according to the drop-the-loser design, based on efficacy or toxicity."
2472678|NCT03086226|Active Comparator|Itraconazole 400mg daily|Given throughout the study for 12 months as the comparator arm.
3192240|NCT00806689||Cardiac surgery patients|Patients in atrial fibrillation being scheduled for cardiac surgery and concomitant ablation procedure
2472830|NCT03085329|Experimental|Seattle-PAP|bubble nasal cpap respiratory support with Seattle-PAP bubbler device, with all other aspects of care per usual care noninvasive respiratory support
2472838|NCT03085329|Experimental|Conventional bubble nasal CPAP|qualified and enrolled infants randomized to this arm will receive noninvasive respiratory support by bubble nasal CPAP, using the Fisher & Paykel bubbler, which is the standard of care at Nationwide Children's.
2472927|NCT03085082||skeletal class II subjects|patients with wits appraisal more than 3 mm measured on a cephalometric x ray obtained during diagnosis
2472929|NCT03085082||skeletal class III subjects|patients with wits appraisal less than -3 mm measured on a cephalometric x ray obtained during diagnosis
2472931|NCT03085082||skeletal class I patients|patients with Wits appraisal between -3 and +3 that is measured from a cephalometric x ray obtained during diagnosis of arch length discrepancy. this group will serve as control and obtained after recruitment of the other 2 groups in 1 to 1 fashion
2472977|NCT03084497|Experimental|Group receiving Infant Massage|The subjects of this group will receive a total of 5 sessions of Infat Massage.
2472979|NCT03084497|No Intervention|Group without intervention|The subjects of this group won´t receive any intervention.
2473017|NCT03084198|Active Comparator|Control group|Standard care for ALF
2473020|NCT03084198|Experimental|Experimental group|Continuous treatment with the hiHep bioartificial liver support system.
2473076|NCT03083899|Experimental|Diatast|Free patient-initiated use of out-patient services
2473077|NCT03083899|Placebo Comparator|Control|Scheduled diabetes control
2473128|NCT03083561|Experimental|LY3337641 Multiple Dose|Multiple doses of LY3337641 administered orally, with a two week follow-up period.
2473132|NCT03083561|Placebo Comparator|Placebo Multiple Dose|Multiple doses of placebo administered orally, with a two week follow-up period.
2473136|NCT03083561|Experimental|LY3337641 Single Dose|Single dose of LY3337641 administered orally, with a two week follow-up period.
2473141|NCT03083561|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally, with a two week follow-up period.
2473241|NCT03083288|Experimental|Single Arm|
2473300|NCT03082625|Experimental|Transdermal Magnesium|5 sprays each on the 2 most effected areas for muscle cramps twice a day
2473305|NCT03082625|Placebo Comparator|Placebo|5 sprays each on the 2 most effected areas for muscle cramps twice a day
2473349|NCT03082144|Active Comparator|Group 1: RT-Intra-MTX|Intrathecal chemotherapy: MTX 15 mg, plus dexamethasone 5 mg, via lumbar puncture,once per week, 4 weeks in total.
2473353|NCT03082144|Experimental|Group2: RT-Intra-Ara-C|Intrathecal chemotherapy:Ara-C 50 mg, plus dexamethasone 5 mg, via lumbar puncture, once per week, 4 weeks in total.
2473419|NCT03081832|Experimental|Oxytocin|Groups of children with Prader Willi Syndrome treated by oxytocin for 7 days during their first 6 months of life.
2473421|NCT03081832|Experimental|Control|Groups of children with Prader Willi Syndrome not treated by oxytocin for 7 days during their first 6 months of life.
2473459|NCT03081455||Women meeting guidelines for genetic testing|Women who present for an OB/GYN office visit (new patient visit, well woman visit, or problem visit) and who meet guidelines for genetic diagnostic testing will provide a blood or saliva sample for genetic diagnostic testing and complete a satisfaction survey.
2473503|NCT03081169|Active Comparator|Early (24 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 24 hours after injury if CT head is stable.
2473505|NCT03081169|Active Comparator|Late (72 hours)|Patients will receive VTE prophylaxis (heparin 5000 U q 8 hrs or enoxaparin 30 mg q 12 hrs) 72 hours after injury if CT head is stable.
2473562|NCT03080831|Active Comparator|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|
2473565|NCT03080831|Active Comparator|Glucion 5%|
2473647|NCT03080571|Experimental|Stem cell group|autologous BMMNC stem cells with standard care
2473648|NCT03080571|Active Comparator|Control|Patients randomised in this group received standard care only
2473714|NCT03079882||Living Donor Recipients|Recipients of renal transplants with the transplanted organ originating from living donors
2473717|NCT03079882||Deceased Donor Recipients|Recipients of renal transplants with the transplanted organ originating from deceased donors
2473732|NCT03079518|Active Comparator|Patients with HFREF & CKD|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
3192241|NCT00806728|Experimental|1|MEDI-507
3192242|NCT00806728|Experimental|2|MEDI-507
2472650|NCT03086798|Experimental|cuff inflation|experimental cuff inflation group: cuff inflation technique to facilitate nasotracheal tube advancement into trachea
2472684|NCT03086278|Experimental|Single Ascending Dose|
2472749|NCT03086161|Active Comparator|Treatment-as-usual|Treatment-as-usual alone provided in the context of a multi-disciplinary teen pregnancy clinic providing wrap-around medical, nutrition, and social work care.
2472755|NCT03086161|Experimental|Interpersonal Psychotherapy|Treatment-as-usual plus a six-session interpersonal psychotherapy program delivered as individual sessions by a trained facilitator every 2-3 weeks throughout pregnancy.
2472781|NCT03085641|Experimental|Nasal high flow oxygen therapy|"The patient is hospitalized for one night.~Initially patients will start with a flow rate of 10 L/min and when they are asleep during the night 90-minute periods of the following settings will be performed:~Moderate flow rate: 20 L/min without additional oxygen (with room air, which means a fractional inspired oxygen (FiO2) of 21%)~High flow rate: 40-50 L/min without additional oxygen~Moderate flow rate: 20 L/min with FiO2 of 28% (comparable to the 2 L/min additional oxygen through a nasal cannula)~High flow rate: 40-50 L/min with FiO2 of 28%"
2472817|NCT03085524||Surgical Bypass|Subjects in the BEST-CLI trial assigned to surgical revascularization.
2472819|NCT03085524||Endovascular|Subjects in the BEST-CLI trial assigned to endovascular revascularization.
2472870|NCT03085173|Experimental|EGFRt/19-28z/4-1BBL CAR T cells|Following enrollment, patients will undergo leukapheresis of peripheral blood for further T cell enrichment, activation and genetic modification using a retroviral vector encoding a CD19targeted CAR, the co-stimulatory ligand 4-1BBL and the EGFRt safety system (EGFRt/19-28z/4-1BBL). These T cells will be expanded and after the appropriate number of cells is generated, the modified T cells may be infused fresh or frozen for later use according to standard operation procedures. Modified T cell infusions will be administered 2-7 days following completion of the treating investigator's choice of conditioning chemotherapy. Serial sampling of blood and bone marrow will be performed following treatment to assess toxicity, therapeutic effects, and survival of the genetically modified T cells.
2472916|NCT03084848|Experimental|Active control|
2472918|NCT03084848|Experimental|Inhibitor control|
2472954|NCT03084575|Active Comparator|Thermal Radiofrequency group|"Group 1 RF group: in which patients will receive thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy."
2472956|NCT03084575|Active Comparator|phenol group|"Group 2 phenol group: in which patients will recieve hyperbaric chemical saddle rhizotomy using 6% phenol in glycerin."
3192243|NCT00806741|Active Comparator|1|NG-monomethyl-L-arginine (L-NMMA)
3192244|NCT00806741|Active Comparator|2|Phenylephrine
3192245|NCT00806741|Placebo Comparator|3|Physiological saline solution
3192246|NCT00806754|Active Comparator|1|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and placebo azelastine nasal spray ( two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
3192247|NCT00806754|Active Comparator|2|Ciclesonide nasal spray (50 mcg/spray, one spray per nostril) and azelastine nasal spray (137 mcg/spray, two sprays per nostril) administered twice daily approximately 1 minute apart, once in the morning and 12 hours later, in the evening.
3192248|NCT00806780|No Intervention|1|routine surgery with cholangiography
3192249|NCT00806780|Experimental|2|routine cholangiography
3192250|NCT00806806|Placebo Comparator|Placebo|
2473255|NCT03082820||Patients|Pain-related evoked potentials (PREP), Quantitative Sensory Testing (QST) and nerve conduction studies (NCS) were performed with patients with peripheral nerve injury.
2473259|NCT03082820||Controls|Pain-related evoked potentials (PREP) and Quantitative Sensory Testing (QST) were performed with healthy adults.
2473295|NCT03082443|Experimental|Therapeutic group|
2473303|NCT03082443|No Intervention|Control group|
2473338|NCT03082222||Group 1|Participants with epilepsy, partial onset seizures with or without secondary generalization with one concomitant antiepileptic drug (AED) at baseline
2473340|NCT03082222||Group 2|Participants with epilepsy, partial onset seizures with or without secondary generalization with two or more concomitant AEDs at baseline
2473342|NCT03082222||Group 3|Participants with epilepsy, partial onset seizures with or without secondary generalization with eslicarbazepine acetate (ESL) as anticonvulsant monotherapy
2473402|NCT03081897|Experimental|SPRANC Block group|General anaesthesia and additional regional anaesthesia (cervical plexus block) on the tumor side.
2473407|NCT03081897|Active Comparator|SPRANC Control group|General anaesthesia
2473440|NCT03081585||Healthy Controls|Normal weight, healthy female participants
2473467|NCT03081325|Experimental|lymphocyte immunotherapy on uRM and RIF|Donor (husband or third party) lymphocytes were prepared by Ficoll-Paque centrifugation; the cells were washed with sterile saline and resuspended in 1 ml at a concentration of 20-40 × 106 cells/ml. The cells were given to the female partner by 4-6 intradermal injected. In this study, the lymphocyte immunization therapies were performed every 3 weeks for 3 times. After that we test Th1/Th2/Treg, if they become normal, the patients can prepare for pregnancy.
2473548|NCT03081091|Active Comparator|Intervention group (A) Acupuncture|The treatments performed will be personalized and the treatment criteria will be based on the use of the Yuan and Luo points. In clinical practice, the Yuan (source) points and the Luo (connecting) points can be used jointly, linking the two associated meridians (external-internal) in such a way that, after assessing the state of a meridian's path, its Yuan point will be combined with the Luo point of its coupled meridian and vice versa; all this depending on the condition of the muscle fibres and on the path that wants to be treated for these.
2473550|NCT03081091|Sham Comparator|Control group (C) Sham Acupuncture:|"The course of action with the patient from the group that will use sham acupuncture will be the same as in the group that receives real treatment: patient in supine position, cleaning of the treated area, use of eye mask during the treatments and selection of points following the previously described Yuan and Luo points' criteria, based on traditional Chinese medicine.~The difference of sham acupuncture will lie on the way of performing the acupuncture technique. It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body."
2473590|NCT03080688||Prizma|Measurement of oxyhemoglobin saturation by OSM-3 oximeter and Prizma oxygen saturation measurement
2474031|NCT03077581|Active Comparator|local infiltration group|
3192251|NCT00806806|Experimental|SKY0402|
3192252|NCT00806832||Medical clowns treatment|Patients scheduled for an elective cataract surgery will receive pre-operative conventional treatment and in addition will be exposed to medical clowns effect
3192253|NCT00806832||Conventional treatment only|Patients scheduled for elective cataract surgery will receive only conventional pre-operative treatment
3192254|NCT00806845||HIV infected individuals, HIV controllers|CD4+ T cell count > 350/µl, HIV load < 1000 copies/ml
2472806|NCT03085849|Experimental|Treatment|"Subjects with ES-SCLC, progressive after platinum-based first-line chemotherapy will receive SGI-110 followed by combined durvalumab plus tremelimumab.~Dose escalation phase: 6-12 patients~MTD expansion cohort: 10 patients"
2472834|NCT03085264|Experimental|Community Health Worker|Patients are paired with community health workers for 30 days after hospital discharge to assist with patient care
2472839|NCT03085264|No Intervention|Usual Care|Patients are not paired with community health workers for 30 days after hospital discharge to assist with patient care
2472907|NCT03085134|Experimental|Test infant formula with HMOs|Extensively hydrolysed infant formula with HMOs taken by infant according to age, weight and appetite.
2472908|NCT03085134|Active Comparator|Control infant formula without HMOs|Extensively hydrolysed infant formula without HMOs taken by infant according to age, weight and appetite
2473015|NCT03084380|Experimental|anti-GPC3 CAR-T|Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion
2473081|NCT03083886|Active Comparator|Usual PCP led care|
2473082|NCT03083886|Experimental|Identify, Coordinated, Enhanced (ICE) Decision Making|
2473084|NCT03083886|Experimental|Individualized Postural Therapy (IPT)|
2473148|NCT03083496|Active Comparator|Potassium Oxalate 5%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2473151|NCT03083496|Active Comparator|Potassium Oxalate 10%|Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2473211|NCT03083210|Experimental|Lanreotide|Lanreotide, at a dose of 120mg will be administered without dose adjustment, by means of deep subcutaneous injection every 28 days.
2473224|NCT03082859|Experimental|Reduced-exertion high-intensity interval training|Cycling Exercise. 2 x 20-sec sprints.
2473232|NCT03082859|Experimental|High Intensity Interval Training (HIT)|Cycling Exercise. 10 x 1 min at approx 85% peak power output (Wmax)
2473235|NCT03082859|Experimental|Moderate Intensity Continuous Exercise|Cycling exercise. 30 min at 50% peak power output (Wmax)
2473238|NCT03082859|No Intervention|Sedentary (no exercise)|No exercise. Rest.
2473283|NCT03082651|Active Comparator|Constant training/Constant footwear|Group 1 - Runners will be assigned identical training sessions over a 7-day period and will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus). The weekly training volume will increase on a weekly basis in order to progressively increase training load in preparation for the half-marathon event.
2473284|NCT03082651|Experimental|Alternate training/Constant footwear|Group 2 - Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period. As with Group 1, weekly training volume will increase on a weekly basis. Runners in Group 2 will perform these runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
2473286|NCT03082651|Experimental|Constant training/Alternating footwear|Group 3 - Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
2473288|NCT03082651|Experimental|Alternating training/Alternating footwear|Group 4 - Runners will be assigned a variation of workouts throughout each 7-day period and will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak).
2473398|NCT03082079|Experimental|ESD group|Patient in this group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate.
2473403|NCT03082079|No Intervention|Follow-up group|Patient in this group are given no intervention,the investigators record the tumor size and EUS features of the first endoscopic examination.Regular follow-up are carried out for these patients on 3 month,6 month,1 year,2 year,3 year,4 year,5 year after this check.Then,tumor size and EUS features of each time are collected accurately.
2473433|NCT03081650|Experimental|Prospective Open label|"All of the patients that will be Selected to participate in the study will be given an AIRVO humidifier by the study sponsor. Patients will be connected to and instructed in the use of the AIRVO. The total flow will be set at 20-25 L/min, exact flow rate will be dependent on the patient's preference. Optiflow oxygen catheter will be used to ensure against unpleasant sensation due to high flow and to avoid push back in the system.~When acceptable flow rated has been established, it is recorded in the patient's folder. The patients is then instructed to use the AIRVO for a minimum eight (8) hour period, preferably at night. Using the humidifier for a longer period of time is allowed. The total number of hours the humidifier was operational will be recorded at the end of the study"
2473520|NCT03081364||Outpatients|MRI; Critical Care Monitoring, Device Programming
2473566|NCT03080818|Experimental|Probiotic|Participants in this arm will receive probiotic supplementation for 12 weeks (Lactobacillus Rhamnosus GG)
2473567|NCT03080818|Placebo Comparator|Control|Participants in this arm will receive placebo that look similar to probiotics
2473629|NCT03080519|Experimental|Endovascular Therapy|Renal artery revascularization
2473695|NCT03079804|Experimental|Experimental MWM|"Other names:~4 mobilizations - 10 seconds 20 seconds of rest"
2473697|NCT03079804|Active Comparator|Experimental Thrust|"Other names:~1 traction with caudal direction in high speed and low amplitude increasing dorsiflexion."
2473701|NCT03079804|Placebo Comparator|Placebo|"Other names:~It will accurately reproduce the positioning of the hand in the specific treatment condition (Thrust or MWM), however, without applying any movement or force. All interactions, procedures and deadlines will be identical."
3192255|NCT00806845||HIV infected individuals, early progressors|CD4+ T cell count > 350/µl, HIV load > 1000 copies/ml
3192256|NCT00806845||HIV infected individuals, late progressors|CD4+ T cell count < 200/µl
2472673|NCT03086317|Active Comparator|Ultrasound-Accelerated Thrombolysis|Participants randomized to this arm will receive ultrasound-accelerated thrombolysis, per standard of care, as treatment for acute submassive pulmonary embolism.
2472760|NCT03086148|Experimental|ketamine group|
2472763|NCT03086148|Placebo Comparator|normal saline group|
2472795|NCT03085602|Experimental|CBT Treatment|Participants receive Cognitive behavioral therapy (CBT). Participants will receive 4 one hour CBT treatments.
2472798|NCT03085602|Active Comparator|Control Group|Participants receive health education treatment. Participants will attend treatment sessions that match the CBT Treatment arm with respect to time and contact.
2472799|NCT03085602|No Intervention|Control Group - Scans|Participants in this new arm to the study will receive no intervention and will receive three scans.
2472847|NCT03085407|Active Comparator|early cholecystectomy|Early cholecystectomy was done within 48 after admission
2472854|NCT03085407|Sham Comparator|delayed cholecystectomy|Delayed cholecystectomy was done after 30 days after randomization.
2472913|NCT03085030|Experimental|antioxidant group|This group will take antioxidant formula tablet once daily orally for one month before IVF/ICSI cycle
2472915|NCT03085030|Placebo Comparator|control group|This group will take placebo tablet once daily orally for one month before IVF/ICSI cycle
2473037|NCT03084601|Active Comparator|calcium hydroxide iodoform paste|intervention administered to control group is a combination of drugs as follow: ciprofloxacin 500mg, cefixime 500 mg, metronidazole 500 mg, simvastain 40mg. all are mixed, placed in pulp chamber only one time and tooth is restored
2473039|NCT03084601|Experimental|3-mixtatin|intervention administered to experimental group is a ready made mixture of calcium hydroxide and iodoform, placed in pulp chamber only one time and tooth is restored
3192257|NCT00806845||HIV infected individuals, late progressors with therapy|CD4+ T cell count < 200/µl, under ART
3192258|NCT00806845||Healthy individuals|Uninfected
2473168|NCT03083392|Experimental|Treatment|treatment of chronic maxillary sinusitis using DIVA system
3192259|NCT00806858||A|
3192260|NCT00806871|Active Comparator|A|
2473314|NCT03082404|Experimental|Inspiratory muscle training group|Six times a week (three supervised at hemodialysis unit and other three times at home), 5 series, 10 repetitions, two-minutes interval or according to the patient tolerance.
2473320|NCT03082404|No Intervention|Control group|The patients in this group will be evaluated at baseline and reassessed after five weeks of follow-up.
2473434|NCT03082014|Active Comparator|Arm A|Amlodipine for 4 weeks, Losartan for 4 weeks, Atenolol for 4 weeks.
2473435|NCT03082014|Active Comparator|Arm B|Atenolol for 4 weeks, Amlodipine for 4 weeks, Losartan for 4 weeks.
2473437|NCT03082014|Active Comparator|Arm C|Losartan for 4 weeks, Atenolol for 4 weeks, Amlodipine for 4 weeks.
2473542|NCT03081143|Experimental|FOLFIRI plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus FOLFIRI (Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle)
2473544|NCT03081143|Active Comparator|Paclitaxel plus Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle plus Paclitaxel 80 mg/m2 on day 1, 8, 15
2473582|NCT03080532||european population|
2473606|NCT03080376|Experimental|Web-based intervention without support|3 months Web-based intervention without support
2473614|NCT03080376|Experimental|Web-based intervention with support|3 months Web-based intervention with support (e-mails)
2473621|NCT03080376|Active Comparator|Traditional intervention|3 months of Printed-based intervention
2473744|NCT03079713|Experimental|Vibratory Anesthesia|Following administration of topical anesthetic and betadine, wearable vibrator will be triggered prior to and during the intravitreal injection
2473747|NCT03079713|Sham Comparator|Standard Injection.|Following administration of topical anesthetic and betadine, wearable vibrator will be placed against the lower lid but NOT triggered prior to and during the intravitreal injection
2473749|NCT03079713|Experimental|Vibratory Anesthesia with Corneal/Conjunctival Sensation Test|Healthy patients not requiring intravitreal injection will be subjected to corneal and conjunctival aesthesiometry with and without the vibrator triggered while in contact with the lower eyelid of a single eye.
2473840|NCT03079115|Active Comparator|High-dose Atorvastatin Arm|High dose Atorvastatin (80 mg QD from 3 days before to 3 days after carotid artery stenting, thereafter conventional dose of Atorvastatin with 20mg QD until 30 days after CAS)
2473841|NCT03079115|Other|Conventional-dose Atorvastatin Arm|Conventional dose Atorvastatin (20mg QD from 3 days before to 30 days after CAS)
2473868|NCT03078465|Experimental|Ticagrelor|Administration of ticagrelor 180mg/day for 12 months.
2473872|NCT03078465|Active Comparator|Clopidogrel|Administration of clopidogrel 150 mg/day for 12 months
2473912|NCT03078322|Experimental|AV-101|L-4-chlorokynurenine 1440 mg daily for 14 days
2473914|NCT03078322|Placebo Comparator|Placebo|Placebo
2474030|NCT03077854|Experimental|Functional Lung Avoidance-TRT|"Functional Lung Avoidance Thoracic Radiotherapy~The avoidance thoracic radiotherapy treatment plan will be designed to optimize such that radiation dose to functional lung identified by four-dimensional (4D) CT ventilation imaging is as low as reasonably achievable"
2474033|NCT03077854|Active Comparator|Standard-TRT|"Standard Thoracic Radiotherapy~The standard thoracic radiotherapy treatment plan will be designed without reference to the functional lung 4D CT ventilation imaging"
2474105|NCT03077347|Experimental|Experimental Stimulation|Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
2474111|NCT03077347|Placebo Comparator|Sham Stimulation|Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
3192261|NCT00806871|Active Comparator|B|
3192262|NCT00806871|Placebo Comparator|C|
3192263|NCT00806884|Other|Control Arm1|Normal optimal medical and physiotherapy treatment
3192264|NCT00806884|Experimental|Treatment Arm 2|Physiotherapy musculoskeletal interventions in addition to normal optimal medical and physiotherapy care
3192265|NCT00806897||A|
2472681|NCT03086876|Experimental|Stepping Stones Triple P|Trained practitioners will deliver Level 4 SSTP to parents in 6 weekly group sessions and will also provide 3 telephone of face to face contacts to each participant but they will not be involved in routine care for participants in either arm. Each therapist responsible for delivering SSTP will be trained in the Group Stepping Stones Training and Accreditation programme which includes three training days and a further half day accreditation workshop after 6 weeks. The group sessions not only educate but actively train the parents in skills and the individual consultations aim to facilitate independent problem solving. The learning objectives focus on maintaining behavioural change, using skills within a group learning environment, learning from peers in the group and sharing difficulties or achievements, providing support, considering if more intensive work is required, referring further if needed, talking about risk and protective factors operating within families.
2472687|NCT03086876|No Intervention|Treatment as usual (TAU)|"TAU will be available to participants in both arms of the trial. It may include a range of services such as:~1. Health visitor services; 2. Primary care engagement and advice; 3. Potentially some version of early intervention maybe provided by either community paediatric services or Child and Adolescent Mental Health Services, although our understanding is that very little is available for children of this age. 4. Parenting advice and support sessions by carers groups or other third sector organisations.~Parents allocated to TAU will receive a list of national and local resources and the Contact a Family guide to challenging behavior with tips and advice on social and health care supports."
3192266|NCT00806910|Active Comparator|Treatment|Subjects will be treated with Intravenous Vaprisol along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
3192267|NCT00806910|Placebo Comparator|Placebo|Subjects will be given Placebo (at the same rate of Vaprisol given in the treatment arm) along with Nesiritide infusion and intravenous Furosemide (either continuous infusion or bolus injections - total dose of Furosemide received will be calculated at the end of the study).
3192268|NCT00806923|Experimental|1|
3192269|NCT00806923|Experimental|2|
2472807|NCT03085550|No Intervention|Control|Conventional dressings management
2472809|NCT03085550|Experimental|Fat grafting only|Patients will undergo conventional fat harvesting as per Coleman technique and infiltration of fat into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
2472811|NCT03085550|Experimental|Fat grafting + Platelet rich plasma|Patients will undergo conventional fat harvesting as per Coleman technique. Fat will be mixed with autologous PRP and infiltrated into diabetic ulcer wound bed in 1cc:10cm2 fat:wound size ratio
2472859|NCT03085290|Experimental|Group A|Subjects assigned to this arm will receive autologous serum eye drops first, followed by a washout period and then allogeneic serum eye drops.
2472861|NCT03085290|Experimental|Group B|Subjects assigned to this arm will receive allogeneic serum eye drops first, followed by a washout period and then autologous serum eye drops.
2472878|NCT03084952|Experimental|1 mg/day|
2472880|NCT03084952|Experimental|4 mg/day|
2472882|NCT03084952|Experimental|8 mg/day|
2472886|NCT03084952|Experimental|12 mg/day|
2472890|NCT03084952|Active Comparator|Glucantime|
2472897|NCT03084952|Experimental|Best dose 18-MC|
2472902|NCT03084952|Experimental|Minimum effective dose 18-MC|
2472947|NCT03084679|No Intervention|Conventional Clinical Care - HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
2472948|NCT03084679|Other|Supervised Exercise Training- HFpEF|Heart Failure patients with preserved ejection fraction (HFpEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
2472949|NCT03084679|No Intervention|Conventional Clinical Care - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care, being instructed to continue and maintain their usual daily activities.
2472950|NCT03084679|Other|Supervised Exercise Training - HFrEF|Heart Failure patients with reduced ejection fraction (HFrEF) randomized to this arm will keep receiving their conventional clinical care and participate in a supervised, facility based training program consisting of stretching exercises and aerobic exercise in treadmill.
2473028|NCT03084263|Experimental|AORIF of Ankle Fractures|Arthroscopic Assisted Open Reduction Internal Fixation of ankle fracture.
2473034|NCT03084263|Active Comparator|ORIF of Ankle Fractures|Open Reduction Internal Fixation of ankle fracture.
2473078|NCT03083821|Experimental|Arm A|
2473160|NCT03083548||Hand osteoarthritis|Men and women (40-70 years) with a diagnosis of hand OA based on clinical or ultrasound examination are included. Patients with systemic inflammatory joint diseases, psoriasis and hemochromatosis are excluded.
3192270|NCT00806923|Placebo Comparator|3|
3192271|NCT00806936||A|
2473219|NCT03082924|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
2473221|NCT03082924|Experimental|Cycle training group|A calibrated cycle ergometer is used to do 30-minute cycling training session 3 days a week.
2473228|NCT03082924|Experimental|Inspiratory training group|A threshold loading device is used to perform 21-minute inspiratory muscle training 3 days a week.
2473234|NCT03082924|Experimental|Combined group|Calibrated cycle ergometer and threshold loading device are applied.A 30-minute cycle training is performed using calibrated cycle ergometer and a 21-minute inspiratory muscle training using threshold loading device 3 days a week.
2473310|NCT03082547||Headache Groub|Headache patients with myofascial trigger points.
2473311|NCT03082547||Healthy Groub|No headache or other diseases can cause headaches of healthy people.
2473358|NCT03082092|Experimental|Methylprednisolone Group|The intervention group will receive a single dose intravenous 125mg methylprednisolone diluted in 2.1ml of diluent on induction of total knee replacement.
2473363|NCT03082092|Placebo Comparator|Placebo Group|The placebo group will receive a single dose intravenous 2.1ml of 0.9% IV saline, which is transparent and has no difference in appearance to methylprednisolone, on induction of total knee replacement
3192272|NCT00806936||B|
3192273|NCT00806962|Experimental|Vaccine Arm 1|50 µg Norwalk VLP Vaccine + Adjuvant/Excipients
2472688|NCT03086486|Experimental|600 mg L x 26 weeks + Pa + B|"1 linezolid 600 mg active tablet once daily for 26 weeks, 1 placebo linezolid 600 mg tablet once daily for 26 weeks, 1 placebo linezolid 300 mg half tablet once daily for 26 weeks plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2472692|NCT03086486|Experimental|600 mg L x 9 weeks + Pa + B|"1 linezolid 600 mg active tablets once daily for 8 weeks, 1 placebo linezolid 600 mg half tablet once daily for 9 weeks, 1 placebo linezolid 300 mg half tablet once daily for 9 weeks (for Weeks 1-9); 2 placebo linezolid 600 mg tablets once daily for 17 weeks, 1 placebo linezolid 300 mg half tablet once daily for 17 weeks (for Weeks 10-26) plus; bedaquiline 200 mg once daily for 8 weeks then 100 mg once daily for 18 weeks plus; pretomanid 200 mg once daily for 26 weeks~The above treatment schemes may require modification due to toxicities as noted below. All dose modifications should be discussed with the Sponsor Medical Monitor prior to implementation, unless a pause or dose reduction is required urgently for a safety concern; the Medical Monitor should be informed within 24 hours of the change if not discussed prior to implementation"
2472785|NCT03085732|Active Comparator|Irrigation with saline solution|during abdominal hysterectomy after vaginal cuff closure abdominal saline irrigation will be done
2472787|NCT03085732|No Intervention|control|routine abdominal hysterectomy will be performed and no abdominal saline irrigation
2472893|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2472899|NCT03085069|Experimental|PD-L1 expression in tumor ≥25-50%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2472904|NCT03085069|Experimental|PD-L1 expression in tumor ≥ 1-25%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2472906|NCT03085069|Experimental|PD-L1 expression in tumor < 1%|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
2472952|NCT03084666|Experimental|Treatment Group|The treatment will receive 200 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
2472957|NCT03084666|Experimental|Control Group|Our control group will receive 20 mmHg of pressure from a Zimmer ATS tourniquet system for three 5 minute intervals.
2473016|NCT03084107|Experimental|Questionnaire|technology acceptance model (TAM) questionnaire
2473072|NCT03083925||Bare metal stent (BMS) TIPS|retrospective patients receiving BMS-TIPS for treatment of complications of portal hypertension.
2473074|NCT03083925||Regular Viatorr (RV) TIPS|retrospective patients receiving RV-TIPS for treatment of complications of portal hypertension.
2473075|NCT03083925||Viatorr Control Expansion (VCX)TIPS|prospective patients receiving VCX-TIPS for treatment of complications of portal hypertension.
2473140|NCT03083574|Experimental|Photopheresis Theraflex ECP™|All patients will initially be treated by 6 cycles of extracorporeal photopheresis (i.e. extracorporeal photopheresis on two consecutive days) administered every 2 weeks. Patients will then be evaluated after 3 months and treatment continuation will be decided based on response.
2473205|NCT03083158|Other|Group 1|Older adults, aged 61-80 years
2473206|NCT03083158|Other|Group 2|Younger adults, aged 40-60 years
2473223|NCT03082911|Experimental|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group).~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.~Each phone call will last approximately 5 minutes."
2473233|NCT03082911|Active Comparator|Standard procedure|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample.
2473269|NCT03082677|Experimental|ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off). The patients will continue on this same dose until taper off from immunosuppressants or 1 year post-HSCT is reached (whichever occurs first) or until the patient develops GVHD or malignant disease relapse/progression occurs.
2473323|NCT03082352|Experimental|BF-Metoprolol Tablet 100mg|During the study session, healthy subjects will be administered a single dose of BF-Metoprolol Tablet 100mg after an overnight fast of approximately 10 hours
2473327|NCT03082352|Active Comparator|Betaloc Tablet 100mg|During the study session, healthy subjects will be administered a single dose of Betaloc Tablet 100mg after an overnight fast of approximately 10 hours
2473412|NCT03081962|Experimental|Bundle application|The patients in this group will undergo an intraperitoneal irrigation with clindamycin and gentamicin solution, fascial closure with triclosan impregnated sutures and application of Mupirocin ointment over the skin staples
2473413|NCT03081962|Active Comparator|Standard care|The patients in this group will follow a standard care, including decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
2473476|NCT03081468||Healthy volunteers|Fifty healthy volunteers. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
2473478|NCT03081468||Participants with confirmed relative afferent pupillary defect|Fifty participants with with eye disease (retinal disease, glaucoma, and neuro-ophthalmic conditions) and confirmed relative afferent pupillary defect. Each participant will attend for a single study visit, lasting approximately 1 hour in duration. Participants will undergo pupillometry examination using the binocular OCT prototype and Konan RAPDx.
2473497|NCT03081026||Ages less than 12|Those having ACL Reconstruction surgery during the desired dates at age 12 or less.
2473498|NCT03081026||Ages 12-13|Those having ACL Reconstruction surgery during the desired dates at ages 12 and 13.
2473499|NCT03081026||Ages 14 - 16|Those having ACL Reconstruction surgery during the desired dates at ages 14 - 16.
2472733|NCT03086044|Experimental|HCV NAT Negative, HCV Ab Positive Donor|"Intervention: HCV viral load monitoring~Participants who receive either heart or lung allografts from a donor who is HCV Ab positive and NAT negative will have close serial HCV viral load monitoring and will be treated with a direct acting antiviral, 400mg / velpatasvir 100mg daily, for 6 weeks if HCV viremia develops."
2472782|NCT03085745|Experimental|Transcranial Magnetic Stimulation (TMS)|15 patients suffering from a writer's cramp, aged 20-80 who are currently treated with botulinum toxin will receive single pulse TMS
2472841|NCT03085511|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
2472842|NCT03085511|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
2472901|NCT03084913|Active Comparator|Prostate Cancer Foundation diet|Intervention: 8-weeks of a Prostate Cancer Foundation diet
2472905|NCT03084913|Experimental|plant- based, olive oil diet|Intervention: 8 weeks of a plant-based, olive oil diet
2472941|NCT03084692|Experimental|Therapeutic Yoga and Resistance Exercise|The individuals with lung cancer and their caregivers will participate in a combined intervention of yoga and resistance exercise for 8-week, two times/week. The dyad will attend a one-hour resistance exercise intervention at the start of the week and a one-hour yoga class with a break of one day between both interventions. The resistance exercise training will involve one-on-one personal exercise session, while the yoga intervention will be offered in a class setting. The participants will be allowed to make up for any missed resistance exercise session based on the available time. Pamphlets will be given demonstrating breathing exercises, meditation, postures, and core resistance exercises to facilitate programming.
3173371|NCT00611338|Active Comparator|Standard of Care, Wait-List Control|Participants received standard medical care, which in most clinics included informational brochures provided by physicians and clinic staff. Participants were given HIV prevention information and materials in English and Spanish and were provided referrals for services. Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the wait-list control participants participated in the Trauma + HIV group arm.
2473181|NCT03083327|Active Comparator|Standard Care|The control group in this study is pragmatic standard nutrition care. Currently after a bone marrow transplant in Australia, patients are normally fed orally for as long as possible. If oral intake fails to provide sufficient calories for a period of two to three days, enteral or parenteral nutrition may be provided.
2473184|NCT03083327|Active Comparator|Early supplemental parenteral nutrition|"Supplemental prophylactic early parenteral nutrition will be commenced 1 day prior to conditioning chemoradiotherapy in patients who are not already malnourished. Supplemental parenteral nutrition continues throughout conditioning chemoradiotherapy and stem cell transplant.~The dose of supplemental parenteral nutrition will be dependent on the total calories also received from oral and/or enteral nutrition intake."
2473263|NCT03082794|Experimental|Study group I|Study group I (53 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
2473264|NCT03082794|Experimental|Study group II|Study group II (51 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
2473317|NCT03082430|Other|knee osteoarthritis patients.|therapeutic management of symptomatic knee osteoarthritis (resistant to medical first-line treatment) by intra-articular injection of autologous PRP prepared in the same procedure and using a dedicated CE marked medical device and a validated and reproducible method of preparation.
2473399|NCT03082040|Experimental|intervention group|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks
2473404|NCT03082040|Other|waiting-list control group|Participants in the control condition will conduct the same breathing training as the intervention group after a four-week waiting list period
2473443|NCT03081624||Preterm Preschoolers|Preterm children who haven't attend school.
2473446|NCT03081624||Term Preschoolers|Term children who haven't attend school.
2473473|NCT03081338||Study cohort|A mix of incident and prevalent patient cases will be included in order to capture patients at different stages of the disease trajectory.
2473518|NCT03081104|Active Comparator|hystroscopy|The procedure will be performed by a gynecological surgeon, under general anaesthesia with the patient in lithotomy position. Antibiotic prophylaxis may be administered, the cervix is grasped with pozzi forceps and dilated up to hegar 9 to facilitate insertion of the hysteroscopy. The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
2473523|NCT03081104|Active Comparator|ultrasound guided aspiration|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control. It was possible to keep the dilators and the suction cannula under constant view by slightly tilting the transducer as required. Advancement of any instrument was allowed only under direct ultrasound control.The completeness of the evacuation was confirmed by the scan in these cases.
2473541|NCT03080987|Experimental|Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.
2473554|NCT03080896|Active Comparator|control group videolaryngoscope/preformed stylet|The control group will intubate using the video-laryngoscope / pre formed stylet. Will convert to using video-laryngoscope and fiber-optic bronchoscope (aScope III) if failure to intubate occurs
2473591|NCT03080584|Experimental|acupucture arm|all participants undergo 12 weeks of acupuncture
2472735|NCT03086031|Active Comparator|Conventional vocational rehabilitation(controls)|Individuals allocated to the control group will receive the conventional VR program provided by the four municipalities over the same period of time. Thus, the participants in the control group will receive VR support by the local municipal authority that may vary in content and intensity. As for the intervention group, each individual in the control group will select a family caregiver that will go through the same questionnaires as the caregivers in the VR intervention group regarding health-related quality of life and functional level. Furthermore, the case manager at the municipalities will oblige to (1) hand out the baseline questionnaires to the participants and their family caregivers, (2) complete a questionnaire about each participants at the beginning, the end of the study, and again at 6-month of follow-up.
2472801|NCT03085784|Experimental|Loading Dose|"20 Patients will receive 4, 2 mg IVT Aflibercept (IAI) a month apart, screening/baseline, weeks 4, 8, & 12. At week 12, patient will be followed & treated per treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
2472804|NCT03085784|Experimental|Treat and Extend|"20 Patients will receive 2 mg IVT Aflibercept (IAI) at screening/baseline followed by a visit at week 4. At week 4, patient will be treated & followed per the treat & extend protocol.~Treat & Extend Protocol entails patients being extended as long as:~Absence of retinal fluid (resolution of intraretinal & subretinal fluid on SD-OCT; Small intraretinal cysts that don't distort foveal contour on SD-OCT are acceptable & can be considered dry.) AND~< 5 ETDRS letter loss from previous visit, due to new or persistent retinal edema.~Each extension will be 2 weeks in duration beyond the initial 4-week interval. If the extension criteria are not met on a follow-up visit, treatment interval will be reduced by 2 weeks. Follow up interval will continue to be reduced by 2 weeks until the extension criteria are met or a 4-week interval is reached."
2472828|NCT03085303|Experimental|Blue light at 415nm|Full body irradiation for 30min (15 min. each body side) with blue light at 415nm peak wavelength with full body blue device.
2472829|NCT03085303|Experimental|Blue light at 450nm|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with full body blue device.
2472837|NCT03085303|Placebo Comparator|Placebo|Full body irradiation for 30min (15 min. each body side) with blue light at 450nm peak wavelength with a low dose setting (not therapeutically active) of the full body blue device.
3192274|NCT00806962|Experimental|Vaccine Arm 2|100 µg Norwalk VLP Vaccine + Adjuvant/Excipients
2473197|NCT03083119|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
2473201|NCT03083119|Placebo Comparator|Placebo Comparator|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
2473225|NCT03082937|Experimental|3 mg [14C]-A4250 capsule|
2473313|NCT03082768|Experimental|[18F]MNI-968|To evaluate [18F]MNI-968 (aka PF-06730110) as a D1 receptor targeted radiopharmaceutical
2473430|NCT03082027||ultrasonography|diagnostic tool
2473432|NCT03082027||operative release|
2473493|NCT03081403|Other|Subjects with sensitive skin|Subjects with a score greater than 50 on the sensitive scale
2473494|NCT03081403|Other|Subjects without sensitive skin|Subjects with result lower than 20 on the sensitive scale
2473654|NCT03080220|Experimental|Astym|The Astym treatment (AT) is specifically used by medical professionals to treat musculoskeletal dysfunctions by stimulating the body's ability to break down adhesions and reabsorb dysfunctional tissue (scar tissue).6-16,19 The treatment induces collagen building, fibroblastic activity, and phagocytosis.17,18 Part of the treatment includes utilizing a series of instruments glided across the skin tissue, in a non-invasive manner, along the route of the underlying muscle fibers' direction. The treatment specifically spares healthy tissue and stimulates growth factors and cellular mediators that stimulate the repair of dysfunctional tissue in the body's internal mechanisms.17,18 Astym is an FDA approved device. Specifically, Astym is registered as having a device class as 1 and regulation number as 890.5660.
2473655|NCT03080220|Experimental|Stick|The Stick treatment (ST) utilizes an instrument to convert non-compliant muscle to compliant muscle by compressing the muscle. The individual spindles of The Stick create a stripping massage by applying progressively deeper strokes over the soft tissue.38 The Stick permits individuals to perform trigger point release on own person, allowing the muscle to become compliant to the wanted movement.
2473658|NCT03080220|Placebo Comparator|Massage|Similar to the protocol previously outlined for the other two independent variables, the massage treatment (MT) will progress from anterior, to medial, to lateral and posterior shank, thigh, and hip. The treatment on each muscle tissue will follow the similar protocol as the Astym treatment (AT) group. However, the flat, non-treatment edge of the Evaluator®, Localizer®, and Isolator® will be put in contact with the muscle tissues in a direction parallel to the muscle fibers being treated, but without over pressure.7 The traditional treatment edge of the instrument has a tapered, machine edge and creates shear forces when glided across the tissue at an angle between 60 and 80 degrees.
2473677|NCT03079817|Active Comparator|Proprioceptive Drills|Includes drills during which participants perform multiplestances on a pillow, a number of different cone and line drills, reaching drills, object retrieval drills and drills using balls to disturb balance.
2473679|NCT03079817|Experimental|Yoga Meditation|The meditation program will use simple poses during which the participant will not move and will concentrate on each of the participant's body parts and where they are in space.
2473728|NCT03079479||Two Years Group|
2473729|NCT03079479||Five Years Group|
2473730|NCT03079479||Ten Years Group|
2473731|NCT03079479||Control Group|
2473777|NCT03079310|Experimental|Spinal cord stimulation|Boston Scientific SCS system
2494200|NCT02941042|Experimental|NNC9204-1177|
2472777|NCT03085654|Experimental|High anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days,24 IU per day in subjects with high trait anxiety.
2472778|NCT03085654|Experimental|Low anxiety group (single dose)|Oxytocin nasal spray or placebo nasal spray of one dose in subjects with low trait anxiety.
2472779|NCT03085654|Experimental|Low anxiety group (3 doses)|Oxytocin nasal spray or placebo nasal spray interleaved during the 5 days( on the 1st,3rd and 5th day),24 IU per day in subjects with low trait anxiety.
2472780|NCT03085654|Experimental|Low anxiety group (5 doses)|Oxytocin nasal spray or placebo nasal spray for 5 days in subjects with low trait anxiety.
2472822|NCT03085472||benigh hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively benigh hematoma (less likely to expand and have a relatively good outcome).
2472823|NCT03085472||malignant hematoma|Patients with novel imaging markers or clinical features suggestive of a relatively bad hematoma (more likely to expand and have a relatively poor outcome).
2472919|NCT03084809|Experimental|Cytokine-induced killer cells + FOLFOX4|"Cytokine-induced killer cells + FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours.The treatment is given for 4-6 cycles, every 3 weeks.~Collected cytokine-induced killer cells (CIK) cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days."
2472922|NCT03084809|Experimental|FOLFOX4|"FOLFOX4 intervention:~Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL 5% dextrose in water (D5W); Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags; Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks."
2472951|NCT03084588|Active Comparator|Methadone|Patients in the methadone group will receive a single dose of methadone 0.2 mg/kg at induction of anesthesia
2472955|NCT03084588|Active Comparator|Interscalene block|Patients in the intersclene block group will receive an interscalene block prior to induction of anesthesia
2472982|NCT03084341|Active Comparator|NMEE Group|Neuromuscular Electrical Elongation
2472983|NCT03084341|Active Comparator|PNF Group|Proprioceptive Neuromuscular Facilitation stretching
2472984|NCT03084341|No Intervention|Control Group|No intervention
2473022|NCT03084172||chronic kidney disease patients group|These patients were screened from 2000000 of the population. The investigator will compare the prevalence rate, awareness rate and treatment rate before and after the completion of the system. The degree of decreased glomerular filtration rate is also an important evaluation index.
2473107|NCT03083613|Experimental|Raltitrexed and Paclitaxel|"All patients receive the combination therapy of Raltitrexed and Paclitaxel for a maximum of 6 cycles~Raltitrexed:3mg/m2,d1 Paclitaxel:80mg/m2,d1,d8,~Eery 3 weeks"
2473175|NCT03083340|Experimental|Deprexis|Participants will complete 8 weeks of online treatment via a web-based program, Deprexis.
2473243|NCT03083067|Experimental|Salvational intervention(SI) group|Budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug on the foundation of original treatment.
2473245|NCT03083067|Active Comparator|Control(CT) group|CT group maintain the original treatment
2473370|NCT03082053|Experimental|Study I|Varlitinib given as monotherapy to Japanese subjects with advanced or metastatic solid tumors
2473372|NCT03082053|Experimental|Study II|Varlitinib given in combination with capecitabine to Japanese subjects with advanced or metastatic biliary tract cancer
2473405|NCT03081819|Experimental|SH003|Participant will take SH003 for 3 weeks.
2473466|NCT03081676|Active Comparator|Glimepiride + GIP|Tablet Glimepiride + infusion of GIP
2473471|NCT03081676|Active Comparator|Placebo + GIP|Placebo tablet + infusion of GIP
2473475|NCT03081676|Active Comparator|Glimepiride + GLP-1|Glimepiride + infusion of GLP-1
2473479|NCT03081676|Active Comparator|Placebo + GLP-1|Placebo tablet + infusion of GLP-1
2473482|NCT03081676|Active Comparator|Glimepiride + Placebo|Glimepiride + infusion of placebo (saline)
2473484|NCT03081676|Placebo Comparator|Placebo + Placebo|Placebo tablet + infusion of placebo (saline)
2473559|NCT03080974|Experimental|Single Arm|All patients undergoing irreversible electroporation will be treated with nivolumab
2473628|NCT03080597|Experimental|Smartphone app condition|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart."
2473687|NCT03080038|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
2473689|NCT03080038|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
2473768|NCT03079427|Active Comparator|Capecitabine|Adjuvant Capecitabine
2473772|NCT03079427|Experimental|Gemcitabine plus cisplatin|Adjuvant Gemcitabine plus Cisplatin
2473795|NCT03078985|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
2473854|NCT03078803|Experimental|Fecal microbiota transplant|Transfer of healthy human gut bacteria
2473855|NCT03078803|Placebo Comparator|Placebo|Water
2473886|NCT03078400|Experimental|Safety Phase|"Six to 12 subjects~Cohort 1 SPL-108 injection daily + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles~Cohort 2 SPL-108 BID injection + 80 mg/m2 PTX weekly on Days 1, 8, and 15 in 28 day cycles"
2472802|NCT03085589||Amulet adaptation and validation|The Amulet development team will develop and configure applications assessing: steps/distance; strength; activity type; gait speed; and real-time, self-monitored activity feedback. Objective measures will be validated with the Amulet from 60 participants ensuring usability and feasibility. Each participant will be asked to come into the clinic for one afternoon for about 2-3 hours.
2472843|NCT03085381|Experimental|HPV vaccine|Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.
2472849|NCT03085381|Placebo Comparator|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
2473004|NCT03084419|Experimental|Abatacept in patients with RA-ILD|Thirty participants with RA-ILD will be treated with abatacept infusions, which will be given fortnightly for the first 4 weeks, then every 4 weeks for a total of 20 weeks.
2473060|NCT03084042||Depression patients (MDD)|Patients with diagnosis of major depression according to DSM criteria
2473065|NCT03084042||Anxiety patients (GAD)|Patients with generalized anxiety disorder according to DSM criteria
2473068|NCT03084042||Healthy controls|Demographically matched healthy controls.
3157629|NCT00369551|Experimental|Treatment (paclitaxel, carboplatin, bevacizumab, radiation)|"Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.~Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
3157630|NCT00369603|Experimental|Razadyne ER|galantamine treatment group
3157631|NCT00369603|Experimental|Aricept|Aricept Treatment Group
2473306|NCT03082612|Experimental|Intervention plus usual care|Participants (patients and their family caregivers) in this study arm will receive the Overcoming Psychological Distress through Hymns Intervention.
2473308|NCT03082612|Active Comparator|Usual care|Immediately after randomization and completion of baseline measures, participants in this study arm will receive usual care. Patients and their family caregivers will receive the Overcoming Psychological Distress through Hymns Intervention after the 3 week period of usual care.
2473393|NCT03082131|Experimental|Group 1|"Order of treatments:~A. Resistant Starch Wheat B. Regular Wheat"
2473397|NCT03082131|Experimental|Group 2|"Order of treatments:~A. Regular Wheat B. Resistant Starch Wheat"
2473463|NCT03081663|Experimental|Quads-Sparing Approach with Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and a tourniquet.
2473464|NCT03081663|Active Comparator|Medial Para-Patellar with Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and a tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
2473465|NCT03081663|Active Comparator|Quads-Sparing Approach w/o Tourniquet|Participants will have a navigated total knee arthroplasty with a quadriceps-sparing mid-vastus approach and no tourniquet.
2473469|NCT03081663|Active Comparator|Medial Para-Patellar w/o Tourniquet|Participants will undergo total knee arthroplasty with a medial para-patellar approach and no tourniquet. An intramedullary femoral guide and extramedullary tibial guide will be used during the surgery.
2473511|NCT03081013|Active Comparator|Private Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest without any identifiable information about the participants.
2473513|NCT03081013|Experimental|Public Arm|At the end of each week, participants will be provided with the number of steps logged by the participants in their group. The number of steps will be ranked from highest to the lowest with the full names of the participants corresponding to the number of steps.
2473579|NCT03080753|Experimental|Intersphincteric implants|Treatment with intersphincteric implants in the anal sphincter using Sphinkeeper
2473635|NCT03080428|Active Comparator|Endopredict®|genomic test Endopredict® realized on surgery tumour samples
2473639|NCT03080428|Active Comparator|Prosigna®|genomic test Prosigna® realized on surgery tumour samples
2473644|NCT03080428|Active Comparator|OncotypeDX®|genomic test OncotypeDX® realized on surgery tumour samples
2473646|NCT03080428|Active Comparator|Mammaprint® assay|genomic test Mammaprint® assay realized on surgery tumour samples
2473719|NCT03079895|No Intervention|Control Arm|After enrollment in the study, the subject will continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being.
2473720|NCT03079895|Experimental|Intervention Arm|"After enrollment in the study, the subject will be granted 8 weeks of access to Thrive, an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy. During the first 4 weeks, they will receive 4 coaching emails and/or phone calls encouraging their participation in the study, and answering any program-related questions. The subject will also continue to receive treatment as usual for their depression from their primary care physician. They then will be asked to complete 2-month and 6-month assessments about their emotional well-being."
2473746|NCT03079401|Experimental|Treatment Arm|"Those randomized to the treatment arm will receive MPCs injected directly into the LV endocardium following clinical surgical maneuvers to recruit the LV (mitral valve repair, aortic valve repair, and/or resection of endocardial fibroelastosis) or BDG.~MPCs will be delivered directly into the LV endocardium via a 23-25 gauge needle following completion of all surgical procedures. A total dose of 20 million cells will be delivered, divided evenly into ~11 injections of 50 µL each. The total volume is not to exceed 2.0 mL."
2494201|NCT02941042|Placebo Comparator|Placebo|
3157632|NCT00369616|Experimental|NicQb vaccine|
3157633|NCT00369616|Placebo Comparator|Placebo vaccine|
3157634|NCT00369694|Active Comparator|1|72 hours of Terlipressin
3157635|NCT00369694|Placebo Comparator|2|24 hours of Terlipressin & then next 48 hours of Dummy of Terlipressin
3157636|NCT00369733|Experimental|Single arm|Aranesp adminsitered every other week for 52 weeks
3157637|NCT00369759||1|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
2472855|NCT03085368|Active Comparator|EC→PH(Epirubicin+Cyclophosphamide--Docetaxel+herceptin)|Table 80mg/ day 1 IV Cyclophosphamide 600 mg/m2 day IV 21 days for a total of 1 cycles, with a total of 4 cycles Docetaxel 100mg/m2 IV day 1 21 days for a total of 1 cycles, with a total of 4 cycles Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
2472857|NCT03085368|Active Comparator|EPH(Paclitaxel+epirubicin+herceptin)|80mg/ M2 day 1 IV epirubicin Paclitaxel 150mg/m2 IV day 1 14 days for a total of 1 cycles, with a total of 6 cycles Also given Trastuzumab 2mg/kg IV QW (first dose 4 mg/kg) Note: trastuzumab was administered at the beginning of the first injection of paclitaxel, with an injection dose of 2mg/kg, 1 times a week, for a total of up to 1 years; followed by trastuzumab 2mg/kg IV, once every 3 weeks for a total of one year
3157638|NCT00369759||2|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
3157639|NCT00369759||3|Bronchiolitis, pneumonia or Lower Respiratory Infection or LRI (Season 1: 2006-'07 and same for Season 2: 2007 - '08)
2473010|NCT03084328||Patients with Vitamin D level of <30ng/dL|This is a cohort of patients with fatty liver disease and also have low levels of vitamin D
2473011|NCT03084328||Patients with Vitamin D level of >30ng/dL|This is a cohort of patients with fatty liver disease and have normal levels of vitamin D
2473070|NCT03083977|Experimental|Intervention group|This group will listen to 1 hour of processed music (Safe and Sound Protocol) for 5 days
2473106|NCT03083626||Prescription opioid abusers|Patients 21-65 years old taking suboxone or methadone, currently experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
2473109|NCT03083626||Healthy control participants|Patients 21-65 years old not taking suboxone or methadone, not experiencing chronic pain, not taking any opioid analgesic medication for painful condition on a regular basis, not have any current psychiatric or neurological illnesses, not have a history of heart disease in order to be healthy enough to complete the cold pressor test.
2473177|NCT03083353|Experimental|isradipine|Participants will receive 15mg of immediate release isradipine.
2473178|NCT03083353|Placebo Comparator|placebo|Participants will receive a placebo pill identical in appearance to isradipine.
2473392|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 1|Part 1, Cohort 1: For the first 3 subjects enrolled, the initial dose will be 10 mg in Sterile Water for Injection (SWFI). TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If Dose Limiting Toxicity(DLT) does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (25, 50, 75, 100, 150 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.
2473396|NCT03081858|Experimental|TSD-001 Administration Part 1, Cohort 2|"Part 1, Cohort 1: For the next 3 subjects enrolled, the initial dose will be 90 mg in SWFI. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure). If DLT does not develop, intravesical instillation 14 days later will be titrated up according to the schedule (180, 270, 360, 450, and 540 mg in SWFI) until DLT (defined as any grade 3 or 4 toxicity or prolonged [greater than 14 days] grade 2 toxicity) is observed.~If no DLT is observed in the first 6 subjects (cohorts 1 and 2) after titration up to 540 mg, then the maximum deliverable dose (MDD) will be defined and dose recommended for part 2 of the study."
2473400|NCT03081858|Experimental|TSD-001 Administration Part 2|"In part 2, the dose will be selected as the MTD/MDD, established in part 1 and provided weekly via the intravesical route.~During part 2, up to 10 additional subjects will receive intravesical instillations of TSD-001 via urethral catheterization of the urinary bladder at the MTD/MDD established in part 1 at weekly intervals for 6 consecutive weeks. TSD-001 will be retained in the bladder for 2 hours (1 hour or more will be acceptable, depending on subject's tolerability of the procedure)."
2473449|NCT03081533|Experimental|Circle Dance Program (CircleCare)|Caregivers (n=20) allocated to the experimental group will participate in 12-week CircleCare twice a week (24 sessions), for 60 min each session. The planning and conduction of the intervention will be the responsibility of the researcher, a Fitness Professional with training in Circle Dance, called focalizer.
2473452|NCT03081533|No Intervention|Control group|Caregivers (n=20) of this group will not receive the intervention, participating only in the assessment protocol. They will be instructed not to initiate any regular exercise program during the study period. At the end of the study, the same CircleCare applied to the experimental group will be offered to the interested of the control group.
2473540|NCT03081234|Experimental|Ribociclib + adjuvant endocrine therapy|Ribociclib in combination with standard adjuvant endocrine therapy
2473546|NCT03081234|Active Comparator|Placebo + adjuvant endocrine therapy|Placebo in combination with standard adjuvant endocrine therapy
2473572|NCT03080675|Experimental|Experimental|Nutritional blend of ingrédients including vitamins and fish oil
2473573|NCT03080675|Placebo Comparator|Control comparator:|control product does not contain any of the active ingredients and is matched for carbohydrate content to the active intervention.
2473630|NCT03080480|Experimental|Pioglitazone|Treatment for chronic granulomatous disease patients with severe infection.
3157640|NCT00369837|Experimental|clevidipine|A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.
3157641|NCT00369850|Experimental|Tamoxifen for 5 years|Patients treated with tamoxifen for 5 years after randomisation.
3157642|NCT00369850|Experimental|Letrozole for 5 years|Patients treated with letrozole for 5 years after randomisation.
3157643|NCT00369850|Experimental|Tamoxifen 2 years plus letrozole 3 years|Patients treated with tamoxifen for 2 years and afterwards with letrozole for 3 years.
3157644|NCT00369850|Experimental|Letrozole 2 years plus tamoxifen 3 years|Patients treated with letrozole for 2 years and afterwards with tamoxifen for 3 years.
2472960|NCT03084783|Experimental|Intervention group|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
2472961|NCT03084783|No Intervention|Control group|Participants receive standard care and no dexamethasone.
2473047|NCT03083938|Experimental|Omental Roll-up|
2473048|NCT03083938|No Intervention|No Omental Roll-up|
2473099|NCT03083743|Experimental|Recombinant human Apo-2 ligand|Recombinant human Apo-2 ligand for Injection
2473102|NCT03083743|Placebo Comparator|Placebo|Mimetic agent for recombinant human Apo-2 ligand for injection
2473157|NCT03083405||Opipramol group|Patients diagnosed with SB and opipramol intervention.
2473158|NCT03083405||SB group|Patients diagnosed with SB and no drug intervention.
2473161|NCT03083405||Healthy controls|Patients without diagnosed SB.
2473203|NCT03083171|Placebo Comparator|Placebo|
2473204|NCT03083171|Active Comparator|Adrecizumab 0.5 mg/kg|A single intravenous dose of 0.5 mg/kg Adrecizumab given over a 1 hour period.
2473207|NCT03083171|Active Comparator|Adrecizumab 2.0 mg/kg|A single intravenous dose of 2.0 mg/kg Adrecizumab given over a 1 hour period.
2473210|NCT03083171|Active Comparator|Adrecizumab 8.0 mg/kg|A single intravenous dose of 8.0 mg/kg Adrecizumab given over a 1 hour period.
2473230|NCT03082833|Experimental|AZD2014 50mg BD|AZD2014 50mg BD continuous schedule of a 28 day cycle
2473273|NCT03082742|Active Comparator|Furosemide|Use of Furosemide, 40mg (1 tablet) per day, over 12 months
2473274|NCT03082742|Active Comparator|Hydrochlorothiazide|Use of Hydrochlorothiazide, 25mg (1 tablet) per day, over 12 months
2473289|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Tablet then Capsule Sequence|Subjects will receive a single oral dose in tablet formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in capsule formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
2473292|NCT03082300|Experimental|Pharmacokinetic phase: ASP8273 Capsule then Tablet Sequence|Subjects will receive a single oral dose in capsule formulation on Day 1 of period 1 under fasted condition, then subjects will receive a single oral dose of ASP8273 in tablet formulation on Day 1 of period 2 under fasted condition. Each period will be for 5 days
2473296|NCT03082300|Experimental|Postpharmacokinetic phase: ASP8273 Capsule Formulation|All subjects will receive ASP8273 capsules in once-daily dosing for 1 cycle (28 days)
2473410|NCT03082118|Experimental|Vesair Arm|Subjects treated with the Vesair Bladder Control System at enrollment.
2473468|NCT03081507|Experimental|LHW-led small media intervention arm (SM-LHW)|
2473472|NCT03081507|Experimental|LHW-led plus small media intervention arm (PN-LHW)|
2473510|NCT03081078|Experimental|TAU w/ mobile app + volunteer support|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention, plus support from volunteers.
2473512|NCT03081078|Experimental|TAU w/ mobile app engagement|Participants will be receiving usual medical treatment from the hospitals with a mobile app engagement intervention.
2473514|NCT03081078|No Intervention|Treatment as Usual (TAU)|Participants will be receiving usual medical treatment from the hospitals, and without the interventions (i.e., mobile app and/or volunteer support) introduced through this randomized control trial.
2473580|NCT03080740|Active Comparator|Clindamycin palmitate hydrochloride|Clindamycin palmitate hydrochloride dispersible tablet 300mg, oral after meal, twice daily, a total of 7days
2473581|NCT03080740|Active Comparator|Metronidazole|Metronidazole Tablet 400mg, oral after meal , twice daily, a total of 7days
2473603|NCT03080415|Experimental|Combined Therapy SOF and DCV|
2473659|NCT03080181|Experimental|pasireotide|Pasireotide was administered in a 12 months period
2473690|NCT03079830|Active Comparator|Ropivacaine continous infusion|Piritramid
2473692|NCT03079830|Sham Comparator|Saline continous|Piritramid
2473975|NCT03077945|Experimental|Intervention Condition|This group will receive the heart rate variability biofeedback intervention in addition to the cognitive reappraisal of stress intervention
2473979|NCT03077945|Placebo Comparator|Control Condition|This group will complete control tasks, including viewing neutral videos.
2474059|NCT03077555|Active Comparator|Meliane ED|20 mcg ethinyl estradiol/70 mcg gestodene
2474061|NCT03077555|Experimental|Zoely|1.5 mg estradiol/2.5 mg nomegestrol acetate
2474149|NCT03076879|Experimental|Intervention group|The selected ASM was associated with risk factors related to direct cervical cancer in Turkey (using age 5 or older oral contraceptives, having three or more children, initiating sexual intercourse 16 years or older, at least one parenthesized smear test between 40-55 years) And randomly assigned to the experimental group to promoting participation in cervical cancer screening
2474184|NCT03076736|Active Comparator|Resource pack|Aphasia resource pack
2474186|NCT03076736|Experimental|Singing group + resource pack|Singing group + Aphasia resource pack
2474222|NCT03076177|Experimental|Kinesio taping group|Participants receiving kinesio taping application
2474226|NCT03076177|Sham Comparator|Non specific taping|Participants receiving non specific taping application
3157645|NCT00370084|Placebo Comparator|Placebo|
3157646|NCT00370084|Experimental|Itopride|
3157647|NCT00370097|Experimental|Subjects receiving HFA|Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily
3157648|NCT00370110|Experimental|Itopride|
3157649|NCT00370110|Other|Placebo|
3157650|NCT00370240|Experimental|Ropivacaïne|
3157651|NCT00370240|Placebo Comparator|placebo|
3157652|NCT00370253|Active Comparator|2|Terlipressin
3157653|NCT00370253|Experimental|1|Noradrenalin
3157654|NCT00370279|Active Comparator|1|scleral buckling
3157655|NCT00370279|Active Comparator|2|Primary vitrectomy without encircling band
3157656|NCT00370279|Active Comparator|3|Primary vitrectomy with encircling band
3157657|NCT00370279|Active Comparator|4|Triamcinolone assisted vitrectomy
3157658|NCT00370305|Experimental|Rosiglitazone treatment|Rosiglitazone will be given to the subjects. All subjects will be analyzed before and after treatment
2472883|NCT03085043|Experimental|Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)|Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
3157659|NCT00370344|Active Comparator|Laparoscopic cholecystectomy|Operation by experts in laparoscopy.
3192275|NCT00806962|Active Comparator|Adjuvant/Excipients (MPL)|14 mg chitosan, 3 mg mannitol, 3 mg sucrose, and 50 mcg MPL
2473032|NCT03084237|Experimental|HLX02+docetaxel|
2473036|NCT03084237|Active Comparator|Herceptin®+docetaxel|
2473079|NCT03083782|Active Comparator|Treatment A: Apixaban alone|Oral apixaban will be administered in healthy volunteers to define baseline apixaban pharmacokinetics
2473080|NCT03083782|Experimental|Treatment B: Cyclosporine with apixaban|Oral cyclosporine will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of cyclosporine
2473083|NCT03083782|Experimental|Treatment C: Tacrolimus with apixaban|Oral tacrolimus will be administered to steady state in healthy volunteers followed by a single oral dose of apixaban to define apixaban pharmacokinetics in the presence of tacrolimus
2473127|NCT03083457|Experimental|PEEP2 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O and scheduled recruiting maneuvers at the beginning of each PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473133|NCT03083457|Experimental|PEEP7 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473135|NCT03083457|Experimental|PEEP12 + RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O and scheduled recruiting maneuvers at the beginning of the PEEP step, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473142|NCT03083457|Experimental|PEEP2 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=2 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473147|NCT03083457|Experimental|PEEP7 - RM|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=7 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473149|NCT03083457|Experimental|PEEP12 - RM.|General anesthetic, 40 minutes of Low-tidal volume ventilation with PEEP=12 cmH2O, continuous fluid administration at a standard dose, fluid resuscitation or amine administration if deemed necessary by the attending physician blinded to the design of the study
2473253|NCT03082963|Other|EMR Feasibility|In this feasibility study, all ten patients will undergo EMR mapping which will be used to guide ablation.
2473275|NCT03082560||Group 1|Healthy adult patients with lichen planopilaris
2473293|NCT03082313|Experimental|Movement intervention|The intervention promotes movement experience from 3 months to sitting onset in infants at risk for developmental delay (AR). The goal of the intervention is to increase amount and type of infant leg movement experience above 1200 movements per hour of awake time with 1/3 single and 2/3 bilateral leg movements.
2473362|NCT03082183|Experimental|All participants|BI 425809 given alone in first period, then in combination with Rifampicin in second period
2473390|NCT03081871|Experimental|Web and mobile app access|Subjects will have access to both the mobile and web-app versions of the study Personal Health Record to communicate with the study pharmacist and enter and track their health data.
2473394|NCT03081871|Active Comparator|Web app only access|Subjects will have access to the web-app version of the study Personal Health Record (and not the mobile app version) to communicate with the study pharmacist and enter and track their health data.
2473436|NCT03081572||Abacavir Group|HIV positive individuals currently taking an abacavir based regimen
2473439|NCT03081572||Tenofovir Group|HIV positive individuals currently taking a tenofovir based regime
3192276|NCT00806962|Sham Comparator|Empty device|Empty device that contains no dry powder formulation. Actuation of the empty intranasal delivery device will deliver a puff of air per device.
2473649|NCT03080207|Experimental|Platelets / Platelet Enriched Plasma Regard (PRP) Method|
2473650|NCT03080207|Experimental|Complex Decongestive Physiotherapy|
2473652|NCT03080207|Experimental|Low Level Laser|
2473680|NCT03079843|Experimental|facemask first then no face mask|wearing of mask each day for the two hours of exposure for the first week of exposure then not wearing the mask each day for the two hours of exposure for the second week of exposure
2473683|NCT03079843|Experimental|no face mask followed by wearing face mask|not wearing the mask each day for the two hours of exposure for the first week of exposure then wearing the mask each day for the two hours of exposure for the second week of exposure
2473771|NCT03079596|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic total gastrectomy, following the ERAS protocols
2473773|NCT03079596|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways
2473824|NCT03078998|Experimental|Juvenile idiopathic Arthritis|
2473828|NCT03078998|Experimental|Obstetric Brachial Plexus Palsy|
2473834|NCT03078998|Experimental|Cerebral Palsy|
2473919|NCT03078608|Experimental|Intervention arm|Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
2473921|NCT03078608|Active Comparator|Active control arm|Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
2473927|NCT03078608|Other|Wait list control arm|Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
2475807|NCT03064893|Active Comparator|Dermacell|Device for immediate implant based breast reconstruction
2472925|NCT03084900|Experimental|Patient-Centered Decision Support|Intervention - computer decision support in diabetes clinic. Investigators will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures. The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
2472926|NCT03084900|No Intervention|Standard Care|Standard pediatric diabetes care will be compared to the computerized decision support system.
2472967|NCT03084536|Active Comparator|Preoperative PECS blocks|"PECS I & II block will be administered preoperatively~For unilateral surgeries, PECS I block will be performed bupivacaine. The PECS II block will be performed with the same solution. If there is a contralateral surgery (simple mastectomy) a PECS II block will also be performed on the other side.~To ensure blind integrity, study drug syringes will be marked only study drug and subject number~Perioperative analgesic will be encouraged.. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative area. All patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist"
2472969|NCT03084536|Placebo Comparator|Placebo PECS blocks|"A sham block (normal saline) will be placed preoperatively~To ensure blind integrity, study drug syringes will be marked only study drug and subject number.~Perioperative analgesic regimen will be encouraged. Gabapentin 300mg, celecoxib 200mg and acetaminophen 1000mg will be administered to all patients following arrival to the preoperative holding area. On the day of surgery all patients will receive premedication of 1-2 mg midazolam IV (age < 65) and 50-100 μg fentanyl IV prior to the block placement or entry to the operating room at the discretion of the regional team or operating room anesthesiologist."
2473051|NCT03084029|Experimental|male participants - oxytocin nasal spray|male participants - receiving a single dose of 40 IU intranasal oxytocin
2473054|NCT03084029|Experimental|female participants - oxytocin nasal spray|female participants - receiving a single dose of 40 IU intranasal oxytocin
2473057|NCT03084029|Placebo Comparator|male participants - placebo nasal spray|male participants - receiving a single dose of 40 IU intranasal placebo
2473061|NCT03084029|Placebo Comparator|female participants - placebo nasal spray|female participants - receiving a single dose of 40 IU intranasal placebo
2473118|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 5g|plant-based protein hydrolysate 1 (5g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times per day for 12-weeks
2473123|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 10g|Plant-based protein hydrolysate 1 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2473134|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (1) 15 g|Plant-based 1 protein hydrolysate (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2473139|NCT03083600|Placebo Comparator|Placebo|Cellulose Placebo stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks.
2473145|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 5g|Plant-based protein hydrolysate 2 (5 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2473146|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 10g|Plant-based protein hydrolysate 2 (10 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2473150|NCT03083600|Active Comparator|Plant-based Protein Hydrolysate (2) 15g|Plant-based protein hydrolysate 2 (15 g) stored in aluminium sachets to be reconstituted with 100 mL of water and administered 2 times daily for 12-weeks
2473220|NCT03083184|Experimental|Intervention group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
2473226|NCT03083184|Other|control group|Enrolled patients will be randomly assigned in a 1:1 ratio either to the intervention group (Ethenox) or to the control group (reference solution: UFH 5000 U/mL or citrate 4% w/v depending on which solution is generally used).
2473290|NCT03082664|No Intervention|Standard dressing|Standard dressing will be applied after C-section.
2473297|NCT03082664|Experimental|PICO dressing|Device: PICO Single Use Negative Pressure Wound Therapy
3192277|NCT00806975|Other|usability and preference|
3192278|NCT00807027|No Intervention|Control Group|The study subjects randomly assigned to the control group is given Temozolomide chemotherapy and radiation therapy for 6 weeks according to the clinical test plans, and then administers Temozolomide only for 6 weeks.
2473530|NCT03081390|Experimental|No migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2473535|NCT03081390|Experimental|No migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2473539|NCT03081390|Experimental|Migraine, normal weight|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2473545|NCT03081390|Experimental|Migraine, obese|"Mixed meal tolerance testing~Skin conductance & cold pressor test~Flow-mediated dilation testing"
2473613|NCT03080623||Suspicious breast lesions|women with Suspicious breast lesions, who need to receive breast ultrasound will be collected in this cohort. According to the diagnosis of breast ultrasound，patients will be assigned to breast biopsy or follow-up
2473693|NCT03080155|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2473764|NCT03079609|Experimental|microsurgery urology|20 patients with varicocele (grade II or III) undergoing subinguinal microsurgery varicocelectomy due to infertility and/or pain in the scrotum.
2473769|NCT03079609|Active Comparator|open general surgery|20 patients (without varicocele) undergoing open hernia repair.
2473831|NCT03079037||Stimulation|Traditional deep brain stimulation
3192279|NCT00807027|Experimental|Test Group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after surgery by administering Temozolomide chemotherapy and radiation therapy same as control group with Immuncell-LC (14 times).
2472946|NCT03084731|No Intervention|Healthy controls|In order to construct a library of gut microbiota of healthy growing children of the same community, one spot fecal sample (1-2 gm) and spot blood sample (2 mL) will be collected from 30 children each who would be aged 12-18 months of either sex, having WLZ and LAZ : >-1
2473001|NCT03084406|Experimental|Enhanced Implementation (EI)|Providers in the Free Talk EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the Free Talk: Group MI for Teens searchable manual and materials via CV-ATOD. Providers may complete an optional CE course following the completion of the training module. EI providers will have access to all EBP implementation tools provided by CV-ATOD. Student providers in the CHOICE EI condition will receive access to CV-ATOD. They will participate in an online training course that mirrors the training in the IAU condition. However, EI providers will also receive access to interactive online exercises and practice activities within the training module. They will have online access to the CHOICE: Group MI for Teens searchable manual and materials via CV-ATOD.
2473003|NCT03084406|No Intervention|Implementation As Usual (IAU)|CMH providers in the Free Talk IAU condition will receive access to the Group MI for Teens website that provides asynchronous, self-paced training videos as well as downloadable intervention materials and resources. CMH providers in this condition are only required to watch the first two training videos before receiving access to download the Free Talk training manual and materials. Providers may also complete an optional CE course following the completion of all training videos. Student providers in the CHOICE IAU condition will receive access to the Group MI for Teens website that provides online training videos as well as downloadable intervention materials and resources. IAU providers are only required to watch the first two training videos before receiving access to download the CHOICE training manual and materials. Providers may also complete an optional EBP knowledge test following the completion of all training videos.
2473043|NCT03084068|Experimental|Human umbilical cord allograft|Open Rotator Cuff Repair patched with human dehydrated umbilical cord allograft
2473044|NCT03084068|Placebo Comparator|Placebo Control|Open Rotator Cuff Repair with standard suture repair
2473092|NCT03083795|Experimental|Social relationships intervention|"Participants randomized to the social interaction cohort will be split into two groups of 12. Each group of 12 will meet together once a month for a two-hour support group. Each participant will be allowed five minutes to check-in with the support group. During the 5 minute period the participant is encouraged to share their innermost thoughts and feelings in the knowledge that this information will not be shared outside the group.~Participants will additionally be paired with another study participant in the same cohort and will be asked to meet outside group sessions once a week for a minimum of 45 minutes. The pairing process will take place by study investigators and will be sensitive to gender, age, and neighbourhood of residence. Participants who find that their paired partner is not suitable may ask the facilitators to help find a more suitable match.~These participants will continue to receive BC Diabetes standard care."
2473095|NCT03083795|No Intervention|Control cohort|Patients in the control group will receive BC Diabetes standard care.
2473212|NCT03083197|Active Comparator|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
2473213|NCT03083197|Active Comparator|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
2473214|NCT03083197|Active Comparator|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
2473276|NCT03082755|Experimental|Gabapentin Enacarbil (GEn)|1 to 2 GEn tablets (300 mg) will be administered by mouth (PO) once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The study drug will be adjusted up to a maximum dosage of 600 mg as tolerated.
2473277|NCT03082755|Placebo Comparator|Placebo|1 to 2 Placebo Oral Tablet(s) will be administered once a day in the evening (about 5 pm) for 8 weeks then tapered for 1 week. The placebo drug will be adjusted up to a maximum dosage of 2 tablets as tolerated.
2473322|NCT03082287||IBD|Adult subjects diagnosed with IBD via endoscopy and histological findings.
2473328|NCT03082287||IBS|Adult subjects with IBS as per the Rome IV criteria.
2473330|NCT03082287||Other GI Disorders|Adult subjects with gastrointestinal disorders not meeting the Rome IV criteria or IBD diagnosis.
2473332|NCT03082287||Healthy Subjects|Adult subjects without any gastrointestinal complaints.
2473375|NCT03081923|Experimental|Durvalumab|Durvalumab, 1500 mg IV, q4 weeks, until disease progression or onset of unacceptable toxicity
2473376|NCT03081923|Experimental|Duralumab and Tremelimumab|Durvalumab, 1500 mg IV, on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity Tremelimumab, 75 mg IV, both on day 1 and q4 weeks, until disease progression or onset of unacceptable toxicity
2473408|NCT03081793||Patients with sinus Rhythm|Patients with sinus rhythm at the beginning of monitoring
2473409|NCT03081793||Atrial fibrillation|Patients with atrial fibrillation at the beginning of monitoring
2473470|NCT03081598|Placebo Comparator|Placebo|Daily dose of 6 capsules of placebo
2473474|NCT03081598|Active Comparator|PBI-4050 400 mg|Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo
2473477|NCT03081598|Active Comparator|PBI-4050 800 mg|Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo
2473481|NCT03081598|Active Comparator|PBI-4050 1200 mg|Daily dose of 6 capsules of PBI-4050
2473515|NCT03080987|Experimental|Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.
2473521|NCT03080987|Experimental|Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
2473526|NCT03080987|Experimental|Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.
2473529|NCT03080987|Experimental|Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
2473536|NCT03080987|Experimental|Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)|Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.
2473634|NCT03080350|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
2473006|NCT03084458|No Intervention|Control|Once consented, recruited ICD patients will complete the baseline psychosocial and quality of life measures. At the first and final visit, a 6-minute walk test will be administered. Participants will be sent text messages to encourage physical activity. Participants will be re-assessed with psychosocial and quality of life measures at 30 and 90 days post enrollment. At the final (90 day) visit participants ICD will be interrogated to obtain accelerometer activity data.
2473008|NCT03084458|Experimental|Fitbit|Same as control condition. In addition, participants in the experimental group will receive a Fitbit device with full instructions and troubleshooting. These participants will be given daily step goals, which will be increased during the course of the study, and be able to monitor their progress using the Fitbit app.
2473030|NCT03084055|Experimental|eMotion intervention|Subjects randomised to the intervention arm will receive eMotion for two months. eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity.
2473033|NCT03084055|No Intervention|Waiting list control|Subjects in the waiting list control group will be given no intervention for two months; the control group will then be able to access eMotion if they wish but this will not form part of the research project
2473093|NCT03083873|Experimental|Cohort 1|Treatment with LN-145, Generation 1 (Gen 1), non-cryopreserved TIL
2473096|NCT03083873|Experimental|Cohort 2|Treatment with LN-145 Generation 2 (Gen 2), cryopreserved TIL
2473098|NCT03083873|Experimental|Cohort 3|Treatment with LN-145 Generation 3 (Gen 3), cryopreserved TIL
2473101|NCT03083873|Experimental|Cohort 4|Treatment with LN-145-S1 cryopreserved TIL
2473103|NCT03083873|Experimental|Cohort 5|LN-145 cryopreserved/LN-145-S1 cryopreserved TIL re-treatment
2473246|NCT03082846|Experimental|hypofractionated group|hypofractionated group using hypofractionated radiation with temozolomide chemotherapy: Malignant gliomas patients received concurrent postoperative radiotherapy and chemotherapy.Intensity-modulated radiotherapy is adopted, the dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1. The planning target volume (PTV2) remain unchanged with 2.5 Gy each time and a total of 50 Gy/20 f. Temozolomide is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
2473285|NCT03082469|Active Comparator|CytoSorb|CytoSorb therapy for 48h
2473287|NCT03082469|No Intervention|Matched controls|60 matched controls with SAP and transpulmonary thermodilution monitoring
2473337|NCT03082235|Experimental|Cohort 1: 10 mg E6742|Participants will receive 10 milligrams (mg) E6742 as a single oral dose in the fasted state.
2473339|NCT03082235|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2473341|NCT03082235|Experimental|Cohort 2: 25 mg E6742|Participants will receive 25 mg E6742 as a single oral dose in the fasted state.
2473343|NCT03082235|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2473344|NCT03082235|Experimental|Cohort 3: 50 mg E6742|Participants will receive 50 mg E6742 as a single oral dose in the fasted state.
2473345|NCT03082235|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2473346|NCT03082235|Experimental|Cohort 4: 100 mg E6742|Participants will receive 100 mg E6742 as a single oral dose in the fasted state. Participants will then receive the same single oral dose of E6742 again in the fed state after a washout interval (at least 7 days or 5 half-lives of E6742, whichever is longer) for the evaluation of food effect.
2473347|NCT03082235|Placebo Comparator|Cohort 4: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state. Participants will then receive the same single oral dose of placebo again in the fed state after a washout interval (at least 7 days ) for the evaluation of food effect.
2473350|NCT03082235|Experimental|Cohort 5: 200 mg E6742|Participants will receive 200 mg E6742 as a single oral dose in the fasted state.
2473352|NCT03082235|Placebo Comparator|Cohort 5: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2473354|NCT03082235|Experimental|Cohort 6: 400 mg E6742|Participants will receive 400 mg E6742 as a single oral dose in the fasted state.
2473356|NCT03082235|Placebo Comparator|Cohort 6: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
2473359|NCT03082235|Experimental|Cohort 7: 800 mg E6742|Participants will receive 800 mg E6742 as a single oral dose in the fasted state.
2473364|NCT03082235|Placebo Comparator|Cohort 7: Matching placebo|Participants will receive a single oral dose of placebo matching E6742 in the fasted state.
3157660|NCT00370344|Active Comparator|Small-incision open cholecystectomy|Operation by experts in small-incision cholecystectomy.
3157661|NCT00370370|Active Comparator|1|Injection of intravitreal bevacizumab
2473458|NCT03081611|Experimental|Ram cannula|NIPPV VIA Ram cannula
2473460|NCT03081611|Active Comparator|Short nasal prongs|NIPPV VIA short nasal prongs
2473543|NCT03081156|Active Comparator|Glycopyrrolate/Formoterol Inhaler|Treatment for 2 weeks with Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
2473549|NCT03081156|Placebo Comparator|Placebo|Treatment for 2 weeks with a placebo Bevespi Aerosphere (Glycopyrrolate/Formoterol) inhaler to determine the effect on exercise tolerance using a constant work rate bicycle ergometer exercise test. The outcome is time in seconds compared to their baseline value.
2473570|NCT03080662|Sham Comparator|Sham valve (Placebo)|Sham Inspiratory valve (without resistance)
2473571|NCT03080662|Experimental|Intervention|Inspiratory valve with increase resistance
3192280|NCT00807053|Active Comparator|1|Ciclesonide HFA 75 mcg (37,5 mcg / actuation, 1 actuation/nostril), once daily
3192281|NCT00807053|Active Comparator|2|Ciclesonide HFA 150 mcg (75 mcg / actuation, 1 actuation/nostril), once daily
3157662|NCT00370370|Active Comparator|2|Injection of bevacizumab + triamcinolone acetonide
3157663|NCT00370383|Experimental|Satraplatin|Satraplatin administered orally once daily for 5 consecutive days followed by erlotinib for 14 consecutive days
2473031|NCT03084146|Experimental|Psoriasis|Psoriasis patients will be placed on an individualized 12-week elimination diet
2473035|NCT03084146|No Intervention|Healthy Control|Healthy Control patients will receive no intervention
2473090|NCT03083860|Other|Arm I|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version (A version of the app the generates recommendations of ADL interventions) , with feedback based on diary information and BEI; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information only.
2473094|NCT03083860|Other|Arm II|15-45 participants will be monitored for 4-6 weeks, using the App in a Closed version followed by 4-6 weeks, using the App in an Open version with feedback based on diary information only followed by 4-6 weeks; followed by 4-6 weeks using the App in an Open version, with feedback based on diary information and BEI. Note the difference between Arm I and Arm II is the order of use of BEI in addition to the diary feedback.
3192282|NCT00807053|Active Comparator|3|Ciclesonide HFA 300 mcg (150 mcg / actuation, 1 actuation/nostril), once daily
3192283|NCT00807053|Placebo Comparator|4|Placebo
3192284|NCT00807066|Experimental|A|Gefitinib
2473237|NCT03082989||fractional flow reserve performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography where the operator decided to use fractional flow reserve to drive the revascularization
2473239|NCT03082989||fractional flow reserve not performed|consecutive patients with ischemic heart disease and clinical indication to coronary artery angiography and satisfying prespecified criteria where the operator decided to not use fractional flow reserve to drive the revascularization
2473281|NCT03082638||Control|served in Gulf War during 1990 - 1991 and have no symptoms of Gulf War Illness based on criteria
2473282|NCT03082638||Case|Served in Gulf War during 1990 -1991 and have Gulf War Illness
2473334|NCT03082248|Other|Physical Therapy Group|10-week supervised physiotherapeutic intervention; all patients will receive educational leaflets and folders for maintenance and adherence to the treatment program.
2473335|NCT03082248|Other|Spinal Surgery Group|Surgical procedures and techniques specific for the low back region, previously discussed and agreed upon among surgeons according to patients description.
2473424|NCT03081910|Experimental|Autologous CD5.CAR/28zeta CAR T cells (Group A)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
2473425|NCT03081910|Experimental|Allogeneic CD5.CAR/28zeta CAR T cells (Group B)|"Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine.If patients have experienced either a partial response or stable disease and completed the 6 week toxicity evaluation without evidence of DLT or other infectious complications, they will be eligible to receive up to 3 additional infusions of CD5 CAR.T cells. Patients remain eligible for up to 3 additional infusions as long as they continue to have a clinical response and absence of safety concerns. If patients experience a complete response following an additional infusion, investigators will recommend they proceed to allogeneic HSCT.~Once dose escalation is completed, the trial will be expanded and treat up to an additional 6 patients (2 cohorts) at the MTD in each group to gather additional safety data and preliminary efficacy data."
2473486|NCT03081429||Perioperative covert stroke|
2473488|NCT03081429||Postoperative cognitive dysfunction|
2473516|NCT03081052|Active Comparator|Lung transplant with iNO|
2473522|NCT03081052|Active Comparator|Lung transplant with iEPO|
2473527|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iNO|
2473528|NCT03081052|Active Comparator|Heart transplant & LVAD implantation with iEPO|
2473576|NCT03080701|No Intervention|Group 1 - Automated Mailing|The mailing process will be identical to those used in the SOS study. Mailing 1 includes an introductory letter on CRC screening and a pamphlet on CRC testing choices (colonoscopy every 10 years, FIT testing yearly, or flexible sigmoidoscopy every 10 years combined with interval FIT testing), and pros and cons of each. The letter will state that they will soon be receiving a FIT kit in the mail, and a number to call if they prefer another option. Mailing 2 includes a brief letter reaffirming the importance of screening, a FIT kit (the one used by Group Health), pictograph instructions, and a postage-paid return envelope. Mailing 3 a reminder letter, is sent to participants not completing the FIT kit after 3 weeks. The intervention for Group 1 includes no incentive.
2473577|NCT03080701|Experimental|Group 2 - Auto Mailing Plus Money|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will receive a monetary thank you gift for completing testing (FIT colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the monetary thank you gift for CRC screening completion. Mailing 4 will include the money with a thank you letter for those who complete the screening
2473637|NCT03080350|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
2494225|NCT02940821|Active Comparator|Whitening and Dentifrice|
3192285|NCT00807066|Active Comparator|B|Platinum based chemotherapy
3192286|NCT00807079|Experimental|single arm|
3192287|NCT00807105|Experimental|depressive patients|patients suffering from deppresion
3192288|NCT00807118|Experimental|A (Cohort I)|
3192289|NCT00807118|Experimental|B (Cohort I)|
3192290|NCT00807118|Experimental|C (Cohort I)|
3192291|NCT00807118|Experimental|B (Cohort II)|
3192292|NCT00807118|Experimental|D (Cohort II)|
3192293|NCT00807118|Experimental|E (Cohort II)|
3192294|NCT00807131|Experimental|1|Patient follow-up
3192295|NCT00807131|Experimental|2|Counseling
3192296|NCT00807131|Experimental|3|Drug dispensing
2473069|NCT03084016||Acute asthma exacerbation|Recruited in secondary care when presenting with acute asthma exacerbation.
2473071|NCT03084016||At risk of acute asthma exacerbation|Recruited in outpatient clinics. Acute exacerbation within the previous 12 months.
3192297|NCT00807131|Active Comparator|4|pharmacy usual care
3192298|NCT00807157|Placebo Comparator|2|Every morning subjects will consume a stick of placebo during 30 days
2473252|NCT03083028|Active Comparator|Non Operative|"Non-Operative~Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon."
2473256|NCT03083028|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks
2473298|NCT03082495|Experimental|Exercise|Aerobic exercise
2473301|NCT03082495|No Intervention|Usual Care|Standard medical care
2473441|NCT03082170|Other|Data review|The investigators will go over the data from the test summary of participants who have already undergone post operative swallowing assessment.
2473444|NCT03082170|Experimental|FEES and SDQ|The participants will undergo six months or more after surgery swallowing assessment which will include the FEES test and the SDQ questionnaire.
2473500|NCT03081286|Experimental|Fat grafting|Following liposuction the fat is decanted and used for fat grafting to the area of pain after breast cancer surgery.
2473501|NCT03081286|Sham Comparator|Sham grafting|Following liposuction the fat is discarded. Instead approximately 50mL of saline is used instead of fat and injected into the area of pain after breast cancer surgery.
2473608|NCT03080844|Experimental|Practice|Participants will be asked to delay time to smoking first cigarette of the day for up to two weeks.
2473616|NCT03080844|Active Comparator|No Practice|Participants will continue with their normal smoking behavior.
2473710|NCT03080077|Active Comparator|Epi-Off CXL|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
2473712|NCT03080077|Experimental|Epi-On CXL|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
2473743|NCT03079466|Active Comparator|Treatment CPAP|A group treated with CPAP
2473745|NCT03079466|Sham Comparator|group without treatment|
2473780|NCT03079219|Experimental|Experimental|Aprepitant, Ondansetron, Dexamethasone and Olanzapine
2473781|NCT03079219|Other|Standard|Aprepitant, Ondansetron, Dexamethasone
2473906|NCT03078790|Experimental|meditation module|The patients in this arm will be offered the meditation/deep breathing module in the pre-operative area.
2473954|NCT03078101|Experimental|Group A|Diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
2473955|NCT03078101|Placebo Comparator|Group B|Diabetic CKD patients receiving Placebo Oral Tablet
2473957|NCT03078101|Experimental|Group C|Non-diabetic CKD patients receiving Empagliflozin 10 MG [Jardiance]
2473958|NCT03078101|Placebo Comparator|Group D|Non-diabetic CKD patients receiving 'Placebo Oral Tablet
3192299|NCT00807157|Experimental|1|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
3192300|NCT00807170|Experimental|ZACTIMA TM|
2474100|NCT03077139|Experimental|Arms|Pacing wires used to stimulate ventricles in a synchronous matter
2474148|NCT03076788||Athletes|"Professional and amateur athletes examined during the medical follow-up at the medical sport centre of Caen University Hospital.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
2474153|NCT03076788||Sedentary controls|"Sedentary patients assessed in the cardiology unit with a normal heart function.~The medical examination consists in a clinical exam, an electrocardiogram and an echocardiography."
2474196|NCT03076424||1|Obese patients (BMI greater than or equal to 30 kg/m2) with Type 2 Diabetes Mellitus.
2474198|NCT03076424||2|Obese patients (BMI greater than or equal to 30 kg/m2) without Type 2 Diabetes Mellitus.
2474199|NCT03076424||3|Normal weight lean controls without Type 2 Diabetes Mellitus.
2474213|NCT03076047||end tidal CO2 (ETCO2) monitoring|We will continuously record capnography data from the patients while they are in the post-anesthesia care unit (PACU). Study personnel will visit each patient while the patient is in the PACU to promote compliance with continuous CO2 monitoring.
3192301|NCT00807183|Placebo Comparator|Tx1|Inactive air filter
3192302|NCT00807183|Experimental|Tx2|New EPA-certified woodstove
2474469|NCT03074422|No Intervention|Control|Local anesthesia after clear and complete information of the procedure given the day prior to the surgery. In order to determine the pain perceived during the procedure, a VAS questionnaire will be used, directly after the frame disposal. The rest of the procédure is similar to the hypnosis group.
3192303|NCT00807183|Experimental|Tx3|Active air filter
3192304|NCT00807196|Experimental|T|
3192305|NCT00807222|Active Comparator|lisdexamfetamine dimesylate|30, 50, or 70 mg
3192306|NCT00807222|Placebo Comparator|placebo|
3192307|NCT00807287|Experimental|1|Placement of jejunal feeding tube using the unguided frictional method
2473278|NCT03082729|Other|Apremilast|Apremilast (Otezla), 30mg oral tablet twice per day for 52 weeks. Single arm, open label study.
2473329|NCT03082274||Men age 40-85 years with an initial negative prostate biopsy|Men age 40 - 85 years of age Previous negative prostate biopsy within 30 months.
2473391|NCT03081988||Responder|"Complete Remission after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
2473395|NCT03081988||non-responder|"Progressive disease or stationary state after chemoradiotherapy in locally advanced or advanced esophageal cancer~evaluation of disease status: endoscopy, CT, and/or PET-CT"
2473538|NCT03081130||Intravenous laser irradiation treatment|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with intravenous laser irradiation of blood (ILIB) via an intravenous catheter for irradiation of the blood under a period of 60 minutes for 10 days.
2473547|NCT03081130||control|We will recruit 30 poor ovarian responders and thin endometrium patients and treat with oral estradiol 8 mg per day and oestrogen gel 4 g per day for 14 days
2473583|NCT03080766|Experimental|decitabine|"Decitabine is a white to almost white powder for concentrate for solution for infusion. It is supplied as a lyophilized preparation in a clear colorless 20ml glass vial containing 50 mg decitabine.~The concentrate should be aseptically reconstituted with 10 ml of water for injections. After reconstitution, the concentrate must be diluted within 15 minutes using cooled infusion fluids and completely administered to patients within 5 hours.~The drug will then be administrated intravenously.~Dosage 20 mg/m2~28-day course, for each course, receive decitabine for 10 days"
2473605|NCT03080363|Active Comparator|Quadratus Lumborum Block|Ultrasound guided Quadratus Lumborum Block with 10 ml %0.5 bupivacaine and 10 ml %2 lidocaine
2473607|NCT03080363|No Intervention|Group Control|No intervention
2473698|NCT03080116|Experimental|ARN-509 + degarelix|Treatment period of 12 weeks before RP + PLND.
2473702|NCT03080116|Active Comparator|placebo + degarelix|Treatment period of 12 weeks before RP + PLND.
2473752|NCT03079453|Active Comparator|Group 1|The patients in Group 1 (n:15) were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly at three points (three points on the connection of the uvula, and palatum molle) before tonsillectomy .
2473756|NCT03079453|No Intervention|Group 2|Group 2 (n:15) patients had tonsillectomy without dexamethasone injection.
2473812|NCT03079128|Experimental|Intervention|Weight Watchers Intervention
2473984|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
3157664|NCT00370383|Experimental|Erlotinib|Erlotinib administered orally once daily. Erlotinib - [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-y]- (3-ethynyl-phenyl)amine hydrochloride, molecular weight 393.4. This is a small molecule that competes with the binding of ATP to the intracellular tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and blocking downstream signal transduction.
3157665|NCT00370409|Experimental|1|Cryotherapy
2474102|NCT03077087|Experimental|Single-stage Integra|"Composed of a porous collagen-chondroitin 6-sulfate fibrillary mat covered with a thin sheet of silastic, it serves to cover wound beds of freshly excised burns and allow for the infiltration of fibroblasts, capillaries, and macrophages, essentially creating a neodermis while also acting as a barrier against infection and a blockade against heat and moisture loss"
3157666|NCT00370409|Placebo Comparator|2|
3157667|NCT00370448|Experimental|1|Training gatekeeper recruited from students and tutors and counselors
3157668|NCT00370448|Active Comparator|2|
3157669|NCT00370448|No Intervention|3|
3157670|NCT00370500|Experimental|A|There is only one arm in this study. All probands receive quetiapine.
3157671|NCT00370513|Experimental|Pazopanib Arm|Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
3157672|NCT00370591|Experimental|Arm 1|
3157673|NCT00370604|Experimental|1|19g needle, 23g catheter
3157674|NCT00370604|Active Comparator|2|traditional =>18g needle
3157675|NCT00370721|Experimental|I|
3157676|NCT00370747|Experimental|Ecabet|Ophthalmic solution in the Study eye four times daily for 90 days.
3157677|NCT00370747|Placebo Comparator|Placebo|Ophthalmic solution in the Study eye four times daily for 90 days.
3157678|NCT00370760|Active Comparator|1|
3157679|NCT00370760|Placebo Comparator|2|
3157680|NCT00370786|Experimental|1|
3157681|NCT00370799|Active Comparator|local anesthetic|Group 1. local anesthetics only
3157682|NCT00370799|Active Comparator|Local anesthetic with generic Celestone|Group 2. local anesthetic with 6mg of non-particulate Celestone
3157683|NCT00370799|Active Comparator|Local anesthetic with Celestone|Group 3. local anesthetic with 6 mg of brand nameCelestone
3157684|NCT00370799|Active Comparator|Local anesthetic with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
3157685|NCT00370812|Active Comparator|A|AMT with conventional medical therapy
3157686|NCT00370812|Active Comparator|B|Medical treatment alone
2473261|NCT03082807|Experimental|Study group I|Study group I (18 participants) received the NCD with exercise (NCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2473262|NCT03082807|Experimental|Study group II|Study group II (19 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2473291|NCT03082417|No Intervention|Pre-Implementation|"Medical records of patients with a fracture visiting the Emergency departments will be reviewed.~Data will be collected as a baseline prior to the intervention regarding how nurses and physicians working at Emergency Departments manage acute pain in targeted population."
2473294|NCT03082417|Experimental|Implementation|"In this stepped-wedge trial design, the experimental arm refers to the time period during patients advertising and educational interventions. It consists in:~Informing patients visiting Emergency department for fracture about Pain Management Nurses and physicians working at the Emergency Departments will receive an educational interventions focused on optimal acute pain management in older adults with fracture."
2473302|NCT03082417|No Intervention|Post-Implementation|Data will be collected after the intervention regarding how the intervention impacted nurses' and physicians' work in the pain management in older adults with fracture visiting Emergency Departments manage acute pain in older adults.
2473379|NCT03082157|Experimental|Mighty Men Intervention|Mighty Men weight-loss intervention including health education and exercise during small group sessions
2473380|NCT03082157|No Intervention|Comparison|Exercise-only small group sessions
2473426|NCT03081754||IUGR|Fifty women with intrauterine growth restricted fetuses were included in the study. Gestational age was based on the precisely dated last menstrual period and ultra-sonographic examination of crown-rump length in the first trimester. Intrauterine growth restriction was diagnosed when fetal abdominal circumference was more than two standard deviations below the mean for gestational age and also confirmed by the serial assessment of the fetal growth parameters (Chitty and Altman, 1999). Detailed obstetric history was available for each patient. Caesarean sections were performed on clinical grounds
2473427|NCT03081754||control group|Twenty five uneventful pregnancies with appropriate for gestational age fetuses are selected as control. Obstetric history Doppler results and placenta were examined for any remarkable pathology. Caesarean sections were performed on clinical grounds. The indications for Caesarean section of the controls, which were tried to be at equivalent gestational ages with the study group, were presentation abnormalities or previous Caesarean section
2473532|NCT03081442|Active Comparator|Misoprostol group|Sixty women received 600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion.
2473534|NCT03081442|Placebo Comparator|placebo group|Sixty women received the placebo vaginally six hours before IUD insertion. Placebo is the same in size, color and shape to misoprostol.
2473601|NCT03080298|Experimental|Treatment with BP101|
2473602|NCT03080298|Placebo Comparator|Treatment with placebo|
3157687|NCT00370851|Experimental|1|Intravitreal injection of Avastin
3157688|NCT00370851|Sham Comparator|2|
2473735|NCT03079440|Experimental|TEMCAP|Temozolomide plus Capecitabine
2473783|NCT03079245|Other|NICU A - E+, CDS, and PAF|This site was assigned to three interventions, Education Plus (E+), Clinical Decision Support (CDS), and Prescriber Audit and Feedback (PAB).
2473784|NCT03079245|Other|NICU B - E+ and CDS|This site was assigned to two interventions, Education Plus (E+) and Clinical Decision Support (CDS).
2473785|NCT03079245|Other|NICU C - E+|This site was assigned to one intervention, Education Plus (E+).
2473786|NCT03079245|No Intervention|NICU D - Usual Care|This site was not introduced to an interdisciplinary intervention.
2473799|NCT03078855|Experimental|Vitamin D plus rituximab|
2473801|NCT03078855|Placebo Comparator|Placebo plus rituximab|
2473899|NCT03078634|Active Comparator|Multi-Disciplinary clinic|
2473901|NCT03078634|Placebo Comparator|Standard Gastrointestinal clinic|
2474085|NCT03077100||Newborns with positive cultures|Positive cultures of newborns hospitalized in the NICU in the past 5 years will undergo laboratory examination and identification
2474120|NCT03076931|Experimental|Study: Airway Reconstruction Patients|These participants have significant airway abnormalities that require invasive surgery, such as Laryngotracheoplasty, to rectify, and whose voice quality may suffer as a result of the surgery. The goal of this study is to improve voice outcomes of these patients, and their clinical data will be collected.
2474123|NCT03076931|Experimental|Control: Normal Airway Patients|These participants have normal airways and voice who will undergo a microlaryngoscopy and voice evaluation, the data from which will be compared to study patients.
2474202|NCT03076450|Active Comparator|Maximum Oxygenation|Using PVC to set the initial peep, check ABG real-time, and according to PaO2+PaCO2≥400mmHg whether or not to adjust maintain PEEP.
2474203|NCT03076450|Experimental|Lung Ultrasound Re-aeration Score|Combine POC-LUS with PVC in set the initial peep, and then dynamic record LUS-RAS to feedback regulate PEEP.
2474276|NCT03075995|Experimental|lapatinib administered with hight-fat breakfast|
2474314|NCT03075397|Other|HIV-1 infected patients|Blood sample and sperm sample are collected
2474523|NCT03074032|Experimental|ONC1-0013B 80 mg|ONC1-0013B 80 mg per os daily
3157689|NCT00370877|Active Comparator|Standard care for post-partum hemorrhage|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage.
3157690|NCT00370877|Experimental|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
3157691|NCT00370890|Experimental|A|Adjuvant chemotherapy and then clinical follow-up and surveillance
2473266|NCT03082781|Experimental|Study group II|Study group II (54 participants) received the low-calorie diet with exercise (LCDsport). This groups had 5% caloric restriction from their maintenance energy requirements and 10% increase in energy expenditure through structured regular exercise.
2473321|NCT03082391|Active Comparator|Heavyweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a heavyweight mesh.
2473326|NCT03082391|Active Comparator|Mediumweight Mesh|Intervention: Patients will undergo ventral hernia repair with implantation of a mediumweight mesh.
2473414|NCT03081936|Active Comparator|A1 formula|Oral consumption of Nutricia Aptamil Stage 1 formula (traditional cow milk)
2473416|NCT03081936|Experimental|A2 formula|Oral consumption of a2® Platinum Stage 1 formula (containing 100% A2® beta -casein)
2473418|NCT03081936|Active Comparator|Breast feeding|Oral consumption of breast milk
2473442|NCT03081559|Experimental|Intervention|Healthy Divas intervention
2473445|NCT03081559|No Intervention|Control|Treatment as usual
2473480|NCT03081299||Total Knee Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473483|NCT03081299||Total Hip Arthroplasty|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473485|NCT03081299||Mastectomy|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473487|NCT03081299||Thoracic Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473489|NCT03081299||Major Abdominal Surgery|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473490|NCT03081299||Spinal Fusion|Descriptive multidimensional tools (the Defense and Veterans Pain Rating Scale (DVPRS) and the electronic Pain Assessment Screening Tool and Outcomes Registry (PASTOR) will be used preoperatively, as an inpatient, and up to 6 months postoperatively.
2473495|NCT03081039|Active Comparator|Arm A|Cisplatin or Carboplatin with Gemcitabine for 6 cycles
2473496|NCT03081039|Active Comparator|Arm B|Gemcitabine alone for 6 cycles
2473560|NCT03080922|Experimental|hematopoietic stem cell|high dose of donor granulocyte colony-stimulating factor（G-CSF）mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
3192308|NCT00807287|Active Comparator|2|Jejunal tube placement using the endoscopic method
3192309|NCT00807300|Active Comparator|brachytherapy|
2473721|NCT03079765|Experimental|Baseline|Participants will be given a written protocol for conducting the relevant assessment procedure (e.g., open-ended interview).
2473724|NCT03079765|Active Comparator|Telehealth Treatment|Participants will receive feedback and error correction on their implementation of the relevant assessment procedure to improve their performance.
3192310|NCT00807300|Other|TACE|transarterial chemoembolization
3192311|NCT00807313||At best response|Patients with oligometastatic colorectal cancer, who presents at best response under chemotherapy, will receive stereotactic body radiotherapy on their residual disease
3192312|NCT00807313||No indication for chemotherapy|Patients with oligometastatic colorectal cancer, who are progressive under chemotherapy or who are no candidates for (further) chemotherapy, will receive stereotactic body radiotherapy on the sites of disease.
2473837|NCT03078842|Active Comparator|Zinc-20|Zinc tablets, 20 mg per day
2473842|NCT03078842|Experimental|Zinc-10|Zinc tablets, 10 mg per day
2473844|NCT03078842|Experimental|Zinc-05|Zinc tablets, 5 mg per day
3192313|NCT00807326|Experimental|Loperamide/simeticone Caplets|Drug (including placebo)
3192314|NCT00807326|Active Comparator|Loperamide/simeticone Chewable Tablets|Drug (including placebo)
2474242|NCT03076073|No Intervention|Evaluating Tendons Structures|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures
2474244|NCT03076073|Active Comparator|Impact of physical activity on tendons|Ultrasound measurements of Patellar Tendon and Achilles Tendon Structures following different types and different intensity of physical activity
2474266|NCT03075709||Experimental - CPW (Urban)|We are working with Regina Qu'Appelle Health Region (RQHR), a primarily urban health region, to develop and implement a clinical pathway (CPW). The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
2474267|NCT03075709||Experimental - CPW (Rural)|Following implementation in RQHR a rural health region will be chosen as an intervention site for a second CPW. The CPW will improve care through the following steps: standardizing diagnostic, coordinating and unifying common components of chronic disease care, coordinating the provision of education and reconditioning programs, and ensuring disease specific care utilizes and delivers evidence-informed practices.
2474268|NCT03075709||Control - Standard Care (Urban)|Saskatoon Health Region (SHR) will act as the urban control site. No attempts will made to alter care in SHR and therefore patients will continue to receive the current standard of care.
2474269|NCT03075709||Control - Standard Care (Rural)|Following implementation in RQHR a rural health region will be chosen to act as the rural control site. No attempts will made to alter care in this health region and therefore patients will continue to receive the current standard of care.
3192315|NCT00807326|Active Comparator|Probiotic Capsules|Drug (including placebo)
3192316|NCT00807339|Experimental|1|Phase I dose escalation
3192317|NCT00807352||level 2|Patients triaged level 2
3192318|NCT00807352||level 3|patients triaged level 3
3192319|NCT00807352||level 4|patients triaged level 4
3192320|NCT00807352||level 5|patients triaged level 5
3192321|NCT00807378||1|AIDS PATIENTS
2473324|NCT03082534|Experimental|Cohort 3|"PD-1/PD-L1 inhibitor-refractory, cetuximab-refractory~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
2473325|NCT03082534|Experimental|Cohort 4|"cutaneous HNSCC~Pembrolizumab (Keytruda®):~Pembrolizumab is administered on an outpatient basis. 200 mg pembrolizumab will be administered as a 30 minute (-5 min/+10 min) intravenous (IV) infusion every 3 weeks.~Cetuximab (Erbitux®):~The initial cetuximab dose of 400mg/m2 is administered on Cycle 1, Day 1 as a 120-minute IV infusion (maximum infusion rate 10mg/min).1 Subsequent weekly cetuximab doses of 250mg/m2 are administered as 60-minute IV infusions (maximum infusion rate 10mg/min)."
3192322|NCT00807378||2|NON-AIDS PATIENTS
2473491|NCT03081416|Experimental|Intranasal Ketamine arm|Intranasal ketamine administered to participant
2473492|NCT03081416|Active Comparator|Standard Therapy|Reglan 10 mg; Benadryl 25 mg administered to all participants Toradol 15-30 mg; dexamethasone 10 mg added at treating providers discretion.
2473619|NCT03080545|Experimental|Open Label Enstilar|open label
2473699|NCT03080090|Experimental|High Intensity Exercise|Individuals in this condition will engage in aerobic exercise 3 times a week for 25 minutes each at 60% to 85% of age-predicted HRmax and smoking cessation intervention through a national quitline while using nicotine replacement patches.
2473703|NCT03080090|Active Comparator|Low Intensity Exercise|The intervention procedures for this group are identical to the Experimental Group group except that the target training intensity will be low intensity exercise, self-selected at 20% to 40% of age-predicted HRmax.
2473823|NCT03079154|Experimental|Teacher-led MBCT course|Eight-session mindfulness-based cognitive therapy course, including an initial orientation session, led by a qualified mindfulness teacher working with the Sussex Mindfulness Centre, a part of the NHS Sussex Partnership Mental Health Trust.
2473825|NCT03079154|Active Comparator|Self-guided MBCT course|Mindfulness-based cognitive therapy course, after an initial information session, which is self-guided using the audiobook Mindfulness: A practical guide to finding peace in a frantic world by Mark Williams and Danny Penman (2011). It consists of eight substantive chapters that map on to the eight-session MBCT course taught by teachers to groups of students. Students will be asked to work through one chapter a week, thus matching the pace of the teacher-led intervention.
2473838|NCT03079154|No Intervention|Wait list control|Students in the wait list (control) arm do not receive any intervention for the same length of time as the experimental and active comparator arms of the intervention are taking place. Students are invited to complete the self-guided MBCT course after the end of the research project.
2473895|NCT03078569|Experimental|testosterone gel|testosterone gel treatment group
2473897|NCT03078569|No Intervention|Control group|without testosterone treatment
2473962|NCT03078114|Experimental|Spinal Manipulation|Subjects with subacute low back pain. Subjects will receive 6 treatments of Spinal Manipulation (SM) over 2 consecutive weeks
2473965|NCT03078114|Placebo Comparator|Placebo Spinal Manipulation|Subjects with subacute low back pain. Subjects will be asked to visit the clinic for 6 times. The clinician will go through SM motions but the spine will not actually be manipulated.
3192323|NCT00807391|Other|TBCA/TBNA|Under fluoroscopy first transbronchial forceps biopsy is performed, afterwards in random order transbronchial catheter aspiration(TBCA) and transbronchial needle aspiration (TBNA).
3192324|NCT00807430|Experimental|1|24 patients receiving active treatment
2474087|NCT03077113|Other|Ventilation Images for Comparison|"Standard of Care: 4-D CT scan will be used to make a radiation treatment plan.~SPECT-CT Scan: This second scan will be done on another day to make a treatment plan for comparison to the first plan."
2474139|NCT03076892|Active Comparator|Conventional PDT|Aktilite® Galderma
2474140|NCT03076892|Experimental|PHOS ISTOS PDT|Light Emitting textile device
2474190|NCT03076541||patients with restless legs syndrome|
2474207|NCT03076125|Experimental|SCORRE group|Stroke risk factor brochure, stroke champions video, counseling on accuracy of perceived stroke risk and strategies to reduce stroke risk, weekly motivational health behavior tips (for physical activity, diet, or smoking cessation) text messages for 8 weeks.
2474209|NCT03076125|Sham Comparator|Attention Control Group|Sexual health education brochure and Safe in the City video, weekly sexual health tips text messages for 8 weeks.
2474287|NCT03075930||Extended Electrocardiogram|Elective patients receiving an AF ablation receiving a extended ECG
2474290|NCT03075930||Body surface potential map|Elective patients receiving an AF ablation receiving a body surface potential map
2474347|NCT03075254|Active Comparator|Healthy Control|normal volunteers (HC) Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2494234|NCT02940821|Active Comparator|Whitening Dentifrice|
3192325|NCT00807430|Placebo Comparator|2|Placebo treatment
3192326|NCT00807443|Experimental|Raltegravir|
3192327|NCT00807469||1|20 healthy individuals not susceptible for COPD (age 18-40 years, >0>10 packyears, FEV1/VC >70%, FEV1 >85% predicted)
3192328|NCT00807469||2|20 healthy individuals susceptible for COPD (age 18-40 years >20 packyears, FEV1/VC >70%, FEV1 >85% predicted) and high prevalence of COPD in smoking family members older than 45 years
3192329|NCT00807469||3|20 healthy individuals very susceptible for COPD (age 18-40 years, > 0 > 10 packyears, FEV1/VC >70%, FEV1 >85% predicted), and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
3192330|NCT00807469||4|30 healthy individuals not susceptible for COPD (age 40-75 years, >20 packyears, FEV1/VC >70%, FEV1 >85% predicted)
3192331|NCT00807469||5|30 COPD patients with GOLD stage II (age 40-75 years, >10 packyears, FEV1/VC <_70%, FEV1 50-80% predicted)
3192332|NCT00807482||1|People who have been definitively diagnosed with primary ciliary dyskinesia (PCD).
2473422|NCT03081767|Other|Patients undergoing digital PET/CT|Single arm prospective study of paired imaging studies. Patients who are referred to Nuclear Medicine and are scheduled to undergo imaging on the standard PET/CT will also have imaging performed on the digital PET/CT.
2473462|NCT03081481|Experimental|PRX302|intraprostatic administration
2473506|NCT03081065|Experimental|Mediterranean Diet+ extra virgin olive oil|Free supply with extra virgin olive oil and nuts plus educational advice
2473508|NCT03081065|Experimental|Mediterranean Diet+ tree nuts|Free supply with tree nuts plus educational advice
2473509|NCT03081065|No Intervention|Control|Usual care
2473592|NCT03080870|Experimental|Intervention|"Art groups are held once a week, each with the duration of 60 minutes. They begin with a 45 minute art intervention and conclude with a 15 minute discussion. The art groups include music, dance and visual arts, which is psychologically, socially, and physically activating. Music has the main emphasis in art intervention. The preferences of the subjects are taken into consideration in art intervention. Art intervention is conducted by trained and experienced art pedagogues.~Art intervention aims to revive previously learned art-related skills, to learn and enhance new skills, and to improve and intensify physiological, emotional, social, motoric, and cognitive abilities."
2473593|NCT03080870|No Intervention|Control|Baseline and follow-up measurements.
2473624|NCT03080272||Spinal Surgery|No intervention will take place. Recruiting Autumn 2017 until spring 2018
2473625|NCT03080272||Gastric sleeve|No intervention will take place. Recruiting Autumn 2017 until spring 2018
2473627|NCT03080272||Total knee arthroplasty|No intervention will take place. Recruiting Spring 2018 until Summer 2018
2473633|NCT03080272||Shoulder arthroplasty|No intervention will take place. Recruiting Winter 2017 until Summer 2018
2473636|NCT03080272||Maxillofacial surgery|No intervention will take place. Recruiting 6 march 2017 until Autumn 2017
2473705|NCT03079934||Absorb-BVS|Bioresorbable vascular scaffold implantation
2473741|NCT03079557|Experimental|Intragastric botulinum toxin type A|Botulinum toxin A (Allergan) injected intragastrically in the antrum
2473833|NCT03079232|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
2473839|NCT03079232|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
2473862|NCT03078517|Active Comparator|I-gel group|After the induction of anesthesia, I-gel is inserted into the oropharyngeal space.
2473870|NCT03078517|Experimental|LMA protector group|After the induction of anesthesia, laryngeal mask airway protector is inserted into the oropharyngeal space.
2473892|NCT03078348|Active Comparator|Targeted Psychoeducational Photo Novella|"Fecal Immunochemical Test (FIT) Kit + Culturally targeted Photo Novella Booklet + culturally targeted reminders. This study involves participation at distinct time points:~Baseline~6 month follow-up"
2473894|NCT03078348|Active Comparator|Standard Brochure Intervention|"FIT Kit + Screen for Life Brochure + standard reminders. This study involves participation at distinct time points:~Baseline~Post 6 month follow-up"
2473959|NCT03078153|Experimental|Financial Incentive|Provided financial incentive at 3-month and 6-month follow-up visits
2473960|NCT03078153|Experimental|Social Media Group|Provided social media support through a facebook group for 6 months
2473964|NCT03078153|No Intervention|Control|No intervention
2473991|NCT03077737|Experimental|Population health management|Population health management for smoking cessation in low-income smokers: the Choose to Change intervention
2473993|NCT03077737|Active Comparator|Enhanced usual care|Usual clinic-based care enhanced by an EHR system that can deliver an electronic referral for quitline treatment
2474083|NCT03077204|Other|BIO4 treatment|Patients undergoing 1 or 2-level Anterior Cervical Discectomy and Fusion (ACDF) spine surgery utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).
3192333|NCT00807508|Experimental|1|daily leucine supplementation
2474251|NCT03076385|Experimental|VAL-506440|
2474252|NCT03076385|Placebo Comparator|Placebo|
2474313|NCT03075358|Experimental|Lidocaine spray|
2474317|NCT03075358|Sham Comparator|Normal saline spray|
2474320|NCT03075358|No Intervention|No spray|
2474342|NCT03075124|Experimental|External Counter Pulsation group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2474344|NCT03075124|No Intervention|Control group|Guideline-driven standard medical treatment
2474393|NCT03074877|Experimental|Family Check-Up (FCU)|"Families recruited in Year 1 who are randomized to the FCU group will be provided with the Family Check-Up (FCU) after the initial in-home assessment and after 1 year follow-up assessment. The FCU is a brief (i.e., typically 3-5 sessions per year) family-centered intervention. The FCU intervention process consists of 3, and in some cases, 4 components: a) family assessment, b) a Get to Know You session, c) feedback, and d) follow-up treatment sessions."
2474404|NCT03075241|Placebo Comparator|Placebo|Study group will receive inactive or inert capsules, which will be used as a comparator, 10pm (before bedtime) for 14 nights
2474525|NCT03074032|Experimental|ONC1-0013B 160 mg|ONC1-0013B 160 mg per os daily
2473382|NCT03081975|Active Comparator|HD white light|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
2473386|NCT03081975|Active Comparator|HD narrow band imaging|Colonoscopy was performed by use of HD-WLC or HD-NBI upon withdrawal
2473453|NCT03081728|Experimental|block|will be given block and continuous infusion with bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
2473455|NCT03081728|Experimental|control|IV analgesia only with diclofenac and paracetamol
2473533|NCT03081208|Experimental|Nolasiban 900 mg|
2473537|NCT03081208|Placebo Comparator|Placebo|
2473638|NCT03080467||Suture|Wound repair with suture
2473643|NCT03080467||Tissue adhesive|Wound repair with tissue adhesive
2473676|NCT03079986|Experimental|Ignoring CL (group A)|Standard care irrespective of CL.
2473678|NCT03079986|Active Comparator|Dietary treatment (group B)|Dietary treatment with medium-chain triglyceride diet (MCT-diet) until resolution of CL.
2473736|NCT03079635|Active Comparator|Normal Weight|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
2473738|NCT03079635|Active Comparator|Overweight and Obese|This group will be administered two breakfast beverages with a one- to two-week washout period between beverages. The beverages will be a control or an isocaloric, macronutrient matched breakfast beverage with omega-3 fatty acids.
2473820|NCT03079206|Experimental|Hazelnut allergy|patients with positive case history of hazelnut allergy and a positive skin testing are undergoing a food challenge and blood sampling for basophile activation testing
3157692|NCT00370890|No Intervention|B|Clinical follow-up and surveillance only
3157693|NCT00370916|Experimental|Arm 1|Physician-initiated medication reconciliation
3157694|NCT00370916|Experimental|Arm 2|Pharmacist-initiated medication reconciliation
3157695|NCT00370916|No Intervention|Arm 3|No formal medication reconciliation
3157696|NCT00370929|Experimental|Meditation|
2474073|NCT03077282|Experimental|group1|Group1 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 100 mg three times a day before meals (for 6 weeks)
2474074|NCT03077282|Experimental|group2|Group2 will take Prasaprohyai 95% ethanolic extract capsules at a dose of 200 mg three times a day before meals (for 6 weeks)
2474121|NCT03077074|Experimental|Low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
2474163|NCT03076684|Experimental|low-fructose diet|Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
2474169|NCT03076684|Experimental|allopurinol treatment|Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
2474176|NCT03076684|No Intervention|control arm|After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.
2474220|NCT03076255|Experimental|Supportive care (MID)|Patients undergo Computed Tomography (CT) simulation with thermoplastic mask and maskless immobilization device (MID) for radiation therapy (RT) planning on day 1. Patients undergo standard of care RT using thermoplastic mask only and cone-beam computed tomography (CBCT) imaging with thermoplastic mask and MID on day 8 and 15.
2474255|NCT03075787||patients with obstructive sleep apneas|
2474387|NCT03075007||Group A|All participants will undergo an amyloid PET scan with Florbetaben F 18 contrast as well as a transcranial Doppler ultrasound.
2474440|NCT03074617|Experimental|LTE field|
2474441|NCT03074617|Sham Comparator|sham field|
2474484|NCT03074279||Cases|Patient with epilepsy who died as a result of confirmed or probable SUDEP and NEAR SUDEP during the study period.
2474490|NCT03074279||Controls|Patient with epilepsy matched by: âge, etiology and type of epilepsy, level of seizure control
2474519|NCT03074006|Experimental|low dose|
2474522|NCT03074006|Experimental|high dose|
2474602|NCT03073694|Active Comparator|Mitomycin C Group|Mitomycin-C initial dose of 15 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion, a maintenance dose of 5 mg/m2 will be administered.
3157697|NCT00370942|Placebo Comparator|GW823093C A|A=45 mg
3157698|NCT00370942|Placebo Comparator|GW823093C B|B=30 mg
3157699|NCT00370942|Placebo Comparator|GW823093C C|C=15 mg
3157700|NCT00370955|Active Comparator|High vacuum group|Those patients who underwent phacoemulsification using high hydrodynamic parameter: 400 mmHg vacuum and 40 ml/min flow rate.
3157701|NCT00370955|Active Comparator|Low vacuum group|Patients who underwent phacoemulsification using low hydrodynamic parameters: 200 mmHg vacuum and 20 ml/min flow rate.
3157702|NCT00370981|Experimental|0.15 mg|
3157703|NCT00370981|Experimental|0.30 mg|
3157704|NCT00370981|Experimental|0.60 mg|
3157705|NCT00370981|Placebo Comparator|PBO|
3157706|NCT00371033|Active Comparator|1|Pregabalin
3157707|NCT00371033|Placebo Comparator|2|Placebo
3157708|NCT00371085|Experimental|1|Video-based patient education on heart failure self care
3157709|NCT00371098|Experimental|active vaccine|patients received active influenza vaccine for season 2004/2005
3157710|NCT00371098|Placebo Comparator|placebo vaccine|patients received placebo influenza vaccine for season 2004/2005 containing all vaccine compounds except viral antigens
3157711|NCT00371111|Active Comparator|1|Intravitreal injection of Triamcinolone
3157712|NCT00371111|Active Comparator|2|Intravitreal injection of Avastin
2473383|NCT03081845|Experimental|Sequence A1-A2|Oral consumption of milk A1 in study phase 1. Oral consumption of milk A2 in study phase 2.
2473385|NCT03081845|Experimental|Sequence A2-A1|Oral consumption of milk A2 in study phase 1. Oral consumption of milk A1 in study phase 2.
2473447|NCT03081702|Experimental|Hydroxychloroquine and Itraconazole|"Hydroxychloroquine, orally (by mouth), at a dose of 100 mg, 200 mg, 400 mg, or 600 mg, twice a day, every day.~Itraconazole, orally (by mouth) at 300 mg, twice a day, every day."
2473517|NCT03081260|Other|Patellar resurfacing|Patellar resurfacing during the total knee prosthesis Anatomic surgery
2473524|NCT03081260|Other|Patellar non-resurfacing|Patellar non-resurfacing during the total knee prosthesis Anatomic surgery
2473584|NCT03080792|Experimental|Exercise|Exercise Intervention, moderate to high-intensity endurance and resistance exercise
2473609|NCT03080337|No Intervention|Traditional Care|If the participant is randomized to the individual prenatal care model, she will continue to receive individualized care in the prenatal clinic. This includes being seen by both a MFM specialist and possibly an endocrinologist at each prenatal visit. During the prenatal visit, the individual caregivers are responsible for discussing educational topics that they feel are relevant to the patient. Patients are seen every two weeks for Traditional Care.
2473617|NCT03080337|Experimental|Group Care|If the participant is randomized into the group prenatal care model she will be placed in a group of approximately 6-10 women of approximately the same gestational age. These women will then have sessions scheduled at the same intervals they would have had their traditional prenatal visits, every two weeks until 36 weeks and then weekly until delivery, 12 sessions in total. Each session will last between 90-120 minutes. In the group prenatal care model, the entire visit time will be face to face with a provider and the group. Billing will be done through the standard reimbursement system since the program will follow the schedule of prenatal visits recommended by the American Congress of Obstetricians and Gynecologist.
3157713|NCT00371163||Contact Dermatitis|Males or females with contact dermatitis
3157714|NCT00371163||Psoriasis|Males or females with psoriasis
2473750|NCT03079583|Placebo Comparator|Control-group|Control Rice used for meal, normal zinc level
2473753|NCT03079583|Active Comparator|Intervention-group|Biofortified Rice used for meal, around 30% higher zinc level
2473821|NCT03079063|Experimental|Eptacog alfa biosimilar for PK|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
2473826|NCT03079063|Active Comparator|Novoseven|Randomized, double-blind, single dose cross-over for PK, with 12 months follow up with eptacog alfa biosimilar provided for treatment of bleeding on demand - or - prophylaxis.
3192334|NCT00807508|Placebo Comparator|2|daily placebo supplementation
3192335|NCT00807521|Active Comparator|1|High dose bolus of dexamethasone before surgery
3192336|NCT00807521|Placebo Comparator|2|Placebo control
3192337|NCT00807534|Active Comparator|ipratropium bromide|acute bronchodilation: ipratropium bromide
2474094|NCT03077386|Experimental|ENCOMPASS program|Clinics assigned to the intervention will receive the ENCOMPASS intervention and a CHN will be matched to their clinic and be available to patients that meet the eligibility criteria.
2474097|NCT03077386|No Intervention|Usual care|Patients not enrolled in the intervention will continue to receive care as usual until their clinic receives the intervention.
2474151|NCT03076801|Experimental|Choral Singing Intervention|In addition to usual medical care, participants in the intervention group will participate in choral singing.
2474154|NCT03076801|No Intervention|Control|The control group will receive usual medical care only. If control group participants join an external singing group during the study period they will not be excluded, but this data will be collected and considered.
2474274|NCT03075865||OmniMax MMF|Patients involved in trauma events will receive intermaxillary fixation with OmniMax MMF system for temporary stabilization of mandibular fracture(s) to maintain proper occlusion during surgery and allow for postoperative fracture healing.
2474333|NCT03075345|Active Comparator|Treatment as usual (weight management intervention)|6 session weight management programme (over 12 weeks).
2474334|NCT03075345|Experimental|Treatment as usual plus acceptance and commitment therapy|6 session weight management programme (over 12 weeks) plus a 4 session acceptance and commitment therapy (ACT) programme. The ACT part will commence straight after the conclusion of the weight management programme.
2474372|NCT03074981|Experimental|Combined TopClosure & Vcare Alpha Treatment|"The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
2474434|NCT03074786|Experimental|Vaginal Matrix Ring|Dapivirine vaginal ring containing 25 mg of dapivirine to be replaced each month.
2474436|NCT03074786|Experimental|Oral Emtricitanbine/Tenofovir Disoproxil|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) tablets to be taken orally daily
3157715|NCT00371163||No skin disease|Males or females with no skin diseases
3192338|NCT00807534|Placebo Comparator|placebo|placebo nebulization
3192339|NCT00807547|Active Comparator|Allergy vaccination|Allergy vaccination by 6 subcutaneous injections to 10,000 SQ-U with 1-3 days intervals, continuation by 2 injections with 10,000 SQ-U with 2-4 weeks intervals
3192340|NCT00807547|Placebo Comparator|Subcutaneous injections|Placebo injections
3192341|NCT00807612|Experimental|Part 1 Cohort 1|AMG 479 at 18 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 18 mg/kg monotherapy for 24 months from study day 1
3192342|NCT00807612|Experimental|Part 1 Cohort 2|AMG 479 at 12 mg/kg in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 at 12 mg/kg monotherapy for 24 months from study day 1
2473384|NCT03082105|Experimental|Intermediate snow|Second test series breathing in dry/wet snow in intermediate season
2473387|NCT03082105|Experimental|Spring snow|Third test series breathing in very wet snow in spring
2473451|NCT03081715|Experimental|Experimental Group|"Peripheral blood lymphocytes will be collected and Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and reinfused back into patients. To avoid allergic reactions, 50 mg hydrocortisone was intravenously injected into the patient 30 min before cells infusion every time. Best supportive care was also provided for patients.~A total of 1 to 10 x 10^9 PD-1 Knockout T cells will be infused each cycle. Patients continued receiving treatment unless they had unacceptable adverse effects, or progressive disease confirmed by CT or they withdrew consent."
2473551|NCT03081247|Experimental|BGF 320/14.4/9.6 µg MDI BID|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
2473552|NCT03081247|Experimental|BFF 320/9.6 µg MDI BID|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
2473585|NCT03080649|Active Comparator|Rotary bur|Device rotary bur
2473588|NCT03080649|Experimental|Er:YAG laser|Device Er:YAG laser
2473612|NCT03080324|Experimental|Fentanyl sublingual + Placebo ev|Fentanyl 100 µg sublingual in acute sever pain + NaCl 0,9% endovenous to mimic fentanyl ev
2473618|NCT03080324|Active Comparator|Fentanyl ev + Placebo sublingual|Fentanyl ev in acute sever pain + Sugar pill manufactured to mimic fentanyl sublingual
2473665|NCT03079921|Active Comparator|Group 1-Propranolol Intra-hepatic islet|The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2473666|NCT03079921|Active Comparator|Group 1-Phentolamine Intra-hepatic islet|The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2473667|NCT03079921|Placebo Comparator|Group 1- Placebo Intra-hepatic islet|Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.
2473668|NCT03079921|No Intervention|Group 2 - Extra-hepatic islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
2473670|NCT03079921|No Intervention|Group 3 - Intra-hepatic auto islet|Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.
2473782|NCT03079284|Experimental|Holding Group|After meeting inclusion criteria and consenting to participation, mothers of infants who have completed at least 24 hours of therapeutic hypothermia treatment will be allowed to hold their infant who will remain on the cooling blanket for a 30-minute period with the use of a thermal barrier. Vital signs will be measured before holding begins, during holding and following completion of holding. Temperature will be recorded every two minutes during holding. Afterwards, a Likert scale questionnaire to assess the mother's and nurse's reactions will be administered.
2473832|NCT03078920|Other|11 unilateral adult cochlear implant users|Speech Reception Threshold (SRT) measured with an adaptive test
2473863|NCT03078673|Experimental|Motor skill training|training intervention. Poling specific indoor motor skill exercises performed 3 times pr week for 10 weeks in addition to regular training
2473871|NCT03078673|Experimental|Maximal strength training|training intervention. Maximal strength exercises performed 3 times pr week for 10 weeks in addition to regular training
2473873|NCT03078673|Experimental|Control group|Only regular training
2473896|NCT03078335|Experimental|Glove based care|The intervention is the use of non-sterile gloves, after standard hand hygiene for all routine patient care needs.
2473898|NCT03078335|Active Comparator|Standard care|The control group will provide standard care, that is, hand hygiene before all patient, bed, and intravenous catheter contact.
2473969|NCT03078088|Placebo Comparator|saline|normal saline
2473970|NCT03078088|Experimental|treatment|tham
3192343|NCT00807612|Experimental|Part 2|"AMG 479 in combination with paclitaxel/carboplatin for 4 to 6 cycles followed by AMG 479 monotherapy for 24 months from study day 1~(AMG 479 dose in Part 2 will be the final AMG 479 dose from Part 1)"
3192344|NCT00807625|Active Comparator|IUCD|Assigned to use a copper intrauterine device
3192345|NCT00807625|Active Comparator|DMPA|Assigned to use Depo Provera
2474106|NCT03077061|Active Comparator|Control - Open flap debridement|The surgical procedure includes flap elevation, debridement of the peri-implant defect and decontamination of the implant surfaces using saline for irrigation. Flaps are replaced in their original position and carefully sutured. Patients are provided with post-surgical information and thereafter called in for regular follow-up visits.
2474114|NCT03077061|Experimental|Test - Bone replacement graft|The surgical procedure is identical to the control procedure with the exception of the application of the bone replacement graft. Following decontamination, Bio-Oss Collagen® is placed into the peri-implant bony defect. Flaps are carefully sutured and patients are provided with the same information and follow-up as patients in the control group.
2474159|NCT03076710||Opioids delivered through PCA|PCA devices used to deliver opioids
2474167|NCT03076710||EXPAREL® infiltration|EXPAREL® infiltration at the site of surgery and nurse-administered opioid as needed
2474241|NCT03076242||Gem Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
3157716|NCT00371163||Atopic Dermatitis|Males of females with atopic dermatitis
2474335|NCT03075228||Lean subjects|Lean is defined as having a BMI of 19-23 kg/m2, waist circumference <80 cm and fasting glucose levels <6.1 mmol/L.
2474526|NCT03074032|Experimental|ONC1-0013B 320 mg|ONC1-0013B 320 mg per os daily
3157717|NCT00371189|Experimental|Group C: Ad35.CS.01-10^10 vp/ml|15 subjects will receive dosage 10^10 vp/mL; 3 subjects will receive placebo.
3157718|NCT00371189|Experimental|Group D: Ad35.CS.01-10^11 vp/ml|15 subjects will receive dosage 10^11 vp/mL; 3 subjects will receive placebo.
3157719|NCT00371189|Experimental|Group A: Ad35.CS.01-10^8 vp/ml|15 subjects will receive dosage 10^8 vp/mL; 3 subjects will receive placebo.
3192346|NCT00807677|Experimental|1|TAK-901
3192347|NCT00807703|Experimental|1|Select Stim: see summary
2473389|NCT03082001|Experimental|12% Sucrose|"The enrolled infants were administered 0.2 ml of 12% sucrose 2 min prior to procedure.~These solution were prepared under all sterile precautions by the laboratory staff unrelated to the study. 12%sucrose was prepared by mixing 1.2 gm of sucrose in 10 ml of distilled water. here were two study groups A & B. The enrolled infants were administered sterile solution of 0.2 ml of 24% sucrose (active control) 2 min prior to procedure.~Out of these solutions 1ml was measured by 1 ml syringe and packed and covered with serially numbered opaque sealed envelopes. At the initiation of venepuncture 2 min prior to procedure 0.2 ml of solution marked with patient serial no was administered by a pre-filled syringe to the patient on the anterior aspect of the tongue avoiding spillage, by the personnel carrying out the procedure. The above mentioned personnel was blinded to the contents of the solution."
2473461|NCT03081689|Experimental|Arm 1|Nivolumab 360 mg IV Q3W + Paclitaxel 200mg/m2 + Carboplatin AUC 6 IV Q3W in resectable stage IIIA N2-NSCLC adult patients followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
3192348|NCT00807716|Experimental|walking skill group|weight-bearing 12 times, 70 minutes
2473611|NCT03080389||Extended urine culture|Each patient will be their own control and two specimens will be obtained from each participant. The first will be a catheterized urine sample to be sent for routine culture and the second will be collected from the same catheterized specimen and sent for extended culture.
3192349|NCT00807716|Active Comparator|usual physiotherapy care|partial weight-bearing, 12 times, 40 minutes
3208631|NCT00976651|Experimental|human chorionic gonadotropin|"Patients undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.~Histology and gene expression is studied on the endometrium"
2473761|NCT03079349|Active Comparator|Traditional Classroom|Medical Education
2473767|NCT03079349|Experimental|Online Synchronous Classroom|Medical Education
2473822|NCT03079024|Experimental|Targeted Cognitive Training (TCT)|Neuroadaptive Cognitive Training
2473830|NCT03079024|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
2473835|NCT03079024|No Intervention|Treatment as Usual (TAU)|Treatment as Usual
2473874|NCT03078543|Other|ANTHEM™ PS Total Knee System implant|The ANTHEM™ PS Total Knee System will demonstrate non-inferiority of 10 year implant survivorship in patients undergoing total knee arthroplasty for osteoarthritis compared to reported literature
2473891|NCT03078309|Experimental|healthy|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
2473893|NCT03078309|Experimental|Retinitis Pigmentosa|All subjects will undergo a full ocular exam and visual functions will be assessed before and after the administration of a single dose of cannabis (THC:CBD 1:40). On the second study day all subjects will receive a single dose of cannabis (THC:CBD 1:1) and undergo the full ocular exam again.
2473961|NCT03078140|Active Comparator|Triferdine|Triferdine 1 tablet by mouth daily. Start after 1st trimester until delivery
2473963|NCT03078140|Active Comparator|Triferdine/Ferli-6|Triferdine or ferli-6 1 tablet by mouth daily base on iodine status. The supplement will give after 1st trimester until delivery
2473995|NCT03077750|Experimental|VBP-245|VBP-245 Topical Gel Applied to Affected Area BID
2473997|NCT03077750|Placebo Comparator|Vehicle|Vehicle Gel Applied to Affected Area BID
2474044|NCT03077529|Experimental|Galacto-oligosaccharide|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
2474045|NCT03077529|Placebo Comparator|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
2474099|NCT03077360|Experimental|Weight loss only|
2474103|NCT03077360|Experimental|Exercise Only|
2474112|NCT03077360|No Intervention|Delayed Intervention Control|
2474161|NCT03076762|Experimental|Intravesical suburothelial injection|Patients assigned for suburothelial injections received 100 U of onabotulinumtoxinA in 20 sites injected in the bladder body on treatment day and follow-up
2474172|NCT03076762|Active Comparator|Intravesical trigonal injection|Patients assigned trigonal injections will receive 100U of onabotulinumtoxinA at 10 sites injected at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone) on treatment day and follow-up.
2474238|NCT03076229|Experimental|Healthy Marriage: Treatment|Intervention: Behavioral: Healthy Marriage Program
2474240|NCT03076229|Experimental|Healthy Marriage: Wait-list Control|Intervention: Behavioral: Healthy Marriage Program
2474292|NCT03075735||Metastatic castration resistant patients|The exposition to the primary analysis risk factor (germline deleterious mutation in BRCA1, BRCA2, ATM or PALB2 gene) will be determined after inclusion. Briefly, a NGS targeted-panel based on the majority of genes included in the BROCA panel and additional DNA-repair related genes has been designed based on the available technology. The pathogenicity of germline variants will be determined according to established American College of Medical Genetics and Genomics and Association for Molecular Pathology current consensus at the time of final primary outcome analyses. Variants will also be reviewed against published literature and public databases. According to their mutation-carrier status patients will be classified as: A) Mutation Carriers in BRCA1, BRCA2, ATM and PALB2 genes; B) Mutation carriers in other genes included in the BROCA panel; C) Mutation carriers in others DNA-repair genes D)Non-carriers
2474327|NCT03075293||Children with appendicitis|All children who came to the ER with appendicitis
3208632|NCT00976690|Active Comparator|1|Azathioprine : 2mg/kg/day
3208633|NCT00976690|Active Comparator|2|Mesalazine : 4g/day
2474599|NCT03073655|Experimental|Group 1|it has been limited evidence of KT is effective
2473429|NCT03082482|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), and 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
2473431|NCT03082482|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on the study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
2473519|NCT03081351|Experimental|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
2473525|NCT03081351|Experimental|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
2473594|NCT03080779||ADP Group|Index group includes participants who have suffered an accidental dural puncture with a 16 gauge Tuohy needle
2473595|NCT03080779||Non-ADP group|Control group includes participants who received an uneventful epidural analgesia with a 16 gauge Tuohy needle
2473669|NCT03079947||Non-hodgkin Lymphoma|300 Non-hodgkin Lymphoma patients (age >=18y) without previous treatment would be administered, including DLBCLs and PTCLs.
2473726|NCT03079739||fractional flow reserve group|consecutive patients undergoing coronary artery angiography for established or suspected ischemic heart disease and receiving in at least one lesion FFR assessment
2473740|NCT03079336|Experimental|State of the art (SOTA) check-in phase|The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
2473742|NCT03079336|Experimental|Prolonged focus on subtle changes|Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.
2473806|NCT03079011|Experimental|A- palbociclib + AI|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme.
2473807|NCT03079011|Experimental|B- Palbociclib + fulvestrant|After randomization, the patient will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with fulvestrant, a selective estrogen receptor down-regulator, 500 mg administered intramuscularly on Days 1, 15, and 29 and once monthly thereafter.
2473810|NCT03079011|Experimental|Selection - Palbociclib + AI|All patients included into the study will be treated with palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle in combination with an aromatase inhibitor (letrozole, anastrozole or exemestane, according to physician's choice and according their respective summary product characteristics) administered once daily in a continuous scheme
2473937|NCT03078179|Experimental|Commercial Cow Milk with Probiotic|"Probiotic enriched cow milk:~200 ml of commercial nutritive milk fortified with probiotic Lactobacillus rhamnosus and Bifidobacterium longum once a day."
2473940|NCT03078179|Placebo Comparator|Commercial Dairy Cow Milk|200 ml of commercial nutritive milk without probiotic, once a day,
3208634|NCT00976729|Placebo Comparator|Placebo i.v.|
3208635|NCT00976729|Experimental|0.03 mg/kg i.v.|
2474037|NCT03077503|Experimental|Dexmedetomidine (Group A)|In induction period, group A received dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline 10 minute through a syringe pump. Three minutes before application of skull pins, group A received infusion of 2 ml of 0.9% normal saline.
2474042|NCT03077503|Active Comparator|Fentanyl (group B)|In induction period, group B received 20ml of 0.9% normal saline.Three minutes before application of skull pins, group B received infusion of fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline
2474122|NCT03077009|Experimental|Treatment arm|Patients with confirmed plantaris friction syndrome will be offered hyaluronic acid injection into the space between the Plantaris and Achilles tendons
2474181|NCT03076619||Clinical ophthalmoscopy in PIH|"An observational study in which the patients for the study are selected from antenatal clinic, antenatal ward and preeclampsia and eclampsia room in Department of Obstetrics and Gynecology and general ophthalmic OPD in case of ambulatory patients during the period of November 2003 to June 2006 randomly."
2474229|NCT03076281|Experimental|Arm A (metformin hydrochloride)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery in the absence of disease progression or unacceptable toxicity
2474230|NCT03076281|Experimental|Arm B (doxycycline)|Patients receive doxycycline PO every 12 hours on days 1 to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
2474232|NCT03076281|Experimental|Arm C (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride PO daily on days 1-3 and twice daily starting on day 4 to the day prior to surgery and doxycycline PO every 12 hours on days 1to the day prior to surgery in the absence of disease progression or unacceptable toxicity.
2474299|NCT03075618||Acute Pancreatitis|Patients with Acute Pancreatitis.
2474397|NCT03075241|Experimental|Zolpidem|Study group will receive zolpidem 10mg capsules, 10pm (before bedtime) for 14 nights
2474402|NCT03075241|Experimental|Zoplicone|Study group will receive zoplicone 7.5mg capsules, 10pm (before bedtime) for 14 nights
2474600|NCT03073655|Experimental|Group 2|it has been not known that KT is effective or not
3208636|NCT00976729|Experimental|0.09 mg/kg i.v.|
2473438|NCT03081494|Experimental|spartalizumab (PDR001) + regorafenib|Subjects with metastatic MSS CRC received a combination of spartalizumab and regorafenib.
2473555|NCT03080909|Active Comparator|Encapsulated nutients|"Encapsulated nutrients known to be able to stimulate GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The encapsulated nutrients will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. test products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
2473558|NCT03080909|Placebo Comparator|Placebo|"Nutrients known to have limited stimulation on GLP-1 and PYY release. Encapsulated with coating providing release at pH≈7.0 (in the distal part of the ileum) expected to start approximately 3 hour following ingestion.~The placebo products will be provided 30 minutes prior to the standardized fixed breakfast (providing 2000 kJ) and 60 minutes prior to the standardized fixed mid-morning snack (providing 1500 kJ), i.e. placebo products will be provided 6 hour and 4 hour before the ad libitum test meal, respectively."
2473626|NCT03080636|Experimental|Men|11 men randomly underwent three experimental sessions in early morning prior to their work routine.
2473631|NCT03080636|Experimental|Women|9 women randomly underwent three experimental sessions in early morning prior to their work routine.
2473671|NCT03079908|Experimental|Da Vinci Skills Simulator®|Participants in this group will undergo robotic virtual reality surgical simulator training (Da Vinci Mimics) and will subsequently be evaluated on a dry lab laparoscopic box
2473672|NCT03079908|Active Comparator|LapSim®|Participants in this group will undergo laparoscopic virtual reality surgical simulator Training (LapSim) and will subsequently be evaluated on a dry lab laparoscopic box
2473673|NCT03079908|Placebo Comparator|Dry lab box laparoscopic training|Participants in this group will undergo dry lab box laparoscopic training only
2473757|NCT03079726||Frail individuals (case)|Individuals classified as frail based on several clinical metrics
2473762|NCT03079726||Non-frail individuals|Individuals failing to meet criteria for frailty based on clinical metrics
2473797|NCT03079167|Experimental|Erythropoietin|Erythropoietin (epoetin alfa) 1000 IU/kg birth weight (capped at 4000IU daily) IV infusion, on Days 1, 2, 3, 5 and 7 of age
2473800|NCT03079167|Placebo Comparator|Placebo|IV normal saline (equiv. volume), on Days 1, 2, 3, 5 and 7 of age
2473884|NCT03078452|Experimental|Arm I (biopsy using power drill)|Patients undergo bone marrow biopsy using the power drill. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
2473885|NCT03078452|Active Comparator|Arm II (biopsy using Jamshidi needle)|Patients undergo bone marrow biopsy using the traditional Jamshidi needle. Patients complete questionnaires at baseline, 30 minutes after biopsy, and on days 1, 3, and 7.
2474014|NCT03077776|Experimental|All included patients|"Patients will undergo a biopsy and provide a blood sample prior to initiating standard neoadjuvant chemotherapy. Additional tissue samples will be collected at the following time points:~(optional) biopsy of primary tumour after 4 cycles of neoadjuvant chemotherapy~At the time of surgery (samples of the primary tumour and lymph nodes which are surplus to diagnostic requirements).~Biopsy of a metastatic site in the event of disease recurrence.~Blood samples will be obtained during neoadjuvant chemotherapy, prior to surgery and at 6-month intervals for up to 5 years post-surgery. In the event of recurrent disease, blood samples will be collected i) at the time of recurrence, ii) at the first CT scan on treatment and iii) at each subsequent relapse for up to 5 years post-surgery."
2474084|NCT03077334||K-type|FDG uptake in pancreatic cancer is similar to that of kidney
2474086|NCT03077334||non K-type|FDG uptake in pancreatic cancer is lower than that of kidney
2474107|NCT03076944|Active Comparator|Neural agent|UltraEZ. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2474115|NCT03076944|Active Comparator|Obliterator agent|Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions
2474117|NCT03076944|Active Comparator|Associative approach|UltraEZ and Enamelast. Prophylaxis of the teeth; an application every 48 hours; 4 sessions. In each session, fistly the UltraEZ (neural agent) will be applied and after the Enamelast (obliterator agent.)
2474141|NCT03076671|No Intervention|Standard of Care|Patients to get usual care from their established neurology care team that is enrolled in the study.
2474143|NCT03076671|Experimental|Standard of Care plus Palliative Care|Patients to get usual care, augmented by palliative care, provided by their established neurology care team that is affiliated with the study, with additional support provided by the University of Colorado Denver Neurology Palliative Care team.
2474145|NCT03076671|Experimental|Clinicians|Clinicians enrolled in the study will receive an 8-hour supportive and palliative care training, followed by monthly coaching and the availability of telemedicine visits for enrolled patients with the university neuro-palliative care team. The unit of randomization is the time when they receive training. Four to five clinical practices will receive training every 6 months during years 2 and 3, at which time all of their enrolled patients will be switched from usual care to the intervention arm.
2474221|NCT03076203|Experimental|Treatment (niraparib, radium Ra 223 dichloride)|Patients receive niraparib orally daily and radium Ra 223 dichloride IV over 1 minute every 4 weeks. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2474295|NCT03075722|Experimental|Saturn nasal mask|Participants to use nasal mask in-home for 7 ± 3 days
2474331|NCT03075306|No Intervention|usual care|usual care and materials on healthy weight
2474332|NCT03075306|Experimental|intervention|the 12-month CHAMPION intervention with a health coach who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents
2474371|NCT03075020|Active Comparator|Active carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration 22%
2474375|NCT03075020|Placebo Comparator|Air|
2474418|NCT03074760||Contaminated acequias|
2474423|NCT03074760||Non-contaminated acequias|
2474480|NCT03074344|Experimental|XLHA+CoQ10|XLHA+CoQ10 eye drop administered four times a day for 12 weeks (90 days).
2474482|NCT03074344|Active Comparator|Hyaluronic acid (HA)|Hyaluronic acid (HA) eye drop administered four times a day for 12 weeks (90 days).
2474518|NCT03074032|Experimental|ONC1-0013B 40 mg|ONC1-0013B 40 mg per os daily
2473457|NCT03081520|Experimental|Affective response HIIT|High-Intensity Interval Training 4-6 x 30-sec sprints on tread mill, >95% HRmax during sprints 4 min recovery between sprints, intensity of approximately 70% of HRmax
2473502|NCT03081195|Experimental|MFG-delivered by trained family peers|"MFG delivered by trained parent peers drawn from local school planning councils:~10 schools; 60 parent peers (6 per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2473504|NCT03081195|Experimental|MFG-delivered by CHWs|"MFG delivered by community health workers (CHW) drawn from local primary care clinics:~10 schools; 60 community health workers (6 assigned to children per school x 10); 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2473507|NCT03081195|No Intervention|Bolstered care|"Comparison (Bolstered care): Mental health wellness materials and educational supports (e.g. books, uniforms)~10 schools; 1,000 children and adult caregivers; children screened to evidence serious emerging and clinically significant DBDs"
2473599|NCT03080805|Experimental|Pyrotinib Plus Capecitabine|
2473600|NCT03080805|Active Comparator|Lapatinib Plus Capecitabine|
2473640|NCT03080246|Active Comparator|Strength Training Group|This group will begin coming to the Clinical Research Center (near the undergraduate campus of Wake Forest University) for exercise classes 2-3 days per week for about an hour each day. The investigators also have a site on High Point University's campus. The class will consist of a 10-minute warm-up, a 20-minute strength training period, 15-minutes of neuromuscular (balance/coordination) training, and a 15-minute cool down. These regular exercise classes at Wake Forest and High Point University will go on for 9 months, followed by another 9 months of option to continue at facility, plus follow-up via email and 2 group meetings/runs at Fleet Feet (at around months 12 and 15).
2473642|NCT03080246|No Intervention|Running Group|This group will be observed as they follow their usual run-training routine over the course of 18 months. Emails will be sent biweekly for 18 months to update the research team on injury/training status. The group will attend 5 group meetings/runs at Fleet Feet (at around months 1, 3, 6, 12, and 15). After the 18 months, the participants will be offered a free 8-week strength training program at the Clinical Research Center or High Point University.
2473700|NCT03079960|Experimental|Original patient group (PG-O)|"DBS implantation: patients undergo standard stereotactical neurosurgery for DBS implantation. Decision for DBS treatment has been made prior to inclusion into this study.~Cables and connectors of the macro electrodes will stay externalized for four days for cDBS adjustment procedures. During externalization, patients take part in test stimulation and recording sessions during which they perform short motor tasks.~The externalized connectors of the macroelectrodes allow for simultaneous stimulation of the STN and obtaining LFP recordings with electrophysiological recording and measurement devices from the STN for the fitting of DBS parameters, according to the standard clinical procedure."
2473704|NCT03079960|No Intervention|Chronic patient group (PG-chronic)|"Patients in this group will take part in one recording session at any desired point in time after they have been implanted with a DBS system as part of their clinical routine treatment. During this session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~Recordings are performed while applying different DBS strategies. The different DBS strategies are selected as a set of safe configurations as they are used in clinical routine. The behavioral tests performed for PG-chronic are the same as conducted for PG-O."
2473707|NCT03079960|No Intervention|Preoperative patient group (PG-pre)|"Patients in this group will take part in one recording session that will take place one week prior to implantation surgery at the earliest, i.e. between day -7 and day 0. Decision for DBS treatment has been made prior to inclusion into this study.~During this recording session, which will be lasting for approx. 60 minutes, patients will execute different motor tasks while neural activity is recorded non-invasively from cortical areas via surface EEG electrodes.~The behavioral tests performed for PG-pre are the same as conducted for PG-O."
2473827|NCT03079180|Experimental|Aged & strength training at 80% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~Training programs:~Frequency: 3 training sessions per week. Duration: 12 weeks. Intensity: 80% of one repetition maximum (1RM). The 1RM of the participants in each of the 3 exercises performed in the training program will be reviewed every 2 weeks during training. If 1RM increase, the training load will be adjusted accordingly.~Training exercises: A Warm-up will first be performed on a cycle ergometer during 10min. The training intervention will then consist in performing two sets on each one of the two exercises used for Patellar tendon stress: leg extension and leg press. To stress Achilles tendon, the subjects will perform four (4) sets using a calf raise machine. The subjects will perform 4 to 8 repetitions at 80% 1RM.~All training sessions will take place under appropriate supervision in UTC for the duration of the interventions according to the study design."
2473836|NCT03079180|Experimental|Aged & strength training at 55% 1RM|"Subjects: 20 subjects aged between 65 and 85 years~The training program and training exercises in this group are the same as for the Aged & strength training at 80% 1RM arm except for the two following parameters.~Training intensity: Intensity of exercises will be 55% of one repetition maximum (1RM).~The subjects will perform 6 to 12 repetitions at 55% 1RM.~The two training programs (55% or 80% of 1RM) are designed to be equal in volume (resistance x repetitions x sets)."
2473843|NCT03079180|Experimental|Young & strength training at 55% 1RM|"Subjects: 20 subjects aged between 18 and 30 years~The training program and training exercises in this group are the same as for the Aged & strength training at 55% 1RM arm"
3208637|NCT00976729|Experimental|0.25 mg/kg i.v.|
2473980|NCT03077971|Experimental|ACT Self-Help|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks.
2473982|NCT03077971|Experimental|ACT Self-Help with Telephone Support|Participants in this arm will receive a self-help book based on Acceptance and Commitment Therapy (ACT). Participants will receive chapters each week, either electronically or by post, for 8 weeks. In addition to this, participants will have weekly telephone calls to support the use of the book.
2473983|NCT03077971|No Intervention|Treatment As Usual|Participants in this arm will have no intervention as part of the trial.
2474026|NCT03077581|Active Comparator|Transevrsus abdominus plane block group|
2474028|NCT03077581|Active Comparator|Rectus sheath block group|
3208638|NCT00976729|Experimental|0.5 mg/kg i.v.|
3208639|NCT00976729|Experimental|1.0 mg/kg i.v.|
2473531|NCT03081104|Active Comparator|blind aspiration|The women were allowed to empty their urinary bladder before induction of anesthesia, but catheterization was not performed. After positioning the patient appropriately on the operating table, bimanual pelvic examination was performed under anesthesia to assess the axis and the size of the uterus. A Sim's speculum was inserted into the vagina; the cervix was visualized and grasped using the Vulsellum forceps. The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used. The aspirate was examined to confirm the presence of products of conception. The completeness of the evacuation was checked by gentle sharp curettage and final suctioning at the end of procedure.
2473620|NCT03080402|Experimental|High KAM|Mechanically-driven neuromuscular training. 2 times per week for 6 weeks for a total of 12 sessions. Perturbation training
2473622|NCT03080402|No Intervention|Normal KAM|No intervention
2473691|NCT03080064|Experimental|Health Coach Intervention|The investigators connected participants at enrollment (median gestation of 12.5 weeks, IQR: 11-15) with a trained health coach who called participants every 2-3 weeks until 36 weeks of gestation. During these phone calls, health coaches helped participants adopt and maintain new healthful lifestyle behaviors that were evidence-based, simple, and easy to track. Goals aimed to promote appropriate gestational weight gain and covered several domains including diet, physical activity, screen time, and sleep.
2473758|NCT03079622|Active Comparator|Electric vacuum aspiration|Electric vacuum aspiration will be performed with Synevac® Vacuum Curettage System 10 (Richmond, CA, USA) with a rigid cannula.
2473766|NCT03079622|Active Comparator|Manual vacuum aspiration|Manual vacuum aspiration will be performed using the 60-mL double valve aspirator, manufactured by Ipas (Chapel Hill, NC, USA) with a flexible cannula.
2473805|NCT03079089|Other|Relapsed or refractory lymphoid hematological disorders|Patients in refractory or relapses with an indication of allo-HSC used the combination of an SET followed by the RIC with the PDLI
2473866|NCT03078621|Experimental|Stem Cells|Intravenous and Intrathecal transplantation of specific populations of purified bone marrow-derived stem cells and mesenchymal stem cells.
2473947|NCT03078062|Active Comparator|Dexamethasone|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of dexamethasone 8 mg (2 ml) will be initiated. The study drug will be administered over 5 -10 minutes diluted in a 500 ml bag of Normal Saline for a total volume of 502 ml. The study drug will be prepared by an independent assistant.
2473950|NCT03078062|Placebo Comparator|Normal Saline|During the performance of spinal anesthesia using isobaric 0.5% bupivacaine 12 mg, an intravenous infusion of 502 ml of Normal Saline will be initiated. The infusion will be administered over 5 -10 minutes. The study drug will be prepared by an independent assistant.
2474011|NCT03077763|Active Comparator|Normoxia and Nitrite (3umol/min-1)|Sodium nitrite stock solution: 100umol/10ml, prepared to concentration according to oxygen sequence. Normoxia (3umol/min-1).
2474012|NCT03077763|Active Comparator|Hypoxia and Nitrite (1umol/min-1)|This will be repeated as per the normoxia cohort, but at a reduced dose of sodium nitrite (1umol/min-1 for 30 minutes) and the volunteers will be asked to breathe 12% oxygen/88% nitrogen for 1-5 minutes before Plethysmography is performed (to get the volunteer to an oxygen saturation of 83-88% peripherally).
3192350|NCT00807729|Active Comparator|ERCP|All ERCP's were performed by one of the authors (JPC), a fulltime faculty member and gastroenterology fellowship instructor in the presence and concurrence of the principal author/ surgeon (SJR). Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
3208640|NCT00976729|Experimental|2.0 mg/kg i.v.|
3208641|NCT00976729|Placebo Comparator|Placebo s.c.|
3208642|NCT00976729|Experimental|0.25 mg/kg s.c.|
2474236|NCT03076060|Experimental|Migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of VLCKD by meal replacements poor in fats and carbohydrates."
2474237|NCT03076060|Sham Comparator|Sham diet migraineurs|"Overweighted or Obese migraineurs that refer to a dietician clinic to treat their ponderal condition.~Intervention: 4-week of non-ketogenic VLCD by meal replacements poor in fats and proteins."
3208643|NCT00976729|Experimental|0.5 mg/kg s.c.|
3208644|NCT00976742|Experimental|Endurance Exercise Training|
2474422|NCT03074812|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation where current will be reduced to zero after standardized ramp up to 2 mA
2474427|NCT03074812|Experimental|Active tDCS|Transcranial direct current stimulation according to protocol maintained for 30 minutes after ramping up to 2 mA
2474533|NCT03074201|Experimental|Cholangioscopy|Participants in this arm undergo radiation-free ERCP facilitated by cholangioscopy
2474588|NCT03073616||Lung ultrasound|Every patient will receive a chest RX and lung US
2474613|NCT03073317|Experimental|INTERVENTION|Clinical protocol using FullPIERS and sFlit/PLGF ratio (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
2474615|NCT03073317|No Intervention|CONTROL|Usual clinic control
2474670|NCT03073070|Experimental|Biotin labeled RBCs in 4-10 year old diabetes children|Biotin labeled autologous RBCs will be transfused to the subjects
2474677|NCT03073070|Experimental|Biotin labeled RBCs in 10-18 year old diabetes children|Biotin labeled autologous red blood cells will be transfused to the subjects
2474814|NCT03072095|Experimental|Text-only|Text-only outreach
2474816|NCT03072095|Experimental|Text + Lottery|Text outreach + financial incentive
2474840|NCT03071614|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
2474843|NCT03071614|Experimental|News without spin|News items reporting results of animal studies without spin.
2474895|NCT03071341|Experimental|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) fusion protein
2475019|NCT03070717||All patients|Patients with diagnosis of high myopia secondary to an anterior-posterior elongation of the bulbus confirmed by ocular examination in either eye using specific criteria.
2473556|NCT03080896|Experimental|Interventional Group videolaryngoscope/fibeoptic bronch|The interventional group will Intubate using the video-laryngoscope and the fiber-optic bronchoscope (aScope III)
2473623|NCT03080558|Experimental|endometriosis recto vaginal node|
2473674|NCT03080051|Experimental|[18F]MNI-952|To evaluate [18F]MNI-952 (also known as [18F]UCB-K), a tau targeted PET radioligand.
2473737|NCT03079674||NICE patients|Non-disabling ischemic cerebrovascular events patients indicate patients with transient ischemic attack and minor stroke (National Institute of Health stroke scale, NIHSS≤3).
2473804|NCT03078829||Trans female adolescents|All transgender males to females youth in pubertal stage Tanner stage 4-5, starting GnRH agonist and estrogen treatment
2473882|NCT03078764|Experimental|Patient Arm using mHealth|Patients with uncontrolled type 2 diabetes
2473883|NCT03078764|Experimental|Community nurses|Nurses who receive mHealth report about patients in the patients' arm.
3192351|NCT00807729|Active Comparator|Lap CBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
3192352|NCT00807755|Experimental|Phase I Dose-Escalation|This is a phase I dose escalation study of RAD001 and carboplatin/etoposide. Patients will be accrued in a standard 3 + 3 design based on toxicities experienced during the first cycle. Ten additional chemotherapy naive extensive stage small cell lung cancer (ES-SCLC) patients will be accrued at the Maximum Tolerated Dose (MTD) for further toxicity and response assessment.
3192353|NCT00807781|Experimental|Mammaglobin-A DNA vaccine|"Patients will receive vaccine day 1 (week 1), week 4 (day 29 +/- 7), week 8 (day 57 +/- 7) with at least 21 days between injection days.~All injections will be given intramuscularly using a jet delivery device.~Patients will be administered the vaccine in lateral shoulder and buttocks positions that will be rotated with each administration in the above order."
2474101|NCT03077295|Experimental|High Fibre to High-Protein (HF-HP)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HF meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HP meals for 4 weeks"
2474109|NCT03077295|Experimental|High Protein to High-Fibre (HP-HF)|"Phase 1: no intervention, habitual diet for 4 days and then 3day maintenance diet~Phase 2: consumption of HP meals for 4 weeks~Phase 3: washout for 1 week, controlled maintenance diet~Phase 4: consumption of HF meals for 4 weeks"
2474160|NCT03076697||Diabetic Eye Disease|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2474164|NCT03076697||Glaucoma|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2474174|NCT03076697||Age related macular degeneration (AMD)|Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2474177|NCT03076697||Retinopathy of Prematurity (ROP)|Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
2474217|NCT03076268|Experimental|Treatment Group|The investigators will deliver the TMP Curriculum to 45 Treatment families. The TMP Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings. This curriculum is delivered in Spanish.
2474223|NCT03076268|No Intervention|Control Group|The investigators will deliver a Nutrition Curriculum to 45Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.This curriculum is delivered in Spanish.
3192354|NCT00807794|Experimental|1|MEDI-507
2474601|NCT03073655|Experimental|Group 3|it has been known that KT has excellent result
2473578|NCT03080701|Experimental|Group 3 - Auto Mailing Plus Lottery|Receives the same number of mailings and materials as group 1 with the following modifications. In Mailing 1 the letter will include the intervention notification that they will have a 1 in 10 chance of winning money (FIT, colonoscopy or flex sig within 6 months). Mailing 2 and mailing 3 (reminder letters for those still not returning kits) will include the same information about the 1 in 10 chance of winning the lottery for CRC screening completion. Mailing 4 will include a thank you letter with money for those who complete their screening and win the lottery. Participants who do not win the lottery will receive a thank you letter.
2473596|NCT03080441|Experimental|Phase 1 Group 1|pressure stockings worn during dialysis treatment
2473597|NCT03080441|Experimental|Phase 1 Group 2|Midodrine before dialysis treatment
2473598|NCT03080441|Experimental|Phase 1 Group 3|pressure stocking and Midodrine
2473604|NCT03080233||Pakistani adult|"Men and women aged 18 years or above,presenting with neurological deficit consistent with stroke in the Emergency Department at Aga Khan University Hospital~Consenting to participate in the study"
2473660|NCT03080194|Experimental|paliperidone palmitate group|The subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement.
2473664|NCT03080194|Active Comparator|control group|The subjects in control group will be applied with oral antipsychotics or other conventional medication.
2473716|NCT03079778|Active Comparator|TACE alone|Transarterial chemoembolization (TACE)
2473718|NCT03079778|Experimental|TACE plus RT|Combination of transarterial chemoembolization and radiation (TACERT)
2473770|NCT03079414||Unexplained Aborted Cardiac Arrest|Survivors of sudden cardiac death with no identifiable etiology following initial diagnostic workup.
3192355|NCT00807794|Experimental|2|MEDI-507
2473875|NCT03078530|Placebo Comparator|Placebo|Placebo (not an active drug/ Inactive component) is given to this group
2473878|NCT03078530|Experimental|Visbiome|Visbiome (probiotic mixture) is given to this group.
2473880|NCT03078530|Experimental|VSL #3|VSL #3 (probiotic mixture) is given to this group
3192356|NCT00807794|Experimental|3|MEDI-507
3192357|NCT00807794|Experimental|4|MEDI-507
2473974|NCT03077815|Other|arm movement more than a total of at least 30 minutes a day|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day
2473978|NCT03077815|Other|arm movement and local press strength 50 mmHg at the upper arm|Using the provided rubber ball grip the ball movement on a daily basis, and grip the ball at a time 3-5 seconds, every 5 minutes, daily at least 6 rounds (for example, according to the daily morning, noon and night-time sports training in the two groups), to reach an arm movement more than a total of at least 30 minutes a day with Elbow proximal 4 (2~6) local press strength 50 mmHg at the upper arm
3192358|NCT00807794|Experimental|5|MEDI-507
3192359|NCT00807807|Placebo Comparator|1|Participants will receive placebo folic acid.
2474158|NCT03076658|Other|asymptomatic EOS Imaging|patients that qualify for study and EOS imaging to analyze spino-pelvic parameters
3192360|NCT00807807|Experimental|2|Participants will receive 100 mcg of folic acid.
3192361|NCT00807807|Experimental|3|Participants will receive 400 mcg of folic acid.
2474322|NCT03075592||ERCP candidates|ERCP candidates
2474411|NCT03074695|Experimental|Dural Puncture Epidural (DPE)|Women who have analgesia initiated with a DPE technique
2474412|NCT03074695|Experimental|Standard Epidural (EPL)|Women who have analgesia initiated with an epidural technique
3192362|NCT00807807|Experimental|4|Participants will receive 1000 mcg of folic acid.
3192363|NCT00807807|Experimental|5|Participants will receive 2000 mcg of folic acid.
3192364|NCT00807833||CBF measurement|"It is a proof of concept study, aimed to evaluate whether the optimal CPP, defined by the best PRx, corresponds to the acceptable CBF values.~Patients admitted with the diagnosis of TBI and SAH in for whom ICP and CPP needs to be monitored on clinical ground will be also monitored with a TD probe and routinely tested for cerebral autoregulation, thus obtaining the CBF corresponding at a given the best CPP and autoregulation status."
2474633|NCT03073395|Experimental|Dynamic group|Dynamic imaging of suspected metastatic lesions with the investigation drug [68Ga]P16-093 in patients with a history of histologically confirmed cancer.
2474636|NCT03073395|Experimental|Biodistribution group|Whole body imaging to determine human dosimetry of the investigational drug [68Ga]P16-093
3192365|NCT00807859|Experimental|Cohort A1|
2474771|NCT03072446|Experimental|Gel-Beads arm|This group will undergo embolization of symptomatic uterine fibroids with Gel-Beads embolic agent
2474774|NCT03071939|Other|patients with schizophrenia and their designated relatives|Evaluation of the patient's insight (an inclusion phase, followed by two evaluation phases on D0 and D7) by the patient, his / her close and two caregivers (inter-judicial fidelity)
3192366|NCT00807859|Experimental|Cohort A3|
3192367|NCT00807859|Experimental|Cohort B1|
3192368|NCT00807859|Experimental|Cohort B3|
3192369|NCT00807872|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
3192370|NCT00807911|Active Comparator|Adjuvant FL|FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
3192371|NCT00807911|Experimental|Adjuvant FOLFOX|FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)
3192372|NCT00807963|Experimental|Stage 1: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of recombinant human hyaluronidase PH20 (rHuPH20) with zoledronic acid (ZA).
3192373|NCT00807963|Experimental|Stage 2: ZA|Participants will receive a dose/concentration of ZA administered without rHuPH20.
3192374|NCT00807963|Experimental|Stage 3: rHuPH20 plus ZA|Participants will receive one of several dose/concentrations of rHuPH20 with ZA.
3192375|NCT00807963|Experimental|Stage 4: ZA|Participants will receive an intravenous (IV) dose of 5 milligrams (mg) ZA.
3192376|NCT00807963|Experimental|Stage 4: ZA with rHuPH20|Participants will receive a subcutaneous (SC) dose of ZA with rHuPH20.
3192377|NCT00807976||Study group|Type 2 diabetic patients aged 70 years and older.
2473656|NCT03080285|Active Comparator|Conventional patch|"The patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Conventional patch is occlusion treatment sticker (Opticlude Eye Patch, 3M, Maplewood, MN, USA) with an adhesive material attached to the skin and serves to cover the eyes."
2473657|NCT03080285|Experimental|over-glasses patch|"the patients were prescribed 2 hours of patching per day for the sound eye and the spectacles were to be worn full-time.~Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is made of fabric and covers the glasses, hence serves to cover the eyes."
2473706|NCT03079856|Experimental|Brief Intervention|ED-based computer-guided intervention for substance use and HIV risk reduction utilizing Motivational Interviewing
2473708|NCT03079856|No Intervention|Enhanced Usual Care|Substance use and sexual health services information within a brochure provided to participants
2473778|NCT03079193||videoscopic laryngeal examination|50 patients post thyroidectomy will do mandatory post thyroidectomy videoscopic examination of the larynx
2473779|NCT03079193||No vedioscopic larygeoscopic examination|50 patients post thyroidectomy will be followed up and will not do vedeoscopic videoscopic laryngeal examination routinely they will do it if indicated
2473888|NCT03078777|Experimental|Pre-Dialysis|Patients will take 120 mg of fexofenadine three hours prior to dialysis and plasma concentration measured three hours following dosing.
2473889|NCT03078777|Experimental|Post-Dialysis|Patients will take 120 mg of fexofenadine at the end of their dialysis session and plasma concentration measured three hours following dosing.
2473923|NCT03078205|No Intervention|The control group|No Intervention
2473929|NCT03078205|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
2473931|NCT03078205|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
3157720|NCT00371189|Experimental|Group B: Ad35.CS.01-10^9 vp/ml|15 subjects will receive dosage 10^9 vp/mL; 3 subjects will receive placebo.
3157721|NCT00371215|Experimental|1|rThrombin
2474051|NCT03077477|Placebo Comparator|SAD|"Cohort will have a total 6 subjects: SAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate);~SAD cohorts are defined as follows:~Cohort 1: One placebo and one AMXT 1501 dicaprate subject will be treated as sentinel subjects receiving one tablet each of their assigned treatment. Assuming no intolerance is noted after at least 3 days, the remaining cohort subjects (placebo, 1 subject and AMXT 1501 dicaprate, 3 subjects) will be treated.~Cohort 2: 2 subjects 2 placebo each and 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 3: 2 subjects 4 placebos each and 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 4: 2 subjects 8 placebos each and 4 subjects 8 AMXT 1501 dicaprate tablets each"
2474053|NCT03077477|Placebo Comparator|MAD|"Each cohort will have a total 6 subjects: MAD (2 subjects receiving placebo and 4 subjects receiving active AMXT 1501 dicaprate); MAD cohorts will receive dosing once daily for 14 consecutive days. Dosing will be contingent on adequate tolerance in Cohorts 1-5.~Cohort 6: 2 subjects 2 placebos each; 4 subjects 2 AMXT 1501 dicaprate tablets each~Cohort 7: 2 subjects 4 placebos each; 4 subjects 4 AMXT 1501 dicaprate tablets each~Cohort 8: 2 subjects 8 placebos each; 4 subjects 8 AMXT 1501 dicaprate tablets each"
2474056|NCT03077477|Active Comparator|FE|"Each cohort will have a total 6 subjects: FE crossover (6 subjects receiving active AMXT 1501 dicaprate).~FE Crossover:~• Cohort 5: 6 new subjects will be randomized to a fed (n=3 standard meal) or fasted (n=3) group and administered the highest dose of AMXT 1501 dicaprate tolerated by previous cohorts. First dose and accompanying assessments will be referred to as Period 1. Subjects will then crossover to the opposite diet plan (fed or fasted) and receive a second administration of study treatment at the same dose level. The second dose and assessments are referred to as Period 2. There will be a 7-day washout between doses administered in Periods 1 and 2."
2474077|NCT03077191||Quality of life|Quality of life of breast cancer patients treated with conservative surgery (quadrantectomy) and adjuvant hypofractionated whole breast radiotherapy according to the institutional standard regimen, to a total dose of 40 Gy in 15 fraction over 3 weeks will be measured with EORTC quality of life questionnaires QLQ-C30 and QLQ-BR 23, before the start of the radiotherapy, at the end of the radiotherapy and then at every follow-up visit ( the first at 6 months after the end of the treatment, then annually for 5 consecutive years after the first follow up visit).
2474142|NCT03077048|No Intervention|Low protein diet|Low protein diet with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
2474144|NCT03077048|Experimental|Supplemented low protein diet|Ketosteril® supplemented low protein diet (sLPD), (1 tablet/5 kg BW/day) with 0.6 g protein/kg BW/day (20-30% high biological value) and an energy intake of 30-35 kcal/kg BW/day
2474188|NCT03076528|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive ankle & foot exercise program (game-based exercise) during hemo-dialysis, approximately 30 minutes, twice per week and for 4 weeks.
2474189|NCT03076528|Active Comparator|Non-technology foot and ankle exercise program|Subjects will be receiving non-technology foot and ankle exercise program during hemodialysis, approximately 30 minutes, twice per week and for 4 weeks.
2474200|NCT03076151|Experimental|Tacrolimus monohydrate (ADOPORT®)|patients with de novo Kidney Transplantation under Tacrolimus (ADOPORT®) treatment.
2474234|NCT03076021|Other|Adolescents|dextromethorphan pre- and post isotretinoin
2474253|NCT03075748|Experimental|Primary study|Patients meeting primary inclusion/exclusion criteria will be enrolled in primary study arm and be treated with the TAAA Debranching Stent Graft System.
2474254|NCT03075748|Experimental|Expanded selection|Patients who fail to meet inclusion criteria for the primary study arm may be enrolled under the expanded selection arm and be treated with the TAAA Debranching Stent Graft System.
2474298|NCT03075514|Active Comparator|Modified ketogenic diet (MKD)|MKD: 80% fat and 5% carbohydrate (% of total energy requirements per day).
2474300|NCT03075514|Active Comparator|Medium chain triglyceride (MCT) diet|MCT: 75% fat (30% of which is medium chain fatty acids taken as a supplement) and 5% carbohydrate (% of total energy requirements per day).
2475809|NCT03064893|Active Comparator|Alloderm|Device for immediate implant based breast reconstruction
3157722|NCT00371228|Experimental|1|Umbilical cord not cut until pulsation stops, in order to provide additional blood to newborn.
2473675|NCT03079869|Other|Ferric Citrate|Auryxia, 210 mg ferric iron tablets equivalent to 1 g of ferric citrate are supplied as 200 tablets in 400-cc high-density polyethylene bottles.
3157723|NCT00371228|No Intervention|2|Umbilical cord cut soon after birth without waiting for pulsing to stop.
3157724|NCT00371280|Active Comparator|1|Pegged unpegged hydroxyapatite orbital implantation
3157725|NCT00371280|Active Comparator|2|Unpegged hydroxyapatite orbital implantation
2473850|NCT03078725|Active Comparator|Glyburide|hypoglycemic agent approved for treatment of GDMA2
2473852|NCT03078725|Active Comparator|Metformin|hypoglycemic agent approved for treatment of GDMA2
2473928|NCT03078426|Experimental|Group 1 : UIP pattern|18 patients with UIP pattern at HRCT and IPF as a definite diagnosis.
2473933|NCT03078426|Experimental|Group 2 : possible UIP pattern|"7 patients with  possible  UIP pattern at HRCT with histopathology given by surgical lung biopsy making the diagnosis of IPF."
2473934|NCT03078426|Experimental|Group 3 : diagnosis of fibrosing sarcoidosis|15 patients with the diagnosis of fibrosing sarcoidosis after multidisciplinary discussion.
2473936|NCT03078426|Experimental|Group 4 : lung diseases without reticulations|20 patients with lung diseases without reticulations (acute or sub-acute hypersensitivity pneumonitis, organizing pneumonia, isolated pleural plaques) .
2473985|NCT03077906||Existing gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who already had a disabling gastroœsophageal reflux resistant to medical treatment in pre-op, and lost it in post-op."
2473987|NCT03077906||De novo gastroœsophageal reflux|"Patients who benefited from a sleeve gastrectomy surgery between 2008 and the end of 2015 in the department of digestive surgery of the CHU Brugmann.~Patients who developped gastroœsophageal reflux de novo."
2474043|NCT03077568|Experimental|My Stress Control|This group gets access to the web-based program for stress-management. They will, by their own, go through the automated program. Measurements are conducted before, after as well as 3 months after the intervention.
2474047|NCT03077568|No Intervention|Wait-list group|The wait-list grop will complete the same measures as the intervention group completes before and after the intervention with similar time spread. The wait-list group will then get access to the web-based program.
2474089|NCT03077321|Active Comparator|CARE|The parent-child dyads in the CARE arm will receive the standard CARE program.
2474090|NCT03077321|Experimental|CARE plus peer mentor|The parent-child dyads in the CARE plus peer mentor arm will receive the CARE program that is delivered with the peer mentor.
2474091|NCT03077321|No Intervention|Control|Wait list control
2474171|NCT03076840|Active Comparator|Kinesio tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip Y shape of (Kinesio Tex® Tape 5cm) insertion to origin technique to relieve the hamstring tightness while the muscle in stretched position for 15 second (hip flexion and knee extension and then application of the tape) with 25% stretch of the tape
2474178|NCT03076840|Sham Comparator|sham tape group|treatment by: application of Kinesio tape in the hamstring muscle by using a 1 strip I shape of (Kinesio Tex® Tape 5cm) with no stretch in the hamstring musculature and the tape applied perpendicular over the upper third of the hamstring muscle while the muscle in stretched position
2474179|NCT03076840|No Intervention|control group|The student in this group had no treatment in the same position of the previous groups (the hamstring muscle maintained in a stretching position for 15 second)
2474233|NCT03076307|Experimental|Parkinson's disease|
2474235|NCT03076307|Active Comparator|Control group|
3157726|NCT00371319|Active Comparator|Tacrolimus|Tacrolimus treatment
2474367|NCT03074968|Placebo Comparator|control|normal saline
2474370|NCT03074968|Active Comparator|benzydamine hydrochloride|Benzydamine Hydrochloride
2474531|NCT03074110|Active Comparator|Isocapnic hyperventilation|After end of surgery, hyperventilation and administration of a small, precalculated amount of CO2 into the breathing circuit will be performed.
2474536|NCT03074110|No Intervention|Standard procedure|After end of surgery, patients will be subdued to a standard weaning procedure.
2474611|NCT03073590|Experimental|Intervention with lunch|Intervention factory with hot lunch program A. Nutritionally enhanced lunch meal program B. Once weekly iron/folate supplement C. Behavior change communications program
2474612|NCT03073590|Active Comparator|Control with lunch|Control factory with lunch program A. Regular lunch meal program B. Behavior change communications program
2474616|NCT03073590|Experimental|Intervention without lunch|Intervention factory without lunch program A. Twice weekly provision of iron/folate supplements B. Enhanced behavior change communications program
2474618|NCT03073590|Active Comparator|Control without lunch|Control factory without lunch program A. Behavior change communications program
2474672|NCT03073083|Active Comparator|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon autograft
2474682|NCT03073083|Active Comparator|Patella tendon autograft|ACL reconstruction surgery with pattella tendon autograft
2474689|NCT03073083|Active Comparator|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon autograft
2474732|NCT03072485|Other|Sirolimus, metformin, diclofenac|First five enrolled participants
2474739|NCT03072485|Other|Metformin, diclofenac|Sixth to tenth enrolled participants
2474786|NCT03072082|Experimental|Danlou Tablet|Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2474955|NCT03071211|Active Comparator|Continuous Drainage Group|Participants randomized to continuous drainage catheter management. Catheters are attached to a leg bag during the day and large drainage bag for convenience overnight.
3157727|NCT00371319|Active Comparator|mycophenolate mofetil|mycophenolate mofetil
3157728|NCT00371371|Experimental|BM-MNC|autologous bone marrow-derived mononuclear cells
3157729|NCT00371371|Placebo Comparator|Placebo|Placebo
3157730|NCT00371384|Experimental|2|structural massage
3157731|NCT00371384|Experimental|1|relaxation massage
3157732|NCT00371423|Experimental|Arm 1|
3157733|NCT00371423|Other|Arm 2|Control data derived from ATLAS Workhorse Trial
2473681|NCT03080025|Experimental|CBCT® for Couples|"The CBCT® (Cognitively Based Compassion-Training) for couples (CBCT®-fC) consists of a ten-week training program with a 2h group session weekly and daily home practice based on prerecorded guided mediations (Emory University, Atlanta, USA; Ozawa-de Silva & Negi, 2013). The ten weeks start with an overview and a take-home ideas for continuing practice. Furthermore the first and the 3rd module will be repeated once resulting in a total of ten weeks. Further couple- and dyadic exercises are added.~It focuses on six essential key parts for the development of compassion:~Developing attentional stability and clarity of the mind (Mindfulness)~Cultivating insight into the nature of mental experience~Cultivating self-compassion~Developing impartiality~Developing appreciation and affection for others~Developing empathy and realizing engaged compassion"
2473684|NCT03080025|No Intervention|Treatment as usual (TAU)|"Treatment as usual: Primary care according to guidelines from the S3- and national healthcare guideline Unipolar Depression [S3-Leitlinie und Nationale VersorgungsLeitlinie (NVL) Unipolare Depression, Ärztliches Zentrum für Qualität in der Medizin], but excluding current psychotherapy after probatory session."
2473759|NCT03079648|Experimental|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 12 weeks.
2473765|NCT03079648|Placebo Comparator|Placebo|Placebo for 12 weeks
2473817|NCT03079076|Active Comparator|thoracolumbar interfascial plane block|Bilateral ultrasound guided thoracolumbar interfascial plane block with 20 ml %0,25 bupivacaine
2473819|NCT03079076|Placebo Comparator|sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
3192378|NCT00807976||Control group|Patients aged 70 years and older, with no history of type 2 diabetes mellitus.
3192379|NCT00808002|Experimental|1|From Baseline to Week48: Raltegravir BID + Tenofovir/Emtricitabine QD + Maraviroc BID From W48 to W72: Raltegravir BID + Tenofovir/Emtricitabine QD
3192380|NCT00808002|Active Comparator|2|Start ARV treatment with : Raltegravir BID + Tenofovir/Emtricitabine
3192381|NCT00808041||Treatment|Breast cancer patients undergoing hormonal therapy before surgery.
3192382|NCT00808054|Experimental|Glucose and EMLA|Received glucose oral and topical EMLA
3192383|NCT00808054|Experimental|Glucose and placebo|Received glucose and no EMLA
2474205|NCT03076086|Experimental|induced sputum procedure|Biomarker assessment (concentration of PiP3 and phosphoproteins in sputum samples) baseline and reproducibility twice in a 3 week interval of the different donors.
3192384|NCT00808054|Experimental|Oral placebo and EMLA|Received oral placebo and EMLA
3192385|NCT00808093|Other|fixed sequence|fixed sequence (14 days fasted followed by 14 days either high fat or standard meal
2474446|NCT03074552|Experimental|Probiotics|The probiotic preparation [ LactoLevure] will consist a combination of four probiotics.
2474447|NCT03074552|Placebo Comparator|Placebo|Placebo will consist of identical capsules of powdered glucose polymer, and they will be constructed by the same industry that manufactures the probiotics capsules.
2474560|NCT03073681||Historical controls|This group of historical controls makes up patients who have previously undergone cataract surgery with a 3.0 add ReSTOR lens in each eye. This group has already completed a satisfaction questionnaire identical to what will be posed in the 2.5/3.0 add lens group.
2474561|NCT03073681||2.5 and 3.0 add lenses|This group will have undergone cataract surgery at least 2 months before conducting a questionnaire. Patients enrolled in this group had cataract surgery with a 2.5 add ReSTOR lens in one eye and a 3.0 add lens in the other.
2474598|NCT03073460|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 40 weeks gestation to assess the fetal ductus arteriosis.
3192386|NCT00808106||Albinism|Patients with albinism
3192387|NCT00808145|Experimental|Gemcitabine/Cisiplatin/Sorafenib|All eligible patients will receive intravenous gemcitabine/cisplatin + daily oral sorafenib until disease progression occurs
3192388|NCT00808158||1|Children ages 9 to 10 years old, with a body mass index (BMI) in the 50th to 98th percentile range
2474772|NCT03072394|Experimental|EMLA anesthetic ointment (AO)|In AO group a layer of 2.5 gr EMLA cream (standard adult dose) is applied to both wrists, 1 cm above the styloid process of the radius 30 minutes before the puncture, by an experienced cathlab nurse.
2474773|NCT03072394|Active Comparator|Local Skin Anesthetic Injection (LA)|In LA group the radial artery is infiltrated with 1-2 mL of 2% lidocaine, using a 26 G needle, 0.5-1 cm proximal to the styloid process one minute before the puncture
2474825|NCT03071900|Experimental|SCCHN|squamous cell carcinoma of the head and neck
2474826|NCT03071900|Experimental|Control|health volunteers
2474873|NCT03071497||Study Group|Detecting iron deficiency using various methods. All patients that fit the inclusion criteria and are willing to participate in the study will be included in this group.
2474922|NCT03071224|Experimental|[18F]MNI-946|To evaluate [18F]MK-6240 (also known as [18F]MNI-946) a tau targeted radiopharmaceutical.
2474982|NCT03070795|Experimental|early feeding|patients undergoing elective cesarean section will be allowed to feed (sips) four hours after cesarean section.
2474983|NCT03070795|Active Comparator|delayed feeding|patients undergoing elective cesarean section will be allowed to feed on post operation day 1 (12 hours post op).
3192389|NCT00808171|Experimental|EMLA and Livopan|Administered EMLA and Livopan
3192390|NCT00808171|Experimental|EMLA and gas placebo|Administered EMLA and oxygen
3192391|NCT00808171|Experimental|Livopan and placebo cream|Administered Livopan and placebo cream
3192392|NCT00808184|Active Comparator|CPT-11|
3192393|NCT00808197|Experimental|1|Observatory, longitudinal, 3-years follow up study
3192394|NCT00808223|Experimental|1. alefacept|
3192395|NCT00808262|Experimental|TNFa Kinoid dose 1|
3192396|NCT00808262|Experimental|TNFa Kinoid dose 2|
3192397|NCT00808262|Experimental|TNFa Kinoid dose 3|
3192398|NCT00808275|Experimental|Dairy calcium|Diet with dairy calcium sources
3192399|NCT00808275|Experimental|Non-dairy calcium|Diet with non-dairy calcium sources
2473722|NCT03079752|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
2473723|NCT03079752|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
2473725|NCT03079752|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
2473727|NCT03079752|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
2473734|NCT03079323|Experimental|PART-trial|External beam radiotherapy
2473808|NCT03079258|Experimental|Exercise|Participants randomized to the exercise intervention group will be required to complete a 24-wk partially supervised exercise programme consisting of 3-4 sessions per week of 15 minutes progressing to 30 minutes over time.
2473811|NCT03079258|No Intervention|Control|Those randomized to the control group will continue with their standard care.
2473856|NCT03078738|Experimental|OMT-28-SAD|OMT-28-SAD, Single ascending dose levels 1 - 3 of OMT-28 (15, 30, 60 mg) Oral, healthy young male
2473857|NCT03078738|Experimental|OMT-28-MAD|Multiple ascending dose of dose levels 1 - 3 of OMT-28 over 14 days (4, 12, 36 mg) Oral, healthy young male
2473858|NCT03078738|Experimental|OMT-28- Food Effect|Single dose of OMT-28 (4 mg) Oral, healthy young male
2473859|NCT03078738|Experimental|OMT-28-Gender|Single dose of OMT-28 (4 mg) Oral, healthy non-child bearing potential female
2473860|NCT03078738|Placebo Comparator|Placebo-SAD|Single dose levels 1 - 3 of matching placebo, Oral, healthy young male
2473861|NCT03078738|Placebo Comparator|Placebo MAD|Multiple dose levels 1 - 3 of matching placebo over 14 days Oral, healthy young male
2473867|NCT03078738|Placebo Comparator|Placebo-Gender|Single dose of matching Placebo Oral, healthy non-child bearing potential female
2473925|NCT03078296||Members of the AAGL|Physicians and other providers who are members of the AAGL.
2473951|NCT03078036||Observation|Human epidermal growth factor receptor 2 negative metastic breast cancer patients who have started 1st line systemic cytotoxic chemotheraphy and are considered to have exhausted hormone therapy options (if HR+ve), per investigator's opinion.
2474110|NCT03077035|Experimental|glass ionomer sealant|
2474113|NCT03077035|Active Comparator|resin-based sealant|
3157734|NCT00371475|Experimental|Arm 1|
3157735|NCT00371475|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V clinical trials
2474214|NCT03076294|Experimental|MT after rTMS group|High frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT). After TMS, patients will be submitted to 45 minutes of manual therapy protocol.
2474216|NCT03076294|Experimental|rTMS after MT group|Patients will be submitted to 45 minutes of manual therapy protocol. After that, high frequency TMS will be applied with an eight-shaped coil angled at zero degrees from the sagittal axis and positioned at the C3 or C4 in accordance with the international 10-20 marking system (JASPER, 1958), which corresponds to the right or left primary motor cortex (M1). Twenty four stimulus trains will be provided at 10 Hz for five seconds each. The interval between the trains will be 25 seconds, totaling 1200 pulses for approximately 12 minutes, with 90% of resting motor threshold (RMT).
2474219|NCT03076294|Sham Comparator|Control group|In this group, the order of interventions will be randomized. Therefore, the volunteer can start with manual therapy or sham TMS. In manual therapy, patients will be submitted to 45 minutes of a protocol. In addition, with regard to sham TMS, the same parameters will be used, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation.
2474415|NCT03074890|Experimental|Intervention (cases)|Intervention: Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC:FFP:PLT) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
2474419|NCT03074890|No Intervention|No Intervention (control))|all patients with massive haemorrhage in which the massive transfusion protocol didn´t apply
2474461|NCT03074422|Experimental|Hypsnosis|During the fixation of the stereotactic frame, a single hypnosis session is performed by a certified senior anesthesiologist. Blood pressure, heart rate and respiratory rate are continuously monitored by the mean of a regular scope. Pain perceived during and after the procedure is quantifies by the mean of the Visual Analogue Scale (VAS) questionnaire. An open, standardized question will be asked to participants concerning feelings and thoughts about the frame fixation. Answers will be audio recorded. A standardized perceived distress questionnaire (PDI-13) will be performed.
3157736|NCT00371488|Experimental|GW572016 in combination with trastuzumab|"Lapatinib:~A specified dose of lapatinib will be orally taken once daily, at least one hour before or one hour after the morning meal. Lapatinib should be taken at the same time of day wherever possible.~The starting dose of lapatinib should be 750 mg/day, which will be increased to 1000 mg/day (dose escalation group) according to the dose escalation criteria.~Trastuzumab:~Trastuzumab (4 mg/kg/day in the first week and 2 mg/kg/day for the 2nd and subsequent weeks) will be administered by intravenous infusion over at least 90 minutes immediately after administration of lapatinib. The fifth (Day 36) and subsequent doses may be administered up to 3 days after the scheduled date. In this case, however, the all following doses should be administered at one-week intervals."
3157737|NCT00371501|Active Comparator|treatment arm 1|
3157738|NCT00371501|Placebo Comparator|Treatment arm 2|
2473733|NCT03079518|Active Comparator|Patients with HFREF|treated with intravenous single-shot 1000mg Ferric Carboxymaltose infusion; additional intervention: blood withdrawal
2473787|NCT03079271|Other|open label|
2473796|NCT03078894||Districts: Contaminated Water|Subjects in this group are from districts that have contaminated water sources.
2473798|NCT03078894||Districts: Uncontaminated Water|Subjects in this group are from districts that do not have contaminated water sources.
2473864|NCT03078699|Experimental|stereotactic body radiation therapy|
2473890|NCT03078374|Other|Reduced Anticoagulation|Reduced anticoagulation
2473909|NCT03078192|Experimental|PVD, left heart disease, lung disease|Patients with Pulmonary Vascular Disease (10 subjects), isolated left sided heart failure (10 subjects), and isolated lung disease(10 subjects) will undergo Xe MRI scans with GE-141, Hyperpolarized 129Xenon gas to develop diagnostic criteria for optimizing the sensitivity and specificity of XeMRI for the diagnosis of PVD
2473913|NCT03078192|Experimental|Pulmonary Vascular Disease|92 subjects being evaluated for undergoing right heart catheterization for evaluation of PAH or other cardiac or pulmonary disease for testing of diagnostic accuracy of XeMRI for diagnosis of PVD
2473967|NCT03078023|Experimental|swallowed sponge device|Swallowing a sponge prior to a clinical upper endoscopy. Patients diagnosed with Eosinophilic Esophagitis (EoE) > than 15 Eosinophils per high power field (phf) and failed to respond to Proton Pump Inhibitors (PPI) therapy. Will be asked to swallow a sponge, this is a 10 minute procedure done in the office prior to their clinical upper endoscopy. This will be sent for histology, >15 Eos phf would be considered active disease. We will compare the results of the sponge using the EPO staining technique compared to histologic response.
2474013|NCT03077698|Experimental|Sodium Cridanimod & progestin therapy|Sodium Cridanimod and progestin therapy (megestrol acetate) combination
2474104|NCT03077178|Experimental|Prospective cohort|Geriatric assessment
2474197|NCT03076463|Experimental|GRAPOM|Daily consumption for 6 weeks of 10 g of dried and milled grape pomaces solved in water. Samples will be collected at the beginning and the end of this period
2474201|NCT03076463|No Intervention|CTR|Follow-up for 6 weeks without intervention. Samples will be collected at the beginning and the end of this period
2474210|NCT03076034|Experimental|Post-menopausal women|We will use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
2474212|NCT03076034|Experimental|Males over 50 years|We will recruit males to this second study arm, to use the handheld Osteoprobe device to measure cortical bone reference point indentation properties.
2474318|NCT03075332|Experimental|protocol with physical exercise|Both groups underwent a combined training intervention consisting of aerobic and resisted exercises in the same training session
2474406|NCT03074851|Experimental|Salt Substitute|To seek the relationship between blood pressure and low sodium salt.
2474409|NCT03074851|Other|informational intervention|to give 1 month informational intervention
2474456|NCT03074474|Other|OviTex Permanent 1S|All subjects included in this post-market study will have a ventral hernia repaired with OviTex Permanent 1S reinforced bioscaffold.
2474511|NCT03074071|Active Comparator|Breast Cancer patient|Patients with Stage IV breast cancer will be taught to build hope by defining attainable goals for themselves in a Hope Enhancement Workshop.
2474515|NCT03074071|Active Comparator|Oncologists|Oncologists will will be taught to build hope by defining attainable goals for themselves and for their patients in a Hope Enhancement Workshop.
2474755|NCT03072368|Active Comparator|Blue eyes|50 babies born with blue eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2474756|NCT03072368|Active Comparator|Brown eyes|50 babies born with brown eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2474757|NCT03072368|Active Comparator|Green eyes|50 babies born with green eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2474758|NCT03072368|Active Comparator|Hazel eyes|50 babies born with hazel eyes will be photographed and followed-up at baseline; 3 months and 12 months of age
2474775|NCT03072004|Sham Comparator|Control|"Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the Low Level Laser Therapy (LLLT) group"
2474776|NCT03072004|Experimental|Low Level Laser Therapy|Leprosy patients with focal demyelinating neuropathy in compression sites of the ulnar and common peroneal nerves who will receive intervention with low-intensity laser therapy (LLLT).
2474815|NCT03071874|Experimental|AZD2014|"AZD2014 will be administered orally at a pre-determine dose~Twice daily for two consecutive days out of every seven days~Cycles will last 28 days"
2474867|NCT03071601|Experimental|Topical anesthesia|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5% Prilocaine applied for at least 30 minutes before laceration repair.
2474871|NCT03071601|Experimental|Subcutaneous injection anesthesia|Local anesthesia by a subcutaneous injection of a solution containing 1% Lidocaine and 0.005 mg/mL Epinephrine in the minutes before laceration repair.
2474964|NCT03071146||Bard® LifeStent® 5F Vascular Stent System|Patients with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be treated with percutaneous transluminal angioplasty (PTA) and the Bard® LifeStent® 5F Vascular Stent System.
2475002|NCT03070535|Experimental|HIGH meal|The HIGH meal is a 700 calorie breakfast style meal, with 50% total fat (25% saturated fat), 30% carbohydrates with a glycemic index of >70, and 20% protein.
2475005|NCT03070535|Experimental|LOW meal|The LOW meal is a 700 calorie breakfast style meal, with 25% of those calories coming from fat (5% saturated fat), 55% carbohydrate (with a glycemic index of <55), and 20% protein.
2475034|NCT03070301|Experimental|LEE011 and everolimus|Subjects will receive LEE011 200 mg daily, in combination with everolimus 5 mg daily; in the setting of toxicity, everolimus dosing will be changed to 2.5 mg daily or 2.5 mg every other day. Subjects will continue treatment until meeting one of the criteria for removal from study.
2475072|NCT03070106|No Intervention|Usual Care|usual care delivered by an endocrinologist
2475928|NCT03063957||Control|Patients that are not diagnosed with microscopic colitis
2473748|NCT03079401|No Intervention|Control Arm|Those subjects randomized to the control arm will receive standard LV recruitment or BDG with no injection.
2473802|NCT03079102|Experimental|inhaled nitric oxide (iNO)|20 ppm iNO delivered via mechanical ventilator connected to the iNO ventilator delivery system (iNOvent). Drug will be started as soon as possible after return of spontaneous circulation (ROSC) but no later than 4h after ROSC. Study drug will be dosed for 12h then tapered off over 1h.
2473803|NCT03079102|Placebo Comparator|Placebo|Nitrogen carrier gas delivered by identical system with similar dose/taper.
2473879|NCT03078660|Experimental|Smartphone Application|Participants will have access to a smartphone application that provides a healthy shopping list based on requirements, budget and discounts to improve dietary practices and weight
2473881|NCT03078660|Active Comparator|Traditional Nutritional Counseling|Participants will participant in a face-to-face counseling session with a registered dietitian.
2473917|NCT03078283|Experimental|Participants|Consumption of a given type of high-fiber snack food, with each individual functioning as her own control
2473945|NCT03078049||Dapagliflozin|Patients taking dapagliflozin
2473948|NCT03078049||Sitagliptin|Patients take sitagliptin
2474016|NCT03077802|Experimental|Modified Seldinger technique, Experienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
2474018|NCT03077802|Active Comparator|Seldinger technique, Experienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by experienced practitioner who were defined as board-certified anesthesiologist staffs and had experience of more than 50 central venous catheterizations in both techniques.
2474020|NCT03077802|Experimental|Modified Seldinger technique, Inexperienced group|Under ultrasound-guide, we will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
2474023|NCT03077802|Active Comparator|Seldinger technique, Inexperienced group|Under ultrasound-guide, the desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. The procedure will be performed by inexperienced practitioner who were junior residents and had experience of less than 50 central venous catheterizations in both techniques.
2474116|NCT03077243|Experimental|≤ 10 pack years smoking history|
2474118|NCT03077243|Experimental|> 10 py smoking history, no p53 mutation|
2474119|NCT03077243|Active Comparator|> 10 py smoking history, p53 mutation|
3157739|NCT00371501|Active Comparator|treatment arm 3|aspirin
2474306|NCT03075670|Experimental|N9-GP|
2474309|NCT03075670|Active Comparator|ALPROLIX®|
2474365|NCT03075059|Experimental|Intervention|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
2474368|NCT03075059|No Intervention|Control|Patients randomized to the control group will not receive the preoperative phone call or written materials and will only receive SOC Child Life services on the day of surgery.
2474425|NCT03074799|Active Comparator|TST-based Screening (Child contacts)|In the control clinics, decision regarding IPT will be made based on TST results, as is now the standard of care in this South African health district. In this setting, all TST negative children are initiated on IPT by the nurse at the local clinic. TST positive children are all referred to the district hospital for further evaluation of TB disease regardless of clinical symptoms. Again, clinical outcome data will be obtained from patient records and the same longitudinal child contact register.
2474433|NCT03074539|Active Comparator|Pulmonary Endarteriectomy - PEA|"CTEPH treatment via PEA. This arm includes patients who will receive Pulmonary Endarteriectomy (PEA) according to local CTEPH board recommendation. A standardized polygraphy will be conducted before the PEA - intervention, to obtain information concerning Sleep Disorder Breathing. 6 months after the PEA surgery another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2494238|NCT02940821|Active Comparator|Dentifrice|
3157740|NCT00371501|Placebo Comparator|treatment arm 4|placebo
3157741|NCT00371592|Experimental|1|Participants will receive acyclovir for 24 weeks
3157742|NCT00371592|Placebo Comparator|2|Participants will receive acyclovir placebo for 24 weeks
3157743|NCT00371709|Experimental|Arm 1|
3157744|NCT00371709|Other|Arm 2|Historical Comparator: control data derived from the TAXUS IV and TAXUS V studies
3157745|NCT00371735|Experimental|Arm 1|
3157746|NCT00371748|Experimental|Arm 1|
3157747|NCT00371748|Other|Arm 2|Historical Comparator: control data derived from a TAXUS V de novo lesion and stent size-matched cohort randomized to receive a single, planned 2.25 mm DES
3157748|NCT00371748|Other|Arm 3|Historical Comparator: control data derived from a TAXUS V de novo lesion size-matched cohort randomized to receive a 2.25 mm or 2.5 mm BMS
3157749|NCT00371774||1|Dermatologic patients in Canada for which Amevive is clinically indicated
2473751|NCT03079388|Experimental|Ready-to-use supplementary food + anti-infective bundle|The women randomized to this arm will receive a ready-to-use-supplementary food (RUSF) designed specifically for pregnancy. The RUSF will provide a total of 520 kcal, 18 g protein, and 200% of recommended daily allowance (RDA) for most micronutrients during pregnancy. The supplement is also optimized to provide excellent protein quality and optimal polyunsaturated fatty acid composition. These women will receive 5 anti-infective interventions: 1) insecticide-treated mosquito net, 2) monthly intermittent preventive treatment of malaria during pregnancy (IPTp) 3) azithromycin at the second and third trimester 4) albendazole given in second trimester, and 5) bacterial vaginosis testing and treatment at enrollment and again at weeks 28-34
2473755|NCT03079388|Active Comparator|Corn-soy-blend|The women randomized to this arm will receive the standard of care for Sierra Leone. The treatment provided to women in this group includes 3.5 kg super cereal with 350 g vegetable oil every two weeks. This provides 250 mg portion/day of the super cereal and 25g oil/day for the mother. Women will receive the food for the duration of their pregnancy. These women will receive the current recommendations of the government of Sierra Leone, which includes standard intermittent preventive treatment of malaria during pregnancy (IPTp) of 2 doses of sulfadoxine/ pyrimethamine, iron and folic acid supplement with a goal of 90 pills/pregnancy, an insecticide-treated mosquito net, and albendazole for deworming in the second trimester.
3192400|NCT00808288|Experimental|PF-00610355|
3192401|NCT00808288|Experimental|PF- 00610355|
2474021|NCT03077490||Single center vs. multicenter|Both Groups operated on by the same device (Transvaginal mesh Uphold TM Vaginal Support System) and in the same manner.
2474067|NCT03077399|Experimental|stroke|stroke patients, application of SCALA
2474069|NCT03077399|Experimental|control|patients without stroke, application of SCALA
2474108|NCT03077126|Other|Pre-surgery Ultrasound|Aixplorer® ShearWave Elastography (SWE™) Ultrasound. Participants will undergo ultrasound prep with Fleet Enema and ultrasound procedure at their pre-op visit one to two weeks before their standard of care prostatectomy.
2474175|NCT03076632|Active Comparator|Non-disabled volunteers|"Volunteers without neurological injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2474180|NCT03076632|Active Comparator|Spinal cord injury|"Volunteers with motor-incomplete cervical spinal cord injury.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2474182|NCT03076632|Active Comparator|Amyotrophic lateral sclerosis|"Volunteers with amyotrophic lateral sclerosis.~Interventions:~Cervical plus transcranial stimulation~Cervical stimulation plus hand/wrist exercise~Electromyographic (EMG)-triggered (closed-loop) stimulation"
2474211|NCT03076164|Experimental|Trametinib 1.5mg + Erlotinib 75mg|Phase 1: Accrue 6 patients on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily Phase 2: Accrue 24 patients (including 6 patients treated during Phase 1) on Trametinib 1.5mg + Erlotinib 75mg by mouth once daily or Trametinib 1.0mg + Erlotinib 100mg by mouth once daily.
3192402|NCT00808288|Experimental|PF - 00610355|
2474374|NCT03075176|Active Comparator|Wavefront optimized LASIK|
2474376|NCT03075176|Active Comparator|Wavefront optimized Photorefractive Keratectomy|
2474377|NCT03075176|Active Comparator|Topography-guided LASIK|
2474378|NCT03075176|Active Comparator|Topography-guided Photorefractive Keratectomy|
2474442|NCT03074656|Experimental|Therapeutic drug monitoring|Administration of infliximab according to a treatment strategy based on therapeutic drug monitoring and assessments of anti-drug antibodies
2474443|NCT03074656|Active Comparator|Standard care|Administration of infliximab according to standard clinical care, without knowledge of drug levels or status of anti-drug antibodies
2474541|NCT03074188||pre-dialysis patients|
2474545|NCT03074188||end stage renal disease|
2474583|NCT03073551|No Intervention|Control Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a pedometer and will be instructed to record their number of steps at the end of each day
2474585|NCT03073551|Active Comparator|Wii Group|Participants in this group will receive diabetic care and education as per the standard of care. They will also be given a Wii console and game to take home. Participants will be instructed on how to set up and use the Wii. These participants will also be given a pedometer and will be instructed to record their number of steps at the end of each day.
2474649|NCT03073343|Active Comparator|diabetic patients with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
2474651|NCT03073343|Active Comparator|non-diabetics with NAFLD|Patients will be prescribed 4 grams of betaine/day (2 grams PO BID) for the first 4 weeks of the study. After 4 weeks, patients in each cohort will be randomized (1:1) to continue receiving betaine 4 grams per day or increase to 8 grams per day for an additional 8 weeks.
2474705|NCT03072784|Active Comparator|group S|short time <90 m aortic cross clamping
2474706|NCT03072784|Active Comparator|group L|> 90 minutes aortic cross clamping
2474733|NCT03072524||Stroke patients|Stroke patients who will undergo the FAST PLUS test within 12 hours from the stroke onset.
2474791|NCT03072134|Experimental|Unresectable disease|Patients with unresectable tumors will undergo a biopsy followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
2474797|NCT03072134|Experimental|Resectable disease|Patients with resectable tumors will undergo a resection followed by injection of neural stem cells loaded with the virus and then receive standard chemoradiotherapy.
2474869|NCT03071718|Experimental|Med-D|Subjects will follow a Mediterranean diet for two months
2474872|NCT03071718|Active Comparator|Cont-D|Subjects will follow a control diet for two months
2474953|NCT03071211|Experimental|Plug-unplug Group|Participants randomized to plug-unplug catheter management. Participants plug and unplug catheters when they feel urge to void or at least every 4 hours during the day. Participants are given the option to use a large drainage bag for convenience overnight.
2474956|NCT03071211|No Intervention|Reference Group|Participants that do not fail inpatient voiding trial and go home without a catheter.
3192403|NCT00808288|Placebo Comparator|Placebo|
2473791|NCT03078933|Experimental|APT001NitricOxide tx 2x week 6 min+ SOC|APT001 Nitric OxideTherapy 2x week for 6 min. treatment time plus standard of care
2473792|NCT03078933|Experimental|APT001Nitric Oxide tx 2x week 12 min+SOC|APT001Nitric Oxide Therapy 2x week for 12 min. treatment time plus standard of care
2473793|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 6 min+SOC|APT001 Nitric Oxide Therapy 4x week for 6 min. treatment time plus standard of care
2473794|NCT03078933|Experimental|APT001Nitric Oxide tx 4x week 12 min+SOC|APT001Nitric Oxide Therapy 4x week for 12 min. treatment time plus standard of care
2473851|NCT03078712|Active Comparator|Peripheral Perfusion guided resuscitation|Resuscitation will be aimed at normalization of capillary refill time.
2473853|NCT03078712|Active Comparator|Lactate guided resuscitation|Resuscitation will be aimed at normalization or significant decrease in lactate levels.
2474039|NCT03077828|Experimental|Treatment (pembrolizumab, etoposide, carboplatin, ifosfamide)|Patients receive pembrolizumab IV over 30 minutes on day 1, etoposide IV over 60 minutes on days 1-3 of courses 1-2, carboplatin IV over 60 minutes on day 2 of courses 1-2, and ifosfamide IV over 24 hours on day 2 of courses 1-2. Pembrolizumab in combination with ICE chemotherapy repeats every 21 days for 2 courses, patients will then receive pembrolizumab as monotherapy on course 3.
2474135|NCT03076905|Experimental|IV drug|AUC0-t of single intravenous dose of F901318
2474162|NCT03076567||case|Stomach cancer cases from two previously conducted studies in China
2474168|NCT03076567||control|Controls from two previously conducted studies in China
2474206|NCT03076112|Experimental|Ipragliflozin|"Ipragliflozin 50 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
2474208|NCT03076112|Active Comparator|Sitagliptin|"Sitagliptin 100 mg in addition to their preexisting sulfonylurea and metformin~** Metformin and sulfonylurea's dosages~Metformin 500 mg - 2550 mg~Sulfonylurea: Glimepiride 1 mg - 8 mg or Gliclazide MR 30 mg - 120 mg"
3192404|NCT00808288|Active Comparator|Salmeterol|
2474308|NCT03075540|Other|YouTube Video|Participants will watch a 15-minute YouTube video. The video will provide information about hereditary breast and ovarian cancer and about the process of genetic counseling and testing.
2474639|NCT03073291|Experimental|Responsible Marijuana Vendor Training|The TrainToTend online responsible marijuana vendor training teaches responsible sales practices in five modules: Module 1, The Laws; Module 2, ID Checking; Module 3, Health Effects; Module 4, Customer Service, and Module 5, Rules of the Trade. The training content will be conveyed using online educational activities providing application and feedback such as in tabs with appropriate graphics and interactive simulations where users apply the skill and receive informative/corrective feedback.
2474641|NCT03073291|No Intervention|Usual and Customary Sales Practices Training|Usual and customary training in retail sales practices delivered to employees at retail recreational marijuana stores by store managers. Some retail stores in Colorado may receive responsible marijuana vendor training of some type from another state-approved training provider. Thus, we consider the outlets in the control group to have usual and customer sales training but not to be entirely untrained.
2474719|NCT03072472|Experimental|Endocuff-assisted Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy with the Endocuff Vision in situ on the scope
2474720|NCT03072472|No Intervention|Standard Flexible Sigmoidoscopy|Patients in this arm will receive their screening sigmoidoscopy without the Endocuff on the scope
3157750|NCT00371904|Experimental|1|
3157751|NCT00371904|Active Comparator|2|
2474908|NCT03071185|Experimental|Group PCA+B|Both intravenous PCA and lower limb blocks were used. For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve block with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.The interventions are femoral nerve block, common peroneal nerve block.
2474909|NCT03071185|No Intervention|Group PCA|Only intravenous patient controlled analgesia (PCA) was used postoperatively.
2474957|NCT03070873|Experimental|group A|accepted Perigee and Apogee mesh(PA)
2474959|NCT03070873|Experimental|group B|accepted Gynecare prolift mesh
2474961|NCT03070873|Placebo Comparator|group C|Traditional surgery without any mesh
2475125|NCT03069911|Experimental|Intervention|One injection of onabotulinumtoxinA (29 units for women and 40 units for men) will be injected into two facial muscles - the corrugator and procerus.
2475128|NCT03069911|Placebo Comparator|Control|One injection of saline solution will be injected into two facial muscles - the corrugator and procerus.
2475147|NCT03069391|Active Comparator|physical, cognitive, then interactive|physical exercise alone (PES) first, then iPACES
2475148|NCT03069391|Active Comparator|cognitive, physical, then interactive|cognitive exercise alone (iCE) first, then iPACES
3157752|NCT00371956|Active Comparator|1|raloxifene
3157753|NCT00371956|Placebo Comparator|2|placebo arm
3157754|NCT00371969|Active Comparator|1 - enhanced MI|Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes)
3157755|NCT00371969|Active Comparator|2- standard MI|The intervention consists of a standard motivational interview or viewing a DVD on HIV self-care.
3157756|NCT00371995|Experimental|1|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
3157759|NCT00372125|Active Comparator|Norditropin SimpleXx|0.3 mg/day or 0.4 mg/day if bodyweight was below or above 100 kg,for 4 weeks, 0.6 mg/day or 0.8 mg/day, for 11 months.
3157760|NCT00372125|Placebo Comparator|Placebo|Placebo for 12 months
3157761|NCT00372138|Experimental|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
3157762|NCT00372151|Experimental|L-Theanine|
3157763|NCT00372151|Placebo Comparator|Placebo|
3157764|NCT00372177|Active Comparator|EP1645|Single-Dose
3157765|NCT00372203|Experimental|Endobronchial ultrasound|
3157766|NCT00372216|Active Comparator|1|Pre-hospital loading dose of 600 mg Clopidogrel as early as possible (in addition to standard infarction therapy)
2473900|NCT03078257|Experimental|dual antiplatelet therapy|clopidogrel +aspirin
2473902|NCT03078257|Experimental|tirofiban in PV|clopidogrel +aspirin + tirofiban in PV
2473904|NCT03078257|Experimental|tirofiban in IC|clopidogrel +aspirin +tirofiban in IC
2473907|NCT03078257|Experimental|antiplatelet thrombolysin|clopidogrel +aspirin +antiplatelet thrombolysin
2473910|NCT03078257|Placebo Comparator|placebo|clopidogrel +aspirin +placebo
2474001|NCT03077867|Experimental|test HA|synthetic hydroxyapatite alone sinus floor augmentation with bone graft
2474002|NCT03077867|Experimental|test HA vicryl|synthetic hydroxyapatite mixed with polylactic-polyglycolic acid sinus floor augmentation with bone graft
2474003|NCT03077867|Experimental|test HA-PRF|synthetic hydroxyapatite mixed with i-PRF sinus floor augmentation with bone graft
2474004|NCT03077867|Active Comparator|control|anorganic bovine bone sinus floor augmentation with bone graft
2474060|NCT03077464|Active Comparator|behavioral nutrition education|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory, for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included: 1) nutrition label literacy; 2) drinking water; 3) eating colors of the rainbow; 4) healthful snacks; 5) benefits of fruit and vegetable consumption; 6) moving more and sitting less; and 7) taking healthy habits home.
2474062|NCT03077464|Experimental|behavioral nutrition education plus skills|Set of curricular nutrition education modules, previously developed and based on Social Cognitive Theory for the HOP'N After-School program, with additional materials from MyPlate. Materials were employed to increase healthy eating behavioral capability, self-efficacy, attitudes, and enjoyment. Topics included:1) nutrition label literacy;2) drinking water;3) eating colors of the rainbow;4) healthful snacks;5) benefits of fruit and vegetable consumption;6) moving more and sitting less;and 7) taking healthy habits home. Designed to differ from behavioral nutrition education condition by devoting at least 15 minutes of each session to an additional behavioral skills training component. The behavioral skills component was designed to bolster behavioral capability, healthy eating attitudes, self-efficacy, and proxy efficacy with activities such as snack preparation sessions, role-playing games, fruit and vegetable tasting, and playing games that promoted healthier dietary behaviors.
2474281|NCT03075956|Experimental|5 mg E4 single-dose|Group A: a single 5 mg E4 dose will be administered under fasted conditions during period 1.
2474284|NCT03075956|Experimental|15 mg E4 single-dose|Group B: a single 15 mg E4 dose will be administered under fasted conditions during period 1.
2474285|NCT03075956|Experimental|45 mg E4 single-dose|Group C: a single 45 mg E4 dose will be administered under fasted conditions during Period 1.
2474286|NCT03075956|Experimental|15 mg E4 multiple-dose|15 mg E4 dose will be administered once daily for 14 consecutive days during Period 2.
2474319|NCT03075319|Experimental|Received perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken and gave to experimental group in the day after surgery.
2474321|NCT03075319|Active Comparator|Didn't receive perioperative photograph|Perioperative knee range of motion (ROM) were measured with long arm goniometer immediately after close the wound. Perioperative knee photographs in full flexion and extension positions were taken but participants in this group didn't receive perioperative photographs.
2474369|NCT03075137|Experimental|External Counter Pulsation (ECP) group|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
2474373|NCT03075137|No Intervention|Control group|Guideline-driven standard medical treatment
2474417|NCT03074734|Other|Exposure to secondhand tobacco smoke|Exposure to secondhand tobacco smoke in outside smoking areas
2474463|NCT03074448|Active Comparator|Sodium Picosulfate solution (Picoprep)|On the eve of the examination, all participants on Sodium picosulfate will take four tablets of Dulcolax with tea or water in the morning, liquid diet (juice, tea or water) at lunch, two capsules of 25mg Dramamine Capsgel in the afternoon, Sodium picosulfate dissolved in 150mL of cold water thirty minutes after, followed by drinking at least five 250-ml cups of water or other light liquids until midnight, with absolute fasting up to the time when the colonoscopy will be performed.
2474468|NCT03074448|Experimental|Aquanet bowel cleansing devices|For bowel preparation with the bowel cleansing device, intestinal lavage will be performed with the device, making use of water, pressure, and gravity to enhance bowel cleansing. The water used in this procedure was previously triple-filtered by passage on carbon, micro-pellets and ultraviolet light. The preparation will be carried out by a trained nurse.
3157767|NCT00372216|No Intervention|2|Standard infarction therapy (without study-specific additions, no Clopidogrel before angiography)
3157768|NCT00372229|Experimental|Valganciclovir Cytomegalovirus (CMV) Prophylaxis|
2474977|NCT03070574|Experimental|2400 MG mesalamine (5-ASA) total|2400mg (1200mg mesalamine/1200mg) mesalamine once daily in the morning for the treatment phase of the study (24 months)
3157769|NCT00372229|Active Comparator|Pre-emptive CMV Therapy|
3157770|NCT00372268|Active Comparator|B|Administration of ropivacaïne 0,2% by direct intra-abdominal administration at the end of the surgery
3157771|NCT00372268|Active Comparator|C|Administration of ropivacaïne 0,75% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
3157772|NCT00372268|Placebo Comparator|A|Administration of Nacl 0,9% by nebulization in the insufflated gas during all the surgical procedure with direct intra-abdominal administration of Nacl 0,9%
3157773|NCT00372268|Placebo Comparator|D|Administration of Nacl 0,9% by direct intra-abdominal administration at the end of the surgery
3157774|NCT00372281|Experimental|Cliavist|
3157775|NCT00372294|Active Comparator|1|Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
3157776|NCT00372294|Active Comparator|2|Intravitreal Clindamycin & Dexamethasone
3157777|NCT00372437|Experimental|1|
3157778|NCT00372476|Experimental|Imatinib + Vinorelbine|
2473865|NCT03078491|Experimental|Intervention|The intervention group will use eCGM (CGM with Diabetes Management Platform(DMP)) and an activity meter. The DMP will be pre-loaded with geriatric-specific education material, weblink to online education and surveys. The CGM, insulin delivery, and activity data uploaded from the DMP will be analyzed by the clinical decision support system (CDS), which will provide insulin dosing recommendations to the study physicians, who will then accept or reject changes in therapy. The DMP can also be configured to route the insulin regimen change approved by the study physician to the designated care providers of the patient. Blue-tooth unabled insulin pens will also provide additional data to verify if the patient is taking recommended insulin doses.
2473869|NCT03078491|No Intervention|Attention Control|The attention control group will receive an android tablet pre-loaded with activity monitor devices, education material, and weblink to online education and surveys. However, the data will not be analyzed by CDS. An independent physician and a study staff member- only caring for the control group subjects will review the insulin and glucose data at in-person and remote study visits and make appropriate dosing adjustments based on self monitoring glucose levels
2473916|NCT03078361|Active Comparator|LATINOS CARES Toolkit|Participants assigned to the LATINOS CARES condition will receive an I-FOBT kit, DVD and photonovella booklet from the study coordinator. The participant will view the DVD in a private area (headphones are available) using a portable DVD player in clinic before seeing the provider. The DVD will be about 8-10 minutes long. The participant will take the LATINOS CARES toolkit and I-FOBT home after the clinic visit. The participant will be instructed to re-review the materials and complete the I-FOBT stool sampling at home.
2473924|NCT03078361|Active Comparator|Standard Intervention (SI)|Participants assigned to the standard brochure (SI) will be provided a packet containing the CDC Spanish-language tri-fold brochure titled Screen for Life and an I-FOBT card. The participant will be instructed to review the materials in clinic and complete the I-FOBT stool sampling at home. This brochure describes CRC, risk factors, symptoms, screening tests, benefits of screening, and insurance coverage.
2473973|NCT03077984|Experimental|the cohort of Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
2473976|NCT03077984|No Intervention|the cohort of western medicine treatment|The cohort of Western medicine treatment refers to the treatment of cerebrovascular disease prevention and cure guideline of China-related programmes, including anti-platelet aggregation, blood pressure,blood glucose,Blood Lipids lowering therapies.
3192405|NCT00808301|Other|A/B|This is a cross-over design, i.e. each patient is treated with either oat or control products in different times.
3192406|NCT00808314|Active Comparator|LL for CAD|Subjects with <5% pre-test low likelihood for CAD based on Diamond and Forrester criteria will be recruited to undergo both rest/stress dipyridamole PET followed by a rest/stress Lexiscan(TM) PET with 30 days.
3192407|NCT00808314|Active Comparator|CAD|Subjects with existing mild-moderate ishemia demonstrated by a recent (< 1 month) rest/stress dipyridamole PET will undergo a rest/stress Lexiscan(TM) PET.
2474088|NCT03077230|Experimental|Pre/Post Test of a Lung Cancer Screening Decision Aid|
2474124|NCT03076918|Active Comparator|Conventional PDT|Aktilite® Galderma
2474125|NCT03076918|Experimental|FLEXITHERALIGHT PDT|Light Emitting Textile Device
2474245|NCT03076437|Experimental|Anti-CD19-CAR transduced T cells|"Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.~Interventions:~Drug: Fludarabine Drug: Cyclophosphamide Biological: Anti-CD19-CAR transduced T cells"
2474262|NCT03075683|Experimental|Cognitive behavioural therapy|Internet-based cognitive behavioural therapy for insomnia
2474264|NCT03075683|Active Comparator|Applied relaxation|Internet-based applied relaxation
2474291|NCT03075488|Active Comparator|Conventional landmark-guided technique|In this arm spinal anesthesia will be performed by using conventional cutaneous landmarks
2474296|NCT03075488|Experimental|Accuro device guided technique|In this arm spinal anesthesia will be performed only after having detected the intralaminar space, the mid-line, the depth and the orientation for spinal needle insertion with pre-procedural scan performed with Accuro device
2474337|NCT03075280|Experimental|High carbohydrate liquid diet|No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
2474338|NCT03075280|No Intervention|Routine ERCP group|Preoperative fasting more than 6 hours as usual.
2474390|NCT03074864|Experimental|EGFR-mutant IIIA/IIIB NSCLC|Erlotinib Hydrochloride 150mg daily intercalated with radiotherapy
3192408|NCT00808327|Active Comparator|1|Bupivacaine alone
2474535|NCT03073863|Active Comparator|Atorvastatin 10mg|5006 patients received continuous medication with atorvastatin 10mg/day after run-in period.
2474538|NCT03073863|Experimental|Atorvastatin 80mg|4995 patients received medication with atorvastatin 80mg/day after run-in period.
2474593|NCT03073564|No Intervention|Incremental cardiopulmonary test|Incremental cardiopulmonary test for upper limbs will be performed only to identify patients who exhibit dynamic hyperinflation during upper limb exercise.
2474594|NCT03073564|Experimental|Endurance test|The endurance test for upper limbs will be performed in two conditions: In the first the patients perform the test in usual breathing, without the use of EPAP. In the second the test will be performed using the EPAP mask.
2474595|NCT03073564|Experimental|Functional test|The functional test for upper limbs will be performed from protocol already published for the 6-min pegboard and ring test (6PBRT). In this stage the patients will perform the 6PBRT in usual breathing and as the use of the EPAP mask.
2474624|NCT03073226|Experimental|Barrett's surveillance Olympus Spectrum|Barrett's surveillance with Olympus Spectrum.
2474625|NCT03073226|Experimental|Barrett's Surveillance Olympus Elite|Barrett's surveillance with Olympus ELITE.
2474626|NCT03073226|Experimental|Polyp Surveillance Olympus Spectrum|Colonic polyp surveillance/screening with Olympus Spectrum.
2474627|NCT03073226|Experimental|Polyp Surveillancewith Olympus ELITE.|Colonic polyp surveillance/screening with Olympus ELITE.
3192409|NCT00808327|Active Comparator|2|Bupivacaine plus Fentanyl
2494307|NCT02940366|Placebo Comparator|Atorvastatin 20 mg orally daily|
3192410|NCT00808366|Experimental|RV4104A ointment|
3192411|NCT00808366|Active Comparator|bifonazole-urea ointment|
3208645|NCT00976755|Experimental|Arm A: Everolimus|"Everolimus:~10mg daily"
2473922|NCT03078218|Experimental|After period group|Consist in a systematic pulse oximetry screening where all eligible newborns will be included in the same maternity wards
2474007|NCT03077633|Active Comparator|Cervical Cerclage + Progesterone|Placement of a Cervical Cerclage plus the daily administration of vaginal progesterone (200mg tab)
2474010|NCT03077633|Placebo Comparator|Progesterone|Daily administration of vaginal progesterone (200mg tab)
2474065|NCT03077451|Experimental|Treatment (nelfinavir mesylate)|"DOSE NELFINAVIR MESYLATE: Patients receive standard dose nelfinavir mesylate PO BID for 4 weeks in the absence of PD. Patients with PD at 4 weeks proceed to high-dose nelfinavir. At week 8, if there is SD or PR, patients advance to high-dose nelfinavir mesylate. Patients discontinue standard dose nelfinavir mesylate 4 weeks after documentation of CR.~HIGH DOSE NELFINAVIR MESYLATE: Patients with PD continue to receive high-dose nelfinavir mesylate PO BID for 4 more weeks. If there is PD documented after 4 weeks at the high dose level, nelfinavir is discontinued. If there is SD or PR, patients continue receiving nelfinavir mesylate for 16 weeks. If there is CR, patients discontinue high-dose nelfinavir mesylate 4 weeks after documentation of CR."
2474096|NCT03077022||Femoracetabular impingent (FAI)|Subjects will be given a prescription for physical therapy specifically for Femoracetabular impingent (FAI). They will then be followed clinically per the investigator's normal routine and the gold standard.
2474131|NCT03076853||Patients with Pharmaceutical Record|
2474157|NCT03076580||cardiomyopathy|Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
2474165|NCT03076580||disease control|Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.
2474173|NCT03076580||healthy control|Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
2474224|NCT03076320|Experimental|PFD+M-DDO|"Pirfenidone with M-DDO Active ingredients: Pirfenidone 10% with modified oxide diallyl disulfide (M-DDO) 0.016% Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency an duration: topically applied every 12 hours for 6 months."
2474227|NCT03076320|Active Comparator|A+PBO|"Adapalene with benzoyl peroxide Active ingredients: 0.1% Adapalene with 2.5% benzoyl peroxide. Dosage form: gel. Dosage: standard finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 month"
2474270|NCT03075813|Experimental|Intervention Cluster|"Surgical surveillance data submitted to the DICON Surgical Database will undergo immediate analysis by optimized SPC methods. If a signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is required.~Optimized SPC methods include the application of two SPC charts. The investigator determined that when either chart identifies a signal, the study will have approximately 90% sensitivity and 65% specificity to identify important increases in rates of SSI."
2474271|NCT03075813|No Intervention|Control Cluster|Local personnel in clusters randomized to traditional surveillance and feedback will receive bar graph reports and data interpretation per routine DICON surveillance. These reports will be provided every 6 months.
2474392|NCT03074955|Active Comparator|Control|"leg wrapping without tension & maintain supine position~Apply elastic bandages to both legs without tension.~Maintain supine position after injecting propofol.~After 3 minutes from propofol injection, remove elastic bandages~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
2474396|NCT03074955|Experimental|Trendelenburg only|"leg wrapping without tension & apply Trendelenburg position~Apply elastic bandages to both legs without tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
2474400|NCT03074955|Experimental|Trendelenburg & leg wrapping|"leg wrapping with tension & apply Trendelenburg position~Apply elastic bandages to both legs with tension.~After injecting propofol, apply Trendelenburg position ( 10 degree )~After 3 minutes from propofol injection, remove elastic bandage and revert to supine position.~induction using propofol 2mg/kg~After bispectral index (BIS) goes below 60 & patient become unconsciousness, inject rocuronium 0.6mg/kg~intubate patient between 3 and 4 minutes after propofol injection~measure blood pressure ( systolic, diastolic, mean ) & heart rate at 1,2,3,4,5 minutes after propofol injection~phenylephrine injection if hypotension develops"
3192412|NCT00808379|Other|Arm 2 (Radiation + boost )|"Radiation dose to pelvis will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Boost Field - Will be given to all the patients in the radiotherapy alone followed by surgery arm.~The boost will be given with by 3dimensional conformal radiotherapy to a dose of 15-20 Gy. After 45Gy the boost will be planned on the original tumor volume."
3192413|NCT00808379|Active Comparator|Arm 1 (standard) Chemoradiation|"The Radiation dose will be delivered at 1.8 Gy per day, five days per week, to give a total of 25 fractions over a period of five weeks for a total of 45 Gy.~Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles."
2474688|NCT03072888|Experimental|TENS|TENS treatment will be apply with 30 minutes sessions seven times per day at the intensity between 9-15 milliamps (mA) which will be adjusted depending on the sensitivity of each individual patient.
2474696|NCT03072888|Sham Comparator|Control|Patients will receive 30 minutes sessions seven times per day of sham TENS therapy without the intensity impulse.
2474737|NCT03072589|Experimental|Regadenoson infusion|Dose escalation of Regadenoson infusion
2474898|NCT03071380|Experimental|T test|Test drug (Repatoxaban) 1 tablet contains 10 mg rivaroxaban
2474899|NCT03071380|Active Comparator|B reference|Reference drug (Xarelto) 1 tablet contains 0 mg rivaroxaban
2473946|NCT03077997|Experimental|Space from Diabetes|Participants will be assigned the 'Space from Diabetes' intervention in a supported mode for 8 weeks. Participants are assigned a clinical supporter, who will be a psychological well-being practitioner in an NHS Mental Health Service. As the participant works through the programme content, the supporter will provide them with a review of their progress and interactions with the platform 6 times over the 8 week supported period.
2473986|NCT03077789|Experimental|TRABECULOTOMY|
2474046|NCT03077516||Mobi-C|Prior recipient of Mobi-C Disc in IDE/Post Approval Study
2474049|NCT03077516||ACDF|Prior control subject in IDE/Post Approval Study
2474080|NCT03077217|Active Comparator|the high-dose rifaximin|The high-dose rifaximin group was given rifaximin 1200 mg/day for 8 weeks.
2474081|NCT03077217|Active Comparator|the low-dose rifaximinl group|The low-dose rifaximin group was given rifaximin 800 mg/day for 8 weeks.
2474082|NCT03077217|Placebo Comparator|the control group|The control group didn't receive rifaximin treatment
3192414|NCT00808392|Experimental|1|
3192415|NCT00808392|Active Comparator|2|
2474185|NCT03076489|Experimental|high consumption habits|high consumption habits of fatty and sugary foods
2474187|NCT03076489|Experimental|low consumption habits|low consumption habits of fatty and sugary foods
2474204|NCT03076138|Experimental|Test group|Bone grafting with gene-activated matrix (OCP + plasmid DNA with VEGF gene)
2474248|NCT03076008||MPFL Reconstruction|Subjects undergoing MPFL Reconstruction
2474272|NCT03075631||Patients with Acute Pancreatitis|Patients with Acute Pancreatitis
2474315|NCT03075423|Experimental|Ipilimumab plus nivolumab|Ipilimumab 1mg/kg plus nivolumab 3mg/kg, both, will be administered i.v. every 3 weeks for 4 times as an induction therapy followed by a maintenance therapy with a flat dose of 240 mg nivolumab biweekly until progression.
2474316|NCT03075423|Active Comparator|Sunitinib|Sunitinib will be administered at a starting dose of 50 mg/die p.o. for 4 weeks on and 2 weeks off per cycle until progression.
2474413|NCT03074721|Other|PCI with PCI Suite Software|
2474416|NCT03074721|Other|conventional PCI|
2474467|NCT03074435|No Intervention|Control|No intervention
2474470|NCT03074435|Experimental|insecticidal paint|The insecticidal paint contains two organophosphates, chlorpyriphos(1.5%) and diazinon (1.5%), and an insect growth regulator (IGR),pyriproxyfen (0.063%), as active ingredients.
2474476|NCT03074435|Experimental|Larvicides|The larvicide is a slow release formulation containing Bacillus thuringiensis Var Israelensis.
2474479|NCT03074435|Experimental|Ivermectin|This arm consists in an injectable dose of Ivermectin given to peri-domestic animals.
2474481|NCT03074435|Experimental|Information, Education, Communication|After a sociological study during the pre-intervention year, this arm will consist in a reinforced communication strategy relative to the nationwide current one
2474516|NCT03073993|Active Comparator|Nasogastric|Feeding tube insertion in nasogastric group
2474520|NCT03073993|Active Comparator|Orogastric|Feeding tube insertion in orogastric group
2474559|NCT03073707||Household|Sample collection will be anticipated for 20 cases of NTS infections and household/environment in order to analyze 10 combinations of NTS strains in the index patient and its environment
2474630|NCT03073473||Concordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy matches the recommendations from the NantHealth GPS Cancer Test.
2474631|NCT03073473||Discordant with GPS Cancer Test|Patients with advanced cancer who undergo GPS Cancer testing whose therapy does not match the recommendations from the NantHealth GPS Cancer Test.
2474632|NCT03073473||CNA controls without testing|Retrospective patients in the COTA database matched by similar characteristics (CNA matched).
2474731|NCT03072693|Active Comparator|Group 1|Home-based remote heart failure management
2474735|NCT03072693|Placebo Comparator|Group 2|Home-based physiological parameter recording only
2474844|NCT03071588|Active Comparator|Control|the conventional protocol in indirect pulp capping include the use of mechanical rotary burs for caries removal in teeth with reversible pulpitis.
2474851|NCT03071588|Experimental|Conservative|the conservative protocol of indirect pulp capping include the use of Carisolv gel for caries removal in teeth with reversible pulpitis.
2474885|NCT03071367|Experimental|Clinical Simulation|
2474888|NCT03071367|No Intervention|Classical Learning|
3157779|NCT00372502|Active Comparator|1|
3157780|NCT00372502|Experimental|2|
2474971|NCT03070756|Other|treatment group (auto-CPAP)|"Participants of this study undergo an diagnostic PSG night. The diagnostic night is followed by an auto-CPAP treatment night.~Interventions:~The treatment night is in line with the routine procedure of the laboratory except the following intervention: the device settings for the treatment night are applied according to the study protocol (minimal intervention)."
2475047|NCT03070145|Experimental|Exercise Intervention|"12-weeks brisk walking and strength training~150 minute moderate aerobic activities, such as brisk walking~Strength training 3 days /week~One on one sessions with exercise physiologist~Optional group sessions"
2475049|NCT03070145|No Intervention|Usual Care|Usual Care provided
3157781|NCT00372515|Experimental|High dose gefitinib|
3157782|NCT00372632|Placebo Comparator|placebo|
3157783|NCT00372632|Experimental|sulfadoxine-pyrimethamine|
3157784|NCT00372645|Experimental|Diet|200 µg folate per day from folate-rich foods
3157785|NCT00372645|Experimental|Folic acid supplement|200 µg folate per day from supplemental folic acid
3157786|NCT00372645|Experimental|Metfolin supplement|200 µg folate per day from supplemental Metafolin®
3157787|NCT00372645|Placebo Comparator|Placebo|Placebo
3157788|NCT00372684||1|with severe malaria hospitalized in ICU
3157789|NCT00372684||2|with uncomplicated malaria
3157790|NCT00372762|Active Comparator|Furosemide|Patients will be assigned to furosemide therapy (20mg to 80mg) orally, once or twice daily for an 8-week period.
3157791|NCT00372762|Active Comparator|Bumetanide|Patients will be assigned to bumetanide therapy at an equipotent dose to furosemide therapy (1mg bumetanide is equivalent to 40mg furosemide)for an 8-week period.
3157792|NCT00372788|Active Comparator|1|Pemetrexed
3157793|NCT00372788|Experimental|2|AZD6244
3157794|NCT00372814|Experimental|Multisystemic Therapy (MST)|Adolescents receiving MST will receive Intensive Home-Based Family Therapy which will consist of home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their daily diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
3157795|NCT00372814|Active Comparator|Telephone Support Calls|Adolescents receiving Supportive Telephone Calls (TS) will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
3157796|NCT00372840|Experimental|Arm I|Patients receive a specific print intervention manual entitled Facing Forward Series: Life After Cancer Treatment and a general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
3157797|NCT00372840|Active Comparator|Arm II|Patients receive the general print intervention fact sheet entitled The Cancer Information Service, Questions and Answers.
3157798|NCT00372853|Experimental|Arm A|
3192416|NCT00808418|Experimental|Cohort|
2474152|NCT03076645|Experimental|Experimental|The Experimental Group will be placed in a group using the matching algorithm. Facilitator support and education intervention
2474228|NCT03076372|Experimental|MM-310 monotherapy|MM-310 will be administered by IV infusion over 90 minutes on the first day of each 21 day cycle.
2474273|NCT03075800|No Intervention|Assertive Community Treatment (ACT) - Only|ACT is a multidisciplinary, team-based approach to providing a range of treatment, rehabilitation, and support services to high-need, high-risk people with severe mental illness who tend not to use clinic-based services; most services are provided on an outreach basis (e.g., in the person's home) and services are available 24 /7(27).
2474275|NCT03075800|Experimental|Assertive Community Treatment+Illness Management and Recovery|IMR follows a manualized curriculum to help clients pursue personal recovery goals and to teach them information, strategies, and skills over 11 modules (e.g., using medications, coping with stress) to manage their psychiatric illness. IMR can be provided in individual or group formats. The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
2474603|NCT03073694|Experimental|Melphalan Group|Melphalan 60 mg/m2 (milligrams per meter squared) 45 minutes into the perfusion.
3157799|NCT00372853|Experimental|Arm B|
3157800|NCT00372879|Experimental|Crossover group 1|Vitamin E first and placebo second
3157801|NCT00372879|Experimental|Crossover group 2|Placebo first then vitamin E
3157802|NCT00372892|Active Comparator|A|Rituximab
3157803|NCT00372892|Placebo Comparator|B|Saline placebo iv infusion
3157804|NCT00372918|Other|1|Transnasal Esophagoscopy
3157805|NCT00372944|Active Comparator|1|Xeloda
3157806|NCT00372944|Experimental|2|AZD6244
3157807|NCT00373009|Experimental|Core stabilization and psychosocial education|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale. In addition, a psychosocial education program (PSEP) will be used for this group.
3157808|NCT00373009|Active Comparator|Core stabilization exercise only|A core stabilization exercise program (CSEP) is used in this group and has sound biomechanical and anatomical rationale.
3157809|NCT00373009|Active Comparator|Psychosocial education class only.|A psychosocial education program (PSEP) will be used in this group.
3157810|NCT00373009|Other|Traditional Army training|Traditional Army training will be used in this group.
3157811|NCT00373048|Placebo Comparator|Placebo, tablet|
3157812|NCT00373048|Experimental|mefloquine, tablet|
3157813|NCT00373061||Pregnant Women Exposed to Xolair®|Women who are exposed to at least one dose of Xolair® within 8 weeks prior to conception or at any time during their pregnancy will be followed to completion of their pregnancies.
3157814|NCT00373074|Active Comparator|15 cc|15 cc of blood used for Epidural Blood Patch
3157815|NCT00373074|Active Comparator|20 cc|20 cc of blood used for Epidural Blood Patch
3157816|NCT00373074|Active Comparator|30 cc|30cc of blood used for Epidural Blood Patch
3157817|NCT00373087|Active Comparator|L-dopa + entacapone|L-dopa + entacapone
3157818|NCT00373087|Experimental|L dopa / placebo|L dopa / placebo
3157819|NCT00373100|Experimental|Zinc|Zinc acetate
3157820|NCT00373100|Placebo Comparator|Placebo|Placebo
3157821|NCT00373152|Experimental|RadioFrequency Ablation for Breast Cancer|
3157822|NCT00373178|Active Comparator|Metformin,lifestyle counselling|
3157823|NCT00373204|Experimental|Xcytrin® (motexafin gadolinium)|
3157824|NCT00373217|Experimental|Group 1|Patients in group one will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin in week 1. Treatment may repeat every 3 weeks for up to four courses. They will then undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to four courses.
3157825|NCT00373217|Experimental|Group 2|Patients in group two will undergo surgery to remove as much of the tumor as possible. Within 2 weeks after surgery, patients will receive an injection of the vaccine once a week for 3 weeks. Treatment may repeat every 14 weeks for two courses. After finishing the first course of vaccine therapy, patients will receive a 3-hour infusion of paclitaxel and an infusion of carboplatin every 3 weeks for up to eight courses. Some patients may undergo a second surgery within 6 weeks after completing the fourth course of chemotherapy and undergo tumor and/or lymph node tissue collection.
3157826|NCT00373230|Experimental|1|Internet based telemedicine weight maintenance program
3157827|NCT00373230|Active Comparator|2|In person weight maintenance monthly consultations
3157828|NCT00373243|Experimental|Subjects receiving GW406381|Subjects will receive single oral dose of 20 milligram (mg) of GW406381.
3157829|NCT00373373|Placebo Comparator|A|Chemotherapy + Placebo
3157830|NCT00373373|Active Comparator|B|Chemotherapy + Sorafenib
2474075|NCT03077308||Rett Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 60 individuals with Rett syndrome.
2474076|NCT03077308||MECP2 Duplication Syndrome|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with MECP2 Duplication syndrome.
2474078|NCT03077308||Rett-related disorders|Auditory and Visual event-related potentials (ERP) and EEG in 18 individuals with CDKL5 syndrome and 14 individuals with FOXG1 syndrome.
2474079|NCT03077308||Controls|Auditory and Visual event-related potentials (ERP) and EEG in 60 Control individuals (30 males and 30 females).
2474095|NCT03076957|Experimental|Treat Regimen|CKD-516(investigational Drug) Irinotecan
2474166|NCT03076827|Experimental|Group A|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the morning
2474170|NCT03076827|Experimental|Group P|Group to begin surgery(total hip replacement or hip hemi-arthroplasty) in the afternoon
2474259|NCT03075657|Active Comparator|Risperidone group|Schizophrenia patients with predominant negative symptoms on Risperidone monotherapy
2474261|NCT03075657|Experimental|Risperidone with Ramelteon group|Schizophrenia patients with predominant negative symptoms on Risperidone with add-on Ramelteon therapy
2474263|NCT03075657|Active Comparator|Haloperidol group|Schizophrenia patients with predominant positive symptoms on Haloperidol monotherapy
2474265|NCT03075657|Experimental|Haloperidol with Ramelteon group|Schizophrenia patients with predominant positive symptoms on Haloperidol with add-on Ramelteon therapy
2474323|NCT03075475|Experimental|CETA Treatment|For treatment group participants, they will then have weekly Common Elements Treatment Approach (CETA) counseling sessions with a counselor lasting no more than 1.5 hours per session, and a total of approximately 10-12 sessions. They will then repeat the assessment instrument after their last session, as well as 6 months after finishing treatment, and these meetings will again last no more than 1.5 hours. All total, it is expected that treatment group participants will have 13 meetings with a study team member or counselor over the course of their participation.
2474324|NCT03075475|No Intervention|Waitlist|Waitlist group participants be contacted by a study team member from the local partner organization regularly (weekly) while they are on the wait list. These contacts from the study team will be short and last less than 30 minutes and will be used to briefly assess symptom levels and safety. At the end of their wait period, they will be asked to complete the assessment instrument a second time and this meeting will take no more than 1.5 hours. For participants in the waitlist group, we estimate 13 meetings total during their wait period (2 meetings of no more than 1.5 hours, 10 contacts less than 30 minutes).
2474349|NCT03075098|Experimental|colposcopy of intraepithelial carcinoma|Digital colposcope will be used to detect the swede score of the lesion
2474421|NCT03074838|Experimental|Transarterial aortic valve implantation|Patients that are treated by trans arterial valve implantation (TAVI)
2474426|NCT03074838|Active Comparator|Surgical aortic valve replacement|Patients that are treated by surgical aortic valve replacement (SAVR)
2474543|NCT03073902||Observed group|The project is planned to explore the correlation of PD-L1 expression in non-small lung cancer tissue and peripheral blood T cell and serum.The investigators have designed to detected the expression levels of PD-L1 protein in cancer tissue and detected the expression levels of PD-L1 in peripheral blood T cell and serum by using variance analysis of repeated measures design information.
2474576|NCT03073629|Active Comparator|Clinical Pathway Cohort|Patients with isolated RV failure will be evaluated and managed in a specialized cardiovascular clinic.
2474579|NCT03073629|No Intervention|Standard Care|Patients with isolated RV failure will receive standard care and follow up.
2474668|NCT03073369|Active Comparator|Oral Ergocalciferol|Oral Ergocalciferol 50000 IU once daily for 6 weeks
2474679|NCT03073369|Placebo Comparator|Placebo|
2474746|NCT03072615||1|receiving TE before and 30 min after TIPS
2474749|NCT03072615||2|receiving SWE before and 7 days, 6 weeks and 3 months after TIPS
2474801|NCT03072173|Experimental|PSG with Xylometazoline then placebo|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive Xylometazoline on night 2 of PSG and placebo on night 3 of PSG."
2474810|NCT03072173|Experimental|PSG with placebo then Xylometazoline|"Patients are administered nasal CPAP with humidifier prior to PSG~Patients in this arm receive placebo on night 2 of PSG and Xylometazoline on night 3 of PSG."
2474834|NCT03071627|Active Comparator|News with Spin|News items reporting results of animal studies with spin.
2474836|NCT03071627|Experimental|News without spin|News items reporting results of animal studies without spin.
2474884|NCT03071393|Active Comparator|Acute Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo an acute intermittent hypoxia protocol with low oxygen air (9-15% inspired oxygen.
2474886|NCT03071393|Sham Comparator|Sham Intermittent Hypoxia|Subjects with chronic spinal cord injury will undergo a sham placebo protocol with normal oxygen air (21% inspired oxygen).
2474943|NCT03071042|Experimental|Apatinib plus Docetaxel|Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
3157831|NCT00373438|No Intervention|A|
3157832|NCT00373438|Experimental|B|Fetoscopic tracheal occlusion
3157833|NCT00373451|Experimental|Abciximab+UFH|Abciximab and unfractionated heparin as bolus given during PCI and abciximab-perfusion for 12 hours after PCI
3157834|NCT00373451|Active Comparator|Bivalirudin|Bivalirudin given only during PCI
3157835|NCT00373503|Experimental|lofexidine, dronabinol, marijuana|lofexidine (.6 mg qid), dronabinol (20 mg tid)
3157836|NCT00373581|Experimental|Vigabatrin, cocaine|
3157837|NCT00373581|Placebo Comparator|placebo, cocaine|
3157838|NCT00373607|Experimental|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin, Hualijian Pharmaceutical Co. Ltd., Guangzhou, China). Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
2474092|NCT03077373|Experimental|Counseling letter (intervention group)|Intervention group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both at the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call. According to the assessments (baseline, month 4, and month 7), participants receive three counseling letters aiming to increase moderate-to-vigorous physical activity and to reduce sedentary time. Additionally, individuals who were daily smokers at baseline, receive three counseling letters aiming to foster the motivation to quit smoking. The first letter is accompanied by a self-help manual covering specific information relevant for the particular stage of motivation to change smoking behavior.
2474093|NCT03077373|No Intervention|No counseling letter (control group)|Control group: Individuals in this group complete a tablet PC-supported assessment at baseline and 12-month follow-up, both in the general practice. At months 4 and 7, follow-up data are collected by study team members via phone call.
2474225|NCT03076216|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of Care chemotherapy either gemcitabine or gemcitabine + Abraxane
2474282|NCT03075852||3D VRS Patients|Those who undergo surgery with NGENUITY (3D VRS-Vitreoretinal surgery)
2474283|NCT03075852||Standard operating microscope|Those who undergo surgery with the standard operating microscope
2474330|NCT03075384||open reduction and internal fixation|A classic method was used to treat unilateral complicated zygomatic fractures without the assistance of computer-assisted navigation system
2474351|NCT03075033|Active Comparator|SOS gruop|Use of The Shikani Optical Stylet In Patients At Risk Of Secondary Cervical Spine Injury
2474355|NCT03075033|Active Comparator|Awake Fiberoptic Intubation|Use of Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury
2474414|NCT03074825|Experimental|chiauranib|Patients take Chiauranib capsules 50mg, orally once daily, 28 days as a cycle.
2474452|NCT03074461|Experimental|Side-to-End|Side-to-End Anastomosis as neorectal reconstruction technique in low anterior resection (LAR)
2474454|NCT03074461|Active Comparator|Transverse Coloplasty|Transverse Coloplasty pouch as neorectal reconstruction technique in low anterior resection (LAR)
2474570|NCT03073824|Experimental|vSculpt, model #VS1100|A novel intravaginal device for females
2474610|NCT03073421|Other|HIV positive pregnant women|HIV positive pregnant women who took part in the P3 program will take part in a 2-hour qualitative interview.
2474664|NCT03072940||Patients with idiopathic RBD|
2474674|NCT03072940||Healthy volunteers|
2474784|NCT03072212||HIV infected with stroke|No intervention will be administered
2474789|NCT03072212||HIV uninfected with stroke|No intervention will be administered
2474852|NCT03071757|Experimental|Part 3B: 18F-AraG Imaging Substudy in HNSCC Participants|Part 3B: Additional participants (with HNSCC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
2474856|NCT03071757|Experimental|Part 3A: 18F-AraG Imaging Substudy in TNBC Participants|Part 3A: Additional participants (with TNBC) will be enrolled in 18F-AraG Imaging Substudy that will further evaluate ABBV-368 intravenous administration Q4W plus ABBV-181.
2474859|NCT03071757|Experimental|Part 2B: Combination Therapy Cohort Expansion|Part 2B: Additional participants (with Head and Neck carcinoma) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W plus ABBV-181.
2474863|NCT03071757|Experimental|Part 2A: Monotherapy Cohort Expansion|Part 2A: Additional participants (triple negative breast cancer [TNBC]) will be enrolled in a dose expansion cohort that will further evaluate ABBV-368 (various dose levels) intravenous administration Q4W.
2474866|NCT03071757|Experimental|Part 1A: Monotherapy Dose Escalation|Part 1A: ABBV-368 (various dose levels) intravenous administration every 2 weeks (Q2W). One cycle of treatment is 28 days, thus there will be 2 doses with ABBV-368 per cycle.
2474904|NCT03071029|Experimental|Intervention (receive data updates)|Intervention clinics will receive a monthly poster that centres will receive which informs service providers of the PAFP LARC uptake rate at their centre. This is a step-wedged randomised controlled trial where all the clinics will eventually receive an intervention by the end of the study.
2474906|NCT03071029|No Intervention|Control (no data updates)|Service providers at these clinics will not receive monthly information on PAFP LARC rates.
2474995|NCT03070652|Experimental|NBO, Newborn behavioral observation|In the intervention group new parents will receive the NBO delivered in connection with the examination of the newborn in a shared observation with the parents in the homevisit of the health visitor 3 weeks post partum
2474998|NCT03070652|Experimental|Practice as usual|In the comparison group new parents will receive practice as usual due to the examination of their newborn in the homevisit of the health visitor 3 weeks post partum
3192417|NCT00808431|Experimental|Lifestyle counseling|Lifestyle counseling
2475098|NCT03069937|Experimental|Docetaxel + Degarelix|Docetaxel (TAXOTERE) will be given for up to 6 cycles every 21 days. During the 5th and 6th cycles, degarelix (Firmagon) will be administered on Cycle 5 day 1 and cycle 6 day 8. After cycle 6, degarelix will continue to be given every 28 days for a 5 more doses, for a total of 7 doses.
2475160|NCT03069508|Experimental|200 mg TID|200 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2475164|NCT03069508|Experimental|300 mg TID|300 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2475166|NCT03069508|Experimental|400 mg TID|400 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2475170|NCT03069508|Experimental|500 mg TID|500 mg clemizole hydrochloride will be administered orally thrice a day for 24 weeks.
2475216|NCT03069040|Experimental|nerve-sparing radical hysterectomy|The patient recived surgury of nerve-sparing radical hysterectomy.
2475221|NCT03069040|Active Comparator|radical hysterectomy|The patient recived surgury of radical hysterectomy.
3192418|NCT00808457||patients with suspected pneumonia|
2474146|NCT03076775|Experimental|Intervention|Women will undergo regular maternal blood glucose screening and treatment of hyperglycemia following BMZ administration to achieve maternal glycemic control until delivery or hospital discharge, for a maximum of 5 days.
2474147|NCT03076775|No Intervention|Usual Care|Routine antenatal care will be performed without any maternal blood glucose screening nor treatment as is usual care at each of the study sites.
2474191|NCT03076476|Active Comparator|DES-std group|(DES: drug-eluting stent). Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
2474193|NCT03076476|Experimental|DES-slow group|"(DES: drug-eluting stent). Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
2474195|NCT03076476|Experimental|BVS group|(Bioresorbable Vascular Scaffold) Introduced after the interim analysis (phase 2) for comparison with DES-slow.
2474256|NCT03076099|Experimental|Dexmedetomidine|Dexmedetomidine was administered intravenously when tracheal extubation, 1.2μg/kg Dexmedetomidine was mixed with 100 ml normal saline and maintained 4 hours constantly.
2474257|NCT03076099|Placebo Comparator|Control group|Normal Saline was administered intravenously when tracheal extubation,equal volume of normal saline was mixed with 100 ml normal saline and maintained 4 hours constantly.
3192419|NCT00808496|Experimental|MRI|Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline.
3192420|NCT00808496|Active Comparator|Radiography|Biannual disease progression monitoring with radiography of both hands and wrists.
2474407|NCT03074929|Experimental|Novel risk communication|Intervention parents will receive a novel risk communication message via a tablet app. Parents will also receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
2474410|NCT03074929|No Intervention|Usual Care|Parents will receive height, weight, and BMI percentile information typically provided by a provider during well-child visits as usual.
2474464|NCT03074513|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab and bevacizumab IV over 60 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2474532|NCT03073850|Experimental|Antiplatelet therapy|acetylsalicylic acid (ASA) 100mg or clopidogrel 75mg if intolerant to ASA
2474537|NCT03073850|Experimental|Low-dose OAC therapy|Edoxaban of 30mg (Reduced dose of 15mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
2474539|NCT03073850|Active Comparator|Standard-dose OAC therapy|Edoxaban of 60mg (Reduced dose of 30mg if body weight < 60kg, CCr< 50 ml/min, concomittant use of P-gp)
2474608|NCT03073499|Experimental|Intervention|(Partial) Oncological Home Hospitalization
2474609|NCT03073499|No Intervention|Control|Standard oncological treatment at the hospital day care unit
3192421|NCT00808496|Placebo Comparator|Standard of Care|Diagnostic imaging results (MRI or radiography) reported to upon requisition.
3192422|NCT00808522|Experimental|hCG|Patients at high risk for breast cancer will be treated with hCG
2474748|NCT03072407|Placebo Comparator|PB-119 injection placebo|totally 8 subjects will have PB-119 injection placebo once per weekly for 4 weeks.
2474751|NCT03072407|Experimental|PB-119 injection 25ug|totally 8 subjects will have PB-119 injection 25 ug once per weekly for 4 weeks
2474752|NCT03072407|Experimental|PB-119 injection 50ug|totally 8 subjects will have PB-119 injection 50 ug once per weekly for 4 weeks
2474753|NCT03072407|Experimental|PB-119 injection 100ug|totally 8 subjects will have PB-119 injection 100 ug once per weekly for 4 weeks
2474754|NCT03072407|Experimental|PB-119 injection 200ug|totally 8 subjects will have PB-119 injection 200 ug once per weekly for 4 weeks
2474777|NCT03072030|Experimental|Active Drug Group|1900 volunteers will be immunized with vaccine GamEvac-Combi They will receive product twice according to the following dosing regimen: on Day 1 (component A) and Day 21 of the study (component B) in the dose of 0.5 ml
2474778|NCT03072030|Placebo Comparator|Placebo Drug Group|100 volunteers will be immunized with placebo They will receive product twice according to the following dosing regimen: on Day 1 (placebo - component A) and Day 21 of the study (placebo- component B) in the dose of 0.5 ml
2474830|NCT03071861|Experimental|Darbepoetin Alpha|IV,10 mcg/kg/dose, Darbepoetin Alpha, one dose at <24 hours of age
2474831|NCT03071861|Placebo Comparator|Placebo|IV, Normal saline (placebo dose), one dose at <24 hours of age
2474880|NCT03071458||Patients with HCC|The cohort is composed of patients with HCC with available tumor and non tumor samples collected retrospectively. These patients have HCC of different stages (localized and advanced stages) It is an observational retrospective study.
2474920|NCT03071198|Experimental|Preoperative neoadjuvant CT|Give neoadjuvant chemotherapy for four cycle ,if achieve cCR or cPR after four cycles neoadjuvant chemotherapy , receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2474924|NCT03071198|Experimental|Preoperative neoadjuvant CT-RCT|Give neoadjuvant chemotherapy for four cycle ,if not achieve cCR or cPR after four cycle neoadjuvant chemotherapy ,give concurrent chemo-radiotherapy,then additional neoadjuvant chemotherapy for 2 cycles ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2474931|NCT03071198|Active Comparator|Concurrent chemo-radiotherapy|Give concurrent chemo-radiotherapy ,then receive Total Mesorectal Excision(TME) ,then received the complete adjuvant therapy
2474986|NCT03070626|Experimental|Interventional group|Carbohydrate-rich, dietary supplement: PreOp® 800ml day before surgery and PreOp® 400ml 2-4hours preoperative.
2474990|NCT03070626|No Intervention|Control group|Standard of care: Fasting from 24hours (midnight), night before surgery.
2475046|NCT03070353|Experimental|Dextran 40|Dextran 40 infusion
2475076|NCT03070015|Experimental|Nutrisystem|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem program for a total of 12 weeks (4 weeks for Part A, and an additional 8 weeks for Part B)
2475078|NCT03070015|Active Comparator|Self-Directed DASH|All subjects provided publically available information on the DASH diet and a sample meal plan. Subjects were instructed to follow a reduced calorie DASH diet meal plan on their own for 4 weeks (Part A only).
3192423|NCT00808522|No Intervention|routine care|Patients receiving routine care will be followed
2474155|NCT03076879|No Intervention|Control Group|The selected ASM is the most common and associated with direct cervical cancer-related risk factors in Turkey (using oral contraceptives for longer than five years, having three or more children, starting sexual intercourse at the age of 16 and before, Women who are randomly assigned to the control group of women who have at least one pap smear test between the ages of 40 and 55 and who have at least one pap smear test in the family (especially a mother and a sister)
2474246|NCT03075943|Experimental|InSea2|2 capsules/day of InSea2 administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
2474247|NCT03075943|Placebo Comparator|Placebo|2 capsules/day of Placebo administered 30 min before a meal (breakfast, lunch or diner) combined with weight loss program (individualized nutritional intervention with a daily restriction of 500 kcal)
2474302|NCT03075605||Subjects with acute pancreatitis|Subjects with acute pancreatitis
2474303|NCT03075605||Subjects with previous attack|Subjects with previous attack
2474304|NCT03075605||Controls|Controls
3192424|NCT00808535||diabetics|
3192425|NCT00808535||healthy controls|
3192426|NCT00808548||Lifestyle counseling|
2474540|NCT03073889|Experimental|Block|Scalp nerve block with 10ml solution of 0.75% ropivacaine before skin incision, n=15
2474544|NCT03073889|Active Comparator|Infiltration|Scalp infiltration with 10ml solution of 0.75% ropivacaine before incision, n=15
2474549|NCT03073889|No Intervention|Control|the control group has no treatment, n=15
3192427|NCT00808561|Active Comparator|1 Alternative Fistula|
3192428|NCT00808561|Active Comparator|2 Forearm AV Graft|
2474685|NCT03072914|No Intervention|The control group|The control group has a sphygmomanometer wound around the upper arm or lower extremity and applies the same pressure, but a 3-way stopcock is installed in the middle so that no pressure is applied.
2474694|NCT03072914|Active Comparator|RIPC with RIPostC group|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
3192429|NCT00808574|Experimental|Intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
3192430|NCT00808574|No Intervention|Control|No risk assessment or presentation
2474944|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
2474947|NCT03070951|Experimental|OBE2109 dose 1 (100mg) + Add-back|
2474949|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
2474950|NCT03070951|Experimental|OBE2109 dose 2 (200mg) + Add-back|
2474951|NCT03070951|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|
2475075|NCT03070119|Experimental|BIIB067|Participants who have completed Parts A, B, or C of study 233AS101 will be placed in this arm.
2475137|NCT03069690|Experimental|HABITpreg; TAUpost|Participants will receive study intervention during pregnant and treatment as usual postpartum.
2475138|NCT03069690|Experimental|HABITpreg, HABITpost|Participants will receive study intervention during pregnancy and study intervention during the postpartum period.
2475139|NCT03069690|Experimental|TAUpreg; HABITpost|Participants will receive treatment as usual during pregnancy and study intervention during the postpartum period.
2475140|NCT03069690|No Intervention|TAUpreg; TAUpost|Participates will receive treatment as usual during pregnancy and treatment as usual during the postpartum period.
3192431|NCT00808587||No Treatment|
2475233|NCT03068962|Experimental|beetroot juice|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of beetroot juice for 5 min,
2475236|NCT03068962|Experimental|low mineral water (Buxton water)|Rinse mouth with low nitrate Buxton mineral water followed by holding 10 ml of low nitrate mineral water in the mouth for 5 min or
2475238|NCT03068962|Experimental|antiseptic mouthwash then beetroot juice|Rinse with antiseptic mouthwash before holding 10 ml of beetroot juice in the mouth for 5 min
2475296|NCT03068637|Experimental|Care planning platform usage|This intervention will focus on the use of the Carevive care planning software for multiple myeloma patients age 65 and older who are at a treatment decision-making timepoint.
2475305|NCT03068325|Experimental|TF-EAT|
2475349|NCT03068234|Experimental|Pirfenidone group|The subjects will receive pirfenidone from 200mg three times a day, oral administrated, with low dose steroids.
2475350|NCT03068234|Placebo Comparator|Control group|The subjects will receive placebo within first 24-week, and pirfenidone 200mg three times a day for the second 24-week, with low dose steroids.
2475379|NCT03067909||Patients undergoing CIED surgery|Patients with standard indications to CIED implantations/replacements receiving concomitant antithrombotic therapy (either or both antiplatelet agents and/or anticoagulants).
2475397|NCT03067740|Active Comparator|Bupivacaine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
2475398|NCT03067740|Experimental|Bupivacaine-Dexmedetomidine group|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
2475878|NCT03064347|Placebo Comparator|Non Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder with separate enteric coating materials as single dose
3192432|NCT00808600|Other|resource-activating training, intensified exercise training|combination of the two interventions: resource-activating behavioural training and intensified exercise training
3192433|NCT00808600|Other|resource-activating training, moderate exercise training|combination of the two interventions: resource-activating training and moderate exercise training
3192434|NCT00808600|Other|relaxation training, intensified exercise training|combination of the two interventions: relaxation training and intensified exercise training
3192435|NCT00808600|Other|relaxation training, moderate exercise training|combination of the two interventions: relaxation training and moderate exercise training
2474278|NCT03075826|Other|Open Label-Single Arm|This is a single arm, open-label study of SGI-110 in patients with MPN. SGI-110 will be administered subcutaneously at a dose of 60 mg/m2 on days 1-5, repeated every 28 days. Toxicity will be evaluated using the NCI Common Terminology Criteria for Adverse Events Active Version 4. The frequency of toxicities per organ system will be tabulated using descriptive statistics. All patients who receive any amount of the study drug will be evaluable for toxicity
2474325|NCT03075371|Active Comparator|intragastric glucose administration|
2474326|NCT03075371|Placebo Comparator|intragastric water administration|
2474391|NCT03075046|Experimental|blue LED 405 nm in vulvovaginal candidiasis|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session. This part of the study will see if there is fungicidal effect of the blue led 405 nm
2474395|NCT03075046|Experimental|blue LED 405 nm in healthy women|It will be applied the a 405 nm blue LED in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.This part of the study will see the security and the effects of the blue led 405 nm in healthy vaginal microflora
2474401|NCT03075046|No Intervention|Sociodemographic data of women with vulvovaginal candidiasis|The women will answer some questions of the anamnesis as: Age, weight, height, form of intimate hygiene, and others to evaluate possible correlations of these data with the presence of vulvovaginal candidiasis
2474450|NCT03074578|Experimental|Night-time desensitization|Watching a video containing verbal and visual violence in the evening, and again in the next morning
2474451|NCT03074578|Sham Comparator|Daytime desensitization|Watching a video containing verbal and visual non-violence in the morning, and then again the evening of the same day
2474553|NCT03074175|Experimental|hyperfractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).
2474555|NCT03074175|Experimental|conventional fractionated radiotherapy group|According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.
2474701|NCT03072810|Experimental|Positive mindfulness program|Participants will receive a 4 week online positive mindfulness program as described in previous sections.
2474702|NCT03072810|Other|Waitlist control|Participants will receive the same intervention as the intervention arm (positive mindfulness program) but will be required to wait 4 weeks before commencing.
2474742|NCT03072355|Active Comparator|Elastic Band|Perform the maximum of the possible repetition with a load of 50% of the 1RM (performing 1½ seconds in the concentric phase and 1½ seconds in the eccentric phase).
2474747|NCT03072355|Active Comparator|Isokinetic dynamometer|Realization of the maximum of the possible repetition to 50% of the MIVM in the speed of 60º / s for abduction and 500º / s in the return of the movement.
2474800|NCT03072108|Experimental|Bonolive|
2474808|NCT03072108|Placebo Comparator|Placebo|
3192436|NCT00808613|Active Comparator|1|Optetrak Posterior Stabilized
2474919|NCT03071055|Active Comparator|ranibizumab|ranibizumab 0.5mg in commercially available vial
2474923|NCT03071055|Experimental|ranibizumab pre filled-syringe|ranibizumab 0.5mg in soon to be available pre-filled syringe
2475013|NCT03070509|Experimental|RYGB|Single dose of lisdexamfetamine 50 mg in RYGB patients
2475015|NCT03070509|Experimental|Nonsurgical Controls|Single dose of lisdexamfetamine 50 mg in non-surgical controls
2475074|NCT03070249||Emergency Department Healthcare Providers|This study will assess compassion fatigue among healthcare providers in a single emergency department (ED) using the Professional Quality of Life (ProQoL) scale.
2475107|NCT03069846|Experimental|Measurement using Spectra-Scope|Short pulsed Nd:YAG laser irradiation onto the skin lesion / measurement with Spectra-Scope
2475156|NCT03069547|Active Comparator|Quadriceps Exercise program|The Quadricepts Exercise (QE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
2475161|NCT03069547|Active Comparator|Hip Exercise program|The Hip Exercise (HE) program runs for 12 weeks, with exercise sessions 3 times per week. Each training session is scheduled to last approximately 30 minutes. The exercise program is home based with monthly supervision visits at the clinic.
2475262|NCT03069144|Experimental|HAT1 topical solution|HAT1 topical solution will come in a labeled spray bottle. This topical medicated solution will be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2475267|NCT03069144|Active Comparator|Calcipotriol ointment (0.005%)|Calcipotriol ointment (0.005%) will come in a labeled tube. The medicated cream will be be applied once in the morning and once in the evening at least 8 hours apart to all lesions. Treatment will continue daily until next visit.
2475307|NCT03068507|Experimental|Prehabilitation group|Trimodal prehabilitation management
2475310|NCT03068507|No Intervention|Control group|The patients will receive the conventional clinical guidance according to Peking Union Medical College Hospital, including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence.
2475355|NCT03068208|Experimental|MB-PDT|
2475356|NCT03068208|No Intervention|Control|
2475394|NCT03067870|Experimental|Stem Cells|Autologous bone marrow-derived stem cell transplantation.
2475879|NCT03064347|Active Comparator|Enteric Coated Sucrose|200kcal sucrose in enteric coating as single dose
3192437|NCT00808613|Active Comparator|2|Optetrak Hi-Flex
3192438|NCT00808626|Experimental|99mTc-rBitistatin|
3192439|NCT00808678|Experimental|1|ABT-143 capsules 20/135 mg
3192440|NCT00808678|Active Comparator|2|ABT-335 135 mg and rosuvastatin 20 mg
3192441|NCT00808691||1|Patients with sepsis
3192442|NCT00808691||2|Patient admitted for postoperative care
3192443|NCT00808691||3|Patients with ARDS
3192444|NCT00808691||4|Patients with ARF
3157839|NCT00373607|Active Comparator|Mefloquine + Artesunate (MAS3)|The MAS3 regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
3157840|NCT00373633|Experimental|Continuous extra-pleural intercostal local anesthesia|intra-operatively placed extrapleural intercostal catheter
2474405|NCT03074916||DIP arthroplasty|
2474408|NCT03074916||DIP arthrodesis|
2474483|NCT03074526|Active Comparator|4mL amniotic fluid|Amniotic Fluid: 4mL dose of amniotic fluid
2474488|NCT03074526|Active Comparator|4mL2x amniotic fluid|Amniotic Fluid: 4mL 2x dose of amniotic fluid
2474495|NCT03074526|Placebo Comparator|4mL Saline Placebo|Normal Saline
2474500|NCT03073980|Experimental|Group 1: IV acetaminophen/PO placebo|In the pre-op suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.
2474505|NCT03073980|Active Comparator|Group 2: IV placebo/PO acetaminophen|In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.
2474507|NCT03073980|Placebo Comparator|Group 3: Placebo / Standard of care|In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.
2474565|NCT03073746|Experimental|Health Search|Access to Health Knowledge Panels and Symptom Search Tool.
2474569|NCT03073746|Experimental|Standard Search|No access to Health Knowledge Panels and Symptom Search Tool, but access to prior version of Google search.
2474572|NCT03073746|No Intervention|No Search|No access to Health Knowledge Panels, Symptom Search Tool, prior version of Google search, or mobile device.
2474605|NCT03073408|Active Comparator|1: Manual control group|The propofol infusion rate is adjusted manually in a pump by the investigator to maintain BIS between 40 and 60. For this titration it is necessary continuous monitoring, clinical experience, and pharmacokinetic/pharmacodynamic knowledge.
2474606|NCT03073408|Experimental|2: PI +Smith group|The closed loop control automatically adjust propofol infusion rate guided by the feedback of the real value of BIS. The automatic system has to achieve a target BIS of 50 and maintain it between 40 and 60.
2474684|NCT03072823|Active Comparator|n-3 polyunsaturated fatty acids|n-3 polyunsaturated fatty acids dosage of 2 g of Eicosapentaenoic acid(EPA) and 1 g of Docosahexaenoic acid (DHA).
2474692|NCT03072823|Placebo Comparator|placebo|olive oil ethyl esters
2474767|NCT03072251||Anyone|Any individual may complete this survey
2474807|NCT03071978|Experimental|LV-fusion pacing|Left Ventricular pacing (without Right Ventricular pacing)
2474811|NCT03071978|Active Comparator|BV pacing|Bi-Ventricular pacing
2474891|NCT03071302|Active Comparator|keratoconus|"Evaluation of Visual System Homeobox 1 (VSX1), Superoxide Dismutase (SOD1), Tissue Inhibitors of Metalloproteinases (TIMP3) genes. Keratoconus with fellow eye without topographic and tomographic keratoconous pattern.Evaluation of tomographic datas. Sometimes we picked up the sample of corneal epithelium, and peripheral blood sample from corneal cross linking surgeries, in that case of keratoconus progression.~Group A Keratoconus/ like sound cornea. Group C Keratoconus / Keratoconus~Group C Keratoconus / Keratoconus"
2474893|NCT03071302|Placebo Comparator|sound cornea|"Evaluation of VSX1, SOD1, and TIMP3 genes. To analyze tomographic aspects, we evaluated the patients that underwent to LASIK (Lasei in situ Keratomileusis) with 2 year with follow up without any sign of ectasia To analyze the genes we picked up the sample of corneal epithelium, and peripheral blood sample from PRK (PhotoRefractive Keratectomy) surgeries. These patients showed topographic and tomographic normal pattern.~Group B Sound Cornea / Sound Cornea"
2474902|NCT03070977|Experimental|Interprofessional study unit|In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.
2474903|NCT03070977|No Intervention|Standard unit|Students in the control group receive training in standard psychiatric wards.
2474972|NCT03070665|Experimental|Increasing blood pressure|Using norepinephrine pump as the initial dose is 0.05μg/Kg.min to increase the patient's blood pressure up to about 150 mmHg for 5 min during ESD.
2474973|NCT03070665|No Intervention|Control group|Patients received normal ESD manipulation.
3192445|NCT00808691||5|Patients who receive liver support treatment
3192446|NCT00808691||6|Patients wiht brain death
3192447|NCT00808717|Experimental|High dose Atorvastatin 80 mg|Administered Atorvastatin 80 mg before intervention
3192448|NCT00808717|Active Comparator|Control|Administered Atorvastatin 10 mg before intervention
3192449|NCT00808730|Experimental|1|fiberoptic fibroscopy
3192450|NCT00808743|Active Comparator|Group 1|Patients receive oral celecoxib twice daily and oral placebo twice daily
2475230|NCT03069222||Patient|SCI patients enrolled at Kessler Institute Rehabiliation
3157841|NCT00373633|Active Comparator|Thoracic Epidural|gold standard
3157842|NCT00373672|Active Comparator|1|armodafinil (Nuvigil) 150 mg
3157843|NCT00373672|Placebo Comparator|2|identical in appearance to active comparator
3157844|NCT00373750|Experimental|Family Spirit Intervention|The Family Spirit Intervention included 43 structured lessons and followed a culturally congruent format. Positive parenting lessons were focused on reducing behaviors (i.e., poor monitoring; coercive interactions;harsh, unresponsive, or rejecting parenting; and abuse/ neglect) associated with early childhood behavior problems, including externalizing, internalizing, and dysregulation problems.
3192451|NCT00808743|Experimental|Group 2|Patients receive oral celecoxib twice daily and oral ursodeoxycholic acid twice daily
3192452|NCT00808756|Experimental|1: Intervention|This group will be fed a diet enriched with fermentable carbohydrates.
3192453|NCT00808756|Placebo Comparator|2: Placebo.|The placebo group will be fed a diet without addition of fermentable carbohydrates. This placebo formula will have the same nutritional values than the intervention (energy, proteins, carbohydrates, fat, vitamins & minerals).
3192454|NCT00808756|No Intervention|BF|The 2 intervention groups will be compared with a breast-fed infants control group.
3192455|NCT00808782|Sham Comparator|Sham rTMS|Sham 5Hz rTMS.
3192456|NCT00808782|Experimental|rTMS|Active 5Hz deep TMS.
3192457|NCT00808795|Experimental|N-acetylcysteine|
2474307|NCT03075462|Experimental|Fluzoparib + Apatinib|Fluzoparib and apatinib will be separately administered to patients on the 1st and 4th day, respectively. Then from the 7th day they are administered continuously and orally in combination, 28 days per cycle, until disease progression or unacceptable toxicity.
2474339|NCT03075189|Experimental|Protein supplement|"During hospitalization the intervention group will receive a protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~Diet registration and testing at baseline, discharge and follow-up."
2474340|NCT03075189|No Intervention|Standard treatment|"The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Diet registration and testing at baseline, discharge and follow-up."
2474366|NCT03074942|Experimental|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
2474485|NCT03074292|Active Comparator|conventional phototherapy|neonates with unconjugated hyperbilirubinemia exposed to conventional phototherapy
2474489|NCT03074292|Active Comparator|extensive phototherapy|neonates with unconjugated hyperbilirubinemia exposed to extensive phototherapy
2474494|NCT03074292|Active Comparator|LED phototherapy|neonates with unconjugated hyperbilirubinemia exposed to LED phototherapy
2474510|NCT03074058|Experimental|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY 77-1931 orally disintegrating tablet (ODT) 500 mg in Period 1 (day 1-3) and Fosrenol chewable tablet 500mg in Period 2 (day 4-6). The washout interval between period 1 and 2 will be at least 14 days.
2474513|NCT03074058|Active Comparator|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol BAY77-1931 chewable tablet in Period 1 and Fosrenol BAY 77-1931 ODT 500 mg in Period 2. The washout interval between period 1 and 2 will be at least 14 days.
2474562|NCT03073733|Experimental|Test (jCell injection) dose level 1|single intravitreal injection of 3.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
2474563|NCT03073733|Other|Sham treated Control|"a mock injection will be performed on the eye with the poorest vision in each Control subject (designated as the study eye)"
2474567|NCT03073733|Experimental|test (jCell injection) dose level 2|single intravitreal injection of 6.0 x 10e6 human retinal progenitor cells into the eye with the poorest visual acuity or, if vision is comparable in both eyes, the non-dominant eye
2474617|NCT03073356|Experimental|Control - Healthy test subjects|Age matched subjects without symptoms of heart failure or ischemic heart disease N=10
2474620|NCT03073356|Experimental|HFrEF - Heart failure patients investigated by PET|Patients with heart failure (HFrEF) N=12
2474621|NCT03073356|Experimental|HFrEF - Right heart catheterization|Patients with heart failure (HFrEF) N=12
2474622|NCT03073356|Experimental|HFrEF - Right heart catheterization study 2|Dose finding study (increasing dosage of 3-OHB)
2474665|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler A|160/4.5microg/inhalation Charcoal
2474675|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler B|160/4.5microg/inhalation Charcoal
2474683|NCT03073057|Experimental|Charcoal and Budesonide/formoterol Easyhaler C|160/4.5microg/inhalation Charcoal
2474690|NCT03073057|Active Comparator|Charcoal and Symbicort Turbuhaler|160/4.5microg/inhalation Charcoal
2474783|NCT03072316||SSM immediate DIEP|Unilateral skin sparing mastectomy with immediate DIEP
2474788|NCT03072316||SSM immediate DIEP and PMRT|Unilateral skin sparing mastectomy with immediate DIEP flap reconstruction and post mastectomy radiotherapy
2474793|NCT03072316||mastectomy, PMRT, delayed DIEP|simple mastectomy, post mastectomy radiotherapy adn then delayed DIEP reconstruction
2474798|NCT03072316||SSM, temporizing implant, PMRT then DIEP|Unilateral SSM with temporizing implant, PMRT and subsequent
2474857|NCT03071575|Active Comparator|Group A:|Group A will receive a measles-rubella vaccine dose at 6 and 9 months
2474860|NCT03071575|Active Comparator|Group B:|Group B will receive a measles-rubella dose at 9 months only
3157845|NCT00373750|No Intervention|Optimized Standard Care Control Group|Optimized standard care consisted of transportation to recommended prenatal and well-baby clinic visits, pamphlets about child care and community resources, and referrals to local services. It also addressed access barriers to health care for young mothers and children, and it overcame concerns that home-visiting programs have operated in parallel, not in partnership, with pediatric care. Family health liaisons conducted the optimized standard care and were not trained in the Family Spirit intervention, to avoid contamination of the control condition.
3157846|NCT00373789|Experimental|Botox A|up to two injections of 200 Units of intra-detrusor Botulinum Toxin A , which must be separated by at least eight weeks and no more than 52 weeks
2475439|NCT03067519|Experimental|Fast track surgery|Intervention: Fast track surgery patients underwent early feeding and mobilization after surgery
2475443|NCT03067519|Active Comparator|Conventional management|usual postoperative care per surgeon
3157847|NCT00373789|Placebo Comparator|Placebo|up to two injections of inactive injection (carrier saline), which must be separated by at least eight weeks and no more than 52 weeks
3157848|NCT00373867|Active Comparator|Standard|Standard treatment-based classification physical therapy
3157849|NCT00373867|Active Comparator|Graded exercise|Treatment-based classification physical therapy plus graded exercise
3157850|NCT00373867|Experimental|Graded exposure|Treatment-based classification physical therapy plus graded exposure
3157851|NCT00373932|Experimental|MOBILE-A|Coached exercise persistence intervention
3157852|NCT00373932|Active Comparator|MOBILE-B|Self-monitored exercise persistence intervention
3157853|NCT00374036|Experimental|1|ECC
3157854|NCT00374036|Experimental|2|FOLFIRI
3157855|NCT00374049|Experimental|One|MUC1 vaccine in conjunction with GM-CSF and Poly-ICLC (Hiltonol)in Arm ONE
3157856|NCT00374062|Experimental|I|relaxation tape 1
3157857|NCT00374062|Experimental|II|relaxation tape 2
3157858|NCT00374062|Placebo Comparator|III|relaxation tape 3
3157859|NCT00374153|Experimental|1|Online personal feedback report.
2474341|NCT03075436|Experimental|Enhanced demand-side sanitation, hygiene|The intervention group will receive a package of enhanced, demand-side sanitation and hygiene interventions that are informed by formative research and facilitated by local government and Emory Ethiopia partners.
2474343|NCT03075436|Active Comparator|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
2474394|NCT03074903||Early cycle insertion|Participants in this group have the intrauterine system inserted during the first seven days of their menstrual cycle.
2474399|NCT03074903||Late cycle insertion|Participants in this group have the intrauterine system inserted during the remainder of their cycle.
2474437|NCT03074591|Active Comparator|Treatment|Active treatment: Ferric Carboxymaltose solution (Ferinject®) for parenteral application, 50 mg/mL iron. Medication will be given as a short time infusion over 15 minutes in 100mL NaCl.
2474439|NCT03074591|Placebo Comparator|Placebo|Placebo: Normal saline (0.9% weight/volume (w/v) NaCl) administered in analogy to active treatment procedures.
2474512|NCT03073928|Active Comparator|Interscalene Block|"Receives interscalene block with 15mL of ropivacaine 0.5% at the level of C6. A total of 15mL will be injected with repeated aspirations to rule out intravascular placement of the needle tip. Once this is done, the needle tip will be moved to the lateral edge of sternocleidomastoid muscle and additional 3mL of 0.5% ropivacaine will be injected between the deep fascia of the sternocleidomastoid and deep investing fascia of the neck (superficial cervical plexus block SCP).~We will administer injection of saline similar to experimental group to blind the patient"
2474514|NCT03073928|Experimental|Paracoracoid SPB|Receives paracoracoid subscapularis plane block with the ultrasound. Using a 50mm 22G block needle 15ml of 0.5% Ropivacaine will be deposited anterior to the fascia of subscapularis muscle after eliciting a motor response with 0.6mA current delivered through the needle. Following this, superficial cervical plexus block will be done using 3mL of 0.5% ropivacaine similar to group 1.
2474578|NCT03073642|Active Comparator|Hydrotherapy|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk."
2474582|NCT03073642|Experimental|Hydrotherapy and Pain Education|"Patients allocated to this group will perform 12 weeks of hydrotherapy treatment, with global exercises. Hydrotherapy sessions will last 45 minutes and will be performed twice a week.~Exercises will involve aerobic exercises (in the pool) with exercises for upper and lower limbs, and trunk.~During the 12 weeks of hydrotherapy treatment, volunteers will also receive 4 sessions of Pain Therapeutic Education, which is also known as Pain Neuroscience Education, which involves patient education on pain neurophysiology, pain chronification and amplification mechanisms, and chronic pain management. These sessions will be performed in specific dates scheduled according to the volunteers' availability, and with intervals that can last from one to two weeks."
2474644|NCT03073278|Other|Group 1|This group of 12 patients will be given 36Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2474646|NCT03073278|Other|Group 2|This group (12 patients) will be given 38Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2474647|NCT03073278|Other|group 3|This group (12 patients) will be given 40Gy of Stereotactic Body Radiotherapy (SBRT) divided into six separate doses. This will be delivered two to three time per week.
2474676|NCT03072849||Stem Cell Transplant Recipients|Pediatric patients ages 6-18 years who have received allogenic hematopoietic stem cell transplant for any reason.
2474745|NCT03072511|Experimental|Spotlight on Smoke-Free Living|Treatment will include a 1.5-hour intervention session combined with daily text-messaging for up to 1 week pre-quit and 4 weeks post-quit. The intervention includes: mindful breathing, visualization, and identification and thinking about goals and priorities inconsistent with smoking. During the text-messaging phase, elements of the intervention discussed during the in-person session will be reinforced. Participants will be provided transdermal nicotine patches (TNP). TNP are a safe and effective approach to nicotine replacement when an individual attempts to stop smoking and are safe for use without prescription. Participants will begin the regimen on the scheduled quit date with an initial dose of 21 mg (4 weeks), followed by 14 mg (2 weeks), and 7 mg (2 weeks). Alterations to dosing will be allowed when appropriate and consistent with manufacturer's recommendations. While TNP will be offered to all participants, they can decline or discontinue use of TNP at any time.
2474750|NCT03072511|Active Comparator|Standard Informational Treatment|Standard informational treatment is based on conventional, information-based smoking cessation approaches commonly found in public health settings. This will include the following information: prevalence/incidence of cigarette smoking and negative health outcomes associated with cigarette smoking (e.g., cancer, respiratory disease, complications), other health consequences resulting from diseases associated with cigarette smoking, personal/financial/social consequences of cigarette smoking. During the text-messaging phase, information about the consequences of smoking discussed during the in-person session will be reiterated. As with the experimental condition, participants will be provided with 8-weeks TNP.
2474785|NCT03072056|Experimental|Extensive Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
2474792|NCT03072056|Experimental|Extensive Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
2474796|NCT03072056|Experimental|Extensive Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
2474802|NCT03072056|Experimental|Poor Metabolizers, 4 mg|subjects will receive 32 mL of MIN-101 as a 0.125 mg/mL oral solution
2474809|NCT03072056|Experimental|Poor Metabolizers, 8 mg|subjects will receive 32 mL of MIN-101 as a 0.25 mg/mL oral solution
2474812|NCT03072056|Experimental|Poor Metabolizers, 16 mg|subjects will receive 32 mL of MIN-101 as a 0.5 mg/mL oral solution
2474846|NCT03071653|Active Comparator|Left Cardiac Sympathetic Denervation (LCSD)|Left Cardiac Sympathetic Denervation (LCSD) in addition to Optimal Medical Therapy (OMT)
2474853|NCT03071653|Other|OMT only|Optimal Medical Therapy (OMT) only
2474914|NCT03071315||CCT participants|Center-based compulsory treatment (CCT) participants who were placed into compulsory treatment centers for two years for a range of punitive treatment such as education, moral teaching, labor work. Very basic health care is provided in the CCT centers.
2474350|NCT03075254|Experimental|Fibromyalgia Only|The diagnosis of FM will require a history of chronic widespread pain as well as the presence of at least eleven out of eighteen paired tender points. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2474353|NCT03075254|Experimental|Chronic fatigue and Fibromyalgia Syndrome|Diagnosis of ME/CFS will require a history of chronic fatigue persisting or relapsing for more than 6 months as well as the presence of at least four out of eight designated symptoms. Undergoing sensory testing, brain and spinal cord neuroimaging and Inventory assessments.
2474424|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
2474457|NCT03074396|Other|before and after use of program|one arm (10 patients and 4 physicians) before and after use of dialysisNet (for doctors) and Avatar Beans (for patients)
2474527|NCT03074214||STEMI patients receiving PCI|patients with STEMI receiving percutaneous coronary intervention
2474584|NCT03073577|Experimental|Treatment Group|PKX-001 will be supplemented to islet preservation CMRL-1066 medium at final concentration of 3 mg/mL during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays. Islets are maintained for minimal 6 hours up to 72 hours in supplemented CMRL1066-based media containing PKX-001 until the time of transplant. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally.
2474658|NCT03073304|Active Comparator|Control|Erythrocyte based prime solution
2474659|NCT03073304|Experimental|Intervention|Crystalloid based prime solution
3192458|NCT00808795|Placebo Comparator|Placebo|
3192459|NCT00808860|Placebo Comparator|Placebo group|Gliclazide + Placebo tea
2474759|NCT03072381|Active Comparator|Platelet Rich Plasma - Group 1|"Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
2474760|NCT03072381|Placebo Comparator|Corticosteroid Control - Group 2|"Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.~If a subject has bilateral elbow common extensor tendon pain, both elbows will be treated in the same study arm."
2474813|NCT03071991||Study group|Preincisional bupivacain will be used
2474817|NCT03071991||Control group|No preincisional anesthetic drug will be used
2474862|NCT03071692|Experimental|Treatment Group|K-877 (pemafibrate) tablet twice daily.
2474864|NCT03071692|Placebo Comparator|Control Group|Matching K-877 placebo tablet twice daily.
2475455|NCT03067038|Active Comparator|Single incision LC|Single incision laparoscopic cholecystectomy (SILC) performed through a single infra-umbilical incision using a single port device or three ports closely placed.
2475464|NCT03067038|Sham Comparator|Three port LC|Three port laparoscopic cholecystectomy (TPLC) performed through three different placed trocars
2475546|NCT03066960|Active Comparator|Radiofrequency neurotomy group|Unilateral radiofrequency neurotomy of medial branches to the dorsal ramus at one or two cervical levels
2475554|NCT03066960|Sham Comparator|Sham group|Unilateral sham treatment of medial branches to the dorsal ramus at one or two cervical levels
2475594|NCT03066349||Patients with PCOS undergoing conventional ovarian stimulation|
2475595|NCT03066349||Patients with PCOS undergoing IVM|
2475621|NCT03066180|Experimental|Group 1|Single study treatment (Viveve SUI treatment) will be administered.
2475623|NCT03066180|Experimental|Group 2|Two study treatments (Viveve SUI treatments) will be administered approximately 6 weeks apart.
2475662|NCT03065959|Experimental|CK-2127107, then Placebo|Participants will first receive CK-2127107 tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching placebo.
2475668|NCT03065959|Experimental|Placebo, then CK-2127107|Participants will first receive Placebo tablets (twice daily) for 14 days. After a 14 day wash out period participants will then receive matching CK-2127107.
2475729|NCT03065491|Active Comparator|Active treatment|Combined nutraceutical
2475730|NCT03065491|Placebo Comparator|Placebo|Placebo
2475784|NCT03065088|Experimental|aLiFE|The aLiFE programme is developed for young older adults, where balance activities, strengthening activities, and specific recommendations for increasing physical activity, are embedded within everyday activities, so that the activities can be performed multiple times throughout the day. The programme is presented by an instructor by use of a paper based manual during a 6 month intervention period in participants homes.
2475787|NCT03065088|Experimental|eLiFE|The aLiFE programme is transferred to a mobile health system, called the eLiFE. The intervention is delivered on smartphones and smartwatches including inertial sensors well suited to monitor physical activity and movement quality in daily life. An instructor teaches the participants how to use the mobile health system during home visits and phone calls during the 6 month intervention period. A virtual instructor teaches the participants the eLiFE programme. Pictures and videos of the aLiFE activities are delivered by use of the system. Behavioural change strategies are also included in the system.
2475792|NCT03065088|Active Comparator|control|The control group follows the World Health Organization's recommendations of physical activity.
2475906|NCT03064308|No Intervention|Control|Participants will receive standard NHS care with no intervention.
2475911|NCT03064308|Other|Exercise|Participants will receive standard NHS care and complete the exercise programme, the intervention.
2475969|NCT03063723||CHC patients|15 treatment-naive CHC patients treated by Ledipasvir-Sofosbuvir orDaclatasvir-Sofosbuvir.
2475979|NCT03063723||Healthy controls|10 Healthy controls without any treatment
2476013|NCT03063346|Experimental|Protein hydrolysate high dose|
3192460|NCT00808860|Active Comparator|GP group|Gliclazide + Gynostemma pentaphyllum tea
3192461|NCT00808873|Experimental|1|brief education and 6 follow-up visits
3192462|NCT00808873|No Intervention|2|treatment-as-usual
3192463|NCT00808912|Active Comparator|1|Subjects will exercise in a high air pollutant environment after ingesting a standard dose of sildenafil.
3192464|NCT00808912|Active Comparator|2|Subjects will exercise in a low pollutant environment after ingesting a standard dose of sildenafil.
3192465|NCT00808912|Placebo Comparator|3|Subjects will exercise in a high pollutant environment after ingesting a placebo.
3192466|NCT00808912|Placebo Comparator|4|Subjects will exercise in a low pollutant environment after ingesting a placebo.
2474577|NCT03073811|Experimental|PeriHab|Provided nutrition counseling and prescribed to consume 1.6 g/kg/body weight as well as provided 30 grams of high quality protein three times per day for two weeks before and four weeks after surgery.
2474581|NCT03073811|Active Comparator|PoshControl|Provided nutrition counseling and prescribed to consume 1.0 g/kg/body weight in the form of educational handouts explained by a Registered Dietitian and one oral nutrition supplement per day for two weeks before surgery.
2474628|NCT03073239||ALS epidemiological characterization|epidemiological characterization
2474629|NCT03073239||Genetic findings in ALS patients|genética characterization
2474671|NCT03072966|Experimental|Distress screening group|Physical activities will be monitored by wearable device. Patient-reported outcomes including distress, depression, physical activities and quality of life are going to be collected by questionnaires based on smartphone application and paper. The algorithm of distress screening will be developed with the analysis of patterns of physical activities.
2474724|NCT03072641|Experimental|ProBion Clinica|Probiotic tablets yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.
2474726|NCT03072641|No Intervention|Control|
2474765|NCT03072277|Active Comparator|Docosa Hexaenoic Acid (DHA)|Omega 3 Fatty Acid
2474768|NCT03072277|Placebo Comparator|Placebo|Corn/Soy Oil
2474804|NCT03071926|Experimental|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin: 20 mg, qw, first 6 weeks ,every 8 weeks
2474848|NCT03071731|Experimental|Bronchodilators|Nebulization of ipratropium bromide/salbutamol sulfate (500 µg/2.5 mg) before the administration of the Glittre ADL-test
2474855|NCT03071731|Placebo Comparator|Placebo|Nebulization of a placebo before the administration of the Glittre ADL-test
2474928|NCT03071159|Other|cases|children (4-18 years) with type 1 diabetes mellitis using the FreeStyle Flash Libre glucose monitoring system (standard care)
2474963|NCT03070847|Experimental|Very low dose|Will receive single bolus of Tranexamic acid. Dose: 5mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
2475231|NCT03069222||Control|age and gender matched with patient enrolled
3192467|NCT00808925|Experimental|research arm|
3192468|NCT00808938|Experimental|Active Treatment|
3192469|NCT00808951|Experimental|Artemether -lumefantrine|Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
3192470|NCT00808951|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
3192471|NCT00808977|Experimental|Dersalazine|
3192472|NCT00808977|Active Comparator|Mesalazine|
3192473|NCT00808977|Placebo Comparator|Placebo|
3192474|NCT00808990|Experimental|OSA and NAFLD patients using CPAP|OSA and NAFLD patients using CPAP being followed for 6 months.
3192475|NCT00808990|No Intervention|control|OSA and NAFLD patients not using CPAP being followed for 6 months.
3192476|NCT00809003||Sjogren's group|
3192477|NCT00809003||Dry eye|
3192478|NCT00809003||Normals|
3192479|NCT00809042|Experimental|1|Hydroxyurea
3192480|NCT00809042|Active Comparator|2|L-carnitine and hydroxyurea
3192481|NCT00809042|Active Comparator|4|L-carnitine , magnesium chloride and hydroxyurea
3192482|NCT00809042|Active Comparator|3|magnesium chloride and hydroxyurea
3192483|NCT00809068|Active Comparator|1|fenofibrate and tibolone
3192484|NCT00809068|Sham Comparator|2|tibolone
3192485|NCT00809081|Other|1|1. Enteral Feeding
3192486|NCT00809081|No Intervention|2|Total Parental support
3192487|NCT00809107|Experimental|1|HCG GROUP
3192488|NCT00809107|No Intervention|2|LH pick
3192489|NCT00809172|Active Comparator|1|Ciclosporin
3192490|NCT00809172|Experimental|2|Methotrexate
3192491|NCT00809198|Experimental|Sodium Hyaluronate|Sodium Hyaluronate (Kynex)
3192492|NCT00809198|Active Comparator|Carboxymethylcellulose sodium|Carboxymethylcellulose sodium (Refresh Plus)
3192493|NCT00809211|Experimental|Nilotinib|
3192494|NCT00809224||ALS|ALS group should have ALS.
3192495|NCT00809224||Control|The control group should not have ALS or any other neurological/psychiatric disorder, and must be over the age of 40.
3192496|NCT00809237|Experimental|Gefitinib, Hydroxychloroquine|"For the lead in phase I study, recruited patients will receive one week of 250 mg of Gefitinib, before HCQ at the assigned dose is introduced in addition to Gefitinib 250 mg om.~After the MTD of HCQ is determined, the phase II study will proceed with the combination of 250 mg of Gefitinib and the MTD dose of HCQ."
3192497|NCT00809250|Experimental|GM-K562/leukemia cell vaccine|Biological/Vaccine: GM-K562/leukemia cell vaccine Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
3192498|NCT00809289|Experimental|One|
3192499|NCT00809289|Placebo Comparator|Two|
3192500|NCT00809289|Active Comparator|Three|Administration of a single oral dse of 400mg moxifloxacin
3192501|NCT00809302|Experimental|1|aplindore 2 mg MR total daily dose
3192502|NCT00809302|Experimental|2|aplindore 6 mg MR total daily dose
3192503|NCT00809302|Experimental|3|aplindore 12 mg MR total daily dose
3192504|NCT00809302|Placebo Comparator|4|Placebo
2474362|NCT03075072|Active Comparator|Whole Brain Radiation|"MRI will be performed prior to radiation is administered~A hippocampal sparing approach will be used when possible~Dose will be 30 Gy in 10 fractions"
2474364|NCT03075072|Experimental|Stereotactic Radiation (SRS)|"MRI will be performed prior to radiation is administered~Radiation will be given in 1-5 fractions (dose depends on the size of the tumor that will be treated)"
2474420|NCT03074773|Active Comparator|paravertebral block with bupivacaine|this group will receive 0.5mg/kg bupivacaine 0.25% diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
2474428|NCT03074773|Active Comparator|paravertebral block with bupivacaine and dexamethasone|this group will receive 0.5mg/kg bupivacaine 0.25% mixed to 0.1 mg/kg dexamethasone diluted with isotonic saline (total volume 15ml) paravertebral block ultrasound guided pre-emptively
3192505|NCT00809315|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
2474592|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16
2474657|NCT03073265||Patients on apixaban|Patients currently on apixaban who meet inclusion/exclusion criteria A blood draw will be done on each patient to measure apixaban concentration in plasma using anti-Xa assay and LCMS.
2474743|NCT03072745|Experimental|Neuropsychological assessment|Assessment with a neuropsychological test battery and self-report measures.
2474805|NCT03072199|Experimental|Rituximab|
2474868|NCT03071770|Experimental|ivosidenib (AG-120)|
2474890|NCT03071289|Active Comparator|The control group (Group A)|In Group A, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method A. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
2474892|NCT03071289|Experimental|The experiment group (Group B)|In Group B, adjuvant radio-chemotherapy is applied. The radiotherapy is performed according to Radiation Method B. The regimen of chemotherapy is cisplatin 30mg/m2 every week.
3192506|NCT00809315|Experimental|Fostering Healthy Futures (FHF) Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Weekly therapeutic skill groups and mentoring over a 9-month period.
3192507|NCT00809367|Other|Collection of Leukemia Cells|Other: Collection of Leukemia Cells Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
3192508|NCT00809380|Experimental|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
2475115|NCT03069651|Active Comparator|Virtual Care|"Subjects randomly allocated to receive 'virtual care' will be shown how to use the oximeter and spirometer, as well as the videoconferencing software.~'Virtual care' subjects will be asked to perform a lung function test (using the spirometer) and record their oxygen saturations (using the oximeter) twice weekly during the videoconference with the CF team."
2475119|NCT03069651|Placebo Comparator|Routine Care|Usual clinical care.
2475224|NCT03069209|Experimental|Stem Cells|Intervention: Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
2475264|NCT03068858|Experimental|SYNTAX score category feedback group|A real-time SYNTAX score category feedback from angiographic core lab will be given to the cardiologists rightafter the angiographies.
2475265|NCT03068858|No Intervention|Controlled group|Cardiologists' subjective SYNTAX score category judgement will be recorded during the angiography.
2475309|NCT03068572||NERD group|45 GERD patients without obviously abnormality were examined by conventional white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system GERD patients with the absence of mucosal breaks at conventional endoscopy,and those patients was given standard or double dose of oral proton pump inhibitor (PPI) for 2 weeks to determine the efficacy of anti-secretory therapy (the so-called PPI test).The response to PPI treatment comprised the NERD group.
2475312|NCT03068572||Control group|45 control patients were examined by white-light endoscopy and then followed by Linked Color imaging(LCI) to evaluate minimal change esophagitis and observation agreement of Los Angeles classification system,those subjects who had undergone endoscopy solely for the purpose of a health check-up at the same time of the study period
2475357|NCT03068221|Active Comparator|Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients with PCOS
2475358|NCT03068221|Active Comparator|non Poly Cystic Ovary Syndrome|anaerobic exercise in overweight patients without PCOS
2475395|NCT03067844|Experimental|Alirocumab|Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
2475396|NCT03067844|Placebo Comparator|Placebo|Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50.
2475402|NCT03067493|Experimental|Neo-MASCT group|Patients in the treatment group will receive a total of 6 courses of Neo-MASCT treatment. The whole period of Neo-MASCT treatment for each patient will be up to 24 months.Three stratification factors are considered, i.e.tumor size (2.1-3.0cm, 3.1-5.0cm), tumor number (1, >1) and type of surgery (RFA，hepatectomy).
2475405|NCT03067493|No Intervention|Control group|Patients in the control group will be actively monitored during the trial period. Patients will receive assessment every 3 months in the first year and every 4 months in the second and third year.
2475447|NCT03067454|Other|conservative group|Treatment with early mobilisation
2475448|NCT03067454|Other|operative group|Treatment with operation
2475475|NCT03067090|Experimental|Intra-articular Aquamid Reconstruction|Intra-articular injection of 3 ml aquamid reconstruction (AR) to the knee. A second injection of 3 ml will take place after 1 month (+/- 2 weeks).
2475880|NCT03064347|Placebo Comparator|Non-Enteric Coated Sucrose|200kcal sucrose with separate enteric coating materials as single dose
2474386|NCT03074994|Experimental|Peri-articular tranexamic acid injection|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue+Medial gutter area+Lateral gutter area)
2474388|NCT03074994|Experimental|Intraarticular tranexamic acid injection|TXA inject into intraaricular knee capsule after multimodal local anesthetic infiltration
2474389|NCT03074994|No Intervention|Control group|Don't receive any route of TXA
2474448|NCT03074565|Experimental|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation only.
2474449|NCT03074565|Active Comparator|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation.
2474491|NCT03074227|Active Comparator|Allogeneic faecal transplantation|Faecal transplantation of donor stool
2474496|NCT03074227|Placebo Comparator|Autologous faecal transplantation|Faecal transplantation of own stool
3157860|NCT00374153|Experimental|2|In-person Motivational Interview with personal feedback report
3157861|NCT00374153|Experimental|3|In-person Motivational Interview only (without a personal feedback report)
3157862|NCT00374153|No Intervention|4|Assessment only
3157863|NCT00374153|No Intervention|5|Delayed Assessment
2474623|NCT03073447|Other|women under 50 years with acute MI|this clinical study is to systematically pool clinical, morphological and biological data of young women (< 50 years) presenting an Acute MI and to assess their short-term (in-hospital) and mid-term (12 months) prognosis. The usual blood tests will be performed at the patient's admission and then repeated at least 24 hours after coronary angiography, including repeated sampling assays for troponin, in order to measure the peak, following the routine of the department The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge.
2474738|NCT03072706|Active Comparator|Standard group|2D X-ray templating technology
2474741|NCT03072706|Experimental|Corin OPS™|Corin Optimised Positioning System (OPS) Dynamic Hip Analysis
2474794|NCT03072121|Experimental|Shexiang baoxin pill|Shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2474803|NCT03072121|Placebo Comparator|SBP placebo|Placebo shexiang baoxin 22.5mg pill by mouth,2 pills three times daily for 6 months & Conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2474835|NCT03071523|Experimental|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
2474837|NCT03071523|Active Comparator|periosteal releasing incision technique|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
2474900|NCT03071419|Experimental|Nutrition and Parenting Intervention|Participants (n=30, father/child dyads in groups of 10) will receive an 8 session (2 hours/session) community-based intervention including nutrition and parent education with between-session technology enhancements.
2474901|NCT03071419|Active Comparator|Wait-list Control|Participants (n=30, father/child dyads in groups of 10) will serve as a wait-list control group and receive the same Nutrition and Parenting Intervention after completing pre and post assessments several weeks apart.
2474991|NCT03070704||Insulin degludec /liraglutide|
2475041|NCT03070405|Active Comparator|Tenofovir|Tenofovir disoproxil fumarate 300mg single dose administration
2475042|NCT03070405|Experimental|Tenofovir + PAS|Tenofovir disoproxil fumarate 300mg single dose, Para-aminosalicylic acid Ca Granule 5.28 g BID seven dose administration
2475080|NCT03070067||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
2475084|NCT03070067||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-.
2475086|NCT03070067||Mimic|Clinical diagnosis of mimic and imaging negative.
2475101|NCT03069729||Control group|non-diabetic; no intervention
2475103|NCT03069729||Diabetics without DPN|diabetics without DPN; no intervention
2475104|NCT03069729||Diabetics with DPN|diabetics with DPN; no intervention
2475881|NCT03064347|Active Comparator|Enteric Coated Whey Protein|200kcal whey protein in enteric coating as single dose
3157864|NCT00374166|Experimental|SSR149415 - 250 mg|SSR149415 250 mg, twice daily for a maximum of 8 weeks
3157865|NCT00374166|Experimental|SSR149415 - 100 mg|SSR149415 100 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
3157866|NCT00374166|Active Comparator|Paroxetine|Paroxetine 20 mg and additional placebo capsules in order that all patients are being administered three capsules twice daily for a maximum of 8 weeks
3157867|NCT00374166|Placebo Comparator|Placebo|Placebo for a maximum of 9 weeks
3157868|NCT00374192|Experimental|1|Eszopiclone
3157869|NCT00374192|Placebo Comparator|2|Placebo
3157870|NCT00374205|Experimental|AL|Artemether plus Lumefantrine 6 dose 3 days treatment
3157871|NCT00374205|Active Comparator|ASAQ|Artesunate plus Amodiaquine
3157872|NCT00374296|No Intervention|1|Elderly (≥65 years) untreated arm
3157873|NCT00374296|Experimental|2|Relapsed/Refractory Arm
3157874|NCT00374361||Caucasian Adolescents|Caucasian Adolescents
3157875|NCT00374361||African-American Adolescents|African-American Adolescents
3157876|NCT00374413|Experimental|Kineflex-C|
3157877|NCT00374413|Active Comparator|ACDF|
2474398|NCT03074877|Experimental|Waitlist Group|Families recruited in Year 1 who are randomized to the wait-list group, and all families recruited in Year 2 will be assigned to the wait-list group. This group will receive the materials provided to all families, noted above, and the initial in-home assessment within 2 weeks of the screening to be conducted by a trained research assistant. At 1 year post-screening, the families in the wait-list group will be administered the follow-up assessment and will begin the Family Check-Up (FCU) intervention.
2474403|NCT03074877|No Intervention|Control Group|These families will be recruited in Year 3 of the study. These families will be provided the materials noted above and will receive the in-home assessments conducted by a trained research assistant. The initial in-home assessments will be conducted within 2 weeks of the screening, and follow-up assessments conducted 1 year post-screening.
2474466|NCT03074604|Experimental|aortic no-touch OPCABG|aortic no-touch OPCABG
2474471|NCT03074604|Experimental|OPCABG with partial clamp applying carbon dioxide|OPCABG with partial clamp applying carbon dioxide
2474474|NCT03074604|Active Comparator|OPCABG with partial clamp|OPCABG with partial clamp
2474517|NCT03074019|Experimental|Xylooligosaccharide (Low Dose)|1.5g XOS95 + 1.5g Maltodextrin powder, taken orally mixed in water, once daily
2474521|NCT03074019|Experimental|Xylooligosaccharide (High Dose)|3g XOS95 powder, taken orally mixed in water, once daily
2474524|NCT03074019|Placebo Comparator|Placebo|3g maltodextrin powder, taken orally mixed in water, once daily
2474591|NCT03073668|Experimental|Heart Failure Patients|After obtaining written informed consent, patients will undergo induction with general anesthesia as per clinical practice. The chest will be open but pericardium left intact. Cardiac hemodynamics will be measured using PA catheter already in place at rest, and then during conditions of increased cardiac preload, induced by passive leg elevation and saline bolus (300 ml administered over 1-2 minutes). The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure. The surgical team will then repeat hemodynamic assessments at rest and with acute volume loading (leg raise + saline) in exactly the same manner as with the pericardium intact.
2474634|NCT03073252|Experimental|Normal Protein|Consumption of normal protein (NP) meal
2474638|NCT03073252|Experimental|High Protein|Consumption of high protein (HP) meal
3157878|NCT00374439|Experimental|Cognitive-behavioral|Participants in this arm received a cognitive-behavioral program
3157879|NCT00374439|Experimental|Interpersonal Therapy|Participants in this arm received a prevention program based on interpersonal therapy for depression
2475685|NCT03065829|Experimental|ASSIST|The ASSIST intervention will deliver daily doses of MMT and vary dose intensity of all components each day based on the subject's biophysical data. Across a 30-day period, the ASSIST intervention will capture and analyze data to deliver on-demand MMT, guided practices to promote sleep hygiene and physical activity. Each day, subjects will receive at least one prompt to practice MMT (about 5 minutes at a time). However, based on the subject's biophysical sensor data, subjects could receive a maximum of 5 alerts or prompts per day from the device to enhance stress reduction, sleep hygiene, or physical activity.
2475686|NCT03065829|Experimental|Attention-Control|This intervention exposes subjects to the wearable technology without the self-management components to minimize novelty effects. Subjects assigned to this condition will wear the device for 30 days, which offers them an opportunity to experientially learn to self-monitor and employ self-regulatory skills by viewing the display biophysical data. Subjects in this condition will not receive any prompts from the device.
2475704|NCT03065426||Roux-en-Y Gastric Bypass|Patients planning to undergo Roux-en-Y Gastric Bypass will be invited to participate in this study.
2475708|NCT03065426||Sleeve Gastrectomy|Patients planning to undergo Sleeve Gastrectomy will be invited to participate in this study.
2475761|NCT03065257||Endoscopic Resection|Patients undergoing Endoscopic Resection
2476097|NCT03062930|Active Comparator|Track 1|Training of non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks followed by sham condition (playing board games/computer games) for 3 weeks
2476098|NCT03062930|Sham Comparator|Track 2|Sham condition (playing board games/computer games) for 3 weeks followed by training of the non-paretic arm for 3 weeks consisting of occupational therapy and kinematic tasks
2476233|NCT03061838|Active Comparator|MabThera®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
2476237|NCT03061838|Experimental|Ritumax®|2 intravenous infusions on Week 0 and Week 2 (14-day interval).
2476279|NCT03061578||NDE|"Non Dry Eye (NDE) group will be used as control for DES diagnosis.~Subjects in the non-dry eye criteria must meet all of the following criteria:~Have a Schirmer's Test (without anesthesia) of ≥10mm/5min in both eyes~OSDI questionnaire score <13.~Fluorescein TBUT > 7 s in both eyes.~CFS of 0 in all areas in both eyes.~The NDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2476344|NCT03061162|Experimental|Study Arm|Gastric cancer patients with peritoneal metastasis undergo pulsed low dose rate 3-dimensional conformal radiation therapy, QD, 5 days a week for 25 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
2476362|NCT03060928|Experimental|Experimental 2|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with the combination of micro-perforations and use of Artelon® Tissue Reinforcement
2497250|NCT02921217|Placebo Comparator|Control|Control
3157880|NCT00374439|No Intervention|No intervention|Participants in this arm did not receive an intervention, but complete assessments only
3157881|NCT00374569|Experimental|Gymnastics|Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
3157882|NCT00374569|Experimental|Non Gymnasts|Non Gymnasts stand on a computerized dynamic posturography Force Plate and Stability is measured and gymnastic routines performed
3157883|NCT00374621|Active Comparator|Misoprostol|
3157884|NCT00374621|Active Comparator|Misoprostol with Isosorbide Mononitrate|
3157885|NCT00374634|Active Comparator|"Individual or standard rFSH dose"|"Patients were randomized to recieve individual (50, 75 or 100 IU/day) or standard (75 IU/day) rFSh dose. The individual dose was prescribed according to a dosage nomogram based on the patient's body weight (kg) and the total antral follicle count (Freiesleben NC et al., RBMOnline 2009;17:632-64)."
2474429|NCT03074799|Experimental|Symptom -based Screening(Child Contacts)|In the intervention clinics, decisions regarding IPT will be made on a clinical basis. If the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT. Children will be followed at least monthly for the duration of the six month course of isoniazid, as is standard of care in South Africa at this time. Clinical outcome data will be obtained from patient records and implementation of a contact register aimed at improving longitudinal care of children on isoniazid preventive therapy.
2474462|NCT03074383|Experimental|Workshop|Self-Care Multidisciplinary Workshop for Diabetes consist in individual meetings with a multidisciplinary team (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) in which education and self-care topics will be approached. The workshop will be offered in 3 different modules with 2-4 weeks difference between them.
2474465|NCT03074383|Active Comparator|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
2474529|NCT03074136|Experimental|Photodinamic therapy|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that, HELBO treatment (Helbo Photodynamic System, Bredent, Senden, Germany) will be applied.
2474530|NCT03074136|Experimental|Diode laser|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius). After that high power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA).
2474534|NCT03074136|Experimental|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degree Celsius).
2474566|NCT03073512|Other|Ultrasound examination|Participants will undergo an ultrasound examination at 32 weeks gestation.
2474652|NCT03072992|Active Comparator|Group A: Paclitaxel & Curcumin|75 patients, treatment with Curcumin (CUC-01, yellow solution), 300mg i.v. plus i.v. Paclitaxel (colorless solution) 80 mg /m2 BS i.e., once weekly for 12 weeks.
2474653|NCT03072992|Placebo Comparator|Group B: Paclitaxel & Placebo|Group B, 75 patients, treatment with Paclitaxel (colorless solution) 80 mg /m2 BS, i.v. plus placebo i.v. solution (250 ml, yellow solution for masking/blinding), once weekly for 12 weeks.
2474714|NCT03072771|Experimental|ASCT + BEAM + Blinatumomab|"Standard of care ASCT with BEAM conditioning (carmustine/etoposide/cytarabine/melphalan) - guidelines below, other conditionings are allowed:~carmustine is typically given intravenously (IV) at a dose of 300 mg/m^2 on Day -7~etoposide is typically given IV at a dose of 100 mg/m^2 twice per day (BID) on Days -6, -5, -4, and -3 (8 doses)~cytarabine is typically given IV at a dose of 100 mg/m^2 BID on Days -6, -5, -4, and -3 (8 doses)~melphalan is typically given IV at a dose of 140 mg/m*2 on Day -2~Auto-SCT will take place on Day 0 as per institutional guidelines~Consolidation with blinatumomab will start 6 weeks following auto-SCT. Patients with CR or PR based on pre-transplant PET/CT will receive blinatumomab as a continuous IV infusion (CIVI) at 9μg/day for 1 week, then 28μg/day for 3 weeks (total of 4 weeks)."
2474781|NCT03072329|Experimental|Pudendal nerve block|Bilateral pudendal nerve block with the administration of 0.1 mL/kg Bupivacaïne 0.5%, regardless of neurostimulation response.
2474865|NCT03071549|Active Comparator|combined azaleic and salicylic acids|Combined azaleic acid 20% with salicylic acid 20% peel every 2 weeks for 4 sessions
2474870|NCT03071549|Active Comparator|Trichloroacetic acid peel|Trichloroacetic acid 25% peel every 2 weeks for 4 sessions
2474916|NCT03071237||Observational group|Patients who would receive total gastrectomy or distal gastrectomy are enrolled in to the study and this group. An optional reconstruction of IPA by enhanced CT scan can be performed before surgery but not a definite require. During the operation, IPA origin location will be photo-taken or video-recorded before its transection.
2474962|NCT03070860|Experimental|PXE Patient|positron emission tomography scanner (PET scan) 18-FDG and 18-NAF: conventionnal use.
2474994|NCT03070561|Experimental|Sublingual film with peanut extract|
3157886|NCT00374634|Active Comparator|"Standard rFSH dose"|"Standard dose of rFSH"
2475180|NCT03069326|Experimental|Cohort A: Ruxolitinib and Thalidomide|After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
2475185|NCT03069326|Experimental|Cohort B: Ruxolitinib and Thalidomide|"A cohort expansion, for patients with baseline thrombocytopenia, will enroll 35 additional patients~After 3 cycles of ruxolitinib treatment, either prior to study enrollment or through the ruxolitinib run-in phase, patients who meet eligibility criteria will be treated with ruxolitinib and thalidomide orally on days 1-28 of a 28 day cycle. Cycles will be continued until the patient wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs."
2475225|NCT03068975|Experimental|Alvimopan|Patients in the study group will be administered a post operative dose of Alvimopan
2475228|NCT03068975|Placebo Comparator|Placebo|Patients in the Placebo group will receive a placebo pill and will be compared with the study group
2475495|NCT03067025||30 youth with MS|
2475502|NCT03067025||30 healthy control participants|
3157888|NCT00374673|Experimental|transcranial magnetic stimulation|repetitive transcranial magnetic stimulation of the motor cortex
3157889|NCT00374673|Sham Comparator|placebo stimulation|repetitive placebo stimulation of the motor cortex
3157890|NCT00374738|Experimental|GIFT Intervention|Guided Imagery for Trauma (GIFT)
3157891|NCT00374738|No Intervention|Music Control|Relaxing Music Audio control; same music used in guided imagery, with no narrative voice.
2474435|NCT03074539|Active Comparator|Balloon Pulmonary Angioplasty - BPA|"CTEPH treatment via BPA. Patients who are suitable for Balloon Pulmonary Angioplasty (BPA) according to the recommendation of the local CTEPH board (e.g. patients not suitable for Pulmonary Endarteriectomy). A standardized polygraphy will be conducted before the first BPA intervention, to gain information about possible sleep-disordered breathing. 6 months after the first BPA intervention another polygraphy will be accomplished and the results compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2474438|NCT03074539|Active Comparator|Medical Treatment|"CTEPH treatment via Medical Treatment. Patients who are inoperable (not suitable for Pulmonary Endarteriectomy) and not eligible for BPA according to the recommendation of the local CTEPH board will get medical treatment with Riociguat. The treatment will be assigned according to the currently valid guidelines (2015 European Respiratory Society / European Society of Cardiology guidelines on the diagnosis and treatment of pulmonary hypertension). A standardized polygraphy will be conducted before the medical treatment starts, another polygraphy will be conducted after 6 months of treatment if Riociguat. The results will be compared with the first polygraphy and the other arms.~If Sleep Disorder Breathing remains, a personalized recommendation on further specific therapy (e.g. nocturnal continuous positive airway pressure ventilation) will be made."
2474473|NCT03074305|Active Comparator|DEB strategy|"DEB procedure will be standardized in order to maximize drug delivery into target segment. Commercially available DEB will be used (Sequent Please, B Braun, Germany or Pantera Lux, Biotronik, German). The below requirements will be mandatorily recommended.~Residual stenosis after lesion preparation : %DS <20%~Delivery time : < 30 seconds~Total inflation time : > at least 1 minute~Previous BVS : DEB diameter ratio : > 1.0:1~Maximum inflation pressure : at least above nominal pressure of DEB"
2474477|NCT03074305|Active Comparator|DES strategy|The implantation of 2nd generation DES will be performed as universally recommended. In the DES group, the newest version of 2nd generation everolimus-eluting stent (Xience Alpine, Abbott Vascular, USA) will be recommended.
2474503|NCT03074097|Active Comparator|Rectus Sheath|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
2474506|NCT03074097|No Intervention|Control|Control group: the patients did not receive any intervention after anaesthesia induction.
3157892|NCT00374751|Experimental|Samarium (153SM)|Injection of Samarium (153SM)
3157893|NCT00374777|Experimental|1|
2474736|NCT03072680|Experimental|BPS PAST + BPS FUT|Participants practice BPS PAST the first week, then they switch fot BPS FUT.
2474740|NCT03072680|Experimental|BPS FUT|Participants practice BPS FUT during the two weeks.
2474744|NCT03072680|Active Comparator|CONTROL|Participants practice DAILY ACTIVITIES for the two weeks.
2474838|NCT03071783|Experimental|Vacuum extraction intelligent system|Measurement and intra-operative feed back of vacuum extraction data: notification signal based an algorithm calculation using traction force (peak and time force integral) and time.
2474839|NCT03071783|No Intervention|conventional|conventional handle
3157894|NCT00374777|Experimental|2|
3157895|NCT00374777|Active Comparator|3|
2474975|NCT03070743||PCDR surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
2475001|NCT03070444|Experimental|Group A: CTC retainer + Essix retainer|"The CTC is bonded directly after debonding. The Essix retainer maxilla is handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
2475004|NCT03070444|Active Comparator|Group B: Essix retainer + Essix retainer|"The Essix retainer maxilla and Essix retainer mandible are handed out to the patient the same day after removal of fixed appliances.~Alginate impressions are taken at the follow-up visits. Questionnaires are completed at the follow-up visits."
2475060|NCT03070223||Experimental: Pitavastatin|Participants who receive pitavastatin in the main study REPRIEVE (A5332).
2475061|NCT03070223||Placebo Comparator: Placebo|Participants who receive placebo for pitavastatin in the main study REPRIEVE (A5332).
2475123|NCT03069703|Active Comparator|Prime-boost strategy|a single dose of 13-valent pneumococcal conjugate vaccine (Prevenar, PCV13) at Day 0 (lying within a window of ± 2 days of the first infusion of rituximab), followed by a single dose of 23-valent unconjugated vaccine (Pneumovax, PPV23) at month 5 (M5)
2475124|NCT03069703|Experimental|Innovative vaccine strategy 1|2 doses of PCV13 at Day 0 and 2 doses of PCV13 at Day 7, followed by a single dose of PPV23 at M5
2475126|NCT03069703|Experimental|Innovative vaccine strategy 2|4 doses of PCV13 at Day 0, followed by a single dose of PPV23 at M5
2475244|NCT03068936|Other|IMRT plus cisplatin group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy),plus synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
3157896|NCT00374777|Placebo Comparator|4|
3157897|NCT00374881|Active Comparator|1|Morphine High Dose
3157898|NCT00374881|Placebo Comparator|2|Morphine Low Dose
3157899|NCT00374881|Placebo Comparator|3|Sorbitol Phenylephrine
3157900|NCT00374881|Experimental|4|Sorbitol high concentration+Phenylephrine+Morphine
3157901|NCT00374881|Experimental|5|Sorbitol low concentration+Phenylephrine+Morphine
3157902|NCT00374933|Experimental|1|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
3157903|NCT00374946||A|THA. Bearing of Zirconia head and UHMWPE liner
3157904|NCT00374946||B|THA. Bearing of CO-Cr-Mo head and liner
3157905|NCT00374946||C|THA. Head og Zirconia head and UHMWPE moulded in shell (Asian)
3157906|NCT00374946||D|THA. Head and shell og Alumina ceramic
3157907|NCT00374972||combined contraceptives|combined contraceptives
3157908|NCT00374972||pregesterone only contraceptives|pregesterone only contraceptives
3157909|NCT00374985|Experimental|one arm|
3157910|NCT00375024|Other|1: Patient Navigator|Patients will meet with a Patient Navigator regarding their treatment and any related concerns.
2474444|NCT03074669|Experimental|ACT program|Participants from the active treatment group will be granted access to seven modules that are structured like chapters of a self-help book adapted for the online environment. In addition, participants from the experimental arm will be guided by an on-line therapist throughout the program duration. The on-line therapists are graduate students in clinical psychology who work under the supervision of an experienced psychotherapist. Participants will be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance) throughout the intervention.
2474445|NCT03074669|No Intervention|Wait-list control group|During the first seven weeks, participants in the wait-list control group will only be asked to fill in a series of self-report measures to monitor their anxiety and some ACT specific processes (i.e., acceptance, mindfulness, experiential avoidance). Following the experimental group's completion of the program, participants in this group will also receive the intervention. All participants will be contacted 6 months after the intervention has concluded in order to conduct a follow-up assessment.
2474486|NCT03074266||Blood coagulation test 1|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct coagulation tests using GEM Hemochron 100 during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention in this study. The interventional procedure (described above) is standard of care and all results of blood coagulation testing using GEM Hemochron 100 performed in this study are not used to influence that care."
2474493|NCT03074266||Blood coagulation test 2|"Therapeutic: Waste blood from heparinized patients undergoing interventional procedures (standard of care) in different clinical settings will be used to conduct duplicate coagulation tests using Signature Elite during the course of the procedure before (baseline) and after heparin administration.~There is no drug administration or therapeutic intervention conducted in the course of this study. The interventional procedure (described above) is standard of care. The only difference in standard of care is that the blood coagulation test is run in duplicate."
2474547|NCT03073954|Active Comparator|Working memory training|Working memory training that increases with difficulty if participants answer two subsequent questions correctly, and standardised healthy lifestyle coaching.
2474551|NCT03073954|Sham Comparator|Sham working memory training|Working memory training that does not increase in difficulty, and standardised healthy lifestyle coaching.
3157911|NCT00375024|Other|2: Without Navigator|Patient will work with existing clinic staff, which does not include a Patient Navigator.
3157912|NCT00375037|Experimental|Hand hygiene|Hand hygiene promotion
3157913|NCT00375037|Active Comparator|Usual care|usual care
3157914|NCT00375050|Experimental|Riluzole|
2474849|NCT03071822|Experimental|PIGLETs|Patient will be given this combination of chemotherapy (cisplatin, ifosfamide, gemcitabine, L-asparaginase, etoposide and dexamethasone) for a total of 6 courses
3157915|NCT00375050|Placebo Comparator|Placebo|
2474984|NCT03070834|Experimental|rIVCF|Randomized to receive insertion of retrievable inferior vena cava filter until chemical anticoagulation can be safely administered.
2474985|NCT03070834|No Intervention|Standard Care|Randomized to not receive insertion of retrievable inferior vena cava filter.
2475094|NCT03069872|Experimental|Intervention|All GPs in Central Denmark Region, are planned to be enrolled in the study during the one year study period.
2475174|NCT03069573||Eosinophilic Esophagitis - EoE|Diagnosis of pediatric EoE under current guidelines.
2475177|NCT03069573||Gastroesophageal reflux disease - GERD|Diagnosis of pediatric GERD under current guidelines.
2475184|NCT03069573||Control|Exclusion diagnosis of EoE or GERD, with non specific gastrointestinal general complaints.
2475196|NCT03069105||Family caregivers|The sample for this study will consist of caregivers of patients with cancer. Eligible subjects who agrees to participate in the research study and sign the consent form will participate by completing paper and pencil or electronic questionnaires.
2475242|NCT03068936|Experimental|IMRT group|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
3157916|NCT00375089||Group 1|Individuals with Prader-Willi syndrome.
3157917|NCT00375089||Group 2|Individuals with Early-onset Morbid Obesity
3157918|NCT00375102|Experimental|Acup|Acupuncture
3157919|NCT00375102|Experimental|RR|Relaxation Response
3157920|NCT00375102|No Intervention|UC|Usual Care
3157921|NCT00375193|Experimental|1|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until cycle 6 or no longer beneficial.
3157922|NCT00375245|Experimental|Rapamycin + Grapefruit juice|
3157923|NCT00375258|Experimental|1|Active
3157924|NCT00375258|Placebo Comparator|2|
3157925|NCT00375310|Experimental|Gemcitabine + Sorafenib & radiotherapy|"Induction: Gemcitabine with Sorafenib for 4 weeks (1 cycle). Chemo-radiotherapy: Gemcitabine with Sorafenib and Radiotherapy for 5 weeks. Sorafenib will be given in escalating dose cohorts.~Sorafenib only: Sorafenib alone for 4 weeks. Consolidation: Gemcitabine with Sorafenib for 16 weeks (4 cycles). Maintenance: Sorafenib alone until disease progression."
3157926|NCT00375336||1|Patients with aortic stenosis (mean transvalvular aortic gradient ≥30 mm Hg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3157927|NCT00375336||2|Patients with nonobstructive aortic sclerosis (mean gradient ≤10 mmHg) plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3157928|NCT00375336||3|Patients with normal aortic valve plus angiographically significant coronary artery disease (more than 50% diameter stenosis)
3157929|NCT00375401|Experimental|CP-945,598 Treatment A|
3157930|NCT00375401|Experimental|CP-945,598 Treatment B|
3157931|NCT00375401|Placebo Comparator|Placebo|
3157932|NCT00375453|Experimental|Arm 1|
3157933|NCT00375466|Experimental|Tranexamic Acid|
3157934|NCT00375466|Placebo Comparator|placebo|
3157935|NCT00375557|Active Comparator|1|Quetiapine
3157936|NCT00375557|Active Comparator|2|Divalproex ER
3157937|NCT00375570|Experimental|1|ME-609
3157938|NCT00375648|Experimental|zoledronate|
3157939|NCT00375661|No Intervention|interferon|
3157940|NCT00375726|Experimental|1|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^3 PFU dose) into the deltoid region of either arm.
2474460|NCT03074318|Experimental|Treatment (avelumab, trabectedin)|Avelumab will be administered every 2 weeks. Trabectedin will be administered every 3 weeks for the first two doses (Week 1 and Week 4), and then every four weeks (Week 7, Week 11,…) moving forward. After Cycle 2 of trabectedin, dosing may extend to every 5 weeks at investigator discretion, for management of trabectedin-associated toxicity only. Delays of trabectedin beyond 5 weeks may be allowed but require written approval from the Sponsor-Investigator. On days where both drugs are scheduled to be administered, avelumab will be administered first. This will continue until unacceptable toxicity or confirmed disease progression.
3192509|NCT00809380|Active Comparator|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
2474575|NCT03073785|Active Comparator|Arm A (chemotherapy, radiation therapy)|Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
2474580|NCT03073785|Experimental|Arm B (zoledronic acid, chemotherapy, radiation therapy)|Patients receive zoledronic acid IV over no less than 15 minutes 1 week prior to radiation therapy. Patients undergo hypofractionated stereotactic body radiation therapy and receive treatment with fluorouracil IV or capecitabine PO as in Arm A. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
2474656|NCT03073096|Other|Intervention arm|LVA at time of nodal dissection
2474712|NCT03072758|Experimental|Men's Club Intervention Group|Participants randomized to this group will receive interventions from the study team.
2474713|NCT03072758|No Intervention|Men's Club Control Group|Male participants in the control group will receive only education pamphlets related to breastfeeding during the 3rd trimester of their female partner's pregnancy
2474717|NCT03072420|Experimental|Group no manual work or activity|Subject with an office or student job.
2474718|NCT03072420|Sham Comparator|Group manual work|Subject working in a manual or predominantly manual.
2474761|NCT03072342|Active Comparator|Intensive Periodontal Treatment (IPT)|
2474762|NCT03072342|Placebo Comparator|Control Periodontal Treatment (CPT)|
2474874|NCT03071809||Early stage neoplasm|Patients with stage I-III early stage non-hematologic neoplasm
2474876|NCT03071809||Healthy Control|Patients undergoing surgery for a non-malignant condition with no prior history of malignancy.
2475000|NCT03070522|Active Comparator|Placebo|Placebo
2475003|NCT03070522|Active Comparator|Treatment|Prednisone
2475064|NCT03070210|Other|EUS-celiac plexus block (EUS-CPB)|"This is the standard technique. In this approach, the needle is passed through the body of the stomach adjacent the celiac artery into the retroperitoneal space in 1 or 2 passes. The injectate (bupivacaine or alcohol) is injected and spreads through the retroperitoneal space, effectively bathing all the ganglia."
2475066|NCT03070210|Active Comparator|EUS-celiac ganglia block (EUS-CGB)|This is a more recent technique which has been often used. In this procedure, the needle is inserted under EUS guidance directly into as many ganglia as possible. For celiac ganglia <1cm in diameter, the solution is injected into the central point; for those ≥1 cm, a needle is advanced to the deepest point into the ganglia and solution is injected as the needle is slowly withdrawn. Injections are continued until an echogenic pattern is produced over the entire celiac ganglia.
2475117|NCT03069885|Active Comparator|Standard postoperative dressing group|30 patients treated with conventional post-operative dressing.
2475120|NCT03069885|Experimental|Prevena group|30 patients treated with PrevenaTM (incisional negative pressure wound therapy)
2475155|NCT03069456|Active Comparator|BIS group|Combined sigmoidal Emax models from the BIS data
2475159|NCT03069456|Experimental|ADMS group|Combined sigmoidal Emax models from the ADMS data
2475200|NCT03069092|Experimental|Aerobic exercise (AE)|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
2475201|NCT03069092|Experimental|Resistance exercise (RE)|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial.
2475203|NCT03069092|Experimental|Combined Resistance and Aerobic Exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
2475209|NCT03069092|No Intervention|No training control|Participants in this group will be asked to maintain their current level of activity during the 1 year study period. After 1 year, they will be offered the training program of their choice (AE, RE, or combined).
2475246|NCT03068832|Experimental|Personalized peptide vaccine and poly-ICLC|"The synthetic long peptide(s) and poly-ICLC will be given on Cycle 1 Day 1 when available.~Additional peptide vaccine doses will be administered again on Days 4, 8, 15, and 22 of the first cycle as a priming strategy. On all subsequent cycles, the peptide vaccine will be given on Day 1.~Peptide vaccine administration will continue until supply is exhausted or development of intolerance or disease progression in the case of fatal high grade neoplasms. Otherwise, vaccination will continue until supply is exhausted or intolerance or one year for non-fatal tumors. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease will be given the option of resuming vaccinations if they develop subsequent progression if remaining vaccine is available."
2475298|NCT03068585|Experimental|Neovasculgen|DNA encoding the 165-amino-acid isoform of human vascular endothelial growth factor (pCMV - VEGF165)
2475299|NCT03068585|No Intervention|Control|Control therapy
2474501|NCT03073941|Active Comparator|Persona CR Total Knee System|All patients randomized into this group will have the Intervention: Persona total knee system
2474504|NCT03073941|Active Comparator|NexGen CR Total Knee System|All patients randomized into this group will have the Intervention: Nexgen total knee system
2474564|NCT03073772|No Intervention|Continued multimodal rehabilitation|No addition of extra training in this group. Only ordinary continued multimodal rehabilitation.
2474568|NCT03073772|Active Comparator|Computer-based cognitive training|This arm also consisted of continued multimodal rehabilitation.
2474571|NCT03073772|Active Comparator|Physical fitness training|This arm also consisted of continued multimodal rehabilitation.
2474669|NCT03072836|Experimental|CD alone|
2474680|NCT03072836|Experimental|SPA alone|
2474691|NCT03072836|Experimental|CD + SPA|
3192510|NCT00809393|Active Comparator|low dose|low dose tranexamic acid
3192511|NCT00809393|Experimental|high dose|
2474779|NCT03071965|Experimental|Cohort 1|Participants completed protocol NTMT-01. All participants received surgery to implant NT-501. All participants received ciliary neurotrophic factor (CNTF).
2474780|NCT03071965|Experimental|Cohort 2|Participants completed protocol NTMT-02. Participants received surgery to implant NT-501 or sham surgery to mimic implant procedure. Participants that received NT-501 implant were exposed to ciliary neurotrophic factor (CNTF).
2474832|NCT03071796|Experimental|multivitamin supplement|liquid multivitamin supplement for 12 weeks
2474833|NCT03071796|Placebo Comparator|placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
2474894|NCT03071432|Active Comparator|Non-diabetic patients|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2474896|NCT03071432|Active Comparator|Diabetic patients with cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2474897|NCT03071432|Active Comparator|Diabetic patients without cardiovascular autonomic neuropathy|Study interventions include a medical history and short physical examination as well as autonomic function tests and cerebral autoregulation tests on the day before surgery. In addition we determine CO2 sensitivity of the cerebral vasculature by three minutes hyperventilation and three minutes CO2 rebreathing. Perioperatively, continuous measurement of heart rate, blood pressure, stroke volume and cardiac output is aquired using the ccNexfin monitor, a non-invasive device using a single finger cuff. Continuous monitoring of cerebral perfusion parameters using transcranial Doppler ultrasound (TCD) of the middle cerebral artery (MCA) and cerebral oxygenation using near-infrared-spectroscopy (NIRS) will be obtained. BRS and condition of CA will be determined preoperatively during autonomic function testing (see below) and 30 minutes after induction of anaesthesia.
2474910|NCT03070990|Experimental|Arm A: Enfortumab vedotin 1.0 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
2474911|NCT03070990|Experimental|Arm B: Enfortumab vedotin 1.25 mg/kg|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
3192512|NCT00809419|Experimental|A|NeoVista Ophthalmic System procedure + Lucentis
3192513|NCT00809432|Experimental|Visit 1|2 hour city centre kerbside walk in Beijing China
3192514|NCT00809432|Experimental|Visit 2|2 hour city centre kerbside walk in Beijing China
3192515|NCT00809484||1: Low risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily
3192516|NCT00809484||2:Moderate risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, +/- Risedronate 35mg orally once a week
2475069|NCT03070132|Experimental|BIIB074|Optimized oral dose three times daily (TID)
3192517|NCT00809484||3:High risk|Anastrozole 1mg/d, Vit D 400 IU and 500mg Calcium daily, Risedronate 35mg orally once a week
3192518|NCT00809510|Experimental|1|
3192519|NCT00809536|Other|Cohort 1|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
3192520|NCT00809536|Other|Cohort 2|This is an open-label, randomized, two period cross-over which will be conducted in 12 healthy adults
3192521|NCT00809549|Placebo Comparator|Normal Saline|
3192522|NCT00809549|Experimental|Filgrastim|
3192523|NCT00809562|Experimental|1|
3192524|NCT00809562|Placebo Comparator|2|
3192525|NCT00809588|Experimental|Melanoma Vaccine|GM-CSF Vaccine
3192526|NCT00809601|Experimental|1|
3192527|NCT00809627|Experimental|1|IV caffeine with saline and opiate
3192528|NCT00809627|Placebo Comparator|2|IV saline with opiate
3192529|NCT00809640|Active Comparator|1|The intervention group will receive prevention of low back pain education through a Back Comic-Book, and their beliefs/knowledge will be tested twice after intervention.
2474509|NCT03074123|Experimental|healthy subjects|20 healthy subjects will undergo low dose cosyntropin stimulation test. Serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
2474654|NCT03073330|Experimental|One Step|The intervention is gestational diabetes screening with 2 hour GTT 75 g load.
2474655|NCT03073330|Active Comparator|Two Step|There is no intervention is this arm as patients will subjected to routine gestational diabetes screening with one hour glucola, 50 g load.
2474766|NCT03072264|Experimental|Body in Mind Training (BMT)|This is a group intervention (10-15 participants) that consists of 5 weekly sessions lasting 2 hours. In our protocol, we added 3 more final sessions of 2 hours in order to emphasize the practices, specially in self-compassion, resulting in 8 weeks of intervention.
2474769|NCT03072264|Active Comparator|Medication|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
2474770|NCT03072264|Active Comparator|Quality of Life Group|This is a group intervention (10-15 participants) that consists of 8 weekly sessions lasting 2 hour in which individuals will receive psychoeducation on various aspects of quality of life that have na impact in reducing anxiety.
3157941|NCT00375726|Experimental|2|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
2474875|NCT03071484|Experimental|Transcranial Direct Current Stimulation|After being randomly allocated, the experimental group will receive a 20 minutes of active 2-mA tDCS once a day on 10 consecutive weekdays.
2474877|NCT03071484|Placebo Comparator|Sham - tDCS|The control group will receive a sham stimulation, which chosen parameters consists in after 40 seconds of real stimulation (2 mA), only a small current pulse occurred every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
2474941|NCT03071003|Experimental|Cohort 1 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) once daily for 7 days.
2474945|NCT03071003|Experimental|Cohort 2 SENS 401 & Placebo|12 subjects will receive 29 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 29 mg SENS-401 or placebo in the morning on Day 7.
2474948|NCT03071003|Experimental|Cohort 3 SENS 401 & Placebo|12 subjects will receive 43.5 mg SENS-401 (approximately 4 male and 4 female subjects) or placebo (approximately 2 male and 2 female subjects) twice daily for 6 days and a single dose of 43.5 mg SENS-401 or placebo in the morning on Day 7.
2474987|NCT03070639|No Intervention|Standard Care Study Condition|The Standard of Care control group will not receive any additional services at the newborn visit.
2474988|NCT03070639|Active Comparator|Attention-Matched Control Condition|The Attention-Matched Control Condition will include the Scald Prevention Intervention.
2474993|NCT03070639|Experimental|Safe Sleep Intervention Condition|The Intervention Condition will include the Safe Sleep Intervention.
2475040|NCT03070340|Experimental|Breast MRI and Contrast Enhanced Mammography (CEDM)|Breast MRI and CEDM will be performed within 30 days of one another after neoadjuvant therapy
2475067|NCT03070041|Experimental|Mothers and staff members|The mothers who will give birth at the study hospital and all the staff members taking care about mothers and/or infants
2475092|NCT03069898|Experimental|TRUE Dads program track|In the TRUE Dads program, fathers and co-parents begin with a Core workshop meeting weekly for 6 weeks. After a check-in, a male-female group leader team focuses on a single topic that represents one of the three main goals of the project as a whole: Co-parenting relationships, Parenting, or Employment and financial stability. From 10 to 18 couples, seated at small tables in a large room, hear mini-lectures, watch videos, and engage in interactive exercises. Fathers then choose to attend one of three intensive workshops focused on couple relationships OR parenting OR economic self-sufficiency meeting 3 hours per week for the next 6 weeks. On an as-needed basis, fathers may be referred for employment programs and fathers and co-parents may be referred for mental health or other services.
2475096|NCT03069898|No Intervention|Control condition study track|Participants (fathers and co-parents) complete intake interview and fill out Baseline survey. They fill out follow-up survey one year later
2475173|NCT03069599||10 IRE locally advanced|patients undergoing in situ IRE for locally advanced pancreatic
2475178|NCT03069599||10 IRE borderline resection|patients undergoing margin accentuation IRE for borderline resectable disease
2475183|NCT03069599||10 resection only|patients undergoing surgical resection only
2475282|NCT03068871|Experimental|CET|CET - Coping Effectiveness Training group.
2475285|NCT03068871|Experimental|ACT|ACT - Acceptance and Commitment Therapy group
2475303|NCT03068403|Other|Chemotherapy and Radiochemotherapy|
2475304|NCT03068403|Other|Radiochemotherapy|
2475343|NCT03068247|Experimental|Interventional|10 weeks of duloxetine beginning at 30 mg per day for week 1, then 60 mg / day thereafter.
2475345|NCT03068247|Placebo Comparator|Placebo|10 weeks of placebo once daily for 1 week, then twice daily therafter.
3157942|NCT00375726|Experimental|3|One subcutaneous vaccination with rDEN3/4delta30(ME) vaccine (10^1 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the immunological response of Arm 1.
3157943|NCT00375726|Placebo Comparator|4|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3157944|NCT00375791|Experimental|Perifosine daily|Patients will take three 50 mg tablets of perifosine daily at bedtime with food. Patients will be examined every three weeks. If patients have no progression it is allowed to receive 8 cycles of perifosine
3157945|NCT00375791|Experimental|Perifosine daily + Dexa twice per week|Patients will take three 50 mg tablets of perifosine daily at bedtime with food until progression. If progressive disease is confirmed by a second measurement at least one week later the patient will receive a combination of 20 mg twice per week dexamethasone (dexa) and 150 mg perifosine daily at bedtime.
3157946|NCT00375843|Active Comparator|Level 1 Treatment: Escitalopram|Level 1 participants who are assigned to escitalopram
3157947|NCT00375843|Active Comparator|Level 2: Sertraline|Participants from Level 1 who do not achieve remission with escitalopram enter Level 2 and switch to sertraline
3157948|NCT00375856|No Intervention|1|DePuy P.F.C.® SigmaTM Posterior Cruciate Substituting Knee
2474667|NCT03073018|Experimental|Fosinopril + Pravastatin|Fosinopril (20 mg) + pravastatin (40 mg) once daily for 4 years
2474678|NCT03073018|Active Comparator|Fosinopril + Placebo|Fosinopril (20 mg) + pravastatin placebo once daily for 4 years
2474686|NCT03073018|Active Comparator|Pravastatin + Placebo|Pravastatin (40 mg) + fosinopril placebo once daily for 4 years
2474695|NCT03073018|Placebo Comparator|Double Placebo|Fosinopril placebo and pravastatin placebo once daily for 4 years
2474782|NCT03072017|Experimental|MBAT|Monitored breathing awareness therapy administered using a mobile device on a nightly basis during sleep onset.
2474824|NCT03071848||Bevacizumab|Participants with advanced cervical cancer (metastatic, recurrent or persistent) who have received treatment with bevacizumab from 01 January 2015 to 01 January 2016 (retrospective and independent from this study) combined with standard chemotherapy (cisplatin/carboplatin or topotecan and paclitaxel) will be observed.
2474915|NCT03071328|Experimental|Bone metastatic site|
2474918|NCT03071328|Experimental|Liver metastatic site|
2474926|NCT03071328|Experimental|Lymph node metastatic site|
2474930|NCT03071328|Experimental|Soft tissue metastatic site|
2474974|NCT03070769||Control|Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.
2474976|NCT03070769||Obstructive sleep apnea (OSA) patients|Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.
2475006|NCT03070457|Experimental|Early discharge group|Patients with a shorter hospital stay, 23 hours after surgery
2475008|NCT03070457|Active Comparator|Conventional discharge|Patients with conventional protocol and 48-72 hours of hospital stay
2475044|NCT03070288||Group 1|Red-green-blue measurements of nasal mucosa images of patients with allergic rhinitis
2475045|NCT03070288||Group 2|Red-green-blue measurements of nasal mucosa images of normal healthy individuals
2475077|NCT03070028|Experimental|Phenol|crystallised phenol application
2475079|NCT03070028|Experimental|platelet rich plasma|PRP application
2475181|NCT03069339|Experimental|Carvedilol+EVL|
2475186|NCT03069339|Experimental|Carvedilol|
2475190|NCT03069339|Active Comparator|EVL|
2475197|NCT03069001|Active Comparator|Sofosbuvir-Simeprevir|"Sofosbuvir 400 mg orally once-daily.~Simeprevir 150 mg orally once-daily.~Group A included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks."
2475199|NCT03069001|Active Comparator|Sofosbuvir-Ribavirin|"Sofosbuvir 400 mg orally once-daily.~Ribavirin orally twice-daily (according to body weight: 1000 mg daily in patients with a body weight of <75 kg and 1200 mg daily in patients with a body weight of ≥75 kg).~Group B included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks."
3157949|NCT00375856|Experimental|2|Rotating Platform Knee
3157950|NCT00375869|Active Comparator|Darbopoeitin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
3192530|NCT00809640|No Intervention|2|The control group will receive no intervention, and their beliefs/knowledge on low back pain will be tested twice after the first assessment.
3192531|NCT00809653|Experimental|Visit 1|2 hour walk in city centre location in Beijing China
2475295|NCT03068598|Experimental|sleep monitoring|The sleep tracker and a smartphone will be given to the patient after discharge. The patient will recieve a brief training on how to use the PulseOn watch or the Suunto Spartan Ultra watch. Patient will be proposed to monitor his sleep during the five nights following the discharge.
2475317|NCT03068351|Experimental|RO6870810|Participants will be administered RO6870810 monotherapy at ascending-dose levels during the dose escalation phase followed by an expansion phase during which RO6870810 will be administered as monotherapy at the recommended dose. Participants will continue to receive study drug as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
2475322|NCT03068351|Experimental|RO6870810 + Daratumumab|Participants will be administered RO6870810 at ascending-dose levels in combination with daratumumab at the recommended dose during the dose escalation phase followed by an expansion phase during which both RO6870810 and daratumumab will be administered each at their recommended dose. Participants will continue to receive the study drugs as long as they experience clinical benefit in the opinion of the Investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression, as determined by the Investigator after an integrated assessment of IMWG response criteria, biopsies/aspirate (if applicable), and clinical status, or withdrawal of consent.
2475361|NCT03067974|Experimental|Intranasal ketamine arm|10mg/kg intranasal ketamine administered one time
2475399|NCT03067831|Experimental|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
2475444|NCT03067467||Brain Tumor Patients|Brain Tumor patients will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI.
2475446|NCT03067467||Controls|Healthy Control subjects will receive a bolus of Hyperpolarized 13C-pyruvate during MRSI. This will be followed by a Brain MRI with gadolinium-based contrast.
2475470|NCT03067116||Subjects|Adult, healthy pregnant women undergoing Posturography Evaluation, Anthropometrics, Vitals and answering Health and daily activity questionnaires
2475543|NCT03066752||7 pediatric-onset multiple sclerosis|
2475549|NCT03066752||7 non-patient healthy volunteers|
2475620|NCT03066505|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks.
2475622|NCT03066505|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 4 weeks. Sham treatment mimicks same noise and sensation of active treatment but provides no treatment.
3208646|NCT00976768|Experimental|FOLFIRI arm|Patients receiving FOLFIRI
2475991|NCT03063866|Active Comparator|M group|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg
2474635|NCT03073187||Students: Step 1 Interviews|20 adolescents with uncontrolled asthma and poor sleep [10 from New York City (NYC); 10 from Rhode Island (RI)] will provide information regarding their asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
2474640|NCT03073187||Caregivers: Step 1 Interviews|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will be asked to provide information regarding their teenager's asthma and sleep routines, and on what they would like to see in an intervention targeting co-morbid asthma and poor sleep.
2474642|NCT03073187||Teachers: Step 2 Interviews|4 high school teachers, 2 from NYC and 2 from RI, will review the developed intervention. They will provide their opinions about the appropriateness of the teaching methods and literacy level for adolescents.
2474643|NCT03073187||Students: Step 3 Focus Groups|20 adolescents with uncontrolled asthma and poor sleep [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility.
2474645|NCT03073187||Caregivers: Step 3 Focus Groups|The caregivers of the 20 adolescents in this step [10 from NYC; 10 from RI] will review the intervention providing feedback on its appropriateness and utility in small groups.
2474666|NCT03072901||EndoBarrier Gastrointestinal Liner|244 subjects; The registry will be open to subjects who meet the EndoBarrier's Indications for Use and none of the Contraindications in the device's Instructions For Use document. Subjects who successfully receive the device implant at a participating registry center will be included in the registry.
2474790|NCT03072290|Experimental|low dose steroid|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2474795|NCT03072290|Active Comparator|comparator|ultrasound-guided steroid injection using 1ml of 40 mg (40mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2474878|NCT03071705|Experimental|Intervention|TKI plus Metformin
2474879|NCT03071705|Active Comparator|Control|TKI
2474921|NCT03071081|Experimental|TOP1288 200mg BID|1 day dosing
2474925|NCT03071081|Placebo Comparator|Placebo to TOP1288 200mg BID|1 day dosing
2474932|NCT03071081|Experimental|TOP1288 1g BID|1 day dosing
2474935|NCT03071081|Placebo Comparator|Placebo to TOP1288 1g BID|1 day dosing
2474936|NCT03071081|Experimental|TOP1288 Xg (where X is <=1g) BID|7 days dosing
2474938|NCT03071081|Placebo Comparator|Placebo to TOP1288 Xg|7 days dosing
2474997|NCT03070691|Active Comparator|LDE225 0.75% cream|
2474999|NCT03070691|Placebo Comparator|Vehicle|
2475053|NCT03070158|Experimental|Attachment Promotion Intervention|Mothers will receive the intervention which includes an education session about newborn care, training in multisensory stimulation with the intervention ATVV and two domiciliary visits to follow up the mother and her premature infant.
2475054|NCT03070158|No Intervention|Usual Care|Mothers will continue to receive usual which consist in education session about newborn care in home.
2475099|NCT03069950|Experimental|HAI FUDR/Dex in addition to Pmab plus FOLFIRI|Panitumumab plus FOLFIRI on Day 1 and Day 15 of each cycle. HAI pump therapy with FUDR and Dex on Day 1 of each cycle. Patients will start protocol therapy approximately 2 weeks after surgery. All patients will receive Panitumumab (6 mg/kg IV over 60 min). The HAI FUDR group will receive FOLFIRI in the following dosing; 5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
2475102|NCT03069950|Experimental|Pmab plus FOLFIRI alone|The dosing of FOLFIRI in the systemic arm will be 5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days), Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour), bolus 5FU 400mg/ m2 and Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and 15.
2475215|NCT03069118|Experimental|Treatment|Three-month intervention on the online Workit Health platform
2475219|NCT03069118|Placebo Comparator|Control|A list of online resources/waitlist
2475270|NCT03068806||Patients with Schizophrenia|Individuals who have been previously diagnosed with schizophrenia and meet our research criteria for symptoms indicative of schizophrenia within their lifetime.
2475272|NCT03068806||Healthy Controls|Individuals who have not met criteria for a psychiatric disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric disorder.
2475320|NCT03068481|Experimental|Healthy volunteer part -Single dose|Single oral dose of KDT-3594
2475326|NCT03068481|Experimental|Healthy volunteer part -Multiple dose|Multiple oral doses of KDT-3594
2475331|NCT03068481|Placebo Comparator|Healthy volunteer part -Placebo|Multiple oral doses of Placebo
2475335|NCT03068481|Experimental|Patient part -Single dose|Single oral dose of KDT-3594
2475338|NCT03068481|Experimental|Patient part -Multiple dose|Multiple oral doses of KDT-3594
2475376|NCT03068000|Experimental|Judo training|Judo intervention will take place twice a week, lasting 50 minutes per session, for 3 months, divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
2475378|NCT03068000|Active Comparator|Ball games|The Ball Games will take place twice a week, with a duration of 50 minutes per session, for 3 months, divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
2475432|NCT03067688|Experimental|"Combination drug:Temisartan+Amlodipine+Rosuvastatin"|"60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks."
2475435|NCT03067688|Active Comparator|Temisartan+Amlodipine|"60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks."
2475437|NCT03067688|Active Comparator|Temisartan+Rosuvastatin|"60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks."
2501749|NCT02889926|Experimental|Bacteriological referred to biopsy|
2474648|NCT03073135|Experimental|Psychodrama Group Therapy (PGT)|The PGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience. The process will be divided into three stages: the first (5 sessions) will be focused on the management of the individual's relationship challenges. The second stage (5 sessions) will focus on the association between the subject's management of their relationships and the excoriation disorder (ED) symptoms. The third (5 sessions) will focus on the development of new skills for the management of ED. Psychodramatic methods will be used throughout the process.
2474650|NCT03073135|Active Comparator|Supportive Group Therapy (SGT)|The SGT is a 15-session weekly program. Sessions last one and a half hours, conducted by two psychologists with more than ten years of experience.
3192532|NCT00809653|Experimental|Visit 2|2 hour walk in city centre location in Beijing China
2474799|NCT03072147|Active Comparator|Group 1- Treatment|20 mcg dosage amounts of teriparatide, in the FDA approved form Forteo, manufactured by Lilly, LLC, are loaded into a 2.4 ml prefilled delivery device (multi injection pen) that administers 28 equal doses as subcutaneous injections in the thigh or abdominal wall. Subjects will inject themselves once a day for 24 weeks.
2474806|NCT03072147|Placebo Comparator|Group 2- Placebo|Saline placebo is packaged by the manufacturer (Lilly, LLC) in the same 2.4 ml injection pen that is used for teriparatide; it will provide 28 doses of placebo. Subjects will inject themselves once a day for 24 weeks.
2474841|NCT03071679|Experimental|Omiganan|
2474845|NCT03071679|Experimental|Imiquimod|
2474854|NCT03071679|Experimental|Omiganan 1% and Imiquimod|
2474858|NCT03071679|Experimental|Omiganan 2.5% and Imiquimod|
2474861|NCT03071679|Placebo Comparator|Placebo|Vehicle
2474939|NCT03071172|Experimental|Recombinant Human Follitropin|Experimental group (domestic rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
2474940|NCT03071172|Active Comparator|Gonal-F|Positive control group (imported rhFSH, powder for injection, 5.5μg (75IU)/vial, initial dose 150-225IU/d, subcutaneous injection, adjust the dose according to ovarian reactivity after 5-7 days of injections, once a day until the HCG trigger day.
2475009|NCT03070613|Experimental|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda will be sprayed onto the colonic surface during colonoscopy or TEM surgery.
2475050|NCT03070262|Experimental|CA group|caffeic acid (300mg, tid, po) continue given until progression of disease or death, or patients are unable to bear the side effects
2475051|NCT03070262|Placebo Comparator|placebo group|the same shape placebo tablets continue given until progression of disease or death, or patients are unable to bear the side effects
3192533|NCT00809666|No Intervention|Mercury|All subsequent blood pressure recording done using mercury sphygmomanometry
3192534|NCT00809679|Experimental|T-62 100 mg bid|
3192535|NCT00809679|Experimental|T-62 200 mg bid|
3192536|NCT00809679|Placebo Comparator|Placebo|
2475245|NCT03068793||Patients with Recent Onset Schizophrenia|Individuals who have been diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder within the past five years and meet our research criteria for symptoms indicative of these diseases within the past five years.
2475249|NCT03068793||Patients with Major Depressive Disorder|Individuals who have been diagnosed with Major Depressive Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
2475251|NCT03068793||Patients with Gambling Disorder|Individuals who have been diagnosed with Gambling Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
2475253|NCT03068793||Patients with Post Traumatic Stress Disorder|Individuals who have been diagnosed with Post Traumatic Stress Disorder within the past five years and meet our research criteria for symptoms indicative of this disease within the past five years.
2475255|NCT03068793||Healthy Controls|Individuals who have not met criteria for a psychiatric, mood, or gambling disorder within their lifetime according to our research criteria for symptoms indicative of a psychiatric, mood, or gambling disorder.
2475315|NCT03068520|Other|PRIMARY BRAIN TUMOR (PBT)|patients with PBT (Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma), before treatment with radiation and chemotherapy.will be followed with PET MRI
2475324|NCT03068520|Other|METASTATIC BT TREATED BY SRS|"patients with lung or breast metastasis to brain treated by SRS in which at least one lesion showed deterioration by MR performed after treatment.~will be followed with PET MRI"
2475329|NCT03068520|Other|METASTATIC BT NOT TREATED BY SRS|"patients with lung or breast metastasis to brain where the SRS treatment was postponed for clinical reasons (getting mutation information for targeted treatment) the lesion size measures 5-40 mm.~will be followed with PET MRI"
2475369|NCT03068039|Active Comparator|OATS PORRIDGE|Oats breakfast porridge 220 kcal served with 240 mL water
2475375|NCT03068039|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge isoenergetic (220 kcal) served with 300 mL water to make it also isovolumteric with the Oats arm
2475416|NCT03067701|Experimental|Carbon Monoxide Inhalation|In healthy young adults 18-39 years of age, The Investigator will determine if intermittent inhalation a 0.1% CO, from a 1-liter bag once every minute for 30-40 minutes, at a level that approaches the CO boost with hookah smoking, augments endothelial function, thus implicating CO as the major endothelial vasodilator substance in hookah smoke.
2475565|NCT03066700||Hemospray application|The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
3192537|NCT00809692|Active Comparator|1|50 subjects with allergic disease receiving histamine challenges by the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
3192538|NCT00809692|Experimental|2|150 additional subjects with allergic disease; undergo genotyping; laser Dopper assessment
3192539|NCT00809705|Experimental|1|
3192540|NCT00809705|Experimental|2|
3192541|NCT00809705|Placebo Comparator|3|
3192542|NCT00809718|Other|raltegravir and rifapentine|Concomitant administration of raltegravir and rifapentine in healthy volunteers
3192543|NCT00809731||Observational Group|All commercially available 2nd-generation antipsychotic with an indication of treating schizophrenia will be prescribed by the physician according to normal practices
2474723|NCT03072433|Active Comparator|Standard of Care|Comparison group will receive the current standard of care. Nurses are instructed to tell mothers about nutrition and water, sanitation and hygiene at any point prior to discharge from hospital. In addition, nurses will tell primary caregivers to play with their children even while they are receiving treatment in a play area with toys available.
2474727|NCT03072433|Experimental|Counseling Intervention Package|Primary caregivers in the intervention group receive group education sessions involving psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene components during a total of four days.
2474819|NCT03072225|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 Prescription (6g/bag，one bag each time, twice a day.) for 6 months
2474820|NCT03072225|Placebo Comparator|The Placebo of Herbal Medicine C-117|Placebo of Herbal Medicine C-117 (6g/bag，one bag each time, twice a day.) for 6 months
2474842|NCT03071666|Experimental|Vitamin B12|cobalamin, 50 µg per day throughout pregnancy and during the first 6 months postpartum.
2474850|NCT03071666|Placebo Comparator|Placebo|Identical taste and appearance with the Experimental arm. Contains no cobalamin
3157951|NCT00375869|Placebo Comparator|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
3157952|NCT00375882|Other|cochlear implantation with mild hypothermia|
2475110|NCT03069768|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
2475113|NCT03069768|Active Comparator|Control|Smokers in this group will not be given the mSMART application.
2475213|NCT03069014|Active Comparator|400mg LM11A-31-BHS|400mg LM11A-31-BHS and 400mg Placebo per day
2475217|NCT03069014|Active Comparator|800mg LM11A-31-BHS|800mg LM11A-31-BHS
2475222|NCT03069014|Placebo Comparator|Placebos|800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day
2475352|NCT03068260|Active Comparator|Active|"Active bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml ropivacaine 0,375% single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2475354|NCT03068260|Placebo Comparator|Placebo|"Placebo bilateral ultrasound-guided transmuscular quadratus lumborum (TQL) block. 60 ml saline single shot.~In both arms, the participants receive 1g Acetaminophen and 400 mg Ibuprofen / 100 mg Celebra. Morphine will be administered IV as part of a PCA-pump regimen or additionally after contact with the nursing staff as it is the standard treatment."
2475401|NCT03067805|Experimental|Oxytocin|Oxytocin nasal spray
2475404|NCT03067805|Placebo Comparator|Placebo|Placebo nasal spray
3157953|NCT00375895|Experimental|Ciclosporin|
2475540|NCT03066869|Experimental|H.P. ACTHAR GEL|
2475610|NCT03066466|Experimental|Arm A: Atorvastatin|The preventative atorvastatin treatment 40mg daily by mouth for GVHD will start at 14 days prior to transplant & continue until 365 days post-transplant or if significant adverse events occur. Patients will also receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
2475612|NCT03066466|Active Comparator|Arm B: Standard of Care|Patients will receive our standard of care for graft versus host disease prevention which consists of two drugs, Methotrexate and Tacrolimus. For all matched unrelated donor allogeneic transplantation patients, the following schedule of Methotrexate 5mg/metered square will be administered IV post-transplant on Days 1, 3 & 6. Tacrolimus will be administered 2 days prior to transplant & continue approximately 180 days post-transplant. Tacrolimus 0.03 mg/kg daily will be administered IV until patient can take it by mouth.
3157954|NCT00375947|Experimental|1|Home-based hand exercise program
3157955|NCT00375947|Placebo Comparator|2|Sham hand cream
3157956|NCT00376012|Active Comparator|1|2EHRZ3/4RH3
3157957|NCT00376012|Experimental|2|2EHRZ3/7RH3
3157958|NCT00376064|Experimental|SMS995 + Carbegolin, Somavert + SMS995|
3157959|NCT00376077|Active Comparator|Placebo and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist. Patients on this arm receive an infusion of placebo (0.9% NaCl) over one hour. Immediately following this dosing, 1 g/kg IVIG (Gammunex ©) is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
3157960|NCT00376077|Experimental|Methylprednisolone and IVIG|"The trial site is blinded to the randomization process. Patients are assigned an arm by a research pharmacist.Patients on this arm receive IV Methylprednisolone 30 mg/kg (1 gram maximum) infused over one hour. Immediately following this dosing, 1 g/kg IVIG Gammunex © is infused over 2 - 3 hours. Following this treatment, complete blood counts are drawn at:~completion of IVIG infusion,~8 hours following the start of the placebo/solumedrol infusion~24 hours following the start of the placebo/solumedrol infusion~72 hours following the start of the placebo/solumedrol infusion~7 days post infusion~21 days post infusion"
2474787|NCT03072082|Placebo Comparator|Danlou Tablet placebo|Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
2474847|NCT03071536|Experimental|Furosemide|"Single dose of furosemide 1.5 mg/kg intravenously will be given to all participants at 3 hours post-reperfusion of kidney allograft.~Urine output will be recorded hourly for 6 hours."
2474887|NCT03071354|Experimental|HMB Protein Supplementation Group|"Intervention patients will receive 2 x 237mL bottles of the commercially available liquid HMB protein supplement (3g) (Ensure Active™ Muscle Health) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
2474889|NCT03071354|Active Comparator|Control Group|"Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) throughout the study.~In addition, all patients will be fed according to the Canadian Critical Nutrition Practice Guidelines, and protein/energy requirements will be determined by the local dietitians according to their local practice standards."
2474942|NCT03071068|Experimental|THR-317 4mg|anti-PlGF recombinant monoclonal antibody, 4mg dose
2474946|NCT03071068|Experimental|THR-317 8mg|anti-PlGF recombinant monoclonal antibody, 8mg dose
2474980|NCT03070600|Active Comparator|Universal PrEP Counselling|All enrolled women receiving antenatal care at facilities assigned to Universal PrEP arm will receive standardized HIV risk counseling and then self-select whether they want to use PrEP.
2474981|NCT03070600|Experimental|Targeted PrEP Clinics|All enrolled women receiving antenatal care at facilities assigned to the Targeted PrEP arm will be assessed for HIV-risk prior to receiving targeted PrEP counseling.
2475057|NCT03070275|Experimental|Group-A|In the experimental Group (Group-A), a two-stage implant will be placed in parallel with an overlying biocomplex (aBM-MSCs/fibrin glue/collagen fleece) that comprises autologous alveolar bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue.
2475059|NCT03070275|Active Comparator|Control Group-B|In Group-B, a two-stage surgical implant placement on the alveolar crest is followed based on the manufacturer's guidelines with no use of adjunctive grafting materials.
2475088|NCT03069963|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
2475089|NCT03069963|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
2475143|NCT03069638|Experimental|Intranasal dexmedetomidine|Dexmedetomidine is given once 4 micrograms per kilogram intranasally. If the sedation is not successful another 2 microgram per kilogram intranasal dose is given. Intravenous dexmedetomidine solution is administrated intranasally with MAD nasal drug delivery device and a syringe.
2475144|NCT03069638|Active Comparator|Nitrous oxide inhalation|Dinitrousoxide (N2O) is given with Livopan administrating device. Livopan consists of 50% oxygen and 50% nitrous oxide. Gas mixture is inhaled 5 minutes before the injection procedure and during the injection procedure.
2475220|NCT03069274|Other|Control|Only general nutritional recommendations were given.
2475223|NCT03069274|Experimental|Intervention|General nutritional recommendations, change their drinking habits.
2475314|NCT03068429|Experimental|Sertraline open label|Sertraline hydrochloride up to 200mg/day or maximum tolerated dosage for 4-weeks.
3192544|NCT00809770|Experimental|1|Contingency management
2475409|NCT03067610|Experimental|Radiation Therapy|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel)
2475485|NCT03067376|Experimental|[14C]-CORT125134|Two capsules each containing 125 milligrams (mg) [14C]-CORT125134 administered to each participant on 1 occasion
3192545|NCT00809770|Other|2|Non Contingent Control Condition
2475616|NCT03066479|Experimental|Fitbit|Patients will wear a Fitbit bracelet during their sleep study.
2475691|NCT03065751|Active Comparator|TPE|
2475692|NCT03065751|No Intervention|Kontroll|
3192546|NCT00809796|Experimental|single arm|Use of pentamidine in second and/or third line metastatic colon cancer
3192547|NCT00809822|Active Comparator|1|Intravenous immunoglobulin
3192548|NCT00809822|Placebo Comparator|2|Physiological saline
3192549|NCT00809861|Active Comparator|1|volar locking plating of distal radius fractures
2474881|NCT03071562|Experimental|Yoga-mindfulness|Groups of 4-5 participants will engage in group-based sessions supervised by yoga-certified physiotherapists, 60 minutes per intervention/session, 3 sessions/week for 12 weeks. The yoga-mindfulness group will participate in a 60-minute Hatha-style yoga class, with meditation, active postures for strengthening and balance, and breathing exercises. Participants will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
2474883|NCT03071562|No Intervention|Control|Participants in this group will not participate in an exercise program. They will be tracked for total distance and steps per day using accelerometers (Fitbit Flex).
2474905|NCT03071107|Active Comparator|Multi-disciplinary intervention arm|Multi-disciplinary intervention on frailty parameters including input from dietitian, physiotherapist and medical team
2474907|NCT03071107|No Intervention|Control arm|Standard of care
2474966|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Placebo Add-back|
2474967|NCT03070899|Experimental|OBE2109 dose 1 (100mg) + Add-back|
2474968|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back|
2474969|NCT03070899|Experimental|OBE2109 dose 2 (200mg) + Add-back|
2474970|NCT03070899|Placebo Comparator|Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back|At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.
2475105|NCT03069820|Experimental|Study Population|Patients with advanced nasopharyngeal carcinoma scheduled to receive the first line, first cycle TP (docetaxel and cisplatin) chemotherapy
2475153|NCT03069495||Healthy Control Adult Subjects|Healthy adult subjects between the ages of 19-50 years will be enrolled.
2475154|NCT03069495||Asthmatic Adult Subjects|Adult subjects between the ages of 19-50 years with mild-to-moderate asthma seen within the UNMC Allergy and Pulmonary Clinics will be invited to be enrolled.
2475157|NCT03069495||Chronic Urticaria Adult Subjects|Adult subjects between the ages of 19-50 years with chronic urticaria seen within the UNMC Allergy Clinics will be invited to be enrolled.
2475306|NCT03068533|Active Comparator|Strontium acetate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
2475311|NCT03068533|Experimental|Arginine/calcium carbonate toothpaste|All eligible patients will receive mechanical debridement in 1 or 2 sessions within 1 week before final evaluation.
2475366|NCT03068182|Experimental|Arm crank Exercise|Sixty-five participated in an arm crank moderate intensity exercise for 40 minutes.
2475372|NCT03068182|Experimental|Treadmill Exercise|Sixty-five participated in a treadmill moderate intensity exercise for 40 minutes.
2475461|NCT03067233|Experimental|Polysomnography|Three polysomnographic recordings will be made on 3 consecutive nights with Electroencephalogry.
3192550|NCT00809861|Active Comparator|2|
3192551|NCT00809874|Active Comparator|Casein|
2475715|NCT03065569|Active Comparator|Standard Epidural Technique|Epidural will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
2475716|NCT03065569|Experimental|Combined Spinal Epidural Technique|CSE will be performed Initial dose of 16 mL of 0.125% bupivacaine will be given Upon patient request, rescue bolus based on protocol will be administered.
2475766|NCT03065153||Healthy|Healthy individuals without any neurological or orthopaedic disorder that could influence motor performance and balance
2475770|NCT03065153||Stroke|Individuals suffered from a haemorrhagic or ischaemic stroke. Diagnosis has to be confirmed on the basis of CT or MRI imaging.
2475818|NCT03064802||BioBurst Fluid, Burst Allograft|Spinal Fusion with BioBurst Fluid or Burst Allograft
2475845|NCT03064477|Experimental|Unified Protocol (UP)|"Investigators in the present study have adapted the UP to implement it in group format in a Public Mental Health setting in Spain. This adaptation is composed of 12 treatment sessions of two hours of duration each, at a rate of one per week.~Participants in the UP will receive UP treatment in group format instead of the usual Cognitive Behavioral Therapy in individual format. Patients in the UP condition will receive pharmacological treatment (i.e., antidepressants and / or anxiolytics) as usual."
2475848|NCT03064477|Active Comparator|Treatment As Usual (TAU)|Cognitive Behavioral Therapy in individual format is the treatment of choice (TAU) by psychologists and psychiatrists at the collaborating Public Mental Health Centers and Primary Care Centers, together with pharmacological treatment (i.e., antidepressants and / or anxiolytics).
2475884|NCT03064191|Active Comparator|calcium hydroxide chlorhexidine|intervention: calcium hydroxide chlorhexidine combination an intra-canal medication composed of calcium hydroxide powder and chlorhexidine solution as a combination to be administered as intra-canal paste for decreasing postoperative symptoms
2475886|NCT03064191|Active Comparator|calcium hydroxide|intervention: calcium hydroxide an intra-canal medicament composed of calcium hydroxide paste for decreasing postoperative symptoms and signs .
2475947|NCT03063892|Placebo Comparator|Control Arm|Will receive intravenous Saline solution placebo bolus dose in the Emergency Center over 10 minutes. The subject will also receive intravenous Saline solution over 8 hours prior to surgery. Another dose will be administered at the time of incision and the final dose three hours later.
2475948|NCT03063892|Experimental|Experimental Arm|Will receive intravenous Tranexamic Acid (TXA) 15mg/kg (maximum 1 gram) bolus dose over 10 minutes in the Emergency Center. The subject will also receive an intravenous dose of Tranexamic Acid (TXA) 15mg/kg over 8 hours prior to surgery. Another 15mg/kg dose of Tranexamic Acid (TXA) will be administered over 10 minutes at the time of incision and the final dose (15mg/kg) of Tranexamic Acid (TXA) intravenously over 10 minutes three hours later.
2476001|NCT03063515|No Intervention|IVGTT without pyridostigmine|An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.
2476002|NCT03063515|Active Comparator|IVGTT with pyridostigmine|An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg
2476058|NCT03063242|Experimental|Project I: Healthy participants|5 healthy participants will be used to optimize the dosage and timing of sargramostim administration with regard to the primary and secondary outcomes. Blood samples will be drawn and analyzed for mDC levels.
3192552|NCT00809874|Active Comparator|Whey Isolate|
3192553|NCT00809874|Active Comparator|Whey Hydrolysate|
2474917|NCT03071315||MMT participants|Methadone maintenance treatment (MMT) participants who have been receiving MMT treatment. In Hai Phong City, during the period of this study, voluntary MMT was provided in the community free for people who were assessed as dependent on heroin.
2475010|NCT03070821|Experimental|Healthy elderly experimental group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
2475011|NCT03070821|Experimental|Patient group|Feedback of the parahippocampal gyrus using rtfMRI neurofeedback training (using 3T MRI).
2475012|NCT03070821|Sham Comparator|Healthy elderly sham-feedback group|Feedback of the postcentral gyrus using rtfMRI neurofeedback training (using 3T MRI).
3192554|NCT00809874|Active Comparator|Alphalact-Albumin|
3157961|NCT00376090|Experimental|Group I Vaccine|
3157962|NCT00376090|Placebo Comparator|Group I Placebo|
2475162|NCT03069586|Other|Low pressure pneumoperitoneum|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg).
2475165|NCT03069586|Active Comparator|low pressure peritoneum and pulmonary recruitment|Surgery on low pressure pneumoperitoneum (8 - 10 mmHg) and at the end of surgery a manual pulmonary recruitment manoeuver (2 x 5sec max 40cmH2O) will be done
2475204|NCT03069131|Experimental|Active rifaximin|
2475210|NCT03069131|Placebo Comparator|Rifaximin placebo|
2475289|NCT03068663|Experimental|Pchir|"Non small cell lung carcinoma patients designated for immediate surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: at consultations after inclusion in the study~faeces: day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
2475292|NCT03068663|Experimental|Pct-chir|"Non small cell lung carcinoma patients who will receive neoadjuvant chemotherapy before the surgery. Intervention in this group is sampling. The sampling will be done for:~blood and saliva: 1st time at consultations after inclusion in the study, 2nd time at consultations after chemotherapy and before surgery~faeces: 1st time the day before the chemotherapy, 2nd time the day before the surgery~lung/tumour tissue, bronchoalveolar lavage: during surgery after lobectomy"
2475367|NCT03068156|Experimental|excimer laser|
2475374|NCT03068156|No Intervention|Control|
2475419|NCT03067766|Experimental|Workshop A (10 weeks - comic art creation workshop)|Patients and a family member, caretaker, or friend participate in an artist-led comic art therapy workshop over 2 hours once a week for 10 weeks. Patients and participants receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop and midway through the workshop.
2475431|NCT03067766|Experimental|Workshop B and C (5 weeks - comic art creation workshop)|Patients participate in an artist-led comic art therapy workshop over 3 hours once a week for 5 weeks. Patients receive a range of assignments that focus on creative art and experimentation with materials and storytelling in order to make a series of small handmade books that relate directly or indirectly to their experience with cancer. Patients undergo a qualitative interview over approximately 45 minutes and complete validated questionnaires within 4 weeks prior to the workshop.
2475459|NCT03067142||Cohort 1 (Phase 1): PH1|Cross-Sectional/Observational
2475472|NCT03067142||Cohort 2 (Phase 1): Controls|Cross-Sectional/Observational
2475486|NCT03067142||Cohort 3 (Phase 2): PH1|Longitudinal/Observational
2475566|NCT03066882|Experimental|Study group I|Study group I (19 participants) received the NCD (details of diet: 15% protein, 75% carbohydrates, 10% fat). Both groups had 15% caloric restriction from their maintenance energy requirements.
2475568|NCT03066882|Experimental|Study group II|Study group II (18 participants) received the LCD or healthy weight maintenance diet (details of diet: 15% protein, 55% carbohydrates, 30% fat).Both groups had 15% caloric restriction from their maintenance energy requirements.
2475593|NCT03066362|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
2475667|NCT03065842|Experimental|Abortion- and contraceptive-use stigma reduction program|Four sessions (à 120 min), every week in 1 month.
2475671|NCT03065842|Active Comparator|Usual standards|Usual standards
2475703|NCT03065504|Active Comparator|Turmeric group|"2,000 mg turmeric per day - supplied by Banyan® Botanicals )~o Each tablet contains 500 mg of Turmeric (Curcuma longa). Subjects will take 2 tablets twice per day, with a total daily dose of 2,000 mg."
2475706|NCT03065504|Active Comparator|Turmeric-containing combination tablets|"• 2,000 mg Healthy Skin™ Tablets, contains:~Turmeric (Curcuma longa) - 50 mg/tablet~Hemidesmus Indicus root (Anantamul)~Indian Madder root~Neem leaf~Gotu Kola leaf~Indian TInospora stem~Amla fruit~Licorice root~Phyllanthus Amarus herb Each tablet contains 500mg total of the above herbs. There is 50 mg of Turmeric in each Healthy Skin ™ tablet. Subjects will take 2 tablets twice per day, which will be a total daily dose of 200 mg of Turmeric. This is comparable to the daily amount of Turmeric in many commercially-available Turmeric supplements; therefore, it is valuable to compare this formulation to the turmeric-only tablets."
2475709|NCT03065504|Placebo Comparator|Placebo tablets group|"Supplement appearing similar to those in the turmeric and curcumin groups, supplied by Banyan® Botanicals~Ingredients (all organic): Placebo ingredients: Rice hulls concentrate, Maltodextrin, Micro Crystalline Cellulose, Beet Root Powder, Dutch coco powder~Dose: subjects in this group will take 2 tablets twice per day"
2475775|NCT03065192|Experimental|VY-AADC01 Single Dose|9.4 x 10^12 vector genomes of VY-AADC01
2475835|NCT03064724|Experimental|Smoking Cessation Group|Patients received the interactive mobile doctor (iMD) intervention.
2475876|NCT03064347|Active Comparator|Coated Sucrose plus Whole Milk|200kcal sucrose plus whole milk powder in enteric coating as single dose
2475997|NCT03063866|Active Comparator|P Group|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v
3157963|NCT00376090|Experimental|Group II Vaccine|
3192555|NCT00809887|Placebo Comparator|1|ALT with placebo with systemic Micafungin therapy
2474965|NCT03070847|Active Comparator|Low dose|Will receive single bolus of Tranexamic acid. Dose: 10mg/kg diluted in 0,9% sodium chloride (0,9% NaCl), administered IV (in the vein), 15 min before admission to operation theatre.
2475014|NCT03070496|Experimental|STEMI cohort|"Patients recruited in the cohort will have 4 additional interventions compared to the usual follow-up :~an additional blood sampling at 6 months~an additional electrocardiogram (ECG) at 6 months~Magnetic Resonance Imaging (MRI)~Quality of life questionnaire"
2475048|NCT03070197||Case/CHD with deleterious mutations|Participants with CHD with damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
2475052|NCT03070197||Control/CHD without deleterious mutations|Participants with CHD without damaging de novo mutations or stringently defined deleterious missense mutations) on whole exome sequencing or whole genome sequencing
2475116|NCT03069924|Active Comparator|No NRT - No Messaging|Brief counseling, but no NRT and no gain-framed messaging.
2475118|NCT03069924|Active Comparator|NRT - No Messaging|Brief counseling plus NRT but no gain-framed messaging.
2475121|NCT03069924|Active Comparator|No NRT - Messaging|Brief counseling plus gain-framed messaging but no NRT.
2475122|NCT03069924|Experimental|NRT plus Messaging|Brief counseling plus NRT and gain-framed messaging.
2475232|NCT03069235|Active Comparator|Standard of Care|group/individual counselling.
2475235|NCT03069235|Experimental|Family member / peer support|Structured family member / peer support.
2475237|NCT03069235|Experimental|Special infant feeding counselor support|Enhanced intervention with counselor support
2475281|NCT03068689|Experimental|Intervention (RIPC)|RIPC treatment prior to partial nephrectomy.
2475284|NCT03068689|Placebo Comparator|Placebo Control|Placebo prior to partial nephrectomy.
2475308|NCT03068377|Placebo Comparator|Placebo|Soft gel capsules without test material
2475313|NCT03068377|Experimental|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
2475377|NCT03068195|Experimental|laparoscopic microwave ablation|laparoscopic microwave ablation will be performed before the renal cysts are decorticated
2475380|NCT03068195|Experimental|percutaneous microwave ablation|percutaneous microwave ablation will be performed to treat the renal cysts without decorticating.
2475383|NCT03068195|Active Comparator|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts.
2475400|NCT03067636|Active Comparator|Physical exercise + stress management activity A|Eight week program of concurrent exercise and stress management training.
2475403|NCT03067636|Active Comparator|Physical exercise + stress management activity B|Eight week program of concurrent exercise and stress management training.
2475406|NCT03067636|No Intervention|Lifestyle as usual|"Eight weeks period with no alteration of usual lifestyle.~Participants randomized to this arm are eligible for re-randomisation to one of the active conditions at the conclusion of week eight."
2475481|NCT03067402|Other|Observation|Patient receives standard observation, i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years.
2475487|NCT03067402|Experimental|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
3192556|NCT00809887|Experimental|2|ALT with Micafungin and heparin with systemic Micafungin therapy
3192557|NCT00809900||Dietary Supplement|Cranberry Juice Consumption
2475658|NCT03065972|Active Comparator|Surgical fistula creation from patient's anatomy|Patients randomized to surgical arteriovenous fistula will have a fistula surgically created from their anatomy to be used for hemodialysis access.
2475663|NCT03065972|Active Comparator|Surgical graft implant|Patients randomized to surgical graft, will have a commercially available graft surgically implanted to be used for hemodialysis access.
2475789|NCT03065231|Active Comparator|EVD|Patients will have extraventricular drain to manage CSF subarachnoid blood.
2475794|NCT03065231|Active Comparator|LD|Patients will have lumbar drain to manage CSF subarachnoid blood.
2475819|NCT03064698||Normal second trimester Doppler|This group consists of women who had normal doppler ultrasound results at second trimester
2475820|NCT03064698||Abnormal second trimester Doppler|This group consists of women who had abnormal doppler ultrasound results at second trimester
3192558|NCT00809913|Experimental|Short treatment|7 days of standard antibiotic treatment (preferably ciprofloxacin) followed by 7 days of placebo
2475927|NCT03063944|Experimental|Treatment (STAT inhibitor OPB-111077, venetoclax, decitabine)|"INDUCTION CYCLE 1: Patients receive STAT inhibitor OPB-111077 PO QD on days 1-28, and venetoclax PO QD on days 4-28 of cycle 1. Patients also receive decitabine IV over approximately 1 hour on days 4-8 of cycle 1. Patients who achieve complete remission (CR) after 1 cycle move on to Maintenance, and patients who do not achieve a CR move on to Cycle 2.~INDUCTION CYCLE 2: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Patients who achieve CR, CRi, PR, or stable disease (or clinically significant hematologic improvement as determined by the investigator) move on to Maintenance.~MAINTENANCE: Patients receive STAT inhibitor OPB-111077, venetoclax, and decitabine as in Induction Cycle 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2475970|NCT03063541|Experimental|Acetylsalicylic acid, BP-target 120|100 mg ASA plus intensified blood pressure management. Recommended systolic blood pressure 120 mm/Hg
2475978|NCT03063541|No Intervention|standard care|blood pressure management according to guidelines
2476093|NCT03063034|Active Comparator|PD21864AA, PD21864AB|Subjects will use PD21864AA for 1 week and then PD21864AB for 1 week.
2476095|NCT03063034|Active Comparator|PD21864AB, PD21864AA|Subjects will use PD21864AB for 1 week and then PD21864AA for 1 week.
2476160|NCT03062579|Experimental|ACTEMRA® (Tocilizumab)|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible.
3192559|NCT00809913|Active Comparator|Standard treatment|14 days of standard antibiotic treatment (initial b-lactam or fluoroquinolone followed by ciprofloxacin through the 8th till 14th day)
3192560|NCT00809939|Active Comparator|1|previous preterm delivery, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
3192561|NCT00809939|Active Comparator|2|previous preterm delivery, treatment with daily vaginal natural progesterone
2474978|NCT03070574|Experimental|1200 MG mesalamine (5-ASA) total|placebo/1200mg mesalamine once daily in the morning for the treatment phase of the study (24 months)
2474979|NCT03070574|Placebo Comparator|Placebo|placebo/placebo once daily in the morning for the treatment phase of the study (24 months)
2475036|NCT03070366|Active Comparator|Chemotherapy combined with stereotactic radiotherapy (RT)|"Chemotherapy is based on patient Performance Status (PS) and comorbidities:~PS 0-1: standard treatment: 6 cycles, every 3 weeks cisplatin (100 mg/m² iv on D1), 5FU (4000 mg/m² total dose starting on Day 1 to Day 4 and during 96h in continuous infusion)~PS 2/cardiac contra-indication to 5 Fluorouracil (5FU): 6 cycles, every 3-4 weeks cisplatin (100 mg/m² iv on Day 1) or carboplatin Area Under Curve (AUC) 4 or 5 on Day 1 In both case: Cetuximab (loading dose 400 mg/m² iv on Day1, then 250 mg/m² weekly or 500mg/m² every 2 weeks).~Cycle 1 of systemic treatment will be administered before the start of the stereotactic RT. Then, following cycles will be performed after the end of stereotactic irradiation.~Cetuximab maintenance: 250 mg/m² iv weekly. It will be given only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until progression or unacceptable toxicity."
2475039|NCT03070366|Experimental|stereotactic radiotherapy|Splitting will be based on the tumor diameter, and proximity of organs at risk which constitutes any limiting toxicities. It will be 3 or 5 fractions based on the recommendations (CARO-Stereotactic Body Radiation Therapy (SBRT) 2012) and for the purpose of harmonization practices. The prescription dose is 3 x 10 = 30 Gy 3 x 11 = 33 Gy or 3 x 15 = 45 Gy (if 3 fractions) with the possibility of 3 x 20 Gy to the peripheral lung nodules with tracking in Cyberknife or 5 x 7 = 35 Gy or 5 Gy x 10 = 50 (if 5 fractions). Beyond 3 cm of tumor diameter and / or to a distance of less than 1 cm from the GTV in an organ critical risk (eg spinal cord), a splitting up into 5 sessions must be privileged.
2475081|NCT03070054|No Intervention|Control|non-LIA group prior to surgery
2475083|NCT03070054|Experimental|Treatment|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
2475141|NCT03069742|Experimental|Decision Aid|Women at high risk for developing breast cancer will use a decision support tool, RealRisks, that facilitates discussion of breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
2475142|NCT03069742|No Intervention|Control Group|Women at high risk for developing breast cancer will receive standard breast health education brochures.
2475187|NCT03069287|Experimental|Patient-caregiver dyads|Dyads will include family caregivers and patients with a diagnosis of cancer who agreed to participate in a therapeutic clinical trial.
2475227|NCT03069066|Experimental|BVS implantation in patients with ISR|BVS implantation in patients with ISR after scoring balloon pre-dilatation
2475290|NCT03068676|Experimental|Space from depression|Space from Depression is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
2475293|NCT03068676|Experimental|Space from Anxiety|Space from Anxiety is an eight-module online CBT-based intervention for depression, composed of cognitive and behavioral components including self-monitoring and thought recording, behavioral activation, cognitive restructuring, and challenging core beliefs. Each module follows a structured format that incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other users are incorporated into the presentation of the material.
2475318|NCT03068338|Active Comparator|Conventional therapy|Intermittent pneumatic compression devices are used for prevention of DVT.
2475323|NCT03068338|Experimental|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
2475368|NCT03068117|Experimental|RESSCT plus Standard Care/Therapy|"Regular Early Specialist Symptom Control Treatment (RESSCT) and Standard Therapy.~Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
2475373|NCT03068117|No Intervention|Standard Care/Therapy|The standard care/therapy control group will continue to receive all appropriate, standard treatment for Malignant Pleural Mesothelioma (MPM) currently available to them and will be initiated by the patient's General Practitioner (GP), the cancer MDT or lead respiratory physician as required.
2475424|NCT03067545|Experimental|step rate increase|increase in running stride rate by 10%
2475471|NCT03067246|Active Comparator|VBM Intubating Laryngeal Tube|Device: VBM Intubating Laryngeal Tube Intervention: VBM Intubating Laryngeal Tube insertion, seal pressure, endotracheal intubation
2475483|NCT03067246|Active Comparator|I-Gel|Device: I-Gel Intervention: I-Gel insertion, seal pressure, endotracheal intubation
3157964|NCT00376090|Placebo Comparator|Group II Placebo|
3157965|NCT00376090|Experimental|Group III Vaccine|
2475617|NCT03066414||non-obese patients with genetic hemochromatosis|"PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
2475801|NCT03065062|Experimental|Combination Of Palbociclib and Gedatolisib|"Palbociclib will be administered orally once daily on Days 1-21 for each of the 4-week cycles at a pre-determined dose.~Gedatolisib will be administered intravenously once weekly on the first day for each of the four weeks during the 4-week cycles at a pre-determined dose."
2476016|NCT03063346|Experimental|Protein hydrolysate low dose|
3157966|NCT00376090|Placebo Comparator|Group III Placebo|
3157967|NCT00376090|Experimental|Group IV Vaccine|
3157968|NCT00376090|Placebo Comparator|Group IV Placebo|
3157969|NCT00376129|Experimental|I|
2474989|NCT03070587|Experimental|Positive Affect Training for SAD|The intervention will be conducted in groups with 68 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
2474992|NCT03070587|No Intervention|Wait list Control|These participants will not be given an intervention until after they have completed the study.
2475035|NCT03070379|Experimental|Experimental group|Topical lidocaine pharyngeal anesthesia was performed.
2475037|NCT03070379|No Intervention|Control group|No topical lidocaine pharyngeal anesthesia was performed.
2475068|NCT03070080|Active Comparator|restrictive group|restrictive fluid strategy, 6 ml/kg/hour of lactated Ringer, during intraoperative period
2475070|NCT03070080|Active Comparator|conservative group|conservative fluid strategy, 12 ml/kg/hour of lactated Ringer, during intraoperative period
2475095|NCT03069794|Other|Use of stable force platform|Ennrollment of every patient programmed for spinal surgery in orthopaedic service
2475150|NCT03069612|Experimental|rTMS Active Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains.
2475152|NCT03069612|Sham Comparator|rTMS Sham Group|Repetitive transcranial magnetic stimulation (rTMS) will be administered bilaterally to the dorsolateral prefrontal cortex (DLPFC) at 20 Hz, 90% RMT in 25 trains with a sham coil.
2475202|NCT03069170|Experimental|Stem Cells|Intravenous administration of purified autologous bone marrow-derived stem cells.
2475206|NCT03069170|Experimental|Stem Cell Transplantation|Intrathecal administration of purified autolgous bone-marrow derived stem cells.
2475258|NCT03068910|Experimental|Spironolactone|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with spironolactone (50 mg twice daily).
2475263|NCT03068910|Placebo Comparator|Placebo|Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
2475316|NCT03068442|Experimental|Carotid atherosclerosis group|This group includes all enrolled subjects (those with carotid disease and plans to undergo surgery).
2475346|NCT03068065|Active Comparator|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
2475347|NCT03068065|Active Comparator|Metformin|the dosage of merformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
2475348|NCT03068065|Active Comparator|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
2475417|NCT03067649|Experimental|Motivational Interview|After the assessment, parents were provided with a 90-minute intervention aimed at increasing the likelihood that the parent would seek treatment for psychiatric problems for themselves.
2475423|NCT03067649|Other|Information only control|After the assessment, parents were given pamphlet with referral information for psychiatric services.
2475458|NCT03067285|Active Comparator|Arm 1|Patients who postpone switching from DTG/3TC/ABC to ELV/COBI/FTC/TAF four weeks:
2475480|NCT03067285|Experimental|Arm 2|Patients who switch from DTG/3TC/ABC to ELV/COBI/FTC/TAF during the baseline visit
3157970|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 20 mg QD|
3157971|NCT00376181|Experimental|Pioglitazone 45 mg/Azilsartan 40 mg QD|
3157972|NCT00376181|Active Comparator|Pioglitazone 45 mg QD|
2475598|NCT03066297||Lobectomy|Lobectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2475603|NCT03066297||Segmentectomy|Segmentectomy will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2475608|NCT03066297||Wide wedge resection|Wide wedge resection will be chosen as the extent of pulmonary resection according to the institutional decision-making algorithm
2475640|NCT03066089|Experimental|Group A|Fenfuro 500 mg capsule by mouth, BD (two times a day), till next follow-up
2475643|NCT03066089|No Intervention|Group B|Investigational product is not being administered to this arm. This arm will regularly be observed on follow-up and laboratory investigations will be performed.
2475683|NCT03065803|Active Comparator|Buccal plate expansion technique in dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
2475684|NCT03065803|Other|Guided Bone regeneration technique for socket preservation|On buccal side, two vertical incisions will be made at mesial and distal papilla of the adjoining teeth. These incisions will be stretched out past mucogingival junction. After full-thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed. The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension-free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0) (Sadeghi et al., 2016).
2475713|NCT03065452||Patients who underwent open decompression surgery|Observational study on patients who underwent open decompression surgery
2475828|NCT03064594||cornuostomy|cornuostomy
3157973|NCT00376272|Experimental|1|
3157974|NCT00376272|Placebo Comparator|2|
3157975|NCT00376337|Active Comparator|1|infusion for 3-12 weeks
3157976|NCT00376337|Experimental|2|infusion for 3-12 weeks
3157977|NCT00376350|Experimental|High dose manipulation|High dose spinal manipulation + ultrasound
3157978|NCT00376350|Experimental|Moderate dose manipulation|Moderate dose manipulation + low dose massage + ultrasound
2474996|NCT03070678|Experimental|SAR439954 with or without mefenamic acid|Period 1: single oral dose of 400 mg sotagliflozin Period 2: initial loading dose of 500 mg in the morning of Day 1, followed by 250 mg from Day 1 H6 to Day 7 of mefenamic acid and a single oral dose of sotagliflozin on Day 2
2475032|NCT03070314|Experimental|Echinaforce junior|Echinaforce is an ethanolic extract from Echinacea purpurea fresh plant and root. The product is registered in Switzerland for children from age 4 years on for Treatment and prevention of respiratory tract infections.
3157979|NCT00376350|Experimental|Low dose manipulation|low dose spinal manipulation + moderate dose massage + ultrasound
3157980|NCT00376350|Other|High dose masssage|high dose massage + ultrasound
2475205|NCT03069027|Placebo Comparator|Group I(control)|patients allocated for external nasal nerve block with saline adrenaline 1/200,000 (placebo)
2475208|NCT03069027|Active Comparator|Group II(block)|'External nasal nerve block by Xylocaine, adrenaline'
2475247|NCT03068780|Experimental|Oleogel-S10|
2475248|NCT03068780|Placebo Comparator|Placebo|
2475334|NCT03068286|Experimental|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
2475336|NCT03068286|Experimental|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
2475340|NCT03068286|Experimental|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
2475454|NCT03067103|Active Comparator|tramadol|Tramadol group will receive 2 mg/kg (2 ml) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2475465|NCT03067103|Active Comparator|ketamine|Ketamine group will receive 0.5 mg/kg (2cc) through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2475482|NCT03067103|Placebo Comparator|Placebo|Placebo group will receive 2mL of saline solution through the peritonsillar fossa. For each tonsil 1 ml will be applied to upper pole, lower pole and between the upper and lower pole with 25-G needle. The depth of the infiltration will be as superficial as 3 mm of needle injected and ballooned out the submucosal tissues of the tonsillar pillar, intratonsillar injection as avoided.
2475525|NCT03066726||CPR less than the 10%le|Group of patients with fetuses with cerebroplacental ratio less than 10%le
2475527|NCT03066726||CPR greater or equal than 10%le|Group of patients with fetuses with cerebroplacental ratio greater or equal than 10%le
2475573|NCT03066583|Placebo Comparator|trephination with placebo|meniscal repair with trephination and placebo
2475574|NCT03066583|Experimental|trephination with platelet rich plasma|meniscal repair with trephination and platelet rich plasma
2475599|NCT03066336|Experimental|Erchonia LunulaLaser|The Erchonia LunulaLaser emits both red light (635 nm) and blue light (405 nm) to the affected toenail for 12 minutes per treatment for 4 treatments, each treatment one week apart.
2475644|NCT03066167||Patients|Patients with oesophageal cancer and dysphagia
2475645|NCT03066167||Controls|Healthy Controls with no known dysphagia
2475697|NCT03065712|Experimental|FES PET/CT|"This is a single arm study that involves FES PET/CT.~Procedure: Computed Tomography~Drug: [F-18] fluoroestradiol: [F-18]FES~Other: Laboratory Biomarker Analysis~Procedure: Positron Emission Tomography"
2475843|NCT03064555||Participants with end stage renal disease|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
2475882|NCT03064347|Placebo Comparator|Non-Enteric Coated Whey Protein|200kcal whey protein with separate enteric coating materials as single dose
3157981|NCT00376415|Experimental|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
3157982|NCT00376415|Placebo Comparator|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
3157983|NCT00376480|Experimental|administration of adoptive donor lymphocyte infusion|administration of donor lymphocytes made using costimulatory blockade ex vivo
3157984|NCT00376493|Active Comparator|1|Use of antibiotics after hospital discharge
3157985|NCT00376493|Placebo Comparator|2|Use of placebo
3157986|NCT00376519|Experimental|Transplant with Treg Cells|Patients receive preparative therapy with Fludarabine, cyclophosphamide, total body irradiation and Treg infusion followed by umbilical cord blood transplantation.
3157987|NCT00376571|Experimental|Stenting of main vessel and side branch|Percutaneous coronary intervention
3157988|NCT00376571|Experimental|No side branch treatment|Percutaneous coronary intervention
3157989|NCT00376584|Placebo Comparator|Placebo → MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by MK-0524A 2 g for the remainder of the study (7 days).
3157990|NCT00376584|Active Comparator|Placebo → Extended Release (ER)-Niacin 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A Placebo for 5 days (drug holiday) followed by ER-Niacin 2g for the remainder of the study (7 days)
3157991|NCT00376584|Experimental|MK-0524A 2g|Following an 8-week active run-in (MK-0524A 1g (4 Weeks) then MK-0524A 2g (4 weeks) participants will be administered MK-0524A 2g for the remainder of the study (approximately 2 weeks).
2475038|NCT03070418|Experimental|Abdulhai|One show man technique, it is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision.
3192562|NCT00809939|Active Comparator|3|short cervical length, treatment with weekly injections of 17 alfa hydroxyprogesterone caproate.
3192563|NCT00809939|Active Comparator|4|short cervical length, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
3192564|NCT00809952||Recombinat FSH|
3192565|NCT00809991|Experimental|Hypofractionated radiation therapy in prostate adenocarcinoma|Participants with histologically confirmed, locally confined adenocarcinoma of the prostate receive 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions).
2475393|NCT03067857|Experimental|Stem Cells|Intravenous and Intrathecal thecal transplantation via interventional radiology of purified autologous bone-marrow derived specific stem cell populations.
2475425|NCT03067597|Experimental|Dinoprostone vaginal insert (DVI)|
3192566|NCT00810004|Experimental|Ferinject|Intravenous infusion of iron
3192567|NCT00810004|Placebo Comparator|Placebo|NaCL 0,9%
3192568|NCT00810017|Experimental|Single arm study|Etoposide 100mg/m2 daily x 3 days Q3W and Trastuzumab 8mg/kg loading dose then 6mg/kg, then single agent until disease progression
3192569|NCT00810030|Experimental|FERINJECT® (Ferric carboxymaltose)|
3192570|NCT00810030|Active Comparator|VENOFER® (Iron Sucrose)|
2475696|NCT03065738|Experimental|osteoarthritis knee ,severe varus deformity|reduction osteotomy in total knee replacement
2475740|NCT03065348|Experimental|Intervention|"Around 2 to 4 weeks before surgery:~Fried frailty score~CARE score assessment~NRS Kondrup assessment~Plasma albumin and CRP values~Start with daily oral whey protein administration until evening before surgery45~Around 5-7 days before surgery:~- Start with immunonutrition~Evening before surgery:~CARE score assessment~NRS Kondrup~CERAD cognition test assessment~Plasma albumin and CRP values, urine specific gravity~Carbohydrate loading~If urine specific gravity is >1.020 then additional tap water drinking will be encouraged~Day of surgery:~Carbohydrate loading~Start anesthesia with spinal anesthesia (continuous)~POD 7:~CARE assessment~CERAD assessment~Plasma albumin and CRP values~POD14:~CARE assessment~Plasma albumin and CRP value~POD 30:~CARE assessment~NRS Kondrup~CERAD assessment~Plasma albumin and CRP values~POD 90:~CARE assessment~NRS Kondrup~CERAD assessment"
2475769|NCT03064932|Active Comparator|SD-Low|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a minimal amount of spices (<1g/day for all diets).~Post prandial test meal will be contain minimal amounts of spice."
2475776|NCT03064932|Experimental|SD-Mod|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a moderate amount of spices (~3g/day in the 2100kcal diet).~Post prandial test meal will be contain a moderate amount of spice."
2475781|NCT03064932|Experimental|SD-Culinary|"Average American Diet (32% of calories from fat, 11% of calories from saturated fat and 3400mg sodium/day) with a culinary dose of spices (6g/day in the 2100kcal diet).~Post prandial test meal will be contain a culinary amount of spice."
2475859|NCT03064789||Women with candidiases infection|Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
3192571|NCT00810056|Active Comparator|Assessment only|Cognitive, academic achievement and mental health screening assessment and report.
3192572|NCT00810056|Experimental|Assessment + FHF|Cognitive, academic achievement and mental health screening assessment and report. Fostering Healthy Futures program (FHF) including weekly therapeutic skill groups and mentoring over a 9-month period.
2475994|NCT03063606|Experimental|Cognitive-Behavioral Therapy (CBT)|"CBT is a specialist focal treatment with three overlapping phases. (1) Establishing a collaborative therapeutic relationship while focusing on educating patients about the nature of binge eating and factors thought to maintain the problem. Specific behavioral strategies (e.g., self-monitoring) are used to help patients identify problematic eating behaviors while establishing a normal structured eating pattern. (2) Integrating cognitive restructuring procedures, focusing on helping patients learn to identify and challenge maladaptive cognitions regarding eating and weight/shape and thoughts that trigger binge eating. (3) Maintaining change and preventing relapse."
2476018|NCT03063346|Placebo Comparator|Placebo|
2476048|NCT03063216||Traumatic cataract group|Cataract patients diagnosed with traumatic cataract.
3192573|NCT00810121|Experimental|1|Ketoprofen 100 mg b.i.d. for 5 days
3192574|NCT00810121|Experimental|2|Ketoprofen 150 mg b.i.d. for 5 days
3192575|NCT00810134|Other|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
3192576|NCT00810134|Other|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
3192577|NCT00810147|Active Comparator|A1|
3192578|NCT00810147|Active Comparator|A2|
3192579|NCT00810147|Active Comparator|A3|
3192580|NCT00810147|Active Comparator|A4|
3192581|NCT00810147|Placebo Comparator|A5|
3192582|NCT00810160|Active Comparator|1|Permeate
3192583|NCT00810160|Active Comparator|2|GOS
3192584|NCT00810160|Active Comparator|3|Bifidobacterium infantis
3192585|NCT00810160|Active Comparator|4|Bifidobacterium animalis
3192586|NCT00810173|Experimental|1|This group received call phone support to incentive the increase of the number of steps during 6 weeks
3192587|NCT00810173|No Intervention|2|This group just received a pedometer to register the number of steps for 6 weeks but this group don´t received a phone call.
3192588|NCT00810186||Newborns needing respiratory monitoring|Premature and term newborn infants (male/female)
3192589|NCT00810212|Active Comparator|1|Autograft
3192590|NCT00810212|Experimental|2|Low Dose MPCs
3192591|NCT00810212|Experimental|3|Medium Dose MPCs
3192592|NCT00810212|Experimental|4|High Dose MPCs
3192593|NCT00810225||1|GWI: veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
3192594|NCT00810225||2|HC: healthy veterans of the 1990-1991 Persian Gulf War
3192595|NCT00810238|Experimental|1|Optimal standard of care + C-Cure
3192596|NCT00810238|No Intervention|2|Optimal standard of care
3192597|NCT00810251||MatrixRIB|
3192598|NCT00810316|Other|Treatment A|
2475073|NCT03070106|Active Comparator|Functional Medicine + Usual Care|Functional Medicine in addition to usual care delivered by an endocrinologist
2475109|NCT03069833|Experimental|Computer-aided diagnosis|
2475114|NCT03069833|No Intervention|traditional diagnosis|
2475167|NCT03069560|Experimental|SMS|The patients will receive from the caregiver a first SMS 48 hours after their discharge from the hospital then a total of 4 messages : 48 hours, S1, S2, and S4.
2475212|NCT03069157|No Intervention|Without lung recruitment maneuver|patient ventilation will be maintained After induction of anesthesia all patients will be ventilated using pressure controlled mode targeting tidal volume 6-8 ml/kg with inspiratory to expiratory ( I: E) ratio 1:1.5 without recruitment but with PEEP 5cm H2O.
2475218|NCT03069157|Active Comparator|recruitment group|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O.
2475259|NCT03068884|Sham Comparator|Tdcs sham|
2475261|NCT03068884|Placebo Comparator|Placebo|
2475266|NCT03068884|Experimental|Tdcs cathodal|
2475268|NCT03068884|Experimental|Tyrosine|
3157992|NCT00376701|Experimental|1|Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
2475436|NCT03067727|Experimental|Dinoprostone vaginal insert|
2475438|NCT03067727|Placebo Comparator|Placebo|
2475466|NCT03067077|Active Comparator|SMILE|SMILE surgery
2475479|NCT03067077|Active Comparator|Wavefront-guided LASIK|Wavefront-guided LASIK
2475545|NCT03066817|Placebo Comparator|Vitamin D control|The control cohort will receive 50cc of propylene glycol as placebo via oral, nasogastric tube, or gastrostomy route on hospital admission.
2475551|NCT03066817|Experimental|Vitamin D intervention cohort|The intervention cohort will receive a one-time 400,000 IU liquid ergocalciferol (50cc of Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]) via oral, nasogastric tube, or gastrostomy route on hospital admission.
2475611|NCT03066401||obese patients with dysmetabolic hyperferritinemia|"PATIENTS: obese patients with dysmetabolic hyperferritinemia undergoing a therapeutic bleeding.~INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver."
2475655|NCT03066154|Experimental|N15DOP|Chemoradiation with ModraDoc/r and radiotherapy of the prostate in dose escalation design, followed by maintenance treatment.
2475699|NCT03065608||Study Group|The study group included 36 patients with pain form of dysfunction.
2475701|NCT03065608||Control Group|The control group consisted of 36 patients with painless form of disorder.
2475749|NCT03065309|Experimental|Single Arm|Patients will receive bolus dose of remifentanil before intubation
2475790|NCT03064945|Sham Comparator|Shame device|
2475793|NCT03064945|Experimental|Livia® Transcutaneous Electrical Nerve Stimulation (TENS)|
2475854|NCT03064776|Experimental|m-RESIST Patients|"m-RESIST is a system designed to improve illness self-management and facilitate recovery in individuals with Treatment-resistant schizophrenia (TRS). The system will be used to~Continuously capture multidimensional behaviour as it occurs in real-time and in real-world environments, using continuous collection and analysis of sensor data.~Detect individual early warning signs, and trigger targeted interventions that may mitigate the severity of worsening or prevent their recurrence altogether, using the clinical decision support system (CDSS) and Recommender operation.~The m-RESIST will deliver both system initiated (i.e. pre-programmed) and patient-initiated (i.e. on-demand) real-time assessments, to the participants and in their own environment."
2475856|NCT03064776|Experimental|m-RESIST Caregivers|m-RESIST is a system designed to improve illness self-knowledge and facilitate the involvement of caregivers in treatment of individuals with treatment-resistant schizophrenia.
3157993|NCT00376701|Experimental|2|Reduced fluence PDT plus intravitreal Avastin
3157994|NCT00376701|Experimental|3|Intravitreal Avastin and sham reduced fluence PDT
2476149|NCT03062423|Experimental|T test|Test drug (Sofodelevier)1 tablet contains 400 mg Sofosbuvir
2476154|NCT03062423|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2476158|NCT03062423|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2476234|NCT03062111|Active Comparator|ProTouch Laser Enucleation of Prostate|The intervention for this group is that the patient will undergo endoscopic ProTouch Laser Enucleation of Prostate (LEP).The laser is used to enucleate large pieces of prostatic tissue which is followed by further ablation of the tissue so that no fragments are left in the bladder
2476238|NCT03062111|Active Comparator|Transurethral Resection of Prostate|The intervention for this group that the patient will undergo endoscopic Transurethral Resection of Prostate (TURP) using bipolar cautery. The prostate is essentially shaved down using sequential cuts and cautery.
2476316|NCT03061552|Experimental|IVCD arm|IVCD-assisted determination of target post-dialysis weight
2476320|NCT03061552|No Intervention|conventional arm|conventional determination of target post-dialysis weight
2476350|NCT03061071|Experimental|Randomized to SPT First: APAP Second|Randomized to order of treatment (SPT first or APAP first) for a total of 6 weeks home use with each treatment.
2476354|NCT03061071|Experimental|Randomized to APAP First: SPT Second|Randomized to order of treatment (APAP first or SPT first) for a total of 6 weeks home use with each treatment.
2476405|NCT03060642||Barrett's esophagus|Barrett's esophagus, without or with dysplasia or adenocarcnoma
2476406|NCT03060642||Controls|Non-BE endoscopic controls
2476473|NCT03060408||Open|Patients underwent open distal pancreatectomy
2476477|NCT03060408||Laparoscopic|Patients underwent laparoscopic distal pancreatectomy
2476565|NCT03060031|Experimental|Oxytocin|Each participant will undergo pain tasks after self-administration of oxytocin
2476566|NCT03060031|Placebo Comparator|Placebo|Each participant will undergo pain tasks after self-administration of placebo
3157995|NCT00376727|Experimental|Phase I dose escalation study|
3157996|NCT00376740|Experimental|Immediate zoledronic acid|Patients on this arm will receive zoledronic acid every 6 months during 2.5 years of letrozole therapy starting within 3 months of the start of letrozole therapy. (5 doses of zoledronic acid)
2475090|NCT03069976|Experimental|1|All included patients, diagnosed with Overlap Syndrome or Primary Sclerosing Cholangitis, will receive treatment (Metronidazole x 14 days) hence single arm study.
2475169|NCT03069534|Experimental|rhIL-2 Group|The patients in rhIL-2 Group were given consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotherapy. rhIL-2 (500，000U/m)regiman was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7. Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months.
2475175|NCT03069534|No Intervention|Control Group|The patients in Control Group were given standard anti-tuberculosis chemotherapy regiman.Standard anti-MDR-TB chemotherapy regiman was totally 24 months,including 6-month Z+KM/AM or CM + PAS/(Pa) + PTO +LFX as an intensive phase treatment, followed by an 18-month Z + LFX + PTO + PAS/(Pa) as a consolidation phase treatment.Then all the group patients were followed up for a minimum of 36 months
2475234|NCT03069079|Experimental|Non surgical Periodontal therapy|"All children will be offered an oral hygiene and tooth scaling and polishing session. For children affected by periodontal disease, subgingival debridement will also be performed according to needs, with the aim to disrupt the subgingival biofilm responsible for the onset and progression of the periodontal pathology. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. In addition, when required, nitrous oxide sedation (NOS) could be used before treatment.~Caries will be treated as necessary (shared care with the general dental practitioners / community dental services). Children with mucosal lesions requiring treatment will be given a letter for their GDP suggesting referral to a collaborating expert in Oral Medicine (Prof. Stephen Porter)."
2475269|NCT03068702||African Canadians|African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
2475328|NCT03068559||Study population|"Patient must have an initial confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx.~Patient has to be aged ≥ 18~Patient has to be able to complete questionnaire in French~Patient must benefit from health insurance~Patient must sign an informed consent form~Patient treatment must be validated in a medical multidisciplinary team meeting: surgery, radiotherapy (RT), chemotherapy (CT), radiochemotherapy (RTCT), induction chemotherapy followed by radiochemotherapy (IND+RTCT), surgery followed by radiotherapy (surgery+RT), surgery followed by radiochemotherapy (surgery+RTCT)."
2475370|NCT03068130|Experimental|Bardoxolone methyl 10 mg|Bardoxolone methyl will be administered orally once daily at 10 mg until it becomes commercially available. Dose de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.
3192599|NCT00810316|Other|Treatment B|
3192600|NCT00810316|Other|Treatment C|
2475576|NCT03066570|Experimental|Single case study|Single case study using Graded exposure.
2475633|NCT03066310||Diagnosed Urinary Bladder Cancers|Patients who are being monitored for bladder cancer will be the experimental group to test the urine-DNA by next generation sequencing for bladder cancer biomarkers
2475634|NCT03066310||Non-Urinary Bladder Cancers|Patients being treated for gross hematuria will provide a negative control to provide data from testing by next generation sequencing for biomarkers in patients being treated for other diseases.
2475673|NCT03065894|Experimental|Stratified Care|"In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care)."
2475674|NCT03065894|Active Comparator|Current Care|"In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain."
3192601|NCT00810329||1|This group consists of patients with Chronic fatigue syndrome, Fibromyalgia and other conditions like Multiple chemical sensitivity, Irritable bowel syndrome, Interstitial Cystitis, Gulf War Illness.
3192602|NCT00810329||2|The healthy control group
3192603|NCT00810381|Active Comparator|1|"Nitroglycerin: (Perlinganit, Nycomet Heilmittelwerke, Vienna, Austria):~0, 0.25, 0.5, 1, 1.5 and 2 µg/kg/min, each infusion step for 20 minutes"
3192604|NCT00810381|Active Comparator|2|"Isosorbide-Dinitrate: (Isoket 0,1 %, Gebro Broschek, Fieberbrunn, Austria):~0, 0.5, 1, 2, 4 and 6 µg/kg/min , each infusion step for 20 minutes"
2475849|NCT03064620||Israel PCV13|Children and their parents living in central Israel and visiting primary pediatric clinics of Hashfela District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
2475850|NCT03064620||East Jerusalem PCV13|Children and their parents living in East Jerusalem and visiting primary pediatric clinics of Jerusalem District, Macabbi Healthcare Services HMO, for any reason during the surveillance period each year.
2475852|NCT03064620||Palestine PCV7 PCV10|Children and their parents living in major cities of the Palestinian Authority and visiting private primary pediatric clinics, for any reason during the surveillance period each year.
3192605|NCT00810381|Active Comparator|3|"Sodium-Nitroprusside: (Nipruss, Sanol-Schwarz, Monheim, Germany):~0, 0.25, 0.5, 1, 2 and 4 µg/kg/min, each infusion step for 20 minutes"
3192606|NCT00810381|Placebo Comparator|4|Physiologic saline solution
3192607|NCT00810433|Experimental|Arm 1|
3192608|NCT00810446||rifabutin|Patients administered Rifabutin.
3192609|NCT00810472|Experimental|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
3157997|NCT00376740|Active Comparator|Delayed zoledronic acid|Patients on this arm will receive zoledronic acid during the 2.5 years of letrozole treatment only after the T-score on bone mineral density testing falls below minus 2.0.
3157998|NCT00376831|Active Comparator|0|fentanyl
3157999|NCT00376831|Active Comparator|1|ketamine
2475195|NCT03068988|Experimental|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
2475198|NCT03068988|Placebo Comparator|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
2475589|NCT03066544|Active Comparator|bupivacaine (Exparel)|subjects assigned by clinician's judgment - standard care choice A
2475590|NCT03066544|Active Comparator|naratriptan pill (Amerge)|subjects assigned by clinician's judgment - standard care choice B
2475591|NCT03066544|Active Comparator|dexamethasone tablet (Decadron)|subjects assigned by clinician's judgment - standard care choice C
2475592|NCT03066544|Active Comparator|ketorolac (Toradol)|subjects assigned by clinician's judgment - standard care choice D
2475600|NCT03066219|Active Comparator|BRM421 Ophthalmic Solution|The active control with BRM421 solution
2475601|NCT03066219|Placebo Comparator|Placebo|The vehicle solution
2475746|NCT03065361||Group A|"Group composed of 21 children and adolescents aged between 9 and 19 years old, treated by hemodialysis in two hospitals of Belo Horizonte. Just in case of some evidence of difference in the results within group A, because of the two types of dialysis (via fistula or catheter), this group can be subdivided in subgroups A1 (n=10) and A2 (n=11), respectively.~Group A was already on hemodialysis, the intervention was not performed by the researcher. Our goal was only to evaluate some characteristics of these individuals."
2475748|NCT03065361||Group B|Group composed of 21 children and adolescents matching age and gender for the Group A participants. The individuals were recruited in schools of Belo Horizonte.
2475796|NCT03064958|Active Comparator|Control|Consumption of a high fat meal (1000kcal, 45g fat)
2475798|NCT03064958|Experimental|Spice 2g|Consumption of a high fat meal (1000kcal, 45g fat) with 2g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
2475800|NCT03064958|Experimental|Spice 6g|Consumption of a high fat meal (1000kcal, 45g fat) with 6g of spice (mix of black pepper, basil, bay leaf, cinnamon, coriander, cumin, ginger, oregano, parsley, rosemary, red pepper, turmeric and thyme) incorporated into the meal.
2475831|NCT03064646|Experimental|Organ Preservation|The experimental strategy is the omission of radical surgery if complete or almost complete response after neoadjuvant treatment for locally advanced rectal cancer
2475902|NCT03064295||Healthy Volunteers|60 healthy male or female (18 or older) adults will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent
2475908|NCT03064295||CAD Patients|110 male or female adults (18 or older) who have undergone clinical myocardial perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
2475916|NCT03064295||CMD Patients|50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC and been diagnosed with coronary microvascular disease (CMD) will receive Myocardial Perfusion Cardiac MRI, including administration of contrast and a pharmacologic stress agent.
2475965|NCT03063567|Other|one month trial of Nasal Mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2475971|NCT03063567|Other|One month trial of Oronasal mask|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2475981|NCT03063567|Other|One month trial of Nasal pillows|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces in randomized order. Trial was 1 month duration for each interface.
2476088|NCT03062787|Experimental|Cingal®|Single 4 ml intra-articular injection of Hyaluronic Acid plus Triamcinolone Hexacetonide
2476090|NCT03062787|Active Comparator|Monovisc®|Single 4 ml intra-articular injection of Sodium Hyaluronate
2476135|NCT03062540|Experimental|TNX-102 SL Tablet, 2.8 mg|2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
2476136|NCT03062540|Placebo Comparator|Placebo SL Tablet|2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
2476229|NCT03061942|Active Comparator|Conventional|Arthroscopic rotator cuff repair without synovectomy
2476232|NCT03061942|Experimental|Synovectomy|Arthroscopic rotator cuff repair with synovectomy
2476289|NCT03061643|Experimental|Docetaxel PLUS ADT|receive docetaxel 40 mg/m2 IV every 2 weeks plus ADT
2476328|NCT03061266|Experimental|E-health education group|E-health education group will be received the shared care program using e-health education.
2476330|NCT03061266|Other|Routine care|Control group will be received the shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
2476371|NCT03060915|Other|Polysomnography and actigraphy|Polysomnography and actigraphy
2476407|NCT03060603||Erythropoietin|Recombinant Human Erythropoietin, EPREX 4000 IU/0.4 ml, three times in a week, until the correction of anemia, approximately two months.
2476552|NCT03059719|Experimental|PB-119 injection|PB119 injection 25ug or 50ug once each week, for three months
2476554|NCT03059719|Active Comparator|Exenatide Injection (Byetta)|Byetta 5ug or 10ug twice each day, for three months
3158000|NCT00376844|Active Comparator|External Beam Radiation Therapy|Postoperative pelvic radiotherapy
3158001|NCT00376844|Experimental|Vaginal Brachytherapy|Postoperative vaginal brachytherapy
3158002|NCT00376870|Active Comparator|Pioglitazone|Pioglitazone 30mg/d
3158003|NCT00376870|Placebo Comparator|Placebo|
3158004|NCT00376896|Experimental|GW876008 20mcg|GW876008 20mcg
3158005|NCT00376896|Experimental|GW876008 200mcg|GW876008 200mcg
3158006|NCT00376896|Placebo Comparator|Placebo|Placebo
3158007|NCT00376909|Experimental|Intervention|Series of telephone support calls from a trained prevention care manager
3158008|NCT00376909|No Intervention|Usual Care|Usual care
3158009|NCT00376922|No Intervention|usual care|
2475106|NCT03069664|Active Comparator|Covered Self-expandable Metal Stent|ERCP (endoscopic retrograde cholangiopancreatography) and placement of a pancreatic duct stent
2475111|NCT03069664|No Intervention|Control group|control group
2475214|NCT03069248|Experimental|treatment arm|"Salvage treatment with CHOP or DHAP followed by high dose therapy and stem cell support prior to consolidative immunotherapy with Rituximab and Alpha interferon.~."
2475257|NCT03068845|Experimental|Drug-eluting Balloon Angioplasty (DEBA)|After predilatation of the target lesion with conventional balloon angioplasty, a drug-eluting balloon will be inflated to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
2475260|NCT03068845|Active Comparator|Conventional Balloon Angioplasty (CBA)|The target lesion will be dilated with a conventional angioplasty balloon to an appropriate inflation pressure, but not exceeding the rated burst pressure of the balloon, for at least a minute.
2475341|NCT03068546||Participants providing samples|NCI employees agreeing to provide samples for microbiome sample study
2475382|NCT03068052|Active Comparator|No incentive|Colon cancer risk assessment and direct access colonoscopy scheduling for those that are eligible.
2475384|NCT03068052|Experimental|Incentive|Loss-framed incentive to participate in risk assessment and additional unconditional pro-social incentive to complete colorectal cancer screening.
2475414|NCT03067662|Experimental|Supervised exercise intervention|Women in the intervention group will perform low intensity aerobic exercise three times per week at 30% HRR (Heart Rate Reserve), under continuous heart rate monitoring. Duration of each session will progress from 26 minutes the first week to 40 minutes (by increasing 2 min/week).
2475415|NCT03067662|No Intervention|Current standard of care|Women in the control group will receive standard physical exercise recommendations.
2475520|NCT03066921|Placebo Comparator|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
2475521|NCT03066921|Experimental|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
3192610|NCT00810472|Placebo Comparator|Random graft assignment|
3192611|NCT00810485|Experimental|ADX10059 50 mg|twice-daily
2475631|NCT03066245|Experimental|MSC-PLGA|The lesion will be treated with curettage then 1 million of bone marrow derived MSC seeded on 5x5 mm2 PLGA scaffold will be engrafted in the cyst of ABC patient.
2475660|NCT03065881|Active Comparator|Dilated versus Natural pupil|
2475665|NCT03065881|Active Comparator|Normal retina versus abnormal retina|
2475694|NCT03065595|Placebo Comparator|Intervention|Ophicephalus striatus extract
2475695|NCT03065595|Active Comparator|Control|Placebo drug
2475737|NCT03065374|Experimental|Treatment arm A|IMM-529, 1000 mg three times daily, orally
2475738|NCT03065374|Placebo Comparator|Treatment arm B|Matching Placebo, three times daily, orally
2475764|NCT03065036|Experimental|Hydrus Aqueous Implant|Hydrus implanted into Schlemm's Canal.
2475767|NCT03065036|Other|IOL placement and Hydrus implant|Cataract Extraction with IOL placement and Hydrus implant into Schlemm's canal
2475834|NCT03064737|Other|This study is a non-drug one arm study|Skin biopsy for genetic analyze
2475918|NCT03064022||Size < the 3rd or 10th percentiles|Infant size smaller than the 3rd or 10th percentiles relative to the Fenton growth chart for weight or head circumference at discharge from neonatal intensive care
2475919|NCT03064022||Rapid early growth|Rapid early growth will be defined as exceeding birthweight in the first week of life
2475920|NCT03064022||Growth velocity calculation methods|We will compare a variety of growth velocity calculation methods used in clinical care and research to compare and assess growth velocity calculation methods
2475921|NCT03064022||Size for gestational age|Small size for gestational age
2476004|NCT03063684|Experimental|Vaginal atrophy|"With decreasing estrogen levels occurring following menopause, changes of the vaginal mucosa appear: it becomes thin and pale and loses its elasticity. The blood supply decreases, normal secretion is reduced, the epithelial cells do not undergo the normal differentiation process, the bacterial population changes with loss of lactobacilli and pH increases. These changes are associated with morphological and histological changes, manifested, among other findings, by alterations in the collagen composition, loss of the trabecular organization of collagen and reduced amount of elastic fibers. Women with reduced vaginal estrogen content may report dryness, itching, discomfort, burning sensation during micturition, pain and dyspareunia. These changes are reversible: topical or systemic estrogen change the vaginal mucosa's characteristics and may also alleviate complaints arising from estrogen deficiency.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
2476005|NCT03063684|Experimental|Lichen sclerosus|"Lichen sclerosus is a chronic cutaneous disease involving the vulvar and peri-anal skin. The involved skin becomes thin and white, with frequently present bruises or petechiae and anatomic changes.~Lichen sclerosus is thought to be an auto-immune disorder and its most frequent signs are itching, irritation or burning. The discoloration may involve the entire vulvar and peri-anal area (sometimes having the form of an 8 or a keyhole surrounding the vulva and anus) or appear as separated spots of various sizes occupying only part of the skin. At advanced stages of lichen sclerosus, scarring may appear, with loss of the labia minor and adhesions which may entirely cover the clitoris.~The treatment is of topical steroid. Lichen sclerosus is a chronic disorder, and even with good treatment, in a certain proportion of cases the skin does not return to its original appearance.~The intervention is 3 treatments with fractional / Pixel CO2 Laser"
2476060|NCT03063203|Experimental|Decitabine|"Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle~Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.~Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle"
2476115|NCT03062644|Experimental|MR308 100 mg bid|Tramadol/Celecoxib)
3192612|NCT00810485|Experimental|ADX10059 100 mg|twice-daily
2475108|NCT03069781|Experimental|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of 17β-estradiol (Estrace, Acerus Pharmaceuticals Corporation, Mississauga, ON, Canada). 7 Day Breg Knee Brace unilateral immobilization.
2475112|NCT03069781|Placebo Comparator|Placebo|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada).7 Day Breg Knee Brace unilateral immobilization.
2475149|NCT03069443|Experimental|IHG+Hypertension lifestyle guidelines|Participants in this group will follow a home-based IHG training protocol. The IHG training will be structured with four sets of 2-minute contractions for each hand, 3 days per week for 20 weeks. In addition, the IHG group will receive information about hypertension-guidelines on lifestyle changes.
2475151|NCT03069443|No Intervention|Hypertension lifestyle guidelines|The usual care group will receive information about hypertension-guidelines on lifestyle changes. The usual care group will have the same amount of hospital visits for measurements of blood pressure and maximal muscle tests as the intervention group in order to ensure similar attention provided by the healthcare professionals.
2475207|NCT03069183|Active Comparator|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
2475211|NCT03069183|Placebo Comparator|Normal Saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
2475250|NCT03068741|Active Comparator|Comparison 1: Prehospital Ceftriaxone|1g of Ceftriaxone will be administered by immediate intramuscular (IM) injection. The drug is provided in a sterile and completely covered vial as a white, odourless powder
2475252|NCT03068741|Placebo Comparator|Comparison 1: Placebo|The placebo is provided in a sterile and completely covered vial.
2475254|NCT03068741|Experimental|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous 0.9% saline solution to all participants in this arm regardless of blood pressure, reassessing for signs of volume overload after each 250ml.
2475256|NCT03068741|Active Comparator|Comparison 2: Conservative fluids|Paramedics will administer 0.9% saline solution to participants who have systolic blood pressure <90mmHg, and will only continue the infusion until the systolic blood pressure is >=100mmHg.
3192613|NCT00810485|Experimental|ADX10059 150 mg|twice-daily
3192614|NCT00810485|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
2475456|NCT03067428|Active Comparator|Glucose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as glucose powder.
2475468|NCT03067428|Placebo Comparator|Fructose|Participants will follow a six-week low fructose diet. The amount of restricted fructose will be supplemented as fructose powder.
2475517|NCT03066908|Experimental|Single Arm|Sinopsys® Lacrimal Stent
2475532|NCT03066635|Experimental|Botulinum Toxin 25 IU|5 patients will be injected with 25 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
2475533|NCT03066635|Experimental|Botulinum Toxin 12.5 IU|5 patients will be injected with 12.5 IU of Botulinum Toxin Type A towards the otic ganglion in the symptomatic side (ipsilateral to the pain)
2475636|NCT03066492|Active Comparator|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
2475637|NCT03066492|Experimental|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
2475680|NCT03065816|Experimental|Sequence 1 (Z0063 to Gaviscon)|The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose
2475681|NCT03065816|Experimental|Sequence 2 (Gaviscon to Z0063)|The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose
2475698|NCT03065439|Experimental|STarT Back Tool group 3|Patients scored as high risk patients by the STarT Back Tool
2475700|NCT03065439|Experimental|STarT Back Tool groups 1+2|Patients scored as low risk or medium risk patients by the STarT Back Tool
3192615|NCT00810524|Experimental|A|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
3192616|NCT00810524|Active Comparator|B|120 subjects (have family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
2475857|NCT03064503|Experimental|Healthy volunteers|Sedentary healthy subjects will be recruited in this study. MRI, skin auto-fluorescence measures and blood sampling will be performed
2475875|NCT03064139|Experimental|MCG - Mindful Walking|Participants will be trained in mindful walking technique
2475877|NCT03064139|Active Comparator|SCG - Education and Self-Care|Participants will receive education in self-management of knee OA
2475926|NCT03063931|Experimental|magnesium|
2475931|NCT03063931|Placebo Comparator|placebo|
2475975|NCT03063632|Experimental|Group I (pembrolizumab, interferon gamma-1b)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity. Patients also receive interferon gamma-1b SC 3 times per week for 12 weeks, and then follow 3 weeks on and 3 weeks off schedule for up to 2 years in the absence of disease progression or unexpected toxicity.
2475985|NCT03063632|Experimental|Group II (pembrolizumab, interferon gamma-1b)|Patients pembrolizumab IV over 30 minutes on day 1 and interferon gamma-1b SC once a week. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unexpected toxicity.
2476074|NCT03063099|Experimental|ReNu™ Injection|ReNu™ is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
2476137|NCT03062696|Experimental|Intervention (CBT-RD)|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-RD. There is no control group.
2476197|NCT03062280|Experimental|Chronocort®|Chronocort® modified release hydrocortisone
2476235|NCT03061877||Anxiety or depression|
2476243|NCT03061877||Non-anxiety or depression|
2476525|NCT03059966|Experimental|Enamel Matrix Derivative|Microsurgery for root coverage associated with Enamel Matrix Derivative
3192617|NCT00810524|Experimental|C|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is lower than 80u/L (early antiviral treatment).
2475145|NCT03069625|Experimental|Sit-to-stand test|Children and adolescents will perform 2 STS tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
2475146|NCT03069625|Active Comparator|6-Minute Walk Test|Children and adolescents will perform 2 6MWT tests. First one is used to eliminate learning effect. Number of repetitions will be noted at the end of the second test.
2475226|NCT03069261||Intervention - ICG angiography|ICG-angiography was used intraoperatively after placement of the flap at the recipient cite, evaluating the viability and perfusion of the flap. Poor perfused areas were excised
2475229|NCT03069261||Control - clinical assessment|A control group receiving identical operations but without ICG-angiography evaluation.
2475390|NCT03067896|Active Comparator|Group C|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
2475391|NCT03067896|Active Comparator|Group D|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .
2475392|NCT03067896|Active Comparator|Group M|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .
2475441|NCT03067532|Experimental|A|
2475445|NCT03067532|Active Comparator|B|
2475460|NCT03067194|Active Comparator|Celecoxib 100mg|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
2475473|NCT03067194|Active Comparator|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
3158010|NCT00376922|Experimental|Music therapy|
3158011|NCT00377026|Experimental|lifestyle|participants receive lifestyle intervention
2475742|NCT03065270|Experimental|A group|
2475744|NCT03065270|Experimental|B group|
2475760|NCT03064997|Active Comparator|Prebiotic Synergy 1-supplemented GFD|The application of a prebiotic Synergy 1 together with a strict gluten-free diet
2475762|NCT03064997|Placebo Comparator|Placebo-supplemented GFD|The application of a placebo together with a strict gluten-free diet
2475826|NCT03064828|Active Comparator|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kilovolts peak (kVp), 100-200mA
2475829|NCT03064828|Experimental|CT colonoscopy(low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon, CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
2475893|NCT03064321|Experimental|Insomnia Intervention|Insomnia intervention delivered via web using Cognitive Behavior Treatment
2475896|NCT03064321|Other|Information Control|General health information website
2475977|NCT03063788|Experimental|HIV uninfected|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 2 HIV uninfected individuals
2475984|NCT03063788|Experimental|HIV infected viremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with viremia who are not receiving antiretroviral therapy
2475990|NCT03063788|Experimental|HIV infected aviremic|A single intravenous infusion of 3mg/kg 3BNC117 combined with Copper-64 to 4 HIV infected individuals with undetectable HIV viral load who are receiving antiretroviral therapy
2476022|NCT03063372|Experimental|Pomegranate Supplement|"Participants in this arm will take a capsule with 500 mg of Pomella pomegranate extract twice each day for 28 days."
2476028|NCT03063372|Placebo Comparator|Placebo|Participants in this arm will take a gelatin placebo capsule twice each day for 28 days.
2476111|NCT03063047|Active Comparator|PD21871AA, PD21872AA|Subjects will use PD21871AA for 1 week and then PD21872AA for 1 week.
2476113|NCT03063047|Active Comparator|PD21872AA, PD21871AA|Subjects will use PD21872AA for 1 week and then PD21871AA for 1 week.
2476148|NCT03062371|Experimental|Playgroup Intervention|The approach of the playgroup is to promote healthy family play routines with an emphasis on child and family well-being. The intervention types for playgroup sessions included the occupation of play, activities to promote play and participation, educating caregivers through modeling and coaching, advocating for the child and family, and the use of group sessions. Specific playgroup strategies included a predictable routine, following the child's lead, imitating the child, modeling of new behaviors, and scaffolding play - within both the social and physical environment. When developing activities, play objects that families have at home and are easily obtained were used and positioned intentionally with respect to the child-caregiver dyad and the group as a whole.
2476206|NCT03062241|Experimental|Cryoablation|The pulmonary vein (PV) isolation in patients randomized to intervention group.
2476242|NCT03061903|Experimental|Prevena|Subjects will receive PREVENA after surgery.
2476246|NCT03061903|Active Comparator|Aquacel|Subjects will receive AQUACEL Ag after surgery.
3158012|NCT00377052|Experimental|Bortezomib + Gemcitabine|
3158013|NCT00377104|Experimental|Treatment (chemotherapy)|Patients receive alvocidib IV over 30 minutes (loading dose), followed by alvocidib IV over 4 hours on days 1, 8, and 15. Treatment repeats every 5 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3158014|NCT00377130|No Intervention|Arm I- Usual psychological care|Usual psychological care- no intervention
3158015|NCT00377130|Experimental|Self administered Stress Management|Self-Administered Stress Management Training Plus Usual Psychosocial Care
3158016|NCT00377182|Active Comparator|PEGASYS with COPEGUS|
3158017|NCT00377182|Experimental|RO5024048 1500mg in combination with PEGASYS|
3158018|NCT00377182|Experimental|RO5024048 3000mg in combination with PEGASYS|
3158019|NCT00377182|Experimental|RO5024048 in combination with PEGASYS and COPEGUS|
3158020|NCT00377195|Experimental|1|
3158021|NCT00377208|Active Comparator|Intervention Condition|Receives web-based feedback specific to their blood-pressure and other health-related conditions.
3158022|NCT00377208|No Intervention|Control Condition|The control group receives preventative feedback, general to the population.
3158023|NCT00377247|Experimental|Dendritic Cells w/Tumor DNA|
3158024|NCT00377286|Placebo Comparator|2|1500 mg of lite lemonade
3158025|NCT00377286|Active Comparator|1|1500 mg glucosamine in 16 oz lite lemonade 1 time daily for 6 months
3158026|NCT00377325|Experimental|1|Participants will receive full dose cyclosporin.
3158027|NCT00377325|Experimental|2|Participants will receive active drug full dose until cleared, then one dose every 4 days.
3192618|NCT00810524|Active Comparator|D|180 subjects (have no family history of hepatic carcinoma or liver cirrhosis). Antiviral treatment are started when ALT is higher than 80u/L (regular antiviral treatment).
3192619|NCT00810550|Other|LV systolic dysfunction|Diagnostic Testing
3192620|NCT00810563|Placebo Comparator|1|Saline solution 0.9% 5mL in each portal
3192621|NCT00810563|Active Comparator|2|Bupivacaine 0.5% 5mL in each portal
3192622|NCT00810589|Experimental|1|
2475351|NCT03068273|Experimental|Intervention|For type 2 patients in the intervention group, CGM data will be viewed real-time.
2475353|NCT03068273|Experimental|Control|For type 2 patients in the control group, CGM data is blinded to all and only gathered for comparison purposes to intervention group.
2475389|NCT03067883|Experimental|interventional Qurevo group|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
2475496|NCT03067337|Experimental|Stainless Steel Crowns (Group A)|Groups that received Stainless Steel Crowns
2475500|NCT03067337|Experimental|Zirconia crowns (Group B)|Groups that received Zirconia crowns
2475531|NCT03066765|Experimental|LTR Treatment|An implant device (Linguaflex Tongue Retractor) will be placed in the tongue and assessed for safety and efficacy
2475583|NCT03066557|Active Comparator|study group|TACE and Apatinib
2475584|NCT03066557|Experimental|control group|TACE alone
2475604|NCT03066271|Experimental|Exercise + usual care|"The supervised exercise training is carried out on a ergometer cycle as individual daily (mon-fri) training and each exercise training session consists of 20min.~The training comprised a warm-up phase followed by 3 exercise phases. Warm-up consisted of 5min light stationary cycling, adjusted to 50-60% of the patients peak power output determine at the incremental cycle test (iPPO). The first exercise phase comprised of 5min interval training consisting of 5x30 sec intervals at 80-95% of the patient's iPPO. Between each interval, there is a 30 sec pause. The 2nd exercise phase consisted of 5min continuous cycling at an intensity equaling 80% of the patient's iPPO. The 3rd exercise phase was similar to the first exercise phase. Intensities increased progressively from the first week to the last week (from 50%, 80% and 70% of iPPO according to the three different phases to 60%, 95% and 80 % of iPPO respectively."
2475607|NCT03066271|Experimental|Control - usual care|The patients randomized to the control group received no training but will be wearing the activity tracker during the intervention.
2475688|NCT03066128|Experimental|Intervention|Participants in the Intervention Group will receive chronic ART management from a Professional Nurse and/or Enrolled Nurse every 2 months, and if stable after 6 months, community pharmacy ART collection through CCMDD. Viral load monitoring will be by a point-of-care viral load testing.
2475690|NCT03066128|Experimental|Standard of Care|Participants in the Standard-of-Care control arm will receive the standard-of-care for the clinic consisting of visits with a professional clinician (Physician or Professional Nurse) and once stable, community pharmacy ART collection through CCMDD.Viral load monitoring will be by lab-based viral load testing
2475711|NCT03065387|Experimental|Arm I (neratinib, everolimus)|Participants receive neratinib PO daily and everolimus PO daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2475712|NCT03065387|Experimental|Arm II (neratinib, palbociclib)|Participants receive Neratinib PO daily for 28 days and Palbociclib PO daily for 21 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2475714|NCT03065387|Experimental|Arm III (neratinib, trametinib)|Participants receive neratinib PO daily and trametinib PO daily as directed. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3192623|NCT00810589|Active Comparator|2|
3192624|NCT00810628|Experimental|1|All subjects in same investigative group with same CBT intervention.
2475890|NCT03064217|Active Comparator|CLP and 12 weeks waiting|After core build-up and initial tooth preparation, a clinical crown lengthening procedure (CLP) will be performed. Restorative treatments will be initiated 12 weeks after CLPs.
2475891|NCT03064217|Experimental|Digital impression taken at surgery|The final impression will be taken at surgery. The final crown will be delivered at suture removal.
2475941|NCT03063762|Experimental|Escalation Part (Arm A): Atezolizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has complete response (CR), treatment may be discontinued and reintroduced if progressive disease (PD), for a maximum duration of 24 months.
2476045|NCT03063216||Congenital cataract group|Cataract patients diagnosed with congenital cataract.
3192625|NCT00810654|Experimental|ANPEP|Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
3192626|NCT00810654|Placebo Comparator|Placebo|
3192627|NCT00810667|Experimental|Lu AE58054|
3192628|NCT00810667|Placebo Comparator|Placebo|
3192629|NCT00810680|Experimental|Valproic acid|
3192630|NCT00810706|No Intervention|1: observation only|Patients have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day). Tamoxifen could have been discontinued up to 6 months prior to study entry.
3192631|NCT00810706|Active Comparator|2: Exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years, following completion of 5-7 years of Tamoxifen treatment
3192632|NCT00810732|Experimental|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
3192633|NCT00810732|Active Comparator|Nifedipine|Nifedipine 30 mg extended release tablets, orally administered once daily (open label arm)
3192634|NCT00810732|Placebo Comparator|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
3192635|NCT00810745|Experimental|rectal resection|
3192636|NCT00810758|Experimental|PF-04878691|
3192637|NCT00810784||1|Patients cared for before our intervention.
3192638|NCT00810784||2|Patients cared for after our intervention.
2475271|NCT03068728|Other|All Study Participants|"Participants received hemostatic packing agent in one nasal cavity and no packing in the other.~Participants were randomized to one of three hemostatic packing agents (Arista, Nexfoam, Nasopore) through sealed envelope, chosen by surgeon prior to placement, with packing agent allocation and sidedness."
2475300|NCT03068494||Coronary Bifurcation Lesion|
3192639|NCT00810823||1:Gastric bypass/diabetes|Patients undergoing gastric bypass surgery, and who are diagnosed with type 2 diabetes.
3192640|NCT00810823||2:Gastric bypass/not Diabetic|Patients undergoing gastric bypass surgery, not diagnosed with diabetes.
2475410|NCT03067818|Experimental|Unaffected Hemisphere|"Application of Unaffected Transcranial Magnetic Stimulation to unaffected hemisphere site prior to physical practice"
2475412|NCT03067818|Experimental|Affected Hemisphere|"Application of Affected Transcranial Magnetic Stimulation to affected hemisphere site prior to physical practice"
2475413|NCT03067818|Active Comparator|Control Site|"Application of Control Transcranial Magnetic Stimulation to control site prior to practice"
2475499|NCT03067051|Experimental|PDT and verteporfin dose finding|"Verteporfin and Interstitial Photodynamic Therapy are the interventions in this dose titration study.~The interventions will be light dose (as laser) using the SpectraCure P18 System and drug intervention with verteporfin as a photosensitizer.~The study will be conducted as a dose titration study to determine the light and drug threshold dose using the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI).~The light is delivered to the tumor via optical fibers and each dose arm will receive Interventional Photodynamic Therapy of Prostate Cancer combined with the drug verteporfin as a photosensitizer ."
2475557|NCT03066713|Experimental|Experimental: A|Skin On French Fry - breakfast Skin On French Fry - lunch Mashed Potatoes - dinner
2475561|NCT03066713|Experimental|Experimental: B|Skin Off French Fry - breakfast Skin Off French Fry - lunch Mashed Potatoes - dinner
2475563|NCT03066713|Experimental|Experimental: C|Hash brown - breakfast Hash brown - lunch Mashed Potato - dinner
2475570|NCT03066713|Experimental|Experimental: D|Pancake - breakfast Pretzels - lunch Macaroni - dinner
2475632|NCT03066323|Active Comparator|Tea extract|Rice with tea extract
2475635|NCT03066323|Placebo Comparator|No tea extract|Rice without tea extract
2475669|NCT03065868|Experimental|eradictaion|H. pylori eradication group
2475672|NCT03065868|No Intervention|non-eradication|H. pylori non-eradication group
2475718|NCT03065556|Experimental|188-0551 Solution|188-0551 Solution applied topically twice daily
2475721|NCT03065556|Placebo Comparator|Vehicle Solution|Vehicle Solution applied topically twice daily
2475741|NCT03065140|Experimental|Healthy Volunteers|"Healthy volunteers will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy Followed by a period of detraining.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
2475743|NCT03065140|Experimental|Diabetic Patients|"Diabetic patients will undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy They will then undergo a supervised training period.~They will then undergo the following:~CPEX with/without stable isotope infusion~Muscle biopsies~Magnetic Resonance Spectroscopy"
2475768|NCT03064971|Experimental|Standard care + PTF DVD|The intervention will include the standard care, with the addition of the PTF DVD. Participants randomized to this condition will receive Pathways to Freedom: Leading the Way to a Smoke-Free Community© (PTF). The content of the intervention parallels the types of education, advice, and cessation/relapse prevention strategies that are delivered in clinic and quitline contexts, except for the focus on the specific needs of the Black community. The 60- minute DVD consists of 7 sections. The cultural adaptations (e.g., focus on menthol, focus on religion/spirituality, Black images and music) were infused throughout the DVD. The PTF DVD is useable at varying levels along the readiness to quit smoking continuum, as viewers are empowered to view sections that match their interests and goals. Quit Coaches will be trained to refer participants to appropriate sections for additional help.
2475777|NCT03064971|Active Comparator|Standard care + standard smoking cessation DVD|"This arm includes standard care, plus a standard smoking cessation DVD. The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies. Narrated by a physician, it describes the process of quitting and strategies for increasing physical activity and healthy nutrition. It includes testimonials from former smokers and dialogue among smokers in a group counseling setting. The information is presented in a standard format, intended for the general population of smokers."
2475783|NCT03064971|Active Comparator|Standard care only|Following the first counseling session, participants may receive up to 3 additional proactive counseling calls. Follow-up calls focus on challenges that may have occurred on the quit date or with the use of medication. Quit Coaches® review and modify the person's quit plan, and provide support as appropriate. Participants also receive standard self-help materials by mail, which is often referred to by Quit Coaches. For individuals who have successfully quit, the Coach will focus on relapse prevention strategies. Quit Coaches provide medication education to all participants eligible and interested in using cessation medications. This study will provide starter NRT kits (2 weeks supply) to all participants. Coaches provide decision support using a database-supported algorithm based on current scientific evidence and the product manufacturer use instructions for each drug.
2475836|NCT03064672|Experimental|induction by transcervical Balloon Catheters insertion|
2475838|NCT03064672|No Intervention|induction without transcervical Balloon Catheters|
2475874|NCT03064334||one medium of focus groups|"The present study aims to understand patient experiences and outcomes post- Total Knee Arthroplasty(TKA). Therefore, a qualitative approach will be most appropriate to facilitate the collection of in-depth experiences and perceptions of patients post-TKA.~The medium of focus groups (with 8-10 patients) is preferred to allow a group of patients to share their perceptions and experiences post-surgery, with sufficient quantity and diversity of views while balancing the facilitator's ability to manage all patients' participation for 90-120 minutes (Bloor, 2006)."
2475924|NCT03063957||Microscopic Colitis|Patients with confirmed microscopic colitis
3192641|NCT00810836|Active Comparator|1|BG00012 480 mg/day
3192642|NCT00810836|Active Comparator|2|BG00012 720 mg/day
3192643|NCT00810836|Placebo Comparator|3|
3208647|NCT00976794|Experimental|lithium plus carbamazepine|combination of the two drugs in standard dosage
2475297|NCT03068624|Experimental|Treatment (cyclophosphamide, T-cells, aldesleukin, ipilimumab)|"PREPARATIVE REGIMEN: Patients receive cyclophosphamide IV over 30-60 minutes on day -2.~T-CELL INFUSION: Patients receive autologous CD8+ SLC45A2-specific T lymphocytes via hepatic arterial infusion via central catheter over 60 minutes on day 0. Within 6 hours of T-cell infusion, patients also receive aldesleukin BID SC for 14 days in the absence of disease progression or unacceptable toxicity.~POST T-CELL INFUSION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity."
2475359|NCT03068026|Experimental|Continuous exercise|Patients will undergo a constant load exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will be consisted of repeated 6-min exercise bouts, separated by 2-min rest periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each resting period participants will breathe normally and perform an IC maneuver to assess the magnitude of dynamic hyperinflation.
2475360|NCT03068026|Experimental|Interval exercise|Patients will undergo an interval exercise protocol with gas exchange analysis on a cycle ergometer. The exercise protocol will consist of repeated 2-min exercise bouts, separated by 2-min resting periods in between work bouts in order to allow application of the VitaBreath device. During the 1st min of each resting period participants will breathe either via the VitaBreath device or normally adopting the pursed lip breathing technique. During the 2nd min of each rest period participants will breathe normally and perform an IC maneuver, to assess the magnitude of dynamic hyperinflation.
2475411|NCT03067779|Other|Survey and mHealth Tool|"A survey has been designed that evaluates CRIC participants' computer and mobile phone usage, and perceived e-health literacy.~There is also a mobile health-based (mHealth) patient safety educational curriculum that evaluates CRIC participants' knowledge of patient safety hazards in CKD. The mHealth patient safety curriculum tool is also known as eCRIC."
2475478|NCT03067363|Experimental|Part 1, MOR107 Dose level 1|MOR107, single subcutaneous injection
2475488|NCT03067363|Experimental|Part 1, MOR107 Dose level 2|MOR107, single subcutaneous injection
2475490|NCT03067363|Experimental|Part 1, MOR107 Dose level 3|MOR107, single subcutaneous injection
2475492|NCT03067363|Experimental|Part 1, MOR107 Dose level 4|MOR107, single subcutaneous injection
2475497|NCT03067363|Experimental|Part 1, MOR107 Dose level 5|MOR107, single subcutaneous injection
2475501|NCT03067363|Experimental|Part 1, MOR107 Dose level 6|MOR107, single subcutaneous injection
2475505|NCT03067363|Placebo Comparator|Part 1, Placebo|Placebo, single subcutaneous injection
2475506|NCT03067363|Experimental|Part 2: MOR107 low dose|MOR107 low dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2475507|NCT03067363|Experimental|Part 2: MOR107 medium dose|MOR107 medium dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2475508|NCT03067363|Experimental|Part 2: MOR107 high dose|MOR107 high dose single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2475509|NCT03067363|Placebo Comparator|Part 2: Placebo|Placebo single subcutaneous injection and low sodium diet for 6 days before dosing and 2 days after dosing
2475614|NCT03066518|Placebo Comparator|Melatonin|Melatonin 5 mg, daily, eight weeks
2475615|NCT03066518|Placebo Comparator|placebo|Placebo, daily, eight weeks
2475646|NCT03066050||SMR MV Repair|This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.
2475647|NCT03066050||MV Replacement|This group of patients had been randomized in the SMR study to mitral valve replacement.
2475648|NCT03066050||MMR MV Repair|This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.
2475649|NCT03066050||CABG|This group of patients had been randomized in the MMR study to receive CABG
2475720|NCT03065660|Active Comparator|Mifepristone|A single dose of oral mifepristone 200mg, followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later
2475722|NCT03065660|Placebo Comparator|Placebo|Oral placebo tablet followed by a single dose of vaginal, oral or sublingual misoprostol 800mcg 2 days later.
2475791|NCT03064984|Active Comparator|CBS eyedrops|Eyedrops prepared from CBS (Cord Blood Serum), and administered 1 drop/each eye/8 times per day, for 30 days
2475795|NCT03064984|Active Comparator|PBS eyedrops|Eyedrops prepared from PBS (Peripheral Blood Serum) from adult donor subjects, administered 1 drop/each eye/8 times per day, for 30 days
2475861|NCT03064633|Active Comparator|Dexamethasone arm (group A)|The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
2475862|NCT03064633|Active Comparator|Dexmedetomidine arm (group B)|The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia.
2475887|NCT03064100||Specimens that meet inclusion criteria|
2475949|NCT03063905||Opioid Taper|Patients tapering off their buprenorphine treatment
2475951|NCT03063905||Opioid Maintenance|Patients starting their buprenorphine treatment
3192644|NCT00810849|Placebo Comparator|Prednisolone|Six-week tapering course of prednisolone and those assigned to the prednisolone control arm will receive the same number of identically-coated placebo tablets.
2476076|NCT03062904|Experimental|drug|
3192645|NCT00810849|Placebo Comparator|Mycobacterium w|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months).
3192646|NCT00810862|Experimental|Pimecrolimus|Pimecrolimus 1% cream
3192647|NCT00810862|Placebo Comparator|2|Placebo cream over affected study area
3192648|NCT00810875||hepatitis C|pregnant women with hepatitis C virus infection and their infants
3192649|NCT00810875||controls|pregnant women without hepatitis C infection and their infants
3158028|NCT00377325|Placebo Comparator|3|Participants will receive active drug full dose until clear, then full dose every 4 days with placebo on the intervening days.
3158029|NCT00377390||Cockroach sensitive|
2475364|NCT03068078|No Intervention|Control-group|The control group will be eating a regular diabetes diet according to the Danish National Recommendations
2475365|NCT03068078|Experimental|Intervention-group|Intervention-group will be eating a low carbohydrate diet, high in monounsaturated fats
2475420|NCT03067792|Active Comparator|FOLFIRI|2nd palliative chemotherapy with FOLFIRI regimen,In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5- fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle. Response evaluation would be done after 3 cycle of chemotherapy in DP group
2475430|NCT03067792|Active Comparator|DP|2nd palliative chemotherapy with Docetaxel/cisplatin regimen, In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle. Response evaluation would be done after 2 cycle of chemotherapy in DP group
2475457|NCT03067259|No Intervention|Control Group|It comprises patients who will not undergo any surgical / anesthetic act
2475469|NCT03067259|Other|Exposure Group|It comprises those patients that will undergo sedation for diagnostic procedure or some surgical / anesthetic process
2475518|NCT03066934||NIV Failure Group|NIV Failure Group consisted of children who failed their noninvasive ventilation session and required intubation or re-intubation
2475519|NCT03066934||NIV success group|Children who successfully managed their noninvasive ventilation therapy
3158030|NCT00377390||Control (cockroach insensitive)|
3158031|NCT00377416|Experimental|1|rAAV2-CB-hAAT Gene Vector
3158032|NCT00377442|Experimental|1|
3158033|NCT00377442|Experimental|2|
3158034|NCT00377442|Experimental|3|
3158035|NCT00377481|Experimental|1|
2475625|NCT03066258|Experimental|Dose 1|3E9 GC/eye of RGX-314
2475626|NCT03066258|Experimental|Dose 2|1E10 GC/eye of RGX-314
2475627|NCT03066258|Experimental|Dose 3|6E10 GC/eye of RGX-314
2475628|NCT03066258|Experimental|Dose 4|1.6E11 GC/eye of RGX-314
2475630|NCT03066258|Experimental|Dose 5|2.5E11 GC/eye of RGX-314
2475661|NCT03065777|Experimental|ONE ENDO|Single file rotary system
2475666|NCT03065777|Experimental|F6 SKYTaper|Single file rotary system
2475670|NCT03065777|Active Comparator|ProTaper Universal|Muti-file rotary system
2475702|NCT03065517|Experimental|VillageWhere App|Parent-youth dyads assigned to the VillageWhere condition will be asked to use the VillageWhere App that has been developed for this study. Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial. The app is designed to be used several times throughout each day.
2475705|NCT03065517|Placebo Comparator|Attention-Control Placebo App|Parent-youth dyads assigned to the control condition will be asked to use a free placebo control app that is well-liked by parents and youth but void of content already part of an existing evidence-based treatment for youth with conduct problems (e.g., geolocation tracking). Parent and youth will be asked upload the app to their phone during the baseline assessment process and asked to use it as often as they would like throughout the duration of the 16 week trial.
2475855|NCT03064516|Experimental|Endocrown|Restorations with ceramic endocrown in endodontically treated teeth
2475858|NCT03064516|Active Comparator|Onlay and fiber pin|Restorations with onlay ceramic and glass fiber pin in endodontically treated teeth
2475897|NCT03064165|Experimental|Obturator nerve block|Postoperative obturator nerve block with 15 mL bupivacain 5 mg/mL and epinephrine 5 µg/mL.
2475899|NCT03064165|Placebo Comparator|Sham block|Postoperative sham-block with normal saline.
2475998|NCT03063528|Experimental|Healthy Eating/Physical Activity (HEPA)|"The goals of the HEPA condition are to encourage healthy eating and physical activity behaviors for gaining a healthy amount of weight during pregnancy and to provide motivation and social support to help overcome challenges to eating healthier and becoming more physically active while pregnant.~12 weeks of group-based health behavior (nutrition/PA focused) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
2475999|NCT03063528|Experimental|Stress Reduction/Management (SRAM)|"The goals of the SRAM condition are to encourage stress reduction and management techniques as well as to provide motivation and social support to reduce stress levels during pregnancy.~12 weeks of group-based health behavior (stress reduction/management) challenges and weight tracking; podcasts (10); weekly pregnancy tips~website and mobile app"
2476046|NCT03063229|Active Comparator|Islet Transplant Patients|Patients with Type 1 Diabetes who are on the waiting list to undergo an islet transplant.
2476117|NCT03062644|Experimental|MR308 150 mg bid|Tramadol/Celecoxib
3158036|NCT00377481|Active Comparator|2|
3158037|NCT00377507|Experimental|catechin|mask containing catechins
3158038|NCT00377559|Experimental|1.|Myocet+docetaxel
3158039|NCT00377598|Experimental|TAK-583 5 mg QD|
3158040|NCT00377598|Experimental|TAK-583 25 mg QD|
3158041|NCT00377598|Experimental|TAK-583 50 mg QD|
3158042|NCT00377598|Experimental|TAK-583 100 mg QD|
3158043|NCT00377598|Placebo Comparator|Placebo QD|
3158044|NCT00377663|Experimental|1|Participants will use the AsthmaNet web site.
3158045|NCT00377663|No Intervention|2|Participants will not use the AsthmaNet Web site.
3158046|NCT00377715|Experimental|Dimebon|Dimebon 20 mg three times a day x 26 weeks
3158047|NCT00377715|Placebo Comparator|Placebo|Placebo 20 mg three times a day x 26 weeks
3158048|NCT00377780|Experimental|1|Myocet + docetaxel + trastuzumab
3158049|NCT00377793|Experimental|Arm 1|
3158050|NCT00377793|Placebo Comparator|Arm 2|
3158051|NCT00377871|Active Comparator|1|Valve design 1
3158052|NCT00377871|Active Comparator|2|Valve design 2
3158053|NCT00377871|No Intervention|Control|Healthy control
2475321|NCT03068299|Experimental|Dance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
2475327|NCT03068299|Experimental|Health care guidance|n=29 participants randomized. Cognition performance, frailty and burden will be measured at baseline and after of interventions (6 months after baseline). Instruments of measurement described in Time Frame.
2475362|NCT03068013|Experimental|Managing Cancer Living Meaningfully|Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
2475363|NCT03068013|Active Comparator|Supportive psycho-oncology intervention|Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
2475418|NCT03067753|Active Comparator|Pulsed steroid|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
2475426|NCT03067753|Experimental|Monosialoganglioside ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
2475462|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
2475476|NCT03067220|Experimental|Virtual out patient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
2475534|NCT03066856|Experimental|Intervention|After baseline examinations, participants are randomized to an active dietary intervention group.The intervention group is invited to attend six full days of life-style intervention activities over the next six months. These activities include six cookery courses followed by lunch, six physical activity sessions (walking for 45 minutes) and six conferences. The intervention and control groups both complete questionnaires on adherence to the Mediterranean diet (MEDAS) at baseline and at the end of the study, and are asked for at least two 24-hour recalls of the previous day's food intake, and details of their physical exercise during the six-month intervention.
2475535|NCT03066856|No Intervention|Control|All participants receive general recommendations for the dietary prevention of cancer. After baseline examinations, women randomized in the control group carry on following the baseline recommendations.
2475596|NCT03066531|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
2475605|NCT03066531|Active Comparator|CBT-based intervention included in Usual Care|"These programs are based on current guidelines for the long- term multi-disciplinary rehabilitation and prevention of obese patients, including Cognitive Behavioral Therapy (CBT), in a group setting, as Gold Standard.~Assigned Interventions: Behavioral: usual care (CBT)"
2475653|NCT03066141||CAD with OSA|coronary artery disease with Obstructive sleep apnea
2475654|NCT03066141||CAD without OSA|coronary artery disease without Obstructive sleep apnea
2475707|NCT03065673|Active Comparator|Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
2475710|NCT03065673|Placebo Comparator|Placebo gel|The patient will receive the application placebo gel on vestibular surface teeth, for 10 minutes.
2475739|NCT03065218|Experimental|99mTc sestamilbi|25 mCi 99mTc sestamibi intravenous injection, once. Then imaged for 45 minutes. More imaging might be required and this will be determined by a nuclear medicine physician onsite
2475759|NCT03065010|Other|BCD-115 in dose escalation regimen|BCD-115 will be administered p.o. with intrapatient dose escalation in the population of patients with ER(+) HER2(-) advanced breast cancer in combination with a standard dose of endocrine therapy.
2475821|NCT03064854|Experimental|Group A: squamous, gem/cis+PDR001|
2475822|NCT03064854|Experimental|Group B: non-squamous, pem/cis+PDR001|
2475823|NCT03064854|Experimental|Group C: paclitaxel/carbo+PDR001|
2475824|NCT03064854|Experimental|Group E: non-squamous, pem/cis (or carbo)+PDR001+canakinumab|
2475912|NCT03064204||OSA+CPAP+HIV+|Individuals (40 years or older) diagnosed with OSA and using CPAP, also with HIV treated to viral suppression.
2475915|NCT03064204||OSA+CPAP+HIV-|Individuals (40 years or older) diagnosed with OSA and using CPAP.
2475953|NCT03063775|Active Comparator|1. Mucograft® Seal + Bio-Oss®|
2475955|NCT03063775|Active Comparator|2. FGG + Bio-Oss®|
2475956|NCT03063775|Active Comparator|3. FGG + Gelatine sponge (Spongostan®)|
2475958|NCT03063775|Active Comparator|4. Spongostan®+ Mucograft® Seal|
2475960|NCT03063775|No Intervention|5. Spongostan®|
3192650|NCT00810914|Experimental|1|Continuous epidural infusion of medication for method of pain relief
2476130|NCT03062449|Active Comparator|L-Serine Gummy Arm|L-serine will be presented in gummies containing 1g serine each. Subjects randomized into the L-serine arm will take 15 grams of L-Serine (15 gummies containing 1g of L-serine) orally twice daily for 246 days after the initial ascending dose period to confirm tolerability of the dose.
2476132|NCT03062449|Placebo Comparator|Placebo Gummy Arm|Placebo gummies containing no L-serine will be packaged in the same manner as that of the L-Serine gummy arm and be given to patients to take two times a day.
3158054|NCT00377910|Active Comparator|1, drug|Injections of polidocanol
3158055|NCT00377910|Placebo Comparator|2 drug|injections of lidocaine
3158056|NCT00377936|Active Comparator|1|Gemcitabine
3158057|NCT00377936|Experimental|2|EndoTag-1 + Gemcitabine
3158058|NCT00377936|Experimental|3|EndoTag-1 + Gemcitabine
3158059|NCT00377936|Experimental|4|EndoTag-1 + Gemcitabine
2475408|NCT03067623|Experimental|PRP-infusion|PRP will be obtained from a fresh whole blood collected from a peripheral vein; the blood sample will be centrifuged at 1500g (RCF) for 10 minutes and the repeated reversal of the tube will allow obtaining the PRP at the concentration required. Then 0,5-1ml of PRP will be infused into the uterine cavity through a Tomcat catheter. The endometrial thickening will be evaluated by ultrasonography 24-48h after the instillation and, if the endometrial lining reaches 7mm the Embryo-transfer will be arranged.
2475503|NCT03067415|Experimental|D565H(Latanoprost 25㎍/㎖)|D565H(Latanoprost 25㎍/㎖)
2475504|NCT03067415|Active Comparator|D565(Latanoprost 50㎍/㎖)|D565(Latanoprost 50㎍/㎖)
2475555|NCT03066674|Experimental|McKenzie group|This group will receive Hand-on technique on the lumbar spine.
2475559|NCT03066674|Experimental|Control group|The Group will not receive Hand-on technique on the lumbar spine.
2475597|NCT03066440|Placebo Comparator|Normal Saline|Intervention: intravenous solutions containing only normal saline as the primary base during the entire treatment of diabetic ketoacidosis.
2475602|NCT03066440|Experimental|Lactated Ringers|Intervention: intravenous solutions containing only lactated ringers as the primary base during the entire treatment of diabetic ketoacidosis.
2475639|NCT03066076|Active Comparator|Thyroidectomy|Total thyroidectomy
2475641|NCT03066076|Active Comparator|Antithyroid drug|Thiamazol, Propylthiouracil
2475682|NCT03065764|Other|Patients|For the first 3 patients, PET scans will be obtained at 1, 72 and 120 hours post tracer injection to determine the optimal scan time point and to perform biodistribution measurements and dosimetry. All subsequent 7 patients receive only 1 PET scan post-injection (i.e. two PET scans).
2475717|NCT03065465|Other|Standard endoscopic treatment|For those assigned to the standard endoscopy group, endoscopic hemostasis is performed using usual CURE hemostasis therapy for the focal GI lesions: injection of dilute (e.g. 1: 20,000) epinephrine (in 1-2 cc aliquots in 4 quadrants next to the SRH) of active bleeding or adherent clots (prior to snaring them off); coaptive coagulation with multipolar electrocautery (MPEC) probe and/or standard through the endoscope hemoclips along the course of the underlying artery as detected by DEP. Hemostasis is performed until active bleeding stops and/or the SRH is obliterated. Residual blood flow after visually guided hemostasis is recorded, but not used as a guide for additional hemostasis in this study.
2475719|NCT03065465|Experimental|Over-the-scope hemoclipping device|For those assigned OTSC, prior to use of the OTSC in UGI lesions with active bleeding or adherent clots, dilute epinephrine (1: 20,000) is injected around the SRH in 1-2 cc aliquots and the clots are cold guillotined off, as previously described (2, 4, 17). As a brief additional description, after initial diagnosis and preparation of the lesion and SRH (as described for standard hemostasis), the therapeutic sized endoscope is removed and this or a diagnostic panendoscope will be affixed with the OTSC of appropriate size for the endoscope and the target lesion. The endoscope is re-introduced and passed to the bleeding site. The SRH is centered in the field of view and within the cap of the OTSC device. Using high suctioning and firm pressure to center the SRH, the lesion and SRH is captured into the cap and the OTSC is deployed by rotating the handle and thereby compressing the bleeding lesion and surrounding tissue with mechanical hemostasis.
2475797|NCT03065101|Other|Trigen Intertan|"Unique integrated interlocking screw and trapezoidal nail shape~Resistance to femoral head rotation and cut-out~Active compression through linear motion without rotation~Single subtrochanteric lag screw option for stable fractures below lesser trochanter~Preloaded cannulated set screw converts construct to fixed angle device~Small proximal diameter of the nail promotes preservation of the lateral wall of the greater trochanter and gluteus medius tendon~Clothespin tip for stress modulation in femoral shaft~Potential for improved patient mobility and recovery~Manufactured by Smith & Nephew Inc., 1450 Brooks Road, Memphis, TN 38116, U.S.A.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
2475799|NCT03065101|Other|Sliding Hip Screw|"SHS is a generic term for a group of devices used for internal fixation of trochanteric hip fractures. Also known as Compression Hip Screw or Dynamic Hip Screw. All devices feature a lag screw inserted into the femoral neck and a side plate held in place by cortical screws inserted into the proximal femoral shaft.~Therapeutic effect is achieved by guided collapse, where the lag screw can slide in the barrel of the side plate which compresses the fracture as the patient begins to weight-bear.~Participating sites may use whichever brand of SHS is currently in use.~Interventions:~Randomisation to either Trigen Intertan or Sliding Hip Screw, Post-Surgery Follow Up"
2475867|NCT03064607||pregnant women|Women undergoing c-section or EXIT procedure
2475932|NCT03064035|Experimental|Fixed dose 4FPCC|"Incorporating a fixed dose of 1500 IU.~If the patient receiving the 1500 IU fixed dose remains in a bleeding state and the INR remains above goal, an additional 500 IU may be administered at the physician's discretion to minimize bleeding and attempt to achieve hemostasis."
2475933|NCT03064035|Active Comparator|Variable dose 4FPCC|"The FDA-approved variable dosing algorithm is as follows:~initial INR 2-3.9: 25 IU/kg (maximum dose 2500 IU), initial INR 4-6: 35 IU/kg (maximum dose 3500 IU), and initial INR >6: 50 IU/kg (maximum dose 5000 IU). The patient weight will be obtained using a scale and documented by the treating registered nurse"
2475973|NCT03063619|Placebo Comparator|Arm A (placebo)|Patients apply placebo gel topically to each breast QD for up to 52 weeks.
2475987|NCT03063619|Experimental|Arm B (afimoxifene)|Patients apply afimoxifene gel topically to each breast QD for up to 52 weeks.
3192651|NCT00810914|Experimental|2|continuous epidural infusion in conjuction with patient controlled anesthesia (PCA)
3192652|NCT00810914|Experimental|3|patient controlled anesthesia only this arm has pt controlled medication delivery. (PCA)
3192653|NCT00810927|Active Comparator|1|Phenylephrine (Neosynephrine®, Abbott Laboratories, North Chicago, IL, USA) dose: 1µg/(kg.min), infusion period 20 minutes
3192654|NCT00810927|Active Comparator|2|NG-monomethyl-L-arginine (L-NMMA, Clinalfa, Läufelfingen, Switzerland) dose: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/(kg.min) over 15 minutes
3192655|NCT00810927|Placebo Comparator|3|Physiologic saline solution
3192656|NCT00810940|Active Comparator|1|Control: Standard treatment for severe head trauma including mannitol
3192657|NCT00810940|Experimental|2|Study drug plus standard treatment
2475407|NCT03067571|Experimental|Treatment (daratumumab)|Patients receive daratumumab IV over 3.25-6.5 hours on days 1, 8, 15 and 22 of cycles 1-2, on days 1 and 15 of cycles 3-6, and on day 1 of subsequent cycles. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2475449|NCT03067389||History of invasive breast cancer|Subjects with a diagnosis of invasive breast cancer within the past 12 months will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
2475450|NCT03067389||No history of invasive breast cancer|Subjects with no history of breast cancer will provide a blood or saliva sample for genetic diagnostic testing and provide information about their personal medical and cancer history and family cancer history.
2475547|NCT03066986|Experimental|25mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison).
2475556|NCT03066986|Experimental|25mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 25mcg (dose finding comparison, adjuvant comparison).
2475560|NCT03066986|Active Comparator|50mcg JJA venom|Subjects will receive semi-rush JJA VIT (without delta-inulin) aiming to achieve a maintenance dose of JJA venom of 50mcg, ie. the current standard of care.
2475564|NCT03066986|Experimental|50mcg JJA venom + 5mg delta-inulin|Subjects will receive semi-rush JJA VIT with delta-inulin (at a fixed dose of 5 mg with each dose of venom) aiming to achieve a maintenance dose of JJA venom of 50mcg (adjuvant comparison).
2475656|NCT03065855|Experimental|Early removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 2 days following surgery.
2475657|NCT03065855|Active Comparator|Normal removal group|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
2475693|NCT03065582|Experimental|Sunscreen application|All subjects will undergo topical application of 3 products and an additional site will serve as a control
3158060|NCT00377988||001|Transdermal Contraceptive System In each 4-week period exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
3158061|NCT00377988||002|Norgestimate-containing oral contraceptives with EE NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days then no pill or a drug-free pill 7 days.
3158062|NCT00378027||Stable Acute Pulmonary Embolism|Administer weight dosed Fondaparinux
3158063|NCT00378066|Active Comparator|Bevacizumab|Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment
3192658|NCT00810953|Experimental|single arm|Use of pentamidine in locally advanced or metastatic pancreatic cancer
2475805|NCT03064906|Other|Meal Performance and/or Exercise|"This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.~Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions."
2475844|NCT03064581|Experimental|Intervention|Gender-specific culturally tailored social-support informed educational intervention session.
2475846|NCT03064581|No Intervention|Control|Usual care with delayed intervention at the end of study.
2475870|NCT03064230||Athletes agonists (Experimental Group)|"I) age between 14 and 40 years who met the definition of competitive sports athletes adopted by the Italian Ministry of Health II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy.~QoL questionnaire SF-12 and and a screening questionnaire were requested"
2475871|NCT03064230||women not agonists (Control Group)|"I) age between 14 and 40 years who did not met the definition of competitive sports athletes adopted by the Italian Ministry of Health; II) absence of malignancies; III) informed consent obtained from the patient; IV) no previous surgical, chemotherapic and/or radiotherapic treatments.~We excluded all patients who presented any conditions that could alter quality of life such as: I) recent traumas; II) recent surgeries; III) oncologic history; IV) uncontrolled systemic illnesses; V) severe or uncontrolled infection; VI) mental illness; VII) pregnancy. QoL questionnaire SF-12 and and a screening questionnaire were requested"
2475900|NCT03064009||Open Fractures|Patients with Open fractures between the distal radius and the distal tibia
2475988|NCT03063827||Treatment group|Patients with chronic SCI causing NDO and urinary incontinence
2475992|NCT03063827||Control group|Female patients who underwent anti-incontinence suregery without lower urinary tract symptoms
2476017|NCT03063268|Experimental|Trust-Enhanced Messaged with Interactive Features on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
2476020|NCT03063268|Experimental|Interactive Features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
2476026|NCT03063268|Active Comparator|Standard E-Consent|Standardized text currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
2476072|NCT03062956|Experimental|Single oral dose of MYK-491|single-dose, oral suspension
2476078|NCT03062956|Placebo Comparator|Single oral dose of placebo|single-dose, oral suspension
2502592|NCT02883192|Experimental|ondansetron|ondansetron
2475421|NCT03067558||Accuracy evaulation|Three age groups (young infants 0 to <2 months, children 2 to <12 months and 12 to 59 months) will participate in the accuracy evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
2475429|NCT03067558||Consistency evaluation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the consistency evaluation. Participants will be enrolled in a ratio 3:1 fast to normal breathers, by age group. Respiratory rate evaluations will be done using the ARIDA test device and the MK2 ARI timer (standard practice).
2475434|NCT03067558||Respiratory rate fluctuation evaulation|Two age groups (children 2 to <12 months and 12 to 59 months) will participate in the respiratory rate fluctuation evaluation. All participants will be normal breathers.Respiratory rate evaluations will be done using the MK2 ARI timer (standard practice). The ARIDA test device will be strapped to the child during the manual RR count with MK2 ARI timer (standard practice).
2475463|NCT03067168|Active Comparator|Bupivacaine Arm|The subjects of this arm will receive an injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 5mL of 0.5% bupivacaine, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalad of the first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
2475474|NCT03067168|Placebo Comparator|Placebo Arm|The subjects of this arm will receive an injection of 5mL of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium into the levator ani muscle, puborectalis. A second injection of 0.9% normal saline, 1-2 cm deep to the surface of the vaginal epithelium will be repeated on the same side, approximately 2-3 cm cephalic from first injection at the iliococcygeus muscle. These 2 injections will then be repeated on the contralateral side.
3192659|NCT00810979|Experimental|1|SLx-4090 dose #1 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
3192660|NCT00810979|Experimental|2|SLx-4090 dose #2 in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
2475863|NCT03064399|Experimental|lateral ligament repairment|
2475865|NCT03064399|Experimental|without lateral ligament repairment|
2475894|NCT03064061|Sham Comparator|Virtual Reality Neutral|neutral VR session before oocytes retrieval
2475898|NCT03064061|Active Comparator|Virtual reality Anxiety|VR session with the goal of reducing anxiety before oocytes retrieval
2475972|NCT03063853|Other|POD4|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 4
2475986|NCT03063853|Other|POD8|REMOVAL OF SURGICAL STAPLES AT POSTOPERATIVE DAY 8
2476032|NCT03063333|Experimental|Coping-oriented hypnosis|
2476034|NCT03063333|Placebo Comparator|Neutral hypnosis|
2476036|NCT03063333|No Intervention|current treatment only|
2476116|NCT03062722|Experimental|keyhole approach|open minimally invasive approach
2476169|NCT03062410|Other|Electronic PRO|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
2476236|NCT03062020|Experimental|Intervention group: QUIPP tool arm|In this group, QUIPP tool will be used to select and manage patients attending our PBPC: high-risk patients will be followed-up in our PBPC and low-risk patients will be discharged from PBPC and managed in a low-risk unit.
2476245|NCT03062020|No Intervention|Control group: no QUIPP tool arm|Women will be managed according to current clinical practice.
2476318|NCT03061539|Experimental|Nivolumab & Ipilimumab|Patients will receive Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses followed by a 6 week gap after last combination dose. The patients will then receive 480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent.
2476338|NCT03060993|Placebo Comparator|Placebo|35 mg of tetrahydrocannabinol/cannabidiol (LT1.0/LT1.0 %) in vaporized form. Placebo will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
2476342|NCT03060993|Active Comparator|Cannabis|35 mg of cannabis (tetrahydrocannabinol/cannabidiol; 18.0/LT1.0 %) in vaporized form. THC/CBD will be vaporized using the Volcano Medic vaporizer. Total volume of vapour administered to each patient will be 5.5 L.
2476430|NCT03060824||CABG with the aid of CPB.|Cardiac surgical patients subjected to coronary artery bypass grafting with the aid of Cardiopulmonary Bypass. Perioperative measurements of osmolality in plasma.
2476461|NCT03060330|Experimental|LVMR|Modified Laparoscopic Ventral Mesh Rectopexy
2476462|NCT03060330|Experimental|LVMR with STARR|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
2476567|NCT03060005|Experimental|primary Sjögren's syndrome|The female patients with primary Sjögren's syndrome receive the Tears Naturale Forte and Liposic.
3192661|NCT00810979|Other|3|Placebo in combination with statin drug. Subjects were dosed with the statin prescribed specifically by their prescribing physician.
3192662|NCT00810992|Active Comparator|1 Program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
3192663|NCT00810992|Experimental|2 Program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
3208648|NCT00976794|Active Comparator|lithium plus valproate|combination of the two drugs in standard dosage
3208649|NCT00976807|No Intervention|Control|
3208650|NCT00976807|Experimental|Intervention|Pulmonary Rehabilitation
3208651|NCT00976833|Active Comparator|Usual Care|Usual Care
2475440|NCT03067480|Experimental|3-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
2475442|NCT03067480|Experimental|6-Month iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
2475467|NCT03067207|Experimental|Experimental|The experimental arm will consist of four groups with a target of 15 participants each: one early intervention group, one wait-list in-person group, one early e-Health group and one wait-list e-health group. All participants will receive the mindfulness intervention, MARS-A, either in-person or via e-health by the end of the 6-month study period. Participants in the in-person groups will meet at in hospital at a designated teen-friendly room containing chairs and yoga mats. Participants in the e-health groups will be encouraged to find a quiet room in their home and will be required to have access to the Internet, a desktop/laptop computer equipped with a webcam or a tablet/smartphone with webcam function.
2475477|NCT03067207|Other|Feasibility|The feasibility arm, which will only take place if the targeted number of study participants (60) is not reached for the experimental arm, will be offered to participants who are not able to commit to the in-person mode of delivery. It will consist of two groups, one early e-health group and one wait-list e-Health group. The intervention delivered, MARS-A, will be identical as the intervention delivered to e-health groups in the experimental arm.
2475526|NCT03066895|Experimental|Experimental|BabyGentleStick
2475528|NCT03066895|Active Comparator|Standard of Care|HMC Standard Lancing Device
2475550|NCT03066596|Experimental|PRAGMATIC|Intervention practices will receive guideline information and assess children's asthma severity and control. For children with persistent/uncontrolled asthma, academic detailing and prompt in EHR following asthma guidelines will guide asthma management; outreach worker will follow up with patients referred to the by providers to receive care coordination to assure that provider management plan is followed by patient at home.
2475606|NCT03066453|Experimental|Standard cure|Antibiotic IV (Nebcin) 14 days and 14 days of tobramycin IV associated with one or more other antibiotic (s) IV in routine care
2475609|NCT03066453|Experimental|Short cure|antibiotic IV (Nebcin)14 days but with only 5 days of tobramycin IV followed 9 days of inhaled tobramycin (Tobi Inhalant Product) associated with one or more other antibiotic (s) IV in routine care
2475675|NCT03066011||Isavuconazonium sulfate Group|Oral and Intravenous
2475676|NCT03066011||Voriconazole Group|Oral and Intravenous
2475677|NCT03066011||Posaconazole Group|Oral and Intravenous
2475772|NCT03065166|Experimental|Raisin Treatment|3.2 ounces of dried Cabernet wine grapes.
2475778|NCT03065166|Other|Bagel Control|One 95g whole wheat bagel.
3158064|NCT00378092|Experimental|Risperidone Long-Acting Injection (RLAI) (Period 1)|Participants will receive 25 milligram (mg) to 50 mg of RLAI intramuscularly (into the muscle) which will be tapered and discontinued over a period of up to 6 weeks. Participants will be followed-up until their first disease relapse or maximum of 36 months.
2475892|NCT03064256|Experimental|Physical training program|"Intervention participants are submitted to supervised aerobic physical training at the predetermined intensity, which is composed of three weekly sessions, lasting one hour, over a period of 12 weeks.~All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise."
2475895|NCT03064256|No Intervention|Control Group|Control participants receive routine outpatient care for a 12-week period.
2475957|NCT03063814|Experimental|APP|In the APP group, a video sequence of each exercise, supported by short written descriptions (in accordance to 'Get set - Train smarter', (9) on how to perform the exercise correctly, was shown to the participants on an iPad. The video-recorded exercises were performed by the same physiotherapist who supervised PHY participants. If required, the participants in the APP group were allowed to watch the video and description several times between trials of the same exercise. The participants approved their own trials when they believed that the exercises had been performed as described.
2475959|NCT03063814|Active Comparator|PHY|In PHY, a physiotherapist demonstrated and explained the focus areas of each of the five exercises before the participant performed the exercises. If needed, verbal feedback was given between trials to correct the performance of the exercise. The physiotherapist approved trials that were performed with proper technique.
2476006|NCT03063489|Experimental|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
2476156|NCT03062618|Experimental|Part A: Single Dose|Two escalating sequences of single oral doses of PRCL-02, in 3 periods, starting at 4 milligrams (mg)
2476163|NCT03062618|Placebo Comparator|Part A: Single Dose (Placebo)|Two escalating sequences of matching placebo oral tablets, in 3 periods
2476166|NCT03062618|Experimental|Part B: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
2476167|NCT03062618|Placebo Comparator|Part B: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
2476170|NCT03062618|Experimental|Part C: Multiple Dose|Multiple oral doses of PRCL-02 for 28 days, at up to 3 dose levels
2476172|NCT03062618|Placebo Comparator|Part C: Multiple Dose (Placebo)|Multiple oral doses of placebo for 28 days, at matching dose levels
2476214|NCT03062033||Cohort 1|Patients without visible signs of involuntary movements (possible TD) at time of clinician assessment
2476217|NCT03062033||Cohort 2|Patients with visible signs of involuntary movements (possible TD) at the time of clinician assessment
2476295|NCT03061422|Experimental|xylitol chewing gum|intervention
2476299|NCT03061422|Experimental|xylitol with bicarbonate chewing gum|intervention
2476301|NCT03061422|Active Comparator|Paraffin pellet|comparator
3208652|NCT00976833|Other|Standardized Rehabilitation|Intervention arm to receive Standardized Rehabilitation Therapy
2475451|NCT03067155|Experimental|Treatment group|The patients for which a suitable donor product can be obtained will be included in the treatment arm of the protocol. Treatment consists of the administration of CMV-specific T-cells, administered through intravenous transfusion. Depending on response in viral load and GVHD status, a second and/or third administration is possible.
2475452|NCT03067155|Active Comparator|Control group|Patients for which the investigator can't obtain a suitable donor product, will be included in the control group consisting of standard anti-viral treatment.
2475510|NCT03067012|Experimental|Oncometabolic reconstruction|Patients undergoing oncometablic surgery
2475523|NCT03066687|Experimental|Treatment Sequence 1: Erdafitinib 9 mg|Participants will receive 9 milligram (mg) dose of erdafitinib under fasted condition [Treatment A] in Period 1, and under fed (with high-fat and high-calorie breakfast) condition [Treatment B] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
2475524|NCT03066687|Experimental|Treatment Sequence 2: Erdafitinib 9 mg|Participants will receive 9 mg dose of erdafitinib under fed (high-fat and high-calorie breakfast) condition [Treatment B] in Period 1, and under fasted condition [Treatment A] in Period 2. Each Treatment Period will be separated by a washout of at least 28 days.
3192664|NCT00811005|Active Comparator|Acitretin-PUVA combination|"Acitretin-PUVA combination:~Acitretin monotherapy: Patients randomized to the acitretin group will receive acitretin in a dose of 1mg /kg daily two weeks prior to additional PUVA treatment.~PUVA treatment (see below) will be applied thrice weekly in addition to acitretin until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
3208653|NCT00976846|Experimental|Baxter Xenium XPH 210|Device: Baxter Xenium XPH 210 dialyzer
3208654|NCT00976859|No Intervention|Waitlist control group|
2475651|NCT03065907|Active Comparator|Vision Rehabilitation Group 1|Vision rehabilitation assessment will be scheduled within 1 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
2475652|NCT03065907|Active Comparator|Vision Rehabilitation Group 2|Vision rehabilitation assessment will be scheduled within 7 months of randomization; interventions will be scheduled and vision rehabilitation appointments will be scheduled accordingly.
2475687|NCT03065699|No Intervention|Standard of Care|For patients with ACLF grade 1 or 2 and randomised to the 'Standard of care' arm, the location of treatment (ICU or general ward) will be determined by their clinical need and will be decided by the site Principal Investigator. They will receive standard of care.
2475689|NCT03065699|Active Comparator|DIALIVE Liver Dialysis Device treatment arm|Patients with ACLF grade 1 and ACLF grade 2 on the background of alcoholic cirrhosis randomized to the DIALIVE arm will receive treatment in an intensive care (ICU) or renal dialysis unit setting. They will receive DIALIVE treatment according to a fixed treatment schedule over a period of 10 days post-randomization.
2475757|NCT03065322||Women with PCOS|Women with confirmed diagnosis of PCOS, based on the Rotterdam Criteria. To assess risk of OSA: the risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed.
2475788|NCT03064919|Experimental|Curriculum Testing|Test an evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals.
3208655|NCT00976859|Experimental|Imagery Modification|Via a internet research patients collect data on skin renewal which is discussed afterwards; in a guided imagery modification the patients imagines the process of skin renewal and the building of new skin cells
2475901|NCT03064048|Active Comparator|Neo-ASA|During this arm the participant will receive a lozenge with nitric oxide as a dietary supplement twice daily.
2475905|NCT03064048|Placebo Comparator|Placebo|During this arm the participant will receive a lozenge which will not contain nitric oxide as a dietary supplement twice daily.
2475993|NCT03063697||patients who check the safety data after taking Dilatrend SR|
2476025|NCT03063424|Other|Healthy subjects|
2476030|NCT03063424|Other|Asthmatics with EIB|
2476327|NCT03061253|Experimental|Nicotine-inclusive e-cigarettes|Participants will receive e-cigarettes (nicotine-inclusive) combined with behavioural change support over a 3 month period.
2476329|NCT03061253|Experimental|Nicotine-free e-cigarettes|Participants will receive e-cigarettes (nicotine-free) combined with behavioural change support over a 3 month period.
2476331|NCT03061253|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy combined with behavioural change support over a 3 month period.
2476368|NCT03060902|Experimental|Dialectical Behavior Therapy Skills|Dialectical Behavior Therapy SKills; 2.5 hour group session/week; 1 year
2476378|NCT03060902|No Intervention|Family Services as Usual|Mothers will continue with services they are receiving in the community
3173372|NCT00611338|Active Comparator|HIV Prevention|Eight, 90 minute group sessions. Three of the sessions focused on health education (e.g., medication adherence, nutrition, exercise) and five focused on HIV prevention skills (e.g., condom skills, communication, social support). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months. At the end of the 12-month assessment, the participants in this arm were given the option to receive the 3 trauma-focused sessions from the Trauma + HIV group arm.
2476478|NCT03060291|Experimental|Web/ Mobile-only|Participants will complete the FCU online independently, without the help of a coach.
2476526|NCT03059966|Placebo Comparator|Placebo|Microsurgery for root coverage associated with a Placebo comparator
2476535|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration
3158065|NCT00378092|Experimental|Oral risperidone and RLAI (Period 2)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus (a muscle) for up to 24 months. Supplementation with oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injections becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
3158066|NCT00378131|Placebo Comparator|1|
2476347|NCT03061006|Experimental|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL 15-30 mL/min)
2476352|NCT03061006|Active Comparator|Warfarin|Dose-adjusted warfarin (INR: 2.0-3.0)
2476441|NCT03060785|Experimental|TFV/FTC dosing in Transgender women|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)for 7days in transgender women taking feminizing hormones
2476442|NCT03060785|Active Comparator|TFV/FTC dosing in Cis men|Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men
2476499|NCT03060265|Active Comparator|Paracetamol|Paracetamol Braun Germany 1 gram in 100ml normal saline, one dose IV
2476500|NCT03060265|Placebo Comparator|Placebo|100ml normal saline, one dose IV
2476537|NCT03059771|Experimental|Mobile Enhancement of Motivation (MEMS)|Facilitators will first collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006). Participants will then receive three sets of interactive text messages each weekday for eight weeks to reinforce and cue goal completion.
2476540|NCT03059771|Active Comparator|Control|Participants will only engage in a goal-setting session where facilitators will collaboratively help participants set personal recovery-goals using Collaborative Goal Technology (Clarke et al., 2006).
2476609|NCT03059550||cardiac rehabilitation|Patients reffered to cardiac Rehabilitation after an acute coronary syndrome
2476610|NCT03059550||Whole French population post-ACS|The whole French population who presented an acute coronary syndrome (ACS) in the years 2013 and 2014.
2476658|NCT03059095|Experimental|Yoga and Meditation|Yoga and Meditation online sessions 2x's a week.
2476672|NCT03058809|Experimental|Metastatic Breast, Colon and Prostate Cancer|Metastatic breast, colon or prostate cancer patients will have their CTC levels determined on 3 days before treatment with the Viatar Oncopheresis System to establish a baseline value, a pretreatment value, a post treatment value and on 4 additional instances over a period of 7 days post treatment to establish a CTC rebound profile using a validated CTC enumeration system.
2476729|NCT03058653|Experimental|Study patients|Small fluid boluses - The first 250ml of fluid will be given in 50ml boluses using a 50ml syringe
2476756|NCT03058341|Sham Comparator|Group S|Patients will be anaesthetized by inhalational anaesthesia using sevoflurane.
2476757|NCT03058341|Experimental|Group P|Patients will be anaesthetized using total intravenous propofol.
2476794|NCT03058068|Experimental|Safety Run-In: Treatment 1 Allo-hMSCs|Treatment 1: 1 subject will receive a single administration of allogeneic MSCs: 20 x 10^6 MSCs (20 million) cells delivered via peripheral intravenous infusion.
2476797|NCT03058068|Experimental|Safety Run-In: Treatment 2 Allo-hMSCs|2 subjects will receive a single administration of allogeneic MSCs: 100 x 10^6 MSCs (100 million) cells delivered via peripheral intravenous infusion.
2476806|NCT03058068|Experimental|Randomized: Cohort 1 Allo-hMSCs|Cohort 1 (5 subjects): 20 million MSCs A single peripheral intravenous infusion of 20 x 10^6 MSCs (20 million cells) will be administered to each subject.
2476811|NCT03058068|Experimental|Randomized: Cohort 2 Allo-hMSCs|Cohort 2 (5 subjects): 100 million MSCs A single peripheral intravenous infusion of 100 x 10^6 MSCs (100 million cells) will be administered to each subject.
2476814|NCT03058068|Placebo Comparator|Randomized: Cohort 3 Allo-hMSCs|Cohort 3 (5 subjects): Placebo A single peripheral intravenous infusion of placebo (PlasmaLyte A containing 1% HSA) will be administered to each subject.
2476921|NCT03057483||Elderly|People over 60 years of age. seasonal influenza vaccine
2476924|NCT03057483||Health care workers|People working in health care services seasonal influenza vaccine
2476930|NCT03057483||Pregnant women|Pregnant women seasonal influenza vaccine
2476931|NCT03057483||Post partum women|Women who have given birth < 45 days seasonal influenza vaccine
2476935|NCT03057483||Children|Children from 6 months to 5 years of age seasonal influenza vaccine
2476987|NCT03056989|Experimental|SPX-101 Low Dose|Inhalation Solution twice daily for 7 days.
2476988|NCT03056989|Experimental|SPX-101 Mid Dose|Inhalation Solution twice daily for 7 days.
2476989|NCT03056989|Experimental|SPX-101 High Dose|Inhalation Solution twice daily for 7 days.
2477060|NCT03056677|Experimental|Control|No Whey Protein
2477069|NCT03056677|Experimental|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
2477073|NCT03056677|Experimental|Modified Whey|Modified whey protein will be given
2477134|NCT03056248|Active Comparator|Lithium|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
2477141|NCT03056248|Placebo Comparator|Placebo|Patients will be identified by chart review and be explained the purpose of the study and informed consent taken
2477169|NCT03055702|Experimental|SMS group|receive a mobile phone text reminder for scheduled clinic appointment 24-72 hours before,
2477170|NCT03055702|No Intervention|Usual care group|Usual care, either telephone reminder or no reminder
2477220|NCT03055546|Experimental|Oxytocin|intranasal administration of oxytocin
2477225|NCT03055546|Placebo Comparator|Placebo|intranasal administration of placebo
2477315|NCT03054831|Active Comparator|Age 2-5 years-Before GA|The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
2477321|NCT03054831|Active Comparator|Age 2-5 years-After GA|In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
2502594|NCT02883192|Placebo Comparator|Placebo|Placebo
3158067|NCT00378131|Experimental|2|RC-1291 50mg
2475536|NCT03066791|Active Comparator|Turmeric group|"Turmeric Tablets:~Each tablet contains 1,000 mg of Turmeric (Curcuma Longa) per tablet. Dose: subjects will take 6 tablets per day, with a total daily dose of 6,000 mg.~Supplied by Sabinsa Corporation"
2475537|NCT03066791|Active Comparator|Curcumin Group|"Curcumin and Bioperine tablets:~Each tablet contains 1,000mg Curcumin + 1.25mg black pepper. Dose: subjects will take 6 tablets per day, with a total dose of 6,000mg curcumin.~Supplied by Sabinsa corporation"
2475539|NCT03066791|Placebo Comparator|Placebo Group|"Placebo tablets made to look like the turmeric and curcumin tablets~Each placebo tablet will contain: microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 6 placebo tablets per day"
2475619|NCT03066375|Experimental|Echocardiography-Doppler|Ultrasonographic recordings, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
2475650|NCT03066024||Children and adolescents|Children and adolescents for elective surgery
3192665|NCT00811005|Experimental|Fumaric acid ester -PUVA combination|"FAE monotherapy:~Patients randomized to this group will receive FAE in weekly incremental doses (initial daily dose: 30 mg dimethylfumarate (DMF), highest daily dose: 720 mg DMF) starting two weeks prior to additional PUVA treatment.~FAE-PUVA combination:~PUVA treatment will be applied thrice weekly in addition to FAE until (near) complete clearance or over a maximum period of 12 weeks. (Near) complete clearance is defined by improvement of the clinical baseline score (see below) by ≥90%.~PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation."
3192666|NCT00811031|Experimental|Taxotere + Prednisone|
2475771|NCT03065049|Experimental|Peer-PA+Fitbit|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
2475779|NCT03065049|Active Comparator|Fitbit Only|Participants will be given a Fitbit activity tracker along with brief advice for increasing physical activity.
2475785|NCT03065049|No Intervention|Usual Care|Participants do not receive any intervention but participate in the assessments only.
2475922|NCT03064360||Biomarker Testing, PROs, PRIs|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (Tnl), symptom and quality of life questionnaires, and patient metrics (activity, sleep, heart rate, heart rate variability).
2475968|NCT03063580|Experimental|SAR439954 with or without rifampicin|Period 1: single oral dose of 400 mg sotagliflozinon Day 1 morning Period 2: once-daily oral doses of 600 mg rifampicin from Days 1 to 10 and a single oral dose of 400 mg sotagliflozin
2476007|NCT03063398||Patients after acute pancreatitis|Such patients will be followed and assessed for the development of Exocrine Pancreatic Insufficiency. 'No intervention, this is an observational study.
3192667|NCT00811044||Entry|This group is just entering the study and will need to be genotyped.
2476168|NCT03062527|Experimental|Low Glycemic Index Diet|"Group consuming low glycemic index diet. Calculated glycemic index of daily diet was lower than 40. Carbohydrate- containing foods included whole rye bread, pumpernickel bread, whole oats, wheat brans, brown rice, buckwheat, vegetables (besides corn, cooked carrots, potatoes and pumpkin) and fruit such as apples, pears, grapefruits, tangerines, prunes, dried apricots and unripe bananas.~Interventions:~The experimental procedure for each participant included a 3-week low glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
2476171|NCT03062527|Experimental|Moderate Glycemic Index Diet|"Group consuming moderate glycemic index diet. Calculated glycemic index of diet was higher than 60. Carbohydrate- containing foods included wheat bread, wheat rolls, potatoes, instant oats, cornflakes, white rice, millet, boiled carrots and fruit (ripe bananas, grapes, raisins, dates, cranberry, honey and high sugar jams)~Interventions:~The experimental procedure for each participant included a 3-week moderate glycemic index diet. Between the 3-week low and moderate glycemic index diets or a moderate and low glycemic index treatment, a 14-day washout period was introduced."
2476226|NCT03061851|Experimental|conventional treatment|given conventional hypoglycemic drug treatment, the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
2476231|NCT03061851|Experimental|conventional treatment + maltose app|the patients were treated with conventional hypoglycemic drugs. The treatment plan was decided by the investigators according to the patient's condition. The intervention was not done in this study.And joint: maltose App intervention.
2476287|NCT03061591|Active Comparator|Wholistic Turmeric capsules|"Oral capsules of wholistic Turmeric capsules (Pukka herbs) (each capsule 100 mg curcumin) divided twice daily, or an identical placebo in 2 divided doses daily all taken before meals.~Pukka's Wholistic Turmeric"
2476288|NCT03061591|Placebo Comparator|Placebo|Identical placebo capsules
3192668|NCT00811044||Affected|This group has been genotyped and has the gene undergoing study at that time.
3192669|NCT00811044||Control|This group has been genotyped and does not have the gene currently under study.
2476457|NCT03060369||Established Shock (Cohort A)|"Meeting criteria i or ii, AND iii:~i. SBP ≤ 90mm Hg for greater than 30 minutes ii. Requirement for vasopressor or ionotrope to maintain SBP > 90mm Hg iii. New dysfunction of at least one organ, including altered mental status, acute renal failure (increase from baseline in serum creatinine >0.3 mg/dL or by 50%), oliguria (<0.5 mL/kg/h for >6h) , or hepatic injury (ALT, AST, or total bilirubin >2xULN)suspected by the treating physician to be caused by organ hypoperfusion"
2476459|NCT03060369||Emerging Shock (Cohort B)|"Meeting criteria i or ii, AND iii:~i. New SBP ≤ 90mm Hg for greater than 30 minutes or recurrent shorter episodes, requiring use of or clinical anticipation of the need for fluid resuscitation or vasopressor/inotropic support to maintain SBP > 90 mm Hg ii. New dysfunction of at least one organ (as defined above), including altered mental status, acute renal failure, oliguria, or hepatic injury not explained by a specific non-hemodynamic cause iii. Does not meet criteria for Established Shock"
2476534|NCT03060044|Experimental|Salmeterol/fluticasone Easyhaler|single dose of Salmeterol/fluticasone Easyhaler
2475571|NCT03066973|Experimental|Intervention group|The trial compares nulliparous pregnant in the second stage of labor instructed regarding breathing exercise with a control group that received standard care service.
2475572|NCT03066973|No Intervention|Control group|control group that received standard care service.
2475613|NCT03066388|Experimental|Pulse pressure variations|Pulse pressure variations, stroke volume, systemic arterial pressure, heart rate, and respiratory rate are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Pulse pressure variations are obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices.
2475638|NCT03066115|Experimental|NOS, COX, and ROS Inhibition|Subjects will receive L-NMMA, ketorolac, then ascorbic acid via intravenous catheter. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound.
2475642|NCT03066115|Experimental|COX, NOS, and ROS Inhibition|"Subjects will receive ketorolac, L-NMMA, then ascorbic acid via intravenous catheter.~Ketorolac will have a 0.3 mg kg-1 loading dose over 5 minutes (3.6 mg kg-1 hr-1) with a minimum loading dose of 15 mg. This will be followed by a maintenance dose of 0.03 mg kg-1 hr-1. L-NMMA will have a 3 mg kg-1 loading dose over 5-minutes (36 mg kg-1 hr-1), followed by a maintenance dose of 1 mg kg-1 hr-1. Ascorbic acid will have a loading dose of 0.035 g kg fat-free mass-1 over 5-minutes (0.42 g kg fat-free mass-1 hr-1), followed by a maintenance dose of 0.060 g kg fat-free mass-1 hr-1. Cerebral blood flow velocity will be measured throughout the drug infusions via transcranial Doppler ultrasound."
2475659|NCT03065686|Experimental|Identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
2475725|NCT03065634|Experimental|Manualized RELIANCE intervention|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions.
2475727|NCT03065634|Active Comparator|Non-manualized socio-legal counseling|two socio-legal counseling sessions delivered by a social worker
2475765|NCT03065114||PGSno.|blastocysts from patients underwent preimplantational genetic screen (PGS) prtocols. only euploid embryos were selected to transfer.
2475813|NCT03064815|Experimental|Spondylarthropathies with GI symptoms|Subjects in this arm will have spondylarthropathies and gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
2475815|NCT03064815|Experimental|Spondylarthropathies without GI symptoms|Subjects in this arm will have spondylarthropathies without gastrointestinal symptoms and will undergo a colonoscopy, videocapsule endoscopy, biomarker testing (PROMETHEUS® IBD sgi Diagnostic™ and fecal calprotectin)
2475832|NCT03064464||CA-MRSA infection|None intervention
2475833|NCT03064464||HA-MRSA infection|None intervention
2475837|NCT03064464||CA-MSSA infection|None intervention
2475907|NCT03064269|Experimental|Arm 1|CD19 CAR-T cells treated central nervous system B-cell acute lymphocytic leukemia.
2475950|NCT03063736|Experimental|Td vaccine with entolimod|Td vaccine (4 ug) + Entolimod (1 ug) (n=25)
2475952|NCT03063736|Placebo Comparator|Td vaccine only|Td vaccine (4 ug) (n=15)
2476008|NCT03063463||Pneumatic Dilation|Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation
2476010|NCT03063463||Surgical Myotomy|Subject with achalasia undergoing routine care EGD with surgical myotomy
2476091|NCT03063112|Active Comparator|Group 1( radiofrequency group )|Bilateral thoracic splanchnic nerves block will be performed by radiofrequency thermocoagulation at two level of vertebra T10 and T11 by using radiofrequency generator device and lidocaine 2% before thermal lesion
2476094|NCT03063112|Placebo Comparator|Group 2 ( alcohol group )|Bilateral thoracic splanchnic nerves block will be performed by ethyl alcohol at one level of vertebraT11 by using of C arm fluoroscopic device.
2476159|NCT03062501|No Intervention|Control (No Hydroxyurea)|Patients in VOC will be treated according to the center's usual practice and analgesia protocol.
2476162|NCT03062501|Experimental|Hydroxyurea|Patients in VOC will receive up to three daily doses of 30-40 mg / kg hydroxyurea.
2476195|NCT03062202|Experimental|Depression group|SilverCloud iCBT for depression.
2476196|NCT03062202|Experimental|Anxiety group|SilverCloud iCBT anxiety disorders.
2476198|NCT03062202|Experimental|Comorbid Depression and Anxiety group|SilverCloud iCBT for comorbid depression and anxiety.
2476271|NCT03061864|No Intervention|Standard Counseling|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology.
2476274|NCT03061864|Experimental|Periviable Birth Plan|Patients at risk of delivery between 20 and 25+6 weeks gestation will receive the normal counseling from Ob/gyn and Neonatology with completion of the written periviable birth plan.
2476311|NCT03061383|Active Comparator|8% Arginine based toothpaste|The procedure will be performed after scaling in group D1 using 8% arginine based toothpaste (Colgate Pro-relief) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2476313|NCT03061383|Active Comparator|8% Strontium acetate based toothpaste|The procedure will be performed after scaling in group D2 using 8% strontium acetate based toothpaste (Sensodyne Rapid Action) . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2476317|NCT03061383|Placebo Comparator|tooth past without active ingredient|The procedure will be performed after scaling in group D3 control group using placebo . Treatment will be done at baseline then patients will use the toothpaste at home twice per day by using soft bristled tooth brush and the given dentifrice using modified stillmans method as explained by examiner
2476357|NCT03060928|Active Comparator|Control|Arthroscopic Rotator Cuff Repair with standard treatment
2476359|NCT03060928|Experimental|Experimental 1|Arthroscopic Rotator Cuff Repair with standard treatment + biological stimulation with micro-perforations
2475678|NCT03065998|Active Comparator|Drug-A|opripramol 150 mg per day (3*50) Opipramol is a selective agonist for sigma-1 receptor. It is clinically used as an antidepressant and anxiolytic agent.
2475679|NCT03065998|Active Comparator|Drug-B|baclofen 90 mg per day (3*30) Baclofen is a GABAb-1 antagonist and has shown partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine.
2475723|NCT03065478||Colon carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult colon cancer patients who experienced a CIPN after adjuvant oxaliplatin-containing chemotherapy."
2475724|NCT03065478||Mamma carcinoma|"Dietary supplementation with OnLife to improve signs and symptoms of CIPN in adult breast cancer patients who experienced a CIPN after adjuvant paclitaxel regimen."
2475774|NCT03065127|Experimental|Cognitive Training|"Participants will independently complete cognitive exercises on the Smartbrain Pro computer software. These exercises aim to train different aspects of executive function. The difficulty level of each exercise will increase relative to each participant's progress. Sessions will last for one hour, occurring twice weekly for a period of 4 weeks."
2475782|NCT03065127|Experimental|Cognitive Behavioural Therapy|Participants will undergo one-on-one sessions of cognitive-behavioural therapy (CBT) working with a therapist to establish an individualized CBT plan which will focus on symptoms of anxiety. Participants will complete a total of eight one-hour sessions over 4 weeks.
2475786|NCT03065127|Experimental|Proprioceptive Training|Participants will complete one-on-one sessions a target matching proprioceptive training protocol using their upper and lower limbs. For the upper limb target-reaching task, participants will be seated in front of a surface marked with ten targets. They will first visualize a specified target, then blindfolded and asked to reach towards that target with the blindfold on. The blindfold will then be removed allowing participants to view their performance relative to the target. This task will be repeated for the remaining targets on both sides and for both upper and lower limbs. Participants will complete a total of eight one-hour sessions over 4 weeks.
2475841|NCT03064685||Group I - Cases|Patients older than 18 years of age with a history of liver transplantation since January 2002 for any cause and who have undergone medical follow-up at HIBA and had at least one event of pyogenic liver abscess after transplantation.
2475842|NCT03064685||Group II - Controls|Patients older than 18 years with a history of liver transplantation since January 2002 for any cause and who have performed their medical follow-up at HIBA without developing any event of pyogenic liver abscess after transplantation
2475872|NCT03064282|Placebo Comparator|Placebo|Drug free base as placebo
2475873|NCT03064282|Experimental|group two- papaverine arm|papaverine in a suitable base
2475923|NCT03063970|Experimental|Experimental Group|Wear of the tailor made Dynamic Lycra Orthosis for up to eight hours every day for eight weeks Usual rehabilitation
2475929|NCT03063970|Active Comparator|Comparison Group|Usual rehabilitation
2476041|NCT03063281||SLE patient|165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without. Biological analysis were performed.
2476043|NCT03063281||healthy patients|48 healthy patients. Biological analysis were performed.
2476064|NCT03062943|Experimental|Nintedanib 150mg BID|nintedanib soft gelatine capsules Dose: 150 mg bid Mode of admin. : Oral Duration of treatment: 1 year Duration of follow-up: 12 months after treatment discontinuation
2476103|NCT03062761|Experimental|Active product: partially hydrolysed proteins|Partially hydrolysed whey protein based infant formula containing prebiotics.
2476105|NCT03062761|Active Comparator|Control product: standard formula (intact protein)|Intact cow's milk protein based infant formula containing prebiotics.
2476138|NCT03062397|Experimental|Low-dose group|JPI-289 Low dose or placebo
2476143|NCT03062397|Experimental|High-dose group|JPI-289 High dose or placebo
2476147|NCT03062397|Placebo Comparator|Placebo group|Same dosage of JPI-289 low and high dose
2476215|NCT03061994||Cardiomyopathy|"Children(older than 18 years old) are diagnosed as cardiomyopathy by three cardiologists and recruited in pediatric heart center,Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography.~Adults are diagnosed as cardiomyopathy by three cardiologists and recruited in the department of cardiology ,Beijing Anzhen Hospital."
2476219|NCT03061994||Control|Healthy children and adults are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination.
2476282|NCT03061721|Experimental|Saroglitazar magnesium 1 mg|Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2476283|NCT03061721|Experimental|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2476284|NCT03061721|Experimental|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.
2476285|NCT03061721|Placebo Comparator|Placebos|Placebo tablet orally once daily in the morning before breakfast for 16 weeks.
2476336|NCT03061110|Active Comparator|Usual Care|Subjects in the Usual Care arm will receive typical therapies to manage the symptoms of dry mouth including but not limited to: chewing gum, sucking sugar-free candy, sipping water, mouth rinses and over-the-counter artificial saliva preparations.
2476337|NCT03061110|Experimental|Stromal Vascular Fraction|Subjects in the Stromal Vascular Fraction arm will receive single injections into each of the six (6) peri-oral salivary glands (parotid, submandibular, sublingual).
2476416|NCT03060863|No Intervention|1. Comparison|Families in this group will not receive any of the interventions.
2476418|NCT03060863|Experimental|2. Executive functioning|"Children in this arm will have the opportunity to use a computer-based working memory training game to practice recalling stimuli with an increasing number of presentations prior (n-back task)."
2476419|NCT03060863|Experimental|3. Food Bias|Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
2476420|NCT03060863|Experimental|4. Emotion Regulation|Children in this arm will use a computer-based, game-like relaxation training to teach emotion regulation and coping strategies.
2476421|NCT03060863|Experimental|5. Future orientation|Children in this arm will participate in an interview training protocol to promote their capacity to utilize and articulate a future oriented perspective.
2476480|NCT03060317||Validation group DOC|Examination with neurological scales.
2475731|NCT03065621|Experimental|Palbociclib with Endocrine Therapy|All subjects will receive palbociclib 125 mg for 4 cycles, orally, once a day, for 21 days followed by 7 days of rest (4 cycles of 28 day long). After the final rest week (therefore post cycle 4), subjects will receive 3 to 7 additional days of palbociclib, as necessary, at the same dose and posology, until the day before curative intent surgery. Depending upon the menopausal status, the patient will receive either letrozole or tamoxifen continuously during the palbociclib treatment (which consists of 4 cycles of 28 days).
3192670|NCT00811083|Active Comparator|DMSA- 1 round|Subjects receive 1 round of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 3 months of placebo
3192671|NCT00811083|Active Comparator|DMSA-7 rounds|Participants receive 7 rounds of DMSA over 4 months; each round consists of 3 days of DMSA (10 mg/kg-dose, 9 doses over 3 days), followed by 11 days off (no treatment), and then repeating.
2475827|NCT03064529|Experimental|Accelerometer Participants|All participants receive an accelerometer to wear around their wrist to measure physical activity continuously beginning 1 week before surgery (when the accelerometer is put on the wrist) and ending 2 weeks after surgery (when the accelerometer is removed from the wrist).
2475864|NCT03064386|Experimental|plate group|internal fixation with the plate
2475866|NCT03064386|Experimental|screw group|internal fixation with the screw
2475903|NCT03064074|Experimental|Stage 1 Low dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 1 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
2475909|NCT03064074|Experimental|Stage 2 High dose|"There are a total of 6 study visits within approximately a 6 month timespan. Investigators will evaluate the safety of a single administration of fresolimumab in adult patients with OI. Subjects will receive a single-dose of 4 mg/kg of fresolimumab (n=4).~At each study visit, the participant may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug"
2475914|NCT03064074|Experimental|Stage 2 Repeat dose every 6 months|"Fresolimumab will be administered every six months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
2475917|NCT03064074|Experimental|Stage 2 Repeat doses every 3 months|"Fresolimumab will be administered every three months for a total treatment period of 12 months (n=4). The dose to be administered (1 or 4 mg/kg) will be chosen after completion of Stage 1. The primary Stage 2 endpoint will be safety measures assessed over 12 months. The secondary endpoints will be changes in markers of bone remodeling, bone mineral density, estimated strength.~At each study visit, participants may have the following testing done:~Physical exam~Vitals~Blood draw for safety labs, pharmacokinetics, etc~If the participant is female, she will have a pregnancy test~EKG~DXA~Infusion of the study drug~Skeletal survey~Peripheral quantitative CT (pQCT) of the forearm~Quality of Life Surveys~Pulmonary function test~Walk test"
2475980|NCT03063658|Active Comparator|Paracetamol|Paracetamol (Paracerol) 1 gram will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
2475982|NCT03063658|Active Comparator|Ibuprofen|Ibuprofen (Intrafen) 800 mg will be administered intravenously. The first dose will be infused for 10 minutes after the induction of anesthesia and before the first surgical incision. The remaining three doses will be administered every 6 hours for postoperative 24 hours.
2476012|NCT03063307|Active Comparator|Atraumatic Restorative Treatment|
2476015|NCT03063307|Experimental|Silver Diamine Fluoride|
2476077|NCT03063008|Other|Lumbar fusion with PEEK cage|Control arm
2476082|NCT03063008|Other|Lumbar fusion with TiPEEK cage|Study arm
2476110|NCT03062657|Experimental|PRESTIGE LP|Patients receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7.
2476139|NCT03062384|Experimental|AT-001|Yeast-selenium supplement
2476142|NCT03062384|Placebo Comparator|Placebo|Yeast supplement devoid of selenium
2476239|NCT03062254|Experimental|Radium-223|
2476293|NCT03061630|Experimental|gemcitabine|cisplatin 60 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on days 1, 8 and 15. On day 1
3192672|NCT00811096|Experimental|Treatment Arm|
3192673|NCT00811096|Active Comparator|Comparator Arm|Comparator Arm
2476469|NCT03060460|Experimental|Ultrasound arm - Randomized group|Ultrasound guided sheath insertion
2476474|NCT03060460|No Intervention|Conventional arm - Randomized group|Conventional arm during randomized phase
2476481|NCT03060460|No Intervention|Historical control group|Conventional arm, non-randomization phase
2476571|NCT03059940|Experimental|Quitline (QL) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider. Participants given shared decision making and discussion about screening with the LDCT provider.~Participants referred to the Quitline for counseling and NRT (nicotine patch). Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
2476604|NCT03059303|Experimental|Part 2: Treatment Sequence G-C2|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
3192674|NCT00811109|No Intervention|Standard|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity
3192675|NCT00811109|Active Comparator|2|With Blood Volume on-line monitoring only
2475758|NCT03065296|Experimental|Musculoskeletal (MSK) Exercise Prescription|"Phase I: Residents will be surveyed as to their knowledge and confidence in both diagnosing specific musculoskeletal (MSK) issues and prescribing the correct home rehabilitation regimen.~In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.~Phase II: Residents will be surveyed again in May 2017 with the same multiple choice questions and Likert style confidence scales from phase 1~The survey will consist of multiple choice and short essay questions, focused on the most common musculoskeletal (MSK) injuries seen in the primary care setting."
2475814|NCT03064867|Experimental|V+RICE|"Venetoclax given in combination with R-ICE chemotherapy (rituximab, ifosfamide, carboplatin, and etoposide)~Phase I part of this study is a 3 + 3 design, with 3 dose levels, a minimum of 6 participants (maximum of 18) will be required to identify the recommended phase 2 dose (RP2D).~Phase II involvs two stages: In stage I, a total of 16 participants will be accrued. If there are 7 or fewer complete responses (CR), the study will be stopped. Otherwise, an additional 30 participants will be accrued in stage II.~The maximum number of treatment cycles with V+RICE is three. Participants who achieve complete remission at the interim response assessment after 2 cycles may omit cycle 3 in order to proceed to subsequent consolidation therapy with autologous stem cell transplant (AHSCT).~Participants will proceeed to other treatment including RICE, other chemotherapy, peripheral blood stemm cell collection, and ASCT per institutional guidelines."
2475962|NCT03063879|Experimental|Sovodak|Sofosbuvir 400 mg and daclatasvir 60 mg
3158068|NCT00378131|Experimental|3|RC-1291 100mg
3158069|NCT00378144|Experimental|1|Pseudoephedrine/Paracetamol
2476133|NCT03062735|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training intervention (Sham-IMT) groups during a 3 months training season. A pressure threshold device (POWERbreathe - HaB International Ltd., UK) will be used to IMT. The IMT group will perform 30 inspiratory efforts, 5 times a week, twice daily, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure (MIP).
2476134|NCT03062735|Sham Comparator|Sham Inspiratory Muscle Training|Sham-IMT group will follow a similar protocol, except the inspiratory effort that will be made against 15% MIP. The duration of each IMT session will be 30 inspirations. After the initial setting of training loads, the IMT group will be instructed to periodically increase load so that only 30 maneuvers could be completed. The Sham-IMT group will not receive these instructions. All the IMT sessions, in both groups will take place before swimming training and will be supervised throughout the intervention period to ensure that technique and load will be appropriate.
2476182|NCT03062293|Experimental|Functional Re-adaptive Exercise Device|Single arm for within subject repeated measures design.
2476272|NCT03062059|Sham Comparator|Control arm|normal saline bladder irrigaiton
2476276|NCT03062059|Experimental|Intervention arm|Intravesical 2000mg/52.6ml gemcitabine instillation during radical nephroureterectomy followed by normal saline bladder irrigation
2476373|NCT03060889|Active Comparator|Cases|Tranexamic acid 10 mg/ kg body weight will be given by intravenous infusion with induction of anesthesia in elective cesarean section for non complicated cases of placenta previa
2476380|NCT03060889|No Intervention|Controls|Control group will not receive Tranexamic acid
2476422|NCT03060681|Experimental|T group|Ultrasound guided Bilateral TLIP Block will be performed 15 minute before the start of surgery Using 15 ml of bupivacaine 0.25 for each side.
2476424|NCT03060681|No Intervention|C group|
2476465|NCT03060421||Aquamid Reconstruction|Patients that have been treated with at least one intra-articular injection of aquamid as a treatment of osteoarthritis of the knee
2476569|NCT03059667|Active Comparator|Arm A : chemotherapy|"Patients randomly assigned to the control arm will receive either:~topotecan (oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended)~or re-induction by carboplatin - etoposide chemotherapy."
2476573|NCT03059667|Experimental|Arm B : immune therapy|Patients randomly assigned to the experimental arm will receive Anti PDL1 ATEZOLIZUMAB (MPDL3280A) at a fixed dose of 1200 mg IV every three weeks until progression or unacceptable toxicity.
2476649|NCT03059199|Experimental|Single-Arm Feasibility Study|12-week, 1x/week, 90-minute face-to-face sessions.
2476702|NCT03058887|Experimental|Arm cranking|exercising for 3 months twice per week.
2476711|NCT03058887|Experimental|Cycling|exercising for 3 months twice per week.
2476718|NCT03058887|No Intervention|Control group|No exercise intervention.
2476776|NCT03058406||Eribulin mesylate|
2476799|NCT03058029|Experimental|Gelesis200|Gelesis200: Three (3) Gelesis200 capsules (2.10 gram (g)) two (2) times per day (id est (i.e.), lunch and dinner)
2476805|NCT03058029|Placebo Comparator|Placebo|Placebo: Three (3) placebo capsules two (2) times per day (i.e., lunch and dinner)
2476901|NCT03057522|Experimental|Intervention Group|This group will undergo home exercise program designed to increase their running cadence.
2476902|NCT03057522|No Intervention|Control Group|This group will not receive any intervention.
2476912|NCT03057262||Study group|Study group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the study group was used the typical acrylic anterior repositioning splint fabricated in tete-a-tete (incisal) jaws position, covered the lower teeth arch to recapture a displaced disc(s) and decrease the intensity of pain. The anterior repositioning splint was recommended to 20 - hour use for a period of four months.
2476948|NCT03057197|No Intervention|Group A|Conventional method group (n=85): caudal injection after advancement of the needle into the sacral canal. Ultrasound is used to achieve accurate needle placement and we will check intravascular injection using digital subtraction angiography.
3158070|NCT00378196|Experimental|A|0.3 mg/0.05 ml dose of ranibizumab
3158071|NCT00378196|Experimental|B|0.5 mg /0.05 ml dose of ranibizumab
3158072|NCT00378248|Experimental|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group- and individual psychotherapy
3158073|NCT00378248|Active Comparator|Outpatient individual psychotherapy|Eclectic individual psychotherapy in outpatient private practice
3158074|NCT00378365|Experimental|1|Arsenic trioxide
3158075|NCT00378404|Experimental|1|
3158076|NCT00378547|Placebo Comparator|Paracetamol|Oral paracetamol 1 g + placebo + placebo
2475811|NCT03064880|Active Comparator|SV maximization|Dynamic fluid responsiveness parameters, such as stroke volume (SV) response to fluid therapy, are precise fluid indicators that specifically determine patient volume status and are helpful for clinicians to determine the appropriate time for fluid bolus. For SV maximization, the investigators maximize SV after anesthetic induction by fluid therapy up to achieve maximized SV maintained.
2475812|NCT03064880|No Intervention|SV normalization|NO active fluid therapy.
2475868|NCT03064568|Experimental|Misoprostol 100Mcg Tab|Patients will receive misoprostol 400mcg per rectum 30 minutes preoperatively.
2475869|NCT03064568|Placebo Comparator|Placebo|Patients will receive identical inert tablets per rectum 30 minutes preoperatively.
2475904|NCT03063996|Other|Standard of Care (peripheral IV access)|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access.
2475910|NCT03063996|Active Comparator|Peripheral IJ access|Patient with a history of difficult access or a patient that currently has difficult peripheral IV access and is randomized into the group that gets peripheral IJ access.
2475966|NCT03063749||Primary Cohort|Subjects receiving stents 2.0 mm - 4.0 mm in diameter will be included in the Primary Cohort.
2475974|NCT03063749||Extra Large Vessel (XLV) Cohort.|Subjects receiving stents 4.5 mm or 5.0 mm in diameter will be included in the Extra Large Vessel (XLV) Cohort.
2476120|NCT03063151|Experimental|Study Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
2476121|NCT03063151|Experimental|Control Group|The Maximum isometric Voluntary Contraction (MVC) was measured by standard muscle testing. Then the subject sat in front of a table with his forearm resting in a comfortable position. The Hand Reaching Spatial Device (HRSD) was located at the maximal hand-reaching range of motion. Participants were requested to point on each target 5 times according to voice prompting that was activated by the EMG software every 10 seconds, for 45 pointing movements. The order of pointing targets was constant for all the participants.
2476176|NCT03062358|Experimental|pembrolizumab + BSC|Participants receive pembrolizumab by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
2476179|NCT03062358|Placebo Comparator|placebo + BSC|Participants receive placebo by intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 cycles of treatment plus BSC.
2476251|NCT03061773|Experimental|Exercise group|Exercise group: physical training lasting 12 weeks, after detraining and in the end the control group receives physical training
2476252|NCT03061773|Active Comparator|Group did not exercise|Group did not exercise: conventional hospital treatment
2476303|NCT03061487||Group I|"Patients affected by central and peripheral aneurismatic disease with maximum statin daily dose ( Atorvastatin 80 mg, Simvastatin 40 mg, Rosuvastatin 40 mg).~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
2476306|NCT03061487||Group II|"Patients affected by central and peripheral aneurismatic disease with minimum statin daily dose.~Patients will undergo Open Surgical Treatment of Aneurysm (Aneurysmectomy).~The investigation consist in:~taking a preoperative blood sample to evaluate the MMPs circulating levels~taking an aneurismatic vassel wall istological sample with an intraoperative biopsy to evaluate the tissue MMPs and miRNAs levels"
2476429|NCT03060837|Active Comparator|Patients given single lung ventilation|The first group will have single lung ventilation applied to ensure reduction. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
2476432|NCT03060837|Active Comparator|Patients given standard ventilation|This group will have standard ventilation. Preoperative Parameters : Hmg, serum creatinine levels Peroperative Parameters : Scope duration, perforation, hemorrhage, etc. complications) Postoperative parameters (stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc) Movement of kidney : Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
2476464|NCT03060278|Active Comparator|Standard Treatment|Participants randomized to Standard Treatment will receive a smartphone with active service, brief advice to quit smoking (self-help materials), an 8-week supply of nicotine replacement therapy (patches), and provided 5 proactive phone counseling sessions by a trained Certified Tobacco Treatment Specialist.
2476467|NCT03060278|Experimental|Automated Treatment|Participants randomized to Automated Treatment will receive smartphone-delivered automated treatment that will provide tailored smoking cessation treatment by way of video clips, text and graphical messages. Participants will receive notifications on study provided smartphone once a week for an 8-week treatment period. Content delivered will be specific to the participants smoking status and motivation to quit.
3192676|NCT00811109|Active Comparator|3|With Blood volume and Blood temperature on-line monitoring
2476577|NCT03059602||Knee group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total knee arthroplasty.
2476578|NCT03059602||Hip group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing total hip arthroplasty.
2476580|NCT03059602||Spine group|Caregivers who will be the primary source of assistance (medical, rehabilitative, daily living, etc) after surgery for patients undergoing Cervical/Thoracic Lumbar Spine Surgery (Discectomy, Foraminotomy, Laminectomy, Fusion, Nerve Root Decompression)
2476712|NCT03059251||Obinutuzumab|All participants with chronic lymphocytic leukemia (CLL) who have received the indication for treatment with Obinutuzumab, as per routine clinical practice in Argentina.
3192677|NCT00811148||Tissue Bank|Collection of clinical data and tumor tissue removed during brain surgeries for future research.
3192678|NCT00811161|Experimental|needle free injector of HA|
2475847|NCT03064555||Healthy participants|"Cardiopulmonary exercise test~Cardiopulmonary exercise testing will be conducted on an electronically braked cycle ergometer using a ramped protocol with participants being required to pedal until exhaustion.~Constant load exercise test~Constant load exercise will be performed for 30 min on an electronically braked cycle ergometer whilst seated in a dialysis chair. Blood sampling and echocardiogram will be measured throughout."
2475913|NCT03064243|Experimental|apatinib group|apatinib 500mg po qd
2475954|NCT03063801||Cardiac surgery|All adult patients having undergone surgery between January 2006 and December 2016 within the CHU Brugmann hospital.
2476066|NCT03062852|Experimental|Medication safety vest|During administration rounds, nurses will wear the medication safety vest.
2476069|NCT03062852|No Intervention|Control|During administration rounds, nurses will be dressed as usual without a safety vest.
2476153|NCT03062683||Non-convulsive syncope patients|Patients with a non-convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
2476157|NCT03062683||Convulsive syncope patients|Patients with a convulsive syncope triggered by a tilting table examination and whose serum lactate, prolactin and creatine kinase conc. in blood samples had been measured after the event.
2476247|NCT03062163|Experimental|Resveratrol lipoic Acid|lipoic and resveratrol was loaded on the patch
2476249|NCT03062163|Experimental|Placebo|normal saline was loaded on transdermal patch
2476369|NCT03060967|Experimental|Depressed patients|Computer-based tasks evaluating size and time discrimination capacities of food and control images
2476379|NCT03060967|Experimental|Normal Healthy Volunteers|Computer-based tasks evaluating size and time discrimination capacities of food and control images
2476437|NCT03060538|Experimental|Multiple Ascending Dose BFKB8488A|Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.
2476439|NCT03060538|Placebo Comparator|Placebo|Participants will receive BFKB8488A-matching placebo.
3158077|NCT00378547|Experimental|Paracetamol + Pregabalin|Oral paracetamol 1g + oral pregabalin 300 mg + placebo
3158078|NCT00378547|Experimental|Paracetamol + pregabalin + dexamethasone|Oral paracetamol 1g + oral pregabalin 300 mg + IV dexamethasone 8 mg
2476507|NCT03060083|Experimental|Switch to VLNC cigarettes|Participants will be instructed to use nicotine patches and gradually switch to very low nicotine content (VLNC) cigarettes throughout the study period. They will receive regular nicotine cigarettes (16.5 mg/g) during week 1, 11.26 mg/g cigarettes during week 2, 5.54 mg/g cigarettes during week 3, 2.54 mg/g cigarettes during week 4, and 0.44 mg/g cigarettes during week 5.
2476510|NCT03060083|Experimental|Reduce CPD|Participants will be instructed to use nicotine patches and gradually reduce the number of regular nicotine content cigarettes that they smoke throughout the study period. They will receive regular nicotine content cigarettes (16.5 mg/g) throughout the study study period. After establishing a baseline CPD during week 1, participants will receive 70% of their baseline CPD during week 2, 35% during week 3, 15% during week 4, and 3% during week 5. Participants will receive a minimum of 1 CPD during week 5.
2476558|NCT03059706|Experimental|RegenoGel-OSP™|
2476562|NCT03059706|Placebo Comparator|Placebo|
2476620|NCT03059407|Other|Dog therapy only|Canine assisted therapy only during echocardiogram
2476627|NCT03059407|Other|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echocardiogram
2476629|NCT03059407|Other|Standard distraction technique only|Standard distraction techniques only during echocardiogram.
2476687|NCT03058926||Chronic Pancreatitis|
2476688|NCT03058926||Diabetes|
2476689|NCT03058926||Pancreatic Cancer|
2476822|NCT03058562|Experimental|Crossover Sequence A|"Each in the fasting state:~Period 1: Single-dose matching placebo~Period 2: Single-dose ABX-1431"
2476827|NCT03058562|Experimental|Crossover Sequence B|"Each in the fasting state:~Period 1: Single-dose ABX-1431~Period 2: Single-dose matching placebo"
2476829|NCT03058562|Experimental|Crossover Sequence C|"Each with a standard high fat meal:~Period 3: Single-dose matching placebo~Period 4: Single-dose ABX-1431"
2476832|NCT03058562|Experimental|Crossover Sequence D|"Each with a standard high fat meal:~Period 3: Single-dose ABX-1431~Period 4: Single-dose matching placebo"
2476929|NCT03057639||Observational (questionnaires)|Patients complete questionnaires at referral, week 4-8, week 10-12, and at the completion of systemic therapy.
2477012|NCT03057054|Experimental|Arm I (Lactobacillus plantarum, alloHCT)|Patients receive Lactobacillus plantarum strains 299 and 299v PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
2477015|NCT03057054|Placebo Comparator|Arm II (placebo, alloHCT)|Patients receive placebo PO or through NJ, NG or G tube QD on day 1 of transplant conditioning regimen to 56 days post alloHCT. Patients undergo alloHCT at day 0.
2477167|NCT03055663|Experimental|Virtual reality sedation|Patients watches virtual reality sedation program that shows underwater world with comfortable music and narrations during surgery.
2477168|NCT03055663|Active Comparator|Sedation with intravenous sedatives|Patients receives intravenous sedative of midazolam (initial bolus 1-2 mg with maintenance dose of 1 mg every 10 - 30 min).
2477775|NCT03051776|Experimental|Kinesio Taping|It was done a four week phase with Kinesio Taping in the arm affected with lymphedema.
3158079|NCT00378612|Experimental|Cypher® sirolimus eluting coronary stent|All pts were given the Cypher sirolimus eluting coronary stent in this open-label, single-arm, non-randomized trial
3158080|NCT00378664|Experimental|Intervention|All enrollees are included in the intervention - lumbar to sacral ventral nerve re-routing procedure surgical nerve re-routing procedure.
3158081|NCT00378690|Active Comparator|Continuous Androgen Deprivation (CAD)|
3158082|NCT00378690|Experimental|Intermittent Androgen Deprivation (IAD)|
3158083|NCT00378716|Active Comparator|Group 1|5-FU + Leucovorin
3158084|NCT00378716|Experimental|Group 2|Uracil/Ftorarur + leucovorin
3158085|NCT00378729|Active Comparator|A|
3158086|NCT00378729|Active Comparator|B|
2475883|NCT03064347|Active Comparator|Enteric Coated Pea Protein|200kcal pea protein in enteric coating as single dose
2475885|NCT03064347|Placebo Comparator|Non-Enteric Coated Pea Protein|200kcal pea protein with separate enteric coating materials as single dose
2475967|NCT03063840|Experimental|Microwave ablation (MWA)|Microwave ablation (MWA)
2476019|NCT03063411|Experimental|Executive function intervention|The intervention comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks requiring working memory and inhibitory control. These tasks are child friendly and are based on established measures of executive function. The working memory tasks involve maintaining information in mind and processing information (for example, finding items hiding in different locations that move around) and suppressing a dominant but incorrect response (for example, a game where children try to catch fish but not sharks). Children receive feedback on their responses. If children score 75% or more correct in a session the difficulty level increases in the following session.
2476024|NCT03063411|Active Comparator|Visual search and simple decision making|The control task program, like the intervention, comprises four weekly sessions lasting 15-20 minutes. In these sessions, children complete computerised tasks not requiring executive function skills. Instead, they require simple attention and decision making skills and visual search skills. For example, finding an item among distractors (e.g., a spaceship), or deciding which of two animals can fly (out of a bird and a fish). Children receive feedback on their responses.
2476108|NCT03063060||total thyroidectomy|patients who underwent total thyroidectomy with available vitamin D levels before surgery, as well as pre and post-operative PTH and calcium levels.
2476164|NCT03062462|Active Comparator|clopidogrel|To observe double standard-dose clopidogrel on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
2476165|NCT03062462|Experimental|ticagrelor|To observe low-dose of ticagrelor on platelet aggregation in clopidogrel resistance's patients with coronary heart disease
2476270|NCT03061916|Experimental|Cinnamon|20% cinnamon will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving cinnamon 20%
2476275|NCT03061916|Experimental|Ginger|20% ginger will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving ginger 20%
2476277|NCT03061916|Active Comparator|Chlorhexidine|Chlorhexidine gluconate 0.2%,will be given after collection of saliva (baseline) and samples will be taken after 30 minutes , one hour and two hours of giving chlorhexidine.
2476319|NCT03061344|Experimental|liquid buccal mucosa graft|DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
2476366|NCT03061045|Experimental|Contrast Enhanced Brain Ultrasound|Neonates with post-hemorrhagic hydrocephalus recruited for this study will all undergo contrast enhanced ultrasound examination of the head, a diagnostic intervention for the study.
2476410|NCT03060707|Experimental|Continuous infusion|The group of participants who are designated to receive continuously infused rocuronium.
2476414|NCT03060707|Active Comparator|Bolus administration|The group of participants who are designated to receive bolus administered rocuronium.
3192679|NCT00811200|Active Comparator|1: Lucentis|
2476543|NCT03059732||Thailand|Thai patients who diagnosed gastric cancer
2476548|NCT03059732||Japan|Japanese patients who diagnosed gastric cancer
2476674|NCT03058939|Experimental|Paclitaxel|Investigators plan to treat patients with paclitaxel weekly for a total of approximately 16 weeks (8 weeks before ultrasonography for response assessment and 8 weeks before surgery in good responders). Paclitaxel 80mg/m2 will be given on days 1, 8, 15 and so on for a total of 8 doses.
2476677|NCT03058939|Other|Carboplatin|After first 8 weeks of paclitaxel, those with progressive disease (based on breast US assessment) or partial response but inoperable will have carboplatin added to their regimen. Patients will receive 8 cycles of weekly paclitaxel and carboplatin (PC).
2476680|NCT03058939|Other|Fluorouracil Epirubicin Hydrochloride Cyclophonsphamide (FEC)|Patients with poor response to 8 courses of paclitaxel followed by 8 courses of PC based on ultrasound assessment will be regarded as failing to respond to treatment. These patients will receive 4 cycles of 3-weekly FEC and will be followed up.
2476683|NCT03058939|Other|LHRH (luteinizing hormone-releasing hormone)|All Premenopausal patients will receive LHRH agonist for two years for contraception and fertility preservation.
2476685|NCT03058939|Other|Tamoxifen or letrozole|Hormone-receptor positive patients will receive hormonal therapy with tamoxifen or letrozole after surgery, radiotherapy and LHRH agonist according to the expression of hormone receptors and according to the state of primary menopause at the onset of the study.
2476686|NCT03058939|Other|Herceptin SC and Perjeta|Patients with HER2-positive disease (see glossary and section 10.3) will receive 5 three-weekly courses of trastuzumab (Herceptin SC) with pertuzumab (Perjeta). After that pts will continue receiving trastuzumab to complete total of 18 doses within 1 year of treatment.
2476745|NCT03058302|Experimental|Full CETA|Full CETA participants will complete 12 CETA sessions. this is the same version of CETA that has been tested in other sites. They will be monitored weekly for clinical purposes (symptoms and safety) during treatment. they will also receive monthly research assessments (research outcomes) for 6 months after baseline assessment and commencement of treatment.
2476746|NCT03058302|Experimental|Brief CETA|Brief CETA participants is a new shorter version of CETA that has the same content as Full CETA but provided in fewer sessions. Each participant will complete 5 CETA sessions and will be monitored weekly for clinical purposes (symptoms and safety) during treatment and thereafter monthly for research purposes (research outcomes) for 6 months after baseline assessment and commencement of treatment.
2476748|NCT03058302|No Intervention|Wait-Control|Wait-control participants will undergo monthly monitoring after enrollment in the study for research purposes (research outcomes) for 6 months after baseline assessment.
2476812|NCT03058159|Other|Subjects with a high dream recall frequency|
2476815|NCT03058159|Other|Subjects with a law dream recall frequency|
3192680|NCT00811200|Active Comparator|2: Kenalog|
3192681|NCT00811200|Sham Comparator|3: No treatment|
2475925|NCT03063983|Experimental|Maintenance therapy|104 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP
2475930|NCT03063983|No Intervention|Control|31 weeks of MAP
2475961|NCT03063645|Experimental|Group ABC|AC-1202, AC-SD-01 (50g), AC-SD-01 (75g)
2475963|NCT03063645|Experimental|Group BCA|AC-SD-01 (50g), AC-SD-01 (75g), AC-1202
2475964|NCT03063645|Experimental|Group CAB|AC-SD-01 (75g), AC-1202, AC-SD-01 (50g)
2476031|NCT03063359|Experimental|Intranasal fentanyl + Oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
2476033|NCT03063359|Active Comparator|Oral morphine + Intranasal placebo|Administration of oral morphine (0.4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
2476112|NCT03062982|Experimental|Group A|Administration of 120mg in fed state in Dosing Period 1 followed by administration of 120mg in fasted state in Dosing Period 2
2476114|NCT03062982|Experimental|Group B|Administration of 120mg in fasted state in Dosing Period 1 followed by administration of 120mg in fed state in Dosing Period 2
2476131|NCT03062436|Experimental|Sustained molecular remission|Patients of CML who remain in sustained molecular remission at 12 months after Stopping the standard drug therapy
2476192|NCT03062319|Active Comparator|Dual-therapy group|Dual-therapy group: single anticoagulant drug and single antiplatelet drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
2476194|NCT03062319|Active Comparator|Single-therapy group|Single-therapy group: single anticoagulant drug. The dosage is determined according to each drug's package insert in Japan. In patients treated with warfarin, the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years is recommended according to the Japanese guidelines.
2476212|NCT03061929||Undernourised|Mother's with BMI less than 18.5
2476213|NCT03061929||Normally Nourished|Mother's with BMI greater than or equal to 18.5 to less than or equal to 25.
2476218|NCT03061929||Overnourished|Mother's with BMI over 25 to less than or equal to 35.
2476286|NCT03061682|Experimental|Add on lens|
2476321|NCT03061292|Experimental|Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation with pectoral nerve block
2476323|NCT03061292|Sham Comparator|Without Pectoral Nerve Block|Patients undergoing cardiac implantable electronic device implantation with local anaesthesia and sedation without pectoral nerve block
2476375|NCT03060941|Experimental|Group 1|Physical activity education
2476381|NCT03060941|Experimental|Group 2|Physical activity education and facility access
2476383|NCT03060941|Experimental|Group 3|Physical activity education and supervised exercise sessions
2476385|NCT03060941|Experimental|Group 4|Physical activity education and self-monitoring (Fitbit)
2476386|NCT03060941|Experimental|Group 5|Physical activity education and active living counseling
2476388|NCT03060941|Experimental|Group 6|Physical activity education, facility access, and supervised exercise sessions
2476390|NCT03060941|Experimental|Group 7|Physical activity education, facility access, and self-monitoring (Fitbit)
2476391|NCT03060941|Experimental|Group 8|Physical activity education, facility access, and active living counseling
2476394|NCT03060941|Experimental|Group 9|Physical activity education, supervised exercise sessions, and self-monitoring (Fitbit)
2476395|NCT03060941|Experimental|Group 10|Physical activity education, supervised exercise sessions, and active living counseling
2476396|NCT03060941|Experimental|Group 11|Physical activity education, self-monitoring (Fitbit), and active living counseling
2476397|NCT03060941|Experimental|Group 12|Physical activity education, facility access, supervised exercise sessions, and self-monitoring (Fitbit)
2476399|NCT03060941|Experimental|Group 13|Physical activity education, facility access, supervised exercise sessions, and active living counseling
2476401|NCT03060941|Experimental|Group 14|Physical activity education, facility access, self-monitoring (Fitbit), and active living counseling
2476402|NCT03060941|Experimental|Group 15|Physical activity education, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
2476403|NCT03060941|Experimental|Group 16|Physical activity education, facility access, supervised exercise sessions, self-monitoring (Fitbit), and active living counseling
2476492|NCT03060239|Experimental|Experimental arm|Patients with Parkinson's disease with severe REM sleep behaviour disorder according to International Classification of Sleep Disorders (ICSD2) criteria.
2476560|NCT03059862|Experimental|Low-tryptophan diet and L-tryptophan.|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + L-tryptophan supplements (3 g/day).
2476563|NCT03059862|Placebo Comparator|Low-tryptophan diet and placebo|Standardized low-tryptophan diet (500-1000 mg of L-tryptophan and 1800 kcal) + placebo.
2476592|NCT03059329||Fycompa-treated epilepsy participants|Adult epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
2476654|NCT03059147|Experimental|SF1126 + Nivolumab|SF1126 900-1100 mg/m2 IV twice weekly + Nivolumab 240 mg IV every 2 weeks
2476691|NCT03058770|Experimental|sensorimotor retraining program|Fifteen 40-minute sensorimotor retraining sessions will be provided over a 5-week period.
2476700|NCT03058770|Active Comparator|Relaxation technique|Subjects will perform fifteen 40-minute relaxation sessions over a 5-week period.
2476770|NCT03058497|Active Comparator|Temperature-Controlled Laminar Airflow Device Active|Temperature-Controlled Laminar Airflow Device
2476773|NCT03058497|Placebo Comparator|Temperature-Controlled Laminar Airflow Device Placebo|Temperature-Controlled Laminar Airflow Device
2476781|NCT03058055|Placebo Comparator|Placebo|Usual lifestyle activities
2476782|NCT03058055|Experimental|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
2476783|NCT03058055|Experimental|Reading|Daily reading (out loud into a voice recorder) for one hour
2476834|NCT03057938|Experimental|18F-Florbetaben (FBB)|18F-Florbetaben
2475934|NCT03063918|Experimental|Supportive Care (personalized dietary intervention)|At 6 months after standard of care treatment, patients receive 10 sessions of personalized dietary intervention over 30 minutes each over 4 months via the telephone. Patients also receive a workbook including reference materials and intervention content.
2476000|NCT03063554|Active Comparator|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement. EUS via either stomach or duodenum.
2476003|NCT03063554|Placebo Comparator|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement only.
2476042|NCT03063190|Placebo Comparator|Hyperparathyroidism_0|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
2476044|NCT03063190|Active Comparator|Hyperparathyroidism_1|Chronic Kidney Disease patients with parathyroid hormone higher than 300pg/ml
2476047|NCT03063190|Placebo Comparator|Adynamic_0|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
2476051|NCT03063190|Active Comparator|Adynamic_1|Chronic Kidney Disease patients with parathyroid hormone lower than 150pg/ml
3192682|NCT00811213|Experimental|1|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
3192683|NCT00811213|Active Comparator|2|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
3192684|NCT00811226||Patients|Patients with arterial hypertension Stade I or Stade II
3192685|NCT00811239|Other|control group|As the antivenom was not yet clinically available until 2006, all patients included during the first two years (2004-2005) received supportive therapy only.
3192686|NCT00811239|Active Comparator|antivenom group|The patients included during the third year (2006) were treated with antivenom therapy and supportive care.
2476185|NCT03062345|Experimental|Single-User Mode first, Multi-User Mode second|
2476187|NCT03062345|Experimental|Multi-User Mode first, Single-User Mode second|
2476292|NCT03061708|Experimental|AZD2014 50mg BD continuous schedule of a 28 day cycle|AZD2014 50mg BD continuous schedule of a 28 day cycle
3192687|NCT00811265|Experimental|Simulated ExAblate MRgFUS|Patients undergoing simulated ExAblate MRgFUS device use
3192688|NCT00811278||step1|asthma patients on step 1 therapy
3192689|NCT00811278||step 2|asthma patients on step 2 therapy
3192690|NCT00811278||healthy|non-asthmatics
2476663|NCT03059069|Experimental|Glitamin|800mg/day
2476665|NCT03059069|Placebo Comparator|Placebo|same shape, color, size tablet as Glitamin
2476720|NCT03058718|Experimental|Procalcitonin-guided antibiotic treatment group|"Patients were divided into 2 subgroups:~No infection group (including patients with procalcitonin<0.1 ng/ml at enrollment, and patients with 0.1 ng/ml ≤procalcitonin ≤0.25 ng/ml at enrollment who are with stable respiratory and hemodynamics, and without serious complications) : the group is not given the application of antibiotics.~Infection group (including patients with procalcitonin>0.25 ng/ml at the time of enrollment, and patients with 0.1 ng/ml ≤ procalcitonin≤0.25 ng/ml at enrollment who have severe disease, unstable hemodynamics, and severe complications or intensive care unit treatment): the group is given the application of antibiotics. According to the guidelines for severe sepsis / septic shock treatment, the standard for discontinuation of antimicrobial agents: If the procalcitonin level falls below <0.1 ng/ml or more than 80%, compared with the baseline before enrollment, it is recommended to discontinue the antimicrobial agent."
2476724|NCT03058718|Active Comparator|Standard antibiotic therapy group|The application of antibiotics is given to patiens according to the doctor's experience.
2476740|NCT03058510||Stable CAD Patients|Stable CAD patients with calcified bifurcation lesion
2476813|NCT03058198|Experimental|High Grade Glioma|"We plan to perform PET scanning on the patients with high grade gliomas after the injection of the second generation of EGFR tracer ,89Zr-ABT806（1-2mCi）, which can be specifically binded to EGFR vⅢ . After fusing the PET and MRI images, we precisely obtained the tissue from thehot-spot on the PET image through multimodal-neuronavigation-guided tumor biopsy. EGFRvⅢ status was detected by Sanger sequencing to analyze the correlation with the 89Zr-ABT806 PET image qualitatively and quantitatively. The final goal was to detect EGFR vⅢ by noninvasive molecular imaging procedure for the clinical outcome prediction and the selection of EGFR-targeted therapies."
2476870|NCT03057808|Experimental|Gestational weight gain intervention (GWG-only)|The GWG intervention will begin upon randomization to the GWG-only or the GWG+PPWL arm, and continue until the birth of the participant's child.
2476874|NCT03057808|Experimental|Postpartum weight loss intervention (PPWL-only)|The PPWL intervention will begin at 6-weeks postpartum (when most women will be approved for weight loss and exercise by their obstetrician) for those participants randomized to the PPWL only or the GWG+PPWL arms, and will continue until 6-months postpartum.
2476876|NCT03057808|Experimental|Combined|During the gestational phase participants will receive the same intervention as the GWG only group. During the postpartum phase participants will receive the the same intervention as the PPWL group.
2476942|NCT03057444|Experimental|Intervention group|"The patients get 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.~Study examinations are before intervention, after 4 weeks and 8 weeks. Stool samples are collected before intervention and each 14 days consecutively until the end of intervention."
2477029|NCT03057028|Experimental|anakinra|Patients will be treated with anakinra, injected SQ daily in a dose of 100mg for 14 days. Before and after this intervention, patients will undergo cardiopulmonary exercise testing (as well as echocardiography, EKG analysis, and serologic analysis). Subjects will be assessed for changes in exercise capacity, as determined by peak oxygen uptake and ventilatory efficiency to CO2 production slope.
2477051|NCT03056495|Experimental|Investigational drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat) capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
2477096|NCT03056326|Experimental|CHF6333 Active|
2477097|NCT03056326|Placebo Comparator|Placebo|
2477204|NCT03055884|Experimental|active tDCS with repeated retrieval practice|active tDCS with verbal paired-associate learning task with repeated retrieval practice
2477207|NCT03055884|Experimental|active tDCS without repeated retrieval practice|active tDCS with verbal paired-associate learning task without repeated retrieval practice
2477209|NCT03055884|Sham Comparator|Sham tDCS with repeated retrieval practice|sham tDCS with verbal paired-associate learning task with repeated retrieval practice
2475942|NCT03063762|Experimental|Escalation Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|Participants will receive RO6874281 in combination with atezolizumab and bevacizumab until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.
2475943|NCT03063762|Experimental|Extension Part (Arm A): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
2475944|NCT03063762|Experimental|Extension Part (Arm B): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once a week for 4 weeks followed by once every 2 weeks afterwards until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
2475945|NCT03063762|Experimental|Extension Part (Arm C): Atezolizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: no new participants are being enrolled in the arm at this time."
2475946|NCT03063762|Experimental|Extension Part (Arm D): Atezolizumab, Bevacizumab, RO6874281|"Based on the maximum tolerated dose or recommended dose as determined in the dose-escalation part, participants will receive RO6874281 in combination with atezolizumab and bevacizumab once every 3 weeks until disease progression, unacceptable toxicities, or withdrawal of consent, or as long as the participant experiences clinical benefit, or if the participant has CR, treatment may be discontinued and reintroduced if PD, for a maximum duration of 24 months.~Note: Arm D is closed for future enrollment"
2476056|NCT03063177|Experimental|1840Newtons/s(N/s);125ms;250 Newtons(N)|Participants will receive a spinal manipulative therapy of 20 Newtons (N) preload leading to a peak force of 250N over 125ms (rate of force application of 1840N/s).
2476057|NCT03063177|Experimental|920N/s;125ms;135N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 135N over 125ms (rate of force application of 920N/s).
2476059|NCT03063177|Experimental|920N/s;250ms;250N|Participants will receive a spinal manipulative therapy of 20N preload leading to a peak force of 250N over 250ms (rate of force application of 920N/s).
2476062|NCT03063177|No Intervention|control|Spinal stiffness will be assessed at each sesssion, however, participants won't receive any spinal manipulative therapy.
2476068|NCT03062839|Experimental|Melatonin|Melatonin 5 mg taken 30 minutes before bed time
2476071|NCT03062839|Placebo Comparator|Placebo|Placebo identical to melatonin capsule taken 30 min before bed time
2476155|NCT03062670|Experimental|Retreat|A full day off-site training session
2476161|NCT03062670|No Intervention|Control|Care teams normal process
2476202|NCT03062098|Experimental|IVF patients|IVF patients before embryo transfer. Before performing embryo transfer in the routine manner, ten patients will be asked to participate in the study. After signing informed consent, participants will undergo the experimental procedure: Speculum will be placed to visualize the cervix. The thin ultrasound probe will be places posterior to the cervix. While viewing the image on the ultrasound screen, the probe will be moved manually to obtain the best imaging of the cervical canal. An empty embryo transfer catheter will be introduced to the cervical canal and will be advanced under ultrasound imaging up to the internal os. The catheter will be withdrawn, and routine embryo transfer will follow.
2476216|NCT03061799|Experimental|HPC-03|"To experimental arm randomly assigned, HPC-03 will administrated twice a day , two capsules each time (total dose of HPC-03: 2g/day) for 12 weeks (84days).~*(HPC-03: extracts of angelica gigas nakai, cnidium rhizome, and cinnamon bark.)"
2476220|NCT03061799|Placebo Comparator|Placebo|To control arm randomly assigned, placebo will administrated twice a day , two capsules each time for 12 weeks (84days).
2476269|NCT03061656|Experimental|High risk neuroblastoma|"Conventional chemotherapy (9 cycles)~Surgery conventional chemotherapy (after 6 cycles of chemotherapy)~Tandem HDCT/autoSCT~First HDCT (cyclophosphamide, etoposide, carboplatin)~Second HDCT (high-dose 131I-MIBG, thiotepa, melphalan)~Local radiotherapy~Retinoic acid, interleukin-2"
2476322|NCT03061357|Experimental|Activity tracker group|Participants in intervention arm were provided with a small and lightweight activity tracker, Misfit Flash (Misfit Wearables Co., Burlingame, CA), that can be worn with a clasp or watch band. A handout detailing the step-by-step instructions for utilizing the activity tracker with Misfit App on their smartphone was provided. There was no intervention component mandated in the curriculum of intervention PAIP courses; rather, participants were continuously encouraged by the instructors to track their activity levels and use all the features in Misfit App on a daily basis as they learned health benefits of PA and as to how to develop individualized, life-long PA plan during the course of semester.
2476324|NCT03061357|No Intervention|Control group|Participants in control arm did not receive any additional instructions other than the scheduled class activities based on the standardized core-curriculum of PAIP
2476345|NCT03061019|Active Comparator|Myofunctional Oral Exercices|Parents and participants of this group will receive instructions for nasal and oral myo-functional exercises, to perform at home each day, for 5 to 10 minutes. A booklet (measure of adherence) and an Phone application for Android/Apple with descriptions/videos of those exercices will be given to them. These exercises will include nasal hygiene procedures, nasal cartilage exercices, lingual posture rehabilitation exercises, lip tone enhancement exercises, and swallowing rehabilitation exercises.
2476361|NCT03061240|Experimental|Postoperative patients|We recruit postoperative patients who undergo open surgery and are not receiving local anesthesia. We install a smart pain assessment tool on patient's skin to capture different type of data.
3192691|NCT00811291|Placebo Comparator|1|
2475976|NCT03063671|Active Comparator|bupivacine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% as one shot 15 minutes before general anesthesia postoperative analgesia done by infusion of bupivacaine 0.125% (5ml/hour through thoracic epidural catheter for 12 hours).
2475983|NCT03063671|Active Comparator|ketamine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus ketamine in a dose 0.5 mg/kg 15 minutes before general anesthesia postoperative analgesia will be preformed by infusion of mixture of (bupivacaine 0.125% plus ketamine 0.5 mg/ml ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours
2475989|NCT03063671|Active Comparator|dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus dexmedetomidine in a dose 1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
2475995|NCT03063671|Active Comparator|ketamine-dexmedetomidine group|preoperative insertion of thoracic epidural at T4-5 and adminstration of 12 ml bupivacine 0.125% plus both ketamine in a dose 0.3 mg/kg and dexmedetomidine in a dose 0.1 ug/kg 15 minutes before general anesthesia Postoperative analgesia will be performed using infusion of mixture of (bupivacaine 0.125% plus dexmedetomedine 2μg/ ml and and ketamine 0.5 mg/ml) in a rate of 5ml/hour through thoracic epidural catheter for 12 hours.
2476009|NCT03063320|Active Comparator|Low Spice|The test meal (~1200kcal and 44g fat) will contain ~0.6g of spice blend
2476011|NCT03063320|Experimental|Moderate Spice|The test meal (~1200kcal and 44g fat) will contain ~3.7g of spice blend
2476014|NCT03063320|Experimental|Culinary Spice|The test meal (~1200kcal and 44g fat) will contain ~7.4g of spice blend
2476087|NCT03063073|Placebo Comparator|Group I (Bupivacaine group)|ultrasound guided modified Pec's block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles and 20 ml between the Pectoralis minor muscle and the serratus muscle
2476089|NCT03063073|Active Comparator|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine Injection [Precedex] (1 µg/kg) divided into 20 ml injected between the pectoralis muscles and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.
2476173|NCT03062566||Severe TBI patients|GCS 3-8
2476256|NCT03062150|Placebo Comparator|Placebo+Placebo|Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.
2476260|NCT03062150|Active Comparator|Fludrocortisone+Placebo|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH."
2476264|NCT03062150|Active Comparator|Placebo+D-Cycloserine|"Placebo: pill, 8mm, single dose, Lichtenstein, Winthrop Arzneimittel GmbH.~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
2476267|NCT03062150|Active Comparator|Fludrocortison+D-Cycloserine|"Fludrocortisone: pill, Astonin H 0,1gm, single dose, Merck Serono GmbH~D-Cycloserine: capsule, Cycloserine 250mg, single dose, King Pharmaceuticals Ltd"
2476294|NCT03061396|Experimental|Electroacupuncture Single point|Single point PC6 means there is only one acupoint to be chosen: Neiguan(PC6)
2476296|NCT03061396|Experimental|Electroacupuncture Matching points|There are three acupoints to be chosen:Bilateral Neiguan(PC6)and Zhongwan(CV12)
3192692|NCT00811291|Active Comparator|2|folic acid and B-vitamin supplement
2476490|NCT03060135|No Intervention|No Intervention: Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
2476494|NCT03060135|Active Comparator|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2476496|NCT03060135|Experimental|Hello Sunday Morning|Internet based program designed to assess drinking patterns, and support self-determined goals for abstinence, by providing users with an online platform and community to discuss progress and goals.
2476545|NCT03059797|Experimental|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
2476550|NCT03059797|Placebo Comparator|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
2476614|NCT03059381||Fycompa-treated epilepsy participants|Adolescent epilepsy participants with partial-onset seizures (with or without secondary generalized seizures) or primary generalized Tonic-clonic seizures who receive long-term treatment with Fycompa
2476706|NCT03059030|Experimental|Subjects with thrombocytopenia secondary to cirrhosis|Evaluate the safety and efficacy of 90Y radioembolization for the management of thrombocytopenia.
2476755|NCT03058536|Active Comparator|Progesterone|400 mg micronized vaginal progesterone daily from randomization to 36 weeks
2476759|NCT03058536|Active Comparator|Arabin Pessary and Progesterone|"Arabin Pessary and Natural Micronized Progesterone~400 mg micronized vaginal progesterone daily from randomization to 36 weeks~The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) in combination with vaginal progesterone."
2476760|NCT03058536|Active Comparator|Arabin Pessary|The device will be placed at randomization and will be removed during the 36th week of gestacional (or earlier if indicated) without vaginal progesterone use.
2476763|NCT03058536|No Intervention|No intervention|Expectant management
2476826|NCT03058003||Patients|subjects suffering from chronic pain undergoing Posturography Evaluation and Central Sensitization Inventory
2476830|NCT03058003||Healthy|subjects self assessed to be in good health undergoing Posturography Evaluation and Central Sensitization Inventory
2476969|NCT03057314|Experimental|Amorphous calcium carbonate|"The investigation product will include:~ACC tablets, containing 200 mg elemental calcium~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
2477013|NCT03056911||ozone|Chemonucleolysis by ozone therapy Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy. Written informed consent was obtained from all participants.
2503928|NCT02873897|Other|"Group meals on wheels at home"|
3192693|NCT00811304||US group|All patients admitted to the labor and delivery suite who request an epidural for labor analgesia.
2475996|NCT03063606|Active Comparator|Naltrexone/bupropion (NB) (on-going from acute stage)|Participants will continue acute blinded pharmacotherapy (consisting of either naltrexone/bupropion combination or placebo), but without added cognitive-behavioral therapy.
3192694|NCT00811330|Experimental|1: Atorvastatin 80 mg.|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
3192695|NCT00811330|No Intervention|2: No Atrovastatine|
2476065|NCT03062878||Breast Cancer/Lymphoma Patient|Breast cancer or lymphoma patients currently undergoing anthracycline-based chemotherapy treatment. Patients are eligible if they have completed at least 1 cycle of chemotherapy. Free of known clinical cardiovascular disease.
2476067|NCT03062878||Breast Cancer/Lymphoma Survivor|Individuals with history of breast cancer or lymphoma (1-5 years removed from last date of chemotherapy) who have a treatment history of anthracycline-based chemotherapy. Free of known clinical cardiovascular disease.
2476070|NCT03062878||Control|Individuals with no history of caner or chemotherapy. Free of known clinical cardiovascular disease
2476145|NCT03062514|Experimental|Experimental|Subjects'Vagus Nerve stimulator is on always
2476151|NCT03062514|Sham Comparator|Control|Subjects'Vagus Nerve stimulator is off from enrollment to 3 month
2476199|NCT03062215|Experimental|Space from depression|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions depression. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page. Also, users have a supporter, who will give feedback asynchronously (D Richards et al., 2015). Research on the SilverCloud interventions has yielded significant clinical outcomes (D Richards et al., 2015).
2476200|NCT03062215|No Intervention|Control Group|Waiting list
3192696|NCT00811343|Experimental|1|
3208656|NCT00976872|Active Comparator|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
2476491|NCT03060148|Active Comparator|Spinal cord stimulation|Medtronic neurostimulation system for spinal cord stimulation
2476493|NCT03060148|No Intervention|Control|No implantation of Medtronic neurostimulation system
2476516|NCT03059823|Experimental|Dose Escalation-Q2W|INCMGA00012 treatment once every 2 weeks.
2476517|NCT03059823|Experimental|Dose Escalation- Q3W|INCMGA00012 treatment once every 3 weeks.
2476519|NCT03059823|Experimental|Dose Escalation- Q4W|INCMGA00012 treatment once every 4 weeks.
2476520|NCT03059823|Experimental|Expansion Cohort|INCMGA00012 treatment for locally advanced or metastatic solid tumors.
2476593|NCT03059303|Experimental|Part 1: Treatment A: FDC [SMV(75mg)+ODV(25mg)+AL-335(800mg)]|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as a fixed-dose combination (FDC) tablet (G008 formulation) after a standardized breakfast on Day 1.
2476594|NCT03059303|Experimental|Part 1: Treatment B: FDC [SMV(75mg)+ODV(12.5mg)+AL-335(800mg)]|Participants will receive single oral dose of SMV 75 mg, ODV 12.5 mg, and AL-335 800 mg, given as an FDC tablet (G007 formulation) after a standardized breakfast on Day 1.
2476595|NCT03059303|Experimental|Part 1: Treatment C: Simeprevir, Odalasvir, and AL-335|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents after a standardized breakfast on Day 1.
2476596|NCT03059303|Experimental|Part 1: Treatment D: Lansoprazole + FDC [SMV+ODV+AL-335]|Participants will receive 30 mg lansoprazole once daily in the morning under fasted conditions on Days 1 to 4, and together with a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast, which is served 2 hours after lansoprazole dosing, on Day 5.
2476597|NCT03059303|Experimental|Part 1: Treatment E: Omeprazole + FDC [SMV+ODV+AL-335]|Participants will receive 20 mg omeprazole once daily in the morning immediately before a (non-standardized) breakfast on Days 1 to 4, and immediately before a standardized breakfast and within 1 hour before a single oral dose of an FDC containing 75 mg SMV, 25 mg ODV, and 800 mg AL-335 (G008 formulation) after a standardized breakfast on Day 5. Treatment E will only be started in case a drug-drug interaction (DDI) is observed for Treatment D.
2476598|NCT03059303|Experimental|Part 2: Treatment Sequence A2-F|Participants will receive single oral dose of simeprevir (SMV) 75 milligram (mg), odalasvir (ODV) 25 mg, and AL-335 800 mg, given as an FDC (Treatment A2 - G008 formulation) on Day 1 of Period 1, and then single oral dose of SMV 75 mg, ODV 25 mg, and AL-335 800 mg, given as an FDC (Treatment F - G012 formulation) on Day 1 of Period 2, under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476599|NCT03059303|Experimental|Part 2: Treatment Sequence F-A2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment A2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476600|NCT03059303|Experimental|Part 2: Treatment Sequence C2-F|Participants will receive single oral dose of 75 mg SMV, 25 mg ODV, and 800 mg AL-335, given as 3 single agents (Treatment C2) on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476601|NCT03059303|Experimental|Part 2: Treatment Sequence F-C2|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment C2 on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476602|NCT03059303|Experimental|Part 2: Treatment Sequence C2-G|Participants will receive Treatment C2 on Day 1 of Period 1 and then 2 tablets of SMV 37.5 mg, ODV 37.5 mg, and AL-335 400 mg, given as FDC (Treatment G - G013 formulation) on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476646|NCT03059186|Experimental|Intervention|Online daily gratitude journal.
2476648|NCT03059186|No Intervention|Control|
3208657|NCT00976872|Placebo Comparator|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
3208658|NCT00976885||Subjects with normal health|
3208659|NCT00976885||Subjects with Stroke|
3208660|NCT00976924|Experimental|Andon|Andon blood glucose test strips with test meter
2476050|NCT03063229|Active Comparator|Insulin Pump Therapy Patients|Patients with Type 1 Diabetes waiting to start on an Insulin Pump.
2476053|NCT03063229|Other|Healthy Volunteers|Participants with no Diabetes.
2476099|NCT03062774|Experimental|PB-119|intervention: PB-119 injection
2476141|NCT03062553|Experimental|MCT + Neuromodulation (MCT-N)|"Participants (n=50) randomly assigned to the MCT-N condition will undergo transcranial alternating current stimulation (tACS) prior to participation in MCT.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~The Metacognitive Training (MCT) group intervention will consist of an 8-module cycle occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
2476144|NCT03062553|Experimental|Sham/MCT group (MCT- S)|"Participants (n=50) randomly assigned to the Sham/MCT (MCT-S) condition will undergo the application of random patterns of low-grade currents to the same brain region as the neuromodulation condition prior to participation in MCT.~MCT is a four week program with eight one-hour sessions. MCT can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of an 8-module cycles occurring twice a week for 4 weeks, for a total of 8 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects."
2476150|NCT03062553|Experimental|Neuromodulation/Treatment as Usual TAU-N|"Participants (n=50) randomly assigned to the Neuromodulation/TAU (TAU - N) condition will undergo transcranial alternating current stimulation (tACS) prior to being placed on the TAU waitlist.~Neuromodulation involving tACS will target increasing the power of the alpha band at dorsomedial prefrontal regions, and this is expected to also decrease the power of the beta band in ventro-medial regions. This will be confirmed by EEG recordings and source estimation during a task.~TAU is a four week waitlist control group."
2476223|NCT03062085||High myopic cataract group|Cataract patients with high myopia.
2476225|NCT03062085||Age-related cataract group|Age-related cataract patients.
2476228|NCT03062085||Ametropic cataract group|Cataract patients with ametropia.
2476312|NCT03061617|Other|volume controlled ventilation (VCV)|VCV mode, tide volume 6ml/kg, f 12-14, set fixed tide volume for each breath
2476315|NCT03061617|Experimental|pressure controlled ventilation (PCV)|PCV mode, pressure is adjusted to achieve tide volume 6ml/kg, f 12-14
2476374|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 12W|"Patients without cirrhosis and previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks."
2476377|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 12W|"Patients with compensated cirrhosis and/or previous history of treatment will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks."
2476382|NCT03061032|Experimental|Sofosbuvir/Ledipasvir for 24W|"Patients with compensated or decompensated cirrhosis and/or previous history of treatment and with contraindication of Ribavirin will be treated with this regimen.~Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks."
2476384|NCT03061032|Experimental|Sofosbuvir/Ledipasvir+Ribavirin for 24W|Patients with decompensated cirrhosis will be treated with this regimen. Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
2476431|NCT03060577|Experimental|Inclisiran-only|Participants will receive subcutaneous injections of inclisiran 300 milligrams (mg) on Day 1 and every 180 days thereafter for up to 4 years.
2476433|NCT03060577|Active Comparator|Switching|Participants will receive self-administered subcutaneous injections of evolocumab 140 mg on Day 1 and every 14 days thereafter until Day 336. Then, the participants will receive subcutaneous injections of inclisiran 300 mg on Day 360 and every 180 days thereafter for up to 4 years.
2476495|NCT03060122|No Intervention|Standard Care|Patient's randomized to this arm will receive standard post operative/post immobilization physical therapy or occupational therapy rehabilitation care without the use of NIN or CES.
2476497|NCT03060122|Experimental|NIN (InterX) and CES (Alpha-Stim)|"The Alpha-Stim Cranial Electrical Stimulation device applies a micro-current trans-cranially via electrodes attached to the ear.The electrical current is controlled through a handheld device. Standard treatment sessions lasting approximately 20-60 minutes.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area. Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
2476498|NCT03060122|Active Comparator|NIN (InterX) and sham CES|"The Alpha-Stim Cranial Electrical Stimulation device intensity will be preset and locked by the manufacturer at its lowest therapeutic dose at 100 mA, a sub-sensory level that serves as a sham treatment.~InterX Therapy (non-invasive) has been developed specifically for the treatment of acute and chronic pain. It is delivered on the skin of the involved area. The device will be applied by a trained therapist along the course of the dermatomes in the affected area.Electrical current is controlled through a handheld device. Standard treatment sessions last approx 20-45 min.~The treatment will be delivered in conjunction with the rehab visit (physical or occupational therapy)"
2476570|NCT03059745||Cholecystitis|Patients consented for robotic assisted cholecystectomy evaluated in study.
2476588|NCT03059316|Active Comparator|nitroglycerin group|this group will receive nitroglycerin infusion for controlled hypotension.0.5-5ug/kg/min to keep MAP 55-65mmhg then Massimo device will be attached to the patients when MAP reached the desired level
2476590|NCT03059316|Active Comparator|labetalol group|this group will receive labetalol infusion fo controlled hypotension 0.4-3mg/kg/hr to keep MAP 55-65mmhg.then Massimo device will be attached to the patients when MAP reached the desired level
2476708|NCT03058874|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
2476716|NCT03058874|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
2476975|NCT03057158||1|Women with Urgency Incontinence (At least three times per week) greater than three months, and without insulin resistance.
2476061|NCT03063242|Experimental|Project II: Patients with CKD stage IV/V|5 Patients with CKD stage IV/V who are cytomegalovirus (CMV) seropositive with mean blood mDC levels <1.0x104/mL will receive sargramostim treatment once all 5 healthy participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
2476063|NCT03063242|Experimental|Project III: kidney transplant patients|5 Kidney transplant recipients who are CMV seropositive with neutropenia (defined as absolute neutrophil count <1.0 x103/mm3) and/or CMV viremia will receive sargramostim treatment once all 5 Project I participants have completed treatment and the data have been analyzed to guide subsequent dosing. Blood samples will be drawn and analyzed for mDC levels.
2476079|NCT03062813|Experimental|Tacrolimus & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
2476084|NCT03062813|Active Comparator|placebo & entecavir|Tacrolimus capsule, 0.5mg/capsule,1.0mg/capsule, 0.05-0.1mg/kg.d by mouth , every 12 hours for a day.Entecavir 0.5mg tablet by mouth every night.
3192697|NCT00811356|Experimental|Single Dose, Repeat Dose, Drug-Drug Interaction|"GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level.~To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121."
3192698|NCT00811369|Experimental|1|Fulvestrant + ZACTIMA Group
2476222|NCT03061890||Prematurity and Respiratory Outcomes Program (PROP)|extant, NIH-supported preterm birth cohort NCT01435187
2476224|NCT03061890||Trial of Late Surfactant (TOLSURF)|extant, NIH-supported preterm birth cohort NCT01022580
2476227|NCT03061890||NICU Hospital Exposures and Long-Term Health (NICU-HEALTH)|extant, NIH-supported preterm birth cohort NCT01963065
2476230|NCT03061890||Preterm Erythropoietin Neuroprotection Trial (PENUT)|extant, NIH-supported preterm birth cohort NCT01378273
2476305|NCT03061435|Other|Screening anal Pap Smear - Negative (75%)|All patients will receive an anal Pap test. 75% of patients with a negative anal Pap will complete study with no further intervention.
2476308|NCT03061435|Other|Screening anal Pap Smear - Negative (25%)|All patients will receive an anal Pap test. Remaining 25% of patients will proceed to high-resolution anoscopy (HRA) clinic to assess the negative predictive rate of HRA.
2476309|NCT03061435|Other|Screening anal Pap Smear - Positive|All patients will receive an anal Pap test. Any patient with abnormal cytology on their Pap test will be referred to HRA clinic for management. This includes potential biopsy and treatment.
2476341|NCT03061058|Experimental|Individualized Group|"mRNA levels of BRCA1, topoisomerase I (TOPO1), and thymidylate synthase (TS) were assessed in tumor tissue. Chemotherapeutic agents were selected based on the mRNA levels.~Patients with high level BRCA1 will receive intraperitoneal docetaxel (15mg/m^2, d1, d15, q4w), intravenous docetaxel (30mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with low level BRCA1 will receive intraperitoneal cisplatin (25mg/m^2, d1, d15, q4w), intravenous oxaliplatin (75mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1 and high level TOPO1 will receive intraperitoneal irinotecan (45mg/m^2, d1, d15, q4w), intravenous docetaxel (90mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w).~Patients with middle level BRCA1, low or middle level TOPO1, and low level TS will receive intraperitoneal pemetrexed (150mg/m^2, d1, q3w), and intravenous pemetrexed (350mg/m^2, d1, q3w)."
2476346|NCT03061058|Active Comparator|Control Group|"mRNA levels of BRCA1, TOPO1, and TS were assessed in tumor tissue for every enrolled patients.~Patients in control group will receive intravenous docetaxel (45mg/m^2, d1, d15, q4w), and oral S-1 (40mg/m^2, d1-14, q4w)."
2476427|NCT03060564|Experimental|AC repair with tendon graft|acromioclavicular repair with tendon graft.
2476428|NCT03060564|Active Comparator|AC repair with no tendon graft|acromioclavicular repair without tendon graft/no intervention
2476479|NCT03060304|Experimental|study group|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If there is a dominant follicle (almost 12 × 12 mm in diameter), endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before ovulation. If there isn't dominant follicle and intramuscular human menopausal gonadotropin at a dose of 75-150 IU was administered each day after day 12 if there follicle development was poor. The embryo transfer day is decided according embryo development.
2476483|NCT03060304|Active Comparator|control group|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3. Follicle diameters are monitored by transvaginal ultrasound and serum levels of E2, P are tested on day 9. If endometrial thickness <7mm and E2<100pg/ml, the dose of estradiol valerate can increase or combine other estradiol. Endometrial thickness and endometrial pattern, as well as follicular diameters, were monitored daily or every other day till embryo transfer. Serum levels of E2, P are tested on the day before endometrium transformation. The embryo transfer day is decided according embryo development. Serum levels of E2, P are tested on the day before embryo transfer.
3192699|NCT00811369|Placebo Comparator|2|Fulvestrant + Placebo Group
3208661|NCT00976924|Active Comparator|Lifescan|Lifescan blood glucose test strips with test meter
2476586|NCT03059290|Active Comparator|protaper next file|the PROTAPER NEXT™ X1 (017/04) file, in one or more passes until the working length is reached. Use PROTAPER NEXT X2 (025/06), exactly as described for PROTAPER NEXT X1 file, until the working length is passively reached. Gauge the foramen with a size 025 hand file and, if this file binds at length, the canal is shaped and ready for disinfection. If the size 025 hand file is loose at length, then continue shaping with the PROTAPER NEXT X3 (30/07) and, when necessary, the PROTAPER NEXT X4 (040/06) or PROTAPER NEXT X5 (050/06), gauging after each instrument with the 030, 040 or 050 hand files, respectively. During canal shaping, irrigate, recapitulate with a small-sized hand file after each sequential PROTAPER NEXT instrument, then re-irrigate. in an endodontic motor according to the manufacturer instructions (X-Smart, Dentsply Maillefer, USA.), with torque 2.0 N.cm and speed 300 rpm.
2476073|NCT03062800|Experimental|P+Cisplatin/Carboplatin+T|"Induction therapy (Platinum based chemotherapy combined with antiangiogenic therapy 4-6 cycles):~Pemetrexed + Platinum + Thalidomide [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle, ivgtt +thalidomide 100-200mg/d ,oral, qn ]~Continue maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Thalidomide 100mg/d ,oral, qn, until either disease progression or unacceptable toxicity."
2476080|NCT03062800|Experimental|P+Cisplatin/Carboplatin|"Induction therapy ( Platinum based chemotherapy 4-6 cycles):~Pemetrexed + Platinum [pemetrexed (500mg/m^2)+cisplatin(75mg/m^2)or carboplatin(AUC=5) on day 1 of 21-days cycle,ivgtt ]~Maintenance therapy (It is defined when a drug included in the induction treatment is used as maintenance .Patients who had not progressed during induction phase will be in this phase):~Pemetrexed (500mg/m^2) on day 1 of 21-days cycle, ivgtt.until either disease progression or unacceptable toxicity"
2476146|NCT03062475|Experimental|lifestyle intervention group|Pregnant women allocated to this group receive lifestyle intervention. With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake. With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed or encourage them to do moderate cycling.
2476152|NCT03062475|No Intervention|control group|Pregnant women allocated to this group receive standard prenatal care.
3192700|NCT00811421|Active Comparator|Trial 1: IPTp-SP+LLITNs|HIV-negative pregnant women receiving 2 doses of IPTp (500mg of sulfadoxine and 25 mg of pyrimethamine) in the context of long lasting Insecticide Treated Nets (LLITNs)
3192701|NCT00811421|Experimental|Trial 1: IPTp-MQ (full dose) + LLITNs|HIV-negative pregnant women receiving 2 full doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
2476514|NCT03059927|Active Comparator|Knee arthroplasty, Cruciate retaining|Total knee replacement with preserved posterior cruciate ligament and a cruciate retaining insert.
2476515|NCT03059927|Active Comparator|Knee arthroplasty, Anterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and an anterior stabilized insert.
2476518|NCT03059927|Active Comparator|Knee arthroplasty, Posterior stabilized|Total knee replacement with sacrificed posterior cruciate ligament and a posterior stabilized design.
2476587|NCT03059277|Experimental|Intravitreal Aflibercept|Intravitreal Aflibercept Injection (IAI)
2476650|NCT03059160|Experimental|open label|
2476670|NCT03058848|Experimental|Consumption of PKU Start|Daily feed, substituting the participant's normal phe-free formula for PKU Start.
3192702|NCT00811421|Experimental|Trial 1: IPTp-MQ (split dose)+LLITNs|HIV-negative pregnant women receiving 2 doses of MQ as IPTp split dose over 2 days (15mg/kg) in the context of long lasting Insecticide Treated Nets (LLITNs
3192703|NCT00811421|Experimental|Trial 2: CTX+IPTp-Placebo+LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (placebo) in the context of long lasting Insecticide Treated Nets (LLITNs)
3192704|NCT00811421|Experimental|Trial 2: CTX + IPTp-MQ+ LLITNs|HIV-positive pregnant women receiving 3 doses of IPTp (15 mg/Kg) in the context of long lasting Insecticide Treated Nets (LLITNs)
3192705|NCT00811447|Experimental|1|Administration of docetaxel 60 mg/m² on Day 1, Cisplatin 60 mg/m² after the end of the docetaxel infusion and 5-fluorouracil (5-FU) 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
3192706|NCT00811447|Active Comparator|2|Cisplatin 75 mg/m² on Day 1, 5-FU 600 mg/m²/day from Day 1 after the end of the cisplatin infusion to Day 5.
3192707|NCT00811460|Experimental|1|
2477466|NCT03053817|Experimental|Exercise group|The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
2477469|NCT03053817|No Intervention|Control|No treatment
2477510|NCT03053544|Experimental|Metformin|Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
2477572|NCT03053232|Experimental|Purse string suture device|Use of purse string suture device to close gastrointestinal perforation.
2477580|NCT03053232|Active Comparator|Endoclips|Use of endoclips to close gastrointestinal perforation.
2477602|NCT03052790|Active Comparator|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
2477604|NCT03052790|Experimental|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
2477624|NCT03052621||Curative group|Locally advance breast cancer and locally recurrent breast cancer without metastasis underwent omental transposition
2477628|NCT03052621||Palliative group|Locally advance breast cancer and locally recurrent breast cancer with metastasis underwent omental transposition
2477660|NCT03052348|Active Comparator|Group R|Polyethylene glycol hexadecyl ether & betamethasone valerate cream 0.1% . ( 4 applications per day for 14 days treatment to taper fortnightly)
2477661|NCT03052348|Experimental|Group A|Fusidic acid & Polyethylene glycol hexadecyl ether,& betamethasone valerate cream 0.1%). ( 4 applications per day for 14 days treatment to taper fortnightly)
3192708|NCT00811486|No Intervention|Usual care|Group II
3192709|NCT00811486|Experimental|Spironolactone and conivaptan|Group I
3192710|NCT00811499|Experimental|ARRY-371797 (Schedule 1)|
3192711|NCT00811499|Experimental|ARRY-371797 (Schedule 2)|
2476092|NCT03062969||Cleavage stage biopsy group|Patients undergoing a PGS cycle with single blastomere biopsy on day 3 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH) If euploid blastocysts were available, patients underwent fresh blastocyst transfer on day 5.
2476096|NCT03062969||Trophectoderm biopsy group|Patients undergoing a PGS cycle with blastocyst biopsy on day 5-7 and analysis using comparative genomic hybridation bacterial artificial chromosome (BAC) arrays (aCGH). If euploid blastocysts were available, patients underwent frozen-thawed blastocyst transfer.
2476189|NCT03062592|No Intervention|Screening/Baseline|A standard OGTT with no supplementation/intervention
2476191|NCT03062592|Experimental|Non-hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of non-hydrolyzed pine nut oil
2476193|NCT03062592|Experimental|hydrolyzed pine nut oil|Standard OGTT supplemented with 3 g of hydrolyzed pine nut oil
2476240|NCT03062007|Experimental|BI-CON-02|The start dose of BI-CON-02 will be 0,3 mg/kg and it will be possible to increase gradually BI-CON-02 doses up to 0,6 mg/kg; 1,2 mg/kg; 2,4 mg/kg; 3,6 mg/kg and 4,8 mg/kg for subsequent dose cohorts. A possibility to include a new dose cohort in the study will be considered by the Data and Safety Monitoring Committee, basing on the data of BI-CON-02 safety and tolerability, received at the Visit (Week 3, Day1) in the previous dose cohort (3 weeks after - 21st day of therapy).
2476300|NCT03061565||Erythropoietin|Patients were treated with EPO during the EPO-TBI study in 2010-2014.
2476302|NCT03061565||Placebo|Patients were treated with placebo during the EPO-TBI study in 2010-2014.
3192712|NCT00811499|Placebo Comparator|Placebo|
3192713|NCT00811538||1 1 (Liv*)|i.v. thrombolysis with rtPA
3192714|NCT00811538||2 (L*)|intraarterial thrombolysis
3192715|NCT00811603|Active Comparator|1|Patients who receive antibiotic prophylaxis after clamping of the umbilical cord
2476613|NCT03059537|Experimental|Stimulation Test|Study meal plus chenodeoxycholic acid: 1,250 mg single dose stimulation
2476703|NCT03058952|Experimental|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
2476714|NCT03058952|Active Comparator|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
2476780|NCT03058445|Experimental|Main group|This the only arm in the study Intervention: Echocariography and assessing T2T and CXR CVC tip to carina distance
2476850|NCT03057990|Experimental|Pyrimethamine Treatment (Intra-patient)|50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
2476891|NCT03057665||Pregnant Women|Measure magnetic field versus time for fetus, using atomic biomagnetometer.
2476958|NCT03057353||lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
2477016|NCT03056963|Experimental|Positive Self-Reference Training|Participants in this arm will complete the Positive Self-Reference Training (PSRT).
2477017|NCT03056963|Placebo Comparator|Neutral Training Control|Participants in this arm will complete the neutral training paradigm.
2477059|NCT03056508|Experimental|Exercise plus Nutrition|6 months of supervised group exercise plus education and strategy training to alter diet to be consistent with recommendations outlined in our brain health food guide (BHFG).
2477068|NCT03056508|Active Comparator|Exercise|Identical exercise to the experimental plus education and passive discussion about brain health and healthy lifestyle to control for experimental group nutrition sessions.
3158088|NCT00378781|Experimental|Arm I|Minocycline hydrochloride + Edetate Calcium Disodium (M-EDTA) flush solution into CVC once daily.
3158089|NCT00378781|Experimental|Arm II|Heparin flush solution into CVC once daily.
2477246|NCT03055208|Experimental|Radiosurgery|"Following intraoperative confirmation of glioblastoma (frozen section):~Early (24-72h post surgery) stereotactic ablation (gamma knife radiosurgery) of residual tumor (defined in early postoperative T1-weighted MRI scanning with and without contrast), followed by standard-of-care therapy (chemo-radiotherapy with 60 Gy external beam radiation therapy (EBRT) and 75 mg/m2/d temozolomide, followed by adjuvant chemotherapy with 150-200 mg/m2/d/cycle temozolomide in a 5/28 days schedule)."
2477280|NCT03055104||severe malnutrition|Patients with severe malnutrition (BMI<13 kg/m2), admitted to Peking University Third Hospital from JAN 2008 are involved in this study. After admission, a multidisciplinary team, consisting of specialists in the field of intensive care, pharmacy, psychology, and physical therapy assessed all patients. Management and treatment of these patients are in accordance with guideline for the management of severe malnutrition in PUTH.
2503935|NCT02873897|Other|"Group residents of old people's homes - EHPAD"|
3158090|NCT00378911|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3158091|NCT00378950|Active Comparator|1|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups.
3158092|NCT00378950|Experimental|2|Participants will receive a 1-hour education session about CHF, symptom recognition, diet, exercise, and daily check ups, as well as additional information on diuretic self adjustment. This group will then get several follow-up phone calls over the course of the year to reinforce these topics and help them master the knowledge and encourage behavior and lifestyle changes to align with these topics.
3158093|NCT00378976|Experimental|1|
3158094|NCT00378976|Placebo Comparator|2|
3158095|NCT00378989|Active Comparator|Intervention|A letter with personal feedback of the results of a health risk appraisal and invitation to a consultation at the occupational health services.
3158096|NCT00378989|No Intervention|Control|Care as usual
3192716|NCT00811603|Experimental|2|Patients who receive antibiotic prophylaxis prior to skin incision
2476221|NCT03062046|Experimental|RF ablation|Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
2476423|NCT03060694||Diabetes group|Patients in this group are recruited from both departments of endocrinology and gastroenterology. The diagnosis of diabetes is confirmed by medical history, using anti-diabetic medicines or laboratory tests.
2476425|NCT03060694||Non-diabetes group|Patients in this group are recruited from department of gastroenterology. The exclusion of diabetes is confirmed by medical history or laboratory tests.
2476466|NCT03060395|Sham Comparator|A1/A2 milk|"Commercial conventional A1/A2 semi-skimmed fresh pasteurised cow milk. Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
2476471|NCT03060395|Active Comparator|A2 milk|"Commercial A2 semi-skimmed fresh pasteurised cow milk.~Progressive intake of intervention milk as follows:~Days 1 and 2: 100 mL twice a day~Days 3 and 4: 150 mL twice a day~Days 5 and 6: 200 mL twice a day~Days 7 to 14: 250 mL twice a day"
2476556|NCT03059758|Experimental|Brain activity during reasoning and measure of math skill|Brain activity during reasoning and measure of math skill
3158097|NCT00379015|Experimental|HER2 over-expressing primary breast cancer group|"Patients receive epirubicin hydrochloride and cyclophosphamide in week 1-3. Treatment with epirubicin hydrochloride and cyclophosphamide repeats every 3 weeks for 4 courses. Patients then receive docetaxel in week 13 and trastuzumab (Herceptin®) in weeks 13-15. Treatment with docetaxel and trastuzumab repeats every 3 weeks for 4 courses.~Patients then undergo appropriate surgery. After surgery, patients with hormone receptor-positive disease receive trastuzumab once weekly and either tamoxifen with or without a luteinizing hormone-releasing hormone agonist or an aromatase inhibitor. Treatment continues for 40 weeks."
3158098|NCT00379067|Active Comparator|1|Tamsulosin OCAS tablet
3158099|NCT00379067|Placebo Comparator|2|Placebo tablet
2476730|NCT03058640|Experimental|Karate Intervention|Participants will be enrolled into PKSA karate classes which includes at least two, standardized 1-hour classes per week for 12 weeks. Participants must attend at LEAST 20/24 classes. Attendance sheets will be signed by parents at each site. Practice at home will also be encouraged. Log sheets will be provided to participants to log their practice
2476731|NCT03058640|No Intervention|Standard Care|Participants will have no initial intervention. Investigators will request that participants do not enroll in a structured martial arts class during the one-year period. Participants will, however, be given the option of receiving the structured karate program at 6 months, once measurements are completed
2476843|NCT03058315||Low back pain patients|Cohort of 800 consecutive low back pain patients, 18 years +, who have been referred from general practice to the secondary sector for further examination and MR scan.
2476884|NCT03057691||No depression/anxiety|patients suffered from ACS who have undergone PCI without depression or anxiety
2476885|NCT03057691||Depression|patients suffered from post-ACS depression who have undergone PCI
2476888|NCT03057691||Anxiety|patients suffered from post-ACS anxiety who have undergone PCI
2476890|NCT03057691||Depression with anxiety|patients suffered from post-ACS depression with anxiety who have undergone PCI
2476919|NCT03057340|Experimental|DRibble vaccine|Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.
2476985|NCT03057106|Active Comparator|Durvalumab and Tremelimumab|Durvalumab q4 weeks until PD + Tremelimumab q 4 wk x 4 doses
2476986|NCT03057106|Active Comparator|Platinum based chemotherapy + Durvalumab + Tremelimumab|"4 cycles platinum plus gem or pem + Durva + Treme (q 3 wk x 4 cycles)~Followed by:~Squamous Cell: Maintenance Durva q 4 wk until PD Non-Squamous Cell: Pemetrexed + Durva q 4 wk until PD"
2477826|NCT03051386|Experimental|VEE Vaccine|0.5 mL of VEE vaccine, Live, Attenuated TC-83, NDBR 102, Lot 4, Run 3
3158100|NCT00379106|Active Comparator|Group1|
3158101|NCT00379106|Experimental|Group 2|
3158102|NCT00379184||A|Osteoarthritis patients scheduled for Total Knee Arthroplasty.
3158103|NCT00379184||B|Osteoarthritis patients not scheduled for Total Knee Arthroplasty.
3158104|NCT00379184||C|Healthy volunteers
3158105|NCT00379223|No Intervention|1|Standard treatment of central retinal vein occlusion : the rheologic correction
3158106|NCT00379223|Experimental|2|Standard treatment of central retinal vein occlusion : the rheologic correction and surgery associating pars plana vitrectomy and radial optic neurotomy
3158107|NCT00379262|Experimental|1A|Concurrent-Adjuvant CRT using P-PF regimen and conventional fractionation radiotherapy
3158108|NCT00379262|Experimental|1B|Concurrent-Adjuvant CRT using P-PF regimen and accelerated fractionation radiotherapy
3158109|NCT00379262|Experimental|2A|Induction-Concurrent CRT using PF-P regimen and conventional fractionation radiotherapy
3158110|NCT00379262|Experimental|2B|Induction-Concurrent CRT using PF-P regimen and accelerated fractionation radiotherapy
3158111|NCT00379262|Experimental|3A|Induction-Concurrent CRT using PX-P regimen and conventional fractionation radiotherapy
3158112|NCT00379262|Experimental|3B|Induction-Concurrent CRT using PX-P regimen and accelerated fractionation radiotherapy
3158113|NCT00379301|Active Comparator|Group 1|Pulmonary vein isolation (PVI) combined with ablation of documented non-PV triggers of atrial fibrillation --- (sites away from the pulmonary veins where consistent abnormal impulses that can trigger AF are identified during the procedure)
3158114|NCT00379301|Active Comparator|Group 2|PVI combined with ablation at documented sites of non-PV triggers, PLUS ablation at sites where non-PV triggers are commonly found
3158115|NCT00379301|Active Comparator|Group 3|PVI combined with ablation at documented sites of non-PV triggers and ablation at sites in the left atrium that demonstrate disorganized electrical impulses called complex fractionated electrograms (CFE).
2476140|NCT03062709|Experimental|All Participants|Breathe Easy Coalition written materials provided to parent/guardian, plus Maine Tobacco Helpline referral provided to smoking adult in the home, plus testing of the child's urine cotinine and results reported to parent/guardian
2476201|NCT03062176|Experimental|Active Treatment|Anakinra (Kineret)
2476310|NCT03061461|Active Comparator|rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the EvoBlue handpiece as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.07 mJ/mm^2 (i.e., setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the radial shock waves set at 15 Hz."
2476314|NCT03061461|Sham Comparator|Sham rESWT|"Treatment of chronic wounds with the Swiss DolorClast (Electro Medical Systems S.A., Nyon, Switzerland) and the placebo EvoBlue handpiece of the Swiss DolorClast (that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves) as follows:~Use of the 15-mm applicator or the 36-mm applicator of the Swiss DolorClast according to the individual wound size.~Six treatment sessions, two treatment sessions per week.~1000 sham radial shock waves per cm^2 wound and treatment session.~Energy flux density 0.00 mJ/mm^2 (setting of the air pressure of the Swiss DolorClast at 2 bar when using the 15-mm applicator, and at 4 bar when using the 36-mm applicator).~Frequency of the sham radial shock waves set at 15 Hz."
2476370|NCT03060954|Experimental|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
2476376|NCT03060954|Other|FineVision ®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
2476472|NCT03060252||The overall individuals taking ZGGJ Pill|The overall individuals taking ZGGJ Pill with recommended dosage and achieving the inclusion criteria.
2476528|NCT03059979|Active Comparator|Methylprednisolone 1000 mg|the methylprednisolone is dissolved in 100 cc of sodium chloride (NaCl 0.9%) by intravenous infusion in 30 minutes on three consecutive days
2476529|NCT03059979|Placebo Comparator|sodium chloride|The placebo intervention with physiologic salt solution is identical in appearance
2476633|NCT03059368|Experimental|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
2476732|NCT03058627|No Intervention|TAVI only|TAVI is performed according to current guidelines and the choice of valve prosthesis is at the operators' discretion.
2476735|NCT03058627|Experimental|TAVI + FFR-guided complete revascularization|TAVI is performed according to current guidelines and the choice of transcatheter heart valve is at the operators' discretion. PCI is performed in any suitable lesion with diameter stenosis > 90% or FFR < 0.80 in vessels ≥ 2.5 mm in diameter .
2476816|NCT03058237|Experimental|Part 1: Regimen A|"One low dose Arbaclofen Placarbil MR Prototype A tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2476817|NCT03058237|Experimental|Part 1: Regimen B|"One low dose Arbaclofen Placarbil MR Prototype B tablet taken under fasting conditions.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2476821|NCT03058237|Active Comparator|Part 1: Regimen C|"One low dose Arbaclofen Placarbil SR tablet taken under fasting conditions as the reference product.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2476823|NCT03058237|Experimental|Part 1: Regimen D|"One low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2476828|NCT03058237|Experimental|Part 1: Regimen E|"An optional regimen of one low dose tablet of the selected Arbaclofen Placarbil MR Prototype administered with 0.6 g/kg of beverage in orange juice.~Part 1 participants receive Regimens A, B, C, D and E in a sequential manner."
2476831|NCT03058237|Experimental|Part 2: Regimen F|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2476833|NCT03058237|Active Comparator|Part 2: Regimen G|"One low dose Arbaclofen Placarbil IR capsule taken under fasting conditions as the reference product.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2476836|NCT03058237|Experimental|Part 2: Regimen H|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2476838|NCT03058237|Experimental|Part 2: Regimen I|"One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions.~Part 2 participants receive Regimens F, G, H, I and J in a sequential manner."
2476840|NCT03058237|Experimental|Part 2: Regimen J|One low dose Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 1) taken under fasting conditions, or a previously dosed MR prototype in the fed state. Part 2 participants receive Regimens F, G, H, I and J in a sequential manner.
2476842|NCT03058237|Experimental|Part 3: Regimen K|"One low dose selected Arbaclofen Placarbil MR prototype tablet (selected based on review of the data in Part 2) taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2476844|NCT03058237|Experimental|Part 3: Regimen L|"One low dose selected Arbaclofen Placarbil MR prototype tablet administered with 0.6 g/kg of beverage in orange juice or in the fed state, or one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
2476846|NCT03058237|Experimental|Part 3: Regimen M|"An optional regimen of one mid-low dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen L) or one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet taken under fasting conditions.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
3192717|NCT00811629||control group|
2476181|NCT03062332||Bipolar disorder,mania|The group includes subjects who are diagnosed to mania episode of bipolar disorder.
2476183|NCT03062332||Bipolar disorder,depressive|The group includes subjects who are diagnosed to depression episode of bipolar disorder.
2476184|NCT03062332||Bipolar disorder,mixed|The group includes subjects who are diagnosed to mixed episode of bipolar disorder.
2476186|NCT03062332||First episode major depression|The group includes subjects who are diagnosed to first episode of major depression.
2476188|NCT03062332||major depression，recurrent|The group includes subjects who are diagnosed to recurrent episode of major depression.
2476190|NCT03062332||Healthy control|The group includes subjects who are Healthy control.
2476241|NCT03061981|Active Comparator|DA-1241:8 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
2476244|NCT03061981|Placebo Comparator|Placebo: 2 subjects in each cohort(Cohort 1-6)|Subjects will participate in 1 of 6 cohorts consisting of 10 subjects per cohort. Within cohorts, subjects will be randomized to a ratio of 8:2 (DA-1241 to matching placebo).
2476248|NCT03061981|Other|DA-1241 in IE Cohort: 8 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
2476250|NCT03061981|Other|Placebo in IE Cohort: 2 subjects in choosen cohort|One of the cohorts will be selected,based on a review of the data from cohort 1-6, to assess the IE of metformin on the PK of DA-1241.
2476290|NCT03061448|Experimental|Inhibitory learning based treatment|The experimental group will go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of inhibitory learning, i.e. the participant is instructed to stay in the frightening situation until his/her expectancy has been maximally violated.
2476291|NCT03061448|Active Comparator|Habituation based treatment|The active comparator group will also go through Internet-based treatment. The exposure treatment is 8 weeks long and based on the principles of emotional processing theory, i.e. the participant is instructed to stay in the frightening situation until anxiety has declined (habituated).
2476355|NCT03061227|Active Comparator|Intravenous glucagon|Low-dose glucagon infusion (0.5 pmol/min/kg body weight) over 150 minutes during a standardized 75 g oral glucose tolerance test
2476356|NCT03061227|Placebo Comparator|Intravenous saline|Saline infusion over 150 minutes during a standardized 75 g oral glucose tolerance test
2476408|NCT03060772|Experimental|Alcohol use disorder - Pioglitazone Treatment|Participants with alcohol use disorder randomized to this group will receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy after taking the study medication for 2 to 4 weeks.
2476411|NCT03060772|No Intervention|Alcohol use disorder - No Pioglitazone|Participants with alcohol use disorder randomized to this group will receive their usual care but will not receive pioglitazone. Study procedures include a bronchoscopy at baseline and an additional bronchoscopy 2 to 4 weeks later.
2476413|NCT03060772|No Intervention|Healthy controls without alcohol use disorder|Healthy individuals who do not have alcohol use disorder will be enrolled will serve as a control group. Healthy controls will be a matched to participants receiving the treatment based on age, gender, and smoking status. This group will have a single bronchoscopy.
2476451|NCT03060187||KU Score|Participants asked to answer questions for the KU Score exam
2476501|NCT03060109||Suspected traumatic brain injury|
2476542|NCT03059784|Experimental|intervention|APP-based multifaceted management, including sending education material, everyday medication reminder, giving risk factor control support, clinical support to patients after PCI through APP.
2476547|NCT03059784|No Intervention|control|usual care without APP
2476617|NCT03059524||patients with multiple organ failure|
2476621|NCT03059524||patients without multiple organ failure|
2476626|NCT03059524||normal subjects|
2476694|NCT03059017|Experimental|Niosomal salbutamol sulphate inhalers|Niosomes
2476707|NCT03059017|Placebo Comparator|salbutamol sulphate inhalers|control testing
2476742|NCT03058523||Non-Pregnant|30 non-pregnant women of childbearing age
2476744|NCT03058523||Pregnant|30 pregnant women
2476795|NCT03058211||pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
2476800|NCT03058211||non-pneumococcal pneumonia|Patients with community-acquired pneumonia due to S.pneumoniae. An Echocardiography will be performed to all patients (one per day during 7 days). A Cardiac magnetic resonance (MRI) will be performed during an acute episode and at month 6 since ICU admission. In addition a blood sample will be drawn daily (one per day during 7 days) to measure myocardial injury and inflammation systemic (interleukins) biomarkers.
2476862|NCT03057769|Experimental|PES group|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
2476866|NCT03057769|Placebo Comparator|Control group|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
2476903|NCT03057379|No Intervention|Control arm|Usual source of care
2476904|NCT03057379|Experimental|1 R/R per Dose|Sending up to one recall notice per dose of HPV vaccine needed
2476905|NCT03057379|Experimental|2 R/R per dose|Sending up to two recall notice per dose of HPV vaccine needed
2476906|NCT03057379|Experimental|3 R/R per dose|Sending up to three recall notice per dose of HPV vaccine needed
2476976|NCT03057158||2|Women with insulin resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
2476203|NCT03061968|Experimental|experimental group|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
2476204|NCT03061968|No Intervention|control group|The control group only receive routine care in sick baby room unite.
2476210|NCT03061786||AKI|
2476211|NCT03061786||non-AKI|
2476254|NCT03061734|Experimental|Naltrexone and Acetaminophen|Patients take one capsule containing naltrexone and one capsule containing acetaminophen together for a qualifying migraine
2476258|NCT03061734|Experimental|Naltrexon/Acetaminophen-High Capsules|Patient take one capsule containing naltrexone (high dose) and one capsule containing acetaminophen together for a qualifying migraine
2476262|NCT03061734|Active Comparator|Naltrexone Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
2476263|NCT03061734|Active Comparator|Acetaminophen Alone Capsules|Patient take one capsule containing naltrexone and one capsule containing placebo together for a qualifying migraine
2476266|NCT03061734|Placebo Comparator|Placebo Capsules|Patient take two capsule containing placebo together for a qualifying migraine
2476304|NCT03061409|Experimental|Pharmavite Nature Made Multi for Him 50+|A supplement containing vitamins and minerals
2476307|NCT03061409|Placebo Comparator|placebo|tablets contain microcrystalline cellulose containing 0.5% magnesium stearate
2476348|NCT03061149|Experimental|Group with low-level laser treatment|"The group received low-level laser therapy (LLLT). The application of a GaAlAs infrared laser with a pencil probe (BTL 5000 Combi, United Kingdom; at 830 nm, 9J/cm2 per point, power output of 100 mW, beam diameter of 5 mm) was performed at five points along the median nerve on the palmar side of the wrist 7. The time of exposure was 10 minutes (2 minutes per point). Both the patient and the therapist wore protective glasses during every session.A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week).~Additionally, nerve and gliding exercises were administered."
2476351|NCT03061149|Active Comparator|Group with ultrasound treament|The group underwent ultrasound treatment. Ultrasound treatment was administered at a frequency of 1 MHz, intensity of 1 W/cm2 ,pulsed mode duty cycle of 1:4 and with a handhold transducer of 5 cm2 (BTL 5000 Combi, UK). The time of application was 6 minutes over the area of the carpal tunnel. Aquasonic gel was used as a couplant. A total of 10 therapeutic sessions were performed during a period of two weeks (five session times per week). Additionally, nerve and gliding exercises were administered.
2476463|NCT03060343|Experimental|Zeushield Cytotoxic T Lymphocytes|Enrolled patients will receive Zeushield Cytotoxic T Lymphocytes by infusion
2476522|NCT03059992|Experimental|Ibrexafungerp (SCY-078)|Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.
3158116|NCT00379327|Experimental|Real Accupuncture|Acupuncture with a real needle that punctures the skin versus acupuncture needle that does not puncture the skin.
3158117|NCT00379327|Placebo Comparator|Non-puncturing Acupuncture|Acupuncture needle that touches but does not puncture the skin
3158118|NCT00379366|Active Comparator|1|14 Gy ionizing radiations
3158119|NCT00379366|No Intervention|2|
2476886|NCT03057730|Experimental|Group 1: Thin Biotype|"Gingival thickness < 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
2476889|NCT03057730|Experimental|Group 2: Thick Biotype|"Gingival thickness ≥ 0.8 mm~Acellular Dermal Matrix (ADM) will be used according to manufacturer's instructions during mucogingival surgery. Subjects will be anesthetized using local anesthesia. An envelope flap design will be involved with no releasing incisions. The ADM will be placed beneath the flap. The flap will then be advanced to the level of cemento-enamel junction (CEJ). The area will be sutured.~Mean root coverage, CPD, CAL, RH, RW, KTW, GT, and CRC will be measured and compared at 3 months, 6 months, 12 months, 24 months and 48 months post-surgery."
2476918|NCT03057392|Experimental|immersion and them sham procedure|"hemodialysis patients will do a 3 hours dialysis session while sitting in a bath and then have a dry session outside the bath"
2476923|NCT03057392|Sham Comparator|sham session and then immersion|dialysis patients will have a 3 hour dialysis session (dry session) and then immersion
2476972|NCT03057080|Other|PTA procedure|Percutaneous transluminal angioplasty (PTA) in patients with ischemic leg ulcer
2476999|NCT03056846|Placebo Comparator|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2477003|NCT03056846|Experimental|Probiotic Combination|A commercially available probiotic mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2477006|NCT03056846|Experimental|Bifidobacterium bifidum|A commercially available probiotic strain (Bifidobacterium bifidum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
2477008|NCT03056846|Experimental|Bifidobacterium longum|A commercially available probiotic strain (Bifidobacterium longum) will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3158120|NCT00379392|Experimental|Mental Imagery and CIT|Mental Imagery and Constraint Induced Therapy
3158121|NCT00379392|Active Comparator|Mental Imagery only|Mental Imagery only
3158122|NCT00379405|Experimental|A|Saquinavir (Invirase): 2 capsules (500 mg) / 12 hours
3158123|NCT00379405|No Intervention|2|IP o NNUCS + 2 NUCS as a HAART therapy .
3158124|NCT00379431|Experimental|Administration of rituximab and methylprednisolone|
3158125|NCT00379470|Active Comparator|Best Standard of Care|Patients randomized to the BSC group will be treated with one chemotherapy according to the BSC practiced at each center.
3158126|NCT00379470|Experimental|NovoTTF-100A|
3158127|NCT00379483|Experimental|Arm 1|
3158128|NCT00379509|Experimental|GW572016|
2476207|NCT03062241|No Intervention|Conventional treatment|Pharmacological treatment according to 2016 ESC (European Society of Cardiology) guidelines for the diagnosis and treatment of acute and chronic heart failure and to 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with European Association for Cardio-Thoracic Surgery (EACTS).
2476253|NCT03061760||1. OAB (-) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2476257|NCT03061760||2. OAB (-) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with no overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2476261|NCT03061760||3. OAB (+) BOO (+)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and with bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2476265|NCT03061760||4.OAB (+) BOO (-)|Patients diagnosed with prostate cancer, undergoing radical prostatectomy, with overactive bladder (OAB) symptoms and without bladder outlet obstruction (BOO). 'Initial evaluation' before the surgery and follow up - 'Evaluation after 1,3,6,9,12 months'.
2476268|NCT03061760||5.Control group|Healthy volunteer individuals aged 20-40. 'Initial evaluation' made only once.
2476339|NCT03060980|Experimental|Experimental: Group 1|ITCA 650 20/60 mcg/day
2476340|NCT03060980|Experimental|Experimental: Group 2|Empagliflozin 10 mg/day and 25 mg/day
2476343|NCT03060980|Experimental|Experimental: Group 3|Glimepiride 1-6 mg/day
2476487|NCT03060213|Experimental|Fun For Wellness (FFW)|Intervention participants will: 1) watch original videos with vignettes performed by professional actors; 2) read and/or watch mini-lectures that teach skills for behavior change; 3) engage in self-reflection exercises, 4) play original interactive games related to vignettes and mini-lectures; 5) interact with other FFW users via chat room functions and; 6) watch funny narrated video clips about well-being.
2476488|NCT03060213|No Intervention|Usual Care (UC)|The Usual Care (UC) group will conduct their lives as usual during the 30 day intervention period.
2476544|NCT03059914|Experimental|InterOss|Maxillary sinus augmentation using ABBM Inteross ( Xenograft)
2476549|NCT03059914|Active Comparator|Bio-oss|Maxillary sinus augmentation using ABBM Bio-oss ( Xenograft)
3158129|NCT00379522|Active Comparator|Vasopressin|Vasopressin, 10 I.U./4 ml, Solution for Injection
3158130|NCT00379522|Placebo Comparator|Saline|Saline placebo 4 ml, Solution for Injection
2476675|NCT03058796|Active Comparator|CCFES Therapy|CCFES uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. CCFES enables stroke survivors to open and close their paretic hand and practice using it in therapy sessions. The treatment regimen includes CCFES-mediated: 1) home-based self-administered hand opening exercises, and 2) lab-based therapist-guided functional task practice.
2476678|NCT03058796|Experimental|CCFES Video Game Therapy|CCFES Video Game Therapy integrates custom designed hand therapy video games with CCFES which enables participants to use the video game component at home instead of repetitive hand opening exercises.
2476825|NCT03058133|Other|fMRI study|
2476882|NCT03057756||TB-MR patients|Patients older than 15 years old receiving Km+ Mfx+ Pto + H + Cfz +E+Z
2476899|NCT03057418|Experimental|Aurixim|"Dosage: 125 mg/m2, 250 mg/m2, 375 mg/m2 and 500 mg/m2. Formulation: concentrate for preparation of infusions 500 mg/50 ml and 100 mg/10 ml.~Mode of administration: intravenous."
2476959|NCT03057275||Threatened PTL|abdominal fetal/maternal monitoring
2476960|NCT03057275||Delivered PTL|abdominal fetal/maternal monitoring
2477023|NCT03056924||Vedolizumab monotherapy|IBD patients on vedolizumab monotherapy, all patients will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2477027|NCT03056924||vedolizumab + immunomodulator|IBD patients receiving combination treatment with vedolizumab and concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine), will be treated with the standard vedolizumab dosing regimen of 300 mg infusions at 8 week intervals and/or receive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2477028|NCT03056924||biologic + immunomodulator|IBD patients on other biologic therapy (infliximab, adalimumab, certolizumab, golimumab, ustekinumab) with concomitant immunomodulator therapy (methotrexate, azathioprine, or 6-mercaptopurine) and receivePneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2477030|NCT03056924||non-immunosuppressive therapy|IBD patients not taking any immunosuppressive therapy (these patients may be taking oral or topical 5-aminosalicylates) and recive Pneumococcal Pneumonia vaccine and/or Influenza vaccine and/or Hepatitis B vaccine.
2477082|NCT03056391|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
2477083|NCT03056391|No Intervention|No Paracetamol|"No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature >39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives."
2477140|NCT03056105||Retreat|Participants registered for a one-month, residential Insight Meditation retreat held at Spirit Rock Meditation Center in either February or March, 2013
2477148|NCT03056105||Comparison|Experienced meditators from the Spirit Rock Meditation Community
3158131|NCT00379535|Experimental|1|Daily dose of 200 µg of potassium iodide
3158132|NCT00379535|Placebo Comparator|2|Daily dose of placebo
3158133|NCT00379548|No Intervention|1|Control group- subjects are on the Asian diet for the entire duration of the study
3158134|NCT00379548|Experimental|2|Asian and Caucasian subjects switch from an Asian Diet to a Western Diet midway through the study.
3158135|NCT00379561|Experimental|Intervention PSA-PAH1|Determination of the therapeutic activity of different concentrations of PSA-PAH1 at increasing doses of per gram of prostate.
2476273|NCT03061604|Experimental|Hemospray|"All subjects will be treated by medical treatment in the terms of combination of vasoactive medication, blood transfusion and Ceftriaxone PLUS Hemospray treatment within 2 hours of admission.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
2476278|NCT03061604|Active Comparator|Non Hemospray|"All subjects will be treated by medical treatment in the terms of combination of Octreotide, blood transfusion and Ceftriaxone.~The medical treatment will be continued till 12 hours after admission and then second endoscopy will be performed (12-24 hours after admission)."
2476358|NCT03061136|Placebo Comparator|Placebo|Placebo administered orally
2476360|NCT03061136|Experimental|Clonazepam 0.1mg|0.1mg clonazepam administered orally
2476363|NCT03061136|Experimental|Clonazepam 0.2mg|0.2mg clonazepam administered orally
2476364|NCT03061136|Experimental|Clonazepam 0.3mg|0.3mg clonazepam administered orally
2476443|NCT03060655|Placebo Comparator|PLGA-Mg material|The fixation of fragments of study group was accomplished with PLGA-Mg material.
2476444|NCT03060655|Placebo Comparator|titanium alloy|The fixation of fragments of control group was accomplished with titanium alloy material.
2476456|NCT03060200|Experimental|Active intervention|Self-administered online CBT plus therapist check in. Moderately depressed participants will be testing a depression app, employing a self administered plus therapist check in, online CBT intervention, for 6 weeks.
2476458|NCT03060200|No Intervention|Waiting list|Moderately depressed participants will be put on a wait list for 6 weeks, after which access to the depression app will be given.
2476460|NCT03060200|Placebo Comparator|Placebo|Sham self-administered online CBT plus therapist check in. Moderately depressed participants will be using a depression app - the same platform and largely in the same format as the tested app, employing a self administered plus therapist check in, online sham intervention, for 6 weeks. The intervention will include the same sections and features as the original app, except for the complete exercises and behavioral activation sections. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense information on psychological well being.
2476527|NCT03060018|Experimental|All included patients|All included patients will undergo the intervention of transcutaneous sensor placement
2476582|NCT03059615|Experimental|Nerofe 48mg/m2|48mg/m2 IV Nerofe - three times a week
2476583|NCT03059615|Experimental|Nerofe 96mg/m2|96mg/m2 IV Nerofe - three times a week
2476584|NCT03059615|Experimental|Nerofe 48mg/m2 + Doxorubicin 10mg/m2|48mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
2476585|NCT03059615|Experimental|Nerofe 96mg/m2 + Doxorubicin 10mg/m2|96mg/m2 IV Nerofe + Doxorubicin 10mg/m2 - once a week
2476603|NCT03059212|Experimental|High frequency rTMS|Real rTMS, one session per day, for 10 days
2476605|NCT03059212|Experimental|High frequency rTMS with cognitive training|Real rTMS and cognitive training, one session per day, for 10 days
2476607|NCT03059212|Sham Comparator|Sham rTMS|Sham rTMS, one session per day, for 10 days
2476713|NCT03059056|Experimental|pharmacokinetic evaluation|Empagliflozin 25 mg
2476764|NCT03058575|Experimental|Dietary MACs|Dietary fiber supplement (blend of resistant starch and dietary fiber food ingredients providing 15g of microbiota accessible carbohydrate/1 scoop serving) will be provided in a powder that will be mixed with 6-10 oz of water (depending on desired thickness) and consumed as a chocolate shake.
2476768|NCT03058575|Other|Control|No Intervention
2476796|NCT03058042|Experimental|Home pelvic floor muscle training|Patients will perform strength training of the pelvic floor muscles daily at home. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will return for consultation, in which the MAP evaluation and training progression will be performed.
2476801|NCT03058042|Sham Comparator|Outpatient pelvic floor muscle training|The patients will perform 24 outpatient sessions of pelvic floor muscle strength training and home training. The training protocol consists of three sets of 30 slow contractions (type I muscle fibers), with maintenance contraction according to the initial evaluation, followed by three rapid contractions (type II muscle fibers) after each slow contraction. The protocol will account for 90 contractions of the pelvic floor muscles per day. At the end of one month, the patients will perform the evaluation of the MAP and progression of the training.
2476865|NCT03057834|Active Comparator|Functionally impaired|Women with urinary incontinence and short physical performance battery score of <9
2476869|NCT03057834|Placebo Comparator|Functionally normal|Women with urinary incontinence and short physical performance battery score of > 10
2476895|NCT03057548|Active Comparator|Pulmonary Vein Isolation (PVI)|"Cryoablation only of Pulmonary Veins~or~Radiofrequency ablation only of Pulmonary Veins~Pulmonary Vein Isolation (PVI) alone."
2476897|NCT03057548|Experimental|PVI & Posterior Left Atrial Ablation|"Cryoablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~or~Radiofrequency ablation of Pulmonary Veins plus RF ablation of Posterior Left Atrial Wall~PVI ablation plus ablation of the Posterior Left Atrial Wall (PLAW)"
2476950|NCT03057288|Experimental|fiducial markers placement|Prospective study with one arm evaluating the feasibility of fiducial markers placement under echoendoscopic guidance, for patients with esophageal or rectal cancer
2477033|NCT03056976|Experimental|Single-implant mandibular overdenture|A single midline implant and an O'ring/ball attachment to retain a mandibular overdenture
2477034|NCT03056976|Experimental|Two-implant mandibular overdenture|Two implants in the canine region and two O'ring/ball attachments to retain a mandibular overdenture
2477037|NCT03056976|Experimental|Fixed mandibular denture|A fixed four-implant mandibular denture
2477080|NCT03056430|Experimental|Training Group 1|Slackline training
2477081|NCT03056430|Experimental|Training Group 2|Slackline training
2477128|NCT03056209|Experimental|KL1333 25mg|Group 1
2477133|NCT03056209|Experimental|KL1333 50mg|Group 2
2477137|NCT03056209|Experimental|KL1333 100mg|Group 3
2477145|NCT03056209|Experimental|KL1333 200mg|Group 4
2477150|NCT03056209|Experimental|KL1333 400mg|Group 5
2476280|NCT03061578||ADDE|"Aqueous Deficiency Dry Eye (ADDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe ADDE group, subjects must meet a predefined medical condition (Rheumatoid Arthritis, Dermatomyositis, Lupus or Sjögren's syndrome) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The ADDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2476281|NCT03061578||LDDE|"Lipid Deficiency Dry Eye (LDDE) group will be define by commonly known signs and symptoms.~In order to classify subjects to the moderate to severe LDDE group, subjects must have moderate to severe Meibomian Gland Dysfunction (MGD score of 3-6) and meet at least one of the following conditions:~Have a Schirmer's Test (without anesthesia) of ≤5mm/5min in either eye~Mean CFS of ≥1 in either eye.~Fluorescein TBUT ≤5 s in either eye.~OSDI questionnaire score ≥20~The LDDE group will undergo the same diagnosis including Tear Film Imager diagnostic and Low Humidity Environmental Exposure Chamber (LH-EEC) stimulation as any other group of patients."
2476470|NCT03060382|Experimental|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into tibia.
2476476|NCT03060382|Placebo Comparator|total knee arthroplasty|For the patients of control group, total knee arthroplasty was conducted.
2476523|NCT03059849|Active Comparator|Temporary increase in adalimumab|
2476524|NCT03059849|No Intervention|Continued monitoring as per standard of care|
2476557|NCT03059654|Active Comparator|Ultrasound PCT|Ultrasound guide Percutaneous tracheostomy
2476561|NCT03059654|Active Comparator|Surgical tracheostomy|Surgical tracheostomy
2476659|NCT03059082|Other|Continued Interaction|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months.They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject. The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is continued throughout the study.~Note: The first 10 subjects will not be randomized and will be assigned to this Arm. The purpose of this is to ensure the fidelity of the intervention. The remaining 60 subjects will be randomized equally among the three Arms. Data from the first 10 subjects will not be considered for the outcome measures."
2476660|NCT03059082|Other|Single interaction|This group will undergo one interaction with the Recovery Navigator prior to the hospital discharge. They will then have a 3 month and 6 month follow up visit with the PI. There is no drug or treatment administered to the subject.The intervention is the conversation/contact with the Recovery Navigator, in this arm, it is conducted once.
2476661|NCT03059082|Other|Control|This group will not have any interaction with the Recovery Navigator. They will then have a 3 month and 6 month follow up visit. There is no drug or treatment administered to the subject.
2476699|NCT03058731||Matristem|Hernia repair with MatriStem Surgical Matrix
2476704|NCT03058731||Control|Other biological mesh
2476784|NCT03058458|Experimental|SAD PIN201104 in Healthy Volunteers (HV)|PIN201104 or placebo IV administration, single dose, 10 dose cohorts
2476788|NCT03058458|Experimental|Repeat dose PIN201104 in HV|PIN201104 or placebo IV administration, 3 doses on single day, 1 cohort
2476790|NCT03058458|Experimental|Single dose PIN201104 in asthma patients|PIN201104 or placebo IV administration, single dose, 2 cohorts
2476791|NCT03058458|Experimental|Single SC dose in HV|PIN201104 or placebo SC administration, single dose, 1 cohort
2476875|NCT03057886||Compare the Spot On with others consecrated thermometers|This study intends to compare the accuracy of the new device(SPOT ON thermometer) with the oral and esophageal in participants submitted to general and spinal anesthesia, in different types of population (pediatric and adult)
3192718|NCT00811668|Experimental|CPAP before SOMNOVentCR|started with CPAP and continued with SOMNOvent CR
2476955|NCT03057210|No Intervention|S1 (Basal)|The behavior of the variables of functional and clinical outcome will be analyzed under no stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
2476956|NCT03057210|Experimental|S2 (Massage)|The behavior of the variables of functional and clinical outcome will be analyzed under stress or recovery technique. In this stage, only the functional tests and the collection of clinical data will be performed.
2476961|NCT03057210|Experimental|S3 (Exercise)|The behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exercise protocol is performed. In this stage the volunteers will first perform the protocol for exhaustion, and in specific moments the blood lactate and clinical data will be collected, and 2h after the beginning of the exercise protocol, the functional tests will be performed.
2476962|NCT03057210|Experimental|S4 (Exercise + Immediate Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed from the exercise protocol, followed by massage. Firstly the volunteers will carry out the protocol for exhaustion and the massage application will be done immediately after the end of the exercise. Blood lactate and clinical data will be collected at specific times during this stage. After 2h of the beginning of the stress protocol, the functional tests will be performed.
2476964|NCT03057210|Experimental|• S5 (Exercise + Active Recovery + Delayed Massage)|In this stage, the behavior of the variables of functional, clinical and metabolic outcome will be analyzed before the exhaustion protocol and the application of the massage after 1h of passive recovery. Firstly the volunteers will perform the protocol for exercise, followed by a passive recovery of 1h and then the massage application. The functional tests will be performed 2 hours after the stress protocol begins. Again, blood lactate collection and clinical data will occur at specific times.
2477004|NCT03056872||AUD only|AUD treatment inpatients without a co-occurring AnxD receiving AUD treatment as usual
2477007|NCT03056872||AnxD+AUD-Cognitive Behavioral Therapy (CBT)|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual in addition to CBT for co-occurring AUD+AnxD
2477011|NCT03056872||AnxD+AUD- No CBT|AUD treatment inpatients with a co-occurring anxiety disorder receiving AUD treatment as usual only.
2477014|NCT03056872||Healthy Controls|Community sample
2477152|NCT03056209|Experimental|KL1333 600mg|Group 6
2477153|NCT03056209|Experimental|KL1333 800mg|Group 7
3192719|NCT00811668|Experimental|SOMNOVentCR before CPAP|began with SOMNOvent CR and ended with CPAP
2476349|NCT03061019|Experimental|Soft Oral Appliance|Parents and participants will be instructed in wearing the soft/flexible oral appliance and how to perform nasal hygiene in order to better tolerate the device. The oral appliance comes in several sizes, adapted to the age of the child; it is constructed in a soft elastomer material, in a position of slight propulsion and opening of the mandible to help clear the pharynx. It has a ramp to guide the tongue in a good position, a labial screen to stretch the labial strap and prevent the tongue from protruding between front teeth.
2476353|NCT03061019|No Intervention|Control Group|Parents and Participants of this group will be reminded the nasal hygiene procedures (application of saline in each nostril three times a day), and given a diary to report daily use.
3192720|NCT00811681|Experimental|Pioglitazone|pioglitazone
3192721|NCT00811681|Placebo Comparator|Control|placebo
2476450|NCT03060226|Other|Control group|
2476455|NCT03060226|Other|radiosensibility group|
2476762|NCT03058549|Experimental|Intervention: Family Expectations|Family Expectations includes 36 hours of relationship education and parenting content, coaching sessions for couples, and group case management/referral information about local resources. Each couple will also complete an initial case management assessment, followed by referrals to any needed services, such as employment, substance abuse, mental health, housing, etc. Based on need, couples will have the option of additional case management/coaching services during their involvement in Family Expectations.
2476766|NCT03058549|No Intervention|Control Group|The control group will not receive the intervention though they are able to seek and obtain any services they wish in the community (Treatment as Usual).
2476839|NCT03058094|Experimental|AC0010|AC0010, 300mg, orally, BID with a 21-day cycle
2476841|NCT03058094|Active Comparator|Chemotherapy|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 on day one of 21-day cycle, with total of 4-6 cycles.
2476920|NCT03057457||Kidney Injury|
2476974|NCT03057093||TIII>TI|Subjects with TIII>TI in initial ECG
2476977|NCT03057093||Non TIII>TI|Subjects without TIII>TI in initial ECG
2476981|NCT03056781|Experimental|social interaction|Participants will engage in a social interaction with another person
2476983|NCT03056781|Experimental|food consumption|Participants will be offered food stuffs to eat/drink
2477040|NCT03056716|Experimental|Silastic drain|Placement of 19FR silastic drain as basal drain
2477042|NCT03056716|Active Comparator|Conventional drain|Placement of 32FR conventional drain as basal drain
2477087|NCT03056469|Active Comparator|Care providers do have access to PROs|Participants complete patient-reported outcome (PRO) questionnaires. Care providers do have access to the PROs and use them in clinical decision making.
2477090|NCT03056469|Active Comparator|Care providers do not have access to PROs|The participants complete patient-reported outcome (PRO) questionnaires. Care providers do not have access to the PROs.
2477092|NCT03056469|No Intervention|Control group|Standard follow-up. The participants do not complete PRO questionnaires.
2477120|NCT03056131|Experimental|Diacutaneous Fibrolysis Treatment|
2477123|NCT03056131|No Intervention|Control Group|
2477206|NCT03055845|Experimental|STA363 dose 1|
2477208|NCT03055845|Experimental|STA363 dose 2|
2477210|NCT03055845|Experimental|STA363 dose 3|
2477213|NCT03055845|Placebo Comparator|Placebo|
2477256|NCT03055390|Placebo Comparator|Control|They received two ml of normal saline intravenously as a placebo
2477257|NCT03055390|Active Comparator|20 mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2477259|NCT03055390|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
2477302|NCT03054935||Subject-CD|Subjects with Crohn's Disease in active or quiescent phase, classified according to Crohn's Disease Activity Index (CDAI >150 active; CDAI < 150 quiescent)
2477394|NCT03054233|Experimental|Obese|Obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
2477405|NCT03054233|Experimental|Non-obese|Non-obese pregnant women received spinal anesthesia using Quincke Needle 25G/27G in crossed leg sitting position for caesarean section
2477470|NCT03053973|Experimental|NIV directly started arm|Patients randomised to this arm will start noninvasive ventilation after baseline measurements are performed.
2477476|NCT03053973|Other|NIV postponed arm|Patients randomised to this arm will, after baseline measurements have been done, first be followed for 3 months while on standard care, and thus serve as the control arm. After this 3 months period, measurements are repeated and patients will also be initiated on noninvasive ventilation.
2477500|NCT03053466|Experimental|Single-Arm|APL-501
3192722|NCT00811694||a|15 male and 15 female patients with glaucoma
2477577|NCT03053206|Experimental|ADE arm|"ADE arm~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
3192723|NCT00811694||b|30 sex matched healthy volunteers
3192724|NCT00811707||1: volunteers|non-pregnant female
2476409|NCT03060668|Experimental|Study Group|"Caloric needs will be determined by indirect calorimetry. Patients in this group will receive 2.0 to 2.2 grams/kg/day of protein.~Nutritional therapy will be initiated in the first 24 hours after admission.~Nutritional formula will be Peptamen Intense (1.0 kcal/ml, 93 g/L protein (Nestle Health Care)."
2476412|NCT03060668|Active Comparator|Control Group|"Patients in this group will receive 25 Kcal/kg/day and 1.4 to 1.5 grams/kg/day of protein.~Nutritional formula in this group will be Novasource senior (Nestle Health Care).~Nutritional therapy will be initiated in the first 24 hours after admission."
2476786|NCT03058263|Experimental|partial dose of neostigmine|Those who received partial dose of neostigmine as rocuronium reversal
2476789|NCT03058263|Experimental|TOF ratio-based dose of neostigmine|Those who received TOF ratio-based dose of neostigmine as rocuronium reversal
2476855|NCT03057925|Experimental|Group A|MWA Percutaneous Microwave Ablation intervention procedure: Ultrasound-guided Percutaneous Microwave Ablation
2476856|NCT03057925|No Intervention|Group B|untreated no treatment; regular ultrasonic image follow-up
2476968|NCT03057574|Experimental|Treatment|Follitropin Alfa (Gonapure)
2476995|NCT03056885|Experimental|Conventional One-lung ventilation|The patients received a Tidal volume of 10 ml/kg (based on Predicted body weight)
2477000|NCT03056885|Experimental|Protective One-Lung Ventilation|The patients received a Tidal volume of 5 ml/kg (based on Predicted body weight)
2477054|NCT03056586|Experimental|1. study group|"100 patients who agree to participate in the study, will be operate according to our protocol for pelvic organ prolapse. At the end of the operation a vaginal pessary will be inserted and suture to the vaginal walls for a 4 week period.~Follow-up will be after 3, 6, and 12 month period."
2477057|NCT03056586|No Intervention|2. control|100 Women who will refuse to participate in the study, will agree to be follow-up by our team for 3, 6, and 12 month post operative.
2477100|NCT03056313|Experimental|proactive support of labor|delayed labor; 1 cm opening and painful contractions
2477101|NCT03056313|Active Comparator|support of labor as usual|delayed labor; 3-4 cm opening of the cervix and regular contractions
2477109|NCT03056014|Active Comparator|N-acetylcysteine 600 mg|
2477110|NCT03056014|Active Comparator|N-acetylcysteine 1200 mg|
2477111|NCT03056014|Placebo Comparator|placebo|
2477112|NCT03056014|Active Comparator|PUFA 1000 mg|
2477113|NCT03056014|Active Comparator|PUFA 2000 mg|
2477115|NCT03056014|Placebo Comparator|Placebo|
2477340|NCT03054662|Experimental|Patients with Haemophilia|Male patients with severe and moderate haemophilia A and B in Ivory Coast
2477342|NCT03054662|Experimental|Carriers for Haemophilia|Carriers for severe and moderate haemophilia A and B in Ivory Coast
3158136|NCT00379613|Placebo Comparator|1|rocuronium + 16.0 mg/kg Org 25969
3158137|NCT00379613|Experimental|2|rocuronium + 2.0 mg/kg Org 25969
2477618|NCT03052686||Childbirth with uterine rupture|No intervention. Follow-up of women with uterine rupture at the childbirth.
2477676|NCT03052439|Active Comparator|Order 1|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2477682|NCT03052439|Active Comparator|Order 2|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2477686|NCT03052439|Active Comparator|Order 3|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2477688|NCT03052439|Active Comparator|Order 4|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2477689|NCT03052439|Active Comparator|Order 5|Subjects would introduce 5 different groups of FODMAPs in a blinded fashion (random order, 1 week on, one week off) while remaining on an otherwise low FODMAP diet while monitoring their IBS symptoms.
2477721|NCT03051906|Experimental|Experimental|Durvalumab, Cetuximab and Radiotherapy followed by adjuvant Durvalumab (6 months)
2477856|NCT03051360|Placebo Comparator|Placebo|Patients will receive bi-weekly placebo.
3158138|NCT00379613|Experimental|3|rocuronium + 4.0 mg/kg Org 25969
3158139|NCT00379613|Experimental|4|rocuronium + 8.0 mg/kg Org 25969
3158140|NCT00379613|Experimental|5|rocuronium + 12.0 mg/kg Org 25969
3158141|NCT00379626|Experimental|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
3158142|NCT00379652|Active Comparator|A|Patient-based intervention
3158143|NCT00379652|Active Comparator|B|Health center-based intervention
3158144|NCT00379652|Active Comparator|C|Combination of patient and health center-based intervention
3158145|NCT00379652|No Intervention|D|Control group: Neither patient-based nor center-based intervention
3158146|NCT00379665|Experimental|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
3158147|NCT00379678||Information not available|
3158148|NCT00379743|Active Comparator|2|Individuals randomized to this arm receive the following interventions: 1) educational materials on recommended cancer-preventive services, plus 2) a health coordinator (patient navigator) who helps the participant schedule and keep appointments for cancer screening and/or treatment.
3158149|NCT00379756|Active Comparator|Levitra|10mg x 4 weeks, with option to increase to 20mg aat that time if desired
3158150|NCT00379756|Placebo Comparator|placebo|
3158151|NCT00379847|Experimental|1|Lower dose
3158152|NCT00379847|Experimental|2|Higher dose
3158153|NCT00379925|Experimental|Behavioral|Participants will take part in the Physical Activity and Dietary Health Promotion Program.
3158154|NCT00379925|No Intervention|Delayed intervention|Participants are assigned to a delayed intervention group and serve as a no-intervention control group.
3158155|NCT00379938|Experimental|1|25 micrograms + MF59 (n=26)
3158156|NCT00379938|Experimental|3|2.5 micrograms + MF59 (n=26)
3158157|NCT00379938|Placebo Comparator|4|saline (n=11)
3158158|NCT00379938|Experimental|2|25 micrograms alone (n=26)
3158159|NCT00379951|Experimental|1|Arm 1: ertapenem sodium
2476426|NCT03060850|Experimental|AC0010MA|This is dose escalation study. Patients will receive AC0010MA 200mg bid,300mg bid,400mg bid or 500mg bid by mouth (the dose escalation whether ended depends on DLT and occupancy) everyday until intolerable toxicity or disease progression
2476449|NCT03060356|Active Comparator|Melanoma|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
2476453|NCT03060356|Active Comparator|Breast|Intravenous infusion 1x10^8 total T cells modified with RNA anti-cMET CAR
2476509|NCT03060070|Placebo Comparator|control group,|saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2476511|NCT03060070|Active Comparator|ketamine group,|ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2476512|NCT03060070|Active Comparator|dexmedetomidine group|dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
2476539|NCT03059693|Experimental|HAT1 topical cream|HAT1 medicated cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The medicated cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. Treatment will continue daily until next visit. If a lesion disappears, patients will continue applying the cream twice daily to the area.
2476541|NCT03059693|Placebo Comparator|Vehicle cream|Vehicle cream will come in a blinded tube. The research team will provide instructions for the correct application of the treatment. The vehicle cream will be applied twice daily (morning and evening) at least 4 hours apart to all lesions. This will be continued daily until next visit.
3158160|NCT00379990|Experimental|GW274150 60 mg once daily for 28 days|60 mg GW274150 taken once daily for 28 days
3158161|NCT00379990|Active Comparator|Prednisolone 7.5 mg once daily for 28 days|7.5 mg prednisolone taken once daily for 28 days
2476723|NCT03058861|Experimental|Discipline education - Play Nicely program|Parents in the intervention group will receive 1) a copy of the Play Nicely Healthy Discipline Handbook (see www.playnicely.org), 2) information about how to view the Play Nicely multimedia program online and 3) the TN ACEs Handout.
2476725|NCT03058861|No Intervention|Control Group|Routine primary care will be provided.
2476761|NCT03058484|No Intervention|Control|Standard of care, i.e. regular clinic services are provided prior to the study.
2476765|NCT03058484|Experimental|Community Health Worker Intervention|This arm is a four-part behavioral intervention that includes: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
2476792|NCT03058120|No Intervention|Stress testing|Patient with chest pain, low risk by modified HEART score, undergoes whatever admission and stress testing plan is determined by ED and inheriting decision unit physicians.
2476793|NCT03058120|Active Comparator|Early discharge|Patient with chest pain, low risk by modified HEART score, is discharged from the emergency room without admission nor stress testing.
2476863|NCT03057899|Experimental|fenugreek seed and Lespedeza cuneata (TFG)|Patients who received investigational products (200 mg TFG) twice per day for 8 weeks at least 30 minutes after food intake
2476867|NCT03057899|Placebo Comparator|Placebo|Patients who received placebo twice per day for 8 weeks at least 30 minutes after food intake
2476900|NCT03057509|Experimental|Gallium PET/MR Imaging|"Siemens PET/MR scanner at Martinos Center for Biomedical Imaging will be use.~Standard Siemens software will be used to perform image analysis and measure parameters such as SUVmean, SUVmax and MTV.~Standard LAR Octreotide will be administered.~Ga-68-DOTA-TOC that will be administered prior to PET/MR imaging at 7 days after standard LAR octreotide administration and again at 28 day.~Ga-68-DOTA-TOC will be administered as a single intravenous dose at a pre-determine dosage."
2476910|NCT03057236|No Intervention|Standard of Care|This arm does not receive the behavioral intervention. Participants will complete HCV treatment per standard of care.
2476913|NCT03057236|Experimental|Cognitive Behavior Coping Skills|The CBCS intervention is a structured module-based group intervention involving 9, 2-hour sessions. Participants will participate in 4 weekly sessions before HCV treatment to learn and practice new cognitive behavioral skills, and 5 sessions during HCV treatment at weeks 2, 4, 6, 8, and 12.
3192725|NCT00811707||2: parturients|parturients was scheduled to receive lumbar epidurals for elective cesaeran delivery labor analgesia
3158162|NCT00379990|Placebo Comparator|Placebo once daily for 28 days|Placebo taken once daily for 28 days
3158163|NCT00380042|Active Comparator|Active Stimulation|
3158164|NCT00380042|Sham Comparator|Sham|
2477155|NCT03055949|No Intervention|pre-ERP|A group of the surgical ICU patients who had standard care before Asan medical center developed an early rehabilitation program (ERP)
2477156|NCT03055949|Experimental|post-ERP|A group of the surgical ICU patients who had an early rehabilitation program (ERP) within SICU care
2477193|NCT03055689|Experimental|Educational telephone intervention|This group will receive a nurse-led educational telephone intervention for bowel preparation 24-48 before the colonoscopy
2477197|NCT03055689|Active Comparator|Standard education for colonoscopy|The control group will receive standard education for bowel preparation at the time of colonoscopy scheduling
2477251|NCT03055351|No Intervention|Control group|Participants will complete the outcome measures but will not receive any intervention.
2477253|NCT03055351|Experimental|Stop&Go Intervention|Participants in this group will participate in an intervention aimed at promoting a healthy and physically active lifestyle. The intervention will be based on Self-determination theory postulates and will have two axes: training and motivation.
2477300|NCT03055052|Active Comparator|Control Formula|Standard formula for preterm infants.
2477301|NCT03055052|Experimental|Experimental formula|Formula with higher protein and new fat blend for preterm infants.
2477906|NCT03050723|Other|Princess® FILLER|
2477932|NCT03050411|Experimental|Apatinib|Apatinib in combination with EGFR-TKIs
3158165|NCT00380055|Experimental|Screening Navigation|Individuals without a study cancer who receive services of a navigator.
3158166|NCT00380055|Experimental|Treatment Navigation|Individuals with a study cancer who receive navigation services.
3158167|NCT00380055|Active Comparator|Screening Education|Rather than receiving navigation, these participants receive general cancer education appropriate to Medicare enrollees.
2476445|NCT03060525|Experimental|Immediate Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 1 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2476446|NCT03060525|Experimental|Immediate Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 1 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2476447|NCT03060525|Other|Delayed Group Intervention|This arm will receive the DWW 2.0 Group intervention in Year 2 of the clinical trial. The group intervention will consist of groups of approximately 6-8 subjects who meet together for 16 weeks, for two hours each week. A trained, deaf, American Sign Language (ASL)-fluent DWW 2.0 counselor will lead the sessions. Subjects will be asked to complete a daily food and physical activity diary during the course of the 16-week intervention. Each intervention session will include a weigh-in, group sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2476448|NCT03060525|Other|Delayed Videophone Intervention|This arm will receive the DWW 2.0 Individual Videophone intervention in Year 2 of the clinical trial. The participant and their intervention counselor will have one-on-one sessions that take place via videophone (like a Skype call), for one hour each week. Each session will be led by a trained deaf, ASL-fluent DWW 2.0 counselor and will be held at a scheduled appointment time that is agreed upon by the subject and the counselor. Subjects will be asked to complete a daily food and physical activity diary during the the course of the 16-week intervention. Each intervention session will include a weigh-in, personal sharing and problem solving, discussion of a weight management topic, which may include watching a powerpoint presentation and/or video; and a discussion on goal setting and action planning for the next week.
2476489|NCT03060161|Experimental|Health in the right measure|"Nutrition counseling and guidance for regular physical activity. An individualized physical exercise program will be proposed according to each participant's level of physical activity and health conditions.~Participants will also receive individualized nutritional guidance. Throughout the project, collective motivational activities will be carried out to promote healthy eating (culinary workshops, talk wheels and others) and individual activities with all participants, in order to evaluate the adherence of nutritional guidelines and to exchange experiences among them."
2476513|NCT03059888|Experimental|Abatacept|125mg abatacept in 1ml solution administered once per week by subcutaneous injection
2476530|NCT03059680|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
2476531|NCT03059680|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake
2476641|NCT03059446|Experimental|Cenicriviroc|Cenicriviroc (CVC) 150 mg tablet once daily in the morning with food until CVC is commercially available or the study is terminated.
2476758|NCT03058588||Analysis with molecular biology|"Any patient with acute leukemia or other myeloid malignancy AND~a first- or second-degree relative with acute leukemia or other myeloid malignancies~a first- or second-degree relative with lymphoproliferative neoplasms~or with clinical features that resemble one of the familial myeloid malignancies predisposition syndromes"
2476922|NCT03057535|Experimental|Sodium Bicarbonate|Ingestion of sodium bicarbonate (0.3 g/kg of body mass)
2476925|NCT03057535|Placebo Comparator|Sodium Chloride|Ingestion of sodium chloride (4 g)
2476998|NCT03057067|Experimental|pelvic vein embolization|female patients referred for assessment of chronic pelvic pain at the gynecological outpatient clinic or the Multidisciplinary Pain Clinic at St. Olavs Hospital, Trondheim, Norway
2477076|NCT03056638|Experimental|Degarelix in conjunction with stereotactic body radiosurgery|Degarelix monthly for 6 months SBRT 8 Gy x 5
2477078|NCT03056638|Experimental|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
2477127|NCT03056118|Experimental|6-month dual anti-platelet therapy|maintain dual anti-platelet agents for 6 months
2477132|NCT03056118|Active Comparator|12-month dual anti-platelet therapy|maintain dual anti-platelet agents for 12 months
2477138|NCT03056118|Active Comparator|Zotarolimus eluting stent arm|implant with zotarolimus eluting stent (Resolute Integrity)
2477144|NCT03056118|Active Comparator|Biolimus eluting stent arm|implant with biolimus eluting stent (Biomatrix)
2477277|NCT03055130||Case group|Female IBD patients who had sexual life between 21-60 years-old were recruited.
2477279|NCT03055130||control group|Female people who perform physical examination in our hospital between 21-60 years-old were recruited as control during the study period.
2477439|NCT03054142||AKI|
2477442|NCT03054142||non-AKI|
2503984|NCT02873871|Other|Control group|Standardized compressive dressing
2476482|NCT03060291|Active Comparator|Web/mobile + coach|Participants will complete the FCU online and will be contacted by a family coach. The coach will conduct motivational interviewing and provide support to parents via phone. Participants in this condition will have contact with a coach at least 2 times.
2476485|NCT03060291|No Intervention|Wait list control|"Participants in this condition will receive middle school as usual, meaning that they will continue to receive whatever services are normally provided by the middle school during the year of their participation in the study. Once their research participation is completed (i.e., after they complete their final follow-up survey), participants in this condition will be offered the opportunity to use the FCU-Online website if they wish, without the support of a coach. No additional data will be collected."
2476532|NCT03059875|Other|Strategy A|Comprehensive Geriatric Assessment before the surgery of breast
2476533|NCT03059875|Other|Strategy B|Comprehensive Geriatric Assessment after the surgery of breast
2476579|NCT03059563|Experimental|Varenicline|A standard dose titration regimen that is used for smoking-cessation will be followed. The pharmacist will prepare capsules of varenicline for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing 0.5 mg VAR each day (0900 h) for 3 days, then one capsule containing 0.5 mg VAR twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing 1 mg VAR twice daily (0900 h, 2100 h) for the next 2 weeks.
2476581|NCT03059563|Placebo Comparator|Placebo|The same procedure used for varenicline treatment will be followed. The pharmacist will prepare capsules of placebo for each week of study participation. Under observation by a study clinician, participants will receive one capsule containing placebo each day (0900 h) for 3 days, then one capsule containing placebo twice daily (0900 h, 2100 h) for 4 days, and finally a capsule containing placebo twice daily (0900 h, 2100 h) for the next 2 weeks.
2476642|NCT03059238|Experimental|Celecoxib group|Celecoxib 200mg oral capsule, 200 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2476645|NCT03059238|Experimental|Parecoxib group|Parecoxib sodium , 40 mg, dissolved in 3 mL 0.9% sodium chloride intravenously one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2476647|NCT03059238|Experimental|Oxycodone group|Controlled-release oxycodone, 10 mg, orally one hour before TACE and once every 12 hours for 2 days after TACE, with totally 5 times.
2476692|NCT03058835|Experimental|PrEP with Truvada|All study participants will be assigned to this arm and will receive Truvada tablets (tenofovir disoproxil and emtricitabine) for PrEP
2476750|NCT03058419|Experimental|Drug Cocktail + JNJ-54175446|All subjects will receive a single dose of drug cocktail (consisting of midazolam [2 milligram (mg)], warfarin [10 mg], caffeine [50 mg], dextromethorphan [30 mg], bupropion [150 mg] and omeprazole [20 mg]) on Day 1, 7 and 11; JNJ-54175446 150 mg on Day 7, 9, 10 and 11 and JNJ-54175446 600 mg on Day 8.
2476824|NCT03058016|Experimental|Personalized recommendations for diet|"After measurement of individual's parameters changes as blood tests, gut microbiome, urine tests, blood pressure, heart performance, body circumferences, mood and mental status as well as monitoring each individual's food intake - a model to predict individual's body reaction according to lifestyle, eating and activity habits will be built.~Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions will be provided on a bi-weekly basis, all Lab tests and dietician control will be performed twice a month."
2476864|NCT03057782||Group A|"Plan for major surgery anticipated to cause pain and agitation (i.e. esophageal atresia treatment);~Patients who are anticipated to receive prolonged post-surgical neuromuscular blockade (NMB)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. These subjects will also receive EMG monitoring. Subjects in this group will also have video recordings that may be used for novel analysis such as subdermal blood flow or micro-movement."
2476868|NCT03057782||Group B|"Plan for major surgery anticipated to cause pain and agitation (i.e. bowel surgery);~Patients who are not anticipated to receive acute post-surgical NMB~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2476872|NCT03057782||Group C|"Plan for minor surgery anticipated to cause pain and agitation (i.e. hernia repair)~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2476873|NCT03057782||Group D|"No plan for surgery~The following devices will be used in this Group: Waveguard (TM) EEG cap; Micro Movement Sensor; Pico Movement Sensor; QS Piezostimulator; tactileTM sensory evaluator. Subjects in this group will also have video recordings that may be used for novel analysis such as sub-dermal blood flow or micro-movement."
2476982|NCT03057119|Experimental|SBIRT Intervention|The interventionist will discuss substance use and misuse, HIV, and the interaction of aging and substance use; will give the patient feedback on their NM-ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change; motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues. Identifying and prioritizing need; problem-solving techniques to help patients identify which services may best help them work towards their goals; will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
2476984|NCT03057119|No Intervention|Treatment as Usual|Participants in the enhanced care treatment as usual group will receive the same illustrated handout depicting their substance use screening score and the same referral resource guide provided to those in the control group. These will be provided with only a quick introduction by the research assistant to minimize intervention elements in the control condition and to resemble the notification and referral strategy that would be standard care.
2477067|NCT03056703|Experimental|Acetylsalicylic acid [1000mg]|
2477075|NCT03056703|Active Comparator|Acetylsalicylic acid [500mg]|
2477121|NCT03056274|Active Comparator|Metformin arm|Metformin
2477124|NCT03056274|Active Comparator|Ursodeoxycholic acid|Ursodeoxycholic acid
2477195|NCT03055780||CT-FFR. CTA. FFR|59 patients with suspected CAD that have been scheduled for an interventional FFR study
2476536|NCT03060044|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
2476538|NCT03060044|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration
2476632|NCT03059472|Experimental|Group 1 (Intervention)|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
2476635|NCT03059472|Experimental|Group 2 (Delayed intervention)|Delayed intervention participants will participate in the same activities as Group 1 but 6 months after Group 1.
2476673|NCT03058783|Experimental|IDP-124 Lotion|Lotion
2476676|NCT03058783|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
2476738|NCT03058614|Active Comparator|CEUS arm|On postoperative day 1 (unless not clinically indicated), each subject will undergo CEUS with an administration of Lumason via their pre-placed nephrostomy tube.
2476739|NCT03058614|Active Comparator|CT scan plus capping trial arm|On postoperative day 1 (unless not clinically indicated), subjects' pre-placed nephrostomy tube will be capped and they will undergo a low dose non-contrast abdominal CT scan.
2476804|NCT03058250|No Intervention|Control|Standard of care, no intervention
2476807|NCT03058250|Active Comparator|Transesophageal echocardiography|Patients will have intraoperative transesophageal echocardiography along with standard of care for management.
2476881|NCT03057873|Experimental|High protein, high fiber|Participants receive a high protein, high fiber dietary supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
2476883|NCT03057873|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber supplement twice daily (30 minutes before breakfast and lunch) for 12 weeks
2476943|NCT03057405||intra-operative CBCT|
2476946|NCT03057405||3D virtual planning + intra-operative navigation|
2476949|NCT03057405||3D virtual planning + intraoperative navigation + IO CBCT|
2476992|NCT03057041|Experimental|Fentanyl|
2476993|NCT03057041|Placebo Comparator|Placebo|
2477062|NCT03056625|Experimental|Fortified rice|Participant will be given vitamin A fortified rice 1 meal/day
2477070|NCT03056625|Placebo Comparator|Control|Participant will be given normal rice 1 meal/day
2477129|NCT03056261|Experimental|Combined general and epidural|Combined general and epidural anesthesia in infants UNDERGOING INTESTINAL SURGERY
2477135|NCT03056261|Placebo Comparator|General anaesthesia|General anesthesia in infants UNDERGOING INTESTINAL SURGERY
2477201|NCT03055754|Experimental|Argon randomized arm|Endoscopic procedure with a full inventory, measurement of the anastomosis diameter, and an argon plasma coagulation. Followup of all patients by a multidisciplinary team (life, food orientations).
2477202|NCT03055754|Active Comparator|Control arm|Full inventory and measurement of the anastomosis diameter, without any intervention. Followup of all patients by a multidisciplinary team (life, food orientations).
2477238|NCT03055429|Experimental|Full Scale Unit|Testing of 6 modules
3192726|NCT00811746|Experimental|1|Rozerem (Ramelteon) 8 mg taken orally 30 minutes before a split-night PSG
2477366|NCT03054311|Experimental|Lifestyle Matters intervention|
3158168|NCT00380055|Active Comparator|Treatment Education|Rather than receiving navigation services, these participants receive cancer education appropriate to Medicare recipients.
3158169|NCT00380120|Experimental|1|Tailoring the duration of anticoagulation according to the ultrasound persistence of residual vein thrombosis
2477460|NCT03053986|Active Comparator|Apple polyphenols|White capsule containing 300 mg of apple extract (Malus Domestica) with glycosilated polyphenols (≥90%) including glycosilated phloritzin (15-30%), chlorogenic acid (10-25%) and quercetin (15-25%)
2477465|NCT03053986|Placebo Comparator|Placebo|Indistinguishable capsules with similar dimension, colour, odour and taste
2477525|NCT03053557|Experimental|Social Skills Coach|The Social Skills Coach arm of the study will be provided access, instruction, and support for using the newly developed multi-platform device to address social impairments among individuals with schizophrenia, based on the evidence-based Social Skills Training (SST) intervention.
2477529|NCT03053557|No Intervention|Social Skills Training course|Social Skills Training classes are widely available and regularly used in the study setting. As such, this group will serve as a treatment as usual control group.
2477570|NCT03053115|Experimental|CASES|treatment with levothyroxine and liothyronine
2477571|NCT03053115|Active Comparator|CONTROLS|treatment with levothyroxine and placebo
2477607|NCT03052829|Experimental|Physical Activity Counseling|Subjects will be given counseling on the benefits of increasing activity, instructions on how to slowly increase their activity over 12 weeks with walking, record their daily step counts, and have bi-weekly phone calls with study staff to reinforce the training and help them overcome barriers to being physically active.
2477608|NCT03052829|Placebo Comparator|Patient Usual Care|Subjects will undergo usual care without intervention in this study arm
2477664|NCT03052205|Experimental|IMO-2125 at escalating dose levels|IMO-2125 at escalating dose levels by intratumoral injection
2477706|NCT03051958|Experimental|Internet mindfulness&exposure treatment|A 12-week treatment where the main treatment components are mindfulness, exposure and response prevention, a form of cognitive behavior therapy. The treatment entails methods to increase acceptance and non-reactivity to aversive thoughts and emotions associated with AD. The treatment is delivered via the Internet and comprises 10 modules, each with a specific theme. Throughout treatment, the patient is given structured exercises to work with on a daily basis.
2477708|NCT03051958|Active Comparator|Treatment as usual|"Participants receive information about moisturizer and anti-inflammatory lotion treatment which is treatment as usual.~After 12 weeks, patients in this arm are crossed over to treatment."
3158170|NCT00380120|Active Comparator|2|Administering a fixed duration of anticoagulation (i.e., discontinue it at the time of randomization in patients with secondary DVT, and prolong it for 3 additional months in patients with idiopathic DVT)
3158171|NCT00380133|Experimental|Randomised, double-blind, five-way crossover|A randomised, double-blind, double-dummy, placebo-controlled, five-way crossover study to assess the effects of single oral doses of SB-681323 (7.5 mg and 25 mg) and prednisolone (10 mg and 30 mg) on biomarkers in induced sputum and blood in COPD patients.
2476546|NCT03059836|Experimental|n3 PUFA|Intervention: n3 PUFA (3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day)
2476551|NCT03059836|Placebo Comparator|Placebo|Intervention: Organic Sunflower Oil 5000mg per day
2476679|NCT03059004|Experimental|1. Home Exercise Program|The Home Exercise group receives the TeMPO Home Exercise Program (including a set of weights, a DVD showing how to complete the TeMPO exercises, and a pamphlet outlining instructions on how to complete the exercises and how often should they be done).
2476681|NCT03059004|Experimental|2. Home Exercise Program + SMS Messages|Subjects in this arm receive the TeMPO Home Exercise Program and motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise regimen.
2476682|NCT03059004|Experimental|3. In-Clinic Topical Therapy|Subjects in this arm receive the TeMPO Home Exercise Program, motivational SMS messages to encourage them to adhere to the TeMPO Home Exercise Program, and 14 in-clinic sessions with a trained physical therapist. The therapist will apply topical therapies: ultrasound, gel, and manual therapy.
2476684|NCT03059004|Experimental|4. In-Clinic Exercise Therapy|Subjects in this arm will receive the TeMPO Home Exercise Program, SMS motivational messages to encourage them to adhere to the TeMPO Home Exercise Program and 14 in-clinic sessions with a trained physical therapist. The therapist will supervise the participant in a rigorous set of strengthening and stretching exercises.
2476767|NCT03058289|Experimental|Cohort A|"INT230-6 injections every 28 days for 5 sessions into only superficial tumors, low starting dose, low concentration per tumor.~Closed to enrollment"
2476769|NCT03058289|Experimental|Cohort B1|"INT230-6 injections every 28 days for 5 sessions into deep tumors, low starting dose, low drug concentration per tumor~Closed to enrollment"
2476771|NCT03058289|Experimental|Cohort EA|"INT230-6 injections every 2 weeks for 5 sessions into superficial tumors, medium starting dose, low drug concentration per tumor~Closed to enrollment"
2476772|NCT03058289|Experimental|Cohort EC|"INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, moderately high starting dose, high drug concentration per tumor~Closed to enrollment"
2476774|NCT03058289|Experimental|Cohort EC2|INT230-6 injections every 2 weeks for 5 sessions into superficial or deep tumors, high starting dose, moderate drug concentration per tumor, higher number of tumors to be treated per session than EC
2476775|NCT03058289|Experimental|Cohort DEC: Safety with INT230-6|"INT230-6 injections every 2 weeks for 5 sessions with the possibility for INT230-6 retreatment into superficial tumors, with addition of anti-PD-1 antibody Keytruda (pembrolizumab) dosed concurrently starting at Day 1 every 3 weeks for two years for selected cancer types.~Closed to enrollment"
2476777|NCT03058289|Experimental|EC3: INT230-6 monotherapy fixed maximal dose|INT230-6 injections every 2 weeks for 5 sessions at fixed maximal dose into superficial or deep tumors, unlimited number of tumors to be treated per session with retreatment once every 9 weeks for two years.
2476778|NCT03058289|Experimental|DEC2: INT230-6 combined with pembrolizumab|INT230-6 per the dosing of cohort EC3 combined with Keytruda (pembrolizumab) dosed per DEC concurrently starting at Day 1 for selected cancers.
2476779|NCT03058289|Experimental|FEC: INT230-6 combined with ipilimumab|INT230-6 per the EC3 regimen combined with Yervoy (ipilimumab) dosed concurrently starting at Day 1 every 3 weeks for four treatments for selected cancer types.
2476858|NCT03057951|Experimental|Empagliflozin|
2476860|NCT03057951|Placebo Comparator|Placebo|
2477339|NCT03054675||Pneumonia|"Patients suffering from postoperative pneumonia including all three of the following:~Clinical signs of a pulmonary infection (i.e. fever ≥ 38°C combined with productive cough and/or dyspnea)~A new rise of inflammatory markers (i.e. WBC count ≥ 10.5 x 109 and elevated CRP)~New radiographic infiltrates on chest x-ray without another explanation. Patients with pneumonia undergo spirometry before and on every second day after lung surgery"
2477341|NCT03054675||No Pneumonia|Patients without pneumonia undergo spirometry before and on every second day after lung surgery
2477344|NCT03054675||Open (no pneumonia)|"Patients undergoing open anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
2477345|NCT03054675||Minimally invasive (no pneumonia)|"Patients undergoing minimally invasive anatomical lung resection who did not show postoperative pneumonia.~All patients undergo spirometry before and on every second day after lung surgery."
2477383|NCT03054402|Experimental|Dose escalation/BAY1834845|Subjects will receive a single dose of BAY1834845 in the morning of the PK profile day
2477391|NCT03054402|Placebo Comparator|Placebo|Subjects will receive a single dose of placebo in the morning of the PK profile day
2477458|NCT03053999||Parathyroidectomy Tissue and Data|"Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.~Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels)."
2477518|NCT03053622|Experimental|Mirikizumab Test Subcutaneous (SC) 1|Mirikizumab test formulation given as a single injection under the skin in healthy participants
2477521|NCT03053622|Experimental|Mirikizumab Test SC 2|Mirikizumab test formulation given as two injections under the skin in healthy participants
2477527|NCT03053622|Experimental|Mirikizumab Test Intravenous (IV)|Mirikizumab test formulation given as an infusion into the vein in healthy participants
2477533|NCT03053622|Active Comparator|Mirikizumab Reference|Mirikizumab reference formulation given as three injections under the skin in healthy participants
2477573|NCT03053011|Experimental|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight
2477619|NCT03052894|Experimental|Hydraulic Monitoring Device|Monitoring device to be compared to electromyographic (EMG) device in the same patient; measures depth of neuromuscular blockade during general anesthesia based on the pressure exerted by the muscles of the thumb.
2477623|NCT03052894|Active Comparator|Standard EMG Monitoring Device|Currently used standard monitoring device; measures depth of neuromuscular blockade during general anesthesia based on the action potential of the muscles of the thumb.
2477637|NCT03052881|Experimental|Robot assisted surgery|To investigate use of an intraocular robotic system to assist the surgeon in performing one of two operation: i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage.
2476559|NCT03059628|Experimental|Personalized Normative Feedback group|A personalized normative feedback using a tablet application will be performed after the BTI at ED. The application installed on the patient's smartphone will automatically repeat the PNF, using a local algorithm, once a month over a 6-months period after discharge, and once every two months in the following 6-month period. It will be also possible to perform the PNF on the server website.
2476564|NCT03059628|Other|Control group|The control group will not receive further counseling or information after the baseline BTI at ED. The application installed in this group will be only used for the evaluation questionnaire at 6 and 12 months
2476656|NCT03059108|Experimental|Early Loading|Implant early loading: prosthesis delivery 4 weeks after implant placement
2476657|NCT03059108|Active Comparator|Conventional Loading|Implant conventional loading: prosthesis delivery 8 weeks after implant placement
2476669|NCT03058757|No Intervention|Control arm|No intervention applied.
2476671|NCT03058757|Experimental|Intervention arm|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation
2476727|NCT03058666|Experimental|Aerosolized Calfactant|"NICU Patients with a clinical diagnosis of RDS~Inspired oxygen ≥21% to maintain adequate oxygen saturation~Not Intubated~Requiring Nasal continuous positive airway pressure"
2476728|NCT03058666|No Intervention|Usual Care|There will be no protocol driven interventions in the usual care group.
2476802|NCT03058224|Experimental|IGN-ES001|Polyclonal avian immunoglobulin IgY containing specific IgY against E. coli F18ab and S. typhimurium in partially delipidated avian egg yolk powder
2476808|NCT03058224|Placebo Comparator|Placebo|Polyclonal avian immunoglobulin IgY containing unspecific IgY in partially delipidated avian egg yolk powder
2476911|NCT03057600|Experimental|Cohort 1 - African ancestry, 3rd line+|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (AA; includes African American).~At least 2 prior lines of systemic therapy for advanced/metastatic disease including a taxane.~Prior taxane (paclitaxel, docetaxel, or nab-paclitaxel) for advanced/metastatic disease is required but must not have been received in the immediate prior line of therapy.~Systemic neoadjuvant and/or adjuvant therapy is considered a line of therapy for advanced/metastatic disease if the time to recurrence from completion of treatment was ≤ 12 mo."
2476915|NCT03057600|Experimental|Cohort 2 - African ancestry, 1st line|"Intervention = Pac-CB combination~Patients must self-identify as African ancestry (includes African American).~No prior systemic therapy for advanced or metastatic disease.~Systemic neoadjuvant or adjuvant therapy, including taxane, is allowed if time to recurrence was > 12 mo."
2476916|NCT03057600|Experimental|Cohort 3 - Non-AA, 3rd line+|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 1."
2476917|NCT03057600|Experimental|Cohort 4 - Non-AA, 1st line|"Intervention = Pac-CB combination~Patients do not self-identify as African ancestry.~Otherwise have the same criteria as Cohort 2."
2477010|NCT03056859||Enrolled Patients|Procedure: Central venous catheter placement with extravascular blood pressure transducer
2477055|NCT03056560|Experimental|Video Bystander Program|TakeCARE video
2477058|NCT03056560|No Intervention|Control Video|Study Skills Video
2477102|NCT03056287|Experimental|Aerobic Exercise|Treadmill aerobic exercise
2477104|NCT03056287|Experimental|rTMS|repetitive transcranial magnetic stimulation
2477106|NCT03056287|Experimental|AET+rTMS|Combined aerobic exercise and rTMS
2477107|NCT03056287|Sham Comparator|Sham|Sham rTMS
2477139|NCT03055962|Experimental|E2609 50 mg|Participants will receive E2609 50 milligrams (mg) orally once a day for 14 days.
2477149|NCT03055962|Placebo Comparator|Placebo|Participants will receive matching placebo orally once a day for 14 days.
2477205|NCT03055819|Experimental|ZiftLift Tissue Anchor|Use of ZiftLift Tissue Anchors for Brow Lift
2477264|NCT03055442||Follicular Fluids|Follicular fluids obtained by 8 oocyte donors
2477317|NCT03054974|Experimental|Modern rehabilitation treatment|Modern rehabilitation treatment
2477322|NCT03054974|Experimental|Modern rehabilitation &TCM|Modern rehabilitation treatment and traditional Chinese medicine
2477328|NCT03054974|Experimental|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment and Baimai Ruangao
2477332|NCT03054974|Experimental|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine treatment
2477362|NCT03054415|Other|Healthy Subjects|
2477381|NCT03054285|No Intervention|No seizure prophylaxis|Participants randomized to this arm will not receive anti-seizure prophylaxis
2477392|NCT03054285|Experimental|Seizure Prophylaxis|Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.
3192727|NCT00811746|Active Comparator|2|Lunesta (Eszopiclone) 3 mg taken 30 minutes before the start of split-night PSG
2477520|NCT03053310||Primary (P) - group|"Patients with a primary diagnosis~Patients treated with curative intent (stage I-IVb)"
2477526|NCT03053310||Relapse (R) - group|"Patients with a recurrent (loco)regional tumour~Patients treated with curative intent (stage I-IVb)"
2477566|NCT03053128|Experimental|CSWT group|Patients in CSWT group will receive cardiac shock wave therapy for three moths, every first week of the month.
2477569|NCT03053128|Sham Comparator|Sham CSWT group|Patients in sham CSWT group will receive sham cardiac shock wave, which segregated by an air-cushion.
3192728|NCT00811746|Other|3|Historical controls (chart review) matched for demographics and comorbidities of the study drug groups.
3192729|NCT00811772|Active Comparator|Bare metal stent|Implantation of one or more bare metal stent(s) to to treat coronary artery stenosis
3192730|NCT00811772|Experimental|Drug eluting stent|Implantation of one or more drug eluting stent(s) to treat coronary artery stenosis
3192731|NCT00811811|Experimental|1|Behavioral neurocardiac training
3192732|NCT00811811|Active Comparator|2|Autogenic relaxation training
3192733|NCT00811824|Active Comparator|1|Immediate physical activity and dietary change intervention
3192734|NCT00811824|Other|2|Delayed physical activity and dietary change intervention
3192735|NCT00811837|Experimental|Remifentail|Remifentanil Infusion
3192736|NCT00811837|Active Comparator|Midazolam|Active Placebo
2476568|NCT03060005|Experimental|secondary Sjögren's syndrome|The female patients with secondary Sjögren's syndrome receive Tears Naturale Forte and Liposic.
2476572|NCT03060005|Experimental|meibomian gland dysfunction|The female patients with meibomian gland dysfunction receive the Tears Naturale Forte and Liposic.
2476575|NCT03060005|Experimental|control|the female had no history of autoimmune disease receive the Tears Naturale Forte and Liposic.
2476612|NCT03059225|Experimental|Experimental|repetitive transcranial magnetic stimulation (rTMS) intervention of contralesional 1Hz-rTMS for 10 daily sessions.
2476618|NCT03059225|Sham Comparator|Sham stimulation|Sham treatment for 2-week inhibitory non-dominate hemisphere rTMS program.
2476622|NCT03059225|Experimental|High frequency rTMS|High-frequency rTMS to ipsilesional region for 10 daily sessions.
2476696|NCT03058965|Experimental|[18F]MNI-958|To evaluate [18F]MNI-958, a tau targeted PET radioligand.
2476747|NCT03058432|Experimental|Intensity-modulated Radiotherapy|Radiotherapy alone was given.
2476749|NCT03058432|Active Comparator|Concurrent chemoradiotherapy|Concurrent cisplatin-based radiotherapy was given.
2476798|NCT03058172|Other|Odors (food and non-food)|Odorants diluted in mineral oil.
2476810|NCT03058172|Other|Pictures (food and non-food)|Pictures of objects or scenes.
3158172|NCT00380146|Experimental|SP plus artesunate|SP (Fansidar®, Roche South Africa) at a dose of 25/1.25mg/kg of sulfadoxine/pyrimethamine respectively on day 0 only, and artesunate (Arsumax®, Sanofi-Aventis, South Africa) at a dose of 4mg/kg on days 0, 1, and 2
2476907|NCT03057327|Active Comparator|comparator|As women exit the changing are they will be asked if they regularly check their skin for concerning moles
2476908|NCT03057327|Experimental|Improve awareness of checking moles|Posters, brochures, and skin self-examination kits consisting of a ruler, and a lighted magnifying lens will be placed into each of the 8 changing rooms in the mammogram facility.
2476944|NCT03057184|Experimental|Intervention group|behavioral intervention program
2476945|NCT03057184|No Intervention|Usual care|Usual care
2477021|NCT03057015|Experimental|Clonidine|50 mcg clonidine + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
2477024|NCT03057015|Placebo Comparator|Placebo|0.5 ml normal saline + 0.5% ropivacaine + 2 mg dexamethasone + 5 mcg/ml epinephrine in 20 ml solution
2477084|NCT03056404|Experimental|control subject|additional blood sample and 15 control subjects will be seen in consultations in the service of pneumology. The visit will include an auscultation, a respiratory functional exploration and a blood test (2 tubes of 7 ml of total blood). A questionnaire of exhibition will be realized to collect the species of birds and the times of exhibition.
2477114|NCT03056157|Experimental|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
2477116|NCT03056157|Active Comparator|Present Centered Therapy|PCT is a manualized evidenced-based PTSD treatment used in several large-scale PTSD trials. It incorporates the essential therapeutic elements common to different types of psychotherapies, including supportive empathic listening and unconditional positive regard. The therapist plays an active role, but does not impart any systematic training. The focus is to create an understanding of how the symptoms of PTSD are related to day-to-day difficulties and to help patients develop new, more adaptive responses to these stressors with a problem-focused and problem-solving approach. In prior trials, PCT showed equivalent change to active therapies at the last follow-up. The VA offers PCT as an evidence-based therapy for PTSD.
2477190|NCT03055637|Active Comparator|patients with isolated cleft palate|Patients requiring isolated cleft palate repair
2477194|NCT03055637|Active Comparator|Patients with isolated cleft palate|Patients requiring isolated cleft palate repair
2477240|NCT03055455||Sepsis|Children with severe sepsis or septic shock
2477289|NCT03055182|Experimental|Low back pain patients|Subjects included in physical rehabilitation program.
2477290|NCT03055182|No Intervention|Control subjects|No intervention administered
2477334|NCT03054779|Experimental|Canola oil|regular canola oil
2477336|NCT03054779|Experimental|High oleic acid canola oil|high stability/high oleic canola oil
2477337|NCT03054779|Active Comparator|Western diet oil combination|"a typical Western diet fat intake comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA"
3192737|NCT00811863||1|Subjects with moderate renal insufficiency defined as an eGFR 30-60 mL/min/1.73 m2
2477568|NCT03053258||Diagnostic Breath Analysis: VAP|Collection of exhaled breath samples
3158173|NCT00380185||1|Subjects with no hemodynamically significant disease (NHSD) of the coronary or peripheral arteries
3158174|NCT00380185||2|Subjects with coronary artery disease only
3158175|NCT00380185||3|Subjects with both coronary artery disease and peripheral arterial disease
3158176|NCT00380237|Experimental|1|Two vaccinations with H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine at a dose of 10^7 TCID50 delivered by nose drops. The second vaccination will be given 4 to 12 weeks after the first.
3158177|NCT00380276|Other|Open Label Arm|Treatment is open-label
3158178|NCT00380406|Placebo Comparator|Placebo|Placebo
3158179|NCT00380406|Active Comparator|depot GnRHa (Leuprolide acetate (LA) 11.25 mg intramuscularly)|
3158180|NCT00380419|Experimental|1|Participants will receive 16 sessions of interpersonal psychotherapy
3158181|NCT00380484|Experimental|1|Budesonide
3158182|NCT00380484|Active Comparator|2|Montelukast
3158183|NCT00380497|Experimental|Pico-Salax|
3158184|NCT00380497|Active Comparator|PEGlyte|
3158185|NCT00380536|Experimental|1|Participants will participate in peer-led medical illness self-management group sessions.
3158186|NCT00380536|No Intervention|2|Participants will receive treatment as usual.
2476574|NCT03059940|Experimental|Quitline-Rx (QL-Rx) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~LDCT provider and patient discuss options for pharmacotherapy.~Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks."
2476576|NCT03059940|Experimental|Integrated Care (IC) Group|"Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan. CO level measured at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.~Participants have a CT scan of chest to look for signs of lung cancer. Participants watch a short video about lung cancer, CT scans, and smoking cessation. Brief cessation counseling given by LDCT provider.~Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,"
2476651|NCT03059134|Experimental|Mirabegron 25mg for 12 weeks|Mirabegron 25mg once-daily for 4 weeks, and continue the same dose of mirabegron for another 8 weeks
2476652|NCT03059134|Active Comparator|Mirabegron 25mg followed by 50mg|Mirabegron 25mg once-daily for 4 weeks, and increase the dose to 50mg for another 8 weeks
2476653|NCT03059134|Active Comparator|Mirabegron 25mg followed by solifenacin|Mirabegron 25mg once-daily for 4 weeks, and shift to solifenacin 5mg for another 8 weeks
2476655|NCT03059134|Active Comparator|Mirabegron 25mg add-on solifenacin|Mirabegron 25mg once-daily for 4 weeks, and add-on solifenacin 5mg for another 8 weeks,
2476698|NCT03058744|Experimental|IDP-118 Lotion|8 Weeks
2476705|NCT03058744|Experimental|HP Monad Lotion|8 Weeks
2476715|NCT03058744|Active Comparator|Ultravate Cream|2 Weeks
2476719|NCT03058744|Active Comparator|Tazorac Cream|4 Weeks
2476845|NCT03058276|Experimental|Exposure|Exposure to a 5 minutes video related to alcohol consumption (updating/retrieval), followed by 10 minutes of the alcohol- AAT(Approach Avoidance Task) (extinction), during 4 days of training (2 weeks).
2476848|NCT03058276|Active Comparator|No exposure|Exposure to a 5 minutes video with neutral content (no retrieval) followed by 10 minutes of the alcohol- AAT (Approach Avoidance Task) , during 4 days of training.
2476849|NCT03058276|Experimental|Active rTMS|Each session (5 sessions along 2 weeks), patients receive active stimulation with repetitive transcraneal magnetic stimulation (rTMS) of the right dorsolateral prefrontal cortex.
2476851|NCT03058276|Sham Comparator|SAM|Pacients receiving a sham stimulation (SAM), with a similar procedure to the experimental condition
3192738|NCT00811863||2|Subjects with severe renal insufficiency defined as an eGFR <30 mL/min/1.73 m2 and ESRD defined as requiring dialysis
2476953|NCT03057223|Experimental|3D Jaw Plate|3D Jaw Plate will be used in internal fixation.
2477018|NCT03056937||Obese with metabolic syndrome|bariatric surgery
2477020|NCT03056937||Obese without metabolic syndrome|bariatric surgery
2477025|NCT03056937||Healthy|Control
2477066|NCT03056482|Active Comparator|Ondansetron 8mg|8mg Ondansetron prepared in a 100mL normal saline mini-bag
2477074|NCT03056482|Experimental|Haloperidol 0.05mg/kg|0.05mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
2477077|NCT03056482|Experimental|Haloperidol 0.1mg/kg|0.1mg/kg of Haloperidol prepared in a 100mL normal saline mini-bag
2477119|NCT03056183|Experimental|Treatment Group|Patients in the Depression Care Transitions intervention will have a Transitional Care Social Worker who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
2477125|NCT03056183|No Intervention|Control Group - Standard of Care|To be followed per standard of care and data from their medical records will be reviewed.
3192739|NCT00811889|Placebo Comparator|Placebo|
3192740|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 75mg|
2477327|NCT03054714|Active Comparator|group A|exchange of the infected catheter with a new one over a guidewire
2477330|NCT03054714|Active Comparator|group B|removal of the infected catheter followed by delayed placement of a new catheter 3 to 10 days later
2477365|NCT03054545|Experimental|Iguratimod treating group|Iguratimod 25mg twice a day, oral administrated.
2477397|NCT03054220|Experimental|CYP2D6 gene score 1|carriers of 1 fully functional and 1non functional CYP2D6 alleles
2477408|NCT03054220|Experimental|CYP2D6 gene score 2|carriers of 2 fully functional CYP2D6 alleles
2477473|NCT03053869|Experimental|Benzodiazepine - Limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
2477478|NCT03053869|Active Comparator|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
3192741|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 150mg|
3192742|NCT00811889|Experimental|Bardoxolone Methyl (RTA 402): 25mg|
2477646|NCT03052491|Experimental|Stem Cell 100+ Intervention|Subjects take one 650 mg capsule by mouth twice daily for an average of 15 weeks
2477685|NCT03052244|Experimental|intervention tDCS+VI|The anode will be placed over C3-C4 (EEG 10/20 system) to target M1 and the cathode over the contralateral supraorbital area. The stimulation will apply to the hemisphere which contralateral to the more painful hemi body. 2mA will be delivered over 20 min via neuroConn DC stimulator combined with video presenting walking legs. A total of 10 sessions (5 per week) will be administrated at the same manner.
3192743|NCT00811902|Experimental|Nerispirdine 50mg|Nerispirdine 50mg once daily for 14 weeks
3192744|NCT00811902|Experimental|Nerispirdine 100mg|Nerispirdine 100mg once daily for 14 weeks
3192745|NCT00811902|Experimental|Nerispirdine 200mg|Nerispirdine 200mg once daily for 14 weeks
3192746|NCT00811902|Placebo Comparator|Placebo|Placebo for Nerispirdine once daily for 14 weeks
2476606|NCT03059303|Experimental|Part 2: Treatment Sequence F-G|Participants will receive Treatment F on Day 1 of Period 1 and then Treatment G on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2476608|NCT03059303|Experimental|Part 2: Treatment Sequence G-F|Participants will receive Treatment G on Day 1 of Period 1 and then Treatment F on Day 1 of Period 2 under fed condition (after a standardized breakfast). A washout period of at least 2 weeks will be maintained between each treatment.
2477005|NCT03056768|Active Comparator|active control|Health promotion provided by local health bureau.
2477009|NCT03056768|Experimental|multidomain intervention|1-year multidomain health promotion (physical activities, cognitive training, nutritional sessions)
2477063|NCT03056547|Experimental|Induced dyspnea|
2477293|NCT03055078|Experimental|mesenchymal stem cells|According to the inclusion and exclusion criteria, selected patients were divided into a cell therapy group and a control group. Umbilical cord derived mesenchymal stem cells at a dose of 100-300 million by intravenous infusion.
3158187|NCT00380549|Active Comparator|CONSERVE® A-Class THA BFH|CONSERVE® A-Class Total Hip with BFH technology. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® acetabular component and the CONSERVE® A-Class BFH femoral head. Blood ion levels will be collected and analyzed.
3158188|NCT00380549|Active Comparator|CONSERVE® Plus Total Resurfacing Hip System|CONSERVE® Plus Total Resurfacing Hip System. Patients in this arm will undergo a unilateral total hip replacement with the CONSERVE® Plus Total Resurfacing Hip System. Blood ion levels will be collected and analyzed.
2477433|NCT03053921|Placebo Comparator|recession coverage|30 recession defects treated with Zucchelli's technique.
2477435|NCT03053921|Active Comparator|recession coverage and membrane|30 recession defects treated with Zucchelli's technique along with placental membrane.
2477449|NCT03053739|Active Comparator|Combination arm A-Sildenafil and Bosentan|"Combination Arm A -Intervention- Drug~Tab Sildenafil 20 mg - three times a day for 6 months,and~Tab Bosentan 62.5mg - twice a day for 6 months"
2477451|NCT03053739|Placebo Comparator|Monotherapy arm-Sildenafil and Placebo|Monotherapy arm B Intervention-Drugs Tab Sildenafil 20mg- three times a day for 6 months, and Placebo tab (matched for bosentan) for 6 months
2477531|NCT03053635|Experimental|0.35 mg/cm^2 TLD1433 Bladder Dose|"TLD1433 infusion and photodynamic therapy treatment (PDT):~TLD1433 is infused for 1 hour and photodynamic therapy treatment is performed after TLD1433 has been rinsed from the bladder. If treatment with the maximum recommended starting dose of 0.35mg/cm^2 does not raise significant safety concerns as determined by the safety monitoring committee, the therapeutic dose of TLD1433 (0.70mg/cm^2) will be used."
2477667|NCT03052478|Experimental|vismodegib arm|. Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
3158189|NCT00380562|Experimental|Volunteer|High intensity volunteering (15 hours a week or greater) in Baltimore City Schools with children in grades K-3
3158190|NCT00380562|No Intervention|Control|Usual activities
3158191|NCT00380601|Experimental|1|
3158192|NCT00380640|Experimental|1|
3158193|NCT00380640|Experimental|2|
3158194|NCT00380666|Other|PET/CT defined target|Target defined by use of fluoro-deoxy-glucose (FDG)-PET/CT scan for planning af stereotactic radiotherapy.
3158195|NCT00380731|Experimental|1|Participants will receive immediate cognitive behavioral therapy
3158196|NCT00380731|Experimental|2|Participants will receive cognitive behavioral therapy with a 16-week delayed start
3158197|NCT00380757|Active Comparator|CPR 30:2|30 chest compressions to 2 ventilations
3158198|NCT00380757|Active Comparator|CPR 15:2|15 chest compressions to 2 ventilations
3158199|NCT00380770|Experimental|HAART alone|Arm 1. HAART These patients will be given one tablet twice daily of Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
3158200|NCT00380770|Active Comparator|Combination HAART and chemotherapy|Arm 2. CTX PLUS HAART. HAART will be given as above. In addition, CTX will be administered at 2 weekly intervals in the Oncology Dept at KEH VIII Hospital and will consist of:- Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
3158201|NCT00380796||Cohort 1|
3158202|NCT00380809|Active Comparator|Rotational Atherectomy + PES|Elective lesion preparation with rotational atherectomy priot to stent implantation
3158203|NCT00380809|Active Comparator|Standard Treatment (PES without Rotational Atherectomy)|Stenting without prior rotational atherectomy, usually preceeded with balloon dilatation
3158204|NCT00381108|Experimental|Pomegranate Tablet|
3158205|NCT00381108|Placebo Comparator|Placebo Tablet|
3158207|NCT00381160|Experimental|1|Provision of non-caloric beverages to home
3158208|NCT00381160|No Intervention|2|
3158209|NCT00381173|Experimental|1|
3158210|NCT00381212|Experimental|1|AGS-004 immunotherapeutic injections.
3158211|NCT00381225|Experimental|Ultra-sound guided radio-frequency ablation|
3158212|NCT00381290|Active Comparator|1|Participants will follow an exercise regimen
3158213|NCT00381290|Active Comparator|2|Participants will follow a calorie-restricted diet
3158214|NCT00381290|Active Comparator|3|Participants will follow a calorie-restricted diet and an exercise regimen
3158215|NCT00381316|Active Comparator|1|Thallous Chloride T1-201
3158216|NCT00381316|Active Comparator|2|Technetium Tc99m Tetrofosmin injections
3158217|NCT00381329|Active Comparator|1|Motivational Interviewing (MI)
3158218|NCT00381329|Active Comparator|2|Structured Brief Advice (SBA)
3158219|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 5 mcg|Exenatide 5 mcg; then exenatide 5 mcg
3158220|NCT00381342|Experimental|Exenatide 5 mcg/exenatide 10 mcg|Exenatide 5 mcg, then exenatide 10 mcg
3158221|NCT00381342|Placebo Comparator|Placebo|Placebo in volumes equivalent to exenatide
3158222|NCT00381407|Experimental|1|Participants will receive organizational skills training program
3158223|NCT00381407|Experimental|2|Participants will receive contingency management program
3158224|NCT00381407|No Intervention|3|Participants will receive wait list condition
3158225|NCT00381420|Experimental|1|sirolimus-coated Bx Velocity stent
3158226|NCT00381420|Active Comparator|2|uncoated Bx Velocity stent
3158227|NCT00381576|Experimental|A|12 weeks of resistance training
3158228|NCT00381589|Experimental|A|Random assignment to investigational spray
3158229|NCT00381654|Experimental|A|Daily oral administration of AV-412
3158230|NCT00381667|Experimental|GW642444M 12.5|
3158231|NCT00381667|Experimental|GW642444M 100mcg|
2476693|NCT03058822|Experimental|Prefilled Syringe Upper Arm|Single subcutaneous dose from prefilled syringe into upper arm of BMS-931699
2476701|NCT03058822|Experimental|Prefilled Syringe Thigh|Single subcutaneous dose from prefilled syringe into thigh of BMS-931699
2476710|NCT03058822|Experimental|Prefilled Syringe Abdomen|Single subcutaneous dose from prefilled syringe into abdomen of BMS-931699
2476717|NCT03058822|Experimental|Drug in Vial Upper Arm|Single subcutaneous dose from drug in vial into upper arm of BMS-931699
2476721|NCT03058822|Experimental|Drug in Vial Thigh|Single subcutaneous dose from drug in vial into thigh of BMS-931699
2476722|NCT03058822|Experimental|Drug in Vial Abdomen|Single subcutaneous dose from drug in vial into abdomen of BMS-931699
2476751|NCT03058367|Experimental|High dose IQP-AE-103 (1980mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2476753|NCT03058367|Experimental|Low dose IQP-AE-103 (990mg)|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2476754|NCT03058367|Placebo Comparator|Placebo|2 capsules IQP-AE-103 by mouth, three times a day after main meals for 12 weeks
2476835|NCT03058081|Experimental|High Flow Nasal Test|Patients will perform one Constant Work-Rate Exercise Test at 80% of maximum workload with High Flow Nasal at 60L/min (with or without additional oxygen)
2476837|NCT03058081|No Intervention|Control Test|Patient will perform one Constant Work-Rate Exercise Test at 80% of maximum workload on room air or with oxygen supplementation
2476887|NCT03057717|Other|Ultrasound|All participants in the study will have fetal thymus size measured using ultrasound.
3158232|NCT00381667|Experimental|GW642444M 400mcg|
3158233|NCT00381667|Experimental|GW642444H 100mcg|
3158234|NCT00381667|Experimental|Placebo|
3158235|NCT00381719|Experimental|1|3 mg
2477219|NCT03055676|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 166)
2477223|NCT03055676|Active Comparator|Late drain removal|Removing drain(s) on postoperative day 5 or later (n = 166)
2477250|NCT03055312|Active Comparator|TPC chemotherapy|"Conventional chemotherapy(choose a):~TX (Taxotere and Xeloda),GT (Gemcitabine and Paclitaxel),GC (Gemcitabine and Carboplatin)"
2477252|NCT03055312|Experimental|Bicalutamide|Bicalutamide 150mg/day every 28 days
2477472|NCT03053791|Experimental|Intervention group|Single-armed study. All patients will receive treatment.
2477514|NCT03053440|Experimental|Arm A (Experimental Arm-BGB-3111)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive BGB-3111 in treatment [Arm A]
2477516|NCT03053440|Active Comparator|Arm B (Active Comparator-Ibrutinib)|Approximately 94 participants with the MYD88 mutation will be enrolled in Cohort 1 and receive Ibrutinib in treatment [Arm B]
2477517|NCT03053440|Experimental|Arm C (Experimental Arm-BGB-3111)|Approximately 22 participants found to have MYD88 wild type will be enrolled in Cohort 2 and receive BGB-3111 in treatment [Arm C]
2477638|NCT03052556|Other|Cohort of women with cystic fibrosis|Includable patients are adult women, transplanted or not, followed at Lyon CRCM (Centre de Ressources et de Compétences de la Mucoviscidose).
3158236|NCT00381719|Experimental|2|20 mg
3158237|NCT00381719|Experimental|3|60 mg
2477704|NCT03051932|Active Comparator|Ofiramev®( IV Acetaminophen)|Patients randomized to the treatment arm will receive 1 g (100 mL) intravenous acetaminophen infused over 15-minutes every 6 hours for 4 doses total.
2477705|NCT03051932|Placebo Comparator|Placebo IV administration|Patients randomized to the placebo arm will receive 100 mL of normal saline infused over 15 minutes every 6 hours for 4 doses total
2477777|NCT03051529||combined spinal epidural|24 patients with dilated cardiomyopathy undergoing vascular surgery in the lower half of the body under combined spinal epidural anesthesia will be enrolled in the study
2477855|NCT03051360|Active Comparator|PCSK9 inhibitor|Patients will receive bi-weekly PCSK9 inhibitor .
3158238|NCT00381719|Placebo Comparator|4|Placebo
3158239|NCT00381732|Placebo Comparator|1|placebo tablet
3158240|NCT00381732|Active Comparator|2|2.5 mg tadalafil tablet
3158241|NCT00381732|Active Comparator|3|5 mg tadalafil tablet
3158242|NCT00381771||Objective salivary function|"Based on the salivary scintigraphy,~Objective salivary normo-function~Objective salivary dysfunction"
3158243|NCT00381784|Experimental|Community PROMISE|Community PROMISE is a community level HIV/STD prevention program that relies on role model stories and peer advocates from the community. Sites will adapt PROMISE for local use remaining faithful to the core elements.
3158244|NCT00381784|Experimental|Mpowerment|MPowerment is a community level HIV/STD prevention program that relies on peer advocates from the community to lead outreach activities including discussion groups (Mgroups), venue-based outreach, social events and a publicity campaign. Sites will adapt MPowerment for local use remaining faithful to the core elements.
3158245|NCT00381914|Experimental|1|400 IU / day vitamin D
3158246|NCT00381914|Experimental|2|800 IU / day vitamin D
3158247|NCT00381914|Experimental|3|1200 IU / day vitamin D
3158248|NCT00381953|Active Comparator|360 PEG IFN|360 mug peginterferon alfa-2a QW
3158249|NCT00381953|Active Comparator|9 MU + 180 PEG IFN|9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
3158250|NCT00381953|Active Comparator|4,5 MU IFN + 180 PEG IFN|4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
3158251|NCT00381979|Experimental|1|set
3158252|NCT00382096|Experimental|Vildagliptin + Metformin Dose 1|
3158253|NCT00382096|Experimental|Vildagliptin + Metformin Dose 2|
3158254|NCT00382096|Active Comparator|Vildagliptin|
2476697|NCT03059043|Experimental|viscoelastic-free system|Eyes in this group will use viscoelastic-free implantation system during the surgery
2476709|NCT03059043|Active Comparator|viscoelastic-assisted system|Eyes in this group will utilize the standard viscoelastic-assisted Implantation system during the surgery
2476741|NCT03058354||Group TIVA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
2476743|NCT03058354||Group GA|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
2476927|NCT03057652|Experimental|ReWalk, then EKSO, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2476932|NCT03057652|Experimental|ReWalk, then REX, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2476936|NCT03057652|Experimental|EKSO, then ReWalk, then REX|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2476938|NCT03057652|Experimental|EKSO, then REX, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2476940|NCT03057652|Experimental|REX, then EKSO, then ReWalk|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
2476941|NCT03057652|Experimental|REX, then ReWalk, then EKSO|Subjects will be asked to complete a screening visit, baseline and post assessment for each intervention training (ReWalk, EKSO, REX) and up to 15 training sessions per device.
3158255|NCT00382096|Active Comparator|Metformin|
2477085|NCT03056651|Other|DayCare-HF|Comprehensive service in day-care unit, including education, diagnostic tools (i.e. electrocardiography, transthoracic echocardiography, implanted cardioverter defibrillator (ICD) / cardiac resynchronization therapy device (CRT) interrogation and possibility of intravenous drug administration (i.e. loop diuretics, dobutamine).
2477117|NCT03056170|Active Comparator|Active tDCS|The anode is placed over the left dorsolateral prefrontal cortex (DLPFC) and the cathode is placed over the left temporo-parietal cortex (TPJ) In active stimulation with a Transcranial Direct Current Stimulation, the device will deliver a charge of 1 mA for 30 minutes.
2477118|NCT03056170|Sham Comparator|Sham tDCS|In sham stimulation, with a Transcranial Direct Current Stimulation, no current will be delivered from one electrode to the other except one 30 s ramp up and down at the beginning and one at the end of the sham stimulation duration (30 min) Same electrode montage than in the active group.
2477262|NCT03055247|Experimental|XCGD mobilization|Treatment with combination of Ibuprofen, Myelostim and Mozobil
2477384|NCT03054363|Experimental|Tucatinib in Combination with Palbociclib and Letrozole|During phase 1b part of this trial (N=20 patients), treatment will be administered in cycles of 28 days and consist of tucatinib 300 mg PO BID, palbociclib 125 mg PO daily for 21 days followed by 7 days off, and letrozole 2.5 mg PO daily. Dose modifications of tucatinib, palbociclib and letrozole will be allowed per protocol. There will be an interim safety analysis performed after enrollment of 10 patients. Safety analysis will take into account proportion of patients requiring dose modifications or interruption for therapy because of toxicity. If excessive toxicity or significant changes in PKs are found, further patients will be enrolled at a lower starting dose level. There will be a second interim safety analysis after enrollment of 20 patients in the study. Once the recommended phase II dose (RP2D) has been determined, testing of this drug combination will be expanded in the phase II part of this trial (N=20 patients) to determine the progression-free survival (PFS) rate.
2477479|NCT03053895|Experimental|CSDH Bedside twist drill technique|For patients randomized to bedside drainage of Chronic Subdural Hematoma, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic.
2477481|NCT03053895|Active Comparator|CSDH Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
2477501|NCT03053479|Experimental|Laparoscopic sacrocolpopexy|Laparoscopic sacrocolpopexy will be performed in the following way: Identification of the promontory, dissection of the peritoneum above the promontory and preparation of the ligamentum longitudinale anterior, peritoneum dissection, dissection of the vesicovaginal septum up to the bladder neck, dissection of the rectovaginal septum towards the perineum, application of Y mesh, fixation to the vaginal apex using non-absorbable sutures, and for anterior and posterior vaginal wall absorbable sutures. Fixation of the upper mesh arm to the ligamentum longitudinale anterior using non-absorbable suture, following with complete peritoneum closure above the mesh. The procedure could include salpingo-oophorectomy, supracervical hysterectomy or total hysterectomy (concomitant procedures are not exclusion criteria).
2477502|NCT03053479|Experimental|Transvaginal mesh procedure|Hydrodissection of the anterior vaginal wall, midline anterior colporrhaphy, preparation beyond the endopelvic fascia, mesh kit with bilateral fixation to sacrospinous ligaments should be used. The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
2477503|NCT03053479|Experimental|Amreich-Richter procedure:|At least unilateral fixation with non-absorbable suture to sacrospinous ligament (fixation could be performed from the anterior approach). At the time of anterior vaginal wall repair or traditional posterior approach, it is possible to use a device for stich fixation (for example Capio, I- stitch etc). The procedure could include salpingo-oophorectomy, total hysterectomy and posterior vaginal wall repair (concomitant procedures are not exclusion criteria).
3158256|NCT00382135|Placebo Comparator|1|placebo tablet
3158257|NCT00382135|Active Comparator|2|20 mg tadalafil tablet
3158258|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 7.5 micrograms|
3158259|NCT00382187|Experimental|MF59 adjuvant H5N1 influenza vaccine 15 micrograms|
3158260|NCT00382187|Experimental|non-adjuvanted influenza vaccine 15 micrograms of H5N1 antigen|
3158261|NCT00382200|Experimental|Decitabine and All-Trans Retonoic Acid (Tretinoin)|Decitabine and All-Trans Retonoic Acid (Tretinoin)
3158262|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 10 mcg|
2476752|NCT03058380||Stated-Preferences Evaluation Group|A stated-preferences evaluation instrument will be provided to participants with knee pain in the Stated-Preferences Evaluation Group. The instrument will measure patient preferences for total knee replacement versus unicompartmental knee replacement.
2476852|NCT03058146|Experimental|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
2476853|NCT03058146|Active Comparator|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
3158263|NCT00382239|Experimental|Exenatide 5 mcg/exenatide 5 mcg|
2477387|NCT03054168|Experimental|Old Testosterone trained|"8 old participants (65-75 years old) who will receive resistance exercise training and Testosterone (Sustanon 250: 250 mg every 2wks)~Drug name: Sustanon 250 Generic Name: Testosterone Proprietary Name: N/A Formulation: 250mg of Testosterone in 1ml volume Dose: 250mg of testosterone Frequency: every 2 weeks Route: intramuscular injection"
2477401|NCT03054168|Placebo Comparator|Old Placebo trained|8 old participants (65-75 years old) who will receive resistance exercise training and Placebo every two weeks.
2477410|NCT03054168|Experimental|Young Zoladex trained|"8 young participants (18-30 years old) who will receive resistance exercise training and Testosterone inhibitor (3.6mg Zoladex subcutaneous injection, one time over the study)~Drug name: Zoladex Generic Name: Gonadotropin-releasing hormone analogue; Goserelin Proprietary Name: N/A Formulation: Solution for injection Dose: 3.6mg Frequency: Single injection one time over the study. Route: Subcutaneous injection (abdomen) performed by clinician."
2477413|NCT03054168|Placebo Comparator|Young placebo trained|8 young participants (18-30 years old) who will receive resistance exercise training and placebo, one time over the study.
2477464|NCT03053843|Experimental|Mediterranean diet plus extra virgin olive oil|These patients will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months.
2477471|NCT03053843|No Intervention|no specific diet|The control group will be assigned to the usual care and patients assigned to this group will not receive any special intervention to follow a particular diet, as occurs in the current clinical practice.
2477621|NCT03052582|Active Comparator|Team 1: skimmed/whole|Milktype: 3 weeks with skimmed milk followed by 3 weeks with whole milk
2477625|NCT03052582|Active Comparator|Team 2: whole/skimmed|Milktype: 3 weeks with whole milk followed by 3 weeks with skimmed milk
2477662|NCT03052387|Placebo Comparator|control|"Crestal pyramidal flap will be done with 2 releasing incisions for adequate exposure.~Buccal& palatal full reflection for adequate exposure and to avoid the interference between the onlay graft and the residual bone.~Decortication of the bone bed to increase the blood supply to the onlay graft.~The block graft harvested from the chin is placed crestal to the residual ridge and stabilized in place using dental implant immediately.~Periosteal incisions are usually needed to allow tension free sutures.~Vicryl 3/0 sutures for closer.~augmentin 1g twice daily for 5 days.~catflam 50g twice daily for 3 days"
2477663|NCT03052387|Active Comparator|Comparator|"Crestal incision with labial flap reflected leaving the palatal tissues without elevation.~Marking of the 3 bony cuts ( 2 vertical cuts & 1 horizontal cut ) using fine fissure bur in the form of perforations along the cuts position.~Drilling of pilot drill and first drill only.~3 full thickness cuts will be performed (2 vertical stop cuts will be made by using the tungsten carbide disc at the distal ends of the horizontal bony cut on the facial surface of alveolar ridge.~splitting osteotomes are used and mallet to complete the splitting of the bony segment.~After bony separation the rectangular bony segment (transport segment) will be mobilized occlusally and pedicled on the palatal mucoperiosteum.~The autogenous block graft harvested from the chin area is placed in the space gained under the mobile bony segment.~Drilling through the bony segment and the block graft.~Immediate implant placement~chin graft block dental implants"
2477707|NCT03052166||Cohort A|The group of asymptomatic subjects who have been given BI-RADS 1 or 2 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
2477709|NCT03052166||Cohort B|The group of asymptomatic women who have been given BI-RADS categories 4 or 4a, 4b, 4c or 5 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan.
3158264|NCT00382239|Experimental|Exenatide 2.5 mcg/exenatide 2.5 mcg|
3158265|NCT00382239|Placebo Comparator|Placebo/placebo|
3158266|NCT00382343|Experimental|sulfamethoxazole/trimethoprim|Antibiotic prophylaxis with sulfamethoxazole/trimethoprim [1-2 mg/kg trimethoprim and 5-10 mg/kg sulfamethoxazole once daily]; in case of intolerance (leucopoenia) and for children younger than 6 months: nitrofurantoin [2 mg/kg once daily]
3158267|NCT00382343|No Intervention|No prophylaxis|
3158268|NCT00382356|Experimental|study drug|Open label, single arm
3158269|NCT00382382|Other|Children with Autism|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in high functioning austistic children.
3158270|NCT00382382|Other|Healthy Volunteers|A diffusion tensor imaging (DTI) will be done to examine the integrity of the white matter pathways in healthy volunteers.
3158271|NCT00382395|Experimental|1|SOLX Gold Shunt
3158272|NCT00382395|Active Comparator|2|Control Ahmed FP7 Shunt
3158273|NCT00382434||EPh Present|the emergency pharmacist is present in the ED when the medical care is provided
3158274|NCT00382447|Experimental|1|Standard nebulizer versus standard breath actuated nebulizer
3158275|NCT00382473|Experimental|exercise|
3158276|NCT00382499|Experimental|Lidocaine|IV lidocaine in OR as described in methods
3158277|NCT00382525||Patients with Cardiac Rhythm Management device|Patients receiving a Medtronic Cardiac Rhythm Device, worldwide
3158278|NCT00382642|Experimental|Ondansetron|Arm 1 = Ondansetron 4 mcg/kg b.i.d.+ Cognitive behavioral therapy
3158279|NCT00382642|Placebo Comparator|Placebo|Arm 2 = Placebo + Cognitive behavioral therapy
3158280|NCT00382668||A|
3158281|NCT00382668||B|
3158282|NCT00382668||C|
3158283|NCT00382681|Experimental|FID 107027|Contact lens solution used as instructed for 90 days.
2476785|NCT03058471|Active Comparator|methotrexate|mehotrexate 10 mg weekly, to be increased by 5 mg in each visit to a maximum of 25 mg
2476787|NCT03058471|Active Comparator|non steroidal anti inflammatory drugs|NSAID in full dose with Pantoprazole. If remission not achieved at 2 months, will be given methotrexate as in methotrexate arm
2476854|NCT03057912|Experimental|TALEN|TALEN (TALEN-HPV16 E6/E7 or TALEN-HPV18 E6/E7) plasmid in gel, administered twice one week for 4 weeks.
2476857|NCT03057912|Experimental|CRISPR/Cas9|CRISPR/Cas9 (CRISPR/Cas9-HPV16 E6/E7T1 or CRISPR/Cas9-HPV18 E6/E7T2 ）plasmid in gel, administered twice one week for 4 weeks.
2476859|NCT03057912|No Intervention|Control group|Observation
2476970|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using Dotarem contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Dotarem
2476971|NCT03057561|Experimental|3.0 Tesla Cardiac MRI using a Gadovist contrast agent|60 randomly selected participants with suspected or known cardiovascular disease will have a 3.0 Tesla Cardiac MRI with contrast agent, Gadovist
2476991|NCT03056820|Active Comparator|A - 25° head-up position|Participants will be positioned at 25° angle for procedure.
2476994|NCT03056820|Active Comparator|B - 55° head-up position|Participants will be positioned at 55° angle for procedure.
2477056|NCT03056664|Experimental|MSC-1|Patient in this arm will receive routine surgery and local MSC injection of 3×10E6/kg
2477061|NCT03056664|Experimental|MSC-2|Patient in this arm will receive routine surgery and local MSC injection of 6×10E6/kg
2477064|NCT03056664|Experimental|Ctrl|Patient in this arm will receive routine surgery and local NS injection
2477157|NCT03056235|Experimental|ELAPR002f|ELAPR002f is a tropoelastin gel cross-linked with derivatised hyaluronic acid
2477159|NCT03056235|Placebo Comparator|Saline control|Saline
2477248|NCT03055234|Experimental|Oral Treprostinil|Extended-release oral tablet for three times daily (TID) administration
2477249|NCT03055234|Placebo Comparator|Placebo|Placebo (sugar pill) for TID administration
2477291|NCT03055091|Experimental|Treatment group|Participants in the treatment arm will receive a Xylitol syrup.
2477292|NCT03055091|Placebo Comparator|Placebo|Participants in the placebo arm will receive sorbitol syrup.
2477319|NCT03054753|Other|Abduction brace wearing time analysis|The abduction brace wearing time analysis is performed in patients, who undergo a rotator cuff repair with postoperative abduction brace treatment
2477376|NCT03054558||patients with recurrent unexplained pregnancy loss|Patients with history of two or more recurrent pregnancy loss (RPL) and no history of living babies who had performed all investigations for recurrent miscarriage (RM) including : laboratory investigation ,trans vaginal ultrasound (TVS) ,autoimmune work up and hystroscopy and all results were free
2477378|NCT03054558||Healthy fertile patients|Healthy fertile patients with no history of previous miscarriage and have at least one uncomplicated pregnancy with no pelvic pathology
2477431|NCT03054025|Experimental|Supportive care (smart phone application)|Participants download the physical activity readiness smart phone application onto their personal smartphone and receive training on how to use the app which includes animated video clips, tailored email reminders, and feedback on progress for 3 weeks.
2477448|NCT03053765|Active Comparator|Individual Supervision in IPT|Bi-weekly individual case supervision in IPT
2477450|NCT03053765|Experimental|Group Supervision in IPT|Bi-weekly group supervision in IPT in groups of 4-6 therapists
2477452|NCT03053765|Experimental|Internet-Based Training in IPT|Access to internet-based training in IPT to review information learned in initial 2-day training
2477453|NCT03053765|No Intervention|Autodidactic Training in IPT|Clinicians allowed access to training materials and can engage in self-study
2477507|NCT03053648|Experimental|Self-acupressure Group|Subjects in this group will attend two weekly 120-minute self-acupressure training sessions in a classroom at the School of Nursing, the Hong Kong Polytechnic University. The subjects will be instructed on how to perform the self-acupressure treatment by a trained instructor. To enhance interaction and ensure the quality of teaching, each course will be conducted in a small group of 6 participants. Subjects will perform self-acupressure daily for 4 consecutive weeks.
2477508|NCT03053648|Active Comparator|Sleep Hygiene Education Group|To control the contact time with professional person in the treatment group, participants in this group will receive two sessions of 120-minute sleep hygiene training session. The participants will be asked to follow the health hygiene instructions daily for 4 consecutive weeks.
2477582|NCT03053167|Experimental|Irinotecan & Raltitrexed|"advanced colorectal cancer patients treated with irinotecan plus raltitrexed as second-line treatment.~Irinotecan:180mg/㎡+NS250ml, ivgtt, 90min, d1~Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks"
2477629|NCT03052712|Active Comparator|Patients|battery of tests of social cognition
2477633|NCT03052712|Active Comparator|Control|battery of tests of social cognition
3158284|NCT00382681|Active Comparator|ReNu MultiPlus|Contact lens solution used as instructed for 90 days.
3158285|NCT00382811|Experimental|1|Daily Phenoxodiol + weekly carboplatin
2477832|NCT03051152|Experimental|Elderly with CCS>5 - D1 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with limited lymphadenectomy
2477842|NCT03051152|Experimental|Elderly with CCS>5 - D2 gastrectomy|Patients aged >75 years with Charlson Comorbidity Score > 5 undergoing gastrectomy with extended lymphadenectomy
2477903|NCT03050788|Experimental|Smartphone confocal microscopy imaging|Subject's skin lesion will be imaged with the smartphone confocal microscopy.
2477926|NCT03050476|Experimental|bRESCAP|Bolus of 1000 IU of bovine intestinal alkaline phosphatase on induction of anaesthesia, followed by an infusion of 9000 IU over the next 24 hours.
2477928|NCT03050476|Placebo Comparator|Placebo|Bolus of of media on induction of anaesthesia, followed by an infusion of media over the next 24 hours.
3158286|NCT00382811|Active Comparator|2|Daily phenoxodiol placebo + weekly carboplatin
3158287|NCT00382850|Active Comparator|open nissen fundoplication|open repair through surgical midline incision
3158288|NCT00382850|Active Comparator|laparoscopic nissen fundoplication|use of laparoscope to do repair
3158289|NCT00382915||1|Smokers with schizophrenia
3158290|NCT00382915||2|Smokers with bipolar disorder
3158291|NCT00382915||3|Smokers without any mental illness
2476818|NCT03058393|Experimental|Teach-Back Group|A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients
2476877|NCT03057821|No Intervention|Control|The control group will not receive any hydrogen peroxide skin preparation
2476880|NCT03057821|Experimental|Treatment|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
2476963|NCT03057470|Active Comparator|0% Bolus Insulin Correction|0% Bolus Insulin Correction
2476965|NCT03057470|Active Comparator|50% Bolus Insulin Correction|50% Bolus Insulin Correction
2476966|NCT03057470|Active Comparator|100% Bolus Insulin Correction|100% Bolus Insulin Correction
2476967|NCT03057470|Active Comparator|150% Bolus Insulin Correction|150% Bolus Insulin Correction
2477026|NCT03056833|Experimental|Ribociclib|Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
2477086|NCT03056443|Experimental|Continuous Positive Airway Pressure-CPAP|CPAP education and discharge with auto-adjusting Continuous Positive Airway Pressure (CPAP) in addition to usual standards of clinical care for heart failure.
2477088|NCT03056443|No Intervention|Standard of Care|CPAP initiation per standard of care based on approval by insurance company and DME company with management as per usual standards of clinical care for heart failure.
3158292|NCT00382954|Experimental|Phase 1 escalation|
3158293|NCT00382980|Experimental|7.5-|7.5 mcg of vaccine without adjuvant administered on Days 0 and 28.
3158294|NCT00382980|Experimental|45-|45 mcg of vaccine without adjuvant administered on Days 0 and 28.
3208662|NCT00976963|Active Comparator|Fosfomycin|Mix sachet with 1/2 glass cold water and stir. Drink immediatley
2477599|NCT03052933|Experimental|Copanlisib/gemcitabine|
2477634|NCT03052660|Experimental|Midazolam|Midazolam, 3.75 mg , oral, once, 30-45 minutes before surgery
2477636|NCT03052660|Placebo Comparator|Placebo|Placebo, oral, once, 30-45 minutes before surgery
2477673|NCT03052218|Experimental|single arm study|pupillometry, CYP2D6 genotyping and phenotyping
2477715|NCT03052075||Parathyroidectomy Data Review|The research plan is for a retrospective review to be performed of a prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center.
2477797|NCT03051438|Other|Subxiphoid uniportal VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
2477799|NCT03051438|Other|Three-port VATS|retrospectively analyzed and compared perioperative data for patients who underwent subxiphoid uniportal and traditional three-port VATS lobectomies
2477825|NCT03051230||Studied group|Women exposed to ovarian hyperstimulation for In Vitro fertilisation
2478172|NCT03049098||Success at the simulation|Participant could correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
2478174|NCT03049098||Failed the simulation|Participant could not correctly set the pacing unit to obtain electrical and mechanical pacing of the mannequin in nine minutes.
2478226|NCT03048734||Group (1): Men with Nocturia ≥2.|
2478229|NCT03048734||Group (2): Men with no nocturia (0-1).|
2478278|NCT03048448|Experimental|Fevipiprant 450mg|450mg Film Coated Tablet
2478946|NCT03043963|Experimental|Sleep Extension|Intervention will include basic education concerning sleep hygiene and an extension of the sleep period.
3158295|NCT00382980|Placebo Comparator|Placebo|Placebo administered on Days 0 and 28.
3158296|NCT00382980|Experimental|15+|15 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
3158297|NCT00382980|Experimental|7.5+|7.5 mcg of vaccine with aluminum hydroxide adjuvant administered on Days 0 and 28.
3158298|NCT00382980|Experimental|15-|15 mcg of vaccine without adjuvant administered on Days 0 and 28.
3158299|NCT00383136|Experimental|1|Tirofiban
3158300|NCT00383136|Active Comparator|2|Abciximab
3158301|NCT00383214|Active Comparator|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
3158302|NCT00383214|Placebo Comparator|Placebo|Intravenous
3158303|NCT00383253|Experimental|10%|
3158304|NCT00383253|Experimental|25%|
3158305|NCT00383253|Experimental|50%|
3158306|NCT00383253|Placebo Comparator|Control|
3158307|NCT00383370|Experimental|ITV-1|VEGF Trap formulation 1
3158308|NCT00383370|Experimental|ITV-2|VEGF Trap formulation 2
3158309|NCT00383370|Experimental|ITV-2 OL|VEGF Trap formulation 2 open label, higher concentration
3158310|NCT00383422|Experimental|1|
3158311|NCT00383422|Active Comparator|2|
3158312|NCT00383474|Experimental|Arm I|Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
3158313|NCT00383513|Experimental|Epratuzumab|
3158314|NCT00383526|Experimental|Study Group 1|
3158315|NCT00383526|Active Comparator|Study Group 2|
3158316|NCT00383539|Experimental|1|Lot 1
3158317|NCT00383539|Experimental|2|Lot 2
3158318|NCT00383539|Experimental|3|Lot 3
3158319|NCT00383539|Active Comparator|4|Control
3158320|NCT00383578|Experimental|Vildagliptin|
3158321|NCT00383578|Active Comparator|Metformin|
3158322|NCT00383656|Experimental|Pulsatile GnRH|All participants will be administered GnRH intravenously by means of a portable infusion pump that delivers boluses at specific intervals.
3158323|NCT00383669|Active Comparator|Multiple RDA multivitamins|Multivitamins (including B, C, and E)
3158324|NCT00383669|Active Comparator|Single RDA Multivitamins|Multivitamins (including B, C, and E)
3158325|NCT00383708|Experimental|1|
3158326|NCT00383734|Experimental|1|newfill
3158327|NCT00383734|Experimental|2|Eutrophill
3158328|NCT00383799|Active Comparator|Group 1|IV procainamide (single dose: 10 mg/kg over 20 min)
3158329|NCT00383799|Active Comparator|Group 2|IV Amiodarone (single dose: 5 mg/kg over 20 min)
2476847|NCT03058237|Experimental|Part 3: Regimen N|"An optional regimen of one mid-high dose of the selected Arbaclofen Placarbil MR prototype tablet (if not previously dosed in Regimen M) or two mid-low dose of the selected Arbaclofen Placarbil MR prototype tablets.~Part 3 participants receive Regimens K and L in a randomised crossover manner as the first two treatments, followed by Regimens M and N in a sequential manner."
3208663|NCT00976963|Active Comparator|TMP/SMX|Sulfamethoxazole-Trimethoprim 800-160 MG Oral Tab (TMP/SMX) Take one twice daily for 3 days for urinary tract infection
2477036|NCT03056729|Experimental|Cohort HV1|
2477038|NCT03056729|Experimental|Cohort HV2|
2477041|NCT03056729|Experimental|Cohort HV3|
2477043|NCT03056729|Experimental|Cohort HV4|
2477044|NCT03056729|Experimental|Cohort HV5|
2477045|NCT03056729|Experimental|Cohort AD1|
2477093|NCT03056365|Experimental|Advanced Nurse (AN)|The outpatient detoxication procedure will be entirely managed by an advanced nurse team, using a predefined protocol decision algorithm. The protocol allows that the AN team autonomously manages the diazepam dosing during the detox period. Addiction physicians only intervenes in case of severe withdrawal symptoms or serious adverse events.
2477094|NCT03056365|Active Comparator|General Practitioner (GP)|"The outpatient detoxication procedure is entrusted to a GP who will manage patients and diazepam dosing as he/she thinks best (as usual control group)"
2477163|NCT03055923||Asthma Patients|30 people who suffer from a confirmed diagnosis of asthma
2477164|NCT03055923||Chronic Obstructive Pulmonary Disease Patients|30 people who suffer from a confirmed diagnosis of COPD
2477165|NCT03055923||Healthy Controls|30 healthy volunteers who have no known diagnosis of Lung disease
2477218|NCT03055585|Experimental|Intervention arm|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
2477222|NCT03055585|Other|Comparison arm|Standard practice dengue control activities
2477275|NCT03055299|Experimental|COMEX|Patients receive comprehensive exercise intervention
2477333|NCT03054909|Experimental|Arm 1: ALT-803 subcutaneous only|
2477335|NCT03054909|Experimental|Arm 2: ALT-803 intraperitoneal and subcutaneous|
2477382|NCT03054467|Active Comparator|CADUET 10mg-20mg|Patients are assigned to receive either amlodipine therapy (NORVASC 10 mg/day) for 6 months.
2477389|NCT03054467|Active Comparator|NORVASC|Patients are assigned to receive amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months
2477430|NCT03054012||CAS group|computer-assisted surgery group
2477482|NCT03053778|Experimental|Intervention|Early follow-up after discharge
2477597|NCT03052946|Active Comparator|Bulking agent|Bulking agent in fecal incontinence
2477598|NCT03052946|Placebo Comparator|Endoanal electrostimulation|Endoanal electrostimulation in fecal incontinence
2477617|NCT03052673|Active Comparator|Ketamine + Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg, ketamine 0.5-mg/kg after induction, followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr + ketamine infusion of 0.2-mg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
2477622|NCT03052673|Active Comparator|Fentanyl Group|"Patients will receive pre-induction fentanyl 1-mcg/kg,followed by intraoperative fentanyl infusion of 0.5-mcg/kg/hr.~Postoperative analgesia will be provided with Intravenous Patient Controlled Analgesia (IV-PCA) pump containing fentanyl citrate-2.5 mcg/ml, which will be attached to all the patients upon shifting to the recovery room. The IV-PCA pump settings will be as follows: 0-ml basal dose; 4-ml PCA dose; 15-minutes lock out interval."
3158330|NCT00383890|Experimental|Dexmedetomidine|Dexmedetomidine 1 mcg/kg load for 10 minutes and Dexmedetomidine Maintenance (0.7 mcg/kg/hr) for 15 min
3158331|NCT00383890|Placebo Comparator|Placebo (PBO)|Placebo load for 10 min and Placebo maintenance for 15 min
2477749|NCT03051828||fencing and patients with breast cancer|patients operated for breast cancer followed at the Hospital Rene Dubos
2477765|NCT03051555|Experimental|18F-FDG PET/CT-based prognostic model of NK/T-cell lymphoma|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
2477811|NCT03051399|Placebo Comparator|Placebo|Maltodextrin, 500 mg/day, single serving
2477812|NCT03051399|Active Comparator|EpiCor|EpiCor, 500 mg/day, single serving
2477824|NCT03051074|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for up to 90 minutes on three separate occasions
2477829|NCT03051074|Active Comparator|Comparison condition|The participant will watch a relaxing 90 minute film as a comparison condition
2477887|NCT03050840|Other|Self-monitoring|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage (SSB) consumption via text messaging. The Way to Health platform will record data.
2477890|NCT03050840|Experimental|Self-monitoring plus gamification|Participants will wear a Fitbit, to self-monitor steps per day, and will report sugar sweetened beverage consumption via text messaging. Participants will be awarded medals and points based on meeting step per day and SSB consumption goals The Way to Health platform will be used to record data.
3158332|NCT00383929|Experimental|1|Candesartan Cilexetil (CC) /HCT 32/12.5mg
3158333|NCT00383929|Experimental|2|Candesartan Cilexetil (CC) /HCT 32/25mg
3158334|NCT00383929|Experimental|3|Candesartan Cilexetil monotherapy
3158335|NCT00383994|Experimental|Immunotherapy with NK Cell, Rituximab + GM-CSF|"Immunotherapy in Non-myeloablative Allogeneic Stem Cell Transplantation~GM-CSF = Granulocyte-Macrophage Colony-Stimulating Factor"
3158336|NCT00384046|Experimental|1|300mcg/day testosterone
3158337|NCT00384046|Placebo Comparator|2|Placebo arm
3158338|NCT00384111|Experimental|1|R-CVP plus Zevalin Therapeutic Regimen
3158339|NCT00384111|Active Comparator|2|R-CVP
3158340|NCT00384137|Experimental|1|
3158341|NCT00384202|Experimental|1|
3158342|NCT00384228|Experimental|Nilotinib|
3158343|NCT00384254|No Intervention|1|Usual Care Control: Patients receive treatment as usual
3158344|NCT00384254|Experimental|2|"5 A Intervention Condition: Patients in this condition receive all five A components (Ask, Advise, Assess, Assist, Arrange) recommended in the Clinical Practice Guideline: Treating Tobacco Use and Dependence."
2476861|NCT03057847|Experimental|SOF/VEL|Sofosbuvir/Velpatasvir, One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
2476909|NCT03057587||NIRS Monitoring|A NIRS sensor will be placed on the forehead of the patient upon entry to the operating room and will remain on, as tolerated, for the duration of surgery
2476947|NCT03057171||Gastric ulcer|patients who will undergo EGD for gastric ulcer
2476952|NCT03057171||Duodenal ulcer|patients who will undergo EGD for duodenal ulcer
2476954|NCT03057171||Stomach cancer|patients who will undergo EGD for stomach cance
2476957|NCT03057171||health individuals|patients who will undergo screening EGD
2477019|NCT03056950|No Intervention|non-oclusion training group|The control (non-occlusion training) group will follow the standard s/p distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
2477022|NCT03056950|Active Comparator|occlusion traingn with tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being used. Intervention: Occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
2477049|NCT03056521|Experimental|Info|"In this arm the patients are counseled preoperatively about post operative pain.~Specific information about post operative pain which includes both pharmacologic and non-pharmacologic treatments, complications of pain and benefits of good pain management. This is in addition to the routine care provided"
2477050|NCT03056521|No Intervention|No info|These patients are in the control group. They are left to receive only the routine preoperative care as made available to them while on ward.
3158345|NCT00384254|Experimental|3|"3 A Condition: Patients receive Ask, Advise, Arrange intervention consisting of the first two A components recommended by the Clinical Practice Guideline: Treating tobacco Use and Dependence, plus Fax-to-Quit referral to a tobacco quit line."
2477131|NCT03056053|Other|Zolpidem|Commercially available zolpidem (5 or 10 mg) will be administered orally once daily during the treatment period (Day 1 to Day 14) following prescribing information from each country participating in this study
2477231|NCT03055598|Experimental|Ferric Citrate|Ferric Citrate (Auryxia) will be dosed initially at 2 tablets three times a day (with meals).
3158346|NCT00384267||Neonates|Inpatient
3158347|NCT00384358|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
2477731|NCT03052114||Stroke|Electrical Impedance Tomography with scalp electrodes
2477733|NCT03052114||Head Injury|Electrical Impedance Tomography with scalp electrodes
2477776|NCT03051594|Active Comparator|visual tactile assessment|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after visual tactile assessment.
2477781|NCT03051594|Active Comparator|caries detector dye|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using caries detector dye to determine the excavation endpoint.
2477783|NCT03051594|Experimental|fluorescent camera|dentine sample collection and then bacterial count by Digital colony counter, Agar diffusion test after after using fluorescent camera to determine the excavation endpoint.
2477827|NCT03051295|Active Comparator|Diagnostic percentages.|Dentist receives diagnostic test results presented in conditional probabilities.
2477837|NCT03051295|Experimental|Diagnostic frequencies|Dentist receives diagnostic test results presented in natural frequencies.
2477847|NCT03051295|Active Comparator|Treatment percentages.|Dentist receives treatment efficacy presented in percentages.
2477849|NCT03051295|Experimental|Treatment frequencies.|Dentist receives treatment efficacy presented in natural frequencies.
2477871|NCT03050853|Experimental|E-Cigarette|The E-cigarette arm will be asked to use e-cigarettes in place of regular tobacco products. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
2477875|NCT03050853|No Intervention|Assessments only|The Assessment only group will be asked to refrain from use of e-cigarettes during participation. The group will be assessed at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 13 weeks, and 26 weeks.
2478047|NCT03049943|Active Comparator|Laser wavelength of 830 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 830 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
2478055|NCT03049943|Experimental|Laser wavelength of 685 nm|This group comprised 15 female patients with hyposalivation whose major salivary glands were treated for 10 consecutive days with low level laser therapy of 685 nm.The whole unstimulated and stimulated saliva was measured each day during 10 days, before and after laser treatment and 10th day after treatment was ended.
2478171|NCT03049436||Patients with program of adapted physical activity|
2478231|NCT03048721|Experimental|Psoriasis|Participants with psoriasis will undergo both skin tape stripping and punch biopsy.
2478232|NCT03048721|Experimental|Control|Participants without psoriasis will undergo both skin tape stripping and punch biopsy.
2478271|NCT03048526|Active Comparator|Hydrabak®|Unpreserved sodium chloride (0.9%) eye drops in ABAK® system
2478295|NCT03048162|Active Comparator|sodium chloride|0.9% isotonic sodium chloride, 500 ml, one package in 30 minutes
3158348|NCT00384358|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
3158349|NCT00384358|Other|C|Control: Surgical fixation
3158350|NCT00384371|Experimental|1|Botulinum Toxin A
3158351|NCT00384371|Placebo Comparator|2|Placebo
3158352|NCT00384462||1|Premature Infants (32-35 wks. GA) who are less than six months of age at start of RSV season and followed until May of the following year.
3158353|NCT00384462||2|Premature newborns (32-35 wks. GA) who are born during the current RSV season and discharged from the hospital after 01 Dec and followed until May of the next year.
3158354|NCT00384527|Experimental|1|
3158355|NCT00384527|Active Comparator|2|
3158356|NCT00384540|Other|Cardiovascular events vs Dobutamine stress echocardiography|
3158357|NCT00384566|Experimental|1|
3158358|NCT00384566|Active Comparator|2|
2476914|NCT03057262||Control group|Control group consisted of 56 subjects of both genders with unilateral or bilateral disc displacement(s) with reduction and pain in the area of temporomandibular joint. Patients were recruited from the Consulting Room of Temporomandibular Joint Dysfunction at the Jagiellonian University in Krakow during the years 2014-2016. In the control group the investigators used the biostymulation laser (Terapus 2, Accuro, Poland), wave length 808 nm, power 32 J in the form of 12 session (duration of a single session was 3 min 45 s), performed every second day, on the area of the both temporomandibular joints (distance to the skin was 1 cm) with opened mouth and systematic performing of muscles self-exercises with a dominant protrusive position of mandible.
2476980|NCT03057145|Experimental|Prexasertib Combine with Olaparib|"Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level.~Prexasertib will be administered intravenously on Days 1 and 15 of a cycle"
2477039|NCT03056742|Experimental|Stem cells|Patients will receive intramuscular and local injection of stempeucel(R) in addition to standard protocol of care
2477098|NCT03056417|Experimental|Intervention|Participants in the Complete Health Improvement Program.
2477099|NCT03056417|No Intervention|No Change to Treatment|Participants who choose not to participate in the Complete Health Improvement Program.
2477130|NCT03056079|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular AMD, macular edema secondary to retinal vein occlusion and diabetic macular edema treated with intravitreal aflibercept in a variable dosing regimen.
2477179|NCT03055728||Group 1 / Study Group|Subjects presenting with signs or symptoms of acute pharyngitis, with a history of culture-proven GAS infection and subsequent 10-day antibiotic treatment within the preceding 28 days. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
2477181|NCT03055728||Group 2 / Control Group|Subjects presenting with signs or symptoms of acute pharyngitis, without a recent history of GAS infection. Subjects will have a rapid strep antigen detection test and a throat culture to determine presence of strep.
2477244|NCT03055481|Active Comparator|High level irradiation|High level irradiation: the target irradiance level is 30-35uW per square centimeter per nano-meter of wavelength.
2477245|NCT03055481|Experimental|Low level irradiation|Low level irradiation: the target irradiance level is 12-15uW per square centimeter per nano-meter of wavelength.
2477263|NCT03055117|Experimental|Group-based exercise rehabilitation|Group-based rehabilitation: Group-based sessions (4-8 patients per group) with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
2477268|NCT03055117|Active Comparator|Individual exercise rehabilitation|Individual rehabilitation: One-on-one sessions with physiotherapist and home training for 8 weeks (maximum of 12 training sessions).
2477270|NCT03055117|Active Comparator|Home exercise|Home exercise: Instruction in home exercise by physiotherapist, with maximum of 4 follow-up consultations over a period of 8 weeks.
2477356|NCT03054623||DRIL procedure|Adult (>18 yo) patients with chronic kidney disease with functioning antecubital-based arteriovenous fistulae and evidence of ischemic steal symptoms
2477399|NCT03054181||HyQvia|Recombinant human hyaluronidase and normal immunoglobulin 10%
2477459|NCT03053934|Active Comparator|Traditional in-person|Participants randomised to this arm will receive traditional in-person counselling (i.e., treatment will be conducted with the client and clinician occupying the same physical location/room)
2477463|NCT03053934|Experimental|Online counselling|Participants randomised to this arm will receive treatment from a clinician via videoconferencing (i.e., communication between the client and clinician will occur via webcam)
2477523|NCT03053583|Active Comparator|Miller Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Miller blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2477530|NCT03053583|Active Comparator|Wis-Hipple Laryngoscope blade|A photo of the best glottic view will be taken during laryngoscopy using Wis- Hipple blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2477534|NCT03053583|Active Comparator|C-Mac Laryngoscope blade|An image of the best glottic view will be saved on C-MAC monitor's SD card during laryngoscopy using C-MAC straight blade. The view of the larynx will be assessed using the POGO score by a blinded assessor.
2477562|NCT03053037|Active Comparator|Group S|mesial canals in Group S will be instrumented to size 25
2477564|NCT03053037|Active Comparator|Group L|mesial canals in Group L will be instrumented to size 35
2477626|NCT03052634|Experimental|RC48-ADC 1.5 mg/kg (HER2 Positive)|
2477630|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Positive)|
2477632|NCT03052634|Experimental|RC48-ADC 2.5 mg/kg (HER2 Positive)|
2477635|NCT03052634|Experimental|RC48-ADC 2.0 mg/kg (HER2 Low Expression)|
3192747|NCT00811915|Experimental|Sirolimus|"Group A : Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14.~Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
3192748|NCT00811915|Active Comparator|B|Tacrolimus (Advagraf) dose to obtain a trough level between 4 and 10 ng/ml
2477745|NCT03051854|Experimental|ICC-T|Intervention: Interaction Competencies with children - for teachers (ICC-T) 5.5 days with 8 hours of training for teachers. Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting
2477747|NCT03051854|No Intervention|Control schools|The control school do not receive any intervention.
2477764|NCT03051542|Experimental|NK/T-cell lymphoma patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
2478380|NCT03047759|Active Comparator|Intervention A|water flosser
3192749|NCT00811967|Experimental|Treatment Arm|
3192750|NCT00811967|No Intervention|Control Arm|
3192751|NCT00811980||Heathy Subjects|
3192752|NCT00811993|Experimental|1|
3192753|NCT00811993|Experimental|10|
3192754|NCT00811993|Experimental|11|
2476951|NCT03057197|Experimental|Group B|New method group (n=85): same as conventional method group except caudal injection right after penetrating the sacrococcygeal ligament.
2476996|NCT03057002||HCM Group|HCM patients will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
2477001|NCT03057002||Control Group|Healthy control subjects will be observed for myocardial hyperpolarized 13C-pyruvate flux during magnetic resonance spectroscopic imaging.
2477189|NCT03055559||Globifer Forte|
2477239|NCT03055520|Experimental|arithmetic training (Kumon method)|
2477241|NCT03055520|Placebo Comparator|nonspecific recreation|
2477265|NCT03055169||intensive care patients|patients with a least one organ dysfunction
2477304|NCT03054948|Experimental|SMOFLipid|Patients in this arm with be randomized to SMOFlipid as their lipid emulsion
2477307|NCT03054948|Active Comparator|Standard therapy|Patients in this arm will be continue with their current lipid emulsion
2477386|NCT03054246|Other|Healthy volunteers|Seventy-five healthy volunteers with no oral/dental problems with Angle I occlusion relationship and without any missing teeth will be included in the study. Evaluation of chewing side preference and laterality will be performed.
2477486|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would recieve this treatment alone.
2477488|NCT03053700|Active Comparator|Treatment with bromonide 0.33% gel & IPL|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
2477506|NCT03053388|Experimental|Group 1 - Nitric Oxide treatment|• Group 1 (NO treatment) - will receive inhalations of 160 ppm NO combined with O2/air for 30 minutes, every 3-4.5 hours, five times a day (24 hours), for up to 5 days (maximum 25 inhalations), in addition to standard supportive treatment.
2477509|NCT03053388|Active Comparator|Group 2 - Control treatment|• Group 2 (Control) - will receive inhalations O2/air using the same treatment schedule and equipment as group 1, in addition to standard supportive treatment.
2477575|NCT03053089|Experimental|Stage 1 (adult)|AGT-181
2477578|NCT03053089|Experimental|Stage 2 (children)|AGT-181
2477627|NCT03052777|Experimental|Telephone Counselling|Participants will be asked to increase their exercise by at least 60 minutes per week and will receive a copy of Canada's Physical Activity Guideline plus 12 weekly telephone counseling sessions aimed at helping survivors follow-through on their exercise intention.
2477631|NCT03052777|No Intervention|Control|Participants will be asked to increase their exercise by at least 60 minutes per week and will be self-directed, only receiving a copy of Canada's Physical Activity Guideline as standard of care.
2477675|NCT03052374|No Intervention|Control Group|Mothers will receive standard care such as referral to psychotherapy (intervention mothers will have the same access) over the same length of time.
2477684|NCT03052374|Experimental|VID-KIDS Intervention Program Group|RN review photos of infant engagement/disengagement cues. NCAST Teaching Activity, mothers asked to perform task advanced for infant's level, recorded. 1st-View, no feedback, mothers reveal infant cues. RN records infant/mother's response, later discussion. 2nd, RN and mother co-view interaction with time for replay/review parts of sensitivity and responsiveness. RN feedback: praising desired maternal behaviours; information on infant cues; maternal response to infant distress; and use of cognitive growth fostering language. 3rd, all concepts discussed in past views, use positive reinforcement to affirm aspects of sensitivity, useful feedback for areas of growth. Post-Debrief, RN and mother discuss interests of the mother. Mothers encouraged to note infants' engagement/disengagement cues.
2477725|NCT03051997|Experimental|Caregiver Contingency Management + Usual Drug Court Treatment|This group will receive a caregiver contingency management intervention plus the standard outpatient substance abuse treatment services provided at JDC.
2477728|NCT03051997|Active Comparator|Usual Drug Court Treatment|This group will receive the standard outpatient substance abuse treatment services provided at JDC.
2477773|NCT03051581|Experimental|18F-FDG PET/CT-based prognostic model of PTCL|The new prognostic model is based on 18F-FDG PET/ CT scans, and combined with clinical and pathological prognostic factors.
2477839|NCT03051321|Experimental|Wellness toileting system|Subjects given SchwabCare Wellness Toileting system
3158359|NCT00384579|Experimental|1|Botulinum Toxin B
3158360|NCT00384579|Placebo Comparator|2|Placebo
2478389|NCT03047759|Active Comparator|Intervention B|air floss
3158361|NCT00384605|Experimental|1|Arm 1: MK0364 2 mg capsule once daily
3158362|NCT00384605|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
3158363|NCT00384605|Experimental|3|Arm 3: MK0364 0.5 mg capsule once daily.
3158364|NCT00384605|Placebo Comparator|4|Arm 4: Pbo capsule once daily.
3158365|NCT00384631|Sham Comparator|2|
3158366|NCT00384631|Experimental|1|
3158367|NCT00384644||1|sepsis, septic shock ptients
3158368|NCT00384644||2|cardiogenic shock patients
3158369|NCT00384657|Experimental|Group I|iv iron sucrose
3158370|NCT00384657|No Intervention|Group II|Patients will receive conventional treatment of Chronic Heart Failure.
3158371|NCT00384683||Endothelial Dysfunction|Participants are scheduled for major chest (lung or esophagus) surgery or are a healthy volunteer. A blood test will quantify the number of cells that are destined to become endothelial cells.
3158372|NCT00384696||Smoking Cessation|Treatment to help quit smoking, including written self-help materials, counseling, and 4 week supply of nicotine patch plus 5 MD Anderson Visits.
3158373|NCT00384735||1A|Intensive - 3 monthly follow up
3158374|NCT00384735||1B|Intensive - 6 monthly follow up
3158375|NCT00384735||IIA|Cost Effective - 3 monthly follow up
2476978|NCT03057158||3|Women with both UUI (at least three times per week for over three months) and Insulin Resistance (pre-diabetes or diabetes based on Hemoglobin A1C).
2476979|NCT03057158||4|Healthy Volunteers
2476997|NCT03056807|Active Comparator|A - 25° head-up position|Participants will be positioned at a 25° head-up position for procedure.
2477002|NCT03056807|Active Comparator|B - 55° head-up position|Participants will be positioned at a 55° head-up position for procedure.
2477046|NCT03056612||Group 1|Group 1 patients with high risk of ACLF development (CLIF-C AD score ≥ 50)
2477047|NCT03056612||Group 2|Group 2 patients with low risk of ACLF (CLIF-C AD score <50)
2477048|NCT03056612||ACLF|ACLF-patients were specified the patients who were admitted at hospital with ACLF,
2477136|NCT03056092|Other|AMD/RVO/DME|Patients presenting to St. Michael's Hospital retina clinic with neovascular age related macular degeneration, macular edema secondary to RVO and diabetic macular edema treated with intravitreal ranibizumab in a variable dosing regimen.
2477192|NCT03055715||Locally advanced NSCLC-patients|Inoperable stage III (A and B) non-small-cell lung cancer (NSCLC) with indication for radical radiotherapy.
2477267|NCT03055325||Surgical patients|Cognitive testing, testing of heart rate variability and collection of blood samples
2477296|NCT03055026|Experimental|Rivaroxaban|Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
2477297|NCT03055026|Placebo Comparator|Placebo|Orally administered, OD for 3 weeks (extended prophylaxis)
2477338|NCT03054688|Experimental|Somnotouch NIBP|Blood pressure measurement with Somnotouch-NIBP device in addition to standard cuff based device
2477487|NCT03053713|Active Comparator|Mediterranean Diet Pattern|Mediterranean diet pattern x 12 weeks.
2477489|NCT03053713|Placebo Comparator|Habitual Diet|Habitual diet (control) x 12 weeks.
3158376|NCT00384735||IIB|Cost Effective - 6 monthly follow up
2477769|NCT03051568|Experimental|PTCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
2477813|NCT03051347|Other|Itch Questionnaire and Interview|Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
2477814|NCT03051347|Other|Stigma Questionnaire and Interview|To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
2477815|NCT03051347|Other|Validation Questionnaire and Interview-Moderate to Severe|For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
2477816|NCT03051347|Other|Validation Questionnaire and Interview-Mild|For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.
2477885|NCT03051022|Active Comparator|Dexamethasone 8 mg|Bupivacaine 0,125% 12,5 mg combined with dexamethasone 8 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
2477889|NCT03051022|Active Comparator|Morphine 2 mg|Bupivacaine 0,125% 12,5 mg combined with morphine 2 mg plus NaCl 0,9% until the volume was 10 cc, prepared in a 10 cc syringe.
2477918|NCT03050463||breast cancer with bilateral mastectomy|This group has patients with breast cancer who have chosen to have a bilateral mastectomy. Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
3158377|NCT00384787|Experimental|1|Group 1 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intramuscularly at Month 6.
3158378|NCT00384787|Experimental|2|Group 2 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost intradermally at Month 6.
3158379|NCT00384787|Experimental|3|Group 3 will receive three vaccinations with the HIV DNA vaccine. Vaccinations will be given at study entry and Months 1 and 2. Participants will also receive an adenoviral vaccine boost subcutaneously at Month 6.
3158380|NCT00384826|Experimental|1|
3158381|NCT00384826|Experimental|2|
3158382|NCT00384852|Experimental|A|1.0 mg/mL rhBMP-2/CPM + SOC
3158383|NCT00384852|Experimental|B|2.0 mg/mL rhBMP-2/CPM + SOC
3158384|NCT00384852|Active Comparator|C|Buffer/CPM + SOC
3158385|NCT00384852|Other|D|Standard of Care Alone (SOC)
3158386|NCT00384891|Experimental|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
3158387|NCT00384891|Active Comparator|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
3158388|NCT00384904|No Intervention|A1|
3158389|NCT00384904|Experimental|A2|
3158390|NCT00384904|Experimental|A3|
3158391|NCT00384904|No Intervention|B1|
3158392|NCT00384904|Experimental|B2|
3158393|NCT00384904|Experimental|B3|
3158394|NCT00384969|Experimental|1|RAD001 and Sorafenib
3158395|NCT00384982|Experimental|A, B, C, D|Early or late; percutaneous intracoronary or combined (intramyocardial and intracoronary) administration of BM-MNCs
3158396|NCT00384995|Experimental|Bicarbonate|Bicarbonate solution infusion
3158397|NCT00384995|Active Comparator|Saline|Standard volume expansion
3158398|NCT00385047|Experimental|Group A|FMP 2.1 50 μg FMP2.1/AS01B
2477254|NCT03055468|Experimental|Peer Support|Participants in this group will receive peer support as well as antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
2477255|NCT03055468|Active Comparator|No Peer support|Participants will only receive antidepressant medications comprised of either Fluoxetine 20mg O.D or Imipramine 75mg nocte.
2477368|NCT03054389||Participants/ Patients|Participants/ Patients from the AskBio009-101 Study
2477369|NCT03054389||Investigators and Study Coordinators|Investigators and Study Coordinators from the AskBio009-101 Study
2477493|NCT03053674|Experimental|Explanation|Explanation to parents on importance of post-partum influenza vaccination on health of their newborn infant with a follow-up questionnaire to determine rate of vaccination
2477495|NCT03053674|Active Comparator|No explanation|No explanation will be given to parents but they will be followed-up with a questionnaire to determine rate of vaccination
2477512|NCT03053336|Experimental|App-technology group|"Participants in the intervention group (App-technology) will use a newly developed smartphone application (app) in which steps are automatically measured and laboratory values from blood sampling within primary care will be shown.~Intervention: App-technology to increase physical activity"
2477515|NCT03053336|No Intervention|Control group|The control group will receive standard care
3158399|NCT00385047|Experimental|Group B|FMP 2.1 50 μg FMP2.1/AS02A
2477739|NCT03051867||Third-trimester pregnant women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
2477742|NCT03051867||Nonpregnant control women|Women differing in their reproductive state (pregnant versus nonpregnant) will consume equivalent dietary intakes of vitamin D and related nutrients as part of a feeding study.
2477830|NCT03051126||Parathyroid Disease Tissue Bank|Participants scheduled for surgical treatment of parathyroid disease and/or patients with MEN1, and/or those presenting with hyperparathyroidism and/or pancreatic lesion, who are scheduled for pancreas tumor intervention.
2477983|NCT03050346||CAD patients|Consecutive patients scheduled for a coronary angiography on the basis of cardiac symptoms and a test positive for inducible coronary ischemia, who are affected by one-vessel or two-vessel CAD at the time of the OS-CMR with breathing maneuvers (HVBH).
2477986|NCT03050346||Healthy subjects|Subjects without current or pre-existing cardiovascular and lung disease and absence of medication with cardiovascular effects.
2478036|NCT03049969|Experimental|Cognitive Remediation|For the 20 cognitive remediation sessions, eligible participants will receive 20 minutes of active tDCS stimulation (up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while they complete the cognitive training tasks. Once the participant has completed his/her 20 sessions a pre/post treatment assessment measures will be completed.
2478080|NCT03049670||latent available chlorine (LAC)|applying LAC on infected wounds
2478131|NCT03049371|Other|sample size 100|24 post-op and 100 pre- non- and post-op TGW Study participants need to be of Thai nationality, at least 18 years old, male at birth and self-identify as post-op TGW for participation in study. Signed informed consent is required for study participation
2478253|NCT03048968|Experimental|study group1: elderly adults|Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS
2478267|NCT03048968|Experimental|study group2: stroke patients|Sit-to-stand movement and treadmill gait with GEMS and without GEMS
2478336|NCT03047993|Experimental|Treatment (glutaminase inhibitor CB-839, azacitidine)|Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.
2478442|NCT03047187||ACLR patients|anterior cruciate ligament reconstruction patients
2478479|NCT03046927|Experimental|Ergocalciferol|Oral administration of 50,000 IU of ergocalciferol one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
2478480|NCT03046927|Placebo Comparator|Placebo|Oral administration of placebo one capsule per week for 2 months; and then once every 2 weeks for 10 months in 20 subjects of 10-21yr with newly diagnosed T1D
2478504|NCT03046563|Experimental|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
2478508|NCT03046563|Sham Comparator|Pressing the sham points|Pressing the sham points for eight minutes total, press once in the morning and afternoon, seven days total and two days for follow the trail.
2478600|NCT03046277||Patients undergoing LTx|Retrospective analysis of clinical data
2478602|NCT03046277||Patients with pretransplant renal functional reserve testing|Prospective analysis of clinical data
2479358|NCT03040817|Experimental|G-POEM|Each participant receive gastric peroral endoscopic pyloromyotomy (G-POEM).
3158400|NCT00385086|Experimental|TNF-alpha blocker|Treatment with TNF-alpha blocker
3158401|NCT00385086|Active Comparator|Placebo|Treatment with placebo
3158402|NCT00385177|Experimental|A|SN2310 Injectable Emulsion
3158403|NCT00385229|Experimental|Induction|induction of labor at gestational age 289(41 weeks+2 days)
3158404|NCT00385229|No Intervention|expectant management|expectant management at gestational age 289(41 weeks+2 days)
3158405|NCT00385242|Active Comparator|PET guided Therapy|Patients will be randomized to undergo positron emission tomography aspart of their clinical work up
3158406|NCT00385242|Active Comparator|Standard care|Patients will be randomized to standard care will under go other types of imaging or work up for revascularization without PET imaging.
3158407|NCT00385346|Experimental|A 1|Expressive writing
3158408|NCT00385411|Experimental|valproate|
3158409|NCT00385450|Experimental|Nelfinavir/placebo|
3158410|NCT00385476||Patient Medication Knowledge Tool|Assessment of Cancer patients' knowledge of their medications in an outpatient acute care setting
3158411|NCT00385502|Experimental|EcoNail™|econazole 5%/SEPA® 18% nail lacquer
3158412|NCT00385632||1|Participants following a drug conservation (DC) regimen in which ART was stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count was at least 350 cells/mm3, and then followed by episodic ART based on CD4 cell count
3158413|NCT00385632||2|Participants following a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count
2477071|NCT03056599|Experimental|Multiple drug microinjection|Patients who are scheduled for surgical biopsy or tumor resection surgery will be injected 4 to 72 hours prior to surgery using the CIVO device. Minute volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer agents will be percutaneously injected in a columnar fashion through each of 8 needles into a single enlarged solid tumor.
2477143|NCT03056027||Group Open|Patient submitted to open inguinal hernia repair
2477147|NCT03056027||Group extraperitoneal laparoscopic|Patients submitted to total extraperitoneal laparoscopic inguinal hernia repair
2477191|NCT03055741|Experimental|Group 1|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 500mg is orally administrated in two divided doses a day for 24 weeks"
2477196|NCT03055741|Experimental|Group 2|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Total 1,000mg is orally administrated in two divided doses a day for 24 weeks"
2477198|NCT03055741|Placebo Comparator|Group 3|"donepezil: 5mg or 10mg is orally administrated once a day for 24 weeks~DHP1401: Placebo is orally administrated in two divided doses a day for 24 weeks"
2477286|NCT03055273|Experimental|SOCIABLE IMMEDIATE|Receive services now
2477288|NCT03055273|Active Comparator|SOCIABLE wait list|Receive services four months post-enrollment
3158414|NCT00385697|Experimental|1|
2477373|NCT03054480|Experimental|Fractional Micro-Needle Radiofrequency|each patient will be treated with FMR DeAge®, applicator device at 4-week intervals for 2 sessions of treatment. This applicator consists of rows of 36 (6x6 needles) insulated microneedles that form an array of positively and negatively charged electrodes. The microneedles will deliver bipolar radiofrequency energy in a fractional manner that extends from 3.0 mm below the surface of the skin. All subjects will be prepared by local anesthesia to induce numbness at the axilla prior to treatment. The targeted axillary side will be treated with a total of 4 passes.
2477374|NCT03054480|Active Comparator|Botulinum toxin type A|50 units of Botulinum toxin type A will be intradermal injected over axillary area. The protocol by using 1-2 units per 1 injection area with the coverage of 1x1 cm2 will be treated.
3192755|NCT00811993|Experimental|12|
3192756|NCT00811993|Experimental|13|
2477563|NCT03053141||All Subjects|All subjects are included in this cohort and are treated with the Rhythmia Mapping System
2477665|NCT03052400|Experimental|Mifepristone 600 mg daily|Mifepristone 300 mg po daily x 2 weeks, followed by mifepristone 600 mg po daily x 10 weeks
2477669|NCT03052400|Placebo Comparator|Placebo|Matching, blinded placebo 1 tablet po daily x 2 weeks, followed by matching, blinded placebo 2 tablets po daily x 10 weeks
2477735|NCT03052036|Other|Invasive Treatment|Coronary angiography with a view to coronary revascularisation
2477737|NCT03052036|Other|Optimal Medical Therapy|Patients to be treated with guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE inhibitors, betabloackers
2477881|NCT03050944||Cases|Lifestyle behaviour and dietary habits assessment in couples achieving pregnancy after in vitro fertilization process.
2477884|NCT03050944||Controls|Lifestyle behaviour and dietary habits assessment in couples failed to achieve pregnancy after in vitro fertilization process.
2477984|NCT03050502|Active Comparator|Chest tube drain|A chest tube placed with the intent of draining all intra-pleural blood.
2477987|NCT03050502|Sham Comparator|Expectant management|No chest tube, but will undergo standard observation/conservative management by the trauma service.
2478037|NCT03049956|Experimental|Patients with clinical suspicion of ocular myasthenia gravis|
2478079|NCT03049683||Normal subjects|Thirty healthy volunteers without a previous history of vertigo or neuro-otologic diseases will be enrolled in this study. The subjects will be also screened with a full history on vestibular disorders, with pure tone audiogram, and head-impulse tests to exclude the possibility of previous vestibular disorders or migraine which may cause abnormal VEMPs.
2478093|NCT03049683||Acute unilateral vestibular neuritis|The criteria for inclusion as a patient with vestibular neuritis involving the superior division (superior VN) included the following: (1) acute onset of vertigo, (2) the appearance of mixed horizontal and torsional nystagmus, (3) impaired horizontal semicircular canal (SCC) function on head-impulse test and a unilaterally absent or reduced caloric response (i.e., a caloric paresis score > 25%), (4) intact inferior division of vestibular nerve as evidenced by normal cVEMP and normal head-impulse test for vertical SCCs, and (5) the absence of auditory and neurologic signs. Thirty patients (aged 32-82 years; mean age, 51.7 years; 16 males) fulfilled the criteria of superior VN.
2478120|NCT03049306|Placebo Comparator|Placebo Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, placebo of propranolol LA (Inderal ® LA) 80 mg will be administered orally at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will is crossed-over with active drug 1 week before or after this study night.
2478124|NCT03049306|Active Comparator|Propranolol Oral Tablet|Subjects will be admitted to the clinical research unit. On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 7 PM, after dinner. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides. This arm will be crossed-over to placebo 1 week later. This arm will is crossed-over with active drug 1 week before or after this study night.
2478126|NCT03049306|Active Comparator|CPAP|Subjects will be admitted to the clinical research unit. They will sleep wearing CPAP according to their usual home settings. Blood pressure will be measured before administration, at 11 PM, and 7 AM. They will sleep from 11 Pm to 7 AM. During sleep blood will be sampled from an indwelling IV for measurement of FFA, glucose, insulin, and triglycerides.
2478199|NCT03048877|Experimental|Apatinib|Apatinib Mesylate Tablets
3158415|NCT00385697|Experimental|2|
3158416|NCT00385697|Experimental|3|
3158417|NCT00385697|Placebo Comparator|4|
3158418|NCT00385710|Experimental|valproic acid|Depakine
3158419|NCT00385710|Placebo Comparator|Placebo|Placebo
3158420|NCT00385853|Experimental|PTK787|Single arm study of PTK787
3158421|NCT00385866|Active Comparator|Comparison Group|The control or lesser intervention group, will receive cancer screening information on a quarterly basis, with no facilitation of services.
2477089|NCT03056378|Experimental|Pooled RBCs|Transfusion of an investigational transfusion blood component: POOLED-RBCs Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type), leukoreduced, and irradiated
2477091|NCT03056378|Active Comparator|Standard RBCs|Transfusion of standard transfusion blood component: additive solution leukoreduced, irradiated RBC product Phenotype matched/ compatible for ABO, D, C, E, and K (blood type of pool will be match patient's type)
3158422|NCT00385866|Active Comparator|Intervention group|The intervention group are those participants who were randomly assigned to receive facilitation of services in the form of patient navigation for the duration of the study.
2477306|NCT03054987|Active Comparator|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
2477310|NCT03054987|Active Comparator|ERCP|At ERCP, the common bile duct will be selectively cannulated using a sphincterotome and guide wire technique. Once biliary access is obtained a stent will be deployed to facilitate biliary drainage.
2477457|NCT03054090|Other|Quality Improvement support|A blended support strategy will include practice facilitation, expert consultation, collaborative learning events, an online support center, and data feedback and benchmarking.
2477496|NCT03053661||primary surgery + adj. C)RT|treatment naive patients to be treated by conventional primary surgery followed by adjuvant (chemo-)radiotherapy with curative intent
2477497|NCT03053661||primary chemoradiation|treatment naive patients to be treated by conventional primary chemoradiotherapy with curative intent
2477557|NCT03053154||Experimental group1|15 stroke patients with right side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
2477558|NCT03053154||Experimental group2|15 stroke patients with left side affection, their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
2477559|NCT03053154||Control group|15 Normal subjects without any diseases or dysfunctions , their age ranged form 45 to 60 were recruited to assess the pelvic tilt angles from sitting position and from the dynamic task of sit to stand.
3158423|NCT00385970|Active Comparator|1|UFT+LV Group: The group treated with UFT and LV
2477778|NCT03051698|Experimental|C1-inhibitor|One gift of intravenous administration of C1-inhibitor (Cinryze, 100U/kg) during one hour
2477782|NCT03051698|Placebo Comparator|Saline|One gift of intravenous administration of 0.9% NaCl during one hour.
2477784|NCT03051698|Experimental|Antibiotics|broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days (washout 36 hours before study day).
2478040|NCT03049722|Experimental|AVOPT Patient|
2478063|NCT03049579|Experimental|Weiquan Yogurt with probiotics|Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
2478067|NCT03049579|Placebo Comparator|Weiquan Yogurt without probiotics|Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
2478139|NCT03049449|Experimental|1|All patients will be receiving starting dose: 0.3x106 CAR+ T cells/kg (weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells /kg)infuse on day 0 and Cyclophosphamide: 300 or 500 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3 and Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamid on days -5, -4,and -3
2478184|NCT03048799|Active Comparator|Radiofrequency on and Kinesiotherapy|The radiofrequency application protocol with CAPENERGY device, which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment, maintained for 2 minutes. Five RF sessions will be performed, with a seven-day interval between them. For the application, participants will be placed in lateral decubitus position. The session will be quick, with an average duration of 20 minutes.Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given.
2478186|NCT03048799|Placebo Comparator|Radiofrequency off and Kinesiotherapy|"The patient will be in lateral decubitus, the anal probe of the radiofrequency apparatus will be introduced, with the gel previously heated. The radio frequency will be off.~Kinesiotherapy will be done once a week, totaling five sessions. Initially, verbal information about location, function, and the correct way to contract the pelvic floor (PA) will be given. In addition, at this point will be advised on the performance of The Knack, which is a pre-contraction of the PA during the performance of some abdominal effort such as coughing, sneezing or laughing."
2478280|NCT03048630|Experimental|Knowledge and behavioral intervention|Owner and worker trainings regarding knowledge and behaviors associated with workplace chemical exposure reduction
2478283|NCT03048630|Other|Delayed intervention|Delayed knowledge and behavioral intervention
3158424|NCT00385970|Experimental|2|UFT+PSK Group: The group treated with of UFT and PSK
3158425|NCT00386035||1: DC Group|HIV infected participants who will stop or defer ART until the CD4 cell count drops below 250 cells/mm3 and who discontinue ART when CD4 cell count reaches above 350 cells/mm3. Participants are followed by episodic ART based on CD4 cell count.
3158426|NCT00386035||2: VS Group|HIV infected participants who continue ART to keep viral loads as low as possible, regardless of CD4 cell count.
3158427|NCT00386048||Standard of Care Observation Group|This group is randomized to continue their current medical management strategies for pain as recommended/prescribed by health care providers. Primary and secondary outcomes are collected at the same time intervals as the biopsychosocial intervention group.
3158428|NCT00386048||Biopsychosocial Intervention Group|This group continues all standard of care procedures for managing pain and adds to this additional cognitive-behavioral treatment (CBT) strategies for managing pain. The intervention explicitly frames the CBT strategies as added, complimentary pain management methods to add to the standard of care treatment.
3158429|NCT00386165|Experimental|Larazotide acetate|Larazotide acetate capsules: 12 mg QD x 3 days
3158430|NCT00386165|Placebo Comparator|Placebo|Placebo capsules: QD x 3 days
3158431|NCT00386178|Experimental|1|Vitamin E supplement rich in gamma tocopherol
3158432|NCT00386191|Experimental|1|50 mg
2477142|NCT03055975||Primary treatments|Patients undergoing primary root canal treatments. Only teeth which have not previously been accessed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
2477146|NCT03055975||Re-treatments|Patients undergoing re-treatments. Only teeth which had a previous root canal treatment which failed are included in this cohort.The source population are adults aged 18-65, referred by their general dental practitioner into specialist endodontic clinics of Guy's Hospital
2477199|NCT03055767|Other|OnabotulinumtoxinA/Saline Placebo|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
2477200|NCT03055767|Other|Saline Placebo/OnabotulinumtoxinA|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
3158433|NCT00386191|Experimental|2|75 mg
3158434|NCT00386217||Telephone Survey|90 minute Telephone survey of female cancer survivors
2477298|NCT03054896|Experimental|VR-EPOCH|"Standard chemotherapy regimen, DA-EPOCH-R, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
2477299|NCT03054896|Experimental|VR-CHOP|"Standard chemotherapy regimen, R-CHOP, with a novel oral Bcl-2 inhibitor, venetoclax will be administered to patients~Chemotherapy cycles will be administered approximately every 3 weeks~Initial venetoclax dose ramp-up will be done in a condensed fashion over approximately 5 days, followed by continuous daily dosing"
2477324|NCT03054701|Experimental|Sidelying hip abduction exercise|"Participants will be lying on the side with both legs stretched and with their head resting on a pillow. Participants will be allowed to place their hand in front of them to fixate their body and maintain balance. The participants will be instructed to abduct their hip to 45 degrees and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
2477329|NCT03054701|Active Comparator|Sitting knee extension exercise|"Participants will be seated at the end of an examination couch with the hip and knee relaxed in a 90 degrees angel. Participants will be allowed to place their hands on the side of the couch and the stabilizing foot may have contact with the floor. The participants will be instructed to extend their knee to a 180-degree angle and return to the resting position afterwards. An elastic band will be used as resistance. This exercise will be applied only on the test limb. A digital metronome will be used to maintain the pace during the exercise.~Load: 12 repetition maximum; Nr. of repetition: 12; Nr. of sets: 3; Rest between sets: 120 seconds; Time under tension: 8 seconds; Distribution of load: Concentric (3 seconds), Eccentric (3 seconds), Isometric (2 seconds)."
3158435|NCT00386230|Experimental|1|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Smother-Sinfant)
3158436|NCT00386230|Experimental|2|Maternal ZDV treatment starting at 35 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Smother-Linfant)
2477462|NCT03053882|Active Comparator|green tea and peppermint|
2477468|NCT03053882|Active Comparator|peppermint and green tea|
2477581|NCT03053076|Placebo Comparator|Placebo1|0.9% sodium chloride infusion 48 hours after birth ,the infusion speed is 4ml/kg/h， 8-12h，
2477584|NCT03053076|Experimental|CBMNC|Autologous Umbilical Cord Blood Mononuclear Cells Therapy 48 hours after birth ,dose is 25 million cells/kg ，the infusion speed is 4ml/kg/h， 8-12h，
2477678|NCT03052413|Active Comparator|Active|
2477683|NCT03052413|Placebo Comparator|Placebo|
2477710|NCT03052023|Experimental|group A (dual approach lap hernioplasty)|dual approach laparoscopic inguinal hernioplasty by combination of TAPP (group B) and pneumo-dissection preperitoneal instead of sharp dissection
2477711|NCT03052023|Active Comparator|group B (TAPP)|trans-abdominal preperitoneal hernioplasty (TAPP) after induction of pneumoperitoneum through peritoneal approach peritoneal incision and preperitoneal dissection then mesh fixation done
2477713|NCT03052023|Active Comparator|group C (Lichtenstein hernioplasty)|open inguinal hernioplasty (lichtenstein) repair through inguinal incision and dissection of the sac anteriorly , excision of the sac and then mesh fixation in the posterior wall of inguinal canal
2477828|NCT03051373|Experimental|nab-paclitaxel plus S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
2477838|NCT03051373|Active Comparator|Gemcitabine plus cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
3192757|NCT00811993|Experimental|2|
2478006|NCT03050086|Experimental|BPX-04 1% Minocycline Topical Gel|once daily topical administration of 1% minocycline gel to the face
2478010|NCT03050086|Experimental|BPX-04 2% Minocycline Topical Gel|once daily topical administration of 2% minocycline gel to the face
2478012|NCT03050086|Placebo Comparator|BPX-01 Vehicle Topical Gel|once daily topical administration of vehicle gel to the face
2478082|NCT03049800||FEP - Treatment as Usual|First Episode Psychosis patients who receive treatment as usual while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
3158437|NCT00386230|Experimental|3|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and three days of infant ZDV treatment starting at birth (Lmother-Sinfant)
2477211|NCT03055884|Sham Comparator|Sham tDCS without repeated retrieval practice|shamtDCS with verbal paired-associate learning task without repeated retrieval practice
2477266|NCT03055377|Experimental|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks
2477269|NCT03055377|Placebo Comparator|Placebo|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks
2477303|NCT03054961||Epilepsy patients|Near-infrared spectroscopy for subjects with partial (focal) epilepsy seizures being studied in the EMU.
2477360|NCT03054597|Experimental|Adults|"The arm consisted of adult participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks Peripheral Light Motion exercises: 4 times over 2 weeks"
2477361|NCT03054597|Experimental|Children|"The arm consisted of child participants who underwent:~Circular Light Motion exercises: 4 times over 2 weeks Diagonal Light Motion exercises: 4 times over 2 weeks"
2477395|NCT03054259|Experimental|Intervention|2 x 1000mg Rituximab and 100mg methylprednisolone
2477406|NCT03054259|Placebo Comparator|Control|2 x 100mg methylprednisolone plus placebo
2477437|NCT03053908|Experimental|Elderly Patients|
2477455|NCT03053752|Experimental|Transcutaneous Electric Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
2477490|NCT03053687|Experimental|Nutritional Standardized Supplementation Formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
2477491|NCT03053687|Placebo Comparator|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
2477524|NCT03053375|Experimental|Acute/subacute; active device|MDCure active device
2477528|NCT03053375|Placebo Comparator|Acute/subacute; sham|MDCure sham device
2477535|NCT03053375|Experimental|Chronic; active device|MDCure active device
2477537|NCT03053375|Placebo Comparator|Chronic; sham|MDCure sham device
3192758|NCT00811993|Experimental|3|
3192759|NCT00811993|Experimental|4|
3192760|NCT00811993|Experimental|5|
2477888|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previous on 25 μg)|Subjects received 25 μg in trial 000129.
2477894|NCT03051009|Experimental|Desmopressin ODT 25 μg (female previously on placebo)|Subjects received placebo in trial 000129
2477896|NCT03051009|Experimental|Desmopressin ODT 25 μg (female)|New female subjects
2477897|NCT03051009|Experimental|Desmopressin ODT 25 μg (male previous on 25 μg)|Subjects received 25 μg in trial 000130
2477898|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on 50 μg)|Subjects received 50 μg in trial 000130
2477899|NCT03051009|Experimental|Desmopressin ODT 50 μg (male previous on placebo)|Subjects received placebo in trial 000130
2477901|NCT03051009|Experimental|Desmopressin ODT 25 μg (male)|Subjects received placebo in trial 000130
2477905|NCT03051009|Experimental|Desmopressin ODT 50 μg (male)|New male subjects
3192761|NCT00811993|Experimental|6|
2477994|NCT03049995||CHEF:Cardiac Resynchronization therapy Forecast|Patients evaluated prior to cardiac resynchronization therapy (CRT), with class I, IIa or IIb for CRT according to ESC 2016 guidelines, and with ejection fraction ≤ 35% and QRS duration ≥ 130 ms. Contractile reserve will be assessed through variations in Wall Motion Score Index and with more advanced parameters such as left ventricular elastance reserve, as the peak stress/baseline ratio of end - systolic pressure/ end-systolic volume (Left ventricular contractile reserve SE). All patients will be followed-up with resting echocardiographic examination to assess left ventricular remodelling and recovery of function. A sample size of 277 patients is required and about the same number is required to predict the response to medical therapy in patients eventually not undergoing CRT (4).
2477995|NCT03049995||BHEF: B-lines in HEart Failure|B- lines are a semiquantitative sign of extravascular lung water present in 1 out of 3 HF patients at rest and in 1 out of 2 during stress, and potentially useful for refining prognostic stratification and titrating diuretic therapy in these patients. We will enroll patients referred to SE with known or suspected HF, with either reduced or preserved ejection fraction. B-lines will be detected using the B-lines SE intervention. A sample size of about 2500 patients is required if the effect on mortality is evaluated.
2477996|NCT03049995||SEHCA: SE in Hypertrophic Cardiomyopathy|Current guidelines recommend SE in hypertrophic cardiomyopathy (HC) solely for evaluation of left ventricular outflow tract obstruction. Large-scale registry data show that SE positivity for ischemic criteria rather than provocable gradients predict adverse outcome in HC. Low-to-intermediate risk symptomatic or asymptomatic HC patients will undergo exercise SE with assessment at each stage and during recovery of wall motion, mitral insufficiency, left ventricular outflow tract gradient (in orthostatic position)(following specific SE protocol), E/e', B-lines and, if feasible, coronary flow velocity reserve. A sample size of about 250 patients is required.
2477998|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
3192762|NCT00811993|Experimental|7|
3192763|NCT00811993|Experimental|8|
3192764|NCT00811993|Experimental|9|
3192765|NCT00812019|Experimental|3.75_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
3192766|NCT00812019|Experimental|3.75_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
3192767|NCT00812019|Experimental|3.75_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
3192768|NCT00812019|Experimental|3.75_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 3.75µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
3192769|NCT00812019|Experimental|7.5_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
3208664|NCT00976976|Experimental|DXP|
2477214|NCT03055533|Experimental|Immediate intervention with Headsprout reading program|Participants randomized to this study arm will begin treatment with the Headsprout program right away. Reading assessments will occur at the beginning and end of 12 weeks of treatment. Participation may be in clinic or via telehealth.
2477216|NCT03055533|No Intervention|Delayed intervention|Participants randomized to this study arm will have reading assessments at the beginning and end of the study, but they will not begin treatment with the Headsprout program until after their participation in the study ends (12 weeks). Participation may be in clinic or via telehealth.
2477379|NCT03054207|Experimental|HIV clopidogrel|clopidogrel 300 mg single dose oral route
2477388|NCT03054207|Experimental|HIV prasugrel|prasugrel 60 mg single dose oral route
2477402|NCT03054207|Active Comparator|Control clopidogrel|clopidogrel 300 mg single dose oral route
2477409|NCT03054207|Active Comparator|Control prasugrel|prasugrel 60 mg single dose oral route
2477474|NCT03053947|Other|Ketamine IN|All participants will receive intranasal Ketamine between 3mg/kg up to 9 mg/kg, once.
2477513|NCT03053531|Experimental|HERO-ED RCT|Subjects will be instructed on use of the HAD. The model that we will use is the PockeTalker Mini-Cog. This is a small (9.0cm X 5.5cm X 2.0cm) battery-powered electronic box that can be worn around the neck which connects via wires to both earphones and headphones (we will supply both earpieces, and let the patient choose). The RA, trained on use of the HAD by an experienced research audiologist, will instruct the patient in use of the HAD, and test the device to ensure proper functioning. The patient will also receive an instruction sheet (Appendix 3). Subjects will be encouraged to use the HAD during any encounters with ED staff.
2477560|NCT03053219|Experimental|AC0010|each participant will be given AC0010 300mg bid
2477610|NCT03052907|Other|BSPAN Expansion|We will expand BSPAN's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/UTSW continues to provide centralized financial review and reimbursement as the Texas BCCS contractor. We will prospectively identify which counties have the necessary program capacity, then test whether implementation of BSPAN tailored to a county's capacity and local needs can lead to equivalent program success in an additional 12 rural counties (BSPAN2 total= 17 counties). Findings will be used to develop a model by which BSPAN benefits can be brought to rural communities across the country.
2477643|NCT03052504||Cx prospective|Cystectomy patients followed with prospective registration of complications
2477648|NCT03052504||Cx retrospective|Cystectomy patients followed with retrospective registration of complications
2477649|NCT03052504||Nx prospective|Nephrectomy patients followed with prospective registration of complications
2477650|NCT03052504||Nx retrospective|Nephrectomy patients followed with retrospective registration of complications
2477672|NCT03052231|Active Comparator|Interactive Mobile Health Information|Receives Interactive Mobile Health Information via caremessage. EAI staff focus group content will include qualitative descriptions of their experiences with training and actual use of the Caremessages.org service, as well as to elicit comments about contributing features and other mitigating or enhancing factors of the intervention's implementation, outreach and promotion, and integration into workflow practices.
2477680|NCT03052231|No Intervention|Usual care|Usual care - clinic education, medication refills without reminders, appointments without reminders
2477740|NCT03052049|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
2477864|NCT03051035|Experimental|KO-947|
2477902|NCT03050710|Other|Princess® VOLUME Lidocaine|
2477921|NCT03050437|Experimental|Pem/Cis|Pem/Cis IV every 3 weeks
2477922|NCT03050437|Active Comparator|Pem alone|Pem IV alone every 3 weeks
3158438|NCT00386230|Active Comparator|4|Maternal ZDV treatment starting at 28 weeks Gestational Age (GA) and continuing through labor and delivery, and six weeks of infant ZDV treatment starting at birth (Lmother-Linfant). This study arm was the reference regimen.
2478209|NCT03048929|Active Comparator|Typhoid Vi Polysaccharide Vaccine|Patients will receive one intramuscular 0.5 mL injection of Typhoid Vi Polysaccharide Vaccine containing 0.025 mg purified Vi polysaccharide.
2478214|NCT03048929|Placebo Comparator|Placebo|Patients will receive one intramuscular 0.5 mL injection of saline placebo.
2478311|NCT03047785||Hospital population|All patients who have had a biochemistry blood tests requested at the trust will have a troponin blood level determined.
3158439|NCT00386282|Other|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone
3158440|NCT00386373|Experimental|Imatinib Mesylate|
3158441|NCT00386386|Other|1|Subject receives two infusions: One by EASI Access and one by IV access, at different sites
3158442|NCT00386399|Experimental|Arm 1|Patients with BRCA2 gene will be treated with Mitomycin-C (MMC) on Day 1 at a dose of 10mg/m2 intravenously. This will be repeated every 28 days, which is one cycle. Treatment will continue until disease progression, serious toxicity, patient withdrawal or maximum cumulative dose of 60 mg/m2
3158443|NCT00386490|Experimental|Larazotide acetate 0.25 mg|larazotide acetate 0.25 mg capsule TID for 10 days
3158444|NCT00386490|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsule TID for 10 days
3158445|NCT00386490|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsule TID for 10 days
3158446|NCT00386490|Experimental|Placebo|Placebo capsule TID for 10 days
3158447|NCT00386516|Experimental|GM-CT-01, 5-FU|GM-CT-01 (280 mg/m2) combined with 5-FU (600 mg/m2) given 4 consecutive days in a 28 days cycle until disease progression.
3158448|NCT00386542|Experimental|ID-JI-0.1|"Group ID-JI-0.1 (n = 16) - reduced 0.1 mL INF doses administered intradermally (ID) by needle-free jet injector (JI) (Biojector® 2000 subcutaneous syringe no. 2 [green color code], with 2 cm investigational spacer, Bioject Medical Technologies, Inc., Portland, OR, USA)"
3158449|NCT00386542|Active Comparator|IM-NS-0.1|"Group IM-NS-0.1 (n = 16) - reduced 0.1 mL INF doses administered intramuscularly (IM) needle-syringe (NS) (via 22-25 gauge needle, minimum 25 mm/1-inch length)"
3158450|NCT00386542|Active Comparator|IM-NS-0.25 control|"Group IM-NS-0.25 (controls) (n = 16) - full 0.25 mL INF doses administered intramuscularly (IM) by needle-syringe (NS) (22-25 gauge needle, minimum 25 mm/1-inch length)"
3158451|NCT00386620||Survey + ED|"Part 1: Survey + Electronic Diaries (ED)~Part 2: 3 Month, 6 Month Survey + ED"
3158452|NCT00386633|Other|1|Lower dosage: 10E7_TCID50
2477217|NCT03055572|Experimental|Olfactory Training with Essential Oils|Participants assigned to this group will do olfactory training using essential oils, while continuing the medical therapy prescribed by their provider.
2477221|NCT03055572|Active Comparator|Olfactory Training with Pure Fragrance Oils|Participants assigned to this group will do olfactory training using pure fragrance oils, while continuing the medical therapy prescribed by their provider.
2477224|NCT03055572|No Intervention|Control Group|The control group will continue the medical therapy prescribed by their provider.
3192770|NCT00812019|Experimental|7.5_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
2477357|NCT03054610|Active Comparator|Control|5 ml of local anesthetic (ropivacaine 7.5%)
2477358|NCT03054610|Active Comparator|Steroid|1ml of steroid Betamethason Sodium Phosphate (Celestone®) and local anesthetic (ropivacaine 7.5%)
2477359|NCT03054610|Experimental|BTX-A|200U Botulinum Toxins, Type A
2477393|NCT03054272||Residents|Anesthesia residents from University of Montreal Anesthesia Department who were watching the video
2477403|NCT03054272||Attending Physicians|Attending physicians from University of Montreal Anesthesia Department who were watching the video
2477484|NCT03054038|Experimental|Experimental|Patients receive afatinib PO QD on days 1-28 and necitumumab IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2477504|NCT03053362|Experimental|Major Depressive Disorder Population|"100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D."
2477505|NCT03053362|Other|Healthy Control Population|50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education
2477583|NCT03053245|Experimental|Mobile Critical Care Recovery Program|The group will receive the Mobile Critical Care Recovery Program (m-CCRP) intervention which includes care coordination and collaborative care model for one year post enrollment.
2477585|NCT03053245|Active Comparator|Attention Control|The attention control group will receive telephone based check ins related to their health from the research study team.
2477620|NCT03052699||vaginal Cesarean Section|patients operated to vaginal Cesarean Section
2477700|NCT03052140|Other|Treatment A, followed by Treatment B|Treatment group that will receive Treatment A for 14 days, followed by Treatment B for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2477701|NCT03052140|Other|Treatment B, followed by Treatment A|Treatment group that will receive Treatment B for 14 days, followed by Treatment A for 14 days. There will be a minimum 7 day washout between Treatments. Lamelleye Dry Eye Drops and Optive Plus will be administered to all subjects in this arm. Treatments will be self-administered at least 3 times a day.
2477751|NCT03051841|Experimental|Treat Regimen|CKD-581(investigational Drug) Bortezomib Dexamethasone
3158453|NCT00386633|Active Comparator|2|10E8_TCID50
3158454|NCT00386672|Experimental|Lite OJ with Ca and VitD|240ml of reduced energy (lite) OJ beverage fortified with 350mg Ca and 100U VitD, 3 times per day.
3158455|NCT00386672|Active Comparator|Lite OJ without Ca and VitD|240ml of reduced energy (lite) OJ beverage, 3 times per day.
2478119|NCT03049163|Other|vitrectomy under retrobulbar anesthesia|27-gauge vitrectomy for vitreous floaters under traditional retrobulbar anesthesia
2478122|NCT03049163|Experimental|vitrectomy under topical anesthesia|27-gauge vitrectomy for vitreous floaters under topical anesthesia
2478211|NCT03049007||Partner|Spousal bereaved individuals (age 25-85) in the Central Denmark Region identified through a data extraction of the Danish Civil Registration System (CPR) every sixth week over a period of one year. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
3158456|NCT00386841|Active Comparator|A Escitalopram 10 mg|Escitalopram 10 mg
3158457|NCT00386841|Placebo Comparator|Placebo|Placebo
3158458|NCT00386893|Other|Treatment as usual|simultaneous EEG/fMRI
3158459|NCT00386906|Other|Sentinel Lymph Node (SLN) Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
3158460|NCT00386945|Other|1|Non-Experiment Intervention consisting of an intervention based on the Clinical Practice Guideline: Treating Tobacco Use and Dependence and modified for use in chiropractic settings.
3158461|NCT00386971|Active Comparator|1|L-carnitine
3158462|NCT00386971|Placebo Comparator|2|Placebo
3158463|NCT00387049|Experimental|Anxiety-specific smoking cessation care|
3158464|NCT00387049|Active Comparator|Standard smoking cessation care|
3158465|NCT00387075|Experimental|[123I]β-CIT and SPECT imaging|To Assess [123I]β-CIT and SPECT imaging
3158466|NCT00387166||1|Mexican-American women, aged 40-65
3158467|NCT00387179|Experimental|Dim Light Melatonin and/or methylxanthine|Dim Light Melatonin and/or methylxanthine
3158468|NCT00387179|Experimental|Placebo and Dim Light or bright light|Placebo and Dim Light or bright light
3158469|NCT00387179|Experimental|Bright light melatonin and/or methylxanthine|Bright light, melatonin, and/or methylxanthine
3158470|NCT00387205|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
3158471|NCT00387270|Experimental|A|Dimebon
3158472|NCT00387322|Experimental|Group 1|Patients receive oral erlotinib hydrochloride once on days 2, 9, and 16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression
3158473|NCT00387322|Experimental|Group 2|Patients receive oral erlotinib hydrochloride once daily on days 2-16 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of unacceptable toxicity or disease progression.
3158474|NCT00387361|Experimental|1|
3158475|NCT00387361|No Intervention|2|
3192771|NCT00812019|Experimental|7.5_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
2477316|NCT03054766|Experimental|Ranibizumab only|"Sham macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Sham macular laser"
2477323|NCT03054766|Experimental|Ranibizumab combined macular laser|"Macular laser photocoagulation treatment after third ranibizumab injection with PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization~Interventions :Ranibizumab injection Interventions :Macular laser photocoagulation"
2477370|NCT03054441||Experimental group|Children, Adolescents and Young with hemiplegia
2477371|NCT03054441||Control group|Children, Adolescents and Young with typical development
3192772|NCT00812019|Experimental|7.5_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 7.5µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
3192773|NCT00812019|Experimental|15_0%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 0% of MF59 three weeks apart.
2477541|NCT03053297||Patients with EGFR mutation (+) NSCLC|Patients with EGFR mutation-positive locally advanced or metastatic NSCLC who have progressed while on or after receiving front-line EGFR-TKI therapy (e.g., gefitinib, erlotinib, afatinib, or icotinib).
2477547|NCT03053297||Patients newly diagnosed NSCLC|Patients newly diagnosed with locally advanced or metastatic NSCLC who are treatment naive or patients who were diagnosed at an earlier stage but have progressed to metastatic NSCLC during the selection period.
3192774|NCT00812019|Experimental|15_25%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 25% of MF59 three weeks apart.
3192775|NCT00812019|Experimental|15_50%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 50% of MF59 three weeks apart.
3192776|NCT00812019|Experimental|15_100%MF59|Subjects received two 0.5mL vaccinations of cell culture derived H5N1 15µg subunit influenza vaccine containing 100% of MF59 three weeks apart.
2478044|NCT03049930|Experimental|Ketamine|Participants randomized to this arm will receive ketamine (1 mg/ml solution) infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
2478045|NCT03049930|Placebo Comparator|Placebo|Participants randomized to this arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
2478046|NCT03049527|Experimental|Education, Incentives and Feedback|Education, Incentives and Feedback are all directed to all study participants.
3192777|NCT00812045|Experimental|1|
3192778|NCT00812045|Placebo Comparator|2|
3192779|NCT00812058|Experimental|RG2417|Oral RG2417 taken twice daily for 8 weeks
3192780|NCT00812058|Placebo Comparator|Placebo|Oral placebo taken twice daily for 8 weeks
3192781|NCT00812084||CAP cohort|Includes cases that were hospitalized because of a community-acquired pneumonia during the study period, and for which we had a baseline EQ-5D score from the start of the study period. These CAP cases are prospectively followed for up to one year using questionnaires for health status and (health) resources.
3192782|NCT00812084||Controls cohort|For each CAP cases, two controls are matched based on age, sex and baseline EQ-5D score measured at the start of the study. These controls are prospectively followed for up to one year using questionnaires for health status and (health) resources.
2478340|NCT03047967|Experimental|PTSE|Prenatal tobacco smoke exposed newborns. Lung function test Nasal brushing
2478348|NCT03047967|Experimental|control|Prenatal tobacco smoke non exposed newborns Lung function test Nasal brushing
2478368|NCT03047538|Active Comparator|Free combination|Free combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks free combination will be changed to fixed combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
2478376|NCT03047538|Active Comparator|Fixed combination|Fixed combination of atorvastatin, perindopril and amlodipine will be given for 8 weeks. After 8 weeks fixed combination will be changed to free combination. The dose of each drug will be selected according to clinical judgement of each investigator, but can not be changed during the coarse of the study.
2478445|NCT03047252|Experimental|Experimental group|"Home-based rehabilitation sessions performed with the novel digital biofeedback system.~Patients will be instructed to perform exercise sessions in at least 5 days per week, but compliance to this schedule is not mandatory per protocol."
2478446|NCT03047252|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week for 8 weeks. Each session will have a duration of 60 minutes. Patients will be instructed to perform additional unsupervised sessions in at least two other days, but compliance to these extra sessions is not mandatory per protocol.
3192783|NCT00812123|Experimental|Calcineurin free|Immunosuppression with Sirolimus, Mycophenolate and Steroids
2478589|NCT03046004|Experimental|Decision aid|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
2478591|NCT03046004|Active Comparator|Control|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
2478639|NCT03045757||Healthy Newborn|Healthy Newborn
2478645|NCT03045757||CHD Neonates|Neonates born with CHD before and after surgical repair
3192784|NCT00812123|Active Comparator|Calcineurin|Immunosuppressive therapy with Cyclosporin A, Mycophenolate and Steroids
3192785|NCT00812162|Experimental|1|High protein diet.
3192786|NCT00812162|Experimental|2|Lower protein diet.
3192787|NCT00812175||Group 1|
3192788|NCT00812188|Active Comparator|Medium Dose UVA-1|Medium dose (60 J/cm2) UVA-1 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream to another morphea plaque twice daily for twelve weeks.
3192789|NCT00812188|Active Comparator|High Dose UVA-1|High dose UVA-1 treatment 3x/week for 12 weeks to one morphea plaque and fluocinonide 0.05% cream twice daily for 12 weeks to another morphea plaque.
3192790|NCT00812201||1|
3192791|NCT00812214|Experimental|1|
3192792|NCT00812214|Placebo Comparator|2|
2477242|NCT03055507|Active Comparator|Control|Standard pain regimen of acetaminophen 650 mg q6hrs while awake until cessation of need for scheduled pain medication with the addition of oxycodone 5 mg q3 hrs PRN pain.
2477243|NCT03055507|Experimental|Ibuprofen|Alternating every 3 hours acetaminophen 650 mg and ibuprofen 400 mg while awake until cessation of need for schedule pain medication with the addition of oxycodone 5 mg q3hr PRN pain.
2477273|NCT03055143|Experimental|SPARC-08-038|2 mg/ml
2477274|NCT03055143|Active Comparator|Ref-08-038|
3192793|NCT00812227|Experimental|Psychodynamic psychotherapy|
3192794|NCT00812240|Experimental|Masitinib (7.5)|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
2477400|NCT03054194|Experimental|Cohort 1: Dose 1 E2730|Participants will receive Dose 1 of oral E2730 on Day 1.
2477411|NCT03054194|Placebo Comparator|Cohort 1: Matching placebo|Participants will receive matching oral placebo on Day 1.
2477414|NCT03054194|Experimental|Cohort 2: Dose 2 E2730|Participants will receive Dose 2 of oral E2730 on Day 1.
2477416|NCT03054194|Placebo Comparator|Cohort 2: Matching placebo|Participants will receive oral matching placebo on Day 1.
2477419|NCT03054194|Experimental|Cohort 3: Dose 3 E2730|Participants will receive Dose 3 of oral E2730 on Day 1.
2477421|NCT03054194|Placebo Comparator|Cohort 3: Matching placebo|Participants will receive oral matching placebo on Day 1.
2477461|NCT03053856|Experimental|Pembrolizumab arm|Adjuvant Pembrolizumab
2477532|NCT03053414|Active Comparator|Treatment Arm # 1|50,000 IU oral vitamin D2 per week for 12 weeks + Dietary counseling
2477538|NCT03053414|Active Comparator|Treatment Arm # 2|50,000 IU oral vitamin D2 per week x 12 weeks then 800 IU/day oral vitamin D3 for 6 months + Dietary counseling
2477542|NCT03053414|Active Comparator|Treatment Arm # 3|50,000 IU oral vitamin D2 per week x 12 weeks then 5,000 IU/day oral vitamin D3 for 6 months+ Dietary counseling
2477546|NCT03053414|Active Comparator|Treatment Arm # 4|5,000 IU oral daily vitamin D3 for 9 months + Dietary counseling
2477565|NCT03053024||Cohort 1: Relapse/refractory MCL (rrMCL ) Participants|Participants characteristics and treatment pattern of relapsed/refractory mantel cell lymphoma [rrMCL]) participants treated by Bortezomib (BTZ) will be observed for cohort 1.
2477567|NCT03053024||Cohort 2: Newly Diagnosed MCL Participants|Participants characteristics and treatment pattern of newly diagnosed MCL participants (if more than 20% of total BTZ-treated MCL) will be analysed for cohort 2.
2477603|NCT03052842|Other|Arm 1|Study subjects will be randomized to receive 9.2 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
2477605|NCT03052842|Other|Arm 2|Study subjects will be randomized to receive 18.4 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects). Study arm will be fully enrolled (i.e., the last subject in an arm has completed Visit 3) before enrollment is initiated in the next study arm.
2477606|NCT03052842|Other|Arm 3|Study subjects will be randomized to receive 36.8 mg C16G2 Strip or Placebo in a 4:1 allocation ratio (8 C16G2 Strip subjects: 2 Placebo Strip subjects).
2477614|NCT03052543||BISblind|The BISblind group will have the BIS monitor and data physically hidden from the anesthesiologist. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
2477615|NCT03052543||BISvisible|BISvisible group will have the BIS monitor and data available for the anesthesiologist to view. The patient will receive an anesthetic as per the anesthesiologist's particular care plan, unaltered by the study.
2477666|NCT03052465|Experimental|Feeding|Test soup meal feeding intervention
3192795|NCT00812240|Experimental|Masitinib (6.0)|Participants receive masitinib (6.0 mg/kg/day), given orally twice daily
3192796|NCT00812240|Active Comparator|Active Comparator (7.5)|Participants receive imatinib at 400 or 600 mg per day
2477835|NCT03051087|Experimental|Ganilever (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
2477841|NCT03051087|Active Comparator|Orgalutran (ganirelix acetate)|Prefilled syringe / 0.25mg/0.5mL
2477868|NCT03050866|Other|Treatment|Treatment intervention with Cabazitaxel with premedication as necessary (antihistamine, corticosteroid, H2 antagonist, antiemetic prophylaxis)
2477953|NCT03050424|Experimental|Active|Ferric Carboxymaltose (FCM) (Ferinject) at 15 mg iron/kg body weight
2477956|NCT03050424|Placebo Comparator|Placebo|Sodium Chloride 0.9%
2478032|NCT03050021||Delirium positive|delirium patients in critically ill surgical patients
2478035|NCT03050021||Delirium negative|non delirium patients in critically ill surgical patients
2478041|NCT03049735|Experimental|Relugolix plus E2/NETA (Group A)|Relugolix co-administered with E2/NETA for 24 weeks.
2478042|NCT03049735|Experimental|Relugolix plus Delayed E2/NETA (Group B)|Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.
2478043|NCT03049735|Placebo Comparator|Placebo (Group C)|Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.
2478153|NCT03049046|Active Comparator|CC100 250 mg|CC100 250 mg once daily by mouth for 7 days
2478159|NCT03049046|Active Comparator|CC100 500 mg|CC100 500 mg once daily by mouth for 7 days
2478165|NCT03049046|Active Comparator|CC100 1000 mg|CC100 1000 mg once daily by mouth for 7 days
2478168|NCT03049046|Placebo Comparator|Placebo|Placebo once daily by mouth for 7 days
2478189|NCT03048786|Active Comparator|Control Arm|Participants will receive automated text messages drawn from the script used by SmokefreeTXT.
2478191|NCT03048786|Experimental|Peer Mentoring Arm|Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor.
2478281|NCT03048591|Experimental|Electroacupuncture group|
2478284|NCT03048591|No Intervention|control group|
3192797|NCT00812240|Active Comparator|Active Comparator (6.0)|Participants receive imatinib at 400 or 600 mg per day
3192798|NCT00812266|Experimental|A|Topotecan + cisplatin
3192799|NCT00812266|Active Comparator|B|Etoposide + carboplatin
3192800|NCT00812279|Experimental|1. SMAR|Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times.
2477305|NCT03054727||Villalta phone score > or = to 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call AND a random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score > or = to 5 at the end of the follow-up call
2477308|NCT03054727||Villalta phone score < 5|patients with VTE in the OPTIMEV cohort with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call AND random selection of patients free from any VTE after the first 3 years of follow-up in OPTIMEV with an Utne and Sandset Villalta phone score < 5 at the end of the follow-up call
2477367|NCT03054532|Experimental|Durvalumab and lenalidomide|"Open-label use of 2 drugs:~Durvalumab 1500 mg intravenously on day 1 of a 28-day cycle until progressive disease or intolerance.~Lenalidomide orally on days 1 through 21 of each 28-day cycle for 6 cycles."
2477425|NCT03054129|Experimental|Rehabilitation and balance training|"Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program."
2477426|NCT03054129|Active Comparator|Rehabilitation program|"Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program."
2477485|NCT03053804|Experimental|MR/PET|hypothesize that MR/PET can have better information than current CT image study
2477498|NCT03053453|Active Comparator|Standard of Care Spinal Surgery|Patients will be given spinal anesthesia with 2.6 mL of 0.5% isobaric bupivacaine.
2477499|NCT03053453|Experimental|Sensor Guided Spinal Surgery|The Verasense Knee System device (OrthoSensor inc., Dania Beach, Florida) is a sterile sensor system that replaces the tibial insert trials used during surgery. The sensor contains a microprocessor and integrated nanosensor system, which wirelessly transmits real-time data to a portable graphic display unit used for read-out of the data. The sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
2477550|NCT03053284|Placebo Comparator|Placebo|Normal saline s.c. injection once
2477552|NCT03053284|Experimental|Pasireotide|Pasireotide 0.6mg s.c. once
2477574|NCT03052998|Active Comparator|Ivermectin|Ivermectin and anti-epileptic treatment
2477579|NCT03052998|No Intervention|no treatment|only anti-epileptic treatment
3192801|NCT00812279|Active Comparator|2 Conventional cigarette (CC)|Subjects will be allowed to smoke without any limit on consumption during the designated smoking times.
3192802|NCT00812279|Active Comparator|3. smoking cessation (SC)|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
2477722|NCT03051919||no reinforcement|Group I: 25 patients; no reinforcement (NoR) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2477723|NCT03051919||fibrin glue|Group II: 26 patients; fibrin glue (FG) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2477730|NCT03051919||suture reinforcement|Group III: 44 patients; suture reinforcement with 2-0 polypropylene suture (S) Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
2477732|NCT03051919||biological buttressing materaia|Group IV: 14 patients; biological buttressing material Observation : Patients would be followed up for any signs of leaks. If any, treatment would be offered appropriataly but the results of treatment are not affiliated as a part in the study.
3192803|NCT00812305|Experimental|Low dose in healthy patients|
2477892|NCT03050983||Phase I|Prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring prior to enabling IPI.
2477895|NCT03050983||Phase II|Enable the Integrated Pulmonary Index (IPI) and IPI alarm for the prospective observation of alarmed events on the general care floor with continuous capnography and pulse oximetry monitoring.
2477933|NCT03050515|Experimental|Fecal Transplant|"Enrolled and screened patients will receive a donor directed fecal transplant via retention enema. This procedure will take place at the University of California Irvine Women's Health Center on the day of the participant's choosing.~The day prior to the procedure, the participant will undergo a bowel prep and stop all prophylactic antibiotics. On the day of procedure, the patient will present to the clinic and undergo a simple, retention enema. This procedure takes about 30-40 minutes to complete and does not require any anesthesia or sedation."
3192804|NCT00812305|Experimental|Low dose in hepatically impaired patients|
3192805|NCT00812318|Experimental|Treatment A|GSK1265744 10mg oral solution
2478054|NCT03049592|Experimental|HIBISCUS counseling|Subject receives a third trimester prenatal appointment with a family planning specialist for contraceptive counseling (utilizing the Contraceptive CHOICE counseling script emphasizing the WHO birth-to-pregnancy recommendation of 18 months) and a follow up postpartum contraception visit with a family planning specialist.
2478059|NCT03049592|No Intervention|Standard counseling|Subect receives standard high-risk prenatal care and postpartum contraception provision by the referring community clinic. The community clinic offer standard family planning counseling that does not emphasize utilizing of long-acting reversible contraception to promote birth-to-pregnancy spacing of 18 months. This scenario is current the standard practice at the institutions.
3192806|NCT00812318|Experimental|Treatment B|GSK1265744 5mg tablet, fasted
3192807|NCT00812318|Experimental|Treatment C|GSK1265744 5mg tablet, fed
3192808|NCT00812344|Experimental|1|
2477326|NCT03054831|Active Comparator|Age 6-8 years-Before GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
2477331|NCT03054831|Active Comparator|Age 6-8 years-After GA|The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU).
2477372|NCT03054454|Active Comparator|intervention|This group will receive Podiatry treatment and care from the MDT which is the intervention group.
2477375|NCT03054454|No Intervention|comparator|This group will receive usual care
3192809|NCT00812344|Active Comparator|2|AZD0837 + Ketoconazole
3192810|NCT00812357||1|Patients treated with Symbicort basic treatment
3192811|NCT00812357||2|Patients treated with Symbicort basic treatment + treatment of symptoms as needed
2477511|NCT03053323|Experimental|Lifestyle Intervention|
3192812|NCT00812370|Experimental|open label|
3192813|NCT00812383|Experimental|Bivalirudin|
3192814|NCT00812383|Active Comparator|Heparin|
2477923|NCT03050671|Active Comparator|Rapid calf-IPC|Cyclic external compression in both calves through a cuff connected to VenaFlow® Elite System, DJO, CA, USA
2477924|NCT03050671|Active Comparator|subjects under slow calf-IPC|Cyclic external compression in both calves through a cuff connected to Kendall SCD™ 700, Covidien, Medtronic, USA
2477955|NCT03050281|Experimental|Simulation/Cadaver Workshop|2-day workshop using the Simulation/Cadaver Lab
2477958|NCT03050281|Placebo Comparator|Didactic Workshop|Lectures
2477992|NCT03050034|Experimental|Vital signs wireless monitoring system|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for hospitalization and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS/ NEWS, undergone to continuous monitoring with wireless monitoring system WIN @ Hospital.
2477993|NCT03050034|Active Comparator|Control arm|All patients with MEWS (Modified Early Warning Score) greater than or equal to 3 and/or NEWS (National Early Warning Score) greater than or equal to 5, at admission, regardless of the reason for admission and all patients with glycemic decompensation and/or severe fluid and electrolyte imbalance, regardless of MEWS NEWS undergone to traditional monitoring performed at regular intervals by the nursing staff.
2478072|NCT03049904|No Intervention|Wait List Control|Participants wait 3 weeks before receiving the intervention.
2478077|NCT03049904|Experimental|Experimental Vr2L 2Spirit|Participants immediately begin their participation in the virtual world.
2478114|NCT03049319|Experimental|Laser|All six interventions will be applied to patient's back.
2478143|NCT03049111|Experimental|Inhaled Allergen Challenge|Der f sensitive, mild asthmatic subjects will undergo inhaled allergen challenge
2478195|NCT03048903|Experimental|Rheum Palmatum Root|Rheum Palmatum Root is commercially certified rhubarb(Rheum palmatum ,Sichuan origin, provided by the pharmacy of my hospital)
2478207|NCT03048903|Placebo Comparator|Starch Corn|Medical Starch is harmless to people
2478341|NCT03048045||Supportive Periodontal Treatment (SPT)|"at least 18 years old.~periodontal treatment (antiinfective therapy with subgingival debridement under local anesthesia and if required periodontal surgery) at the Dept. of Periodontology starting after April 2005 durchgeführt.~complete periodontal charting (PPD and PAL-V at 6 sites per tooth, furcation involvement [Hamp et al. 1975] at all furcation sites of multi-rooted teeth) prior to treatment (baseline, T0) and after completion of active periodontal treatment (APT) (reevaluation 1 or 2/start of supportive periodontal therapy, T1)~radiographs of all teeth (periapical radiographs or panoramic radiograph) from baseline~written informed consent"
2478410|NCT03047603||Healthy control|The healthy control group consist of people undergoing routine medical examination. Serum samples are collected.
2478415|NCT03047603||Metastatic liver cancer patients|Serum samples are collected.
2478417|NCT03047603||Hepatocellular carcinoma patients|Serum samples are collected before liver resection.
2478418|NCT03047603||Chronic liver disease patients|This group is comprised of liver cirrhosis and chronic hepatitis B patients. The diagnosis of liver cirrhosis are based on triple-phase contrast enhanced computed tomography, magnetic resonance imaging.
2478455|NCT03047018|Experimental|CHANGE Program|Participants with ASD will complete the The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) program.
2478524|NCT03046784||Pregnant women in third trimester|"Non-labouring pregnant women hospitalised during their third trimester of pregnancy has an haemodynamic evaluation with Nexfin technology and transthoracic cardiac ultrasonography.~Evaluation is performed in two positions : dorsal decubitus and left lateral decubitus."
2478594|NCT03046251|Other|natalizumab|Participants in this group are those who opt to receive treatment with natalizumab IV 300mg/day given q 4 weeks for 48 weeks.
2478595|NCT03046251|No Intervention|Control|Participants in this group may initiate any FDA approved DMT at any time post delivery or remain on no therapy.
2478649|NCT03045731||Kidney transplant recipients|Patients who have received kidney transplantation in Zhongshan Hospital.
2478721|NCT03045432|Experimental|video-teaching materials|"regular passive ROM exercise~regular rehabilitation programe~alternative video-teaching materials"
2478722|NCT03045432|Other|control group|"regular passive ROM exercise~regular rehabilitation programe~regular oral-teaching materials"
2478779|NCT03044873|Experimental|BMS 986165 and Rosuvastatin|
2478858|NCT03044470|Experimental|Cold saline|Saline stored at 4 degrees centigrade
2478867|NCT03044470|Experimental|Normal Saline|Saline stored at room temperature
3192815|NCT00812396|Active Comparator|1|Low dose testosterone
3192816|NCT00812396|Active Comparator|2|High dose testosterone
3192817|NCT00812396|Placebo Comparator|3|Placebo
3192818|NCT00812409|Experimental|1|Control group: non-protein supplement with resistance and aerobic exercise.
3192819|NCT00812409|Experimental|2|Low protein supplement with resistance and aerobic exercise.
3192820|NCT00812409|Experimental|3|Moderate protein supplement with resistance and aerobic exercise.
3192821|NCT00812409|Experimental|4|High protein supplement with resistance and aerobic exercise.
3192822|NCT00812422|Experimental|Dexibuprofen 1|Dexibuprofen 2.5 or 5 mg/kg
3192823|NCT00812422|Experimental|Dexibuprofen 2|Dexibuprofen 3.5 or 7 mg/kg
3192824|NCT00812422|Active Comparator|Ibuprofen|Ibuprofen 5 or 10 mg/kg
3192825|NCT00812435|Experimental|Eptifibatide|PCI with administration of eptifibatide
2477398|NCT03054298|Active Comparator|Cohort 1|Single dose of 1-3x10^7/m^2 lentiviral transduced huCART-meso cells
2477407|NCT03054298|Active Comparator|Cohort 2|Cyclophosphamide 1 grams/m^2 administered 2-4 days prior to a single dose of 1-3x10^7 /m^2 lentiviral transduced huCART-meso cells
2477412|NCT03054298|Active Comparator|Cohort 3|PERMANENTLY CLOSED
2477415|NCT03054298|Active Comparator|Cohort 4|PERMANENTLY CLOSED
2477417|NCT03054298|Active Comparator|Cohort 5|Single dose of 1-3x107 huCART-meso cells/m2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen. Subjects in this cohort will be enrolled after safety is demonstrated at this dose level by completion of Cohorts 1 and 2. Subjects in Cohort 5 may be enrolled in parallel to Cohort 6.
2477418|NCT03054298|Active Comparator|Cohort 6|Dose of 1-3x107 huCART-meso cells/m2 via IV infusion on Day 0, following a flat dose of 1 gram/m2 of cyclophosphamide administered 2-4 days prior to huCART-meso cells (~Day -4 to -2). This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells. Cohort 6 was activated with Protocol V6. Enrollment into Cohort 6 will occur in parallel with Cohort 5.
2477420|NCT03054298|Active Comparator|Cohort 7|a single dose of 1-3x107 huCART-meso cells/m2 via intraperitoneal (i.p.) administration, following lymphodepleting chemotherapy with cyclophosphamide 300 mg/m2/day and fludarabine 30 mg/m2/day given over 3 days by intravenous infusion. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells. Infusion #1 for the first three subjects in Cohort 7 will be staggered by at least 21 days to allow for the assessment of DLTs. Enrollment into Cohort 7 will occur in parallel with Cohort 5 and Cohort 6.
2477483|NCT03053830|Experimental|Intervention Group|Veterans with Major Depressive Disorder getting up to 6 infusions of 0.5mg/kg ketamine in normal saline; one infusion per week, 40 minutes per infusion with time points lasting up to 5 hours.
2477540|NCT03053505|Experimental|Recurrent CDI FMT|"Non-randomized group (R) for treatment of recurrent CDI with FMT"
2477544|NCT03053505|Active Comparator|Primary CDI antibiotic|"Randomized group (F AB) for the treatment of primary CDI with antibiotics (vancomycin or fidaxomicin)"
2477548|NCT03053505|Experimental|Primary CDI FMT|"Randomized group (F FMT) for the treatment of primary CDI with FMT"
2477609|NCT03052595||SM|Patients with newly diagnosed multiple sclerosis undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Patients undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
2477611|NCT03052595||Control|Age, sex, Body Mass Index (BMI) matched healthy subjects undergo Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load Healthy controls undergo testing of autonomous nervous system function and testing of cognitive function (Stroop test)
2477677|NCT03052361|Experimental|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage. Posology of ondansetron will be adapted to weight: doses of 2 mg for children weighting between 8 and 15 kg, 4 mg for children weighting between 15 to 30 kg and 8 mg for children heavier than 30 kg
2477681|NCT03052361|Placebo Comparator|control|Patients allocated to this arm will receive an identical looking/tasting placebo in the ED triage.
2477714|NCT03051945|Experimental|Ketamine|Ketamine will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
2477718|NCT03051945|Placebo Comparator|Placebo|Normal saline will be infused via intravenous catheter over 40 minutes (0.75 mg/kg/hr over 40 minutes, 0.5 mg/kg total).
2477756|NCT03051724|Experimental|Intervention group|"These OSA patient's are not familiarized with the use of internet and mobile technologies and with CPAP prescription. They follow the intervetion follow up that consists in an adaptation session where the tecnitian delivers them an automatic CPAP machine. Patient's are titrated with this automatic device in 5-7 days and are treated with the automatic device during 3 months.~The other part of the follow up consists on a voicemail where the patient can contact us 24h a day and on an , with an internet-connected tablet with a special app where the patient's answer a questionnaire once two weeks."
2477757|NCT03051724|No Intervention|Control group|These patient's are patient's that follow the process that all patient's take during CPAP treatment. During the three months of study, the follow up will be the usual.
2477803|NCT03051490|Experimental|Liprotamase|Individually-optimized dose to be administered orally
2477805|NCT03051490|Active Comparator|porcine PERT|Individually-optimized dose to be administered orally
2477886|NCT03050996||robotic radical prostatectomy patients|Patient scheduled to undergo robotic assisted radical prostatectomy
2477937|NCT03050554|Experimental|SBRT+Avelumab|"SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)~Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles"
2478015|NCT03050138||Dabigatran|In the RE-COVER- and RE-COVER II studies, one group of DVT and/or PE patients were randomized to receive 6 months of treatment with dabigatran (150 mg twice daily). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
2478092|NCT03049800||FEP - Targeted Cognitive Training|First Episode Psychosis patients who receive targeted cognitive training exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
3192826|NCT00812448|Experimental|tea catechin extracts containing mask|wearing the tea catechin extracts containing mask
3192827|NCT00812500|Experimental|1|Young men, age 21-46 years.
3192828|NCT00812500|Experimental|2|Old Men, age 63-81 years.
3192829|NCT00812500|Experimental|3|Young women, age 21-46 years.
3192830|NCT00812500|Experimental|4|Old women, age 63-81 years.
2477454|NCT03053726|Experimental|Variable Frequency Stimulation|Subjects in this group received variable frequency stimulation of deep brain stimulation
2477456|NCT03053726|Sham Comparator|Constant Frequency Stimulation|Subjects in this group received constant frequency stimulation of deep brain
2477519|NCT03053570|Experimental|Cryoballoon|
2477522|NCT03053570|Experimental|Radiofrequency Energy(Contact Force)|
3192831|NCT00812539|Experimental|"Diabetes Connected Health Tool Deluxe"|Subjects enrolled into the intervention arm will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal, where they can view their glucose readings and detailed graphical representation of their blood glucose levels over time, read educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to these subjects' information on the web portal).
3192832|NCT00812539|Active Comparator|"Diabetes Connected Health Tool Basic"|Control group will measure their glucose levels by using a glucometer. An iMetrikus modem will upload the blood glucose readings to a secure, web-based portal. Participants will be given login information to access this portal. where they can view their glucose readings in tabular form. Their physicians will not have access to this information.
3192833|NCT00812552||Case|Late or very late drug-eluting stent thrombosis
2477859|NCT03051048||Group 1|The patient received reperfusion therapy between 1999 January 1 and 2009 December 31
2477860|NCT03051048||Group 2|The patient received reperfusion therapy between 2010 January 1 and 2016 December 31
2477943|NCT03050580|Experimental|Self-esteem enhancement group|The self-esteem enhancement group service for abused women will receive a six-session program for recognizing strengths and resources through group activities and sharing.
2477950|NCT03050580|Active Comparator|Standard care|The shelter standard care for abused women includes residential accommodations, emotional support, legal, housing and financial advice and referral service.
2478025|NCT03050151|Experimental|1 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by auto-injector device
2478028|NCT03050151|Experimental|2 - Dupilumab (Part A)|Dose (dose 1) as per protocol delivered by prefilled syringe
2478030|NCT03050151|Experimental|3 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by auto-injector device
2478031|NCT03050151|Experimental|4 - Dupilumab (Part B)|Dose (dose 2) as per protocol delivered by prefilled syringe
2478085|NCT03049553|Other|HPV-test|Cobas HPV-DNA test is performed on the cervical sample in addition to the routine cytology
2478096|NCT03049553|No Intervention|Routine|Screening with cytology as usual in the cervical screening program
2478138|NCT03049293|No Intervention|Control group using Propofol|Sedation will be established by administering 100mcs of Fentanyl, and 1-1.5mg/kg of body weight of Propofol.
2478154|NCT03049293|Experimental|Study group Midazolam group|Sedation will be established by administering Midazolam 1mg, 100mcs of Fentanyl, and 0.5-1mg/kg of body weight of Propofol. Further boluses of Propofol will be given according to the need of the patient and time consumed for oocyte retrieval.
2478190|NCT03048851|Experimental|Low dosage SES group|Low dosage SES group received the low dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
2478192|NCT03048851|Experimental|High dosage SES group|High dosage SES group received the high dosage SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
2478200|NCT03048851|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 1.5 hours per day.
2478208|NCT03048851|Experimental|VRCIT+SES group|VRCIT+SES group received the VRCIT and SES training in addition to traditional rehabilitation.
2478213|NCT03048851|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
2478261|NCT03048435||Cervical Cancer Patients|Adult, English-speaking cervical cancer patients, who have been treated with curative intent chemo-radiotherapy.
2478263|NCT03048435||Oncologist|Oncologists who treat cervix cancer, with at least one consenting patient enrolled in the study.
2478325|NCT03048084|Active Comparator|Levetiracetam|Patients in this treatment arm will receive levetiracetam monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d levetiracetam in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d levetiracetam. In step 4, levetiracetam is increased to 2x1500mg/d. In the fifth treatment step, patients will receive 2x1500 mg/d levetiracetam, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
2478332|NCT03048084|Active Comparator|Valproic acid|Patients in this treatment arm will receive valproic acid monotherapy. The dosage depends on the specific treatment step, as indicated in the protocol. In step 1, patients will receive 2x500 mg/d valproic acid in the form of tablets. In step 2, dosage is increased to 1x250 plus 1x500 mg/d and in step 3 to 2x1000 mg/d valproic acid. In step 4, valproic acid dosage is increased to a maximum of 2x1250mg/d. In the fifth treatment step, patients will receive 2x1250mg valproic acid, and another AED will be added. The type and dosage of this add-on AED is according to the physician's preference, but in line with current clinical practice in the Netherlands.
2478373|NCT03047499||Scar Length|
2478381|NCT03047499||Vancouver scar scale|
2478392|NCT03047499||Scar width|
2478512|NCT03046719|Active Comparator|Bupivacaine 0,5%|Subjects received subconjunctival bupivacaine 0,5% 2,5ml in between stitches.
2478515|NCT03046719|Placebo Comparator|NaCl 0,9%|Subjects received subconjunctival NaCl 0,9% in between stitches.
3192834|NCT00812552||Control|No drug-eluting stent thrombosis
3192835|NCT00812578|Active Comparator|Cholecalciferol|
3192836|NCT00812578|Placebo Comparator|Placebo pill|
3192837|NCT00812617|Experimental|Mineral water 1|
3192838|NCT00812617|Experimental|Mineral water 2|
3192839|NCT00812630|Experimental|1|In the second part of the trial, subjects will apply MENT or placebo gel transdermally for 12 weeks and will have 24-hour blood pressure monitoring at baseline, Week 6 and Week 12.
3192840|NCT00812656||Stroke Panel group|Patients undergoing cardiac surgery with the use of cardiopulmonary bypass
3192841|NCT00812669|Experimental|Fludarabine, Cylophosphamide and Rituximab|
2477758|NCT03052153||Lung Transplant Surgery|Subjects included in the study will have undergone a single or bilateral lung transplant surgery at The Ohio State University Wexner Medical Center between 01 JAN 2014 and 18 NOV 2016. No investigational intervention performed for this study.
2477801|NCT03051477|Experimental|Helixor® M|Advanced solid tumors
3192842|NCT00812695|No Intervention|1|
3192843|NCT00812695|Active Comparator|2|CPAP
3192844|NCT00812721|Placebo Comparator|1|Preservative Free Saline
2477969|NCT03050255|Experimental|ESWT order 1|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)"
2477971|NCT03050255|Experimental|ESWT order 2|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~medical air (MA)~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)"
2477973|NCT03050255|Experimental|ESWT order 3|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Medical air (MA)~Oxygen (4 Liter/min)"
2477974|NCT03050255|Experimental|ESWT order 4|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (2 Liter/min)~Oxygen (4 Liter/min)~Medical air (MA)"
2477975|NCT03050255|Experimental|ESWT order 5|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Medical air (MA)~Oxygen (2 Liter/min)"
2477976|NCT03050255|Experimental|ESWT order 6|"Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:~Oxygen (4 Liter/min)~Oxygen (2 Liter/min)~Medical air (MA)"
3192845|NCT00812721|Active Comparator|2|Optive (TM)
3192846|NCT00812721|Active Comparator|3|Refresh Moderate/Severe (TM)
3192847|NCT00812721|Active Comparator|4|Systane (TM)
2478173|NCT03049085|Active Comparator|Aspirin group|a 75 mg uncoated aspirin is administered 2 hours prior to OPCAB
2478175|NCT03049085|Placebo Comparator|Placebo group|75 mg Vit. C is administered 2 hours prior OPCAB
2478235|NCT03048708|Experimental|Obese patients treated with bariatric surgery|Patients with morbid obesity who were eligible for and willing to have bariatric surgery performed
2478237|NCT03048708|No Intervention|Obese patients not treated with bariatric surgery|Age and BMI matched patients with morbid obesity who either were not eligible for or were not willing to have bariatric surgery performed - no sufficient number of matched patients has completed the study; the arm of obese patients not treated with bariatric surgery has been discarded for the purpose of the analyses
2478248|NCT03048331|Experimental|Functional Electrical Stimulation|"Before surgery, the donor muscle is stimulated via surface electrodes in a loaded position or against resistance 3 times a week for 30 minutes.~After surgery, the patients receive the same standard therapy as the control group. The electrical stimulation is performed once a day in combination with standard therapy for 30 minutes against gravity or resistance or in a loaded position."
2478258|NCT03048331|No Intervention|Standard therapy|Postoperatively, 20 min passive and active movements of the hand or arm are applied manually by a therapist. Additionally, the patients actively perform the same exercises once a day for 20 min. The movements are based on a standardised post-surgical treatment protocol.
2478328|NCT03047811|Experimental|TCR - T cell therapy|Peripheral blood mononuclear cells collected: draw 100-150 ml of peripheral blood in patients and separate of the peripheral blood mononuclear cells, the total number of cells 1.5 * 10 ^ 7 / kg - 1 * 10 ^ 8 / kg Fludarabine 25 mg/m2 + NS 250 ml, ivgtt qdx5d, CTX 60 mg/kg + NS 250 ml, ivgtt qd x2d, should be in front of the TCR - T cells infusion of 4 days reinfusion the total number of T cells （1* 10 ^ 8 / kg - 10 * 10 ^ 8 / kg） in 3 days , infusion 10-15 minutes, should not be more than 20 minutes.
2478383|NCT03047733|Active Comparator|continuously excimer laser treatment|"In this group, lesions treated twice weekly through out the whole trial length (9 months).~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
2478391|NCT03047733|Experimental|cyclic excimer laser treatment|"In this group, one cycle consists of a 2-month treatment period (on) and a consecutive 1-month intermission period (off).~Total 3 cycles of cyclic treatment through out the whole trial length (9 months). During the treatment period, lesions treated twice weekly.~Application of topical tacrolimus 0.1% ointment through out the whole trial length (9 months)."
2478452|NCT03047070|Active Comparator|Lidocaine|IV Lidocaine infusion
2478459|NCT03047070|Placebo Comparator|Control|IV normal saline infusion
2478493|NCT03046693|Experimental|Group A|Subjects in group A get citicoline 1000 mg per day for 60 days
2478494|NCT03046693|Placebo Comparator|Group B|Subjects in group B get placebo for 60 days.
2478640|NCT03045770|Experimental|mFOLFIRI|The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
3192848|NCT00812721|Active Comparator|5|Systane Ultra (TM)
3192849|NCT00812734||surgery|
3192850|NCT00812747||1|
3192851|NCT00812760|Experimental|1|
3192852|NCT00812773|Experimental|3 day repeat dose|
3192853|NCT00812799|Active Comparator|Grass pollen extract|Subjects will receive 19.000 BU grass pollen extract daily sublingually
3192854|NCT00812799|Placebo Comparator|Placebo control|Subjects will receive matching placebo control daily sublingually
3192855|NCT00812825|Experimental|PF-04173127|
3192856|NCT00812825|Active Comparator|Prednisolone|
3192857|NCT00812825|Placebo Comparator|Placebo|
3192858|NCT00812825|Sham Comparator|Solution Placebo|
3192859|NCT00812825|Experimental|PF-04171327 Tablet|
2477600|NCT03052868|Other|Data Collection|The study visit will be scheduled for three to six months after completing adjuvant chemotherapy treatment. At the study visit, informed consent will be obtained and neurocognitive attention testing will be performed. The assessments chosen were carefully selected based on breadth, psychometric properties, standardized broad clinical use, good external validity and time efficiency. The testing time for the battery of neuropsychological tests is approximately 45-60 minutes. Participants will also be asked to complete a packet of several questionnaires including several self-rated measures of mood and quality of life, in addition to a brief questionnaire to obtain information about exercise, sleep, and education and employment backgrounds. It is estimated that questionnaire completion will require no more than 30 minutes. Participants will be seen on only one occasion, and may receive, upon request, written feedback about the results of the evaluation.
2477612|NCT03052647|Active Comparator|Subcuticular arm|closure technique that the Adhesive Latch arem (dermaclip) arm is being compared to
2477613|NCT03052647|Active Comparator|Adhesive Latch Arm (Demaclip arm)|This is the arm which the adhesive latch system is used and it is being compared to the arm of subcuticular
3192860|NCT00812864|Experimental|Capecitabine|
3192861|NCT00812903|No Intervention|Control|Control group
3192862|NCT00812903|Experimental|Exercise|Intervention group
2477792|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 500 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 500 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
2477793|NCT03051451|Active Comparator|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Dosage: The dose will depend on the period of treatment in which the patient is:~Single dose treatment (from visit 2 (from day 0 to day 30 ± 7), the patient will take 1 metformin hydrochloride tablet 850 mg / fluoxetine 20 mg and 1 placebo tablet , every 24 hours in the morning for 30 days).~Treatment at double dose (from visit 3 and until visit 8), the patient will take 2 tablets of metformin hydrochloride 850 mg / fluoxetine 20 mg and 2 tablets of Placebo, every 24 hours in the morning for 150 days)."
2477794|NCT03051451|Placebo Comparator|Placebo Oral Tablet|Placebo
2477817|NCT03051191||1: No ACVD/NIHF or cancers|The patients who do not have ACVD, NIHF or cancers
2477818|NCT03051191||2: Cancers but no ACVD/NIHF|The patients who have cancers but no ACVD/NIHF
2477820|NCT03051191||3: ACVD and cancers|The patients who have ACVD and cancers
2477821|NCT03051191||4: ACVD but no cancers|The patients who have ACVD but no cancers
2477822|NCT03051191||5: NIHF and cancers|The patients who have NIHF and cancers
2477823|NCT03051191||6: NIHF but no cancers|The patients who have NIHF but no cancers
2477893|NCT03050762||Endocrine Disease Group|"Information from the medical record recorded and entered into a research database.~Starting about 2-3 years after testing and/or diagnosis and/or treatment and continuing for up to 15 years after surgery, research team will contact participant by phone to follow up."
2477938|NCT03050489||On-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed with cardiopulmonary bypass.
2477946|NCT03050489||Off-Pump CABG|Patients with coronary artery bypass graft (CABG) surgery performed without cardiopulmonary bypass.
2477952|NCT03050489||BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation.
2478029|NCT03050060|Experimental|Treatment (nelfinavir, immunotherapy, radiation therapy)|Beginning 7-14 days prior to start of pembrolizumab, nivolumab, or atezolizumab, patients receive nelfinavir mesylate PO BID on days 1-7 or 1-14 (dependent upon when treatment is started) up to 11-12 weeks. Patients also receive pembrolizumab, nivolumab or atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21-28 days in the absence of disease progression or unacceptable toxicity. Patients then undergo hypofractionated radiation therapy over 3-14 days starting after cycle 1 and before cycle 3 of pembrolizumab, nivolumab or atezolizumab. The study will exclude irradiation of liver metastases as an added precaution.
2478081|NCT03049566||preoperative questionnaires|Patients on long-term acetylsalicylic acid undergoing non-cardiac surgery
2478136|NCT03049384|Active Comparator|Traditional Exercise|A classical exercise intervention based on current guidelines for cancer survivors.
2478146|NCT03049384|Experimental|Tailored Exercise|A tailored and individualized exercise intervention based on the results of pre-intervention testing.
2478193|NCT03048890||Patients with PAD|Patients with PAD will be in 1 cohort and will have their physical activity levels closely monitored by researchers and physicians.
2478201|NCT03048890||Patients without PAD|Patients without PAD will be allowed to contribute their data to the application, but they will not be as closely monitored.
2478259|NCT03048578|Experimental|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
2478266|NCT03048578|Placebo Comparator|Placebo|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
2478318|NCT03048110|Experimental|ODM-201|All subjects will receive a single dose of BAY1841788 (ODM-201) (600 mg) in the first treatment period of the study, then all subjects will receive twice daily 200 mg itraconazole on 1 day and once daily 200 mg itraconazole for the following 6 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the second treatment period, then all subjects will receive once a day 600 mg rifampicin for 10 days and a single dose of BAY1841788 (ODM-201) (600 mg) in the third treatment period
2478370|NCT03047629|Experimental|ENT-01|ENT-01 at a to-be-determined dose taken by mouth every day upon awakening.
2478377|NCT03047629|Placebo Comparator|Placebo Comparator|Placebo to be taken by mouth every day upon awakening
3192863|NCT00812942|Active Comparator|fobt|faecal occult blood test
3192864|NCT00812942|Active Comparator|colonoscopy|colonoscopy screening
3192865|NCT00812994|Placebo Comparator|Placebo|
3192866|NCT00812994|Experimental|Escitalopram|
3192867|NCT00813007||Questionnaire|Radical trachelectomy outcomes for cervical cancer
3192868|NCT00813020|Experimental|A|
3192869|NCT00813020|Experimental|B|
3192870|NCT00813020|Experimental|C|
3192871|NCT00813033|Other|patient decision aid|
2477639|NCT03052881|No Intervention|Control|A control group of patients underwent either i) epiretinal, or inner limiting, membrane peel and ii) displacement of sub macular haemorrhage without the use of a robot i.e. the surgery was done in the standard manner.
2477658|NCT03052270|Experimental|Vaginal progesterone and Pessary|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care plus Arabin pessary"
2477659|NCT03052270|Active Comparator|Vaginal progesterone only|"Short cervical length equal or less than 20 mm~Singleton pregnant women between 18 -24 weeks with no prior history of preterm deliveries.~18 years or older at the time of enrollment.~Consent to participate in the study~Vaginal progesterone as standard of care"
2477690|NCT03052179|Active Comparator|VSL#3|VSL#3 poly-biotic 450 billion in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
2477691|NCT03052179|Placebo Comparator|Placebo|Maltose in sachet orally, two sachets in the morning and two sahcets in the evening for 30 days
2477753|NCT03051893|Experimental|Part A1|Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
2477754|NCT03051893|Experimental|Part A2|Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.
2477755|NCT03051893|Experimental|Part B|The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.
2477785|NCT03051503|Active Comparator|The Transdermal Therapeutic System-Fentanyl (TTS-F) group|(TTS-F) group (n=30) 50ug/h patch, placed 12 hs preoperatively.
2477788|NCT03051503|Placebo Comparator|Intravenous patient-controlled analgesia (PCA) morphine|IV (PCA) morphine for pain in the postoperative period.
2477840|NCT03051243|Active Comparator|Linagliptin and Basal Insulin|linagliptin (trajenta) 5mg once daily combined with basal insulin (glargine Lantus; sanofi) 0.15-0.3 units/kg TDD before bed time.
2477846|NCT03051243|Active Comparator|Basal Insulin and Bolus Insulin|Basal Insulin (Glargine Lantus; Sanofi) based therapy once daily before bedtime and glulisine (Apidra; sanofi) before meals. insulin dose will be 0.5 units/kg divided half as insulin glargine once daily and half as insulin glulisine before meals.
3192872|NCT00813046|Experimental|gpASIT+TM|
3192873|NCT00813059|Experimental|1|
3192874|NCT00813072|Experimental|1. PEP02|liposome irinotecan
3192875|NCT00813072|Active Comparator|2. irinotecan|
3192876|NCT00813072|Active Comparator|3. docetaxel|
3192877|NCT00813085|Other|Electronic disease management decision support|An electronic Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS).
2477988|NCT03050047|Experimental|BCD-100 0.3 mg/kg|Patients who receive BCD-100 in a dose of 0.3 mg/kg
2477989|NCT03050047|Experimental|BCD-100 1 mg/kg|Patients who receive BCD-100 in a dose of 1 mg/kg
2477990|NCT03050047|Experimental|BCD-100 3 mg/kg|Patients who receive BCD-100 in a dose of 3 mg/kg
2477991|NCT03050047|Experimental|BCD-100 10 mg/kg|Patients who receive BCD-100 in a dose of 10 mg/kg
2478053|NCT03049891||Children down-referred from DNH|This group includes children who were transferred from DNH to a study facility. The investigators will first abstract data from the electronic data system 'Tier.net' for these children, which will tell us where they were down-referred. For children who were labeled as down-referred from DNH in Tier.net, data abstraction of the child's clinical data will be conducted at the down-referral site and from the National Health Laboratory Service (NHLS) data.
2478060|NCT03049891||Children LTF from DNH|This group includes children who began ART at DNH and were subsequently LTF. The investigators will first abstract data from the electronic data system 'Tier.net', which will classify them as LTF followed by examination of the the NHLS laboratory data to determine whether these children had received care at another facility since they were LTF.
2478066|NCT03049891||Caregivers of LTF|This group includes the caregivers of a subset of children in the 'LTF from DNH' and 'down-referred from DNH' groups. Among those children down-referred and LTF from DNH, the investigators will use their clinical and laboratory data to determine whether they are still receiving care or not. For children identified as LTF based on their abstracted data will be traced in order to contact their caregivers. If located, caregivers will be interviewed to ascertain if and why these children are no longer in care through a 'Tracing questionnaire'.
2478069|NCT03049891||DNH only|This group includes children who are still in care at DNH, died while in care at DNH, or were transferred to facilities from tier.net will not have any additional information collected other than what is recorded in the Tier.net database.
2478236|NCT03048981|Experimental|Fish oil intake|Healthy volunteers given maximum dose of fish oil for 10 days.
2478319|NCT03048097|Experimental|All Participants|Subjects with high-likelihood of cardiac sarcoidosis.
2478403|NCT03047590|Experimental|Choice-No Affect|These participants self-select (i.e., choose) their exercise intensity with the goal of walking 30-60 minutes on most days of the week. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with no focus on positive affect.
2478412|NCT03047590|Experimental|Choice-Affect|These participants self-select their exercise intensity with the goal of walking 30-60 minutes on most days of the week. They're instructed to choose the intensity that makes them feel the best. For safety reasons, they are instructed not to exceed 59% of their heart rate reserve. This is choice-based exercise intensity with a focus on positive affect.
2478413|NCT03047590|Experimental|No Choice-Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). Meanwhile, these participants are instructed to focus on the good feelings that come with exercise. this is heart rate-based exercise intensity with a focus on positive affect."
2478651|NCT03045705|Active Comparator|Labor+routine pain management|Women that will be treated by the medical team in the delivery room as if not part of a study regarding pain management.
3192878|NCT00813085|No Intervention|2|Usual care by Family Physician
2477674|NCT03052335|Experimental|Pillcam® COLON 2 Capsule and colonoscopy|Persons with positive immunochemical fecal occult blood tests will be examined by second generation colon capsule endoscopy (CCE2) and optical colonoscopy afterwards.
3192879|NCT00813137|Experimental|Folfox4 plus Endostar|
2477759|NCT03051685|Experimental|DFN-15 Dose 1|
2477760|NCT03051685|Experimental|DFN-15 Dose 2|
2477761|NCT03051685|Experimental|DFN-15 Dose 3|
2477762|NCT03051685|Active Comparator|Active Comparator|
2477806|NCT03051425|Experimental|Test group|Probiotic yogurt supplementation
2477808|NCT03051425|Placebo Comparator|Placebo group|Placebo supplementation
3192880|NCT00813163|Experimental|PEP02|Liposome Irinotecan
3192881|NCT00813189|Experimental|1 : early start (GH treatment) group|in the early start group, patients were treated with growth hormone for one year immediately after randomisation
3192882|NCT00813189|No Intervention|2 :delayed start (GH treatment) group|in the delayed start group patients took GH treatment for 1 year , 6 months after randomisation
3192883|NCT00813202|Experimental|Nesiritide|
2478052|NCT03049644|Active Comparator|Mechanical Diagnosis and Therapy|Mechanical diagnosis refers to the classification based on examination of posture and range of motion of the spine, associated with the assessment of subjective symptomatic responses.
2478061|NCT03049644|Active Comparator|Manual Therapy|Manual therapy (MT) is a broad term encompassing many techniques which attempt to affect possible pain contributors such as joints, tendons, ligaments, and muscles, typically using the therapist's hands but may also utilize a tool or instrument in the case of some soft tissue mobilization therapies as well as low force instrument assisted spinal manipulation therapy.
2478115|NCT03049332|Experimental|All participants|HIV+ Chinese women in China and a family member will be recruited for the pilot testing of the intervention.
2478137|NCT03049124|Experimental|Exercise|Participants will be asked to complete a 12-week exercise intervention and all study assessments.
2478212|NCT03048955|Active Comparator|Indirect Decompression System|Superion® IDS surgical procedure
2478215|NCT03048955|Active Comparator|Direct decompression Surgery|Open, direct decompression surgical procedure
2478298|NCT03048214|Sham Comparator|General Anaesthesia|Patients would receive routine general anaesthesia for their distal radial fracture surgery
2478301|NCT03048214|Experimental|Regional Anaesthesia|Patients would receive routine infraclavicular nerve block for their distal radial fracture surgery
2478312|NCT03047850||Study Group|All patients included in this study.
2478390|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF with trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) with trilineage aplasia excluding Fanconi Anemia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
2478400|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/o trilineage aplasia|Patients with acquired or inherited bone marrow failure (iBMF) without trilineage aplasia will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
2478405|NCT03047746|Other|TCRalpha/beta Tcell Depletion for BMF w/ Fanconi Anemia|Patients with acquired or inherited bone marrow failure (iBMF) with Fanconi Anemia and related DNA Repair Disorders will be given previously established, disease-specific chemotherapy and/or radiation based conditioning regimens prior to hematopoietic stem cell transplantation using TCRalpha/beta and B cell depleted peripheral blood stem cells from unrelated or partially matched related donors.
2478449|NCT03047096|Experimental|HA & CS group|hyaluronic acid and corticosteroids
2478456|NCT03047096|Experimental|HA group|hyaluronic acid
2478502|NCT03046667|Experimental|Test drink|Test drink: Barley β-glucan
2478503|NCT03046667|Placebo Comparator|Control drink|Control drink: barley beverage
2478596|NCT03046264||coronary angiography|patients undergoing routine coronary angiography, invasive and non-invasive determination of central blood pressure
2478638|NCT03045783|Experimental|Prophylactic use of antibiotics group|Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
2478642|NCT03045783|No Intervention|On-demand group|Routine endoscopic examination and treatment. Antibiotics are not used during endoscopic treatment
2478672|NCT03045471||R-EPOCH|
2478676|NCT03045471||R-CHOP|
2478701|NCT03045211|Experimental|In-Home Standing Table|"Participants in this arm will receive a dynamic standing table to be used in their home for at least two hours per day for at least five days per week for a 16-week period. Specific activities will be tracked with a logbook. PD subjects will be coached by a physical therapist on proper body positioning at the table, use of anti-fatigue mat, and optimal monitor height. The physical therapist will adhere to the neutral body positioning guidelines as provided by the OSHA. The physical therapist will also perform an in-home safety assessment of the office or room in which the table will be placed to ensure safety not only for the users but also for family members or children. The physical therapist will monitor each participant throughout the study by making biweekly compliance phone calls.~In addition, this group will received standard of care, which is weekly group exercise sessions during the 16-week period of table use."
2478705|NCT03045211|No Intervention|Standard of Care|this group will received standard of care only, which is weekly group exercise sessions during a 16-week period. Instructions, coaching, and compliance phone calls will also be provided to the participants of this arm such that both arms have the same amount of contact time with the physical therapist.
2478833|NCT03044639|Experimental|Provision of Olive oil emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of Olive-oil/ LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2477687|NCT03052244|Sham Comparator|tDCS Sham+VI Sham|The stimulation will be turned on for only short duration (up to 30 sec), the video film will contains graphical illustrations or nature movie without human movement.
2477717|NCT03051984|Experimental|NMES|Neuromuscular electrical stimulation (NMES) will be administered for 5 weeks post-TKA in the quadriceps of the surgical leg. Treatment will occur 5 days per week, twice daily for 45 minutes on each occasion.
2477720|NCT03051984|No Intervention|Control|No intervention will be administered during the 5 weeks post-TKA in the surgical leg.
2477767|NCT03051711|Experimental|GBT440 Dose 1|Dose 1
2477770|NCT03051711|Experimental|GBT440 Dose 2|Dose 2
2477834|NCT03051334||BiAV|Bicuspid aortic valve
2477844|NCT03051334||TAV|Tricuspid aortic valve
2477909|NCT03050684|Active Comparator|vaginal lavage group|We will make vaginal lavage with steril %0.9 NaCl serum ( 20cc) before inserting dinoprostone (Propess ®) 10 mg vaginal ovule
2477910|NCT03050684|Placebo Comparator|Control group|We will insert dinoprostone (Propess ®) vaginal ovule without vaginal lavage.
2477944|NCT03050385|Active Comparator|active stimulation during cognitive rehabilitation|"active transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA(milliampere)~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
2477951|NCT03050385|Sham Comparator|sham stimulation during cognitive rehabilitation|"sham transcranial direct current stimulation 20 minutes per session twice a day interval between sessions: more than 20 minutes 7 cm x 5 cm electrodes anodal electrode on F3 cathodal electrode on right forehead 2 mA~cognitive rehabilitation 10-minute calculation task followed by 10-minute task of local (Japanese) language test"
2478011|NCT03050112|Experimental|Congenital cardiopathy|Patients having had surgery in adulthood for a congenital heart disease, at the Brugmann University Hospital. The group consists in patients aged 16 years or older, having had surgery between 01/01/1998 and 31/12/2015.
2478050|NCT03049605|Experimental|Magnetic Therapy|Twenty five patient were exposed to low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss for 30 minutes / session for 2 times per week for 3 months .
2478058|NCT03049605|Experimental|Laser Therapy|Twenty five patients were treated with 24 sessions of laser therapy at a rate of two sessions / week for three months. Each patient will be exposed to Helium neon infrared laser (850 nano-meter continuous wave mode from a comfortable prone lying position.
2478064|NCT03049605|Experimental|Medical therapy|Fifteen patients were received only medical treatment .
2478177|NCT03049345|Experimental|Sentinel Node Sampling Arm|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Patients will then under regular gastric cancer resection with D2 lymphadenectomy as per routine in our institution.
2478233|NCT03048682|Experimental|Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #2, 3, or 4"
2478234|NCT03048682|Active Comparator|Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in this group will have their repeat voiding trial on post-op day #7 or after. This is our current practice."
2478245|NCT03048318|Experimental|Arterial and Portal Flushing of Graft|Back table flush of portal vein and graft artery
2478247|NCT03048318|Active Comparator|Portal Flushing only of Graft|Back table flush of portal vein only
2478292|NCT03048240|Experimental|"perPDT"|Single arm : per-operative PhotoDynamic Therapy (perPDT) during the surgery of Glioblastoma excision.
2478407|NCT03047421||All patients included|For all patients scheduled for an anesthetic preoperative consultation, a comparison of accuracy of DES-OSA and P-SAP scores with PSG (polysomnography) will be performed.
2478451|NCT03047213|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2478534|NCT03046550|Experimental|Cohort A|Cohort A will have 8 total subjects. 6 subjects will receive 0.33 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2478538|NCT03046550|Experimental|Cohort B|Cohort B will have 8 total subjects. 6 subjects will receive 0.66 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2478540|NCT03046550|Experimental|Cohort C|Cohort C will have 8 total subjects. 6 subjects will receive 1 mg/kg of NTM-1634 and 2 subjects will receive placebo.
2478568|NCT03046030|Experimental|Healthy Volunteers|In this experiment, we will apply a crossover design in healthy subjects. Each subject will receive four treatments in four separate sessions: 1) VGAIT, 2) VGAIT control condition, 3) real acupuncture, and 4) sham acupuncture. Each session will be separated by at least 7 days. Subjects will participate in five experimental sessions: a training and familiarity behavioral session and four fMRI sessions during which the subject will receive one of the four treatments.
2478624|NCT03045874||30 parent-child dyads|Stratified purposive sampling will assure representation proportional to the minority representation in the community and will include equal subsamples (15 families each) of families with children 6-18 months of age and children aged 19-36 months.
2478625|NCT03045874||30 primary care providers|"Investigators will purposively recruit 30 primary care providers to assure proportional representation of physicians and NPs with a snowball method. The sample sizes should be sufficient to achieve saturation of the data for qualitative analyses, but we will recruit more participants if saturation is not obtained with the planned sample."
2478627|NCT03045874||focus groups|The investigators will hold separate focus groups for parents of the two age groups and clinicians. We anticipate conducting approximately 6 focus groups with 8-10 participants in each to review and refine the sleep program.
2478628|NCT03045874||22 parent-child dyads|The investigators will conduct feasibility testing of a 3 week sleep health promotion intervention. The intervention will be delivered to parents of children ages 12-36 months enrolled in one childcare center.
2478629|NCT03045874||5 childcare teachers|Teachers will be trained to deliver a brief sleep health intervention
2477692|NCT03052192||FAM group (n=98)|"≥65 years. Acutely admitted medical patients.~Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup.~Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality.~If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician.~Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size."
2477694|NCT03052192||Control group 1 (n=54)|"≥65 years. No hospital admissions within the past two years.~Matched individually with patients in the FAM group by age, sex, and municipality.~Examined at inclusion and 52 weeks after inclusion.~Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality."
2477696|NCT03052192||Control group 2 (n=60)|"20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.)~Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples."
2477724|NCT03051880|Experimental|Repair Control EGF®|EGF cream was applied. One half side of face and one hand were treated with emollient containing EGF.
2477727|NCT03051880|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half side of face and the other hand were treated with only emollient which was not containing EGF.
2477833|NCT03051139|Experimental|ICU A and ICU B|This is the intervention group.
2477843|NCT03051139|No Intervention|ICU C and ICU D|This is the usual care group.
2477870|NCT03050879|Experimental|Indocyanine Green Tracer|Indocyanine Green Tracer will be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
2477873|NCT03050879|Active Comparator|No Indocyanine Green Tracer|Indocyanine Green Tracer will not be used in laparoscopic gastrectomy with lymph node dissection for gastric adenocarcinoma in this group.
2477942|NCT03050645||previous GDM|Women with previous GDM
2477948|NCT03050645||no previous GDM|Women without previous GDM matched on age, pregestational body mass index end time of pregnancy.
2478016|NCT03050190|Experimental|Therapeutic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
2478048|NCT03049787|Experimental|home exercise|For the home exercise protocol alone arm, subjects will be given an experimental home exercise program and study team will demonstrate the exercises in the clinic and will direct the subjects to perform the exercises 1-2 times daily until symptom resolution.
2478056|NCT03049787|Active Comparator|physical therapy|Patients will be prescribed routine physical therapy protocol where they will see a physical therapist twice a week and will be instructed by the physical therapist to perform physical therapy exercises at home daily until symptom resolution, as is the routine practice.
2478112|NCT03049410|Active Comparator|iRARC|Intracorporeal Robot Assisted Radical Cystectomy
2478113|NCT03049410|Active Comparator|Open Radical Cystectomy (ORC)|Open Radical Cystectomy
2478134|NCT03049137|Experimental|Computer Guided Stent Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using autogenous bone ring graft covering them with Platelet-rich fibrin (PRF) using computer guided stent.
2478148|NCT03049137|Active Comparator|Free Hand Augmentation|Patients with defective maxillary anterior alveolar ridges requiring implant insertion will have simultaneous implant placement with ridge augmentation using Free hand simultaneous implant placement with ridge augmentation and covering them with Platelet-rich fibrin (PRF).
3192884|NCT00813215|Experimental|1|Relatives to patients with type 2 diabetes.
2478342|NCT03047954|Experimental|Broncho-Vaxom|1 capsule (3.5 mg) per day, administered over 9 months
2478347|NCT03047954|Placebo Comparator|Placebo|Matching placebo capsule
2478375|NCT03047473|Experimental|Newly diagnosed GBM|single arm, open label Addition of Avelumab to standard treatment
2478464|NCT03047239|Experimental|Open angle glaucoma|SENSIMED Triggerfish
2478500|NCT03046485|Experimental|Self management program|Self management program 'Living with Vision Loss' 6 week course that met for 2 hours each week led by a trained leader.
2478501|NCT03046485|No Intervention|Wait list control|Wait list control
3192885|NCT00813215|Active Comparator|2|Controls with no family history of type 2 diabetes.
3158476|NCT00387374|Experimental|Stratum I (radiotherapy, bevacizumab, chemotherapy)|Patients undergo prophylactic radiotherapy on days 1-5 and 8-12. Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 15. Patients also receive paclitaxel IV over 3 hours or carboplatin IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 36 (course 2).
2478709|NCT03045341|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2478710|NCT03045341|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 16 weeks of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
2478924|NCT03043937||cardiac patients WHO class 1,2|
2478927|NCT03043937||cardiac patients WHO class 3,4|
3192886|NCT00813241|Active Comparator|A|A single dose of 200 mg celecoxib capsule administered as 1 x 200 mg celecoxib capsule, (Reference Formulation)
3192887|NCT00813241|Experimental|B|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet formulation containing granule type A1
3192888|NCT00813241|Experimental|C|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type B2
2477712|NCT03052166||Cohort C|The group of women who have been given BI-RADS categories 1, 2, 3, 4 or (4a, 4b, 4c), 5 or 6 based on their most recent standard of care assessment. All subjects will receive a QT Ultrasound scan. Subjects are assigned to Cohort C when it has been determined they cannot be assigned to Cohort A or Cohort B.
2477766|NCT03051789|Experimental|Menstrual Cup|One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
2477768|NCT03051789|Experimental|Cash Transfer|Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
2477771|NCT03051789|Experimental|Cups and Cash|A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
2477772|NCT03051789|No Intervention|Control|'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
2477850|NCT03051282|Active Comparator|non-carrier control group|Subjects who do not carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
2477854|NCT03051282|Active Comparator|G143E carriers group|Subjects who carry the CES1 variant G143E (rs71647871) will receive 10 mg Enalapril orally once daily for 7 consecutive days.
2477872|NCT03050827|Active Comparator|3% oxybutynin|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the active drug arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
2477874|NCT03050827|Placebo Comparator|Placebo|Subjects with IENF loss of between 20-75% of normative values11 and thus amenable to therapy-induced recovery, will be randomized into the placebo group arm (N=30) and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 in2 region of skin adjacent to the initial biopsy site,
2477925|NCT03050593||HFpEF group|clinical or radiographic evidence of heart failure and left ventricular ejection fraction > 50% on transthoracic echocardiography
2477927|NCT03050593||HFrEF group|Clinical or radiographic evidence of heart failure and left ventricular ejection fraction < 40% on transthoracic echocardiography
2477929|NCT03050593||Healthy control group|Asymptomatic controls (age and sex-matched) without known heart disease
2478007|NCT03050242|Experimental|Glycopyrrolate|Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
2478013|NCT03050242|No Intervention|Control|No injection is conducted in this group.
2478051|NCT03049826|Experimental|Stem cell transplantation (SCT)|Children undergoing stem cell transplantation (SCT)
2478062|NCT03049826|No Intervention|Home parenteral nutrition (HPN)|Children receiving home parenteral nutrition
2478065|NCT03049826|No Intervention|Healthy reference group|Healthy children
2478140|NCT03049358|Experimental|Arm I (olfactory training)|Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.
2478147|NCT03049358|Sham Comparator|Arm II (sham training)|Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks.
2478223|NCT03048669|Experimental|Continuous quality improvement (CQI)|Quality improvement initiatives implemented at facility level using participatory data-driven approaches and on-site monitoring and supervisory support
2478224|NCT03048669|No Intervention|Standard of care|In health districts randomized to standard of care, the same strengthening of the data collection system for the monitoring of indicators as in the intervention group will be implemented. At least once a month, a study staff will visit each clinics irrespective of their randomization to extract information for the mother-infant register into an electronic database. No report on indicators will be produced for those clinic for the duration of the study. Staff from clinics and health district bureau in the standard of care group will not be associated with the quarterly review of the indicators. The study will not influence with any other HIV service provision activity in the standard of care group.
3158477|NCT00387374|Experimental|Stratum II (radiotherapy, chemotherapy, bevacizumab)|Patients undergo prophylactic radiotherapy and receive paclitaxel and carboplatin as in stratum I. Patients also receive bevacizumab IV over 30-90 minutes on day 15 (course 1). In both strata, treatment with paclitaxel, carboplatin, and bevacizumab repeats every 21 days for 5-6 courses in the absence of disease progression or unacceptable toxicity. Patients with complete or partial response or stable disease may continue to receive single-agent bevacizumab every 21 days in the absence of disease progression or unacceptable toxicity.
2478324|NCT03047798|Experimental|aqueous single-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in aqueous single-phase form.
2478331|NCT03047798|Experimental|oil-water two-phase mouthrinse|This contained sodium fluoride and the additional ingredients of bamboo salt, magnolia bark and centella asiatica extracts in oil-water two-phase form.
2478334|NCT03047798|Placebo Comparator|Control|The control mouthrinse only contained sodium fluoride
2478385|NCT03047655|Active Comparator|Physical activity only|pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal
2478394|NCT03047655|Active Comparator|Physical activity + Dietary treatment|"pedometers have to be used throughout all days; daily amount of steps is reported via App or website; 10000 steps are defined as daily goal~additionally, subjects will be provided with one healthy muffin per day (450 kcal; low GI, high load of PUFA and isomaltulose) over 6 weeks"
2478505|NCT03046771|Experimental|Transport PLUS group|EMTs randomized to the Transport Plus group will view a 60-minute training video and then complete a 60-minute simulation training exercise on how to conduct the home fall hazard assessment (FHA) and the discharge comprehension assessment (DCA) and how to complete the FHA and DCA checklists. The FHA involves performing a visual assessment of the home environment and noting certain fall hazards. The DCA involves engaging the patient or caregiver in a conversation to assess their level of understanding of the elements of the discharge instructions. The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence
2477719|NCT03052062|Experimental|Lipidrive|Dose 1 : 2,6 g (4 capsules) Lipidrive per day during 12 weeks Dose 2 : 5,2 g (8 capsules) Lipidrive per day during 12 weeks, 2 weeks (wash-out period) between the 2 doses
2477795|NCT03051750|Active Comparator|CPT+P|Complex Physical Therapy plus Pressotherapy during three weeks
2477800|NCT03051750|Experimental|Kinesio Taping|Kinesio Taping during three weeks
2477876|NCT03050931||Epilepsy with intracranial electrodes|Electrical Impedance Tomography with depth electrodes or intracranial electrode mats
2477877|NCT03050931||Epilepsy with scalp electrodes|Electrical Impedance Tomography with scalp electrodes
2477941|NCT03050606|Experimental|Pilates|"This group will perform a modified Pilates exercise program, which will be performed using mat, accessories and studio apparatus, in individual sessions, twice a week, lasting 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
2477949|NCT03050606|Active Comparator|Aerobic|"This group will perform aerobic exercise, performed on the treadmill or stationary bike according to the choice of the patient. The training will be performed controlling the heart rate of training. The exercises will be performed individually, twice a week and each session will last 60 minutes.~Both groups will also receive an educational booklet with information on fibromyalgia and self-care strategies for pain management, sleep improvement, depression improvement, stress and fatigue control."
2478003|NCT03050099||Mild ACVS-definite|Clinical diagnosis of ACVS, and imaging positive (either DWI+ or CT/CTA+).
2478005|NCT03050099||Mild ACVS-possible|Clinical diagnosis of ACVS, and DWI- and/or CTA-
2478008|NCT03050099||Mimic|Clinical diagnosis of mimic and imaging negative.
2478083|NCT03049839|Experimental|Intervention_ structured|One year Structured intervention program for members of high-risk group (People with glucose intolerance in the OGTT and FINDRISC score ≥12 points) 10 educational group sessions where they will receive information to change lifestyle (1 per 1.5 month)
2478090|NCT03049839|Experimental|Intervention_ Informative|"Program information intervention for the group with moderate risk. One year Informative intervention program (People with normotolerant or impaired fasting glucose in the OGTT and FINDRISC score ≥12 points).~There is a single group session where they receive information to prevent cardiomatabolic risk factors"
2478098|NCT03049839|Experimental|Intervention_ Communitarian|"One year, Intervention program at Community level. People with a FINDRISC less than 12 points.~Campaigns are carried out at the community level with different strategies (leaflets, booklets) to prevent cardiomatabolic risk factors"
3192889|NCT00813241|Experimental|D|A single dose of 150 mg celecoxib administered as 1 x 150 mg tablet containing granule type C1
3192890|NCT00813254||Questionnaire|Longitudinal measure of QOL, sexual functioning and symptoms in women with recurrent, platinum-resistant ovarian cancer receiving multiple second-line treatment regimens
3192891|NCT00813267|Experimental|stem cell|mesenchymal stem cell infusion and bone marrow mononuclear cell infusion
2478323|NCT03047837|Placebo Comparator|Arm A|placebo Aspirin (1 tablet daily) + placebo Metformin (1 tablet BID)
2478329|NCT03047837|Experimental|Arm B|placebo Aspirin (1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
2478335|NCT03047837|Experimental|Arm C|active Aspirin (100 mg, 1 tablet daily) + placebo Metformin (1 tablet BID)
2478337|NCT03047837|Experimental|Arm D|active Asprin (100 mg, 1 tablet daily) + active Metformin (850 mg, 1 tablet BID)
2478395|NCT03047460||healthy|"healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses~Intervention: multimodal evoked potentials"
2478401|NCT03047460||multiple sclerosis|"All types of Multiple sclerosis patients:~Aged 18 to 58 years old, inclusive, at the time of informed consent.~Expanded Disability Status Scale (EDSS) 0.0 to 6.5.~Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb~Have no comorbid condition (ie neuropathy) that could affect testing.~Intervention: multimodal evoked potentials"
2478447|NCT03047044|Active Comparator|Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
2478458|NCT03047044|Experimental|Optimizing B.I (New) PCA mode|(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
2478518|NCT03046797|Experimental|B group|Mask ventilation will be continued and fiberoptic intubation will be performed from Boussignac valve opening by an experienced anesthetist.
2478519|NCT03046797|Active Comparator|C group|mask ventilation will be terminated then fiberoptic intubation will be done by an experienced anesthetist.
2478586|NCT03046186||Gastric sleeve operated subjects|12 patients who have undergone gastric sleeve operation >12 month prior to inclution.
2478587|NCT03046186||Control Subjects|12 Healthy un-operated control subjects matched to the gastric sleeve group in a one to one manner with respect to BMI, sex and age
2478588|NCT03046186||Gastric bypass operated subjects|12 patients, who have undergone Roux-en-Y gastric bypass >12 month prior to inclution, matched to the gastric sleeve group in a one to one manner with respect to pre-operative BMI, post-operative BMI, sex and age.
2479497|NCT03039842|Experimental|DM+MM|dextromethorphan+memantine+ valproate
3192892|NCT00813280||hyperglycemia|hospitalized patients with BG >300 ml/dL
3192893|NCT00813306|Experimental|A|AZD2066
3192894|NCT00813306|Placebo Comparator|B|Placebo
3192895|NCT00813306|Experimental|C|AZD2066
3192896|NCT00813306|Experimental|D|AZD2066
3192897|NCT00813306|Placebo Comparator|E|Placebo
3192898|NCT00813332|Experimental|1|Endostar combined with Docetaxel for Advanced NSCLC: All eligible patients will receive Endostar in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Endostar treatment will continue after completion of first 4 cycles until disease progression.
3158478|NCT00387387|Experimental|FOLFOX 6 + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with FOLFOX 6.
3158479|NCT00387387|Experimental|CapeOx + Pazopanib|Subjects will receive escalating doses of Pazopanib in combination with CapeOx. CapeOx treatment consisted of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment was administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine was reduced to 850 mg/m^2 twice daily.
3158480|NCT00387413|Experimental|Treatment Arm A1|In treatment Arm A1 Period 1 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. In treatment Arm A1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
2477807|NCT03051412||Current Patellofemoral Pain|This group has current patellofemoral pain
2477809|NCT03051412||Recovered|This group has a previous history of patellofemoral pain, but currently self reports as recovered.
2477810|NCT03051412||Control|This is a control group with no history of knee pain.
2477878|NCT03050957|Experimental|menthol 10 mM (millimolar)|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 10 mM
2477879|NCT03050957|Experimental|menthol 1 mM|Patients were studied during the deglutition of one series of 5, 10 and 20 mL nectar control boluses and two series of 5, 10 and 20 mL nectar boluses supplemented with the corresponding concentration of menthol 1 mM
2477930|NCT03050632|Experimental|Working Memory Intervention (N-back)|Participants will complete the working memory priming task either for the first 3 days of the intervention or the last 3 days of the intervention, with order counterbalanced across participants. The working memory prime is the N-back test, a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back) (Jaeggi et al., 2010).
2477931|NCT03050632|Placebo Comparator|"White Bear Task"|Participants will complete this non-working-memory control task either for the first 3 days of the intervention or the last 3 days of the intervention, depending on counterbalanced order. The task consists of a procedure developed by Wegner and colleagues (1987) in a study of thought suppression, which instructs participants to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
2478022|NCT03050229|Experimental|Empagliflozin|Empagliflozin 10mg/day is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
2478026|NCT03050229|Placebo Comparator|Placebo|Placebo is administrated orally before or after breakfast for 12 weeks while continuing the existing treatment for hypertension (include AngiotensinII Receptor Blocker [ARB]) and diabetes.
2478086|NCT03049657|Active Comparator|ANGIOLITE|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
2478101|NCT03049657|Active Comparator|Xience|Compare the efficacy of Angiolite Stent versus a second-generation drug-eluting stent such as Xience stent.
2478132|NCT03049176||HIV+male/HIV-female|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or semen washing
2478145|NCT03049176||HIV+female/HIV-male|discordant couple given the choice of using at least one of the following: Antiretrovirals, PrEP (Truvada), or artificial vaginal insemination
2478198|NCT03048760|Experimental|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan & 1 after approx. 2 weeks of radiotherapy treatment.
2478291|NCT03048604|Experimental|Genio(TM) system therapy|
2478306|NCT03047915|No Intervention|Control Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects randomized to the control group will continue the ED visit as usual.
2478307|NCT03047915|Experimental|Music Group|All subjects enrolled will respond to questions assessing anxiety using the State Trait Anxiety Inventory (STAI), and pain using a 1-10 numerical score, and will have blood pressure and heart rate taken. Subjects who are randomized to receive a music-listening intervention will listen to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones. An hour after enrollment, participants will be asked the same questions assessing anxiety and pain, and will also have blood pressure and heart rate taken again.
2478350|NCT03047772|Placebo Comparator|Phase A: Atorvastatin|Atorvastatin routine dose + placebo transplantation
2478352|NCT03047772|Experimental|Phase A: Low dose BMMSC|Atorvastatin routine dose + low dose BMMSC Transplantation
2478354|NCT03047772|Experimental|Phase A: Middle dose BMMSC|Atorvastatin routine dose + middle dose BMMSC Transplantation
2478355|NCT03047772|Experimental|Phase A: High dose BMMSC|Atorvastatin routine dose + high dose BMMSC Transplantation
2478357|NCT03047772|Placebo Comparator|Phase B: Atorvastatin|Atorvastatin routine dose + placebo transplantation
2478360|NCT03047772|Active Comparator|Phase B: Atorvastatin+Transplantation|Atorvastatin routine dose+ Optimal dose BMMSC Transplantation
2478362|NCT03047772|Placebo Comparator|Phase B: Intensive Atorvastatin|Atorvastatin Intensive dose + placebo transplantation
2478363|NCT03047772|Experimental|Phase B: Intensive Atorvastatin+Transplantation|Atorvastatin Intensive dose + Optimal dose BMMSC Transplantation
2478382|NCT03047382|Active Comparator|Worthing Hospital site|AKI Care bundle instituted at Worthing site
2478393|NCT03047382|No Intervention|Chichester Hospital site|Continues standard care
2478448|NCT03047291|Placebo Comparator|Control group: placebo oral tablet|Placebo tablets. Intervention: 30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
2478457|NCT03047291|Experimental|Test group: probiotic oral tablet|Probiotic tablets (Periobalance®, Sunstar, Switzerland). Intervention: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
2478487|NCT03046745||Gastric cancer group|The patients aged more than 18 years who were diagnosed primary gastric adenocarcinoma.
2478490|NCT03046745||Control group|The participants aged more than 40 years without previous history of gastric cancer.
3192899|NCT00813332|Placebo Comparator|2|Docetaxel combined with placebo for Advanced NSCLC: All eligible patients will receive placebo in combination with Docetaxel chemotherapy for 2 cycles (21 days for each cycle) and cases of good response(CR+PR+SD) will continue treatment for 2 cycles. Placebo will continue after completion of first 4 cycles until disease progression.
2477831|NCT03051269|Experimental|calcium chloride|Only one arm. All 6 enrolled patients are treated with calcium electroporation.
2477883|NCT03050749|Other|Princess® VOLUME|
2477940|NCT03050567||Healthy Volunteers|Healthy volunteers with no previous history of cerebrovascular disease and aged over 18 years old.
2477947|NCT03050567||Subjects with symptomatic carotid artery stenosis|Patients with symptomatic cerebrovascular event (stroke, transient ischaemic attack or amaurosis fugax) and image confirmed carotid artery stenosis of >30%. This will include patients scheduled for carotid endarterectomy (>50% for men and >70% for women, by North American Symptomatic Carotid Endarterectomy Trial criteria) or treated conservatively with an optimal medical therapy (if patient declined surgical intervention or is outside surgical criteria for carotid endarterectomy).
2478024|NCT03050164|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fasting conditions.
2478027|NCT03050164|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fasting conditions.
2478049|NCT03049696|No Intervention|Control Group (Standard of Care)|All patients will receive the Centre for Metabolic and Bariatric Surgery (CMBS) standard of care including two to four multidisciplinary visits over six months, exercise counseling (kinesiologist), completion of a the CMBS behavior modification program (Craving ChangeTM), and achievement of lifestyle and dietary modification goals in order to be scheduled for surgery. The standard of care will be used as the control group (n=24). Matched historical controls (1:1) will be selected (based on age, gender, and body mass index) from the existing CMBS database.
2478057|NCT03049696|Experimental|Intervention Group-ENCOURAGEING START|Intervention group participants (n=24) will receive the standard of care and complete a 16-week supervised physical activity/behaviour modification program at no cost. The first eight weeks of the program involves structured exercise (two per week) and education classes that patients must attend. Progression to a moderate/high-intensity interval program based the patient's capabilities will occur. Participants will also attend education sessions on risk factor reduction, healthy eating, exercise, stress management and promotion of self-managed care. During the second eight week period, participants will be given access to attend drop-in exercise classes or can opt to complete at home exercise. Participants will have an opportunity to meet with the kinesiologist on at least 4 occasions (60 minutes/meeting) for additional physical activity counseling and assistance with overcoming barriers preventing physical activity.
2478117|NCT03049423||the trial group|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
2478121|NCT03049423||the control group|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
2478219|NCT03049020||With levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and suffering with levator ani avulsion
2478221|NCT03049020||Without levator ani avulsion|Patients indicated for sacrocolpopexy for pelvic organ prolapse and without levator ani avulsion
2478244|NCT03048474|Experimental|Nivolumab and Ipilimumab|Nivolumab will be administered at a fixed dose of 240 mg every 2 weeks for a maximum period of 2 years. Nivolumab will be given in combination with ipilimumab on week 1, 7, 13 and 19. Ipilimumab will be administered at the dose of 1 mg/Kg.
2478364|NCT03048266||MEN1 Patients Who Have Developed Aggressive PNETs-Cases|
2478365|NCT03048266||MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls|
2478475|NCT03046992|Experimental|YH25448|"Dose Escalation Phase: Consists of 7 Cohorts~Dose Expansion Phase: Consists of 5 Cohorts~Dose Extension Phase: Consists of 2 Cohorts"
2478530|NCT03046537|Active Comparator|ovulatory|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant.
2478536|NCT03046537|Active Comparator|PCOS|Comparison in metabolic state between ovulatory and PCOS women by collecting breath test from participant
2478570|NCT03046173|Experimental|the experimental group|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
2478573|NCT03046173|Experimental|the control group|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
3192900|NCT00813345|Experimental|A - Light therapy|Light therapy (1500 lux)
3192901|NCT00813345|Placebo Comparator|B - identical control lamp|identical control lamp
3192902|NCT00813371|Active Comparator|1|Airway Pressure Release Ventilation Arm
3192903|NCT00813371|Active Comparator|2|ARDSnet protocol
3192904|NCT00813384|Experimental|Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD), if feasible, and evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 208.
3192905|NCT00813384|Experimental|Dose Expansion|The dose expansion will consist of up to 30 subjects and the dose level of AMG 208 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
2479499|NCT03039842|Placebo Comparator|placebo|Placebo+valproate
3192906|NCT00813397|Experimental|Sepraspray|Receive Sepraspray
3192907|NCT00813397|No Intervention|Control|No Treatment, No Placebo
3192908|NCT00813423|Experimental|Treatment (sunitinib malate, hydroxychloroquine)|Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3192909|NCT00813436|Experimental|1|Oxytocin
3192910|NCT00813436|Placebo Comparator|2|Placebo
3192911|NCT00813449|Experimental|A|Experimental group : Endostar combined with dacarbazine
2477779|NCT03051776|Active Comparator|Compression garment|It was done a four week phase with Compression garment in the arm affected with lymphedema.
2477836|NCT03051308|Experimental|First Application in Hour 0|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 0' non-cold ischemia tissue group
2477845|NCT03051308|Experimental|First Application in Hour 6|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 6' cold ischemic tissue group
2477848|NCT03051308|Experimental|First Application in Hour 12|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 12' cold ischemic tissue group
2477851|NCT03051308|Experimental|First Application in Hour 18|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour 18' cold ischemic tissue group
2477853|NCT03051308|Experimental|First Application in Hour 24|Viability, Calcium-sensing receptor, Vitamin D receptor and parathormone levels of Parathyroid cells (10^7 cells) at 'First Application in Hour' 24 cold ischemic tissue group
2477891|NCT03050736|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
2477934|NCT03050528|Experimental|Combined Exercise and ACT treatment|Participants will attend a weekly group-based multidisciplinary pain programme for a period of eight weeks. The programme will combine exercise with the psychological approach acceptance and commitment therapy (ACT).
2477935|NCT03050528|Active Comparator|Standalone supervised exercise|Participants will attend a weekly group-based supervised exercise class for a period of eight weeks.
2478017|NCT03050125|Experimental|Hypo-osmolar drop 1|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the lowest osmolarity of the two hypo-osmolar drops.
2478020|NCT03050125|Experimental|Hypo-osmolar drop 2|Subject will receive regular instillations of hypo-osmolar sterile saline drops with the highest osmolarity of the two hypo-osmolar drops.
2478023|NCT03050125|Experimental|Iso-osmolar drop|Subject will receive regular instillations of sterile iso-osmolar saline drops.
2478089|NCT03049761|Active Comparator|Water Flosser|Power interdental Cleaning Device
2478099|NCT03049761|Active Comparator|String floss|Manual interdental cleaning device
2478104|NCT03049761|Active Comparator|Manual Toothbrush|ADA standard manual toothbrush
2478155|NCT03049254||Proband|Proband - the person who is the first to present with a diagnosis of AVC
2478162|NCT03049254||Family members (consultands)|First-degree relatives of probands with AVC (who may be living or deceased) In some circumstances where multiple family members are or may be affected, they may be eligible.
2478202|NCT03048825|Experimental|Colchicine + Spironolactone +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2478210|NCT03048825|Experimental|Spironolactone +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone 25 mg tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2478217|NCT03048825|Experimental|Colchicine +/- SYNERGY Stent|"Colchicine 0.5 mg tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2478220|NCT03048825|Placebo Comparator|Placebo +/- SYNERGY Stent|"Colchicine-placebo tablet + Spironolactone-placebo tablet.~Trial participants who receive a SYNERGY Bioabsorbable Polymer Drug-Eluting Stent during their index PCI for STEMI will be included in the embedded SYNERGY Stent Registry."
2478238|NCT03048370|Experimental|Left body temperature VS|Left body temperature (37°C) vestibular stimulation
2478239|NCT03048370|Experimental|Right body temperature VS|Right body temperature (37°C) vestibular stimulation
2478240|NCT03048370|Experimental|Left warm CVS|Left warm (44°C) caloric vestibular stimulation
2478241|NCT03048370|Experimental|Right warm CVS|Right warm (44°C) caloric vestibular stimulation
2478242|NCT03048370|Experimental|Left cold CVS|Left cold (30°C) caloric vestibular stimulation
2478243|NCT03048370|Experimental|Right cold CVS|Right cold (30°C) caloric vestibular stimulation
2478294|NCT03048175|Experimental|Cases: wisdom tooth pathology|Subjects affected by bilateral wisdom tooth pathology, undergoing surgical removal
2478297|NCT03048175|No Intervention|Controls: no wisdom tooth pathology|Subjects showing agenesia/previous extraction/no symptoms of the lower third molars.
2478321|NCT03047902|Active Comparator|Parent Present|"The adolescents in group 1 (Parent Present) will be aware that their parents will be able to share the information on the questionnaire, but they will be assured of the confidentiality of the CO test. This will also be explained to the parent.~Intervention: Parents will be present for the questionnaire but not for the CO test."
2478327|NCT03047902|Active Comparator|Parent Absent|"The adolescents in group 2 (parents not present) will be assured of the confidentiality of the questionnaire and CO test. The confidentiality of the test will also be explained to the parent.~Intervention: Parents will not be present for the questionnaire or the CO test"
2478461|NCT03047304|Other|Women in risk for preterm labor|Women in risk for preterm labor treated with magnesium.
2478499|NCT03046498|Experimental|Program participants|Patients enrolled in the DSMP and DPP who provide consent.
2478552|NCT03046368|No Intervention|Standard cover letter|"The group will receive a standard cover letter to the survey that is designed to have broad appeal:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark."
2478553|NCT03046368|Experimental|Targeted cover letter 1|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sleep problems."
2478654|NCT03045705|Active Comparator|Labor+experimental pain management|Women that will not be asked at all by the medical team in the delivery room regarding analgesia during labor but will be able to receive analgesia at wish at the time of choice.
2477869|NCT03050905|Experimental|Treatment|The study will include 1 group. Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (VEKIRAX) and Dasabuvir (EXVIERA).
3192912|NCT00813449|Placebo Comparator|2|Control group : Dacarbazine combined with placebo
3192913|NCT00813475|Experimental|tight control|
3192914|NCT00813475|Experimental|standard control|basal bolus insulin regimen
2478087|NCT03049540|Active Comparator|Tadalafil|Tadalafil 20 MG, p.o., once per day for 3 years
2478100|NCT03049540|Placebo Comparator|Placebo|Placebo 20 MG, p.o., once per day for 3 years
2478118|NCT03049202||Never-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
2478123|NCT03049202||Ex-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that stopped smoking. Definition of smoking: > 10 pack years. Definition of ex-smoker: > 2 years since smoke cessation.
2478125|NCT03049202||Current-smoker COPD participants|COPD patients with mild-to-moderate COPD (GOLD I-II) that are currently smoking. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
2478127|NCT03049202||Current-smoker healthy controls|Current-smokers that are otherwise healthy, with normal lung function. Definition of smoking: > 10 pack years. Definition of current-smoker: > 10/cigarettes/dat the past 6 months.
2478128|NCT03049202||Never-smoker healthy controls|Healthy participants that have never smoked. Definition of never-smoker: Lifetime consumption of <100 cigarettes. No cigarettes the past 2 years.
2478216|NCT03048942|Experimental|Cabazitaxel|6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle
2478222|NCT03048942|Active Comparator|Paclitaxel|6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.
2478256|NCT03048357|Active Comparator|Freedom Bed|Freedom Bed Continuous Lateral Rotation Therapy System
2478270|NCT03048357|Other|Standard Hospital Bed & Protocol|Standard Hospital Bed with manual caregiver re-positioning every 2 hours
2478308|NCT03047928|Experimental|Patient group|"All patients receive the same treatment. Patients included in the protocol are treated with Nivolumab according to usual guidelines, implying outpatient IV infusions of 3 mg/kg biweekly until progression.~The vaccine is administered on the same day as the administration start of Nivolumab. The vaccination is given biweekly for a total of 6 times, then every fourth week up to week 47, whereupon no additional vaccines will be given. In total, 15 vaccines will be administered. A vaccine consist of 100 μg IDO long peptide, 100 μg PD-L1 long1 peptide and 500 microliters Montanide as adjuvant.~Patients who complete all vaccines will continue Nivolumab treatment after standard guidelines."
2478374|NCT03047668|Active Comparator|low-carb with PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), amplified with walnuts and walnut-sunflower muffins
2478386|NCT03047668|Active Comparator|low-carb without PUFA|49 weeks of hypo- to isocaloric low-carb diet (< 40 EI% carbs), without walnuts / walnut-sunflower muffins
2478397|NCT03047668|Active Comparator|low-fat with PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), amplified with walnuts and walnut-sunflower muffins
2478402|NCT03047668|Active Comparator|low-fat without PUFA|49 weeks of hypo- to isocaloric low-fat diet (< 30 EI% fat), without walnuts / walnut-sunflower muffins
2478467|NCT03047109|Active Comparator|Group P|Patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
2478469|NCT03047109|Active Comparator|Group E|Patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
2478506|NCT03046654|Experimental|Cervical cerclage|Women with a poor obstetric history that require cervical cerclage in order to avoid late abortion/early delivery.
2478619|NCT03046238|Active Comparator|dexmetedomedine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
2478623|NCT03046238|Placebo Comparator|control|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
2478671|NCT03045562|Placebo Comparator|Control group|Patients will be assigned to receive 100ml of normal saline
2478675|NCT03045562|Experimental|Experimental group|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline
2478695|NCT03045185|Experimental|Treatment Group|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.
2478784|NCT03044847||COPD group|The post-bronchodilator FEV1/FVC ratio < 0.70 was used as definition of COPD, which was proposed by the Global Initiative for Chronic Obstructive Lung Disease
2478793|NCT03044847||GOLD 0 group|GOLD 0 is defined as having chronic respiratory symptoms and/or high risk factors, but without airflow (post-BD FEV1/FVC ≥ 0.7). Chronic respiratory symptoms is defined as chronic cough, phlegm production, chest tightness, short of breath, dyspnea, wheeze, ect. High risk factors is defined as cigarette smoking, passive smoking, occupational exposures, bio-fuels exposures ect.
2478874|NCT03044457|Experimental|TKA by reversed gap technique|new operative technique of positioning the femoral and tibial component based on soft tissue tension and femoral 3D geometry.
2478880|NCT03044457|Active Comparator|TKA by gap technique|standard operative technique serving as control. tibia component positioning according to the mechanical axis, femoral component positioning according to the mechanical axis and soft tissue tension in flexion
2478934|NCT03043924|Other|PCOS women|26 PCOS women who receive consultation for hyperandrogenism needing treatment with Cyproterone Acetate + estradiol will be recruited.
2478938|NCT03043924|Other|Healthy volunteers|26 Healthy volunteers subjects who receive consultation contemplating oral contraceptives (Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet ) will be recruited.
2478967|NCT03043339||Renal transplant recipient|"Participants who are scheduled for a planned renal transplant as the recipient of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
2478971|NCT03043339||Renal transplant donor|"Participants who are scheduled for a planned renal transplant as the donor of the kidney.~All participants will complete the following interventions:~Stool Specimen Collection~Anal Swab Sampling~Short Diet Assessment (SDA)~NHANES Dietary Screener Questionnaire (DSQ)"
2479669|NCT03038581||Traumatic wrist injury|Wrist injury by not self-inflicted trauma
2477919|NCT03050463||breast cancer without bilateral mastectomy|This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
2477920|NCT03050463||healthy subjects|Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
3192915|NCT00813514|Experimental|1|Open longitudinal study with observer masked analysis
3192916|NCT00813527|Experimental|Lapaquistat Acetate 100 mg QD + Fenofibrate 145 mg QD|
3192917|NCT00813527|Active Comparator|Fenofibrate 145 mg QD|
3192918|NCT00813540|Experimental|1|Exercise
2478129|NCT03049072||Ion beam therapy|All patients treated with ion beam therapy at MedAustron who consent to the participation in the registry.
2478227|NCT03048994|Placebo Comparator|Placebo|Placebo
2478230|NCT03048994|Active Comparator|Glutamine|Glutamine
2478251|NCT03048396|Experimental|Uterus transplantation|
2478309|NCT03048292||Mobilized Neurointervention Team|Patients undergoing endovascular stroke interventions.
2478313|NCT03048292||Mobilized Patient|
2478315|NCT03048292||Core Comprehensive Stroke Center Treatment|
2478421|NCT03047512|Experimental|Internet-based program|The internet based program includes the following modules: (1) information and psychoeducational material, (2) symptom monitoring with personalized automatic feedback, (3) forum (peer support moderated by mental health professionals) and (4) chat (individualized support by mental health professionals). It also considers (5) the referral to face-to-face treatment of cases with symptoms that require it. (6) In addition to the web page in the institutions, there will be a monthly health promotion booth during breaks.
2478424|NCT03047512|No Intervention|Control Group|The control group will receive two psychoeducational workshops / conferences. In addition, the adolescents in the control group can participate in the monthly health promotion booths offered by the program.
2478477|NCT03047005|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2478478|NCT03047005|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
2478513|NCT03046589|Experimental|Treatment Period 1|DP13 capsules (dose level 1 ) and placebo capsules
2478514|NCT03046589|Experimental|Treatment Period 2|DP13 capsules (dose level 2) and placebo capsules
2478517|NCT03046589|Experimental|Treatment Period 3|DP13 capsules (dose level 3) and placebo capsules
2478520|NCT03046589|Experimental|Treatment Period 4|DP13 capsules (dose level 4) and placebo capsules
2478522|NCT03046589|Experimental|Treatment Period 5|DP13 capsules (dose level 5) and placebo capsules
2478525|NCT03046589|Experimental|Treatment Period 6|DP13 capsules (dose level 6) and placebo capsules
2478597|NCT03046043|Experimental|Low-Voltage & CFAE guided ablation|"Pulmonary isolation will be performed~Complex fractionated atrial electrogram(CFAE) and voltage mapping will be performed if atrial fibrillation the patient is still in atrial fibrillation after pulmonary vein isolation~CFAE and voltage mapping will be performed simultaneously using small electrode Pentaray® Catheter with CARTO®3 MEM version or CARTO®3 CONFIDENSE™~Automatic characterization of CFAE signals will be performed with an CARTO® CFAE software module.~CFAE areas within low voltage zone in the left atrium should be targeted first. If atrial fibrillation persist after left atrial ablation, target areas in the right atrium should be mapped and ablated. (Low-Voltage & CFAE guided ablation)"
2478603|NCT03046043|Active Comparator|PV Isolation Only|"Pulmonary vein isolation will be performed.~Electrical cardioversion to sinus rhythm will be performed if the patient is still in atrial fibrillation after pulmonary vein isolation."
2478653|NCT03045666|Experimental|Intervention group|Patients stable on Macitentan therapy will exercise twice a week for 12 weeks, supervised by physiotherapists. The exercise program includes aerobic and strength exercises, at 2-3 minutes intervals.
2478656|NCT03045666|No Intervention|Control Group|Patients stable on Macitentan therapy that will continue to receive it, without exercise.
2478714|NCT03045367||Outpatients|Phacoemulsification, intraocular lens implant, vitrectomy.
2478769|NCT03045042||Treated patients|Patients with late onset Pompe disease treated with the enzyme replacement therapy
2478770|NCT03045042||Non treated patients|Patients with late onset Pompe disease non treated with the enzyme replacement therapy
2478830|NCT03044639|Experimental|Provision of LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of LCT-based lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2478832|NCT03044639|Experimental|Provision of MCT/LCT emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of MCT/LCT lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2479672|NCT03038646|Experimental|Regimen B|32 mg MIN-101 MR administered in the fasted state
3192919|NCT00813540|Other|2|Usual Care, no intervention
3192920|NCT00813553|Placebo Comparator|beta-alanine 0|
3192921|NCT00813553|Experimental|beta-alanine 1|
3192922|NCT00813553|Experimental|beta-alanine 2|
3192923|NCT00813566||Diagnostic|
3192924|NCT00813605|Experimental|Arm A|AMG 655 10 mg/kg plus AMG 479 placebo in combination with FOLFIRI every 14 days
3192925|NCT00813605|Active Comparator|Arm C|AMG 479 Placebo plus AMG 655 Placebo in combination with FOLFIRI every 14 days
3192926|NCT00813605|Experimental|Arm B|AMG 479 12 mg/kg plus AMG 655 placebo in combination with FOLFIRI every 14 days
3192927|NCT00813618|Experimental|1|MEDI-507
3192928|NCT00813618|Experimental|2|MEDI-507
3192929|NCT00813618|Experimental|3|MEDI-507
3208665|NCT00977002|Experimental|PPNIV|Patient randomized to this group will be ventilated with Positive Pressure Noninvasive Ventilation post extubation
3192930|NCT00813631|Experimental|silver-releasing dressings|Silver, in its common ionic (active) form (Ag+), is particularly attractive as an antibacterial agent because it can be readily incorporated into dressing materials. Silver-dressing are wound products designed to control infection and provide a wound environment conducive to management exudates, pain, and malodour.
3192931|NCT00813644||1|uromentor training
2478033|NCT03049982|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
2478068|NCT03049709||cardiovascular disease|patients with cardiovascular disease, invasive and non-invasive determination of central blood pressure
2478070|NCT03049709||healthy controls|healthy controls, invasive and non-invasive determination of central blood pressure
3158481|NCT00387413|Experimental|Treatment Arm A2|In treatment Arm A2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm A2 Period 2 subject will receive 50 mcg GSK189254 plus Duloxetine Placebo in Week 1, in Week 2 subject will receive 100 mcg GSK189254 plus Duloxetine Placebo and in Week 3 subject will receive GSK189254 Placebo plus Duloxetine Placebo. There will be a washout of approximately one week between periods 1 and 2.
3158482|NCT00387413|Experimental|Treatment Arm B1|In treatment Arm B1 Period 1 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. In treatment Arm B1 Period 2 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. There will be a washout of approximately one week between periods 1 and 2.
2478264|NCT03048916|Other|general swallowing therapy|"including:~oral exercises~tactile stimulation~compensatory techniques~swallowing maneuvers"
2478274|NCT03048916|Experimental|the NMES therapy with VitalStim therapeutic device|The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS
2478275|NCT03048916|Active Comparator|: the combined NMES and general swallowing therapies|
2478351|NCT03048019||Tirofiban Therapy|
2478353|NCT03048019||Cangrelor Therapy|
2478472|NCT03047343||Uni-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an uni-ventricular reparation.
2478474|NCT03047343||Bi-ventricular reparation|All patients treated with pulmonary artery strapping between 2005 and 2016 at the Queen Fabiola Children Hospital. Patients benefiting from an bi-ventricular reparation.
2478526|NCT03046641|Experimental|continuous training group|With the continuous training program
2478528|NCT03046641|Experimental|interval training group|With the interval training program
2478598|NCT03046121|Experimental|Fam-FFC|The intervention consists of :Component 1- Environmental and Policy Assessments; Component II- Education of Nursing Staff; Component III-Ongoing Training/Motivation of Nursing Staff. The Fam-FFC Nurse will work with the champions to mentor and motivate nursing staff to provide: (a) role modeling Fam-FFC, reinforcing performance of Fam-FFC, and brainstorming about ways to overcome challenges; (b) highlighting staff role models; Component IV Implementation of the FamPath Pathway which includes: (a) information on the admitting condition, diagnostics, treatment;(b) family/patient education; (c) transitional hand-off to post-acute providers; and (d) post-acute follow-up to provide ongoing education and modification of the function-focused care plan.
2478604|NCT03046121|No Intervention|Attention Control (Fam- FFC Ed-only)|Education of the nursing staff in participating hospital units (exactly as offered in treatment sites), and education of family caregivers about hospital orientation and reinforcement of discharge teaching (medications/treatments, medical follow-up).
2478647|NCT03045692|Active Comparator|Control group|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
2478648|NCT03045692|Experimental|Study group|4 hour creatinine clearance is used to decide colistin maintenance dosage.
2478713|NCT03045419||Patients group|"with small hepatic nodules (10-19mm) or atypical hepatic nodule (= or > 20mm) and high-risk group of HCC~scheduled for gadoxetic acid-enhanced liver MRI or liver nodule biopsy"
2478719|NCT03045419||Living liver donor candidates|"living liver donor candidates without history of liver disease~schedule for gadoxetic acid-enhanced liver MRI as preoperative workup~only used for control of normal liver parenchymal enhancement on hepatobiliary phase"
2478813|NCT03044561|Experimental|Sildenafil citrate|
2478814|NCT03044561|Placebo Comparator|placebo|
3192932|NCT00813644||2|non uromentor training
3192933|NCT00813657|Experimental|Lifestyle counseling|
2478963|NCT03043521|Experimental|CJ-12420 50mg|T1=CJ-12420 50mg QD evening (9PM)
2478964|NCT03043521|Experimental|CJ-12420 100mg|T2=CJ-12420 100mg QD evening (9PM)
2478965|NCT03043521|Experimental|CJ-12420 200mg|T3=CJ-12420 200mg QD evening (9PM)
2478966|NCT03043521|Active Comparator|Dexlansopazole 60mg|R=dexlansoprazole 60mg QD evening (9p.m)
2479023|NCT03043196|Active Comparator|Rosuvastatin Group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
2479028|NCT03043196|Placebo Comparator|Placebo Group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2479066|NCT03042845|Active Comparator|Judkins L3.5/R4 cardiac catheters|
2479068|NCT03042845|Experimental|Tiger cardiac catheter|
2479172|NCT03041961|Placebo Comparator|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 1-hard capsule regimen (500 mg)
2479174|NCT03041961|Active Comparator|Aronia full spectrum|Formulation of an aronia full spectrum ingredient in a 1-hard capsule regimen (500 mg)
2479179|NCT03041961|Active Comparator|Aronia extract|Formulation of an aronia extract ingredient in a 1-hard capsule regimen (500 mg)
3192934|NCT00813670|Experimental|Cohort 1: Single dose of XPF-001|
3192935|NCT00813670|Experimental|Cohort 2: Single dose of XPF-001|
2479296|NCT03041337||Healthy subjects|Cohort of patients referred to our echocardiography laboratory to work assessment procedures and without any cardiovascular risk factor. They will underwent stress echocardiography.
3192936|NCT00813670|Experimental|Cohort 3: Single dose of XPF-001|
3192937|NCT00813670|Experimental|Cohort 4: Single dose of XPF-001|
3192938|NCT00813670|Experimental|Cohort 5: Single dose of XPF-001|
3192939|NCT00813670|Experimental|Cohort A: Repeated doses of XPF-001|
3192940|NCT00813670|Experimental|Cohort B: Repeated doses of XPF-001|
2477997|NCT03049995||SEDIA: SE in Diastolic Heart failure|Patients with suspected diastolic heart failure according to guidelines (3) will be selected (1).The diastolic assessment should be included into all exercise SE tests by measuring standard Doppler-derived mitral inflow velocity, pulsed Tissue Doppler of mitral annulus, and retrograde tricuspid gradient of tricuspid regurgitation as well as diastolic left ventricular volume index and B-lines (to provide a direct imaging of extra-vascular lung water accumulation as a direct cause of dyspnea). The test is considered positive for diastolic dysfunction when all of the following three conditions are met during exercise: average E/e' > 14 or septal E/e' ratio > 15, peak tricuspid regurgitant jet velocity >2.8 m/sec and septal e' velocity < 7 cm/s. A sample size of about 250 patients is required.
2477999|NCT03049995||SETA: SE in Transcatheter Aortic Valve implantation|Transcatheter Aortic Valve Implantation is an extraordinarily effective novel technology, and its short and long term morbidity and mortality remains significant. Patients with previous (from 6 months to 10 years) surgical or Transcatheter Aortic Valve Implantation capable of exercising will be enrolled and studied with semisupine SE. The full quantitative evaluation of mitral regurgitation and aortic stenosis will be performed. A sample size of about 100 patients is required to detect a significant stress-induced increase in mitral regurgitation severity. For the prognostic analysis 250 patients with 3 years follow-up are required.
2478001|NCT03049995||SEO: SE in Outdoor in Extreme conditions|SE can also be performed outdoors, with pocket size or portable instruments, in a setting of ecological stress entirely different from standard indoor testing. The diagnostic target is the early subclinical identification of pulmonary edema. Subjects involved in extreme sporting events (competitive triathlon, marathon, apnea diving etc) or ordinary exercise in extreme environments (trekking at high altitude) will undergo lung ultrasound scan for B-lines before, soon after (within 10 minutes) and (when positive) soon after, later after (6 to 24 h) the acute extreme exercise. A sample size of 80 patients is required to detect a significant stress-induced increase in B-lines in each of the three major study subgroups: high altitude trekkers (n=100); marathon runners (n=80) and apnea divers (n=70).
2478002|NCT03049995||SETOF: SE in operated Tetralogy of Fallot|Patients with repaired Tetralogy of Fallot or Fallot-like pathology (double-outlet right ventricle Fallot type, tetralogy of Fallot with pulmonary atresia), evaluated at least 1 year after the last surgical or percutaneous procedure, will be recruited by regional reference centers for congenital heart disease. Additional inclusion criteria are age > 10 years, height > 140 cm, New York Heart Association class I or II. Right ventricular function will be assessed at baseline and peak stress with variations (rest and peak stress) of tricuspid annular plane systolic excursion. A sample size of about 250 patients is required to detect a significant stress-induced increase in tricuspid annular plane systolic excursion.
2478004|NCT03049995||DOSPAH: Doppler SE in Pulmonary Arterial Hypertension|Patients at risk, borderline, or early established pulmonary hypertension capable of exercising will be recruited by regional reference centers, a physical stress will be performed and the hemodynamic assessment will include the assessment of pulmonary hemodynamics. The primary positivity criteria are the increase in systolic pulmonary artery pressure (> 40 mmHg) and the flow-adjusted variation in pulmonary vascular resistances. A sample size of about 250 patients is required to detect a significant stress-induced hemodynamic changes with a 3 -year follow-up.
2478009|NCT03049995||DITSE: Diagnosis of CAD by imaging SE|"A clear step-up in diagnostic sensitivity (with a modest loss in specificity) and risk stratification capability is obtained with assessment of coronary flow velocity reserve in the left anterior descending coronary artery,left ventricular contractile reserve through changes in left ventricular elastance, and B-lines. Allcomers referred to the SE lab with suspected CAD will be evaluated with standard regional wall motion analysis and also - whenever feasible - with left ventricular coronary flow reserve and left ventricular elastance reserve and - when possible- B-lines (quadruple imaging).A sample size of about 5,000 patients will be required."
2478014|NCT03049995||GENES: Genetic Stress echocardiography|The identification of phenotype-negative and genotype positive carriers of pathologic mutations is an important, still elusive, target. We will initially select 75 patients (25 for each disease) with documented disease and mutant gene. We will enroll 250 first-degree relatives of the initially considered probands, with normal findings at rest and age range preferentially between 10 and 21 years. SE testing will be tailored on the specific question: hypertrophic cardiomyopathy as in protocol 3 (left ventricular outflow tract gradient); pulmonary hypertension as in protocol 8 (pulmonary vascular resistances);dilated cardiomyopathy as in protocol 1 (left ventricular elastance). A sample size of about 80 patients for each disease will be required.
2478094|NCT03049631|Active Comparator|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
2478097|NCT03049631|Experimental|Raspberry|Red raspberries (1 cup equivalent)
2478150|NCT03049241||knee extensors|
2478158|NCT03049241||ankle plantar|
2478317|NCT03047941||All patients|All patients included in the present study
3192941|NCT00813670|Experimental|Cohort C: Repeated doses of XPF-001|
3192942|NCT00813683|Experimental|1|"Stimulation of 67 Bladder point"
3192943|NCT00813683|Sham Comparator|2|"Stimulation of 45 Stomach point (sham)"
3192944|NCT00813696|Experimental|A|cisplatin + gemcitabine
2478521|NCT03046524||Parathyroid Carcinoma|Charts from participants with histopathological diagnosis of parathyroid carcinoma.
2478523|NCT03046524||Atypical Parathyroid Neoplasm|Charts from participants with parathyroid tumors with some atypical features found in parathyroid carcinoma, but not enough histologic criteria to make the diagnosis of parathyroid carcinoma.
2478576|NCT03046199|No Intervention|Control|
2478579|NCT03046199|Experimental|Questionnaire|
2478580|NCT03046199|Experimental|Coordination|
2478583|NCT03046199|Experimental|Questionnaire + coordination|
2478636|NCT03045770|Experimental|mFOLFOX|The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
3192945|NCT00813696|Active Comparator|B|gemcitabine
3192946|NCT00813722|Active Comparator|phone calls|patients received phone calls
3192947|NCT00813722|Placebo Comparator|no phone calls|patients received no phone calls
3192948|NCT00813722|Active Comparator|current treatment|calcium chanel blocker and at1 antagonist
3192949|NCT00813722|Active Comparator|tradittional treatment|beta blocker and diuretic
2478000|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound
2478078|NCT03049878|Active Comparator|analgesic group|preoperative oral dose of paracetamol-codeine
2478091|NCT03049878|Placebo Comparator|placebo group|preoperative placebo (starch)
2478141|NCT03049267|Experimental|Apremilast|N=15
2478149|NCT03049267|Placebo Comparator|Placebo Oral Tablet|N=5
2478197|NCT03048812|Experimental|O'Ring attachment (A)|One arm of our research will receive O'Ring attachment for 3 months and after this period they will recieve the second attachment Equator for more 3 months
2478204|NCT03048812|Experimental|Equator attachment (B)|The second arm of our research will receive Equator attachment for 3 months and after this period they will recieve the second attachement O Ring for more 3 months
2478367|NCT03047694|Experimental|Tablet group|Patients will continue their usual care (1 or more sessions of weekly speech therapy) and will benefit from the therapy on tablet for 3 months.
2478372|NCT03047694|Active Comparator|Control group|Patients will continue their usual care (1 or more sessions of weekly speech therapy)
2478428|NCT03047148||Regional Anesthesia|Hospital records from patients who have undergone surgery in regional anesthesia.
2478429|NCT03047148||General Anesthesia|Hospital records from patients who have undergone surgery in General anesthesia.
2478454|NCT03046940|No Intervention|Control group|No communication with a doctor
2478463|NCT03046940|Experimental|Patient-centered|Participants communicate with a doctor that uses a patient-centered style of communication
2478466|NCT03046940|Experimental|Doctor-centered|Participants communicate with a doctor that uses a doctor-centered style of communication
2478527|NCT03046732|Experimental|Explore Transplant Ontario|"Intervention 'Implementing Explore Transplant Education'"
2478529|NCT03046732|No Intervention|Control|The control arm (Usual Treatment) is at the Toronto General Hospital dialysis center.
2478571|NCT03046160|Experimental|experimental group|"where treatment will involve conventional and Manual therapy (Mobilization with movement)+ tape (postural correction of scapular anterior tilt)~The Manual therapy (Mobilization with movement)intervention was of grade III mobilizations with movement performed in sitting for 6-10 repetitions for 3 sets~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
2478574|NCT03046160|Active Comparator|control group|"treatment will consist of the conventional approach+ tape (postural correction of scapular anterior tilt)~tape (postural correction of scapular anterior tilt)~A program of 12 neck and scapular exercises."
2478778|NCT03044652|Experimental|Medical Device: WO2085 Moisturising Cream|"WO2085 is a hormone-free Moisturizing Cream and is used to treat vulvovaginal dryness symptoms."
2478782|NCT03044652|Active Comparator|Drug: Estriol Cream 0.1%|Estriol Cream 0.1% is a standard therapy for the treatment of vulvovaginal atrophy in postmenopausal women.
2478860|NCT03044314|Experimental|Iloprost and nitric oxide administration|Each patient will receive 40 ppm inhaled nitric oxide and 2.5-5 mcg inhaled iloprost in the catheterization laboratory with assessment of hemodynamic response. Patients will also receive 2.5-5 mcg iloprost during echocardiographic assessment.
2478902|NCT03043807|Experimental|chemohormonal and definitive therapy after prostatectomy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 2 years of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
2479130|NCT03042663|Experimental|Intervention group|In patients meeting the inclusion criteria and with absence of any exclusion criteria, and after taking PI and Doppler Blood flow values hourly for 3 hours (control values), the procedure for administering the USG Stellate ganglion block on the side of the arterial cannula will be started
2479170|NCT03042013|Experimental|ASP8273|Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
3158483|NCT00387413|Experimental|Treatment Arm B2|In treatment Arm B2 Period 1 subject will receive GSK189254 Placebo plus Duloxetine Placebo for all 3 Weeks. In treatment Arm B2 Period 2 subject will receive 30 milligram (mg) Duloxetine plus GSK189254 Placebo in Week 1, in Week 2 60 mg Duloxetine plus GSK189254 Placebo and in Week 3 30 mg Duloxetine plus GSK189254 Placebo. There will be a washout of approximately one week between periods 1 and 2.
2479324|NCT03041077|Experimental|Instaflex Advanced|Dietary supplement: Joint function
2479326|NCT03041077|Placebo Comparator|Placebo|Dietary supplement: Placebo
3158484|NCT00387439|Experimental|standard medical treatment|standard medical treatment
3158485|NCT00387439|Experimental|standard medical treatment + anoperineal physiotherapy|standard medical treatment + anoperineal physiotherapy
3158486|NCT00387452|Active Comparator|1|
3158487|NCT00387452|Active Comparator|2|
3158488|NCT00387452|No Intervention|3|No intervention, only testing during 6 months.
3158489|NCT00387478|Experimental|1|modified Tree pollen allergen absorbed to Tyrosine and containing MPL adjuvant
3158490|NCT00387478|Experimental|2|modified Tree pollen allergen absorbed to Tyrosine
3158491|NCT00387478|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
3158492|NCT00387530|Other|Single Arm Study of Biopsy|
2478018|NCT03050177|Experimental|Gefitinib Tablet 250mg of Hunan Kelun|During the study session, healthy subjects were orally administered a single dose of Gefitinib Tablet 250mg of Hunan Kelun under fed conditions.
2478021|NCT03050177|Active Comparator|Iressa® Tablet 250mg of AZN|During the study session, healthy subjects were orally administered a single dose of Iressa® Tablet 250mg of AZN under fed conditions.
3192950|NCT00813735|Experimental|Eszopiclone|Drug: Eszopiclone 2mg, Drug: Escitalopram 10mg or 20mg
3192951|NCT00813735|Placebo Comparator|Placebo|Drug: Placebo, Drug: Escitalopram 10mg or 20mg
2478135|NCT03049059|Experimental|Fractional Picosecond 1,064 nm laser and 4% hydroquinone cream|
2478152|NCT03049059|Active Comparator|4% hydroquinone cream alone|
2478194|NCT03048838|Experimental|Risk reduction behavioral intervention|"Couples randomized to the risk reduction behavioral intervention (Conectando Latinos en Pareja) will participate in four weekly sessions with a facilitator. Each session will last 2 hours. Participants will receive information and complete activities, participate in games and discussions to improve their relationship and improve health."
2478203|NCT03048838|Active Comparator|Wellness Promotion Intervention|Couples randomized to the wellness promotion control group will receive the same number of hours of attention as the active experimental group but will not receive the risk reduction intervention. Information presented will consist of topics related to general health.
2478249|NCT03048565|No Intervention|Usual care|No intervention
2478260|NCT03048565|Experimental|Mindfulness based Stress Reduction|This is an active intervention The MBSR programme is delivered online with weekly telephone and email contact from a trained mindfulness teacher. Participants are encouraged to practice mindfulness exercises and homework between sessions. The online programme was developed be a trained mindfulness teacher.
2478293|NCT03048188|Experimental|Burn with or without split-skin graft|Second degree burns and third degree burns with split-skin graft that need wound dressings
2478320|NCT03047876||All neonates and infants undergoing aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
2478384|NCT03047707|Experimental|S-Shearwave and TE|
2478471|NCT03047330|Experimental|Unfragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some unfragmented sleep periods.
2478473|NCT03047330|Experimental|Fragmented sleep|All subjects will receive one dose of Leuprolide Acetate and will have some fragmented sleep periods.
2478554|NCT03046316|Other|local consolidative treatment|Patients will be referred to multiple disciplinary treatment discussion for the decision of local consolidative treatment to primary or metastatic lesions including surgery, radiotherapy or interventional therapy.
3192952|NCT00813774|Active Comparator|Reference|Lyophilized formulation (reference)
2478740|NCT03045250|Active Comparator|Type 1 Diabetes|Subjects with known Type 1 diabetes
2478744|NCT03045250|Placebo Comparator|Healthy Controls|Healthy controls
2478780|NCT03044756|Experimental|-ve arm|The women who do not receive the GnRH antagonist dose on the day of triggering of ovulation (omitted GnRH antagonist arm)
2478789|NCT03044756|No Intervention|+ve arm|The women who receive the routine dose of GnRH antagonist on the day of triggering of ovulation (the usual protocol)
3192953|NCT00813774|Experimental|Liquid|Liquid Formulation (test)
2478896|NCT03044002||4French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
2478897|NCT03044002||6French Intervention|Patient with infrainguinal Peripheral Artery Disease (PAD), requiring endovascular treatment
2478929|NCT03043664|Experimental|Arm 1|Keytruda (pembrolizumab) 200 mg intravenous (IV) every 3 weeks and Somatuline Depot (lanreotide depot) 90mg subcutaneous (SQ) every 3 weeks
2478990|NCT03043443|Placebo Comparator|Placebo|participants will receive placebo 1 capsule/day 1 hour before sleeping for 4 weeks
2478996|NCT03043443|Active Comparator|Melatonin|participants will receive melatonin 1 capsule (5mg)/day 1 hour before sleeping for 4 weeks
2479031|NCT03042936|Experimental|Arm 1|Insulin Superheroes Club Curriculum
2479059|NCT03042741|Experimental|V6 recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive V6 - oral atherosclerosis vaccine administered once per day for one month
2479063|NCT03042741|Placebo Comparator|Placebo recipients|Arm will comprise 150 individuals with overweight problem or obesity randomly assigned to receive placebo pills given once per day as a single pill for one month
2479109|NCT03042494|Placebo Comparator|Control|Isocaloric food without the test prebiotic.
2479110|NCT03042494|Experimental|Prebiotic|Prebiotic consumed as one daily serving of 7 g in Group 1 and consumed as one daily serving of 2.5-3 g in Group 2.
2479187|NCT03042182|Experimental|Single pill of V3-X vaccine administered once daily|One pill of oral therapeutic vaccine V3-X administered to patients with cholangiocarcinoma for two months and changes in CA19.9 tumor marker from baseline levels versus post-treatment levels will be assessed as correlates of changes in tumor burden
2479359|NCT03040765|Active Comparator|Denosumab|"Denosumab 60 MG/ML Prefilled Syringe~Denosumab Dose: 60 milligrams, subcutaneous injection, every 6 months (twice a year)"
2479362|NCT03040765|Active Comparator|Zoledronic Acid|"Zoledronic Acid 5Mg/Bag 100Ml Inj~Zoledronic acid will be 5 milligrams, Intravenous injection, once a year"
2479466|NCT03039972||Pulmonary Hypertension|Adult outpatients with suspected or prediagnosed pulmonary hypertension irrespective of subclass and all chronic kidney disease stages
2479611|NCT03038958|Active Comparator|Isobaric 2-chloroprocaine|The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy
3192954|NCT00813774|Experimental|Pre-filled Syringe|Pre-filled syringe (test)
3192955|NCT00813787||A. glioma|A. glioma population
3192956|NCT00813787||B. Normal brain|B. Normal brain
3192957|NCT00813826|Experimental|SLC022|300mg TID
3192958|NCT00813826|Placebo Comparator|Placebo|Matching placebo capsule
3192959|NCT00813839|Experimental|1 SmartCare|automated ventilator controlled adjustment of pressure support
3192960|NCT00813839|Active Comparator|2 spontaneous breathing Trial|daily SBT on minimum pressure support
3192961|NCT00813852|Experimental|2|exercise training, CPAP, and inspiratory muscle strengthening program
2478019|NCT03050138||Warfarin|In the RE-COVER- and RE-COVER II studies, the other group of DVT and/or PE patients were randomized to receive 6 months of treatment with warfarin (once daily to maintain international normalized ratio (INR) 2.0-3.0). All patients received an initial 5-7 day phase of parenteral anticoagulant treatment.
3192962|NCT00813878||Normal participants|
2478176|NCT03049033|Experimental|Neurologic Music Therapy (NMT)|Neurologic Music Therapy is a 5-week intervention using different musical instruments and auditory cues to specifically improve fine motor movements.
2478178|NCT03049033|Active Comparator|Occupational Therapy (OT)|Standard of care occupational therapy uses traditional motor training.
2478179|NCT03049033|No Intervention|Waitlist Control|Participants assigned to the waitlist-control condition will not immediately receive services. The no-treatment duration for these participants is yoked to the amount of time their respective NMT- and OT-condition participants receive services (5 weeks). After the wait period, these participants will then be randomized to receive either NMT, MST or OT sessions.
2478180|NCT03049033|Active Comparator|Music Supported Therapy (MST)|Music Supported Therapy uses musical instruments to train fine motor movements.
2478262|NCT03048695|Experimental|Goal Management Training|Cognitive rehabilitation
2478272|NCT03048695|No Intervention|Waiting list|
2478338|NCT03047824|Other|Continuous monitoring-guided therapy|Healthcare providers were allowed to use the blood glucose values displayed on the intravascular continuous monitoring to adapt insulin therapy
2478343|NCT03047824|Other|Standard of care|Healthcare providers used the usual intermittent method to adapt insulin therapy; the blood glucose values measured by the intravascular continuous monitoring were not displayed but recorded. Usual care involves the adjustment of insulin infusion based on BG values measured with a blood gas analyser 4-6 times per day.
2478398|NCT03047577|No Intervention|Standard care arm|Treatment as usual and discussion according to the treating clinicians in the hospital
2478404|NCT03047577|Other|Intervention arm|Patients receive a brief intervention, including a short discussion, opportunity for an appointment with a social worker and written information about effects of alcohol on health and contact information for seeking additional support
2478433|NCT03047083||IC eligible AML patients with FLT3 mutation|Newly diagnosed AML patients
2478434|NCT03047083||IC ineligible patients with FLT3 mutation|Newly diagnosed AML patients
2478435|NCT03047083||AML patients after R/R with FLT3 mutation|R/R are relapse/refractory patients
2478436|NCT03047083||IC eligible patients without FLT3 mutation|Newly diagnosed AML patients
2478437|NCT03047083||IC ineligible patients without FLT3 mutation|Newly diagnosed AML patients
2478438|NCT03047083||AML patients after R/R without FLT3 mutation|R/R are relapse/refractory patients
2478495|NCT03046888|Experimental|PCNL|Percutant nephrolithotomy is a standard procedure for stones treatment over 2 cm.The puncture will be performed with an 18-G nephrostomy needle. The access thus gained guaranteed the transpapillary route of the percutaneous tract, a basic condition for the prevention of bleeding. Subsequently, following withdrawal of the puncture needle and urine drainage, a flexible guidewire will be inserted and advanced to the upper calyx or ureter.
2478496|NCT03046888|Experimental|Robot assisted pyelolithotomy|Robot assisted pyelolithotomy, is a new technique to remove stones of more than 2 cm. A 12-mm camera port is placed at the level of the umbilicus and lateral. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
2478543|NCT03046394|Active Comparator|C-SACH|All the interventions will be administered to the patient in this single-subject trial, each 6 times
2478546|NCT03046394|Active Comparator|B-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
2478547|NCT03046394|Active Comparator|A-DER|All the interventions will be administered to the patient in this single-subject trial, each 6 times
3192963|NCT00813878||Breast Cancer Patients|
3192964|NCT00813891|Active Comparator|Pre-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week prior to the first PDT with verteporfin.
3192965|NCT00813891|Active Comparator|Post-PDT|Participants in this group will receive an intraocular Ranibizumab injection one week post the first PDT with verteporfin.
2478797|NCT03044665|Active Comparator|High-intensity statin monotherapy|Statin monotherapy
2478802|NCT03044665|Experimental|Statin plus ezetimibe combination therapy|Statin plus ezetimibe combination therapy
2478837|NCT03044379|Active Comparator|Dapivirine Gel|Participants will be randomized to receive a single dose of dapivirine gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
2478840|NCT03044379|Placebo Comparator|Placebo Gel HEC|Participants will be randomized to receive the universal HEC placebo gel rectally, followed by 7 daily doses of the same product to be administered under direct observation in the clinic.
2478848|NCT03044119|Active Comparator|Dental Implant with PRFM|Intervention in the form of Dental Implants placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix a biological material procured from patient's peripheral blood
2478849|NCT03044119|Experimental|Dental Implant with PRFM and PBMSCs|Intervention in the form of Dental Implant placement in the adjacent edentulous bone with the placement of platelet rich fibrin matrix and peripheral blood mesenchymal stem cells which are the biological materials procured from patient's peripheral blood
2478944|NCT03043963|Active Comparator|Sleep Timing|Intervention will include basic education concerning sleep hygiene and regularity of sleep timing
2479680|NCT03038646|Experimental|Regimen C|32 mg MIN-101 MR administered in the fasted state
2478095|NCT03049800||FEP - General Cognitive Exercises|First Episode Psychosis patients who receive general cognitive exercises while participating in an associated randomized controlled trial examining the effect of computerized cognitive training.
2478103|NCT03049800||Healthy Controls|Age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
3192966|NCT00813891|Active Comparator|No PDT|Participants in this group will receive an intraocular Ranibizumab injection with no accompanying PDT with verteporfin.
3208666|NCT00977002|Active Comparator|O2I|Patient randomized to this group will be submitted to traditional oxygen therapy post extubation
2478225|NCT03048643|No Intervention|Standard of Care|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy for infective endocarditis according to usual care.
2478228|NCT03048643|Experimental|Outpatient Parenteral Antibiotic Therapy|Subjects will receive medication-assisted treatment for opioid use disorder and will complete IV antibiotic therapy via outpatient parenteral antibiotic therapy (OPAT).
2478252|NCT03048409||Enteral tube fed adults|Enteral formula
2478310|NCT03048279||Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Consented individuals will be interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
2478314|NCT03048279||Close Relatives of Registered MDACC MEN Patients|Participants will be asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
2478406|NCT03047681||Study group|patients undergoin transcatheter aortic valve implantation
2478409|NCT03047681||Control group|patient undergoing diagnostic coronary angiography
2478443|NCT03047161||High-risk pregnancy|abnormal fetal heart rate or rhythm or risk of abnormal fetal heart rate or rhythm
2478444|NCT03047161||Uncomplicated pregnancy|uncomplicated pregnancy
2478486|NCT03046901|Experimental|Vancomycin group|It is a single arm open label study and will constitute only one group that will be taking vancomycin for recurrent PSC post liver transplantation.
2478511|NCT03046511|Experimental|Intraperitoneal|One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter
2478516|NCT03046511|Active Comparator|Intravenous|One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion
2478612|NCT03046290|Active Comparator|Pudendal Block|The anesthesia is produced by blocking the pudendal nerves near the ischial spine of the pelvis.Local anesthetic (mixed of ropivacaine and lidocaine) is injected into the pudendal canal where the pudendal nerve is located.
2478616|NCT03046290|Active Comparator|Penian Block|The anesthesia is produced by blocking the dorsal penile nerves. Local anesthetic (mixed of ropivacaine and lidocaine)is injected under the pubis symphysis just below the Buck fascia where the nerve is located.
2478684|NCT03045523|Experimental|GLPG2222 Dose 1|
2478685|NCT03045523|Experimental|GLPG2222 Dose 2|
2478688|NCT03045523|Placebo Comparator|Placebo|
2478747|NCT03045107|Experimental|Intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected and a side-to-side anastomosis is fashioned with a laparoscopic stapler.
2478748|NCT03045107|Active Comparator|Extracorporeal ileocolic anastomosis|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. Then, a primary ileocolic side-to-side handsewn or mechanical anastomosis is fashioned extracorporeally.
2478796|NCT03044769||Patient with CLA with surgery|
2478804|NCT03044769||Patient with CLA without surgery|
2478838|NCT03044392|Active Comparator|Next Bolus Interval 15 minutes|Next Bolus Interval 15 minutes
2478841|NCT03044392|Active Comparator|Next Bolus Interval 30 minutes|Next Bolus Interval 30 minutes
2478843|NCT03044392|Active Comparator|Next Bolus Interval 45 minutes|Next Bolus Interval 45 minutes
2478854|NCT03044067|Experimental|Pain neuroscience education + Exercise|Pain neuroscience education can be defined as an educational session or sessions describing the neurobiology and neurophysiology of pain, and pain processing by the nervous system. It will be applied three times (at baseline, one week and one month after intervention). Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities.
2478866|NCT03044067|Active Comparator|Exercise|Exercise will be based on a set of 4 exercise implicating flexion, extension, lateral rotation and abduction of lower and upper extremities. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
2478909|NCT03043859|Experimental|Pure Prairie Living Program|Participants in the intervention arm will participate in 5 weekly education sessions ( 2hours / session) on nutrition education and healthy lifestyle.
2478910|NCT03043859|No Intervention|Wait Listed Control|Participants in the control arm will not receive any intervention.
2478955|NCT03043586||Treatment Pattern|The first phase of this study will be to contact all subjects in the cohort by a mailing introducing them to the study. This will be followed by a phone call and administration of a questionnaire by phone or by mail. A phone script will be utilized to obtain verbal informed consent from subjects for this phase of the study. The questionnaire will collect current information on acromegaly treatment, morbidities and other relevant history. Subjects will provide verbal consent to participate in this questionnaire part of the study and review of their medical records by the PI and study staff.
2478983|NCT03043248|Experimental|Cohort A|TRK-700 + Digoxin
2478985|NCT03043248|Experimental|Cohort B|TRK-700 + Midazolam
2479039|NCT03043053|Experimental|oxytocin|oxytocin nasal spray (24 IU nasal spray, 4 times per day for 8 weeks)
2479040|NCT03043053|Placebo Comparator|placebo|placebo nasal spray (4 times per day for 8 weeks)
2479105|NCT03042676||ATLG group|ATLG treatment for GVHD prophylaxis.
2479107|NCT03042676||no ATLG group|No ATLG treatment.
3208667|NCT00977015|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
3208668|NCT00977015|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
3208669|NCT00977028|Experimental|Tumescent Lidocaine with liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine with liposuction
2478157|NCT03049228||Type 2 Diabetic Patients|"Obese (BMI > 27 kg/m2 < 35 kg/m2)~Non-insulin dependent; they must be on sulphonylurea(SU)- derivate or metformin therapy for at least six months with a constant dose for at least two months, or on dietary treatment for at least six months~They should have a (moderately) well-controlled diabetes (defined by a HbA1c<8%)"
2478163|NCT03049228||Obese Subjects|"A similar BMI as T2DM patients (BMI > 27 kg/m2< 35)~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
2478166|NCT03049228||Lean subjects|"BMI between 20-25 kg/m2~Normo-glycemic with fasting plasma glucose levels lower than 6,1 mmol/L."
2478254|NCT03048656|Experimental|Individuals with leg-length discrepancy|Patients of Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences diagnosed with leg-length discrepancy. The examination of participants included a measurement of the length of lower limbs and the weight distribution as well as performing the static posturography.
2478268|NCT03048656|Active Comparator|control group|The group with healthy individuals; without leg-length discrepancy. The examination of participants included a measurement of the weight distribution as well as performing the static posturography.
2478316|NCT03048123|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intraarterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
2478322|NCT03048123|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA)
2478366|NCT03047525|No Intervention|control group|patients will just regularly chemotherapy
2478369|NCT03047525|Experimental|DC-CIK and CIK Immunotherapy|patients will receive chemotherapy with 4 cycles of DC-CIK treatment and 4 cycles of CIK treatment .
2478462|NCT03047317|Experimental|MABp1|
2478488|NCT03046836|Experimental|Oxytocin|Each participant will self-administer 40 IU intranasal Oxytocin
2478491|NCT03046836|Placebo Comparator|Control|Each participant will self-administer matching saline placebo
3208670|NCT00977028|Experimental|Tumescent Lidocaine No Liposuction|Determine maximum safe mg/kg dosage of tumescent lidocaine without liposuction
2478614|NCT03045952|Experimental|microwave ablation|Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
2478657|NCT03045640|Experimental|FSI ECD|"Vulnerable Households (ubudehe 1 or 2) in the Government of Rwanda's poverty classification system, when categories ranged from 1 to 6; the system has since been restructured to have four categories only. Often a way to identify households for public works opportunities or other government assistance programs. For this arm, families had to be Ubudehe 1 or 2 and have a child aged 0-3 years. Households meeting these criteria in the catchment area(s) received the FSI ECD home-based parenting intervention from bachelor-level interventionists/coaches."
2478724|NCT03045354|Experimental|Mashed potatoes|Eggs with a side of mashed potatoes
2478725|NCT03045354|Experimental|French fries|Eggs with a side of French fries
2478727|NCT03045354|Experimental|Beans|Eggs with a side of beans
2478730|NCT03045354|Experimental|Traditional breakfast|Cereal, milk, toast and jam
2478734|NCT03045354|Experimental|Breakfast skipping|No breakfast
2478795|NCT03044795|Experimental|Part A|Patients with TNBC, platinum sensitive high grade serous ovarian cancer or BRCA-mutated (non-)breast and (non-)ovarian cancer will be included prior to the RAD51 assay and treated with veliparib irrespective of the assay result. All patients, including TNBC patients, will receive veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment.
2478801|NCT03044795|Experimental|Part B|Only patients with a RAD51 assay HR deficiency will be included. First there will be a pre-screening procedure followed by a tumor lesion biopsy on which the RAD51 assay will be performed. In case of a RAD51 assay indicating HR proficiency, patients will not be eligible for treatment in this study and cannot be included. Patients with a RAD51 assay indicating HR deficiency will be included. Eligible patients will be treated with veliparib monotherapy until at least the first tumor assessment after 8 weeks of treatment. In case of 0/15 patients within one patient subgroup having RAD51 tests showing HR-deficiency inclusion for this sub-group will be closed.
2478851|NCT03044444|Experimental|high dose citrus extract|this group will receive a high dose (500mg/day) of the citrus extract for 8 weeks
2478855|NCT03044444|Experimental|low dose citrus extract|this group will receive a low dose (400mg/day) of the citrus extract for 8 weeks
2478864|NCT03044444|Placebo Comparator|placebo|this group will receive a placebo (500mg maltodextrin per day) for 8 weeks
3208671|NCT00977041|Experimental|Neurofeedback|See Intervention description below.
2479278|NCT03041389|Experimental|CCBT-I Group|The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.
2479280|NCT03041389|Active Comparator|Control Group|"The patients who will be randomized control group will be given a reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. The control group will have access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.~To identify PD-specific barriers to Internet usage and CCBT-I, all patients at the end of the study or at the time of drop out will have a questionnaire on the barriers to CCBT-I."
2478196|NCT03048773|Experimental|shockwave therapy|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee with jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
2478206|NCT03048773|Placebo Comparator|placebo|"0.24mJ/mm2，1600 shots over 8 assigned sites of single knee without jelly between applicator pad (20) and handpiece~Physical therapy with TENS + MF + stretching + strengthening exercise, 3 times per week for 3 weeks"
2478265|NCT03048539||Transoral endoscopic thyroidectomy|Patient who fit with the eligible criteria and choose endoscopic thyroidectomy by himself.
2478273|NCT03048539||Conventional thyroidectomy|Patient who fit with the eligible criteria and choose conventional thyroidectomy by himself.
2478339|NCT03048136|Experimental|Flat-Dose|Nivolumab flat dose + Ipilimumab
2478345|NCT03048136|Experimental|Weight-Based Dose|Nivolumab weight-based dose + Ipilimumab
3192967|NCT00813930|Experimental|INTERxVENT Program|Participants in INTERxVENT will complete a 'Baseline Assessment' and 'Follow-up' questionnaire, and will have a health professional visit his/her home for an initial assessment (BP,height,weight,waist measurement) and blood collection (blood glucose and cholesterol levels). As part of the program, each participant will also complete a self-reported 'Health History Questionnaire' (HHQ); a follow-up HHQ will be completed about 12 weeks into the program to monitor progress. Each participant randomized to INTERxVENT receives educational articles which address diabetes management issues. A structured, individualized program, consisting of educational materials and 12 live mentoring/coaching telephone calls will take place over 6 months. The mentors consist of allied health professionals. The sequence by which educational content is administered will be both self-directed and guided by the mentors using an algorithmic approach according to the participant's readiness-to-change scores.
2478581|NCT03045991|Experimental|sequential training group (SEQ)|"The sequential training group (SEQ) will first receive 30-minutes aerobic exercise training followed by 30-minutes computerized cognitive training. All participants will receive a training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
2478584|NCT03045991|Active Comparator|control intervention group (CI)|"The control intervention group (CI) will receive a control training session for 60 minutes per day, three days per week for 12 weeks, a total of 36 training sessions.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
2478650|NCT03045744|Experimental|incomplete SCI patients|
2478693|NCT03045406|Experimental|Apixaban|orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)
2478694|NCT03045406|Active Comparator|Dalteparin|subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months
3192968|NCT00813930|No Intervention|Usual medical care|Each participant randomized to this group will not receive any formal intervention but will receive the same care over the 6-month period as he/she usually receives from his/her health care team. Participants in this group will undergo the same baseline and outcome assessment as those in the intervention group, including blood pressure (BP) measurement, physical assessment (height, weight, waist measurement) and blood collection (blood glucose and cholesterol levels), as well as completion of the 'Baseline Assessment' and 'Follow-up' questionnaires.
3192969|NCT00813956|Experimental|1|standard chemotherapy plus BSI-201
2478939|NCT03043703|Experimental|AirSense 10 AutoSet for Her|Treatment for 1 night with ResMed AirSense 10 AutoSet for Her. Intervention: Administration of PAP Treatment with suboptimal pressure for 1 night.
2478981|NCT03043417|Experimental|CHC's given the intervention|Three CHC sites where all staff receive all components of the intervention. Training, Media, Art workshops, and a Policy analysis as well as survey completion.
2478984|NCT03043417|No Intervention|CHC's with NO intervention|Three CHC sites where all staff and a selection of clients complete surveys but receive no intervention.
2479134|NCT03042403||Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds. During the 20 seconds of applying of technic, in the three series the maximum inspiratory and expiratory pressures reached during the carrying out of technic. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
2479173|NCT03041948|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL).
2479188|NCT03042039||Study group 'New Care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
2479219|NCT03041558|Experimental|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
2479229|NCT03041558|Active Comparator|SafeCare (SC)|SafeCare intervention as usual
2479230|NCT03041753||Intervention group|ischemic stroke patients in the anterior circulation territory (NIHSS ≥7) within 12 hours from last seen well, treated either with systemic thrombolysis or endovascular treatment.
2479686|NCT03038646|Experimental|Part 2 selected dose|32 mg MIN-101 of MR administered in the fed state
2478218|NCT03049007||Child|Parental bereaved individuals (age 18 or above) that are children of the partner group. The group will complete a survey at respectively 2 (T1), 6 (T2), 11 (T3), 18 (T4), and 26 (T5) months post-loss.
2478279|NCT03048552|No Intervention|Standard of Care|This arm is comprised of caregiver-youth dyads randomized to work with the youth's probation officer as usual to link youth to substance use services.
2478282|NCT03048552|Experimental|Family CONNECT|This arm is comprised of caregiver-youth dyads randomized to work with linkage specialists to link youth to substance use services.
2478356|NCT03048032||Acute heart failure patients|Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.
2478358|NCT03048032||Control group|Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.
2478378|NCT03047408|Experimental|patients with PD-RBD|"patients with PD-RBD having already underwent vPSG, clinical and neuropsychological in clinical setting or in the study RBHP 2013 DURIF  at least three years ago."
2478539|NCT03046810|Experimental|Wellness toileting system|This group will use the wellness toileting system for their perineal hygiene and treatment of dermatitis
2478565|NCT03046069||Subjects included in telephone interviews|Approximately 10 subjects with COPD per country will be included in qualitative concept elicitation telephone interviews.
2478567|NCT03046069||Subjects included in in-person focus groups|1 in-person focus-group per country including up to 5 subjects with COPD will be included in the qualitative analysis.
2478569|NCT03046069||Subjects included in DCE surveys- cognitive interviews|Up to six subjects with COPD in each of the UK, US and Germany will be asked to complete and provide feedback on the surveys.
2478572|NCT03046069||Subjects included in modified DCEs|Up to 20 subjects with COPD in each country will be included in pilot testing of the modified DCEs.
2478575|NCT03046069||Subjects included in Final DCE|150 subjects with COPD in each of the UK, US and Germany will be included in the final online market specific DCE survey.
2478637|NCT03045835|Experimental|BASKA mask|Selection of size : size 3 (30-50kg), size 4 (50-70kg), size 5 (70-100kg)
2478641|NCT03045835|Active Comparator|Endotracheal intubation|Selection of size : ID 7.0-7.5mm (women), ID 7.5-8.0mm (men)
2478669|NCT03045484|Experimental|The moderate group|Patient who was suffering from moderate pain in the mouth, pharynx, or larynx during the treatment of chemoradiotherapy consented to take controlled-release oxycodone, oxycodone was begun at the level of mild pain. We called this the moderate group. Controlled-release oxycodone was used to relieve oral mucositis pain induced by chemoradiotherapy in this group.
2478673|NCT03045484|Experimental|The severe group|Patients who did not ask for controlled-release oxycodone until the pain reached a moderate level during the treatment of chemoradiotherapywere called the severe group. Controlled-release oxycodone was also used to relieve oral mucositis pain induced by chemoradiotherapy in this group..
2478728|NCT03045172|Active Comparator|Group 1|20 subjects with Platelet Rich Plasma injections
2478731|NCT03045172|Placebo Comparator|Group 2|10 subjects with placebo injections
2478786|NCT03044834||Pleuropulmonary Blastoma|"Patients born between 01/01/2000 and 01/01/2016 ;~Followed up for PPB~Treated in a French department of paediatric oncology or paediatric surgery~Study agreement"
2478876|NCT03044262|Experimental|Cohort 7|This is a sub-study testing the effect of real output applied under two adhesive strips (standard adhesive strip and new adhesive strip) on the skin after 8 hours.
2478904|NCT03043833|Experimental|Wellbeing Course|Will receive the French-Canadian version of the Wellbeing Course consisting of five lessons based on cognitive behavior therapy delivered through the Internet over eight weeks.
2478906|NCT03043833|No Intervention|Waitlist-control|The Waitlist Control Group will receive the French-Canadian version of the Wellbeing Course once the treatment group will have completed treatment.
3192970|NCT00813969|Experimental|Autologous MSC transplantation|
2479054|NCT03043040|Experimental|Telephone follow up|"Patients discharged from hospital A and B after a suicide attempt receive a protocolized telephone follow which is added to their usual treatment (TAU). Calls are made by nurses at weeks 1,2,4,12 and 24 after the index suicide attempt.~TAU: Includes whatever treatment the doctor decides to offer to that patient (psychopharmacology, psychotherapy etc)."
2479061|NCT03043040|Active Comparator|Control|Patients discharged from hospital C after a suicide attempt receive treatment as usual (whatever treatment the doctor decides to offer to that patient: psychopharmacology, psychotherapy etc).
3192971|NCT00814021|Experimental|sunitinib,|
3192972|NCT00814034||1:Tamoxifen|
3192973|NCT00814034||2:Steroidal Aromatase Inhibitor|
3192974|NCT00814034||3:Non-steroidal Aromatase Inhibitor|
3192975|NCT00814060|Experimental|1|40-mg tablet
3192976|NCT00814060|Experimental|2|240-mg tablet
2479353|NCT03040752|Active Comparator|Nifedipine|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
3192977|NCT00814060|Experimental|3|80-mg capsule
3192978|NCT00814073|Experimental|Masitinib & BSC|Masitinib (6 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
3192979|NCT00814073|Placebo Comparator|Placebo & BSC|Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)
3192980|NCT00814086|Experimental|Treatment (paclitaxel, cisplatin)|Patients receive paclitaxel IV over 3 hours and cisplatin intraperitoneally (IP) on day 1 and paclitaxel IP on day 8. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3192981|NCT00814099|Active Comparator|1|Participants will receive care at a pediatric ICU that is continuing the usual approach to sedation management.
2478255|NCT03048344|Experimental|Part 1|Subjects will receive oral ORH-2014 at a planned starting dose of 5 mg once daily (QD) in the fasted state. If escalation criteria are met, the administered dose will increase by 5 mg increments to a maximum of 50 mg QD. The starting daily dose is approximately half the typical IV dose (0.15 milligram per kilogram [mg/kg]) extrapolated to a 70-kg person.
2478269|NCT03048344|Experimental|Part 2|Subjects will receive a daily oral dose of ORH-2014 at the recommended dose identified in Part 1. ORH-2014 will be administered in the fasted state.
2478326|NCT03048071||Homograft in pulmonary position replacement|All patients having had the replacement of an homograft in pulmonary position between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
2478333|NCT03048071||Contegra conduct replacement|All patients having had the replacement of a Contegra conduct between January 1999 and October 2016, within the Queen Fabiola Children Hospital of Brussels, Belgium.
2478387|NCT03047642||Malawi febrile patients|Children and adults with fever presenting at the outpatient department
2478396|NCT03047642||Brazil febrile patients|Children and adults with fever presenting at the outpatient department
2478399|NCT03047642||Gabon febrile patients|Children with fever or with a recent history of fever presenting at the outpatient department
2478476|NCT03047135|Experimental|Olaparib 300 mg BID|Patients will be administered olaparib orally twice daily at 300mg bid continually. Two 150mg of olaparib tablets should be taken twice daily, approximately 12 hours apart with one glass of water.
2478549|NCT03046381|Other|Tocilizumab|Tocilizumab 162mg 1x weekly as subcutaneous syringe
2478590|NCT03046017|Active Comparator|real tDCS|In this group, the tDCS stimulates areas of the brain being examined in this study to increase their activity.
2478592|NCT03046017|Sham Comparator|sham tDCS|In this group, sham tDCS does not provide real stimulation though participants will not know this until the debriefing at the end of the study. Sham will be used to determine if the results of this study are due to the tDCS or other reasons.
2478593|NCT03046017|Other|control group|In this group, participants will receive tDCS but will only receive a cream on their lower back.
2478666|NCT03045601|Experimental|CT-FFR|Analyse With New CT-FFR Method
2478668|NCT03045601|Active Comparator|Stress echocardiography|Analyse With invasive FFR and stress echocardiography
2478754|NCT03044925|Experimental|Remote magnetic navigation|Persistent atrial fibrillation ablation with remote magnetic navigation
2478756|NCT03044925|Active Comparator|Cryoablation|Persistent atrial fibrillation ablation with cryoballoon
2478805|NCT03044717||Cardiology fellows and faculty|"Fill out a nutrition survey three times at 0, 3, and 6 months and be present at a prevention educational conference every 5 weeks until the end of the study.~This group will also complete a 3-hour nutrition module prior to study completion."
2478872|NCT03044327|Other|LPS challenge|LPS inhalation and bronchial instillation
3192982|NCT00814099|Experimental|2|Participants will receive care at a pediatric ICU that is implementing the team approach to sedation management.
3192983|NCT00814112||1 septic shock|septic shock, ICU
2479079|NCT03042754|Other|suspected TB|Patients suspected with TB will be sent for XpertMTB/RIF and urine LAM test
2479111|NCT03042377|Active Comparator|Single-Visit Retreatment|Root canal retreatment were performed according to the guidelines for single-visit endodontic treatments.
2479112|NCT03042377|Active Comparator|"Multiple-Visit-Calcium Hydroxide"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2479117|NCT03042377|Active Comparator|"Multiple-Visit-Corticosteroid Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2479119|NCT03042377|Active Comparator|"Multiple-Visit-Antibiotic Paste"|Root canal retreatment were performed according to the guidelines for multiple-visit endodontic treatments.
2479168|NCT03042026||Acromegaly patients|Acromegaly patients
2479175|NCT03042026||Healthy subjects|Healthy volunteers
2479225|NCT03041714||Normal volunteers|people who are healthy and without tremor
2479235|NCT03041714||Essential tremor|Patients with essential tremor
2479240|NCT03041714||Dystonic tremor|patient with tremor who also have dystonia
2479299|NCT03041350|Experimental|Smartphone video-assisted ALS & Conventional CPR|"In study period, using this video medical control, high-quality CPR, cardiac arrest rhythm confirmation, defibrillation, proper drug administration instructions, advanced airway insertion, etc. are performed. The medical director then decides on patient transfer if the asystole and pulseless electrical activity findings are persistent even after more than 20-minutes of ALS.~The conventional CPR is Basic life support only in the automatic external defibrillator (AED) mode 5-10 minutes at the scene, are not allowed to stop resuscitation at the scene unless there is a return of spontaneous circulation (ROSC) or pre-hospital cardiac arrest patient has already been transported to a hospital."
2479348|NCT03040830|Experimental|Egg retrieval arm|67 ICSI cases are started daily 100 mg IM prontogest on the day of egg retrieval until the day of pregnancy test.
2479351|NCT03040830|Active Comparator|Embryo transfer arm|66 ICSI cases are started daily 100 mg IM prontogest on the day of embryo transfer until the day of pregnancy test.
2479396|NCT03040440|Active Comparator|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated in 32 participants
2479398|NCT03040440|Experimental|TaperGuard endotracheal tube|TaperGuard endotracheal tube was intubated in 32 participants
2479436|NCT03040180|Experimental|Electrochemotherapy with bleomycin|"Systemic injection of bleomycin followed by electroporation of the primary tumor. Bleomycin administration: 15.000 IU/m2 BSA.~BSA by Du Bois formula."
2479439|NCT03040180|No Intervention|Standard care|Standard care
2479500|NCT03039816|Active Comparator|Active|The patients were randomly assigned to active (Nasaleze cellulose powder) or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
2479536|NCT03039413|Experimental|Diagnostic (Copper Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT after 60 minutes. Patients then undergo standard of care cystectomy and/or biopsy 1 to 4 weeks later.
3192984|NCT00814112||2 controls|matched controls
2478296|NCT03048162|Active Comparator|Hydroxyethylstarch|6% hydroxyethylstarch, 500 ml, one package in 30 minutes
2478299|NCT03048162|Active Comparator|Ringer-Lactate Infusion Solution Bag|Ringer's lactate, 500 ml, one package in 30 minutes
2478344|NCT03047863|Experimental|Repair Control EGF®|EGF cream was applied. Half of face was treated with emollient containing EGF.
2478349|NCT03047863|Placebo Comparator|Cream without rhEGF|Placebo cream without EGF was applied. The other half of face was treated with only emollient which was not containing EGF.
3192985|NCT00814125|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
3192986|NCT00814125|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
2478453|NCT03046979|Experimental|Apatinib|a molecular targeted anti-tumor drugs. Small molecule vascular endothelial growth factor receptor 2 inhibitor.
2478507|NCT03046706|Active Comparator|standard voice rest|This group maintains postoperative voice rest. Namely, absolute voice rest for a week, followed by a week of relative voice rest sound (talking is allowed for 20 minutes a day). post operative voice rest
2478509|NCT03046706|Experimental|no voice rest|This group has no limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions.
3192987|NCT00814125|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
3192988|NCT00814151||MicroPhage|Blood Culture positive specimens available within 24 hours of alarm.
2478732|NCT03045445|Experimental|Double Low-Dose protocol CT|Low radiation dose + low amount of iodine contrast media at spectral CT (Philips Healthcare)
2478736|NCT03045445|Active Comparator|Standard protocol CT|Standard protocol quadriphasic liver CT according to current liver CT protocol in our institution, at spectral CT (Philips Healthcare)
2478781|NCT03044860|Experimental|Type 2 diabetes|Adult patients with type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
2478788|NCT03044860|Experimental|Healthy|Adult subjects without type 2 diabetes undergoing double-balloon enteroscopy (DBE) with biopsy retrieval using a DBE-device.
2478844|NCT03044483||18-34 year olds|Healthy adults aged 18-34 years old
2478845|NCT03044483||35-54 year olds|Healthy adults aged 35-54 years old
2478847|NCT03044483||55 and over year olds|Healthy adults aged 55 years old and over
2478947|NCT03044054|Experimental|ECHOPULSE|ECHOPULSE HIFU
2478975|NCT03043261|Experimental|Psycho-Behavioral Intervention|"Williams LifeSkills modules which cover 10 core skills designed to improve coping skills, stress management and interpersonal relationships: 1) being aware of negative thoughts and feelings, 2) making a decision, 3) deflection skills, 4) problem solving or action skills, 5) assertion, 6) saying no, in addition to the following preventive skills: 7) speaking up, 8) listening, 9) empathy and 10) increasing positives"
2479027|NCT03043183|Experimental|Preoperational nutrition support group|Scored patient-generated subjective global assessment(PG-SGA) ≥2，<9 Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
2479029|NCT03043183|No Intervention|Conventional group|PG-SGA ≥2，<9
2479037|NCT03042858||Infants with PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If a PPV is present, the subject will be followed for up to 18 years of age.
2479038|NCT03042858||Infants without PPV|During laparoscopy for pyloric stenosis, the surgeon will turn the camera downward to answer the first question, whether the inguinal canal is patent or closed. If there is no PPV, meaning they have normal anatomy, the patient demographic data will be recorded and this will terminate their participation.
3192989|NCT00814151||Standard of Care|Blood Culture positive specimens.
3192990|NCT00814190|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
2479197|NCT03042143|Experimental|Human umbilical cord derived CD362 enriched MSCs|Maximum tolerated dose from the phase 1 trial will be infused over 30 to 90 mins
2479199|NCT03042143|Placebo Comparator|Placebo (Plasma-Lyte 148) infusion|Plasma-Lyte 148 infused over 30 to 90 mins
2479234|NCT03041532|Experimental|proximal retroflexion|Procedure: The endoscopy explore right colon with frontal view and a second look with proximal retroflexion
2479241|NCT03041532|Active Comparator|frontal view of right colon|Procedure: The endoscopy explore right colon with frontal view and frontal view
2479272|NCT03041259|Experimental|Rejuveinix Low Dose|Intravenous dosing of two doses per week of Rejuveinix
2479273|NCT03041259|Experimental|Rejuveinix High Dose|Intravenous dosing of two doses per week of Rejuveinix
3192991|NCT00814190|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
2479413|NCT03040219|Active Comparator|Treatment group|
2479416|NCT03040219|Placebo Comparator|Control|
2479505|NCT03039764|No Intervention|Standard occupational therapy|This group will receiving standard occupational therapy for the treatment of acute stroke.
2479507|NCT03039764|Experimental|SOT plus VR Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
2479539|NCT03039361|Experimental|Equine Assisted Psychotherapy|6 week Equine Assisted Psychotherapy program
2479543|NCT03039361|No Intervention|Control|Standard of Care, Existing PTSD therapy
3192992|NCT00814203||Chronic obstructive lung disease|those with a condition
3192993|NCT00814216|Experimental|QAV680|
3192994|NCT00814216|Placebo Comparator|Placebo|
3192995|NCT00814216|Active Comparator|Fluticasone Propionate Inhaler|
3192996|NCT00814229|Active Comparator|Vaccine 1|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
3192997|NCT00814229|Active Comparator|vaccine 2|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
3192998|NCT00814229|Active Comparator|Vaccine 3|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
3158493|NCT00387556|Experimental|Ketamine + Ondansetron|ketamine 1 mg/kg IV (maximum single dose 100 mg)+ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
2478379|NCT03047564|Experimental|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
2478388|NCT03047564|Active Comparator|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
2478468|NCT03047265|Experimental|Paclitaxel|Paclitaxel plus Cisplatin combine with IMRT
2478470|NCT03047265|Active Comparator|Cisplatin|Cisplatin combine with IMRT
2478489|NCT03046628|Experimental|Patients with diabetic feet ulcers|Each patient will be examined twice, first with TcPO2 (TCM400, Radiometer Medical ApS, Denmark) and then with a green laser (harmonic of continuous neodymium-doped yttrium aluminium garnet laser 532-nm wavelength and fast camera (PixelLink PLE531) system.
2478533|NCT03046459|Experimental|BNZ132-1-40|a range of IV doses
2478663|NCT03045718|Experimental|Horticultural Therapy|Horticultural Therapy will consists of 1 hour sessions, weekly for 9 months, to engage subjects in gardening-based activities.
2478664|NCT03045718|Other|Waitlist Control|The control group will be placed on a waiting list and only be contacted for assessments. They will receive the same Horticultural Therapy intervention after the active treatment group at a later date.
2478735|NCT03045263|Active Comparator|Pivotal Response Treatment|Pivotal Response Training with children ages 3-6 years of age with an Autism Spectrum Disorder diagnosis
2478737|NCT03045263|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
2478794|NCT03044821|Experimental|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
2478826|NCT03044405|Other|Responders and non-responders|Fluid challenge of 500 ml of crystalloids over 15 minutes is given. Positive fluid responsiveness is defined by an increase in stroke volume (SV) of at least 15% assessed by focused transthoracic echocardiography.
2478850|NCT03044171|Experimental|G-FLUOR+LASER|The corresponding hemiarcade received the application of Low Level Laser Therapy as a desensitizing treatment prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride after dental bleaching.
2478852|NCT03044171|Experimental|G-FLUOR|The correspondent hemiarcade received only the positioning of the inactive laser tip (placebo), prior to in-office dental bleaching, followed by the application of 1.1% sodium fluoride as a desensitizing treatment after dental bleaching
2478949|NCT03043612|Experimental|Ureteral Study Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent that is coextruded with an alpha-blocker medication
2478950|NCT03043612|Active Comparator|Ureteral Control Stent|Commercially available Cook Sof-Flex® Double Pigtail Ureteral Stent
2479095|NCT03042533|Active Comparator|Conventional Compression|Nail will be seated using conventional compression technique
2479096|NCT03042533|Active Comparator|Standard Backslapping|Nail will be seated using standard backslapping technique
2479097|NCT03042533|Active Comparator|Dynamic Locking with Backslapping|Nail will be seated using backslapping with dynamic locking
2479133|NCT03042247||Hodgkin lymphoma patients|Hodgkin lymphoma patients with confirmed histological diagnosis
2479138|NCT03042247||DLBC non Hodgkin lymphoma patients|DLBC non Hodgkin lymphoma patients with confirmed histological diagnosis
2479263|NCT03041402|Active Comparator|PSP ventilation|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
2479265|NCT03041402|Active Comparator|NAVA ventilation|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
2479268|NCT03041402|Experimental|PSN ventilation|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
2479304|NCT03041064|Experimental|SPF 50/SPF 100|SPF 50 assigned to left side of face and body. SPF 100 assigned to right side of face and body
2479308|NCT03041064|Experimental|SPF 100/SPF 50|SPF 100 assigned to left side of face and body. SPF 50 assigned to right side of face and body
3158494|NCT00387556|Placebo Comparator|Ketamine + Placebo|ketamine 1 mg/kg IV (maximum single dose 100 mg)+2 ml normal saline solution IV (placebo
2479393|NCT03040531|Experimental|Genistein|"Each tablet will contain 27 mg of 98% pure genistein + 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will receive a tablet containing only 500mg Calcium + 200 IU Vit. D3."
2479399|NCT03040531|Active Comparator|Alendronate|"Each tablet will contain 500mg Calcium + 200 IU Vit. D3. Subjects will receive 2 tablets per day 6 days/week for all the duration of the study.~Once a week subjects will take one tablet containing 70mg alendronate."
2479454|NCT03040089|Experimental|picosecond laser & 2% hydroquinone cream|PICO+4 laser system and Neoquine Cream 2% (2% hydroquinone cream) for melasma
2479458|NCT03040089|Sham Comparator|2% hydroquinone cream|Only Neoquine Cream 2% (2% hydroquinone cream) for melasma
2479493|NCT03039712||Micra leadless pacemaker therapy|All Medicare patients implanted with Micra leadless pacemaker system
2479496|NCT03039712||Single Chamber Transvenous pacemaker|All Medicare patients implanted with full system (e.g. lead and generator) single- chamber ventricular transvenous pacemakers
2504190|NCT02871856|Other|Single|Single arm only, CT screening of lung
3158495|NCT00387569|Experimental|Cohort 1|Experimental (20ug); Active Comparator/Placebo
3158496|NCT00387569|Experimental|Cohort 2|Experimental (60ug); Active Comparator/Placebo
3158497|NCT00387569|Experimental|Cohort 3|Experimental (200ug); Active Comparator/Placebo
3158498|NCT00387582|Experimental|I|Lucentis injections for the first three months of the study and then per the protocol for the duration of the trial.
3158499|NCT00387582|Active Comparator|II|Argon Laser treatment at enrollment and then per the protocol for the duration of the study.
3158500|NCT00387634|Active Comparator|Arm 1|Blood draw only, no vaccine
3158501|NCT00387634|Active Comparator|Arm 2|Blood draw only, no vaccine
3158502|NCT00387634|Active Comparator|Arm 3|Blood draw only, no vaccine
3192999|NCT00814229|Active Comparator|Vaccine 4|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
3193000|NCT00814229|Active Comparator|Vaccine 5|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
2478408|NCT03047356|Experimental|"First-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the first person (if I...then I...). Ifs are critical situations, thens are appropriate responses."
2478411|NCT03047356|Experimental|"Second-person if-then plan"|"Participants are asked to form if-then plans and the instructions are presented in the second person (if you...then you...). Ifs are critical situations, thens are appropriate responses."
2478414|NCT03047356|Placebo Comparator|Control|"Participants are presented with ifs (critical situations) and thens but are not asked to form if-then plans."
3193001|NCT00814229|Active Comparator|Vaccine 6|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
3193002|NCT00814229|Active Comparator|Vaccine 7|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
2478544|NCT03046407|Experimental|retinal pigment epithelium transplantation|transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
2478644|NCT03045913||Genoss DES|Subject implanted Genoss DES for coronary artery disease
2478665|NCT03045458|Active Comparator|Tissue level dental implant|Tissue level dental implants (Straumann AG, Waldenburg, Switzerland) were inserted in patients group I (n=20).
2478667|NCT03045458|Active Comparator|Bone level dental implant|Bone level dental implants (Straumann AG, Waldenburg, Switzerland ) were inserted in patients group II (n=20).
2478700|NCT03045198|Experimental|Azithromycin|oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks
2478761|NCT03045055|Experimental|RIC group|RIC (remote ischemic conditioning) paired with endovascular treatment.
2478763|NCT03045055|Sham Comparator|Sham group|Sham RIC (remote ischemic conditioning) paired with endovascular treatment.
2478774|NCT03044678|Experimental|Experimental: REACH for Success|Experimental: Exposure-based, cognitive and behavioral, social skills training intervention 6-weeks - 6 session -20-30 min each
2478775|NCT03044678|Active Comparator|Active Comparator: Self-study|"Active Comparator: Books What to do when you are scared and worried?How to do homework without throwing-up? How to get organized without losing it? Reading at home"
2478812|NCT03044535||Group 1: Longitudinal assessment|Assessments will be performed pre-MCS, 3 months post-MCS and 6 months post-MCS. Participants in this group must be scheduled for MCS implant.
2478816|NCT03044535||Group 2: Cross-sectional assessment|A one-time assessment will be performed on participants who are post-MCS implant (between 3 months and 10 years post-implant). Participants in this group must already have an MCS device in place.
3193003|NCT00814229|Active Comparator|Vaccine 8|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
3193004|NCT00814229|Active Comparator|Vaccine 9|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
2478931|NCT03043690||Ammonium succinate|Patients in main pooled study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
2478932|NCT03043690||Placebo|Patients in placebo study group received 2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
2478976|NCT03043404|Experimental|Lotus Valve Flex System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve FLEX System
2479026|NCT03043144||End stage renal disease|Observational study, no intervention
2479070|NCT03042793|Experimental|Vaccination|Vaccine: PD-L1 peptide.
2479132|NCT03042507|Other|Open Trial|This is a non-randomized open trial of a behavioral intervention for young children with tics
2479169|NCT03042000|Experimental|Group A1|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'radical surgery + adjuvant chemotherapy (ACT)'
2479176|NCT03042000|Active Comparator|Group A2|Patients with cT3a-bN0-1aM0 mid rectal cancer who undergo the treatment modality of 'NCRT + radical surgery + ACT'
3193005|NCT00814229|Active Comparator|Vaccine 10|influenza H9N2 vaccine virosomal containing 5microg haemagglutinin by intramuscular injection
3193006|NCT00814229|Active Comparator|Vaccine 11|influenza H9N2 vaccine virosomal containing 15microg haemagglutinin by intramuscular injection
3193007|NCT00814229|Active Comparator|Vaccine 12|influenza H9N2 vaccine virosomal containing 45microg haemagglutinin by intramuscular injection
3193008|NCT00814229|Active Comparator|Vaccine 13|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
3193009|NCT00814229|Active Comparator|Vaccine 14|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
3193010|NCT00814242|Active Comparator|hepatectomy|Patients with HCC adjacent to major blood vessels recieved radical resection.
3193011|NCT00814242|Experimental|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation
3193012|NCT00814268|Experimental|Combination therapy|Administration of Aspirin + Clopidogrel for 30 days
3193013|NCT00814268|Active Comparator|Monotherapy|Administration of Aspirin + Clopidogrel placebo for 30 days
3193014|NCT00814281|Placebo Comparator|1|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
3193015|NCT00814281|Placebo Comparator|2|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting a placebo.
3193016|NCT00814281|Experimental|3|Subject will exercise in high levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
3193017|NCT00814281|Experimental|4|Subject will exercise in low levels of ultrafine and fine particulate air pollution 1 hour after ingesting Montelukast 10 mg orally.
3193018|NCT00814294|Placebo Comparator|1; Placebo|Patients receive a sugar pill.
3193019|NCT00814294|Experimental|2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)|Patients receive Oral HDV-Insulin (U-5).
2478416|NCT03047590|Active Comparator|No Choice-No Affect|"These participants regulate their exercise intensity using their heart rate, with the goal of walking 30-60 minutes on most days of the week. The intensity is moderate according to the American College of Sports Medicine (40-59% of their heart rate reserve). This is heart rate-based exercise intensity with no focus on positive affect."
2478460|NCT03047057|Experimental|Lidocaine|IV Lidocaine infusion
2478465|NCT03047057|Placebo Comparator|Control|IV normal saline infusion
2478531|NCT03046680|Experimental|Health Coaching|Individualized follow-up, supporting the individual for a better autonomy in personal care.
2478537|NCT03046680|Active Comparator|Multiprofessional Team|Physician, nurse, nutrionist usual care.
2478577|NCT03046095|Experimental|Unilateral Resistance Exercise|One of the participant's legs will be randomized to a unilateral resistance training arm for 10 weeks in duration. The leg chosen to be trained will undergo resistance exercise three days per week (Monday, Wednesday, and Friday) for the entirety of the study.
2478578|NCT03046095|Experimental|Immobilization|One of the participant's legs will be chosen to be immobilized during the last two weeks of the study. Therefore, one leg will be resistance exercising from week 0-10 whereas the other leg will be immobilized during weeks 8-10.
2478635|NCT03045822|Experimental|Patients with cardiac implantable electronic devices|
2478692|NCT03045510|Experimental|Ultra small dose decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
2478741|NCT03045133|Active Comparator|MT group|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
2478745|NCT03045133|Active Comparator|MF group|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
2478811|NCT03044548|Experimental|Experimental|Supportive supervision
2478815|NCT03044548|No Intervention|Control|No intervention
2478856|NCT03044275|Experimental|Cohort 8|"This is a sub-study testing the effect of real output on the skin applied under two adhesive strips.~New adhesive strip Standard adhesive strip"
2478922|NCT03043976|Active Comparator|feedback and goal-setting group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'walk test (6MWT), will undertake a blood sample (BNP). In the run-in period (1 week) patients will wear an Actigraph GT9X Link device which only displays the time and the battery level; all activity data will be recorded. Then participants will wear an Actigraph GT9X Link device which shows real time data about the number of steps and will upload their data via the Study Admin Mobile application for smartphones/tablets. Patients will be asked to aim for an average specified number of steps/day week by week and will receive a weekly report with results from the previous week and targets to achieve. After 8 weeks, patients will attend visit 2 (6MWT, SF36 and BNP assessment) and will carry on wearing the activated device for 8 weeks receiving weekly feedbacks and targets. After 8 weeks patients will attend visit 3 (6MWD, SF36 and BNP will be assessed) which is the end of the study.
2478926|NCT03043976|Active Comparator|Control group|At the baseline, patients will fill a questionnaire about their quality of life (SF36), will perform a 6'WT and will undertake a blood sample (BNP). After a run-in period (1 week) with an Actigraph GT9X Link device disabled from showing the number of steps, patients will wear an Actigraph GT9X Link device which still only displays time and battery level and will upload data via the Study Admin Mobile application for smartphones/tablets without receiving any feedback. After 8 weeks, patients will be assessed (SF36, 6'WT, BNP) and will start to wear a new device enabled to display the daily step count. Patients will be asked to aim for an average specified number of steps/day, receiving a weekly summary of the previous week with targets to achieve week by week. After 8 weeks, patients will be assessed (6'WT, SF36, BNP) and will carry on wearing the device and receiving feedbacks and targets for a further 8 week period, after that patients will be finally assessed (SF36, 6'WT, BNP)
2478930|NCT03043976|Placebo Comparator|newly diagnosed patients|"In the week leading up to their inpatient admission for diagnostic investigations, patients who are treatment-naïve will be given the Actigraph GT9X Link device which will only display the time and the charge level of the battery. Patients will be asked, as well, to fill a questionnaire about their quality of life, to perform a 6MWT and a blood sample (BNP). As soon as patients start the drug therapy, patients will wear a second Actigraph GT9X Link device still disabled from showing real time data about the number of daily steps. Participants will not receive any feedback during the whole period and will be asked, as well, to upload the data collected through the remote mobile system. At their first clinical assessment (after about 4 or 5 weeks), 6'WT, BNP and questionnaire about quality of life will be reassessed.~If patients are not being started on drug therapy then they will be withdrawn from the study"
2478973|NCT03043430|Experimental|Ketamine|Ketamine 100 mg/mL concentration administered in a single 1.0 mg/kg dose with a maximum of 50mg intranasal via mucosal atomization device.
2478978|NCT03043430|Active Comparator|Midazolam|Midazolam 5 mg/mL concentration administered in a single administered in a single 0.3 mg/kg dose with a maximum of 5mg intranasal via mucosal atomization device.
2479053|NCT03043118|Experimental|Variety|Children receive three servings of vegetables each prepared with a different herb and spice blend.
2479060|NCT03043118|No Intervention|No Variety - Control|Children receive three servings of vegetables each prepared with the same herb and spice blend.
2479098|NCT03042637||Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus
2479162|NCT03042273|Experimental|High Strength Cranberry|1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months
2479164|NCT03042273|Placebo Comparator|Placebo|1 capsule of Matching Placebo orally daily for 6 months
2479290|NCT03041376|Experimental|Walking intervention|
2479293|NCT03041376|No Intervention|Control|
2479341|NCT03040921|Experimental|Uterine Transposition|Patients submitted to uterine transposition.
2479387|NCT03040583||ASSESS (PHRC) patients|Primary Sjögren's Syndrome Patients who have already participated to the study ASSESS
2479417|NCT03040232|Experimental|MPFl Reconstruction|subjects that have had MPFL reconstruction surgery
2479419|NCT03040232|Active Comparator|Active Controls|subjects that have not had MPFL reconstruction surgery
2479488|NCT03039673|Experimental|low dose interleukin-2|"Patients randomized to this arm will receive subcutaneous injections of low-dose interleukin-2 in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: IL-2"
2505119|NCT02866071|Placebo Comparator|Placebo|50mg IN placebo
3193020|NCT00814294|Experimental|3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)|Patients receive Oral HDV-Insulin (U-15).
3193021|NCT00814359|Experimental|Magic Mouthwash Plus Sucralfate|
2478450|NCT03046953|Experimental|Avleumab|Avelumab 10mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days.
2478492|NCT03046758|Experimental|Participants|
2478550|NCT03046355|Experimental|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
2478551|NCT03046355|Active Comparator|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
2478611|NCT03045965|Experimental|Salpingectomy|Concomitant salpingectomy at the time of hysterectomy for a benign reason
2478615|NCT03045965|No Intervention|No salpingectomy|No salpingectomy at the time of hysterectomy for a benign reason
2478652|NCT03045627|Active Comparator|Experimental|"Ara-C, Aclarubicin Combined PEG-G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, PEG-G-CSF 6mg subcutaneously on days 0. One course includes 28 days."
2478655|NCT03045627|Active Comparator|Active comparator|"Ara-C, Aclarubicin Combined G-CSF~ARA-C subcutaneously in a 12-hour infusion on days 1 through 14, Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8, G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14. G-CSF was postponed or interrupted in case of white blood cell (WBC) count greater than 20 × 109/L .~One course includes 28 days."
3193022|NCT00814359|Active Comparator|Benzydamine HCl|
3193023|NCT00814372|Experimental|MBX-102 400|
2478798|NCT03044587|Experimental|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI [Irinotecan liposome], 5-FU [5-Fluorouracil], Leucovorin Cycle q2w
2478803|NCT03044587|Other|Arm Cisplatin + Gemcitabine (Arm B, standard of care)|Cisplatin, Gemcitabine Cycle q3w
2478859|NCT03044301|Other|BMI < 25kg/m²|Subcutaneous high ZENEO® injection Intramuscular ZENEO® injection
2478869|NCT03044301|Other|27.5 > BMI > 25 kg/m²|Intramuscular ZENEO® injection
2478870|NCT03044301|Other|BMI > 27.5 kg/m²|Intramuscular ZENEO® injection
2478879|NCT03044301|Other|No special BMI|Subcutaneous low ZENEO® injection
2478923|NCT03043781|Experimental|Intermittent epidural bolus (IEB)|Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
2478928|NCT03043781|Active Comparator|Continuous epidural infusion (CEI)|Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
2478995|NCT03043469||Healthy participants|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2479000|NCT03043469||Restrictive lung disease group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2479006|NCT03043469||Primary dysfunctional Breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2479009|NCT03043469||Secondary dysfunctional breathing group|"Day 1: Hospital assessments (~3 hours): Demographic data, Manual Assessment of Respiratory Motion, Slow-breathing task, Six-minute exercise test, Indirect calorimetry, Oxygen saturation monitoring, heart rate variability analysis, continuous measurement of arterial blood pressure, lung function test, the Nijmegen Questionnaire and the Self-Evaluation of Breathing Questionnaire, the Hospital anxiety and depression scale, Asthma Control Questionnaire, and the Short-Form Survey Instrument, Breath-hold test, Lung function test, respiratory muscle function assessment.~Days 2-8: Physical Activity Monitoring"
2479150|NCT03042351|Other|Unique arm|Magic Kegel app
2479160|NCT03041883|Experimental|Kpro with crosslinked graft-support|Patient will receive a crosslinked corneal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then one drop of riboflavin 0.1%/dextran 20% will be applied to 3 minutes on the de-epithelialized cornea for 15 minutes. Then, the source of ultraviolet A (UVA) will be irradiating the cornea for 30 minutes with a wavelength of 370 nanometer(nm) length with 5.4 joules(J)/ square centimeter (cm2) and 3 milliwatts(mW)/cm2. Meanwhile, the instillation of a drop of 0.1% riboflavin/dextran 20% continues every 5 minutes. Goggles against UVA are mandatory. The crosslinked graft-support will be forwarded to the surgeon according to standard procedure.
3193024|NCT00814372|Experimental|MBX-102 600|
3193025|NCT00814372|Placebo Comparator|Placebo|
3193026|NCT00814372|Active Comparator|Actos|30-45 mg
3193027|NCT00814385|Active Comparator|Vaccine arm 1|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3158503|NCT00387634|Active Comparator|Arm 4|Blood draw only, no vaccine
3158504|NCT00387686|Experimental|A|1.0 mg/mL rhBMP-2/CPM + surgical fixation
3158505|NCT00387686|Experimental|B|2.0 mg/mL rhBMP-2/CPM + surgical fixation
2478483|NCT03046914|Experimental|HLA-B*5801 screen test|An arm in which a participant takes HLA-B*5801 test before administration of allopurinol
2478532|NCT03046615||EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that is commonly used for recording.
2478535|NCT03046615||Standard Needles|The current solution to monitor eye movement during surgery is to place standard needles in the muscles surrounding the eye.
2478559|NCT03046147||RYGB patients with preoperative type diabetes|Recruited from a previously investigated cohort (NCT 01202526)
2478561|NCT03046147||RYGB patients with preoperative normal glucose tolerance|Recruited from a previously investigated cohort (NCT 01202526)
2478620|NCT03045900|Active Comparator|Translucent bulk-fill resin composite|*Shaded bulk-fill resin composite. Bulk-fill resin composite which has no shade and could match any other shade. It will be compared for shade accuracy to the haded bulk-fill resin composite.
2478622|NCT03045900|Experimental|Shaded bulk-fill resin composite|*Translucent bulk-fill resin composite Bulk-fill resin composite which has a specific shade and should only be filled in teeth with the corresponding shade
2478711|NCT03045380|Experimental|Game based rehabilitation|Game based rehabilitation will be administered once a week for 8 weeks.
2478716|NCT03045380|Active Comparator|Conventional rehabilitation|Conventional physiotherapy program will be administered once a week for 8 weeks.
2478720|NCT03045380|No Intervention|No intervention|Waitlist
3158506|NCT00387686|Active Comparator|C|Buffer/CPM + surgical fixation Intervention
3158507|NCT00387686|Other|D|Standard of Care: Surgical fixation intervention
3158508|NCT00387738|Experimental|1|TOLAMBA™ dose-intense regimen
3158509|NCT00387738|Experimental|2|TOLAMBA™ lower-dose regimen
3158510|NCT00387738|Placebo Comparator|3|
3158511|NCT00387855|Experimental|1|receive SOS program
3158512|NCT00387868|Other|Registration|Cisplatin, Etoposide & concurrent radiotherapy
3158513|NCT00387868|Other|Surgical Resection|No distant Progression post Registration Arm
2478790|NCT03044600||Young MEN1 Negative Group|Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
2478871|NCT03044041|Experimental|Low dose|single dose of intra-articular Tranexamic acid 500 miligrams
2478878|NCT03044041|Active Comparator|High dose|Single dose of intra-articular Tranexamic acid 3 grams
2478901|NCT03043794|Experimental|SBRT to the breast then surgery|Stereotactic Body Radiation of 21 gy followed by standard of care surgery
2478943|NCT03043625|Experimental|Visceral manipulation Group (VMG)|The VMG wil be treated with visceral manipulation to the stomach and liver
2478945|NCT03043625|Placebo Comparator|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
3158514|NCT00387868|Other|Post Resection|Assessment post surgical procedure to determine if at higher risk of recurrence or if complete resection could not be achieved.
3158515|NCT00387907|Experimental|Larotaxel + Trastuzumab|
2479492|NCT03039842|Experimental|30 mg DM|30mg dextromethorphan+valproate
3158516|NCT00387920|Experimental|Treatment (enzyme inhibitor therapy)|"PART A: Patients receive oral sunitinib malate once daily on days 1-28 days. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive sunitinib malate capsule contents sprinkled over applesauce or yogurt once daily on days 1-28. Treatment repeats every 42 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. After the first course, patients may switch to capsule formulation for convenience."
3158517|NCT00387933|Experimental|Gleevec + PTK787/ZK 22584 + Hydroxyurea|Patients with recurrent or relapsing glioblastoma multiforme (GBM) will be given daily doses of Gleevec and PTK787/ZK 22584 orally in combination with fixed doses of hydroxyurea.
3158518|NCT00387998|Experimental|Risk primer|"Booklet written by investigators know your chances"
3158519|NCT00387998|Active Comparator|Control booklet|AHRQ staying healthy booklet
3158520|NCT00388011|Experimental|1|Intranasal morphine 3.75 mg
3158521|NCT00388011|Experimental|2|Intranasal morphine 7.5 mg
3158522|NCT00388011|Experimental|3|Intranasal morphine 15 mg
3158523|NCT00388011|Experimental|4|Intranasal morphine 30 mg
3158524|NCT00388011|Active Comparator|5|Intravenous morphine 7.5 mg
3158525|NCT00388011|Placebo Comparator|6|Intranasal placebo
3158526|NCT00388024||cancer patients about to be treated with radiation therapy|Patienta with histologically confirmed squamous cell or lymphoepithelioma of oral cavity, oropharynx, hypopharynx, larynx, nasopharynx, or unknown primary of the head and neck about to be treated with radiation therapy
3158527|NCT00388050|Experimental|Diabetes Medication Choice decision aid|Patients in this arm will discuss diabetes medication for glucose control with the help of a decision aid that covers five commonly prescribed anti-hyperglycemic medications.
3158528|NCT00388050|Other|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
3158529|NCT00388076|Experimental|Part 1|pazopanib and paclitaxel
3158530|NCT00388076|Experimental|Part 2|pazopanib, paclitaxel, and carboplatin
3158531|NCT00388076|Experimental|Part 3|pazopanib, paclitaxel, and lapatinib
3158532|NCT00388115|Experimental|RFA prior to surgery|
3158533|NCT00388128|Placebo Comparator|A|
3158534|NCT00388141|Experimental|NIDCAP|In the intervention NIDCAP group the staff has been introduced and trained in the principles of the NIDCAP-care, where main core is to see, organize and conduct the care of the preterm infant on behalf of the childs actually resources and competences
3158535|NCT00388167||1|Caspofungin
3158536|NCT00388193|Experimental|1|
3158537|NCT00388271|Active Comparator|1|xatral
3158538|NCT00388271|Placebo Comparator|2|standard treatment
2478439|NCT03047278|Active Comparator|Control Group|Adult patients (18 - 59 years old) with neuropathic pain of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting (phase I). To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10). In phase II, after 15 days (wash-out) from phase I, cetirizine hydrochloride (10 mg) was administered orally, twice a day, as pills, for five days. On the last day of cetirizine treatment, an oral single dose of gabapentin (300 mg), as capsule, was administered. Serial blood and urine samples were collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling.
2478440|NCT03047278|Experimental|Controlled Diabetes Group|Adult patients (18 - 59 years old) with controlled type 2 diabetes (glycated hemoglobin ≤ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
2478441|NCT03047278|Experimental|Uncontrolled Diabetes Group|Adult patients (18 - 59 years old) with uncontrolled type 2 diabetes (glycated hemoglobin ≥ 8.0%) and diabetic neuropathy of score ≥ 4 that do not use gabapentin were recruited. All patients received oral single dose of gabapentin (300 mg) as capsules after 12 hour-fasting. To investigate GBP pharmacokinetics, blood samples were collected in heparinized tubes up to 36 hours after GBP administration. The urine of the patients was collected up to 36 hours after GBP administration. The intensity of pain was evaluated in each time of blood sampling through the visual analog scale (0-10).
2478497|NCT03046875|Experimental|Transcutaneous Spinal Cord Stimulation|Subjects will participate in a single session of Transcutaneous Spinal Cord Stimulation, involving 30 minutes of stimulation with isokinetic strength testing of knee extension.
2478498|NCT03046875|Sham Comparator|Sham|Subjects will participate in a single session of isokinetic strength testing of knee extension with sham stimulation.
2478613|NCT03045939|Other|12 hours|This arm is the standard management that includes insertion of the DBD into the cervical canal according to manufacture guidelines, removal after 12 hours followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
2478617|NCT03045939|Active Comparator|6 hours|Removal of the DBD after 6 hours, followed by artificial rupture of membranes and oxytocin infusion according to departments protocol. (a total of 10 units of oxytocin is infused, initiated with 10 cc/h, increased by 10cc every 20-30 min until 3-5 contractions are present, total of not more than 120 cc\h)
2478670|NCT03045588|Experimental|Low group|This subjects in this group conducts all their morning exercise sessions with high fat oxidation (in a fasted condition). Thus, the subjects in this group after high intensity exercise in the evening do not get any carbohydrates to eat after training until the exercise session the following morning has been conducted.
2478674|NCT03045588|Active Comparator|High group|This subjects in this group conducts all their morning exercise sessions with low fat oxidation (in a fed condition). Thus, the subjects in this group after high intensity exercise in the evening do get carbohydrates to eat after training until the exercise session the following morning has been conducted.
2478726|NCT03045237|Experimental|Intervention Group|The program consists in 3 physical exercise classes, one of them in the pool.
2478729|NCT03045237|No Intervention|Control Group|The control group has the basic information through health professionals.
2478772|NCT03044912|Experimental|treatment group|Mirabegron 50 mg for comparison
2478773|NCT03044912|Active Comparator|Comparative group|Patient take Mirabegron 25 mg
2478819|NCT03044522|No Intervention|No Nurse Education|Subjects who are enrolled into study arm with no Nurse Pain Educator will be monitored every month to assess their use of their medication, quality of life, physical and mental well-being. No intervention will be conducted with these subjects beyond that of standard of care at the facility.
2478821|NCT03044522|Other|Nurse Education|Subject enrolled into the Nurse Pain Educator arm will be educated (Opioid Education) on different opioid pain management topics with a focus on safe and appropriate use and consumption of opioid analgesics.
2478915|NCT03043989|Active Comparator|Docetaxel and clarithromycin combination|"Docetaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
2478919|NCT03043989|Active Comparator|Cabazitaxel and clarithromycin combination|"Cabazitaxel will be administered by intravenous infusion over 1 hour every 3 weeks on day 1 of each (3 week) cycle for a total of 18 weeks.~Clarithromycin will be administered orally at 500mg twice a day for 3 days per cycle on days -1, 1, and 2."
2478977|NCT03043391|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO is an altered form of the live polio vaccine. It was produced by removing a piece of the virus and replacing it with a piece from a common cold virus. This was done to make sure PVSRIPO cannot cause polio even when injected into the brain.
2479020|NCT03043157|Other|Dose-finding group|The first patient will receive rocuronium 0,6mg/kg. After that, every patient's dose will depend on the outcome of the previous patient. It will go up 0,1mg/kg if the laparoscopic conditions were not excellent or go down 0,1mg/kg otherwise.
2479042|NCT03042897|Experimental|Supportive Care (exercise and diet)|Patients undergo aerobic exercise thrice weekly over 95 minutes for up to 16 weeks. Patients also undergo multi-lifestyle interventions based on the DASH diet once weekly over 1 hour for up to 16 weeks.
2479088|NCT03042546|Active Comparator|Calcium Sulphate|
2479091|NCT03042546|Active Comparator|PMMA|
2479092|NCT03042546|Active Comparator|Nothing|
3193028|NCT00814385|Active Comparator|Vaccine arm 2|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
2479298|NCT03041337||cardio-respiratory diseases|patients with any possible cardiovascular and respiratory condition. They will underwent stress echocardiography.
2478510|NCT03046771|No Intervention|Routine Care|Providers randomized to routine care will not be trained on the FHA or DCA or the completion of the checklists. All EMTs in both groups (Transport Plus and standard education), will be asked to answer some demographic questions and will be trained to collect responses to 3questions commonly used to assess a patient's risk of falling and to collect best contact information for phone follow up from patients or their caregivers and to obtain permission for a follow-up phone call from research personnel.
2478582|NCT03046303|Experimental|ERAS group|Patients were admitted 1-3 days prior to their respective dates of operation. A ERAS protocol was used in the ERAS group.
2478585|NCT03046303|No Intervention|conventional pathway group|The conventional pathway group received conventional care.
3193029|NCT00814385|Active Comparator|Vaccine arm 3|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3193030|NCT00814385|Active Comparator|Vaccine arm 4|Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3193031|NCT00814385|Active Comparator|Vaccine arm 5|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
3193032|NCT00814385|Active Comparator|vaccine arm 6|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
2478800|NCT03044613|Experimental|Arm A|Nivolumab 240mg administered IV over 30 minutes every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation
2478807|NCT03044613|Experimental|Arm B|Nivolumab 240mg administered IV over 30 minutes followed by relatlimab 80mg administered IV over 60 minutes on Day 1 every 2 weeks for 2 cycles and then standard of care chemoradiation (weekly carboplatin/paclitaxel and concurrent radiation).
2478884|NCT03044080|Active Comparator|IncobotulinumtoxinA|Injection of 200-300 units of IncobotulinumtoxinA (Xeomin ®)
2478886|NCT03044080|Active Comparator|OnabotulinumtoxinA|Injection of 200-300 units of onabotulinumtoxiA (Botox®)
2479012|NCT03043495|Active Comparator|Group A|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 0.5ml (2mg) Dexamethasone, 1.5ml Normal saline.
2479015|NCT03043495|Active Comparator|Group B|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 1ml (4mg) Dexamethasone, 1ml Normal saline.
2479016|NCT03043495|Active Comparator|Group C|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml (8mg) Dexamethasone.
2479017|NCT03043495|Active Comparator|Group Control|N-12 Ultrasound guided supraclavicular brachial plexus block will be preformed using a total volume solution of 20ml: 18ml Bupivacaine 0.5%, 2ml Normal saline.
2479078|NCT03042871|Active Comparator|Group A|Group A included 30 patients treated with one 0.5mg intravitreal ranibizumab injection. All patients were followed monthly for 12 months with additional injections performed as needed.
2479080|NCT03042871|Active Comparator|Group B|Group B included 30 patients treated with three monthly 0.5mg intravitreal ranibizumab injections. All patients were followed monthly for 12 months with additional injections performed as needed.
2479128|NCT03042416|Experimental|18F-DOPA scan|18F-DOPA (4 MBq/kg, minimum 110 MBq, maximum 600 MBq) intravenous. Single-dose 20-80 minutes prior to PET/CT scan of brain or whole body (depending on specific imaging protocol for patient).
2479158|NCT03042078|Experimental|Zero-fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX and without the use of fluoroscopy.
2479159|NCT03042078|Active Comparator|Conventional fluoroscopic ablation|Paroxysmal supraventricular tachycardia will be ablated under the guidance of Ensite NavX plus fluoroscopy.
2479201|NCT03041779|Active Comparator|Paracetamol|Paracetamol 500Mg Suppository
2479202|NCT03041779|Active Comparator|Voltaren|Diclofenac Sodium 50Mg Suppository
2479250|NCT03041506|Active Comparator|Sedation|"Analgesia and sedation through IV medication for pain relief will be administered to the patient.~Midazolam: up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 second).~Ketamine: up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds)."
2479252|NCT03041506|Experimental|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15-20 ml."
3193033|NCT00814385|Active Comparator|Vaccine arm 7|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
3193034|NCT00814385|Active Comparator|Vaccine arm 8|Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
2479453|NCT03040349|Experimental|TiTAN Intervention|The TiTAN Crete program has adapted the existing curricula and resources originally developed at the University of Ottawa Heart Institute and which are specific to primary practice settings. To facilitate maximum uptake the intervention program was adapted to reflect: language; cultural appropriateness; local patient beliefs and attitudes regarding tobacco-use and cessation; local social and clinical norms; provider perceptions surrounding 5As delivery; and, practice characteristics. The TiTAN multi-component training includes: 1) a 1-day foundational tobacco treatment training program for general practitioners, 2) the dissemination of provider and patient tools, and 3) E-blasts and webinars to supplement skills development and continuing medical education through e-learning.
3193035|NCT00814385|Active Comparator|Vaccine arm 9|No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks
3193036|NCT00814398|Experimental|SET on day 3|Single embryo transfer on day 3 of embryo development
2478699|NCT03045679|Experimental|RYGB-group|Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
2478704|NCT03045679|Experimental|OAGB/MGB-group|Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
2478771|NCT03045029||Oral treprostinil|Sustained-release oral tablets for three times daily (TID) administration in prostacyclin naive and prostacyclin transition patients
2478951|NCT03044145|Experimental|Project 1: The Cultural Formulation Interview-Engagement Aid|The first project is creating the intervention through patient and clinician feedback at JHMC and expert consensus with the K23 mentoring team. The CFI-EA is a list of questions that clinicians can use to customize patient treatment plans based on a cultural competence assessment.
2478952|NCT03044145|Experimental|Project 2: The Cultural Formulation Interview-Engagement Aid|In this arm the study team will test the revised CFI-EA against treatment as usual in a pilot trial.
2478954|NCT03044145|Active Comparator|Project 2: Treatment as usual|Treatment as usual at JHMC consists of clinicians creating treatment plans for patients without any specific training in medical communication or treatment negotiation.
2478999|NCT03043235||African American Females|No intervention
2479002|NCT03043235||African American Males|No intervention
2479004|NCT03043235||Caucasian Females|No intervention
2479010|NCT03043235||Caucasian Males|No intervention
2479055|NCT03043066|Placebo Comparator|Group A -control group|15 subjects underwent scaling and root planing
2479062|NCT03043066|Active Comparator|Group B-Interventional group|15 subjects underwent scaling and root planing along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
2479086|NCT03042520||IFN-based therapy historical controls|Patients who had ever participated the parent studies, GS-US-334-0115 or GS-US-337-0131, will be invited to participate the current study in outpatient clinic. For the patients who have participated study will be invited to participate the current study as matched historical control n our outpatient clinic,
2479087|NCT03042520||Sofosbuvir-based therapy observational group|"Patients ≥ 20 of years who had ever participated in parent studies, GS-US-337-0131 (NCT02021656) or GS-US-334-0115 (NCT02021643)~Patients who had received at least one dose of sofosbuvir-based therapy in the parent studies.~Who IFN-based therapy historical controls, matched with sex, age, level of liver fibrosis and virological response:~Patients ≥ 20 of years who had received peginterferon plus ribavirin therapy with match of sex, age, level of liver fibrosis and virological response~Patients who have ever participated study will be collected as historical control."
2479156|NCT03042065|Experimental|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
2479157|NCT03042065|Active Comparator|jet nebulizer|Receive, in the same aerosol solution, 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using a jet nebulizer
2479223|NCT03041545||Fitbit|All participants will be asked to wear the Fitbit as much as possible and to sync it at least once a week, from one week prior to start of chemotherapy treatment to six months after ending chemotherapy.
2479301|NCT03041363|Experimental|Triheptanoin|Dose 1 C7 administered as 40% daily caloric intake. Dose 2. C7 administered as 45% daily caloric intake.
2479347|NCT03040791|Experimental|Nivolumab|All patients will receive Nivolumab 240 mg every 14 days until progression or unacceptable toxicity
3193037|NCT00814398|Experimental|DET on day 3|Double embryo transfer on day 3 of embryo development
2479476|NCT03039855|Experimental|Treatment|Transcatheter mitral valve replacement with the TIARA valve and transapical delivery system
2479533|NCT03039374||OASI patients|All patients older than 18 and a 3rd or 4th degree perineal tear during birth meet the inclusion criteria. All women who have obtained such a injury during birth in the Vaasa or Seinäjoki Central hospitals will be evaluated for eligibility.
3193038|NCT00814398|Experimental|SET on day 5|Single embryo transfer on day 5 of embryo development
3193039|NCT00814398|Experimental|DET on day 5|Double embryo transfer on day 5 of embryo development
3193040|NCT00814411|Experimental|Group Counseling|Group family planning counseling
2479875|NCT03037359||Bivigam|Patients with primary immunodeficiency disease treated with Bivigam™
3193041|NCT00814411|Active Comparator|Individual Counseling|Individual family planning counseling with gynecological patients who have unmet need
3193042|NCT00814424|Active Comparator|1|ERCP patients monitored using currently marketed smart biteblock o2
3193043|NCT00814424|Experimental|2|ERCP patients monitored using experimental biteblock delivering up to 10 lit/min oxygen
3193044|NCT00814437||Donors|Oocyte donor
3193045|NCT00814476|Active Comparator|2|Regular treated group in the first segment and CareLink treated group in the second segment
3193046|NCT00814476|Experimental|1. CareLink team supported group|CareLink team supported group
3193047|NCT00814515|Active Comparator|1|Ciclosporin 0.1%
3193048|NCT00814515|Placebo Comparator|2|Vehicle
3193049|NCT00814528|Experimental|1|"Application of 5-ALA PDT to some lesions on skin with Blue U light source (417 nm)."
3193050|NCT00814528|Experimental|2|5-FU, Imiquimod or treatment with cryotherapy to lesions on the skin.
3193051|NCT00814541|Experimental|1|Relapsed patients, previously treated with VAD or VAD like regimen (VAMP, C-VAMP and Z-Dex are examples of VAD like therapy) and who have had autologous transplants at least 1 year previously.Patients may proceed directly to PAD therapy or have had a maximum of one other line of therapy before PAD.
3193052|NCT00814541|Experimental|2|Relapsed patients, previously treated with VAD or VAD-like regimen who have not had autologous transplantation and achieved at least PR (Appendix A). Patients may proceed directly to PAD therapy or have had a maximum of two other lines of therapy before PAD.
2478555|NCT03046368|Experimental|Targeted cover letter 2|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and contact to family and friends."
2478556|NCT03046368|Experimental|Targeted cover letter 3|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, alcohol and sex"
2478557|NCT03046368|Experimental|Targeted cover letter 4|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and contact to family and friends."
2478558|NCT03046368|Experimental|Targeted cover letter 5|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sleep problems and sex."
2478560|NCT03046368|Experimental|Targeted cover letter 6|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as stress, sex and contact to family and friends."
2478562|NCT03046368|Experimental|Targeted cover letter 7|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and contact to family and friends."
2478563|NCT03046368|Experimental|Targeted cover letter 8|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, sleep problems and alcohol."
2478564|NCT03046368|Experimental|Targeted cover letter 9|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as sex, alcohol and contact to family and friends."
2478566|NCT03046368|Experimental|Targeted cover letter 10|"This group will receive a cover letter to the survey including the paragraph:~You have been randomly selected to participate in a survey of well-being, health and disease among adolescents and adults in Denmark. The questionnaire will address themes such as alcohol, sleep problem and contact to family and friends."
2478631|NCT03045848||Biofreedom drug-coated stent|Subject implanted Biofreedom DCS for coronary artery disease
2478738|NCT03045393|Experimental|Mirvetuximab Soravtansine|Participants will receive 2 doses of Mirvetuximab Soravtansine after neoadjuvant chemotherapy and before surgical resection of tumor.
2478799|NCT03044808|Experimental|Lidocain|Patient gets the experimental treatment with IV lidocain 0,5mg/ml, 1,5mg/kg bolus before induction of anesthesia, after that infusion of 1,5mg/kg/h is started and continued until 2 hours after end of surgery.
2478806|NCT03044808|Placebo Comparator|Control|Patients get the same amount in ml and duration as if it was the experimental arm. Only in this arm it is isotonic saline instead.
3193053|NCT00814541|Experimental|3|Patients refractory (MR, NC or PD) to VAD or VAD-like therapy. Patients should proceed directly to PAD therapy. Patients with NC or PD may proceed to PAD after a minimum of two cycles of VAD or VAD-like therapy or a minimum of 4 cycles, if MR.
3193054|NCT00814554|No Intervention|control|no intervention was carried out in high school
3193055|NCT00814554|Experimental|Educational strategy|Educational strategy was carried out in high school.
3193056|NCT00814554|Experimental|Screening strategy|Screening strategy was carried out in high school.
2479129|NCT03042390||DArunavir/cobicistat|Patients starting treatment with a regimen containing Darunavir / cobicistat for at least 24 weeks
2479166|NCT03041922||Healthy group|Every participant passes one ultrasound exam for soft tissues in buttocks in order to measure the elasticity of soft tissues in sitting and lying down positions. This kind of exam may help to predict a development in pressure ulcers
3193057|NCT00814554|Experimental|Environmental strategy|Environmental strategy was carried out in high school.
3193058|NCT00814554|Experimental|Educational and Screening strategies|Educational strategy and Screening strategy were carried out in high school
3193059|NCT00814554|Experimental|Screening and Environmental strategies|Screening strategy and Environmental strategy were carried out in high school
3193060|NCT00814554|Experimental|Educational and Environmental strategies|Educational strategy and Environmental strategy were carried out in high school
3193061|NCT00814554|Experimental|the three strategies|Educational strategy, Screening strategy and Environmental strategy were carried out in high school.
3193062|NCT00814567|Active Comparator|Arm I (control)|Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.
3193063|NCT00814567|Experimental|Arm II|Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
3193064|NCT00814567|Experimental|Arm III|Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.
3193065|NCT00814593|Experimental|Arm I|Patients undergo intracranial placement of polifeprosan 20 with carmustine implant (Gliadel® wafer) at the time of therapeutic craniotomy.
3193066|NCT00814593|Experimental|Arm II|Patients undergo leukapheresis to obtain autologous lymphokine-activated killer (LAK) cells, followed 3-7 days later by therapeutic craniotomy. The autologous LAK cells are then instilled into the tumor bed cavity at the time of therapeutic craniotomy.
3193067|NCT00814606|Experimental|Single Group|8 weeks period of escalating doses of fluvastatin to a goal dose of 80mg daily, then patients will start treatment of HCV at week 9 with the usual standard of care protocol for medication dose, office visits and laboratories. Peginterferon alfa2a 180 mcg/ml SQ injection once a week for 48 weeks and ribavirin 1000-1200 mg daily orally in two divided doses for 48 weeks. Patients weighing < 75 kg will receive 1000mg per day (400mg in the morning and 600mg in the evening). Patients weighing ≥ 75 kg will receive 1200 mg per day (600mg in the morning and 600 mg in the evening).
2478599|NCT03046108|Active Comparator|blind injection of Morton neuroma|"Percoutaneous blind injection in Morton neuroma by subcutaneous needle group 1 are going to be injected by an experimented orthopaedic surgeon based on anatomic landmark. There is no internal control of the needle placement.~Mixture of 1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2478605|NCT03046108|Active Comparator|blind injection of Mepivacaine|"1 cc of 2% mepivacaine (Mepivacaina Normon 2%® )+ 40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2478607|NCT03046108|Active Comparator|blind injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
2478608|NCT03046108|Experimental|ultrasound guided injection|US guided injection in Morton neuroma by subcutaneous needle. group 2 are going to be injected by an experimented musculoskeletal radiologist under ultrasound guidance. There is internal control of needle placement by ultrasound.
2478609|NCT03046108|Experimental|guided injection of mepivacaine|"2% mepivacaine (Mepivacaina Normon 2%® ) in each of the web spaces affected with Morton neuroma is injected.~Up to 4 injections are allow in the first three months of follow-up"
2478610|NCT03046108|Experimental|guided injection of Triamcinolone|40 mg of triamcinolone (Trigon Depot®) in each of the web spaces affected with Morton neuroma is injected. Up to 4 injections are allow in the first three months of follow-up
2478690|NCT03045315|Experimental|women included in a IVF program|
2478723|NCT03045146||Multimodal brain imaging|Consecutive patients experiencing an acute ischemic stroke treated by thrombectomy according to the current recommendations. Clinical outcome will be compared according to the baseline imaging profile processed after patient treatment.
2478828|NCT03044938|Experimental|Salbutamol|Salbutamol is a bronchodilator that relaxes the muscles of the airways and increases the flow of air to the lungs. With the aid of a spacer, 400mcg of the drug will be administered once during the protocol.
2478831|NCT03044938|Placebo Comparator|Placebo|Inoculant treatment through a substance that does not have an inherent power to produce an effect that is desired or expected. Four placebo puffs will be offered through a device similar to the salbutamol intervention device.
2478863|NCT03044132|Experimental|DermACELL AWM|Human acellular dermal matrix (ADM) recovered from human donors, decellularized, provided with at least 97% DNA removal, terminally sterilized in its final package, and ready to use.
2478912|NCT03043898||Part A(i) Healthy Volunteers|50 healthy volunteers. Intervention: Lung sound recording for part A(i) of the study.
2478918|NCT03043898||Part A(ii) Patients|100 patients with wheezing and/or crackles due to respiratory disease. Intervention: Lung sound recording for part A(ii) of the study.
2478920|NCT03043898||Part B(i) 'normal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having a 'normal' lung structure.~Intervention: Lung sound transmission measurement for part B(i) of the study."
2478925|NCT03043898||Part B(ii) 'abnormal' lung structure|"25 patients who are scheduled to have a Bronchoscopy as part of their standard care and are identified by a medical professional as having an 'abnormal' lung structure.~Intervention: Lung sound transmission measurement for part B(ii) of the study."
2478992|NCT03043456|Active Comparator|Thermoplastic Resin group|Thermoplastic complete denture placement is done (Thermoplastic Comfort Systems, inc.)
2478997|NCT03043456|Placebo Comparator|conventional acrylic resin group|Conventional acrylic resin complete denture placement is done. (Acrostone, inc.)
2479051|NCT03043001|Other|add-on memantine therapy|add-on memantine treatment
2479115|NCT03042624|Experimental|Fermented rice|7 g of fermented rice flour powder obtained from Lactobacillus paracasei CBA L74 to be diluted in milk or water
2479118|NCT03042624|Placebo Comparator|Maltodextrins|7 g of maltodextrins powder to be diluted in milk or water
2479196|NCT03042104|Experimental|TAVR|Transcatheter aortic valve replacement (TAVR)
2479198|NCT03042104|No Intervention|CS|Clinical surveillance (CS)
2479302|NCT03040999|Experimental|Pembrolizumab + Cisplatin + CRT|Participants receive a priming dose of pembrolizumab before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of pembrolizumab and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of pembrolizumab alone as maintenance therapy for a total of 17 cycles of pembrolizumab. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with pembrolizumab.
2479306|NCT03040999|Placebo Comparator|Placebo + Cisplatin + CRT|Participants receive placebo before initiation of CRT (either accelerated or standard fractionation radiotherapy regimen). During CRT, participants receive 2 doses of placebo and up to 3 cycles of Cisplatin (2 cycles during accelerated and 3 cycles during standard fractionation radiotherapy). Participants also receive up to an additional 14 cycles of placebo alone for a total of 17 cycles of placebo. If cisplatin and/or radiation therapy is discontinued, the participant may continue on treatment with placebo.
2479516|NCT03039582||Probable grad 2|Perineal laceration Probable grad 2
2479518|NCT03039582||Suspected grade 3|Perineal laceration Suspected grade 3
2479520|NCT03039582||Probable grad 3|Perineal laceration Probable grad 3
2479578|NCT03039231|Experimental|Freespira Breathing System (FBS)|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with panic disorder (PD). FBS has received FDA clearance for the treatment of PD adults and is currently commercially available with more than 150 therapist providing the treatment nationally. FBS has not yet been tested for efficacy in an adult post traumatic stress disorder (PTSD) population. It has been suggested that there is overlap in the presence and persistence of symptoms between PD and PTSD patients. The primary goal of this study is to determine whether the FBS will produce similar benefit (both in quality and magnitude) in the defined population of patients with PTSD.
2479606|NCT03038945|Experimental|2/0 barbed suture|Use barbed suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
2478632|NCT03045796||Maintenance Hemodialysis Patients|Following the initial recruitment, all individuals who are willing to participate and sign the informed consent document will be provided with a medical history form to complete. In addition, we will ask them to sign a HIPAA authorization form in order to look into their medical records for monthly blood work (blood chemistry), anthropometric data (height and weight), interdialytic weight gain (weight gain since last treatment) history, and current medications.
2478691|NCT03045536||Patients with TFR|Patients treated with TFR for oncologic or non-oncologic reason
2478715|NCT03045159|Experimental|Strong Families|parenting program
2478718|NCT03045159|Active Comparator|Strong Parents|self-care program
2478785|NCT03044951|Experimental|cryoballoon ablation|patients who accept cryoballoon ablation
2478792|NCT03044951|Active Comparator|radiofrequency ablation|patients who accept radiofrequency ablation
2478834|NCT03044366||Characteristics of Anesthesia management|Evaluate the average value of these data.
2478836|NCT03044366||Comorbidities|Evaluate the average value of these data.
2478875|NCT03044158|No Intervention|Control group|Onsite ZN or LED fluorescence microscopy + hub-based GeneXpert testing per existing protocols
2478882|NCT03044158|Experimental|Intervention|Onsite molecular testing for TB with GeneXpert I + process redesign to facilitate same-day TB diagnosis and treatment + performance feedback
2478911|NCT03043677||Non-inflamed|
2478917|NCT03043677||Inflamed ulcerative colitis|
2478921|NCT03043677||inflamed Crohn´s disease|
3193068|NCT00814619|Experimental|Arm I|Patients receive panitumumab IV over 30-90 minutes on days 1, 15, 29, 43, and 57 and oral capecitabine twice daily on days 8-40. Beginning on day 8, patients undergo daily fractions of 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning approximately 6 weeks after completion of panitumumab and chemoradiotherapy, patients undergo surgery.
3193069|NCT00814619|Active Comparator|Arm II|Patients receive oral capecitabine twice daily on days 1-33. Patients undergo concurrent 3-D conformal radiotherapy 5 days a week for 5 weeks. Beginning 6 weeks after completion of chemoradiotherapy, patients undergo surgery.
3193070|NCT00814645|Active Comparator|Dose level 1|a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization
2479089|NCT03042442||Patients with pancreatic cancer|Patients with pancreatic ductal adenocarcinoma, based on the results of an endoscopic ultrasonography (EUS) biopsy or surgery were enrolled at the diagnosis, before any therapeutic intervention.
2479090|NCT03042442||health patients (controls)|Health patients
3193071|NCT00814645|Active Comparator|Dose level 2|a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
3193072|NCT00814645|Active Comparator|Dose level 3|a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
2479238|NCT03041740|No Intervention|Usual Care (Control) Group|Control subjects will be treated as per standard of care for preterm infants with BPD.
2479243|NCT03041740|Active Comparator|Perfluorooctylbromide (PFOB) Group|Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
3193073|NCT00814645|Active Comparator|Dose level 4|a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization
2479339|NCT03040778|Experimental|Standard of Care + PENTO|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014) AND PENTO regimen consisting of 400mg pentoxifylline (PTX) and 400IU tocopherol twice-daily PO for a total of 800mg/day PTX and 800 IU/day tocopherol
2479340|NCT03040778|Placebo Comparator|Standard of Care|The current standard of care for MRONJ as outlined by the American Association of Oral and Maxillofacial Surgeons position paper based on stage of disease (Ruggiero 2014). Placebo drugs to be taken in the control group 2 pills BID.
2479367|NCT03040518|Experimental|Narrative SMS|"Participants will receive narrative SMS for 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2479371|NCT03040518|Experimental|Narrative SMS and Endowment Incentive|"Participants will receive narrative SMS for 12 months. In addition, they will receive an endowment incentive for verified weight loss.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2479378|NCT03040518|No Intervention|Waiting List Control Group|"Participants will be on a waiting list for 12 months to receive the narrative SMS which will commence after 12 month outcome data has been collected. There will be no interim measurements or contacts by the research team. Men are therefore free to choose whether to try to lose weight during the 12 months.~Participants in all three trial arms will receive information (web or print) about weight loss and a pedometer."
2479420|NCT03040258|Experimental|Intervention group- Health-E-PALS-Pilot|Group of students receiving the school-based intervention: Health-E-PALS (pilot), it consists of in class activities and lessons.
2479422|NCT03040258|No Intervention|Control group|Group of students not receiving any intervention
3193074|NCT00814645|Placebo Comparator|Expansion arm|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
3193075|NCT00814723|Active Comparator|Fluvastatin|Fluvastatin 80 mg MR
3193076|NCT00814723|Active Comparator|Fluvastatin + Ezetimibe|Fluvastatin MR 80 mg plus Ezetimibe 10 mg
2479615|NCT03038958|Active Comparator|Hyperbaric prilocaine 2%|The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy
2479650|NCT03038659||Penile Duplex|Measuring intima media thickness
2505871|NCT02860442|Placebo Comparator|Enhanced Usual Care (EUC)|
3193077|NCT00814736|Experimental|UK369,003 + Placebo or sildenafil|All subjects will receive 17 days daily dosing of UK-369,003 100 mg MR Subjects will receive single oral doses of the following interactant treatments in a randomized order On Day 14, a single dose of sildenafil-matching placebo or 100 mg sildenafil and on Day 17 a single dose of 100 mg sildenafil or a sildenafil matching placebo
3193078|NCT00814749|Active Comparator|surgical therapy|
2478643|NCT03045770|Experimental|FOLFPTX|The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.
3193079|NCT00814749|Active Comparator|individual management|
2478776|NCT03044964|Active Comparator|Ranolazine|At randomization, patients will be started on 500mg of Ranolazine, twice daily for 1 week. After 1 week, the dosage may be increased to 1000mg of Ranolazine, twice daily for 5 weeks.
2478777|NCT03044964|Placebo Comparator|Placebo|At Randomization, patients will be started on 500mg of a placebo, twice daily for 1 week. After 1 week, the dosage of the placebo may be increased to 1000mg, twice daily for 5 weeks.
2478822|NCT03044509||TB exposure|
2478824|NCT03044509||TB infection (latent TB)|
2478825|NCT03044509||TB disease (active TB)|
3193080|NCT00814762|Experimental|HIV 732462 Group|Subjects received 2 doses of the HIV Vaccine 732462 into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
3193081|NCT00814762|Placebo Comparator|Placebo Group|Subjects received 2 doses of the placebo vaccine into the deltoid muscle of the dominant arm, on a 0, 1 Month schedule.
3193082|NCT00814814||Cardiopulmonary arrest|
2478941|NCT03043638|Experimental|CAF+ADM+PRP|Surgery will include Coronally advanced flap(CAF) plus acellular dermal matrix (ADM) combined with platelet rich plasma (PRP)
2478942|NCT03043638|Active Comparator|CAF+ADM|Surgery will include only Coronally advanced flap CAF technique including ADM placement without PRP
2478970|NCT03043352|Experimental|Group A (intervention)|'Management of SAM at home' LHWs will identify and treat all cases of severe acute malnutrition (SAM) as per the study eligibility criteria (MUAC < 11.5 cm) and manage all cases of SAM without complications at home with 'Standard CMAM program'. The LHWs will also identify SAM with complications for further assessment to the BHU Doctor and subsequent referral to the stabilization center . They will also provide one to one health and Infant and Young Child Feeding (IYCF) counselling to care takers of children in their catchment area.
2478974|NCT03043352|Active Comparator|Group B (Control)|'Management of SAM at facility' LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
2479025|NCT03043131|Active Comparator|Ringer Lactate|patients randomized to this arm are given ringer's lactate solution for cardiopulmonary bypass prime, which is the standard practice
2479030|NCT03043131|Experimental|Plasmalyte A|patients randomized to this arm are given Plasma Lyte - A solution for cardiopulmonary bypass prime
2479052|NCT03042806|Other|experimental group|COPD patients will be asked to fill in the Maugeri Physical Activity Questionnaire (MaPAct) to assess self perceived physical activity.
2479124|NCT03042611|Experimental|Apatinib|
2479127|NCT03042611|Experimental|Placebo|
2479261|NCT03041480||GROUP I|Estimation of serum lipid levels and Lp-PLA2 in generalized severe chronic periodontitis
2479262|NCT03041480||GROUP II|Estimation of serum lipid levels and Lp-PLA2 in generalized moderate chronic periodontitis
2479264|NCT03041480||GROUP III|Estimation of serum lipid levels and Lp-PLA2 in systemically and periodontally healthy controls
3193083|NCT00814840|Active Comparator|Triple-site group|Triple-site resynchronization group
3193084|NCT00814840|Active Comparator|Standard resynchronization group|Standard (double-site) resynchronization group
3193085|NCT00814853||Extubation readiness testing|Patients who pass the ERT.
3193086|NCT00814866|Other|Adalimumab|Open label
3193087|NCT00814905|Placebo Comparator|vaginal delivery 1|no further antibiotics after delivery (the patient will receive a saline infusion instead of antibiotics)
2479456|NCT03039998||HAP Patients|HAP, intubated and mechanically ventilated.
3193088|NCT00814905|Active Comparator|vaginal delivery antibotics2|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following vaginal delivery
3193089|NCT00814905|Other|cesarean delivery one dose3|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
2479574|NCT03039257|Other|Vitamin A|Participants receive single dose vitamin A supplementation prior to HSCT. A 3x3 dose escalation/de-escalation design will be used for this study.
2479617|NCT03038971|Other|Concentration 1: Short and Tall Ragweed Mix|
2479623|NCT03038971|Other|Concentration 2: Short and Tall Ragweed Mix|
2479627|NCT03038971|Other|Placebo: Saline with 0.4% Phenol|
3193090|NCT00814905|Other|cesarean multiple antibiotics 4|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
3193091|NCT00814918|Experimental|1|5-ALA Application and exposure using Blu-U light to 1/2 of face.
3193092|NCT00814918|Experimental|2|5-ALA Application and exposure using Candela V-beam Pulse Dye Laser to 1/2 of face.
3193093|NCT00814931|Experimental|1|Treatment Group
3193094|NCT00814931|Placebo Comparator|2|
3193095|NCT00814944|Experimental|Dose Group 1|
3193096|NCT00814944|Experimental|Dose Group 2|
3193097|NCT00814944|Experimental|Dose Group 3|
3193098|NCT00814944|Placebo Comparator|Dose Group 4|
3193099|NCT00814957|Experimental|Open-label|D3 receptor antagonist
3193100|NCT00814996||1: employment|
3193101|NCT00814996||2: unemployment|
3193102|NCT00815009|No Intervention|A (Std of Care)|Standard of Care/Control, including Lifestyle Advice (attend a basic healthy nutrition class as well as follow up appointments with GI MD).
3193103|NCT00815009|Experimental|B (Low Fat)|Standard of Care, plus Low Fat Diet and Moderate Exercise
3193104|NCT00815009|Experimental|C (Mod Fat)|Standard of Care, plus Moderate Fat/Low Processed Carbohydrate Diet and Moderate Exercise
2478846|NCT03044340|Experimental|erythermalgia patient|patient will be measured chlorine ions impedance with the SUDOSCAN and evaluation on pain du to temperature with the THERMOTEST
2478873|NCT03044093|Active Comparator|MISOPROSTOL alone|the common practice currently in our medical center for second trimester medical abortion/ Placebo
2478881|NCT03044093|Experimental|Mifepristone and Misoprostol|"in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.~Mifepristone"
2478933|NCT03043768||PD patients|Male and female PD patients (idiopathic parkinsonism, Hoehn and Yahr [H&Y] scores 1-2) aged 35 to 80 years
2478936|NCT03043768||Control subjects|Age-and gender matched healthy control subjects
3158539|NCT00388310|Active Comparator|Cephalexin|Cephalexin 250 mg PO q6h x5 days
2479049|NCT03042832|Experimental|LOCI|Leadership development with coaching and organizational change support
2479057|NCT03042832|Active Comparator|Internet Based Training|Internet based Webinar leadership training
2479120|NCT03042585|Experimental|Dose Level 1|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.64 Gy per Fraction for a total of 8 Fractions. The total amount would be 13.12 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2479122|NCT03042585|Experimental|Dose Level 2|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.76 Gy per Fraction for a total of 8 Fractions. The total amount would be 14.08 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2479125|NCT03042585|Experimental|Dose Level 3|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 1.88 Gy per Fraction for a total of 8 Fractions. The total amount would be 15.04 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2479126|NCT03042585|Experimental|Dose Level 4|The participants will receive Palifermin on Day -10, -9 and -8. Total Body Irradiation 2.00 Gy per Fraction for a total of 8 Fractions. The total amount would be 16 Gy. The participants will receive total body irradiation twice a day for four days (Day -7, -6, -5, and Day -4). Over the following two days, the participants will receive cyclophosphamide (Day -3 and -2). The participants will receive stem cell infusion on Day 0 and G-CSF given daily until engraftment occurs. Participants will receive Palifermin on Day 0, +1 and +2.
2479195|NCT03042052||Patients suffering from NDO managed with Botox|"Doses used were 300 units Botox® from January 2001 to January 2011 and 200 units after 2011~Frequency depended on patient's symptoms~Duration was an outcome of the study"
2479216|NCT03041597|Experimental|Immediate loading|
2479222|NCT03041597|Active Comparator|delayed loading|
2479270|NCT03041246|Experimental|Study group - Treatment with PFFM|Manual treatment for the pelvic floor will be provided in two sessions two weeks apart as long as guidance towards exercise for strengthening of the pelvic floor
2479271|NCT03041246|No Intervention|Control group -|Guidance towards exercise for strengthening of the pelvic floor with no other interventional treatment.
2479309|NCT03041012|Placebo Comparator|antiretrovirals|Standard of care
2479310|NCT03041012|Active Comparator|antiretrovirals + romidepsin|Standard of care + LRA
2479311|NCT03041012|Active Comparator|antiretrovirals + 3BNC117|Standard of care + bNAb
2479312|NCT03041012|Active Comparator|antiretrovirals + romidepsin + 3BNC117|Standard of care + LRA + bNAb
2479383|NCT03040648|Experimental|cervical TFEB under DSA|cervical TFEB was performed under DSA
2479385|NCT03040648|Active Comparator|TFEB under RTF|cervical TFEB was performed under RTF
2479438|NCT03040271|Experimental|Intervention group- Health-E-PALS|Group of students receiving the school-based intervention: Health-E-PALS, it consists of in class activities and lessons.
2479443|NCT03040271|No Intervention|Control group|Group of students not receiving any intervention
2479501|NCT03039894||Intervention|The middle school selected 2 advisory classrooms to participate in the Gradebook game during 6th grade. Students in these 2 classrooms were block randomized to teams by baseline grade book and student engagement scores. These small student teams stay together for an entire year and meet once or twice a week. Teams are led by 8th grade student team captains, picked by school staff for their positive leadership skills. Every 2 weeks throughout the year, teams are randomly matched in head-to-head competition. In each 2-week-long game (i.e. Gradebook Game), individual team members accrue points from teachers and administrators for academic performance, effort, and school behavior. Team wins are announced and public scoreboards are updated frequently. The investigators will collect student survey data at baseline and after the intervention, approximately 5-6 months apart.
2479547|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir cluster of differentiation (CD) 4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
3158540|NCT00388310|Active Comparator|Clindamycin|Clindamycin 300 mg PO q6h x5 days
3193105|NCT00815009|Experimental|D (Exercise only)|Standard of Care plus Moderate Exercise only
3193106|NCT00815022|Active Comparator|1|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 20 degree celsius
2478702|NCT03045549|Experimental|Experimental group|Home-based rehabilitation sessions performed with the digital biofeedback system. Patients will be instructed to perform exercise sessions at least 5 days a week, but compliance to this schedule is not mandatory.
2478706|NCT03045549|Active Comparator|Conventional rehabilitation group|Home-based rehabilitation sessions provided by a Physical Therapist, 3 times a week, each with 1h duration. Patients will be instructed to perform 2 additional unsupervised sessions per week, but compliance to these sessions is not mandatory.
2478751|NCT03045016|Experimental|Prazosin, ALPRESS® LP 2,5 et 5 mg|Patients included in this study will be adults with acute stress as a result of a direct experience traumatic event. They will be treated with Prazosin, ALPRESS® LP 2,5 et 5 mg during 28 days.
2478787|NCT03044743|Experimental|PD-1 knockout EBV-CTL|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISP-Cas9 system and EBV-CTL will be generated in the laboratory (PD-1 Knockout EBV-CTL).~Fludarabine at 30mg/m2 and Cyclophosphamide at 300mg/m2 single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout CTL will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given daily( iv) since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit（IU）/day . Patients will receive a total of four cycles of treatment."
2478877|NCT03044288|Experimental|Cohort 9|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin.~Standard adhesive strip and a strip with a newly developed adhesive (new adhesive strip)"
2478903|NCT03043846||Tight control and Treat to Target arm|For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
2478905|NCT03043846||Usual care arm|For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
3193107|NCT00815022|Experimental|2|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 10 degree celsius
3193108|NCT00815022|Experimental|3|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 15 degree celsius
3193109|NCT00815022|Experimental|4|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 25 degree celsius
2479083|NCT03042728|Active Comparator|Dog interaction|Dog interaction will be received by patients in addition to usual care of fibromyalgia.
2479085|NCT03042728|Active Comparator|Human Interaction|Human interaction will be received by patients in addition to usual care of fibromyalgia.
2479131|NCT03042325|Experimental|Alogliptin|Alogliptin 25 mg, tablets, orally, once, daily for 26 weeks in addition to standard care for the management of Type 2 Diabetes Mellitus (T2DM). Dose will be adjusted as per creatinine clearance [CrCl].
2479186|NCT03041974||Transfused critical care patients|Patients included in the Age of BLood Evaluation (ABLE) trial in either arms and included in a French center.
3193110|NCT00815022|Experimental|5|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 30 degree celsius
2479279|NCT03041155|Experimental|treatment|Muscle respiratory training
2479281|NCT03041155|No Intervention|control|No intervention
2479313|NCT03040973|Experimental|INC280|The starting dose of study treatment for patients in this protocol should be the same as the dose provided in the parent INC280 protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
2479314|NCT03040973|Experimental|INC280/EGF816|Starting dose of the study treatment for patients should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated. Dose modifications are permitted.
2479315|NCT03040973|Active Comparator|INC280/Gefitinib|The starting dose of the study treatment for patients in this protocol should be the same as the dose provided in the parent protocol at the time when the rollover protocol is initiated.
2479386|NCT03040609||Group 1|The duration of follow-up of group 1 in the study is 1 day.
2479389|NCT03040609||Group 2|The duration of follow-up of group 2 in the study is 2 weeks.
2479390|NCT03040609||Group 3|The duration of follow-up of group 3 in the study is 6 months.
2479424|NCT03040141|Experimental|VIS410 low dose|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
2479427|NCT03040141|Experimental|VIS410 high dose|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
2479431|NCT03040141|Placebo Comparator|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
2479612|NCT03039140|Experimental|Supportive care (CR program)|Patients participate in a CR program consisting of 1-hour CR intervention sessions, based on a personalized exercise prescription, 3 times per week for 14 weeks (a total of 36 sessions). Components of the exercise prescription includes intensity, mode, duration, and frequency. Intensity of exercise is guided by the results of a graded exercise stress test, RPE, heart rate, and symptoms, such as chest pain/angina or shortness of breath. If exercise is well-tolerated during CR sessions, patients are encouraged to supplement their exercise program at home, increasing their exercise frequency to up to 5 times per week. Patients may attend weekly educational sessions offered by the Phase 2 CR program which covers topics such as stress management, smoking cessation, nutrition, and weight loss.
2479649|NCT03038555||Disease group (subject to strategy)|Choose subjects that have ever got PE before as the diseases group.
2479663|NCT03038555||Control group|Pair the same age, gestational weeks, children's gender and healthy subject as a control group in the ratio of 1:1. The control group should exclude subject that have ever got heart or lung diseases, diabetes, chronic nephrosis, immune disease and other hereditary disease.
2479737|NCT03038347|Experimental|Training|In the training group, participants work six weeks on the training program, one module per week. The modules contain PDF-files with text-based information, video files, case studies with associated questions as well as practical exercises that participants perform independently. The main purpose of this intervention is the improvement of cross-cultural competencies in psychotherapists
3193111|NCT00815022|Experimental|6|Mixture of anesthetic including hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg, with the temperature of 35 degree celsius
3193112|NCT00815048|Active Comparator|Remifentanil|"Atropine~Remifentanil"
2478703|NCT03045497|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren lipid microspheres IV and then undergo contrast-enhanced ultrasound imaging over approximately 1 hour prior to transarterial chemoembolization with drug eluting beads, at 1-2 weeks and 1 month post transarterial chemoembolization with drug eluting beads. Patients also undergo contrast-enhanced MRI at 1 month post-treatment per standard of care.
2478755|NCT03045003|Other|Arm A: Low Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit.
2478757|NCT03045003|Other|Arm B: High Intensity|RESIL Intervention provided by nurses and oncologists of the outpatient oncology unit plus 5 nurse-led consultations (3 face-to-face and 2 telephone consultations)
2478887|NCT03044015|Experimental|Intervention|a defined strategy for the identification of OF. To carry out a primary care based intervention about lifestyle, diet and drug prescription, if needed, with an intensive follow-up
2478890|NCT03044015|Active Comparator|Control|Intervention as usual
2478913|NCT03043742|Experimental|Phase I Open Label|"open label bone marrow derived autologous CD133+ selected stem cell application in patients receiving trans-myocardial laser revascularization to improve regional myocardial function as detailed below:~Drug: CD133+ selected stem cells Dosage: Single injection of 0.1-0.2 ml around each laser channel Frequency: 10-20 channels Duration: Trans-Myocardial Revascularization"
2478969|NCT03043547|Experimental|Nal-IRI + 5-FU + leucovorin (Arm A)|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion), 5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
2478972|NCT03043547|Other|5-FU + leucovorin (Arm B)|Control intervention/standard arm: 5-FU (2400 mg/m2 as 46 hour infusion) and leucovorin (400 mg/m2 as 0.5 hour infusion) (q2w)
2479050|NCT03043027|Experimental|Liposomal bupivicaine|
2479056|NCT03043027|Active Comparator|bupivicaine|
2479064|NCT03043027|Placebo Comparator|saline|
3158541|NCT00388310|Active Comparator|trimethoprim/sulfamethoxazole|trimethoprim/sulfamethoxazole 160 mg/800 mg PO q12h x 5 days
2479136|NCT03042208|Experimental|Intervention|Access to Weight Watchers in-person meetings and online tools.
2479139|NCT03042208|Other|Self-Guided Control Group|Received handout with basic weight management advice.
2479165|NCT03041935|Active Comparator|Caudal-epidural nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The CE group will receive an US-confirmed CE nerve block with 0.8 mL/kg of 0.2% ropivacaine (maximum 15 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
2479167|NCT03041935|Experimental|Ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL). An additional 0.2 mL/kg of ropivacaine 0.2% (max 4mL) will be used for scrotal skin infiltration.
2479274|NCT03041129||Untreated PCOS|PCOS per NIH criteria. Obese Lifestyle treatment only.
2479275|NCT03041129||Metformin PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 1500 mg of metformin or more per day for at least 6 months.
2479276|NCT03041129||Oral Contraceptive PCOS-(Study arm not funded)|PCOS per NIH criteria. Obese Taking 30 mcg of ethanyl estradiol or more per day for at least 6 months.
2479277|NCT03041129||Obese Control group-(Study arm not funded)|Obese Regular menses at least 18 months post-menarche Females only
2479330|NCT03040895|Experimental|ICDP-intervention for caregivers|Group-based ICDP-intervention for caregivers through a sequence of eight meetings. The groups are led by facilitators trained in the ICDP.
2479332|NCT03040895|Other|Treatment as usual|Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
2479370|NCT03040661|Experimental|Figure of 8 Suture|Hemostasis after an ablation for atrial fibrillation with a figure of 8 suture.
2479375|NCT03040661|Active Comparator|Manual Hemostasis Group|Hemostasis after an ablation for atrial fibrillation with the Manual Hemostasis Technique.
3158542|NCT00388310|Placebo Comparator|Placebo|
3158543|NCT00388323|Experimental|1|
3158544|NCT00388375|No Intervention|CVC Internal Jugular or Subclavian Vein|
3158545|NCT00388388|Experimental|1|Losartan treatment
3158546|NCT00388388|Active Comparator|2|Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
3158547|NCT00388427|Other|Advanced Solid Malignancies|
3158548|NCT00388518|Active Comparator|Actos|
3158549|NCT00388518|Experimental|Aleglitazar 1|
3158550|NCT00388518|Experimental|Aleglitazar 2|
3158551|NCT00388518|Experimental|Aleglitazar 3|
2478758|NCT03044899||Adult surgical patients|All surgeries in adult patients
2478783|NCT03044626|Experimental|study group A|"Patients with metastatic non-squamous NSCLC with the necessity of radiotherapy of a metastatic site (e.g. bone) in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
2478791|NCT03044626|Other|study group B|"Patients with metastatic non-squamous NSCLC without the necessity of radiotherapy in 2nd-line or 3rd-line treatment:~Nivolumab 240 mg fixed dose (q2w)."
2478857|NCT03044236|Experimental|Novel Stretching Technique|Participants will perform the novel stretch in a supine position. Participants will place a small ball between their knees and squeeze the ball. Participants will be then bridge as high as possible . Participants will then flex their shoulder and elbow to 90°, and actively rotate to the end of ROM. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
2478865|NCT03044236|Active Comparator|Traditional Stretching Technique|Participants will perform the modified sleeper stretch in a side-lying position on the side of the throwing shoulder with the throwing shoulder and elbow flexed to 90° . The participants will be instructed to allow the throwing shoulder to naturally fall into internal rotation to the end ROM where resistance will be felt . The participants will be then instructed to use the non-throwing hand to push the throwing shoulder into further internal rotation to the point of mild discomfort by applying pressure at the area of the wrist joint.
2478935|NCT03043950||low risk|Low risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2478937|NCT03043950||medium risk|Medium risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2478940|NCT03043950||high risk|High risk according to metastatic Colorectal Cancer Prognostic Score (mCCS)
2479045|NCT03042988|Experimental|Heat Stress|Passive heat-stress using a commercial heating pad applied on the trunk
2479047|NCT03042988|Sham Comparator|Control (Non-heating)|Commercial heating pad applied on the trunk but turned off
2479099|NCT03042572|Experimental|Allogeneic Mesenchymal Stromal Cell|Intramuscular Allogeneic Bone marrow-derived Mesenchymal Stromal Cell Injection
2479103|NCT03042572|Placebo Comparator|Placebo|Intramuscular placebo injection
2479145|NCT03042195|Active Comparator|Intervention group|Supplementary parenteral nutrition
2479149|NCT03042195|No Intervention|Control group|The control group will receive standard nutritional care
2479259|NCT03041454|Experimental|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers. Participants receiving the intervention will be asked to read and answer questions using a novel systematic review format.
2479260|NCT03041454|No Intervention|Traditional systematic review format|Control participants will be asked to read and answer questions using a traditional systematic review format.
2479291|NCT03041142|Experimental|Interdisciplinary Intervention|"Children 3 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy.~Mothers~1 sessions/week 50-60 minutes of physical activity;~1 session/week 60 minutes nutrition education week;~1 session/week 120 minutes behaviour therapy."
2479294|NCT03041142|Active Comparator|Routine|Mothers and children followed their routine activities
2479344|NCT03040934|Active Comparator|Firehawk implantation|98 subjects will be enrolled to receive a test device (Firehawk™).
2479345|NCT03040934|Active Comparator|XIENCE implantation|98 subjects will be enrolled to receive a control device (XIENCE).
2479457|NCT03040063|Experimental|Combined endovascular approach|Combined endovascular approach using covered stent and flexible stent in the popliteal artery
2479461|NCT03040063|Experimental|Standard optimal therapy (OPT)|standard therapy of popliteal artery aneurysm using thrombolysis and surgery
2479616|NCT03038828|Experimental|Arm A|Cohort A - 200IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off two weeks, then repeat 200IU 5 days/week x 2 weeks.
2479621|NCT03038828|Experimental|Arm B|Arm B - 400IU Leukocyte Interleukin, Injection 5 days/week x 2 weeks, off 2 weeks, 400IU 5 days/week x 2 weeks.
2479655|NCT03038646|Experimental|Regimen A|32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state
3158552|NCT00388518|Experimental|Aleglitazar 4|
3158553|NCT00388518|Placebo Comparator|Placebo|
3158554|NCT00388544|Experimental|1|
3158555|NCT00388544|Experimental|2|
3158556|NCT00388544|Experimental|3|
3158557|NCT00388544|No Intervention|4|Recreational activities are not tailored to either style of interest or function
3158558|NCT00388557|Experimental|1|
3158559|NCT00388609|Experimental|T|5 mg (ST) to 50 mg (LT)
3158560|NCT00388609|Experimental|U|10 mg (ST) to 50 mg (LT)
3158561|NCT00388609|Experimental|V|25 mg (ST) to 50 mg (LT)
3158562|NCT00388609|Experimental|W|50 mg (ST and LT)
3158563|NCT00388609|Experimental|X|25 mg/d (X1 wk), 5 mg/d (X11 wks) (ST) to 50 mg (LT)
3158564|NCT00388609|Experimental|Z|"Open label: 50 mg/d (X 4 wks) 100 mg/wk (X8 wks) (ST) to 50 mg (LT)~Once daily (x 4 weeks), once daily (x 8 weeks)"
3158565|NCT00388609|Placebo Comparator|Y|0 mg (ST and LT)
3158566|NCT00388661|Active Comparator|Melatonin|melatonin 3mg
3158567|NCT00388661|Placebo Comparator|Placebo|
3158568|NCT00388700|Experimental|GM-CT-01|
3173373|NCT00611338|Active Comparator|HIV Prevention plus Trauma|The same format as the HIV Prevention arm with eight, 90 minute group sessions. The participants received the same five HIV prevention skills sessions along with three sessions that focused on reducing trauma-related stress (e.g., breathing training, relaxation exercises, grounding exercises, coping, trauma-related triggers). Each individual completed assessments at immediate post intervention, 3-, 6-, and 12- months.
3173374|NCT00611364|Experimental|Study group|
3173375|NCT00611364|Active Comparator|Control group|
3173376|NCT00611377||1|
3173377|NCT00611390|Active Comparator|1|treatment with spray containing aromatic essential oils of some herbal plants.
2478712|NCT03045341|Experimental|NB medication|Participants randomly assigned to this arm will receive 16 weeks of NB medication. NB medication will combine naltrexone sustained-release (SR, 32 mg/day) combined with bupropion SR (360 mg/day) taken daily in pill form.
2478717|NCT03045341|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 16 weeks of placebo. Placebo will be inactive and taken daily in pill form.
3193113|NCT00815048|Placebo Comparator|Fentanyl|"Atropine~Fentanyl~Succinylcholine"
3193114|NCT00815074||1|Women in the military who have returned from deployment within the past 12 months.
3193115|NCT00815100|Placebo Comparator|Placebo|
2478988|NCT03043300||US Travelers to South or Southeast Asia|"Adult individuals who are planning a short term trip to South or Southeast Asia and meet all eligibility criteria will complete the questionnaires and/or provide stool specimens at the following time points:~No greater than 4 weeks prior to travel departure: Screening Criteria Review~One week prior to travel departure: Pre-Travel Questionnaire and Pre-Travel Stool Specimen Collection~Two weeks after return from travel: Short-Term Post-Travel Questionnaire and Short-Term Post-Travel Stool Specimen Collection~14 weeks after return from travel: Long-Term Post-Travel Questionnaire and Long-Term Post-Travel Stool Specimen Collection"
2479065|NCT03042884|Experimental|Wearable Exercise Trackers - Inpatient Group|"Questionnaires completed at baseline and within 24 hours of discharge.~Participant given a wearable exercise tracker to be worn 24 hours a day while in the acute inpatient rehabilitation unit."
2479067|NCT03042884|Experimental|Wearable Exercise Trackers - Outpatient Group|"Questionnaires completed at baseline and again in 14 days.~Participant given a wearable exercise tracker to be worn 24 hours a day for 14 days."
2479151|NCT03042455|Experimental|Robot and rTMS|Robot-Assisted upper arm training and Repetitive Transcranial Magnetic Stimulation group(intervention group 1)
2479152|NCT03042455|Experimental|Robot|Robot-Assisted upper arm training group(intervention group2)
2479154|NCT03042455|Active Comparator|Conventional|Conventional training group(control group)
2479191|NCT03041818|Experimental|hippotherapy|16 sessions of horseback riding therapy
2479248|NCT03041610|Experimental|Walking intervention|
2479249|NCT03041610|No Intervention|Control|
2479282|NCT03041207||Pre-antibiotic guideline|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection prior to the implementation of the antibiotic guideline
2479283|NCT03041207||After antibiotic guideline implementation|Infants for whom antibiotics have been initiated for suspected ventilator-associated infection after the implementation of the antibiotic guideline
2479286|NCT03041207||Microbiome Study Group|Infants intubated and anticipated to require mechanical ventilation for at least several days
2479349|NCT03040739||case|
2479350|NCT03040739||control|
2479392|NCT03040453|Other|Microwave ablation|20 patients will be treated with microwave ablation
2479397|NCT03040453|Other|Irreversible electroporation|20 patients will be treated with irreversible electroporation
3193116|NCT00815100|Active Comparator|Ivabradine|
3193117|NCT00815113||1|First degree relative of gastric cancer patient
2479490|NCT03039660|Experimental|RefreshMD|An online course for sleep improvement in medical students
2479491|NCT03039660|Placebo Comparator|Bond Between Us|An online course covering communication skills and the physician-patient relationship
2479522|NCT03039504|Experimental|Potensa|succinate-based dietary supplement
2479525|NCT03039504|Placebo Comparator|Placebo|placebo
2479562|NCT03039205|Active Comparator|Chronic kidney dysfunction Clopidogrel|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
2479566|NCT03039205|Active Comparator|Chronic kidney dysfunction Ticagrelor|Patients with creatinine clearance <60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
2479569|NCT03039205|Active Comparator|Normal kidney function Clopidogrel|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to clopidogrel group
2479572|NCT03039205|Active Comparator|Normal kidney function Ticagrelor|Patients with creatinine clearance ≥60ml/min/m2 (estimated by MDRD formula) randomized to ticagrelor group
2479595|NCT03038919|Experimental|Anabolic patients|Intramuscular injection of testosterone cypionate 200mg every 15 days in addition to standard nutrition and physical therapy at ICU.
2479598|NCT03038919|Other|Control|Standard nutrition and physical therapy at ICU without administration of testosterone cypionate
2479656|NCT03038685|Experimental|prospective, multicenter cohort|A group of 175 patients will be recruited in 4 Belgian stroke centers during the six months period. All data will be collected prospectively and patients will be treated during six months period.
2479667|NCT03038685|No Intervention|historical, single center cohort|A historical cohort of Sint-Janhospital (2011 - Bruges, Belgium) with prospectively collected data will be used as comparator for the experimental arm. These data were published in Vanacker P, Couvreur T, Vanhooren G. Can we improve cerebrovascular risk reduction in real-life? A single centre's experience. Cerebrovasc Dis 2011;31(suppl 2):289
2479749|NCT03038334|Experimental|Magnesium sulfate|All participants will apply magnesium sulfate transdermally a total of 250mg equivalent to 2 mEq every four hours per day for 90 days.
2479772|NCT03037957||Group A Strep Assay|
2479791|NCT03037697|Experimental|TheraTogs Arm|TheraTogs Arm The participating children will wear TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day, to allow the children to become acclimated to the system+ Traditional treatment 3 months
2479795|NCT03037697|Active Comparator|Traditional Treatment Arm|"Traditional Treatment Arm~1-Trunk control exercises 2-Core stability training 3-Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board~3 months"
2479876|NCT03037359||Other IGIV|Patients with primary immunodeficiency disease treated with other IGIVs
2480482|NCT03033290|Placebo Comparator|placebo control|similar placebo capsule 4gm tid, 12gm a day for 2 months
3193118|NCT00815113||2|Consecutive gastro-esophageal reflux patients
3193119|NCT00815126|Active Comparator|Mucocutaneous symptoms from NSAIDs|
2478739|NCT03045120||dasatinib cohort|Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2478742|NCT03045120||imatinib cohort|Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2478743|NCT03045120||nilotinib cohort|Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2478746|NCT03045120||bosutinib cohort|Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.
2478823|NCT03044496||Supraclavicular Nerve Block|Patients undergoing vascular surgery for creation or revision of an arterio-venous fistula. Intervention: supraclavicular plexus block for anaesthesia. NIRS measurement before and after brachial plexus block.
2478862|NCT03044210|Other|Cockayne patients|"Interventions performed:~blood sample~urinary collection~metabolic evaluation~clinical evaluation"
2478868|NCT03044210|Other|Control subjects|"Interventions performed:~urinary collection~metabolic evaluation~clinical evaluation"
2478914|NCT03043820|Active Comparator|Raloxifene|Raloxifene 120 mg (2 tablets of 60mg) daily for 12 weeks.
2478916|NCT03043820|Placebo Comparator|Placebo|Placebo 2 tablets daily for 12 weeks.
2478994|NCT03043482|Experimental|Single VS-105/placebo to healthy|Single ascending dose VS-105 or placebo to healthy subjects
2479001|NCT03043482|Experimental|Multiple VS-105/placebo to healthy|Multiple ascending dose VS-105 or placebo to healthy subjects
2479005|NCT03043482|Experimental|Multiple VS-105/placebo to HD subjects|Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
2479032|NCT03042923||Treatment|Twenty patients, known to us through care at Women's Surgery Center and the private practice of Dr. R. Scott Furr, will be invited to enroll based on a history of pelvic pain and a plan for surgical evaluation and intervention
2479033|NCT03042923||Control|Ten healthy female patients, without pelvic pain or history of autoimmune disease, will be asked to participate as controls.
3193120|NCT00815126|Active Comparator|Respiratory symptoms from NSAIDs|
2479113|NCT03042364|No Intervention|No intervention|Standard treatment
2479116|NCT03042364|Experimental|Intervention|Endometrial scratching before standard treatment
2479210|NCT03042117||No Coronary Artery Disease (CAD)|Patients with no known cardiovascular disease.
2479211|NCT03042117||CAD without Myocardial Infarction (MI)|Patients with cardiovascular disease without a myocardial infarction.
2479212|NCT03042117||CAD with MI|Patients with cardiovascular disease with previous history of a myocardial infarction.
3193121|NCT00815126|Active Comparator|NSAIDs tolerant individuals|
3193122|NCT00815139||ZES group|Groups who were treated with zotarolimus eluting stent
2479395|NCT03040505||Patients with schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
2479400|NCT03040505||Control participants|- Control participants without psychiatric nor neurological history
2479437|NCT03040167|Placebo Comparator|Control group|PEC 1 block with injection of 0.4 mL/kg of normal saline under echoguidance.
2479442|NCT03040167|Active Comparator|Treatment group|PEC 1 block with injection of 0.4 mL/kg of 0.25% bupivacaine with 1/400 000 epinephrine under echoguidance.
2479548|NCT03039439||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tumor tissue and blood samples are analyzed via immunohistochemical profiling for identifying potential genes showing molecular aberrations as other types of cancer.
2479620|NCT03039049|Experimental|GnRH agonist|"Drug: Triptorelin 0.1mg Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg.~Other Names:~• Decapeptyl 0.1 mg"
2479626|NCT03039049|No Intervention|Control|No intervention
2479658|NCT03038594|Experimental|Growth Hormone|Daily subcutaneous injections of 0.05 mg/kg/day of Growth Hormone [somatropin, Genotropin, Pfizer, New York, NY] will be administered, from one week prior to discharge until 9 months post-burn.
2479674|NCT03038594|Placebo Comparator|0.09% saline solution|Daily subcutaneous injections of 0.09% of saline solution will be administered, from one week prior to discharge until 9 months post-burn.
2479740|NCT03038256|Experimental|4 Cycles XELOX pre- TME|experimental group (arm B): concurrent capecitabine-based long-term radiotherapy, 4 cycles of XELOX as neoadjuvant chemotherapy and TME surgery
2479750|NCT03038256|Active Comparator|6 Cycles XELOX post- TME|control group (arm A): concurrent capecitabine-based long-term radiotherapy, TME surgery and 6 cycles of XELOX as adjuvant chemotherapy.
2479811|NCT03037840||cancer patients|Low intensity amplitude-modulated RF EMFs
2479817|NCT03037840||healthy participators|Low intensity amplitude-modulated RF EMFs
2479878|NCT03037450|Other|Miniinvasive corneal neurotization|
2479959|NCT03037047|Placebo Comparator|Control group|patients will be treated by 0.9% sodium chloride injection on the basis of conventional therapy for 14 days.
2479963|NCT03037047|Experimental|Experimental group|patients will be treated by salvianolate injection on the basis of conventional therapy for 14 days.
2480021|NCT03036319|Experimental|Active TES + Cognitively based intervention|This condition combines active TES and cognitively based interventions for some or all of the study sessions
2480556|NCT03032848|Active Comparator|Conjugated Estrogen Group|use of 1 gram per day
3193123|NCT00815152|Experimental|1|Twenty five caregivers will randomly be assigned to receive active coping skills training and 25 caregivers will randomly receive usual care at The Preston Robert Tisch Brain Tumor Center at Duke.
3193124|NCT00815152|Placebo Comparator|2|Caregivers that will receive ususal care.
2478749|NCT03045068|Experimental|Study Group|"Platelet Transfusion Management~Pre-Termination of CPB- Platelet Transfusion 10ml/kg to be administered to the patient via central venous access when the patient has been rewarmed to 35*C, (the Sano or BT shunt clip is still on in children with SV physiology)~Post CPB- Platelet transfusion 10ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
2478750|NCT03045068|Active Comparator|Control Group|"Platelet Transfusion Management~Pre-Termination of CPB- No intervention~Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion."
3193125|NCT00815165||Protocol 04-039 subjects|At least 50 and maximum of 100 healthy adolescent female subjects aged 12-17 years who were vaccinated in protocol 04-039 will be enrolled.
3193126|NCT00815165||Positive and Negative Controls|Approximately 100 screened subjects will be enrolled to serve as positive and negative controls.
2478853|NCT03044184|Active Comparator|Intervention|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will have 1gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) intravenously infused over 10 minutes within 3 hours of symptom presentation and another 1 gram of tranexamic acid (diluted in 100ml of normal saline 0.9%) infused over 8 hours."
2478861|NCT03044184|No Intervention|Control|"Standard management for patients with spontaneous intracerebral hemorrhage according to 2015 AHA/ASA Guidelines for the Management of Intracerebral Hemorrhage~AND~Patients will 100ml of normal saline 0.9% intravenously infused over 10 minutes within 3 hours of symptom presentation and another 100ml of normal saline 0.9% infused over 8 hours."
3193127|NCT00815178|Experimental|Inspiratory muscle training|
3193128|NCT00815178|Placebo Comparator|Placebo|
3193129|NCT00815204||posttraumatic stress disorder|
3193130|NCT00815204||history of trauma exposure but no PTSD|
2479013|NCT03043222|Experimental|PAE-Prostate Arterial Embolization|PAE-Prostate Arterial Embolization
2479014|NCT03043222|Active Comparator|PUL- Prostatic urethral lift|PUL- Prostatic urethral lift
3193131|NCT00815204||healthy controls|
2479153|NCT03042169|Active Comparator|continuation of chemotherapy|"Patients assigned to arm A will continue to receive the same chemotherapy regimen they received before randomization. Chemotherapy should be restarted between D1 and D30 after randomization.~In case of poor tolerance to the induction chemotherapy, alternative chemotherapy regimen might be discussed, according to local standards and national guidelines (www.tncd.org)."
2479155|NCT03042169|Experimental|surgical removal of the primary tumour and treatment of the metastatic site followed by chemotherapy|"Patients assigned to arm B will undergo gastrectomy (subtotal or total according to the location of the primary tumour) between D1 and D30 after randomization.~Subtotal gastrectomy is recommended if it allows a complete resection of the primary tumour to limit postoperative morbidity in such metastatic situations, based on the results of REGATTA"
2479171|NCT03041831||Older adult individual interviews|The investigators will conduct 8 semi-structured 60-minute interviews with patient participants.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2479177|NCT03041831||Clinician individual interviews|The investigators will conduct 6 semi-structured 60-minute interviews with primary care clinicians who care for older adult populations.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2479180|NCT03041831||Community leader individual interviews|The investigators will conduct 4 semi-structured 60-minute interviews with community leaders.The goal of these interviews is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2479182|NCT03041831||Focus group discussions|The investigators will lead four 90-minute focus group discussions consisting of 6-8 older adult participants each. The goal of these focus groups is to determine the acceptability, utility, and perceived value of mobile health (mHealth) in helping older adults overcome barriers to health behavior change.
2479218|NCT03041675|Experimental|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
2479227|NCT03041675|Sham Comparator|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
2479292|NCT03041272||Nurses and nursing personnel|All registered nurses and assistive nursing personnel, including patient care associates (PCAs) , patient care technicians (PCTs), clinical technicians (CTs), primary employment on the study unit, minimum of 24 hours per week of employment on study unit.
2479337|NCT03040947||Healthy Volunteer|Healthy Volunteers will undergo a cardiovascular magnetic resonance imaging scan.
2479338|NCT03040947||Diseased (Suspected or Known Cardiac Conditions)|Patients will undergo a cardiovascular magnetic resonance imaging scan.
2479384|NCT03040622||Watchman Left Atrial Appendage Closure|
2479440|NCT03040310|Experimental|Back Rx program|Study patients will use their smartphone apps to view their Back Rx program content, exercises, and videos.
2479582|NCT03039530|Experimental|Treatment Group|Group CBT for PPD. Women in the treatment group will attend a 9-week group CBT intervention for PPD. This intervention was developed at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week.
2479610|NCT03038945|Active Comparator|Vicryl suture|Use VICRYL suture for the closure of the vaginal vault in patients with total Laparoscopic hysterectomy caused by a benign gynecologist pathology
2479659|NCT03038581||Self-inflicted wrist injury|Wrist injury by self-infliction
3193132|NCT00815217|Experimental|1 lipoaspirate|wounds which have received the lipoaspirate
3193133|NCT00815217|Placebo Comparator|2 control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
2478835|NCT03044639|Experimental|Provision of SMOF lipid emulsions in PN|Intervention: Lipid Emulsions, Intravenous. Daily provision of SMOF lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
2479142|NCT03042234|Experimental|Group Insulin-resistant|Insulin-resistant obese adolescents
2479146|NCT03042234|Experimental|Group Insulin-sensitive|Insulin-sensitive obese adolescents
2479193|NCT03041844|Experimental|Low Frequency, Low Intensity Ultrasound|Low Frequency, Low Intensity therapeutic ultrasound applied weekly for up to 16 weeks.
2479194|NCT03041844|Sham Comparator|Sham Ultrasound|Sham ultrasound applied weekly for up to 16 weeks.
2479256|NCT03041571||Medical Honors Students|The Medical Honors Program students will fill out the Patient Provider Orientation Scale (PPOS). MHP students will then interview a patient with a chronic or life limiting illness.
2479258|NCT03041571||Patients with chronic illnesses|The patients will fill out the PPOS scale. The patient will then have an Interview performed by MHP student
2479316|NCT03041103|Experimental|Adult|Food Product 1:50 grams of fortified nutritious product from legumes administered to adults, for 2 weeks
2479318|NCT03041103|Experimental|Children|Food Product 1: 50 grams of fortified nutritious product from legumes administered to children 9-13 years of age, for 1 weeks
2479448|NCT03040102|Experimental|Hospice Video Educational Tool|"The hospice video educational tool is a 6 minute video~Participants will watch an approximately 6-minute digital video regarding hospice on an iPad"
2479451|NCT03040102|Active Comparator|Hospice Verbal Narrative|"The RA will read a verbal narrative that is identical to the narrative of the video to participants~Standard of Care practice is used"
2479549|NCT03039322||HCC|
2479552|NCT03039322||liver cirrhosis No HCC|
2479619|NCT03039127|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
3173378|NCT00611390|Placebo Comparator|2|spray containing placebo.
3173379|NCT00611416|Experimental|1|Active treatment A
2479764|NCT03038074|Experimental|Test Group|The subjects will be enrolled in the test group and will receive Pulse Oximeter with respiration rate sensor to examine the respiration rate.
2479775|NCT03037918|Experimental|Treatment Group|"Participants will receive 2 x 65mL doses of Yakult light per day, for 28 days.~Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28."
2479777|NCT03037918|No Intervention|Control Group|Participants will consume a high-fat (65% of kilocalories) high-calorie (150% of requirements) diet from day 21 to day 28.
2479828|NCT03037684||chronic pain|individuals suffering from chronic pain
2479830|NCT03037684||neuropathic pain|individuals suffering from neuropathic pain
2479901|NCT03037320|Experimental|group A|root coverage to be performed by semilunar vestibular incision technique
2479906|NCT03037320|Other|group B|root coverage by coronally advanced flap
2479954|NCT03036891|Experimental|Study Group|Naloxegol 25 mg, oral tablet, daily for 4 weeks
2479957|NCT03036891|Placebo Comparator|Placebo Control|Placebo Oral Tablet, 25 mg, oral tablet, daily for 4 weeks
2480015|NCT03036501|Experimental|[^14C]-Risdiplam|Participants will be administered with [^14C]-Risdiplam solution orally under fasted conditions on Day 1.
2480068|NCT03036202||one group|All patients treated for cardiac arrest, meeting our inclusions criteria will be enrolled in the study. No interventions regarding the national guidelines will be jeopardized, as the plasma concentration following a single dose of epinephrine will be measured in all patient.
2480113|NCT03035877|Experimental|Multisystemic Therapy-Emerging Adults|This group will receive Multisystemic Therapy-Emerging Adults.
2480115|NCT03035877|Active Comparator|Enhanced Treatment as Usual|This group will have access to an enhanced version of services typically delivered to young adults who have a substance use disorder and have been in trouble with the law.
2480145|NCT03035643|Experimental|AMDS Implantation|AMDS implantation is performed during an open chest procedure for intervention of aortic dissection repair.
2480189|NCT03035474|Other|Direct & Digital|Health system engagement to improve local QI programs and patient engagement to improve self-management/medication adherence
2480190|NCT03035474|Other|Direct & Registry|Health system engagement to improve local QI programs and patient and control
2480191|NCT03035474|Other|Digital & Registry|Patient engagement to improve self-management/medication adherence and control
2480192|NCT03035474|No Intervention|Registry|Control
2480316|NCT03034473|Other|Blood and tissue samples during therapy|Collection of blood and tissue samples during preoperative multimodal treatment (Radiochemotherapy (RCTx) followed by total mesorectal excision (TME) and Chemotherapy (CT)) in rectal cancer.
2480389|NCT03034161||Stage IV Pressure Ulcer|Ten patients with a Stage IV decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
3173380|NCT00611416|Experimental|2|Active treatment B
3173381|NCT00611416|Experimental|3|Active treatment C
3173382|NCT00611416|Active Comparator|4|Positive control
3173383|NCT00611416|Placebo Comparator|5|Placebo
3173384|NCT00611429|Experimental|Group A|Participants will receive treatment consisting of at least three individual counseling sessions and one group workshop over 12 months
3173385|NCT00611429|Active Comparator|Group B|Participants will receive treatment consisting of one individual counseling session and one group workshop during the last month of the study
3173386|NCT00611481|Experimental|Tai Chi|
3173387|NCT00611481|Active Comparator|B. Strength training|
3173388|NCT00611481|Other|C. Low-Impact|
3173389|NCT00611494|Active Comparator|A|MMF
3173390|NCT00611494|Active Comparator|B|EC-MPS
3173391|NCT00611520||1|Patients with COPD treated with budesonide/formoterol
3173392|NCT00611546|Placebo Comparator|1|Perenteral nutrition bottle and tubing are not protected from light
3173393|NCT00611546|Active Comparator|2|Perenteral nutrition bottle and tubing are protected from light
3173394|NCT00611572|Active Comparator|1|Active iomazenil and ketamine
3173395|NCT00611572|Placebo Comparator|2|placebo iomazenil and ketamine
3173396|NCT00611585|Other|Hip Resurfacing|Birmingham Hip Resurfacing
3173397|NCT00611598||1|second primary lung cancer
2478987|NCT03043508||Participants With Confirmed MEN1 With PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
2478989|NCT03043508||Participants With Confirmed MEN1 Without PNET|"Retrospective review of a prospectively maintained MEN1 database.~Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history."
3173398|NCT00611598||2|single primary lung cancer
3173399|NCT00611611||1|SLE
2479114|NCT03042598|Experimental|Biphasic Cuirass Ventilation|Patients requiring emergent intubation in the Emergency Department will be provided ventilation during the apnic phase of intubation via the use of BCV.
2479143|NCT03042130|Experimental|Iron Carboxymaltose|"standard of care + double dose of IV iron ferinject~the medicine will be given twice within one week."
2479148|NCT03042130|Other|control|standard of care
2479204|NCT03041857||GMK Sphere|Subjects with a unilateral Medacta GMK Sphere TKA
2479206|NCT03041857||GMK PS|Subjects with a unilateral Medacta GMK Primary PS Fixed Bearing TKA
2479208|NCT03041857||GMK UC|Subjects with a unilateral Medacta GMK Primary UC Fixed Bearing TKA
2479251|NCT03041493|Experimental|Electronic cigarettes (EC) smokers|
2479253|NCT03041493|Experimental|traditional cigarette (TC) smokers|
2479254|NCT03041493|Active Comparator|nonsmokers|
2479388|NCT03040570|Experimental|Conservative oxygenation target|Children in the conservative oxygenation target group receive treatment targeting oxygen saturation values of 88-92%.
2479391|NCT03040570|Active Comparator|Liberal oxygenation target|Children in the liberal oxygenation target group receive treatment targeting oxygen saturation values of >94%.
2479444|NCT03040193|Experimental|Nebulized Lignocaine|4% Lignocaine administered as nebulization for topical anaesthesia during bronchoscopy procedure
2479445|NCT03040193|Placebo Comparator|Nebulized Saline|Normal Saline administered as nebulization for topical anaesthesia during bronchoscopy procedure
2479477|NCT03039829|Experimental|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine; 1.0 gram nitrate, 3.0 grams dextrose)
2479478|NCT03039829|Active Comparator|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine; 2.0 grams nitrate)
2479486|NCT03039829|Placebo Comparator|Placebo|Placebo at 6.0 grams dextrose
2479632|NCT03038776|Experimental|1|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen)
2479634|NCT03038776|Experimental|2|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-1 adjuvant
2479637|NCT03038776|Experimental|3|Two i.m. administrations 4 weeks apart of recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7 antigen) + Advax-2 adjuvant
2479639|NCT03038776|Experimental|4|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) antigen
2479640|NCT03038776|Experimental|5|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-1 adjuvant
2479643|NCT03038776|Experimental|6|Two i.m. administrations 4 weeks apart of T cell epitope modified recombinant influenza hemagglutinin corresponding to avian H7N9 virus strain (rH7m antigen) + Advax-2 adjuvant
2479782|NCT03038048|Experimental|33 g needle - right eye|33 g needle for intravitreal injection of Lucentis or Eylea for right eye and 30 g needle for left eye
2479783|NCT03038048|Experimental|33 g needle - left eye|33 g needle for intravitreal injection of Lucentis or Eylea for left eye and 30 g needle for right eye
2479788|NCT03037632|Experimental|Communication Tool|
2479789|NCT03037632|No Intervention|No Communication Tool|
2479889|NCT03037177||CHL like GZL|Classical Hodgkin Lymphoma like Grey Zone Lymphoma (morphology of CHL and phenotype of PMBCL)
2479896|NCT03037177||PMBCL like GZL|Primary Mediastinal B Cell Lymphoma like Grey Zone Lymphoma(morphology of PMBCL and phenotype of CHL)
2479904|NCT03037177||Composite|with a morphology of CHL on the one side and of PMBCL on the other side of the same diagnosis biopsy
2479938|NCT03036969||Non-urgent emergencies|Outpatients in the Emergency Department with the MTS-Triage category blue, green or yellow
2479997|NCT03036683|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo anodal transcranial direct current stimulation (tDCS). tDCS will be delivered by a battery-driven, constant-current stimulator connected to two saline-soaked surface sponge electrodes. An anodal electrode (25cm2) will be placed over the right dorsolateral prefrontal cortex and one cathodal electrode (100cm2) will be placed over the left supraorbital area at least 5cm from the anode. Scalp electrodes will be positioned according to the 10-20 EEG international system. A current of 2mA will be applied for 20 minutes and the current will be ramped up and down over 20 seconds at the beginning and end of the stimulation period.
2480006|NCT03036683|Sham Comparator|Sham stimulation|The sham tDCS condition will involve the same placement of the electrodes, current intensity, and ramp-up/down time as the active tDCS condition, but stimulation will only last for 30 seconds.
3173400|NCT00611611||2|healthy controls
3173401|NCT00611637|Experimental|1|
3173402|NCT00611650|Experimental|Arm I|Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3173403|NCT00611650|Placebo Comparator|Arm II|Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
3173404|NCT00611663|Experimental|1|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE) at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)
3173405|NCT00611663|Placebo Comparator|2|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
3173406|NCT00611676|Experimental|A|All subjects receive placebo for the first two weeks and then Venlafaxine for the next 10 weeks, but they are blind to what they are receiving
3173407|NCT00611689|Experimental|A|Imatinib and PTK/ZK222584
3173408|NCT00611741|Experimental|Drug intervention, longitudinal|Furosemide and Na supplements
3173409|NCT00611780|Experimental|1|Reduced tube voltage of 100kV.
3173410|NCT00611780|Active Comparator|2|Standard tube voltage of 120kV.
2478991|NCT03043287||BOTOX®|Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study.
2479074|NCT03043014|Experimental|Mifépristone group|
2479075|NCT03043014|Active Comparator|misoprostol group|
2479101|NCT03042429|Experimental|experimental arm|Drug: Cycles N8, N5, and N6 Drug: topotecan, cyclophosphamide, and etoposide (N8 cycle) followed by Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
2479106|NCT03042429|Active Comparator|standard arm|Drug: Cycles N5 and N6 Drug: cisplatin, etoposide, and vindesine (N5 cycle) and Drug: vincristine, dacarbacine, ifosfamide, and doxorubicine (N6 cycle) followed by myeloablative chemotherapy with autologous stem cell transplantation (melphalan, carboplatin, etoposide) and by 9 x retinoic acid cycles (6 months, 3 months break, 3 months)
2479190|NCT03041987||Chronic Kidney Disease|"Specified estimated glomerular filtration rate (eGFR) range according to different CKD etiologies. For glomerular nephrology patients, the eGFR should be ≥15 ml/minute per 1.73m(2). For diabetic nephrology patients, the defining eligibility was 15 ml/minute per 1.73m(2)≤eGFR <60 ml/minute per 1.73m(2) or eGFR≥ 60 ml/minute per 1.73m(2) with nephrotic range proteinuria, which is defined as 24-hour urinary protein ≥3.5 g or urinary albumin creatinine ratio ≥2 000 mg/g or corresponding values of urine dipstick test or urinary protein creatinine ratio. For non-glomerular nephrology and non-diabetic nephrology patients, 15 ml/minute per 1.73m(2) ≤eGFR<60 ml/minute per 1.73m(2) is set for enrollment."
2479220|NCT03041584|Experimental|Materialise Universal®/ mucosa (Mat Mu)|
2479231|NCT03041584|Experimental|Materialise Universal®/ bone (Mat Bo)|
2479239|NCT03041584|Experimental|FacilitateTM/ mucosa (Fac Mu)|
2479242|NCT03041584|Experimental|FacilitateTM/ bone (Fac Bo)|
2479244|NCT03041584|Active Comparator|mental navigation (Mental)|
2479245|NCT03041584|Active Comparator|pilot-drill template (Templ)|
2479325|NCT03041051|Experimental|PCV13|
2479327|NCT03041051|Experimental|PPV23|
2479364|NCT03040700|No Intervention|Clinical|Regular medical visits every 6 months.
2479365|NCT03040700|Experimental|Myocardial Perfusion Scan|Myocardial perfusion stress test using cardiac scintigraphy (Sestamibi) at rest and during pharmacological stress (dipyridamole)
2479366|NCT03040700|Experimental|Coronary CTA|Coronary computed tomography angiography
2479426|NCT03040284|Experimental|aneurysmal subarachnoid hemorrhage|
2479464|NCT03039946|Experimental|Closed-loop GDFT|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid maintenance with Plasmalyte is carried out using a closed-loop system guided by the Clearsight non-invasive hemodynamic flow monitor.
2479465|NCT03039946|Active Comparator|Restrictive fluid therapy|This group consists of patients undergoing laparoscopic and/or robotic abdominal surgery where fluid management is based on a restrictive (4ml/kg/h) Plasmalyte infusion.
2479511|NCT03039647||Entry Point IR (SSPG, HOMA-IR)|All subjects will undergo baseline indirect (HOMA-IR) and direct (SSPG) measures of IR. The investigators hypothesize that a higher entry point IR will predict steeper decline in memory and executive function performance and hippocampal connectivity.
2479513|NCT03039647||Change in IR (HOMA-IR)|The investigators predict that change in IR (as measured by HOMA-IR) will predict the pattern of decline in memory and executive function performance and hippocampal connectivity.
2479535|NCT03039387|Active Comparator|anodal tDCS|transcranial direct current stimulation of the left dlPFC with 1mA
2479541|NCT03039387|Placebo Comparator|Sham stimulation|Double blind sham stimulation (stimulation will be ramped down after 30 sec.)
3158569|NCT00388739|Active Comparator|Usual care|Systemic steroids (4 days of prednisone, 1mg/kg/dose to a maximum of 40 mg/dose to be given twice a day). Subjects will also receive standardized discharge medication instructions for using albuterol nebulizer treatments: they will receive a prescription for 2.5mg of albuterol in 3cc Normal Saline for aerosol use via compressor every 3 times a day as a chronic care regimen if they are either in the treatment arm and 1-5 years of age or if they are in the control group and already own a nebulization compressor. Children in the control group that do not own a nebulization compressor will be given a prescription for an albuterol MDI with mask and spacer with instructions to deliver 2 puffs (90mcg per actuation) 3 times a day as a standard chronic care regimen. Instructions to follow-up with their primary care physician in 3-5 days (as is standard care practice) will be given at discharge for patients in the control or treatment arm.
3158570|NCT00388739|Experimental|Usual care + 6 months of inhaled steroids|In addition to the usual care described above, patients randomized to the intervention/experimental arm will also be given a one month supply as well as a prescription (for a 6 month supply) for Budesonide respules (children with mild persistent disease will receive 0.25 mg bid whereas children with moderate or severe persistent disease will receive 0.5 mg bid).
3158571|NCT00388843||Dose Increased|Patients presenting with symptoms of coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, and whose statin dose is increased to moderate to high dose by their clinicians.
3158572|NCT00388843||Dose Maintained|Patients presenting with symptoms due to coronary artery disease or stroke/suspected stroke, with carotid plaque > 1.1 mm, on no statins or whose statin dose was unchanged by their clinicians.
2480234|NCT03035084|Experimental|Group-2-D3|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to vitamin D3
2480236|NCT03035084|Placebo Comparator|Group-2-Placebo|Subjects with total 25(OH)D more= 20 nmol/l and less= 40 nmol/l will receive vitamin D2 then randomly assigned to placebo oral capsule.
2480238|NCT03035084|Experimental|Group-1-D2|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less= 65 nmol/l will be randomly assigned to vitamin D2.
2480240|NCT03035084|Placebo Comparator|Group-1-Placebo|Subjects with 25(OH)D3 more= 40 nmol/l and total 25(OH)D less =65 nmol/l will be randomly assigned to placebo oral capsule.
2480433|NCT03033472|Experimental|Clindamycin|600 mg of Clindamycin orally 30 minutes before root canal treatment
3158573|NCT00388908|Experimental|A|Multifaceted intervention
2479082|NCT03042650|Experimental|Intensive Referral Intervention Group|Intensive Referral Intervention will by done by trained probation officers
2479084|NCT03042650|Active Comparator|Standard Practice Facilitated Group|Standard Current Practice will be provided by untrained probation officers
2479121|NCT03042338|Experimental|Central Executive Training1|Training tasks targeting working memory
2479123|NCT03042338|Active Comparator|Central Executive Training2|Training tasks targeting inhibitory control and response speed
2479189|NCT03042091|Active Comparator|Arm I (mechanical bowel prep, oral antibiotics)|Patients receive polyethylene glycol orally (PO), neomycin PO, and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
2479192|NCT03042091|Experimental|Arm II (oral antibiotics)|Patients receive neomycin PO and metronidazole hydrochloride PO on day -1. Patients undergo colorectal resection on day 0.
2479380|NCT03040596|Experimental|inhaled steroid + voice therapy|fluticasone inhaler, 88mcg (2 puffs), twice a day for 4 weeks + standard voice therapy
2479382|NCT03040596|Other|voice therapy only|standard voice therapy
2479441|NCT03040206||Nodal PTCL|"newly-diagnosed, pathologically-proven nodal PTCLs (PTCL, NOS; Angioimmunblastic T-cell lymphoma; anaplastic large cell lymphoma [ALCL], anaplastic lymphoma kinase [ALK]-negative) between January 1, 2005 and Jun 30, 2016~initially treated with curative intent~Standard PET or PET-CT data available at the time of diagnosis and at the end of primary treatment"
2479481|NCT03039933|Active Comparator|Fear of Hypoglycemia Intervention|Cognitive behavioral therapy based psychological intervention occurring every other week for 12 weeks.
2479484|NCT03039933|Other|Treatment As Usual|Control group completes questionnaires but does not receive any study intervention. Receives medical care as usual.
2479546|NCT03039556|Experimental|Change in physical activity for older adults|Older adult participants undergo alterations in daily ambulation by completing Normal Daily Steps for one week, followed by a two-week Step-Reduction and a subsequent Return to Normal Daily Steps for two weeks
2479702|NCT03038516|Active Comparator|Vitamin D|Cholecalciferol (Detremin) solved in MIGLYOL® 812
2479705|NCT03038516|Placebo Comparator|Placebo|MIGLYOL® 812
2479803|NCT03037723|Other|Prone/Supine Simulation|It is institutional policy to perform CT simulation in left-sided breast cancer patients with and without the respiratory gating (this is one CT scan), in the face-up position. It is also standard of care to perform the face-down CT simulation in large breasted women. Both of these simulations are meant to reduce the exposure of the heart and lungs to radiation. In this study, all left-sided breast cancer patients that consent will receive face-up CT simulation with and without gating AND face-down CT simulation, regardless of breast size; thus, each patient is their own control.
2479846|NCT03037502|Experimental|Intervention: Tailor Made|Intervention Arm: In the pilot intervention, participants will receive: tailored goals/ messages, self-monitoring, weekly small groups to receive health education and community-based information and resources. Participants will also complete two assessment with blood work and anthropometric measurements. These intervention components were selected based on investigator's formative research and experience using them in prior studies. These components will be implemented simultaneously as they complement one another. While all of these components have not been tested together in an intervention for this population, they are variations and enhancements of previous interventions by the investigators.
2479849|NCT03037502|No Intervention|Comparison|Comparison Condition: Participants in the attention control group will receive self-help materials on how to improve healthy eating, physical activity and weight loss, self-monitoring, and complete two assessments with blood work and anthropometric measurements. Participants in this condition will receive a copy of their assessment data and the nurses will provide this personalized information as well as answer any questions participants may have about their assessment results.
2480044|NCT03036358|Other|Teledermatology consult|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment will be entered into the patients chart.
2480047|NCT03036358|Other|Routine Care|To determine the benefit of teledermatology to differentiate cellulitis from pseudocellulitis in emergency departments through the analysis of time spent in the emergency department (ED), admission to the inpatient hospital, antibiotic use, time to improvement, and 30-day remission rate. This arm will undergo imaging, a dermatologic assessment will be performed, AND this assessment WILL NOT be entered into the patients chart
3158574|NCT00388908|Active Comparator|B|Usual Care
3158575|NCT00388934|Experimental|Drug eluting stent (Cypher)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Cypher)
3158576|NCT00388934|Experimental|Drug eluting stent (Taxus)|Percutaneous coronary intervention with implantation of drug eluting coronary stent (Taxus)
3158577|NCT00388960|Experimental|Amrubicin|Amrubicin 45mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
3158578|NCT00388960|Experimental|Amrubicin plus Cisplatin|Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> IV day 1 of each 21-day cycle until disease progression.
3158579|NCT00388960|Active Comparator|Cisplatin plus etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 each 21-day cycle until disease progression.
3158580|NCT00388986|Experimental|1|
3158581|NCT00388986|Experimental|2|
3158582|NCT00388986|Experimental|3|
3158583|NCT00388999|Other|0 mg/kg|
3158584|NCT00388999|Other|0.5 mg/kg|
3158585|NCT00388999|Other|1.0 mg/kg|
3158586|NCT00389038|Active Comparator|Coping Skills Training + Amitriptyline|Behavioral coping skills training--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
3158587|NCT00389038|Active Comparator|Headache Education + Amitriptyline|Behavioral headache education
3158588|NCT00389077|Experimental|Perifosine Daily Dose|Daily dose perifosine 50 mg.
3158589|NCT00389077|Experimental|Perifosine Twice Daily Dose|Twice daily dose perifosine 50 mg.
3158590|NCT00389090|Experimental|Temozolomide + O6BG|
2479041|NCT03042949|Experimental|Blood pressure measurement|Patients requiring blood pressure measurement will have their blood pressure measured in the standard manner by plethysmography, and then with the Elfor -1 device , the new optical sensor, in order to determine the performance of the new sensor.
2479104|NCT03042689|Experimental|Regorafenib|
2479135|NCT03042260|Experimental|Trimethoprim-Sulfamethoxazole (TMP-SMX)|Trimethoprim-Sulfamethoxazole 180mg/800mg oral tablet, 3 times a week, for 6 months. Subjects may remain on the drug longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months.
2479140|NCT03042260|Placebo Comparator|Placebo|"Tablets that look exactly the same as the experimental drug, 3 times a week, for 6 months.~Subjects may remain on the placebo longer (maximum 1 year), if they continue to receive intermediate or high dose steroids at the end of 6 months."
2479163|NCT03041870|Experimental|Dominance|Healthy subjects
2479226|NCT03041766|Experimental|Group 1|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 2.5 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
2479237|NCT03041766|Experimental|Group 2|Adults with an infectious history of S. haematobium and S. mansoni and pretreated with 1 dose of Praziquantel (3 weeks prior to the first vaccine injection) receiving three (3) intramuscular injections of 50 μg Sm14 with 5.0 μg GLA-SE solution at D0, W4, W8 (D=day; W=week). Three-month follow-up (W12, W20).
2479297|NCT03041220||cesarean section|Obese pregnant patients who have had a cesarean section.
2479343|NCT03040869||CHD Patients|coronary angioplasty confirmed coronary heart disease.
2479346|NCT03040869||non-CHD patients|coronary angioplasty confirmed no coronary heart disease.
2479372|NCT03040557|Active Comparator|Flexible footwear|The intervention with flexible footwear in women with plantar fasciitis (MFG), acute n=12 and chronic=15) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
2479376|NCT03040557|Active Comparator|Orthopedic insole|The intervention with orthopedic insole in women with plantar fasciitis (COIG, acute n=14 and chronic=14) will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
2479430|NCT03040297|Active Comparator|TGI 6 L/min|Tracheal gas insufflation 6 L/min
2479432|NCT03040297|Active Comparator|TGI 11 L/min|Tracheal gas insufflation 11 L/min
2479434|NCT03040297|Active Comparator|TGI 0 L/min|Tracheal gas insufflation catheter, without gas flow
2479510|NCT03039920|Active Comparator|Electronic cigarette with or without nicotine|Electronic cigarette assisted cessation program
2479512|NCT03039920|Active Comparator|Smoker control|Conventional cigarette smoking continuation
2479538|NCT03039335||Adults with an AAT Deficiency|Subjects over the age of 18 that have been recently diagnosed with an Alpha-1 Antitrypsin deficiency will be enrolled into the study to observe the interval between first symptom and initial diagnosis.
2479584|NCT03039166|Experimental|parkinson|
2479585|NCT03039166|Experimental|partial epilepsy|
2479587|NCT03039166|Experimental|alzheimer disease|
2479590|NCT03039166|Experimental|multiple sclerosis|
2479592|NCT03039166|Experimental|amyotrophic lateral sclerosis|
2479593|NCT03039166|Active Comparator|healthy control patients|
2479654|NCT03038763||Mothers|Black or white mothers who have or have had hepatitis C and were born between 1945-1964. Participants must have at least one child over the age of 18.
2479661|NCT03038763||Adult Children|Adult children of Black or white mothers who have or have had hepatitis C and were born between 1945-1964. From speaking with these mothers, it must be possible that participants were exposed to hepatitis C virus while in the womb.
3193134|NCT00815243|Experimental|Telemed|Group of trauma&orthopedic patients - for determination of clinical strategy and treatment plan telemedicine will be used
3193135|NCT00815243|Active Comparator|InternalControl|Group of trauma&orthopedic patients from 3rd level trauma center - for determination of clinical strategy and treatment plan usual clinical approaches will be used
3193136|NCT00815243|Active Comparator|ExternalControl|Group of trauma&orthopedic patients from 1-2rd level trauma centers (in rural and small municipal hospitals) - for determination of clinical strategy and treatment plan personal arriving of the expert by the car (so-called Urgent Expert Care) will be used
2479955|NCT03036800|Experimental|Targeted Prescribing Pathway (LIRA 3mg + Standard Care)|Standard care plus targeted use of the intervention Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply
2479958|NCT03036800|Active Comparator|Standard Care|standard Tier 3 obesity specialist service care
2480011|NCT03036462|Experimental|Verum group (FCM)|I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is > 16.0 g/dL or ferritin is > 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
2480019|NCT03036462|Placebo Comparator|Placebo group (NaCL)|Administration of i.v. NaCl at a volume according to the dosing rules for FCM, i.e. as described for the verum group.
2480140|NCT03035812|Experimental|Alkali|Patients in whom an oral alkalinization whatever the formulation
3193137|NCT00815256|Experimental|Cross linking (CXL)|Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
2480220|NCT03035149|Experimental|Weight Management Program|Obese subjects participate in a year long medically supervised weight management program.
2480227|NCT03035149|No Intervention|Normal Weight Controls|Normal weight age and sex-matched controls. Unlike the obese subjects, the controls did not participate in the Weight Management Program. Pulmonary function, exercise performance and dyspnea results for normal weight controls were compared against the results for obese subjects.
2480444|NCT03033472|Placebo Comparator|Placebo|placebo 30 minutes Orally before treatment
2479246|NCT03041727|Active Comparator|Standard Group|"The subjects will be treated with a standard protocol of stretching and strengthening exercises , we require them to do the exercises by themselves during five weeks, one a day.~To make sure that they will do the protocol, we'll give them a diary to sign the daily section."
2479247|NCT03041727|Experimental|Intervention group|The subjects will be treated with the same protocol of the Standard Group, but in two section, they will receive a Fascial Manipulation approach.
3158591|NCT00389103|Placebo Comparator|placebo|
3158592|NCT00389116|Experimental|1|
3158593|NCT00389116|Placebo Comparator|2|
2479553|NCT03039270|Active Comparator|Control (Without sonic activation)|Desensitizing gel applied without sonic activation, for 10 minutes, previously to the in-office bleaching.
2479557|NCT03039270|Experimental|With sonic activation (SMART Device®)|Desensitizing gel applied with sonic activation, 30 seconds per tooth, previously to the in-office bleaching.
2479596|NCT03038984|Experimental|Every 3 months|screening every 3rd month: (home monitoring: FC and DA)
2479599|NCT03038984|Active Comparator|On demand|screening On demand: (home monitoring: FC and DA)
2479668|NCT03038724|Other|Targeted testing|Patients complete a questionnaire on risk factors for HIV acquisition and are offered rapid (fingerprick) HIV testing if their questionnaire responses indicate they have HIV risk factors
2479679|NCT03038724|Other|Non-targeted screening|Patients offered a brief information on HIV and HIV testing and are then offered rapid (fingerprick) HIV testing without completing an HIV risk factor assessment
2479726|NCT03038321|Active Comparator|solifenacin|(Sofenacin ''solifenacin 10 m'') [Marcyrl Pharmaceutical Industries - Egypt]
2479730|NCT03038321|Active Comparator|levofloxacin|(Tavanic ''levofloxacin 500 mg'') [Sanofi-Aventis - Egypt]
2479731|NCT03038321|Active Comparator|lornoxicam|(Xefo ''lornoxicam 8 mg'') [Multi-Apex - Egypt, under license of: NYCOMED, Austria]
2479816|NCT03037814|Other|Compomer|Adhesive agent+Compomer
2479820|NCT03037814|Other|RMGIC|Primer+RMGIC
2479824|NCT03037814|Other|Giomer|Adhesive Agent+ Giomer
2479825|NCT03037814|Other|Amalgam|Amalgam
2479902|NCT03037229||STEMI|"Subjects in which a STEMI protocol has been initiated.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
2479908|NCT03037229||Chest Pain|"Subjects presenting at the emergency department with chest pain.~An attempt will be made to do the standard 12-lead ECG first, followed immediately after by the Smartphone ECG~If the initial standard 12-lead ECG was already obtained, such as when the patient was first diagnosed with STEMI, a repeat ECG will be performed at the same time as the Smartphone ECG~If possible, the two ECGs will be taken in the Emergency Department, the critical care unit (CCU), or the catheterization laboratory just prior to cardiac catheterization. If not, then the two ECG's will be taken just after the cardiac catheterization is completed (i.e., within one hour of the procedure) while the patient is still in the catheterization laboratory and waiting for transport to the CCU~Both ECGs will be sent to the designated ECG reading station, to be read and evaluated by three independent cardiologists"
2479937|NCT03036826||Piperacillin/Tazobactam|Group of patients receiving Piperacillin/Tazobactam as antiinfective therapy
2479941|NCT03036826||Meropenem|Group of patients receiving Meropenem as antiinfective therapy
2480026|NCT03036579|Experimental|Glazed Fired, Calibra Céram|Celtra Duo crowns will be glaze-fired in a porcelain oven and cemented with Calibra Ceram Cement
2480028|NCT03036579|Experimental|Hand Polished, Calibra Universal|Celtra Duo crowns will be hand-polished and cemented with Calibra Universal Cement
3158594|NCT00389155|Experimental|vinflunine and gemcitabine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
3158595|NCT00389155|Placebo Comparator|placebo and gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
3158596|NCT00389181|Experimental|Medical management|Patients with unruptured BAVMs will receive symptomatic medical management alone.
3158597|NCT00389181|Active Comparator|Interventional therapy|Patients with unruptured BAVMs will receive symptomatic medical management with invasive therapies (any combination of surgery, endovascular embolization, or radiotherapy).
2480462|NCT03033459|Experimental|Motivational Interviewing|Participants assigned to the Motivational Interviewing condition will receive an approximately 45 (± 5) minute intervention provided by a female masters-level supervised psychologist with training in Motivational Interviewing.
2480464|NCT03033459|Active Comparator|Psychoeducation Control|Participants who have been randomly assigned to participate in the attention-control group session will receive approximately 45 (± 5) minutes of psychoeducation on typical developmental stages and infant feeding methods. The psychoeducation will be provided by a female masters-level supervised psychologist.
2480522|NCT03033082||Erectile dysfunction patients|Questionnaire sheets.
2480524|NCT03033082||Normal males|Questionnaire sheets.
3158598|NCT00389220|Active Comparator|BioMatrix Flex stent|Coronary stent placement with Biolimus A9 coated stent with biodegradable polymer
3158599|NCT00389220|Active Comparator|Cypher Select stent|Coronary stent placement with Sirolimus coated stent with durable polymer
3158600|NCT00389233|Experimental|1|2L gut cleansing solution
3158601|NCT00389233|Active Comparator|2|4L preparation
3158602|NCT00389259|Experimental|A|IV Scopolamine 0.25mg in adults and 0.006mg/kg in children Q4h
3158603|NCT00389259|Placebo Comparator|B|IV Look alike drug Q 4h
3158604|NCT00389311|Active Comparator|Nonoxynol-9|Gynol-II, 2% N-9, 5 mL
3158605|NCT00389311|Other|Normosol-R|Normosol-R, 5 mL, single administration, negative control
3158606|NCT00389311|Experimental|Normosol with simulation, endoscopy and biopsy|Normosol-R, 5 mL following simulation, endoscopy and biopsy
2479161|NCT03041883|Active Comparator|KPro with normal graft-support|Patient wil receive a normal graft-support for the KPro type I. Under sterile conditions, the corneo-scleral button will be inspected, then placed on an artificial anterior chamber. The epithelium of the donor will be removed mechanically. Then, one drop of riboflavin 0.1% / dextran 20% will be applied to 30 secondes for 5 minutes on the de-epithelialized cornea.The minimally manipulated normal graft-support will be forwarded to the surgeon according to standard procedure.
3158607|NCT00389376|Other|Group 1|Placebo and 140 mg single dose + every 8 hours
3158608|NCT00389376|Other|Group 2|Placebo and 280 mg single dose
2479469|NCT03039985|Experimental|Bruxism + lithium disilicate crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
2479471|NCT03039985|Experimental|No bruxism + lithium disilicate crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from lithium disilicate.
2479472|NCT03039985|Experimental|Bruxism + zirconia crown|Participant with sleep bruxism receives a monolithic molar crown manufactured from zirconia.
2479473|NCT03039985|Experimental|No bruxism + zirconia crown|Participant without sleep bruxism receives a monolithic molar crown manufactured from zirconia.
2479600|NCT03038932||Discovery Cohort|"A minimum of 50 recurrent Atopic Dermatitis with a history of Eczema Herpeticum(ADEH+), 500 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-), and 237 Non-Atopic (NA) European American participants from the Atopic Dermatitis Research Network (ADRN) DNA Repository.~The study will learn from this cohort:~All Single Nucleotide Variants (SNVs) in ADEH+~ADEH+ specific deleterious SNVs~The study will determine the function of:~4. ADEH+ risk variants"
2479605|NCT03038932||Independent populations of participants|"Two independent populations of participants:~Children, aged 3-17 years and~Adults 18-64 years of age.~A minimum of 12 recurrent Atopic Dermatitis with a history of Eczema Herpeticum (ADEH+) with ≥3 Eczema Herpeticum (EH) episodes, 12 Atopic Dermatitis without a history of Eczema Herpeticum (ADEH-) and 12 Non-Atopic (NA) participants will be enrolled in each of the two populations."
2479653|NCT03038750||EDNRA Sub-study|"Study population will be split into two groups defined by the allele of EDNRA the participant possesses:~Participants Homozygous for the A-allele of EDNRA, are assigned to the 'case' group.~Participants that are Homozygous for the G-allele will be assigned to the 'control' group.~20 participants will be recruited to each group, 40 in total."
2479666|NCT03038750||PNPLA3 Sub-study|"Study population will be split into two groups defined by the allele of PNPLA3 the participant possesses:~Participants Homozygous for the G-allele of PNPLA3, are assigned to the 'case' group.~Participants that are Homozygous for the C-allele of PNPLA3 will be assigned to the 'control' group.~60 participants will be recruited to each group, 120 in total."
2479673|NCT03038750||PROCR Sub-study|"Study population will be split into two groups defined by the allele of PROCR the participant possesses:~Participants Homozygous for the G-allele of PROCR, are assigned to the 'case' group.~Participants that are Homozygous for the A-allele of PROCR will be assigned to the 'control' group.~30 participants will be recruited to each group, 60 in total."
2479805|NCT03037736|Placebo Comparator|Placebo|Patients will receive 0.1mL of normal saline injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2479809|NCT03037736|Active Comparator|5-Fluorouracil|Patients will receive 0.1mL of 5-Fluorouracil, 5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2479814|NCT03037736|Active Comparator|Bevacizumab|Patients will receive 0.1mL of bevacizumab, 2.5mg/0.1mL, injected subconjunctival in the area of the excised pterygium and 1 and 2 months postoperative.
2479919|NCT03037437|Experimental|No prior systemic treatment|Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
2479920|NCT03037437|Experimental|Progress on sorafenib|As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
2479970|NCT03036748|Experimental|TX control|Kidney transplant recipients with ACR <30mg/g
2479971|NCT03036748|Experimental|TX Proteinuria|Kidney transplant recipients with ACR> 300mg/g
2479993|NCT03036449||A|Group A: Phase 1: Observations (Baseline rate of errors); Phase 2: Main Educational program; Phase 3: Observations; Phase 4: Maintenance Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
2479994|NCT03036449||B|Group B: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: Main Educational program; Phase 5: Observations; Phase 6: Maintenance Educational program; Phase 7: Observations; Phase 8: Maintenance Educational program; Phase 9: Observations.
2479998|NCT03036449||C|Group C: Phase 1: Observations (Baseline rate of errors); Phase 2: No intervention; Phase 3: Observations (Baseline rate of errors); Phase 4: No intervention; Phase 5: Observations (Baseline rate of errors); Phase 6: Main educational program; Phase 7: Observations; Phase 8: Maintenance educational program; Phase 9: Observations.
3158609|NCT00389376|Other|Group 3|Placebo and 280mg every 8 hours
3158610|NCT00389376|Other|Group 4|Placebo and 280 single dose + every 8 hours
3158611|NCT00389376|Other|Group 5|Placebo and 560 mg single dose + every 8 hours
3158612|NCT00389376|Other|Group 6|Placebo and 560 mg single dose + every 8 hours
3158613|NCT00389376|Other|Group 7|Placebo and 700 mg single dose + every 8 hours
3158614|NCT00389480|Experimental|I|Dose escalating
3158615|NCT00389558|Active Comparator|2|Biseptine
3158616|NCT00389558|Active Comparator|1|Amukin
3158617|NCT00389610|Experimental|Stratum I|Patients receive booster vaccination comprised of an allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given subcutaneously (SC). Treatment repeats every 6 months.
3158618|NCT00389610|Experimental|Stratum II|Patients receive priming vaccinations comprised of allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine, given SC once a month for 3 months and then receive booster vaccinations as in stratum I.
3158619|NCT00389636|Active Comparator|1|TheraGauze alone
2479178|NCT03042000|Experimental|Group B1|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with combined chemotherapy (Capox regimen) + radical surgery + ACT'
2479183|NCT03042000|Active Comparator|Group B2|Patients with cT4NanyM0 or cTanyN2M0 mid/low rectal cancer who undergo the treatment modality of 'NCRT with single-agent chemotherapy (Capecitabine) + radical surgery + ACT'
2479184|NCT03042000|Experimental|Group C1|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the transanal endoscopic microsurgery (TEM) excision of the lesion.
2479185|NCT03042000|Active Comparator|Group C2|Patients with locally advanced rectal cancer, being clinically staged cCR after NCRT, who undergo the radical resection of the lesion.
2479217|NCT03041519|Experimental|Zero-fluoroscopy ablation|Zero-fluoroscopy ablation will be performed under the guidance of Ensite NavX for mapping and ablation and fluoroscopy will not be used during the procedure.
2479221|NCT03041519|Active Comparator|Conventional fluoroscopy ablation|Conventional fluoroscopy ablation will be performed under fluoroscopic guidance plus Ensite NavX for mapping and ablation during the procedure.
2479285|NCT03041311|Experimental|trilaciclib+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive trilaciclib 240 mg/m2 administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
2479288|NCT03041311|Experimental|placebo+etoposide/carboplatin/atezolizumab|"Induction: Patients will receive placebo administered IV once daily on Days 1, 2 and 3 of each 21-day E/P/A therapy cycle (up to 4 cycles in total). Etoposide 100 mg/m2 will be administered IV daily on Days 1, 2, and 3 of each 21-day cycle. Carboplatin will be administered on Day 1 of each 21-day cycle using the Calvert formula with a target AUC = 5 milligrams per milliliter per minute (mg/mL/min) to calculate the dose. Atezolizumab 1200 mg will be administered as an IV on Day 1 of each 21-day cycle.~Maintenance: Following the induction phase, patients will receive maintenance atezolizumab at a dose of 1200 mg on Day 1 of every 21-day cycle until disease progression, withdrawal of consent, death, or study termination by the Sponsor."
2479394|NCT03040544|Experimental|LTB-Curriculum|First group/arm undergo MIS training according to the LTB curriculum after the first own laparoscopic cholecystectomy in the OR as a baseline. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using the Global Operational Assessment of Laparoscopic Skill (GOALS) score.
2479401|NCT03040544|Active Comparator|no LTB-Curriculums|Second group/arm will not undergo any MIS trains after their first laparoscopic CHE in the OR. After 6 weeks, the participants in this group/arm will perform their second CHE. The video recordings of the MIS procedures will be analysed and compared using GOALS score.
2479459|NCT03040128|Placebo Comparator|placebo|normal saline infusion
2479462|NCT03040128|Experimental|minocycline|intravenous minocycline
2479716|NCT03038451|Experimental|s-amlodipine besylate 2,5 and 5 mg tablets|
3158620|NCT00389636|Active Comparator|2|Theragauze + Regranex
3158621|NCT00389675|Experimental|Darusentan|Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
2480030|NCT03036514|Experimental|Case|Sublingual sufentanil tablet system (SSTS) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. Orange-coloured tablets containing 15mcg sufentanil, the patient-controlled device is designed to deliver a single tablet with a minimum lockout interval of 20 minutes.
2480033|NCT03036514|Active Comparator|Control|Patient-controlled intravenous analgesia (PCIA) for postoperative pain relief after laminectomy or spinal fusion in the first 72 hour period. This classic patient-controlled IV-pump contains 1mg/ml morphine and 50mcg/ml dehydrobenzperidol. Pump characteristics include 1ml each asked bolus, lockout interval of 8 minutes.
2480557|NCT03032848|Active Comparator|Promestriene Group|use of 1 gram per day
3158622|NCT00389675|Active Comparator|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
3158623|NCT00389727|Experimental|Group 1 Patients|Radiotherapy Patients
3158624|NCT00389727|No Intervention|Group 2|
3158625|NCT00389779|Experimental|Darusentan|Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily for 14 weeks
3158626|NCT00389779|Active Comparator|Guanfacine|Placebo to match darusentan for 2-week placebo run-in period, followed by guanfacine 1 mg capsules administered orally once daily for 14 weeks
3158627|NCT00389779|Placebo Comparator|Darusentan Placebo|Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
3158628|NCT00389792|No Intervention|ATI-2042 200 mg|
3158629|NCT00389792|No Intervention|ATI-2042 400 mg|
3158630|NCT00389792|No Intervention|ATI-2042 600 mg|
3158631|NCT00389792|No Intervention|ATI-2042 Placebo|
3158632|NCT00389844|No Intervention|1|Routine care
3158633|NCT00389844|Active Comparator|2|Exercise only
3158634|NCT00389844|Active Comparator|3|Motivation only
3158635|NCT00389844|Experimental|4|Exercise plus motivation
3158636|NCT00389883|Active Comparator|1|propofol et remifentanil
3158637|NCT00389883|Experimental|2|sevoflurane et sufentanil
3158638|NCT00389909|Active Comparator|1|Treatment based on patient weight;
3158639|NCT00389909|Active Comparator|2|Treatment based on a chart taking into account weight, age and gender
3158640|NCT00389922|Experimental|A (Daily Dosing)|"Oral lapatinib given daily for 28 days plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
2479181|NCT03041948|Experimental|ilioinguinal/iliohypogastric nerve block|All patients will receive acetaminophen (15mg/kg) within one hour of induction of anesthesia. Inhalation induction of anesthesia will be performed with sevoflurane in 100% O2. A single dose of up to 2-4 mg/kg of propofol and Remifentanil 0.5-1mcg/kg will be given prior insertion of a laryngeal mask airway or endotracheal tube. Anesthesia will be maintained with Propofol and Remifentanil (2.5mcg/ml) which will be started at 300 mcg/kg/min and titrated to effect. If necessary additional boluses of Propofol (1mg/kg) and/or Remifentanil (0.5-1mcg/kg) and/or Morphine 0.05mg/kg boluses IV will be administered. Ondansetron (0.1mg/kg) and Dexamethasone (0.15mg/kg) will be given as antiemetic prophylaxis for all patients. Ketorolac 0.3mg/kg will be given to each patient. The IIG/IHG group will receive a unilateral US guided IIG/IHG with 0.4mL/kg of ropivacaine 0.2% (max 12 mL).
2479295|NCT03041428|Experimental|Recruited patients|Ultraprotective ventilation
2479360|NCT03040882|Experimental|cotton sock|
2479363|NCT03040882|Active Comparator|Elastic Compression Wraps|
2479425|NCT03040401|Experimental|Cohort 1: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 1 will receive only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4."
2479429|NCT03040401|Experimental|Cohort 2: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 2 will receive Ceplene® in combination with Proleukin® during all treatment cycles (1-4)."
2479433|NCT03040401|Experimental|Cohort 3: Ceplene® and Proleukin®|"Enrolled subjects will receive histamine dihydrochloride (HDC; Ceplene®) and IL-2 (Proleukin®) subcutaneously (s.c.) twice daily (BID) in 3-week periods followed by 3 week rest periods for a total of 4 treatment cycles.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2 injections.~Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2."
2479555|NCT03039452|Experimental|High intensity interval training|
3193138|NCT00815269|Active Comparator|1|Halothane anesthesia: induction and maintenance with different doses
2479696|NCT03038529|Other|A: Classic approach|"Intradiscal O3 injection through classic postrolateral extraarticular percutaneous approach.~The participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2. The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
2479700|NCT03038529|Active Comparator|B: Transforaminal approach (Yess approach )|"Participants will receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach).~The ozone-oxygen mixture was produced in real-time by a medical ozone generator (Ozonline E 80, Medica srl, Bologna Italy)."
2479738|NCT03038204||PMA+MVA+CABG|patients with ischemic cardiomyopathy and mitral regurgitation who underwent coronary artery bypass grafting, mitral annuloplasty, and papillary muscles approximation.
2479745|NCT03038204||MVA+CABG|patients with ischemic cardiomyopathy who underwent coronary artery bypass grafting and mitral valve annuloplasty.
2479771|NCT03037970|Experimental|ABSOLVE|Type I collagen sheet soaked in a solution containing rhPDGF-BB.
2479773|NCT03037970|Placebo Comparator|Placebo|Collagen sheet soaked with saline solution.
3173411|NCT00611793|Experimental|1|PTK787/ZK222584 and Bevacizumab
2480031|NCT03036436|Experimental|Intervention|Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
2480084|NCT03036085|Active Comparator|Bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with 0.5% bupivacaine with 1% epinephrine. In the bupivacaine group 20 ml of 0.5% bupivacaine with 1% epinephrine will be diluted to a total volume of 40 ml using 20 ml normal saline. From those 40 ml, 30 ml will be used for the posterior intercostal nerve block and 10 ml will be injected locally into the surgical wounds.
2480089|NCT03036085|Experimental|Liposomal bupivacaine|Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine (13.3 mg/ml). In the liposomal bupivacaine group, a total dose of 266 mg of liposomal bupivacaine (one 20 ml vial of 13.3 mg/ml) per patient will be diluted to a total volume of 40 ml using 20 ml normal saline.
2480141|NCT03035604||Nutritional geriatric assessment|Participants undergo nutritional geriatric assessment over 15 minutes in person or on the phone every 3 months for 12 months.
2480171|NCT03035526||3161 men (45-84 years old)|3161 men without known coronary artery disease
2480218|NCT03035305|Experimental|SMC and LNS (intervention group)|Children included in the 9 health areas of the intervention group receiving both lipid-based nutrient supplement and seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
2480228|NCT03035305|Other|SMC only (control group)|Children included in the 9 health areas of the control group receiving seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine
2480251|NCT03034850||CRS/HIPEC|Patients with a confirmed histological diagnosis of peritoneal disease treated by cytoreductive surgery (CRS) with hyperthermic intraperitoneal peroperative chemotherapy (HIPEC).
3173412|NCT00611819|Experimental|1|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 24 weeks
3173413|NCT00611819|Active Comparator|2|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
3173414|NCT00611832|Active Comparator|Standard|"Standard information-only version of the television series that includes only modeling and demonstration of the targeted parenting skills"
2479284|NCT03041285|Experimental|Group 1 NOX66 400mg and SBRT|Group 1 patients will receive 400mg of Idronoxil (NOX66) suppository (1 suppository) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
2479287|NCT03041285|Experimental|Group 2 NOX66 800mg and SBRT|Group 2 patients will receive 800mg of Idronoxil (NOX66) suppository (2 suppositories) daily from Day 0 (1 day before radiotherapy) until 7 days after completion of radiotherapy. Stereotactic Body Radiation Therapy will be given on Days1-5 (5 fractions). Total treatment course is 13-15 days, depends on whether radiotherapy is given on consecutive days or over the weekend.
2479369|NCT03040726|Experimental|Group I (netupitant, palonosetron hydrochloride)|Patients receive netupitant orally (PO) and palonosetron hydrochloride PO on days 1, 6, and 11 in the absence of disease progression or unacceptable toxicity.
2479373|NCT03040726|Placebo Comparator|Group II (placebo)|Patients receive placebo PO on days 1, 6, and 11.
2479480|NCT03039868||Normal Pap smears|This is the control group.
2479483|NCT03039868||Abnormal Pap smears|This is the case group.
2479514|NCT03039608|Experimental|combination group|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
2479515|NCT03039608|Active Comparator|control group|oral steroid administration（prednisone）
3193139|NCT00815269|Experimental|2|Isoflurane anesthesia: induction and maintenance with different doses
2479671|NCT03038711|Experimental|Dose Panel 1|BMS-986166 or Placebo matching BMS-986166
2479681|NCT03038711|Experimental|Dose Panel 2|BMS-986166 or Placebo matching BMS-986166
2479685|NCT03038711|Experimental|Dose Panel 3|BMS-986166 or Placebo matching BMS-986166
2479735|NCT03038217|Experimental|ACT group|Group of patients with pathologically confirmed Stage II-III colorectal cancer who receive postoperative treatment with chemotherapeutic agent (ACT) using Capecitabine +/- Oxaliplatin.
2479742|NCT03038217|Experimental|Non-ACT group|Group of patients with pathologically confirmed stage II colorectal cancer who receive no adjuvant chemotherapy.
2479753|NCT03038217|Experimental|LR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo local resection (LR)
2479758|NCT03038217|Experimental|RR group|Group of patients with clinically staged T1-2N0 rectal cancer who undergo radical resection (RR)
2479792|NCT03037788|Experimental|WO3979|Formulation containing WO3979 for topical application
2479794|NCT03037788|Experimental|WO3970|Formulation containing WO3970 for topical application
2479797|NCT03037788|Experimental|WO3992|Formulation containing WO3992 for topical application
2479800|NCT03037788|Placebo Comparator|Placebo of WO3988|Formulation containing Placebo of WO3988 for topical application
3193140|NCT00815269|Experimental|3|Sevoflurane anesthesia: induction and maintenance with different doses
2479974|NCT03037034|Experimental|Forcep Strip Method Treatment|patients who have Gastrointestinal Subepithelial Tumors Originating from the Muscularis Propria are enrolled
2480085|NCT03036228|Experimental|Dose escalation|Karonudib is an oral inhibitor of MTH1 and will be supplied as an oral solution or tablets to be taken BID. Each cycle is defined as 28 days.
2480162|NCT03035799|Experimental|Paleolithic Diet|Paleolithic Diet
2480167|NCT03035799|Active Comparator|General Healthful Diet|General Healthful Diet
2480224|NCT03035357|Experimental|Daratumumab|Participants receive Daratumumab by vein over about 1 hour 1 time a week during Weeks 1-4.
2480310|NCT03034707|Experimental|Biotin arm|biotin 10 mg/day for 7 days
2480377|NCT03034304|Experimental|MASCT-I alone or in combination with chemical drugs or in comb|"Group 1: treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.~Group 2: treatment with MASCT-I in combination with ifosfamide. In the event of disease progression, treatment with a combination of PD1 antibodies is added. Patients with soft tissue sarcomas should be discontinued and treated with MASCT-I +PD1 antibody only until disease progression occurs again.~Group 3: Advanced metastatic or recurrent urothelial carcinoma, soft tissue sarcoma/osteosarcoma, and cholangiocarcinoma that progressed after first-line chemotherapy were treated with MASCT-I combined with PD1 antibody until the disease progressed. If disease progression occurs during treatment, treatment is discontinued and follow-up is initiated.~Group 4: Recurrent metastatic solid tumors that had failed previous treatment with PD1 antibody were treated with MASCT-I regimen 2 + PD1 antibody until the disease progressed."
2480423|NCT03033654|Experimental|Intervention|Two Consecutive Sunscreen Applications
2480470|NCT03033381|Active Comparator|operated side testis|Operated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
2480471|NCT03033381|Sham Comparator|Contralateral testis|Nonoperated side testis volume and blood flow will be evaluated with color doppler ultrasound before and after the surgery (Preoperative, 7 day and 30 day)
2480501|NCT03033056||Anxiety Clinic Patients|Adult males and females being treated at the anxiety disorders clinic at the University of Minnesota predominantly for clinical anxiety.
2480502|NCT03033056||Healthy Comparisons|Sex, age, and socioeconomically matched healthy controls
2480536|NCT03032861|Experimental|Orange juice|Ten women will consume 100% orange juice (300 mL/day) during 60 days.
2480587|NCT03032653|Active Comparator|Late WB|Intervention: Patients receive a plaster splint in the operating room. They are not permitted to WB or ROM on the affected limb at this stage. At the first follow-up appointment (two weeks post-op), the splint is removed and a removable pre-fabricated walking boot applied. At this stage the patient is permitted to WB as tolerated while wearing the boot, and to perform ROM exercises with the boot removed. At six weeks post-op, the boot is discontinued and full unrestricted and unprotected weightbearing and ROM is permitted.
2480597|NCT03032653|Experimental|Immediate unprotected WB and ROM|Patient do NOT receive a brace or splint of any kind. They are permitted to weightbear and range of motion as tolerated within the limitations of their own comfort. Use of ambulatory aids of any kind is permitted as needed without restrictions.
2480636|NCT03032198|Experimental|Imagio OA/US Scan|Imagio opto-acoustic gray-scale ultrasound scan
2480700|NCT03031990|Experimental|Yoga intervention|The participants who elect to include yoga as part of their infertility treatments will self select one of three groups: 1) In person yoga for fertility group; 2) Online yoga for fertility group; 3) In person discussion only group
2479317|NCT03041324|Experimental|Experimental: Cohort 1: SB-913: Starting Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2479320|NCT03041324|Experimental|Experimental: Cohort 2: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2479322|NCT03041324|Experimental|Experimental: Cohort 3: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2479323|NCT03041324|Experimental|Experimental: Cohort 4: SB-913 at Next Ascending Dose|A single dose of each of the three components of SB-913 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
2479368|NCT03040635|Experimental|Risdiplam '2' Milligrams (mg)|A single dose of 2 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2479374|NCT03040635|Experimental|Risdiplam '6' mg|A single dose of 6 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2479377|NCT03040635|Experimental|Risdiplam '12' mg|A single dose of 12 mg Risdiplam will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2479379|NCT03040635|Placebo Comparator|Placebo|A single dose of placebo will be administered to all participants randomized to this arm under fasted conditions as an oral drinking solution on Day 1.
2479414|NCT03040245||intervention group|The intervention group was instructed to complete the questionnaires at least 48 hours after the intervention that is, after reading the information booklet
2479415|NCT03040245||control group|The same items were included as in the initial folder, with an additional questionnaire enabling the intervention group to qualitatively assess the information booklet. If there was no response, reminders were sent by email, then by telephone, and lastly by post.
2479452|NCT03040050|Other|Men scheduled for prostate biopsy randomized to Control|
2479455|NCT03040050|Experimental|Men scheduled for a prostate biopsy randomized to Intervention|
2479545|NCT03039465|Experimental|Modified Trans-Esophageal Prosthesis|Patients satisfying the selection criteria would be subjected to the insertion of the TEP and evaluated at subsequent time points for the success of the procedure.
2479618|NCT03039075|Active Comparator|Metformin SR Tablet|Metformin hydrochloride sustained-release tablets made in Conquer pharmaceutical co., LTD
2479622|NCT03039075|Active Comparator|Glucophage|The original drug of metformin
2479664|NCT03038633|Experimental|Cohort 1|"900 mg novel medical food containing 22.2mg iron~receive 900 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to General Clinical Research Center, (GCRC) for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2479677|NCT03038633|Experimental|Cohort 2|"1800 mg novel medical food containing 44.4 mg of iron~receive 1800 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2479684|NCT03038633|Experimental|Cohort 3|"2700 mg novel medical food containing 66.6 mg of iron~receive 2700 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2479687|NCT03038633|Experimental|Cohort 4|"3600 mg novel medical food containing 88.8 mg of iron~receive 3600 mg by mouth (3 capsules, one at each meal) daily; after Day 28 remain on level for additional 2 months if clinically indicated~receive a phone call from coordinator between Day 5-9 to assess side effects and medications~return to GCRC for a blood draw at days 14, 28, 60, and 90 while on novel medical food"
2479732|NCT03038282|Experimental|Chromium Chloride|Participants transdermal chromium chloride 50 to 600 mcg/day.
2479739|NCT03038282|Experimental|Individual Exercise|Exercise 150 minutes per week (over 3 to 5 days) for 12 weeks.
2479741|NCT03038282|No Intervention|Control Group|Participants or participant's caregiver will be provided educational materials on starting an exercise program and instructions for the application of transdermal chromium chloride, but will receive no formal support for their exercise program.
2479810|NCT03037879|Experimental|SPT|Speed of Processing Training
2479815|NCT03037879|Active Comparator|Control Group SPT|Control group to SPT treatment group
2479821|NCT03037879|Experimental|mSMT|Story Memory Technique
2479822|NCT03037879|Active Comparator|Control mSMT|Control group to mSMT treatment group
2479888|NCT03037333|Other|fluoroscopy|
2479895|NCT03037333|Other|ECG/ECHO|
2479966|NCT03036904|Experimental|Venetoclax plus DA-EPOCH-R|Venetoclax will be given in conjunction with 6 cycles of DA-EPOCH-R (doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone, rituximab). The dosing schedule and regimen for DA-EPOCH-R will follow established protocols. Venetoclax will be administered days 1-10 of each 21-day cycle, with the exception of cycle 1, during which venetoclax dose will commence on day 3 and continue through day 12, so as to clarify attribution of any observed TLS and/or infusion reactions, and minimize tumor lysis syndrome (TLS) risk.
2480000|NCT03036319|Experimental|Active TES|"Participants will receive real tES (tDCS, tACS, tRNS) in which they receive up to 4 milliamps (mA) of stimulation per electrode for up to 40 minutes for up to 260 sessions. As this may be a cross-over design, some participants may receive active and sham conditions."
2480009|NCT03036319|Placebo Comparator|Sham TES|Participants undergoing this condition will have the exact same procedures as the active group, with the exception that they will receive only sham stimulation for up to 260 sessions.
2480016|NCT03036319|Experimental|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation.
3193141|NCT00815269|Experimental|4|Desflurane anesthesia: induction and maintenance with different doses
3193142|NCT00815269|Experimental|5|Enflurane anesthesia: induction and maintenance with different doses
3193143|NCT00815282|Other|Patients|patients were girls aged 15 to 18 immunised with the HPV vaccine according to dutch vaccination guidelines
2479508|NCT03039959||Pulmonary hypertension cohort|Consecutive adult Pulmonology inpatients with suspected or pre-diagnosed pulmonary hypertension undergoing invasive right heart catheterization.
2479509|NCT03039959||Heart failure cohort|Consecutive adult Cardiology inpatients with a new or pre-existing diagnosis of heart failure who are referred to the consultant nephrologist with a history of diuretic-resistant fluid overload and impaired renal function.
2479532|NCT03039348||Breast reconstruction|The patients choosing for breast reconstruction after mastectomy for breast cancer.
2479534|NCT03039348||No breast reconstruction|The patients not choosing breast reconstruction after mastectomy for breast cancer.
3193144|NCT00815334|Experimental|Patients with decreased bladder compliance|Patients who have decreased bladder compliance
3193145|NCT00815334|Active Comparator|Patients with normal bladder compliance|Patients who have normal bladder compliance
2479710|NCT03038477|Experimental|Durvalumab|Patients in Arm A will be given anti-PD-L1 antibody, durvalumab, every 2 weeks for a maximum of 26 doses if there is no radiographic evidence of disease recurrence. For Arm A, one cycle constitutes two durvalumab treatments on Day 1 and Day 15, respectively, repeated every 28 days.
2479712|NCT03038477|No Intervention|No Durvalumab|Patients in Arm B will be observed.
2479719|NCT03038178|Experimental|LAI plus multi-drug regimen|once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance with the 2007 ATS/ IDSA guidelines
2479786|NCT03038022|Experimental|MGL-3196|Study Drug
2479787|NCT03038022|Placebo Comparator|Placebo|Matching Placebo
2479842|NCT03037567|Experimental|Modified Weight Watchers plan|Modified Weight Watchers Plan which includes a food plan, activity plan, group support and cognitive behavior modification. Weekly study-specific group meetings; electronic tools through iPhone app for 24 weeks.
3193146|NCT00815373|Active Comparator|1|Cosopt* b. i. d. (dosed morning and bedtime) will be administered topically
3193147|NCT00815373|Active Comparator|2|Xalacom* q.d.(dosed bedtime) and placebo vehicle q.d. (dosed morning) topically in the other group
2479975|NCT03036722|Experimental|Flaxseed porridge group|22 volunteer will be given 80g of a pre prepared porridge meal containing 40 g of ground (flaxseed) to consume daily.
2479976|NCT03036722|Placebo Comparator|Placebo control porridge group|22 volunteer will be given 78.5g preprepared control porridge matched for energy and fat content to consume daily ( Matching food products: 22g MCT (medium chain Triglyceride), 5.5g pure egg white powder, 11g cream of rice).
3193148|NCT00815386|Experimental|PTMA implanted|Enrolled patients receiving a PTMA implant
3193149|NCT00815399|Experimental|1|
3193150|NCT00815399|Active Comparator|2|
3193151|NCT00815412|Active Comparator|Counseling in use of health care|
3193152|NCT00815412|Active Comparator|Counseling in diet, exercise|
3193153|NCT00815412|Placebo Comparator|Contol group|
3193154|NCT00815425||African Americans with RA|1063 participants with RA
3193155|NCT00815425||African-Americans without RA|550 participants without RA
3193156|NCT00815438|Experimental|Surgical Procedure|Laparoscopic transvaginal cholecystectomy with endoscopic assistance.
3193157|NCT00815451|Placebo Comparator|placebo dark chocolate|polyphenol-poor dark chocolate
3193158|NCT00815451|Experimental|polyphenol-rich dark chocolate|
3193159|NCT00815464|Experimental|Antiviral Therapy|Liquid Acupuncture(Herb Acupoints Injection) Therapeutics was researched and developed by Herbalist Yu Ru Lin in early of 1950s and used by Yu Medical Garden till now. It is an integrated therapeutics,according to individual condition, select the Acupoints(not limit to current used common acupoints) and proper herbs made individually.It is a special medical treatment conception, which theory is utilizing patients' condition, mobilizing their individual internal curability,therefore the final efficacy can be retrieved.
3193160|NCT00815477|Active Comparator|1|Waitlist control with generic Information about lifestyle and hypertension
3193161|NCT00815477|Experimental|2|Web-based intervention of lifestyle counseling messages based on the transtheoretical model of readiness for change.
3193162|NCT00815503|Active Comparator|Ropivacaine|
3193163|NCT00815503|Placebo Comparator|Saline|
3193164|NCT00815542|Active Comparator|double balloon catheter|Cervical ripening by double balloon catheter
3193165|NCT00815542|Placebo Comparator|prostaglandins E2|cervical ripening using prostaglandins E2
3193166|NCT00815555||1|Women diagnosed with receptor positive breast cancer, treated with Tamoxifen
3193167|NCT00815568|Experimental|Regimen|Conditioning regimen for AML with FLT3 mutation, AML/MDS unfavorable cytogenetic risk group, chemorefractory NHL or HD, or ALL/CML
3193168|NCT00815581|Other|photorefraction|
3193169|NCT00815620||1|patients undergoing local ablative therapy such as transcatheter-arterial chemoembolization or selective interal radiotherapy
3193170|NCT00815620||2|patients undergoing surgery or radiofrequency ablation
3193171|NCT00815620||3|patients undergoing peptide receptor radiotherapy
3193172|NCT00815646|Experimental|Sildenafil|Measurements of pulmonary and systemic pressures during cold water immersion before and after sildenafil 50 mg orally.
3193173|NCT00815672|No Intervention|Treatment Arm 1|Usual Care: Standard care monitoring
3193174|NCT00815672|Experimental|Treatment arm 2|Home-based Exercise: Progressive walking and resistance exercise treatment.
3193175|NCT00815724|Experimental|1|Participants will take part in a distance learning group.
3193176|NCT00815724|No Intervention|2|Participants in the control group will not receive any study materials or take part in any study activities.
3193177|NCT00815737|Experimental|A|
3193178|NCT00815737|Placebo Comparator|B|
3193179|NCT00815750|Other|Phase I - Information Gathering|
3193180|NCT00815750|Other|Phase 2 - Decision Aid|
3193181|NCT00815763|Experimental|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg once a day and continued for 14 days
3193182|NCT00815763|Placebo Comparator|placebo|infusion placebo (group B)once a day and continued for 14 days
2479354|NCT03040752|Active Comparator|Ritodrine|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor.
3193183|NCT00815789|Experimental|Intervention|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
2479504|NCT03039803|Active Comparator|single-layer continuous uterotomy suture|Single-layer continuous uterotomy suture
2479506|NCT03039803|Active Comparator|double-layer continuous uterotomy suture|double-layer continuous uterotomy suture
2479550|NCT03039426|Experimental|Group Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
2479558|NCT03039426|Active Comparator|Group Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
3193184|NCT00815789|No Intervention|Control|Receive educational material about CVD reduction at baseline
3193185|NCT00815815|Active Comparator|Continued inpatient treatment|Participants will undergo inpatient hospital treatment until they have gained enough weight to be discharged.
3193186|NCT00815815|Experimental|Sequenced treatment|Participants will begin with inpatient treatment, transition to day patient treatment, and then transition to outpatient treatment.
3193187|NCT00815828|Other|1|Group that don't do the resistance exercises
3193188|NCT00815854|Experimental|Folate|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
3193189|NCT00815854|Placebo Comparator|Placebo|"During Phase 1, participants will undergo screening for metabolic syndrome and have genetic makeup, body size, and endothelial functioning measured. During Phase 2, participants will receive daily folic acid as a treatment for metabolic syndrome.~Phase 2B participants will receive either daily folic acid or placebo as a treatment for metabolic syndrome."
3193190|NCT00815867|Experimental|A|Patient will receive Epoetin Beta
2479943|NCT03037008|Active Comparator|continent men after RALP|perineal sonography, questionnaires, 24h pad tests
2479946|NCT03037008|Active Comparator|incontinent men after RALP|perineal sonography, questionnaires, 24h pad tests
2480001|NCT03036553||Chronic musculoskeletal pain|"(i) men / women over the age of 18 (ii) participants with musculoskeletal pain (pain intensity of 3 or more on a numerical scale of pain 0-10) will be included in this study, among all of the following conditions: pain around the axial skeleton (neck, lower back And / or pelvis) or peripheral joints (shoulder, elbow, wrist, knee and / or ankle). We included people with clinical diagnoses of chronic pain (shoulder pain, neck pain, whiplash disorder, temporomandibular joint disorders, pelvic pain syndrome, ankle pain and epicondylalgia), non-specific low back pain, fibromyalgia, chronic fatigue syndrome and those with a radiological diagnosis of osteoarthritis.~(iii) duration of symptoms: more than 3 months."
2480045|NCT03036189|Experimental|Intervention arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
2480048|NCT03036189|Experimental|Wait-list control arm|There are no devices or drugs used in this trial. The treatment is the same for the intervention arm and the wait-list control arm. The treatment is group trial of 7 meetings designed to improve chronic illness self-management. The name of the treatment is baa nnilah.
3193191|NCT00815867|No Intervention|B|
3193192|NCT00815880|Active Comparator|Implantable Counterpulsation Therapy|The study is a single arm study with 20 patients being treated with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. These patients will receive the C-Pulse System Implant as intervention therapy. There is not a control arm in this feasibility study.
3193193|NCT00815893|Experimental|1 dex group|received dexmedetomidine (1.0 mcg/kg) infusion
2480173|NCT03035513||CSWS patients|The data of CSWS patients will be statistically compared to healthy volunteers
2480174|NCT03035513||healthy volunteers|The data of CSWS patients will be statistically compared to healthy volunteers
2480199|NCT03035240|Experimental|Financial Education Intervention|
2480200|NCT03035240|No Intervention|No Financial Education Intervention|
2480261|NCT03035058|Experimental|Vedolizumab IV 300 mg Q4W|Vedolizumab 300 mg, intravenous (IV), once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 4 weeks (Q4W) starting from Week 6 to Week 102.
2480262|NCT03035058|Experimental|Vedolizumab IV 300 mg Q8W + Placebo|Vedolizumab 300 mg, IV, once at Day 1 and Week 2; followed by vedolizumab 300 mg, IV, once every 8 weeks (Q8W) starting from Week 6 to Week 102 (and placebo, IV, Q8W starting from Week 10 to Week 98.
2480263|NCT03035058|Placebo Comparator|Placebo|Vedolizumab placebo-matching, IV, at Day 1 and Week 2; followed by Vedolizumab placebo-matching, IV, Q4W starting from Week 6 to Week 102.
2480379|NCT03034213|Active Comparator|Treatment|Gentrix(TM) Surgical Matrix
2480382|NCT03034213|Active Comparator|Control|Standard of care mesh
2480406|NCT03033680|Experimental|Multiple System Atrophy (MSA)|Eight subjects with a probable MSA diagnosis will be recruited for this study. Each subject will undergo a [F-18]PBR06 PET scan at baseline, and at 9 months follow-up.
2480436|NCT03033524|Experimental|Cohort 1|Patients will be treated with 8mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
2480447|NCT03033524|Experimental|Cohort 2|Patients will be treated with 12mg/kg of TTAC-0001 on day 1, day 8 and day 15 in every 4 weeks of cycle.
2480452|NCT03033524|Experimental|Cohort 3|Patients will be treated with 12mg/kg of TTAC-0001 weekly in every 4 weeks of cycle.
2480526|NCT03033186||Everolimus (afinitor)|Patients using everolimus as therapy for cancer: Advanced (Hormone-Receptor [HR]-positive, HER2-negative) breast cancer (BC), advanced or unresectable neuroendocrine tumours of pancreatic (pNET), gastrointestinal or lung origin and metastatic renal cell carcinoma (mRCC)
2480645|NCT03032237|Experimental|Protein-rich assortment|The intervention groups receives protein-rich meals and protein-rich dairy products.
2479361|NCT03040817|Active Comparator|Esomeprazole + Mosapride|Each participant receive Esomeprazole+ Mosapride. The dosages are：Nexium 40mg bid， Mosapride Citrate Tablets 5mg tid.
2479410|NCT03040375|Experimental|Peer counselling|There were two types of intervention: one providing breast-feeding and complementary feeding counselling + psychosocial stimulation interventions.
2479411|NCT03040375|No Intervention|Non peer counselling|Usual health messages
2479449|NCT03040076|Experimental|Cognitive Bias Treatment|Intervention condition
2479450|NCT03040076|Active Comparator|Relaxation Condition|Active control condition
2479474|NCT03039751|Experimental|AdvVEGF-D|Intramyocardial AdVEGF-D
2479475|NCT03039751|Placebo Comparator|Control|Intramyocardial placebo (buffer solution without gene)
2479717|NCT03038490|Experimental|Study group|The treatment group would be given 2 Sackets of an oral mixture of arginine, glutamine and HMB (ABOUND) every day for a maximum period of 4 weeks, either orally or via enteral feeding.
2479718|NCT03038490|No Intervention|Control group|All patients would be assessed by a dietitian to ensure them receiving nutritional support of at least 30 kcal/kg/day and of at least 1.2 g/kg/day of protein regardless of feeding method. During the study period, vitamin C and zinc supplement would not be given.
2479784|NCT03038035|Active Comparator|MLC901|"NeuroAid II MLC901 is a derivative product of NeuroAid MLC601. It is a simplified formula based on the 9 Herbal ingredients that are present in NeuroAid MLC 601. Neuroaid II has been approved for sale as a Chinese Proprietary Medicine in Singapore by the HSA since March 2010. 24 weeks intervention. Dosage: 2 capsules 3 times a a day~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
2479785|NCT03038035|Placebo Comparator|Placebo|"24 weeks intervention with orally placebo. 2 capsules 3 times a day.~Upon completion of 24 weeks, subject will be given an option to continue an open-label extension for another 24 weeks."
2479903|NCT03037164|Experimental|INTERCEPT (Test)|Red blood cell components treated with the INTERCEPT Blood System for Red Blood Cells ordered and administered to study patients by their treating physicians according to the local standards of care
2479907|NCT03037164|Active Comparator|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
2479972|NCT03036761|Experimental|AUR+: Auriculotherapy|Patients benefit from 3 sessions of auriculotherapy at one month intervals.
2479973|NCT03036761|No Intervention|AUR-: No auriculotherapy|Patients do not benefit from auriculotherapy.
3158641|NCT00389922|Experimental|B (Intermittent Dosing)|"Oral lapatinib given days 2-5, 9-12 and 16-25 plus IV vinorelbine given weekly (3 out of 4 weeks)~Cohorts of 3-6 patients receive escalating doses of lapatinib ditosylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during course 1. At least 6 patients are treated at the MTD. Once the MTD of lapatinib has been determined, patients may be accrued to group B or to a separate pharmacokinetics cohort in group A."
3158642|NCT00389935|Experimental|Treatment|
2480082|NCT03035968|Experimental|Vojta arm|Patients in the interventional arm are treated with Vojta therapy from randomization until discharge.
2480083|NCT03035968|Active Comparator|conventional physiotherapy arm|Patients in this control arm are treated with conventional physiotherapy for motor improvement from randomization until discharge.
2480275|NCT03034733|Experimental|dexamethasone 0,15 mg/kg|single-dose intravenous dexamethasone 0,15 mg/kg, intraoperative
2480279|NCT03034733|Experimental|dexamethasone 0,25 mg/kg|single-dose intravenous dexamethasone 0,25 mg/kg, intraoperative
2480284|NCT03034733|Placebo Comparator|Sodium Chloride, (24)NaCl 0,9%|single-dose intravenous saline, intraoperative
2480322|NCT03034486|Experimental|A single sequence, 3-period|
3158643|NCT00390000|Experimental|Arm I|See Detailed Description
3158644|NCT00390039|Experimental|A|MNS075 7.5mg
3158645|NCT00390039|Placebo Comparator|B|Placebo
3158646|NCT00390039|Active Comparator|C|IV Morphine
3158647|NCT00390039|Experimental|E|MNS075 15mg
3158648|NCT00390039|Placebo Comparator|D|Placebo
3158649|NCT00390039|Placebo Comparator|F|Placebo
3158650|NCT00390052|Experimental|Arm I|Patients will receive a 2-hour infusion of 3-AP once in week 1. Beginning in week 2, they will receive 3-AP by mouth twice a day 3 days a week for 3 weeks. Treatment with 3-AP by mouth may repeat every 4 weeks for as long as benefit is shown.
3158651|NCT00390065|Experimental|Study group|Hypoxemic Respiratory Failure treated by Nitric Oxide;
3158652|NCT00390065|Placebo Comparator|Control|Hypoxemic Respiratory Failure control (Placebo);
3158653|NCT00390065|No Intervention|Reference|Reference (Non hypoxemic respiratory failure)
3158654|NCT00390078|Active Comparator|1|20 Subjects, 1x 10E8_TCID50 MVA-mBN32
3158655|NCT00390078|Placebo Comparator|2|10 Subjects 1x 10E8_TCID50 IMVAMUNE
3158656|NCT00390117|Experimental|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
3158657|NCT00390130|Active Comparator|Pentacel|The subjects in this arm will be vaccinated with Pentacel
3158658|NCT00390130|Active Comparator|Prevnar|The subjects in this arm will be vaccinated with Prevnar
3158659|NCT00390143|Experimental|Group A|Subjects previously primed with meningococcal vaccine 134612.
3158660|NCT00390143|Active Comparator|Group B|Subjects previously primed with Mencevax™ ACWY.
3158661|NCT00390195|Experimental|1. Daily|Taking orally the investigational drug daily
3158662|NCT00390195|Experimental|2. Weekly|Taking orally the investigational drug weekly
3158663|NCT00390208|Other|Group 1|Combination triple therapy of Lucentis, Dexamethasone and Visudyne Therapy
3158664|NCT00390208|Other|Group 2|Monotherapy: One 0.5 mg intravitreal Ranibizumab injection
3158665|NCT00390312|Active Comparator|4|Intravenous morphine
3158666|NCT00390312|Experimental|1|Intranasal morphine 7.5 mg
3158667|NCT00390312|Experimental|2|Intranasal morphine 15 mg
3158668|NCT00390312|Active Comparator|3|Oral morphine 60 mg
3193194|NCT00815893|Placebo Comparator|2 control group|received 0.9% saline
3193195|NCT00815893|Active Comparator|3 Propofol group|received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)
3193196|NCT00815906|Experimental|SBI-087 0.15 mg IV|
3193197|NCT00815906|Experimental|SBI-087 0.5 mg IV|
3193198|NCT00815906|Experimental|SBI-087 100 mg SC|
3193199|NCT00815906|Experimental|SBI-087 200 mg SC|
2479847|NCT03037528|Experimental|Positive Affect, Mindfulness, Tracking|Participants will receive information about positive affect and mindfulness, in addition to being asked to actively track what they eat and receiving the core program
2479850|NCT03037528|Experimental|Mindfulness, Tracking|Participants will receive information about mindfulness, be asked to actively track what they eat, and receive the core program.
2479852|NCT03037528|Experimental|Positive Affect, Tracking|Participants will receive information about positive affect, be asked to actively track what they eat, and receive the core program.
2479854|NCT03037528|Experimental|Tracking|Participants will be asked to actively track what they eat in addition to receiving the core program.
2479856|NCT03037528|Experimental|Positive Affect, Mindfulness|Participants will receive information about positive affect and mindfulness in addition to the core program.
2479857|NCT03037528|Experimental|Positive Affect|Participants will receive information about positive affect in addition to the core program.
2479858|NCT03037528|Experimental|Mindfulness|Participants will receive information about mindfulness in addition to the core program.
2479861|NCT03037528|Experimental|No Extras|Participants will receive the core program.
2479883|NCT03037138|Other|Washed-out scale after using BFR profiling|Blood flow profiling will be used as intervention for washed-out dialysis patients
2479928|NCT03036995|Experimental|Apremilast - Group A|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
2479933|NCT03036995|Placebo Comparator|Placebo - Group B|Patient will receive UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment and placebo during 24 weeks.
2480004|NCT03036592|Experimental|MTNR1B CC|Test glucose tolerance in homozygous non-carriers (CC) for MTNR1B rs10830963 in Early OGTT and Late OGTT
2480014|NCT03036592|Experimental|MTNR1B GG|Test glucose tolerance in homozygous (GG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
2480018|NCT03036592|Experimental|MTNR1B CG|Test glucose tolerance in heterozygous (CG) risk allele carriers for MTNR1B rs10830963 in Early OGTT and Late OGTT
2480076|NCT03036007|Active Comparator|Prescribed Physical Activity|General physical exercises combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2480079|NCT03036007|Experimental|Exercises with Internet support|Neck-specific exercises with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2480206|NCT03035422|Other|Patients with primary refractory acute myeloid leukemia|Patients with primary refractory acute myeloid leukemia
2480250|NCT03034941|Active Comparator|metformin group|Drug: metformin
2480254|NCT03034941|Active Comparator|COMBI group|Drug: liraglutide + metformin
2480257|NCT03034941|No Intervention|CONTROL group|control group of obese PCOS patients without therapy
2480317|NCT03034603|Experimental|Nutri-jelly with PEITC|Continuous intake of Nutri-jelly with PEITC for 200 milligrams per day, five days per week for 3 months.
2480320|NCT03034603|Placebo Comparator|Nutri-jelly|Continuous intake of Nutri-jelly for 200 milligrams per day, five days per week for 3 months.
2480374|NCT03034174||tigecycline|"Each patient will receive: tigecycline (200 mg q 12 hours i.v.), meropenem (2 g q 8 hours i.v). In each case CVVHD will be started.~Blood samples (3 mL) will be collected 2, 4, 8 and 12 hours after each dose of tigecycline for 3 consecutive days."
2480422|NCT03033849|Experimental|Blood glucose measurement|Every study subject shall test three out of the five devices. The testing order of the BGMS will be changed on each subject to minimize any order effects on measurement results.
2480481|NCT03033290|Experimental|Bu-Zhong-Yi-Qi-Tang (BZYQT)|capsule of BZYQT, 4gm tid, 12gm a day for 2 months
3193200|NCT00815932|Experimental|1-CRPS|10 tDCS naïve patients with CRPS-related neuropathic pain in upper limb
3193201|NCT00815932|Experimental|2-DN|20 tDCS naïve patients with diabetic neuropathy
3193202|NCT00815932|Experimental|3-RPNP|20 tDCS naïve patients with resistant peripheral neuropathic pain
3193203|NCT00815932|Experimental|4-CIPN|10 tDCS naïve patients with CIPN-Chemotherapy Induced Pain Neuropathy patients
3193204|NCT00815945|Experimental|PegLiposomal Doxorubicin + Carboplatin|Subjects will receive PegLiposomal Doxorubicin (40mg/m²) and Carboplatin (AUC6) every 28 days. Treatment period up to 6 months (therapy can be continued in case of tumor response and benefit for the patient)
3193205|NCT00815958|Experimental|A|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)
3193206|NCT00815958|Active Comparator|B|Reaming with conventional reamer
3193207|NCT00815971||NSCLC|Patients with non-small cell lung cancer carcinoma treated with erlotinib
3193208|NCT00815984||Schoolchildren with asthma.|Schoolchildren with asthma.
3193209|NCT00816010|Experimental|1|Lifestyle and compliance counseling via telephone contact with structured set of questions and reinforcements provided
3193210|NCT00816010|No Intervention|2|Control arm with usual care as per local hospital practice
3193211|NCT00816049|Active Comparator|6MPfixed|Fixed dose 6-mercaptopurine days 30-85
3193212|NCT00816049|Experimental|6MPindividualized|Individualized dose increments of 6-mercaptopurine days 30-85
3193213|NCT00816075|Experimental|1, Distilled water|the group of patients with superficial bladder cancer in the intermediate risk group who had their first recurrence after 6 months from the initial TUR. We plan to administer 200 ml of distilled water as immediate instillation for 2 hours
3193214|NCT00816088||neutropenia|Patients undergoing stem cell transplantation or chemotherapy likely to lead to prolonged neutropenia.
2479489|NCT03039673|Placebo Comparator|Placebo|"Patients randomized to this arm will receive subcutaneious placebo injections (5% glucose water solution) in addition to oral Riluzole treatment.~Intervention: Riluzole Intervention: 5% glucose water solution"
2479624|NCT03039062||Chemotherapy group|A total of 120 malignant tumor patients who need to receive chemotherapy are involved for miR-122 detection. They are from 3 centers, 40 for each center. For the first cycle of chemotherapy, the investigators will collect 0.5-1ml blood from the remained blood sample after routine blood test during chemotherapy for each patient.Each patient will have a routine blood test before(±3 days) each cycle of chemotherapy and 7(±3)days after chemotherapy. A routine blood test will include the test of ALT,AST,ALP and TBIL. Sample collection will stop after 4 cycles of chemotherapy. All blood samples collected by investigators are the remained sample after routine tests. Patients in routine care will also have blood tests before each cycle and on day 7(+/- 3) of each cycle of chemotherapy. These patients will also have blood test at these time points even if they are not in this trial.
2479629|NCT03039062||Healthy population|Twenty healthy women or men who come to hospitals for annual physical examinations are enrolled in this study for miR-122 detection. Investigators will collect 0.5-1 ml blood from the remained blood samples after routine blood tests during their annual physical examinations.
2479630|NCT03039062||Patients of intensive care unit|Fourty patients are enrolled in this group for miR-122 detection. The investigators will collect 0.5-1ml blood from the remained blood samples of their routine blood tests or when they need blood tests.
2479675|NCT03038607|Active Comparator|Aspirin group|
2479682|NCT03038607|No Intervention|No intervention|
2479827|NCT03038009|Active Comparator|One-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 1 month.
2479829|NCT03038009|Experimental|Twelve-month therapy|Pantoprazole, 40mg, tablet, oral, once daily for 12 months.
2479879|NCT03037346|Experimental|Supportive Care (questionnaires, educational video)|Participants (patients and family caregiver/MPOA) complete questionnaires about knowledge, attitudes, and beliefs of MPOAD. Participants without a MPOAD watch a 4-minute educational video about the importance of the role of MPOA.
3158669|NCT00390312|Placebo Comparator|5|Intranasal placebo
2480034|NCT03036371|Experimental|High Intensity Interval Exercise|home exercise sessions
2480090|NCT03036020|Experimental|Contraindication anesthesiologists|Ability of anesthesiologists to detect contraindications to thrombolysis in acute stroke patients prehospital by interpretation of prehospital cerebral CT scans
2480222|NCT03035110|Experimental|Dialectical Behavioural Therapy (DBT) skills group|Four group sessions, based on DBT, over two weeks, with a group of four to eight participants in attendance located on the hospital ward where the participant is a patient.
2480483|NCT03033355||Pre- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction prior to receiving intradetrusor injection of Botulinum Toxin-A.
2480485|NCT03033355||Post- BTX-A injection|Female patients with confirmed diagnosis of Multiple Sclerosis referred to our Neurourology clinic with neurogenic lower urinary tract dysfunction who receive intradetrusor Botulinum Toxin-A.
2480517|NCT03032978|Experimental|Calcium silicate|intervention
2480519|NCT03032978|Active Comparator|Calcium Hydroxide|Comparator
2480641|NCT03032692|Experimental|SWORD and exercise with biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. During the session, SWORD will be providing real-time audiovisual feedback. The patient has to start in the baseline position and fill the progress bar without violating movement or posture constraints. If the patient does not reach the goal or violates constraints he will receive a negative audio feedback, the progress bar will turn red and be reset. The patient has to return to the baseline position to restart the movement.
2480649|NCT03032237|Placebo Comparator|Standard assortment|The control group receives standard meals and food products.
3158670|NCT00390312|Placebo Comparator|6|Oral placebo
3158671|NCT00390312|Placebo Comparator|7|Intravenous placebo
3158672|NCT00390338|Experimental|peptide-pulsed type-1-polarized dendritic cells|intralymphatic vaccination with peptide-pulsed type-1-polarized dendritic cells (aDC1)
3158673|NCT00390338|Experimental|peptide-pulsed mature non-polarized dendritic cells (cDCs)|intralymphatic vaccination with peptide-pulsed mature non-polarized dendritic cells (cDCs)
3158674|NCT00390481|Other|Intervention|EC-IC Bypass
3158675|NCT00390481|No Intervention|Control|Best Medical Therapy
3158676|NCT00390533|Experimental|Saredutant 30 mg|Saredutant 30 mg once daily for a maximum of 8 weeks
3158677|NCT00390533|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily for a maximum of 8 weeks
3158678|NCT00390533|Placebo Comparator|Placebo|Placebo for saredutant once daily for one week during the screening phase and for a maximum of 8 weeks during the acute phase
3158679|NCT00390585|Experimental|A|Iodixanol 320
3158680|NCT00390585|Active Comparator|B|Iomeprol 350
3158681|NCT00390598|Active Comparator|senna 36 mG + PEG 2L|Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
3158682|NCT00390598|Active Comparator|4 L PEG|Bowel preparation with 4 L PEG prior to colonoscopy.
3158683|NCT00390637|Experimental|1|Low Protein, Low GI Diet
3158684|NCT00390637|Experimental|2|Low Protein, High Glycemic Index Diet
3158685|NCT00390637|Experimental|3|High Protein, Low Glycemic Index diet
3158686|NCT00390637|Experimental|4|High Protein, High glycemic index diet
3158687|NCT00390637|Experimental|5|Control diet (current recommendations)
3158688|NCT00390702|Experimental|VSD occluder|transcatheter implantation of a VSD occluder (Nitinol coil)
3158689|NCT00390741|Active Comparator|1|Home-based exercise program
3158690|NCT00390741|No Intervention|2|Usual care
3158691|NCT00390754|Experimental|Pregnancy Test Group|Group got free home pregnancy test kits
2479502|NCT03039816|Placebo Comparator|Placebo|The patients were randomly assigned to active or placebo groups using an identical device to be puffed in each nostril 3 times daily. The nasal powders were supplied in plastic containers, which deliver the powder from a nozzle when squeezed. The exact amount delivered is not standardized and the variation in the patterns of deposition in the nose is not known. The placebo was a lactose powder with the same particle size, appearance and the same tinge of mint taste as the cellulose powder.
2479540|NCT03039400|Experimental|Web-based physio group|Those in the web-based physio group will have an individual exercise program set up by a treating physiotherapist on webbasedphysio.com after an initial face-to-face assessment. They will be encouraged to undertake their exercise program at least twice per week and diarize their work. Participants will receive a weekly phone call from their treating physiotherapist for the first two weeks. The treating physiotherapist will review the exercise diary of each participant every two weeks, and remotely alter the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
2479544|NCT03039400|Active Comparator|Standard care group|Those in the standard care group will have their exercise program explained to them at an initial face-to-face assessment with a treating physiotherapist as per usual care. They will receive a written, home-based exercise program. Participants in the usual care group will also be encouraged to undertake their exercise program at least twice per week, and will be asked to keep an exercise diary, in paper format. Participants in the usual care group will also receive a weekly phone call from the physiotherapist for the first two weeks to check on progress.
2479601|NCT03039101|Experimental|Montelukast|Subjects take 1 montelukast 10mg tablet orally, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week
2479604|NCT03039101|Placebo Comparator|Placebo|Subjects take 1 placebo oral pill, daily and effect on nasal allergen challenge (based on results of epicutaneous skin testing) induced recruitment of cd49d neutrophils in the peripheral blood and nasal lavage determined at 1 week.
2479695|NCT03038542|Experimental|Treatment Text Arm|
2479698|NCT03038542|Active Comparator|Standard Text Arm|
2479720|NCT03038243|Experimental|Cohort 1|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2479722|NCT03038243|Experimental|Cohort 2|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2479724|NCT03038243|Experimental|Cohort 3|Group 1, 2.25 x 10^11 Sf2aWC cells +10 µg dmLT Group 2, 2.25 x 10^11 Sf2WC cells Group 3, 2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
2479802|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 5W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 0.7 mm/s, laser power 5 W, LEED 71 J/cm
2479804|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 7W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1 mm/s, laser power 7 W, LEED 70 J/cm
2479807|NCT03037827|Active Comparator|Endovenous laser ablation (EVLA) 10W|One of three different regimens of endovenous laser ablation, the fiber pullback speed 1.5 mm/s, laser power 10 W, LEED 67 J/cm
3158692|NCT00390754|No Intervention|2|Group did not receive free home pregnancy test kits
3158693|NCT00390767|Experimental|MultiGeneAngio|Escalating doses of MultiGeneAngio
2479936|NCT03037021||SCD Adult Patients|Focus group or individual interview and survey
2479940|NCT03037021||SCD Adolescent Patients|Focus group or individual interview and survey
2479947|NCT03037021||SCD Healthcare Providers|Focus group or individual interview and survey
2479949|NCT03037021||Parents of SCD Adolescents|Focus group or individual interview and survey
2480007|NCT03036605|Active Comparator|Group Bupivacaine|4 ml %0.5 bupivacaine and 1 ml %0.9 NaCl infiltration into nasal packing to both sides
2480017|NCT03036605|Active Comparator|Group Bupivacaine+Dexamethasone|4 ml %0.5 bupivacaine and 4mg(1 ml) dexamethasone infiltration into nasal packing to both sides
2480161|NCT03035578|Experimental|Morphine Blood and Saliva sampling|"The infants will receive a 50 mcg/kg loading dose of morphine followed by a constant infusion.Morphine Injection: 10mg/mL, 1mL ampoules.Two strengths of stock syringes:~a)patients <1.5kg, morphine 0.5mg/25mL; b)patients 1.5kg to <5kg, morphine 1mg/25mL.~Time blood samples will be collected for measurement of whole blood concentration of morphine in 24h. Total morphine, morphine-3-glucuronide and morphine-6-glucuronide concentrations; volume of blood required is 0.25 ml. Sparse sampling strategy will be used for those neonates < 1250; total volume of blood required is 0.50 ml. Frequent sampling strategy will be used for those neonates ≥ 1250 gm; total volume of blood required is 0.50 ml.Saliva samples will be collected at 10 and 30 minutes and at 6, 12 and 24h after morphine infusion started.100 uL of saliva, captured using a collection swab."
2480217|NCT03035383|Experimental|Purse String Technique|Thyroidectomy closure is performed using purse string technique.
2480221|NCT03035383|Active Comparator|Conventional technique|Thyroidectomy closure is performed using conventional technique.
2480375|NCT03034161||Stage I Pressure Ulcer|Ten patients with a Stage I decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2480381|NCT03034161||Stage II Pressure Ulcer|Ten patients with a Stage II decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2480385|NCT03034161||Stage III Pressure Ulcer|Ten patients with a Stage III decubitus pressure ulcer will be included to be analyzed with a thermal imaging camera.
2480558|NCT03032848|Active Comparator|Estriol Group|use of 1 gram per day
3158694|NCT00390793|Experimental|Treatment (chemotherapy, dasatinib)|See detailed description in outline.
3158695|NCT00390832|Active Comparator|A|recombinant human erythropoietin beta
3158696|NCT00390832|Placebo Comparator|B|0.9% NaCl solution
3158697|NCT00390845|Experimental|SB681323|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
3158698|NCT00390845|Experimental|Placebo|Patients with pain associated with peripheral nerve injury and/or compression will be recruited for this study.
3158699|NCT00390871|Active Comparator|Fentanyl/Propofol sedation first|Patient given fentanyl only first, then sedated with fentanyl/propofol as needed to have Richmond Agitation Sedation Scale (RASS) Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/dexmedetomidine to have RASS Score 0 to -1.
2479503|NCT03039894||Control|The middle school has chosen three 6th grade classrooms that will not play the Gradebook game. The investigators will collect school gradebook and behavior information weekly for 8 to 10 time points before and after the intervention is implemented. Students will complete a survey at baseline and after the intervention, approximately 5-6 months apart.
2479554|NCT03039478|Active Comparator|Xylitol 7g in 300mL tap water|12 volunteers receive 7g xylitol in 300mL tap water via a nasogastric tube
2479559|NCT03039478|Active Comparator|Xylitol 17g in 300mL tap water|12 volunteers receive 17g xylitol in 300mL tap water via a nasogastric tube
2479561|NCT03039478|Active Comparator|Xylitol 35g in 300mL tap water|12 volunteers receive 35g xylitol in 300mL tap water via a nasogastric tube
2479565|NCT03039478|Active Comparator|Erythritol 10g in 300mL tap water|12 volunteers receive 10g erythritol in 300mL tap water via a nasogastric tube
2479568|NCT03039478|Active Comparator|Erythritol 25g in 300mL tap water|12 volunteers receive 25g erythritol in 300mL tap water via a nasogastric tube
2479571|NCT03039478|Active Comparator|Erythritol 50g in 300mL tap water|12 volunteers receive 50g erythritol in 300mL tap water via a nasogastric tube
3193216|NCT00816127|Experimental|1|DDAVP
2479836|NCT03037658|Experimental|Personal - self|Participants had the opportunity to earn money for themselves by increasing their average steps per day.
2479837|NCT03037658|Experimental|Prosocial - loved one|Participants had the opportunity to earn money for a loved one of their choice by increasing their average steps per day.
2479839|NCT03037658|Experimental|Prosocial - charity|Participants had the opportunity to earn money for a charity of their choice by increasing their average steps per day.
2479841|NCT03037658|Experimental|Choice|Participants were given the choice to earn money either for themselves, a loved one, or a charity by increasing their average steps per day.
2479843|NCT03037658|No Intervention|Control|Participants were not offered a financial incentive to increase their average steps per day. They simply wore the pedometer for three weeks.
2479911|NCT03037242|Other|Transtibial pullout technique|Evaluation of the clinical and radiographic outcomes for patients undergoing a meniscus root repair (MRR) using a transtibial pullout technique.
2479925|NCT03036865|Experimental|Cohort 1: 1 mg, IV BOS161721|Each participant will receive a single intravenous (IV) dose of BOS161721 1 milligram (mg).
2479926|NCT03036865|Placebo Comparator|Cohort 1: matching placebo|Each participant will receive matching IV placebo.
2479927|NCT03036865|Experimental|Cohort 2: 3 mg, SC BOS161721|Each participant will receive a single subcutaneous (SC) dose of BOS161721 3 mg.
2479930|NCT03036865|Placebo Comparator|Cohort 2: matching placebo|Each participant will receive matching SC placebo.
2479935|NCT03036865|Experimental|Cohort 3: 10 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 10 mg.
2479939|NCT03036865|Placebo Comparator|Cohort 3: matching placebo|Each participant will receive matching SC placebo.
2479944|NCT03036865|Experimental|Cohort 4: 30 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 30 mg.
2479948|NCT03036865|Placebo Comparator|Cohort 4: matching placebo|Each participant will receive matching SC placebo.
2479953|NCT03036865|Experimental|Cohort 5: 60 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 60 mg.
2479956|NCT03036865|Placebo Comparator|Cohort 5: matching placebo|Each participant will receive matching SC placebo.
2479960|NCT03036865|Experimental|Cohort 6: 22 mg, IV BOS161721|Each participant will receive a single IV dose of BOS161721 22 mg.
2479961|NCT03036865|Experimental|Cohort 7: 120 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 120 mg.
2479964|NCT03036865|Placebo Comparator|Cohort 7: matching placebo|Each participant will receive matching SC placebo.
2479965|NCT03036865|Experimental|Cohort 8: 240 mg, SC BOS161721|Each participant will receive a single SC dose of BOS161721 240 mg.
2479967|NCT03036865|Placebo Comparator|Cohort 8: matching placebo|Each participant will receive matching SC placebo.
2479999|NCT03036332|Experimental|intervention|Aerobic interval training
2480008|NCT03036332|No Intervention|Control group|The participants performed only initial evaluation and at the end of the study
3193217|NCT00816127|Active Comparator|2|Standard Treatment
3193218|NCT00816140|Active Comparator|Klaricid, triple therapy|Klaricid based triple therapy
2480148|NCT03035565|Experimental|Computerized Cognitive Training Brain HQ|Computerized cognitive training intervention using Brain HQ initiated and continued 1 hour/day, 5 days/week for 8 weeks
2480151|NCT03035565|Active Comparator|Computerized Crossword Puzzles|General cognitive stimulation puzzles intervention initiated and continued 1 hour/day, 5 days/week for 8 weeks
2480153|NCT03035565|No Intervention|Usual Care|No computerized cognitive intervention
2480229|NCT03035370|Experimental|Viaskin PT 25 mcg|Viaskin PT 25 mcg
2480231|NCT03035370|Experimental|Viaskin PT 50 mcg|Viaskin PT 50 mcg
2480233|NCT03035370|Placebo Comparator|Viaskin PT Placebo|Viaskin PT Placebo
2480245|NCT03034811|Other|PPK subjects|Subjects that receive the Persona Partial Knee system
3193219|NCT00816140|Experimental|Cravit, triple therapy|Cravit based triple therapy
3193220|NCT00816153|Experimental|PVI|PVI guided fluid management
3193221|NCT00816153|No Intervention|Control|
3193222|NCT00816192|Active Comparator|1|"The externally irrigated-tip catheter is an open system in which saline is continuously infused and empties into the blood pool. For the externally irrigated-tip catheter, RF energy delivery settings were: power ≤ 35 watts and temperature ≤ 43°C with a variable flow-rate to obtain a temperature around 40°C."
3193223|NCT00816192|Experimental|2|"For the internally irrigated tip catheter (reference catheter), radiofrequency (RF) energy delivery settings will be: power ≤ 35 watts, temperature ≤ 47◦C and a fixed flow rate of 0.6 ml/s.~The advantage of the Chili thermo-cooled tip system is that no saline solution leaves the catheter system and flows into the patient."
3193224|NCT00816205|Experimental|Single Arm|This is an open label, dose-finding study. After detrminig baseline resting anal pressure with a manometric test, coated Suppositories will be administered intra rectally. Subjects will take rectally a total of 3 Coated Suppositories per study.
2479521|NCT03039517|Experimental|ACTitouch - ACT-Adaptive Compression Therapy|a dual treatment pneumatic compression device offering two operational modes: sustained compression mode and intermittent compression mode. The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
2479523|NCT03039517|Experimental|Standard Compression Stocking|The control group will receive care using elastic compression stocking.
2479580|NCT03039218|Active Comparator|Active|Subjects assigned to this group will receive Active treatments using the Dornier Aries 2.
2479581|NCT03039218|Placebo Comparator|Placebo / Sham|Subjects assigned to this group will receive placebo / sham (no active treatment).
2479607|NCT03038906||Cohort|Patients enrolling in NHLBI PETAL Network ROSE study of cisatracurium for moderate/severe ARDS at participating centers
2479652|NCT03038737|Active Comparator|group 1|patients will receive partial denture constructed from breflex material
2479662|NCT03038737|Experimental|group 2|patients will receive partial denture constructed from PEEK material
2479743|NCT03038373||Group I|Morbid Obese Type 2 Diabetics, undergo Laparoscopic Sleeve Gastrectomy
2479754|NCT03038373||Group II|Morbid Obese Non Diabetics, undergo Laparoscopic Sleeve Gastrectomy
2479757|NCT03038373||Group III|Lean Diabetics, No surgery
2479760|NCT03038373||Group IV|Lean Non Diabetics, No surgery
2479834|NCT03037593|Experimental|Intervention|4000 IU vitamin D3 +prenatal vitamin
2479835|NCT03037593|No Intervention|Control|standard prenatal vitamin
2479890|NCT03037294|No Intervention|Control group|Subjects in the control group will receive no intervention.
2479897|NCT03037294|Experimental|Protein group|Subjects in the protein group will receive a daily 40 g pre-sleep protein supplement during the 2-week preoperative period.
2479924|NCT03036943|Experimental|Fluciclovine (18F) PET/CT|
2479981|NCT03036696||Pregnant Mothers Interview|(1) 18 years old or over, (2) between 28-38 weeks of pregnancy, (3) lives in Gainesville, Florida, and (4) are committed to exclusively breastfeeding through 6 months.
2479982|NCT03036696||Breastfeeding Mothers Interview|(1) 18 years old or over, (2) actively breastfeeding infant less than 12 months of age, and (3) lives in Gainesville, Florida.
2480032|NCT03036345|Experimental|Surgery patients|Patients receiving shoulder surgery in the Beach Chair Position, and monitored by both INVOS and FORE-SIGHT monitors.
2480071|NCT03036059|Active Comparator|Control group|400 μg/kg Ivermectin + 400 mg Albendazole Tablets given every year for 2 years
2480073|NCT03036059|Experimental|Expanded frequency group|400 μg/kg Ivermectin + 400 mg Albendazole, Tablets given every 6 months for 2 years
2480116|NCT03035838|Other|Treatment|There is only one arm in this study. Intracranial pressure and brain swelling will be monitored before and after administration of fosaprepitant
2480157|NCT03035669|Experimental|Mindfulness group|Mindfulness based stress reduction: 8 week program, including meditation, body-awareness, and yoga practices. Daily assignments and home practices during 50 minutes per day.
2480166|NCT03035669|Active Comparator|Reading group|Reading and sharing group: 8 week program, including readings, interpersonal exchanges, group discussion, listening and role playing exercises. Daily assignments and home practices during 50 minutes per day.
2480195|NCT03035266|Experimental|Blood Flow Restriction (BFR)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation. One week following surgery, subjects randomized to the BFR group will begin combining BFR with all lower extremity strengthening exercises supervised in clinic up to 3 times per week for 12 weeks.
2480196|NCT03035266|Active Comparator|Standard rehabilitation (control group)|All subjects will perform traditional post-operative rehabilitation until discharge from the hospital following surgery and continue until formal discharge from physical therapy upon completion of rehabilitation.
2480243|NCT03035071|Experimental|minimally invasive esophagectomy|minimally invasive (laparoscopic) gastric mobilisation and gastric tube formation.
2480244|NCT03035071|Active Comparator|open esophagectomy|open gastric mobilization and gastric tube formation
2480272|NCT03034746|Experimental|Alzheimer's Disease (G1)|(G1) physical activity (PA)
2480278|NCT03034746|Experimental|Alzheimer's Disease (G2)|(G2) cognitive treatment (CT)
2480283|NCT03034746|No Intervention|Healthy Old Subjects (G1)|Control group old
2480287|NCT03034746|No Intervention|Healthy young Subjects (G2)|Control group young
2480302|NCT03034499|Active Comparator|Single-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by single-port sacrocolpopexy.
2480303|NCT03034499|Active Comparator|Multi-port sacrocolpopexy|Patients with vaginal apex prolapse randomized to undergo repair by multi- port sacrocolpopexy.
2480335|NCT03034395|Other|Wide Local Excision 1cm|
2480339|NCT03034395|Other|Wide Local Excision 2cm|
2480357|NCT03034109|Experimental|tDCS conventional stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left dorsal lateral prefrontal cortex (DLPFC) and the cathode will be placed over the right supraorbital cortex. This is the standard 1 anode by 1 cathodal convention. Stimulation will last 20 minutes."
2480358|NCT03034109|Experimental|High Definition (HD)-tDCS stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and 4 cathodes will be placed surrounding the anode. This is the 4 cathode by 1 anode HD-tDCS montage for more focal stimulation. Stimulation will last 20 minutes."
2480359|NCT03034109|Sham Comparator|tDCS sham stimulation|"Transcranial Direct Current Stimulation:~The anode will be placed over the left DLPFC and the cathode over the right supraorbital cortex. A short stimulation will be given to the subjects that will mimic the sensation of an actual stimulation but will last much shorter. The session will still last 20 minutes in total to blind both subjects and investigators."
2480560|NCT03032848|Placebo Comparator|Vaginal Moisturizer Cream|use of 1 gram per day
3193225|NCT00816218|Experimental|Pioglitazone|Fifty type 2 diabetic patients (25 diet-treated and 25 treated with diet plus sulfonylurea) will have pioglitazone, 45 mg daily; added to their therapeutic regimen. All patients will be closely monitored and, in addition to periodic contacts and clinical visits, metabolic and vascular parameters will be assessed at the beginning and after 3 and 6 months of therapy. Euglycemic hyperinsulinemic clamp with muscle biopsies will be performed at the beginning and after 6 months of treatment.
3193226|NCT00816231|Experimental|Alcohol and Nicotine Group|Alcohol and Nicotine Drug/Cue Interactions
2479642|NCT03038802|Active Comparator|Standard vaccine|Subjects will receive regular intramuscular injections of a commercial hepatitis B vaccine (HBsAg containing aluminium hydroxide adjuvant) according to the same study schedule as the subjects in the experimental arm
2479644|NCT03038802|Experimental|Experimental therapeutic vaccine|Subjects will receive regular intramuscular injections of the experimental therapeutic hepatitis B vaccine (preS HBsAg containing Advax-2 adjuvant) in two cycles with the first cycle of four immunisations administered on days 0, 14, 28, 42. and the second cycle of four immunisations on days 70, 84, 98, and 112.
2479736|NCT03038425|Placebo Comparator|Saline infusion|Participants in this group will receive normal saline infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
2479751|NCT03038425|Active Comparator|Ropivacaine infusion|Participants in this group will receive ropivacaine 0.2% infusion (5ml/hr, patient controlled bolus 5ml, lockout 30min) in the adductor canal, starting in PACU on post-operative day 0 and continuing for 96 hours
2479774|NCT03037944|Experimental|Group A-LNG|"The Levonorgestrel releasing intrauterine device - IUD- will be Metraplant-E, which is used in this study for group A, is a modified Levonorgestrel-releasing intrauterine system from the old IUD Metraplant, Metraplant-E design has a T-shaped frame containing Levonorgestrel and Ethylene Vinyl Acetate as well as Barium Sulphate to make it radio-opaque, All the T frame, the bulb of 20 mm length and sleeves contain: Ethylene Vinyl Acetate, Levonorgestrel and Barium Sulphate, ensure more exposure of the endometrial surface to the system and hence expect more endometrial suppression."
2479776|NCT03037944|Experimental|Group B-COCs|Group B will receive combined oral contraceptive pills (Yasmin) COCs which will be Monophasic pills that have a constant dose of both estrogen and progestins in each of the hormonal active pills throughout the entire cycle . Yasmin (ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets, provides an oral contraceptive regimen, it will be used continuously for 6 months with stoppage after 3 months for withdrawal bleeding.
2479831|NCT03037645|Experimental|Dose escalating cohorts of SNS-062|Sequential groups, 25, 50, 100, 200, 300, 400 and 500 mg twice daily to determine maximum tolerated dose and recommended dose (RD) in the treatment of various hematological cancers followed by expansion of the recommended dose cohort in Phase 2 of the study treating hematological cancers.
2479877|NCT03037268||Patients undergoing dilated examination|"examined in the Retina Service of Wills Eye Hospital~with and without visually significant posterior retinal or optic nerve pathology~imaged with a Lytro Plenoptic Camera and 28D lens"
2479950|NCT03037073|Active Comparator|Group D|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
2479952|NCT03037073|Active Comparator|Group C|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
2479995|NCT03036527|Experimental|Activity-based locomotor training|To understand the effects of weight-bearing activity-based locomotor therapy on bladder function and sexual function. Activity-based locomotor training interventions include locomotor step training with a harness and body-weight support, 5 days a week for a total of 80, 1-hour sessions.
2480005|NCT03036527|Experimental|Activity-based stand training|To understand the effects of weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based stand training interventions include stand training with a harness and body-weight support or stand training over ground, 5 days a week for a total of 80, 1-hour sessions.
2480013|NCT03036527|Experimental|Activity-based upper arm ergometry|To understand the effects of non-weight-bearing activity-based stand therapy on bladder and sexual function. Activity-based upper arm ergometry interventions may include arm crank training (upper arm ergometry) in while seated in the wheelchair 5 days a week for a total of 80, 1-hour sessions.
2480075|NCT03036033|Experimental|SaeboGlove Therapy|All participants will be given a SaeboGlove for a 4-week period to use along side their routine functional based training program.
2480131|NCT03035825|Experimental|Oral Moisturizing Jelly|Daily intake of oral moisturizing jelly 5 times/day for two months
2480133|NCT03035825|Active Comparator|Artificial saliva|Daily use of non-edible oral lubricating gel 5 times/day for two months
2480149|NCT03035539|Active Comparator|Standard treatment|Standard treatment after randomization
2480150|NCT03035539|Experimental|Cardiac Rehabilitation|The rehabilitation programme includes education, physical exercise, optimisation of the medical treatment, and discussion of implications for the daily life of each participant.
2480203|NCT03035409|Experimental|Supportive Care (anamorelin, physical activity, counseling)|Patients receive anamorelin hydrochloride PO QD and undergo physical activity consisting of resistance exercises and a home walking program. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo nutritional counseling on day 21.
2480270|NCT03034824|Experimental|Scaling and root planing (SRP)-Control|Only non-surgical initial periodontal treatment (scaling and root planing)
2480274|NCT03034824|Experimental|SRP+940±15 nm diode laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received 940±15 nm Diode laser
2480280|NCT03034824|Experimental|SRP+Er,Cr:YSGG laser|In addition to non-surgical initial periodontal treatment (scaling and root planing), individuals received Er,Cr:YSGG laser
2480363|NCT03034356|Experimental|Levetiracetam, Then Placebo|4 weeks of levetiracetam administration (125 mg pill, bid), followed by a 4-week washout, then 4 weeks of placebo pill administration (bid).
2480366|NCT03034356|Experimental|Placebo, Then Levetiracetam|4 weeks of placebo administration (bid), followed by a 4-week washout, then 4 weeks of levetiracetam administration (125 mg pill, bid).
3193227|NCT00816231|Active Comparator|Alcohol Only Group|Alcohol Only Drug/Cue Interactions
3193228|NCT00816231|Active Comparator|Nicotine Only Group|Nicotine Only Drug/Cue Interactions
2479551|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV/PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2479556|NCT03039491|Experimental|HIV+ 50-65, CD4>200 PPV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count >200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2479560|NCT03039491|Experimental|HIV+ 50-65, CD4<200 PCV|"HIV+ individuals , 50-65 years of age with a nadir CD4 count <200 to receive PPV23 only~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2479563|NCT03039491|Active Comparator|HIV- 50-65, PCV/PPV|"HIV- individuals , 50-65 years of age immunized with PCV13 followed by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2479567|NCT03039491|Active Comparator|HIV- 50-65, PPV|"HIV- individuals, 50-65 years of age immunized with PPV23 only.~Intervention: 23 valent pneumococcal polysaccharide vaccine only"
2479570|NCT03039491|Active Comparator|HIV+ 21-40, CD4>200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count >200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
2479573|NCT03039491|Active Comparator|HIV+ 21-40, CD4<200 PCV/PPV|"HIV+ individuals , 21-40 years of age with a nadir CD4 count <200 to receive PCV13 vaccine followed 8 weeks later by PPV23~Intervention: 13 valent Pneumococcal conjugate vaccine (PCV13) followed 8 weeks later by 23 valent pneumococcal polysaccharide vaccine"
3193229|NCT00816231|Placebo Comparator|Placebo and Placebo Group|Placebo Only Drug/Cue Interactions
3193230|NCT00816244|Experimental|Atorvastatin|
2479748|NCT03038230|Experimental|MCLA-117 bispecific antibody|"Dose escalation cohorts, with escalating doses of MCLA-117 until MTD or RP2D is reached. The dose is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment.~Part 2-Expansion Cohort: The RP2D of MCLA-117 is given weekly after initial ramp-up dosing steps. Each Cycle is 28 days. Single agent treatment."
2479801|NCT03037775|Other|Investigated group|Subjects underwent procedures: hemodynamic indices will be measured at baseline and during 1/ e-cigarette without nicotine smoking, 2/ e-cigarette with nicotine and during 3/ traditional cigarette smoking in random order
2479886|NCT03037424|Active Comparator|Fibrinogen concentrate Octafibrin|
2479892|NCT03037424|Active Comparator|Cryoprecipitate|
3193231|NCT00816270|Experimental|1|Experimental operatory wound closure with liquid bandage (Johnson & Johnson, Skillman, NJ, USA).
3193232|NCT00816296||Controls|Obese (BMI>30) and normal AST and ALT. Between the ages of 5 and 18 years old.
3193233|NCT00816296||Liver Disease|Obese (BMI>30) and elevated AST and/or ALT (evidence of NAFLD). Between the ages of 5 and 18 years old.
2480078|NCT03036111|Sham Comparator|Hemorrhoidectomy|Patients will undergo Millgan-Morgan hemorrhoidectomy as classically described before
2480080|NCT03036111|Active Comparator|trimebutine|Patients will undergo Millgan-Morgan hemorrhoidectomy then triembutine suppository will be inserted in the anal canal intraoperatively and then every six hours for 24 hours.
2480172|NCT03035773|Experimental|ARM A|SCP document delivered to the patient & Primary Care Provider
2480175|NCT03035773|Experimental|ARM B|SCP document provided to the patient in an in-person survivorship visit and copy sent to PCP
2480177|NCT03035773|Experimental|ARM C|SCP document provided to the patient in an in-person survivorship visit with an additional follow-up visit and copy of the document sent to PCP
2480223|NCT03035214|Other|Prevention of dysplasia through steroids|Failure of lung tolerance to oxygen reduction will be defined as oxygen saturation 80 to 87% for 5 minutes, or <80% for 1 minute, then inspired oxygen will be increased back to the base line. This will be considered as an early predictor of evolving bronchopulmonary dysplasia. If there is no hypoventilation, dexamethasone will be given 0.25 mg/ kg/ d divided twice for 5 days intravenous.
3193234|NCT00816309|Experimental|Acapella Physiotherapy|Physiotherapy with acapella versus no physiotherapy
3193235|NCT00816309|No Intervention|No physiotherapy|Physiotherapy with acapella versus no physiotherapy
3193236|NCT00816322|Active Comparator|omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
2480503|NCT03033030||Tomosynthesis|Patients undergoing Digital Breast Tomosynthesis
2480559|NCT03032835||Study participants|No intervention
3193237|NCT00816322|Placebo Comparator|Placebo|high oleic oil
3193238|NCT00816335|Experimental|Arm 1|F-FDG-directed surgery for known or suspected malignancy using gamma detection probes.
2480674|NCT03032081|Experimental|High Intensity Group|3 set of 4 minutes of cycling intense exercise, 4 days per week, for 8 weeks at about 80% to 90% of heart rate reserve
2480676|NCT03032081|Active Comparator|Moderate Intensity Group|40 to 47 minutes of continuous cycling exercise at 50% to 60% of heart rate reserve, 4 days per week, for 8 weeks.
2480850|NCT03030690|Experimental|Glass Carbomer Cement|GCP Glass Fill, Glass Carbomer™Tech, Ridderkerk, Netherlands
2506589|NCT02855671||Severe sepsis/septic shock|
3193239|NCT00816374|Other|1|Group I
3193240|NCT00816374|Other|2|Group II
3193241|NCT00816387|Active Comparator|IUI|Intrauterine insemination using standard catheter
3193242|NCT00816387|Experimental|FSP|Fallopian tube sperm perfusion using a commercial device for hysterosalpingography and tubal hydropertubation
3193243|NCT00816426|Other|1|Dosing 2 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
2479576|NCT03039244|Experimental|Test Group|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
2479579|NCT03039244|Sham Comparator|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
2479631|NCT03038893|Experimental|POCUS + EDUS|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
2479633|NCT03038893|Active Comparator|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
2479711|NCT03038503|No Intervention|A|standard care septic shock according sepsis bundles
2479714|NCT03038503|Experimental|B|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
2479715|NCT03038503|Experimental|C|after defined refractory shock (adequate fluid resuscitation + add NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
2479767|NCT03038061|Experimental|Experimental group|Patients undergoing Laparoscopic Surgery
2479819|NCT03037749|Experimental|Distressed Violent Partners|Distressed violent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
2479823|NCT03037749|Experimental|Distressed Nonviolent Partners|Distressed nonviolent partners engage in a placebo-controlled alcohol administration study with an emotion-regulation task.
2479882|NCT03037372|Experimental|ART-Atorvastatin adjunct therapy|ART, atorvastatin
2479885|NCT03037372|Experimental|ART-Rosuvastatin adjunct therapy|ART, rosuvastatin
2479891|NCT03037372|Experimental|ART-without statin adjunct therapy|ART, no statin
2479899|NCT03037372|Experimental|Healthy-HIV-negative|Age-matched HIV-negative, healthy volunteers from the same community
2479929|NCT03036774|Experimental|Diabetic patient|Diabetic patients (type 1 or type 2 diabetes) with scheduled surgery . Ultrasonic measurement of antral area
2479931|NCT03036774|Other|Non diabetic patient|"Patients with scheduled surgery without history of diabetes or a current, treated or untreated, diabetic disease.~Ultrasonic measurement of antral area"
2479986|NCT03036618|Placebo Comparator|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
2479987|NCT03036618|Experimental|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
3193244|NCT00816426|Other|2|Dosing 4 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
3193245|NCT00816426|Other|3|Dosing 8 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
2480201|NCT03035227|Active Comparator|Catheter Ablation|Catheter ablation procedure of atrial and/or ventricular arrhythmias.
2480207|NCT03035227|Active Comparator|Medical Therapy|Medical management using antiarrhythmic drugs per standard of care of treating physician.
2480253|NCT03035019|Experimental|Lantern for primary care patients|All patients between the ages of 20-65 at specific primary care practices and score 5 or greater on the GAD7 questionnaire are offered the Lantern app to help with stress/anxiety.
2480305|NCT03034694|Placebo Comparator|Routine Care|The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
2480307|NCT03034694|Experimental|Teledermatology INtervention|The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
2480380|NCT03034317|Active Comparator|NeuRx DPS|Subjects who have initiated noninvasive ventilation (NIV) and receive the NeuRx diaphragm pacing system (DPS).
2480386|NCT03034317|No Intervention|No DPS|Subjects who have initiated noninvasive ventilation (NIV) and do not receive the DPS device.
2480513|NCT03033342|Experimental|Oral single doses of MRX-4|Single escalating oral doses of MRX-4 from 250 mg to 3000 mg
2479583|NCT03039530|Active Comparator|Control Group|Standard Care. The usual care group will receive standard care from their family physician and midwife or obstetrician. They will also be made aware of the perinatal programming available to them through Niagara Region Public Health. Women and family physicians will also receive a copy of the Canadian Practice Guidelines for the Treatment of Perinatal Depression.
2479635|NCT03038854|Experimental|Test GUM|This group will drink a test toddler growing up milk (GUM) with higher amounts of key nutrients
2479636|NCT03038854|Active Comparator|Standard GUM|This group will drink a standard toddler growing up milk (GUM)
2479638|NCT03038854|Placebo Comparator|Comparator Group|This group will drink liquid full fat cows' milk
2479641|NCT03038854|No Intervention|Population Group|This group will eat and drink their usual foods with no interventions.
2479862|NCT03037476|Experimental|Web-Based PFI|Participants randomized to the web-based PFI in Studies 2 and 3 will receive a 5 component Personalized Feedback Tool. The first component is presented immediately after the baseline survey and a link to each of the remaining 4 components is sent to participants spaced 1 to 2 weeks apart. The PFI components cover: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol. Each component is comprised of personalized feedback presented in text and graphic format, and each component includes links to tips for making changes if and when the participant is contemplating or ready to commit to change. These tips include general relapse prevention strategies, as well as information about the importance of regular class attendance, study habits, and sleep habits for academic success. General educational tips/strategies for time management, as well as tips for initiating behavior change are also included. Each component takes approximately 5-10 minutes to review.
2479863|NCT03037476|Experimental|In-person PFI|Participants randomized to the in-person PFI condition in Study 3 will be scheduled to meet with a trained intervention provider in a Student Counseling and Health Center setting for a 1.5 hour session to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback. The intervention provider will utilize a motivational interviewing approach in reviewing the students personalized feedback with them. They will use the student's past experiences with PSM as a starting point and will help the student to develop discrepancies, elicit change talk, provide students with opportunities to more thoroughly explore and question their beliefs, and offer alternatives by reviewing their personalized responses.
2479864|NCT03037476|No Intervention|Control|The control group will only receive assessments in Studies 2 and 3.
2479893|NCT03037190|Experimental|Group A|Group A:withdrawal of gluten from the diet, Group A will have a gluten free diet for a year after the onset of diabetes
2479898|NCT03037190|No Intervention|B normal diet|Group B will have normal not glutenfree diet, no planned intervention
2480023|NCT03036631||Conscious Sedation/Monitored Anesthesia Care|
2480025|NCT03036631||General Anesthesia|
2480092|NCT03036176|Other|SAM intervention group|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
2480100|NCT03036176|Other|SAM control Group|The control children received routine medical treatment and nutritional rehabilitation services in hospital. Though they had access to playground facilities neither the control children nor their caregivers had access to the playroom materials and the basic orientation on child care, feeding and stimulation.
2480154|NCT03035734|Active Comparator|A|Single oral dose BMS-986141 Form A tablet under fasting conditions
2480159|NCT03035734|Experimental|B|Single oral dose BMS-986141 Form B tablet (low-dose) under fasting conditions
2480165|NCT03035734|Experimental|C|Single oral dose BMS-986141 Form B tablet (high-dose) under fasting conditions
2480169|NCT03035734|Experimental|D|Single oral dose BMS-986141 Form B tablet (high-dose) under fed conditions
2480208|NCT03035279|Experimental|Arm A|SC-006 Dose regimen finding
2480211|NCT03035279|Experimental|Arm B|SC-006 Dose expansion
2480213|NCT03035279|Experimental|Arm C|SC-006 and ABBV-181 Combination escalation and expansion
2480384|NCT03034330|Experimental|Two-Tier Stroke Family Empowerment|The intervention is individualized, tailor-made according to caregivers' needs. The intervention will last for 2 to 3 months with 6 to 10 weekly sessions at the home of caregivers or stroke survivors. Each session will last for 60 to 90 minutes. The care managers will determine the intensity of the intervention after the initial family assessment.
2480390|NCT03034330|Active Comparator|Volunteer Support Psychoeducation|The intervention will last for 2 months with 4 weekly sessions at the home of caregivers or stroke survivors in the first month and 2 telephone contacts in the second month (6 contact points in total). Each session will last for 60 to 90 minutes. Care managers will not provide any direct intervention for participants in the control group.
2480437|NCT03033706|Active Comparator|Study group|Brain tumor excision under general anesthesia. Intervention (Pulse pressure variation guided fluid therapy): Study group will receive restricted fluid management with 1 ml/Kg/hr with concomitant PPV monitoring. PPV will be measured using invasive blood pressure monitor. Fluid bolus of 3 ml/Kg of ringer solution will be administrated whenever PPV is higher than 13%.
2480450|NCT03033706|Placebo Comparator|Control group|Brain tumor excision under general anesthesia. Intervention (Traditional fluid therapy): Control Group will receive standard fluid management of 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
2480527|NCT03033160|Experimental|Estradiol Ring|Estradiol Ring per vagina every 3 months
2480529|NCT03033160|No Intervention|Observation|Observation
2480635|NCT03032679||Single group of patients|Non interventional study. Observational with questionnaires
2480682|NCT03032016||sVOD patient treated with defibrotide|Patient diagnosed with severe hepatic VOD and treated with defibrotide
2479746|NCT03038152|Experimental|Diagnostic (Magseed marker)|Patients receive the Magseed marker via ultrasound guided injection into the previously clipped lymph node or within perinodal tissue =< 3mm from the clipped node. Patients then undergo axillary lymph node localization and targeted dissection within 30 days.
2479796|NCT03037801|No Intervention|Control|
2479799|NCT03037801|Experimental|Intrapulmonary Percussive Ventilation|15 minutes of IPV physiotherapy
3193246|NCT00816426|Other|4|Dosing 12 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
2479909|NCT03037125|Active Comparator|Control Arm|Split crest without PRF
2479912|NCT03037125|Experimental|Intervention Arm|Split crest with PRF
2479932|NCT03036878|Experimental|ReNu Injection|Injection of ReNu allograft into the joint capsule.
2480460|NCT03033420|Experimental|Intervention group|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
2480467|NCT03033420|No Intervention|Control group|Treatment-as-usual
2480512|NCT03033095|Experimental|etanercept|"The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.~Modality of administration :~Etanercept : 50 mg / week subcutaneously, every 7 days The clinical response will be evaluated after 6 months of etanercept treatment, at the M6 visit."
2480581|NCT03032757|Experimental|Resting leg of young males|
2480582|NCT03032757|Experimental|Exercising leg of young males|
2480583|NCT03032757|Experimental|Resting leg of elderly males|
2480584|NCT03032757|Experimental|Exercising leg of elderly males|
2480767|NCT03031444|Active Comparator|chemotherapy plus cetuximab|Cetuximab plus FOLFIRI/FOLFOX:FOLFIRI plus cetuximab [Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1;Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1;5-fluoruracil(5-FU) 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion.Repeat every 2 weeks.Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks] or FOLFOX plus Cetuximab [Oxaliplatin 85 mg/m2 IV over 2 hours, day 1 Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks;Cetuximab 500 mg/m2 IV over 2 hours, day 1, every 2 weeks]
2480769|NCT03031444|Active Comparator|perioperative chemotherapy alone|FOLFIRI/FOLFOX/CapeOX:routine perioperative chemotherapy including FOLFIRI[Irinotecan 180 mg/m2 IV over 30-90 minutes, day 1 Leucovorin 400 mg/m2 IV infusion to match duration of irinotecan infusion, day 1 5-FU 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion Repeat every 2 weeks] or FOLFOX[Oxaliplatin 85 mg/m2 IV over 2 hours, day 1;Leucovorin 400 mg/m2 IV over 2 hours, day 1 5-FU 400 mg/m2 IV bolus on day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) IV continuous infusion Repeat every 2 weeks] or CapeOX[Oxaliplatin 130 mg/m2 IV over 2 hours, day 1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks] was adopted in this control arm.
2480797|NCT03031015|Experimental|Cemented K-wire Fixation|The mean age of group A was 41 years (range, 18-63 years). There were 56 male and 11 female patients. The mean time from injury to operation was 5±4.53 days. Injured digits included index (n=24), long (n=19), ring (n=9), and little (n=15) fingers. Types of fractures were transversal (n=31), oblique or spiral (n=14), and comminuted (n=22) fractures. The patients were treated with Cemented K-wire Fixation.
2480799|NCT03031015|Active Comparator|Plating|The mean age of group A was 39 years (range, 19-61 years). There were 51 male and 13 female patients. The mean time from injury to operation was 6±5.53 days. Injured digits included index (n=21), long (n=17), ring (n=10), and little (n=16) fingers. Types of fractures were transversal (n=34), oblique or spiral (n=11), and comminuted (n=19) fractures.The patients were treated with Plating.
2480836|NCT03030794|Active Comparator|Repetitive TMS|Subjects will receive the repetitive transcranial magnetic stimulation study procedure.
2480838|NCT03030794|Placebo Comparator|No (blocked) repetitive TMS|Subjects will not receive the repetitive transcranial magnetic stimulation study procedure by blocking the stimulation between the coil and the head, but the audiovisual conditions will be mimicked.
2480869|NCT03030508||Group cap|Patients receiving capecitabine chemotherapy after operation
2480920|NCT03030339||Group 1: High VA intake, recent VAS|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake
2480921|NCT03030339||Group 2: High VA intake|Children who are exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
2480922|NCT03030339||Group 3: Low/adequate VA intake|Children who are not exposed to multiple vitamin A (VA) programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
2480957|NCT03029949|Experimental|ACT with VR|acceptance and commitment therapy with vestibular rehabilitation in addition to clinical management
2506838|NCT02854085|Experimental|Art Therapy|Art Therapy, 24 sessions
2479721|NCT03038295|Experimental|oral propranol group|"Enrolled preterm newborns will receive oral propranolol 0.25mg/kg daily(every 24 hours).~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
2479723|NCT03038295|Placebo Comparator|oral placebo group|Enrolled preterm newborns will receive oral normal saline 0.25mg/kg daily(every 24 hours) and other disposals will be done similarily to the oral propranol group.
2479725|NCT03038295|Experimental|eye drop propranol group|"Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette,in each eye, four times daily (every 6 hours) .~The treatment will be started as soon as the diagnosis of stage 1 or 2 ROP without plus is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days."
2479728|NCT03038295|Placebo Comparator|eye drop placebo group|Enrolled preterm newborns will receive placebo as ophthalmic solution in the same way of eye drop propranolol and other disposals will be done similarily to the eye drop propranol group.
2479812|NCT03037866|Experimental|LifeSkills Training for College|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the intervention group (n=2000) will participate in the LST program adapted for college which consists of six 30-minute online sessions (content-specific instruction and skills building activities along with opportunities to apply newly acquired knowledge and practice new skills) and three 60-minute small groups sessions (facilitator-led sessions with fellow incoming students that complement the online modules).
2479818|NCT03037866|No Intervention|Treatment as Usual (Control)|All students who consent to participate in the proposed study will complete pre, post, six- and 12-month follow-up surveys. Those randomized to the control group (n=2000) will not participate in LST but will receive the sexual violence and substance abuse educational content normally provided by their schools.
2479872|NCT03037463||Parkinson's Disease|
2479873|NCT03037463||Control|
2479910|NCT03037099|Experimental|Enhanced GI Concept Education|This group will receive enhanced GI concept nutrition education including GI values of foods, low GI recipes, menus, and application through websites with chat rooms, online videos and print materials. These will be reinforced through email, text messaging/phone calls, and postal mail.
2479913|NCT03037099|No Intervention|Usual Care|Usual care group will receive only standard printed copies of Canada Food Guide and Canadian Diabetes Association GI resources.
2480066|NCT03036241|Experimental|Drug-eluting balloon|
2480069|NCT03036241|Active Comparator|Conventional angioplasty|
2480118|NCT03035851|Experimental|Aerobic exercise|Participants will take part in a supervised 6-month-long aerobic (walk/jog) training program held 3 days/week. Each session will include a 5-min warm-up, 20-40 min of aerobic exercise (walking, jogging), 5-min cool-down, and stretching. Exercise prescriptions will follow current principles and guidelines established by ACSM/AHA, including sufficient warm-up, cool-down, and ongoing provision of safety precautions/exercise tips. As participants progress, the duration of aerobic exercise will increase from 20 (month 1) to 30 (months 2-3) and 40 min (months 4-6), with proportional increases to warm-up and cool-down periods. Exercise intensity will be based on individual maximal oxygen uptake (VO2 max), measured at baseline. Intensity will build from 30-45% (months 1-3) to mitigate the risk of injury and will progress to 60-70% (months 4-6) heart rate reserve (HRR).
2480121|NCT03035851|Other|Stretch and Strength|A control group will meet on a similar schedule as the exercise group for sessions on stretching and toning but without aerobic exercise. Based on prior RCTs of similar interventions the investigators expect this control to be ineffective or minimally effective, but anticipate that it will increase participant enthusiasm and retention. All assessments will be conducted in this arm.
2480144|NCT03035591|Experimental|ODM-207|Escalating doses of ODM-207
2480181|NCT03035500|Experimental|Supportive Care (long-term follow-up)|Patients undergo long-term follow-up and receive a written survivorship care plan including comprehensive health evaluation and health education beginning 1 year post surgery.
2480219|NCT03035175|Experimental|Video Laryngoscopy Group|Subjects enrolled in this arm received real-time guidance from a supervisor utilizing the screen of the video laryngoscope while the subjects performed direct neonatal intubations in the NICU.
2480226|NCT03035175|Active Comparator|Traditional Laryngoscopy Group|Subjects enrolled in this arm, received traditional guidance while they performed direct neonatal intubations in the NICU.
2480264|NCT03034889||Exposed|Children age 4-10 who required general anesthesia before the age of 36 months in the context of surgical and diagnostic procedures or sedation during intensive care, excluding neurosurgical interventions or cardiac surgery as well as preexisting hereditary or acquired neurocognitive deficits
2480266|NCT03034889||Control|Children age 4-10 who did not require any anesthesia before the age of 36 months. Excluding preexisting hereditary or acquired neurocognitive deficits.
2480311|NCT03034681|Other|Vojta|Vojta therapy consists in activating certain overall and innate locomotion patterns or complexes: reflex creeping and reflex rolling, which provokes the contraction of striated muscle in the entire body in a determined coordination with the central nervous system (CNS). These patterns are triggered from different positions (prone, supine and side lying) and only with certain stimulation. They contain all the locomotion components: automatic postural control, uprighting and phase movements. This therapy allows for the changing from pathological patterns to painless and cheaper patterns. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
2480318|NCT03034681|Active Comparator|TENS|TENS procedure used at our unit consists in applying a high frequency current (80Hz), which is the most effective way to combat pain, for a phase duration of 60-200 microseconds at a comfortable range. Electrodes are placed on the skin over the sciatic nerve path, the (-) cathode on the most painful area as it is the most stimulating and the (+) another is placed distal. This group received 15 sessions of treatment. Treatment lasted 30 minutes per sesion.
2480369|NCT03034278||Post surgery patients|Patients prescribed with opioid analgesic medications following surgery.
2480740|NCT03031925|Experimental|SLE patients|Systemic Lupus Erythematosus
2479733|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
2479887|NCT03037151|Experimental|HCV mono-infection Treatment naives|HCV treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
2479894|NCT03037151|Experimental|HCV mono-infection Treatment experienced|HCV treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
2479900|NCT03037151|Experimental|HCV/HIV co-infection Treatment naives|HCV/HIV coinfected, treatment-naïve patients will be treated with the combination of grazoprevir plus elbasvir for 12 weeks.
2479905|NCT03037151|Experimental|HCV/HIV co-infection Treatment experienced|HCV/HIV co-infected treatment-experienced patients, including null responders, partial responders or post-treatment relapsers, will be assigned to treat with the combination plus weight-based RBV for 16 weeks.
2480054|NCT03036137|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS for five consecutive days, current of 2 mA, in the temporoparietal left area, and right prefrontal cortex.
2480055|NCT03036137|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of Sham tDCS for five consecutive days in the temporoparietal left area, and right prefrontal cortex.
2480086|NCT03035890|Experimental|Radiation Therapy + Immunotherapy|3-5 fraction course of radiation therapy to target lesion concurrent with an immuno-therapeutic agent
2480155|NCT03035695|Experimental|Axiostat® Size|"Device: Axiostat® Size: 8 x 5 cm Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
2480160|NCT03035695|Active Comparator|Cotton Gauze|Cotton Gauze Size: 8 x 5 cm
2480225|NCT03035331|Experimental|Treatment (pembrolizumab, dendritic cell therapy, cryosurgery)|Patients receive pembrolizumab IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive dendritic cell therapy IT on days 2, 8, and 15 of cycles 2 and 3, and day 2 of cycles 4 and 5. Patients undergo cryosurgery on day 2 of cycle 2 and receive pneumococcal 13-valent conjugate vaccine by injection on day 2 of cycles 2-5. Treatment repeats every 21 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients who are CR, PR, or SD after completion of therapy, may receive pembrolizumab for an additional 18 cycles in the absence of disease progression or unacceptable toxicity.
2480258|NCT03034759|Experimental|All participants|+Pediatric patients with T1D. All comparisons will be made within group pre and post intervention.
2480331|NCT03034668|Experimental|CS16-003 Full dose|350 mg capsule QD Rhodiola rosea L. & Rhaptonticum carthamoides extracts
2480333|NCT03034668|Experimental|CS16-003 Half dose|175 mg capsule QD 50% Rhodiola rosea L. & Rhaptonticum carthamoides extracts + 50% Maltodextrin
2480338|NCT03034668|Placebo Comparator|Placebo|Maltodextrin
3158700|NCT00390871|Active Comparator|Fentanyl/Dexmedetomidine sedation first|Patient given fentanyl only first, then sedated with fentanyl/dexmedetomidine as needed to have RASS Score 0 to -1. After washout with fentanyl only, patient sedated with fentanyl/propofol to have RASS Score 0 to -1.
3158701|NCT00390923|Experimental|1|
2480388|NCT03034005|Experimental|Patients with asthma|6 weeks treatment with 1600 ug budesonide
2480391|NCT03034005|No Intervention|Healthy Controls|Healthy controls to establish baseline level of Na/K pumps.
2480429|NCT03033732|Other|Methadone|Opioid agonist treatment for opioid use disorder. Ingested in liquid oral form via strict initial daily witnessed ingestion as per local guidelines.
2480430|NCT03033732|Other|Buprenorphine/Naloxone|Opioid agonist treatment for opioid use disorder. Ingested orally via sublingual tablet form, flexible take home dosing.
2480484|NCT03033121|Active Comparator|group A|Sixteen growth hormone (GH) deficiency children were assigned to receive daily growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
2480486|NCT03033121|Active Comparator|group B|Sixteen growth hormone (GH) deficiency children were assigned to receive three time weekly growth hormone therapy for 12 months. The investigators used an initial weekly dose of 0.175 mg/kg (corresponding to the daily dose of 0.025 mg/Kg) of GH with a gradual increase every 6 months in order to always maintain the insulin growth factor (IGF)-I levels in the normal range. In detail, from months 1 to 6 the investigators used the mean weekly dose of 0.175 mg/kg and from months 6 to 12 the mean weekly dose of 0.20 mg/kg.
2480549|NCT03032991||Control|Children at 8 years old born from healthy pregnancies
2480552|NCT03032991||GDM|Children at 8 years old born from mothers with gestational diabetes during pregnancy
2480588|NCT03032588|Experimental|Group 1: sIPV|Participants will receive single intramuscular injection of the trivalent inactivated poliovirus vaccine based on Sabin strains produced on PER.C6 cells (sIPV) on Day 1.
2480596|NCT03032588|Active Comparator|Group 2: cIPV|Participants will receive single intramuscular injection of the currently used trivalent inactivated poliovirus vaccine IMOVAX POLIO, based on the conventional Salk poliovirus strains produced on Vero cells (cIPV) on Day 1.
3158702|NCT00390923|Placebo Comparator|2|
3158703|NCT00390936|No Intervention|1|4 dosages
3158704|NCT00391001|Experimental|1|
3158705|NCT00391001|Placebo Comparator|2|
3158706|NCT00391014|Experimental|1|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
2479744|NCT03038347|Active Comparator|Education only|In the education only group, participants work six weeks on a slimmed down version of the training program. The modules only contain text-based information without any exercises. After completion, participants receive access to the practical exercises, case studies and video files as well. Main purpose of the education only group is to determine whether the practical part of the training program can offer additional benefit.
2479755|NCT03038347|No Intervention|Waiting control|Initially, participants do not receive any training contents. After a six week waiting period, they can participate in the training program as well. Modules are equivalent to those of the training group. Purpose of this group is to determine whether the training program is effective.
2479798|NCT03037853||Healthy volunteers|Healthy volunteers
2479838|NCT03037554|Experimental|Lateralized Thermal Sleepwear|For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics
2479840|NCT03037554|Sham Comparator|Sham-Lateralized Sleepwear|For two consecutive nights subjects will wear Sham-Lateralized Sleepwear
2479934|NCT03037086||One single cohort|One single cohort of NSCLC patients with disease diagnosis between January 2010 and December 2014. The locally advanced or metastatic NSCLC patients should have initiated 1st line palliative chemotherapy by end of 2014.
2480074|NCT03036254|Experimental|HBOT intervention|The multiplace HBOT unit at Asaf Harofeh. The inside looks like an airplane, with comfortable chairs for 11 subjects and the nurse who stays throughout the session. The HBOT protocol is 90 minutes, 5 times/week, 60 sessions, 100% oxygen at 2 ATA with 5 minute air breaks every 30 minutes.
2480077|NCT03036254|Sham Comparator|Sham intervention|Except for pressure, all the conditions of the HBOT intervention are provided in the sham intervention (nurse measures vitals and asks about health before entering the chamber, time in the chamber, number of sessions per week and overall, nurse in the chamber at all times, mask on the face, etc.).
3193247|NCT00816426|Other|5|Dosing 24 hours before surgery. -Rifampicin (RIF) will be dosed orally at 600mg or 50mg for subjects under 50kg of bodyweight;-Isoniazid (INH) will be dosed orally at 300mg;-Pyrazinamide (PZA) will be dosed orally at 1.5g;-Moxifloxacin (MXF) will be dosed orally at 400mg;-Kanamycin (KM) will be dosed intramuscularly at 1g or 750mg for subjects under 50kg of body weight
2480205|NCT03035162|Experimental|Active tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow continuously during 20 minutes for the active conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
2480210|NCT03035162|Active Comparator|Sham tDCS & PT|Dual transcranial direct current stimulation (tDCS) will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Current intensity is fixed at 2 mA and current will flow only 2 minutes for the sham conditions. Physical therapist will give an intervention program exactly the same in all cases. The scope of intervention is administered to improve strength of weakened and postural lower limbs muscles such as trunk muscles, hip flexors/extensors/abductors, knee flexors/extensors.
2480299|NCT03034993|Experimental|Text Messaging|This group will receive text messages with appointment reminders, medication taking education and motivation, and for reporting of mood.
2480301|NCT03034993|Placebo Comparator|Control|This group will receive simple text messages about general health promotion, such as about the importance of drinking water on hot days, using sunscreen, etc.
2480337|NCT03034408|Other|Alcohol Use Disorder|30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
2480340|NCT03034408|Other|Healthy Control|30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule
2480394|NCT03034070|Other|Diagnostic performance 3D T1|A 3D T1-weighted GE mDixon MR imaging sequence will be added to the routine 3D T1-weighted FSE sequence. mDixon sub-sequences (Fat and In Phase) are compared to 3D T1-weighted FSE in terms of diagnostic accuracy for M and N staging in prostate cancer patients: Fat, In Phase, Fat+In Phase and the routine 3D T1 will be analyzed separately, blindly and randomly.
2480425|NCT03033719|Active Comparator|Laparotomy|Open surgery
2480427|NCT03033719|Experimental|Laparoscopy|Minimally invasive surgery
2480548|NCT03032887|Experimental|voice prompts|Agitation (education, reminders and optimising materials) plus voice prompts
2480553|NCT03032887|Other|no voice prompts|only Agitation (education, reminders and optimising materials); no voice prompts
2480590|NCT03032536|Experimental|Treatments A, B, C|"Part 1: Cross-Over~Treatment A: AL-3778 6 x 100-mg capsules (fasted) once.~Treatment B: AL-3778 2 x 300-mg tablets (fasted) once~Treatment C: AL-3778 2 x 300-mg tablets (high-fat meal) once."
2480595|NCT03032536|Experimental|Treatments D, E, F|"Part 2 (optional): Cross-Over~Treatment D: AL-3778 2×300-mg tablets (fasted) once.~Treatment E: AL-3778 tablet Dose (fasted) once. Dose will match Treatment F dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg~Treatment F: AL-3778 tablet Dose (high-fat meal) once. Dose will match Treatment E dose and will be:~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2480604|NCT03032536|Experimental|Treatment G|"Part 3: AL-3778 twice daily administered under fasted conditions for 14 days.~Dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2480607|NCT03032536|Active Comparator|Treatment H|Part 3: Entecavir 0.5 mg once daily administered under fasted conditions for 14 days
2479752|NCT03038139|Experimental|Cervical exercises|"Group A= Cervical correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~Applying exercises 3 times per week."
2479756|NCT03038139|Experimental|Lumbosacral exercises|"Group B= Cervical + Lumbosacral correction program The cervical exercise program consist of 3 strengthening exercises and 2 stretching exercises.~The lumbosacral exercise program consist of 2 strengthening exercises and 4 stretching exercises.~Applying exercises 3 times per week."
2479806|NCT03037892|Active Comparator|Midazolam and Fentanyl|Midazolam and Fentanyl Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain
2479808|NCT03037892|Experimental|Midazolam and Remifentanil|Midazolam and Remifentanil Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
2479813|NCT03037892|Experimental|Remifentanil|Remifentanil Group Patients will receive only Remifentanil in the same doses as given in group 2. During the procedure if the pain is excessive and persistent in spite of increasing the respective doses as prescribed in each group, or causing loss of cooperation of patient and interfering in the performance of procedure, the patients will be given sleep dose of Inj Propofol and further anaesthesia care as required will be provided for same.
2479880|NCT03037398|Active Comparator|Novel Arm|Programming completed by a novel method
2479881|NCT03037398|Other|Standard of Care Arm|Programming completed as Standard of care
2480038|NCT03036306|Experimental|1.0 % SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 1.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
2480040|NCT03036306|Experimental|3.0% SCX-001 cream|Subjects randomized to this arm will have one lateral hip wound treated with 3.0% SCX-001 cream and one wound treated with placebo. Intra-subject hip wound treatment is randomly allocated
2480042|NCT03036306|Placebo Comparator|Placebo cream|Subjects randomized to this arm will have both lateral hip wounds treated with Placebo cream. Intra-subject hip wound treatment is randomly allocated
3193248|NCT00816465|Experimental|1|Patients receiving Hoodia
3193249|NCT00816465|Placebo Comparator|2|Patients receiving placebo
2480163|NCT03035617|Placebo Comparator|Controlled Arm|Mesh will be soaked in normal saline solution as is routinely done.
2480168|NCT03035617|Experimental|Intervention Arm|Mesh will be soaked in .5% bupivacaine solution before application.
2480230|NCT03035253|Experimental|OMP-305B83 combined with FOLFIRI or FOLFOX|
2480255|NCT03034798||Type 1 Diabetes Exercisers|Participants performed 2 different forms of exercise of identical duration and similar total energy expenditure. One form was purely aerobic in nature and the other was intermittent, high-intensity exercise.
2480309|NCT03034720|Experimental|Intervention|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
2480312|NCT03034720|No Intervention|Control|Adolescent subjects in the control group will receive care as usual from their health care providers, a standard that is ethically acceptable.
2480378|NCT03034291|Experimental|Cacao 70%|Consumption for eight weeks of 50 grams of chocolate with 70% cocoa solids equivalent to not less than 430 mg of cocoa polyphenols at each dose.
2480383|NCT03034291|Placebo Comparator|White chocolate|Consumption for eight weeks of 50 grams of chocolate free of cocoa solids as placebo.
2480399|NCT03033771|Experimental|Treatment|Patients presenting with chronic type B aortic dissection will have the MFM implanted.
2480407|NCT03033589|Active Comparator|Adductor Canal Nerve Block|
2480409|NCT03033589|Active Comparator|Femoral Nerve block|
2480441|NCT03033485|Experimental|Melanoma patients|Melanoma patients enrolled for the clinical diagnosis study are performed with both 18F-P3BZA PET/CT and18F-FDG PET/CT scans before surgery.
2480498|NCT03033251|Active Comparator|Non invasive ventilation|Patients will receive non invasive ventilation with setting decided by the attending physician.
2480499|NCT03033251|Active Comparator|High Flow 50 L/min|High Flow Oxygen Cannula with a flow set at 50 L/min.
2480500|NCT03033251|Active Comparator|High Flow 30 L/min|High Flow Oxygen Cannula with a flow set at 30 L/min.
2480531|NCT03032874||Training set|All the patients with rectal bleeding who had colonoscopy performed at Obafemi Awolowo University Teaching Hospitals Complex
2480533|NCT03032874||Validation set|All the patients with rectal bleeding who had colonoscopy performed at University College Hospital, Ibadan and University of Ilorin Teaching Hospital
2480585|NCT03032666|Experimental|sofosbuvir/velpatasvir|Epclusa
2480683|NCT03031951|Experimental|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 90-120 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum. Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
3193250|NCT00816478|Experimental|1|Galactose
3193251|NCT00816491|Active Comparator|A|Conventional white light colonoscopy
2479832|NCT03037606|Experimental|Rabelis DDR 50 mg Capsules and 1 placebo tablet|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
2479833|NCT03037606|Active Comparator|Pariet 20 mg Enteric Coated Tablets and 1 placebo capsule|Placebo as comparator group is not used. Since study is double-blind, one placebo capsule and tablet is added to treatment groups in order to remove the discrepancy between investigational products.
2479914|NCT03037112|Active Comparator|Education|All providers will receive identical training on the appropriate prescribing of antibiotics for ARTIs in a 20 minute presentation. Follow up refresher video clips will also be available for all providers to view at their convenience throughout the study. Parents in both arms will receive identical high quality education on the pros and cons of antibiotics and tips for communicating with their provider.
2479915|NCT03037112|Active Comparator|Communication Skills|Providers randomized to the communication intervention will receive additional training on communication skills in a 40 minute communication skills training session. This training session will include good and bad communication examples, training on positive and negative behavioral framing, and education regarding key drivers of patient satisfaction.
2479942|NCT03036787||moderate-early preterm infants|infant who births in 32 weeks to 37 weeks with family based intervention
2479945|NCT03036787||extremely-very preterm infants|infant who births in 27 weeks to 32 weeks with family based intervention
2480029|NCT03036566|Experimental|Bridge|Three unit high strength ceramic (lithium disilicate/emaxCAD by Ivoclar) bridges replacing a single tooth.
2480067|NCT03036046|Experimental|F901318 with fluconazole low dose|safety assessment
2480070|NCT03036046|Experimental|F901318 with fluconazole high dose|safety assessment
2480072|NCT03036046|Experimental|F901318 with posaconazole|safety assessment
2480300|NCT03034980||Coronary Artery Disease (CAD) patients|Patients with proven coronary artery disease, who underwent the full cardiac revalidation program at Jessa Hospital from 10-1-2013 till 12-9-2016.
2480334|NCT03034421|Active Comparator|Modified medical care|Patients will undergo 48-hours bed rest after endoscopic valve implantation.
2480342|NCT03034421|No Intervention|Standard medical care|Patients will be treated with standard medical care without restriction to bed rest after endoscopic valve implantation.
3158707|NCT00391066|Active Comparator|1|"FCR~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
3158708|NCT00391066|Experimental|2|"FCR + Lumiliximab (L)~L (Lumiliximab): Day 2 50 mg/m2, Day 4 450 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks.~F (Fludarabine): 25 mg/m2 daily, every four weeks for 21 weeks~C (Cyclophosphamide): 250 mg/m2 daily, every four weeks for 21 weeks~R: (Rituximab): Day 1 50 mg/m2, Day 3 325 mg/m2, for the first week, then single doses of 500 mg/m2 every four weeks, for 21 weeks"
2480877|NCT03030586||Alzheimer|400 patients in total, with approximately 200 patients with mild Alzheimer's disease and 200 patients with moderate to severe Alzheimer's disease will be recruited for sampling blood, urine (and other peripheral body fluids: tears and saliva as optional) for validation of biomarkers
3158709|NCT00391131|Experimental|Ig NextGen 16%|
2480918|NCT03030131|Experimental|Durvalumab|durvalumab 750 mg IV J1, J15, J29
3158710|NCT00391170|Experimental|Active|Dexamethasone 0.01%
3158711|NCT00391170|Placebo Comparator|Placebo|Placebo oral rinse
3158712|NCT00391183|Active Comparator|Endoscopic stenting|patients with biliary obstruction will undergo endoscopic stenting.
3158713|NCT00391183|No Intervention|Best supportive care|
3158714|NCT00391196|Placebo Comparator|Placebo|
3158715|NCT00391196|Experimental|CP-945,598|
3158716|NCT00391196|Experimental|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
3158717|NCT00391209|Experimental|1|
3158718|NCT00391209|Experimental|2|
3158719|NCT00391235||BPD|Children with bipolar disorder
3158720|NCT00391235||HC|Healthy comparison children
3158721|NCT00391287||erythropoietin treatment in CRF|Patients exposed to EPREX or other marketed erythropoietin products administered by the subcutaneous route of administration for the treatment of anemia of Chronic Renal Failure
3158722|NCT00391352||MS|MS patient is matched to healthy volunteer
3158723|NCT00391352||Control|
3158724|NCT00391404|Active Comparator|Alendronate|Oral alendronate 70 mg weekly
3158725|NCT00391404|Placebo Comparator|Placebo|Conventional drug treatment
3158726|NCT00391521|Active Comparator|1|Regimen 1
3158727|NCT00391521|Active Comparator|2|Regimen 2
3158728|NCT00391521|Active Comparator|3|Regimen 3
3158729|NCT00391534|Experimental|Oxcarbazepine MR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
3158730|NCT00391534|Active Comparator|Oxcarbazepine IR|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
3158731|NCT00391560|Experimental|Group 1 on Perifosine|"Patients with AML, MDS, CML-BP non-lymphoid, CMML, or Agnogenic Myeloid Metaplasia (AMM).~After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
3173415|NCT00611832|Experimental|Enhanced|"Enhanced behavior activation version of the television series that includes all of the content of the standard information-only version, but is also designed to actively promote parental behavior change, through additional content elements addressing attributions, self-efficacy and expectancies, social support, and emotional reactivity."
2479848|NCT03037515|Active Comparator|Intravenous Tranexamic Acid|The IV TXA group will receive the standard dosing for our institution of 1 g TXA (diluted in 100 mL normal saline) given as an IV bolus immediately before incision and another 1 g TXA given before closure.
2479851|NCT03037515|Active Comparator|Oral Tranexamic Acid|The oral TXA group will receive 1950 mg TXA (3 tablets of 650 mg) approximately 2 hours before incision.
2479884|NCT03037216|Experimental|Experimental Exercise-Training Intervention|Subjects will undergo a 10-week aerobic exercise protocol.
2479951|NCT03036982||Use of Mobile ACT|Will answer ACT (or cACT) and other asthma questions using mobile app
2480046|NCT03036644|Experimental|e-cigarette nic_O LT|e-cigarette (without nicotine; low temperature)
2480049|NCT03036644|Experimental|e-cigarette Nic_1 LT|e-cigarette (with nicotine; low temperature)
2480050|NCT03036644|Experimental|e-cigarette Nic_0 HT|e-cigarette (without nicotine; high temperature)
2480051|NCT03036644|Experimental|e-cigarette NIC_1 HT|e-cigarette (with nicotine; high temperature)
2480052|NCT03036644|Active Comparator|Tobacco cigarette|Tobacco cigarette
2480053|NCT03036644|Placebo Comparator|Placebo|No E-cigarettes, Nor tobocco cigarettes
2480091|NCT03035903|Experimental|Not holding, then holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken while not holding, then holding a MedGem® Indirect Calorimeter.
2480098|NCT03035903|Active Comparator|Holding, then not holding the MedGem®|Subjects will be seated in an armless chair and have a RMR measurement taken holding, then not holding a MedGem® Indirect Calorimeter.
2480152|NCT03035682|Active Comparator|Traditional Group|The control group will receive traditional PT services as deemed clinically appropriate via examination to include traditional home exercise prescription.
2480156|NCT03035682|Experimental|Augmented Media Group|The Augmented Media group will receive traditional PT services as deemed clinically appropriate via examination and include home exercise prescription via a mobile health application.
2480202|NCT03035396|Experimental|Diassess Influenza A and B Test|
3193252|NCT00816491|Experimental|B|Chromoendoscopy
2480344|NCT03034382|Experimental|Morphine|5 mg morphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
2480346|NCT03034382|Experimental|Nalbuphine|5 mg nalbuphine in 5ml volume injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.
2480348|NCT03034382|Experimental|Morphine and Nalbuphine|"5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected as adjuvants to 10 ml of lidocaine and epinephrine 1:400,000.~combination of 5 mg morphine and 5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block"
2480349|NCT03034382|Placebo Comparator|Bupivacaine 0.5%|10 ml of lidocaine 1% and epinephrine 1:400,000 and 5 ml of Bupivacaine 0.5% in interscalene block.
2480408|NCT03033537||Verapamil|Intracavernosal injection of Verapamil
2480410|NCT03033537||Phentolamine|Intracavernosal injection of Phentolamine to treat erectile dysfunction for a period of 2 wweks
2480435|NCT03033498|Experimental|ABBV-951 Dose 1|Participants will receive dose 1 of ABBV-951.
2480446|NCT03033498|Experimental|ABBV-951 Dose 2|Participants will receive dose 2 of ABBV-951.
2480451|NCT03033498|Experimental|ABBV-951 Dose 3|Participants will receive dose 3 of ABBV-951.
2480454|NCT03033498|Experimental|ABBV-951 Dose 4|Participants will receive dose 4 of ABBV-951.
2480456|NCT03033498|Experimental|ABBV-951 Dose 5|Participants will receive dose 5 of ABBV-951.
2480457|NCT03033498|Experimental|ABBV-951 Dose 6|Participants will receive dose 6 of ABBV-951.
2480458|NCT03033498|Experimental|ABBV-951 Dose 7|Participants will receive dose 7 of ABBV-951.
2480459|NCT03033498|Experimental|ABBV-951 Dose 8|Participants will receive dose 8 of ABBV-951.
2480535|NCT03033043|Experimental|Experimental: Relay Pro|The Relay Pro arm includes subjects who receive the device. The Relay Pro Stent Graft System is administered to treat complicated Type B aortic dissections.
2480618|NCT03032406|Experimental|HCQ alone (Arm A)|
2480619|NCT03032406|Experimental|EVE alone (Arm B)|
2480623|NCT03032406|Experimental|combination HCQ and EVE (Arm C)|
2480625|NCT03032406|Experimental|observation (Arm D)|
2480673|NCT03032107|Experimental|Pembrolizumab Combine With Trastuzumab Emtansine|"Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle~Pembrolizumab will be administered prior to T-DM1 administration~Pembrolizumab will be given at a predetermine dose~T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle~T-DM1 will be given at a predetermine dose"
2480689|NCT03031704||Endoscopic mucosectomy|
2480731|NCT03031587|Experimental|MRI examination|Each patient coming to the hospital for cardiac MRI examination can participate to the study if he/she meets the eligibility criteria
2480771|NCT03031314|Active Comparator|Standard suture|standard suture used (monocryl)
2480773|NCT03031314|Active Comparator|Barbed suture|barbed suture used (Quill suture, Surgical Specialties)
2480802|NCT03031028|Other|ketogenic diet|Ketogenic diet
2480901|NCT03030560|Active Comparator|Lidocaine group|Patients will receive lidocaine infusion.
2480902|NCT03030560|Placebo Comparator|Control group|Patients will receive 0.9% Sodium-chloride infusion infusion
2480955|NCT03030053|Experimental|Active|Cocoa-Flavanol Supplements: 3 capsules per day each containing 300mg (total dose of 900mg daily) for 24 weeks
2480956|NCT03030053|Placebo Comparator|Control|Control Supplements: 0mg cocoa-flavanols per day for 24 weeks
2481044|NCT03029338|Experimental|CD19 CAR T cells|CD19 CAR T cells will be intravenously infused to patient in a three-day split-dose regimen: 10% on day 0, 30% on day 1 and 60% on day 2.
2481088|NCT03029377|Experimental|Chronic Fatigue Patients|Patients between 18-60 years of age with fatigue symptoms who meet preliminary chronic fatigue phenotype criteria and complete preliminary screening surveys. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
3193253|NCT00816504|Experimental|1|Galactose
3193254|NCT00816517|Experimental|botulinum toxin|injection of botulinum toxin type A
3193255|NCT00816530||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
2479969|NCT03037060|Experimental|Experimental|"5 experimental sessions per participant:~(1) [11C]-(+)-PHNO PET scan, (2), Alcohol Self-Administration, (3) Craving Task, (4) MRI scan and (5) Neuropsychological Assessment."
2479996|NCT03036410|Other|bimodal user|wearing one hearing aid and one CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2480003|NCT03036410|Other|unilateral hearing aid users|wearing one hearing aid Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2480012|NCT03036410|Other|bilateral hearing aid users|wearing two hearing aids Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2480020|NCT03036410|Other|CI users|wearing CI Intervention: Standard Phone, DECT Phone, Easy Call, Duo Phone
2480093|NCT03035981|Experimental|White rice, low amylose|Cooked white rice with low amylose content
2480097|NCT03035981|Experimental|White rice, high amylose|Cooked white rice with high amylose content
2480102|NCT03035981|Experimental|White rice, slow|Cooked white rice with slow digesting starch
2480105|NCT03035981|Experimental|White rice, resistant|Cooked white rice with resistant starch
2480110|NCT03035981|Experimental|Brown rice, low amylose|Cooked brown rice with low amylose content
2480112|NCT03035981|Experimental|Brown rice, high amylose|Cooked brown rice with high amylose content
2480114|NCT03035981|Experimental|Fructooligosaccharide (FOS)|Fermentable carbohydrate solution
2480146|NCT03035656|Experimental|Experimental|Administration of epidural Ropivaciane
2480147|NCT03035656|Placebo Comparator|Control|Administration of saline
2480182|NCT03035435||study group|fast-track rehabilitation
2480183|NCT03035435||control group|standard care rehabilitation
2480204|NCT03035201||Cocoa extract + multivitamin|2 capsules containing 500 mg/d cocoa extract; daily MTV
2480209|NCT03035201||Cocoa extract + multivitamin placebo|2 capsules containing 500 mg/d cocoa extract; daily MTV placebo
2480212|NCT03035201||Cocoa extract placebo + multivitamin|Cocoa extract placebo (2 capsules/d); daily MTV
2480214|NCT03035201||Cocoa extract placebo + multivitamin placebo|Cocoa extract placebo (2 capsules/d); daily MTV placebo
2480277|NCT03035006|Experimental|Lipotecan based chemoradiotherapy|Patients will receive Lipotecan based CCRT. Lipotecan will be given as a 30-minute (±3 minutes) iv infusion qw for 6 weeks at the predefined dose level for each cohort. A total of 6 doses of Lipotecan will be administered to each patient in conjunction with RT at 3.5 Gy per fraction for 16 fractions. During CCRT period, Lipotecan should be given within 2 hours prior to the start of RT, and the Lipotecan and RT should be delivered on the same day, unless any conditions fulfils with the dose interruption standards. Radiotherapy treatment, at the allocated dose level, is only permitted if the normal tissue dose constrain criteria are maintained
2480313|NCT03034512||Patients with Alpers-Huttenlocher|Patients confirmed to have Alpers Huttenlocher Syndrome
2480321|NCT03034512||Siblings|Siblings of patients with Alpers Huttenlocher Syndrome
2480424|NCT03033667|Experimental|Glucose group (G group)|patients received 500 cc of glucose 10% that containing 50 g of glucose and provides patients with 200 Kcal with 556 mosmoles/L.
2480426|NCT03033667|Experimental|Lipid Group (L group)|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid and provides patients with 200 Kcal with osmolarity of 380 mosmoles /L.
2480428|NCT03033667|Experimental|Control Group (C group)|patients was fasting overnight from 11 pm till 9 am except for clear fluids that was allowed till 5 am.
2480544|NCT03033316|Experimental|IV Liposomal Dexamethasone|IV Liposomal Dexamethasone given 1 to 4 times in total over period of maximally 4 weeks
2480600|NCT03032614|Experimental|Combination of Carboplatin, Eribulin, and Veliparib|Eribulin will be administered intravenously (IV) on days 1 and 8 of each cycle at a dose of 1.1 mg/m2 over a 2-5 minute time period; on cycle day 1. Carboplatin will be administered intravenously at a dose of AUC 5 on day 1 of each cycle, over 30 min, immediately following eribulin infusion, per institutional guidelines. Veliparib will be given at 120 mg bid (two times a day), on days 2-12 for the first cycle of the safety run-in period and thereafter at 240 mg bid.
2480637|NCT03032146|Experimental|participation in cardiac rehabilitation|Patients with at least a month of cardiac rehabilitation at The Emek Medical Center, Afula. Rehabilitation includes a multidisciplinary program based on physical exercise.
2480638|NCT03032146|No Intervention|control|Patients who chose not to participate in the rehabilitation program, despite being offered the option.
2480699|NCT03031964||revision multihole acetabular cup|Revision total hip arthroplasty using multihole revision acetabular cup
2480752|NCT03031522|Experimental|18F-IRS : EGFR+ Patients|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
2480753|NCT03031522|Experimental|18F-IRS :post-TKI EGFR+ Patients|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study .
2480754|NCT03031522|Experimental|18F-IRS:post-chemo EGFR+|18F-IRS:post-chemo EGFR+ Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
2480755|NCT03031522|Experimental|18F-IRS:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2480757|NCT03031522|Experimental|18F-IRS:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
2480759|NCT03031522|Experimental|18F-IRS:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
2480803|NCT03031080|Active Comparator|Splinted|Patients will be given Thermoplastic Hand Splint to wear overnight for 12 weeks.
2480806|NCT03031080|No Intervention|Un-Splinted|Patients will not wear a night splint
2480893|NCT03030664|Active Comparator|L.reuteri|probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
2480897|NCT03030664|Placebo Comparator|Placebo|Same formulation as probiotics, without active substance. 5 drops per day will be delivered
2480951|NCT03030079|Experimental|Experimental Electrical stimulation Regimen|Explore the efficacy of an electrical stimulus regimen on the treatment of chronic phantom limb pain using a standard-of-care electrical stimulation system
2481007|NCT03029689|Experimental|Current ART + Raltegravir|Current ART + Raltegravir
2481009|NCT03029689|Placebo Comparator|Current ART + placebo|Current ART + placebo
2480002|NCT03036488|Experimental|Pembrolizumab + Chemotherapy|Participants receive pembrolizumab every 3 weeks (Q3W) + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by pembrolizumab Q3W + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of pembrolizumab Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
2480010|NCT03036488|Active Comparator|Placebo + Chemotherapy|Participants receive placebo (normal saline solution) Q3W + paclitaxel weekly + carboplatin (weekly or Q3W) x 4 cycles, followed by placebo + (doxorubicin OR epirubicin) + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy prior to surgery; followed by 9 cycles of placebo Q3W as adjuvant therapy post-surgery. Each cycle is 21 days.
2480215|NCT03035123|No Intervention|"Usual care"|Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
2480216|NCT03035123|Experimental|Interventional|"Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.~Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.~To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer."
2480247|NCT03034837|Active Comparator|Resin sealant|"Sealing pit and fissures of the included permanent first molars using SDI conseal f resin sealant material once at the baseline of the study."
2480249|NCT03034837|Experimental|ART sealant|"Sealing pit and fissures of the included permanent first molars using 3M ESPE KetacTM Molar Easymix glass ionomer cement material once at the baseline of the study."
2480304|NCT03034642|Experimental|Healthy Participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
2480306|NCT03034642|Experimental|COPD participants|"Procedure/Surgery: Bronchoscopy with bilateral bronchoalveolar lavages.~Drugs: No test substances, only moderate conscious sedation using standard medications.~Devices: No test devices."
2480421|NCT03033810||Consecutive patients with FFR and iFR|Patients with stable angina pectoris with suitable for coronary angiography will be suitable for the study
2480496|NCT03033368|Experimental|opened label|Open-label, single-arm study, rilpivirine is the study drug
2480554|NCT03032952|Experimental|"Feel Stress Free"|"Access to the Feel Stress Free mobile application intervention for 12 weeks. Instructed to use it at least once per week for 15 minutes, for the first 6 weeks, then given free access thereafter."
2480555|NCT03032952|No Intervention|Wait list control|Given access to the intervention at the end of the 12 weeks of the trial.
2480574|NCT03032575|Other|sample size 100|Study Design: This is a prospective observational cohort of Thai MSM who initiated ART at the time of AHI, defined as the first 30 days after HIV acquisition (Fiebig stages 1 through 5). Volunteers will be examined at baseline to determine the prevalence of HPV infection and HSIL at HIV diagnosis. They will then be followed longitudinally for new incidence of HPV and HSIL, as well as progression or regression of existing lesions.
2480629|NCT03032367|Other|Sequence 1|Bedaquiline 4 x 100mg administered in a whole tablet form, followed by bedaquiline 4 x 100mg administered in crushed form as a once only oral dose
2480630|NCT03032367|Other|Sequence 2|Bedaquiline 4x 100mg administered in crushed form, followed by bedaquiline 4 x 100mg administered in a whole tablet form, as a once only oral dose
2480671|NCT03032055||VOC|"Patients who won't develop a secondary Acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate and chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults. It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
2480672|NCT03032055||2°ACS|"Patients who will develop a secondary acute chest syndrome during a vaso occlusive crisis within 15 days after admission.~Secondary Acute chest syndrome is defined by a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds .~A vaso-occlusive crisis is a common painful complication of sickle cell anemia in adolescents and adults.It is a form of sickle cell crisis. Sickle cell anemia - most common in those of African, Hispanic, and Mediterranean origin - leads to sickle cell crisis when the circulation of blood vessels is obstructed by sickled red blood cells, causing ischemic injuries."
3173416|NCT00611832|No Intervention|Control|Waitlist control
3173417|NCT00611871|Experimental|1|Propranolol following traumatic memory
2480732|NCT03031574|Active Comparator|Food Effect|SUVN-D4010 tablets single dose
2480734|NCT03031574|Active Comparator|Gender Effect|SUVN-D4010 tablets single dose
2480737|NCT03031574|Active Comparator|Age Effect|SUVN-D4010 tablets single dose
2480750|NCT03031288|Experimental|"Start feeding with Device A, standard"|Alternatively feeding with standard feeding bottle (Device A) and vented base feeding bottle (Device B)
2480751|NCT03031288|Experimental|"Start feeding with Device B, vented"|Alternatively feeding with vented base feeding bottle (Device B) and standard feeding bottle (Device A)
2480857|NCT03031145|Active Comparator|Felis Domesticus treated Non-smoker|
2480858|NCT03031145|Active Comparator|Felis Domesticus treated E-cigarette smoker|
2480859|NCT03031145|Active Comparator|Felis Domesticus treated Cigarette smoker|
2481018|NCT03029520|Active Comparator|pain AHPlus Vital pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) vital pulp.
3173418|NCT00611871|Active Comparator|2|Propranolol following neutral memory
3173419|NCT00611871|Placebo Comparator|3|Placebo following traumatic memory
2480022|NCT03036319|Experimental|Sham TES + Cognitively based intervention|This condition combines sham TES and cognitively based interventions for some or all of the study sessions
2480024|NCT03036319|Experimental|Active TES, Sham TES, Cognitively based interventions|This condition combines active and sham TES with cognitively based interventions using a cross-over design
2480027|NCT03036319|Experimental|Active and Sham TES|Participants will receive active and sham TES
2480350|NCT03034369||Safety Net Clinic Patients|A Cohort of patients in 12 different primary care clinics will be studied to measure how changes in different integration factors impacts the following patient reported outcomes at baseline and 12 months: Access to Care, Patient-Provider Relationship, Patient-Clinic Interactions, Stigma, Provider Continuity, Symptom Severity, Diagnoses, and Social Support. Health care claims data will be accessed to analyze Depression Screening, Preventive Screening, Inpatient Hospitalization Utilization, Inpatient Readmissions, and Post-Admission follow-up at baseline and 12 months.
3158732|NCT00391560|Experimental|Group 2 on Perifosine|"Patients with CLL, ALL, or CML-BP lymphoid. After a one-time loading dose of 600 mg (150 mg x 4 at least 4 hours apart) during the first cycle, perifosine will be given orally at 100 mg once a day continuously. Cycles are 28 days in length.~Intra-patient dose escalation for the maintenance dose to 150 mg daily will be done in the second cycle if no non-hematological toxicities beyond grade 0-1 occurred during the first cycle are observed."
3158733|NCT00391612|Sham Comparator|2|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy but no stents are placed
2480413|NCT03033693|Other|The deep anesthesia group|
2480416|NCT03033693|Other|The light anesthesia group|
2480510|NCT03033004|Active Comparator|Conventional Cryolipolysis|Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
2480511|NCT03033004|Active Comparator|Contrast Cryolipolysis|Subjects will receive one treatment session of contrast cryolipolisys. Subcutaneous fat tissue will be heated for 10 minutes, cooled for 60 minutes, and heated again for 10 minutes with the cryolipolitic device. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
2480514|NCT03033004|Active Comparator|Reperfusion Cryolipolysis|Subjects will receive one treatment session of Reperfusion Cryolipolysis. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes and heated for 10 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
3158734|NCT00391612|Experimental|1|subject receives optimal medical management, supervised pulmonary rehabilitation therapy and undergoes bronchoscopy during which up to six Exhale drug-eluting stents are placed in the lungs
3158735|NCT00391638|Experimental|HIV antiretroviral therapy, TRUVADA , PEGASYS 180μg|Week-8 up Week0: HIV antiretroviral therapy Week 0 up Week 48: HIV antiretroviral therapy + TRUVADA + PEGASYS 180μg Week 48 up Week 72: HIV antiretroviral therapy + TRUVADA Week 72 up Week 144: HIV antiretroviral therapy
2480640|NCT03032341||Patient group|20 patient in poor mobility group (MAT-sf < 51.38 in men and <45.61 in women), mid-mobility group (51.38< MAT-sf≤65.5 in men and 45.61≤MAT-sf<54.02) and high mobility group (MAT-sf>65.5 in men and MAT-sf>54.02 in women) for a total of 60 patients.
2480643|NCT03032341||Surrogate group|A family member/caregiver that attends visits with the patient and will be asked to answer the Mobility Assessment Test questionnaire on behalf of the patient at the initial visit and the follow up visit 1-14 days later.
2480717|NCT03031977|Experimental|visceral mobilization|Conventional physical therapy and visceral mobilization. The experimental group was also submitted to mobilization of the ascending colon, descending colon, sigmoid colon and sphincters (cardiac, pyloric, Oddi, duodenojejunal and ileocecal) with the patient in the supine position, knees flexed, feet supported and abdomen exposed. Contact was made with the region to be treated, leading it in the direction of immobility, with pressure maintained for one minute on each region with intensity based on the sensitivity to tension observed on the feedback of the individual.
2480718|NCT03031977|Sham Comparator|sham mobilization|Conventional physical therapy and sham mobilization. In the control group, sham mobilization was performed, which consisted of superficial contact with no pressure on the abdominal region corresponding to the loops of the large intestine.
2480766|NCT03031418||Cohort 1|Enroll up to 500 patients to confirm performance of ExoDx Prostate IntelliScore (EPI) for men scheduled for initial biopsy. The treating physician will collect a urine sample from from a consented subject to test before their scheduled prostate biopsy (during your established clinic visit).
2480768|NCT03031418||Cohort 2|Enroll up to 500 patients to evaluate how the results of the urine test influences the decision process for determining whether to perform a prostate biopsy. The treating physician will collect a urine sample for testing and 2 weeks later discuss whether to perform a prostate biopsy with the subject knowing the results of the urine test and comparing them to the overall consensus report from Cohort 1 as well as other clinical factors the treating physician would otherwise use to determine whether they should have a prostate biopsy.
2480810|NCT03031002|Experimental|Exposure Treatment|Participants of this arm receive two 60-minute sessions of exposure treatment for spider fear
2480811|NCT03031002|No Intervention|No Exposure Treatment|Participants of this arm receive no exposure or other adequate treatment
2480832|NCT03030742||Post-cesarean delivery|Women who have undergone cesarean delivery
2480834|NCT03030742||Post-vaginal delivery|Women who have undergone vaginal delivery
3158736|NCT00391651|Active Comparator|1|Nitrofurantoin 100mg BID x 5 days
3158737|NCT00391651|Active Comparator|2|TMP/SMX DS BID x 3 days
2480927|NCT03030326|Experimental|Heart rate variability biofeedback|This group will receive treatment in the first three months of the study and will be observed during the second three months
2480931|NCT03030326|No Intervention|Observation first|This group will be observed during the first three months and given biofeedback during the second three months
2480944|NCT03029936||Obesity Group|
2480945|NCT03029936||Asthma Group|
2480946|NCT03029936||Obesity-Asthma Group|
2480947|NCT03029936||Control|
2481035|NCT03029845|Active Comparator|propranolol 1|20 mg propranolol twice a day
2508467|NCT02842177|Active Comparator|uterine sound sparing group|
3173420|NCT00611910|Experimental|DES|drug-eluting stents
2480197|NCT03035448|Experimental|Video 1: Counselor Alone|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
2480198|NCT03035448|Experimental|Video 2: Doctor + Counselor|"Participants complete 3 assessment questionnaires during an already-scheduled office visit.~Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services."
2480265|NCT03035045|Experimental|Comparator1: Paracetamol 650 mg (325 mg/tablet) oral|Drug: Paracetamol Comparison pain score between paracetamol and placebo
2480267|NCT03035045|Placebo Comparator|Comparator 2: Placebo oral|Drug: placebo Comparison pain score between paracetamol and placebo
2480364|NCT03034343|Experimental|TAU+mindfulness applied face to face|4 sessions of 90 minutes/session Mindfulness based intervention applied in groups of 10-12 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is one month.
2480367|NCT03034343|Experimental|TAU + Mindfulness ICTs intervention|4 sessions of 60 minutes/session Mindfulness based intervention applied by ICTs (Internet-based program). The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the online program is two months.
2480368|NCT03034343|No Intervention|Usual medical treatment (TAU)|In this group the general practitioner will apply the usual treatment (medication) but there will be no psychological treatment.
2480417|NCT03033862||Intervention with Bioresorbable Vascular Scaffold|Implant of Abbott Bioresorbable stent
2480418|NCT03033862||Intervention with Drug Eluting Stent|implant of drug eluting stent
2480461|NCT03033433|Experimental|DCB-DM101, 500 mg tablet, determination of optimal dose|Stage 1:Dose level 1(1 tablet of DCB-DM101 q.d. for 7 days orally);Dose level 2(2 tablets of DCB-DM101 q.d. for 7 days orally);Dose level 3(4 tablets of DCB-DM101 q.d. for 7 days orally) Stage 2:Optimum dose of DCB-DM101 determined in Stage 1 as add-on treatment in T2DM patients for 14 days, q.d., orally
2480575|NCT03032471||DCI group|"Patients that experience DCI, defined as~Cerebral infarction identified on imaging or proven at autopsy, after exclusion of procedure-related infarctions; and~Clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration will be assigned to the DCI group."
2480578|NCT03032471||non-DCI group|Patients not experiencing DCI as defined above.
2480658|NCT03032276|Experimental|Intervention|"'Safe motherhood and newborn health promotion package' will be implemented in the intervention arm which comprise 15 randomly selected unions (lowest level of administrative unit)."
2480663|NCT03032276|No Intervention|Comparison|Another 15 union will be selected where no intervention will be implemented
2480713|NCT03031886|Experimental|high GI|Cereal, milk, tea, cheese, steamed glutinous rice with chicken, carrots, bread, strawberry jam, margarine, high GI sweetener (sucrose).
2480720|NCT03031886|Experimental|Low GI|Cereal, milk, tea, steamed basmati rice with chicken, spinach, bread, strawberry jam, low GI sweetener (isomaltulose).
2480800|NCT03031366|Experimental|3D roadmap|TIPS was established using 3d roadmap guidance
2480805|NCT03031366|Active Comparator|conventional TIPS|conventional TIPS procedure using wedged hepatic venography
2480831|NCT03030820|Experimental|Dental cleaning|Patients with cirrhosis and healthy controls will undergo dental examination and subsequent dental cleaning if necessary.
3158738|NCT00391677|Experimental|1|Participants will receive social skills training with attention shaping procedures
2481016|NCT03029520|Active Comparator|pain iRoot SP sealer Vital Pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) vital pulp.
2481017|NCT03029520|Active Comparator|pain iRoot SP sealer Devital pulp|Evaluation of Postoperative pain after root canal obturation with iRoot SP sealer (Innovative BioCeramix Inc., Vancouver, Canada) with patients who has (mandibular premolar/molar) devital pulp.
3158739|NCT00391677|Active Comparator|2|Participants will receive social skills training without attention shaping procedures
3158740|NCT00391703|Experimental|1|Quadriceps electrostimulation program, performed prior to an endurance retraining program using a cycloergometer
3158741|NCT00391703|Active Comparator|2|Usual sport activity, performed prior to an endurance retraining program using a cycloergometer
3158742|NCT00391729|Placebo Comparator|1|
3158743|NCT00391729|Experimental|2|
3158744|NCT00391755|Active Comparator|1|ramelteon 8 mg po qhs with sleep and migraine journal
3158745|NCT00391755|Placebo Comparator|2|Placebo po qhs with sleep and migraine journal
3158746|NCT00391794|Experimental|ESSG|eight weekly 90-minute sessions
3158747|NCT00391794|Active Comparator|ES|one 4-hour educational program
3158748|NCT00391859|Experimental|Health service provision|Health service provision within the first few months of diagnosis which includes physical examination, radiographs, education, exercise, weight loss, assistive devices and pharmacologic therapy.
3158749|NCT00391911|Active Comparator|NAC and CRRT|N-Acetylcysteine and CRRT Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label,
3158750|NCT00391911|Other|NAC and non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
3158751|NCT00391911|Other|Placebo and CRRT|Patients are assigned to placebo treatment and CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT is open label.
3173421|NCT00611910|Active Comparator|BMS|bare metal stents
3173422|NCT00611936|Placebo Comparator|2|Second arm is placebo
3173423|NCT00611936|Experimental|1|One arm is atomoxetine 40 mg per day
2480088|NCT03035994|Experimental|Overloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% greater than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2480095|NCT03035994|Experimental|Underloading|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at 10% lower than the participant's baseline vertical ground reaction force. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2480103|NCT03035994|Experimental|Average|Participants will walk on a force-instrumented treadmill for 20 minutes and will be provided visual biofeedback consisting of bilateral vertical ground reaction force. A target will be placed at the average of each participant's baseline vertical ground reaction force between limbs. Participants will be asked to alter their walking gait in an attempt to reach the target line with each step.
2480106|NCT03035994|No Intervention|Control|Participants will walk for 20 minutes on a force-instrumented treadmill and will not be provided biofeedback.
2480158|NCT03035721|Experimental|Low protein formula group|Full term healthy infants randomized to receive a low protein formula for the first 4 months of life
2480164|NCT03035721|Active Comparator|Standard protein formula group|Full term healthy infants randomized to receive a standard protein formula for the first 4 months of life
2480170|NCT03035721|No Intervention|Breastfeeding group|Breastfed full term healthy infants
2480269|NCT03035344||ALL paediatric patients|Metabolome study in children diagnosed with ALL after bone marrow biopsy
2480273|NCT03035344||Healthy matched controls|Metabolome study in healthy children matched for gender and age with the patients group
3158752|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. This is the standard of care arm. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
3158753|NCT00391937|Experimental|1|ASR prosthesis placed using CAS
2480360|NCT03034083||Couples Elevate Weekly Series|Participants in a couple relationship receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
2480361|NCT03034083||Foster Parents Elevate Weekend Intensive|Foster parent participants receive 8 hours of classes over a weekend in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
2480397|NCT03033953|Placebo Comparator|Milk supplementation|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g milk protein.
2480398|NCT03033953|Experimental|Native whey|11 (elderly) or 12 (young) weeks of strength training and daily supplementation of 2x20g native whey protein.
2480438|NCT03033602|Experimental|Written exposure therapy|5 sessions of imaginal exposure therapy.
2480445|NCT03033602|Active Comparator|CPT, cognitive only|12 sessions of cognitive therapy.
2480515|NCT03033173||CTS group|
2480520|NCT03033173||Healthy subjects|
2480564|NCT03032809||Intracranial vasculopathy|Patients diagnosed intracranial vasculopathy will be imaged further by high resolution vessel wall MR imaging on a 3Tesla MR scanner.
2480642|NCT03032419|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
2480644|NCT03032419|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh. Each subject randomised to this group will receive three primary injection at 6, 10, and 14 weeks of age and one booster injection at 9 months of age
2480792|NCT03031483|Experimental|Experimental: clarithromycin and lenalidomide|CLARITHROMYCIN: daily orally administration in cycles of 28 days; 500mg film-coated tablets LENALIDOMIDE: every cycle of treatment lasts 28 days; daily orally administration is of 21 consecutive days with a week of rest. 20mg capsule hard. The maximum treatment duration is 12 months.
2480843|NCT03030729||Intermediate AMD|
2480844|NCT03030729||Advanced AMD|
2480845|NCT03030729||DR without macular edema|
2480846|NCT03030729||DR with macular edema|
2480878|NCT03030482|Experimental|Touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
2480880|NCT03030482|No Intervention|control|standard care ICU
2480926|NCT03030287|Experimental|OMP-305B83 plus paclitaxel|
2481024|NCT03029884|Active Comparator|Active DBS|Chronic brain recording and stimulation with unilateral or bilateral implantation in pain-related brain regions. Both thalamic pain syndrome and phantom pain participants will participate in active DBS, blinded to the participant.
2481028|NCT03029884|Sham Comparator|Inactive DBS|Non-active chronic brain stimulation in pain-related brain regions. Brain recordings will remain active during this period. Both thalamic pain syndrome and phantom pain participants will participate in inactive DBS, blinded to the participant.
3158754|NCT00391937|Active Comparator|2|ASR prosthesis placed by conventional method
3158755|NCT00392080|Placebo Comparator|3|
3158756|NCT00392080|Experimental|1|75 mg BID
3158757|NCT00392080|Experimental|2|
3158758|NCT00392106|Active Comparator|Control|Class I or III anti-arrhythmic drug for the treatment of AF
3158759|NCT00392106|Experimental|Treatment|Pulmonary vein ablation with HIFU
3158760|NCT00392145|Active Comparator|1|
3158761|NCT00392145|Experimental|2|
3158762|NCT00392184|Experimental|APBI|Accelerated Partial Breast Irradiation with interstitial Brachytherapy
3158763|NCT00392314|Experimental|Early favorable|patients with early favorable disease Ia IIA will have a PET/CT following 2 cycles of ABVD
3158764|NCT00392314|Experimental|Early Unfavorable|Patients with early favorable disease Ia or IIa with risk factors :large mediastinal mass extra nodal disease elevated esr, three or more involved areas, age equal or >50 , lymphocytic depleted or mixed cellularity
3173424|NCT00611949|Active Comparator|1 Geranium Oil|
3173425|NCT00611949|Active Comparator|2 Geramium Oil|
2480232|NCT03035188|Experimental|Vismodegib|Continuous once-daily oral dosing of vismodegib at a dosage of 150 mg per administration
2480252|NCT03034785|No Intervention|Group 1|Term
2480256|NCT03034785|No Intervention|Group 2|Preterm
2480259|NCT03034785|Experimental|Group 3|Term
2480260|NCT03034785|Experimental|Group 4|Preterm
2480324|NCT03034616|Experimental|ex vivo activation|"'OLIVA device' in patients that undergo oophorectomy on the cortex of the removed ovary we will perform 5 parallel slashes 3 cm long.~this will be followed by investigation by the pathologist as to the depth of cuts."
2480328|NCT03034616|Active Comparator|in vivo activation|'OLIVA device' in patients undergoing oophorectomy before the resection from is pedicle on cortex of the ovary we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels.
2480330|NCT03034616|Active Comparator|POI OLIVA|'OLIVA device' in patients with premature ovarian failure and following safety data from arm 2 activation by ovarian slashing will be performed laparoscopically by closed cutting device (OLIVA). follow-up by sonography and hormonal markers of ovarian activity
2480371|NCT03034148|Other|Coronary artery disease|blood sampling for biomarkers assessment in a population undergoing coronary angiogram
2480432|NCT03033875|Experimental|Tele-Savvy Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Tele-Savvy program immediately.
2480440|NCT03033875|Other|Attention Control Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to participate in the Healthy Living Education Program. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
2480448|NCT03033875|No Intervention|Usual Care Group|Informal caregivers of persons living with Alzheimer's disease will be randomized to continue to receive care through whatever arrangement has been in place. Persons in this group will be able to participate in the Tele-Savvy intervention after a delay of 6 months.
2480488|NCT03033199|Active Comparator|Probiotic Agent Combining HD-DXM|"probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.~Dexamethasone 40mg per day, 4 consecutive day"
2480490|NCT03033199|Active Comparator|HD-DXM|Dexamethasone 40 mg per day, 4 consecutive days
2480545|NCT03032926||Open Trial|N/A - Open Trial
3158765|NCT00392314|Experimental|advanced disease|patients with advanced disease low IPS score 0-2 will start chemotherapy with ABVD for 2 cycles followed by PET/CT further therapy will be given according to PET/CT results
2480652|NCT03032302|Experimental|Multivitamin|Swisse Womens 50+ Ultivite Multivitamin. Once daily.
2480655|NCT03032302|Experimental|Omega-3 Fatty Acids|Holland and Barrett Triple Strength Omega-3 Fish Oils. Once Daily
2480660|NCT03032302|No Intervention|Control|Treatment as usual (cognitive rehabilitation, occupational therapy, physiotherapy; as required)
2480721|NCT03031756|Experimental|test|SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation, glycine powder air-polishing (GPAP) was performed for 10 seconds per surface after the instrumentation (Air-Flows Perio Powder, EMS, Nyon, Switzerland) was applied using a Perio-Flows hand-piece connected to an airflow unit (Air-Flow Masters, EMS).
2480722|NCT03031756|Active Comparator|control|In the control group, SRP was performed using routine ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland) and hand instrumentation.
2480815|NCT03031093|Experimental|Healthy, non obese + HFNC|Healthy, non obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480818|NCT03031093|Active Comparator|Healthy, non obese|Healthy, non obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480820|NCT03031093|Experimental|COPD, non obese + HFNC|non obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480853|NCT03030690|Active Comparator|Resin Modified Glass Ionomer Cement|GC Fuji II LC Capsule, GC International, Tokyo, Japan
2480854|NCT03030690|Active Comparator|Composite Resin|Filtek Z250, 3M ESPE, St Paul, MN, USA
2480879|NCT03030586||Non-Alzheimer neurodegenerative disease|"200 patients comprising:~75 patients with behavioural variant of Fronto-Temporal Lobe Degeneration (FTD),~50 patients with Parkinson's disease dementia (PDD),~50 patients with Dementia with Lewy Bodies (DLB) and~25 patients with Progressive Supranuclear Palsy (PSP) or cortico-basal degeneration (CBD)"
2480881|NCT03030586||Healthy Controls|200 healthy subjects
3158766|NCT00392314|Experimental|advanced disease IPS 3-7|Patients with advanced disease IPS score 3-7 will start chemotherapy with escalated beacopp. following 2 cycles PET/CT will be carried out and according to results further chemotherapy will be given
3173426|NCT00611988|Experimental|1|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
3173427|NCT00611988|Active Comparator|2|Attention control group will receive routine follow-up phone calls
2480142|NCT03035630|Experimental|Avelumab then Sunitinib for Investigational Arm A|"First-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory an inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
2480143|NCT03035630|Experimental|Sunitinib then Avelumab for Investigational Arm B|"First-Line Medication:~Sunitinib 50 mg po once daily from D1 to D14 of every 21 day cycle until RECIST 1.1 disease progression criteria is documented.~Subjects will have a mandatory inter-line washout period (14-60 days) before receiving first dose of second-line medication.~Second-Line Medication:~Avelumab 10mg/kg IV on D1 and D15 of every 28 day cycle, until irRECIST 1.1 disease progression criteria is documented.~Subjects who do not have disease progression at end of first-line treatment and are removed due to toxicities or personal decision, may switch to either the second-line therapy or be monitored during the inter-line period until progression, which may be longer than 60 days."
2480193|NCT03035136||Patients with colorectal lesions|Patients with a full colonoscopy that showed either a cancer or a polyp.
2480194|NCT03035136||Patients without colorectal lesions|Patients with a full colonoscopy that showed no polyps.
2480332|NCT03034655|Experimental|CDP exercises (10 sessions)|Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
2480336|NCT03034655|Experimental|CDP exercises (5 sessions)|Group B. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
2480341|NCT03034655|Experimental|Mobile posturography exercises (10 sess)|Group C. Up to six tasks with the most prominent deviations from normative control values were included in the training program. Training was performed by using the training function of Vertiguard1-RT device. This neurofeedback system contains one vibration stimulator on the front, back, left and right side, respectively. Training was performed daily under supervision of a physician over 2 weeks (10 sessions, weekend was excluded). A training session consisted of 5 repetitions of six selected training tasks. The patient received a vibrotactile feedback signal during training in those directions which showed a higher body sway than preset thresholds. Vibration was reinforced with increasing sway No vibrotactile feedback was applied if the patient's sway was below preset thresholds. The exercise difficulty was progressively increase throughout the rehabilitation sessions.
2480343|NCT03034655|Experimental|Mobile posturography exercises (5 sess)|Group D. Same as group A, except for the number of sessions (5) and the distribution of sessions (one daily, every other day, two weeks).
2480431|NCT03033550|Experimental|single|single arm- behavioral educational intervention of a brief negotiated mobile application
2480487|NCT03033264|Experimental|BMI>30+Dinoprostone|Women with a BMI>30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
2480489|NCT03033264|Experimental|BMI<30+Dinoprostone|Women with a BMI<30 at term that will be induced for obstetrical indications with 10 mg of a Dinoprostone vaginal insert.
2480491|NCT03033264|Experimental|BMI>30+Cervical ripening balloon|Women with a BMI>30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
2480494|NCT03033264|Experimental|BMI<30+Cervical ripening balloon|Women with a BMI<30 at term that will be induced for obstetrical indications with a double lumen cervical ripening balloon.
2480540|NCT03032913||Pancreatic ductal adenocarcinoma patients|Patients with recent diagnosis of pancreatic ductal adenocarcinoma (PDAC) or with strong suspicion PDAC
2480543|NCT03032913||Non-cancer patients|Patients with no Cancer
2480586|NCT03032562||1|Patients with neuromuscular disease
2480593|NCT03032562||2|Patients with chronic obstructive pulmonary disease
2480695|NCT03032003|Active Comparator|Cysticlean arm|Cysticlean (2 BID for 15 days)
2480698|NCT03032003|Placebo Comparator|Placebo arm|Placebo (2 BID for 15 days)
2480738|NCT03031548||ultrasound exam|Child undergoing procedure in CVL requiring ETT and CXR as standard of care - received point-of-care ultrasound exam as part of the study
3173428|NCT00612001|Experimental|dendritic cell vaccine|
2480989|NCT03029728||Participants with Hereditary Angioedema|Participants diagnosed with Hereditary Angioedema disease aged between 2 months and 60 years
3173429|NCT00612014|Placebo Comparator|1|
3173430|NCT00612014|Experimental|2|40 micrograms/kg
3173431|NCT00612014|Experimental|3|80 micrograms/kg
3173432|NCT00612014|Experimental|4|160 micrograms/kg
3173433|NCT00612014|Experimental|5|320 microgram/kg
3193256|NCT00816543|Experimental|1|3 cycles of neoadjuvant chemotherapy of Docetaxel, Oxaliplatin and S-1. Surgery 5 to 6 weeks after completion of the chemotherapy.
3193257|NCT00816569|Experimental|Keratoconus|One eye of Keratoconus patient
2480325|NCT03034434||Patients after vaginal delivery|Patients after vaginal delivery willing to undergo 3 trans-vaginal ultrasounds within the 48 hours after delivery.
2480373|NCT03034239|Experimental|Insect protein group|Exercise + insect protein 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Insect protein supplementation (4g/kg) after each training + before sleep at training days, and once in the morning at non training days.
2480376|NCT03034239|Placebo Comparator|Placebo group|Exercise + isocaloric carbohydrate 8 weeks of 4/week progressive resistance training (2 days upper body, 2 days lower body). Carbohydrate supplementation (isocaloric to protein group) after each training + before sleep at training days, and once in the morning at non training days.
2480434|NCT03033836|Experimental|single arm|ARV treatment based on Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine
2480492|NCT03033212|Experimental|Early Structured Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 7 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
2480493|NCT03033212|Experimental|Delayed Rehabilitation|Patients will begin Therapist-Guided Rehabilitation at 13 weeks postoperatively with a certified physical therapy. The patients will perform rehabilitation for 10 total weeks.
2480495|NCT03033212|Active Comparator|Self Rehabilitation|Patients will begin Self-Guided Rehabilitation at 7 weeks postoperatively in a self-guided fashion. They will be provided with instructions for recommended exercises. They will undergo rehabilitation for a total of 10 weeks.
2480572|NCT03032731|Experimental|Website and pedometer Intervention|Participants allocated to this group will be given a one-off set-up session in which a researcher will show them the intervention website, create a user profile for them and provide guidance on how to use the site to gain health information, set personal behavioural goals and record and monitor their behaviour in relation to their goals. The researcher will also provide the participant with a pedometer and instruct them how to use this and where they can record their daily steps on the website. For 6 weeks, participants will be asked to use the website and be sent weekly email reminders to do so and log their goal progress. After 6 weeks, no further emails will be sent but participants will still be able to access the website and use the pedometer if they wish.
2480573|NCT03032731|Other|Control|Participants allocated to this group will be given a one-off session in which a researcher shows them publicly available web-based resources for health behaviour change (provided by the National Health Service (NHS)). Like those participants in the intervention group, they will be assessed again after 6 and 12 weeks. Participants in the control arm will be offered the intervention (access to the study website and a pedometer) after 12 weeks.
3193258|NCT00816608||type 2 diabetes|
3193259|NCT00816621|Experimental|ABC for Children Adopted Internationally|ABC for Children Adopted Internationally: 10 session in home intervention that targets parent nurturance, synchrony, pseudo-autistic behaviors, and indiscriminate sociability
2480653|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 7|
2480656|NCT03032042|Experimental|azithromycin at day 0, albendazole at day 7|
2480659|NCT03032042|Experimental|albendazole at day 0, azithromycin at day 0|
2480664|NCT03032042|Other|Delayed treatment|albendazole at day 7, azithromycin at day 7
2480747|NCT03031743||rotavirus (Rotarix TM) vaccination|Infants who received rotavirus vaccination (Rotarix TM) at 6 and 10 weeks, 10 and 14 weeks or 6,10, and 14 weeks. This is a nested study and infants received the vaccination in the overarching study: The Immunogenicity of ROtavirus Vaccine Under Different Age Schedules and the Impact of Withholding Breast Feeding around the Time of Vaccination on the Immunogenicity of Rotarix Vaccine (clinicaltrials.gov: NCT01199874)
2480777|NCT03031184|Experimental|Mirtazapine|15mg of Mirtazapine over encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
2480778|NCT03031184|Placebo Comparator|Placebo|Lactose powder encapsulated to produce a blinded product that looks identical to the other arms. Starting dose is one capsule per day, escalating to 2 capsules per day after 2 weeks if no side effects and up to 3 capsules per day after 4 weeks.
2480847|NCT03030937|Experimental|Irinotecan plus apatinib|"Irinotecan:160mg/m2, ivgtt,given on the eighth day; Apatinib:initial dose:250mg,oral,once a day, after meal ( try to take the medicine at the same time of the dauntoy ).~Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities."
2480848|NCT03030937|Active Comparator|Irinotecan|Irinotecan:180mg/m2, ivgtt,given on the eighth day. Repeat the therapeutic schedule every 2 weeks till progressive disease or intolerable toxicities.
2480887|NCT03030456|No Intervention|Control Group|Elderly women receiving a list of general health orientations through an 8 week period
2480891|NCT03030456|Experimental|Power Plate®|Power Plate®: training of elderly women
2480933|NCT03030209||Distal Pancreatectomy|Patients undergoing distal pancreatectomy
3193260|NCT00816621|Active Comparator|DEF for Children Adopted Internationally|DEF for Children Adopted Internationally: 10 session in home intervention that targets cognitive and motor delays
3193261|NCT00816634|Active Comparator|1|"Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks"
2481090|NCT03029273|Experimental|Anti-NY-ESO-1 TCR-transduced T cells|"NYESO-1 TCR-T cell are prepared via lentiviral infection. DLT was administered in a dose escalation test according to the 3 + 3 design. Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with Cyclophosphamide (250-500mg/m2/day) and Fludarabine (25mg/m2/day) for 3 days.~A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject."
3193262|NCT00816634|Active Comparator|2|"XT Regimen:~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks"
3193263|NCT00816647|Active Comparator|1|Medial patellofemoral ligament reconstruction
3193264|NCT00816647|Active Comparator|2|Medial reefing
3193265|NCT00816660|Experimental|1|
2480314|NCT03034447|Other|Asthma|Children and teenagers with persistent asthma will perform questionnaires, lung function test, and home sleep study
2480411|NCT03033615|Active Comparator|Chest CT|Conventional processing vs. PixelShine processing
2480414|NCT03033615|Active Comparator|Abdominal CT|Conventional processing vs. PixelShine processing
2480466|NCT03033407|Experimental|Intervention-Maintenance group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. This study was divided into two phases. In six-month phase 1 study, the participants in I-M group received tailored mobile coaching. And during the second half six-month phase 2 study, they could receive only regular information messages without individualized coaching.
2480469|NCT03033407|Active Comparator|Control-Intervention group|Intervention was adding 'Tailored mobile coaching messages' onto conventional diabetes management. In six-month phase 1 study, the participants in Control-Intervention group maintained usual care for diabetes. During the second half six-month phase 2 study, they received tailored mobile coaching.
2480602|NCT03032484|Experimental|Bevacizumab and TVB-2640|Bevacizumab every 2 weeks in combination with TVB-2640 dosed at 100mg/m2 daily (rounded to 50mg tab dose), from day 1 until day 28 of the first cycle.
2480609|NCT03032484|Experimental|Bevacizumab|Bevacizumab alone every 2 weeks, on days 1 and 15 until day 28 of the first cycle.
2480668|NCT03032185|Active Comparator|Active TENS|Active TENS, 10 Hz/200 μs
2480669|NCT03032185|Sham Comparator|Not Active TENS|Sham TENS
2480710|NCT03031808|Other|Lidocaine spray|Endotracheal lidocaine spray prior to intubation
2480716|NCT03031808|Other|Muscle relaxant|Muscle relaxant prior to intubation
2480719|NCT03031808|Other|No Muscle relaxant, no Lidocaine|'No Muscle relaxant, no Lidocaine Control group
2480782|NCT03031327|Experimental|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
2480785|NCT03031327|Experimental|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
2480787|NCT03031327|Active Comparator|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
2480812|NCT03030911|Active Comparator|Dexmedetomidine group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group I patients will have dexmedetomidine (0.075 µg.kg-1.mL-1). Dexmedetomidine infusion will be started at 0.15 µg.kg-1.hr-1 (2 mL.hr-1) and will be adjusted by 0.15 µg.kg-1.h-1 increments to a maximum of 0.75 µg/kg/h (10 ml.h-1)~Intervention: indirect calorimetry"
2480814|NCT03030911|Placebo Comparator|midazolam group|"Patients will receive analgesia with fentanyl at a ﬁxed dose of 1 µg.kg.hr-1. Each patient will receive the study drug within 24 hours after intubation. Sedatives used before study enrolment will be discontinued 6 hours prior to the initiation of study drug.~Group II patients will have midazolam (0.5 mg.mL-1). Midazolam will be started at 1 mg.h-1 (2 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (10 mL.h-1). All infusions will be adjusted by increments of 2 mL.hr-1 to maintain blinding. Patients in either group not adequately sedated by the maximum infusion rate of the study medication will receive a bolus dose of fentanyl 0.5 µg.kg-1.~Intervention: indirect calorimetry"
2480860|NCT03030651|Experimental|Breastfeeding Education and Support|Pregnant women in the intervention arm will receive breastfeeding education and support intervention for nine months starting in their third trimester
2480861|NCT03030651|No Intervention|Usual or routine care|Pregnant women in the intervention arm will continue to receive the usual/routine care.
2480912|NCT03030365||Healthy Controls|"Age matched controls for the various clinical groups will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi (millicurie) of 18F (fluorodeoxyglucose) -FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2480913|NCT03030365||Amnestic Mild cognitive impaired|"Patients diagnosed with mild cognitive impairment, exhibiting impairment mostly in memory that is significant but does not interfere with everyday activities.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2480914|NCT03030365||Alzheimer's disease patients|"Patients exhibiting significant loss of intellectual ability that interferes with everyday functioning that meet Alzheimer's pattern of decline, and following exclusion of alternative neurodegenerative, cerebrovascular, and metabolic etiologies.~Subjects will undergo standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI, using Biograph mMR PET-MR (3T)."
2480971|NCT03030040|Experimental|MBCT-SH|MBCT-SH will be an unguided, mindfulness-based cognitive therapy, book-based self-help intervention.
2480975|NCT03030040|No Intervention|Control|A wait list control group who will receive no intervention during the 21 weeks of the study. Control participants will be provided with the self-help book that the MBCT-SH group received after week 21.
2481031|NCT03029572|Active Comparator|Standard diet|Standard healthy diet after RYGB surgery
2481036|NCT03029572|Experimental|Micro-nutriments' supplementation|Healthy diet and probiotics, minerals, aminoacids, omega-3 acids vitamin and mineral supplementation after RYGB surgery
3158767|NCT00392353|Experimental|Treatment (azacitidine, vorinostat)|Patients receive azacitidine SC QD on days 1-7 and vorinostat PO 2-3 times daily on days 3-5, 3-9, or 3-16. Treatment repeats every 28 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
2481232|NCT03028246|Experimental|ExAblate 4000 System|MR-Guided Focused Ultrasound
3158768|NCT00392509|Experimental|2|Unfractionated Autologous Mononuclear Bone Marrow
3158769|NCT00392535|Active Comparator|Control arm|conventional radiotherapy (74 Gy delivered in 37 fractions over 7·4 weeks)
3158770|NCT00392535|Experimental|Hypofractionated arm 1|Hypofractionated radiotherapy (60 Gy in 20 fractions over 4 weeks)
3158771|NCT00392535|Experimental|Hypofractionated arm 2|Hypofractionated radiotherapy (57 Gy in 19 fractions over 3·8 weeks)
3158772|NCT00392561|Experimental|1|Selenium
3158773|NCT00392561|Experimental|2|Vitamin E
3158774|NCT00392561|Experimental|3|Vitamin E + Selenium
2480323|NCT03034551|Experimental|Intervention Arm|Subjects in the treatment arm will be offered a $150 incentive to use the Wellth app each day to log one daily self-weighing and one medication check-in. If a sudden jump in weight is detected among any subjects receiving the Financial Incentive, Mobile Phone App, and Cellular Scale, a UMCPP physician or nurse will then call the patient to assess the patient's symptoms (i.e. increasing shortness of breath or decreases in exertional tolerance, medication and dietary adherence).
2480326|NCT03034551|No Intervention|Standard of Care (Control) Arm|Patients randomized to the standard of care arm will not receive the Wellth app or scale. They will have the usual discharge instructions as prescribed by their health care team.
2480404|NCT03033940||ATTUNE TM subjects|
2480405|NCT03033940||PFC Sigma subjects|
2480443|NCT03033563||Testicular tissue versus ejaculate|Evaluation of ICSI outcome.
2480532|NCT03033329|Experimental|Single intravenous doses of MRX-4|Single escalating intravenous doses of MRX-4 from 150 mg to 1800 mg
2480534|NCT03033329|Placebo Comparator|Single intravenous doses of placebo|Single intravenous doses of placebo to match MRX-4
2480537|NCT03033329|Active Comparator|Multiple intravenous doses of MRX-4|Twice daily escalating intravenous doses of MRX-4 for 10 days: 600 mg, 900 mg, 1200 mg, and 1500 mg
2480538|NCT03033329|Placebo Comparator|Multiple intravenous doses of placebo|Twice daily intravenous doses of placebo to match MRX-4 for 10 days
2480541|NCT03033329|Active Comparator|Single dose of intravenous and oral MRX-4|Crossover of single dose of intravenous and oral MRX-4
2480603|NCT03032549|Experimental|RTD|2.1 g. beta alanine, 1.3 g arginine nitrate, 200 mg caffeine, 65 mg niacin, 325 mcg folic acid, 45 mcg vitamin B12
2480610|NCT03032549|Placebo Comparator|Placebo|dextrose and non-caloric flavoring
2480694|NCT03031652||Enrolled group|Patients who had senile cataract and underwent phacoemulsification with topical anesthesia.
2480723|NCT03031535|Experimental|Study Part 1 - Arm 1|Day 1 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 7 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms.
2480724|NCT03031535|Experimental|Study Part 1 - Arm 2|Day 1 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 5 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 2000 micrograms.
2480725|NCT03031535|Experimental|Study Part 1 - Arm 3|Day 1 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 3 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 400 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 1200 micrograms.
2480726|NCT03031535|Experimental|Study Part 1 - Arm 4|Day 1 - Subcutaneous octreotide acetate (Sandostatin Injection) - 100 micrograms; Day 3 - Intranasal octreotide acetate (DP1038) - 2000 micrograms; Day 5 - Intranasal octreotide acetate (DP1038) - 1200 micrograms; Day 7 - Intranasal octreotide acetate (DP1038) - 400 micrograms.
2480729|NCT03031535|Experimental|Study Part 2 - Arm 1|Day 1 - 1 microgram/kilogram of growth hormone-releasing hormone (GHRH) + 30 grams arginine hydrochloride; Day 3 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
2480730|NCT03031535|Experimental|Study Part 2 - Arm 2|Day 1 - 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 3 - SC octreotide acetate (Sandostatin Injection) 100 micrograms + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride; Day 5 - Intranasal octreotide acetate (DP1038) - dose to be determined from Study Part 1 PK results + 1 microgram/kilogram of GHRH + 30 grams arginine hydrochloride.
2480790|NCT03031171|Experimental|Navigated: Screening patient navigation|Clinic patients who received navigation
2480791|NCT03031171|Active Comparator|Non-Navigated|Randomly matched sample of non-navigated clinic patients
2480837|NCT03030859|Experimental|Group I (Usual Care)|Patients receive monthly automated system telephone call for 12 months.
2480840|NCT03030859|Experimental|Group II (Usual Care plus LEF-SCP)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients also review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed.
2480842|NCT03030859|Experimental|Group III (Usual Care plus LEF-SCP plus Follow-Up)|Patients undergo LEF-SCP training comprising of MI session over 1 hour and LEF self-care training session over 1 hour weekly for 3 weeks. Patients receive monthly automated system telephone call for 12 months. Patients review LEF self-care educational manual and watch self-care videos monthly or more frequently as needed. Patients also meet with the study lymphedema therapist over 1 hour at 3, 6, and 9 months.
2480900|NCT03030469|Experimental|10-pill default|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
2480903|NCT03030469|Experimental|5-pill default|New opioid analgesic prescriptions will automatically default to 5 pills.
2480904|NCT03030469|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
3158775|NCT00392561|No Intervention|Arm 4|
3158776|NCT00392574|Experimental|1|Prulifloxacin
3158777|NCT00392574|Placebo Comparator|2|Placebo
3158778|NCT00392639|Experimental|1-2|Comparison of 2 cooling procedures
3158779|NCT00392652|Experimental|Arm I (low-dose oral diindolylmethane)|Participants receive low-dose oral diindolylmethane (BR-DIM) twice daily for 4 weeks.
3158780|NCT00392652|Experimental|Arm II (high-dose oral diinolylmethane)|Participants receive high-dose oral BR-DIM twice daily for 4 weeks.
3158781|NCT00392691|Experimental|Zevalin, Rituximab, Melphalan|
3158782|NCT00392730||1|Preterm infants in NICU and age-matched controls
3158783|NCT00392730||2|Term infants in NICU and age-matched controls
3158784|NCT00392730||3|Children on home PN (to age 6) and age-matched controls
3158785|NCT00392743||pet/spect scan|
2480400|NCT03033797|Experimental|MoviLetrando-MoveHero|Half of the children will play first two different levels of the game MoviLetrando (2 minutes each) and, after the game MoveHero, more 2 minutes
2480401|NCT03033797|Experimental|MoveHero-MoviLetrando|The other half of the children will play first 2 minutes of the game MoveHero and after, two different levels of the Game MoviLetrando, two minutes each.
2480453|NCT03033576|Active Comparator|Arm I (ipilimumab)|Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2480455|NCT03033576|Experimental|Arm II (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2481033|NCT03029494|Experimental|Treatment 1: stabilization splint, placebo oral tablet|stabilization splint during night and 1 placebo oral tablet daily, for 6 months
2481038|NCT03029494|Active Comparator|Treatment 2: placebo splint, vitamin C|placebo splint during night and 1000 mg Vitamin C tablet daily, for 6 months
2481042|NCT03029494|No Intervention|Control group|determination of oxidative stress biomarkers and cortisol in saliva of healthy control subjects
2481101|NCT03029130|Experimental|Catheter Extension|Patients in this arm will have a foley catheter re-passed, to remain in situ for an additional 14 days, after which time the catheter will be removed and the patient discharged to return for follow up exam at 3 months postop.
2481104|NCT03029130|No Intervention|Discharge|Patients in this arm will be discharged, to return for follow up exam at 3 months postop.
2481143|NCT03028792|Experimental|Attention Modification Training|Attention Modification Program Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral stimuli.
2481147|NCT03028792|Sham Comparator|Attention Control Training|Placebo Comparator: Attention Control Condition Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral stimuli or the threat stimuli.
2481224|NCT03028545|Other|schizophrenia|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in schizophrenia
2481231|NCT03028545|Other|bipolar disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in bipolar disorders
2481236|NCT03028545|Other|eating disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in eating disorders
2481238|NCT03028545|Other|personality disorders|Exploring and understanding, through a multidisciplinary exploration (medical, anthropological and sociological) representations and recovery strategies in personality disorders
2481258|NCT03027960|Experimental|Placebo, then empagliflozin|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
2481259|NCT03027960|Experimental|Empagliflozin, then Placebo|"Patients are randomized upon enrollment to determine whether they take empagliflozin or the matched placebo during the first 2-week treatment phase of the study. All patients then undergo a 2-week washout period before crossing over to the alternate therapy."
2481316|NCT03027635|Experimental|PleurX|The PleurX catheter is a tunnelated peritoneal catheter, designed for permanent placement in the peritoneal cavity. The catheter is placed by a physician under sterile conditions. Drainage of ascites is done using vacuum bottles connected to the catheter. This can be managed by a home nurse or the patient.
2481317|NCT03027635|Active Comparator|Large Volume Paracentesis|Large volume paracentesis is performed in sterile technique, a small incision is made through the skin, and a catheter is inserted through muscle and peritoneum. After the procedure, the patient remains in hospital for observation until the fluid is drained.
2481373|NCT03027336|Experimental|coleosoma|coleosoma 500mg tablet daily
2481377|NCT03027336|Placebo Comparator|placebo|placebo tablets
2481410|NCT03026933|Experimental|Treatment|KI1107
2481412|NCT03026933|Active Comparator|Control|Rosuvastatin calcium
2481476|NCT03026673||NSAID use|The purpose of this study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
2481516|NCT03026205|Experimental|Single Arm|ARMS-I dosage of 0.75 mg will be sprayed orally in the mouth once as a single dose of four sprays on Day 1, and then three times a day starting on Day 3 for 4 Days.
2481566|NCT03026023|Experimental|Treatment with grazoprevir + elbasvir +/- ribavirin|12 to 16 weeks of treatment with combination tablet of grazoprevir + elbasvir +/- ribavirin
3158786|NCT00392756|No Intervention|off treatment|Subjects undergo the baseline evaluation off treatment
3158787|NCT00392756|Experimental|GnRH Treatment|Subjects receive long term pulsatile GnRH therapy
3158788|NCT00392847|Active Comparator|2|The first group will receive routine follow-up as currently provided by national community health and social services.
3158789|NCT00392847|Experimental|1|will receive home visits by community workers. These visits will start during pregnancy and will continue up to the child's second birthday.
3158790|NCT00392873|Experimental|EAMD+Calories|This group contains women with exercise-associated menstrual disturbances (EAMD) and receives an intervention of increased caloric intake during the 12-month intervention. The targeted increase in caloric intake is 20-30% of baseline energy expenditure.
3158791|NCT00392873|No Intervention|EAMD Control|This group contains women with exercise-associated menstrual disturbances (EAMD) and undergoes the same procedures as the EAMD+Calories group. However, this group is instructed to maintain exercise and eating habits.
3173434|NCT00612014|Experimental|6|600 microgram/kg
2480362|NCT03034226|Active Comparator|Single episode of hypoglycemia|Day 1: Hyperinsulinemic hypoglycemic clamp 30 min Day 2: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
2480365|NCT03034226|Active Comparator|Two episodes of hypoglycemia|Day 3: No intervention (normal blood glucose) Day 4: Hyperinsulinemic euglycemic clamp and hyperinsulinemic hypoglycemic clamp 7 hours
2480396|NCT03033927||Participants with Stage IV Pancreatic Cancer|
2480442|NCT03033641|Experimental|Ablation procedure|
2480566|NCT03032796|Experimental|BBT|Body-Brain Trainer
2480567|NCT03032796|Active Comparator|Body Trainer|Participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present, while completing all of the physical aspects of BBT. Thus this will be a physical training protocol.
2480569|NCT03032796|Active Comparator|Brain Trainer|"The Brain Trainer group will train using the same platform as the BBT group, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects)."
2480571|NCT03032796|Placebo Comparator|Expectancy Matched Control Group|The placebo-matched control group will engage in a battery of three apps in the laboratory that we believe will have no significant impact on cognition
3193266|NCT00816660|Active Comparator|2|
3193267|NCT00816673|Placebo Comparator|placebo|
2480784|NCT03031132|Experimental|HP-Beverage Breakfast|For 7 days, the participants will consume high protein beverage breakfast meals each morning. These meals will consist of shakes and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35g CHO, and 10g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
2480786|NCT03031132|Experimental|HP-Solid Breakfast|For 7 days, the participants will consume high protein solid breakfast meals each morning. These meals will consist of traditional solid breakfast meals and will include commonly consumed breakfast foods (e.g., burritos, waffles, etc.) and will be 350 kcal. The macronutrient composition of these meals will contain 30 g of dietary protein, 35 g CHO, and 10 g fat. The HP-S and HP-B meals will be matched for energy density, sugar content, macronutrient content and types of proteins.
2480788|NCT03031132|Experimental|Breakfast Skipping|For 7 days, the participants will skip the morning meal. No food or calorie-containing beverages will be consumed before 12pm on acclimation days and no food consumed until ~5h post habitual breakfast time on testing day 7.
2480833|NCT03030885|Experimental|131I-MIP-1095|"FirstTherapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
2480868|NCT03030573|Other|Device: Round ligament and the bile duct|The investigators describe the safety and efficacy of the reconstruction of the bile duct with the Round ligament.
2480932|NCT03030313|Experimental|Respiration rate monitoring|Reassure Non-Contact Respiration Monitor
2481006|NCT03029676|Experimental|Group B|spinal anesthesia premedication with benzodiazepine and opioid
2481008|NCT03029676|Active Comparator|Group K|spinal anesthesia premedication with opioid
2481073|NCT03029351|Experimental|Exenatide extended release|Exenatide extended release treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to placebo.
2481076|NCT03029351|Placebo Comparator|Placebo|Placebo treatment for 1 year on albuminuria levels in T2DM patients with micro- and macroalbuminuria compared to Exenatide extended release.
2481102|NCT03029026||Those patients for TAVR|Those patients who are undergoing TAVR (clinical decision) who are recruited at the Barts Heart Centre will undergo clinical echocardiography, research DPD scintigraphy and clinical TAVR work-up CT (with research post contrast acquisitions at 3-5 minutes), unless already performed prior to recruitment. Those patients undergoing TAVR (clinical decision) who are recruited at the John Radcliffe Hospital will undergo clinical echocardiography and research DPD scintigraphy only. N=150.
2481105|NCT03029026||Those patients for sAVR|Those patients who are undergoing sAVR (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy, research CMR and endomyocardial biopsy at the time of surgery. N=50.
2481108|NCT03029026||Those patients for medical management|Those patients who are decided for medical management (clinical decision) will undergo clinical echocardiography, research DPD scintigraphy and any other imaging as per work-up/trial prior to no intervention decision. N=50.
2481202|NCT03028558||HEALTHY VOLUNTEER RESEARCH SUBJECTS|"Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.~Between the ages of 21-35 years old."
2481205|NCT03028558||HEALTHY E-CIGARETTE SMOKING SUBJECTS|Criteria is identical to the healthy never-smoker group except that they must have a history of smoking e-cigarettes >5 days/wk for a minimum of 6 months with no prior traditional tobacco exposure.
2481245|NCT03028168|Experimental|Intervention Yôga|Active protocol with yôga body movements performed along with respiratory vigorous, without contentions. Two sessions per week, with 45 minutes duration.
2481248|NCT03028168|Experimental|Intervention breathing technique|Passive protocol, seated patient, no significant body movements. Breathing technique, with alternate nostril breathing combined to inspiratory and expiratory retentions.Two sessions per week, with 45 minutes duration
2481249|NCT03028168|Experimental|Control group|Control group (standard pharmacological treatment). Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization.
3193268|NCT00816673|Experimental|Circadin|
3193269|NCT00816686|Experimental|1. AGS-16M18 Dose 1|
3193270|NCT00816686|Experimental|2. AGS-16M18 Dose 2|
3193271|NCT00816686|Experimental|3. AGS-16M18 Dose 3|
2480395|NCT03033992|Experimental|Treatment (Optune System)|Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory. All patients will use the study device Optune System (Tumor Treating Fields, TTFields).
2480412|NCT03033628|Experimental|DV group|"Device: injection using DentalVibe comfort system. giving maxillary infiltration dental local anesthesia with the aid of DentalVibe comfort system on one side of the maxillary arch prior extraction of primary molar tooth"
2480415|NCT03033628|Active Comparator|C group|"Device: traditional dental injection giving maxillary infiltration dental local anesthesia without the aid of DentalVibe comfort system on the other side of the maxillary arch prior extraction of primary molar tooth"
2480465|NCT03033446|Experimental|Y90-Radioembolization and Nivolumab|
2480617|NCT03032458|Active Comparator|Pethidine|Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)
2480621|NCT03032458|Active Comparator|Ketorolac|Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)
2480622|NCT03032458|Active Comparator|Xylocaine Gel|Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)
2480661|NCT03032120|Experimental|Fresh orange juice|Intervention: The subjects drank 5 mL/kg body weight of fresh-squeezed orange juice (FOJ).
2480665|NCT03032120|Experimental|Processed orange juice|Intervention: The subjects drank 5 mL/kg body weight of processed orange juice (POJ).
2480667|NCT03032120|Experimental|Control|The subjects drank 5 mL/kg body weight of control drink compounded by water mixed with sugars in a similar concentration of orange juices (5.2% of sucrose, 2.5% of fructose, 2.1% of glucose, 0.75% of citric acid, and malic acid 0.25%, flavored and colored with some drops of orange essence).
3193272|NCT00816686|Experimental|4. AGS-16M18 Dose 4|
2480779|NCT03031158|Experimental|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles.
2480780|NCT03031158|Active Comparator|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles.
2480824|NCT03030950|Experimental|Dexmedetomidine group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
2480826|NCT03030950|Placebo Comparator|Control group|Adductor canal block will be performed before induction of general anesthesia. Patients will be positioned in the supine position with knee slightly flexed and leg externally rotated followed by ultrasound scanning of the middle of thigh using 13-6 MHz linear array probe. The ultrasound probe will be placed over the anterior aspect of the patient's thigh, mid-point between the inguinal crease and medial femoral condyle. The scan will be focused on the femoral artery pulsations aiming to try to visualize the nerves in the adductor canal on both sides (lateral and medial) of the pulsating femoral artery. 20 ml bupivacaine 0.25% combined with 75 mcg dexmedetomidine will be injected. The study solution will be injected underneath the fascia of sartorius muscle.
2480906|NCT03030677|Other|Interventional Without Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound without injecting 10 ml of lidocaine 1% as a dissecting solution
2480907|NCT03030677|Other|Interventional With Dissectioin|confirming insertion of B Braun Catheter Kit Contiplex with 18 Gauge needle using ultrasound after injecting 10 ml of lidocaine 1% as a dissecting solution
2480939|NCT03030001|Experimental|PD-1 antibody expressing CAR-T cells|PD-1 antibody expressing mesothelin specific CAR-T cells
2480992|NCT03029793||Biomarkers and Imaging analysis|This study will prospectively collect the tissue and blood samples of locally advanced esophageal cancer patients, perform CRT resistance biomarkers testing and functional imaging analysis including SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI before treatment, 2-3 weeks after the initiation of CRT, and 4 weeks post-nCRT. The investigators will use advanced statistical tools to establish the model and further validate the model in another group of patients. The investigators will also establish a model for survival prediction.
2481095|NCT03029260|Experimental|Neural mobilization - tension|It is anticipated that 30 participants will be in this group. They will receive tension type neural mobilization of the peroneal nerve in the dominant limb. This will consist of positioning the lower limb with inversion and plantar flexion of the ankle, extension of the knee and maximum flexion of the hip without pain. A physiotherapists will move the hip from this maximum position of flexion in direction to extension (for example if the participants reaches 80º of flexion the mobilization will be between 40º and 80º of flexion). Each participant will receive four series of 10 mobilizations with 1 minute rest between series.
2481096|NCT03029260|Active Comparator|Neural mobilization - sliding|It is anticipated that 30 participants will be in this group. They will receive sliding neural mobilization of the peroneal nerve in the dominant limb. Each participant will receive four series of 10 mobilizations with 1 minute rest between series of the following combination of movement: from ankle dorsiflexion, knee extension and hip extension to ankle plantarflexion, knee and hip flexion.
2481127|NCT03028805|No Intervention|Usual care and order set A|Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
3193273|NCT00816686|Experimental|5. AGS-16M18 Dose 5|
3193274|NCT00816699|Placebo Comparator|1|Routine anesthetic risk information
2480439|NCT03033888|Other|Intervention Group|Intervention includes: Trained community health workers will deliver 1) 1.5-2 hour health literacy training offered in a group format at an approved community site that is most convenient to the majority of participants ; and 2) monthly phone follow-up and navigation assistance for 6 months. We will offer a Human Papilloma Virus (HPV) mobile app for participant's adolescent/young adult child (11-26 yrs), as an option rather than part of the standardized protocol. The app will be introduced at the end of the health literacy group training session for the intervention group; those who choose to download the app will be given a link with study specific password. They will be encouraged to go through the key HPV related contents with their children at home at a time that is most convenient for them.
2480449|NCT03033888|No Intervention|Control Group|
2480478|NCT03033277|Placebo Comparator|Control group|Hormone replacement therapy, placebo transplantation.
2480480|NCT03033277|Experimental|Experimental group|Hormone replacement therapy,HUC-MSCs transplantation.
2480539|NCT03033017||HIV-infected on antiretroviral therapy 2 years|HIV-infected participants who have been on antiretroviral therapy (ART) for at least two years.
2480591|NCT03032640|Active Comparator|Group 1- Healthy Lean subjects|Group 1 will receive Sodium Saccharin 200mg capsule, 2x/day, Day 1-14
2480599|NCT03032640|Active Comparator|Group 2- Healthy Lean subjects|Group 2 will receive Placebo 500mg capsule, 2x/day, Day 1-14
2480606|NCT03032640|Active Comparator|Group 3- Healthy Lean subjects|Group 3 will receive Sodium Saccharin 200mg + lactisole 335mg capsule, 2x/day, Day 1-14
2480612|NCT03032640|Active Comparator|Group 4- Healthy Lean subjects|Group 4 will receive Lactisole 335mg capsule, 2x/day, Day 1-14
2480670|NCT03032068|Experimental|At-Home Monitoring|Patients will follow-up in clinic postoperatively at 4, 8, and 12 weeks and their recovery will also be monitored using sensors and communication devices while they are at home after surgery.
3158792|NCT00392873|No Intervention|Heathy Control|This group contains exercising women with regular, ovulatory menstrual cycles. this group is instructed to maintain body weight and exercise and eating habits.
2480960|NCT03029871|Experimental|Arm 1|Nine subjects (3 cohorts, 3 subjects/cohort) with medically inoperable stage I/IIA (T1a - T2b) NSCLC with tumors measuring > 2 to ≤ 5 cm will receive a single intratumoral injection of the oncolytic Ad5-yCD/mutTKSR39rep-ADP adenovirus at one of three dose levels (1 x 1011 vp, 3 x 1011 vp, 1 x 1012 vp). Depending on the location of the target lesion, the adenovirus will be injected either transbronchially (central tumors) or percutaneously under computed tomography (CT)-guidance (peripheral tumors). Two days later, subjects will be administered (orally) a 10 day course of 5-fluorocytosine (5-FC) and valganciclovir (vGCV) prodrug therapy along with 48 Gy (4 fractions of 12 Gy) of SBRT. Prior to and following the adenovirus injection, subjects will be administered [18F]-FHBG, a HSV-1 TK substrate, and will undergo PET imaging to quantify HSV-1 TK gene expression.
2481043|NCT03029637|Experimental|No preparation resin bonded bridges|RBBs with no or minimal preparation of their abutment teeth
2481045|NCT03029637|Active Comparator|Routine resin bonded bridges|RBBs with routine tooth preparation of their abutment teeth
2481085|NCT03029182|Experimental|Walking+simulated-altitude|8-week exercise training program that involves 3 supervised, treadmill walking sessions each week with 16% oxygen, which will be administered through an exercise mask.
2481087|NCT03029182|Active Comparator|Walking (control)|8-week exercise training program that involves 3 supervised, treadmill walking session each week.
2481178|NCT03028909|Experimental|Oseltamivir + low dose MEDI8852|Low Dose of MEDI8852 + Oseltamivir will be studied
2481180|NCT03028909|Experimental|Oseltamivir + high dose MEDI8852|High dose of MEDI8852 + Oseltamivir will be studied.
2481182|NCT03028909|Active Comparator|Oseltamivir + Placebo|Oseltamivir in conjunction with placebo will be studied.
2481342|NCT03027401||Group A|Adult/pediatric with suspected or confirmed malignancy, family history of malignancy, undergoing surgery with no malignancy; tissues collected previously under CLIA or for research.
2481403|NCT03027141|Active Comparator|Pre-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI)
2481406|NCT03027141|Experimental|Post-Transplant Time Point|Participants will be imaged in the Magnetic Resonance Imaging scanner (MRI). Patients for whom a pre-transplant fMRI was obtained will undergo functional MRI scanning at three-points post-transplant (approximately 2 and 4 months +/- 2 months post-operation and again at 1 year +/- 3 months post-transplant).
2481522|NCT03026374|No Intervention|control group|patients from both groups were provided medical, social, or psychological care if necessary, as assessed by primary oncologists. Additionally, all patients received an educational brochure about breast cancer every 1 to 2 months, and relaxation therapy was provided to both groups to prevent demoralization from random assignment.
2481574|NCT03025763||Coronal, nonsyndromic craniosynostosis|Participants with coronal, nonsyndromic craniosynostosis when biological parents are not available
2481664|NCT03025282|Placebo Comparator|CD10367 solution placebo - Non-desquamated zone|CD10367 solution placebo serves as negative control.
3158793|NCT00392886|Experimental|Regimen C|Patients receive induction therapy of vincristine IV on days 1, 8, and 15 of courses 1-3, oral temozolomide once daily on days 1-5, and carboplatin IV over 4 hours on days 1 and 2. Patients also receive G-CSF SC beginning on day 6 and continuing until blood counts recover. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients receive consolidation therapy of carboplatin IV over 4 hours on days -8 to -6 and thiotepa IV over 3 hours on days -5 to -3, undergo reinfusion of bone marrow or peripheral blood stem cells on day 0, and receive G-CSF SC beginning on day 1 and continuing until blood counts recover. Beginning within 6 weeks after transplantation, some patients undergo radiotherapy once daily 5 days a week for 4-6 weeks in the absence of disease progression or unacceptable toxicity and some patients undergo radiotherapy if there is evidence of tumor remaining after completion of induction chemotherapy.
3173435|NCT00612027||1|patients with gastrointestinal disorders and patients with acid associated gastrointestinal symptoms treated with esomeprazole.
3173436|NCT00612079|Experimental|2|Healthy volunteers with high sensory gating levels.
3173437|NCT00612079|Experimental|1|Healthy volunteers with low sensory gating levels.
3173438|NCT00612092|Experimental|1|Standard spiral CT protocol
3173439|NCT00612092|Active Comparator|2|Sequential CT protocol
3173440|NCT00612144|Experimental|1|Amaryl M group
3173441|NCT00612144|Active Comparator|2|Metformin group
2480507|NCT03033147|Experimental|Amoxicillin/Clavulanate Potassium|Amoxicillin/Clavulanate Potassium 875 mg-125 mg orally 30 minutes before root canal treatment
2480509|NCT03033147|Placebo Comparator|Placebo|placebo 30 minutes before root canal treatment
2480565|NCT03032783|Experimental|Treatment (TBI, DLI, chemotherapy, HSCT)|Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.
3173442|NCT00612157|Active Comparator|OSA CPAP|
2480704|NCT03031691|Experimental|Brontictuzumab and trifluridine/tipiracil|Brontictuzumab will be administered per protocol and trifluridine/tipiracil per label.
2480789|NCT03031353|Experimental|Misoprostol|After preparing for elective caesarean section, the pessary will be given containing the misoprostol medication 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
2480793|NCT03031353|Active Comparator|Placebo|After preparing for elective caesarean section, the pessary will be given containing placebo 1 hour before , women in the operating room, and the anaesthetic and surgical techniques will be standardized
2480892|NCT03030872||Predicate software|Olea Sphere PACS with Perfusion and DWI Modules
2480895|NCT03030872||Investigational software|Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging
2480941|NCT03030196|Active Comparator|Denosumab|subcutaneous injection with 60 mg Denosumab once
2480943|NCT03030196|Placebo Comparator|Placebo|subcutaneous injection with NaCl once
2480970|NCT03029754|Experimental|Passive leg raise|Participant's legs will be raised with a bolster prior to IV insertion.
2480974|NCT03029754|No Intervention|No leg raise|Participants will lie flat prior to IV insertion.
2481097|NCT03029013|Experimental|experimental group|Apatinib and chemotherapy
2481168|NCT03028766|Experimental|Group A - Pre-operative|Patients will receive the cohort specified dose of AZD1775 by mouth, twice a day for 3 days, commencing on days 1 and 8. Cisplatin 40mg/m2 IV delivered over 1 hour on day 8. Patients in this group will commence surgery within 42 days of commencing pre-operative chemotherapy.
2481171|NCT03028766|Experimental|Group B - Post-operative:|Patients will received the cohort specified dose of AZD1775 by mouth, twice a day for 3 days on days 2, 9, 23 and 30. Cisplatin 40mg/m2 IV delivered over 1 hour on days 2, 9, 16, 23 and 30. Intensity Modulated Radiotherapy will be delivered 5 days a week (once daily, Monday to Friday) for 6 weeks commencing within 3 months of surgery.
2481323|NCT03027713|Other|NAVA group with a specific catheter|The patients were allocated in the NAVA weaning protocol group
2481326|NCT03027713|Other|PSV group without a specific catheter|The patients were allocated in the PSV (pressure-support ventilation) weaning protocol group
2481370|NCT03027323|Other|AxoTrack System guided CVC insertion|AxoTrack System guided CVC
2481375|NCT03027323|No Intervention|CVC insertion guided by landmark|Anatomical landmarks to guide CVC
2481454|NCT03026985||Observational cohort|"Ultrasound measurement of quadriceps muscle size and echogenicity will be obtained at baseline (within 48 hours of ECMO commencement), 10 days and 20 days after baseline measurement.~Measures of muscle strength and highest mobility level will be obtained at day 10 and day 20 after baseline measurement in order to determine the relationship between these volitional measures and the ultrasound parameters."
2481470|NCT03026400|Other|Subumbilical incision|The subumbilical incision was standardised. A curvilinear horizontal incision was performed to be able to reach the base of the umbilicus. The aponeurosis was incised with a scalpel and the peritoneal layer was open with a Kelly clamp. The incision was completed with the Hasson technique and a X-stitch was used for closure.
2481471|NCT03026400|Other|Transumbilical incision|The transumbilical incision was also standardised, inverting the umbilicus with graspers, then incising vertically the skin to reach the umbilical physiological hernia to enlarge it. The incision was also completed with the Hasson technique and a X-stitch was used for closure.
2481514|NCT03026231|Active Comparator|PRIM-DJ2727|Subjects with PD will be randomly assigned to receive PRIM-DJ2727 in orally administered enteric-coated capsules
2481515|NCT03026231|Placebo Comparator|Placebo|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
2481597|NCT03025672||clostridium difficile|Patients that have been infected by clostridium difficile during their stay in hospital
2481601|NCT03025672||no clostridium difficile|Patients that have not been infected during their stay in hospital.
2481624|NCT03025334|Sham Comparator|Sham tDCS|sham tDCS (30sec ramp-up and 3sec ramp-down)
2481628|NCT03025334|Active Comparator|Real tDCS right|Real anodal tDCS (right DLPFC)
3173443|NCT00612157|Placebo Comparator|Placebo|
2481690|NCT03024905|Experimental|Division 1|"The first division receives baseline data collection for 6 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2481867|NCT03023774|Other|neupogen|neupogen (granulocyte colony-stimulating factor) 30 IU once intrauterine at the time of ovum pickup
2510335|NCT02828852|Experimental|No pregnancy|Blood sample
3173444|NCT00612170|Experimental|3|
3173445|NCT00612170|Sham Comparator|4|
3173446|NCT00612170|Experimental|1|
3173447|NCT00612170|Experimental|2|
3173448|NCT00612196|Experimental|1|
3173449|NCT00612196|Experimental|2|
3173450|NCT00612196|Experimental|3|
3173451|NCT00612196|Experimental|4|
3173452|NCT00612196|Experimental|5|
3173453|NCT00612196|Experimental|6|
3173454|NCT00612196|Experimental|7|
3173455|NCT00612196|Experimental|8|
3173456|NCT00612196|Experimental|9|
3173457|NCT00612196|Placebo Comparator|10|
3173458|NCT00612209|Experimental|1|
3173459|NCT00612248|Experimental|SG|Study group
2480516|NCT03033342|Experimental|Oral multiple doses of MRX-4|Twice daily escalating oral doses of MRX-4 for 10 days: 500 mg, 750 mg, 1000 mg, and 1500 mg
2480518|NCT03033342|Experimental|MRX-4 co-administered with omeprazole|Impact of concomitant food or omeprazole on the pharmacokinetics of oral MRX-4.
2480523|NCT03033342|Placebo Comparator|Oral single doses of placebo|Single oral doses of placebo to match MRX-4
2480528|NCT03033342|Placebo Comparator|Oral multiple doses of placebo|Multiple oral doses of placebo given twice daily for 10 days to match MRX-4
2480530|NCT03033342|Placebo Comparator|Placebo co-administered with omeprazole|Oral placebo given on Day 1, Day 7 to match MRX-4 dosing with omeprazole
3173460|NCT00612248|No Intervention|CG|Control group
3173461|NCT00612261|Experimental|1|The group 1 patients receive AV sheathotomy for macular edema secondary to branch retinal vein occlusion.
2480633|NCT03032354|Experimental|Probiotics arm: Probiotics group|combination of probiotics: Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 in the same capsule
2480634|NCT03032354|Placebo Comparator|Placebo arm: Placebo group|Placebo - maltodextrin
2480708|NCT03031639||Endoscopic|This group is the patients who underwent endoscopic approaches thyroidectomy.
2480714|NCT03031639||Conventional|This group is the patients who underwent conventional approach thyroidectomy
2480898|NCT03031392||Peri-implantitis|Individuals with implants ≥2mm of radiographic bone loss
2480899|NCT03031392||non-peri-implantitis patients|Individuals with implants <2mm of radiographic bone loss
2480917|NCT03030144|No Intervention|Control group|Routine nursing care
2480919|NCT03030144|Other|Intervention group|Evidence based nursing recommendations for the management of urinary incontinence will be introduced.
2480935|NCT03029975|Active Comparator|RDA|Participants will be asked to consume the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein consumption will be emphasized and participants will consume a beef meal after each training session.
2480936|NCT03029975|Experimental|2x RDA|Participants will be asked to consume the twice the RDA for protein for a 10 week period while also undergoing progressive resistance training exercise three times a week. Beef protein will be emphasized and participants will consume a beef meal after each training session.
3173462|NCT00612261|Active Comparator|2|The group 2 patients receive IVTA.
3173463|NCT00612274|Experimental|1|sirolimus, tacrolimus and short course methotrexate
2481092|NCT03029286|Experimental|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
2481094|NCT03029286|Active Comparator|Usual Care Arm|Women will be assigned to view a website that will take them to the American Cancer Society website to view general risk information for breast cancer related to breast density.
2481107|NCT03028831|Active Comparator|Resistant Starch|70g high-amylose maize starch which contains 42g of type 2 resistant starch
2481110|NCT03028831|Placebo Comparator|Digestible Starch|70g of fully digestible starch comprised of amylopectin corn starch.
2481164|NCT03028714|Experimental|Technology-based nutrition education|Participants will receive access to a website including educational information about nutrition and related topics. Through the website they will be asked to play online quiz-games relevant to the content of the website to improve their knowledge.
2481167|NCT03028714|No Intervention|Control group|Participants in the control group will receive no intervention.
2481456|NCT03026868|Experimental|quadrilateral surface plate|The fragments of the acetabulum were fixed with novel quadrilateral surface plate through Stoppa approach.
2481506|NCT03026361||oral lichen planus (OLP)|"Histopathologically confirmed samples of OLP underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OLP changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2481508|NCT03026361||oral squamous cell carcinoma (OSCC)|"Histopathologically confirmed samples of OSCC underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of clinically OSCC changed and adjacent healthy mucosa underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2481511|NCT03026361||healthy mucosa|"Archival samples of healthy oral mucosa underwent immunohistochemical analysis of IGF2 and IGF2R expression.~Fresh-frozen samples of healthy mucosa taken during alveolotomy underwent global proteomic profiling and two proteins were subsequently validated with Western blot."
2481563|NCT03026036||MDD|Patients with current Major Depressive Disorder
2481564|NCT03026036||rMDD|Patients with a history of Major Depressive Disorder
2481565|NCT03026036||HC|Healthy control participants
3173464|NCT00612287|Experimental|A|
2510446|NCT02828072|Sham Comparator|control|standard medical therapy
3173465|NCT00612300|Experimental|A-B|Gait training by an automatic gait trainer (Lokomat) for 3 weeks followed by 3 weeks of categorized gait training by a physical therapist
3173466|NCT00612300|Experimental|B-A|Categorized gait training by physical therapists for 3 weeks followed by 3 weeks of lokomat training
3173467|NCT00612326||1|Patients with newly diagnosed locally or regionally advanced transitional cell carcinoma of the bladder.
3173468|NCT00612365||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) for abdominal aortic calcium (AAC) who have undergone computed tomography (CT) scans of the abdomen
3173469|NCT00612378|Experimental|1|
3173470|NCT00612391|Experimental|Lateral, Minimally Invasive Approach|Lateral, Minimally Invasive Approach in GT fractures treated operatively (plates and screws)
3173471|NCT00612391|Active Comparator|Deltopectoral approach:|Deltopectoral approach for GT fracture treated operatively
3173472|NCT00612404||1|patients with gastrointestinal disorders who need an endoscopy.
3173473|NCT00612417|Experimental|1|recombinant FVIII
3173474|NCT00612417|Placebo Comparator|2|Placebo
3173475|NCT00612443|Experimental|1|non-contact Healing Touch treatment for 20-30 minutes once a week during the course of radiation therapy
3173476|NCT00612443|Sham Comparator|2|A RN graduate assistant will provide a sham treatment of 20-30 minutes of presence.
3173477|NCT00612469|Placebo Comparator|NaF|Sodium fluoride application
3173478|NCT00612469|Experimental|V3|Topical application of 3% vancomycin
2480521|NCT03033238||Early or mild knee symptoms|"Existing Cohort study participants (3,026) were enrolled in 2003-2005, Surviving participants without endstage knee osteoarthritis will be asked to participate in the 144-, 152-, 160- and 168-month follow-up contacts [2,660 were enrolled].~New Cohort study participants (1,500) will be recruited and enrolled in 2016-2018 [1,525 were enrolled]."
2480589|NCT03032770||placenta accreta|Having at least one sign suggestive of placenta accreta
2480594|NCT03032770||normal placenta|Never having any of the signs suggestive of placenta accreta
2480654|NCT03032315|Experimental|TAH(80/10/12.5) tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide(80/10/12.5) tablet
2480657|NCT03032315|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
2480687|NCT03031847|Other|Pacemaker|Cardiac resynchronization therapy Pacemaker
2480688|NCT03031847|Other|Defibrillator|Cardiac resynchronization therapy Defibrillator
2480707|NCT03031613|Experimental|PEEP group|Application of 5 cmH2O PEEP during mechanical ventilation
2480709|NCT03031613|Active Comparator|ZEEP group|No application of PEEP during mechanical ventilation
2480756|NCT03031379|No Intervention|A - control|standard fast, at least 6 hours prior to tracheotomy
2480758|NCT03031379|Experimental|B - shortened fast|fast of only 45 minutes prior to incision
2480862|NCT03031119|Placebo Comparator|Placebo|Tablets administered once or twice daily, with food, in Part A for 14 days.
2480863|NCT03031119|Experimental|PF-06835919|Tablets administered once or twice daily, with food, in Part A for 14 days. Tablets administered once or twice daily, for 4 days at a low dose and for 4 days at a higher dose, with food and atorvastatin in Part B.
2480866|NCT03031119|Experimental|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without a low dose of PF-06835919 for 4 days and a higher dose of PF-06835919 for 4 days.
2480930|NCT03030300|Experimental|Novolin 30R;Pioglitazone;Metformin|Drugs: Insulin (Novolin 30R) monotherapy or combined with one or two oral drugs (metformin 0.5 mg tid and pioglitazone hydrochloride 15 mg qd).
2480967|NCT03029923|Experimental|Smoking Cessation and Mood Management|Participants will receive standard smoking cessation plus Behavioral Activation based mood management. Will be offered the nicotine patch if medically cleared.
2480969|NCT03029923|Active Comparator|Smoking cessation and Health and Wellness|Participants will receive standard smoking cessation plus health and wellness education. Will be offered the nicotine patch if medically cleared.
2481114|NCT03029104|Active Comparator|Group 1|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
2481116|NCT03029104|Active Comparator|Group 2|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 6 mW/cm2 cycled On/Off at 15 second intervals for 20 minutes.
2481118|NCT03029104|Active Comparator|Group 3|Ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using CXLO Corneal Strengthening Solution and a UVA irradiance of 4 mW/cm2 cycled On/Off at 15 second intervals for 30 minutes.
2481183|NCT03028662|Experimental|Immediate exposure|Exposure to video on alcohol (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2481187|NCT03028662|Active Comparator|Delayed exposure|Exposure to a video of alcohol consumption (update phase) followed (6 hours) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2481188|NCT03028662|Active Comparator|No exposure|Exposure to a video of neutral situations (update phase) followed (10 minutes) by the task of approach-avoidance of alcohol (extinction phase) (Retrieval-Extinction Learning), during 4 days of training.
2481193|NCT03028285|Experimental|Unifusol 250 ml IV, 3 ml/mil|Twelve healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at a dose 250 ml and infusion rate 3 ml/min.
2481194|NCT03028285|Experimental|Unifusol 250 ml IV, 4.5 ml/min|Twenty-four healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 250 ml and infusion rate 4.5 ml/min
2481195|NCT03028285|Experimental|Unifusol 500 ml IV, 4.5 ml/min|Twelve healthy volunteers will receive arginine sodium succinate 1.4% solution (Unifusol) intravenously at a dose 500 ml and infusion rate 4.5 ml/min
2481264|NCT03028194|Experimental|Curettage|Postpartum uterine curettage performed immediately after delivery of the placenta.
2481265|NCT03028194|Placebo Comparator|Placebo|No procedure performed after delivery of the placenta.
2481301|NCT03027791|Experimental|Parishoners at HUMC|African-American adults aged 18-85 who attend services at Holman United Methodist Church will be exposed to Group Sessions for 12 weeks and Virtual Reality for 6 weeks.
2481340|NCT03027518|Other|Group 1|Group 1 will be active in the WILD 5 Wellness program the first 30 days and inactive the 2nd 30 days.
2481349|NCT03027518|Other|Group 2|Group 2 will be inactive in the WILD 5 Wellness program the first 30 days and active the 2nd 30 days.
2481427|NCT03027115|Experimental|Treatment|treatment with a selective alpha1-adrenoceptor antagonist
2481429|NCT03027115|No Intervention|Control|no treatment
2481541|NCT03026413|Experimental|PVAM|pulomonary vein antrum modification with contact force monitoring for AF
2481544|NCT03026413|Active Comparator|Control arm|pulmonary vein isolation without contact force
2481598|NCT03025815|Experimental|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
2481600|NCT03025815|Sham Comparator|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
2481660|NCT03025269||Relapsing MS patients treated with Ocrelizumab|30 patients diagnosed with relapsing forms of multiple sclerosis and newly beginning treatment with Ocrelizumab according to neurologists' orders
2480592|NCT03032432|Experimental|Dynamic elastic garment and injection|
2480598|NCT03032432|Active Comparator|Corticosteroid injection|
2480678|NCT03032211|Experimental|Treatment|Alfapump
2480702|NCT03031782|Experimental|Treatment Period 2 - active|secukinumab (AIN457 - pre-filled syringe) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
2480703|NCT03031782|Placebo Comparator|Treatment Period 2 - placebo|Placebo comparator (matched to secukinumab treatment) for patients with a minimum American college of Rheumatology (ACR) 30 response in Treatment Period 1
2480760|NCT03031210|Experimental|Twice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
2480761|NCT03031210|Active Comparator|Thrice a day regimen|Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
2480801|NCT03031054|Experimental|hyaluronic acid hydrodissection|Ultrasound-guided hydrodissection with 2.5cc hyaluronic acid between carpal tunnel and median nerve.
2480804|NCT03031054|Active Comparator|Normal saline hydrodissection|Ultrasound-guided hydrodissection with 2.5cc normal saline between carpal tunnel and median nerve.
2480884|NCT03030625|Other|IGRT/VMAT focal therapy boost to DIL|Localized prostate cancer (PCa) of intermediate and high risk according to NCCN criteria
2480972|NCT03030248|Active Comparator|Vancomycin treated group|This group will be given vancomycin oral capsules, 125 mg, every 6 hours, for 14 days.
2480977|NCT03030248|Placebo Comparator|Placebo group|This group will be given placebo oral capsules every 6 hours for 14 days.
2481000|NCT03029533|Experimental|DWJ108J (leuprolide acetate)|DWJ108J (leuprolide acetate)
2481002|NCT03029533|Active Comparator|Leuplin DPS Inj|Leuplin DPS Inj
2481055|NCT03029416|Experimental|Single Fraction of SBRT|Stereotactic Body Radiation Therapy delivered in a single session on one day
2481058|NCT03029416|Experimental|Fractionated SBRT|Stereotactic Body Radiation Therapy delivered in three to five fractions with one fraction delivered every other day
3158794|NCT00392886|Experimental|Regimen D2|In courses 1, 3, and 5, patients receive cisplatin IV over 6 hours on day 1, cyclophosphamide IV over 1 hour and etoposide IV over 2 hours on days 2 and 3, high-dose methotrexate IV over 4 hours on day 4, vincristine IV on days 1, 8, and 15 (in courses1 and 3), and filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until blood counts recover. In courses 2 and 4, patients receive oral temozolomide once daily on days 1-5, oral etoposide once daily on days 1-10, cyclophosphamide IV over 1 hour on days 11 and 12, vincristine IV on days 1, 8, and 15 (in course 2), and G-CSF SC beginning on day 13 and continuing until blood counts recover. Patients receive consolidation therapy as in regimen C in combination with etoposide IV over 3 hours on days -5 to -3 and undergo autologous bone marrow or peripheral blood stem cell transplantation, receive G-CSF, and undergo radiotherapy as in regimen C.
3158795|NCT00392899|Active Comparator|UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
2481201|NCT03028311|Other|Treatment (angiography, yttrium Y-90 radioembolization)|"The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging.~All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours."
2481271|NCT03027895|Experimental|Lumen-apposing metal stent(LAMS)|Lumen-apposing metal stent(LAMS) will be deployed by endoscopist under the guidance of EUS
2481272|NCT03027895|Active Comparator|Double pigtail plastic stent(DPPS)|Double pigtail plastic stent(DPPS) will be deployed by endoscopist under the guidance of EUS
2481315|NCT03027739|Experimental|Arm 1|CART-19 cells treated
2481365|NCT03027414|Active Comparator|Substudy 1 and 2 Active|HVs that receive active TMS over the right dlPFC
2481369|NCT03027414|Sham Comparator|Substudy 1 and 2 Sham|HVs that receive sham TMS over the right dlFPC
2481374|NCT03027414|Experimental|Substudy 3 offline|HVs will receive offline TMS to the lest IPS (FPN)
2481437|NCT03026907|Active Comparator|Alitretinoin|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with alitretinoin.
2481438|NCT03026907|Active Comparator|Azathioprine|Patients with severe chronic non-hyperkeratotic hand eczema, randomized to treatment with azathioprine.
2481474|NCT03026478|Experimental|Betamethasone dipropionate 0.05%|topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
2481475|NCT03026478|Active Comparator|Clobetasol propionate 0.05%|Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month
2481572|NCT03025763||Coronal Nonsyndromic Craniosynostosis, trios|Participants with diagnosis of coronal, nonsyndromic craniosynostosis including affected and unaffected biological parents
3158796|NCT00392899|No Intervention|Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3158797|NCT00393055|Experimental|xylitol lozenge|1g xylitol lozenge. Five/day, dissolved in mouth
3158798|NCT00393055|Placebo Comparator|inactive lozenge|1g placebo lozenge. Five/day, dissolved in mouth
3158799|NCT00393120|Experimental|Treatment A - INCB009471 100mg IR|INCB009471, 100 mg IR orally once daily
3158800|NCT00393120|Experimental|Treatment B - INCB009471 300mg SR|INCB009471, 300 mg SR orally once daily
3158801|NCT00393120|Placebo Comparator|Treatment C - Placebo|Placebo matching INCB009471
3158802|NCT00393172|Experimental|exercise|5 days per week exercise for 4 months
3158803|NCT00393172|No Intervention|no exercise|
3158804|NCT00393198|Experimental|Arm 1|
2480562|NCT03032744|Experimental|Intervention|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the intervention group will be prescribed the appropriate asthma therapy based on their assessment (i.e. providing 'asthma assessment & management'), and receive the morning dose of their daily asthma controller medication at school on school days.
2480563|NCT03032744|Active Comparator|Usual Care|All participants will undergo an initial asthma assessment per the NAEPP-EPR3 (National Asthma Education and Prevention Program - Expert Panel Report 3) guidelines, as well as asthma education. Participants randomized to the usual care group will be provided with the results of their asthma assessment and be instructed to follow up with their primary care provider. They will continue to receive all of their daily asthma controller medication at home.
2480615|NCT03032445|Experimental|Alcoholic beer|At least 6% alcohol content
2480616|NCT03032445|Placebo Comparator|Non alcoholic beer|Less than 0.5% alcohol content
2480648|NCT03032159|No Intervention|Control Group|Participants randomized to the control group will receive their usual asthma care from their provider. Additionally, participants in the control group will receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment.
2480651|NCT03032159|Experimental|Text2Breathe Study Group|"The study group spends about 10-20 minutes learning about ways to have better communication with their child's primary care provider about his/her asthma. Additionally this group is enrolled in the Text2Breathe messaging program which sends asthma related educational text messages 2 times a week for 3 months. Participants randomized to the study group will also receive reminder texts to schedule with their child's PCP and to get an annual flu shot. Participants will be surveyed over the phone for 20-30 minutes 3, 6, 12, 18, and 24 months after enrollment."
2480691|NCT03031912|Active Comparator|Group 1: 50 HIV-infected adults CD4 ≥ 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2480693|NCT03031912|Active Comparator|Group 2: 50 HIV-infected adults CD4 > 350 and < 500 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2480696|NCT03031912|Active Comparator|Group 3: 50 HIV-infected adults CD4 ≥ 200 and ≤ 350 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of theV920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2480697|NCT03031912|Active Comparator|Group 4: HIV infected adolescents CD4 ≥ 200 cells/mm^3|Participants will be randomly assigned to receive one dose of ≥2 x 107 pfu of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine or the placebo
2480744|NCT03031509|Experimental|hAECs treatment|Human Amniotic Epithelial Cells of 50 million transplant to nonunion site after debridement surgery
2480745|NCT03031509|Sham Comparator|debridement surgery|debridement surgery
2480915|NCT03031197|Experimental|Tailored realtime triggered reminder pkg|The core intervention will utilize innovative wireless technology to provide patients with 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. The core intervention will be personalized by each intervention arm patient, who may choose features to suit their preferences.
2480916|NCT03031197|No Intervention|Control|Comparison subjects will receive usual care and an offer of counseling at monthly clinic visits.
2480979|NCT03030014|Experimental|educational programm|"Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.~Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children."
2480982|NCT03030014|Placebo Comparator|no educational programm|without educational program Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
2481010|NCT03029559|Experimental|IH + ITL|Subjects will be exposed to a session of Intermittent hypoxia (IH) (45 minutes, 2 minutes of hypoxia alternating with 1 minute of hyperoxia) followed by 5 sets of Inspiratory threshold loading (ITL) at 80%MIP (10 breaths per set).
2481011|NCT03029559|Experimental|Intermittent hypoxia (IH)|Subjects will only be exposed to a session of intermittent hypoxia.
2481013|NCT03029559|Experimental|Sham IH + ITL|Sham Intermittent Hypoxia + Inspiratory threshold loading (ITL) subjects will be exposed to a single 45-minute session of sham IH (normoxia). This will consist of the subject breathing room air (FiO2=21%) through a 4 way valve connected to the hypoxicator. Exposure to normoxia will be followed by 5 sets of ITL at 80%MIP (10 breaths per set).
2481015|NCT03029559|Sham Comparator|Sham IH|Sham intermittent hypoxia subjects will be exposed to a single 45-minute session of sham IH alone.
3158805|NCT00393198|Placebo Comparator|Arm 2|
2481263|NCT03027947|Experimental|Spinal cord stimulation|"Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.~Participants in this study receive spinal cord stimulation will be trans-tibial and trans-femoral amputees that are at least six month post--amputation. Subjects will have varying levels of phantom limb sensation and pain, but should have no other significant neurological disorders."
2481268|NCT03028181||3|Patients with acute pancreatitis non-exposed to tobacco smoking
2481269|NCT03028181||4|Patients with acute pancreatitis exposed to tobacco smoking
3158806|NCT00393198|Active Comparator|Arm 3|
3158807|NCT00393224||cohort|hospital based family cohort
3158808|NCT00393250|Experimental|1|Hypnosis
3158809|NCT00393250|Active Comparator|2|Control
3158810|NCT00393263|Experimental|1|pimecrolimus
3158811|NCT00393263|Active Comparator|2|clobetasol
3173479|NCT00612469|Experimental|V10|Topical application of 10% vancomycin
3173480|NCT00612469|Active Comparator|CHX|Topical application of 1% chlorhexidine
2480601|NCT03032718|Experimental|Intervention|Patients in the intervention group will receive a defined exercise program twice a week in addition to their usual treatment. Training sessions start immediately after randomization and will be supervised by trained sport students. They will take place twice a week, for twelve weeks in specific training rooms designed to meet the needs of oncological patients in the respective centers. The vibration exercises will take place on a side-alternating vibration platform (GalileoTM, Pforzheim, Germany) ®) according to the previously determined optimal (highest neuromuscular response) setting for each individual. Each session will last for about 15 to 30 minutes, leaving sufficient time for regeneration. Training will consist of four vibration exercises, chosen from a standardized pool of exercises with increasing difficulty in order to allow for individual, optimal progression. All sessions will be documented by the supervisor.
2480608|NCT03032718|No Intervention|Control|Patients in the control group will receive treatment as usual and will be given the opportunity to participate in the intervention after completion of the study.
3193275|NCT00816699|Active Comparator|2|Preprint preoperative risk information
3193276|NCT00816712|Active Comparator|A|Testosterone - 300 mg IM
2480736|NCT03031561|Experimental|Diagnostic (standard ultrasound, MicroPure, biopsy)|Patients undergo grayscale and MicroPure ultrasound imaging followed by sonographic or stereotactic guided core needle biopsy or surgical resection. Surgical specimens are then x-rayed.
2480772|NCT03031249|Active Comparator|High Dose of Cytarabine|Patients receive high dose of cytarabine.
2480774|NCT03031249|Experimental|HDAC + ATRA + ATO|Patients receive high dose of cytarabine plus ATRA and ATO treatment.
2480849|NCT03030976|Experimental|Reduce B cells|Patients receive cyclophosphamide to reduce B cells before CD19-CART infusion. It will also reduce the side effects of cell damage due to antitumor activity.
2480851|NCT03030976|Experimental|Treatment of SLE|Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
2480873|NCT03030430|Experimental|BAT1706|BAT1706 injection
2480875|NCT03030430|Active Comparator|EU-sourced Avastin|EU-sourced Avastin
2480876|NCT03030430|Active Comparator|US-sourced Avastin|US-sourced Avastin
2480959|NCT03030274|Experimental|Occlutech AFR Device|Prospective, non-randomized, pilot study to assess safety and efficacy of a novel Atrial Flow Regulator in Heart Failure Patients with with reduced Ejection Fraction (HFrEF) and Heart Failure Patients with preserved Ejection Fraction (HFpEF); the AFR-Prelieve Trial
3193277|NCT00816712|Active Comparator|B|Testosterone - 100 mg IM
3193278|NCT00816712|Placebo Comparator|C|Placebo - IM
3193279|NCT00816725|Experimental|Self-help course and information|
3193280|NCT00816764|Experimental|1. AGS-8M4 Dose 1|
2481191|NCT03028623|Other|Control|Tubal sterilization will be performed by standard tubal ligation, either Parkland or Pomeroy technique, at the time of cesarean section
2481192|NCT03028623|Experimental|Experimental|Tubal sterilization will be performed by bilateral salpingectomy using a ligasure device at the time of cesarean section.
2481243|NCT03028233|Experimental|Healthy Lifestyles|The study will test the impact of a community health worker (CHW)-delivered intervention aimed at helping families overcome barriers to childhood obesity prevention. Barriers include social, environmental, and family issues.
2481244|NCT03028233|Active Comparator|Positive Parenting|The control condition consists of a community health worker (CHW)-delivered intervention aimed at helping families improve positive parenting skills.
2481302|NCT03027921|Experimental|hepatic ultrasound|all patients will have hepatic ultrasound
3193281|NCT00816764|Experimental|2. AGS-8M4 Dose 2|
3193282|NCT00816764|Experimental|3. AGS-8M4 Dose 3|
3193283|NCT00816764|Experimental|4. AGS-8M4 Dose 4|
2481528|NCT03026426|Experimental|CONEMO|"Participants in the intervention arm will receive a smartphone with CONEMO, an application with 18 sessions that are delivered 3 times a week for 6 weeks.~Additionally, all study participants, including those in the intervention arm, who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional."
2481531|NCT03026426|No Intervention|Control Group|Participants in the control group will receive enhanced usual care. Participants who present a high risk of suicide and/or have a PHQ-9 score ≥20 are referred to the system for follow up. Participants with lower levels of depressive symptoms receive the recommendation of going to a mental health professional.
2481569|NCT03025841|Other|Ceftaroline|Patients receive Ceftaroline 600mg BID
2481661|NCT03025282|Experimental|CD10367 3% Solution - Non-desquamated zone|
3193284|NCT00816790|Active Comparator|Dose Adjusted|This arm will receive their broad spectrum antibiotic as an adjusted dose based on their renal function as measured when sepsis is diagnosed and antimicrobials are initiated
3193285|NCT00816790|Experimental|Unadjusted Dose|This arm will receive their broad spectrum antibiotic as an unadjusted dose regardless of their renal function
3193286|NCT00816803|Experimental|BM transplant with physiotherapy|Autologous BM transplant
3193287|NCT00816803|Active Comparator|Physiotherapy only|conventional physical therapy for chronic spinal cord injury.
3193288|NCT00816816|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3193289|NCT00816855|Other|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of three cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3193290|NCT00816868|Experimental|non-small cell lung cancer (NSCLC)|erlotinib in combination with capecitabine as first-line treatment in elderly patients with stage IIIB/IV adenocarcinoma non-small cell lung cancer (NSCLC)
3193291|NCT00816881|Experimental|1|flutter mucus clearance device
3193292|NCT00816881|No Intervention|2|Observation
2480611|NCT03032536|Experimental|Treatment I|"Part 3: AL-3778 twice daily with entecavir 0.5 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2480613|NCT03032536|Active Comparator|Treatment J|Part 3: Tenofovir disoproxil fumarate 300 mg once daily administered under fasted conditions for 14 days
2480614|NCT03032536|Experimental|Treatment K|"Part 3: AL-3778 twice daily and tenofovir disoproxil fumarate 300 mg once daily both administered under fasted conditions for 14 days.~AL-3778 dose will be determined by Part 1 and/or Part 2 and will be one of the following tablet dosages:~600mg: 2 x 300-mg OR~1000mg: 2 x 500-mg OR~800mg: 1 x 300-mg + 1 x 500-mg OR~700mg: 1 x 200-mg + 1 x 500-mg"
2480647|NCT03032094|Active Comparator|1mm thick graft|connective tissue graft of 1mm thickness
2480650|NCT03032094|Active Comparator|2mm thick graft|connective tissue graft of 2mm thickness
2480883|NCT03030547|Experimental|Muscle Disease Group|Adult patients with muscle diseases diagnosed by neurologist, will wear SenseWear activity monitor for 5 days
2480885|NCT03030547|Active Comparator|Healthy Individuals Group|Healthy individuals with similar demographic characteristics as adult patients with muscle diseases, will wear SenseWear activity monitor for 5 days
2481068|NCT03029468|Experimental|Computerized CBT|Computerized cognitive behavioral therapy (cCBT) for pain via an integrated smartphone and web-based skills training program: The training plan will help users learn how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation. The cCBT arm emphasizes skills acquisition and learning through practice; thus, the program involves regular homework assignments, and follow-up with the care coach and social network about issues faced and what skills were or could be used. This intervention is consistent with the tailored behavioral services patients would receive individually or as a group when working with a psychologist or behavioral pain specialist.
2481069|NCT03029468|Active Comparator|e-Education|Participants will receive pain education through online modules that they will be asked to complete using their personal or study-provided smartphone. Each module includes learning tasks, a reading assignment, and a short quiz based on material. The education group will receive care coach contact on the same schedule as the cCBT group. The care coach will provide supportive therapy and encouragement to complete modules and apply the lessons to their daily life.
2481070|NCT03029468|No Intervention|Usual Care|Participants who are not eligible or who are not randomized into one of the intervention arms of this study will serve as a comparison group to ensure we are treating a representative sample of patients. Further, patients who were eligible but were not randomized into one of the intervention arms will serve as a usual care control group.
2481112|NCT03029065||lung adenocarcinoma with brain (meningeal) metastasis|
2481174|NCT03028779|Experimental|Fast-track total hip or knee arthroplasty|Be able to return patient home on the same day of a total hip or knee surgery.
2481220|NCT03028441|Experimental|Group 1- low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day1 and at Day 29 for 25 subjects, placebo for 5 subjects
2481222|NCT03028441|Experimental|Group 2-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1 and at Day 85 for 25 subjects, placebo for 5 subjects
2481228|NCT03028441|Experimental|Group 3-low dose|30 Subjects: 5 x 10^4 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
2481233|NCT03028441|Experimental|Group 4 -high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1 and at Day 29 for 25 subjects, placebo for 5 subjects
2481237|NCT03028441|Experimental|Group 5-high dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 85 for 25 subjects, placebo for 5 subjects
2481240|NCT03028441|Experimental|Group 6-dose-High Dose|30 Subjects: 5 x 10^5 TCID50 MV-CHIK at Day 1and at Day 169 for 25 subjects, placebo for 5 subjects
2481286|NCT03027908|Experimental|Fluoride Toothpaste 1|Toothpaste containing Sodium Fluoride at 1450 ppm F
2481289|NCT03027908|Active Comparator|Fluoride Toothpaste 2|Toothpaste containing Sodium Fluoride at 1450 ppm F
2481325|NCT03027583|Experimental|Probiotic|63 subjects will be randomized to the experimental arm. The experimental product is a vegetable capsule containing a probiotic strain. Subjects will consume 1-2 capsules daily together with breakfast, equivalent to a dose of 50 bill CFU for 6 weeks.
2481327|NCT03027583|Placebo Comparator|Placebo|63 subjects will be randomized to the placebo arm.The placebo product is the same vegetable capsule as the experimental product, identical in composition, taste and appearance but without probiotics. Subjects will consume 1-2 capsules daily with breakfast for 6 weeks.
2481372|NCT03027258|Experimental|Intervention|mHealth intervention
2481433|NCT03026946|Active Comparator|Alitretinoin|Patients with severe recurrent vesicular hand eczema, randomized to treatment with alitretinoin.
2481435|NCT03026946|Active Comparator|Cyclosporin A|Patients with severe recurrent vesicular hand eczema, randomized to treatment with cyclosporin A.
2481466|NCT03026517|Experimental|Dabrafenib, Trametinib & Phenformin|This is a multi-institution single-arm phase I trial with an expansion cohort at the MTD of Phenformin, in patients with metastatic BRAFV600E/K mutated melanoma. In the dose escalation phase, cohorts of patients will be treated with standard dose Dabrafenib (150 mg PO BID) plus Trametinib (2 mg PO QD) and increasing doses of Phenformin. In the dose-escalation phase of the trial, both patients who have already been treated with a BRAF and/or MEK inhibitor, and treatment-naïve patients will be eligible. The maximally tolerated Phenformin dose was determined to be 100 mg BID. The dose-expansion cohort will enroll up to 10 patients who are treatment- naïve for BRAF inhibitor. In this cohort, patients may be treated with any of the 3 FDA-approved BRAFi/MEKi combinations: dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib.
2481518|NCT03026244|Active Comparator|Nutritional intervention product|Milk protein, prebiotics, vitamin D
2481520|NCT03026244|Placebo Comparator|Placebo product|placebo product
2481602|NCT03025997|Active Comparator|Active yoghurt|Yoghurt snack containing encapsulated lipid
2481605|NCT03025997|Placebo Comparator|Placebo yoghurt|"Yoghurt snack containing non-encapsulated lipid~+ empty encapsulation matrix"
2480620|NCT03032497|Experimental|EEG-based BCI analysis of fear avoidance|"All participants complete two experiments one after another-EEG patterns, skin conductance and pulse rate are recorded. The EEG cap is mounted on the participant's head, the GSR sensor secured on the fingers and the PPG sensor secured on the wrist using a Velcro strap. Exp 1-participants watch a series of 15, 1 min videos of people doing daily activities. Exp 2-participants do 15 movements (15 reps each in 1 min) as guided by a physiotherapist. 2 identical buzzers (labelled lesser pain and more pain) are available to press accordingly should participants experience 'lesser' or 'more' pain any time during the experiment. If 'more' pain experienced, participants' condition will be assessed and they can choose to continue the experiment at a lower intensity or stop."
2480662|NCT03032133|Active Comparator|Regional pain control|Regional pain catheter
2480666|NCT03032133|Experimental|Local pain control|Local intraarticular pain catheter
2480742|NCT03031626|Experimental|Arm A: Medical air followed by oxygen|
2480743|NCT03031626|Experimental|Arm B: Oxygen followed by medical air|
2480775|NCT03031223|Experimental|low-level laser therapy|"The treatment group will receive LLLT following the protocol outlined below:~LLLT protocol - radiance will be administered to the injury site transcutaneously at a wavelength of 808 nm using a Twin Flex Evolution diode laser (MMO Equipamento Opto-Eletronicos, Brazil). Twelve sessions will be held (three per week over four weeks). The dose administered to the surface of the skin will be 983 J/cm2 per session, with a treatment area of 4.72 W/cm² and total radiant energy of 25 J. According to the literature, this dose is capable of enhancing functional recovery following an injury."
2480776|NCT03031223|Placebo Comparator|placebo|laser therapy is applied at low intensity without emitting radiation.
2480813|NCT03030963|Experimental|Equal-ratio ventilation(ERV) group|ventilator inspiration to expiration ratio will be set 1:1.
2480816|NCT03030963|Active Comparator|Control group|ventilator inspiration to expiration ratio will be set 1:2.
2480889|NCT03030703|Experimental|350 mg phytic acid|350 mg phytic acid (inositol hexaphosphate) at week 0 (before supplementation) and at week 4 (after supplementation)
2481027|NCT03030170|Experimental|Experimental|Stapling of the pancreas with ENDO GIA Reinforced reload
2481032|NCT03030170|Active Comparator|Control|Stapling of the pancreas with ENDO GIA X-tra Thick reload
2481083|NCT03029195|Experimental|Study group|Nasoalveolar molding therapy for cleft lip and palate infants
2481084|NCT03029195|No Intervention|Control group|No nasoalveolar molding therapy for cleft lip and palate infants
2481086|NCT03029195|No Intervention|Age matched Norms|Normal (non-cleft) age matched infants
2481098|NCT03028883||buprenorphine dose adjustments|To determine if a relationship exists between buprenorphine dose adjustments and gestational age in opioid-maintained pregnant women
2481172|NCT03028753|Experimental|All subjects|All subjects enrolled in the study will have a back-fill voiding trial performed at the time of catheter removal after urogynecologic surgery.
2481218|NCT03028428|Experimental|Placenta Derived Mesenchymal Stem Cell|Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
2481219|NCT03028428|Active Comparator|sodium hyaluronate|Sodium hyaluronate administered into the knee joint once
3173481|NCT00612482|No Intervention|1|"Participants in the no intervention condition will receive the usual high school science curriculum."
2481538|NCT03026309||depressed|un medicated diagnosed with major depression and scheduled to start SSRI treatment.
2481539|NCT03026309||healthy|healthy volunteers.
2481644|NCT03025503|Experimental|nipple stimulation|
2481646|NCT03025503|No Intervention|no intervention|
2481689|NCT03024983|Active Comparator|Control|Glucose monohydrate (isoglucidic portion -50 g of available carbohydrates-)
2481700|NCT03024983|Experimental|Semolina|Semolina soup (isoglucidic portion -50 g of available carbohydrates-)
2481713|NCT03024983|Experimental|Bread|Bread (isoglucidic portion -50 g of available carbohydrates-)
2481722|NCT03024983|Experimental|Short pasta (fresh)|Fresh penne (isoglucidic portion -50 g of available carbohydrates-)
2481725|NCT03024983|Experimental|Short pasta (dry)|Short pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
2481727|NCT03024983|Experimental|Long pasta (dry)|Long pasta (dry) (isoglucidic portion -50 g of available carbohydrates-)
2481893|NCT03023527|Experimental|nivo-pom-dex|Nivolumab in combination with Pomalidomide and low dose dexamethasone
3173482|NCT00612482|Experimental|2|"Participants in the experimental arm will receive the 5-lesson, science-based substance abuse prevention curriculum in their science classes."
3173483|NCT00612521|Other|1|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
3173484|NCT00612521|Other|2|Either Placebo or Adenosine mixed with normal saline at a concentration of 6 micrograms per milliliter.
3173485|NCT00612547||Observation|Children under the age of five years (2 months to 5 years) residing in the zone covered by the community-based service provider throughout the entire follow-up period
3173486|NCT00612612|Experimental|Treatment (obatoclax mesylate, fludarabine, rituximab)|"Patients receive obatoclax mesylate IV over 3 hours on days 1 and 3, fludarabine IV over 20-30 minutes on days 1-5, and rituximab IV over 4 hours on day 1 (days 1 and 3 of course 1 only). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo peripheral blood collection for correlative studies. Samples are analyzed for expression of pro- and anti-apoptotic Bcl-2 family members by western blot; apoptosis induction by measurement of lymphocyte count, Annexin V staining, and Caspase and PARP cleavage; activated Bax by immunoprecipitation; and Bax promoter polymorphism by PCR amplification and direct sequencing."
3173487|NCT00612625|Experimental|GLP-1|A graded glucose infusion with an infusion of GLP-1 (1½ pmol/kg/min)
3173488|NCT00612625|Experimental|Saline|A graded glucose infusion together with a continuous infusion of saline
3173489|NCT00612638|Experimental|1|Pts receiving Dilantin, Tegretol or Phenobarbital
3173490|NCT00612638|Experimental|2|Pts on anti-convulsants other than Dilantin, Tegretol / Phenobarbital / pts not on any anti-convulsants
3173491|NCT00612651|Other|enzyme-inducing anti-epileptic drugs (EIAEDs)|Patients receiving enzyme-inducing anti-epileptic drugs (EIAEDs)such as carbamazepine, phenobarbitol, phenytoin, phosphenytoin, oxcarbamazepine, primadone)
3173492|NCT00612651|Other|no enyzme-inducing anti-epileptic drugs|Patients on non CYP3A4-inducing anti-convulsants or patients not on any anti-convulsants.
2480646|NCT03032692|Active Comparator|SWORD and exercise without biofeedback|The patient will perform one repetition of the exercise shoulder flexion with elbow flexion at 90 degrees under monitoring from SWORD. The recorded parameters will be used to define: baseline and target angle; execution time; maximum postural sway. Two additional repetitions will be performed to ensure reproducibility. The patient will then be instructed to perform as many movements as possible during the allocated time (4 minutes), at a comfortable pace, starting at or below the baseline and trying to reach maximum flexion without significant pain or discomfort. During the session, the SWORD system will be recording the patient´s movement without providing feedback to the patient.
2480905|NCT03031236|Active Comparator|ECD+|Behavioral: Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
2480908|NCT03031236|No Intervention|Only regular health messages|Only regular health message from government health services
2480925|NCT03030066|Experimental|Experimental Drug DS-1001b|Oral administration
2480948|NCT03029962|Experimental|Experimental: Girl2Girl|Girl2Girl is a 7-week teenage pregnancy prevention program delivered daily via text messaging to 14-18 year old females who self-identify as lesbian, bisexual, gay, or other sexual minority. In addition to program content, participants are paired with another participant (i.e., a Text Buddy) with whom they can text throughout the program to provide support; and an on-demand advice line, Girl2Genie, which shares information about sex, relationships, and the lesbian, gay, bisexual, transgender (LGBT) community.
2480949|NCT03029962|No Intervention|No Intervention: Health Lifestyle|The attention-matched control arm message content consists of information publicly available online related to living a healthy lifestyle. Content discussed includes: nutrition and sleep hygiene, self-esteem and body image, bullying, and drugs and alcohol. The control arm is 7-weeks in length (Week 7 is a review booster) and is delivered via text messaging. Messages are didactic and not tailored to user sexual experience. Additionally, the Text Buddy and G2Genie intervention program components are not available.
2481034|NCT03029702|Active Comparator|Usual Care|Participants will undergo standard counseling and be prescribed a treatment for their GDM. Treatments include insulin, glyburide, and metformin.
2481037|NCT03029702|Active Comparator|Individualized Treatment|Participants will undergo standard counseling and be matched to therapy based on their GDM mechanism. Treatments include insulin, glyburide, and metformin.
2481146|NCT03029156|Active Comparator|Small volume jet nebulizer|Administration of bronchodilator through small volume jet nebulizer. The nebulized solution contains ipratropium / albuterol.
2481150|NCT03029156|Experimental|Aeroneb nebulizer|Administration of bronchodilator via Aeroneb nebulizer. The nebulized solution contains ipratropium / albuterol.
2481221|NCT03028519|Experimental|Treatment|Vitamin D levels will be measured at the time of routine blood work. If Vitamin D levels are found to be low, patients will take 50,000 IU of vitamin D3 weekly daily as maintenance therapy. There is no prospective control arm.
2481255|NCT03028038|Experimental|Platelet Rich Plasma|Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
2481256|NCT03028038|Experimental|No Platelet Rich Plasma|No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
2481294|NCT03027856|Experimental|Magmaris|Implantation of sirolimus eluting bioresorbable magnesium stent
2481358|NCT03027596|Experimental|Remote ischemic conditioning|Four cycles of 5 min occlusion and reperfusion in an extremity using a tourniquet.
2481360|NCT03027596|No Intervention|Control group|no intervention
2481439|NCT03027076||Men with UCPPS|Genitourinary Specimen Collection for microbiome evaluation
2481441|NCT03027076||Asymptomatic Men|Genitourinary Specimen Collection for microbiome evaluation
2481442|NCT03027076||Women with UCPPS|Collect midstream urine samples
2481443|NCT03027076||Asymptomatic Women|Collect midstream urine samples
2481486|NCT03026491||Children with chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
2481488|NCT03026491||Children without chewing dysfunction|Descriptive characteristics including age, height, weight, transition time to additional food, meal time, number of meals, initial teething time, and number of teeth, were noted. The presence of open mouth, open bite, high palate, gag reflex, and oral hygiene were scored as absent or present as an observational oral motor assessment. Chewing evaluation was performed and scored with the Karaduman Chewing Performance Scale (KCPS). The International Dysphagia Diet Standardisation Initiative (IDDSI) was used to determine the tolerated food texture of children.
2481593|NCT03025893|Experimental|Sunitinib|Patients in this experimental arm will receive sunitinib in a high-dose, intermittent schedule.
2480684|NCT03031951|No Intervention|Control Group - Waiting List|"Participants assigned to the control group will have access to the intervention after the 12-month period - waiting list. Meanwhile, participants will receive multimedia health information fortnightly by e-mail over the first 4-month period. The health information covers healthy lifestyle topics.~During the 12 months of study participation, control group participants will be instructed to maintain their baseline level of physical activity. Individuals assigned to the control group will be asked to maintain their current nutritional practices and physical activity patterns."
2480705|NCT03031665||Current MDD|Subjects experiencing a current episode of Major Depressive Disorder.
2480712|NCT03031665||Remitted MDD|Subjects who have a history of Major Depressive Disorder, but have not had a depressive episode for at least two months.
2480715|NCT03031665||Control Subjects|Subjects who have no history of clinical depression or other psychological disorder.
2480762|NCT03031405|Experimental|Oxytocin and trauma film paradigm|
2480763|NCT03031405|Placebo Comparator|Placebo and trauma film paradigm|
2480794|NCT03031067|Experimental|Machine perfusion - Kidney|The marginal kidney will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
2480795|NCT03031067|No Intervention|Static cold storage - Kidney|The marginal kidney that was stored to cold (SCS), previously.
2480796|NCT03031067|Experimental|Machine perfusion - Liver|The marginal liver will be perfused with oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion.
2480798|NCT03031067|No Intervention|Static cold storage - Liver|The marginal liver that was stored to cold (SCS), previously.
2480839|NCT03030846|Experimental|stabilization exercises|stabilization exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for the training group.
2480841|NCT03030846|Experimental|control group|electrotherapy include of 20 minutes TENS conventional and Ultrasound pulse for 10 minutes without any exercises for the control group.
2480870|NCT03030495||Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve<2 & Index of microvascular resistance>25U
2480874|NCT03030495||No Overt microvascular disease|Fractional flow reserve>0.80, coronary flow reserve>2 & Index of microvascular resistance<25U
2480973|NCT03030105|Placebo Comparator|A) P:P:P|Scopolamine placebo : BPN14770 placebo : Donepezil placebo
2480976|NCT03030105|Placebo Comparator|B) S:P:P|Scopolamine 0.5mg : BPN14770 placebo : Donepezil placebo
2480980|NCT03030105|Experimental|C) S:B:P|Scopolamine 0.5mg : BPN14770 10mg : Donepezil placebo
2480983|NCT03030105|Experimental|D) S:B:P|Scopolamine 0.5mg : BPN14770 50mg : Donepezil placebo
2480984|NCT03030105|Active Comparator|E) S:P:D|Scopolamine 0.5mg : BPN14770 placebo : Donepezil 10mg
2480985|NCT03030105|Experimental|F) S:B:D|Scopolamine 0.5mg : BPN14770 50mg : Donepezil 10mg
3158812|NCT00393276|Experimental|A|HCV-infected defined as a positive result using polymerase chain reaction (PCR) without previous HCV-based therapy and without the presence of Child's B or C cirrhosis. These participants will be HIV-uninfected.
3158813|NCT00393276|Experimental|B|HIV-infected and ARV naive, with a CD4 cell count of 300 cells/mm3 or greater, with no prior or current opportunistic infection, and with no indication for HIV therapy. These participants will be HCV-uninfected.
3158814|NCT00393276|Experimental|C|HCV/HIV-coinfected as defined above in Arms A and B.
3158815|NCT00393302||1 & 2|"Retrospective chart review: HIV testing rates~Prospective cohort group: HIV testing rates"
2481322|NCT03027505|Experimental|MUAC<125mm|no medical complication
3158816|NCT00393328|Active Comparator|A|
3158817|NCT00393328|Active Comparator|B|
2481390|NCT03026959|Experimental|Mindfulness Group|Participants assigned to the mindfulness group will attend four weekly sessions that are each 1.5 hours in length. The sessions will follow the structure described by Short, Mazmanian, Ozen, & Bédard (2015). The structure is designed to first enhance learners' foundation skills in mindfulness and progresses into teaching learners more advanced mindfulness skills.
2481391|NCT03026959|No Intervention|Social (control) Group|Participants assigned to the social group will also attend four weekly sessions that are each 1.5 hours in length. Each session will have participants focus on a creative tasks while permitting task related discussion. In this way the format is designed to parallel the mindfulness group, where participants engage in a new activity each week and have an opportunity to discuss the activities with the group without engaging in any formal intervention.
2481453|NCT03026829|Experimental|CART sound therapy|
2481523|NCT03026387|Other|Neuropsychological battery tests|"All participants performed the same evaluation: clinical and neuropsychological assessment.~All of them are suicide attempters without psychotic features"
2481757|NCT03024411|Experimental|Music/video games|iPod (Music/video games)
2481765|NCT03024411|No Intervention|No intervention|No intervention
2481831|NCT03024255|Experimental|BBI-4000 Concentration 1|Low Concentration
2481836|NCT03024255|Experimental|BBI-4000 Concentration 2|Medium Concentration
2481839|NCT03024255|Experimental|BBI-4000 Concentration 3|High Concentration
2481842|NCT03024255|Placebo Comparator|Vehicle|Vehicle (Placebo)
2481886|NCT03023618|No Intervention|control group|patients before 2014, in which fluids were administered without FloTrac monitoring
3158818|NCT00393341||Case|Women with breast cancer
3158819|NCT00393341||Control|Women without breast cancer
3158820|NCT00393445|Experimental|Intravenous infusion|intravenous infusion of test substances
3158821|NCT00393575|Experimental|Community Mobilization|The intervention population is defined as the community each site is attempting to mobilize.
3158822|NCT00393627|Experimental|1|Sleep Education Program: The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
3158823|NCT00393627|Placebo Comparator|2|Routine medical care
2480701|NCT03031990|No Intervention|Control|These are patients that have a history of IVF failure or who are undergoing elective egg freezing who elect to be included in the study but are not interested in including yoga as a part of their treatment.
2480809|NCT03031457||1|Patients undergo primary fascial closure of abdominal donor-site
2480835|NCT03030768||HIV-1 serodiscordant couples|Couples where one partner is HIV-1 infected and the other is uninfected, who will receive counseling on timed condomless sex, ART and PrEP adherence. The study intervention focuses on ART use by the HIV-1 infected partner, PrEP (Truvada) use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
2480890|NCT03030521||experimental group|In this group, the specimen of aortic wall is bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
2480896|NCT03030521||control group|In this group, the specimen of aortic wall is not bound by a band to restrict its dilation in the fourth step of the aortic delamination test.
2480978|NCT03030157|Experimental|Long-term Intravesical Instillation of pirarubicin(THP)|A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
2480981|NCT03030157|Active Comparator|Single Intravesical Instillation of pirarubicin|A single intravesical instillation of THP after nephroureterectomy was performed. This instillation was initiated within 72-168 hours after surgery . THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
2481012|NCT03029546||Glucose load|"50 subjects undergoing routine gestational diabetes screen with 50g glucose load.~5 subjects undergoing follow-up gestational diabetes screen with 100g glucose load."
2481014|NCT03029546||Control|50 subjects undergoing water ingestion with the same study measurements as the glucose load group at the same time intervals.
2481063|NCT03029364||Male and Female Adults|Completion of Study Protocol
2481177|NCT03029078|Experimental|Fecal transplantation|"Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study.~Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant.~Patient will be monitored for 24h to rule out potential adverse events."
2481197|NCT03028389|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
2481198|NCT03028389|No Intervention|Convention|Elderly patients undergoing non-cardiac surgery received no treatment after induction of anaesthesia
2481254|NCT03028207||COPD|Subjects with FEV1/FVC score less than 0.70 post-bronchodilator test will be allocated to COPD group and the prevalence of COPD will be evaluated. Subjects in this group will be categorized in 4 groups namely GOLD I - IV depending on the disease severity.
2481257|NCT03028207||Non-COPD|Subjects with FEV1/FVC score greater than or equal to 0.70 post-bronchodilator test will be allocated to non-COPD group.
2481309|NCT03027804||Ross Operation|Patients undergone Ross Operation. Patients requiring reoperation
2481343|NCT03027492|Active Comparator|1. NCWS retrospective patients|The clinical charts of NCWS female patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca will be reviewed with a retrospective method. They had all been diagnosed with NCWS between January 2001 and June 2011 and included in a previously published study. These charts included specific sections for associated gynaecological disorders. Incomplete clinical charts will be excluded. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481346|NCT03027492|Active Comparator|2. CD retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients had been randomly chosen by a computer-generated method from female patients diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481351|NCT03027492|Active Comparator|3. IBS retrospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients had been randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2001-2011) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group was asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481357|NCT03027492|Active Comparator|4. NCWS prospective patients|The investigators prospectively will survey adult female patients with functional gastroenterological symptoms according to the Rome III criteria, and a suspected diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at the same 2 centers. Most of the patients will be referred owing to gastrointestinal and extraintestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. In addition, patients will be asked about the presence and characteristics of gynaecological disorders using an ad hoc questionnaire. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481361|NCT03027492|Active Comparator|5. CD prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of CD female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481663|NCT03025282|Experimental|CD10367 1% Solution - Non-desquamated zone|
3158824|NCT00393640|Active Comparator|A|Breast pump given and used on regular intervals
2480781|NCT03031470|Experimental|Reparixin|Reparixin 2.772 mg/kg/hour 168 hrs continuous intravenous infusion
2480783|NCT03031470|Other|Standard Care Procedures|No treatment; standard care procedure
2480822|NCT03030898|Other|respiratory variation of the right internal jugular vein|
2480852|NCT03030716|Experimental|0.03 mg 95% condensed proanthocyanidin|0.03 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.03 g 95% condensed proanthocyanidins from grape seed extract at week 4
2480855|NCT03030716|Experimental|0.25 g 95% condensed proanthocyanidin|0.25 g 95% condensed proanthocyanidins from grape seed extract at week 0 0.25 g 95% condensed proanthocyanidins from grape seed extract at week 4
2480856|NCT03030716|Experimental|1.5 g 95% condensed proanthocyanidin|1.5 g 95% condensed proanthocyanidins from grape seed extract at week 0 1.5 g 95% condensed proanthocyanidins from grape seed extract at week 4
2480867|NCT03030443||Oral Sedation|"Patients in this group will receive a standard procedure first trimester abortion using oral sedation for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
2480871|NCT03030443||Nitrous Oxide|"Patients in this group will receive a standard procedure first trimester abortion using titrated nitrous oxide for pain management following the clinic's protocol.~Patients in both groups will be administered a Visual Analog Scale (VAS) assessing pain on an unmarked 100mm VAS scale with anchors at 0mm (left) being no pain and 100mm (right) being pain as bad as it could be before their procedure and immediately following procedure completion."
2480928|NCT03030352|Experimental|How-to Parenting Program|The How-to Parenting Program consists of seven 2 ½-hour weekly sessions. It is a manual-based program in which participants have their own exercise booklet containing parenting skills and exercises. Groups are led by 2 group leaders and formed of 6 to 10 parents.
2480929|NCT03030352|No Intervention|Wait-list Control Group|Parents assigned to the wait-list control group will receive no intervention for the duration of the trial. The How-to Parenting Program will be delivered to them the following year. This delayed participation is ethically sound, as the program does not target at-risk families.
2480961|NCT03029910|Experimental|Cryotherapy and eccentric exercise|
2480964|NCT03029910|Experimental|Vibration and eccentric exercise|
2480966|NCT03029910|No Intervention|Control|
2481046|NCT03029611|Experimental|Treatment (chemotherapy, IGFBP-2 vaccine)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour followed by IGFBP-2 vaccine ID 2 weeks later. Treatment repeats every 3 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity. After completion of 3 cycles, patients then undergo cytoreductive surgery.
2481176|NCT03028935|Experimental|Prevention (exercise, nutrition education program)|Exercise Intervention & Nutritional Intervention. Participants undergo instructor-led exercise and nutrition education classes for 60 minutes twice a week for 12 weeks.
3158825|NCT00393640|No Intervention|B|
3158826|NCT00393640|Active Comparator|c|Breast pump given to be used on regular interval
3158827|NCT00393640|No Intervention|D|
3158828|NCT00393679|Experimental|1|AS-AQ
3158829|NCT00393679|Experimental|2|"DHAPQ~TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities."
2481331|NCT03027726|Active Comparator|Control group|Family-based lifestyle education and psycho-educational program
2481333|NCT03027726|Experimental|Exercise group|Supervised exercise plus family-based lifestyle education and psycho-educational program
2481432|NCT03027180|Active Comparator|0 (zero) cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 0 cmH2O
2481434|NCT03027180|Experimental|4 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 4 cmH2O
2481436|NCT03027180|Experimental|15 cmH2O|After draining, people will be asked about the level of pain via visual numeric scale and then subjected to chest computed tomography (Aquilion 64-Toshiba Medical Systems®, Japan), using positive airway pressure in the airways with 15 cmH2O
2481579|NCT03025685|Experimental|TRUST technique + Coronary Stenting|PCI with coronary stenting using TransRadial Ultra Support technique for support improvement
2481581|NCT03025685|Active Comparator|Anchoring technique + Coronary Stenting|PCI with coronary stenting using Wire Anchoring Pass technique for support improvement
2481612|NCT03025451|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
2481895|NCT03023527|Experimental|nivo-pom-dex-elo|Pomalidomide in combination with Nivolumab , dexamethasone and elotuzumab
3158830|NCT00393679|Experimental|3|AL
3158831|NCT00393679|Experimental|4|"Lapdap + AS~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
3158832|NCT00393744|Experimental|1|
3158833|NCT00393744|Active Comparator|2|
3158834|NCT00393770|Experimental|L-acetylcarnitine|
3158835|NCT00393783|Experimental|1|HER2 ECD DNA.
3158836|NCT00393822|Experimental|Palifermin|50 subjects to receive palifermin 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
3158837|NCT00393822|Placebo Comparator|Control Group|50 subjects to receive matched placebo 3 days prior to the first day (day 1) of each cycle of 5-FU/ LV chemotherapy.
3158838|NCT00393900||1|Children with tympanostomy tubes for chronic OME
3158839|NCT00393952|Experimental|1|FlutiForm 250/10
3158840|NCT00393952|Active Comparator|2|FlutiForm 100/10
2480733|NCT03031600|Active Comparator|Radiodilution via Daxor BVA-100|In study arm 1, actual blood volume will be measured using the Daxor Blood Volume Analyzer-100 (BVA-100). In this technique, the subject is injected with 1 ml of human serum albumin labeled with iodine131 (25 microcuries). A small amount of blood is collected from the subject just before injection and at 12, 18, 24, 30, and 36 min after injection.
2480735|NCT03031600|Experimental|Hemodilution via hematocrit measurement|In study arm 2, estimated blood volume will measured via hemodilution. . A blood sample (5 ml) will be drawn for baseline determination of hematocrit via iSTAT and lab measurement from the non-dominant arm. After the baseline hematocrit blood sample is drawn, a volume of normal saline equivalent to 10% of the subject's ideal blood volume will be administered over a 12-minute period through the dominant arm IV catheter. Twelve minutes after the infusion is complete, a second blood sample (5 ml) will be drawn from the non-dominant arm for determination of post-bolus hematocrit via iSTAT and lab. Subjects will then be asked to void into a urinal, and urine output will be measured in ml.
2480764|NCT03031301|Active Comparator|Vibrant capsule|Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment
2480765|NCT03031301|Sham Comparator|Sham capsule|Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment
2480807|NCT03031041|Experimental|Short-axis hydrodissection|Ultrasound-guided short-axis hydrodissection with normal saline between carpal tunnel and median nerve
2480808|NCT03031041|Active Comparator|Long-axis hydrodissection|Ultrasound-guided long-axis hydrodissection with normal saline between carpal tunnel and median nerve
2480937|NCT03029897|Experimental|experimental|Patients are educated on the use of a mobile application to report adverse drug reactions
2480938|NCT03029897|No Intervention|control|Patients are not educated on the use of a mobile application to report adverse drug reactions
2480996|NCT03029806|Active Comparator|Afr-Amer risk allele|African Americans carrying the LSD1 affected allele
2480997|NCT03029806|Placebo Comparator|Cauc risk allele|Caucasians carrying the LSD1 affected allele
2480998|NCT03029806|Placebo Comparator|Afr-Amer non-risk allele|African Americans carrying the LSD1 non-risk allele
2480999|NCT03029806|Placebo Comparator|Cauc non-risk allele|Caucasians carrying the LSD1 non-risk allele
2481054|NCT03029390|Experimental|Berberine hydrochloride|"Berberine capsules, 500 mg, three per day before each meal during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study, they will be receive three 500 mg capsules (before each meal)"
2481057|NCT03029390|Experimental|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 12 weeks.~The patients will have a forced titration period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study, they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
2481154|NCT03029117||corrected and uncorrected rheumatic valve lesions|
2481179|NCT03028597|Experimental|Intervention Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
2481181|NCT03028597|Active Comparator|Control Values Affirmation|The task first asks patients to reflect on a list of 11 personal values or self-defining skills.
2481235|NCT03028350|Experimental|Ifetroban Oral Capsule|Oral ifetroban, 200 mg daily for 8 weeks
2481241|NCT03028350|Placebo Comparator|Placebo Oral Capsule|Oral placebo daily for 8 weeks
2481288|NCT03027843|Active Comparator|GH group|patients in group mini-dose GnRH-a long protocol combine with growth hormone
2481292|NCT03027843|No Intervention|control group|patients in group mini-dose GnRH-a long protocol without growth hormone
2481330|NCT03027622||long term quality of life|to evaluate conservatively managed third molars with mild pericoronitis at first, third and sixth months by using OHIP-14 TR
2481386|NCT03027245||Eribulin-treated participants|Participants treated with eribulin according to Fachinformation and managed according to clinical practice
2481455|NCT03026790|Active Comparator|Telecare collaborative management (TCM)|Uses medication management approach delivered by a clinical pharmacist care manager with a collaborating physician to address common barriers to effective pain medication management in primary care.
2481457|NCT03026790|Active Comparator|Integrated pain team (IPT)|Uses a biopsychosocial management approach delivered by a multidisciplinary team that emphasizes non-pharmacological pain management options.
2481458|NCT03026790|Active Comparator|Standard taper options|The standard taper options arm uses patient education and shared decision-making to guide opioid medication management.
2481460|NCT03026790|Active Comparator|Expanded taper options|The expanded taper options arm uses patient education and shared decision-making to guide opioid medication management and includes the additional option of rotation to buprenorphine-naloxone.
2480741|NCT03031925|Active Comparator|control subjects|age- and sex-matched control subjects
2480909|NCT03031262|Active Comparator|High Dose of Cytarabine|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine.
2480911|NCT03031262|Experimental|HDAC + Chidamide|CBF Patients who reach CR after reduction therapy receive high dose of cytarabine plus chidamide.
2480940|NCT03030027|Experimental|Connecting Through Caregiving|This arm focuses on perspective-taking reappraisal procedures.
2480942|NCT03030027|Other|Basic Skills Building|This arm focuses on skill building.
2480988|NCT03029767|Experimental|Aerobic exercise|Aerobic exercise training will be carried out as an intervention activity
2480990|NCT03029767|Experimental|Resistance exercise|Resistance exercise training will be conducted as an intervention activity
2480991|NCT03029767|Experimental|Aerobic and resistance exercise|Aerobic and resistance training will be implemented
2480993|NCT03029767|No Intervention|Control group|standard or usual activity carried out.Additional intervention will not be given.
2481021|NCT03029455|Experimental|Part A: VX-659 or Matching Placebo|Part A includes single-dose escalation.
2481022|NCT03029455|Experimental|Part B: VX-659 or Matching Placebo|Part B includes multiple-dose escalation.
2481023|NCT03029455|Experimental|Part C: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part C includes multiple dose escalation of VX-659 administered in Triple Combination (TC).
2481026|NCT03029455|Experimental|Part D: VX-659 in TC with TEZ/IVA or Matching Triple Placebo|Part D includes subjects with CF. Participants will receive TC or matching placebos.
2481135|NCT03029039||patients with severe sepsis|Blood samples will be collected at inclusion.
2481137|NCT03029039||patients with inflammatory syndrome without sepsis|Blood samples will be collected at inclusion.
2481139|NCT03029039||blood donor voluntary|Blood samples will be collected.
2481185|NCT03028610|Experimental|Acessa™ System|radiofrequency generator
2481211|NCT03028337|Experimental|Spine Radiosurgery - 1 Dose|Participants receive spine radiosurgery in a single large dose.
2481215|NCT03028337|Active Comparator|Spine Radiosurgery - 3 Doses|Participants receive spine radiosurgery over 3 smaller doses.
2481290|NCT03027999|Experimental|Patient with tight nursing follow-up|Compared as usual, Patient with tight nursing follow-up will be contacted
2481295|NCT03027999|No Intervention|Patient without tight nursing follow-up|Compared as usual, Patient without tight nursing follow-up will not have interventions
2481318|NCT03027531|Experimental|Control|Control group entered sexual history via computer assisted self-interview and provided specimens for chlamydia, gonorrhea and pregnancy(females) testing. The do not receive the feedback intervention of eKISS: electronic KIOSK for safer-sex
2481319|NCT03027531|Experimental|Intervention|Intervention group entered sexual history via computer assisted self-interview and received the interactive computer-based intervention with individualized feedback eKISS: electronic KIOSK for safer-sex. They provided specimens for chlamydia, gonorrhea and pregnancy(females) testing.
2481362|NCT03027349||Study group|"Patients aged between 18-90 years old with primary hyperparathyroidism who had been diagnosed in the Unit of Endocrinology of the University of Modena and Reggio Emilia.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
2481364|NCT03027349||Control group|"Patients that underwent biochemical examination by primary care physician or by endocrinologist in order to assess their parathyroid function and calcium metabolism state with results into the normal ranges.~The exclusion criteria will be:~age younger than 18 years~renal and liver failure and insufficiency~active metabolic bone disease (such as Paget's disease of the bone, osteomalacia, rickets, etc)~any type of cancer~malnutrition, severe obesity (BMI > 40 kg/m2) and malabsorption~transplantation~sarcoidosis~endocrinological disorders such as hypercortisolism, diabetes insipidus, hyperthyroidism, pseudohypoparathyroidism~familial hypocalciuric hypercalcemia~hypophosphoremia sustained by genetic causes or secondary to other causes."
2481408|NCT03027063|Experimental|10,000 steps|"For the 10,000 steps group, participants will be asked to achieve a goal of 10,000 steps a day and to engage in 30 minutes of continuous exercise every day. Steps will be monitored with the under Armour fitness tracker which participants will receive.~For motivation, messages will be sent to study participants in this group via the messaging center in the Under Armor application three times a week. The frequency of messaging will be increased for participants who fail to meet their goals for three consecutive days. Study participants will also receive a weekly call to assess for side effects and provide additional encouragement."
2481411|NCT03027063|Active Comparator|Usual care|This will be the usual care group. Participants will also receive a fitness tracker to enable monitoring of steps and will be given a flyer that references the ACC/AHA guidelines for exercise and physical activity for the general population. Participants will not receive text messages or phone calls.
2481448|NCT03026699||Intervention - Primary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of primary brain tumor patients.
2481450|NCT03026699||Intervention - Secondary Brain Tumor|eSNAP Intervention Plus Questionnaires: Family caregivers of secondary brain tumor patients.
2481451|NCT03026699||Control - Primary Brain Tumor|Questionnaires Only Control: Family caregivers of primary brain tumor patients.
2481452|NCT03026699||Control - Secondary Brain Tumor|Questionnaires Only Control: Family caregivers of secondary brain tumor patients.
2481521|NCT03026374|Experimental|intervention group|The BRBC program consists of education and group discussion, and lasted for 12 months. Women in IG attended weekly meetings lasting for 120 minutes. Education took approximately 45 minute. Qualified professionals from various disciplines were invited to provide lessons to ensure the quality of the educational sessions. The group discussion followed the presentation and began with mentors sharing their experience with the topic, followed by participant discussions regarding life changes since diagnosis (e.g., physical, emotional, social, spiritual). Each group consisted of 7-9 patients and 3 leaders (2 mentors and 1 facilitator, including a clinical psychologist, nurse clinician, or social worker). The time of group discussion varied from 45-75 minutes. This was intended to foster support among group members,both in and out of sessions.
2480821|NCT03031093|Active Comparator|COPD, non obese|non obese COPD participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480823|NCT03031093|Experimental|healthy, obese + HFNC|Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480825|NCT03031093|Active Comparator|healthy, obese|Healthy obese participants will perform the following inhalation protocol: aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total dose volume 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland) with free flow. The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480827|NCT03031093|Experimental|COPD, obese + HFNC|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
2480828|NCT03031093|Active Comparator|COPD, obese|Obese COPD participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). The volunteer will be positioned seated in a chair. A mouthpiece associated with a T-tube with Inspiratory and Expiratory branches will be positioned in his mouth for preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; bag of air accumulation. Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
3193293|NCT00816894|Experimental|D-serine arm|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes.
3193294|NCT00816894|Active Comparator|Olanzapine arm|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
3193295|NCT00816920||1|Outpatients with suspected leg DVT after exclusion of proximal DVT
3193296|NCT00816933|Experimental|one port|Patients undergo one port appectomy. Skin incision about 2cm size is made upon umbilicus and dissection is performed to make opening. Then, wound retractcor(Alexis) is iserted on opening site and wound is extended. Rubber glove built-in three 5mm trocars is applied over wound retractor. Pneumoperitoneum is achieved via trocar and appendectomy is performed. After appendectomy, wound is repaired.
2481077|NCT03029312|Experimental|Whole Body Vibration|Twice daily WBVT at home using the Galileo M device, 3x3 min, with 3 minute breaks (total daily WBVT 18 min) for 5 months. Children stand upright on the device, with knees bent (10-45 degrees, semi-squat or squat position). A schedule of increasing intensity of vibration exercise was used over time, allowing some adjustment to the patient's physical capability. Amplitude 1 was used for the first 2 weeks, then increased to amplitude 2 and further increased up to amplitude 3, if individually possible, always using frequencies between 20-25Hz. Children also perform exercises on the platform, including shifting their weight from one side to the other, increase/decrease their knee and hip angle, weight shift with trunk rotation, and alternate flexion and extension of knees.
2481078|NCT03029312|No Intervention|Regular Care|Regular Care, including physiotherapy for 5 months
3193297|NCT00816933|Active Comparator|Three ports|"Paitents will undergo three port appendectomy. 10 mm trocar is inserted on umbilicus, and two 5mm trocas is inserted low abdomen, left flank respectively.~Appendectomy is performed vis these trocas. After operation, wounds are repaired."
3193298|NCT00816946|No Intervention|Routine LHW Advice|Arm receiving routine advice by their local Lady Health Workers (LHWs)
3193299|NCT00816946|Active Comparator|Enhanced LHW Advice|Arm receiving enhanced nutrition and health advice from the local Lady Health Workers (LHWs)during their routine community visits.
3193300|NCT00816959|Active Comparator|Arm I: R-mabHDI and ABVD|
3193301|NCT00816959|Active Comparator|Arm II: ABVD|
3193302|NCT00816972|Active Comparator|DL 2.5 mg|Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
3193303|NCT00816972|Active Comparator|OXY 5 mg|Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
2481230|NCT03028376||Moderate TBI patients|GCS 9-13
3193304|NCT00816972|Experimental|DL 2.5 mg + OXY 2.5 mg|Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
3193305|NCT00816972|Experimental|DL 2.5 mg + OXY 5 mg|Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
2481305|NCT03027830|Experimental|iFR pressure-wire|
3193306|NCT00816972|Placebo Comparator|Placebo|Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
3193307|NCT00816985|Experimental|Liposuction + Questionnaires|Liposuction, followed by Quality of Life Questionnaires and extended follow-up period.
2480952|NCT03030092|Experimental|Intervention group|Maximal Strength Training
3193308|NCT00816998|Other|Early|Participants randomized to this arm will begin physical therapy of their fractured wrist approximately one week following surgery
2481113|NCT03028857|Placebo Comparator|Participants will take placebo|Participants will take placebo. Corn oil every day in place of choline
2481115|NCT03028857|Active Comparator|Drug: Choline|Participants will take 4500 mg of phosphatidylcholine twice per day, the equivalent of approximately 1250 mg of choline per day until delivery
2481156|NCT03028701|Experimental|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
2481226|NCT03028532|Experimental|Clomid|All participants will be receiving Clomid and will follow the same study procedures.
2481279|NCT03027973|Experimental|UPA Treatment Group|UPA 5mg capsule daily + Placebo 2 capsules 4 times a day
2481283|NCT03027973|Active Comparator|TEA Treatment Group|TEA 500mg 2 capsules 4 times a day + Placebo 1 capsule daily
2481344|NCT03027544|Experimental|experimental arm|"Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.~Intervention：tomotherapy"
2481388|NCT03027102|Experimental|Patient Arm|Patients will receive DNT cells from healthy donors.
2481389|NCT03027102|No Intervention|Donor Arm|Healthy volunteer donors will donate blood.
2481440|NCT03026855|Experimental|Autologous PRP Gel and PRP Injection|Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.
2481478|NCT03026543|Experimental|Pulmonary recruitment maneuver|One minute of ventilator-piloted PRM at the end of laparoscopic cholecystectomy, intending to remove residual carbon dioxide (CO2) from the abdomen.
2481481|NCT03026543|Active Comparator|Control group|Ordinary ventilation at the end of laparoscopic cholecystectomy.
2481527|NCT03026140|Active Comparator|group 1|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV)
2481532|NCT03026140|Experimental|group 2|drug: ipilimumab 1 mg/kg day 1 (IV) drug: nivolumab 3 mg/kg on day 1 and day 15 (IV) drug: celecoxib 200 mg daily (oral)
2481573|NCT03025750|Experimental|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
2481575|NCT03025750|Active Comparator|IPV SSI|IPV SSI contains the full dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. Each subject randomised to this group will receive a total of three primary injections - one at 2 months, 4 months and 6 months of age.
2481648|NCT03025490|No Intervention|standard of Care|Patient undergoing sedation, treatment team does not have capnography data available.
2481650|NCT03025490|Experimental|Capnography|Patient undergoing sedation, treatment team does have capnography data available.
2481826|NCT03024229|Other|LifePort® perfusion machine|Metabolomic analysis of the preservation fluid of the graft, donor and recipient urine by nuclear magnetic resonance spectroscopy, and if possible by liquid and gas chromatography coupled with mass spectrometry.
2481854|NCT03023852|Experimental|Panel 1: Group 1|Participants will receive Treatment A (JNJ-63623872 600 milligram (mg) (2*300 mg) oral tablets [reference]) followed by Treatment B (JNJ- 63623872 600 mg (2*300 mg) concept oral tablet formulation 1 (test 1) and then Treatment C (JNJ-63623872 600 mg (2*300 mg) concept oral tablet formulation 2 (test 2). Each treatment period will be separated 7 days washout period.
2481855|NCT03023852|Experimental|Panel 1: Group 2|Participants in Group 2 will receive Treatment A followed by Treatment C and then Treatment B with a washout period of minimum 7 days.
2481856|NCT03023852|Experimental|Panel 1: Group 3|Participants in Group 3 will receive Treatment B followed by Treatment A and then Treatment C with a washout period of minimum 7 days.
2481857|NCT03023852|Experimental|Panel 1: Group 4|Participants in Group 4 will receive Treatment B followed by Treatment C and then Treatment A with a washout period of minimum 7 days.
2481858|NCT03023852|Experimental|Panel 1: Group 5|Participants in Group 5 will receive Treatment C followed by Treatment A and then Treatment B with a washout period of minimum 7 days.
2481859|NCT03023852|Experimental|Panel 1: Group 6|Participants in Group 6 will receive Treatment C followed by Treatment B and then Treatment A with a washout period of minimum 7 days.
2481860|NCT03023852|Experimental|Panel 2: Group 7|Participants in Group 7 will receive Treatment D [JNJ-63623872/37.5 mg Oseltamivir oral fixed dose combination (FDC) tablet concept formulation (test 3)] followed by Treatment E (JNJ-63623872 600 mg, administered as 2*300 mg and Oseltamivir 75 mg, administered as 1*75 mg). Both treatment periods will be separated with a minimum of 7 days washout period.
2481861|NCT03023852|Experimental|Panel 2: Group 8|Participants in Group 8 will receive Treatment E followed by Treatment D with a washout period of minimum 7 days.
2481896|NCT03023514|Experimental|ALA + P|Oral alpha-lipoic acid + vaginal Progesterone
2481898|NCT03023514|Active Comparator|P|vaginal Progesterone
2482034|NCT03023202||PMMTB|"This study of the PMMTB will include all patients >= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor.~All standard of care functions will be performed by standard procedures."
2482139|NCT03021928|Experimental|60 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2482142|NCT03021928|Experimental|132 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2482144|NCT03021928|Experimental|228 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2480958|NCT03029949|Active Comparator|Self-treatment VR|self-treatment vestibular rehabilitation in addition to clinical management
3193309|NCT00816998|Other|Delayed|Participants randomized to this group will begin physical therapy of their fractured wrist approximately 6 weeks from their surgery. This is the approximate time frame in which therapy begins for patients not involved in the study. The term Delayed refers to therapy being delayed in starting from those in the study who begin therapy at one week post-operatively, not a delay in current care practice.
3193310|NCT00817011|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine, citalopram or sertraline
3193311|NCT00817011|Active Comparator|non-SSRI treated group|non-SSRI treated group are depressive patients treated with venlafaxine, nortriptyline, bupropion, duloxetine, trazodone or mirtazapine
3193312|NCT00817024|Experimental|Xuefu Zhuyu Capsules|
3193313|NCT00817024|Active Comparator|Sheng Mai Capsules|
2481173|NCT03028688|No Intervention|Current standard of care|Participants in the current standard of care will receive the usual anesthesia care for upper GI endoscopy. In addition participants will have transcutaneous PCO2 measurements performed.
2481175|NCT03028688|Experimental|High flow nasal cannula group|Participants in the high flow nasal cannula group will receive high flow nasal cannula oxygen and will also have transcutaneous PCO2 measurements performed.
2481203|NCT03028454|Experimental|Ginger Root Capsule|
2481206|NCT03028454|Placebo Comparator|Placebo Capsule|
2481277|NCT03028116|Active Comparator|Allantoic split inactivated seasonal influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
2481281|NCT03028116|Placebo Comparator|Placebo|Water for Injection
2481329|NCT03027687|Experimental|Real transcranial Direct Current Stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for three days in one week.
2481332|NCT03027687|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
2481394|NCT03027167|Active Comparator|Aspirin and MCDs|ASA with MCDs- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will receive MCDs for a period of 10 days post-surgery. ASA 325mg BID will be prescribed for a period of 6 weeks.
2481395|NCT03027167|Experimental|Aspirin only|ASA only- Patients will receive MCDs intraoperatively and during the immediate post-operative recovery period, and will NOT receive MCDs after being discharged from hospital. ASA 325mg BID will be prescribed for a period of 6 weeks.
3193314|NCT00817024|Placebo Comparator|Placebo|
2481535|NCT03026270|Other|seven layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
2481537|NCT03026270|Other|ten layers|Volunteers will be submitted to the application of seven layers therapy paraffin surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded. .The Application will be made with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide)
2481604|NCT03025906|Experimental|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
2481607|NCT03025906|Experimental|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
2481655|NCT03025204|Active Comparator|GAP Surgical Access (GAP + OFD, 15 patients)|Patients diagnosed with generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive will receive open flap debridement.
2481657|NCT03025204|Experimental|GAP Surgical Access + EMD (GAP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized aggressive periodontitis (GAP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
2481658|NCT03025204|Active Comparator|GCP Surgical Access + EMD (GCP + OFD/EMD, 15 patients)|Patients with a diagnosis of generalized chronic periodontitis (GCP), in which the previously selected intrabony defect will receive open flap debridement and, in addition, application of the EMD in the defect.
2481691|NCT03024879|Active Comparator|Erythromycin|40 mg of erythromycin will be administered intravenously over a period of 20 min in a saline solution of 100 ml
2481703|NCT03024879|Placebo Comparator|Placebo|a saline solution of 100 ml will be administered intravenously over a period of 20 min
2481759|NCT03024645|Experimental|BeAMom|High-risk (HR) women will receive a web-based preventive intervention for PPD (the Be a Mom program). In addition, women will receive postpartum and and pediatric treatment as usually performed in primary care settings (TAU).
2481763|NCT03024645|Active Comparator|Control|High-risk (HR) women will receive postpartum and pediatric treatment as usually performed in primary care settings (TAU). During medical appointments, health professionals may ask women and provide information about psychological problems during the postpartum period.
2481822|NCT03024151|Active Comparator|T4/T3 combination replacement|Comthyroid
2481830|NCT03024151|Active Comparator|T4 mono replacement|Synthroid
2481888|NCT03023839||Severe trauma patients|Severe Trauma patients (ISS >15) admitted to Intensive Care Unit (ICU)
2482004|NCT03022942|Experimental|Costal mobilization & Diaphragm Release|Costal mobilization. Lying: two sets of ten deep respiratory cycles with one minute interval between sets. Sitting: two series with interval of one minute between them. Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
2482005|NCT03022942|Active Comparator|Manual Diaphragm Release|Manual Diaphragm Release Technique: will be applied during two series of ten deep respiratory cycles, with one minute interval between sets.
2482087|NCT03022500|Experimental|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
2510497|NCT02827786|Experimental|Electromagnetic Acoustic Imaging|
3193315|NCT00817037|Experimental|Sitaxsentan|"Once daily oral sitaxsentan 100mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
2480986|NCT03029741|Experimental|Bioavailability of AZD0284|"To assess the absolute bioavailability of a single oral dose of AZD0284 in healthy subjects.~To assess the pharmacokinetics (PK) of a single intravenous (IV) microdose of [14C]AZD0284 in healthy subjects."
2481030|NCT03029507|Experimental|ACT enhanced ShipShape (ACT +SS)|"The ACT+SS intervention will be delivered in 8 1.5-hour weekly group sessions. The ACT~+SS protocol integrates ACT concepts and strategies within the existing standard SS protocol."
2481040|NCT03029507|Active Comparator|Standard ShipShape (SS)|Standard ShipShape (SS) The standard SS-only protocol will be delivered in 8 1.5-hour weekly group psychoeducation sessions.
3158841|NCT00393952|Active Comparator|3|Fluticasone 250
3158842|NCT00393952|Active Comparator|4|Formoterol 10
2481273|NCT03027934|Active Comparator|Group 1|
2481274|NCT03027934|Active Comparator|Group 2|
2481414|NCT03026920|Experimental|clinical outcome|Less invasive method was applied to pelvic or acetabular fracture of old people. Thus, the clinical outcome of Pelvic or acetabular fractures in old man was assessed.
2481467|NCT03026686||readmit|women who were re-admitted in the post partum period for a hypertensive disorder
2481468|NCT03026686||Controls|women with similar risk factors but did not require readmission
2481637|NCT03025607|No Intervention|Control|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight.
2481639|NCT03025607|Experimental|JOOL-Only|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, and will receive the JOOL Health mobile phone application.
2481641|NCT03025607|Experimental|JOOL-Plus|Participants in this group will receive information on prediabetes and evidence-based ways to decrease progression to diabetes, a list of resources for mHealth tools to monitor diet, physical activity and weight, the JOOL Health mobile phone application, a digital scale, and a Fitbit.
2481723|NCT03024996|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (q3w) for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
2481726|NCT03024996|Placebo Comparator|Placebo|Participants will receive placebo matching to atezolizumab q3w for 16 cycles (each cycle=21 days) or 1 year (whichever occurs first).
2481849|NCT03023943|Experimental|IASTM group|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
2481891|NCT03023605|No Intervention|Pre-intervention PE Diagnosis|Patients visited in Emergency Department, with suspected Pulmonary Embolism, before the training intervention.
2481892|NCT03023605|Experimental|Post-intervention PE Diagnosis|"Patients visited in Emergency Department, with suspected Pulmonary Embolism, after the training intervention.~Training intervention centered on emergency department staff, regarding the application of clinical probability scores (Wells and Geneva scores) to guide the determination of D-dimer and the performance of pulmonary CT in patients with suspected pulmonary embolism."
2481925|NCT03023267|Experimental|Interventional|Applying music therapy with kangaroo care to mothers and fathers during their NICU hospitalization
2481928|NCT03023267|Active Comparator|Control|Applying only Kangaroo care to mothers and fathers during their stay in the NICU
2481967|NCT03023020|Other|Abbreviated antiplatelet regimen|"Dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and a single antiplatelet agent is continued until at least 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, dual antiplatelet therapy is discontinued immediately after randomization (i.e. 1 month post stent implantation), and either Aspirin or Clopidogrel is continued until 5 months post randomization (i.e. 6 months post stent implantation). Oral anticoagulation is continued until at least 11 months post randomization (i.e. 12 months post stent implantation)"
2481968|NCT03023020|Other|Prolonged antiplatelet regimen|"Aspirin is continued for at least 11 months post randomization (i.e. 12 months post stent implantation), the P2Y12 inhibitor being taken at the time of randomization is continued for at least 5 months and up to 11 months post randomization (i.e. 12 months post stent implantation).~In patients on oral anticoagulants, aspirin and Clopidogrel are continued for at least 2 months post randomization (i.e. 3 months post stent implantation) and up to 11 months post randomization (i.e. 12 months after stent implantation). Either aspirin or Clopidogrel is continued up to 11 months post randomization (i.e. 12 months post stent implantation)"
2482194|NCT03021382||severity of calcification|All vessels were divided into tertile groups according to the severity of coronary calcification evaluated by the Agatston score.
2482213|NCT03021382||minimal lumen diameter (MLD) ≥1.0 mm|All lesions were divided according to an MLD ≥1.0 mm, and <1.0 mm by OCT in order to isolate the lesions which an MLD below the OCT catheter size.
2482260|NCT03021148||High-school children|"High-school children, age range from 13 to 18 years, from Liceo Classico and Liceo Artistico Tommaso Fazello of Sciacca, Agrigento, Italy"
3158843|NCT00393952|Placebo Comparator|5|Placebo
3158844|NCT00393991|Experimental|1|FlutiForm 100/10 μg
3158845|NCT00393991|Active Comparator|2|Fluticasone 100 μg
3158846|NCT00393991|Active Comparator|3|Formoterol 10 μg
3158847|NCT00393991|Placebo Comparator|4|Placebo
3158848|NCT00394017|Active Comparator|Intervention group|Reminder letters and usual implementations vs. usual implementation
3158849|NCT00394017|No Intervention|Control group|usual implementations
3158850|NCT00394030|Experimental|Group A|In Group A healthy subjects will be randomized to receive 16 milligram (mg) of GSK716155 to abdomen.
3158851|NCT00394030|Experimental|Group B|In Group B healthy subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
3158852|NCT00394030|Experimental|Group C|In Group C Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to abdomen.
3158853|NCT00394030|Experimental|Group D|In Group D Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to arm.
3158854|NCT00394030|Experimental|Group E|In Group E Type II diabetes subjects will be randomized to receive 16 mg of GSK716155 to leg.
3158855|NCT00394030|Experimental|Group F|In Group F Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to abdomen.
3158856|NCT00394030|Experimental|Group G|In Group G Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to arm.
2481072|NCT03029429|Experimental|Theophylline|Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)
2481075|NCT03029429|Placebo Comparator|Placebos|Theophylline capsule by mouth once daily or Theophylline elixir by mouth q6h
2481099|NCT03028961|Experimental|Group I (Stanford Letter, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the Stanford Letter and complete and return the form by the day of BMT. After completion of the Stanford Letter, patients undergo a semi-structured, research staff-led interview to evaluate personal perceptions of uncertainty with end-of-life decisions, understanding of the ACP form received, and satisfaction with the ACP form.
2481103|NCT03028961|Active Comparator|Group II (traditional advance directive, interview)|Patients listen to a dialogue on the purpose of ACP. Patients receive a paper copy and online web link to the CA Advance Health Care Directive Form and complete and return the form by the day of BMT. After completion of the CA Advance Health Care Directive Form, patients undergo interview as in Group I.
2481163|NCT03028675||Multiple Sclerosis|
2481165|NCT03028675||Healthy Volunteer|10 age-matched control volunteers
3158857|NCT00394030|Experimental|Group H|In Group H Type II diabetes subjects will be randomized to receive 64 mg of GSK716155 to leg.
2481462|NCT03026725|Experimental|Tri-calcium Phosphate|clinpro tooth creme, i.e. Tri-calcium Phosphate, for 30 min/day after bleaching 4h with carbamide peroxide 20%
2481464|NCT03026725|Placebo Comparator|Placebo|a placebo creme will be applied for 30 min/day after bleaching 4h with carbamide peroxide 20%
2481530|NCT03026296|Experimental|Participators in HLCs|Adults with high risk of non-communicable diseases (musculoskeletal disease, obesity, physical distress) about to start a 3 months structural support for lifestyle change in a Healthy Life Center (HLC) in Norway
2481577|NCT03025880|Experimental|Single arm|"Eligible patients will be enrolled and treated with Pembrolizumab (P) at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle in combination with Gemcitabine (G) at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with P in the initial exploratory run-in-phase if necessary) as a IV infusion on day 1 and 8 of each 21-day cycle.~Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of G in combination with fixed doses of P."
2481623|NCT03025347|Experimental|Control|Experimental day where participants rest.
2481627|NCT03025347|Experimental|Exercise|Experimental day where participants complete a run.
2481775|NCT03024762|Experimental|Intervention arm|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
2481780|NCT03024762|No Intervention|Control arm|The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
2481824|NCT03024125|Experimental|High protein diet (HP)|Diet with 1.2 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
2481828|NCT03024125|Placebo Comparator|Normal protein diet (NP)|Diet with 0.8 protein g/kg body mass/day for postmenopausal women practitioners of resistance exercise. The physical strength training will be performed equally by both groups
2481880|NCT03023761|Active Comparator|low level laser|A single visit Endodontic retreatment was done. After biomechanical preparation, Low Level Laser was irradiated to the buccal and lingual mucosa overlying the apices of the target tooth in the experimental group
2481885|NCT03023761|Placebo Comparator|laser sham|In the control group patients received placebo laser to eliminate the probable psychological effects of laser.
2481939|NCT03023345|Experimental|Microwave|Microwave trans rectal focal treatment
2481996|NCT03022864||Chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain more than 3 points according the Numerical Rating Scale, then it can be considered that the patient has chronic pain.
2482003|NCT03022864||No chronic pain|Follow up the patients for three months after surgery using the designed table. If the patient evaluate the pain no more than 3 points according the Numerical Rating Scale, then it can be considered that the patient doesn't have chronic pain.
2482032|NCT03022578|Experimental|Treatment (LITT, lomustine)|Patients undergo LITT at baseline and receive lomustine PO on day 1. Treatment with lomustine repeats every 42 days for up to 6 cycles in the absence of disease progression or unaccepted toxicity.
2482153|NCT03021928|Experimental|324 hours|Time to delay the initiation of anticoagulation is determined at randomization. The Time-To-Treatment Randomization of 60 hours correlates to starting treatment on Day 3, 132 hours starts on Day 6, 228 hours starts on Day 10, and 324 hours starts Day 14.
2510501|NCT02827760|Placebo Comparator|Maltodextrin DE19|Placebo
3158858|NCT00394043|Experimental|Osteopathic Manipulative Treatment|A protocol of specific osteopathic manipulative techniques was applied.
3158859|NCT00394043|Placebo Comparator|Placebo ultrasound|Sub-therapeutic ultrasound was applied.
3158860|NCT00394043|No Intervention|Standard Medical care|Subjects did not receive either study treatment, but continued to receive standard medical care.
3158861|NCT00394056|Other|Period 1|
3158862|NCT00394056|Other|Period 2|
3158863|NCT00394056|Other|Period 3|
3158864|NCT00394069|Experimental|Montelukast sodium|Participants receive montelukast sodium for 14 days.
3158865|NCT00394134|Other|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
3158866|NCT00394173|Experimental|1|
3158867|NCT00394173|Placebo Comparator|2|
2481019|NCT03029520|Active Comparator|pain AHPlus Devital Pulp|Evaluation of Postoperative pain after root canal obturation with AH Plus sealer (Dentsply Maillefer, Ballaigues, Switzerland) with patients who has (mandibular premolar/molar) devital pulp.
2481089|NCT03029299|No Intervention|Control|Subjects receive standard of care testing as determined by the clinician.
2481091|NCT03029299|Experimental|Intervention|Subjects are tested using the FilmArray RP EZ and the results are provided to the clinician for use in determination of patient care (along with any other clinician-ordered testing)
2481100|NCT03028922|Other|creos xenogain|Patients in need of bone augmentation prior to implant insertion will undergo GBR procedure using Creos xenogain bone graft substitute
2481160|NCT03028727|Active Comparator|Ultrasonic Scaling, Root planing|Ultrasonic Scaling and Root planing at day 0 and at 1 week.
2481161|NCT03028727|Experimental|980 nm diode Laser irradiation|Irradiation of periodontal pockets with with 980 nm diode Laser after scaling and root planing at day 0 and after 1 week.
2481213|NCT03028493|Experimental|Adapted SAFE Intervention|Adapted version of the SAFE Health Behavior and Exercise intervention.
2481217|NCT03028493|Active Comparator|Original SAFE Intervention|Original version of the SAFE intervention.
2481275|NCT03028077|Experimental|GS-3K8|GS-3K8 (6 cap/day, 500 mg/cap) for 12 weeks
2481278|NCT03028077|Experimental|GINst15|GINst15 (6 cap/day, 500 mg/cap) for 12 weeks
2481284|NCT03028077|Placebo Comparator|Placebo|Placebo for 12 weeks
2481339|NCT03027648|Other|patients with LNG-IUS|Placement of levonorgestrel-releasing intrauterine system
2481392|NCT03027206|Experimental|Vibration technique|Rhythmic and rapid movements of isometric contraction of the forearm, applied manually over the anterior region of the thorax
2481393|NCT03027206|Experimental|Acceleration of expiratory flow|Soft compression of the thorax applied with one hand on the lower ribs and the other using the ulnar border on the supramammary line
3158868|NCT00394199|Experimental|1|FlutiForm 100/10ug
2481517|NCT03026465|Experimental|Coroflex ISAR stent|PCI with a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR stent) with very thin struts (50 µm). During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
2481519|NCT03026465|Active Comparator|Biomatrix stent|PCI with a biodegradable-polymer biolimus-eluting stent (Biomatrix stent) with 120 µm struts. During the PCI, an OCT assessment (baseline and post-implantation) will be performed.
2481615|NCT03025594|Experimental|Gonyautoxin|Gonyautoxin 40mcg
2481617|NCT03025594|Active Comparator|Control|Mix of chirocaine 0,2%, ketorolac and epinephrine..
2481651|NCT03025139|Active Comparator|Arm A (MAPs)|Patients attend a mindfulness meditation class over 2 hours once weekly for 6 weeks. Patients then attend in person booster sessions that include guided meditation, questions, and discussion of how to maintain a mindfulness practice over 1 hour once monthly for 2 months.
2481652|NCT03025139|Active Comparator|Arm B (SE)|Patients attend a survivorship education class over 2 hours once weekly for 6 weeks. Patients also receive monthly electronic newsletters with tailored information about topics of interest to younger survivors, including cancer-related events in the community and tips about following through on recommendations for healthy living.
2481653|NCT03025139|Active Comparator|Arm C (USUAL CARE/DELAYED TREATMENT CONTROL GROUP)|Patients receive usual care for 9 months. Patients are then offered a choice of participating in Arm A or Arm B.
2481684|NCT03024866||Electronic Brachytherapy|Previously completed treatment for non-melanoma skin cancer using Xoft eBx Electronic Brachytherapy System
2481697|NCT03024866||Mohs Surgery|Previously completed treatment for non-melanoma skin cancer using Mohs Surgery
2481915|NCT03023436|Experimental|CRS + HIPEC + Systemic Chemotherapy|"Cytoreductive surgery(CRS) followed by Hyperthermic Intraperitoneal Chemotherapy(HIPEC) and systemic chemotherapy will be performed for the treatment of patients assigned to this group.~CF regimens or other first line regimens based on Fluoropyrimidine and Cisplatin according to the National Comprehensive Cancer Network（NCCN） Guidelines （Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial."
2481961|NCT03023059|Experimental|Escalating dose of carbidopa-levodopa|The intervention is that patients will receive open label, commercially available Carbidopa-Levodopa 25 Mg-100 Mg oral tablet, once daily hs for one month, followed by one tablet dosed three times daily, in the morning, with supper and hs for one month, followed by two tablets dosed three times daily, in the morning, with supper and hs for one month (100-600 mg of levodopa daily). This is the equivalent of very low to moderate doses of carbidopa-levodopa in patients with Parkinson's disease (daily dose of levodopa 200-800 mg).
2482007|NCT03022812|Active Comparator|Exercises at a physiotherapy clinic|Neck-specific exercise at a physiotherapy clinic, 24 times during 12 weeks (plus an additional first visit).
2482008|NCT03022812|Experimental|Exercises with Internet support|Neck-specific exercise with Internet support combined with 3 visits at a physiotherapy clinic (plus an additional first visit), exercises mainly performed outside the health care system during 12 weeks.
2482080|NCT03022474|Experimental|Intervention group|
2482085|NCT03022474|No Intervention|Control group|
2482156|NCT03022032|Experimental|Comparing Steps Collected by Accelerometer (HOPE)|"10 patients will be enrolled in stage 1 to refine the HOPE App intervention~All participants will receive :~HOPE App~The Fitbit Zip~The Fitbit Charge 2 The amount of step collected by each device will be compared. This will allow the team to identify which wearable accelerometer to use in stage 2"
2482158|NCT03022032|Other|Usual care (HOPE)|"Stage 2 will consist of arm 2-5 and will enroll 100 randomized patients.~Usual care~The app will also collect passive data from the smartphone"
2482160|NCT03022032|Experimental|Wearable accelerometer (HOPE)|"Participants will be asked to wear the Fitbit~The Hope App will measure daily steps~The app will also collect passive data from the smartphone"
2482163|NCT03022032|Experimental|Refined smartphone app (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~The app will also collect passive data from the smartphone"
2483610|NCT03012360|Placebo Comparator|no antibiotic treatment for VAT|3 days of placebo
3158869|NCT00394199|Experimental|2|Fluticasone 100
2481199|NCT03028272|Active Comparator|Fascia|Autologous donor substrate
2481200|NCT03028272|Experimental|Skye Barrier|Amniotic membrane allograft
2481251|NCT03028155|Active Comparator|Oxaliplatin: BSA-based HIPEC|Intervention: oxaliplatin: BSA-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution during 30 minutes. Volume of the carrier solution: depended on the capacity of the abdominal cavity of the patient.
2481253|NCT03028155|Active Comparator|Oxaliplatin: Concentration-based HIPEC|Intervention: oxaliplatin: concentration-based HIPEC HIPEC will be performed using oxaliplatin as chemotherapeutic agent at a dose of 460 mg/m2 mixed in 0.9% saline carrier solution at 2L/m2, which equals a concentration of 230 mg/L during 30 minutes.
2481310|NCT03027765||Egyptian children|"Population1:~Egyptian children with constructed space maintainers at Cairo University."
2481311|NCT03027765||Pediatric dentists|"Population2:~Pediatric dentists at Cairo University."
2481402|NCT03027154|Experimental|TB subjects in 5-18 years old|24 cases TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2481404|NCT03027154|Experimental|non-TB subjects in 5-18 years old|24 cases non-TB subjects in 5-18 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2481405|NCT03027154|Experimental|TB subjects under 5 years old|24 cases TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2481407|NCT03027154|Experimental|non-TB subjects under 5 years old|24 cases non-TB subjects under 5 years old are injected ESAT6-CFP10 in left arm and TB-PPD in right arm or ESAT6-CFP10 in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2481483|NCT03026712|Experimental|Real tDCS|
2481487|NCT03026712|Sham Comparator|Sham tDCS|
2481582|NCT03025620|Placebo Comparator|Sunflower arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of sunflower oil (with a high content in linoleic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with sunflower oil (60% fat) that replaced butter on the breakfast toasts.
2481583|NCT03025620|Active Comparator|Rapeseed arm|Participants were supplied with the usual diet of the hospital, daily enriched with 17.5g fat as follows during 42 days: 10 g of rapeseed oil (with a high content in alpha-linolenic acid) were added into the dinner soup and 7.5g delivered through a 12.5g portion of margarine made with rapeseed oil (60% fat) that replaced butter on the breakfast toasts.
2481649|NCT03025386|Other|Adult cochlear implant users|Evaluation of a concordance between the mismatch negativity amplitude mesured by electroencephalography and the capacity of logatoms discrimination by using a logatoms test
2481687|NCT03024944|Experimental|Brain Imaging with 18F-THK-5351|This group consists of 30 adult subjects: 10 with Type 2 diabetes, 10 with pre-diabetes, and 10 with normal glucose tolerance. Each subject will receive a baseline scan and a follow-up PET scan with 18F-THK-5351.
2481760|NCT03024658|No Intervention|Zero PEEP|This group of patients did not receive any PEEP at the time of induction of general anesthesia (n= 30)
2481768|NCT03024658|Experimental|PEEP- 10 cm of H2O|This group comprised of patients who received a PEEP of 10 cm H2O at the time of induction of general anesthesia (n= 30)
2481808|NCT03024216|Experimental|Arm 1|Atezolizumab1200 mg IV week 1 and week 4 followed by Sipuleucel-T administered weeks 6, 8, and 10
2481814|NCT03024216|Experimental|Arm 2|Sipuleucel-T administered week 1, 3, and 5 followed by Atezolizumab1200 mg IV weeks 7 and 10
2481879|NCT03023696|Experimental|Foraminotomy Group|Prophylactic bilateral cervical keyhole foraminotomy will be done in addition to their decompression surgery
2481884|NCT03023696|Active Comparator|Control Group|Cervical decompression will be done without prophylactic bilateral foraminotomy
2481953|NCT03023280||Patients undergoing radio frequency ablation|Patients undergoing radio frequency for large symptomatic heterotypic gastric mucosa
3158870|NCT00394199|Active Comparator|3|Formoterol 10
2482019|NCT03022669|Experimental|Text Message Group|"The TM group will use the VA Annie text messaging program to remind patients to take antiplatelet medications. The content for the text messages will be determined through preliminary focus groups that will be conducted prior to the RCT."
2510514|NCT02827552|Other|ARPEGE BioM|N/A (not a randomized study)
3158871|NCT00394290|Experimental|PPC|Night time device for positive pulmonary pressure
3158872|NCT00394303|Experimental|1|Intervention
3158873|NCT00394303|No Intervention|2|Control
3158874|NCT00394381|Experimental|CIK infusion|Infusion of autologous CIK cells in study group. There is only one arm to this study
3158875|NCT00394407|Active Comparator|sliding scale regular insulin|sliding scale insulin given acqhs
3158876|NCT00394407|Active Comparator|glargine insulin and glulisine insulin|glargine basal insulin once a day with prandial glulisine insulin tid
3158877|NCT00394459|Active Comparator|A|Perifix Standard
3158878|NCT00394459|Experimental|B|Perifix New
3173493|NCT00612664|Active Comparator|Arm 1|0.1 mg/kg every 3 weeks
2481039|NCT03029845|Active Comparator|propranolol 2|10 mg propranolol twice a day
2481041|NCT03029845|Placebo Comparator|Placebo|Placebo twice a day
2481136|NCT03029169|Active Comparator|Propafenone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 35-70 mg intravenous propafenone followed by continuous infusion of 400-840 mg/24h."
2481138|NCT03029169|Active Comparator|Amiodarone i.v.|"Patients in septic shock with a new onset supraventricular arrhythmia are randomized either to arm treated with propafenone or with amiodarone. Both arms will have standard treatment, there are no limits to indicated electric cardioversion as part of treatment.~Intervention: Bolus of 150-300 mg of intravenous amiodarone followed by continuous infusion of 600-1800 mg/24h."
2481227|NCT03028571|Placebo Comparator|Intact Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of saline at 48 ml/hr IV
2481234|NCT03028571|Experimental|Blocked Day|The rates of endogenous glucose appearance (Ra) and peripheral glucose uptake (Rd) will be measured during a regular insulin clamp with concomitant infusion of trimethaphan (4mg/min) IV.
2481291|NCT03027986|Experimental|postural rehabilitation program based on sensory-motor control|
2481297|NCT03027986|No Intervention|Standard physiotherapy|
2481345|NCT03027570|Experimental|Control|Five-month program at two centers for the treatment of overweight children.
2481352|NCT03027570|Experimental|Exergame activity_EXG|Adding an exergame activity application to the regimen at a center for the treatment of overweight children.
2481428|NCT03027024|Experimental|IOL Implantation|Implantation of IOL: PhysIOL POD F GF
2481545|NCT03026049|Active Comparator|deep venous stent|Patients will receive deep venous stenting in the iliaco(femoral) region
2481549|NCT03026049|No Intervention|conservative managment|Conservative management of complaints
2481618|NCT03025568|Active Comparator|group 1|Patient will receive partial denture constructed from Bre_flex
2481620|NCT03025568|Experimental|group 2|Patients will receive removable partial denture constructed from PEEK
2481679|NCT03025178|Experimental|Central venous catheterization|Central venous catheterization will be performed using 4Fr central venous catheter at left internal jugular vein in infant. The tip of central venous catheter will be confirmed by transthoracic echocardiography. The actual insertion depth of central venous catheter will be compared to the predicted insertion depth derived from two calculation methods using height and the distance between the anatomical landmarks.
2481783|NCT03024775|Active Comparator|Active Comparator 1|Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
2481784|NCT03024775|Active Comparator|Active Comparator 2|Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.
2481785|NCT03024775|Placebo Comparator|Placebo 1|Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.
2481788|NCT03024775|Placebo Comparator|Placebo 2|Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.
2481801|NCT03024008|Experimental|Intervention Arm|"Clinical Interventions:~Blood tests: complete blood count, full blood chemistry and biochemistry including phosphate, alkaline phosphatase, calcium, renal and liver function, and coagulation. Serology tests: HIV, Hepatitis B, Hepatitis C.~Xray~Urine Test~CT~Liposuction - harvest of 50-300ml autologous adipose tissue from the subject's abdomen~Single transplantation of Investigational Medicinal Product BonoFill-II into long bone extra-articular comminuted fracture or large bone defect/critical gap"
3193316|NCT00817037|Placebo Comparator|Placebo|"Once daily oral placebo tablet given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
3193317|NCT00817037|Active Comparator|Nifedipine|"Open labeled active comparator~Once daily oral nifedipine 30mg given over a period of 6 weeks.~24hr proteinuria, 24hr blood pressure and arterial stiffness measured at day 1, week 3 and week 6 of treatment"
2481938|NCT03023241|Experimental|all study patients|Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.
2481980|NCT03022890|Experimental|Hatha yoga|12 weeks of hatha yoga classes, once per week
2481981|NCT03022890|Placebo Comparator|Health education|12 weeks of health education classes, once per week
2482011|NCT03022643|No Intervention|Pain Patients|40 Pain Patients will be screened for social and behavioral rhythms with no treatment involved. All patients will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
2482013|NCT03022643|No Intervention|Controls|40 Controls will be screened for social and behavioral rhythms with no treatment involved. All Controls will be evaluated an Actigraph by Philips for 8-days to assess sleep and activity.
2482020|NCT03022643|Experimental|Treatment|10 patients from the original 40 will receive Interpersonal Social Rhythms Psychotherapy and Bright Light Device therapy to improve social and behavioral rhythms.
3193318|NCT00817050|Active Comparator|Nasonex Followed by Flonase|
3193319|NCT00817050|Active Comparator|Flonase Followed by Nasonex|
2482198|NCT03021356|Active Comparator|Trifecta aortic xenograft|The Trifecta aortic xenograft is implanted in these patients.
2482211|NCT03021356|Active Comparator|Magna Ease aortic xenograft|The Magna Ease aortic xenograft is implanted in these patients.
2482252|NCT03021161|Experimental|intervention group|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019 (probiotic formula).
2482266|NCT03021161|Placebo Comparator|Placebo Oral Capsule|The control group will receive once daily similar capsules containing placebo.
2483862|NCT03010761|Experimental|medication pills 3: Placebo - Cap|placebo once daily, 8 weeks
3193320|NCT00817076|Experimental|1|
3193321|NCT00817102|Other|CorCTA|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures
3193322|NCT00817115|No Intervention|1|Subjects undergoing routine cardiac catheterization or interventional procedures using the standard fluoroscopy system.
2481053|NCT03029442|Experimental|Denosumab, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
2481059|NCT03029442|Placebo Comparator|Placebo, AIS Grade C (non-ambulatory)|8 subjects with AIS grade C will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
2481061|NCT03029442|Experimental|Denosumab, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to receive Denosumab (Prolia 120mg SC) administered at baseline and 6 months.
2481064|NCT03029442|Placebo Comparator|Placebo, AIS Grade D (ambulatory)|8 subjects with AIS grade D will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
2481145|NCT03029052|No Intervention|Control group|Medical and pharmaceutical management (at admission, during hospitalization and at discharge) will follow standard healthcare procedures of the department.
2481149|NCT03029052|Experimental|Reconciliation group|Standard healthcare procedures and pharmacist's involvement
2481184|NCT03028584||Clinicians|"Observe up to N=10 clinicians. Observations will include:~Oncology history and care plan development by clinicians including use of EHR technology to develop care plans and methods used to secure necessary information for care plan creation~Provision and coordination of survivorship care occurring during care team meetings, discussions among clinicians, and survivor visits with clinicians, especially visits in which a care plan is provided to a survivor~Clinician seeking survivorship related information or resources through use of technology or discussion with other clinicians~Survivorship work or tasks performed by the clinician including adding, modifying or extracting information from the EHR and adding or modifying information in the care plan"
2481186|NCT03028584||Clinicians and Patients|"Surveys of N=30 breast cancer, colon cancer, and prostate cancer patients. Subjects will complete 1st survey electronically in-clinic. Subjects will either be e-mailed or mailed a survey at 4 weeks.~Survey of clinicians will be sent via e-mail."
2481212|NCT03028298|Experimental|Low dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to low dose sildenafil citrate and will receive a 20mg oral dose and a subsequent 10mg intravenous dose of sildenafil citrate.
2481216|NCT03028298|Experimental|High dose sildenafil|Twelve patients with cerebral vasospasm following aneurysmal subarachnoid hemorrhage will be assigned to high dose sildenafil citrate and will receive a 60mg oral dose and a subsequent 30mg intravenous dose of sildenafil citrate.
2481341|NCT03027700|Active Comparator|Health/Normal Controls|Health/normal control subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2481347|NCT03027700|Active Comparator|F1/F2 fibrosis|Type 1 and 2 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2481350|NCT03027700|Active Comparator|F3/F4 fibrosis|Type 2 and 3 liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2481356|NCT03027700|Active Comparator|Hepatic steatosis with fibrosis|Hepatic steatosis with liver fibrosis subjects will undergo MRI using several different imaging sequences (MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer) designed to detect and quantify hepatic fibrosis.
2481421|NCT03027037||Remitted Major Depression Group|Women in this group will have experienced at least one episode of major depression in their lifetime, but no episodes in the two months prior to study enrollment.
2481425|NCT03027037||Control Group|Women in this group will never have experienced any Diagnostic and Statistical Manual of Mental Disorders, 5th Edition Axis I psychological disorder.
2481533|NCT03026179|Other|Intervention parents|Parents were asked to view 5-10 minutes of a program designed to educate about discipline.
2481603|NCT03025932||Patient cohort|Patients who underwent laparoscopic hernia repair of giant hiatal hernia with mesh and received anterior fundoplication
2481625|NCT03025321|Experimental|transcranial direct current stimulation|This group will receive bilateral tDCS (left cathodal/right anodal) over the DLPFC. The stimulation will take place two times daily for 13 minutes with a rest interval of 20 minutes for five consecutive days.
2481630|NCT03025321|Sham Comparator|Sham tDCS|The control group receives sham, for which the stimulator will be gradually turned off after 30 seconds.
2481673|NCT03025061||15 children with moderate asthma|Assessment of E-nose measurements: three E-nose measurements on 15 children with moderate asthma (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the outpatient clinic of Pediatric Allergology & Pulmonology (PAP) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (IBIM CNR).
2481676|NCT03025061||30 healthy children|"Assessment of E-nose measurements: three E-nose measurements on 30 healthy children (of both sex and 6-11 years old): first measurement, second one after 30 minutes, third one after 7 days. These children attend the primary schools involved in the municipal project Educational Pathways (Palermo)."
2481772|NCT03024801|Experimental|autologous platelet-rich plasma group|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
2481778|NCT03024801|Experimental|normal saline group|The patients with knee cartilage injury were randomized to the normal saline group.
2481813|NCT03024177|Experimental|Vapendavir 528 mg|
2481819|NCT03024177|Placebo Comparator|Placebo|
3158879|NCT00394511|Experimental|Arm I|Radiotherapy. Irradiation of the prostatic bed using megavoltage equipment with effective photon energies of greater than 4 MV.
3158880|NCT00394511|No Intervention|Arm II|No further treatment.
2482006|NCT03022877|Placebo Comparator|Placebo|Placebo is given as a Bolus (instead of Bolus application of Levosimendan) over 10 min i.v., starting 10 min before recanalization.
3158881|NCT00394550|No Intervention|control|If laryngomalacia is found, then in the control group, no supraglottoplasty will be performed. Only the tonsils and adenoids will be removed.
3158882|NCT00394550|Experimental|Treatment|"If laryngomalacia is found, then in the Treatment group, a supraglottoplasty with laser will be performed, as well as removal of the tonsils and adenoids.~Intervention: supraglottoplasty with laser"
2481079|NCT03029221||Marriage & Relationship Ed Skills-Couples|This group will receive the PREP 8.0 curriculum developed by PREP. In Years 2-5, 4 7-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Couples will receive 11 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
2481080|NCT03029221||Marriage & Relationship Ed Skills-Individuals|This group will receive the Within My Reach curriculum developed by PREP. In Years 2-5, 4 9-week class series will be held each year in Clearfield and Centre Counties (PA); 32 adults will be served each year. In Year 1, 8 adults will be served. Participants will receive 15 hours of curriculum instruction. This group will also receive two 30-minute presentations on available financial management, and job and career advancement services through two partnering organizations (CareerLink and Central PA Community Action, Inc.). Participants will also have access to optional parenting skills training provided by CAS (i.e., Triple P - Positive parenting Program). Referrals to community agencies based on individual/family needs will be provided by participant's case managers, as needed.
2481081|NCT03029221||Pre-Marital Ed and Marriage Skills|This group will receive healthy marriage and relationship education to pre-marital couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 10-hour weekend workshops will be held each year in nine central PA counties; 72 adults will be served each year. In Year 1, 24 adults will be served.
2481082|NCT03029221||Marriage Enhancement and Marriage Skills|This group will receive healthy marriage and relationship education to married couples using Within Our Reach 8 Hours curriculum developed by PREP. In Years 2-5, 9 12-hour weekend workshops will be held each year in nine central PA counties; 174 adults will be served each year. In Year 1, 60 adults will be served.
2481123|NCT03028948|Experimental|Arm I (ITW)|Patients access ITW and complete each module over 30-40 minutes. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
2481126|NCT03028948|Active Comparator|Arm II (usual care)|Patients receive usual care and are then offered ITW. All patients in Phase II complete surveys over 20-40 minutes at 8, 24, and 48 weeks.
2481424|NCT03026998|Other|MRI|
2481484|NCT03026608|Experimental|Intervention Group|Communities randomized to the intervention group receive the Veggie Van program shortly after randomization.
2481491|NCT03026608|Active Comparator|Delayed Intervention Control Group|This group will receive the Veggie Van intervention approximately 6 months after baseline data collection and randomization (after the collection of 6 months outcomes data).
2481546|NCT03026153|Other|Control group - Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
2481552|NCT03026153|Other|Intervention Group - Oral Survey 2|Oral Survey 2 will be administered as the intervention : patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
2481567|NCT03025776||stroke|individuals chronic (> 6 months) post-stroke
2481568|NCT03025776||age matched health controls|age matched (double sample size anticipated) healthy controls
2481631|NCT03025555|Active Comparator|group 1|patients will receive partial denture constructed from breflex material.
2481632|NCT03025555|Experimental|group 2|patients will receive partial denture constructed from PEEK material.
2481771|NCT03024684|Experimental|Statin|Atorvastatin 10mg oral once daily
2481776|NCT03024684|Placebo Comparator|Placebo|Matched placebo (sugar pill) once daily
2481797|NCT03024060|Experimental|ALA 20 mW|ALA + IBL 10J at 20 mW (8min 20 sec)
2481799|NCT03024060|Experimental|ALA 10 mW|ALA + IBL 10J at 10 mW (16 min 40 sec)
2481802|NCT03024060|Placebo Comparator|Vehicle|Vehicle (VEH) group will be randomized (1:1) to be balanced for the two active groups; receiving light treatment delivered at 20 mW/cm2 OR 10 mW/cm2. Subjects receiving VEH will be considered a single treatment group
2481875|NCT03023579|Experimental|The star excursion balance test|The star excursion balance test: simple test for dynamic balance
3158883|NCT00394563|Experimental|1|monoclonal antibody
3158884|NCT00394563|Experimental|2|
2481977|NCT03023007|Experimental|Loco-regional anaesthesia|Loco-regional anaesthesia Anesthesia technique used : loco-regional PECS for patients requiring Mastectomy; And/or Axillary node dissection ; And/or Reconstruction of breast by prosthesis
3158885|NCT00394563|Experimental|3|
3158886|NCT00394563|Experimental|4|
3158887|NCT00394563|Experimental|5|
3158888|NCT00394563|Placebo Comparator|placebo|
3158889|NCT00394576|Experimental|usual care plus Internet-based nutrition module|usual care plus Internet-based nutrition module
3158890|NCT00394576|Active Comparator|usual care|usual care
3158891|NCT00394602||Patients|Patients receiving chemoradiation for abdominal-pelvic tumors.
3158892|NCT00394602||Caregiver Controls|Healthy controls with no prior cancer diagnosis.
3158893|NCT00394810|Experimental|1|
3158894|NCT00394849|Experimental|suture one tonsillar fossa|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
3158895|NCT00394849|No Intervention|One side not sutured|Intervention: one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
3158896|NCT00394966|Experimental|SCH 619734 Dose 1|
3158897|NCT00394966|Experimental|SCH 619734 Dose 2|
3158898|NCT00394966|Experimental|SCH 619734 Dose 3|
3158899|NCT00394966|Experimental|SCH 619734 Dose 4|
3158900|NCT00394966|Placebo Comparator|Placebo|
3158901|NCT00394992|Active Comparator|1 oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
2481093|NCT03029377|Active Comparator|Healthy Controls|Patients between 18-60 years of age with no known conditions or prescription medications who meet preliminary screening criteria. Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function.
2481106|NCT03028844|No Intervention|Sucrose alone|"These infants will receive an oral sucrose solution (Sweetease) only prior to venepuncture"
2481109|NCT03028844|Experimental|Music intervention plus sucrose|These infants will receive both oral sucrose solution and music therapy prior to venepuncture.
2481159|NCT03028740|Experimental|Drug: Cenicriviroc|150 mg cenicriviroc
2481162|NCT03028740|Placebo Comparator|Drug: Placebo|Placebo
2481589|NCT03025633|Other|Group A - PEARL|Group A will receive a combination of verbal and visual pre-treatment information via the use of PEARL.
2481592|NCT03025633|No Intervention|Group B - NON PEARL|Group B will receive verbal only pre-treatment information.
2481685|NCT03025165|Experimental|Community Adherence Clubs|ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker to a club meeting of 20-25 HIV+ patients every three months, with two clinic visits every year for clinical review and laboratory monitoring
2481699|NCT03025165|Experimental|Home-Based ART Delivery|Individuals receive ART adherence support, symptom screening and dispensation of pre-packed medications by community health worker at their household every three months, with two clinic visits every year for clinical review and laboratory monitoring
2481711|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
2481749|NCT03024567|Active Comparator|Salt|6 grams sodium chloride per day for 14 days
2481752|NCT03024567|Placebo Comparator|Placebo|6 grams gelatine per day for 14 days
2481810|NCT03024320|Experimental|M2M|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability.
2481817|NCT03024320|Experimental|M2Mplus|A theory-driven eHealth platform and innovative physical activity program referred to as movement-to-music (M2M), delivered customized and for the home-based for adults with physical disability. This arm also includes a social networking platform where participants will be able to interact and encourage one another through the program, as well as group-based tele-coaching session.
2481825|NCT03024320|Active Comparator|Attention Control|Participants receive health-focused articles and infographics throughout 48 weeks and receive a Fitbit.
3158902|NCT00394992|Experimental|2 oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
3158903|NCT00395031|Other|Ziprasidone|Open label
3158904|NCT00395070|Experimental|Treatment Arm|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
3158905|NCT00395070|Active Comparator|Control Arm|DTIC 1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR TMZ 150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
2481950|NCT03023098|Experimental|Drug-eluting balloon|
2481955|NCT03023098|Active Comparator|Conventional PTA|
2482018|NCT03022773|Other|Carotenoid measurements|Subjects are asked to have carotenoid levels measured in the eye, skin and/or blood.
2482126|NCT03021772|Active Comparator|Group N|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
2482132|NCT03021772|Active Comparator|Group D|30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
2482588|NCT03018808||Subjects met inclusion with at least one exclusion criteria|Subjects who meet all the inclusion criteria, but have at least one exclusion criteria or not agree to participate in the whole study will be invited to sign a special ICF in order to complete a minimal questionnaire.
2482591|NCT03018808||Subjects who satisfy all inclusion/exclusion criteria|Subjects who satisfy all inclusion/exclusion criteria and agree to sign the ICF, an interview will be conducted for information regarding medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
2482592|NCT03018808||Spirometry confirmed COPD Subjects|The spirometry confirmed COPD patients will be requested to complete the COPD Assessment Test (CAT), self-administered questionnaire related to quality of life on COPD patients.
2482657|NCT03018392|Experimental|Tritanium|TLIF with Tritanium® PL cage and pedicle screw fixation
2482690|NCT03018067|Placebo Comparator|Placebo|Microcrystalline Cellulose (MCC), 2 g qd. Subjects assigned to the Placebo group will be randomly assigned in a 1:1:1 ratio to receive either one, two, or three bottles of drug per day.
2482693|NCT03018067|Experimental|10 g qd|RDX227675, 10 g qd
2482696|NCT03018067|Experimental|20 g qd|RDX227675, 20 g qd
2482702|NCT03018067|Experimental|30 g qd|RDX227675, 30 g qd
2482813|NCT03017183|Other|EBUS-TBNA - Endobrochial Forceps Biopsy|In this arm, EBUS-TBNA will be done first, followed by endobronchial forceps biopsy
2484009|NCT03009760|Experimental|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
3158906|NCT00395174|Experimental|FluBlok|"Recombinant Trivalent Hemagglutinin Influenza Vaccine: 2005-2006 formulation containing 45μg of each hemagglutinin derived from A/New Caledonia (H1N1), A/Wisconsin (H3N2) and B/Ohio~135μg total"
3158907|NCT00395174|Active Comparator|TIV (Fluzone)|"Licensed trivalent influenza vaccine (TIV): 2005-2006 formulation containing 15μg of each hemagglutinin derived from A/Wisconsin (H3N2), A/New Caledonia (H1N1) and B/Malaysia~45μg total~(Fluzone, sanofi pasteur)"
3158908|NCT00395200|Experimental|MSC Treatment|
3158909|NCT00395213||1|Children and adolescents with a pre-specified anxiety disorder, depressive disorder, eating disorder, or obsessive-compulsive disorder
3158910|NCT00395239|Experimental|1|
3158911|NCT00395252|Experimental|one arm study|Cetuximab (Erbitux®) and Gemcitabine treatment over 6 months
3158912|NCT00395278||HIV negative|HIV negative without Kaposi sarcoma
3158913|NCT00395278||HIV positive|HIV positive without Kaposi sarcoma
3158914|NCT00395278||HIV positive KS|HIV positive with Kaposi sarcoma
2481129|NCT03028805|Active Comparator|Usual care and order set B|Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
2481130|NCT03028805|Active Comparator|Automatic inclusion and order set A|COPD order set is automatically included in admission orders as a static list.
2481133|NCT03028805|Active Comparator|Automatic inclusion and order set B|COPD order set is automatically included in admission orders as a dynamic and end user tested version.
2481189|NCT03028649|Experimental|β-hydroxy-β-methylbutyrate (HMB)|"Group taking oral supplementation with calcium salt of β-hydroxy-β-methylbutyric acid produced by Olimp Laboratories. A single capsule contained 1250 mg Ca-HMB, which corresponds to 1000 mg of β-hydroxy-β-methylbutyrate.~Interventions:~The experimental procedure for each athlete included a 12-week HMB supplementation - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
2481190|NCT03028649|Placebo Comparator|Placebo (maltodextrin)|"Group taking oral supplementation with placebo (maltodextrin). A single capsule contained 1000 mg of maltodextrin.~Interventions:~The experimental procedure for each athlete included a 12-week placebo administration - 3 capsules of the assigned preparation a day in 3 doses: upon waking, immediately after training, and before sleep. On non-training days, the participants were instructed to consume one serving with each of three separate meals throughout the day.~Between the 12-week HMB and PLA or a PLA and HMB treatment, a 10-day washout period was introduced."
2481223|NCT03028259||lab results|monitoring of
2481270|NCT03028051||chronic pain patients|Finnish speaking, adult chronic pain patients, aged 18 - 75 years, referred to pain clinic
2481306|NCT03027752|Active Comparator|carotid endarterectomy patch angioplasty|Carotid endarterectomy with longitudinal incision carotid endarterectomy patch angioplasty
2481308|NCT03027752|Experimental|Carotid endarterectomy with autoarterial remodeling|Carotid endarterectomy with autoarterial remodeling of bifurcation of the common carotid artery
2481415|NCT03026842|Experimental|Decitabine|Six cycles of decitabine IV over one hour at 20 mg/m2/day for 5 days, every 6 weeks
2481416|NCT03026842|Active Comparator|Conventional chemotherapy|Four cycles of conventional chemotherapy for 5 days, every 12 weeks. conventional chemotherapy includes in: DA regimen: Daunorubicin 45 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; MA regimen: Mitoxantrone 8 mg/m2/day for 3 days, cytarabine 100 mg/m2/day for 5 days; AA regimen: Aclacinomycin 20 mg/day for 5 days, cytarabine 100 mg/m2/day for 5 days.
2481489|NCT03026621|Placebo Comparator|Placebo|This will be an herbal tea the looks similar to the control.
2481493|NCT03026621|Experimental|Lignite Extract|This will be the Restore gut supplement
3158915|NCT00395317|Placebo Comparator|Arm 1|placebo (4 tablets)
3158916|NCT00395317|Experimental|Arm 2|SB-683699 150 mg bid (1 x 150mg + 3 placebo tablets)
3158917|NCT00395317|Experimental|Arm 3|SB-683699 600 mg bid (2 x 300mg + 2 placebo tablets)
2481809|NCT03024099|Experimental|Hippotherapy once a week|Hippotherapy once a week;
2481815|NCT03024099|Experimental|Hippotherapy twice a week|hippotherapy twice a week
2481963|NCT03023033|Experimental|Clinic group 1|Clinics using SMS health promotion and reminder messages (mhealth messaging)
2481964|NCT03023033|Experimental|Clinic group 2|Clinics using SMS health promotion and reminder messages + Clinics providing payment scaled to reflect typical transport costs to facility (transport payments)
2481966|NCT03023033|No Intervention|Clinic group 3|Services provided under the Ministry of Health standard care
2481997|NCT03022734|Experimental|chemotherapy with radiotherapy|Cetuximab or Bevacizumab, FOLFOX or FOLFIRI, radiotherapy
2482042|NCT03022552||MINOCA|Women with myocardial infarction (MI) with demonstrated non-obstructive coronary artery disease during cardiac catheterization (less than 50% blockage in any major vessel).
2482044|NCT03022552||MI-CAD|Women with myocardial infarction (MI) with demonstrated obstructive coronary artery disease during cardiac catheterization (50% or greater blockage in any major vessel) or previous history of percutaneous coronary intervention (PCI) or or coronary artery bypass graft (CABG).
2482045|NCT03022552||CATH-NOCA|Women with stable angina that are age and race matched to women in the MINOCA arm that are clinically referred for cardiac catheterization
2484014|NCT03009760|Experimental|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
3158918|NCT00395317|Experimental|Arm 4|SB-683699 900 mg bid (3 x 300 mg + 1 placebo tablet)
3158919|NCT00395317|Experimental|Arm 5|SB-683699 1200 mg bid, male subjects only (4 x 300 mg tablets)
3158920|NCT00395382|Active Comparator|1|Alendronate
3158921|NCT00395382|Placebo Comparator|2|Placebo
3158922|NCT00395421|Experimental|A|NM283(200 mg QD)plus Peg-IFNα-2a (180 µg QW)
3158923|NCT00395551|Active Comparator|ranibizumab|ranibizumab 0.5mg intravitreal injection
3158924|NCT00395681|Active Comparator|propofol|propofol 200 mg versus 350 mg
3158925|NCT00395681|Active Comparator|Propofol|Propofol 350 mg versus 200 mg
3158926|NCT00395707|Active Comparator|1|Lucentis 0.3mg/0.05 ml
3158927|NCT00395707|Active Comparator|2|Lucentis 0.5mg/0.05 ml
3158928|NCT00395720|Active Comparator|1|Group 1 (10 volunteers): 5 x 10^7 pfu
3158929|NCT00395720|Active Comparator|2|Group 2 (10 volunteers): 1 x 10^8 pfu
3158930|NCT00395772|Active Comparator|Arm 4|
3158931|NCT00395772|Experimental|Arm 1|
3158932|NCT00395772|Experimental|Arm 2|
3158933|NCT00395772|Experimental|Arm 3|
3158934|NCT00395889|Experimental|Rehabilitation + Lifestyle Counseling|Multicomponent Pulmonary Rehabilitation Program including structured exercise training
3158935|NCT00395889|Active Comparator|Lifestyle Counseling|
3158936|NCT00395941|Active Comparator|Control|Acitretin
3158937|NCT00395941|Experimental|Experimental|Pioglitazone
3158938|NCT00396071|Experimental|1|Vildagliptin 100 mg qd
3158939|NCT00396071|Placebo Comparator|2|Matching placebo
3158940|NCT00396149|Placebo Comparator|Placebo|Placebo group
3193323|NCT00817115|Experimental|2|Subjects undergoing routine cardiac catheterization or interventional procedures using the region-of-interest fluoroscopy (x-ray fovea imaging) system.
2481348|NCT03027375|Experimental|Qishen granules|The QSG treatment group will receive Qishen granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks; dosage based on the requirements of Pharmacopoeia of the People's Republic of China).
2481354|NCT03027375|Placebo Comparator|placebo granules|The placebo group will receive placebo granules (13.6 g/pouch, twice per day-30 minutes after breakfast and dinner-for 12 weeks).
2481419|NCT03027011|Active Comparator|Remote Ischemic Preconditioning(RIPC)|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
2481423|NCT03027011|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2481477|NCT03026569|Experimental|Orange juice|Orange juice: twenty-three patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were supplemented with 100% commercial pasteurized orange juice (500 mL/d) during 8 weeks.
2481480|NCT03026569|No Intervention|Control|Control: twenty patients with chronic hepatitis C under pegylated interferon combined with ribavirin treatment were monitored for consumption of orange juice during 12 weeks.
2481542|NCT03026192||no PDA|These are infants who do not have a patent ductus arteriosus (PDA) as determine by echocardiography
2481543|NCT03026192||hsPDA|These are infants who have a hemodynamically significant PDA (hsPDA) as determined by echocardiography
2481588|NCT03025828|Experimental|Acthar|Acthar will be administered subcutaneously (SC) 80 units for the first week and then 80 units twice weekly
2481694|NCT03025373||Patients - prolonged ICU stay (> 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
2481707|NCT03025373||Heart surgery patients (< 5 days)|Controlled visual and acoustic stimulation in a virtual reality setting
3193324|NCT00817128|Experimental|1|PEPT after randomization
3193325|NCT00817128|Experimental|2|CBO after randomization
2481793|NCT03024073||SG|Study group (patients who underwent pseudophakic presbyopic correction with bilateral bifocal lenses implantation
2481795|NCT03024073||CG|Control group (age-matched participants without pseudophakic presbyopic correction)
2481847|NCT03023982|Experimental|Pectoralic block group|After general anesthesia, 40ml of 0.25% Bupivacaine Hydrochloride will be administered before procedure Thoracotomy. Block will be administrated between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib., in assistance of ultrasound for visualization anesthetic injection point.
2481848|NCT03023982|Active Comparator|Control group|Patients in this group will receive standard pain control with opioids and NSAIDs
2481869|NCT03023566||Dotarem Enhanced MRI|All pediatric patients (< 18 years) scheduled for clinically indicated contrast enhanced MRI (Brain MRI with/without contrast) will receive a single IV bolus injection of Dotarem at a dose of 0.1 mmol/kg bw at a flow rate of 1-2 mL/sec followed by saline flush (routine/ standard of care).
3193326|NCT00817141||Without urinary catheter|
3193327|NCT00817154|Experimental|Hopes-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
2482146|NCT03021837||all patients|Patient receiving antenatal corticosteroid course for fetal lung maturity consisting of betamethasone or dexamethasone Women without known gestational diabetes and women with non-insulin requiring gestational diabetes (A1GDM)
2482192|NCT03021616|Experimental|Energy drink|Two 16 oz bottles of energy drink will be consumed at baseline.
2482201|NCT03021616|Active Comparator|Moxifloxacin control|32oz of active control drink will contain 400mg moxifloxacin with inactive flavoring ingredients.
2482216|NCT03021616|Placebo Comparator|placebo control|32oz placebo control drink
2482255|NCT03021044|Other|STANDARD OF CARE|The standard of care group will be recommended about medications and a correct life style (physical activity, low salt and low fat diet, no smoking) in order to prevent cardiovascular events. In this 15-minutes talk study doctor will explain to patients and relatives the importance of aerobic physical activity (30-60 minutes daily, moderate intensity, for example speedy walking, for at least 5 days/weekly) with the aim of reducing cardiovascular risk. Patients will also receive a brochure with clear explanations. Study doctor and study coordinator will be helpful for any question and they will ensure that patients and relatives understand the importance of physical activity for cardiovascular health.
2482270|NCT03021044|Experimental|PHYSICAL ACTIVITY INTERVENTION|Besides standard of care, the experimental group will participate to a program of physical activity intervention. Following hospital discharge, participants in stable clinical conditions will be referred by their cardiologist to the exercise-based secondary prevention program. All exercise testing and training sessions will be performed without discontinuing the prescribed medications. On admission to the program, and quarterly during follow-up, each patient will perform a 1-km treadmill walk test as previously described (1k-TWT).
3193328|NCT00817167|Experimental|inReach (A)|Bronchoscopy procedure is planned using inReach planning software
3193329|NCT00817167|Active Comparator|Control (B)|Bronchoscopy procedure is planned using standard CT viewer software
3193330|NCT00817180|Active Comparator|A|Positive Expiratory Pressure (PEP) - an airway clearance technique
3193331|NCT00817180|Active Comparator|B|High Frequency Chest Wall Oscillation (HFCWO) also known as the 'Vest technique' - an airway clearance technique.
3193332|NCT00817193|Experimental|Physical Activity|Participants will begin to participate in walking sessions and strength building classes that will be offered at each location. Participants will be asked to attend a minimum of 1 strength class per week, with a target of doing 150 minutes of moderate exercise each week. The exercise classes will include stretching and counseling to help participants understand and address the barriers to becoming and staying involved in regular exercise.
2481276|NCT03027869|Active Comparator|Real Left DLPFC tDCS|Real tDCS on the left dorsolateral prefrontal cortex
2481280|NCT03027869|Sham Comparator|Sham tDCS|30sec ramp-up and 30sec ramp-down
2481282|NCT03027869|Active Comparator|Real Right DLPFC tDCS|Real tDCS on the right dorsolateral prefrontal cortex
2481336|NCT03027674|Experimental|10% nifedipine cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of 10% nifedipine cream in one hand and 5 grams of 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
2481338|NCT03027674|Active Comparator|5% sildenafil cream|Patient hands (right versus left) were randomized to treatment with topical sildenafil or nifedipine cream. The thumbs of both hands didn't receive any cream so that each subject served as her own control. Subjects were instructed to apply 5 grams of topical10% nifedipine cream in one hand and 5 grams of topical 5% sildenafil cream to the opposite hand. Vinyl gloves were supplied to improve the absorption of the cream into the hand, leaving the thumb of both hands out of the glove without any cream.
2481387|NCT03027128|Experimental|haNK™ for Infusion|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous Infusion
2481431|NCT03026881|Experimental|Fluzoparib + Apatinib + Paclitaxel|
2481586|NCT03025958|Experimental|Nimotuzumab|Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).
2481633|NCT03025399|Experimental|Tangwang Prescription|The prescription was composed five Chinese herbal medicines,every bag has 4.87g granules, take it one bag each time, two times a day.
2481634|NCT03025399|Placebo Comparator|Placebo|Placebo is a simulated drug of tangwang Prescription,every bag has 4.87g granules, take it one bag each time, two times a day.
2481688|NCT03025009|Experimental|LY3192767 (Part A)|Escalating doses of LY3192767 administered subcutaneously (SC).
2481701|NCT03025009|Placebo Comparator|Placebo (Part A)|Placebo matching LY3192767 administered subcutaneously (SC).
2481710|NCT03025009|Experimental|LY3192767 (Part B)|LY3192767 administered as a SC injection in one of three study periods.
2481719|NCT03025009|Active Comparator|Basal Insulin Peglispro (Part B)|Basal insulin peglispro administered as a SC injection in one of three study periods.
2481724|NCT03025009|Active Comparator|Insulin Glargine (Part B)|Insulin glargine administered as a SC injection in one of three study periods.
2481735|NCT03024528||CAM-ICU (+)|Delirious patients.
2481736|NCT03024528||CAM-ICU (-)|Non-delirious patients
2481786|NCT03024424|Experimental|Early disclosure|Early disclosure group receives results of genetic testing at Week 4
2481787|NCT03024424|Active Comparator|Late disclosure|Late disclosure group receives results of genetic testing at final study visit (Month 12)
2481904|NCT03023540|Active Comparator|PXT3003 dose 1|Period 1, PXT3003 : Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months
2481907|NCT03023540|Active Comparator|PXT3003 dose 2|"Period 1, PXT3003: Liquid oral solution (1.2 mg/mL baclofen, 0.14 mg/mL naltrexone HCl and 420 mg/mL D-sorbitol), 5 mL bid (taken morning and evening with food) for 9 consecutive months~Period 2, PXT3003: Liquid oral solution (0.6 mg/mL baclofen, 0.07 mg/mL naltrexone HCl and 210 mg/mL D-sorbitol), 10 mL bid (taken morning and evening with food)"
2481940|NCT03023111|Active Comparator|Sbv|"Meglumine antimoniate (Glucantime):~Dosage: 20 mg / kg / day, intravenously, during 20 days."
2481945|NCT03023111|Experimental|Miltefosine plus placebo|Miltefosine (28 days / 2.5mg / Kg / day at a maximum dose of 150mg / day orally) + Topical placebo (gel cream, 2 times a day for 28 days)
2481946|NCT03023111|Experimental|Miltefosine plus GM-CSF|Miltefosine (28 days / 2.5mg / kg / day at a maximum dose of 150mg / day orally) + Topical GM-CSF (0.01% gel cream, 2 times a day for 28 days)
2481986|NCT03022760|Active Comparator|Work-related measures|"One-day training for GP:s and rehabilitation coordinators~A treatment protocol which includes contact with the patient's employer~Clinical support from the Institute of Stress Medicine"
2481988|NCT03022760|No Intervention|Treatment as usual|
2482082|NCT03022331||Observational|
2482114|NCT03021902|Experimental|IV amino acid + in-bed cycle ergometry|Beginning within 96 hours of initiation of mechanical ventilation, participants will receive the combined intervention that includes IV amino acids supplementation and in-bed cycle ergometry exercise
2482115|NCT03021902|No Intervention|Usual care|Participants randomized to the usual care arm will receive usual care protein and exercise.
2482241|NCT03021655|Experimental|Adventure-based intervention group|Adventure-based intervention group included 1 day-camp and will be divided into 2 parts: (1) physical activity such as wall climbing, ropes course etc, (2) health education delivering about the relationship of self-efficacy, self-esteem, emotion and smoking abstinence. The training will be held before the 6-month follow-up. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2482300|NCT03020693|Experimental|Invasive electrostimulation combined with exercises.|Dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to therapeutic intensity) combined with exercises program.
3158941|NCT00396149|Experimental|Active group|rBet v 1 tablets
3158942|NCT00396188||Normals|"Patients seeking initial laser vision correction that were screened to be good candidates for the procedure.~No history of refractive or other ocular surgery.~No corneal pathologies.~Normal corneal topography.~Contact lens wearers should discontinue use at least 2 weeks for hard contacts, and 3 days for soft lenses prior to imaging."
3158943|NCT00396188||Keratoconus|"An irregular cornea determined by distorted keratometry mires, distortion of the retinoscopic, or ophthalmoscopic red reflex (or a combination of these)~At least one of the following biomicroscopic signs: Vogt's striae, Fleischer's ring of >2 mm arc, or corneal scarring consistent with keratoconus.~Contact lens wearers should discontinue use preferably 1 day or at least half an hour prior to imaging."
3173494|NCT00612664|Active Comparator|Arm 2|1 mg/kg every 3 weeks
2481293|NCT03027778|Experimental|Exercise|Participants will engage in pedalling exercise 3 times per week during the first 2 hours of dialysis treatment for the duration of 4 months.
2481298|NCT03027778|No Intervention|Usual care|Participants receive their usual dialysis for the duration of 4 months.
2481334|NCT03027609|Experimental|AR-105|One intravenous infusion of AR-105 20mg/'kg
2481337|NCT03027609|Placebo Comparator|Control|Matching placebo
3158944|NCT00396188||Myopic Laser Vision Correction|"Patients who have undergone myopic:~LASIK~PRK~LASEK"
3158945|NCT00396188||Hyperopic Laser Vision Correction|"Patients who have undergone hyperopic:~LASIK~PRK~LASEK"
2481469|NCT03026452|Experimental|RFA(radiofrequency ablation)|The investigators used percutaneously US-guided RFA(radiofrequency ablation) for small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
2481626|NCT03025581|Active Comparator|Intervention group|Nipple stimulation.
2481629|NCT03025581|No Intervention|Control group|No intervention (expectant management only).
2481686|NCT03025087|Experimental|Phase 1|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery.
2481698|NCT03025087|Experimental|Phase 2|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg daily until the day of MRI imaging on postoperative day 1-5
2481708|NCT03025087|Experimental|Phase 3|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 400 mg twice daily (800 mg total) until the day of MRI imaging on postoperative day 1-5.
2481716|NCT03025087|Experimental|Phase 4|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ on the day prior to surgery followed by 500 mg twice daily (1000 mg total) until the day of MRI imaging on postoperative day 1-5.
2481720|NCT03025087|Experimental|Phase 5|6 evaluable subjects (3 cardiac, 3 noncardiac patients): 1000 mg HCQ 1-2 hours after separation from CPB or at end of noncardiac surgery followed by the highest tolerated dose from the previous 4 phases divided into 2 equal daily doses until the day of MRI imaging on postoperative day 1-5.
2481756|NCT03024554|Experimental|treatment|aortic aneurysm involving iliac arteries treatment with the Bifurcated Multilayer Flow Modulator (BMFM)
2481804|NCT03024138||Repeat CT|
2481862|NCT03023930|Experimental|Evidenced-based Practice Dissemination|Evaluating standard dissemination practice compared with implementation facilitation
2481897|NCT03023501|Experimental|Gabapentin|Gabapentin 1200mg capsule was administered orally 2 hours before surgery
2481901|NCT03023501|Placebo Comparator|Placebo|Placebo capsule was prepared by hospital pharmacy and was administered orally 2 hours before surgery.
2481931|NCT03023228|Experimental|diabetes self-management education|Diabetes survival skills self-management education (DSME) program content was aligned with American Diabetes Association and Joint Commission suggested key areas for hospital diabetes education. Content areas were as follows: when and how to take diabetes medications; glycemic goals and self-blood glucose monitoring; definition, prevention, recognition, and treatment of hypoglycemia and hyperglycemia; what to do before you see the dietitian; sick day management; and when to call the doctor or go to the ED. Program content was created for delivery via either DVD or print format.
2482012|NCT03022968|Experimental|Alzheimer disease|[18F]T807 PET
2482014|NCT03022968|Experimental|Benson disease|[18F]T807 PET
2482022|NCT03022968|Experimental|Healthy volunteer|[18F]T807 PET
2482257|NCT03021252|Experimental|High intensity IEMT|Inspiratory and expiratory muscle training + standard swallow therapy.
2482268|NCT03021252|Sham Comparator|Sham IEMT|Sham inspiratory and expiratory muscle training + standard swallow therapy
2482298|NCT03020654|Experimental|Treatment group|Virtual environment with fast moving objects these are graded in intensity from 1-7. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
2482299|NCT03020654|Active Comparator|Control group|Virtual environment with no movement graded at grade 0. Participants complete head and eye exercises within the environment using focus points such as benches and lanterns for a six week treatment program.
3158946|NCT00396188||Orthokeratology|1. Patients using specially designed rigid contact lenses to reshape the cornea to temporarily reduce or eliminate refractive error.
3158947|NCT00396188||Others|1. Corneal conditions (diseases/ pathologies/surgeries) that can potentially affect the corneal surface that are not listed above (e.g. pellucid marginal degeneration; postoperative corneal transplant, intra-corneal ring segments, refractive keratotomy, conductive keratoplasty; peripheral ulcerative keratitis, Terrien's marginal degeneration; etc.).
3158948|NCT00396214|Experimental|1|
3158949|NCT00396214|Experimental|2|
3158950|NCT00396214|Active Comparator|3|
3158951|NCT00396227|Experimental|1|Vildagliptin 100mg + Met
3158952|NCT00396227|Active Comparator|TZD|TZD + metformin
3158953|NCT00396305|Experimental|Group 2, Control Double Dose|12 elderly and 6 young participants. This group will be vaccinated with a double dose of vaccine without booster on Day 0. These subjects will receive a double-dose of vaccine administered as 2 consecutive injections (2 injections of 0.5 mL) in the same deltoid. The control group for Group 2 is group 1, Cohort 2.
3158954|NCT00396305|Experimental|Group 3-Control late booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 21. The control for Group 3 is Group 1, Cohort 3.
3158955|NCT00396305|Active Comparator|Group 1, Control|12 elderly and 8 young participants. Group 1 will be further divided into 4 equal cohorts (each containing 3 elderly and 2 young adults). Cohorts 2, 3, and 4 will receive the standard dose of vaccine and placebo (0.5 mL saline) on Day 0, 21, or 7 respectively. Cohort 1 will be vaccinated with the standard dose of vaccine without placebo/vaccine booster.
3158956|NCT00396305|Experimental|Group 4-Control early booster|12 elderly and 6 young participants. This group will be vaccinated with the standard dose of vaccine (0.5 mL) on Day 0 and with a booster dose of vaccine (0.5 mL) on Day 7. The control for Group 4 is Group 1, Cohort 4.
3158957|NCT00396344|Placebo Comparator|1|Saline control
3158958|NCT00396344|Experimental|2|
3158959|NCT00396344|Experimental|3|
3158960|NCT00396357|Experimental|vildagliptin + metformin|
3193333|NCT00817193|Active Comparator|Wellness|Participants will begin to participate in a wellness program that will meet at each site twice per month. The first meeting will involve a lecture or presentation on a wellness-related topic. The second meeting will follow-up on concepts that were introduced in the first meeting, and will also to provide participants an opportunity to share experiences. Participants will be asked to attend both wellness sessions each month for whole year that the program is running.
2481355|NCT03027362|Experimental|Cognitive behavioral therapy (CBT) and medication|Following clinical ketamine treatment, the intervention includes sixteen CBT sessions over 14 weeks. In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or by a psychiatrist unaffiliated with the trial. Participants will remain on the medication they were prescribed when they entered the study and will be expected not to adjust the medication unless clinically urgent.
2481359|NCT03027362|Active Comparator|Psychoeducation and medication|Following clinical ketamine treatment, the intervention includes psychoeducational sessions over 14 weeks.In addition, standard of care medications for treatment of depression, will be prescribed by the principal investigator or a by psychiatrist unaffiliated with the trial.
2481409|NCT03027050|Experimental|Titanium-prepared platelet rich fibrine|T-PRF was applied with open flap debridement in test group.
2481413|NCT03027050|Active Comparator|Open Flap Debridement alone|T-PRF was not applied to control groups. Only open flap debridement was applied to control groups.
2481472|NCT03026660|Experimental|Moringa treatment|Moringa Oleifera was distributed in two 500mg capsules of dried and powdered Moringa Oleifera leaves. Two capsules were taken daily.
2481473|NCT03026660|Placebo Comparator|Placebo|The placebo consisted of dried and powdered cabbage in two 500mg capsules. Two capsules were taken daily.
2481526|NCT03026218|Experimental|Group and Glucose Mama|Enrolled subjects with have GlucoseMama application and group care.
2481529|NCT03026218|Placebo Comparator|Group and No Glucose Mama|Enrolled participants will be enrolled in group care but will not have access to GlucoseMama application.
2481534|NCT03026218|Experimental|Traditional and glucoseMama|Enrolled subjects will have traditional care and glucoseMama
2481536|NCT03026218|No Intervention|Traditional and no GlucoseMama|enrolled subjects will not have access to group care or GlucoseMama.
2481619|NCT03025529|Experimental|Active Cerebellar rTMS|Cerebellar rTMS will be carried out in ET subjects using a MagPro stimulator with a double cone coil at 1Hz (1 pulse every second) for 3 minutes on the left and 3 minutes on the right, at the cerebellar location indicated by resting state functional connectivity MRI analysis. Subjects with ET will undergo 5 consecutive daily sessions of cerebellar rTMS at either the connectivity map generated target or sham rTMS and then crossover to the other target after 2 weeks. Subjects will be blinded to the treatment order assignment. The intensity of the stimulation will be determined as 90% of the resting motor threshold, to be determined at the beginning of the first visit.
2481621|NCT03025529|Sham Comparator|Sham Cerebellar rTMS|In sham rTMS, the same parameters and procedures as Treatment Procedures 4-8 will be used, except that the coil will be angled 90 degrees from the scalp, resting on one wing of the coil.
2481622|NCT03025529|No Intervention|Healthy control pilot|This pilot phase is done to assess feasibility of obtaining MRI and cerebellocortical inhibition measures in healthy control subjects.
2481692|NCT03025113|Experimental|EMS association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
2481704|NCT03025113|Active Comparator|Miosan®|The patient will take 2 tablets (cyclobenzaprine isolated), oral, per day, each 12h.
2481744|NCT03024580|Experimental|Megestrol acetate|Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481747|NCT03024580|Active Comparator|Anastrozole|Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481750|NCT03024580|Active Comparator|Letrozole|Letrozole 2.5 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481753|NCT03024580|Active Comparator|Exemestane|Exemestane 25 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481754|NCT03024580|Active Comparator|Tamoxifen|Tamoxifen 20 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481755|NCT03024580|Active Comparator|Fulvestrant|Fulvestrant 500 mg intramuscularly (IM) d1, d14, d28 and q28 days until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
2481933|NCT03023085|Experimental|BLI4700|BLI4700 Bowel Preparation
2481982|NCT03022955|Active Comparator|Dark chocolate: FDG-PET|100 g dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
2481983|NCT03022955|Active Comparator|Dark chocolate: Physiological Measurement|150 g dark chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
2481984|NCT03022955|Placebo Comparator|White chocolate: FDG-PET|100 g white chocolate bar (0% cocoa solids (~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
2481985|NCT03022955|Placebo Comparator|White chocolate: Physiological Measurement|150 g white chocolate mousse (~500kcal, ~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
2482035|NCT03022604|Experimental|C4/Generation 4|12 grams of C4/Generation 4 Extreme
2482038|NCT03022604|Active Comparator|C450X|12 grams of C4X (150% of regular dose)
2482040|NCT03022604|Placebo Comparator|Placebo|12 grams of flavored dextrose
2482460|NCT03019770|Experimental|PrEP Decision Aid|All participants in the study will go through the Decision Aid with a provider.
2481324|NCT03027479|Experimental|Case group|women with ovarian and/or endometrial cancer and weight loss will have muscle, adipose tissue, ovarian tumor and blood samples
2481328|NCT03027479|Other|Control group|women scheduled for an intervention for benign ovarian/ endometrial disease and no weight loss will have muscle, adipose tissue and blood samples
2481371|NCT03027284|Experimental|Merestinib (Part A Dose Level 1)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
2481379|NCT03027284|Experimental|Merestinib (Part A Dose Level 2)|Merestinib administered orally. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
2481382|NCT03027284|Experimental|Merestinib + Cisplatin + Gemcitabine (Part B)|Merestinib administered orally with cisplatin and gemcitabine administered intravenously (IV). Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met, but Cisplatin and gemcitabine treatment will be limited to a maximum of 8 cycles.
2481417|NCT03026894|Active Comparator|CD group|Panoramic Radiographs and T-Scan III occlusal system
2481418|NCT03026894|Active Comparator|IOD group|Panoramic Radiographs and T-Scan III occlusal system
2481551|NCT03026101|Experimental|Migraine Intervention|Subjects who will be administered 200 micrograms of nitroglycerin once into branches of their external carotid artery to determine the role of dilation of this artery to cause migraine-like pain
2481606|NCT03025789|Experimental|Open label arm|children and adults to receive fexinidazole either as inpatients or outpatients.
2481654|NCT03025243|Experimental|50 micron|surgical guide constructed with 3D printing with printing layer thickness 50 micron
2481656|NCT03025243|Active Comparator|100 micron|surgical guide constructed with 3D printing with printing layer thickness 100 micron
2481696|NCT03024918||MCDA cohort|Unselected monochorionic diamniotic (MCDA) twin pregnancies, included between 11 and 14 weeks of gestation
2481709|NCT03024918||TTTS cohort|Pregnancies complicated by twin-twin transfusion syndrome (TTTS) undergoing laser treatment, included at the time of diagnosis or referral
2481715|NCT03024918||sIUGR cohort|Pregnancies complicated by selective intrauterine growth restriction (sIUGR), included at the time of diagnosis or referral. We define sIUGR as a discordance in estimated fetal weight of ≥ 20%.
2481746|NCT03024632||trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a trial of labor
2481751|NCT03024632||No trial of labor|Pregnant women with a history of 3 or more cesarean sections who desired a a repeat cesarean section
2481843|NCT03024333||Healthy subjects|"Healthy subjects are:~Between 19-60 years old~Able to sign the informed consent after the whole study is explained to them~Self-reporting no history of swallowing disorders, neurological deficits and/or cancer of the mouth, neck or brain, or head or neck surgery~Able to sit upright with or without back support of chair~No other diseases affect swallowing function"
2481873|NCT03023657|Experimental|Severe brain-damaged patient in coma awakening|For each patient, video sessions of the face will be performed during a waking period, until the spontaneous macro-EFE (Emotional Facial Expression) reappears. The video sessions will be done without stimulation or with visual, auditory or tactile stimulation. The sessions will be daily for 7 days then weekly for a maximum duration of 4 weeks.
2481987|NCT03022786|No Intervention|Understanding patient perspective|Patients will be interviewed who have been diagnosed with stasis dermatitis. The Principal Investigator will learn their perspective on their leg swelling, impact on quality of life, and obstacles to wearing compression stockings
2481989|NCT03022786|No Intervention|Refining tool kit|"Using in-depth interviews for our inpatients selected using the same criteria as in Phase 1 and independent focus groups of providers, The study staff will obtain feedback to refine the items in our toolkit before implementing them in January 2017.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
2481990|NCT03022786|Other|Implementation|Our patient education materials and toolkit include an order set to help providers guide patients to adhere to compression, the gold standard of care for this condition. This will also direct patients to know who to contact if itching or pain persists, what the patient can do at home, when to go to the hospital, as well as information on financial and home care assistance as it relates to managing their chronic condition.
2482072|NCT03022305|Experimental|Group one - standard therapy|Standard physical therapy treatment for shoulder and hip malalignment will be administered for one week.
2482076|NCT03022305|Experimental|Group two - neuromuscular therapy|Experimental neuromuscular physical therapy treatment for shoulder and hip malalignment will be administered for one week. This therapy is exercised based.
2482079|NCT03022305|No Intervention|Group three - no treatment|No physical therapy treatment will be given to this group.
2482143|NCT03022058|Experimental|Patients with type 1 diabetes mellitus|
2482195|NCT03021603|Experimental|Intervention Group|"This is a 4-week Brief Hope Intervention~Four sessions in total:~two face-to-face sessions (1-hour) and two telephone follow up sessions (30 mins) in between.~Homework : A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
2482214|NCT03021603|Experimental|Control Group|"Standard care:~Clinic follow up and normal hospital care. Logistic call and social communication On completion of the 4-week standard care, the 4-session brief hope intervention will be offered"
2482259|NCT03021174|Experimental|Exercise|Exercise for Cancer Patients (EXCAP©®), developed by Dr. Karen Mustian, involves face-to-face instruction and a prescription for an at-home progressive walking and resistance exercise program.
2482267|NCT03021174|Active Comparator|Nutrition Education Control|Nutrition education (control) involves equal time and attention as the exercise arm, but the content covers nutrition for cancer patients and lacks an exercise prescription.
2482302|NCT03020706|Experimental|Magnesium|magnesium sulfate, injectable intravenous administration (50mg/kg diluted in 100ml normal saline) during general anesthesia
2482303|NCT03020706|No Intervention|Control|No intervention
2482324|NCT03020433|Active Comparator|rTMS Contralesional M1 Inhibition|
2482326|NCT03020433|Active Comparator|rTMS Contralesional PMC facilitation|
2482330|NCT03020433|Active Comparator|rTMS Ipsilesional PMC facilitation|
2482333|NCT03020433|Sham Comparator|rTMS Sham at Ipsilesional M1|
2481363|NCT03027492|Active Comparator|6. IBS prospective control patients|To compare the presence and characteristics of gynaecological disorders in NCWS female patients, a control group of IBS female patients will be randomly chosen by a computer-generated method from female subjects diagnosed during the same period (2017-2018) and age- (+2 years) matched with the NCWS female patients. Similar to NCWS patients, also this control group will be asked for gynaecological disorders and the answers reported in the patients clinical charts. All the patients will be evaluated at baseline (i.e. at diagnosis) and after at least a 6-months period of gluten-free diet.
2481420|NCT03026972|Experimental|Population I|Population I has 25 subjects,and it is considered as Tuberculin purified protein derivative(TB-PPD) skin test and specific gamma-interferon (γ-IFN) detection result all negative.Population I are coxal muscle injection of placebo or low dose adjuvant or low dose vaccine.
2481422|NCT03026972|Experimental|Population II|Population II is considered as Tuberculin purified protein derivative(TB-PPD) skin test , ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all negative.It has 30 subjects.Population II are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.
2481426|NCT03026972|Experimental|Population III|Population III is considered as ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result negive,but Tuberculin purified protein derivative(TB-PPD) skin test positive.Population IV is needed 30 subjects.These subjects are coxal muscle injection of placebo or high dose adjuvant or high dose vaccine.This arm is uninfected TB PPD positve population.
2481430|NCT03026972|Experimental|Population IV|Population IV is considered as Tuberculin purified protein derivative(TB-PPD) skin test and ESAT6-CFP10 skin test and specific gamma-interferon (γ-IFN) detection result all positive.We are called latent infection population,and need to screen 50 subjects through these three selection method.Population III are coxal muscle injection of placebo or adjuvant( including low dose adjuvant or high dose adjuvant) or vaccine(including low dose vaccine high dose vaccine).
2481485|NCT03026439||Non-dyspneic smokers/ normal spirometry|Male or female current or former smokers. Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) >0.7. FVC >lower limit of normal (LLN). Modified Medical Research Council (mMRC) dyspnea score = 0.
2481490|NCT03026439||Dyspneic smokers/ normal spirometry|Male or female current or former smokers. FEV1/FVC >0.7. FVC >LLN. mMRC dyspnea score ≥1.
2481492|NCT03026439||Non-dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score =0.
2481495|NCT03026439||Dyspneic mild COPD patients|Male or female current or former smokers. FEV1/FVC ≤0.7. FEV1 >80% of predicted value. mMRC dyspnea score ≥1.
3158961|NCT00396357|Active Comparator|Metformin|
3158962|NCT00396370|Experimental|Group A: BCG ID/Placebo PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): Placebo ID/Placebo PO.
2481578|NCT03025724|No Intervention|Control|After the surgical excision, subjects will be asked to fill out a satisfaction survey. They will not receive any PDT treatment.
2481580|NCT03025724|Experimental|Intervention Group|Subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours. At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals). Lastly, they will be asked to fill out a satisfaction survey.
2481613|NCT03025412|Experimental|Endoscopic surgery|Ambulatory surgery. Postoperative rehabilitation. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
2481614|NCT03025412|Active Comparator|Conservative treatment|Physiotherapy and exercise. First physiotherapy consultation: Information, advice, instructions. Exercise regime during 12 weeks in three phases.
2481680|NCT03025191|Experimental|Prison Connect|
2481734|NCT03024671|Experimental|patch test|Patients with patch test of cosmetics
2481789|NCT03024437|Experimental|Phase I - Dose Escalation|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and ANY or NO prior treatments.~Three dose levels of entinostat will be tested in 3-patient cohorts according to the 3 + 3 standard design (1 mg, 3 mg and 5 mg). The starting dose level of entinostat will be 1 mg orally every 7 days. The Phase II dose will be recommended phase II dose of entinostat (i.e., the highest tested dose that is declared safe and tolerable by the Investigators and Sponsor)."
2481790|NCT03024437|Experimental|Phase II - Cohort A|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and NO prior treatments.~Patients in Cohort A will be treated with atezolizumab, bevaciuzmab, and the recommended phase II dose of entinostat. During Phase II, the study will have a run-in period with entinostat for one cycle followed by atezolizumab and bevacizumab for the second cycle, and then the combination phase (i.e., atezolizumab + bevacizumab + entinostat for all cycles thereafter)."
2481791|NCT03024437|Experimental|Phase II - Cohort B|"Open to patients meeting eligibility criteria with advanced renal cell carcinoma and at least one prior treatment with a PD1 or PDL1 inhibitor.~Patients in Cohort B will be treated with the same combination therapy as in Cohort A."
2481838|NCT03023995|Experimental|CAF with Platelet Rich Fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it.
2481840|NCT03023995|Active Comparator|CAF with connective tissue graft|In control group, connective tissue graft harvesting was carried out which was followed by placement of connective tissue graft on the recipient site. The connective tissue graft was placed on the recipient site and secured in position with 5-0 vicryl sutures
3158963|NCT00396370|Experimental|Group B: BCG ID/Placebo PO; BCG ID/Placebo PO|Primary vaccination: BCG ID (Danish)/Placebo PO; secondary vaccination (1 year later): BCG ID (Danish)/Placebo PO.
3158964|NCT00396370|Experimental|Group C: Placebo ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
3158965|NCT00396370|Experimental|Group D: Placebo ID/BCG PO; Placebo ID/BCG PO|Primary vaccination: Placebo ID/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/BCG PO (Danish).
3173495|NCT00612664|Active Comparator|Arm 3|1 mg/kg every 6 weeks
3173496|NCT00612664|Active Comparator|Arm 4|5 mg/kg every 3 weeks
2481396|NCT03027193|Experimental|Group 1|Group 1 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^9 vp through intramuscular route.
2481397|NCT03027193|Experimental|Group 2|Group 2 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 2.5 x 10^10 vp through intramuscular route.
2481398|NCT03027193|Experimental|Group 3|Group 3 volunteers (n= 3 to 6) will be administered ChAdOx2 HAV, 5 x 10^10 vp through intramuscular route.
2481399|NCT03027193|Experimental|Group 4|Group 4 volunteers (n= 3) will be administered MVA HAV, 5 x 10^7 pfu through intramuscular route.
2481400|NCT03027193|Experimental|Group 5|Group 5 volunteers (n= 3) will be administered MVA HAV, 2 x 10^8 pfu through intramuscular route.
2481401|NCT03027193|Experimental|Group 6|Group 6 volunteers (n= 10) will be administered ChAdOx2 HAV, 5 x 10^10 vp followed by MVA HAV, 2 x 10^8 pfu (8 weeks apart) through intramuscular route.
2481465|NCT03026504|Experimental|Baricitinib Therapy|4 milligrams oral Baricitinib daily for 52 weeks
2481502|NCT03026335|Experimental|Positive Action Curriculum|"A school-wide program was implemented in the experimental schools referred to as Positive Action and was integrated with the existing Health and Family Life Education curriculum."
2481504|NCT03026335|Active Comparator|Control/Comparison Group|Business as usual with students in non-intervened schools
2481547|NCT03026062|Experimental|Arm I (sequential tremelimumab, durvalumab)|Patients receive tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Upon progression, patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity. This arm is closed to enrollment.
2481550|NCT03026062|Experimental|Arm II (combination tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
2481587|NCT03025711||Pertuzumab|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Pertuzumab under Spanish compassionate use or early access program
2481590|NCT03025711||Trastuzumab emtansine|Patients with HER2-positive metastatic or locally recurrent unresectable breast cancer and who are treated with Trastuzumab emtansine (T-DM1) under Spanish compassionate use or early access program
2481609|NCT03025477|Active Comparator|Control arm|"Initial or interval surgery associated with 6 cycles of chemotherapy in intravenous (IV) of carboplatin and paclitaxel.~The regimen of administration of the chemotherapy is as following:~Carboplatin AUC 6 - IV - Day (D) 1~Paclitaxel 80mg / m² - IV - D1, D8, D15~one cycle every 3 weeks"
2481610|NCT03025477|Experimental|Experimental arm|"Initial or interval surgery associated with 6 cycles of chemotherapy of cisplatin and epirubicin.~Cisplatin is administrated in intraperitoneal (IP) if no macroscopic residual tumor at the end of the intervention (initial or interval). If evidence of macroscopic residual tumor, cisplatin is administered in IV. Epirubicin is always given in IV.~Second cytoreduction surgery at mid-term of chemotherapy cycles, only in patients operable in response after 3 cycles and with persistent residual disease after initial surgery or incomplete initial staging.~The regimen of administration of the chemotherapy is as following:~Cisplatin 80mg / m² - IV or IP - D1~Epirubicin 60mg / m² - IV - D3~one Cycle every 3 weeks."
3158966|NCT00396370|Experimental|Group E: BCG ID/BCG PO; Placebo ID/Placebo PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): Placebo ID/Placebo PO.
2481841|NCT03024268|Experimental|A: interventional closure of iASD|Interventional closure of iASD (n=40) with an Figulla Flex Occluder (Occlutech)
2481844|NCT03024268|No Intervention|B: no intervention|Best medical supportive care (n=40)
3158967|NCT00396370|Experimental|Group F: BCG ID/BCG PO; BCG ID/BCG PO|Primary vaccination: BCG ID (Danish)/BCG PO (Danish); secondary vaccination (1 year later): BCG ID (Danish)/BCG PO (Danish).
2481935|NCT03023306|Active Comparator|preemptive group|"The preemptive group will receive the anti-emetic regimen i.v. (4 mg of ondansetron) 1h before the start of surgery. During surgery, 30 min before the end of operation, this group will receive i.v. 0.9% NaCl in equal volumes.The intervention consists of the different time points of antiemetic treatment, thus 1h before surgery vs intraopertively.~Intervention: Antiemetic treatment 1h before surgery"
2481941|NCT03023306|Other|intraoperative group|"The preventive group will receive i.v. 0.9% NaCl 1h before surgery and ondansetron 4 mg 30 min before the end of surgery at equal volumes.~Intervention: Antiemetic treatment intraoperatively"
2482000|NCT03022838|Active Comparator|Caffeine|Caffeine tablets (Recip) 100 mg, 300-800 mg
2482002|NCT03022838|Placebo Comparator|Placebo|Placebo tablets
2482048|NCT03022513|Active Comparator|NCWS patients|Fifty consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2017 and January 2018 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
2482049|NCT03022513|No Intervention|CD patients|Fifty sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as first control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo, Italy.
2482050|NCT03022513|No Intervention|IBS patients|Fifty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as second control group. All subjects will undergo clinical evaluation and hands and feet joints ultrasonography at the Rheumatology Unit of the University of Palermo.
2482060|NCT03022227|Experimental|group A start with the remote session followed by on site|
2482066|NCT03022227|Active Comparator|group B start with on site followed by telemedecine|
2482147|NCT03022110|Active Comparator|plastic stent|Endoscopic Ultrasound-guided Drainage with plastic stent
2482151|NCT03022110|Experimental|lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage with lumen-apposing metal stent
3193334|NCT00817232|Experimental|Treatment 1|50 microamp amplitude
2481461|NCT03026738|Experimental|Laparoscopic anterior mesh rectopexy|A superficial peritoneal window will be made over the right part of the sacral promontory and extended caudally over the right outer border of the mesorectum down to the right side of the pouch of Douglas. In females, the vagina will be retracted anteriorly and a careful dissection of the rectovaginal septum will be performed down to the pelvic floor. A strip of polypropylene (3×20 cm) mesh will be introduced and sutured as distally as possible on the anterior rectal wall/ perineal body with three, interrupted nonabsorbable sutures.The posterior wall of the vagina will be fixed to the mesh using absorbable sutures. The mesh is then secured tension-free to the sacral promontory using three absorbable sutures. The mesh will be peritonealized by suturing the free edges of the previously divided peritoneum over the mesh to provide additional ventral elevation of the enterocele and avoid small bowel adhesions to the mesh.
2481463|NCT03026738|Active Comparator|Laparoscopic posterior mesh rectopexy|"Mobilization of the mesorectum posteriorly from the sacral promontory to the pelvic floor. Lateral stalks will not be divided. Bowel resection and circumferential division of the peritoneum will not be done in this study. A T-shaped polypropylene mesh will be placed with the vertical leg laying flush with the anterior surface of the sacrum, and secured to the promontory and sacrum with three absorbable sutures. The mesh wings will be sutured to the lateral sides of the rectum/mesorectum with two absorbable sutures on each side. The visceral peritoneum will be left open."
2481548|NCT03026322|Active Comparator|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
2481553|NCT03026322|Active Comparator|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
2481570|NCT03025737||athletes|Healthy highly trained elite athletes, recreational athletes, young and master athletes free of known structural myocardial disease
2481571|NCT03025737||controls|Healthy volunteers without a history of competitive physical exercise
2481616|NCT03025516||Adults with pulmonary TB symptoms|"All patients will be tested with both the reference and index TB diagnostic tests. Index test results will not be used to inform case management.~All samples must be collected before the patient starts any form of TB treatment. Patients will be randomized to receive either the TB Breathalyser or AeonoseTM on Day 1, and will be tested with the remaining breath-test on Day 2. A follow-up evaluation will be required after 8 weeks for all patients who do not have microbiologic confirmation of TB (smear or culture). Two additional breath samples may also be collected upon follow-up."
2481681|NCT03025152|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with an oral dose of 10 g/day during entire follow up period (2 years).
2481683|NCT03025152|Placebo Comparator|placebo|Patients in this arm receive placebo, with an oral dose of 10 g/day during entire follow up period (2 years).
2481743|NCT03024593|Experimental|Searching condition|To simulate participants' natural behavior they are requested to search online for personally relevant health or illness information in their usual manner. By doing so their attentional focus lies on the searching process and the information they obtain.
2481745|NCT03024593|No Intervention|Waiting condition (i.e. non- searching, no distraction)|Participants are requested to do nothing and not to distract themselves by reading or using their smartphone for instance. By doing so, it is expected that their attentional focus lies on their induced worries and symptoms.
2481812|NCT03024359|Active Comparator|obese individuals|Individuals with BMI between 30 and 35 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and brain activity (18F-FDG PET/MRI; in a subsample of 5 obese individuals)will be collected.
2481820|NCT03024359|Active Comparator|normal weight individuals|Individuals with BMI between 18.5 and 24.99 kg/m2 will be included in this group and will receive 4 weeks of extra virgin olive oil. Before and after the intervention period data regarding dietary intake and physical activity, brown/beige adipose tissue activity, body composition (DXA), lipid profile and inflammatory markers and and brain activity (18F-FDG PET/MRI; in a subsample of 10 normal weight individuals) will be collected.
3158968|NCT00396370|Experimental|Group G: Connaught strain BCG ID|Primary vaccination: Connaught strain BCG ID; secondary vaccination (1 year later): none.
3158969|NCT00396435|Experimental|Group A|High Hb target
2482061|NCT03022279|Active Comparator|TAP blocks|TAP block group will receive three injections performed by an Anesthesiologist trained in the procedure, prior to initiation of the surgical procedure. Bilateral posterior transversalis fascial plane blocks and a right sided subcostal transverse abdominal plane block will be placed under ultrasound guidance. Normal saline will be used to confirm proper muscle layer placement before instillation of the local anesthesia. All patients will receive 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL (divided equally amongst the injection sites).
3158970|NCT00396435|Active Comparator|Group B|Low Hb Target
3158971|NCT00396448|Experimental|CP-945,598 Treatment B|
3158972|NCT00396448|Experimental|CP-945,598 Treatment A|
3158973|NCT00396448|Placebo Comparator|Placebo|
3158974|NCT00396461|Active Comparator|TPN A (Group I)|Emulsion based on 20% MCT/LCT (50:50 ratio)
3158975|NCT00396461|Experimental|TPN B (Group II)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides
3158976|NCT00396474||SGA patients|Infants born small for SGA who either received GH, no GH, or growth within normal ranges.
3158977|NCT00396552|Experimental|1|
3158978|NCT00396552|Sham Comparator|2|
3158979|NCT00396643|Experimental|A|
3158980|NCT00396643|Placebo Comparator|B|Coconut oil
3158981|NCT00396669|Experimental|Dopamine release|
3158982|NCT00396721|Active Comparator|A|
3158983|NCT00396721|Experimental|B|
3158984|NCT00396747|Active Comparator|A|Methotrexate
3158985|NCT00396747|Active Comparator|B|MTX + MP
3158986|NCT00396747|Active Comparator|C|MTX + IFX
3158987|NCT00396786|Experimental|Arm 1|
3193335|NCT00817232|Experimental|Treatment 2|500 microamp amplitude
2481677|NCT03025126|Experimental|HEAD Rehabilitation|rehabilitation with IT multimedial devices
2481678|NCT03025126|Active Comparator|Usual care program|usual care program
2481737|NCT03024723||FmCPAP|CPAP ventilation administered via face mask
2481832|NCT03024164||Young adult stroke patients|Young adult (18-45 years old) patients with confirmed first-ever acute ischemic stroke
2481877|NCT03023787|Experimental|Hepalatide|Hepalatide 4.2mg, 6.3mg and 8.4mg
2481883|NCT03023787|Placebo Comparator|Placebo|Placebo 4.2mg, 6.3mg and 8.4mg
2481934|NCT03023293||gestational diabetes mellitus|The investigators plan to establish a prospective GDM cohort and collect n-3 PUFAs consumption and irisin information at 24-28 weeks'gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum, respectively.
3193336|NCT00817245|Active Comparator|1|Oral Amoxicillin Capsule Metronidazole Tablet Omeprazole Capsule
3193337|NCT00817245|No Intervention|2|No medical treatment
3193338|NCT00817258|Other|1|All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
3193339|NCT00817271|Experimental|1|
2482149|NCT03021863|Active Comparator|Group A Reminder|Tone of reminder email (duty 14 days followed by duty for non-responders 28 days)
2482152|NCT03021863|Active Comparator|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement for non-responders 28 days)
2482155|NCT03021863|Active Comparator|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
2482157|NCT03021863|Active Comparator|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
2482159|NCT03021863|Active Comparator|Group E Reminder|Tone of reminder email (generic reminders at 14 days followed by generic for non-responders 28 days)
2482162|NCT03021863|Active Comparator|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
2482166|NCT03021863|Active Comparator|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
2482168|NCT03021863|Active Comparator|Group H Reminder|Tone of reminder email (duty 14 days followed by generic for non-responders 28 days)
2482169|NCT03021863|Active Comparator|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic for non-responders 28 days)
2482193|NCT03021369|Active Comparator|Pleural drainage system Medela|These patients receive the digital Medela system
2482205|NCT03021369|Active Comparator|Pleural drainage system Ocean|These patients receive the analogue Maquet system
3193340|NCT00817271|Experimental|2|
3193341|NCT00817284|Experimental|arm I|Bevacizumab + Irinotecan and concomitant radiotherapy
3193342|NCT00817284|Experimental|Arm II|Bevacizumab and Temozolomide and concomitant radiotherapy
3193343|NCT00817297|Other|V60 Mask, Then Conventional Mask|Experimental V60 Mask Ventilator for treating adult patients with COPD, then Comparator Conventional Mask Ventilator for treating adult patients with COPD
2482533|NCT03019224|Placebo Comparator|Group 1|The use of desensitizing dentifrice [Sucralose (S) Control dentifrice)] in plastic tray.
2482534|NCT03019224|Experimental|Group 2|The use of desensitizing dentifrice [Sodium fluoride (FS) with 1450ppm of fluorine (Close up triple, Unilever)] in plastic tray.
2482535|NCT03019224|Experimental|Group 3|The use of desensitizing dentifrice [Arginine, calcium carbonate (ACC) and sodium monofluorophosphate with 1450 ppm fluorine (Colgate sensitive pro-relief, Colgate-Palmolive)] in plastic tray.
2482536|NCT03019224|Experimental|Group 4|The use of desensitizing dentifrice [Sodium fluoride based dentifrice with 1450 ppm of fluorine associated with 5% potassium nitrate] in plastic tray.
2482597|NCT03018795|Active Comparator|Ozone Group|Decontamination of implant surfaces with saline irrigation and additional ozone therapy in combination with regenerative surgery
2482598|NCT03018795|Active Comparator|Control Group|Decontamination of implant surfaces with saline irrigation alone in combination with regenerative surgery
2482681|NCT03018457||patients who need a dental implants|
3193344|NCT00817297|Other|Conventional Mask, Then V60 Mask|Comparator Conventional Mask noninvasive Ventilator for treating adult patients with COPD, then Experimental V60 Mask noninvasive Ventilator for treating adult patients with COPD.
2482838|NCT03017157||Anterior Myocardial Infarction|Patients who have suffered anterior myocardial infarction in our hospital
2482862|NCT03016858|Experimental|NIIASV|undergoing Thoracoscopic Bullectomy Surgery under nonintubated intravenous anesthesia with spontaneous ventilation(NIIASV)
2482863|NCT03016858|Active Comparator|IASLV|undergoing Thoracoscopic Bullectomy Surgery under intubated anesthesia with single-lung mechanical ventilation(IASLV)
2482915|NCT03016676|Experimental|Spinal manipulation|Spinal manipulation -High velocity low amplitude thrust (HVLA), Dosages : 2 repetition at the same time, Duration-10-20 minutes. total 2 weeks.
2482922|NCT03016676|Experimental|Exercise therapy|Exercise Therapy(ET): Exercise therapy (ET) 3 program: self education, supervised exercise visits, and home exercise. Duration-45 minutes,Total number of visits 12 for 2 weeks.
2482960|NCT03016364|Experimental|APP in dosage adjustment|Through the guidance of APP software, clinical doctors try to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain.
2483043|NCT03016091|Experimental|Arm 1|IV Pembrolizumab 200mg, given every 3 weeks until disease progression or intolerable toxicity
2483159|NCT03014947|Experimental|MSB11022|
2483160|NCT03014947|Active Comparator|US-licensed Humira|
3193345|NCT00817310||Severe IVH|Infants born at less than 1500g with diagnosis of Grade II or IV IVH
3193346|NCT00817310||control|infants born at less than 1500g without IVH on HUS
3193347|NCT00817323|Experimental|Quetiapine fumurate (Seroquel)|See Detailed description
2481576|NCT03025763||Unaffected controls|Unaffected controls who may have undergone clinically indicated craniofacial surgery for trauma or conditions other than craniosynostosis or bone disease
2481682|NCT03025022|Experimental|14C-JNJ-42847922 40 miiligram (mg)|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 on Day 1.
2481766|NCT03024710|Experimental|Intervention cluster|"The study participants (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria for the intervention group.All the mothers of the selected infants along with family member/s will receive training on standard complementary feeding practices . Refresher training will be arranged 3 months after the first training.~The CHRW will visit each infant house till the infant reaches at 12 month of age at every two month interval. During the visit CHRWs will measure weight through standard SECA digital weighing scale in nearest 100 gm (precision 20 gram) and length in nearest 0.1 cm by local made standard length board with movable foot board."
2481769|NCT03024710|No Intervention|Controlled cluster|The participants for control clusters will be (the infant who has completed his/her 6 month of age from the date of birth along with their mother) will be enrolled from MNCH database according to criteria. The mother-infant pairs from control cluster will receive the usual care.
2481823|NCT03024190|Experimental|with Kinesiotaping|"stretching exercises combined with Kinesiotaping~regular OT rehabilitation program for 3 weeks"
2481829|NCT03024190|Other|control group|"the patients will receive 15-min stretching exercises~regular OT rehabilitation program for 3 weeks"
2481874|NCT03023644|Experimental|Cogmed Working Memory Training|The group randomized to the intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the children's responses, time spent on each task, and evolution curves.
2481882|NCT03023644|No Intervention|Standard of Care|Children randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, a child in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like children assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
2482110|NCT03022136|Experimental|Epidural Block|Epidural block for patients undergoing urological surgery
2482230|NCT03021330|Active Comparator|DA Regimen|Patients receive standard DA induction regimen including daunomycin and cytarabine.
2482231|NCT03021330|Experimental|Intermediate Dose of DA Regimen|Patients receive DA induction regimen including daunomycin and intermediate dose of cytarabine.
2482438|NCT03020030|Other|Initial Low Risk (Initial LR)|"Meets all the following criteria: B-ALL, Age 1-<15 years, WBC < 50,000/microliter, CNS-1 or CNS-2, no BCR-ABL1, no iAMP21, and no VHR characteristics.~Treated with Induction IA (vincristine, dexamethasone, pegaspargase), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
2482439|NCT03020030|Other|Initial High Risk (Initial HR)|"Meets at least one of the following criteria: Age >=15 years, WBC >=50,000/microliter, CNS-3, T-ALL, iAMP21, BCR-ABL1~And: No VHR characteristics~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
3158988|NCT00396786|Experimental|Arm 2|
3158989|NCT00396786|Experimental|Arm 3|
3158990|NCT00396786|Experimental|Arm 4|
3158991|NCT00396786|Experimental|Arm 5|
3158992|NCT00396786|Active Comparator|Arm 6|
3158993|NCT00396825|Experimental|Active treatment|Subjects randomized to this arm will receive the Family Caregiver Kit composed of the Williams LifeSkills Family Caregiver Video and Workbook and will also receive telephone coaching
3158994|NCT00396825|No Intervention|Control|Subjects randomized to this arm will receive no intervention and serve as wait list controls. They will undergo the same evaluations as the Intervention arm subjects at comparable times. In a crossover design, once subjects have finished serving as controls, they will be given the video, workbook, and telephone calls from a social worker and tested one more time.
3158995|NCT00396864|Experimental|NPI-0052|Advanced Solid Tumor Malignancies and Refractory Lymphoma
3158996|NCT00396994|Experimental|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
3158997|NCT00396994|Placebo Comparator|2|10 minutes per day standing on sham low mechanical stimulation platform
3158998|NCT00397072|Experimental|ZK-EPO|administered iv for 3 h every 21 days; dose reductions to 12 or 9 mg/m2 ZK-EPO were allowed in order to manage any treatment-related toxicity.
3158999|NCT00397137|Experimental|Stapled Anopexy|Circular stapled anopexy
3159000|NCT00397137|Active Comparator|Conventional Haemorrhoidectomy|Closed diathermy haemorrhoidectomy
3159001|NCT00397163|Active Comparator|Remote preconditioning|Simultaneous inflation (5min) and deflation (5min) of cuffs placed on upper arm and thigh - cycle repeated 2 times
3159002|NCT00397163|Placebo Comparator|Placebo|Deflated cuffs placed on upperarm and thigh for 20 minutes
3159003|NCT00397202|Active Comparator|The DivaCupTM|
3159004|NCT00397228|Experimental|ALTROPANE®|ALTROPANE® dosing
3159006|NCT00397345|Experimental|Trovax|
3159007|NCT00397345|Placebo Comparator|Placebo|
3173497|NCT00612742|Experimental|testosterone gel|1% testosterone transdermal gel
2481591|NCT03025971|Other|Single arm observational study|Intervention: J-Valve Transcatheter Aortic valve replacement. Prospective, multi-center, single arm observational study. Subjects will include patients with severe aortic valve stenosis and/or severe aortic regurgitation who require replacement of their native aortic valve.
3173498|NCT00612742|Placebo Comparator|placebo gel|placebo transdermal gel
2481645|NCT03025230|Experimental|Experimental group|Dry needling technique and the application of a rectangular, biphasic, asymmetric analgesic electric current by selecting a frequency of 2 Hz with a pulse width 40 μs, with an intensity located at the tolerance threshold and for a time of 20 minutes.
2481647|NCT03025230|Active Comparator|Control group|Dry technique in PG.The needle will be moved in-and-out into different directions to encounter sensitive spots in PG region.
2481693|NCT03024957|Active Comparator|Dexmedetomidine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine in 1 mL volume intrathecally.
2481706|NCT03024957|Active Comparator|Morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 0.5 mg morphine sulphate in 1 mL volume intrathecally.
2481717|NCT03024957|Active Comparator|Dexmedetomidine + morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 mL volume and 5 μg of dexmedetomidine plus 0.5 mg of morphine sulphate in 1 mL volume intrathecally.
2481758|NCT03024515|Experimental|Standard Practice Arm|Standard Practice Arm with opioids titration of physicians' choice
2481764|NCT03024515|Experimental|Structured Tritration Arm|Structured titration method with predefined titration steps with the use of oxycodone immediate-release and oxycodone sustained-release preparations.
2481821|NCT03024242|Experimental|Tight vaginoscope|The vaginoscope was extracted and loaded inside a thick rubber ring before its reinsertion inside the vagina again. To avoid leakage from the center of the thick rubber ring, the vaginoscopy is inserted through a premade central cruciate incision.
2481864|NCT03023917|Active Comparator|umbilical cord clamping immediately|"Umbilical cord was clamped immediately, or as close as possible, after delivery of the infant's shoulders. (This was standard practice in the study hospital, thus it served as the control group)."
2481866|NCT03023917|Experimental|umbilical cord milking|preterm baby were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
2481912|NCT03023475|Active Comparator|LigaSure endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the LigaSure device.
2481913|NCT03023475|Active Comparator|TLS2 endoscopic radial harvesting|The endoscopic vessel harvesting will be performed using the TLS2 device.
2481937|NCT03023163||Older SCI|Individuals that are between the ages of 50-75 years old, have a traumatic SCI, level of injury between C1-T12, non-ambulatory (wheelchair dependent), AIS grade A, B, or C, and injury occurred more than 1 year ago.
2481943|NCT03023163||Older Able-Bodied Controls|Individuals that are between the ages of 50-75 years old and primary language is English.
2481949|NCT03023163||Longitudinal SCI|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
2481951|NCT03023163||Longitudinal Able-Bodied Controls|Individuals that are between the ages of 28-54 years old and previously participated in the Impact of Age on Cardiovascular, Cerebrovascular, and Cognitive Health study in a 3-5 year span.
3173499|NCT00612755|Experimental|1|Peginterferon alfa-2a 180 mcg/week + 1000-1200 mg/day ribavirin during 24 weeks
2482084|NCT03022188||Observational|Observational
2482121|NCT03021824||Moderate-Severe ARDS|All adults admitted to participating ICUs with study-defined moderate-to-severe ARDS.
2482196|NCT03021408|Experimental|MIRT + Treadmill|In the context of MIRT, the gait training in this group will be performed by using a treadmill without cues.
2482210|NCT03021408|Experimental|MIRT + Treadmill Plus|In the context of MIRT, the gait training in this group will be performed by using a treadmill with visual and auditory cues.
2482217|NCT03021408|Experimental|MIRT + Virtual Reality|In the context of MIRT, the gait training in this group will be performed by using Virtual Reality with enhanced perceptions (visual, auditory, and haptic inputs).
2482247|NCT03021057|Experimental|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
2482400|NCT03020108||Group 1|The group 1 will comprise of 30 patients with benign ovarian cysts such as mature teratoma or simple serous cysts on ultrasound examination.
2482402|NCT03020108||Group 2|The group 2 will comprise of 30 patients with diagnosis of stage 1-2 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
2482405|NCT03020108||Group 3|The group 3 will comprise of 30 patients with diagnosis of stage 3-4 endometriosis in guidance with the revised American Society for Reproductive Medicine classification.
2482453|NCT03019809|Experimental|Plerixafor/G-CSF for HSCT conditioning|Myeloablative conditioning regimen with Plerixafor and G-CSF as addition agents before stem cell transplantation in WAS patients.
2482486|NCT03019471||Lung cancer|Isolate Tumor DNA from the patients blood.
2482498|NCT03019471||Breast cancer|Isolate Tumor DNA from the patients blood.
2482506|NCT03019471||Colorectal cancer|Isolate Tumor DNA from the patients blood.
2482507|NCT03019471||Glioma|Isolate Tumor DNA from the patients blood.
2482556|NCT03019120|Experimental|Active Comparator: Intervention group|Vitamin D supplementation for subjects with below normal levels of this vitamin.
2482627|NCT03018704|Placebo Comparator|Placebo|a placebo control arm
2482633|NCT03018704|Experimental|Topiramate|Topiramate an FDA approved anticonvulsant has been shown effective in the treatment of alcohol use disorder but there is no data supporting use in minority patients.
2482697|NCT03017976||Competitive swimmers|Regular and naïf competitive swimmers will be followed for a mean period of 90 days. A battery of measurements and biological samples will be collected at the baseline evaluation and 90 days after, in order to evaluate long-term changes in respiratory health biomarkers. Measurements will also be performed before and after a single regular training session in order to assess acute effects in respiratory health biomarkers.
2482819|NCT03017183|Other|Forceps - EBUS-TBNA|In this arm, endobronchial forceps biopsy will be done first, followed by EBUS-TBNA
3173500|NCT00612755|No Intervention|2|
2481594|NCT03025893|Active Comparator|Lomustine|Patients in this control arm will receive lomustine, currently used as second-line treatment in the case of recurrence.
2481662|NCT03025256|Experimental|Treatment (nivolumab)|Patients receive nivolumab IT over 5 minutes on day 1 of every cycle. Beginning in cycle 2, patients also receive nivolumab intravenously (IV) over 30 minutes on day 1 (4 hours after the IT dose). Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2481695|NCT03024853|Experimental|BPS PAST|Participants write down about themselves in a past when they displayed their best self. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
2481705|NCT03024853|Experimental|BPS PRESENT|Participants write down about themselves in in the present, focusing on what currently makes the best version of themselves (skills, features...). Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.
2481714|NCT03024853|Experimental|BPS FUTURE|"Participants write down about themselves in the future after everything has gone as well as it possibly could. Then, they make a video with this text and a chosen song, watch the video and then they visualize (imagine) the content.~This is the original BPS exercise (already validated in other studies)."
2481721|NCT03024853|Active Comparator|CONTROL|Participants write down the activities they did during the last 24 hours. Then, they visualize (imagine) the content. They practice the visualization exercise for 7 consecutive days.
2481762|NCT03024541||LASA study|
2481767|NCT03024541||InterRAI consortium|
2481827|NCT03024294|Other|Patients undergoing VATS lobectomy or segmentectomy|Patients undergoing VATS lobectomy or segmentectomy performed by one of the surgeons in the Division of Thoracic Surgery who are then placed on this specific post-operative care pathway to determine the rate of discharge of these patients by post-operative day (POD) three.
2481909|NCT03023865|Experimental|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
2482029|NCT03022747|Active Comparator|Standard maintenance therapy|Standard maintenance therapy with 6 mercaptopurine and methotrexate
2482030|NCT03022747|Experimental|Allopurinol treatment|The second 12 week phase during which allopurinol is added to oral 6-mercaptopurine and methotrexate therapy
2482058|NCT03022318|Experimental|once daily|carbidopa-levodopa 25-100 mg tablets once daily hs for up to 32 days
2482059|NCT03022318|Experimental|3 times daily|carbidopa-levodopa 25-100 mg tablets 3 times daily,in the morning, with supper and hs for up to 32 days
2482133|NCT03022123|Experimental|pegylated liposomal doxorubicin|PL-doxorubicin 35-40 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
2482137|NCT03022123|Active Comparator|Epirubicin|Epirubicin 70 mg/m(2) was given on day 1 in combination with standard dosage of prednisone, vincristine, cyclophosphamide (according to CHOP regimen) every 21 days for six courses;Rituximab 375 mg/m(2) was given on day 0.
2482199|NCT03021486|Experimental|Group I (haloperidol)|Patients receive haloperidol IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
2482207|NCT03021486|Experimental|Group II (chlorpromazine)|Patients receive chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
2482218|NCT03021486|Experimental|Group III (haloperidol, chlorpromazine)|Patients receive haloperidol and chlorpromazine IV over 3-15 minutes every 4 hours in the absence of unacceptable toxicity.
2482251|NCT03020979|Experimental|500mg apatinib|Patients will receive 500mg of apatinib tablet orally, once daily.
2482331|NCT03020771|Active Comparator|5 mcg IM|
2482335|NCT03020771|Active Comparator|5 mcg SC|
2482337|NCT03020771|Placebo Comparator|5 mcg IM control|0.9% NaCl Solution
2482342|NCT03020771|Placebo Comparator|5 mcg SC control|0.9% NaCl Solution
2482349|NCT03020771|Active Comparator|10 mcg IM|
2482350|NCT03020771|Active Comparator|10 mcg SC|
2482401|NCT03020134|Experimental|PKGroup(Ravidasvir/Danoprevir/Ritonavir)|Ravidasvir + Danoprevir/ Ritonavir
2482404|NCT03020134|Placebo Comparator|Placebo Group|Placebo
2482480|NCT03019419|Experimental|Perampanel 4mg|Once daily 4mg of perampanel with dose-escalation tolerable from 2mg to 4mg for 48 weeks
2482481|NCT03019419|Experimental|Perampanel 8mg|Once daily 8mg of perampanel with dose-escalation tolerable from 2mg to 8mg for 48 weeks
2482482|NCT03019419|Placebo Comparator|Placebo|Once daily placebo for control for 48 weeks
2482570|NCT03018977|Active Comparator|Sedative weaning protocol|We create the new sedative weaning protocol and then use the sedative weaning protocol.
2482575|NCT03018977|Placebo Comparator|Usual Care|no use sedative weaning protocol. Sedative or/and analgesic medications are adjusted base on physician
2482605|NCT03018626|Active Comparator|DA-EPOCH-R|DA-EPOCH-R regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, etoposide(50 mg/m2), doxorubicin(10 mg/m2) and vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours), cyclophosphamide(750 mg/m2)/dayg IV on days 5, prednisone (60 mg/m2) given orally bid on days 1 through to 5.All patients received granulocyte colony-stimulating factor (G-CSF) beginning on day 6 and continued until the ANC was more than 5 × 109/L above the nadir level. The adjustment paradigm was based on the ANC nadir in the previous cycle as previously described(Wilson, Grossbard et al. 2002)
2482911|NCT03016793|Active Comparator|β- tricalcium phosphate alone|β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing
3173501|NCT00612781|Other|A|
3173502|NCT00612781|Other|B|
3173503|NCT00612794|Experimental|1|exenatide once weekly, 0.8mg
3173504|NCT00612794|Experimental|2|exenatide once weekly, 2.0mg
3173505|NCT00612794|Placebo Comparator|3|volume equivalent to 0.8mg of exenatide once weekly
3173506|NCT00612794|Placebo Comparator|4|volume equivalent to 2.0mg of exenatide once weekly
3173507|NCT00612833|Active Comparator|cautery excision with fascial interposition|Contraception using cautery and excision with fascial interposition
3173508|NCT00612833|Active Comparator|B|Cautery and excision without fascial interposition
3173509|NCT00612833|Active Comparator|C|Ligation and excision with fascial interposition
3173510|NCT00612846|Experimental|A|
3173511|NCT00612846|Experimental|B|
2481608|NCT03025659||Pediatric post-cardiac surgery|All immediately post-operative pediatric cardiac patients will be enrolled. Standard of care laboratory analysis will be performed based on current clinical protocols. Results for lactate, blood gases, liver enzymes, creatinine, glucose, hemoglobin, hematocrit and other direct and indirect measure of cardiac output will be collected. Investigators will also measure pyruvate levels at specific time points, which is not part of standard of care. To measure pyruvate, an additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw. The lactate/pyruvate ratio will be calculated and compared to direct and indirect measure of cardiac output described above.
2481668|NCT03025295|Experimental|Dexmedetomidine group|Induction dose of dexmedetomidine is 1ug/kg with 10min, maintain dose is 0.4ug/kg/h until 30 min before surgery completion.
2481669|NCT03025295|Placebo Comparator|Saline group|Control group given equal volume of saline with the dexmedetomidine group.
2481738|NCT03024814|Experimental|acetaminophen group|Babies who took acetaminophen
2481739|NCT03024814|Experimental|Placebo group (Dextrose 5)|Babies who took placebo
2481796|NCT03024385||Mothers of healthy infants|Mothers of young infants presenting for well child visits between the ages of 0-2 years of age
2481850|NCT03023956||ANF|anatomic neck fractures of proximal humerus
2481851|NCT03023956||SNF|surgical neck fractures of proximal humerus
2481876|NCT03023592|Experimental|Iguratimod|Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
2481944|NCT03023358|Experimental|chidamide regimen|patients receive chidamide (30mg twice every week) po, cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
2481947|NCT03023358|Active Comparator|CDOP regimen|patients receive cyclophosphamide (750mg/m2) iv on day 1, liposomal doxorubicin (30mg/m2) iv on day 1, vincristine (1.4mg/m2, max to 2mg) iv on day 1 and prednisone (100mg/d) po on day 1-5.
2482028|NCT03022695|Experimental|Treatment with high-intensity focused ultrasound|
2482062|NCT03022409|Experimental|AZD6738|AZD6738 (160 mg) tablet twice daily continuous dosing for a minimum of 9 days and a maximum of 21 days.
2482067|NCT03022409|Experimental|Olaparib|Olaparib (300 mg) tablets administered orally twice daily continuously for a minimum of 9 days and a maximum of 21 days.
2482112|NCT03021980|Experimental|SuperFIT|This is the intervention group. They will receive the intervention SuperFIT.
2482113|NCT03021980|No Intervention|Control|This is the control group. Participants will receive 'care as usual' in this arm.
2482175|NCT03021733||Non-operative|Patients whom elected non-operative treatment
2482177|NCT03021733||Operative|Patients whom elected operative treatment
2482209|NCT03021460|Experimental|Treatment (ibrutinib, pembrolizumab)|Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3193348|NCT00817362|Experimental|IPI-504 and Trastuzumab|"IPI-504 IV infusion 300 mg/m2 once weekly in combination with trastuzumab infusion every 3 weeks. (Continuous schedule)~Three week cycle with IPI-504 twice per week for 2 weeks and trastuzumab once per cycle followed by one week without treatment.~Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.~IPI-504 and trastuzumab will be administered for all cycles. Until progression or unacceptable toxicity develops."
2482334|NCT03020459|Experimental|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX), the intervention of peeling-reposition was used to peel and unfold the ILM. And the postoperative posture would be prone position in two weeks for all patients after the operation."
2482336|NCT03020459|Active Comparator|peeling|"After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany) with the help of Constellation 23-gauge vitrectomy system, the intervention of peeling was used to grasped ILM with end-gripping forceps. And the postoperative posture would be prone position in two weeks for all patients after the operation."
2482454|NCT03019757||Alzheimer's disease|Individuals with a clinical diagnosis of Alzheimer's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2482457|NCT03019757||Lewy Body dementia|Individuals with a clinical diagnosis of Lewy Body Dementia will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2482464|NCT03019757||Parkinson's disease|Individuals with a clinical diagnosis of Parkinson's disease will undergo the interventions including DaTscan, F18-AV-45, FDG-PET, APOE genotype, Polysomnogram, and Clinical Assessment.
2482538|NCT03019211|Experimental|Hydrotherapy|Exercise performed in an aquatic environment. The participants will perform static/dynamic exercises (balance and resistance training) in an aquatic environment. Training volume and intensity we will increase systematically over 12 weeks.
2482540|NCT03019211|Active Comparator|Control|The participants will perform exercises (balance and resistance training) like hydrotherapy group but out of the aquatic environment, during a 12 weeks training period (3sessions/week). Training volume and intensity we will increase systematically over 12 weeks.
2482619|NCT03018730|Experimental|PRX-102|PRX-102 infusion every 2 weeks
2482698|NCT03018145|Experimental|Standard stretcher group|Use a standard stretcher car as a transporting method in the operating room
2482706|NCT03018145|Active Comparator|Wagon group|Use a wagon as a transporting method in the operating room
2482843|NCT03017443|Experimental|Nutrisystem My Way|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem My Way plan.
2482845|NCT03017443|Experimental|Nutrisystem Turbo 10|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem Turbo 10 plan.
2482847|NCT03017443|Experimental|Nutrisystem DASH|All subjects received Nutrisystem pre-packaged, portion-controlled foods and followed the Nutrisystem DASH plan.
2482957|NCT03016260||Infliximab biosimilar (Remsima®/ Inflectra®)|
2482958|NCT03016260||Etanercept biosimilar (Benepali®)|
2481732|NCT03024840|Experimental|sevoflurane|Sevoflurane is inhalated with 1%-2% after anesthesia induction until end of the surgery.
2481733|NCT03024840|Experimental|propofol|Propofol is injected with 9-15 mg/kg/h after anesthesia induction until end of the surgery.
2481748|NCT03024489|Experimental|Palbociclib-Cetuximab-IMRT|"IMRT will be administered 5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.~Cetuximab will be administered 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.~Palbociclib will be administered orally daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49) on 3 dose levels and the MTD."
2481792|NCT03024086|Experimental|DWJ1252|DWJ1252 + Placebo of Gasmotin
2481794|NCT03024086|Active Comparator|Gasmotin|Gasmotin + Placebo of DWJ1252
2481845|NCT03023969|Active Comparator|group A|percutaneous ozone intradiscal injection group A receive 10 ml of ozone oxygen mixture 40 ug O3/ ml O2
2481846|NCT03023969|Active Comparator|group B|percutaneous ozone intradiscal injection group receive 10 ml of ozone oxygen mixture 30 ug O3/ ml O2.
3159008|NCT00397384|Experimental|Treatment (cetuximab and erlotinib hydrochloride)|Patients receive cetuximab IV over 1-2 hours on days 1, 8, and 15 and erlotinib hydrochloride PO QD on days 8-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
2481965|NCT03023319|Experimental|Bosutinib and Pemetrexed|Bosutinib and pemetrexed
2482017|NCT03022708|Experimental|Xeltis Bioabsorbable Pulmonary Valved Conduit|"The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device.~The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~In addition, the PV conduit can be used for the following indications:~replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).~Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve."
2482081|NCT03022344|Sham Comparator|Healthy|Patients in this cohort consist of 100 healthy patients
2482086|NCT03022344|Sham Comparator|Diabetes mellitus|Newly diagnosed (< 1 year) diabetes patients clinically classified as type-2 diabetes patients of both sex
2482154|NCT03022006|Other|Dialysis patients with genotype 1 HCV infection|elbasvir/grazoprevir
2482188|NCT03021525|Experimental|Individualized Goal Directed Therapy (iGDT)|Patients receive fluids and catecholamines following a protocol of individualized parameters achieved by extended hemodynamic monitoring.
2482189|NCT03021525|Active Comparator|Control|Patients in the control group will be treated according to established basic treatment goals.
2482264|NCT03021200|Experimental|Indocyanine green in Conventional Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (SPY-Elite) for conventional oncological surgeries
2482272|NCT03021200|Experimental|Indocyanine green in minimally invasive Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Pinpoint) for minimally invasive oncological surgeries
2482274|NCT03021200|Experimental|Indocyanine green in robot-assisted Oncological Surgery|Use of indocyanine green laser fluorescence angiography (AFLIICG) platforms (Firefly) for robot-assisted oncological surgeries
2482446|NCT03019848|Experimental|Curcumin|Each patient of this group will receive 1.67 grams of curcumin ( 7 capsules of 231 mg) divided in 3 doses daily for 6 months.
2482455|NCT03019848|Placebo Comparator|Placebo|The control group will receive 7-capsules/ day identical in color and size, containing placebo for 6 months.
2482565|NCT03018899|Experimental|paravertebral block|patients received ultrasound guided two-segment paravertebral block for percutaneous nephrolithotomy
2482574|NCT03018899|Active Comparator|Epidural|patients received thoracic epidural anesthesia for percutaneous nephrolithotomy
2482623|NCT03018587|Experimental|TruSculpt|Subject(s) will receive 1 radio frequency treatment in desired area.
2482674|NCT03018301|Active Comparator|Ketamine group|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
2482677|NCT03018301|Placebo Comparator|Control group|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
2482759|NCT03017807|Experimental|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance.
2482842|NCT03017404|Experimental|treatment group:35 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2482844|NCT03017404|Experimental|treatment group:40 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2482846|NCT03017404|Experimental|treatment group:45 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
2482849|NCT03017404|Experimental|treatment group:50 mg/m(2)|Doxorubicin Hydrochloride Liposome injection combination with cyclophosphamide and sequential treatment of docetaxel, 4 cycles (each cycle is 21 days) of chemotherapy
3159009|NCT00397423|Active Comparator|1|1,G-CSF,intervention
3159010|NCT00397423|Placebo Comparator|2|2,NS,intervention
3159011|NCT00397436|Experimental|1|Comparing irradiated skin to non irradiated skin.
3159012|NCT00397449|Experimental|1, 2, 3|
3159013|NCT00397501|Active Comparator|HER-2 positive subjects|HER-2 positive subjects treated with trastuzumab
3159014|NCT00397501|Active Comparator|HER-2 negative subjects|HER-2 negative subjects not treated with trastuzumab
3159015|NCT00397553|Experimental|Insulin Glulisine|
3159016|NCT00397605|Experimental|Crossover|
3159017|NCT00397657|Active Comparator|Extended release niacin|
3159018|NCT00397657|Active Comparator|Ezetimibe|
3159019|NCT00397696|Experimental|[123I] 5-IA|To assess [123I] 5IA and SPECT imaging
2481665|NCT03025282|Active Comparator|Betneval ointment - Non-desquamated zone|This comparator containing Betamethasone valerate 0.1% serves as positive control.
2481666|NCT03025282|Experimental|CD10367 3% Solution - Desquamated zone|
2481667|NCT03025282|Placebo Comparator|CD10367 solution placebo - Desquamated zone|
2481731|NCT03024827|Experimental|Medical Cannabis Oil|CanniMed® 1:20
2481807|NCT03024372|Active Comparator|Conventional sutures|AV fistula creation with sutures
2481816|NCT03024372|Active Comparator|Anastoclips|AV fistula creation with clips
3193349|NCT00817375|Experimental|SSRI treated group|SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline
3193350|NCT00817375|Active Comparator|non-SSRI treated group|non-SSRI treated group is depressive patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
3193351|NCT00817388||1|patients will be asked to provide a urine specimen and complete a questionnaire.
2481932|NCT03023046|Experimental|Treatment (chemotherapy)|Patients receive etoposide IV over 96 hours, doxorubicin IV over 96 hours, and vincristine sulfate IV over 96 hours on days 1-4. Patients also receive cyclophosphamide IV over 1 hour on day 5 and prednisone PO BID on days 1-5. Patients who are Ph+ also receive imatinib mesylate or dasatinib PO QD on days 1-14. Patients who are CD20+ also receive rituximab IV on day 1 or day 5. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
2482088|NCT03022175|Experimental|SPR741|"SPR741 is a novel chemical entity known as a potentiator that specifically interacts with the outer membrane of Gram-negative bacteria to increase the membrane's permeability. This increase in permeability allows Gram-positive antibiotics to enter and kill the cell.~SAD cohorts: Subjects will receive single doses of SPR741 over 60 minute IV infusion. Planned doses to be studied are 5, 15, 50, 100, 200, 400, 600 and 800 mg.~MAD cohorts: Subjects will receive SPR741 over 60 minute IV infusion three times a day (TID). Four dose groups will be studied. Doses will be determined by assessing SAD cohort data."
2482089|NCT03022175|Placebo Comparator|Placebo|"The placebo used during this study is normal saline (0.9% sodium chloride for injection).~SAD: Subjects will receive single infusions of placebo (0.9% sodium chloride for injection) over 60 minutes.~MAD: Subjects will receive TID infusions of placebo over 60 minutes for 14 days"
2482127|NCT03021850|Active Comparator|Stretching associated with shortwave heating|Applying deep heat through the shortwave equipment for 20 minutes, in coplanar application to the posterior part of the thigh associated with flexibility training of the hamstrings in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles in 10 repetitions of 30 seconds, with a 10 second pause between each repetition.
2482131|NCT03021850|Active Comparator|Stretching associated with cryotherapy|Cryotherapy application for 20 minutes, applied to the posterior part of the thigh associated with flexibility training of the hamstring muscles in the last 10 minutes of the session, performed by passive static stretching of the hamstring muscles, in 10 repetitions of 30 seconds , with a 10 second pause between each repetition.
2482135|NCT03021850|Other|Stretching isolated|The flexibility training of the hamstring muscles will be by passive static stretching of the hamstring muscles in 10 repetitions of 30-second , with a 10-second pause between each repetition.
2482197|NCT03021577|Active Comparator|Orbital Atherectomy System (OAS) Group|Subjects randomized to OAS. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
2482208|NCT03021577|Active Comparator|Rotational Atherectomy (RA) Group|Subjects randomized to RA using the Rotablator Rotational Atherectomy System. In a subset of patients (n= 20) a baseline cardiac magnetic Resonance Imaging (MRI) scan will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
2482246|NCT03021083|Experimental|IONSYS Administration|"Patients who have elective multi-level spinal fusions under general anesthesia (who do not receive methadone) will be enrolled. In addition, all patients will receive Pepcid 20 mg, dexamethasone 10 mg, and ondansetron 4 mg.~When patients will arrive in the post anesthesia care unit (PACU), pain will initially be controlled with IV hydromorphone to achieve an NRS score of 3 or less. Once transferred to the step down unit (SDU), the IONSYS patch will be applied. IONSYS should be utilized when they have pain, but rescue analgesia will be available. If severe pain continues, the chronic pain service will be consulted, to potentially change the medications.~Patients will be assessed for pain at rest and with PT in the AM and PM of POD 1 and POD 2. The IONSYS system will be discontinued after 48 hours, and a total dose of fentanyl received per 24 hours will be recorded. PT milestones for discharge will be assessed on the afternoon of POD 1 and POD 2."
2482329|NCT03020511|Other|Ancient wheat flours|"We prospectively will survey 30 nuns from the Congregazione delle Suore Collegine della Santa Famiglia, Palermo, Italy. The subjects will be recruited between January 2017 and June 2017 and will be examined before and after the diet period (30 days) with ancient grains, undergoing clinical evaluation and blood and feces samples collection. Ancient wheat flours will be administered in open label for 30 days"
2482375|NCT03020238|Placebo Comparator|BiClamp group|BiClamp forcep (BiClamp® forcep, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
2482378|NCT03020238|Active Comparator|water jet group|water jet (ERBEJET®2, ERBE Elektromedizin, GmbH, Tuebingen, Germany) is used to dissect inferior hypogastric plexus
2482470|NCT03019601|Experimental|Group education|Non pregnant HIV+ mothers were exposed to a structured educational intervention on family planning facilitated by Peer Champions.
2482485|NCT03019354|Experimental|high-flow nasal oxygen|high-flow nasal oxygen was used during intravenous general anesthesia
2482500|NCT03019354|Active Comparator|Oxygen mask|oxygen mask was used during intravenous general anesthesia
2482552|NCT03019081|Experimental|Anorexia nervosa-study drug|"Drug: Isoproterenol Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant. The isoproterenol dose will range from 0.1 micrograms to 4.0 micrograms and exposure during each visit will not exceed 25.0 micrograms. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names: Isuprel"
2482571|NCT03018990|Active Comparator|Alcoholic liver fibrosis|
2482576|NCT03018990|Active Comparator|Non-alcoholic steatohepatitis|
2481670|NCT03024892|Experimental|ICG gallbladder|patients who received ICG injection via gallbladder and received fluroscence image guided surgery
2481671|NCT03024892|Experimental|ICG IV|patients who received ICG injection via peripheral vein and received fluroscence image guided surgery
2481672|NCT03024892|Sham Comparator|LC conventional|Patients received conventional laparoscopic cholecystectomy
2481675|NCT03024892|Sham Comparator|LC conventional and IOC|Patients received conventional laparoscopic cholecystectomy + intraoperative cholangiography
2481773|NCT03024697|Active Comparator|PECs Block|Patients randomised to receive pectoral plane blocks and a sham local anaesthetic infusion wound catheter
2481777|NCT03024697|Active Comparator|LA Infusion|Patients randomised to receive a local anaesthetic infusion wound catheter; No sham pectoral plane block performed as patients usually under general anaesthetic at time of block.
2481781|NCT03024697|Active Comparator|PECs Block & LA Infusion|Patients randomised to receive pectoral plane blocks and a local anaesthetic infusion wound catheter.
2481890|NCT03023904|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks for up to 2 years (104 weeks) in the absence of disease progression or unacceptable toxicity.
2482031|NCT03023254|Other|hydrotherapy group|"Subjects included in the hydrotherapy group will undergo a 3-week Avène hydrotherapy in addition to their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
2482033|NCT03023254|No Intervention|Control group|"Subjects included in the control group will not undergo the hydrotherapy and will keep following their usual psoriasis and/or pruritus management (treatments and/or skin care products)."
2482064|NCT03022201|Experimental|DA-9701|In this arm, the study participants will receive DA-9701 30mg + placebo domperidone tablet tid ac for 4 weeks.
2482071|NCT03022201|Active Comparator|Domperidone|(This study is a randomized, double-blinded, non-inferiority trial. Thus it is designed to have no placebo arm.) In this arm, the study participants will receive domperidone 10mg + placebo DA-9701 tablet tid ac +for 4 weeks.
2482122|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
3193352|NCT00817427|No Intervention|Baseline|CKD subjects and healthy, matched controls will have measures of cardiovascular function (BP, HR) measure of hormonal fluid balance (renin/aldosterone) measure and measures of glucose metabolism (response to glucose load and over 24 hr profile) with 3 days of habitual sleep time
3193353|NCT00817427|Experimental|CKD- Sleep extension|Measures as in baseline but with bed time increased by 2 hours
2482280|NCT03020875|Active Comparator|PO Acetaminophen|"Preop:~Eligible patients will receive oral acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered oral acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• Oral Acetaminophen 1,000 mg every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of oral acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
2482281|NCT03020875|Active Comparator|Intravenous Acetaminophen|"Preop:~Eligible patients will receive IV acetaminophen within 3 hours of OR start time.~Postop:~Eligible patients will be administered IV acetaminophen following 1 and 2 level LLIFs supplemented with instrumented posterior fusion to evaluate pain management outcomes. Dosing for the group will be the following:~• IV Acetaminophen 1,000 mg [100 ml] every 6 hours for 48 hours postoperative. Medication will be given at least 6 hours following initial preoperative dose of IV acetaminophen.~Postop supplemental pain medications:~All patients will receive a standardized hydromorphone IV-PCA order set for 24 hours postoperatively. The use of tramadol and tapentadol will specifically be discouraged due to challenges in determining morphine-equivalent dosing with these specific agents. Similarly, acetaminophen containing combination products (e.g. oxycodone/acetaminophen or hydrocodone/acetaminophen) will not be allowed due to overlap with the primary study medications."
2482295|NCT03020563|Active Comparator|Liposomal Bupivacaine|Time release Bupivacaine
2482297|NCT03020563|Placebo Comparator|Bupivacaine|Immediate Acting Bupivacaine
2482327|NCT03020485|Experimental|Isomaltulose|50g of isomaltulose dissolved in 250ml of water
2482332|NCT03020485|Experimental|Sucrose|50g of sucrose dissolved in 250ml of water
2482380|NCT03020251|Active Comparator|control group (C group)|patient will receive preoperative chest physiotherapy (standard supportive care)
2482383|NCT03020251|Experimental|rehabilitation group (R group)|patient will receive preoperative chest physiotherapy and a preoperative rehabilitation program at home (exercise training)
2482428|NCT03019822|Other|Placebo, LSD, d-Amphetamine, MDMA|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, lysergic acid diethylamide (LSD), d-Amphetamine or methylenedioxymethamphetamine (MDMA) and followed by all other drugs each separated by a wash-out phase
2482429|NCT03019822|Other|LSD, d-Amphetamine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2482430|NCT03019822|Other|d-Amphetamine, MDMA, LSD, Placebo|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2482433|NCT03019822|Other|MDMA, LSD, Placebo, d-Amphetamine,,|Cross-over within-subjects design with all treatment conditions, arms starting with either Placebo, LSD, d-Amphetamine or MDMA and followed by all other drugs each separated by a wash-out phase
2481702|NCT03024905|Experimental|Division 2|"The second division receives baseline data collection for 9 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2481712|NCT03024905|Experimental|Division 3|"The third division receives baseline data collection for 12 months then experiences interventions for the remainder of the trial.~Interventions are behavioural and device:~Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2481718|NCT03024905|Experimental|Division 4|"The fourth division receives baseline data collection for 15 months then experiences interventions for the remainder of the trial.~nterventions are behavioural and device: Behavioural: education about safety of delivery at a health facility, reminders to go for antenatal care, and a voucher for transport to the health facility at the time of delivery.~Device: A birth kit with clean delivery supplies (soap, 2 pairs of gloves, cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage)."
2481740|NCT03024502|Experimental|EPP-AF Gel 1%|Group of patients that will be treated with EPP-AF mucoadhesive gel 1%, during 7 day, 1x/day.
2481741|NCT03024502|Experimental|Clotrimazole cream|Group of patients that will be treated with clotrimazole cream, during 7 day, 1x/day.
2481742|NCT03024502|Experimental|EPP-AF Gel 2%|Group of patients that will be treated with EPP-AF mucoadhesive gel 2%, during 7 day, 1x/day.
2481833|NCT03024307|Experimental|Involvement of pharmacists in improving medication|Pharmacists involved care group. Tools used to improve medication adherence, (1)Patient medication guide (2)tailored Short Messaging Service (SMS) (3)Pharmaceutical follow-up
2481835|NCT03024307|No Intervention|usual care only|Patients were provided with usual care.
2481902|NCT03023800|Experimental|Buckle|Macular buckling and intraocular gas (C3F8) injection.
2481905|NCT03023800|Active Comparator|Vitrectomy|Vitrectomy, internal limiting membrane peeling, and gas tamponade (C3F8).
2481936|NCT03023189|Active Comparator|Tranexamic acid|At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h
2481942|NCT03023189|Placebo Comparator|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h
2482174|NCT03021720|Active Comparator|Femoral arterial access|Femoral arterial puncture for the uterine fibroid embolization procedure
2482176|NCT03021720|Experimental|Radial arterial access|Radial arterial puncture for the uterine fibroid embolization procedure
2482237|NCT03021421|Sham Comparator|Group USA|(Marcain Heavy 0.5%; AstraZeneca®, London, UK) using a 25-G Quincke spinal injector (B. Braun®, Melsungen, Germany).
2482238|NCT03021421|Active Comparator|Group PCS|"(Stimupleks A; B. Braun®, Melsungen AG, Germany) to lumbar plexus in psoas muscle compartment (injected material 20 ml local anaesthetic mixture5 ml of 2% lidocaine + 15 ml of 0.5% bupivacaine)~%2 Aritmal ampul (Osel İlaç,Turkey) and Marcaine %0.5 flacon (AstraZeneca®, London, UK)"
2482314|NCT03020758|Experimental|Dried Fruit|Daily consumption of ¾ cup blend of dried plums, figs, dates and raisins (DPFDR) for 4 weeks
2482317|NCT03020758|Experimental|Control|Daily consumption of isocaloric and macronutrient matched snack food for 4 weeks
2482364|NCT03020329|Experimental|Paclitaxel liposome, Cisplatin, 5-Fu,|Patients receive paclitaxel liposome(135mg/m2 on day 1), cisplatin (75mg/m2 on day 1,Separate injection on day 1 to 3) and fluorouracil (3750mg/m2 CIV 120h) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy(Intensive modulate radiotherapy,IMRT)and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
2482461|NCT03020017|Experimental|Treatment (NU-0129)|Patients receive NU-0129 IV over 20-50 minutes and undergo standard of care tumor resection within 8-48 hours.
3173512|NCT00612872|Experimental|Assess [123-I]CLINDE and brain imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
3173513|NCT00612898|Experimental|1|800mg BID apricitabine plus optimised background
2482546|NCT03019146|Experimental|High Intensity Interval Training (HIIT)|3 x 15 minute sessions per week for 6 weeks. Sessions include 5x intervals of cycling at 110% of Wmax derived from CPET, interspersed with 90s rest periods of unloaded cycling.
2482550|NCT03019146|Experimental|Isometric Handgrip (HOLD)|3x 15 minute sessions per week for 6 weeks Sessions include 4x intervals of 2minutes isometric handgrip contraction of dominant arm at 30% Maximal voluntary contraction, interspersed with 2minute rest periods
2482554|NCT03019146|Experimental|Remote Ischaemic Preconditioning (HUG)|3x 15 minute sessions per week for 6 weeks. Sessions include 3x intervals of 3 minutes of arm ischaemia (blood pressure cuff inflated to 200mmHg on dominant arm) interspersed with 3 minute rest periods.
2482561|NCT03019146|No Intervention|Control|No intervention
2482611|NCT03018509|Experimental|JTE-451 Dose 1|JTE-451 dose 1 for 28 days
2482613|NCT03018509|Experimental|JTE-451 Dose 2|JTE-451 dose 2 for 28 days
2482615|NCT03018509|Experimental|JTE-451 Dose 3|JTE-451 dose 3 for 28 days
2482617|NCT03018509|Experimental|JTE-451 Dose 4|JTE-451 dose 4 for 28 days
2482618|NCT03018509|Experimental|Placebo|Placebo for 28 days
2482700|NCT03017976||Recreational swimmers and swimming pool staff|Swimming pool physicochemical and microbiological characteristics and the association between each parameter measured as an indicator of water and air quality, contamination of surfaces will be evaluated and the association with recreational users, swimming teachers and pool attendants health parameters will be studied.
3173514|NCT00612898|Active Comparator|2|150mg BID lamivudine plus optimised background
3173515|NCT00612911||Major group|Patients with Idiopathic dilated cardiomyopathy
3173516|NCT00612950|Experimental|GLP-1|
3173517|NCT00612950|Experimental|GIP|
3173518|NCT00612950|Placebo Comparator|saline|
2481761|NCT03024450||HER2 positive AGC treated with H+CT|HER2 expression was assessed by IHC first. In the cases with IHC 2+, fluorescence in situ hybridization (FISH) was used to detect HER2/neu amplification levels. Only patients with high level of HER2 expression (IHC 3+ or IHC 2+ plus FISH positive) were eligible in this study.
2481834|NCT03024203|Experimental|Executive Training|Executive Training (ET) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. ET will be delivered in both individual and group settings.
2481837|NCT03024203|Experimental|Perceptual Training|Perceptual Training (PT) involves training on computerized cognitive exercises that have graded increases in difficulty so that the participant is always challenged. A therapist will be in the room with participants to address any difficulties with the program and facilitate generation of strategies. PT will be delivered in both individual and group settings.
2481899|NCT03023748|Experimental|intravenous paricalcitol solutions|"Intravenous paricalcitol will be administered twice or thrice weekly post-hemodialysis with a dose based on the baseline iPTH level divided by 120.~For instance, with a baseline iPTH 1200pg/mL, an induction dose of 10mcg twice or thrice weekly will be given. The maximum weekly dose allowed is 30mcg. Subsequent dose titration may be required depending on the serum PTH level. Intravenous paricalcitol will be continued up to 24 months."
2481920|NCT03023215|Experimental|Guided Meditation Group (GM)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
2481922|NCT03023215|Active Comparator|Focused Breathing Group (FB)|"Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.."
2481924|NCT03023215|Active Comparator|Standard of Care Group (SC)|"Participants listen to a 10 minute neutral-content audio clip from National Public Radio prior to stereotactic breast biopsy (SBB).~Electroencephalogram (EEG) activity and heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.~Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB."
2482025|NCT03022929|No Intervention|Adapted Intervention|The investigators will use GetSmart materials published by the CDC appropriate to the emergency department and urgent care settings and select and adapt brochures and other campaign messages for acute care providers.
2482027|NCT03022929|Experimental|Enhanced Intervention|"The investigators will use all of the methods of the Adapted Intervention. In addition to these methods, the investigators will add posters within exam rooms which will include modified GetSmart content and other nudges such as physician pictures with their signed public commitment to antibiotic stewardship or flair denoting commitment to stewardship. The investigators will also provide physicians with personalized monthly performance ranking with each physician receiving the designation of top performer or not a top performer based on their appropriate antibiotic prescribing practices for acute respiratory infections. This will be the Enhanced Antimicrobial Stewardship Commitment and Feedback intervention."
3159020|NCT00397735|Experimental|N-Acetylcysteine|The subjects enrolled in our research protocol must have evidence of infection/inflammation at amniocentesis in order to receive N-acetylcysteine. Women with positive amniocentesis results The dose of N-acetylcysteine is the one recommended to be used in humans to prevent acetaminophen toxicity: 150 mg/kg loading dose (60 min), followed by 50mg/kg IV continuous infusion rate for 4 hours, and followed by 100 mg/kg IV continuous infusion rate for the following 16 hours. Acetadote (Cumberland Pharmaceuticals) is the only FDA-approved intravenous N-acetylcysteine formulation and will be used in our study.
2482123|NCT03022071|Experimental|Cognitive behavior therapy|The included patients will receive cognitive therapy for depression for 16 weeks and monthly booster sessions up to 28 weeks.
2482128|NCT03022071|Active Comparator|Psychodynamic psychotherapy|The included patients will receive time-limited psychodynamic psychotherapy for 28 weeks.
2482316|NCT03020797|Experimental|perampanel|perampanel 2mg QD for 2 weeks perampanel 4mg QD for 2 weeks perampanel 6mg QD for 2 weeks perampanel 8mg QD for 30 weeks
2482318|NCT03020797|Placebo Comparator|placebo|placebo 1 tablet QD for 2 weeks placebo 2 tablets QD for 2 weeks placebo 3 tablets QD for 2 weeks placebo 4 tablets QD for 2 weeks
2482374|NCT03020303|Placebo Comparator|Placebo Oral Tablet|A tablet with no active medication that will be an exact match of the active spironolactone in taste and appearance
2482376|NCT03020303|Active Comparator|Spironolactone 25 MG Tablet|25 mg of active spironolactone in tablet form
3173519|NCT00612976||1|Patients with COPD treated with budesonide/formoterol
2482531|NCT03019159||Tele-consulting|One visit out of two takes place with teleconsulting and the other is a face-to-face consultation
2482532|NCT03019159||No tele-consulting|
2482612|NCT03018652|Experimental|Intervention group|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
2482616|NCT03018652|Placebo Comparator|Control group|Normal saline (0.9% NaCl) 5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks) n=8
3173520|NCT00612989|Experimental|1|Schedule 1
3173521|NCT00612989|Experimental|2|Schedule 2
3173522|NCT00612989|Experimental|3|Schedule 2, Neulasta-supported
2482959|NCT03016260||Infliximab biosimilar (Flixabi®)|
2481779|NCT03024476|Experimental|Intensive management arm|"Description:~Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan~Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).~Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP.~Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee."
2481782|NCT03024476|Active Comparator|Control arm|"Description:~Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians.~Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups)."
2481872|NCT03023670|Active Comparator|Group A|This group will include patients with low flow of mixed oxygen / air (1:1L) during the period of cardiopulmonary bypass
2481878|NCT03023670|Active Comparator|Group B|This group will receive low rate (4\min) with low tidal volume ( 2ml/kg ) during the period of cardiopulmonary bypass.
2481954|NCT03023332|Experimental|Self-management need|SM-need (i.e. need for bipolar education or resourcefulness training or HRV-focused biofeedback training or no need for any)
2481958|NCT03023332|Experimental|Self-management preference|SM-preference (i.e. preference for bipolar education or resourcefulness training or HRV-focused biofeedback training or no intervention)
2481960|NCT03023332|No Intervention|Control|No intervention or treatment
2481962|NCT03023332|Active Comparator|Usual care|Bipolar education
2481993|NCT03022721||Patients with diabetes|"Patients with both type 1 and type 2 Diabetes will be enrolled, Independent of Diabetes Duration, therapy etc.~No interventions are planned."
2481995|NCT03022721||Pre-Diabetics|"Patients who have either imparied fasting Glucose or impaired Glucose tolerance in the oral Glucose tolerance test.~No interventions are planned."
2482001|NCT03022721||Healthy controls|"Study participants without Diabetes or Pre-diabetes in the oral Glucose tolerance test.~no interventions are planned."
3193354|NCT00817427|Experimental|Controls short sleep|Measures as in baseline but with sleep disruption
3193355|NCT00817440|No Intervention|Control|control: muscle and fat biopsies and basal aminoacid and glucose turnover
2482116|NCT03021889|Experimental|Nutritional therapy group|The group nutritional therapy intervention was subjected to a protocol that included: nutritional counseling and weekly phone calls for 12 weeks.
2482117|NCT03021889|Other|Control group|The control group received conventional care consisting of usual medical care. The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
2482204|NCT03021694|Experimental|Young Males Week 1|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2482219|NCT03021694|Experimental|Young Males Week 3|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2482222|NCT03021694|Experimental|Young Males Week 5|Six separate 3 x 14 [condition (micellar casein, micellar casein and native whey blend, and native whey) x time (-15min, 0 min, 15min, 30min, 45min, 60min, 90min, 150min, 180min, 210min, 240min, 270min, 300min, and 360min)] repeated measures ANOVAs will be used to analyze blood concentrations of leucine, ∑branched chain amino acids, ∑essential amino acids, ∑amino acids, glucose, and insulin.
2482340|NCT03020355|Experimental|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord-the cord will unclamped and the blood will drained until the flow ceased.
2482344|NCT03020355|Active Comparator|not Placental Blood Drainage|In the control group, the clamped cord will not released.
2482397|NCT03020186|Placebo Comparator|Physical activity|Physical activity (PA) group will receive free gym memberships and the instruction necessary to engage in moderate-intensity physical activity, ~80% of which will have an aerobic component. The participants will get basic health promoting guideline for healthy diet .
3193356|NCT00817440|Experimental|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
3193357|NCT00817440|Experimental|Fasting|3 days of fasting and then the same as arm 1
3193358|NCT00817453||1|Clinically diagnosed Early iPD
2481887|NCT03023618|Active Comparator|case group|patients after 2014, after management of fluid therapy has been guided by FloTrac parameters as a standard clinical practice (NICE protocol)
2481926|NCT03023410||Partial Revision|"A partial revision will be indicated when only the tibial liner is changed or only the tibial liner with the tibial tray or only the tibial liner with the femoral component."
2481930|NCT03023410||Total Revision|"A total revision will be indicated when all components are completely removed and replaced (tibial tray, femoral component and tibial liner)."
2481978|NCT03022994||NCWS patients|"Forty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients will be recruited between January 2016 and February 2017 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
2481979|NCT03022994||IBS patients|"Forty sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled, at the same 2 centers, as control group. All subjects will undergo upper gastrointestinal endoscopy and proctoscopy at the Gastroenterology Unit at the University Hospital of Palermo, Italy. Duodenal and rectal biopsies will be evaluated at 2 centers: the Pathology Unit at the University Hospital of Palermo, Italy, and the Institute of Pathology at the Spedali Civili of Brescia, Italy."
2482016|NCT03022656|Active Comparator|Monitor Only|A brace monitor will be embedded inside the brace to monitor compliance.
2482024|NCT03022656|Active Comparator|Active Brace System|An active brace device will be embedded inside the brace to dynamically control interface pressure and monitor compliance.
3193359|NCT00817453||2|Age/gender matched controls without neurodegenerative diagnosis
3193360|NCT00817453||atypical or late Parkinsonian Syndromes|Includes subjects facing or having undergone DBS, diagnoses of MSA, PSP or other atypical syndromes.
3193361|NCT00817466|Experimental|Racemic adrenaline, fixed intervals|Active drug with fixed intervals of inhalation, adjusted at least every 24h.
3193362|NCT00817466|Experimental|Racemic adrenalin, on demand|Racemic adrenaline, inhalations on demand (max every 2 hrs)
3193363|NCT00817466|Active Comparator|Saline, fixed intervals|Saline inhalation fixed intervals, adjusted at least every 24 hrs
2482134|NCT03021785|Experimental|0.5mg|In the core study, patients will receive 0.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2482138|NCT03021785|Experimental|1.0mg|In the core study, patients will receive 1.0mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2482141|NCT03021785|Experimental|1.5mg|In the core study, patients will receive 1.5mg TK001 in a 50-μL solution administered as an intravitreal injection every 4 weeks. In the extension study, they will be evaluated every 4 weeks and administrated PRN (pro re nata) with their assigned dose.
2482258|NCT03021226|Experimental|Group I: Adults|Participants in Group I will be adults ages 20 to 24 years of age, 50 hours of instruction provided over a six-week period, and address three major topic areas: Fatherhood Development, Relationship Enhancement, and Financial Literacy/Work.
2482269|NCT03021226|No Intervention|Group II: No Intervention: Adults|Participants in Group II will be adults ages 20 to 24 years of age who do not receive any hours of intervention.
2482304|NCT03020667||IQOS Users|"The criteria defining an IQOS user are listed in the section Eligibility."
2482307|NCT03020667||Cigarette (CC) Smokers|"The criteria defining a CC smoker are listed in the section Eligibility."
3193364|NCT00817466|Active Comparator|saline on demand|Saline inhalations on demand, max every 2 hrs, adjusted every 12 hrs
3193365|NCT00817492||1|Subjects with mild to moderate kidney disease
3193366|NCT00817492||2|Healthy Control Subjects
3193367|NCT00817505|Active Comparator|1|AZD1656 tablet + food
2482537|NCT03018912|Experimental|Sleep VS|"Patients check-in for their primary care physician visit and are provided a Sleep VS survey packet. Investigators or research associates will review the Sleep VS, and patients that screen positive on their Sleep VS will be asked to complete an extended set of sleep questions. A triaging algorithm will be available based on answers to the extended sleep questions to assist the primary care physician with assessment and triaging care. Patients that screen negative will not be asked the extended sleep questions nor will they be brought to the attention of the primary care physician and proceed with usual care."
2482542|NCT03018912|No Intervention|Usual Care|"Patients check-in for their primary care physician visit and proceed with usual care. Although the sleep vital sign will not be collected, the medical providers can still use the extended sleep questionnaire and triaging algorithm, if in the course of caring of the patient a potential sleep disorder is recognized."
2482667|NCT03018132|Other|Mental Health Screening Education and Referral|Investigators will prospectively assign all 200 women to this screening, education and referral intervention, without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. The health-related intervention, in this case, is an educational program and related process-of-care changes.
3193368|NCT00817505|Active Comparator|2|AZD1656 susp. without food
3193369|NCT00817505|Active Comparator|3|AZD1656 tablet
3193370|NCT00817518|Experimental|1|
3193371|NCT00817518|Experimental|2|
3193372|NCT00817544|Experimental|ORM-12741|ORM-12741
3193373|NCT00817557|Active Comparator|Loteprednol|Loteprednol BID
3193374|NCT00817557|Placebo Comparator|Rewetter|Rewetter BID
3193375|NCT00817570||1|Transfemoral Amputees using the C- Leg knee.
3193376|NCT00817570||2|Transfemoral Amputees using a Multiaxial Knee.
3193377|NCT00817570||3|Able bodied.
3193378|NCT00817583|Experimental|1|All patients will receive docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous intravenous fluorouracil infusion at 500 mg/m2/d on days 1 through 5. Cycles are repeated every 21 days for a total of two cycles. Patients then will receive definitive radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.The radiation dose is 66-76Gy to the GTV, 60Gy to CTV1, and 54Gy to CTV2.
2481957|NCT03023072||Phase 1|Subjects will use the incontinence pad with incontinence detection notifications turned on
2481959|NCT03023072||Phase 2|Subjects will use the incontinence pad with incontinence notification turned off
2481999|NCT03022851|Experimental|Occlutech AFR Device|Patients who will get the AFR Device implantation
2482041|NCT03022565|Experimental|Vorinostat|"Vorinostat:~400 mg orally, once daily for 15 days."
2482065|NCT03022253|Experimental|Liberal Platelet transfusion group|"Platelet transfusion to maintain a platelet count above 1,00,000 per microliter until one of the endpoints is met.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
2482073|NCT03022253|Active Comparator|Restrictive platelet transfusion group|"Platelet transfusion for standard criteria.~As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
2482118|NCT03021876|Placebo Comparator|ordinary group|usual intake prior to liver surgery
2482119|NCT03021876|Active Comparator|carnitine group|treatment with oral L-carnitine, 1500 mg/body per day for 2 weeks prior to liver surgery
2482212|NCT03021681|Other|COPD group(self control)|Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively
2482256|NCT03021135|Active Comparator|Conventional Mucosal Resection|C-EMR will be made with saline injection with the indigo carmine.
2482262|NCT03021135|Experimental|Underwater Mucosal Resection|UW-EMR will be made after the complete filling of lumen with water.
2482292|NCT03020680|Experimental|ubiquinol|It is the reduced form of coenzyme Q10
2482293|NCT03020680|Active Comparator|ubiquinone|It is the oxidized form of coenzyme Q10
3193379|NCT00817609|Experimental|A|
3193380|NCT00817609|Placebo Comparator|B|
3193381|NCT00817622|Placebo Comparator|A|"Placebo, Placebo :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day) Placebo pearl + corn oil 400 mg per day for 12 weeks"
3193382|NCT00817622|Active Comparator|B|"EPA, Placebo :~EPA pearls,500 mg QID for 12 Weeks (2000 mg per day),From MINAMINUTRITION Company(Belgium)+ Placebo pearl ,corn oil 400 mg per day for 12 weeks"
2482491|NCT03019341||Patients with enhanced CT scan|Patients undergo CT examination after the administration of non-ionic contrast media for clinical need.
2482581|NCT03019198|Experimental|TXA|Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.
2482582|NCT03019198|Placebo Comparator|Control|This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.
2482630|NCT03018496|Experimental|Older Men|Healthy male adults aged 18-35 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
2482636|NCT03018496|Experimental|Younger Men|Healthy male adults aged 65-85 Subjects will receive both HMB and placebo on separate visits in a crossover fashion
2482744|NCT03017859|Experimental|High flow nasal cannula treatment|Airvo 2 device will be used to administer high flow air during the night
3193383|NCT00817622|Placebo Comparator|C|"Placebo ,Vitamin E :~Placebo pearls,500 mg QID for 12 Weeks (2000 mg corn oil per day)+ Vitamin E pearls, 400 mg from DANA Company(IRAN) per day for 12 weeks"
3193384|NCT00817622|Active Comparator|D|"EPA, Vitamin E :~EPA pearls,500 mg QID From MINAMINUTRITION Company(Belgium) for 12 Weeks (2000 mg EPA per day)+ Vitamin E pearls, 400 mg from DANA Company ( IRAN) per day for 12 weeks"
2482835|NCT03017118|Experimental|Turmeric|Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
2482836|NCT03017118|Placebo Comparator|Control|Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.
2482876|NCT03016910||Type 2 diabetes|This group will consist of 300 patients with type 2 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year and CCTA will be performed at baseline and after one year.
2482877|NCT03016910||Type 1 diabetes|This group will consist of 50-100 patients with type 1 diabetes mellitus without symptoms or known coronary heart disease. The group will be followed for one year. CCTA will be performed at baseline and after one year.
2482928|NCT03016650|Active Comparator|Paracetamol|Patients will receive 100 mL of physiologic saline with 1 g IV acetaminophen (paracetamol) 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
2482929|NCT03016650|Active Comparator|ibuprofen|Patients will receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after percutaneous nephrolithotomy, respectively.
2482952|NCT03016260||Infliximab (Remicade®)|
2482953|NCT03016260||Adalimumab (Humira®)|
2482954|NCT03016260||Etanercept (Enbrel®)|
2482955|NCT03016260||Golimumab (Simponi®)|
2482956|NCT03016260||Certolizumab Pegol (Cimzia®)|
3193385|NCT00817648|Experimental|1|Quetiapine fumarate, flexible doses(600-750 mg/d)
3193386|NCT00817648|Active Comparator|2|risperidone, flexible doses(3-6 mg/d)
3193387|NCT00817661|Experimental|1|Vitamin A group
3193388|NCT00817661|Placebo Comparator|2|Placebo group
3193389|NCT00817674||1|CKD subjects
3193390|NCT00817674||2|Healthy Controls
3193391|NCT00817687|Experimental|1|
3193392|NCT00817687|No Intervention|2|
2482070|NCT03022214|Experimental|Placebo|5 capsules of placebo (microcrystalline cellulose) taken once in the morning with breakfast and once in the evening with dinner for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal
2482074|NCT03022214|Experimental|Intervention|"For presentation to volunteers, the daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~EnduraCell broccoli sprout powder: 3 capsules~Bulk Powders Green tea extract: 1 capsule~Bulk Powders Cinnamon Bark Extract: 1 capsule to be taken for two days prior to the study supervised exercise period and then one dose taken on the morning of the exercise test with the first meal"
3159021|NCT00397735|Placebo Comparator|Placebo|The subjects enrolled in our research protocol must have infection/inflammation in order to be randomized to receive N-acetylcysteine or placebo. Placebo-assigned patients will receive sodium chloride solution without N-acetylcysteine
3159022|NCT00397774|Active Comparator|Exercise|Physical exercise twice a week for 8 weeks, and best supportive care
2482226|NCT03021317|Experimental|Treated Group|Open label, single arm treatment study using MRI and laboratory markers to assess efficacy of ACTHAR in MS patients who are undergoing relapses.
2482305|NCT03020862|Experimental|Placebo ---> Dietary beetroot|"Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial.~The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.~Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days."
2482309|NCT03020862|Experimental|Dietary beetroot juice --> Placebo|The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days.
2482339|NCT03020394||Noninvasive ventilation|Noninvasive positive pressure ventilation is achieved by Philips Respironics V60/Vision ventilator. Choose bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before.
2482345|NCT03020394||Invasive ventilation|Intubated immediately and connected to the ventilator. Parameter adjustment and weaning of IPPV follow the protocols used before.
2482348|NCT03020394||High flow nasal cannula|High flow nasal cannula of different models (large, medium and small) are selected depending on the size and comfort of the patient's nostrils. Adjusting the oxygen flow rate (O2 Flow) maintains the patient's SpO2 88% to 92%. The flow was initially adjusted to 25 L/min and the flow was gradually adjusted to the patient's maximum tolerance. The inspiratory gas temperature (31 to 37 °C) was set to the patient's maximum tolerance level. If the patient's condition deteriorates and the tracheal intubation standard is met , the patient is recommended to undergo invasive ventilation treatment, but the choice of the final respiratory support method should be decided by the attending physician, patient and family.
2482384|NCT03020212|Active Comparator|Oxygen|Long-term oxygen therapy in patients with chronic obstructive pulmonary disease (COPD)
2482385|NCT03020212|No Intervention|Not oxygen|No intervention ( no therapy with oxygen)
2482528|NCT03019237|Experimental|intranasal anti-IgE|Anti-IgE (Xolair) will be freshly diluted in sterile 0.9% sodium chloride solution (438 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2482529|NCT03019237|Active Comparator|intranasal allergen|GMP produced rBet v 1 will be freshly diluted in sterile 0.9% sodium chloride solution (50 μg/ml) and will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2482530|NCT03019237|Placebo Comparator|intranasal saline|Sterile 0.9% sodium chloride solution will be administered using a metered pump delivering 15 μl per puff to both nostrils on three consecutive days.
2482544|NCT03018873|Experimental|long-term RIPC group|"routine treatment + interventions interventions: once preoperative RIPC and once RIPC/day after PCI for one year. Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention(PCI).~Once RIPC/day after PCI for one year:Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg."
2482549|NCT03018873|Active Comparator|preoperative RIPC group|routine treatment + Once preoperative remote ischemic preconditioning （RIPC） : Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg before primary percutaneous coronary intervention.
2482553|NCT03018873|No Intervention|control group|routine treatment, no RIPC
2482656|NCT03018743||dapoxetine treatment group|Consecutive patients who seek medical treatment for PE will be enrolled in the study.
2482694|NCT03018054|Experimental|E6007 30 mg|Participants will receive E6007 30 milligrams (mg) once daily after breakfast.
2482701|NCT03018054|Experimental|E6007 60 mg|Participants will receive E6007 60 mg once daily after breakfast.
2482708|NCT03018054|Placebo Comparator|Placebo|Participants will receive matching placebo once daily after breakfast.
3159023|NCT00397774|Other|No exercise|Best supportive care, no exercise
3159024|NCT00397787|Experimental|Treatment (sunitinib malate)|Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3159025|NCT00397826|Other|MK0733,simvastatin|20 patients with total cholesterol ≧ 240 mg/dL or LDL-C > 160 mg/dL for primary hypercholesterolemia; LDL-C ≧ 130 mg/dL for secondary hypercholesterolemia with identifiable risk factors will be enrolled into study to receive simvastatin 40 mg once daily for 12 weeks.
3159026|NCT00397865|Experimental|A|
2482009|NCT03022877|Active Comparator|Bolus Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization.
2482010|NCT03022877|Active Comparator|Bolus and infusion Levosimendan|Levosimendan is given as Bolus (12 µg/kg over 10 min i.v.), starting 10 min before recanalization and additionally as continuous infusion (0.1-0.2 µg/kg/min i. v. for 24 hours).
2482075|NCT03022487||ICD Patients with Ischaemic cardiomyopathy|A standard 30-minute electrophysiological (EP) cardiac stimulation protocol will be performed at the end of the ICD implant at baseline. Participants will be followed up for at least 12 months for endpoints.
2482125|NCT03022019|No Intervention|No ReNovaCell treatment|Lesion on the same patient that receives only standard therapy, no ReNovaCell treatment.
2482130|NCT03022019|Experimental|ReNovaCell treatment|Lesion on the same patient that receives the ReNovaCell treatment
2482202|NCT03021629||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2482215|NCT03021629||high myopia patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2482221|NCT03021629||age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay
2482253|NCT03021109|Experimental|Inferior vena cava diameteres|Measurement of inferior vena cava diameters with ultrasound
2482319|NCT03020784|Placebo Comparator|Placebo|IV placebo
2482320|NCT03020784|Experimental|PF-06818883|Experimental drug
2482373|NCT03020316|No Intervention|Usual Care|"Subjects will be encouraged to follow-up with their primary physicians.~Subjects will be informed that they will be periodically contacted by telephone and/or email by the research team for future assessments."
2482377|NCT03020316|Active Comparator|Peer Mentor & Transcendental Meditation|"Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments.~In addition to the peer mentor, subjects will be instructed in transcendental meditation (TM) in the standard manner by a trained TM instructor."
2482381|NCT03020316|Active Comparator|Peer Mentor|"We are no longer recruiting in this arm.~Subjects will be assigned a peer mentor (a volunteer with CAD). After initial contact, the peer mentor and subject will be encouraged to communicate at whatever frequency or medium they deem most appropriate. This may include speaking by telephone, personal email or meeting in person. Mentors (and subjects if willing) will be asked to keep a log of such contacts, which will be provided to the study staff at interval reassessments."
2482488|NCT03019588|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to approximately 2 years.
2482501|NCT03019588|Active Comparator|Paclitaxel 80 mg/m^2|Participants receive paclitaxel 80 mg/m^2 IV infusion on Days 1, 8 and 15 of each 4-week cycle for up to approximately 2 years.
2482568|NCT03018886|Other|healthy control subjects|126 healthy controls underwent the GHRH plus arginine stimulations test
2482578|NCT03018886|Experimental|patients with suspected GH deficiency|34 patients with pituitary disease and suspicion of GH deficiency underwent the GHRH plus arginine test
2482604|NCT03018639||Dialectical Behavior Therapy|The program's purpose is to help patients achieve the following therapeutic goals: (1) reduction of suicidal behaviors, (2) reduction of therapy-interfering behaviors, and (3) other risky or destabilizing behaviors. Standard DBT aims to achieve these goals by (1) conveying behavioral capabilities (skills), (2) motivation for applying these skills, (3) generalization of learned skills to the patient's natural environment, (4) structuring the treatment environment to reinforce functional behavior, and (5) conveying therapeutic resources and motivation to effectively treat patients with BPD.
2482651|NCT03018418|Experimental|Proton Therapy and Chemotherapy|Standard chemoradiation using 5-FU, Mitomycin, with pencil beam proton radiotherapy
3159027|NCT00397917|Active Comparator|400 micrograms of folic acid|Blinded study with two arms one of 400ug in arm 1
3159028|NCT00397917|Active Comparator|4mg of folic acid|Second arm is 4mg of folic acid in arm 2
2482797|NCT03017469|Experimental|ARISE Intervention|Nurses who participate in the 1.5 day ARISE Intervention
2482800|NCT03017469|No Intervention|Control Group|Nurses who do not participate in the ARISE Intervention
3159029|NCT00398008|Experimental|1|DC-HIV plus buprenorphine maintenance.
3159030|NCT00398008|Experimental|2|DC-HIV plus naltrexone maintenance
2482977|NCT03016468|Experimental|Parenteral Remodulin then Oral Treprostinil|
2483042|NCT03015987|Experimental|diode laser activated irrigation|Laser-activated irrigation (LAI) has been introduced as a powerful method enhancing irrigant action; The laser radiation produces transient cavitation in the liquid through optical breakdown by strong absorption of the laser energy. The high-power diode laser has been tested in several areas of dentistry such as bleaching, depigmentation and gingivectomy, with promising results in dentinal disinfection. The diode laser has proved to be a resource worth testing, because of the it's properties and its low cost and availability in comparison to most lasers used in endodontics.
2483046|NCT03015987|Active Comparator|ultrasonic activated irrigation|"ultrasonics have been developed to improve the penetration and effectiveness of irrigation in peripheral areas of the root canal space. The efficiency of sonic and ultrasonic devices is based on the creation of hydrodynamic phenomenon in well-shaped canals filled with an irrigant.~Such active root canal irrigation has been shown to facilitate the disruption of biofilms and make the cell membrane of bacteria more permeable to NaOCl."
2483100|NCT03015584||Septic patients admitted to the ICU|
3159031|NCT00398060|Experimental|A|
3159032|NCT00398190|Active Comparator|Control|Students receive standard anti-tobacco education
3159033|NCT00398190|Experimental|Media Literacy|Students receive media literacy based anti-smoking education
3159034|NCT00398229|Active Comparator|A|receiving hCG injection
3159035|NCT00398229|Placebo Comparator|B|
3159036|NCT00398281|Experimental|Arm I|Patients receive oral dutasteride once daily on days 1-14.
3159037|NCT00398281|Placebo Comparator|Arm II|Patients receive oral placebo once daily on days 1-14.
3159038|NCT00398333|Experimental|Eicosapentaenoic acid enriched nutritional supplement|
3159039|NCT00398333|No Intervention|No supplementation|
3159040|NCT00398359|Experimental|1|
3159041|NCT00398463|Experimental|1|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
3159042|NCT00398463|Placebo Comparator|2|Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo
3159043|NCT00398515|Experimental|Treatment (antiangiogenesis, chemotherapy, enzyme inhibitor)|Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 and oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3159044|NCT00398554|Experimental|VECOPA|dose and time intensified consoloditation chemotherapy cycle
2482225|NCT03021291|Experimental|Gelesis100|Gelesis100 (2.25 g) twice daily
2482254|NCT03020953|Experimental|Exercise + Estrogen|Strength training 3 times a week for 12 weeks. Estrogen patches which provide 100 um pr. 24 hours.
2482265|NCT03020953|Active Comparator|Exercise + Placebo|Strength training 3 times a week for 12 weeks. Placebo patches.
2482424|NCT03019861|Active Comparator|Ayurvedic nutritional counseling|Patients will receive three Ayurvedic nutritional counselings (according to tradition) after 1, 3 and 8 weeks after Baseline.
2482425|NCT03019861|Active Comparator|Conventional nutritional counseling|Patients will receive three conventional nutritional counselings (according to German Nutrition Society - DGE) after 1, 3 and 8 weeks after Baseline.
2482452|NCT03019731|Experimental|Children with Tourette syndrome|Eligible children, between ages 7-13 years, with the diagnosis of Tourette syndrome or chronic motor/vocal tic disorder will be recruited from the Tourette Syndrome Clinics at Johns Hopkins (Dr. Singer). The Johns Hopkins Center has been acclaimed a Center of Excellence by the Tourette Association of America. This center currently follows more than 1,000 tic patients and averages 4-6 new referrals and 4 follow up patients weekly. Children will be randomly assigned to either the Therapist-directed Behavioral Therapy group or the Home-based DVD therapy group.
3159045|NCT00398645|Experimental|Arm 1|
3159046|NCT00398684|Experimental|1|One dose maternal NVP treatment at onset of labor, and one dose of infant NVP treatment 48-72 hours after birth (NVP-NVP)
2482555|NCT03019029|Experimental|Peripheral nerve amyloidosis|Patients with pathologically-confirmed peripheral nerve amyloidosis will undergo 18-F Florbetapir PET/MR scan on a GE SIGNA PET/MR scanner.
2482676|NCT03018002|No Intervention|Control group|HIV-infected participants identified from the churches randomized to CG will be referred to PEPFAR-supported HIV clinics that provide comprehensive care including counseling, laboratory testing, ART and ongoing support during treatment as the standard of care. The study team will not be involved in their care beyond data collection.
2482679|NCT03018002|Experimental|iSTAR|HIV-infected participants identified from the churches clustered within the randomized health facilities will receive interventions from the study team.
2482775|NCT03017833|Experimental|Treatment (metformin, sapanisertib)|Patients receive metformin PO 1-3 times daily on days 1-42 and sapanisertib PO daily on days 15-42 of cycle 1. Patients then receive metformin PO daily and sapanisertib PO daily on days 1-28 of cycle 2 and beyond. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2482808|NCT03017196|Experimental|Intervention|Sites randomized to intervention will be expected to implement the My Life, My Healthcare Discussion Aid in their practice for at least a 6-month period.
2482818|NCT03017196|No Intervention|Control|Sites randomized to control will not be expected to implement the My Life, My Healthcare Discussion Aid in practice. They will be expected to practice chronic care as usual.
2482878|NCT03016962|Experimental|Cap-assisted colonoscopy|cap-assisted colonoscopy
2482879|NCT03016962|Active Comparator|Standard colonoscopy|Standard colonoscopy
2482935|NCT03016611|Active Comparator|Chewing Ticagrelor|
2482937|NCT03016611|Experimental|Chewing Prasugrel|
2482976|NCT03016273|Experimental|Bladder flap|The bladder flap is made by superficially incising and dissecting the peritoneal lining to separate the urinary bladder from the lower uterine segment.
2482980|NCT03016273|No Intervention|Non bladder flap|
2483028|NCT03016026|Experimental|ERAS|Preoperative education,breathing training and atomizing during the time of preoperative preparation.Shorten fasting time and carbohydrate load.The intravenous fluid therapy is restricted.Drainage and nasogastric tube are not placed (except the concerns of surgical safety).All patients undergo laparoscopic distal gastrectomy.An optimal management of acute postoperative pain is multimodal analgesia consists of surgical site infiltration, a nonsteroidal anti-inflammatory drug for postoperative three days (POD) and epidural analgesia.Early oral take and move.
2483077|NCT03015675|Experimental|Ascorbic Acid with mFOLFOX6 group|"Ascorbic Acid with mFOLFOX6 Ascorbic Acid (20g/day, D1-3) every 2 weeks~mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
2483133|NCT03015350||two lung ventilation of Desflurane|In GroupSa, 6 % desflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
3159047|NCT00398684|Experimental|2|One dose maternal NVP treatment at onset of labor, and one dose of infant placebo 48-72 hours after birth. (NVP-Placebo)
3159048|NCT00398684|Placebo Comparator|3|One dose maternal placebo at onset of labor, and one dose of infant placebo 48-72 hours after birth. This was the reference study arm. (Placebo-Placebo)
3159049|NCT00398710|Experimental|Perifosine|Patients will receive perifosine orally at 150 mg daily after food for 28-d cycles.
3159050|NCT00398723|Experimental|Vitiligo|adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
3159051|NCT00398749||Epoetin alfa|Epoetin alfa 40 000 IU once weekly variable treatment length
3159052|NCT00398814|Experimental|Perifosine + Sorafenib|
3159053|NCT00398827|Experimental|Dexmedetomidine 0.5 mcg/kg load|
3159054|NCT00398827|Experimental|Dexmedetomidine 1 mcg/kg load|
3159055|NCT00398827|Placebo Comparator|Placebo|
3159056|NCT00398853|Experimental|Chromium Picolinate|Chromium
3159057|NCT00398853|Other|Placebo|Placebo
3159058|NCT00398879|Experimental|Arm 1: Perifosine + Capecitabine|Perifosine 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
3173523|NCT00613002|Experimental|testosterone gel|1% testosterone transdermal gel
2482023|NCT03022669|Experimental|Application Group|"The App group will use a mobile application to remind patients to take antiplatelet medications. The commercially available mobile app will be selected by participants through preliminary focus groups that will be conducted prior to the RCT."
2482026|NCT03022669|Experimental|Website-Control|"The Website-Control group will will be offered the American Heart Association patient education website (My Life Check - 7 Steps To Healthy Living) and will serve as an attention-control. The website will be offered to participants in all three groups. The 7 small steps to big changes are to manage blood pressure, control cholesterol, reduce blood sugar, get active, eat better, lose weight, and stop smoking."
2482053|NCT03022266|Experimental|Intervention Arm|Participants receiving the Financial Incentive and Mobile Phone App will be given an smartphone app offering pill reminders and $50/month financial incentives for three months to upload photos of medication each day for 90 days. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
2482054|NCT03022266|No Intervention|Usual Care Control Arm|Participants in the usual care control arm will receive the usual education about medications provided by hospital staff. Medication adherence will be measured via a CleverCap(R) electronic monitoring pillbox.
2482109|NCT03022149|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 6 months
2482111|NCT03022149|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 6 months
2482187|NCT03021434|Experimental|Standard Testing|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Household-specific water quality information will be delivered to households within 72 hours, and households will be informed whether their drinking water was found to be contaminated. A study team member will review the information from the laboratory tests with the household and review information covered in the informational materials on safe water handling, storage, and use behaviours.
2482190|NCT03021434|Experimental|Test Kits|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. Data collectors will demonstrate the use of the low-cost microbiological water test kits and test household stored drinking water. A study team member will return to the household within 72 hours and review the household-specific water quality information from the initial test with household members. Households will be given 10 water test kits to use at their discretion over the 1-2 month follow up period. They will be appropriately trained in how to both perform the test and interpret the results. Households will also review information on safe water handling, storage, and use behaviours.
2482191|NCT03021434|Active Comparator|Comparison|Households will participate in community and household water safety education sessions, during which they will be given generalized information on water quality and safe water handling. A water sample from these households will be collected for laboratory analysis. Results from this analysis will be returned to the household at project endline. A study team member will return to the household within 72 hours to review the information on safe water handling, storage, and use behaviours.
2482248|NCT03021239|Active Comparator|1) Echo Guided Testing -|This testing uses echocardiography to create images of the heart and make measurements while gradually increasing the heart pump speed. The final pump speed and medical treatment are determined using the echo measurements. This will take about 45 minutes.
2482249|NCT03021239|Active Comparator|2) Hemodynamic-Echo Ramp Testing -|This testing is performed during a right heart catheterization procedure which provides hemodynamic measurements (pressure and blood flow) in addition to the echocardiography measurements. With this method, more echo images and measurements are taken. The final pump speed and medical treatment adjustments are made using the hemodynamic measurements as well as the information from the echo. This test will take about 1 hour and 45 minutes.
2482496|NCT03019536|Experimental|LY3303560 IV|Multiple doses of LY3303560 administered intravenously (IV) for up to 48 weeks, followed by a 16 week follow-up period
3193393|NCT00817700|No Intervention|Normal (8 hours) sleep time|Subjects are studied under normal sleep time conditions.
2482170|NCT03021811|Other|LumiHeal|Treatment of chronic wounds with KLOX LumiHeal BioPhotonic System
2482232|NCT03021278|Experimental|Saline Injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
2482234|NCT03021278|Experimental|Sham Injection|In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
2482236|NCT03021278|No Intervention|Control Group|The control group will not receive any kind of pain or pinprick sensation.
3193394|NCT00817700|Experimental|Sleep restriction|"Sleep restriction to 4 hours of sleep per night.~Overnight sleep recording, measures of endocrine and metabolic (from blood), cardiovascular (measures of blood pressure and heart rate), performance ( before and after sleep restriction and after sleep recovery."
3193395|NCT00817713|Active Comparator|anthelminthic treatment|Albendazol plus fix-dose Praziquantel plus Ivermectin
3193396|NCT00817713|No Intervention|HIV care, no anthelminthic treatment|HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines
3193397|NCT00817726||1- RBD|polysomnographically diagnosed RBD patients. RBD is a sleep disorder diagnosed by a sleep lab in which the individual has muscle movements during the phase of deep sleep during which the muscles should be relaxed. Suspicion of RBD by history will be confirmed during screening.
3193398|NCT00817726||2 - control|"control:~must not have any neurological degenerative diagnosis.~must NOT have RBD.~must be able to age and/or gender-match to RBD and PD subjects already enrolled."
2482487|NCT03019666|Experimental|Multiple Myeloma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and elotuzumab for Multiple Myeloma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
2482497|NCT03019666|Experimental|Non-Hodgkin Lymphoma|After a lymphodepleting preparative regimen of cyclophosphamide and fludarabine, patients receive expanded NAM-NK cells followed by a short course of interleukin-2 (IL-2) to facilitate natural killer cell survival and expansion in vivo. Monoclonal antibodies and rituximab for Non-Hodgkin Lymphoma patients, will be administered prior to and after the natural killer cell infusion(s) to facilitate tumor targeting and antibody dependent cellular cytotoxicity (ADCC).
2482560|NCT03019133|No Intervention|Usual Care|Usual care will be provided.
2482566|NCT03019133|Active Comparator|Sound reduction|Use of noise reduction headphones. Pro For Sho safety ear muffs with a noise reduction rate of 34dB will be used.
2482572|NCT03019133|Active Comparator|Sound masking|Use of headphones and relaxing music. Sennheiser HD 280 pro headphones will be used for sound masking.
2482649|NCT03018405|Experimental|Hematological tumors|The dose escalation arm for hematological tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort 10-11 (only in AML/MDS) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
2482650|NCT03018405|Experimental|Solid Tumors|The dose escalation arm for solid tumors will use a 3 +3 design to determine the maximum tolerated dose. Two additional cohorts will be added in this dose escalation arm with the aim to provide a more intense treatment during the induction treatment (cycle 1 of injection). Cohort cohort 8-9 ( only in CRC) will evaluate a tighter schedule of NKR-2 injections at 1x109 or potentially 3x109 NKR-2 per injection with the three first injections within the induction cycle (cycle 1) separated by a 1-week interval followed two weeks later by a second cycle (cycle 2) with a 2-weeks interval between each three NKR 2 injections.
2482720|NCT03018041|Experimental|Marine n-3 PUFAs|3 capsules of Omacor 1000 mg daily, corresponding to a dose of 2.5 g / day of marine n-3 PUFAs (EPA plus DHA).
2482724|NCT03018041|Placebo Comparator|Placebo|Corresponding placebo oral capsules with olive oil, three capsules daily.
2482840|NCT03017352|Experimental|Intervention|Exenatide 10 mikrogram, thrice daily, subcutaneous injection prior to main meals, 6 months.
2482841|NCT03017352|Placebo Comparator|Placebo|Placebo, thrice daily, subcutaneous injection prior to main meals, 6 months.
2482883|NCT03016832|Experimental|Huangkui|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing
2482885|NCT03016832|Active Comparator|controlled|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
2482888|NCT03016832|Other|combined treatment|irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.
2482966|NCT03016351|Experimental|Aerobic Training|Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
2483005|NCT03016221|Experimental|Dolor-X Classic Gel|Intervention: Dolor-X Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2483007|NCT03016221|No Intervention|Dolor-X Classic Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Classic Gel control.
2483161|NCT03014947|Active Comparator|EU-approved Humira|
2482063|NCT03022240|Experimental|Inhalational Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction. After inhalation induction of anesthesia with sevoflurane (in 100% O2), an IV will be obtained. Anesthesia will be maintained with sevoflurane (in a mixture of air:oxygen) with a minimum alveolar concentration of 1.0-1.3, titrated to effect. No long acting opioids or nitrous oxide will be used. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
2482069|NCT03022240|Experimental|Total Intravenous Anesthetic Technique|All patients will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to IV insertion. Once an IV is established, patients will receive an IV bolus of propofol (2-6mg/kg). Anesthesia will be maintained with a propofol infusion starting at 250 mcg/kg/min and titrated to effect. Airway management will be at the discretion of the anesthesiologist. Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
3193399|NCT00817739|Active Comparator|Continuous Therapy|Continuous complete androgen suppression therapy with leuprorelin 3.75 mg sustained release (SR), injection, subcutaneously once every 28 days and flutamide, 250 mg, tablet, orally thrice daily until there are signs of disease progression.
3208672|NCT00977054|Experimental|DFPP and Peg-IFN + RBV|Double filtration plasmapheresis (Day 1, Day 2, Day 4, Day 8, and Day 9 from the onset of treatment; overall 5 session, each session for 4 hours) and weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1 to week 48; body weight < 75 kg, 1,000 mg/day and body weight >= 75 kg, 1,200 mg/day)
2482315|NCT03020823|Experimental|SCB01A alone|intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
2482371|NCT03020290||patients with femoropopliteal lesion|patients with femoropopliteal lesion - Endovascular treatment for PAD during medical care
2482426|NCT03020056|Placebo Comparator|waiting surgery|Cataract surgery will be performed at 1 year after enrollment.These participants will be provided with Phacolin eye drops(Zhongshan ophthalmic center, China).
2482427|NCT03020056|Experimental|expedited surgery|Cataract surgery will be performed within 4 weeks.
2482462|NCT03019705||Participants|Individuals with pathological health anxiety
2482483|NCT03019484|Experimental|Intervention|The intervention consisted on breastfeeding support at three stages: a) week 28-39 pregnancy: women were provided with written information and watch a breastfeeding self-efficacy enhancing video; b) during hospitalization after birth: based on their responses to the Breastfeeding Self-Efficacy Scale-Short Form (BSES-SF) questionnaire and the observation of a whole breastfeed, nurses provided specific advice using active listening. All the relevant information was registered; c) within one week after birth: a nurse or midwife made a phone call to follow-up mothers breastfeeding behaviour, addressing issues that during the hospitalization needed reinforcement, solving any question or matter that they had and providing positive reinforcement.
2482493|NCT03019484|No Intervention|Control: Standard Care|"This group received standard antenatal and postnatal care by midwives and nurses caring for them during their regular antenatal visits and after delivery.~The professionals delivering the intervention were the same than those providing the standard care. That was the reason to first collect the data from the control group and after that organising the training of health professionals to deliver de intervention."
2482719|NCT03018366|Active Comparator|17Beta Estradiol, Progesterone|17Beta Estradiol (0.1mg/day) , Progesterone (200mg) or Medroxyprogesterone (10mg) for patient with a peanut allergy because progesterone 200mg is a peanut based product
2482721|NCT03018366|Placebo Comparator|Transdermal Placebo Patch, Placebo Pill|Placebo Transdermal Patch, Placebo Pill
2482783|NCT03017599|Experimental|Intervention group|EUS-FNB using 20-gauge procore needle
2482795|NCT03017222|Active Comparator|Ondansetron group|
2482799|NCT03017222|Experimental|Ramosetron group|
2482858|NCT03017092|Experimental|tablet-guided|Study participants will be administered a brief tobacco intervention by a Salvation Army staff person who is guided by a tablet computer
2482887|NCT03016702|Experimental|High Risk Alzheimer's Disease|This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.
2482890|NCT03016702|Experimental|Low Risk Alzheimer Disease|This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.
2482942|NCT03016442|Experimental|Cook double balloon catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination İt is placed for 12 hours
2482943|NCT03016442|Active Comparator|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
2482991|NCT03016156|Experimental|Stratum I: Initial Evaluation Group|Initially, a small group of patients diagnosed with congenital or infantile cataracts, congenital glaucoma or retinoblastoma and who meet the eligibility criteria will undergo testing with CRADLE on Day 1.
2482992|NCT03016156|Experimental|Stratum II: Leukocoria Evaluation Group|A separate group of participants who are referred for evaluation of leukocoria or any other eye condition will undergo red reflex testing testing with CRADLE on Day 1.
2482998|NCT03016156|Experimental|Stratum III: Retinoblastoma Group|A separate group of participants with known retinoblastoma and who are undergoing ocular salvage treatments will be screened with red reflex testing using direct ophthalmoscopy on Day 1. They will also undergo testing with the CRADLE software application defined as the most effect in Stratum I on Day 1 then for three additional consecutive visits which typically occur every 3 to 4 weeks.
2483050|NCT03015766|Experimental|Auricular acupressure therapy|Participants in the treatment group will received AAT on five active acupoints including Acup.1. Shen Men (Spiritual Gate, TF4), Acup.2. Jiao Gan (Sympathetic autonomic, AH6a), Acup.3. Xin (Heart, CO15), Acup.4. Pi Zhi Xia (Subcortex, AT4), Acup.5. Nei Fen Mi (Endocrine, CO18)
2482068|NCT03022279|Active Comparator|Local Wound Infiltration|Local wound infiltration (LWI) will be performed by the operative surgeon using 2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine with maximum of 60 mL divided amongst the four port sites. 40% of the total dose will be given at the umbilicus, and 20% will be given at each of the other 3 ports. The majority of the anesthetic will be administered at the peritoneal level. Laparoscopic/robotic cholecystectomy will be performed with a port at the umbilicus and three smaller ports in a standard fashion in the subxiphoid and right upper quadrant regions. If conversion to open cholecystectomy occurs, the study data will still be collected, but the patient's data will be excluded from analysis.
2482150|NCT03021941|Other|Elelyso 60 units/kg|All patients receive 60 units/kg of Elelyso.
2482183|NCT03021512||Group 1 (BFG)|(Bifocal group). Subjects that underwent bifocal intraocular lenses implantation. (ie. Phaco with Restor intervention).
2482184|NCT03021512||Group 2 (TFG)|(Trifocal group). Subjects that underwent trifocal intraocular lenses implantation. (ie. Phaco with Panoptix intervention).
2482278|NCT03020927|Active Comparator|Therapist Delivered|Children in the therapist-delivered condition will receive two, 60-minute long sessions of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. Parents will be permitted to observe sessions via live video, but will not be directly involved in intervention.
2482279|NCT03020927|Experimental|Parent + Therapist Delivered|Children in the parent + therapist-delivered condition will receive one, 60-minute long session of Reciprocal Imitation Training each week for ten consecutive weeks. These sessions will be delivered by trained graduate, undergraduate, and post-graduate research staff. During the same period of time, parents/guardians of children will receive one, 60-minute long parent education session per week with graduate and post-graduate research staff, aimed at teaching parents to implement Reciprocal Imitation Training at home with the child.
2482322|NCT03020589|Experimental|CYP3A5 based tacrolimus dosing|Subjects in this treatment arm will receive initial tacrolimus based on their genotype i.e., CYP3A5*1/*1 and CYP3A5*1/*3 (Expressers) will receive the initial tacrolimus dose of 0.2 mg/kg/day, with maximum of 20 mg/day in 2 divided doses. For CYP3A5*3/*3 (Non-Expressers), the subjects will receive initial tacrolimus dose of 0.1 mg/kg/day in 2 divided doses.
2482323|NCT03020589|No Intervention|Control|Subjects in the prospective control group will receive standard tacrolimus dosing as recommended per package insert and will not be dosed based on their genotype. Similarly, subjects that underwent renal transplant after 2010 and received standard tacrolimus dosing (per package insert) will serve as historical controls.
2482379|NCT03020277|Other|ASD children families|
3159059|NCT00398879|Placebo Comparator|Arm 2: Perifosine Placebo + Capecitabine|Perifosine Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks until progression
2482513|NCT03019302|Experimental|Arrow PICC with Chloragard Technology|Arrow Peripherally- Inserted Central Catheters with Chloragard Technology. The application of Chlorag+ard® Technology uses a proprietary process whereby chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body.
2482569|NCT03019042|Experimental|Hou Gu Mi Xi|Patients in this arm receive Hou Gu Mi Xi, with oral dose of 30 g/day (contain 10.1 herb materials) during entire follow up period (2 years). HGMX is composed of 10 dietary Chinese herbs (including ginseng (Renshen), tuckahoe (Fuling), coixenolide (Yiyiren), Chinese yam (Shanyao), lotus seed (Lianzi), amomum (Sharen), platycodon (Jiegen), white hyacinth bean (Baibiandou), licorice (Gancao), and orange peel (Jupi)), early rice, and oats.
2482577|NCT03019042|Placebo Comparator|placebo|Patients in this arm receive placebo, with oral dose of 30 g/day during entire follow up period (2 years). The placebo is only consist of early rice and oats.
2482609|NCT03018535|Experimental|RITUXIMAB|1 g. IV of Rituximab on days 1 and 15
2482610|NCT03018535|Active Comparator|Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for 3 doses; oral methylprednisolone (0.4mg/kg/day) or prednisone (0.5/mg/kg/day); Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
2482675|NCT03018262||Healthy Volunteers - Sub-study 1|Healthy Volunteers
2482678|NCT03018262||Healthy Volunteers - Sub-study 2|Healthy Volunteers
2482680|NCT03018262||Healthy Volunteers - Sub-study 3|Healthy Volunteers
2482774|NCT03017794||Gleason score 6 or less|Prostate adenocarcinoma with Gleason score 6 or less
2482776|NCT03017794||Gleason score 7|Prostate adenocarcinoma with Gleason score 7
2482777|NCT03017794||Gleason score 8 -10|Prostate adenocarcinoma with Gleason score 8 -10
2482837|NCT03017300|Experimental|COPD（threshold IMT training）|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
2482839|NCT03017300|Experimental|COPD（resisive training）|COPD patient use Inspiratory muscle trainer (PFLEX®)
2482940|NCT03016481|Active Comparator|the Community Health Worker -Personalized Support for Progress|Patients will work with a Community Health Worker (CHW) to complete a prioritization tool and meet as needed over the course of the next 6 months to navigate services and overcome barriers. In addition, patients will receive referrals to other professionals based on their prioritization and meet with the CHW at the time and place of their choice.
2482941|NCT03016481|Active Comparator|Care as Usual- Social Worker|Patients in the Care as Usual- Social Worker (CAU-SW) arm, will do intake with a social worker, who follows hospital procedures for intake and referrals, does a needs assessment, and offers safety planning in referral.
2482981|NCT03016208||Misoprostol vaginal insert for max. 24hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 24 hours
2482985|NCT03016208||Misoprostol vaginal insert for max. 10hrs|69 patients matching the inclusion criteria and received MVI for labour induction for a maximum of 10 hours
2483078|NCT03015675|Active Comparator|mFOLFOX6 group|"mFOLOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
3159060|NCT00398892|Other|1|Crossover - placebo then active
3159061|NCT00398892|Other|2|Crossover - active then placebo
3159062|NCT00398905|Experimental|Arm 1|
3159063|NCT00398905|Experimental|Arm 2|
3159064|NCT00398905|Experimental|Arm 3|
3159065|NCT00398905|Experimental|Arm 4|
3159066|NCT00398905|Experimental|Arm 5|
3159067|NCT00398905|Active Comparator|Arm 6|
3159068|NCT00398970|Active Comparator|Traditional flouroscopy guided sampling|
2482083|NCT03022292|Experimental|IAI Treatment|Intravitreal injection of aflibercept 2 mg/0.05 ml at baseline, week 4, week 8, week 16, week 24, week 36, and week 48. Additional injections can be administered during the remaining visits on an as needed basis per Primary Investigator (PI) discretion based on the presence of any intraretinal or subretinal fluid on OCT, heme visualized on examination, reduction of BCVA by 5 or more ETDRS letters, or evidence of either increased area, density, or activity of the brush border of the neovascularization on OCT-angiography. There will be a minimum of 21 days between subsequent injections. Each subject will therefore receive a minimum of 7 injections and up to a maximum of 13 injections throughout the study period.
2482140|NCT03021954|Experimental|Platelet rich plasma|Platelet rich plasma injected intramuscularly in pelvic floor muscle immediately following labor and before perineoraphy, simultaneously with the injection of local anesthesia
2482145|NCT03021954|No Intervention|Control|No intervention given, patient will only get local anesthesia injection before perineoraphy
3193400|NCT00817739|Experimental|Intermittent therapy|Intermittent complete androgen suppression therapy starting at randomization with interruption of treatment given in the induction period until PSA levels reach >=10 ng/mL or other signs of progression appear. Upon treatment resumption, leuproreline 3.75 mg SR, injection, subcutaneously once every 28 days and flutamide 250 mg, tablet, orally thrice daily, until PSA levels are <normal (that is, <4 ng/mL) and no signs of disease progression appear. The intermittent therapy will be continued similarly until the study end or the appearance of signs of disease progression under treatment.
3193401|NCT00817752|Experimental|1|Receives Ashwagandha herb.
2482489|NCT03019653|Active Comparator|ANX-042 first, then Placebo|In the first intervention period the subjects will receive an infusion of ANX-042. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of placebo
2482499|NCT03019653|Active Comparator|Placebo first, then ANX-042|In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
3193402|NCT00817765|Active Comparator|Posaconazole alone|400mg posaconazole BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
3193403|NCT00817765|Active Comparator|Fosamprenavir ritonavir|Fosamprenavir 700mg / ritonavir 100mg BID for 10 days
3193404|NCT00817765|Experimental|Fosamprenavir posaconazole|Fosamprenavir 700mg / posaconazole 400mg BID for 10 days (start on day 1 with 200mg QD, day 2 200mg BID; from day 3 onwards 400mg BID)
3193405|NCT00817791|Experimental|HBO|
2482722|NCT03018353|Other|Navigation services with sof/vel therapy|This a single group demonstration project in which, patients are treated with the FDA-approved drug, Sofosbuvir/Velpatasvir (Epclusa). If a patients is released during their treatment regimen, they will receive patient navigation services to continue their care and treatment in the community.
2482753|NCT03017651|Experimental|OM3-supplement 1|1 g capsule for OM3-supplement 1 given once
2482760|NCT03017651|Active Comparator|OM3-supplement 2|1 g capsule for OM3-supplement 2 given once
2482796|NCT03017365|Active Comparator|M-SRT|Machine-based stable resistance training. Exercising 'traditional' machine-based resistance training.
2482801|NCT03017365|Experimental|F-URT|Free weight unstable resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
2482802|NCT03017365|Experimental|M-ART|Machine-based adductor/abductor resistance training. Exercising with 'traditional' adductor/abductor machines.
3193406|NCT00817817|Experimental|Group 1|
3193407|NCT00817817|Experimental|Group 2|
2482972|NCT03016234|Active Comparator|Desflurane|inhalation anesthesia administration for maintenance of anesthesia
2482973|NCT03016234|Active Comparator|Propofol|intravenous anesthesia administration for maintenance of anesthesia
2483048|NCT03015922|Experimental|Lenalidomide or pomalidomide, plus REOLYSIN|"Lenalidomide capsules, oral, maximum 10mg daily on days 1-21 of 28-day cycles. OR Pomalidomide capsules, oral, maximum 1mg daily on days 1-21 of 28-day cycles.~Plus (all patients):~REOLYSIN® , intravenous infusion, maximum 3x10^10 TCID50 on days 1, 8, 15 and 22 of 28-day cycles."
2483082|NCT03015519|Experimental|Albiglutide cohort 1: Part A|Approximately 12 eligible subjects, aged between 14 to 18 years, will receive a single dose of 30 mg albiglutide post-randomization.
2483083|NCT03015519|Placebo Comparator|Placebo cohort 1: Part A|Approximately 3 eligible subjects, aged between 14 to 18 years, will receive a single dose of matching placebo post-randomization.
2483089|NCT03015519|Experimental|Albiglutide cohort 2: Part A|Approximately 12 eligible subjects, aged between 10 to 14 years, will receive a single dose of 30 mg albiglutide post-randomization.
2483092|NCT03015519|Placebo Comparator|Placebo cohort 2: Part A|Approximately 3 eligible subjects, aged between 10 to 14 years, will receive a single dose of matching placebo post-randomization.
2483093|NCT03015519|Experimental|Albiglutide: Part B|Approximately 120 eligible subjects, aged between 10 to 18 years, will receive albiglutide 30 mg once weekly post-randomization.
2483094|NCT03015519|Placebo Comparator|Placebo: Part B|Approximately 60 eligible subjects, aged between 10 to 18 years, will receive matching placebo once weekly post-randomization.
3193408|NCT00817830|Experimental|lodenafil carbonate|Evaluate cardiovascular safety of lodenafil carbonate in patients with coronary artery disease undergoing physical effort, before and after using lodenafil carbonate.
2511611|NCT02819791|Experimental|Intervention group|
3193409|NCT00817869|Experimental|New Flooring|Will receive 8.3mm thick floor covering (Omnisports EXCEL) to replace previous floor covering.
3193410|NCT00817869|No Intervention|Standard Flooring|Ward will remain with standard floor covering. The overlay will have a comparable slip resistance rating to the new flooring. The sub-floor will also be comparable.
3193411|NCT00817882|Experimental|1|individually targeted vocational rehabilitation
3193412|NCT00817882|Active Comparator|2|routine back pain rehabilitation
3193413|NCT00817895|Experimental|5-FU+Cisplatin|50 HCC patients will be implanted 600mg sustained released 5-FU and 60mg sustained released cisplatin into liver incisal margin after tumor is resected.
3193414|NCT00817895|Active Comparator|5-FU|50 HCC patients will be implanted 600mg sustained released 5-FU into liver incisal margin after tumor is resected.
3193415|NCT00817895|Experimental|control|
2482165|NCT03022032|Experimental|Refined smartphone app and accelerometer (HOPE)|"Participants will be prompted to answer questions about their quality of life and physical health daily~The HOPE App will present tailored advice to improve symptoms if one or more low-risk toxicities are reported. If the symptoms are determined to be high-risk, the App will prompt the patient to call their clinician.~Participants will be asked to wear the Fitbit~-The Hope App will measure daily steps The app will also collect passive data from the smartphone"
2482167|NCT03022032|Experimental|SMART Study Arm|"Two smartphone apps and a wearable accelerometer (Fitbit) in 30 patients with gynecologic cancers receiving chemotherapy at two NCI Community Oncology sites.~The SMART intervention refers to the combination of both smartphone apps (SMART app and Beiwe app) and the accelerometer (Fitbit).~The SMART app is the technology that is actively collecting symptom reporting information from patients (e.g. patients are receiving surveys, recording their symptoms daily, and receiving tailored symptom management materials on their phone in response).~The Beiwe app is the technology involved in the passive data collection of participants' symptoms (GPS and accelerometer data) without their involvement."
2482206|NCT03021395|Experimental|MRD-positive|MRD-positive patients receive Decitabine regimen.
2482220|NCT03021395|No Intervention|MRD-negative|MRD-negative patients receive no intervention.
2482263|NCT03021122|Experimental|Arm A (PedAMINES™ / Conventional Method)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of PedAMINES™ first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of a Conventional Method.
2482273|NCT03021122|Active Comparator|Arm B (Conventional Method / PedAMINES™)|A 2-period study where nurses will be randomized to a 15-minute CPR scenario to prepare and deliver Dopamine with the help of a Conventional Method first, then crossover (incl. washout period) to prepare and deliver Norepinephrine with the help of PedAMINES™.
3193416|NCT00817908||1|Patients at high risk for CMV infection (CMV serostatus: D+/R-) who are expected to receive three months of antiviral prophylaxis.
3193417|NCT00817921||1|former premature children treated by ibuprofen
3193418|NCT00817921||2|former premature children not treated by ibuprofen
3193419|NCT00817921||3|former term children (control)
3193420|NCT00817934||PREVENTION AND TREATMENT|PATIENTS 50 YEARS AND OLDER REQUIRE SCREENING COLONOSCOPY. PATIENTS WITH FAMILY HISTORY OF COLON CANCER WILL REQUIRE IT BEFORE THE AGE OF 50.
3193421|NCT00817947|Active Comparator|Usual airway clearance technique|Airway clearance using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure or oscillating positive expiratory pressure
2482512|NCT03019276|Experimental|TQ-B3101|TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2482562|NCT03019094|Experimental|Treatment|Implantation of the RENOVA tibial nerve stimulation system
2482629|NCT03018717|Other|Tele-monitoring Constant|To analyze the efficacy and cost-efficacy of incorporating tele-monitoring of bio-parameters into the shared comprehensive clinical care plan. Patients will receive in their home a kit consisting of a briefcase containing all equipment (scale, pulse-oximeter ... etc) and a logo access to devices (Tablet) through mobile communications m2m between patient and platform Management for Chronic Patients.
2482637|NCT03018717|Other|Standard clinical care|Standard clinical care plan shared between plan of attention to the patient with Pluri-pathological process and the care plan for patients with chronic diseases, based on a comprehensive clinical assistance shared between Primary Care and Hospital Care
2482668|NCT03018171|Experimental|SC|this arm will receive intrathecal clonidine addiction to sufentanil during combined spinal epidural analgesia for labor
2482670|NCT03018171|Active Comparator|S|this arm will receive intrathecal sufentanil during combined spinal epidural analgesia for labor
2482718|NCT03017898|Experimental|Laser coagulation|Treatment of anal fistulae meeting the inclusion criteria
2482748|NCT03017677||Group|
2482866|NCT03017066|Experimental|Infant formula|Patients were given infant formula 6 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
2482868|NCT03017066|Experimental|Carbohydrate drink|Patients were given carbohydrate drink 2 hours prior to surgery. Gastric volume was assessed before ingestion, 1 hour prior to the surgery, and before the induction of general anesthesia using ultrasound.
2482880|NCT03016663||Breast Lipofilling Technique|Preliminary MRI breast were performed for volumetric measurement. Fat harvesting performed by same surgeon using water-assisted liposuction (WAL) and subsequent washing with buffered lactate in a standardized technique. Fat transfer performed using Berlin autologous lipotransplantation technique according to the BEAULI protocol .Patient were followed up monthly and MRI breast were repeated at 1st and 6th months after lipofilling. Clinical assessment and MRI Volumetric measurement performed using OsiriX (v7.0.3, 64 bit, Pixmeo c) software by same radiologist based on predefined operational procedure
2482944|NCT03016546|Experimental|BEST-maCARE|BEST-maCARE intervention will be refined to accommodate our target population using pertinent information attained through interviews conducted with patients representative of the target group and stakeholders from the clinics where the intervention will be pilot tested.
2482945|NCT03016546|Active Comparator|time-matched attention control condition|Participants will be randomly assigned. The control group will receive an intervention that is time and attention equivalent to the experimental condition, though substantively neutral.
2482993|NCT03016182|Active Comparator|Remote Ischemic Preconditioning(RIPC)|3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg will be given to RIPC
2482999|NCT03016182|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2483072|NCT03015883|Experimental|Diffusing Alpha Radiation Emitters Therapy (DaRT)|Intratumoral Diffusing alpha-emitters Radiation Therapy (DaRT) Seed Devices
2483129|NCT03015428|Experimental|Psychoeducation|"Interventions:~Give information Teach and train strategies"
3193422|NCT00817947|Other|HFCWO|High frequency chest wall oscillation
2484017|NCT03009760|Experimental|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
3193423|NCT00817960|Experimental|Methylphenidate|
3193424|NCT00817973|Active Comparator|Casein|
3193425|NCT00817973|Active Comparator|Whey|
3193426|NCT00817973|Active Comparator|Cod|
2482200|NCT03021590|Experimental|Clarithromycin :Concomitant Therapy|Amoxicillin 1000 mg Tablets, Clarithromycin 500 mg Tablets , Tinidazole 500 mg Tablets and Esomeprazole 20 mg Capsule each every 12 hours for 14 days all by mouth
2482203|NCT03021590|Active Comparator|Levofloxacin :Concomitant Therapy|Levofloxacin 500 mg Tablets Amoxicillin 1000 mg Tablets,Tinidazole 500 mg Tablets and Esomeprazole 20 mg each every 12 hours for 14 days all by mouth
2482244|NCT03021070|Experimental|Cash transfer arm|The intervention is a conditional cash transfer payment for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
2482245|NCT03021070|No Intervention|Non-cash transfer arm|The control is a mobile phone airtime transfer value of 50 Ksh. transferred through the electronic system for each health facility appointment honoured for ANC, delivery, postnatal care and childhood immunization; and referrals related to any of these visits.
2482306|NCT03020732|Experimental|test groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups.In test groups, a special centrifuge machine(Medifuge) and subjects venous blood were used to obtain Concentrated growth factor. A special compress was used to transform Concentrated growth factor membrane.
2482308|NCT03020732|Active Comparator|control groups|In this split mouth study, bilaterally gingival recession defects were randomly treated in test(CGF+CAF) or control(SCTG+CAF) groups. In control groups, subepithelial connective tissue graft was taken from the palatal canine teeth-first molar teeth area with a trap door technique according to the width of the exposed root surface and the adjacent bone margins. The graft's thickness was adjusted between 1.5 and 2 mm.
2482341|NCT03020368|Experimental|Leeches|"One-time topical application of 2-3 leeches (medileech, Hirudo verbana) periarticularly on the painful thumb base"
2482346|NCT03020368|Active Comparator|Diclofenac|3 times daily topical application of Diclofenac gel (1 g with 10 mg diclofenac-Na) over 4 weeks
2482386|NCT03020173||BMI above 30|Oocytes and granulosa of infertile women with BMI above 30
2482388|NCT03020173||BMI below 30|Oocytes and granulosa of infertile women with BMI above 30
3193427|NCT00817973|Active Comparator|Gluten|
3193428|NCT00817986|Experimental|Arbaclofen placarbil 20 mg|Arbaclofen placarbil 20 mg, BID, for 14 days including the taper period.
3193429|NCT00817986|Placebo Comparator|Placebo for Arbaclofen placarbil|Placebo for 14 days
3193430|NCT00817986|Experimental|Arbaclofen placarbil 30 mg|Arbaclofen placarbil 30 mg, BID, for 14 days including the taper period.
3193431|NCT00817986|Experimental|Arbaclofen placarbil 40 mg|Arbaclofen placarbil 40 mg, BID, for 14 days including the taper period.
3193432|NCT00818025|No Intervention|Standard of Care|All subjects will receive standard care to prepare for discharge that consists of a one-on-one, pre-discharge educational session delivered by the transplant coordinator prior to hospital discharge and provision of a reference binder for each lung transplant recipient to take home.
2482509|NCT03019562|Experimental|Oxycodone|4mg of oxycodone iv bolus
2482511|NCT03019562|Active Comparator|Fentanyl|50ug of fentanyl iv bolus
2482557|NCT03019016||Robotic RC (IA)|Benign or malignant disease under going a right colectomy.
2482564|NCT03019016||Robotic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
2482573|NCT03019016||Laparoscopic RC (IA)|Patients with benign or malignant disease under going a right colectomy.
2482579|NCT03019016||Laparoscopic RC (EA)|Patients with benign or malignant disease under going a right colectomy.
2482642|NCT03018574||ADHD-patients|The whole blood sample from diagnoses of the children 6-14 years old with ADHD. Diagnoses of the children with ADHD were made in Xijing Hospital and Children's Hospital Affiliated to Soochow University according to criteria described in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). Children with ADHD had an IQ score above 70.
2482643|NCT03018574||Controls-healthy children|The whole blood sample from age- and gender- matched healthy 6-14 years old children
2482661|NCT03018119|Active Comparator|Anesthesiologists|Total: 11 Intervention: Survey
2482662|NCT03018119|Active Comparator|Obstetricians|Total: 11 Intervention: Survey
2482663|NCT03018119|Active Comparator|Registered Nurses|Total: 10 Intervention: Survey
2482664|NCT03018119|Active Comparator|Surgical Technicians|Total: 6 Intervention: Survey
2482716|NCT03017963|Experimental|dose-escalation cohort|Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.
2482750|NCT03017703|Experimental|Type 2 Diabetes|8 weeks of treatment with Aldosterone blocker Eplerenone
2482756|NCT03017703|Experimental|Healthy|8 weeks of treatment with Aldosterone blocker Eplerenone
2482848|NCT03017443|Active Comparator|Dieting on Your Own (DIY) - DASH|All subjects provided publically available information on the DASH diet and instructed to follow a reduced calorie DASH diet meal plan on their own.
2482905|NCT03016793|Experimental|puerarin and β- tricalcium phosphate|"purabone (puerarin) is an osteoinductive bone grafts used to augment bone healing.~β- tricalcium phosphate is an osteoconductive bone graft used to augment bone healing"
3193433|NCT00818025|Experimental|Pocket PATH hand-held device|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
3193434|NCT00818038||TYSABRI|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
3193435|NCT00818051|Active Comparator|Arm I (control)|Patients undergo sequential boost dose intensity-modulated radiotherapy (IMRT) 5 days a week for 4.6 weeks (23 fractions; 56 Gy).
3193436|NCT00818051|Experimental|Arm II|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 48 Gy).
2482382|NCT03020225|Active Comparator|White cheese|Reference group- animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
2482387|NCT03020225|Experimental|Green peas|Plant food source: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
2482389|NCT03020225|Experimental|Mankai|Plant food source: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
2482468|NCT03019692||enrolled babies with neonatal intracranial bleed|all babies who suffered from intra cranial or intraventricular bleed during neonatal period
3159069|NCT00398970|Experimental|Ultrasound guide sampling|
3159070|NCT00398996|Active Comparator|1 - Early integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of starting tuberculosis treatment
2482543|NCT03018964|Experimental|Solo-SILC|Solo surgery using a laparoscopic camera holder instead of a camera operator in SILC
2482548|NCT03018964|Active Comparator|Ca-SILC|No solo surgery, operation with a camera operator in SILC
2482599|NCT03018665|Experimental|Exenatide and Metformin|Exenatide in Combination With Metformin
2482600|NCT03018665|Active Comparator|BIAsp30 and Metformin|BIAsp30 in Combination With Metformin
2482654|NCT03018431||Physician routine evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon clinical and biological, associated with standard radiographs, performed by the physician in chrage of the patient.
2482655|NCT03018431||independent evaluation|systematic evaluation of the probability of tracheobronchitis or pneumonia based upon early CT scan, and repeated lung ultrasonography, performed by an independent operator.
2482931|NCT03016559|Other|releasing muscle|The physical therapist placed thumbs on the quadratus lumborum to release muscle.
3159071|NCT00398996|Active Comparator|2 - Late integrated-therapy group|antiretroviral therapy to be initiated within 4 weeks of completing the intensive phase of tuberculosis treatment
2483041|NCT03015935||Optical|visual-assisted entry
2483045|NCT03015935||Veress|Veress entry
2483123|NCT03015545|Active Comparator|Control|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval, but no vibration will be given.
2483130|NCT03015545|Active Comparator|High intensity whole body vibration|This group will stand with knee flexion 60 degrees on the same vibration platform for 60 seconds for 5 times with 60-seconds rest interval. The whole body vibration platform will be set with frequency at 30Hz and amplitude at 1.5mm.
2483169|NCT03014960|Experimental|Experimental Condition|Online Cognitive Behavioral Therapy for Insomnia Intervention
2483181|NCT03014960|No Intervention|Control Condition|No intervention
2483302|NCT03014375|Experimental|Etamicastat|Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules
2483418|NCT03013218|Experimental|Evorpacept (ALX148)|The Part 1 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks.
2483419|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab infusions.
2483420|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab infusions.
2483422|NCT03013218|Experimental|Evorpacept (ALX148) + Rituximab|The Part 2 Dose Escalation/Expansion: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with rituximab infusions.
2483425|NCT03013218|Experimental|Evorpacept (ALX148) + Pembrolizumab + 5FU + Platinum|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with pembrolizumab + 5FU + platinum infusions.
2483428|NCT03013218|Experimental|Evorpacept (ALX148) + Trastuzumab + Ramucirumab + Paclitaxel|The Part 2 Dose Escalation: Evorpacept (ALX148) infusions will be administered weekly or every two weeks in combination with trastuzumab + ramucirumab + paclitaxel infusions.
2483549|NCT03012867|Active Comparator|fat-based|Patients receive a fat-based enteral nutrition formula, which is routinely used as standard care in our ICU
2483550|NCT03012867|Active Comparator|glucose-based|Patients receive a glucose-based enteral nutrition formula, which is routinely used as standard care in our ICU
2484020|NCT03009760|Experimental|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
3159072|NCT00398996|Active Comparator|3 - Sequential-therapy group|Antiretroviral therapy to be initiated within 4 weeks after completing tuberculosis treatment
3159073|NCT00399061|Active Comparator|1|Systane
3159074|NCT00399061|Active Comparator|2|Optive
3159075|NCT00399061|Placebo Comparator|3|Restasis
3159076|NCT00399074|No Intervention|chloroquine|Weekly CQ
3159077|NCT00399074|No Intervention|Sulfadoxine-pyrimethamine|Monthly SP
3159078|NCT00399087|Experimental|Perifosine D1 + Docetaxel|
3159079|NCT00399087|Experimental|Perifosine D1+ Docexatel+Prednisone|
3159080|NCT00399087|Experimental|Perifosine+ D1,8 and 15+Docetaxel+Prednisone|
3159081|NCT00399152|Experimental|Perifosine+Sunitinib malate|
3159082|NCT00399165|Active Comparator|1|Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
3159083|NCT00399165|Active Comparator|2|Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
3159084|NCT00399204|Active Comparator|Control|Metformin
3159085|NCT00399204|Experimental|Experimental|Pioglitazone
3159086|NCT00399334||001|
3159087|NCT00399373||Quality Improvement Initiative|The initial step in the quality improvement initiative was a letter sent from JHHC Care Management Department to the quality improvement initiative group, inviting them to take advantage of the case management services that are part of their current benefits in the Priority Partners MCO. It is similar to the standard letter sent to PPMCO members who are appropriate for a JHHC disease or case management program. A substance abuse outreach staff initiated telephonic contact with the members in the intervention group. The staff member then refered to substance abuse treatment when possible and appropriate and refered to medical case management.
2482242|NCT03021655|Experimental|WhatsApp intervention group|For WhatsApp intervention group, not more than 8 subjects with same gender will be assigned into a group. Messages about mood and stress management will be sent to the group per week and the group will last for 6 months. It aims to relieve their pressure and emotion by sharing their unhappy things with other subjects. Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2482243|NCT03021655|Other|Control group|For the control group, the subjects will receive telephone counseling on quitting smoking at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month.
2482261|NCT03020914|Experimental|Audiovisual Distraction|Patients get audiovisual distraction during surgery and in the recovery room using video goggles and headphones; patients can choose a movie from a preexisting library; with an initial dose of midazolam in preparation for the administration of the neuraxial anesthesia, additional sedation with midazolam in 1 mg increments if requested by the patient or deemed necessary by the anesthesia provider.
2482271|NCT03020914|No Intervention|Standard of care sedation|Standard of care sedation with with a initial dose of midazolam in preparation for the administration of the neuraxial anesthesia; propofol infusion titrated to effect.
2482294|NCT03020628|Experimental|NBP607-QIV 0.5mL|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
2482296|NCT03020628|Active Comparator|NBP607-TIV 0.25mL|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
3193437|NCT00818051|Experimental|Arm III|Patients undergo concurrent boost dose IMRT 5 days a week for 3 weeks (15 fractions; 53 Gy).
2482403|NCT03020121|Experimental|BD HPV assay on Viper LT|"The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.~Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects."
3193438|NCT00818064|Experimental|A, HV|Dose cohort 1 (3 subjects active, 1 placebo)
3193439|NCT00818064|Experimental|B, HV|Dose cohort 2 (3 subjects active, 1 placebo)
3193440|NCT00818064|Experimental|C, HV|Dose cohort 3 (3 subjects active, 1 placebo)
2482638|NCT03018769||chronic SCAD|
2482703|NCT03018015|Experimental|Ibuprofen 400 mg oral powder|oral fasted administration of 1 sachet of Ibuprofen 400 mg oral powder (Hermes Arzneimittel GmbH, Germany), containing 400 mg ibuprofen
2482707|NCT03018015|Active Comparator|Brufen 400 mg film-coated tablets|oral fasted administration of Brufen 400 mg film-coated tablets (Abbott Scandinavia AB, Sweden), containing 400 mg ibuprofen
2482711|NCT03018015|Active Comparator|Spalt forte 400 mg Weichkapseln|oral fasted administration of Spalt forte 400 mg Weichkapseln (Pfizer Consumer Healthcare GmbH, Germany), containing 400 mg ibuprofen
2482769|NCT03017716|No Intervention|IBP patients on standard therapy|IBP patients on standard therapy.
2482771|NCT03017716|Active Comparator|IBP patients on standard therapy and GFD|IBP patients on standard therapy and GFD
2482889|NCT03017274||NCWS patients|Fifty consecutive adult patients with an IBS-like clinical presentation, according to Rome III criteria, and a definitive diagnosis of NCWS. The patients was recruited between January 2015 and November 2016 at 2 centers: the Department of Internal Medicine at the University Hospital of Palermo, Italy, and the Department of Internal Medicine of the Hospital of Sciacca, Agrigento, Italy. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
2482891|NCT03017274||CD control patients|To compare the abdominal ultrasonographic features of NCWS patients, a control group of CD patients was randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- and sex-matched with the NCWS patients. All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
2482947|NCT03016494|Experimental|Test/Reference Drug|DWJ1386 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
2482949|NCT03016494|Experimental|Reference/Test Drug|co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1386 Tab.
2483011|NCT03016117|Experimental|Pecs II block and parasternal block|Pecs II block and parasternal block performed to provide anesthesia of breast, before of quadrantectomy with or without axillary dissection. Pecs II block performed at the 4th rib level and 20 ml of 0.5% Levobupivacaine injected, and parasternal block performed at the level of the 2nd and 4th intercostal space level, and 4 ml of 0.375% Levobupivacaine injected
2483037|NCT03015870|Experimental|Feedback|Behavioral: Vocal exercise with real-time feedback.
2483039|NCT03015870|Active Comparator|Recording|Behavioral: Vocal exercise with recording
2483101|NCT03015597|Experimental|Contingency Management: smoking|"Contingency Management: smoking~Participants receive rewards contingent on biochemical verification of tobacco smoking abstinence"
2483106|NCT03015597|Placebo Comparator|Contingency Management: attendance|"Contingency Management: attendance~Participants receive rewards contingent on attending the stop smoking clinic (independent of smoking status)"
3193441|NCT00818064|Experimental|D, HV|Dose cohort 4 (3 subjects active, 1 placebo)
3193442|NCT00818064|Experimental|E, HV|Dose cohort 5 (3 subjects active, 1 placebo)
3193443|NCT00818064|Experimental|A, RA|Dose cohort 1 (3 subjects active, 1 placebo)
2483409|NCT03013439|Experimental|cohort 1 iron isomaltoside|treated with first dose level of iron isomaltoside
2483414|NCT03013439|Experimental|cohort 2 iron isomaltoside|treated with second dose level of iron isomaltoside
3193444|NCT00818064|Experimental|B, RA|Dose cohort 2 (3 subjects active, 1 placebo)
3193445|NCT00818064|Experimental|C, RA|Dose cohort 3 (3 subjects active, 1 placebo)
3193446|NCT00818077||Metformin, Type 2 Diabetes|
3193447|NCT00818090|Experimental|TP|paclitaxel and cisplatin every 3 weeks
3193448|NCT00818103|Experimental|Atorvastatin, β-interferon, EPO|
3193449|NCT00818129|Experimental|1|
3193450|NCT00818129|Placebo Comparator|2|
3193451|NCT00818142||eating disorder, type 1 diabetes|Individuals diagnosed with type 1 diabetes and an eating disorder who withhold their insulin.
2482301|NCT03020693|Active Comparator|Placebo electrostimulation and exercises.|Sham dry needling + TENS ( 4 Hz 200 microseconds during 30 minutes to non-therapeutic intensity) with surface electrodes combined with exercises program.
2482338|NCT03020420|Experimental|treatment arm|receive cicatricell cream
2482343|NCT03020420|No Intervention|control arm|to treatment
2482390|NCT03020199|Experimental|A1|80 patients (65 in Arm A1a and 15 in Arm A1b) with new-onset psoriasis will receive 300 mg secukinumab by s.c. injection at baseline, Weeks 1, 2, 3, 4 and then every 4 weeks until Week 48 inclusive.
2482391|NCT03020199|Active Comparator|B1|80 patients (65 in Arm B1a and 15 in Arm B1b) with new-onset psoriasis will receive 1 or 2 cycles of nb-UVB of 12 weeks each with a maximum break of 28 weeks between cycles (patients with PASI 90 at Week 40 will not receive a second treatment cycle).Only during the first 4 weeks of each cycle, nb-UVB treatment should be applied in combination with topical calcipotriol 50 μg/g and betamethasone 0.5 mg/g.
2482393|NCT03020199|Experimental|A2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
2482394|NCT03020199|Experimental|C1|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 48 inclusive (last dose administered at Week 48)
2482396|NCT03020199|Experimental|C2|secukinumab 300 mg s.c. administered at baseline, once weekly at Weeks 1, 2, 3 and 4; and thereafter every 4 weeks until Week 100 inclusive (last dose administered at Week 100)
2482450|NCT03019718|Experimental|GSA-Online plus|Patients receive access to the internet-based aftercare program after inpatient treatment.
2482494|NCT03019523|Placebo Comparator|Sugar Pill|Maltodextrin (~2 grams to match weight of active treatment) placebo pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
2482504|NCT03019523|Active Comparator|Caffeine Blend|75 mg caffeine, 75 mg theanine, and 2g tyrosine pre-testing (1 dose w/3 oz of water) 30 minutes following ingestion exercise and Makoto testing were completed.
2482614|NCT03018782|Other|Brief Pain Inventory Short Form|Completes the Brief Pain Inventory Short Form
2482652|NCT03018327||Case group|250 Renal Transplant Recipients; 125 women and 125 men
2482653|NCT03018327||Control group|250 healthy controls; 125 women and 125 men
2482781|NCT03017521|Experimental|TAS-117|TAS-117, 16mg, orally, daily
2482896|NCT03016572|Experimental|Enhanced Treatment As Usual (E-TAU)|The patient will be referred for regular (Standard of Care) outpatient psychiatry/ psychology services or continue with the services that they were receiving prior to admission. They will be followed up by calling patient families at 3 months (post their initial appointment) and at 12 months. They will also have 1 research visit at 6 months (with Dr. Falcone), which they will schedule during their 3 month follow-up call; the Suicide Ideation Questionnaire (SIQ) will be administered. The patients assigned to this group will also be receiving 10 caring follow-up post cards at the following weeks and months (post-discharge from the inpatient unit): 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 5 months, 7 months, 9 months, 12 months, and on the patient's birthday.
2482901|NCT03016572|Experimental|TAU + Crisis Center (CC) Follow Up|Frontline Services will be administering (at least 9) crisis intervention phone calls to the patients; more calls will be made if they feel it is necessary for the safety and health of the patient. Follow up calls will ask the patient questions about following up in the future, whether they have had thoughts about suicide, whether they are in imminent danger of suicide by the end of the call, and whether the patient is stable. At the end of the call, the patient will be asked to rate their suicidality on a scale of 1 to 10.
2482907|NCT03016572|Experimental|TAU + CC Follow Up + Wraparound Services|This group will be linked with a care coordinator through Tapestry services. Wraparound is an intensive, individualized care coordination and treatment planning process that involves all of the important people in a child's life to work together to make the child successful in school, at home and in the community.
3159088|NCT00399373||Control group|No additional improvement modalities
3159089|NCT00399412||LQTS|Long QT syndrome
2483165|NCT03014856||OB-NMR|overweight and obese children and adolescents
2483171|NCT03014856||NMR-C|normal-weight children and adolescents
2483254|NCT03014778|Experimental|The Chlorhexidine gluconate arm|35 women undergoing surgery will be vaginally pre-op washed by 0.05% chlorhexidine gluconate, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
2483265|NCT03014778|Active Comparator|The Povidone iodine arm|35 women undergoing surgery will be vaginally pre-op washed by 10% Povidone iodine, 50 cc for 1 minute. 3 samples will be taken for culture: before, 10 minutes and 30 minutes after the wash.
2483321|NCT03014258|Active Comparator|Control Cohort 1|Immunologic malaria-naïve subjects will undergo CHMI #2 with 5 NF54 P. falciparum-infected mosquitoes at months 8-9. n=6.
2483323|NCT03014258|Active Comparator|Control Cohort 2|Immunologic malaria-naïve subjects will undergo a CHMI #3 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #2. n=6.
2483327|NCT03014258|Active Comparator|Control Cohort 3|Immunologic malaria-naïve subjects will undergo a CHMI #4 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #3. n=6.
2483329|NCT03014258|Active Comparator|Control Cohort 4|Immunologic malaria-naïve subjects will undergo a CHMI #5 with 5 NF54 P. falciparum-infected mosquitoes at 6-12 months post CHMI #4. n=6.
2483330|NCT03014258|Experimental|Repeat CHMI|Subjects will initially be challenged with 5 uninfected mosquitoes (mock), followed by 5 challenges (CHMI # 1-5) with 5 NF54 P. falciparum-infected mosquitoes 2, 8, 14-20, and 20-32, and 32-36 months later. n=10.
3159090|NCT00399412||HF|Heart Failure
3159091|NCT00399412||CRT|Cardiac Resynchronization Therapy
3159092|NCT00399412||Wide QRS|QRS > 120 milliseconds
3159093|NCT00399438|Other|1|0 mg
3159094|NCT00399438|Other|2|25 mg
3159095|NCT00399438|Other|3|100 mg
3159096|NCT00399477|Active Comparator|Rasagiline mesylate|
3159097|NCT00399477|Experimental|Rasagiline mesylate plus adjunct therapy|Rasagiline mesylate with one of three adjunct therapies
3159098|NCT00399555||One|Patients with HLHS that have had surgical palliation with the Norwood procedure (Stage I palliation) at Children's Healthcare of Atlanta after January 1, 2001. These patients must be between the ages of 2.5 years and 6 years of age.
3173524|NCT00613002|Placebo Comparator|placebo gel|placebo transdermal gel
2482310|NCT03020836|Other|Hypertension patient referral|Referral to primary care physician for hypertension control: Patients with uncontrolled hypertension were referred to a primary care physician for treatment.
2482311|NCT03020836|Other|Smoking cessation patient referral|Referral to smoking quit line: Patients that were current smokers were referred to the Maryland smoking cessation quit line if they were willing.
2482351|NCT03020381||Cognitively Normal (Control Group)|Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD.
2482354|NCT03020381||Subjective Cognitive Impairment (SCI)|"Participants aged 60 and older, with absence of Dementia (by DSM IV and DSM V) criteria. Normal age-, sex-, and education-adjusted performance on standardized cognitive tests, which are used to classify mild cognitive impairment (MCI) or prodromal AD. Self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event. Answering yes to both of the following questions: Do you feel like your memory or thinking is becoming worse? and Does this concern you?"
2482356|NCT03020381||Mild Cognitive Impairment (MCI)|Participants aged 60 and older that have self-experienced persistent decline in cognitive capacity and unrelated to an acute event. MCI is operationalized following Peterson's criteria as: i) presence of subjective memory complaints from the patient and family; ii) objective memory impairment in cognitive tests (below 1.5 SD on standardized cognitive tests adjusted by age, sex, and education-); iii) preserved activities of daily living (assessed using the Lawton-Brody scale); iv) absence of clinical dementia established using DSM-IV-TR (from 2007 to 2013) and DSM V (from 2014 and onwards)
2482392|NCT03020147||early BCG|Children received BCG soon after their birth between 2008 and 2013.
2482395|NCT03020147||delayed BCG|Children received BCG when they are 2,5kg between 2008 and 2013.
2482490|NCT03019640|Experimental|Treatment (chemotherapy, NK infusion, stem cell transplant)|See Detailed Description.
2482683|NCT03018483|Experimental|Variable PSV|
2482686|NCT03018483|Active Comparator|Conventional PSV|
2482687|NCT03018483|Active Comparator|Automated PSV|
2482692|NCT03018483|Active Comparator|NAVA|
2482755|NCT03017768|Active Comparator|Acute tryptophan depletion|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine) lacking tryptophan to investigate the effect of tryptophan depletion on esophageal sensitivity
2482762|NCT03017768|Placebo Comparator|Placebo|Administration of an amino acid mixture consisting of 15 amino acids, (4.1g L-alanine, 2.4g glycine, 2.4g L-histidine, 6.0g L-isoleucine, 10.1g L-leucine, 6.7g L-lysine, 4.3g L-phenylalanine, 9.2g L-proline, 5.2g L-serine, 4.3g L-threonine, 5.2g L-tyrosine, 6.7g L-valine, 3.7g L-argine, 2.0g L-cysteine, 3.0g L-methionine and 3.0g L-trypyophan). Since this amino-acid mixture contains tryptophan it is used as the placebo arm of this cross-over study
2482793|NCT03017339|Experimental|Laser Group|The subjects participated in a functional exercise program associated with low level laser therapy applied in the quadriceps, hamstrings and triceps sural
2482794|NCT03017339|Placebo Comparator|Placebo Group|The subjects participated in a functional exercise program associated with placebo low level laser therapy applied in the quadriceps, hamstrings and triceps sural
2482824|NCT03017131|Experimental|Treatment (decitabine, genetically modified T cells)|COURSE 1: Patients receive decitabine IV daily over 1 hour on days -8 to -6, cyclophosphamide IV over 2 hours on days -4 and -3, and genetically engineered NY-ESO-1-specific T lymphocytes IV and IP on day 0. Patients also receive aldesleukin SC BID on days 1-14..
2482894|NCT03016767|Experimental|oral stimulation|"All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care.~Infants of the experimental group, in addition, will be applied a manual oral stimulation protocol designed ad hoc for this study, which consists of 12 maneuvers performed by a physiotherapist."
2482900|NCT03016767|No Intervention|non oral stimulation|All the subjects of the study will receive the usual medical and nursing care for premature babies. They also will receive the physiotherapeutic treatment prescribed by the rehabilitation physician, focused mainly on respiratory and musculoskeletal care. But this group will not be applied the oral stimulation protocol.
2482962|NCT03016520|Experimental|Test drug|DWJ1392
2482964|NCT03016520|Experimental|Reference drug|DWC20164
2483065|NCT03016052|Experimental|ABMT|The attention bias modification treatment comprises of six computerized sessions, twice a week, in purpose of modulate biases in attention for threat stimuli.
2483098|NCT03015467|Active Comparator|treatment for part 1|Fecal Microbiota Transplantation (FMT) and traditional treatments according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 1.
2483103|NCT03015467|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline (NS) according to associated guidelines will be used in patients with severe acute pancreatitis(SAP) in part 2.
2483158|NCT03015064||Myocardial Infarction|Patients with first myocardial Infarction
2483230|NCT03014830|Active Comparator|Alirocumab|Subjects will receive alirocumab for 6 weeks.
2483231|NCT03014830|Placebo Comparator|Placebos|Subjects will receive placebo for 6 weeks.
2483315|NCT03014128||Inspection and Packaging|self-descriptive
2483317|NCT03014128||Grinding, Polishing and Matting|self-descriptive
2483320|NCT03014128||All other employees at Aesculap (not in first 2 groups)|including administration and offices as well as all other mechanical workplaces
2483417|NCT03013517|Experimental|Viaskin Peanut 250µg|
2483511|NCT03012919|Other|active decision support system (GDT protocol)|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
2483538|NCT03012542|Experimental|Diet 1|Administered for 8 weeks.
2483541|NCT03012542|Experimental|Diet 2|Administered for 8 weeks.
2484021|NCT03009734|Other|ATx201 (2% dermal formulation A) and Placebo|
2482321|NCT03020602|Experimental|Treatment (BPM31510)|Patients receive ubidecarenone injectable nanosuspension IV over 72 hours twice weekly. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2482372|NCT03020264|Experimental|Patients older than 75 years|Collection of hypoglycaemia épisodes with the glycemic sensor FREESTYLE Libre Pro
2482431|NCT03019991|Experimental|PK Group (Danoprevir,Ritonavir)|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14;100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13;
2482434|NCT03019991|Placebo Comparator|Placebo Group|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13; Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13 for 14 days;
2482467|NCT03019679||Study group|Patients with polycystic ovary syndrome
2482469|NCT03019679||Control group|Patients without polycyctic ovary syndrome
2482477|NCT03019380|Experimental|Impacted cerumen|removing cerumen from external ears of patients with impacted cerumen, obscuring the canal and the tympanic membrane.
2482523|NCT03019250|Experimental|Colostrum|Intervention patients will be received enteral formula and colostrum powder 20 g/kg/day given via nasogastric tube as boluses q 4hrs.
2482524|NCT03019250|Placebo Comparator|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2482539|NCT03018951||Tool Development Stage|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2482545|NCT03018951||Pilot Test 1|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2482551|NCT03018951||Pilot Test 2|Older adults aged ≥65 years with a diagnosis of functional mental illness who show some signs of potentially being frail (presence of ≥2 of the following frailty indicators: Aged ≥75 years old, prescribed ≥5 medications, a history of ≥1 fall/s in the 6-month period prior to assessment, admission to hospital in the 6-month period prior to assessment. In receipt of weekly support for Activities of Daily Living (ADL) tasks, In receipt of daily support for Instrumental Activities of Daily Living (IADL) tasks, ≥2 chronic physical health conditions).
2482607|NCT03018613|Active Comparator|treatment for part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with chronic functional constipation in part 1.
2482608|NCT03018613|Placebo Comparator|Placebo for part 2|The traditional treatments and normal saline will be used in patients with chronic functional constipation in part 2 according to associated guidelines.
3193452|NCT00818155|Experimental|desvenlafaxine succinate SR|desvenlafaxine succinate SR
3193453|NCT00818155|Placebo Comparator|Placebo|
2482810|NCT03017417|Experimental|Exercise Intervention arm|"exercise training intervention to include:~DEXA scan will collect data on via a full body scan to determine post-cranial appendicular whole body LM, whole body fat free mass (FFM) and whole body FM.~Muscle Strength assessment~Physical function assessment~Questionnaires and diet diaries"
2482817|NCT03017417|Active Comparator|standard of care arm|"standard treatment~exercise advice~Questionnaires"
2482861|NCT03017014||Pediatric participants receiving adalimumab|Pediatric participants receiving adalimumab for CD in real-life conditions.
2482892|NCT03016585|Experimental|Tai Chi Training|Tai Chi exercises 3 times per wk for 12 weeks
2482899|NCT03016585|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 weeks.
2483057|NCT03015831|Active Comparator|Colchicine|Intervention by administering an active copmarator of 1 mg colchicine one day pre op and 0.5 mg daily after surgery until discharge
2483061|NCT03015831|Placebo Comparator|Placebo Oral Tablet|Identical tablet (placebo) administered in a similar way as that in the active comparator arm
3193454|NCT00818181|Experimental|Solution of birch pollen allergen extract|In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
3193455|NCT00818194|Experimental|A. tacrolimus first|Subjects receive extended release tacrolimus in first dosing interval then cross over to cyclosporine A for second dosing interval
2482473|NCT03019614|Experimental|Group 1|"Volunteers in group 1 received the following interventions:~Chronocort® 30 mg given at night (~ 23:00h) as a combination of one 10mg capsule and one 20mg capsule (n=18).~Chronocort® 30mg given as one 20mg capsule at night (~ 23:00h) and as one 10mg capsule in the morning (~ 7:00h) following the initial night-time dose (n=18).~Hydrocortisone 30mg given at night (~ 23:00h) given as three 10mg tablets (n=18).~Each administration of IMP was separated by a washout period of at least 7 days."
2482474|NCT03019614|Experimental|Group 2|"Volunteers in group 2 received the following interventions:~Chronocort® 5mg given at night (~ 23:00h) as one 5mg capsule (n=12).~Chronocort® 10mg given at night (~ 23:00h) as one 10mg capsule (n=12).~Chronocort® 20mg given at night (~ 23:00h) as one 20mg capsule (n=12).~Each administration of IMP was separated by a washout period of at least 7 days."
2482525|NCT03019185|Experimental|Phase 2 Cohort|Patients in the Phase 2 cohort will receive bardoxolone methyl throughout the study. Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
2482526|NCT03019185|Active Comparator|Phase 3 Bardoxolone Cohort|Patients with baseline ACR ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline ACR > 300 mg/g will be titrated to a maximum dose of 30 mg. Adult patients (≥ 18 years of age) receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate to 10 mg at Week 2, to 20 mg at Week 4, and then to 30 mg at Week 6 (only if baseline ACR >300 mg/g) unless contraindicated clinically and approved by the medical monitor. Patients under the age of 18 receiving bardoxolone methyl will start 5 mg every other day during the first week and begin once-daily dosing with 5 mg during the second week of the study, and then continue with once-daily dosing following the same aforementioned dose titration scheme based on baseline ACR at Weeks 2, 4, and 6.
2482527|NCT03019185|Placebo Comparator|Phase 3 Placebo Cohort|Patients randomized to placebo will remain on placebo throughout the study, undergoing sham titration.
2482583|NCT03018834|Experimental|A: ANAKINRA|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
2482586|NCT03018834|Placebo Comparator|B: Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
2482625|NCT03018470||Control cohort|Patient with COPD and home NIV admitted for planned respiratory review and without any sign of exacerbation
2482632|NCT03018470||Exacerbation cohort|Patient with COPD and home NIV admitted for acute exacerbation of COPD
2482634|NCT03018470||Outpatient exacerbation|Patient with COPD and home NIV admitted for planned respiratory review and with signs of acute exacerbation of COPD but not requiring inpatient management
3159099|NCT00399581|Experimental|HFOV-Lo|High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
3159100|NCT00399581|Experimental|HFOV-Hi|High Frequency Oscillatory Ventilation using higher mean airway pressures
2482975|NCT03016286|Experimental|WBV group|whole-body vibration (WBV) group
2483029|NCT03016039|Experimental|Dietary supplementation|This group will receive Dietary supplementation
2483031|NCT03016039|No Intervention|conventional treatment|conventional Antibiotic treatment without curcumin supplementation
2483117|NCT03015623|Experimental|Low dose cohort|SBI-101 device containing 250 million MSCs
2483126|NCT03015623|Experimental|High dose cohort|SBI-101 device containing 750 million MSCs
2483131|NCT03015623|Sham Comparator|Control|Sham device containing no MSCs
2483178|NCT03015025||Stable treatment with acenocoumarol|Patients in stable anticoagulant treatment with acenocoumarol for auricular fibrillation, venous thromboembolic disease and/or cardiac valve replacement.
2483243|NCT03014713|Active Comparator|Control Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h.
2483244|NCT03014713|Experimental|Dexmedetomidine Group|Patients in this group receive intravenous Patient-Controlled Analgesia(PCA) pump after surgery.The intravenous PCA protocol is dezocine 0.01mg/kg/h,flubiprofen 0.05mg/kg/h,dexmedetomidine 0.1μg/kg/h.
2483296|NCT03014219|Experimental|Only 1 arm: treatment with MSC-AFP|Single Treatment Group: Eligible patients will be treated with a Gore Bio-A Fistula Plug that has been coated with autologous mesenchymal stromal cells. This is a drug study, specifically phase 1 study of autologous mesenchymal stromal cells. Single dose of 20 million cells.
2483337|NCT03013998|Experimental|BAML-16-001-S1 (Closed)|This is an open-label Phase 1b/2 clinical study of Samalizumab given in addition to standard induction chemotherapy/consolidation, followed by Samalizumab maintenance, in newly diagnosed acute myeloid leukemia. Patients that are marker negative, as defined based on the Beat AML Master Protocol assignment or with CBF karyotype/interphase cytogenetics/molecular testing defined by presence of t(8;21)(q22;q22) or the molecular equivalent RUNX1/RUNX1T1 fusion transcript or inv(16)(p13q22) or t(16;16)(p13;q22) or the molecular equivalent CBFB/MYH11 fusion transcript based on the Beat AML will receive Samalizumab in combination with induction therapy followed by Samalizumab maintenance.
2483357|NCT03014063||Hemodynamic responders|Those with a mean arterial pressure of at least 65mmHg and a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
3159101|NCT00399594|Experimental|A|Targeted LV lead placement
3159102|NCT00399594|Active Comparator|B|Usual LV lead placement
3159103|NCT00399607||Aim 1|Participants previously randomized for the parent study will be eligible for a portion of the adjunct biomarker study.
3159104|NCT00399607||All aims|Participants entering the parent study will be eligible for all sample collections of the adjunct biomarker study.
3173525|NCT00613041||1|Patients with one or more pulmonary nodules 5-15 mm in diameter.
3173526|NCT00613054|Experimental|Zactima + Gleevec + Hydrea|
2482398|NCT03020186|Experimental|Physical activity+ MED diet|On top of the PA intervention described in Arm 1, the participants will be guided for moderate weight loss with a traditional Mediterranean (MED) diet, low in simple carbohydrates. The diet will include 1oz/day of walnuts that will be provided free of charge.
2482399|NCT03020186|Experimental|Physical activity+ green-MED diet|"On top of the PA intervention described in Arm 1, the participants will guided for moderate weight loss with a MED diet, low in simple carbohydrates that will be rich in plants and polyphenols and low in processed meat. The diet will include 1oz/day of walnuts, 3-4 cups/day of green tea and ~500cc green shake/dinner based on specific strain of duckweed [Wolffia globose, Mankai], an aquatic plant, which might serve as a plant protein source. All the above will be provided free of charge."
2482447|NCT03019835|Active Comparator|GROUP 1|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 1 response of 4 in TOF mode (Train Of Four)
2482456|NCT03019835|Active Comparator|GROUP 2|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 2 response of 4 in TOF mode (Train Of Four)
2482459|NCT03019835|Active Comparator|GROUP 3|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 3 response of 4 in TOF mode (Train Of Four)
2482463|NCT03019835|Active Comparator|GROUP 4|A group receiving neostigmine (40 mcg / kg) when the block Neuromuscular block's recovery measured by acceleromyography is 4 response of 4 in TOF mode (Train Of Four)
2482466|NCT03019835|Active Comparator|CONTROL|A control group : not receiving an antagonist (spontaneous recovery)
2482502|NCT03019393|Other|Beef|Beef topside fully cooked, 200g
2482541|NCT03019172|Experimental|Lactobacillus reuteri|Women in experimental branch will receive two sachets. Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
2482547|NCT03019172|Placebo Comparator|Sachet with cranberry + placebo|Women in control branch will receive two sachets. Sachet one contains only Maltodextrin and sachet two contains instant cranberry drinkcomposed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica Both sachets should be emptied in a glass and mixed with 200 ml of cold water
2482622|NCT03018678||Patients with HOFH|No intervention
2482671|NCT03018314||Group 1|The first group will comprise of 30 women with polycystic ovaries in ultrasound examination or anovulatory cycles.
2482672|NCT03018314||Group 2|The second group will comprise of 30 women with diagnosis of unexplained infertility, normal menstrual periods and without known male factor infertility.
2482673|NCT03018314||Group 3|The third group will comprise of 30 women those partners with sperm count between 5x106 -15x106 /mL, type A + type B motility <%32 and Kruger morphology <4%.
2482742|NCT03017872|Active Comparator|Standard of Care (SoC) arm|2 x NRTIs + darunavir/ritonavir 800mg/100mg po od
2482743|NCT03017872|Experimental|Dolutegravir arm|Dolutegravir 50mg + darunavir/ritonavir 800mg/100mg po od
2482745|NCT03017872|Experimental|Dolutegravir 2NRTI arm (D2N)|Dolutegravir 50mg + 2 x NRTIs (tenofovir plus emtricitabine or lamivudine)
2482833|NCT03017105|Active Comparator|Control|Usual rehabilitation: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm
2482834|NCT03017105|Experimental|Experimental|Cross-education of strength-training: non-operative management of the fracture; will undergo usual physiotherapy rehabilitation for the injured arm but will also undergo strength-training for the uninjured arm
2482857|NCT03016936||Subgroup for NTproBNP Substudy|Planned subgroup analyses in patients undergoing vascular, orthopaedic, thoracic surgery, and in patients aged 65 years or older with a RCRI <2 and NSQIP- MICA <1%
2482903|NCT03016715|Experimental|Treatment|Sirolimus, 2% topical ointment will be used during randomization
2482908|NCT03016715|Placebo Comparator|Vehicle|A placebo topical ointment will be used during randomization.
2483014|NCT03016104|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2483015|NCT03016104|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2483044|NCT03015753|Experimental|Tai Chi training|The participants in this arm will receive 12-week Tai Chi training (1 hour per day, 5 days per week).
2483047|NCT03015753|Other|Waiting list control group|Participants in this arm will be asked to maintain their usual lifestyles and exercises for 12 weeks. At the end of the trial , the participants will be offered Tai Chi training similar as Tai Chi group.
3159105|NCT00399672|Active Comparator|1|The 4 participating sites are designated either High Intensity or Low Intensity. High Intensity sites have access to: full time specialist physicians, access to full time nurses and counselors. All weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
3173527|NCT00613067|Experimental|GAD|35 patients with Generalized Anxiety disorder
3173528|NCT00613093|Active Comparator|Patients with glioblastoma multiforme|
3173529|NCT00613093|Active Comparator|Patients with Anaplastic Glioma|
3173530|NCT00613132|Experimental|1|Pts receiving EIACDs
2483209|NCT03014882|Other|Antioxidant treatment|
2483236|NCT03014557||WATCHMAN|subjects with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN left atrial appendage closure device
2483311|NCT03014388|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and to be used for bone augmentation with sinus lift.
2483316|NCT03014388|Experimental|Mineralized Plasmatic Matrix (MPM)|Patients with defective posterior maxillary alveolar ridges requiring implant insertion will receive bone graft using Mineralized plasmatic matrix.
2483366|NCT03013907|Experimental|UPLIFT|Eligible participants will complete 8 weekly group sessions by phone. The intervention builds cognitive-behavioral and mindfulness skills to help reduce depressive symptoms. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
2483383|NCT03013725||The Homocysteine Study|Conducted in 1992-93, ca. 18000 participated.
2482517|NCT03019263|Experimental|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
2482520|NCT03019263|Active Comparator|Control|Nutritional counseling
3173531|NCT00613132|Experimental|2|Pts not receiving EIACDs
2482626|NCT03018548|Experimental|subject blood drawns|subjects will have blood drawn which will then be exposed to blast via CO2 cartridge
2482705|NCT03018275|Experimental|1|"Vials of lyophilized R mucosa (103, 104, or 105 CFU)"
2482765|NCT03017781||Study Group|Offspring (15-25 years old) of parents with Bipolar Disorder (BD) with at least mild impairment in psychosocial functioning were observed to evaluate the relationship of impairment in psychosocial functioning with the manifestation of mood symptoms over 24 months
2482770|NCT03017781||Control Group|A group of offspring of bipolar parents with no impairment in psychosocial functioning will be used for comparison.
2482804|NCT03017209|Experimental|Locally-prepared bar|The bar is similar to one tested recently in a pilot study and is a locally prepared bar designed to facilitate growth and cognitive development. It will provide 300 kcal/day and will have ≈20-30% of energy from protein (of which 25-50% is from an animal protein source), 20-35% from total carbohydrate and ≈40-60% from fat. The bar will be fortified with vitamins and minerals to meet USAID recommendations for moderate malnutrition and Dietary Reference Intake recommendations for at-risk and healthy children of the ages studied, and at the same time will not exceed Upper Level nutrient recommendations for any micronutrient. Ingredients in the bar will be a combination of local products and imported shelf-stable ingredients.
2482805|NCT03017209|Active Comparator|USAID Corn Soy Blend Plus|The usual-intervention condition will be 300 kcal/day of USAID Corn Soy Blend Plus cooked in the usual manner with fortified vegetable oil (10:3 ratio) and sugar. The community health workers or other designated villagers will prepare the supplement freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
2482806|NCT03017209|Placebo Comparator|Locally-purchased rice|The placebo condition will be 300 kcal/day of locally-purchased rice cooked with a small amount of oil (10:2 ratio), which mimics the usual breakfast of children in this region. The community health workers or other designated villagers will prepare the rice freshly each intervention day using locally accepted standards for hygiene, and a quality control process for ratios of ingredients assigned by the research team to ensure consistent composition.
2482852|NCT03016988|Other|Bortezomib,Fludarabine and Cytarabine|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11; Fludarabine(F) 25mg/m2, intravenously day 1-3; Cytarabine(A) 500mg/m2 for 3 days(day1-3).
2483038|NCT03015857|Active Comparator|phenylephrine,|- Phenylephrine group (n=100): will receive 100 mcg phenylephrine as a single bolus just after intrathecal injection of 10 mg bupivacaine plus 20 mcg fentanyl. The dose will be diluted in 5 mL and given over seconds. A continuous infusion with placebo (normal saline) will start after the first bolus.
2483040|NCT03015857|Active Comparator|norepinephrine|- Norepinephrine group (n=100): will receive bolus of norepinephrine (10 mcg) directly after spinal block using 10 mg bupivacaine plus 20 mcg fentantanyl followed by continuous infusion of norepinephrine with a rate of 0.1 mcg/kg/min till delivery of the fetus.
2483099|NCT03015506|Active Comparator|White Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber).
2483104|NCT03015506|Experimental|Pea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) pea flour.
2483108|NCT03015506|Experimental|Green Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) green lentil flour.
2483119|NCT03015506|Experimental|Red Lentil Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) red lentil flour.
2483124|NCT03015506|Experimental|Chickpea Bread|Portion of bread containing 50g available carbohydrate (defined as total carbohydrate minus dietary fiber) containing 18% (by weight) chickpea flour.
2483166|NCT03015090|Experimental|theophylline|
2483250|NCT03014752|Active Comparator|Classical ketogenic diet|The classical ketogenic diet with 4:1 ketogenic ratio, each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced.
2483259|NCT03014752|Active Comparator|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
2483313|NCT03014297|Experimental|everolimus + fosbretabulin|everolimus + fosbretabulin
2483358|NCT03013842|Experimental|Administration of Fetal Oximetry Probe|Administration of Raydiant Oximetry Sensor System on 36 weeks or greater pregnant women
2483455|NCT03013595|Experimental|TRAM feedback|"The completion of the Transition Readiness and Appropriateness Measure (TRAM, a standardized structured assessment ) prior to the transition boundary by the child and adolescent mental health service (CAMHS) clinician, young person and parent/carer.~Feedback of TRAM findings to the CAMHS clinician to support decisions made regarding transition, communication with stakeholders and the transition process. Clinicians will be expected to communicate the findings to the young person and parent/carer, and, if a referral is made, to send the TRAM feedback to the adult clinician along with the referral letter.~The clinicians will also receive information prior to recruitment begin on the use of TRAM and the way in which it fits in with optimal transition."
2483457|NCT03013595|No Intervention|Usual care|Patients, parent/carers and clinicians in the control arm will complete the TRAM prior to the transition boundary, but the clinicians won't receive any feedback from it nor any information on the benefits of using the decision support tool.
2483532|NCT03012555||Sickle Cell Disease and Vitamin D deficiency|
3173532|NCT00613145|Active Comparator|A|Treatment with Capecitabine and Sorafenib
3173533|NCT00613145|Active Comparator|B|Treatment with Capecitabine and Sorafenib
3173534|NCT00613158||1|Participants from the Multi-Ethnic Study of Atherosclerosis (MESA) with significant subclinical atherosclerosis (SA) and a low Framingham risk score
3173535|NCT00613158||2|Participants from MESA with no SA and a low Framingham risk score
3173536|NCT00613158||3|Healthy participants from Northwestern University
3173537|NCT00613184|Experimental|1|Nylon Flocked swab Left Nasal Wash right
3173538|NCT00613184|Experimental|2|Nylon Flocked swab R Nasal Wash L
3159106|NCT00399672|Active Comparator|2|The 4 participating sites are designated either High Intensity or Low Intensity. In the Low intensity group, all patients will have access to: full time primary care physicians, specialist physicians and access to part time nurse or counselor by appointment. Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
3159107|NCT00399685|Active Comparator|A|
3159108|NCT00399685|Active Comparator|B|
2482752|NCT03017560|Experimental|Computerized cognitive treatment|Chosen exercises from the rehabilitation package of a commercially available, computerized, cognitive training program called Happy Neuron Pro will be used. This program was designed by a team of neurologists, neuropsychologists and cognitive psychologists, and has been successfully adapted for varying conditions of cognitive dysfunction.
2482758|NCT03017560|No Intervention|Wait list control|Participants assigned to the wait list control arm will receive no treatment while the experimental arm is participating in the computerized treatment. However, the computerized treatment program will be made available for these participants to utilize at the end of the study period.
2482830|NCT03017430|Experimental|Pregabalin|This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
2482832|NCT03017430|Active Comparator|Clonidine|This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..
2482853|NCT03016897||Group 1|Participants enrolled solely in ALS AT HOME Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2482854|NCT03016897||Group 2|Current participants of the Answer ALS study Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2482855|NCT03016897||Group 3|Participants without neurological disease (controls) Outcome measurement devices will be provided. Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
2482912|NCT03016741|Other|Arm I (abiraterone acetate, prednisone)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive abiraterone acetate PO and prednisone PO BID in the absence of disease progression or unacceptable toxicity. Patients then undergo cognitive assessment comprising of neuro-cognitive tests and assessments of overall quality of life, fatigue, pain, and symptoms at baseline, 3, 6, and 12 months. Patients also undergo MRI program for 40 minutes comprising of DTI, fMRI, ASL MRI, MPRAGE MRI, FLAIR MRI, and BOLD MRI at baseline and 3 months.
2482916|NCT03016741|Other|Arm II (enzalutamide)|Patients receive standard of care treatment with GnRH agonist/antagonist therapy. Patients also receive enzalutamide PO QD in the absence of disease progression or unacceptable toxicity. Patients undergo cognitive assessment and MRI program as in Arm I.
2482979|NCT03016221|Experimental|Axanova hot gel|Intervention: Axanova hot gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2482983|NCT03016221|No Intervention|Axanova hot gel control|No product application. The contralateral lumbar back side acts as a Axanova hot gel control.
2482984|NCT03016221|Experimental|Axanova activ gel|Intervention: Axanova activ gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2482986|NCT03016221|No Intervention|Axanova activ gel control|No product application. The contralateral lumbar back side acts as a Axanova activ gel control.
2482987|NCT03016221|Experimental|Perskindol Dolo Gel|Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2482988|NCT03016221|No Intervention|Perskindol Dolo Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Dolo Gel control.
2482989|NCT03016221|Experimental|Perskindol Classic Gel|Intervention: Perskindol Classic Gel is a topical product with a revulsive effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2482990|NCT03016221|No Intervention|Perskindol Classic Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Classic Gel control.
2482994|NCT03016221|Experimental|Perskindol Cool Kühl-Gel|Intervention: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2482997|NCT03016221|No Intervention|Perskindol Cool Kühl-Gel control|No product application. The contralateral lumbar back side acts as a Perskindol Cool Kühl-Gel control.
2483002|NCT03016221|Experimental|Dolor-X Hot Gel|Intervention: Dolor-X Hot Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2483004|NCT03016221|No Intervention|Dolor-X Hot Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Hot Gel control.
2483085|NCT03015389||Barrett's associated esophageal dysplasia|
3159109|NCT00399685|Active Comparator|C|
3159110|NCT00399685|Active Comparator|D|
3159111|NCT00399776||Group A|Adolescents taking haloperidol, risperidone, or olanzapine
3159112|NCT00399776||Group B|Healthy adolescents
3159113|NCT00399789|Active Comparator|Perifosine 150 mg qd|A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg to be given in one dose at bedtime.
3173539|NCT00613184|Experimental|3|Nasal Wash Left Nylon Flocked swab Right
3173540|NCT00613184|Experimental|4|Nasal Wash R Nylon flocked swab L
2482440|NCT03020030|Other|Initial Very High Risk (Initial VHR)|"Any of the following are present: IKZF1 deletion, MLL (KMT2A) rearrangement, low hypodiploidy, t(17;19)~Treated with Induction IA (vincristine, dexamethasone, pegaspargase, doxorubicin + dexrazoxane), Induction IB (cyclophosphamide, cytarabine, mercaptopurine), Consolidation IA (vincristine, high-dose methotrexate + leucovorin, mercaptopurine). IT chemotherapy in all phases. Final risk group assigned by end of Consolidation IA."
2482441|NCT03020030|Other|Final Low Risk (Final LR)|"Initial Low Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, methotrexate, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2482442|NCT03020030|Other|Final Intermediate Risk (Final IR)|"Initial High Risk and Low MRD (<0.0001) at first time point (Day 32)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2482444|NCT03020030|Other|Final High Risk (Final HR)|"Initial Low Risk or Initial High Risk with High MRD (>=0.0001) at first time point (Day 32) but low MRD (<0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by randomization or direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by randomization or direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~All treatment completed 24 months from date of complete remission."
2482445|NCT03020030|Other|Final Very High Risk (Final VHR)|"Initial VHR or any patient with high MRD (>=0.001) at second time point (week 10-12)~Final Risk Group assigned at end of Consolidation IA. Subsequent therapy as follows:~Consolidation IB/B-ALL (High-dose methotrexate + leucovorin, cyclophosphamide, etoposide, IT chemotherapy); Consolidation IB/T-ALL (nelararbine, cyclophosphamide, etoposide); Consolidation IC (High-dose cytarabine, etoposide, dexamethasone, pegaspargase [by direct assignment], IT chemotherapy); CNS phase (vincristine, dexamethasone, mercaptopurine, pegaspargase [by direct assignment], IT chemotherapy); Consolidation II (vincristine, dexamethasone, mercaptopurine, doxorubicin + dexrazoxane, pegaspargase [by direct assignment], IT chemotherapy); Continuation (vincristine, dexamethasone, mercaptopurine, methotrexate, IT chemotherapy).~Dasatinib administered daily during all phases to pts with ABL1-class fusions. All treatment completed 24 months from date of complete remission."
2482451|NCT03020030|Active Comparator|Fixed Dose Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks at standard fixed-dose (2500 IU/m2/dose).
2482458|NCT03020030|Experimental|Reduced Dose (PK-Adjusted) Pegaspargase|Final LR, IR, HR patients who consent to randomization and are assigned to receive 15 doses of pegaspargase every 2-weeks beginning at a reduced dose (2000 IU/m2/dose); subsequent doses adjusted based on nadir serum asparaginase activity (NSAA) levels, with goal of maintaining NSAA between 0.4 and 1.0 IU/mL
2482465|NCT03020030|Other|Direct Assignment|All VHR patients, and any Final LR, IR, HR patients who decline randomization: Assigned to receive standard dosing of pegaspargase (15 doses of pegaspargase every 2-weeks at standard fixed-dose; 2500 IU/m2/dose).
2482584|NCT03018821|Active Comparator|Standard CMF|"Standard Chinese medical formulas (CMF) for the corresponding TCM syndromes, plus an anti-virus treatment of western drugs (such as Entecavir or Tenofovir).~Yinchengao Decoction plus Ganlu Detoxification Pill for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Chaihu Shugan San for the TCM syndrome: Liver depression and qi stagnation~Xiaoyao powder for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Yiguan Decoction for the TCM syndrome: Yin deficiency of liver and kidney~Fuzilizhong Decoction plus Jinkui Shenqi Bolus for the TCM syndrome: Yang deficiency of spleen and kidney~Ge Xia Zhu Yu Decoction for the TCM syndrome: Internal blood stasis"
2482585|NCT03018821|Experimental|Advanced CMF|"Advanced TCM formulas for corresponding TCM syndromes provided by famous TCM doctors who were national wide known in China, plus an anti-virus western drugs (such as Entecavir or Tenofovir).~Taohong Huazhuo Decoction for the Traditional Chinese Medicine (TCM) syndrome: Damp-heat blocking middle jiao~Soothe the liver and regulate qi Decoction for the TCM syndrome: Liver depression and qi stagnation~Supplemented Ganbi Decoction for the TCM syndrome: Stagnation of liver qi and spleen deficiency.~Supplemented Zimu Dan for the TCM syndrome: Yin deficiency of liver and kidney~Guifu Erxian Decoction for the TCM syndrome: Yang deficiency of spleen and kidney~Supplemented Ganji Decoction for the TCM syndrome: Internal blood stasis"
2482587|NCT03018821|Experimental|Pure Entecavir or Tenofovir|Use an anti-virus western drug alone (such as Entecavir or Tenofovir).
2482644|NCT03018379||Assessment of body composition|The collection of the samples and the analyses were undertaken according to the guidelines of the International Atomic Energy Agency. In brief, after having emptied the bladder, each participant provided a predose saliva sample using a cotton ball.A 99.8 % deuterium dose of 0.5 g per kg body weight was given orally to the participant. The postdose sample was collected from 3h to 4h after the administration of the dose. The saliva samples were stored at 20°C until analysis by Fourier transform infrared spectroscopy (FTIR).
2482646|NCT03018379||Assessment of energy expenditure|"Each participant provided a predose urine sample. A dose of doubly labelled water 2.625 ml per kg body weight was given orally to the participant.~The post dose sample was collected at 3h to 4h , and on days 3, 7 and 14 after dosing. An aliquot of those samples were stored at 20°C in tightly sealed containers until analysis by isotope-ratio mass spectrometry (IRMS)."
2482648|NCT03018379||Assessment of physical activity|The participants were instructed to wear the accelerometer triaxial (GT3X+) attached to an elasticized belt around the waist, once they woke up until bed time at night for 7 consecutive days and to remove the accelerometer any time they were to perform activities that involve the use of water and when going to bed.
2482754|NCT03017820|Experimental|Group A (VSV-IFNbeta-NIS)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
2482505|NCT03019536|Experimental|Placebo IV|Multiple doses of placebo administered IV for up to 48 weeks, followed by a 16 week follow-up period
2482717|NCT03017911||Patients with PICC Lines|All patients included in this study have undergone PICC Line placement before enrollment.
2482768|NCT03017690||lanreotide group (Somatuline Depot®)|
2482772|NCT03017690||octreotide LAR group (Sandostatin LAR®)|
2482893|NCT03016871|Experimental|Cohort A (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 14 days for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with CR or PR receive nivolumab for an additional 6 weeks. Patients with only SD after 6-week nivolumab treatment receive nivolumab for an additional 6 weeks or receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2 every 21 days for 6 weeks per physician/investigator's discretion. Patients with PD after 6-week nivolumab treatment or patients with PR, SD, or PD after 12-week nivolumab treatment receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
2482898|NCT03016871|Experimental|Cohort B (nivolumab, etoposide, ifosfamide, carboplatin)|Patients receive nivolumab IV over 30 minutes on cycle 1 (cycle 1 is 14 days), day 1 in the absence of disease progression or unacceptable toxicity. Beginning in cycle 2, patients receive nivolumab IV over 30 minutes on day 1, etoposide IV on days 1-3, ifosfamide IV continuously over 24 hours on day 2, and carboplatin IV on day 2. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
2483049|NCT03015779|Experimental|experimental group|cultured autologous oral mucosal epithelial cell sheet
2483109|NCT03015610|Placebo Comparator|Placebo|participants will receive oral blinded matched placebo once daily
2483114|NCT03015610|Experimental|Genotype-guided Lansoprazole|participants will receive oral blinded commercially available lansoprazole once daily with a dose appropriate for the participant's metabolizer phenotype
2483177|NCT03014986||Patients who receive HCV treatment|HSCT patients with HCV who are receiving (or has recently received) HCV treatment
2483187|NCT03014986||Patients who do not receive HCV treatment|HSCT patients with HCV who have not received treatment
3159114|NCT00399789|Active Comparator|Perifosine 900 mg per week|A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 1,200 mg divided into four doses of 300 mg.
2483400|NCT03013582|Experimental|Amnion wrapping + Tenolysis|Standard surgical tenolysis + wrapping of the released tendon with amnion.
2483403|NCT03013582|Placebo Comparator|Tenolysis control|Standard surgical tenolysis alone
2483500|NCT03013075|Experimental|SPINAL PLUS GENERAL ANESTHESIA|Patient will receive the intervention SPINAL ANESTHESIA before the start of surgery using Bupivacaine heavy 40 mg and Morphine 250 micro grams comprising a total volume of 8 ml to achieve a spinal block up to T2 level followed by general anesthesia
2483503|NCT03013075|Active Comparator|ONLY GENERAL ANESTHESIA|Patient will receive only general anesthesia before the start of surgery
2483519|NCT03012581|Experimental|Nivolumab|Nivolumab 240 mg IV over 60 minutes every 14 days.
2483573|NCT03012386|Experimental|Sildenafil citrate|Sildenafil citrate 20 mg three times a day
2483603|NCT03012048|Experimental|MadiDrop (ceramic tablet)|"Households receive a MadiDrop (silver-impregnated ceramic tablet) in a safe-storage water container to use for all drinking water needs in the household. MadiDrops are replaced every 6 months over the 2-year intervention study period.~In July 2017, all households in the MadiDrop arm were crossed over to the ceramic water filter arm due to inconsistent silver release from the ceramic tablets."
2483604|NCT03012048|Active Comparator|Silver-impregnated ceramic water filter|"Households receive a silver-impregnated ceramic filter in a safe-storage water container to use for all drinking water needs in the household. Filters are replaced at the end of the 2-year intervention study period.~In December 2017, all silver-impregnated ceramic water filters were replaced with the same ceramic filters without silver due to continued inconsistencies with silver release."
2483605|NCT03012048|Active Comparator|Safe-storage water container|Households receive a safe-storage water container alone to use for all drinking water needs in the household.
2483611|NCT03012048|No Intervention|No intervention|Households are encouraged to continue their usual water treatment practices.
2483638|NCT03011775|Experimental|study|20 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes. Included pioglitazone 15 mg 1 time per day in the morning for 6 months.
2483642|NCT03011775|Other|control|23 patients who received standard medical therapy complex: isosorbide dinitrate 10-20 mg 2 times a day, acetylsalicylic acid 75 mg 1 time a day, bisoprolol 2.5 mg 1 time a day, rosuvastatin 20 mg 1 time a day, ramipril 5 mg 1 time a day. Patients also received recommendations on diet and lifestyle changes.
2483789|NCT03011047|Active Comparator|trans-orbital surgical approach|trans-orbital surgical approach through the lower eyelid Sub-ciliary incision ( through the lower eyelid) The skin incision is made just below the eyelashes.
3159115|NCT00399789|Active Comparator|Perifosine 50 mg tid|A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients experience no grade 2 toxicities during their first month of therapy, the dose will be escalated to 200 mg divided into four doses of 50 mg.
3159116|NCT00399906|Active Comparator|A1|10 mg
3159117|NCT00399906|Active Comparator|A2|30 mg
3159118|NCT00399906|Active Comparator|A3|100 mg
3159119|NCT00399906|Placebo Comparator|P1|10 or 100 mg
3159120|NCT00399919|Experimental|PLC|Investigational drug
3159121|NCT00399919|Placebo Comparator|Placebo|
3159122|NCT00399971|Experimental|Hemathera|Patients will receive cell-based immunotherapy.
3159123|NCT00399984|Experimental|1|
3159124|NCT00399984|No Intervention|2|
3159125|NCT00400010|Experimental|Expert System Intervention|Computerized Expert System Intervention based on the Transtheoretical Model of Change: 1. Normative feedback and feedback on motivational variables during the first week of hospital stay 2. Ipsative feedback on drinking behavior and motivation to change after three months
2482559|NCT03019081|Placebo Comparator|Anorexia nervosa-placebo|"Drug: Normal Saline Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.~Other Names:~Saline"
2482602|NCT03018600||1|We included 15 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) to the patients every morning at 8am for at least five days.
2482603|NCT03018600||2|We included 10 inpatients admitted to the Immunology Department, Peking Union Medical College Hospital (PUMCH), Beijing, China from April 1, 2016 to September 1, 2016.Intervention including glucocorticoid: using less than 15mg/day prednisone-equivalent glucocorticoid maintenance for at least 3 months and now treating with 1-2mg/kg/day prednisone-equivalent (intravenous/oral methylpredisolone or oral prednisone) for the relapse of primary autoimmune disease for at least five days.
2482645|NCT03018444|Experimental|Atorvastatin|2 weeks treatment with Atorvastatin (1st week 40 mg once daily on day, 2nd week 80 mg (2x40mg) once daily)
2482647|NCT03018444|Placebo Comparator|Placebo|2 weeks treatment with placebo tablets of comparable sizes and color to the Atorvastatin tablets (1st week one tablet once daily, 2nd week two tablets once daily)
2482665|NCT03018093|Experimental|C-CAR011|In day 0, 1 and 2, CAR011 cells will be intravenous infused at the 10%, 30% and 60% ratio respectively.
3193456|NCT00818194|Experimental|B. cyclosporine first|Subjects receive cyclosporine A in first dosing interval then cross over to extended release tacrolimus for second dosing interval
3193457|NCT00818220|Experimental|1-Delayed Cord Clamping (DCC)|Immediately after birth, the infant is placed in a warm blanket and held lower than the placenta. The research nurse counts out 30 to 45 seconds for the obstetrician. The cord is milked once and then clamped at 30 to 45 seconds after birth.
2482764|NCT03017547|Experimental|IC14|IC14 4 mg/kg IV on Study Day 1, then IC14 2 mg/kg IV once daily on Study Days 2-4.
2482767|NCT03017547|Placebo Comparator|Placebo|Placebo IV once daily on Study Day 1-4
2482930|NCT03017287|Experimental|GlucoMe App|Self monitoring of glucose blood measurements using the GlucoMe glucose monitoring glucose device and App
3193458|NCT00818220|Active Comparator|2-Immediate Cord Clamping (ICC)|Routine care which is immediate cord clamping
2483281|NCT03014102|Experimental|TPOqd|Recombinant Human Thrombopoietin 300U/kg/d ih quaque die, day-3/-2/-1 before mobilization
2483282|NCT03014102|Active Comparator|TPOqod|Recombinant Human Thrombopoietin 300U/kg/d ih qua altera die, day-3/-1/+2 before mobilization
2483331|NCT03014076|Experimental|GP2 peptide + GM-CSF + trastuzumab|HLA-A2+/A3+ subjects receive GP2 + GM-CSF vaccine and trastzumab
2483332|NCT03014076|Active Comparator|Trastuzumab|HLA-A2-/A3- subjects followed as controls receiving trastuzumab.
2483387|NCT03013738|Experimental|Growing Pro-Social (GPS) program|"The Growing Pro-Social (GPS) program is a cognitive-behavioral group program for offenders. GPS is based on schema therapy, which conceptualizes aggressiveness as a result of a distorted view of the self and of the others. The ultimate goal of the GPS is to promote change in dysfunctional core beliefs about the self and the others.~GPS consists of 40 sessions, each lasting about 90 minutes. Sessions must be carried out by two therapists who should be skillful in schema therapy. Sessions are grouped into five modules: (1) human communication, (2) interpersonal relationships, (3) cognitive distortions, (4) function and meaning of emotions, and (5) early maladaptive schemas.~The treatment group attended the GPS program in addition to the Treatment AsUsual (TAU) delivered at Portuguese prisons."
2483388|NCT03013738|Other|Treatment As Usual|Subjects in this group received Treatment As Usual in Portuguese prisons (supervision of school frequency, occupational and job-related tasks and sentence planning supervision over time) and did not attend the GPS program or any other structured program during the research period.
2483436|NCT03013387|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|"The 90Y--DOTA-tyr3-Octreotide initial, Cycle 1 dose will be 50 mCi/m2 in children; 120 mCi in adults. Treatment consists of 3 cycles, 6-8 weeks apart. Cycle 1 dose is fixed. Cycles 2 and 3 doses will be determined by dosimetry-based calculation of renal doses from previous cycles; total renal dose ≤ 23Gy. 90Y-DOTA-tyr3-Octreotide will be administered with an amino acid solution to prevent radiation damage to kidneys. Amino acid infusion will begin 30 min prior to infusion of 90Y-DOTATOC and continue 3.5 hrs after infusion of study drugs.~68Ga-DOTATOC will be administered intravenously to perform the PET/CT scan. The dose will be 3-5 mCi (target 4mCi). The pediatric dose will be 0.043 mCi/kg with a minimum dose of 0.3 mCi and a maximum dose of 3 mCi in children <18 years old."
2483478|NCT03013023|Placebo Comparator|Routine care|Control group
2483483|NCT03013023|Active Comparator|Behavioral-support interventions (BS)|NNS, FT, positional support, and oral sucrose feeding will be provided while infants are undergoing painful procedures
2483487|NCT03013023|Active Comparator|Parent-infant transaction program (PITP)|The PITP will be a six-session, one-on-one teaching intervention beginning on day 22 after birth, with four sessions at bedside, and two home-visit sessions within the first month after discharge.
2483489|NCT03013023|Active Comparator|BS+PITP|Behavioral-support interventions + Parent-infant transaction program
2483551|NCT03012711|Experimental|Training|Neuromuscular exercise training group will complete a 5 week NME training program
2483555|NCT03012711|No Intervention|Control|Control group will have 5 weeks with no intervention prior to being re-tested
2483679|NCT03012087|Experimental|Intervention Group|MyHealthyChoices
2483680|NCT03012087|Placebo Comparator|Control Group|Health Risk Assessment
2483769|NCT03011281||RA patients who start Tofacitinib|Korean RA patients who start Tofacitinib with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate or biologics.
2483866|NCT03011021|Experimental|UCB-Treg plus Liraglutide|Subjects will receive a single infusion of ex vivo expanded umbilical cord blood derived Treg product (2 x 10^6). Dose escalation of liraglutide up to 1.2 mg will be started 3 days after Treg infusion only if no severe side effects showed. Subjects continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as a routine therapy.
2483867|NCT03011021|Active Comparator|UCB-Treg|Subjects will receive a single infusion of ex vivo expanded Treg product (2 x 10^6). Insulin will be continued as a routine therapy.
2484022|NCT03009734|Other|ATx201 (2% dermal formulation B) and Placebo|
2482606|NCT03018626|Experimental|Modified R-ACVBP|R-ACVBP regimen: rituximab (375 mg/m2) given intravenously (IV) on day 0, doxorubicin (75 mg/m2) and cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1, vindesine (2 mg/m2) given on days 1 and 5, bleomycin (10 mg) given IV on days 1 and 5, prednisone (60 mg/m2) given orally on days 1 through to 5.
2482658|NCT03018158|No Intervention|dentulous|MR Imaging was collected with condition at the tongue at rest position.
2482659|NCT03018158|No Intervention|edentulous without denture wear.|MR Imaging was collected without denture wear.
2482660|NCT03018158|Experimental|edentulous with denture wear.|MR Imaging was collected with denture wear.
2482726|NCT03017989|Experimental|NIRF imaging|After the white light (WL) imaging, NIRF imaging will be performed. 2.5 mg of ICG will be administered i.v. up to 5 times if needed. The lesions identified in WL, are inspected in NIRF mode. The surgeon indicated whether the lesions are more easily identified in WL or the NIRF mode and scores the visibility on a 1-10 scale. Next, inspection will take place for lesions that are seen in NIRF mode but not in WL. Biopsies will be taken from the lesions and from normal tissue for reference and sent for histology. Evaluation will take place whether the lesions differ in histological characteristics
2482766|NCT03017638||Patients receiving QLB and questionaires|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours and 48 hours and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
2482773|NCT03017638||Historical control|"The control subjects' data will be assessed reviewing patient records. Data will include:~Maximal PACU VAS pain score (per nursing charts)~Overall POD 24 hours and 48 hours and 4 weeks opioid consumption (overall morphine mg/kg equivalent dose)~POD 24 and 48 hours and 4 weeks Respiratory complications"
2482815|NCT03017326|Other|Group A Very Low Risk HB|Patients with well differentiated foetal histology will receive 2 cycles of Cisplatin (2x 100mg/m2). Patients will non-well differentiated histology will be followed up only (no intervention).
2482821|NCT03017326|Active Comparator|Group B Low Risk HB|Patients who are resected after 2 cycles of Cisplatin will be randomised to receive 4 or 6 cycles of Cisplatin overall (80mg/m2). Patients who are not resected will continue to receive up to 6 cycles of Cisplatin (80mg/m2) until resection.
2482823|NCT03017326|Active Comparator|Group C Intermediate Risk HB|Patients will be randomised to receive Cisplatin (80mg/m2), Carboplatin (500mg/m2) and Doxorubicin (60mg/m2) as SIOPEL-3HR (5 cycles), Cisplatin (100mg/m2), Doxorubicin (60mg/m2) 5-Fluorouracil (600mg/m2) and Vincristine (4.5mg/m2) as C5VD (6 cycles), or 6 cycles of high dose Cisplatin (100mg/m2)
2482826|NCT03017326|Active Comparator|Group D High Risk HB|Patients will receive SIOPEL-4 regimen (Cisplatin 70mg/m2, Doxorubicin 30mg/m2) then have surgery. Post surgery, patients with remaining metastases will be randomised to receive 6 cycles of either Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Carboplatin (800mg/m2) and Etoposide (400mg/m2), or Carboplatin (500mg/m2) and Doxorubicin (40mg/m2) alternating with Vincristine (3mg/m2) and Irinotecan (250mg/m2). Patients with no metastases will receive the standard treatment of 3 cycles of Carboplatin (500mg/m2) and Doxorubicin (40mg/m2).
2482828|NCT03017326|Other|Group E Resected HCC|Patients with an underlying predisposition to HCC through genetic, viral or metabolic conditions will be followed up (no intervention). De novo or fibrolamellar HCC patients will receive 4 cycles of PLADO regimen (Cisplatin (80mg/m2) and Doxorubicin (60mg/m2)) over 4 cycles.
2482831|NCT03017326|Active Comparator|Group F Unresected HCC|Patients will be randomised to receive up to 6 cycles of PLADO (Cisplatin 80mg/m2, Doxorubicin 60mg/m2) with Sorafenib (300mg/m2) or up to 8 cycles of PLADO with Sorafenib and GEMOX (Gemcitabine 1000mg/m2, Oxaliplatin 100mg/m2) with Sorafenib (300mg/m2)
3159126|NCT00400010|No Intervention|Control group|Controls received a brochure on health behavior
3159127|NCT00400023|Experimental|1|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
3159128|NCT00400023|Active Comparator|2|"During the Cross-Over Pharmacokinetic Phase, patients will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single dose of 50 mg S-1 (2 capsules of 25 mg) on Day 1 followed by a single dose of 800 mg FT (8 capsules of 100 mg) on Day 8~Sequence B: Single dose of 800 mg FT on Day 1 followed by a single dose of 50 mg S-1 on Day 8"
3159129|NCT00400062||ICU survivors|The investigators will measure the independent contribution of risk factors such as delirium and exposure to sedative and analgesic medications to the incidence of long-term CI.
3159130|NCT00400088|Experimental|lithium group|Start at 600 mg po hs. Dose titrated up to a serum level of between 0.6 and 1.1 mmol/l.
3159131|NCT00400088|Active Comparator|paroxetine group|Start dose at 20 mg po od. If no clinical improvement(<20% reduction in MADRS score) by week 4 dose to be increased to 40 mg po od.
2483064|NCT03015909|Other|Eutropin pen inj.|
2483107|NCT03015493|Experimental|Neural mobilization and traction|Patients in this group are treated with neural mobilization techniques combined with cervical traction
2483111|NCT03015493|Experimental|Traction group|Patients in this group are treated with cervical traction
2483118|NCT03015493|No Intervention|Control group|Patients in this group comprise the control group and are not treated with any intervention
2483385|NCT03013725||The Hordaland Health Study (HUSK)|Conducted in 1997-99, ca. 26000 participated.
3159132|NCT00400114|Experimental|sunitinib|
3159133|NCT00400127|Experimental|amputee|
3159134|NCT00400140|Experimental|A|
3159135|NCT00400166|Experimental|1|Recovery Mentor: peer-based supportive care
3159136|NCT00400166|No Intervention|0|No Recovery Mentor, services as usual
3159137|NCT00400231|Active Comparator|1|Metformin
3159138|NCT00400231|Active Comparator|2|Fenofibrate
3159139|NCT00400231|Active Comparator|3|Fenofibrate and Metformin
3159140|NCT00400231|Placebo Comparator|4|
3159141|NCT00400257||1|People at high risk of heart failure.
2482620|NCT03018561|Active Comparator|aged-gender matched healthy controls|Healthy subjects: with no MetS and no-documented coronary heart disease (CHD), both males and females, aged>18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living.
2482621|NCT03018561|Experimental|patients with metabolic syndrome|Patients with MetS and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Metabolic syndrome (MetS) will be defined according to recent updated criteria (Alberti et al. 2005):presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l.
2482624|NCT03018561|Experimental|patients with coronary heart disease|CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy).
2482631|NCT03018561|Experimental|patients with chronic heart failure|"Patients with documented stable chronic heart failure will be recruited if they show the following inclusion criteria:~≥18 years~Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by a multigated acquisition Scan, echo or radiological ventriculography)~NYHA functional class I-III~Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).~Able to perform an symptom limited exercise test.~Capacity and willingness to sign the informed consent form."
2482699|NCT03018236|Experimental|Alcohol N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
2482704|NCT03018236|Placebo Comparator|Alcohol Placebo|A placebo capsule matching color and smell of the active medication
2482709|NCT03018236|Experimental|Cocaine N-acetylcysteine|600 mg N-acetylcysteine capsule by mouth, every 12 hours for 8 weeks
2482710|NCT03018236|Placebo Comparator|Cocaine Placebo|A placebo capsule matching color and smell of the active medication
2482746|NCT03017664||RFG|Retrospective review of enteral feeding in pediatric ICU patients for up to 5 days
2482747|NCT03017664||PFG|Pediatric ICU population to be fed a peptide-based enteral formula with higher protein and higher calories for up to 5 days
2482798|NCT03017456|No Intervention|Usual Care (UC)|Patients in the UC arm will not receive the study intervention (behavioral) and instead will receive care according to usual practice. This usually involves a brief office visit (approximately 5-10 minutes) with pertinent history and physical examination related to surgical/radiation recovery, review of the pathology and general instructions regarding the next step in follow-up.
2482803|NCT03017456|Active Comparator|SCP-Intervention vs usual care|behavioral intervention vs control Patients in the SCP-Int arm will be asked to attend a one-time appointment with a trained oncology nurse. The SCP-Int is comprised of a 30-minute nurse-led face-to-face intervention and the provision of a tailored PC-specific SCP (PC-SCP). Persistent effects and concerns that are identified will prompt the development of a tailored management plan captured within the PC-SCP. Relevant patient education materials will be linked electronically. Nurses will use motivational interviewing techniques to effective in increase healthy behaviors and empower the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support.
2482918|NCT03017053|Experimental|Radiotherapy|Primary surgery & Radiotherapy
2482924|NCT03017053|Active Comparator|Elective neck dissection|Primary surgery & Elective neck dissection
2482950|NCT03016377|Experimental|iC9-CAR19 cells|The 3+3 design in adult subjects and an independent study using 3+3 design in pediatric subjects. The starting dose of 5 x 10^5 transduced cells/kg will enroll 3 adult subjects in the initial cohort. If there are no dose limiting toxicities w/in 4 weeks of the cell infusion in these 3 subjects, then the next cohort will evaluate 1 x10^6 transduced cells/kg in adults. If there is toxicity in 1/3 patients in the initial cohort, the cohort will be expanded to enroll up to 6 adult patients. If the dose level 1 is determined to be above the tolerated cell dose, de-escalation would occur to dose level -1 where subjects would receive 1 x 10^5 transduced cells/kg. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before administration of iC9-CAR19 T cells.
2482951|NCT03016377|Experimental|Expansion Cohort Second Administration of iC9-CAR19 cells|After the recommended phase 2 dose (RP2D) of iC9-CAR19 T cells has been determined in adults, up to 18 additional adult subjects will be enrolled in an expansion cohort at the RP2D. In the expansion cohort, subjects will be offered a second infusion of iC9-CAR19 T cells based on B-cell recovery and minimal residual disease (MRD) status. All subjects will receive a lymphodepleting regimen of fludarabine and cyclophosphamide before second administration of iC9-CAR19 T cells.
2483070|NCT03015948|Experimental|2.5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 2.5 mg SHR4640 (n=8) or placebo (n=2)
2483071|NCT03015948|Experimental|10mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 10mg SHR4640 (n=8) or placebo (n=2) 10mg.
2483074|NCT03015948|Experimental|20mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 20mg SHR4640 (n=8) or placebo (n=2) .
2483075|NCT03015948|Experimental|Placebo|For each dose cohort, 10 subjects will be randomized in a 4:1 ratio to receive a single dose of either SHR4640 (n=8) or placebo (n=2)
2483076|NCT03015948|Experimental|5mg SHR4640|10 subjects will be randomized in a 4:1 ratio to receive a single dose of either 5 mg SHR4640 (n=8) or placebo (n=2)
2483128|NCT03015350||two lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and blood samples will be taken at intervals of 10 minutes starting from the 40th minute.
2483132|NCT03015350||one lung ventilation of Sevoflurane|In GroupSa, 1,5 % sevoflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
3159142|NCT00400296|Experimental|1|
3159143|NCT00400309|Experimental|REPEVAX® after REVAXIS®|REVAXIS® at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
2482628|NCT03018756|Active Comparator|Fentanyl Citrate|Single dose, nebulized 100 mcg fentanyl citrate. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
2482635|NCT03018756|Placebo Comparator|Placebo|Single dose, nebulized 0.9% saline solution. This is a double-blind, placebo-controlled, two-period crossover study comparing the effects of a single dose of nebulized 100 mcg fentanyl citrate to that of a placebo (0.9% saline). Treatments will be in randomized order: patients in one study arm will receive fentanyl at the first treatment visit and placebo at the second treatment visit, patients in the other arm will receive placebo first and fentanyl second.
2482666|NCT03018197|Experimental|Medication Education|Patients will receive training on the use of the personal health record and health education via the personal health record.
2482669|NCT03018197|No Intervention|No Medication Education|Patients will receive the current standard of care for the personal health record. Patients will not receive training on the use of the personal health record or health education via the personal health record.
2482727|NCT03017950|Experimental|Part1 (A)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330~IPs for Period 2: CKD-330 + D086"
2482729|NCT03017950|Experimental|Part1 (B)|"Number of Subjects: 10~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: CKD-330"
2482732|NCT03017950|Experimental|Part2 (A)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: D086~IPs for Period 2: CKD-330 + D086"
2482735|NCT03017950|Experimental|Part2 (B)|"Number of Subjects: 30~Number of days for Period 1: 8~Number of days for Period 2: 8~Number of days for wash-out between period 1 and period 2: 14~IPs for Period 1: CKD-330 + D086~IPs for Period 2: D086"
2482751|NCT03017586|Experimental|STN|DBS target with Subthalamic Nucleus (STN).
2482757|NCT03017586|Experimental|GPi|DBS target with Globus Pallidus Internus (GPi).
2482809|NCT03017378|Active Comparator|TB/FLU-01L (intranasal application)|Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.
2482816|NCT03017378|Active Comparator|TB/FLU-01L (sublingual application)|Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.
2482870|NCT03017001|Experimental|CHO (carbohydrate) group|Patients received a 8h preoperative fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g) and no infusion of intraoperative w-3-PUFA
2482872|NCT03017001|Experimental|W-3 PUFA group|Patients received preoperative fast for solids but allowed to drink 200 mL of water until 2h before anesthesia, and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
2482874|NCT03017001|Experimental|CHO plus intravenous w3-PUFA group|Patients received a 8h fast for solids and 2h fast with 200mL of a drink containing water plus 12.5% maltodextrin (25g), and an intravenous intraoperative dose of intravenous w-3-PUFA (0.2 mcg/kg)
2482875|NCT03017001|No Intervention|Control|Patients received preoperative fast for solids for 8h but allowed to drink 200 mL of water until 2h before anesthesia; and no infusion of intraoperative intravenous w-3-PUFA
2482934|NCT03016624|Active Comparator|OCT guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
2482936|NCT03016624|Active Comparator|Angiography guided Magmaris implantation|Percutaneous coronary intervention with Magmaris
2482971|NCT03016247|Active Comparator|Enhanced Usual Care|Group will receive a single visit with a Nutritionist for dietary and physical activity counseling
2482974|NCT03016247|Experimental|TRUST intervention|Group will receive parent-adolescent trust-building and weight self-management training.
2483054|NCT03015974||corticosteroid|pediatric IgA nephropathy treated with only corticosteroid
2483056|NCT03015974||corticosteroid and cyclophosphamide|pediatric IgA nephropathy treated with corticosteroid and cyclophosphamide
2483059|NCT03015974||corticosteroid and mycophenolate mofetil|pediatric IgA nephropathy treated with corticosteroid and mycophenolate mofetil
2483137|NCT03015298||Gastric cancer|Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
2483176|NCT03014973|Experimental|prostate cancer patients resistant to castration|
2483186|NCT03014973|Experimental|patients naif of hormonal treatment|
2483239|NCT03014661||Single group study|Single Group study investigating retrospectively the Quality of life of patients with pollinosis under or after specific immunotherapy with Pollinex quattro
2483284|NCT03014401|Experimental|Stem Cells|Fat pad harvest with stem cell transplantation and standard arthroscopic debridement.
2483294|NCT03014401|Active Comparator|Placebo|Standard arthroscopic debridement with fat pad harvest WITHOUT stem cell transplantation
2483391|NCT03013686|Active Comparator|Interval Appendectomy|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~Interval appendectomy is performed at two months after the primary treatment, all patients also undergo colonoscopy prior to appendectomy."
2483393|NCT03013686|Active Comparator|Follow-up with MRI|"The periappendicular abscess, diagnosed by a CT-scan or MRI, is initially treated conservatively with antibiotic therapy and with drainage, if necessary.~The patients undergo abdominal magnetic resonance imaging at two months after the primary treatment, all patients also undergo colonoscopy right after the MRI."
2483479|NCT03013361|Active Comparator|Group B (n=20)|Group B (n=20): The patients in this group were infiltrated with 3 mL of 0.5% bupivacaine.
2483482|NCT03013361|Active Comparator|Group R (n=20):|Group R (n=20): The patients in this group were infiltrated with 3 mL of 0.5% ropivacaine.
2483484|NCT03013361|Placebo Comparator|Group S (n=20, Control):|Group S (n=20, Control): The patients in this group were infiltrated with 3 mL of normal saline.
2483552|NCT03012698|Experimental|RMS treatment|
2483567|NCT03012269|Experimental|Working Memory Training|The subjects of experimental group received a series of working memory training, 30 min for 5 days per week during 6 weeks.
3193459|NCT00818233||Observation|Variability will be assessed between each examiner.
2482782|NCT03017534|Experimental|Gender Match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
2482784|NCT03017534|Experimental|Gender Match, Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
2482785|NCT03017534|Experimental|Gender Match, No Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
2482786|NCT03017534|Experimental|Gender Match, No Labcoat, No Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
2482788|NCT03017534|Experimental|Gender Mis-match, Labcoat, Explanation|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat and receive a detailed anatomic explanation of the technique.
2482790|NCT03017534|Experimental|Gender Mis-match, Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, wearing a labcoat, and receive a colloquial discussion of the technique.
2482791|NCT03017534|Experimental|Gender Mis-match, No Labcoat, Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender mis-matched therapist, not wearing a labcoat, and receive a detailed anatomic explanation of the technique.
2482792|NCT03017534|Experimental|Gender Mis-match, No Labcoat, No Explan.|Subjects will receive Spinal Manual Therapy (sham thoracic spine manipulation) by a gender matched therapist, not wearing a labcoat, and receive a colloquial discussion of the technique.
2482895|NCT03017170|Experimental|Cranberry|500mg Dried Cranberry
2482902|NCT03017170|Placebo Comparator|Placebo Oral Capsule|Color Matching Placebo
2482967|NCT03016416||chronic stroke patients|Participants for the study group will be recruited from the Clalit Health Services- Ben Yair Rehabilitation Center in Jaffa Israel.
2482969|NCT03016416||control group|The control group will be with equivalent age and lifestyle as the studt group. Participants for the control group will be recruited via solicitation adds at the Ben Yair Rehabilitation Center and at near-by clinics.
3193460|NCT00818285|No Intervention|1|Physicians in this arm will be using the standard electronic prescription interface.
2483066|NCT03015701|Experimental|Arm 1|Mifepristone 200 mg orally daily for two years
2483068|NCT03015701|Placebo Comparator|Arm 2|Placebo orally daily for two years
2483087|NCT03015415|Experimental|surgical|Patients undergoing surgical elbow arthrolysis. Elbow Open Arthrolyses
2483091|NCT03015415|Experimental|non-surgical|Patients submitted to a non-surgical rehabilitation protocol using splints Non-surgical intervention
2483182|NCT03015207|Experimental|NNC0194-0499|Injected s.c. /subcutaneously (under the skin)
2483189|NCT03015207|Placebo Comparator|Placebo|Injected s.c. /subcutaneously (under the skin)
2483245|NCT03014687|Placebo Comparator|Standard Nasal Care|One dose of preoperative intravenous (iv) antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Postoperative antibiotics: Study participants will receive one dose only of postoperative intravenous antibiotic (e.g., cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Placebo PO BID (twice daily) will commence on the morning of postoperative day 1 and continue for 7 days.
2483246|NCT03014687|Experimental|Standard Nasal Care + Oral Antibiotics|One dose of preoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg) will be administered within 60 minutes of start of surgery. Repeat intraoperative dosing of antibiotics is permitted if length of surgery exceeds recommended dosing interval. IV antibiotic dosing schedules: Cefazolin 1 gm iv Q6 hr -or- Cefuroxime 1.5gm iv Q8 hr -or- Clindamycin 300 mg iv Q12 hr. Participants will receive 1 dose only of postoperative iv antibiotic (cefazolin 1gm, or cefuroxime 1.5gm, or clindamycin 300mg [cephalosporin allergic patients]) according to the recommended dosing schedule described above. This dose of antibiotics is in addition to the preoperative dose. Oral antibiotics will commence on the morning of postoperative day 1; this group will receive oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.
2483297|NCT03014245||Pregnant|Normal pregnant women (first baby) singleton
2483301|NCT03014245||Control|Non pregnant healthy women
3193461|NCT00818285|Experimental|2|In addition to the standard electronic prescription module, physicians in this arm will receive targeted drugs alert and decision support for psychotropic drug management
3193462|NCT00818298|Experimental|1|ziprasidone
2483434|NCT03013465|Other|Control Diet|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of broccoli (control).
2483444|NCT03013465|Active Comparator|Brassica Diet|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily.
2483481|NCT03013062||WITH PULMONARY HYPERTENSION|It is defined as MPAP > 25 mm Hg at rest or >30 mm Hg during exercise with PVR > 3 wood units and PCWP < 15 mm Hg.
2484026|NCT03009734|Other|ATx201 (2% dermal formulation C) and Placebo|
3193463|NCT00818311|Other|5|
3193464|NCT00818350|Experimental|SUNITINIB|
3193465|NCT00818402||Non-small cell lung cancer patients|
3193466|NCT00818415|Experimental|Arm 1|
3193467|NCT00818415|Active Comparator|Arm 2|
3193468|NCT00818428|Active Comparator|1|Speech Production Intervention + Articulation Parent Group
3193469|NCT00818428|Experimental|2|Speech Production Intervention + Dialogic Reading Parent Group
3193470|NCT00818428|Experimental|3|Speech Perception Intervention + Articulation Parent Group
3193471|NCT00818428|Experimental|4|Speech Perception Intervention + Dialogical Reading Parent Group
2482814|NCT03017144||Resuscitation team|Resuscitation pit crew model is educated to the resuscitation team.
2482859|NCT03017027|Experimental|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
2482860|NCT03017027|Other|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
2482978|NCT03016299||Osteoarthritis hip joint|specimen of head of femur will be used- after total hip arthroplasty (due to Degenerative Osteoarthritis hip joint )
2482982|NCT03016299||Non-Osteoarthritis hip joint|specimen of head of femur will be used- after Hip Hemiarthroplasty -Partial replacment (due to traumatic fracture)
3159144|NCT00400309|Active Comparator|REPEVAX® after Placebo|Placebo at Visit 1 (Day 0) and REPEVAX®) at Visit 2 (Day 28).
3159145|NCT00400322|Active Comparator|Valganciclovir|
2483084|NCT03015441|Other|Arm 1: Fermented milk product containing probiotics|
2483088|NCT03015441|Other|Arm 2: Milk-based non-fermented dairy product|
2483193|NCT03014895|Placebo Comparator|Cohort 1: Placebo|Intravenous placebo infusion
2483197|NCT03014895|Experimental|Cohort 1: E3112|Intravenous E3112 infusion
2483198|NCT03014895|Placebo Comparator|Cohort 2: Placebo|Intravenous placebo infusion
2483199|NCT03014895|Experimental|Cohort 2: E3112|Intravenous E3112 infusion
2483200|NCT03014895|Placebo Comparator|Cohort 3: Placebo|Intravenous placebo infusion
2483202|NCT03014895|Experimental|Cohort 3: E3112|Intravenous E3112 infusion
2483203|NCT03014895|Placebo Comparator|Cohort 4: Placebo|Intravenous placebo infusion
2483204|NCT03014895|Experimental|Cohort 4: E3112|Intravenous E3112 infusion
2483205|NCT03014895|Placebo Comparator|Cohort 5: Placebo|Intravenous placebo infusion
2483208|NCT03014895|Experimental|Cohort 5: E3112|Intravenous E3112 infusion
2483256|NCT03014518||Suicide Attempt Study Group|Adolescents admitted to the Cleveland Clinic inpatient child and adolescent psychiatry unit after suicide attempt. Clinical assessments and blood samples; follow-up for 12 mos.
2483264|NCT03014518||Healthy Control Group|Healthy adolescents with no history of suicide attempt. Clinical assessments and blood samples; no 12mo follow-up.
2483371|NCT03014050|Experimental|EH: Stimulation of Head Point|Electrical stimulation of the head point of the hand (EH, experimental stimulation); intervention with e-Tapper TT-R1
2483375|NCT03014050|Active Comparator|CS: Control Stimulation|Electrical stimulation of the leg point of the hand (CS, control stimulation); intervention with e-Tapper TT-R1
2483429|NCT03013478|No Intervention|Standard treatment as usual (TAU)|Treatment normally offered at this primary care clinic
2483432|NCT03013478|Active Comparator|TAU plus CBT4CBT program|Treatment normally offered at this clinic PLUS 8 weeks of CBT4CBT computerized therapy.
2483506|NCT03013101|Experimental|humanized anti-PD-1monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 3mg/kg Q2w until disease progresses or unacceptable tolerability occurs
2483575|NCT03012399|Experimental|Group I (hypnosedation)|Patients undergo hypnosedation performed by a mind-body specialist before surgery begins and continuing until after surgery is complete.
2483578|NCT03012399|Active Comparator|Group II (verbal support)|Patients speak to a mind-body specialist before surgery and prior to receiving general anesthesia.
2483641|NCT03011957||Group 1|HIV positive viral load < 200 copies/ml 50-65 years old CD4 > 350 cells/ml Male or Female
2483644|NCT03011957||Group 2|HIV negative 50-65 years old CD4 > 350 cells/ml Male or Female
2483703|NCT03011632|Experimental|mometasone nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months,
2483712|NCT03011632|Placebo Comparator|placebo mometasone|a group of children without immunoglobulin E (IgE) - dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
2483791|NCT03011177|Experimental|teneligliptin|teneligliptin 20mg qd
2483795|NCT03011177|Active Comparator|linagliptin|linagliptin 5mg qd
2483853|NCT03010787|Experimental|Part 1|Single ascending dose of oral V565
2483856|NCT03010787|Experimental|Part 2 - V565|Single dose level of oral V565 TID for 14 days
2483859|NCT03010787|Placebo Comparator|Part 1 and 2 - placebo|Oral placebo single dose (Part 1) or TID for 14 days (Part 2)
2483863|NCT03010787|Experimental|Part 3|Single dose of V565 in patient volunteers
2483865|NCT03010787|Experimental|Part 4|Single ascending dose of V565 in patients with Crohn's Disease
2483928|NCT03010267|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2483931|NCT03010267|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2484037|NCT03009838|Active Comparator|letrozole|letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day
2484081|NCT03009578|Active Comparator|Oral ferrous bis-glycinate|Women will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets
3159146|NCT00400322|Placebo Comparator|Placebo|
3159147|NCT00400361|Experimental|1|
3159148|NCT00400374|Experimental|Erlotinib, Celecoxib|
3159149|NCT00400387|Other|Multivitamin supplement|
3159150|NCT00400387|Experimental|Multivitamin supplement + dalteparin sodium|
3159151|NCT00400465|Active Comparator|Control group|Pressure dressing
2482761|NCT03017820|Experimental|Group B (VSV-IFNbeta-NIS, ruxolitinib)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days -1 to 9. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
2482763|NCT03017820|Experimental|Group C (VSV-IFNbeta-NIS, ruxolitinib, cyclophosphamide)|Patients receive VSV-IFNbeta-NIS IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days -1 to 9. Patients also receive cyclophosphamide IV over 2 hours on day 2. Patients undergo SPECT/CT scans at baseline, and at days 3 and 8 after VSV-IFNbeta-NIS infusion.
2482850|NCT03016884|Experimental|RA patients|RA patients will be administered Zostavax vaccine once 2 weeks before initiation of bDMARD, and be monitored accordingly
2482851|NCT03016884|Experimental|Healthy Controls|healthy control patients will be administered Zostavax vaccine and be monitored accordingly
2482882|NCT03016780|Active Comparator|Treatment in part 1|Fecal microbiota transplantation and traditional treatments will be used in patients with ulcerative colitis in part 1.
2482886|NCT03016780|Placebo Comparator|Placebo in part 2|The traditional treatments and normal saline will be used in patients with ulcerative colitis in part 2 according to associated guidelines.
2482961|NCT03016455||DSA positive patients without cAMR|Presence of DSA w/o cAMR
2482963|NCT03016455||DSA positive patients with cAMR|Presence of DSA w/ cAMR
2482965|NCT03016455||Stable patients|No DSA No cAMR
2483183|NCT03015129|Experimental|Durvalubmab|Patients will receive intravenous infusion of durvalumab 1500mg Fixed Dose every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
2483190|NCT03015129|Experimental|Durvalubmab + Tremelimumab|Patients will receive 1500mg Flat Dose durvalubmab via intravenous infusion every 4 weeks for up to 4 cycles and 75mg tremelimumab via intravenous infusion every 4 weeks for up to 4 cycles, and then continue 1500mg Fixed Dose durvalumab every 4 weeks until patient develops a loss of clinical benefit or experiences unacceptable toxicities.
3159152|NCT00400465|Experimental|Experimental group|Normal dressing
3159153|NCT00400478|Active Comparator|A|Treatment
3159154|NCT00400478|No Intervention|B|Observation
3159155|NCT00400491|Experimental|1|
3159156|NCT00400491|Placebo Comparator|2|
3159157|NCT00400595|Experimental|1|Polysporin tRIPLE ointment (topical ointment in widespread use for other skin lesions)
2483359|NCT03013803|Experimental|Nutricomp Drink Plus Fibre|Nutricomp® Drink Plus Fibre (flavours vanilla, coffee, peach-apricot and chocolate)
2483497|NCT03013140|Experimental|Goal-directed preloading|"Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until change in SV (ΔSV) <5%"
2483502|NCT03013140|Active Comparator|Preloading|"Fluid therapy: Within 30 mins before spinal anaesthesia, infuse 1000ml Ringer's injection with a pressurizer within 15 minutes."
2483523|NCT03012646|Experimental|Active Inhaled Treprostinil|Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
2483589|NCT03012451|Experimental|Advancing Adolescents|Received structured eight-week psychosocial sessions
2483591|NCT03012451|No Intervention|Control|Controls wait-listed for the intervention, matched for age and urban residence
2483650|NCT03011879||1.STEMI patients with symptom onset within 30 days|First round enrollment of STEMI patients with symptom onset within 30 days
2483662|NCT03011879||2.STEMI patients with symptom onset within 30 days|Second round enrollment of STEMI patients with symptom onset within 30 days
2483667|NCT03011879||3.STEMI patients with symptom onset within 30 days|Third round enrollment of STEMI patients with symptom onset within 30 days
2483702|NCT03011541|Active Comparator|Arm 1|BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
2483708|NCT03011541|Active Comparator|Arm 2|BMSC provided retrobulbar, subtenon, intravitreal and intravenous for one or both eyes
2483714|NCT03011541|Active Comparator|Arm 3|BMSC provided either intraoptic nerve or subretinal for eye with worse vision with fellow eye receiving either retrobulbar and subtenon or retrobulbar, subtenon and intravitreal; followed by intravenous.
2483816|NCT03010995|Active Comparator|18 mg nicotine|E-cigarette with 18 mg nicotine
2483818|NCT03010995|Active Comparator|9 mg nicotine|E-cigarette with 9 mg nicotine
2483820|NCT03010995|Placebo Comparator|0 mg nicotine|E-cigarette with 0 mg nicotine
2483876|NCT03010410||Influenza/respiratory virus pts <65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
2483878|NCT03010410||Influenza/respiratory virus pts ≥ 65 yrs|Patients with a primary microbiologic diagnosis of influenza (any strain) or other routinely clinically identified respiratory viruses
2483880|NCT03010410||Sepsis/septic shock patients < 65 yrs|Sepsis and septic shock patients
2483883|NCT03010410||Sepsis/septic shock patients ≥ 65 yrs|sepsis and septic shock patients
2483929|NCT03010228|Active Comparator|VLA15 12 µg with Alum|VLA15 12 µg (microgram) with Alum has an injection volume of 100 µl (microliter). The amount of Alum per injection is 0.05 mg (milligram).
2483930|NCT03010228|Active Comparator|VLA15 12 µg w/o Alum|VLA15 12 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 100 µl (microliter).
2483933|NCT03010228|Active Comparator|VLA15 48 µg with Alum|VLA15 48 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter). The amount of Alum per injection is 0.2 mg (milligram).
2483936|NCT03010228|Active Comparator|VLA15 48 µg w/o Alum|VLA15 48 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 400 µl (microliter).
2483937|NCT03010228|Active Comparator|VLA15 90 µg with Alum|VLA15 90 µg (microgram) with Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter). The amount of Alum per injection is 0.375 mg (milligram).
3159158|NCT00400595|Active Comparator|2|Mupirocin
3159159|NCT00400647|Experimental|EC MPS|Up to 1440mg taken in two doses
3159160|NCT00400647|Active Comparator|Mycophenolate mofetil|250 mg or 500 mg in two equal doses
3159161|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
3159162|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
2482778|NCT03017495|Experimental|Food effect and Drug-Drug interaction|Treatments will be given to all subjects in the same fixed sequence: Treatment A (Day 1, single dose of midazolam, fasted), Treatment B (Day 2, single dose of ACT-541468 followed by single dose of midazolam, fasted), Treatment C (Day 4, single dose ACT-541468, fed), Treatment D (multiple doses of ACT-541468 from Day 5 to Day 8 + single dose of midazolam on Day 8, fasted).
2482811|NCT03017248|Active Comparator|Morphine and Placebo|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an injection of Placebos (0.9% normal saline 0.05ml/kg)
2482820|NCT03017248|Experimental|Morphine and Ketamine 0.15|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.15mg/kg
2482822|NCT03017248|Experimental|Morphine and Ketamine 0.3|Morphine IV, Dose: 0.1 mg/Kg followed 10 minutes later by an IV bolus of Ketamine at the dose of 0.3mg/kg
2482856|NCT03016923|Experimental|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
2482897|NCT03016728|Experimental|Physical Activity|Participants in the experimental arm (i.e., physical activity) will be asked to complete the 12-week home-based physical activity program and to complete all study assessments.
2482909|NCT03016728|No Intervention|Wait-List Control|Participants in the no intervention arm (i.e., wait-list control) will be asked to maintain their usual lifestyle activities and to complete all study assessments. Participants in this arm will be provided with the 12-week home-based physical activity program in the exact same way as participants in the experimental arm (i.e., physical activity) at the end of the study.
2483009|NCT03016130|Active Comparator|Liberalized Hospital Diet (Diet A)|Diet A would include fresh fruits and/or fresh vegetables in a liberalized hospital diet, and subjects will be encouraged to eat at least one daily serving of fresh fruits and/or vegetables.
2483013|NCT03016130|Active Comparator|Neutropenic Diet (Diet B)|Diet B is the hospital neutropenic diet.
2483030|NCT03015805|Experimental|Contingency Management|This group will receive regular probation services but will also receive the Contingency Management program for substance abuse from their juvenile probation officer during regular meetings.
2483033|NCT03015805|Active Comparator|Probation as Usual|This group will receive regular services that are usually provided by juvenile probation officers.
2483097|NCT03015571|Experimental|NBI|Use of Narrow Band Imaging with regular care of cervical inlet patches detection.
2483102|NCT03015571|Placebo Comparator|WL|Use of High Definition White Light (WL) with regular care of cervical inlet patches detection.
2483110|NCT03015571|Experimental|NBI increased care|Use of Narrow Band Imaging with increased care of cervical inlet patches detection.
2483115|NCT03015571|Placebo Comparator|WL increased care|Use of High Definition White Light (WL) with increased care of cervical inlet patches detection.
2483188|NCT03015012|Active Comparator|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
2483191|NCT03015012|Experimental|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
2483240|NCT03014635|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2483242|NCT03014635|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
3193472|NCT00818467|Experimental|Tanning spray|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a group of normal subjects with skin types I and II while using multiple applications of 3% DHA for five weeks.
2483480|NCT03013543|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
2483564|NCT03012490|Active Comparator|Standard remote monitoring|Remote monitoring of CRT-P and CRT-D is activated. The physician will only receive the notifications related to technical events and ventricular arrhythmias. Therapy will be added or changed in response to these notifications and/or the symptoms and signs observed during ambulatory visits.
2483565|NCT03012490|Experimental|Comprehensive remote monitoring|Remote monitoring of CRT-P and CRT-D is activated, as well as remote assessment of symptoms and signs. In addition to notifications related to technical events and ventricular arrhythmias, the physician will receive notifications related to heart failure parameters, atrial arrhythmias, and patient's symptoms and signs. Therapy will be added or changed in response to these notifications, and/or to the symptoms and signs observed during ambulatory visits.
2483588|NCT03012152|Active Comparator|Standard conservative group|"Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .~."
2483590|NCT03012152|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
2483637|NCT03011918||Observational Single Event Faller|one documented fall as an in-patient. It is hypothesized that the nutrition factors present prior to the first fall may be related to fall frequency. Data on exposure to nutrition supplementation will be collected for future analysis. Subpopulation alalysis of individuals with dementia will also be conducted
2483639|NCT03011918||Observational Multiple event faller|multiple falls documented during in-patient stay It is hypothesized that frequent fallers will demonstrate statistically greater weight decline, Hgb decline, Vitamin D deficiency and Higher C-Reactive Protein values prior to the first fall. Data on exposure to nutrition supplementation will be collected for future analysis.. Subpopulation analysis of individuals with dementia will also be conducted.
2482807|NCT03017391|Active Comparator|algorithm 1 first metoclopramide|metoclopramide 10 mg tablets 3x daily orally and in those patients that cannot swallow tablets the medication will be substituted by suppositories 10 mg 3x daily rectally. In case of failure, granisetron patch 3.1mg/24 hours will be added to the treatment and a loading dose of 2 mg granisetron oral if the patient can swallow. In case of toxicity metoclopramide will be stopped. In case of failure of the combination (second step) or toxicity, an oral dose of dexamethasone 8 mg will be added daily.
2482812|NCT03017391|Active Comparator|algorithm 2 first granisetron|"granisetron patch 3.1 mg/24 hours will be offered to the patient, and a loading dose of 2 mg granisetron oral if the patient can swallow In case of failure, metoclopramide 10 mg tablets 3x daily orally will be added and in those patients that cannot swallow tablets the oral medication will be substituted with rectal suppositories 10 mg. The granisetron patch will only be withdrawn from patients that suffer from clinically relevant toxicity. Metoclopramide will then be administered.~In the case of secondary failure or toxicity, dexamethasone 8 mg orally daily will be added."
2482864|NCT03016949|Experimental|Group A|3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
2482865|NCT03016949|Experimental|Group B|3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
2482867|NCT03016949|Experimental|Group C|2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2482869|NCT03016949|Experimental|Group D|2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
2482871|NCT03016949|Experimental|Group E|3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
2482873|NCT03016949|Experimental|Group F|3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
2482906|NCT03016637|Experimental|EUS biopsy|EUS guided SharkCore (TM) biopsy of pancreatic lesions suspected of malignancy
2483026|NCT03016065|Experimental|Pea Fiber|Snacks fortified with 10 g of pea hull fiber will be administered for two weeks, followed by a two-week washout, and a two-week period with control snacks.
2483027|NCT03016065|Placebo Comparator|Control|Control snacks will provided for 2 weeks, followed by a two-week washout, and snacks with 10 g/d of pea fiber for 2 weeks.
2483067|NCT03015688||knee OA|OA diagnosis was on the basis of the diagnosis and treatment guideline of the American Academy of Orthopedic Surgeons Participants who met the following criteria were excluded：the knee OA concomitant with hip OA, suppurative and rheumatoid arthritis, gout patients, patients who underwent knee arthroscopy surgery within 6 months, bilateral or unilateral knee replacements, the knee joint trauma patients, histories of glucocorticoid and/or sterol hormones.
2483069|NCT03015688||Control|"no often have pain, aching or stiffness in your Left/right knee during last month,no Left/right knee trauma history,no histories of glucocorticoid and/or sterol hormones normal knee X-ray images,"
2483081|NCT03015480|Experimental|Remote counseling|This group of people will be asked to track dietary information on MyFitnessPal and receive remote dietary counseling with a dietitian.
2483138|NCT03015272|Experimental|Auditory-Motor Mapping Training (AMMT)|Auditory-Motor Mapping Training (AMMT) is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention.
2483141|NCT03015272|Active Comparator|Speech-Repetition Therapy (SRT)|Speech-Repetition-Therapy (SRT) is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT
2483170|NCT03014921|Placebo Comparator|placebo injection group|saline solution injection as placebo
2483179|NCT03014921|Active Comparator|iron injection group|iron injection
2483238|NCT03014726|Experimental|DCB Treatment|Stricture patients treated by DCB
3159163|NCT00400660|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GSK615915A with a starting dose of 250 micrograms.
3159164|NCT00400660|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms followed by placebo.
2483362|NCT03013855|Active Comparator|FIT-SOC|Fecal immunochemical test performed on spontaneously passed stool as noted in the standard instructions.
2483365|NCT03013855|Experimental|FIT-DRE|Fecal immunochemical test completed with stool collected during digital rectal exam.
2483441|NCT03013556|Active Comparator|Group A,TDF|The subjects in group A will be treated by TDF for 96 weeks
2483447|NCT03013556|Experimental|Group B,TDF+PEG|The subjects in group B will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
2483453|NCT03013556|Experimental|Group C,TDF+PEG|The subjects in group C will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks
2483520|NCT03012880|Experimental|Treatment (ixazomib, lenalidomide, daratumumab, dexamethasone)|"INDUCTION PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-21. Patients receive daratumumab IV over 3-7 hours on days 1, 8, 15, and 22 of courses 1 and 2, on days 1 and 15 of courses 3, 4, and 5, and on day 1 of courses 7 and beyond. Patients also receive dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive ixazomib citrate PO on days 1, 8, and 15 and daratumumab IV over 3-7 hours on day 1. Courses repeat every 28 days for up to 36 months from registration in the absence of disease progression or unacceptable toxicity."
2483678|NCT03011723|Experimental|Music therapy|10 weekly sessions of in-home music therapy for PWDs and a caregiver, including weekly practicing of the interventions with the caregiver between the sessions. The treatment is administered individually.
3159165|NCT00400660|Experimental|Subjects receiving GSK615915A: Part 3|Eligible subjects will receive GSK615915A with a starting dose of 250 micrograms.
3159166|NCT00400660|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo.
3173541|NCT00613197|Experimental|1 Epanova|
3173542|NCT00613197|Placebo Comparator|2 Placebo|
3173543|NCT00613210||1|women without contraction at 24-34 weeks of gestation
2482904|NCT03016806|Other|Full Intensity, TBI-based Conditioning|Full Intensity TBI-based Conditioning Total Body Irradiation 1200 cGy in fractions of 150 cGy days -8 or -7 to -4 Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: TBI/Cy
2482910|NCT03016806|Other|Full Intensity, Chemo-based Conditioning|Full Intensity, Chemotherapy Conditioning Busulfan days -7 to -4 Recipients <5 years - 1 mg/kg/dose x 16 doses every 6 hours Recipients >/= 5 years - 0.8 mg/kg/dose x 16 doses every 6 hours Cyclophosphamide 60 mg/kg/day x 2 doses days -3 and -2 Mesna 60 mg/kg/day with 20% loading dose with first Cyclophosphamide followed by continuous infusion over 24 hours x 2 doses [to be completed 24 hours after final Cyclophosphamide dose] followed by Cord Blood Infusion Other names: Bu/Cy
2482914|NCT03016806|Other|Reduced Intensity Chemotherapy|Reduced Intensity Chemotherapy Fludarabine 30 mg/m2/day x 5 doses days -6 to -2 Melphalan 140 mg/m2/day x 1 dose day -2 Cord Blood Infusion Other names: Flu/Mel
2482920|NCT03016806|Other|Non-Myeloablative Conditioning|Fludarabine 40 mg/m2/day x 5 doses days -6 to -2 Cyclophosphamide 50 mg/kg/day x 1 dose day -6 Mesna 50 mg/kg/day with 20% loading dose with Cyclophosphamide dose followed by continuous infusion over 24 hours x 1 dose [to be completed 24 hours after Cyclophosphamide dose] Total Body Irradiation 200 cGy in a single fraction day -1 Cord Blood Infusion Other names: Flu/Cy/TBI
2483001|NCT03016143|Active Comparator|Group #1 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers aged 18 to 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
2483003|NCT03016143|Active Comparator|Group #2 (Allantoic Split Inactivated Seasonal flu Vaccine)|100 volunteers over the age of 60 years, which introduced the vaccine allantoic split inactivated seasonal influenza
2483006|NCT03016143|Experimental|Group #3 (Vaccine VAXIGRIP)|50 volunteers aged 18 to 60 years, which introduced vaccine VAXIGRIP
2483008|NCT03016143|Experimental|Group #4 (Vaccine VAXIGRIP)|50 volunteers over the age of 60 years, which introduced vaccine VAXIGRIP
2483032|NCT03015818|Experimental|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|
2483116|NCT03015636|Experimental|Behavioral: Adjusted CBT-i for ADHD|Cognitive Behavioral group intervention for sleep problems in ADHD, based on Cognitive Behavioral Therapy for insomnia and behavioral treatment for Sleep Phase Disorders.
2483127|NCT03015636|Other|Treatment as Usual|Treatment as Usual. (After about ten weeks, participants in this condition are offered the experimental group treatment.)
2483175|NCT03015051|Experimental|High flow|High flow (2 L/kg/min) nasal cannula oxygen therapy
2483185|NCT03015051|Active Comparator|Low flow|Low flow (max 3 L/min) oxygen therapy
2483233|NCT03014544||Group 1: Sequence AABB|Participants of main study with Major Depressive Disorder (MDD) will be assigned in test sequence group AABB (Group 1) to undergo sequential cognitive performance evaluations by Test A (Computer- administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test B (Examiner-administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4 (Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
2483235|NCT03014544||Group 2: Sequence BBAA|Participants of main study with MDD will be assigned in test sequence group BBAA (Group 2) to undergo sequential cognitive performance evaluations by Test B (Examiner-administered test battery) on Test Day 1 (Study Day 1) and Test Day 2 (Study Day 15 to 22) followed by Test A (Computer- administered test battery) on Test Day 3 (Study Day 29 to 43) and Test Day 4(Study Day 43 to 64). Each separated by a memory washout period of 14 to 21 days.
2483322|NCT03014167|Experimental|Community-wide deworming|Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.
2483324|NCT03014167|Active Comparator|Targeted deworming|Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.
2483370|NCT03013751|Experimental|Drug|Udenafil administered for 52 weeks
2483439|NCT03013309|Experimental|Intervention|Receives the Family Check-Up 4 Health
2483446|NCT03013309|Experimental|Control|Receives Treatment as Usual
2483486|NCT03013010|Experimental|Preoperative radiochemotherapy|"1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~5 weeks preoperative chemoradiotherapy.~1 cycle preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
2483490|NCT03013010|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin.~Gastric resection. 3 cycles adjuvant chemotherapy with S-1(Tegafur-Gimeracil-Oteracil Potassium)+ oxaliplatin."
3193473|NCT00818467|Active Comparator|UVB|To characterize the 25(OH)D response to 4 weeks of thrice weekly 40 mJ of UV-B light in a control group of normal subjects with skin types I and II who are not using 3% DHA applications.
3193474|NCT00818480|Experimental|1. YM155|
3193475|NCT00818493|Experimental|1|Q8003, flexible ascending dose
3193476|NCT00818493|Experimental|2|Low dose Q8003
3193477|NCT00818493|Active Comparator|3|Percocet (oxycodone and acetaminophen)
2484109|NCT03009032|Placebo Comparator|PLACEBO|Lactose
3193478|NCT00818506||Late onset MDD|Patients with major depressive disorder between 50 and 70 years of age that did not suffer from depression before the age of 50.
3193479|NCT00818506||Controls|Healthy controls (matched for age, sex, and tobacco use status)
3193480|NCT00818532||1|Measurement device
3193481|NCT00818545|Placebo Comparator|2|
3193482|NCT00818545|Experimental|hydroxypropyltetrahydropyrantriol|
3193483|NCT00818558|Experimental|1|stade IA [pT1 N0M0]
3193484|NCT00818558|Experimental|2|stade IB [pT2 N0M0]
3193485|NCT00818558|Experimental|3|stade IIA [pTI N1M0]
3193486|NCT00818558|Experimental|4|stade IIB [pT2 N1 et T3N0M0]
3193487|NCT00818558|Experimental|5|control groupe [tabagic subject]
3193488|NCT00818558|Experimental|6|Control group B [intervention for a pulmonaire non tumoral pulmonary lesion]
3193489|NCT00818571|Experimental|Vildagliptin 25 mg qd in Renal Impaired (RI) patients|
2482932|NCT03016975|Experimental|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System plus guideline directed medical therapy (GDMT)
2482933|NCT03016975|No Intervention|Control|Guideline directed medical therapy (GDMT)
2482996|NCT03016169|Other|Treatment|All subjects will receive the Trifecta GT valve
2483051|NCT03015727|Experimental|IC+RT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2. And then radiation using IMRT/TOMO without concurrent chemotherapy.
2483052|NCT03015727|Active Comparator|IC+CCRT group|3 cycles of TP neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2 and cisplatin 75mg/m2.And then chemoradiation using IMRT/TOMO with 2 cycles of cisplatin concurrent chemotherapy at 100mg/m2.
2483194|NCT03014908||NMR-T1DM|type 1 diabetic children and adolescents
2483196|NCT03014908||NMR-C|non-diabetic children and adolescents
2483232|NCT03014596|Experimental|Intervention|The Assert-method will be used in the counselling of adolescents with mental health problems
2483234|NCT03014596|No Intervention|Control|Treatment as usual, i.e. tha Assert-method will not be used in the counselling
2483307|NCT03014336|No Intervention|Control|Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
2483309|NCT03014336|Experimental|memsorb|Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
2483468|NCT03013452|Active Comparator|Autogenic drainage|Chest physiotherapy by autogenic drainage daily for 15 minutes each day, for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
2483469|NCT03013452|Active Comparator|oPEP|Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
2483514|NCT03012789|Other|Post Surgery|
3159167|NCT00400673|Other|Chemotherapy|Risk-oriented chemotherapy for remission induction (application of sequential high-dose cytarabine course to patients unresponsive to standard chemotherapy course 1) and postremission consiolidation(standard risk: blood stem cell supported high-dose cytarabine course [x3]; high risk: allogeneic SCT)
2483635|NCT03011983||Adolescents With Concussion|Adolescents with a concussion (n=120) will undergo neuroimaging (MEG and MRI) and neuropsychology assessments at two time points in the acute and chronic periods after injury, respectively. Brain imaging injury measures will be compared to a control normative database we will create. These brain measures will also be associated with cognitive and clinical outcomes.
2483636|NCT03011983||Adolescents Without Concussion|Age- and gender-matched healthy controls (n=160) will be recruited to establish a normative database of whole-brain slow-wave maps from MEG resting-state data as well as white-matter diffusion measures from MRI.
2483727|NCT03011528|Other|VDC - IE x2 & Surgery|"Patients in Arm A receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine Doxorubicine Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
2483729|NCT03011528|Other|VDC - IE & TEMIRI & Surgery|"Patients in Arm B receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by surgery of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision. Radiotherapy can be added~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
2483732|NCT03011528|Other|VDC - IE x2 & Radiotherapy|"Patients in Arm C receive~VDC-IE x2: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if good response after the 4th treatment, followed by:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
2483736|NCT03011528|Other|VDC - IE & TEMIRI & Radiotherapy|"Patients in Arm D receive~VDC-IE & TEMIRI: Intensified induction phase:~4 cycles of VDC (Vincristine-Doxorubicine-Cyclophosphamide) association alternative with 4 cycles of IE (Ifosfamide-Etoposide) association if poor response after the 4th treatment, followed by:~4 cycles of TEMIRI (Temozolomide-Irinotecan) association~Local treatment by radiotherapy of primary tumour/metastatic sites (outside pulmonary sites): indicated before of after consolidation phase (BuMel) among multidisciplinary decision.~Consolidation BuMel High dose chemotherapy (Busulfan-Melphalan) followed by Peripheral Blood Stem Cell Infusion~Maintenance phase~1st year : VC (Vincristine Cyclophosphamide) association~2nd year : Cyclophosphamide po 25 mg/m²"
2483844|NCT03010748||Chinese population|Chinese population of different nation from several provinces.
2483925|NCT03010280|Experimental|Immunonutrition|Patients receiving a preoperative balanced energy high-protein formula, enriched with Omega - 3 fatty acids (Immunonutrition formula)
2483926|NCT03010280|Active Comparator|Balanced high-protein formula|Patients receiving a preoperative balanced energy high-protein formula, without including Omega - 3 fatty acids
2483966|NCT03009903||P. acne subjects|14-50 year of age, P. acne diagnosed subjects
2483968|NCT03009903||None P. acne subjects|14-50 year of age, none P. acne diagnosed subjects
3159168|NCT00400699|Other|REview|
3159169|NCT00400725|Experimental|1|
3159170|NCT00400725|Placebo Comparator|2|
3193490|NCT00818571|Experimental|Vildagliptin 50 mg qd in RI Patients|
3193491|NCT00818571|Experimental|Vildagliptin 25 mg qd in matched Healthy Volunteer (HV)|
2483055|NCT03015896|Experimental|Treatment (lenalidomide, nivolumab)|Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 60 minutes on days 1 and 15 of courses 1-4 and on day 1 of courses 5-12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2483105|NCT03015324|Experimental|Hydroxychloroquine|Hydroxychloroquine
2483192|NCT03015155|Experimental|Hypothermia|Infusion of Cold Saline into Local Infarction Myocardium. A standard working guide-wire, Runthrough NS (Terumo, Japan), is advanced into the distal part of the target coronary artery by using angiography. Compared to the standard PPCI after the balloon expansion, the aspirated catheter (Diver C.E. MAX, Italy) is firstly placed at the location of the distal occlusion lesion to achieve local myocardial hypothermia by infusing the cold saline (4℃, 2.5ml/min, 5min). Then we retract the aspirated catheter, following the balloon expansion and the drug eluting stent implanting. Subsequently, the infusion catheter is tautologically placed at the location of the opened occlusion, within the stent, to persistently perfuse the infarct myocardium with cold saline (4℃, 2.5ml/min, 15min).
2483195|NCT03015155|No Intervention|Standard treatment|We place a standard working guide-wire, Runthrough NS (Terumo Corporation, Japan), crossover the criminal lesion of to the distal of the target coronary artery after angiography. Then the pre-dilated balloon is placed at the occluded lesion site to expand the criminal vessel without hypothermia intervention. The operation will be completed when the flow of target coronary artery achieves TIMI class 3 after the drug eluting stent implanting.
3193492|NCT00818571|Experimental|Vildagliptin 50 mg qd in matched HV|
3193493|NCT00818584|Experimental|1. micafungin lower dose|
3193494|NCT00818584|Experimental|2. micafungin higher dose|
2483379|NCT03013699|Active Comparator|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
2483380|NCT03013699|Experimental|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
2483421|NCT03013491|Experimental|CX-072|Monotherapy CX-072
2483423|NCT03013491|Experimental|CX-072 with Ipilimumab #1|Combination CX-072 + ipilimumab (Schedule 1)
2483424|NCT03013491|Experimental|CX-072 with Ipilimumab #2|Combination CX-072 + ipilimumab (Schedule 2)
2483427|NCT03013491|Experimental|CX-072 with Vemurafenib|Combination CX-072 + vemurafenib
2483431|NCT03013491|Experimental|CX-072 expansion|Monotherapy CX-072
2483545|NCT03012724|Active Comparator|H1-Coil|Device: Brainsway H1-Coil Deep TMS System. An FDA cleared deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the lateral prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
2483547|NCT03012724|Experimental|H7-Coil|Device: Brainsway H7-Coil Deep TMS System. A deep transcranial magnetic stimulation device. The coil is designed to allow deeper brain stimulation in the medial prefrontal cortex, including the anterior cingulated cortex without a significant increase of electric fields induced in superficial cortical regions.
2483572|NCT03012178||Mitral Valve Surgery|Patients undergoing ACC/AHA guideline directed mitral valve surgery for mitral insufficiency.
3193495|NCT00818597|Experimental|EISS-treatment|In this arm patients receive additional treatment with the EISS-bioreactor
3193496|NCT00818610|Experimental|Monotherapy|
3193497|NCT00818610|Active Comparator|Bi-therapy|
3193498|NCT00818636|Experimental|Expressive Writing|In addition to attending group therapy as usual, participants write about their feelings about an issue of their choosing three times during a two week period for at least 20 minutes each time.
3193499|NCT00818636|Active Comparator|Treatment as Usual|Participants attend group therapy as usual only.
2483991|NCT03009851|Experimental|OBCHI|This small group process intervention focuses upon the cultural heritage of the residents in LTC settings measuring quality of life, activity engagement and social participation.
2483995|NCT03009851|No Intervention|Control|The control group only received the typical activities conducted in LTC facilities.
2484080|NCT03009578|Experimental|Intravenous iron|Women will receive iron sucrose (sacrofer ampules 100 mg/5ml) A patient's total body iron deficit will be calculated using the Ganzoni formula (total iron dose = [body weight (kilogram)× (15-actual Hemoglobin)] × 2.4 + 500 mg) then the total dose will be divided on 3 settings
3193500|NCT00818675|Experimental|Ridaforolimus|
3193501|NCT00818675|Placebo Comparator|Placebo|
3193502|NCT00818688||1|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
3193503|NCT00818688||2|Patients eligible for enrolment were all consecutive patients aged 18 years or over, with a symptomatic ST of the lower limbs at least 5 cm long on compression ultrasonography. Patients who had undergone surgery under general or loco-regional anaesthesia in the previous 10 days, those in whom ST had occurred after sclerotherapy within the previous 30 days and those whose follow-up was not considered to be feasible were ineligible.
3193504|NCT00818701|Placebo Comparator|1: low dose BNP alone|low dose BNP with placebo
3193505|NCT00818701|Active Comparator|2: low dose BNP + PDEVI|low dose BNpo + PDEVI
3193506|NCT00818714|Experimental|1|Dose escalation study to define the maximum tolerated boost dose of stereotactic body radiation therapy (SBRT) to the residual primary tumor after definitive therapy with concurrent chemotherapy and external beam radiation.
3193507|NCT00818740|Experimental|ORM-12741 i.v.|
3193508|NCT00818740|Experimental|ORM-12741 oral solution|
3193509|NCT00818740|Experimental|ORM-12741 oral capsule with food|
3193510|NCT00818740|Experimental|ORM-12741 oral capsule without food|
3193511|NCT00818792|Active Comparator|Drug-eluting stent Xience V|
2482968|NCT03016351|Experimental|Resistance Training|Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
2483018|NCT03016000|Experimental|Thalidomide|Thalidomide 50mg daily by mouth( increase 50mg after 2 weeks if tolerated until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if the patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/day, thalidomide discontinuation was allowed.
2483019|NCT03016000|Other|Observation|Observation
2483058|NCT03015714|Active Comparator|MIRT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment (MIRT).
2483062|NCT03015714|Active Comparator|MIRT-AT|Patients in this group will undergo a 4-week Multidisciplinary Intensive Rehabilitation Treatment associated with Aquatic Therapy (MIRT-AT).
2483079|NCT03015454|Experimental|With InSight|Healthcare provider receives an alert from InSight for patients trending towards severe sepsis. Healthcare provider also receives information from the severe sepsis detector in the UCSF electronic health record.
2483080|NCT03015454|Active Comparator|Without InSight|Healthcare provider does not receive any alerts from InSight. Healthcare provider receives information from the severe sepsis detector in the UCSF electronic health record.
2483135|NCT03015285|Experimental|Anxiety Sensitivity Cognitive Therapy|Participants in the Cognitive Behavioural Therapy for AS condition will complete 8 weekly 50-minute therapy sessions and will be asked to continue with some parts of the intervention (i.e., interoceptive exposure) independently for the next 4 weeks, with short weekly check-ins by phone with their therapist.
2483139|NCT03015285|Active Comparator|Disorder specific Cognitive Therapy|Participants in the disorder-specific Cognitive Behavioural Therapy intervention will receive 12 weekly 50-minute therapy sessions following established, evidence-based protocols for each of the disorders included in the study.
2483168|NCT03014999|Experimental|High frequency rTMS|Volunteers will be submitted to high frequency of repetitive transcranial magnetic stimulation (10Hz)
2483173|NCT03014999|Experimental|Low frequency rTMS|Volunteers will be submitted to low frequency of repetitive transcranial magnetic stimulation (1Hz)
2483184|NCT03014999|Sham Comparator|Sham rTMS|Volunteers will be submitted to sham session of repetitive transcranial magnetic stimulation
2483248|NCT03014622|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2483258|NCT03014622|Placebo Comparator|Placebo|Biological/Vaccine: Placebos Intramuscular injection
2483292|NCT03014154|Active Comparator|Video training Game|"Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each), followed by 5 minutes of cool-down again on the mat. The game used for training was the reflex Ridge Kinect Adventure (Xbox-360). At a higher level, it is necessary for the child to perform a greater number of jumps, squats, lateral movements and arm movements. All the activity was monitored against FC and SpO2. To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions."
2483299|NCT03014154|Active Comparator|Endurance muscle training|Patients were submitted prior to the treadmill warming the 2kmh during 1° minutes before each session. Then held 30 minutes of aerobic interval training with video game (10 rounds of 3 minutes with 30 seconds of rest between each) followed by 5 minutes of cool-down again on the mat.Then the children were subjected to low intensity to endurance muscle training with 3 sets of 15 repetitions to upper limbs diagonally primitive and flexion and extension to lower lumbs. All the activity was monitored against FC and SpO2.To determine the intensity of physical activity energy expenditure assessments were made. In which four are for the pre and post intervention evaluation and sixteen training sessions.
2483335|NCT03013972||Colorectal cancer patients|Colorectal cancer patients during adjuvant chemotherapy
2483386|NCT03013673||HIV|HIV infected individuals residing in VL-endemic areas in Northern Ethiopia
2483448|NCT03013400|Active Comparator|Ebselen|Three Ebselen capsules each containing 200mg taken orally twice a day for 3 weeks
2483452|NCT03013400|Placebo Comparator|Placebo|Three Placebo capsules each containing 200mg taken orally twice a day for 3 weeks
2483491|NCT03012945|Experimental|Combined epidural-general anesthesia|Patients assigned to this group (experimental group) receive combined epidural-general anesthesia and postoperative patient-controlled epidural analgesia.
2483494|NCT03012945|Active Comparator|General anesthesia|Patients assigned to this group (control group) receive general anesthesia and postoperative patient-controlled intravenous analgesia.
2483524|NCT03012607|Experimental|Perfect Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] once daily for 6 weeks
2483529|NCT03012607|Experimental|Moderate Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 4 times per week (Monday, Wednesday, Friday, and Saturday) for 6 weeks
2483533|NCT03012607|Experimental|Poor Adherence|Participants will receive a single tablet of TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA] 2 times per week (Monday, Thursday) for 6 weeks
3193512|NCT00818792|Active Comparator|Bare-metal stent Vision|
3193513|NCT00818818|Experimental|Meglumine antimoniate|Treated with 5mg/kg/d of pentavalent antimony (meglumine antimoniate) intravenously for 20 consecutive days.
3193514|NCT00818844|Experimental|Nepafenac|Nepafenac 0.1% dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
3193515|NCT00818844|Placebo Comparator|BSS|BSS dosed topically TID for 3 months after Epiretinal Membrane (ERM) Surgery
3193516|NCT00818857|Active Comparator|1|Early intervention.
3193517|NCT00818857|Active Comparator|2|Delayed intervention
3193518|NCT00818870|Active Comparator|Omeprazole 20 mg|
2483010|NCT03016221|Experimental|Dolor-X Cool Gel|Intervention: Dolor-X Cool Gel is a topical product with a cooling effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
2483012|NCT03016221|No Intervention|Dolor-X Cool Gel control|No product application. The contralateral lumbar back side acts as a Dolor-X Cool Gel control.
2483073|NCT03015740|Experimental|Treatment (sitravatinib, nivolumab)|Patients receive sitravatinib PO QD on days 1-14 and receive nivolumab IV over 60 minutes on day 1 starting cycle 2. Cycles repeat every 14 days for cycles 1-6 and then every 28 days for subsequent cycles in the absence of disease progression or unacceptable toxicity. Patients who receive at least 6 infusions of nivolumab with no DLTs related to nivolumab, may then receive nivolumab every 4 weeks.
2483122|NCT03015311|Experimental|Intensive BP control|SBP within 110 - <130 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 110 - <130 mm Hg.
2483125|NCT03015311|Active Comparator|Standard BP control|SBP within 130 - <150 mm Hg. Participants randomized into the Intensive BP control arm will have a goal of SBP 130 - <150 mm Hg.
2483206|NCT03014869|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37 degree centigrade.
2483210|NCT03014869|No Intervention|Noninvasive positive ventilation|Parameters are set according to NPPV protocols
2483249|NCT03014570|Active Comparator|Education-Only Control|This arm includes the education provided to all sites (this is Step 2 of the EIT-4-BPSD intervention). The sites are given the opportunity to decide how they want the education around management of behavioral symptoms to occur-face-to-face by a research staff member, via a powerpoint they can use on their own or via a webinar.
2483255|NCT03014570|Experimental|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
2483286|NCT03014310|Experimental|Arm 1: 3.75 mcg A/H5N8 + AS03|3.75 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
2483289|NCT03014310|Experimental|Arm 2: 15 mcg A/H5N8 + AS03|15 mcg A/H5N8 + AS03 given IM on Day 1 and 22, n=30
2483295|NCT03014310|Active Comparator|Arm 3: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day 1 and 22, n=15
2483300|NCT03014310|Experimental|Arm 4: 3.75 mcg A/H5N8 + MF59|3.75 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
2483304|NCT03014310|Experimental|Arm 5: 15 mcg A/H5N8 + MF59|15 mcg A/H5N8 + MF59 given IM on Day 1 and 22, n=30
2483306|NCT03014310|Active Comparator|Arm 6: 15 mcg A/H5N8 unadjuvanted|15 mcg A/H5N8 unadjuvanted given IM on Day and 22, n=15
2483394|NCT03013712|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen by infusion.
2483438|NCT03013348||Adults (22-99),|Male or female subject between the ages of 22-99, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2483445|NCT03013348||Adolescents (13-21)|Male or female subject between the ages of 13-21, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2483451|NCT03013348||Children (2-12)|Male or female subject between the ages of 2-12, previously admitted to the Medical University of South Carolina for inpatient vEEG monitoring in the MUSC Epilepsy Monitoring Unit with at least one PNES was recorded during that admission. Validation of Brain Sentinel's sEMG Post-processing algorithm will involve prospective evaluation of at least 30 PNES events in this group.
2483499|NCT03013049|Active Comparator|Non cultured epidermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, non cultured epidermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and non cultured epidermal cell suspension will be done.
2483505|NCT03013049|Experimental|Non cultured dermal cell suspension|In 20 patients who have stable vitiligo with the duration of stability more than 3 months, combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done. Patients will be divided into 2 subgroups of 10 patients each of stability duration of 3-6 months and more than 1 year respectively and combination of non cultured epidermal cell suspension and non cultured dermal cell suspension will be done.
2483556|NCT03012620|Experimental|Pembrolizumab|Pembrolizumab 200 mg IV as a 30 minute infusion on Day 1 of every 21 day cycle
2483571|NCT03012217||Specimens that meet inclusion criteria|
2483649|NCT03012035|Experimental|experimental group|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
2483654|NCT03012035|Other|comparator group|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
2483717|NCT03011593|Experimental|Nutrition Support Product|Participants were asked to take a nutrition support product twice per day for a period of 6 weeks.
2483857|NCT03010761|Experimental|medication pills 1: escitalopram 10mg|10mg once daily, 8 weeks
2511832|NCT02818309|Placebo Comparator|Placebo|Placebo
3193519|NCT00818870|Experimental|Vecam 20/300|
3193520|NCT00818870|Experimental|Vecam 40/300|
2483113|NCT03015662|Experimental|Dry Needling Therapy|Active or latent MTrPs (myofascial trigger points) will be remarked in black or red, respectively. Active or latent MTrPs will be needled in the same position employed by the blinded examiner for diagnosis. All dry needling procedures will be performed by the same investigator, and the technique used will be similar to the Hong method, using sterile Ener-Qi needles (EQ 1661) for the punction of TrPs (trigger points).
2483120|NCT03015662|Active Comparator|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
2483262|NCT03014817|Experimental|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel. Direction of dissection undecided but by experience most naturally fundus first.
2483266|NCT03014817|Active Comparator|Electrocautery|Dissection with electrocautery. Direction of dissection undecided but by experience most naturally cystic duct first.
2483326|NCT03014271|Experimental|Sources of Strength Suicide (SOS)|Receive Sources of Strength Suicide (SOS) Prevention Program
2483328|NCT03014271|Active Comparator|SOS Waitlist Control|Delayed implementation of Sources of Strength Suicide Prevention Program after 16 months.
2483374|NCT03013777|Experimental|Cognitive behavioral therapy (CBT)|The patient would participate in eight forty-five minute sessions of CBT with a mental health therapist. Cognitive behavioral therapy (CBT), defined as a program of interventions that utilize education to teach relaxation, healthy coping skills, stress management, assertiveness training in order to help the individual identify and correct maladaptive beliefs in combination with education to help practice symptom reduction and improve quality of life and function.
2483475|NCT03012997|Active Comparator|Active Comparator: 40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the induction, surgery and in Postoperative care unit.
2483477|NCT03012997|Active Comparator|Active Comparator: 100% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen during 100% induction and with 60-70% ( determined according to the arterial blood gas sample results) during surgery and in Postoperative care unit.
2483525|NCT03012763|Placebo Comparator|non-caloric water|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml non-caloric water 3 h thereafter
2483527|NCT03012763|Active Comparator|caloric drink|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml caloric drink 3 h thereafter
2483530|NCT03012763|Active Comparator|grapefruit juice|50 mg sulfasalazine given in 240 ml table water after 6 h fasting and 250 mg paracetamol, 120 mg fexofenadine and 40 mg valsartan given in 240 ml grapefruit juice 3 h thereafter
2483579|NCT03012204|Experimental|combined rTMS at both M1|combined rTMS at both M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / real 6 Hz rTMS on affected M1
2483582|NCT03012204|Experimental|real primed LFrTMS at unaffected M1|real primed LFrTMS at unaffected M1: real 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
2483585|NCT03012204|Active Comparator|real LFrTMS at unaffected M1|real LFrTMS at unaffected M1: sham 6 hertz(Hz) rTMS on unaffected M1 / real 1 Hz rTMS on unaffected M1 / sham 6 Hz rTMS on affected M1
2483586|NCT03012204|Sham Comparator|all sham stimulation|all sham stimulation： sham 6 hertz(Hz) rTMS on unaffected M1 / sham 1 Hz rTMS on unaffected M1 /sham 6 Hz rTMS on affected M1
2483632|NCT03011905|Experimental|Dexamethasone|Single dose of dexamethasone (Dexagalen) 16 mg iv during operation.
2483633|NCT03011905|Placebo Comparator|Control|Single dose of NaCl, 4 ml, iv during operation.
3193521|NCT00818909|Experimental|Systane|Systane ocular product
3193522|NCT00818935|Experimental|Low-Intermediate-Glycemic Index diets|
2483942|NCT03010189|Experimental|Patient|Cluster headache patients are examined with light reflex pupillometry, two weeks actigraphy and heart-rate variability monitoring both in headache phase and remission phase.
2483943|NCT03010189|Active Comparator|Controls|Healthy controls undergo the same examinations once: light reflex pupillometry, actigraphy and heart-rate variability monitoring.
2484024|NCT03009747||sphincter-preserving surgery|Patients meet the inclusion criteria will be enrolled into this observing group
2484079|NCT03009370||Recurrent miscarriage|RM is defined as three or more pregnancy losses at< 20 weeks of gestation.
3193523|NCT00818935|Active Comparator|High GI diet|
3193524|NCT00818948|Placebo Comparator|Placebo|2 subjects of each cohort (cohort 1 to 6) will receive placebo
2484262|NCT03008109|Experimental|EGFR-TK inhibitor plus RH-endostatin|EGFR-TKI icotinib:125mg Tid RH-endostatin:15mg/m2 ,d1-7
2484303|NCT03007784|Experimental|2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
2484381|NCT03007160|Experimental|Experimental group|Potassium Citrate Extended-release Tablets
3193525|NCT00818948|Other|AMG811|Six subjects in each cohort (cohort 1 to 6) will receive AMG 811
3193526|NCT00818987|Other|Operative|Treatment arm - intervention = Open Reduction Internal Fixation or Reduction & Immobilization
3193527|NCT00818987|No Intervention|Non Operative|Placebo arm
3193528|NCT00819000||Treated MS Subjects|Subjects who are treated with Glatiramer Acetate or Interferon (IFN)-β and receive their therapy from one of the participating Specialty Pharmacies
3193529|NCT00819065|Active Comparator|1-BTA Lanzhou/Allergan|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Lanzhou at allocation and after twelve weeks will receive the same drug from laboratory Allergan.
3193530|NCT00819065|Active Comparator|2. BTA Allergan/Lanzhou|Patients randomly allocated to this arm will receive botulinum toxin type A from laboratory Allergan at allocation and after twelve weeks will receive the same drug from laboratory Lanzhou.
3193531|NCT00819078|Active Comparator|Bupropion Sr|40 adolescent patients
3193532|NCT00819078|Placebo Comparator|Placebo (sugar pill)|40 adolescent patients will receive placebo
3193533|NCT00819104|Experimental|1|FDC of Metoprolol XL 50mg + Amlodipine 5mg
2483034|NCT03015792|Experimental|Treatment (ibrutinib, lenalidomide, dexamethasone)|"PHASE I: Patients receive ibrutinib PO on days 1-28, lenalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Beginning course 25, patients receive lenalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 84 days in the absence of disease progression or unacceptable toxicity.~PHASE II: Patients receive ibrutinib and dexamethasone as in phase I and lenalidomide PO on days 1-21 beginning course 2. Beginning course 25, patients receive lenalidomide and dexamethasone as in phase I."
2483143|NCT03015259|Experimental|Treatment 1|Generic Budesonide/Formoterol Fumarate Dihydrate (80mcg/4.5mcg) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2483146|NCT03015259|Active Comparator|Treatment 2|Symbicort (Budesonide/Formoterol Fumarate Dihydrate) Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2483148|NCT03015259|Placebo Comparator|Treatment 3|Placebo Inhalation Aerosol, two inhalation twice daily, consisting of a 2-week run-in period followed by a 6-week treatment period
2483274|NCT03014466|Active Comparator|Tablet|Preoperative patients will utilize a video tablet for addressing pre anesthesia anxiety
2483275|NCT03014466|Experimental|Video Projector|Preoperative patients will utilize a video projection unit for addressing pre anesthesia anxiety
2483395|NCT03014024|Experimental|Low-Level Laser therapy|After inclusion in the study, patients will be treated with LLLT. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated from dorsal side of the wrist on the fracture area, and distal ulna area from the palmar side. Total 20 second on each side (3 points), with 3,6 J/cm2. the light from the laser is not visible to the eye, and will not give any perceptible stimulus. The x-ray will be used to find the fracture line.
2483397|NCT03014024|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, patients will be treated with placebo LLLT. This placebo laser is identical in appearance to the other super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Patient will be treated on the same areas, and have the same procedure and time. Since the light from the laser is invisible neither the participant nor the therapist will know whether the laser is a placebo.
2483473|NCT03013322|Active Comparator|Treatment Group|The treatment group receives an infusion of 0.04 mg/kg physostigmine salicylate with a maximum dose of 4 mg. The infusion is administered at 0.4 mg/min (= 1 mL/min = 60 mL/h). The initial dose is followed by a continuous infusion of 0.017 mg/min, i.e. 1 mg/h (= 0.042 mL/min = 2.5 mL/h) for 2-5 days, i.e. 48-120 hours (treatment phase).
2483476|NCT03013322|Placebo Comparator|Placebo Group|The placebo group is treated with 0.9% sodium chloride.
2483526|NCT03012750|Experimental|foot perfusion|intravenous application of indocyanine green in patients receiving tibial Bypass surgery
2483606|NCT03012464||Pathologic and functional assessment|Patients of both genders, aging below 45 years with internal or external rectal prolapse
2483657|NCT03011788|Active Comparator|Single day|Single day Golytely purge 4L purge
2483660|NCT03011788|Active Comparator|2 day colon purge|Two days of Golytely purge 8L purge
2483720|NCT03011580|Experimental|Immediate supplementation arm|"Fultium-D3 (oral cholecalciferol or vitamin D3) will be given at a dose of 9,600 IU/day for 8 weeks (three capsules once daily as each Fulitium D-3 capsules contains 3,200 IU vitamin D3). Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it.~All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study."
2483726|NCT03011580|Placebo Comparator|Delayed supplementation arm|Oral placebo will be given for 8 weeks at a dose of three capsules once daily. Fultium-D3 and placebo will be identical in appearance and taste. Participants may also be given a Sensemedic dispenser each for real-time adherence monitoring and shown how to use it. All participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day at the end of the study.
2483803|NCT03010956||Patients with uncontrolled diabetes mellitus|Patients with uncotrolled tyre 1 or type 2 diabetes mellitus
2483805|NCT03010956||Patients with controlled diabetes mellitus|Patients with controlled type 1 or type 2 diabetes mellitus
2483843|NCT03010722||Regorafenib|"160 mg orally (po) od for 3 weeks of every 4-week cycle~All patients will be required to have pre-treatment dynamic contrast enhance computed tomography (DECT) scan pre-treatment and at 8 weeks. Suitable patients will also be required to have dynamic contrast enhanced magnetic resonance imaging (DEC-MRI) and diffusion weighted (DW)-MRI, pre-treatment and at 2 weeks. All patients will also be required to have an Ultrasound (USS) or CT-guided biopsy of suitable metastatic lesion."
2483888|NCT03010449|Experimental|Intra-bronchial valve and blood|Bronchoscopic lung volume reduction using intra-bronchial valves combined with autologous blood instillation.
2483959|NCT03010111|Other|health care workers|health care workers including doctors, nurses, technicians and orderly who were hired in 2016 at the Hanyang University Hospital
2484006|NCT03009708|Experimental|Allograft patients|Allograft patients followed at the Institut de Cancérologie Lucien Neuwirth perform blood samples during their post graft follow up in the usual practice, weekly. With the present study, two more blood tubes will be collected with the weekly blood samples.
2484119|NCT03009409|Active Comparator|Ketamine Group|Participants randomized to the ketamine group will receive a 0.25 mg/kg loading dose of intravenous ketamine immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, for approximately 45 minutes, up to a maximum cumulative dose of 100 mg. This dose is in accordance with the guidelines from the recently published Clinical Practice Guidelines for the management of post-operative pain. The attending anesthesiologist will confirm whether the use of ketamine is appropriate for each patient prior to enrolling the patient in the study.
2484120|NCT03009409|Placebo Comparator|Control Group|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion.
2484180|NCT03008642|Experimental|CO-Rebreathing|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
2484351|NCT03007680|Experimental|Core muscle activation|Core muscle will be activated by physical fitness using plank, crunch and leg extension.
2484353|NCT03007680|No Intervention|No core muscle activation|
2483053|NCT03015766|Sham Comparator|sham auricular acupressure therapy|Participants in the control group (SAA group) will receive auricular acupressure on five Helix points (HX 5-9), which were clearly remote from the inner ear area. These points have no evidence for insomnia management.
2483174|NCT03015168||Observational Group|Patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
2483288|NCT03014362|Active Comparator|TMS active|"Neuronetics NeuroStar XPLOR magnetic stimulator - Active;~Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC (Standard of Care)."
2483291|NCT03014362|Sham Comparator|TMS sham|"Neuronetics NeuroStar XPLOR magnetic stimulator - Sham;~Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
2483338|NCT03013959||Resting control group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are observed as control group
2483340|NCT03013959||Resting test group|The rest group is to study the effect of the inhibition of recurrence . Patients with redness, pain, decreased visual acuity and other reaction activity in the past 30 days are treated with pranoprofen and observed as test group
2483342|NCT03013959||Active control group|The active control group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are observed as control group
2483344|NCT03013959||Active test group|The active test group is to study the effect of anti--inflammatory. Patients with a new redness, pain, decreased visual acuity and other reaction activity recently are treated with pranoprofen and observed as test group
2483392|NCT03013647|Other|Actinic Keratosis|Twenty patients with multiple thin AK on the face will be treated with Daylight Photodynamic Therapy with methyl aminolevulinate Skin biopsies before and after treatment will be performed in an AK lesion and in a field cancerization area.
2483407|NCT03013335|Experimental|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
2483462|NCT03013166||Cohort 1|IR hydrocortisone
2483463|NCT03013166||Cohort 2|IR prednisolone
2483464|NCT03013166||Cohort 3|MR hydrocortisone
2483466|NCT03013166||Cohort 4|IR to MR hydrocortisone
2483522|NCT03012893|Experimental|Ultrasound transverse scan|Transvers scan by identifying the C7 transvers process using vertebral artery and absence of anterior tubercle as a landmark and then scan back following articular process, lamina and then find out the spinous process of C7
2483528|NCT03012893|Experimental|Ultrasound sagittal scan|Sagittal scan by identifying the first and second ribs and scan medially to depict the C7 transvers process.
2483531|NCT03012893|Active Comparator|Floroscopic technique|Fluoroscopy image will do on lateral view including all cervical spines and upper thoracic spines. C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
2483574|NCT03012321|Active Comparator|Arm I: Abiraterone + Prednisone|Abiraterone 1000 mg orally once daily and prednisone 5 mg orally twice daily, days 1-28 in 28 day cycles.
2483577|NCT03012321|Active Comparator|Arm II: Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2483581|NCT03012321|Active Comparator|Arm III: Abiraterone + Prednisone + Olaparib|Abiraterone 1000 mg orally once daily, prednisone 5 mg orally twice daily, olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2483583|NCT03012321|Active Comparator|Olaparib|Olaparib 300 mg orally twice daily for days 1-28 in 28 day cycles.
2483681|NCT03011827|Experimental|Prospective cohort|Fibrinogen and/or platelet administration
2483698|NCT03011424|Experimental|Early Postoperative Extracorporal Liver Support Therapy (ELS)|Early Postoperative Extracorporal Liver Support Therapy (ELS) by using the Molecular Adsorbent Recirculating System (MARS)
2483792|NCT03011268|Experimental|Anti TNF discontinuation|Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
2483797|NCT03011268|Active Comparator|Anti TNF continuation|Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)
2483836|NCT03010670|Experimental|Oxytocin (OT) spray|Syntocinon nasal spray (product code RVG 03716) will be used to intranasally administer one single dose (24 IU) of OT (3 puffs of 4 IU per nostril).
2483839|NCT03010670|Placebo Comparator|Placebo (PL) spray|Physiological water (a solution of sodium chloride (NaCl) in water) will be used to intranasally administer one single dose (24 IU) of PL (3 puffs of 4 IU per nostril).
2483889|NCT03010436|Other|Open-Label|All subjects will receive the study medication- benralizumab
3193534|NCT00819104|Experimental|2|FDC of Metoprolol XL 25mg + Amlodipine 2.5mg
3193535|NCT00819104|Active Comparator|3|Extended release Metoprolol succinate
2484019|NCT03009786||Elderly institutionalized subjects or outpatients|
2484130|NCT03008720|Active Comparator|tDCS active|Transcranial stimulation ( tDCS ) active will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle.
2484131|NCT03008720|Placebo Comparator|tDCS sham|Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.
3193536|NCT00819104|Active Comparator|4|Extended release Metoprolol succinate
3193537|NCT00819104|Active Comparator|5|Amlodipine 5mg in immediate release formulation
3193538|NCT00819117|Active Comparator|Transvenous Lead (TVN CRT)|Control group: resynchronization via a transvenous left ventricular lead (TVN CRT)
2483060|NCT03016013|Placebo Comparator|Placebo plus MTX|Patients received placebo SC plus MTX weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
2483063|NCT03016013|Experimental|Experimental: RC18 160 mg+MTX|Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
2483086|NCT03015402|Experimental|Sodium Nitrite|
2483090|NCT03015402|Placebo Comparator|Placebo|
3193539|NCT00819117|Experimental|Epicardial Lead (EPI CRT)|Treatment group: resynchronization via an epicardial left ventricular lead (EPI CRT)
3193540|NCT00819169|Experimental|Part 1 Cohort 3|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg IV (day 1 of each Q3W cycle)
2483470|NCT03013634|Experimental|Dexmedetomidine Group|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
2483472|NCT03013634|Placebo Comparator|Normal saline Group|Equal volume normal saline substitute for dexmedetomidine
2483512|NCT03012776|Experimental|TOPS System|Investigational surgical treatment using TOPS System
2483513|NCT03012776|Active Comparator|Transforaminal Lumbar Interbody Fusion (TLIF)|Control surgical treatment using interbody fusion and placement of posterolateral instrumentation
2483607|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
2483612|NCT03012165|Experimental|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
2483615|NCT03012165|Placebo Comparator|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops
2483634|NCT03011762|Other|Computer Controlled Mandibular Positioner|All study participants will undergo the computer controlled mandibular positioner test.
2483691|NCT03011658|Placebo Comparator|GROUP A|5 ml of venous blood will be obtained from this group who do not have oral lichen planus and suffering from anxiety and/or depression. They will be administered a HADS standard questionnaire and their stress related issues calculated accordingly. This group has 30 patients totally
2483692|NCT03011658|Other|GROUP B|The group has 30 oral symptomatic lichen planus diagnosed patients also suffering with anxiety and/or depression. 5 ml of venous blood will be obtained from them for serum cortisol level analysis. HADS questionnaire will be administered for this group for evaluation of levels of anxiety and depression
2483747|NCT03011320|Experimental|Cohort 1|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at <8 hours prior to surgery"
2483749|NCT03011320|Experimental|Cohort 2|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 4 mg/m2 EC1456 at 48±4 hours prior to surgery"
2483755|NCT03011320|Experimental|Cohort 3|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at <8 hours prior to surgery"
2483760|NCT03011320|Experimental|Cohort 4|"Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.~One dose of 8 mg/m2 EC1456 at 48±4 hours prior to surgery"
2483799|NCT03010943|Experimental|Brain surgery with virtual reality headset|
2483877|NCT03010735|Active Comparator|Probiotics|The patient take two chewing tablet per day, which contain 4.0E+10 CFU of probiotics.
2483879|NCT03010735|Placebo Comparator|Placebo|The patient take two placebo chewing tablet per day.
3159171|NCT00400738|Experimental|1|different dose per arm
3159172|NCT00400738|Experimental|2|different dose per arm
3159173|NCT00400738|Experimental|3|different dose per arm
3159174|NCT00400738|Experimental|4|different dose per arm
2484038|NCT03009838|Active Comparator|laparoscopic drilling|laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle
2484107|NCT03009032|Experimental|PMT25341|A mixture of prebiotics, probiotics, oligonutrients, essential aminoacids, omega-3 fatty acids
3159175|NCT00400816|Experimental|Temozolomide|Temozolomide, 150 mg/m2/d x days 1-7 and 15-21
3159176|NCT00400842|Experimental|L|
3159177|NCT00400842|Experimental|H|
3159178|NCT00400842|Placebo Comparator|P|
3159179|NCT00400855|Experimental|Arm 1|study drug
3159180|NCT00400868|Active Comparator|standard joint protection education|psycho-educational joint protection vs. usual care (standard joint protection education)
3159181|NCT00400933|Experimental|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
3159182|NCT00400998|Placebo Comparator|Vienna Challenge Chamber in season (Phase 3)|"Phase 3 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200micrograms (μg) fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy."
3173544|NCT00613210||2|women without contractions between 24-34 weeks of gestation with a history of preterm labor
3173545|NCT00613210||3|women with preterm contractions 24-34 weeks of gestation
2483134|NCT03015350||one lung ventilation of desflurane|In GroupSa, 6 % desflurane will be apply continuously and first samples will taken at the 40. minutes and collection of blood samples will be continue at intervals of 10 minutes after one lung ventilation started.
2483167|NCT03014934||Cases: Prior Invasive Aspergillosis|History of probable or proven Invasive Aspergillosis according to EORTC 2008 criteria
2483172|NCT03014934||Controls: No prior proven Invasive Aspergillosis|Patients really negative for Invasive Aspergillosis and those with possible Invasive Aspergillosis
2483389|NCT03013660|No Intervention|Comparison|Participants will be provided with standard information about the benefits of STSC and breastfeeding and will be encouraged to come into the NICU every day for at least 1 hour of STSC. To facilitate increased let down of breast milk, all participants will be provided a hospital grade breast pump free of charge during the stay of their babies in the NICU and assistance will be provided to the mothers in procuring a Medicaid covered breast pump to keep when the baby leaves the NICU. The hospital grade breast pump will be provided to her as soon as she enrolls into the study and will remain with her until her baby is discharged or transferred.
2483390|NCT03013660|Experimental|Treatment: Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment. The participants selected for the intervention arm will be asked not to discuss the payment with any other study participants (such as the members of any other families they may see at the NICU) or other health care staff at the NICU. Participants will also receive everything that the Comparison group receives.
2483435|NCT03013374||Human milk fed infants|"Infants fed fortified human milk at enrollment~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
2483442|NCT03013374||Preterm formula|"Infants fed preterm formula milk at enrollment.~Any intervention is performed. Groups distinction is made according to own mother's milk availability."
2483507|NCT03013114|Experimental|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
2483592|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (A)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
2483595|NCT03012373|Experimental|Ear acupressure & Electroacupuncture (B)|Electroacupuncture plus Ear acupressure or Ear acupressure alone for four weeks followed by an one week wash-out period. Then with crossover to the othe.
2483627|NCT03011853||Non-invasive only|Non-invasive ventilation as first and only respiratory support
2483628|NCT03011853||Invasive|Invasive ventilation with intubation as first respiratory support
2483629|NCT03011853||NIV+Inv|Non-invasive ventilation as first respiratory support followed by invasive ventilation with intubation
2483722|NCT03011450|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator for 12 weeks
2483724|NCT03011450|Active Comparator|40 week extension|K-877 or fenofibrate comparator for 40 weeks
2484010|NCT03009565||study patients|Study participants will be individuals aged 30-80 arriving to Rabin Medical Center with suspected CAD and able to provide informed consent. Participants will provide medical, lifestyle, and nutritional questionnaires. Blood pressure and heart-rate measurements will be taken during hospitalization as well as blood tests and fecal samples and/or rectal swabs. In order to evaluate and/or treat suspected atherosclerotic disease patients will undergo cardiac CT and/or cardiac catheterization in accordance with the standard of care and based upon the decision of the treating cardiologist. Diagnostics and treatment options will be based only on their medical condition and regardless of the aforementioned study protocol.
2484015|NCT03009565||control|The control group will be selected to represent an age, sex and cardiovascular risk factors -matched group without current CAD. Further exclusion criteria in the control group will be antibiotic consumption in the following 3 months, inflammatory bowel disease, or other significant chronic disease that may influence the microbiota (such as cancer, autoimmune disease, and chronic immunosuppressive treatment). The control group will undergo cardiac CT or coronary angiography according to clinical suspicion in order to rule-out CAD and irrespective of the study protocol.
2484064|NCT03009357||thyrotoxicosis|patients with newly detected or recurrent thyrotoxicosis
2484077|NCT03009357||control|euthyroid, healthy adults
3173546|NCT00613223|Experimental|Vandetanib and Etoposide|Patients will be stratified based on whether they are receiving an enzyme-inducing anti-epileptic drug (EIAED). The dose level of vandetanib will be increased in successive cohorts of subjects. Etoposide will be given daily at a dose of 50 mg/ day for 21 days followed by 7 days with no etoposide.
3173547|NCT00613249|Experimental|A|
3173548|NCT00613249|Experimental|B|
3173549|NCT00613249|Placebo Comparator|C|
3173550|NCT00613288|Experimental|A|
3173551|NCT00613340|Experimental|1|Cervical medial branch blocks with 0.25 ml of injectate
3173552|NCT00613340|Experimental|2|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
2484211|NCT03008603|Experimental|Procedures with XACT Robotic System|CT-guided minimally invasive percutaneous procedures using the XACT Robotics system
2484341|NCT03007628|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2484346|NCT03007628|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2484418|NCT03007056||Period 1|year 2011 nCPAP
2484426|NCT03007056||Period 2|year 2014 nCPAP and high flow nasal cannula
2484587|NCT03005873|Experimental|TLC599 LD group|12 mg DSP with 100 µmol PL (1.0 mL)
2484589|NCT03005873|Experimental|TLC599 HD group|18 mg DSP with 150 µmol PL (1.5 mL)
3173553|NCT00613353||I|Caucasian and African American females between the ages of 18 and 65.
2483150|NCT03015246|Placebo Comparator|Extended-Release Morphine + placebo stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. The placebo stressor will be administered on one day.
2483151|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day.
2483152|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + placebo stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. The placebo stressor will be administered on one day.
2483153|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + placebo stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. The placebo stressor will be administered on one day.
2483154|NCT03015246|Experimental|Extended-Release Morphine + active stressor|Participants will be maintained on extended-release morphine (dose tailored to the individual, based on pre-experimental opioid use amount), in three divided daily doses. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
2483155|NCT03015246|Experimental|Buprenorphine/Naloxone low dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 1.4/0.36 mg/day. The placebo stressor will be administered on one day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
2483156|NCT03015246|Experimental|Buprenorphine/Naloxone moderate dose + active stressor|Participants will be maintained on Buprenorphine/Naloxone (Zubsolv™) sublingual tablet doses of 4.2/1.08 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
2483157|NCT03015246|Experimental|Buprenorphine/Naloxone high dose + active stressor|Participants will be maintained on Buprenorphine-Naloxone (Zubsolv™) sublingual tablet doses of 12.8/3.16 mg/day. Yohimbine 60mg powder + Hydrocortisone (Cortef™) 20mg tablet administered on one day.
2483207|NCT03014843|Active Comparator|Naloxone|Administration of a centrally acting µ-opioid receptor antagonist Naloxone (20µg/kg/h intravenous infusion after 0.4mg bolus) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
2483211|NCT03014843|Active Comparator|Methylnaltrexone bromide|Administration of a peripherally acting µ-opioid receptor antagonist Methylnaltrexone (12mg/0.6mL subcutaneous injection) to investigate the effect of esophageal sensitivity assessed by multimodal esophageal stimulation.
2483212|NCT03014843|Placebo Comparator|Placebo|Administration of placebo injection (1mL 0.9% saline IV or 0.6 IM) as a control condition to compare to the administration of naloxone or methylnaltrexone bromide in the multimodal esophageal stimulation protocol.
2483237|NCT03014531|Experimental|almond|In this group, participants were provided with 56 g of almonds per day either as preload before meals or snack between meals. A snack was defined as an eating event that occurred between participants' regular meals, specifically two hours before and after meals. All the participants in almond group were provided daily portions of packaged almonds.
2483241|NCT03014531|Other|high-carbohydrate control food item|In this group, participants were provided with high-carbohydrate control food item that had a similar number of calories as 56 g of almonds.
2483325|NCT03014349||primary open-angle glaucoma and/or glaucoma suspects|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
2483368|NCT03013881|Experimental|UB-921 2 mg/kg (Main-study)|Intravenous infusion
2483373|NCT03013881|Experimental|UB-921 6 mg/kg (Main-study)|Intravenous infusion
2483376|NCT03013881|Experimental|UB-921 8 mg/kg (Main-study)|Intravenous infusion
2483377|NCT03013881|Experimental|UB-921 6 mg/kg (Sub-study)|Intravenous infusion
2483378|NCT03013881|Active Comparator|Herceptin 6 mg/kg (Sub-study)|Intravenous infusion
2483433|NCT03013413|Experimental|Diagnostic (elastography imaging using the Aixplorer system)|Patients undergo ultrasound-based elastography imaging using the Aixplorer system followed by standard of care ultrasound-guided prostate biopsy over approximately 25 minutes.
2483485|NCT03013036|Other|Group I|Patients between 1 and 2 years
2483488|NCT03013036|Other|Group II|patients between 3 and 5 years
2483492|NCT03013036|Other|Group III|patients between 6 and 8 years
3173554|NCT00613392|Experimental|1|
3173555|NCT00613392|Placebo Comparator|2|
2483618|NCT03012139||Cancer with cachexia|Men and women (ages 35-80 years) with cancer cachexia (≥5% drop in body mass in less than 12 months)
2483619|NCT03012139||Cancer without cachexia|Men and women (ages 35-80 years) with cancer but without cachexia of similar age and sex as the group with cachexia
2483620|NCT03012139||No cancer|Men and women (ages 35-80 years) without cancer, but similar age and sex as groups with cancer.
2483645|NCT03011710|Experimental|E-cigarette with nicotine|Nicotine level: 6 mg/ml
2483652|NCT03011710|Experimental|E-cigarette without nicotine|Nicotine level: 0 mg/ml
2483664|NCT03011710|Experimental|Conventional cigarette|Nicotine content: 0,5mg
2483671|NCT03011710|Placebo Comparator|Cigarette tip|Placebo device
2483693|NCT03011476|Active Comparator|Donepezil|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
2483694|NCT03011476|Placebo Comparator|Placebos|dosage: 5mg, 10mg frequency: once a day duration: 12 weeks
2483821|NCT03011229|Active Comparator|Pro Core|Subject is randomized to ProCore standard needle.
2483822|NCT03011229|Experimental|Medtronic Shark Core|Subject is randomized to Medtronic Sharkcore needle
2483852|NCT03010579|Experimental|erythropoietin group|For those lymphoma patients with hemoglobin level less than 100 g/L on day +15 after autologous hematopoietic stem cell transplantation, erythropoietin will be administered. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
2483855|NCT03010579|Active Comparator|iron supplementation|If necessary，oral ferrous succinate, vitamins B12 and folic acid will be administered.
2484066|NCT03009279||The MS group|Patients with metabolic syndrome(MS).
3173556|NCT00613418|Other|single|Historical control
2483162|NCT03015077|Active Comparator|Glutamine|"intake of 5g glutamine and 10g maltodextrin. Oral glutamine is a food additive issued by food and drug government in Taiwan with number 009929.L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin.~The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy."
2483163|NCT03015077|Placebo Comparator|placebo|intake of 15g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
3193541|NCT00819169|Experimental|Part 1 Cohort 1|AMG 479 18 mg/kg IV plus AMG 655 1 mg/kg IV (day 1 of each Q3W cycle)
2483283|NCT03014323|Experimental|Galantamine then Placebo, WW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in white women (WW)
2483285|NCT03014323|Placebo Comparator|Placebo then Galantamine, WW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks in white women (WW)
2483293|NCT03014323|Experimental|Galantamine then Placebo, AAW|4 mg (1 capsule) galantamine twice a day for 4 weeks then placebo (1 capsule) twice a day for 4 weeks in African American Women (AAW)
2483298|NCT03014323|Placebo Comparator|Placebo then Galantamine, AAW|Placebo (1 capsule) twice a day for 4 weeks then 4 mg (1 capsule) galantamine twice a day for 4 weeks African American Women (AAW)
2483396|NCT03013790|Active Comparator|Melatonin 5mg|This arm will be given 5mg tablets of Melatonin nightly for the duration of their hospital stay
2483398|NCT03013790|Active Comparator|Melatonin 3mg|This arm will be given 3mg tablets of Melatonin nightly for the duration of their hospital stay
2483401|NCT03013790|Placebo Comparator|Placebo|This arm will be given a Sucrose tablet nightly for the duration of their hospital stay
2483450|NCT03013270|Experimental|ARIS group|Aerobic-Resistance-Inspiratory
2483454|NCT03013270|Active Comparator|AT/RT group|Aerobic-Resistance
2483456|NCT03013270|Active Comparator|AT/IMT group|Aerobic-Inspiratory
2483458|NCT03013270|Active Comparator|AT group|Aerobic Training
2483493|NCT03012932|Other|HPV Self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
2483518|NCT03012737|Other|MPV arm|Subjects use mouth piece ventilation (MPV) accoring to their will to alleviate dyspnea for 24 hours.
2483609|NCT03012412|Experimental|Mindfulness Based Program for Infertility|"Behavioral: MBPI~The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 15 participants)."
2483613|NCT03012412|No Intervention|Treatment As Usual (TAU)|Standard infertility medical treatment provided by IVF clinics (public and private) - no psychological intervention being pursued.
2483630|NCT03011801|Experimental|Behavioral: Interpersonal Therapy|Individual psychotherapy that includes an initial engagement session and a total of 8 sessions. IPT focuses on psychoeducation and interpersonal skill building to decrease interpersonal conflict and increase interpersonal support and competence.
2483631|NCT03011801|Placebo Comparator|Enhanced Usual Care|Maternity support services (MSS) is the usual standard of care for pregnant women. A multi-disciplinary team of obstetric care providers routinely screen women for possible depression diagnosis. If a woman screens positive, she is seen by a behavioral health specialist (BHS) for further assessment and to initiate treatment, if necessary. The goals of MSS include offering services to promote healthy pregnancies and positive birth and parenting outcomes, including integrating mental health and prenatal care. Women with elevated depressive symptoms are seen by BHS throughout the pregnancy and postpartum period and then bridged to mental health treatment. BHS provides eclectic-based care but does not provide IPT.
2483688|NCT03011671|Experimental|Acetazolamide with Temozolomide|Subjects will receive daily ACZ together with TMZ in 28 day cycles for up to 6 cycles if they do not experience either disease worsening or unacceptable side effects.
3173557|NCT00613431|Experimental|1|6 dose groups, 9 subjects on active, 3 subjects on placebo in each group
3173558|NCT00613431|Placebo Comparator|2|3 subjects on placebo in each group
3173559|NCT00613444|Experimental|LumaCare LC-122M non-coherent light source|"Split Face Comparison. One half of subject's face will receive topical photosensitizer applications followed by LumaCare LC-122M non-coherent light source illumination. Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.~The other half of the face will not receive any treatment and will serve as internal control."
3173560|NCT00613457|Experimental|I|o Arm I (closed to accrual as of 6/30/2006): Patients receive prednisone (PRED) on days 8-28.
3173561|NCT00613457|Experimental|II|o Arm II (closed to accrual as of 6/30/2006): Patients receive dexamethasone (DEXA) on days 8-28.
3173562|NCT00613457|Experimental|Reintensification Arm I|o Arm I (standard reinduction therapy, protocol II [closed to accrual as of 6/30/2006]): SR and IR patients receive DEXA on days 1-22; VCR and doxorubicin hydrochloride (DOX) in weeks 2-5; ASP on days 8, 11, 15, and 18; CPM on day 36; ARA-C and thioguanine (TG) on days 36-49; and MTX IT on days 38 and 45. Patients then proceed to maintenance therapy.
2484016|NCT03009604|Experimental|Simethicone|women take 6 tablets (2 tablets after each meal) and to fast overnight before the operation
2484018|NCT03009604|Active Comparator|Enema|women take 3 rectal Enema (8:00 pm, 12:00 am & 8:00 am) and to fast over night before the operation.
2484061|NCT03009305|Experimental|Lower body negative pressure|Single-arm, lower body negative pressure, continuous positive airway pressure, positive expiratory pressure.
2484198|NCT03008525|Experimental|obese patients (group OB)|patients with body mass index ≥ 35 kg/m²
2484201|NCT03008525|Active Comparator|non-obese patients (group NO)|patients with body mass index < 30 kg/m²
2484272|NCT03008200||RDS +|postpartum RDS developed group
2484275|NCT03008200||RDS -|postpartum RDS undeveloped group
3193542|NCT00819169|Experimental|Part 1 Cohort 2|AMG 479 18 mg/kg IV plus AMG 655 3 mg/kg IV (day 1 of each Q3W cycle)
2483260|NCT03014505|Experimental|FMT|Fecal Microbiota Transplantation via endoscope and/or cenema and the traditional treatments
2483267|NCT03014505|Active Comparator|The traditional treatments|
2483303|NCT03014232|Experimental|SLED-f with HCO dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using novel high cut-off dialyzer which had larger pore size than standard high-flux dialyzer was assigned as the new intervention to compare the efficacy of cytokine removals with the control arm.
2483305|NCT03014232|Active Comparator|SLED-f with HF dialyzer|Online sustained low-efficiency diafiltration (online SLED-f) using standard high-flux dialyzer in septic acute kidney injury patients was assigned as the control group
2483384|NCT03013933|Experimental|Treatment (cyclosporine, verapamil, brentuximab vedotin)|Patients receive cyclosporine PO BID on days 1-5, verapamil hydrochloride PO QID on days 1-5, and brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2483410|NCT03013244|No Intervention|Waitlist Control|Participants in this condition completed assessments at baseline, 1 week, and 5 weeks.
2483413|NCT03013244|Experimental|The Body Project: More Than Muscles|Participants in this condition competed the 2-session dissonance-based eating disorder prevention protocol (2 hours per session).
2483459|NCT03013192|No Intervention|Control|No text message reminders, usual patient protocol
2483461|NCT03013192|Experimental|Intervention (text messaging)|Text message reminders for PT
2483495|NCT03012971|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2483496|NCT03012971|Placebo Comparator|Control group|Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
3159183|NCT00400998|Placebo Comparator|Vienna Challenge Chamber out of season (Phase 1)|"Phase 1 will consist of two treatment periods each lasting 8 days, with a 10 day wash-out between each treatment period.~Subjects will administer 200μg fluticasone propionate or fluticasone propionate matched placebo nasal spray, once daily for 8 days. Dosing will be supervised on the first and last days of each treatment period (Day 1 and Day 8).~Immediately following the last dose received on Day 8 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy.~An intermediate study follow-up visit will take place 7-14 days after the last dose is received in treatment period 2."
3159184|NCT00400998|Placebo Comparator|Park In Season (Phase 2)|"Phase 2 will consist of 2 treatment periods lasting either 8 to 14 days (D) (depending on out-door conditions). There will be a 10D wash-out between this treatment period in Phase 2 and that in Phase 3.~Subjects will administer 200μg fluticasone propionate (or fluticasone propionate matched placebo nasal spray, once daily up to 14D, with dosing supervised on the first and last days of each treatment period (D1 and either D8 or up to D14).~Immediately following the last dose received on either D8 or up to D14 baseline measures will be taken (time = 0). The subject is then taken by bus to the Park and the first measurement will be taken 15 minutes after the subjects leave the bus and enter the Park.~Immediately following the last dose received on D8 or up to D14 the subject's signs and symptoms will be monitored: subjective symptom score every 15 minutes for rhinomanometry and measurement of nasal secretion every 30 minutes, and FEV1, AEs and symptoms of local irritancy"
2483666|NCT03011996|Experimental|CJ-12420 100mg|CJ-12420 100mg BID for 5 days
2483670|NCT03011996|Experimental|CJ-12420 50mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 50mg and CLR 500mg/AMX 1g BID for 7 days
2483672|NCT03011996|Active Comparator|Pantoprazole 40mg + CLR 500mg + AMX 1g|coadministration of Pantoprazole 40mg and CLR 500mg/AMX 1g BID for 7 days
2483673|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg + AMX 1g|coadministration of CJ-12420 100mg, CLR 500mg/AMX 1g BID for 7 days
2483675|NCT03011996|Experimental|CLR 500mg/AMX 1g|CLR 500mg/AMX 1g BID for 5 days
2483677|NCT03011996|Experimental|CJ-12420 100mg + CLR 500mg/AMX 1g|coadministration of CJ-12420 100mg and CLR 500mg/AMX 1g BID for 7 days
2483763|NCT03011294|Active Comparator|CPAP (in the partner)|Positive airway pressure for treating OSA in the bed partner.
2483765|NCT03011294|Placebo Comparator|Nasal strips (in the partner)|Nasal dilator as a placebo for treating OSA in the bed partner.
2483824|NCT03011060|Experimental|NAC not achieving pCR|"Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.~Capecitabine 1000mg/m2 tablets twice a day for 8 cycles."
2483825|NCT03011060|Experimental|NAC achieving pCR|Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.
2483828|NCT03011060|No Intervention|Adjuvant Chemotherapy|Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.
3159185|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib|All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
3159186|NCT00401011|Experimental|Phase II: Perifosine + Bortezomib + Dexa|If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
3159187|NCT00401011|Experimental|Phase I: Dose 1: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks.
2484075|NCT03009279||The non-MS group|Patients without metabolic syndrome(MS).
2483180|NCT03015103|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
2483253|NCT03014804|Experimental|Group I (DCVax-L)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine ID on days 0, 7, 14, and weeks 4, 6, 8, 11, 14, 17 and 20.
2483261|NCT03014804|Experimental|Group II (DCVax-L, nivolumab)|Patients receive autologous dendritic cells pulsed with tumor lysate antigen vaccine as in Group I, and nivolumab IV over 30 minutes on days 0, 14, and weeks 4, 6, 8, 11, 14, 17, and 20.
2483308|NCT03014115|Active Comparator|combination ARA+ DHA|combination 0.76% ARA+ 0.4% DHA in infant formula per day
2483310|NCT03014115|Experimental|DHA|0% ARA +0.4% DHA in infant formula per day
2483381|NCT03013829|No Intervention|Usual Care|"Potential LKDs and recipients will receive standard-of-care LD (Live Donor) and KPD education. As noted previously, during standard care, incompatible potential LKDs are informed of the KPD option and the potential LKD is provided with living donation information and a link to the UNOS KPD website, which includes a written description of KPD. This information is available in English and Spanish. For those who do not have internet access, the written educational materials are mailed. The potential LKD is advised to call the donor nurse coordinator with any questions about KPD and/or to initiate the full donation evaluation. This process occurs for the intended recipient only if their potential donor decides to initiate the full evaluation.~For study purposes, potential LKDs and waitlisted recipients assigned to the UC group will be sent an email after randomization, which will include a link and a reminder to review their transplant center's standard of care educational materials."
2483382|NCT03013829|Experimental|Video-Based KPD education|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch the embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
2483406|NCT03013426|Experimental|NVX-508|Administration of 1, 2 or 4 doses of NVX-508 at three dose levels; 0.05ml/kg. 0.1ml/kg and 0.17ml/kg in a 3 + 3 design.
2483440|NCT03013205|Experimental|PT+IA+CHL|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Coracohumeral ligament triamcinolone injection~Physiotherapy"
2483449|NCT03013205|Active Comparator|PT+IA|"Intraarticular triamcinolone injection~Intraarticular Xylocaine injection~Physiotherapy"
2483498|NCT03012958||Health control group|"Who are 18 years or older, have no history of pre-existing lung disease, and report no respiratory illness in the four weeks preceding enrollment.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
2483501|NCT03012958||Deployment-related lung disease|"Defined as the presence of unexplained chest symptoms in a deployer who, on surgical lung biopsy is found to have bronchiolitis or granulomatous pneumonitis without other known causes.~This study consist of one visit: If the potential subject meets the Inclusion and exclusion then they will have the LCI testing."
2483587|NCT03012438|Experimental|NIRF imaging in thyroid surgery|"7.5 mg ICG is administered i.v. and the system will be switched to fluorescence mode. If needed, a second dose of 7.5 mg ICG can be administered. After identification of the parathyroid glands, surgery will continue until there is a desire to visualize the parathyroid glands again, another dose of ICG can be given. After complete removal of thyroid, another 7.5 mg of ICG will be given to assess the perfusion of the parathyroid gland. Directly after the procedure the researcher will ask the surgeon whether he/she thinks the technique is feasible.~After surgery, the serum calcium levels will be determined in patients after total thyroidectomy on day 1, 2 and after two weeks. TSH will be determined after 2 weeks. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands. Video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the TBR."
2483665|NCT03011931|Experimental|Simvastatin|Simvastatin tablet, 20 mg, one time by mouth
2483709|NCT03011515||LRTI patients|Patients with suspicion of LRTI, excluding episodes of COPD exacerbations
2483715|NCT03011515||Non-infectious patients|Afebrile patients with no apparent infectious disease
2483719|NCT03011515||LRTI patients with COPD|Patients with suspicion of LRTI in a sub-group of patients with COPD
2483785|NCT03011242||Longitudinal Cohort: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis starting standard of care treatment with a TNFi or non-biologic DMARD.
2483788|NCT03011242||Assay Development: Healthy or Psoriatic Arthritis|Individuals that are healthy or with a diagnosis of Psoriatic Arthritis will be enrolled for blood draws for assay development and/or for an ultrasound for development of techniques and scoring system validation.
2483793|NCT03011242||Cross-Sectional: Psoriatic Arthritis|Individuals diagnosed with Psoriatic Arthritis in good disease state on stable non-biologic DMARDS or on stable TNFi.
2483870|NCT03010813|Experimental|Novel single port robotic system|A single port innovation designed to deliver an articulating 3D high definition camera and three fully articulating instruments through a single 25-mm cannula
2483918|NCT03010241|Experimental|Tangbi Prescription|Based on the standard medical care, experimental group were treated with Tangbi Prescription 4.87g granules, 2 times/d, which The prescripton was composed by five Chinese herbal medicines.
2483920|NCT03010241|Placebo Comparator|Placebo|Based on the standard medical care, placebo-controlled group were treated with Placebo 4.87g granules, 2 times/d
2483987|NCT03009955||Group P|patients who received primary caesarean section
2483988|NCT03009955||Group R|patients who received repeated caesarean section
2484012|NCT03009630|Experimental|RFA group|Patients with early-stage peripheral lung cancer will be performed RFA with the guidance of ENB. Post treatment response and follow up will be evaluated and carried out according to the standard procedure.
3193543|NCT00819169|Experimental|Part 2|AMG 479 18 mg/kg IV plus AMG 655 15 mg/kg Q3W, or the MTD, as determined in Part 1 of the study
3193544|NCT00819195||RRMS|Relapsing-remitting multiple sclerosis patients who have not yet received glatiramer acetate (Copaxone) therapy recommended as part of clinical care
3193545|NCT00819195||HC|Healthy control volunteers
3193546|NCT00819208|Active Comparator|Physical Activity Program + General Health Education Materials|Intervention Arm
3193547|NCT00819208|Active Comparator|General Health Education Materials|Control Arm
2483314|NCT03014089|Experimental|mRNA-1325|
2483318|NCT03014089|Placebo Comparator|Placebo|0.9% sodium chloride
2483399|NCT03013764|Placebo Comparator|normal protein intake|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
2483402|NCT03013764|Experimental|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
2483405|NCT03013296|Placebo Comparator|Placebo|Saline
2483408|NCT03013296|Other|GIP-A|Infusion of GIP-A alone as study tool.
2483411|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
2483412|NCT03013296|Other|GIP-A + Exendin[9-39]|Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
2483465|NCT03013153|Experimental|Low ligation with apical lymph node dissection|Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
2483467|NCT03013153|Active Comparator|High ligation|Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
2483543|NCT03012854|Experimental|short-myotomy|Short-POEM for patients with esophageal achalasia
2483544|NCT03012854|Active Comparator|long-myotomy|Long-POEM for patients with esophageal achalasia
2483546|NCT03012854|Experimental|full-thickness myotomy|Full-thickness-POEM for patients with esophageal achalasia
2483548|NCT03012854|Active Comparator|circular myotomy|Circular-POEM for patients with esophageal achalasia
2483570|NCT03012230|Experimental|Treatment (pembrolizumab, ruxolitinib phosphate)|Patients receive pembrolizumab IV over 30 minutes on day 1 and ruxolitinib phosphate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2483621|NCT03011970|Active Comparator|Oxytocin; 24IU, 15min|Intranasal administration, 24 international units (IU) oxytocin. Imaging starting 15min after nasal spray administration.
2483622|NCT03011970|Active Comparator|Oxytocin; 24IU, 45min|Intranasal administration, 24 IU oxytocin. Imaging starting 45min after nasal spray administration.
2483623|NCT03011970|Active Comparator|Oxytocin; 24IU, 75min|Intranasal administration, 24 IU oxytocin. Imaging starting 75min after nasal spray administration.
2483624|NCT03011970|Active Comparator|Oxytocin; 12IU, 45min|Intranasal administration, 12 IU oxytocin. Imaging starting 45min after nasal spray administration
2483625|NCT03011970|Active Comparator|Oxytocin; 48IU, 45min|Intranasal administration, 48 IU oxytocin. Imaging starting 45min after nasal spray administration
2483626|NCT03011970|Placebo Comparator|Placebo|Placebo nasal spray.
2483682|NCT03011684|Experimental|ER Positive - Letrozole|
2483683|NCT03011684|Experimental|ER Positive - Tamoxifen|
2483684|NCT03011684|No Intervention|ER Negative|
2483745|NCT03011385|Experimental|Individual Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity) will be formed. Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
2483748|NCT03011385|Experimental|Dyadic Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans as well as coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad. This target person will be selected jointly by the participants if both participants are healthy. If one participant has a chronic disease, e.g. diabetes or a cardiovascular disease, the plans are formed for the person with a disease."
2483753|NCT03011385|Experimental|Collaborative Planning|"The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans and coping plans will be formed. Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (both partners) and include some plans for joint physical activity."
3159188|NCT00401011|Experimental|Phase I: Dose 2: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
2483786|NCT03011047|Experimental|endoscopic trans-antral approach|The maxillary sinus and prolapsed orbital contents will be visualized employing a 30-degree endoscope for the repair of orbital blow out fracture (sinus scope 4 mm, 30 degrees short one 17 cm).
2483860|NCT03010761|Experimental|medication pills 2: moclobemide 150mg|150mg once daily, 8 weeks
3193548|NCT00819273||1|patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
3193549|NCT00819299|Experimental|AcuFocus Corneal Inlay|Implantation of the AcuFocus Corneal Inlay ACI 7000PDT in emmetropic presbyopic patients.
2483251|NCT03014791||Healthy Volunteers|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min and 30μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
2483257|NCT03014791||Hypertensive Patients (Case-control)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Glyceryl trinitrate 500 μg (Sublingual administration to stimulate endothelium-independent vasodilatation)~Salbutamol 2 x 200 μg (Administered by spacer device to stimulate endothelium-dependent vasodilatation)~Forearm blood flow~Acetylcholine: 7.5μg/min, 15μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-dependent vasodilatation)~Sodium nitroprusside: 3μg/min, 10μg/min (Intra-arterial administration via brachial artery to stimulate endothelium-independent vasodilatation)~LNMMA: 2μmol/min, 4μmol/min (Intra-arterial administration via brachial artery to block basal nitric oxide production)"
2483268|NCT03014791||Hypertensive Patients (Cross-sectional)|"No IMP to be administered, only challenge agents as part of the physiological assessments.~Large artery endothelial function:~Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Forearm blood flow Same challenge agents as healthy volunteer and hypertensive patient (Case-control) arms~Recruited from community-based cohort studies - CLEAREST and ACCT~Equal recruitment across the following parameters:~Age: 3 groups <30, 30-60, >60 years~Gender~BMI: 3 groups <25, 25-30, >30 Kg/m2"
2483360|NCT03013816|Experimental|Testimonial Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
2483364|NCT03013816|Experimental|Informational Messaging|This video mirrors common educational campaigns and included segments of HRSA's animated video, Organ Donation and Transplantation: How Does it Work? The IM video presents facts about donation, including the current supply-demand problem in transplantation, common reasons for/against donor designation, donation myths, and the importance of communicating with parents about donation. Information about how to register as a donor is also included. The video contains no personal testimonials.
2483369|NCT03013816|Experimental|Blended Messaging|This video features four personal testimonials with strong emotional appeal, including an adolescent kidney transplant recipient, a pediatric liver transplant recipient, a young adult kidney transplant candidate, and an adolescent whose twin brother was a deceased organ donor. There are minimal facts about transplantation or donation.
2483404|NCT03013530||Patients with chronic disease|
2483426|NCT03013257|Experimental|High Intensity Focused Ultrasound|Try to use the machine 'Echopulse' with High Intensity Focused Ultrasound to treat the relapsed Graves' disease
2483430|NCT03013257|No Intervention|Fixed-dose radioiodine-131|Using the traditional treatment, fixed-dose radioiodine-131, to treat the relapsed Graves' disease
2483510|NCT03013088|Experimental|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
2483517|NCT03012516|Experimental|PAP-treatment by physiotherapist.|Enhanced PAP-support by physiotherapist including fitness test, individualized dialogue concerning PA, prescribed PAP and a 7 times follow-up during the one year intervention..
2483521|NCT03012516|Active Comparator|Ordinary PAP-treatment at the health care centre.|Ordinary PAP-treatment at the health care centre including individualized dialogue concerning PA, prescribed PAP and an individually adjusted follow-up.
2483608|NCT03012347|Experimental|Sunscreen Users|Subjects will participate in a 2-Day study involving three applications of a single test article each day. The first application will be followed by an exposure of 30 minutes in a hot room.
2483640|NCT03011814|Experimental|Arm I (durvalumab)|Patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2483643|NCT03011814|Experimental|Arm II (durvalumab, lenalidomide)|Patients receive durvalumab IV over 1 hour on day 1 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 (+/- 3) days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2483721|NCT03011359|Experimental|1) Conventional PCA mode|(Mode setting; total volume: 140 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 15 minutes)
2483723|NCT03011359|Active Comparator|2) Optimizing B.I PCA mode|Optimizing Basal Infusion (New) PCA mode(Mode setting; total volume: 140 ml, flow rate: changable by patients' requirement, bolus volume: 0.5 ml, and LOT: 15 minutes)
2483770|NCT03011164||WV 1|The condition of this group will be set as participants walking at 3.5km/h
2483773|NCT03011164||WV 2|The condition of this group will be set as participants walking at 4.0km/h
2483775|NCT03011164||RV 1|The condition of this group will be set as participants running at 3.5km/h
2483778|NCT03011164||RV 2|The condition of this group will be set as participants running at 4.0km/h
2483808|NCT03010904|Experimental|pasteurized milk|milk that has undergone pasteurization treatment
2483810|NCT03010904|Experimental|homogenized pasteurized milk|Milk that has undergone homogenization and pasteurization treatment
2483811|NCT03010904|Experimental|UHT milk|Milk that has undergone homogenization and ultra high temperature treatment
2483837|NCT03010657|Experimental|Experimental intervention|Subjects will add certain foods to what they normally eat.
2483840|NCT03010657|No Intervention|Non-experimental intervention|Subjects will continue eating normally.
2483842|NCT03010657|No Intervention|Observational|Subjects will continue eating normally.
2483881|NCT03010475|Experimental|Furosemide/Rosuvastatin/SNAC/Semaglutide|
2483939|NCT03010228|Active Comparator|VLA15 90 µg w/o Alum|VLA15 90 µg (microgram) without (w/o) Alum (aluminum hydroxide) has an injection volume of 750 µl (microliter).
2483287|NCT03014141|Active Comparator|Oat bran (Oatwell 28)|A beverage containing 11 gram (3 gram of oat beta-glucan) of Oat bran (Oatwell 28) will be consumed before breakfast
2483290|NCT03014141|Placebo Comparator|Maltodextrin|A beverage containing 11 gram of maltodextrin will be consumed before breakfast.
2483474|NCT03013231||s/p ACLR|Patients having undergone ACL Reconstruction Surgery with goal of returning to sport. 6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
3193550|NCT00819312|Active Comparator|Arm 1|
2483735|NCT03011619|Active Comparator|Control Condition|usual standard of care during an inpatient psychiatric hospitalization; medication management, group therapy, and individual therapy.
2483737|NCT03011619|Experimental|CBT Condition|If a patient is randomly assigned to the enhanced CBT group, they will participate in manualized CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
2483832|NCT03011112||KL 1|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 1 according to Kellgrence/Lawrence score.
2483833|NCT03011112||KL 2|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 2 according to Kellgrence/Lawrence score.
2483834|NCT03011112||KL 3|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 3 according to Kellgrence/Lawrence score.
2483835|NCT03011112||KL 4|All patients (>50 years) are classified to be Kellgrence/Lawrence grade 4 according to Kellgrence/Lawrence score.
3193551|NCT00819325|Experimental|Intensive glycemic control|Included routine use of pioglitazone (30 mg/d) for 6 months in addition to titration of their other oral hypoglycemic agents in order to get the HbA1c<6%.
3193552|NCT00819325|Active Comparator|conservative glycemic control|Included titration of oral hypoglycemic agents to get HbA1c<7% without the use of a thiazolidinedione.
3193553|NCT00819338|Active Comparator|polyunsaturated|5g per day of polyunsaturated fatty acids (3.5g EPA and DHA).
2483976|NCT03009968|No Intervention|Traditional backfill assisted voiding trial|Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. A post void residual (PVR) is measured after voiding (or attempt to void) using either an in and out catheter or a bladder scanner. The participant is considered to have passed the void trial if they have a PVR of less than 100 mL or less than half the voided volume if voided volume is greater than 200 mL.
2483981|NCT03009968|Experimental|Post-void residual free voiding trial|The post-void residual free voiding trial (intervention): Backfill the bladder with up to 300 ml as tolerated of normal saline or sterile water through an indwelling Foley catheter. The catheter is removed and the patient is given 15 minutes to void and the voided volume is measured. The participant is considered to have passed the void trial if they void more than 1/2 the instilled volume. A PVR will not be performed.
2484052|NCT03009435|Experimental|prophylactic manual rotation|"Only obstetricians will participate in the study. Manual rotation is performed at full dilatation.The technique employed will be at the discretion of the operator performing the procedure :~Tarnier and Chantreuil technique~or SOGC technique"
2484053|NCT03009435|No Intervention|expectative management|Expectative management . No manual rotation
2484094|NCT03009045|Experimental|Drug: 200mg oral Tedizolid|200mg oral tablet of tedizolid to be taken once daily
2484242|NCT03008187|Experimental|SEL24/MEN1703|"SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.~Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.~Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1."
2484291|NCT03007836|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484295|NCT03007836|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484342|NCT03007537|Placebo Comparator|control group|0.9% sodium chloride 1ml, subcutaneous injection, once, applied 1day before cardiac surgery
2484345|NCT03007537|Experimental|Erythropoietin group|10000 IU erythropoietin, subcutaneous injection, once, applied 1day before cardiac surgery
2484410|NCT03007017|Experimental|Arm 1|Patients selected for this arm will receive the left kidney from the new method of organ retrieval.
2484419|NCT03007017|Active Comparator|Arm 2|Patients selected for this arm will receive the normal standard of care operational kidney from retrieval.
2484457|NCT03006549|Experimental|Emergency Manual|emergency manual present
2484459|NCT03006549|No Intervention|No Emergency|NO emergency manual present
2484478|NCT03006315||Cohort A: <65 years|Cohort A will be comprised of participants <65 years old and will accrue a total of 20 patients.
2484479|NCT03006315||Cohort B: >/= 65 years|Cohort B will be comprised of participants >/= 65 years and will accrue a total of 20 patients.
2484562|NCT03006120||Group 1|Conservative management
2484567|NCT03006120||Group 2|Angiografic stenting
2484574|NCT03006120||Group 3|Surgery
2484629|NCT03005717|Experimental|Active High|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.2 mcg SX/mL Total Weekly Dose: up to 3.0 mcg SX
2484635|NCT03005717|Experimental|Active Low|Drug: LIPO 202 (Salmeterol Xinafoate for Injection), 0.02 mcg SX/mL Total Weekly Dose: up to 0.3 mcg SX
2484643|NCT03005717|Placebo Comparator|Placebo|Placebo for LIPO 202 (Salmeterol Xinafoate for Injection)
2484684|NCT03005132||Normal brain tissue|Normal brain tissue from GBM patients
2484686|NCT03005132||GBM tissues|GBM tissues from GBM patients
2484691|NCT03005132||Metastasis tissues|Metastasis tissues from GBM patients
2484772|NCT03004547||Chronic hemodialysis patients|Patients on standard in-centre 3 times a week hemodialysis
2483339|NCT03013998|Experimental|BAML-16-001-S2|"This is an open-label Phase 1b/2 clinical study of BI 836858 given in combination with azacitidine, followed by BI 836858 plus azacitidine maintenance, in newly diagnosed acute myeloid leukemia. The target population is assigned by the Beat AML Master Protocol (the umbrella study). Eligible patients will have previously untreated acute myeloid leukemia, age greater than or equal to 60, with any 1 of the following: mutated TET2, IDH1, IDH2, or WT1, or marker negative as defined by the overall Beat AML umbrella protocol."
2483341|NCT03013998|Experimental|BAML-16-001-S3|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of IDH2-mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH2 inhibitor AG-221 for IDH2 R140 and R172-mutant patients. The dosing will be based on phase 1 experience of AG-221, which has established 100 mg daily as a safe and tolerated dose, with preliminary suggestion of efficacy. These will be administered continuously in 28 day cycles. Hydroxyurea will be allowed for the purposes of cytoreduction.
2483343|NCT03013998|Experimental|BAML-16-001-S4 (Closed)|This is a 2 cohort phase 1b/2 clinical trial to assess the feasibility and efficacy of entospletinib (ENTO) stepwise approach to the treatment of patients with balanced translocations of MLL identified cytogenetically (Cohort 1) and patients with MLL-partial tandem duplications identified molecularly (Cohort 2). All enrolled participants will be initiated on monotherapy with ENTO 400 mg PO BID. This dose will be administered continuously in 28 day cycles.
2483345|NCT03013998|Experimental|BAML-16-001-S5 (Closed)|This is a phase 2 clinical trial to assess the feasibility and efficacy of a stepwise approach to the treatment of patients with TP53 mutations (identified molecularly) with/without complex karyotype (Cohort A) or complex karyotype (3 or greater metaphase abnormalities without TP53) (Cohort B). All enrolled participants will be initiated on entospletinib 400 mg orally twice daily. This dose will be administered continuously in 28 day cycles.
2483346|NCT03013998|Experimental|BAML-16-001-S6|The study is an open-label phase 2 study of entospletinib in younger and older AML patients with NPM1+/FLT3ITD-AML. It includes patients age ≥18 years who are able and willing to receive 7 + 3 intensive chemotherapy. Entospletinib is administered daily with IV daunorubicin (days 1-3 for Cycle 1) and cytarabine (days 1-7 for Cycle 1). If a second induction is required, it is given with IV daunorubicin (days 1-2 for Cycle 2) and cytarabine (days 1-5 for Cycle 2).
2483347|NCT03013998|Experimental|BAML-16-001-S9 (Closed)|This is an open-label phase 2 clinical trial of a stepwise approach to the treatment of patients with TP53 mutation AML. On day 1, all enrolled participants will be initiated on therapy with pevonedistat (20 mg/m2) day 1, 3 and 5 together with azacitidine (75 mg/m2 days 1-7 or day 1-5 then day 8, 9) every 28 days. During cycle 1, patients with rapidly progressive disease or severe organ dysfunction, not correctable by hydroxyurea cytoreduction will not be eligible to continue. Those patients who achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 4 will continue on pevonedistat and azacitidine until disease progression, unacceptable toxicity, or 12 cycles of therapy. After 12 months of combined therapy, pevonedistat will be continued until progression of disease, unacceptable toxicity, or up to 2 years of total therapy.
2483348|NCT03013998|Experimental|BAML-16-001-S16 (Closed)|This is an open-label phase 2 clinical study to assess the feasibility and efficacy of a combination based approach to the treatment of IDH1 mutant AML. On day 1 of the trial, all enrolled participants will be initiated on therapy with the IDH1 inhibitor AG-120 given daily together with azacitidine (days 1-5 and 8-9 or 7 consecutive days 1-7) in 28 day cycles for IDH1 mutant patients. Those patients who have achieved a response, defined as complete response or complete response with incomplete blood count recovery, by the end of cycle 6, will continue on combination therapy for a total of 12 cycles and then patients will go onto receive monotherapy with AG-120 until disease progression or unacceptable side effects that mandate discontinuation of therapy. Patients who cannot complete 12 cycles of azacitidine may proceed onto monotherapy with AG-120.
2483350|NCT03013998|Experimental|BAML-16-001-S8|This is an open-label Phase 1b/2 clinical study of gilteritinib monotherapy, gilteritinib in combination with decitabine, or gilteritinib in combination with decitabine and venetoclax in untreated FLT3 mutated AML with high and low variant allele frequency. Initially, the combination of gilteritinib and decitabine was tested (Group 1); however, subsequently the combination of decitabine and venetoclax was shown to be a highly effective therapy for older AML patients, so the triple combination of gilteritinib in combination with decitabine and venetoclax (Group 2) is now being evaluated in this study.
2483352|NCT03013998|Experimental|BAML-16-001-S10 (Closed)|This is a phase 1b/2 clinical trial to assess the safety and efficacy of the combination of AZD5153 and venetoclax. In a phase 1b component, safety and tolerability of the combination will be assessed in relapsed/refractory AML patients ≥ 18 years of age. Following determination of the recommended Phase 2 dose (RP2D), newly diagnosed, marker negative patients age ≥ 60 will be enrolled in the phase 2 component; these patients will be treated at the previously identified RP2D for the combination. The RP2D will be the highest dose level with ≤ 1 out of 6 patients with dose limiting toxicity and defined as the maximum tolerated dose.
2483353|NCT03013998|Experimental|BAML-16-001-S14|The study is an open-label Phase 1b/2 clinical study of TP-0903 given in addition to decitabine in patients ≥ 60 years with newly diagnosed, previously untreated AML with TP53 mutations and/or complex karyotype. The Phase 1b portion of this study will use a standard 3 + 3 design with dose escalation based upon dose limiting toxicities. The maximum tolerated dose will be defined as the highest dose where at most 1 patient in 6 experiences dose-limiting toxicity, and this is generally the recommended Phase 2 dose (RP2D). Once the RP2D is determined from Phase 1b, patients will be enrolled at this dose level to initiate the Phase 2 portion of the study.
2483354|NCT03013998|Experimental|BAML-16-001-S18|This is an open-label Phase 1b clinical study of AZD5991 + azacitidine in patients aged ≥60 years with newly diagnosed, previously untreated, hypermethylated and marker-negative AML. The phase 1b1 study will adopt a standard 3+3 design with dose escalation based upon dose limiting toxicities. The recommended Phase 2 dose (RP2D) is defined in this study as the highest dose level where less than 2 dose limiting toxicities (DLT) are observed out of 6 patients. Once the RP2D is defined, patients will be enrolled into 2 separate cohorts (hypermethylation and marker negative group) for the phase 1b2 expansion. These 2 groups will both be treated at the RP2D determined from phase 1b1.
2483504|NCT03013127|Experimental|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg i.v. every 3 weeks for up to 35 cycles
2483539|NCT03012659|Experimental|Intervention Arm|Full-day contraceptive counseling training for health center staff
2483542|NCT03012659|No Intervention|Control Arm|Usual care
2483361|NCT03014063||Hemodynamic non-responders|Those without a mean arterial pressure of at least 65mmHg and/or a decrease in catecholamine dose (in norepinephrine equivalents) from initiation of exogenous vasopressin therapy to the time of the sample collection used for analysis of plasma vasopressin concentration
2483471|NCT03013608|Experimental|relocation of nail plate|the simple relocation of the nail plate in nailbed injuries in paediatric population
3193554|NCT00819338|Placebo Comparator|monounsaturated|5g a day of oleic enriched sunflower oil
3193555|NCT00819351|Experimental|PEG-asparaginase 6 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
3193556|NCT00819351|Active Comparator|PEG-Asparaginase 2 weeks intervals|"PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (from week 13 after diagnosis to week 33).~All additional therapy (High Dose Methotrexate, Vincristin, Dexamethasone, 6-Mercaptopurine, doxorubicin, intrathecal chemotherapy) is the same in both arms."
3193557|NCT00819364|Experimental|1|Participants with autism will receive BCRI intervention program.
3193558|NCT00819364|Active Comparator|2|Participants with autism will receive standard care available in the community.
3193559|NCT00819377|Placebo Comparator|Normal saline|Normal saline by inhalation over 15 min
2483659|NCT03012074|Experimental|Patients with Type II Diabetes|Patients with Type II Diabetes
2483752|NCT03011606|Experimental|Robotic surgery|Single arm. All Registered patients will undergo robotic surgery
2483790|NCT03011086||oral sub mucous fibrosis|patients suffering with oral sub mucous fibrosis due to gutka/pan chewing confirmed by clinical examination
2483796|NCT03011086||control group|patients having gutka/ pan chewing habit without oral sub mucous fibrosis in oral cavity
3193560|NCT00819377|Active Comparator|Milrinone|Inhaled milrinone 5 mg(as for the injectable solution)
3193561|NCT00819416|Experimental|1|5% albumin
2483955|NCT03010046|Experimental|ANX005 Monotherapy|ANX005 intravenous infusion
2483960|NCT03010046|Experimental|ANX005 and IVIg Combination Therapy|ANX005 intravenous infusion in combination with intravenous immunoglobulin (IVIg)
2483963|NCT03010046|Placebo Comparator|Placebo|Placebo intravenous infusion
2484025|NCT03009682|Other|Olaparib 300 mg|Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days
2484082|NCT03009344|Experimental|tazemetostat 800 mg|Participants will receive oral tazemetostat at a starting dose of 800 milligrams (mg) as a single dose (Cycle 0) and 800 mg twice a day as continuous dosing (Cycle 1 and later).
2484176|NCT03008850|Active Comparator|Group M|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally
2484177|NCT03008850|Active Comparator|Group P|2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally
2484219|NCT03008421|Experimental|Study group (GBS positive w/o infection)|Treatment with study medication twice daily for 2 weeks (from study visit 1 to study visit 2)
2484220|NCT03008421|Placebo Comparator|Placebo group (GBS positive w/o infection)|Treatment with placebo twice daily for 2 weeks (from study visit 1 to study visit 2)
3193562|NCT00819416|Other|2|Normal saline
2484445|NCT03006757|Experimental|Column titanium dioxide|patient take titanium dioxide denture participants will receive titanium dioxide denture ( made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial.
2484446|NCT03006757|Experimental|column placebo|patient will take denture with conventional acrylic ( 20 minutes cure ) for 1 month in the initial phase
2484488|NCT03006419|Active Comparator|Group A (Basiliximab group)|Basiliximab (Simulect) induction therapy: 20 mg IV at day of transplant (to be administered 2 hours prior to transplant and up to 4 hours after transplant) and second dosage (20 mg) at fourth day after kidney transplantation.
2484493|NCT03006419|Experimental|B (Low-dose Thymoglobulin group)|Thymoglobulin induction therapy (1 mg/kg rounded by 25 mg increments) at day of transplant followed by same dosage (1 mg/kg rounded by 25 mg increments) during day 1 and day 2 after transplant in order to complete 3 mg/kg accumulated dose.
2484599|NCT03005756|Experimental|Robot-assisted Radiofrequency Ablation|CT-guided radiofrequency ablation of hepatocellular carcinoma using needle guiding robot
2484640|NCT03005457|Experimental|Stroke|
2484646|NCT03005457|Experimental|Hemiparesis other|
2484679|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later).~Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU.~Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
2484682|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred."
2484735|NCT03004885|Experimental|Minimal Distension|Tidal volume 4 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) + ECCO2R
2484738|NCT03004885|Experimental|Maximal Recruitment|Tidal volume 4 ml/kg PBW and PEEP adjusted to maintain plateau pressure between 23 - 25 cmH2O + ECCO2R
2484740|NCT03004885|Active Comparator|Standard|Tidal volume 6 ml/kg PBW and PEEP based on the ARDSNet PEEP/FiO2 table (ARMA) without ECCO2R
2485804|NCT02997579|Experimental|patellar resurfacing|patellar resurfacing TKA
2483372|NCT03013907|Active Comparator|Usual Care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study for the UC group and outside of the study (for the intervention group) will be assessed at each time point.
2483437|NCT03013504|Experimental|HD201 in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2-8), followed by surgery, then adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, and subsequent 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
2483443|NCT03013504|Active Comparator|Herceptin® in combination with docetaxel|"8 mg/kg i.v. loading dose over 90 mins in Cycle 1 and 6 mg/kg i.v. dose every 3 weeks over 60 mins then 30 mins for subsequent cycles (cycles 2 -8) for cycles 2-8, followed by surgery, and subsequent adjuvant period of 8mg/kg i.v. loading dose over 90 mins in cycle 9, then 6mg/kg (if therapy is missed by >1 week, a re-loading dose of 8mg/kg should be given) over 30 mins for subsequent 9 cycles (cycles 10-18), disease progression, unacceptable toxicity, non-compliance, or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever occurs first.~Neoadjuvant chemotherapy:~Cycles 1-4: Docetaxel 75 mg/m² on day 1 of each 3-weeks cycle via 1h i.v. Infusion Cycles 5-8: EC on day 1 of each 3-weeks cycle: Epirubicin 75 mg/m² via 3-30 mins i.v. Infusion, Cyclophosphamide 500 mg/m² via 3-30 mins i.v. Infusion"
3193563|NCT00819429|Experimental|1|"Omega-3 + Standard treatment~Children in this group will be given 400 mg of DHA and 600 mg of EPA. Caregivers will be instructed to give two 500mg Omega-3 capsules twice a day, at breakfast and at the evening meal for 6 months. Parents will be seen by the attending on a monthly basis for standard treatment procedure."
2483656|NCT03012113|Other|Short term mild cooling|Subjects will undergo a short term mild cooling protocol consisting of personalized water cooling method for approximately 2 hours.
2483661|NCT03012113|Active Comparator|Mirabegron|Subjects will receive one dosage of 200 mg Mirabegron (Astellas Pharma).
2483668|NCT03012113|Placebo Comparator|Placebo|Subjects will receive one dosage of Placebo, which is packed and labeled to mach the active compound.
2483730|NCT03011489|Experimental|Vacuum formed aligners group|This group will receive Vacuum formed aligners in addition to taping for 3 Months with follow-up every 1-2 weeks
2483733|NCT03011489|No Intervention|control group|This group will not receive any treatment
2483772|NCT03011190|Experimental|Iconic Therapy|The Iconic Therapy program consists of two parts: a) an intensive program of 10-12-week basic skills group 60-minute duration with a range of 6 to 8 face-to-face inserted sessions and b) an additional one-year program of 4 to 6 gradually less frequent face-to-face sessions. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients. Added to these established sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
2483776|NCT03011190|Active Comparator|Support therapy|Support therapy consist of 10-12 weekly group sessions of 60-minute duration. Patients and trainers will learn and debate about different behavioral aspects of the borderline personality disorder: emotional instability and impulses control, Jacobson relaxation technique, self-image and communicational styles, mindfulness, self-esteem or social skills to name a few. The groups are typically lead by two trainers -therapist and co-therapist- for about 8-12 outpatients.Added to these established group sessions, a variable number of face-to-face individual sessions with the principal investigator will also take place. They will depend on participant´s requirements. They will consist on coaching their demands and providing human support throughout the study.
2483807|NCT03010891|Active Comparator|control condition|Preterm infants in the control condition will receive only usual NICU care, plus positioning and gentle touch during intrusive procedures.
2483809|NCT03010891|Experimental|experimental condition|The bundle of supportive interventions will be designed to alleviate preterm infants' stress/pain from birth to discharge from the hospital NICU.
3193564|NCT00819429|Experimental|2|"Social skills + Omega-3 placebo + Standard treatment~Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months. They will also undergo a manualised group social problem solving skills training protocol of 12 weekly 1-hour sessions (Ang & Ooi, 2003a, 2003b). There will be booster sessions scheduled at 3-week intervals after the initial treatment period of 12 weeks, for a total of 4 booster sessions."
3193565|NCT00819429|Experimental|3|"Omega-3 + Social skills + Standard treatment~Children in this group will receive omega-3 supplement and social skills training on top of standard treatment. Procedures for administration of Omega-3 supplement are similar to those stated in (1) and (2)."
2484043|NCT03009513|Experimental|single arm|
3193566|NCT00819429|Placebo Comparator|4|"Omega-3 placebo + Standard treatment.~Children in this group will receive placebo as well as a course of the standard treatment. Procedure for administering the placebo capsules is similar to that outlined in (2)."
3193567|NCT00819442|Placebo Comparator|1|patients without heart failure, with cardiobiopsy
2484148|NCT03008668|Experimental|experimental group: Acupuncture|acupuncture on 5 most sensitized points/ acupoints
2484158|NCT03008668|Active Comparator|Control group: Acupuncture|acupuncture on 5 least low/non-sensitized points
2484193|NCT03008512|Experimental|Genexol-PM|Genexol-PM 100 mg/m2 intravenously for 1 hour on days 1, 8, and 15 of a 28-day cycle up to 8 cycles. Patients will receive study treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
3193568|NCT00819442|Experimental|2|patients with heart failure in NYHA class I, II
3193569|NCT00819442|Experimental|3|Patients with heart failure in NYHA class III, IV
3193570|NCT00819455|Active Comparator|2|In person lifestyle advice at baseline, 6, 12, 18 months.
2483415|NCT03013439|Experimental|cohort 3 iron isomaltoside|treated with third dose level of iron isomaltoside
2483416|NCT03013439|Experimental|cohort 4 iron isomaltoside|treated with fourth dose level of iron isomaltoside
2483460|NCT03013179||Black/African American Women and their 3-5 year old children|
2483508|NCT03012984|Experimental|Dexmedetomidine group|Dexmedetomidine supplemented morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2483509|NCT03012984|Placebo Comparator|Control group|Morphine analgesia will be provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), diluted with normal saline to a total volume of 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
2483553|NCT03012503|Placebo Comparator|Control|Five minutes before cervical manipulation, controls received a placebo gel applied to their neck.
2483554|NCT03012503|Experimental|Treatment|Five minutes before cervical manipulation the treatment group received a menthol containing gel (Biofreeze®) applied to their neck.
2483663|NCT03011944||Quality Improvement Program|This group will consist of hospitalized and SNF, at-risk/malnourished patients being discharged to home health and outpatients at-risk/malnourished patients enrolled in home health.
2483669|NCT03011944||Control|This group will consist of historical controls, concurrent controls, and matched concurrent controls across other sites within the health system.
2483706|NCT03011554|Experimental|Implantable Miniature Telescope (IMT)|Intervention: Implanting the Implantable Miniature Telescope (IMT) in pseudophakic eyes of patients suffering from binocular end-stage AMD.
2483813|NCT03011008|Experimental|Liraglutide + insulin|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
2483815|NCT03011008|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
2483845|NCT03010605|Active Comparator|Standard of care physical therapy|Patients will receive 2 weeks of in-home physical therapy consisting of 3 sessions per week followed by 4 weeks of outpatient physical therapy three times weekly.
2483847|NCT03010605|Active Comparator|MED Device|Patients will perform 10 repetitions with the MED device 3 times daily at 8am, 2pm, and 8pm and will transmit the 10th measurement of each time point to the clinicians office.
2483915|NCT03010384|Active Comparator|Intervention|Consultation with a physician specialized in social medicine. The consultation lasted about one hour. Together with the patient a return-to-work (RTW) schedule was made to ascertain the need for contact to the workplace (to adjust work functions), municipality, general practitioner or short-term supportive consultations with a psychologist. If relevant, patients were offered up till 5 sessions with a psychologist.
2483916|NCT03010384|No Intervention|Control|Standard treatment from the Department of Rheumatology
2483950|NCT03009981|Active Comparator|Arm A: Degarelix Monotherapy OR Leuprolide/Bicalutamide|Patients will receive degarelix OR leuprolide with bicalutamide.
2483954|NCT03009981|Experimental|Arm B: Degarelix/Apalutamide|Patients will receive apalutamide and either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
2483956|NCT03009981|Experimental|Arm C: Degarelix/Apalutamide/Abiraterone/Prednisone|Patients will receive apalutamide and abiraterone acetate, in addition to either degarelix OR leuprolide. Patients on this arm will NOT take bicalutamide at any point in the treatment course.
2484090|NCT03009071|Experimental|Doin with Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels). Cervical Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise (rotation) as needed.
2484093|NCT03009071|Active Comparator|Acupuncture|An acupuncture physician will administer acupuncture at 6-12 acupoints in the upper and middle trapezius area (mandatory points: both SI15, TE15, and LI16; and selective points: GB20, BL10, GV14, SI14, and Hyeopcheok (Huatuo Jiaji, EX B2) points at C3-5 levels).
2484134|NCT03008694|Experimental|1|PET/CT
3193571|NCT00819455|Experimental|1|In person lifestyle advice at baseline, 6, 12, 18 months. Receive reminders by internet based, mobile phone text messaging (Frequency, time and number(s) of messages according to participants requirement)
2484312|NCT03007771|Experimental|MR-HIFU|"Philips 1.5T MRI scanner equipped with a Sonalleve V2 HIFU system will be used~Will be scanned in the MRI in 1 or more positions to the extremities and/or pelvis while aligned to the HIFU system. The HIFU device will then be used to apply sub-clinical levels (≤ 41°C) of heat to one or more small volumes. Regions will be heated to the desired temperature for variable short durations of time not exceeding 30 minutes.~After the session is complete, the patient will be removed from the MR-HIFU system and, following a 15-30-minute period of monitoring for any adverse events, allowed to leave.~Before the scan, after the scan and 5-10 days following the scan, participants will be asked to rate any pain, discomfort, in the area to be heated, as well as any anxiety or claustrophobia on a scale of 1-10 with 1 being minimal/none and 10 being extreme. The skin area to be treated will also be reviewed for any redness/discoloration."
2484364|NCT03007329|Active Comparator|Dapagliflozin & Exenatide|Dapagliflozin 10mg orally once daily & Exenatide 2mg subcutaneous once weekly
2484365|NCT03007329|Placebo Comparator|Dapagliflozin & Placebo|Dapagliflozin 10mg orally once daily & Exenatide matching Placebo 2mg subcutaneous once weekly
2484436|NCT03006952|Active Comparator|pentoxifylline & losartan|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
2483534|NCT03012815|Experimental|Gabapentin|Patients will receive gabapentin taper over 9 days with the option to add divalproex for patients who have a history of seizures or severe withdrawal. Will still undergo CIWA-Ar scoring but will not be administered a benzodiazepine.
2483536|NCT03012815|Active Comparator|Benzodiazepine|Patients will receive a benzodiazepine if scoring greater than 9 on the CIWA-Ar scale.
2483594|NCT03012243|Active Comparator|Cholecystostomy|Percutaneous cholecystostomy, leaving drain in situ
2483597|NCT03012243|Experimental|Gallbladder aspiration|Gallblader aspiration without drain
2483674|NCT03011866|Experimental|Experimental|"Loading dose: 100ml 0.9% normal saline(NS) intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 5ml/hr 0.9% NS intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 500mg TXA in 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
2483676|NCT03011866|Other|Control|"Loading dose: 10mg/kg tranexamic acid(TXA) in 100ml 0.9% NS intravenous infusion, 15-20min prior to operation initiation.~Maintenance dose: 1mg/kg/hr TXA intravenous infusion till the last suture. Bolus dose: the wound topically irrigated with 250ml 0.9% NS for 5min. Waste fluid was then removed by suction, and the wound was closed."
2483695|NCT03011502|Experimental|Experimental arm|
2483787|NCT03011255|Experimental|peptide specific CTL arm|peptide specific CTL, radiation
2483846|NCT03010826||40 Demyelinating Disease patients|
2483848|NCT03010826||40 Non-patient participants|
2483952|NCT03010072|Active Comparator|low-dose sucroferric oxyhydroxide|Low dose 250 mg sucroferric oxyhydroxide (PA21) per day (1x 250mg tablets/day) for 14 days.
2483958|NCT03010072|Active Comparator|high-dose sucroferric oxyhydroxide|Uniform dose 2000 mg of sucroferric oxyhydroxide (PA21) per day (4x 500mg tablets/day) for 14 days
2484059|NCT03009422|Experimental|Treatment|CO2 fractional laser with local application of Pentostam
2484068|NCT03009422|Active Comparator|control|Intra-lesinal Pentostam injedction
2484126|NCT03008902||Non-patients|Non-patients, who have not had vertebral fractures or hyperkyphosis, and have not been seen at BIDMC, will be recruited from the community as described in section B3C and B6 below. The non-patient group will consist of 16 healthy adults ages 18-40.
2484129|NCT03008902||Patients|Patients, who have been seen at BIDMC for vertebral fractures or hyperkyphosis, will be identified by review of medical records as described in B3C and B6 below. The patient group will consist of 32 adults ages 75 and older who have previously been diagnosed with a thoracic vertebral fracture at BIDMC.
2484204|NCT03008629|Experimental|Podofix nail brace|for mild ingrown toenails
2484206|NCT03008629|Experimental|Combiped nail brace|for Severe dystrophic ingrown toenails
2484208|NCT03008629|Experimental|Podofix and then Combiped nail brace|for Ingrown toenails with pyogenic granuloma
2484252|NCT03008161|Experimental|Cohort 1|Participants will receive monthly IV infusions of either low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
2484253|NCT03008161|Experimental|Cohort 2|Participants will receive monthly IV infusions of either mid-low dose NPT088 (6 participants) or placebo (3 participants) for a total of 6 months
2484254|NCT03008161|Experimental|Cohort 3|Participants will receive monthly IV infusions of either mid-high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
2484255|NCT03008161|Experimental|Cohort 4|Participants will receive monthly IV infusions of either high dose NPT088 (16 participants) or placebo (8 participants) for a total of 6 months
2484319|NCT03007368|Experimental|Rice|Cooked white rice and tomato-based sauce
2484321|NCT03007368|Experimental|Potato|Cooked white peeled potato and tomato-based sauce
2484324|NCT03007368|Experimental|Pasta|Cooked macaroni product and tomato-based sauce
2484328|NCT03007368|Experimental|Sorghum thick porridge|Sorghum thick porridge and tomato-based sauce
2484333|NCT03007368|Experimental|Millet thick porridge|Millet thick porridge and tomato-based sauce
2484336|NCT03007368|Experimental|Millet couscous|Cooked millet couscous and tomato-based sauce
2484340|NCT03007368|Experimental|Millet thin porridge|Millet thin porridge
2484348|NCT03007368|Experimental|Millet thin monikuru porridge|Millet thin porridge containing cooked millet granules (monikuru)
2484409|NCT03006978|Experimental|TearCare|Subjects will receive a 12-minute treatment session with the TearCare System followed by manual expression of the meibomian glands.
2484412|NCT03006978|Active Comparator|Warm Compress|Subjects will apply a warm compress to the eyelids for 5 minutes daily for 4 weeks.
2484471|NCT03006614|Experimental|PERS:NVB,DDP,GEM,CAP,H etc.|vinorelbine 25mg/m2 d1,d8 iv,q3w cisplatin 70mg/m2 d1，q3w gemcitabine 1000mg/m2 d1,d8,q3w capecitabine 1000mg/m2,bid,d1-14,q3w Trastuzumab
2484472|NCT03006614|Active Comparator|EPI+CTX-T+/-H|Epirubicin 90mg/m2 d1+ CTX 600mg/m2 d1 q2w, Docetaxel 75mg/m2 +/-herceptin d1,q3w
3159189|NCT00401011|Experimental|Phase I: Dose 3: Perifosine + Bortezomib|Perifosine 50 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
3159190|NCT00401011|Experimental|Phase I: Dose 4: Perifosine + Bortezomib|Perifosine 100 mg at bedtime and bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks
3159191|NCT00401024|Experimental|Treatment|Imatinib mesylate 600mg orally once a day for seven consecutive days prior to surgery with last dose taken one day prior to surgery
3159192|NCT00401063|Other|Single arm|Acupuncture treatment
3159193|NCT00401076|Experimental|1|
3159194|NCT00401089|Experimental|Ginsana-115|Ginsana-115 (Panax Ginseng formulation obtained from Boehringer Ingelheim Pharmaton Inc. Switzerland )is available in oral dosage form of capsules. Two dosages of Ginsana-115 will be tested: 100 mg once daily oral dosage ( 1 100-mg Ginsana-115 capsule) and 200 mg once daily dosage ( 2 100-mg Ginsana-115 capsule). The total duration of each dosage is 8 weeks.
3159195|NCT00401089|Placebo Comparator|Sugar Pill|Placebo capsules formulated identical to the active drug: Ginsana-115 are to be obtained from Boehringer Ingelheim Pharmaton, Switzerland. Two dosages of Placebo capsules will be administered once daily for 8 weeks : a) Placebo 100 mg capsule: 1 placebo capsule daily; b) Placebo 200 mg capsule: 2 placebo-capsule daily
3159196|NCT00401115|Experimental|1|Subconjunctival injection
3159197|NCT00401115|Experimental|2|Intraocular injection
3159198|NCT00401154|Experimental|Intervention Stationary Cycling|Subjects receiving the intervention performed stationary cycling 3 times a week for 30 sessions over 12 weeks.
2483566|NCT03012256|Experimental|Cardio-respiratory management model|Additional home care management includes medication reconciliation, self-care education, advanced care planning, as well as physician communication and transfer protocols
2483568|NCT03012256|No Intervention|Control|Home care (standard of care)
2483646|NCT03012100|Experimental|Arm I (FRalpha peptide vaccine, sargramostim)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of cycle 1 only. Starting cycle 2, patients receive multi-epitope folate receptor alpha peptide vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
2483653|NCT03012100|Placebo Comparator|Arm II (placebo, sargramostim)|Patients receive cyclophosphamide as in Arm I. Starting cycle 2, patients receive placebo vaccine with sargramostim ID on day 1. Treatment repeats every 28 days for cycles 2-7 and every 6 months for cycles 8-14 in the absence of disease progression or unacceptable toxicity.
2483823|NCT03010930|Experimental|Increased exposure to MSG|Subjects consume vegetable broth daily containing MSG
2483826|NCT03010930|Sham Comparator|No change in exposure to MSG|Subjects consume low glutamate vegetable broth daily, sodium-matched to the broth of the experimental group with NaCl
2484023|NCT03009812|Active Comparator|Group 1|26 subjects who are planned for transverse uterine incision
2484027|NCT03009812|Active Comparator|Group 2|26 subjects who are planned for longitudinal uterine incision
2484083|NCT03009318|Other|MRS imaging and 11C-MET PET/CT|Each patient underwent both MRS and MET PET before surgery.
3159199|NCT00401232|Other|Arm 1|
3159200|NCT00401310|Placebo Comparator|1|Placebo
2484223|NCT03008408|Experimental|Arm I (ribociclib, everolimus, letrozole)|Patients receive ribociclib PO QD, everolimus PO QD, and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2484224|NCT03008408|Experimental|Arm II (everolimus, letrozole)|Patients receive everolimus PO QD and letrozole PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2484329|NCT03007576|Experimental|RegStem|Autologous MSC, 5×10^7 cells, one injection
2484499|NCT03006510|Active Comparator|Alert|If glucose <90 mg/dl and hypoglycemia prediction score >35, then alert with suggestion for intervention sent to treating team
2484506|NCT03006510|No Intervention|No alert|Routine standard care. If glucose <90 mg/dl and hypoglycemia prediction score >35, then report for investigators will be collected, but no active alert will be sent to teams.
2484573|NCT03006081|Experimental|2mg intravitreal aflibercept injection|2mg intravitreal aflibercept (Eylea) injection at baseline, 1M, 2M, 3M, 4M, and 5M
2484661|NCT03005613|Active Comparator|sacrospinous ligament fixation group|The patients will receive sacrospinous ligament fixation operation.
2484664|NCT03005613|Experimental|ischial spine fascia fixation group|The patients will receive ischial spine fascia fixation operation.
2484773|NCT03004703|Experimental|Active drug|Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
2484777|NCT03004703|Placebo Comparator|Placebo|Sodium chloride 0.9%; 100 ml i.v. once.
2484827|NCT03004287|Experimental|Study Treatment|"Induction Chemotherapy: Carfilzomib, Thalidomide, Dexamethasone, Daratumumab , CisPlatin, Adriamycin, Cyclophosphamide and Etoposide (KTD-Dara-PACE).~Autologous Stem Cell Transplant (ASCT) 1: Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 1: Daratumumab.~Consolidation 1: Daratumumab, Carfilzomib, Dexamethasone (Dara-KD).~ASCT 2 (optional): Melphalan, Dexamethasone, ASCT.~Immunological Consolidation 2: Daratumumab.~Maintenance: Dara-KD alternating with Daratumumab, lenalidomide, and Dexamethasone (Dara-RD) in 3-month blocks.~Bortezomib may be substituted for carfilzomib throughout the regimen at the discretion of the treating physician."
3159201|NCT00401310|Experimental|2|MK0724
2484978|NCT03003208|Other|Pulmonary rehabilitation|
2485003|NCT03002987|Active Comparator|Intervention, education|Education of leaders (3 hours) in how to implement Active Pregnancy policy at their departements/workplaces
2485007|NCT03002987|No Intervention|control|as usual
2485064|NCT03002649|Experimental|Tofacitinib|All subjects will be provided Tofacitinib 11mg tablets for oral administration once daily. 12-week treatment period with optional 4-week treatment extension period.
3159202|NCT00401323|Experimental|docetaxel plus cisplatin|Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
2485247|NCT03001323|Experimental|Degludec|Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
3159203|NCT00401323|Active Comparator|cisplatin plus 5-FU|Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
3159204|NCT00401323|Experimental|docetaxel plus 5-FU|"Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5~Arm only in the phase II part of the study"
3159205|NCT00401336|Experimental|Magnetic Resonance Imaging|New magnetic resonance imaging multiecho gradient-echo sequence
3159206|NCT00401362|Experimental|Arm 1|
3159207|NCT00401362|Placebo Comparator|Arm 3|
3159208|NCT00401362|Experimental|Arm 2|
3159209|NCT00401388|Experimental|Group A: chondrosarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
3159210|NCT00401388|Experimental|Group B: alveolar soft part sarcoma|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of alveolar soft part sarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
3159211|NCT00401388|Experimental|Group C: extra-skeletal myxoid|"Patients with sarcoma subtype: histologically or cytologically confirmed diagnosis of extra-skeletal myxoid chondrosarcoma.~Supportive Care Guidelines for perifosine include antiemetic prophylaxis (antiemetics will be administered at the treating investigator's discretion), diarrhea management (loperamide), and hyperuricemia prophylaxis (allopurinol)."
2483569|NCT03012269|No Intervention|Non-Working Memory Training|The subjects of control group performed traditional cognitive rehabilitation without working memory training, 30 min for 5 days per week during 6 weeks.
2483616|NCT03012126|Experimental|Clinically Based: Healthy Weight Clinic|All families referred to the Healthy Weight Clinic intervention arm will be scheduled for a 30-45 minute orientation clinic visit to orient the child and family to the program. During this visit, the family will meet with the community health worker who will provide a schedule of clinic visits and dietitian contacts. The community health worker will assess the child's social and environmental context to allow treatment tailoring. For the first 6 months, each family will be asked to attend two clinic visits per month and complete weekly 20-30 minute contacts with the dietitian via telephone. The program aims to deliver approximately 30 contact hours in the 6-month period. This will be followed by monthly visits to the Healthy Weight Clinic and monthly calls with their dietitian.
2483617|NCT03012126|Experimental|Community Based: Healthy Weight & Your Child|All families referred to the Healthy Weight and Your Child intervention arm will be scheduled for a 60-minute family information session to orient the child and family to the program. During this visit, the family will receive information about the program and logistics such as program schedule and format and attendance. The program is delivered over 12 months, which includes 16 weekly sessions, followed by 4 sessions delivered every other week and concluding with 5 monthly sessions. Most sessions are 2 hours in length and include a group of about 8-15 children and their caregivers. The first hour is delivered in a classroom setting and the second hour in an additional area conducive for physical activity.
2483651|NCT03011736|Experimental|Supportive Care (parathyroidectomy)|Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery.
2483711|NCT03011567|Experimental|Severe HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
2483716|NCT03011567|Experimental|Mild HDP- NSAID|This arm will be assigned a postpartum analgesic regimen with ibuprofen.
2483718|NCT03011567|Experimental|Severe HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
2483725|NCT03011567|Experimental|Mild HDP- No NSAID|This arm will be assigned a postpartum analgesic regimen with acetaminophen.
2483874|NCT03010540|Experimental|Morphine Plus Fentanyl|
2483875|NCT03010540|Active Comparator|Fentanyl only|
2483927|NCT03010215|Other|Minimally Invasive Surgery (MIS)|Patients with plantar chronic diabetic foot ulcers will be treated by Distal Metatarsal Minimally invasive Osteotomy (DMMO).
2484002|NCT03009916|Other|Healthy controls|Healthy controls found according to the protocol
2484003|NCT03009916|Other|Patients with BAM|Patients with bile acid malabsorption found according to the protocol
2484057|NCT03009448||Late onset depression|
3159212|NCT00401440|Active Comparator|A|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
3159213|NCT00401440|Active Comparator|B|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
2484277|NCT03008057|Active Comparator|vitamin D supplementation|patients with type 2 diabetes receive 1 tablet (4000 IU ) vitamin D supplementation, one time a day, for 3 months.
2484280|NCT03008057|Placebo Comparator|vitamin D placebo|patients with type 2 diabetes receive one tablet of vitamin D placebo for 3 months
2484344|NCT03007602|Experimental|Treatment group: aerobic exercise|The upper extremity aerobic exercise training with an arm ergometer will be performed in the treatment group so that training intensity will be between 60% and 80% of the maximum heart rate, dyspnea perception will be 3-4 according to Modified Borg Scale and fatigue perception will be 5-6 according to Modified Borg Scale, training duration will be a 6-week.
2484349|NCT03007602|No Intervention|Control group: deep breathing exercise|Deep breathing exercises combinated with arm movements will be given as a home schedule in the control group. Training duration will be a 6-week.
2484385|NCT03007147|Experimental|Arm A (imatinib mesylate, EsPhALL chemotherapy)|See Detailed Description
2484386|NCT03007147|Experimental|Arm B (imatinib mesylate, COG/BFM chemotherapy)|See Detailed Description.
2484387|NCT03007147|Experimental|Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)|See Detailed Description
2485143|NCT03002155|Experimental|Exercise|EnhanceFitness exercise class, 1 hour, 3 times a week, duration of 12 weeks.
2485144|NCT03002155|No Intervention|Control|Usual care.
3159214|NCT00401466|Experimental|1|Prolonged follow-up intervals every 12 months
3159215|NCT00401466|Active Comparator|2|Standard follow-up intervals of 3 months
3159216|NCT00401570|Experimental|Cohort 1|Volociximab (10 mg/kg every other week (qowk)) and Gemcitabine
3159217|NCT00401570|Experimental|Cohort 2|Volociximab (15 mg/kg weekly (qwk)) and Gemcitabine
3159218|NCT00401583|Experimental|Pazopanib receivers|During Days 1 and 2 subjects will be dosed with only probe drugs, and with no drugs on Days 3-5. During Days 6 to the end of the study, subjects will receive 800 mg daily pazopanib, and on Days 23-24 subjects will receive probe drugs in addition to pazopanib
3159219|NCT00401661|Experimental|1|Alfuzosin for 24 weeks
3159220|NCT00401674|Experimental|SINGLE ARM|
3159221|NCT00401739|Experimental|I|Treatment with CSL360
3159222|NCT00401765|Experimental|Cohort 1A (Docetaxel and CNTO 328)|In cohort 1A, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel every 3 weeks and 6 mg/kg CNTO 328 every 2 weeks will be administered in the treatment phase.
3159223|NCT00401765|Experimental|Cohort 1B (Docetaxel and CNTO 328)|In cohort 1B, 6 mg/kg CNTO 328 will be administered in run-in phase and 75 mg/m2 docetaxel will be administered every 3 weeks plus 6 mg/kg CNTO 328 will be administered every 2 weeks in the treatment phase.
3159224|NCT00401765|Experimental|Cohort 2 (Docetaxel and CNTO 328)|In cohort 2, 75 mg/m2 docetaxel will be administered in run-in phase and 75 mg/m2 docetaxel plus 9 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
3159225|NCT00401765|Experimental|Cohort 3 (Doctaxel and CNTO 328)|In cohort 3, 75 mg/m2 docetaxel will be administered in the run-in phase and 75 mg/m2 docetaxel plus 12 mg/kg CNTO 328 will be administered every 3 weeks in treatment phase.
3159226|NCT00401791|Experimental|1|
3159227|NCT00401791|No Intervention|2|
3159228|NCT00401856|Experimental|1|This arm will receive eplerenone
3159229|NCT00401856|Placebo Comparator|2|This group will receive the placebo
3159230|NCT00401895|Active Comparator|1|patients treated with 10 mm stent
3159231|NCT00401895|Active Comparator|2|patients treated with 8 mm stent
3159232|NCT00401921|Placebo Comparator|Minocycline arm|Minocycline 100mg/Placebo 0mg Minocycline 100mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
2483932|NCT03010124|Other|Patients with ovarian cancer|
2483997|NCT03009877|Active Comparator|Preoxygenation with face mask|Standard preoxygenation with a mask will be performed for five minutes. Once preoxygenation is complete, patients will be induced with standard induction medications including lidocaine, midazolam, fentanyl and propofol. Once the patient is apneic, one breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. The 5.5mm flexible intubation scope will be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope. Once the flexible intubation scope is in the trachea, the endotracheal tube (7.0 mm unless otherwise specified) will be advanced. Ventilation will not begin until the primary or secondary endpoints are reached.
2483999|NCT03009877|Experimental|Preoxygenation via hi flow nasal cannula|The high flow nasal cannula (Optiflow) will be applied as soon as the patient is in the operating room. The patient will be preoxygenated with high flow nasal cannula at 50 L/min for 5 minutes. After induction, general anesthesia will be maintained with a propofol infusion. One breath will be given via facemask to confirm ventilation and then 0.6 mg/kg of rocuronium will be administered. Upon apnea, the Optiflow™ flow will be increased to 70 L/min and jaw thrust will be performed until the patient is adequately relaxed. The video laryngoscope (C-MAC) will then be introduced into the oropharynx and the flexible intubation scope advanced into the trachea with the assistance of the C-MAC. Once the flexible intubation scope is in the trachea, the endotracheal tube will be advanced.
2484049|NCT03009487|Experimental|Amlodpine, Olmesartan, Rosuvastatin|co-administration of Olmesartan, Amlodipine and Rosuvastatin
2484050|NCT03009487|Placebo Comparator|Olmesartan, Rosuvastatin|co-administration of Olmesartan and Rosuvastatin
2484051|NCT03009487|Placebo Comparator|Amlodipine, Olmesartan|co-administration of Amlodipine and and Olmesartan
2484097|NCT03009058|Experimental|IMM-101 + Gem panc ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2484098|NCT03009058|Experimental|IMM-101+Gem/nab-paclitaxel panc ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484099|NCT03009058|Experimental|IMM-101+Gem+capecitabine panc ca|"IMM-101 will be given in combination with gemcitabine +capecitabine combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484305|NCT03007784|Active Comparator|0.2 mA anodal tDCS stimulation|Anodal tDCS stimulation at 0.2 mA applied to the left dorsolateral prefrontal during 20 minutes five days a week for two consecutive weeks
2484591|NCT03005873|Placebo Comparator|Placebo group|1.5 mL normal saline
3159233|NCT00401921|Placebo Comparator|Placebo arm|Placebo 0mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
3159234|NCT00402012|No Intervention|1|
3159235|NCT00402012|Experimental|2|
3159236|NCT00402038|Experimental|Arm 1|
3159237|NCT00402038|Placebo Comparator|Arm 2|
3159238|NCT00402077|Experimental|1|
3159239|NCT00402077|Experimental|2|
3159240|NCT00402077|Experimental|3|
3159241|NCT00402077|Placebo Comparator|4|
3159242|NCT00402142|Active Comparator|Pulsed dendritic cells untreated patients|Untreated patients receiving a dendritic cell based vaccine pulsed with autologous heat iactivated virus
3159243|NCT00402142|Placebo Comparator|non pulsed dendritic cells untreated patients|
3159244|NCT00402142|Active Comparator|pulsed dendritic cell treated patient|treated patients will be immunized with a dendritic cell vaccine pulsed with heat inactivated autologous virus immediately before art interruption
3159245|NCT00402142|Active Comparator|pulsed dendritic cell in treated patients|patients will be immunized with a dendritic cell vaccine pulsed with heat inactivted autologous virus immediately after interruption of art
3159246|NCT00402142|Placebo Comparator|non pulsed dendritic cells|
3159247|NCT00402155||1|Normal subjects
3159248|NCT00402155||2|Reading discomfort subjects
3159249|NCT00402181|Experimental|Treatment Plan A|Siltuximab 6 milligram per kilogram (mg/kg) as intravenous (directly into the vein) infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days (if participant have complete or partial response) along with dexamethasone (starting from Cycle 2, If participant do not have complete or partial response) 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles.
3159250|NCT00402181|Experimental|Treatment Plan B|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks along with dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles (duration of each cycle is 28 days) after that on Day 1 to 4 up to 12 cycles.
3159251|NCT00402220|Active Comparator|1|active TMS
3159252|NCT00402220|Placebo Comparator|2|Sham TMS
3159253|NCT00402272|Experimental|1|XIENCE V® Everolimus Eluting Coronary Stent System
3159254|NCT00402350|Placebo Comparator|Placebo|Subjects (2) from each of the 4 dose escalation arms
3159255|NCT00402350|Experimental|25 mcg IV and Inhaled Crossover|Single dose crossover (IV vs Inhaled)
3159256|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 2|Inhaled Staccato fentanyl, 25 mcg x 2
3159257|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 4|Inhaled Staccato fentanyl, 25 mcg x 4
3159258|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 6|Inhaled Staccato fentanyl, 25 mcg x 6
3159259|NCT00402350|Experimental|Inhaled fentanyl 25 mcg x 12|Inhaled Staccato fentanyl, 25 mcg x 12
3159260|NCT00402389|Experimental|1|Participants assigned to take omega-3 fatty acids
3159261|NCT00402389|Placebo Comparator|2|Participants assigned to take placebo
3159262|NCT00402415|Experimental|1|
3193572|NCT00819468|Experimental|Participants with Moderate Hepatic Impairment|Participants with moderate hepatic impairment (Child-Pugh score of 7-9) will receive 20 mg of teduglutide.
2483812|NCT03010865|Experimental|Sodium Butyrate|Dietary Supplement: Sodium Butyrate 4.38 gms of sodium butyrate per day for 12 weeks
2483814|NCT03010865|Placebo Comparator|Placebo Oral Capsule|Placebo Oral Capsule placebo capsules containing approximately 9 mg of sodium butyrate per day
2483898|NCT03010644||Underserved school-aged children|Underserved school-aged children at risk for obesity
2483938|NCT03010085|Active Comparator|A (Open left-sided hepatectomy)|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
2483940|NCT03010085|Experimental|B (Laparoscopic left-sided hepatectomy)|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
2484071|NCT03009292|Experimental|24 mg lenvatinib|Participants will receive once daily oral dosing of lenvatinib 24 milligrams (mg)
2484164|NCT03008876|Experimental|acetaminophen|Group of patients randomized to receive acetaminophen to treat their PDA
2484170|NCT03008876|Active Comparator|ibuprofen|Group of patients randomized to receive ibuprofen to treat their PDA
2484205|NCT03008434|Experimental|Yoga Group|Yoga twice a week for 8 weeks focusing on balance and pain.
2484243|NCT03008239|Experimental|FiberSense sensor|"Type 1, Type 2 and prediabetic subjects will wear one FiberSense sensor, randomly allocated to either the upper arm (50%) or abdomen (50%) for 28 days. In addition, these subjects will wear a Dexcom sensor on the other side of the abdomen for 7 days in one of the four study weeks.~In all 4 CAPD subjects, one FiberSense sensor will be placed in the upper arm for 28 days. No additional comparator sensor will be placed in CAPD subject."
2484273|NCT03007914||TCM cohort|Patients continue to receive the routine TCM treatments recommended by 2011 Chinese treatment guidelines of TCM for COPD.
2484276|NCT03007914||Conventional medicine cohort|Patients continue to receive the conventional medicine recommended by 2014 GOLD and Chinese treatment guidelines for COPD.
3193573|NCT00819468|Active Comparator|Healthy Volunteers|Healthy volunteers with normal hepatic function matched to hepatic impaired participants by age, gender, BMI, and renal function as measured by creatinine will receive 20 mg of teduglutide.
3193574|NCT00819481||3DKnee|Post Market Study
2484366|NCT03007290|Experimental|Treatment group|Group with therapeutic drug monitoring
2484411|NCT03007043||Normal responders|Normal response following IVF
2484420|NCT03007043||Suboptimal responders|Suboptimal response following IVF
2484467|NCT03006601|Placebo Comparator|Placebo group|After enrollment, patients will be randomized into either treatment group or placebo group. Patients will receive placebo procedure which were designed to look like real vergence/accommodative therapy procedures yet not stimulate vergence, accommodation, of fine saccadic eye movement skills beyond normal daily visual activities. Office-based procedures (60 minutes per visit, one time per week, 12 weeks) and home procedures (15 minutes each time, five times per week, 12 weeks) will be provided to patients.
2484469|NCT03006601|Experimental|Treatment group|After enrollment, patients will be randomized into either treatment group or placebo group. Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks) will be provided to patients of treatment group.
2484485|NCT03006250|Experimental|Desflurane|Desflurane group: The rule of 24 will be applied, which means that the fresh gas flow (l/ min) multiplied by volume percent of desflurane must not exceed 24. Therefore, once the patients return of spontaneous ventilation, an anesthesiologist turns on oxygen 1 l/ min, nitrous oxide 1 l/ min, and desflurane 12 vol% for 1-2 minutes. When the end-tidal desflurane reaches 3-3.5% (approximately 0.5 MAC), the anesthesiologist will decrease oxygen and nitrous oxide to each 0.5 l/ min and desflurane to 6 vol% (1 MAC). Desflurane concentration will be adjusted to maintain the end-tidal desflurane around 3-6% (0.5-1 MAC).
2484490|NCT03006250|Active Comparator|Sevoflurane|Sevoflurane group: The oxygen and nitrous oxide each 1 l/min will be turned on with sevoflurane 4 vol% for 1-2 minutes or until the end-tidal sevoflurane reach 1-1.2% (approximately 0.5 MAC). After that, the flow of oxygen and nitrous oxide is reduced to each 0.5 l/ min and concentration dial of sevoflurane is set to 2 vol% (1 MAC). During the operation, sevoflurane concentration will be adjusted to maintain the end-tidal sevoflurane around 1-2% (0.5-1 MAC)
2484583|NCT03006016|Experimental|Omega 3|The patient will take Omega 3 before intervention 4-week course of 1.500 Mg/ day without caloric restriction
2484586|NCT03006016|Placebo Comparator|Placebo|The patient will take placebo before intervention 4-week course of 1.500 Mg/ day without caloric restriction
2484607|NCT03005587||Cirrhotics with no previous decompensation|
2484609|NCT03005587||Cirrhotics with previous one or more than one decompensation|
2484688|NCT03005379|Active Comparator|1|Fecal Microbiota Therapy (FMT)
2484692|NCT03005379|Placebo Comparator|2|Placebo
2484760|NCT03004820|Experimental|Remote Ischemic Conditioning|RIC (remote ischemic conditioning) consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
2484792|NCT03004443|Experimental|Infliximab|Participants will be randomized to receive one intravenous (IV) infusion of infliximab.
2484794|NCT03004443|Placebo Comparator|Placebo|Participants will be randomized to receive one intravenous (IV) infusion of placebo.
2484855|NCT03004196|Active Comparator|Control Group|They were not given probiotic toothpaste or chlorhexidine mouthwash
2484857|NCT03004196|Experimental|Probiotic Group|"Patients were asked to brush twice daily with given G.D Probiotic Toothpaste and were asked not to eat or drink anything for half-an-hour."
3193575|NCT00819494|Sham Comparator|Healthy controls|
3193576|NCT00819494|Active Comparator|Patients with immediate reactions|
3193577|NCT00819520|Experimental|Ivermectin|ivermectin Stromectol®)
3193578|NCT00819520|Active Comparator|Malathion|malathion(Prioderm®)
3193579|NCT00819533|Experimental|sensor|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
3193580|NCT00819546|Other|Only one arm on this study.|
2483614|NCT03012360|Experimental|antibiotic treatment for 3 days|"Patients randomized in one of the two experimental groups will receive 3 days of antimicrobials. Antibiotic treatment is standardized, based on the time of onset of VAT, and presence of risk factors for MDR bacteria:~patients with early-onset VAT (< 5 days of mechanical ventilation), with no risk factor for MDR will receive ceftriaxone .~patients with late-onset VAT (≥5 days of mechanical ventilation), or with at least one risk factor for multidrug resistant bacteria will receive imipenem , and ciprofloxacin as empirical treatment.~When methicillin-resistant Staphylococcus aureus (MRSA) is suspected linezolid will be added to empirical treatment.~3 days of imipenem and ciprofloxacin with optional linezolid, followed by 4 d of placebo"
2483647|NCT03011749|Experimental|FLT PET/CT|FLT PET/CT
2483701|NCT03011645|Active Comparator|Ziprasidone|Ziprasidone 60 mg tablet by mouth, once a day for one day.
2483705|NCT03011645|Active Comparator|Lorcaserin|Lorcaserin 20 mg tablet by mouth, once a day for one day.
2483713|NCT03011645|Placebo Comparator|Placebo Oral Tablet|Sugar pill (in place of ziprasidone and lorcaserin) by mouth, once a day for one day.
2483771|NCT03011138||V 1|Gait velocity will be set at 1.0km/h.
2483774|NCT03011138||V 2|Gait velocity will be set at 1.5km/h.
2483777|NCT03011138||V 3|Gait velocity will be set at 2.0km/h.
2483779|NCT03011138||V 4|Gait velocity will be set at 2.5km/h.
2483780|NCT03011138||V 5|Gait velocity will be set at 3.0km/h.
2483781|NCT03011138||V 6|Gait velocity will be set at 3.5km/h.
2483782|NCT03011138||V 7|Gait velocity will be set at 4.0km/h.
2483854|NCT03010852|No Intervention|Standard of care incentive spirometer|Patients in the SOC cohort will not receive the preoperative education and only one postoperative visit per day to collect their self-reported use of IS, if prescribed, and respiratory symptoms but avoiding increasing their awareness of POH, O2 therapy and IS.
2483858|NCT03010852|Experimental|Focused incentive spirometer education and monitoring|One of the study investigators will meet eligible patients in the preoperative visit to the UCH Weight Loss Surgery clinic, inform and consent the patient and introduce the first education on IS therapy, highlighting its possible benefits and the importance of compliance (patient's inspiratory effort and frequency). This IS education will be repeated in the preoperative area immediately before surgery. The site will then follow the patient postoperatively. The site will directly check on the patient in the PACU and later in his/her hospital room at least 3 times a day during the first 3 days or sooner if their O2 therapy is discontinued for 2h. During these PO check ups The site will reinforce the IS use, monitor the patient's performance of IS and ask him/her about other respiratory symptoms.
2483891|NCT03010358|Experimental|Treatment (entospletinib, obinutuzumab)|Patients receive entospletinib PO either QD or BID on days -7 to -1 (run-in phase) depending on the assigned dose level. Patients also receive obinutuzumab IV on days 1, 2, 8, and 15 of the first cycle, and on day 1 of subsequent cycles. Treatment with obinutuzumab repeats every 28 days for up to 6 cycles and daily treatment with entospletinib continues every 28 days for up to 12 cycles in the absence of disease progression or unexpected toxicity.
2483990|NCT03010020|Experimental|STI-Positive: PCC|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using Personalized Cognitive Counseling (PCC) and treated with appropriate antibiotic therapy
2483994|NCT03010020|Placebo Comparator|STI-Positive: Traditional Counseling|MSM diagnosed with rectal GC and/or CT infection counseled for HIV prevention using traditional risk reduction counseling and treated with appropriate antibiotic therapy
2483998|NCT03010020|No Intervention|STI-Negative|MSM without rectal GC and/or CT infection
2484007|NCT03009539|Experimental|eHealth Familias Unidas Primary Care|"eHealth Familias Unidas consists of 12 sessions: eight (12 - 15 minute) mock parent sessions in Spanish and four (30 - 45 minute) online family sessions delivered in either Spanish and/or English."
2484011|NCT03009539|No Intervention|Treatment as Usual|Participants in this condition will not receive an intervention.
2484054|NCT03009227|Active Comparator|D2 lymph node dissection|Colonic resection with D2 lymph node dissection
2484055|NCT03009227|Experimental|D3 lymph node dissection|Colonic resection with D3 lymph node dissection
2484160|NCT03008759|Placebo Comparator|Placebo|Dentifrice without fluoride
2484167|NCT03008759|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF). Positive control
2484173|NCT03008759|Experimental|Dentifrice 50% Nano-F|Dentifrice experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF
2484174|NCT03008759|Experimental|Dentifrice 100% Nano-F|Dentifrice experimental with fluoride 100% Nanoencapsulated
2484229|NCT03008356|Experimental|L-carnitine|Oral L-carnitine 1000mg twice daily
2484234|NCT03008356|Experimental|L-carnitine + health coaching|Oral L-carnitine 1000mg twice daily and weekly 10-15 minute health coaching calls
2484238|NCT03008356|Placebo Comparator|Placebo|Placebo capsules twice daily
2484279|NCT03007940|Experimental|NIATx Strategy|"The implementation intervention, NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective."
2484281|NCT03007940|Placebo Comparator|Wait List Control|The wait-list control group will receive the NIATx strategy at the end of the twelve month implementation period for the initial cohort. During the first year of the study, they will follow a business as usual approach to the integration of co-occurring substance use and mental health services.
2484343|NCT03007563|Experimental|newborn infants checked for jaundice|an experimental way of bilirubin concentration estimation from smartphone pictures is applied and compared with two standard methods: bilirubin concentration measured in standard blood samples, and bilirubin concentration measured by transcutaneous device.
2484417|NCT03007069|Experimental|Autogenous bone graft (Gold Standard).|Patients with defective maxillary alveolar ridges requiring implant insertion will have Autogenous bone graft (Gold standard) and collagen membrane to be used for bone augmentation around exposed threads of inserted dental implants.
2483648|NCT03012009|Active Comparator|Full ablative CO2 laser + MAL PDT|The treatment starts with a full ablative CO2 laser pretreatment under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with a LED lamp. This treatment is repeated after 14 days.
2483655|NCT03012009|Active Comparator|Fractional ablative CO2 laser+ MAL PDT|The treatment starts with a fractional ablative CO2 laser ablation under local anaesthesia with injectable lidocaine hydrochloride 2% with epinephrine. This ablation is followed by photodynamic therapy: MAL is topically applied, followed by a 3 hours incubation under occlusion, whereafter 10 minutes of illumination with LED lamp. This treatment is repeated after 14 days.
2483740|NCT03011372|Experimental|Pemigatinib|
2483827|NCT03010878|Experimental|Yoga Arm|Yoga administered twice a week for 8 weeks. Self-management education sessions administered once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic (Pain Clinic). Yoga interventions were administered twice a week at the Pain Clinic.
2483829|NCT03010878|Experimental|Wait-list Control Arm|Participants received only self-management intervention, which is provided once a month through the University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic.
2483882|NCT03010553|Experimental|Oropharynx|Tumors of the oropharynx T1T2N0 treated with radiotherapy
2483884|NCT03010553|Experimental|Larynx|Tumors of the T1T2N0 larynx treated by surgery, laser or robot
2483941|NCT03010202|Experimental|Induction phase: Rituximab+Dexamethasone|Open-label, intravenous infusions of rituximab 1000 mg and oral dexamethasone 20 mg daily for 4 days given on day 1 and day 15.
2483945|NCT03010202|No Intervention|Induction phase: Rituximab|Open-label, intravenous infusions of rituximab 1000 mg given on day 1 and day 15.
2483947|NCT03010202|Experimental|Maintenance phase: Rituximab|Patients who respond to rituximab in the induction phase will be proceed into the maintenance phase and randomized to rituximab infusion of 500 mg in week 1 and week 24, or
2483948|NCT03010202|No Intervention|Maintenance phase: Placebo|Infusion of normal saline 0,9% in week 1 ande week 24 in second randomization.
2484039|NCT03009773|Experimental|multitasking walking|Multitasking Group: rehabilitation multitasking walking.
2484040|NCT03009773|Active Comparator|walking simple task|Simple task group : Traditional walking rehabilitation
2484058|NCT03009149|Experimental|AEROBIC EXERCISE|The effects of 12 week aerobic exercise will record
2484149|NCT03008993|Experimental|Post-Intervention|The HQIS comprises three phases: 1) clinician training - to improve communication-relational skills and to instruct on the project; 2) center support - 4 on site visits by experts of the project team, aimed to introduce the project and boost motivation, instruct staff on how to implement recommendations, help with context analysis and identification of solutions; assess actual implementation in the center; 3) implementation of EBM recommendations.
2484155|NCT03008993|No Intervention|Control|
2484225|NCT03008330|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484227|NCT03008330|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484282|NCT03008044|Experimental|Device: FiberSense system|10 subjects will wear 2 FiberSense system in abdomen and upper arm respectively and Dexcom G4 Platinum CGM sensor for 1 day.
2484283|NCT03008044|Experimental|Extension Phase|2 subjects will extend the wearing of the sensors up to 14 days (2 FiberSense systems to Day 14 and Dexcom sensor to Day 7±1) after the glucose clamp study.
2484332|NCT03007589|Other|Location|Location and Intensity of Exposure to Sunlight otc sunscreens sun protection fabrics optical filters
2484337|NCT03007589|Other|Single Duration or SPF Test|Single exposure of interventions or multiple exposures of interventions (SPF or PPD-PF tests) otc sunscreens sun protection fabrics optical filters
3193581|NCT00819559|Active Comparator|Open PCRT group|Patients who underwent preoperative chemoradiotherapy and open resection
2484482|NCT03006367|Experimental|NFC-1 100 mg|Single Dose of NFC-1 100 mg
2484483|NCT03006367|Experimental|NFC-1 200 mg|Single Dose of NFC-1 200 mg
2484486|NCT03006367|Experimental|NFC-1 400 mg|Single Dose of NFC-1 400 mg
2484491|NCT03006367|Experimental|NFC-1 800 mg|Single Dose of NFC-1 800 mg
2484551|NCT03005951|Experimental|Lean males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
2484554|NCT03005951|Experimental|Obese males|This is a randomized, two-period, cross over design with the intervention of consuming breakfast versus fasting for breakfast to study the effects on hormone responses and cognitive function using CTET in lean and obese male adolescents. These two study groups will be randomized to one of two orders:: (A,B) or (B,A) where A = Yes breakfast and B=No breakfast
2484618|NCT03005730|Experimental|Group 1|Submitted to a session of phototherapy with 39,27 Joules per point in muscle masseter and temporal bilateral.
2484623|NCT03005730|Placebo Comparator|Group 2|Submitted to a session of phototherapy placebo with 0,0 Joules per point in muscle masseter and temporal bilateral.
2484685|NCT03005340|Active Comparator|Group A|Period 1: Bazedoxifene 20 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
2484690|NCT03005340|Active Comparator|Group B|Period 1: Bazedoxifene 20 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Cholecalciferol granule 10 mg
2484694|NCT03005340|Active Comparator|Group C|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg
2484698|NCT03005340|Active Comparator|Group D|Period 1: Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
2484702|NCT03005340|Active Comparator|Group E|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Cholecalciferol granule 10 mg Period 3: Bazedoxifene 20 mg
2483696|NCT03011463|Active Comparator|trospium intravenous|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o.
2483697|NCT03011463|Active Comparator|trospium oral|Oral administration of 30 mg trospium chloride with 240 ml tap water
2483699|NCT03011463|Active Comparator|trospium intravenous with ranitidine|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 300 mg ranitidine with 240 ml tap water
2483700|NCT03011463|Active Comparator|trospium intravenous with clarithromycin|Intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and oral administration of 500 mg clarithromycin with 240 ml tap water
2483704|NCT03011463|Active Comparator|trospium oral with ranitidine|Oral administration of 30 mg trospium chloride together with 300 mg ranitidine with 240 ml tap water
2483710|NCT03011463|Active Comparator|trospium oral with clarithromycin|Oral administration of 30 mg trospium chloride together with 500 mg clarithromycin with 240 ml tap water
2483817|NCT03011125|Placebo Comparator|placebo|
2483819|NCT03011125|Experimental|Dexlansoprazole Injection|
2483851|NCT03010618|Other|Study Group|
2483892|NCT03010345|Experimental|Osmed self inflating tissue expanders|All patients will undergo a two-stage procedure ,second stage under General endotracheal anesthesia. The first stage will be placement of the expanders. The second stage will be 21 days later, with removal of the expanders, palatal revision, and closure of the oronasal fistula
2483893|NCT03010345|Experimental|Iliac bone graft|Placement of bone graft without the use of self inflating expanders
2483944|NCT03010098|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
2483946|NCT03010098|Experimental|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.Take blood sample before and after surgery to measure the levels of protein S100beta and NSE.
2484029|NCT03009799|Active Comparator|Eye drops containing Iota-Carrageenan|Eye drops 3.2mg/ml
2484031|NCT03009799|Placebo Comparator|Ocular Lubricant Eye Drops|Carmellose 0.5% sterile solution
2484056|NCT03009214|Experimental|AMC303|"cohorts will receive ascending doses of AMC303 as intravenous infusion~Planned doses are:~0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 4 mg/kg, 10 mg/kg and 20 mg/kg"
3193582|NCT00819559|Experimental|Open no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and open resection
3193583|NCT00819559|Active Comparator|LAP PCRT group|Patients who underwent preoperative chemoradiotherapy and laparoscopic resection
2484354|NCT03007667||Colorectal cancer patients|Colorectal cancer patients
2484416|NCT03006809|Experimental|1|pretreatment antibiotics + FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
2484425|NCT03006809|Experimental|2|no antibiotics, FMT delivered by colonoscopy + FMT capsules per week x 6 weeks
2484429|NCT03006809|Experimental|3|pretreatment antibiotics + FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
2484433|NCT03006809|Experimental|4|no antibiotics, FMT delivered by colonoscopy + FMT delivered by enema once per week x 6 weeks
2484477|NCT03006445|Experimental|FYU-981|
2484525|NCT03006211|Active Comparator|corneal endothal|Evaluate the effects of nitrogen protoxide to corneal endothal and compare with oxygen.
2484529|NCT03006211|Active Comparator|Cell density|Evaluate the effects of nitrogen protoxide to Cell density and compare with oxygen.
2484561|NCT03005886|Experimental|AMI+CP:|"GCF sampling,periodontal examination,phase I therapy:~Patients, who met the AMI diagnostic criteria with chronic periodontitis. Baseline periodontal examination of AMI patients and 24-48h GCF sampling was carried out in their hospital bed under sufficient illumination using artificial light. Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology. Mucoperiosteal flap operation was performed in cases where needed."
2484565|NCT03005886|Active Comparator|Chronic Periodontitis (CP)|"GCF sampling,periodontal examination,phase I therapy:~Systemically healthy chronic periodontitis patients.Phase I periodontal therapy including comprehensive proper plaque control program, scaling, subgingival curettage and root planning in Department of Periodontology.Mucoperiosteal flap operation was performed in cases where needed."
2484571|NCT03005886|Sham Comparator|Healthy controls|clinically healthy individuals not having any periodontal and systemic diseases history.Comprehensive medical and periodontal examination to confirm that they did not have systemic and periodontal diseases
2484621|NCT03005561|Experimental|Intervention|100 participants that will be participating in the Play Back meetings.
2484624|NCT03005561|No Intervention|Control|100 participants that will not be participating in the Play Back meetings.
2484675|NCT03005353|Experimental|Cumin seed extract|Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
2484676|NCT03005353|Active Comparator|clotrimazole|Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
2484748|NCT03004898|Experimental|education arm|multidisciplinary education: multidisciplinary CKD education involving case management nurse, dietitian, social worker, pharmacists.
3193584|NCT00819559|Experimental|LAP no PCRT group|Patients who did not undergo preoperative chemoradiotherapy and laparoscopic resection
3193585|NCT00819572|Experimental|1|DLX105 low dose
3193586|NCT00819572|Experimental|2|DLX105 high dose
3193587|NCT00819572|Placebo Comparator|3|
3193588|NCT00819598||SUSPECTED ARTERIAL DISEASE|
3193589|NCT00819611|Experimental|Working memory training|
3193590|NCT00819611|Sham Comparator|Control version of working memory training|
3193591|NCT00819624|Other|Interactive Voice Response System|
3193592|NCT00819624|Other|Personal Digital Assisstant|
3193593|NCT00819650|Experimental|Licartin|patients who receive Licartin therapy after liver resection
2483707|NCT03011437||cases|Patients who undergo esophagogastroduodenoscopy during 01/12/2016 and 31/12/2016 in the First People's Hospital of Kashgar Region.
2483783|NCT03011203|Experimental|Ketone-ester drink|Oral intake - physical exercise
2483784|NCT03011203|Active Comparator|Carbohydrate drink|Oral intake - physical exercise
2483861|NCT03010839|Active Comparator|Modified Remote Ischemic Preconditioning(mRIPC)|modified RIPC was induced at 24 h, 12 h and 1 h before surgery to reinforce the protective effects of RIPC. The single RIPC protocol was induced by three cycles of upper-limb ischemia, a standard blood-pressure cuff was placed on the ringt upper arm, then inflated the cuff to 200 mm Hg for 5 minutes, followed by 5 min of cuff deflation.
2483864|NCT03010839|Placebo Comparator|Control|Control group without remote ischemic preconditioning
2483895|NCT03010319|Experimental|PriMatrix|Arm will receive PriMatrix Dermal Repair Scaffold plus secondary dressings to maintain a moist wound healing environment and an appropriate off-loading device.
2483896|NCT03010319|Active Comparator|Standard of Care|Arm will receive moist wound therapy consisting of 0.9% Sodium Chloride gel plus secondary dressings and an appropriate off-loading device.
2483980|NCT03009994|Other|Exteriorization group|After delivery of the fetus and placenta, the surgeon bring uterus yet out from peritoneal cavity by manual handling of the uterus uterus from fundus and extracted out of the abdominal cavity before starting to close it. After repair of the uterus , uterus returned to abdominal cavity and repair anterior abdominal wall as following.
2483982|NCT03009994|Other|Non exteriorization group|Uterine incision will be repaired intra abdominally
2484008|NCT03009617|Experimental|Intervention Group|The educational program and counseling Pre-test before intervention Monitoring, education, and consultation through the Web At least two reminders via e-mail or phone message a week The last test after three months The website was closed three months later.
2484013|NCT03009617|No Intervention|Control Group|Pre-test No intervention The last test after three months Opening the website to the control group
2484072|NCT03009383|Experimental|A bedside portable endoscopy|
2484140|NCT03008954|Placebo Comparator|Placebo|Microcyrstalline cellulose (Avicel): provided in 5 capsules (350 mg each), twice daily (BID) prior to lunch and dinner.
2484145|NCT03008954|Experimental|GSP3 (2.25g)|GSP3: provided in 3 capsules (750 mg each), plus 2 placebo capsules (350 mg each), twice daily (BID) prior to lunch and dinner
2484159|NCT03008954|Experimental|GSP3 (3.75g)|GSP3: provided in 5 capsules (750 mg each), twice daily (BID) prior to lunch and dinner
2484233|NCT03008395|Experimental|EMMA|These participants will receive diabetes self-management education using the dialogue tools, which emphasize empowerment and use the principles of motivational communication and behaviour modification. There will be a series of four visits using the dialogue tools to guide the patient toward meaningful self-management tasks. This is not the typical approach, where providers tell the patient the behaviours they, not the patient, consider priorities. This intervention will evaluate if medical outcomes (A1c) and adherence are improved using a patient-centered not a clinician-cantered approach in individuals with poor diabetes control.
2484239|NCT03008395|Active Comparator|Treatment as Usual|The participants will receive standard diabetes education via group and individual sessions with certified diabetes educators. In this method the patient is provided structured education in which there is an emphasis on covering clinician-determined aspects of diabetes knowledge and self-management. The emphasis vis on diabetes educator recommendations.
2484264|NCT03007992|Experimental|Vinorelbine Oral|Test product: Navelbine® 20 mg / 30 mg soft capsules
2484302|NCT03007693|Experimental|JNJ-61393215 (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 once daily for 7 days. 4 sequential cohorts will be enrolled to evaluate escalating doses which will be defined, based on safety, tolerability and pharmacokinetic (PK) data from the preceding cohorts. Dose adjustment/selection (increase/decrease) for the next cohort will be based on the JNJ- 61393215 PK profile up to and including the last day of dosing (24 hours postdose) and the safety and tolerability profile of the current cohort.
2484304|NCT03007693|Placebo Comparator|Placebo (Multiple Ascending Dose Phase)|Participants will receive JNJ- 61393215 matching placebo for 7 days.
3193594|NCT00819650|No Intervention|placebo|control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive Licartin therapy after liver resection
3193595|NCT00819663||Crohns patients|Established Crohn's disease patients who underwent CTE imaging before and after initiating infliximab therapy
3193596|NCT00819676||subjects with asthma|
2484505|NCT03006328|Experimental|Obese Subjects + GEM|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
2484508|NCT03006328|Active Comparator|Obese Subjects + Enhanced Usual Care|Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity
2484553|NCT03006003|Experimental|Raloxifene group|Raloxifene treatment
2484558|NCT03006003|Active Comparator|Comparator group|Alendronate treatment
2484560|NCT03006003|No Intervention|Control group|To refuse anti-osteoporosis treatment
2484637|NCT03005691||Whiplash-Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the presence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The minimum will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
2484642|NCT03005691||Whiplash-no Pain|Subjects with chronic whiplash syndrome and pain. The inclusion criteria for pain include the ausence of daily pain during the previous 8 weeks. Specifically, pain will be diagnosed based on the pain intensity measured on the 0 to 10 numerical rating scale. The maximun will be 2 points. Subjects will be recruited between the 4 months until 2 years after the whiplash.
2484648|NCT03005691||Non-injured|Subjects without whiplash syndrome. The inclusion criteria are defined as a absence of previous or actual symptoms or signs of neck pain.
2484741|NCT03005145|Active Comparator|Short duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
2484742|NCT03005145|Active Comparator|Long duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
3193597|NCT00819676||healthy subjects|
2483751|NCT03011346|Active Comparator|Symetis ACURATE neo/TF transfemoral TAVI system|Symetis ACURATE neo/TF transfemoral TAVI system: self-expandable transcatheter aortic bioprosthesis, support frame made of nitinol, supra-annular processed trileaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland)
2483758|NCT03011346|Active Comparator|Edwards Sapien 3 Transcatheter Heart Valve|Edwards SAPIEN 3 Transcatheter Heart Valve system: balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
2483800|NCT03010917|Experimental|Fish Oil with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
2483801|NCT03010917|Placebo Comparator|Placebo with ethanol and placebo ethanol infusions|Between days 30-40 subjects will participate in 2 test days at least 2 days apart and during the test day will receive an IV infusion of ethanol (placebo vs. targeted Breath Alcohol Concentration ((BrAC) of 100mg%) in a clamped fashion. Test days will be in a randomized order.
2483871|NCT03010514||case|
2483872|NCT03010514||control|
3193598|NCT00819702|Experimental|Model Care|The Model Care approach was implemented in 7 practices, where PCPs were trained to address major risk factors for CM, including maternal depression, alcohol/substance abuse, intimate partner violence, food insecurity, harsh punishment and major stress. We taught how they can be briefly assessed and initially addressed. The initial training consisted of one 4-hour in-person session. Use of the Parent Screening Questionnaire (PSQ) was discussed, as was the importance of applying it universally during regular checkups. PCPs SEEK Parent Handouts on each targeted problem. We held 1-hour booster sessions every 6 months over the subsequent 2.5 years.
3193599|NCT00819702|No Intervention|Standard Care|PCPs in Standard Care group served as the controls. They continued to practice as usual.
2484067|NCT03009136|Experimental|SCRT group|3g, three times a day, each taken before or between meals
2484074|NCT03009136|Placebo Comparator|placebo group|3g, three times a day, each taken before or between meals
3193600|NCT00819715||1|Small for gestational age preterm infants
3193601|NCT00819715||2|Appropriate for gestational preterm infants
2484285|NCT03008083|Active Comparator|3 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 3 months.
2484287|NCT03008083|Active Comparator|12 months DAPT Intervention|After implantation of Firehawk coronary stents, all subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and thienopyridines (clopidogrel or ticagrelor)for 12 months.
2484318|NCT03007511|Experimental|Fidmi|Placement of Fidmi enhanced enteral feeding device; internal tubes replacement during follow up and device removal after 3 month from placement Fidmi enhanced enteral feeding device
2484439|NCT03007186||Case group|The oral glucose tolerance test that these women undergo in pregnancy between 24+0 and 28+0 showed pathological measurements.
2484443|NCT03007186||Control group|The oral glucose tolerance test of these women showed no pathological measurements.
2484501|NCT03006497|No Intervention|Control|The control group will not participate in any exercise program. However, at the end, home based exercises and special advice will be given to the participants.
2484504|NCT03006497|Experimental|Intervention|The intervention group will participate in an exercise program based on motor learning principles for 4 weeks/3 sessions per week, for a total of 12 sessions of 30-45 minutes each.
2484577|NCT03006055|Experimental|MBC Group|metastatic breast cancer Age：18-75 ECOG:0-2
2484579|NCT03006055|Experimental|Control Group|benign breast tumour Age：18-75 ECOG:0-2
2484617|NCT03005665|Experimental|Group A - Acetazolamide|Acetazolamide 5 mg/kg diluted in 10 ml normal saline through orogastric Ryle's Tube soon after the induction of anaesthesia followed by 10 ml normal saline flush.
2484620|NCT03005665|Placebo Comparator|Group s - Normal saline|20 ml normal saline total volume.
3193602|NCT00819728|Experimental|Taxotere/Irinotecan|
3193603|NCT00819754|Experimental|IXO regimen + bevacizumab|This is phase I/II safety and efficacy study. There is only one arm of Irinotecan, Xeloda and Oxaliplatin (IXO) regimen with Avastin (bevacizumab)
2484865|NCT03004313|Experimental|Migraine|"20 subjects experiencing 1-14 migraines per month will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging (during and outside of a migraine attack)"
2484868|NCT03004313|Active Comparator|Healthy|"20 healthy subjects will undergo the following:~Blood and urine samples will be collected~Complete a series of questionnaires; some of which will be completed daily~Quantitative Sensory Test (QST)will be performed~Magnetic Resonance Imaging (MRI)~PET imaging"
2484878|NCT03003702|Experimental|ETH|Overnight monitoring
2484889|NCT03003702|Other|CTH|Morning monitoring
2484961|NCT03003559|Experimental|High flow nasal cannula|High flow nasal cannula(OptiflowTM); Flow 25-60 L/min is set according to patients' comfort; FiO2 is adjusted to maintain peripheral capillary oxygen saturation(SpO2) 90-95%; temperature is set at 37.
2484965|NCT03003559|No Intervention|Nasal cannula|Nasal cannula;set oxygen flow to keep SpO2 90-95%
2485040|NCT03003026|Experimental|Novel task-specific program|Intervention arm - see detailed intervention group description below
2485042|NCT03003026|Active Comparator|Parent-led home-based program|Comparison arm - see detailed comparison group description below
2485084|NCT03002363|Experimental|Video Modeling Intervention|The intervention group receives a video that is a behavior modeling video that walks through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment.
2485085|NCT03002363|Placebo Comparator|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
2483756|NCT03011385|Active Comparator|Education|The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a partner-partner dyad and discusses individual guidelines for both dyadic partners.
2483806|NCT03010982|Experimental|Tazemetostat and [14C] Tazemetostat|"Tazemetostat 800 mg BID orally as tablets continuously starting on Day 1, with the exception of the morning dose on Day 16;~A single IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat on Day 15;~A single oral dose of 800 mg tazemetostat as a solution containing approximately 400 µCi (14.8 MBq) of [14C] tazemetostat on Day 16."
2483838|NCT03010696||Healthy subjects|Normal kidney function
2483841|NCT03010696||ESRD patients|Diagnosed as ESRD with hemodialysis
2484035|NCT03009461|Experimental|Sor-HAIC group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily. hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks.
2484036|NCT03009461|Active Comparator|Sor group|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
2484078|NCT03009188||Pedigree of the family with ARS|Nine members of the same family with ARS
2484144|NCT03008967||Total Knee and Hip Arthroplasty|Rehabilitation, observational. Identification of risk factors for poor response to rehabilitation programs after TJR and use these to identify patients who are most susceptible to poor outcomes
2484189|NCT03008499|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484194|NCT03008499|No Intervention|Control|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3159263|NCT00402428|Active Comparator|1|180 mcg PEG-IFNx2a every 1 week (48 doses) + Ribavirin 1000 or 1200 mg/day
2484314|NCT03007420|Experimental|Occipital Nerve Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction, the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
2484315|NCT03007420|Experimental|Cervical Medial Branch Block|"After enrollment in the study, patients will be randomized (but not blinded) to receive either an occipital nerve block or a cervical medial branch block. These are injections of anti-inflammatory medications (steroids) and numbing medications (local anesthetics -lidocaine) in nerves located at the back of the head and neck. If patients exhibit a > or = 50% pain reduction on receiving the block evaluated after four weeks, then they may continue to receive blocks as needed, but not more than one every three months.~If patients exhibit < 50% pain reduction the patient will be treated as per the clinician's judgment with the possibility of a cross over to the other treatment option."
2484369|NCT03007264|Experimental|CAP treated|volar arm will be treated with cold atmospheric plasma.
2484371|NCT03007264|Experimental|CAP on bacteria|volar arm with bacteria will be treated with cold atmospheric plasma.
2484373|NCT03007264|No Intervention|no CAP on bacteria|volar arm with bacteria will not be treated with cold atmospheric plasma. Sham comparator for measurements of skin parameters TEWL, temperature and bacterial load.
3159264|NCT00402428|Experimental|2|900 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
2484538|NCT03006146|Experimental|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
2484582|NCT03005834||Atherosclerotic CVD|Atherosclerotic cardiovascular diseases (CVD) included coronary artery diseases, aortic diseases and peripheral artery diseases.
2484584|NCT03005834||Non-atherosclerotic CVD|Non-atherosclerotic cardiovascular diseases (CVD) were any CVD except atherosclerotic CVD and congenital CVD.
2484602|NCT03005626|Experimental|Therapeutic education|Structured therapeutic education programs
2484603|NCT03005626|Active Comparator|Control group|standard outpatient follow-up
2484705|NCT03005093||CAREGIVERS|Caregivers of pediatric patients with swallowing disorders will be recruited.
2484709|NCT03005093||CHILDREN OF CAREGIVERS|Pediatric patients with swallowing disorders will be recruited.
2513086|NCT02810041|Placebo Comparator|yoghurts non enriched with XXS|
3159265|NCT00402428|Experimental|3|1200 mcg alb-IFN every 2 weeks (24 doses)+ Ribavirin 1000 or 1200 mg/day
3159266|NCT00402467|Experimental|Arm 6|
3159267|NCT00402467|Experimental|Arm 1|
3159268|NCT00402467|Experimental|Arm 2|
3159269|NCT00402467|Experimental|Arm 3|
3159270|NCT00402467|Experimental|Arm 4|
3159271|NCT00402467|Experimental|Arm 5|
3159272|NCT00402493|Active Comparator|Latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
3159273|NCT00402493|Active Comparator|Brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
2483794|NCT03011216|Experimental|Adaptive emotional cognitive control training|"Adaptive emotional n-back task: On each trial of this task, participants are presented with an emotional facial expression. Participants have to indicate whether the emotion presented in the current trial is the same as n trials back. In order to train participants at their individual ability level, the n-level varies by trial block based on participants' performance on the previous block.~The adaptive emotional n-back task is assumed to train the ability to continuously update emotional material in working memory."
2483798|NCT03011216|Active Comparator|Placebo training|"Adaptive non-emotional feature match task: On each trial of this task, participants are presented with two panels containing 8-12 shapes each. Participants are asked to compare the two panels and decide whether or not they are identical. The panels contain a minimum of 8 shapes and a maximum of 12 shapes, depending on participants' performance on the previous block.~The adaptive non-emotional feature match task is assumed to train the speed of responding (involving processes like visual search and concentration). It does not trait working memory updating."
2483849|NCT03010774|Experimental|Intervention - Risk Stratification|Study participants will be risk stratified according to the eCART scoring algorithm each night. If they are stratified as low risk, they will not receive routine nighttime spot-check vital signs unless indicated by a change in patient status or monitor alarm.
2483850|NCT03010774|Active Comparator|Control - Usual Care|Study participants will be woken at night for routine nighttime spot-check vital signs regardless of patient disease severity or risk.
2483902|NCT03010371|Experimental|Positive Psychotherapy|A group of breast cancer survivors are randomly allocated to the presential version of the positive psychotherapy
2483903|NCT03010371|Experimental|Positive Online Psychotherapy|A group of breast cancer survivors are randomly allocated to the online version of the positive psychotherapy
2483905|NCT03010371|Experimental|Cognitive Behavioral Therapy|A group of breast cancer survivors are randomly allocated to the presential cognitive behavioral therapy (Cognitive Behavioral Stress Management, CBSM)
2483934|NCT03010033|No Intervention|regular care|[Control group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary and regular rehabilitation-propaganda; postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time) and early ambulation unless serious patients.
2483935|NCT03010033|Experimental|pulmonary rehabilitation|[Study group] preoperative treatment: smoking cession, aerosol inhalation for expectorant and antiasthmatic, anti-infection therapy if necessary, regular rehabilitation-propaganda and interventional pulmonary rehabilitation (preoperative part); postoperative treatment: regular postoperative treatment (anti-infection, pain control, oxygen Inhalation aerosol inhalation for expectorant and antiasthmatic), patting back (3 times/day, 15min/time), early ambulation unless serious patients and interventional pulmonary rehabilitation (postoperative part).
2483993|NCT03009864|Experimental|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
2483996|NCT03009864|Placebo Comparator|Placebo|"Treatment with placebo corresponding to each dose of Tangshen Prescription~, every bag weighs 4.87g, take it one bag each time, two times a day."
2484047|NCT03009526|Active Comparator|Sulfadoxine-pyrimethamine|Intermittent preventive treatment with Sulfadoxine-pyrimethamine: Monthly dose of 3 co-formulated tablets containing 500 mg sulfadoxine and 25 mg pyrimethamine
2484048|NCT03009526|Experimental|dihydroartemisinin-piperaquine|"Intermittent preventive treatment with dihydroartemisinin-piperaquine: Monthly course of daily doses of co-formulated DP tablets containing 40 mg dihydroartemisinin and 320 mg piperaquine, dosed based on the woman's weight, for 3 days:~24-35.9 kg: Two tablets~36-59.9 kg: Three tablets~60-79.9 kg: Four tablets~≥80 kg: Five tablets"
2484089|NCT03009084|Experimental|Intervention group|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
2484091|NCT03009084|No Intervention|Control group|Usual care.
2484136|NCT03008785|Experimental|group isoflavone and exercise|The isoflavone group received daily 100mg of isoflavones.
2484139|NCT03008785|Experimental|group placebo and exercise|The placebo group received 100mg containing starch of corn.
2484191|NCT03008447|Experimental|LEM5; LEM10; PBO; ZOL|Participants will receive LEM5 (one lemborexant [LEM] 5 milligram [mg] tablet and one zolpidem [ZOL]-matched placebo [PBO] tablet) in Treatment Period 1. In Treatment Period 2, participants will receive LEM10 (one LEM 10 mg tablet and one ZOL-matched PBO tablet). In Treatment Period 3, participants will receive PBO (one LEM-matched PBO tablet and one ZOL-matched PBO tablet). In Treatment Period 4, participants will receive ZOL (one LEM-matched PBO tablet and one ZOL 6.25 mg tablet).
2484197|NCT03008447|Experimental|LEM10; ZOL; LEM5; PBO|Participants will receive LEM10, ZOL, LEM5, and PBO in Treatments Periods 1, 2, 3, and 4, respectively.
2484200|NCT03008447|Experimental|ZOL; PBO; LEM10; LEM5|Participants will receive ZOL, PBO, LEM10, and LEM5 in Treatment Periods 1, 2, 3, and 4, respectively.
2484203|NCT03008447|Experimental|PBO; LEM5; ZOL; LEM10|Participants will receive PBO, LEM5, ZOL, and LEM10 in Treatment Periods 1, 2, 3, and 4, respectively.
3193604|NCT00819806|Experimental|A|PF-3512676, and three MHC class I Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102 will be administered in three separate subcutaneous (under the skin) injections.
3193605|NCT00819806|Experimental|B|This vaccine injection contains all the same components of Arm A and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm). Cyclophosphamide is an agent that is thought to increase the anti-tumor response of vaccines.
2484313|NCT03007446|Experimental|Apatinib plus Oxaliplatin/S-1|"Apatinib :~A starting dose of apatinib was administered 500 mg daily on days 1 through 21 of each 3-week cycle.~Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle.~S-1:40mg，bid，d1-14，po，in a 21 day cycle."
2484375|NCT03007251|Experimental|"Eurythmy Therapy Movement R"|"EYT exercise R: Positioned between two steps and forearms parallel to the ground, the patient performs a rolling movement like wheels on a wagon. The movement is positioned below shoulder height and is initiated from the shoulder blade."
2484382|NCT03007160|No Intervention|Blank control group|Subjects do not take the investigational product
2483868|NCT03011021|Active Comparator|Liraglutide|Patients will be subjected to a dose escalation of liraglutide up to 1.2 mg, then continue to receive the reached liraglutide dose once daily for 6 months thereafter. Insulin will be continued as routine therapy.
2483869|NCT03011021|Active Comparator|Insulin|Patients will receive insulin injection as a routine therapy.
2483949|NCT03010150||Observational (blood tests, questionnaires)|Participants provide blood samples prior to and at the 6-month visit after receiving radiation therapy. Participants also complete questionnaires either at home, in clinic, or via internet over 30 minutes prior to receiving radiation therapy and within 14 days of blood sample collection.
3193606|NCT00819806|Experimental|C|PF-3512676, Montanide ISA 720 VG and the peptides NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102, NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-1 157-170 will be administered in three separate subcutaneous injections.
3193607|NCT00819806|Experimental|D|This vaccine injection contains all the same components of Arm C and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
2484181|NCT03008655|Active Comparator|Nd-YAG|ND-YAG only
2484183|NCT03008655|Experimental|Nd-YAG and intradermal tranexamic acid|Nd-YAG combine with intradermal tranexamic acid
2484228|NCT03008291||Heart Failure Group|Patients who have left bundle branch block (LBBB), right bundle branch block (RBBB) or interventricular conduction delay (IVCD) with a QRS duration of greater than 120 ms and left ventricular ejection fraction (LVEF) ≤ 35% will be enrolled in this arm. The primary care physician will have recommended either CRT-D Implantation or CRT-P Implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
2484235|NCT03008291||Atrioventricular Block Group|Patients who have developed second or third degree atrioventricular block (AV block). The primary care physician will have recommended dual chamber pacemaker implantation. (This is Standard of Care for this patient population; the procedures will occur even if the patient does not participate in the study.)
3193608|NCT00819806|Experimental|E|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein will be administered in three separate subcutaneous injections.
2484335|NCT03007342|Experimental|Experimental group|Oral tablet 1000 mg of Amoxicillin/ clavulanic acid combination every 12 hours for five days.
2484338|NCT03007342|Placebo Comparator|control group|Oral tablet placebo every 12 hours for five days.
2484406|NCT03006861|Experimental|Oral creatine supplementation|21 g/d oral creatine for 7 days
2484407|NCT03006861|Placebo Comparator|Oral placebo supplementation|21 g/d oral placebo for 7 days
2484484|NCT03006536|Experimental|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
2484489|NCT03006536|Sham Comparator|Sham|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
2484600|NCT03005743|Experimental|MR based BT|Magnetic Resonance Image based Brachytherapy
2484601|NCT03005743|Other|Conventional BT|Conventional Radiograph based Brachytherapy
2484628|NCT03005444|Experimental|Anticoagulation|Rivaroxaban：10mg/d for 2 years
2484634|NCT03005444|No Intervention|Non-anticoagulated|No anticoagulants will be used.
2484695|NCT03005158|Other|Validation Phase|All six hospital sites currently use the ARCHITECT STAT high- sensitive troponin I assay in the assessment of patients with suspected acute coronary syndrome and use sex-specific thresholds upper reference limits (99th centile) to rule out myocardial infarction. This validation phase of up to 10 months will provide baseline information for each site on patients with suspected acute coronary syndrome in whom myocardial infarction is ruled out.
2484697|NCT03005158|Other|Randomization Phase|Participating centres will be randomized to implement the HighSTEACS pathway (intervention). The order of implementation will be randomized, with paired participating centres implementing in steps over a 6 month period.
2484701|NCT03005158|Active Comparator|Implementation Phase|A final phase of up to 10 months after implementation of the HighSTEACS pathway will be matched by calendar month in each site to that of the validation phase, allowing each participating centre to act as its own control and to adjust for seasonal differences in the incidence of myocardial infarction and mortality.
2484746|NCT03004781|No Intervention|Waiting-list|8-week period without intervention, N=45
2484750|NCT03004781|Experimental|self-efficacy|8-week group-based parenting program on self-efficacy beliefs, N=19
2484753|NCT03004781|Experimental|self-efficacy/emotion coaching|8-week group-based parenting program on self-efficacy beliefs and emotion coaching practice, N=26
2484860|NCT03004599|Other|Transcatheter Aortic Valve Implantation (TAVI)|
2484899|NCT03003780|Experimental|Mindful Steps|Web-based behavioral intervention
2484903|NCT03003780|No Intervention|Usual Care|
2484948|NCT03003507|Active Comparator|Diet 1|Low-carbohydrate Enteral Formula With Fructose
2484954|NCT03003507|Active Comparator|Diet 2|Low-carbohydrate Enteral Formula Without Fructose
2485029|NCT03003078|Other|OncoSil™ plus SOC Chemotherapy|OncoSil™ implanted with concurrent Standard of care Chemotherapy - either FOLFIRINOX or gemcitabine + Abraxane.
2485077|NCT03002532|Active Comparator|Whole-brain radiotherapy (WBRT) group|Conventional whole-brain radiotherapy for brain metastases from breast cancer with dose of 37.5 Gy in 15 fractions.
2515692|NCT02792075||VH-IVUS|Patients with IVUS-derived virtual histology
3193609|NCT00819806|Experimental|F|This vaccine injection contains all the same components of Arm E and will also be administered in 3 separate subcutaneous injections. However, 3 days prior to your 1st, 3rd, 5th, 7th, 9th and subsequent monthly vaccinations, you will have low-dose cyclophosphamide administered intravenously (through a vein in your arm).
3193610|NCT00819819|Active Comparator|1 Gluten containing diet|Gluten added to diet at 6 months per American Academy of Pediatrics recommendations
3193611|NCT00819819|Active Comparator|2 Gluten free diet|Non gluten containing food starch added to diet from 6-12 months
3193612|NCT00819845|Experimental|Ramipril|
3193613|NCT00819845|Experimental|Carvedilol|
3193614|NCT00819858|Experimental|RUTF|RUTF supplement (Plumpynut®) of 500 kcal/day for 2 weeks
3193615|NCT00819858|No Intervention|control|no supplement given
2483907|NCT03010306|No Intervention|Nutrition only|Monthly food baskets were provided to the nutrition only group. Food baskets included basic foods to sustain a family of three over one month's time, such as rice and evaporated milk. Food baskets were valued at approximately $28 US Dollars per basket.
2483908|NCT03010306|Active Comparator|Nutrition + CASITA|The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation & knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
2484028|NCT03009695|Experimental|High frequency repetitive dTMS + Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): present."
2484030|NCT03009695|Experimental|High frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active high frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz, Duration of the train: 2 sec, Inter-train interval: 20 sec, Trains number: 80, Total pulses: 2880, Total treatment duration: 29.3 min, Cue (sight of food preferred by patient): absent."
2484032|NCT03009695|Experimental|Low frequency repetitive dTMS+ Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment with cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT) Frequency: 1 Hz Duration of the train: 10 min Inter-train interval: 1 min Trains number: 4 Total pulses: 2400 Total treatment duration: 43 min Cue (sight of food preferred by patient): present"
2484033|NCT03009695|Experimental|Low frequency repetitive dTMS - No Cue|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to active low frequency repetitive dTMS treatment without cue.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 1 Hz, Duration of the train: 10 min, Inter-train interval: 1 min, Trains number: 4, Total pulses: 2400, Total treatment duration: 43 min, Cue (sight of food preferred by patient): absent."
2484034|NCT03009695|Sham Comparator|Sham|"10 obese individuals fulfilling all inclusion/exclusion criteria for the study will be randomized to sham stimulation.~Stimulation will be performed 3 times per week, for 5 weeks (15 treatments).~In this group, stimulation will be performed with the following features:~Intensity of stimulation: 120% of the resting Motor Threshold (rMT), Frequency: 18 Hz (50% of patients) and 1 Hz (50% of patients), Duration of the train: 2 sec or 10 min, Inter-train interval: 20 sec or 1 min, Trains number: 80 or 4, Total pulses: 2880 or 2400, Total treatment duration: 29.3 or 43 min, Cue (sight of food preferred by patient): present."
2484308|NCT03007745|Experimental|REVAMP|Veterans randomized to this arm will have access to the Remote Veteran Apnea Management Platform (REVAMP) a personalized, interactive website that allows Veterans to be evaluated for OSA without travelling to the sleep center.
2484309|NCT03007745|Active Comparator|In-person management|Veterans randomized to this arm will receive standard in-person management of their sleep apnea in the sleep center.
2484325|NCT03007303||schizophrenia|"15 patients with schizophrenia will be treated with anyone of the atypical psychotics(including olanzapine, quetiapine , ziprasidone and risperidone)or combined with MECT.~The fluctuating dosage depends on the changes of symptom according to the total scores of Positive and Negative Syndrome Scale from schizophrenia patients after treated."
2484327|NCT03007303||health controls|15 healthy individuals were collected from Dalian seventh people's hospital and were matched on age and sex to schizophrenia group
2484413|NCT03007108|Experimental|healthy infants|
3159274|NCT00402493|Active Comparator|ibuprofen|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
3159275|NCT00402519|Experimental|APBI|Accelerated Partial Breast Irradiation with multicatheter brachytherapy
2484605|NCT03005795|Experimental|Music and colposcopy|Women will hear Mozarts symphony Nr. 40 during the colposcopic examination
2484606|NCT03005795|Active Comparator|Colposcopy without music|During the colposcopic examination women will not hear music
2484652|NCT03005392|Experimental|Evaluate physical fitness|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2484653|NCT03005392|Experimental|Evaluate Cardiological changes|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2484703|NCT03005340|Active Comparator|Group F|Period 1: Bazedoxifene 20 mg+Cholecalciferol granule 10 mg Period 2: Bazedoxifene 20 mg Period 3: Cholecalciferol granule 10 mg
3159276|NCT00402519|Active Comparator|EBRT|Standard External Beam Whole Breast Irradiation
3159277|NCT00402532|Active Comparator|Everolimus|
3159278|NCT00402532|Active Comparator|Mycophenolatmofetil|
3159279|NCT00402558|Experimental|Thymoglobulin + Busulfan + Fludarabine|"Thymoglobulin 1.5 mg/kg by vein for 3 days. Busulfan 130 mg/m^2 by vein for 4 days. Fludarabine 40 mg/m^2 by vein for 4 days. Alloreactive NK infusion from haploidentical donor on Day -8. Alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7 NK Cells plus systemic interleukin-2 treatment. The 4th dose level is 3 x 107 NK cells/kg plus systemic interleukin-2 at a dose of 0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4.~G-CSF 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count is > 500 x 109/L for 3 consecutive days. Tacrolimus starting dose of 0.015 mg/kg daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present. Methotrexate 5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant."
3159280|NCT00402623|Placebo Comparator|1|placebo
2483970|NCT03009890|Experimental|Open reduction internal fixation|Surgical open reduction internal fixation (ORIF)
2483973|NCT03009890|Active Comparator|Plaster immobilization|Standard local hospital protocol for cast treatment
2484004|NCT03009643|Experimental|iNO Group|Patients are treated with iNO at a concentration of 5-10 ppm for 3-5 days according to the clinical conditions
2484005|NCT03009643|Other|Control|Patients are treated without iNO.
2484060|NCT03009266|Experimental|Normal controls|Normal controls who will undergo dose-ranging studies to determine the optimal dose of phosphatidylserine-containing microbubbles that does not produce delayed myocardial opacification on myocardial contrast echocardiography (MCE).
2484070|NCT03009266|Experimental|Patients with ACS|Subjects with ACS who have undergone primary percutaneous intervention in whom MCE with phosphatidylserine-containing microbubbles will be performed to determine whether the risk area can be detected and spatially defined.
2484141|NCT03008928|No Intervention|Control|No intervention
2484151|NCT03008928|Experimental|Alcooquizz app|Alcooquizz is a smartphone app designed to promote reductions in alcohol consumption among people who drink in a hazarzdous fashion
2484284|NCT03007875|Experimental|High-activity natural killer|In this group, the patients will receive multiple times of high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484286|NCT03007875|No Intervention|ControL|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484347|NCT03007550|Experimental|Laparoscopic total gastrectomy|The surgeon will perform LTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
2484352|NCT03007550|Other|Open total gastrectomy|The surgeon will perform OTG with D1+/D2-10 lymphadenectomy for patients enrolled in this group.
2484487|NCT03006692||Take arterial blood gas|Patients with impaired consciousness are randomised into having analysed a arterial blood gas.
2484492|NCT03006692||Do not take arterial blood gas|Patients with impaired consciousness are randomised into not having analysed a arterial blood gas.
2484552|NCT03006107|Experimental|intraligamentary injection of piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
2484557|NCT03006107|Active Comparator|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
2484650|NCT03005782|Experimental|Monotherapy (REGN3767)|Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.
2484651|NCT03005782|Experimental|Combination Therapy (REGN3767+cemiplimab)|Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion
2484775|NCT03004547||Peritoneal dialysis patients|Patients on peritoneal dialysis
2485050|NCT03002714|Experimental|Exercise|Performance of two resistance exercise sessions
3159281|NCT00402623|Active Comparator|2|quercetin (food supplement)
3159282|NCT00402636|Experimental|1|rapamycin plus 17beta estradiolvalerat-eluting stent
3159283|NCT00402636|Experimental|2|rapamycin-eluting stent
3159284|NCT00402675|Active Comparator|Immediate Intervention|Patients with NSTEMI undergo immediate invasive angiography (< 2 hours)
3159285|NCT00402675|Active Comparator|Early Intervention|Patients with NSTEMI undergo early invasive angiography (12-48 hours)
3159286|NCT00402675|Active Comparator|Selective invasive angiography|Patients with NSTEMI undergo selective invasive angiography
3159287|NCT00402701|Experimental|1|Students in school with active walk-to-school promotion programs.
3159288|NCT00402701|No Intervention|2|Students in schools with access to standard school district transportation resources.
3159289|NCT00402753|Experimental|Group 1|Physical exercise group: Combined supervised physical activity: Endurance and Resistive strength
3159290|NCT00402753|No Intervention|Group 2|Usual care control group
3159291|NCT00402766|Experimental|Cisplatin + Imatinib + Pemetrexed|Cisplatin 60 mg/m^2 by vein, Over 2 Hours. Imatinib 300 mg PO Daily. Pemetrexed 500 mg/m^2 by vein, Over 40 Minutes. Dexamethasone 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
3159292|NCT00402792|Experimental|Arm 1: hydrocodone / acetaminophen extended release|
3159293|NCT00402792|Experimental|Arm 2: hydrocodone / acetaminophen extended release|
3159294|NCT00402792|Placebo Comparator|Arm 3: Placebo|
3159295|NCT00402857|Experimental|1|Participants will receive the Incredible Years Program, a group parenting intervention
3159296|NCT00402857|Other|2|Participants assigned to the waitlist condition will receive the Incredible Years Program after a 1-year waiting period
2483951|NCT03010059|Experimental|Panel 1: Treatment ABC|Participants will receive 240 milligram (mg) JNJ-64041575 as 6.0 milliliter (mL) of a 40-milligram per milliliter (mg/mL) current oral suspension formulation (reference 1) under fasted conditions (Treatment A) in period 1, then 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 1) under fasted conditions (Treatment B) in period 2 followed by 4.0 mL of a 60-mg/mL new concept oral suspension formulation (test 2) under fed conditions (Treatment C) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483953|NCT03010059|Experimental|Panel 1: Treatment BCA|Participants will receive Treatment B (test 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483957|NCT03010059|Experimental|Panel 1: Treatment CAB|Participants will receive Treatment C (test 2) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483962|NCT03010059|Experimental|Panel 1: Treatment ACB|Participants will receive Treatment A (reference 1) in period 1, then Treatment C (test 2) in period 2 followed by Treatment B (test 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483965|NCT03010059|Experimental|Panel 1: Treatment BAC|Participants will receive Treatment B (test 1) in period 1, then Treatment A (reference 1) in period 2 followed by Treatment C (test 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483969|NCT03010059|Experimental|Panel 1: Treatment CBA|Participants will receive Treatment C (test 2) in period 1, then Treatment B (test 1) in period 2 followed by Treatment A (reference 1) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483972|NCT03010059|Experimental|Panel 2: Treatment DEF|Participants will receive JNJ-64041575 as 1 tablet of the 250-mg current oral tablet formulation (reference 2) under fasted conditions (Treatment D) in period 1, then 1 tablet of the 250-mg new concept oral tablet formulation (test 3) under fasted conditions (Treatment E) in period 2 followed by 1 tablet of the 250-mg new concept oral tablet formulation (test 4) under fed conditions (Treatment F) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483974|NCT03010059|Experimental|Panel 2: Treatment EFD|Participants will receive Treatment E (test 3) in period 1, then Treatment F (test 4) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483977|NCT03010059|Experimental|Panel 2: Treatment FDE|Participants will receive Treatment F (test 4) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment E (test 3) then in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483979|NCT03010059|Experimental|Panel 2: Treatment DFE|Participants will receive Treatment D (reference 2) in period 1, then Treatment F (test 4) in period 2 followed by Treatment E (test 3) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483983|NCT03010059|Experimental|Panel 2: Treatment EDF|Participants will receive Treatment E (test 3) in period 1, then Treatment D (reference 2) in period 2 followed by Treatment F (test 4) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2483986|NCT03010059|Experimental|Panel 2: Treatment FED|Participants will receive Treatment F (test 4) in period 1, then Treatment E (test 3) in period 2 followed by Treatment D (reference 2) in period 3 on Day 1. There will be a washout period of at least 14 days between study drug intake in subsequent treatment periods.
2484062|NCT03009123||Erectile dysfunction group|Group contains men with physician-diagnosed erectile dysfunction
2484065|NCT03009123||General population men without ED|Men 50 years and older having no ED and pre-existing prostate cancer
2484076|NCT03009123||Symptomatic BPH group without ED|Men 50 years old older with symptomatic prostatic hypertrophy but with no ED nor pre-existing prostate cancer
2484135|NCT03008941|Experimental|FMT|"Fecal microbiota capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
2484138|NCT03008941|Placebo Comparator|Placebo|"Placebo capsules (provided by Openbiome).~Dosage:~Induction: 10 capsules (single dose)~Maintenance: 5 capsules, weekly, during 7 weeks."
2484192|NCT03008486|Active Comparator|DOC - real|Spastic patients with disorders of consciousness receiving the real soft splint
2484195|NCT03008486|Placebo Comparator|DOC - placebo|Spastic patients with disorders of consciousness receiving the placebo soft splint
2484199|NCT03008486|Active Comparator|Stroke - real|Spastic patients stroke receiving the real soft splint
2484202|NCT03008486|Placebo Comparator|Stroke - placebo|Spastic patients stroke receiving the placebo soft splint
2484250|NCT03008148|Active Comparator|Radiation,Temozolomide|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).~Rest Phase: Rest for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.~Maintenance Phase: No maintenance treatment until disease progression confirmed."
2484251|NCT03008148|Experimental|Radiation,Temozolomide,Siroquine(JP001)|"CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks) + Daily JP001 (2 tablets once a day for 6 weeks).~Rest Phase: Daily JP001(2 tablets/day) for 4 weeks.~Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) until disease progression confirmed."
2484289|NCT03007823|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer (HANK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484294|NCT03007823|No Intervention|Control|In this group, the patients will receive no special treatment and as a control group. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484358|NCT03007524|Experimental|High dose rosuvastatin|20mg/d quaque nocte(qN), at least 6 months
2484361|NCT03007524|Active Comparator|Low dose rosuvastatin|10mg/d quaque nocte（qN）, at least 6 months
3159297|NCT00402948|Experimental|TPI ASM8|ASM8 0.25mg
3159298|NCT00402948|Experimental|ASM8 as TPI ASM8|TPI ASM8 0.5mg
2484041|NCT03009500|Active Comparator|Local Anesthetic|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve to a maximum of 20 cc
2484042|NCT03009500|Active Comparator|Local Anesthetic with steroids|Injection of 2-6 cc of LA (0.25% bupivacaine) per nerve containing steroids (methylprednisolone (Depo-Medrol) 4 mg per cc) to a maximum of 20 cc
2484044|NCT03009500|Placebo Comparator|Saline|Injection of 2-6 cc of saline (0.9% sodium chloride) per nerve to a maximum of 20 cc
2484088|NCT03009097|Active Comparator|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with DFDBA
2484092|NCT03009097|Active Comparator|DFDBA with Atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
2484146|NCT03008746|Experimental|not Pseudomonas aeruginosa colonized|
2484156|NCT03008746|Experimental|Pseudomonas aeruginosa colonized|
2484166|NCT03008746|Experimental|Pseudomonas aeruginosa OprD mutant colonized|
2484231|NCT03008304|Experimental|High-activity natural killer|In this group, the patients will receive multiple high-activity natural killer immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484237|NCT03008304|No Intervention|Control group|In this group, the patients will receive no special treatment. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484278|NCT03008018|Other|KA2507 (HDAC6 inhibitor)|This is a single arm dose escalating study. Patients will be treated with open label KA2507 (HDAC6 inhibitor) capsules.
2484298|NCT03007641|Experimental|Provider Didactic Intervention|"Phase 1 - Providers complete a needs assessment questionnaire.~Phase 2 - Providers participate in an hour long didactic session, and begin enrolling eligible metastatic breast cancer (MBC) patients. Enrolled MBC patients complete a comprehensive geriatric assessment (CGA). Providers complete a treatment plan questionnaire and a CGA utility questionnaire.~Phase 3 - Providers are administered a final questionnaire evaluating their overall view of this educational intervention."
2484320|NCT03007381|Experimental|Ketorolac tromethamine|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the ketorolac intervention group, then the participant will receive 30 mg of intravenous (IV) ketorolac tromethamine. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
2484323|NCT03007381|Sham Comparator|Normal Saline|Each patient will undergo mastectomy(ies) if immediate reconstruction is being performed, followed by uni- or bilateral abdominally based free flap harvest, microsurgical anastomoses, and flap inset. If randomized to the control group the patient will be given a sham IV medication. The sham medication will be normal saline at the same volume as ketorolac, which corresponds to 3 ccs. The anaesthetist will give participants their first study drug intravenously at the conclusion of surgery. The participant will then continue to receive their assigned drug every 6 hours for 72 hours, for a total of 13 doses. Patients all receive 1:1 care from nursing staff in the early postoperative period, and their nurse will administer all drugs given on the surgical ward.
2484389|NCT03007212|Experimental|HCC patients with Pranch portal vein thrombosis|Thirty HCC patients (24 male, 6 females) Child A cirrhotics with branch PVT. Follow up was done at 1, 3, 6 and 12 months after first TACE. All patients underwent laboratory investigations including liver function tests to assess deterioration in liver functions, triphasic spiral CT to assess radiological response according to mRECIST criteria. Survival analysis was performed using Kaplan-Meier estimations.
2484449|NCT03006770|Experimental|PLX-PAD|PLX-PAD will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
2484450|NCT03006770|Placebo Comparator|Placebo|Placebo will be administered via 30 IM injections (0.5 mL each). Each subject will be treated twice, with an interval of 8 weeks between treatments.
2484527|NCT03006198||Cohort 1: Rheumatoid Arthritis|Participants with Rheumatoid arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2484531|NCT03006198||Cohort 2: Ankylosing Spondylitis|Participants with Ankylosing spondylitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2484532|NCT03006198||Cohort 3: Psoriatic Arthritis|Participants with Psoriatic arthritis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2484533|NCT03006198||Cohort 4: Crohn's Disease|Participants with Crohn's disease as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
2484534|NCT03006198||Cohort 5: Ulcerative Colitis|Participants with Ulcerative colitis as the major disease treated with REMICADE, SIMPONI or STELARA in clinical practice in the emerging regions of North Africa, the Middle East, and Western Asia will be observed for disease characteristics, treatment and outcomes.
3159299|NCT00402961|Active Comparator|1|Acupuncture is the insertion of needles at certain body points.
3159300|NCT00402961|Sham Comparator|2|sham acupuncture
3159301|NCT00403013|Experimental|1|lateral, head-down position during axillary plexus block
3159302|NCT00403013|Active Comparator|2|standard position during axillary plexus block
3159303|NCT00403039|Other|Open-label ranibizumab|Subjects will receive open-label intravitreal injections of ranibizumab administered every 28 ± 7 days for a total of 3 injections. Thereafter they are to be evaluated monthly for re-treatment until Month 48.
3159304|NCT00403052|Experimental|1|Low dose of 1018 ISS
3159305|NCT00403052|Experimental|2|Middle dose of 1018 ISS
3159306|NCT00403052|Experimental|3|High dose of 1018 ISS
2484000|NCT03009591|Experimental|Expermiental group|All patients included in the experimental group should be on prophylactic treatment with FVIII / FIX concentrates. Likewise, the factor should be administered on the same day that they receive each of the fascial therapy treatment sessions. Each session will last approximately 50 minutes, with three physiotherapy sessions taking place over a period of 3 weeks. The treatment program includes 11 maneuvers that must be administered bilaterally:
2484001|NCT03009591|No Intervention|Control group|Subjects included in the control group will not receive physical therapy through fascial therapy and will continue with their usual routine of physical activity and exercise, and with the same pharmacological treatment regimen with FVIII / FIX. At the end of the study period the intervention will be applied under the same conditions as the experimental group, analyzing the overall sample at the end of the study.
2484045|NCT03009474|Experimental|CJ-30060|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
2484046|NCT03009474|Active Comparator|Exforge tab 5/160mg, Crestor tab 10mg|Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg
2484069|NCT03009110|Experimental|Prophylactic NPWT|Women assigned to prophylactic NPWT will have the Prevena device applied and secured with fixation adhesion strips. The device will be monitored while the patient is in the hospital to confirm that it is functioning well. The device will be removed prior to discharge, typically on postoperative day 4, but longer for up to 7 days for patients who remain hospitalized.
2484073|NCT03009110|Active Comparator|Standard Dressing|Women assigned to standard care will receive routine postoperative wound dressing consisting of layers of gauze and adhesive tap. The dressing will be removed after 24 - 48 hours.
2484137|NCT03008798|Experimental|Herbal Medicine C-117|Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
2484142|NCT03008798|Placebo Comparator|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 6g granules by mouth,every 12 hours for 1 year
2484190|NCT03008473|Experimental|video laryngoscope and chest CT iminge|First,the operator calculate the distance between the carina and the glottis by CT image and make a marker on the Uniblocker. Then the operator inserted the Uniblocker into the trachea and advanced toward the left main-stem bronchus via the video laryngoscope untill see marker just at the glottis then stopped the insertion .Second, a single lumen tube with appropriate size was intubated via video laryngoscope into the appropriate depth.Third,the Fiberoptic bronchoscopy(FOB) was inserted into single lumen tube to assess the position of the Uniblocker and the injuries of bronchi and carina
2484196|NCT03008473|Experimental|Conventional intubation of Uniblocker|First, a conventional single lumen tube (SLT) was inserted into trachea at optimal depth via video laryngoscope. Second, a Uniblocker was inserted through SLT and directed to the left main-stem bronchus. Third, an FOB was inserted into the SLT to adjust the Uniblocker to optimal position and assessed the injuries of bronchi and carina.
2484247|NCT03008265||Colonic cancer resection|
2484290|NCT03007888|Other|Sequence 1|Treatment Period 1: ER CD-LD Capsules - 15 days; Washout Period 7-days; Treatment Period 2- IR CD-LD Tablet - 15 days
2484293|NCT03007888|Other|Sequence 2|Treatment Period 1- IR CD-LD Tablet - 15 days; Washout Period 7-days; Treatment Period 2- ER CD-LD Capsules - 15 days
2484330|NCT03007459||Female Fitness Athletes|Psychological health and physiological health of fitness athletes
2484334|NCT03007459||Female, physically active Controls|Psychological health and physiological health of female controls
2484414|NCT03006835|Experimental|Domestic Clopidogrel 300mg|Domestic Clopidogrel 300mg
2484423|NCT03006835|Experimental|Domestic Clopidogrel 600mg|Domestic Clopidogrel 600mg
2484428|NCT03006835|Experimental|Imported Clopidogrel 300mg|Imported Clopidogrel 300mg
2484435|NCT03006835|Active Comparator|Imported Clopidogrel 600mg|Imported Clopidogrel 600mg
2484451|NCT03006523|Active Comparator|Intrauterine Insemination with 200 µl|The sperm sample will be concentrated by centrifugation to a volume of 200 µl
2484452|NCT03006523|Experimental|Intrauterine Insemination with 500 µl|The sperm sample will be concentrated by centrifugation to a volume of 500 µl.
2484475|NCT03006380|Experimental|oxytocin before placental delivery|patients who will receive 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly at delivery of anterior shoulder of the fetus and an identical placebo injection (normal saline, NACL 0.9%) intramuscularly following delivery of the placenta.
2484476|NCT03006380|Experimental|oxytocin after placental delivery|patients who will receive placebo injection (normal saline, NACL 0.9%) intramuscularly at delivery of anterior shoulder of the fetus and 10 IU of oxytocin (syntocinon®, NOVARTIS, Egypt) intramuscularly following delivery of the placenta.(opposite medication sequence)
2484518|NCT03006185|Active Comparator|Test Area A|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
2484522|NCT03006185|Active Comparator|Test Area B|Two 50 cm2 test areas (Test Area A and B) are demarcated on the skin of each study participant. One test area is randomized to receive the intervention: Ablative Fractional Carbon Dioxide (CO2) Laser prior to standard daylight photodynamic therapy. The other test area is randomized to receive the intervention: microdermabrasion prior to standard daylight photodynamic therapy.
2484581|NCT03005912|Placebo Comparator|Conventional acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with acoustic transmission of the speech signal.
2484585|NCT03005912|Active Comparator|Conventional bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a conventional mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
2484588|NCT03005912|Active Comparator|VoIP acoustic telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with acoustic transmission of the speech signal.
2484590|NCT03005912|Active Comparator|VoIP bluetooth telephony|Telephone speech comprehension in hearing aided patients (Cochlear Implant or GN Resound hearing aid) for a VoIP mobile phone call with direct bluetooth transmission of the speech signal to the cochlear implant or hearing aid.
2484063|NCT03009240|Experimental|Treatment (pevonedistat, decitabine)|Patients receive pevonedistat IV over 1 hour on days 1, 3, and 5 and decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unexpected toxicity.
2484161|NCT03008733|Active Comparator|NMMCB|patient with Neuropathies with Motrices Multifocal Conduction Block
2484168|NCT03008733|Active Comparator|PICD|patient with Inflammatory demyelinating polyneuropathy Chronicle
2484172|NCT03008733|Active Comparator|anti MAG|patient with neuropathy antibody Anti-MAG
2484175|NCT03008733|Placebo Comparator|healthy|healthy patient
2484226|NCT03008317|Active Comparator|non metallic|PEEK denture base,
2484230|NCT03008317|Placebo Comparator|metallic denture base|cobalt chromium alloy denture base
2484270|NCT03008031|Experimental|arm A (40%)|Patients randomized in arm A will receive a second CESM exam with 40% of the initial dose of the contrast agent.
2484271|NCT03008031|Experimental|arm B (60%)|Patients randomized in arm A will receive a second CESM exam with 60% of the initial dose of the contrast agent.
2484274|NCT03008031|Experimental|arm C (80%)|Patients randomized in arm A will receive a second CESM exam with 80% of the initial dose of the contrast agent.
2484331|NCT03007615|Experimental|Experimental group|
2484380|NCT03007238|Experimental|Supportive care (aldesleukin and ECP)|Patients receive aldesleukin SC daily for 12 weeks. Patients also undergo ECP twice weekly on weeks 1-4 and then receive 2 ECP treatments every 2 weeks on weeks 5-12. Patients responding to upfront therapy with aldesleukin and ECP have the option to continue combination therapy per the discretion of the treating physician until clinical benefit is maintained or toxicities develop.
2484440|NCT03006822|Experimental|Application 90 minutes pressure release|Subjects will receive a pressure release technique for 90 seconds in the levator scapula muscle
2484442|NCT03006822|Experimental|Application 60 minutes pressure release|Subjects will receive a pressure release technique for 60 seconds in the levator scapula muscle
2484444|NCT03006822|Experimental|Application 30 minutes pressure release|Subjects will receive a pressure release technique for 30 seconds in the levator scapula muscle
2484509|NCT03006432|Active Comparator|FOLFOX|Cycles every 15 days until progression desease
2484511|NCT03006432|Experimental|TFOX|Cycles every 15 days until progression desease
2484707|NCT03005366|Active Comparator|Flecainide|Conventional cardioversion group using intravenous flecainide.
2484710|NCT03005366|Active Comparator|Vernakalant|Atria-preferential and atrial-specific blockade group using intravenous vernakalant.
2484757|NCT03004742|Experimental|Flavonoid|Flavonoid supplement
2484759|NCT03004742|Placebo Comparator|Placebo|Placebo
2484800|NCT03004495|Experimental|CHF5259 and CHF6001|(T): CHF6001 + CHF5259 b.i.d. for 14 days
2484802|NCT03004495|Active Comparator|CHF5259 + placebo|(R1): CHF5259 25µg b.i.d. for 14 days
2484803|NCT03004495|Active Comparator|CHF6001 + placebo|(R2): CHF6001 b.i.d. for 14 days
2484837|NCT03004118|Active Comparator|Ursochol|About 10.5mg/kg/day of ursochol (calculated before start study for each participant individually) (combination of ursochol 150 and 300) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
2484842|NCT03004118|Placebo Comparator|Placebo|Same amount of pills as ursochol (calculated before start study for each participant individually) divided in 2 doses per day (during lunch and dinner). Oral intake. Tablets. 4 weeks.
2484900|NCT03003689|Active Comparator|Scaling and Root Planing|"Hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
2484904|NCT03003689|Experimental|Scaling and Root Planing + Er:YAG Laser|"Er:YAG Laser, hand instruments + ultrasonic scaler~PD, CAL, plaque index and gingival bleeding index will be measured at baseline, 6 weeks and 3 months. Microbial load will be measured at baseline and 3 months."
2484940|NCT03003416||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of Diabetic Macular Edema.
2484991|NCT03002870|Other|Endometriosis|Patients whom pathology results post surgery document endometriosis
2485037|NCT03002779|Experimental|JNJ-53718678|
2485054|NCT03002428|Experimental|Teriparatide (PF708)|PF708 20 mcg once-daily subcutaneous injection for 24 weeks
2485055|NCT03002428|Active Comparator|Teriparatide (Forteo)|Forteo 20 mcg once-daily subcutaneous injection for 24 weeks
3159307|NCT00403091|Experimental|Intervention|
3159308|NCT00403091|Active Comparator|Control|
3159309|NCT00403104|Experimental|E|ONO-2506PO in the presence of Riluzole
3159310|NCT00403104|Placebo Comparator|P|Placebo in the presence of Riluzole
3159311|NCT00403169|Experimental|Lenalidomide for Advanced RCC|25 mg/day Lenalidomide for 21 days per cycle.
3159312|NCT00403247|Experimental|A|vitamin capsule
3159313|NCT00403247|Placebo Comparator|B|placebo capsule
3159314|NCT00403286|Experimental|C 10/1|
3159315|NCT00403286|Experimental|C 5/2|
3159316|NCT00403286|Experimental|C 5/1|
3159317|NCT00403286|Experimental|FP 1000|
3159318|NCT00403286|Experimental|FF 20|
3159319|NCT00403286|Active Comparator|AD 250/50|
3159320|NCT00403286|Placebo Comparator|Plc|
3159321|NCT00403286|Experimental|C 10/2|
3159322|NCT00403351||ARM-CAD 1|Cross-sectional analysis using coronary angiogram results
3159323|NCT00403351||ARM-CAD 2|Prospective cohort for incident cardiovascular events and mortality
3159324|NCT00403377|Experimental|Intervention|Phase II include two arms. In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
3159325|NCT00403377|No Intervention|Control|Phase II include two arms. In the control arm, a souvenir photograph is taken of the participants and they then receive product samples that are irrelevant to skin cancer risk reduction (e.g., skin moisturizer, hair gel, chewing gum). Participants also receive educational materials at the completion of the study.
3159326|NCT00403416|Active Comparator|Mycophenolic Acid / tacrolimus|
3159327|NCT00403416|Experimental|AEB071 / tacrolimus arm 1|
3159328|NCT00403416|Experimental|AEB071 / tacrolimus arm 2|
2484084|NCT03009253|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
2484085|NCT03009253|Experimental|Chemotherapy Group|"Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)~Followed by Concurrent chemoradiotherapy:~(Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks)"
2484163|NCT03008772||PCI with Commercially available DES|Patients who have undergone PCI and received a commercially available drug eluting stent
2484171|NCT03008772||Stent Types|the stent types for angina classification at follow up
2484207|NCT03008538|Experimental|Mineralized Plasmatic Matrix|MPM(Mineralized plasmatic matrix) insertion in extraction sockets for socket preservation for later implant placement and histomorphometric analysis.
2484209|NCT03008538|Active Comparator|Autogenous Bone Graft (Gold Standards).|Socket preservation using Autogenous bone graft for later implant placement and histomorphometric analysis.
3159329|NCT00403429|Experimental|Capecitabine|
3159330|NCT00403507|No Intervention|Clean Control|Probable Alzheimer's disease in the context of no excluding medical conditions.
3159331|NCT00403507|No Intervention|CoMorbid Control|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
3159332|NCT00403507|Experimental|Clean Exercise|Probable Alzheimer's disease in the context no comorbid medical conditions.
2484421|NCT03006783||Cross-face nerve graft treated|People treated by a solitary cross-face nerve graft or in combination with another procedure.
2484432|NCT03006783||Hypoglossal-facial treated|People treated with a solitary hypoglossal-facial anastomosis.
2484460|NCT03006640|Placebo Comparator|Control group|
2484461|NCT03006640|Active Comparator|NTG group|
2484514|NCT03006289||The thyroid cancer group|The postoperative pathology of thyroid is malignant
2484516|NCT03006289||The thyroid nodule group|The postoperative pathology of thyroid is benign
2484556|NCT03005990|Experimental|Exercise training group|Exercise group will attend a supervised aerobic plus resistance exercise training class 3 times a week totally for 24 weeks.
2484559|NCT03005990|No Intervention|Control group|Control group only provide standard outpatient care program.
2484611|NCT03005808|No Intervention|control group|All patients had the same protocol of anesthesia and analgesia. The control group didn´t received block.
2484613|NCT03005808|Experimental|TAP 0.25 group|The TAP 0.25 group received TAP block with ropivacaine 0.25% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
2484615|NCT03005808|Experimental|TAP 0.5 group|The TAP 0.5 group received TAP block with ropivacaine 0.5% 0.4ml/kg. All patients had the same protocol of anesthesia and analgesia.
2484696|NCT03005314|Other|Surgery|Postoperative chemotherapy group
2484700|NCT03005314|Other|Chemotherapy|Preoperative chemotherapy group
2484752|NCT03004807|Experimental|Multivitamin|Centrum Silver Men's Formula Multivitamin/Multimineral Supplement: 1/day
2484755|NCT03004807|Placebo Comparator|Control|Matching tablet to active multivitamin arm: 1/day
2484828|NCT03004404|Experimental|BI 730357|
2484835|NCT03004404|Placebo Comparator|Placebo|
2484879|NCT03003988|Experimental|Creatine monohydrate|Creatine monohydrate (6.0 g.) + dextrose (0.5 g.)
2485276|NCT03000933||Young same-sex attracted men|Same-sex attracted men aged 16 to 20
3159333|NCT00403507|Experimental|CoMorbid Exercise|Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.
3159334|NCT00403520|Experimental|Experimental 1|
3159335|NCT00403520|Placebo Comparator|Placebo Comparator|
3159336|NCT00403611|Active Comparator|Praziquantel 40mg/kg|Praziquantel (Distocide) 40mg/kg single oral dose
3159337|NCT00403611|Experimental|Praziquantel 60mg/kg|Praziquantel (Distocide) 60mg/kg single oral dose
3159338|NCT00403650|Experimental|1|
3159339|NCT00403676|Experimental|Follow up by nurse|Patient randomized for follow-up by a nurse
3159340|NCT00403676|Experimental|follow up by medical doctor|Patients randomized for follow up by a medical doctor
3159341|NCT00403689|Experimental|x|capsules containing beta glycan
3159342|NCT00403689|Placebo Comparator|y|capsules containing placebo (waxy maize starch)
3159343|NCT00403780|Active Comparator|A|Active intervention with pregabalin
3159344|NCT00403780|Placebo Comparator|B|placebo arm with capsule Lyrica Placebo
3159345|NCT00403793|Active Comparator|Arm 1|etonogestrel with testosterone undecanoate
3159346|NCT00403793|Placebo Comparator|Arm 2|Placebo
3159347|NCT00403806|Active Comparator|1|Intravenous dexamethasone 0.05 mg per kg bodyweight
3159348|NCT00403806|Active Comparator|2|Intravenous dexamethasone 0.15 mg per kg bodyweight
3159349|NCT00403806|Active Comparator|3|Intravenous dexamethasone 0.5 mg per kg bodyweight
3159350|NCT00403806|Placebo Comparator|4|Intravenous saline
3159351|NCT00403897|Experimental|1|Ages 2 - 6: Day 1= 1 sachet/day; Day 3= 1 sachet BID; Day 5= 1 sachet TID Ages 7 - 11: Day 1= 1 sachet BID; Days 3 & 5 = 2 sachets BID;
3159352|NCT00403923||Patients with known lactose intolerance|
3159353|NCT00403949|Active Comparator|Azelaic acid 15% Gel|Azelaic acid 15%
3159354|NCT00403949|Placebo Comparator|Placebo|Non-active base from Azelaic acid 15% gel
3159355|NCT00404014|Active Comparator|AL-208|1 dose of 300 mg
3159356|NCT00404014|Placebo Comparator|Placebo|
3159357|NCT00404144|Experimental|Drug Eluting Balloon|treatment of small vessel with drug eluting balloon
3159358|NCT00404170|Experimental|B-CIT and SPECT imaging|To assess B-CIT injection and SPECT scanning. Optional ongoing B-CIT SPECT imaging scans at follow-up visits
3159359|NCT00404183|Experimental|hydrocodone/acetaminophen extended release|
3159360|NCT00404183|Placebo Comparator|Placebo|
3159361|NCT00404222|Experimental|hydrocodone / acetaminophen extended release|
3159362|NCT00404222|Active Comparator|Hydrocodone/Acetaminophen Immediate Release (Norco ®)|
3159363|NCT00404222|Placebo Comparator|Placebo|
3159364|NCT00404261|Other|Arm 1|Fluticasone/Salmeterol HFA MDI without counter
2484100|NCT03009058|Experimental|IMM-101 + FOLFIRINOX panc ca|"IMM-101 will be given in combination with standard FOLFIRINOX (FOLinic acid, Fluorouracil, IRINotecan and OXaliplatin) treatment.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484101|NCT03009058|Experimental|IMM-101+FOLFOX colorectal cancer|"IMM-101 will be given in combination with standard FOLFOX (FOLinic acid, Fluorouracil and OXaliplatin) treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484102|NCT03009058|Experimental|IMM-101+FOLFIRI+CETUXIMAB CRC|"IMM-101 will be given in combination with standard FOLFIRI (FOLinic acid, Fluorouracil and IRInotecan) + cetuximab combination treatment.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484103|NCT03009058|Experimental|IMM-101+Gem cholangio|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2484106|NCT03009058|Experimental|IMM-101+Gem lung ca|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter
2484108|NCT03009058|Experimental|IMM-101+Gem + nab-paclitaxel lung ca|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM 101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484110|NCT03009058|Experimental|IMM-101+anti-PD1 lung ca|"IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab.~In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen."
2484111|NCT03009058|Experimental|IMM-101+Gem melanoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2484112|NCT03009058|Experimental|IMM-101+anti-PD1 melanoma|IMM-101 will be given in combination with standard treatment with either pembrolizumab or nivolumab. The first 3 patients entering the anti-PD1 (pembrolizumab or nivolumab) cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
2484113|NCT03009058|Experimental|IMM-101+ anti-CTLA-4 melanoma|IMM-101 will be given in combination with standard treatment with ipilimumab. In order to ensure that there are no increased immune-related adverse events (AEs), the first 3 patients entering the ipilimumab cohort will receive IMM-101 at an increased dosing interval of every 4 weeks. In the absence of safety concerns for these patients after 3 doses of IMM-101, and following a robust safety review, all subsequent patients recruited to this treatment cohort will switch to the standard, more intensive (2-weekly induction dosing) IMM-101 dosing regimen thereafter.
2484114|NCT03009058|Experimental|IMM-101+Gem breast cancer|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2484115|NCT03009058|Experimental|IMM-101+Gem/ nab-paclitaxel breast|"IMM-101 will be given in combination with standard gemcitabine + nab-paclitaxel combination therapy.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484116|NCT03009058|Experimental|IMM-101 + Gem sarcoma|IMM-101 will be given in combination with standard gemcitabine monotherapy. The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
2484117|NCT03009058|Experimental|IMM-101+cyclophosphamide|"IMM-101 will be given in combination with low dose cyclophosphamide (300mg/m2 in patients with solid malignancies.~The treatment regimen with IMM-101 will be one dose given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter."
2484212|NCT03008616|Active Comparator|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
2484214|NCT03008616|Placebo Comparator|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
2484260|NCT03008005|Placebo Comparator|Placebo Oral Capsule|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
2484263|NCT03008005|Experimental|Dronabinol Cap 5 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
2484132|NCT03008720|Active Comparator|FES active|Functional electrical stimulation (FES) active will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 μs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold.
2484133|NCT03008720|Placebo Comparator|FES sham|Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA.
2484215|NCT03008577|No Intervention|Ambient operating room temperature of 67°F|These patients will have an operating room temperature of 67°F for cesarean delivery, the standard of care at our institution.
2484216|NCT03008577|Active Comparator|Ambient operating room temperature of 75°F|Intervention: Ambient operating room temperature of 75°F for cesarean delivery, which is closer to World Health Organization recommendations.
2484356|NCT03007654|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around surgery area
2484359|NCT03007654|No Intervention|No treatment|standard treatment for surgery
2484363|NCT03007654|Active Comparator|Adept|adhesion barrier, Adept, to apply medical device fully around surgery area
2484408|NCT03007030|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2484453|NCT03006484||Before Period|Patients who developed in-hosptial cardiac arrest before the implementation of new legislation on life-sustaining treatments
2484454|NCT03006484||After Period|Patients who developed in-hosptial cardiac arrest after the implementation of new legislation on life-sustaining treatments
2484507|NCT03006354|Experimental|nHFOV|"Ventilator-derived nHFOV will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nHFOV settings are: MAP: 8cmH2O, Frequency:10 MHz, Amplitude:35 cmH2O (will be adjusted to achieve adequate chest wall vibration), I:E=1:1 and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nHFOV failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
2484510|NCT03006354|Active Comparator|nCPAP|"Ventilator-derived nCPAP will be administered using binasal prongs. Standard Device: Leoni-Plus or Leoni-2 Ventilator, Heinen Löwenstein, Germany Initial nCPAP settings are: PEEP:6 cmH2O and FiO2: adjusted to keep preductal sPO2 between %90-95.~Failure is defined as FiO2 requirement of >%60, capillary blood gas obtained at the 4th hour of therapy showing pH<7.20 or pCO2>65 cmH2O.~When nCPAP failure occurs, nasal intermittent positive pressure ventilation (nIPPV) will be applied as a rescue therapy with the following settings: Frequency:30/min, PIP:18 cmH2O, PEEP:6 cmH2O, inspiration time:0.50 sec., inspiratory flow:10 L/min, FiO2:adjusted to keep preductal sPO2 between %90-95."
2484564|NCT03005938|Experimental|Spinal manipulation|Spinal manipulation
2484572|NCT03005938|Sham Comparator|Imitation of the spinal manipulation|Imitation of the spinal manipulation
2484616|NCT03005600||Asian Indian|"Recruitment to the Indian cohort will be carried out in urban areas of Chennai and be coordinated from Madras Diabetes Research Foundation (MDRF).~As a part of their routine care, all pregnant women will undergo regular blood tests at presentation, a dating scan if the last menstrual period is unknown and an ultrasound at 20 weeks of pregnancy for foetal anomalies.~3400 pregnant women in early pregnancy will be studied in this cohort."
2484619|NCT03005600||African|"Recruitment to the Kenyan cohort will be based and coordinated from Moi Teaching and Referral hospital (MTRH). The bulk of the recruitment will happen at MTRH with significant contribution from Usain Gisu District hospital (UGDH) and Medi-Heal.~4000 pregnant women in early pregnancy will be studied in this cohort."
2484689|NCT03005301|Experimental|Experimental group|Selected acupoints will be stimulated by the new intelligent electro-acupuncture instrument.
2484693|NCT03005301|Active Comparator|Control group|Selected acupoints will be stimulated by the Hwato electroacupuncture instrument.
2484733|NCT03004833|Experimental|Arm A|4 Cycles of Nivolumab plus AVD followed by IF-RT (30 Gy)
2484734|NCT03004833|Experimental|Arm B|4 Cycles of Nivolumab, followed by 2 cycles of Nivolumab plus AVD, followed by 2 Cycles of AVD followed by IF-RT (30 Gy)
2484780|NCT03004573|Experimental|Deep brain stimulation|
2484832|NCT03004105|Experimental|Intermittent Arm - Selumetinib + Durvalumab|Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off, and Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
2484839|NCT03004105|Experimental|Safety Run In|"Short safety run-in prior to the start of randomization. Participants on the safety run-in treated with Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.~Safety run-in beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle.~During the safety run in portion of the trial, enrollment will be open to all comers, regardless of KRAS mutation status."
2484844|NCT03004105|Experimental|Continuous Arm - Selumetinib + Durvalumab|"Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.~Participants receive Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle."
2484905|NCT03003806|Experimental|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
2484912|NCT03003806|Active Comparator|Control group-medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
3159365|NCT00404261|Other|Arm 2|Fluticasone/Salmeterol HFA MDI with counter
3159366|NCT00404274|Experimental|Treatment regimen A|In treatment regimen A subject will co-administer casopitant and warfarin over three-day period (Day 1 150 milligram per day [mg/day], Day 2 50 mg/day, Day 3 50 mg/day) and from Days 4 to 10 subject will administer only warfarin.
2484998|NCT03002844|Experimental|EGFR-TKI and Chemotherapy|gefitinib with pemetrexed/gemcitabine and carboplatin
2484999|NCT03002844|Experimental|EGFR-TK Inhibitor|Gefitinib
3193616|NCT00819871||PLI|patients with postoperative lung injury
2484143|NCT03009006|Experimental|Calcium Hydroxide Mixed With Chlorhexidin|efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria.
2484153|NCT03009006|Experimental|Calcium Hydroxide|The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
2484162|NCT03009006|Placebo Comparator|Placebo|Mechanical preparation without intracanal medications.
2484261|NCT03007901|Experimental|Pilot Cohort 1|This Pilot Study will be conducted to allow us to evaluate and test the various study processes, including: consent/enrollment, run-in-trial monitoring, measurement tools, outcome assessment, educational materials, and especially the mindfulness-based climate action trainings. The pilot study does not include a control group, and data will not be used for efficacy outcome analysis.
2484301|NCT03007797||vaccination rate- pregnant- influenca|
2484322|NCT03007433|Experimental|healthy volunteers|60 healthy volunteers with no functional dyspepsia as defined by the Rome Questionnaire and no more than mild symptoms on maximum 1 days a week on the GSRS, that meet inclusion and exclusion criteria will be recruited. Eligible subjects will be block randomized by sex and age such that 10 men and women in each age group (<40, 41-60, >60) are recruited.
2484326|NCT03007433|Experimental|Functional dyspeptic patients|20 patients with functional dyspepsia with postprandial distress syndrome as defined by the Rome IV Questionnaire and at least moderate symptom severity on at least 3 days a week that meet the inclusion and exclusion criteria will be recruited to provide pilot data in the local patient population
2484394|NCT03007199||AGNES Controls|AGNES controls are individuals with a first acute ST-elevation myocardial infarction but without ventricular fibrillation.
2484395|NCT03007199||AGNES cases|AGNES cases have ECG- registered ventricular fibrillation occurring before reperfusion therapy for an acute and first ST-elevation myocardial infarction.
2484447|NCT03006744|Experimental|Phonological awareness training|Parents will be given specific training on how to improve phonological awareness using books provided by the investigator. Parents watch a video with examples of how to improve phonological awareness. Suggestions include placing emphasis on rhyme and alliteration, segmenting long words into syllables and talking about how words sound and what they mean.
2484448|NCT03006744|Placebo Comparator|Reading enjoyment training|Parents will be given general training on how to make reading fun. Parents watch a video with examples of how they can bring books to life with funny voices, actions, and so on. The training is of a similar duration to the intervention arm.
3159367|NCT00404274|Experimental|Treatment regimen B|In treatment regimen B subject will co-administer casopitant 60 mg/day and warfarin for 14 days.
3159368|NCT00404274|Experimental|Treatment regimen C|In treatment regimen C subject will co-administer warfarin and casopitant 30 mg/day for 14 days.
2484569|NCT03005977|Other|Urodynamics, pyridium pad & cough stress|"The Pelvic Floor Bother Questionnaire, a questionnaire standardized by Cleveland Clinic Florida, the Urogenital Distress Inventory (UDI-6), and the numerical analog scale are to be administered prior to and 6 weeks after the surgical intervention. (14, 15)~Prior to surgery, patients will be scheduled for a UDS performed by a qualified nurse practitioner or physician and will be given instructions in verbal and written form to undergo a 24 H pyridium pad test at least 72 hours before the UDS. Patients will be given pyridium TID and report if orange stain is noted on their pad in this period of time. A supine and a standing cough stress test will also be performed."
2484604|NCT03005639|Experimental|Vemurafenib/Cobimetinib|Vemurafenib and cobimetinib as a combination has been approved by the United States Food and Drug Administration (FDA) for patients with more advanced melanoma. In this trial, vemurafenib and cobimetinib combination is considered to be experimental since safety of this combination prior to lymph node surgery has not been studied.
2484631|NCT03005431|Experimental|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
2484636|NCT03005431|No Intervention|Waitlist control group|These parents will receive regular or typical services
2484731|NCT03004976|Experimental|Umbilical Cord Blood|A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.
2484732|NCT03004976|Placebo Comparator|Placebo|A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.
2484779|NCT03004547||Adult and paediatric patients with CKD stage 1-5|Patients with chronic kidney disease stage 1-5 (not dialysis dependent)
2484781|NCT03004690|Experimental|Performance temperature 22°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 22°C.
2484782|NCT03004547||Healthy adult and paediatric controls|Subjects without kidney disease
2484152|NCT03008863|Experimental|Education Intervention|"The investigators will use an electronic learning (E-learning) curriculum with an educational video and a user-centered checklist for anesthesia residents. This E-learning curriculum will cover how to care for geriatric patients in the preoperative, intraoperative and postoperative settings, and specific interventions that have been shown to improve postoperative outcomes in older patients.~The checklist will be user-centered. It will remind providers of what they learned in the video and online curriculum, and how to apply these lessons in real-time while they are caring for older patients."
2484165|NCT03008863|No Intervention|Control|Residents randomized to this group will receive the current, standard education provided for all Duke Anesthesiology residents.
2484210|NCT03008551|Experimental|Empagliflozin group|Each participant will receive empagliflozin 25mg daily for 3 months
2484213|NCT03008551|Active Comparator|Metformin group|Each participant will receive metformin 1500mg daily for 3 months
2484256|NCT03008122|Experimental|Group 1|5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29 , n=45 (2 sentinels, 43 non-sentinels) or placebo, n=5
2484257|NCT03008122|Experimental|Group 2|2.5 mcg ZPIV administered IM in a homologous prime-boost regimen on Day 1 and Day 29, n=35 or placebo, n=5
2484299|NCT03007810|Experimental|Hemay005|Four subjects in cohort 1 and six subjects in each cohort (2 to 6) will receive Hemay005.
2484300|NCT03007810|Placebo Comparator|Placebo|Two subjects in each cohort (cohorts 2 to 6) will receive placebo.
2484350|NCT03007407|Experimental|durvalumab and tremelimumab|
2484388|NCT03006913|Active Comparator|Randomization to counseling: In-person|Behavioral: Comparing genetic counseling modes.
2484390|NCT03006913|Active Comparator|Randomization to counseling: By phone|Behavioral: Comparing genetic counseling modes.
2484391|NCT03006913|Active Comparator|Randomization to counseling: By video|Behavioral: Comparing genetic counseling modes.
2484464|NCT03006731|Experimental|High Intensity Training|High Intensity Interval Training patients will attend the centre 3 times/week for 24 weeks. All subjects will participate in MICE aerobic training 5 days/week in the first four weeks of the study to provide a foundation of fitness and endurance for the safe prescription of HIIT. Subsequently, the HIIT group will replace 3 MICE training days with 3 HIIT. HIIT sessions will include two 20 minute protocols; 30:60 second work:active rest ratio, and 120:180 second work:active rest ratio on a treadmill with a harness for fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community, which has been shown to be both safe and effective
2484466|NCT03006731|Active Comparator|Moderate Intensity Exercise|Moderate Intensity Continuous Exercise patients will attend the centre 3 times/week for 24 weeks. Participants will be progressed to 30 to 60 minutes of continuous exercise at the heart rate that occurred at the anaerobic threshold on the exercise test. Participants will exercise on a treadmill with a harness ofr fall protection. In addition to supervised exercise training (3 times/week), MICE will be conducted 2 times/week in the home/community by both cohorts.
2484528|NCT03006237|Experimental|IV IS-001 drug|IV IS-001 given during hysterectomy performed with da Vinci® Si/Xi Surgical System
2484550|NCT03005899|Experimental|SyB P-1501 group|One patch of SyB P-1501 contains 10.8 mg of fentanyl hydrochloride (fentanyl 9.7 mg) and produces an electric current to deliver the drug iontophoretically after the system is activated. 40 µg fentanyl per on-demand dose, each delivered over 10 minutes for a maximum of 6 doses/hr for 24 hours or maximum of 80 doses. Each system will inactivate at 80 doses or 24 hours, whichever occurs first.
2484555|NCT03005899|Placebo Comparator|SyB P-1501 placebo group|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
2484660|NCT03005522|Placebo Comparator|placebo|dosed with placebo
2484663|NCT03005522|Active Comparator|intervention|10mg oral dexamethasone
2484880|NCT03003845||Interstitial Cystitis|Patients with Interstitial Cystitis will be followed with Questionnaires and blood collection at 3, 6,and 12 months
2484950|NCT03003533|Experimental|SPK-8011|All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.
2484988|NCT03002909|Active Comparator|epidural group|an epidural catheter will be inserted under sterile conditions through the T9- 12 interspace using the 'loss-of-resistance' technique. The catheter will be advanced 4 cm cephalad. .
2484993|NCT03002909|Active Comparator|preperitoneal group|preperitoneal catheters will be placed in the subfascial (ie, pre-peritoneal) space under direct vision.
2485097|NCT03002285|Experimental|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
2485103|NCT03002285|Active Comparator|Control group|Group with typical development that performed the Fitts law in a computer task
2485170|NCT03001986|Experimental|vaccine (3.0 EU)|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
3159369|NCT00404287|Active Comparator|fluvastatin|fluvastatin 80 mg
3159370|NCT00404287|Placebo Comparator|placebo|
3159371|NCT00404313|Experimental|1|MK0633 10 mg
3159372|NCT00404313|Experimental|2|MK0633 50 mg
3159373|NCT00404313|Experimental|3|MK0633 100 mg
3159374|NCT00404313|Placebo Comparator|4|placebo
3159375|NCT00404365|Experimental|Arm I (control)|Arm I (control): Patients complete screening questionnaires about their mood and experience with lung cancer once before and once after a visit with their physician. Neither the patient nor physician receives the screening results before the visit.
3159376|NCT00404365|Experimental|Arm II|Arm II: Patients complete screening questionnaires as in arm I. Only the patient receives the screening results before their visit with the physician; the physician remains blinded to the results.
3159377|NCT00404365|Experimental|Arm III|Arm III: Patients complete screening questionnaires as in arm I. Only the physician receives the screening results before their visit with the patient; the patient remains blinded to the results.
3159378|NCT00404365|Experimental|Arm IV|"Arm IV: Patients complete screening questionnaires as in arm I. Both physician and patient receive the screening results before the visit.~All patients and physicians are notified of the screening results before the patient leaves the clinic. All patients are offered supportive counseling."
2484169|NCT03008681|Experimental|Andresen functional removable orthodontic appliance|"All the enrolled patients was applied the Andresen Activator (a removable orthodontic appliance) 12-14 hours in a day in total.~Functional appliances helped the movement of the teeth, with the achievement of good facial muscle function. All patients in the cohort were treated with the andresen actovator appliancev for deep bite and class II malocclusion correction.~The appliances were individually manufactured of acrylic resin, with a central screw and a vestibular arch, fabricated through a wax bite registration; the patient was guided to close the mouth in mandibular protrusion with coincidence of the upper and lower midlines. The registration bite was very thin in order to obtain a minimum vertical dimension. The activator was modified every three months increasing its posterior vertical dimension in order to stimulate the mandibular ramus growth thanks to the dislocation of the mandibular condyle."
3193617|NCT00819871||without PLI|patients without postoperative lung injury
3193618|NCT00819871||PLI/PKI|patients with at least one organ injury of lung or kidney after surgery
2484367|NCT03007485|No Intervention|Standard of Care|Standard pulmonary rehabilitation
2484368|NCT03007485|Experimental|Intervention|Telehealth delivered pulmonary rehabilitation
2484396|NCT03006991||good efficacy|using therapeutic drug monitoring to adjust the dose of methotrexate. patients can reach effective outcome.
2484398|NCT03006991||poor efficacy|patients can not reach effective outcome.
2484521|NCT03006718|Experimental|Patients|"Participants must have SCD (HbSS, HbSC, HbSβ0 thalassemia, HbSβ+ thalassemia, HbSOArab), within the age range of 8 - 21 years, and be admitted to the hospital for vaso-occlusive crisis (VOE)-related pain. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study.~All participants will use the PROMIS for Pain Management App over 5 consecutive weeks (starting at hospital discharge)."
2484563|NCT03005925|Experimental|connected group|remote monitoring by smartphone in the care management of patients with rheumatoid arthritis
2484566|NCT03005925|Active Comparator|control group|standard outpatient follow-up by physical consultation
2484625|NCT03005652|Experimental|Mindfulness intervention|consists of eight weekly group-based sessions of 2 hours duration and an individual pre-class interview, in which the participants will be socialised to the treatment. The intervention will combine intensive training in mindfulness and compassion meditation and gentle yoga practices with psycho-educational components targeted at helping individuals to deal more effectively with emotional difficulties and stressors commonly encountered in old age. These will include addressing concerns about cognitive functioning and health, and will have a particular emphasis on cultivating wholesome attitudes towards self and others.
2484630|NCT03005652|Active Comparator|Health education intervention|"follow the same format and structure as the mindfulness-based intervention, and will be matched to the mindfulness-based intervention in administration, dosage, and duration.~The treatment is based on a published manual, with every session of the program covering different subjects, including self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with family, friends, and healthcare professionals, eating, weight management, and planning for the future. Participants will be provided with information about these subjects and engage in group exercises and discussions about these subjects. They will be given a workbook and asked to actively engage in activities described in by the workbook to improve health and well-being on 6 out of 7 days each week, matching home assignments in the mindfulness-based intervention."
2484668|NCT03005210|Experimental|T test|Test drug (Magicbuvir Plus)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2484669|NCT03005210|Active Comparator|B reference (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2484670|NCT03005210|Active Comparator|B reference (second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
2484767|NCT03004625|Experimental|Study Arm|HCV-1b patients without baseline NS5A resistance-associated variants receiving Daclatasvir (60mg/day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/d) for 12 weeks. (daclatasvir, asunaprevir plus ribavirin)
2484807|NCT03004352|Experimental|control subjects-retrograde flow|Retrograde flow was induced in control subjects.
2484808|NCT03004352|No Intervention|control subjects-control|
2484809|NCT03004352|Experimental|hypoxemic COPD-retrograde flow|Retrograde flow was induced in hypoxemic COPD patients.
2484810|NCT03004352|No Intervention|hypoxemic COPD-control|
2484811|NCT03004352|Experimental|normoxemic COPD-retrograde flow with oxygen|Retrograde flow was induced in COPD patients with normalized arterial oxygen saturation.
2484812|NCT03004352|Experimental|normoxemic COPD-control with oxygen|COPD patients with normalized arterial oxygen saturation.
2484822|NCT03004092|Experimental|Total cohort|
2484875|NCT03004027|Experimental|Enhanced|self help leaflet enhanced with implementation intentions
2484876|NCT03004027|Active Comparator|Standard|self help leaflet standard (without implementation intentions)
2484877|NCT03004027|No Intervention|Waiting list control|Baseline measures administered only. self help intervention will be made available once the study has finished.
2484960|NCT03003598|Active Comparator|Videolaryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2484963|NCT03003598|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2485001|NCT03003091|Experimental|Needs-based patient education|The participants received self-administered questionnaire to choose what topics they wanted to know and how much information they would like to know. After completing the questionnaire, the participants submit the questionnaire to their physicians (investigators). The surgeon then provided patient education based on participant needs.
2485008|NCT03003091|Active Comparator|Traditional patient education|The participants received all structured information
2485065|NCT03002636|Experimental|Morbid Obesity group|Morbid Obesity group(n=300)
2485067|NCT03002636|Experimental|severe Obesity group|severe Obesity group (n=300)
2485070|NCT03002636|Other|non-Obesity group|non-Obesity group(n=300)
3193619|NCT00819871||without PLI/PKI|patients without lung or kidney injury after surgery
2485202|NCT03001544|Experimental|Experimental Ascending Dose Cohort|TS23
3193620|NCT00819884|Experimental|1|twice daily during 4 days
3193621|NCT00819884|Experimental|2|once daily during 4 days
2484232|NCT03008343|Experimental|Electroporation and natural killer|In this group, the patients will receive regular irreversible electroporation (IRE) treatment in combination with multiple natural killer (NK) immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484236|NCT03008343|Active Comparator|Electroporation|In this group, the patients will receive regular irreversible electroporation (IRE) treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2484258|NCT03007927|Experimental|Bupivacaine-Dexamethasone|bupivacaine 1,5 mg/kg + dexamethasone 8 mg 2ml
2484259|NCT03007927|Active Comparator|Bupivacaine- physiological solution|bupivacaine 1,5 mg/kg + physiological solution
3159379|NCT00404378|Experimental|Cohort 1 Treatment Period 1|Subjects will receive single oral dose of 100 milligram (mg) of Casopitant. There will be wash out period of 7 days.
3159380|NCT00404378|Experimental|Cohort 1 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 100 mg along with ketoconazole.
2484374|NCT03007316|Experimental|Immediate Implants + VIP graft.|Immediate implants placed with simultaneous vascularized interpositional periosteal (VIP) connective tissue graft augmentation.
2484376|NCT03007316|No Intervention|Immediate Implants only|Immediate Implants only without soft tissue augmentation.
2484463|NCT03006679|Experimental|Meropenem-Vaborbactam HABP|Participants with a clinical diagnosis of HABP will be treated with meropenem 2 grams (g) and vaborbactam 2 g in 250 milliliters (mL) infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
2484465|NCT03006679|Active Comparator|Piperacillin/Tazobactam HABP|Participants with a clinical diagnosis of HABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
2484468|NCT03006679|Experimental|Meropenem-Vaborbactam VABP|Participants with a clinical diagnosis of VABP will be treated with meropenem 2 g and vaborbactam 2 g in 250 mL infused intravenously for 3 hours every 8 hours for 7 days to a maximum of 14 days.
2484470|NCT03006679|Active Comparator|Piperacillin/Tazobactam VABP|Participants with a clinical diagnosis of VABP will be treated with piperacillin 4 g and tazobactam 0.5 g in 100 mL infused intravenously for 30 minutes every 6 hours for 7 days to a maximum of 14 days.
2484496|NCT03006224|Active Comparator|Group S (non smoking and secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
2484500|NCT03006224|Active Comparator|Group SS (secondary smoking)|I want to see the effects of seconder smoking to intraoperative arterial oxygen tension during one lung ventilation for lobectomy surgery.
2484592|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A|The participants in this arm will receive Upadacitinib (ABT-494) dose A.
2484593|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose B.
2484594|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose C|The participants in this arm will receive Upadacitinib (ABT-494) dose C.
2484595|NCT03006068|Experimental|Participants receiving Placebo|The participants in this arm will receive placebo until study is unblinded.
2484596|NCT03006068|Experimental|Participants receiving Upadacitinib (ABT-494) Dose A or Dose B|The participants in this arm will receive Upadacitinib (ABT-494) dose A or dose B.
2484942|NCT03003572||patients with primary Sjögren's syndrome|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA) in patients with primary Sjögren's syndrome according to the American-European Consensus Criteria.
2485026|NCT03002948||Low orgasm|Female Sexual Function Index orgasm score below 3.6
3193622|NCT00819923|Experimental|1|Patients receiving bio-active stent during the intervention
2485190|NCT03001817|Placebo Comparator|12 Week Efficacy|K-877 or placebo comparator twice daily for 12 weeks
2485192|NCT03001817|Active Comparator|40 Week Extension|K-877 with placebo matching fenofibrate or fenofibrate with placebo matching K-877 for 40 weeks
3159381|NCT00404378|Experimental|Cohort 2 Treatment Period 1|Subjects will receive single oral dose of 50 mg of Casopitant. There will be wash out period of 7 days.
3159382|NCT00404378|Experimental|Cohort 2 Treatment Period 2|Subjects will receive ketoconazole 400 mg once daily on Days 1 - 7. On Day 4 subjects will receive a single dose of oral casopitant 50 mg along with ketoconazole.
3159383|NCT00404391|Experimental|Arm 1: hydrocodone/acetaminophen extended release|
3159384|NCT00404391|Experimental|Arm 2: hydrocodone/acetaminophen extended release|
3159385|NCT00404391|Placebo Comparator|placebo|
3159386|NCT00404417|Experimental|1|Botox/Placebo
3159387|NCT00404417|Experimental|2|Botox/Botox
3159388|NCT00404417|Experimental|3|Placebo/Botox
3159389|NCT00404417|Placebo Comparator|4|Placebo/Placebo
3159390|NCT00404430||Exacerbated COPD patients|Patients with exacerbated COPD
3159391|NCT00404430||Stable COPD patients|Patients with stable COPD
3159392|NCT00404443|Sham Comparator|1|arm 1: placebo needle
3159393|NCT00404469|Active Comparator|CORT|Peritendinous corticosteroid injections at 0 and 4 weeks. 12 weeks total
3159394|NCT00404469|Experimental|ECC|12 weeks of eccentric unilateral decline squats
3159395|NCT00404469|Experimental|HSR|Heavy slow resistance training. 3/week. 12 weeks
3159396|NCT00404521|Experimental|Arm 1|
3159397|NCT00404534|Experimental|1|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
3159398|NCT00404534|Placebo Comparator|2|Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days
3159399|NCT00404586|Experimental|Treatment period 1|In treatment period subjects will receive once daily 100 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3159400|NCT00404586|Experimental|Treatment period 2|In treatment period subjects will receive once daily 200 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
2484265|NCT03008005|Experimental|Dronabinol Cap 10 milligrams (MG)|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (5mg or 10mg) or placebo (PBO) approximately two hours prior to MR scanning and task performance in 78 patients with PTSD.~One-third of the participants will receive 5mg dronabinol (n=26) , one-third of the participants will receive 10mg dronabinol (n=26), and the remaining one-third of the participants will receive placebo (n=26)."
3193623|NCT00819923|Active Comparator|2|Patients receiving everolimus-eluting stent during the intervention
2484397|NCT03006874|Experimental|CJ-12420 50mg QD|CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.
2484399|NCT03006874|Experimental|CJ-12420 100mg QD|CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.
2484401|NCT03006874|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.
2484480|NCT03006627|Active Comparator|Male group|All male patients scheduled for upper abdominal surgeries
2484481|NCT03006627|Active Comparator|Female group|All female patients scheduled for upper abdominal surgeries
2484535|NCT03006159|Experimental|Cohort 1|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 5 mg SHR0534 or matching placebo.
2484536|NCT03006159|Experimental|Cohort 2|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 10 mg SHR0534 or matching placebo.
2484537|NCT03006159|Experimental|Cohort 3|Twelve Type 2 Diabetic Patients were randomized in 5:1 ratio to receive multiple (30 days) oral dose of 25 mg SHR0534 or matching placebo.
2484575|NCT03005860|Active Comparator|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anaesthesia will be induced with Thiopental 5 - 7mg/kg, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with sevoflurane 2-2.2 % to maintain a target MAC value between 0.8 & 1.0.
2484578|NCT03005860|Experimental|2,6 diisopropylphenol|In Propofol group, anesthesia will be will be induced with Propofol TCI [target controlled infusion pump - Injectomat® TIVA Agilia (Fresenius Kabi)] using Schneider model to achieve target site concentration of 4-6mcg/ml, fentanyl citrate 2mcg/kg and atracurium besylate 0.5mg /kg to facilitate LMA placement. Anaesthesia will be maintained with TCI propofol at 3 - 6 mcg/ml as effect site concentration to maintain BIS 40-60.
2484666|NCT03005535|Active Comparator|Vitaminized corn oil|Vitaminized corn oil (plus B6 and E vitamins), 30 g per day, per 8 weeks, with meals (15 g per meal)
2484667|NCT03005535|Placebo Comparator|Olive oil|Olive oil (not extra-virgin), 30 g per day, per 8 weeks, with meals (15 g per meal)
2484683|NCT03005015|Experimental|Lenvatinib|Lenvatinib 24 mg orally every day. Treatment is continued until unacceptable toxicity, progressive disease or patient withdrawal
2484687|NCT03005015|Active Comparator|Doxorubicin|Doxorubicin 60 mg/m² iv bolus every 3 weeks. Treatment is continued for a maximum of 6 cycles or until unacceptable toxicity, progressive disease or patient withdrawal.
2484751|NCT03004859||Adults ≥ 65 with a positive test result|Adults ≥ 65 that are got a positive test result were asked to visit their general practitioner and are called for an interview two times, 8 weeks and 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacies as well as of the two telephone interviews are compared to the results of the adults ≥ 65 with a negative test result.
2484754|NCT03004859||Adults ≥ 65 with a negative test result|Adults ≥ 65 that are got a negative test result are called for an interview 12 months after the screening in the pharmacy. The results of the data collection and screening in the pharmacy as well as of the telephone interview are compared to the results of the adults ≥ 65 with a positive test result.
2484789|NCT03004586|Experimental|EBUS-TBNA:First Using a 25-Gauge Needle Then 22-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 25-gauge needle, followed by a 22-gauge needle.
2484790|NCT03004586|Experimental|EBUS-TBNA:First Using a 22-Gauge Needle Then 25-gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by first using a 22-gauge needle, followed by a 25-gauge needle.
2484852|NCT03004157|Experimental|Two finger technique|Two finger technique TFT: the pediatric thorax is compressed with the tips of two fingers and is recommended for lone rescuer during infant CPR by international CPR guidelines
2484854|NCT03004157|Experimental|Two thumb technique|Two thumb technique TTHT: the two thumbs of the rescuer are placed over the lower third of the sternum, with the fingers encircling the torso and supporting the back. This technique is recommended for two rescuers during infant CPR by international CPR guidelines
2484856|NCT03004157|Experimental|new two-thumb technique|new two-thumb technique' (nTTT): this technique consists in using two thumbs directed at the angle of 90 degrees to the chest while closing the fingers of both hands in a fist
2484911|NCT03003923|Experimental|Taste Exposure|Children will be repeatedly offered the single vegetable which is unfamiliar to them over the 12 week period. Children will be in their natural setting at nursery and will be offered 40g of the vegetable by their usual nursery staff. The vegetable will be weighed before and after using a digital scale by the researcher.
2484916|NCT03003923|Experimental|Nutritional Education|Nursery staff will be trained by the PhunkyFoods team to deliver the nutritional education programme. Children will be taught Eat Well (learning about different food groups) and Strive for Five (learning about eating fruits and vegetables) components of the PhunkyFoods education programme by their usual nursery staff. Nurseries will be advised to deliver as much as possible of the two components over the 12 week period.
2484919|NCT03003923|Experimental|Taste Exposure and Nutritional Education|Children will be repeatedly offered a single unfamiliar vegetable over the 12 week period as well as receive the PhunkyFoods educational programme (Eat Well and Strive for Five components). Children will be in their natural setting at nursery and will be offered the vegetable and nutritional education by their usual nursery staff.
2484922|NCT03003923|No Intervention|Control|Children will be offered single unfamiliar vegetable at the beginning, end and at the follow-up. There will be no repeated taste exposure or education during the study phase or follow-up; they will be offered the nutritional education after the study has completed.
2484990|NCT03003065|Other|Foscan|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
2515694|NCT02792075||OCT|Patients with Optical coherence tomography
2484370|NCT03007277|Experimental|PANJO Intervention|201 nulliparous women will be recruited within the PMI public services. Nurses/Midwives will propose to enroll in the PANJO group, which consist in receiving 6 to 12 home visits by a home visitor trained by the PANJO team The visits will consist on 45 to 90-minutes interventions aiming at supporting the family in the everyday challenges they may encounter, and to support the development of qualitative parent-child relationships.
2484372|NCT03007277|Active Comparator|Service as usual|246 nulliparous women will be recruited within several maternity wards. They will recieve the services they may request from (a) the maternities, (b) the maternal and child protection services (PMI, usually 1 or 2 home visit without any standards) or any other service available. They will be provided with the address and telephone of the closest maternity ward.
2484402|NCT03007004|Experimental|Botulinum toxin group|400 units in one injection site（0.2mL） Total 2000 units（1.0mL） （For both hands total 4000 units; 2.0 mL）
2484405|NCT03007004|Sham Comparator|Physiological saline (control drug) group|"0.2mL in one injection site~Total 1.0mL (For both hands total 2.0 mL)"
2484456|NCT03006666|Active Comparator|Control Group (Data Only)|The teams randomly allocated to the Control Group will not have access to CHWs.
2484458|NCT03006666|Experimental|Intervention Group: (CHW Health Coaching Integrated into Team)|Teams randomly allocated to the Intervention Group will also receive regular panel data on their pre-DM patients and will have a CHW join the team, attend team meetings, and provide an outreach intervention to all prediabetic patients in the panel, as described below. CHWs and the researchers will provide regular updates to the team on these activities.
2484526|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CY/GVAX/CRS-207|
2484530|NCT03006302|Experimental|Epacadostat/Pembrolizumab/CRS-207|
2484576|NCT03005821|Experimental|pediatric massage|Patients will receive Montmorillonite Powder and racecadotril granules as usual care according to different age or weight. Intravenous infusion, Oral Rehydration Salts (ORS), Zn,and antibiotics will be used if the pediatrician in charge considers necessary. Patients will receive Chinese pediatric massage once per day and for three days continuously. A cloak which can cover the child's hands and upper body will be required to put on, all the manipulations will be done under the cloak. Six acupoints will be adopted,i.e. Neibagua, Dachang,Xiaochang, Banmen, Fu, Tuishang Qijiegu. Each visit, children who are under 2 years old will receive manipulations on Neibagua for 500 times, 300 times for the other 5 acupoints each; if they are from 2-3 years old, the manipulations on Neibagua will be 700 times and 500 times for the other 5 acupoints respectively; while the manipulations on Neibagua will be 1000 times, and 800 times for the other 5 acupoints if the children are from 4-6 years old.
2484580|NCT03005821|Sham Comparator|sham massage|Patients will receive the same usual care as the experimental group. For the sham massage, the therapist will use one hand to hold the childrens' hand or just put one hand on childrens' body and the other hand will do the manipulations on the therapist's own hand instead childrens' hand or childrens' body. Patients will be required to put on the same kind of cloak as that for the the experimental group, all the manipulations will be done under the cloak. The manipulation times for each acupoints will be the same as those for experimental group in accordance with different age. The sham massage will be given once per day for 3 days continuously.
2484662|NCT03005574|Experimental|TSW-HP|TSW-HP Intervention implemented by a cognitive specialist over a 6-month treatment period which includes 24 hours (1 hour per week) of facilitated cognitive exercise sessions, which will be supplemented by approximately 24 hours of home practice sessions on a tablet computer.
2484665|NCT03005574|Active Comparator|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program, which includes a one hour cognitive exercise practice session per week at Brooklyn Community Services (BCS) for 6 months. This group will not receive home based cognitive practice exercises.
3193624|NCT00819936|Experimental|2|Backward walking,
2484774|NCT03004560|Active Comparator|Standard Laparoscopic Approach|Minimally invasive laparoscopic procedure with 5-10 mm incisions.
2484776|NCT03004560|Active Comparator|Percutaneous Approach|Minimally invasive laparoscopic procedure with 2-3 mm incisions.
2484836|NCT03004339|Experimental|SOR007 Ointment 2.0%|Topical application once daily during a 12-day treatment period (10 treatments)
2484841|NCT03004339|Experimental|SOR007 Ointment 1.0%|Topical application once daily during a 12-day treatment period (10 treatments)
2484843|NCT03004339|Experimental|SOR007 Ointment 0.3%|Topical application once daily during a 12-day treatment period (10 treatments)
2484845|NCT03004339|Experimental|SOR007 Ointment 0.15%|Topical application once daily during a 12-day treatment period (10 treatments)
2484846|NCT03004339|Placebo Comparator|SOR007 Ointment Placebo|Topical application once daily during a 12-day treatment period (10 treatments)
2484849|NCT03004339|Active Comparator|Taclonex® Ointment|Topical application once daily during a 12-day treatment period (10 treatments)
2484908|NCT03003728|Experimental|Study Treatment|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26; Melphalan 200 mg/m2 Ivia intravenous infusion on day -3; ASCT on day -2; ENK infusion on day 0; ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22.
3159401|NCT00404586|Experimental|Treatment period 3|In treatment period subjects will receive once daily 400 mcg of GW784568X and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive GW784568X and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
2485004|NCT03002831|Experimental|CIK combined chemotherapy|Autologous Cytokine induced killer cells combined Tegafur, Gimeracil and Oteracil Potassium Capsules. After 2 to 4 days of chemotherapy, about 5×10９autologous cytokine induced killer cells are transfused into the vein of the patients in one hour.
2485010|NCT03002831|Active Comparator|Chemotherapy|Tegafur,Gimeracil and Oteracil Potassium Capsules 40-60mg, bid, po, D1-14, Q3w
2485078|NCT03002584||IBS & general population|"The participants will be given the IGQ questionnaire to complete as well as other self-reported questionnaires.~Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale."
2485130|NCT03002103|Experimental|ET+P+G|
2485133|NCT03002103|Active Comparator|Control|
2485208|NCT03001700|Experimental|Treatment|Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device
2484377|NCT03007251|Experimental|"Eurythmy Therapy Movement L"|"EYT exercise L: In a circular and flowing movement the patient leads his hands upwards in front of his body and down again laterally. During elevation of the arms, the patient performs a small hop onto the toes and into knock knees. Lowering his arms, he releases the legs and straightens up again."
2484378|NCT03007251|Experimental|"Eurythmy Therapy Movement B"|"EYT exercise B: The patient describes an embracing movement with both arms and the left leg while balancing on one foot. He then returns to the initial position and repeats the movement using the other leg."
2484379|NCT03007251|Active Comparator|Normal movements during walking or standing|Control exercise: Participants slowly walk across the room, their arms swinging in a natural way. This was designed to control for the most basic upright movement, shifting thermoregulation from resting conditions to exercise conditions, triggering non-thermal factors.
2484392|NCT03006900|Experimental|Pilates and massage|Pilates (twice per week for 50 minutes) and massage (once per week for one hour)
2484393|NCT03006900|Active Comparator|Massage|Massage (once per week for one hour)
2484494|NCT03006705|Experimental|Nivolumab group|"Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
2484495|NCT03006705|Placebo Comparator|Placebo group|"Placebo: Placebo solution intravenously for 30 min in every 3 weeks (maximum 1 year).~Chemotherapy: S-1 Therapy or CapeOX Therapy is determined by the investigator.~S-1 therapy(maximum 1 year):~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off~CapeOX Therapy(maximum 6 months):~Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off."
2484622|NCT03005405|Active Comparator|restoration - control|Restoration
2484626|NCT03005405|Experimental|sealant - test|Sealant
2484718|NCT03004989||Programme 1|RTW group in day clinics
2484722|NCT03004989||Programme 2|RTW group in day clinics for people with fibromyalgia
2484724|NCT03004989||Programme 3|My work and I
2484765|NCT03004729|Other|CoMiSS|Measure of CoMiSS followed by two weeks eviction Cow's milk protein diet and second CoMiSS measurement.
2484795|NCT03004430|Experimental|MAM|Mantra Meditation Group
2484799|NCT03004430|Active Comparator|PMR|Progressive Muscle Relaxation Group
2484859|NCT03004209|Other|EPO|Erythropoietin injection: three times per a week, 100 IU/kg for each patients Trade name: epokine prefilled injection
2484901|NCT03003819|Active Comparator|Control Collagen Wound Dressing|Bovine collagen sponge used to control bleeding, stabilize blood clots and protect dental wounds
2484907|NCT03003819|Active Comparator|Test Collagen Matrix|Bilayer, porcine collagen matrix for soft tissue regeneration used as a socket seal in extraction socket grafting
2484964|NCT03003377|Experimental|Device: laryngeal mask supreme|Determine the Sevoflurane concentration associate with remifentanil for the insertion of the laryngeal mask supreme
2484967|NCT03003377|Active Comparator|Device: laryngeal mask proseal|Determine the Sevoflurane concentration associate with remifentanil for insertion of the laryngeal mask ProSeal
2484995|NCT03003039|Experimental|GB241|GB241:375 mg/m2, iv, one infusion
2484997|NCT03003039|Active Comparator|Rituximab|Rituximab: 375 mg/m2, iv, one infusion
2485087|NCT03002402|Experimental|Internet-based CBT-I|"Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of cognitive-behavioral treatment for insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is allocated out over time through 6 Cores. Users obtain access to a new Core based on a time and event-based schedule (e.g., 7 days after completion of previous Core). SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window)."
2485187|NCT03002025|Experimental|Cohort 1: JNJ-64304500 50 milligram (mg) or placebo|Participants (Japanese) will receive single subcutaneous (SC) dose of JNJ-64304500 50 mg or placebo on Day 1.
2485189|NCT03002025|Experimental|Cohort 2: JNJ-64304500 150 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 150 mg or placebo on Day 1.
2485191|NCT03002025|Experimental|Cohort 3: JNJ-64304500 400 mg or placebo|Participants (Japanese) will receive single SC dose of JNJ-64304500 400 mg or placebo on Day 1.
2485193|NCT03002025|Experimental|Cohort 4: JNJ-64304500 150 mg or placebo|Participants (Caucasian) will receive single subcutaneous (SC) dose of JNJ-64304500 150 mg or placebo on Day 1.
3159402|NCT00404586|Placebo Comparator|Treatment period 4|In treatment period subjects will receive once daily Placebo and fluticasone propionate 200 mcg once daily for 7 days. Subjects will receive Placebo and fluticasone propionate via intranasal route. There will be a wash out period of 14 days.
3159403|NCT00404612|Placebo Comparator|Placebo|
3159404|NCT00404612|Active Comparator|LX211, 0.2 mg/kg|
3159405|NCT00404612|Active Comparator|LX211, 0.4 mg/kg|
3159406|NCT00404612|Active Comparator|LX211, 0.6 mg/kg|
3159407|NCT00404677|Placebo Comparator|Standard|Methacholine challenges are performed using the standardized two minute tidal breathing method
3159408|NCT00404677|Active Comparator|Modified|Five deep inhalation maneouvers are incorporated into the standardized methacholine challenge
3159409|NCT00404690|Active Comparator|1|Operative attempt at closure
3159410|NCT00404690|Experimental|2|bedside silo
3159411|NCT00404703|Experimental|1|
3159412|NCT00404729|Other|Citicoline treatment|Ten OAG patients will be untreated (NT-AOG, 10 eyes), while 20 OAG patients (T-AOG, 20 eyes) and 15 NION patients (T-NION, 14 eyes) were treated with Citicoline (oral treatment:1600 mg/die per 60 days)
3159413|NCT00404742|Placebo Comparator|Placebo|
3159414|NCT00404742|Active Comparator|LX211, 0.2 mg/kg|
3159415|NCT00404742|Active Comparator|LX211, 0.4 mg/kg|
3159416|NCT00404742|Active Comparator|LX211, 0.6 mg/kg|
3193625|NCT00819936|Active Comparator|1|Forward walking
2484400|NCT03006965||Hemophilia A patients|"Group of patients in prophylactic treatment with Advate® (octocog alfa) or Adynovi® (rurioctocog alfa pegol), or patients using already myPKFit®.~Patients will be given a dose of octocog alfa or rurioctocog alfa pegol according to usual clinical practice, and two blood samples will be taken in case of octocog alfa: one sample will be extracted 3-4h postdose (+/- 30 minutes), and the second sample will be extracted 24-32h postdose (+/- 60 minutes). In case of rurioctocog alfa pegol, the first sample is taken in the same conditions than octocog alfa, and the second sample will be extracted 48h postdose (+/- 120 minutes), and other sample post 72h(+/- 120 minutes) optional."
2484497|NCT03006406|Active Comparator|Long term GnRH-a for 1 month|patient in this group only receive GnRH-a 3.75 for 1 month
2484502|NCT03006406|Experimental|patient in this group only receive GnRH-a 3.75 for 2 month|patient in this group only receive GnRH-a 3.75 for 2 month
2484570|NCT03006029|Experimental|TAB08( Theralizumab)|TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
2484633|NCT03005678|Active Comparator|Denosumab|denosumab subcutaneous 60mg every 6 months
2484639|NCT03005678|Placebo Comparator|Alendronate|alendronate 70mg orally every week
2484736|NCT03005236|Experimental|Envarsus|Basiliximab induction with maintenance therapy of Envarsus, mycophenolate mofetil and corticosteroids. Envarsus constitutes the experimental component of immunosuppression in older kidney transplant recipients.
2484739|NCT03005236|Active Comparator|Standard twice daily tacrolimus|Basiliximab induction with maintenance therapy of standard tacrolimus, mycophenolate mofetil and corticosteroids. Standard tacrolimus constitutes the control component of immunosuppression in older kidney transplant recipients.
2484769|NCT03004651||Obese Patients|Power Doppler ultrasound on obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
2484771|NCT03004651||Non obese patients|Power Doppler ultrasound on non obese patients with PR comparating with a clinical evaluation (swollen joint count (SJC) as componant of SDAI)
2484823|NCT03004365|Active Comparator|Study Arm 1|Subjects in Study Arm 1 will receive up to 1 mL of 27.2 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2484825|NCT03004365|Active Comparator|Study Arm 2|Subjects in Study Arm 2 will receive up to 1 mL of 13.6 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2484831|NCT03004365|Active Comparator|Study Arm 3|Subjects in Study Arm 3 will receive up to 1 mL of 54.4 mg C16G2 Varnish or Placebo Varnish on day 1, followed by two additional applications a week and two weeks later, for a total of 3 study drug applications. Study drug will be administered via a small brush typically used in varnish applications.
2484885|NCT03003884|Experimental|Remimazolam Tosilate 1|IV of Remimazolam Tosilate at 5mg for initial dose
2484893|NCT03003884|Experimental|Remimazolam Tosilate 2|IV of Remimazolam Tosilate at 7mg for initial dose
2484896|NCT03003884|Experimental|Remimazolam Tosilate 3|IV of Remimazolam Tosilate at 8mg for initial dose
2484897|NCT03003884|Experimental|Remimazolam Tosilate 4|IV of Remimazolam Tosilate at 5mg for initial dose.At the end of the endoscopy, flumazenil was injected.
2484898|NCT03003884|Active Comparator|Propofol|IV of Propofol at 1.5mg/kg for initial dose
2484941|NCT03003403|Experimental|Intervention Program|Balance Intervention Program: Participants randomly assigned to the 12-month digital health behavioral intervention will receive: tailored behavior change goals with interactive self-monitoring and feedback; network-connected scales to track their weight; skills training materials; and stepped coaching (via phone and/or text) from Registered Dieticians serving as health coaches within a local network of community health centers.
2484943|NCT03003403|No Intervention|Usual Care Program|Balance Usual Care Program: Participants randomly assigned to the Usual Care program will receive the standard primary care offered by their providers; health information/skills training materials to maintain a healthy weight; and automated (non-tailored) text messages with health information.
2485056|NCT03002467|Experimental|PESI score|treating physicians must formally calculate PESI and report in the clinical record form* each day of hospitalization on top of routine clinical practice (standard care)
2485058|NCT03002467|No Intervention|Standard care|standard care (i.e. no formally calculation of PESI on top)
2485095|NCT03002246||Average for Gestational Age|This cohort will include a sample size of 90 subjects. Fetuses will have an estimated fetal weight greater than 10th percentile and less than 90th percentile based on clinical ultrasound assessment. This cohort will receive an ultrasound examination 4-7 days before their delivery.
2485098|NCT03002246||Large for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight greater than 90th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
2485105|NCT03002246||Small for Gestational Age|This cohort will include a sample size of 30 subjects. Fetuses will have an estimated fetal weight less than 10th percentile based on clinical ultrasound assessment.This cohort will receive an ultrasound examination 4-7 days before their delivery.
2485177|NCT03001934||Nephrotic syndrome patients|Patients diagnosis as nephrotic syndrome (NS)
3159417|NCT00404781|Experimental|optimal antiplatelet|cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
3159418|NCT00404781|Active Comparator|standard antiplatelet|aspirin and clopidogrel for all patients
3159419|NCT00404885|Placebo Comparator|Placebo|
3159420|NCT00404885|Active Comparator|LX211, 0.2 mg/kg|
3159421|NCT00404885|Active Comparator|LX211, 0.4 mg/kg|
3159422|NCT00404885|Active Comparator|LX211, 0.6 mg/kg|
3159423|NCT00404911|Experimental|MFG therapy|Participants will receive multi-family group therapy
3159424|NCT00404911|Active Comparator|Standard of Care|Participants will receive standard care
3159425|NCT00405002||1|ALI/ARDS patients
3159426|NCT00405015|Experimental|1|Placebo first
3159427|NCT00405015|Experimental|2|Rosiglitazone first
3159428|NCT00405041|Experimental|A|
3159429|NCT00405054|Other|1|continuous infusion every 14 days
2484415|NCT03007121|Experimental|Morphine intrathecal|An intrathecal administration of preservative-free morphine 0.3 mg in 3 ml NS prepared in a sterile ampoules by a hospital pharmacy will be performed before induction of anaesthesia in a sitting position between L2 and L3 - L4/L5 vertebrae. Standard general anaesthesia will be performed. After surgery, the patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
2484424|NCT03007121|Active Comparator|Bupivacaine + Sufentanil epidural|An epidural catheter will be inserted before induction of anaesthesia in a sitting position between T9 and T10 - T12 and L1 vertebrae. A test dose of 4 ml 0.5 bupivacaine will be administered to rule out intravascular injection or subarachnoid or subdural block. Standard general anaesthesia will be performed. Thirty minutes before the end of the surgery, patients will be administered a bolus of a mixture of bupivacaine 0.5% (3 ml) + sufentanil 10 mcg (2 ml) + NS 5 ml followed by a continuous infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h. At the same time patients will have the possibility to use PCA device with morphine, bolus dose 1 mg, lock-out interval 5 min for 3 days at a surgical ICU.
2484430|NCT03007121|Active Comparator|Morphine intravenous|Patients will be administered standard general anaesthesia. After surgery, bolus doses of morphine 2 mg will be administered until level of pain will be < 4 (VAS 0 - 10). Analgesia will be continued by PCA device using morphine, bolus dose 1 mg, lock-out interval 5 min. for 3 days at surgical ICU.
2484931|NCT03003611||Hypnose|the group of patient who's operated under hypnose sedation
2484932|NCT03003611||traditional anesthesia|The match is realized with a patient operated in the same period as the patient in the hypnose group and it's need a comparative type of surgery.
2484945|NCT03003260|Experimental|Treatment A - Treatment B|20 patients receive first 3 weeks treatment A and after a week wash-out 3 weeks treatment B
2484946|NCT03003260|Experimental|Treatment B - Treatment A|20 patients receive first 3 weeks treatment B and after a week wash-out 3 weeks treatment A
2485036|NCT03002688||Sequential Cataract Surgery with Survey|Subjects eligible for the study will fall into the sequential cataract surgery group and be administered brief surveys.
2485081|NCT03002441|Active Comparator|Same-day Dilators|Participants will have Dilapan-S cervical dilators placed 4-6 hours prior to D&E and will receive 400 mcg buccal misoprostol pills 3 hours prior to D&E.
2485083|NCT03002441|Active Comparator|Overnight dilators|Participants will have Dilapan-S cervical dilators placed the day prior to their D&E procedure and will receive buccal placebo pills (vitamin B12) 3 hours prior to D&E.
3159430|NCT00405080|Experimental|Treatment Period 1|Subject will receive single oral dose of 150 milligram (mg) of Casopitant. There will be wash out period of 7 days.
3159431|NCT00405080|Experimental|Treatment Period 2|Subjects will receive rifampin 600 mg once daily on Days 1 - 9. On Day 8 subjects will receive a single dose of oral casopitant 150 mg along with rifampin.
3159432|NCT00405262|Active Comparator|1|
3159433|NCT00405262|Experimental|2|
3159434|NCT00405262|Experimental|3|
3159435|NCT00405301|Other|Arm 1|Arm 1: will receive Isoniazide(5mg/kg/day), Rifampicin(10mg/kg/day) and Pyrazinamide(25mg/kg/day) in full doses on day 1 and continued further
3159436|NCT00405301|Other|Arm 2|Arm 2 : will receive Rifampicin(10mg/kg/day) in full dose on day 1 and continued, Isoniazide(5mg/kg/day)in full dose on day 8 and continued, Pyrazinamide(25mg/kg/day)on day 15 and continued
3159437|NCT00405301|Other|Arm 3|Arm 3 will receive 100 mg/day of Isoniazide on day 1 which is gradually increased to maximum dose (5mg/kg/day) by day 4 and continued. Rifampicin is introduced on day 8 in a dose of 150 mg/day which is gradually increased to maximum dose (10mg/kg/day) by day 11 and continued. Pyrazinamide is introduced on day 15 in a dose of 500mg/day which is gradually increased to maximum dose (25mg/kg/day) by day 18 and continued.
3159438|NCT00405327|Experimental|DC vaccine therapy|Tumor lysate-pulsed dendritic cell (DC) vaccine following HSCT
3159439|NCT00405340|Experimental|Drug|Rituximab
3159440|NCT00405366|Other|Single Arm Study|
3159441|NCT00405405|Experimental|Treatment|A combination of Cisplatin, Docetaxel, Bevacizumab, Erlotinib, and Radiotherapy
3159442|NCT00405418|Experimental|1|Insulin Glargine
3159443|NCT00405418|Active Comparator|2|Insulin Detemir
3159444|NCT00405431|Active Comparator|1|Patients received restasis eyedrops during 6 month post-operative period
3159445|NCT00405431|Placebo Comparator|2|Patients receive artificial tears (Endura) during 6 month post-operative period
3159446|NCT00405444|Experimental|1|
3159447|NCT00405444|Placebo Comparator|2|
3159448|NCT00405457|Other|A|
3159449|NCT00405470|Active Comparator|Medial Pivot|
3159450|NCT00405470|Active Comparator|Posterior Stabilized|
3159451|NCT00405483|Active Comparator|Minimally invasive exposure|Surgical technique, minimal incision
3159452|NCT00405483|Active Comparator|Standard exposure|Standard Incision
3159453|NCT00405535|Experimental|A|glycine powder
3159454|NCT00405535|Placebo Comparator|B|placebo powder
3159455|NCT00405561|Experimental|AMT2003|
3159456|NCT00405574|Experimental|High Dose|ATN-224 dose 300mg
3159457|NCT00405574|Experimental|Low Dose|ATN-224 dose: 30mg
3159458|NCT00405600|Active Comparator|Device|Device used in surgery with or without instrumentation
3159459|NCT00405665|Experimental|1|
3159460|NCT00405665|Experimental|2|
3159461|NCT00405678|Experimental|1|Subjects receiving chemo and exercise training
3159462|NCT00405678|Experimental|2|Subjects receiving chemo only
3159463|NCT00405730|Experimental|Nepafenac|One drop in the study eye 3 times daily for 23 days
3159464|NCT00405730|Active Comparator|Ketorolac Trometamol|One drop in the study eye 3 times daily for 23 days
3159465|NCT00405730|Placebo Comparator|Nepafenac Vehicle|One drop in the study eye 3 times daily for 23 days
3159466|NCT00405743|Experimental|Arm A|CP4055, 2 and 4 hour IV infusion
3159467|NCT00405743|Experimental|Arm B|CP-4055, Continuous IV infusion
3159468|NCT00405769|Placebo Comparator|1|placebo control
3159469|NCT00405769|Active Comparator|2|red yeast rice
3159470|NCT00405782|Active Comparator|Immediate Exercise Group|Exercise Intervention begins immediately
3159471|NCT00405782|Active Comparator|Delayed Exercise Group|Exercise intervention delayed by 16 weeks
2484422|NCT03007069|Active Comparator|MPM Augmentation.|Mineralized plasmatic matrix (MPM) to be used without collagen membrane to augment the defect in the maxillary bone and cover the exposed threads of the dental implants.
2484455|NCT03006575|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose at the initial course: 40-51Gy/10-17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-24 Gy/5-8f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
2484641|NCT03005483|Experimental|Gabapentin|Gabapentin 10 mg/kg in children submitted unilateral limb surgery
2484645|NCT03005483|Placebo Comparator|Placebo|Placebo in children submitted unilateral limb surgery
2484677|NCT03005223|Experimental|Study effect of DWC20163 on DWC20155/DWC20156 PK|To study effect of DWC20163 on DWC20155/DWC20156 PK
2484680|NCT03005223|Experimental|Study effect of DWC20155/DWC20156 on DWC20163 PK|To study effect of DWC20155/DWC20156 on DWC20163 PK
2484797|NCT03004521|Active Comparator|Lithium|Lithium will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
2484798|NCT03004521|Experimental|Quetiapine|Quetiapine will be prescribed to patients in this arm as an augmenter on top of a patient's existing antidepressant treatment.
2484826|NCT03004144|Other|FLOAT-Support|
2484873|NCT03004014|No Intervention|Natural Sleep|OSA subjects referred for surgical treatment will evaluated endoscopically during natural sleep
2484874|NCT03004014|Other|Propofol Induced Sleep|"Sleep endoscopy during propofol induced sleep~OSA subjects referred for surgical treatment will be evaluated endoscopically during propofol induced sleep"
2484921|NCT03003650|Experimental|Symetis ACURATE TF™|Patient implanted with ACURATE TF™Bioprosthesis.
2484947|NCT03003351||Fistula|Patients with Fistulaê that are not caused by Crohn's disease
2484953|NCT03003351||Fistula and Crohn's disease|Patients with Fistulae that are caused by underlying Crohn's disease
2485012|NCT03003117|Experimental|Intervention Program|Experimental: Intervention Program
2485017|NCT03003117|Active Comparator|Usual Care|Active comparator: Usual Care
2485073|NCT03002558||control (non-OSA)|Patients without sleep apnoea
2485074|NCT03002558||OSA-treated|Patients with sleep apnoea who are treated (CPAP, surgery or MAD)
2485075|NCT03002558||OSA-non treated|Patients with sleep apnoea who are not treated
2485125|NCT03002181|Experimental|PNE group|Pain neurophysiology education group.
2485126|NCT03002181|Experimental|Red Flag group|Red Flags education group.
3159472|NCT00405808|Experimental|1|Administration of one tablet containing 20 mg of Rimonabant
3159473|NCT00405808|Placebo Comparator|2|Administration of one Rimonabant placebo tablet.
3159474|NCT00405873|Experimental|AMT2003|
3159475|NCT00405886|Experimental|Neramexane 25mg/d|
3159476|NCT00405886|Experimental|Neramexane 50mg/d|
3159477|NCT00405886|Experimental|Neramexane 75mg/d|
3159478|NCT00405886|Placebo Comparator|Placebo|
3159479|NCT00405899||Immunotherapy|Patients starting immunotherapy
3159480|NCT00405899||Non-immunotherapy|Patients being treated using methods other than immunotherapy
3159481|NCT00405925|Active Comparator|combivir/kaletra|All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)
3159482|NCT00405925|Experimental|Trizivir|patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra
3159483|NCT00405951|Experimental|Obatoclax Mesylate + Docetaxel|Obatoclax Mesylate 250mL in combination with Docetaxel
3159484|NCT00405977|Placebo Comparator|Physiologic saline|
3159485|NCT00405977|Active Comparator|Magnesium sulphate|
3159486|NCT00406003|Experimental|Subjects receiving treatment sequence ABC|Eligible subjects will receive treatment sequence ABC; A= paroxetine 12.5 milligrams, B= paroxetine 25 milligrams, and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
3159487|NCT00406003|Experimental|Subjects receiving treatment sequence BAC|Eligible subjects will receive treatment sequence BAC; B= paroxetine 25 milligrams, A= paroxetine 12.5 milligrams and C= paroxetine 37.5 milligrams separated by a wash-out period of 10 days.
3159488|NCT00406003|Experimental|Subjects receiving treatment sequence CBA|Eligible subjects will receive treatment sequence CBA; C= paroxetine 37.5 milligrams, B= paroxetine 25 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
3159489|NCT00406003|Experimental|Subjects receiving treatment sequence BCA|Eligible subjects will receive treatment sequence BCA; B= paroxetine 25 milligrams, C= paroxetine 37.5 milligrams and A= paroxetine 12.5 milligrams separated by a wash-out period of 10 days.
3159490|NCT00406003|Experimental|Subjects receiving treatment sequence CAB|Eligible subjects will receive treatment sequence CAB; C= paroxetine 37.5 milligrams, A= paroxetine 12.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
3159491|NCT00406003|Experimental|Subjects receiving treatment sequence ACB|Eligible subjects will receive treatment sequence ACB; A= paroxetine 12.5 milligrams, C= paroxetine 37.5 milligrams and B= paroxetine 25 milligrams separated by a wash-out period of 10 days.
3159492|NCT00406016|Experimental|1|
3159493|NCT00406055||1|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
3159494|NCT00406068|Experimental|Mycobacterial cell wall-DNA complex|Mycobacterial cell wall-DNA complex
3159495|NCT00406081||Participants with AD|Children with AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit (including a group of AD subjects with eczema herpeticum)
3159496|NCT00406081||Nonatopic controls|Children without AD who received the chicken pox vaccine 2 to 16 weeks prior to the study visit
3159497|NCT00406094|Experimental|1|montelukast
3159498|NCT00406094|Placebo Comparator|2|placebo
2484427|NCT03006796||group 1 (AZL/C)|Group 1 - patients receiving azilsartan medoxomil/chlorthalidone 40/12.5 mg or 40/25 mg per os once a day for 6 months.
2484434|NCT03006796||group 2 (IRB/H)|Group 2 - patients receiving irbesartan/hydrochlorothiazide 150/12.5 mg or 300/25 mg per once a day for 6 months.
2484462|NCT03006588|Experimental|EUS-FNA for RPLN in NPC patients|Fine needle aspiration guided by EUS in retropharyngeal lymph node in suspicious recurrent naspharyngeal carcinoma.
2484512|NCT03006263|Experimental|Totally Laparoscopic Total Gastrectomy|Totally Laparoscopic Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2484513|NCT03006263|Experimental|Laparoscopy Assisted Total Gastrectomy|Laparoscopy Assisted Total Gastrectomy will be performed for the treatment of patients assigned to this group.
2484597|NCT03005964|Experimental|AM001 Cream, 7.5%|A white to off-white Cream free from any foreign particles
2484598|NCT03005964|Placebo Comparator|Vehicle Cream|A white to off-white Cream free from any foreign particles.
2484608|NCT03005496|Placebo Comparator|Intervention|"Nifedipin 4x10 mg oral~Dexamethasone 2x6 mg iv for 2 days~Zinc 50 mg/day~Beta-carotene 25,000 IU~Vitamin D3 50,000 IU/weekly"
2484610|NCT03005496|Active Comparator|Control|"Nifedipin 4x10 mg~Dexamethasone 2x6 mg iv for 2 days"
2484699|NCT03005171|Active Comparator|Epidural|"Epidural catheters will be placed in the 9th or 10th thoracic intervertebral space prior to induction of anesthesia.Through the thoracic epidural catheter 0.125% bupivacaine at a rate of 5 mL/h will be infused.~The infusion continues for 24h"
2484704|NCT03005171|Active Comparator|Lidocaine|"Intravenous lidocaine infusion will typically start in the operating room prior to induction of anesthesia at a rate of 2 to 3 mg/min. Postoperatively, the rate will be decreased to 0.5 to 1 mg/min.~The infusion continues for 24h"
2484737|NCT03004768|Experimental|Single dose of radiolabeled BMS-986165|
2484796|NCT03004677|Experimental|Continuous skin-to-skin contact|Infants assigned to SSC will rest skin-to-skin on parents' chest 24 hours a day for four days alternating between the parents.
2484801|NCT03004677|Active Comparator|Standard Care|Infants and parents will receive standard care provided in the NICU
2484824|NCT03004183|Experimental|Single arm|"ADV/HSV-tk (5 x 1011 virus particles) in a 2-mL total volume will be injected intratumorally on Day 0.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days from Day 1 to Day 15.~SBRT of 30 Gy (6 Gy X 5 fractions) will be administered over 2 weeks from Day 2 to Day 16.~Pembrolizumab (200 mg) will be administered intravenously over 30 minutes every 3 weeks starting on Day 17 and continuing until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression."
3193626|NCT00819949|Experimental|Arm 1|Potential eligible subjects for the trial will be individuals between ages 18-85, with a confirmed diagnosis of PD that experience freezing.
2484982|NCT03003195|Experimental|Vaccination: P10s-PADRE/MONTANIDE ISA 51 VG|100mL vaccination on Weeks 1, 2, 3 and 8
2485028|NCT03002935|Experimental|BPM31510 Oral Nanosuspension 4%|Study subjects will self-administer 80 mL (4 vials of 20 mL) of oral BPM31510 (Ubidecarenone, USP; 40 mg/mL) nano-suspension 3 times daily every 4 to 6 hours for a total daily dose 9600 mg/day of BPM31510 for 14 consecutive days. The last study dose (morning dose only) is administered at the clinic on Day 15.
2485038|NCT03002571|Experimental|IDP-124 Lotion|Lotion
2485039|NCT03002571|Active Comparator|IDP-124 Vehicle Lotion|Vehicle
2485086|NCT03002389|Other|All COPD Subjects|"All subjects will be assessed with hyper polarized xenon-129 MRI, pulmonary function test, quality of life measures (BDI, TDI, SGRQ, CRQ, BODE, GOLD), and blood test.~Intervention: All subjects will received Anoro one puff once a day for 30 days first, then 3 day washout, then Arnuity 250 microgram one puff twice a day for 30 days to complete the study."
2485128|NCT03001999|Experimental|Intervention Arm|Participants will all undergo a 16-week PP-MI health behavior intervention.
2485195|NCT03001726|Experimental|Gastrectomy plus chemotherapy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
2485197|NCT03001726|Other|chemotherapy alone|Patients received chemotherapy alone.All patients received oral S1 80 mg/m2 per day (80-120 mg/day total dose depending on the patient's body surface area as follows: <1.25 m2, 80 mg; 1.25-1.5 m2, 100 mg; and >1.5 m2, 120 mg) on days 1-21 of every 3-week cycle, oxaliplatin 100 mg/m2 on day 1 of every 3-week cycle and docetaxel 40mg/m2 on day 1 of every 3-weeks cycle.
3159499|NCT00406237|Experimental|1|
3159500|NCT00406250|Experimental|Bevacizumab|
3159501|NCT00406432|Experimental|Subjects receiving paroxetine|Eligible subjects will receive single dose of paroxetine 25 milligrams controlled release formulation followed by wash-out period of 5 days. Subjects will receive multiple doses of paroxetine 25 milligrams for further 14 days.
3159502|NCT00406458|Experimental|SB-509|60 mg SB-509 injected IM into lower limbs every 2 months
3159503|NCT00406458|Placebo Comparator|Normal Saline|Normal saline injected IM into lower limbs every 2 months
3159504|NCT00406471|Active Comparator|1|500 micrograms of ranibizumab
3159505|NCT00406471|Active Comparator|2|300 microgram ranibizumab
3159506|NCT00406484|Experimental|1|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)
3159507|NCT00406484|Active Comparator|2|Standard drug counseling
3159508|NCT00406536|Active Comparator|1|
3159509|NCT00406536|Placebo Comparator|2|
3159510|NCT00406575|Placebo Comparator|Placebo|Participants receive diluent via continuous IV infusion for 48 hours.
3159511|NCT00406575|Experimental|Low Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 100 µg/kg/day (corresponding to a dose of 4.2 µg/kg/hr).
3159512|NCT00406575|Experimental|High Dose rhRlx|Participants receive recombinant human relaxin (rhRlx) via continuous IV infusion for 48 hours at a rate of 500 µg/kg/day (corresponding to a dose of 21.0 µg/kg/hr).
3159513|NCT00406588|Experimental|1|
3159514|NCT00406588|Placebo Comparator|2|
3159515|NCT00406614|Experimental|1|Literacy-focused high blood pressure intervention. The intervention group will receive the health literacy -focused hypertension management intervention that will be delivered through 6 weeks of highly interactive group sessions in a classroom setting, followed by telephone counseling once a month for 12 months. Also, the intervention group will concurrently use home blood pressure monitoring with telephone transmission for 12 months.
2484437|NCT03006952|Active Comparator|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
2484786|NCT03004456|Experimental|Distraction|"Patients randomized to the Distraction group will be permitted to choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw."
2484788|NCT03004456|No Intervention|Standard of care|"Patients randomized to the Standard of Care group will not be provided with an iPad."
2484830|NCT03004300|Active Comparator|group 1|Patients with atresic maxilla without upper airway obstruction submitted to rapid maxillary expansion
2484834|NCT03004300|Experimental|group 2|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion before adenotonsillectomy
2484838|NCT03004300|Experimental|group 3|Patients with atresic maxilla and adenotonsillar hypertrophy submitted to rapid maxillary expansion after adenotonsillectomy
2484913|NCT03003897||Soluble Fiber Treatment|Participants receiving soluble fiber.
2484917|NCT03003897||Placebo Treatment|Participants receiving placebo.
2484975|NCT03003442|Experimental|Supradyn® Energy 3RDA|Supradyn® Energy 3RDA, 1 multivitamin/mineral tablet administered by mouth daily for 28 days
2484977|NCT03003442|Placebo Comparator|Placebo|Placebo, 1 tablet administered by mouth daily for 28 days
2485165|NCT03001960|Experimental|Group 1- PREloading BEFORE TAVI|"Aspirin 100 mg loading orally 6-12 hours before TAVI and~Clopidogrel 600mg loading 6-12 before TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
2485166|NCT03001960|Experimental|Group 2 - POSTLoading AFTER TAVI|"Aspirin 100 mg loading orally 6-12 hours after TAVI and~Clopidogrel 600mg loading 6-12 hours after TAVI followed by maintenance dose of 100mg aspirin and 75mg clopidogrel per day"
3159516|NCT00406614|Active Comparator|2|Wait-list control group will initially receive usual care from a regular medical provider. Participants in the control group will take part in the intervention once the study has been completed.
3159517|NCT00406679|Experimental|1|
3159518|NCT00406679|Placebo Comparator|2|
3159519|NCT00406679|Active Comparator|3|
3159520|NCT00406757|Active Comparator|Pediatric Arm 1|"Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose."
3159521|NCT00406757|Active Comparator|Pediatric Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
3159522|NCT00406757|Active Comparator|Adult Arm 1|"Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose."
3159523|NCT00406757|Active Comparator|Adult Arm 2|Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
3159524|NCT00406757|Active Comparator|Pediatric Arm 3|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
3159525|NCT00406796|Active Comparator|1|0.5mg Ranibizumab
3159526|NCT00406796|Active Comparator|2|0.3mg Ranibizumab
3159527|NCT00406809|Experimental|Phase 1a and 1b|Relapsed or refractory lymphoid malignancies
3159528|NCT00406809|Experimental|Arm A (Phase 2a)|Relapsed or refractory follicular lymphoma
3159529|NCT00406809|Experimental|Arm B (Phase 2a)|Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
3159530|NCT00406809|Experimental|Extension Study|Relapsed or refractory follicular lymphoma or Relapsed or refractory mantle cell, peripheral T-cell, cutaneous T-cell lymphoma including mycosis fungoides and Sezary syndrome, or other indolent B-cell lymphomas such as marginal zone lymphoma
3159531|NCT00406913|Experimental|Mupirocin ointment|
3159532|NCT00406913|Active Comparator|Standard of Care sterilization|
3159533|NCT00406978|Experimental|MPTD|
3159534|NCT00407069||Active Atopic Dermatitis (AD)|Pediatric and adult subjects who fulfill the criteria for AD, a chronic inflammatory skin disease.
3159535|NCT00407069||Inactive Atopic Dermatitis (AD)|Adult subjects with a prior history of active AD that has been quiescent for at least 1 year.
3159536|NCT00407069||Psoriatics|Adult subjects who fulfill the criteria for plaque psoriasis, a chronic inflammatory skin disease.
3159537|NCT00407069||Asthmatics (without a history of AD)|Adult subjects who fulfill the criteria for asthma (reactive airway disease) and have a negative history of skin disease.
3159538|NCT00407069||Eczema Herpeticum (EH|Pediatric and adult AD subjects with a history of EH.
3159539|NCT00407069||Healthy Volunteers|Healthy individuals with no history of skin or respiratory disease.
3159540|NCT00407082|Experimental|Fluocinolone acetonide 0.59mg|Fluocinolone acetonide ocular implant 0.59mg
3159541|NCT00407082|Experimental|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
3159542|NCT00407082|No Intervention|No intervention|Fellow eye
3159543|NCT00407095|Experimental|1|
3159544|NCT00407147|No Intervention|Control|Standard treatment
3159545|NCT00407147|Experimental|PCT|PCT guided arm
3159546|NCT00407160||Group 1 Standard Immunosuppression|"Anti-thymocyte Globulin (Rabbit)] ,tacrolimus, mycophenolate mofetil and prednisone~Patients with End Stage Renal Disease (ESRD) and high Panel Reactive Antibody (PRA) who randomize to the control group. These patients will get induction therapy prior to transplant with Thymoglobulin 1.5 mg/kg/day for 4 days to a total dose of 6mg/kg.~They will receive maintenance immunosuppression with three drugs : tacrolimus, cellcept and prednisone."
3159547|NCT00407160||Group 2 Campath Immunosuppression|"Alemtuzumab,tacrolimus~Patients with ESRD and high PRA who randomize to the study group. These patients will get induction therapy prior to reperfusion of the kidney, during the transplant operation, with Campath (Alemtuzumab) 30mg, one dose. They will receive maintenance immunosuppression with tacrolimus alone (monotherapy)."
3159548|NCT00407173|Experimental|1|HCV-796 1000mg single dose
3159549|NCT00407186|Experimental|1chemoradiotherapy|5 weeksadjuvant treatment; radiotherapy and concomitant chemotherapy with cisplatin and capecitabine.
3159550|NCT00407186|Active Comparator|2chemotherapy|3 adjuvant courses epirubicin, cisplatin, capecitabine.
3159551|NCT00407277|Experimental|1A|
3193627|NCT00819962|Other|TAP|ksu
2484568|NCT03005847|Experimental|FPP arm|active treatment with fermented papaya preparation
2484627|NCT03005704|Experimental|Antiplatelet Treatment|Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
2484632|NCT03005704|No Intervention|Control|Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.
2484671|NCT03005249|Experimental|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
2484672|NCT03005249|Experimental|the control group|The patients will be assigned to the control group for cerebral palsy.
2484747|NCT03004937|Experimental|Single-Arm, Non-Randomized, Stepped Wedge|All patients who meet the inclusion criteria will receive the same intervention.
2484784|NCT03004508|Experimental|Gingko biloba Extract|
2484787|NCT03004508|Placebo Comparator|Placebo|
2484858|NCT03004274|Active Comparator|Running sutures|Deep layers will be closed using running sutures
2484863|NCT03004274|Experimental|Interrupted sutures|Deep layers will be closed using interrupted sutures
2484886|NCT03003832|Experimental|Intervention|"The intervention condition consists of a change to the electronic health record so that new opioid analgesic prescriptions automatically default to 10 pills (i.e., the quantity dispensed field is pre-populated). This value is modifiable by providers who can tailor the prescription based on clinical factors."
2484892|NCT03003832|No Intervention|Standard of care|The control condition will be the usual electronic health record interface. The default number of pills varies by medication, most medications currently have either a blank default or a default of 30 pills.
2485025|NCT03003013|Active Comparator|Biphasic Bone Graft With Autologous Platelet-rich Fibrin|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material in combination with PRF in the cystic cavity
2485030|NCT03003013|Active Comparator|Biphasic Bone Graft Material only|Patients will undergo complete removal of the cystic cavity with the application of SYMBIOS biphasic bone graft material without PRF in the cystic cavity
2485059|NCT03002545|Placebo Comparator|Placebo|identically tasting and looking Placebo
2485063|NCT03002545|Active Comparator|Magnesium|Supplementation with 400 mg Magnesium from Magnesium citrate once daily
2485093|NCT03002220|Experimental|open-label|Patient will be treated with radium-223 at a dose of 55 kBq (after 2015 NIST implementation) per kilogram body weight, given at four-week intervals for six intravenous injections.
2485156|NCT03001895|Experimental|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT Scan
2485172|NCT03001622|Other|IFX-1|
2485215|NCT03001505||Patients with pancreatic cancer|Patients diagnosed with pancreatic cancer evaluated at this institution.
3159552|NCT00407277|Placebo Comparator|1B|
3159553|NCT00407277|Experimental|2A|
3159554|NCT00407303|Experimental|1|30mg obatoclax, 1.0mg/m2 bortezomib
3159555|NCT00407303|Experimental|2|obatoclax 30 mg, bortezomib 1.3 mg/m2
3159556|NCT00407303|Experimental|3|Obatoclax 45 mg, Bortezomib 1.3 mg/m2
3159557|NCT00407589|Experimental|BOL-303224-A|Systemic exposure of BOL-303224-A following single and multiple topical doses
3159559|NCT00407641|Experimental|Tinzaparin|Patients will receive Tinzaparin as anticoagulant during the HD session.
3159560|NCT00407641|Active Comparator|Heparin|Patients will receive Heparin as an anticoagulant during the HD session
3159561|NCT00407667|Experimental|1|patients receive 20 min of anodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3159562|NCT00407667|Experimental|2|patients receive 20 min of cathodal transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3159563|NCT00407667|Sham Comparator|3|patients receive 20 min of sham transcranial stimulation plus 20 min of repetitive arm training with a therapy robot(Bi-Manu-Track)
3159564|NCT00407732|No Intervention|SC|standard care
3159565|NCT00407732|Experimental|INT|psychosocial intervention
3159566|NCT00407836|Experimental|Vaccination|One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
3159567|NCT00407875|Active Comparator|Permanent interstitial prostate brachytherapy (PIPB)|patient will undergo permanent interstitial prostate brachytherapy (PIPB) using a transperineal approach to deliver 125Iodine Rapidstrand® seeds at the facilities of the British Columbia Cancer Agency (BCCA) by one or more of the certified prostate brachytherapists in the BCCA Prostate Brachytherapy Program. The minimum peripheral dose (MPD) to the prostate gland of the implant will be 144 Gy as per TG 43 protocol. A modified peripheral loading technique will be utilized in an effort to maintain the periurethral dose to < 150% of the MPD. Within 48 hours of the implant, the patient will undergo a day 0 CT scan of the pelvis to assess post implant dosimetry using the standard BCCA protocol.
3159568|NCT00407875|Experimental|Intensity modulated external beam radiation therapy (IMRT)|patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) to a volume encompassing the prostate gland. The total radiation dose will be 70 Gy delivered in 28 fractions, so that the minimum dose to the PTV is 70 Gy, with CT simulation used for planning the treatment. Prior to starting the course of IMRT, fiducial markers will be placed in the prostate to assist in localization of the prostate for planning and quality assurance during treatment.
3159569|NCT00407901||A, B|A: High functioning visually challenged (legally blind) B: Low-functioning visually challenged (legally blind)
3159570|NCT00407914|Experimental|1|Aquamid
3159571|NCT00407914|Active Comparator|2|Restylane
3159572|NCT00407979||People with Atopic Dermatitis|
3159573|NCT00407979||People with Psoriasis|
3159574|NCT00407979||Generally healthy people|
3159575|NCT00407979||People with Atopic Dermatitis and Eczema Herpeticum|
3159576|NCT00407992|Experimental|Occipital nerve stimulation ON|
3159577|NCT00407992|Other|Occipital nerve stimulation OFF|
3159578|NCT00408031|Experimental|1|Randomization to 2 treatment groups. One group receives adjuvant treatment with D-cycloserine, up to 1 g/day. The second group receives adjuvant treatment with placebo, up to 1 g/day.
3159579|NCT00408083|Experimental|1|MultiHance MRI contrast agent
3159580|NCT00408083|Active Comparator|2|Magnevist contrast agent for MRA
3159581|NCT00408096|Active Comparator|1|The Copeland uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
3159582|NCT00408096|Active Comparator|2|The Global Cap uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact area used as a treatment for shoulder osteoarthritis
2484656|NCT03005470|Experimental|TELEM group|Participants in the telemonitoring home blood pressure group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
2484657|NCT03005470|Experimental|TELEMEV group|In the telemonitoring of lifestyle group, participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent to the smarphones on four of the five days of the week at random times using a software developed for this study.
2484658|NCT03005470|Experimental|TELEM-TELEMEV group|Participants in the telemonitoring home blood pressure plus telemonitoring of lifestyle group (TELEM-TELEMEV) will receive both interventions as previously described.
2484659|NCT03005470|Active Comparator|Usual clinical treatment (UCT)|Participants in the control group will be under antihypertensive treatment, chosen at the discretion of the assistant physician. Participants will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
2484673|NCT03005028||Control|
2484743|NCT03004963|Active Comparator|clinical group|evaluate the volume status just according to clinical indexes in this group.
2484744|NCT03004963|Experimental|clinical and BCM group|Both body composition monitor (BCM) and clinical indexes are used to evaluate the volume status of patients in this group.
2484829|NCT03004131|Experimental|fixed drug combination|MP29-02 or MP-AzuFlu as fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray (Dymista) plus Placebo tablet
2484833|NCT03004131|Placebo Comparator|Placebo|Nasal spray with no active dose plus Placebo tablet
2484840|NCT03004131|Active Comparator|active control|fluticasone propionate nasal spray (Flonase) plus loratadine 10 mg tablets (Claritin)
3159583|NCT00408148|Placebo Comparator|2|Administration of one rimonabant placebo tablet once daily in the morning
3159584|NCT00408148|Experimental|1|Administration of one tablet containing 20 mg of active rimonabant once daily in the morning
2484984|NCT03003234|Other|Duodenal fluid aspiration|
2485027|NCT03002896|Experimental|Pep-Pal + Treatment as Usual|If the caregiver is assigned to the Pep-Pal intervention condition, the RA will provide access to the mobilized website (passcode) through an email. Caregivers will be instructed to watch each session at least once. It will be recommended that caregivers watch one to two new sessions per week so that they can have enough time to practice the skills between sessions. In addition, they will be told that they can go back and watch the sessions for review as many times as they like. Full participation will be defined as watching at least 7/9 sessions (75% of program) based on previous criteria for similar intervention completion in a prior trial with advanced cancer patients.
2485031|NCT03002896|Active Comparator|Treatment as Usual|Treatment as usual provides voluntary (at the caregiver's discretion) support services for the caregivers which is rarely used by the caregivers.
2485124|NCT03002168|Active Comparator|Alpha-cyclodextrin|Two 1 gram Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets (6 grams) per day for the first two consecutive days of active treatment period. Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
2485127|NCT03002168|Placebo Comparator|Placebo|Two Placebo Alpha-cyclodextrin tablets given per fat-containing meal. A total of 6 tablets per day for the first two consecutive days of placebo treatment period.Triolein radiolabeled with 100 microcuries of 3^Hydrogen and Tripalmitin radiolabeled with 20 microcuries of 14^Carbon given orally with liquid breakfast meal.
2485157|NCT03001752|Active Comparator|Open flap immediate implant|Open flap immediate implant insertion, without bone grafting
2485158|NCT03001752|Active Comparator|Open flap immediate implant and bone grafting|Open flap immediate implant insertion and bone grafting
2485159|NCT03001752|Active Comparator|Flapless immediate implant|Immediate implant insertion without opening flap of inserting bone grafting
2485179|NCT03001609|Experimental|AC0010|each participant will be given a single dose of 14C-labeled AC0010
3159585|NCT00408161|Active Comparator|1|prize contingency management (CM) plus standard case management treatment -- patients earn the chance to win prizes by submitting negative breath samples and by complying with steps toward treatment goals
3159586|NCT00408161|Active Comparator|2|standard case management treatment
3159587|NCT00408187|Active Comparator|1.|
3159588|NCT00408187|Placebo Comparator|3.|
3159589|NCT00408187|Active Comparator|2.|
3159590|NCT00408213|Experimental|1|
3159591|NCT00408213|Placebo Comparator|2|
3159592|NCT00408226|Experimental|1|
3159593|NCT00408239|Experimental|1|Dose regimen 1
3159594|NCT00408239|Active Comparator|2|
3159595|NCT00408239|Experimental|3|Dose regimen 2
3159596|NCT00408252|Experimental|Arm A|patients will receive SU011248 in monotherapy
3159597|NCT00408291||1|Winsta PH osteosynthesis device (Fischer Medical)for treatment of humeral fracture
3159598|NCT00408330|Active Comparator|1|azelaic acid 15%
3159599|NCT00408330|Placebo Comparator|2|Inactive 15% gel base
3159600|NCT00408395|Experimental|1: Trivalent Seasonal Influenza Vaccine|
3159601|NCT00408395|Experimental|2: Adjuvanted Trivalent Seasonal Influenza Vaccine|
3159602|NCT00408447|Other|SCD group|Sickle Cell Disease patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
2484612|NCT03005509|No Intervention|Pre-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will not be introduced during this phase."
2484614|NCT03005509|Other|Post-intervention group|"All injured patients to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority triage category will be eligible for inclusion.~The Trauma Quality Improvement Meeting (TQIM) checklist will be used at all Trauma Quality Improvement Meetings (TQIMs)"
2484674|NCT03005327|Experimental|X4P-001|"Initial Treatment Phase: Participants will initiate treatment with mavorixafor at 50 milligrams (mg) once daily (QD) orally or a higher dose, with potential escalation based on area under the curve for absolute neutrophil count and absolute leukocyte count (AUCANC/ALC) values to a maximum total daily dose of 400 mg. Participants are expected to receive treatment for 24 weeks in the initial Treatment Period or until development of a treatment-limiting toxicity (TLT).~Extension Phase: All participants will receive mavorixafor; the dose will not exceed 400 mg. In the Extension Phase, treatment may continue until mavorixafor becomes available via an alternative mechanism (for example, drug is commercially available, an expanded access program, etc.) or until the study is terminated by the sponsor."
2484902|NCT03003975|Active Comparator|PVI by single cryoballoon application|"A single cryoballoon application for pulmonary vein isolation will be guided by a Multipolar Recording Catheter (Achieve Mapping Catheter), passed through the inner lumen of the cryoablation catheter. A single application of 4 minutes will be used per vein guided by recording of loss of electrograms and by a defined drop of temperature within 2 minutes application. If a stable position with adequate occlusion of the vein the Achieve catheter should be located proximally for evaluation of entrance block during application, but can be advanced deeper for stability and then retracted to the ostium to evaluate vein isolation (entrance block).~If the vein then is isolated after a single application, the operator can move on to the next vein."
2484909|NCT03003975|Active Comparator|PVI by 2 cryo applications|Cryoballoon ablation with a conventional guidewire passed through the inner lumen of the catheter for stability will be used. Ablation will be performed with 2 consecutive applications for 4 minutes each in each vein guided by degree of occlusion and temperature drop at the discretion of the physician.
2484937|NCT03003338|Experimental|OBV/PTV/r with DSV followed by placebo|OBV/PTV/r in combination with DSV for 12 weeks followed by 12 weeks matching placebo.
2484938|NCT03003338|Experimental|Placebo followed by OBV/PTV/r with DSV|Matching placebo for 12 weeks followed by 12 weeks OBV/PTV/r in combination with DSV.
2484992|NCT03003143|Experimental|Vigabatrin treatment group|
2485066|NCT03002324|Active Comparator|Current CDC Message Arm|Participants randomized to this arm will receive a message developed to directly follow the current message on the CDC's website.
2485069|NCT03002324|Experimental|Cervical Cancer Message Arm|Participants randomized to this arm will receive a message focused on cervical cancer risks and prevention and framed to highlight perceived susceptibility, perceived benefit, and self-efficacy.
2485071|NCT03002324|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short message about the costs and benefits of bird feeding.
2485122|NCT03002064|Experimental|DP group|Docetaxel plus cisplatin. Docetaxel: 60mg per square metre on day 1 and Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
2485123|NCT03002064|Active Comparator|PF group|Cisplatin plus 5-fluorouracil. Cisplatin: 60mg per square metre on day 1 and 5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles.
2485176|NCT03001739|Experimental|Intensive BP control (<120mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to < 120 mm Hg
2485178|NCT03001739|Active Comparator|Conventional BP control (120-140mmHg)|Urapidil Hydrochloride Injection (100-400ug/min) or other antihypertensive agents to decrease the BP to 120-140 mm Hg
3159603|NCT00408447|Other|BT group|Beta Thalassemia patients receiving chemotherapy (Busulfan, Fludarabine and Alemtuzumab) will undergo allogeneic stem cell transplant.
3159604|NCT00408512|Active Comparator|Thiazides|Thiazidic diuretic
3159605|NCT00408512|Active Comparator|Non Tiazidic|Non tiazidic diuretic treatment: Any other therapy can be considered in this arm: example: CCB, BB, ACEi, ARB
3159606|NCT00408525|Experimental|1|Donepezil
3159607|NCT00408551|Experimental|FOLFOX6|Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
3159608|NCT00408551|Experimental|FOLFIRI|Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
3159609|NCT00408551|Experimental|FUDR|Patients receive floxuridine IV continuously on days 1-14.
3159610|NCT00408616|Experimental|1|Grazax treatment
3159611|NCT00408616|Placebo Comparator|2|Grazax Placebo
3159612|NCT00408642|Experimental|1|enhanced adherence support for patients initiating antiretroviral therapy
3159613|NCT00408642|Active Comparator|2|standard adherence support
3159614|NCT00408655|Experimental|Arm I|"PART A: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30-60 minutes on day 1 and temsirolimus IV over 30 minutes on days 8 and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive paclitaxel and carboplatin as in part A. They also receive temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity."
3159615|NCT00408733|No Intervention|1|
3159616|NCT00408733|Experimental|2|Intervention
3159617|NCT00408772|Experimental|Unresectable colorectal liver mets|
3159618|NCT00408785|Experimental|A|Injection
3159619|NCT00408785|Placebo Comparator|B|Injection
3159620|NCT00408850|Active Comparator|Pioglitazone|pioglitazone 15 mg for 6 weeks followed by 30 mg for 6 weeks
3159621|NCT00408850|Placebo Comparator|sugar pill|Placebo comparator
3159622|NCT00408863|Active Comparator|Tibolone|Tibolone 2.5 mg/day
3159623|NCT00408863|Placebo Comparator|Placebo|Placebo
3159624|NCT00408954|Placebo Comparator|Placebo|
3159625|NCT00408954|Active Comparator|UK-369,003|
2484638|NCT03005548|Experimental|Active tDCS|Experimental: Transcranial direct current stimulation (tDCS). Patients assigned to the active treatment group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by tDCS (20 minutes of 2 milliamperes (mA) anodal tDCS over the ipsilateral cortex for 5days/week).
2484647|NCT03005548|Sham Comparator|Sham tDCS|Sham Control Group: Patients assigned to the control group (n=31) will receive IV morphine followed by IV morphine PCA (IV morphine bolus 1 mg, lockout time 10 mins.), preceded by sham tDCS stimulation (30 sec over the ipsilateral cortex, 5 days/week).
2484712|NCT03005184|Experimental|S/V+Pla, S/V+I, Enal+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484714|NCT03005184|Experimental|S/V+Pla, Enal+I, S/V+I, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484715|NCT03005184|Experimental|S/V+Pla, Enal+Pla, Enal+I, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484716|NCT03005184|Experimental|S/V+I, S/V+Pla, Enal+I, Enal+P|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484720|NCT03005184|Experimental|S/V+I, Enal+Pla, S/V+Pla, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484721|NCT03005184|Experimental|S/V+I, Enal+I, Enal+Pla, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484723|NCT03005184|Experimental|Enal+Pla, S/V+Pla, S/V+I, Enal+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484725|NCT03005184|Experimental|Enal+Pla, S/V+I, Enal+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484726|NCT03005184|Experimental|Enal+Pla, Enal+I, S/V+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484727|NCT03005184|Experimental|Enal+I, S/V+Pla, Enal+Pla, S/V+I|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484728|NCT03005184|Experimental|Enal+I, S/V+I, S/V+Pla, Enal+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484729|NCT03005184|Experimental|Enal+I, Enal+Pla, S/V+I, S/V+Pla|Enal indicated Enalapril 10 mg bid for seven days, and S/V indicates Sacubitril-Valsartan 200 mg bid for seven days. Pla indicates intravenous placebo given on the seventh day of treatment, whereas I indicates intravenous icatibant given on the seventh day of treatment. Each treatment period is separated by a three-week washout during which patients receive Valsartan 80 mg bid.
2484851|NCT03004170|Experimental|Tele-Motivational Interviewing Plus Behavioral Skills Training|The Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training (teleMI+BST) intervention comprises 5 sessions lasting approximately 45-50 minutes each. Sessions occur in weeks 3, 4, 8, and 12 post-enrollment, with a follow-up booster session in week 24. The Information-Motivation-Behavioral Skills (IMB) Model (Fisher & Fisher, 1992) provides the theoretical framework for behavior change mechanisms of teleMI+BST. The IMB posits that knowledge about condom use practices, condom use motivation, and acquisition and application of requisite condom use skills lead to engagement in condom-protected sex. The focus of this intervention is to help participants process ambivalence about engaging in condomless sex acts that risk HIV transmission.
2484853|NCT03004170|Active Comparator|Tele-Coping Effectiveness Training|The Telephone-Administered Coping Effectiveness Training (teleCET) intervention is the attention-equivalent comparator and also comprises 5 sessions lasting approximately 45-50 minutes each. The teleCET intervention is based on the Lazarus and Folkman Transactional Model of Stress and Coping (Lazarus & Folkman, 1984) and uses cognitive-behavioral principles to: (a) appraise stressor severity, (b) develop problem- and emotion-focused coping skills, (c) determine the match between coping strategies and stressor controllability, and (d) optimize coping through use of social support resources.
2515696|NCT02792283|Experimental|patients undergoing hemodialysis|
2484654|NCT03005392|Experimental|Evaluate activity physical|An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform
2484655|NCT03005392|No Intervention|control grup|The control group will be recommended to maintain a level of physical activity they would routinely and habitually have during the 4 months that the study will last.
2484678|NCT03005119|Experimental|PTL201|Up to 30 mg/day (30 mg THC, 10 mg CBD), recommended to be administered after meals and if required before bed time. Patients will be instructed not to take more than 10 mg (two capsules) at a single dosing session.
2484681|NCT03005119|Placebo Comparator|Placebo|PTL201 and placebo capsules will be identical in appearance
2484862|NCT03004053||Volunteers will be identified by the Head and Neck Service|25 volunteers (Part I - 8 volunteers. Part II - 17 volunteers). during the course of 12 months. The volunteers will be imaged with the endoscope, and the images will be evaluated visually and with qualitative (descriptive) statistics.
2484883|NCT03003910|Experimental|Best Possible Self|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
2484895|NCT03003910|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts occurred in the past 24 hours.
2485096|NCT03002298|Experimental|DMD gesture task|Experimental group that made the task using a gesture in front of a webcam
2485102|NCT03002298|Experimental|DMD button-press task|Experimental group that made the task pressing the button
2485107|NCT03002298|Active Comparator|Control group gesture task|Control group that made the task using a gesture in front of a webcam
2485112|NCT03002298|Active Comparator|Control group button-press task|Control group that made the task pressing the button
2485163|NCT03001882|Experimental|Combination therapy|Nivolumab + Ipilimumab
3159626|NCT00408967|Experimental|Tucotuzumab celmoleukin (EMD 273066)|
3159627|NCT00409019|Experimental|1|Study cancelled: Withdrawn before enrollment of any participants
3159628|NCT00409019|Experimental|2|Study cancelled: Withdrawn before enrollment of any participants
3159629|NCT00409019|Experimental|3|Study cancelled: Withdrawn before enrollment of any participants
3159630|NCT00409058|Experimental|Teen Online Problem Solving|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
3159631|NCT00409058|Experimental|Internet Resources Comparison|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
3159632|NCT00409071|Experimental|1|cocculine
3159633|NCT00409071|Placebo Comparator|2|placebo
3159634|NCT00409084|Active Comparator|1|endoscopic variceal band ligation
3159635|NCT00409084|Active Comparator|2|subjects will receive nadolol (beta blocker) at 20mg/day with dose titration
3159636|NCT00409136||Alert|Physicians alerted about their high risk patients who are not receiving any VTE prophylaxis.
3159637|NCT00409136||No Alert|Physicians not alerted about their high risk patients who are not receiving any VTE prophylaxis.
3159638|NCT00409149|Experimental|CALM BP|dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques.
3159639|NCT00409149|Active Comparator|DASH|standard dietary DASH approach in hypertensive patients
3159640|NCT00409227|Active Comparator|1|double blind placebo control
3159641|NCT00409227|Placebo Comparator|2|placebo control blinded arm
3159642|NCT00409253|Active Comparator|Urapidil|
3159643|NCT00409253|Active Comparator|Nicardipine|
3159644|NCT00409279|Experimental|1|multi-component psychosocial intervention
3159645|NCT00409279|No Intervention|2|
3159646|NCT00409318|Active Comparator|1|Etanercept
3159647|NCT00409318|Placebo Comparator|2|Placebo
3159648|NCT00409396|Experimental|1|Fecal calprotectin and urinary PGEm levels will be tested on all participants.
3159649|NCT00409435|Active Comparator|pyridostigmine|Active study drug
3159650|NCT00409435|Placebo Comparator|Placebo|Control
3159651|NCT00409448|Experimental|CAPS|Participants will receive the Internet-based counselor-assisted problem-solving group treatment
3159652|NCT00409448|Active Comparator|IRC|Participants will receive the Internet resource comparison group treatment
3159653|NCT00409487|Experimental|1|8 weeks of Valsartant treatment, 4 weeks of washout, 8 weeks of CPAP and 8 weeks of Valsartant plus CPAP treatments
3159654|NCT00409487|Experimental|2|8 weeks of CPAP , 4 weeks of washout, 8 weeks of Valsartant treatment and 8 weeks of Valsartant plus CPAP treatments
2484719|NCT03005002|Experimental|Treatment (durvalumab, tremelimumab)|Patients receive durvalumab IV over 60 minutes and tremelimumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Beginning at week 17, patients receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 4 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity.
2484819|NCT03004417|Experimental|CHF 6001 Dose1|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2484820|NCT03004417|Experimental|CHF 6001 Dose 2|CHF6001 via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2484821|NCT03004417|Placebo Comparator|Placebo|Matching placebo via NEXThaler® dry powder inhaler (DPI), b.i.d. for 32 consecutive days.
2484869|NCT03004040||Case|older adult patients (over the age of 65) admitted to Health Sciences North with laboratory confirmed influenza illness (LCII)
2484870|NCT03004040||Control|matched control subjects (non-LCII)
2484952|NCT03003585|Active Comparator|Fiberoptic bronchoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2484958|NCT03003585|Active Comparator|Direct laryngoscopy|Evaluate the difference between the two groups about hemodynamic and intraocular pressure responses.
2484989|NCT03003104|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to the face twice daily for 12 weeks
2484994|NCT03003104|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to the face twice daily for 12 weeks
2485035|NCT03002675|Experimental|exenatide|Participants will receive exenatide (Bydureon, 2mg s.c. 1x/wk, AstraZeneca) during 12 weeks
3159655|NCT00409552|Experimental|1|Virtual Reality with head display
3159656|NCT00409552|Active Comparator|2|Virtual Reality with flat projection display
2485164|NCT03001947||IgAN patients|Biopsy-proven primary IgAN patients
2485207|NCT03001570|Experimental|Arm 1|"Radiotherapy treatment associated with concurrent Cetuximab administration.~Patients candidate to curative concurrent Cetuximab and Radiotherapy are eligible for this study. After expressing written informed consent, patients will perform CT simulation. Then an IMRT-SIB (Simultaneous Integrated Boost) treatment plan will be elaborated and deliver the following Cetuximab pharmacokinetic:~Length: 6 weeks; 1 fraction daily (From Monday to Friday) 30 Total Fractions (5 per week, 6 weeks of treatment). Cetuximab will be administered weekly from a week before starting radiotherapy until the end of treatment for 7 subsequent administration accordingly to the standard schedule (1 before and 6 during radiotherapy)."
3159657|NCT00409552|Active Comparator|3|non-interactive video with head display
3159658|NCT00409552|Active Comparator|4|non-interactive video with flat projection display
3159659|NCT00409552|No Intervention|5|No distraction
3159660|NCT00409591|Active Comparator|1|"NVP-NVP:~In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
3159661|NCT00409591|Experimental|2|"PL-NVP:~In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours"
3159662|NCT00409591|Experimental|3|"LPV/r:~In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery"
3159663|NCT00409604|Experimental|1|Standard PCI procedure + pacing post conditioning
3159664|NCT00409604|No Intervention|2|Standard PCI procedure
3159665|NCT00409695|Experimental|High Dose Thymoglobulin (ATG)|High Dose Thymoglobulin (ATG): 1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
3159666|NCT00409695|Experimental|Low Dose Thymoglobulin (ATG)|Low Dose Thymoglobulin (ATG): 2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
3159667|NCT00409721|Experimental|Memantine Low Dose|
3159668|NCT00409721|Experimental|Memantine High Dose|
3159669|NCT00409734||Children with pyloric stenosis|Male or female children age two to nine weeks with history of vomiting and feeding intolerance, and abdominal sonogram showing presence of pyloric stenosis
3159670|NCT00409734||Children without pyloric stenosis|Male or female children age two to nine weeks without pyloric stenosis admitted to the hospital for other reasons
3159671|NCT00409799|Experimental|1|Experimental - high dose
3159672|NCT00409799|Experimental|2|Experimental - low dose
3159673|NCT00409799|Active Comparator|3|Autograft
3159674|NCT00409864|Active Comparator|PTBD|percutaneous biliary drainage
3159675|NCT00409864|Active Comparator|Endoscopic stenting|ERCP and stenting
3159676|NCT00409916|Placebo Comparator|Standard Care Arm|In the Standard Care Arm, the treating clinician will adjust therapy according only to the clinical assessment of signs and symptoms of heart failure since the ICG information is blinded to the treating clinician.
3159677|NCT00409916|Active Comparator|ICG Arm|In the ICG Arm, the treating clinician will adjust therapy according to the clinical assessment of signs and symptoms of heart failure, in addition to the ICG hemodynamic information obtained from the printed report.
3159678|NCT00409942|Experimental|1|Torasemide prolonged released
3159679|NCT00409942|Active Comparator|2|Furosemide
3159680|NCT00409968||Screening Study|Screening study to find out if Patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the body are eligible to take part in 1 of 4 different research studies.
3159681|NCT00409994|Experimental|Rapamycine|rapamycine 6 mg dd
3159682|NCT00410007|Other|Patients with ADPKD, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3159683|NCT00410007|Other|Patients with ADPKD, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3159684|NCT00410007|Other|Healthy Control Subjects, HS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3193628|NCT00819975|Active Comparator|Casein|
3193629|NCT00819975|Active Comparator|Whey Isolate|
2484768|NCT03004664||Support Empowerment Model|"The Center for Diabetes Education at the University of New Mexico Hospital (CDE) uses the Diabetes Self-Management Support Empowerment Model (DSMS). The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions. Patients attend a six-week group instructional session with 9 hours of class plus an individual follow-up with a certified diabetes educator. The group sessions have discussion supported by didactic conversation maps where the facilitator guides but does not control the conversation based on session thematic goals."
2484770|NCT03004664||The Chronic Care Model|One Hope Centro de Vida Diabetes Program is based on the Chronic Care Model (CCM). The CCM involves 6 synergistic domains: 1.) Improved access to care, 2.) Patient self-management support, 3.) Patient decision support, 4.) Care coordination, 5.) Integrated health information systems, and 6.) Access to community resources. To create a holistic care regime, the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design.
2484866|NCT03004378|No Intervention|Control|Participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
2484867|NCT03004378|Experimental|Intervention|Fitbit (activity tracker) + participants will receive the clinic standard of care which includes individual assessment and management by: a pediatric gastroenterologist, a pediatric surgeon, a dietitian, and a fitness instructor who are present at every visit.
3193630|NCT00819975|Active Comparator|Whey Hydrolysate|
3193631|NCT00819975|Active Comparator|Alphalact-Albumin|
2484974|NCT03003286|Experimental|UOT Students and Parents|Unstuck and on Target (UOT) provided in the classroom for students at Title 1 schools
2484976|NCT03003286|Experimental|PATSS Students and Parents|Parents and Teachers Supporting Students (PATSS) provided in the classroom for students at Title 1 schools
2485011|NCT03002961|Experimental|Cohort 1|Subjects to receive low dose of RBP-6000 subcutaneously as a single injection
2485014|NCT03002961|Experimental|Cohort 2|Subjects to receive medium dose of RBP-6000 subcutaneously as a single injection
2485019|NCT03002961|Experimental|Cohort 3|Subjects to receive high dose of RBP-6000 subcutaneously as a single injection
2485022|NCT03002961|Experimental|Cohort 4|Subjects would receive medium dose RBP-6000 as a single injection after up to 12 mg daily dosing of sublingual (SL) suboxone tablets for 7 days
2485053|NCT03002493|Experimental|Eribulin mesylate + Rifampicin|
2485180|NCT03001921||Hemodialysis patients|End stage renal disease patients receiving hemodialysis treatment
2485211|NCT03001427|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
2485213|NCT03001427|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
3159685|NCT00410007|Other|Healthy Control Subjects, LS|Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given.
3159686|NCT00410215|Active Comparator|1|sodium phosphate
3159687|NCT00410215|Active Comparator|2|picosalax
3159688|NCT00410215|Active Comparator|3|picosalax plus bisacodyl
3159689|NCT00410306||Group 1|
3159690|NCT00410332|Active Comparator|A|TRAUMEEL S
3159691|NCT00410332|Placebo Comparator|B|
3159692|NCT00410345|Experimental|Pitocin|Treatment with Pitocin after mifegine
3159693|NCT00410345|Active Comparator|Cytotec|Treatment with cytotec after mifegine
3159694|NCT00410358|Experimental|LBQ707|
3159695|NCT00410371|Experimental|GI267119|25 mg ODT tablet strength
3159696|NCT00410397|Experimental|A|Osteopathic Manipulative Medicine
3159697|NCT00410397|Placebo Comparator|B|
3159698|NCT00410436|Experimental|Resistance Training Group|Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM).
3159699|NCT00410436|Active Comparator|Control Group|Subjects will not be performing resistance exercise but will continue performing aerobic exercise at the same volume, duration and intensity as they did at baseline.
3159700|NCT00410475||U.S. radiologic technologists|Radiologic technologists certified by the American Registry of Radiologic Technologists (ARRT) during 1923-1980 and residing in any U.S. state or territory.
3159701|NCT00410553|Experimental|Treatment (combination chemotherapy)|Patients receive eribulin mesylate IV and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 OR on days 1 and 8. Courses repeat every 28 or 21 days* in the absence of disease progression or unacceptable toxicity.
3159702|NCT00410566|Experimental|1|
3159703|NCT00410566|Experimental|2|
3159704|NCT00410566|Experimental|3|
3159705|NCT00410566|Experimental|4|
3159706|NCT00410566|Experimental|5|
3159707|NCT00410579||Patients treated in NSABP R-02, R-03, C-05, C-06 or C-07|Study population to be interviewed comprises patients who were treated at least 5 years ago for colon or rectal cancer in NSABP trials R-02, R-03, C-05, C-06 or C-07
3159708|NCT00410683|Experimental|Radiotherapy|Beginning within 4-8 weeks after surgery or 2-6 weeks after chemotherapy, patients undergo adjuvant thoracic conformal radiotherapy once daily, 5 days per week, for 6 weeks.
3159709|NCT00410683|Active Comparator|No radiotherapy|Patients do not undergo adjuvant thoracic radiotherapy. After completion of study therapy, patients are followed periodically for up to 10 years.
2484783|NCT03004690|Experimental|Performance temperature 28°C|Participants wearing PPE suit A or PPE suit B perform tests I -IV at 28°C.
2484864|NCT03004261|Experimental|CMV-CTL|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA levels will be monitored weekly for at least 60 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive one additional injection of CMV-CTLs. If the CMV levels in the blood continue to rise after the dose of T cells then the patient will receive treatment with Ganciclovir or Foscarnet.
2484910|NCT03003754|Experimental|High Intensity Training (HIT) + Resistance Training (RT)|"To HIT program will be use cycle ergometers adapted for children (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) were used. Each participant performed a range of 8 to 14 cycling intervals during the intervention period. The time of each work interval cycling will be increased progressively weekly, and ranged between 40-60 s (40 s weeks 1-2; 50 s weeks 3-5; 60 s week 6), with 120 s of passive rest (over the bicycle without movement) between each interval of work.~The RT will consist in voluntary concentric/eccentric exercise during 1 minute until to get a high subjective effort perception (i.e., between 8-10 points based on the modified and subjective Borg scale of 1 to 10 points. Subjects will perform 4 exercises (biceps curl, leg-extension, shoulders press, and upper row exercise) during 6-weeks."
2484915|NCT03003754|Active Comparator|Control group|We will compare within each group (G)-1, G-2, and G-3 sub-group according to both RT and HIT intervention both pre-post changes as well as if are there some anthropometric, cardiovascular, and performance variable predicting changes in homeostasis model assessment (HOMA-IR).
2484933|NCT03003455|Active Comparator|Conventional Nasotracheal Intubation (CVT)|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
2484934|NCT03003455|Experimental|Nasotracheal Intubation Over a Bougie (NIB)|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
2484981|NCT03003221|Active Comparator|AIR-P Dental Toolkit|Families will be provided with the Autism Intervention Research Network on Physical Health (AIR-P) Dental Toolkit.
2484983|NCT03003221|Experimental|Parent Training|Families randomized to the Parent Training condition will be provided with the AIR-P Dental Toolkit and a 10-week behavioral parent-training intervention with additional booster sessions.
2485041|NCT03002883|Placebo Comparator|Usual Care|"Students referred to student health for tobacco cessation resources including campus Quit Kits"
2485044|NCT03002883|Active Comparator|Brief Motivational Interviewing|Students received brief motivational interviewing by a student peer educator about tobacco cessation
2485045|NCT03002883|Active Comparator|Direct referral to quitline|Students were directly referred to the state quitline for follow-up counseling
2485129|NCT03002051|Experimental|EUS guided drainage|Patients suffering from the conditions in focus would receive EUS guided drainage with the lumen apposing stent
2485169|NCT03001765|Other|Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac|Intensive monitoring strategy of discharging from the Emergency Department with an external 30 day cardiac monitoring system. A negative 30 day external monitor report will be followed by an implantable cardiac monitor.
3159710|NCT00410696|Active Comparator|Filgrastim|Filgrastim administration starting 1 day after autologous stem-cell reinfusion up to hemopoietic reconstitution (defined as more than 500/mm3 for 2 days)
3159711|NCT00410696|Experimental|Pegfilgrastim|Pegfilgrastim administered the day after autologous stem-cell reinfusion
3159712|NCT00410722|Experimental|Full-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts (at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3159713|NCT00410722|Experimental|Half-Dose Nut|Subjects will be given tree nuts (almonds, hazelnuts, pistachios, macadamia nuts, pecans, walnuts, and cashews) and peanuts as well as the control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3159714|NCT00410722|Active Comparator|Control|Subjects will be given a control supplement (wheat bran muffin)(at a predetermined amount to consume based on their recommended energy intake), and advised to follow a diabetic diet.
3159715|NCT00410735|Placebo Comparator|P|
3159716|NCT00410735|Experimental|E|
3159717|NCT00410852|Experimental|A|
3159718|NCT00410852|Experimental|B|
3159719|NCT00410852|Active Comparator|C|
3159720|NCT00410865|Experimental|INGN 201|INGN201 injection + oral rinse, day 1, courses 1-6. Twice-daily oral rinses, days 2-5, courses 1-6.
3159721|NCT00410956|Experimental|UNRESECTABLE PRIMARY HEPATIC MALIGNANCY|All patients enrolled in the study will receive HAI FUDR (0.16 mg/kg X pump volume / pump flow rate), Dexamethasone (1 mg/m2/day) and IV Bevacizumab at 5mg/kg. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days post surgical placement of HAI pump; patients will receive their first treatment with Bevacizumab no sooner than 28 days post surgical placement of HAI pump.
3159722|NCT00410982|Experimental|Gemcitabine + Busulfan + Melphalan + HCT|HCT = Hematopoietic Cell Transplantation
3159723|NCT00411099|Experimental|1|
3159724|NCT00411099|Experimental|2|
3159725|NCT00411099|Placebo Comparator|3|
3159726|NCT00411138|Active Comparator|Radiation Therapy|Pelvic Radiotherapy alone
3159727|NCT00411138|Experimental|Radiation Therapy and Chemotherapy|Pelvic Radiation plus 2 concurrent cycles cisplatin followed by 4 adjuvant cycles carboplatin and paclitaxel
3159728|NCT00411177|Active Comparator|Post-dilution on-line hemodiafiltration|Post-dilution on-line hemodiafiltration
3159729|NCT00411177|Other|High-flux hemodialysis|High-flux hemodialysis
3159730|NCT00411190|Experimental|Session 1|Subjects will receive 500 mg acetaminophen on Day 1, 400 mg ibuprofen on Day 2, 40 mg atorvastatin on Day 3.
3159731|NCT00411190|Experimental|Session 2|Subjects will be randomized to receive relacatib 60 mg or 120 mg from Day 1-14. On Day 15 subjects will receive 500 mg acetaminophen, 400 mg ibuprofen on Day 16 and 40 mg atorvastatin on Day 17 with usual dose of relacatib.
3159732|NCT00411203|Active Comparator|Tamoxifen Citrate|
3159733|NCT00411203|Placebo Comparator|Placebo|
3159734|NCT00411229|Active Comparator|1|Capecitabine + Oxalipatin
2484785|NCT03004547||Heart failure patients with and without renal dysfunction|Heart failure patients (atrial fibrillation etc ...) with and without renal dysfunction
2484850|NCT03004248|Experimental|DaxibotulinumtoxinA 40 units|Biological/Vaccine: Botulinum Toxins, Type A Intramuscular injection
2484918|NCT03003663|Experimental|SensableCare System|Device:The interrupted time series design will alternate between the following on a monthly basis: (1) standard medical care and (2) standard medical care and the SensableCare System.
2485002|NCT03003169||ambulatory surgery description|
2485100|NCT03002662||BMI <18.5 underweight (Group 1)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMI <18.5 underweight (Group 1)
2485106|NCT03002662||BMİ: 18.5 - 24.9 normal weight (Group 2)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 18.5 - 24.9 normal weight (Group 2)
2485108|NCT03002662||BMİ: 25- 29.9 overweight (Group 3)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ: 25- 29.9 overweight (Group 3)
2485111|NCT03002662||BMİ>30 obese (Group 4)|BMI was calculated as weight in kilograms divided by the square of height in meters. BMİ>30 obese (Group 4)
2485134|NCT03001908|Active Comparator|control oscillation|control subjects with normal shoulders will undergo the glenohumeral mobilization-oscillation
2485136|NCT03001908|Active Comparator|control sustained|control subjects with normal shoulders will undergo the glenohumeral mobilization-sustained
2485138|NCT03001908|Experimental|stiff oscillation|subjects with stiff shoulders will undergo the glenohumeral mobilization-oscillation
2485141|NCT03001908|Experimental|stiff sustained|subjects with stiff shoulders will undergo the glenohumeral mobilization-sustained
2485199|NCT03001713|Active Comparator|Arm 1: Immediate implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system at the start of study year 2. Arm 1 CHCs will receive implementation support that will be pragmatically iterated to address any barriers to adoption / sustained use of the CDS that are identified through study activities. The investigators will apply these learnings to improve adoption rates in Arm 2.
2485201|NCT03001713|Active Comparator|Arm 2: Delayed implementation|30 safety net community health centers (CHCs) will be randomized to implement the sophisticated CV Wizard clinical decision support (CDS) system 18 months later than Arm 1. The investigators will measure the intervention's impact on CVD risk factor control in CHCs.
3159735|NCT00411229|No Intervention|2|
3159736|NCT00411242|Experimental|1|
3159737|NCT00411242|Experimental|2|
3159738|NCT00411242|Placebo Comparator|3|
3159739|NCT00411281|Experimental|Group I|Patients receive very low-dose cytarabine subcutaneously twice daily on days 1-7. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease or complete or hepatic clinical remission undergo observation.
3159740|NCT00411281|Other|Group II|Patients are observed. If symptoms of intermediate- or high-risk disease develop, patients may crossover to group I.
3159741|NCT00411320|Active Comparator|Group 1|Smokers with asthma
3159742|NCT00411320|Active Comparator|Group 2|Ex-smokers with asthma
3159743|NCT00411320|Active Comparator|Group 3|Non-smokers with asthma
3159744|NCT00411320|No Intervention|Group 4|Non smokers without asthma
3159745|NCT00411320|No Intervention|Group 5|Smokers without asthma or COPD
3159746|NCT00411359|Experimental|Cardiac rehabilitation|8-week cardiac rehabilitation programme
3159747|NCT00411359|No Intervention|Monitoring|Carry on life as normal
3159748|NCT00411385|Experimental|1|900 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
3159749|NCT00411385|Experimental|2|1200 mcg alb-IFN every 2 weeks (12 doses) + Ribavirin 800 micrograms per day
3159750|NCT00411385|Active Comparator|3|180 mcg PEG-IFNx2a every 1 week (24 doses)+ Ribavirin 800 micrograms per day
3159751|NCT00411424|Experimental|1|
3159752|NCT00411424|Placebo Comparator|2|
3159753|NCT00411528|Experimental|1: 8 mg/m2 study drug + prednisone|Patupilone 8 mg/m2 + prednisone 5 mg bid daily
3159754|NCT00411528|Experimental|2: study drug + prednisone days 1 -8|Patupilone 10 mg/m2 + prednisone days 1 -8 at 25 mg bid, day 9 at 20 mg bid, day 10 at 15 mg bid, day 11 at 10 mg bid, day 12 - 21 at 5 mg bid
3159755|NCT00411528|Experimental|3: Study drug + prednisone days 1 - 4|Patupilone 10 mg/m2 + prednisone days 1 - 4 at 5 mg bid, days 5 -12 at 25 mg bid, day 13 at 20 mg bid, day 14 at 15 mg bid, day 15 at 10 mg bid, day 16 - 21 at 5 mg bid
3159756|NCT00411528|Active Comparator|4: Docetaxel 75 mg/m2 + prednisone 5 mg bid daily|Docetaxel 75 mg/m2 once every 3 weeks + prednisone 5 mg bid daily
3159757|NCT00411580|Experimental|1|CAD106
3159758|NCT00411580|Placebo Comparator|2|Placebo
3159759|NCT00411593|Experimental|Avastin® + Bortezomib|"Phase I - 3 * 3 design, enrolling patients to receive Avastin® at a fixed dose of 15 mg/kg every 3 weeks and Bortezomib dosed at 1.6 mg/m2 weekly for 2 weeks out of 3.~Phase II - The MTD for Bortezomib from the weekly schedule that is chosen will be combined with Avastin® to estimate the rate of progression-free survival."
3159760|NCT00411606||1|Subjects with no allergies
3159761|NCT00411658|Experimental|Investigational Device|
3159762|NCT00411658|Active Comparator|Cryopreserved|
3159763|NCT00411697|Experimental|Group A|
3159764|NCT00411723|Experimental|1|
3159765|NCT00411723|Placebo Comparator|2|
3159766|NCT00411736|Experimental|A|Stratification group: Age under 8 years, no CF siblings at home.
3159767|NCT00411736|Experimental|B|Stratification group: Age >/= 8 years, no CF siblings at home.
3159768|NCT00411736|Experimental|C|Stratification group: Age >/= 8 years, CF siblings at home.
3159769|NCT00411801|Experimental|Uniplas|Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
3193632|NCT00819988|Placebo Comparator|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
2484791|NCT03004612|Experimental|Linagliptin + Metformin plus lifestyle|Patients are randomized to receive for 24 months Linagliptin 2.5mg + metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
2484793|NCT03004612|Active Comparator|Metformin plus lifestyle|Patients are randomized to receive for 24 months Metformin 850mg every 12 hours. The start of the dose in this group will be gradual so that at the month of treatment the patient can be with the full doses. Together with this, patients will receive a lifestyle modification program seeking to reduce 5-7% of body weigh and increase physical activity to 90-150min/week.
2484847|NCT03004222|Experimental|Local anesthetic (Bupivicaine)|The experimental arm intervention is 75 subjects will receive the study agent (20 mL of 0.5% bupivacaine) to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
2484848|NCT03004222|Placebo Comparator|Placebo 20 ml|75 subjects will be treated with normal saline/placebo to be sprayed at the cecum after the appendix has been removed and all planned irrigation and aspiration has occurred
2484906|NCT03003936|Experimental|Early Dinner Timing|Test the lack of concurrence of meal timing with endogenous melatonin concentrations
2484914|NCT03003936|Experimental|Late Dinner Timing|Test the concurrence of meal timing with elevated endogenous melatonin concentrations
2484956|NCT03003468|Experimental|Arm A - Phase Ib|"Dose Escalation Cohort Cohort 1 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 of each 21 day cycle. Imprime PGG will be administered at 2mg/kg on Day 1,8, and 15 of cycles 1-4, and on Day 1 of cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab.~Experimental: Arm A - Phase II Investigational Treatment The maximum safe dose of Imprime PGG in combination with pembrolizumab (as determined in the phase Ib cohort) will be given on Day 1,8, and 15 for cycles 1-4, and on Day 1 of cycles 5-16.~Cohort 2 will consist of 3-6 patients who will receive pembrolizumab 200mg IV on Day 1 and Imprime PGG at 4mg/kg on Day 1,8, and 15 for Cycles 1-4 and on Day 1 only for Cycles 5-16. On Day 1 of each cycle, the Imprime PGG intravenous infusion is given first followed 15-30 minutes later by the pembrolizumab."
2485021|NCT03002922|Experimental|Healthy subjects|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams. Subject should sweat profusely.
2485173|NCT03001791|Experimental|Er:YAG laser|Excisional biopsy of fibrous hyperplasia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
2485174|NCT03001791|Experimental|CO2 laser|Excisional biopsy of fibrous hyperplasia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
2485175|NCT03001791|Experimental|Scalpel|Excisional biopsy of fibrous hyperplasia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
3159770|NCT00411801|Active Comparator|Cryosupernatant plasma|Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
3159771|NCT00411814|Placebo Comparator|Placebo|Saline
3159772|NCT00411814|Active Comparator|Active|GSK679586
3159773|NCT00411827|Active Comparator|1|PRK
3159774|NCT00411827|Active Comparator|2|LASIK
3159775|NCT00411866|Experimental|Subjects receiving ketoconazole for 8 days|In Session 1, subjects will receive a single oral dose of SB-773812 20 milligrams (mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 8 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
3159776|NCT00411866|Experimental|Subjects receiving ketoconazole for 14 days|In Session 1, subjects will receive a single oral dose of SB-773812 (20mg), followed by 21 days-washout. In Session 2, subjects will receive once daily oral dose of ketoconazole 400 mg repeated for 12 days. On day 5, single oral dose of SB-773812 20 mg will be dosed concomitantly with ketoconazole.
3159777|NCT00411879|Placebo Comparator|Control Group|Patients with refractory cardiac arrest (as defined in methods) treated according to the latest guidelines for resuscitation and receiving placebo instead of vasopressin and corticosteroids
3159778|NCT00411879|Experimental|Study Group|Patients with refractory cardiac arrest treated with combined vasopressin, epinephrine, and methylprednisolone during resuscitation. Patients receive stress-dose hydrocortisone for postresuscitation shock
3159779|NCT00411892|Experimental|A|
3159780|NCT00411892|Active Comparator|B|
3159781|NCT00411957|Active Comparator|1|ATV/r 300/100 mg
3159782|NCT00411957|Active Comparator|2|ATV/r 200/100 mg OD
3159783|NCT00411996|Other|1|IDV/r 600/100 mg + rifampicin
3159784|NCT00412022|Active Comparator|A|Triptorelin 3.75 mg IM every 4 weeks and Tamoxifen 20 mg daily, for 5 years
3159785|NCT00412022|Active Comparator|B|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily, for 5 years
3159786|NCT00412022|Experimental|C|Triptorelin 3.75 mg IM every 4 weeks and Letrozole 2.5 mg daily for 5 years + zoledronic acid 4 mg every 6 months.
3159787|NCT00412035|Active Comparator|Botox|Botulinum toxin A injection
3159788|NCT00412035|Placebo Comparator|Placebo|saline injection
3159789|NCT00412048|Other|ALZHEIMER DISEASE|
3159790|NCT00412048|Other|MOLD COGNITIVE IMPAIRMENT|
3159791|NCT00412048|Other|CONTROLS|
3159792|NCT00412165|No Intervention|usual care|Usual care arm receives standard physical activity, nutrition and weight loss information from their primary care provider. The study offers and pays for a series of weight management sessions provided by Rady's Children's Hospital and Health Center's Nutrition Dept.
3193633|NCT00819988|Experimental|Pregabalin|Single dose of 75 mg given 30-60 minutes preoperatively, then 50 mg every 8 hours for 3 days postoperatively if creatinine clearance > 60 ml/min OR 25 mg every 8 hours for 3 days postoperatively if creatinine clearance 30-60 ml/min
3208673|NCT00977054|Active Comparator|Peg-IFN + RBV|Weekly subcutaneous peginterferon alfa-2a 180 ug (week 1 to week 48) and daily oral ribavirin 1,000-1,200 mg (week 1-48; body weight < 75 kg, 1,000 mg/day and body weight >=75 kg, 1,200 mg/day)
2484928|NCT03003624|Experimental|Colorado microdissection needle group|In patients selected for Colorado® needle group incision was given with Colorado® needle tip ( N103 A which is 3 cm length straight, 3/32 in sleeve diameter),
2484929|NCT03003624|Experimental|Cautery group|Electrosurgery tip was used to give incisions.
2484930|NCT03003624|Active Comparator|BP Blade group|No.15 surgical blade was used to give incisions.
2484959|NCT03003247|Experimental|IDP-120 Gel|IDP-120 Gel is a combination treatment
2484962|NCT03003247|Active Comparator|IDP-120 Component A Gel|IDP-120 Monad Gel of Component A
2484966|NCT03003247|Active Comparator|IDP-120 Component B Gel|IDP-120 Monad Gel of Component B
2484969|NCT03003247|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel
2485000|NCT03002857|Experimental|Classical LMA|Classical LMA insertion: LMA-C insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2485006|NCT03002857|Experimental|I-gel|I-gel LMA insertion: The I-gel LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2485013|NCT03002857|Experimental|The Baska Mask®|The Baska Mask® insertion: The Baska Mask® insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and end-tidal carbon dioxide pressure waveform.
2485080|NCT03002597|Experimental|Blind Children|Children between the ages of 4 and 17 who are blind (documented visual acuity of light perception or worse) in both eyes from an eye care provider.
2485082|NCT03002597|Experimental|Sighted Children|Children between the ages of 4 and 17 who are sighted in both eyes.
2485146|NCT03002116|Active Comparator|Group N|Healthy volunteers without peripheral arterial disease according to clinical examination and Duplex ultrasound
2485149|NCT03002116|Experimental|Group DN|Patients suffering from diabetes and diabetic foot without vascular compromise according to clinical assessment continuous-wave Doppler and Duplex ultrasound
2485150|NCT03002116|Experimental|Group DC|Diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
2485151|NCT03002116|Experimental|Group NDC|Non diabetic patients with Rutherford-Becker 5 or 6 critical limb ischemia, verified by clinical examination, abnormal continuous-wave Doppler or Duplex ultrasound and intra-arterial angiography.
2485205|NCT03001635|Experimental|conventional treatment and oxytocin|26 patients admitted to the ICCU under a diagnosis of STEMI will receive treatment with oxytocin as an add on to the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). At admission, a continuance infusion with oxytocin will be initiated for a time period of 6 hours. 10 units of oxytocin will be diluted in 1 liter of 0.9% normal saline. the infusion will start at a rate of 2.5 milliunits/min. dosage will be increased at a rate of 5 milliuinits/min every 30 min if there are no side effect, up to a maximum dosage of 30 milliunits/min.
2485206|NCT03001635|Placebo Comparator|conventional treatment only|26 patients admitted to the ICCU under a diagnosis of STEMI will receive the conventional treatment (e.g. primary PCI, aspirin, ADP receptor inhibitors, high dose statin, beta blockers & ACE inhibitors). On admission, an infusion of 0.9 normal saline will be stared as placebo.
3159793|NCT00412165|Experimental|Intervention - Web|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition.
3159794|NCT00412165|Experimental|Intervention - Group|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and has access to monthly group session with other teen and parent participants.
3159795|NCT00412165|Experimental|Intervention - Cell Phone|This group receives access to a program internet site with weekly challenges aimed at weight loss through increased physical activity and nutrition and are provided with cell phones to use during the program. The cell phone allows for the transfer of text messages from the study to the participant that are tailored to their health goals. In addition, self-monitoring and uploading capabilities to the program website are included.
3159796|NCT00412191|Experimental|Subjects in treatment regimen A|Subjects in treatment regimen A will receive 100 and 200 mg lamotrigine XR in fasting condition.
3159797|NCT00412191|Experimental|Subjects in treatment regimen B|Subjects in treatment regimen B will receive 100 mg lamotrigine XR in fasting condition.
3159798|NCT00412191|Experimental|Subjects in treatment regimen C|Subjects in treatment regimen C will receive 100 mg lamotrigine XR in fed condition.
3159799|NCT00412204|Active Comparator|1|Tiotropium
3159800|NCT00412204|Placebo Comparator|2|Placebo
3159801|NCT00412230||no treatment|
3159802|NCT00412230||2|
3159803|NCT00412321|Experimental|Cohort 1 (CNTO 328)|Patients will receive 4 administrations of 3 mg/kg CNTO 328 every 2 weeks till Day 43.
3159804|NCT00412321|Experimental|Cohort 2 (CNTO 328)|Patients will receive 4 administrations of 6 mg/kg CNTO 328 every 2 weeks till Day 43.
3159805|NCT00412321|Experimental|Cohort 3 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
3159806|NCT00412321|Experimental|Cohort 4 (CNTO 328)|Patients will receive 7 administrations of 6 mg/kg CNTO 328 every week till Day 43.
3159807|NCT00412321|Experimental|Cohort 5 (CNTO 328)|Patients will receive 4 administrations of 12 mg/kg CNTO 328 every 2 weeks till Day 43.
3159808|NCT00412321|Experimental|Cohort 6 (CNTO 328)|Patients will receive 3 administrations of 12 mg/kg CNTO 328 every 3 weeks till Day 43.
3159809|NCT00412321|Experimental|Cohort 7a (CNTO 328)|Patients responding to CNTO 328 treatment will receive 9 mg/kg CNTO 328 every 3 weeks.
3208674|NCT00977067|Experimental|A|
2484926|NCT03003637|Experimental|Nivolumab with or without Ipilimumab|First dose scheme will be 2x nivolumab 240 mg flat dose, weeks 1 and 3. When feasible and safe, the next patients will be treated with the following dose scheme: the combination of 1x ipilimumab 1 mg/kg + nivolumab 240 mg flat dose in week 1 and nivolumab mono-therapy 240 mg flat dose in week 3
2484935|NCT03003273|Experimental|arm (A) - stoppage of antibiotics|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
2484936|NCT03003273|Active Comparator|arm (B) - oral antibiotics till ANC ≥ 500|patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.
2484985|NCT03003182||in clinical trials|
2484986|NCT03003182||out of clinical trials|
2485032|NCT03002792||general anesthesia|caries treatment under general anesthesia
2485033|NCT03002792||caries treatment only|caries treatment without general anesthesia
2485061|NCT03002480|Other|Severe Hemophilia A subjects w/ inhibitors|Males age 4-70 years diagnosed with severe hemophilia A with inhibitors who are currently treated with prophylaxis or on-demand treatment will be enrolled.
2485092|NCT03002259|No Intervention|Control|No placebo required
2485101|NCT03002259|Active Comparator|Dexamethasone|Dexamethasone, 1 mg/kg (maximal dose 100 mg), single dose administration before cardiopulmonary bypass
2485171|NCT03001973||LN patients|Patients diagnosis as lupus nephritis
3159810|NCT00412321|Experimental|Cohort 7b (CNTO 328)|Patients responding to CNTO 328 treatment will receive 12 mg/kg CNTO 328 every 3 weeks as extended administration.
3159811|NCT00412334|Experimental|1|
3159812|NCT00412334|Experimental|2|
3159813|NCT00412334|Experimental|3|
3159814|NCT00412334|Experimental|4|
3159815|NCT00412386||BAV|patients with BAV
3159816|NCT00412386||Normal control|normal patients
3159817|NCT00412412|Experimental|A|Patients with HER2- Breast Cancer
3159818|NCT00412412|Experimental|B|Patients with HER2+ Breast Cancer
3159819|NCT00412477|Experimental|Group 1 - LFn-p24 ISOug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3159820|NCT00412477|Experimental|Group 2 - LFn-p24 300ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3159821|NCT00412477|Experimental|Group 3 - LFn-p24 450ug with Alhydrogel|"HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed. Product is administered IM, 1ml. Six subjects (4 vaccines and 2 placebos).~Placebo recipients will receive a saline preparation in similar volume given IM.~Immunizations given at 0, 4 and 16 weeks"
3159822|NCT00412490||Smoking Behavior Group|Individuals Having Surgery for Oral Cavity Cancer.
3159823|NCT00412555|Experimental|1|
3159824|NCT00412568|Active Comparator|1|PRK control group
3159825|NCT00412581|Experimental|Lenalidomide + Dacarbazine|
3159826|NCT00412594|Experimental|Treatment (cladribine and rituximab)|Patients receive cladribine IV over 2 hours QD on days 1-5 and rituximab IV once weekly for 8 weeks beginning on day 28 in the absence of disease progression or unacceptable toxicity.
3159827|NCT00412620|Placebo Comparator|Sugar Pill|
3159828|NCT00412620|Experimental|Group 1 Part 1 - ABT-925|
3159829|NCT00412620|Experimental|Group 1 Part 2 - ABT-925|
3159830|NCT00412620|Experimental|Group 2 - ABT-925|
3159831|NCT00412659|Active Comparator|Midline excision|Midline excision for pilonidal sinus disease.
3159832|NCT00412659|Active Comparator|Karydakis|Karydakis operation for pilonidal sinus disease.
3159833|NCT00412685||TGA group|The TGA group consists of 15 patients treated withMustard or Senning procedures for surgical repaired of D-TGA atrial switch operation.
3159834|NCT00412685||TOF group|The TOF group consists of 15 patients with surgically corrected TOF.
3159835|NCT00412685||Control group|The control group C consists of 15 control subjects (AH) with normal Doppler Echocardiographic echocardiographic examinations.
3159836|NCT00412698|Experimental|1|
3159837|NCT00412698|Placebo Comparator|2|
3159838|NCT00412776|Experimental|1|Proxinium plus Best Supportive Care
3159839|NCT00412776|No Intervention|2|Best Supportive Care
3159840|NCT00412789|Experimental|EPO906|
3159841|NCT00412802|Experimental|1|dose adaptation of Enoxaparine at the renal deficient patients
3159842|NCT00412802|Active Comparator|2|No dose adaptation of Enoxaparine at renal normal patients
3159843|NCT00412997|Experimental|LBH589|
3159844|NCT00413075|Experimental|oral belinostat|
3159845|NCT00413101|Experimental|1|
3159846|NCT00413114|Experimental|Obatoclax Mesylate|Obatoclax Mesylate 30mg
3159847|NCT00413127|Experimental|1|Lidocaine i.v
3159848|NCT00413127|Active Comparator|2|intraoperatively lidocaine epidural postoperatively lidocaine i.v.
3159849|NCT00413127|Active Comparator|3|intraoperatively lidocaine i.v. postoperatively lidocaine epidural
3159850|NCT00413127|Active Comparator|4|lidocaine epidural
3159851|NCT00413127|Placebo Comparator|5|placebo i.v.
3159852|NCT00413205|Placebo Comparator|Placebo|po daily
3159853|NCT00413205|Experimental|RAR Gamma|5mg po daily
3159854|NCT00413257|Experimental|1|nefopam infusion will start before the surgical incision, at the induction time of anesthesia and will be continued until postoperative H48
3159855|NCT00413257|Experimental|2|nefopam administration will start at the end of the surgery and will be continued until postoperative H48
2484861|NCT03004196|Experimental|Chlorhexidine Mouthwash Group|"Patients were asked to rinse daily with Dr. Reddy's Clohex chlorhexidine mouthwash of 10ml without dilution for three times a day after meals (Breakfast, Lunch Dinner) for 3-4 minutes and were asked not to eat or drink anything for half-an-hour."
2484882|NCT03003715|Experimental|Refractory Trigeminal Neurpathic Pain (TNP) Patients|All patients receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
2484891|NCT03003715|Experimental|Healthy volunteers|All volunteers receive QST prior to PET scan used to obtain baseline measures, then placebo tDCS, followed by QST and Active tDCS, over the course of a 90 minute PET scan; QST is used again to take final measurements 30 minutes later.
2484949|NCT03003364|Experimental|XCEL-UMC-BETA/placebo|Ex vivo cultured human mesenchymal stem cells from Wharton jelly, in a blinded syringe (initial treatment) / Placebo (month 6)
2484955|NCT03003364|Placebo Comparator|Placebo/XCEL-UMC-BETA|Placebo in a blinded syringe (initial treatment) / XCEL-UMC-BETA (month 6)
3159856|NCT00413257|Placebo Comparator|3|control group that will receive a placebo from the induction time of anesthesia until H48
3159857|NCT00413296|Placebo Comparator|1|Tablets, no active ingredient, 1-6 tablets/day for 12 wks in the 2 nd phase of the trial.
3159858|NCT00413296|Active Comparator|2|Levetiracetam, 500mg (1-6 tablets /day) for 12 wks in the 2nd phase of the study.
3159859|NCT00413322|Experimental|Single-arm dose escalation|
3159860|NCT00413361|Placebo Comparator|A|placebo
3159861|NCT00413361|Experimental|B|versus hydroxychloroquine
3159862|NCT00413387|Experimental|1|chf1535
3159863|NCT00413387|Active Comparator|2|Symbicort
3159864|NCT00413439|Experimental|Low dose isavuconazole intravenous solution|
3159865|NCT00413439|Experimental|High dose isavuconazole intravenous solution or oral capsules|
3159866|NCT00413452|Experimental|50 mg|50 mg once weekly
3159867|NCT00413491|Experimental|1|Comparison of MR and mammography
3159868|NCT00413543|Experimental|interventional, rehabilitation|'early pulmonary lung rehabilitation'
3159869|NCT00413543|No Intervention|control|"standard care"
3159870|NCT00413556|Active Comparator|1|
3159871|NCT00413556|Placebo Comparator|2|
3159872|NCT00413595||Observation|Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease
3159873|NCT00413608|Experimental|1|Clopidogrel
3159874|NCT00413608|Experimental|2|Clopidogrel
3159875|NCT00413647|Experimental|CardioPET|
3159876|NCT00413673|Experimental|1|PRK
3159877|NCT00413686|Experimental|1|AZD7762 monotherapy followed by AZD7762 + gemcitabine
3159878|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 2|Patients enrolling from Phase 2 studies
3159879|NCT00413699|Experimental|Open-Label Active Treatment Enrolled from Phase 3|Patients enrolling from Phase 3 studies
3159880|NCT00413725|Experimental|1|Three doses of MRKAd5 HIV-1 gag/pol/nef vaccine
3159881|NCT00413725|Placebo Comparator|2|Placebo
3159882|NCT00413764|Experimental|1|tibolone
3159883|NCT00413764|Active Comparator|2|transdermal continuous combined E2-NETA (estradiol-norethisterone)
3159884|NCT00413790|Experimental|1|Darifenacin
3159885|NCT00413790|Active Comparator|2|Tolterodine
3159886|NCT00413790|Placebo Comparator|3|Placebo
3159887|NCT00413803|Other|1|Four-hour dialysis session, blood flow rate 300-400 ml/min
3159888|NCT00413803|Active Comparator|2|Eight-hours dialysis session, blood flow rate 200-250 ml/min
3159889|NCT00413829|Other|1|
3159890|NCT00413881|Active Comparator|2|Conventional LASIK Enhancement
3159891|NCT00413881|Experimental|1|Wavefront guided LASIK Enhancement
3159892|NCT00413933|Experimental|Intrevention group|each subject in intervention group will get 15 weekly sessions (each session - 45 minutes) of specified exercise from a physical therapist that specializes in fall prevention and walking device recommendations. All subjects will get brochure for home exercise. It will be expected for intervention group to exercise twice daily, each time for 20 minutes in addition to the PT sessions
3159893|NCT00413933|No Intervention|Control group|"Those who agree to participate in the study will fill in questionnaire about falls (causes, circumstance, results). All will pass through: cognitive assessment by the Mini-Mental State Examination (MMSE), affective assessment by the 15-item Geriatric Depression Scale (GDS), functional assessment by Barthel Index (BI), visual assessment by Snellen charts and basic gait assessment by a Timed get Up and Go test (TU&G).~Participants that fulfill inclusion criteria will be randomly assigned to the intervention group or the control group"
3159894|NCT00413946|Experimental|Erythropoietin|Three doses of rErythropoietin (3000 U/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth.
3159895|NCT00413946|Placebo Comparator|saline|Three doses of placebo (0.9% saline 1 ml/kg body weight) intravenously at 3, 12-18 and 36-42 hours after birth
3159896|NCT00413998|Experimental|CABG + Mitral valve repair|
3159897|NCT00413998|Active Comparator|CABG only|
3159898|NCT00414037|Experimental|eszopiclone (Lunesta) 3mg|Subchronic (1-week) administration of 3mg Lunesta (eszopiclone)
3159899|NCT00414037|Placebo Comparator|Placebo|Placebo-treated group
3159900|NCT00414102|Experimental|Ramelteon 8 mg QD|
3159901|NCT00414102|Placebo Comparator|Placebo QD|
3159902|NCT00414128|Experimental|mycophenolate mofetil|Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
3159903|NCT00414128|Active Comparator|cyclophosphamide|pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
3159904|NCT00414141|Experimental|1|Grass MATA MPL
3159905|NCT00414141|Placebo Comparator|2|
3159906|NCT00414297|Active Comparator|1 ECP|active ECP Therapy
3159907|NCT00414297|Placebo Comparator|2|Sham ECP Treatment
3159908|NCT00414349|Experimental|1|
3159909|NCT00414349|Active Comparator|2|
3159910|NCT00414349|Experimental|3|
3159911|NCT00414375|Active Comparator|1|Drainage with interval appendectomy
3159912|NCT00414375|Experimental|2|appendectomy on presentation
2484881|NCT03004001|Experimental|Alirocumab and atorvastatin|Alirocumab 150 mg bi-weekly and atorvastatin 20 mg/d
2484887|NCT03004001|Placebo Comparator|Alirocumab placebo and atorvastatin|Alirocumab placebo biweekly and atorvastatin 20 mg/d
2485076|NCT03002519|Experimental|PLX-R18|Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.
2485131|NCT03002090|Experimental|Iron trained|
2485132|NCT03002090|Experimental|Iron Untrained|
2485135|NCT03002090|Experimental|BZKL Trained|
2485137|NCT03002090|Experimental|BZKL Untrained|
2485139|NCT03002090|Experimental|Placebo Trained|
2485140|NCT03002090|Placebo Comparator|Placebo Untrained|
2485167|NCT03001687|Experimental|vitamin D +|"Patients in the vitamin D group will receive enteral supplementation with vitamin D, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
2485168|NCT03001687|Placebo Comparator|vitamin D -|"Patients in vitamin D - group do not receive enteral supplementation with vitamin D and represent the control group, blood collection 3mL is performed in the first 24 hours after admission and one week later for serum hepcidin measurement"
2485216|NCT03001466|Experimental|urea-loaded nanoparticles eye drops|This arm include 40 cases (67 eyes) received urea-loaded nanoparticles eye drops (one drop five times a day for 8 weeks)
2485217|NCT03001466|Placebo Comparator|Balance Salt Solution eye drops|This arm include 11 cases (22 eyes) recieved Balance Salt Solution eye drops (one drop five times a day for 8 weeks)
3159913|NCT00414401|Other|Arm 1|
3159914|NCT00414414|Active Comparator|prednisone|
3159915|NCT00414414|Placebo Comparator|placebo|
3159916|NCT00414479||children 9-12 years of age|Children with schistosomiasis, malaria and anaemia
3159917|NCT00414531|Other|SIM|Patients diagnosed to have or not to have Statin induced Myopathy
3159918|NCT00414570|Experimental|[18]F-FLT PET scan|Radioactive dose of 2.59 MBq/kg (range 100 - 350 MBq) [18]F-FLT per injection prior to Positron Emission Tomography (PET) imaging. [18]F-FLT PET scans at baseline/pre-treatment and at disease progression, up to a maximum of two separate [18]F-FLT PET scans per participant.
3159919|NCT00414583||Observation|all adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology
3159920|NCT00414648|Experimental|1|Participants will receive sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
3159921|NCT00414648|Placebo Comparator|2|Participants will receive placebo sirolimus daily for 1 year followed with serial pulmonary functional tests and 6-minute walk tests over a 2-year period.
3159922|NCT00414687|Experimental|Arm 1|
3159923|NCT00414713|Active Comparator|1|Regular transfusion
3159924|NCT00414713|Active Comparator|2|Restricted transfusion
3159925|NCT00414804|Active Comparator|Spinal Cord Stimulation (SCS) Group|Spinal Cord Stimulation (SCS) Treatment Group
3159926|NCT00414804|Active Comparator|Nerve Blocks and PT|
3159927|NCT00414869|Experimental|NCX-1000|Experimental drug under evaluation
3159928|NCT00414869|Placebo Comparator|Placebo|Placebo powder
3159929|NCT00414921|Active Comparator|1|clonidine
3159930|NCT00414921|Active Comparator|2|methylphenidate
3159931|NCT00414921|Active Comparator|3|methylphenidate and clonidine
3159932|NCT00414921|Placebo Comparator|4|
3159933|NCT00414934||metastatic bone lesion for patients with cancer|
3159934|NCT00414986|Experimental|1|Practice in this arm will receive the Chronic Care Improvement intervention
3159935|NCT00414986|Experimental|2|Practices in this arm will receive the standard CQI intervention. An in-practice CQI coordinator will assist the practices in implement a chronic disease registry.
3159936|NCT00414986|Active Comparator|3|Practice in this arm will have access to all chronic care tools, but will not have an in-practice change agent.
3159937|NCT00415038|Experimental|Rostafuroxin 50 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3159938|NCT00415038|Experimental|Rostafuroxin 150 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3159939|NCT00415038|Experimental|Rostafuroxin 500 micrograms capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3159940|NCT00415038|Experimental|Rostafuroxin 1.5 mg capsules|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3159941|NCT00415038|Experimental|Rostafuroxin 5 mg capsule|5 weeks, once a day capsule treatment of active drug or placebo, followed by a 5 weeks, once a day capsule treatment of placebo or active drug according to a cross-over design
3159942|NCT00415077|Active Comparator|2|LASEK- laser-assisted subepithelial keratectomy
3159943|NCT00415077|Active Comparator|3|Mitomycin C PRK
3159944|NCT00415077|Active Comparator|1|PRK- Photorefractive keratectomy
3159945|NCT00415090|No Intervention|1|Follow with same ARV treatment
3159946|NCT00415090|Experimental|2|Switch one of ARV drugs to Nevirapine
3159947|NCT00415103|Experimental|1|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days Palonosetrón: 0.25 mg iv every 48 horas starting day 1
3159948|NCT00415103|Active Comparator|2|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment.
3159949|NCT00415129|Experimental|Study Group 1|Vaccine with adjuvant
3159950|NCT00415129|Experimental|Study Group 2|Vaccine without adjuvant
3159951|NCT00415142|Experimental|Saredutant 100 mg|Saredudant100 mg once daily for a maximum of 32 weeks
3159952|NCT00415142|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily for a maximum of 32 weeks
3159953|NCT00415142|Placebo Comparator|Placebo|Placebo once daily for one week during screening phase and a maximum of 8 weeks during the acute phase
3159954|NCT00415155|Experimental|A|
2484884|NCT03003871|Experimental|advanced oral hygiene care programmes|participants were provided with a powered toothbrush (Oral-B® AdvancePowerTM 400 series), 0.2% chlorhexidine gluconate mouth rinse, 10 mls twice daily (CorsodylPTMP), standardized toothpaste (Colgate Maximum Cavity Protection) and oral hygiene instruction.
2484890|NCT03003871|Active Comparator|conventional oral hygiene care programme|participants were provided with a manual toothbrush (Oral-B® Pro-Health All-In-One), supply of a standardized toothpaste (Colgate Maximum Cavity Protection®) and oral hygiene instruction
2484944|NCT03003429|Experimental|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
2484987|NCT03003156|Experimental|25 Hz magnetic seizure therapy|10 treatment sessions of 25 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
2484996|NCT03003156|Experimental|50 Hz magnetic seizure therapy|10 treatment sessions of 50 Hz MST, three times per week in the first two weeks, two times per in the following two weeks.
2485043|NCT03002740||NVAF patients newly prescribed apixaban|
2485046|NCT03002740||NVAF patients newly prescribed rivaroxaban|
2485047|NCT03002740||NVAF patients newly prescribed dabigatran|
2485048|NCT03002740||NVAF patients newly prescribed VKA|
2485120|NCT03002376|Experimental|REGN2810|REGN2810 treatment
2485212|NCT03001804||Cohort A|Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
2485214|NCT03001804||Cohort B|Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr < 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
3159955|NCT00415233|Experimental|1.1Gbq with rhTSH|Patients receive 1.1GBq dose of radioactive iodine and rhTSH
3159956|NCT00415233|Experimental|3.2 GBq with rhTSH|Patients receive 3.2GBq dose of radioactive idodine and rhTSH
3159957|NCT00415233|Experimental|1.1GBq without rhTSH|Patients only receive 1.1GBq dose of radioactive iodine and no rhTSH
3159958|NCT00415233|Experimental|3.2GBq without rhTSH|Patients only receive 3.2GBq dose of radioactive iodine and no rhTSH
3159959|NCT00415259|Experimental|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
3159960|NCT00415259|Other|Flat control insoles|
3159961|NCT00415311|Other|0 mg/kg|
3159962|NCT00415311|Other|0.5 mg/kg|
3159963|NCT00415311|Other|1.0 mg/kg|
3159964|NCT00415324|Experimental|Arm 1|Patients receive eribulin mesylate IV over 5 minutes on days 1, 8, and 15 and cisplatin IV over 30-60 minutes on day 1.
3159965|NCT00415350|Active Comparator|Azithromycin treatment 1|
3159966|NCT00415350|Placebo Comparator|Placebo 2|
3159967|NCT00415389|Active Comparator|1|interactive educational program
3159968|NCT00415389|Active Comparator|2|usual medical care
3159969|NCT00415402|Placebo Comparator|placebo|non vitamin D containing sugar granules
3159970|NCT00415402|Experimental|Vitamin D3|vitamin D granules
3159971|NCT00415428||1.|
3159972|NCT00415441|Experimental|Active physiotherapy|Manual therapy and home exercise program
3159973|NCT00415441|Placebo Comparator|Placebo physiotherapy|Manual therapy and home exercise program
3159974|NCT00415454|Experimental|Gene therapy|Adenovirus injection followed by 3 weeks of 5-FC + vGCV prodrug therapy and a 6 week course of capecitabine-based chemoradiation
3159975|NCT00415467|Experimental|GliaSite Radiation Therapy System (RTS)|Surgical removal of brain tumor followed by GliaSite RTS targeted brachytherapy to the specific brain tumor site
3159976|NCT00415545|Experimental|1|Fluid Watchers LITE program
3159977|NCT00415545|Experimental|2|Fluid Watchers PLUS program
3159978|NCT00415545|No Intervention|3|Usual care control group
3159979|NCT00415584|Experimental|Cinacalcet HCl|
3159980|NCT00415649|Experimental|A|DNA vaccine at baseline, Month 1, and Month 2, and the adenoviral vector vaccine at Month 6.
3159981|NCT00415649|Placebo Comparator|B|Placebo vaccine
3159982|NCT00415675||Respiratory Tumor + Normal Tissue Motion|
3159983|NCT00415701|Experimental|1|Etomidate as a single induction dose
3159984|NCT00415701|Active Comparator|2|Propofol as a single induction dose
3159985|NCT00415701|Other|3|Hydrocortisone substitution or placebo (50-50%) in etomidate-group
3159986|NCT00415766|Active Comparator|rHCG 250 ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
3159987|NCT00415766|Active Comparator|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
3159988|NCT00415766|Active Comparator|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
3159989|NCT00415805|Experimental|1|
3159990|NCT00415805|Active Comparator|2|
3159991|NCT00415818|Experimental|Arm 1|MVA-MUC1-IL2 in combination with 1st line Chemotherapy
3159992|NCT00415818|Active Comparator|Arm 2|1st line Chemotherapy without a MVA-MUC1-IL2 combination
3159993|NCT00415961|Experimental|1|CoStar Paclitaxel drug eluting stent
3159994|NCT00415974|Other|Enhanced Usual Care|"Enhanced Usual Care Arm: This group will receive 2 face-to-face sessions with a health educator for dietary and health counseling in addition to an initial physician-patient visit. Educational materials that a patient might receive at his/her physician's office will also be provided at the initial health educator visit and monthly thereafter. This condition is called Enhanced Standard Care because it is, in fact, more than most obese adolescents currently receive in primary care offices in San Diego."
3173563|NCT00613457|Experimental|Reintensification Arm II|• Arm II (reduced-intensity reinduction therapy, protocol III [closed to accrual as of 6/30/2006]): SR patients receive DEXA on days 1-15; VCR and DOX on days 1 and 8; ASP on days 1, 4, 8, and 11; CPM on day 15; ARA-C and TG on days 15-28; and MTX IT on days 16 and 23. Patients then proceed to maintenance therapy.
2484888|NCT03003988|Active Comparator|Creatine nitrate|Creatine nitrate (5.0 g. creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio).
2484894|NCT03003988|Placebo Comparator|Placebo|6.5 g. dextrose
2485104|NCT03002701|No Intervention|Control - standard care|Prior to implementation of the intervention package the current standard of care will be maintained.
2485109|NCT03002701|Active Comparator|Intervention group|After implementation the intervention package will be implemented as standard care.
2485160|NCT03001856|Experimental|Oblique Intradermal Suture|OIS is very similar to conventional interrupted intradermal suture (IS), except that the suture in OIS is canted or angled relative to the vertical plane (Figure 1). To perform OIS, the needle is passed from deep to superficial dermis and canted 30°-60° from the normal vertical plane. The needle is then inserted into the opposite wound edge from superficial to deep dermis in a mirror-image fashion. The thread is tied with a square knot to finish the suture.
2485162|NCT03001856|Experimental|Intradermal Suture|Conventional interrupted intradermal suture
2485186|NCT03001596|Experimental|Neoadjuvant chemoradiotherapy|Neoadjuvant chemoradiotherapy (NCRT) is performed followed by minimally invasive esophagectomy in enrolled patients.
2485188|NCT03001596|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy (NCT) is performed followed by minimally invasive esophagectomy in enrolled patients.
3159995|NCT00415974|Experimental|Stepped Care|"PACE-PC is a 1-year stepped-care intervention (subdivided into three 4-month blocks) utilizing multiple modalities including clinician and tailored health educator counseling, phone counseling, mailed content for overweight adolescents and their family to promote improved diet and physical activity behaviors aimed at weight loss and weight loss maintenance.~PACE-PC is designed to be based in the primary care setting and promotes involvement, management, and decision-making by the primary care provider about the level of PACE-PC step for each enrolled patient~Participants randomized to the PACE-PC condition will be enrolled in Step 1 (the most intensive) for the first 4 months. Depending upon response at the end of Step 1, for the next 4 months adolescents will be triaged to Step 2 (less intensive) or will repeat Step 1. At 8 months, again based upon treatment response, triage will occur to either Step 3 (least intensive) or repetition of the previous step."
3159996|NCT00416039|Experimental|1|Midazolam and morphine
3159997|NCT00416039|Placebo Comparator|2|placebo, Nacl 0.9 %, morphine 0.5 mg/kg
3159998|NCT00416130|Experimental|Vorinostat|A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
3159999|NCT00416208|Experimental|Bortezomib|Bortezomib 1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
3160000|NCT00416208|No Intervention|Observation|Observational arm
3160001|NCT00416234|Active Comparator|1|Laparoendoscopic Rendez vous (one stage management of cholelithiasis/choledocholithiasis)
3160002|NCT00416234|Active Comparator|2|preoperative ERCP and CBD clearance followed by lap cholecystectomy (two stage management of cholelithiasis/choledocholithiasis)
3160003|NCT00416260|Experimental|HFO-TGI|Patients with severe Acute Respiratory Distress Syndrome receiving sessions of high frequency oscillation and tracheal gas insufflation according to the study protocol
3160004|NCT00416260|No Intervention|CMV|Patients with severe Acute Respiratory Distress Syndrome receiving only conventional mechanical ventilation according to the study protocol
3160005|NCT00416273|Experimental|Treatment group|Participants in the treatment group will receive Bortezomib at a dosage of 1.6 mg/m2.
3160006|NCT00416273|Experimental|Observation group|Participants in the observation group will not receive any consolidation therapy.
3160007|NCT00416351|Experimental|Clofarabine|Patients will receive intravenous clofarabine once daily for three consecutive days. Doses of clofarabine will start at 4 mg/m2/day and will be escalated to higher dose levels.
3160008|NCT00416364||1|
3160009|NCT00416364||2|
3160010|NCT00416364||3|
3160011|NCT00416364||4|
3160012|NCT00416403|Experimental|Arm I|Patients receive oral fluvastatin sodium once daily for 3-6 weeks in the absence of disease progression or unacceptable toxicity.
3160013|NCT00416403|Experimental|Arm II|Patients receive oral fluvastatin sodium as in arm I at a higher dose.
3160014|NCT00416403|Experimental|Arm III|Patients do not receive fluvastatin sodium. breast Cancer surgery only
3160015|NCT00416481||Patient assessment|"Patients undergo assessments of cognition and performance status using the healthcare professional-rated Karnofsky performance scale. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed.~Patients also complete self-administered questionnaires that measure level of functioning and need for services. It also includes questionnaires that measure higher levels of physical functioning, performance related to survival and clinically significant illness and measures of comorbidity and the impact on daily activities. Lastly, questionnaires are administered to measure the impact of cancer on patients' social functioning and perceived availability of social support.~Patients then begin planned treatment."
3160016|NCT00416637|Experimental|Bevacizumab (Avastin)|Bevacizumab given and then BP checked and skin biopsies obtained.
3160017|NCT00416650|Experimental|Therapeutic Intervention|Patients will receive erlotinib (OSI-774) 150 mg daily by mouth. If specified toxicities occurs, the dose may be reduced.
3160018|NCT00416663|Experimental|single arm|open label,single arm,intervention is Angiogenic Cell Precusors(ACPs)
3160019|NCT00416689||Breast or lung CA pt undergoing chemoTx|
3160020|NCT00416702|Experimental|1|QAB149
3160021|NCT00416741||1 Usual Care-Lifestyle counseling|Metabolic syndrome
3160022|NCT00416741||2 Intensive care-Lifestyle counseling|Metabolic Syndrome Implementation of guidelines
3160023|NCT00416767|Experimental|FOLFIRI|
3160024|NCT00416819|Experimental|methotrexate, leucovorin calcium, rituximab, and temozolomide|Determine the rate of toxicity, in terms of percentage of patients with grade 4 neurotoxicity, in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.
2485057|NCT03002337|Experimental|Aromatherapy massage|Ten aromatherapy group received 70 minutes of aromatherapy massage once biweekly by certified aromatherapy therapist for 20 weeks.
2485060|NCT03002337|Experimental|Yoga exercise|The yoga group participated in two weekly 70-minute yoga sessions led by a midwife certified as a yoga instructor for 20 weeks
2485062|NCT03002337|No Intervention|Control|the control group received only routine prenatal care.
2485147|NCT03002233|Experimental|TRK-820|PartA: 5 μg PartB: 2.5-10 μg
2485203|NCT03001661|Active Comparator|Propess|Control intervention: Propess® (dinoprostone) Slow release vaginal drug delivery system (Prostaglandin E2).
2485204|NCT03001661|Experimental|Dilapan-S|Experimental intervention: DILAPAN-S® A synthetic osmotic cervical dilator for insertion into the cervical canal, using as many rods as necessary.
3160025|NCT00416910|Active Comparator|FCM|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) q28d, max. 6 cycles
3160026|NCT00416910|Experimental|FCM + G-CSF|Fludarabine i.v. (25 mg/m2/d, d1-3) Cyclophosphamide i.v. (200 mg/m2/d, d1-3) Mitoxantrone i.v. (8 mg/m2, d1) Filgrastim (G-CSF) s.c. (5 µg/kg/d beginning on day +6 until neutrophil recovery above 1500/µl.) q28d, max. 6 cycles
3160027|NCT00416923|Experimental|intrathecal rituximab|3 dose levels of intrathecal rituximab, 10mg, 25mg, 50mg
3160028|NCT00416975|Other|Breast Cancer Risk Assessment Screening|Counseling Intervention and Eduation Intervention
3160029|NCT00417040|Other|(Internet-based STAR database)|"Patients are registered into the STAR database, obtain a password, undergo STAR training, and complete a patient-STAR questionnaire after seeing their clinician (baseline self-report) on day 1 of course 2* of chemotherapy. Patients are reminded to complete online STAR questionnaire before seeing their clinician on day 1 of courses 3, 4, 5, and 6* of chemotherapy. Clinicians review these patient reports before creating their own assessment. Patients also complete a patient feedback survey on day 1 of course 4* of chemotherapy. Clinicians complete feedback survey at study completion.~NOTE: *All time points are based on scheduled therapy with clinical trial CALGB-90401, CALGB-30607, CALGB-30704, CALGB-40601, CALGB-40603, CALGB-40502, CALGB-70604, CALGB-80405, or CALGB-40503."
3160030|NCT00417105||1|hemodialysis twice weekly 4 hours
3160031|NCT00417105||2|nocturnal dialysis twice weekly 8 hours
3160032|NCT00417105||3|nocturnal hemodialysis, 8 hours every other night
3160033|NCT00417105||4|nocturnal hemodialysis, 8 hours, six times per week
3160034|NCT00417118|Experimental|Saredutant 100 mg|Saredutant 100 mg once daily in the morning for a maximum of 8 weeks
3160035|NCT00417118|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg once daily in the morning for a maximum of 8 weeks
3160036|NCT00417118|Placebo Comparator|Placebo|Placebo for one week during the run in period and for a maximum of 8 weeks during the active period
3160037|NCT00417209|Experimental|Larotaxel (XRP9881)|
3160038|NCT00417209|Active Comparator|5-Fluorouracil or capecitabine|Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
3160039|NCT00417222|Active Comparator|Olmesartan medoxomil|olmesartan medoxomil
3160040|NCT00417222|No Intervention|Standard therapy|Standard therapy
3160041|NCT00417235|Experimental|3-days dressing frequency/CHX sponge|"Interventions:~Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
3160042|NCT00417235|Experimental|7-days dressing frequency/CHX sponge|"Interventions:~Behavioural: 7-day catheter dressing frequency Device: 'Chlorhexidine Sponge (Biopatch TM)' on the insertion site"
3160043|NCT00417235|No Intervention|3-days dressing frequency/No CHX sponge|No intervention, classical protocol of dressing frequency every 3-days and no other device
3160044|NCT00417235|Experimental|7-days dressing change/No CHX sponge|Interventions:Behavioural: 7-day catheter dressing frequency
3160045|NCT00417261|Experimental|1|ATF936
3160046|NCT00417261|Experimental|2|AXT914
3160047|NCT00417261|Placebo Comparator|3|Placebo
3160048|NCT00417287|Active Comparator|High dose|128 mg/m2
3160049|NCT00417287|Active Comparator|Low dose|54 mg/m2
3160050|NCT00417326|Placebo Comparator|P|
3160051|NCT00417326|Experimental|E|
3160052|NCT00417339||hemodialysis, 4h, twice weekly|hemodialysis, four hours, twice weekly
3160053|NCT00417339||hemodialysis, 8h, twice weekly|hemodialysis, eight hours, twice weekly
3160054|NCT00417339||hemodialysis, 8h, every other day|hemodialysis, eight hours, every other day
3160055|NCT00417339||hemodialysis, 8h, six days per week|hemodialysis, eight hours, six days per week
3160056|NCT00417378|Active Comparator|1|Intraaortic balloon counterpulsation (IABP)
3160057|NCT00417378|Experimental|2|Left Ventricular Assist Device (Impella LP2.5)
3160058|NCT00417391|Experimental|1 mg RR110|1 mg RR110
3160059|NCT00417391|Experimental|4 mg RR110|4 mg RR110
3160060|NCT00417404|Active Comparator|vitamin A|
3160061|NCT00417404|Sham Comparator|sham injection|
3160062|NCT00417456|Active Comparator|1|Office Visits
3160063|NCT00417456|Experimental|2|Evisit
3160064|NCT00417508|Experimental|Nutritional supplement|2 packages/day with nutritional supplement containing a total of 600 kcal and 40 g protein
3160065|NCT00417508|Active Comparator|Dietary advice|ordinary dietary advice with a recommendation of four meals per day or similar dietary advice
3160066|NCT00417521|Experimental|Family therapy|
3160067|NCT00417560|Experimental|Influenza A/H5N1 Vaccine|Two 90ug Doses of Intramuscular Inactivated Influenza A/H5N1 Vaccine
3160068|NCT00417599|Experimental|Lifestyle intervention|Behavioral lifestyle intervention versus control group. The Behavioral intervention consists of behavioral lessons delivered over the internet.
3160069|NCT00417599|Experimental|control|The intervention for the waiting list control group was usual care.
3160070|NCT00417638|Experimental|patients with acute STEMI - treatment with Hypothermia +PCI|"Hypothermia using endovascular cooling with the Celsius Control System as an adjunct therapy.~Hypothermia before reperfusion by a combination of infusion of cold saline and endovascular catheter cooling as an adjunct therapy in patients with a STEMI scheduled to undergo primary percutaneous coronary intervention (PCI)."
2485145|NCT03002142|Experimental|Patients treated with hearing aids|Patients fitted with functional hearing aids (Phonak Audéo BR)
2485148|NCT03002142|Placebo Comparator|Patients treated with placebo device|Patients fitted with non-functional hearing aids
2485181|NCT03001648||PGS|Patients with RIF scheduled for PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridation (aCGH) underwent one or more stimulation cycles. If euploid blastocysts were available, patients underwent frozen embryo transfer/s.
2485183|NCT03001648||Standard IVF|Patients with RIF scheduled for standard IVF (In Vitro Fertilization) underwent a single stimulation cycle with the fresh embryo transfer and the subsequent frozen embryo transfers if there were surplus frozen embryos and the fresh embryo transfer was unsuccessful.
3160071|NCT00417638|Active Comparator|Patients with an acute STEMI eligible for primary PCI|Standard of care treatment or the control group Patients with an acute STEMI eligible for primary PCI
3160072|NCT00417690|Experimental|A|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
3160073|NCT00417690|Placebo Comparator|P|One packet of oral granules administered three times daily for 2 weeks followed by one packet two times daily for two weeks
3160074|NCT00417729|Active Comparator|acarbose, glibenclamide|acarbose vs. glibenclamide (background metformin therapy)
3160075|NCT00417768|Active Comparator|Tissue Plasminogen Activator|tPA administered by drainage tube into abscess, allowed to dwell for one hour and then drained into drainage bag. Dose of tPA administered to be determined by the volume of drainage immediately post drain insertion. This intervention is done on day 0, 1 and 2.
3160076|NCT00417768|Sham Comparator|Instillation of Normal Saline|Insertion of abdominal drainage tube to drain intra-abdominal abscess. Normal Saline administered immediately post drain insertion. Normal Saline (10 cc) allowed to dwell for one hour, then allowed to drain into drainage bag.
3160077|NCT00417794|Active Comparator|1|Atomoxetine HCL (Strattera)
3160078|NCT00417794|Placebo Comparator|2|
3160079|NCT00417807|Experimental|Gleevec/Glivec|
3160080|NCT00417911|Active Comparator|No treatment|
3160081|NCT00417911|Experimental|Bortezomib consolidation|Bortezomib consolidation : 20 injections starting 3 months after ASCT
3160082|NCT00417937|Active Comparator|1|Azelaic acid 15 % gel once daily
3160083|NCT00417937|Active Comparator|2|Azelaic acid 15 gel twice daily
3160084|NCT00418067|Active Comparator|Cypher|Sirolimus-eluting stent
3160085|NCT00418067|Active Comparator|Taxus Liberte|Paclitaxel-eluting stent
3160086|NCT00418067|Experimental|Endeavor|Zotarolimus-eluting stent
3160087|NCT00418106||1|Mothers who are pumping breast milk and who are willing to kangaroo hold their infant.
3160088|NCT00418132|Experimental|1|Participants will receive thalidomide.
3160089|NCT00418132|Placebo Comparator|2|Participants will receive placebo thalidomide.
3160090|NCT00418210|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)
3160091|NCT00418288|Active Comparator|A|
3160092|NCT00418288|Placebo Comparator|P|
3160093|NCT00418392|Experimental|Minocycline group|After successful simple aspiration, minocycline pleurodesis will be performed.
3160094|NCT00418392|Placebo Comparator|Control group|After successful simple aspiration, nothing will be performed.
3160095|NCT00418418|Active Comparator|A|Patient group receiving the stem cell injections during the CABG
3160096|NCT00418418|Placebo Comparator|B|The patient group receiving autologous serum injections during the CAGB operation
3160097|NCT00418470|Experimental|A|Higher concentration of antibiotic in NS
3160098|NCT00418470|Experimental|B|Lower concentration of antibiotic in NS
3160099|NCT00418483|Experimental|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg
3160100|NCT00418483|Experimental|Plasmin (Human) 50 mg|Plasmin (Human ) 50 mg
3160101|NCT00418483|Experimental|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg
3160102|NCT00418483|Experimental|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
3160103|NCT00418483|Experimental|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg
3160104|NCT00418483|Experimental|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg
3160105|NCT00418483|Experimental|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg
3160106|NCT00418496|Experimental|Aldekleukin Plus Dose Escalation Sorafenib|Patients will be admitted to a dedicated nursing unit for HD aldesleukin administration. Patients will receive bolus aldesleukin at a dose of 600,000 IU/Kg every eight hours on days 1-5 with a goal of 10-12 doses.
3160107|NCT00418587|Experimental|1|800 IU oral daily dose level
3160108|NCT00418587|Experimental|2|2000 IU oral daily dose level
3160109|NCT00418587|Experimental|3|4000 IU oral daily dose level
3160110|NCT00418600|Other|1|Hectorol capsules at 1.0 times current injection dose
3160111|NCT00418600|Other|2|Hectorol capsules at 1.5 times current injection dose
3160112|NCT00418600|Other|3|Hectorol capsules at 2.0 times current injection dose
3160113|NCT00418613|Experimental|1|MK0633
3160114|NCT00418613|Placebo Comparator|2|Placebo
3160115|NCT00418626|Experimental|Nilotinib|
3160116|NCT00418652|No Intervention|No TMS stimulation|The patients performed 2 tasks: a study and a control assignments with no TMS stimulation.
3160117|NCT00418652|Experimental|TMS over the dorsal stream|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the dorsal stream area (PO3 EEG site).
3160118|NCT00418652|Sham Comparator|TMS over the vertex|The patients performed 2 tasks: a study and a control assignments under TMS stimulation over the vertex area.
3160119|NCT00418730|Experimental|1|
3160120|NCT00418730|Active Comparator|2|
3160121|NCT00418730|Placebo Comparator|3|
3160122|NCT00418756|Experimental|Rifampin + nilotinib|
3160123|NCT00418769|Experimental|Nilotinib Tablet Formulations|
3160124|NCT00418769|Active Comparator|Established Nilotinib Capsule Formulation|
3160125|NCT00418782|Active Comparator|1|
3160126|NCT00418782|Experimental|2|
3160127|NCT00418782|Placebo Comparator|3|
3160128|NCT00418847|Experimental|1|
3160129|NCT00418860|Experimental|A|
2485079|NCT03002532|Experimental|Hippocampal-sparing WBRT (HS-WBRT) group|Hippocampal-sparing whole brain radiotherapy is performed using modern intensity-modulated radiotherapy (IMRT) technique to avoid conformally the hippocampal neural stem-cell structure during WBRT. Prescription dose is 37.5 Gy in 15 fractions.
2485185|NCT03002129|Other|fluid challenge|
3160130|NCT00418873|Experimental|1. Zotepine|
3160131|NCT00418873|Active Comparator|2. Risperidone|
3160132|NCT00418899||GLIOGENE|International Multi-Center, Multidisciplinary Study Consortium
3160133|NCT00419029|Active Comparator|control|brief telephone check-in (no motivational interviewing)
3160134|NCT00419029|Experimental|telephone-administered motivational interviewing|motivational interviewing sessions
3160135|NCT00419055||1 Control|Patients are discharged the day after PCI
3160136|NCT00419055||2 Study group|Patients will be discharged 4-6 hrs after PCI
3160137|NCT00419133|Experimental|1|Cholera Vaccine
3160138|NCT00419133|Placebo Comparator|2|Placebo
3160139|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E + C (active)|
3160140|NCT00419146|Experimental|Ethyl EPA (active) and Vitamins E+C (placebo)|
3160141|NCT00419146|Experimental|Ethyl EPA (placebo) and Vitamins E+C (active)|
3160142|NCT00419146|Placebo Comparator|Ethyl EPA (placebo) and Vitamins E+C (placebo)|
3160143|NCT00419198|Experimental|1|Post-conditioning during angioplasty
3160144|NCT00419198|Active Comparator|2|standard angioplasty
3160145|NCT00419211|Experimental|Lifestyle counseling|Tailored exercise program
3160146|NCT00419211|No Intervention|No Intervention|Usual care group
3160147|NCT00419237|Active Comparator|Healthy subjects|Subjects with normal liver function test will be administered a single oral inhaled dose of 400 micrograms (mcg) GW685698X in the morning of the study day. Each healthy subject will be matched as closely as possible for age, gender, bodyweight and race to a subject with impaired liver function.
3160148|NCT00419237|Experimental|Subjects with hepatic impairment|Subjects with Child Pugh B hepatic dysfunction will be administered a single oral inhaled dose of 400 mcg GW685698X in the morning of the study day.
3160149|NCT00419250|Experimental|dose-escalation to 5 mg lenalidomide (len)|escalate up to 5 mg once daily / 28-day cycle
3160150|NCT00419250|Experimental|dose-escalation to 10 mg lenalidomide (len)|escalate up to 10 mg once daily / 28-day cycle
3160151|NCT00419250|Experimental|dose-escalation to 15 mg lenalidomide (len)|escalate up to 15 mg once daily / 28-day cycle
3160152|NCT00419250|Experimental|dose-escalation to 20 mg lenalidomide (len)|escalate up to 20 mg once daily / 28-day cycle
3160153|NCT00419250|Experimental|dose-escalation to 25 mg lenalidomide (len)|escalate up to 25 mg once daily / 28-day cycle
3160154|NCT00419276|Experimental|Prolonged infusion|At least 100 hours of femoral perineural ropivacaine infusion.
3160155|NCT00419276|Placebo Comparator|Standard-of-Care|Overnight femoral perineural ropivacaine infusion followed by a femoral perineural normal saline infusion (placebo) until postoperative day 4.
3160156|NCT00419328|Experimental|A|
3160157|NCT00419406|Experimental|A: UVA1|
3160158|NCT00419406|Experimental|B: NB UVB|
3160159|NCT00419432|Active Comparator|Group A (standard pre-operative analysis)|
3160160|NCT00419432|Experimental|Group B (additional pre-operative analysis)|
3160161|NCT00419471|Experimental|Escitalopram|
3160162|NCT00419471|Placebo Comparator|Placebo pill|
3160163|NCT00419497|Active Comparator|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
3160164|NCT00419549|Active Comparator|1|Valdecoxib
3160165|NCT00419549|Active Comparator|2|
3160166|NCT00419549|No Intervention|3|
3160167|NCT00419588||1-Healthy Infants|"Group 1: We have recruited 50 healthy infants born >37 weeks gestation, and between 2 and 36 months of age. Infants were excluded for any of the following reasons.~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications for more than one time~Small for gestational age at birth~More than one respiratory illness~More than one episode of wheezing"
3160168|NCT00419588||3-Premature Infants|"Group 3: We will recruit 115 infants born prematurely, 23-35 weeks gestation. Subjects will be evaluated at the corrected age between 2 and 24 months. The subjects will have no oxygen requirements, and be clinically stable outpatients when evaluated. Infants will be excluded for any of the following reasons.~Congenital cardio-respiratory disease~Severe developmental delay"
3160169|NCT00419588||2-Healthy Infants CT|"Group 2: The investigators recruited 50 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
3160170|NCT00419601|Active Comparator|2|Fentanyl
3160171|NCT00419601|Experimental|1|Remifentanyl
3160172|NCT00419640|Experimental|LAS + DAO ON|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned ON.
3160173|NCT00419640|Experimental|LAS + DAO OFF|The right atrial lead is placed in the low atrial septal position and the DAO algorithm is turned OFF.
3160174|NCT00419640|Experimental|RAA + DAO ON|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned ON.
3160175|NCT00419640|Active Comparator|RAA + DAO OFF|The right atrial lead is placed in the right atrial appendage position and the DAO algorithm is turned OFF.
3160176|NCT00419653|Experimental|1|
3160177|NCT00419653|Active Comparator|2|
3160178|NCT00419653|Active Comparator|3|Haloperidol
3160179|NCT00419692|Experimental|Sequence WAXBYZCDE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and E: 2 x 3 mg CR-RLS (fasted).
3208675|NCT00977093|Experimental|Perfusion CMR examination|All patients will undergo perfusion CMR examination, single-photon emission computed tomography, and conventional invasive coronary angiography.
2485194|NCT03001830|Experimental|Treatment Arm|Treatment with AAV2/8-HLP-FVIII-V3
3160180|NCT00419692|Experimental|Sequence WAXBYZCED|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), C: 1 x 6 mg CR-RLS (fasted), E: 2 x 3 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
3160181|NCT00419692|Experimental|Sequence WAXBYZDCE|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), C: 1 x 6 mg CR-RLS (fasted) and E: 2 x 3 mg CR-RLS (fasted).
3160182|NCT00419692|Experimental|Sequence WAXBYZDEC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), D: 1 x 6 mg CR-RLS (high fat fed), E: 2 x 3 mg CR-RLS (fasted) and C: 1 x 6 mg CR-RLS (fasted).
3160183|NCT00419692|Experimental|Sequence WAXBYZECD|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted),C: 1 x 6 mg CR-RLS (fasted) and D: 1 x 6 mg CR-RLS (high fat fed).
3160184|NCT00419692|Experimental|Sequence WAXBYZEDC|Subjects will receive ropinirole as follows W: 1 x 0.5 mg CR-RLS (normal fed), A: 1 x 1 mg CR-RLS (fasted), X: 1 x 2 mg CR-RLS (normal fed), B: 1 x 3 mg CR-RLS (fasted), Y: 2 x 2 mg CR-RLS (normal fed), Z: (2 x 2 mg) + (1 x 1 mg) CR-RLS (normal fed), E: 2 x 3 mg CR-RLS (fasted), D: 1 x 6 mg CR-RLS (high fat fed) and C: 1 x 6 mg CR-RLS (fasted).
3160185|NCT00419705|Experimental|Transcranial Laser Therapy|
3160186|NCT00419705|Sham Comparator|Sham control procedure|
3160187|NCT00419731|Active Comparator|1|Bupropion+Placebo
3160188|NCT00419731|Experimental|2|Bupropion+Naltrexone
3160189|NCT00419783|Experimental|1|Bilastine 20 mg
3160190|NCT00419783|Experimental|2|Bilastine 100 mg
3160191|NCT00419783|Active Comparator|3|Bilastine 20 mg + Ketoconazole 400 mg
3160192|NCT00419783|Active Comparator|4|Moxifloxacin 400 mg
3160193|NCT00419783|Placebo Comparator|5|Placebo
3160194|NCT00419822|Active Comparator|Acupuncture|
3160195|NCT00419822|Sham Comparator|Sham Acupuncture|
3160196|NCT00419822|Placebo Comparator|Standard of Care|
3160197|NCT00419848|Experimental|1|
3160198|NCT00419848|Active Comparator|2|
3160199|NCT00419861||Group 1|Adults >/= 50 years of age, hospitalized for respiratory illness in Davidson County, TN.
3160200|NCT00419913|Experimental|A|Dehydroepiandrosterone (DHEA) 25mg tid
3160201|NCT00419913|Placebo Comparator|B|
3160202|NCT00419939||1|ab 10 patientsr with acquired severe brain injury (GCS 3 - 9), >18 år, PTA phase at the end (GOAT scoring), RLAS score at minimum 4 and informed consent in writing
3160203|NCT00419991|No Intervention|1 Tigecycline|
3160204|NCT00420030|Active Comparator|1|Arm 1 - routine upfront administration of Reopro (Abciximab)
3160205|NCT00420030|Other|2|Reopro (Abciximab) only if needed - according to physician
3160206|NCT00420043|Experimental|imatinib 800mg|
3160207|NCT00420043|Active Comparator|imatinib 400mg|
3160208|NCT00420082|Experimental|1|Bilastine 20 mg
3160209|NCT00420082|Active Comparator|2|Fexofenadine 120 mg
3160210|NCT00420082|Active Comparator|3|Cetirizine 10 mg
3160211|NCT00420082|Placebo Comparator|4|Placebo
3160212|NCT00420160|Experimental|Exercise|3x/wk 50 minutes of moderate intensity walking on treadmills + health education videos
3160213|NCT00420160|Other|Health Education|Contact control group attending 3x/wk 50 minutes of health education videos
3160214|NCT00420173||Patients with CLE|
3160215|NCT00420186|Experimental|1|
3160216|NCT00420277|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3160217|NCT00420277|Active Comparator|Control|Voluven (HES 130/0.4)
3160218|NCT00420355|Experimental|Arm A|Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.
3160219|NCT00420355|Experimental|Arm B|Subjects on lopinavir/ritonavir will add atazanavir.
3160220|NCT00420433||1|Patients with breast cancer that has spread to the bones.
3160221|NCT00420485|Experimental|Daily times five schedule|
3160222|NCT00420485|Experimental|Continuous schedule, twice daily|
3160223|NCT00420524|Experimental|Arm A (Normal liver function)|
3160224|NCT00420524|Experimental|Arm B (Mild liver dysfunction)|
3160225|NCT00420524|Experimental|Arm C (Moderate liver dysfunction)|
3160226|NCT00420537|Active Comparator|mycophenolate|Mycophenolate mofetil with cyclosporine trough levels between 100 and 150
3160227|NCT00420537|Active Comparator|Everolimus|Everolimus with cyclosporine trough levels between 40 and 90 ng/ml
3160228|NCT00420563|Experimental|CYCLOPHOSPHAMIDE|
3160229|NCT00420563|Active Comparator|MEGESTROL|
3160230|NCT00420576|Experimental|1|Low Dose Danggui Buxue Tang (1.5g)
3160231|NCT00420576|Experimental|2|Middle Dose Danggui Buxue Tang(3g)
3160232|NCT00420576|Experimental|3|High Dose Danggui Buxue Tang (6g)
3160233|NCT00420589|Placebo Comparator|1|Arm 1: MK0364 Pbo capsules once daily
3160234|NCT00420589|Experimental|2|Arm 2: MK0364 0.5 mg capsule once daily
3160235|NCT00420589|Experimental|3|Arm 3: MK0364 1 mg capsule once daily
3160236|NCT00420589|Experimental|4|Arm 4: MK0364 2 mg capsule once daily
3160237|NCT00420602|Other|Single Arm, Open Label|Single Arm, Open Label
3160238|NCT00420615|Experimental|Patupilone and Omeprazole|patupiloe + omeprazole
3160239|NCT00420615|Experimental|patupilone + midalzolam|patupilone + midalzolam
3160240|NCT00420654|Active Comparator|A1|
3160241|NCT00420654|Placebo Comparator|A2|
3160242|NCT00420654|Other|A3|
3160243|NCT00420680|Experimental|Arm 1|Sugammadex 2.0 mg/kg
3160244|NCT00420680|Experimental|Arm 2|Sugammadex 4.0 mg/kg
3160245|NCT00420680|Placebo Comparator|Arm 3|Placebo
3160246|NCT00420732|Experimental|Vaccine Group|
3160247|NCT00420758|No Intervention|Control|
3160248|NCT00420758|Experimental|LNS|Lipid-based nutrient supplement
3160249|NCT00420758|Experimental|CSB|Corn-soy blend supplement
2485161|NCT03001869|Experimental|68Ga-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT
2485182|NCT03001583|Experimental|Education Program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
2485184|NCT03001583|Active Comparator|Education without cooking|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
2485218|NCT03001531|Active Comparator|HydroSun|application of ultraviolet light for 30 minutes
2485219|NCT03001401|Active Comparator|iDesign|Eyes will under LASIK using iDesign platform for treatment of sphere and cylinder power
2485220|NCT03001479|No Intervention|Standard: Liquid HMF and liquid protein|This is our standard breast milk fortification in our NICU. One packet (5 mL) of Similac Human Milk Fortifier Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. After infants reach full feedings (160 ml/kg/d), 3 ml/kg of Similac Liquid Protein Fortifier is added (0.5 g/kg protein). This is increased to 6 ml/kg (1 g/kg protein) the next day.
2485221|NCT03001440||ZYBAN/WELLBUTRIN users|Subjects who currently use or who have filled a prescription for ZYBAN, WELLBUTRIN, WELLBUTRIN SR, or WELLBUTRIN XL for smoking cessation within the previous 6 months will be included in the study. Subjects will be required to complete the KAB survey either online or through a telephone interview.
2485222|NCT03001531|Active Comparator|Hilotherm|application of heat (maximum of 43°C) for 30 minutes
2485223|NCT03001479|Experimental|Intervention: HMF Hydrolyzed Protein Concentrated Liquid|One packet (5 mL) of Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid is added to breast milk feedings when infants reach 100 ml/kg/day. A second packet is added the next day (10 mL total), to make 24 kcal/oz. Feedings then continue to be advanced to full volume (160 ml/kg/d).
2485225|NCT03001401|Active Comparator|SMILE|Eyes will under SMILE using Visumax platform for treatment of sphere and cylinder power
2485224|NCT03001375|Active Comparator|Mobilization group|Laparoscopic splenic flexure mobilization will be done.
2485226|NCT03001375|Active Comparator|Non mobilization group|No mobilization of splenic flexure.
2485227|NCT03001414|Experimental|Placebo followed by Autologous EPCs transfected with eNOS|4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 1 followed by 4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 2
2485228|NCT03001414|Experimental|Autologous EPCs transfected with eNOS followed by Placebo|4 monthly IV injections of Autologous EPCs transfected with human eNOS (total of 80 million cells) during Course 1 followed by 4 monthly IV injections of Placebo (Plasma-Lyte A) during Course 2
2485230|NCT03001414|Experimental|Autologous EPCs transfected with eNOS|4 monthly IV injections of Autologous EPCs transfected with human eNOS in Course 1 followed by 4 monthly injections of Autologous EPCs transfected with human eNOS in Course 2 (total of 160 million cells)
2485229|NCT03001362|Experimental|Radical External Beam RT for Colorectal Ca|A single arm consisting of: Radical external beam RT dose of 54 Gy in 30fx with radiosensitizing chemotherapy as per institutional standard
2485233|NCT03001518||Surgery|No intervention. Patients who undergo surgical resection of their pancreatic cancer.
2485234|NCT03001271|Experimental|Healthy Subjects|Placebo and Angiotensin-(1-7) acute infusion
2485236|NCT03001271|Experimental|Hypertensive Subjects|Placebo and Angiotensin-(1-7) acute infusion
2485235|NCT03001297|Experimental|MEDI5884 Dose 1|Participants will receive single dose of MEDI5884 Dose 1 injection SC on Day 1.
2485237|NCT03001284||Multiple sclerosis patients|patients with confirmed multiple sclerosis, diagnosed according to the revised McDonald's criteria
2485238|NCT03001284||Control subjects|control subjects, matched for age, gender, and presence of cardiovascular risk factors
2485239|NCT03001297|Placebo Comparator|Placebo|Placebo will be administered subcutaneously (SC).
2485240|NCT03001310|Experimental|Biological-Low dose AAV - CNGB3|Subretinal administration of a single low dose of range AAV - CNGB3
2485241|NCT03001297|Experimental|MEDI5884 Dose 2|Participants will receive single dose of MEDI5884 Dose 2 injection SC on Day 1.
2485242|NCT03001310|Experimental|Biological-medium dose AAV - CNGB3|Subretinal administration of a single medium dose of range AAV - CNGB3
2485243|NCT03001297|Experimental|MEDI5884 Dose 3|Participants will receive single dose of MEDI5884 Dose 3 injection SC on Day 1.
2485244|NCT03001310|Experimental|Biological-high dose AAV - CNGB3|Subretinal administration of a single high dose of range AAV - CNGB3
2485246|NCT03001297|Experimental|MEDI5884 Dose 4|Participants will receive single dose of MEDI5884 Dose 4 injection SC on Day 1.
2485283|NCT03001141||Single group - observational|
3160250|NCT00420823|Placebo Comparator|Placebo pill|4 placebo pills daily for 3 months
3160251|NCT00420823|Experimental|Taurine 4g|Taurine 4g daily comprising four 1g pills
3160252|NCT00420888|Experimental|Safety group|6-12 patients
3160253|NCT00420888|Experimental|1|
3160254|NCT00420888|Other|2|Standard treatment with IFN-alpha without add-on of ABR-217620/naptumomab estafenatox
3160255|NCT00420940|Experimental|90 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
3160256|NCT00420940|Experimental|30 Hz whole-body vibration|20-minute daily whole-body vibration at 90 Hz and 0.3g
3160257|NCT00420940|No Intervention|control|control group (receiving no vibration)
3160258|NCT00421005|Experimental|1|Fluvastatin 80mg
3160259|NCT00421005|Active Comparator|2|Fluvastatin 20, tapered up according to LDL concentration
3160260|NCT00421018|Sham Comparator|Symptom-guided group|Anti-inflammatory treatment is guided conventionally according to symptoms and beta-2-agonist use.
3160261|NCT00421018|Active Comparator|FeNO-guided group|Anti-inflammatory treatment is guided according to the level of exhaled nitric oxide
3160262|NCT00421044|Experimental|Arm A (Normal liver function)|
3160263|NCT00421044|Experimental|Arm B (Mild liver dysfunction)|
3160264|NCT00421044|Experimental|Arm C (Moderate liver dysfunction)|
2485248|NCT03001349|Experimental|Diagnostic (gallium Ga 68-edotreotide, PET/CT)|Participants receive gallium Ga 68-edotreotide intravenously. After 1 hour, participants undergo PET/CT scan over 60 minutes.
2485304|NCT03000842|Experimental|Healthy Subjects|transcutaneous vagal nerve stimulation
2485306|NCT03000842|Experimental|Hypertensive Subjects|transcutaneous vagal nerve stimulation
2485326|NCT03000543|No Intervention|Vitamin A pool size in infants without inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
2485327|NCT03000543|Experimental|Vitamin A pool size in infants with inflammatory condition|Assessing vitamin A (VA) pool size in infants without inflammatory condition using model based compartmental analysis from the fraction of oral dose-derived 13C10-VA and 13C4-VA in plasma over time.
2485392|NCT03000257|Experimental|ABBV-181 plus Venetoclax|Venetoclax will be taken once daily beginning 7 days prior to cycle 1 and continuing daily for a 28 day cycle and ABBV-181 will be administered every 4 weeks.
2485393|NCT03000257|Experimental|ABBV-181|ABBV-181 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Based on available safety, pharmacokinetic, and pharmacodynamic data from the dose-escalation part of the study, participants will be enrolled in dose-expansion cohorts to further evaluate ABBV-181 at a dose level which is at or below the Maximum tolerated dose (MTD). In the Monotherapy Expansion portion of the study, ABBV-181 will be administered in 28-day dosing cycles at either 1 dose per cycle or 2 doses per cycle. Based on available safety, PK and PD data from the single agent dose-escalation part of the study, a dose for ABBV-181 will be selected to evaluate in combination with Rovalpituzumab Tesirine or venetoclax.
2485395|NCT03000257|Experimental|ABBV-181 plus Rovalpituzumab Tesirine|Rovalpituzumab Tesirine will be given once every six weeks times two doses and ABBV-181 will be administered every 3 weeks.
2485452|NCT02999815|Active Comparator|Human tetanus immunoglobulin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intrathecal 500 IU
2485453|NCT02999815|Sham Comparator|Intramuscular antitoxin|Human tetanus immunoglobulin (Tetagam-P): Injection (prefilled syringe) 250 IU in 1 ml - Intramuscular 3000 IU OR Equine antiserum - 21,000 units
2485508|NCT02999555|Experimental|Aspirated follicular fluid|Follicular fluid aspirated by follicle size and tested for the novel markers after eggs were identified and separated for the purpose of fertilization
2485543|NCT02999217|Active Comparator|Treatment|1 g of intravenous iron isomaltoside given postoperatively for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
2485546|NCT02999217|Placebo Comparator|Control|The same amount of intravenous saline for patients with preoperative anaemia (Hb 90-120 g/l and plasma ferritin<100 mkg/l).
2485633|NCT02998606|Experimental|Study Group|MOVANTIK™ (Naloxegol) 25 mg oral capsule, daily
2485645|NCT02998606|Placebo Comparator|Control Group|Placebo Oral Capsule 25 mg, daily
2485710|NCT02998268|Other|Cohort 1|"Subjects in Cohort 1 receive conventional induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
2485712|NCT02998268|Experimental|Cohort 2|"Subjects in Cohort 2 receive pembrolizumab along with induction chemotherapy with taxol/ carboplatin followed by weekly chemoradiation (taxol/ carboplatin) with pembrolizumab. Following surgery, pembrolizumab is administered every 3 weeks for 1 year.~Pembrolizumab dosing is 200 mg administered as a 30 minute IV infusion."
2485764|NCT02997800|Experimental|Esmolol|Esmolol infusion and 1 ml saline infusion
2485767|NCT02997800|Experimental|Labetalol|Labetalol Bolus and saline infusion
2485768|NCT02997800|Active Comparator|Fentanyl|Fentanyl Bolus and saline infusion
2485815|NCT02997475||Women with Bulimia Nervosa|
2485817|NCT02997475||Women Healthy Controls|
3160265|NCT00421057||Exercise Group|Taught to perform a specific regimen for strength-training and walking exercises.
3160266|NCT00421057||Nonexercise Group|Follow usual routines of standard care but not taught to perform a specific regimen for strength-training and walking exercises; will keep record of any exercises done that are not a part of this study.
3160267|NCT00421070|No Intervention|Treatment as usual|Observational component
2485250|NCT03001323|Active Comparator|Standard long-acting|Discharge on 0.3 U/kg of admission long acting insulin glargine or detemir (provided by diabetes and endocrine clinic) regardless of their home insulin regimen at the time of admission with reduction to 0.2 U/kg in CKD with GFR <30 ml/hr.
3193634|NCT00820001|Experimental|Acute Treatment Protocol Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in the booster dose of treatment. The treatment provided in this arm includes specific booster treatment based on the 8 modules of the initial treatment study. Saliva samples were also collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3193635|NCT00820001|Experimental|Acute Treatment Protocol No-Booster|Child participants in this arm were initial participants enrolled in the parent study and randomized to receive the specialty treatment from study clinicians in either the clinic or community setting. In this continuation study, the participants were enrolled at the 36 month assessment and randomized to participate in assessments only thus not receiving any additional booster treatment. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3193636|NCT00820001|Active Comparator|Treatment As Usual|Child participants in this arm were initial participants enrolled in the parent study in the clinically referred Treatment As Usual comparison group. These participants were initially enrolled in treatment services with identified providers and received treatment services as provided in that community agency. In this continuation study, the participants were enrolled at the 36 month assessment and participated in the ongoing follow-up assessments only. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
3193637|NCT00820001|Other|No Intervention Healthy Comparison|The Healthy Control subjects enrolled initially in the parent study are incorporated in a related project designed to evaluate the role of biological measures in differentiating antisocial and normal children. All Healthy Control participants were initially matched to cases in the clinical sample (both the acute treatment and the clinically referred Treatment as Usual).
3193638|NCT00820014|Experimental|1|ESBA105 eye drops
3193639|NCT00820014|Placebo Comparator|2|Placebo control (vehicle)
3193640|NCT00820053|No Intervention|no adjuvant TACE|controll group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group with patients who receive adjuvant TACE after liver resection
3193641|NCT00820053|Experimental|adjuvant TACE|patients who adjuvant TACE after liver resection
2485366|NCT03000816|Experimental|Experimental Arm|Patients in this arm will receive a treatment of SBRT for their oligometastatic lesions.
3193642|NCT00820079|Experimental|ADX10059 120 mg|Twice-daily
3193643|NCT00820079|Placebo Comparator|ADX10059 Matching Placebo|twice-daily
3193644|NCT00820092|Active Comparator|Xerecept 1.0|1.0 ug/kg/hr hCRF -24 hour IV infusion
3193645|NCT00820092|Active Comparator|Xerecept 2.0|2.0 ug/kg/hr-24 hour IV infusion
2485428|NCT03000192||Breast cancer|Women aged <50 years
2485430|NCT03000192||Gynaecological cancers|Includes: cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer and vulval cancer
2485433|NCT03000192||Non-Hodgkin Lymphoma|Diffuse large B cell
2485554|NCT02999412|Active Comparator|Comprehensive medication review (I1)|
2485555|NCT02999412|Active Comparator|Comprehensive medication review with active follow-up (I2)|
2485556|NCT02999412|Other|Usual care (Control)|
2485557|NCT02999334|No Intervention|Individual ANC (standard care)|Individual ANC is the standard of care. Women arrive at the clinic and and are provided ANC services on a first come, first serve basis. While waiting women who are present listen to a health lecture. Women then complete laboratory tests, including HIV testing (at the first visit), then meet individually with a midwife for a brief one-on-one physical assessment. Four ANC visits are recommended.
2485558|NCT02999334|Experimental|Group ANC (intervention)|Women in CP-based group antenatal care (intervention) arrive at clinic at the scheduled appointment time and go directly to the group space. The same group of 12 women and the midwife and co-facilitator are present at each session. Women measure and record their own vital signs and weight. Each then has a brief one-on-one assessment with the midwife in the group space room. Instead of health lectures, the group engages in facilitated and interactive discussions using activities. Four ANC visits are recommended.
2485559|NCT02999048|No Intervention|control group|Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
2485560|NCT02999048|Other|intervention group|Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
2485593|NCT02998866|Other|Multi-center, prospective outcomes registry|The study is a multi-center, prospective outcomes registry
2485608|NCT02998840|Active Comparator|B244 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
2485609|NCT02998840|Sham Comparator|Vehicle 4 pumps applied to the face|4 pumps total of spray to saturate the entire face. Applications should occur in the morning and at night for 4 weeks.
2485612|NCT02998840|Active Comparator|B 244 8 Pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
2485659|NCT02998697|Experimental|Treated Group|Systolic heart failure patients received Ferrous Sulfate 200 mg t.i.d for 90 days
3160268|NCT00421070|Active Comparator|Intervention|Massage therapy adjunct comparator
3160269|NCT00421096|Experimental|patient with cervix cancer|will receive gemcitabine + cisplatin + radiotherapy
2485261|NCT03001050|Other|PINPOINT system|The operative intervention will proceed as current standard protocol dictates for the described procedure. No changes in the operative technique will be undertaken apart from injection of the dye and visualization with the camera. The idea would be to place the Pinpoint probe within the subacromial space, to check the vascular status of the tendon, and then take a bite of the tendon and place the pinpoint back to check if the vascularity has decreased. The Indocyanine Green dye kit will be used along with the PINPOINT system .
2485316|NCT03000868|Experimental|Cold EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare without electrocautery.
2485317|NCT03000868|Active Comparator|Hot EMR group|Patients who have small colorectal polyps (<1cm) who receive endoscopic mucosal resection using snare with the use of electrocautery.
2485338|NCT03000855|Active Comparator|ECDS|EUS-guided choledocho-duodenostomy
2485340|NCT03000855|Active Comparator|ERCP with CSEMS|Endoscopic retrograde cholangiopancreatography with covered metallic stent
3193646|NCT00820092|Active Comparator|Xerecept 3.0|3.0 ug/kg/hr-24 hour infusion
2485483|NCT02999607|Experimental|active transcranial direct current stimulation|Stimulation at three different intensities during FDG-PET scan
2485484|NCT02999607|Sham Comparator|Sham tDCS|Comparator to active arm
2485507|NCT02999516|Experimental|Motor imaginary|Intervention with Motor imaginary with video
2485515|NCT02999516|Experimental|Non Motor imaginary|Intervention with Rest without motor imaginary
2485517|NCT02999516|Experimental|tDCS|tDCS stimulation during 20 minutes in the motor cortex.
2485518|NCT02999516|Sham Comparator|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex and then 19 minutes and 30 seconds without any stimulation.
2485520|NCT02999516|Experimental|Neurofeedback|EEG monitoring in real time with positive feedback in the computer screen when participants motor cortex is activated.
2485521|NCT02999516|Sham Comparator|Neurofeedback sham|EEG monitoring in real time with randomized feedback in the computer screen despite the motor cortex activation.
2485569|NCT02999074|Active Comparator|Resistance exercise|
2485572|NCT02999074|Active Comparator|Aerobic exercise|
2485575|NCT02999074|Other|Waitlist control|
2485722|NCT02998190|Experimental|Single oral dose of EB8018|Single ascending doses, sequential group design
2485725|NCT02998190|Placebo Comparator|Single oral dose of placebo|Single doses, matching placebo
2485729|NCT02998190|Experimental|Multiple oral doses of EB8018|Multiple ascending doses, daily for 14 days
2485734|NCT02998190|Placebo Comparator|Multiple oral doses of placebo|Multiple ascending doses, daily for 14 days
3160270|NCT00421109|Experimental|1|Bilastine 20 mg
3160271|NCT00421109|Active Comparator|2|Levocetirizine 5 mg
3160272|NCT00421109|Placebo Comparator|3|Placebo
3160273|NCT00421122|Active Comparator|1|Bricasol®
3160274|NCT00421122|Experimental|2|Bricasol® + Pulmicort®
3160275|NCT00421122|Experimental|3|Bricasol® + Symbicort®
3160276|NCT00421135|Experimental|Single Arm|ZIO-201
3160277|NCT00421187|Experimental|1|AmBisome® will be given on day 0 (10 mg/kg), day 2 (5 mg/kg), and day 5 (5 mg/kg)
3160278|NCT00421187|Active Comparator|2|AmBisome as a constant daily dose of 3 mg/kg for a maximum of 14 days or until the resolution of fever and neutropenia
3160279|NCT00421200|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3160280|NCT00421200|Active Comparator|Control|Voluven (HES 130/0.4)
3160281|NCT00421213|Experimental|Single Arm|
3160282|NCT00421239||A|
3160283|NCT00421239||B|
3160284|NCT00421252|Active Comparator|Clopidogrel 600 mg pre-treatment|Patients will receive 600 mg Clopidogrel load >2 hours pre-angiography with possibility for ad hoc PCI based on angiographic results
3160285|NCT00421252|Active Comparator|No clopidogrel 600 mg pretreatment|Patients will receive 600 mg Clopidogrel load after PCI, if performed
3160286|NCT00421252|Active Comparator|5Fr arterial access sheath|Patients will have angiography performed using 5Fr sheath. If PCI required, sheath will be upsized.
3160287|NCT00421252|Active Comparator|6Fr arterial access sheath|Patients will have angiography performed using 6Fr sheath
3160288|NCT00421278|Experimental|1|Arm 1: Drug
3160289|NCT00421330|Active Comparator|OR|Open Aneurysm Repair
3160290|NCT00421330|Experimental|EVAR|Endovascular Aneurysm Repair
3160291|NCT00421356||Transfemoral Power Knee group|Transfemoral amputees who used the power assisted Ossur Power Knee who used the knee daily without adjustments for at least 90 days prior to the study.
3160292|NCT00421356||Transfemoral C-Leg knee group|Transfemoral amputees who used the stance control Otto Bock C-Leg who used the knee daily without adjustments for at least 90 days prior to the study.
3160293|NCT00421356||Transfemoral Mauch knee group|Transfemoral amputees who used the mechanical fluid controlled Mauch Swing and Stance Knee who used the knee daily without adjustments for at least 90 days prior to the study.
3160294|NCT00421356||Non amputee control group|Healthy, non-amputee control group
3160295|NCT00421395|Experimental|multi|escalating in increments of 2.5 mCi/m2
2485262|NCT03001115||Participants with Hidradenitis suppurativa (HS)|Participants with HS treated with adalimumab (HUMIRA®) in routine clinical practice.
3193647|NCT00820105|Experimental|ADX10059 25 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
3193648|NCT00820105|Experimental|ADX10059 50 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
2485474|NCT02999659||Control group|The control group implies patients with non-acute cerebral disease (e.g. cerebral aneurysm without symptoms). The pupilometer data are once collected during ambulant routine examination. The patients do not undergo any further study related examinations.
2485476|NCT02999659||Treatment group|The treatment group implies patients with an acute cerebral disease ensured by CT, MRI or spinal tap. Pupillometry measurements are done during neurological routine examinations. Generally, during the initial diagnosis examination, followed by daily routine measurements and after 3 and 6 month upon hospital discharge.
2485550|NCT02999399|Experimental|[D10]phe and Brussels sprouts|All subjects are given 1 microgram [D10]phe before and after consuming Brussels sprouts once daily for 7 consecutive days.
2485602|NCT02998905|Experimental|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban
2485605|NCT02998905|Active Comparator|Acetylsalicylic Acid|Acetylsalicylic acid
2485673|NCT02998489|Experimental|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
2485677|NCT02998489|Active Comparator|Traditional milk advancement|20 cc/kg/d of human milk or formula milk administered by orogastric tube or by suction
2485788|NCT02997839|No Intervention|group 2|no intervention
2485791|NCT02997839|Other|group 1|sleep disruption
2485809|NCT02997384||General practitioner|
2485813|NCT02997384||gynecologist|
2485816|NCT02997384||radiologist|
2485881|NCT02997189|Active Comparator|OTO-104|One of the subject's ears will receive up to three administrations of study drug prior to cisplatin-based therapy
2485891|NCT02997189|No Intervention|Control|The ear not receiving OTO-104 will receive no treatment
3193649|NCT00820105|Experimental|ADX10059 100 mg|Weeks 1-2: once daily Weeks 3-12: twice daily
3193650|NCT00820105|Placebo Comparator|ADX10059 Matching Placebo|Weeks 1-2: once daily Weeks 3-12: twice daily
2486047|NCT02995928|Experimental|Decompressive craniectomy|Decompressive craniectomy and best medical treatment
2486048|NCT02995928|Active Comparator|Control|Only best medical treatment. Decompressive craniectomy is employed only if intracranial pressure >25 mm Hg for 1-12 hours to keep the patients safe.
2486112|NCT02995629|Experimental|green (532 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
2486113|NCT02995629|Experimental|yellow (577 nm) laser|scatter laser indirect ophthalmoscopy pan retinal photocoagulation
2486178|NCT02995005|Experimental|Tenofovir Disoproxil Fumarate|Women early in pregnancy (end of first or beginning second trimester) will be treated with TDF to determine the efficacy of this strategy to bring >=95% of women to undetectable HBV DNA levels at delivery.
2486225|NCT02994485|Active Comparator|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks
2486228|NCT02994485|No Intervention|no treatment|no treatment
3193651|NCT00820118|Experimental|Intermittent treatment|6 months on antiretroviral treatment and 6 months off treatment
2486366|NCT02993393||Teachers|Anesthesiologists who have involved in SBL and PBL with more than 3 years of experience in teaching
2486374|NCT02993393||Students|Students were nurse anesthetist students in the academic years of 2015
2486505|NCT02993120||Cohort 1|For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.
2486510|NCT02993120||Cohort 2|• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.
2486511|NCT02993120||Cohort 3|For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks
2486633|NCT02991573|Active Comparator|existing adhesive (control)|control adhesive
2486640|NCT02991573|Experimental|new adhesive: technique 1|Prime & Bond Universal: technique 1
2486647|NCT02991573|Experimental|new adhesive: technique 2|Prime & Bond Universal: technique 2
2486660|NCT02991261|Experimental|SPARC001 type I|Treatment type I
2486661|NCT02991261|Experimental|SPARC001 type II|Treatment type II
2486662|NCT02991261|Active Comparator|Reference001 type I|Hydrocodone-Acetaminophen
2486664|NCT02991261|Active Comparator|Reference type II|Hydrocodone-Acetaminophen
2486746|NCT02990975|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
2486748|NCT02990975|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Transversus Abdominis Plane block.
2486750|NCT02990975|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2486858|NCT02990299|No Intervention|Usual Care|Participants will receive their usual care for the first year of their enrollment in the study. They will receive a referral to a diabetes educator and a clinical pharmacist, a one-page sheet of contact information for their healthcare providers, and paper-based, low-literacy diabetes information. After one year, they will crossover to the mDAS intervention arm for one year.
2486866|NCT02990299|Experimental|mHealth for Diabetes Adherence Support|Participants will receive in-person support from a health coach and a clinical pharmacist with whom they will meet with regularly via videoconference. After one year, participants who have completed the mDAS intervention will be monitored for an additional year with usual care to evaluate maintenance.
3193652|NCT00820131|Experimental|1|
2485263|NCT03001063|Experimental|Intervention|This arm will receive the Supported Self- Management intervention, which consists of bibliotherapy that is provided with the regular support of health or social workers for a duration of two months.
2485265|NCT03001063|Other|Control|This arm will receive enhanced treatment as usual, which consists of a leaflet with information about depression and regular care as provided by primary care centres. The control arm will receive the intervention after the intervention arm has completed the intervention period.
3160296|NCT00421434|Experimental|Nitazoxanide-Peginterferon|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a.
3160297|NCT00421434|Experimental|Nitazoxanide-Peginterferon-Ribavirin|One oral nitazoxanide 500 mg tablet with food twice daily for 12 weeks followed by 36 weeks of one oral nitazoxanide 500 mg tablet plus weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses.
2485345|NCT03000413|Experimental|Ketamine|Intravenous ketamine infusion: bolus 2mg per kg and continuous infusion (2mg/kg/h)
2485347|NCT03000413|Active Comparator|Fentanyl|Fentanyl: bolus infusion 1μg per kg and continuous infusion (1μg/kg/h)
2485381|NCT03000322|Experimental|Cooling Vest|During the four-week Treatment Period, participants should use the Cooling Vest two times per day (once in the morning for one hour and once in the evening for one hour.)
2485505|NCT02999490|No Intervention|Controls|The controls are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the controls sleep for an hour in a quiet room before scanning.
2485512|NCT02999490|Experimental|Patients|The patients are intravenous injected of 185 to 370 MBq 18F-FDG.Then,the patients sleep for an hour in a quiet room before scanning.
2485539|NCT02999204|Active Comparator|Vitamin D3 5,000 units per week|Patient receive a dose that is considered within the standard dosing range for Vitamin D3 for one year.
2485541|NCT02999204|Experimental|Vitamin D3 50,000 units per week|Patients receive a more aggressive Vitamin D3 dosing regimen of 50,000 units weekly for the first 3 months. At this point Vitamin D3 levels are measured. If the patient is Vitamin D3 replete (>75 nmol/L) then the dose is reduced to the equivalent of 25,000 units per week for the next 9 months. If the level is below this threshold then 50,000 units per week is continued for the next 9 months
2485586|NCT02998957|Experimental|AcuTENS|"Stimulation using a portable TENS electrostimulation device at Dingchuan point using a biphasic rectangular wave with a frequency of 2Hz and a pulse width of 200 ms. The stimulation will be achieved using the highest intensity tolerated by the patient without pain during 40 minuts.~Once a day during 5 consecutive days."
2485589|NCT02998957|Sham Comparator|Sham AcuTENS|"Stimulation using a modified portable TENS electrostimulation device at Dingchuan point with no electrical output, even though the screen will light up and display the same data as in the unmodified device during 40 minuts. Patients in this group will be informed that, due to the frequency of stimulation, it is unlikely that they will feel the electric stimulation.~Once a day during 5 consecutive days."
2485635|NCT02998619||Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
2485700|NCT02998385|Active Comparator|Radiotherapy|"Arm A~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC."
2485702|NCT02998385|Experimental|Radiotherapy + concomitant cisplatin|"Arm B Concomitant systemic treatment with cisplatin + radiotherapy~According to standard protocol of concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 maximum cycles).~Radiation therapy: 66 to 70 Gy in fractions of 2 Gy, 1 fraction/day, 5 fractions per week.~Radiation therapy will be conducted by conformational intensity modulation radiotherapy (IMRT) or protontherapy. Irradiation by 3D conformational radiotherapy can be discussed on a case by case with the Intergroup Coordinator GORTEC"
2485746|NCT02998008|Other|Diabetes type 2 patients|diabetes type 2 patients whose cardiac function is tested after 4x4 high intensity interval training
2485747|NCT02998008|Other|Healthy volunteers|healthy volunteers whose cardiac function is tested after 4x4 high intensity interval training
2485852|NCT02997267|Experimental|Early closure|Closure of the ileostomy 14 days after the primary operation, in which it was created.
2485854|NCT02997267|Active Comparator|Late closure|Closure of the ileostomy more than 90 days after the primary operation, in which it was created.
2485942|NCT02996825|Experimental|Treatment (IMGN853, gemcitabine hydrochloride)|Patients receive mirvetuximab soravtansine IV on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
2486012|NCT02996201|Experimental|Electronic reporting of PRO-CTCAE items|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
2486018|NCT02996201|No Intervention|Standard practice|
2486056|NCT02995902|Experimental|FLT-PET/MRI|
2486084|NCT02995512|Experimental|Myocardial Infarction (MI) Patients|
2486134|NCT02995304|Active Comparator|Morphine and Midazolam premedication|30 children will receive 0.025 mg/kg midazolam IV followed by 0.1 mg/kg morphine 20 to 30 min before surgical incision.
2486135|NCT02995304|Active Comparator|Midazolam only premedication|30 children who will receive 0.025 mg/kg midazolam IV followed by saline 20 to 30 min before surgical incision.
2486220|NCT02994615||hypertrophic cardiomyopathy|
2486229|NCT02994615||Control|
2487999|NCT02982135|Other|group 1 direct bypass|direct bypass : patients recieve direct bypass treatment
3160298|NCT00421434|Active Comparator|Peginterferon-Ribavirin|Weekly injections of 180 µg peginterferon alfa-2a plus oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
3160299|NCT00421447||Breast Cancer patients|A group of women with breast cancer prescribed Anastrozole
3160300|NCT00421447||Healthy women wit no breast Cancer|A group of healthy women wit no breast cancer prescribed Anastrozole
3160301|NCT00421525|Other|Multiple Doses|Multiple Dose levels
3160302|NCT00421538|Active Comparator|LMWH|Therapeutic dose of Nadroparin
3160303|NCT00421538|Placebo Comparator|Placebo|Injectable placebo
3160304|NCT00421551|Experimental|1|
2485264|NCT03000972|Active Comparator|Standard Nail|Hip fracture surgery with a PFN-A Nail (Proximal Femoral Nail Augmentation).
2485266|NCT03000972|Experimental|Augmented Nail|Hip fracture surgery with a PFN-A Nail with Cement augmentation with TraumaCemV+
2485267|NCT03001232|Experimental|Movement-oriented Dementia Care|The experimental group received movement-oriented dementia care for a period of twelve months.Movement-oriented dementia care is a multidisciplinary approach in which all involved disciplines focus on stimulating physical activity and independence as much as possible. This way physical activity is stimulated at all times for the participants.
2485268|NCT03001232|No Intervention|Care as usual|The control group received care as usual
2485323|NCT03000803|Experimental|Early Total Caloric Intake|The Early Total Caloric Intake study group will consume the majority of their daily calories during breakfast.
2485324|NCT03000790|Experimental|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior arch will make the Ring around the tongue"
2485325|NCT03000803|Active Comparator|Late Total Caloric Intake|The Late Total Caloric Intake study group will consume the majority of their daily calories during dinner.
2485354|NCT03000465||Patients|Patients undergoing laparoscopic colorectal surgery
3160305|NCT00421551|Active Comparator|2|
3160306|NCT00421655|Experimental|1|
2485487|NCT02999919|Active Comparator|BMI ≥ 30|BMI ≥ 30
2485488|NCT02999919|Active Comparator|BMI < 30|BMI <30
2485491|NCT02999685|Active Comparator|Home-base Pulm Rehab w/ Health Coaching|The intervention group starts with 8 weeks of Home-base Pulmonary Rehab with Health Coaching, followed by 8 weeks of observation.
2485493|NCT02999685|Active Comparator|Control/Wait|The Control/Wait group starts with 8 weeks of observation, followed by 8 weeks of intervention (Home-base Pulm Rehab w/ Health Coaching).
3160307|NCT00421655|Placebo Comparator|2|
3160308|NCT00421668|Experimental|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate, and B12
2485568|NCT02999282|Experimental|Presymptomatic real tDCS|Asymptomatic subjects - 10 days anodal transcranial direct current stimulation
2485573|NCT02999282|Sham Comparator|Presymptomatic sham tDCS|Asymptomatic subjects - 10 days sham transcranial direct current stimulation
2485576|NCT02999282|Experimental|Symptomatic real tDCS|Symptomatic patients - 10 days anodal transcranial direct current stimulation
2485577|NCT02999282|Sham Comparator|Symptomatic sham tDCS|Symptomatic patients - 10 days sham transcranial direct current stimulation
2485621|NCT02998801|Placebo Comparator|Watch video using IPAD|Patient will watch the educational video using an IPAD
2485622|NCT02998801|Active Comparator|Watch video using VR goggles|Patient will watch the educational video using VR goggles
3193653|NCT00820131|Active Comparator|2|
2485709|NCT02998112|Placebo Comparator|control|5-ASA 4g/day enema through TET for 1 week; 200ml saline infusion through TET for 3 times every other day in one week
2485711|NCT02998112|Experimental|Study group|5-ASA 4g/day enema through TET for 1 week; 200ml fecal microbiota suspension infusion through TET for 3 times every other day in one week
2485769|NCT02997917|Experimental|Education|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the real education group, solutions at suprathreshold concentration for detection will be given with a subsequent comment on the flavor and an explanation of the components and preparation of the soup (low temperature cooking to preserve flavors).
2485771|NCT02997917|Sham Comparator|Sham|Solutions of the five basic tastes (sweet, salty, sour, bitter and umami) and the 3 main components of the probe soup (onion, leek and carrot) will be given every 10 min with a mouthwash after each test. In the sham education group solutions at subthreshold concentration for detection with no explanation will be provided.
2485773|NCT02997644|Experimental|Video Education|Video education delivered on a tablet computer
2485777|NCT02997644|Placebo Comparator|Usual Care Group|Regular information about opioid usage they typically receive from their surgeon.
3160309|NCT00421668|Experimental|Multivitamins + Zinc|Vitamins C, E, B1, B2, niacin, B6, folate and B12, and zinc
3160310|NCT00421668|Experimental|Zinc|zinc
2485824|NCT02997540||female breast ultrasound exam|females with at least one benign or probably benign mass, up to 2 cm in size, in one breast, detected during a standard-of-care breast ultrasound examination
2485883|NCT02997150|Experimental|IL-2 low dose|
2485916|NCT02996708||Group with teleconsultation - before period|
2485917|NCT02996708||Group without teleconsultation - before period|
2485919|NCT02996708||Group with teleconsultation - after period|
3160311|NCT00421668|Placebo Comparator|Placebo|placebo
3160312|NCT00421681|Experimental|A|"Treatment Arm A will develop tailored/negotiated contracts with the exercise instructor to maintain post intervention exercise adherence at home or in the community. Half of the participants in this negotiated maintenance arm will be randomly assigned to receive telephone calls to reinforce adherence and half will be assigned to a no telephone calls group."
3160313|NCT00421681|Experimental|B|"Treatment Arm B will be mainstreamed into an ongoing facility-based exercise program for post intervention exercise adherence. Persons in this mainstream follow up arm will be randomly assigned such that half will receive regular telephone reinforcement follow up and half will not."
3160314|NCT00421759|Experimental|1|85 elderly individuals with somatosensory deficits
3160315|NCT00421759|Experimental|2|85 elderly individuals with recurrent falls
3160316|NCT00421824|Experimental|A|
3160317|NCT00421824|Experimental|B|
3160318|NCT00421837||controls|household and other close contacts
2485269|NCT03000985|Experimental|Psychoeducation|6 session of a psychoeducation program with the family. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
2485270|NCT03001089|Active Comparator|Fludrocortisone 10 µg tablets|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
2485271|NCT03000985|No Intervention|Control|Treatment as usual
2485272|NCT03001089|Placebo Comparator|placebo oral tablet|Oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
2485273|NCT03001206||ICCU patients|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patient diagnosed with acute coronary syndrome (ACS) in the intensive cardiac care unit (ICCU) before and after planed catheterization procedure."
2485274|NCT03001206||Stress test subjects|"The use of the Master Caution System (MCS) for continuous monitoring and detection of dysrhythmias and ischemic events :~For patients referred to stress imaging with suspected ischemia."
2485275|NCT03001193|Experimental|DF01 low dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in low dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2485279|NCT03001193|Experimental|DF01 medium dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in medium dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2485282|NCT03001193|Experimental|DF01 high dose|The subjects will receive intravenous infusion of DF01 (tafoxiparin) in high dose as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2485285|NCT03001193|Placebo Comparator|PL1|The subjects will receive intravenous infusion of placebo as an Adjunct Treatment to Oxytocin for up to 36 hours initiated by a pre-defined bolus dose as a therapeutic intervention until delivery
2485315|NCT03000738||non-hodgekin lymphoma|100 non-hodgekin lymphoma patients (age >=18y) without previous treatment would be administered, including 50 DLBCLs and 50 PTCLs.
2485348|NCT03000764|Experimental|Biomarkers|
2485349|NCT03000725|Active Comparator|UPLIFT|Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is a home-based intervention that teaches cognitive and mindfulness skills to people with epilepsy by phone to reduce their depression and improve quality of life (QOL).
2485352|NCT03000725|Active Comparator|USUAL CARE|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
2485368|NCT03000504|Experimental|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned chest drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
2485369|NCT03000504|Active Comparator|Standard intercostal drain|Patients will have a standard 12F-16F Rocket Medical chest drain inserted as per usual clinical guidelines, using the Seldinger technique.
2485382|NCT03000296|Experimental|Hematopoietic Stem Cell Transplantation|High doses immunosuppression Cyclophosphamide (200 mg/kg total dose for four days) and rabbit antithymocyte globulin (6.5 mg/kg total dose for four days) followed by unselected autologous hematopoietic stem cell transplantation rescue.
2485387|NCT03000270|Active Comparator|Prolonged unloading prior to PPCI|Activation of Impella CP for a 30 minute duration prior to primary percutaneous coronary intervention
2485389|NCT03000270|Active Comparator|Immediate unloading prior to PPCI|Activation of Impella CP immediately prior to primary percutaneous coronary intervention
2485397|NCT03000231||Healthy Controls|Matched by age, race, gender and BMI to adrenal insufficiency subjects
2485398|NCT03000231||Adrenal Insufficiency Patients|Eligible patients will have either primary adrenal insufficiency or secondary adrenal insufficiency and will be age 18 and older.
2485409|NCT03000114|Active Comparator|Percutaneous Needle Aponeurotomy|Percutaneous Needle Aponeurotomy (PNA) involves the surgeon anaesthetizing the skin over the Dupuytren's cord, then using a small gauge needle inserted percutaneously, cutting the cord with the sharp edge of the needle using a sweeping motion. This is repeated up the length of the cord to weaken it, allowing an extension force to be applied over the finger to rupture the cord.
2485410|NCT03000114|Active Comparator|Collagenase Injection|Collagenase Injection (CI) involves the injection of collagenase clostridium histolyticum (0.58 mg), directly into the Dupuytren's cord. The patient then returns to see the surgeon within one week, has local anaesthetic is administered, and an extension force is applied to the affected digit to rupture the already weakened cord.
2485426|NCT02999997|Experimental|Ronnie Gardiner Method (RGM)|Exercising two times/week according to the RGM program in groups of 15 participants (2 groups).
2485427|NCT02999997|No Intervention|Control group|Participants in the control group are instructed to live their ordinary life.
2485444|NCT02999971|Experimental|circuit class therapy in water|CCT on water. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
2485445|NCT02999971|Experimental|circuit class therapy on land|CCT on land. The intervention developed in this study will be through the realization of an exercise program in circuit (CCT). One of the groups will receive treatment in the water (intervention group), and the other on land (control group). In both groups, the intervention will be a 7-week class therapy, 3-times weekly, giving a total of 20 sessions.
2485448|NCT02999776|Active Comparator|Standard of care|Daily self-administration of 1 to 5g Daivobet (Calcipotriol 50ug/g +Betamethasone, 0,5mg/g Gel) ointment, which is applied topically once per day for 8 weeks on one pre-selected randomized plaque.
2485449|NCT02999776|Experimental|Laser plus etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
2485277|NCT03001154|Experimental|One-session VRET face-to-face|One-session Virtual Reality Exposure Therapy led by therapist (face-to-face), followed by a 4-week therapist-guided Internet-administered progressive maintenance program.
2485280|NCT03001154|Experimental|Waiting-list, then Internet-administered VRET|4-week waiting list, followed by therapist-guided, Internet-administered VRET with a 4-week progressive maintenance program.
2485336|NCT03000647|Active Comparator|Guided Pelvic floor exercises|Pelvic floor exercises guided by a physiotherapist
2485339|NCT03000647|Active Comparator|Non-guided pelvic floor exercises|Pelvic floor exercises not guided
2485372|NCT03000361|Experimental|Motorized Spiral Colonoscopy|Motorized Spiral Colonoscopy (MSC) with the novel motorized spiral endoscope represents a new technology which offers all of the advantageous options of spiral-assisted endoscopy with a faster and less invasive approach
2485379|NCT03000335||Relapse|B-ALL patients who have succumbed to relapse
2485380|NCT03000335||Remission|B-ALL patients who are in remission
2485414|NCT03000101|Experimental|Pomegranate juice|The pomegranate juice is 100% pomegranate juice, not from concentrate.
2485418|NCT03000101|Placebo Comparator|Placebo beverage|The placebo beverage consists in water added with sugar and citric acid.
2485459|NCT02999841|Experimental|Group A|Acarbose
2485462|NCT02999841|Active Comparator|Group B|Vildagliptin
2485490|NCT02999750|Other|individual therapy|individual therapy
2485506|NCT02999529|Experimental|Education Group|Participants offered a consent for chemotherapy treatment will watch an educational video.
2485531|NCT02999230|Active Comparator|Caries Free|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Study toothpaste will be assigned.
2485534|NCT02999230|Placebo Comparator|Caries Free- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
2485537|NCT02999230|Active Comparator|Caries Active|Gums will be examined and caries assessment performed. On some visits Saliva and plaque will be collected. Study toothpaste will be assigned.
2485540|NCT02999230|Placebo Comparator|Caries Active- Placebo|Gums will be examined and caries assessment performed. On some visits Saliva and supragingival plaque will be collected. Marketed Toothpaste will be assigned.
2485542|NCT02999347||Cases|Women having undergone at least one pregnancy/delivery after their MUS surgery
2485545|NCT02999347||Controls|Every case will be matched with two controls. The controls will be matched with the study cases' age and year of surgery (+- 2 years of age if a perfect match is not obtainable). These controls have not undergone a subsequent pregnancy/delivery.
2485588|NCT02998970|Placebo Comparator|Placebo|The placebo group acts as a control group. This is in order to objectively isolate empagliflozin's effect on cardiac structure and function as determined by CMR imaging.
2485591|NCT02998970|Active Comparator|Empagliflozin|The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
3160319|NCT00421837||cases|elderly (>55) subjects hospitalized with Influenza
2485628|NCT02998515|Experimental|ESWT order: 1.liquid oxygen, 2. concentrator|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a portable liquid Oxygen device (Companion) and continue on the day after with ESWT by using supplemental Oxygen from a portable concentrator.
2485629|NCT02998515|Experimental|ESWT order: 1. concentrator, 2. liquid oxygen|Patients will start with the endurance shuttle walk test (ESWT) by using supplemental Oxygen from a concentrator and continue on the day after with ESWT by using supplemental Oxygen from a portable liquid Oxygen device.
2485658|NCT02998658|Experimental|Vaginal cuff closure using barbed sutures|Vaginal cuff is closed with barbed sutures
2485662|NCT02998658|Active Comparator|Vaginal cuff closure using conventional sutures|Vaginal cuff is closed with conventional sutures
2485691|NCT02998281|Active Comparator|Treatment Group|The treatment group received Inspiratory muscle training (IMT) at 40% of maximal mouth pressure (PImax) by using Threshold IMT and training loads were adjusted to maintain 40% of the PImax weekly. The PImax was measured at supervised sessions each week, and 40% of the measured value was determined as the new training work load.
2485692|NCT02998281|Sham Comparator|Control Group|The control group received sham Inspiratory muscle training (IMT) at a fixed work load, 5% of PImax by using Threshold IMT.
2485693|NCT02998242|Active Comparator|RT alone|symptomatic bony metastatic site(s) receive SBRT less than 5 fractions
2485694|NCT02998242|Experimental|RT with apatinib|selected dose administered PO during and after SBRT
2485714|NCT02998099|Experimental|Aged 18-45 years|A single dose of IV rivipansel over 20 minutes.
2485715|NCT02998099|Experimental|Aged 65 and older|A single dose of IV rivipansel over 20 minutes.
2485724|NCT02998086|Experimental|Individual (1:1)|Individual, 1:1 version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
2485727|NCT02998086|Experimental|Group|Group-based version of the Promoting Resilience in Stress Management for Parents (PRISM-P) intervention
2485731|NCT02998086|No Intervention|Usual Care|Usual non-directed psychosocial supportive care
2485787|NCT02997787||adenomyosis|First group called adenomyosis was consisted of patients who were pathologically diagnosed pure adenomyosis after hysterectomy
3160320|NCT00421863|Other|Intensive Strategy|
3160321|NCT00421863|Other|Usual Strategy|
3160322|NCT00421902|Experimental|Acupuncture|Acupuncture of the patients
3160323|NCT00421967|Experimental|1|
3160324|NCT00421967|Active Comparator|2|
3160325|NCT00422006|Experimental|1|Non diabetic non dyslipidemic patient
3160326|NCT00422006|Experimental|2|Patient with metabolic syndrome
3160327|NCT00422006|Experimental|3|Patients with type II diabetes
3160328|NCT00422006|Experimental|4|Patient with a single lipidic anomaly
3160329|NCT00422019|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
2485284|NCT03001102|Sham Comparator|Bathing with 4% Chlorhexidine gluconate|Two baths with chlorhexidine using precise methods, including to scrubb the whole body with 50mL of undiluted solution, at night before surgery and the morning of surgery.
2485287|NCT03001102|Experimental|Bathing with10% PVPI degermante|Two baths with PVPI using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
2485286|NCT03001037||Group A - Low Back Pain|"Group A:~Subject provides written authorization and/or consent per institution and geographical requirements~Subjects in Group A with a predominant complaint of Low back pain, with a minimum daily average VAS ≥ 30/100~Subjects in Group A are intended to be assessed with ViMove based on standard of care~Subject is willing to participate in follow-ups at 3, 6, 12 months post initial assessment~Observational study, no intervention"
2485288|NCT03001037||Group B - Without Low Back Pain|"Subject is without current low back pain~Subject does not have a history of low back pain lasting longer than 3 months in the past 12 months~Subject is willing to follow up 3 months post initial assessment~Observational study, no intervention"
2485289|NCT03001102|Active Comparator|Bathing with soap without antiseptic.|Two baths with soap using precise methods, including to scrubb the whole body with 50mL of undiluted solution for each bath, at night before surgery and the morning of surgery.
2485290|NCT03000946|Experimental|Somatostatin|Continuous intravenous infusion of somatostatin-14, 6 mg per day during 6.5 days
2485293|NCT03000946|Active Comparator|Octreotide|Subcutaneous octreotide 100 μg 3 times a day for 6.5 days.
2485318|NCT03000621||Patients with liver injury|
2485319|NCT03000660|Experimental|Venetoclax and Dexamethasone|Venetoclax will be given at one of four escalating doses (100 mg/day, 200 mg/day, 400 mg/day, or 800 mg/day) by mouth on each day of the cycle. Dexamethasone will be given at 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
2485320|NCT03000621||Healthy subjects|
2485350|NCT03000582|Experimental|Creatine monohydrate|5 gm creatine monohydrate, 1.5 gm dextrose
2485353|NCT03000582|Active Comparator|Creatine nitrate-1|1 gm creatine monohydrate, 0.5 gm nitrate, 5 gm dextrose
2485355|NCT03000478|Active Comparator|Prolonged Exposure|12 sessions of PE as per protocol
2485359|NCT03000582|Active Comparator|Creatine nitrate-2|2 gm creatine monohydrate, 1 gm nitrate, 3.5 gm dextrose
2485360|NCT03000478|Experimental|VRET|12 sessions of Virtual Reality Exposure Therapy
2485363|NCT03000582|Placebo Comparator|Placebo|6.5 gm dextrose
3193654|NCT00820144|Experimental|1|voie nasale 0.25 mg
3193655|NCT00820144|Experimental|2|0.5mg of CTB by oral way
2485422|NCT03000205|Experimental|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder spin
2485423|NCT03000205|Placebo Comparator|Normal Saline|normal saline and Lidocaine as placebo for sham group
3193656|NCT00820144|Experimental|3|1mg of dukoral by oral way
2485478|NCT02999932|Experimental|Low SpO2 group|SpO2 90-95%, with FiO2 as low as possible.
2485481|NCT02999932|Active Comparator|High SpO2 group|SpO2 96-100%, with FiO2 no lower than 30%.
2485502|NCT02999828|Experimental|3.0 EU in Children|healthy children (6-71 months old) have been injected by inactivated EV71 vaccine (KMB-17) of 3.0 EU (neutralization antibodies titer unit; 100 U in phase III clinical trials, or 320 EU (Elisa assay unit) in phase I and II clinical trials)
2485504|NCT02999503|Experimental|Nutritional intervention|Patients subject to nutritional education by CINUSA group protocol
2485511|NCT02999503|No Intervention|No intervention|Patients not subject to nutritional education
2485544|NCT02999165||CPAP group|25 infants undergoing treatment with continuous nCPAP who are making attempts at breast feeding and receiving nasogastric feeds.
2485547|NCT02999165||HHFNC group|25 infants undergoing treatment with continuous HHFNC oxygen who are making attempts at breast feeding and receiving nasogastric feeds.
2485548|NCT02999152|Experimental|Total Body Irradiation|Patient suffering from a malignant blood disease that requires a total body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, for 3 days. Blood and urines samples will be performed at days 0, 1, 2 and 3 of the treatment plan.
2485549|NCT02999152|Experimental|Partial Body Irradiation|Patient with at least one bone metastasis localized at the pelvis and requiring partial body radiation therapy without associated chemotherapy, according to the following protocol: 4 Gray per day for 5 days will perform blood and urines samples at days 0, 1, 2 and 3 after the beginning of the radiation treatment.
2485552|NCT02999308|Experimental|single arm|
2485597|NCT02998918|Experimental|PolyResveratrol Supplementation|Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
2485598|NCT02998918|Experimental|Curcumin Supplementation|Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.
2485599|NCT02998892|Active Comparator|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
2485601|NCT02998892|Experimental|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
2485604|NCT02998931|Experimental|Glutamin|Intervention patients will be received enteral formula and glutamine 0.3 g/kg/day given via nasogastric tube as boluses q 4hrs.
3193657|NCT00820144|Experimental|4|0.25mg of CTB by sublingual way
3193658|NCT00820144|Experimental|5|1mg of CTB by sublingual way
3193659|NCT00820157|Active Comparator|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE
3193660|NCT00820157|Experimental|TACE|TACE alone
3193661|NCT00820183|Experimental|quality improvement plan|It will be the group of primary health care teams who will undertake the quality improvement plan for hypertensive patients
2485291|NCT03000998|Experimental|Web App Intervention Group|The BoyVac mobile web app will be evaluated in a pair-matched group-randomized pretest-posttest controlled design. In Year 2, 30 clinics in New Mexico will be pair-matched and one member of each pair will be randomized to the intervention (mobile web app) or a usual and customary (UC) HPV vaccine adoption procedures comparison group. Clinics will be paired based on similarities in patient demographic (ethnicity and % Medicaid patients) and location (urban and rural).
2485292|NCT03001128||Cohort A: ART initiated during chronic infection|Cohort A will include 36 participants who initiated ART during chronic infection.
2485294|NCT03000998|Active Comparator|Usual Customary Care Group|Currently in pediatric clinics in New Mexico, the HPV vaccines are offered to parents and adolescents as part of annual well-child checkups. Typically for boys aged 11-13, parents initiate this checkup as part of a back-to-school activity. As part of the well-child checkup, clinic staff (physician, physician assistant and/or nurse) talk with parents and adolescents about the recommendation that their sons or daughters receive the HPV vaccination. Well-child pediatric visits to promote good health and development are recommended for all children from infancy through adolescence by the American Academy of Pediatrics.
2485295|NCT03001128||Cohort B: ART initiated during acute or early infection|Cohort B will include 30 participants who initiated ART during acute/early HIV infection.
2485455|NCT02999789|Active Comparator|Intervention group|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The intervention group will have SMS reminder and audiovisual reminder functions turned on. SMS reminders will be sent twice daily to child's caregiver's cell phone reminding them to administer daily asthma medication. SmartInhaler with reminder function turned on that is attached to Inhaler medication will remind child's caregiver twice daily to administer daily asthma medication.
2485458|NCT02999789|Placebo Comparator|Placebo|After an initial six week run-in period, participants will be randomized to either the intervention group or placebo group. The placebo group will have SMS reminder and audiovisual reminder functions turned off. The SmartInhaler will only function to measure daily adherence. Once intervention group has finished their 6 week period, this group will have intervention turned on.
2485495|NCT02999542|Experimental|Music|Children will receive music via headphones
2485501|NCT02999542|Experimental|No music|Children will listen to silence via headphones
2485533|NCT02999321|Experimental|0% aspartame (water)|participants will not have any aspartame, this is a control.
2485536|NCT02999321|Experimental|5 mg aspartame|participants will receive 5 mg aspartame in a beverage.
2485538|NCT02999321|Experimental|15mg aspartame|participants will receive 5 mg aspartame in a beverage, and 10mg in capsules.
2485582|NCT02998983|Experimental|Racotumomab|Dosage form: intradermal injection. Dosage: 0.4 mg. Frequency: the first 5 doses: biweekly injections; the following 10 doses: monthly injections. Duration: 12 months
2485812|NCT02997592|Experimental|SpinCare|Patients with partial thickness burns treated with the SpinCare dressing
2485877|NCT02996916|Active Comparator|Olmesartan|Olmesartan 10-40mg daily
2485887|NCT02996916|Active Comparator|Amlodipine|Amlodipine 2.5-10mg daily
3160330|NCT00422019|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.
3160331|NCT00422045|No Intervention|2|No Laser done. All outcome measures are the same.
2485986|NCT02996565|Active Comparator|Best Practice Clinic-Based Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Best Practice Clinic-Based Care intervention.
2485989|NCT02996565|Active Comparator|Telehealth Care|Patients with uncontrolled hypertension who receive primary care in clinics assigned to the Telehealth Care intervention.
2486011|NCT02996045|Experimental|Treatment|Clinical Decision Support (CDS)
2486016|NCT02996045|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
2486057|NCT02995863|Experimental|Experimental Group|Rigid rocker sole footwear
2486058|NCT02995863|Active Comparator|Control Group|Therapeutic footwear
2486076|NCT02995707|Experimental|thalidomide thalassemia|thalidomide:50mg/d p.o
2486093|NCT02995382|Experimental|Anterior Intramuscular Transposition|This is the only arm in our study, patients with cubital tunnel syndrome will undergo anterior intramuscular transposition, one of many surgical techniques utilized on patients with Cubital Tunnel Syndrome to alleviate symptoms.
2486140|NCT02995226|Other|Anorexia nervosa|"Patients with DSM-5 criteria of anorexia nervosa"
2486141|NCT02995226|Other|First degree relatives|First degree relatives (of patients suffering from anorexia nervosa) with no eating disorder
2486142|NCT02995226|Other|Controls (with no eating disorder)|Other
2486157|NCT02995083|Sham Comparator|Knee injection with air|Using clinically accepted methods, subjects will undergo a palpation guided injection of air into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2515698|NCT02792075||NIRS|Patients with Near-infrared spectroscopy
3160332|NCT00422045|Experimental|1|Low Level Laser Therapy
3160333|NCT00422149|Active Comparator|1|SUBLIVAC® Grasses treatment
3160334|NCT00422149|Placebo Comparator|2|Placebo treatment
3160335|NCT00422188|Experimental|Deoxycholic Acid Injection 0.5%|Participants received 0.5% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3160336|NCT00422188|Experimental|Deoxycholic Acid Injection 1.0%|Participants received 1.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3160337|NCT00422188|Experimental|Deoxycholic Acid Injection 2.0%|Participants received 2.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3160338|NCT00422188|Experimental|Deoxycholic Acid Injection 4.0%|Participants received 4.0% deoxycholic acid administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
3160339|NCT00422188|Placebo Comparator|Placebo|Participants received matching vehicle placebo administered at a volume dependent on the size of the lipoma up to a maximum of 5 mL for 2 treatments at 28-day intervals.
2485296|NCT03000907|Experimental|Intervention|"diet: assessment of nutritional status and nutritional requirements and establishment of personalized nutritional plan with monthly dietetic controls.~physical exercise: a multi-component physical exercise program that will include aerobic exercise and strengthening, balance and flexibility exercises as well as a weekly group session of health education, during six months."
2485298|NCT03000907|No Intervention|Control|Clinical practise
2485365|NCT03000634|Experimental|Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD|Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
2485367|NCT03000634|Other|VRD-bortezomib, lenalidomide, dexamethasone|Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
2485413|NCT03000062|Experimental|Intervention group|"12 Family physicians in primary care will constitute the Intervention group. They will enroll 10 patients each from their ordinary practice. The physicians will be provided with a specific course on the treatment model of the study, including how to collect and register data. They will have a detailed manual indicating the content of each visit.~Following recruitment and consent, the patient will meet for the first visit in the study one week later. At this visit the patient will be provided with detailed information on the content and preparation for all meals. Data will be collected.~The manual describes a diet in accordance with official guidelines providing the patient 1600Kcal per day.~The following visits will take place after 4 weeks, 8 weeks, 4 months, 8 months and 12 months from the first visit. Data will be collected at all visits, and also at 6 and 12 months follow-up."
2485419|NCT03000062|No Intervention|Control group|"12 Family physicians in primary care will constitute the Control group. They will enroll 10 patients each from their ordinary practice. The physicians will not be provided with any information of the treatment model of the study but they will have all information about how to collect and register data.~The patients on this group will also sign consent to provide data and therefore they will know about the study but they do not get any specific information about weight loss other than the general information that their physician may tell them.~The patients in the Control Group will be asked to give data on inclusion visit and again 12 months later, and also at 6 and 12 months thereafter (i.e. 0, 12, 18 and 24 months from inclusion)."
2485465|NCT02999906|Placebo Comparator|Placebo|Matching placebo (sugar pill)
2485466|NCT02999906|Active Comparator|Active|Oral treprostinil sustained release tablet
2485510|NCT02999477|Experimental|Nab-Paclitaxel|"2 weeks Nab-Paclitaxel Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 15 weeks"
2485514|NCT02999477|Experimental|Pembrolizumab|"2 weeks Pembrolizumab Run in~Biopsy will be performed~Post mono therapy Nab-Paclitaxel administered weekly~Post mono therapy Pembrolizumab administered every 3 weeks~Agents administered for a total of 14 weeks"
2485687|NCT02998411||AI treatment and dosage|
2485713|NCT02998125||before and after total knee arthroplasty|assess the functional outcome before and 6 months after total knee arthroplasty
2485766|NCT02997930|Experimental|Elderly Hip Fracture|Postoperative assess cognitive function in elderly subjects after fracture hip surgery. Measure function connectivity and DTI (diffusion tensor imaging) via: fMRI. Subjective measures will include: Montreal Cognitive Assessment (MoCA), Digital Clock Drawing Test Command and Copy, Wide Range Achievement Test reading subtest, Hopkins Verbal Learning Test (HVLT), General Depression Scale (GDS)
3160340|NCT00422305||1-Healthy Infants|"Group 1: The investigators will recruit 80 healthy infants born at > 37 weeks gestation, and between 2 and 36 months of age. Infants will be excluded for any of the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications~Small for gestational age at birth"
2485940|NCT02996539||Type 2 diabetes|With Clinical examination and laboratory measurements
2485988|NCT02996344|Active Comparator|Didactic training|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos.
2485991|NCT02996344|Experimental|Didactics and standardized patients|Behavioral; participants will view the approximately one hour Commitment to Living: Primary Care (CTL:PC) didactic training videos plus two practice standardized patient interactions.
2486022|NCT02996058|Active Comparator|DEX I 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
2486027|NCT02996058|Active Comparator|DEX II 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale.
2486070|NCT02995720|Experimental|1|A fixed dose combination of Fimasartan/Amlodipine/Rosuvastatin
2486072|NCT02995720|Active Comparator|2|Co-administration of Fimasartan/Amlodipine combination drug and Rosuvastatin
2486100|NCT02995434|Experimental|Intervention Group|Participants will be randomly assigned to the intervention group (50 in total).The VR intervention will be identical for each participant and consist of a PC running the immersive virtual reality application with a Virtual Reality headset 110 degrees field of view head mounted display. The VR will be a set of commercial exploratory virtual environment games designed for the HTC Vive headset. The intervention will be used for one month to enable customization to the therapy and record data over a long enough period of time to account for individual short- term changes in pain experience. Participants will be asked to use the VR therapy every day with a time exposure of 30 minutes for four consecutive weeks. There will be one rest day a week (normally a Sunday) where no therapy is given.
2486102|NCT02995434|Active Comparator|Control Group|The control group will be exposed to 2D PC equivalent versions of the same multimedia experiences but on their PC screen (without the Virtual Reality headset use). These will be functionally similar to the VR experiences.
2486155|NCT02995083|Active Comparator|Knee injection with corticosteroids|Using clinically accepted methods, subjects will undergo a palpation guided injection of corticosteroids into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2486156|NCT02995083|Placebo Comparator|Knee injection with saline|Using clinically accepted methods, subjects will undergo a palpation guided injection of saline into the knee joint. Subjects will then return for follow-up visit at 12 weeks for a physical exam of the knee. Patients will fill out questionnaires online at 1, 6, 12 and 24 weeks.
2488013|NCT02982161|Active Comparator|MR308 100 mg bid|Tramadol/Celecoxib 100 mg
2485297|NCT03000920|No Intervention|1_Control|Classic screening invitation strategy with at least an invitation mail and then one or two reminder by mail if necessary.
2485299|NCT03000920|Experimental|2_SMS Reminder 1|Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
2485300|NCT03000894|Experimental|CBT-I plus standard care|The group CBT-I will receive both CBT-I and standard care. CBT-I covers sleep-wake cycle as well as sleep hygiene education, activity scheduling, stimulus control, sleep restriction, relaxation training, and cognitive therapy. Standard care will include those treatments provided by the psychiatrists according to their clinical needs.
2485301|NCT03000920|Experimental|3_SMS before invitation|One SMS a few days before the Invitation by mail and then one or two reminder(s) by mail if necessary.
2485302|NCT03000894|No Intervention|Standard care|Only standard care will be provided to this group. Medications will be prescribed and referral to community nurse, social worker and psychologist will be made by the doctors according to their need.
2485303|NCT03000920|Experimental|4_SMS before invitation + SMS Reminder 1|One SMS a few days before the Invitation by mail then reminder 1 by SMS if necessary then reminder 2 by mail if necessary
3193662|NCT00820183|No Intervention|non intervention|It will be the group of primary health care teams that will not undertake the quality improvement plan for hypertension control
3193663|NCT00820261||Diarrhea|children and infants (less than 5 years of age) presenting with severe diarrhea will be enrolled
3193664|NCT00820274|Experimental|amniotic membranes|
3193665|NCT00820300|Experimental|Punctal plug|
3193666|NCT00820313|Other|Lifestyle Intervention|Comprehensive lifestyle intervention for reversal of heart disease
3193667|NCT00820326|Active Comparator|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
2485331|NCT03000595|Experimental|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
2485332|NCT03000595|Placebo Comparator|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
2485370|NCT03000400|Experimental|Intervention group|Patient and family members receiving the 8 week family centered intervention, The Traumatic Brain Injury Family System Intervention.
2485376|NCT03000400|Active Comparator|Control group|Family members attend one ongoing psycho-educational group session provided by Oslo University Hospital (OUH).
3193668|NCT00820326|Placebo Comparator|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
2485400|NCT03000127|Experimental|Single arm crossover|All patients will receive testosterone gel and placebo gel during some months, but the months that they are on each treatment will be unknown to the patient
3193669|NCT00820339|Active Comparator|Selective Hepatic Vascular Exclusion|Patients with HCC received Selective Hepatic Vascular Exclusion in hepatectomy.
2485439|NCT02999984|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
2485463|NCT02999711|Experimental|Cohort 1|REGN3500 low dose or placebo
2485464|NCT02999711|Experimental|Cohort 2|REGN3500 medium dose or placebo
2485471|NCT02999737|Other|Platelet Rich Plasma for 4 sessions|Autologous Platelet Rich Plasma injected in the scalp monthly x 3 then every 3 months x 1
2485472|NCT02999737|Other|Platelet rich plasma for 2 sessions|Autologous Platelet Rich Plasma injected in the scalp every 3 months
2485516|NCT02999464|Experimental|Qigong|Experimental group will receive a total of 50 minutes of qigong training 3 times per week and for 16 weeks.
2485519|NCT02999464|Active Comparator|Fitness Exercise|Fitness exercise group will receive home fitness exercise 3 times per week and for 16 weeks.
2485522|NCT02999451|Experimental|snare group|snare-assisted POEM
2485523|NCT02999451|Active Comparator|conventional group|knife-assisted POEM
2485584|NCT02999126|Experimental|Group 1|Patients < 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
2485587|NCT02999126|Experimental|Group 2|Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS <40 or >65 propofol target concentration will be modified by 0,3 mcg/ml.
3193670|NCT00820339|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3193671|NCT00820352|Active Comparator|bosentan|Patients in this arm receive bosentan twice a day for 12 weeks
2485631|NCT02998580|Active Comparator|Convential Sequential Bilateral rTMS|"LFR followed by HFL.~1 Hz stimulation of the right DLPFC for 600 pulses followed by 10 Hz stimulation of the left DLPFC for 3000 pulses (4 seconds on 26 seconds off for 75 trains). Treatment will occur 5 times per week for 4 to 6 weeks."
2485664|NCT02998697|Placebo Comparator|Control Group|Systolic heart failure patients received placebo oral capsule t.i.d for 90 days
3193672|NCT00820352|Placebo Comparator|placebo|patients in this arm receive 12 placebo twice a day for 12 weeks
3193673|NCT00820378||atherosclerosis|Patients With Clinically Evident Arterial Disease or Cardiovascular Risk Factors
3193674|NCT00820391|Experimental|KIDNET|Narrative Exposure Therapy for Children
3193675|NCT00820391|Experimental|Meditation/Relaxation|
3193676|NCT00820404|Experimental|1|BLI-489
3193677|NCT00820404|Placebo Comparator|2|Placebo
3193678|NCT00820417|Experimental|a|Dose-escalation
3193679|NCT00820417|Experimental|B|Maximum tolerated dose (MTD)
3193680|NCT00820430||Control--Non-Osteoporotic Knee|Kellgren-Lawrence (KL) scale score of 0, Age: 18-35 years
3193681|NCT00820430||Minimal Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 1 or 2, Age: Older than 18; no upper limit
3193682|NCT00820430||Moderate Osteoarthritis, Knee|Kellgren-Lawrence (KL) scale score of 3, Age: Older than 18; no upper limit
3208676|NCT00977119||Capecitabine|Women with breast cancer receiving capecitabine as treatment for their breast cancer.
2485307|NCT03000881|Experimental|Cohort 6|This is a sub-study testing the effect of real output applied under two adhesive strips after 8 hours.
2485371|NCT03000556|Experimental|experience|
2485374|NCT03000556|No Intervention|control|
2485415|NCT03000140|Experimental|High Intensity Interval Training|Cycling on cycle ergometers (OXFORDTM, model BE2601, OXOFORD Inc, Santiago, Chile) for 1 min at a subjective intensity of 8-10 points of the modified Borg scale of 1-10 points, and interspersed by inactive (without movement over the bicycle) of 2 minutes as recovery period.
2485421|NCT03000140|Active Comparator|Control group|Pre-hypertensive group was compared with healthy groups in the 2 manin variables systolic/diastolic blood pressure, as well as in other co-variables in pre-post changes. Thus, after the training intervention, and following the R and NR classification, we will compare the NR prevalence between both Pre-hypertensive and Healthy group.
2485457|NCT02999880|Experimental|Polychromatic layering (Control):|Using and mixing different composite shades, opalescents and intensives.
2485460|NCT02999880|No Intervention|Dual-shade layering (Intervention):|Only two composite resin material shades the opaque dentin composite and enamel shade composite.
2485492|NCT02999581|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 10 mg Bitter Orange (Citrus Aurantium) fruit standardized for 30% synephrine (Advantra Z), 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
2485494|NCT02999581|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine alpha-ketoglutarate, 250 mg vitamin C, 150 mg N-Acetyl-Tyrosine, 135 mg caffeine, 7.5 mg L-Dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, and 0.035 mg vitamin B12.
2485498|NCT02999581|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
2485525|NCT02999295|Experimental|Phase 1|Ramucirumab: 8 mg/kg, every two week Nivolumab: 3.0 mg/kg or 1.0 mg/kg (optional), every two weeks
2485526|NCT02999295|Experimental|Phase 2|Ramucirumab: 8 mg/kg, every two week Nivolumab: recommended dose established in the phase 1, every two weeks
2485592|NCT02999035||corneal sensitivity measurement|"Air jet aesthesiometry and liquid jet aesthesiometry:~All patients will receive the same intervention of corneal sensitivity measurement with air jet aesthesiometry and liquid jet aesthesiometry.~Thresholds represent the intensity of air / liquid jet that can just be perceived by the patients."
2485636|NCT02998723|Experimental|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
2485642|NCT02998723|Active Comparator|Late booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback.
2485652|NCT02998723|No Intervention|Control group|The control group will receive no booster at all.
2485695|NCT02998333|Active Comparator|Open surgical ankle stabilization|These patients will receive open surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
2485697|NCT02998333|Active Comparator|Arthroscopic surgical ankle stabilization|These patients will receive arthroscopic surgical stabilization of the ankle joint after failed conservative treatment with complaints for at least 6 months.
2485730|NCT02998034|Experimental|Cemented monoblock hemiarthroplasty|The cemented monoblock hemiarthroplasty is a double tapered polished stem with a hemiarthroplasty head cemented in place (Zimmer incorporated, UK)
2485735|NCT02998034|Experimental|Hyroxyapatite coated prosthesis|the Furlong Hyroxyapatite coated prosthesis (JRI orthopaedics limited UK) is a hydroxyapatite coating uncemented a hip prosthesis with a hemiarthroplasty head. The implant is uncemented.
2485795|NCT02997748|No Intervention|Observational group|No intervention, standard care
2485797|NCT02997748|Sham Comparator|Sham RIPC|Three cycles of 5- min upper limb sham ischemia
2485798|NCT02997748|Experimental|RIPC-Group 1|Three cycles of 5- min upper limb ischemia
2485799|NCT02997748|Experimental|RIPC-Group 2|Three cycles of 7-min upper limb ischemia
2485802|NCT02997748|Experimental|RIPC-Group 3|Three cycles of 10-min upper limb ischemia
2485803|NCT02997748|Experimental|RIPC-Group 4|Three Cycles of 5-min upper limb ischemia. If there is no response this will be followed by 2 cycles of 10-min upper-limb ischemia
2485840|NCT02997280|Experimental|Ruxolitinib treatment|Ruxolitinib 10 mg bid for adults and children with body weight > 40 kg, 0.15 mg/kg bid for children with body weight < 40 kg.
2485879|NCT02997020||CRS Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
2485889|NCT02997020||Control Patients|Endoscopically-directed sinus potential difference (EDSPD) will be conducted in either the operating room or in the rhinology clinic setting to quantify CFTR activity in the sinus cavities. The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
2485930|NCT02996643|No Intervention|Traditional method|The traditional brace design method will be used to design a spinal brace.
2485932|NCT02996643|Active Comparator|Intervention|A custom Providence brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
2485981|NCT02996422|Experimental|School-based water campaign|Students who attend middle and high schools in the intervention counties will receive a school-based water campaign. A sample of students from each school will complete surveys before and after the installation of the water refilling stations to measure beverage consumption, knowledge, attitudes, and self-efficacy.
2485984|NCT02996422|No Intervention|Comparison schools|A sample of students who attend middle and high schools in the comparison county, which does not receive any intervention components, will complete surveys to measure beverage consumption, knowledge, attitudes, and self-efficacy.
3193683|NCT00820456||Colorectal Cancer, Hepatic Metastasis|Eligible participants in Arm A enrolled in this imaging study will: be older than 18, have metastatic colorectal cancer with at least one hepatic lesion, and be treated with FOLFOX in combination with bevacizumab.
3193684|NCT00820456||Primary Tumor Undefined, Hepatic Metastasis|Eligible participants in Arm B enrolled in this imaging study will: be older than 18, must have prior histological documentation of any types of cancer with metastasis to the liver, and must be in stable treatment conditions prior to and between scans.
2485416|NCT03000153|Experimental|Completing the Goals Form|In this arm, client participants will complete the Goals Form in collaboration with their therapists at the start of every session.
2485420|NCT03000153|No Intervention|therapy as usual|In this arm, clients will have therapy as usual.
2485479|NCT02999867|Experimental|M1 triticale and mung bean|M1: triticale and mung bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
2485480|NCT02999867|Experimental|M2 adzuki bean|M2: adzuki bean as a processed food is assigned to patients at a dose of 50-100 g/d for 30-day dietary intervention.
2485551|NCT02999360|Experimental|Treatment 1|
2485553|NCT02999360|Active Comparator|Treatment 2|
2485600|NCT02998827|Experimental|thalidomide|use thalidomide tablet by mouth, every night for at least 6 months
2485603|NCT02998827|Active Comparator|other treatment|the treatment include infliximab, azathioprine or enteral nutrition at least 6 months
2485657|NCT02998567|Experimental|Escalation|Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
2485663|NCT02998567|Experimental|Expansion|Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
2485705|NCT02998229|Experimental|Artisse™ Intrasaccular Device|
2485792|NCT02997982|Experimental|Valaciclovir treatment|Valaciclovir 500Mg Tablet
2485834|NCT02997345||PPROM (Preterm Premature Rupture of Membranes)|PPROM / Preterm Premature Rupture of Membranes <37 weeks
2485885|NCT02997033||Total study cohort|
2485925|NCT02996630|Other|Healthy fetuses|Pregnant patients carrying a healthy fetus. Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging and bailey test.
2485928|NCT02996630|Other|Congenital Hearth Disease|Pregnant patients carrying a fetus with a moderate-severe congenital heart disease Interventions in this group will be: cord blood sample, sonography, Magnetic Resonance Imaging, Surgical intervention, brain monitoring and bailey test.
2485978|NCT02996305|Experimental|OV101 regimen 1|OV101 once daily
2485980|NCT02996305|Experimental|OV101 regimen 2|OV101 twice daily
2485982|NCT02996305|Placebo Comparator|Placebo|Twice daily
2486020|NCT02995954|Active Comparator|Fixed|The Fixed group received one single tablet containing Perindopril/Amlodipine (Reaptan) at the appropriate dose
2486023|NCT02995954|Active Comparator|Free|The Free group, received Perindopril and Amlodipine in separate tablets at the appropriate dose
2486068|NCT02995733|Active Comparator|PARTICS|addition of PARTICS strategy - Patient Activated Reliever-Triggered Inhaled CorticoSteroid (PARTICS) using QVAR . Patient will use inhaled corticosteroid at time of rescue inhaler use
2486071|NCT02995733|No Intervention|Usual Care|Provider-enhanced usual care arm; no change in asthma management
2486114|NCT02995291|Placebo Comparator|Control|1.7ml saline water
2486115|NCT02995291|Experimental|OraVerse|1.7ml OraVerse
3193685|NCT00820469|Experimental|1|Patients treated by rituximab
3193686|NCT00820469|Experimental|2|Patients treated by rituximab and plasma exchange
2486160|NCT02994758|Other|Personalised medicine arm|"This is a prospective n-of-1 type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care."
2486218|NCT02994602|Experimental|Nestorone (NES) + testosterone (T) combined gel|A combination gel with Nestorone® (NES) and Testosterone (T) applied transdermally. The volume of gel to be applied will be approximately 5 mL. This gel volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day and will also contain 8.3 mg of NES that will deliver about 0.8 mg NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel) in 5 ml of combined gel.
2486256|NCT02994147|Placebo Comparator|Placebo|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
2486257|NCT02994147|Experimental|AC-201CR 72mg|"Subjects will initiate blinded study medication at a once daily (QD) regimen for 4 weeks, then titrate to twice daily (BID) for the remainder of the 24-week blinded treatment period.~At Week 24, subjects will discontinue blinded study medication and start open-label treatment with AC-201CR. All subjects will initiate open-label AC-201CR QD for 4 weeks, then titrate to BID for the remainder of the study."
2486318|NCT02993861||Levetiracetam|Children with epilepsy who are treated with levetiracetam per local standard of care
2486319|NCT02993861||Valproic Acid|Children with epilepsy who are treated with valproic acid per local standard of care
2486320|NCT02993861||Topiramate|Children with epilepsy who are treated with topiramate per local standard of care
2486321|NCT02993861||Oxcarbazepine|Children with epilepsy who are treated with oxcarbazepine per local standard of care
2486357|NCT02993380|Experimental|Stir-fried olive oil group|olive oil in heated under 150 degrees
2486362|NCT02993380|Experimental|Natural olive oil group|olive oil in without heated
2486420|NCT02993159|Experimental|Arm I (afimoxifene, placebo)|Patients apply afimoxifene gel to both breasts and receive placebo PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
2486423|NCT02993159|Active Comparator|Arm II (placebo, tamoxifen citrate)|Patients apply placebo gel to both breasts and receive tamoxifen citrate orally PO daily for 4-10 weeks in the absence of disease progression or unexpected toxicity.
3193687|NCT00820482|Active Comparator|Group A|Group A: 75 UI/day of Hp-hMG (Menopur®, Ferring, Copenhaghen, Dinamarca)
3208677|NCT00977132|Experimental|Lenalidomide|Lenalidomid in combination valproic acid
2485328|NCT03000751|Active Comparator|Track A|Simple Audit Report In-Person Meeting Multi-Component Intervention
2485329|NCT03000751|Active Comparator|Track B|In-Person Meeting Simple Audit Report Multi-Component Intervention
2485330|NCT03000751|Other|Track C|Simple Audit Report Multi-Component Intervention
2485375|NCT03000374|Experimental|Panitumumab + mFOLFOX-6|"- Modified FOLFOX-6 regimen: 5-Fluorouracil (5-FU), oxaliplatin and leucovorin will be administered intravenously once every 14 days, according to the mFOLFOX-6 regimen:~Day 1: Oxaliplatin 85 mg/m² in IV infusion of 250-500 mL and leucovorin 200 mg/m² IV, both injected over two hours, followed by 5-FU 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².~- Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.~Treatment will continue until 6 cycles have been administered, followed by surgery, 5 weeks +/- 1 week after the last dose of neoadjuvant treatment"
3193688|NCT00820482|Experimental|Group B|75UI/day of rFSH (Gonal®, Serono, Ginebra, Suiza) + 75UI/day of rLH (Luveris®, Serono, Ginebra, Suiza)
3193689|NCT00820495|Experimental|Web + Phone|Highly interactive tailored Web-based smokeless tobacco cessation program plus phone counseling
2485473|NCT02999698||Psoriasis Group|Patients with psoriasis complete the questionnaires for psychological impact.
2485475|NCT02999698||Hidradenitis Suppurativa Group|Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
2485532|NCT02999438||Patients with hemodynamically significant heart disease|"Patients with either:~Single ventricle physiology s/p Fontan~Heart failure diagnosed by a cardiologist~Pulmonary hypertension diagnosed by cath"
2485535|NCT02999438||Controls|Healthy controls as defined in inclusion- exclusion criteria
3193690|NCT00820495|Experimental|Web Only|Highly interactive tailored Web-based smokeless tobacco cessation program
3193691|NCT00820495|Experimental|Phone Only|Phone counseling intervention for smokeless tobacco cessation
3193692|NCT00820495|Experimental|Control|Usual care (initial call plus self-help materials)
3193693|NCT00820508|Experimental|1|Oral, once daily administration of CHR-2845 to determine safety and tolerability
3193694|NCT00820521|Experimental|active|
3193695|NCT00820521|Placebo Comparator|placebo|
2485671|NCT02998424|Experimental|Propofol 1 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 1 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2485672|NCT02998424|Experimental|Propofol 2 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 2 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2485675|NCT02998424|Experimental|Propofol 3 µg/ml|"Patients received a propofol infusion at an effect-site concentration of 3 µg/ml at the beginning of induction of general anesthesia for elective surgery.~Pupillary diameter measurement after 10 minutes."
2485770|NCT02997865|Experimental|Stepped Care for Depression|Participants will receive cognitive behavior therapy for depression, plus referral to their own physician for discussion of antidepressant medication if symptoms do not improve within 5-10 weeks. Participants will also receive individually-tailored heart failure self-care education and support.
2485774|NCT02997865|No Intervention|Enhanced Usual Care|Participants will receive individually-tailored heart failure self-care education and support. With the participant's permission, his or her personal physician will be notified about the patient's depression. The participant will be asked to discuss depression treatment options with his or her personal physician.
2485821|NCT02997527|Experimental|Intraluminal impedance testing|"During the participant's clinical endoscopy the 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope.~The catheter (tiny tube) will be placed through the endoscope in your esophagus 1 cm above where your stomach and esophagus meet for 5 seconds.~At 2 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~And at 3 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 4 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds.~At 5 cm above where the participants stomach and esophagus meet the catheter will be placed for 5 seconds."
2485859|NCT02997137|Active Comparator|BOT-01|Dietary supplement: specific amino acid composition with micronutrients
2485864|NCT02997137|Placebo Comparator|Placebo|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties
2485962|NCT02996461|Experimental|Group 1|ZIKV DNA vaccine administered IM via needle and syringe at a single dosage of 4 mg on Day 0, week 4 and week 8.
2485964|NCT02996461|Experimental|Group 2|ZIKV DNA vaccine administered IM via needle and syringe as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
2485965|NCT02996461|Experimental|Group 3|ZIKV DNA vaccine administered IM via needle-free injection device, PharmaJet, as a split dose of two .5 ml injections on Day 0, week 4 and week 8.
2486060|NCT02995876|No Intervention|Zirconia and E-max Press|The first design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press.
2486063|NCT02995876|Experimental|Zirconia and E-max Press and Glaze|The second design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with a glaze layer to improve adhesion.
2486066|NCT02995876|Experimental|Zirconia and E-max Press twice|The third design is going to be fabricated with CAD/CAM Zirconia and the occlusal surface from E-max Press and the internal surface coated with an E-max Press layer to improve adhesion.
2486091|NCT02995447||epilepsy patients|The group consists of patients with therapy refractory epilepsy, in which intracerebral electrodes were implanted to locate the seizure origin and to determine whether the patients are eligible for epilepsy surgery. In an observational study, differences between surface and intracerebral EEG are recorded.
2486144|NCT02995213|Experimental|Feedback Intervention|
3193696|NCT00820547|Experimental|(FEC / Docetaxel) + Bevacizumab|Neoadjuvant treatment: 4 cycles FEC + Bevacizumab followed by 4 cycles Docetaxel + Bevacizumab Adjuvant: Bevacizumab for 1 year
2515707|NCT02791997|Experimental|Brain-damaged patients|
3193697|NCT00820560|Experimental|INCB07839 100mg, immediate release (IR) capsules|
3193698|NCT00820560|Experimental|INCB07839 200 mg IR capsules|
2485333|NCT03000699|Experimental|Cognitive Bias Modification|64 training paragraphs, approximately 10-20 seconds each, digitally recorded and presented stereophonically through headphones, delivered over the course of one week.
2485335|NCT03000699|No Intervention|Assessment-Only Control|No training will be provided.
2485356|NCT03000712|Experimental|Autologous Adipose Tissue derived MSCs|Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml, 1 time injection(at 1week after high tibial osteotomy)
2485362|NCT03000712|No Intervention|No treatment|No treatment (after high tibial osteotomy)
2485373|NCT03000387|Experimental|Experimental Condition|Participants unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus additional active nicotine patches until achieving 7 consecutive days of abstinence over the next 5 weeks; maximum daily patch dose, 84mg/day
2485377|NCT03000387|Placebo Comparator|Placebo Condition|Participant unable to quit smoking after 2 weeks of treatment with 21mg nicotine patch will get 21mg nicotine patches plus placebo patches until 7 consecutive days of abstinence over the next 5 weeks; Maximum daily patch dose, 21mg active nicotine patch plus 3 placebo 21mg patches.
2485378|NCT03000387|Active Comparator|Quit condition|Participants able to quit for 7 consecutive days during the first 2 weeks of treatment with 21mg nicotine patch will continue open label 21mg active nicotine patches for the remaining 10 weeks.
2485411|NCT03000218|Experimental|UDCA 8 wks|Day 1 to 56: Ursodeoxycholic acid 300mg bid
2485412|NCT03000218|Experimental|UDCA for 4wks/UDCA+metformin for 4wks|Day 1 to 28: Ursodeoxycholic acid 300mg bid Day 29 to 56: Ursodeoxycholic acid 300mg and Metformin 500mg bid
2485417|NCT03000218|Placebo Comparator|Placebo|Day 1 to 56: Placebo bid
2485438|NCT03000036|Other|Cardiovascular Magnetic Resonance|Twenty-seven female patients were imaged in a 3T magnet after consecutively enrolled in the study if they had received a breast cancer diagnosis at the Center for Integral Attention to Women's Health (University of Campinas) and had prescribed endovenous doxorubicin as part of their chemotherapy regimen.
2485454|NCT02999802|Experimental|Exercise|Determining the effect of 12 weeks of resistance training exercise on the response of muscle amino acid sensing
2485486|NCT02999724|Experimental|gabapentin|gabapentin 300-600 mg 1 hour preop
2485489|NCT02999724|Placebo Comparator|placebo|placebo capsule(s) 1 hour preop
2485497|NCT02999594|Experimental|tramadol|50mg tramadol hydrochloride will be used intramuscularly as an experimental drug for evaluating its safety and efficacy as labor analgesic
2485499|NCT02999594|Placebo Comparator|distilled water|2ml distilled water intramuscularly will be used as a placebo.
2485527|NCT02999256|Placebo Comparator|Placebo|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~Placebo composition: Water (100ml), Cherry Squash Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
2485528|NCT02999256|Experimental|Montmorency Tart Cherry Juice|"130ml serving twice daily (immediately before breakfast and dinner) for 20 days.~MTCJ Composition: 100ml water and 30ml Montmorency tart cherry concentrate (Cherry Active, Sunbury, UK)."
2485529|NCT02999243|Experimental|HIV self-testing|HIV self-testing kits plus harm reduction education materials will be offered to the intervention group.
2485530|NCT02999243|Placebo Comparator|Education|Harm reduction educational materials will be offered to the control group.
2485561|NCT02999009|Other|Trident II Tritanium Acetabular Shell|
2485638|NCT02998775|Other|6 participants with mild renal impairment|Renal Impairment Mild: creatinine clearance, 50 to 80 milliliters per minute (mL/min)
2485647|NCT02998775|Other|6 participants with moderate renal impairment|Renal Impairment Moderate: creatinine clearance, 30 to 49 mL/min
2485654|NCT02998775|Other|6 participants with severe renal impairment|Renal Impairment Severe: creatinine clearance, 15 to 29 mL/min
2485656|NCT02998775|Other|8 participants normal renal status|Renal status normal as defined by creatinine clearance ≥ 81 mL/min, otherwise age, gender, and smoking characteristics matching renal-impaired participants
2485661|NCT02998775|Other|6 participants with mild hepatic impairment|Hepatic impairment mild: total score on the Child-Pugh classification system between 5 and 6
2485665|NCT02998775|Other|6 participants with moderate hepatic impairment|Hepatic impairment moderate: total score on the Child-Pugh classification system between 7 and 9
2485667|NCT02998775|Other|6 participants with severe hepatic impairment|Hepatic impairment severe: total score on the Child-Pugh classification system between 10 and 15
2485668|NCT02998775|Other|8 participants normal hepatic status|Hepatic status normal, otherwise age, gender, and smoking characteristics matching hepatic-impaired participants
2485706|NCT02998164|Experimental|Technology-assisted language intervention|This intervention will incorporate augmentative and alternative communication software delivered on iPads into speech-language therapy
2485708|NCT02998164|Active Comparator|usual care|This group will be usual care children are already receiving.
2485755|NCT02997943|Experimental|Step 1: Optimal First Line Treatment|"Participants will first be randomized to an optimal first line treatment in order to compare APP vs. APP + coaching. Participants assigned to Step 1 treatment APP will receive a study-specific smartphone application. Participants assigned to Step 1 treatment APP + coaching will receive a study-specific smartphone application plus 12 weekly telephone coaching sessions."
2485756|NCT02997943|Experimental|Step 2: Optimal Strategy to Address Nonresponse|Beginning at week 2, participants who are identified as treatment non-responders will be re-randomized in order to compare two strategies to address non-response: a modest step-up or vigorous step-up treatment augmentation tactic. Step 2 treatment strategy: modest step-up will include provision of an additional mHealth intervention component (push notifications). Step 2 treatment strategy vigorous step-up will include provision of an additional mHealth intervention component (push notifications), plus a traditional weight loss intervention component (coaching, meal replacements). Participants will continue to receive their first line treatment.
2485759|NCT02997956|Experimental|Tocilizumab|"Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.~The first part of the trial will be Phase Ib and will enroll 18 participants. Participants will receive TACE on day 1 and Tocilizumab at dose level 1, 2, or 3 on days 1, 29 and 57. Maximum tolerated dose (MTD) of Tocilizumab will be determined.~The second part of the trial will be a Phase II and will enroll 50 subjects. Participants will receive TACE on day 1 and Tocilizumab at the MTD on days 1, 29 and 57."
2485443|NCT02999958|No Intervention|Control|Sequential culture media without addition of antioxidants
2485446|NCT02999958|Active Comparator|Treatment|Sequential culture media with the addition of antioxidants
2485496|NCT02999620|Active Comparator|Alpha-cycoldextrin|All subjects randomized to receive Alpha-cycoldextrin will orally ingest two tablets containing Alpha-cyclodextrin, with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
2485500|NCT02999620|Placebo Comparator|Placebo|All subjects randomized to receive placebo will orally ingest two placebo tablets with their standardized liquid breakfast (100 micro Ci of [3H]triolein and 20 micro Ci of [14C]tripalmitin). The tablets will be consumed with 150 ml of still water immediately prior to consuming each meal. Subjects will be observed for a period of 48 hours as an in-patient, and then an additional 24 hours as an out-patient. During this time they will undergo a meal fatty acid metabolism study, through blood and fecal sampling, to assess meal fatty acid oxidation and storage.
3160341|NCT00422305||2-Healthy Infants computerized Tomography|"Group 2: The investigators recruited 4 infants born at > 37 weeks gestation and they were evaluated between 2 and 36 months of age when scheduled for high resolution computed tomography (HRCT) imaging for non-respiratory medical problems. Subjects were enrolled and HRCT of the chest were obtained. Infants were excluded for the following reasons:~Congenital cardio-respiratory disease~Hospitalization for respiratory illness~Treatment with asthma medications"
3160342|NCT00422305||3-Premature Infants|"Group 3: The investigators have recruited 45 infants born prematurely at 23-35 weeks gestation. Subjects were evaluated at corrected age at between 2 and 24 months. The subjects had no oxygen requirements, and were clinically stable outpatients when evaluated. Infants were excluded for any of the following reasons:~Congenital cardio-respiratory disease~Severe developmental delay"
2485594|NCT02999269|Experimental|600 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2485595|NCT02999269|Experimental|700 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2485596|NCT02999269|Active Comparator|800 mA Right Unilateral ECT|MECTA Spectrum 5000Q Amplitude
2485632|NCT02998593|Experimental|extracted red Bahman and white bahman|500 mg of extracted red Bahman and white bahman that is used once a day.
2485641|NCT02998593|Placebo Comparator|Placebo|500 mg of placebo once time a day
3160343|NCT00422344|Experimental|RAD001 AND SUNITINIB|RAD001 AND SUNITINIB IN METASTATIC RENAL CELL CARCINOMA PATIENTS
2485707|NCT02998294|Experimental|Respiratory monitoring group|
2485721|NCT02998073|Experimental|Conduct Disorder|Participants are justice-involved youth with conduct disorder. Participants will receive Stop, Now and Plan (SNAP) psychosocial intervention.
2485726|NCT02998073|No Intervention|Control|Participants are healthy males. Participants receive no intervention.
2485733|NCT02997969|Active Comparator|Group 1: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6. All injections are via needle and syringe.
2485737|NCT02997969|Active Comparator|Group 2: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine in the left deltoid at months 0, 1, and 6. They will receive placebo in both deltoids at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6. All injections are via needle and syringe.
2485739|NCT02997969|Placebo Comparator|Group 3: Placebo|Participants will receive placebo in both deltoids at months 0, 1, 3, and 6. All injections are via needle and syringe.
2485741|NCT02997969|Active Comparator|Group 4: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine via Biojector in the left deltoid at months 0, 1, 3, and 6. They will receive placebo in the right deltoid at months 0 and 1, and the Protein/MF59 vaccine at months 3 and 6, via needle and syringe.
2485743|NCT02997969|Active Comparator|Group 5: DNA + Placebo + Protein/MF59|Participants will receive the DNA-HIV-PT123 vaccine at months 0, 1, and 6, and placebo at month 3, in the left deltoid via Biojector. They will receive placebo at month 3, and the Protein/MF59 vaccine at months 0, 1, and 6, in the right deltoid via needle and syringe.
2485745|NCT02997969|Placebo Comparator|Group 6: Placebo|Participants will receive placebo in the left deltoid via Biojector, and in the right deltoid via needle and syringe, at months 0, 1, 3, and 6.
2485781|NCT02997631|Experimental|MEDi Distraction|The intervention will be the use of the MEDi robot. The robot will be at the child's eye level, and will be programmed to introduce itself, interact with the child, and make encouraging comments about how brave he/she was. The duration of its actions will coincide with the length of the procedure (approximately 5-8 minutes).
2485782|NCT02997631|No Intervention|Standard Care|The control group will receive standard care, which generally includes the use of topical anesthetic cream. This comparison is based on the pragmatic preferences of physicians at the Stollery Children's Hospital as well as precedent in the literature. Overall, it is felt that any new intervention (e.g., the MEDi robot) should be compared to what is currently in practice (i.e., standard care), as no single distraction therapy is consistently and routinely employed in EDs at this time.
2485785|NCT02997774|Active Comparator|Standard Dialysis|Patient will undergo dialysis at 36.5 degrees Celsius to assess if this affects the liver function and perfusion
2485790|NCT02997774|Experimental|Cooler Dialysis|Patient will undergo dialysis at 35 degrees Celsius to assess if this affects the liver function and perfusion
2485823|NCT02997488||McGrath|McGrath Videolaryngoscope
3160344|NCT00422435|Experimental|Drug eluting stent|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter
3160345|NCT00422487|Experimental|MBX-2044 1.5 mg|
3160346|NCT00422487|Experimental|MBX-2044 4.5 mg|
3160347|NCT00422487|Experimental|MBX-2044 15 mg|
3160348|NCT00422487|Experimental|MBX-2044 30 mg|
3160349|NCT00422487|Experimental|MBX-2044 60 mg|
3160350|NCT00422487|Experimental|MBX-2044 90 mg|
3160351|NCT00422487|Placebo Comparator|Placebo|
3160352|NCT00422500||Chemotherapy Symptoms|Study participants with advanced-stage lung cancer.
3160353|NCT00422565|Experimental|Endeavor|Zotarolimus-eluting stent
2485450|NCT02999776|Active Comparator|Laser alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
2485509|NCT02999568||Experimental|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
2485513|NCT02999568||Control group|Women who practice low level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years
3193699|NCT00820586|Experimental|Mononuclear bone marrow derived cells|Intramyocardial injection of total mononuclear bone marrow derived cells
3193700|NCT00820586|Experimental|Selected CD34+ bone marrow derived cells|Intramyocardial injection of selected CD34+ bone marrow derived cells
3193701|NCT00820625|Active Comparator|1|ablation: pulmonary vein isolation
2485634|NCT02998502|Experimental|Device Group|The Freespira Breathing System (FBS) developed by Palo Alto Health Sciences, Inc, is a portable home device used for breathing biofeedback in adults with PD. FBS has now received FDA clearance for the treatment of PD adults and is currently commercially available and more than 150 therapist have provided the service nationally. However, FBS has not yet been tested for efficacy in a pediatric populations. Due to its portability, FBS may pose an advantage for use in younger age groups, compared to multiple therapy sessions required for CBT or lower acceptability for long-term medication use for adolescent PD. In this pilot intervention study, the efficacy of the FBS system in youth will be tested.
2485646|NCT02998502|No Intervention|Control Group|The device will be given to those in the control group after 8-week baseline period.
2485775|NCT02997878|Experimental|PSC patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
2485778|NCT02997878|Experimental|AiH patients|Selected Mesenchymal Stromal Cells (dose selection and efficacy) - Orbcel-C. dose selection, combination of 0.5, 1.0,2.5 million cells/kg (3 dose levels). IV single-infusion.
2485833|NCT02997436|Experimental|PAD patients|"Patients referred for vascular ultrasound investigation for suspicion of peripheral artery disease (PAD).~Intervention is measurement of microvascular response to current application on the skin by Laser speckle flowmetry"
2485880|NCT02997059|Experimental|Fluconazole|200mg per day for 6 months
2485890|NCT02997059|Placebo Comparator|Placebo|One capsule per day for 6 months
2485923|NCT02996578|Active Comparator|Solid Matrix - Intervention|"Dietary Supplement: polyphenol rich chocolate bar~17.5g of commercially available dark chocolate will be consumed daily for 8 weeks"
2485926|NCT02996578|Active Comparator|Powder Matrix - Intervention|"Dietary Supplement: polyphenol rich cocoa powder~6g of commercially available cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
2485929|NCT02996578|Placebo Comparator|Solid Matrix Intervention - Placebo|"Dietary Supplement: low polyphenol chocolate~17.5g of commercially available, nutritionally similar, dark chocolate will be consumed daily for 8 weeks"
2485931|NCT02996578|Placebo Comparator|Powder Matrix - Placebo|"Dietary Supplement: nutritionally similar low polyphenol cocoa powder~6g of commercially available, nutritionally similar, cocoa powder (provided as 6 x 1g gelatine capsules) will be consumed daily for 8 weeks"
2485990|NCT02996370|Active Comparator|Test group- ı shape incision|Second stage surgery was made I shape incision technique .
2485992|NCT02996370|Active Comparator|Control group- midcrestal incision|In the control group second stage surgery was made using the conventional method, midcrestal technique.
3193702|NCT00820625|Active Comparator|2|ablation: pulmonary vein isolation with additional ablation of fragmented potentials
3193703|NCT00820638|Experimental|1|observational
2486137|NCT02995148|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486172|NCT02994810|Experimental|Intervention group|Guidelines and review of the breastfeeding techniques.
2486176|NCT02994810|No Intervention|Control group|The control group will receive home visits only when the baby is 6 months of life, they will be re-evaluated by the researchers as the practice of exclusive breastfeeding and the technical and nursing management, and will be asked about the main difficulties encountered in maintaining breastfeeding.
2486288|NCT02994550|Experimental|FSH/LH 2/1|dose: 300IU FSHrec and 150IU LHrec
2486290|NCT02994550|Experimental|FSH/LH 4/1|dose: 300IU FSHrec and 75IU LHrec
2486323|NCT02993692|Other|fiberoptic bronchoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about fiberoptic bronchoscopy.
2486324|NCT02993692|Other|direct laryngoscopy|I want to see the difference between the two group about hemodynamic and intraoculer pressure responses about direct laryngoscopy.
2486371|NCT02993458|Experimental|DASH diet-Low Na diet|DASH style diet, low sodium (1500 mg/d).
2486378|NCT02993458|Active Comparator|DASH diet-High Na diet|DASH style diet, high sodium (3500 mg/d).
2486383|NCT02993458|Active Comparator|Usual diet-Low Na diet|Diet reflecting typical dietary pattern of American adolescents, low sodium (1500 mg/d).
2486385|NCT02993458|Active Comparator|Usual diet-High Na diet|Diet reflecting typical dietary pattern of American adolescents, high sodium (3500 mg/d).
2486424|NCT02993029|Experimental|99Tc-MDP|99Tc-MDP group:15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
2486426|NCT02993029|Active Comparator|celecoxib|celecoxib capsule 200mg qd by mouth.
2486453|NCT02992795||Cohort Ia|Athletes in this cohort serve as control subjects participating in Division 1 Athletics at the University of Wyoming. They will be enrolled once they meet eligibility. Upon enrollment, all athletes will have an initial BrainPulse recording. Once a subject from this cohort sustains an injury, they crossover to Cohort II. Also, a matched control for every concussed subject will be selected from Cohort Ia.
2486457|NCT02992795||Cohort Ib|Athletes in this cohort are subjects currently subscribed to the Head Health Network. They will have a BrainPulse recording completed every week through the entire season. Similarly, if subjects in this cohort sustain an injury, they will crossover to Cohort II.
3193704|NCT00820651|Placebo Comparator|Placebo|
2485456|NCT02999854|Experimental|ATIR101|T-cell depleted HSCT from a related, haploidentical donor, followed by IV infusion with ATIR101 at a single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT
2485461|NCT02999854|Active Comparator|PTCy|T-cell replete HSCT from a related, haploidentical donor, followed by IV infusion of post-transplant cyclophosphamide (PTCy) 50 mg/kg/day at 3 and 4/5 days after the HSCT
2485580|NCT02999139||ACL Return to Play|A specific training program, with emphasis on hamstring strengthening. There will also be a specificity on pivoting and jumping safely.
2485583|NCT02999139||Gait Retraining|Will receive training that is specific to running. Drills will help enforce a more efficient running form, as well as strengthening important muscle groups such as the hip abductors and adductors.
2485590|NCT02999139||Private Training|Participants will receive a broad training program, targeting all major muscle groups. The goal is to increase muscle strength, mobility and aerobic capacity to reduce the risk of injury.
2485624|NCT02998736|Experimental|Intervention|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
2485640|NCT02998463|Experimental|Snuby® users|This group receives the Snuby® skin-to-skin facilitating garment to use in the first six weeks following birth with their baby. The use of the Snuby® garment is participant led, and used for as long and as often as they wish in the six week period.
2485650|NCT02998463|No Intervention|Conventional Care|This group does not receive any intervention, and collects data on the research outcomes when having conventionally facilitated skin-to-skin contact, using a towel, blanket, or clothing as preferred. Skin-to-skin contact frequency and duration is dictated by the participant.
2485699|NCT02998307|Experimental|Monthly|Receive bedside CPR training monthly
2485701|NCT02998307|Experimental|3 months|Receive bedside CPR training every 3 months
2485703|NCT02998307|Experimental|6 months|Receive bedside CPR training every 6 months
2485704|NCT02998307|No Intervention|Control|No additional training and only performance evaluation after 1 year
2485723|NCT02998047|Experimental|IV infusion of Lintuzumab AC225|"Starting dose - 0.5 μCi/Kg IV infusion of Lintuzumab AC225 on Day 1 of each cycle with dose escalation 1 μCi/Kg and 1.5 μCi/Kg or de-escalation to 0.25 μCi/Kg.~1 cycle = 28 days, up to 3 to 8 cycles (depending on the cohort)."
3160354|NCT00422565|Active Comparator|Cypher|Sirolimus-eluting stent
2485839|NCT02997306|Experimental|Superior/Medial Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Superior/Medial half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
2485843|NCT02997306|Experimental|Inferior/Lateral Running Sutures|In this cohort, the running sutures will be randomized to be oriented on Inferior/Lateral half of the scar, and the remaining half of the scar will be closed with simple interrupted sutures.
2485884|NCT02996942||Replacement therapy|Hemophilia A receiving replacement therapy (prophylaxis or on demand)
2485953|NCT02996695|Experimental|204,800 PfSPZ of PfSPZ Challenge|204,800 PfSPZ of PfSPZ Challenge every 4 weeks x 3 doses by DVI, n=31
2485956|NCT02996695|Placebo Comparator|NaCl placebo|NaCl placebo every 4 weeks x 3 doses by DVI, n=31
2486009|NCT02996175|Experimental|SMART|"Treatment group targeting behavioral sleep problems for 5 weeks.~Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
2486010|NCT02996175|Active Comparator|WISE|Standard of care sleep treatment enhanced with psychoeducation. 1 Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome 2 Introduction to understanding and interpreting results from clinical evaluations 3 Introduction to educational planning, expectations, and transition planning 4 Introduction to lifespan development and advocacy and support services available 5 Feedback on current concerns and methods for obtaining services to manage concerns
2486147|NCT02994927|Experimental|CCX168 (avacopan)|CCX168 in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
2486149|NCT02994927|Active Comparator|Prednisone|Prednisone in combination with rituximab or in combination with cyclophosphamide followed by azathioprine
2486304|NCT02993887|Placebo Comparator|Mindfulness|Mindfulness (Decentering) only using the Stop, Breathe, Think Smart Phone application
2486307|NCT02993887|Experimental|Resourcefulness and Mindfulness|Resourcefulness Training (a cognitive behavioral intervention that teaches self-help and help-seeking skills) and Mindfulness using the Stop, Think, Breathe app.
3160355|NCT00422565|Active Comparator|Taxus|Paclitaxel-eluting stent
3160356|NCT00422630|Active Comparator|Average American Diet|
3160357|NCT00422630|Active Comparator|The DASH diet|
3160358|NCT00422630|Active Comparator|The Low Glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
3160359|NCT00422682|Experimental|1|BSI-201 + topotecan
3160360|NCT00422682|Experimental|2|BSI-201 + temozolomide
3160361|NCT00422682|Experimental|3|bsi-201 + gemcitabine
3160362|NCT00422682|Experimental|4|bsi-201 + carboplatin/paclitaxel
3160363|NCT00422747|Experimental|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
3160364|NCT00422773|Experimental|Cetuximab+ FOLFOXIRI|Cetuximab and Irinotecan, Oxaliplatin, 5FU and Folinic acid
3160365|NCT00422786|Experimental|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period.
3160366|NCT00422825|Experimental|Imatinib 800mg|
3160367|NCT00422825|Active Comparator|Imatinib 400mg|
3160368|NCT00422838||1|Chronic HCV Genotype 1 monoinfection, never had interferon and ribavirin treatment
2485467|NCT02999945|Active Comparator|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term)
2485468|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
2485469|NCT02999945|Active Comparator|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
2485470|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term).
2485524|NCT02999425|Experimental|Education|Educational intervention to study participants
2485563|NCT02999087|Active Comparator|Arm A Patient FIT|"Lead-in phase (Day-8) : no treatment~Concomitant radiotherapy phase : Radiotherapy by IMRT + cisplatin 100mg/m2~Maintenance phase : no treatment until follow-up phase"
2485566|NCT02999087|Experimental|Arm B Patient FIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase : Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
2485570|NCT02999087|Experimental|Arm C Patient UNFIT|"Lead-in phase (Day-8) : Cetuximab 400mg/m2 and avelumab 10mg/kg~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2 and avelumab 10mg/kg~Maintenance phase : avelumab 10mg/kg every 2 weeks during 12 months"
2485574|NCT02999087|Active Comparator|Arm D Patient UNFIT|"Lead-in phase (Day-8): Cetuximab 400mg/m2~Concomitant radiotherapy phase: Radiotherapy by IMRT + cetuximab 250mg/m2~Maintenance phase : no treatment until follow-up phase"
2485637|NCT02998632|Experimental|Interventional|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution.~Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
2485648|NCT02998632|Active Comparator|Comparator|"Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery.~The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane.~Osstell instrument will be used to measure and record fixture primary stability in ISQ units.~Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed."
2485696|NCT02998359|Active Comparator|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
2485698|NCT02998359|Active Comparator|Total hip replacment|A cemented polished double taper stem arthroplasty inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
2485740|NCT02998060|Active Comparator|Robot-guided|Robotic guidance (SpineAssist®or Renaissance® (Mazor Robotics Ltd. Caesarea, Israel) will be used for navigation and insertion of pedicle screws.
2485742|NCT02998060|Active Comparator|Navigated|A computer-assisted method of navigation (CT- or 3D-Fluoroscopy-based) will be used for navigation and insertion of pedicle screws.
2485744|NCT02998060|Active Comparator|Freehand|Pedicle screws will be inserted using the freehand technique under fluoroscopic control.
2485779|NCT02997683|Experimental|3-month home based training on whole body vibration platform|This Group will receive a training device to perform their given exercises on
2485780|NCT02997683|Placebo Comparator|3-month home based training on floor|This Group will perform their given exercises at home on the floor
2485844|NCT02997449||NSCLC, SABR, nodal staging|Patients with a clinical or pathological diagnosis of Non-Small Cell Lung Cancer (NSCLC), and who are medically inoperable or refuse surgery, are eligible if Stereotactic ablative radiotherapy (SABR) is recommended by a multi-disciplinary tumor board. All patients undergo complete mediastinal and hilar staging procedure (EBUS+EUS-B). Pre endoscopy imaging data will be compared with endosonography data.
2485897|NCT02996981||Cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2016 and September 2016 and discharged home with an indwelling urinary catheter following the surgery. This group of people had cranberry juice capsules prescribed.
2485900|NCT02996981||No cranberry group|Patients underwent pelvic floor gynecologic surgery performed by a physician at Cincinnati Urogynecology Associates, TriHealth Inc between April 2015 and September 2015. This group of people did not have cranberry juice capsules prescribed.
2485948|NCT02996604|Experimental|Low-He point(ST36)|Zusanli (ST36, the Low-He point of stomach) is the most important point for gastrointestinal disorder, including functional dyspepsia. Everyone in the group will be punctured at unilateral Zusanli.
2485949|NCT02996604|Experimental|Mu point(CV12)|Zhongwan (CV12, the Mu point of stomach) is also good at regulating gastric function. Everyone in the group will be punctured at Zhongwan.
2485966|NCT02996409|Experimental|High-Volume Image-Guided Injection|HVIGI: Injection of 50 cc ( 40 cc 0,9% sodium chloride solution + 10 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
3193705|NCT00820651|Experimental|Diamel|
2485503|NCT02999646|Experimental|MVX-ONCO-1|MVX-ONCO-1 vaccine treatment once weekly starting on week 1 for 4 weeks followed by two additional treatments 2 weeks apart (total 6 treatments over 8 weeks). Each treatment consists of two macrocapsules containing the MVX-1 cell line and lethally irradiated autologous tumor cells.
3193706|NCT00820677|Experimental|DVD/Video|Parents of newborns in the experimental group attending their first baby visit will be shown a video about newborn care.
3193707|NCT00820690||Clinical stage III|Women with invasive breast cancer; clinical stage III, condition to receive neoadjuvant chemotherapy based in doxorubicin/ cyclophosphamide and paclitaxel followed by surgery (mastectomy and axillary lymph node dissection)
2485862|NCT02997241|Other|high genetic risk and high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2485867|NCT02997241|Active Comparator|low genetic risk but high clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method，randomized design，and chemotherapy for colorectal carcinoma
2485868|NCT02997241|Active Comparator|high genetic risk but low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2485872|NCT02997241|Other|low genetic risk and low clinical risk|on the basis of genetic risk judged by Oncocare and clinical risk judged by Clinical routine method
2485951|NCT02996617|Active Comparator|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF（ruibai 100ug）.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L for total 4 courses.
2485954|NCT02996617|Experimental|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle for total 4 courses.
2486006|NCT02996227|Experimental|TAP block with Exparel|Bilateral Transversus Abdominis Plane (TAP) block procedure following injection of liposomal bupivacaine (Exparel)
2486007|NCT02996227|Active Comparator|Epidural analgesia with Bupivacaine|Epidural catheters with an infusion of Bupivacaine standard solution without additives
2486067|NCT02995889|Experimental|FLT-PET|
2486109|NCT02995460|Experimental|interval training|4x4 high intensity interval training was performed on a stationary bicycle with a supervisor twice a week and by one self-training a week.
2486111|NCT02995460|No Intervention|controls|No change in diet and training habits
2486136|NCT02995122|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486194|NCT02994524|Other|transsphincteric perianal fistula|Rerouting technique done in patients with high transsphincteric fistula or with high internal opening.
2486231|NCT02994316|Experimental|children under the age of 16 diabete with ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm with ketoacidosis (bicarbonate < 15mmol/L)"
2486233|NCT02994316|Sham Comparator|children under the age of 16 diabete without ketoacidosis|"At diagnosis mellitus type 1 (measure of blood glucose level) bicarbonate levels will be measured and children will included in the arm without ketoacodosis (bicarbonate> 15 mmol/L)"
2486259|NCT02994030||Participants with Duchenne Muscular Dystrophy (DMD)|Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years
2486351|NCT02993562||Hypothyroid patients|Hypothyroid patients treated with Levothyroxine as part of normal treatment.
2486352|NCT02993562||Healthy volunteers|Matched on age and BMI. 18 Persons.
2486396|NCT02993211|Active Comparator|Standard resection|For patients undergoing bipolar transurethral standard resection, bladder tumour is resected in a piecemeal manner.
2486397|NCT02993211|Experimental|En bloc resection|For patients undergoing bipolar transurethral en bloc resection, bladder tumour is resected and removed in one piece.
2486463|NCT02992886|Experimental|preCRT+surgery|Treatment including preoperative chemoradiotherapy (preoperative radiation with concurrent chemotherapy) with Raltitrexed followed by surgery. Radiotherapy will be delivered to a planning target volume with a dose of 45-50.4Gy (1.8-2.0Gy daily) using with Intensity-Modulated Radiotherapy or Volumetric-Modulated Arc Therapy technique. During the radiation treatment, concurrent chemotherapy will be delivered (Raltitrexed, intravenous infusion, 3 mg/m2, on d1 and d22). Pelvic surgery is planned 6 weeks after completion of CRT based on the decision of MDT.
2486500|NCT02992535|Experimental|Single arm|Intense pulse light therapy (E-Schwin)
3193708|NCT00820716|Experimental|CA|Exercise training with alternate load
3193709|NCT00820716|Active Comparator|CC|Exercise training with constant load
3193710|NCT00820729||1|Patients with interstitial pulmonary disease
3193711|NCT00820742||Phase IV Post Marketing Surveillance Study|Open-label, observational study
3193712|NCT00820768|Experimental|ABI-010|
2486808|NCT02990611||Cohort 1: Nivolumab/Ipilimumab combination therapy|Participants who start a new systemic therapy with nivolumab/ipilimumab combination therapy for the first time
2486810|NCT02990611||Cohort 2: Nivolumab monotherapy|Participants who start a new systemic therapy with nivolumab monotherapy for the first time
2486814|NCT02990611||Cohort 3: Nivolumab adjuvant therapy|Participants who start adjuvant treatment with nivolumab after complete surgical tumor resection and no evidence of disease
2486856|NCT02990273|Active Comparator|TEG|Blood transfusion
2486864|NCT02990273|Active Comparator|Prothrombin Time (PT)/International normalized ratio (INR)|Blood transfusion
2486906|NCT02989948|Experimental|Main Arm - Physician-modified fenestrated endovascular graft|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
2486907|NCT02989948|Experimental|Expanded Access Arm - Physician-modified fenestrated endovascular graft.|Use of a physician-modified fenestrated Cook Zenith Alpha Thoracic Endovascular Graft for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal, thoracic, or abdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair in an expanded use population.
2486940|NCT02989571|Placebo Comparator|Group 1 - Placebo Arm|Intravenous normal saline administered at 125ml/hr
2485606|NCT02998931|Placebo Comparator|maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
2485684|NCT02998528|Active Comparator|Platinum doublet chemotherapy|Specified dose on specified days
2485685|NCT02998528|Experimental|Nivolumab plus platinum doublet chemotherapy|Specified dose on specified days
2485686|NCT02998528|Experimental|Nivolumab plus Ipilimumab|Specified dose on specified days
2485961|NCT02996487|Placebo Comparator|Placebo|Placebo every 6 hours. A placebo will look like the drug being studied, but have no active ingredients, in this case it will be fruit punch with vitamins added to mimic the taste of vancomycin.
2485963|NCT02996487|Active Comparator|vancomycin|Vancomycin 125 mg by mouth every 6 hours
2486008|NCT02996188||Patients with refractory tense ascites|
2486040|NCT02995941||Raters|No interventions will be administered. Raters will be state licensed as physical therapists working as outpatient physical therapists in the St. Luke's University Health Network.
2486042|NCT02995941||Patients|No interventions will be administered as a component of this study. Patients will be recruited from a convenience sample of consecutive patients presenting for physical therapy consultation for shoulder pain.
2486092|NCT02995616|Experimental|Lokomat training|Patients will be tested in 3 Lokomat training sessions on 3 separate days. During the first session patients will walk in the Lokomat according to their regular therapy settings. During the second and third session patients will walk in the Lokomat with 2 different levels of guidance force (100% guidance force and 60% guidance force).
2486132|NCT02995174|Experimental|Intervention (dichoptic video game play)|Mild amblyopic subjects will be asked to play dichoptic video game in an i-Pod touch device for 1 hour per day in 6 weeks.
2486133|NCT02995174|Placebo Comparator|Control (video game play)|Mild amblyopic subjects will be asked to play video game in an i-Pod touch device for 1 hour per day in 6 weeks.
2486184|NCT02994836|Active Comparator|Anti-TNF|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) or Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)
2486187|NCT02994836|Placebo Comparator|Anti-TNF discontinuation (Placebo)|Physiological saline solution (Infusion-Intravenous use) or Physiological saline solution (Injection-subcutaneous use)
3193713|NCT00820781|Active Comparator|Portacaval shunt|Undergo portacaval shunt surgery
3193714|NCT00820781|Active Comparator|Sclerotherapy|Undergo endoscopic sclerotherapy
3193715|NCT00820794|Experimental|Cohort 1a|Subjects are treated with single dose lithium first. Then after at least 7 day washout, the subjects start PD 0332334 treatment from day 1 to day 9. At day 4 of PD 0332334 treatment, single dose lithium is given to subjects.
3193716|NCT00820794|Experimental|Cohort 1b|Subjects are treated with PD 0332334 from day 1 to 9 and a single dose of lithium is given at day 4. After at least 7 day washout, the subjects are treated with single dose of lithium.
3193717|NCT00820807|Experimental|1|3g/day
3193718|NCT00820807|Experimental|2|6g/day
2486296|NCT02993874|Experimental|Creatine|Creatine monohydrate (Cr) Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
2486297|NCT02993874|Placebo Comparator|Placebo|Dextrose Loading - 4 doses of 5g / day for 7 days Maintenance - 1 dose of 3g / day for 49 days Clinical treatment (30-45 minutes of walking, 3 times per week)
2486407|NCT02993289|Active Comparator|Detoxification and pharmacological prophylactic treatment|Group A: Two months detoxification program combined with pharmacological prophylactic treatment from start.
2486410|NCT02993289|Active Comparator|Pharmacological prophylactic treatment|Pharmacological prophylactic treatment from start without detoxification.
2486414|NCT02993289|Active Comparator|Detoxification|Two months detoxification program with postponed pharmacological prophylactic treatment after ended detoxification.
2486418|NCT02993289|No Intervention|Control group 1: Episodic migraine|
2486421|NCT02993289|No Intervention|Control group 2: Healthy volunteers|
3193719|NCT00820807|Placebo Comparator|Placebo beverage|0g/day
3193720|NCT00820820|Active Comparator|Rouvax|
3193721|NCT00820820|Placebo Comparator|Placebo|Sub cutaneous injection of vehicle
2486679|NCT02991508|Placebo Comparator|Placebo|Vehicle (20 mM His/HCl pH 6.0)
2486681|NCT02991508|Active Comparator|Adrecizumab 0.5 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2486684|NCT02991508|Active Comparator|Adrecizumab 2.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2486686|NCT02991508|Active Comparator|Adrecizumab 8.0 mg/kg|To assess the safety, tolerability and pharmacokinetics/-dynamics of single escalating doses of ADRECIZUMAB (0.5 mg/kg, 2,0 mg/kg and 8,0 mg/kg administered as single infusion over 1 hour) in healthy male subjects.
2486804|NCT02991001|Experimental|Normal saline hydrodissection|Ultrasound-guided hydrodissection with normal saline between carpal tunnel and median nerve.
2486806|NCT02991001|Placebo Comparator|Normal saline|Ultrasound-guided injection with normal saline at subcutaneous layer beyond the carpal tunnel region
2486862|NCT02990260|Active Comparator|Live Saccharomyces cerevisiae|Live Saccharomyces cerevisiae. 2 capsules per day (1 g).
2486869|NCT02990260|Active Comparator|Yeast cell wall|Yeast cell wall. 2 capsules a day (700 mg).
2486872|NCT02990260|Placebo Comparator|Placebo|Maize starch and magnesium stearate. 2 capsules a day.
2486938|NCT02989857|Active Comparator|AG-120 experimental study drug|AG-120, 500mg daily continuous dosing
2486943|NCT02989857|Placebo Comparator|AG-120 matched placebo|AG-120 matched placebo, daily continuous dosing. Subjects who experience disease progression and were receiving placebo, will be allowed to cross-over and receive AG-120
2487004|NCT02989051|Experimental|Restrictive fluid treatment|Restrictive fluid regimen
3193722|NCT00820833|Placebo Comparator|1|Standard infant formula
3193723|NCT00820833|Experimental|2|Test formula
3193724|NCT00820833|No Intervention|3|Breastfeeding reference group
3193725|NCT00820846|Experimental|Part A, Group 1|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
2485614|NCT02998814|Active Comparator|acid-etch only|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid-etch only will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2485617|NCT02998814|Active Comparator|self-etch adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for self-etch adhesive will be treated with self-etch adhesive (AdperTM EasyBond, 3M ESPE) for 10 seconds followed by light curing for 20 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2485620|NCT02998814|Active Comparator|etch-and-rinse adhesive|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch-and-rinse adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, etch-and-rinse adhesive (Single BondTM, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2485623|NCT02998814|Active Comparator|self-etch adhesive after acid-etch|Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for acid etch + self-etch adhesive will be treated with 37% phosphoric acid for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved. Then, self-etch adhesive (AdperTM EasyBond, 3M ESPE) will be treated with for 10 seconds followed by light curing for 20 seconds.Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
2485639|NCT02998450|Experimental|Cohort 1|"4 Subjects will receive a single low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2485649|NCT02998450|Experimental|Cohort 2|"4 Subjects will receive a single low-mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2485653|NCT02998450|Experimental|Cohort 3|"4 Subjects will receive a single mid-low dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2485655|NCT02998450|Experimental|Cohort 4|"4 Subjects will receive a single mid dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2485660|NCT02998450|Experimental|Cohort 5|"4 Subjects will receive a single mid-high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
2485666|NCT02998450|Experimental|Cohort 6|"4 Subjects will receive a single high dose of IMR-687, administered orally following an overnight fast.~2 Subjects will receive a single dose of Placebo, administered orally following an overnight fast."
3160369|NCT00422838||2|Chronic HCV Genotype 2 or 3 monoinfection,never had interferon and ribavirin treatment
3160370|NCT00422851||1|Normal tympanic membrane
3160371|NCT00422851||2|tympanosclerosis
3160372|NCT00422851||3|dimeric (atrophic)
2485784|NCT02997709||Radiation Therapy Group|Participants with prostate cancer diagnosis who are scheduled to undergo standard of care radiotherapy with or without the addition of Androgen Deprivation Therapy (ADT) will be evaluated
2485786|NCT02997709||Prostatectomy Group|Participants with prostate cancer diagnosis who are scheduled to undergo prostatectomy will be evaluated
2485836|NCT02997410|Experimental|Ozone|Ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
2485838|NCT02997410|Placebo Comparator|Placebo|Sham ozone application to the greatest points of pain in the related muscle, 3 times per week for 2 weeks
2485842|NCT02997410|Experimental|Occlusal splint|Occlusal splint use every night over a period of 4 weeks.
2485860|NCT02996955|Experimental|SoSup group|usual care will be provided and social support and treatment of illness perceptions and activity advice and wearing the activ8
2485865|NCT02996955|Active Comparator|C group|usual care will be provided and treatment of illness perceptions and activity advice and wearing the Activ8
2485924|NCT02996669||Autism Spectrum Disorder|During Screening Visits, the Autism Diagnostic Observational Schedule (ADOS) will be administered to confirm diagnosis. Criteria for group inclusion is: diagnosis of Autism Spectrum Disorder based on Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the Autism Diagnostic Observation Schedule (ADOS-G), and the Autism Diagnostic Interview-Revised, short form (ADI-R). Diagnostic evaluations will be completed by research staff and supervised by a licensed psychologist.
2485927|NCT02996669||Typical Development|Typically Developing (TD) participants from each site will be roughly matched by age and sex to the ASD group.
3193726|NCT00820846|Placebo Comparator|Part A, Group 2|Participants will receive four placebo injections
2486015|NCT02996032||Heart Failure|Patients admitted to the hospital with acute decompensated heart failure expected to be hospitalized for at least 72 hours
2486094|NCT02995564|Experimental|Social Skills Intervention|The intervention is a 16-week social skills therapy program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the peer generalization portion. During the group therapy session young adults will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with typically developing peer volunteers.
2486124|NCT02995200|Experimental|Group Post-Stroke|2 sessions of in-home accelerometer based feedback about paretic arm use
2486127|NCT02995200|No Intervention|Healthy Control Group|
2486369|NCT02993328|Experimental|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
2485615|NCT02998840|Sham Comparator|Vehicle 8 pumps applied to face and torso|8 pumps total - 4 pumps of spray to saturate the entire face and 4 pumps to the torso Applications should occur in the morning and at night for 4 weeks.
2485630|NCT02998437|Experimental|Ilaprazole 10mg|"Period 1: Ilaprazole 10mg 1 tab.m one a day~Period 2: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap. twice a day, 6 days Ilaprazole 10mg, one a day at the 5 day"
2485644|NCT02998437|Active Comparator|Clarithromycin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at the 5 day"
2485651|NCT02998437|Active Comparator|Amoxicillin 500mg|"Period 1: Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day~Period 2: Ilaprazole 10mg 1 tab., twice a day, 6 days Clarithromycin 500mg 1 tab. + Amoxicillin 500mg 2 cap., one a day at 5 day"
2485752|NCT02997995|Experimental|Immune-attractant/lymphocyte activation|After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks. After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial i.e. lymphocyte activation. In this second part, patients will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months. The pathological response will be checked by surgery.
2485808|NCT02997514|Active Comparator|Intensive Solution Focused Coaching|Participants will engage in 5 solution focused coaching sessions, each up to 60 minutes in duration
2485811|NCT02997514|Active Comparator|Solution Focused Coaching|Participants will engage in 1 solution focused coaching session up to 60 minutes in duration
2485861|NCT02997215|Experimental|intravenous lidocaine|intravenous lidocaine 1.5mg/kg during induction then infused at 2mg/kg/h until the end of procedure.
2485866|NCT02997215|Placebo Comparator|saline placebo|same amount volume saline infusion
2485915|NCT02996760|Experimental|Endometrium with less than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~Less than 5mm despite 10 days with standard doses of estrogen"
2485918|NCT02996760|No Intervention|Endometrium with more than 5mm|"Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type.~More than 5mm despite 10 days with standard doses of estrogen"
3193727|NCT00820846|Experimental|Part B, Group 3|Participants will receive two injections of the pGA2/JS7 DNA vaccine and then two injections of the MVA/HIV62 vaccine
3193728|NCT00820846|Experimental|Part B, Group 4|Participants will receive three injections of the MVA/HIV62 vaccine and one injection of the placebo
3193729|NCT00820846|Placebo Comparator|Part B, Group 5|Participants will receive four placebo injections
2486101|NCT02995590|Experimental|MRI of lung motion during breathing|"A medical history will be obtained defining any present and past history of respiratory illnesses, medications, and hospitalizations and the ability to have MR imaging.~A urine pregnancy test will be done for women of childbearing potential, who report the possibility that they might be pregnant.~Before and after MR imaging, a physical exam, spirometry, and a baseline %PO2 will be performed.~During the MR imaging procedure, the subject's heart rate and blood oxygen saturation will be monitored using an MR compatible pulse oximeter.~Once positioned in the MR scanner, conventional proton images of the thorax will be obtained to define the lung boundaries for subsequent image alignment. -Free breathing conventional MR imaging will be performed.~Hyperpolarized helium 3 imaging will be performed at breath hold."
2486121|NCT02995161|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3193730|NCT00820859|Experimental|1|
3193731|NCT00820859|Active Comparator|2|
2486217|NCT02994329|Active Comparator|Oral HIV self test|In this arm, community health workers conducting door-to-door HIV testing will offer oral HIV self testing (OraQuick® HIV Self-Test (Orasure Technologies, Thailand)) as an alternative to standard of care finger-prick HIV testing for individuals who are present at the time of the visit. In addition they will provide demonstration to an adult who is present at the time of the visit and leave up to 2 oral HIV self test kits to allow testing with the partner
2486219|NCT02994329|No Intervention|Standard of Care|In this arm community health workers will conduct door-to-door HIV testing using the current Zambian national HIV testing algorithm of finger-prick rapid HIV tests
2486254|NCT02994160|Experimental|FastLIFE electrodes|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
2486300|NCT02993939|Active Comparator|Interscalene block|Ultrasound guided Brachial plexus block injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml, in the Interscalene groove.
2486376|NCT02993328|Placebo Comparator|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
3193732|NCT00820885|Other|cohort A|20 mg dose 20 mg/ML concentration and placebo
3193733|NCT00820885|Other|Cohort AR|20 mg in 50 mg/ml concentration and placebo
3193734|NCT00820885|Other|Cohort C|25 mg in 50mg/ml concentration and placebo
3193735|NCT00820885|Other|Cohort D|15 mg in 50mg/ml concentration and placebo
3193736|NCT00820885|Other|Cohort E|10 mg in 50mg/ml concentration and placebo
3193737|NCT00820885|Other|Cohort F|30mg in 50mg/ml concentration and placebo
3193738|NCT00820885|Other|Cohort H|50mg in 50mg/ml concentration and placebo
3193739|NCT00820885|Other|cohort I|80mg in 50mg/ml concentration and placebo
3193740|NCT00820911|Active Comparator|cyclosporine (reduced exposure) / everolimus|
3193741|NCT00820911|Experimental|AEB071 300 mg b.i.d. / everolimus|
3193742|NCT00820911|Experimental|AEB071 200 mg b.i.d. / everolimus|
3193743|NCT00820924|Experimental|LAPATINIB|LAPATINIB 1500MG ORAL ONCE DAILY
3193744|NCT00820950|Experimental|Treatment 1: Ruxolitinib|Ruxolitinib -- 0.5%
3193745|NCT00820950|Experimental|Treatment 2: Ruxolitinib|Ruxolitinib -- 1.0%
3193746|NCT00820950|Experimental|Treatment 3: Ruxolitinib|Ruxolitinib -- 1.5%
3193747|NCT00820950|Placebo Comparator|Treatment 4: Placebo|Placebo Cream
2485761|NCT02997852|Experimental|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
2485763|NCT02997852|No Intervention|Control|Usual care in the intensive care unit.
2485825|NCT02997566||Autistic Disorder|Age: 3 to 14 years-old Gender: male and female Autism Spectrum Disorder
2485827|NCT02997566||Typical|Age: 3 to 14 years-old Gender: male and female Typical
2485886|NCT02997124|Experimental|Local Infiltration with TAP block|Ultrasound guided Transversus Abdominis Plane block is administered intraoperatively using 0.2% Ropivacaine.
2485893|NCT02997124|Experimental|Local Infiltration only|Local Infiltration with 0.2% Ropivacaine.
3193748|NCT00820950|Active Comparator|Treatment 5: Dovonex® calcipotriene|Dovonex® calcipotriene 0.005% cream
3193749|NCT00820950|Active Comparator|Treatment 6: Diprolene® AF betamethasone diproprionate|
2486088|NCT02995668|No Intervention|Control|Non-active comparator
2486089|NCT02995668|Active Comparator|Strength-Function|Active comparator
2486090|NCT02995668|Experimental|Balance-Proprioception|Experimental
2486128|NCT02995187|Experimental|Apatinib Mesylate tablet|Patients received oral apatinib 500 mg in tablet once daily, a treatment cycle was defined as 28 days (4 weeks).
2486168|NCT02994875|Placebo Comparator|Placebo First|Placebo - Participants will receive placebo for one week. Following a two-week washout period, they will receive NAC for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
2486174|NCT02994875|Active Comparator|NAC First|N-acetylcysteine - Participants will receive NAC for one week. Following a two-week washout period, they will receive placebo for one week. NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications
2486213|NCT02994342|Active Comparator|Vaginal gel, Medical Device Class 2A|Every subject has been treated for 56 consecutive days, twice daily with a vaginal application
2486215|NCT02994342|No Intervention|Lifestyle counseling|Every subject has been observed for 56 consecutive days
2486244|NCT02994173|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
2486246|NCT02994173|Active Comparator|Ketamine 0.25|Oxycodone 1 mg / ml + S-ketamine 0.25 mg / ml (ratio 1:0.25)
2486249|NCT02994173|Active Comparator|Ketamine 0.5|Oxycodone 1 mg / ml + S-ketamine 0.5 mg / ml (ratio 1:0.5)
2486251|NCT02994173|Active Comparator|Ketamine 0.75|Oxycodone 1 mg / ml + S-ketamine 0.75 mg / ml (ratio 1:0.75)
3193750|NCT00820963|Experimental|Arm I|Patients undergo standard radiotherapy 5 days a week for 6 weeks.
3193751|NCT00820963|Experimental|Arm II|Patients undergo hypofractionated radiotherapy 5 days a week for 2 weeks.
3193752|NCT00820963|Experimental|Arm III|Patients receive oral temozolomide on days 1-5. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2486349|NCT02993406|Experimental|Bempedoic Acid 180 mg|Bempedoic acid 180 mg tablet taken orally, once daily.
2486350|NCT02993406|Placebo Comparator|Placebo Comparator|Matching placebo tablet taken orally, once daily
2487552|NCT02985580|Active Comparator|Blueberry|Blueberry concentrate consumed daily for 12 weeks.
2487553|NCT02985580|Placebo Comparator|Placebo|Placebo concentrate consumed daily for 12 weeks.
2487601|NCT02985203|Experimental|Vinorelbine oral|Oral Navelbine plus Cisplatin followed by metronomic oral vinorelbine.
2487602|NCT02985203|No Intervention|Physician's choice|Observation or maintenance therapy other than orla navelbine.
2487638|NCT02984865|Active Comparator|group S|Patients were attach with PCA containing 100ml combination of sulfentanyl 2.5ug/kg and flubiprofen axetil 100mg after receiving the loading dose of sulfentanyl 5 ug and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
3193753|NCT00820976|No Intervention|control|remission induction with cytosine arabinoside amd idarubicine
3193754|NCT00820976|Experimental|G-CSF|G-CSF was administered starting on Day 8 until neutrophil recovery
3193755|NCT00820989|Experimental|A|Time points after IV Endotoxin administration compared to baseline (immediately before Endotoxin administration).
3193756|NCT00821002|Experimental|Plug placement|
3193757|NCT00821028|Experimental|Paclitaxel|Participants will receive Paclitaxel.
3193758|NCT00821054|Experimental|Period 1|Treatment A, B or C
3193759|NCT00821054|Experimental|Period 2|Treatment A, B or C
3193760|NCT00821054|Experimental|Period 3|Treatment A, B or C
3193761|NCT00821067|Active Comparator|1|A 6 gm/day (3 gm/bid) dose of D-ribose
3193762|NCT00821067|Placebo Comparator|2|A 6 gm/day (3 gm/bid) dose of dextrose.
3193763|NCT00821080|Experimental|Vandetanib and Sirolimus|Single arm study
3193764|NCT00821106|Experimental|Right transradial approach|Coronary diagnostic or interventional procedures performed through right radial approach
3193765|NCT00821106|Experimental|Left transradial approach|Diagnostic or interventional procedures performed through left radial approach
3193766|NCT00821132||ALS families|Patients with either inherited or sporadic ALS or PLS and selected family members
3193767|NCT00821145|Active Comparator|1|50 patients operated using a conventional open surgery to exclude an abdominal aortic aneurysm
3193768|NCT00821145|Experimental|2|50 patients operated using a total laparoscopic aortic aneurysm resection
3193769|NCT00821145|Active Comparator|3|25 patients using a laparoscopic approach for AAA resection with a stapled proximal anastomosis
3193770|NCT00821158|Placebo Comparator|1|Placebo tablet and iv
3193771|NCT00821158|Experimental|2|Placebo tablet and intervention iv
3193772|NCT00821158|Experimental|3|Intervention tablet and placebo iv
2485643|NCT02998580|Experimental|Bilateral Theta Burst Stimulation|"cTBS followed by iTBS.~continuous theta burst stimulation (cTBS) of the right DLPFC for 600 pulses followed by intermittent theta burst stimulation (iTBS) of the left DLPFC for 600 pulses. Treatment will occur 5 times per week for 4 to 6 weeks."
2485718|NCT02998320|Experimental|Genvoya|Genvoya (E/C/F/TAF) Tablet (oral use) : 150/150/200/10 mg, one tablet each day for 28 days
2485760|NCT02997696|Experimental|Experimental arm 1|ONO-4474 low dose every day for 4 weeks
2485762|NCT02997696|Experimental|Experimental arm 2|ONO-4474 high dose every day for 4 weeks
2485765|NCT02997696|Placebo Comparator|Placebo arm|Placebo matching ONO-4474 every day for 4 weeks
3193773|NCT00821197|Active Comparator|long-limb bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
3193774|NCT00821197|Active Comparator|Distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
3193775|NCT00821210|Sham Comparator|2|
3193776|NCT00821210|Active Comparator|1|
2486049|NCT02995785|Other|Experimental:simulation-based training|Experimental
2486051|NCT02995785|Other|Active comparatorr: traditional training|Traditional
2486118|NCT02995538||Neurogenetic Patients|The Neurogenetics Clinic, which started in 2016, provides clinical care for undiagnosed patients with complex neurological disorders in which a genetic etiology is considered and for children with diagnosed rare neurogenetic disorders - provide pre test counseling, diagnostic services for the undiagnosed patients and long-term management of patients with a wide range of diagnosed genetic disorders of the nervous system.
2486180|NCT02994992|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486216|NCT02994472|Experimental|Healthy volunteers|"Each participant will have to eat scrambled egg on day 1 and porridge on day 2; both meals will contain the radioactive tracer 99mTc-DTPA.~Participants will be scanned by a trained technologist. The scans will be carried out using a General Electric, Discovery 360 Gamma Camera.The scanning process will take approximately three hours in total, however the imaging will be carried out in stages."
2486240|NCT02994186||Surgical Weight Loss|Patients in this group are those that will be undergoing bariatric surgery (either Roux-en-Y gastric bypass or vertical sleeve gastrectomy).
2486242|NCT02994186||Medical Weight Loss|Patients in this group are those who are being enrolled in a supervised medical weight loss program.
2486267|NCT02993952|Active Comparator|Active stimulation|A constant current (anodic) of 2mA will be applied for 20 minutes on the Primary motor cortex.
2486271|NCT02993952|Sham Comparator|Sham stimulation|A constant current (sham) of 2mA will be applied, but the stimulator will be turned off after 30 seconds on the Primary motor cortex.
2486322|NCT02993718|Experimental|Dexmedetomidine|Intraoperative sedation is performed by using dexmedetomidine.
2486325|NCT02993718|Experimental|Propofol|Intraoperative sedation is performed by using propofol
2486346|NCT02993432|Active Comparator|Prostaglandin|Administration of the prostaglandin for cervical ripening of the clinician's choice, ie Prostin (Prostin E2 Vaginal Gel 1mg intravaginally) or Cervidil (dinoprostone, 10 mg vaginal insert)
2486348|NCT02993432|Experimental|Foley catheter filled to 80cc|Insertion of a Foley catheter through the cervix and filling to 80cc
3193777|NCT00821223|Active Comparator|manual small incision cataract surgery|surgical intervention by small incision cataract surgery
2486479|NCT02992470|Experimental|Hydrolyzed oyster extract|A 250 mg, film-coated oblong (rectangle) shaped tablet of oyster extract
2486480|NCT02992470|Placebo Comparator|Placebo|A 250 mg, film-coated oblong (rectangle) shaped tablet of maltodextrin
2486518|NCT02992392|Experimental|Liposic|Liposic was applied to one eye of patients in this group
2486523|NCT02992392|Experimental|Tears Naturale Forte|Tears Naturale Forte was applied to one eye of patients in this group
2486548|NCT02992093||obese with PCOS|all the indicators
2486549|NCT02992093||nonobese with PCOS|all the indicators
2486550|NCT02992093||PCOS with IGT|all the indicators
2486551|NCT02992093||PCOS with T2DM|all the indicators
2486552|NCT02992093||Healthy volunteers|all the indicators
2486572|NCT02991872|Other|V49_24E1 Group|Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49_24 (NCT01680016), will be invited to participate to this extension study.
2486612|NCT02991781|Experimental|COPD Patients|"C.O.P.D. patients: Presence of a post-bronchodilator forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 0.70 with symptoms as dyspnea, chronic cough, chronic sputum production~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
2486614|NCT02991781|Experimental|Asthma Patients|"Asthma patients: Presence of 2 or more of symptoms of airflow obstruction (cough, wheezing, dyspnea). Airflow obstruction at least partially reversible demonstrated by spirometry with FEV1 increased by >12% following b2 agonist inhalation) or evidence of bronchial hyperresponsiveness by metacholine provocation test (demonstrated by provocative concentration causing a 20% fall (PC20) <8 mg or mannitol provocation test (with FEV1 decrease of 15%)~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Passive Control"
2486615|NCT02991781|Experimental|Smokers|"Smokers will consist of a group of patients that are under the age of 35, unemployed and healthy according to a standard clinical evaluation.~Biofeedback and Neurofeedback Training~Varenicline use for smoking cessation~Sham Neurofeedback~Passive Control"
2486689|NCT02991248|Experimental|robotic training & stimulation|Device: robotic treadmill training paired with active spinal cord electrical stimulation, three times a week for 6 weeks.
2486695|NCT02991248|Active Comparator|robotic training & sham|Device: robotic training paired with sham spinal cord stimulation, three time a week for 6 weeks.
2486699|NCT02991248|Placebo Comparator|treadmill only|Device: treadmill Conventional treadmill training only, three time a week for 6 weeks.
2486784|NCT02990923|No Intervention|Control|In this group, patients will use traditional standard hemodialysis connector and receive typical disinfection management
2486787|NCT02990923|Experimental|Only High-Flow Valve|In this group, patients will use High-Flow Needleless Valve instead of traditional standard hemodialysia connector, but still receiving typical disinfection management
2485869|NCT02997046||Pre-transplant assessment|"CTA abdominal and aortoiliac vasculature before transplantation~FeMRA abdominal and aortoiliac vasculature & CMR before transplantation"
2485871|NCT02997046||Mapping & surveillance (for fistula)|"US vascular mapping before fistula creation~6 week US fistula arm~FeMRA fistula arm/central veins & CMR before fistula creation and at 6 weeks"
2485874|NCT02997046||Mapping & surveillance (for graft)|"US vascular mapping before graft creation~6 week US graft arm~FeMRA fistula arm/central veins & CMR before graft creation and at 6 weeks"
2485952|NCT02996786|Experimental|Danggui Buxue Tang group|Danggui Buxue Tang group receive orally supplementation of 7.5 g/day of Danggui Buxue Tang for 10 days
2485955|NCT02996786|Placebo Comparator|Placebo group|Placebo group receive orally supplementation of 7.5 g/day of placebo for 10 days
3160373|NCT00422877|Experimental|Taxoprexin|Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.
3160374|NCT00422916|Experimental|intervention arm|Lifestyle Intervention based on Nutrition Treatment, exercise Treatment and behavorial treatment
3160375|NCT00422916|No Intervention|waiting list|waiting 6 months for Intervention without any intervention
2486263|NCT02995343|Experimental|Hypogastric and/or uterine artery ligation|Patients who had been ligated hypogastric artery and or uterine artery for ceasing uterine bleeding during c-section
2486265|NCT02995343|No Intervention|Normal postpartum women|
2486444|NCT02992834|Active Comparator|IL-2 pre-treated CD19 cells|Initial therapy: IL-2 (interleukin,IL)stimulated, CD28-ζ-vector (cluster of differentiation 28,CD28)transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
2486445|NCT02992834|Active Comparator|IL-7/IL-15 pre-treated CD19 cells|Initial therapy: IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
2486491|NCT02992639|Placebo Comparator|Control group|No calorie restriction group
2486492|NCT02992639|Experimental|Weight loss group|Mild calorie restriction group (300kcal/day intake reduction)
2486540|NCT02992327||Cohort|Patients age ≥ 8 years of age with a GCS >13 presenting to the emergency department with a diagnosis of concussion.
2486569|NCT02992028|Experimental|Intravenous vitamin C injection|During the first 30 min after beginning of the rotator cuff repair, treatment group received infusion of 3 g vitamin C (ascorbic acid) in 500 ml of Ringer.
2486578|NCT02992028|Placebo Comparator|Intravenous saline injection|During the first 30 min after beginning of the rotator cuff repair, sham group received 6 ml normal saline in 500 ml of Ringer.
2486632|NCT02991612|Experimental|Rifaximin Treatment Group|Rifaximin 400mg bid for 2 months,
2486644|NCT02991612|No Intervention|Control Group|Receive routine endoscopic treatment without having rifaximin for 2 months
2486659|NCT02991352|Experimental|Experimental|Image guided needle placement into vascular malformations based on MRI
2486713|NCT02991131||Tedizolid|Hospitalized ABSSSI patients treated with tedizolid
2486714|NCT02991131||Linezolid|Hospitalized ABSSSI patients treated with linezolid
2486768|NCT02990806|Experimental|NI-071|Proposed biosimilar
2486774|NCT02990806|Active Comparator|Infliximab|Reference product
2486957|NCT02989558|Active Comparator|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
2486962|NCT02989558|Active Comparator|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
2486995|NCT02989259|Experimental|apatinib|apatinib 500mg p.o. qd
2487173|NCT02988063|Experimental|Compression plus PEM|Patients will receive 4-5 weeks of compression therapy, followed by treatment with 1% polidocanol endovenous microfoam (PEM) and 12 additional weeks of compression therapy. If the treating physician determines that the vein is not closed after a subjective assessment of vein patency via standard-of-care limited duplex imaging, patients will be re-treated with PEM on Day 4.
2487219|NCT02987699|Experimental|Full Dosage|Full Dosage Chemotherapy regimen administered by HAI
2487224|NCT02987699|Experimental|Low Dosage of 5-Fu|Low Dose of 5-Fu Chemotherapy regimen administered by HAI
2487227|NCT02987699|Experimental|Low Dosage of oxaliplatin|Low Dose of oxaliplatin Chemotherapy regimen administered by HAI
3160376|NCT00422929||chronic otitis media with effusion (OME)|history of chronic effusion (3 months if both ears, 6 months if one ear, or 3 episodes of effusion each lasting for 2 months or longer)
3160377|NCT00422929||recurrent AOM|recurrent acute otitis media (3 episodes in 6 months or 4 episodes in 1 year)
3160378|NCT00422929||no OM|no history of significant otitis media (i.e., does not meet criteria for chronic OME or recurrent AOM)
2487874|NCT02983123||1 hour-troponin|1-hour troponin collected of all recruited patients in addition to the daily routine with serial troponins collected at 0- and 4/6 hours.
3160379|NCT00422955|Experimental|Arm 1|
3160380|NCT00422968|Active Comparator|coronary artery bypass graft|coronary artery bypass graft
3160381|NCT00422968|Experimental|percutaneous coronary intervention|Using silorimus eluting stent
3160382|NCT00422981|Active Comparator|AL-108 5 mg|5 mg QD
3160383|NCT00422981|Active Comparator|AL-108 15 mg|15 mg BID
3160384|NCT00422981|Placebo Comparator|Placebo|Placebo
3160385|NCT00423007|Experimental|Bromfenac|Ophthalmic Solution
3160386|NCT00423007|Placebo Comparator|Placebo|Vehicle ophthalmic solution
3160387|NCT00423072||1|children with cleft palate birth-24 months of age
3160388|NCT00423124|Experimental|A|
3160389|NCT00423215||Patients with Type II diabetes|
3160390|NCT00423228|Experimental|ZT-1|ZT-1 (investigational product)
3160391|NCT00423228|Active Comparator|Donepezil|Donepezil
3160392|NCT00423241|Experimental|SEMPERFLO Pain Management System|
3160393|NCT00423241|Active Comparator|ON-Q PainBuster Post-Op Pain Relief System|
3160394|NCT00423254|Experimental|Low Dose Cohort|
3160395|NCT00423254|Experimental|High Dose Cohort|
3160396|NCT00423280|Active Comparator|1|700mg/day 6R-BH4
3193778|NCT00821223|Other|phacoemulsification|surgical intervention by phacoemulsification
3193779|NCT00821249|Experimental|ARRY-520|
2485753|NCT02997813||Cohort 1|All consecutive patients with complete set of data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and plerixafor
2485754|NCT02997813||Cohort 2|All consecutive patients with complete data (and who underwent apheresis) treated between 2009 and 2013 with G-CSF and cyclophosphamide
2485796|NCT02997670|Experimental|Main patient cohort|Algorithmic Cardiac Resynchronisation Therapy Optimisation; Patients requiring CRT-D enrolled to receive algorithmic CRT optimisation at their device implantation. They will then be programmed to standard CRT settings for 12 weeks. Assessments will be performed and they will again undergo CRT optimisation using the specified algorithm. This time, they will be programmed to the settings giving maximal cardiac output on echocardiography, as assessed by LVOT VTI. After a further 12 weeks, they will again undergo assessment and the study will terminate.
2485841|NCT02997332|Experimental|Patients with squamous cell carcinoma of the oral cavity,|The aim is to evaluate safety, PK and pharmacodynamics of durvalumab in adult patients with squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx previously untreated, with indication of induction chemotherapy.
2485882|NCT02996929|Experimental|Study group|Subjects who are scheduled for CIED lead extraction with the LC system
2485933|NCT02996721|No Intervention|Standard of Care|Patients randomized to the standard of care arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey at baseline and at study conclusion. No other contact is planned with the standard of care patients. Follow-up will be done by the querying of electronic records, which includes any 25[OH] Vit D testing, use of vitamin D supplementation, and outcomes.
2485934|NCT02996721|Experimental|Treatment|Patients randomized to the treatment arm will have a 25[OH] Vit D test performed, a sample taken and stored for future tests, and completion of a PHQ-9 depression survey. If at baseline a patient has a 25[OH] Vit D >40 ng/mL then follow-up testing will occur 1 year from baseline and the patient will continue current treatment strategy (no supplementation or current supplementation dosage). If baseline 25[OH] Vit D levels are <40 ng/mL then the patient will initiate or increase dose and return in 3 months (±15 days) to determine 25[OH] Vit D level. At 3 months, if 25[OH] Vit D >40 ng/mL then current dose should be kept and the patient will return in 1 year for follow-up testing. However, if 25[OH] Vit D <40 ng/mL then patients should double current dose and test again in 3 months. This should occur until 25[OH] Vit D reaches a level >40 ng/mL and once achieved, the patient will return in 1 year for follow-up 25[OH] Vit D testing.
2485993|NCT02996383|Active Comparator|Cemented hemiarthroplasty|Treatment of the fracture by a replacement arthroplasty with a cemented CPT hemiarthroplasty (manafactured by Zimmer company, Warsaw IN, USA) inserted via an anteriolateral approach to the hip
2485995|NCT02996383|Active Comparator|Internal fixation|Internal fixation of the fracture with a screw and plate device (Targon FN plate, Aesculap cooperation, Tuttingham, Germany)
2486034|NCT02996019|Experimental|Part 1: Etrolizumab AI|Participants will receive a single dose of etrolizumab via subcutaneous (SC) injection using the AI on Day 1.
2486037|NCT02996019|Active Comparator|Part 1: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
2486038|NCT02996019|Experimental|Part 2: Etrolizumab AI|Participants will receive a single dose of etrolizumab via SC injection using the AI on Day 1.
2486041|NCT02996019|Active Comparator|Part 2: Etrolizumab PFS-NSD|Participants will receive a single dose of etrolizumab via SC injection using the PFS-NSD on Day 1.
2486103|NCT02995655|Experimental|CX-01 + Azacitidine|"CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.~Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.~Up to 6 cycles of treatment allowed"
2486143|NCT02995018|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3193780|NCT00821249|Experimental|ARRY-520 + G-CSF support|
2486208|NCT02994355|Experimental|Intervention Clinics|Clinics randomized to the intervention will be introduced to the Systems Analysis and Improvement Approach (SAIA) to understand barriers to HIV testing in family planning clinics. Sequential process flow mapping will be used to highlight areas for improvement and then specific interventions will be implemented for the clinics with the goal of increasing HIV testing rates.
2486211|NCT02994355|No Intervention|Control Clinics|Clinics randomized to the control arm of the study will continue HIV testing as per usual procedures.
3193781|NCT00821249|Experimental|ARRY-520 + dexamethasone + G-CSF support|
2486519|NCT02992509|Other|Treatment|This pilot study group is a prospective observational study. It is not blinded and there is no control. This is a single arm study (treatment group) which will receive intravesical electrical stimulation with a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks.
3193782|NCT00821262|Experimental|sevoflurane|The study group will receive Sevoflurane for a 4-6 hours period (from anesthesia induction to transfer to ICU).
3193783|NCT00821262|Active Comparator|propofol|The control group will receive propofol for the same 4-6 hours period.
3193784|NCT00821275|Active Comparator|pregnancy expectation|The patients who desire for future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
3193785|NCT00821275|Active Comparator|No pregnancy expectation|The patients who don't desire for reserving uterus and/ or future pregnancy will enroll into this arm , and will be divided into UAE group and SURGERY group.
3193786|NCT00821288|Experimental|Survivorship Intervention|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention
3193787|NCT00821288|Active Comparator|Facing Forward|Latina and Caucasian breast cancer survivors treated in an urban academic medical center receiving Survivorship Intervention Facing Forward: Life after Cancer Treatment manual
2485716|NCT02998255|Experimental|Single dose of 2L PEG|2 L of PEG solution was used on the day of colonoscopy.
2485717|NCT02998255|Active Comparator|Split-dose of 4L PEG|Split-dose of 4l PEG was used before and on the day of colonoscopy
2485750|NCT02997891||intervention group|Patients with primary, unilateral hip osteoarthritis in inpatient orthopedic acute treatment, who have a medical indication of a necessary artificial hip replacement implantation.
2485751|NCT02997891||control group|Volunteers without chronic pain. As a control condition for comparing the variation in cognitive performance and everyday activity the investigators use a group of pain-free and mobility-unrestricted subjects, who do not receive or have an artificial hip.
2485772|NCT02997657|Experimental|Positive Psychotherapy for Smoking Cessation|Smoking cessation treatment that incorporates exercises and text messages derived from positive psychology interventions that are designed to boost positive moods, cognitions, and behaviors.
2485776|NCT02997657|Active Comparator|Standard smoking cessation treatment|Smoking cessation counseling that provides support and problem solving skills for avoiding smoking.
2485832|NCT02997371|Placebo Comparator|Placebo|Isotonic saline administered as an injection and infusion
2485835|NCT02997371|Experimental|1.5 g Kineret|Kineret provided as a 500 mg injection followed by a 1g infusion.
2485837|NCT02997371|Experimental|3.0 g Kineret|Kineret provided as a 500 mg injection followed by a 2.5g infusion.
2485907|NCT02996838|Experimental|TQ-B3234|TQ-B3234 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3193788|NCT00821340|Experimental|rAAV2-hRPE65|
3193789|NCT00821353|Active Comparator|RFCA|
3193790|NCT00821353|Active Comparator|Drug|
2486222|NCT02994641||Adverse discharge disposition|Patients who were discharged to a skilled nursing facility or died in the hospital
2486226|NCT02994641||No adverse discharge disposition|Patients who were not discharged to a skilled nursing facility or did not die in the hospital
3160397|NCT00423280|Active Comparator|2|400mg/day 6R-BH4
3160398|NCT00423280|Placebo Comparator|3|Placebo
2486360|NCT02993367|Experimental|the Butylphthalide Soft Capsules group|600mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
2486365|NCT02993367|Placebo Comparator|the placebo group|60mg Butylphthalide Soft Capsules/day,po tid,period of 6 months
2486428|NCT02993133|Experimental|60 patients will be used to build and validate the system|The first 30 patients will be used to build and validate the pharmacokinetic modeling of MPA in pemphigus.The 30 patients included later will provide additional data.
2486450|NCT02992873|Experimental|Layperson allocated to fetch an AED and start CPR|In the intervention group mobile lifesavers will be directed to fetch the nearest AED and then attach it to the victim of OHCA. At least 1 volunteer will be directed to start CPR only
2486451|NCT02992873|Active Comparator|Layperson allocated to start CPR|In the control group all mobile lifesavers will be directed to the patient to start CPR.
2486556|NCT02992275|Experimental|NMES + MMBI|Neuromuscular electrical stimulation applied to hip abductors along with participation in a multi-modality balance intervention
2486627|NCT02991833|Experimental|Of A New Incontinence Care Product|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product ( the novel incontinent care product) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
2486638|NCT02991833|Active Comparator|Diaper|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 days. The visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. To evaluate skin integrity, the perineal skin of the patients was observed every day by researcher and was recorded to the Perineal Skin Integrity Assesment Form. The number of defecation, stool consistency, and the number of care product (diaper ) was observed daily and was recorded to the Patient Observation Form. The main study outcomes was IAD.
2486717|NCT02991105||Solid organ transplant recipients|National cohort = 85,410 solid organ transplant recipients receiving their transplant between January 1st 1985 to December 31st 2015
2486766|NCT02990832|Experimental|Exciton|Treatment of diabetic foot ulcer with Exciton Exsalt wound dressing
2486918|NCT02990013|Experimental|Treatment arm|All patients will be in the treatment arm where they will be subject to skin testing with various cleansing agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
2486978|NCT02989428|Experimental|Early parathyroidectomy group|Parathyroidectomy (surgery), is performed as soon as possible in the experimental group after randomization.
2486979|NCT02989428|No Intervention|Late parathyroidectomy group|Parathyroidectomy (surgery), is performed three months after study inclusion.
2487047|NCT02989064|Experimental|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
2487113|NCT02988674||Participants with Spondylarthritis|Participants with Spondylarthritis (ankylosing spondylitis and psoriatic arthritis) treated with adalimumab in routine clinical settings in the Russian Federation.
2487212|NCT02987881|Experimental|Adult women with early stage localized endometrial cancer|Adult women with early stage localized endometrial cancer at least 2 months following hysterectomy
2487263|NCT02987465||Chronic Kidney Disease patients|Up to 12 patients with anaemia associated with CKD.
2515715|NCT02791997|Experimental|Control participants|
3160399|NCT00423306|Experimental|Single Arm|
3160400|NCT00423371|Experimental|EUFLEXXA™|
3160401|NCT00423371|Placebo Comparator|Placebo|
3160402|NCT00423384|Experimental|1|Ibandronate
3160403|NCT00423384|Placebo Comparator|2|
3160404|NCT00423410|Experimental|EPC2407 (crinobulin)|
2485719|NCT02998203|No Intervention|Conventional phase|During the conventional phase, participants are asked to maintain their usual dietary choices for 40 days.
2485720|NCT02998203|Experimental|Organic phase|During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
2485783|NCT02997826|Other|1 to 21-days old child|
2485818|NCT02997501|Experimental|AZD9291|Single arm of AZD9291, starting dose of 80mg
2485957|NCT02996526||Intact Vocal Cord Mobility|Patients with normal laryngeal function post thoracic surgery
2485958|NCT02996526||Vocal Cord Dysfunction|Patients with abnormal vocal cord movement of 1 or both vocal cords post thoracic surgery
2486021|NCT02996240|Experimental|Omega-3 FFA|Patients will take 12 capsules daily with meals, divided twice daily (example, 6 with breakfast and 6 with dinner).
2486059|NCT02995798||Group A|T-score ≥-1
2486062|NCT02995798||Group B|-2.5<T-score<-1.0
2486064|NCT02995798||Group C|T-score≤-2.5
2486116|NCT02995473|Experimental|NP000888|Pharmaceutical form: Ointment
2486117|NCT02995473|Placebo Comparator|Vehicle|Pharmaceutical form: Ointment
2486150|NCT02994953|Experimental|Avelumab and M9241|
2486151|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (MTD)|
2486152|NCT02994953|Experimental|Avelumab (once weekly) + M9241 (RP2D) (Expansion cohort)|
2486438|NCT02992990|Other|Bladder tumor biopsy|All subjects will undergo a bladder tumor biopsy followed by transurethral resection.
3160405|NCT00423475|Active Comparator|I|Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
3160406|NCT00423475|Experimental|II|Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
3160407|NCT00423501|Experimental|1|
3160408|NCT00423501|Experimental|2|
3160409|NCT00423501|Experimental|3|
2486757|NCT02990689|Active Comparator|809M|bifocal intraocular lens (IOL)
2486758|NCT02990689|Active Comparator|839MP|trifocal intraocular lens (IOL)
2486759|NCT02990689|Active Comparator|SN6AD1|bifocal intraocular lens (IOL)
2486845|NCT02990585|Active Comparator|One individual back school session|The 1 individual session will consist of a 60 min 1-on-1 education/exercise session with an athletic trainer. Information will be an abbreviated version of the 8-session school and fill focus on the strengthening, stretching, pain control and movement re-education most needed for the individual.
2486846|NCT02990585|Active Comparator|8 group session of back school|All sessions last 45-60 minutes. There will be up to 8 participants in each session which will be led by an athletic trainer or rehabilitation trainer. Pain management, prevention strategies, and active treatment will be covered in the 8 sessions. Active treatment includes strengthening, stretching, pain control, movement re-education, and walking.
3160410|NCT00423501|Experimental|4|
3160411|NCT00423501|Experimental|5|
3160412|NCT00423501|Placebo Comparator|6|
3160413|NCT00423514|Experimental|cytoreduction regimen & stem cell transplant|This is a single arm phase I/II clinical trial to assess efficacy (the antileukemic potential and relapse rate), and safety (peri-transplant morbidity and mortality) of a novel cytoreduction regimen in preparation for allogeneic hematopoietic stem cell transplantation (HSCT).
3160414|NCT00423618|Active Comparator|Control arm|Radiotherapy Conventional treatment arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The first 50 Gy in 25 fractions will be given to CTV1 and subsequent 16 Gy in 8 fractions will be delivered to CTV2.
3160415|NCT00423618|Experimental|Research arm|Radiotherapy Research arm A total of 33 fractions each of 2Gy should be given once a day for 5 days per week over 6 weeks and 3 days in week 7, totalling 66Gy. The 66Gy in 33 fractions will be delivered to CTV2 alone. No attempt will be made to include drain/biopsy sites or the surgical scar.
3160416|NCT00423631|Experimental|Standard Care and Web|Standard care plus a web site based on cognitive behavioral principals.
3160417|NCT00423631|Active Comparator|Standard Care|Subject recieve standard care from their primary care provider.
3160418|NCT00423644|Experimental|Single Arm|
3160419|NCT00423696|Experimental|bevacizumab + FOLFIRI|
3160420|NCT00423696|Experimental|bevacizumab + XELIRI|
3160421|NCT00423787|Experimental|Ragweed MATA MPL|modified Ragweed pollen allergen absorbed to Tyrosine and containing MPL adjuvant
3160422|NCT00423787|Placebo Comparator|Placebo|4 injections of placebo 0.5 ml (2% tyrosine)
3160423|NCT00423865|Experimental|cisplatin & RAD001|This will be a single institution phase I study of low dose weekly cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15) plus escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle) for patients with advanced solid tumors
3160424|NCT00423956|Sham Comparator|Sham Comparator|One side is experimental and the opposite side is Sham control.
2485789|NCT02997787||leiomyoma|Second group called leiomyoma was consisted of patients who were pathologically diagnosed pure leiomyoma after hysterectomy
2485793|NCT02997787||control|Third group called control group was consisted of healthy patients who were pathologically diagnosed no neoplasm after hysterectomy
2485849|NCT02997397||tourniquet (+)|The cases in which the tourniquet technique is used
2485850|NCT02997397||tourniquet(-)|The cases in which the tourniquet technique is not used
2485973|NCT02996318|Experimental|Sirolimus coated Balloon|treatment of coronary DES-ISR with a sirolimus coated balloon
2485976|NCT02996318|Active Comparator|Paclitaxel coated balloon (SeQuent Please)|treatment of coronary DES-ISR with a paclitaxel coated balloon
2486053|NCT02995772|Active Comparator|Neoadjuvant hormonal therapy|Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen
2486055|NCT02995772|Active Comparator|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy: FAC 6 cycles
2486122|NCT02995356||Doubt for ectopic pregnancy group|This group participants have doubt for ectopic pregnancy in terms of beta-HCG pregnancy follow-up results and ultrasonography results.
2486123|NCT02995356||Normal intrauterine pregnancy group|This groups participants have normal intrauterine pregnancy
2486163|NCT02994901||Group 1|Geriatric patient with Sarcopenia
2486165|NCT02994901||Group 2|Geriatric Patient without Sarcopenia
2486169|NCT02994901||Group 3|healthy control group
2486232|NCT02994628|Active Comparator|Water|Intervention, water and no banana carbohydrate: consume 3 ml/kg water every 15 min during 75 km cycling
2486234|NCT02994628|Experimental|Mini banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Mini banana with 3 ml/kg water every 15 minutes during 75 km cycling
2486235|NCT02994628|Experimental|Cavendish banana|Intervention, banana carbohydrate: ingest 0.2 g carbohydrate/kg body weight from Cavendish banana with 3 ml/kg water every 15 minutes during 75 km cycling
2486236|NCT02994628|Experimental|6% sugar beverage|Intervention: pure banana carbohydrate in sugar beverage; ingest 0.2 g carbohydrate/kg body weight from a 6% sugar beverage every 15 minutes during 75 km cycling (contains 60 grams sugar per liter using the same sugar profile found in Cavendish bananas)
2486277|NCT02993965|No Intervention|Control 11-17|No additional intervention done aside from usual care for 11-17 year olds
2486282|NCT02993965|Experimental|1 R/R per Dose 11-17|Sending up to one recall notice per dose of HPV vaccine needed for 11-17 year olds
2486283|NCT02993965|Experimental|2 R/R per Dose 11-17|Sending up to two recall notices per dose of HPV vaccine needed for 11-17 year olds
2486286|NCT02993965|Experimental|3 R/R per Dose 11-17|Sending up to three recall notices per dose of HPV vaccine needed for 11-17 year olds
2486287|NCT02993965|No Intervention|Control 11-14|No additional intervention done aside from usual care for 11-14 year olds
2486291|NCT02993965|Experimental|Phone R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via autodialer for 11-14 year olds
2486292|NCT02993965|Experimental|Mail R/R 11-14|Sending up to two recall notices per dose of HPV vaccine needed via mailed postcards for 11-14 year olds
3160425|NCT00423982|Active Comparator|Rifampicin-combination therapy|Cloxacillin or vancomycin in combination with Rifampicin. Treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
3160426|NCT00423982|Active Comparator|Monotherapy|Cloxacillin or vancomycin in the treatment of early staphylococcal prosthetic joint infections in addition to debridement and retention of the prosthesis.
2486690|NCT02991170|Active Comparator|control group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
2486693|NCT02991170|Experimental|interventional group|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
2486849|NCT02990468|Experimental|Radiation Therapy, Cisplatin and BMX-001|In Phase 1, safety and tolerability of BMX-001 will be assessed using a Continual Reassessment Method and a maximum tolerated dose (MTD) will be determined using a single arm design. In Phase 2, the severity of radiation-induced mucositis and xerostomia will be assessed using a single arm design.
2486898|NCT02989974|Experimental|KY LEADS Survivorship Care - Survivor|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to individuals diagnosed with lung cancer (survivor).
2486900|NCT02989974|Experimental|KY LEADS Survivorship Care - Caregiver|The KY LEADS Survivorship Care condition involves providing a targeted and tailored psychosocial support intervention to caregivers of individuals diagnosed with lung cancer (caregiver)
2486988|NCT02989285||HIV+ cognitively impaired (HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
3160431|NCT00424125|Experimental|Enhanced Pharmacy Care|Received enhanced community pharmacy based services.
2485805|NCT02997579|No Intervention|patellar non-resurfacing|patellar non-resurfacing TKA
2485846|NCT02997319||Night Shift-Workers|
2485848|NCT02997319||Day Workers|
2485851|NCT02997007|Experimental|MCI-active|Patients will receive verum tDCS over the angular gyrus on five consecutive days.
2485853|NCT02997007|Sham Comparator|MCI-sham|Patients will receive sham tDCS over the angular gyrus on five consecutive days.
2485855|NCT02997007|Experimental|Healthy Old-active|Participants will receive verum tDCS over the angular gyrus on five consecutive days.
2485856|NCT02997007|Sham Comparator|Healthy old-sham|Participants will receive sham tDCS over the angular gyrus on five consecutive days.
2485946|NCT02996773|Experimental|Cyclophosphamide and Bendamustine|"Experimental: Cyclophosphamide and Bendamustine Control: Cyclophosphamide~Interventions:~Drug: Bendamustine~Drug: Cyclophosphamide"
2485994|NCT02996292|Experimental|Traditional brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using traditional brackets; American Orthodontics Master® MBT 0.022 Brackets"
2485996|NCT02996292|Experimental|Active self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using active self-ligating brackets; American orthodontics active self-ligating Empower® MBT 0.022"
2485998|NCT02996292|Experimental|Passive self-ligating brackets|"Fixed orthodontic appliances will be applied for aligning and leveling of teeth up to 19*25 stainless steel wires using passive self-ligating brackets; American orthodontics passive self-ligating Empower® MBT 0.022"
2486014|NCT02995993|Experimental|Moss-aGal|Single administration of 0.2 mg/kg recombinant human alpha-galactosidase A produced in moss (moss-aGal) as intravenous infusion
3160432|NCT00424138|Experimental|Group A - 3 FDG-PET/CT Scans|Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
3160433|NCT00424138|Experimental|Group B - 2 FDG-PET/CT + 1 Optional|One FDG-PET/CT prior to 1st cycle of chemotherapy; 1 FDG-PET/CT after the 1st cycle of chemotherapy; 1 optional FDG-PET/CT after the 2nd cycle of chemotherapy. All three with optional volumetric CT scans.
2486105|NCT02995395||Mucosal Impedance Balloon catheter|At the conclusion of the endoscopy, all fluids will be aspirated from the esophagus. The endoscope will then be left in place in the mid-esophagus and a custom Mucosal Impedance (MI) balloon assembly four axial arrays of 10 sensors (total of 40 sensors) will be positioned along the esophageal mucosal wall under direct visualization to directly measure MI at uniform intervals. Once in place, impedance readings will be recorded for a total of 2 minutes. At this point both the endoscope and impedance catheter will be withdrawn simultaneously.
2486139|NCT02995135|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486269|NCT02994771|Active Comparator|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
2486276|NCT02994771|Active Comparator|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
2486345|NCT02993640|Experimental|vasopressin + nitro|vasopressin + nitroglycerin in simultaneous infusion
2486400|NCT02993263|Other|Noncardiac surgery|VectraplexECG System with CEB® will be recorded after surgery and on day 1, 2 and 3 post operatively
2486442|NCT02992964|Experimental|Nivolumab|"Regimen: Nivolumab will be administered every 14 days until disease progression or treatment discontinuation due to unacceptable toxicities. Treatment may extend up to 2 years in patients who show clinical and radiological benefit.~Dose: 3 mg/kg intravenously as a continuous infusion over 60 min (+/-10 min window)"
2486468|NCT02992678|Experimental|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
2486469|NCT02992678|Placebo Comparator|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
2486486|NCT02992483|Experimental|MIK665|
2486538|NCT02992340|Experimental|Phase 1B|Varlitinib (starting dose at 200 mg BID) Cisplatin Gemcitabine
2486571|NCT02991976|Active Comparator|35% O2|Patient receiving 35% O2 during carotid endarterectomy, Intervention - oxygen concentration
2486580|NCT02991976|Active Comparator|100% O2|Patient receiving 100% O2 during carotid endarterectomy, Intervention - oxygen concentration
2486642|NCT02991703|Active Comparator|SphygmoCor®|
2486648|NCT02991703|Experimental|pOpmètre®|
2486691|NCT02991378|Experimental|Intervention group|"Subjects in this group will receive the Children's emotional and stress coping program which train the children the emotional self-regulation skills and stress coping skill with a standardized protocol."
2486696|NCT02991378|No Intervention|Control group|"Subjects in this group will not receive the Children's emotional and stress coping program."
2486737|NCT02991014|Active Comparator|researcher-selected frequency-modulated music|
2486739|NCT02991014|Placebo Comparator|researcher-selected non-modulated music|
2486741|NCT02991014|Experimental|participant-selected non-modulated music|
2486793|NCT02990676|Experimental|Computerised cognitive training group|Participants will be asked to complete the training programme provided using HAPPYneuron software for a minimum of 30 minutes 3 times a week for 12 weeks. The intervention will be completed in participant homes with the help of email or telephone reminders, as preferred.
2486798|NCT02990676|No Intervention|Control group|Asked to continue as normal
2486947|NCT02989688|Active Comparator|standard drink|Dietary Supplement - 125 ml Fortisip compact (Nutricia)
3160434|NCT00424138|Experimental|Group C - Test-Retest|Test-retest sequence for FDG-PET/CT; two scans with optional volumetric CT to be completed prior to 1st cycle of chemotherapy.
3160435|NCT00424164|Experimental|Tamoxifen-lapatinib|Tamoxifen alone at cycle 1 and as of cycle 2 in combination with Lapatinib.
3160436|NCT00424164|Experimental|Lapatinib-tamoxifen|Lapatinib will be given alone for 2 weeks during cycle 1. As of cycle 2, you will receive the combined treatment Lapatinib and Tamoxifen
3160437|NCT00424203|Experimental|Myocet, Endoxan|
3160438|NCT00424242|Experimental|Escalating doses of Pemetrexed|Escalating doses of Pemetrexed beginning at 500 mg/m2
2485806|NCT02997618|Active Comparator|Control|"1. Usual care (control)~Usual care given to patients on AAA surveillance. This includes six-monthly or annual ultrasound measurements of AAA, attendance to surveillance clinic and written (APPENDIX A) and verbal advice on managing cardiovascular risk. This advice will be based on current widely available NHS patient information15 and consists of the following information with regard to:~Smoking Exercise Weight Diet"
2485807|NCT02997618|Experimental|Community Based Exercise Programme|"Community based-exercise (in addition to usual care) with the choice of either:~Home-based exercise training Participants choosing to exercise at home will follow the programmes intended for this setting, with each exercise designed to be possible without the need for specialist equipment.~Gym-based exercise training Participants will exercise at their nearest Life Leisure LTD gym, following one of the instructor designed programmes , using a combination of aerobic and resistance equipment, as well as simple floor exercises.~Duration and Frequency At least 50 minutes of exercise per day on three non-consecutive days of the week for 20 weeks."
2485830|NCT02997293||Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences after Enhanced Recovery After Surgery implementation, between the dates of June 1, 2015 to November 30, 2016
2485831|NCT02997293||pre-Enhanced Recovery|Those subjects who had major colorectal surgery at the University of Arkansas for Medical Sciences prior to Enhanced Recovery After Surgery implementation between the dates of January 1, 2014 to December 31, 2014
3193791|NCT00821366|Active Comparator|1|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment only group
3193792|NCT00821366|Active Comparator|2|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment and ARV peer adherence support group
2485972|NCT02996396||1|Patients diagnosed with AAA who are considered candidates for Endovascular Repair and meet the study eligibility criteria and sign the Informed consent may be subsequently enrolled in the study.
2486032|NCT02996110|Active Comparator|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab
2486033|NCT02996110|Experimental|Nivolumab + Relatlimab|Nivolumab + Relatlimab
2486036|NCT02996110|Experimental|Nivolumab + BMS-986205|Nivolumab + BMS-986205
2486039|NCT02996110|Experimental|Nivolumab + BMS-813160|Nivolumab + BMS-813160 (CCR2/5 dual antagonist)
2486145|NCT02995031|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486188|NCT02994693||OFDI capsule imaging|Subject will swallow the OFDI capsule and imaging will be acquired using the OFDI imaging system.
2486223|NCT02994433|Experimental|Nitrous Oxide|One hour inhalation of nitrous oxide
2486227|NCT02994433|Placebo Comparator|Placebo Gas|One hour inhalation of placebo gas
2486258|NCT02994017|Other|cystic fibrosis patients|
2486312|NCT02993835|Active Comparator|Labeled iron salt (Fe54)|Labeled iron salt (Fe54) with bouillon
2486313|NCT02993835|Active Comparator|Labeled iron salt (Fe57)|Labeled iron salt (Fe57) with bouillon
2486315|NCT02993835|Experimental|Labeled iron salt (Fe58)|Labeled iron salt (Fe58) with bouillon
2486358|NCT02993484|Experimental|non-diabetic Sham control|Heart tissue obtained from non-diabetic patients undergoing surgery will not receive drugs or ischemia
2486361|NCT02993484|Experimental|non-diabetic Ischemia reperfusion|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive ischemia
2486372|NCT02993484|Experimental|non-diabetic Ischemic preconditioning|Heart tissue from non-diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
2486379|NCT02993484|Experimental|non-diabetic Dimethyl malonate|Heart tissue from non-diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
2486384|NCT02993484|Experimental|Diabetic Sham control|Heart tissue obtained from diabetic patients undergoing surgery will not receive drugs or ischemia
2486387|NCT02993484|Experimental|Diabetic Ischemia reperfusion|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive ischemia
2486388|NCT02993484|Experimental|Diabetic Ischemic preconditioning|Heart tissue from diabetic patients undergoing surgery will not receive drugs but will receive short periods of ischemia prior to index ischemia
2486389|NCT02993484|Experimental|Diabetic Dimethyl malonate|Heart tissue from diabetic patients undergoing surgery will receive a drug (Dimethyl Malonate) prior to index ischemia
2486425|NCT02993016|Experimental|patient-specific instruments group|procedure: PSI (patient-specific instruments) will be used as the cutting guide in total knee arthroplasty.
2486427|NCT02993016|Active Comparator|conventional instruments group|procedure: Conventional instruments will be used as the cutting guide in total knee arthroplasty.
2486568|NCT02992210|Experimental|effectiveness of 4SCAR-GD2 T cells|The 4SCAR-GD2-modified T cells can recognize and kill tumor cells through the recognize of GD2 .This study will evaluate the side effects and effective doses of 4SCAR-GD2 T cells in treating refractory and recurrent solid tumors
2486636|NCT02991716||Recorded patients|Patients requiring Intracradiac Defibrillator (ICD) implantation, Electrophysiology (EP) study or a holter monitor recording, mainly due to suspected ventricular tachy - arrhythmias
2486763|NCT02990715|Active Comparator|Up to 45 subjects|Subjects with known polyp lesions≥10mm which were not removed because of poor preperation or the need to perform polypectomy at hospital will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
2486771|NCT02990715|Experimental|Up to 25 subjects|Subjects who were reffered to screening colonoscopy as an average risk for CRC will ingest the C-Scan cap and then will be schduled to polypectomy. The subjects will perform FIT test during the procedure and it will be compared with C-Scan System results.
2486893|NCT02989870|Experimental|SBRT, Sorafenib and Bavituximab|This will be a 3+3 design with 3 dose cohorts. Following the dose escalation phase, an additional 6 patients will be enrolled as part of the dose expansion cohort.
2485810|NCT02997605|Active Comparator|Glucocorticoid (GC) tapering|"GC tapering group: patients will be asked to taper prednisone taken every morning at 8.00 AM by decreasing the daily dose by 1 mg every month as soon as they are in remission or Low Disease Activity (LDA). In addition they will receive a placebo of 20 mg/day of hydrocortisone (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg/day (at 8.00 AM) of hydrocortisone placebo for 3 months before discontinuing the hydrocortisone placebo."
2485814|NCT02997605|Active Comparator|Hydrocortisone replacer|"Hydrocortisone replacer group: patients will replace prednisone with 20 mg of hydrocortisone on a daily basis (10 mg at 8.00 AM, 10 mg at 12.00 AM) for 3 months then 10 mg daily (at 8.00 AM) for 3 months then stop as soon as they are in remission or LDA, as well as a prednisone placebo (at 8.00 AM) with a schedule to taper the prednisone placebo by 1mg/day every month until discontinuation."
2485894|NCT02996890|Experimental|High dose - single shot|MV-ZIKA, high dose, one vaccination, day 0
2485896|NCT02996890|Experimental|Low dose|MV-ZIKA, low dose, two vaccinations, day 0 and day 28
2485898|NCT02996890|Experimental|High dose|MV-ZIKA, high dose, two vaccinations, day 0 and day 28
2485899|NCT02996890|Placebo Comparator|Placebo|Physiological saline, two treatments
2485959|NCT02996513|Experimental|Retinol Isotope dilution (RID)|A once-off dose of 0.4 mg 13C4-retinyl acetate will be administered to subjects as a capsule
2486019|NCT02996214|Experimental|LP group|Liposome paclitaxel(Lipusu®) plus cisplatin. Paclitaxel liposome Sterile injection powder 175 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
2486025|NCT02996214|Active Comparator|GP group|Gemcitabine (Gemzar®) plus cisplatin. Gemcitabine hydrochloride for injection 1000 mg/m^2, given on days 1 and 8 of a 21-day cycle, for 4-6 cycles. Cisplatin 75 mg/m^2, given on day 1 of a 21-day cycle, for 4-6 cycles.
2486075|NCT02995681|Experimental|Pulmonary rehab and balance training|The intervention group will receive standard pulmonary rehab plus additional balance training.
2486079|NCT02995681|Active Comparator|Pulmonary rehab|The control group will receive pulmonary rehab only and a pulmonary rehab home program (walking and lower extremity resistance exercises) upon discharge from pulmonary. They will also receive the same monthly phone calls and three home visits at three, six and nine months to ensure proper technique and progression.
2486119|NCT02995265|Experimental|Exoskeleton Program|Exoskeleton-based walking rehabilitation until discharge (or to a maximum of 8 weeks), 3 - 5 days a week for 30-60 minutes per session. Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke. The exoskeleton will allow standing and walking with full weight bearing from the first sessions in rehabilitation.
2486120|NCT02995265|Active Comparator|Usual Care Program|Standard physiotherapy stroke rehabilitation which includes training for regaining walking as well as other functional tasks, 3 - 5 days a week for 30-60 minutes per session until discharge (or to a maximum of 8 weeks). Participants will be assessed upon admission to the study, discharge, as well as at 6 months post-stroke.
2486162|NCT02994966|Experimental|Surrosense|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear as well as wear SurroSense Rx® in-shoe pressure-sensing arrays, which provide visual and auditory/vibratory feedback alerts (relating to high plantar pressures) and offloading guidance to a watch display intended to assist in the recurrence of diabetic foot ulcers. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
2486166|NCT02994966|Active Comparator|Standard care|Subjects randomized to this group will receive standard care, including appropriate off-loading and footwear. They will also be advised to perform daily self-checks of their feet for redness, callous and wounds. A daily checklist will be provided to participants to evaluate compliance.
2486279|NCT02994498|Experimental|DCB-BO1301 1 capsule|DCB-BO1301 1 capsule, tid (around 1 hour before meal) for at most 48 weeks
2486285|NCT02994498|Experimental|DCB-BO1301 2 capsules|DCB-BO1301 2 capsules, tid (around 1 hour before meal) for at most 48 weeks
2486289|NCT02994498|Experimental|DCB-BO1301 3 capsules|DCB-BO1301 3 capsules, tid (around 1 hour before meal) for at most 48 weeks
2486326|NCT02993679|Other|double-bundle ACL reconstruction|surgical reconstruction of the anterior cruciate ligament
2486327|NCT02993679|Other|anterolateral ligament reconstruction|surgical reconstruction of the anterolateral ligament
3193793|NCT00821366|Active Comparator|3|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme - ARV treatment, ARV peer adherence support and nutritional support group
3193794|NCT00821366|No Intervention|4|Randomly selected households from the general community served by the selected health facility, excluding households where someone is known to receive ARV treatment - comparison/control group
2486440|NCT02992977|Experimental|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
2486471|NCT02992730||Women Diagnosed with Breast Cancer|Observational - Usual Care
2486487|NCT02992431|Active Comparator|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
2486489|NCT02992431|Experimental|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
2486764|NCT02990949|No Intervention|Control group|
3193795|NCT00821392|Active Comparator|1 Febuxostat 40mg|
3193796|NCT00821392|Active Comparator|2 Febuxostat 80mg|
3193797|NCT00821392|Active Comparator|3 Febuxostat 120mg|
3193798|NCT00821392|Sham Comparator|4 Allopurinol 300mg|
3193799|NCT00821392|Placebo Comparator|5 Placebo|
3193800|NCT00821405||peritoneal dialysis|peritoneal dialysis patient lasting for more than 3 months
3193801|NCT00821418|Experimental|PulsHaler first|
3193802|NCT00821418|Placebo Comparator|Placebo first|
3193803|NCT00821444|Active Comparator|Geodon fed|Commercial Geodon (ziprasidone) capsules given with food
3193804|NCT00821444|Experimental|B16 Fasted|Experimental reduced food effect formulation given without food
3193805|NCT00821444|Experimental|B16 Fed|Experimental reduced food effect formulation given with food
2485863|NCT02997098||Patients undergoing hepatectomy|Patients undergoing hepatectomy, or liver resection, for a non-transplant indication.
2485941|NCT02996799|No Intervention|Deferred Cord Clamping|Neonate is held at the level of placenta (level of introitus (vaginal delivery ) and mother's thigh or operating table (C/S) and cord clamping is deferred for 60 seconds.
2485944|NCT02996799|Experimental|Umbilical cord milking|Manually stripping 20cm of cord segment toward the umbilicus over a period of 2-3 seconds three times before cord clamping.
2485974|NCT02996357||Cases|Patients with IAD Category 2 (red skin with skin breakdown)
2485977|NCT02996357||Controls|Patients with IAD Cat. 0 (at risk, no redness and skin intact)
2486050|NCT02995850|Experimental|anti-cancer drug|
2486082|NCT02995551|Experimental|Arthroscopy|Arthroscopic meniscal repair or resection will be conducted at the discretion of the operating surgeon (this cannot be determined before the surgeon has visual confirmation about the exact knee pathology and extend of the meniscal tear by scope).
2486083|NCT02995551|Active Comparator|Exercise and Education|Patients allocated to exercise therapy and education will participate in a 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear. Furthermore, they will participate in a patient education program developed through interviews with pilot study participants, from our experiences from the Good Life with osteoArthritis in Denmark (GLA:D) program for patients with knee and hip pain. Both the exercise and education will take place in a number of private physiotherapy clinics associated with the GLA:D program, specifically trained to supervise and lead the treatment in this study.
2486146|NCT02995252||Group 1: Hepatitis C infection|Participants with chronic hepatitis C infection; includes both hepatitis C mono infected and hepatitis C-HIV coinfected. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. No drugs will be given to this group.
2486148|NCT02995252||Group 2: Hepatitis B infection|"Participants with chronic hepatitis B: includes patients with hepatitis B with and without hepatitis C and/or HIV. Participants will attend study visits for research blood draws (once a year with optional additional visits), and a one-time optional knowledge questionnaire. Participants who are already taking hepatitis B treatment are eligible.~Hepatitis B treatment sub-study: In this treatment sub-study, participants with hepatitis B monoinfection will receive tenofovir alafenamide (TAF) pill once a day for 2 years with study visits every 3 months. Liver transient elastography will be reviewed or obtained. In addition, approximately 40 participants will be invited to undergo optional liver biopsies at the start, end of year 1 and end of year 2 of the sub-study."
2486191|NCT02994680|Experimental|Intervention arm|"Will receive:~Three-burner LPG stove (at enrollment)~Delivery of LPG tanks (beginning at enrollment for one year)~The study will be conducted over three years, with staggered enrollment over one year, one year of observations during the intervention period, and one year of follow-up observations after the intervention period for each participant.~Participants in the intervention arm will receive an LPG stove upon enrollment and the research team will deliver fuel twice monthly to their homes during the first year. Participants in the intervention arm will not receive fuel during the second year, but researchers will encourage these participants to continue using LPG fuel for cooking."
2486192|NCT02994680|Active Comparator|Control arm|"Will receive:~Three-burner LPG stove (one year after enrollment)~Vouchers for LPG tanks (one year after enrollment)~Participants in the control arm but will not receive an LPG stove or fuel during the first year. Instead, participants will receive an LPG stove at the end of the first year and vouchers to obtain free fuel at distribution centers during the course of the second year."
2486196|NCT02994368||Primary Cohort|No intervention
2486197|NCT02994368||Expansion Cohort|No intervention
2486224|NCT02994290|Experimental|receive inpatient HPV vaccine|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
2486230|NCT02994290|Experimental|decline the inpatient dose|We will select a purposive sample of postpartum women into two groups: those who receive inpatient HPV vaccine and those who decline the inpatient dose to interview until we reach thematic saturation which we anticipate to occur with about 8-10 individuals per group. Patients will be selected to include diverse representation in age, race, ethnicity, and parity.
2486316|NCT02993848||Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
2486317|NCT02993848||Non-Operative Scapula Fracture|No intervention. Inclusion criteria and data collection is the same for both cohort.
3193806|NCT00821457|Active Comparator|Group 1|250ng Juvista vs placebo
3193807|NCT00821457|Active Comparator|Group 2|500 ng Juvista vs placebo
2486472|NCT02992912|Experimental|Cohort 1: metastatic colorectal cancer|
2486473|NCT02992912|Experimental|Cohort 2: metastatic non-small lung cancer|
2486474|NCT02992912|Experimental|Cohort 3: metastatic renal cell carcinoma|
2486475|NCT02992912|Experimental|Cohort 4: metastatic sarcoma|
3193808|NCT00821470|Experimental|bone marrow graft group|core decompression + bone marrow implantation into the necrotic lesion
3193809|NCT00821470|Active Comparator|control|core decompression
2486795|NCT02990923|Experimental|Both Divices|In this group, patients will receive both High-Flow Needleless Valve and DualCap Disinfection Devices in hemodialysis
3193810|NCT00821483|Placebo Comparator|1: placebo|
3193811|NCT00821483|Active Comparator|2 Frovatriptan|
3193812|NCT00821496|Experimental|Oral Contraceptive|
3193813|NCT00821535|Other|Active group|maraviroc dosing group
3193814|NCT00821548|Experimental|1|Electrostimulation of the muscles of the scapular belt and the femoris quadristocks
3193815|NCT00821574|Experimental|1|Fluvastatin: daily 80 mg, oral
2485829|NCT02997553|Experimental|sentinel lymph node detection|"Each patient receive both injections of Technetium99 (standard care) and indocyanine green.~The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery."
2485945|NCT02996552|Experimental|M & T Repair Group|Both mitral and tricuspid valves repair
2485947|NCT02996552|Active Comparator|Mitral-Only Group|Only mitral valve repair
2486013|NCT02996266|Experimental|Fever Prevention|Fever will be prevented using a surface targeted temperature management system
2486017|NCT02996266|Active Comparator|Standard Care|Standard care in which fever may spontaneously develop
2486085|NCT02995486|No Intervention|Control|Standard care with only an educational pamphlet.
2486086|NCT02995486|Experimental|Intervention|Post-discharge exercise group
2486273|NCT02995317||Fall accidents|
2486311|NCT02993744||Case Group|75 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, threatening preterm delivery, application of Betamethasone
2486314|NCT02993744||Control Group|65 woman between the age of 18 to 50 years, week of gestation 23+0 - 34+6, no threatening preterm delivery
2486370|NCT02993523|Placebo Comparator|Placebo followed by Azacitidine|Matching Placebo for Venetoclax 400 mg orally QD on Days 1 - 28 plus Azacitidine 75 mg/m^2 SC or IV QD on Days 1 - 7 (28-day cycle)
2486373|NCT02993523|Active Comparator|Venetoclax followed by Azacitidine|Venetoclax 400 mg orally every day (QD) on Days 1 - 28 plus Azacitidine 75 mg/m^2 subcutaneously (SC) or intravenous (IV) QD on Cycle Days 1 - 7 (28-day cycle)
2486529|NCT02992379|Active Comparator|stabilizing splint|Active Comparator: stabilizing splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
2486531|NCT02992379|Experimental|pivot splint|"Experimental: pivot splint A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks.~Other Names: PS"
2486561|NCT02992041|Experimental|Lower dose VVZ-149 Injections|
2486564|NCT02992041|Experimental|Higher dose VVZ-149 Injections|
2486566|NCT02992041|Placebo Comparator|Placebo|
2486604|NCT02991742||Iodixanol|Iodixanol contrast media
2486607|NCT02991742||Ioxaglate|Ioxaglate contrast media
2486658|NCT02991521|Experimental|FAST examination after Right sided roll (FASTeR)|Subjects will have a standard FAST exam, and will then be rolled onto their right side and the FAST exam will be repeated.
3193816|NCT00821574|Experimental|2|Valsartan
3193817|NCT00821574|Experimental|3|Hydrochlorothiazide
2486851|NCT02990169|Active Comparator|Goldmann Tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
2486853|NCT02990169|Active Comparator|CATS tonometer|determine if the CATS tonometer prism effectively reduces sensitivity to IOP errors produced by corneal thickness and therefore provides a more accurate IOP reading compared to the reference tonometer (Goldmann prism), based upon the correction value table for Goldmann tonometer prism
2486912|NCT02989961|Experimental|A-Resticutis|Autologous, Activated-Platelets type of preparation.
2486913|NCT02989961|Placebo Comparator|C-Platelet-Poor Plasma PPP|Platelet-Poor Plasma type of preparation achieved by centrifugation of blood samples at high speed conditions. Resticutis is administered instead if the patient doesn't achieve full healing after 6 injections.
2486959|NCT02989519|No Intervention|no progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation
2486961|NCT02989519|Experimental|oral progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received oral progesterone (dydrogesterone 10 mg; Duphaston™) per oral three times a day
2486963|NCT02989519|Experimental|vaginal progesterone|All women with preterm labor underwent standard tocolysis, which was administered for at least 48 hours, to allow corticosteroid promote fetal lung maturation. All women in this arm received vaginal progesterone (micronized progesterone 200 mg; Utrogestan™) at bed time.
2486982|NCT02989220|Experimental|Intervention group|Will receive the PRCI in addition to the current recommended care pathway
2486983|NCT02989220|No Intervention|Control Group|Will follow the current recommended care pathway
2487051|NCT02988999|Experimental|D-allulose|D-allulose 5 gm 3 times a day
2487055|NCT02988999|Active Comparator|erythritol|erythritol 5 gm 3 times a day
2487099|NCT02988713|Experimental|Spinal cord stimulation|Spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
3193818|NCT00821600|Experimental|001|risperidone IR and LAI formulation 1 mg risperidone IR single injection followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
3193819|NCT00821652|Other|Dose-esclation|Part I represents a dose-escalation part with topical resiquimod in an open-label fashion.
2487311|NCT02987296|Active Comparator|Immunonutrition with arginine|Patients will receive the nutritional supplement for 5 days prior to surgery and for 5 days after. The drink will contain arginine.
2488014|NCT02982096|Active Comparator|Cellutome treatment|Cellutome Device: Use of Cellutome on burn wounds
2485936|NCT02996812|Active Comparator|Dose A|Subcutaneous injection of Dose A of Exendin (9-39)
2485938|NCT02996812|Active Comparator|Dose B|Subcutaneous injection of Dose B of Exendin (9-39)
2485939|NCT02996812|Active Comparator|Dose C|Subcutaneous injection of Dose C of Exendin (9-39)
2485943|NCT02996812|Active Comparator|Dose D|Subcutaneous injection of Dose D of Exendin (9-39)
2485979|NCT02996331|Active Comparator|2 hour arm|All participants in this arm are assigned a 2-hour repositioning interval.
2485983|NCT02996331|Experimental|3 hour arm|All participants in this arm are assigned a 3-hour repositioning interval.
2485985|NCT02996331|Experimental|4 hour arm|All participants in this arm are assigned a 4-hour repositioning interval.
2486024|NCT02996071|Active Comparator|low waist to height ratio|laparoscopic sleeve gastrectomy
2486026|NCT02996071|Active Comparator|high waist to height ratio|laparoscopic sleeve gastrectomy
2486081|NCT02995746|Experimental|0.7mg dexamethasone intravitreal implant|Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period
2486096|NCT02995369|Other|Dryshield Isolation (right)|Dryshield will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
2486097|NCT02995369|Other|Cotton Roll Isolation (right)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the right side of the mouth to place the sealants
2486098|NCT02995369|Other|Dryshield Isolation (left)|Dryshield will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
2486099|NCT02995369|Other|Cotton Roll Isolation (left)|Cotton rolls will be used to isolate the maxillary and mandibular teeth on the left side of the mouth to place the sealants
2486138|NCT02995109|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486159|NCT02994784|Experimental|Evomela|Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation
2486204|NCT02994563|Experimental|Open arm|Thrombectomy device to be used to retrieve clot and restore blood flow.
3160439|NCT00424450||PAD patients|30 PAD patients
3160440|NCT00424606|Experimental|1|
2486293|NCT02993913|Experimental|Simmiparib tablet monotherapy|Drug: Simmiparib tablet oral Qd or Bid
2486368|NCT02993627|Experimental|Spirulina|daily intake of spirulina tablets weight reduction diet therapy
2486380|NCT02993627|Placebo Comparator|placebo|daily intake of placebo tablets weight reduction diet therapy
2486406|NCT02993068|Experimental|Arm A (online education)|Patients watch genetic testing online educational video and receive genetic testing online test results report.
2486409|NCT02993068|Experimental|Arm B (online education, post telephone counseling)|Patients watch genetic testing online educational video, receive genetic testing online test results report, and post-telephone genetic counseling.
2486411|NCT02993068|Active Comparator|Arm C (online education, pre- and post-telephone counselling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, genetic testing online test results report, and post-telephone genetic counseling.
2486412|NCT02993068|Experimental|Arm D (online education, pre-telephone counseling)|Patients watch genetic testing online educational video, receive pre-telephone genetic counseling, and genetic testing online test results report.
3160441|NCT00424606|Experimental|2|
3160442|NCT00424710|Other|Single Arm study|"Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year"
3160443|NCT00424801|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment to lower blood pressure
3160444|NCT00424814|Experimental|1|Kaletra (lopinavir/ritonavir)
3160445|NCT00424814|Active Comparator|2|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
3160446|NCT00424853|Experimental|A|
3160447|NCT00424853|Experimental|B|
3160448|NCT00424866|Placebo Comparator|Placebo|The dosing groups correspond to total doses of 0 µg/kg of FGF-1.
3160449|NCT00424866|Active Comparator|Human FGF-1|The dosing groups correspond to total doses of either 3, 10 or 30 µg/kg of FGF-1.
3160450|NCT00424905|Experimental|1|Enterogermina® vials containing 2×109 spores of polyantibiotic resistant Bacillus clausii (test drug)
3160451|NCT00424905|No Intervention|2|No treatment (reference group)
3160452|NCT00424931|Experimental|001|JNJ-17216498 10mg one time
3160453|NCT00424931|Experimental|002|JNJ-17216498 50mg one time
3160454|NCT00424931|Active Comparator|003|Modafinil 200 mg X 2
3160455|NCT00424944|Experimental|I, GMZ2 vaccine arm|20 volunteers will receive GMZ2 vaccine on days 0, 28, and 56
3160456|NCT00424944|Active Comparator|II, Rabies vaccine arm|20 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
3160457|NCT00424970|Placebo Comparator|acetazolamide|acetazolamide 250mg /day oral administration, for 6 months
3160458|NCT00424983|Experimental|Zometa q 4 weeks|
3160459|NCT00424983|Active Comparator|Zometa q 12 weeks|
3160460|NCT00425074|Experimental|SR-ASA|slow release acetylsalicylic acid 150 mg
3160461|NCT00425074|Active Comparator|ASA|normal release acetylsalicylic acid
3160462|NCT00425191|Experimental|1|
3160463|NCT00425191|Experimental|2|
3160464|NCT00425191|Experimental|3|
3160465|NCT00425204|Experimental|Open Label|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
3160466|NCT00425295|Active Comparator|1|
3160467|NCT00425295|Experimental|2|
3160468|NCT00425321|Experimental|RWJ-445380 100 mg|
3160469|NCT00425321|Experimental|RWJ-445380 200 mg|
3160470|NCT00425321|Experimental|RWJ-445380 300 mg|
3160471|NCT00425321|Placebo Comparator|Placebo|
3160472|NCT00425334|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3160473|NCT00425334|Active Comparator|Control|Ringer's lactate
3160474|NCT00425451|Experimental|PerioChip Plus|
3160475|NCT00425451|Experimental|Flurbiprofen Chip|
3160476|NCT00425451|Active Comparator|PerioChip|
2486539|NCT02992301|Experimental|Open Label|All enrolled patients will receive open label Praluent (Alirocumab).
2486555|NCT02992015|Experimental|Gemcitabine|The entire therapy on this study is one dose of gemcitabine. No intrapatient dose modifications are necessary. Gemcitabine will be given at 2100 mg/m2 IV over 30 minutes within 4 hours of planned surgical procedure.
2486998|NCT02989298||PD patients|End stage renal disease patients receiving peritoneal dialysis treatment
3160477|NCT00425451|Placebo Comparator|Placebo Chip|
3160478|NCT00425464|Experimental|Synchrony® Dual Optic Intraocular Lens|
3160479|NCT00425464|Active Comparator|Standard Monofocal Intraocular Lens|
3160480|NCT00425516|No Intervention|standard (A)|3 FEC100 followed 3 Taxotere
3160481|NCT00425516|Experimental|Modulated (B)|possibility treatments receive: 2 FEC100 followed by 4 Taxotere 4 FEC100 followed by 2 Taxotere 6 FEC 100
3160482|NCT00425542|Experimental|Outpatient treatment|
3160483|NCT00425542|No Intervention|Inpatient care|
3160484|NCT00425620|Experimental|Amphotericin B|
3160485|NCT00425659|Active Comparator|3|
3160486|NCT00425659|Experimental|1|
3160487|NCT00425659|Other|2|usual practice
3160488|NCT00425711|Experimental|DUI Court Participants|Individuals enrolled in the DUI Court treatment site will be recruited for the 13 week open-label trial of acamprosate.
3160489|NCT00425763|Experimental|AQAS|
3160490|NCT00425776|Active Comparator|Real acupuncture|
3160491|NCT00425776|Sham Comparator|Sham acupuncture|
3160492|NCT00425776|No Intervention|No intervention|
3160493|NCT00425815|Experimental|Org 24448 250 mg|Two capsules (one Org 24448 250 mg capsule and one placebo capsule that is identical to the active treatment) will be ingested orally daily for eight weeks.
3160494|NCT00425815|Experimental|Og 244448 500 mg|Two capsules (two Org 24448 250 mg capsules) will be ingested orally daily for eight weeks.
3160495|NCT00425815|Placebo Comparator|Inactive Capsule|Two capsules (two placebo capsules that are identical to the active treatment) will be ingested orally daily for eight weeks.
3160496|NCT00425880||Pregnant Asthmatics|
3160497|NCT00425880||Pregnant Smokers|
3160498|NCT00425880||Healthy Pregnant Controls|
3160499|NCT00425893|Active Comparator|1|health education
3160500|NCT00425893|Experimental|2|hand hygiene
3160501|NCT00425893|Experimental|3|masks and hand hygiene
3160502|NCT00425906|Experimental|Nicotine inhaler|
3160503|NCT00425906|Placebo Comparator|Placebo inhaler|
3160504|NCT00425932|No Intervention|Rituximab/Placebo|Patients will be randomized at Baseline to either Placebo or Rituximab. At Week 24 and up to Week 48 if patient DAS28 score is >2.6, patient will be retreated with open label Rituximab.
3160505|NCT00425932|Active Comparator|Open Label|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
3160506|NCT00426010|Active Comparator|1|overt then covert caffeine
3160507|NCT00426010|Active Comparator|2|covert then overt caffeine
3160508|NCT00426010|Active Comparator|3|overt then covert placebo
3160509|NCT00426010|Active Comparator|4|covert then overt placebo
3160510|NCT00426023|Experimental|1|this group of patients is treated with the experimental drug (Cyclosporine A 0,05% eye drops) 2 times daily
3160511|NCT00426023|Active Comparator|2|
3160512|NCT00426101|Experimental|Etoposide, Dexamethasone, Cyclosporin A plus IT MTX & Steroids|"As compared to the HLH-94 treatment, the main changes are that~Cyclosporin A is administered from day 1 and~Intrathecal steroids are added to the intrathecal methotrexate.~Drugs, dosage, frequency and duration are described in the paragraph Interventions below."
3160513|NCT00426140|Experimental|EPO906|
3160514|NCT00426166|Experimental|1|Low Level Laser Therapy
3160515|NCT00426166|No Intervention|2|No Laser Therapy. Outcome Measures the same.
3160516|NCT00426218|Experimental|1|ACZ885
3160517|NCT00426244|Sham Comparator|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
3160518|NCT00426244|Active Comparator|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
3160519|NCT00426244|No Intervention|Standard Care|Subject only receives care from her OB provider. Subjects were allowed to receive conventional obstetrical care with the exception of OMT, massage therapy, physical therapy, chiropractic manipulation, or therapeutic ultrasound intended to treat musculoskeletal disorders.
3160520|NCT00426257|Experimental|1|Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy
3160521|NCT00426257|Active Comparator|2|Secondary debulking surgery
3160522|NCT00426322|Active Comparator|1|small particles
3160523|NCT00426322|Active Comparator|2|large particles
3160524|NCT00426348|Active Comparator|1|In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo
3160525|NCT00426348|Experimental|2|Valsartan(80-160mg/day) + Probucol(750mg/day)
3160526|NCT00426413||1|Obese AA subjects with DKA or severe hyperglycemia
2485888|NCT02997111|Other|Energy drink|Single group study. Platelet function analyzed with PFA-100 before and 60 minutes after ingestion of 250 ml sugar-free energy drink
2485920|NCT02996656|Active Comparator|Cefazolin|During an open shoulder surgery, the Cefazolin will be administered to some patient. The Cefazolin is a first generation cephalosporin. It is a beta lactam which targets gram positive cocci and some gram negative bacilli. The INESS Antibiotic Prophylaxis in Orthopedic Guide recommends the use of Cefazolin at induction for all orthopaedic procedure with implantation of internal fixation device. The dosage is 2g intravenous if the patient weights less than 120kg or 3g if the patient weights more than 120kg. The dose should be repeated if the procedure lasts for more than three hours or if the blood loss is greater than 1500mL.
2485922|NCT02996656|Experimental|Ceftriaxone|During an open shoulder surgery, the Ceftriaxone will be administered to some patient. The Ceftriaxone is a third generation cephalosporin. It targets gram positive cocci such as staphylococcus and streptococcus, gram negative bacilli and some anaerobes, including P. acnes. The prophylactic dose is of 2g IV given a minimum of 30 minutes prior to skin incision. It is effective 12h so no other dose is needed during surgery.
2485968|NCT02996435|Experimental|Mobile Adherence Platform|Participant adherence will be monitored using a mobile application and platform which provides a real-time reminder that alerts the participant to take his or her medication. The application will also send an alert to the participant when a refill is needed based on calculated medication or pill supply. The intervention will focus only on daily adherence to rivaroxaban.
2485971|NCT02996435|Other|Control: Standard of Care|Participants will receive physician- or nurse-guided standard of care for their rivaroxaban adherence. No drug will be administered as part of this study.
3193820|NCT00821652|Experimental|2|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I.
2486087|NCT02995603|Experimental|Patient rotation|Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.
2486268|NCT02995239|Active Comparator|CJ-12420 formulation 1|CJ-12420 formulation 1
2486270|NCT02995239|Active Comparator|CJ-12420 formulation 2|CJ-12420 formulation 2
3193821|NCT00821665|Experimental|Sucrose|Sucrose
3193822|NCT00821665|Placebo Comparator|Water|Water
2486673|NCT02991495|Active Comparator|Stamaril, Sanofi Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2486675|NCT02991495|Experimental|Stamaril, Sanofi Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486676|NCT02991495|Active Comparator|Yellow fever vaccine, Bio-Manguinhos: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2486677|NCT02991495|Experimental|Yellow fever vaccine, Bio-Manguinhos: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486678|NCT02991495|Active Comparator|Yellow fever vaccine, Institut Pasteur: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2486680|NCT02991495|Experimental|Yellow fever vaccine, Institut Pasteur: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486682|NCT02991495|Active Comparator|Yellow fever vaccine, Chumakov Institute: Standard dose|Subcutaneous administration of 1 dose of a standard yellow fever vaccine
2486683|NCT02991495|Experimental|Yellow fever vaccine, Chumakov Institute: Fractional dose|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486685|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in Children|Subcutaneous administration of 1 dose of the yellow fever vaccine
2486687|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in Children|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486688|NCT02991495|Active Comparator|YF, Chumakov Institute: Standard dose in HIV+ adults|Subcutaneous administration of 1 dose of the yellow fever vaccine
2486692|NCT02991495|Experimental|YF, Chumakov Institute: Fractional dose in HIV+ adults|Subcutaneous administration of 1/5th of a standard dose of yellow fever vaccine
2486781|NCT02990754|Experimental|Intervention Group|Individuals attending one or more fearless physical activity events
2486861|NCT02990143|No Intervention|Glaucoma Drainage implant no Ologen|The first group will use the routine technique for glaucoma drainage implant without placement of Ologen.
2486868|NCT02990143|Active Comparator|Glaucoma Drainage implant with Ologen|the second group will undergo the same procedure but will have the Ologen placed and secured over the plate of the AGV-FP7, under the conjunctiva, during the surgery.
2486904|NCT02989922|Experimental|SHR-1210 Q2W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
2486905|NCT02989922|Experimental|SHR-1210 Q3W|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks
3193823|NCT00821691|Other|1|"Amantadin - Placebo: 5 amantadin caps - 4 days wash out - 5 placebo caps~5 amantadin caps (100mg); 2 caps a day during 3 days; after wash out period (4 days): 5 placebo caps (2 caps a day during 3 days)"
3193824|NCT00821691|Other|2|"Placebo - Amantadin: 5 placebo caps - 4 days wash out - 5 amantadin caps~5 placebo caps: 2 caps a day during 3 days after wash out period (4 days): 5 amantadin caps(100mg) (2 caps a day during 3 days)"
2487048|NCT02989077||Group A|Having combined coronary and cerebral ischemia.
2487053|NCT02989077||Group B|Having only coronary ischemia
2487056|NCT02989077||group C|Having only cerebral ischemia
2487093|NCT02988752|Experimental|Electronic Mobile Device|Use an Electronic Low Cost Mobile Device To Determine C/D Ratio And Compare Results With Gold Standard Optical Coherence Tomography Results. The equipment needs mydriatic conditions and does not touch the patient's eye. The equipment uses a panoptik and a camera to access eye fundus.
2487094|NCT02988752|Active Comparator|Optical Coherence Tomography|Device considered as gold standard to determine c/d ratio. Needs mydriatic conditions.
2487117|NCT02988388||Lung biopsy/lobectomy|Adults ages 21 or older who are undergoing lung surgery for suspected malignancy or metastases.
2487286|NCT02987114|Experimental|PLT101|PTL101 capsules (50 or 100 mg CBD per capsule) up to 25 mg/kg/day or up to 450 mg/day, the lower of the two. Twice daily (morning and evening).
2515723|NCT02791997|Experimental|Migraine patients|
2485950|NCT02996604|Active Comparator|He-Mu-point combination(ST36 and CV12)|In traditional Chinese acupuncture theory，synergistic effect can be produced by acupoints combination and the He-Mu-point combination is a classical acupoints combination formula for gastrointestinal diseases. Everyone in the group will be punctured at unilateral Zusanli and Zhongwan.
2485997|NCT02996279||group 1|maternal chorioamnionitis
2485999|NCT02996279||group 2|no maternal chorioamnionitis
2486080|NCT02995811||Observational Cohort|"On Days 1, 3, 7 and 10 of ICU admission, patients will undergo ultrasound assessment of the diaphragm, transverse and rectus abdominis, quadriceps rectus femoris, and tibialis anterior muscles. Imaging all four muscles together requires approximately 1 hour.~Physical activity monitoring: On Days 1-10 of ICU admission patients will wear an activity monitor. These devices use several inertial motion sensors to track the movement and acceleration of the limbs in horizontal and vertical directions.~Patients will also undergo daily assessment of global peripheral skeletal muscle strength assessed by the Medical Research Council Sum-score and global function measured by the Chelsea Critical Care Physical Assessment Scale"
2486107|NCT02995408|Experimental|Experimental: 3RP treatment|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
2486110|NCT02995408|Active Comparator|Waitlist control|An adapted version of the Relaxation Response Resiliency Program (3RP) for parents of children with ASD. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies.
2486341|NCT02993809|Experimental|BM-ECs and PRPE|Multipoint of intramuscular injections into ischemic limbs.Injections composed of bone marrow derived endothelial cells (BM-ECs) and platelet-rich plasma extract (PRPE).
2486342|NCT02993809|Active Comparator|BM-ECs|Intramuscular injection of bone marrow derived endothelial cells only.
3193825|NCT00821717|Experimental|1:|
2486470|NCT02992717||Patients undergoing elective general anaesthesia|Male and female adult patients undergoing elective general anaesthesia.
2486521|NCT02992444|Experimental|Cohort 5|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin after 8 hours.~There is one visit:~Two adhesive strips (standard adhesive strip and Experimental adhesive strip)are applied on the peristomal skin and allowed to sit for 8hours before being removed."
2486553|NCT02992145||Case group: This group will include forty (40) preeclampt|
2486554|NCT02992145||Control group: This group will include forty (40) normoten|
2486585|NCT02991885|Experimental|HAL-MPE1|HAL-MPE1 is an off-white to white liquid suspension containing modified peanut extract
2486588|NCT02991885|Placebo Comparator|HAL-MPE1 placebo|HAL-MPE1 placebo without modified peanut extract
2486626|NCT02991560|Experimental|Kinesio tape (KT)|The KT group was taped 2 days a week for 4 weeks using the muscle and fascia correction techniques
2486637|NCT02991560|Experimental|Athletic taping (AT)|An athletic tape with adhesive backing was used (38 mm wide-Muller Protape-The Netherlands).
2486665|NCT02991274||T790M mutation test|genomic testing of T790M mutation
2486783|NCT02990871||early rehabilitation|Patients started rehabilitative treatment during ICU hospitalization
2486788|NCT02990871||no-early rehabilitation|Patients started rehabilitative treatment after admission in Neuro-rehabilitation department
2486820|NCT02990403|Experimental|aspirin+LMWH group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100U,hypodermic injection，qd
2486825|NCT02990403|Experimental|aspirin+LMWH+immunoglobulin group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks
2486828|NCT02990403|Experimental|aspirin+LMWH+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + prednisone,5-10mg/day,po,qd
2486831|NCT02990403|Experimental|aspirin+LMWH+IVIG+prednisone group|aspirin, 75-100mg/day, po,bid + low molecular weight heparin,4100IU/day,hypodermic injection,qd + immunoglobulin 300mg/kg（with 100ml normal saline）,intravenous injection,once every two weeks + prednisone,5-10mg/day,po,qd
2486833|NCT02990403|Other|dydrogesterone group|dydrogesterone 20-30mg/day, po, tid
2486887|NCT02990078||Acute TBI|Subjects will be recruited from the neurointensive care unit within 72 hours of their injury. At the time of informed consent, the investigators will perform fNIRS testing with a hypercapnia challenge, fNIRS with hypercapnia challenge 60 minutes after a single oral dose of 50mg sildenafil citrate, outcome qustionaires and symptom checklists (including: Glasgow Outcomes Scale-Extended, Rivermead Post-Concussive Symptom Questionnaire, Brief Symptom Inventory, Alcohol Consumption Questionnaire, Patient Health Questionnaire, and Insomnia Severity Index). This will all be administered again at 14 days, 90 days, 180 days, 1 year, 2 years, 3 years, and 4 years after injury.
2486888|NCT02990078||Sub-acute/Chronic TBI|Subjects who suffered a TBI previously and have now entered a subacute or chronic phase of their TBI will be approached by the research team at their clinic visit with a TBI specialist. In those subjects, study timing will be based on the time of their original injury, therefore will start study visits at the next possible time point.
2486889|NCT02990078||Healthy Controls|"The investigators will also enroll healthy peer controls. These control subjects will be family members and friends of TBI subjects. These peer controls are likely to have similar environmental and socioeconomic exposures/support which may impact recovery after TBI and may also impact CVR. These control subjects will meet the same inclusion/exclusion criteria as TBI subjects without the requirement for an injury or acute brain imaging. These subjects will be tested in the same way as both TBI groups, but will only have one visit."
2486942|NCT02989688|Active Comparator|macronutrient matched drink|Dietary Supplement - 125 ml Fortisip Compact Protein (Nutricia) plus 20ml Calogen (Nutricia)
3160527|NCT00426413||2|obese nondiabetic subjects, age 19-65.
3160528|NCT00426413||3|Any subjects with recurrent DKA. Recurrent DKA is defined as more than one admission to Grady Memorial Hospital.
3160529|NCT00426426|Active Comparator|Meta-Cognitive Therapy|first Meta-cognitive therapy then Cognitive Behaviour Therapy
3160530|NCT00426426|Active Comparator|Cognitive Behaviour Therapy|first Cognitive Behaviour Therapy then Meta-cognitive therapy
3160531|NCT00426426|Other|Waiting List|Waiting List
3160532|NCT00426439|Experimental|1 Coartem|Treatment of documented malaria in children following the dosages recommended by the manufacturer.
2485969|NCT02996409|Placebo Comparator|Low-Volume Image-Guided Injection|LVIGI: Injection of 2 cc (1.6 cc 0.9% Sodium chloride solution + 0.4 cc 1% lidocain) in combination with a progressive exercise program and gradual return to sports activities.
2486029|NCT02996123|Experimental|cad/cam maxillary dentures|single maxillary dentures fabricated by cad/cam method
2486031|NCT02996123|Active Comparator|conventional dentures|heat cured single maxillary dentures
2486073|NCT02995759||SE before Seizure Action Plan|450 patients with status epilepticus prior to seizure action plan initiation
2486077|NCT02995759||SE after Seizure Action Plan|450 patients with status epilepticus after seizure action plan initiation
2486153|NCT02995070|Experimental|CTG + LLLT|The irradiation will be performed with a GaAlAs diode laser that will continuously emits a wavelength of 660 nm with a power of 30 milliwatts. The patients allocated for the LLLT group will receive the following protocol for laser application: Five (5) points of irradiation will be performed using a total energy density (fluence) of 15 J/cm2 and a time of 20 seconds. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment will be calibrated prior to each application.
2486154|NCT02995070|Sham Comparator|CTG + SHAM|The patients allocated to the control group will receive sham irradiation. For this, black rubber protection will be placed at the tip of the laser device, which will not allow the light to reach the tissue. The applications will be performed by a different operator from the one who will measure the study parameters. During irradiation, the tip of the laser probe will be placed perpendicularly with slight contact on the area. Laser therapy will be initiated in the immediate postoperative period (just after sutures) and will be repeated by seven more applications performed every other day, with a total of 8 laser applications.
2486193|NCT02994667||Pacemaker After TAVR|The study cohort will comprise all consecutive patients who undergo permanent pacemaker placement for new conduction disturbances after TAVR at THHBP between 1/1/2015 and 12/31/2016.
2486209|NCT02994381|Experimental|[14C]-RPC1063 Solution (0.1 g/mL)|1 mg; 10 mL [14C]-RPC1063 HCl oral dose containing NMT 1.3 MBq (37 μCi) 14C
2486243|NCT02994212|Experimental|Intervention group|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF. Anthropometric measurements were taken on a weekly basis for 4 weeks to monitor treatment response.
2486294|NCT02993978||Control group|Pediatric patients and their parents who were treated with radiotherapy during baseline period and enrolled in the study. Recruitment to the Control Group took Place during one year.
2486295|NCT02993978||Case group|Pediatric patients and their parents who were treated with radiotherapy during case period and enrolled in the study. Recruitment to the case group took place during one year after introduction of new methods and equipment in the in the clinic..
2486381|NCT02993705|Experimental|Trabectedin|Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter.
3160533|NCT00426439|Active Comparator|2 Chloroquine|The antimalarial actually used in Guinea-Bissau is the dosage of 50 mg/kg given twice a day for 3 days.
2486493|NCT02992665|Experimental|Ca ionophore|Artificial activation of the oocytes using Calcium ionophore in the cases of severe male factor infertility.
2486494|NCT02992665|Experimental|Placebo|Placebo was used to control the group of Calcium ionophore
2486630|NCT02991846||Patients with cGVHD|All consecutive patients undergoing allogenic stem cell transplant for any underlying disease who develop chronic graft-versus-host disease (cGVHD)
3160534|NCT00426491|Active Comparator|A|Four 200 ug tablets of Misoprostol
2486761|NCT02990741||Usual screening group|ECG recordings at baseline plus at 1 and 2 year of follow-up; three ECG recordings in total.
2486770|NCT02990741||Intensive screening subgroup|ECG recordings at baseline plus quarterly during follow-up, at months 3, 6, 9 ,12, 15, 18, 21 and 24; 9 ECG recordings in total.
2486778|NCT02990741||More intensive screening subgroup|ECG recordings at baseline plus weekly during the first month of follow-up and quarterly afterwards, at weeks 1, 2, 3 and 4 and months 3, 6, 9, 12, 15, 18, 21 and 24; 13 ECG recordings in total.
2486863|NCT02990546|Experimental|Intervention|In the intervention arm 10 mg of midodrine will be given orally three times daily starting at the time of stable or decreasing intravenous vasopressor support
2486871|NCT02990546|Other|Control|The control arm will receive standard of care for septic shock with IV vasopressor support as needed to maintain MAP goal > 65 mmHg
2486894|NCT02989844|Experimental|N-803|
2486914|NCT02989662|Active Comparator|Mifepristone|Mifepristone is a high affinity antagonist of the glucocorticoid receptor (GR). It is FDA approved to treatment hyperglycemia caused by high cortisol levels in adults with endogenous Cushing's syndrome.
2486915|NCT02989662|Placebo Comparator|Placebo - Cap|This is an inactive compound which appears physically identical to active medication.
2486952|NCT02989480||Sarcoidosis|Patients with cardiac sarcoidosis diagnosed according to the Japanese Ministry of Health and Welfare criteria will be included. All patients will have histologically proven sarcoidosis (cardiac biopsy not mandatory) and no other potential cardiac disease. They will have no family history of cardiomyopathy.
2486954|NCT02989480||Arrhythmogenic RV cardiomyopathy|Patients with ARVC diagnosed according to the Task Force criteria with in addition either a positive family history for the condition or harbour a known pathological mutation associated with it.
3160535|NCT00426491|Placebo Comparator|B|
3193826|NCT00821717|Placebo Comparator|2|
2487133|NCT02988024|Experimental|LY03005|LY03005 80 mg
2487134|NCT02988024|Active Comparator|Pristiq|Pristiq 50 mg
2487229|NCT02987569|Experimental|Group One|Intervention
3160536|NCT00426504|Experimental|radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
3160537|NCT00426530|Experimental|RAD001 Daily Schedule|5mg or 10mg
3160538|NCT00426530|Experimental|RAD001 Weekly Schedule|30mg
3160539|NCT00426582|Experimental|Patupilone only|Cycle 1 patupilone alone Cycle 2 and onward patupilone and carboplatin
3160540|NCT00426582|Active Comparator|Carboplatin alone|Cycle 1 Carboplatin alone Cycle 2 and onward patuilone and carboplatin
2485987|NCT02996422|Experimental|Community cooking classes|Adults in the same intervention counties as the school-based water campaign will enroll in group cooking classes. They will complete a baseline and two follow-up surveys to measure changes in fruit and vegetable consumption, attitudes, and self-efficacy.
2486028|NCT02996136|Experimental|Nasal Swab|Nasal Swab
2486030|NCT02996136|Experimental|Nasopharyngeal Swab|Nasopharyngeal Swab
2486095|NCT02995642|Experimental|18F-FPPRGD2|Subjects (with either carotid atherosclerosis stenosis or AAA) will receive a single intravenous injection of 10mCi of 18F-FPPRGD2 and will undergo positron emission tomography/computed tomography (PET/CT) or PET/MRI (PET/magnetic resonance imaging) imaging 45-60 minutes after injection.
2486125|NCT02995044|Experimental|SPF evaluation|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2486164|NCT02994888||all patients|All patients will be treated with cetuximab 500mg/m2 every 2 weeks until the time of progression
2486203|NCT02994576|Experimental|Stage IB(≥ 2 cm)-IIIA non N2, resectable and untreated NSCLC|
2486347|NCT02993354||Pregnant women|Pregnant women with singleton pregnancy with gestational age greater than or equal to 24 weeks.
2486402|NCT02993237|Experimental|Group 1: DRV/COBI Placebo followed by D/C/F/TAF Placebo|Participants will receive fixed dose combination (FDC) of darunavir/cobicistat (DRV/COBI) matching placebo tablets (Intake 1) and FDC of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
2486403|NCT02993237|Experimental|Group 2: D/C/F/TAF Placebo followed by DRV/COBI Placebo|Participants will receive FDC of D/C/F/TAF matching placebo tablets (Intake 1) and FDC of DRV/COBI matching placebo tablets (Intake 2) on Day 1. Both the intakes will be separated by at least 30 minutes.
2486464|NCT02992925|Experimental|Cohort 1: BK1310-High|
2486465|NCT02992925|Experimental|Cohort 1: BK1310-Low|
2486466|NCT02992925|Experimental|Cohort 2: BK1310-High or -Low|Either BK1310-High or -Low will be chosen based on the result of cohort 1
2486467|NCT02992925|Active Comparator|Cohort 2: ActHIB® and Tetrabik|
2486520|NCT02992457|Active Comparator|Sof-Riba|Sofosbuvir ribavirin 6 months.
2486524|NCT02992457|Active Comparator|Sof- Riba- Pegylated interferon|Sofosbuvir, Ribavirin and Pegylated-interferon alfa-2a 3 months
2486525|NCT02992457|Active Comparator|Sof- Olysio|Sofosbuvir and simeprevir for 3 months.
2486526|NCT02992457|Active Comparator|Sof- Dacla|Sofosbuvir and Daclatasvir for 3 months.
2486527|NCT02992457|Active Comparator|Harvony|Sofosbuvir and ledipasvir for 3 months
2486528|NCT02992457|Active Comparator|Ritaprevir, paritaprevir, ombetasvir|Querevo for 3 months
2486530|NCT02992457|Active Comparator|Salvage therapy|sofosbuvir, daclatasvir, simeprevir,ribavirin or sofosbuvir and querevo
2486577|NCT02991950|Experimental|parnaparin sodium|"Women in LMWH arm are administered with routine ovulation induction protocol and prophylactic dose of parnaparin sodium (LMWH), starting the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until the delivery or the end of pregnancy. Women in the LMWH arm will be tested for blood cell count twice in the first 10 days of therapy.~Parnaparin will be administered at the dose of 100 IU/kg/day from the day before the beginning of stimulation phase of the cycle until the result of the procedure is confirmed in terms of pregnancy yes or no and in case of pregnancy until delivery or the end of the pregnancy.~Used dosages Parnaparin 0.4 4250 UI Parnaparin 0.6 6400 UI"
2486584|NCT02991950|No Intervention|no treatment|Women in the control arm are administered with routine ovulation induction protocol, without the addition of parnaparin sodium.
3193827|NCT00821743|Other|1|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
3193828|NCT00821756|Experimental|1|Assertive intervention in OPAC-style: Outreach,problem solving,adherence,continuity
2486705|NCT02991209|Experimental|Tostran 2%|1 years treatment with transdermal Tostran 2%
2486706|NCT02991209|Placebo Comparator|Placebo|1 years treatment with placebo gel
3160541|NCT00426608|Experimental|Session 1|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 gram per kilogram (g/kg) and Dose 2 of AEBCD sequence. In AEBCD sequence A is placebo, E Alprazolam, B GSK6561679 10 milligram (mg), C GSK6561679 50 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3193829|NCT00821756|No Intervention|2|Control arm: Treatment as usual
2486817|NCT02990429|Experimental|Forced Air warmer (bair hugger)|".~In groups: A = 45, receiving intraoperative forced air warming( bair hugger). The forced air was delivered at the high setting of 43ºC"
2486818|NCT02990429|Experimental|Intravenous Fluid Warmer(ranger warmer)|In groups:B =45, having intraoperative intravenous fluid via a fluid warmer patients received intravenous fluid via a fluid warmer after induction anesthesia. The device automatically heated fluid up to 41ºC as set point.
2486855|NCT02990221|Active Comparator|Ingenol mebutate|application of ingenol mebutate for 3 consecutive days on an area of face/scalp of 25 cm2
2486865|NCT02990221|Active Comparator|cryotherapy|application of criotherapy on actinic keratosis present in an area of face/scalp of 25 cm2 different from the ingenol mebutate area
2486892|NCT02989831|Experimental|Vibrating insoles 'on'|Duration: 30-60 seconds
2486895|NCT02989831|No Intervention|Vibrating insoles 'off'|Duration: 30-60 seconds
2486937|NCT02989688|Active Comparator|modified carbohydrate drink|Dietary Supplement - renal specific slow release carbohydrate ONS (220 ml Nepro HP (Abbott Nutrition)
3193830|NCT00821834|Experimental|Clopidogrel|"Patients received:~clopidogrel 300 mg as a loading dose, then 75 mg once daily as a maintenance dose,~ticlopidine matching placebo twice daily."
3193831|NCT00821834|Active Comparator|Ticlopidine|"Patients received:~ticlopidine 100 mg twice daily,~clopidogrel matching placebo once daily."
3193832|NCT00821847||1:experimental|male, caucasian, HIV infected patients with glomerular filtration rate between 60 and 30 ml/min (estimated with cockcroft and Gault formulae)
3193833|NCT00821860|Experimental|Arm I|Patients undergo video-assisted thoracoscopic cytoreductive pleurectomy either at the time of biopsy or after confirmation of biopsy results.
2486104|NCT02995577||Feeding tolerant|Patients that are able to reach 80-100% of full enteral feeds (whether fed by mouth or through a nasogastric tube) 7 days after the initiation of feeds. Patients will be excluded from this group if they are ever diagnosed with NEC at any time during this hospitalization.
2486106|NCT02995577||Feeding intolerant|Patients with GI symptoms (vomiting, abdominal distention, diarrhea, hematemesis, and/or hematochezia) that persist for 48 hours or longer while needing to be NPO, this patient is retrospectively categorized into the feeding intolerance group. Patients with feeding intolerance may also include infants that are made NPO, placed on bowel rest, and are started on antibiotics to rule out NEC, but are never diagnosed with NEC. Exclusion criteria include patients that are continued on antibiotics for greater than 48 hours due to diagnosed bacterial sepsis or diagnosed NEC, and those that have a positive blood, urine, or sputum culture.
2486108|NCT02995577||Necrotizing enterocolitis|Any infant that is diagnosed (radiographically, by Bell's criteria) with and treated for NEC.
2486129|NCT02995057||Nickel allergic|Participants have proven nickel allergy
2486167|NCT02994862|Experimental|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
2486170|NCT02994862|Active Comparator|Conventional Bonding|Normal Bonding Method
2486200|NCT02994537||acute autoimmune hepatitis|Patients diagnosed autoimmune hepatitis(AIH) are divided into acute cohort or chronic cohort (acute-on-chronic and chronic were all included)by biochemical results, such as liver function and coagulation, then the investigators will compare the histological results, treatment effects and prognosis between the two groups. Further more, the investigators will study the pathogenesis of different forms of autoimmune hepatitis. Even more, the investigators want to explore drug induced AIH and viral hepatitis related AIH.
2486237|NCT02994277|Experimental|UVa and ITBA/UNLP algorithm arm|To control glycaemia in T1DM patients through UVa and ITBA/UNLP algorithm
2486260|NCT02994043|Active Comparator|MBRP|
2486262|NCT02994043|Active Comparator|RP|
2486339|NCT02993770|Experimental|Endoscopic DCR|Endoscopic DCR will be performed by a single ophthalmic plastic surgeon expert in endoscopic surgery (F.P.) with a modified powered endonasal endoscopic technique described by Wormold.
2486340|NCT02993770|Active Comparator|External DCR|External DCR will be performed in a conventional mannervia a nasal side straight skin incision 1 cm medial to medial canthal area, 1 cm long, then orbicularis oculi muscle will be separated using blunt dissection to expose the periosteum overlying and medial to the anterior lacrimal crest
2486390|NCT02993315|Experimental|nDC vaccination arm|Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
2486391|NCT02993315|Placebo Comparator|placebo arm|Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
2486439|NCT02993042|Experimental|Robot-assisted gait training|Robot-assisted gait training using an exoskeletal robot (Walkbot_S; P&S Mechanics Co. Ltd., Seoul, Korea)
2486447|NCT02992756|Experimental|Instillation of growth factors|Patients candidates to an IVF/ICSI cycle with low follicular reserve: after at least one cycle of stimulation obtaining 0-3 oocytes.
2486507|NCT02992652|Active Comparator|Study Group|Received 600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
2486509|NCT02992652|No Intervention|Control Group|Underwent ERCP without allopurinol prophylaxis
3193834|NCT00821860|Active Comparator|Arm II|Patients undergo talc pleurodesis via an indwelling intercostal chest drain or via thoracoscopy either at the time of biopsy or after confirmation of biopsy results.
3193835|NCT00821912|Experimental|Taxotere Xeloda|"Taxotere i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule.~Xeloda orally day 1-14 every 3 weeks."
2486700|NCT02991365|Active Comparator|nasal insulin|daily administration of 160 U of human insulin as nasal spray
2486702|NCT02991365|Placebo Comparator|placebo spray|daily administration of placebo solution as nasal spray
2486765|NCT02990962|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (5cc) between carpal tunnel and median nerve.
2486773|NCT02990962|Active Comparator|Perineural injection with steroid|Ultrasound-guided perineural injection with 1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and median nerve.
2486822|NCT02990494|Active Comparator|STANDARD|12-week Internet-delivered behavioral weight loss program
2486826|NCT02990494|Experimental|PREVENT|an enhanced 12-week Internet-delivered behavioral weight loss program focused on preventing future negative consequences
2486829|NCT02990494|Experimental|PROMOTE|an enhanced 12-week Internet-delivered behavioral weight loss program focused on promoting future benefits
2486876|NCT02990195|Other|Double enterostomy|
3193836|NCT00821938|Active Comparator|CRT-ICD|
3193837|NCT00821938|Placebo Comparator|DDD-ICD|
2487046|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
2487050|NCT02989129|Experimental|Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group|"Questionnaires completed at Baseline and at End of Study Visit.~Participants take Quercetin tablets by mouth 2 times every day for 12 weeks."
2487164|NCT02988154||Arm A: Simulation training cohort|Recruits to Arm A undergo simulation training (computer simulation of the procedure, followed by simulation on a dead animal model), after which they will attempt to perform an EVD procedure on their own, on a 3D-printed skull model that we designed.
3193838|NCT00821977|Experimental|Vildagliptin Dose 1|
3193839|NCT00821977|Experimental|Vildagliptin Dose 2|
3193840|NCT00821977|Placebo Comparator|Placebo|
3193841|NCT00821990|Active Comparator|Chemotherapy|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
3193842|NCT00821990|Active Comparator|Supportive care|Eligible patients will be first offered randomization. If willing to participate RCT, the patient will be randomized to chemotherapy or best supportive care. If patients refuse to participate in RCT, but nevertheless agree to receive treatment of their preferences, they are offered their treatment of choice (chemotherapy or supportive care).
2486126|NCT02995330|Experimental|Bone marrow transplantation|"Bone marrow transplantation followed by Cytoxan and testosterone~Day -6 to -1: Subjects will be treated with a standard non-myeloablative conditioning regimen~Day 0: subjects will be infused with non-T-cell depleted bone marrow from a related female donor.~Subjects will receive GVHD prophylaxis consisting of:~Day +3 and +4: Cytoxan (Cy) 50mg/kg IV Day +5 through Day +180: tacrolimus (IV or PO) beginning [dose adjusted to maintain trough level of 5-15 ng/mL] Day +5 through Day +35: Mycophenolate mofetil (MMF) 15 mg/kg PO TID, with a maximum dose of 1g TID.~Day +5: filgrastim (G-CSF) 5 mcg/kg/day, continued until ANC ≥ 1500/mm3.~Day +60, +90, and +120: testosterone cypionate 400 mg IM every 30 days x 3 doses~Subjects will be maintained on continuous LHRH agonist/antagonist therapy (if not previously surgically castrated). Subjects who achieve biochemical CR will stop LHRH agonist/antagonist treatmentat day 180."
2486189|NCT02994706|Experimental|Home monitoring|Home monitoring will involve participants recording their symptoms twice weekly on a modified mobile phone and recording their lung function twice weekly using a digital spirometer. This data will be automatically transmitted to the CF team and we will contact patients on the mobile phone if symptoms and/or lung function decline below a set threshold, suggesting the onset of a pulmonary exacerbation. We will contact patients within 24 hours of symptoms and/or lung function falling below this set threshold.
2486190|NCT02994706|Active Comparator|Clinical Care|Throughout the study period, participants will attend outpatient clinic visits as usual and treatment with antibiotics as clinically indicated.
2486206|NCT02994420||Lean women|BMI 18-25, weight in kg / height in m2
2486207|NCT02994420||Obese women|BMI 30-35, weight in kg / height in m2
2486221|NCT02994225|Experimental|Study arm|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
2486264|NCT02994095|Experimental|Single intervention arm|Trained CHAs in Motivational Interviewing in pilot study
2486335|NCT02993822|Experimental|Orvepitant 10mg|Orvepitant 10mg tablet, once daily for 12 weeks
2486336|NCT02993822|Experimental|Orvepitant 20mg|Orvepitant 20mg tablet, once daily for 12 weeks
2486337|NCT02993822|Experimental|Orvepitant 30mg|Orvepitant 30mg tablet, once daily for 12 weeks
2486338|NCT02993822|Placebo Comparator|Placebo|Placebo to match tablet, once daily for 12 weeks
2486431|NCT02993003|Other|Children between 7 months and 12 months|nasopharyngeal probe will be marked with indelible ink from 2-10 cm in 1-cm increments and inserted 10 cm
2486433|NCT02993003|Other|children between 1 and 5 years|nasopharyngeal probe will be marked with indelible ink from 2-15 cm in 1.5-cm increments and inserted 10 cm
2486436|NCT02993003|Other|children between 6 and 12 years|a nasopharyngeal probe will be marked with indelible ink from 2 to 20 cm at 2 cm increments from its tip, and inserted 20 cm
2486454|NCT02992782|Active Comparator|Standard Care|Standard care Intervention: including a home program of therapeutic (decongestive) exercise, which will include active, non-resistive motion of the involved limb. Participants will perform the exercise once daily for about 10 minutes and will be required to wear their compression sleeve for at least 12 hours per day, each day of the week. After 24 weeks, they will be given the opportunity to take part in the decongestive progressive resistance exercise program and will be provided with an adjustable compression garment to use during exercise.
2486456|NCT02992782|Experimental|Exercise and Compression Garment|Intervention will include having participants wear a compression sleeve during exercise. They will wear the sleeve while carrying out the decongestive progressive resistance exercise program and will continue wearing their day-time compression garment for at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 Weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness center or at home.
2486458|NCT02992782|Experimental|Exercise and Adjustable Compression Wrap|Intervention will include having participants will be fitted for an adjustable compression wrap. They will be required to wear the adjustable compression wrap during the decongestive progressive resistance exercise program and will continue wearing their compression sleeve at least 12 hours per day, each day of the week. They will attend a supervised decongestive progressive resistance exercise program twice a week for 12 weeks at the Cancer Rehabilitation Clinic in Corbett Hall at the University of Alberta. Exercise session will take approximately 60-90 minutes. After 12 weeks, participants will continue the same program twice weekly for an additional 12 weeks in a community-based fitness centre or at home.
2486497|NCT02992561|Active Comparator|Narrative Exposure Therapy (FORNET, adapted version)|Version of Narrative Exposure Therapy for Forensic Offender Rehabilitation including one lifeline session and 5 exposure sessions as well as 6 group sessions adapted from behavioral-therapy approaches for addiction problems.
2486499|NCT02992561|No Intervention|Waitlist control or treatment as usual|No intervention or non-specific measures of support on request
3193843|NCT00822003|Active Comparator|1|Human GLP-1
3193844|NCT00822003|Placebo Comparator|2|Placebo tablet
2486654|NCT02991534|Other|Arm 1|"The investigators will use a nonrandomized stepped wedge design to evaluate the implementation in four VA Women's Practice Based Research Network (PBRN) sites. In this nonrandomized stepped wedge design, the intervention is turned on when a primary care provider (PCP) uses a CV screening template which maps to the patient CV self-screener. This design relies on sequential roll-out to participating sites over time, while using other sites as controls until they begin implementation. The investigators will use nonrandomized stepped wedges (rather than randomized) given their suitability for studying implementation. The design explicitly considers the timing of implementation spread and addresses the statistical issues introduced by lack of randomization in implementation starts and processes. The investigators will analytically compensate for the design by collecting patient-, provider-, and site-level data that may be associated with timing of the adoption of each intervention."
2486703|NCT02991235|Experimental|PRJ212|PRJ212 is a nutritional product with active food ingredients.
2486704|NCT02991235|Placebo Comparator|Placebo|Placebo is like PRJ212 without active food ingredients.
2486760|NCT02990949|Experimental|Testing group|Timing of trigger at end of ovarian stimulation in an IVF cycle: trigger when 2 follicles reach 18mm, OR 1 follicle reaches 18mm AND 1 follicle is between 16-18mm.
3193845|NCT00822029|Experimental|1|FOSAMAX (oral bisphosphonate)
2486158|NCT02994745|Experimental|A fixed dose combination group|A fixed dose combination of Fimasartan/Atorvastatin
2486161|NCT02994745|Active Comparator|Co-administration group|Co-administration of Fimasartan and Atorvastatin
2486210|NCT02994589|Experimental|OASIS® wound matrix|OASIS wound matrix is a biologic extracellular matrix derived from porcine small intestine submucosa. Some components of OASIS wound matrix are similar to human dermis including types of collagens, elastin, glycoproteins and proteoglycans. In addition, OASIS wound matrix retains some growth factors that have been suggested to aid in the wound healing process. It is a FDA approved wound dressing indicated for use in a variety of ulcers, abrasions and surgical wounds.
2486212|NCT02994589|Active Comparator|Tegaderm™(Absorbant, 3M)|Transparent dressing allows for wound monitoring without changing the dressing Clear design takes the guesswork out of application over the wound Novel acrylic polymer pad technology designed to handle low to moderate wound drainage. No dressing breakdown in the wound. Low friction surface minimizes potential for friction and shear. Allows for gentle removal from skin. Barrier to external contaminants, body fluids, bacteria and viruses.
2486214|NCT02994589|Active Comparator|Xeroform™|Xeroform™ Occlusive Petrolatum Gauze. 3% Bismuth Tribromophenate in a special petrolatum blend on fine mesh gauze. Non-adherent. Clings and conforms to all body contours.
2486239|NCT02994199|Experimental|Active video gaming|Participants will engage in active video game play.
2486275|NCT02993991|Experimental|Mocetinostat and Durvalumab|"Patients will start therapy with mocetinostat within 10 days of study enrollment. Mocetinostat will be given in 2 dose levels (n = 6 evaluable patients each) of 70mg three-times weekly and 90mg three-times weekly for 2 weeks.~Durvalumab will be given as a single infusion at a dose of 1500mg, over a period of 1-hour, on day 8 of the study."
2486343|NCT02993666|Experimental|upper body|warming with upper body blankets
2486344|NCT02993666|Experimental|lower body|warming with lower body blankets
3193846|NCT00822029|Placebo Comparator|2|PLACEBO
3193847|NCT00822042||1|Patients with corticotherapy lasting more than 3 months
2486515|NCT02992626|Experimental|starting with dog|Participants in this arm complete the first session in the presence of a dog. The second session is under control condition in the presence of a stuffed toy dog.
2486517|NCT02992626|Experimental|starting with control|Participants in this arm complete the first session under control condition in the presence of a stuffed toy dog while the second session the tests are completed in the presence of a dog.
3193848|NCT00822055|Active Comparator|1|brimonidine/timolol Fixed-combination monotherapy
3193849|NCT00822055|Active Comparator|2|dorzolamide/timolol fixed-combination monotherapy
3193850|NCT00822055|Active Comparator|3|prostaglandin analogue + brimonidine/timolol fixed combination
3193851|NCT00822055|Active Comparator|4|prostaglandin analogue + dorzolamide/timolol fixed combination
3193852|NCT00822068|Experimental|anodal tDCS|
3193853|NCT00822068|Active Comparator|2|cathodal tDCS
3193854|NCT00822068|Placebo Comparator|3|sham stimulation
2486707|NCT02991196|Experimental|DS-8273a + nivolumab|Participants will receive their treatment dose until discontinuation for any reason, or trial completion, within two years
2486792|NCT02990884|Active Comparator|block and ketamine|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
2486796|NCT02990884|Active Comparator|ketamine atropine; laryngeal mask|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
2486801|NCT02990884|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane MAC and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2486843|NCT02990351||HCC patients|29 HCC patients who had loco regional therapies for HCC were analyzed. Twenty patients met the Milan criteria (68.97%) & 4 (13.8%) were beyond Milan but met UCSF criteria and 5 were exceeding UCSF criteria (17.2%).All patients underwent preoperative LRTs, The protocol of bridging/down staging, methods, duration of follow up, the number of the patients who were successfully down-staged before LT and their outcomes after LT were recorded.
2486881|NCT02990130||Study Group|This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
2486933|NCT02989766|Active Comparator|A - Intervention|Education on Breast Feeding 3 activity sheets prenatally-study related. Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
2486936|NCT02989766|No Intervention|B - Standard of Care|Complete a pre-questionnaire, a pre-delivery and a postpartum questionnaire
2486980|NCT02989376|Experimental|carotid duplex ultrasound|Single arm study. After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.
2487024|NCT02989038|Experimental|NNC, INC, VLNC|Normal Nicotine Content (NNC), Intermediate Nicotine Content (INC), Very Low Nicotine Content (VLNC)
2487026|NCT02989038|Experimental|NNC, VLNC, INC|Normal Nicotine Content, Very Low Nicotine Content, Intermediate Nicotine Content
2487030|NCT02989038|Experimental|INC, VLNC, NNC|Intermediate Nicotine Content, Very Low Nicotine Content, Normal Nicotine Content
2487034|NCT02989038|Experimental|INC, NNC, VLNC|Intermediate Nicotine Content, Normal Nicotine Content, Very Low Nicotine Content
2487037|NCT02989038|Experimental|VLNC, NNC, INC|Very Low Nicotine Content, Normal Nicotine Content, Intermediate Nicotine Content
2487040|NCT02989038|Experimental|VLNC, INC, NNC|Very Low Nicotine Content, Intermediate Nicotine Content, Normal Nicotine Content
2487233|NCT02987569|Active Comparator|Group Two|Control
2487505|NCT02985905|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment
3193855|NCT00822081|Active Comparator|1|brimonidine/timolol. Fixed-combination monotherapy.
3193856|NCT00822081|Active Comparator|2|dorzolamide/timolol. Fixed-combination monotherapy.
3193857|NCT00822081|Active Comparator|3|prostaglandin analogue+ brimonidine/timolol fixed combination.
2486173|NCT02994719||Neurological Disease subjects|Parkinson's Disease and other Parkinsonian Disorders subjects. Other Parkinsonian Disorders include Atypical Parkinsonism such as Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Primary Gait Freezing Disorder, Indeterminate Parkinsonian Syndrome. During the first visit no intervention will take place. There is an optional second visit during which subjects with Parkinson's Disease are asked to come come off antiparkinson medication and if applicable, off both medication and deep brain stimulation.
2486175|NCT02994719||Healthy control subjects|The healthy control subjects will be age- and sex-matched to the Neurological Disease subjects.
2486177|NCT02994719||Ataxia Subjects|The ataxia subjects will participate in an additional cohort that will test and validate the gait model.
2486179|NCT02994719||Huntington Disease Subjects|The Huntington Disease subjects will participate in an additional cohort that will test and validate the gait model.
3193858|NCT00822081|Active Comparator|4|prostaglandin analogue+dorzolamide/timolol fixed combination.
2486301|NCT02993900|Experimental|Image-Guided Brachytherapy|Magnetic Resonance Imaging (MRI) guided brachytherapy Procedure: Image-Guided Brachytherapy
2486367|NCT02993588|Experimental|Melatonin|Melatonin 6 mg tablet once daily.
2486377|NCT02993588|Placebo Comparator|Placebo|Placebo tablet once daily
3160542|NCT00426608|Experimental|Session 2|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of BACED sequence. In BACED sequence B is GSK6561679 10 mg, A placebo, C GSK6561679 50 mg, E Alprazolam, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3193859|NCT00822133|Active Comparator|lodocaine|lidocaine 5% cream will be put on the skin
2486476|NCT02992704|Experimental|PEG 24 weeks|peginterferon alpha 2a 180mcg for 24 weeks
2486477|NCT02992704|Experimental|PEG 48 weeks|peginterferon alpha 2a 180mcg 48 weeks
2486478|NCT02992704|No Intervention|Control|No treatment for 72 weeks
2486503|NCT02992405|Experimental|FOCUS Resilience Enhancement Program|Those assigned to the immediate treatment group will participate in the 10-week treatment.
2486508|NCT02992405|Experimental|Waitlist Treatment|After the 10-week immediate treatment period, wait-list control participants will be administered the treatment.
2486586|NCT02992171|Experimental|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
2486618|NCT02991690|Experimental|Hypothermia|Intravascular hypothermia will be initiated within 24 hours post-injury and 33 degrees Celsius will be maintained for 48 hours.
2486619|NCT02991690|No Intervention|Control|Standard of care medical treatment, specific to each individual.
2486669|NCT02991326|Experimental|Test Group (TG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to Osteopathic Manipulative Treatment - OMT.
2486670|NCT02991326|Sham Comparator|Control Group (CG)|The Individuals who already is subject to Clinical Treatment with splints offered at the Occlusion Clinic will be subject to sham intervention (Osteopathic Manipulative Treatment simulated).
2486747|NCT02991053|Active Comparator|block and ketamine|Transversus Abdominis Plane block after ketamine atropine induction and continued with ketamine only in anesthesia
2486749|NCT02991053|Active Comparator|block; ketamine with laryngeal mask; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Transversus Abdominis Plane block.
2486751|NCT02991053|Active Comparator|block and ketamine ıh/ıl|Ilioinguinal / iliohypogastric block after ketamine atropine induction and continued with ketamine only in anesthesia
2486752|NCT02991053|Active Comparator|ıh/ıl block; ketamine; inhalation anesthesia|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and applied Ilioinguinal / iliohypogastric block.
2486753|NCT02991053|Active Comparator|control group|After ketamine atropine induction, a laryngeal mask was inserted and anesthesia administration was continued with 2 sevoflurane minimum alveolar concentration and oxygen / air mixture and Non-block, postoperative analgesia with paracetamol IV
2486802|NCT02990650|Active Comparator|Standard physical therapist|A combination of nine balance training tasks where the physical therapist provides guarding against loss of balance
2486805|NCT02990650|Experimental|standard robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance
2486807|NCT02990650|Experimental|challenge based robotic guarding|A combination of nine balance training tasks where the robotic system provides guarding against loss of balance while the participant works at a level greater than their current balance capability
2486860|NCT02990312|Experimental|Sirolimus + Maraviroc|Participants will be placed on the combination of Sirolimus and Maraviroc, unless they are already on one of these medications.
2486944|NCT02989571|Active Comparator|Group 2 - Intervention Arm|Intravenous normal saline administered at 250ml/hr
3193860|NCT00822133|Experimental|ketamine|ketamine 5% will be put on the skin
2486181|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 200 et 160|According to the score obtained with the onco geriatric evaluation, patients with a score between 200 and 160 will receive a normo fractionated radiotherapy (66 Grays in 33 fractions). This scheme of radiotherapy is already used in the clinical practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2486182|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation between 159 et 120|According to the score obtained with the onco geriatric evaluation, patients with a score between 159 and 120 will receive an hypo fractionated radiotherapy (42,56 Grays in 16 fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2486185|NCT02994914|Experimental|Score of the Onco Geriatric Evaluation inferior to 119|According to the score obtained with the onco geriatric evaluation, patients with a score inferior to 119 will receive a large hypo fractionated radiotherapy (30 Grays in 5 weekly fractions). This scheme of radiotherapy is already used in the usual practice, but not allocated according to a score obtained at an oncogeriatric evaluation.
2486205|NCT02994407|Experimental|N8-GP s.c.|
2486328|NCT02993653|Experimental|Intensity-modulated radiotheapy arm|Intensity-modulated radiotheapy with stereotactic boost or intracavitary radiotherapy
2486364|NCT02993419|Experimental|Bacillus licheniformis Intervention|The intervention is use Bacillus licheniformis particles，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
2486375|NCT02993419|Placebo Comparator|placebo Intervention|The intervention is use placebo，The drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
2486429|NCT02993185|Experimental|Your Move|Sex education intervention
2486432|NCT02993185|Active Comparator|Eat Smart|Nutrition education intervention
3160543|NCT00426608|Experimental|Session 3|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of CBEAD sequence. In CBEAD sequence C is GSK6561679 50 mg, B GSK6561679 10 mg, E Alprazolam, A placebo, and D GSK6561679 400 mg. Wash-out period will be of 7 days.
2486573|NCT02992158|Experimental|behavioral activation|The core principles of the BA model are: (1) the key to changing how people feel is helping them change what they do, (2) changes in life can lead to depression, and short-term coping strategies may keep people stuck over time, (3) the clues to figuring out what will be antidepressant for a particular client lie in what precedes and follows the client's important behaviors, (4) structure and scheduling of activities should follow a plan, not a mood, (5) change will be easier when starting small, (6) activities that are naturally reinforcing should be emphasized, (7) the therapist should act as a coach, (8) a problem-solving empirical approach should be emphasized with recognition that all results are useful, (9) patients should be encourages to not just talk, do! (10) possible and actual barriers to activation should be examined. Patients can also receive medications in this arm.
2486582|NCT02992158|Other|treatment-as-usual|Patients will receive psychotherapy (and potentially medications) as part of treatment-as-usual provided in the CMHC setting.
2486634|NCT02991677|Other|control|This is an attention control group with regular contact by study staff.
2486645|NCT02991677|Experimental|aerobic exercise|Aerobic exercise intervention is for 12 weeks 3 times weekly with training on site.
2486649|NCT02991677|Experimental|resistive training|Intervention is for 12 weeks 3 times weekly with training on site.
3193861|NCT00822133|Placebo Comparator|placebo|non-active cream will be put on the skin
3193862|NCT00822146|Experimental|1|
2486877|NCT02990208|Experimental|VR exposure + diaphragmatic breathing|Virtual Reality Exposure Therapy + Diaphragmatic breathing
2486879|NCT02990208|Active Comparator|VR exposure|Virtual Reality Exposure Therapy
2486932|NCT02989753|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
2486935|NCT02989753|Experimental|VAL070-A|Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
2486941|NCT02989753|Experimental|VAL070-B|Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
2487032|NCT02989311|Active Comparator|Study 1:Morning test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the morning test meal A:12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
2487036|NCT02989311|Active Comparator|Study 1:Afternoon test meal+Iron+MNP|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g). Iron compound added to the afternoon test meal B:12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10mg of 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP + Iron)"
2487074|NCT02988804|Active Comparator|endotracheal tube|"Procedure: Endotracheal tube~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
2515729|NCT02792140|No Intervention|Baseline|reporting of dreams
2486261|NCT02994082|Experimental|Tailored Intervention|The tailored behavioral intervention includes both behavioral and pharmacological components. The behavioral component will consist of six sessions of cognitive behavioral therapy and coping skills training delivered over the telephone. In addition, participants will be screened for conditions commonly associated with tobacco use (depressive symptoms, risky alcohol use, weight concerns) and offered supplementary behavioral treatment modules to address these issues. Participants will also be offered pharmacotherapy for tobacco cessation, with decisions regarding specific medication(s) based on patients' medical history, contraindications, prior experiences, and preferences.
2486266|NCT02994082|Active Comparator|Facilitated tobacco quit line referral|Participants assigned to this condition will receive information about the VA telephone tobacco quit line and educational materials and encouraged to enroll in treatment. In addition, they will be given information regarding available medications for smoking cessation and encouraged to contact their primary care provider to discuss their options.
2486356|NCT02993510|Active Comparator|microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair
2486359|NCT02993510|Experimental|Microfracture with Chondro-Gide sutured|Microfracture covered with a collagen membrane (Chondro-Gide®) using atraumatic sutures in a one-step mini-arthrotomy procedure
2486363|NCT02993510|Experimental|Microfracture with Chondro-Gide glued|Microfracture covered with a collagen membrane (Chondro-Gide®) using fibrin glue in a one-step mini-arthrotomy procedure
2486435|NCT02993055|Experimental|Ulimorelin|Active
2486437|NCT02993055|Placebo Comparator|Placebo|Placebo
2486449|NCT02992860|Experimental|Treatment Arm|JNJ-56022473 will be given intravenously to all subjects at a dose of 9 mg/kg once every 14 days for an initial treatment period of 3 months (6 infusions). Responders will then receive up to 20 additional infusions whereas for non-responders the initial treatment will be followed by a up to 9 months observation period without further JNJ-56022473 treatment. Thus, the individual study duration for a subject will be approx. 1 year. A follow up visit will be performed after 3 months after last study drug administration for all patients to track pregnancy status according to IB.
2486488|NCT02992496|Active Comparator|Ketamine treatment group|Each patient will undergo six treatment sessions with 1mg/kg oral ketamine over 2 weeks.
2486490|NCT02992496|Active Comparator|Control group|Each patient will undergo six treatment sessions with 0.03mg/kg oral midazolam over 2 weeks
2486532|NCT02992366|Experimental|socket shield (A)|"Following local anesthetic infiltration opposite to the root to be extracted the root is sectioned in a mesiodistal direction along its long axis as far apical as possible.~After sectioning the root into labial and palatal halves, the palatal half is removed with preservation of the labial root section.~The labial half is prepared to be Flushing or 1mm above the labial alveolar crest. Then thinned slightly to a concave contour in an apico-coronal and mesiodistal direction.~The implant will be inserted in place of the palatal half with the labial surface of the implant facing the labial root shield (root-implant interface)~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
2486533|NCT02992366|Active Comparator|conventional immediate implant (B)|"Following local anesthetic infiltration opposite to the root to be extracted non traumatic extraction of the tooth or remaining root by periotome.~The implant fixture will be inserted in the empty socket by conventional manner.~primary closure will not be attempted as the patients will undergo immediate non-functioning provisionization."
2486560|NCT02991911|Experimental|Arm A|MEDI3726 Post-Chemo
2486563|NCT02991911|Experimental|Arm B|MEDI3726 Pre-Chemo
2486565|NCT02991911|Experimental|Arm C|MEDI3726 & Enzalutamide Combo
2486608|NCT02991664|Active Comparator|Equia Forte, randomly applied|Placing glass ionomer restorations, the dentin and enamel of cavities were washed, and briefly dried. Equia Forte Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Forte Coat was applied and photocured for 20 seconds using a photo-curing light.
2486610|NCT02991664|Active Comparator|G-aenial Posterior, randomly applied|After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
2486672|NCT02991456|Active Comparator|Sequence A|Daily ondansetron alone for 3 weeks, followed by the use of rolapitant (one dose on day 22) plus continued daily ondansetron for 3 weeks.
2486674|NCT02991456|Active Comparator|Sequence B|Single dose of rolapitant (one dose on day 1) plus daily ondansetron for 3 weeks, followed by daily ondansetron alone for 3 weeks.
2486799|NCT02990637|Active Comparator|OLECOL|Olive leaf extract
2486803|NCT02990637|Placebo Comparator|Placebo|Maltodextrin
3160544|NCT00426608|Experimental|Session 4|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of ECABD sequence. In ECABD sequence E is Alprazolam, C is GSK6561679 50 mg, A placebo, B GSK6561679 10 mg and D GSK6561679 400 mg. Wash-out period will be of 7 days.
3160545|NCT00426608|Experimental|Session 5|Subjects will be randomized to receive Dose 1 of Metyrapone 0.04 g/kg and Dose 2 of GSK561679 400 mg and alprazopam placebo. Wash-out period will be of 7 days.
3160546|NCT00426621|Experimental|1|
3160547|NCT00426621|Placebo Comparator|2|
3160548|NCT00426647|Experimental|Buprenorphine|Norspan transdermal patch
3160549|NCT00426647|Active Comparator|Tramadol|Tramadol SR tablets
3160550|NCT00426712|Experimental|1|Low dose
3160551|NCT00426712|Experimental|2|Middle dose
3160552|NCT00426712|Experimental|3|High dose
3160553|NCT00426712|Active Comparator|4|
3160554|NCT00426725|Experimental|A|This group uses the EasyLabour device according to the protocol
3160555|NCT00426725|No Intervention|Control|
3160556|NCT00426777|Active Comparator|risedronate|
2486353|NCT02993497|Experimental|Respiratory monitoring group|
2486415|NCT02993198|Experimental|Prophylactic Carvedilol|Carvedilol 3.125 mg by mouth every 12 hours, titrated to a max dose of 25 mg by mouth every 12 hours, depending on blood pressure and heart rate, until completion of study.
2486419|NCT02993198|No Intervention|No Therapy|Standard of care monitoring without prophylactic treatment.
2486460|NCT02992938|Experimental|Acetazolamide|250 mg VO of acetazolamide will be administered the day of the surgery 2 hours before anesthesia induction
2486461|NCT02992938|Placebo Comparator|Placebo|An oral tablet without active principle acetazolamide but with the same physical characteristics will be administered the day of the surgery 2 hours before anesthesia induction
2486512|NCT02992574|Experimental|Post Mastectomy Radiation Therapy (PMRT)|Post mastectomy radiotherapy will be given
2486514|NCT02992574|No Intervention|Observation (No PMRT)|No adjuvant radiotherapy will be given.
2486570|NCT02992054||Stimulating activities with the use of tactile tablet computer|Stimulating activities through the use of a tactile tablet computer. These tablets are linked to an internet-based service platform and offer a very easy and intuitive interaction for the user, even when this person is suffering from a moderate cognitive and/or physical impairment.
2486579|NCT02992054||Stimulating activities with usual stimulation activity program|No Stimulating activities through the use of a tactile tablet computer
3160557|NCT00426777|Placebo Comparator|placebo|
2486789|NCT02990845|Experimental|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
2486834|NCT02990455|Experimental|Reduced Nicotine Cigarette - Moderate|Nicotine Research Cigarette Drug Supply Program Category Codes NRC600 and NRC601 (menthol); each cigarette contains 0.8mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
2486835|NCT02990455|Experimental|Reduced Nicotine Cigarette - Low|Nicotine Research Cigarette Drug Supply Program Category Codes NRC102 and NRC103 (menthol); each cigarette contains 0.03mg nicotine; participants will be instructed to smoke these cigarettes according to their usual smoking patterns
2486882|NCT02990117||Asthmatic patient|Asthma patients aged >18 in out-patient clinic of the first affiliated hospital of Xi'an Jiaotong university from November 2016 to January 2018 were investigated. A two-stage study was applied which was non-assumptive deep dive qualitative scoping to investigate the determinants of poor compliance in stage 1 asthma patients, and developed new questionnaire for cross sectional survey in stage 2 to obtain more accurate information about the critical issues on asthma management.
2486939|NCT02989792|Other|Unique study arm|
2487027|NCT02989337||hyperemesis gravidarum with dehydration|The first group was formed of the patients diagnosed hyperemesis gravidarum with dehydration
2487031|NCT02989337||Control group|The control group was formed of the patients who were healthy pregnant women admitted to the clinic just for routine examination without any symptoms
2487141|NCT02988440|Other|PDR001 + Sorafenib|PDR001 at 400 mg given intravenously every 4 weeks and sorafenib 400 mg taken orally once or twice per day (escalating doses)
3160558|NCT00426816|Experimental|Crossover population|All study population receive placebo and doses of SB-649868 at 10mg, 30mg and 60mg in a crossover desing
3160559|NCT00426829|Experimental|Proton Therapy + Bevacizumab|Proton Therapy + Bevacizumab
2487247|NCT02987491|Experimental|Exercise Metabolic Study Day|"Participants will perform a single bout of moderate intensity exercise on a cycle ergometer for 60 minutes.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
2487250|NCT02987491|No Intervention|Resting Metabolic Study Day|"Participants will rest quietly in bed for 60 minutes and resting energy metabolism will be measured with a ventilated hood.~A total of 3 muscle biopsies will be collected throughout the study day. Insulin sensitivity will be measured using a hyperinsulinemic-euglycemic clamp with glucose tracers."
2487280|NCT02987244|Experimental|C-CHOEP|experimental arm will be treated by Chidamide combined CHOEP ( cyclophosphamide, epirubicine, vindesine, etoposide and prednisone) regimen for 6 cycles.
2487375|NCT02986646||physical therapy (PT) and rest|This group of subjects will be prescribed a physical therapy home exercise program and rest (of the injured elbow).
2487378|NCT02986646||PT and intra-tendinous steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-tendinous corticosteroid injection into the area of the ECRB origin (of the injured elbow).
2487380|NCT02986646||PT and intra-articular steroid injection|This group of subjects will be prescribed a physical therapy home exercise program and will received an intra-articular corticosteroid injection into the elbow joint (of the injured elbow).
2487391|NCT02986360|Active Comparator|Vidscrip educational video|Patients receive Vidscrip education video discussing breast density in the context of their normal mammogram result
3160560|NCT00426868|Experimental|Treatment|
3160561|NCT00426868|Placebo Comparator|Placebo|
3160562|NCT00426881|Experimental|1|Twice weekly resistance training for 52 weeks.
3160563|NCT00426881|Experimental|2|Once weekly resistance training for 52 weeks.
3160564|NCT00426881|Experimental|3|Twice weekly balance and tone training for 52 weeks.
3160565|NCT00426907|Experimental|1|Full postoperative weightbearing
3160566|NCT00426907|Active Comparator|2|Partial weightbearing 6 weeks postoperative
3160567|NCT00427076|Experimental|A|Cotrimoxazole
3160568|NCT00427076|Active Comparator|B|Vancomycin
3160569|NCT00427089|Experimental|1|2L gut cleansing solution
3160570|NCT00427089|Active Comparator|2|
3160571|NCT00427154|Active Comparator|A|
3160572|NCT00427154|Active Comparator|B|
3160573|NCT00427206|Active Comparator|1|acetaminophen 4 g/day
3160574|NCT00427206|Placebo Comparator|2|placebo undistinguishable from active drug
3160575|NCT00427219|Experimental|Ozarelix|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received ozarelix on Day 0 and Day 14.
3160576|NCT00427219|Placebo Comparator|Placebo|All participants completing the placebo run in period were randomized to enter the treatment phase of the study and received placebo Day 0 and Day 14.
2486303|NCT02993939|Experimental|Diaphragm-sparing block|Ultrasound guided combinated infraclavicular-Suprascapular block of the braquial plexus, injecting 20 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml dorsal to the axillary artery in the infraclavicular fossa plus an Ultrasound guided injection of 10 ml of levobupivacaine 0,25% plus epinephrine 5 micrograms per ml in the suprascapular fossa.
2486405|NCT02993276||Treatment Group|All subjects receiving the Neurocap® device when surgically treated for their symptomatic peripheral end-neuroma.
2486446|NCT02992808|Active Comparator|Recombinant preparations|
2486448|NCT02992808|Active Comparator|HP-HMG|Highly purified human menopausal gonadotropin
2486495|NCT02992600||study group|1000 Male and female patients undergoing non-cardiac surgery at the Affiliated Hospital of Xuzhou Medical University [Jiangsu China]. We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
2486496|NCT02992600||control group|we enroll 50 healthy volunteers and do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test at 1 day (baseline), 1 week, 3 months, 1 year and 3 years without safety issue.
2486541|NCT02992314|Experimental|Metaqil™ Oral Rinse|"In this arm the test article, Metaqil ™ oral rinse, a proprietary formulation of agents including Monk fruit extract, which can minimize the metallic taste in the mouth caused by the patient's medications.~Subjects rinse twice a day with 10 mL of the oral rinse for 30 seconds for 30 days.~They will note, in the daily oral hygiene diary, the date and time of brushing and rinsing."
2486542|NCT02992314|Placebo Comparator|Placebo Oral Rinse|This arm will use a placebo with out the active ingredients same way the experimental arm do.
2486557|NCT02991963||Case|Malaria patient defined by positive RDT or blood smear
2486558|NCT02991963||Control|Non-malaria patient defined by negative RDT or blood smear
2486622|NCT02991651|Experimental|Dose Level 1|IRX4204 5 mg/day PO + erlotinib 100 mg/day PO
2486625|NCT02991651|Experimental|Dose Level 2|IRX4204 5 mg/day PO + erlotinib 150 mg/day PO
2486635|NCT02991651|Experimental|Dose Level 3|IRX4204 10 mg/day PO + erlotinib 150 mg/day PO
2486667|NCT02991287||Chronic post-surgical pain patients|Patients scheduled for differents types of surgery (inguinal, hernia repair, abdominal hysterectomy, vaginal hysterectomy, and thoracotomy).
2486873|NCT02990156|Experimental|Coil Embolization System|Coil Embolization System,or deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame,and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm.
2486875|NCT02990156|Active Comparator|Control device from Medronic|Control device from Medronic,include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils, which are manufactured by ev3 (Medtronic, Irvine, California, USA);
2486931|NCT02989818||Lesion of the Gastrointestinal tract|Investigator will collect prospective data on the Endoscopic Submucosal dissection that is used as part of the subjects standard of care to remove the Gastrointestinal lesion
2486975|NCT02989350|Active Comparator|Lactobacillus reuteri DSM 17938|2 x 10(8) CFU. Both L reuteri DSM 17938 and placebo will be taken orally, twice daily 5 drops, for consecutive 5 days.
2486977|NCT02989350|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
2487001|NCT02989116|Experimental|Preterm Inhibition|"In children born very preterm:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2487007|NCT02989116|Experimental|Full-term Inhibition|"In children born full-term:~Inhibition training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2487012|NCT02989116|Experimental|Full-term Working memory|"In children born full-term:~Working memory training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2487016|NCT02989116|Experimental|Full-term Mindfulness|"In children born full-term:~Mindfulness training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2487020|NCT02989116|Active Comparator|Full-term Active control|"In children born full-term:~Active control training, Saliva collection, Brain Magnetic Resonance Imaging, Cognitive testing"
2487087|NCT02988635|Experimental|Early Palliative Care|Subjects receive standard of care with early palliative care.
2487088|NCT02988635|No Intervention|Standard of Care|Subjects receive standard of care.
3193863|NCT00822198|Experimental|plantar vibration|Subject will use Juvent plantar vibration device daily in the home or office for six months.
3193864|NCT00822211|Experimental|Vildagliptin Dose 1|
2487322|NCT02987036|Experimental|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Aerogen
2487324|NCT02987036|Other|Jet Nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet Nebulizer
2487345|NCT02986698|Experimental|in utero hematopoietic stem cell transplantation|"Perform in utero hematopoietic stem cell transplantation at the time of intrauterine transplantation in fetuses with alpha-thalassemia major. The cellular product is: Semi-allogeneic, Related, Maternal Bone Marrow-Derived, Miltenyi CliniMACS Plus enriched CD34+ hematopoietic stem cells administered in utero at a dose of 1 x 10^7-10^9 cells/kg fetal weight with equal to or less than 1% CD3+ T cells (equivalent to 10^5-10^7 T cells/kg fetal weight) in a final volume of 2-5ml suspended in 5% human serum albumin in Normosol buffer (Hospira, Inc.).~Stem cells will be administered immediately before the red blood cells intravenously via the umbilical vein during the clinically indicated IUT. All participants will receive one dose of stem cells but may receive additional transfusions as clinically indicated."
2487417|NCT02986425|Experimental|STRIP intervention|The intervention will take place during the initial hospital admission (Index Hospitalisation) or an equivalent situation for outpatients. STRIP is a structured method to perform pharmacotherapy optimisation. The STRIP-intervention consists of 9 steps.
2487574|NCT02985294||Cross-sectional cohort|Multiple Excitability Measures of peripheral nerves on patients with chronic peripheral neuropathic pain
3193865|NCT00822211|Experimental|Vildagliptin Dose 2|
3193866|NCT00822211|Placebo Comparator|Placebo|
3193867|NCT00822224|Experimental|1|Use of MEOPA during the painful care
2486382|NCT02993341|Experimental|Tranexamic Acid Wash|Participants in the experimental arm will receive a wash of tranexamic acid topically at the site of surgery.
2486386|NCT02993341|Placebo Comparator|Saline Wash|Participants in the control arm will receive a wash of saline topically at the site of surgery.
2486401|NCT02993094|Experimental|Ixazomib/Carboplatin|"Accelerated dose-escalation phase with a single-patient cohort per dose level until defined DLT is observed during cycle 1, or until dose level 4 is reached. At this dose level the cohort is expanded to three patients and dose escalation reverts to a conventional 3+3 escalation design.~Intervention (experimental): Ixazomib; po; 3mg escalated to 4mg; day 1, 8, 15 Intervention (backbone): AUC 1.5 escalated to AUC 2.5; day 1, 8, 15"
2486452|NCT02992847||Dotarem|At least 5 injection with Dotarem exclusively
2486455|NCT02992847||Multihance|At least 5 injection with Multihance exclusively
2486501|NCT02992613|Experimental|Ultra-Congruent(UC) group|Ultra-Congruent(UC) insert will be used in total knee arthroplasty.
2486502|NCT02992613|Active Comparator|posterior-stabilized(PS) group|Posterior-stabilized(PS) insert will be used in total knee arthroplasty.
2486629|NCT02991586|Experimental|Dialectical Behavior Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral treatment that was originally developed to treat chronically suicidal individuals diagnosed with borderline personality disorder (BPD) and it is now recognized as the gold standard psychological treatment for this population. In addition, research has shown that it is effective in treating a wide range of other disorders such as substance dependence, depression, post-traumatic stress disorder (PTSD), and eating disorders. In this research DBT skills will be taught to parents of adolescents with high emotional instability
2486641|NCT02991586|No Intervention|Control|"Control: The No intervention arm in this research is defined as follow:, sons and daughters are in their respective treatment but parents are nor receiving any DBT intervention"
2486668|NCT02991417|Experimental|CDVAX|
2486728|NCT02991092|Experimental|the experimental group|After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h
2486729|NCT02991092|Other|the control group|"patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
2486777|NCT02990702|Active Comparator|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block group patients (Group R) will receive 30 cc %0.5 Bupivacaine
2486780|NCT02990702|Active Comparator|Ultrasound guided infraclavicular block|Ultrasound guided coracoid infraclavicular block group patients (Group C) will receive 30 cc %0.5 Bupivacaine
2486852|NCT02990325|Experimental|ABX464 150mg|ABX464, 50mg per Capsule Three Capsules per day for 28 days
2486854|NCT02990325|Experimental|ABX464 50mg|ABX464, 50mg per Capsule One Capsule per day for 28 or 84 days
2486897|NCT02989935|Experimental|Fluticasone vilanterol bronchodilator|"Inhalation of fluticasone furoate/vilanterol trifenatate, 100 mcg/25 mcg combination, bronchodilator,using standard dry powder inhaler.~Interventions include ventilation, parasternal EMG, and phrenic magnetic stimulation."
3193868|NCT00822250|Other|1|cutting hair, skin phenotype description
3193869|NCT00822263|Placebo Comparator|2|control
2487130|NCT02988518|Experimental|COGMED program|Cognitive remediation using COGMED program on bipolar euthymic patients with memory complaints
2487139|NCT02987998|Experimental|Resectable Patients|Chemoradiation (Cisplatin + Etoposide + Pembrolizumab with concurrent radiation). Patients will be assessed for surgery followed by consolidation therapy
3193870|NCT00822263|Experimental|1|Active medicine
3193871|NCT00822276||ADEH+ participants colonized with MSSA|
3193872|NCT00822276||ADEH+ participants colonized with MRSA|
3193873|NCT00822276||Uncolonized ADEH+ participants|
3193874|NCT00822276||ADEH- participants colonized with MSSA|
3193875|NCT00822276||ADEH- participants colonized with MRSA|
2487454|NCT02986113|Experimental|Men and Providers Preventing Suicide|Tailored interactive multimedia intervention, aimed at activating suicidal middle-aged men to disclose and discuss their suicide thoughts with and be receptive to treatment offers from a primary care provider during a linked office visit
2487457|NCT02986113|Active Comparator|Sleep hygiene video|A brief (3 minute) video regarding sleep hygiene, accompanied by introductory text summarizing research linking sleep problems with increased suicide risk.
3193876|NCT00822276||Uncolonized ADEH- subjects|
3193877|NCT00822276||Non-atopic uncolonized S. aureus participants|
3193878|NCT00822302|Placebo Comparator|1.Saline Infusion|Patients randomised to this arm will receive an infusion of saline
3193879|NCT00822302|Active Comparator|2.recHDL|Patients randomised to the active comparator arm of the study will receive 40mg/kg reconstituted High density lipoproteins (lot nos 05422-00006) over a period of 4 hours, 24 hours prior to carotid endarterectomy.
3193880|NCT00822315|Active Comparator|1|efavirenz
3193881|NCT00822315|Experimental|2|raltegravir 400 mg
3193882|NCT00822315|Experimental|3|raltegravir 800 mg
3193883|NCT00822367|Experimental|Nutritional suplements|
3193884|NCT00822380|Experimental|Anemic children|
3193885|NCT00822393|Active Comparator|1|Busulfan
3193886|NCT00822393|Experimental|2|Treosulfan
3193887|NCT00822406|Active Comparator|1|This arm received individualized homeopathic medicine during 6 months (initial phase), and completed three years (second phase)
3193888|NCT00822406|Placebo Comparator|2|This arm received placebo during 6 months. After this period, all patients received individualized homeopathic medicine for three years.
3193889|NCT00822419|Active Comparator|lidocaine|Lidocaine 5% cream 5 gr will be double blindly put on the skin preoperatively
3193890|NCT00822419|Experimental|ketamine|ketamine cream 5% 5gr will be put on the skin preoperatively
3193891|NCT00822419|Sham Comparator|placebo|non-drug similar cream will be put on the skin preoperatively
3193892|NCT00822432||1|
2486506|NCT02992522|Experimental|Treatment (lenalidomide, venetoclax, obinutuzumab)|Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2486543|NCT02991989|Experimental|Exercise Snacking Group|For 28 days, this group will be asked to perform two 'exercise snacks' a day; once in the morning and once in the evening. They will also be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers.
2486544|NCT02991989|Other|Yogurt Only Group|For 28 days, this group will be asked to consume 150 g of yogurt with the breakfast meal. The yogurt will be provided by the researchers. Apart from consuming the yogurt, this group will be asked to continue their normal lifestyle.
3160577|NCT00427310|Experimental|Arm 1: Postoperative 5 FU + sodium heparin|Continuous portal vein infusion with 5 FU 600 mg/m2 + 5000 units sodium heparin per day given for a total of 7 consecutive days.
3160578|NCT00427310|Active Comparator|Arm 2: Postoperative observation|
2486709|NCT02991313|Experimental|Endocardial Ablation Procedure|ablation with Linear type catheter
2486800|NCT02990858|Experimental|PRO 140|
2486816|NCT02990442|Experimental|rTMS|treatment with repetitive transcranial magnetic stimulation for 30 days
2486870|NCT02990234|Active Comparator|Capsular Repair|Capsular Repair arm. The first hip is randomized, opposite treatment on second hip. One Hip will receive the capsular repair while the other hip will not.
2486874|NCT02990234|Placebo Comparator|No Capsular Repair|Placebo arm. One hip is randomized to capsular repair while the other hip has no capsular repair.
2486901|NCT02989883|Other|Peroral endoscopic myotomy (POEM)|Patients who received POEM
2486955|NCT02989623|Experimental|Diagnostic (copper Cu 64 TP3805, PET/CT, biopsy)|Patients receive copper Cu 64 TP3805 IV over 5 minutes and 30 minutes and 2 hours later, undergo whole body Positron Emission Tomography/Computed Tomography (PET/CT) imaging over 1 hour.
2487028|NCT02989207|Active Comparator|Trabeculectomy with Mitomycin-C|The current standard surgical treatment for glaucoma remains trabeculectomy.
2487029|NCT02989207|Active Comparator|Baerveldt tube surgery with Mitomycin C|It consists of a tube, draining aqueous humour to a plate
2487033|NCT02989207|Active Comparator|Baerveldt tube surgery without Mitomycin C|It consists of a tube, draining aqueous humour to a plate
2487104|NCT02988726|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.
2487145|NCT02988323|Experimental|Cervicovestibular Physio (CV PT)|In addition to the standard protocol of rest followed by exertion, the CV PT group will participate in a combination of cervical spine and vestibular rehabilitation as per a standardized treatment algorithm based on individual assessment findings. This form of therapy combines treatment techniques for both the cervical spine and vestibular system that are commonly used in physiotherapy practice. Cervical spine treatments may include neuromotor retraining, sensorimotor retraining, manual therapy, soft tissue techniques, and range of motion exercises. Vestibular rehabilitation may include gaze stabilization, habituation, standing balance, dynamic balance and canalith repositioning maneouvers.
2487150|NCT02988323|Experimental|Low-Level Aerobic Exercise (LLAE)|Participants will exercise at 60% maximum heart rate for 15 minutes. This heart rate will be calculated by taking 220-age (in years) and multiplying by 0.6 to determine the target heart rate while performing the low level aerobic exercise. Aerobic exercises may include treadmill, walking or stationary cycling. Exercise will be performed 5-6 times per week independently at home and monitored by their parents. Individuals will be taught how to monitor their heart rate. This protocol has previously been found to be feasible and of minimal risk to participants.
2487154|NCT02988323|Other|Combination (LLAE and CV PT)|The combination group will complete a protocol that includes both the cervicovestibular physiotherapy and LLAE interventions described above. As described above, the study participants will be seen once weekly by the study physiotherapist for CV PT and also complete a protocol of LLAE at home.
2487197|NCT02987855|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe lipoaspiration harvest of subdermal fat
2487198|NCT02987855|Experimental|AD-cSVF Arm 2|ADcSVF Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction
2487199|NCT02987855|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2487309|NCT02987192|Experimental|traditional group|Traditional group patients will receive cutting type 22 gauge needles
2487312|NCT02987192|Experimental|minimally invasive group|minimally invasive group patients will receive pen type 27 gauge needles
2487367|NCT02986724||Vedolizumab|Bio-naïve participants with UC or CD will be treated with vedolizumab as per local prescriptions from physician in routine medical practice for up to 52 Week. Participants who fail on vedolizumab may be switched during the study to another biologic treatment as prescribed by the physician during routine medical practice for up to 52 Weeks.
2488016|NCT02982161|Active Comparator|MR308 150 mg bid|Tramadol/Celecoxib 150 mg
2486459|NCT02992795||Cohort IIa|Athletes from Cohort I will be assigned to cohort IIa once they sustain an injury other than concussion. They will have been pulled out of the game by the athletic trainer and removed from play until at least the end of the game. Once the subjects have been assigned to Cohort IIa, they will have a BrainPulse recording and a symptom evaluation within 3 days of their injury. After two weeks of recovery, subjects in this cohort will return to Cohort 1 and resume their participation in the study in their respective sub-cohort.
2486462|NCT02992795||Cohort IIb|Athletes in this cohort are injured subjects who sustain a non-penetrating head injury and are confirmed to have had a concussion according to the protocol reference standard and by their physician. All subjects enrolled in this cohort are required to have a BrainPulse recording within 3 days of their injury. Each BrainPulse recording will be accompanied by a symptoms evaluation and medical data collection documented in the case report forms. Subjects will complete 3 weeks of follow-up visits post injury.
2486498|NCT02992548|Experimental|pravastatin group|Use of pravastatin 20mg to 40mg
2486559|NCT02992184||HCV patients|228 HCV patients
2486562|NCT02992184||control|189 controls
2486621|NCT02991768|Experimental|Entocort EC|Subjects will take 6mg Entocort EC by mouth daily for 8 weeks.
2486624|NCT02991768|Placebo Comparator|Placebo|Subjects will take 6mg matching placebo pill daily for 8 weeks.
2486694|NCT02991404|Active Comparator|Continuous adductor canal block|"After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time (Initial bolus) 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.~Multimodal peripheral nerve block injection."
2486698|NCT02991404|Sham Comparator|Single injection block with sham cath|Single Shot Adductor Canal Block . Patients will receive single injection adductor canal block (Initial Bolus) with bupivacaine 0.25%, epinephrine, clonidine, buprenorphine and dexamethasone. These patients will have a sham infusion catheter of inert saline placed in the same fashion as the other group.
2486782|NCT02990936||head and neck squamous cell carcinoma|Patients with T1 to T4 head and neck squamous cell carcinoma from oral cavity, oropharynx, larynx and hypopharynx eligible for radiotherapy or concomitant chemoradiotherapy
2486836|NCT02990364|Active Comparator|Control: EMLA Topical Product|"This represents the control group and it is the traditional analgesic used for circumcisions.~EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures. Seventy minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. 1 gram of EMLA cream will be applied by the nurse to the penis using a syringe and then wrapped with a dressing (Tegaderm). After sixty minutes the Tegaderm and drug will be removed, and the infant will be left to settle until the circumcision."
2486837|NCT02990364|Active Comparator|EMLA + Sucrose|"There is high-quality evidence for the beneficial effect of sucrose (24%) with non-nutritive sucking (pacifier dipped in sucrose) or 0.5 mL of sucrose orally in preterm and term infants. To assess this, 10 ml of sucrose (24%) will be given to the infant during the course of the circumcision.~In combination to the EMLA cream, the infant will be given sucrose during the circumcision to test the effects of sucrose and sucking on pain management."
2486839|NCT02990364|Active Comparator|EMLA + Sucrose + Ring Block|"Ring block will be done with 1% lidocaine without epinephrine injected in a band around the penis halfway along the shaft. Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with the legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the ring block and will be injected in a band around the penis. The block will be done by the circumciser.~In combination with the ring block, EMLA + sucrose will be given during the circumcision."
2486841|NCT02990364|Active Comparator|EMLA + Sucrose + DPNB|"Dorsal penile nerve block (DPNB) will be done with 1% lidocaine without epinephrine injected at two sites at the base of the penis (2 and 10 o'clock). Ten minutes prior to circumcision, the newborn will be placed in the circumcision mold with legs restrained, and attached to a monitor. A total of 2 mg/kg of 1% lidocaine without epinephrine will be used to perform the block, and equal aliquots in milliliters will be injected at the two sites at the base of the penis. The block will be done by the circumciser.~In combination with the DPNB, EMLA + sucrose will be given during the circumcision."
2486923|NCT02989987|Active Comparator|Narrative Exposure Therapy|According to the NET manual (one lifeline session and 7 exposure sessions; see Schauer et al. 2011).
2486927|NCT02989987|Active Comparator|Treatment-as-usual|Social support (provided on demand)
2486981|NCT02989415||Mechanical Ventilation|Patients undergoing mechanical ventilation during robotic surgery
2487045|NCT02989025|Experimental|Experimental|To determine if the addition of 17 OHPC to the management of Severe PE diagnosed prior to 34 weeks gestation improves maternal and perinatal outcomes.
2487096|NCT02988739|Experimental|Laser assisted epidermal application|"Laser pretreatment: 4 adjacent areas of 2 cm² each (14mm x 14 mm) will be pretreated with an Erbium Yttrium Aluminium Garnet laser (22,7 J/cm², 2 pulses, Density: 5%) generating micropores with a depth of approximately 91 µm.~0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be topically administered on the laser-treated area."
2487101|NCT02988739|Active Comparator|Intradermal application|0,1 ml of Intanza (15 µg, seasonal trivalent influenza vaccine) will be intradermally injected in the deltoid area.
2487214|NCT02987634|Experimental|PeriActive mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 15 ml of Periactive
2487218|NCT02987634|Active Comparator|chlorhexidine 0.12% mouthwash|patient is directed to rinse twice a day for 4 weeks. each rinse is 10 ml of Periactive
2487294|NCT02987426|Experimental|Mindfulness-oriented intervention|Patients will get a mindfulness-oriented intervention daily for 10 minutes.
2487297|NCT02987426|No Intervention|Treatment as Usual|This group will continue receiving their normal inpatient psychiatric care and receive information (paper brochures) about health promotion.
2487358|NCT02986906|Experimental|5% dextrose|The perineural injection with 5% dextrose is a new and potential treatment for peripheral entrapment neuropathy
2487776|NCT02983929||BMI <30 kg.m-2|Patients with a BMI inferior to the obesity limit defined by the World Health Organization.
2486536|NCT02992353|Active Comparator|Three-port pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2486537|NCT02992353|Active Comparator|Single-port or two-port surgery|Treated by minimally invasive video assisted thoracoscopic single-port or two-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2486574|NCT02991937|Active Comparator|Medical Therapy|Subjects in the medical therapy arm will be treated with piperacillin/tazobactam for at least 24 hours. Ciprofloxacin/metronidazole will be used in penicillin-allergic patients. Subjects will be maintained on nothing by mouth with intravenous fluids for at least 12 hours. Subjects will be transitioned to oral antibiotics when their WBC is normal, they have a decrease in CRP by ≥ 15%, and they have been afebrile for 24 hours on IV antibiotics.
2486581|NCT02991937|Active Comparator|Surgical Intervention|Subjects in the surgical treatment arm will receive intravenous antibiotics until the time of operation, and will be maintained on intravenous fluids and no oral intake until they undergo appendectomy as per standard of care. Appendectomy will occur within 24 hours of enrollment. Subjects in the surgical treatment arm will receive post-operative antibiotics as per standard of care.
2486631|NCT02991625|Experimental|Placebos|Chronic Back Pain participants will enter an optional placebo trial. This phase of the study will test the clinical usefulness of the biomarkers. We will measure how expectation of starting a new treatment reduces 'clinical back pain' in each participant. Positive treatment expectations will be induced by giving them capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
2486643|NCT02991625|Other|Waitlist|Chronic Back Pain participants will not be given any placebo and will be requested to report their pain on paper forms organized as a calendar.
2486646|NCT02991625|Other|Healthy Controls|Healthy control participants will complete the main part of the study, but will not be asked to take a placebo or be placed on a waitlist.
2486663|NCT02991339|Experimental|Dexamethasone|Dexamethasone 10 mg iv on day 1 and day 2, then 5 mg iv on day 3. For the patients the serum total bilirubin did not decrease to 1.5 ULN, then 5 mg iv on day 4.
2486666|NCT02991339|No Intervention|control|Patients are not treated with glucocorticoids.
2486719|NCT02991079|Active Comparator|Control: Lifestyle counseling|Counseling on physical activity and Mediterranean diet.
2486721|NCT02991079|Experimental|Intervention group|Add for three months a smartphone with an app (EVIDENT) to improve alimentation and physical activity, five cardio-health rides and feeding workshop.
2486756|NCT02990767||observational women|collecting maternal factors, biophysical and biochemical markers at 11-13 weeks of gestation.
2486859|NCT02990286|Experimental|Rituximab with Mycophenolate Mofetil|
2486867|NCT02990286|Placebo Comparator|Placebo of rituximab with Mycophenolate Mofetil|
2486925|NCT02989779|Experimental|Active/Placebo crossover|NK1 Antagonist 7 days followed by placebo 7 days.
2486928|NCT02989779|Active Comparator|Placebo/Active Crossover|Placebo for 7 days followed by NK1 Antagonist 7 days.
3193893|NCT00822458|Experimental|Arm I|"Patients receive oral hedgehog antagonist GDC-0449 once daily on days 1 and 4-28 in course 1 and on days 1-28 in all subsequent courses. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected periodically for pharmacokinetic studies. Archival tumor tissue samples are collected and analyzed for the expression of genes that activate the SHH (e.g., Gli1, Gli2, SFRP1, ATOH1, and PTCH2) or WNT (e.g., DKK2 and DKK4) cell signal pathways by in situ hybridization and reverse transcriptase real time-PCR."
3193894|NCT00822471|Other|Diabetes Self-Management Education|Education intervention with historic self-controls.
3193895|NCT00822484|Active Comparator|ILV-095|6 SC single dose injections
2487114|NCT02988570|Experimental|children born very preterm|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
2487163|NCT02988206|Other|Personalized Objects|"The item Functional Object Use was assessed by using personalized objects (e.g., cigarette, paper) and non-personalized objects, which presented in a random order.."
2487168|NCT02988206|Other|non-personalized objects|"The item Functional Object Use was assessed by using non-personalized objects"
2487207|NCT02987790|Experimental|C-reactive Protein|In this group, the attending physicians will be instructed to follow the decision flowchart based on the CRP values. Antibiotic suspension will be encouraged when levels of this marker are <35mg/L (if peak PCR below 100mg/L); or reduce 50% of the highest value (if PCR peak > 100mg/L), with a limit of seven days, if there is clinical improvement. If a given patient has persistently elevated CRP levels (> 100 mg/l or fall less than 50% relative to the time of inclusion), the investigators will encourage attending physicians to maintain antibiotics and to perform a careful search for persistent infection. In case of doubts, if the patient is well clinically and without signs of active infection, the duration of antibiotic therapy should be the same as suggested for the Best Practice group.
2487208|NCT02987790|No Intervention|Best Practice|"Patients will be initially treated according to the current protocols used in the intensive care units. Decisions about interruption or continuation of treatment will be made according to pre-established time and also according to the clinical evolution of the patients. CRP levels will not be measured and will not be considered in the decision to discontinue antimicrobials. Any decision ultimately rests with the clinical assistants. Suggestions on the suspension of antibiotics will be provided by the researchers as follows:~7 full days for most infections~10 full days for pneumonia caused by Gram negative non-fermenting bacteria or Gram negative bacteria carbapenemase producing.~14 days of treatment for necrotizing pneumonia, confirmed by chest computed tomography."
2487265|NCT02987465||Healthy Volunteers|Up to 12 healthy subjects will be recruited such that age and gender are similar to the CKD patients. These subjects will be recruited as negative controls for a baseline assessment of healthy physiology. These subjects will not be treated with Darbepoetin.
2487281|NCT02987075|Other|Early compaction embryo group|patients have compacting embryos at 66±2 hours after ICSI
2487288|NCT02987075|Other|Cleavage stage embryo group|patients have non-compacting embryos with 7-9 cells, under 20% fragmentation. at 66±2 hours after ICSI
2515751|NCT02791620|Experimental|A nanofractional radiofrequency device|
2486576|NCT02992106|Other|Normal weight during pregnancy|"Offspring of 156 women with a normal weight during their pregnancy recruited by Bogaerts et al, in 3 belgian hospitals. Results of maternal data published in 2013. Now the children will be recruited. This group wil function as a control group.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2486583|NCT02992106|Other|Obese mothers without intervention|"This subgroup will be compiled of the offspring of women recruited in two different studies. First of all there is the offspring of 65 women from the cohort that was recruited by Guelinckx et al, data published in 2010. This population was recruited in the University hospital of Leuven as control group for women receiving lifestyle interventions during pregnancy. Secondly there are children of 63 women from the cohort of Bogaerts et al of 2013 that had a BMI > 29 kg/m² during their singleton pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2486587|NCT02992106|Other|Obese mothers & lifestyle intervention|"This one will also be a composition of study subjects of two different study cohorts. Firstly there are children of about 100 Belgian women that were included in the DALI cohort, a European randomized controlled trial. All of them underwent a lifestyle intervention during pregnancy, concerning diet and/ or exercise. Secondly there is the offspring of the other subgroup of the cohort recruited by Guelinckx et al. 130 women were divided into 2 groups which underwent lifestyle interventions during pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2486589|NCT02992106|Other|History of bariatric surgery|"The PABAS cohort (Pregnancy After Bariatric Surgery) provides children of 49 women who underwent bariatric surgery before their singleton pregnancy. The women were included in five Flemish hospitals before 15 weeks of pregnancy. Furthermore we will recruit the offspring of 200 women that are recruited in the ongoing AURORA cohort (bAriatric sUrgery Registration in women Of Reproductive Age). Women in this cohort are recruited from the start of their process undergoing bariatric surgery and are followed until after their pregnancy.~All participating children will undergo the same examinations:~Parental questionnaires~Blood sample~Urine sample~Anthropometric measurements~Abdominal ultrasound (fat mass)~EndoPAT"
2486655|NCT02991443|Experimental|Mindfulness based stress reduction|Parents of children with IBD will undergo mindfulness based stress reduction (MBSR) intervention consisted of 8 group sessions. The effect on stress and anxiety will be assessed using 3 validated questionnaires which will be filled prior to intervention, at the end of intervention and 3 months following intervention.
2486708|NCT02991222|Experimental|SPARC001 type I|Treatment type I
2486710|NCT02991222|Experimental|SPARC001 type II|Treatment type II
2486711|NCT02991222|Active Comparator|Reference001 type I|Treatment type I
2486712|NCT02991222|Active Comparator|Reference type II|Treatment type II
2486754|NCT02990728|Experimental|Mirena® + metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
2486755|NCT02990728|Active Comparator|Mirena®|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
2486809|NCT02990624|Active Comparator|High risk group|Patients with psoriasis and atherosclerosis will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
2486812|NCT02990624|Active Comparator|Low risk group|Patients with psoriasis but no atherosclerosis detected, will receive PUVA therapy for 36 sessions divided as 3 sessions weekly
2486813|NCT02990624|No Intervention|Control group|Age-matching apparently normal individuals will receive no interventions but will perform investigational tests.
2486857|NCT02990247|Experimental|AMARS|Evaluation the resting ventilatory flow by applying a new technique called anharmonic morphological analysis of the respiratory signals (AMARS).
2486896|NCT02989909|Active Comparator|Goldmann Tonometer|Goldmann Tonometer prism will be used as a based line comparator for tolerance assessment versus the active test comparator CATS tonometer prism
2486899|NCT02989909|Experimental|CATS tonometer|CATS tonometer prism being used as the test product to assess IOP measurement versus active comparator the Goldmann Tonometer prism
3193896|NCT00822484|Placebo Comparator|Placebo|Placebo
2487076|NCT02988804|Active Comparator|Laryngeal mask|"Procedure: Laryngeal mask~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
2487777|NCT02983929||BMI >30 kg.m-2|Patients with a BMI superior to the obesity limit defined by the World Health Organization.
3193897|NCT00822497|Experimental|1|Music-Based Imagery
3193898|NCT00822497|Experimental|2|Music Alternate Engagement
3193899|NCT00822497|No Intervention|Control|Debridement under standard care with no music therapy interventions
3193900|NCT00822536|Active Comparator|1|Bi therapy : aspirin/ clopidogrel
3193901|NCT00822536|Active Comparator|2|Monotherapy: aspirin
2486725|NCT02991183|Experimental|Acceptance and Commitment Therapy|Two half day (2.5 hours) group ACT sessions delivered one week apart followed by a third session 2 weeks following the second session.
2486769|NCT02990780|Active Comparator|Conventionally fractionated CRT|Induction chemotherapy followed by conventionally fractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
2486775|NCT02990780|Experimental|Accelerated hypofractionated CRT|Induction chemotherapy followed by accelerated hypofractionated concurrent chemo-radiotherapy,with prophylactic cranial irradiation for those who achieve a good response after combined chemoradiotherapy.
2486823|NCT02990533|Placebo Comparator|Placebo|Placebo Supplement Placebo Injection
2486827|NCT02990533|Experimental|Testosterone|Placebo Supplement Testosterone Injection
2486830|NCT02990533|Experimental|Protein Supplement|Protein Supplement Placebo Injection
2486832|NCT02990533|Experimental|Protein Supplement + Testosterone|Protein Supplement Testosterone Injection
2486919|NCT02989740||Group A|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings with NO thin-cap fibroatheroma
2486920|NCT02989740||Group B|Patients with negative FFR (> 0.80) in the target lesion & decided on OCT (Optical Coherence Tomography) imaging findings presence of ≥ thin-cap fibroatheroma
2486921|NCT02989740||Group C|Patients hosting FFR-positive target lesions that have been treated with PCI as per standard care and have further no TCFA lesions.
2486966|NCT02989467|Active Comparator|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
2486968|NCT02989467|Placebo Comparator|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
2487043|NCT02989181|Experimental|Continues Positive Airway Pressure|Use of Continues Positive Airway Pressure (CPAP) mask every night under six months period.
2487044|NCT02989181|No Intervention|Consultation of conservative measures|Study participants with DCM and OSA (no-CPAP), participants receive consultation of conservative measures such as avoiding alcohol before bedrest, sleeping on the side...
2487091|NCT02988791|Experimental|Probiotic (Bifidobacterium)|Active, Bifidobacterium BB12
2487092|NCT02988791|Placebo Comparator|Placebo|Placebo
2487162|NCT02988453|Experimental|MBT-CD|Mentalization-based treatment program
2487205|NCT02987816|Sham Comparator|Sham tDCS|Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
2487206|NCT02987816|Experimental|Anodal tDCS|Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
2487249|NCT02987517|Experimental|Cadence|Runners who use an increased running cadence of 7.5 percent over preferred running cadence.
2487252|NCT02987517|Experimental|Forefoot Strike|Runners who use a forefoot strike instead of a rear foot strike
2487275|NCT02987218|Active Comparator|PROPOFOL|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP(Intracranial pressure) Better cognitive Function preservation
2487277|NCT02987218|Active Comparator|DESFLURANE|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
2487330|NCT02986945|Experimental|Immediate|"Resiliency App: Study participants randomized to the Immediate group will receive the text-messaging app, B-RESILIENT-an adaptation of a Resiliency Course for improving mood in individuals with depressive symptoms--for 4 weeks.~Wk 1: BOOST - manage unhealthy thoughts. Wk 2: BREAK - doing pleasant activities. Wk 3: BUDDY - effective communication for social support. Wk 4: Review of first 3 weeks. Each day, users will receive a daily affirmation text message, a series of approximately 5-10 text messages on the topic of the day, and a daily goal corresponding to the day's content (e.g. do a pleasant activity). At the end of the day, users will receive text messages asking them to report whether they completed the daily goal, followed by a daily mood measure."
2487334|NCT02986945|Other|Delayed|Resiliency App: The Delayed arm will receive the intervention after the Immediate Arm completes its use of the intervention.
3193902|NCT00822549||1|all the patients included in the study received intravenous morphine in PACU and in the wards
3193903|NCT00822562|Active Comparator|Procedure/Surgery|surgery
3193904|NCT00822562|Experimental|Procedure|PRFA or PMCT
3193905|NCT00822575|Active Comparator|A|
3193906|NCT00822575|Sham Comparator|B|
2487636|NCT02985086|Active Comparator|Immediate induction with antibiotic prophylaxis|Immediate induction with antibiotic prophylaxis
2487639|NCT02985086|Active Comparator|Immediate induction without antibiotic prophylaxis|Immediate induction without antibiotic prophylaxis
2487643|NCT02985086|Active Comparator|Delayed induction with antibiotic prophylaxis|Delayed induction (>= 12 hours after PROM) with antibiotic prophylaxis
2487687|NCT02984579||All Subjects|"All strains in Phase 1 and all Sputum samples in Phase 2 were tested with Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2, and YD REBA MTB-MDR diagnostic tests.~Investigators and Operators were blinded to all other results for a sample upon data entry."
2487778|NCT02983955|Other|SCI with Tetraplegia|
3193907|NCT00822601|Experimental|1|
3193908|NCT00822601|Placebo Comparator|2|
3193909|NCT00822614|Active Comparator|Active Comparator|Current BTP Medication
3193910|NCT00822614|Experimental|Fentanyl TAIFUN|Titration for dose confirmation followed by observation period
3193911|NCT00822627|Experimental|Vaccination group|Vaccination group
3193912|NCT00822627|Experimental|Education/referral|Education/referral
3193913|NCT00822640|Experimental|1|Columbus Knee Prosthesis with rotating Platform
3193914|NCT00822640|Active Comparator|2|Columbus Knee Prosthesis with fixed platform
3193915|NCT00822653|Experimental|Calf Muscle Pump Stimulation|Subjects serve as self-control. Six weeks of dialysis data without intervention will be compared to six weeks post intervention
3193916|NCT00822666|Active Comparator|1|patients homozygous for the 2C19*1 genetic variant
2486606|NCT02991638|Other|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
2486656|NCT02991482|Experimental|Pembrolizumab arm|Pembrolizumab is administrated at 200 mg fixed dose i.v. on day 1 of every 3 week cycle for a maximum or 2 years (expected maximum of 36 doses), or until progression of disease determined according to RECIST 1.1 criteria or lack of tolerability, or until the patient declines further treatment.
2486657|NCT02991482|Active Comparator|Standard chemotherapy arm|"Gemcitabine (i.v. 1000 mg/m2) or vinorelbine (i.v. 30 mg/m2, or p.o 60/80 mg/m2) chemotherapy will be chosen on a per patient basis and delivered according to local standards. Chemotherapy will be administered on days 1 and 8 of every 3-week cycle. A maximum number of treatment cycles is not mandated.~Patients randomised to the control arm will be allowed to cross over to receive pembrolizumab at progression, if cross-over criteria are met. Pembrolizumab administration will follow the same schedule as for patients in the experimental arm, i.e. 200 mg fixed dose i.v. on day 1 of every 3-week cycle for a maximum of 2 years or until trial termination."
2486720|NCT02991066||Patients|patients with de novo acute promyelocytic leukemia with hemorrhage.
2486723|NCT02991066||Control|healthy volunteers.
3160579|NCT00427375|Experimental|1|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
3160580|NCT00427375|Active Comparator|2|Standard surgery
3160581|NCT00427388|Experimental|Treatment|500 mg of methylprednisolone divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
3160582|NCT00427388|Placebo Comparator|Placebo|500 mg of matching placebo (normal saline solution) divided into two intravenous doses of 250 mg each, one during anesthetic induction and the other on CPB initiation
3160583|NCT00427414|Experimental|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
3160584|NCT00427440|Experimental|AMG 102 at 10 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
3193917|NCT00822666|Experimental|2|carriers of the 2C19*2 genetic variant (homozygous or heterozygous)
2486984|NCT02989233|Active Comparator|Brochure-Female-8/10|Female 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486985|NCT02989233|Active Comparator|Brochure-Male-8/10|Male 8-10 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486987|NCT02989233|Active Comparator|Model-Female-8/10|Female 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486990|NCT02989233|Active Comparator|Model-Male-8/10|Male 8-10 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486991|NCT02989233|Active Comparator|Video-Female-8/10|Female 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486993|NCT02989233|Active Comparator|Video-Male-8/10|Male 8-10 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486997|NCT02989233|Active Comparator|Brochure-Female-11/13|Female 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2486999|NCT02989233|Active Comparator|Brochure-Male-11/13|Male 11-13 years Theoretical Test Application Giving a brochure Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2487005|NCT02989233|Active Comparator|Model-Female-11/13|Female 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2487013|NCT02989233|Active Comparator|Model-Male-11/13|Male 11-13 years Theoretical Test Application Expression with a model Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2487015|NCT02989233|Active Comparator|Video-Female-11/13|Female 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2487022|NCT02989233|Active Comparator|Video-Male-11/13|Male 11-13 years Theoretical Test Application Showing a video Bleeding on probing, plaque index and gingival index Non-surgical periodontal treatment
2487102|NCT02988778|Experimental|Budesonid 50mcg (Noex)|"Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
2487103|NCT02988778|Active Comparator|Budesonid 50mcg (Busonid)|"Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.~Treatment of 28 days."
2487128|NCT02988362|Experimental|Candesartan 16mg and Amlodipine 10mg|Candesartan 16mg and Amlodipine 10mg
2487129|NCT02988362|Experimental|HL068|HL068(combination of Candesartan 16 mg and Amlodipine 10 mg)
2487171|NCT02988011|Active Comparator|Gastric by-pass surgery|Gastric by-pass surgery without prior low-caloric diet
2487172|NCT02988011|Active Comparator|Low-caloric diet|Low-caloric diet followed by gastric by-pass surgery
2487231|NCT02987712|No Intervention|Survey 1|Common practice
2487238|NCT02987712|Experimental|Survey 2|Thromboelastography based protocol
3160585|NCT00427440|Experimental|AMG 102 at 20 mg/kg Dose Level|Up to 40 subjects will be treated at this dose level based upon investigator assessment of responses observed.
3160586|NCT00427492|Active Comparator|Magnesia|Medical laxative
3160587|NCT00427492|Placebo Comparator|Placebo|Placebo
3160588|NCT00427583|Experimental|STI571|
3160589|NCT00427609|Placebo Comparator|1|
3160590|NCT00427609|Active Comparator|2|
3160591|NCT00427674|Experimental|injection of 5 mCi of 123-I mZINT|
3160592|NCT00427739||CCT exam|
3160593|NCT00427752|Experimental|Whipple|Patients with pancreatic cancer who will proceed to a Whipple procedure.
3160594|NCT00427843|Experimental|Exercise Home-Based Program|Patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. The exercise program will be performed 3 times per week for 8 weeks.
2486969|NCT02989454||Tako Tsubo Cardiomyopathy patients|Any patient who has suffered from Tako Tsubo Cardiomyopathy since 2011.
2487062|NCT02988947|Experimental|Intervention Group (PNE+HyP)|Patients in this group will have 3 pre-surgical + 1 (or 2) reinforcement sessions in adition to standard TKA care. These interventions are based on Pain Neuroscience Education and Hypnosis and delivered according to standardized scripts.
2487063|NCT02988947|No Intervention|Control Group|No intervention / Standard care
2487108|NCT02988648|Experimental|radioiodide (I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
2487272|NCT02987400|Experimental|Treatment|Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
2487355|NCT02986971|Experimental|New IMD|Subjects with contraceptive implants to be removed, are subjected to the novel device by personnel skilled in traditional removal.
2487418|NCT02986451|Experimental|Intervention|All patients received clarithromycin, lenalidomide, and dexamethasone in 28-day cycles. Dexamethasone (40 mg) was given orally on days 1, 8, 15, and 22. Clarithromycin (500 mg) was given orally twice daily.Lenalidomide (25 mg) was given orally daily on days 1 to 21
3160595|NCT00427856|Experimental|Obatoclax mesylate 40mg|40 mg over 3 hrs q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
3160596|NCT00427856|Experimental|Obatoclax mesylate 60mg|60 mg obatoclax mesylate over 24 hours, q/weekly for 12 weeks, 4 weeks combo with rituximab, another 8 weeks single-agent obatoclax
3160597|NCT00427947|Experimental|1|Continuous sciatic nerve bloc : ropivacaine infusion
3160598|NCT00427947|Placebo Comparator|2|Continuous sciatic nerve bloc : NaCl Infusion
3160599|NCT00428012|Experimental|QOLT|Quality of Life Therapy (QOLT) 8 weekly individual counseling sessions
3160600|NCT00428012|Active Comparator|ST|Supportive Therapy (ST) 8 weekly individual counseling sessions
3160601|NCT00428012|No Intervention|Standard Care|
2487824|NCT02983773|Placebo Comparator|Placebo|Placebo marijuana cigarette
3160602|NCT00428025|Placebo Comparator|placebo suppository|
3160603|NCT00428025|Active Comparator|diclofenac suppository|
3160604|NCT00428038||1|"Group 1:~Infants born prematurely at a gestational age < 32 weeks with a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
3160605|NCT00428038||2|"Group 2:~Infants born prematurely at a gestational age < 32 weeks without a diagnosis of chronic lung disease. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Oxygen requirements~Congenital heart disease"
3160606|NCT00428038||3|"Group 3:~Infants born full term at a gestational age > 37 weeks. Subjects will be evaluated at a corrected-age between 1 month and 24 months when they are clinically stable and free of acute respiratory symptoms for > 3 weeks. Subjects will be excluded for the following reasons:~Hospitalization for a respiratory illness~History of wheezing, asthma, or treatment with asthma medications~Congenital heart disease"
3160607|NCT00428051||All eligible patients|
3160608|NCT00428129|Experimental|1|
3160609|NCT00428142|Experimental|Bortezomib + BCVP-R|BCVP-R - q 21 days x 4 cycles Bortezomib: 1.3 mg/m2 Days 1 & 8 Cyclophosphamide: 750 mg/m2 IV Day 1 Vincristine: 1.4 mg/m2 IV Day 1 (dose capped at 2 mg) Prednisone: 40 mg/m2 po Days 1-5 Rituximab: 375 mg/m2 IV Day 1
3160610|NCT00428168|Experimental|Betahistine 24 mg|
3160611|NCT00428168|Placebo Comparator|Placebo|
3160612|NCT00428181|Active Comparator|1 Brief Intervention|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
3160613|NCT00428181|Active Comparator|2) Booster|The primary purpose of the proposed research is to compare the effectiveness of brief intervention, brief intervention plus a booster and treatment as usual for adult patients with an alcohol related injury.
3160614|NCT00428194|Experimental|Cohort 1|Erlotinib 100 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3160615|NCT00428194|Experimental|Cohort 2|Erlotinib 125 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3160616|NCT00428194|Active Comparator|Cohort 3|Erlotinib 150 mg/day by mouth beginning on day 1 of radiotherapy (RT) and cisplatin dosing (40 mg/m^2 intravenous every 7 days during RT) and continuing daily through radiation
3160617|NCT00428233|No Intervention|Leukemia Cell Harvest|Procedure/Surgery: Leukemia cell harvest Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
3160618|NCT00428272|Experimental|1|Lexatumumab alone dose escalation
3160619|NCT00428272|Experimental|2|Lexatumumab with interferon - dose escalation
3160620|NCT00428272|Other|3|Lexatumumab 10mg/kg with interferon expansion at
3160621|NCT00428285|Experimental|Single Arm|
3160622|NCT00428337|Experimental|1|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0 and 28 and one injection of MVA-mBN32 or placebo in each arm on Days 84 and 168
3160623|NCT00428337|Experimental|2|Participants will receive one injection of DNA vaccine EP-1233 or placebo in each shoulder on Days 0, 28, 84, and 168
3160624|NCT00428337|Experimental|3|Participants will receive one injection of MVA-mBN32 or placebo in each arm on Days 0, 28, 84, and 168
3160625|NCT00428402||Focus Group|Participant is a 4th-8th grade student in select schools from Bastrop Independent School District (BISD).
3160626|NCT00428428|Placebo Comparator|1|Saline irrigation
3160627|NCT00428428|Active Comparator|2|ISO irrigation
3160628|NCT00428454|Experimental|Zotarolimus eluting stent|Zotarolimus eluting stent
3160629|NCT00428454|Active Comparator|Sirolimus eluting stent|Sirolimus eluting stent
2486842|NCT02990416|Experimental|A-dmDT390-bisFv(UCHT1)/Radiation/Pembrolizumab|A-dmDT390-bisFv(UCHT1): 2.5 µg/kg 2x x 4 days, Ionizing Radiation: single treatment on day five of 14-24 Gy to a tumor, Pembrolizumab: 2 mg/kg IV every 3 weeks
2486902|NCT02990039|Experimental|Counseling letter (intervention group)|Participants of the intervention group received a brief counseling letter intervention aiming to reduce sedentary time and to increase physical activity. The intervention comprised up to three tailored letters based on separate questionnaires.
2486903|NCT02990039|No Intervention|No counseling letter (control group)|Participants of the control group did not received the brief counseling letter intervention.
3160630|NCT00428480|Experimental|1|Daily reinforcement of walking speed
3160631|NCT00428480|Active Comparator|2|No reinforcement of walking speed
2487019|NCT02989272|Placebo Comparator|saline group|Control group (30 patients), who will receive Treatment by venous infusion of saline solution
2487023|NCT02989272|Experimental|Sulfate group|magnesium group (30 patients) who will receive pre- Venous infusion of magnesium sulphate 60 mg / kg
2487085|NCT02988830|Experimental|Chronic lumbar pain|
2487132|NCT02988492|Other|MRI perfusion imaging|MRI screening will be performed as per standard-of-care by the MRI technologist staff. Imaging will be performed with 1.5 T or 3 T systems (Magnetom Vision; Siemens, Erlangen, Germany) using a multisection, single shot, spin echo, echo planer imaging sequence. Diffusion gradients will be applied in each of the x, y and z directions with three b values (0, 500 and 1000 s/mm2). Imaging parameters include a TE of 94 ms, field of view of 23 cm, matrix of 128 and section thickness of 5.5 mm for the 1.5 T system and a TE of 83 ms, field of view of 23 cm, matrix of 128 and section thickness of 3 mm for the 3 T system. Conventional spin echo imaging also will be performed at each examination under T1 and T2 weighted conditions, with a fluid attenuated inversion recovery sequence and Time-of-flight MRA of the Circle-of-Willis.
2487447|NCT02986126|Active Comparator|Resources for Services|Resources for Services (RS) is an evidence-based depression QI toolkit developed for primary care, but adapted for health- and community-based programs. Protocols support training licensed providers in clinical assessment, medication management, and CBT; all staff in team management; and non-clinical staff in addressing patient safety, screening, behavioral management skills (behavioral activation, problem solving) to enable education, coordination, and referral. RS is offered as an initial 1-day / 8-hour training with follow-up through 12 webinars, 3 each on team management, medication management, psychotherapy, and case management. Programs will be invited to have a staff lead per training component, with no limit on number of staff at trainings. Training experts include a psychiatrist, psychologist/CBT trainer, case manager, support staff, and patient / community advocate liaison. All enrolled study participants will be nested within programs participating in RS.
2487449|NCT02986126|Active Comparator|Resiliency Class +|"Resiliency Classes (RC) are a manualized, 7-session, CBT, psychoeducation class, lead by community health workers, that teaches skills to enhance mood. The RC manual covers: Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation Each RC will be 90-120 minutes in duration; once a week in community settings with up to 10 participants. RC will be supplemented with automated mobile text reminders about basic concepts and follow-up for care. Half of enrolled participants will be randomized to the Resiliency Class +. As of July 12, 2018, we will be offering bus tokens and $5 for completion of a satisfaction survey."
2487577|NCT02985307|Experimental|Short Message Text Service|Participants receive short messages daily via their mobile phone
2487579|NCT02985307|Active Comparator|Standard Weight Management Group|Participants attend standard group weight management sessions
2487630|NCT02984917|Experimental|anterior transversalis fascia approach|Patients with inguinal hernia will undergo inguinal hernia repair via the anterior transversalis fascia approach.
2487632|NCT02984917|Experimental|preperitoneal space approach|Patients with inguinal hernia will undergo inguinal hernia repair via the preperitoneal space approach.
2487752|NCT02984189|Experimental|Inspiratory Critical Pressure Group|Inspiratory Critical Pressure will be used for training and will be determined, from a progressive inspiratory threshold-loading test will start with 50%MIP followed by 10%MIP increments, every 3min until subjects reached a load that there were unable to sustain for at least 1min (PThMAX). On another day, the subjects will perform a constant inspiratory loading test against a resistance of 95%, 100% and 105%PThMAX, for as long as they could tolerate. The intensity loads will be applied according the results of block randomization. The time elapsed until task failure was defined as inspiratory muscle endurance time, and will use to set the PThC. The respiratory work done (inspiratory pressure values) will be plotted in abscissa and the time-to-exhaustion in ordinate, and a linear regression going through the 3 points will be applied using the pressure-1/t relationship. The slope of the parallel line displaced downward projecting to the origin produce the PThC value.
2487754|NCT02984189|Active Comparator|60% Maximal Inspiratory Pressure Group|60% of maximal inspiratory pressure will be used for training.
2487755|NCT02984189|Sham Comparator|Sham Group|6 cmH20 will be used for training.
2487817|NCT02983773|Experimental|High THC dose|1 marijuana cigarette (7.2% THC)
2487821|NCT02983773|Experimental|Low THC dose|1 marijuana cigarette (3.0% THC)
3160632|NCT00428519|Placebo Comparator|1|
3160633|NCT00428519|Active Comparator|2|
3160634|NCT00428519|Active Comparator|3|
3160635|NCT00428545|Experimental|Bevacizumab + Bortezomib|Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days.
3160636|NCT00428558|Active Comparator|2|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
3160637|NCT00428558|Experimental|1|BRAS INDUCTION SEQUENTIAL
3160638|NCT00428571|Placebo Comparator|Intensive Medical Management|Medical management of obesity including medication optimization and lifestyle and dietary advice.
3160639|NCT00428571|Active Comparator|Laparoscopic Gastric Bypass|
3160640|NCT00428571|Active Comparator|Laparoscopic Adjustable Gastric Band|
3160641|NCT00428649|Experimental|1|20 µg selenium as selenomethionine
3160642|NCT00428649|Experimental|2|40 µg selenium as selenomethionine
2486844|NCT02990507|Experimental|AVEED|AVEED is composed of arm and leg cranks that can be used independently or together with a virtual exercise environment (VEE). Participants rotate arm and/or leg cranks under 4 conditions for 5 min each with a 5 min rest between: 1) Arm rotation with VEE, while sitting or standing (AVEED: Arm rotation, video display); 2) Arm rotation without VEE, while sitting or standing (AVEED: Arm rotation, without video display); 3) Leg rotation with arm-energy input to assist the legs with VEE, while sitting (AVEED: Leg rotation, arm-energy input, video display); 4) Leg rotation with arm-energy input to assist the legs without VEE, while sitting (AVEED: Leg rotation, arm-energy input, without video display). VEE controlled with voice commands, leaning, or keyboard buttons.
2486883|NCT02990052|Active Comparator|Volar plating|Volar fixed-angle plating for dislocated distal radius fracture after closed reduction.
2486884|NCT02990052|Active Comparator|Conservative treatment|Primary conservative treatment (closed reduction and casting) for dislocated distal radius fracture.
3193918|NCT00822705|Active Comparator|ORAL GLP-1, TABLET|
3193919|NCT00822705|Active Comparator|Oral PYY3-36|
3193920|NCT00822705|Active Comparator|Oral GLP-1 plus oral PYY3-36|
3193921|NCT00822705|Placebo Comparator|4|
2487058|NCT02988973|Experimental|rHuEPO or DA to ASP1517|Participants will receive roxadustat according to the prior randomization treatment, with starting doses of 70mg thrice weekly (TIW) to participants on <4500 IU/week of rHuEPO or <20 microgram (μg)/week of darbepoetin alfa (DA) and 100mg TIW to participants on ≥4500 IU/week rHuEPO or ≥ 20 μg/week DA. Participants roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
2487059|NCT02988973|Experimental|rHuEPO or DA to DA|Participants will receive DA according to the prior randomization treatment, with starting doses of 15 μg/2weeks to participants on ≤ 1500 IU/week of rHuEPO or <11.25 microgram (μg)/week of DA, 30μg/2weeks to participants on >1500 to <6000 IU/week of rHuEPO or ≥ 11.25 to < 22.5 μg/week of DA, 60μg/2weeks to participants on ≥ 6000 IU/week of rHuEPO or ≥ 22.5 to < 37.5 μg/week of DA, 90μg/2weeks to participants on ≥ 37.5 to < 52.5 μg/week of DA, 120μg/2weeks to participants on ≥ 52.5 to < 75 μg/week of DA, 180μg/2weeks to participants on ≥ 75 μg/week of DA. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 15, 30, 60, 90, 120, and 180 μg.
2487060|NCT02988973|Experimental|Epoetin beta pegol to ASP1517|Participants will receive roxadustat according to the prior registration treatment, with starting doses of 70mg thrice weekly (TIW) to participants on ≤100 μg/week of Epoetin beta pegol and 100mg TIW to participants on >100 μg/week of Epoetin beta pegol. Participant's roxadustat dosage will be adjusted every 4 weeks to maintain Hb level within the target range 10.0 to 12.0 g/dL. Dose adjustment steps will be as follows: 20, 40, 50, 70, 100, 150, 200, 250, 300 mg.
2487161|NCT02988076|No Intervention|Control|The Control group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Treatment/Experimental group. A clinician treating a Control Group subject will NOT receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
2487166|NCT02988076|Active Comparator|Treatment|Intervention - Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report - Treatment group subjects will undergo all procedures e.g. medication washout and baseline electroencephalogram, administered to the Control group. A clinician treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
2487220|NCT02987764|Experimental|Cord Milking|The research team member will untwist the cord, and hold it in a vertical position. The cord will then be milked twice towards the abdominal insertion of the cord. The cord will be cut 1 inch above the abdominal wall. After milking for exact measurement of the cord will be obtained.
2487225|NCT02987764|No Intervention|Observational|Observational infants will receive usual care with immediate cord clamping by the delivering obstetrician. The time of cord clamping will be recorded for both groups using a timer.
2487274|NCT02987452|Experimental|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
2487276|NCT02987452|Active Comparator|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
2487282|NCT02987452|Active Comparator|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
2487351|NCT02986867|Experimental|SAbR|SAbR treatment of lesions
2487393|NCT02986477|Other|Contrast Ultrasound|Patients with vesicoureteral reflux will receive contrast ultrasound via Foley catheter for study of vesicoureteral reflux.
2487429|NCT02986217|No Intervention|Control Group|Participants randomized to the Control Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the control group will receive traditional feedback methods as determined by each participant's training program. Subjects in the control group will repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
2487575|NCT02985294||Longitudinal cohort|Multiple Excitability Measures of peripheral nerves on painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, surgery)
3193922|NCT00822731|Experimental|Lymphoma|patients diagnosed as lymphoma
3193923|NCT00822744|Experimental|SSR411298 10 mg|SSR411298 10 mg, one capsule once daily for 8 weeks
3193924|NCT00822744|Experimental|SSR411298 50 mg|SSR411298 50 mg, one capsule once daily for 8 weeks
3193925|NCT00822744|Experimental|SSR411298 200 mg|SSR411298 200 mg, one capsule once daily for 8 weeks
3193926|NCT00822744|Active Comparator|Escitalopram 10 mg|Escitalopram 10 mg, one capsule once daily for 8 weeks
2486847|NCT02990559||Iron Repletion|Subjects participating in the associated study under the Iron Repletion arm will also undergo MRI (Magnetic Resonance Imaging) scan/fMRI (functional Magnetic Resonance Imaging) scan on two occasions, while performing cognitive tasks.
2486848|NCT02990559||Placebo|Subjects participating in the associated study under the Placebo arm will also undergo MRI/fMRI scans on two occasions, while performing cognitive tasks.
2486885|NCT02990026|Experimental|Treatment|Specialty mental health probation - delivered by probation officers who receive specialized training and ongoing clinical consultation with a licensed mental health professional and who have reduced caseloads of exclusively mentally ill offenders.
2486886|NCT02990026|Active Comparator|Control|Standard probation - delivered by a standard probation officer - care as usual
2486924|NCT02989701|Experimental|Single arm|
3193927|NCT00822744|Placebo Comparator|Placebo|Placebo (for SSR411298), one capsule once daily for 8 weeks
3193928|NCT00822783|Active Comparator|Omalizumab|
2487111|NCT02988583|Experimental|low viscosity silicone oil|Retinal detachment surgery using low viscosity silicone oil
2487112|NCT02988583|Active Comparator|high viscosity silicone oil|Retinal detachment surgery using high viscosity silicone oil
2487174|NCT02988232|Experimental|Treatment(SGHH)|Admission to Sogyeonghwalhyeol-tang granule
2487177|NCT02988232|Placebo Comparator|Placebo|admission to placebo
3193929|NCT00822783|Placebo Comparator|Placebo|
3193930|NCT00822796|Experimental|A|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
2487304|NCT02987153|Experimental|KYPHO-IORT - 10 Gy and Kyphoplasty|Intra-operative radiation therapy followed by standard kyphoplasty
2487347|NCT02986828|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2487356|NCT02986828|Active Comparator|Normal saline|Normal saline for ultrasound-guided hydrodissection
3193931|NCT00822796|Active Comparator|B|Burn patients with >20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management
2487522|NCT02985632|Experimental|Mild Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
2487523|NCT02985632|Experimental|Moderate Hepatic Impairment Subjects|Subjects given an oral dose of BMS-986141.
2487525|NCT02985632|Experimental|Healthy Subjects|Subjects given an oral dose of BMS-986141.
3193932|NCT00822809|Experimental|A|"Patients will receive premedication of 25 mg (i.v.) prednisolone 30 minutes prior start of infusion of catumaxomab.~Catumaxomab will be infused i.p. with 3 hour constant rate infusions via an indwelling catheter."
2487691|NCT02984566|Experimental|SABR with or without KIM|All patients will receive liver SABR. Kilovoltage Intrafraction Monitoring (KIM) tracking will be trialed during mock treatment. If KIM is successful, it will be used throughout treatment. If unsuccessful, cone beam CT will be used instead.
3193933|NCT00822809|Other|B|Catumaxomab will be administered in a dosage identical to Arm A but without the prednisolone premedication.
3193934|NCT00822822||A|Health History Process
2487839|NCT02983370|Experimental|Blind volunteer|Blind volunteers will be implanted with our existing vision neuroprosthetic system, which utilizes a FDA cleared microelectrode array, using a minicraniotomy. The array will be implanted near the occipital pole or in extra striate areas. The investigators will collect descriptive feedback regarding thresholds, evoked perceptions and stimulation parameters leading to recognizable patterns.
2487853|NCT02983071|Experimental|Once-Daily G1T38 Dosing|G1T38 (lerociclib) orally (once daily) in combination with fulvestrant.
2487858|NCT02983071|Experimental|Twice-Daily G1T38 Dosing|G1T38 (lerociclib) orally (twice daily) in combination with fulvestrant.
2487927|NCT02982824|Experimental|Magnesium add-on|20 children with drug resistant epilepsy will receive oral magnesium sulfate 6 ml per day which equivalent to 400 mg elemental magnesium (Yuen & Sander, 2012) for 6 months and their regular antiepileptic drugs.
2487934|NCT02982824|Placebo Comparator|Antiepileptic drugs only|20 children with drug resistant epilepsy will receive their regular antiepileptic drugs and placebo for 6 months.
2487937|NCT02982824|No Intervention|Healthy controls|To asses serum magnesium level for comparison with the intervention group.
2487995|NCT02982434|Experimental|Group 1|All patients underwent conventional CABG surgery. After the main stage of the surgery new pharmaceutical composition containing botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2487996|NCT02982434|Active Comparator|Group 2|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2488039|NCT02982057|Active Comparator|Bioresorbable vascular scaffold(BVS)+ OMT|"hypothesis: scaffolding a non culprit coronary plaque with BVS could facilitate the stabilization process into the atherosclerotic plaque with modification of plaque morphology.~Intervention:Device"
2488043|NCT02982057|Active Comparator|OMT|"Comparator with ONLY optimal medical treatment (OMT): the aim of the study is to compare the evolution of non culprit lesions after treatment by BVS versus Optimal Medical Therapy at 2 years follow- up.~Intervention: medical treatment"
2488095|NCT02981693|Experimental|iRoot SP sealer|iRoot SP sealer was used as root canal sealer in root canal obturation.
2486890|NCT02990065|Experimental|PROTEIN-FORTIFIED DIET|The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
2486891|NCT02990065|No Intervention|STANDARD DIET|The standard diet consists on an energy goal based on weight formula (20-25 kcal/kg/die). According to the ICU nutritional protocol, EN is started at an initial rate of 10ml/h, and increased by 20ml/h every 12 hours in the absence of significant gastric residuals (<250ml), with the aim of reaching the energy goal within 72 hours from admission. The EN formulae used are standard (1-1,5 kcal/ml, 40g/l protein). If enteral nutrition is not tolerated or is not indicated, supplemental PN is used to make up the energy shortfall. The PN formula used is standard (1000 kcal/l, 37 g/l protein).
3193935|NCT00822835|Active Comparator|ILV-095|6 SC single dose injections
2487035|NCT02989194|Experimental|VIS410 low dose|Single intravenous fixed low dose of VIS410
2487038|NCT02989194|Experimental|VIS410 high dose|Single intravenous fixed high dose of VIS410
2487042|NCT02989194|Placebo Comparator|Placebo|Single intravenous placebo infusion
2487193|NCT02987842|Experimental|Experimental group|Patients in the experimental group will receive feedback using the TruScan Neurofeedback system in order to increase the power of EEG in the range of their individual upper alpha (as determined by the peak alpha frequency)
2487195|NCT02987842|Sham Comparator|Sham group|Patients in the sham group will receive feedback using the TruScan Neurofeedback system for electrical static activity of a disconnected electrode.
2487211|NCT02987608|No Intervention|Control Phase (No Power Up)|60 young people will receive CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires will be administered three months later.
2487213|NCT02987608|Experimental|Intervention Phase (Power Up)|60 young people use Power Up alongside CAMHS treatment as usual. Measures of empowerment, activation, and symptoms will be completed by participants soon after their referral to the service. The same measures plus shared decision making questionnaires and a Power Up feedback form will be administered three months later.
2487264|NCT02987439|No Intervention|Standard care group|"Standard medical treatment for the exacerbation of COPD~Standard medical treatment of COPD according to GOLD~A visit by a pulmonary nurse at the patients own home 3-5 days after discharge. Lung function and smoking history is recorded. Correct use of inhaler is instructed.~Visit in the outpatient clinic within the next 2-6 months after discharge as follow-up~In the outpatient clinic they will receive an offer of pulmonary rehabilitation"
2487266|NCT02987439|Experimental|Rehabilitation group|"The group will begin pulmonary rehabilitation during hospital admission. Afterwards a rehabilitation program twice weekly for 7 weeks.~Beside rehabilitation they will receive same treatment as the standard care group"
2487344|NCT02986880|Experimental|Group D1|Patients receiving the toxin in SCM and the placebo in trapezius muscle and splenius capitis. Patients receiving the dose of 30 units (U) at injection point, totalling 120 U.
2487349|NCT02986880|Experimental|Group D2|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 60 units (U) at injection point, totalling 240 U.
2487357|NCT02986880|Experimental|Group D3|Patients receiving the toxin in the SCM and the placebo in the trapezius muscle and the splenius capitis. Patients receiving the dose of 100 units (U) at injection point, totalling 400 U.
2487362|NCT02986880|Experimental|Group A1|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 30 units (U) at injection point, totalling 180 U.
2487365|NCT02986880|Experimental|Group A2|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 60 units (U) at injection point, totalling 360 U.
2487368|NCT02986880|Experimental|Group A3|Patients receiving the toxin in trapezius muscle and splenius capitis and the placebo in SCM . Patients receiving the dose of 100 units (U) at injection point, totalling 600 U.
2487371|NCT02986880|Experimental|Group F1|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 30 units (U) at injection point, totalling 300 U.
2487373|NCT02986880|Experimental|Group F2|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 60 units (U) at injection point, totalling 600 U.
2487374|NCT02986880|Experimental|Group F3|Patients receiving the toxin in the third muscles groups. Patients receiving the dose of 100 units (U) at injection point, totalling 1000 U.
2487376|NCT02986880|Placebo Comparator|Group P|Patients receiving placebo in the third muscles groups
2487448|NCT02986321|Experimental|CHF6001 DOSE1|DOSE1
2487452|NCT02986321|Experimental|CHF6001 DOSE2|DOSE2
2487455|NCT02986321|Experimental|CHF6001 DOSE3|DOSE3
2487458|NCT02986321|Experimental|CHF6001 DOSE4|DOSE4
2487460|NCT02986321|Placebo Comparator|Matched placebo|placebo control
2487461|NCT02986321|Active Comparator|Budesonide|Budesonide DPI 800µg
2487475|NCT02985814||patients with airway obstruction|Patients referred for pulmonary function test diagnosed with airway obstruction (FEV1/FVC < 0.7) willing to sign an informed consent.
2487676|NCT02984696|Experimental|Hormonal Replace Therapy|1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months
2486908|NCT02990091|Experimental|1,000mg/day n-3 HUFA|Subjects will take one capsule daily starting at study enrollment (within 24 hours of injury) for 14 consecutive days.
2486909|NCT02990091|Experimental|4,000 mg/day n-3 HUFA|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
2486910|NCT02990091|Placebo Comparator|1 capsule safflower seed oil|Subjects will take 1 capsule daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
2486911|NCT02990091|Placebo Comparator|4 capsules safflower seed oil|Subjects will take 2 capsules twice daily starting at enrollment (within 24 hours of injury) for 14 consecutive days.
3193936|NCT00822835|Placebo Comparator|Placebo|Placebo
3193937|NCT00822848|Experimental|Sorafenib, Epirubicin, Ifosfamide|
2486996|NCT02989103||Hyperthyroidism Follow-up Cohort Study|Hyperthyroid patients enrolled and treated between 1946 and 1964 in 25 U.S. and 1 UK site
2487082|NCT02988921|Experimental|Esophageal or esophagogastric cancer|
2487125|NCT02988557|Experimental|Treadmill|
2487143|NCT02988089|Experimental|clarithromycin dependant group|"Patients in this group will receive 14-day bismuth-based quadruple therapies guided by the susceptibility of clarithromycin. Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d.~The kinds of 2 antibiotics will be depend on the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
2487147|NCT02988089|Experimental|6 antibiotics dependant group|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, a bismuth and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.~Ilaprazole 5 mg b.i.d is used as the proton pump inhibitor (PPI). The dose of colloidal bismuth pectin is 200 mg b.i.d."
2487153|NCT02988089|Other|salvage therapy for negative culture|when the results of culture are negative, patients will receive Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, Colloidal Bismuth Pectin 200 mg (IAFB regimen) or Ilaprazole 5 mg, amoxicillin 1 g, furazolidone 100 mg, tetracycline 750 mg (IAFT regimen)，all are used twice daily except tetracycline which is taken 3 times daily.
2487157|NCT02988089|Other|salvage therapy for failed eradication|If failed with AST guided eradication therapy, patients will take another therapy according to the former AST results. One susceptible antibiotics not involved in last therapy will be used as a component of 14-day bismuth-based quadruple regimen with Ilaprazole 5 mg b.i.d, amoxicillin 1 g b.i.d and Colloidal Bismuth Pectin 200 mg b.i.d.
2487215|NCT02987673|Experimental|Mini/One anastomosis gastric bypass|Execution of a laparoscopic mini/one anastomosis gastric bypass (MGB/OAGB)
2487217|NCT02987673|Active Comparator|Laparoscopic sleeve gastrectomy|Execution of a laparoscopic sleeve gastrectomy (LSG)
2487303|NCT02987361|Experimental|treatment group 1|anodal stimulation on the lesioned primary motor cortex DC-STIMULATOR PLUS
2487306|NCT02987361|Experimental|treatment group 2|cathodal stimulation on the non-lesioned primary motor cortex DC-STIMULATOR PLUS
2487308|NCT02987361|Experimental|treatment group 3|dual stimulation such as anodal stimulation on the lesioned side and cathodal stimulation on the non-lesioned side DC-STIMULATOR PLUS
2487310|NCT02987361|Sham Comparator|sham group|sham group
2487338|NCT02986737|Experimental|ACURATE neo™ and ACURATE TA™ LP|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System
2487395|NCT02986542|Active Comparator|USG with the in-plane technique|Intervention: Femoral artery catheterization under USG guidance with the in-plane technique.Patients will have their femoral arterial lines inserted under the guidance of USG. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
2487398|NCT02986542|Active Comparator|USG with the out-of-plane technique|Intervention: Under USG guidance femoral artery catheterization will be done with the probe placed for the out-of-plane technique. The ultrasound equipment used is LOGIQ e GE medical system(China) CO.LTD
2487413|NCT02986191|Experimental|Mucograft|One side of the mouth will be subjected to Mucograft in this split-mouth study design.
2487414|NCT02986191|Active Comparator|Connective tissue graft|The opposite side of the mouth will be subjected to a connective tissue graft.
3193938|NCT00822861|Experimental|Dose level No.1|TPI ASM8 1 mg BID
3193939|NCT00822861|Experimental|Dose level No.2|TPI ASM8 2 mg BID
2487554|NCT02985229|Experimental|All participants|All participants in the study will be given the option of home administration of 200 mg oral mifepristone and 800 μg buccal misoprostol for medical abortion.
2487606|NCT02985164|Experimental|PDSa (Pocket radiation dosimeter a)|"A co-researcher reset and prepared 4 pocket dosimeters (PDS) and labelled as PDSa1, PDSa2, PDSb1 and PDSb2.~The PDSa1 and PDSa2 were placed on the outside and inside of a lead shirt respectively. The shirt-covered box was close to an anesthetic machine. This box would represent anesthetic personnel on duty and marked as position A. Position A was 160 cm. above the floor"
2487611|NCT02985164|Experimental|PDSb (Pocket radiation dosimeter b)|"The PDSb1 and PDSb2 were placed on the outside and inside of the glass shield of control room respectively. This glass shield would represent all personnel working in the operating theatre and marked as position B.~Position B was 160 cm. above the floor."
2487648|NCT02984852|Experimental|Treatment sequence ABC|Participants will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) Treatment A (whole tablet) as reference in session 1 then Treatment B(split tablet) as test in session 2 followed by Treatment C (crushed tablet mixed in applesauce) as test in session 3 under fed conditions (standardized breakfast) on Day 1 of each treatment session. There will be a washout period of at least 7 days between consecutive drug intakes.
2487649|NCT02984852|Experimental|Treatment sequence ACB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment A in treatment session 1, then Treatment C in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
3193940|NCT00822861|Experimental|Dose level No.3|TPI ASM8 4mg BID
3193941|NCT00822861|Experimental|Dose level No.4|TPI ASM8 8 mg Die
3193942|NCT00822874|Experimental|in-vitro maturation of oocytes|
2486930|NCT02989675|Experimental|Dextrose|Children in the intervention group will immediately receive intravenous 5ml/kg 10% dextrose, Dextrose administration will continue as a maintenance infusion of intravenous 10% dextrose for 24 hours at standard maintenance rates. Capillary blood glucose monitoring will be repeated at 30 minute intervals with repeated equivalent bolus doses given until levels reach ≥5.0mmol/l. All children will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
2486934|NCT02989675|No Intervention|Control|Usual care - the care that is currently provided in the hospital - will be provided. All children in the control group will be kept in the emergency department for a minimum of 60 minutes and have their vital signs checked at discharge from the emergency room to the ward.
2486972|NCT02989363|Experimental|O-Arm in deep brain stimulation surgeries (DBS)|Use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
2486973|NCT02989363|Experimental|Control group Not O-Arm in deep brain stimulation surgeries|Not use of image surgery with technology O-Arm in deep brain stimulation surgeries (DBS)
2486974|NCT02989363|Experimental|O-Arm in complex back surgeries (RAQUIS)|Use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
2486976|NCT02989363|Experimental|Control group Not O-Arm in complex back surgeries (RAQUIS)|Not use of image surgery with technology O-Arm in complex back surgeries (RAQUIS)
2487002|NCT02989090|Experimental|Group A (Intervention Group)|Receive Detailed ICD Information-electronic: Receive ICD Patient Notification Summary via MyChart Patient Portal Account - Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
2487008|NCT02989090|Active Comparator|Group B (Intervention Group)|Receive Detailed ICD Information-paper: Receive ICD Patient Notification Summary via paper Receive training to familiarize yourself with using the ePHR, MyChart Complete baseline, 3 month and 6 months survey
2487014|NCT02989090|No Intervention|Group C (Control Group)|Receives Standard of Care-No Report Complete baseline, 3 month and 6 months survey
2487146|NCT02988245|Experimental|Genetically-Guided Treatment for HTN|Using a patient's genetic composition to guide BP prescribing for patients with hypertension, post diagnosis.
2487149|NCT02988245|Active Comparator|JNC-8-Guided Treatment|Using traditional (JNC-8) guidelines for BP prescribing for patients with hypertension, post diagnosis.
3160643|NCT00428649|Experimental|3|60 µg selenium as selenomethionine
3160644|NCT00428649|Experimental|4|80 µg selenium as selenomethionine
2487296|NCT02987387||TPVI|Transcatheter Pulmonary Valve Implantation with the SAPIEN XT THV
2487360|NCT02986776|Active Comparator|Inpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving inpatient treatment
2487364|NCT02986776|Active Comparator|Inpatient Care + No Need for Inpatient|Individuals with low alcohol involvement or mid-high cognitive functioning receiving inpatient treatment
2487366|NCT02986776|Active Comparator|Outpatient Care + Needs Inpatient|Individuals with high alcohol involvement or low cognitive functioning receiving outpatient treatment
2487369|NCT02986776|Active Comparator|Outpatient Care + No Need for Inpatient|Individuals with low alcohol involvement and or mid-high cognitive functioning receiving outpatient treatment
2487435|NCT02986386|Experimental|Intervention 1|Dental occlusion restoration by placement of dental implants and prosthesis on missing teeth.
2487443|NCT02986386|Other|Wait list control 1|Group of patients that will be evaluated until they receive the dental occlusion restoration procedure.
2487445|NCT02986386|Experimental|Intervention 2|Orthodontic treatment of malocclusion.
2487450|NCT02986386|Other|Wait list control 2|Group of patients that will be evaluated until they receive the orthodontic treatment of malocclusion.
2487482|NCT02985892|Experimental|SSASG|Stabilization and stretching group, 12 session, 60 minutes each. This group will perform stretching for back muscles in different positions, associated with stabilization exercises using a protocol developed by Richardson, 2005.
2487483|NCT02985892|Experimental|SSPSG|Stabilization Group, 12 session, 60 minutes each. This group will perform placebo stretching for upper limb muscles (the muscle is not stretched in it maximum extent) with stabilization exercises, using a protocol developed by Richardson, 2005.
2487538|NCT02985541|Experimental|Levonorgestrel IUS (Mirena, BAY86-5028)|Mirena, an Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day.
2487572|NCT02985177|Active Comparator|INF + HM|The participant will receive a dose of intranasal fentanyl (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral hydromorphone (0.04mg/kg up to a maximum of 2 mg).
2487573|NCT02985177|Active Comparator|INF + IBU|The participant will receive a dose of intranasal (1.5 mcg/kg up to a maximum of 100 mcg) AND a dose of oral ibuprofen (10 mg/kg up to a maximum of 600 mg)
2487637|NCT02984969||Slow transit constipation|subjects met the Rome III criteria for STC
2487641|NCT02984969||Healthy subjects|Healthy controls
2487801|NCT02983708|Experimental|mPBMC group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. mPBMCs group would be included all patients who received mPBMCs at M1 or M7.
2487804|NCT02983708|Placebo Comparator|Placebo group|G-CSF would be administered for 5 days and then mobilized peripheral blood mononuclear cells (mPBMCs) would be collected in all included patients. One month after cryopreservation of the mPBMCs (M1), patients will be randomized to receive either mPBMCs or placebo. Six months after randomization (M7), cross-over infusion of mPBMCs or placebo will be performed and the patients are observed for another 6 months. Placebo group would be included all patients who received placebo at M1 or M7.
3160645|NCT00428649|Experimental|5|100 µg selenium as selenomethionine
3160646|NCT00428649|Experimental|6|120 µg selenium as selenomethionine
3160647|NCT00428649|Placebo Comparator|7|placebo
3160648|NCT00428727|Experimental|1|Nitric oxide patches
3160649|NCT00428727|Placebo Comparator|2|Placebo patches
3160650|NCT00428779|Experimental|1|patients running during 24 hours without sleep
3160651|NCT00428779|Placebo Comparator|2|patients without sleep during 24 hours
2486950|NCT02989584|Experimental|Atezolizumab, Gemcitabine, Cisplatin|"This is a two phase study with a single study arm for each phase.~For Phase 1: Following enrollment participants will be treated with combination therapy on a 21 day cycle x 6 cycles. Gemcitabine (1000 mg/m2 on Day 1 and Day 8), cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously.~Phase 2: Following enrollment participants will be treated with a single dose of atezolizumab alone followed by combination therapy on a 21-day cycle x 4 cycles, followed by a single dose of atezolizumab alone. Gemcitabine 1000mg/m2, cisplatin (70 mg/m2 on Day 1), and atezolizumab (1200 mg on Day 8) will be administered intravenously."
2487003|NCT02989142|No Intervention|Control arm|No intervention
2487009|NCT02989142|Experimental|INTER-ACT arm|"Four pre-conception coaching sessions : postpartum week 6, week 8, week 12, 6 months.~Three pregnancy coaching sessions: at the time of the planned ultrasound scans."
2487137|NCT02988297|Experimental|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
2487142|NCT02988297|Placebo Comparator|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
2487191|NCT02987920|Active Comparator|Placebo - Concentrate|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Placebo - Concentrate by mouth.~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain"
2487192|NCT02987920|Experimental|Dextromethorphan|"preoperative oral medications given one time: acetaminophen 1000mg tablet, oxycodone extended release 10mg tablet, celecoxib 400mg tablet, pantoprazole 40mg tablet, and Dextromethorphan 60mg tablet~postoperative medications given for 2 days: Acetaminophen 1000mg every 6hr, Ketorolac15mg IV q6hrs x4 doses, Oxycodone 5mg po q3hrs prn moderate pain, Oxycodone10mg po q3hrs prn severe pain, Gabapentin100-300mg once at night, Dilaudid 0.2mg IV q2hrs prn severe pain, and dextromethorphan 60mg by mouth twice daily"
2487307|NCT02987413|Experimental|Autologous Mesenchymal stem cells|Two escalated intrathecal infusions of autologous mesenchymal stem cell
2487387|NCT02986555|Placebo Comparator|Stress relief with existing biofeedback|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with existing biofeedback approach to relieve stress.
2487388|NCT02986555|Active Comparator|Stress relief with biofeedback and VR|After distressing virtual reality video and full resting time to relieve this stress, the investigators are going to give cognitive distress with serial seven, accompanied with biofeedback combined to virtual reality relaxation.
3193943|NCT00822887|Experimental|Vandetanib|Dose level 1:100 mg qd, 2:200 mg qd, 3:300 mg qd. Fractionated Stereotactic Radiotherapy: all patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
3193944|NCT00822913|Experimental|Botulinum A toxin|Botulinum A toxin intravesical injection
3193945|NCT00822965||Patient Knowledge Assessments|Questionnaires + Phone Interview
2487557|NCT02985359||Comparison district|Existing routine community health services by government
2487560|NCT02985359||Program district|In addition to existing routine community health services by the government, daily 20g Nutributter (Lipid-based Nutrient Supplement, LNS) will be provided to children 6 to 24 month of age and caregivers will participate in Social and Behavior Change Communications (SBCC) activities including the promotion of infant and young child feeding (IYCF) behaviors and water, sanitation and hygiene (WASH) behaviors will be conducted with caregivers.
2487605|NCT02985112||Patients with FFR > 0.80|Group of patients with physiologically non-significant coronary stenoses who will not undergo coronary revascularization
2487610|NCT02985112||Patients with FFR < 0.80|Group of patients with physiologically significant coronary stenoses who will undergo coronary revascularization
2487678|NCT02984891||Treatment|Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) will be used in patients with coronary artery disease.
2487747|NCT02984319|Active Comparator|Cherry|Cherry concentrate
2487750|NCT02984319|Placebo Comparator|Placebo|Placebo concentrate
2487779|NCT02983851|Experimental|Noninvasive mechanical ventilation|Patients in this group will receive Noninvasive mechanical ventilation as the initial mechanical ventilation (MV) strategy, irrespective of whether Invasive mechanical ventilation is used later during the following treatment.
2487780|NCT02983851|Active Comparator|Invasive mechanical ventilation|Patients in this group will receive Invasive mechanical ventilation as the initial MV strategy, irrespective of whether Noninvasive mechanical ventilation is used later during the following treatment.
2487830|NCT02983513|Experimental|Early Intervention|"The early intervention program is delivered during the NICU stay, according to the MITP and Premie Start Protocol, in order to train parents to: recognize signs of infant stress and alert-available behavior to promote mother-infant interaction; adopt principles of graded stimulation; optimize interactions and avoid overwhelming infants through facilitation strategies (for example, engage and support the visual attention of the newborn). The program is held in eight main sessions and one additional post-discharge session.~In addition parents are trained and invited to daily promote preterm baby massage therapy and visual attention according to a detailed protocol."
2487832|NCT02983513|No Intervention|Standard Care|Standard Care according to NICU protocols including Kangaroo Mother Care, nesting and minimal handling
2487972|NCT02982486|Experimental|Nivolumab and ipilimumab|Nivolumab 240 mg IV every 2 weeks plus Ipilimumab 1 mg/m2 IV every 6 weeks
2488096|NCT02981706|Active Comparator|Arteriovenous Fistula (AVF) Group|Patient will receive an arteriovenous fistula (connection between native artery and vein) as his/her dialysis access
2515809|NCT02791477|Other|Attune FB PS|Attune FB PS knee arthroplasty
3193946|NCT00822978|Active Comparator|ACHN-490 Injection|ACHN-490 Injection in escalating doses
3193947|NCT00822978|Placebo Comparator|2|Placebo is normal saline
3193948|NCT00822991|Active Comparator|Group of CE-US|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
3193949|NCT00822991|Active Comparator|Group of B-mode US|screening by conventional B-mode US every 3-5 months
2486989|NCT02989285||HIV+ cognitively normal (no-HAND)|Participants will be assessed based on their performance on the neuropsychological test battery at study entry. HAND status will be diagnosed per FRASCATI research criteria and this will determine which study cohort they are allocated to. Participants will continue to receive their standard of care treatment during the study period.
3160652|NCT00428805|Experimental|intervention 1|This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
3160653|NCT00428805|No Intervention|control 2|measurement only control arm
3160654|NCT00428831||1|Patients with respiratory illnesses.
3160655|NCT00428870|Experimental|Arthroscopic acromioplasty|Arthroscopic acromioplasty
3160656|NCT00428870|Placebo Comparator|Sham surgery|Shoulder arthroscopy without active treatment and subacromial arthroscopy without bursectomy, decompression or other active interventions
3160657|NCT00428870|Active Comparator|Conservative treatment|Standardized exercise rehabilitation (supervised by physiotherapist)
3160658|NCT00428896|Experimental|1|ZD1839
3160659|NCT00428909|Other|Drug-Drug interaction|
3160660|NCT00428935|Experimental|Low Dose|Low dose cohort - 2.0E10 vg/kg
2487151|NCT02988258|Experimental|Cohort 1 - 10^4 transduced cells/kg|The first 3 patients will receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^4 T cells/kg recipient weight
2487156|NCT02988258|Experimental|Cohort 2 - 10^5 transduced cells/kg|If no cases grade III-IV GVHD in Cohort 1 the remaining patients (N=7) each receive a single infusion of bulk CMV-TCR transduced donor-derived T cells on first CMV reactivation post allogeneic HSCT, at a dose of 10^5 T cells/kg recipient weight
2487159|NCT02988258|Experimental|Cohort 1a - 10^3 transduced cells/kg|If 1 case grade III-IV GVHD in Cohort 1, next three patients to be treated with a single infusion of bulk CMV-TCR transduced donor-derived T cells of 1 x 10^3 T cells/kg recipient weight
3160661|NCT00428935|Experimental|High Dose|High Dose - 1.0E11 vg/kg
2487314|NCT02987049||ICR (Intensive Cardiac Rehab)|The Intensive Cardiac Rehabilitation (ICR) group will follow their physician-prescribed series of supervised exercise sessions and educational sessions in a cardiac rehab facility. The education component includes a series of Pritikin videos, nutrition workshops and cooking classes led by a registered dietitian, one-on-one dietary consultation with a registered dietitian, and a Pritikin notebook. The intervention for this study is comprised of 24 exercise sessions plus 24 educational sessions in 24 visits.
2487315|NCT02987049||CR (conventional Cardiac Rehab)|The conventional Cardiac Rehabilitation (CR) group will follow their physician-prescribed series of supervised exercise sessions in the same cardiac rehab facility as the ICR group. The intervention for this study is comprised of 24 exercise sessions during 24 visits.
2487329|NCT02986750|Experimental|Experimental: Patients with dry eye syndrome 1|40 Patients with dry eye syndrome
2487335|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 2|40 Patients with dry eye syndrome
2487337|NCT02986750|Active Comparator|Experimental: Patients with dry eye syndrome 3|40 Patients with dry eye syndrome
2487409|NCT02986503||Chemotherapy for Good responder|Doxorubicin + cisplatin + ifosfamide Pre-operative and post-operative chemotherapy for patients with good responder high grade osteosarcoma
2487411|NCT02986503||Chemotherapy for Poor responder|Doxorubicin+cisplatin+ifosfamide+methotrexate Pre-operative and post-operative chemotherapy for patients with poor responder high grade osteosarcoma
2487480|NCT02986061|Active Comparator|Control Group|Patients with indwelling urinary catheter
2487481|NCT02986061|No Intervention|Study Group|Patients without indwelling urinary catheter
2487548|NCT02985606|Active Comparator|Caffeine -60|Caffeine at 60 minutes prior to time trial
2487549|NCT02985606|Active Comparator|Caffeine -30|Caffeine at 30 minutes prior to time trial
2487550|NCT02985606|Active Comparator|Caffeine 0|Caffeine immediately prior to time trial
2487551|NCT02985606|Placebo Comparator|Placebo|Placebo drink at all time points
2487558|NCT02985216|Experimental|YHD1119|YHD1119 150mg for the first 1 week, then forced titrated to YHD1119 300mg for the 1 week. And then YHD1119 150~600mg for the 2 weeks, then YHD1119 fixed dose was administrated for 8 weeks.
2487561|NCT02985216|Active Comparator|Lyrica|Lyrica 150mg for the first 1 week, then forced titrated to Lyrica 300mg for the 1 week. And then Lyrica 150~600mg for the 2 weeks, then Lyrica fixed dose was administrated for 8 weeks.
2487621|NCT02985099|Active Comparator|Rosuvastatin group|Oral prophylaxis followed by 1.2% Rosuvastatin drug in gel form placed in intrabony defects
2487623|NCT02985099|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2487731|NCT02984241|Active Comparator|eHealth Coping Skills Training + Coach|Access to StopSpinningMyWheels.org + Coach Support
2487732|NCT02984241|Active Comparator|eHealth Coping Skills Training Only|Access to StopSpinningMyWheels.org
3160662|NCT00429013|No Intervention|2|no medical device
3160663|NCT00429013|Experimental|1|medical device
3160664|NCT00429091|Placebo Comparator|1|
3160665|NCT00429091|Experimental|2|
3160666|NCT00429091|Active Comparator|3|
3160667|NCT00429117||Survey|Physician members of the International Gynecologic Oncologists Society or the Society of Gynecologic Oncologists.
3160668|NCT00429156|Active Comparator|1|Home non-invasive ventilation
3160669|NCT00429156|Sham Comparator|2|Home sham non-invasive ventilation with CPAP 5 cm H2O
3160670|NCT00429234|Experimental|Dasatinib + Gemcitabine|Dasatinib starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks. Gemcitabine starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
3160671|NCT00429247|Experimental|1|Her
3160672|NCT00429247|No Intervention|2|Follow up
3160673|NCT00429312|Experimental|Single Arm|Intratumoral injection(s) of Recombinant Vaccinia GM-CSF, JX-594
3160674|NCT00429338|Experimental|AIR-MRSI|Endorectal MRSI with Air
3160675|NCT00429338|Experimental|PFC-MRSI|Endorectal MRSI with PFC
2486992|NCT02989324|Experimental|Vaginal Misoprosto|Vaginal Misoprosto for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Section
2486994|NCT02989324|Active Comparator|Misoprostol Plus Foley Catheter|Misoprostol Plus Foley Catheter for Late Second Trimester Termination of Pregnancy With Previous Multiple Cesarean Sections
2487098|NCT02988895|Experimental|episcleral brachytherapy|single fraction of 24 Gy Strontium90 episcleral brachytherapy
2487119|NCT02988375|Experimental|dCBTI|Online access to the digital CBTI program Sleepio
2487120|NCT02988375|Placebo Comparator|Sleep Education|Weekly email messages with sleep hygiene recommendations
2487187|NCT02987933||Chronic Pain|Adults, > 6 months duration, daily pain
2487189|NCT02987933||Healthy Normals|Age and gender matched controls
2487234|NCT02987647|Experimental|Hidrafemme|"The arm in question will have 14 patients who use the Hidrafemme product, encoded as group A.~Name: hidrafemme Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2487241|NCT02987647|Active Comparator|Vagidrat|"The arm in question will have 14 patients who use the Vagidrat product, encoded as group B.~Name: vagidrat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2487243|NCT02987647|Active Comparator|Lubrinat|"The arm in question will have 14 patients who use the Lubrinat product, encoded as group C.~Name: lubrinat Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2487245|NCT02987647|Active Comparator|Antrofi|"The arm in question will have 14 patients who use the Antrofi product, encoded as group D.~Name: antrofi Dosage form: applicator Dosage: the applicator must be complete (full) Frequency: twice a week Duration: 28 days"
2487346|NCT02986659|Active Comparator|Metformin then Placebo|Metformin dosing at 425, 850 and 1700 mg with GLUCOPHAGE® (metformin hydrochloride) Tablets. Treatment with metformin will be initiated at a dose of 425 mg (half pill) taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night at a dose of 850 mg for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two 850 mg pills, one in the morning and one at night, for a total dose of 1700 mg which is within the range of the usual effective dose of 1500 to 2000 mg/day for the remainder of the 3 months. Will then cross over to 3 months on placebo.
2487350|NCT02986659|Placebo Comparator|Placebo then Metormin|Dietary Supplement: Placebo with Methylcellulose capsules. Treatment with placebo will be initiated at a dose of a half pill taken orally once a day at night for 7 days. After the week, the participant will be called to assess tolerance and will be asked to increase dose to one pill at night for one week. At the end of the second week, participants will be called again and if they tolerated the second dose, they will be asked to take two pills, one in the morning and one at night for the remainder of the 3 months. After 3 months on placebo, participants will then cross over to 3 months of metformin as described in the other arm.
2487415|NCT02986399||Standard care|Hip fracture patients operated at Akershus University hospital in 2012 and 2013.
2487416|NCT02986399||Fast track patient pathway|Hip fracture patients operated at Akershus University hospital in 2014 and 2015.
3160676|NCT00429429|Experimental|Peanut protein solution|Subjects receiving the peanut sublingual peanut protein drops. Sublingual Immunotherapy.
2487489|NCT02985749|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
2487562|NCT02985476|Active Comparator|Interventional|Care as usual plus 8 weekly ELIJAH health reports shared with the participant and General Practitioner for 6 months i.e.: My history, My plan, My Update delivered via post or by email (dependant on participant preference) in addition to care as usual.
2487563|NCT02985476|No Intervention|Observational|Care as usual dictated by disease pathway of diagnosed inflammatory bowel disease i.e.; access to out-patient and in-patient hospital based care and community health resources via General Practitioner.
2487612|NCT02985125|Experimental|Phase I - Dose Level 1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 250mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2487615|NCT02985125|Experimental|Phase I - Dose Level 2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 300mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2487617|NCT02985125|Experimental|Phase I - Dose Level -1|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 200mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2487618|NCT02985125|Experimental|Phase I - Dose Level -2|"Treatment cycles are 28 days long.~LEE011 (taken orally) - 150mg Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2487619|NCT02985125|Experimental|Phase II - Dose|"Treatment cycles are 28 days long.~LEE011 (taken orally) - the recommended phase II dose Once daily on days 1-21~Everolimus (taken orally) - 2.5mg Once daily on days 1-28"
2487734|NCT02984241|Active Comparator|eHealth Usual Web Care|Access to StopSpinningMyWheels.org usual care
2516101|NCT02789449||precapillary|patients with PH and PAWP<12mmHg
3160677|NCT00429442|Active Comparator|1|
3160678|NCT00429442|Placebo Comparator|2|
3160679|NCT00429455||Survey Participants|Female patients who had a hematopoietic stem cell transplantation between January 1987 and September 2004 at M. D. Anderson Cancer Center.
3160680|NCT00429546|Experimental|Intervention|Participants will receive a cognitive-behavioral intervention designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child
3160681|NCT00429546|Active Comparator|Control|Participants will receive treatment as usual
3160682|NCT00429559|Experimental|A|
3160683|NCT00429650|Experimental|1|Increased amount of exercise to maintain weight loss.
3160684|NCT00429650|Experimental|2|Combination of Exercise and Diet to maintain weight loss
3160685|NCT00429650|Active Comparator|3|Use diet alone to maintain weight loss.
3160686|NCT00429715|Experimental|Alum-ALM + BCG|Alum-ALM + BCG
3160687|NCT00429715|Active Comparator|BCG|BCG
3160688|NCT00429715|Placebo Comparator|BCG diluent|Diluent
3160689|NCT00429754|Other|aprepitant|Aprepitant treatment
3160690|NCT00429780|No Intervention|Alum-ALM + BCG|Alum-ALM + BCG
3160691|NCT00429780|No Intervention|Placebo|BCG diluent
2487010|NCT02989051|Active Comparator|Liberal fluid treatment|This is seen as current standard clinical treatment, wherein patients will receive a more liberal fluid regimen.
2487075|NCT02988869|Experimental|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
2487077|NCT02988869|Active Comparator|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
2487078|NCT02988869|Active Comparator|Tiotropium + Formoterol|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
2487131|NCT02988531|Experimental|PET/MR|Participants to have PET/MR scan
2487175|NCT02987985|Experimental|Opioid-free anesthesia|Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis
2487180|NCT02987985|Active Comparator|Opioid-sparing anesthesia|Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis
3160692|NCT00429806|Placebo Comparator|Placebo|Placebo suppository; once daily for 7 days.
3160693|NCT00429806|Experimental|DHEA 0.50%|DHEA 0.50% (6.5 mg) suppository; once daily for 7 days.
2487474|NCT02986100|Experimental|C-14 labeled rucaparib|"Each patient will receive a single oral dose of 600 mg [14C] rucaparib (approximately 140 µCi) in the fasted state. Patients will be confined at the study site for the collection of blood samples and excreta for a maximum of 13 days, from Day -1. The patient can be discharged sooner than Day 13, if the discharge criteria are met.~After completion of Part I, patients with a deleterious BRCA mutation will have the option to participate in Part II by receiving 600 mg BID rucaparib tablets orally in 28 day cycles until disease progression, unacceptable toxicity, death, or discontinuation for other reasons"
2487507|NCT02985671|Experimental|Experimental Drug & Voltaren Placebo|"Orphenadrine + acetaminophen + caffeine + diclofenac sodium & Placebo of Voltaren~01 tablet of experimental drug (orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg) + 01 tablet of placebo of Voltaren, to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
2487517|NCT02985671|Active Comparator|Voltaren® + Experimental Drug Placebo|"Voltaren & Placebo of Orphenadrine + acetaminophen + caffeine + diclofenac sodium~01 tablet of Voltaren + 01 tablet of placebo of experimental drug (orphenadrine, acetaminophen, caffeine and diclofenac sodium), to be administrated orally, three times a day, respecting the interval of 08 hours between administrations, during 7 days."
2487555|NCT02985372|Experimental|Acute myeloid leukemia|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
3160694|NCT00429806|Experimental|DHEA 1.0%|DHEA 1.0% (13 mg) suppository; once daily for 7 days.
3160695|NCT00429806|Experimental|DHEA 1.8%|DHEA 1.8% (23.4 mg) suppository; once daily for 7 days.
2487652|NCT02984826|Active Comparator|Strength training|Intervention with specific strength training program runs for 10 weeks.
2487655|NCT02984826|Active Comparator|Ergonomic and posture|Intervention, the control group will be trained in ergonomics and posture.
2487711|NCT02984514|Experimental|Type 1 diabetes|Positron emission tomography with tracer 18F-deoxy glucose
2487739|NCT02984098|Experimental|Dextrose gel 40%|before heel lance, 2 ml oral dextrose gel 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
2487741|NCT02984098|Active Comparator|Dextrose gel 25%|before heel lance, 2ml oral dextrose gel 25% was administered, and pain related intensity was evaluated with premature infant pain profile scale
2487796|NCT02983890|Active Comparator|Arm of study1|Dicloxacillin tablets.
2487798|NCT02983890|Placebo Comparator|Arm of study 2|No treatment
2487895|NCT02983409||Pstone|Adult Patients (> 18years) who were diagnosed as the urinary stone in the ED. All patients who visited the ED with compalin of acute pain, and urinary stone was idenfied by urinary CT in the ED.
2487928|NCT02982733|Active Comparator|ABS|Ankaferd blood stopper
2487936|NCT02982733|Placebo Comparator|CS|Conventional sterile gauze
2487943|NCT02982733|Active Comparator|TR BAND|Dedicated hemostatic device
2488030|NCT02982395|Experimental|Nanoxel®M|75 mg in 100mL normal saline
2488036|NCT02982395|Active Comparator|Mitomycin|40 mg in 100mL normal saline
2488094|NCT02981732|Experimental|Shen (Kidney) yin deficiency|Shen (Kidney) yin deficiency
2488101|NCT02981732|No Intervention|the control group|the control group,there is no intervention
2488126|NCT02981381|Experimental|Active sTMS (NEST-1)|"Subjects randomized to this group will receive 20 active synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 active sTMS sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place on the last day of active sTMS.~Participants that elect to participate in the open-label continuation phase, will receive an additional 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
2488142|NCT02981316|Active Comparator|RBX7455 Group D|2 days of 1 capsule twice daily RBX7455 for 10 subjects.
3160696|NCT00429871|Experimental|1|DF
3160697|NCT00429871|Experimental|2|DC
3160698|NCT00429936|Active Comparator|100 mg fenretinide softgel capsules|Three (3) 100-mg fenretinide softgel capsules
3160699|NCT00429936|Active Comparator|Fenretinide and placebo softgel capsules|One (1) 100-mg fenretinide softgel capsule and two (2) placebo softgel capsules
3160700|NCT00429936|Placebo Comparator|Placebo softgel capsules|Three (3) placebo softgel capsules
3160701|NCT00429962|Experimental|A|intravitreal ranibizumab used in combination with verteporfin photodynamic therapy
3160702|NCT00429962|Active Comparator|B|intravitreal ranibizumab
3160703|NCT00430014|Experimental|Atiprimod|
3160704|NCT00430040|Experimental|carvedilol|carvedilol
3160705|NCT00430040|Active Comparator|lisinopril|lisinopril
3160706|NCT00430066|Experimental|Imatinib Mesylate|400 mg/day by mouth for 6 months (+ 6 months in case of responsiveness)
2487039|NCT02989311|Active Comparator|Study 2: Consecutive meals+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous Fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meals:Test meal A will contain 12mg of ferrous sulphate given as 2mg 54Fe and 10mg 56Fe. Test meal B will contain 12mg of ferrous sulphate given as 2mg 57Fe and 10mg 56Fe.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
2487041|NCT02989311|Active Comparator|Study 2:Alternate meal+Iron+MNP+GOS|"The MNP contains 400 μg Vitamin A, 5 μg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as Ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g) Iron compound added to the test meal C: 12mg of ferrous sulphate given as 2mg 58Fe and 10mg.~Intervention: Dietary supplement: Fortified maize porridge (MNP+ Iron + GOS)"
2487095|NCT02988765|Experimental|Invasive vulvar cancer (IVC)|"Vulvar carcinoma (stromal infiltration > 1 mm)~Histotypes different from squamous cells carcinomas are included"
2487115|NCT02988414||Staphylococcus aureus Infection|Patients with blood culture confirmed S. aureus bloodstream infections.
2487116|NCT02988414||Gram Negative Infection|Patients with blood culture confirmed Gram Negative bloodstream infecrions
2487118|NCT02988414||Endocarditis|Patients admitted for evaluation of acute endocarditis classified using the Duke Criteria.
2487165|NCT02988180|Other|intervention group|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
2487170|NCT02988180|Other|control group|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
2487203|NCT02987751|Experimental|Glargine + Glulisine|Insulin Glargine + Glulisine (12U/day + 4U/day) at pre-breakfast/dinner for 24 weeks
2487204|NCT02987751|Active Comparator|Premixed Analogue Insulin (70/30)|Premixed analogue Insulin (70/30) 16U/day at pre-breakfast/dinner for 24 weeks
3193950|NCT00823004|Active Comparator|1|A/L: Poor responders who will receive letrozole and GnRH antagonist for ovarian stimulation
2487327|NCT02986672|Active Comparator|Calanus oil|Children receiving omega-3 in form om calanus oil in capsule form
2487328|NCT02986672|Placebo Comparator|Placebo|Children receiving medical paraffin in capsule form (2 ml volume per day)
2487394|NCT02986568|Experimental|Cervical cancer|"Primary cervical cancer patients, FIGO stage IB1-IIB~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
2487397|NCT02986568|Experimental|Uterine cancer|"Primary uterine cancer patients, FIGO stage IA, grade3, IB-IVA~Refractory uterine cancer who does not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent uterine cancer after concurrent chemoradiotherapy or radiotherapy"
2487399|NCT02986568|Experimental|Cervical cancer, pelvic sidewall invasion|"Cervical cancer patients showing pelvic sidewall invasion~Primary cervical cancer~Refractory cervical cancer patients who do not respond to concurrent chemoradiotherapy or radiotherapy~Recurrent cervical cancer after concurrent chemoradiotherapy or radiotherapy"
2487402|NCT02986568|Experimental|Non-cervical cancer, pelvic sidewall invasion|"Gynecologic cancer patients other than cerivcal cancer, showing pelvic sidewall invasion with or without distant metastasis~Patients showing uncontrolled pelvic pain due to the tumor invasion"
2487419|NCT02986152|Experimental|CDC Mobile App Treatment|Subjects who are randomized to the CDC mobile app treatment arm will be asked to perform the app's full suite of intervention tools such as learning about PTSD, assessment, finding support, and mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) over the entire 8-week study period.
2487424|NCT02986152|Other|CDC Mobile App Wait-List Control|Subjects who are randomized to the CDC mobile app wait-list control arm will be asked to perform only the learning about PTSD, assessment, and finding support activities for the first 4 weeks. Following completion of the Week-4 questionnaires, subjects will then be asked to additionally perform the mind/body exercises (e.g., guided imagery, meditation, and relaxation exercises) for the duration of the 8-week study period.
2487476|NCT02986048||Proton Beam Therapy|All patients treated with proton beam therapy at the UH Proton Therapy Center who consent to have their health information recorded, including whether the cancer was cured and if any complications occur ed due to treatment
2487530|NCT02985619|Active Comparator|IVB randomised group II|"Randomised patients (IVB group II) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.05ml (1.25mg) intravitreous injection of Bevacizumabe prn (pro re nata, or as needed), with monthly visits for central subfoveal thickness map more than 300µm by Optic Coherence Tomography."
2487531|NCT02985619|Active Comparator|IVT randomised group I|Randomised patients (IVT group I) with central foveal thickness >300µm on OCT were submitted to 6 months treatment with 0.03ml (1.20mg) intravitreous injection of triamcinolone each 3 months (prn, as needed) for central sufoveal thickness map more than 300µm by Optic Coherence Tomography.
2487532|NCT02985619|Other|IVB group III (not randomised)|Patients with central foveal thickness ≤300µm were allocated to group III (IVB)
2487582|NCT02985346|Experimental|BMSC group|Patients received Bone marrow mesenchymal stem cells (BMSC) plus standard treatment
2487587|NCT02985346|Active Comparator|Control group|Patients received standard treatment
2487689|NCT02984670|Experimental|Behavior Therapy|
2487692|NCT02984670|Experimental|Cognitive Therapy|
2487694|NCT02984670|Other|Waitlist|
2487749|NCT02984228|Active Comparator|Platelet-rich plasma (PRP)|Patients will receive an injection of PRP.
2487753|NCT02984228|Active Comparator|Hyaluronic Acid|Patients will receive an injection of hyaluronic acid.
2487979|NCT02982616|Placebo Comparator|neutral emotion and saline|neutral emotion induction combine with saline intragastric infusion
2487049|NCT02989012|Experimental|Drugs for experimental group|GanMaoKangNing Granules， blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous Oseltamivir Phosphate Capsules,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
2487054|NCT02989012|Sham Comparator|Drugs for control group|Oseltamivir Phosphate Capsules ,take oral,2 times a day,1 capsule each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.); Analogous GanMaoKangNing Granules, blunted by boiled water , 3 times a day, 2 bags each time, for a course of five days(During experiments, The condition of the subjects sicker or complications, Whether need to change or increase the treatment measures were determined by the researchers ,Stop using the medicine , completion of the relevant inspection and evaluation after medication,Quit the test,the case according to the invalid qualified cases statistics.).
2487152|NCT02988310||Individuals with below knee limb loss|Individuals with below knee limb loss will be participants of the group.
2487155|NCT02988310||Individuals with above knee limb loss|Individuals with above knee limb loss will be participants of the group.
2487158|NCT02988310||Healthy individuals|Healthy individuals will be participants of the group.
3193951|NCT00823004|Active Comparator|2|MF: In this arm poor responders are treated by microdose GnRH agonist flare protocol
3193952|NCT00823017|Experimental|1|Patient-preferred music
2487295|NCT02987101|Experimental|Autologous SVF + Standard of care|"local injection around and under wound with autologous stromal vascular fraction.~Standard wound care is given independent of this study."
2487299|NCT02987101|Other|Standard of care|Standard wound care is given independent of this study.
3193953|NCT00823017|Experimental|2|Relaxation Music
3193954|NCT00823017|Placebo Comparator|3|Standard of Care
3193955|NCT00823030|Placebo Comparator|Placebo|Placebo instillation: 20 ml of normal saline instilled intravesically
3193956|NCT00823030|Experimental|experimental arm|The experimental instillation will include 8 ml of 2% lidocaine, 3 ml of sodium bicarbonate, and 9 ml of normal saline.
2487465|NCT02986295||BioMimeTM Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with BioMimeTM Stent
2487466|NCT02986295||Ultimaster® Stent|No intervention / Ischemic heart disease with percutaneous coronary intervention with Ultimaster® stent
2487486|NCT02985788||Video Instructions|Instructions on how to take a flexion/extension picture will be delivered in video format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
2487491|NCT02985788||Written instructions|Instructions on how to take a flexion/extension picture will be delivered in a written, on paper format. These instructions will be followed by written instruction on how to take pictures examining pronation/supination.
2487559|NCT02985515|Experimental|Smell Training|Participants will first undergo a 30-day trial of budesonide nasal saline irrigation. If there is no subsequent improvement in olfaction, participants will undergo a 12-week smell training intervention.
2487604|NCT02985138|Experimental|Unilateral fixation|Patients undergoing TLIF and unilateral pedicle screw fixation
2487609|NCT02985138|Active Comparator|Bilateral fixation|Patients undergoing TLIF and bilateral pedicle screw fixation
2487657|NCT02984813|Experimental|GlaucoHealth|2 pills once daily in the morning for 3 months
2487658|NCT02984813|Experimental|GlaucoSelect|2 pills once daily in the morning for 3 months
2487660|NCT02984813|Placebo Comparator|Placebo|2 pills once daily in the morning for 3 months
2487707|NCT02984475|Active Comparator|treatment arm|30 patients receiving blood transfusion and taking iron-chelating therapy along with metformin tablets (500 mg once daily for the first week then twice daily for 6 months).
2487708|NCT02984475|No Intervention|control arm|30 patients receiving blood transfusion and taking iron-chelating therapy.
2487756|NCT02984072|Active Comparator|Menthol|5% menthol in aqueous cream (Dermacool Forte)
2487757|NCT02984072|Placebo Comparator|Placebo|Aqueous cream
2487818|NCT02983734|Active Comparator|D-cycloserine|"To compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.~DCS = d-cycloserine~Dosage: 100mg~Dosage form: Pill, administered orally~Frequency: Daily for four weeks"
2487822|NCT02983734|Placebo Comparator|Placebos|To provide a control group to compare efficacy of the novel therapeutic approach of DCS in improving cognitive functioning in GW veterans with GWI.
2487875|NCT02983149|Other|Double lumen tube|One lung ventilation will be achieved using a double lumen tube
2487879|NCT02983149|Other|Fuji blocker|One lung ventilation will be achieved using the Fuji blocker
2487884|NCT02983149|Other|EZ blocker|One lung ventilation will be achieved using the EZ blocker
2487906|NCT02982798|Experimental|Group I|Period I: administration of Metformin + Rosuvastatin Period II: JLP-1310
2487907|NCT02982798|Experimental|Group II|Period I: JLP-1301 Period II: administration of Metformin + Rosuvastatin
2487974|NCT02982616|Experimental|positive emotion and fatty acid|positive emotion induction combine with 2.g Dodecanoic acid intragastric infusion
2487976|NCT02982616|Experimental|neutral emotion and fatty acid|neutral emotion induction combine with 2.g Dodecanoic acid intragastric infusion
2487977|NCT02982616|Experimental|positive emotion and saline|positive emotion induction combine with saline intragastric infusion
2516109|NCT02789449||postcapillary|patients with PH and PAWP>18mmHg
3193957|NCT00823056|Placebo Comparator|1|
3193958|NCT00823056|Active Comparator|2|
3193959|NCT00823108|Experimental|1|Glucose-insulin-potassium
3193960|NCT00823108|No Intervention|2|Control
2487083|NCT02988661|Active Comparator|Chronic Disease Self-management Program (CDSMP)|A random sample of African American women with SLE selected from the Georgians Organized Against Lupus (GOAL) parent cohort will be used to recruit participants into the CDSMP. This group will be identified as the WELL Cohort.
2487084|NCT02988661|No Intervention|Usual Care|African American women consented into the parent Georgians Organized Against Lupus (GOAL) cohort who have not been selected to be enrolled in the intervention will comprise the usual care group. This group will continue their longitudinal assessments as part or the GOAL cohort data collection efforts.
3193961|NCT00823121|Active Comparator|frozen-embryo transfer|In this group all embryos are cryopreserved and two months later embryo transfer will perform.
3193962|NCT00823121|Active Comparator|fresh embryo transfer|In this arm fresh embryo transfers are performed on day 2 or 3.
2487244|NCT02987556|Active Comparator|Usual System (open-loop)|In open loop, patients will be provided with an Continuous Glucose Monitoring (CGM) and an external insulin pump programmed with its usual treatment previously prescribed by its physician.
2487246|NCT02987556|Experimental|DIABELOOP System (closed-loop)|In the closed-loop, patients will be provided with the Diabeloop system consisting of insulin pump Cellnovo or Kaleido driven by remote control augmented by Diabeloop software and connected to the CGM Prescription of insulin doses proposed by a predictive algorithm.
2487273|NCT02987140|Experimental|PD+FoG|PD patients with FoG
2487278|NCT02987140|Active Comparator|PD-FoG|PD patients without FoG
2487283|NCT02987140|Active Comparator|Control|age-matched non-disabled adults
2487333|NCT02986919|Experimental|CPI-0610 Treatment|CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break.
2487423|NCT02986607|Experimental|Hypoparathyroidism|"Subcutaneous 24h microdialysis before PTH treatment and during continous subcutaneous PTH treatment. PTH, Natpara (parathyroid hormone 1-84) 50 µg doses with a concentration of 800 µg/ml, will be delivered by an insulin-pump (OmniPod) which delivers the infusion gear continous subcutaneously based on units (U) of insulin. 1 µg Natpara equals 0.125 U of infusion. The starting dose for pump treatment will be 0.50 µg per kilo per day and adjusted according to Calcium levels.~Controls: patients With hyperparathyroidism and healthy volunteers will perform 24h microdialysis."
2487497|NCT02986035|Experimental|Intervention|
2487600|NCT02985554|Experimental|Nivolumab|Nivolumab will be administrated intravenously. Standard dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
2487704|NCT02984540|Experimental|LOW-CARBOHYDRATE DIET|The low-carbohydrate diet will consist of a meal plan of less than 20 grams of carbohydrates per day to be consumed over 6 weeks. Foods that provide high levels of healthy fats (preferably low in saturated fats) will be generously included in the diet plan. Various lean meats, fish, and nutrient rich foods that meet the requirement of less than 20 grams total carbohydrates per day will be included in the meal plans. Carbohydrates will be expected to make up less than 10% of total caloric intake. Participants in the low-carbohydrate diet group will receive a supply of extra virgin olive oil at study visits to incorporate into their individualized meal plans.
2487705|NCT02984540|Experimental|LOW-FAT DIET|The low-fat diet will consist of a low-fat, higher-carbohydrate meal plan to be consumed over 6 weeks. Participants will be encouraged to limit their amount of fat intake to less than 40 grams per day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber. Various lean meats and other sources of protein will be included in the diet plan. Carbohydrates will be expected to make up 50-60% of total caloric intake.
2487761|NCT02984085|Experimental|Genetically corrected cultured epidermal autograft|"The surgery will be carried out in 2 stages, the first aims at taking biopsy to isolate epidermal cells including stem cells. The biopsy will be processed in a laboratory of a regenerative medicine manufacturing site where they will be corrected, expanded and prepared as final sheets to be implanted.~In the second surgery, genetically corrected cultured epidermal autograft (Hologene 7) will be implanted into the selected area. The specialist surgeon will either use a local or general anaesthetic for the implant operation. The treated area will be immobilized for some days after this operation. Antibiotics and anti-inflammatory drugs will be administered (if necessary) to prevent infections and to minimise swelling."
2487792|NCT02983747|Experimental|PRP Treatment(P)|PRP intra-disk injection therapy combined with NSAIDs medication (Loxoprofen Sodium tablets).
2487795|NCT02983747|Active Comparator|Medication Treatment(M)|NSAIDs medication(Loxoprofen Sodium tablets) therapy only.
2487877|NCT02983422|Active Comparator|Group aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
2487880|NCT02983422|Placebo Comparator|Group frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h，with placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
2487909|NCT02982759|Other|Comparison Arm|The comparison group will receive 2 generic newsletters
2487913|NCT02982759|Experimental|Intervention Arm|The intervention arm will receive the multi-level intervention.
3208678|NCT00977145|Experimental|intratumoral IFN-gamma plus MELITAC 12.1,|intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1, an emulsion of a mixture of 12 class I MHC-restricted melanoma-derived peptides (12-MP) and a class II MHC-restricted tetanus toxoid-derived helper peptide (Peptide-tet).
2488041|NCT02982031|Sham Comparator|shamrock|shamrock: both left and right sided scan,both intertransverse and transverse process window
2488048|NCT02982031|Active Comparator|paramedian transverse scan|paramedian transverse scan (PMTS): both left and right, both intertransverse and transverse process window
2488113|NCT02981745|Experimental|CT-1530|
2488153|NCT02981303|Experimental|Melanoma|Imprime PGG + Pembrolizumab
2488155|NCT02981303|Experimental|Triple Negative Breast Cancer|Imprime PGG + Pembrolizumab
2488216|NCT02980900|Placebo Comparator|Placebo supplement|Post exercise placebo supplement Pre bed placebo supplement
2488219|NCT02980900|Active Comparator|Post exercise supplement|Post exercise protein-polyphenol supplement Pre bed placebo supplement
2487086|NCT02988908|Experimental|Drug: Donepezil|"Participants received Donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
2487089|NCT02988908|Placebo Comparator|Placebo (Control)|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
2487121|NCT02988466|Experimental|Arm A: Haplo-HCT <55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients <55 years old with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2
2487122|NCT02988466|Experimental|CLOSED Arm B: Haplo-HCT ≥55 years old|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients ≥55 years old or younger with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
2487123|NCT02988466|Experimental|Arm C: Haplo-HCT HCT-CI ≤2 aged ≥55 and < 65yo|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≤2 aged ≥55 and < 65 years old.
2487124|NCT02988466|Experimental|Arm D: Haplo-HCT aged ≥65 and ≤75yo OR any age HCT-CI ≥3|Reduced-intensity conditioning and transplantation of human leukocyte antigen (HLA) -haploidentical related donor stem cells for patients patients ≥65 and ≤75 years old OR any age group with hematopoietic cell transplantation Comorbidity Index (HCT-CI) ≥3.
2487138|NCT02988037|Experimental|A-DBT-A|Began Adapted Dialectical Behaviour Therapy for Adolescents
2487185|NCT02987946|Active Comparator|Fraxiparine|Intervention: All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice. After randomization the patients in this arm will be subjected to fraxipareine 2850 IE daily. According to current guidelines in the LUMC the Fraxiparine dose is doubled to 5600 IE in patients with a weight above 100 kg.
2487186|NCT02987946|Experimental|IPD|Intervention: IPD Device: After randomization the patients in this arm will be subjected to fraxiparine 2850 IE daily and intermittent pressure devices for at least 48 hours or until mobilization. The intermittent pressure device is a leg pump delivered by Converis(R).
3193963|NCT00823147|Experimental|Pain Catastrophizing Induction Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Catastrophizing group: 10-minute catastrophizing induction. Participants self-rate their level of emotional distress.~Subsequent blood draws occur per protocol time points:~25 minutes following IV placement (BASELINE)~15 minutes post catastrophizing induction (stress experiment)~90 minutes (1.5 hours) post-induction~150 minutes (2.5 hours) post-induction~210 minutes (3.5 hours) post-induction~270 minutes (4.5 hours) post-induction"
3208679|NCT00977158||Throat Swab|Infants who have been diagnosed with cystic fibrosis
2487285|NCT02987166|Experimental|Arm A: HDCRT administered with first dose of pembrolizumab|"Pembrolizumab (200 mg) plus HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) are both administered beginning on day 1.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
2487290|NCT02987166|Experimental|Arm B: HDCRT administered between doses 1& 2 of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 22.~Pembrolizumab (200 mg) will be administered on days 1, 43, 64, 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the 4 doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 22."
2487292|NCT02987166|Experimental|Arm C: HDCRT administered prior to first dose of pembrolizumab|"Pembrolizumab (200 mg) begins on day 1. HDCRT (24 Gy in 3 fractions of 8 Gy each for bone and/or soft tissue lesions; 30 Gy in 5 fractions of 6 Gy each for the prostate gland) begins on day 1.~Pembrolizumab will be administered on days 22, 43, 64, and 85. Subjects who have measurable disease outside of the radiation field and who have derived benefit from the four doses of pembrolizumab may continue to receive pembrolizumab every 3 weeks for up to 2 years.~HDCRT will be administered to the primary tumor and/or sites of metastatic disease (1 or more sites permitted) over a period of 3-5 days. The length of time for administration of the HDCRT will depend on the site of disease that is to be radiated. HDCRT will begin on day 1."
2487343|NCT02986815|Experimental|[11C]Acetate Brain Imaging|[11C]Acetate will be administered The patient will have one intravenous line placed prior to [11C]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which [11C]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
2487396|NCT02986490|Other|patient with antipsychotic/neuroleptic|Blood sample performed on patients requiring the establishment of treatment with antipsychotic / neuroleptic
2487436|NCT02986204|Other|removal of ENG implant group|20 women who have an ENG implant that is difficult to feel on exam and would like to have it removed.
2487441|NCT02986204|Other|continuation of ENG implant|20 women who have are continuing to use their ENG implant.
2487500|NCT02985905|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate,every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
3208680|NCT00977210|Experimental|OXi4503|
3208681|NCT00977223|Experimental|Aprepitant|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
2487097|NCT02988700|Active Comparator|Spinal group|"Intrathecal hyperbaric bupivacaine 0.25mg/kg will be give by lumber puncture that will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.~be given by ."
2487100|NCT02988700|Active Comparator|Caudal group|"caudal plain bupivacaine 2.5mg/kg 0.25% will be given caudally in The sacral hiatus between the sacral conru that will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2-3mm deeper."
2487293|NCT02987179||ESRD Patients|"The following inclusion criteria must be met for each subject.~Age ≥18 years and able to give written informed consent to the study~On chronic hemodialysis for ≥ 90 days at time of enrollment~Ability to read~Consent to have video recording taken during study visit"
3193964|NCT00823147|No Intervention|Control Group|"Collect salivary cortisol kit if subject did not mail from home Full battery of self-report measures given. Pain ratings taken (0-10). Height and weight measured. Heart monitor affixed. Catheter placed; 25 minute rest.~Control group: Persons in this group will rest, complete puzzles, read emotionally-neutral material or watch videos provided to them.~Blood draws and saliva samples gathered per protocol time points:~25 minutes following IV placement (BASELINE- T1)~25 minutes following baseline T2~115 minutes (1 hour 55 min) post baseline T3~175 minutes (2 hours 55 min) post baseline T4~235 minutes (3 hours 55 min) post baseline T5~295 minutes (4 hours 55 min) post baseline T6"
3193965|NCT00823160|Active Comparator|1: Sternotomy|Patients who are randomized to a sternotomy after the finding of blood in the pericardial sac.
2487439|NCT02986269|Experimental|Group SB|"Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is spontaneous breathing(SB) without pressure support ventilation (PSV) under laryngeal mask airway (LMA).~General anesthesia across LMA under SB without PSV"
2487444|NCT02986269|Active Comparator|Group PSV|General anesthesia across LMA under SB with PSV Patient is scheduled for elective conisation or hysteroscopy under general anesthesia. The ventilation mode for this group is SB with PSV under LMA.
3193966|NCT00823160|Active Comparator|2: Subxyphoid window|Patients who receive a subxyphoid window after the finding of blood in the pericardial sac.
3193967|NCT00823173|Experimental|Topical ESBA105|ESBA105 applied as eye drops
3193968|NCT00823186|Experimental|Phyxol,cancer,intra vascular flow|weekly cisplatin plus paclitaxel for 3 cycles as neoadjuvant chemotherapy (NAC) for FIGO IB2 and bulky IIA, squamous cell cervical cancer followed by radical hysterectomy and pelvic lymphedectomy
2487713|NCT02984371|Experimental|Group 1|Coronary artery bypass grafting + epicardial ganglionated plexi ablation
2487714|NCT02984371|Active Comparator|Group 2|Coronary artery bypass grafting
2487766|NCT02984007|Experimental|Motivational Interviewing|Educational session based on the motivational interviewing
2487768|NCT02984007|Other|Information flyer|Information flyer on childhood vaccines
3193969|NCT00823225|Other|A: Standard therapy|
3193970|NCT00823225|Experimental|B: Urokinase|
2487947|NCT02982694|Experimental|Atezolizumab and Bevacizumab|Atezolizumab will be administered intravenously at 1200 mg on Day 1 every 3 weeks. The dose of bevacizumab in this study is 7.5 mg/kg administered by IV infusion every 3 weeks on Day 1 of each 21 days cycle. Atezolizumab will be administered first, followed by Bevacizumab, with a minimum of 5 minutes between dosing. The interval between cycle infusions must not be < 10 days.
2488019|NCT02982356|Other|Fetal Selective Reduction Technology|Potassium chloride fetal heart injection in the dichorial twins with abnormal chromosome and structure
2488023|NCT02982356|No Intervention|control group|normal dichorial twins without any intervention
2488082|NCT02981940|Experimental|Abemaciclib with Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule~Patients who require re-operation will receive a short preoperative course of Abemaciclib~Tissue will be used to investigate the ability of Abemaciclib to pass through the blood brain barrier.~After recovery from surgery, participants will resume Abemaciclib. Each cycle lasts 28 days.~NOTE: enrollment to this arm is complete"
2488088|NCT02981940|Experimental|Abemaciclib without Surgery|"Abemaciclib will be administered on a continuous twice daily dosing schedule. Each Cycle last 28 days.~NOTE: enrollment to this arm is complete"
2488093|NCT02981940|Experimental|Cohort 1 Surgery Arm|Participants who require reoperation will be treated with abemaciclib for 10-14 days prior to surgery. Tissue will be used to further investigate the abilities of Abemaciclib. After surgery participants will come off study and pursue standard of care treatments at their treating physician's discretion.
2488182|NCT02981082|Active Comparator|Dimethyl Fumarate (DMF)|Twice daily oral doses of Dimethyl Fumarate (DMF) 120mg for the first 7 days followed by the maintenance dose of Dimethyl Fumarate (DMF) 240mg twice a day. Subjects will be dosed for 24 weeks
2488183|NCT02981082|Placebo Comparator|Placebo|Twice daily oral doses of placebo for 12 weeks
2488241|NCT02980718|Experimental|intensive olfactory training|90 participants will undergo intensive olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 4 minutes) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
2488244|NCT02980718|Experimental|ordinary olfactory training|90 participants will undergo ordinary olfactory training. They will sniff on four selected odors (10 seconds on each odor bottle in a total of 40 seconds) every morning and evening for 3 months and they will be instructed in the principles of the logbook for olfactory training.
2488245|NCT02980718|No Intervention|controls|20 participants represent a control group with no olfactory training
2488319|NCT02980094|Experimental|Milk Antioxidant group(A)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diet: control (C) +vitamin E+ selenium (A).
2516342|NCT02787733|Placebo Comparator|Placebo|Identical looking placebo
3193971|NCT00823238|Active Comparator|systemic|
3193972|NCT00823238|Active Comparator|inhaled|
3193973|NCT00823251|Experimental|IlluminOss device|IlluminOss bone-pin device
3193974|NCT00823277||1|Overweight and obese Children (BMI SDS > 90th percentile according to Danish BMI sheets) 5-20 Years of age. Recruited from the Paediatric department, University Hospital Holbaek, Region Zealand, Denmark, University of Copenhagen
2487106|NCT02988596|Active Comparator|Enhanced Graded Exertion|At the time of the injury, participants will be given guided activity instructions regarding what activities to consider and how to observe for increases in symptoms. The focus will be on guided activity and not on restriction. Symptoms will be assessed at the end of each day. Once the patient has been asymptomatic for 24 hours or within 85% of their baseline symptom score (BSS) they will begin the enhanced graded exertion progression (Zurich/Berlin protocol). This protocol will follow the Zurich/Berlin guidelines, but will be enhanced to include sports and skill specific activities. Each step will be completed on a separate day. A medical professional will determine the symptom status of the athlete and when the graded exertion will begin.
2487107|NCT02988596|Experimental|Multidimensional Active Rehabilitation|At injury, participants are given instructions regarding guided activities to consider and how to observe for symptom increase. Focus is on guided activity, not restriction. The intervention consists of 5 phases designed to facilitate an active approach to concussion rehabilitation. Phases are symptom stabilization, impairment reduction, activity integration, recovery acceleration, and sport specific application. Participants complete phase specific activities under direction of a clinical professional, and progress upon meeting specific requirements. Participants are required to spend at least 2 days in Phase 1; subsequent phases are completed on separate days. Once asymptomatic for 24 hours or within 85% of their BSS they begin the enhanced graded exertion progression (Zurich/Berlin protocol).
3193975|NCT00823316|Experimental|1|at a dose of 1x1,000,000 hMSC/kg
3193976|NCT00823316|Experimental|2|at a dose of 5x1,000,000 hMSC/kg
2487230|NCT02987725|Active Comparator|Attention Control|Participants will listen to a 30-minute historical story.
2487237|NCT02987725|Experimental|Hypnosis|Participants will receive a 30-minute hypnosis session
2487298|NCT02987322|Experimental|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months for the patients in the honey group.
2487353|NCT02986893|Experimental|Dietary Intervention Arm|Participants will be assigned to follow a specific dietary intervention for 6 months
2487359|NCT02986893|Experimental|Non-dietary Intervention Arm|Participants will continue their usual diet and will be invited to attend monthly meetings at the MS Center for 6 months
2487401|NCT02986412|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
2487473|NCT02986178|Experimental|Polio/Rhinovirus Recombinant (PVSRIPO)|Polio/Rhinovirus Recombinant (PVSRIPO)
3193977|NCT00823342|Placebo Comparator|Group A|CLEVUDINE 30 mg qd + TENOFOVIR Placebo
2487566|NCT02985190|Experimental|Azacitidine 75mg/m²/day|"Azacitidine 75mg/m²/j subcutaneously daily for 7 days every 4 weeks for a minimum of 6 cycles (unless overt disease progression, especially to Acute Myeloid Leukemia (AML) occure before 6 cycles) Azacitidine will be continued after 6 cycles~in patients with hematological response of myelodysplastic syndrome to azacitidine according to IWG2006 criteria by 6 cycles (Complete Response (CR), Partial Response (PR), marrow Complete Response (CRm), stable disease with Hematological Improvment (HI)), for another 6 cycles~in patients with complete or partial response of Systemic Auto-Immune Disorders (SAID) after 6 cycles of Azacitidine, even if Myelodysplastic Syndrome remains only stable per IWG2006 criteria"
2487686|NCT02984631|Other|Preventing pulm HTN during exercise 2nd|Standard of care invasive cardiopulmonary exercise test (CPET) followed by CPET with pre-load control.
2487690|NCT02984631|Other|Preventing pulm HTN during exercise 1st|Pre-load control of invasive cardiopulmonary exercise test (CPET) followed by standard CPET.
2487725|NCT02984254|Experimental|functional patellofemoral neoprene brace|26 Patients will use a a functional patellofemoral neoprene brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
2487728|NCT02984254|Experimental|neoprene sleeve brace.|26 Patients will use a neoprene sleeve brace and answer WOMAC, Lequesne questionnaires, perform Timed-up-and-go (TUG), five-times-sit-to-stand-test (FTSST) and the six-minute walk test.
2487814|NCT02983812||Activity Monitoring - Smartphone|Patients in the activity monitoring - smartphone group will be randomly assigned to track their data using a smartphone app (which collects step counts) for 6 months. There will be no intervention for either group, both are being passively monitored.
2487815|NCT02983812||Activity Monitoring - Wearable|Patients in the activity monitoring - wearable device group will be randomly assigned to track their data using a wearable activity tracker (which collects step counts and sleep patterns/duration). There will be no intervention for either group, both are being passively monitored.
2487883|NCT02983357||Case Series Study|Subjects who received a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of Orthopaedic Surgery at University of Nebraska Medical Center / Nebraska Medicine and are now at least 9 years out from surgery.
2487923|NCT02982811|No Intervention|Control group|Therapy as usual, i.e. occupational therapy, physiotherapy, etc.
2487930|NCT02982811|Experimental|Experimental group|Therapy as usual together with 3x45min training with i-ACT system during 6 weeks.
2487991|NCT02982460|Experimental|Isoinertial + eccentric exercise|The isoinertial training will be based on 4 sets of 8 maximal repetitions using a YoYo-Squat (YoYo Technology AB, Stockholm, Sweden). This exercise device use the inertia of a spinning flywheel (moment inertia = 0.11 kg m-2), offering resistance during coupled concentric and eccentric actions, and allows for high demanding to rotator cuff exercises while offering the possibility to perform with an eccentric overload.Two initial repetitions in any set were aimed at accelerating the flywheel, before executing the subsequent 8 actions at maximal effort. Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder.
2487992|NCT02982460|Active Comparator|Eccentric exercise|Eccentric exercise will based on a set of 4 exercise implicating abduction, lateral rotation, extension and flexion of the shoulder. Participants will attend three appointments per week over three weeks. They will complete three sets of 10 repetitions, with the exercises progressed in difficulty at each appointment.
3193978|NCT00823342|Active Comparator|Group B|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
3193979|NCT00823342|Placebo Comparator|Group C|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
3193980|NCT00823355|Experimental|BCX1777|
3193981|NCT00823368||Arbaclofen followed by Placebo|
3193982|NCT00823368||Placebo followed by Arbaclofen|
3193983|NCT00823381|Experimental|Resveratrol|
3193984|NCT00823381|Placebo Comparator|Placebo|
2487109|NCT02988609|Experimental|Concussion Group|Players with a recent (<72 hours) history of concussion will be assessed 3 times. just after concussion, after disappearance of clinical symptoms and 3 months after the previous visit. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
2487110|NCT02988609|Active Comparator|Control Group|a control group with no history of concussion will be the comparator. Participants will be assessed 3 times. Visits will be the same for the control group and duration between visits in this group will be matched to the concussion group. During each visit, participant will undergo a neurological and a neuropsychological assessment and a structural and resting state fMRI.
2487135|NCT02988271|Experimental|Group I (meditation)|Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
2487136|NCT02988271|Active Comparator|Group II (waitlist control)|Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
2487194|NCT02987907|Experimental|treatment group|use dexamethasone 10mg (2ml) I.A. during TACE
2487196|NCT02987907|Placebo Comparator|control group|use normal saline 2ml I.A. during TACE
2487228|NCT02987595|Experimental|Whole-grain rye then wheat|Whole-grain rye, high lignan Whole-grain rye products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain wheat products for 8 weeks
2487232|NCT02987595|Experimental|Whole-grain wheat then rye|Whole-grain wheat, low lignan Whole-grain wheat products for 8 weeks, then a wash-out period of 8 weeks, and then whole-grain rye products for 8 weeks
2487279|NCT02987270|Experimental|Mass screening and treatment|Each member (approximately 30,000 individuals) residing within the mass screening and treatment arm were visited three times a year and tested for malaria by rapid diagnostic test; those testing positive were treated with an appropriate antimalarial- dihydroartemisinin-piperaquine was the first-line therapy. Long-lasting insecticidal net (LLIN) coverage was topped up prior to the intervention to universal coverage (one bednet for every two household participants).
2487287|NCT02987270|No Intervention|Control arm|Members of the control arm received standard of care, which includes universal (LLIN) coverage and standard malaria case management (laboratory confirmation prior to antimalarial treatment) at the study health facilities.
2487383|NCT02986633||Patients with heart failure and CRT|Heart failure with left ventricular ejection fraction less than 35 % treated with CRT
2487433|NCT02986334|No Intervention|No Treatment Intervention|Observational Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
2487440|NCT02986334|Active Comparator|Active Treatment Intervention|Naproxen & Omeprazole Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
2487446|NCT02986334|Placebo Comparator|Placebo Treatment Intervention|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment)
2487498|NCT02985723|Experimental|939MP|AT LISA tri toric 939MP intraocular lens
2487536|NCT02985567||Intraocular pressure evaluation|Intraocular pressure evaluation using Icare tonometer 25 minutes after sedation, and then every 10 minutes until sedation is complete
2487537|NCT02985567||Safety of sedation|"Documentation of:~The need for repeat dosing of chloral hydrate.~The level of alertness of the patient at the end of sedation and the total time between induction and readiness for discharge~Interventions required for the patient including administration of oxygen, and need for intubation."
2487556|NCT02985333|Experimental|Intervention|paclitaxel 175 mg/m(2) IV over 3 h d1,cyclophosphamide 200 mg/m(2) IV d1,3,5 and dexamethasone 20mg IV d1-4 in patients with relapsed or refractory MM.
2487628|NCT02985073|Experimental|Veritas® mesh|Use of Veritas mesh in conjunction with immediate breast reconstruction on one side
2487629|NCT02985073|Experimental|TIGR® mesh|Use of TIGR® mesh in conjunction with immediate breast reconstruction on one side
3193985|NCT00823381|Active Comparator|Calorie Restriction|
3193986|NCT00823394||Windsor Village United Methodist Church|Questionnaire + Body Measurements + Self-help Materials
2487855|NCT02983279|Experimental|Dietary counseling, caloric restriction diet|Patients then undergo 25% caloric intake for 3-12 weeks prior to definitive cancer surgery.
2487940|NCT02982889|Experimental|LIQ865A bupivacaine formulation|Liquidia's PRINT bupivacaine free base/PLGA (poly D,L-lactic-co-glycolic acid) suspension for subcutaneous injection at doses ranging from 150mg to 600mg
2487946|NCT02982889|Experimental|LIQ865B bupivacaine formulation|Liquidia's PRINT bupivacaine free base suspension for subcutaneous injection at doses ranging from 150mg to 600mg
2487950|NCT02982889|Placebo Comparator|Diluent for LIQ865|Negative control for subcutaneous injection. Each subject will act as his own control, receiving a LIQ865 formulation subcutaneous injection in one calf, and a diluent subcutaneous injection in his other calf
2487952|NCT02982889|Active Comparator|0.5% bupivacaine hydrochoride|Positive control arm to be used with one of the LIQ865 cohorts, with each subject acting as his own positive control (i.e., one leg will receive subcutaneous injection of LIQ865A or LIQ865B, and the other leg will receive subcutaneous injection of 0.5% bupivacaine hydrochloride).
3193987|NCT00823407|Other|MDA|
3193988|NCT00823420|Experimental|in-vitro maturation of oocytes|
3193989|NCT00823433|Experimental|Oral Penicillin|2 grams of oral penicillin V given within 4 hours of delivery
2487169|NCT02988154||Arm B: ''See one, do one'' cohort|Recruits to Arm B will witness an EVD placement as performed by an experienced surgeon, after which they will attempt to perform an EVD procedure on their own, using the aforementioned 3D-printed skull model. This mimics the ''see one, do one'' paradigm prevalent in surgical training.
2487221|NCT02987738|Experimental|dapagliflozin|two administrations of 10 mg dapagliflozin as tablet
2487223|NCT02987738|Placebo Comparator|Placebo Oral Tablets|two administrations identical to the experimental drug
2487267|NCT02987335||Lean Diabetes Subjects|N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.
2487268|NCT02987335||Type 2 Diabetes Mellitus Subjects|N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp
2487270|NCT02987335||Type 1 Diabetes Mellitus Subjects|N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp
2487271|NCT02987335||Nondiabetic Subjects|N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp
2487317|NCT02987062||Acenocoumarol|Patients with AF treated with acenocoumarol.
2487319|NCT02987062||Warfarin|Patients with AF treated with warfarin.
2487320|NCT02987062||Apixaban|Patients with AF treated with apixaban.
2487321|NCT02987062||Dabigatran|Patients with AF treated with dabigatran.
2487323|NCT02987062||Rivaroxaban|Patients with AF treated with rivaroxaban.
2487332|NCT02986685|Experimental|trimebutine maleate + rabeprazole|trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily
2487336|NCT02986685|Other|rabeprazole|rabeprazole 20mg once daily
3160707|NCT00430079|Experimental|Diagnostic (etanidazole)|Patients receive etanidazole derivative EF5 IV over 1-2½ hours once within 1-2 days before surgical resection or biopsy. Tumor tissue, normal tissue, and/or tumor-infiltrated lymph node samples are collected during surgery and stained for biological markers. Fluorescent immunohistochemistry techniques are used to determine the presence, distribution, and levels of EF5 binding.
2487490|NCT02985697|Experimental|IN DEX|Group IN DEX will receive a placebo dose of flavored water followed by 3 mcg/kg intranasal dexmedetomidine in conjunction with 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or placebo will not be given.
2487503|NCT02985697|Experimental|MIDDEX|Group MIDDEX will receive 3 mcg/kg intranasal dexmedetomidine and 0.5 mg/kg oral midazolam and 100% oxygen at a calculated flow rate (oxygen administration to function as placebo for nitrous oxide). If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2487510|NCT02985697|Experimental|NOMIDDEX|Group NOMIDDEX will receive 3 mcg/kg intranasal dexmedetomidine, 0.5 mg/kg oral midazolam, and 50/50 nitrous oxide/oxygen at a calculated flow rate. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2487515|NCT02985697|Active Comparator|CTRL|The control group, Group CTRL, will receive a placebo dose of normal saline and 0.5 mg/kg oral midazolam and 50/50 nitrous oxide/oxygen at a calculated flow rate. Midazolam was chosen as the control due to its well documented history of use in pediatric procedural sedations. If adequate sedation is not obtained within 60 minutes of drug administration, the sedation will be considered a failure and the procedure will be terminated and rescheduled for completion of care using deep sedation or general anesthesia, in keeping with normal office policy. Second doses of intranasal dexmedetomidine or oral midazolam will not be given.
2487576|NCT02985320|Experimental|Phase I Adult Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
2487578|NCT02985320|Experimental|Phase I Adult Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
2487580|NCT02985320|Experimental|Phase I Child Group - High dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of high dosage investigational sIPV"
2487586|NCT02985320|Experimental|Phase I Child Group - Medium dosage|"Single intramuscular injection of the investigational vaccine(0.5 ml) on Day 0;~Intervention: Single-dose regimen of medium dosage investigational sIPV"
2487589|NCT02985320|Experimental|Phase I Infant Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
2487591|NCT02985320|Experimental|Phase I Infant Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
2487593|NCT02985320|Experimental|Phase I Infant Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
2487594|NCT02985320|Experimental|PhaseⅡExperimental Group - High dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of high dosage investigational sIPV"
2487595|NCT02985320|Experimental|PhaseⅡExperimental Group - Medium dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of medium dosage investigational sIPV"
2487597|NCT02985320|Experimental|PhaseⅡExperimental Group - Low dosage|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of low dosage investigational sIPV"
2487242|NCT02987504|Experimental|Samalizumab 10, 15, 20 milligrams (mg)/kilogram (kg) Dose|"Participants received escalating doses of 10, 15, and 20 mg/kg of samalizumab IV every 21 days. Enrollment at each dose level and safety assessments were completed prior to enrolling at the next dose level; intra-participant dose escalation was not allowed.~3 participants were enrolled into a dose cohort: If 0/3 participants developed dose limiting toxicities (DLT) within Cycle 1, enrollment began at the next higher dose to a maximum of 20 mg/kg. If 1/3 participants developed a DLT, the dose cohort was expanded to include 3 new participants. If 0/3 new participants developed a DLT within Cycle 1, enrolment began at the next higher dose level. If ≥1 of 3 new participants developed a DLT within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD. If ≥2 of 3 participants developed DLTs within Cycle 1, dose-escalation was terminated, and the dose level 5 mg/kg below the current dose was considered the MTD."
2487340|NCT02986984||Confirmed Diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who satisfy pre-specified criteria for diabetic nephropathy.
2487342|NCT02986984||Confirmed Non-diabetic Nephropathy|Patients undergoing a clinically indicated kidney biopsy with a history of diabetes who fail pre-specified criteria for diabetic nephropathy.
2487463|NCT02986243|Experimental|Treatment|Subjects receive a diet plan and exercise regimen.
3193990|NCT00823446|Experimental|Revera Wound Care|
3193991|NCT00823446|Placebo Comparator|Normal Saline|
2487564|NCT02985437|Experimental|Surfactant|Alveofact® (Bovine Lung Surfactant), 0.5 mg/ml per day (solution) all two days maximal eight times
2487565|NCT02985437|Active Comparator|Saline|0.9% Sodium chloride solution (NaCl solution), 2 ml per day (solution) all two days maximal eight times
2487620|NCT02985047|Experimental|Brief Admission|Participants randomised to Brief admission (BA) will have the possibility of admitting themselves to hospital for a maximum duration of three consecutive days at a maximum frequency of three times per month. Apart from BA they have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
2487622|NCT02985047|No Intervention|Control|Participants randomized to Treatment as Usual will receive no intervention from the study protocol, except the baseline assessments and repeated assessments administered on the same schedule as described above for the treatment group. They will not be given the evaluation measures that are specific to the intervention. Participants have access to all psychiatric care that they would have if they had not participated in the study (including general admission to hospital).
2487667|NCT02984722|Experimental|1|PCOS women treated with 1500 mg/die of extended-release metformin
2487670|NCT02984722|Experimental|2|PCOS women treated with 1500 mg/die of immediate-release metformin
2487702|NCT02984462|Experimental|screw fixation|Surgical Percutaneous Akin osteotomy with fixation by a percutaneous cannulated screw and forefoot surgery dressing.
2487703|NCT02984462|No Intervention|No fixation|Surgical Percutaneous Akin osteotomy non-fixed, hold by forefoot surgery dressing.
2487758|NCT02984137|Experimental|idiopathic RBD group|A group of patients diagnosed as idiopathic RBD that is confirmed by polysomnography. Interventions as testing, evaluation, samplings at baseline, then repeat at 2 years and 4 years of prospective follow-up. thereafter only clinical observations until Lewy body disease is diagnosed.
2487759|NCT02984137|Active Comparator|incident PD group|A group of patients who are newly diagnosed as Parkinson's disease, and never been treated with prolonged history of probable RBD. Interventions as testing, evaluation, sampling at baseline and then evaluations only at 3 year follow-up after anti-parkinsonian treatment.
2487760|NCT02984137|Placebo Comparator|Control|Control group includes elderly controls without neurodegerative diseases examined by neurologists. Interventions as testing, evaluation, sampling at baseline only.
2487805|NCT02983760|Active Comparator|Planar V/Q-based strategy|Control arm
2487809|NCT02983760|Active Comparator|CTPA-based strategy|Control arm
2487811|NCT02983760|Experimental|V/Q SPECT-based strategy|Experimental arm
2487902|NCT02983175|Experimental|ultrasound assessment of gastric content|
2487933|NCT02982655|Experimental|Individualized BP lowering|Management policy is to lower the systolic or diastolic BP by 10-15% within 2 hours of randomization and sustained for 7 days. Sites were provided with protocols for different intravenous agents and used whichever routinely available drugs were in their hospital.
2487941|NCT02982655|Active Comparator|Guideline recommended BP lowering|Patients received management of BP based on the standard guidelines at the time, as published by the Chinese Society of Neurology (CSN) in 2014. The attending clinician may consider commencing BP treatment and sustained for 7 days if the systolic BP > 200 mmHg or diastolic BP >110 mmHg in patients with ischemic stroke, and systolic BP > 180 mmHg or diastolic BP > 110 mmHg in patients with cerebral hemorrhage.
2488085|NCT02981771|Experimental|experiment|A physical activity program that is based on balance and coordination exercises
2488089|NCT02981771|Placebo Comparator|control|A physical activity program that is based on strength exercises
2488122|NCT02981446|Experimental|DE-117 ophthalmic solution|
2488124|NCT02981446|Active Comparator|Latanoprost ophthalmic solution 0.005%|
2488168|NCT02981121|No Intervention|Conventional Management|A patient will receive 30 minutes of individual education from the investigator, based on the standard guidelines of the Korean Diabetes Association. And will be followed up every 6 months for 36 months.
2488171|NCT02981121|Experimental|Life style modification|"Proceed according to the Intervention Protocol developed by the Nutrition Committee of the Korean Diabetes Association. Aim to lose more than 5% of weight within 6 months, and then aim to keep weight loss constantly. After randomization, the diabetes educator team (physician / nurse / dietician) applies the intervention program for exercise therapy and diet therapy, and manages it through online education (telephone visit) and offline education (institution visit).~Exercise: Moderate or abnormal exercise for more than 150 minutes per week (moderate or abnormal exercise for 30 minutes or more per day)~Diet remedies: Train Calorie intake, nutrient intake and Monitoring."
2488172|NCT02981121|Active Comparator|Metformin|After randomization, take 250 mg once a day for 2 weeks. If there is no side effect, take 500 mg once a day for 2 weeks. If there are no side effects, the maximum dose can be increased to 1000mg.
2488226|NCT02980900|Active Comparator|Pre bed supplement|Post exercise placebo supplement Pre bed protein-polyphenol supplement
3193992|NCT00823485|Active Comparator|2|drainage of hemorraghia
2487300|NCT02987348||exenatide once weekly|type 2 diabetes patients who were first prescribed with exenatide once weekly in the index period identified from CPRD database of UK primary care
2487301|NCT02987348||basal insulin_1|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide once weekly group identified from CPRD database of UK primary care
2487302|NCT02987348||exenatide twice daily|type 2 diabetes patients who were first prescribed with exenatide twice daily in the index period identified from CPRD database of UK primary care
2487305|NCT02987348||basal insulin_2|type 2 diabetes patients who were first prescribed with basal insulin in the index period and matched with exenatide twice daily group identified from CPRD database of UK primary care
3193993|NCT00823485|Experimental|1|Actylise
3193994|NCT00823498||African American Parents|
2487431|NCT02986308||Intestinal Polyps|The patients who were diagnosed with Intestinal Polyps.
2487438|NCT02986308||Normal colonoscopy|People who were diagnosed by colonoscopy without intestinal polyps.
2487484|NCT02985944||Standard scope-short time|Standard colonoscopy with unmonitored withdrawal time
2487495|NCT02985944||FUSE scope-short time|Wide-angle colonoscopy with unmonitored withdrawal time
2487502|NCT02985944||Standard scope-long time|Standard colonoscopy with monitored withdrawal time
2487509|NCT02985944||FUSE scope-long time|Wide-angle colonoscopy with monitored withdrawal time
3193995|NCT00823498||African American Youth|African American Youth between ages of 12-15 Years Old
2487772|NCT02983994||Patients with asthma with an inhaled steroid|Patients with a diagnosis of asthma with indication of Treatment with an inhaled steroid (CI)
2487773|NCT02983994||Patients with asthma with an inhaled Beta agonist|Patients with a diagnosis of asthma with indication of Treatment with an inhaled Beta agonist (LABA)
3160708|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot III|
2487997|NCT02982447|Active Comparator|Blue Laser Imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
2487998|NCT02982447|Experimental|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
2488040|NCT02982044|Experimental|Experimental-Control|"Participants will undergo all interventions, while simultaneously serving as their own within-subject control. The left side of the body will be designated experimental, and all interventions will be applied to the left arm. The right side of the body will be designated as control, and will not receive any interventions."
2488108|NCT02981654|Experimental|Femilift treatment|"The Alma Lasers Pixel carbon dioxide laser system delivers fractionated laser energy through a special lens that divides the energy into a 9 x 9 (81) matrix of 1 cm square area. The fractional laser rays cause thermal damage that reaches the vaginal sub - epithelium to stimulate the growth of new collagen.~Intervention: FemiLift vaginal handpiece is inserted into the vagina, to deliver CO2 laser energy. The vaginal epithelium is covered by rotation of vaginal handpiece in 360 degrees, releasing laser energy at 6-8 points, and than withdrawn 1 cm each time to perform the same process, to cover the the total vaginal length."
2488131|NCT02981329|Experimental|Group A: Hydroxyurea + Metformin|Subjects who are currently taking Hydroxyurea as part of standard of care and have sickle cell anemia.
2488133|NCT02981329|Experimental|Group B: Metformin (Group B has closed to enrollment)|Subjects who are not taking Hydroxyurea as part of standard of care and have sickle cell anemia.
2488217|NCT02980835|Experimental|Intervention|Patients who receive injections of A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) at the beginning of surgery and second set of injections containing a mixture of B (contains 10 mL of 0.9% normal saline) and C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) prior to the closure
2488221|NCT02980835|Active Comparator|Control|Participants who receive injection of B (contains 10 mL of 0.9% normal saline) at the beginning of surgery and injectate A (a total of a 10 mL-solution that consists of 9 mL of ropivacaine HCl 0.5% and 1 mL of dexamethasone 4mg/mL preparation) and injectate C (a total 25 mL solution that consists of 24 mL of ropivacaine HCl 0.5%, 1 mL of dexamethasone-4mg/mL preparation, and 0.125 mL of epinephrine-1:1000 preparation) at the end of procedure prior to the closure (which mimics standard care) is the control group
2488281|NCT02980315|Experimental|CAR-T cells|the group treat with CAR-T cells
2488287|NCT02980315|No Intervention|placebo|the group treat with CAR-T cells
2488330|NCT02980120||Anorexia Nervosa Group|n=50 female patients with Anorexia Nervosa (AN) who fulfill the criteria for DSM-IV, BMI z-scores will be used for age and sex specific cut-off points that are extrapolated from the adult BMI cut-off <17.5 Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2488333|NCT02980120||Bulimia Nervosa Group|n=30 female patients with Bulimia Nervosa (BN) who have BMI z-scores from the adult range <17.5-25.0 (this reflects the lower prevalence rates of BN compared to AN) Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2488334|NCT02980120||Healthy Control Group|n=30 healthy females who have BMI z-scores from the adult range from 19.0-25.0 and who do not fulfill diagnostic criteria for any psychiatric disorder.Interventions:EDI-2, EAT, SCID-I, SCID-II, LoPF, HAWIK-IV, fMRI
2488407|NCT02979691|Active Comparator|SIB-IMRT|SIB-IMRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday).
2488665|NCT02977416|Experimental|patients without TNF blockade|22 patients without TNF blockade
3160709|NCT00430118|Experimental|Induction Prot I/Pred - reinduction Prot III|
3160710|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction Prot II|
3160711|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction Prot II|
3160712|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 2x Prot III|
3160713|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 2x Prot III|
3160714|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 3 HR courses + 3x Prot III|
2487313|NCT02987296|Placebo Comparator|Immunonutrition without arginine|This group of patients will also receive a nutritional drink but containing no arginine for 5 days before surgery and for 5 days after surgery.
2487348|NCT02986763||Professional pesticides|A specific questionnaire with professional information about pesticide uses is added for this arm Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
2487352|NCT02986763||Volunteers|Questionnaire to collect domestic pesticide use, diet, household characteristics Dust sampling Blood sampling Urine sampling Hair sampling
2487421|NCT02986464|Active Comparator|Standard pharmacological treatment|
2487427|NCT02986464|Experimental|Virtual Reality distraction|
2487467|NCT02986022|Experimental|Resilience|Participants will receive four sessions covering Resilience intervention content
2487468|NCT02986022|Active Comparator|Resilience+Information|Participants will receive four sessions covering Resilience intervention and Information intervention contents.
2487479|NCT02985762|Other|EXPAREL 266 mg/20 mL|Eligible subjects, whose surgical incision must be at least 8 cm in length, will receive a single dose of EXPAREL (266 mg/20 mL) expanded in volume with 20-60 mL normal saline, depending on the size of the incision
2487545|NCT02985593|Experimental|KHK4083|IV/SC administration
2487546|NCT02985593|Placebo Comparator|Placebo|IV/SC administration
2487584|NCT02985268|Active Comparator|MitraClip/Optimal Medical Therapy (OMT) and CRT ON|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to ON
2487588|NCT02985268|Active Comparator|MitraClip/OMT and CRT OFF|Patient to be implanted with both MitraClip and CRT-D. Will also receive optimal medical therapy. CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON
2487590|NCT02985268|Active Comparator|OMT and CRT ON|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to ON"
2487592|NCT02985268|Active Comparator|OMT and CRT OFF|"Patient to be implanted with only the CRT-D and will receive optimal medical therapy.~CRT-D will be programmed to OFF until the 6-month follow-up visit in which the CRT will be turned ON"
2487656|NCT02984839||Intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
2487659|NCT02984839||Non-intra-abdominal surgery group|"The study population will include patients presenting for elective or non-elective non intra-abdominal surgery requiring general anesthesia with neuromuscular blockade at OhioHealth Doctors Hospital.~Quantitative TOF will be recorded by Stimpod NMS450 in PACU."
2487709|NCT02984501|Experimental|Single Arm|Patients treated with induction chemotherapy with gemcitabine and oxaliplatin; for patients without disease progression as detected through restaging exams, chemotherapy was followed by radiochemotherapy which consisted of conformal radiation therapy and concurrent gemcitabine at the dose of 600 mg/mq weekly.
2487763|NCT02984059||IBD w/abdominal pain|"Patients with IBD with abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for both genomic DNA and calprotectin, and stool analyzed for microbiome. If no blood is drawn then a buccal swab done for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
2487765|NCT02984059||IBD w/out abdominal pain|"Patients with IBD and no abdominal pain. Colonoscopy done for standard of care, extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.~Pain questionnaires:~Pain Frequency-Severity-Duration Scale Pain Catastrophizing Scale-Child Version Pain Burden Interview Pediatric Quality of Life Inventory Adolescent Pediatric Pain Tool Anxiety/Depression Questionnaires Revised Children's Anxiety and Depression Scale Children's Somatization Inventory Adult Responses to Children's Symptoms"
2487767|NCT02984059||Colonoscopy other reasons no abd pain|Patients who have a colonoscopy for other reasons, rectal bleeding or polyp surveillance, no abdominal pain. Extra colonic biopsies for RNA analysis. If blood and stool samples are collected for standard of care:blood analyzed for genomic DNA and calprotectin and stool analyzed for microbiome. If no blood is drawn then a buccal swab for the genomic DNA analysis and stool analyzed for calprotectin.
3193996|NCT00823511||Female Partners|Female partners of HIM Study participants
3193997|NCT00823524|Experimental|donor NK cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
3193998|NCT00823550|Experimental|A|entecavir 0.5 mg QD
3193999|NCT00823550|Active Comparator|B|lamivudine 100 mg QD
2487885|NCT02983032|Experimental|Brief behavioural treatment for insomnia (BBTI)|A behavioural therapy for improving symptoms of insomnia in older adults focussing on sleep-related behaviour such as napping and when a person gets up and goes to bed.
2487935|NCT02982837|Experimental|PEG-IFN & NUCLEOTIDE ANALOGUES|Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.
2487938|NCT02982837|Active Comparator|NUCLEOTIDE ANALOGUES|Nucleoside same dose as they started the study.
2487982|NCT02982343|Experimental|Falls management plus exercise training|Falls management and education session. Home proximal lower limb strength training and multi-sensory balance training.
2487984|NCT02982343|Active Comparator|Falls management only|Falls management and education session only.
3194000|NCT00823576|Active Comparator|1|"Group witness: one receiving a single bolus of analgesic~Seepage simple person the end of intervention of 200mg of ropivacaïne 0,5 % at the level of zones it"
3194001|NCT00823576|Active Comparator|2|Group catheter: receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
3194002|NCT00823589|Experimental|pathological group|pathological group
3194003|NCT00823589|Experimental|healthy aged|healthy aged
3194004|NCT00823602|Experimental|1|"GnRH antagonist ganirelix 0.25 mg fromm 6th ovarian stimulation"
2487331|NCT02986932|Experimental|BBB opening|ExAblate focused ultrasound under MRI-guidance delivered through the intact human skull in conjunction with timed intravenous ultrasound contrast agents (Definity®) to temporarily and focally open the BBB.
2487451|NCT02986594|Experimental|aspirin group|low dose aspirin, 75-100mg, bid, after pregnancy
2487453|NCT02986594|Experimental|low molecular weight heparin group|low molecular weight heparin, 4100u, qd, after pregnancy
2487456|NCT02986594|Experimental|combination group|low molecular weight heparin, 4100u, once a day and low dose aspirin, 75-100mg, bid. After pregnancy
2487493|NCT02985866|Experimental|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump, study continuous glucose monitor (CGM), and a study glucometer. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
2487504|NCT02985866|Active Comparator|Sensor Augmented Therapy|Subjects will continue to use their personal insulin pump with a study continuous glucose monitor (CGM) and study glucometer.
2487570|NCT02985411|Active Comparator|Immediate Gardening Intervention|Wait-listed, will receive the gardening intervention after a 1-year period
2487571|NCT02985411|Active Comparator|Delayed Gardening Intervention|Individuals in this group will serve as their own control
2487736|NCT02984150|Experimental|fatty acid|the nutrient that can be widely found in daily food.
2487737|NCT02984150|Sham Comparator|saline|saline
2487820|NCT02983916||Group 1: adhesiolysis|Group 1 (the operative group) consisted of all patients who underwent laparoscopy and/or laparotomy. Typically patients had positive cine-MRI. A few patients with inconclusive cine-MRI who underwent diagnostic laparoscopy are also included in this group. Patients with no adhesions found during operation remain in group 1, because analysis is performed on intention-to-treat basis.
2487823|NCT02983916||Group 2: Adhesions, conservative|Patients with evidence of adhesions based on cine-MRI who did not undergo laparoscopy or laparotomy.
2487827|NCT02983916||Group 3: No adhesions|Patients in whom no evidence of adhesions was found on cine-MRI, and who did not undergo laparoscopy or laparotomy .
2487844|NCT02983214|Active Comparator|Clopidogrel|Clopidogrel 75 mg/day
2487845|NCT02983214|Active Comparator|Clopidogrel plus cilostazol|Clopidogrel 75 mg/day plus cilostazol 100 mg twice/day
2487893|NCT02983019||Therapy with interferons' inducers|Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis
2487894|NCT02983019||Therapy without interferons' inducers|Therapy according to routine practice Groups will be splitted during the final data analysis
2488007|NCT02982304|Active Comparator|Pallidal (GPi) Deep Brain Stimulation|GPi is the standard target for treating most dystonia. This setting will be the active comparator
2488010|NCT02982304|Experimental|Thalamic (Vim) Deep Brain Stimulation|Vim is the standard target to treat cerebellar dysfunction in movement disorders. It is not routinely used in secondary dystonia
2488015|NCT02982304|Experimental|GPi + Vim (Multi-Target) Deep Brain Stimulation|Combined stimulation of GPi and Vim stimulation (both electrodes ON)
2488080|NCT02981901||Patient with ovarian epithelial cancer|Ovarian epithelial cancer diagnosed in 2012
2488123|NCT02981485|Experimental|Experimental|Treatment of breast cancer related lymphedema by fat grafting
2488164|NCT02981147|Experimental|Intervention|Phytus (Cisti, thyme and Ivy leaves) given to patients on day 1 and day 4. On 4th day, night and day cough score along with adverse event will be assessed. Sponsor will bear the treatment cost during the study time period.
2488194|NCT02980861|Experimental|Laparoscopic total gastrectomy|Participants including in the laparoscopic total gastrectomy (LTG) group will undergo LTG with spleen-preserving splenic hilum lymph nodes dissection.
2488195|NCT02980861|Active Comparator|Open total gastrectomy|Participants who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
2488247|NCT02980679|Experimental|CTC and G-PERT Imaging|One experimental (CTC) and one standard (G-PERT) scan, at least 48 hours apart, before thyroid surgery. The order of the scans will be randomized.
2488292|NCT02980393|Experimental|Lifestyle intervention|Participants are guided by a fitness specialist who will help the participants to incorporate physical activity into their daily life. Based on the cardiologist assessment, an individual home-based exercise program will be developed. Participants are also guided and advised on nutrition with emphasis on low fat content and increased fiber. The nutrition counseling will focus on sustainable changes and will help participants to make healthy food choices.
3160715|NCT00430118|Experimental|Induction Prot I/Pred - reinduction 3 HR courses + 3x Prot III|
3160716|NCT00430118|Experimental|Induction Prot I/Dexa - reinduction 6 HR courses + Prot II|
3160717|NCT00430118|Active Comparator|Induction Prot I/Pred - reinduction 6 HR courses + Prot II|
3160718|NCT00430144|Experimental|CKD-602|
2488518|NCT02978807||Pregnant women between 24 to 32 weeks|"Pregnant women with a singleton pregnancy who presented to care between 24 -32 weeks of their pregnancy were included in this study.~All patients enrolled in the study will receive a random point of care blood sugar, point of care and venous fasting blood sugar, point of care and venous 1 hr/2hr glucose tolerance test, and point of care and venous HbA1c."
2488668|NCT02977416|Experimental|healthy subjects|22 matched healthy subjects by pubertal stage and sex
2488847|NCT02976168|Experimental|-12° head down tilt|Subjects will be in 12° head down supine Position for 21 hours
3160719|NCT00430170|Active Comparator|1|dipyridamol during 7 days and before ischemic exercise caffeine 4mg/kg
3160720|NCT00430170|Placebo Comparator|2|dipyridamol during 7 days and before ischemic exercise placebo
3160721|NCT00430287||1: Primary open angle glaucoma|Patients with a form of primary open angle glaucoma
3160722|NCT00430287||2: No known eye disease (controls)|Patients with no known eye disease (controls)
3160723|NCT00430313|Experimental|Electro-Stimulation (Active Site)|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
3160724|NCT00430313|Experimental|Electro-Stimulation (Inactive Site)|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
3160725|NCT00430365|Placebo Comparator|placebo group|Administration of oral placebo
3160726|NCT00430365|Experimental|lenalidomide group|Administration of lenalidomide
2487339|NCT02987010|Experimental|Cohort A|Neoadjuvant administration of IDH305 at 550 mg BID for 6 weeks followed by surgical resection at 6 weeks. If there is no evidence of progressive disease at 6 weeks (clinical, radiographic or histopathologic exam), the patient will continue on IDH305 at 550 mg BID post-operatively for a maximum of 11 additional 28 day cycles. Subsequent assessment of disease will occur every 2 months starting in Cycle 2.
2487341|NCT02987010|Experimental|Cohort B|Patients who have inoperable tumors but measurable 2HG pre-treatment will be treated with IDH305 at 550 mg BID x 6 weeks. If there is adequate sustained knockdown of 2HG on MRS and disease is stable or improved, then the patient will continue on treatment for a maximum of 11 additional 28 day cycles.
2487400|NCT02986529|Active Comparator|GV-971 150mg/capsule|900mg, oral
2487403|NCT02986529|Experimental|GV-971 300mg/capsule|900mg, oral
2487404|NCT02986529|Experimental|GV-971 450mg/capsule|900mg, oral
2487405|NCT02986529|Placebo Comparator|Placebo|Oral
2487420|NCT02986165|Placebo Comparator|Placebo control|100 g of flavoured water
2487425|NCT02986165|Experimental|Low dose pomace extract|1 g pomace extract powder
2487426|NCT02986165|Experimental|High dose pomace extract|2.5 g pomace extract powder
2487494|NCT02985983|Experimental|KHK4827|KHK4827 administered SC
2487501|NCT02985983|Placebo Comparator|Placebo|Placebo administered SC
2487603|NCT02985242|Experimental|Empagliflozin/glimepiride placebo|"Empagliflozin 25 mg film-coated tablet p.o. daily and glimepiride matching placebo p.o. daily~Duration of treatment: 12 months"
2487608|NCT02985242|Active Comparator|Glimepiride/empagliflozin placebo|"Glimepiride 2 mg tablet p.o. daily and empagliflozin matching placebo p.o. daily~Duration of treatment: 12 months"
2487633|NCT02984800|Experimental|Group I|Patients will receive one PVB injection at L1-L2 .
2487634|NCT02984800|Experimental|Group III|Patients will receive three PVB injections at T12-L1, L1-L2 and L2-L3.
2487685|NCT02984605|Experimental|Interventional group|"Arm：Hypoglycemic agents + Nutrition meal replacement & exercise prescription~Hypoglycemic agents in combined with 1 times a day with bags of nutritional meal replacement and exercise"
2487688|NCT02984605|No Intervention|Control group|"Arm：Hypoglycemic agents~without take nutrition meal replacement & exercise prescription"
2487729|NCT02984293|Active Comparator|Atorvastatin|The participants will receive atorvastatin (80 mg) orally once daily for 28 days.
2487730|NCT02984293|Placebo Comparator|Placebo|The participants will receive matched placebo orally once daily for 28 days.
2487774|NCT02983942|Experimental|ketogenic diet group|Ketogenic diet is given in combination to standard HD-MTX chemotherapy to primary central nervous system lymphoma patients. Blood ketone is kept no less than 2mmol/L during the initial 4 cycles of chemotherapy. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
2487775|NCT02983942|Active Comparator|routine diet group|Standard HD-MTX chemotherapy is given with routine diet.Blood ketone is measured and recorded. The adverse events is monitored and recorded. Tumor response is evaluated and recorded.
2487793|NCT02983591|Experimental|Misoprostol|Rectal misoprostol
2487797|NCT02983591|Experimental|Oxytocin|intravenous oxytocin
2487882|NCT02983383|Active Comparator|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
2487886|NCT02983383|Active Comparator|Group without TAP (Group P)|Patients in Group P will have adjuvant added to spinal anesthesia.
2487968|NCT02982538|Other|Standard PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE.
2487970|NCT02982538|Other|Extended PE Training Condition|Providers in this condition will complete a 4-day training workshop in PE and will receive expert PE case consultation on two PE training cases via weekly phone consultation.
2488002|NCT02982252|Experimental|CoPILOT (6 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
2488003|NCT02982252|No Intervention|Standard of Care (6 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 6 hours total training time (1 hour training sessions, 3 days per week for 2 weeks).
2488005|NCT02982252|Experimental|CoPILOT (12 weeks)|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
2488009|NCT02982252|No Intervention|Standard of Care (12 weeks)|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair consisting of 12 hours total training time (1 hour training sessions, 4 days per week for 3 weeks).
3194005|NCT00823602|Active Comparator|2|GnRH agonist, suprefact, stimulation with a standard long protocol
2488243|NCT02980744|Experimental|STUFFS|Participants will undergo a sedentary behaviour intervention which includes breaking up prolonged sitting by standing and walking around for 5 minutes every half-hour, standing and walking during television commercial breaks, doing 2 sets of 10 sit-to-stand transitions three times per day, and going to the kitchen to grab some drink every hour. A wrist-worn Misfit activity monitor - a motivational tool that will track adherence to the intervention will be used throughout the intervention period (i.e. 8 weeks). This device which is commercially available provides activity feedback for the user in real time.
2488284|NCT02980445|No Intervention|Control|
2488291|NCT02980445|Experimental|Outdoor Activity 1|40min outdoor time in total.
2488293|NCT02980445|Experimental|Outdoor Activity 2|80min outdoor time in total
3194006|NCT00823628|Active Comparator|iopromide|
3194007|NCT00823628|Experimental|iodixanol|
2487363|NCT02986906|Active Comparator|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|The Ultrasound-guided injection with 2cc 0.9% normal saline+3cc Triamcinolone (30mg)
2487407|NCT02986347|Active Comparator|Intravenous regional anesthesia (Bier)|The anesthetic technique described by Bier will be done by the anesthesiologist. The following steps were followed: 1)Placement double tourniquet on the proximal portion of the arm 2)Asepsis and antisepsis of the operative limb 3)Puncture and venous catheterization most distal in the limb 4)Elevation of limb for 1 to 2 minutes, next the limb will be spirally wrapped with Esmarch from the distal to proximal 5)The proximal cuff will be inflated 6)Withdrawal of Esmarch and injection of 40ml of lidocaine without epinephrine at 0.5% 7)Removal the canula until the distal cuff is inflated and the proximal cuff is emptied 8)Removal of the club must be done after the surgery, at least 40 minutes after the injection of the anesthetic.
2487408|NCT02986347|Active Comparator|Local anesthesia with adrenaline|Patients will be anesthetized by surgeons, who are familiar with the technique described by Lalonde. Around thirty minutes before surgery, will be infused with 20 ml of an anesthetic solution. The infiltrated solution is composed of 1% lidocaine with epinephrine in 1: 100,000. Initially 10 mL of the solution will be applied slowly in the flexion fold region of the wrist just below the skin and subfascial plane. The needle is moved slowly. The needle is then redirected to the radial side of the proximal palmar region for infiltration of another 2-3 mL of the subcutaneous solution. The remaining 7-8mL in the subdermal plane and anterior to the transverse carpal ligament.
3194008|NCT00823641|Experimental|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
3194009|NCT00823654||Premenopausal Women with Early Stage Breast Cancer|
2487526|NCT02985645|Experimental|Treatment|maxillary sinus augmentation with CGF
2487581|NCT02985385||Abnormal Fetal Ultrasounds|"Abnormal fetal ultrasounds:~Those consistent with lethal malformations are provided with palliative management without providing respiratory support. Are given feeding and oxygen~Those compatible with life are managed by full investigation and given standard care for each case"
2487585|NCT02985385||Normal Fetal Ultrasounds|Given normal care
3194010|NCT00823654||Unaffected High Risk Women with BRCA mutations|
2487791|NCT02983721|Active Comparator|Transfemoral|in case of transfemoral approach our preference was to use right femoral route. The groin was prepared and draped and the site was punctured for femoral access after anesthetizing the skin with 2-4 ml of 1% lignocaine. Once the femoral puncture was done 6F sheath of Cordis variety was introduced and 6F Judkins, catheter was introduced and it was guided under fluoroscopic guidance through the aortic route.
2487794|NCT02983721|Active Comparator|Transradial|Our preference was to use the right radial and right femoral routes as they are nearest to operator while facing cardiac monitors, in our hospital. For the radial approach, the wrist was sterilized and draped in usual fashion. Hyperextension over an arm board was done and skin over the puncture site was anesthetized with 2 - 3 ml of 1% lignocaine. A small scaled incision was performed 1 cm proximal to styloid process of radius where arterial pulse was best felt. The radial artery was punctured with a 21 G needle and 6 F sheath (Cardis, Terumo) were introduced into the artery, using Seldinger technique. All patients received verapamil (5mg) to reduce radial artery spasm. Heparin (weight adjusted) was used only in PCIs to prevent artery occlusion and not in elective diagnostic coronary studies. Long 0.038 Terumo guide wire was used under fluoroscopic guidance.
2487834|NCT02983435|Experimental|G1 - Thrust manipulation|G1 - Thrust manipulation is an osteopathic technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
2487835|NCT02983435|Active Comparator|G2 - Muscle Energy|G2 - Muscle Energy is a manual therapy technique based in muscular contraction and stretching. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
2487859|NCT02983084|Experimental|Multiforce|Variable modulus version of a current orthodontic archwire
2487860|NCT02983084|Active Comparator|CuNiTi A|".016 current orthodontic archwire"
2487863|NCT02983084|Active Comparator|CuNiTi B|"0.014 and 0.018 current orthodontic archwire sequence"
2487955|NCT02982876|No Intervention|Medical Management Group|The patients assigned to the medical management group will be placed on a scheduled institution protocol using mucolytic and expectorant therapy (nebulizer treatments using mucolytic (N-acetylcysteine) for 15 minutes BID, Guafenesin (Mucinex®) 1200 mg BID, codeine as needed and Flutter valve BID.
2487956|NCT02982876|Active Comparator|Treatment group|The patients assigned to treatment group will undergo flexible bronchoscopy with dynamic maneuvers, rigid bronchoscope , tracheobronchial wash and airway stent placement
2487988|NCT02982369|Experimental|Spinal Manipulation|"High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region and pain education.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
2487990|NCT02982369|Sham Comparator|Pain Education|"Pain education and a simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.~The subjects will receive the treatment twice a week, for four weeks, totaling eight sessions, with an average duration of 30 minutes."
2488875|NCT02975960|Experimental|Stromal vascular fraction injection|Injection of autologous stromal vascular fraction on hand.
3194011|NCT00823667|Active Comparator|Phase 1 Usual care|
3194012|NCT00823667|Active Comparator|Phase 2 Intervention|
3194013|NCT00823680|Placebo Comparator|Placebo|
3194014|NCT00823680|Experimental|RO5027838 200mg|
3194015|NCT00823680|Experimental|RO5027838 50mg|
2487389|NCT02986438|Active Comparator|Active rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation. Each patient will receive treatment stimulation in the left dorsolateral prefrontal cortex (lDLPFC) with a frequency of 5 Hz, that includes 2 sessions per day for 10 consecutive business days for 2 weeks. Then a target frequency will be determined for the remaining of the study. If this arm's target frequency is chosen, then the participants will receive the maintenance intervention of 2 sessions per week for 12 months. Each session will consist of the application of rTMS at a frequency of 5Hz, to 100% of the motor threshold.
2487390|NCT02986438|Sham Comparator|Sham rTMS frequency at 5 Hz|The intervention will be Repetitive Transcranial Magnetic Stimulation (Sham). rTMS will be used with a coil that allows simulated stimulation (Coil AP) at a frequency of 5 Hz, with the software necessary for the operator to remain blind to the stimulation condition. This arm will only last for 2 weeks.
2487434|NCT02986256|No Intervention|Conventionnal Group|No intervention for this group. Patients will be followed by a usual care.
2487442|NCT02986256|Experimental|"Telepied Group"|Patients will be followed by a nurse referring to ulcers of the diabetic foot.
2487487|NCT02985918|Experimental|High-intensity NPPV|The patients will receive high-intensity noninvasive positive pressure ventilation.
2487492|NCT02985918|Active Comparator|Conventional-intensity NPPV|The patients will receive conventional-intensity noninvasive positive pressure ventilation.
2487583|NCT02985255|Experimental|Neoadjuvant Arm|Study Subjects, eligible for NACT would undergo a pretreatment workup with Evaluation Under Anesthesia for tumor Mapping and tissue biopsy along with a PET-CT scan. They would undergo 3 cycles of NACT (weekly thrice) with injection Docetaxel, Cisplatin and 5-FU after which reassessment with PET-CT and EUA +/- biopsy would be done. Those achieving CR would undergo adjuvant CTRT while subjects with PR in PET-CT scan will be reclassified based on the biopsy report. If biopsy is negative for malignancy, they will undergo adjuvant CTRT but would undergo surgery if in the PR group. Subjects with SD or PD would undergo surgery. PET-CT and EUA +/- HPE analyses would be repeated on follow-up after 3 months of treatment completion.
3194016|NCT00823680|Experimental|RO5093151 10mg|
2487781|NCT02983864|Active Comparator|Alcohol and Relaxation|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing termed BASICS and a brief (1.5 hour) relaxation intervention
2487783|NCT02983864|Active Comparator|Alcohol and Relationships|This arm will receive a brief (4-hour), two session, integrated alcohol and relationship intervention based on motivational interviewing designed to increase healthy alcohol use and sexual behavior. The interventions are based on an integrated BASICS and integrated Bystander protocols
2487904|NCT02983253||Patients with HHT|blood sample of patients with HHT
2487905|NCT02983253||probands|blood sample of healthy controls
2487959|NCT02982642|Experimental|1612 capsule|Subjects will take 1612 capsule 3 capsules per time(0.38g per capsule), 3 times per day for 52 weeks
2487960|NCT02982642|Placebo Comparator|Placebos|Subjects will take palcebo identified to 1612 capsule 3 capsules per time, 3 times per day for 52 weeks
2488021|NCT02982317||Study group|All patients recruited will undergo the same protocol. An anesthesiologist will perform manual palpation of the patients lumbar spine and identification of the intervertebral spaces from L1-S1. A member of the UBC Department of Engineering will perform the US scanning and level identification using the novel US technology. In addition, freehand US will be used by two practitioners to determine the participant's lumbar level locations as per gold standard.
3194017|NCT00823680|Experimental|RO5093151 400mg|
3194018|NCT00823693|Active Comparator|Bimosiamose Cream|
2488335|NCT02980055|Experimental|Test: collagen matrix|Root coverage using collagen matrix
2488336|NCT02980055|Active Comparator|Control: connective tissue graft|Root coverage using connective tissue graft
2488374|NCT02979834||Early perception group|The group with early perception of fetal movement (<25th percentile)
2488378|NCT02979834||Average perception group|The group with average perception of fetal movement (>25th and <75th percentile)
2488382|NCT02979834||Late perception group|The group which late perception of fetal movement (>75 percentile)
2488503|NCT02978859|Experimental|MGCD516|Patients with locally advanced and unresectable or metastatic sarcoma will receive MGCD516 at the discretion of the principal investigator until disease progression, unacceptable toxicity or adverse event(s) or withdrawal of consent.
2488576|NCT02978521|Experimental|Intervention Group|"Patients in the IG will be scheduled to receive Pulmonary Rehabilitation:~12 sessions (60 minutes approximately) over a period of 4-6 weeks (2-3 session/week). Sessions will progress as patients tolerance to exercise and will include breathing techniques, resistance training on ergometer and treadmill."
2488580|NCT02978521|No Intervention|Control Group|CG will receive information and recommendations on physical activity
2488618|NCT02978053|Experimental|Bright light|10 000 lux
2488627|NCT02978053|Placebo Comparator|Red light|400 lux
2488676|NCT02977611|Experimental|High Dose, Rapid Infusion Iron Sucrose|Patients will receive an infusion of 500 mg of iron sucrose over one hour and will be monitored for four hours.
2488715|NCT02977130|Experimental|Map group|patients receiving general shared care for diabetes and the conversation map intervention
2488720|NCT02977130|Active Comparator|Control group|patients receiving general shared care for diabetes
2488787|NCT02976922|Active Comparator|Probiotic lozenge|Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)
2488790|NCT02976922|Placebo Comparator|Placebo|Placebo lozenge, one lozenge twice daily for 3 months
2488899|NCT02975882|Experimental|Treatment (nab-rapamycin, temozolomide, irinotecan)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8 beginning on cycle 1. Patients also receive temozolomide PO and irinotecan hydrochloride PO on days 1-5 beginning on cycle 2. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
2488999|NCT02975271|Experimental|Serlopitant|Dose of experimental drug Serlopitant
2489005|NCT02975271|Placebo Comparator|Placebo|Matching dose of Placebo
2489075|NCT02974712|Experimental|Fentanyl|After routine Induction, fentanyl was administrated.
2517067|NCT02782858|Experimental|Dose 3 GNbAC1|Monthly IV repeated dose
3194019|NCT00823693|Placebo Comparator|Placebo Cream|
2487392|NCT02986360|No Intervention|Standard of care|Receive normal mammogram result and standard letter about breast density without any additional educational tools to contextualize breast density
2487432|NCT02986230|Experimental|PCP-focused group|The PCP-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services.
2487437|NCT02986230|Experimental|SDMT-focused group|The SDMT-focused group will receive a point of care clinical decision support tool called cancer prevention wizard (CP Wizard) that is integrated into the EHR. The CP Wizard provides evidenced- based recommendations to the provider and patient related to overdue cancer prevention screening services. The SDMT-focused arm also provides shared decision making tools to patient and provider at the time of the visit.
2487472|NCT02985931||Suspected CAD subjects|
2487499|NCT02985775|Experimental|Donor-derived CMVpp65-specific T cells|Intervention to be adminstered is about 1 million per kg CMVpp65-specific T cells infusion once acute GVHD ocurred post haploidentical transplantation.
2487568|NCT02985489|Experimental|Experimental Group|Participants assigned to the experimental group will commence Olimel Parenteral Nutrition therapy delivered through central venous catheter (CVC) access within 24-48 hours of admission.
2487569|NCT02985489|No Intervention|Control Group|Participants assigned to the control group will receive standard of care (SOC) nutritional therapy. Control group patients will be assessed by the RD assigned to the medical unit to which the patient has been admitted (independent RD assessment). The unit RD will follow standard nutrition screening processes to determine nutrition risk, followed by a complete nutrition assessment in the presence of nutrition risk.
2487640|NCT02985060|Experimental|Therapeutic hypothermia group|Therapeutic hypothermia using surface cooling device (Arctic Sun) Stroke care based on international guidelines except therapeutic hypothermia using surface cooling device (Arctic Sun)
2487645|NCT02985060|Other|Control group|Stroke care based on international guidelines
2487698|NCT02984592||Group 1|The participants in group 1 will state that they participate regular exercise programs in the previous 6 months
2487701|NCT02984592||Group 2|The participants in group 2 will state that they do not perform any regular exercise in previous 6 months.
2487746|NCT02984163|Experimental|Exercise Intervention|Participant exercise sessions will be conducted in groups of 10-15 under the direct supervision of the community-based exercise specialist. Sessions will be twice a week for 12-weeks. Participants will have the option to continue with the exercise program after the 12-weeks on a fee-for-service basis.
2487786|NCT02983799|Experimental|gBRCAm;|germline BRCA mutant
2487787|NCT02983799|Experimental|sBRCAm and germline BRCA wild type;|somatic BRCA mutant, germline BRCA wild type
2487788|NCT02983799|Experimental|myChoice® HRD positive and BRCAwt;|genomic instability positive and no BRCA mutation
2487789|NCT02983799|Experimental|myChoice® HRD negative and BRCAwt|genomic instability negative and no BRCA mutation
2487925|NCT02982746|Experimental|gPCC-G (Gothenburg Person Centred Care) Group|gPCC-G Patients randomized to the intervention group were contacted and scheduled to attend a meeting at the oncology clinic with the nurse specialist in oncology
2487931|NCT02982746|No Intervention|Control group|Control Group Patients randomized to the control group received usual care and return visits were scheduled according to the treatment procedure described under the previous heading and based on the Regional care program for patients with HNC. CG patients were recruited at the same time and in the same way as those in the intervention group
2487966|NCT02982525|Experimental|No Mussels|The control group will continue to consume their normal habitual diet
2487969|NCT02982525|Experimental|One mussel portion|One 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption.
2487971|NCT02982525|Experimental|Two mussel portions|Two 75g portions of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
2487973|NCT02982525|Experimental|Three mussel portions|Three 75g portion of Scottish mussels provided per week for 12 weeks on top of normal habitual shellfish consumption
3160727|NCT00430378|Experimental|Acupuncture|Acupuncture Before the Radiation Treatment
3160728|NCT00430378|Experimental|Standard Care|Standard Care Without Acupuncture
2488138|NCT02981498|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
2488174|NCT02981095|Active Comparator|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
2488178|NCT02981095|Placebo Comparator|Saline|Saline solution (%0.9 sodium chloride), 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
2488280|NCT02980354||Lacunar stroke|Blood samples will be taken from 50 patients who have been diagnosed to have lacunar stroke and are 65 years of age or above.
2488282|NCT02980354||Cortical stroke|Blood samples will be taken from 50 patients who have been diagnosed to have cortical stroke and are 65 years of age or above.
2488286|NCT02980354||Elderly healthy volunteers|Blood samples will be taken from 50 healthy individuals who are 65 years of age or above.
2488295|NCT02980354||Young healthy volunteers|Blood samples will be taken from 50 healthy individuals who are between 18 and 64 years of age.
2488318|NCT02980094|Placebo Comparator|Milk Control group(C)|Using a randomized block design, 25 institutionalized elderly to receive the milk 3 times per day produced by lactating cows fed with the following diet, one of the group is control (C), without vitamin E, selenium, sunflower oil in the cow's food.
3160729|NCT00430391|Experimental|DVD patient high risk|Patients with a diagnosis of schizophrenia/schizoaffective disorder randomized to the DVD, high risk version
3160730|NCT00430391|Experimental|DVD patient low risk|Patient with a diagnosis of schizophrenia/schizoaffective disorder randomized to DVD consent, low risk version
3160731|NCT00430391|Experimental|DVD normal high risk|Participants with no psychiatric diagnosis randomized to DVD consent, high risk version
3160732|NCT00430391|Experimental|DVD normal low risk|Participants with no psychiatric diagnosis randomized to DVD consent, low risk version
2487422|NCT02986425|Sham Comparator|Control|Participants in the control group will receive medication review by the prescribing physicians in accordance with usual care. If an extended drug review is in place in a ward/specialty corresponding characteristics are collected on cluster level.
2487485|NCT02985970||ČSARIM - questionnaire|Members of Czech society of anesthesiology, resuscitation and intensive care will obtain the questionnaire
2487544|NCT02985528||TUS positive|Ultrasound detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
2487547|NCT02985528||CXR positive|Radiographic detection of pleuro-pulmonary disease and further diagnostic and imaging when needed
2487607|NCT02985281|Active Comparator|Arm 1|"20 patients will be randomly assigned into arm 1; treated for fixed 24 duration with Gratisovir (Sofosbuvir) and Ribavirin. First intervention 'Sofosbuvir oral product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
2487613|NCT02985281|Active Comparator|Arm 2|"20 patients will be randomly assigned into arm 2; treated as response guided duration; patient who show very rapid virological (undetectable HCV RNA after 2 weeks) will be treated for 16 weeks duration and reset will complete the 24 weeks duration.~Intervention 'Sofosbuvir Oral Product' 200 mg tablet with food on daily doses based on body weight (20-29.9 kg will take one 200 mg tab daily); (30-39.9 kg will take 1.5 tab 200 mg daily); (> 40 kg will take 2 tab 200 mg daily).~Second intervention 'Ribavirin oral product' 200 mg tab on (15 mg/kg daily) doses based on body weight."
2487662|NCT02984774|Experimental|Infertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
2487663|NCT02984774|Experimental|Fertile endometriosis|Cystic wall segment from cystectomy material, endometrial sampling during the surgery and peripheric blood sampling during intravenous catheterization during anesthesia.
2487666|NCT02984774|Other|Control|Ovarian tissue sampling, endometrial sampling from hysterectomy and oophorectomy pieces and peripheric blood sampling during intravenous catheterization during anesthesia.
2487715|NCT02984410|Other|Intensity-Modulated Radiation Therapy (IMRT)|PTV prescription to tumor and high risk areas will be delivered daily for 5 days per week to a total dose of 66-70Gy in 2 Gy/fraction over 6 weeks, elective/prophylactic mucosal and nodal areas will receive a total dose of 54.25- 54.45 Gy in 33-35 fractions of 1.55-1.65 Gy over 6 weeks.
2487716|NCT02984410|Other|Trans Oral Surgery (TOS)|"The following surgical techniques are allowed:~Transoral Robotic Surgery (TORS) Transoral Microsurgery (TLM) Conventional trans-oral Surgery (CTOS)"
2487782|NCT02983838||depression with cognitive impairment|depression onset after 60 years old with subjective cognitive impairment
2487784|NCT02983838||depression without cognitive impairment|depression onset after 60 years old without subjective cognitive impairment
2487785|NCT02983838||normal control|older than 65 years, free from other neurocognitive disorder
2487825|NCT02983487||Index case (WP1a)|"Infant under 6 months old with clinical signs of whooping cough syndrome.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing"
2487828|NCT02983487||Control case (WP1b)|"Contact cases of infant with a positive diagnosis for whooping cough.~Nasopharyngeal sampling:~A nasopharyngeal sample collected from each nostril by aspiration or swabbing~Blood sampling:~A blood sample collected by fingerprick"
2487831|NCT02983487||Seroepidemiological cohort (WP2)|"Children between 3 and 15 years old with complete primo-vaccination against B.Pertussis~Blood sampling:~A blood sample collected by fingerprick"
2487896|NCT02983110||Cohort B|Group B will be HIV Infected post-menopausal women who are not receiving hormonal therapy to provide tissue, blood, and cells
2487897|NCT02983110||Cohort C|Group C will be HIV infected transgendered women receiving hormone therapy to provide tissue and blood
2487898|NCT02983110||Cohort E|Group E will be HIV infected men
2487922|NCT02982707|Experimental|Mild Hepatic Subjects|Subjects are given a single dose of BMS-986177
2487932|NCT02982707|Experimental|Moderate Hepatic Subjects|Subjects are given a single dose of BMS-986177
2487939|NCT02982707|Experimental|Healthy Match Subjects|Subjects are given a single dose of BMS-986177
2487985|NCT02982421|Experimental|Research|Group Art Therapy
2487987|NCT02982421|Sham Comparator|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
2488029|NCT02982148|Experimental|methylene blue intradermal injection|For patients randomized to intradermal injection before surgery began, 0.5ml 0.4% methylene blue(1ml methylene blue mixed up with 1.5ml saline) would be injected sub-areola (12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock) intradermally, 0.1ml respectively, or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
2488034|NCT02982148|Active Comparator|methylene blue subcutaneous injection|For patients randomized to subcutaneous injection before surgery began, 0.5ml 100% methylene blue would be injected sub-areola subcutaneously(12 o'clock , 3 o'clock , 6 o'clock , 9 o'clock), 0.1ml respectively or peritumoral depending on the tumor location, 10-15 minutes before skin incision. The breast was massaged for 5 minutes to facilitate the identification of blue lymphatic vessels and the lymph nodes.
2488097|NCT02981680|Experimental|RIPC|Patients in the remote ischemic preconditioning (RIPC) group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, surgery will be started. The entire pre-conditioning phase will last 30 minutes.
2488102|NCT02981680|Sham Comparator|sham-RIPC|Patients in the sham-RIPC group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the RIPC group, patients in the sham-RIPC group will undergo the same 30 minute delay before starting surgery.
2488134|NCT02981316|Active Comparator|RBX7455 Group A|4 days of 4 capsules twice daily RBX7455 for 10 subjects.
2488137|NCT02981316|Active Comparator|RBX7455 Group B|2 days of 4 capsules twice daily RBX7455 for 10 subjects.
2488140|NCT02981316|Active Comparator|RBX7455 Group C|2 days of 2 capsules twice daily RBX7455 for 10 subjects.
2487430|NCT02986217|Experimental|Experimental Group|Participants randomized to the Experimental Group will submit a video of surgical performance of vaginal cuff closure during a hysterectomy. Subjects in the experimental group will then receive feedback within 5 business days of video submission and repeat the process of video submission of the same procedure using the same surgical approach every 2 weeks for 2 cycles. At 6 weeks, participants will submit a final video performing vaginal cuff closure during hysterectomy.
2487470|NCT02986009|Experimental|Parenting|To receive the parenting intervention
2487471|NCT02986009|Experimental|Information|To receive the information intervention
2487488|NCT02985736|Experimental|open label|
2487567|NCT02985502||pancreatogenic diabetes|patients with pancreatogenic diabetes after pancreatectomy will be recruited
3194020|NCT00823732|Active Comparator|Phase 2 Intervention|GROUP II (palliative care intervention): Patients receive an individualized interdisciplinary palliative care intervention comprising learner-centered, knowledge-centered, assessment-centered, and community-centered concepts. Patients undergo 4 teaching sessions, focused on physical, psychological, social, and spiritual well-being, once weekly in weeks 3-6. Patients then receive 4 follow-up phone calls in weeks 9, 13, 17, and 21.
2487680|NCT02984618|Experimental|Treatment group|Patients will receive sphenopalatine ganglion block with ropivacaine 0.375% 3ml on each side
2487683|NCT02984618|Active Comparator|Control group|Patients will receive classic epidural blood patch with 20ml of autologous blood
2487699|NCT02984345|Active Comparator|Mycoprotein beverage|
2487700|NCT02984345|Placebo Comparator|Milk protein beverage|
2487738|NCT02984176|Active Comparator|Simethicone|Arm 1 or Group I or Simethicone 40mg. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
2487743|NCT02984176|Placebo Comparator|placebo|Arm 2 or group 2 or placebo group. 3 tablets (one tablet after each meal) and to fast overnight the day before the operation.
3194021|NCT00823732|No Intervention|Phase I Usual Care|GROUP I (usual care): Patients receive standard care.
2487872|NCT02983136|Experimental|Study site|The study arm will consist of managers and staff at at the operating department of a University hospital in western Sweden' The intervention is based on partnership, dialogue and inter-professional learning
2487878|NCT02983136|No Intervention|Control site|The Control arm will consist of managers and staff at at the operating department of a University hospital in south Sweden
3194022|NCT00823745|Experimental|1|[14C]-PF-00868554
2488052|NCT02981966|Active Comparator|Normal Glucose Tolerance (NGT)|Individuals with normal glucose tolerance - dapagliflozin vs placebo
2488054|NCT02981966|Active Comparator|T2DM individuals|Individuals with type 2 diabetes mellitus - dapagliflozin vs placebo
2488106|NCT02981615|Experimental|treatment arm|Subjects allocated to the treatment arm of the study will be administrated Levofloxacin 500mg/d given p.o. once a day, starting on day 10 from beginning of each cycle until day 28 on an ambulatory basis. Levofloxacin will be continued in the first 4 Azacytidine cycles.
2488111|NCT02981615|Placebo Comparator|placebo|Subject allocated to the placebo arm will be treated with placebo once a day, starting on day 10 from beginning until day 28 of each of the first 4 cycles.
2488148|NCT02981251|Experimental|Intervention|Health education with support by trained female health volunteer
2488151|NCT02981251|No Intervention|Control|Extra intervention will not be provided except usual care by their physician of the participant.
2488190|NCT02981030|Experimental|Simplified medical abortion|Women seeking medical abortion will be offered the option self-administering the medications, mifepristone and misoprostol at home.
2488313|NCT02980172||Pain triage complaint|Patients admitted at GUH ED triaged with a main complaint requiring a pain evaluation.
2488404|NCT02979509||Endoscopic ultrasound- (EUS) guided tissue sampling|All patients scheduled to undergo EUS with tissue sampling (TS) as medically indicated will be considered for the study. Patients in whom EUS-TS is considered as part of their standard medical care will be offered to participate in this study.
3194023|NCT00823758||1|Parents of children under 8 years of age who have ever given their children an over- the-counter medication.
3194024|NCT00823758||2|Adolescents who are 13 to 20 years of age who have ever heard of over-the-counter medication.
3194025|NCT00823758||3|Adults (21 years of age or older) who have used over-the-counter medication in the past 2 years.
3194026|NCT00823758||4|Primary care physicians will be Family Practitioners or General Internist, with an active Texas license, who devote at least 50% of their time to clinical practice.
2488577|NCT02978222|Experimental|FRα peptide plus adjuvant (GM-CSF)|FRα peptide vaccine with GM-CSF adjuvant ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
2488581|NCT02978222|Placebo Comparator|Adjuvant (GM-CSF) Alone|GM-CSF adjuvant alone ID administration monthly for 6 months followed by booster administrations every 3 months for up to 1.5 years
2488646|NCT02977871|No Intervention|No Bladder Flap group|Routine uterine incision performed during cesarean section without incision and dissection of the bladder peritoneum.
2488647|NCT02977871|Active Comparator|Bladder Flap group|Routine uterine incision performed during cesarean section with an incision and a dissection of a bladder flap.
2488659|NCT02977442|Experimental|exercise|12 week exercise program, 5 days/week, 60 min/day
2488661|NCT02977442|No Intervention|standard of care|12 week standard of care recommendations
2488726|NCT02977260|Experimental|Test Meal 1|Thin/Low Energy
2488730|NCT02977260|Experimental|Test Meal 2|Thin/High Energy
2488732|NCT02977260|Experimental|Test Meal 3|Thick/Low Energy
2488734|NCT02977260|Experimental|Test Meal 4|Thick/High Energy
2517072|NCT02782858|Placebo Comparator|Placebo|Monthly IV repeated dose
3194027|NCT00823758||5|Pharmacists holding a PharmD degree and licensure in the state of Texas and work at least half-time in a community pharmacy setting.
3194028|NCT00823771||Reviewed by radiation oncologist|
2487598|NCT02985320|Active Comparator|PhaseⅡControl Group -commercialized sIPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention:Three-dose regimen of commercialized sIPV"
2487599|NCT02985320|Active Comparator|PhaseⅡ Control Group -commercialized IPV|"Three intramuscular injections of the investigational vaccine(0.5 ml) on Day 0, Day 30 and Day 60 respectively;~Intervention: Three-dose regimen of commercialized IPV"
2487668|NCT02984748||Cochlear Implant Recipients|
2487679|NCT02984488|Experimental|single visit endodontic treatment.|•single visit endodontic Treatment of necrotic teeth using Protaper next.
2487682|NCT02984488|Active Comparator|Two visits endodontic treatment|•Two visits endodontic Treatment of necrotic teeth using Protaper next.
2487697|NCT02984332|Experimental|Lower limb immobilisation|All participants will undergo 7 days of unilateral leg immobilization. Participants will wear a leg brace (Donjoy X-ACT, DJO Global, USA) on one of their legs which will fix the leg at 40 degrees of flexion for the 7 days. Participants will not be allowed to remove the brace at any stage and are prohibited from bearing weight on the immobilized leg, and will ambulate on crutches throughout the week of immobilization.
2487745|NCT02984202|Experimental|Safety/Efficacy|Patients will be implanted with the AMI and evaluated for safety and efficacy over a 2-year period. The placement of the AMI array into the inferior colliculus will also be evaluated.
2487800|NCT02983903|Experimental|Single intervention arm - transbronchial biopsy|Patients enrolled in this single arm study will have lung nodules biopsied by traditional forceps followed by transbronchial cryobiopsy
3160733|NCT00430391|Experimental|Routine control high risk|Participants with no psychiatric diagnosis randomized to routine consent, high risk version
3160734|NCT00430391|Experimental|Routine control low risk|Participants with no psychiatric diagnosis randomized to routine consent, low risk version
3160735|NCT00430391|Experimental|Routine patient low risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, low risk version
3160736|NCT00430391|Experimental|Routine patient high risk|Participants with schizophrenia/schizoaffective disorder randomized to routine consent, high risk version
2488031|NCT02982109||Postop pain level 1|Minor postoperative pain anticipated
2488035|NCT02982109||Postop pain level 2|Might experience postoperative pain
2488046|NCT02982109||Postop pain level 3|Moderate pain/substantial surgery performed
2488049|NCT02982109||Postop pain level 4|Severe postoperative pain expected/major surgery
2488074|NCT02981797||Radium 223 Standard of Care|Standard of Care and Blood Collection for Baseline Circulating Tumor Cells (CTCs) Numeration and H2AX Assay. Participants who have chosen Radium 223 treatment for their prostate cancer that has spread to the bone and causing pain. Week 1 starts with the first Radium 223 treatment and week 24 ends 4 weeks after the last or sixth Radium 223 treatment. The circulating prostate cancer cell analysis will be performed within 24 hours of blood draw. Any unused blood samples for circulating prostate cancer cell analysis will be disposed per lab protocol.
2488135|NCT02981290|Experimental|Renodapt Then Mycept Then Cellmune Then CellCept|Participants will receive Renodapt in first treatment period (each treatment period= 3 days) followed by Mycept in second treatment period then Cellmune in third treatment period and CellCept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2488136|NCT02981290|Experimental|Mycept Then CellCept Then Renodapt Then Cellmune|Participants will receive Mycept in first treatment period (each treatment period= 3 days) followed by CellCept in second treatment period then Renodapt in third treatment period and Cellmune in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2488139|NCT02981290|Experimental|Cellmune Then Renodapt Then CellCept Then Mycept|Participants will receive Cellmune in first treatment period (each treatment period= 3 days) followed by Renodapt in second treatment period then CellCept in third treatment period and Mycept in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2488141|NCT02981290|Experimental|CellCept Then Cellmune Then Mycept Then Renodapt|Participants will receive CellCept in first treatment period (each treatment period= 3 days) followed by Cellmune in second treatment period then Mycept in third treatment period and Renodapt in fourth treatment period. A washout period of 7 days will be separating each treatment period.
2488211|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
2488214|NCT02980913|Experimental|Experimental: Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
2488255|NCT02980588|Other|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
2488299|NCT02980289||Patients|Patients over 18 years old with advanced cancer defined as metastatic disease, no curable treatment options. The patients may not have received chemotherapy or irradiation within 4 weeks, no operations within 2 weeks and no general anesthesia within 4 days.
2488331|NCT02980068|Experimental|15N Nitrate|single 1,000mg dose of 15N nitrate with 3g of conjugated linoleic acid (CLA).
2488332|NCT02980068|Experimental|14N Sodium Nitrate|single 1,000mg dose of 14N sodium nitrate with 3g of conjugated linoleic acid (CLA)
3160737|NCT00430404|No Intervention|Usual care (controlled group)|Usual care for management of depression
3160738|NCT00430404|Experimental|collaborative care (Intervention)|Collaborative care for management of depression for intervention group. We provided multidisciplinary groups of care from psychiatrist, psychologist, social counselor, general practitioners and case managers for intervention group.
3160739|NCT00430417||3 groups|Group 1: post-partum breastfeeding women
3160740|NCT00430417||Group 2|Group 2: post-partum bottlefeeding women
3160741|NCT00430417||Group 3|Group 3: normal non-pregnant controls who are age and race-matched to Group 1
3160742|NCT00430430|Experimental|High MUFA|high monounsaturated fat background diet to portfolio diet
3160743|NCT00430430|Active Comparator|Low MUFA|low monounsaturated fat background diet to portfolio diet
3160744|NCT00430456|Other|Arm 1|Higher Intensity, Shorter Duration Treadmill Training
3160745|NCT00430456|Active Comparator|Arm 2|Lower Intensity, Longer Duration Treadmill Training
2487627|NCT02984930|Experimental|PPI + mosapride group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
2487631|NCT02984930|Placebo Comparator|PPI + placebo group|After diagnosis(GERD), patient of this group will be taken proton pump inhibitor (40mg) plus placebo drug of mosapride for 4weeks. After then, patient of this group will be undergo upper endoscopy and scintigraphy.
2487693|NCT02984657||2012 patients|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.
2487695|NCT02984657||2015 patients|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.
3194029|NCT00823771||Reviewed by general practitioner|
3160746|NCT00430560|Active Comparator|1|work therapy
3160747|NCT00430560|Experimental|2|work therapy plus cognitive remediation
2487921|NCT02982993||WTC responders participating in HCV infection study|Members of the World Trade Center Health Program cohort born from 1945 to 1965 who choose to participate in this research study on hepatitis C infection
2487978|NCT02982577|Experimental|Pilocarpine|Spray with Pilocarpine
2487980|NCT02982577|Placebo Comparator|Placebo|Spray without Pilocarpine
3160748|NCT00430586|Experimental|20 U NT 201|
3160749|NCT00430586|Placebo Comparator|Placebo|
3160750|NCT00430586|Experimental|10 U NT 201|
3160751|NCT00430586|Experimental|30 U NT 201|
3160752|NCT00430612||1|Non-voluntary registry of consecutive patients diagnosed as having a MI at each study site
2488468|NCT02979093|Other|Addicted|The addiction group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
2488473|NCT02979093|Other|Control|The control group will be scanned twice using functional magnetic resonance imaging (fMRI). Subjects will be randomly assigned to receive either the active comparator (intranasal oxytocin spray) or the placebo comparator before the first scanning session. For the second scan (approximately one month later), the subject will receive the other spray which she did not receive at the time of the first scan.
2488511|NCT02978742|Experimental|Coached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program and will be linked with a healthcare professional who will provide standardized coaching, in the way of feedback and support to participants for the duration of the program.
2488514|NCT02978742|Active Comparator|Uncoached Recovery Record App|Participants will complete the 8-week adaptive Recovery Record app program on their own (i.e., without a coach providing feedback and support).
2488694|NCT02977351|Experimental|Atherosclerosis|Patients with atherosclerosis and chronic periodontitis
2488696|NCT02977351|Active Comparator|Systemically healthy|Patients with Systemically healthy and chronic periodontitis.
3160753|NCT00430651|Experimental|1|Docetaxel + Carboplatin
3160754|NCT00430651|Experimental|2|Docetaxel
3160755|NCT00430690||1|Cocaine dependent subjects
3160756|NCT00430690||2|Healthy controls
3160757|NCT00430690||3|Siblings of cocaine dependent subjects
3160758|NCT00430703|Experimental|1|Patients with severe traumatic brain injury
3160759|NCT00430703|Experimental|2|Healthy volunteers
3160760|NCT00430742|Experimental|1|Arm 1: MK0364 0.5 mg capsule once daily
3160761|NCT00430742|Experimental|2|Arm 2: MK0364 1 mg capsule once daily
3160762|NCT00430742|Experimental|3|Arm 3: MK0364 2 mg capsule once daily
3160763|NCT00430742|Placebo Comparator|4|Arm 4: Pbo capsule once daily
3160764|NCT00430820||1|30 patients
3160765|NCT00430820||2|30 patients
3160766|NCT00430820||3|30 patients
3160767|NCT00430846|Experimental|A|
3160768|NCT00430859|Experimental|1|BIAP
3160769|NCT00430859|Placebo Comparator|Placebo|Placebo, saline
3160770|NCT00430872||MDASI-Spine Tumor Module Survey|M. D. Anderson Symptom Inventory-Spine (survey) of patients with a tumor on the spine or spinal cord.
3160771|NCT00430885|Placebo Comparator|Saline|
3160772|NCT00430885|Experimental|Octagam (IVIG)|Octagam (IVIg) is intravenous immunglobulin
3160773|NCT00430898|Placebo Comparator|1. Placebo|Placebo to mimic 40 mg of Simulect
3160774|NCT00430898|Experimental|2. 40 mg Simulect|40 mg of Simulect
3160775|NCT00430924|Active Comparator|1|Eplerenone
3160776|NCT00430924|No Intervention|2|Control
3160777|NCT00430963|Placebo Comparator|Placebo|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding to total placebo volume 0.5 mL; mode of administration: intramuscular injection
3160778|NCT00430963|Experimental|IncobotulinumtoxinA (Xeomin) (20 Units)|IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl), 20 units, total volume 0.5 mL, mode of administration: intramuscular injection
3160779|NCT00431028|No Intervention|colirio|prednisolone 1% eye drops + ciprofloxacin 0,3% eye drops
3160780|NCT00431054|Experimental|Perifosine + Docetaxel|
3160781|NCT00431080|Experimental|1|FEC -> TXT
3160782|NCT00431080|Experimental|2|FEC -> TXL
3160783|NCT00431093|Experimental|1|tibolone
3160784|NCT00431093|Active Comparator|2|low-dose estradiol/noresterone
3160785|NCT00431106|Active Comparator|1|Vinorelbine/Gemcitabine (VG)
3160786|NCT00431106|Active Comparator|2|Capecitabine (Cap)
3160787|NCT00431158|Active Comparator|1|ARDSnet Protocol
3160788|NCT00431158|Active Comparator|2|OLA Protocol
3160789|NCT00431210|Experimental|Biological/Vaccine|Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
3160790|NCT00431223|Active Comparator|Active Group|7 patients were assigned to Cognitive Remediation Therapy..
2487642|NCT02984865|Experimental|group N1|Patients were attach with PCA containing 100ml combination of nalbuphine 1.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2487644|NCT02984865|Experimental|group N2|Patients were attach with PCA containing 100ml combination of nalbuphine 2mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2487646|NCT02984865|Experimental|group N3|Patients were attach with PCA containing 100ml combination of nalbuphine 2.5mg/kg and flubiprofen axetil 100mg after receiving the loading dose of nalbuphine 5 mg and flubiprofen axetil 50mg intravenously 30 mins before the end of the operation .
2487647|NCT02984865|Other|Group ESRD|30 patients with ESRD who underwent PD catheter placement using left lateral transversus abdominis plane (TAP) block combined with rectus sheath (RS) block from our center. The TAP and RS blocks were respectively conducted with 15 ml of 0.5% ropivacaine and 10 ml of 0.5% ropivacaine. Pain intensity was evaluated by verbal rating scale (VRS), and the degree of patient and surgeon satisfaction was qualified by a categorical scale.
2487681|NCT02984527|Active Comparator|water and soap first day|Intimate hygiene performed with water and soap first day and disposable wet wipes second day
2487684|NCT02984527|Active Comparator|disposable wet wipes first day|Intimate hygiene performed with wet wipes first day and water and soap second day
2487706|NCT02984306|Experimental|Dietary supplement|
2487762|NCT02984124|Experimental|Intervention|Participants (n= approximately 100 plus family members) who are randomized to the intervention arm of the study will participate in a discussion about CPR with a study doctor.
2487764|NCT02984124|Placebo Comparator|Usual Care with Attention Control|Participants (n= approximately 100 plus family members) who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
2487816|NCT02983669|Experimental|Thyme|Zataria multiflora Boiss powder capsule 350 mg twice daily for 3 months
2487819|NCT02983669|Placebo Comparator|Placebo|Wheat powder capsule 350 mg twice daily for 3 months
2487848|NCT02983201|Active Comparator|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
2487849|NCT02983201|Experimental|thumbtack needle+filiform needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
2487924|NCT02982967|Other|Physical Activity|Single-arm study with recreational physical activity intervention by 10 weeks (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
2487964|NCT02982499||control group|Healthy participants will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
2487967|NCT02982499||optic neuropathy group|Participants with optic neuropathy will receive a one-time assessment of quantitative Magnetic Resonance Imaging (MRI) and spectrum domain optical coherence tomography (OCT).
2488011|NCT02982278|Experimental|CINGS Intervention|CINGS is a 12-week nurse coordinated, Community Health Worker (CHW) intervention structure. Registered Nurse (RN) developed After hospital care plan with home visits sessions will be conducted by the CHW and intermittent televideo RN interactions. After baseline assessment, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly during months two and three. follow up assessments at 3, 6, and 12-month intervals.
2488012|NCT02982278|Experimental|Control|Control group will receive usual care. Base line visit and follow up at 3, 6, and 12 months post stroke enrollment.
2488092|NCT02981914|Experimental|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks. Treatment will be administered for up to 24 months, provided that neither disease progression, nor development of a dose-limiting toxicity (DLT), has occurred.
2488143|NCT02981407|Active Comparator|Liberal Transfusion Strategy|Red blood cell transfusion - One unit of packed red cells is transfused following randomization followed by enough red blood cell units to raise the hemoglobin concentration above 10 g/dL any time the hemoglobin concentration is detected to be below 10g/dL during the hospitalization for up to 30 days.
2488144|NCT02981407|Active Comparator|Restrictive Transfusion Strategy|Permitted to receive a red blood cell transfusion if the blood count is below 8 g/dL and the physician believes it is in the patient's best interest. A transfusion will be strongly recommended if the blood count drops to less than 7 g/dL. If the patient has symptoms of angina (e.g., chest discomfort described as pressure or heaviness) that do not go away with medication, a blood transfusion will be ordered regardless of the blood count.
2488368|NCT02979808|Experimental|Navina Smart|Navina Smart will be used during 12 months for transanal irrigation (TAI).
2488405|NCT02979457|No Intervention|no awareness of Degree of Worry|Call handler is not made aware of caller's DOW on computer screen
2488410|NCT02979457|Experimental|awareness of Degree of Worry|Call handler is made aware of caller's DOW on computer screen alongside patient information as address etc.
2488454|NCT02979288|Experimental|A Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli. Intervention with vaginal probiotics with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
2488459|NCT02979288|Active Comparator|B Nugent 4 + Lactobacilli|Intermediate vaginal Flora Nugent 4 with Lactobacilli, NO Intervention
2488462|NCT02979288|Experimental|C Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, Intervention with vaginal probiotics, with 'Lactobacillus casei rhamnosus (Lcr 35 regenerans)
2488463|NCT02979288|Active Comparator|D Nugent 4 NO Lactobacilli|Intermediate vaginal Flora Nugent 4 NO Lactobacilli, No Intervention
2487650|NCT02984852|Experimental|Treatment sequence BCA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment C in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2487651|NCT02984852|Experimental|Treatment sequence BAC|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment B in session 1 then Treatment A in session 2 followed by Treatment C in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2487653|NCT02984852|Experimental|Treatment sequence CAB|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment A in session 2 followed by Treatment B in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2487654|NCT02984852|Experimental|Treatment sequence CBA|Participants will receive a single oral tablet of D/C/F/TAF [FDC] Treatment C in session 1 then Treatment B in session 2 followed by Treatment A in session 3 under fed conditions (standardized breakfast) on Day 1 with washout period of at least 7 days between consecutive drug intakes.
2487748|NCT02984384|Active Comparator|Low Molecular Weight Heparin (LMWH)-Enoxaparin|Injection of 30 mg enoxaparin, twice a day via injection
2487751|NCT02984384|Active Comparator|Acetylsalicylic acid (ASA)-Aspirin|Enteral ingestion or administration of 81 mg ASA, twice a day
2488078|NCT02981888||IBS-C|all patients with IBS -C will undergo an abdominal x-ray for assessment of colonic transit
2488079|NCT02981888||IBS-D|all patients with IBS-D will undergo an abdominal x-ray for assessment of colonic transit
2488083|NCT02981888||heathy control|all healthy controls will undergo an abdominal x-ray for assessment of colonic transit
2488128|NCT02981355|Active Comparator|Microfracture treatment|Microfracture surgery of the femoral condyle
2488129|NCT02981355|Experimental|BST-CarGel plus microfracture treatment|BST-CarGel combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following an arthroscopic microfracture surgery.
2488301|NCT02980380||Locked-in and complete locked-in state patients|Amyotrophic lateral sclerosis patients in complete locked-in state as well as in transition from locked-in to complete locked-in state who have no means of communication.
3160791|NCT00431223|No Intervention|Control Group|4 patients were assigned to Control group or no cognitive remediation therapy.
2488623|NCT02977858||Dissemination|Educational practice for HCPs,Dissemination only - Practices who will participate in education for constipation management guidelines via dissemination of webinar alone.
2488625|NCT02977858||Dissemination + ISE|Educational practice for HCPs,Spaced Education - Practices who will participate in education for constipation management guidelines via dissemination of webinar along with a web-based format referred to as Interactive Spaced Education.
2488680|NCT02977598||non-diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2488683|NCT02977598||prediabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2488686|NCT02977598||diabetic|According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.
2488707|NCT02977078|Sham Comparator|Control|Inhaler use monitored by device but no feedback to participants (control); this group is unaware of the second arm receiving feedback on inhaler use.
2488711|NCT02977078|Experimental|Active|Inhaler use monitored with feedback to participants (active); participants randomized to this group sign an additional consent to receive feedback on inhaler use
2488830|NCT02976454|Experimental|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will include 14 meetings over 6 months to mimic the structure of the proposed Medicare funding for obesity treatment for adults. These meetings will include a single one-hour meeting and 13 twenty-minute meetings that occur in the clinic. During this time, the health coach will assess patient/parent readiness to engage in behavior change, assess barriers and facilitators to behavior change, engage in behavior change and problem solving, and provide feedback and accountability.
3160792|NCT00431249|Other|one|
3160793|NCT00431275|Experimental|Commercial Formulation|Commercial Formulation
3160794|NCT00431275|Experimental|Current Formulation|Current Formulation
3160795|NCT00431301||Case|PSP Cases
3160796|NCT00431301||Control|Healthy Controls
3160797|NCT00431353|Experimental|1|
3160798|NCT00431353|Experimental|2|
3160799|NCT00431418|Active Comparator|1|Sildenafil oral solution.
3160800|NCT00431418|Placebo Comparator|2|Placebo oral solution.
3160801|NCT00431431|Experimental|1|tibolone
3160802|NCT00431431|Active Comparator|2|raloxifene
3160803|NCT00431457|Active Comparator|Implantation intracranial electrode with immediate stimulation|
3160804|NCT00431457|Placebo Comparator|Implantation intracranial electrode without stimulation|
3160805|NCT00431457|Active Comparator|Resective surgery: amygddohyppocampertomy|
3160806|NCT00431483|Other|Pharmaceutical counseling|
3160807|NCT00431561|Experimental|AP 12009 10 µM|
3160808|NCT00431561|Experimental|AP 12009 80 µM|
3160809|NCT00431561|Active Comparator|Chemotherapy|
3160810|NCT00431600|Experimental|1|12 healthy male subjects
3160811|NCT00431613|Experimental|1|DG -> RT
3160812|NCT00431613|Experimental|2|DG -> RT -> DCarbo
3160813|NCT00431639|Active Comparator|Comparison|For the comparison condition, subjects will be asked to choose one of four topics that will be determined thatday with a recreational therapist for 20 minutes.
3160814|NCT00431639|Active Comparator|Treatment|The treatment condition will consist of a 20-minute visit by a therapy dog and its owner. Therapy dogowners will be instructed to limit conversation with the patient to topics of the therapy dog, thepatients pets, and pets in general.
3160815|NCT00431678|Experimental|Arm 1|
3160816|NCT00431678|Active Comparator|Arm 2|
2487664|NCT02984787|Experimental|3D Laparoscopic total gastrectomy|Participants including in the 3D laparoscopic total gastrectomy (3D-LTG) group will undergo 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
2487669|NCT02984787|Active Comparator|2D Laparoscopic total gastrectomy|Participants including in the 2D laparoscopic total gastrectomy (2D-LTG) group will undergo 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection.
2487710|NCT02984449|Experimental|Pre+postoperative Cardiac rehabilitation|receive a cardiac rehabilitation program consisting of three phases. 1) A preoperative optimization phase (3x p/wk, 4-6 weeks, before surgery), 2) a postoperative in-patient phase (15 to 18 days in rehabilitation center, weekend at home) and, 3) an outpatient patient clinical rehabilitation phase (2x p/wk, 4 weeks). During each phase, patients will visit a physical therapist (group sessions of inspiratory muscle training (IMT), strength training, aerobic cycling and breath, cough and relaxation sessions), a dietician and a psychologist to optimize general health and receive advice on lifestyle, anxiety and stress management. Two additional components are coaching to stop smoking
2487712|NCT02984449|Active Comparator|Postoperative Cardiac rehabilitation|Patients who are randomized to the POST group receive an out-patient cardiac rehabilitation program after surgery. In general, this program starts three to six weeks after discharge (phase ǀǀ) and patients always start with an exercise program, which is supervised by a physical therapist for about six weeks (twice a week). On indication support of psychological and/or dietary consult is added.
2487911|NCT02982681|Experimental|Platelet rich Fibrin|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site secured with vicryl sutures.
2487915|NCT02982681|Active Comparator|Bioactive glass|The intrabony defects were treated with Full thickness mucoperiosteal flap was raised and thorough open flap debridement done under local anesthesia and The control site were packed with the graft alone
2488042|NCT02982564|Experimental|Low Intensity Exercise|Participants engage in low intensity endurance exercise.
2488045|NCT02982564|Experimental|Moderate Intensity Exercise|Participants engage in moderate intensity endurance exercise.
2488098|NCT02981667||Active men and women|Healthy, active men and women ages 18-45 yr completed 1 bout of high intensity interval training and moderate intensity continuous training in a randomized, crossover design.
2488125|NCT02981394||BMAC Group|Intervention Group
2488205|NCT02981134||bioabsorbable scaffold|Patients with BVS(bioabsorbable scaffold) for coronary stenosis
2488251|NCT02980653|Experimental|Megestrol|Single arm
3160817|NCT00431691|Active Comparator|1|
3160818|NCT00431691|Placebo Comparator|2|
3160819|NCT00431704|Experimental|vinorelbine, carboplatin, trastuzumab|
2488554|NCT02978430|Active Comparator|Standard of care|This group (started retrospectively before the first included patient of the closed-loop goal-directed fluid therapy group) consists of patients undergoing major abdominal surgery where fluid management is carried out based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output).
2488555|NCT02978430|Active Comparator|Computer-assisted GDFT|"This group consists of patients undergoing major abdominal surgery where fluid management is carried out with a closed-loop (automated) system to deliver fluid by a goal-directed fluid therapy (GDFT) standardized protocol.~Confer: Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery (NCT02312999)"
3160820|NCT00431769|Experimental|Bortezomib|
3160821|NCT00431795|Experimental|1|Epi
2488660|NCT02977533|Experimental|GZ402668|Dose 1 (up to a maximum optional Dose 2) will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
3160822|NCT00431795|Experimental|2|Cael
3160823|NCT00431808|Experimental|I, AMA1 vaccine|20 volunteers will receive 3 doses of the vaccine
3160824|NCT00431821|Other|Arm 1|Home-based exercise prescriptions with weekly motivational telephone calls.
3160825|NCT00431821|Other|Arm 2|Stroke education program with matched attention phone calls
3160826|NCT00431873|Experimental|1|MGCD0103 administered orally three times per week.
3160827|NCT00431912|Experimental|Single-arm, trinomial 2-stage design|
3160828|NCT00432029|Other|1|IDDM
3160829|NCT00432029|Other|2|Hypercholesterolemia and/or Hypertension
3160830|NCT00432029|Other|3|age/sex matched healthy control subjects
3160831|NCT00432055|Experimental|I|Botox
3160832|NCT00432055|Placebo Comparator|II|
3160833|NCT00432068|Experimental|Octreotide pamoate|
3160834|NCT00432094|Experimental|2 Transplants|Patients with Germ Cell Tumors (GCT) treated with a second tandem autologous stem cell transplant (AuSCT) with non-cross-resistant conditioning regimens.
3160835|NCT00432094|Active Comparator|1 Transplant|Patients with Germ cell tumors who receive one transplant only.
3160836|NCT00432107|Experimental|2-stage mono therapy of APO866|The treatment period consists of 3 consecutive 28 day cycles. Each cycle starts with a 4 day continuous infusion of the study medication followed by a 24 day break
3160837|NCT00432120|Active Comparator|A|"nonselective - clopidogrel 600 mg >6 hours before coronary angiography;"
3160838|NCT00432120|Active Comparator|B|"selective - clopidogrel 600 mg in the cath-lab after coronary angiography, only in case of percutaneous coronary intervention"
3160839|NCT00432133|Experimental|1|Protection motivation theory-based tailored intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
2487665|NCT02984761|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy is an FDA approved treatment for lung cancer. However, for purposes of this study, it is being delivered to an operable population that is typically treated with surgical resection. Participants randomized to stereotactic radiotherapy will be treated according to the location of the tumor. Peripheral tumors will receive either 18 Gy x 3, 14 Gy x 4, or 11.5 Gy x 5 fractions, while central tumors will be treated with 10 Gy x 5. There will not be any elective coverage of local microscopic spread or regional lymph nodes.
2487671|NCT02984761|Active Comparator|Surgery|Participants randomized to surgery will undergo a standard lobectomy or limited anatomic pulmonary resection (segmentectomy) under general anesthesia. Non-anatomic (wedge) resections are not permitted. Pathological specimens must contain a separately divided pulmonary artery and bronchus, as well as sampled lymph nodes from mediastinal lymph node stations. Participants found to have incidental nodal involvement after surgery will be referred for adjuvant chemotherapy, with our without postoperative radiotherapy.
2487717|NCT02984397|Experimental|KF group|In each study visit, patients will receive enough pills for the next month. At the first visit, patients receiving ketotifen (KF) will receive four vials sequentially numbered (1 to 4) containing enough pills for one week each, and will be instructed by the clinician and by the pharmacist to use vial 1 for the first week (0.5 mg of KF BDI), vial 2 for the second week (1mg of KF BDI), vial 3 for the third week (2 mg of KF BDI), and vial 4 for the fourth week (3mg of KF BDI). As for weeks 4, 8 and 12 visits, patients treated with KF will receive four equal vials containing enough pills for one week each (3 mg of KF BDI)
2487718|NCT02984397|Placebo Comparator|Placebo group|Patients participating in the placebo group will also receive sequentially numbered vials at the first visit. Similarly, patients taking placebo will also receive four equal vials of pills on the next visits.
2487719|NCT02984397|Active Comparator|SOC|Standard of care - patients who refuse to participate in the study but allow us to compare their clinical data to that of participants of the study
2487769|NCT02984046|Experimental|acute bronchiolitis|Prospective, monocentric, case-control and study Primary end-point: correlation between serum CC16 level and severity of the bronchiolitis, evaluated by a clinical scoring system
2487806|NCT02983682|Experimental|Lidocaine Infusion|All participants will receive intravenous lidocaine infusion of 42 mcg/kg/minute over 2 hours, for a total of 5 mg/kg. No bolus dose will be given.
2487957|NCT02982629|Placebo Comparator|Usual Care|Patients in this group do not receive any letters or phone calls after missing follow-up appointment.
2487958|NCT02982629|Active Comparator|Reminder Letter Intervention|Patients in this group receive letters and phone calls after missing follow-up appointment to reschedule the appointment.
2488001|NCT02982382|Experimental|Manipulative Treatment|Subjects will receive Manipulative Therapy
2488004|NCT02982382|Sham Comparator|Pain Education|Subjects will receive Pain Education and manual contact over lumbar region
2488081|NCT02981862|Experimental|CaptHPV method|
2488278|NCT02980458|Experimental|Deferiprone 500 Lipomed film-coated tablets|Oral fasted administration of one film-coated tablet of Deferiprone 500 Lipomed film-coated tablets (Lipomed AG, Switzerland), containing 500 mg deferiprone
2488279|NCT02980458|Active Comparator|Ferriprox® film-coated tablets|Oral fasted administration of one film-coated tablet of Ferriprox® film-coated tablets (Apotex Europe B.V., Germany), containing 500 mg deferiprone
2488326|NCT02980159||Before triage liaison physician|All patients admitted before the introduction of the function of triage liaison physician.
2488329|NCT02980159||After triage liaison physician|All patients admitted after the introduction of the function of triage liaison physician.
2488363|NCT02979912|Experimental|Platelet Lysate|Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.
2488395|NCT02979665||Ranibizumab Ophthalmic|DME consults requiring anti-VEGF treatment
2488396|NCT02979665||Control|DME consults not requiring anti-VEGF
2488447|NCT02979366|Experimental|S64315 (also referred as MIK665) administered once a week|
2488448|NCT02979366|Experimental|S64315 (also referred as MIK665) administered twice a week|
2488535|NCT02978612|Experimental|Arm Capecitabine|Capecitabine 1000 mg/m2 bid day 1-14 q3 weeks, 8 cycles
2488536|NCT02978612|No Intervention|Arm No treatment|no chemotherapy, observation
2488593|NCT02978300|Active Comparator|NIV/HFNC group|Continuous NIV for at least 4 hours until clinical improvement then intermittent 1-hour sessions for a minimal duration of 12 hours a day. Between NIV sessions HFNC will be delivered as in the HFNC group.
2488595|NCT02978300|Experimental|HFNC group|Continuous HFNC alone 24h/24 until weaning or intubation.
2488632|NCT02977923|Active Comparator|Standard pharmacological treatment|According to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
2488633|NCT02977923|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
2488658|NCT02977546||Heart Failure|Patients with chronic heart failure NYHA >= 2 based on a reduced left ventricular ejection fraction (LV-EF <= 45%). All patients receive pulmonary artery catheterization and noninvasive pulse contour Analysis.
2488765|NCT02977026|No Intervention|Control|A questionnaire that asks individuals what components of an online intervention they might find useful.
2488898|NCT02975999|Placebo Comparator|Normal saline|Normal saline will be provided on a drip infusion to the selected group once coming off cardiopulmonary bypass following the Fontan operation.
2487677|NCT02984735||Evaluation of children with spastic CP|Children with a diagnosis of spastic CP aged 2 to 12 years who were referred due to chewing/swallowing problems by pediatric neurologists were included. The inclusion criteria were above the age of 24 months, and had complaints about chewing function. Children under the age of 24 months, requiring tube feeding or taking any oral nutritional supplements, and used any medicine and/or oral appliances that could affect the chewing performance, were excluded.
2487720|NCT02984358|Placebo Comparator|Animal protein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by animal products (meat and fish).
2487721|NCT02984358|Active Comparator|Low-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-depleted mycoprotein products (commercial Quorn products).
2487723|NCT02984358|Active Comparator|High-nucleotide mycoprotein based diet|Seven day fully controlled normocaloric diet (1.2 g/ kg body weight of protein per day), with the main protein source at the two main meals (lunch and dinner) being provided by nucleotide-rich mycoprotein products.
2487771|NCT02984033||Head and Neck patients|Patients affected by squamous cell carcinoma of head and neck (oral cavity, larynx, pharynx and hypopharynx) with no metastasis
3160840|NCT00432133|Experimental|2|Environmental access and awareness intervention to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
2487833|NCT02983461|Placebo Comparator|Placebo|Double Blind Placebo 3 times a day for 10 weeks.
2487836|NCT02983461|Active Comparator|Sildenafil|Double Blind Sildenafil, 20mg x 3 times a day, 10 weeks.
2487876|NCT02983097|Experimental|R²-DHAP|"Combination treatment with immunochemotherapy (R-DHAP) and lenalidomide~Dosage:~Rituximab 375 mg/m² day 1, i.v. Cisplatin 100 mg/m² or Carboplatin AUC5 day 2, i.v. Cytarabine 2000 mg/m², administered twice, on day 3, i.v. Dexamethasone 40 mg, days 2-5, p.o. Lenalidomide 5-20 mg, day 1-7 / day-6-+7, p.o. PEG-Filgrastim 6 mg, day 6, s.c.~peripheral stem cell collection after cycle 1 or 2"
3160841|NCT00432133|Experimental|3|Combination intervention combining protection motivation and environmental intervention components to promote physical activity delivered via interactive technology (computer interactive session, automated telephone counseling, tailored newsletters).
3160842|NCT00432185|Active Comparator|1|One day treatment
3160843|NCT00432185|Active Comparator|2|Two day treatment
2487993|NCT02982512|No Intervention|Control recording|Recording of local field potentials without drugs from the deep brain stimulator
2487994|NCT02982512|Experimental|Dexmedetomodine recording|Recording of local field potentials at different dexmedetomidine concentrations from the deep brain stimulator
2488006|NCT02982070|Experimental|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
2488008|NCT02982070|No Intervention|College as Usual|no training provided
2488084|NCT02981927|No Intervention|Control|24 h habitual physical activity fed in energy balance
2488087|NCT02981927|Experimental|Bed rest matched diet|24 hour period of whole body bed-rest with a matched diet
2488091|NCT02981927|Experimental|Bed rest balanced diet|24 hour period of whole body bed-rest fed in energy balance
2488162|NCT02981459|Experimental|Mirabegron 25 mg or 50 mg|
2488209|NCT02980926|Experimental|Mepivacaine Spinal Anesthetic|Mepivacaine 3 mL intrathecal injection of 2% solution
2488213|NCT02980926|Active Comparator|Bupivacaine Spinal Anesthetic|Bupivacaine 12 mg of 8.25% solution
2488257|NCT02980562|Active Comparator|2L Polyethylene glycols-Asc|1 L of PEG containing ascorbic acid (PEG A) was taken at 8:00 pm on the day before the colonoscopy, followed by an extra 500 mL of water. The second 1-L of PEG containing ascorbic acid was taken 4 h before the colonoscopy examination, with an additional 500 mL of water. Each liter of preparation and the extra 500 mL water had to be consumed within 2 h of the procedure. All colonoscopies were performed between 9 am and 1 pm.
2488258|NCT02980562|Active Comparator|1L PEG-Asc plus bisacodyl|10 mg bisacodyl at 9:00 pm on the day before the colonoscopy. Four hours before the colonoscopy examination, 1 L of PEG containing ascorbic acid was taken, followed by an additional 1 L of water. The preparation was completed 2 h before the examination. All colonoscopies were performed between 9 am and 1 pm.
2488308|NCT02980237|Experimental|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. The course could be access in the workplace but they will be additional support.
2488312|NCT02980237|Active Comparator|eHealth|This group will receive an e-learning education program same as the intervention group . However, the participants will not receive additional support by team.
2488440|NCT02979379||Pain|Individuals with COPD who experience chronic pain (episodes of daily pain for a duration greater than three months)
2488441|NCT02979379||No Pain|Individuals with COPD who do not experience pain on a regular basis.
3194030|NCT00823784|Experimental|1THD group|Series of 135 patients with 3rd degree Hemorrhoids treated by THD device under spinal anaesthesia
2488561|NCT02978469|Experimental|Life style changing: reducing sedentary behavior|Meetings with social worker and physical therapist.
2488567|NCT02978469|Active Comparator|Physical exercise group|Physical therapy exercise training in group, strengthening and stretching muscles.
2488672|NCT02977689|Experimental|IDH305|IDH305 550 mg, oral, two times per day
2488706|NCT02977104|Other|Patients in afib or flutter|Maestro ECG
2488713|NCT02977104|Other|Patients in sinus rhythm|Maestro ECG
2488783|NCT02976571|Active Comparator|Placebo+Intraperitoneal|Sub cutaneous Nacl 0.9%+ Intraperitoneal bupivacaine
2488785|NCT02976571|Placebo Comparator|Placebo+Placebo|Sub cutaneous Nacl 0.9%+ Intraperitoneal Nacl 0.9%
2488826|NCT02976350||Patients with HFpEF|Male patients with heart failure with preserved ejection fraction
2488958|NCT02975674|Experimental|MT-12 dental implant|MT-12 dental implant with Morse taper implant-abutment connection
3160844|NCT00432198|Experimental|1|Oral
3160845|NCT00432198|Experimental|2|Oral
3160846|NCT00432198|Placebo Comparator|3|Oral
3160847|NCT00432211|Placebo Comparator|1|Complete Scar Excision
3160848|NCT00432211|Placebo Comparator|2|Staged Excision of scar
2487696|NCT02984436||ED Patients with Acute Chest Pain|Emergency Department (ED) Patients with Acute Chest Pain will have blood samples collected for High sensitivity cardiac troponin T (hs-CTnT) analysis. Results from this analysis will be integrated into the HEART Score/Pathway. It will later be seen if integration of the hs-cTnT outperforms the use of HEART Score/Pathway alone.
2487740|NCT02984111|Active Comparator|group A|20000 IU erythropoietin infusion during aortic cross clamp in 45-60 minutes
2487742|NCT02984111|Active Comparator|group B|20000 IU erythropoietin infusion after induction of anesthesia and before undergoing cardiopulmonary bypass pump in 45-60 minutes
2487744|NCT02984111|Placebo Comparator|control|50 ml normal saline infusion during aortic cross clamp in 45-60 minutes
3194031|NCT00823784|Active Comparator|2 stapler group|135 patients with 3rd degree hemorrhoids will be treated by staple hemorrhoidopexy
2487851|NCT02983266|Experimental|Group 1: Low Hertz|"Participants will receive 10 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2487857|NCT02983266|Experimental|Group 1: High Hertz|"Participants will receive 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2487861|NCT02983266|Sham Comparator|Group 1: Control|"Participants will receive 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2487864|NCT02983266|Experimental|Group 2: Pre-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
2487865|NCT02983266|Experimental|Group 2: Post-stressor|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session after experimental sympathetic induction.~Device: InTENsity MicroCombo"
2487866|NCT02983266|Placebo Comparator|Group 2: Control|"Participants will receive 10 or 30 hertz stimulation to a non-vagally innervated region of the left ear, delivered in one 15 minute session prior to receiving experimental sympathetic induction.~Device: InTENsity MicroCombo"
2487867|NCT02983266|Experimental|Group 3: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session.~Device: InTENsity MicroCombo"
2487868|NCT02983266|Experimental|Group 4: 30 Hz|"Participants will receive 10 or 30 hertz stimulation to the left auricular branch of the vagus nerve, delivered in one 15 minute session. Participants will also receive stimulation on a subsequent session prior to urodynamic testing.~Device: InTENsity MicroCombo"
2487869|NCT02983266|Experimental|Group 1: Response|"Participants will receive 10-30 hertz stimulation to the left auricular branch of the vagus nerve, delivered over the course of 1 hour.~Device: InTENsity MicroCombo"
3194032|NCT00823810|Experimental|Colorectal cancer|
3194033|NCT00823849|Experimental|1|
2488053|NCT02981979|Active Comparator|Leflunomide group|Use Leflunomide 20mg qd po. for 24 weeks for induced remission therapy combine with the basic prednisone therapy(start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. If the subject has not achieve clinical remission,do not change prednisone dose）. Subjects who have achieved clinical remission, with the prednisone dose reduced to 10mg within 20 weeks and maintained to the end of 24 weeks enter the maintenance therapy.The next 32 weeks for maintenance therapy use leflunomide combine with prednisone 10mg per day.
2488055|NCT02981979|Placebo Comparator|Control Group|Use Placebo for 24 weeks for induced remission therapy(24 weeks) and use leflunomide 20mg qd po. for maintenance therapy in the next 32 weeks. Prednisone is used as basic therapy during the whole trial (start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission. Then maintain 10mg per day until the end of the study). All subjects in control group enter maintenance therapy.
2488119|NCT02981576|Active Comparator|Recipient of AT-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from AdiposeTissue by Intrathecal injection of stem cells that will be performed 3 times.
2488120|NCT02981576|Active Comparator|Recipient of BM-MSC|Patients who will receive Autologous Mesenchymal Stem Cells from Bone marrow by Intrathecal injection of stem cells that will be performed 3 times.
2488169|NCT02981173|Active Comparator|Psilocybin High Dose|
2488170|NCT02981173|Active Comparator|Psilocybin Low Dose|
2488173|NCT02981173|Placebo Comparator|Placebo|
2488207|NCT02980822||Sweden, Denmark, Norway|"Group: Degenerative lumbar disc disease patients treated in Sweden and included in the Swespine register~Group: Degenerative lumbar disc disease patients treated in Norway and included in the NORspine register~Group: Degenerative lumbar disc disease patients treated in Denmark and included in the DaneSpine register"
3194034|NCT00823849|Experimental|2|
2488381|NCT02979756|Experimental|Decentralized GDM screening and initial management|In this arm, the intervention consists of screening all pregnant women for GDM using the nationally recommended oral glucose tolerance test that will take place during antenatal care consultations in 10 randomly selected primary health care facilities. Overall, 80 women who are diagnosed with GDM and who consent to participate will receive initial nutritional counseling and will be closely followed up.
2488383|NCT02979756|No Intervention|Standard GDM screening and management practice|In this arm, screening for GDM will follow standard practice. 80 women diagnosed with GDM in 10 randomly selected primary health care facilities and who consent to participate will be followed up.
2488414|NCT02979561|Experimental|group of dabigatran|
2488415|NCT02979561|Active Comparator|group of warfarin|
3194035|NCT00823849|Experimental|3|
3194036|NCT00823849|No Intervention|4|Control Group
3194037|NCT00823862|Experimental|Active (SD-101)|SD-101 in cohorts of escalating doses
3194038|NCT00823875|Experimental|1|
3194039|NCT00823875|Experimental|2|
3194040|NCT00823875|Experimental|3|
3194041|NCT00823875|Other|4|Control Group
3194042|NCT00823927||1|Alveolar macrophage proteomes from HIV-seropositive smokers with emphysema
3194043|NCT00823927||2|Alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers.
3194044|NCT00823940|Placebo Comparator|Cohort A1|Dose escalation: 5 - 100mg and placebo in 4 planned doses
3194045|NCT00823940|Placebo Comparator|Cohort A2|Dose escalation: 100-600mg and placebo in 4 planned doses
2487813|NCT02983786||Non-Invasive Monitoring|"One non-invasive optode patch will be placed adjacent to the area of invasive monitoring and the second patch will be placed contralaterally. (12 hrs. daily is chosen primarily for budgetary reasons). The information for the non-invasive technology will be compared to the invasive technology.~ICG (Indocyanine Green) will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable)."
2487871|NCT02983318||PET/MRI using 18[F]EPPA ligand|given experimental ligand FEPPA during MRI/PET scan to identify glutamate activity in the brain using FEPPA ligand
2487929|NCT02982941|Experimental|Dose Escalation & Cohort Expansion|enoblituzumab administered IV weekly
2487981|NCT02982408|Experimental|Low birth weight (LBW)|25 males born at term (weeks 39-41) in 1979-1981 with LBW (BW<10th percentile)
2487983|NCT02982408|Experimental|Normal birth weight (NBW)|25 BMI- and age-matched males born at term (weeks 39-41) with normal birth weight (NBW) control individuals (BW: 50-90th percentile)
2488050|NCT02982122|Experimental|CPPopt intervention group|Patients are managed according to Brain Trauma Foundation guidelines, except for CPP where the CPPopt is targeted.
2488051|NCT02982122|Active Comparator|CPP control group|"Patients are managed according to Brain Trauma Foundation guidelines with CPP between 60 and 70 mmHg.~CPPopt information is recorded but hidden for the treating clinicians."
3160849|NCT00432302|Experimental|Sagopilone|Subjects received 28 mg ZK 219477, containing 14 kBq/7.8 µg [14C]-ZK 219477 in the first infusion (Treatment course 1) followed by subsequent infusions (Treatment courses 2 to n [till disease progression]) of 16 mg/m2 ZK 219477 without radioactive label. Interval between the treatments was at least 21 days.
3160850|NCT00432315|Experimental|1|Resectable NSCLC
2488584|NCT02978235|Experimental|TAS4464|
2488728|NCT02977234|Experimental|Iso-Amyl 2-Cyano Acrylate|Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx
2488757|NCT02976792||Renal Resistive Index/NephroCheck™test|Patients undergoing a transcatheter aortic valve implantation
2488778|NCT02976636|Active Comparator|Family-based behavioral therapy (FBT)|Family-based behavioral therapy for pediatric weight loss
2488781|NCT02976636|Experimental|Parenting training and FBT|Family-based behavioral therapy for pediatric weight loss + parenting training to enhance outcomes
2488818|NCT02976363||Quadrantectomy Group|The Quadrantectomy Group sample performed adjuvant radiotherapy with a linear accelerator, whose the total dosage was 5000 centigray (cGy), the daily dose 200 cGy distributed into twenty-five sessions, totaling 25 days of treatment. And data from Maximal Respiratory Pressures (MIP/MEP) were collected at two phases in the sample of Quadrantectomy Group: before the first session of radiotherapy and after the twenty-fifth session corresponding to the last day of the radiotherapy treatment.
2488822|NCT02976363||Control Group|While for the control group women with no breast cancer history were invited. Data from Maximal Respiratory Pressures (MIP/MEP) were collected at one phase in the sample of control group.
2488932|NCT02975375||Preoperative geriatric consult or assessment|Patients who have a geriatric assessment of consult billed in the 4 months before surgery
2488937|NCT02975375||No Preoperative geriatric consult or assessment|Patients who do not have a geriatric assessment of consult billed in the 4 months before surgery
2489113|NCT02974517||Time-lapse-Auto|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by KID Score system.
2489116|NCT02974517||Time-lapse-Manual|All embryos are cultured in EmbryoScope®; embryo scores are evaluated on day 3 by embryologist.
2489119|NCT02974517||Conventional Group|All embryos are cultured in our daily used incubators; embryo scores are evaluated on day 3 by embryologist.
2489177|NCT02974205|Active Comparator|Rehabilitation with orthosis (Jack brace)|
2489180|NCT02974205|Active Comparator|Rehabilitation without orthosis|
2489183|NCT02974205|Active Comparator|Rehabilitation with orthosis (össur brace)|
2489220|NCT02973906|Other|ADAPT Self Directed web|ADAPT Self Directed Web. In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum)
2489221|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
2489222|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics
2489275|NCT02973594|Active Comparator|Ivabradine|Patients will receive ivabradine 2.5-7.5 mg PO bid in addition to baseline maximum-tolerated beta-blocker therapy.
3160851|NCT00432315|Experimental|2|Unresectable NSCSC
3160852|NCT00432367|Experimental|1|OptiMAL® antigen screening and treatment with SP plus LLIN
3160853|NCT00432367|Experimental|2|OptiMAL® antigen screening and treatment with AQ+AS plus LLIN
3160854|NCT00432367|Active Comparator|3|SP-IPTp plus LLIN
3160855|NCT00432406|Active Comparator|1|infliximab
3160856|NCT00432406|Active Comparator|2|etanercept
3160857|NCT00432432|Placebo Comparator|2|placebo with infliximab
3160858|NCT00432471|Experimental|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
3160859|NCT00432484|Placebo Comparator|1|Placebo with Lingzhi(Granoderma Lucidum) and Sen Miao San
3160860|NCT00432510|Experimental|Single Dose|1,000 Units (U) of C1INH-nf administered intravenously (IV).
3160861|NCT00432510|Experimental|First Dose Followed by Second Dose|1,000 U of C1INH-nf administered IV, followed by a second 1,000 U dose 60 minutes later.
3160862|NCT00432575|Placebo Comparator|1|
3160863|NCT00432575|Active Comparator|2|surinabant 2,5 mg/day
3160864|NCT00432575|Active Comparator|3|surinabant 5 mg/day
3160865|NCT00432575|Active Comparator|4|surinabant 10 mg/day
3160866|NCT00432614|Experimental|Group 1|SR58611A 350mg twice daily with escitalopram 10mg once daily
3160867|NCT00432614|Active Comparator|Group 2|placebo with escitalopram 10mg once daily
3160868|NCT00432614|Placebo Comparator|Group 3|placebo
2487826|NCT02983565|No Intervention|Sleep study on usual long-term oxygen therapy flow rate|Participants will have a sleep study on their usual LTOT flow rate.
2487829|NCT02983565|Experimental|Sleep study on the intelligent oxygen therapy system|Participants will have a sleep study on the intelligent oxygen therapy system. This system will supply variable flow oxygen to match a pre-set oxygen saturation target of 93% during sleep.
2487846|NCT02983188|Active Comparator|Berberine|Patients will receive berberine pills in additional to current atypical antipsychotic agents
2487847|NCT02983188|Placebo Comparator|Placebo|Patients will receive placebos pills in additional to current atypical antipsychotic agents
2487912|NCT02982980|Experimental|Physiotherapy Guidance Mastectomy|Patients who underwent radical breast surgery, received pre and postoperative assessment and orientation.
2487916|NCT02982980|Experimental|Phys Muscle strengthening Mastectomy|Patients who underwent radical breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
2487918|NCT02982980|Experimental|Physiotherapy Guidance Quadrantectomy|Patients who underwent partial breast surgery, received pre and postoperative assessment and orientation.
2487919|NCT02982980|Experimental|Phys Muscle strengthening Quadrantectomy|Patients who underwent partial breast surgery, in addition to receiving guidance, had, weekly, physical therapy sessions with the goal to increase muscle strength in the upper limbs, between one and three months after surgery.
2487965|NCT02982551|Experimental|Hyperinsulinemic Clamp|Participants will complete two MRI scans approximately one hour apart - one under baseline conditions and the second during an insulin infusion. Each scan will include data collected during rest, and a taste task. The taste task involves receiving milkshake or a tasteless solution. After the first scan, an isoglycemic-hyperinsulinemic clamp will be implemented. An IV will be placed in the antecubital vein of of arm for infusion of insulin and dextrose. HumuLIN®-R regular insulin will be infused at 40 mU/m2/min. A second IV will be inserted in the back of the hand on the opposite arm to allow for frequent sampling of blood glucose levels. Dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline value. The study team will monitor blood glucose levels and adjust dextrose infusions as necessary. Thirty minutes after starting the insulin infusion, participants will be moved back into the bore of the MRI scanner for the repeat scans.
2488038|NCT02982226|Experimental|ReNu Injection|Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
2488044|NCT02982226|Active Comparator|Corticosteroid Injection|Plantar Fascia injection with Corticosteroids.
2488114|NCT02981641|Experimental|Intraoperative radiotherapy (IORT) Group|Radiotherapy (Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1) + Sequential chemotherapy
2488115|NCT02981641|Experimental|Concurrent Chemoradiotherapy (CCRT) Group|Three dimensional conformal radiation therapy (3D-CRT) (Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30) + Concurrent chemotherapy (Gemcitabine(GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d) + Sequential chemotherapy
2488163|NCT02981160|No Intervention|Standard Care Group|The participants assigned to this group will follow a standard weight loss program for 12-months. This patients will be instructed by the Weight loss program registered dietitian/diet tech in clinic in terms of nutrition regimen, daily intake and calories.Patients will be followed up monthly as per clinic protocol. All visits will include physical measurements including body mass index (BMI) based on height and weight, blood pressure, and body composition (fat percentage). Body composition will be assessed during clinic visits by bio-impedance. Waist circumference (cm) will be measured at the umbilicus.
2488165|NCT02981160|Experimental|Mobile Device Assistant Group|"This group will follow the same weight loss protocol, monitoring, and clinic visits as the standard weight loss group described above, but will also use the mobile health tool (Breezing) to track REE every visit. This data will be loaded onto an accompanying electronic pad using the Breezing app and will be transmitted electronically to the study investigators who will use the information to adjust dietary and physical activity recommendations and targets. The test will be performed at initial visit, 2 weeks, 1, 3, 6 and 12 months after started."
3194046|NCT00823940|Other|Cohort B1|Glucagon challenge test
3194047|NCT00823940|Active Comparator|Cohort B3|Glucagon challenge test + selected dose of GSK1362885
2488401|NCT02979704|Active Comparator|Rosuvastatin|Intervention: Tablet Rosuvastatin (5-10) mg orally once daily dose for 08 weeks.
2488402|NCT02979704|Active Comparator|Atorvastatin|Intervention: Tablet Atorvastatin (10-20) mg orally once daily dose for 08 weeks
2488464|NCT02979236||STEMI treated with STENTYS Xposition S|Patients 18 years of age and older presenting with symptoms consistent with a ST-Elevation Myocardial Infarction (STEMI) lasting ≤12 hrs in duration, with ≥2 mm of ST-segment elevation in ≥2 contiguous leads, treated with primary stent implantation (Xposition S planned per operator's assessment).
2488519|NCT02978755|Experimental|GM102 escalating doses|8 successive cohorts
2488526|NCT02978755|Experimental|GM102 escalating doses + carboplatin+paclitaxel|2 successive cohorts
2488529|NCT02978755|Experimental|GM102 recommended dose|3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers
2488553|NCT02978261|Experimental|PLB1001|There are 4 dose cohorts, including 50mg BID,100mg BID, 200mg BID and 300mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
2488607|NCT02978105|Experimental|Experimental|self-conditioning techniques plus standard care
2488609|NCT02978105|Active Comparator|Control|Standard care: dietary recommendations, exercise recommendations, and behavioral recommendations
2488718|NCT02977091||GH deficiency or idiopathic short stature|growth hormone (GH) deficiency or idiopathic short stature children before they start GH treatment
2488723|NCT02977091||short stature|healthy short children
2488772|NCT02976857|Experimental|C-CAR011|C-CAR011 infusion In the first cell therapy 0, 1 and 2 days, respectively 10%, 30% and 60% ratio three times reinfusion.
2488904|NCT02975921|Experimental|Benign Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2487850|NCT02983344|Active Comparator|fascia iliaca compartment block|Patient will receive 40ml of ropivacaine 0.375% at the fascia iliaca compartment under the guidance of ultrasound. It will be given 20 minutes before patient is positioned for spinal anaesthesia
2487852|NCT02983344|Active Comparator|intravenous fentanyl|Patient will receive 0.5 mcg/kg of intravenous fentanyl. It will be given 5 minutes before patient is positioned for spinal anaesthesia
3160869|NCT00432627|Experimental|Mild hepatic impaired|
3160870|NCT00432627|Experimental|Moderate hepatic impaired|
3160871|NCT00432627|Experimental|Severe hepatic impaired|
3160872|NCT00432627|Experimental|Healthy volunteers|Controlled group
2488166|NCT02981186|Experimental|IOL Implantation experimental|Implantation of POD F GF in one of the eyes of the study subject
2488167|NCT02981186|Active Comparator|IOL Implantation Comparator|Implantation of POD F in the contralateral eye of the study subject
3160873|NCT00432640|Experimental|1|Endoscopic ultrasound staging
3160874|NCT00432640|Active Comparator|2|Surgical staging
2488254|NCT02980484|Experimental|Active rTMS|Subjects will receive a full course of 20 rTMS treatments over 20 consecutive weekdays as described above.
2488256|NCT02980484|Sham Comparator|Sham/crossover rTMS|Rather than receiving active treatment, subjects will receive sham treatment designed to be indistinguishable from active treatment to the patient. After completion of the sham course, patients will have the option to receive open-label active treatment at no cost.
2488309|NCT02980263|Experimental|Kawasaki patients|
2488371|NCT02980016|Active Comparator|3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Year 1
2488377|NCT02980016|Active Comparator|p3HP (rifapentine + isoniazid)|Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), (with adjustment for participants weighing ≤50 kg) given for 12 weeks in Study Years 1 and 2
2488380|NCT02980016|Active Comparator|6H|Daily self-administered isoniazid (at a dose of 300 mg/daily) (with adjustment for participants weighing ≤24 kg) given for 26 weeks (6 months) in Study Year 1
2488436|NCT02979327|Experimental|Adderall first, then Placebo|Participants will receive an Adderall capsule at the first study visit, then a Placebo capsule at the second study visit.
2488437|NCT02979327|Experimental|Placebo first, then Adderall|Participants will receive a Placebo capsule at the first study visit, then an Adderall capsule at the second study visit.
2488444|NCT02979080|Experimental|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 120 days
2488522|NCT02978677|Experimental|Grade II tumors (macroscopic)|Radiotherapy 68 Gy(RBE)
2488527|NCT02978677|Experimental|Grade III tumors (macroscopic)|Radiotherapy 72 Gy(RBE)
2488530|NCT02978677|Active Comparator|Grade II/III tumors (completely resected)|Radiotherapy 60 Gy(RBE)
2488651|NCT02977793||Non-pathologic young adults|18-28 years old
2488652|NCT02977793||Non-pathologic adults|29-80 years old
2488653|NCT02977793||Pathologic adults|29-80 years old
2488692|NCT02977364|Experimental|HS-10241 100mg|HS-10241 100mg daily
2488695|NCT02977364|Experimental|HS-10241 200mg|HS-10241 200mg daily
2488697|NCT02977364|Experimental|HS-10241 400mg|HS-10241 400mg daily
2488699|NCT02977364|Experimental|HS-10241 600mg|HS-10241 600mg daily
2488701|NCT02977364|Experimental|HS-10241 800mg|HS-10241 800mg daily
2488702|NCT02977364|Experimental|HS-10241 1000mg|HS-10241 1000mg daily
2488828|NCT02976961|Experimental|Intervention|Implantable cardioverter defibrillator implant + usual care + supportive care given via an e-health platform. The supportive care consists of information, dialogue with a nurse or psychologist, CBT-based psychological intervention online, quizzes to increase knowledge
2488845|NCT02976961|No Intervention|Usual care|Implantable cardioverter defibrillator implant + usual care
2488884|NCT02975921|No Intervention|Malignant Effusion - Usual Care|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2488892|NCT02975921|Experimental|Malignant Effusion with Pleurodesis|Patients who had a pleural effusion secondary to a malignant etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had intrapleural Povidone-Iodine administered at time of placement (100mL of 2% solution). They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2488896|NCT02975921|No Intervention|Benign Effusion - Usual Care|Patients who had a pleural effusion secondary to a benign etiology and subsequently underwent tunneled pleural catheter (TPC) placement and had usual care during and afterwards. Usual care is the TPC only with no intrapleural medications. They would have nursing care in the recovery area afterwards and home nursing three times weekly.
2488929|NCT02975453||Rivaroxaban|Non-valvular atrial fibrillation (NVAF) patients treated with rivaroxaban for at least 6 months prior to the study inclusion
3160875|NCT00432796|Active Comparator|1|"patients are randomized post-operative to receive either active treatment or placebo.~Active treatment is Dalteparin injectable. Patients randomized to active treatment will receive Dalteparin 5,000 iu or 200 iu/kg once daily depending on the type of surgery they have had."
3160876|NCT00432796|Experimental|2|patients will be randomized post-operative to receive either active treatment or placebo
3160877|NCT00432861|Active Comparator|1|Pancrecarb(R) MS-16 Capsules
3160878|NCT00432861|Placebo Comparator|2|
3160879|NCT00432874|Experimental|1|"Anterior stromal hydration (Wong method)"
3160880|NCT00432874|Active Comparator|2|Traditional lateral wound hydration
3160881|NCT00432900|Active Comparator|Healthy Volunteer|Healthy Volunteers
3160882|NCT00432900|Experimental|Patient|Multiple Sclerosis Patients
3160883|NCT00432913|Active Comparator|1g EPA per day|
3160884|NCT00432913|Active Comparator|2g EPA per day|
3160885|NCT00432913|Placebo Comparator|Placebo|
2487854|NCT02983240|Experimental|60 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 20-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2487856|NCT02983240|Experimental|80 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 40-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2487862|NCT02983240|Experimental|120 Minute Study|After a 20-minute pre-intervention control period the electrical inhibition will be used intermittently, only when there is monitored contraction, during the 80-minute intervention study period. At the end of the intervention period there will be a 20-minute post-intervention control period. The FHR patterns, tocogram, EMG and EHG, and fECG recordings will be compared to before and after the use of the electrical uterine pacemaker device.
2487908|NCT02982902|Experimental|CMV specific adoptive t-cells|This study involves a one-time infusion of the experimental CMV specific adoptive t-cells. After this infusion, patients will be followed for 4 weeks.
2487961|NCT02982603|Experimental|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761 .Qinggongshoutao bolus 70 pills every time (7g), 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
2487962|NCT02982603|Active Comparator|Ginkgo Biloba Extract 761|Ginkgo Biloba Extract 761 and placebo identified to Qinggongshoutao bolus.The subjects will take Ginkgo Biloba Extract 761 2 times per day, 2 pills per time(80mg) ,and identified to Qinggongshoutao bolus 70 pills every time, 2 times per day for 48 weeks.
2487963|NCT02982603|Placebo Comparator|Placebos|Placebo identified to Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761.Placebo identified to Qinggongshoutao bolus 70 pills every time, 2 times per day and placebo identified to Ginkgo Biloba Extract 761, 2 pills per time, 2 times per day for 48 weeks.
2488027|NCT02982291|Active Comparator|Standard|
2488033|NCT02982291|Experimental|Individualized|
2488076|NCT02981784||Ponatinib (PACE trial)|"PACE trial : Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL), NCT01207440"
2488077|NCT02981784||Allogenis stem cell transplantation (EBMT registry)|EBMT : European Group for Blood and Marrow Transplantation
3194048|NCT00823953|Placebo Comparator|Placebo|placebo powder (wheat flour) The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
2488176|NCT02980991|Experimental|Neoadjuvant chemotherapy group|Two cycles of pemetrexed and cisplatin given to patients before surgery
2488228|NCT02980770||Obstructive Sleep Apnea (OSA)|Patients with OSA
2488231|NCT02980770||Obesity-Hypoventilation Syndrome (OHS)|Patients with OHS
2488233|NCT02980770||Normal Blood Gases|Normal Blood Gases
2488264|NCT02980575|Experimental|Exercise with music|Participants will listen to music when they exercise
2488269|NCT02980575|Active Comparator|Exercise|Participants will not listen to music when they exercise
2488300|NCT02980198|Experimental|IFN-Kinoid|IFN-Kinoid + ISA 51
2488302|NCT02980198|Placebo Comparator|Placebo|Placebo + ISA 51
3194049|NCT00823953|Active Comparator|Momordica charantia|"Thirty patients will be assigned to each arm in a double blind manner. The active arm will be administered capsules containing a total of 500 mg of Momordica charantia freeze dried powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.~The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3."
3194050|NCT00823992|Placebo Comparator|placebo|
2488432|NCT02979275||BRAIN+THENAR MUSCLE INVOS|Patients undergoing open heart surgery on cardiopulmonary bypass.
2488456|NCT02979106|Experimental|oral fructose load|test meal calculated to provide 25% of basal energy requirement containing 13C-labeled fructose (0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg).
2488521|NCT02978950|Experimental|Surveillance arm|Bilateral duplex ultrasound surveillance
2488525|NCT02978950|Active Comparator|No surveillance arm|no duplex ultrasound surveillance
2488560|NCT02978391|Experimental|EWD|Adhesive, synthetic biopolymer powder
2488568|NCT02978391|Active Comparator|epinephrine|Submucosal epinephrine injection
2488617|NCT02978027|Active Comparator|Brief Advice|The brief advice protocol was designed by removing MI-consistent elements from the NIAAA Clinician's Guide. The protocol involves screening and assessment using the NIAAA pre-screen and single-question screen and assessing for quantity and frequency. Patients exceeding recommended limits receive feedback, information, and advice to cut down drinking to recommended levels. All patients are provided with a tip sheet on strategies for cutting down and encouraged to follow-up with a behavioral health provider with any questions or concerns.
2488621|NCT02978027|Active Comparator|NIAAA Clinician's Guide|"The NIAAA brief intervention was adapted directly from the NIAAA publication Helping Patients Who Drink Too Much: A Clinician's Guide. The protocol screens using the NIAAA pre-screen and single-questions. Patients exceeding recommended limits receive feedback, information, and advice to cut down. For patients unwilling to make a change, the clinician restates their concern, encourages self reflection by asking the patient about reasons to cut down on drinking and barriers to change, and reaffirms willingness to help. For patients willing to make a change, the clinician helps the patient develop a plan to cut down within maximum limits, agree on specific steps and strategies, and provides a tip sheet on strategies for cutting down."
2488642|NCT02977780|Active Comparator|Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Temozolomide will also be administered post radiation for up to 6 cycles (5 days/cycle)"
2488644|NCT02977780|Experimental|Neratinib with Temozolomide|"Daily Radiation for a maximum of 49 days.~Temozolomide will be administered orally on a daily dosing schedule~Temozolomide will be administered approximately 2-3 hours before each session of radiotherapy~Neratinib will be taken post radiation at a daily oral pre-determine dose"
3194051|NCT00823992|Experimental|taspoglutide|
3194052|NCT00824057|Experimental|1|
2488071|NCT02981836|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine;"
2488072|NCT02981836|Sham Comparator|Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine;"
2488116|NCT02981537|Experimental|two-staged|positioning endobronchial blockers to appropriate bronchus with two-staged methods
2488117|NCT02981537|Active Comparator|single-staged|positioning endobronchial blockers with traditional single-staged methods
2488223|NCT02980965|Experimental|neoadjuvant chemo-endocrine therapy|In the experimental arm, patients received concurrent chemotherapy (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles) with endocrine therapy (letrozole with or without leuprorelin) as a neoadjuvant treatment
2488227|NCT02980965|Active Comparator|neoadjuvant chemotherapy alone|In the control group, patients received neoadjuvant chemotherapy alone (fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles)
2488303|NCT02980302|Other|Patient|
2488304|NCT02980302|Other|Asymptomatic carrier|Father of the patient : asymptomatic carrier of the same mutation
2488305|NCT02980302|Other|Two control patients|
2488351|NCT02980003|Active Comparator|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The infusion rate will be 1 mL/kg/h in the first 5 hours they will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or New York Heart Association (NYHA) functional class III or IV). Then, will be infused at 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h
2488352|NCT02980003|Active Comparator|i.v. sodium bicarbonate|in the first 5 hours patients will receive isotonic saline at 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV). Then, a solution of 1.4% sodium bicarbonate (167 mEq/L; 334 milliosmol (mOsm/L)) will be infused: the initial intravenous bolus will be 3 mL/kg/h for 1 hour immediately before contrast medium injection; following this, patients will receive the same fluid at a rate of 1 mL/kg/h (reduced to 0.5 mL/kg/h if with ejection fraction <35% or NYHA functional class III or IV) during the exposure to contrast and for 6 hours after the procedure. Later, patients will resume hydration with isotonic saline for further 6 hours.
2488356|NCT02980003|Experimental|oral sodium bicarbonate:|"patients will start hydration with isotonic saline as well as Arm Hydration Alone. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water. The drug will be weighed with a precision balance with a sensitivity of ± 0.1 mg and placed in a labeled sterile plastic container. The label will report the lot number, expiry date of the sodium bicarbonate lot, the signature of the pharmacist carrying out the weighing process, a serial number to identify the sample and the patient identification number.~Documentation will be stored in the Laboratory of Galenic Preparations, Pharmacy Division, of the hospital."
3194053|NCT00824083||1|sarcoma survivors
3194054|NCT00824083||2|healthy subjects
2488507|NCT02978911|Experimental|Skull base tumors|Patients who presented a skull base tumor that requires a surgical removal
2488571|NCT02978547|Experimental|Metformin|All patients will receive metformin 500 mg per oral twice daily with food for at least 7 days, until 2 days prior to surgery. Metformin therapy should be discontinued 2 days before surgery to reduce the risk of lactic acidosis associated with fasting.
2488639|NCT02978079|Experimental|Pupillometry in stroke patients|All eligible patients will undergo pupillometry test for the finding of Horner's syndrome
2488656|NCT02977520|Experimental|Interventional group|Obtain the CTA data of cerebral aneurysms and built the 3D printing models. Combined with the 3D model, the neurosurgeon can complete the discussion of preoperative prediction of aneurysms and recognize the adjacent bone, blood vessels, aneurysm directions and so on. In addition, the model can also be used to the young doctor's training, and the patient and their families can be convenient and intuitive understanding of the disease, so as to form a good communication between doctors and patients.
2488657|NCT02977520|No Intervention|general group|Obtain the CTA data of cerebral aneurysms, the neurosurgeon complete the discussion of preoperative prediction of aneurysms.
2488760|NCT02976805|Experimental|Regimen A|4L PegLyte + 15 mg bisacodyl
2488761|NCT02976805|Experimental|Regimen B|6L PegLyte + 15 mg bisacodyl
2488777|NCT02976571|Experimental|Sub cutaneous+Intraperitoneal|Sub cutaneous Bupivacaine+ Intraperitoneal bupivacaine
2488780|NCT02976571|Active Comparator|Sub cutaneous+Placebo|Sub cutaneous Bupivacaine+ Intraperitoneal Nacl 0.9%
3194055|NCT00824109|Other|Single Arm Study|Consecutive patients meeting the selection criteria
3194056|NCT00824122||1|Children greater than 6 months receiving at least one dose of Vancomycin and Red Man Syndrome
3194057|NCT00824122||2|Children greater than 6 months receiving at least one dose of Vancomycin and has not had Red Man Syndrome
3194058|NCT00824135|Experimental|1|
3194059|NCT00824148|Experimental|Real-time glucose monitoring|Use of Guardian REAL-Time Continuous Glucose Monitoring System, (Medtronic Minimed, Northridge, CA) for 1 month, followed by observation for 2 months.
3194060|NCT00824148|Active Comparator|Self-monitoring of plasma glucose|Conventional self-monitoring of plasma glucose by finger-prick sampling for 1 month, followed by 1 month observation.
3194061|NCT00824174||Questionnaire|1 questionnaire, about 15-20 minutes.
3194062|NCT00824187|Experimental|Arm 1|
3194063|NCT00824187|Placebo Comparator|Arm 2|
3208682|NCT00977223|Placebo Comparator|placebo|7 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
2487948|NCT02982850|Experimental|Dabigatran|Previous treatment of aspirin or warfarin will be changed to dabigatran treatment in patients allocated to dabigatran group.
2487953|NCT02982850|Active Comparator|Conventional Treatment|Acetylsalicylic acid or warfarin treatment will be continued in patients allocated to conventional treatment group.
2488024|NCT02982330|Experimental|Low Carbohydrate Breakfast|Breakfast composition containing <10% carbohydrate, 75% fat, 15% protein Matched calories
2488025|NCT02982330|Active Comparator|Guidelines Breakfast|Breakfast composition containing 55% carbohydrate, 30% fat, 15% protein Matched calories
2488070|NCT02981810|Active Comparator|control|tonsillectomy
2488073|NCT02981810|Experimental|coblation|coblation of the tonsills
2488147|NCT02981212|Experimental|Mycophenolate Mofetil|MYREPT® capsule(CKDpharm, KOREA) and corticosteroid
2488150|NCT02981212|Active Comparator|Conservative treatment|maintain conservative treatment (ACE inhibitor or ARB)
3160886|NCT00432926|Experimental|1|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
3194064|NCT00824200|Experimental|Behavioral and Exercise Therapy (M-BET)|Multicomponent behavior and exercise therapy program (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema. M-BET alone will be given with placebo capsules.
3194065|NCT00824200|Active Comparator|Drug Therapy w/ Behavioral Placebo|alpha-adrenergic antagonist medication with a placebo behavioral intervention
2488267|NCT02980510|Experimental|A=Experimental group|FOLFIRINOX + Panitumumab oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² given as a 2-hour intravenous (IV) infusion with the addition, after 30 minutes of irinotecan 150 mg/m² given as a 90-minute intravenous infusion through a Y-connector immediately followed by fluorouracil 400 mg/m² IV bolus then 5-fluoruracil (5-FU) 2400 mg/m² over 46 hours continuous infusion.
2488273|NCT02980510|Active Comparator|B=Control group|mFOLFOX6 + Panitumumab mFOLFOX6 every 2 weeks: oxaliplatin 85 mg/m² IV infusion over 2 hours immediately followed by folinic acid 400 mg/m² IV infusion over 2 hours followed by fluorouracil 400 mg/m² IV bolus then 5-FU 2400 mg/m² over 46 hours continuous infusion.
2488323|NCT02980146||"Group patients with colorectal cancer"|Major patients treated surgically for colorectal cancer at Nantes University Hospital or at the Institut de Cancerologie de l'Ouest and agreeing to participate in the study
2488491|NCT02979132|Active Comparator|Oral Iron Supplementation|Eisensulfat LOMAPHARM 50 mg administration for 90 days
2488492|NCT02979132|Active Comparator|Intravenous Iron Supplementation|Single-dose Ferinject(R) administration
2488493|NCT02979132|Active Comparator|Food Fortification with Iron|Consumption of iron-fortified biscuits (15 mg Fe in form of FeSO4) for 90 d
2488534|NCT02978638|Other|Finetech Vocare Bladder System|This is a pilot study of the Finetech Vocare Bladder System to improve continence and voiding in human subjects with chronic spinal cord injury. Each subject will act as their own control, comparing function with the Finetech Vocare Bladder System in use and not in use.
2488557|NCT02978287|No Intervention|BAVU Solution 0. hour (control)|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 0. hour
2488564|NCT02978287|Experimental|BAVU Solution 6. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 6. hour
2488569|NCT02978287|Experimental|BAVU Solution 12. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 12. hour
2488575|NCT02978287|Experimental|BAVU Solution 18. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 18. hour
2488579|NCT02978287|Experimental|BAVU Solution 24. hour|Viability, Calcium sensing receptor and parathormone levels of Parathyroid cells at 24. hour
2488619|NCT02977975|Experimental|Raw sauerkraut|75 grams of raw, traditionally produced, lacto-fermented sauerkraut, each day for 6 weeks.
2488624|NCT02977975|Other|Pasteurized sauerkraut|75 grams of pasteurized sauerkraut, each day for 6 weeks.
2488671|NCT02977624|Experimental|Hadassah Medical Organization, Jerusalem, Israel|
2488716|NCT02977195|Experimental|NP137|Therapeutic Class Recombinant humanized IgG1 monoclonal antibody against Netrin 1, Administered. Route of Administration is intravenous infusion over 180 min, given every 2 week at 14 mg/kg.
2488769|NCT02976844||Low PEEP group|The positive end-expiratory pressure was less than 10cmH2O
2488771|NCT02976844||High PEEP group|The positive end-expiratory pressure was higher or equal to 10cmH2O.
2488831|NCT02976467|Experimental|Fulacimstat (BAY1142524)|30 patients with left-ventricular dysfunction after acute myocardial infarction
2488843|NCT02976467|Placebo Comparator|Placebo|30 patients with left-ventricular dysfunction after acute myocardial infarction
2488867|NCT02975726|Experimental|Peritoneal Dialysis Catheter Insertion|Catheters will be inserted at the bedside in a special procedure room.Argyle PD catheter kits will be used:2 cuffed curled catheters at 57cm or 62cm lengths. At time of PD catheter insertion,most patients will be drained of 5-10L of ascites or more to decrease the chance of catheter leaks.The volume removed will be at sole discretion of physician doing the procedure.Patients will be administered 25% Human Serum Albumin injection: 100cc after the 5-10L drainage,and 200cc if 10-15L is removed.Patients will undergo an initial drain and training with a specialized nurse.Patients in this arm will be instructed to drain a maximum of 2L per day after the initial drain.Monthly bloodwork will be performed.
2488872|NCT02975726|Active Comparator|Large Volume Paracentesis|Patients in this arm of the study will continue their usual practice of LVP as required. They will continue to undergo their LVP procedures through their regular means.Monthly bloodwork will be performed.
2488930|NCT02975440|Experimental|Treatment|Treatment A (Period 1): a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam Treatment B (Period 2): 600 mg Rifampicin once daily (qd) for 7 days followed by administration of a single oral dose of 4 mg Vilaprisan and 1 mg Midazolam followed by 600 mg Rifampicin 12 hours after Vilaprisan and Midazolam administration and continued dosing of 600 mg Rifampicin once daily for 3 days
2489086|NCT02974907|Experimental|RGN-259|RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2489088|NCT02974907|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
2489138|NCT02974374|Experimental|PF-06835919|
2488000|NCT02982135|Other|group 2 indirect bypass|indirect bypass: patients recieve indirect bypass treatment
2488028|NCT02982005|Experimental|KHK4827|KHK4827 administered SC
2488032|NCT02982005|Placebo Comparator|Placebo|Placebo administered SC
2488105|NCT02981758||Data Collection Phase 1|All women who had vaginal deliveries between 2010 and 2015 who had a procedure code indicative of transfusion (99.0x) or received a diagnosis suggestive of peripartum hemorrhage (e.g. diagnosis x code 666.xx, 641.x, 645.x, 646.x 674.x).
2488109|NCT02981758||Data Collection Phase 2|All women who delivered (vaginally) at HackensackUMC who had blood loss and measured quantitatively by Triton and qualitatively (i.e., EBL) by obstetrician.
3194066|NCT00824200|Active Comparator|Combination Therapy|Combination therapy: MBET and alpha-adrenergic antagonist medication
2488427|NCT02979392|Experimental|Phase I|Part A, Dose escalation TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (Phase I starting dose 75 mg/m2) Part B, Expansion TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) IV once every 3 weeks (RP2D dose determined in part A)
2488458|NCT02979145||Patients with CMT|Two groups of patients will be included: Group 1 (Definitive): Children with known CMT where genetic testing confirms the diagnosis, or children with a clinical diagnosis including electrophysiology confirming the presence of CMT and a corresponding family history where a first or second degree relative has a genetic diagnosis; or Group 2 (At risk): A clinical diagnosis of CMT awaiting genetic testing or confirmatory electrophysiology and evidence of a genetic diagnosis in a first or second degree relative; or individuals identified as being at risk of a CMT diagnosis (prodromal patients), without the onset of signs or symptoms.
2488461|NCT02979145||Controls|Healthy controls will be included from unaffected family members or friends accompanying patients at INC sites. Healthy controls are defined as boys and girls aged 0-≤4 years without a diagnosis of CMT or any of the other study exclusion criteria.
2488510|NCT02978846||Observational (side effects evaluation using cards)|Patients are shown two groups of cards on the last day of radiation treatment. Group A lists 48 physical side effects and group B lists 27 psychosocial side effects. The cards are shuffled and patients view one card at a time and select the side effects they attribute to their current treatment. Patients rank the selected cards from each group by order of severity. The top 5 cards from each group are then shuffled together and patients rank the remaining 10 cards in order of severity.
2488583|NCT02978534||Quetiapine|Patients taking quetiapine during pregnancy are eligible to participate in the study. Their dose and plasma concentration levels of quetiapine will be monitored throughout pregnancy and up to three months postpartum.
2488643|NCT02978014|Experimental|ProSpare Arm|ProSpare (obturator) image guided IMRT (i.e. radiotherapy administered to patients with the ProSpare device inserted in the rectum)
2488645|NCT02978014|No Intervention|Non-ProSpare Arm|Standard of Care (non-obturator) image guided IMRT (i.e. radiotherapy administered to patients without the ProSpare device inserted in the rectum)
3160887|NCT00432926|Experimental|2|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
3160888|NCT00432926|Active Comparator|3|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
3160889|NCT00433043|Active Comparator|1|CRT and b-blocker uptitration to target dose
3160890|NCT00433043|Active Comparator|2|CRT and continuation of entry b-blocker dose to 6 month evaluation
2488749|NCT02977039|Experimental|NDPR diet|Subjects randomized to the nutrient dense plant rich (NDPR) diet will eat foods with high micronutrient density, and favorable glycemic index. The diet is low in saturated fat, high in fiber, and rich in phytochemicals. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include vegetables (30-70% of calories), fruits (15-20% of calories), Beans/Legumes (20-30% of calories), raw nuts and seeds (10-20% of calories), fish or fat-free dairy (twice weekly or less), poultry, eggs and oils (once weekly or less) and limited beef, cheese/milk, processed food and beef.
2488752|NCT02977039|Experimental|USDA diet|Subjects randomized to the healthy U.S.-Style pattern diet will eat the types and proportions of foods Americans typically consume, but in nutrient-dense forms and appropriate amounts. It is designed to meet nutrient needs while not exceeding calorie requirements and while staying within limits for overconsumed dietary components. Total caloric intake will range from 1600-2000/day based on individual needs. Foods include fruits, vegetables (dark green, red/orange, beans, and peas, starchy vegetables), grains (whole grains and refined grains), protein foods (meat, poultry, eggs, seafood, nuts, seeds and soy products), dairy, and oils.
2488774|NCT02976701|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
2488775|NCT02976701|Placebo Comparator|Placebo|Placebo is administered two tablets three times daily, everyday for four weeks of study period
2488835|NCT02976337|Experimental|High-dose naloxone|Naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration)
2488846|NCT02976337|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
2488866|NCT02975856|Experimental|Table Red Wine|250 ml Table Red Wine (12% ethanol)
2488870|NCT02975856|Experimental|Young Port Red Wine|150 ml Young Port Red Wine (20% ethanol)
2488949|NCT02975648|Active Comparator|Usual Care|At discharge, paticipants received guidance from health professionals. The paticipants had a medical return five to seven months after the percutaneous coronary intervention.
2488951|NCT02975648|Experimental|Educational model + follow up|The paticipants received the hospital's instructions at discharge and participated in the educational program (booklets with telephone follow-up). The paticipants had a medical return five to seven months after discharge
3160891|NCT00433056|Experimental|1|STI
3160892|NCT00433056|Active Comparator|2|stable HAART, Any registered regimen containing NRTIs (AZT or D4T or 3TC or TDF or DDI), NNRTIs (EFV or NVP) or PIs (RTV-boosted ATV; IDV; LPV, fosAPV, SQV; unboosted ATV or NFV)is allowed according to international guidelines
2488017|NCT02982096|Other|Standard of Care|Standard of Care: Acellular wound management
2488086|NCT02981875|Experimental|experimental|oculomotor training
2488090|NCT02981875|Placebo Comparator|control|placebo vision training exercises
2488149|NCT02981420|No Intervention|Pre-intervention|Pre-intervention baseline comparison
2488152|NCT02981420|Experimental|Safety Planning|Intervention group
2488154|NCT02981420|No Intervention|Regression discontinuity|Subthreshold no intervention
2488177|NCT02981017|No Intervention|Control|Subjects within the control arm will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, no Cook Biodesign Porcine intestinal submucosal graft will be used to cover the operative site. Light nasal packing will be placed in the nasal cavity for hemostasis. No placebo will be utilized.
2488180|NCT02981017|Experimental|Cook Biodesign|Subjects within the experimental group will undergo the Draf III/Endoscopic Modified Lothrop procedure to address their sinus disease. At the end of the procedure, a small piece of Cook Biodesign porcine intestinal submucosal xenograft will be used to cover the exposed bone of the operative site along the frontal beak. It will be bolstered with light nasal packing to keep the graft in place during healing.
2488230|NCT02980796|Experimental|Exercise + practice|Individuals will complete 20 minutes of exercise on a recumbent bicycle before practicing a novel motor task.
2488232|NCT02980796|Active Comparator|Rest + practice|Individuals will rest for 20 minutes before practicing a novel motor task. Attention will be controlled during this time.
3194067|NCT00824239|Active Comparator|1. Intermittent sedation|
3194068|NCT00824239|Active Comparator|2. Daily interruption of sedation|
3194069|NCT00824252||Spousal Support|Questionnaire for Head and Neck Cancer Patients + Spouses
3194070|NCT00824304||Fe, Zn, Fe+Zn, Placebo|placebo comparator
3194071|NCT00824317|Placebo Comparator|1|Placebo
2488370|NCT02979782||Endo-CABG, surgical group|the minimal invasive cardiac surgery group
2488375|NCT02979782||PCI, comparative surgical group|a comparative minimal invasive procedure
2488379|NCT02979782||Healthy volunteer, control group|to exclude any learning effect or natural variation in neurological testing
2488417|NCT02979483|Other|Integrative Supportive Care|All planed procedures established during the first consultation with the investigator is successfully completed within the 14-day (+/-2 days)
2488488|NCT02979119||Cohort I|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2000 until January 1st 2009 who have been or are to be treated with coagulation proteins in one of the participating centres
2488489|NCT02979119||Cohort II|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2009 until January 1st 2020 who have been or are to be treated with coagulation proteins in one of the participating centres
2488490|NCT02979119||Cohort III|Children with mild ( FVIII/IX 6 to 25%), moderate (FVIII/IX 1 to 5%) or severe (FVIII/IX <1%) haemophilia A or B, born from January 1st 2020 until January 1st 2030 who have been or are to be treated with coagulation proteins in one of the participating centres
2488559|NCT02978313|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
2488566|NCT02978313|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
2488608|NCT02977988|Experimental|Mindfulness Meditation|Mindfulness-Based Relapse Prevention-Women (MBRP-W)
2488610|NCT02977988|Active Comparator|Active Comparator|Brain and Recovery (B&R)
2488664|NCT02977715|Experimental|Intervention|Up to 1600 male and female healthcare personnel ages 18 years and older in Tshuapa Province in The Democratic Republic of Congo at risk for monkeypox will receive two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation [n=1000 subjects] or lyophilized formulation [n=600 subjects]) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
2488712|NCT02977182|No Intervention|Control Group|The control group will receive standard speech therapy treatments but not lymphedema treatment and will serve as the baseline for comparison for assessment of the effects of CDT.
2488717|NCT02977182|Experimental|Active Treatment Group|The active treatment group will receive standard speech therapy treatments in addition to complete decongestive therapy from a certified Speech Language Pathologist (CCC-SLP) trained in CDT.
2488762|NCT02976909|Experimental|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
2488807|NCT02976545|Other|PNES|Psychogenic Non-epileptic Seizures subjects
2488811|NCT02976545|Other|PTSD|Post Traumatic Stress Disorder
2488812|NCT02976545|Other|Healthy controls|Healthy controls
2488842|NCT02976168|No Intervention|Horizontal|Subjects will be in horizontal supine Position for 21 hours
3194072|NCT00824317|Experimental|2|methylphenidate
3194073|NCT00824330|Other|Control Phase; Exercise Phase|"Participants act as their own control.~Control Phase:~Participants will not change their activity during the 3 month control phase (defined as no strength training and less than 30 minutes brisk walking/moderate exercise per week, no vigorous exercise) Baseline measures will be obtained.~Exercise Phase:~This phase will consist of a Titration phase followed by an Intervention Phase. During the Titration phase, under the guidance of a trainer, subjects will increase their number of steps by 20% per week until they have reached 10,000 steps or 3 months have passed. During the Intervention Phase subjects will continue to walk 10,000 steps (or the number of steps they reached in the Titration phase)."
3194074|NCT00824343|Experimental|Single P276-00 arm|This is a single experimental arm study
3194075|NCT00824356|Active Comparator|GSK1004726 (1000mg)|1000mg aqueous suspension
3194076|NCT00824356|Placebo Comparator|Placebo|Intranasal spray
3194077|NCT00824356|Active Comparator|GSK1004723 (200mg)|200 mg aqueous suspension
3194078|NCT00824395||1|Individuals with diabetes
3194079|NCT00824395||2|Individuals without diabetes
3194080|NCT00824447|Placebo Comparator|Placebo control|Placebo control
3194081|NCT00824447|Active Comparator|Grass pollen extract, twice weekly|Grass pollen extract, 9,500 BU, given twice weekly
3194082|NCT00824447|Active Comparator|Grass pollen extract daily|Grass pollen extract, 9,500 BU, given daily
2488018|NCT02982161|Active Comparator|MR308 200 mg bid|Tramadol/Celecoxib 200 mg
2488020|NCT02982161|Active Comparator|Tramadol 100 mg qid|Tramadol IR 100 mg
2488022|NCT02982161|Placebo Comparator|Placebo|Placebo to match MR308 and Tramadol IR
2488107|NCT02981719|Experimental|simultaneous gemcitabine and irreversible electroporation|gemcitabine intravenous infusion prior to irreversible electroporation treatment.
2488112|NCT02981719|Other|IRE group|percutaneous irreversible electroporation for locally advanced pancreatic cancer.
2488156|NCT02981264|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
2488157|NCT02981264|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
2488215|NCT02980952|Placebo Comparator|Energy-balanced diet|Forearm immobilization whilst consuming an energy-balanced diet
2488220|NCT02980952|Experimental|High-fat overfeeding|Forearm immobilization whilst consuming a high-fat diet, 50% energy excess
3194083|NCT00824447|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen extract, 19,000 BU, given daily
3194084|NCT00824486|Active Comparator|TIPP|Injury prevention education using TIPP materials
2488386|NCT02979743|Placebo Comparator|Occupational therapy group|The children worked with an occupational therapist for 4 hours a day for 5 days per week (totaling 40 hours) and initially concentrated on unilateral activities with the hemiplegic hand,and added bilateral activities during the second week.
2488387|NCT02979743|Active Comparator|Occupational therapy puls acupuncture and massage methods|The patients receive occupational therapy puls acupuncture and massage methods.
3194085|NCT00824486|Experimental|Safe Home Model|Injury prevention education using safe home model
3194086|NCT00824499|Experimental|DPA|Regional complex intervention based on the Chronic Care Model
3194087|NCT00824499|No Intervention|VR|
2488469|NCT02979067|Active Comparator|High-flow 100% oxygen|Nasal oxygen flow
2488472|NCT02979067|Active Comparator|Low-flow 100% oxygen|Nasal oxygen flow
2488475|NCT02979067|Active Comparator|High-flow 30% oxygen|Nasal oxygen flow
2488504|NCT02978768|Experimental|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2488505|NCT02978768|Experimental|Cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2488506|NCT02978768|Experimental|Physico-Mental training|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
2488556|NCT02978482|Experimental|durvalumab|durvalumab alone
2488563|NCT02978482|Experimental|durvalumab+tremelimumab|durvalumab plus tremelimumab
2488655|NCT02977637|Experimental|Feraheme group|All patients enrolled in the study will receive Feraheme MRI/MRA to detect vascular malformations. Ferumoxytol in its standard concentration (510 mg in 17 cc) will be administered IV at 0.15-0.21 mg/kg prior to MRI/MRA.
2488733|NCT02977299|Experimental|Aripiprazole Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial and initiate adjunctive aripiprazole. The starting dose will be 5mg daily. The dose may be reduced to as low as 2mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial). The dose may be adjusted in 2 or 5mg increments. The minimum time per increment will be 7 days. The maximum dose will be set at 15mg daily. For patients who are not on potent cytochrome 2D6 inhibitors (such as paroxetine, fluoxetine, duloxetine) or on potent cytochrome 3A4 inhibitors (such as fluvoxamine and nefazodone) and who are able to tolerate 15mg daily, the maximum dose can be raised to 20mg daily for efficacy.
2488737|NCT02977299|Experimental|rTMS Augmentation|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics at their current dose throughout the 8-week trial. We will use clinical TMS stimulators with focal figure-of-eight coils. We will start by measuring the patient´s motor threshold (MT), which is a measure of cortical excitability used to standardize the intensity of stimulation across subjects.
2488738|NCT02977299|Experimental|Switching To Venlafaxine XR|Patients randomized to this treatment arm will be instructed to continue all permitted psychotropics throughout the 8-week trial, except for their antidepressant(s). They will be instructed to discontinue all antidepressants and initiate venlafaxine that day, as direct switch to serotonergic antidepressants is well tolerated and avoids loss of precious therapeutic time (Montgomery et al., 2014), including to switching to venlafaxine in STAR*D (Rush et al., 2006b). For patients who do not prefer a direct switch, or when clinically indicated otherwise in the opinion of the site investigator, a gradual tapering during the screening period will be permitted as long as a direct switch to venlafaxine is made on the baseline visit from the final antidepressant dose. The starting dose of venlafaxine will be 75mg daily. The dose may be reduced to as low as 37.5mg for tolerability issues (this will be the lowest dose permitted for continuation in the trial).
2488803|NCT02976532|Other|EMT Arm|The study is performed with a single arm, as the system is an additional tool for derotation measurement and the surgical procedure itself and its technique is not changed.
2488834|NCT02976194|Experimental|pro-re-nata|Ranibizumab 0.5mg is injected in to the vitreous cavity. An injection is given every 4 weeks three times, and then the patient will be followed up every 4 weeks. An addition injection is given as needed. Recurrence is defined as increase of exudative changes, or increase of 10% or more in central subfield macular thickness (CSMT) measured using optical coherence tomography. Aqueous humor is sampled from the anterior chamber before injection at baseline, 8 weeks and 20 weeks.
2488893|NCT02975999|Experimental|Vasopressin|Vasopressin at 0.4mU/kg/min
3194088|NCT00824551|Experimental|Hyperbaric Oxygen Therapy|2 HBOT treatments
3194089|NCT00824551|Active Comparator|2|Standard care and treatment
3194090|NCT00824577||250~300 patients|heart rate variability, heart function and Kt/V
3194091|NCT00824590|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined by creatinine clearance of less than 30 mL/min but not yet on dialysis
3208683|NCT00977236|Experimental|Orthokeratology lenses|Children wearing orthokeratology at night for partial correction and spectacles at daytime for residual refractive error will be study group
3208684|NCT00977236|Other|Single-vision spectacle lenses|Children wearing single-vision spectacles in the daytime for correcting the refractive error will serve as control group
2488075|NCT02981823|Experimental|hip replacement|The patients undergo total hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
2488118|NCT02981563|Experimental|Time Together|"Time Together as described under Interventions"
2488145|NCT02981199|Active Comparator|Micro-SCT|"patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.~microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles"
2488146|NCT02981199|Active Comparator|Auto-SCT|patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.
2488239|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula A|Single oral dose of one tablet containing 120 mg gliclazide
2488240|NCT02980757|Active Comparator|Gliclazide 120 mg MR Tablets Formula B|Single oral dose of one tablet containing 120 mg gliclazide
2488242|NCT02980757|Active Comparator|DIAMICRON MR® 60 mg x 2|Two x oral dose of one tablet containing 60 mg gliclazide
2488260|NCT02980419|Experimental|intervention arm|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
2488311|NCT02980250|Experimental|low dose|The premature infant in this group will be feed with 0.2mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2488314|NCT02980250|Experimental|normal dose|The premature infant in this group will be feed with 0.4mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2488315|NCT02980250|Experimental|over dose|The premature infant in this group will be feed with 0.6mg/kg/tds domperidone suspension(motilium;100ml)for 7 days and will be tested the residual percentage everyday.
2488316|NCT02980250|Placebo Comparator|placebo|The premature infant in this group will be feed with some vitamin which will dilute into the 5% glucose and have the same appearance and taste with the experimental team for 7 days and will be tested the residual percentage everyday.
2488348|NCT02979886|Experimental|triptorelin|GnRH-a will be given everyday to the patient undergoing IVF treatment from middle luteal phase to the day of HCG. After 14 days of injection, serum FSH/LH/E2 will be checked. Then ovarian stimulation will be started by giving daily subcutaneous injection of recombinant FSH 150~300 IU. An appropriate dose of HMG (75~150 IU) will be added when follicles are larger than 12~14mm in diameter. When one leading follicle is >18mm in diameter, or two follicles are >17mm in diameter, or three follicles are >16mm in diameter, final ovulation will be triggered by a single injection of HCG 4,000~10,000 IU or Ovidrel® 250μg (equivalent to HCG 6,500 IU)
2488416|NCT02979678|Experimental|Questionnaire|Breast cancer
2488452|NCT02979158|Experimental|CPB Low Dose|Conduct of cardiopulmonary bypass using a low heparin dose verified by the activated clotting time at 250 s
2488455|NCT02979158|Experimental|CPB High Dose|Conduct of cardiopulmonary bypass using a high heparin dose verified by the activated clotting time at 480 s
2488520|NCT02978937||Metabolically healthy and abnormal obese|Obese patients divided into two groups according to their metabolic profile (healthy vs unhealthy)
2488543|NCT02978456|Experimental|quantitative coronary angiography guided|
2488544|NCT02978456|Active Comparator|Intravascular ultrasound guided|
2488601|NCT02978209|No Intervention|Only moisturizer, no carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. One body half
2488603|NCT02978209|Active Comparator|Moisturizer + 7,5 % carbamide|20 patients with Ichthyosis Vulgaris at age 0-80 years old. Other body half
2488673|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|Thoracic Magnetic Resonance Imaging (MRI)
2488714|NCT02977117|Experimental|Dialysate magnesium 1.0 mmol/L|Increase dialysate magnesium from 0.5 mmol/L to 1.0 mmol/L.
2488719|NCT02977117|Active Comparator|Dialysate magnesium 0.5 mmol/L|Maintain dialysate magnesium at 0.5 mmol/L.
2488759|NCT02976870|Experimental|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
2488794|NCT02976623|Other|feedback group|"this group will receive the intervention metric-based feedback training on their performance. this will be based on validated metrics and errors, a trained investigator will deliver this feedback. It will be accompanied by deliberate practice"
2488797|NCT02976623|No Intervention|control group|"this control group will receive a standard type feedback on their performance no intervention. It will be delivered by a consultant anaesthetist who will be instructed to deliver feedback as they ordinarily do during their clinical practice"
2488824|NCT02976324|Experimental|external diaphragmatic pacemaker group|use the external diaphragmatic pacemakerI 9 counts per minute, with stimulate frequency 40 Hz
2488840|NCT02976324|No Intervention|control group|No inervention, just receive conventional therapy
2488909|NCT02976064|Experimental|PreHab_Intervention|Experimental group of the prehabilitation trial
2488913|NCT02976064|No Intervention|PreHab_Control|Control group of the prehabilitation trial
2488915|NCT02976064|Experimental|Chronic patients_Intervention|Experimental group of the Rehabilitation in chronic stable patients in primary care trial
2488917|NCT02976064|No Intervention|Chronic patients_Control|Control group of the Rehabilitation in chronic stable patients in primary care trial
2488919|NCT02976064|Experimental|Citizens & mild disease_Intervention|Experimental group of the Rehabilitation in mild chronic patients and citizens at risk trial
2488920|NCT02976064|No Intervention|Citizens & mild disease_Control|Control group of the Rehabilitation in mild chronic patients and citizens at risk trial
3160893|NCT00433069|Experimental|Intervention|Pioglitazone 15 mg QD + pegylated interferon Alfa-2a 180 μg QW + ribavirin 1000-1200 mg QD for 12 weeks, to be continued to a total of 48 weeks in case of complete early virological response, defined as undetectable serum HCV RNA after 12 weeks of triple therapy
3160894|NCT00433121|Experimental|A|Discontinuation of neuroleptic or anti depressants
3160895|NCT00433173|Placebo Comparator|1|1) Group 1: Placebo
3160896|NCT00433173|Active Comparator|2|2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
3160897|NCT00433173|Active Comparator|3|3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
3160898|NCT00433186|Experimental|A|Mycophenolate
3160899|NCT00433212|Active Comparator|A|Non-invasive respiratory support via nasal intermittent positive pressure ventilation
3160900|NCT00433212|Active Comparator|B|Non-invasive respiratory support via nasal Continuous Positive Airway Pressure
3160901|NCT00433316|Experimental|study|Receiving 10ml of 1% ropivacaine
2488259|NCT02980406|Active Comparator|Fructans|Fructans (FODMAP) are oligosaccharides containing fructose chains. Since the human body lacks hydrolases to break down these saccharides, fructans are poorly absorbed molecules in everybody. The fructan solution used in this study has a concentration of 38g/L.
2488262|NCT02980406|Active Comparator|Fructose|Fructose can be found in the diet as free fructose, in sucrose or as polymer structure in fructans. Absorption varies and occurs more rapidly in the presence of glucose than for free fructose because glucose cotransport is involved in the uptake of fructose. Therefore, when fructose is in excess of glucose, it is regarded as a FODMAP. The fructose concentration used in this study is 100g/L.
2488266|NCT02980406|Active Comparator|FODMAP mix|The FODMAP mix consists of 20g fructans, 10g galacto-oligosaccharides (GOS), 30g fructose, 10g sorbitol and 10g mannitol in one liter of tap water.
2488271|NCT02980406|Placebo Comparator|Glucose|Glucose is a carbohydrate that is not classified as FODMAP, and is therefore used as a control in this study. The concentration of the glucose solution in this study is 100g/L.
2488307|NCT02980185||Laparoscopic primary cytoreduction|Patients in whom primary cytoreduction was performed using a laparoscopic approach
2488310|NCT02980185||Abdominal primary cytoreduction|Patients in whom primary cytoreduction was performed using an open abdominal approach
2488362|NCT02979990|Placebo Comparator|Control Video|Subjects will have access to general videos on the in vitro fertilization process. They will not have access to instructional videos related to the administration of controlled ovarian stimulation.
2488367|NCT02979990|Experimental|Experimental Video|Subjects will be asked to view instructional videos related to the administration of controlled ovarian stimulation medication during their own controlled ovarian stimulation
2488408|NCT02979548|Experimental|Group A : Aprepitant (Add on therapy)|Aprepitant group will receive aprepitant capsules 1 h prior to chemotherapy on days 1-3 in addition to 5HT3 RA (Ondansetron). The dose of aprepitant will be given based on weight groups Weight 15-40 kg : Aprepitant 80 mg on days 1-3 Weight > 41kg: Aprepitant 125 mg on day 1 followed by 80 mg on days 2-3 Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
2488412|NCT02979548|Active Comparator|Group B : 5HT3 RA (Ondansetron)|"On the day of chemotherapy, ondansetron will be administered to all patients as per our institutional practice in a dose of 0.15 mg/kg as an intravenous bolus 30 minutes before chemotherapy followed by every 8 hourly for 8 days.~Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day."
2488446|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
2488486|NCT02978976|Experimental|betamethasone|will receive two doses of 12mg betamethasone, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug (betamethasone), 24 hours after the last dose, and on the day of elective Cs.
2488487|NCT02978976|Placebo Comparator|Saline|will receive saline injection placebo, then the pulsatility index (PI), resistance index (RI), systolic/diastolic ratio (SD), and the acceleration-time/ejection-time ratio (At/Et) will be determined in all cases after recruitment, just before the administration of the drug ( placebo), 24 hours after the last dose, and on the day of elective Cs.
2488496|NCT02978664|Active Comparator|Air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
2488497|NCT02978664|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
2488498|NCT02978664|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
2488540|NCT02978586||[Ga-68]PSMA PET/MR|Up to 3 experimental PET/MRI scans will be performed to determine the level of [Ga-68]PSMA tumor uptake
2488551|NCT02978274||experimental group|MMF withdrawal by engraftment post haplo-SCT
2488552|NCT02978274||control group|MMF withdrawal by 2 month post haplo-SCT
2488599|NCT02978144|Other|Healthy volunteers|Healthy controls who never smoked (less than 100 lifetime cigarettes) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2488600|NCT02978144|Other|Current smokers|Healthy controls who are currently smoking (> 10 pack years) with normal spirometry will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2488602|NCT02978144|Other|Patients with moderate COPD|Patients with moderate COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2488604|NCT02978144|Other|Patients with severe COPD|Patients with severe COPD will be injected with AxV-128 labeled with 99mTc followed by SPECT-CT (AxV-128/Tc SPECT-CT imaging).
2488662|NCT02977416|Experimental|patients treated withTNF blockade|22 patients treated with TNF blockade
3160902|NCT00433316|Placebo Comparator|Control|Receiving 10ml of saline
3160903|NCT00433342|Experimental|I|Flucloxacillin
3160904|NCT00433342|No Intervention|II|
3160905|NCT00433394|Experimental|Stratum 1: No Consent for personal identification|Data to be collected for this stratum include histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries.
2488100|NCT02981706|Active Comparator|Arteriovenous Graft (AVG) Group|Patient will receive an arteriovenous graft (synthetic connection between artery and vein) as his/her dialysis access
2488159|NCT02981277|Active Comparator|Transcricoid|Lignocaine delivery using transcricoid injection
2488161|NCT02981277|Active Comparator|Spray as You go|Lignocaine delivery using spray as you go method
2488224|NCT02980939|Placebo Comparator|Euhydration - no thirst|
2488225|NCT02980939|Experimental|Dehydration - no Thirst|
2488253|NCT02980614|Experimental|Participants to 4D flow imaging|"In addition to the standard clinical MR protocol, 2 added sequences:~4D MR sequence in cine mode 4D velocity mapping sequence"
2488283|NCT02980328|Experimental|LLLT group|Low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each
2488288|NCT02980328|Placebo Comparator|Placebo-controlled group|Placebo low-level light therapy (LLLT) was self-performed for 12 weeks, 3 times a day for 20 minutes each. The placebo LLLT device was identical to the active device but did not radiate light as the hole was blocked.
2488317|NCT02980081||Plain abdominal x-ray|All patients admitted to 2 EDs and with a prescription of an abdominal plain x-ray.
2488349|NCT02979964|Experimental|Arm 1, Positive Framing|All metrics in the audit and feedback practice reports presented with 'positive' framing, where the proportion of patients safe from risk (i.e., appropriate/desirable prescribing behaviours) is described.
2488354|NCT02979964|Experimental|Arm 2, Negative Framing|All metrics in the audit and feedback practice reports presented with 'negative' framing, where the proportion of patients at risk (i.e., due to inappropriate/undesirable prescribing behaviours) is described.
2488358|NCT02979964|Experimental|Arm 3, Top Quartile Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the 75th percentile for performance by physicians working in nursing homes in the province for each metric.
2488361|NCT02979964|Experimental|Arm 4, Average Comparator|All metrics in the audit and feedback practice reports presented and the physician-recipient's performance is compared against the average performance by physicians working in nursing homes in the province for each metric.
2488445|NCT02979314|Experimental|Galvanic Vestibular Stimulation|A standard placement of the electrodes will be used for GVS and sham, placed on the mastoids. Weak currents up to maximally 3 mA will be used (tested before in each participant individually, and expected mean current will be around 1.5 mA). Previous studies have used Magnetic Resonance (MR) compatible GVS without reporting any discomfort for the participants, however weak sensations of nausea could be possible and in case that they are disturbing for the participants the experiment will be aborted. Continuous stimulation for up to 30min with intensities of 1-1.5 mA is generally considered as safe and free of any considerable side effects.
2488481|NCT02979015|Experimental|Alirocumab|Subcutaneous injection of a single dose of alirocumab, dose level according to ascending dose design
2488482|NCT02979015|Placebo Comparator|Placebo|Subcutaneous injection of a single dose of matching placebo
2488508|NCT02978729|Active Comparator|Telephone|Telephone telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via telephone. The participant will be in a private room at the study site. Telephone sessions will utilize a private phone line. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
2488513|NCT02978729|Experimental|Videoconference|Two-way videoconferencing telegenetics counseling: A trained Penn genetic counselor will conduct genotype disclosure visits with the participant via two-way videoconferencing. The participant will be in a private room at the study site. Videoconferencing sessions will utilize tablets or laptops with web cameras and secure/confidential software for teleconferencing. The genetic counselor will use standardized disclosure checklist and visual aids for the disclosure session.
3194092|NCT00824590|Experimental|normal renal function|Subjects with normal renal function defined by creatinine clearance of greater than 80 mL/min and demographically comparable to subjects with impaired renal function
3194093|NCT00824603||primary care provider|attending insulin CME Training
2488678|NCT02977819|Experimental|Meditation program|Meditation courses and at-home practice
2488681|NCT02977819|Active Comparator|English learning courses|English learning courses and at-home practice
2488685|NCT02977819|No Intervention|No intervention|Follow-up without Meditation courses or English Learning courses
2488741|NCT02977052|Experimental|Arm A: 2 courses ipi 3 + nivo 1|Patients receive 2 courses standard combination of ipilimumab 3 mg/kg + nivolumab 1 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2488742|NCT02977052|Experimental|Arm B: 2 courses ipi 1 + nivo 3|Patients receive 2 courses ipilimumab 1 mg/kg + nivolumab 3 mg/kg q3wk prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2488743|NCT02977052|Experimental|Arm C: 2 courses ipi 3 + 2 courses nivo 3|Patients receive 2 courses of ipilimumab 3 mg/kg q3wks, directly followed (> 2 hours and < 24 hours) by 2 courses nivolumab 3 mg/kg every 2 weeks prior to surgery at week 6. Blood for PBMCs and biopsies will be taken for translation research.
2488745|NCT02977052|Experimental|PRADO extension cohort|"Patients will be treated with 2 courses ipilimumab and nivolumab at the dose level defined as the winner dosing scheme from OpACIN-neo, which is the dosing schedule of arm B.~Surgery and adjuvant therapy~Patients achieving a pCR or pnCR will not undergo CLND and will not receive any adjuvant treatment. Structural follow-up will be perfomed every 12 weeks by CT, ultrasound of regional lymph nodes.~Patients achieving a pPR will undergo CLND and start structural follow-up (including CT and physical examination) every 12 weeks thereafter without any adjuvant treatment.~Patients achieving no response (pNR) will undergo CLND and start at week 12 with adjuvant nivolumab 480mg q4wks for 52 weeks + radiotherapy (according to patient's and physicians' decision). In patients that are BRAF V600E/K mutation positive, adjuvant BRAF+MEK"
2488819|NCT02976259|Experimental|Patient HIV primary infection|HIV primary infection Patient male receiving Dolutegravir
2488957|NCT02975687|Experimental|Arm A|"CD19 CAR T cells will be administered by i.v. injection as a using a split dose (total dose of 5x10^6/kg-5x10^7/kg) approach to dosing:10% on day 0, 30% on day 1 and 60% on day 2."
2489018|NCT02975141|Experimental|Afatinib 40Mg Tab, Gemzar, Abraxane +1|Dose Level +1 Afatinib 40 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
2489143|NCT02974374|Placebo Comparator|Placebo|
3194094|NCT00824629|Experimental|1|Afterloading embryo transfer procedure
2488103|NCT02981693|Active Comparator|AH Plus sealer|AH Plus sealer was used as a gold standard to be compared with iRoot SP sealer in root canal obturation.
3194095|NCT00824629|Active Comparator|2|Direct embryo transfer procedure
3160906|NCT00433394|Experimental|Stratum 2: Consent for personal identification - No Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries. No contact for future to ask me to consider taking part in Research Network approved studies
3160907|NCT00433394|Experimental|Stratum 3: Consent for personal identification - Contact|Data will be collected for this study include:child's name, parent's name, address, telephone number, child's date of birth, race, ethnicity, histology, primary site, treating hospital, and institutional principal investigator. Data will be coded using the North American Association for Central Cancer Registries (N.A.A.C.C.R.) data standards for cancer registries Someone from the Childhood Cancer Research Network may contact me in the future to ask me to consider taking part in Research Network approved studies
3160908|NCT00433407|Experimental|trastuzumab|blood sample collected on different days from patients receiving trastuzumab
2488516|NCT02978651|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
2488523|NCT02978651|Placebo Comparator|Placebo|Placebo
2488654|NCT02977468|Experimental|Single Arm open label|"Participants receive 'Merck 3475 Pembrolizumab' by vein one to two times before Intraoperative radiation therapy (IORT).~The Intrabeam® Photon Radiosurgery System is a miniature electron beam-driven X-ray source which provides a point source of low energy X-rays (50 kV maximum) at the tip of a 3.2 mm diameter tube. The radiation source can be inserted into the area of interest immediately after excision of the tumor and switched on for 20-35 minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and early clinical applications of this device have been well studied and this is the device which was utilized in the international TARGIT trial."
2488721|NCT02977325||Physical activity|One group participated in therapeutic programs centered on the physical activity
2488724|NCT02977325||water cure exclusively|This group followed exclusively the water cure
2488801|NCT02976896|Experimental|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
2488815|NCT02976233||Acute Respiratory Failure in NIV|
2489055|NCT02974920|Active Comparator|Aspirin 100 mg|100 mg of aspirin daily for 180 days
2489060|NCT02974920|Active Comparator|Rivaroxaban 10 mg|10 mg of Rivaroxaban daily for 180 days
2489127|NCT02974530||Stroke population|Patient with stroke will be explored during their acute phase and in 6 months of diagnosis.
2489129|NCT02974530||Healthy population|Healthy subjects will be explored in Grenoble in research laboratory
2489235|NCT02973750||Pre-Surgery Chemotherapy Patients|All participants. Patients receiving chemotherapy with carboplatin and paclitaxel before their debulking surgery, who may have more chemotherapy after surgery. Sampling procedures will include: Baseline Biopsy; Tissue Collection; Blood Draws.
2489343|NCT02972918||Levosimendan|At least 12 hours before surgery: Infusion of levosimendan (0,1 mcg/kg/min). 24 hours of infusion without a bolus.
2489390|NCT02972723|Experimental|Metformin therapy, single arm|Open label trial, participants will be expected to take Metformin twice a day for 2 weeks
2489419|NCT02972541|Experimental|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will receive neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 3-5 weeks after the last cycle of chemotherapy, type and extent of the surgery will be selected by the surgeon.
2489422|NCT02972541|Active Comparator|Stenting with Immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days after inclusion. Type and extent of the elective surgery will be selected by the surgeon.
2489501|NCT02971865|Experimental|CBT/CMT|The CBT/CMT program does not focus specifically on a particular condition such as diabetes. All treatment included patient education on nutrition content and mindfulness practice (emotions, and sensations in the present moment without trying to change them, awareness of breathing, and social economic problems) with manual therapy.
2489502|NCT02971865|Active Comparator|traditional primary care visit|Provide high quality primary care for men, women, and children of all ages. Our providers work together to ensure that you receive the most comprehensive care possible. Primary care is described as the medical setting in which patients receive most of their medical care and, therefore, is typically their first source for treatment
2489653|NCT02971150|Experimental|BBTI|Participants will receive Brief Behavioral Treatment for Insomnia (BBTI). This will be administered over the course of 4 weeks. BBTI is based on the concepts of sleep restriction and stimulus control. The first and third session are in person and the 2 and 4th session are conducted over the phone. Throughout the treatment, participants will complete daily sleep dairies. After 4 weeks of treatment, participants randomized to this group will cross over to the no intervention group and will be called once a week to assess mood and sleep symptoms.
2489657|NCT02971150|No Intervention|Control|Participants will not receive treatment. They will be contacted by phone once a week to complete assessments of mood and sleep. After 4 weeks, they will cross over to the experimental BBTI group.
2489695|NCT02970708|Experimental|EFG group|amblyopia in EFG group will receive Eyetronix Flicker Glassess treatment.
2489697|NCT02970708|Active Comparator|Patching group|amblyopia in patching group will receive patching treatment.
3160909|NCT00433433|Active Comparator|Favorable - Standard - any PET outcome|ABVDx3 cycles + Involved node RT (IN-RT) 30 Gy (+boost of 6Gy to residual lesions); FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
3160910|NCT00433433|Experimental|Favorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx2 without further RT (total of 4 cycles!)"
3160911|NCT00433433|Experimental|Favorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT30Gy (+boost 6Gy to residual lesions)."
2488127|NCT02981381|Sham Comparator|Sham sTMS (SHAM)|"Subjects randomized to this group will receive 20 sham synchronized Transcranial Magnetic Stimulation (sTMS) treatments (30 minutes each) over a period of 40 calendar days. Treatment windows will be 10 calendar days to complete 5 sham sessions. Serial assessments will be completed every 5 sessions. Post-treatment (PT1) endpoint assessments will take place immediately after the final sham session.~Participants that elect to participate in the open-label continuation phase, will receive 20 sTMS treatments (using the NEST-2 device), following the same administration structure as the sham-control series.~Participants will return to complete post-treatment follow-up assessments (PT2) 1 month after their last treatment session (either PT1 or OL PT1)."
2488199|NCT02981069|Active Comparator|Byetta / Bydureon|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc"
2488201|NCT02981069|Active Comparator|Dapagliflozin|4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg
2488203|NCT02981069|Active Comparator|Byetta/Bydureon plus Dapagliflozin|"Exenatide:~4 weeks Byetta, 5 to 10ug sc (daily) 12 weeks Bydureon 2mg sc PLUS~Dapagliflozin:~4 weeks Dapagliflozin, Farxiga, 10mg 12 weeks Dapagliflozin, Farxiga, 10mg"
2488206|NCT02981069|Placebo Comparator|Placebo|Placebo group (4 weeks and 12 weeks)
3194096|NCT00824642|Experimental|Group 1|Applied Acu-TENS prior to exercise
3194097|NCT00824642|Experimental|Group 2|Applied Acu-TENS prior to and during exercise
2488364|NCT02979769|Experimental|Palovarotene|"All participants will receive non-flare-up based treatment of 5 mg palovarotene once daily for 24 months.~Participants who continued non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to an additional 48 months (therefore 72 months over the entire study).~Participants who start non-flare-up based treatment under Amendment 1 will receive non-flare-up based treatment for up to 48 months.~Participants that are skeletally immature will receive weight-adjusted doses.~In the event of an eligible flare-up all participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days. Participants under the age of 18 years will receive weight-adjusted doses."
3194098|NCT00824642|Placebo Comparator|Group 3|Applied placebo TENS prior to exercise
3194099|NCT00824681|Experimental|1|Sound Of Family Together (S.O.F.T.) Music Program
3194100|NCT00824681|Active Comparator|2|Non-Therapy Related Activities (NTRA)
3194101|NCT00824694|Active Comparator|Intervention|The intervention will consist of targeted SMBG, provider training and patient education-all of which are focused on normalizing the most significant glucose abnormalities at any given time. SMBG will alternate between 2 strategies: glucose profiling and target monitoring. Intervention PCP's will use 380 View to identify a patient's most significant glucose elevations(s) and devise a treatment plan that includes drug type, dose increases, monitoring times, goal for the target, and stop criteria.
3208685|NCT00977249|Active Comparator|varenicline|"Varenicline for 12 weeks.~The treatment schedule for varenicline is:~Varenicline tablets, 0.5 mg x 1 daily, day 1-3 Varenicline 0.5 mg x 2, day 4-6 Varenicline 1 mg x 2, day 7 up to 12 weeks"
2488648|NCT02977767|Experimental|Conversational hypnosis|Use of conversational hypnosis during the tracheal cannula replacement
2488687|NCT02977429|Active Comparator|standard group|"The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2≥70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
2488688|NCT02977429|Sham Comparator|control group|"The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.than collect the data of ScvO2 and Pcv-aCO2:~ScvO2<70%，and furthermore, Pcv-aCO2 is divided into ≤6mmHg and >6mmHg"
2488755|NCT02977013||Patients with pulmonary embolism treated with enoxaparin|Anti-Xa assay correlation to the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
2488795|NCT02976675|Experimental|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
2488799|NCT02976675|Experimental|PEG-somatropin per two weeks|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
2488800|NCT02976675|Active Comparator|Jintropin AQ|Jintropin AQ, injection, 30IU/10 mg/3ml/cartridge, 0.25mg/kg/w, once per day for 26 weeks
2488858|NCT02976155|No Intervention|Pre-intervention|enteral nutrition according routine practice
2488860|NCT02976155|Experimental|Post-intervention|The intervention in this arm is the application of a standard enteral nutrition protocol
2488876|NCT02975791|Active Comparator|palpation|"Marking the cricothyroid membrane after ultrasound~The intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy. The doctors mark the cricothyroid membrane with a pen after using palpation for identification."
2488879|NCT02975791|Active Comparator|ultrasound|"Marking of the cricothyroid membrane after Palpation~intervention is to mark the cricothyroid membrane in order to know exactly where it is in case that it should be needed fur emergency cricothyrotomy doctors mark the cricothyroid membrane with a pen after using ultrasonography for the identification"
2488961|NCT02975661||Observational 1|Huaier Granule
2488968|NCT02975661||Observational 2|Radiotherapy or chemotherapy
2488975|NCT02975661||Observational 3|treatment abandoned
2488981|NCT02975661||Observational 4|Huaier Granule & Radiotherapy or chemotherapy
2489009|NCT02975180|Experimental|FES|Unilateral and bimanual activities are performed with FES applied to the hemiparetic arm.
2489014|NCT02975180|Experimental|Conventional|Unilateral and bimanual activities are performed with no FES applied to the hemiparetic arm.
2489072|NCT02974777|Active Comparator|Bleeding prevention group|Patients with reduction of standard dose DAPT due to low platelet reactivity to asprin and/or P2Y12 inhibitor
2489076|NCT02974777|Active Comparator|Ischemia prevention group|Patients with intensification of standard dose DAPT due to high platelet reactivity to asprin and/or P2Y12 inhibitor
2489195|NCT02974049|Experimental|ALB 400 mg x2 per year|Albendazole 400 mg given at 0, 6, 12, 18, 24 and 30 months
2489196|NCT02974049|Experimental|ALB 800 mg x2 per year|Albendazole 800 mg given at 0, 6, 12, 18, 24 and 30 months
2489198|NCT02974049|Experimental|ALB 400mg + IVM 200mcg/kg + DEC 6mg/kg|Albendazole 400 mg plus Ivermectin 200 µg/kg body weight plus Diethylcarbamazine 6 mg/kg body weight given one time only
2489239|NCT02973763|Experimental|Alflutinib|patients take Alflutinib orally once per day at different dose
2488175|NCT02981056|Active Comparator|Wash + Lotion regimen|"Johnson's Baby Top-To-Toe Wash (Ideally 7 times a week, at least 5 times a week) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
2488179|NCT02981056|Active Comparator|Water + Lotion regimen|"Water (in lieu of bathing products) + Johnson's Baby Lotion (at least once a day).~The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso."
2488181|NCT02981056|Active Comparator|Water only|Water (in lieu of bathing products) only. The products/treatment were used for a period of 3 months, and the products were placed on skin and with attention to applying the products on the arms, legs and torso.
3208686|NCT00977249|Placebo Comparator|placebo|Placebo for 12 weeks
3208687|NCT00977262|Experimental|Healthy control subjects, High saturated fat shake|
2488341|NCT02980276|Active Comparator|Treatment|Participants randomised to the treatment arm will receive active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg).
2488342|NCT02980276|Placebo Comparator|Control|Participants randomised to the placebo arm will receive placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group.
2488389|NCT02979730|Active Comparator|Core Lab Testing Arm|For patients with clinical concern for influenza, the usual workflow in the BMC ED is that physicians order the collection of a nasopharyngeal swab (NPS) for influenza A/B testing to be performed in the core microbiology laboratory using one of two assays. The two influenza A/B-only assays available in the core lab are a) an instrumented fluorescent immunoassay rapid antigen test, the Sofia influenza A+B FIA (Quidel Corporation) and b) an automated real-time PCR test, the Xpert Flu (Cepheid, Inc.). Which test is ordered is at the discretion of the physician. Both the Sofia and Xpert assays provide a result callout to distinguish influenza type A from type B.
2488391|NCT02979730|Experimental|ED Point of Care Testing Arm|Prior to the study the Cobas Liat Influenza A/B assay will be verified for patient care at BMC. The instrument and test kits will be available in the ED for use with study subjects randomized to this study arm. The Cobas Liat assay provides a result callout to distinguish influenza type A from type B.
2488419|NCT02979405|Experimental|group 1|Phenylephrine 40 mcg/min, infusion during 5 minutes
2488421|NCT02979405|Placebo Comparator|group 2|Saline solution 21 cc, infusion during 5 minutes
2488465|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline)
2488509|NCT02978898||LN Lymph nodes|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
2488512|NCT02978898||PB peripheral blood|"Samples obtained from patients with :~LF: Follicular lymphoma MCL: Mantle cell lymphoma CLL/SLL: chronic lymphocytic leukemia/small lymphocytic leukemia MZL : splenic marginal zone Clt :control B-cells"
2488585|NCT02978573|Experimental|Cartiva|Cartiva Synthetic Cartilage Implant
2488622|NCT02978040|Experimental|Cangrelor|Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
2488628|NCT02978040|Active Comparator|Tirofiban|Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min).
2488631|NCT02978040|Active Comparator|Prasugrel|Prasugrel oral integer or chewed at an identical loading dose of 60 mg
2488727|NCT02977273|Experimental|Test Meal 1|Thin/100% portion
2488731|NCT02977273|Experimental|Test Meal 2|Thin/150% portion
2488735|NCT02977273|Experimental|Test Meal 3|Thick/100% Portion
2488736|NCT02977273|Experimental|Test Meal 4|Thick/150% Portion
2488763|NCT02976727|Experimental|GroupA (Vit-D pretreated AFL-PDT group )|Group A was treated with topical VitD-assisted AFL-PDT
2488764|NCT02976727|Active Comparator|GroupB (Conventional AFL PDT group )|Group B was treated with conventional AFL-PDT
2488805|NCT02976493||MM patients receiving elotuzumab|Non-Interventional Study of all patients with relapsed or refractory multiple myeloma (MM) who are beginning to receive elotuzumab at the selected sites.
2488857|NCT02976246|Active Comparator|RenaKvit-vessel Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on vascular calcification
2488861|NCT02976246|Placebo Comparator|RenaKvit-vessel Control|One tablet of non-active drug given once daily
2488863|NCT02976246|Active Comparator|RenaKvit-bone Active|One tablet of 360 micrograms vitamin K2 given once daily to examine the effect on bone metabolism
2488864|NCT02976246|Placebo Comparator|RenaKvit-bone control|One tablet of non-active drug given once daily
2488891|NCT02975739|Experimental|Holmium-166 microspheres|Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.
2488954|NCT02975570|Experimental|DAZZLE-24 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 24 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2488963|NCT02975570|Experimental|DAZZLE-32 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 32 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2488966|NCT02975570|Experimental|DAZZLE-40 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen: delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 40 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2488208|NCT02980809|Experimental|Apatinib and topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5, apatinib 250mg/d, every 21 days, until disease progression.
2488210|NCT02980809|Placebo Comparator|Topotecan|Patients receive IV topotecan 1.5 mg/m2/d on days 1 through 5 every 21 days, until disease progression.
2488248|NCT02980627|Experimental|Therapy with Mobile App Enhancement|Participants will complete initial assessments and then take part in a 3-month intervention consisting of 12 weekly individual therapy sessions with daily RR app use between sessions. At the end of the 3-month intervention period, an exit interview will be conducted and participants will complete a second assessment consisting of questionnaires and an ED diagnostic interview, a blood specimen for HbA1c, and 3-days of blinded CGM monitoring. Participants will then enter a 6-month follow-up period during which time they may continue to use the app, but will no longer attend individual sessions. Participants will be return to the clinic at 6 and 9 months for follow-up.
3160912|NCT00433433|Active Comparator|Unfavorable - Standard - Any PET outcome|ABVDx4 cycles + IN-RT 30Gy (+boost 6Gy to residual lesions). FDG-PET after two cycles of ABVD for comparison with the experimental arm will be performed but no treatment adaptation will take place.
3160913|NCT00433433|Experimental|Unfavorable - Experimental - PET negative|"ABVDx2 cycles; then FDG-PET evaluation:~PET negative: ABVDx 4 cycles, without RT (total of 6 cycles)"
2488366|NCT02979821|Experimental|Poziotinib|The study drug(poziotinib) will be administered orally as one 12 mg tablet once a day until disease progression or manifestation of unacceptable toxicity. The initial dose of the study drug 12 mg daily can be reduced to 8 mg once daily according to dose reduction criteria.
3160914|NCT00433433|Experimental|Unfavorable - Experimental - PET positive|"ABVDx2 cycles; then FDG-PET evaluation:~PET positive: presumed poor-risk: switch to escalated BEACOPPx2 + INRT 30Gy (+boost 6Gy to residual lesions)."
3160915|NCT00433459|Active Comparator|COPP|procarbazine-containing consolidation chemotherapy arm
3160916|NCT00433459|Experimental|COPDAC|procarbazine-free consolidation chemotherapy arm
2488485|NCT02978963|Experimental|Cognitive Behavioral Therapy|All participants will receive cognitive behavioral therapy for excessive worry. Focus in treatment will be on reducing participants' intolerance uncertainty through in vivo and imaginary exposure to uncertainty inducing situations and thoughts. Treatment will also contain psycho education about anxiety and worry, as well as planning for maintenance of treatment gains. Parents of the participants will receive support and education about worry through an internet-delivered program.
2488517|NCT02978716|Experimental|Group 1: Gemcitabine/Carboplatin|GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
2488524|NCT02978716|Experimental|Group 2: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV prior to GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 1 and 8 in 21-day cycles.
2488528|NCT02978716|Experimental|Group 3: Trilaciclib (G1T28) + Gemcitabine/Carboplatin|Trilaciclib (G1T28) IV on Days 1, 2, 8 and 9. GC chemotherapy (gemcitabine 1000 mg/m2 and carboplatin AUC = 2 administered IV) on Days 2 and 9 in 21-day cycles.
2488756|NCT02977000|Experimental|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h. investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
2488786|NCT02976662|Experimental|Artificial shrinkage|Elimination of blastocoelic fluid by creating a large hole in the zona pellucida at the cellular junction of the trophectoderm cells located far away from the inner cell mass with a laser pulse before vitrification.
2488791|NCT02976662|No Intervention|Without Artificial shrinkage|Vitrify expanded blastocysts.
2488832|NCT02976376|Experimental|The Box|"After randomization, patients in the intervention group will receive a box (The Box) with all the devices described above. Instructions about the installation and usage of the devices will be given. Patients will be asked to measure their weight and blood pressure once a day. Furthermore, patients will be asked to record an ECG using the AliveCor once a day. Moreover, they are asked to record an ECG in case of any symptoms of possible cardiac origin, as judged by the patient. All data will be automatically transferred to the Leiden University Medical Center. Lastly, two of the four outpatient clinical visits will be done via a video connection. The content of the interview will be comparable to the content of a regular outpatient clinic visit."
2488844|NCT02976376|No Intervention|Control|Patients who are randomized to the control group will receive regular care.
2488902|NCT02976012|Active Comparator|IAI q8 week Group|"Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q8 week Group) where 4 additional mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up. Starting at week 20 in the q8week group eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment"
3160917|NCT00433472|Other|MRI -|"MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI~Procedure/surgery magnetic resonance imaging (MRI)"
3160918|NCT00433498|Experimental|Carboplatin/cisplatin and Etoposide with Pravastatin|
3160919|NCT00433498|Placebo Comparator|Carboplatin/cisplatin and Etoposide with Placebo|
3160920|NCT00433563|Experimental|Once daily radiotherapy|Once daily radiotherapy
3160921|NCT00433563|Active Comparator|Twice daily radiotherapy|Twice daily radiotherapy
3160922|NCT00433576|Experimental|Treatment (resveratrol, colorectomy)|"STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm colorectal adenocarcinoma histology and require surgical resection continue on study stage 2.~STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day 9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes."
3160923|NCT00433589|Active Comparator|Arm I (anthracycline-based)|"FEC 100~Canadian CEF~CAF~FAC~E-CMF"
3160924|NCT00433589|Experimental|Arm II (docetaxel and capecitabine)|"Docetaxel~Capecitabine"
3160925|NCT00433615|Experimental|1|
3160926|NCT00433615|Experimental|2|
3160927|NCT00433641|Placebo Comparator|1|placebo tablet
3160928|NCT00433641|Experimental|2|sibutramine
3160929|NCT00433641|Experimental|3|sibutramine
3160930|NCT00433693|Experimental|1|
3160931|NCT00433706|Experimental|Control position by 3DOBI daily|
3160932|NCT00433706|Active Comparator|Standard imaging|
3160933|NCT00433719|Experimental|1|Combivir, efavirenz for 12 months
2488229|NCT02980900|Active Comparator|Post exercise + pre bed supplement|Post exercise protein-polyphenol supplement Pre bed protein-polyphenol supplement
2488263|NCT02980497|Active Comparator|Listerine Zero Mouthwash (without alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Zero Mouthwash (without alcohol) for 30 seconds.
2488268|NCT02980497|Active Comparator|Listerine Antiseptic Mouthwash (with alcohol)|Brushing twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush and rinsing with 20 ml of Listerine Antiseptic Mouthwash (with alcohol) for 30 seconds.
2488272|NCT02980497|No Intervention|Brush only|Brush only twice daily in the usual manner with an ADA-Accepted Fluoride Toothpaste (Colgate Cavity Protection) using a soft-bristled toothbrush.
3194102|NCT00824694|Active Comparator|Control Arms|Subjects will repeat the dose titration cycle under the guidance of a case manager until the target is reached, maximal recommended doses of medications are used, or a stop criterion is met. They will then resume glucose profiling to identify the next target. This process is repeated until all targets reach their optimal value. Control patients will monitor and be treated in the customary manner.
3194103|NCT00824707|Experimental|anti-virus therapy|100 HCC patients will be allocated to receive anti-virus therapy.
3194104|NCT00824707|Active Comparator|conventional therapy|100 patients will undergo conventional therapy
2488451|NCT02979041|Active Comparator|control|Patients in the control group will receive standard physiotherapy and medical care, as provided to all patients with neck pain in the aviation medicine clinic. This will reflect the standard care that has been provided to all patients.
2488453|NCT02979041|Experimental|intervention|Standard care (as provided to controls) with the addition of virtual reality training (a self-exercise program) using a VR system to address the fast, accurate head control required in flying tasks.
3194105|NCT00824759|Placebo Comparator|placebo|
3194106|NCT00824759|Active Comparator|oxygen|
3194107|NCT00824785|Active Comparator|Arm A EOX|EOX chemotherapy (epirubicin, oxaliplatin and capecitabine)
3194108|NCT00824785|Active Comparator|Arm B EOX + panitumumab.|EOX chemotherapy with the addition of panitumumab 9mg/kg every 21 days
2488908|NCT02975895|Other|Hydrophobic IOL: Vivinex (HOYA)|Intraocular lens with hydrophobic properties: Vivinex (HOYA).
2488912|NCT02975895|Other|Hydrophilic IOL: INCISE (Bausch+Lomb)|Intraocular lens with hydrophilic properties: INCISE (Bausch+Lomb).
2488938|NCT02975479|Placebo Comparator|Intralymphatic placebo injections|ALK Diluent, ATC-code V07AB. 3 injections with 4-7 weeks interval.
2488946|NCT02975479|Active Comparator|Intralymphatic active injections|"ATC-code V01AA02. 3 injections with 4-7 weeks interval in an up-dosing protocol; 1000 SQ-U, 3000 SQ-U, 10000 SQ-U.~***IMPORTANT INFORMATION! The up-dosing protocol is changed due to an adverse event at the last injection. New regimen: 1000 SQ-U, 3000 SQ-U, 3000 SQ-U. ***"
2488991|NCT02975102|Experimental|CBL-101 Eye Drops|The test article, CBL-101 Eye Drops, is a CE-marked medical device containing 0.15% hyaluronic acid. An oxide (Oxyd®) used as mild preservative, rapidly turns into oxygen, water and ions on contact with the eye. The formula is presented in 10 mL bottles.
2488995|NCT02975102|Active Comparator|Vismed® Multi|The comparator product, Vismed® Multi ophthalmic solution (CE marked), contains 0.18% sodium hyaluronate, is unpreserved and presented in 10 mL bottles.
3194109|NCT00824798||haemophiliacs A and B|haemophiliacs A and B mild, moderate or severe from 4 to 80 years old, with or without inhibitors.
3194110|NCT00824811|Experimental|Group 1: Cyclosporine eye drops|Cyclosporine Eye Drops (Restasis) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
2489269|NCT02973633|Active Comparator|Healthy Volunteers|DTI will be performed in healthy volunteers to characterize normal fiber architecture in the heart and provide a comparison group for the patients imaged in the other arms.
2489270|NCT02973633|Active Comparator|Patients with Recent Myocardial Infarction|Patients with recent ST elevation myocardial infarcts will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with remodeling of the left ventricle.
2489271|NCT02973633|Active Comparator|Patients with Left Ventricular Hypertrophy|Patients with left ventricular hypertrophy and a history of heart failure will be recruited and imaged serially with DTI to detect changes in fiber architecture and their correlation with the onset and progression of heart failure.
2489350|NCT02972970|Other|Aveera|This is a prospective, open label study to assess the scan, print and fit process to see if the Aveera will be able to be used with conventional CPAP therapy devices
2489399|NCT02972762|Active Comparator|L Group|The participants in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 50 to 60.The values of BP,P,PetCO2 will be controled in proper site. each participant will be given postoperative analgesia pump to release postoperative pain.
2489401|NCT02972762|Active Comparator|D Group|The participant in L Group will receive Lumbar plexus and sciatic nerve block with ropivacaine before anesthesia induction.The investigator use Diprivan TCI target-controlled infusion during anesthesia induction period, target effect-site concentration is set at 4.0g / kg. After reaching the target concentration, sufentanil 0.2g / kg is administrated, Laryngeal mask will be placed into participant's mouth at 2 min after sufentanil is given. Anesthesia will be maintained with remifentanil TCI target-controlled infusion and Diprivan BIS close-loop target controlled infusion,BIS ranges from 35 to 45.The values of BP,P,PetCO2 will be controled in proper site. The investigator use postoperative analgesia pump to control postoperative pain for each participant.
2489446|NCT02972476|Active Comparator|1: Symbicort 400/12 & Eklira Genuair|Budesonide 400mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2489538|NCT02971722|Experimental|0.3mg JY09(cohort 1)|0.3mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2488306|NCT02980432|Experimental|intervention arm|all participants will be assigned to the same arm. Interventions applied include presenting a visual line or a rod with or without a moving (rotating) background while being in different whole-body roll positions. Participants will be asked to adjust the line or the rod along perceived direction of gravity.
2488369|NCT02980029|Experimental|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme.
2488373|NCT02980029|Placebo Comparator|Placebo|Placebo
2488418|NCT02979496|Other|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2488420|NCT02979496|Experimental|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2488422|NCT02979496|Experimental|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2488423|NCT02979496|Other|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
2488466|NCT02979171|Active Comparator|LMA-Classic|airway management with LMA-Classic
2488467|NCT02979171|Active Comparator|LMA-Flexible|airway management with LMA-Flexible
2488470|NCT02979171|Active Comparator|LMA-Proseal|airway management with LMA-Proseal
2488501|NCT02978820|Experimental|SEAS exercise group|This group received SEAS exercises in addition to brace wearing for four months
2488502|NCT02978820|Experimental|CS exercise group|This group received core stabilization exercise training (CS) in addition to brace wearing for four months
2488558|NCT02978560||control|The source population for this cohort will be 30 healthy individuals with no know cardiovascular disease or wound healing defects. Subjects will be recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once.
2488565|NCT02978560||Wound Group|The source population will be 30 patients who present to wound care clinic with Diabetic Foot Ulcers. Candidate subjects will have had a standard wound evaluation and medical history taken as a matter of their standard of care. On the basis of the evaluation, the physician-investigators will determine if the patient meets the eligibility criteria. If so, the study will be explained to the patient at that time, and Informed Consent will be obtained. 30 healthy subjects will also be included, recruited by word-of-mouth, who receive no remuneration and who will be selected for the study on the basis of the following inclusion and exclusion criteria. They will undergo fluorescence-mediated photoplethysmography once at the onset of their wound care.
2488598|NCT02978131||Patients with a clinical diagnosis of TB|Patients with a clinical diagnosis of TB. Retrospective study on biopsy samples
2488626|NCT02977832|Experimental|odyliresin|Odyliresin (Iresine celosia) 2 ml
2488630|NCT02977832|Experimental|alphalytic|alpha-antagonist (alfuzosin 10 mg)
3194111|NCT00824811|Experimental|Group 2: Lubricant Eye Drops|Lubricant Eye Drops (Refresh Endura) 1 drop twice/day for 84 days to both eyes + Fluorometholone Eye Drops (FML Forte) on declining dose schedule.
3194112|NCT00824837|Experimental|A|New larger pore membrane
2488806|NCT02976558|Experimental|Treatment Group|"Interventions:~Acupuncture, music therapy (TaKeTiNa) and Clown theatrical performance starting before allogenic stem cell transplant until three months after transplantation.~Interventions each twice a week for 4 weeks, then once a week for 4 weeks, then once every two weeks for 4 weeks"
2488809|NCT02976558|No Intervention|Control Group|control group. No interventions
3194113|NCT00824837|Active Comparator|B|Standard haemodialysis membrane
3194114|NCT00824863|Experimental|one arm|All 10 patients receive ketoconazole 2% foam in the uncontrolled study.
2488989|NCT02975076|Experimental|Sanchitongshu & placebo of lopidogrel|sanchitongshu 1 capsule each time ,three times a day and Aspirin 75mg for 90 days ; placebo of clopidogrel 75mg daily for 21 days after randomization
2488993|NCT02975076|Placebo Comparator|placebo of Sanchitongshu & lopidogrel|placebo of sanchitongshu1 capsule each time ,three times a day and Aspirin 75mg for 90 days;clopidogrel 75mg per day for 21 days after randomization
2489087|NCT02974673|Experimental|Ejaculatory test|Measures of sphincter pressures during ejaculation
2489108|NCT02974439|Experimental|LANDI-Amlodipine Besylate Tablet 5mg|During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.
2489109|NCT02974439|Active Comparator|Norvasc Tablets 5mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.
2489147|NCT02974244||exenatide once weekly|type 2 diabetes who initiated exenatide once weekly treatment in the index period
2489151|NCT02974244||basal insulin|type 2 diabetes patients who initiated basal insulin treatment in the index period
2489227|NCT02973997|Experimental|Treatment (lenvatinib, pembrolizumab)|Patients receive lenvatinib PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment for up to 35 cycles.
2489339|NCT02973217|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2489409|NCT02972801|Experimental|Testicular tissue biopsy|Testicular biopsy
3194115|NCT00824889|Other|1|Healthy volunteer
2489883|NCT02969330|Active Comparator|PES|Single session of short PES treatment before glucose ingestion.
3194116|NCT00824889|Other|2|atopic dermatitis patient
3194117|NCT00824889|Other|3|contact dermatitis patient
3194118|NCT00824889|Other|4|psoriasis patient
3194119|NCT00824889|Other|5|lichen planus patient
3194120|NCT00824889|Other|6|GVH patient
3194121|NCT00824889|Other|7|melanoma patient
3194122|NCT00824902|Experimental|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
3194123|NCT00824928||Observational|Patients with locally recurrent prostate cancer that have chosen salvage cryotherapy
2488320|NCT02980094|Experimental|Milk Oil group(O)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
2488322|NCT02980094|Experimental|Milk Antioxidant and oil(AO)|Using a randomized block design, 25 institutionalized elderly to receive the milk produced by lactating cows fed with the following diets: control C+sunflower oil+vitamin E+selenium (AO) .
2488346|NCT02979847|Experimental|Treated|hybrid approach (epicardial and subsequent endocardial mappings and ablations)
2488347|NCT02979847|Active Comparator|Control|conventional endocardial approach
2488397|NCT02979717|Experimental|high protein, high fiber|Participants receive a high protein, high fiber dietary supplement pre-load
2488398|NCT02979717|Placebo Comparator|Low protein, low fiber|Participants receive a low protein, low fiber isocaloric pre-load
2488442|NCT02979353|Experimental|Shed-Meds: A Patient-Centered Deprescribing Intervention|Participants assigned to the intervention group will receive a clinical review of their prescribed medications by a research clinician (Pharmacist, Physician, and/or Nurse Practitioner) followed by a patient interview to assess their willingness to discontinue or reduce some of their medicines based on the clinical recommendations of the team. Hospital and out-patient providers also will be part of the deprescribing decision process. Deprescribing actions will be initiated in the hospital prior to discharge and continue through the skilled nursing facility stay.
2488443|NCT02979353|No Intervention|Control Group|Participants assigned to the control group will receive usual care as it is normally provided by the hospital and skilled nursing facility treatment teams. Research staff will monitor their prescribed medications in both care settings but not make any recommendations or changes, unless a safety issue is identified.
2488474|NCT02979028|Experimental|TEAS group|Electric stimulation was given through electrode attached to acupoints SP6 and ST36 .TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
2488476|NCT02979028|Sham Comparator|Sham group|Non-acupoint is located 2cm inward to the specific acupoints.TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.
2488477|NCT02979028|Placebo Comparator|Control group|Control patients will receive the same treatment without electrical stimulation.
3194124|NCT00824967|No Intervention|1- The reference group|one will take care of the patient in a habitual way: no consultation additional, step of exam on top of that...
3194125|NCT00824967|Other|2- The intervention group|Training and valuation of the treating personnel
3194126|NCT00824980|Experimental|IP10.C8 Gel|
3194127|NCT00824980|Placebo Comparator|Placebo Gel|
3194128|NCT00825006|No Intervention|Control|Dual site pacing (LV tip electrode and RV tip electrode)
2488689|NCT02977377|Active Comparator|Whole body vibration/ Exercise|Exercise therapy and whole body vibration will be applied together for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. Whole body vibration (20-30 Hz, minimum amplitude) will be applied to cases in the form of 4 sets (1 min application and 1min rest) before exercises. After 1 week washout period, exercise program will apply for 8 weeks.
2488690|NCT02977377|Active Comparator|Exercise/ Whole body vibration|Exercise therapy will be applied for 8 weeks. Selected balance, coordination and walking exercises according to the individual needs of patients. After 1 week washout period exercise therapy and whole body vibration will be applied together for 8 weeks.
2488758|NCT02976987|Experimental|Cidofovir|Women receiving an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (CIN 2 and 3).
2488816|NCT02976272||patients with myeloma multiple|
3194129|NCT00825006|Experimental|Triple site pacing|Triple site pacing(LV tip electrode,RV tip electrode and RV ring electrode)
3194130|NCT00825019|Experimental|1|
3194131|NCT00825019|Placebo Comparator|2|
3194132|NCT00825019|Active Comparator|3|paroxetine
3194133|NCT00825032|Active Comparator|1: comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
3194134|NCT00825032|Experimental|2: UEET + PR|Experimental program consisting in additional 15 daily sessions of unsupported UEET over and above the same PR program used for control patients.
2489264|NCT02973646|Experimental|Nucleos(t)ide analogues treatment|Patients with interferon receptor level down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 24th week, then nucleos(t)ide analogues (entecavir tablet 0.5mg/d or tenofovir tablet 300mg/d) from 25th to 36th week, then peginterferon alfa-2b injection 80ug/d again from 36th to 48th week.
2489265|NCT02973646|Active Comparator|Peginterferon treatment|Patients with interferon receptor level not down-regulated at the 24th week. Patients of this group will receive peginterferon alfa-2b injection 80ug/d from baseline to 48th week.
3194135|NCT00825045|Experimental|Treatment with risperidone|Gradual titration of risperidone according to clinical response
3194136|NCT00825058|Experimental|1|
3194137|NCT00825058|Placebo Comparator|2|
3194138|NCT00825058|Active Comparator|3|
3194139|NCT00825071|Active Comparator|Group D|Dexamethasone group : This group received 8 mg dexamethasone
3194140|NCT00825071|Active Comparator|Group O|Ondansetron Group: received 4 mg ondansetron
3194141|NCT00825071|Placebo Comparator|Group P|(Group P) received normal saline (Placebo)
3194142|NCT00825084|Experimental|single dose cohort-Japanese group|Japanese healthy subjects
3194143|NCT00825084|Experimental|single dose cohort-Western group|Western healthy subjects
3194144|NCT00825084|Experimental|multiple dose cohort-Japanese group|Japanese healthy subjects
3194145|NCT00825084|Experimental|multiple dose cohort-Western group|Western healthy subjects
3194146|NCT00825097|Experimental|Neurotomy Group|8 patients undergoing a selective tibial neurotomy under general anesthesia
3194147|NCT00825097|Active Comparator|BTX Group|8 patients undergoing a botulinum toxin injection in the calf muscles under EMG-control
3194148|NCT00825110||No treatment|confirmed diagnosis of colorectal carcinoma
3194149|NCT00825123|Experimental|Ivabradine|
2488483|NCT02978989|Placebo Comparator|LC & nonsolo approach|The surgical intervention is nonsolo LC.
2488484|NCT02978989|Active Comparator|LC & solo approach|The surgical intervention is solo LC.
2488573|NCT02978404|Experimental|Radiosurgery and Nivolumab|"Interventions: Nivolumab (240mg IV q2week or 480mg IV q4week) and Radiosurgery (15-20 Gray (Gy) in 1 fraction)~Upon entering this trial, patients with metastatic brain disease(s) will receive Nivolumab. One to 2 week after receiving the first dose of Nivolumab, radiosurgery will be delivered at doses ranging from 15 to 20 Gy in 1 fraction to the brain metastases to a maximum volume of 10 cubic centimeter."
2488638|NCT02978001||Patients with Psoriasis|Patients with moderate to severe psoriasis (PASI>8)
2488641|NCT02978001||Healthy Control Subjects|Healthy subjects matching the patients with psoriasis regarding age, gender and BMI
2488722|NCT02977221|Experimental|Piezosurgery|Piezosurgery will be performed on the anterior lower segment of the dental arch in order to accelerate the correction of mandibular anterior crowding.
2488725|NCT02977221|No Intervention|Ordinary Alignment|Treatment will be provided to the patients without any surgical interventions.
2488773|NCT02976883|Experimental|[18F]HX4 diagnostic PET/CT scan|[18F]HX4 (370 MBq) will be administered by a single intravenous injection, after which patients will be required to wait for ≤4.0 h and undergo a PET/CT scan.
2488859|NCT02976480|Active Comparator|Irrigation|The subjects randomized to this group will have their simple lacerations irrigated with a normal saline solution.
2488862|NCT02976480|Experimental|No Irrigation|The subjects randomized to this group will not have their simple lacerations directly irrigated with a normal saline solution.
2488974|NCT02975362|Experimental|Acupuncture combined rehabilitation|Acupuncture Treatment Rehabilitation Treatment
2488977|NCT02975362|Experimental|Rehabilitation|Rehabilitation Treatment
2489020|NCT02975063|Experimental|A&T IYCF intervention|A&T IYCF intervention is includes comprehensive IYCF counseling which includes intensive activity that aims to deliver one-on-one counseling at home or in a health facility.
2489028|NCT02975063|No Intervention|Control|No intervention.
2489190|NCT02974257|Experimental|Thiamine|Intervention: Thiamine 500mg IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
2489193|NCT02974257|Placebo Comparator|Placebo|Intervention: Placebo (100mL normal saline) IV every 12 hours for 2 days. Oxygen consumption will be monitored with a non-invasive monitor continuously for 2 days and lactate, pyruvate dehydrogenase and other routine lab values will be checked at serial time points.
2489234|NCT02973867||Cohort called Elodie|Obese patients
2489300|NCT02973308|Other|Treadmill-Test operator A|Randomised to motorised treadmill group A for inter reliability, observer A will perform both exercise tests
2489303|NCT02973308|Other|Treadmill-Test operator B|Randomised to motorised treadmill group B for intra reliability, observer A will perform one exercise test, followed by observed B
2489309|NCT02973308|Other|Cycle-Test operator A|Randomised to cycle group B for inter reliability, observer A will perform both exercise tests
2489313|NCT02973308|Other|Cycle-Test operator B|Randomised to cycle group B for intra reliability, observer A will perform one exercise test, followed by observed B
3160934|NCT00433719|Placebo Comparator|2|Placebo for 2 months followed by Combivir and efavirenz for 10 months
3160935|NCT00433797|Experimental|1|Tomato
2489505|NCT02971787|Experimental|Probiotics and salt|Lactobacillus enrichment and salt increase
2489578|NCT02971696|Experimental|HCC patients (Group 1)|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
2489579|NCT02971696|Active Comparator|HCC patients (Group 2)|Patient will take best supportive care
2489649|NCT02971176|Experimental|Low-dose protocol|Patients undergo low-dose protocol computed tomography-guided lung biopsy on day 1.
2489651|NCT02971176|Active Comparator|Standard-dose protocol|Patients undergo standard-dose protocol computed tomography-guided lung biopsy on day 1.
2489690|NCT02970747||Car/Len/Dex (KRd)|Patients treated with carfilzomib, lenalidomide and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
2489692|NCT02970747||Car/Dex (Kd)|Patients treated with carfilzomib and dexamethasone dosage form, dosage, frequency and duration of treatment according to current SmPC
2489693|NCT02970747||Car/Dex/Dara (KdD)|Patients treated with carfilzomib, dexamethasone and daratumumab dosage form, dosage, frequency and duration of treatment according to current SmPC
2489735|NCT02970448|Experimental|LITT with Radiation and Temozolomide|Laser interstitial thermal therapy (LITT) followed by Radiation therapy, three-dimensional conformal radiotherapy (3D-CRT) or intensity modulation radiation therapy (IMRT), 60 Gy/30 fractions. Radiation given with chemotherapy Temozolomide
2489765|NCT02970071||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
2489790|NCT02969889|Active Comparator|intubation time|handling the device till the endotracheal tube passing through the glottis
2489791|NCT02969889|Active Comparator|insertion time|handling of the device till the glottic visualization
2518164|NCT02775526|Active Comparator|TOT|TOT
3160936|NCT00433797|Experimental|2|Multi-diet
3160937|NCT00433797|Active Comparator|3|Control
3160938|NCT00433849|Experimental|1|
3160939|NCT00433849|Experimental|2|
3160940|NCT00433888|Experimental|1|
3160941|NCT00433888|Experimental|2|
3160942|NCT00433927|Active Comparator|Arm A|FOLFIRI plus Cetuximab
3160943|NCT00433927|Active Comparator|Arm B|FOLFIRI plus Bevacizumab
3160944|NCT00433940||Infantile Hemangioma Patients|Infants with infantile hemangioma being treated clinically with oral prednisolone sodium phosphate suspensions.
3160945|NCT00434005|Experimental|Diesel Exhaust|
3160946|NCT00434005|Sham Comparator|Filtered Air|
3160947|NCT00434096|Experimental|1|
3160948|NCT00434096|Placebo Comparator|2|
3160949|NCT00434135|Experimental|A|Gemcitabine 1,250 mg/sqm days 1 and 8 + Alimta 500 mg/sqm day 8, every 3 weeks
3160950|NCT00434135|Active Comparator|B|Paclitaxel 120 mg/sqm days 1 and 8 + Gemcitabine 1,000 mg/sqm days 1 and 8, every 3 weeks
3160951|NCT00434174|Experimental|everolimus + Pemetrexed - daily|Daily treatment
3160952|NCT00434174|Experimental|everolimus + Pemetrexed - weekly|Weekly treatment
2488586|NCT02978352|Experimental|face-to-face|Traditional learning group (face-to-face): 4 different sessions will be conducted to suit the participants' convenience Duration of each session is 60-90 minutes Each session comprises lecture, video demonstration of CAM-ICU assessment, discussion, volunteer participation during class demonstration
2488587|NCT02978352|Experimental|E-learning|60-90 minute online course will be accessible through intranet Wi-Fi The course encompasses types, incidence, risk factors, significance and effects of delirium, diagnostic criteria and CAM-ICU application Inclusion of video demonstration of simulated patients and CAM-ICU application, common pitfalls of healthcare providers, and practice questions
2488616|NCT02977962|Experimental|Cognitive-Behavior Therapy|This consists of 16 weekly sessions up to 90 minutes each that helps the participant learn to cope with anxiety by facing fears, thinking more logically, and calming oneself.
2488620|NCT02977962|Placebo Comparator|Treatment as Usual|Participants randomized to this condition will wait for a period of 16 weeks before receiving treatment in the context of the study. During this time, youth may receive psychotherapy and/or initiate or change current psychiatric medication (if applicable).
2488649|NCT02977585|Active Comparator|group 1|high level support
2488650|NCT02977585|No Intervention|group 0|low level support
2488682|NCT02977390|Other|Passive Leg Raise (PLR)|"The patient is placed in a 45 degree recumbent position. Stroke volume is measured in ml.~Intervention:The patient is placed horizontal and the legs are passively raised to 45 degrees.~Measurement:The effect of the PLR on Stroke Volume is measured. Thereafter the patient is repositioned to the initial position and Stroke Volume is measured again."
2488747|NCT02977065|Active Comparator|Atorvastatin 20 mg|To administrate Atorvastatin 20 mg and 4 Placebos, PO, QD for 4weeks
2488748|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 50 mg|To administrate Atorvastatin 20 mg, CKD-519 50 mg and 3 Placebos, PO, QD for 4weeks
2488750|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 100 mg|To administrate Atorvastatin 20 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
2488751|NCT02977065|Experimental|Atorvastatin 20 mg + CKD-519 200 mg|To administrate Atorvastatin 20 mg, CKD-519 200 mg and 2 Placebos, PO, QD for 4weeks
2488753|NCT02977065|Active Comparator|Rosuvastatin 10 mg|To administrate Rosuvastatin 10 mg and 4 Placebos, PO, QD for 4weeks
2488754|NCT02977065|Experimental|Rosuvastatin 10 mg + CKD-519 100 mg|To administrate Rosuvastatin 10 mg, CKD-519 100 mg and 3 Placebos, PO, QD for 4weeks
2488821|NCT02976610|No Intervention|1|This is the control group where no intervention takes place. Blood sampling carried out according to routine at the emergency department.
2488827|NCT02976610|Experimental|2|"During the blood sampling the health care professional will screen all vacuum Lithium Heparin tubes, with the Hemolysis point-of-care test (H-POCT). If the health care professional receives a negative test the bloodsample is sent to the local laboratory.~If H-POCT indicates a positive test, of free hemoglobin in plasma, the bloodsample and H-POCT will be discarded and a new sample will be collected and screened for hemolysis. This can be repeated 3 times."
2488887|NCT02976051|Experimental|Treatment with HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cisplatin and nimorazole
2488960|NCT02975596|Other|Youth|Youth between the ages beteen ages 13-18 will be offered awareness, education, empowerment and accessibility intervention components.
2488965|NCT02975596|Other|College|Age between 18-23 will be offered awareness, education, empowerment and accessibility intervention components.
2488971|NCT02975596|Other|Adult|parents of adolescents and young adults will be offered awareness, education, and accessibility intervention components.
2488980|NCT02975596|No Intervention|Parent focus group|Parents discussed barriers and reviewed MenB education materials.
2488983|NCT02975596|No Intervention|Provider focus groups|Providers discussed barriers and reviewed MenB education materials.
2489006|NCT02975011||Lumbar stenosis group|Lumbar stenosis patients will be administered integrative Korean medicine treatment consisting of herbal medicine, Chuna manipulation, bee venom pharmacopuncture and pharmacopuncture, acupuncture, electroacupuncture, cupping, and other interventions, as needed.
2489146|NCT02974335||Identify screening and intervention approaches|Key stakeholders including: informatics/Epic leaders, medical providers, and patients from the two health systems that will be involved in the study, as well as national health information technology leaders from other large health systems.
2489194|NCT02974049|Active Comparator|Standard Treatment|Albendazole 400 mg + Ivermectin 200 µg/kg body weight administered annually (at 0, 12 and 24 months)
3160953|NCT00434239|Experimental|Treatment: Lenalidomide and Ancestim|Drug: Lenalidomide + Ancestim Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
3160954|NCT00434317|Experimental|ZOL446|
3160955|NCT00434408|Experimental|1|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
3160956|NCT00434408|Experimental|2|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
3160957|NCT00434408|Active Comparator|3|dry cord care
3160958|NCT00434447|Experimental|Zoledronic Acid|ZOL446
3160959|NCT00434460||1|Patients receiving invasive mechanical ventilation > 48 hours.
3160960|NCT00434473|Placebo Comparator|Placebo|
3160961|NCT00434473|Experimental|A-001|
3160962|NCT00434499|Active Comparator|placebo first|placebo first then crossover to EGCG
3160963|NCT00434499|Active Comparator|EGCG first|EGCG first then crossover to placebo
3160964|NCT00434525|Experimental|1 Sleeve gastrectomy with omentectomy|
3160965|NCT00434525|Active Comparator|2 Sleeve gastrectomy|
3160966|NCT00434551||1|Patients with suspected Crohn's disease
3160967|NCT00434616|Placebo Comparator|1|saline injections
3160968|NCT00434616|Active Comparator|2|autologous bone marrow transplantation into the ischemic leg
2488409|NCT02979691|Experimental|S1 based SIB-IMRT|S1 based SIB-IMRT receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (59.92Gy and 50.4Gy in 28 fractions) concurrently with oral S-1(40-60mg, orally twice daily, on every weekday) followed by four cycles of S-1 (40-60mg, orally twice daily, d1-14, every 3 weeks) as an adjuvant chemotherapy.
3194150|NCT00825123|Active Comparator|Metoprolol|
2488515|NCT02978690|Experimental|BI655130|
2488550|NCT02978365|Experimental|Patients|Male patients who undergone shoulder surgery to repair chronic instability (at least 1 shoulder dislocation prior to surgery). Time since surgery will be between 26 and 28 weeks. Patients will go through filling questionnaires and isokinetic strength measurements.
2488596|NCT02978196|Experimental|Injection of 99m-Tc-NM-01|All patients with NSCLC who have undergone biopsy of primary tumour lesion will be administered 3-12 MBq/kg of 99m-Tc-NM-01 in a single injection.
2488637|NCT02977910|Experimental|with repair of deltoid ligament|open reduction and internal fixation with repair of deltoid ligament
2488640|NCT02977910|No Intervention|without repair of deltoid ligament|open reduction and internal fixation without repair of deltoid ligament
2488669|NCT02977559|Experimental|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable for ventilation
2488674|NCT02977559|Experimental|Laryngeal Mask Airway AuraGain|Laryngeal Mask Airway AuraGain for oxygenation and ventilation
2488710|NCT02977143|Experimental|Fluid responsiveness test|"First, apply 10 cmH2O positive endexpiratory pressure (PEEP) and measure the increase in central venous pressure (CVP) as well as other preload indexes (central venous pressure, mean arterial pressure, stroke volume variation).~Second, measure the increase in cardiac index after administration of volulyte 300 ml.~If cardiac index increase more than 10%, fluid responsiveness is confirmed."
2488788|NCT02976506|Experimental|Unsupervised exercise program|To verify the interference of an unsupervised exercise program on blood pressure, physical fitness, quality of life and safety in elderly hypertensive patients. Participants were divided into the study group or control group
2488792|NCT02976506|Experimental|Physical fitness and quality of life|To verify the interference of a walking program on physical fitness and quality of life.
2488829|NCT02976311|Active Comparator|Misgav-Ladach|cesarean section(C/S) via the modified 'Misgav-Ladach' technique
2488841|NCT02976311|Active Comparator|Pfannenstiel-Kerr|cesarean section(C/S) via the 'Pfannenstiel-Kerr' technique
2488895|NCT02976025|Experimental|Longitudinal Remote Consultation|This is the active treatment arm consisting of 10 cluster randomized health centers receiving both training in collaborative care and longitudinal remote consultation (LRC) support.
2488897|NCT02976025|Active Comparator|Collaborative Care|This comparator arm will consist of 10 cluster randomized health centers who receive training in collaborative care.
2488959|NCT02975518|Active Comparator|Intra-venous infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-venously at an activity equal to that injected with the labelled endothelial cells.
2488969|NCT02975518|Active Comparator|Intra-Arterial infusion of Flourodeoxyglucose|As a control for radio labelled cells, Flourodeoxyglucose will be administered intra-arterially at an activity equal to that injected with the labelled endothelial cells.
2488972|NCT02975518|Experimental|Intra-venous injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-venously with their distribution tracked using PET CT.
2488978|NCT02975518|Experimental|Intra-Arterial injection of radio-labelled endothelial cells|Endothelial cells labelled with flourodeoxyglucose will be injected intra-arterially with their distribution tracked using PET CT.
2489017|NCT02975050||Side location|u-Cor device will be applied on side location
2489025|NCT02975050||Front location|u-Cor device will be applied on front location
3194151|NCT00825123|Placebo Comparator|Placebo|
3194152|NCT00825136|Active Comparator|relaxation|The patients of this arm practice on-line muscle relaxation for 8 weeks.
3194153|NCT00825136|Experimental|relaxation & biofeedback|The patients of this arm practice on-line muscle relaxation plus finger temperature biofeedback for 8 weeks.
2489365|NCT02973243||Manual Respiration Rate Measurement|Patients with manually measured respiratory rate
2489367|NCT02973243||Automatic Respiration Rate Measurement|Patients with automatically measured respiratory rate
2489413|NCT02972645|Experimental|LY3305677|Single escalating doses of LY3305677 administered subcutaneously (SC)
2489414|NCT02972645|Placebo Comparator|Placebo|Placebo administered SC
2489450|NCT02972307||caregiver|dyad of caregiver and the wheelchair user to whom they provide care
2489518|NCT02972125|Experimental|Treatment A - B|Single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet), followed by a Wash-Out Period of at least 7 days and a single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup).
2489521|NCT02972125|Experimental|Treatment B - A|Single administration of the test drug (Treatment B, a single dose of LCM 100 mg given as dry syrup), followed by a Wash-Out Period of at least 7 days and a single administration of the reference drug (Treatment A, a single dose of Lacosamide (LCM) 100 mg tablet).
2489584|NCT02971462|Experimental|RIC group|Experimental: RIC group The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 1 month after stroke. In addition, all participants receive a standard clinical therapy.
2489585|NCT02971462|No Intervention|Control group|The participants receive a standard clinical therapy after diagnosed ischemic stroke.
3208688|NCT00977262|Experimental|Healthy control subjects, High Monounsaturated fat shake|
2491450|NCT02959099||Controls|Patients without acute coronary syndrome (ACS).
3208689|NCT00977262|Experimental|Healthy control subjects, High Polyunsaturated fat shake|
3208690|NCT00977262|Experimental|Healthy obese subjecs, High saturated fat shake|
3208691|NCT00977262|Experimental|Healthy obese subjects, High monounsaturated fat shake|
3208692|NCT00977262|Experimental|Healthy obese subjects, High polyunsaturated fat shake|
3208693|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Saturated fat shake|
2488457|NCT02979223|Experimental|PMC/PEG-Asc|Picolyte 1 bottle/170cc at one day before colonoscopy, 7 PM. And then, Intake Coolprep 1L at the day of colonoscopy, 5 AM
2488460|NCT02979223|Active Comparator|PEG-Asc/PMC|Intake Coolprep 1L at one day before colonoscopy, 7 PM. And then, Intake Picolyte 1 bottle/170cc at the day of colonoscopy, 5AM
2488499|NCT02978924|Active Comparator|Cathodal tsDCS|20 min of active treatment
2488500|NCT02978924|Sham Comparator|Sham tsDCS|20 min of sham treatment
2488539|NCT02978599|Experimental|AVL-3288 10 mg|AVL-3288 10 mg daily for 5 days
2488541|NCT02978599|Experimental|AVL-3288 30 mg|AVL-3288 30 mg daily for 5 days
2488542|NCT02978599|Placebo Comparator|Placebo|Placebo daily for 5 days
2488597|NCT02978170|Experimental|Diagnostic (CBCT)|Patients undergo CBCT during standard of care bronchoscopy.
2488611|NCT02977897||Diarrhea on MMF|Solid organ transplant recipients on MMF who develop diarrhea while taking the drug. Fecal calprotectin will be measured in their stool and Octreotide Acetate will be used to treat their diarrhea.
2488666|NCT02977728||Mild Traumatic Brain Injury|The investigators will include patients who have been diagnosed with a mild traumatic brain injury (Glasgow Coma Scale 13 and above). The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
2488667|NCT02977728||Orthopaedic Injury|The investigators will include patients who have been diagnosed with a traumatic orthopedic injury to one of their limbs. The patients will be aged between 18 and 55 years old and admitted to the Hospital Visp in the 24 hours preceding the testing.
2488729|NCT02977247||Women undergoing routine diagnostic breast evaluation|Non-Interventional: Women presenting to enrollment sites for diagnostic examinations of symptoms or imaging findings, as recommended by a physician, and assigned BI-RADS category 4 or 5 (biopsy indicated).
3160969|NCT00434655|Active Comparator|1 LAP BAND|
2488900|NCT02975934|Experimental|Rucaparib|Oral rucaparib (monotherapy).
2488906|NCT02975934|Active Comparator|Abiraterone acetate or Enzalutamide or Docetaxel|Oral abiraterone acetate (monotherapy, given in combination with prednisone). Oral enzalutamide (monotherapy). Intravenous docetaxel (monotherapy, given in combination with prednisone or prednisolone).
2489188|NCT02974179||Subjects who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
2489228|NCT02973945|Experimental|High Flow Nasal Cannula|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through High Flow Nasal Cannula (HFNC) while they are training aerobic capacity on the treadmill.
2489230|NCT02973945|Active Comparator|The Venturi Mask|During a 8 week Pulmonary Rehabilitation Program patients will receive oxygen through The Venturi Mask (VM) while they are training aerobic capacity on the treadmill.
2489290|NCT02973542|Experimental|ethosuximide|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
2489293|NCT02973542|Placebo Comparator|placebo|A responder will correspond to a decrease in abdominal pain score (11-points NRS pain) of at least 30% compared to the score before treatment and a score of 6 or 7 on the SGA scale. At endpoint (12-weeks treatment period), it will be compared the responder rate between the 2 treatment arms (ethosuximide vs placebo).
2489527|NCT02971826|Experimental|Thrombectomy using the REVIVETM SE device|Thrombectomy using the REVIVETM SE device in patient with an ischemic stroke
2489556|NCT02971514|Experimental|Floss-Brush group|The participants flossed first followed by brushing
2489563|NCT02971514|Active Comparator|Brush-Floss group|They used dental floss after brushing
2489638|NCT02971085||Active surveillance|This is the prospective cohort study with single group of active surveillance. We define our cohort group as the patients with following criteria: Men < 80 years, pathologically proven adenocarcinoma of the prostate by transrectal prostate biopsy ≥ 10 cores, pre-biopsy PSA ≤ 10ng/ml, PSA density < 0.15 ng/ml/ml, clinical stage T1-2a, biopsy Gleason score ≤ 6, number of positive cores ≤ 2, maximum cancer involvement in any one core ≤ 20%, and no PIRADS 5 lesion on multiparametric prostate MRI (1.5T or 3T).
2489726|NCT02970786|Experimental|68Ga-NODAGA-E(c[RGDyK])2 PET|One injection of 68Ga-NODAGA-E(c[RGDyK])2 PET (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
2489749|NCT02970214||Heart Failure|Patients with chronic heart failure and with/without reduced left ventricular ejection fraction (EF) at baseline (HFrEF, HFmrEF, HFpEF)
2489750|NCT02970214||Cardiometabolic risk|Patients with cardiovascular diseases and metabolic risk factors at baseline
2489802|NCT02969980|Experimental|PTCy|Patients who receive post-transplantation cyclophosphamide
2489863|NCT02969538|Other|Total etching time|Dentin etching (35% phosphoric acid) by time recommend by manufacturer (15 seconds)
2489864|NCT02969538|Experimental|Half-reduced etching time|Dentin etching (35% phosphoric acid) by 7 seconds
2489911|NCT02969213||Genetic|patients with Gene detection (+)
2489913|NCT02969213||Metabolism|patients with Metabolic disturbance
2489917|NCT02969213||Immune|patients with Immunological marker and Immunotherapy (+)
2489919|NCT02969213||infection|patients with the Infection of central nervous system
2489920|NCT02969213||structure|patients with abnormal image of brain
2489921|NCT02969213||unknown|patients not found any reason
2490051|NCT02968147|Experimental|Conventional ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and conventional ventilation
3160970|NCT00434655|Experimental|2 Sleeve gastrectomy|
3160971|NCT00434811|Experimental|Islet Transplantation|Participants will receive up to three separate islet transplants and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG), sirolimus, and low-dose tacrolimus.
3160972|NCT00434824|Active Comparator|Arm 1|Oral testosterone undecanoate (Andriol)
3160973|NCT00434824|Placebo Comparator|Arm 2|Placebo
2488572|NCT02978495|Experimental|A- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
2488574|NCT02978495|Active Comparator|B- BRCA Mutation|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
2488578|NCT02978495|Experimental|C- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks."
2488582|NCT02978495|Active Comparator|D- BRCA wild-type|"Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:~Paclitaxel 80 mg/m2 once a week, for 12 weeks."
2488634|NCT02977884|Experimental|The Complete Health Improvement Program|Participants in The Complete Health Improvement Program
2488675|NCT02977494|Experimental|Daratumumab Bortezomib|
2488744|NCT02976974|Experimental|Manual therapy (MT)|MT: Manual Therapy. Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
2488746|NCT02976974|Experimental|Therapeutic exercise (E)|"E: Therapeutic Exercise.~Shoulder extension: Elastic bands. Shoulder flexion: Elastic bands Shoulder external rotation: Elastic bands. Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
2488770|NCT02976688|Experimental|Sodium propionate|Sodium propionate will be administered with a daily intake of 2 x 500 mg in form of capsules for 12 weeks.
2488833|NCT02976441|Experimental|Focal RT, Temozolomide, Stem Cell Collection/Reinfusion|"Autologous stem cell collection will be performed 1-4 days prior to initiating radiation therapy and temozolomide~Focal radiation therapy: standard of care dose daily for approximately 6 weeks~Temozolomide: standard of care dose by mouth daily for 6 weeks with radiation~2-7 days after the end of the radiation therapy and temozolomide the stem cells will be reinfused into the patient~Temozolomide: standard of care dose by mouth on days 1-5 every 28 days for 6 months following a 4-6 week rest period after the initial radiation and temozolomide"
2488886|NCT02975869|Active Comparator|Standard Leukemia Care|Standard Leukemia care
2488894|NCT02975869|Experimental|Collaborative Palliative and Oncology Care|Collaborative care from Palliative Care and Leukemia will be given
2488935|NCT02975427||Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
2488992|NCT02975310|Experimental|Endoscopic polypectomy in clinic (EPIC)|Patients assigned to this arm of the study will undergo the In Clinic Polypectomy Performed in Clinic
2488996|NCT02975310|Active Comparator|Endoscopic Sinus Surgery (ESS)|Patients assigned to this arm will undergo endoscopic sinus surgery (ESS),
3194154|NCT00825149|Experimental|A: R/R FL: Obinutuzumab Low Dose + CHOP|Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m^2), vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3194155|NCT00825149|Experimental|B: R/R FL: Obinutuzumab High Dose + CHOP|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, and cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
2489191|NCT02974270|Experimental|Leuprolide acetate|
2489223|NCT02973919|Experimental|Eye movements|Eye Movement Desensitization and Reprocessing Therapy + virtual reality exposure therapy
2489226|NCT02973919|Active Comparator|Control|virtual reality exposure therapy
2489261|NCT02973607||Donors|Patients who donated a kidney and took part in the original CRIB-DONOR study.
2489262|NCT02973607||Controls|Healthy subjects who took part in the original CRIB-DONOR study.
2489276|NCT02973399|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule for 2 cycles after a CR or until the cancer progresses or the subject is unable to tolerate the therapy
2489332|NCT02973204||HCC sorafenib|HCC patients referred for Sorafenib treatment
2489334|NCT02973204||HCC curative treatment|HCC patient undergoing potential curative treatment, eg. radiofrequency ablation (RFA) or resection
2489336|NCT02973204||NET everolimus|Pancreatic NET patients referred for Everolimus treatment
2489337|NCT02973204||NET ssta|Small intestinal or unknown primary NET patients referred for treatment with somatostatin analogues, eg. lanreotide and octreotide
3194156|NCT00825149|Experimental|C: R/R FL: Obinutuzumab Low Dose + FC|Participants with R/R FL will receive obinutuzumab 400 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3208694|NCT00977262|Experimental|Obese diabetes type 2 subjects, High Monounsaturated fat shake|
2489941|NCT02968940|Experimental|Avelumab and hypofractionated radiation therapy(HFRT)|"Avelumab 10 mg/kg intravenously (IV) every 2 weeks.~Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions"
2488590|NCT02978443|Experimental|Nivolumab-Ipilimumab Combination Therapy|All patients will receive nivolumab administered IV over 60 minutes at 1 mg/kg combined with ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks until progression, intolerable toxicity, or a maximum of 48 weeks, whichever comes first (Maintenance). Patients exhibiting complete response (CR) should continue nivolumab monotherapy at least 12 weeks beyond documentation of CR, if possible.
2488612|NCT02977845|Experimental|Primary aim|The primary aim of this study is to assess the effect of Qigong on managing dyspnea, fatigue, and anxiety (as a cluster) in lung cancer patients.
2488613|NCT02977845|Experimental|Secondary aim|The secondary aim of this study is exploring the effect of Qigong on cough which is another common symptom linked with dyspnea, fatigue, and anxiety as a cluster, and QOL in lung cancer patients.
2488705|NCT02977169|Experimental|Arm I (PORT)|Participants in the Arm I will receive four cycles of adjuvant chemotherapy and after that, sequential adjuvant thoracic conformal radiotherapy (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered. PORT begins within 2-4 weeks after chemotherapy.
2488708|NCT02977169|Placebo Comparator|Arm II (no PORT)|Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, do not undergo adjuvant thoracic conformal radiotherapy.
2488804|NCT02976831|Experimental|AZD0284|"Part 1A:~Following an overnight fast of at least 10 hours, each subject will receive a single dose of AZD0284 or matching placebo in the form of an oral solution with water. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 1B (food cohort):~Subjects, will receive a single dose of AZD0284 at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing. The total volume that the subject will receive (IMP and water) will be 240 mL.~Part 2:~In Part 2, subjects will receive 1 dose level of AZD0284 (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (IMP with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
2488810|NCT02976831|Active Comparator|Placebo|"Part 1A: Following an overnight fast of at least 10 hours, each subject will receive a single dose of placebo in the form of an oral solution with water. The first cohort will receive 4.0 mg AZD0284 or placebo on Day 1. The actual dose for subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the SRC Part 1B (food cohort): In Part 1B, subjects, will receive a single dose of placebo at a dose level in the range of or slightly above the dose level anticipated to yield therapeutic exposure, currently predicted to be achieved with 28 mg AZD0284 at twice daily dosing.~Part 2: In Part 2, each subject will receive 1 dose level of placebo (once or twice daily) with water from Day 1 to between (including) Day 7 and Day 14. The total volume that the subject will receive (placebo with water) will be 240 mL. Subjects may be dosed in either the fasted or fed state depending on emerging data from Part 1."
2488817|NCT02976207||OSA diagnosed patients|patients at the age range of 18-90, male or female, who are diagnosed as suffering from OSA and are surgery candidates for their condition.
2488880|NCT02976116|Experimental|Fruquintinib & Gefitinib|Drug: Fruquintinib and Gefitinib
2488939|NCT02975505|Experimental|Strict SBP Target|Target Systolic Blood Pressure <120 mm Hg
2488944|NCT02975505|No Intervention|Usual SBP Target|Target Systolic Blood Pressure 130-140 mm Hg
2489057|NCT02974946|Experimental|Study group|Patients will receive the RenalGuard system
2489061|NCT02974946|No Intervention|Control group|Standard practice will be performed with no RenalGuard system
2489073|NCT02974569||C-SCAT|C-SCAT arm: Completes and uses Computerized Symptom Capture Tool (C-SCAT) during visit with provider for two clinic visits.
2489181|NCT02974465|Experimental|Experimental Group|protocol of Biofeedback Electromyography plus conventional physical therapy treatment
2489185|NCT02974465|Sham Comparator|Control Group|consisted of Sham- Biofeedback Electromyography plus conventional physical therapy treatment
2489213|NCT02973893|Placebo Comparator|Placebo plus Standard Care|Placebo plus Standard Care
2489214|NCT02973893|Experimental|VF001-DP LD plus Standard Care|VF001-DP (14 micrograms per treatment) and Standard Care (low dose [LD])
2489219|NCT02973893|Experimental|VF001-DP HD plus Standard Care|VF001-DP (140 micrograms per treatment) and Standard Care (high dose [HD])
3194157|NCT00825149|Experimental|D: R/R FL: Obinutuzumab High Dose + FC|Participants with R/R FL will receive obinutuzumab 1600 mg IV infusion on Days 1 and 8 of Cycle 1 and 800 mg IV infusion every 4 weeks on Days 1 of subsequent cycles (for 46 cycles) in the induction period; Fludarabine 25 mg/m^2/day and cyclophosphamide 250 mg/m^2/day IV infusion every 4 weeks on Days 13 of each cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 800 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3194158|NCT00825149|Experimental|E: First-Line FL: Obinutuzumab + Bendamustine|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 4 weeks on Day 1 of subsequent cycles (for 46 cycles) in the induction period; Bendamustine 90 mg/m^2 IV infusion on Days 2 and 3 of Cycle 1 and every 4 weeks on Days 1 and 2 of each subsequent cycle for 46 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
2489385|NCT02972879|Active Comparator|Therapeutic Modalities|"Group 1: Metal orthotic, keeping 0º of the extension of the proximal interphalangeal joint, during all day, for 5 weeks, stopping the use only for bathing~Group 2: 10 LLLT sessions applications on the A1 pulley and lump formed on the flexor tendon of the the affected finger; Two sessions per week, five weeks of treatment.~Group 3: Paraffin bath 2 times a week for 20 minutes (total of 10 sessions)."
2489386|NCT02972879|Active Comparator|Corticosteroid injection|Group 4: Corticosteroid injection in the A1 pulley, 1 application.
2489425|NCT02972528|Active Comparator|Platelet Lysate|Patients will receive 5ml peri-lesional injections of Platelet Lysate at weekly intervals, for 4 consecutive times (week 0,1,2,3).
2489431|NCT02972528|Placebo Comparator|Platelet Poor Plasma|Patients will receive 5ml peri-lesional injections of Platelet Poor Plasma at weekly intervals, for 4 consecutive times (week 0,1,2,3).
2490014|NCT02968459|Experimental|Umbilical cord MSCs Group|1*10^7 Umbilical cord MSCs
2488629|NCT02978027|Experimental|Motivational Interviewing (MI)|The MI intervention condition was also adapted from the NIAAA Clinician's Guide, with additional modification to include elements of MI. Clinicians normalize Screening and Brief Intervention (SBI) and ask the patient's permission before discussing alcohol use. The NIAAA pre-screen and single-question screen are administered. Assessment of quantity, frequency, and Alcohol Use Disorder symptoms is done using open questions. The ask-tell-ask technique is used to share feedback and exchange information regarding U.S adult drinking patterns. For patients low in readiness to make a change, clinicians build readiness using structured MI tools. For patients high in readiness to change, the ask-tell-ask technique is used to explore strategies for cutting down and develop an action plan.
3194159|NCT00825149|Experimental|F: First-Line FL: Obinutuzumab + CHOP|Participants with first-line FL will receive obinutuzumab 1000 mg IV infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 mg/m^2, vincristine 1.4 mg/m^2 capped at 2 mg, cyclophosphamide 750 mg/m^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 1000 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
3194160|NCT00825188|Active Comparator|eplerenone|
2488802|NCT02976766|Experimental|Gypenosides|
2488808|NCT02976766|Placebo Comparator|Placebo|
2488852|NCT02976220|Experimental|Digital Education|1 month digital education program
2488865|NCT02975830||0-2 years|Children aged from birth to 24 months Three dimensional CT based images
2488869|NCT02975830||2-4 Years|Children aged from 25-48 months Three dimensional CT based images
2488874|NCT02975830||4-6 Years|Children aged from 49-72 Three dimensional CT based images
2488878|NCT02975830||6-8 years|Children aged from 73-96 months Three dimensional CT based images
2488955|NCT02975609|Active Comparator|Conventional Fractionated Radiotherapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the control group undergoing the conventional fractionated radiotherapy to all metastatic sites and the primary tumor.
2488964|NCT02975609|Experimental|Stereotactic Body Radiation Therapy|The patients enrolled receive firstly 4-6 cycles chemotherapy (platinum-based doublet chemotherapy), and achieve response(stable disease or partial response or complete response). Patients will be randomized into the experimental group undergoing SBRT to all metastatic sites and the primary tumor.
2488990|NCT02975089|No Intervention|Control|A leaflet of healthy diet for elderly
2488994|NCT02975089|Experimental|Nutritional Intervention 1|"Multi-nutrient supplement"
2488997|NCT02975089|Experimental|Nutritional Intervention 2|"Multi-nutrient & soy protein supplement"
2488998|NCT02975089|Experimental|Nutritional Intervention 3|Nutrition education on balanced diet & food supplement
3194161|NCT00825188|Active Comparator|amlodipine|Amlodipine 5-10mg daily times 8 weeks
2489152|NCT02974322|Experimental|GED-0301 1 x 160 mg once daily|GED-0301 1 x 160 mg tablet once daily (QD)
2489155|NCT02974322|Experimental|GED-0301 - 4 x 40 mg once daily|GED-0301 4 x 40 mg tablets once daily (QD)
2489158|NCT02974322|Placebo Comparator|Placebo once daily|Placebo once daily (QD)
2489471|NCT02972229|Experimental|partial body group|10x(3-5) Gy IMRT on partial vertebral body
2489474|NCT02972229|Active Comparator|whole body group|10x3 Gy IMRT on whole vertebral body
2489519|NCT02972034|Experimental|A: MK-8353 BID Continuous+Pembro|Participants receive MK-8353 orally (PO) two times each day (BID) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab (pembro) 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 35 cycles.
2489522|NCT02972034|Experimental|B: MK-8353 QD Continuous+Pembro|Participants receive MK-8353 PO once each day (QD) on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 35 cycles.
2489523|NCT02972034|Experimental|C: MK-8353 QD 1 Week On/1 Week Off+Pembro|Optional Arm: Participants receive MK-8353 PO QD on Days 1 to 7, Days 15 to 21 and Days 29 to 35 PLUS pembrolizumab 200 mg IV on Day 1 and Day 22 of each 42-day period (based on 2 cycles of 21 days) for up to 35 cycles.
2489526|NCT02972034|Experimental|D: MK-8353 QD Run-in→MK-8353 QD Continuous+Pembro|Optional Arm: Participants undergo an MK-8353 PO QD run-in period from Day -14 to Day -1 prior to Cycle 1 during which they receive MK-8353 PO QD. After the run-in period, participants receive MK-8353 PO QD on Days 1 through 21 of each 21-day cycle PLUS pembrolizumab 200 mg IV on Day 1 of each 21-day cycle for up to 36 cycles.
2489596|NCT02971384|Experimental|Echinaforce Junior Tablets|Hydroalcoholic extract of Echinacea purpurea herb and radix
2489600|NCT02971384|Active Comparator|Vitamin C Tablets|synthetically produced ascorbic acid
2489671|NCT02970877|Experimental|Allogenic treatment group|Fecal filtrate from 150 g stool from healthy lean donors
2489673|NCT02970877|Placebo Comparator|Autologous control group|Fecal filtrate from 150 g of the recipient's own stool
3194162|NCT00825201|Experimental|Treatment (paclitaxel albumin-stabilized nanoparticle)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation given IP on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3194163|NCT00825214|Active Comparator|1|Use of zapperclick on mosquito bite
2489785|NCT02969967|Experimental|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities
2489825|NCT02969772|Experimental|Assessment of upper limb variables|Assessment of clinical variables of tetraplegics reach-and-grasp pattern
2489829|NCT02969772|Experimental|Training protocol|Training with electrical stimulation of upper limb
2518165|NCT02775526|Active Comparator|TVT|TVT
3194164|NCT00825214|Placebo Comparator|2|use of inactivated zapperclick on mosquito bite
3194165|NCT00825240||Cancer Survivorship Study|Survey of colorectal cancer patients within one year from treatment end.
3194166|NCT00825279|Active Comparator|1-BMS|Bare Metal Stent (Euca STS Flex)
3194167|NCT00825279|Experimental|2-DES|Drug Eluting Stent (Euca STS Flex DE), Paclitaxel Eluting stent with biodegradable polymer
3194168|NCT00825292|Active Comparator|2|HDNBI colonoscopy followed by standard white light colonoscopy
3194169|NCT00825292|Active Comparator|1|standard white light colonoscopy followed by HDNBI colonoscopy
2488663|NCT02977533|Placebo Comparator|Placebo|A dose of matching placebo will be given as a single subcutaneous administration under fed conditions. Acyclovir will be given twice daily starting on Day 1 and continuing for 28 days after investigational medicinal product administration.
2488704|NCT02977208|Active Comparator|Homozygous for the wild type allele|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
2488709|NCT02977208|Active Comparator|Homo- or heterozygous for rare alleles|"Patients with 18 years old or older with epilepsy, neuropathic pain or any chronic pain undergoing chronic treatment with gabapentin are being recruited.~Sparse blood sampling are being collected up to 4 h after administration of the drug for pharmacokinetic study. Urine sampling are being collected during the dosing interval, only in patients hospitalized at the Hospital Estadual de Américo Brasiliense (HEAB). Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms."
2488853|NCT02976142|Experimental|neoadjuvant chemoimmunotherapy|Patients with gastric cancer and verified free cancer cells who receive 1 course of intraperitoneal immunotherapy with interleykin-2 + 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
2488855|NCT02976142|No Intervention|neoadjuvant chemotherapy|Patients with gastric cancer and verified free cancer cells who receive 3 courses of systemic chemotherapy (Cisplatin + 5-FU). In case of downstaging (M1 -> M0) surgical treatment will be performed.
2488883|NCT02975843|Experimental|CHF5993|99mTc Radiolabelled Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
2488953|NCT02975622|Active Comparator|Subclavian|Subclavian vein will be individualized and approached by longitudinal incidence, according to previous studies. Skin puncture will be made next to the transducer, lateral to the first rib, maintaining constant visualization of the needle tip.
2488962|NCT02975622|Active Comparator|Jugular|Jugular vein will be identified by transverse or longitudinal approach, and skin puncture will be made by transverse or longitudinal incidence, according to operator's preferences. Using transverse approach, the needle will be maintained in a 45 degree angle with the skin, and the insertion site will be exactly the same as the measured distance between asking and jugular vein wall.
2489004|NCT02975167|Experimental|Inpatient|"Subjects randomized to this group will receive the same intervention as the outpatient group -- cervical ripening with Foley catheter -- but remain within the hospital. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to inpatient cervical ripening"
2489013|NCT02975167|Experimental|Outpatient|"Subjects randomized to this group will receive the same intervention as the inpatient group -- cervical ripening with Foley catheter -- but will be discharged home. Subjects will be asked to return to the hospital when the catheter falls out or if 24 hours has elapsed. They will be given detailed instructions and provided a 24 hour phone number to call should they have any concerns. Subjects will be asked to complete a survey assessing their fears, opinions, anxiety, satisfaction and hours of sleep before and after the catheter is placed and removed, respectively.~The intervention: randomization to outpatient cervical ripening"
2489216|NCT02973971||Healthy subjects|
2489218|NCT02973971||Alzheimer patients|
2489255|NCT02973698|Other|chin-down posture maneuver|The patients in received an intervention program consisting of four weekly individual sessions of 30 minutes. In these sessions, it was performed the training of Chin-down postural maneuver with saliva and water. The participants were trained to perform the maneuver twice a day, swallowing saliva, and during meals, throughout the week, at home. The participants received a form, so they recorded the number of times they performed the maneuver at home. It allowed the control of adherence, being reinforced at each session the importance of adherence to treatment. Besides, the subjects received instructions regarding feeding. All the instructions, as well as the explanation about the maneuver, were submitted to the patients through a written document.
2489257|NCT02973698|Other|Control|The participants of this group underwent evaluation of swallowing, and the same assessment was repeated after four weeks, without any intervention during that period.
2489259|NCT02973698|Other|Orientations about swallowing|The individuals participated in an intervention program which consisted of four individual sessions a week, with 30 minutes. In these sessions, the instructions about feeding were performed. The individuals received all the instructions on a written document. In the sessions, it was verified doubts about the guidelines and treatment adherence. In this group, it was not applied the Chin-down postural maneuver.
2489272|NCT02973360|Experimental|Dose Level 1|Target dose 20 mg/kg Docosahexaenoic acid
2489274|NCT02973360|Experimental|Dose Level 2|Target dose 36 mg/kg Docosahexaenoic acid
2489278|NCT02973360|Experimental|Dose Level 3|Target dose 60 mg/kg Docosahexaenoic acid
2489288|NCT02973360|Placebo Comparator|Placebo|Soybean oil
2489361|NCT02972983|Placebo Comparator|Placebo|51 patients receiving a daily placebo infusion for five days on top of standard of care treatment for methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia
2489363|NCT02972983|Experimental|Daptomycin|51 patients receiving daily daptomycin infusion for five days on top of standard of care treatment for MSSA bacteremia
2489851|NCT02969642|Sham Comparator|Sham|Sham low energy laser using approximately 1/1000 th energy of treatment laser.
3160974|NCT00434837|Experimental|Low-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the Low-tension group will receive the low-tension treatment with initial graft tension set so that the anterior-posterior (A-P) displacement of the reconstructed knee is equal to that of the uninjured knee.
2488793|NCT02976779|Experimental|OWC MGC cream|Cannabis based topical cream 3% CBD and 3% THC. The cream was designed to treat Psoriasis . The cream will be applied twice daily.
2488796|NCT02976779|Placebo Comparator|OWC Control Cream|Carrier cream. CBD and THC were taken out from the formulation. The cream will be applied twice daily.
2488825|NCT02976298|Sham Comparator|transcranial magnetic stimulation|sham transcranial magnetic stimulation
2488839|NCT02976298|Experimental|supplementary motor area stimulation|supplementary motor area transcranial magnetic stimulation
2488848|NCT02976298|Experimental|cerebellar stimulation|cerebellar transcranial magnetic stimulation
2488882|NCT02975947|Active Comparator|Control Group|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
2488888|NCT02975947|Experimental|Study Group|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide delivered into the open peritoneal cavity.
2489022|NCT02974959|Experimental|gammaCore active device|Patients in this arm will be using an active device which delivers a treatment dose of current to the vagus nerve twice daily for 120 seconds
2489029|NCT02974959|Sham Comparator|gammaCore Sham device|Patients in this arm will be using a sham device which does not deliver a treatment dose of current, but will deliver enough current to cause tingling on the skin.
2489097|NCT02974790||Circulatory failure|Patients with a circulatory failure due to a sepsis or not
2489132|NCT02974387|Active Comparator|Fluorometholone(FMl)|Patients will be randomized to the eye and will receive FML in one eye.
2489134|NCT02974387|Active Comparator|Loteprednol (Lotemax)|Patients will be randomized to the eye and will receive Lotemax in contralateral eye.
2489232|NCT02973737|Experimental|arm 1|pyrotinib plus capecitabine pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2489233|NCT02973737|Active Comparator|arm 2|placebo plus capecitabine placebo(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2489282|NCT02973490|Experimental|Transanal Tube Drainage|patients with transanal tube drainage after ESD
2489289|NCT02973490|No Intervention|Without Transanal Tube Drainage|patients without transanal tube drainage after ESD
2489387|NCT02973191|Experimental|JCAR015 administration|Single dose of 1.0-3.0 mg/m^2 IV cyclophosphamide, JCAR015 Dose 1 1x10^6 Tcells/kg, JCAR015 Dose 2 3x10^6 Tcells/kg
2489507|NCT02971891|Experimental|CLS006 (Furosemide)|CLS006 (Furosemide) Topical Gel, 0.125%
2489511|NCT02971891|Placebo Comparator|Vehicle|Vehicle Topical Gel
2489617|NCT02971358|Experimental|Radical prostatectomy arm|In this arm the investigators will include patients with locally advanced or metastatic prostate cancer, who will undergo cytoreductive radical prostatectomy with extended lymph node dissection.
2489643|NCT02971072|Experimental|Patients|Subjects with shoulder tendinopathy who will undergo both a subacromial injection and physical therapy
2489725|NCT02970695|Active Comparator|Treatment arm 1|"To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. The subjects will be asked to wear a pair of laser protective goggles so as to blind them during treatment."
2489727|NCT02970695|Active Comparator|Treatment arm 2|Subjects will receive LAT. A laser device (Pointer Pulse™) will be used in this study.
2489728|NCT02970695|Experimental|Treatment arm 3|Subjects will receive a combined approach that includes the use of LAT plus MAT. LAT will be administered prior to MAT application on the selected auricular points, and the procedures used will be similar to the procedures described for Group 1 and Group 2.
2489816|NCT02969798|No Intervention|Healthy normal glucose tolerance (NGT) subjects|Subjects (Fasting Plasma Glucose or FPG < 100 mg/dl and 2-h PG < 140 mg/dl) without FH (family history) of diabetes in a first degree relative
2489822|NCT02969798|Active Comparator|Isolated IGT with Dapagliflozin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive dapagliflozin, 10 mg/day
2489823|NCT02969798|Active Comparator|Isolated IGT with Saxagliptin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive saxagliptin, 5 mg/day
2489828|NCT02969798|Active Comparator|Isolated IGT with Pioglitazone|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
3160975|NCT00434837|Experimental|High-tension|Patients recruited to study the initial graft tension during ACL reconstruction surgery who were randomized to the High-tension group will receive the high-tension treatment with the initial graft tension set to reduce A-P displacement by 2 millimeters relative to that of the uninjured knee.
3160976|NCT00434837|No Intervention|Uninjured Control Group|Uninjured age, sex, and race matched control group
3160977|NCT00434850|Experimental|Allogeneic Pancreatic Islet Cells|Participants in this study can receive up to three separate islet transplants. They will begin receiving antithymocyte globulin (ATG) and sirolimus 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant. Participants will continue taking sirolimus for the duration of the study. On the day of transplant, participants will receive DSG and etanercept, in addition to ATG and sirolimus. The DSG infusion will be administered over 3 hours and will immediately precede the islet transplant. Participants will continue receiving daily 3-hour infusions of DSG through Day 6 post-transplant. Etanercept will also be administered on Days 3, 7, and 10 post-transplant. Tacrolimus will be administered on Day 1 post-transplant and continued throughout the study.
3160978|NCT00434889||1|Memory problems
3160979|NCT00434889||2|No memory problems
3160980|NCT00434941|Experimental|Radiotherapy + Capecitabine|Radiotherapy (for 25 days; Dose: 50 Gy) + Capecitabine (for 35 days; Dose: 825 mg/m2 twice per day p.o.) Experimental treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
3160981|NCT00434980|Experimental|Treatment|Participant and family take part in FCA treatment program.
3160982|NCT00435032|Active Comparator|1|Early appendectomy
2488739|NCT02977286|Experimental|Naloxegol Oral Tablet|"Intervention: Naloxegol 25 mg (or 12.5 mg) tablet po (enteral) daily AND Docusate Sodium 100mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: Movantik"
2488740|NCT02977286|Placebo Comparator|Placebo Oral Tablet|"Intervention: Placebo tablet po (enteral) daily AND Docusate Sodium 100 mg Oral Capsule twice daily AND Study laxative protocol daily [that may include Senna 217 mg Oral Tablet, Polyethylene Glycols (Miralax), Magnesium Citrate Oral Liquid Product (Citromag), Bisacodyl 10 mg Suppository (Dulcolax) and Methylnaltrexone (Relistor)] until one of the following:~Adverse event potentially attributable to the study drug.~Use of Relistor.~Scheduled opioid therapy is stopped for ≥ 24 hours and participant has ≥ 1 SBM since enrollment.~The participant has been administered 10 days of study medication.~The participant is discharged from the ICU.~The participant requires the initiation of a strong CYP3A4 inhibitor medication.~Other Name: AstraZeneca provided Movantik placebo"
2488820|NCT02976597|Active Comparator|Bupivacaine 0.25%|Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side on each side at end of the surgery.
2488823|NCT02976597|Active Comparator|Morphine 10mg|Morphine 10mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery.Patients will recieve 5mg morphine on each side
2488837|NCT02976597|Active Comparator|Morphine 15mg|Morphine 15mg and Bupivacaine 0.25% 20ml will be administered for ultrasound guided TAP block on each side at end of the surgery. Patients will recieve 7.5mg morphine on each side
2488890|NCT02975817|Experimental|Hibler's|Insert description from protocol
2488901|NCT02975817|Active Comparator|Warm Air|Insert description from protocol
2488943|NCT02975531|Experimental|Simulator's construction|To build the simulator was selected a volunteer (VF) as a model. This volunteer had no complaints of pain or trauma to the cervical region. This region was used to collect the displacement of the skin and cytometry neck.
2488948|NCT02975531|Experimental|Model Features|Thirty-nine volunteers (GT) were selected men and women aged over 18 years without history of trauma in the cervical region in order to determine the characteristics of the model: skin elasticity and cirtometry neck.
2488950|NCT02975531|Experimental|Parameterization technique|Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
2488952|NCT02975531|Experimental|Simulator training|Twenty-six volunteers (GE) were selected, men and women, aged over 18 years without prior knowledge of the technique for simulator training.
2488956|NCT02975531|Experimental|Training Evaluation|A physical therapist (VE) was selected to evaluate the volunteers (GE) before and after training in the simulator.
2489001|NCT02975037|Experimental|sildenafil+erythromycin|Sildenafil 25 mg PO (single dose); Erythromycin 250 mg PO (3 doses); Sildenafil 25 mg PO + Erythromycin 250 mg PO (single dose)
2489012|NCT02975037|Experimental|sildenafil+itraconazole|Sildenafil 25 mg PO (single dose); Itraconazole 100 mg PO (3 doses); Sildenafil 25 mg PO + Itraconazole 100 mg PO (single dose)
3160983|NCT00435032|Active Comparator|2|Interval appendectomy
3160984|NCT00435071|Active Comparator|1|
3160985|NCT00435071|Active Comparator|2|
2489139|NCT02974283|Experimental|NBO group|Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.
2489142|NCT02974283|No Intervention|Control group|The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy.
2489236|NCT02973815|Experimental|NU-HOME Intervention|Participants randomized to the intervention condition will receive the NU-HOME family intervention program that includes group sessions with other families focused on nutrition education, cooking skills, and physical activity. The intervention program also includes individual goal setting phone calls with parents and online, complementary materials.
2489238|NCT02973815|No Intervention|Delayed Intervention|Participants randomized to the delayed intervention condition will not receive any educational materials or training until after the final data collection. Once all data collection is completed, they will receive a shortened version of the NU-HOME intervention program that was offered to the intervention families.
2489295|NCT02973529|Experimental|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
2489301|NCT02973529|Experimental|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
2489445|NCT02972372|Active Comparator|CRT group|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in IMRT mode (total of 50Gy given in 25 fractions) will be given over a period 5-6 weeks.
2489449|NCT02972372|Active Comparator|Surgery group|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
2489520|NCT02972060|Active Comparator|ADT|"The standard treatment for this stage of the disease is ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
2489540|NCT02971722|Experimental|1.5mg JY09(cohort 1)|1.5mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
3160986|NCT00435084|Experimental|Single-arm mono therapy|APO866 will be administered by civ infusion at 0.126 mg/m2/hr for 4 consecutive days (96 hours). This constitutes 1 cycle.
3160987|NCT00435123|Active Comparator|A|Patients are randomly assigned to receive either Active Comparator (ProStat 64) or placebo for the first 3 months. At the end of this, all patients receive open label ProStat64.
2488766|NCT02977026|Experimental|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to provide personalized normative feedback aimed at motivating reductions in drinking"
2488767|NCT02977026|Experimental|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding drinking."
2489000|NCT02974998|Experimental|Young Women's Health CoOp (YWHC)/ HTC|Participants received an enhanced gender-focused HTC intervention.
2489008|NCT02974998|Active Comparator|Standard HTC|Participants received the standard HTC available in South Africa for this population.
2489153|NCT02974491|Experimental|Apple Juice|
2489202|NCT02974075|Experimental|Salvage lymph node dissection|Patients will undergo extended pelvic salvage lymph node dissection
2489296|NCT02973295|Experimental|Group Silymarin|Silymarin 2x200 mg 8 weeks (2x2 caps) Silymarin 2x100 mg 16 weeks (2x1 caps)
2489307|NCT02973295|Placebo Comparator|Group Placebo|2x2 placebo caps 8 weeks 2x1 placebo caps 16 weeks
2489328|NCT02972996|Experimental|Blueberry|
2489329|NCT02972996|Placebo Comparator|Placebo|
2489406|NCT02972814||Thoracic pain|Patients presenting to the emergency room with thoracic pain probably due to a non-STEMI
3160988|NCT00435123|Placebo Comparator|B|Patients are randomly assigned to Placebo Comparator or Active Comparator (ProStat 64). At the end of 3 months, all patients receive active ProStat 64
3160989|NCT00435149|Active Comparator|1|
2489534|NCT02971995|Experimental|Prostate cancer/TEP scan|
2489537|NCT02971995|Active Comparator|Prostate cancer/mpMRI|
2489570|NCT02971475|Experimental|ESWL alone|Patients in this group would be treated with extracorporeal shock wave lithotripsy only. Otherwise, extra endoscopic procedures will be carried out in case of continuous and aggravated pain. Analgesics will be administrated as needed and recorded.
2489573|NCT02971475|Active Comparator|ESWL combined with ERCP|People in this group would be treated with ESWL followed be endoscopic drainage of the main pancreatic duct in 48 hours. Analgesics will be administrated as needed and recorded.
2489766|NCT02970058|Active Comparator|Platelet-rich Plasma|30 patients will receive platelet-rich plasma post-spinal anesthesia
2489769|NCT02970058|Placebo Comparator|Control|30 patients will receive sterile saline post-spinal anesthesia
2489893|NCT02969083|Other|Radical nephro-ureterectomy (RNU)|Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) <55 ml/min or unfit for cisplatin-based chemotherapy)
2489895|NCT02969083|Other|Gemcitabine/Cisplatin plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery
2490017|NCT02968459|Placebo Comparator|Placebo-Controlled Group|1ml of 0.9% saline
3160990|NCT00435149|Active Comparator|2|
3160991|NCT00435227|Experimental|Motavizumab|Participants will receive a single IM dose of 30 mg/kg of motavizumab on Day 0 of the study.
3160992|NCT00435227|Placebo Comparator|Placebo|Participants will receive a single IM dose of placebo matched to motavizumab on Day 0 of the study.
3160993|NCT00435253|Experimental|BLVR Treatment|BLVR Treatment
3160994|NCT00435266|Experimental|1|Remote ischemic preconditioning
3160995|NCT00435266|No Intervention|2|
3160996|NCT00435279|Experimental|Eszopiclone|
3160997|NCT00435279|Experimental|Placebo|
3160998|NCT00435292|Experimental|flavocoxid 250 mg|flavonoid mixture
3160999|NCT00435292|Active Comparator|flavocoxid 500 mg|flavonoid mixture
3161000|NCT00435292|Active Comparator|naproxen|nonsteroidal antiinflammatory drug
3161001|NCT00435331|Experimental|1|Open Label
3161002|NCT00435357|Experimental|mobile-bearing TKA|
3161003|NCT00435357|Active Comparator|fixed- bearing TKA|
3161004|NCT00435383||Observational|Group 1 received a presurgical caudal block and group 2 received a intravenous narcotics.
3161005|NCT00435396|Experimental|Group A|
3161006|NCT00435474|Active Comparator|1|Silver product
3161007|NCT00435474|Experimental|2|Honey product
3161008|NCT00435513||Transsexual group|Female-to-male and male-to-female transsexuals
3161009|NCT00435513||Controls|Healthy blood donors
3161010|NCT00435617|Experimental|A|Hand Mentor
3161011|NCT00435630|Other|1|Completing simulator training sessions
3161012|NCT00435643|Active Comparator|A|10 patients with severe OSAS (Apnea Hypopnea Index of more than 30 events per hour of sleep) were treated with nCPAP for three months and all mentioned measurements above were repeated.
3161013|NCT00435695|Active Comparator|GSK163090|one infusion only
3161014|NCT00435708|No Intervention|1|
3161015|NCT00435708|Experimental|2|5 portions fruit and vegetables/day
3161016|NCT00435760|Active Comparator|Tiotropium|1 puff, 1 day treatment
3161017|NCT00435760|Placebo Comparator|Placebo|Tiotropium or Aclidinium Placebo, 1 day treatment
3161018|NCT00435760|Experimental|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
3161019|NCT00435799|Active Comparator|A|
3161020|NCT00435864|Other|allogeneic donor from a file|
3161021|NCT00435864|Other|Registry geno-identical donor family|
3161022|NCT00435864|Other|transplantation of HSCs derived from placental blood|
3161023|NCT00435890|No Intervention|1|No triage liaison physician
3161024|NCT00435916|Experimental|1|
3161025|NCT00436020|Active Comparator|1|Active
3161026|NCT00436020|Placebo Comparator|2|Sham TMS
3161027|NCT00436033|Placebo Comparator|Placebo|
2488768|NCT02976740|Experimental|SBRT+GM-CSF+Tα1|Metastasis lesion will be treated with a SBRT of 50Gy/4-10F from day 1 to day 10 . Subcutaneous injection of Immunological Agent- human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle. Subcutaneous injection of another Immunological Factors Thymosin Alpha 1(1.6mg Biw)will be executed from the fist WEEK to the 12th Weeks.
2488836|NCT02976402|Experimental|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
2488889|NCT02975986|Other|Controlled metabolic diet|All study patients will be placed on an instructed controlled metabolic diet. Intervention: Uptake of radioactive isotope by the kidney Radiotracer: 123I-BMIPP, 99mTc-MAG3
2488970|NCT02975544|Experimental|Intervention group|Received CRECES programme during 5 weeks as part of the extracurricular plan
2488976|NCT02975544|No Intervention|Control group|Continued with their habitual school routine
2489032|NCT02975154|Active Comparator|Microcurrent therapy, type A|"Microcurrent therapy: Channel A: 100 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10.~Previous treatments will be continued."
2489033|NCT02975154|Active Comparator|Microcurrent therapy, type B|Microcurrent therapy: Channel A: 25 µA; 200 Hz; Channel B: 100 µA; 300 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
2489035|NCT02975154|Sham Comparator|Sham Microcurrent therapy|Microcurrent therapy: Channel A: 0 µA; 0 Hz; Channel B: 0 µA; 0 Hz. Duration of each treatment session: 30 minutes. Number of sessions: 10. Previous treatments will be continued.
2489037|NCT02975154|No Intervention|No Intervention|No Intervention. Previous treatments will be continued.
2489082|NCT02974647|Experimental|rel/ref PTCLtumors are known to contain mutations associ|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2489083|NCT02974647|Experimental|with rel/ref PTCL with functional evidence of JAK/STAT|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours). Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2489085|NCT02974647|Experimental|with rel/ref PTCL who do not meet criteria for cohort 1 or 2.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Ruxolitinib should be taken by mouth every 12 hours approximately the same time each day (+/- 2 hours).Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2489089|NCT02974647|Experimental|Rare sub-type expansion cohort: T-PLL and T-LGL and non-MF CTCL with JAK fusion mutations.|Patients will receive ruxolitinib 20mg BID orally on 28 day cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by the treating physician, or termination of the study.
2489160|NCT02974348|Active Comparator|arm 1: Arthemeter-lumefantrine|Arthemeter-lumefantrine (ART-LUM) is an antimalaria drug manufactured as fixed combination tablets, each containing 20 mg of artemether and 120 mg of lumefantrine. ART-LUM was administrated according to body weight as six consecutive doses: The first dose at diagnosis and the second dose eight hours later, 0- 24-48 hours
2489162|NCT02974348|Active Comparator|arm 2 : Artesunate mefloquine|Artesunate mefloquine (ASMQ) is an antimalaria drug administered as a combination of artesunate, 4 mg/kg/day, with mefloquine, 8 mg/kg/day orally once a day for 3 days or three times, at an interval of 24 hours (0 h - 24 h - 48 h).
2489164|NCT02974348|Active Comparator|arm 3 : Dihydroartemisinin piperaquine|Dihydroartemisinin piperaquine (DHA-PQ ) is an antimalaria drug administered as a combination of dihydroartemisinin, 2.5 mg per kg, with piperaquine phosphate, 20mg per kg daily for 3 days or three times, at an interval of 24 hours
2489167|NCT02974348|Other|Paracetamol|Oral paracetamol is administered at of 50mg/kg body weight per day in three divided doses for fever exceeding 37.5oC.
2489173|NCT02974348|Other|Amoxicillin|amoxicillin is an antibiotic administered at 50mg per kg body weight per day for seven days in the event of concomitant bacterial infection, absent on day 0 but present during the follow up.
2489175|NCT02974348|Other|Quinine|Quinine is an antimalarial recommended by the WHO and NMCP to be used as second line treatment for malaria. In this study, for cases of treatment failure with the artemisinin based combination therapies, quinine sulphate is administered as a second line or rescue drug at a dose of 25mg base per kg body weight per day in three divided doses for five days. The participant is then classified as ETF or LTF and excluded from the study.
2489237|NCT02973841|Experimental|Sono-ease group|insertion IJV catheter using sono-ease device
2489273|NCT02973555|Experimental|PRP injection|
2489400|NCT02972788|Experimental|Experimental Group|Group will receive enamel matrix protein derivative treatment along with scaling and root planing.
2489403|NCT02972788|Sham Comparator|Control Group|Group will receive placebo (saline) treatment along with scaling and root planing.
2489447|NCT02972320|Experimental|temozolomide maintain therapeutic|Lobaplatin combined with etoposide for first-line treatment of extensive stage small cell lung cancer,then clinical benefit patients for temozolomide maintain therapeutic.This study have only one arm which temozolomide maintain at dose of 150mg/m2 D1-5 Q4W.
2489529|NCT02972112|Active Comparator|Study group|will receive 2 sessions of 90 minutes each of a cognitive behavioral protocol for the treatment of Tokophobia administered by a CBT trained midwife.
2489532|NCT02972112|Sham Comparator|Control group|will receive 2 sessions of a delivery preparation course (practice as usual).
3194170|NCT00825331||1|patients for elective catheterization without special risks
2489637|NCT02971059|Experimental|Adult Males >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
3194171|NCT00825331||2|patients for elective catheterization with special risks
3194172|NCT00825331||3|patients for PCI without GP IIb/IIIa
2488779|NCT02976935||Healthy Volunteers|Subjects will receive 1L non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath while the MRI scan is performed. Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2:Identical to Study Visit 1 but with the further series of inhalations being up to a maximum of 4 (maximum total exposure to hyperpolarised 129Xenon will be 5L).Optional Study Visit #3: Identical to Study Visit 2 (maximum total exposure to hyperpolarised 129Xenon will be 5L)
2488782|NCT02976935||Chronic Obstructive Pulmonary Disease|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
2488784|NCT02976935||Idiopathic Pulmonary Fibrosis|Subjects will receive 1L bag of non-hyperpolarised 129Xenon to inhale. Then:Subjects will inhale the first hyperpolarised 129Xenon calibration dose (up to 1L, which may be a mix of hyperpolarised 129Xenon and N2) and hold their breath for required time while the MRI scan is performed.Then:A further series of inhalations will be performed up to a maximum of 3 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L). Optional Study Visit #2: Identical to Study Visit 1 (maximum total exposure to hyperpolarised 129Xenon will be 3.6L)
2488850|NCT02976389|Experimental|$40/month|Financial incentives: Participants will be randomized to receive $40/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2488854|NCT02976389|Active Comparator|$20/month|Financial Incentives: Participants will be randomized to receive $20/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2488856|NCT02976389|Active Comparator|$10/month|Financial Incentives: Participants will be randomized to receive $10/month in incentive dollars for the purchase of SNAP eligible fruits and vegetables. Purchasing behaviors will be tracked.
2488868|NCT02975765|Experimental|Piezosurgery|Piezosurgery-assisted corticotomy will be performed to enhance teeth alignment
2488873|NCT02975765|No Intervention|Traditional method|No intervention is going to be applied to the patients in this group.
2488941|NCT02975635||Oral patient information only|Patients are given oral information only (information as usual). After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
2488947|NCT02975635||Written patient education before oral patient information|Patients are given a flow chart in advance of oral information. After patients have made their decisions (repair or replacement), a questionnaire survey is conducted.
2489007|NCT02975232|Experimental|Treatment|F&V economic incentive with Cooking Matters store tour
2489016|NCT02975232|No Intervention|Control|no intervention
2489066|NCT02974816|No Intervention|Standard of Care|Subjects in this arm will visit their physician once every 3 months and will receive usual care.
2489067|NCT02974816|Experimental|Remote Monitoring|Subjects in this arm will visit their physician once every 3 months and will receive usual care. In addition, in between clinic visits, subjects will measure their blood glucose (BG) readings at least once a day and share their BG readings with their CDE using Glooko's mobile application. Once a week, the CDE will review the subject's BG readings on Glooko's population tracker and reach out to the subjects if he/she experienced clinical incident(s). During the conversation, the CDE will either recommend medication or lifestyle modification to address the clinical incident.
2489136|NCT02974504|Experimental|evogliptin|evogliptin 5mg qd
2489141|NCT02974504|Active Comparator|linagliptin|linagliptin 5mg qd
2489197|NCT02974062|Experimental|Lumbar stabilization exercise|Lumbar stabilization exercised is a low-intensity exercise that focuses on motor control of deep abdominal and back muscles, rather than their strength or endurance. There are 3 main levels in this exercise; 1) co-contraction of deep abdominal and back muscles, 2) co-contraction with limb movement (self-perturbation), and 3) co-contraction with functional movement (i.e. walking, running, etc.)
2489199|NCT02974062|No Intervention|Healthy control|No intervention was given to this group of participants. They were asked to rest and wait for 15 minutes, then post-test was performed.
2489247|NCT02973828||A) Volunteer Imaging Studies|Non-patient Volunteer Imaging Studies of Normal Tissue (n = 18 - 54) per centre In the first stage, participants will be non-patient volunteers who agree to undergo MR imaging on the MR Linac on a single or multiple occasions (up to 12) to examine the anatomic sites listed above for normal tissue visualisation.
2489248|NCT02973828||B) Patient Volunteer Imaging Studies|Patient Volunteer Imaging Studies of Normal Tissue (n = 39 - 72 per centre) In the second stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine multiple tumour sites (n=11) for tumour/target visualisation.
2489250|NCT02973828||C) Pathway development studies|Pathway development studies (n = 39 - 208 per centre) In the third stage, participants will be patient volunteers, who agree to undergo MR imaging on the MR Linac on a single or multiple (up to 12) occasions to examine intra and inter observer variability on target and organs at risk visualisation using the exam cards from Stage B.
2489252|NCT02973828||D) On going imaging development & quality improvement|This stage of the study will run in parallel or subsequent to stages B and C. The purpose will be to recruit patient or non-patient volunteers to help optimise MR guided radiotherapy delivery e.g. investigate radiotherapy immobilisation and equipment for patient positioning and set up development and/or development of new/novel imaging sequences, optimisation of existing sequences and undertaking continuing image quality improvement.
2489277|NCT02973386|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
2489281|NCT02973386|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
2489333|NCT02973139|Active Comparator|Thoracoscopy group|Patients randomized to the Thoracoscopy group will undergo medical thoracoscopy.
2489335|NCT02973139|Active Comparator|Fibrinolytic group|Patients randomized to the Fibrinolytic group will receive intrapleural therapy of combined tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)
2488838|NCT02976454|Active Comparator|Family-based behavioral obesity treatment|The active control group will receive usual care, i.e. PCP provides obesity management using decision support tools in the electronic health record and refers to a tertiary care program at the academic center. This program is the traditional family-based behavioral weight control program which consists of 20 one-hour, group-based sessions over 6 months.
3194173|NCT00825331||4|Patients for PCI with GPIIb/IIIa and emergencies
2489058|NCT02974933|Experimental|apatinib|combined with pemetrexed
2489079|NCT02974556|Active Comparator|Standard surgical treatment group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
2489080|NCT02974556|Experimental|Proactive management group|"Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. At the end of surgical procedure HIPEC will be performed with oxaliplatin 460 mg/m2 and before the beginning of HIPEC an intravenous infusion of 400 mg/m2 of 5-FU and 20 mg/m2 of leucovorin will be administered.~Standard adjuvant systemic chemotherapy (FOLFOX or CAPOX regimens for 6 months) will be reserved in pT3 tumors with poor prognostic factors, pT4 tumor and if lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT."
3194174|NCT00825383|Active Comparator|1|High Fiber Diet
3194175|NCT00825383|Active Comparator|2|Moderate Fiber Diet
2489209|NCT02973880|Experimental|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
2489211|NCT02973880|Active Comparator|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
2489249|NCT02973711|Experimental|Nilotinib + Ruxolitinib|"The first part of the trial will be Phase I and will enroll 25 participants. Participants will receive nilotinib BID and either 10, 15 or 20 mg of ruxolitinib BID. Maximum tolerated dose (MTD) of ruxolitinib will be determined.~The second part of the trial will be a Phase II and will enroll 25 subjects. Participants will receive nilotinib and the MTD of ruxolitinib."
3194176|NCT00825396|Experimental|C-KAD Ophthalmic Solution|
3194177|NCT00825422|Experimental|A|first bolus of 20 ml of ropivacaine(5mg/ml) and continuous infiltration (8ml/h)of ropivacaine (2mg/ml)
3194178|NCT00825422|Placebo Comparator|B|first bolus of 20 ml of physiological saline solution(9%) and continuous infiltration (8ml/h)of physiological saline solution(9%)
3194179|NCT00825435|Experimental|1|Coronary CT angiogram plus Standard of care (CTA+SOC)
2489371|NCT02972905|Placebo Comparator|Session 1: Placebo|Subjects will receive a single dose inhalation of GSK2269557 matching placebo via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2489373|NCT02972905|Experimental|Session 1: GSK2269557 200 mcg|Subjects will receive a single dose inhalation of GSK2269557 200 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2489375|NCT02972905|Experimental|Session 1: GSK2269557 500 mcg|Subjects will receive a single dose inhalation of GSK2269557 500 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2489376|NCT02972905|Experimental|Session 1: GSK2269557 700 mcg|Subjects will receive a single dose inhalation of GSK2269557 700 mcg via the ELLIPTA DPI. The washout period between the two dosing sessions will be at least 10 days.
2489378|NCT02972905|Placebo Comparator|Session 2: Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2489381|NCT02972905|Experimental|Session 2: GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269577 200mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2489382|NCT02972905|Experimental|Session 2: GSK2269557 500 mcg|Subjects will receive repeated doses of GSK2269577 500mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2489383|NCT02972905|Experimental|Session 2: GSK2269557 700 mcg|Subjects will receive repeated doses of GSK2269577 700mcg once daily via the ELLIPTA DPI for 10 days. The washout period between the two dosing sessions will be at least 10 days.
2489434|NCT02972567|Experimental|Probiotic|Lactobacillus strain
2489435|NCT02972567|Placebo Comparator|Control|Maltodextrin
2489479|NCT02972203|Experimental|Mindfulness Training for Primary Care|• Mindfulness Training for Primary Care (MPTC) is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
2489541|NCT02971722|Experimental|6.0mg JY09(cohort 1)|6.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
3194180|NCT00825435|No Intervention|2|Standard of Care (SOC)
3194181|NCT00825448|Experimental|2|patient in hospital a week before the date of surgery for the treatment of his addiction alcohol
3194182|NCT00825448|No Intervention|1|no treatment of his addiction alcohol during a week before the date of surgery
3194183|NCT00825461||1|Anorexia with tube feeding
3194184|NCT00825461||2|Anorexia without tube feeding
3194185|NCT00825461||3|Control
3194186|NCT00825474|Experimental|survival rate|therapeutic effect of partial hepatectomy or TACE plus PEI for small hepatocellular carcinoma
3194187|NCT00825487|Experimental|ARQ 621 treatment|
2488849|NCT02976428|Active Comparator|Standard Soft Tissue Balancing|In the control group where the sensor device is not used in optimization of knee balance and alignment, definitive implants will be cemented in place and the sensor trial inserted using a thickness based on prior standard bearing insert trialing. Peak load data will be captured intraoperatively through full ROM. Custom shims will be affixed to the sensor to replicate thickness of the standard trial. The knee will then be cycled and loads recorded in the medial and lateral compartments at 10, 45 and 90 degrees of flexion. The surgeon will be blinded to the sensor output and the system will be located outside of their visual field.
2488851|NCT02976428|Experimental|Sensor Guided Soft Tissue Balancing|In the experimental group where the sensor device is used to optimize balance and alignment, the sensor trial will be inserted and tibial baseplate rotated until medial and lateral femoral contact points are parallel on the sensor output. Quantitative balance is defined as a mediolateral intercompartmental loading difference of ≤15 pounds. Flexion balance is achieved when femoral contact point position is within the midposterior third of the tibial insert and intercompartmental loads are balanced. Loads in the medial and lateral compartments are recorded at 10, 45 and 90 degrees. If compartment loads differ by >15 lbs between compartments, unbalanced, further soft tissue release/bone resection will be done to achieve a side to side compartment pressure difference of <15 lbs through ROM.
2488903|NCT02975778|Experimental|Aged, 65 and over|
2488936|NCT02975583|Active Comparator|Experimental: Vorapaxar|Drug: Vorapaxar 2.08 mg orally daily for a year Other name: Zontivity
2488942|NCT02975583|Placebo Comparator|Placebo Comparator: Placebos|Medication: Matching Placebo Daily tablet
2489002|NCT02975219|Experimental|Treatment group|4.5mg Bevacizumab-800CW intravenously
2489056|NCT02974881|Experimental|transcatheter mitral valve replacement|HighLife TMVR System is a novel and innovative approach developed as an alternative treatment for severe MR when medical treatment is maximal and surgical interventions not possible or at high risk. The HighLife TMVR system is composed of a Transcatheter Mitral Valve (TMV), a sub-annular implant (SAI), and their delivery systems and loading tools. The HighLife Valve is a 31 mm mitral bioprosthesis made of a self-expanding Nitinol frame covered with polyester graft and supporting bovine pericardium leaflets. The bioprosthesis is used in conjunction with the Sub-Annular Implant (SAI).
3194188|NCT00825513|Experimental|Akreos Toric|Akreos Toric Intraocular Lens
3194189|NCT00825513|Active Comparator|Akreos Advanced|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)
2489224|NCT02973958|Active Comparator|No ketorolac|15 mg/kg oral dose of acetaminophen is administered prior to surgery. General anesthesia will be induced with sevoflurane via facemask. After establishing venous access, a laryngeal mask will be inserted, and anesthesia maintained with 1 minimum alveolar anesthetic concentration (MAC) of sevoflurane in oxygen/air 50/50 mixture. The DPNB nerve block is done using a 23 GA needle inserted below the Buck fascia. Once the needle tip is positioned appropriately and after a negative aspiration test, 0.2mL/kg (maximum 10mL) of 0.25% bupivacaine is injected in small aliquots, with intermittent aspiration throughout. In all patients, skin incision is performed at least 5 min after placement of the nerve block. Patients will be advised to take ibuprofen and acetaminophen post-operatively as needed.
2489229|NCT02973958|Experimental|Peri-operative ketorolac|Exactly same as the no ketorolac group except at the beginning of the circumcision, once the patient is asleep, patients in the perioperative ketorolac group will also receive a 0.5 mg/kg intravenous dose of ketorolac.
2489299|NCT02973425|Active Comparator|NRT and mHealth assessment tool without feedback|"For the comparison group, implementation will be balanced in all variables except the Take a Break Intervention. The investigators will balance the two groups further by having the comparison (NRT-Sampling group) complete mHealth assessments (without feedback or goal-setting) as an attention control.~Participants randomized to the comparison group will only have access to a mHealth assessment tool similar to the Challenge Quizzes but without feedback."
2489305|NCT02973425|Experimental|Take a Break as an augmentation to NRT in Motivation|"The Intervention: Take a Break as an augmentation to NRT-sampling in Motivation Phase. Take a Break is an intervention in which smokers are encouraged to engage in smoking abstinence. The main element, the Break, is a two-week challenge where smokers report days they are smoke-free. The Break is preceded by a 1-week training challenge where Challenge Quizzes (ecological momentary assessments) collect information to guide the smokers during the Break. At baseline, all smokers will be provided NRT lozenges for sampling. At weeks 1 and 3 of the Marathon, our Tobacco Treatment Specialist will call all smokers, assess their experiences and collect data.Participants in the intervention will receive the full tool suite."
2489338|NCT02973022||Community CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group in the community will be exposed to the modified CC&S educational sessions in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational sessions. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
2489344|NCT02973022||Community Control Group|Once participants are randomized, they will be given survey 1. The control group in the community will be exposed to a nutrition education program in a series of 2 one hour and 15 minute sessions on consecutive Monday nights. A free meal will be provided at both educational session. Childcare will be provided for community sessions. Once the final educational session is completed, all participants will be given survey 2.
2489348|NCT02973022||ACEC CC&S Group|Once participants are randomized, they will be given survey 1. The intervention group at ACEC (Adams-Columbia Electric Company) will be exposed to the modified CC&S educational sessions in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. The researchers anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
3194190|NCT00825526|Experimental|Early Intervention, MBSR therapy|Group that receives Mindfulness Based Stress Reduction Therapy immediately after randomization
3194191|NCT00825526|Active Comparator|Delayed Treatment Arm, MBSR Therapy|Group that receives Mindfulness Based Stress Reduction Therapy within 3 months of randomization
3194192|NCT00825539|Placebo Comparator|Placebo|
3194193|NCT00825539|Experimental|AQW051|
3194194|NCT00825578|Active Comparator|1|Upper-lobe predominant emphysema
3194195|NCT00825578|Active Comparator|2|Non-upper lobe predominant emphysema
2488905|NCT02976012|Active Comparator|IAI q16 week Group|Eyes will be randomized on the day of endolaserless vitrectomy surgery or first postoperative 1-2 week visit to a group (q16week Group) where 2 additional mandatory postoperative q4weeks IAI will be followed by mandatory q16weeks IAI for 52 weeks follow-up. Starting at week 12 in the q16 group, eyes may be eligible to receive additional 2mg IAI (intravitreal aflibercept) (monthly) treatment.
2489483|NCT02972177|Experimental|Radiofrequency ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial radiofrequency ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
2489485|NCT02972177|Experimental|Microwave ablation group|Patients with inoperable peripheral lung tumor will be performed transbronchial microwave ablation with the guidance of navigation bronchoscopy. Post treatment response will be evaluated and follow up will be carried out according to the standard procedure.
2489531|NCT02971878|No Intervention|Control|Culture media without addition of antioxidants
2489536|NCT02971878|Active Comparator|Treatment|Culture media with the addition of antioxidants
2489568|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
2489571|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
2489574|NCT02971436|Active Comparator|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
2489575|NCT02971436|Active Comparator|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
2489577|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
2489580|NCT02971436|Active Comparator|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
2489655|NCT02971137|Experimental|Smoking Cessation plus CBI (SMK-CBI)|An intervention that includes a proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
2489658|NCT02971137|Active Comparator|Smoking Cessation Standard (SMK-STD)|A contact-equivalent control that provides standard smoking cessation telephone counseling
2489710|NCT02970656|Experimental|Teens.Connect|The Teens-Connect internet-based program has two complementary components - TEENCOPE and Managing Diabetes. Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. TEENCOPE consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist.
2489714|NCT02970656|No Intervention|Control|Wait listing will serve as the control condition. Usual care at the Yale Pediatric Diabetes Center consists of quarterly visits with physicians and nurse practitioners, accessibility to nutritional and psychological consultation, and 24/7 on call service. Following completion of the 6 month data point, youth will be offered the opportunity to participate in the internet program.
2490070|NCT02968095|Experimental|Text Message Craving Program|Text messages designed to help smokers to modify their thinking styles to be more adaptive, delivered 2-3 times per day.
2490072|NCT02968095|Active Comparator|Self-Help Manual Plus Control Texts|A print, self-help manual plus general motivational text messages delivered 2-3 times per day.
2490102|NCT02967848||Patients with Cancers in Liver|Adult patients with primary liver cancer or liver metastases from any other histology who will be measured before and after Radiotherapy by '99mTc-mebrofenin hepatobiliary scintigraphy (HBS), Indocyanine Green and Liver Elasticity.
2490233|NCT02966847|Experimental|CBCT Acquisition|The anesthesia and surgery will take place in the usual way. The intervention consists in the CBCT acquisition after the initiation of single-lung ventilation, after the introduction of trocars.
2490258|NCT02966535|Experimental|1:2, 1:1 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:2 during the first one hour of laparoscopy and then switched to I:E ratio of 1:1 during the rest time of laparoscopy.
2490259|NCT02966535|Active Comparator|1:1, 1:2 group|Inspiratory to expiratory time ratio (I:E ratio) of 1:1 during the first one hour of laparoscopy and then switched to I:E ratio of 1:2 during the rest time of laparoscopy.
2490306|NCT02966366|Experimental|Cochlear implantation|Evaluation of tinnitus before and after cochlear implantation
2490352|NCT02966041|Experimental|Ondansetron|Ondansetron 4mg IV at time of discontinuation of Propofol Infusion
2490357|NCT02966041|Placebo Comparator|Saline|2 mL IV Normal Saline at time of discontinuation of Propofol Infusion
3161028|NCT00436033|Experimental|Minalcipran|
2519425|NCT02767167|No Intervention|Control group|Normal diet for 12 weeks
3161029|NCT00436098|Experimental|1|physical training
3161030|NCT00436098|No Intervention|2|
3161031|NCT00436137|Experimental|1|Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach
3161032|NCT00436150|Experimental|A|Participants will receive interpersonal therapy-based treatment
3161033|NCT00436150|Active Comparator|B|Participants will receive standard care
3161034|NCT00436176|Experimental|1|Intervention clinicians receive monthly performance reports, cultural competency training, and health navigation training
3161035|NCT00436176|No Intervention|2|Control clinicians function within the context of the generic chronic care model.
3161036|NCT00436241|Experimental|1|
3161037|NCT00436254|Experimental|Arm I|Patients receive pNGVL3-hICD vaccine admixed with GM-CSF intradermally once a month for 3 months in the absence of disease progression or unacceptable toxicity.
3161038|NCT00436293|Experimental|1|Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
3161039|NCT00436293|Active Comparator|2|Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
3161040|NCT00436306|Experimental|Individualized Intervention: stage-matched/tailored counseling|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
2488907|NCT02976077|Experimental|RC2S+|"RC2S+~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Social Cognition (ERF-CS)~Psychoeducation about social cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 22):~Paper-and-pencil session~Simulation session~Home-based task~Transfer sessions (sessions 23 & 24):~Transfer of skills in dayly life - generalization~Assessment of the achievement of objectives"
2488911|NCT02976077|Active Comparator|Control therapy|"Control therapy~Preparation sessions (sessions 1 & 2):~Functional Outcomes Scale - Neurocognition~Psychoeducation about cognitive impairments~Concrete objectives~Cognitive remediation (sessions 3 to 24):~Paper-and-pencil session~Simulation session~Home-based task"
2488933|NCT02975466|Experimental|AirQ Blocker supra-glottic airway device|Group of patients in which the Air-Q Blocker will be used and measured as an intubation conduit.
2488940|NCT02975466|Experimental|AuraGain supra-glottic airway device|Group of patients in which the AuraGain will be used and measured as an intubation conduit.
2488945|NCT02975466|Experimental|I-Gel supra-glottic airway device|Group of patients in which the I-Gel will be used and measured as an intubation conduit.
2489026|NCT02975128|Experimental|Patients|
2489071|NCT02974764||Chemotherapy Group|This cohort includes patients who will receive chemotherapy at any stage or their treatment.
2489074|NCT02974764||Radiation therapy Group|This cohort includes patients who will receive radiation therapy at any stage or their treatment.
2489077|NCT02974764||Surgical resection of the primary tumor|This cohort includes patients who will undergo resection of the primary tumor.
2489112|NCT02974452||Group I: Older adults|healthy subjects older than 68 years old whose shoulder muscle are measured by surface electromyography
2489115|NCT02974452||Group II: Adults|healthy subjects 43 to 67 years old, whose shoulder muscle are measured by surface electromyography
2489118|NCT02974452||Group III: Young adults|healthy subjects 20 to 42 years old, whose shoulder muscle are measured by surface electromyography
3194196|NCT00825591|Active Comparator|1|Individuals with abnormal rhythmicity will be treated with melatonin to assess if sleep patterns are improved.
3194197|NCT00825591|Placebo Comparator|2|
3194198|NCT00825604|No Intervention|Without PCI|Optimized medical treatment, physical training and smoking cessation
2489555|NCT02971592|Experimental|Experimental|
2489561|NCT02971592|Placebo Comparator|Placebo|
2489640|NCT02971033|Placebo Comparator|placebo|placebo
2489644|NCT02971033|Experimental|20mg/day ezetimibe|20mg/day ezetimibe
2489648|NCT02971033|Experimental|40mg/day exetimibe|40mg/day ezetimibe
3194199|NCT00825604|Active Comparator|With PCI|optimized medical treatment, physical training and smoking cessation with complimentary treatment with percutaneous coronary intervention(PCI)
3194200|NCT00825617|Experimental|HRT|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
3194201|NCT00825643||Insulin detemir|
2489862|NCT02969551||Sleep apnea, Manometry and possibly DISE|Sleep apnea Patients recieved manometry measures and those who were not considered for CPAP Therapy recieved Drug induced sleep endoscopy.
2489894|NCT02969265|Experimental|TCV-116CCB (Candesartan 8 mg Plus Amlodipine 5 mg)|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Single-blind monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: TCV-116CCB 8/5 mg tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 8 weeks."
2489896|NCT02969265|Experimental|Amlodipine 5 mg|"Run-in Period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine placebo-matching capsules, orally, once daily up to 2 weeks.~Monotherapy treatment period: TCV-116CCB placebo-matching tablets, orally, once daily along with amlodipine 5 mg capsules, orally, once daily up to 4 weeks.~Double-blind treatment period: Amlodipine 5 mg capsules, orally, once daily along with TCV-116CCB placebo-matching tablets, orally, once daily up to 8 weeks."
2490001|NCT02968732|Experimental|Surgical|
2490036|NCT02968251|Experimental|Hand Washing Program (HWP)|Clusters in this arm will be given a Hand Washing Program (HWP) which will consist of: integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
2519439|NCT02766972|Experimental|RVP|
3194202|NCT00825656|Experimental|1|Sinol-M
3194203|NCT00825656|Active Comparator|2|Sinol
3194204|NCT00825669|Active Comparator|survival rate (TACE)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
3194205|NCT00825669|Active Comparator|survival rate (TACE plus laser ablation)|to compare the effects of TACE and TACE plus laser ablation for treating patients with PVTT
3194206|NCT00825695|Active Comparator|flavanol-rich cocoa|
3194207|NCT00825695|Placebo Comparator|flavanol-poor cocoa|
3194208|NCT00825708|Active Comparator|rTMS|rTMS session
3194209|NCT00825708|Sham Comparator|SHAM|sham session
3194210|NCT00825721|Active Comparator|1.3% (low dose)|
3194211|NCT00825721|Active Comparator|2% (medium dose)|
3194212|NCT00825721|Active Comparator|2.6% (high dose)|
3194213|NCT00825721|Placebo Comparator|Placebo|
3194214|NCT00825760|Other|1|Single treatment
3194215|NCT00825760|Other|2|12 treatments, once weekly
3194216|NCT00825773|Active Comparator|Excel|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
3208695|NCT00977262|Experimental|Obese diabetes type 2 subjects, High polyunsaturated fat shake|
3208696|NCT00977288|Experimental|1|MK0859 10 mg + placebo
2488924|NCT02975388|Experimental|Label: RO7079901 (Mild) (Part 1)|Participants with mild renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2488925|NCT02975388|Experimental|RO7079901 (Moderate) (Part 1)|Participants with moderate renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2488926|NCT02975388|Experimental|RO7079901 (Severe) (Part 1)|Participants with severe renal impairment (but not undergoing hemodialysis) will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2488927|NCT02975388|Active Comparator|RO7079901 (Normal) (Part 1)|Control group of participants with normal renal function will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2488928|NCT02975388|Experimental|RO7079901 (End-stage) (Part 2)|Participants with stable end-stage renal disease undergoing hemodialysis will be enrolled in this arm. Participants will receive the specified dose of RO7079901.
2488988|NCT02975245||Men receiving chemotherapy|Semen collection and analysis
2489021|NCT02974985|Experimental|Women aged 40-50|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
2489027|NCT02974985|Experimental|Women aged 50-60|"Intervention--Injections of volumizing products Restylane L and Restylane Lyft with endpoint  a dramatic result is seen that is agreed upon by both subject and injector. The number of injections will be determined (and quantified) by both the patient and the PI to achieve this endpoint."
2489090|NCT02974738|Experimental|Part 1A|"Drug: PART 1A: Belzutifan for the treatment of advanced solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of solid tumors."
2489092|NCT02974738|Experimental|Part 1B|"Drug: PART 1B: Belzutifan for the treatment of advanced ccRCC~Belzutifan inhibits HIF-2α and is a novel approach to treatment of ccRCC."
2489094|NCT02974738|Experimental|Part 2|"Drug: Part 2: Belzutifan for the treatment of other specified solid tumors~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
2489098|NCT02974738|Experimental|Part 2A|"Drug: Part 2A: Belzutifan for the treatment of patients with recurrent GBM who have been previously treated with radiation therapy and temozolomide~Belzutifan inhibits HIF-2α and is a novel approach to treatment of specified solid tumors."
2489149|NCT02974361|Active Comparator|Part A Ibuprofen control|
2489154|NCT02974361|Experimental|Part A Ibuprofen-LDH|
2489156|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 1|
2489157|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 2|
2489159|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 3|
2489161|NCT02974361|Experimental|Part A Ibuprofen-LDH Excipient Combo 4|
2489163|NCT02974361|Active Comparator|Part A Ibuprofen Lysine|
2489165|NCT02974361|Active Comparator|Part B Ibuprofen|
2489169|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 1|
2489172|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 2|
2489176|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 3|
2489178|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 4|
2489179|NCT02974361|Active Comparator|Part C Ibuprofen|
2489184|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 1|
2489187|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 2|
2489189|NCT02974361|Experimental|Part C Ibuprofen LDH Excipient Combo 3|
2489192|NCT02974361|Experimental|Part B Ibuprofen LDH Excipient Combo 5|
3161041|NCT00436306|Placebo Comparator|Control: Enhanced usual care counseling|The Enhanced Usual Care arm was the control group. It provided computer-based information regarding contraceptive methods, but was not individualized or tailored to the participant stage of change.
3161042|NCT00436319|No Intervention|1|In the control group (group 1) the initiation of the ovarian stimulation will be realized according to the typical long luteal protocol, two weeks after the initiation of the GnRH agonist administration.
2489491|NCT02972151|Experimental|Comprehensive treatment of TCM|The intervention is Comprehensive treatment of TCM,which including Oral medicine ,tradition chinese medicine enema, external treatment.
2489492|NCT02972151|Active Comparator|Expectant therapy|"Expectant treatment group patients were not treated during the observation period.~（3 months after the start of the trial and 1 months after the end of the trial.）"
2489650|NCT02971020|Other|Surgical Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
2489652|NCT02971020|Other|Transcatheter Aortic Valve Replacement|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
2489684|NCT02970734|Experimental|Breathe|6 sessions of Internet-based cognitive behavioural therapy (CBT) with limited telephone and e-mail support
2489686|NCT02970734|Active Comparator|Resource webpage|Webpage that provides general resources on anxiety
2489734|NCT02970487|Experimental|investigational device|Subjects implanted with the Precisight intraocular lens.
2489867|NCT02969460|Experimental|Neurotrack Virtual Cognitive Health Program|This program is a multi-domain lifestyle intervention designed to prevent or delay cognitive decline and impairment in older at-risk adults. The first 6 months of the program emphasizes lifestyle change, while the last 6 months of the program emphasizes habit reinforcement. The program focuses on nutrition, physical exercise, and cognitive training.
3161043|NCT00436319|Other|2|In the study group (group 2) the initiation of the ovarian stimulation will be effectuated on the second day of the menstrual period.
3161044|NCT00436358||Group A|IS case deemed children
3161045|NCT00436358||Group B|LRTI-related post-neonatal deaths deemed Children
3161046|NCT00436358||Group C|A random sample of children from an annual birth cohort within the electronic IMSS dataset
3161047|NCT00436358||Group D|All children from a single annual birth cohort with IS identified in their electronic IMSS data
3161048|NCT00436358||Group E|A sample of children from the electronic IMSS dataset selected to match the selected IS cases on age, gender, and hospital of birth.
2488967|NCT02975674|Active Comparator|CON.INT dental implant|CON.INT dental implant with internal hexagon implant-abutment connection
2489019|NCT02975024||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a xenogeneic collagen matrix (Mucograft).
2489023|NCT02975024||strip gingival graft + Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement and quantitative determination of VEGF after mandibular vestibuloplasty. Individuals of this pre-defined group are candidates of vestibuloplasty, where the keratinized gingiva will be enlarged by a combination of apically repositioned split thickness flap with a strip gingival graft and a xenogeneic collagen matrix (Mucograft). The strip gingival graft is harvested from the patient's palate.
2489081|NCT02974660|Active Comparator|Protamine sulfate|After obtaining optimal valve deployment patients will receive protamine sulfate (1 mg for each 100 units of UFH i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after protamine sulfate administration).
2489084|NCT02974660|Placebo Comparator|0.9% NaCl|After obtaining optimal valve deployment patients will receive 0.9% saline (20 ml i.v.). Measurement of activated clotting time (ACT) will be performed (after heparin administration and after placebo administration).
2489148|NCT02974426|Experimental|Arm I (PORT-first strategy)|Concurrent chemoradiotherapy + sequential chemotherapy or PORT + sequential chemotherapy: Participants in the Arm I will receive PORT at the first day of therapy. For lung adenocarcinoma, the first day of radiotherapy will be administered concurrently with chemotherapy (two cycles of chemotherapy given during radiotherapy); then continue to give two cycles of sequential chemotherapy. For squamous cell lung carcinoma, PORT will be administered first followed by subsequent four cycles of sequential chemotherapy.
2489150|NCT02974426|Active Comparator|Arm II (PORT-last strategy)|Four cycles of chemotherapy + sequential PORT: Participants in the Arm II will receive four cycles of adjuvant chemotherapy and after that, sequential PORT (50.4 Gy, 1.8 Gy once daily over 5.5 weeks) will be administered.
2489266|NCT02973659|Experimental|patients with palmar hyperhidrosis|oxybutynin Vs placebo
2489267|NCT02973659|Experimental|patients with plantar hyperhidrosis|oxybutynin Vs placebo
2489268|NCT02973659|Experimental|patients with axillary hyperhidrosis|oxybutynin Vs placebo
2489298|NCT02973334|Experimental|Sugar|Effects of ingestion of sugar-sweetened beverages on acute stress response
2489304|NCT02973334|Experimental|Artificial sweetener|Effects of ingestion of artificially-sweetened beverages on acute stress response
2489310|NCT02973334|Active Comparator|Water|Effects of ingestion of water on acute stress response
2489341|NCT02973035|Experimental|Amlodipine|Amlodipine 2.5mg added to antihypertensive therapy
2489346|NCT02973035|Experimental|Valsartan|Valsartan 40mg added to antihypertensive therapy
2489412|NCT02972697|Experimental|11C-acetate PET|11C-acetate and FDG PET/MRI and PET/CT will be performed.
2489455|NCT02972294|Experimental|TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and tranexamic acid
2489458|NCT02972294|Experimental|Placebo TXA + IIM|The patients randomized to this arm will have iron isomaltoside 1000 and Placebos tranexamic acid
2489463|NCT02972294|Experimental|TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and tranexamic acid
2489466|NCT02972294|Experimental|Placebo TXA + Placebo IIM|The patients randomized to this arm will have Placebos iron isomaltoside 1000 and Placebos tranexamic acid
2489499|NCT02971813|Experimental|Facebook group|The Facebook group will receive peer support, education and provider support via social media.
2489500|NCT02971813|Active Comparator|Comparison group|The comparison group will receive the same educational materials as the Facebook™ group but will receive it in handout form, or via email if the patient misses cardiac rehabilitation on a particular week.
3194217|NCT00825773|Sham Comparator|Cypher|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
3194218|NCT00825799||Major Depressive Disorder|Adults with major depressive disorder who are experiencing a current depressive episode.
2489740|NCT02970409|Active Comparator|heparin|Catheter Lock Therapy with Heparin
2489743|NCT02970409|Experimental|saline|Catheter Lock Therapy with saline
2489793|NCT02970084|Experimental|Group with K2|"The nutraceutical product (PLAK2) based on vitamin K2, will be administered once a day (a tablet 800mg) for 12 months.~All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)"
2489794|NCT02970084|No Intervention|Control group (no vitamin K2)|The control group did not take the supplement of Vitamin K2. All patients enrolled will continue to be treated according to the clinical standard (100 mg Cardioaspirin, cp 1 day : Acetylsalicylic acid)
3194219|NCT00825799||Healthy controls|Individuals without any Axis I psychiatric diagnosis who are matched to depressed subjects by age and sex.
3194220|NCT00825838|Experimental|1|Oral ingestion of 6mg chili pepper extract
2490004|NCT02968537|Experimental|Alc-IT (50/50) (morning)|Alc-IT (50/50) (morning): This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
2490022|NCT02968680|Experimental|Diagnostic (sonazoid, ultrasound imaging, SLNB)|Patients receive sonazoid ID and undergo ultrasound imaging. Patients also undergo standard of care SLNB.
2490056|NCT02968147|Experimental|Jet ventilation|Catheter ablation for persistent atrial fibrillation with general anesthesia and high frequency jet ventilation
3208697|NCT00977288|Experimental|2|MK0859 40 mg + placebo
2488973|NCT02975570|Experimental|DAZZLE-48 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 48 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2488979|NCT02975570|Experimental|DAZZLE-56 wks|Delamanid, Linezolid, Levofloxacin, Pyrazinamide (DAZZLE) treatment regimen- delamanid 100 mg PO BID, linezolid 600 mg PO QD, levofloxacin 1000 mg PO QD, and pyrazinamide 20-30 mg/Kg PO QD for 56 weeks, with linezolid dose reduction to 300 mg daily after 16 weeks (these doses are the usual doses for treatment of TB for all 4 study agents).
2488982|NCT02975570|Active Comparator|WHO MDR-TB regimen- 9 mos or 20-24 mos|MDR-TB treatment with 9-month or 20-24 month WHO approved regimen. The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine.
2489003|NCT02974972||Pith Moromo 2 Cohort|
2489050|NCT02974894|Experimental|Probiotic|Capsules containing potato starch as a filler and Lactobacillus plantarum
2489053|NCT02974894|Placebo Comparator|Placebo|Capsules containing potato starch
3161049|NCT00436371|Experimental|1|Amisulpride 400-800mg per day on a twice-a-day regimen
3161050|NCT00436423|Experimental|1|Gemcitabine with TS-1
3161051|NCT00436527|Other|1|
2489140|NCT02974400|Experimental|Internet-based guided self-help|Internet-based, guided, CBT-oriented self-help treatment for persecutory ideation and auditory verbal hallucinations with access to a self-help website including regular written electronic contact with a guide and access to smartphone-based interactive worksheets (8 weeks)
2489145|NCT02974400|No Intervention|Wait-List|Wait-list control group (8 weeks)
2489217|NCT02974036|Experimental|Patient education for osteoarthritis|The intervention in the education program consists of three group lessons of about 90 minutes each where information about ethiology, risk factors, treatment and coping strategies concerning OA is included. The first two lessons are held by a physiotherapist and the third by a so-called expert patient that is a person with OA who shares his or her experiences of how to live with the disease. After the intervention patients are able to choose if they want to exercise at home or in a group, supervised by a physiotherapist.
2489263|NCT02973672|Experimental|SGM-101|
2489280|NCT02973347|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via the nasogastric tube is applied less than 30 mins.
2489287|NCT02973347|Active Comparator|Continuous enteral feeding|Continuous enteral feeding via the nasogastric tube using infusion pump is applied for 24 hours.
2489354|NCT02973178|Other|Usability|Evaluate and validate the user-interface of the Scanadu Urine Device by the intended users for human factors and user interface of the Scanadu Urine Device.
2489355|NCT02973178|Active Comparator|Method Comparison|"Evaluate and validate the clinical performance of the Scanadu Urine Device in the hands of intended users as compared to:~The visual read of chemical test strips performed by lab technicians utilizing the Siemens Multistix® 10SG technology (K905396),~Scanadu Urine Device tests performed by lab technicians."
2489356|NCT02973178|Other|Reproducibility|Evaluate the reproducibility in the hands of the lay-users after repeated testing of samples with known test levels.
2489396|NCT02972684|No Intervention|Conventional coagulation management|management of perioperative haemorrhage following cardiac surgery using conventional blood coagulation tests.
2489397|NCT02972684|Experimental|Thrombo-elastometry POC testing|management of perioperative haemorrhage following cardiac surgery using the thrombo-elastometry point of care test.
2489457|NCT02972411|Experimental|Intervention|Voluntary increase in respiration
2489462|NCT02972411|Active Comparator|Acetazolamide|Administration of Acetazolamide 125mg. since 24 hours before ascent and until 48 hours post altitude exposure, and absence of altitude sickness symptoms
2489513|NCT02972047|Experimental|Diaphragmatic Breathing|"Subjects randomized to the experimental intervention arm will receive instructions and rationale for Diaphragmatic Breathing in the postprandial state and receive detailed instruction in diaphragmatic breathing.~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will practice diaphragmatic breathing for 30 minutes after each meal.~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
2489514|NCT02972047|Sham Comparator|Life style counseling|"Subjects randomized to the Sham Comparator intervention arm will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~Following the office visit the patients with upright GERD and healthy persons will undergo a further 24 hours of pH impedance monitoring. This group will will engage in sham therapy (listening to music/watching TV for 30 minutes after each meal)~During the second 24 hour period patients with GERD and healthy persons will again consume the standard pH neutral refluxogenic meal note this with an event marker~After 48 hours patients with GERD and healthy persons will present to the esophageal laboratory for probe removal"
2489554|NCT02971618||Total group|Patients T2D with dapagliflozin treatment
2489715|NCT02970617|Active Comparator|Group A (no bell after final radiation)|Patients undergo standard of care radiation therapy with or without chemotherapy.
2489719|NCT02970617|Experimental|Group B (ring bell after final radiation treatment)|On the final day of standard of care radiation therapy, patients ring a bell in the clinic.
2489783|NCT02970201|Other|Period I EpxDialysis (SMS Messaging)|SMS Messaging arm receives the intervention (EpxDialysis) first, then resumes standard of care at crossover (8 weeks).
2489786|NCT02970201|Other|Period II EpxDialysis (Control)|Control arm receives standard of care first, then receives the intervention (EpxDialysis) at crossover.
2489810|NCT02969746|Experimental|Charcoal|Patients will receive a single dose (20 gram) of oral activated charcoal
2489818|NCT02969746|No Intervention|control|Standard practice
2489869|NCT02969369|Experimental|SEP-363856|SEP-363856 (25, 50, or 75mg/day), once daily
2489870|NCT02969369|Placebo Comparator|Placebo Capsule|Placebo once daily
2490041|NCT02968251|No Intervention|No Hand Washing Program (NHWP)|Clusters in this arm will be allowed to continue with their usual practice regarding hand washing/hygiene
2489010|NCT02975193|Active Comparator|Control group|"Healthy adults ages 18-90 without movement disorders, psychiatric disorders, or dementia. They will complete computer games and questionnaires at one time point.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
2489015|NCT02975193|Active Comparator|Parkinson's disease group with DBS|"Parkinson's disease patients who have elected to receive DBS for treatment of their side effects of PD consent to complete computer games and questionnaires at baseline, computer games during deep brain stimulation, and computer games and questionnaires up to 2 years after surgery.~Specific interventions: Computer task assessing cognition, Impulsive-Compulsive Disorders in Parkinson's Disease, Montreal Cognitive Assessment"
2489125|NCT02974699|Experimental|Potato Starch (Bob's Red Mill)|Daily dietary supplementation with Potato Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
2489126|NCT02974699|Placebo Comparator|Resource ThickenUp Pregelatinized Starch|Daily dietary supplementation with Pregelatinized Starch (48g total/day) suspended in water. 24g will be consumed 2 times per day.
2489182|NCT02974166|Active Comparator|Conventional Group|Individuals with temporomandibular disorder were used rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions during four weeks.
2489186|NCT02974166|Experimental|Osteopathic Group|Individuals with temporomandibular disorder received the same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week until the end of dental and speech therapy treatments (4 weeks).
2489297|NCT02973581|Experimental|metamizol|analgesic drug
2489302|NCT02973581|Experimental|acetaminophen|analgesic drug
2489308|NCT02973581|Experimental|0,5 % bupivacaine with of 2% lidocaine|a volume of 5 ml of analgesic solution for regional peribulbar block
2489312|NCT02973581|Experimental|Proxymetacaine|topical analgesia
2489314|NCT02973581|Placebo Comparator|control group|patients will receive no pre-emptive analgesia. standard doses of fentanyl will be used intraoperatively.
2489357|NCT02972931||LoViReT|HIV-infected subjects with extremely low or undetectable HIV-1 DNA levels in peripheral blood despite having initiated cART during chronic HIV-1 infection
2489358|NCT02972931||Standard Reservoir Level|HIV-infected subjects who initiated cART during chronic HIV-1 infection and that show standard HIV-1 DNA levels in peripheral blood
2489391|NCT02972736||Interventional Cardiology|All procedures performed by interventional cardiologists
2489392|NCT02972736||Electrophysiology|All procedures performed by electrophysiologists
2489393|NCT02972736||Interventional Radiology|All vascular and non vascular procedures performed by interventional radiologists
3194221|NCT00825838|Placebo Comparator|2|Oral ingestion of 0 mg chili pepper extract (matching placebo)
2489506|NCT02971917|Experimental|Clinical study of TRUVIEW ART|Chest x-ray image acquisition Creation of TRUVIEW ART applied image Comparison of TRUVIEW ART image with original image
2489567|NCT02971644|Experimental|cobalt alloy pedicle screw implantation|The spinal tuberculosis patients with severe kyphosis deformity who will undergo cobalt alloy pedicle screw implantation.
3194222|NCT00825851|Active Comparator|continuous smoking|subjects smoke 20 cigarettes per day
3194223|NCT00825851|Active Comparator|smoking cessation and NRT|subjects quit smoking and use transdermal nicotine patch
3194224|NCT00825851|Placebo Comparator|smoking cessation and placebo patch|subjects quit smoking and use placebo patch
2489797|NCT02969902|Experimental|Buzzy® device|The Buzzy® device is applied just above the selected site of the venipuncture; an ice pack is attached under the device; the device is turned on and after 15 second the venipuncture is made.
2489800|NCT02969902|Active Comparator|Hand-held computer|Using an hand-held computer, children start to play with an age-appropriate videogame three minutes before the procedure. They continue to play during the venipuncture.
2489808|NCT02969603|Other|Healthy volunteers- MRI|MRI scan for morphological assessment of muscle structures and anatomy
2489809|NCT02969603|Other|Healthy Volunteers- PET/MRI|The volunteers will undergo a combined [11C]acetate PET/MRI scan
3194225|NCT00825851|No Intervention|never smokers|subjects being never smokers and who refrain from smoking
3194226|NCT00825864|Active Comparator|1diclofenac drops treatment|four times a day for 3 months
2490003|NCT02968654|Other|Restrictive Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 7 g/dL (as suggested by current guidelines in general ICU population)"
2490006|NCT02968654|Other|Liberal Transfusion Strategy|"Blood Transfusion will be given when hemoglobin concentration will be below 9 g/dL"
3194227|NCT00825864|Active Comparator|2dexamethasone drops|
2490083|NCT02967770|Experimental|Molecularly Tailored Therapy|Patients will be treated according to their molecular profile and accordingly, the 29 evaluable patients enrolled may receive one of a dozen, or dozens of treatment regimens.
3194228|NCT00825903|Experimental|1|Aquatic based exercise
3194229|NCT00825929||1|Treated with one of the antiretroviral agents under study, PK parameters during pregnancy will be compared with PK parameters after pregnancy (within the same woman)
3194230|NCT00825942|Experimental|C-KAD Ophthalmic Solution|
3194231|NCT00825955|Experimental|Brivanib|
3194232|NCT00825955|Placebo Comparator|Placebo|
3194233|NCT00825968||Data collection group|Patients having procedures done at the electrophysiology Laboratories at the Ross Heart Hospital at The Ohio State University Medical Center.
3194234|NCT00825981||coronary artery bypass graft|patients undergoing elective coronary artery bypass graft with or without cardiopulmonary bypass
3194235|NCT00826033||Therapy monitoring|
3208698|NCT00977288|Experimental|3|MK0859 100 mg + placebo
3208699|NCT00977288|Experimental|4|MK0859 300 mg + placebo
3208700|NCT00977288|Experimental|5|MK0859 10 mg + atorvastatin 10mg
3208701|NCT00977288|Experimental|6|MK0859 40 mg + atorvastatin 10mg
3208702|NCT00977288|Experimental|7|MK0859 100 mg + atorvastatin 10mg
3208703|NCT00977288|Experimental|8|MK0859 300 mg + atorvastatin 10mg
3208704|NCT00977288|Placebo Comparator|9|Placebo + atorvastatin 10mg
3208705|NCT00977288|Placebo Comparator|10|Placebo
2489011|NCT02975323|Experimental|Single|To administer Carvedilol 12.5 mg orally and measure Wedge pressure gradient in hepatic veins followed by change in hepatic vein wave form
2489068|NCT02974829||All patients|Continuing with marketed anti-HBV or off-treatment in real-life setting
3208706|NCT00977301|Experimental|fosamprenavir/ritonavir/olanzapine|single dose of 15 mg olanzapine after 13 days of fosamprenavir/ritonavir 700mg/100mg BID
3208707|NCT00977301|Active Comparator|single dose olanzapine|Single dose of 10 mg olanzapine
3208708|NCT00977327|Other|Intraoperative MR|Use of intraoperative MR during resection of intraaxial tumor, Glioma
2489591|NCT02971501|Experimental|Arm I (osimertinib, bevacizumab)|Patients receive osimertinib PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2489592|NCT02971501|Experimental|Arm II (osimertinib)|Patients receive osimertinib PO QD on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2489689|NCT02970721||Bipolar disorder-treated|Individuals in this group are taking any medication (mood stabilizer, antipsychotic, antidepressants, antianxiety) during pregnancy
2489691|NCT02970721||Bipolar Disorder-Not Treated|Individuals in this group are not taking any medications during pregnancy
2489723|NCT02970461|Placebo Comparator|Control Group|"Subjects will see in their Personal Health Record home page a simple text link pointing to their Bio page. Once in their Bio page, the site will display their personal information as usual with the only addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
2489724|NCT02970461|Experimental|Gamified Group|"Subjects will see in their Personal Health Record home page a graphical representation of the percentage of completeness their Bio page has that when clicked acts as a link to their Bio page. Once in their Bio page, the site will display graphical elements such grayed out fields, graphical representations of the percentage of completeness for each data group and on mouse hover over any field a tooltip will inform of what percentage of completeness will be awarded if the data is validated. Also, an addition of a validate data button next to any non-validated field. The option to edit fields will also be present."
2489779|NCT02970188|No Intervention|Normal Feeding|Subjects will be instructed to eat within their normal feeding window.
2489782|NCT02970188|Experimental|Time Restricted Feeding|Subjects will be instructed to eat with an 8 hour feeding window, starting between 10:30-11:30 AM and stopping between 5:30-6:30 PM.
2489826|NCT02969785|Experimental|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
2489832|NCT02969785|Active Comparator|G2: back strengthening exercises|Back strengthening exercises. The Group 2 (G2) will perform therapy including strengthning of back muscles on a Roman chair machine for flexion and extension of trunk with load progression from training volume for endurance and strength gains.
3208709|NCT00977327|Other|Intraoperative Ultrasound|Use of intraoperative ultrasound during resection of intraaxial tumor, Glioma
3208710|NCT00977340|Experimental|Imagery Rehearsal Treatment|Imagery Rehearsal Treatment; 1 session on-site and 4 weeks of individual daily training; following principles Krakow and Zadra (2006)
2490053|NCT02968121|Experimental|Part A: Single Dose Injection: Subcutaneous|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
2490057|NCT02968121|Experimental|Part A: Single Dose Injection: Intramuscular|Drug: Brexpiprazole, OPDC-34712 Once, subcutaneous
2490059|NCT02968121|Experimental|Part B: Cohort 1|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2490061|NCT02968121|Experimental|Part B: Cohort 2|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2490066|NCT02968121|Experimental|Part B: Cohort 3|Drug: Brexpiprazole, OPDC-34712 Once, SC or IM
2490089|NCT02967861|Active Comparator|SRP & pranayama (lifestyle modification)|30 chronic periodontitis subjects treated with SRP & pranayama for 3 months
2490097|NCT02967861|Placebo Comparator|Scaling and root planing|30 chronic periodontitis subjects treated with scaling and root planing only
2490226|NCT02967159|Experimental|Treatment A (Abediterol )|Treatment A: The subjects will receive Abediterol 2.5 μg via DPI
2490228|NCT02967159|Experimental|Treatment B (AZD7594)|Treatment B: The subjects will receive AZD7594 440 μg via DPI
2490231|NCT02967159|Experimental|Treatment C (AZD7594/abediterol )|Treatment C: The subjects will receive AZD7594/ abediterol 440 μg/2.5 μg FDC via DPI
2490236|NCT02967159|Experimental|Treatment D (AZD7594 and abediterol)|Treatment D: The subjects will receive AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
2490274|NCT02966457|Experimental|Selective intestinal decolonization|Drug: Decolonization with Colistimethate sodium (2 mln I.U. 4x/day PO) for 14 days
2490276|NCT02966457|No Intervention|"Wait and watch strategy"|Group without decolonization interventions
2490358|NCT02966249|Other|Levobupivacaine intrathecally|3 ml Levobupivacaine 0,5% (15mg) given intrathecally once for anesthesia in total knee arthroplasty
2490360|NCT02966249|Active Comparator|Dexmetomidine intrathecally|5 μgr Dexmetomidine given intrathecally once for anesthesia in total knee arthroplasty
2490364|NCT02966249|Active Comparator|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously starting 10 min before spinal anesthesia in total knee arthroplasty
2490366|NCT02966249|Placebo Comparator|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
2490368|NCT02966249|Other|Normal Saline added intrathecally|Normal Saline added intrathecally up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
2490374|NCT02966249|Other|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously for total knee arthroplasty will start 10 minutes before spinal anesthesia to the end of the operation
2490410|NCT02965430|Experimental|AL-SENSE diagnostic pantyliner|AL-SENSE diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods.
2490465|NCT02965365||TTN positive group|The group which subsequently diagnosed as TTN
2490468|NCT02965365||TTN negative group|The group which is not diagnosed as TTN
2489024|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane 0|Dose Level 0 Afatinib 30 mg Nab-paclitaxel 125 mg/m2 BSA Gemcitabine 1000 mg/m2 BSA
2489030|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -1|Dose Level -1 Afatinib 30 mg Nab-paclitaxel 100 mg/m2 BSA Gemcitabine 800 mg/m2 BSA
2489031|NCT02975141|Experimental|Afatinib 30Mg Tab, Gemzar, Abraxane -2|Dose Level -2 Afatinib 30 mg Nab-paclitaxel 75 mg/m2 BSA Gemcitabine 600 mg/m2 BSA
2489110|NCT02974621|Experimental|Arm A (olaparib, cediranib maleate)|Patients receive olaparib PO BID and cediranib maleate PO once QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2489111|NCT02974621|Experimental|Arm B (bevacizumab)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2489251|NCT02973776|Experimental|LEO 90100 aerosol foam|"LEO 90100 calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate) aerosol foam~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489253|NCT02973776|Active Comparator|Dermoval®/Dermovate®|"Dermoval®/Dermovate® (clobetasol propionate 0.05%) cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489254|NCT02973776|Active Comparator|Diprosone®|"Diprosone® betamethasone 0.5 mg/g (as dipropionate) ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489256|NCT02973776|Active Comparator|Elocon®|"Elocon® mometasone furoate 0.1% cream~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489258|NCT02973776|Active Comparator|Locoid®|"Locoid® hydrocortisone-17-butyrate 0.1% ointment~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489260|NCT02973776|Placebo Comparator|LEO 90100 foam vehicle|"LEO 90100 foam vehicle~Each subject has all 6 treatments applied topically at the same time, however, the location on which the treatments are applied is randomised. Subjects will receive approximately 20 μl of each investigational product applied in circles with a diameter of 2.2 cm once."
2489340|NCT02973061||GH treated patients|All participants family member and teacher will fill questionnaires regarding signs of ateention deficit prior to GH treatment and after 6 and 12 months
2489347|NCT02973061||Healthy control|All participants family member and teacher will fill questionnaires regarding signs of atention deficit at baseline and after 6 and 12 months
2489388|NCT02972710|Active Comparator|Supine thoracic spine manipulation|Supine thoracic spine thrust manipulation (lying face-up on the treatment table) will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
2489389|NCT02972710|Active Comparator|Seated thoracic spine manipulation|Seated thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
2489557|NCT02971527|Experimental|Oste-scan 500A-SONOST3000|In this group, the investigators will measure calcaneal bone strength index of each subject by experimental device firstly and then by control device.
2489564|NCT02971527|Experimental|SONOST3000-Oste-scan 500A|In this group, the investigators will measure calcaneal bone strength index of each subject by control device firstly and then by experimental device.
2489776|NCT02970097|Active Comparator|single shot IBP block|Subjects will receive single shot infraclavicular brachial plexus block with 20ml bolus of 0.5% ropivicaine given preoperatively to help with operative and postoperative pain
2489778|NCT02970097|Active Comparator|local infiltration|Subjects will receive local infiltration into portal space and joint space with 10ml of 0.5% ropivicaine given intraoperatively to help with operative and postoperative pain
2489833|NCT02969629|Experimental|apomorphine|1.5 mg apomorphine, administered subcutaneously
2489836|NCT02969629|Placebo Comparator|Normal saline|saline, administered subcutaneously
3161052|NCT00436540|Active Comparator|1|clobetasol propionate (Clobex®) spray
3161053|NCT00436540|Active Comparator|2|clobetasol propionate (Olux®) foam
3161054|NCT00436579|Experimental|Arm I (higher-dose enzyme inhibitor therapy)|Patients receive higher-dose oral sorafenib tosylate twice daily on days 15-36.
3161055|NCT00436579|Active Comparator|Arm II (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate three times daily on days 15-36.
3161056|NCT00436579|Active Comparator|Arm III (standard-dose enzyme inhibitor therapy)|Patients receive standard-dose oral sorafenib tosylate twice daily on days 15-36. (closed to accrual as of 4/29/2009)
3161057|NCT00436592|Experimental|1|
3161058|NCT00436631|Experimental|diet|
3161059|NCT00436657|Experimental|Surgery + CHPP of Escalating Cisplatin|Abdominal Surgery + CHPP of Escalating Cisplatin (Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.)
3161060|NCT00436670|Experimental|AMG 317 75 mg|75 subjects
3161061|NCT00436670|Placebo Comparator|Placebo Arm|75 subjects
3161062|NCT00436670|Experimental|AMG 317 300 mg|75 subjects
3161063|NCT00436670|Experimental|AMG 317 150 mg|75 subjects
3161064|NCT00436683|Experimental|1|Dose titration on active
3161065|NCT00436683|Active Comparator|2|Dose titration
3161066|NCT00436696||Ancillary-correlative (SNP analysis)|DNA samples are derived from participants' banked blood or uninvolved bone marrow. A whole genome scan of DNA samples is employed to identify candidate single nucleotide polymorphisms (SNPs). The candidate SNPs are investigated, using a gene-centric haplotyping approach, to identify 10-20 true disease-associated alleles. The disease-associated alleles are again investigated, using a gene-centric haplotyping approach, to validate 5-10 disease-associated SNPs. SNPs are then analyzed for heritable predisposition.
3194236|NCT00826059|Active Comparator|Active Stimulation|"Implantation/ISS Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First stimulation initiated within 24 hours from stroke onset, following implantation completion. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: ISS Stimulation treatment sessions repeated daily. Each treatment will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last ISS Stimulation treatment session, imaging performed for assessing Injectable Neuro Stimulator (INS) positioning and/or lesion. Implant removal procedure will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
2489133|NCT02974309|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer.
2489135|NCT02974309|Sham Comparator|Routine|All youth in this condition are asked to follow the routine that their clinical team has established.
2489215|NCT02974101|Experimental|spinal cord stimulation(RestoreSensor)|
2489244|NCT02973685|Experimental|Hepatic arterial infusion chemotherapy|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: Folfox Protocol. Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
2489246|NCT02973685|Active Comparator|Transarterial chemoembolization|Procedure/Surgery: Transarterial chemoembolization Drug: TACE Drug Protocol. Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, with or without MMC), and embolization with polyvinyl alcohol particles (PVA).
2489279|NCT02973373|Experimental|MRI with HF-NIV|Intervention: Acquisition of MRI with High-Frequency non-invasive ventilation (HF-NIV)
2489286|NCT02973373|Active Comparator|MRI without HF-NIV|Intervention: MRI without High-Frequency non-invasive ventilation (HF-NIV)
2489364|NCT02973152|Active Comparator|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
2489368|NCT02973152|Active Comparator|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
2489394|NCT02972619|Experimental|Intervention|Structured multicomponent intervention (MCI)
2489395|NCT02972619|No Intervention|Usual Care|Control group receive usual care in the polyclinics
2489410|NCT02972489|Experimental|3D OFDI guidance arm|Bifurcation percutaneous coronary intervention (PCI) optimized by online-3D OFDI during and after procedure
2489411|NCT02972489|Active Comparator|Angio guidance arm|Bifurcation percutaneous coronary intervention (PCI) guided by angiography
2489451|NCT02972281|Other|Patients with bacterial infections|Patients with recurrent and/or severe bacterial infections
2489528|NCT02971943|Other|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging preoperatively and 3 months postoperatively.
2489569|NCT02971566||Gastrointestinal complications|"Development of one ore more of the following gastrointestinal complications:~necrotizing enterocolitis (stage ≥2)~spontaneous intestinal perforation~feeding intolerance, defined as enteral feeding withholding ≥1 day because of suggestive clinical signs"
2489572|NCT02971566||Controls|no evidence of gastrointestinal complications during the hospitalization
2489623|NCT02971306|Active Comparator|Standard Medical therapy|standard medical therapy
2489624|NCT02971306|Experimental|G-CSF|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
2489625|NCT02971306|Experimental|G-CSF and NAC|standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days plus NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution)
2489641|NCT02970929|Experimental|SEP-363856|SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
2489733|NCT02970526||colorectal cancer survivors|
3194237|NCT00826059|Sham Comparator|Sham Stimulation|"Sham Implantation and Sham Stimulation during 5 consecutive days & Standard of Care (SoC).~Day 1: First Sham stimulation initiated within 24 hours from stroke onset, following Sham implantation procedure. All subjects will be treated according to SoC for treatment of Acute Ischemic Stroke.~Day 2-4: Sham Stimulation sessions repeated daily. Each Sham Stimulation will be initiated within 18-26 hours from the preceding treatment.~Day 5: Following completion of the last Sham Stimulation session, imaging performed for lesion assessment. Sham Implant removal will then be performed. Subsequently, patients will be evaluated for safety and effectiveness.~Subjects will continue with SoC as needed and discharged from the hospital based on the judgment of the study investigator."
3194238|NCT00826072||ALI|patients with acute lung injury at 24h after cardiac surgery
3194239|NCT00826072||Control|patients without acute lung injury 24h after cardiac surgery
2490088|NCT02967796||Supplemented group|6 capsule of Proteochoc during 4 day, from day 0 (day of delivery) to day 4
2490095|NCT02967796||Control group|no supplementation, just the same follow-up as supplemented group
3194240|NCT00826085|Experimental|Thermodox in combination with hyperthermia|Single arm study
3194241|NCT00826098|Experimental|1 (PRP)|Total knee replacement with PRP
3194242|NCT00826098|No Intervention|2 (non-PRP)|Total knee replacement without PRP
2489078|NCT02974712|Placebo Comparator|Saline|After routine Induction, same volume saline was administrated.
2489170|NCT02974478|Experimental|Orange juice with meals|Effect of orange juice consumption with three meals per day (without snacking) on glucose metabolism and antioxidative status
2489171|NCT02974478|Experimental|Orange juice between meals|Effect of orange juice consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
2489174|NCT02974478|Experimental|Sugar sweetened beverage between meals|Effect of sugar sweetened beverage consumption between three meals per day (without snacking) on glucose metabolism and antioxidative status
2489225|NCT02973932|Experimental|Internet-based psychotherapy|
2489316|NCT02973269|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
2489317|NCT02973269|Placebo Comparator|Placebo|Placebo Intramuscular injection
2489345|NCT02972957|Experimental|LAIV-vaccinated group 1|Nasovac-S vaccination group A , blood samples days 0, 2, 21
2489349|NCT02972957|Experimental|LAIV-vaccinated group 2|Nasovac-S vaccination group B, blood samples at days 0, 7, 21
2489352|NCT02972957|No Intervention|Unvaccinated|control group C
2489353|NCT02972957|Experimental|Oral Azithromycin & vaccination|group D - a single dose of oral Azithromycin will be given 28 days prior to Nasovac-S vaccination
3194243|NCT00826124|Active Comparator|I|Two epidural steroid injections two weeks apart based on history and physical exam alone
2489516|NCT02972099|Experimental|TcPRF Group|"According to the standard application of the device, for the PRF procedure one 5 x 13 cm skin electrode will be placed over the forehead, the other one over the posterior aspect of the neck. PRF with a duty load of 14.8 msec/sec and an average pulse frequency of 5.11 Hz will be applied for 25min. The voltage will be set to generate a current of 1 A.~Voltage and impedance will be monitored continuously during treatment and if necessary the voltage will be corrected to ensure the proper current."
2489517|NCT02972099|Placebo Comparator|Placebo Group|The setup will be made as for active treatment but no current will be delivered. The patients will not be able to feel any difference to the real treatment.
2489605|NCT02971540|Experimental|bupivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
2489609|NCT02971540|Experimental|ropivacaine, LA, solution|an a local anesthetic administered for local wound infiltration on each side in a single dose of 10 ml of 0,2% solution per segment of vertrebral columne with potential duration time of up to 8 hours according to manufacturers data
2489611|NCT02971540|Experimental|metamizol, analgesic, solution|an analgesic drug administered intravenously for pre-emptive analgesia in a initial dose of 1-1,25g with potential duration time of up to 6 hours according to manufacturers data
2489613|NCT02971540|Experimental|tramadol, analgesic, solution|a half-opioid drug administered intravenously for pre-emptive analgesia in a initial dose of 2 mg per kg of body weight with potential duration time of up to 6 hours according to manufacturers data
2489618|NCT02971540|Experimental|control group|no pre-emptive analgesia will be used.
2489666|NCT02970903|Experimental|VitalPAD|Using VitalPAD prototype device
2489667|NCT02970903|Active Comparator|Control|Using traditional tools (monitors, paper records)
2489702|NCT02970630|Experimental|Envarsus once a day, everolimus b.i.d.|"Tacrolimus tablets at starting dose of 0.07 mg/kg/day will be administered once daily in the morning.~Everolimus tablets at starting dose of 2 mg/day (1 mg b.i.d.) will be administered twice daily, every 12 hours."
2489762|NCT02970279|Experimental|Enhanced Behavioural Activation Groups|"Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;~Implementation intentions~Dose-response psychoeducation"
3194244|NCT00826124|Active Comparator|II|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
3194245|NCT00826137|Experimental|A|Treated with prebiotics.
3194246|NCT00826137|Placebo Comparator|B|Placebo treated.
2489970|NCT02968784|Experimental|ExAblate MRgFUS|"Up to 50% of the prostate gland will be treated. Treatment will include the Index lesion which is visible on MRI + tumor free margins of 3-mm; tumor free margins will not extend beyond the posterior aspect of the prostate capsule.~Urethral and bilateral neurovascular bundle preservation will be preferred whenever clinically justified.~Additional foci in the same hemisphere that are confirmed by biopsy and are < Gleason Score 7 (up to 3+4 or 4+3) or suspected to be positive for malignancy based on multi parametric-MRI) will also be included in the treated volume, providing total treatment volume does not exceed 50% of the gland."
2490047|NCT02968264||TOF participants|Tetralogy of fallot patients at any age
2490109|NCT02967809||final diagnosis after portable echography|Experimental group: final diagnosis after portable cardiac echograph examination
2490111|NCT02967809||final diagnosis without portable echography|Group control: Final diagnosis for patient ( same medical condition and history) hospitalized in units without portable cardiac echograph examination avaible
2490135|NCT02967497|No Intervention|Blank|No intervention, just observation.
2490138|NCT02967497|Experimental|YQ1 group|Cisplatin-based chemotherapy + YQ1
2490178|NCT02967263||Hospital-acquired AKI|Adult patients with Hospital-acquired AKI
2490196|NCT02966925|Experimental|Treatment with Cellular Matrix|Patients will be treated with a combination of PRP/HA prepared with Cellular Matrix BCT-HA Kit
3194247|NCT00826163|Active Comparator|stable COPD|Postbronchodilator FEV1> or = 50% predicted
3194248|NCT00826163|Sham Comparator|Asthma|Postbronchodilator FEV1 > or = 50% predicted
3194249|NCT00826215|Experimental|1|Electroacupuncture treatment
3194250|NCT00826215|Sham Comparator|2|Sham laser acupuncture
3194251|NCT00826293|Active Comparator|True Stabilization Group|Patients will be randomized to one of the two treatment groups (true stabilization vs. sham stabilization). Patients will be exercising with a belt that is expected to reduce impingement of the rotator cuff tendons.
3194252|NCT00826293|Sham Comparator|Sham Stabilization|Patients receive sham stabilization. The sham procedure imitates the treatment without any true effect.
3194253|NCT00826306|Experimental|Video-based education arm|Subjects receiving the video-based educational material
3194254|NCT00826306|Active Comparator|Written education arm|Subjects receiving the written educational material
2489137|NCT02974413|Experimental|Intervention|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.
2489144|NCT02974413|No Intervention|Control|The study will also include a Control Group (CG), and the participants of this group will participate in conversation circles at the beginning and the end of the six month follow-up.
3208711|NCT00977340|Experimental|Confrontation|Confrontation with nightmare content, until fear reaction habituates; 1 session on-site and 4 weeks of individual daily training
2489285|NCT02973464||Valganciclovir 900mg a day|Valganciclovir 900mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
2489291|NCT02973464||Valganciclovir 450mg a day|Valgancigclovir 450 mg tablet by mouth begin within 10 days after renal transplant，once a day till to Day 100 posttransplant.
2489294|NCT02973464||Ganciclovir|Ganciclovir 5mg/kg fluids by intravenous after renal transplant，once a day for the first 14 days；and than sequential Ganciclovir 1g tablet by mouth，third a day till to Day 100 posttransplant.
2489342|NCT02973074|Other|OLEOvital|30mg iron are being administered orally twice a day for a period of 4 Weeks it is a granulated powder which is taken orally and then solved with saliva, without taking water
2489461|NCT02972424|Experimental|Teriparatide Prefilled Syringe|TPTD is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 250 mcg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
2489464|NCT02972424|Placebo Comparator|Placebo|Placebo is supplied as a sterile, colorless, clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable delivery device (pen) for subcutaneous injection. Each prefilled delivery device is filled with 2.7 mL to deliver 2.4 mL. Each mL contains 0.41 mg glacial acetic acid, 0.1 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3 mg Metacresol, and Water for Injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4.
2489508|NCT02972021|Other|control|Pure oxygen by nasal cannula group
2489510|NCT02972021|Experimental|HFNC|oxygen by High-flow nasal cannula
2489706|NCT02970513|Experimental|patients operated on for colorectal cancer|
2489744|NCT02970357|Other|Enrolled patient|Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
3161067|NCT00436800|Experimental|1|Gemcitabine on Day 1 followed by Oxaliplatin on Day 2. The regimen is given every 2 weeks to a maximum of 12 cycles.
2489849|NCT02969681|Experimental|Ascorbic Acid with chemotherapy group|"Ascorbic Acid with mFOLFOX6 with or without bevacizumab Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks~mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
2489852|NCT02969681|Active Comparator|Chemotherapy group|"mFOLFOX6:~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
2489897|NCT02969083|Other|RNU plus Gemcitabine/Cisplatin|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery
2490087|NCT02967939|Experimental|DA-2802|DA-2802 319mg tablet qd
3161068|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (DB period)|Participants received cladribine tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 milligram per kilogram (mg/kg) along with interferon (IFN)-beta therapy (Rebif® new formulation [RNF] 44 mcg three times a week, subcutaneously; Avonex® 30 microgram (mcg) every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the Double blind period (DBP) of 96 weeks.
3161069|NCT00436826|Placebo Comparator|Placebo, IFN-beta (DB period)|Participants received matching placebo tablets orally over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during the DB period of 96 weeks.
3161070|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the open label (OL) extension (Ext.) period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
3161071|NCT00436826|Placebo Comparator|Placebo, IFN-beta, Cladribine 3.5 mg/kg (OL Ext)|Participants who received placebo initially and completed DB period entered in the OL Ext. period. In OL Ext. period, participant who met the eligibility criteria received OL oral cladribine 3.5 mg/kg over maximum of 48 weeks along with IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
2489245|NCT02973724|Experimental|Remifentanil|Extubation was performed when remifentanil was maintained a predetermined concentration throughout the emergence periods.
2489284|NCT02973451|Active Comparator|Laparoscopic|Laparoscopic Guided Transversus Abdominis Plane Block using Bupivacaine
2489292|NCT02973451|Active Comparator|local|Trocar Site Infiltration of Bupivacaine
2489331|NCT02973126|Other|FFRct versus SPECT|Comparison of the diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD
2489370|NCT02972866|Experimental|Noex 32mcg|"Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
2489372|NCT02972866|Experimental|Budecort Aqua 32 mcg|"Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day.~Tretament of 28 days."
2489427|NCT02972593|Other|Liberal|Blood and blood products for transfusion. Transfusion will be done to keep Hgb >7 g/dL.
2489430|NCT02972593|Other|Conservative|Blood and blood products for transfusion. Transfusion will be done to keep Hgb > 5.5 g/dL.
2489469|NCT02972268|Experimental|Group I|Tamsulosin 0.2mg + Solifenacin 5mg
2489470|NCT02972268|Placebo Comparator|Group II|Tamsulosin 0.2mg + Placebo(Solifenacin)
2489493|NCT02972008||Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) having at least one new cerebral ischemic lesion on postoperative cerebral MRI
2489494|NCT02972008||No Cerebral Lesion|Patient over 70 years with severe aortic stenosis requiring percutaneous aortic valvular replacement (TAVI) with no cerebral ischemic lesion on postoperative cerebral MRI
2489504|NCT02971774||questionnary|self administered questionnary
2489558|NCT02971709|Experimental|Shade Sail|Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.
2489562|NCT02971709|No Intervention|Unshaded Control|Passive recreation areas in public parks that remained unshaded at pretest and posttest.
2489621|NCT02971241|Experimental|Immediate intervention group|"A randomized, waitlist controlled trial with three hundred fifty older adult subjects with type 2 diabetes and 280 young adult subjects will be conducted in Taipei Tzu Chi Hospital and Hualien Tzu Chi Hospital in Taiwan. The patients who are randomized to the immediate intervention group will be assigned to the training course as soon as a course is available.~The intervention is a 12-week program which consists of 8-week training sessions followed by 4-week consultation service for technical support. Both will be provided by the young volunteers with a lead instructor."
2489622|NCT02971241|Other|Waitlist control group|The patients randomized to the waitlist control group will need to wait for four months to serve as no intervention control, and then assigned to the training course.
2489636|NCT02970994||Preterm neonates <34 wks|Haemodynamicaly stable preterm neonates <34 weeks with in 48 hours of admission
2489670|NCT02970864|Experimental|Polynerve|Participants found to have a nerve gap of at least 5 mm and no greater than 20mm will undergo repair with the Polynerve.
2489708|NCT02970591|Experimental|Diet B|Low carbohydrate diet
2489711|NCT02970591|Active Comparator|Medical treatment|Optimized Medical treatment
2489716|NCT02970591|Experimental|Diet A|Traditional dietary advice and low FODMAP content
2489753|NCT02970253|Active Comparator|Capsular resection|Capsular resection
2489757|NCT02970253|Active Comparator|Capsular retention|Capsular retention
2489773|NCT02969954|Experimental|Intervention arm|Study has one arm - who will all receive the intervention
3161072|NCT00436826|Experimental|Cladribine 3.5 mg/kg, IFN-beta (Safety follow up)|Participants who received cladribine 3.5 mg/kg initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
3161073|NCT00436826|Placebo Comparator|Placebo, IFN-beta (Safety follow up)|Participants who received placebo initially and completed DB period entered in the OL ext. safety follow up period. In this period, participants who did not meet eligibility criteria received only IFN-beta therapy (RNF 44 mcg three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) up to 48 weeks.
3161074|NCT00436839|Experimental|1|Docetaxel 75mg/m² intravenously (day 1) every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
3161075|NCT00436839|Active Comparator|2|Mitoxantrone 12mg/m² intravenously every 21 days, plus prednisone 10mg orally given daily, minimal for 6 cycles and up to 10 cycle
2490076|NCT02968082|Placebo Comparator|Placebo group (P group)|"The group that not existed scopolamine ingredient.~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that not existed scopolamine ingredient."
2490077|NCT02968082|Experimental|Scopolamine group (S group)|"'Scopolamine (1.5mg) 1 patch'~The group that existed scopolamine ingredient~dosage form: apply~dosage: 1.5 mg~frequency: 1 times (at 9 p.m. of the day before the operation day)~duration: Until the 24hr after operation.~Patients will be applied patch that existed scopolamine ingredient."
2490108|NCT02967757||liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg|
2521803|NCT02751723||pancreatic cancer|validated questionnaires
3161076|NCT00436865|Other|PCOS|PCOS women receiving weight loss intervention
3161077|NCT00436865|Other|Control|Non-PCOS women receiving weight loss intervention
3161078|NCT00436878|Experimental|Portion Size|Each experiment manipulated food portion size of beverages, entrees, and side dishes
3161079|NCT00436930|Experimental|Arm I|Patients receive irradiated autologous tumor cells subcutaneously (SC) and sargramostim (GM-CSF) SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
2489283|NCT02973594|Placebo Comparator|Placebo|Patients will receive placebo bid in addition to baseline maximum-tolerated beta-blocker therapy.
2489330|NCT02973113|Experimental|EBVST Cells + Nivolumab|"PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~EBVST- 1 x 10^8/m2 at days +1 and +15. PD1 inhibitor - nivolumab 3 mg/kg (max dose: 240 mg) Q 2 weeks for total 4 doses and repeat a day prior to each EBVST infusion.~Can receive up to 3 additional infusions of EBVSTs with a single dose of nivolumab at 6-12 week intervals starting at least 6 weeks after the second infusion if stable disease or a partial response at Week 8 evaluation"
3161080|NCT00436930|Experimental|Arm II|Patients receive autologous dendritic cells loaded with irradiated autologous tumor cells SC and GM-CSF SC once weekly for 3 weeks and then once monthly for up to 5 months in the absence of disease progression or unacceptable toxicity.
2489417|NCT02972580||Cohort A|DMD/BMD Female Carriers who have/had an affected child (n=150)
2489420|NCT02972580||Cohort B|DMD/BMD Female non-carriers controls who have/had an affected child (n=50)
2489423|NCT02972580||Cohort C|Healthy Age-Matched Controls (n=50)
2489429|NCT02972580||Cohort D|DMD/BMD Female Carriers with no affected children (n=25)
2489477|NCT02972255|Experimental|Part I: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 1000 and 2000 milligrams (mg) intravenous (IV) infusion on Days 1 through Day 7 every 8 hours (q8h), for a total of 19 doses, with the last dose administered on the morning of Day 7.
2489478|NCT02972255|Placebo Comparator|Part I: Placebo|Participants will be randomized in two dose cohorts to receive single dose of placebo matching to RO7079901 on Days 1 through Day 7 q8h, for a total of 19 doses, with the last dose administered on the morning of Day 7.
2489480|NCT02972255|Experimental|Part II - Single Dose and Repeat Dose: RO7079901|Participants will be randomized in two dose cohorts to receive single dose of RO7079901 IV infusion at a dose above the previously studied dose levels in Part I (greater than [>] 2000 mg) on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
2489482|NCT02972255|Placebo Comparator|Part II - Single Dose and Repeat Dose: Placebo|Participants will be randomized in two dose cohorts to receive single dose placebo matching to RO7079901 on Day 1, with the option to extend to q8h dosing for 7 days (i.e., starting on Day 3 through Day 9); once PK, safety and tolerability have been confirmed up to 48 hrs after the single dose.
2489484|NCT02972255|Experimental|Part III: RO7079901 + Meropenem|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem IV infusion in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of 2000 mg meropenem IV infusion on Day 1. On Day 2, participants will receive a single dose of RO7079901 IV infusion. Participants randomized to Sequence 2 will receive a single dose of RO7079901 IV infusion on Day 1. On Day 2, participants will receive a single dose of 2000 mg meropenem IV infusion. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 in combination with meropenem IV infusion q8h, regardless of sequence. Escalation to a maximum dose of RO7079901 5000 mg q8h may be considered on the basis of safety and tolerability data from the previous cohorts.
2489486|NCT02972255|Placebo Comparator|Part III: RO7079901 Placebo + Meropenem Placebo|Participants will be randomized in three dose cohorts to receive RO7079901 and Meropenem matching placebos in one of the 2 treatment sequences. Participants randomized to Sequence 1 will receive a single dose of placebo matching to meropenem on Day 1. On Day 2, participants will receive a single dose of placebo matching to RO7079901. Participants randomized to Sequence 2 will receive a single dose of placebo matching to RO7079901 on Day 1. On Day 2, participants will receive a single dose of placebo matching to meropenem. Starting on Day 3 and continuing through Day 9 (i.e., for a total of 19 doses, last dose in the morning of Day 9) all participants will receive RO7079901 and meropenem matching placebos q8h, regardless of sequence.
3208712|NCT00977340|Placebo Comparator|Imagination|Imagination of a safe and pleasant site; 1 session on-site and 4 weeks of individual daily training
2489628|NCT02971345|Experimental|Endovascular Brachytherapy&Stent&TACE|"Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.~Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
2489629|NCT02971345|Active Comparator|TACE alone|Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
2489668|NCT02970890|Placebo Comparator|Placebo group|Subjects received placebo therapy. The placebo Portable Pain Away™ device was identical to the active device, displayed the same settings and emitted the same sound regardless of the comparator.
2489669|NCT02970890|Active Comparator|PBMT group|Subjects received active photobiomodulation therapy (PBMT). The active Portable Pain Away™ device was identical to the placebo device, displayed the same settings and emitted the same sound.
2489713|NCT02970604|Experimental|Aspirin|Non-enteric coated Aspirin 75mg once daily for 7 days
2489717|NCT02970604|No Intervention|No treatment|No treatment for 7 days
2489768|NCT02969941|Active Comparator|Real Stimulation|Participants will receive active transcranial magnetic stimulation (TMS) daily for two weeks
2489770|NCT02969941|Placebo Comparator|Placebo Stimulation|Participants will receive sham transcranial magnetic stimulation (TMS) daily for two weeks
3161081|NCT00436943||A|Smokers
3161082|NCT00436995|Other|Single|
2489873|NCT02969343|Experimental|Intervention|Patients and providers on hospital care units where the PSLL patient safety health information technology tools are implemented, during the interventional phase of a stepped wedge randomized trial design.
3161083|NCT00437021|Active Comparator|Group C|Dryvax® vaccine or placebo on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3161084|NCT00437021|Experimental|Group D|Standard dose IMVAMUNE® vaccine or placebo on Day 0 and Dryvax® vaccine or placebo on Day 7. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3161085|NCT00437021|Experimental|Group E|Dryvax® vaccine and standard dose IMVAMUNE® vaccine or 2 placebos on Day 0. This arm was discontinued from original protocol. Subjects already enrolled in this group will continue follow-up per protocol.
3208713|NCT00977353|Experimental|sarcosine|sarcosine
3208714|NCT00977353|Active Comparator|citalopram|citalopram
3161086|NCT00437021|Experimental|Group F|Standard dose IMVAMUNE® vaccine or placebo on Day 0.
3161087|NCT00437021|Experimental|Group B|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 28.
3161088|NCT00437021|Experimental|Group A|Standard dose IMVAMUNE® vaccine or placebo on Days 0 and 7.
2489415|NCT02972671|Experimental|MiStent (MT005) Coronary Artery Stent|A balloon expandable crystalline sirolimus eluting stent with an absorbable polymer coating will be implanted.
2489416|NCT02972671|Active Comparator|Xience Coronary Artery Stent|Balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating will be implanted
2489472|NCT02972216||Nolbaxol|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
2489475|NCT02972216||Taxotere|For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 ~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
2489509|NCT02971982|Experimental|rituximab /Dex/CTX|rituximab /Dexamethasone/cyclophosphamide 6 cycles followed by rituximab (at least 2 cycles) rituximab:375mg/m2 d1 Dexamethasone:40mg d1-4 cyclophosphamide:750mg/m2,d1-28
2489512|NCT02971982|Experimental|Velcade/Dex/CTX|Velcade/Dexamethasone/cyclophosphamide 6 cycles followed by velcade (at least 2 cycles) Velcade:1.3mg/m2 d1,d4,d8,d11 Dexamethasone:20mg d1-2,d4-5,d8-9,d11-12 cyclophosphamide:750mg/m2,d1-28
2489694|NCT02970916|Experimental|FOLFIRI+aflibercept|
2489718|NCT02970435|Experimental|Video Discharge Instructions|These videos contain the same instructions that a patient receives via the standard-of-care verbal and written discharge instructions. These instructions will be delivered by the same nursing and medical staff that also regularly provides verbal and written discharge instructions to patients. There will be no difference in the content between the standard-of-care verbal and written instructions and the video discharge instructions. Patients in this group will receive telecommunication reminders on how to access discharge videos.
2489721|NCT02970435|Active Comparator|Verbal and Written Discharge Instructions|Nursing and medical staff will provide verbal and written discharge instructions as is standard of care post surgery
2489909|NCT02969252|Other|Open label|Single and multiple dose, open label, pharmacokinetics and safety study
2489930|NCT02968966|Experimental|Therapy regime|Two medical drugs will be administered in a predefined order (1. Phenhydan® (Phenytoin), 2. Lacosamide (Vimpat®) to investigate whether this enables an effective reduction of seizures in early onset epileptic encephalopathies..
2490013|NCT02968472|Experimental|prophylactic 4SCAR19 cells|Patients who have relapsed and refractory B cell leukemia after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells.
2490052|NCT02968199|Experimental|Referred women|A brief intervention based on the'5 A' model developed by the Agency for Health Care Policy and Research in the United States.
2490161|NCT02967614|Experimental|[A]→[A]+[B]|"Period 1 : At each dosing of Treatment A eye drops is administered for 8days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 92days"
2490170|NCT02967614|Experimental|[B]→[A]+[B]|"Period 1 : At each dosing of Treatment B eye drops is administered for 92days~Period 2 : At each dosing of Treatment A + Treatment B eye drops is administered for 8days"
2490198|NCT02966977|Active Comparator|Conventional microbiological diagnostics|Conventional microbiological identification by culture plate (overnight cultures with subsequent bacterial/fungal identification).
2490199|NCT02966977|Experimental|Conventional plus mass spectrometry|Conventional microbiological identification by culture plate plus Direct mass spectrometry identification from urine sample. This additional diagnostic procedure is supplied additionally to conventional diagnostics.
2490266|NCT02966730|Experimental|Follicular Lymphoma|Participants will be receive Ibrutinib as an oral capsule preparation once daily for a period of 2 years. The dose will be 560mg daily. Toxicities will be recorded and graded. Response to treatment will be determined by FDG-PET imaging every 6 months, or as clinically indicated, in conjunction with clinical assessment by a physician, including physical examination, every 4 weeks from day 1 (baseline) for the first 3 months and then every 3 months until the end of treatment at 2 years.
2490466|NCT02965157|Experimental|CART20|
2490521|NCT02964962|Experimental|29 mm LOTUS Edge™|
2490601|NCT02964598|Experimental|Control|Minimal information on sleep timing
2490602|NCT02964598|Experimental|Psychoeducation|An extensive psychoeducational platform
2490603|NCT02964598|Experimental|Bright light|Bright light treatment with 10 000 lux at max
2490604|NCT02964598|Experimental|Gamified intervention|A new gamified intervention designed for mobile phones
2490605|NCT02964598|Experimental|Bright light and gamified intervention|A combination of the two
2490606|NCT02964598|Experimental|Sleep coaching|A new intervention protocol including a personified approach to solve problems and increase motivation for better sleep behavior
2490607|NCT02964598|Experimental|Sleep coaching + bright light|A combination of the two
2491455|NCT02958917|Placebo Comparator|pirfenidone 2403 mg/d|Subjects will be randomized in a 2:1 ratio to receive either pirfenidone 2403 mg/d or a placebo equivalent.
2521804|NCT02751723||stomach cancer|validated questionnaires
3161089|NCT00437060||Ancillary/Correlative (neurocognitive assessment, biomarkers))|"Patients complete neurocognitive tests to assess thinking, memory, attention, and concentration. The baseline test is administered during the consolidation phase of chemotherapy and further tests are done at 1 year from baseline and 1 year after* the completion of study therapy.~Patients undergo blood and cerebrospinal fluid collection periodically for biomarker, genotypic polymorphisms, and pharmacokinetic analysis. Patients undergo MRI diffusion-tensor imaging to correlate imaging with neuropsychological outcomes."
3194255|NCT00826319||Bioimpedance sub-study cohort|Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population. The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events. Subjects are followed at 6 months intervals for 2 years.
3194256|NCT00826319||Ethnic enrichment cohort|Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
3194257|NCT00826319||Original CanPreddict cohort|The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
2489456|NCT02972346|Experimental|ACTH(+)|routine treatment + ACTH
2489460|NCT02972346|No Intervention|ACTH(-)|routine treatment
2489530|NCT02972073|Experimental|Exercise intervention|"There are 4 different exercise interventions (4 independent intervention studies) based on different concepts in this entire project. Interventions include:~core stabilization exercise~movement system impairment approach~neuromuscular activation using suspension~kinematic linkage imbalance"
2489533|NCT02972073|No Intervention|Healthy control|This healthy control group will be informed to maintain usual daily activities and avoid participating in activities that involve trunk muscle exercise
2489560|NCT02971449|Experimental|Tablets only|100 VHTs will receive Amazon Fire Tablets with pre-loaded instructional videos; this is the intervention arm since this involves introduction of a new technology to this realm
2489565|NCT02971449|Active Comparator|ICCM traditional training|100 VHTs will receive traditional 1 day 'in-person' training as an active comparator intervention, but participants in this arm will not receive any tablets
2489660|NCT02971215|Experimental|High-intensity laser therapy|High-intensity laser therapy application through iLux Laser device
2489661|NCT02971215|Sham Comparator|Sham device|Sham high-intensity laser therapy application through sham iLux Laser device
2489729|NCT02970682|Experimental|Aromatase Inhibitor|SFX-01 with Aromatase Inhibitor SFX-01 when used in combination with aromatase inhibitors. All patients will continue to receive their AI and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
2489730|NCT02970682|Experimental|Fulvestrant|SFX-01 with Fulvestrant SFX-01 when used in combination with fulvestrant. All patients will continue to receive fulvestrant 500 mg IM in 28 day cycles. As patients will already have been taking this, a repeat loading dose is not necessary. Commencing on study D1 patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart, after food (preferably within 2 hours).
2489731|NCT02970682|Experimental|Tamoxifen|SFX-01 with Tamoxifen SFX-01 when used in combination with tamoxifen All patients will continue to receive tamoxifen and, at the start of the study (D1), patients will take SFX-01, which is provided as 300 mg capsules, one to be taken twice daily, 12 hours apart after food (preferably within 2 hours).
2489767|NCT02970019|Experimental|K0706|K0706 will be administered once a day
2489771|NCT02970019|Experimental|Placebo|Placebo will be administered once a day
2489827|NCT02969824|No Intervention|Usual Care Group|"These individuals will undergo a period of physical rest and standard care until symptoms spontaneously resolve. For the purposes of this study, rest will be defined as the avoidance of any activities beyond those of daily living, including participation in sport and physical activity. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines."
2489831|NCT02969824|Experimental|Supervised Exercise Group|These individuals will begin to exercise at Day 3 post-injury. These participants will be asked to complete a total of eight exercise sessions over the course of 11 days, with one day of rest after two consecutive sessions. Two of the sessions (i.e., first and mid-point) will be an in-person exercise sessions at the lab with a member of the research team while the remaining six sessions will be home-based exercise sessions with remote communication by phone (i.e., call or text) with a member of the research team. Once individuals in this group achieve asymptomatic status, they will be directed through the existing return to play guidelines.
3194258|NCT00826332|Active Comparator|Abdominal|Transabdominal ultrasound guided embryo transfer
3194259|NCT00826332|Active Comparator|Vaginal|Transvaginal ultrasound guided embryo transfer
3194260|NCT00826345|Experimental|Acupuncture/Moxibustion|Diagnostic Acupuncturists assessments will inform acupuncture/moxibustion treatment prescriptions for persons with HIV/AIDS experiencing distal peripheral neuropathy. This protocol is tailored specifically for the subject's unique diagnosis according to the symptoms being reported at each diagnostic acupuncture (DA) session.
3194261|NCT00826345|Placebo Comparator|Placebo Acupuncture / Moxibustion|Sham/placebo Arm: Points will be administered away from the classic/traditional true point location.
3194262|NCT00826358|Experimental|A|ABT-143 capsules 5/45mg
3194263|NCT00826358|Active Comparator|B|ABT-335 45mg and rosuvastatin 5mg
3194264|NCT00826371|Experimental|1|
3194265|NCT00826397|Experimental|Acupuncture Arm|Patients in the treatment arm will receive acupuncture administered twice weekly for six weeks and will be allowed to take pain medication as necessary.
3194266|NCT00826397|Sham Comparator|Control Arm|The control patients will receive a form of sham acupuncture, which will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks.
3194267|NCT00826410|Experimental|subcutaneous drain|"Use of subcutaneus suction drain (Redon) after laparotomy"
2490143|NCT02967315|Experimental|Study Group|"Procedures include:~Two Cardiac Magnetic Resonance Imaging (CMRIs) A central venous line placement, A chest X-ray Electrocardiogram (ECG) Fluid administration Blood draw Pregnancy test"
2490254|NCT02966522|Experimental|Thalidomide|Patient with cardiac amyloidosis receive thalilomide with dexamethasone
2490301|NCT02966392|Experimental|Continuous Pressure Control (CPC)|Continuous endotracheal cuff pressure control using Tracoe cuff pressure controller during their intubated stay on ICU.
2490302|NCT02966392|No Intervention|Standard Care|Intermittent cuff pressure control through manual measurement performed 3 times per day (standard care)
3194268|NCT00826436||8 subjects for Cohort 1|
3194269|NCT00826436||8 subjects for Cohort 2|
3208715|NCT00977366|Active Comparator|Hydrochloric acid infusion|
2489351|NCT02973022||ACEC Control Group|Once participants are randomized, they will be given survey 1. The control group at ACEC will be exposed to a nutrition education program in a series of 6 thirty minute sessions before the work day begins over the course of several weeks. We anticipate that two sessions will occur per week and therefore the delivery of the whole intervention will take 3 weeks. A free meal will be provided at all 6 educational sessions. Once the final educational session is completed, all participants will be given survey 2.
2489402|NCT02972749|Experimental|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
2489404|NCT02972749|No Intervention|Control|No intervention. patients are instructed to continue prescribed medical therapy.
2489426|NCT02972450|Experimental|Injection only: Active:placebo (3:1)|"GTU-MultiHIV B-clade + MVA HIV-B:~GTU-MultiHIV B-clade - 2 mg of DNA in 1ml encoding a multi HIV antigen (synthetic fusion protein) administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4 and MVA HIV-B 0.5ml(1 x108 pfu/ml) MVA encoding the full-length codon-optimized sequence of Gag administered intramuscularly into the non-dominant deltoid muscle at week 12."
2489432|NCT02972450|Experimental|Infusion only: Active:placebo (3:1)|Vedolizumab will be administered in the participant's dominant arm as an intravenous infusion over 30 mins.
2489433|NCT02972450|Experimental|Injection and Infusion: Active:placebo (3:1)|GTU-MultiHIV B-clade + MVA HIV-B + Vedolizumab
2489436|NCT02972450|Placebo Comparator|Placebo|"Placebo1 for DNA: Sodium chloride for injection, 0.9% in 1ml administered intramuscularly into the non-dominant deltoid muscle at weeks 0 and 4.~Placebo 2 for MVA: S08 buffer in 0.5ml administered intramuscularly into the non-dominant deltoid muscle at week 12.~Placebo for mAb: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
2489487|NCT02972164|No Intervention|Control|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the control group. Control children are assessed for the same measures as the intervention group at the beginning and end of the intervention but receive none of the intervention modules.
2489489|NCT02972164|Experimental|Weight loss program for school children|Each year, 100 school children age 9-12 who meet inclusion criteria are selected from 5 randomly chosen schools to participate in the intervention group. The intervention children take part in the integrated approach for weight management consisting of (1) intensive weight loss camp (2) twelve weeks of after school clubs for consolidation purposes, and (3) social media and wearable sensors for support and monitoring.
2489559|NCT02971553|Experimental|Upright Resuscitator with PEEP|Ventilation with the Upright Resuscitator with PEEP
2489566|NCT02971553|Active Comparator|Upright Resuscitator|Ventilation with the Upright Resuscitator (without PEEP)
2489626|NCT02971254|Active Comparator|Sevoflurane group|inhalation anaesthetic Sevoflurane, 1 M.A.C. during surgery
2489627|NCT02971254|Active Comparator|Desflurane group|inhalation anaesthetic Desflurane, 1 M.A.C. during surgery
3161090|NCT00437086|Experimental|PS-341|Designed to assess the toxicity and pilot response of PS-341 in patients with advanced myeloproliferative diseases.
3161091|NCT00437099|Experimental|1|subjects with BPD receiving Omacor 1.680 mg/d
3161092|NCT00437099|Experimental|2|BPD patients randomized to Omacor 3.360 mg/d
2490060|NCT02968160|Experimental|Telmisartan+Rosuvastatin|"Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks~* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
2490064|NCT02968160|Active Comparator|Telmisartan/Rosuvastatin|"Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks~* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit."
2490090|NCT02967835|Experimental|Telepsychiatry Consult|One time tele-psychiatry consultation to provide treatment recommendations for patients primary care physician.
2490132|NCT02967627|Experimental|Incisional Negative Pressure Wound Therapy (iNPWT)|Patients in the iNPWT group will have their incision covered by a single layer of Mepitel wound contact layer followed by application of a KCI V.A.C Simplace ™ Dressing composed of a strip of black foam covering the entire length of the incision followed by coverage of the incision, Mepitel, and foam with an occlusive Tegederm ™ dressing to establish an airtight seal. Negative pressure will then be applied using a SensaT.R.A.C. Pad ™ to a setting of 100 mmHg continuous suction. Dressings shall remain in place and will be removed by the surgical team on the morning of the third post-operative day and left open to air thereafter. Any loss of seal of the dressing shall be reinforced using occlusive dressings.
2490139|NCT02967627|Active Comparator|Standard Therapy|Patients in the conventional dressings group will receive a standard Mepore ™ dressing applied to cover the entire incision. This will be left in place and and removed by the surgical team on the morning of the second postoperative day and will be left open to air thereafter. Dressings may be either reinforced or changed at the discretion of the surgical team due to drainage or saturation during the first two postoperative days.
2490180|NCT02967185|Experimental|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis.
2490183|NCT02967185|No Intervention|Waitlist Control|Participants in this group will receive no intervention, but will complete the same set of assessments as those in the Experimental Group. They will be given the option of receiving the behavioral treatment program at no charge.
2490206|NCT02966912|Experimental|Magnesium|20 participants will be treated with 400 mg of Magnesium Oxide twice daily
2490212|NCT02966912|Active Comparator|Comparator|20 participants will receive no treatment
2490279|NCT02966665|Experimental|Healthy Young Volunteers (18-30 years)|Healthy volunteers between the ages of 18 and 30 years with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2489405|NCT02972827|Experimental|NICOM/FloTrac|500-1000ml Crystalloid fluid challenge (normal saline or plasmalyte) to be given for positive passive leg raise test by either device, and also will be given at baseline, regardless of baseline PLR response.
2489418|NCT02972463|Placebo Comparator|Placebo|9 maltodextrin capsules, once daily for 12 weeks
2489421|NCT02972463|Experimental|IgY Max Low-Dose (1g IgY Max)|2 Immunoglobulin Y capsules and 7 maltodextrin capsules, once daily for 12 weeks
2489424|NCT02972463|Experimental|IgY Max Mid-Dose (2g IgY Max)|4 Immunoglobulin Y capsules and 5 maltodextrin capsules, once daily for 12 weeks
2489428|NCT02972463|Experimental|IgY Max High-Dose (4.5g IgY Max)|9 Immunoglobulin Y capsules, once daily for 12 weeks
2489473|NCT02972190|Experimental|Bilateral decompression with TLIF|Patients undergoing bilateral decompression with TLIF
2489476|NCT02972190|Active Comparator|laminectomy with PLIF|Patients undergoing laminectomy with PLIF
3161093|NCT00437099|Placebo Comparator|3|patients with BPD randomized to Placebo
2489586|NCT02971423|Experimental|Part A; Cohort 1: 0.25 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a single ascending dose (SAD) of intravenous (IV) ETX2514. Participants in Cohort 1, aged 18 to 55 years, will receive 0.25 grams (g) IV ETX2514/placebo infused over 3 hours.
2489587|NCT02971423|Experimental|Part A; Cohort 2: 0.5 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 2, aged 18 to 55 years, will receive 0.5 g IV ETX2514/placebo infused over 3 hours.
2489588|NCT02971423|Experimental|Part A; Cohort 3: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 3, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
2489589|NCT02971423|Experimental|Part A; Cohort 4: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 4, aged 18 to 55 years, will receive 1.0 g IV ETX2514/placebo infused over 2 hours.
2489590|NCT02971423|Experimental|Part A; Cohort 5: 2.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 2.0 g IV ETX2514/placebo infused over 3 hours.
2489593|NCT02971423|Experimental|Part A; Cohort 6: 4.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 5, aged 18 to 55 years, will receive 4.0 g IV ETX2514/placebo infused over 3 hours.
2489594|NCT02971423|Experimental|Part A; Cohort 7: 8.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 7, aged 18 to 55 years, will receive 8.0 g IV ETX2514/placebo infused over 3 hours.
2489595|NCT02971423|Experimental|Part A; Cohort 8: 1.0 g IV ETX2514/placebo|Part A of the study will explore the safety and tolerability of a SAD of IV ETX2514. Participants in Cohort 8, aged 65 years or older, will receive 1.0 g IV ETX2514/placebo infused over 3 hours.
2489598|NCT02971423|Experimental|Part B; Cohort 9: 0.25 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of multiple ascending doses (MAD) of IV ETX2514. Participants in Cohort 9, aged 18 to 55 years, will receive 0.25 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2489602|NCT02971423|Experimental|Part B; Cohort 10: 0.5 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 10, aged 18 to 55 years, will receive 0.5 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2489604|NCT02971423|Experimental|Part B; Cohort 11: 1.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 11, aged 18 to 55 years, will receive 1.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2489608|NCT02971423|Experimental|Part B; Cohort 12: 2.0 g IV EXT2514/placebo|Part B of the study will explore the safety and tolerability of MAD of IV ETX2514. Participants in Cohort 12, aged 18 to 55 years, will receive 2.0 g IV EXT2514/placebo infused over 3 hours, every 6 hours (4 times a day) for 7 consecutive days, and then will receive 1 dose on Day 8.
2489610|NCT02971423|Experimental|Part C; Cohort 13: ETX2514/placebo with sulbactam|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (1.0 g) and/or imipenem/cilastatin (0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 1.0 g IV sulbactam infused over 3 hours. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time. The actual Day 1 and Day 5 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
2489614|NCT02971423|Experimental|Part C; Cohort 14: ETX2514/placebo with SUL and/or IM/CIL|Part C of the study will explore the safety and tolerability of IV ETX2514 when administered as a single dose in combination with sulbactam (SUL: 1.0 g) and/or imipenem/cilastatin (IM/CIL: 0.5 g) to healthy participants. On Day 1, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours. On Day 3, participants will receive a single dose of 0.5 g IV imipenem/cilastatin infused over 30 minutes. On Day 5, participants will receive a single dose of 1.0 g IV ETX2514/placebo infused over 3 hours plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. On Day 8, participants will receive a single dose of 1.0 g IV ETX2514/placebo plus 1.0 g sulbactam infused over 3 hours at the same time plus 0.5 g imipenem/cilastatin infused over 30 minutes initiated at the same time as ETX2514/placebo. The actual Day 1, Day 5, and Day 8 ETX2514 dose and infusion time will be determined based on PK and safety data from Part A.
2489619|NCT02971423|Experimental|Part D; Cohort 15: ETX2514/placebo with SUL and/or IM/CIL|Part D of the study will explore the safety and tolerability of multiple doses of combined IV ETX2514/sulbactam (1.0 g)/imipenem/cilastatin (0.5 g) to healthy participants. Participants in Cohort 15 will receive 1.0 g IV ETX2514/placebo and 1.0 g IV sulbactam both infused over 3 hours and 0.5 g IV imipenem/cilastatin infused over 30 minutes every 6 hours (4 times a day) for 10 days and will receive 1 dose on Day 11. The actual ETX2514 dose and infusion time will be determined based on PK and safety data from Part C.
2489672|NCT02970838|Experimental|Intervention|Patients take part in a structured weight-loss program over 15 weeks including a fasting phase with formula diet over six weeks
2489448|NCT02972333|Experimental|AZD9291 80mg oral each day±RT|AZD9291(80mg, QD, p.o.) was provided to patients with confirmed EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI and concurrent with brain metastasis. Radiation therapy will be implemented according to investigator's clinical practice(A 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.).
2489515|NCT02972086|Experimental|Parent|Parent of a child who is a patient at the NYU Bellevue Attention Deficit Hyperactivity Disorder (ADHD) Clinic
3194270|NCT00826462|Experimental|1|"Corticosteroid injection in combination with physical therapy~Injection with triamcinolone 10 mg and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn Entero 500 mg bid for 14 days"
2489645|NCT02971098|Experimental|Reduced activity|participants will undergo a reduced physical activity period (75% step reduction) for two weeks.
3194271|NCT00826462|Placebo Comparator|2|"Placebo injection in combination with physical therapy~Injection with sodium chloride and 10 mg of lidocaine at start and at 3 weeks in combination with physiotherapy for 6 weeks (12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises) Naprosyn entero 500 mg bid for 14 days"
3194272|NCT00826462|Active Comparator|3|Control group: wait-and-see treatment Naprosyn entero 500 mg bid for 14 days
2489775|NCT02970175|Experimental|Bronchoscopy with terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
2489777|NCT02970175|Placebo Comparator|Bronchoscopy without terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done without terlipressin administration
2489812|NCT02969720|Experimental|Phytosterol|Daily consumption of 2 grams (8 ml) nano-phytosterols per 180 days.
2489817|NCT02969720|Placebo Comparator|Placebo|Daily consumption of 8 ml of a solution with Titanium Dioxide per 180 days.
2489872|NCT02969447|Experimental|Oxytocin administration after fetal expulsion|Administration of 10 units of intra venous oxytocin after fetal expulsion
2489879|NCT02969447|No Intervention|No additional medication after fetal expulsion|
2489906|NCT02969148|Experimental|The bursectomy and D2 lymphadenectomy|Laparoscopic bursectomy and D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach are that anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN)
2489908|NCT02969148|Active Comparator|The D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.The key of this approach is that D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN) without dissociation of anterior lobe of transverse mesocolon and capsula pancreatis.
2489937|NCT02968927|Active Comparator|2HRbEZ/4HRb|2HRbZE
2489940|NCT02968927|Experimental|Everolimus|Everolimus 0.5 MG
2489944|NCT02968927|Experimental|Auranofin|Auranofin 6 MG
2489946|NCT02968927|Experimental|Vitamin D|Vitamin D3
2489947|NCT02968927|Experimental|CC-11050|CC-11050
2489992|NCT02968615|Experimental|fiber & protein|A single dietary change condition that focuses exclusively on increasing fiber and protein.
2490046|NCT02968342|Experimental|Vaginal progesterone 8%|Vaginal progesterone application 8%
2490054|NCT02968342|Placebo Comparator|Placebo|Oral multivitamin supplement
2490103|NCT02967952|Active Comparator|supraglottic airway (SGA)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of supraglottic airway (SGA).
2490107|NCT02967952|Active Comparator|endotracheal intubation (ETI)|Adult patients with non-trauma causes of OHCA who are resuscitated by emergency medical technician paramedic (EMTP) in the prehospital setting and received airway management of endotracheal intubation (ETI).
2490145|NCT02967536||Mild OSA|Untreated OSA patients. Apnoea-Hypopnoea Index (AHI) >5 events/hour and <10 events/hour with Epworth Sleepiness Score (ESS)>9.
2490148|NCT02967536||Severe OSA|Untreated OSA patients. AHI >30 events/hour, with excessive sleepiness (ESS >9).
2490150|NCT02967536||Healthy control|Healthy control. AHI <5 events/hour.
2490239|NCT02967224|Experimental|Toujeo|Toujeo will be administered once daily in addition to noninsulin antidiabetic agents
2490241|NCT02967224|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir or Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to noninsulin antidiabetic agents
3194273|NCT00826475|Experimental|Mindfulness|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
3194274|NCT00826475|Active Comparator|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
2490503|NCT02965313|Active Comparator|SSLS Procedure|
2490505|NCT02965313|Active Comparator|BSSVF-M Procedure|
2490523|NCT02964715|Experimental|Interventional arm|Patients with NAFLD and Type 2 Diabetes prescribed 25mg empagliflozin(JARDIANCE) daily for 6 months
2490595|NCT02964533|Experimental|TFM|thunder-fire moxibustion therapy
2490597|NCT02964533|Active Comparator|MSM|common moxa-stick moxibustion therapy
2490629|NCT02964169|Experimental|Family Planning Support|Family planning voucher and phone reminders
2490632|NCT02964169|No Intervention|No Family Planning Support|Routine care
3194275|NCT00826488|Other|observational|Observational
3194276|NCT00826501|Active Comparator|1|Endoscopic cyst-gastrostomy with a neurolytic block along with oral/transdermal analgesic therapy
3194277|NCT00826501|Active Comparator|2|Surgical cyst-gastrostomy with neurolytic block and pain managed by only oral/transdermal analgesic
3194278|NCT00826553|Experimental|GABA agonist|
3194279|NCT00826553|Experimental|Alpha 2 agonist|
3194280|NCT00826566|Active Comparator|1|500 mg caffeine capsules per day
3194281|NCT00826566|Placebo Comparator|2|500 mg placebo capsules
3208716|NCT00977366|Placebo Comparator|Saline|
2489452|NCT02972476|Active Comparator|2: Seretide 500/50 & Eklira Genuair|Fluticasone propionate 500mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2489453|NCT02972476|Active Comparator|3: Seretide 250/50 & Eklira Genuair|Fluticasone propionate 250mcg & salmeterol 50mcg: 1 inhalation twice daily, inhalation powder and Aclidinium bromide 322mcg: 1 inhalation twice daily, inhalation powder for 3 months
2489454|NCT02972476|Active Comparator|4: Duaklir Genuair|Aclidinium bromide 340mcg & formoterol fumarate 12mcg: 1 inhalation twice daily, inhalation powder for 3 months
2489498|NCT02971904||Human milk collection|Lactating mothers should have enough milk to provide enough maternal milk their preterm infant(s) require plus additional collection of samples (3mL). After consenting to the study, milk from lactating mothers of preterm infants in the local ICU will be analyzed daily from the moment they express sufficient milk volume beyond their child's requirement until discharge (from 4th day of admission until 15th day of hospitalization ). Three mL of sample milk will be collected every morning and analyzed, according to hospital routine. Personal details of mothers and their infants will be collected by applying a questionnaire on the first day of analysis. The nutritional composition of the last meal before the milk sample collection and also a nutrition questionnaire intake will be evaluated.
2489539|NCT02971748|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2489606|NCT02971397|Experimental|Treatment (cytarabine, daunorubicin hydrochloride, biopsy)|"INDUCTION: Patients receive cytarabine IV continuously over 24 hours on days 1-7 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo bone marrow aspirate and biopsy on day 14. Patients with bone marrow cellularity >= 10% and > 5% leukemic blasts, may receive a second induction of cytarabine IV continuously over 24 hours on days 1-5 and daunorubicin hydrochloride IV continuously over 24 hours on days 1-2 in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving remission receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with CBF AML may receive 4 courses of therapy."
2489674|NCT02970773|Other|rivaroxaban|Rivaroxaban Oral Tablet
2489707|NCT02970539|Experimental|Oraxol +Ramucirumab|"Oraxol (oral HM30181 + oral paclitaxel)~HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets~Paclitaxel - supplied as 30-mg capsules Ramucirumab - supplied as a solution at a concentration of 10 mg/mL"
2489780|NCT02970240||ME/CFS group|Patients with a verified diagnosis of ME/CFS according to the Canada criteria
2489781|NCT02970240||Fatigue group|Patients with fatigue, but not ME/CFS
2489784|NCT02970240||Control group|Healthy control persons
2489813|NCT02969759|Other|Patients|ALS defined by El Escorial Criteria.
2489820|NCT02969759|Other|Controls|Asymptomatic subjects with normal examination.
2489874|NCT02969473|Active Comparator|PF group|This is the active comparator group. All patients in this group will receive concurrent chemoradiotherapy with PF regimen (5-fluorouracil plus cisplatin).
2489877|NCT02969473|Experimental|DP group|This is the experimental group. All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).
2489939|NCT02968849|Active Comparator|ALVAC-HIV + subtype C gp120/MF59|2700 participants will receive an IM injection of ALVAC-HIV (vCP2438) at months 0 and 1, and an IM injection of ALVAC-HIV (vCP2438) + Bivalent Subtype C gp120/MF59 at months 3, 6, and 12.
2489943|NCT02968849|Placebo Comparator|Placebo|2700 participants will receive Sodium Chloride for injection, 0.9% at months 0, 1, 3, 6, and 12.
2489987|NCT02968628||Cases: Infants of Diabetic Mothers|"Cases: Neonates born at or over 35 weeks gestation whose mother's were recommended to receive medication for diabetes during pregnancy. This includes pre-gestational and gestational diabetics.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
2489989|NCT02968628||Controls|"Controls: Neonates born at or over 35 weeks gestation whose mother's had normal glycemic control testing during pregnancy.~Interventions:~Video Electroencephalogram (EEG)~Point-of Care Blood Sugar Testing~Medical Record Data Extraction~Maternal Questionnaire"
2490028|NCT02968225|Experimental|Computer Game|"All Computer Game participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~2 month intervention~Eye-tracking post-testing"
2490029|NCT02968225|No Intervention|Waitlist control|"All Treatment as usual control participants will complete:~online screening~Diagnostic and eye-tracking pre-testing~Eye-tracking post-testing"
2490079|NCT02968056|Experimental|Hybrid group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation followed by catheterized radiofrequency ablation within the same procedure
2490080|NCT02968056|Active Comparator|MIS group|Minimally invasive surgical radiofrequency ablation of atrial fibrillation only
2490114|NCT02967731|Experimental|480 Mometasone Furoate Sinus Drug Depot|480 Mometasone Furoate Sinus Drug Depot
2490142|NCT02967406|Experimental|Lifestyle modification|4 x 4 lifestyle modification intervention, addressing four health behaviors including physical activity, diet, smoking and alcohol drinking, at four different levels, i.e. individual, household, group/ knowledge management, and community levels
2490147|NCT02967406|No Intervention|Control|No special intervention will be given. Prevention and treatment in normal practice is allowed
2490194|NCT02967211|Experimental|Toujeo|Toujeo will be administered once daily in addition to non-insulin antidiabetic agents
2490195|NCT02967211|Active Comparator|"Standard of care commercially available basal insulin"|Lantus, Humulin Neutral Protamine Hagedorn (NPH), Levemir, and Tresiba or other basal insulin, including biosimilar insulin will be administered once or twice daily according to label in addition to non-insulin antidiabetic agents
3194282|NCT00826579|Experimental|Colon cancer|Colon cancer patients of all stages
3194283|NCT00826592|Experimental|Video-based education arm|Subjects receiving the video-based educational material
3194284|NCT00826592|Active Comparator|Written education arm:|Subjects receiving the written educational material
3194285|NCT00826605||Urobilinogen increase|Increase in urobilinogen increase on routine dipstick test at prenatal appointment after 37 weeks gestation
2489481|NCT02972203|Active Comparator|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance (CHA) mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
2489495|NCT02971930||Prophylaxis treatment of BAY94-9027_1|2 infusions per week during the extension study
2489496|NCT02971930||Prophylaxis treatment of BAY94-9027_2|infusion every 5 days during the extension study
2489497|NCT02971930||Prophylaxis treatment of BAY94-9027_3|every 7 days during the extension study
3194286|NCT00826605||Weight Loss at Term|Weight loss since previous prenatal appointment after 37 weeks gestation
3194287|NCT00826631|Active Comparator|1|Fast food intake, doubling of caloric intake, in combination with sedentary behavior (no exercise)
2489630|NCT02971189|Other|Librata endometrial ablation|Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
2489696|NCT02970968|Experimental|Study Drug|VLY-686 (Tradipitant) oral capsule for 4 weeks.
2489698|NCT02970968|Placebo Comparator|Placebo|Placebo oral capsule for 4 weeks.
3194288|NCT00826631|No Intervention|2|Control group, parallel
3194289|NCT00826644|Experimental|Belotecan plus Cisplatin|
3194290|NCT00826644|Active Comparator|Etoposide plus Cisplatin|
3194291|NCT00826657|Placebo Comparator|placebo|Receive placebo (sugar pill) during the intervention. Received a 1000 mg vitamin B12 injection at the end of the study.
2490035|NCT02968290|Active Comparator|Hydrofobic material-Alcon AcrySof SA60AT|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrofobic material.
2490038|NCT02968290|Active Comparator|Hydrophilic material-Bausch Lomb AkreosA|Intervention- Cataract Surgery with implantation of intraocular lens. In this arm will be implantation hydrophilic material.
3194292|NCT00826657|Active Comparator|Vitamin B12|Received 500 micrograms vitamin B12 per day during the study Received a 1000 mg vitamin B12 injection at the start of the study
3194293|NCT00826670|Experimental|Topical decolonization|
2490202|NCT02966990|Other|hand orthosis patients|Patients using hand orthosis for better hand function
2490247|NCT02966769||Chemoradiation Group|Analyze overall survival in the group of patients treatment by Concurrent Radiotherapy (>/= 60 Gy) plus Platinum-based Chemotherapy
2490249|NCT02966769||Neoadjuvant treatment plus Surgery Group|Analyze overall survival in the group of patients treatment by Neoadjuvant Platinum-based Chemotherapy or Chemoradiation (Platinum-based plus >/= 45Gy) followed by Surgery
2490308|NCT02966444|Experimental|MUFA-rich HF Meal|High-fat meal rich in monounsaturated fatty acids
2490312|NCT02966444|Experimental|PUFA-rich HF Meal|High-fat meal rich in polyunsaturated fatty acids
2490314|NCT02966444|Experimental|SFA-rich HF Meal|High-fat meal rich in saturated fatty acids
3194294|NCT00826670|Placebo Comparator|Placebo|
3194295|NCT00826683|Other|Control group of healthy subjects|Control group of healthy subjects : simple blood analysis of EPCs
3194296|NCT00826683|Active Comparator|COPD|COPD: one initial blood sample and simple clinical follow-up
2490514|NCT02965014|Experimental|Face-to-Face Young Women's CoOp (YWC)|Participants in this arm will be offered a two-session face-to-face Young Women's CoOp (YWC) intervention.
2490515|NCT02965014|Experimental|mHealth Young Women's CoOp (YWC)|Participants in this arm will be offered training on the mobile health application mHealth Young Women's CoOp (YWC) and offered tablets with the mHealth application to complete the two-session intervention.
2490516|NCT02965014|Active Comparator|HIV Counseling and Testing|Participants will be offered standard HIV counseling and testing services.
2490532|NCT02964637||Progressive supranuclear palsy|Observational Study
2490537|NCT02964637||Corticobasal syndrome|Observational Study
2490541|NCT02964637||Behavoral variant FTD|Observational Study
2490545|NCT02964637||Semantic variant PPA|Observational Study
3194297|NCT00826683|Active Comparator|NSCLC|NSCLC: one initial blood sample and usual clinical follow-up
3194298|NCT00826709|Experimental|Arm 1|2 Nasal swabs
3194299|NCT00826709|Experimental|Arm 2|2 Nasopharyngeal swabs
3194300|NCT00826709|Experimental|Arm 3|Nasal wash or aspirate
3194301|NCT00826735|Experimental|Guided imagery|The experimental group received a relaxation focused guided imagery intervention to use through the remainder of pregnancy plus a physiologic guided imagery intervention during the third stage of labor. These interventions were scripted and prerecorded on CDs.
3194302|NCT00826761|Active Comparator|1|High dose Lb. casei
3194303|NCT00826761|Active Comparator|2|Low dose Lb. Casei
3194304|NCT00826761|Placebo Comparator|3|
3194305|NCT00826774|Active Comparator|Ususal Care|
3194306|NCT00826774|Experimental|Breif Lifestyle Counseling|
3194307|NCT00826774|Experimental|Enhanced Brief Lifestyle Counseling|
3194308|NCT00826813|Experimental|stenting|The conventional esophageal stent or 125I radiation stent is placed in the patients with dysphagia who are enrolled to the study.
3194309|NCT00826826|Active Comparator|Amiodarone|
3194310|NCT00826826|Placebo Comparator|Placebo|
3194311|NCT00826839|Experimental|OCP/MDL|Oral contraceptive pills/microdose lupron
3194312|NCT00826839|Experimental|E2/antagonist|Estradiol patch/gonadotropin-releasing hormone antagonist
3194313|NCT00826878|Experimental|Tivozanib (AV-951)|
3194314|NCT00826904||Lean|Healthy, pregnant women with BMI of 20 - 26 kg/m2
3194315|NCT00826904||Obese|Healthy, obese pregnant women with BMI 30 - 38 kg/m2
3194316|NCT00826917||Objective 1: XI VOCALTM in 3D fetal volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
3194317|NCT00826917||Objective 2: XI VOCALTM in 3D placental volumetry measurement|group 1: multiplanar; group 2: VOCALTM; group 3: XI VOCALTM
2489525|NCT02971761|Experimental|Treatment (pembrolizumab, enobosarm)|Patients receive pembrolizumab IV over 30 minutes on day 1 and enobosarm PO QD on days 1-21. Courses repeat every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
2489603|NCT02971371|Experimental|Virtual Reality|This group performed 40 45-min Lokomat sessions, five times a week, by using a visual feedback showing a Virtual Reality run game where the patient had to collect or avoid objects, to motivate him/her to walk actively.
2489607|NCT02971371|Active Comparator|Only RAGT|This groups performed 40 Lokomat sessions (40-45min), five times a week, between 9am and 11am, in this case was not provided an avatar, and a smile indicating the goodness of each leg movement.
2489646|NCT02971124||Healthy Elderly|
2489647|NCT02971124||Mild Cognitive Impaired Elderly|
2489732|NCT02970474|Other|All Participants|All participants will undergo the same schedule. Each participant will be fitted with a conventional and a 3D printed bolus prior to receiving radiation therapy. Each bolus will be assessed for optimal dose distribution of the radiation to the tumor through computer stimulation. The bolus, either conventional or 3D printed, that is found to be superior will be used for the actual radiation therapy treatment.
2489787|NCT02970123|Experimental|SLIMM Intervention|Sit Less, Interact, Move More (SLIMM): instruction and monitoring feedback to promote decrease in sedentary activity duration, increase in casual walking duration, and increase in sedentary breaks
2489788|NCT02970123|No Intervention|Standard of Care|Subjects will receive standard of care treatment for chronic kidney disease, with no instruction or feedback to alter sedentary or casual walking durations
2489815|NCT02969694||Patients who use psychostimulants products in sexual contexts|"Patients who come to the CSAPA at the Croix-Rousse Hospital, Lyon France following the use of psychostimulants products in sexual contexts.These patients come for an addictologique support.~The patients will answer to the G-STAT questionnaire."
2489912|NCT02969239|Experimental|norepinephrine|norepinephrine 5mcg intravenously administered
2489916|NCT02969239|Active Comparator|phenylephrine|phenylephrine 100mcg intravenously administered
2490000|NCT02968667|Experimental|Intervention|Intervention group received 6 weeks of empowerment program
2490002|NCT02968667|No Intervention|Treatment as usual|Medications
3194318|NCT00826917||Objective 3: Comparison between 2 ultrasound machine|"intramachine reliability for (i)fetal, (ii)gestational sac and (iii)placenta volumetry measurement for (a)multiplanar and (b)VOCALTM:- group 1:Accuvix; group 2:Voluson 730~intermachine reliability for fetal, gestational sac and placenta volumetry measurement for (a)multiplanar and (b)VOCALTM for Accuvix and Voluson 730"
3194319|NCT00826917||Objective 4:3D volumetry in fetuses at risk of Hb Bart's|Measurement of fetal, gestational sac and placenta volume per CRL quotient using multiplanar technique:- group 1: affected; group 2: unaffected
3194320|NCT00826930|Experimental|1A|0.5 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
2490125|NCT02967666|Experimental|FDG PET/MRI, DOTANOC PET/MRI|FDG PET/MRI and DOTANOC PET/MRI will be performed.
2490156|NCT02967341|Other|Ciprofloxacin administration|Blood will be drawn, in all participants, via Port A Cath and via a peripheral draw.
2490213|NCT02967081||Pulp necrosis|
2490216|NCT02967081||Pulpitis (painless)|In this group the dentinal fluid will be sampled/collected twice: Firstly after the removal of the primary caries lesion. Subsequently the cavity will be temporized. Secondly, after removal of the temporary filling material (before final restoration).
2490221|NCT02967081||Irreversible pulpitis|
2490224|NCT02967081||Normal pulp|
2490260|NCT02966613|Active Comparator|CI|TKA using conventional instrumentation (CI)
2490262|NCT02966613|Experimental|PSCG|TKA performed using Patient specific cutting guides (PSCG)
2490263|NCT02966613|Experimental|PSCG-D|TKA performed using fully disposable Patient specific cutting guides (PSCG-D)
2490305|NCT02966327|Experimental|Compression Stockings-Exercise|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the intervention group and will be prescribed compression stockings and individualized exercise. They will also receive standard education on lymphedema risk reduction.
2490309|NCT02966327|Other|Control Group|At T2 (4-6 weeks post-operatively), 25 study participants will be randomized to the control group and will receive standard education on lymphedema risk reduction.
3194321|NCT00826930|Experimental|2A|0.75 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
3194322|NCT00826930|Experimental|3A|1.0 mg/kg TSC, anticonvulsants at Baseline - phenytoin only or none
3194323|NCT00826930|Experimental|4A|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - phenytoin only or none
3194324|NCT00826930|Experimental|1B|0.5 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
3194325|NCT00826930|Experimental|2B|0.75 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
2521805|NCT02751723||oesophageal cancer|validated questionnaires
3194326|NCT00826930|Experimental|3B|1.0 mg/kg TSC, anticonvulsants at Baseline - any except phenytoin-only or none
3194327|NCT00826930|Experimental|4B|Dose of TSC either 0.5 mg/kg, 0.75 mg/kg, or 1.0 mg/kg based on the Data Monitoring Committee decision, anticonvulsants at Baseline - any except phenytoin-only or none
3194328|NCT00826969|Active Comparator|1|Ciclesonide 320µg
3194329|NCT00826969|Placebo Comparator|2|Placebo
3194330|NCT00826982||Pancreatic Cancer|
3194331|NCT00826995|Experimental|Video-based education arm:|Subjects receiving the video-based educational material
3194332|NCT00826995|Active Comparator|Written education arm:|Subjects receiving the written educational material
3194333|NCT00827008|Experimental|1, verum|
3194334|NCT00827021|Experimental|ESAs 1 low dose|
3194335|NCT00827021|Active Comparator|ESAs 2 high dose|
3194336|NCT00827034|Other|A|A: Warfarin alone
3194337|NCT00827034|Other|B|B: Dimebon and Warfarin co-administration
3194338|NCT00827047|Active Comparator|Total Hemihepatic Vascular Exclusion|Patients with HCC received Total Hemihepatic Vascular Exclusion in hepatectomy.
2489524|NCT02972060|Experimental|ODM 201|"ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) bid for a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food.~Subjects who have clinical benefit at week 24 may continue to receive ODM-201 at the discretion of the investigator until disease progression, objective or clinical, or occurrence of an unacceptable toxicity. This includes those that will receive external beam radiation therapy.~Any anti-cancer therapy other than the study drug given as single agent will not be considered part of the protocol treatment."
2489601|NCT02971410|Experimental|Treatment (simvastatin)|Patients receive standard of care chemotherapy for up to 3 courses and simvastatin (PO) daily 2 days before the first dose of chemotherapy for up to 2 days after the last dose of chemotherapy. Treatment with simvastatin continues in the absence of disease progression or unacceptable toxicity.
2489701|NCT02970565|Experimental|Nutrition and Play Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Nutrition and Play Intervention group.
2489704|NCT02970565|Experimental|Family Nurture Intervention|Mother-child dyads who are enrolled into the study will be randomly assigned to the Family Nurture Intervention group.
2489752|NCT02970331|Experimental|pefcalcitol|pefcalcitol 0.005% BID for 8 weeks
2489789|NCT02969993|Experimental|Questionnaire|Questionnaire to previously operated patients
2489814|NCT02969733|Experimental|Xylocaine|intravenous administration
2489821|NCT02969733|Experimental|Ketamine|intravenous administration
2489824|NCT02969733|Placebo Comparator|isotonic saline serum|isotonic saline serum intravenous administration
2490034|NCT02968329||CVA cases|patients who experienced an ischemic CVA or TIA during the study duration and experienced a recurrence.
2490037|NCT02968329||CVA controls|patients who experienced an ischemic CVA or TIA during the study duration, but who didn't experience a recurrence.
2490040|NCT02968329||AF cases|patients who experienced an ischemic CVA or TIA during the study duration and who got diagnosed with 'new' AF
2490042|NCT02968329||AF controls|patients who experienced an ischemic CVA or TIA during the study duration but who didn't get diagnosed with 'new' AF during the study duration
2490113|NCT02968017||MCA-PI|Measurement Middle cerebral artery pulsatility index
2490158|NCT02967471||ARDS group|
2490166|NCT02967471||control group|
2490227|NCT02967133|Active Comparator|Arm A|Nivolumab q 14 days until disease progression/toxicity
2490229|NCT02967133|Active Comparator|Arm B|"Nivolumab every 21 days until disease progression~Nab-paclitaxel every 21 days"
2490299|NCT02966496|Experimental|the test group|The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
2490300|NCT02966496|Experimental|the control group|The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
2490319|NCT02966158|Experimental|AIT Group|"The AIT Group will perform usual care CR exercise for the 1st month of the program. This includes performing aerobic exercise 5 times/week and resistance training twice/week (offered 2 weeks after program start). In month two, this group will begin to perform AIT three days/week, along with two MICE and two RT sessions.~The AIT exercise protocol includes the following components:~Warm Up Period: 5-10 minutes of walking performed at an intensity that will feel fairly light. Heart rate monitors and watches will be used to gauge their effort.~Intervals: Between two to four 4-minute intervals of walking/jogging performed at an intensity that is close to participants' maximal effort, based on the exercise tests that were performed at the beginning of the program. These hard intervals will be separated by 3-minutes of active recovery performed at a very light intensity.~Cool Down Period: 5 minutes of walking performed at a fairly light intensity."
2490322|NCT02966158|No Intervention|MICE Group|"This group will perform usual care CR for 6 months, which includes both resistance and aerobic exercise (MICE) training. Aerobic exercise is prescribed in the first exercise class and performed 5 times/week, the resistance training program is offered after 2 weeks in the program and performed 2 times/week. Participants will be asked to keep a record of the exercise that they do.~Resistance/Strength Training: Patients will be performing 1-2 sets of 5 to 10 resistance training exercises using a combination of hand-held dumbbells, elastic bands of varying thicknesses, as well as their own body weight for resistance.~Aerobic Training: Patients will have their aerobic exercise prescription set at an intensity and duration that will be comfortable for them, based on the tests conducted at the beginning of the program to ensure their safety."
2490369|NCT02965937|Experimental|Story-Centred Care Intervention Program|A theory-guided approach that emphasises a health-promoting potential of nurse-person dialogue about a health challenge.Participants randomised to the IG will be made to participate in a 4-week long story-centred care intervention program conducted by a trained researcher.
2490372|NCT02965937|Active Comparator|Health consultation control condition|Participants randomised to the control group will receive a health consultation from a trained researcher once a week for 4 weeks. The health consultation will be tailored to the participants' needs. Based on a previous study, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
2490489|NCT02965209|Experimental|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach.
2490530|NCT02964793|Experimental|Intervention group|The intervention consists in the standardization of current practices. Clinicians in the intervention maternity units will follow a standardized protocol, and will be asked to measure SFH at each antenatal appointment, collect EFW from the 3rd trimester US, report these values on the chart, and monitor fetal growth according to the protocol guidelines
2490536|NCT02964793|No Intervention|Control group|In the control arm women will benefit from the current routine screening practice for growth failure. The management of pregnancies will remain unchanged. Consultants will be free to monitor growth according to their usual practice. In each maternity unit in the control arm, an information session will be organized on site but its content will be limited to the rational, the objectives of the trial and the study logistics.
2489542|NCT02971722|Placebo Comparator|Placebo(cohort 1)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2489543|NCT02971722|Experimental|0.7mg JY09(cohort2)|0.7mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2489544|NCT02971722|Experimental|3.0mg JY09(cohort2)|3.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2489545|NCT02971722|Experimental|12.0mg JY09(cohort2)|12.0mg JY09 administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2489547|NCT02971722|Placebo Comparator|Placebo(cohort 2)|Placebo administered once subcutaneous injection to healthy participants in 1 of 3 treatment periods
2489631|NCT02971332||Treatment Group|Patients candidated to STARR after the failure of medical and dietary therapy and after a complete radiological and functional study.
2489665|NCT02970955||Inoperable thoracic nodes metastases|Oligometastatic patients with inoperable thoracic nodes metastases from any primary
2489705|NCT02970643|Experimental|Olanzapine group|Palonosetron and Olanzapine Without Dexamethasone in moderate risk chemotherapy induced nausea and vomiting group
3161094|NCT00437112|Experimental|1|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with insulin glargine and OAM continuation followed by 24 week treatment period with HIIP and OAM continuation~8 week follow up period"
3194339|NCT00827047|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy.
2489936|NCT02968875|Active Comparator|Endurance Training|The first group of 40 people will do endurance training; 20 of them will perform a continuous exercise on cycle ergometer at a power equivalent to 70% of the maximal heart rate, twice a week. The other group will do Interval Training, with a four minute long base and one minute long peak, twice a week. The base workload will be equivalent to an intensity of 60% of the maximal heart rate and the peak will be equivalent to 80% of the maximal heart rate.
2489938|NCT02968875|Active Comparator|Control group|20 persons will be in the control group and they will not perform the endurance training. However, they will have 9 therapeutic education meetings.
2489968|NCT02968693||combination therapy group|antibiotic-loaded calcium sulfate and antibiotic-loaded polymethyl methacrylate (PMMA) and Vancomycin
2489973|NCT02968693||PMMA group|antibiotic-loaded polymethyl methacrylate and Vancomycin
3194340|NCT00827047|Experimental|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3194341|NCT00827086||1|Patients with non-infectious Uveitis
3194342|NCT00827086||2|Patients with scleritis
2490112|NCT02967887|Experimental|cisplatin and 5-fluorouracil|Enrolled patients with pre-treatment tumor biopsy will receive Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system. This treatment will be repeated every 4 weeks, up to 6 times.
2490172|NCT02967328||RP% Measurement by FCM as a Diagnostic Test for ITP|The investigators are undertaking a multi-center, prospective blind trial of 500 adults with thrombocytopenic disorders with a platelet count less than 60000/uL from 4 medical centers in China. In brief, 15 ul aliquots of anti-coagulated whole blood were incubated for 70 min with 5 ul of phycoerythrin-conjugated anti-CD42b monoclonal antibody (BD Pharmingen, Tokyo, Japan) and 1 ml of thiazole orange (Retic-COUNT; Becton-Dickinson, San Jose, CA, USA) diluted 10 times by phosphate-buffered saline. RP% was analyzed on a flow cytometer (FACScan, Becton-Dickinson) by measuring 10,000 events in the CD42b-positive fraction.
2490268|NCT02966483|Experimental|Transanal Total Mesorectal Excision|The rectum is mobilized and resected transanally (from bottom to up) according to TME principles, via transanal platform (either rigid or flexible platform).An ideal TaTME is defined as the extraperitoneal portion of the rectum being mobilized from below.
2490271|NCT02966483|Active Comparator|Laparoscopic Total Mesorectal Excision|The traditional laparoscopic TME (LpTME) was performed via standard laparoscopic techniques, including multiple trocars and conventional laparoscopic instruments.
2490350|NCT02966067|Experimental|Microneedle Device|Local Dental Anaesthetic Solution Delivery System: Microneedle device with an array of 2x3 pyramidal wet-etch silicone microneedles of 280µm height to inject anaesthetic solution.
2490353|NCT02966067|Active Comparator|30-gauge Short Hypodermic Needle|Local Dental Anaesthetic Solution Delivery System: Standard thirty-gauge short hypodermic needle to inject anaesthetic solution.
2490419|NCT02965742|Experimental|The study population: first 25 patients|"The study population consists of patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
2490427|NCT02965742|Experimental|The study population: last 25 patients|"The study population consists of sportsmen patients referred to the Nuclear Medicine and Medical Biophysics Department of the Montpellier University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body and sub-regions exams using the Stratos Intervention: Whole body and sub-regions exams using the Hologic QDR 4500A Intervention: Whole body and sub-regions exams using the Hologic HORIZON A"
2490482|NCT02965105|Experimental|First Coloplast Test Catheter; then Speedicath|The subjects allocated to this arm first test Coloplast Test Catheter and then after cross over test the comparator Speedicath Catheter
2490486|NCT02965105|Experimental|First Speedicath; then Coloplast Test Catheter|The subjects allocated to this arm first test Speedicath Catheter and then after cross over test Coloplast Test Catheter
2490520|NCT02964806|Other|Ordinary Diet|Ordinary Diet
2490524|NCT02964806|Other|Modified Atkin's Diet|Modified Atkin's Diet
2490528|NCT02964806|Other|Ketogenic Diet|Ketogenic Diet
3194343|NCT00827138|Experimental|DCC-2036|This is a single arm study
3194344|NCT00827151|Active Comparator|Estrogen and lifestyle|
3194345|NCT00827151|No Intervention|Lifestyle|
3194346|NCT00827164|Experimental|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
3208717|NCT00977405|No Intervention|Control|Primary closure after standard washing of wound with chlorhexidine solution
2489639|NCT02971059|Experimental|Adult Females >65 years|Participants will be seen initially for pre-study assessment (3 hour). They will then be studied weekly for up to 7 levels of phenylalanine intake (7 Study periods). Each study period will include a period of 3 days. The first 2 days they will consume a liquid milkshake based diet at home. On the 3rd day they will come to the hospital for a total of 8 hours.
2489699|NCT02970825|Experimental|Exercise|The experimental, intensive exercise regime will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining structured aerobic exercise (at least 20 minutes jogging and moderate to high intensity active games) and anaerobic lactic resistance exercise (power training with gymn weights).
2489700|NCT02970825|Active Comparator|Relaxation|The control activity will include 50-min sessions four times a week during five weeks (for a total of about 17 hours) combining mindfulness, stretching and low intensity active games (breath control, proprioception, walking, social relaxation, flexibility training).
2489747|NCT02970344|Experimental|Diabetes Coping Skills training (DCST)|Twelve sessions are delivered over 6 months using a faded contact model involving 6 weekly sessions, 3 biweekly sessions and 3 monthly sessions.
2489748|NCT02970344|No Intervention|Diabetes Education|one 60 minute diabetes education session.
3194347|NCT00827164|Other|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
3194348|NCT00827177|Experimental|ARQ 197 in combination with sorafenib|
2489856|NCT02969564||prostate cancer patient, with up to five metastases|prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mTc-MDP-SPECT/CT.
2489884|NCT02969304||Off-Label|Any DMF prescription for MS patients <18 years of age, or for patients diagnosed with non-MS indications, such as psoriasis.
2489886|NCT02969304||On-Label|Prescriptions for patients who are ≥18 years of age and diagnosed with MS
2489905|NCT02969070|Active Comparator|LopiGLIK™ group|4 weeks of LopiGLIK™ therapy 1 capsule/day
2489907|NCT02969070|Active Comparator|Armolipid Plus group|4 weeks of Armolipid Plus therapy 1 capsule/day
3194349|NCT00827190|Experimental|1|ILS-920
3194350|NCT00827203|Experimental|Cohort|
3194351|NCT00827216|Placebo Comparator|Physiologic saline|
3194352|NCT00827216|Active Comparator|Erythromycine|
2490134|NCT02967302|Experimental|Morphine Sulfate|Morphine 3 mg intraarticular once at baseline
2490140|NCT02967302|Active Comparator|Triamcinolone|Triamcinolone 40 mg intraarticular once at baseline
2490146|NCT02967302|Placebo Comparator|Placebo|NaCl 0,9% 5 ml intraarticular at baseline
2490214|NCT02967120||p16 hydroxymethylation status|patients with p16 hydroxymethylation
2490255|NCT02966691|Active Comparator|Patients 'sick'|"The patients of this arm have a clinical signs of bladder cancer with :~a positive result of bladder endoscopy~or an negative endoscopy and a positive result of the conventional cytology~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice .This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized"
2490256|NCT02966691|Active Comparator|Patients 'healthy'|"The patients of this arm have no suspicion of bladder cancer with negative results of their bladder endoscopy and conventional cytology.~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
2490257|NCT02966691|Active Comparator|Patients 'monitoring'|"The patients of this arm have a history of bladder cancer, but the results of their follow up examinations (cytologic and endoscopic) are negative (no tumor).~The intervention consists to collect an additional urine sample (50 ml), the day of the bladder endoscopy, which is performed during the current practice . This urine sample will be used for the preparation of cytology slides according to the Visiocyt protocol, in order to be digitized."
3194353|NCT00827229|Other|LaborPro, active Labor, Vaginal Examination|
3194354|NCT00827268|Other|Arm 1|Repeated probes every 8 hours of treatment (1/week)
2490428|NCT02965677|Experimental|LEGFLOW OTW group|in this group subject will be treated by Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW) and followed up
2490441|NCT02965677|Active Comparator|Admiral Xtreme|in this group subject will be treated by Peripheral Balloon Dilatation Catheter (Admiral Xtreme) and followed up
3194355|NCT00827281|Experimental|1|DCS-augmented CBT for smoking cessation
3194356|NCT00827281|Placebo Comparator|2|Placebo-augmented CBT for smoking cessation
3194357|NCT00827294|Experimental|Self-delivered mirror therapy|All participants were directed to self-deliver mirror therapy for 20 minutes per day.
3194358|NCT00827307|Experimental|Combination|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg.
3194359|NCT00827307|Active Comparator|Conctrol|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
3194360|NCT00827333|No Intervention|Phase I-Usual Care|
3194361|NCT00827333|Active Comparator|Phase 2 - Intervention|
3194362|NCT00827346|Active Comparator|Group 1|600-mg double dose
3194363|NCT00827346|Active Comparator|Group 2|600/600-mg double loading dose (first dose 600 mg given immediately upon arrival at the hospital and the second dose 600 mg, 3 hours after the first loading dose for a total of 900 mg
3194364|NCT00827346|Active Comparator|Group 3|Clopidogrel 900mg
3194365|NCT00827346|Active Comparator|Group 4|First dose 600 mg given immediately upon arrival at the hospital and the second dose 300 mg, 3 hours after the first loading dose for a total of 900 mg
3194366|NCT00827385||hypertensive|
3194367|NCT00827385||normotensive|
3194368|NCT00827411|Experimental|1: Monitoring Arm|"First randomization:~Monitoring Arm: dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay (VerifyNow)."
3194369|NCT00827411|Active Comparator|2: Conventional Arm|"First randomization:~Conventional Arm: fixed dose regiment of both aspirin and clopidogrel in all patients following DES implantation according to international guidelines"
2489736|NCT02970396|Active Comparator|SMART Intervention|Participants (a total of 120 individuals) will be randomly assigned to either SMART (N=60) or the wait-list control (N= 60), in a 1:1 ratio.
2489738|NCT02970396|Active Comparator|Wait-list|Participants assigned to the wait-list will start the SMART intervention 6 months following randomization.
3161095|NCT00437112|Experimental|2|"4 week pretreatment phase consists of continuation of usual OAM therapy~24 week treatment period with HIIP and OAM continuation followed by 24 week treatment period with insulin glargine and OAM continuation~8 week follow up period"
3161096|NCT00437151|Active Comparator|1|More frequent than normal office visits
2489928|NCT02969096|Experimental|Targeted Cryoablation Therapy|liver cancer patients received targeted cryoablation therapy.
2489957|NCT02968823|Active Comparator|Licorice|Licorice gargle
2489959|NCT02968823|Placebo Comparator|Sugar water|Sugar gargle
2490115|NCT02967692|Experimental|Investigational treatment arm|"Part 1: Safety run-in Up to 18 evaluable patients with previously untreated unresectable or metastatic BRAF V600 mutated melanoma will be enrolled and treated at different dose levels to determine the recommended Phase 3 regimen of PDR001 in combination with dabrafenib and trametinib.~Part 2: Biomarker cohort Approximately 20 patients with previously unresectable or metastatic BRAF V600 mutated melanoma will be enrolled to describe changes in the immune microenvironment and biomarker modulations~Part 3: Randomized double blind Approximately 500 patients with previously untreated unresectable and metastatic BRAF V600 mutated melanoma will be enrolled to compare the anti-tumor activity of PDR001 in combination with dabrafenib and trametinib versus placebo plus dabrafenib and trametinib."
2490117|NCT02967692|Placebo Comparator|Placebo comparator arm|Matching placebo in combination with dabrafenib and trametinib
2490237|NCT02966808||Clinical measures|multiple sclerosis patients in treatment with fampridine
2490324|NCT02966561|Experimental|Pedometer-based activity promotion|In the context of pulmonary rehabilitation (standard care), the intervention group (IG) additionally receives a pedometer-based physical activity behaviour change intervention (BCI).
2490326|NCT02966561|Active Comparator|Short patient education and exercise|In the context of pulmonary rehabilitation (standard care), the control group (CG) additionally receives a short patient education in combination with related exercise.
3161097|NCT00437151|Active Comparator|2|Electronic reminders (voice, e-mail, text messages)
3161098|NCT00437151|Active Comparator|3|Parental involvement / intervention reminders
2490471|NCT02965222|Experimental|Intervention arm|After injecting HCG 38- 40 hours , the patient's oocytes will be taken with ICSI , then placed in the Time-Lapse. The oocytes will be IVF after 4 hours and will be stripped surrounding cumulus cell ,then will be placed in the Time-Lapse.The third day the top-grade embryo will be selected by time-lapse imaging (TLI) . The cleavage pattern and time parameters for marker embryo development were recorded daily after insemination.
2490478|NCT02965222|Experimental|Control arm|The development of the embryos at time-lapse was recorded directly and was not disturbed by temperature changes.
3161099|NCT00437151|Active Comparator|4|No intervention or reminders
3161100|NCT00437190|Active Comparator|Anterior Cervical Discectomy Fusion|
3161101|NCT00437190|Experimental|BRYAN Cervical Disc Prosthesis|BRYAN Cervical Disc Prosthesis is a cervical intervertebral disc prosthesis designed to provide for motion like the normal cervical functional spinal unit.
3161102|NCT00437216||1|Monotherapy - Subjects who are not currently being treated with anti-psoriatic medication and start using Clobex®
3161103|NCT00437216||2|Add-on therapy - Subjects who are taking some form of anti-psoriatic medication and add Clobex® treatment
3161104|NCT00437229|Experimental|Subjects in Part A|In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).
3161105|NCT00437229|Experimental|Subjects in Part B|In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.
3161106|NCT00437255|Active Comparator|1|Clobex® Spray
3161107|NCT00437255|Active Comparator|2|Taclonex® Ointment
3161108|NCT00437307|Active Comparator|1|Topotecan: 0,75 mg/m²/d, Tage 1-3 und Carboplatin: AUC 5 (after Cockroft and Gault formula) am Tag 3 nach Topotecan, q 21d.
3161109|NCT00437307|No Intervention|2|Paclitaxel 175 mg/m2/d, day 1 and Carboplatin: AUC 5 (after Cockroft and Gault formula), day 1, q21d OR gemcitabine 1000 mg/m2/d, day 1 and 8 and Carboplatin AUC 4 (after Cockroft and Gault formula), day 1, q 21d.
3161110|NCT00437320|Experimental|1|
3161111|NCT00437320|Placebo Comparator|2|
3161112|NCT00437346|Active Comparator|Group A|Patients is given thorough information based on the tests taken plus medical treatment.
3161113|NCT00437346|Active Comparator|Group B|Patients receive simple written information based on the tests taken plus medical treatment.
3161114|NCT00437359|Other|Fareston|Toremifene citrate: 40-mg tablets by mouth once daily.
3161115|NCT00437359|Other|Arimidex|Anastrozole: 1-mg tablets by mouth once daily.
3161116|NCT00437372|Experimental|Sunitinib plus Radiation|Sunitinib plus Radiation
3161117|NCT00437385|Active Comparator|1|Continuation-Medication with Antidepressants (after WBS Guidelines)
3161118|NCT00437385|Experimental|2|Continuation-ECT with Antidepressants
3161119|NCT00437385|Experimental|3|"Continuation-Psychotherapy (Cognitive Behavioral Group Psychotherapy including the Situational Analysis of CBASP)"
3161120|NCT00437411|Experimental|Workshop|Affective Self Awareness intervention
3161121|NCT00437411|No Intervention|Control|Waiting-list control.
3161122|NCT00437424|Experimental|1|
3161123|NCT00437437|Experimental|1|
2489703|NCT02970578|Experimental|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
2489763|NCT02970383|Experimental|10 group|Initial prescription for 10 narcotic tabs
2489764|NCT02970383|Active Comparator|30 group|Initial prescription for 30 narcotic tabs
2489847|NCT02969577|Experimental|Staying Strong & Healthy Intervention (SS&H)|Participants will take part in a 6-month exercise program and diet and nutrition coaching program. Also part of this arm is a nutritional and lifestyle counseling program to be lead by a member of the study team. Participants will also receive the usual care they would normally receive if not taking part in this study.
2489850|NCT02969577|Active Comparator|Usual Care with Attention (UCA)|Participants will receive the usual care they would normally receive if not taking part in this study.
2489891|NCT02969291|Other|Reduced Sedentary Time Intervention|Reduced Sedentary Time Intervention (RSTI)
2489951|NCT02969057|No Intervention|Breakfast only|Control breakfast providing 50g carbohydrate
2489953|NCT02969057|Active Comparator|Breakfast with rice bran oil gel|Control breakfast, plus 25g rice bran oil gel (solid)
2489955|NCT02969057|Active Comparator|Breakfast with rice bran oil|Control breakfast, plus 25g rice bran oil (liquid)
2489956|NCT02969057|Active Comparator|Breakfast with palm oil gel|Control breakfast, plus 25g palm oil gel (solid)
2489958|NCT02969057|Active Comparator|Breakfast with palm oil|Control breakfast, plus 25g palm oil (liquid)
2490020|NCT02968394|Experimental|NEVIT|Co treatment with omalizumab during another attempt of immunotherapy introduction
3208718|NCT00977405|Experimental|Collatamp G|Primary closure of wound with collatamp G in subcutaneous layer
2490100|NCT02967822||Patients with MRKH syndrome|"Biological samples for patients.~Inclusion of patients presenting MRKH syndrome, and who are followed in clinical centres participating in the study."
2490104|NCT02967822||Healthy relatives|"Biological samples for healthy relatives.~Inclusion of healthy relatives of patients included in the study (parents, brothers, sisters)"
2490173|NCT02967432|Experimental|Mupirocin|
2490174|NCT02967432|Placebo Comparator|Petroleum jelly|
2490208|NCT02967042|Other|18F-PET-TT|
2490321|NCT02966704|Experimental|meal 1|mixed meal with high level of intrinsically labeled milk protein
2490323|NCT02966704|Experimental|meal 2|mixed meal with low level of intrinsically labeled milk protein
2490340|NCT02965950|Experimental|TP53 mutated, LABC|Patients with locally advanced breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
2490344|NCT02965950|Experimental|TP53 mutated, MBC, first line|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide first line metastatic disease
2490348|NCT02965950|Experimental|TP53 wt, LABC|Patients with locally advanced breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
2490351|NCT02965950|Experimental|TP53 wt, MBC|Patients with metastatic breast cancer, TP53 wt disease. Dose-dense cyclophosphamide, after taxanes and anthracyclines.
2490354|NCT02965950|Experimental|TP53 mutated, MBC|Patients with metastatic breast cancer, TP53 mutated disease. Dose-dense cyclophosphamide, after taxanes +/- anthracyclines.
2490426|NCT02965586|Active Comparator|intravenous dexmedetomidine group|intrathecal 2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and will receive intravenous dexmedetomidine infusion as prepared. Dexmedetomidine will be diluted to a volume of 50 ml (4 mg ml-1) and presented as coded syringes by an anesthesiologist. I.V. bolus of dexmedetomidine 1 ug kg-1 administered by a syringe pump over a 10-min period followed by an infusion of 0.4 ug kg-1h-1 dexmedetomidine during the surgery. Just after intrathecal injection, all drugs were infused intravenously. The infusions will be stopped at the end of surgery.
2490442|NCT02965586|Active Comparator|intrathecal dexmedetomidine group|intrathecal2.5 ml of heavy bupivicaine 0.5% pulse 0.5 mg morphine and dexmedetomidine (10µg) and will receive an equal volume of saline intravenously
2490449|NCT02965586|Placebo Comparator|control group|intrathecal 2.5 ml of heavy bupivicaine0.5% pulse 0.5 mg morphine and will receive an equal volume of saline intravenously
2490470|NCT02965170||MS Tysabri|Patients with relapsing forms of multiple sclerosis and who are currently undergoing Tysabri® therapy at Rocky Mountain Multiple Sclerosis Research Group.
2490526|NCT02964975|Active Comparator|Optimal medical therapy|conservative treatment
2490531|NCT02964975|Active Comparator|Percutaneous coronary intervention|Percutaneous coronary intervention of chronic total occlusion
2490651|NCT02964286|Experimental|Acupressure group|The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
2490653|NCT02964286|No Intervention|Control group|The patients of the control group are not admitted any acupoints press-related interventions, only take clinical treatment protocol as usual.
2490679|NCT02963844|Experimental|Inspiratory Muscle Training|The components of this group held the IMT load equivalent to 75% of the Pimáx. (measured weekly) for eight weeks.
2490686|NCT02963844|Sham Comparator|Inspiratory Muscle Training Sham|This group simulate the training, conducted the training without charge for the same period the intervention group.
2490752|NCT02963545|Experimental|Patients presenting cerebral infarction|no intervention of health product administration,
2490755|NCT02963545|Other|Historical controls|no intervention of health product administration, patients characteristics, history, matched with patients for age, gender, tobacco consumption and season of inclusion, free of neurologic or psychiatric disease or psychotropic medications or medications known to impact on serotonin
2490827|NCT02963116|Experimental|Treatment A|10 mg rosuvastatin tablet alone (fasting state)
2489830|NCT02969798|Active Comparator|Isolated IGT with Metformin|Healthy subjects with isolated IGT (FPG < 100; 2-h PG = 140-199) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2489834|NCT02969798|Active Comparator|Isolated IFG with Dapagliflozin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive dapagloflozin, 10mg/day
2489837|NCT02969798|Active Comparator|Isolated IFG with Saxagliptin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive saxagliptin, 10mg/day
2489839|NCT02969798|Active Comparator|Isolated IFG with Pioglitazone|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
2489840|NCT02969798|Active Comparator|Isolated IFG with Metformin|Healthy subjects with isolated IFG (FPG = 100-125; 2-h PG < 140) will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2489841|NCT02969798|Active Comparator|IGT plus IFG with Dapagliflozin|Healthy subjects with IGT plus IFG will receive dapagliflozin, 10mg/day
2489842|NCT02969798|Active Comparator|IGT plus IFG with Saxagliptin|Healthy subjects with IGT plus IFG will receive saxagliptin, 10mg/day
2489843|NCT02969798|Active Comparator|IGT plus IFG with Pioglitazone|Healthy subjects with IGT plus IFG will receive pioglitazone, the dose will increase from 15 mg/day to 30 mg/day at month two
2489845|NCT02969798|Active Comparator|IGT plus IFG with Metformin|Healthy subjects with IGT plus IFG will receive Metformin, starting at 1000 mg/day and increased to 2000 mg/day at month 2.
2489969|NCT02968719|Experimental|Donepezil TDS Version A|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
2489974|NCT02968719|Experimental|Donepezil TDS Version B|"Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system.~1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods."
2489975|NCT02968719|Active Comparator|10 mg Aricept|5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days
2489977|NCT02968719|Experimental|Donepezil TDS Version D|Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.
2489979|NCT02968719|Experimental|Donepezil TDS Version E|Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week
3161124|NCT00437463|Experimental|1|Ramipril
2490084|NCT02967913|Experimental|Bladder flap performed as per routine|Bladder flap surgical step performed at time of non-urgent primary cesarean delivery as per routine
2490091|NCT02967913|No Intervention|Bladder flap is omitted|No bladder flap performed at time of non-urgent primary cesarean delivery
2490151|NCT02967588|Experimental|Intervention|
2490197|NCT02967198|Experimental|CT/US fusion|patients undergo routine conventional feasibility planning ultrasound, and clinical decision of percutaneous liver biopsy or RFA feasibility is made based on conventional planning ultrasound. Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging.
2490246|NCT02966782|Experimental|Venetoclax monotherapy (Cohort 1)|
2490248|NCT02966782|Experimental|Venetoclax + azacitidine (Cohort 2)|
2490250|NCT02966782|Experimental|Safety Expansion (Cohort 3)|
3161125|NCT00437463|No Intervention|2|
2490331|NCT02966106|Active Comparator|Right prefrontal low frequency rTMS.|Right prefrontal low frequency rTMS (1Hz). A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
2490333|NCT02966106|Placebo Comparator|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
2490355|NCT02965911|Active Comparator|UDCA Standard treatment|All subjects will reiceive UDCA at a dose of 13-15mg/kg/d by oral for 12 months, and UDCA will be maintained after 12 months.
2490359|NCT02965911|Experimental|Fenofibrate Combined with UDCA Treatment|All subjects will be treated with UDCA,13-15mg/kg/d, and Fenofibrate, 200mg/d by oral for 12 month,
2490525|NCT02964923||Olanzapine group|Following the baseline assessment, subjects will enter an open treatment group with Olanzapine(Zyprexa) lasting 6 weeks. The subjects will start with a dose of 5-10mg/d , which would be adjusted to as low as 10 mg/d or as high as 20 mg/d, based on clinical response.And drug dose adjustments must be completed within 1 week.
2490529|NCT02964923||Risperidone group|Following the baseline assessment, subjects will enter an open treatment group with Risperidone oral solution(Risperdal) lasting 6 weeks. The subjects will start with a dose of 1ml/d , which would be adjusted to as low as 4 ml/d or as high as 6 ml/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 4~6ml/d within 1 week.
2490534|NCT02964923||Ziprasidone group|Following the baseline assessment, subjects will enter an open treatment group with Ziprasidone Hydrochloride Capsules(Zeldox) lasting 6 weeks. They started with a dose of 40mg/d , which would be adjusted to as low as 80mg/d or as high as 160/d, based on clinical response.Drug dose adjustments interval is generally not less than 2 days, and should reach a effective dose of 80~160mg/d within 10 days.
2490598|NCT02964585|Active Comparator|Active Arm|100 mg of Canagliflozin for 16 weeks
2490600|NCT02964585|Placebo Comparator|Placebo Arm|Placebo for 16 weeks
3194370|NCT00827411|Experimental|3: Pursuit Arm|"Second randomization after one year of follow-up:~Pursuit Arm: Pursuit of a dual oral antiplatelet therapy (aspirin and clopidogrel) beyond one year"
3208719|NCT00977418|No Intervention|No intervention|Seniors undergo all testing but remain current lifestyle
2489878|NCT02969343|No Intervention|Usual Care|Patients on hospital care units where the PSLL patient safety health information technology tools have been implemented or are to be implemented, but are not during the usual care phase of a stepped wedge randomized trial design.
2489950|NCT02968888|Placebo Comparator|Milk|Participants performed a bout of strength training and consumed 20g of milk protein
2489952|NCT02968888|Experimental|Whey protein concentrate 80|Participants performed a bout of strength training and consumed 20g of whey protein concentrate 80
2489954|NCT02968888|Experimental|Native whey|Participants performed a bout of strength training and consumed 20g of native whey
2490005|NCT02968498|Active Comparator|Study arm 1|Lactulose crystals 10 g vs lactulose crystals 20 g vs oral glucose 20 g vs still water
2490008|NCT02968498|Active Comparator|Study arm 2|Lactulose liquid 10 g vs lactulose liquid 20 g vs oral glucose 20 g vs still water
3161126|NCT00437476|Experimental|A|LPV/r + selected NRTIs for 26 weeks, followed by LPV/r monotherapy and anti HCV drugs for 48 weeks. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
3173564|NCT00613457|Experimental|Reintensification Arm III|• Arm III (reduced-intensity reinduction/second delayed reinduction therapy [double reintensification therapy] [closed to accrual as of 6/30/2006]): IR patients receive reduced-intensity reintensification therapy as in arm II. After a 10-week interim maintenance phase, treatment repeats once for a second delayed course of reintensification therapy. Patients then proceed to maintenance therapy.
2490171|NCT02967276|Experimental|Metformin and HDdexamethasone|"Metformin XR is initially administered at a dose of 500mg / daily by oral administration for 7 days. Patients who have a good tolerance (lack of adverse events of grade 3 or 4) may be staggered metformin dose to 2500 mg / day.~Patients in turn receiving dexamethasone pulse prescription (HDdex). A dose of dexamethasona 40 mg / day taken in a daily for four days every 8 days from 1st to 2nd cycle every 35 days and 1x per week for 4 weeks every 28 days from the 3rd to 6th cycle. The dose will be administered at 4 mg tablets, which are to be swallowed whole by 30 minutes after a meal. Patients over age 75 used 20 mg / day."
2490293|NCT02966405||Healthy pregnant women|A descriptive analysis involving 300 healthy pregnant women according NACB to the establish of trimester-specific reference ranges for thyroid tests in pregnant women.
2490294|NCT02966405||Normal pregnant population|According to the selection criteria, 700 cases were selected as the normal pregnant population to establish a self-sequential longitudinal reference range. The aim of this study to monitor the change of thyroid function and antibody during the course of pregnancy in those who suffer from various thyroid disorders and normal control.
2490522|NCT02964702|Experimental|Thrombectomy Device(T-01)|Mechanical Thrombectomy with T-01
2490588|NCT02964468|Experimental|Treatment with IMRT Dose Escalation|Dose Escalation Intensity Modulated Radiotherapy treatment
2490589|NCT02964468|Active Comparator|Treatment with 3DCRT|3DCRT treatment (sequential boost)
2490630|NCT02964156|Experimental|Walking test using insoles|Supersole
2490635|NCT02964156|Experimental|Walking test not using insoles|no intervention
2490696|NCT02963909|Experimental|ZPIV in Flavivirus-naïve Subjects|Two doses of 5.0mcg ZPIV or placebo on Days 1 and 29. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive a 5.0 mcg of ZPIV or placebo on Day 224
2490704|NCT02963909|Experimental|ZPIV in JEV (IXIARO®)|Two 0.5mL doses of IXIARO® (Valneva) Days 1 and 29 followed by two ZPIV or placebo doses will be administered on Days 112 and 140. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 336
2490712|NCT02963909|Experimental|ZPIV in YFV (YF-VAX®)|One 0.5mL dose of YF-VAX® (Sanofi Pasteur) on Day 1 followed by two ZPIV or placebo doses on Days 84 and 112. N=20 ZPIV, N=5 placebo. Subjects who consent to a third ZPIV dose will receive it on Day 308
2490731|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
2490732|NCT02963389|Experimental|Tripegfilgrastim 60ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 60ug/kg, S.C, 24hr after completion of chemotherapy
2490733|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=6 and <12-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
2490734|NCT02963389|Experimental|Tripegfilgrastim 100ug/kg, >=12 and <19-year-old patients|A single dose of Tripegfilgrastim 100ug/kg, S.C, 24hr after completion of chemotherapy
2490808|NCT02963337||remifentanil PCA|The patients in the remifentanil group will receive remifentanil hydrochloride (Ultiva, GlaxoSmithKline, Oslo, Norway) diluted in physiologic saline to a concentration of 40µg/ml and administered using PCA pump with a bolus duration of 20 sec. A stepwise bolus doses from 15 to 30 µg, maximum 40 per 2 min will be applied with no background infusion.
2490809|NCT02963337||Combined spinal-epidural analgesia PCA|A 27-gauge needle will be placed via the shaft of the epidural needle inserted at the L2-3/L3-4 inter-space by the investigator. After confirming the CSF, 2,5 mg of bupivacaine with 20 µg of fentanyl will be injected. That will be followed by the placement of a 20-gauge multi-hole catheter into the epidural space which will be connected to the PCA pump with a possibility of injecting 6-10 ml 0,1% bupivacaine with 2 µg of fentanyl/ml every 20 min with no background infusion.
2490869|NCT02962791|Experimental|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual, except the additional stimulation lead. Standard Echocardiography will be done at one year
2521810|NCT02751723||colorectal cancer|validated questionnaires
3173565|NCT00613457|Experimental|Reintensification Arm IV|"• Arm IV (standard reintensification therapy [closed to accrual as of 6/30/2006]): HR patients receive one sequence of the following HR therapy elements, in this order: 1, 2, 3, following standard reinduction therapy protocol II repeated twice after a four weeks Interim Maintenance phase. Patients then proceed to maintenance therapy.~Element HR-1: Patients receive DEXA on days 1-5; VCR on days 1 and 6; ARA-C twice on day 5; MTX and CPM every 12 hours on days 2-4 (5 doses); ASP on day 6 ; and MTX/ARA-C/PRED IT on day 1.~Element HR-2: Patients receive DEXA on days 1-5; vindesine on days 1 and 6; DNR on day 5; MTX and ifosfamide every 12 hours on days 2-4 (5 doses); ASP on day 6; and MTX/ARA-C/PRED IT on day 1.~Element HR-3: Patients receive DEXA on days 1-5; ARA-C every 12 hours on days 1-2 (4 doses); etoposide five times daily on days 3-5; ASP on day 5; and MTX/ARA-C/PRED IT on day 1."
2489881|NCT02969434|Experimental|Sleep questionnaires assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
2489910|NCT02969135|Experimental|Progressive early passive and active movement|Active exercise starts one week after surgery.
2489914|NCT02969135|Active Comparator|Limited early passive movement|Active exercise starts six weeks after surgery.
2489931|NCT02968901|Experimental|bitherapy|Macitentan and tadalafil
2489993|NCT02968641|Active Comparator|LNF 25 mg bid and RTV 100 mg bid|Patients will take lonafarnib 25 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2489994|NCT02968641|Active Comparator|LNF 50 mg bid and RTV 100 mg bid|Patients will take lonafarnib 50 mg BID and ritonavir 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2489995|NCT02968641|Active Comparator|LNF 100 mg bid|Patients will take lonafarnib 100 mg BID. Patients will also take an anti-hepatitis B virus (HBV) nucleos(t)ide analog (NUC) from the first dose of LNF through the end of the study.
2490030|NCT02968186|Experimental|Implementation program|Health professionals will receive a training and support implementation program
2490032|NCT02968186|No Intervention|Waiting list|Health professionals will be assigned to a waiting list to receive the implementation program
2490086|NCT02968030|Experimental|Muscle strength|Evaluate the effects of a eight weeks program of strengthening exercise on balance and functional mobility in irregular active elderly women
2490149|NCT02967601||Elective Cesarean Section|
2490181|NCT02967237|Experimental|Insulin glargine (U300)|Type 2 diabetes mellitus patients uncontrolled with their current basal insulin therapy switched according to the physician decision, to insulin glargine (U300) administered subcutaneously and once daily using a pre-filled pen
2490261|NCT02966574|Experimental|metastatic breast cancer|
3194371|NCT00827411|Active Comparator|4: Interruption Arm|"Second randomization after one year of follow-up:~Interruption Arm: Interruption of clopidogrel therapy."
3194372|NCT00827424|Experimental|1|This arm will receive Lifestyle counseling by applying a modified PACE protocol
2490381|NCT02965859|Experimental|Metacavir Enteric-coated Capsule 80mg|"Metacavir Enteric-coated Capsules 80mg~Metacavir Enteric-coated Capsules Placebo 240mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2490383|NCT02965859|Active Comparator|Metacavir Enteric-coated Capsules 160mg|"Metacavir Enteric-coated Capsules 160mg~Metacavir Enteric-coated Capsules Placebo 160mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2490386|NCT02965859|Placebo Comparator|Metacavir Enteric-coated Capsules 320mg|"Metacavir Enteric-coated Capsules 320mg~Adefovir Dipivoxil Capsule Placebo 10mg"
2490389|NCT02965859|Active Comparator|Adefovir Dipivoxil Capsule|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule 10mg;"
2490390|NCT02965859|Placebo Comparator|Placebo|"Metacavir Enteric-coated Capsules Placebo 320mg~Adefovir Dipivoxil Capsule Placebo 10mg;"
2490429|NCT02965443|Active Comparator|Verum|Dapagliflozin 10 mg + Saxagliptin 5 mg, each once daily, for 24 weeks
2490446|NCT02965443|Placebo Comparator|Placebo|Placebo 1 10 mg + Placebo 2 5 mg, each once daily, for 24 weeks
2490506|NCT02965131|No Intervention|Non-temporary portocaval shunt|No temporary portacaval shunt is created. Full mobilization of the liver was followed by dissection of the hilar structure.
2490509|NCT02965131|Experimental|Temporary portocaval shunt|Temporary portocaval shunt is created when inadvertent massive perihepatic bleeding or technical difficulties due to untypical patients' perihepatic anatomy are encountered during total hepatectomy. Hilar dissection preceded the dissection of the retrohepatic vena cava from the native liver. Its creating prolongs the duration of the anhepatic phase.
2490527|NCT02964754|Experimental|the observation group|32 patients with complex long bone fractures will be randomized to undergo digital three-dimensional models will be established by CT scan for internal fixation in the observation group.
2490535|NCT02964754|Experimental|the control group|31 patients will be randomized to undergo conventional internal fixation in the control group.
3194373|NCT00827424|No Intervention|2|Subject in this arm will be recruited but will receive no intervention
2490633|NCT02964195|Experimental|Rifaximin Group|Rifaximin 400 mg bid for 2 month,
2490639|NCT02964195|No Intervention|Control|Routine endoscopic treatment without prophylactic use of antibiotics
2490699|NCT02963896|Experimental|gentamicin|intratympanic application of gentamicin 0.5 ml
3194374|NCT00827437|Other|1|
3194375|NCT00827450|Placebo Comparator|Ctl|control isocaloric diet; no coffee
2490833|NCT02962999|Experimental|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
2490836|NCT02962999|Placebo Comparator|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively. Anesthesia will be maintained with %4-6 desflurane and 0,25-0,5 microgram/dk/min remifentanil.
2490866|NCT02962726||Patients|100 female patients between the age of 12 and 18 years suffering from anorexia nervosa.
2490871|NCT02962726||Age matched Controls|100 females volunteers between the age of 12 and 18 years old without eating disorder.
2490935|NCT02962492|Active Comparator|Dapagliflozin Arm:|dapagliflozin 10mg (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
2490936|NCT02962492|Active Comparator|Exenatide extended release Arm:|subcutaneous injection of Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin placebo
3194376|NCT00827450|Placebo Comparator|HF|Hypercaloric. high fructose diet; no coffee
3194377|NCT00827450|Experimental|C1|Hypercaloric, high fructose diet; caffeine-free, torrefied coffee
3194378|NCT00827450|Experimental|C2|Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee
3194379|NCT00827450|Experimental|C3|Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee
3194380|NCT00827463|Experimental|NFS and iron in the first quater|first arm: dosage NFS and iron during the beginning of the pregnancy then in the sixth month of pregnancy then in th delivery.
2489892|NCT02969278|Experimental|Vulvar cancer patients cN0 unfit for sentinel node biopsy|"All invasive vulvar cancer patients with cN0 status:~T > 4 cm;~multicentric tumors (mono or bilateral);~primary lesion completely excised during prior diagnostic surgery~patients candidate to bilateral lymphadenectomy because of unilateral groin lymph node involvement, contralateral cN0~previous radiotherapy a/o chemotherapy (sequential or concurrent). These patients are submitted to 18FDG PET/TC and sentinel node biopsy associated with standard preoperative imaging and radical groin lymphadenectomy"
2489929|NCT02969005|Experimental|surgery group|The dissection was continued into the deeper layers until the bone lesion was visualized, and the bone lesion was then thoroughly resected.
2489960|NCT02968836|Active Comparator|Active group|Blend of amino acids
2489965|NCT02968836|Placebo Comparator|Placebo group|maltodextrin only
2489986|NCT02968511|Experimental|fecal microbiota transplant|250 mL of fecal transplant material by enema as treatment
3194381|NCT00827463|Experimental|No NFS and iron in the first quater|second arm: dosage NFS and iron during the sixth month of pregnancy then in th delivery. No dosage of NFS and iron during the beginning of the pregnancy
3194382|NCT00827476|Experimental|ovarian transplantation|tissue will be used for xenotransplantation or in vitro culture
2490128|NCT02967744|Experimental|NSAID treatment|8 weeks of NSAID treatment
3194383|NCT00827489|Experimental|HTC-867|
2490217|NCT02966886|Active Comparator|Participants with 10-15 degrees of glenoid retroversion|
2490222|NCT02966886|Active Comparator|Participants with >15 degrees of glenoid retroversion|
3194384|NCT00827489|Placebo Comparator|Placebo|
3194385|NCT00827515|Experimental|One|
2490330|NCT02966236|Experimental|Tranexamic Acid Group|Tranexamic acid 1g IV during anesthesiology induction, single dose
2490334|NCT02966236|Placebo Comparator|Placebo group|normal saline 1g IV during anesthesiology induction, single dose
2490371|NCT02965872||Healthy individuals|
2490406|NCT02965755|Other|Genetic profiling|All participants will undergo genetic profiling. Archival tissue will be requested to undergo routine review for possible treatment recommendations. Blood samples will be obtained to study research correlates (plasma tumor DNA, ptDNA) and tissue comparison.
2490422|NCT02965404|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated varicella vaccine."
2490432|NCT02965404|Active Comparator|Positive Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated varicella vaccine."
2490440|NCT02965404|Sham Comparator|Negative Control Group|"Single intramuscular injection of the diluent of lyophilized vaccine (0.5 ml) on Day 0;~Intervention: diluent of lyophilized vaccine."
2490481|NCT02965118|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0% will be applied to treatment area twice daily for 8 weeks.
2490485|NCT02965118|Placebo Comparator|PAC-14028 cream Vehicle|PAC-14028 cream Vehicle will be applied to treatment area twice daily for 8 weeks.
2490560|NCT02964871|Active Comparator|LTCF with RIDT|Nasal swabs will be tested by nursing personnel at each intervention site using SOFIA Fluorescent Immunoassay Analyzer Influenza A+B (LTCF with RIDT). Anonymous results will be sent, via wireless transmission, for daily review by the study team and public health personnel. A positive influenza detection will trigger direct communication with LTCF personnel with advice on antiviral treatment, antiviral prophylaxis, and appropriate infection control practices. We will collect data from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns.
2490562|NCT02964871|Placebo Comparator|LTCF Control|"Usual care.~Data will be collected from each site regarding the prescribing of influenza antivirals for treatment and prophylaxis, number of hospitalizations, number of deaths, and associated healthcare costs during annual, dynamic, 4-month risk windows, based on Wisconsin surveillance of influenza patterns."
2490637|NCT02964403|Experimental|Cox-2|Cox-2 inhibitor ParecoxibNa 40mg pre-ERCP injection
2490643|NCT02964403|Active Comparator|Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
2490698|NCT02963883|Experimental|SVO2 group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells by the individual value of ScvO2, whose value must be greater than 70% after elimination of hypovolemia, hypotension or hypoxemia.
2490708|NCT02963883|Active Comparator|control group|After optimization of oxygenation and blood volume, concentrate transfusion (s) of red blood cells based on the hemoglobin values, as recommended by the National Health Authority for Anesthesiology, Surgery, Emergency (November 2014 ): transfusion threshold of <9 g / dl for patients with cardiovascular antecedents.
3194386|NCT00827515|Experimental|Two|
3194387|NCT00827515|Experimental|Three|
3194388|NCT00827515|Experimental|Four|
3194389|NCT00827528|Experimental|SIS graft|this group will use a biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
3194390|NCT00827528|Active Comparator|2|this group will use a traditional repair on correction of anterior vaginal wall prolapse.
2490956|NCT02962245|Active Comparator|berberine group|regular treatment and receive oral berberine 300mg three times daily untill recurrence in one year
3194391|NCT00827554|Experimental|LMWH plus TACE|50 HCC patients will be allocated to receive Nadroparin 4100 AXa iu twice daily 3 days after TACE which lasted for 6 weeks
3194392|NCT00827554|Active Comparator|TACE alone|50 HCC patients randomly assigned to receive TACE without LMWH
3194393|NCT00827580|Experimental|Eniluracil|
3194394|NCT00827593|Active Comparator|Standard behavioral weight loss|University-based behavioral weight loss treatment
3194395|NCT00827593|Active Comparator|Weight Watchers|Weight Watchers program
3194396|NCT00827593|Active Comparator|Combined Treatment|University-based behavioral weight loss treatment followed by Weight Watchers
3194397|NCT00827619|Other|1|single arm non-randomized post-market study
3194398|NCT00827645||Uterine artery embolization|Women with symptomatic uterine fibroids scheduled for uterine artery embolization
2489898|NCT02969083|Other|M-VAC protocol plus RNU|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery
2489899|NCT02969083|Other|RNU plus M-VAC protocol|Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF > or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery
2489988|NCT02968589|Experimental|@ctiveHip intervention|"A training session for caregivers of patients with hip fracture on patient management.~The @ctiveHip tele-rehabilitation system. This system includes a 3-months occupational therapy and exercise-based program, recommendations for patients and their caregivers and the option of chats and videoconferences.~The program consists of 5 sessions/week of 50-60 minutes that patients will do at home. Each session includes videos with the prescribed activities and exercises that the patients will find in the private site of www.activehip.es."
2489991|NCT02968589|Active Comparator|Other training|"A training session for caregivers of patients with hip fracture on patient management.~The usual care for hip fracture patients at hospital discharge. In addition, patients and their families will receive a triptych with information on recommendations and exercises to do at home."
2490045|NCT02968303|Experimental|Induction treatment|Induction vemurafenib and cobimetinib (6 weeks) directly followed by ipilimumab and nivolumab
2490050|NCT02968303|No Intervention|No induction treatment|Upfront ipilimumab and nivolumab without induction by vemurafenib and cobimetinib
2490116|NCT02967718||Control group|the healthy patients
2490118|NCT02967718||Metabolic syndrome group|Include patients who are accordance with diagnostic criteria of metabolic syndrome
2490119|NCT02967718||CHD stable stage group|Include patients who are accordance with diagnostic criteria of asymptomatic angina, stable angina or stable (more than 1 month) acute coronary syndrome
2490120|NCT02967718||Acute coronary syndrome group|Include patients who are accordance with diagnostic criteria of unstable angina or non-ST-segment elevated myocardial infarction
2490121|NCT02967718||PCI or CABG group|Include the patients who will undergo percutaneous coronary intervention of coronary artery bypass grafting
2490123|NCT02967718||CHD heart failure group|Include the patients who suffered heart failure cause by CHD
2490165|NCT02967380|Experimental|Diagnostic (Magnevist/Multihance, Gadavist, DCE-MRI)|Patients receive standard of care gadopentetate dimeglumine IV twice within 5 minutes or gadobenate dimeglumine IV twice within 5 minutes and then undergo DCE-MRI on day 1. Patients also receive gadobutrol IV twice within 5 minutes and then undergo DCE-MRI over approximately 30 minutes on day 3, 4, 5, 6, or 7.
2490207|NCT02966899|Experimental|Omega-3 fatty acids|30 patients with pulmonary hypertension who are identified as having elevated myocardial triglyceride content by cardiac MRI will receive 4 grams/day of omega-3 fatty acids for six months.
2490243|NCT02966717|Active Comparator|parallel control of conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
2490244|NCT02966717|Experimental|experimental group|Intervention of Rituximab combined with mesenchymal stem cells group: as follows, Rituximab, 100mg/time every one week, the infusion should be a total of 4 times; and then after at least 4 days interval after the first and the third infusion of the Rituximab , the dosage of mesenchymal stem cells tends to be 10^6/kg/time every 2 weeks, while the infusion should be a total of 2 times.
2490289|NCT02966418|Active Comparator|Mild hypoxia preconditioning|Patients will be treated with mild hypoxia (Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%) before surgery.
2490291|NCT02966418|Sham Comparator|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) before surgery.
2490325|NCT02966197|Experimental|Balloon group|Prophylactic Internal Iliac Artery Balloon Catheterization
2490327|NCT02966197|No Intervention|Control group|no intervention
3194399|NCT00827658|Active Comparator|Hypothenar Palm block|Hypothenar Palmar block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
2490552|NCT02964624|Other|Rehabilitation|The rehabilitation protocol will consist of three exercise session/week for eight weeks
2490592|NCT02964442|Experimental|Capsinoids|8 gel capsules equivalent to 12mg
2490593|NCT02964442|Experimental|Cooling Vest|Using Cooling vest (at approxiamately14 degrees Celsius) to cool the body.
2490693|NCT02963792|Experimental|Structured group intervention|"Experimental: Structured group intervention a 'structured' intervention, leaning mostly on tools designed to prevent burnout and promote resilience, including predetermined exercises and topics as discussion goals in each meeting.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
2490701|NCT02963792|Experimental|Semi-Structured group intervention|"Experimental: Semi-Structured group intervention a 'semi-structured' intervention, based on tools for developing an emotional discourse, building a supporting team and self reflection.~The 'semi-structured' intervention offers predetermined contents that are discussed through the stories and needs presented by group members.~Fidelity will be checked and monitored at the end of each meeting, when facilitators fill out a form that summarizes the content, topics and coping skills acquired in each session."
2522527|NCT02746887||Term control cohort|Healthy term infants
3208720|NCT00977418|Experimental|Training|Groups will undergo either physical or mental training. Physical training is 1 hour aerobic training 3 times per week for 12 weeks. Mental training is 1 hour Strategic Memory Advanced Reasoning Training 3 times per week.
2490096|NCT02967705|Experimental|Pain management group|6 + 1 meetings 2 hours each
2490099|NCT02967705|No Intervention|Treatment as usual|Waiting list - will receive treatment as usual
2490211|NCT02966938||Nut allergic patients|Allergic patient and their family with allergy to peanut or other tree nuts that are in elimination diet.
2490252|NCT02966756|Experimental|Cohort 1: Venetoclax|Participants with 17p deletion status will receive various doses of venetoclax once daily (QD).
2490253|NCT02966756|Experimental|Cohort 2: Venetoclax|Participants who have failed a B-Cell Receptor Signaling Pathway Inhibitor (BCRI) therapy and who have also failed, were intolerant to, or were unable to receive chemoimmunotherapy (CIT) irrespective of 17p status will receive various doses of venetoclax once daily (QD).
3161127|NCT00437476|Active Comparator|B|LPV/r+ selected NRTIs for 24 weeks, followed by the same HAART and anti-HCV drugs for 48 weeks. At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decision. All the patients will be followed-up for 24 weeks after the end of anti-HCV drugs for the evaluation of SVR.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day . At the end of week 12 of combined therapy, only patients who will reach an early virological response will continue anti-HCV drugs.
3161128|NCT00437502|Experimental|tumor peptide vaccine|2 cohorts: High and low dose tumor peptide vaccine
2490435|NCT02965547|Experimental|RIPC Group|RIPC was induced by 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation).All subjects will take RIPC intervention, blood collection and 7 dCA measurements.
2490617|NCT02964390|Experimental|Balloon Pulmonary Angioplasty|This arm includes patients qualified to BPA procedure. They have a baseline workup performed before the initiation of BPA treatment and had a follow up examination from 3 to 6 months after the last BPA session.
2490675|NCT02964000|Active Comparator|Low level 1 Watt|"The Phoenix Thera-Lase System will be on 1 watt while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
2490676|NCT02964000|Experimental|Phoenix Thera-Lase System 42|"The Phoenix Thera-Lase System will be on 42 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
2490677|NCT02964000|Experimental|Phoenix Thera-Lase System 74|"The Phoenix Thera-Lase System will be on 74 watts while retaining appropriate blinding of both the operator and the patient.~Treatments will be applied to the primary area of the body associated with pain for which analgesic (pain) medication is currently required.~Each treatment session will last for 20-40 minutes."
3161129|NCT00437567|Active Comparator|Prebiotics|Babies randomized to this arm will receive galacto-oligosaccharide supplements
3161130|NCT00437567|Placebo Comparator|Placebo|Babies randomized to this arm will receive placebo
2490870|NCT02962921|Experimental|Diabetic patients|"Diabetic patients were treated with insulin loads, left ventricle functional parameters were compared to those of healthy persons.~Metabolic indices of insulin effect: blood insulin levels, glucose disposal rates under insulin infusion, were compared to respective group of healthy persons, studied earlier at our institution Insulin LISPRO intravenous loading"
2490984|NCT02962011|Experimental|Knotless barbed suture|
2490985|NCT02962011|Active Comparator|polyglactin 910|Vicryl
3161131|NCT00437606|Experimental|1|
3161132|NCT00437606|Experimental|2|
3161133|NCT00437606|Experimental|3|
3161134|NCT00437619|Experimental|1|
3161135|NCT00437632|Experimental|Subjects in Cohort-1 of Section 1|Subjects will be randomized to receive either GSK598809 10 mg or Placebo.
3161136|NCT00437632|Experimental|Subjects in Cohort-2 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
3161137|NCT00437632|Experimental|Subjects in Cohort-3 of Section 1|Subjects will be randomized to receive either GSK598809 25 mg or Placebo.
3161138|NCT00437632|Experimental|Subjects in Cohort-4 of Section 1|Subjects will be randomized to receive either GSK598809 40 mg or Placebo.
3161139|NCT00437632|Experimental|Subjects in Cohort-5 of Section 2|Subjects will be randomized to receive either ascending doses of GSK598809 75, 120 and 175 mg or Placebo. There will be a washout period of 6 days between the doses.
3161140|NCT00437632|Experimental|Subjects in Cohort-6 of Section 3|Subjects will receive caffeine on day -1 and after randomization subject will either receive GSK598809 or Placebo on Day 1. After washout period of 1-week subject will either receive GSK598809 or Placebo for 28 days.
3161141|NCT00437671|Experimental|Entered study|
3161142|NCT00437684|Experimental|A|LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
3161143|NCT00437684|Active Comparator|B|LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
3161144|NCT00437723|Experimental|1|
3161145|NCT00437723|No Intervention|2|
3161146|NCT00437736|Experimental|Single arm dose escalation|
3161147|NCT00437749|Active Comparator|CBT-1|
3161148|NCT00437749|Placebo Comparator|Placebo|
3161149|NCT00437762|Experimental|1|Botulinum Toxin A Injection
3161150|NCT00437762|Placebo Comparator|2|Placebo injection
2489915|NCT02969122|Active Comparator|Chemotherapy-first|Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
2489918|NCT02969122|Experimental|Surgery-first|Patients in this arm will receive standard gastrectomy with D2 lymphadenectomy after randomization. Hyperthermic intraperitoneal chemotherapy (HIPEC) and extensive intraperitoneal lavage (EIPL) will be applied before abdominal closure. After surgery, 8 cycles of postoperative chemotherapy will be performed.
2489962|NCT02968771||Patients with Physical Cardiac Stress|Patients with Physical Cardiac Stress
2489964|NCT02968771||Patients with Physical and Pharmacological Cardiac Stress|Patients with Physical and Pharmacological Cardiac Stress with adenosine agonist
2489966|NCT02968771||Patients with Pharmacological Cardiac Stress|Patients with Pharmacological Cardiac Stress with adenosine agonist
2489990|NCT02968485|Experimental|SHR7390|60 subjects with advanced solid tumors were received single and then multiple oral doses of SHR7390(2 cycles,each cycle 28days).
2490044|NCT02968316||Pregnant women|all consecutive pregnant women presenting for prenatal care
3194400|NCT00827658|Active Comparator|Volar Wrist Block|Volar Wrist block group. Local anesthetic is placed at this location in this study group. The same local composition (Intervention) is used for both study groups. The trial is a comparison of location not the Intervention.
3194401|NCT00827671|Other|Pre-operative chemotherapy|
3194402|NCT00827684|Active Comparator|Response or stable disease|will receive Temsirolimus
3194403|NCT00827684|Experimental|Progression|Will receive a combination of Temsirolimus and Irinotecan
2490163|NCT02967289|Experimental|Arm A|mFOLFIRINOX Folfox Protocol + Irinotecan
2490168|NCT02967289|Active Comparator|Arm B|mFOLFOX 6 Folfox Protocol
2490320|NCT02966470||General surgery patient|General surgery patient admitted to the Section of General Surgery, Trauma, and Surgical Critical Care who are over 60.
2490356|NCT02965963|Experimental|Dopamine|Dependent variables measured with intravenous low dose dopamine infusion at rest, 60%, and 85% of VO2max
2490361|NCT02965963|Experimental|Metoclopramide|Dependent variables measured with oral metoclopramide ingestion at rest, 60%, and 85% of VO2max
2490365|NCT02965963|Experimental|Placebos|Dependent variables measured with orally ingested placebo pill and intravenous saline at rest, 60%, and 85% of VO2max
3194404|NCT00827710|Active Comparator|1|patients who received point-of-care report cards and were listed on provider performance report card
3194405|NCT00827710|Active Comparator|2|Patients who received point-of-care diabetes report cards but were not listed on provider performance report card
2490510|NCT02965040|Experimental|Roxadustat: subjects with normal renal function|Normal renal function: eGFR is equal to or greater than 90 mL/min/1.73 m^2. Single dose of roxadustat
2490511|NCT02965040|Experimental|Roxadustat: subjects with severely impaired renal function|Severely impaired renal function: eGFR is less than 30 mL/min/1.73 m^2. Single dose of roxadustat
2490512|NCT02965040|Experimental|Roxadustat: subjects with ESRD on CAPD or APD|ESRD subjects on CAPD or APD need to be on the same mode of dialysis for at least 4 months. Single dose of roxadustat
2490513|NCT02965040|Experimental|Roxadustat: subjects with ESRD on HD or HDF|ESRD subjects on HD or HDF need to be on the same mode of dialysis for at least 4 months and should have dialysis sessions three times weekly. Single dose of roxadustat, in both treatment periods
2490533|NCT02964650|No Intervention|Standard rate-response settings|Patients allocated to standard rate-response settings.
2490540|NCT02964650|Experimental|Personalised rate-response settings|Patients allocated to optimised rate-response settings.
3194406|NCT00827710|Active Comparator|3|Patients who did not receive point-of-care report card but who were listed on provider performance report card
2490636|NCT02964130|Other|Follow-up patient|Medical follow-up visit
2490860|NCT02962635||Hemodialysis patients|"A total of 30 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
2490861|NCT02962635||Peritoneal dialysis patients|"A total of 15 patients~- measuring volume status by bioelectrical impedance measurement as well as clinical evaluation and comparing with the novel biomarker"
2490962|NCT02962557|No Intervention|Control|The control group will receive no prompts by the recorded voice.
2490963|NCT02962557|Experimental|Experimental|The experimental group will receive playback of recorded verbal prompts to breathe with an optional shoulder shake.
2491011|NCT02961881|Experimental|blinatumomab|
2491035|NCT02961478|Experimental|Iohexol plasmatic clearance|
2491091|NCT02961322|Experimental|lobo isthmectomy|
2491135|NCT02960945|Experimental|CTP-543|Tablet, single oral dose
2491137|NCT02960945|Active Comparator|Jakafi|Tablet, single oral dose
2489922|NCT02969226|Active Comparator|Once daily screening + PS SBTs|In this arm, RTs will screen patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS> 0 and =< 8 cm H2O with PEEP> 0 and =< 5 cm H2O.
2489923|NCT02969226|Experimental|At least twice daily screening + PS SBTs|In this arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team [RTs and physicians]. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only PS>0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O.
2489925|NCT02969226|Active Comparator|Once daily screening + T-piece SBTs|In this arm + PS SBT' arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hrs of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
2489927|NCT02969226|Active Comparator|At least twice daily screening + T-piece SBTs|In this arm, RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently In the 'at least twice daily + PS SBT' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hrs and 13:00 - 15:00 hrs daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol. RTs will conduct SBTs using only T-piece (off the ventilator).
3161151|NCT00437827|Active Comparator|1|Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)
3208721|NCT00977444|Experimental|kondrium|intraarticular injections once month
2490043|NCT02968238|Active Comparator|CBT preference arm|CBT preference arm consists of participants who are randomized to the preference condition and choose to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
2490048|NCT02968238|Active Comparator|Yoga preference arm|Yoga preference arm consists of participants who are randomized to the preference condition and choose to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
2490055|NCT02968238|Active Comparator|CBT randomized arm|CBT randomized arm consists of participants who are randomized to the random condition and are randomized to receive cognitive-behavioral therapy (CBT). CBT consists of 10 weeks of weekly treatment.
2490058|NCT02968238|Active Comparator|Yoga randomized arm|Yoga randomized arm consists of participants who are randomized to the random condition and are randomized to receive yoga. Yoga consists of 10 weeks of bi-weekly treatment (total = 20 treatments).
2490101|NCT02967874|Experimental|Intra-articular auto-SVFs injection|"The participants will undergo a standard liposuction to harvest adipose tissue. The adipose tissue will then be processed to obtain the SVFs.~This group of subjects (n=16) will receive a single injection of auto-SVFs into affected knees (3.0 mL cell suspension/joint)."
2490105|NCT02967874|Active Comparator|Intra-articular Hyaluronic Acid|This group of subjects (n=11) will receive a single injection of Synocrom Forte 2% into affected knees (1.0 mL/joint).
2490155|NCT02967419||RIF group|People who were diagnosed as repeated implantation failure after IVF-ET
2490159|NCT02967419||Control group|People who had normal pregnancy
2490215|NCT02967094|Experimental|A - mucolytic solution|Mucolytic solution consisting of 100 ml of water, 100 mg of simethicon and 400 mg of N-acetylcystein administered 30 minutes prior to upper endoscopy.
2490219|NCT02967094|No Intervention|B - no intervention|Upper endoscopy without neither mucolytic solution nor water prior to upper endoscopy.
2490225|NCT02967094|Placebo Comparator|C - water|100 ml of water given 30 minutes prior to upper endoscopy.
2490296|NCT02966600|Experimental|Progressive resistance exercise (PRE)|Progressive resistance exercise (PRE) in akinetic-rigid Parkinson's disease patients. Intervention included sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
2490297|NCT02966600|No Intervention|Physical Activity|The control group followed its usual weekly physical activity routine
2490339|NCT02966145||PSP & CBD|Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).
2490343|NCT02966145||o/vPSP|Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.
2490347|NCT02966145||Normal Volunteers|Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.
2490418|NCT02965612|Experimental|ITS with Injex|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
2490425|NCT02965612|Active Comparator|SCIT: ITS via subcutaneous|For Each patient, at each monthly vaccination session and randomly in alternate mode, will be administered two vaccine doses of 0.25 ml each at 20 minutes from one another in the two arms, in an alternating manner via Injex and via subcutaneous.
2491291|NCT02960191|Other|healthy volunteers|subject with no current or past personal history of psychiatric disorders and about never having carried out suicide attempt
3208722|NCT00977444|Experimental|kondrium f|
3194407|NCT00827710|No Intervention|4|Patients who did not receive point of care report card and who did were not listed on provider performance report card
3194408|NCT00827723||Alcoholic|Alcoholic cirrhotic patient with resectable hepatocellular carcinoma
2490011|NCT02968550||Low shunt group|patients with shunt less than 30% in one-lung ventilation at ZEEP
2490016|NCT02968550||High shunt group|Patients with shunt equal or more than 30% in one-lung ventilation at ZEEP
2490031|NCT02968212|Experimental|clofazimine|Participants receive lamprene
2490033|NCT02968212|Placebo Comparator|sugar pill|Participants receive placebo
2490110|NCT02967926|Experimental|ERCP without Fluoroscopy|Non-fluoroscopic common bile duct stone extraction
3194409|NCT00827723||Viral|Viral cirrhotic patient with resectable hepatocellular carcinoma
3194410|NCT00827736|Experimental|Botox injection|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline. In addition, a placebo ointment has to be applied to the anoderm six times a day
3194411|NCT00827736|Active Comparator|ISDN ointment|application of ISDN 1% ointment 6 times a day. injection of placebo into internal anal sphincter
3194412|NCT00827762||Phenylketonuria|Individuals with mild phenylketonuria/hyperphenylalanemia who are beginning treatment with Kuvan.
2490447|NCT02965560||HC,CHB,AD,ACLF|HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
2490500|NCT02965300||Primary lung cancer|patients newly diagnosed with lung cancer by tissue biopsy and did not receive any treatment aiming at the tumor, including chemotherapy and radiotherapy.
2490501|NCT02965300||Benign lung lesion|Patients diagnosed with pulmonary benign diseases.
2490504|NCT02965300||Healthy control|Patients without any pulmonary abnormal symptoms or diseases
2490584|NCT02964455|Experimental|Docetaxel + Nedaplatin + Radiotherapy|Docetaxel and nedaplatin 5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) for 4-6 weeks during chest radiation.
2490624|NCT02964260|Experimental|TAE combined ablation simultaneously|TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
2490627|NCT02964260|Other|TACE combined ablation sequentially|TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).
2490700|NCT02963818|Experimental|Smartphone breathalyzer device & app|This is a small device that connects to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in an actual bar and during a two-week field period.
2490705|NCT02963818|Experimental|BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in an actual bar and during a two-week field period.
2490711|NCT02963818|Experimental|Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in an actual bar and during a two-week field period.
2490739|NCT02963467|Other|Healthy Volunteers - non-smokers|control group: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke a dummy cigarette. Then V/Q will be measured again after 15 minutes.
2490741|NCT02963467|Other|Healthy Volunteers - occasional smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
2490745|NCT02963467|Other|Healthy Volunteers - heavy-smokers|intervention: After baseline measurements V/Q will be measured by MIGET. After a 2 hour wash out period, the Volunteers will smoke 4 conventional cigarettes. Thereafter, V/Q will be measured again after 15, 30, 45, 60 and 120 minutes.
2490796|NCT02963155|Experimental|Metastatic prostate cancer blood samples|
3194413|NCT00827788|Active Comparator|iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
3194414|NCT00827788|Active Comparator|iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
3194415|NCT00827801||Group 1|MDASI-HF questionnaire provided to Doctor for symptom management.
3194416|NCT00827801||Group 2|MDASI-HF questionnaire collected not provided to Doctor.
2491185|NCT02960932|Experimental|hemiplegic cerebral child|Ultrasound scanner used to the SSI technical reproducibility.
3194417|NCT00827814|Experimental|Dutasteride|
2491335|NCT02959801|Experimental|Percutaneous Mechanical Thrombectomy|Percutaneous mechanical thrombectomy（PMT）uses a number of catheter-based mechanical devices to deliver the thrombolytic agent as well as to produce some combination of thrombus fragmentation, distribution of thrombolytic drugs throughout the thrombus, and/or thrombus aspiration.
2491357|NCT02959645||Cervical Dystonia|patients will have Cervical Dystonia
3194418|NCT00827840|Experimental|1. Paliperidone ER|New antipsychotics
3194419|NCT00827840|Active Comparator|2 Risperidone|
3194420|NCT00827853|Experimental|1|Conventional angioplasty balloon post-dilation of nitinol self expanding stents
3194421|NCT00827853|Experimental|2|Cryoplasty balloon post-dilation
3194422|NCT00827866|Other|1|Counselor-Initiated Tobacco Quit Line Group QL where the counselor contacts the client with a standardized intervention protocol)
3194423|NCT00827866|Other|2|Self-Paced Tobacco Quit Line Group which leaves the calling up to participants
3194424|NCT00827879|Experimental|Strength at Home Couples Group|PTSD-Focused Cognitive Behavioral Therapy for Couples
2489967|NCT02968706|Experimental|High flow cannula arm|Patients in the experimental arm (the high flow nasal cannula group) will receive heated humidified high flow oxygen of 50L/min at FiO2 of 40% throughout the colonoscopy. A patient satisfaction survey will be administered after procedure.
2489971|NCT02968706|Active Comparator|Conventional cannula arm|Participants in control arm (the conventional nasal cannula group) will receive an oxygen flow of 2-5 L /min. A patient satisfaction survey will be administered after procedure.
3194425|NCT00827879|Placebo Comparator|Supportive Group Therapy|Supportive therapy for couples
2490152|NCT02967653|Placebo Comparator|Placebo|Patients will be randomized to a placebo a day using simple 1:1 randomization using random.org, for 12 weeks.
2490153|NCT02967653|Experimental|Atorvastatin|Patients will be randomized to Atorvastatin 20mg/day for 12 weeks or pill placebo.
2490200|NCT02967146|Experimental|Mediclore|
2490201|NCT02967146|No Intervention|Not done|Standard treatment for surgery
2490292|NCT02966743|Experimental|midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
2490295|NCT02966743|Active Comparator|dexmedetomidine|administration of dexmedeomidine during spinal anesthesia for target bispectral index 75-80
2490349|NCT02966171|Experimental|HMPL-453|Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
2490438|NCT02965768|Active Comparator|LDN arm|Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) x24 weeks
2490445|NCT02965768|Other|Placebo/LDN arm|"Naltrexone HCl 4.5mg (standard-dose) or 3.0mg (optional-dose) Placebo~Individuals will be switched between drugs as per approved schedule during the 24 weeks."
2490477|NCT02965183|Experimental|Temperature measurements|
2490572|NCT02964936|Experimental|ASP1517 Low dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
2490573|NCT02964936|Experimental|ASP1517 High dose group|Study drug will be dosed three times weekly for 24 weeks and dose adjustments will be made during the study.
2490638|NCT02964104|Experimental|Insulin 287 + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
2490644|NCT02964104|Active Comparator|Insulin degludec + placebo|Each dose group will consist of 16 subjects randomised for once-weekly s.c. (subcutaneous, under the skin) administration of insulin 287 and once daily s.c. placebo (n=12) or once-weekly s.c. placebo and once daily s.c. insulin degludec (n=4)
2490874|NCT02962752|Experimental|Blackadder Juice|Cold pressed Blackadder blackcurrant juice. Standardised at 500mg of polyphenols per 60kg of body weight
2490880|NCT02962752|Placebo Comparator|Placebo|Sugar, flavour and volume matched placebo control drink.
2490910|NCT02962479||TNF blocker-naïve ankylosing spondylitis patients|
2490911|NCT02962479||TNF blocker-exposed ankylosing spondylitis patients|
2490912|NCT02962479||TNF blocker-naïve nrSpA patients|
2490913|NCT02962479||TNF blocker-exposed nrSpA patients|
2490914|NCT02962479||Healthy Participants|
3194426|NCT00827892|Experimental|1|
2491013|NCT02961738|Active Comparator|Full-CAT|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (CAT). This means that they are assessed then then receive a narrative reformulation, that then leads onto a sequential diagrammatic reformulation and then the change methods and completion.
2491014|NCT02961738|Experimental|An 8-session CAT without narrative reformulation (CAT-NR)|Participants in this arm receive an intervention of a full 8-session course of cognitive analytic therapy (as described above), but crucially with the narrative reformulation (NR) aspect removed. All other aspects of treatment remain the same.
2491057|NCT02961517||Patients|All patients with type 2 diabetes and/or cardiovascular disease who will complete the questionnaire
2491064|NCT02961179|Experimental|Increased dairy product|Subjects will be asked to consume a total of 3 to 5 servings per day.They will be instructed on options and variations for incorporating the dairy foods into their routine dietary pattern.
2491067|NCT02961179|Placebo Comparator|Dietary counselling|Subjects will review the standard dietary recommendation(http://www.diabetes.ca/diabetes-and-you/nutrition/meal-planning-guide/) by a registered dietitian.
2491124|NCT02961075|Experimental|Cricothyroid|local surface anesthesia by Cricothyroid
2491128|NCT02961075|Experimental|Laryngeal tube|local surface anesthesia by Laryngeal tube
2491146|NCT02960763|Experimental|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets), titrated from 2-15 mg daily based on symptom severity and side effects.
2491149|NCT02960763|Experimental|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, titrated from 150-300 mg daily based on symptom severity and side effects.
2491150|NCT02960763|Experimental|Switch to Bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended, titrated from 150-300 mg daily based on symptom severity and side effects.
3194427|NCT00827892|Placebo Comparator|2|
3194428|NCT00827905||Hospitalized|Patients admitted to the hospital
3194429|NCT00827957|Active Comparator|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
2490007|NCT02968537|Experimental|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
2490009|NCT02968537|Placebo Comparator|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
2490010|NCT02968537|Experimental|Alc-IT (50/50) (afternoon)|"Alc-IT (50/50) (afternoon): As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2490012|NCT02968537|Experimental|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2490015|NCT02968537|Placebo Comparator|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
2490078|NCT02968069|Experimental|Suspected gastric cancerous lesions|Magnifying endoscopy with NBI would be conducted for every patient included in our study
2490085|NCT02967783|Active Comparator|ID Needle and Syringe|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe
2490094|NCT02967783|Experimental|ID Adaptor (Helm)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered using a needle and syringe with an ID adaptor
2490098|NCT02967783|Experimental|ID Jet Injector (Tropis, Pharmajet)|Fractional (0.1mL) dose of inactivated poliovirus vaccine (IPV) administered by needle and syringe with a disposable syringe jet injecto
2490136|NCT02967445|Experimental|Cervical pessary|Arabin Pessary
2490144|NCT02967445|Active Comparator|Cervical cerclage|McDonald Cerclage
2490193|NCT02967250|Experimental|Ursodeoxycholic acid treatment|Each subject will receive UDCA intervention for six weeks.
2490240|NCT02966821|Experimental|Surufatinib|Surufatinib 300mg once-daily
3208723|NCT00977444|Active Comparator|corticosteroid|intraarticular injections once month
3208724|NCT00977457|Experimental|Diagnostic (specimen collection)|Patients receive prostatic massage and undergo a digital rectal examination. Laboratory assessments are performed and blood samples are collected for molecular biology testing. On the day of the scheduled prostatectomy, a second blood collection is performed prior to surgery.
3161152|NCT00437827|Experimental|2|Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.
3161153|NCT00437840|Experimental|Treatment Arm A|In Arm A dosing subject will receive Placebo in Week 1, 10 milligram (mg) of GSK598809 in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
2490430|NCT02965508|Experimental|Home-based Primary Care Arm|Participants in this arm will be assigned a Mount Sinai Visiting Doctors primary care physician who makes a home based primary care visit.
2490439|NCT02965508|Active Comparator|Usual Care Arm|Participants in this arm will receive the usual care at office based visits
2490473|NCT02965235||non-POCD|Patients who don't develop POCD after surgery.
2490476|NCT02965235||POCD|Patients who develop POCD after surgery.
2490539|NCT02964949|Experimental|Edoxaban 75 mg|Edoxaban 60 mg + edoxaban 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
2490543|NCT02964949|Active Comparator|Edoxaban 60 mg|Edoxaban 60 mg + placebo 15 mg orally, once daily, at the same time (preferably morning) for up to 12 months, with a 2-4 week follow-up period. If needed when the patient completes or discontinues the study, an open-label transition dose of 30 mg and 15 mg edoxaban tablets will be provided.
2490848|NCT02963324|Experimental|Ivermectin|Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
2490900|NCT02962622|Experimental|Hispanic women living with HIV|High intensity interval training (HIIT) on normally active but physically untrained HIV+ Hispanic women, one with (n=15) and other without (n=15) neuro-cognitive impairment (HAND) on antiretroviral therapy (CART) receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
2490901|NCT02962622|Experimental|Hispanic women living without HIV|High intensity interval training (HIIT) on a comparison group of 15 Hispanic women without HIV receive 2 weeks, 6 sessions of 8 x 60 seconds cycling bouts eliciting approximately 80% of maximal heart rate with 60 second rest between bouts after which they will receive 4 week, 12 sessions of 10 x 60 seconds cycling bouts eliciting approximately 90% of maximal heart rate with 60 second rest between bouts.
2490951|NCT02962323|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
2490952|NCT02962323|Active Comparator|Reference|Crestor 40 mg of AstraZeneca Pharmaceuticals LP, USA
3161154|NCT00437840|Experimental|Treatment Arm B|In Arm B dosing subject will receive 10 mg of GSK598809 in Week 1, Placebo in Week 2, 25 mg of GSK598809 in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
2490081|NCT02968043|Active Comparator|control group|Control group will perform generalised physiotherapy exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Generalised physiotherapy exercises consist of stretching and strengthening activities.
2490082|NCT02968043|Experimental|intervention group|Intervention group will perform physiotherapeutic scoliosis specific exercises for a 60-min period for 2 or 3 times a week under the guidance of experienced physiotherapists with expertise in scoliosis in an outpatient clinic and for a 20-min period per day under the supervision of the parents at home. Physiotherapeutic scoliosis specific exercises consist of patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living.
2490160|NCT02967640|Experimental|Ketalar|ketalar injection, subacromial
2490167|NCT02967640|Placebo Comparator|Placebo|physiological sodium chloride (NaCl 9%) injection, subacromial
2490203|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 500mg bid|Tenofovir 300mg qd + DWPUR001 500mg bid for up to 12 months
2490204|NCT02966964|Experimental|Tenofovir 300mg qd + DWPUR001 300mg bid|Tenofovir 300mg qd + DWPUR001 300mg bid for up to 12 months
2490205|NCT02966964|Placebo Comparator|Tenofovir 300mg qd + DWPUR001 Placebo bid|Tenofovir 300mg qd + DWPUR001 Placebo bid for up to 12 months
2490251|NCT02966639||LDS Patients|All patients with a diagnosis of single-level Lumbar Degenerative Spondylolisthesis who present to the DHMC Spine Center.
2490285|NCT02966431|Experimental|Counseling|Receive counseling for 8-wks
2490287|NCT02966431|Placebo Comparator|Control|Does not receive counseling for 8-wks
2490376|NCT02965976|Experimental|Arm I (botulinum toxin type A, esophagectomy)|Patients receive botulinum toxin type A injection IM while undergoing standard minimally invasive esophagectomy.
2490378|NCT02965976|Active Comparator|Arm II (esophagectomy)|Patients undergo standard minimally invasive esophagectomy.
2490413|NCT02965482|Active Comparator|Aerogen Solo|Volumetric method of methacholine challenge testing performed using the Aerogen Solo nebulizer
2490415|NCT02965482|Active Comparator|Wright|Two-minute tidal breathing method of methacholine challenge testing performed using the Wright nebulizer
2490480|NCT02965248|Active Comparator|Arm A|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months.
2490487|NCT02965248|Experimental|Arm B|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC with raltitrexed (3mg/m2) intraperitoneally for 60 minutes during surgery or within 10 days after the operation.
2490491|NCT02965248|Experimental|Arm C|Patients undergo radical resection of colorectal cancer (open/laparoscopic) and receive standard adjuvant systemic chemotherapy comprising mFOLFOX6/CapeOx/sLV5FU2/Cape. Systemic chemotherapy will continue for 6 months. Patients also undergo HIPEC comprising oxaliplatin (130mg/m2) intraperitoneally during surgery and hyperthermia for 30 minutes, following leucovorin calcium (20mg/m2 intravenously) and 5-FU (400 mg/m2 intravenously)
2490581|NCT02964676|Experimental|AIT group|PACG in AIT group will receive ab interno trabeculectomy with Trabectome and before AIT, Laser Peripheral Iridectomy (LPI) will be performed first.
2490582|NCT02964676|Active Comparator|Trab group|PACG in AIT group will receive trabeculectomy.
2490642|NCT02964273|Active Comparator|Phase A Tolvaptan|Participants will be randomized to receive active tolvaptan for 12 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is based on weight.
2490646|NCT02964273|Placebo Comparator|Phase A Placebo|Participants receive matching-placebo spray dried, immediate release tablets orally as a split-dose, with first dose taken upon awakening and second dose taken approximately 8 hours later.
2490649|NCT02964273|Active Comparator|Phase B Tolvaptan|Participants will receive open-label tolvaptan for 24 months. Study medication will be administered orally as a split dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. The starting dose is weight based.
2490682|NCT02963740|Experimental|Weight Loss Intervention Group|Participants will take part in supervised exercise and home-based exercise sessions. Participants will be asked to follow a specific diet. Participants will be asked to take part in weekly behavioral group phone calls.
2490748|NCT02963558|Experimental|Intervention|The intervention group will receive in-bed cycle ergometry within 48 hours of randomization if safety criteria are met. The intervention arm will receive early physical therapy (PT). This PT will be performed according to a protocol of additional ICU and hospital-administered rehabilitation strategies that have been previously developed. Patients will receive 30 minutes of PT at least 5 times per week while conscious. If unconscious, subjects will only receive passive range of motion (PROM) for 10 repetitions per body part daily. Once conscious, subjects will progress through PT with an emphasis on ambulation. Therapy for the intervention arm patients will continue while on the floor. Outpatient therapy will be provided at the discretion of the patient's treating physicians.
2490753|NCT02963558|No Intervention|Usual Care|The control group will receive usual care physical therapy as ordered by the treating team both in the ICU and on the floor through hospital discharge. These subjects will also receive therapy as outpatients only as ordered by their regular physicians.
2490816|NCT02963142||SCAP requiring ECMO|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require extra-corporeal membrane oxygenation and a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
2490820|NCT02963142||SCAP requiring ITU support|"Patients diagnosed with severe respiratory failure due to community acquired pneumonia that require intensive care support and undergo a routine bronchoscopy for clinical purposes.~Molecular laboratory techniques will be applied to residual respiratory tract samples including bronchoalveolar lavage and non-directed bronchoalveolar lavage. Comparisons will be made to conventional diagnostic tests used in the diagnosis of community acquired pneumonia."
2491531|NCT02958540|Placebo Comparator|placebo|12 subjects receiving placebo
2490092|NCT02967770|Active Comparator|Physician's Discretion Standard of Care|Patients will be treated according to physician discretion standard of care regimen.
2490162|NCT02967549|Experimental|NAVA then PAV|Infants randomised to NAVA then PAV
2490169|NCT02967549|Experimental|PAV then NAVA|Infants randomised to PAV then NAVA
2490209|NCT02967029|Active Comparator|b group|b group controlled hypotension with esmolol hydrochloride
2490210|NCT02967029|Active Comparator|r group|r group controlled hypotension with remifentanil hydrochloride
2490303|NCT02966652|Active Comparator|Testosterone undecanoate|Cohort 1: single dose of 120 mg (3 x 40 mg) DITEST followed by a single dose of 80 mg (2 x 40 mg) testosterone undecanoate or a single dose of 80 mg (2 x 40 mg) testosterone undecanoate followed by single dose of 120 mg (3 x 40 mg) DITEST. The two treatments are separated by a minimum of a 7-day washout period, with both treatments given in the fed state.
2490304|NCT02966652|Experimental|DITEST|Cohort 2: single dose of 200 mg (5 x 40 mg) DITEST (fed) followed by a single dose of 200 mg DITEST (fasted) or a single dose of 200 mg DITEST (fasted) followed by single dose of 200 mg (5 x 40 mg) DITEST (fed). The two treatments are separated by a minimum of a 7-day washout period.
2490367|NCT02966080|Other|Adjusted-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.
2490373|NCT02966080|Other|Fixed low-dose heparin|Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.
2490431|NCT02965651|Experimental|ECA System|Access to website and virtual patient advocate
2490443|NCT02965651|No Intervention|Standard of Care|Patient information sheets and meditation CD
2490497|NCT02965261|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
2490498|NCT02965261|Active Comparator|Reference|Warner Chilcott LLC's Sarafem® Tablet 20 mg
3194430|NCT00827957|Active Comparator|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
3194431|NCT00827970|Experimental|1 Screening|Individuals receiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
3194432|NCT00827970|No Intervention|2 Control|Control group receiving usual care
2490710|NCT02963766|Experimental|Dose 1 Dulaglutide|Dulaglutide given subcutaneously (SC).
2490714|NCT02963766|Experimental|Dose 2 Dulaglutide|Dulaglutide given SC.
2490716|NCT02963766|Placebo Comparator|Placebo|Placebo given SC.
2490826|NCT02963103|Experimental|Tacrolimus group|oral
2490865|NCT02962778||treatment-resistant hypertension|patients with Treatment-resistant arterial hypertension receiving standard antihypertensive treatment with at least 3 antihypertensive agents including one diuretic
2490937|NCT02962570|Experimental|Only Arm|"Two minutes: Intervention: Device: On Demand Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Two minutes intervention: Device: Traditional, Always-On, Oxygen Delivery 20 sec or 3 breaths, whatever comes first: Intervention: Device: Oxygen Flow Stopped~Repeat until the end of the surgical procedure"
3194433|NCT00828035|Other|1, REL|rel group : patients with light endoscopic robot
3194434|NCT00828035|Active Comparator|2, AO|AO group : Patients with surgery assistant
3194435|NCT00828048||Pancreatic Cyst|Pancreatic Cyst
2491022|NCT02961530|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2491023|NCT02961530|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2491078|NCT02961426|Experimental|sofosbuvir + ravidasvir|12 weeks for non-cirrhotic patients, 24 weeks for cirrhotic patients
3194436|NCT00828087|Experimental|Everolimus Arm|Everolimus Eluting Coronary Stent System
3194437|NCT00828087|Active Comparator|non drug eluting stent Arm|cobalt chromium balloon expandable stent
3194438|NCT00828126||PET-CT Scan|
3194439|NCT00828152|Experimental|1|Internet-delivered CBT. Contact with therapist thru an e-mail system. 12 weeks.
2491433|NCT02959125|Experimental|Intervention|"Intervention~NutFish based supplementation for 60 days~Multiple micro nutrient for 60 days~Health education in pregnancy class"
2491436|NCT02959125|Active Comparator|Control|"Control~Government food supplementation for 60 days~Iron Folic acid for 60 days~Health education in pregnancy class"
2491480|NCT02958774|Experimental|Hypofractionated Radiation Therapy|Daily for 4 weeks
2491520|NCT02958566|Active Comparator|Narcotic|"Morphine, Dilaudid or Fentanyl patient controlled anesthesia (PCA) for the immediate postoperative period, in addition to Norco 5-325 mg 1-2 tabs Q4H PRN, or equivalent medication.~Post-operative day 1: PCA will be discontinued and the patients will have IV narcotics PRN: Morphine 1-2 mg Q2H PRN, fentanyl 50-75 mcg Q2H PRN or Dilaudid 0.5 mg Q2H PRN"
3194440|NCT00828152|Placebo Comparator|2|On line discussion group.
3194441|NCT00828165|Experimental|ARRY-300|
3194442|NCT00828165|Placebo Comparator|Placebo|Placebo
3194443|NCT00828217|Experimental|with APA|Children have adapted physical activity during their hospitalization
3194444|NCT00828217|No Intervention|without APA|Children don't have adapted physical activity during their hospitalization
3194445|NCT00828230|Experimental|1|2mg rectal budesonide per day for 8 weeks
3194446|NCT00828230|Placebo Comparator|2|One application of placebo foam once daily for 8 weeks
3194447|NCT00828243||Genetic association|Infants with and without neonatal respiratory distress syndrome undergo surfactant gene sequencing to identify genomic variants associated with neonatal respiratory distress syndrome
3194448|NCT00828243||Nutrient|To newborn infants with respiratory distress syndrome, we administer stable isotopically labeled nutrients (precursors of surfactant phospholipids or proteins) to permit mass spectrometry-based comparison of surfactant phospholipid and protein turnover.
3194449|NCT00828269|No Intervention|1|Liver tissue biopsy
2490220|NCT02966951|Experimental|adipose tissue mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of ATMSC in each dose
2490270|NCT02966678||Glaucoma|Patients with a diagnosis of glaucoma will undergo color vision test
2490315|NCT02966301|Experimental|interventional|Single arm : Arsenic trioxide Injectable Solution
3194450|NCT00828282|Experimental|1|
3194451|NCT00828334|Experimental|Transcatheter PDA Coil|Transcatheter occlusion of Patent Ductus Arteriosus (PDA) with the flex and medium Nit-Occlud PDA.
3194452|NCT00828373|Placebo Comparator|Placebo|
3194453|NCT00828373|Active Comparator|Lidocaine|
2490544|NCT02964988|Experimental|uPAR PET/CT|Injection of 68Ga-NOTA-AE105 followed by PET/CT scan. Administration will be performed twice in approximately 8 weeks.
2490585|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase I)|
2490586|NCT02964507|Experimental|GSK525762 + Fulvestrant (Phase II)|
2490587|NCT02964507|Placebo Comparator|Placebo + Fulvestrant (Phase II)|
2490703|NCT02963948||Medical Staff|Approximately 40 medical staff will be enrolled for the focus groups
2490713|NCT02963948||Medical staff surveyed using SAAS|Approximately 100 medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS)
2490715|NCT02963948||Wave 1 Patients|Approximately 200 patients at a Wave 1 clinic
2490756|NCT02963454|Experimental|levosimendan 0.2 μg/kg/min|"Treatment with levosimendan 0.2 μg/kg/min 24h (without bolus).~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
2490757|NCT02963454|Active Comparator|dobutamine 5 μg/kg/min|"Treatment with dobutamine 5 μg/kg/min. Dobutamine were administered during all the 72 hours study period.~Muscle microdialysis was performed using a microdialysis probe inserted into the quadriceps femoris muscle."
2490782|NCT02963077|Experimental|Cohort 1 SAD - 0.1 mg A4250|Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
2490787|NCT02963077|Experimental|Cohort 2 SAD - 0.3 mg A4250|Dose: 0.3 mg of A4250.
2490789|NCT02963077|Experimental|Cohort 3 SAD - 1 mg A4250|Dose: 1 mg A4250.
2490792|NCT02963077|Experimental|Cohort 4 SAD - 3 mg A4250|Dose: 3 mg A4250.
2490797|NCT02963077|Experimental|Cohort 5 SAD - 10 mg A4250|Dose: 10 mg A4250.
2490801|NCT02963077|Placebo Comparator|Cohort 1 SAD placebo|Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
2490803|NCT02963077|Placebo Comparator|Cohort 2 SAD placebo|Dose: 0.3 mg A4250 matching placebo.
2490805|NCT02963077|Placebo Comparator|Cohort 3 SAD placebo|Dose: 1 mg A4250 matching placebo.
2490810|NCT02963077|Placebo Comparator|Cohort 4 SAD placebo|Dose: 3 mg A4250 matching placebo.
2490811|NCT02963077|Placebo Comparator|Cohort 5 SAD placebo|Dose: 10 mg A4250 matching placebo.
2490812|NCT02963077|Experimental|Cohort 1 MAD - 1 mg A4250 qd|Dose: 1 mg A4250 qd for 7 days.
2490813|NCT02963077|Placebo Comparator|Cohort 1 MAD placebo|Dose: 1 mg A4250 matching placebo qd for 7 days.
2490815|NCT02963077|Experimental|Cohort 2 MAD - 3 mg A4250|Dose: 3 mg A4250 qd for 7 days
2490818|NCT02963077|Placebo Comparator|Cohort 2 MAD placebo|Dose: 3 mg A4250 matching placebo qd for 7 days.
2490819|NCT02963077|Experimental|Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.|Dose: 1.5 mg A4250 b.i.d. for 7 days.
2490822|NCT02963077|Placebo Comparator|Cohort 3 MAD placebo|Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
2490824|NCT02963077|Experimental|Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d|Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
2490829|NCT02963077|Active Comparator|Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d|Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
2490832|NCT02963077|Experimental|Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
2490834|NCT02963077|Placebo Comparator|Cohort 5 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
2490840|NCT02963077|Active Comparator|Cohort 6 MAD - 1 g CRC|Dose: 1 g CRC b.i.d
2490843|NCT02963077|Placebo Comparator|Cohort 6 MAD CRC placebo|Dose: 1 g CRC matching placebo b.i.d.
2490844|NCT02963077|Experimental|Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d|Dose: 3 mg A4250 qd + 1 g CRC b.i.d
2490845|NCT02963077|Placebo Comparator|Cohort 7 MAD A4250 placebo + CRC placebo|Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
3208725|NCT00977483|Experimental|Drug: Thioctic Acid|600mg tablet Thioctic Acid (alpha-lipoic acid) once daily throughout the trial
2490988|NCT02962115|Experimental|Decision Aid Invitation|Electronic invitation to complete a web-based lung cancer screening decision aid
2491048|NCT02961608|Experimental|study group|
2491084|NCT02961231|Active Comparator|PCV 2p+1|PCV 2p+1 schedule: WHO recommended 2 primary at 2, 4 months and a booster dose at 12 month
2491093|NCT02961231|Active Comparator|PCV 3p+0|PCV 3p+0 schedule: WHO recommended 3 primary doses at 2, 3 and 4 months
2491104|NCT02961231|Experimental|PCV 1p+1|PCV 1p+1 schedule: one primary dose at 2 month and a booster at 12 month
2491114|NCT02961231|Experimental|PCV 0p+1|PCV 0p+1 schedule: no primary dose, only a booster at 12 month
2491145|NCT02960776|No Intervention|Habitual Sleep (HS)|Participants will be asked to follow a fixed bedtime routine based on the participant's regular bed- and wake-times during the habitual sleep (HS) phase.
2491148|NCT02960776|Experimental|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time during the sleep restriction (SR) phase.
2491545|NCT02958631|Experimental|Fimasartan|Fimasartan 60mg, QD
3208726|NCT00977483|Placebo Comparator|Drug: Placebo|1 tablet once daily throughout the trial
3208727|NCT00977496||Nasal Swab|New chronic hemodialysis patients with no evidence of nasal carriage of Staphylococcus aureus from Boston Dialysis Center Inc., the outpatient hemodialysis clinic of Tufts Medical Center
3208728|NCT00977522|Experimental|PF-03463275|
2490133|NCT02967484|Experimental|Treatment Group|"Participants will recieve the therapy as follows: Huo Xue San Feng acupuncture method+Routine care for ischemic stroke+One type of antihypertensive medication.~Intervention:Acupuncture(choosing the bilatral acupoint: Renying(ST9),Hegu(L14), Taichong(LR3),Quchi(LI11),Zusanli(ST36))+Drugs(one type of antihypertensive medicine)"
2490137|NCT02967484|No Intervention|Control Group|"Participants recieve the therapy as follows:Routine care for ischemic stroke +One type of antihypertensive medication.~Intervention:Acupuncture(choosing the acupoint: Neiguan(PC6),Renzhong(10), Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).)+Drugs(one type of antihypertensive medicine)"
2490218|NCT02967107|Active Comparator|Cold snare polypectomy|Cold snare resection, if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
2490223|NCT02967107|Active Comparator|Endoscopic mucosal resection|Endoscopic mucosal resection (EMR), if necessary, multi-piece to resect sessile serrated adenoma (SSA) 8-20mm
2490269|NCT02966587|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over 60 minutes on day 1. Courses repeat every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
2490332|NCT02966262||Optical Coherence Tomography registry group|Patients who had undergone optical coherence tomography within coronary intervention
2490363|NCT02965885|Experimental|TAS-116|
2490405|NCT02965625||open elective cardiac surgery patients|Including coronary artery bypass graft and valve replacement surgery patients
2490412|NCT02965469|No Intervention|Usual care|Participants randomized to this arm will have no change to their usual care
2490414|NCT02965469|Experimental|Cell phone app|"Participants randomized to this arm will use a stress reduction cell phone app called Breathe2Relax to assess feasibility and acceptability"
2490496|NCT02965326|Other|Cystic fibrosis, treated|Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor
2490499|NCT02965326|Other|Cystic fibrosis, non treated|Cystic fibrosis patients, non treated by a CFTR modulator
2490502|NCT02965326|Other|Non-Cystic fibrosis|Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations
2490549|NCT02964728|Experimental|Botulinum toxin type A|Botulinum neurotoxin injections
2490550|NCT02964728|Placebo Comparator|Placebo|Normal saline solution injections
2490596|NCT02964481||Malignant Hyperthermia Phenotype cases|Samples from persons who identify as having the malignant hyperthermia phenotype by the North American MH Registry (NAMHR)
2490599|NCT02964481||Caffeine Halothane Contracture Test negative controls|Controls who had negative Caffeine Halothane Contracture Test (CHCT) from North American MH Registry (NAMHR)
2490695|NCT02963753||hyperemesis gravidarum group|The study group consisted of women hospitalized for hyperemesis during first trimester of their pregnancy
2490706|NCT02963753||the control group|whereas the control group included all other women who delivered in the same period.
3194454|NCT00828386|Experimental|Induction chemotherapy + concurrent chemoradiotherapy|"Induction chemotherapy (Docetaxel + Cisplatin + 5-FU):~Docetaxel 75 mg/m² administered on D1 of each course, every 3 weeks, via one-hour IV infusion~Cisplatin 75 mg/m² administered on D1 via one-hour infusion followed by~5-Fluorouracil (as a continuous infusion): 750 mg/m²/d administered as a continuous infusion from D1 to D5.~The cycles will be repeated every 3 weeks up to a total of 3 courses. Followed by concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks)."
2490945|NCT02962336|Experimental|Test|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide (40+10+25) mg Tablets
2490948|NCT02962336|Active Comparator|Reference|Tribenzor (40+10+25) mg Tablets of Daichi Sankyo Inc, USA
2490986|NCT02961959|Experimental|Surgery|Arthrodesis of SI-joint/s, physiotherapy
2490987|NCT02961959|Active Comparator|Non-surgery|Non-surgery, physiotherapy
2491028|NCT02961621|Experimental|Stress Reduction Training Group|This group will complete a 7-week online mindfulness-based resiliency training: Stress Reduction Training for 9-1-1 Telecommunicators
2491031|NCT02961621|No Intervention|Control Group|This group is a wait-list control and will be offered the training after all data collection has been completed.
2491083|NCT02961413||cohort 1|Compound glycyrrhizin tablets / injection
2491092|NCT02961413||cohort 2|Isoglycyrrhizinate magnesium injection / diammonium glycyrrhizinate enteric-coated capsules
2491102|NCT02961413||cohort 3|Bicyclol
2491110|NCT02961413||cohort 4|Silibinin capsules
2491115|NCT02961413||cohort 5|Ursodeoxycholic acid capsules
2491117|NCT02961413||cohort 6|N- acetylcysteine
2491161|NCT02960841|Experimental|Intracavitary Manual Lymphatic Drainage|Intracavitary Manual Lymphatic Drainage technique.
2491163|NCT02960841|Active Comparator|Conventional treatment|Conventional treatment active comparator
3194455|NCT00828386|Active Comparator|Concurrent radiochemotherapy alone|Concurrent chemoradiotherapy with Cisplatin : weekly Cisplatin 40 mg/m2 starting on D1 of the radiation therapy (70 Gy/7 weeks).
3194456|NCT00828399|Experimental|Glutamine|
2491298|NCT02960191|Other|emotional witness|subject having had a personal history of unipolar or bipolar depressive disorder and who have never done in his life attempted suicide
2491514|NCT02958722|Active Comparator|carbon dioxide|Diagnostic hysteroscopy performed with the carbon dioxide (gas)
3194457|NCT00828399|Placebo Comparator|Whole protein|
3194458|NCT00828425||1|Diabetic patients with retinopathy
3194459|NCT00828438|Experimental|Lorcaserin 10mg|
3194460|NCT00828477|Active Comparator|1|Xibrom (bromfenac)
3194461|NCT00828477|Active Comparator|2|Nevanac (nepafenac)
3194462|NCT00828490||Pediatric Asthmatics|Medicaid beneficiaries ≤21 years of age who meet the HEDIS criteria for persistent asthma
3208729|NCT00977522|Placebo Comparator|Placebo|
2490141|NCT02967575||1- or 2-level cTDR|patients suffering from intractable symptomatic cervical disc disease (SCDD) requiring 1- or 2-level reconstruction of the disc from C3-C7
2490179|NCT02967172|Experimental|Peri-incisional injection|"A single, 25 cc multimodal analgesic cocktail will be injected following completion of ankle fracture fixation/instrumentation while the patient remains under general anesthesia and prior to skin closure. The injection will be administered as such:~20 mL injected into the peri-incisional soft tissues in a circumferential fashion~5mL injected into the ankle joint This cocktail includes 200 mg of 0.8% ropivacaine, 0.6 mg of epinephrine, 5 mg of morphine sulfate, and sodium chloride solution. All infiltrations will be completed with a blunt trochar to minimize the risk of intravascular injection.~Interventions:~Drug: Ropivacaine Drug: Epinephrine Drug: Morphine Drug: 0.9% sodium chloride solution Following surgery, patients in the treatment and non-treatment groups will both be provided with the same intravenous (patient-controlled analgesia) and oral pain medications scheduled per needed."
2490182|NCT02967172|No Intervention|Control|Ankle fracture fixation/instrumentation will be completed per the standard of care. No peri-incisional injection will be completed.
2490234|NCT02966860|Experimental|Oxycodone and acetaminophen (OC/APAP)|Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)
2490307|NCT02966288|Experimental|Toradol injection|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
2490311|NCT02966288|Active Comparator|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
2490384|NCT02966054|Experimental|Intervention|"Patients will be provided with a booklet from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors. The intervention group will be given a Fitbit® Flex to wear throughout the study and will receive daily text messages to support increased physical activity."
2490385|NCT02966054|No Intervention|Control|"Patients in the control arm will be provided with a booklet at baseline from the UCSF Dept. of Physical Therapy and Rehabilitation Science: Moving Through Cancer: A Guide to Exercise for Cancer Survivors."
2490417|NCT02965664|Experimental|PresbiDrops (CSF-1)|Participants self-administer PresbiDrops (CSF-1) , with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
2490420|NCT02965664|Placebo Comparator|Placebo|Participants self-administer Placebo, with the supervision or help of the hospital staff - one drop in each eye on the day of treatment
2490492|NCT02965274|Experimental|Test|Torrent's Fluoxetine Tablets 20 mg
2490494|NCT02965274|Active Comparator|Reference|Warner Chilcott LLC, USA
2490554|NCT02964858|Active Comparator|Standard Arm|45 Gy in 25 fractions of 1.8 Gy per fraction over 5 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
2490556|NCT02964858|Experimental|Experimental Arm|36 Gy in 20 fractions of 1.8 Gy per fraction over 4 weeks Involved Field radiotherapy (IFRT)/ Involved Site Radiotherapy (ISRT)
2490717|NCT02963714|Experimental|60 µg dose hepatitis B vaccine|60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2490720|NCT02963714|Experimental|20 µg dose hepatitis B vaccine|20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
2490736|NCT02963402||Tocilizumab treated|
2490738|NCT02963402||Anti-TNF treated|
2490788|NCT02963298|Active Comparator|CRRT after cardiac arrest|Continuous renal replacement therapy (CRRT) after cardiac arrest for 72 hours for elimination of Glutamate. Repetitive testing of blood Glutamate levels.
2490791|NCT02963298|No Intervention|control|Repetitive testing of blood Glutamate levels without CRRT
2490854|NCT02962947|Placebo Comparator|PLACEBO|Placebo will be taken daily during the study period
2490855|NCT02962947|Active Comparator|PROPRANOLOL|Study participants in the treated group will take 80 mgR propranolol once daily .
2490904|NCT02962583|Experimental|Probiotic|Daily probiotic consumption
2490905|NCT02962583|Placebo Comparator|Placebo|Daily placebo consumption
3161155|NCT00437840|Experimental|Treatment Arm C|In Arm C dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, Placebo in Week 3, 75 mg of GSK598809 in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3161156|NCT00437840|Experimental|Treatment Arm D|In Arm D dosing subject will receive 10 mg of GSK598809 in Week 1, 25 mg of GSK598809 in Week 2, 75 mg of GSK598809 in Week 3, Placebo in Week 4. Subjects will have a wash-out of period of one week before receiving another dose.
3161157|NCT00437892|Experimental|Atorvastatin and lipid lowering diet|
3161158|NCT00437892|Active Comparator|lipid lowering diet|
2491056|NCT02961686||Patients with prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach that comprise exclusive radiotherapy, psychological and andrologic evaluation.
2491090|NCT02961192|No Intervention|Control|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts.
2491100|NCT02961192|Experimental|Supportive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In addition to playing the game, participants will identify a family member or friend to receive updates and support them in their progress.
2491107|NCT02961192|Experimental|Competitive|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into competitive groups with one or two other participants to play the game.
2491549|NCT02958631|Active Comparator|Losartan|Losartan 50mg, QD
3161159|NCT00437931||A|patients with subclinical hypothyroidism
3161160|NCT00437931||B|patients with subclinical hyperthyroidism
3161161|NCT00437931||C|patient with normal thyroid function.
3161162|NCT00437957|Experimental|Temazolomide, Valproic Acid and Radiation|Temazolomide, Valproic Acid and Whole Brain Radiation Therapy
3161163|NCT00437970|Active Comparator|A|Arm A- Metformin
3161164|NCT00437970|Active Comparator|B|Arm B- Pioglitazone
3161165|NCT00438009|Experimental|CAVATAK|
3161166|NCT00438022||1|Group 1 will include participants with AD, EH, and recurrent herpes simplex virus (HSV)
3194463|NCT00828490||Antipsychotic Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and ≥3 antipsychotic Rx within past 12 months
3194464|NCT00828490||Bipolar Therapy|Medicaid beneficiaries ≥18 years of age and enrolled ≥6 months of the past 12 months with enrollment in at least one of the past 3 months and a diagnosis of Bipolar in past 3 years, and ≥ 1 antidepressant Rx in past 6 months, and no mood stabilizer in past 6 months.
3194465|NCT00828490||Opioid Therapy|"Medicaid beneficiaries ≥18 years and enrolled ≥6 of prior 12 months with enrollment in ≥1 of prior 3 months and ≥1 opioid fill in prior 3 months and none of the following in prior 12 months:~Hospice CPT code or Primary diagnosis of cancer or Oncology CPT code"
2490395|NCT02965794||Usual care|quality of care will be measured in the participating hospitals, using a retrospective patient record analysis
2490397|NCT02965794||Care Pathway|Care pathways for colorectal cancer
2490407|NCT02965495|Experimental|YYD302 2ml|YYD302 2ml
2490408|NCT02965495|Experimental|YYD302 3ml|YYD302 3ml
2490409|NCT02965495|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
2490490|NCT02965092|Experimental|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2 in the absence of disease progression or unacceptable toxicity.
2490579|NCT02964819|Active Comparator|exercise group|Manual cervical traction, Myofascial release of upper trapezius muscle, 3 sets of 1 minute;Sleeper's stretch, during 3 series of 30 seconds,Punch exercise, Knee push-up plus, Prone V-raise exercise (arms abducted at 120°), rotador cuff exercise (internal rotation), rotador cuff exercise (external rotation), Rotation on the wall using a ball (internal rotation), Rotation on the wall using a ball (external rotation).
2490580|NCT02964819|Experimental|exercise + Interferential current group|Addition to the exercise protocol performed in the exercise group the interferential current. Four self-adhesive electrodes (8x5 cm), two upper and two lower ones (forming a square) will be placed around the center of the shoulder. The electrodes will be positioned crosswise, following the parameters: 4KHz (carrier frequency), 1/1 second (swing pattern), 100 Hz Frequency modulation amplitude (AMF), 50 Hz (sweep frequency), automatic vector mode, With intensity at the motor threshold of sensation, with duration of 50 minutes.
2490583|NCT02964819|Placebo Comparator|exercise + US group|In addition to the exercise protocol performed in the exercise group, an ultrasound device will be used. The appliance will be used off, without any individual participant having knowledge. For this, the individual will be asked to position himself in the dorsal position on the stretcher, the therapist will perform the application of the transducer head, with gel on its surface, in the anterolateral region of the affected shoulder.
3194466|NCT00828490||Fraud and Abuse|Medicaid beneficiaries who filled at least 3 opioid Rx in the last 12 months
3194467|NCT00828490||Pediatric Antipsychtotic Therapy|Medicaid beneficiaries <18 years of age with at least 3 antipsychotic Rx's in the past year.
2490817|NCT02963090|Active Comparator|Topotecan|Topotecan IV at 1265mg/m^2 Days 1-5 of every 21 day cycle
2490821|NCT02963090|Experimental|Pembrolizumab|Pembrolizumab IV 200mg infusion Day 1 of every 21 day cycle
2490876|NCT02962713|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
2490881|NCT02962713|Experimental|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal restoration in primary molars using Giomer Beautifil-Bulk Restorative (SHOFU Inc)
2491030|NCT02961725|Experimental|UCMSC treatment|UCMSC: umbilical cord mesenchymal stem cells
2491061|NCT02961387|Experimental|Hydrogen generator treatment|Inhalation of hydrogen-oxygen mixed gas.
2491062|NCT02961387|Sham Comparator|Oxygen-making machine treatment|Inhalation of oxygen.
2491086|NCT02961101|Experimental|Anti-PD-1 antibody+decitabine|Decitabine will be administrated at 10mg/d on day1 to 5, followed by Anti-PD-1 antibody 200mg on day8 IV Q3 weeks until progression.
2491094|NCT02961101|Experimental|Anti-PD-1 antibody|Anti-PD-1 antibody 200mg IV Q3 weeks until progression.
2491106|NCT02961101|Experimental|Anti-PD-1 antibody+chemotherapy|Chemotherapy will be given depends on the cancer type and treatment regimen before enrollment. Chemotherapy was administrated on day1 , followed by Anti-PD-1 antibody 200mg on day2 IV Q3 weeks until progression.
2491181|NCT02960802|Active Comparator|kidney transplant patient|kidney transplantation is intervention
2491186|NCT02960802|No Intervention|healthy control|no intervention
2491233|NCT02960308||Diagnostic (WNCTP scan)|Patients undergo WNCTP scan over 2-3 minutes during standard of care CT.
2491311|NCT02960035|Experimental|etanercept 50mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 will be randomised to one of three arms (period 2): this arms will receive ETN 50 mg weekly (unchanged). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2491315|NCT02960035|Experimental|etanercept 25mg/week|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive ETN 25 mg weekly (half dose). In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2491320|NCT02960035|Placebo Comparator|PLACEBO|Patients who entered the study continued on the same NSAIDs medications. The NSAIDs dose was kept unchanged throughout the study. All patients were provided with the once-weekly 50 mg dose in the form of etanercept for 24 weeks. After 24 weeks, those patients who had maintained a ASDAS-CRP ≤2.1 during period 1 were randomised to one of three arms (period 2): this arms will receive placebo weekly. In all three arms, the patients continued NSAIDs, and other medications, at the same dose.
2491367|NCT02959658|Active Comparator|Active drug|Dimethyl fumarate, 240mg twice daily for 48 weeks
2491371|NCT02959658|Placebo Comparator|Placebo|Placebo Oral Capsules, 2 tablets twice daily for 48 weeks
2491413|NCT02959294|Experimental|Microcannula Harvest Adipose|Acquisition Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via close syringe microcannula harvest from subdermal fat deposits
2490280|NCT02966665|Experimental|Healthy Older Controls (over 65 years)|Healthy volunteers 65 years of age or older with no diseases or conditions that would affect their participation in the study, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2490282|NCT02966665|Experimental|Coronary Angiography patients|Patients undergoing routine coronary angiography, but who do not require intracoronary procedures or have history of myocardial disease, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2490284|NCT02966665|Experimental|Chronic Obstructive Pulmonary Disease patients|Patients diagnosed with mild to moderate COPD, but not severe COPD patients, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2490286|NCT02966665|Experimental|Pulmonary Arterial Hypertension patients|Patients with idiopathic or heritable Group 1 pulmonary arterial hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2490288|NCT02966665|Experimental|Heart Failure patients|Patients with Class I - III New York Heart Association symptoms of Heart Failure who are not anemic or taking medications that affect blood clotting, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
2490290|NCT02966665|Experimental|Hypertension patients|Patients with chronic high blood pressure, but with less than severe hypertension, administered various treatments to assess their effect on blood flow and metabolic demand of tissues under wide-ranging conditions, including Maximum Exercise Tests, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid, L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Norepinephrine, Phentolamine and MitoQ.
3194468|NCT00828503|Active Comparator|1 Certican + Valganciclovir|Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression
3194469|NCT00828503|Active Comparator|2 Valganciclovir alone|Valganciclovir will be added alone.
3194470|NCT00828581|Experimental|Lorcaserin|
2490507|NCT02965027|Experimental|Prazosin|Prazosin capsules beginning at 1 mg orally at bedtime. Titrate over 5 weeks to maximum dose of 5 mg in the morning and 20 mg at bedtime.
2490508|NCT02965027|Placebo Comparator|Placebo|Placebo capsules
2490561|NCT02964689|Experimental|Combination of binimetinib, pemetrexed and cisplatin|"The trial consists of two parts:~Part 1: dose escalation based on the 3+3 design with 2 doses of binimetinib~Part 2: expansion cohort at the recommended maximum tolerated dose (MTD) level of binimetinib"
2490618|NCT02964351||High PSA (prostate-specific antigen) levels|
2490659|NCT02964026||Pulmonary artery catheter (PAC)|Patients received a PAC for monitoring purposes
2490660|NCT02964026||No pulmonary artery catheter (PAC)|Patients did not receive a PAC for monitoring purposes
2490681|NCT02963727|Experimental|Wharton Jelly mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection will be given for each patient in 2 doses, 50 million of WJMSC in each dose
2490758|NCT02963636|Experimental|Pharmacist clinical intervention|Patients exposed to the pharmacist intervention
2490778|NCT02963129|Experimental|Mupirocina|topical mupirocin nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
2490785|NCT02963129|Placebo Comparator|Control|topical placebo nasal ointment and nasal solid petroleum jelly for 5 consecutive days and then just nasal solid petroleum jelly to complete the 60 total days
3161167|NCT00438022||2|Group 2 will include participants with AD and recurring HSV infections but without EH
3161168|NCT00438022||3|Group 3 will include participants with AD but without EH or HSV infection
3194471|NCT00828594|Experimental|Phase 1: RAD001 plus sorafenib|
3194472|NCT00828607||liver mass|The group will comprise any patients with an unknown liver mass at the time of diagnostic imaging.
2490942|NCT02962206|Active Comparator|Standard of care|Patients will undergo standard closed fracture reduction. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician. Point-of-care ultrasound will not be used.
2490946|NCT02962206|Experimental|Experimental Group|Patients will undergo standard closed fracture reduction with the addition of point-of-care ultrasound use to assess post-reduction dorsal angulation. The sedation type, reduction method, and immobilization method will be at the discretion of the treating physician.
2490981|NCT02961868|Experimental|Prospective cohort|3 years follow-up
2491027|NCT02961556|Experimental|AJG555|After 2 weeks of the screening period, participants will be administered AJG555 starting on the day of the formal enrollment and continuing for 12 weeks.
2491087|NCT02961257|Experimental|Arm A|"Cabazitaxel 25 mg/m² intravenously over 1 hour on Day 1of a 3-week cycle, plus prednisone (or prednisolone) 10 mg orally given daily for a maximum of 10 cycles (ie 30 weeks of treatment).~Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel."
3194473|NCT00828620||PET-CT|Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab
3194474|NCT00828646|Experimental|BMS-708163 - Panel 1|(Age 20-45 years)
3194475|NCT00828646|Experimental|BMS-708163 - Panel 2|(Age 20-45 years)
3194476|NCT00828646|Experimental|BMS-708163 - Panel 3|(age 65 or above)
3194477|NCT00828646|Experimental|BMS-708163 - Panel 4|(age 65 or above)
3194478|NCT00828659|Placebo Comparator|Placebo|
2490337|NCT02966132|Experimental|iMD|"Participants will receive interactive Mobile Doctor (iMD) intervention in English, Chinese, Korean or Vietnamese languages that delivers video education tailored to patient's responses on a computer tablet during the clinic visit to enhance patient-provider discussion of tobacco use. The iMD intervention implements the 5As (Ask, Advice, Assess, Assist, and Arrange) recommended by the Clinical Practice Guideline for treating tobacco dependence. A summary printout including provider recommendation options, brief summary of smoking status, quit intention and concerns are provided to patients to empower them to discuss tobacco use with their providers."
2490338|NCT02966132|Active Comparator|NPA|Participants will receive a video education providing nutrition and physical activity recommendations right before before seeing their providers. A printout summarizing topics presented in the education videos will be provided to the patient
2490393|NCT02965807|Experimental|Bronchial Thermoplasty|Moderate bronchial asthma patients under the Bronchial Thermoplasty.
2490416|NCT02965521|Experimental|Intervention|Participants will be given print material on diet for cancer survivors and access to a web-based dietary intervention with text messaging for 12 weeks.
2490421|NCT02965521|No Intervention|Control|Participants randomized to the control arm will receive print materials on diet for cancer survivors. After completion of their 12-week follow-up assessments, control participants will be given access to the web-based dietary intervention with text messaging for 12 weeks.
2490484|NCT02965287||19-21 weeks' gestation|"The test validation will be performed on the 1943 serum samples of pregnant women at 19-21 weeks' gestation recruited in New Zealand for the SCOPE Study.~All the samples will be analyzed to extract and purify the whole metabolome. Metabolites will be characterized through mass spectrometric techniques. These data will be interpreted by means of a bioinformatic algorithm specifically designed for this purpose."
2490488|NCT02965287||14-16 weeks' gestation|Five hundred subjects at 14-16 weeks gestation were randomly selected from the whole cohort of patients. The serum samples collected at 14-16 weeks gestation will be used to test the diagnostic performance at this earlier gestational phase.
2490553|NCT02964884|Active Comparator|NF1: Lovastatin + reading tutoring|"Participants (NF-1 patients) will receive 20mg of Lovastatin per day for the first two weeks, the dose will be escalated 40 mg for the remaining 11 weeks.~And one week of intensive, one-on-one reading tutoring intervention"
2490557|NCT02964884|Placebo Comparator|NF1: Placebo + reading tutoring|Participants (NF-1 patients) will receive placebo daily And one week of intensive, one-on-one reading tutoring intervention
2490558|NCT02964884|Placebo Comparator|RD: Reading tutoring|Participants (RD-only participants) will receive one week of intensive, one-on-one reading tutoring intervention
2490559|NCT02964884|Sham Comparator|RD: Other Academic (sham) tutoring|"Participants (RD-only participants) will receive one week of intensive, one-on-one tutoring intervention with an academic focus other than reading.~These participants will have the opportunity to receive reading tutoring upon finishing study participation."
3161169|NCT00438022||4|Group 4 will include participants in good general health without AD, EH, or HSV infection
3161170|NCT00438048|Active Comparator|a,b|Compare Pilocarpine and Artificial saliva
3161171|NCT00438087|Placebo Comparator|2|placebo versus methylprednisolone
2490746|NCT02963493|Experimental|melphalan flufenamide (melflufen) + dexamethasone|Melphalan flufenamide (melflufen) 40 mg Day 1 and dexamethasone 40 mg (reduced dose for patients 75 years or older) on Days 1, 8, 15 and 22 of each 28-day cycle.
2490775|NCT02963051|Experimental|Neuroendocrine prostate cancer (NEPC)|"Subjects with neuroendocrine prostate cancer (NEPC)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2490776|NCT02963051|Experimental|Adenocarcinoma CRPC with non-liver/peritoneal metastases|"Subjects with adenocarcinoma CRPC with non-liver/peritoneal metastases (lymph nodes, bone, or lung)~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2490777|NCT02963051|Experimental|Adenocarcinoma CRPC with liver and/or peritoneal mets|"Subjects with adenocarcinoma CRPC with liver and/or peritoneal metastases~Copper will be administered intravenously at a dose of 1, 3, 5, or 7 mg on cycle 1 days 1, 8, 15. Disulfiram will administered orally at a dose of 80 mg three times a day starting on cycle 1 day 2. Copper gluconate will be administered orally at a dose of 1.5 mg three times a day starting on cycle 1 day 16."
2490859|NCT02962804|Experimental|Nivolumab plus radiation|Nivolumab plus radiation
2490950|NCT02962544|Active Comparator|Visumax device for FS-SMILE group|(FS-SMILE )femtosecond small incision lenticule extraction procedure using Visumax laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
2490953|NCT02962544|Active Comparator|FS 200 device for FS-LASIK group|(FS-LASIK)femtosecond assisted LASIK procedure using Fs200 laser device as a surgical intervention for correction of myopia and myopic astigmatism will be done for 30 eyes of patients with myopia or myopic astigmatism.
2490991|NCT02961829|No Intervention|Antiretroviral Treated (ART) Group|Five patients will receive no further intervention this group (control group)
3161172|NCT00438087|Experimental|1|placebo versus methylprednisolone
3161173|NCT00438113|Active Comparator|Aggressive Blood Pressure control|"The experimental arm will receive open label therapy to achieve a target systolic blood pressure less than or equal to 120 mmHg.~If the average BP is found to be > 120 mmHg at the baseline, telephone or clinic followup visits, treatment will be recommended based on the following regimen (For details, please see Appendix 4):~Step 1 - Accupril, titrated to maximum tolerated dose, beginning at 20 mg po od followed by 40 mg successively Step 2 - combination of Accupril with Hydrochlorothiazide 12.5 mg po od. Step 3 - Addition of Atenolol 50 mg po od. Step 4 - Addition of Norvasc 2.5-10 mg po od. Step 5 - Addition of Terazosin 1 mg po od."
3194479|NCT00828659|Active Comparator|Active Comparator #1|
3194480|NCT00828659|Active Comparator|Active Comparator #2|
3194481|NCT00828659|Active Comparator|Active Comparator #3|
3194482|NCT00828659|Experimental|Lorcaserin Dose #1|
3194483|NCT00828659|Experimental|Lorcaserin Dose #2|
3194484|NCT00828659|Experimental|Lorcaserin Dose #3|
2490342|NCT02966119|Experimental|Start antiplatelet drug(s)|If the patient is randomized in this arm, an antiplatelet agent (aspirin or clopidogrel or dypyridamole), chosen by the patient's physician before the randomisation, will be prescribed to the patient during the study period
2490346|NCT02966119|No Intervention|Avoid antiplatelet drug(s)|If the patient is randomized in this arm, antiplatelet drugs will not be prescribed to the patient during the entire study period
3161174|NCT00438113|No Intervention|Standard Blood Pressure control|Treatment will be carried out as per the CHEP guidelines. These patients may require ACEi or ARBs for their treatment. No changes to their drug regimen will be made as long as BP measurements are congruent with current guidelines. These modifications will be made as per standard practice by the physician who is primarily involved with their care (this may be a family physician or a specialist, depending on the patient). Patients with diabetes in the standard arm will be treated to a target BP of <130/80 as per the CHEP guidelines.
3161175|NCT00438152|Active Comparator|Invirase® tablets|
3161176|NCT00438152|Active Comparator|Kaletra® tablets|
2490411|NCT02965417|Experimental|Sym004|All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
2490493|NCT02965352|Experimental|Hand strength|Volunteers without motor abnormalities. The tests were performed in a single session lasting 30 minutes, when volunteers used the door handle device, the linear switch device, and the door key device, in order to quantify the hand strength.
2490517|NCT02964832|Active Comparator|PocketCPR;Grasp method|Subject grasp a smartphone in the hand and compress the chest of manikin.
2490518|NCT02964832|Active Comparator|PocketCPR;Armband-in-hand method|Grab the smartphone-contained-armband in hand when performing chest compression
2490519|NCT02964832|Active Comparator|PocketCPR;Armband-on-arm method|Fix the smartphone-contained-armband on upperarm when performing chest compression
2490563|NCT02964611||Alzheimer's disease|Observational Study
2490565|NCT02964611||Parkinson's disease|Observational Study
2490568|NCT02964611||Frontotemporal Lobar Degeneration|Observational Study
2490571|NCT02964611||Healthy Controls|Observational Study
3161177|NCT00438165|No Intervention|1|Control group
3161178|NCT00438165|Experimental|2|Nurse home visits
3161179|NCT00438243|Placebo Comparator|1|1 drop affected eye twice daily.
2490838|NCT02963233||Non-operative Group|Patients treated within the non-operative group will be treated with gentle reduction by the orthopaedic surgery team in the emergency department under procedural sedation. Immobilization and maintenance of reduction will be obtained through either taping of the elbow in a flexed (100-110 degree) and pronated position or through long-arm casting at 90 degrees of flexion. Immobilization type and position will be noted.
2490841|NCT02963233||Operative Group|Patients treated operatively will be largely treated with closed reduction and percutaneous pinning with 2-3 laterally-based k-wires, followed by long-arm immobilization. Immobilization type and position will be noted.
3161180|NCT00438243|Experimental|2|Bromfenac (Xibrom) 1 drop to affected eye twice a day.
2490931|NCT02962453|Experimental|Morning walk|Rehabilitation using end-effector type gait robot for 5days.
2490933|NCT02962453|Active Comparator|Ground Walker|Rehabilitation using walker for 5days.
2490968|NCT02962050||ALS|Participants enrolled will complete the following tests: Videofluoroscopic Swallowing Study, Voluntary Peak Cough Flow Testing, lingual strength and endurance trials using the Iowa Oral Performance Instrument, reflexive cough testing, Pulmonary Function Testing; Eating Assessment Tool-10 (EAT-10), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), and the The Center for Neurologic Study Bulbar Function Scale (CNS-BFS).
2491169|NCT02960750|Experimental|Intervention group|Had access to the W@WS website program during 19 weeks.
2491173|NCT02960750|Active Comparator|Active comparison group|Maintained habitual behavior.
2491236|NCT02960347|Experimental|Active tDCS|open label active tDCS treatment
2491303|NCT02960191|Other|patient suicide|subject having had a personal history of unipolar or bipolar depressive disorder and having realized in his life at least one suicide attempt
2491364|NCT02959762|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
3161181|NCT00438282|No Intervention|1|Control group
3161182|NCT00438282|Experimental|2|Paraprofessional home visits
3161183|NCT00438282|Experimental|3|Nurse home visitation
3161184|NCT00438308||1|Subjects who begin therapy immediately after fracture.
3161185|NCT00438308||2|Subjects delay therapy for 3 weeks after injury.
3161186|NCT00438321|Placebo Comparator|Placebo|Placebo injection, gel and pill
3161187|NCT00438321|Active Comparator|Testosterone only|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
3161188|NCT00438321|Active Comparator|Testosterone and Estrogen|Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
3161189|NCT00438347||group 1|Intervention Group- aerobic exercise
3161190|NCT00438347||group 2|Control Group- stretching and toning
3161191|NCT00438425|Experimental|Intensive Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 7 visits during a 6-month period with the study dietitian.
3194485|NCT00828685|Active Comparator|Operative (CRPP)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized.
2490977|NCT02961972|Placebo Comparator|control group|Oral ingestion of placebo pills (maltodextrin) during three weeks
2490978|NCT02961972|Experimental|creatine supplementation|Oral supplementation with 5 g of monohydrate and micronized creatine during three weeks
2491051|NCT02961699|Experimental|Transpose ® RT System|Adipose-derived stem cells (also known as stromal vascular fraction or SVF) will be injected subcutaneously around the rim of the wound bed following standard would debridement. The standard collagen dressing material will also be saturated with SVF after placement within the would itself. Normal (standard) dressing of wound will be placed over wound.
2491053|NCT02961699|Active Comparator|debridement/dressing of wound|Wound will be debrided and collagen dressing placed within wound bed as per standard of care. Standard dressing will cover wound. No adipose-derived stem cells (SVF) will be applied to control subject wounds.
2491065|NCT02961166||IgM enriched Immunoglobulins|ARDS patients with septic shock requiring ECMO therapy were treated for 3 days by IgM-enriched Immunoglobulin
2491068|NCT02961166||Control|ARDS patients with septic shock requiring ECMO therapy were NOT treated by IgM-enriched Immunoglobulin
3194486|NCT00828685|Active Comparator|Operative (ORIF)|If indicated, the wrist fracture would be treated with surgery-the specific operative procedure would be randomized
3194487|NCT00828698||Acute Myocardial Infarction patients|
2491188|NCT02960633|Active Comparator|THA with Collar|THA with Collar
2491193|NCT02960633|Active Comparator|THA without Collar|THA without Collar
2491234|NCT02960321||CAG without PCI|Diagnostic coronary angiography only
2491240|NCT02960321||CAG with PCI|Diagnostic coronary angiography and subsequent percutaneous coronary intervention (PCI)
2491267|NCT02960100|Experimental|Arm I (mHealth HPV vaccine intervention)|Participants receive targeted HPV vaccine narrative-style video via the mobile-friendly website. Participants also receive monthly HPV vaccination reminders via email or by text message.
2491271|NCT02960100|Active Comparator|Arm II (standard HPV information and HPV VIS)|Participants receive standard information with the HPV Vaccine Information Statement via the mobile-friendly website.
2491308|NCT02960061|Experimental|HIPEC|After receiving neoadjuvant chemotherapy and D2 radical resection, Hyperthermic intraperitoneal perfusion chemotherapy is conducted,4 catheters are placed in 4 position in the peritoneal cavity: ① under the left diaphragm ② hepatorenal recess ③ left pelvis ④ right pelvis.catheters, all four tubes are connected to the perfusion device.Perfusion prescription: cycle 1, Paclitaxel 75mg/ m2 diluted with 3000ml normal saline heated up to a fixed temperature of 43°C circulate continuously for 60min at a speed of 400-500ml/h; cycle 2 start within 24-48 hours after cycle 1, dosage of paclitaxel adjust to 100mg/ m2, the rest of the same. A total of two cycle is administered, routine adjuvant chemotherapy using SOX (oxaliplatin plus S-1 capsule)or XELOX regimens follows within 4-6 weeks.
2491314|NCT02960061|Sham Comparator|controlled group|After receiving neoadjuvant chemotherapy and D2 radical resection, patients receive peritoneal lavage with 3000ml distilled water.Adjuvant chemotherapy using SOX or XELOX regimens is administered as routine within 4-6 weeks.
3194488|NCT00828724|Experimental|Lorcaserin 10mg|
3194489|NCT00828737|Experimental|Arm 1|
2491359|NCT02959632|Experimental|Patients receiving AAT|"Hospitalized patients receiving Animal Assisted Therapy (AAT).~Animal Assisted Therapy (Pet Visit) will be provided to the hospitalized patients."
2491365|NCT02959749|Active Comparator|Docetaxel, bevacizumab|docetaxel, 75mg/m2, intravenous infusion on day 1. VEGF monoclonal antibody bevacizumab, 7.5 mg/m2, intravenous infusion on day 1, every 21days a cycle，until disease progression, intolerable toxicities, or patient death.
2491373|NCT02959749|Experimental|EGFR TKI|osimertinib 80mg oral once daily，until disease progression, intolerable toxicities, or patient death.
2491384|NCT02959515|Active Comparator|Capnothorax|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg .Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
2491385|NCT02959515|Active Comparator|Capnothorax and CPAP|Capnothorax is obtained by the insufflation of CO2in the right pleural cavity and maintained at a preset pressure of 10 mmHg. CPAP on the non ventilated lung is set at 10 cm H2O and FiO2=1. Arterial and central venous blood gasanalyses, hemodynamic and respiratory variables will be recorded.
2491409|NCT02959268|Other|Single arm Al-Sense diagnostic|Investigator blinded to subject assessments
2491411|NCT02959346|Sham Comparator|Sham Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture.
2491412|NCT02959346|Experimental|Acupuncture|After recruitment, participants will be randomized to receive acupuncture or sham acupuncture treatment. In the acupuncture group, participants will receive acupuncture.
2491430|NCT02959086||1|Patients were diagnosed since January 2002.
2491451|NCT02959034||BMI > 95%|No Intervention
2491454|NCT02959034||Healthy Weight Siblings|Control
2491456|NCT02958930|Experimental|TEMT Treatment|Patients in this arm will receive Transcranial Electromagnetic Treatment (TEMT) twice daily for a two-month treatment period utilizing the MemorEM 1000 head device.
2491458|NCT02958943|Experimental|Electronic Alert|Each provider in the alert group will receive an on-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation.
2491464|NCT02959034||Healthy Weight Unrelated|Control
2491466|NCT02958943|No Intervention|No Alert|Each provider in the non-alert group will receive no such notification.
2491501|NCT02958735|No Intervention|Rest|Participants randomly assigned to this arm rest quietly for thirty minutes instead of participating in the exercise challenge.
2491502|NCT02958735|Experimental|Mild Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 60% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
3194490|NCT00828763|Experimental|1|[14C]-GSK1349572 administered as a single oral dose
3194491|NCT00828776|Experimental|1|Heparin Cristália
3194492|NCT00828776|Active Comparator|2|Heparin - Roche
3194493|NCT00828802|Experimental|Cohort 1|Lenalidomide (5mg) and Decitabine
2490464|NCT02965053|Experimental|Period 1 Arm 1|EOS789 Dose 1 in treatment sequence 1, Placebo in treatment sequence 2
2490467|NCT02965053|Experimental|Period 1 Arm 2|Placebo in treatment sequence 1, EOS789 Dose 1 in treatment sequence 2
2490472|NCT02965053|Experimental|Period 2 Arm 1|EOS789 Dose 2 in treatment sequence 1, EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 2
2490479|NCT02965053|Experimental|Period 2 Arm 2|EOS789 Dose 2 + Sevelamer carbonate in treatment sequence 1, EOS789 Dose 2 in treatment sequence 2
2490576|NCT02964741|Active Comparator|Migraine Patients Active Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).~*Active Comparator"
2490577|NCT02964741|Sham Comparator|Migraine Patients Sham Group|"Episodic migraine patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).~*Sham Comparator"
2490578|NCT02964741|No Intervention|Healthy Control Group|"Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NINDS-K23062946 project [IRBMED #HUM00027383; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
2490611|NCT02964299||Standard|Standard bite block
2490612|NCT02964299||Mandibular advancement bite block|Mandibular advancement by 3 mm, 6 mm or 9 mm from neutral position
2490650|NCT02964091|Other|Harvoni|sofosbuvir/ledipasvir once daily for 12 weeks
2490697|NCT02963870|Experimental|security plan|groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with security plan and the usual treatment
2490707|NCT02963870|Active Comparator|standard treatment only.|group receiving standard treatment only.
2490781|NCT02963038|Experimental|CD19 CAR T cells|Autologous CD19-targeting CAR T cells
2490868|NCT02962973|Experimental|Carmat TAH|The surgical intervention takes place through a midsternotomy utilizing cardiopulmonary bypass. The device is then connected via a percutaneous driveline to an external controller and batteries and takes over the circulation.
2490922|NCT02962375|Experimental|Active Treatment|100% orange juice with orange pomace fiber
2490925|NCT02962375|Placebo Comparator|Control Treatment|100% orange juice
2490992|NCT02961829|Experimental|ART Intensification Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks
2490993|NCT02961829|Experimental|ART Intensification + Nicotinamide Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks.
2490995|NCT02961829|Experimental|ART Intensification + Auranofin Group|Five patients will receive antiretroviral intensification with maraviroc and dolutegravir for 48 weeks and the gold salt auranofin for 24 weeks.
2490997|NCT02961829|Experimental|ART Intensification + DC vaccine Group|Five patients will receive antiretroviral intensification with dolutegravir and for 48 weeks, and dendritic cell vaccine.
2491001|NCT02961829|Experimental|Multi Interventional Group|Five patients will receive antiretroviral intensification with dolutegravir and the Sirtuin Histone deacetylase inhibitor nicotinamide for 48 weeks, and gold salt for 24 weeks and dendritic cell vaccine.
2491039|NCT02962102|Experimental|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
2491042|NCT02962102|Experimental|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5 days
2491046|NCT02962102|Placebo Comparator|Placebo|Equal volume of medium chain triglyceride (MCT) oil daily x 5 days
2491081|NCT02961361|Experimental|Group Control|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
2491082|NCT02961361|Experimental|Group Dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
3194494|NCT00828802|Experimental|Cohort 2|Lenalidomide (10 mg) and Decitabine
3194495|NCT00828802|Experimental|Cohort 3|Lenalidomide (15 mg) and Decitabine
2491164|NCT02960880||Rivaroxaban|NVAF patients who were newly initiated on Rivaroxaban for stroke prevention
2491166|NCT02960880||Phenprocoumon|NVAF patients who were newly initiated on Phenprocoumon for stroke prevention
2491187|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1A|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491192|NCT02960906|Experimental|ccRCC molecular subgroup 1: 1B|"ccRCC molecular subgroup 1 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491197|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4A|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491201|NCT02960906|Experimental|ccRCC molecular subgroup 4: 4B|"ccRCC molecular subgroup 4 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491326|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4a)|
2491327|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (4b)|
3194496|NCT00828802|Experimental|Cohort 4|Lenalidomide (20 mg) and Decitabine
2490469|NCT02965066|Experimental|First Coloplast Test catheter; then Speedicath catheter|The subjects allocated to this arm first test Coloplast Test catheter and after cross over test the comparator speedicath catheter
2490475|NCT02965066|Experimental|First Speedicath catheter; then Coloplast Test catheter|The subjects allocated to this arm first test Speedicath catheter and after cross over test the Coloplast test catheter
2490538|NCT02964845|Experimental|WISH with CHW and referral to HFM|Subjects will be assigned a CHW for intervention sessions along with receiving primary care from Highland Family Medicine. CHWs will use the SDT-based, trauma-specific motivational approach in the intervention to engage women during 6 sessions. The duration of the intervention is 3 months. Each session will last 1 hour and will take place in a community location. CHW's will also help facilitate primary care by linking subjects to primary care and will use electronic records to update and receive input from medical providers, and support treatment recommendations from Trillium Health. CHWs will empower women to convey their needs to providers for HIV risk reduction, SUD, co-morbidity (MH, IPV) treatment and will support autonomy and competence for treatment in the intervention sessions.
2490542|NCT02964845|Other|Enhanced Treatment as Usual control|eTAU participants will be given an HIV risk reduction information sheet made in cooperation with Trillium Health, HIV health providers. The sheet will include sex and drug behavioral risk reduction strategies and information on obtaining PrEP. The eTAU group is also facilitated to receive healthcare by having a cell phone, a primary care clinic which accepts patients, and bus passes.
2490590|NCT02964520|Experimental|A/T Neurofeedback training|10 sessions of uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
2490591|NCT02964520|Sham Comparator|Sham neurofeedback training|"5 sessions of (sessions 1,3,5,7,9) up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz).~5 sessions of (sessions 2,4,6,8,10) down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)"
3194497|NCT00828802|Experimental|Cohort 5|Lenalidomide (25 mg) and Decitabine
2490877|NCT02962843|Experimental|IY TCM|Incredible Year (IY) Teacher Classroom Management (TCM) training, 6 full-day workshops (42 hours)
2490882|NCT02962843|No Intervention|Comparison|No Incredible Year (IY) Teacher Classroom Management (TCM) training.
2490927|NCT02962466|Experimental|CC-Test diagnosis and Day 3 transfer|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos + the extra cumulus cell based diagnosis and transfer of the best embryo based on morphology and CC diagnosis on day 3 of embryo growth (cleavage stage embryo).
2490929|NCT02962466|No Intervention|D3 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 3 of embryo growth (cleavage stage embryo).
2490930|NCT02962466|No Intervention|D5 transfer control group|Patients undergo the standard ART treatment, as prescribed by the treating physician, with standard morphology based scoring of the embryos and transfer of the best embryo based on day 5 of embryo growth (blastocyst stage embryo).
2491012|NCT02962063|Experimental|Esophageal Cancer|This is a phase Ib/II trial of durvalumab (MEDI4736), a monoclonal antibody against programmed death ligand-1 (PD-L1)), and tremelimumab, an anti-CTLA-4 antibody, in combination with chemoradiation for patients with locally advanced (TanyN+M0 or T3-4NanyM0) esophageal or gastroesophageal (GE) junction adenocarcinoma.
2491055|NCT02961634|Experimental|Nailner 2 in 1 + Ciclopirox 8%|"Patients should apply Nailner 2 in 1 daily in the affected nail 2X a day, morning and night for 30 days. After 30 days passed to apply only 1x daily. No need to sand the nail before the application and the product should be applied on the entire nail, including the sides and the area affected by ringworm. Avoiding wett the nail after application and expose the nail.~They should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun."
2491059|NCT02961634|Active Comparator|Ciclopirox 8%|Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
2491060|NCT02961452||Peanut allergic children|
2491076|NCT02961127||group 1|no drugs were used in our study
2491077|NCT02961127||group 2|
2491089|NCT02961114|Experimental|Microcannula Harvest Adipose|Acquisition of AD-tSVF via closed syringe microcannula harvest from subdermal fat deposits
2491101|NCT02961114|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 closed system to create AD-cSVF
2491109|NCT02961114|Experimental|IV Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline for deployment via IV
3194498|NCT00828828||Sarcoidosis|Sarcoidosis patients who are assigned to receive influenza vaccine
3194499|NCT00828828||Healthy Controls|Healthy controls who are assigned to receive influenza vaccine
2491196|NCT02960815|Active Comparator|Intramuscular vaccine|The control intervention consists in the administration of the standard intramuscular influenza vaccine (Mutagrip®), containing 15 μg of each of the three viral strains without imiquimod.
2491199|NCT02960815|Experimental|Imiquimod and intradermal vaccine|In the imiquimod and intradermal vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intradermal influenza vaccine preparations containing 15 μg of each of the three viral strains (Intanza®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
2491223|NCT02960451|Experimental|PRIME care|Specialized care in the PRIME clinic
2491226|NCT02960451|Active Comparator|Usual care|Usual care in the community
3194500|NCT00828854|Experimental|treatment|Continued treatment with same AI at labeled dose and schedule, plus Entinostat (5mg PO every week)
3194501|NCT00828867|Experimental|Cohort 1|100mg
2490474|NCT02965196|Active Comparator|Dexamethasone Therapy|Three consecutive doses of IV Dexamethasone with be administered over three days. The doses will be tapered according to the following: 1st dose, 26mg., 2nd dose, 20mg., and the third dose will be 10 mg. Each dose will be administered over 24 hours in a slow drip, in a 100cc. normal saline bag (0.9%).
2490483|NCT02965196|Placebo Comparator|Placebo Therapy|Three consecutive doses of 100cc IV normal saline (0.9%), will be administered over three days. Each dose will be administered over 24 hours in a slow drip.
3194502|NCT00828867|Experimental|Cohort 2|200mg
3194503|NCT00828867|Experimental|Cohort 3|400mg
2490702|NCT02963961|Experimental|Cognitive Training|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
2490709|NCT02963961|No Intervention|No Training|Patients will not undergo preoperative cognitive training. Patients will receive standard preoperative care.
2490742|NCT02963519|Experimental|VistaCare®|VistaCare® Medical device for treatment into an editable atmosphere
2490743|NCT02963519|Active Comparator|Dressings|Dressings Adapted to the case
2490790|NCT02963181|Experimental|Effects of Yohimbine|Investigation into the integrity of post-ganglionic sympathetic nerves in patients with idiopathic neurogenic orthostatic hypotension
2490795|NCT02963181|Experimental|Effects of melatonin on blood pressure|Investigation into the effects of melatonin at two separate dosages (2 and 5mg) on nocturnal blood pressure in NOH patients with intact versus denervated post-ganglionic sympathetic nerves
3194504|NCT00828867|Experimental|Cohort 4|800mg
3194505|NCT00828867|Experimental|Cohort 5|1500mg
2490920|NCT02962232|Experimental|LEGFLOW OTW group|in the LEGFLOW OTW group the subject will be treated by the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter (LEGFLOW)
2490921|NCT02962232|Active Comparator|AMPHIRION DEEP group|in the AMPHIRION DEEP group the subject will be treated by PTA catheter (AMPHIRION DEEP)
2491016|NCT02961816|Experimental|Cohort A: Diffuse Large B-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2491017|NCT02961816|Experimental|Cohort B: Hodgkin's Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2491019|NCT02961816|Experimental|Cohort C: T-Cell Lymphoma|"Palifermin on Days -13 to -11 and on Days 0, +1, and +2.~Panobinostat daily from Day -9 to -2.~Gemcitabine administered on Days -8 and -3.~Busulfan test dose administered on day -10. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.~Melphalan on Days -3 and -2.~Rituximab on Day -9 for participants with CD20+ tumors.~Dexamethasone twice a day from Day -8 AM to Day -2 PM.~Caphosol oral rinses 30 mL four times a day used from Day -8.~Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.~Pyridoxine three times a day from Day -1.~Stem cells administered by vein on Day 0.~G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal."
2491096|NCT02961257|Experimental|Arm B|Cabazitaxel 16 mg/m2 on Day 1 and Day 15 of a 4-week cycle plus prednisone (or prednisolone) 10 mg per day up to 10 cycles (ie 40 weeks of treatment). Prophylactic Granulocyte colony-stimulating factor G-CSF (Granocyte) will be injected from Day 3 to Day 7 after every administration of cabazitaxel.
2491125|NCT02961036|Experimental|Group 1 Information|Group 1 Information about the prize draw incentive for 100% of an Amazon gift (or currency equivalent) in the invitation letter.
2491127|NCT02961036|Active Comparator|Group 2 Information|Group 2 Information about the prize draw incentive for 75% of an Amazon gift (or currency equivalent) in the invitation letter.
2491130|NCT02961036|Active Comparator|Group 3 Information|Group 3 Information about the prize draw incentive for 50% of an Amazon gift (or currency equivalent) in the invitation letter.
2491131|NCT02961036|Active Comparator|Group 4 Information|Group 4 Information about the prize draw incentive for 25% of an Amazon gift (or currency equivalent) in the invitation letter.
2491132|NCT02961036|Active Comparator|Group 5 No Information|Group 5 No Information incentive for an Amazon gift certificate (or currency equivalent) in the invitation letter.
2491133|NCT02961036|Experimental|Group A reminder|One survey reminder at 14 days
2491134|NCT02961036|Active Comparator|Group B reminders|Two survey reminders 14 days and 28 days
2491167|NCT02960581|Experimental|Group 1A|HIV-uninfected participants
3194506|NCT00828867|Experimental|Cohort 6|2000mg
3194507|NCT00828867|Experimental|Cohort 7|800mg with food
3194508|NCT00828867|Experimental|Cohort 8|3000mg
3194509|NCT00828867|Experimental|Cohort 9|4000mg
3194510|NCT00828880||DRX9000|
3194511|NCT00828906|Experimental|1|DuoTrav
3194512|NCT00828919|Experimental|Treatment|Patients continue the same treatment (axitinib monotherapy or in combination with crizotinib) as in prior axitinib study
3194513|NCT00828932|Experimental|Lorcaserin 10mg|
3194514|NCT00828971|Experimental|Arm 1|
3194515|NCT00828971|Active Comparator|Arm 2|
2490546|NCT02964637||Non-fluent variant PPA|Observational Study
2490547|NCT02964637||FTD-motor neuron disease|Observational Study
2490548|NCT02964637||Healthy controls|Observational Study
2490615|NCT02964429|Experimental|Diacap Pro High-Flux|1.3/ 1.6/ 1.9 sqm
3161192|NCT00438425|Experimental|Routine Portfolio|The portfolio dietary advice will conform to current therapeutic diets appropriate for hypercholesterolemic subjects (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal. Participants received 2 visits during a 6-month period with the study dietitian.
3161193|NCT00438425|Active Comparator|Control|Advice focused on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
3161194|NCT00438477|Experimental|Injection Methods|One injection site with radioactive tracer intraparenchymal/peritumoral (around the tumor), and other subareolar (around the nipple)
3161195|NCT00438516|No Intervention|1|Control group
3161196|NCT00438516|Experimental|2|Nurse home visitation
3161197|NCT00438555|Experimental|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
3161198|NCT00438555|Experimental|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
3161199|NCT00438555|No Intervention|Control group|control group, no intervention, medical follow up only
3161200|NCT00438568|Placebo Comparator|1|saline
3161201|NCT00438568|Experimental|2|10 Units
3161202|NCT00438568|Experimental|3|20 Units
2490754|NCT02963363|Experimental|Interventional|"Home-Based Adapted Physical Activity intervention during neoadjuvant chemotherapy :~150 minutes per week of aerobic and muscle strengthening exercises during 18 weeks"
2490780|NCT02963194|Experimental|Oxytocin|Oxytoxin nasal spray
2490786|NCT02963194|Placebo Comparator|Placebo|Placebo nasal spray
3194516|NCT00828997|Other|Prevenar vaccine|all participants are immunized with a dose of pneumococcal conjugate vaccine
3194517|NCT00829023|Experimental|betadine, DuraPrep, ChloraPrep|surgical skin preparation solution
2491329|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5a)|
2491330|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (5b)|
3161203|NCT00438594|No Intervention|Control group|Control group
3161204|NCT00438594|Experimental|Paraprofessional home visits|home visitation by Paraprofessional
3161205|NCT00438594|Experimental|Nurse home visits|home visitation by Nurse
3161206|NCT00438607|Other|1|BIIB014 at MTD from Part A
3161207|NCT00438607|Other|2|BIIB014 at dose immediately below MTD from Part A
3161208|NCT00438607|Placebo Comparator|3|
3161209|NCT00438698|Experimental|Low Glycemic Index Diet|Diet with low glycemic index carbohydrates
3161210|NCT00438698|Active Comparator|High Fiber Diet|Diet with high cereal fibre choices
3161211|NCT00438763||1|Subjects using the neoprene splint.
3161212|NCT00438763||2|Subjects using the orthoplast splint.
3161213|NCT00438776|Active Comparator|olanzapine|active zyprexa (olanzapine)
3161214|NCT00438776|Placebo Comparator|sugar pill|Placebo (fake pill)
3161215|NCT00438828|Experimental|Dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
3161216|NCT00438867|Experimental|1|
3161217|NCT00438867|Experimental|2|
3161218|NCT00438867|Placebo Comparator|3|
3161219|NCT00438893|Other|A portfolio of cholesterol-lowering foods|Dietary advice to consume a dietary portfolio of cholesterol-lowering foods
3161220|NCT00438919|Experimental|1|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
3161221|NCT00438958|Active Comparator|Arm I|Patients undergo filgrastim (G-CSF)-mobilized sibling donor peripheral blood SCT on day 0.
3161222|NCT00438958|Experimental|Arm II|Patients undergo G-CSF-mobilized sibling donor bone marrow transplantation on day 0.
3161223|NCT00438984|Experimental|Treatment (chemotherapy, immunosuppressive, lymphocytes)|"All patients receive high-dose cyclophosphamide IV on days -3 and -2 and autologous antigen-specific cytotoxic CD8+ T-lymphocyte clones IV over 30-60 minutes on day 0.~COHORT I: Beginning within 6 hours of T cell infusion, patients receive low-dose aldesleukin SC twice daily on days 0-14.~COHORT II: Beginning within 6 hours of T cell infusion, patients receive high-dose aldesleukin IV 3 times daily on days 0-5."
3161224|NCT00439036|Experimental|Behavior Therapy: Acceptance and Commitment Therapy|"The Act-ODT intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.~--------------------------------------------------------------------------------"
2490569|NCT02965001|Experimental|68Ga-NOTA-AE105|All participants have an uPAR-PET/CT scan performed before initiation of the routine radiotherapy
2490655|NCT02964052||Acute ischemic stroke patients|Acute ischemic stroke patients who received intravenous (IV) thrombolysis and/or intra-arterial (IA) recanalization treatment
3161225|NCT00439036|Active Comparator|Drug Counseling|The Drug Counseling intervention consists of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
3161226|NCT00439049||A|Cocaine Dependent Subjects
3161227|NCT00439075|Experimental|CPAP|positive airway pressure
2490735|NCT02963428|No Intervention|Standard of Care (SOC)|Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
2490737|NCT02963428|Experimental|Enhanced Care (EC)|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
2490793|NCT02963285||0 to 6 months|
2490798|NCT02963285||7 months to less than 1 year|
2490800|NCT02963285||1 to less than 2 years|
2490804|NCT02963285||2 to less than 6 years|
2490806|NCT02963285||6 to 12 years|
2490928|NCT02962401|Experimental|Idelalisib and Obinutuzumab|"6 cycles of Idelalisib and Obinutuzumab~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. (2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Obinutuzumab 1000mg I.V. day 1~Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
2491007|NCT02962037|No Intervention|Base line|the subject will take the tests in the morning and the evening
2491008|NCT02962037|Experimental|After treatment|the subject will take the tests in the morning and the evening
2491025|NCT02961569|Other|One open-label arm|Patients suspected of pulmonary TB will have sputum collection for acid fast bacilli by the classical strategy (Day 1, Day 2 and Day 3) and the intervention sputum collection for acid fast bacilli by the same day strategy (Hour 1, 2 and 3)
2491112|NCT02961192|Experimental|Collaborative|Participants will receive a wireless weight scale and a wearable activity tracker to monitor their weight and step counts. Additionally, participants will play a game designed with insights from behavioral economics. The game will involve points and levels. In this arm, participants will be placed into collaborative groups with one or two other participants to play the game.
2491140|NCT02961400|Experimental|PUSH text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE).
2491141|NCT02961400|Experimental|PULL text messages|Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant.
2491143|NCT02961400|Other|No text messages|No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE).
2491159|NCT02960828|Experimental|"Intervention-Device:_Laser"|"Subthreshold focal photocoagulation~Intravitreal Anti-vascular endothelial growth factor (Anti-VEGF) injection"
2491160|NCT02960828|No Intervention|Control|Contralateral eye
2491217|NCT02960477|Experimental|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain. Topics addressed during the educational sessions will include the characteristics of acute versus chronic pain; how pain becomes chronic (plasticity of the nervous system, modulation, modification, central sensitization, etc.); potential sustaining factors of central sensitization like emotions, stress, pain cognitions, and pain behaviour; the decision to have shoulder surgery; surgical experiences and environmental issues' effects on nerve sensitivity; recovery after shoulder surgery; scientific evidence for the PNE content; and the opportunity to reflect and write questions to ask the surgeon prior to surgery.
3161228|NCT00439075|Active Comparator|standard medical therapy|conventional oxygen therapy
2491220|NCT02960477|Active Comparator|Biomedical Education|A biomedical session covers the normal course of shoulder pain; anatomy, physiology and biomechanics of the shoulder; the expected course of postoperative shoulder pain; and the importance of self-care. Also, professional and leisure time activities will be discussed. Ergonomic advices will be given: e.g. how is the best way to catch a container, how I should move my shoulder in this sport/activity, what is a good work posture? The content of the biomedical education will be biomedically-/biomechanically-focussed.
3161229|NCT00439101|Experimental|1|
2491331|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6a)|
3161230|NCT00439101|Placebo Comparator|2|Placebo
3161231|NCT00439166|Experimental|1 AD combined doxycycline + rifampin|Doxycycline 100 mg b.i.d. plus rifampin 300 mg o.d. for 12 months.
3161232|NCT00439166|Experimental|2 AD Doxycycline only|Doxycycline 100 mg b.i.d. plus placebo matched to rifampin o.d. for 12 months.
3161233|NCT00439166|Experimental|3 Rifampin only|Rifampin 300 mg o.d. plus placebo matched to doxycycline b.i.d. for 12 months.
3161234|NCT00439166|Placebo Comparator|4 Double Placebo|Placebo matched to Doxycycline b.i.d. plus placebo matched to rifampin o.d. for 12 months.
3161235|NCT00439205||MDM + FastEEM4|Multispectral digital microscope (MDM) + FastEEM4 Systems
2490608|NCT02964572|Active Comparator|Glimepiride|Glimepiride (anti-diabetic drug) as a comparison group
2490610|NCT02964572|Experimental|Empagliflozin|Empagliflozin (anti-diabetic drug) as a study group
2490783|NCT02963168|Experimental|Oradoxel|To determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered once every 3 weeks, then to determine the MTD of Oradoxel (oral docetaxel and oral HM30181A) when administered for two days every three weeks.
2490949|NCT02962310|Experimental|Test|Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets 40 mg
2490955|NCT02962310|Active Comparator|Reference|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
2490989|NCT02961998|Experimental|Celecoxib group|Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
2490990|NCT02961998|Active Comparator|Control group|Patients take sorafenib only.
2491033|NCT02961582|Experimental|Sacral Neuromodulation|
2491036|NCT02961582|Other|Personalized Conservative Treatment|
2491097|NCT02961335|Experimental|Patient who need to undergo bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
2491151|NCT02960763|Experimental|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
2491152|NCT02960763|Experimental|Switch to Nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml.
2491200|NCT02960503|Active Comparator|Treatment arm (azithromycin)|Treatment arm: azithromycin 500 mg three times a week for 6 months
2491205|NCT02960503|Placebo Comparator|Placebo arm|Control arm: placebo three times a week for 6 months
2491257|NCT02960204|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (5 mg) twice a day.
2491258|NCT02960204|Active Comparator|Emricasan (25 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (25 mg) twice a day.
2491259|NCT02960204|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with emricasan (50 mg) twice a day.
2491260|NCT02960204|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension will be administered orally with a matching placebo twice a day.
2491332|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (6b)|
2491349|NCT02959788||Chest pain patients|All patients who present to the ED with chest pain.
2491368|NCT02959580|Experimental|medical|Hydrocortisone butyrate cream(0.1%) was applied to the breast by the patient twice a day on alternate days until the termination of treatment.
2491370|NCT02959580|Active Comparator|surgical|lesion extended excision
2491376|NCT02959697|Experimental|Subcut. + Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, with an added injection of local anesthetic (Xylocaine) beneath the conjunctiva of the lid being operated on. They will still receive the standard subcutaneous local anesthetic given during blepharoptosis repair.
2491379|NCT02959697|Sham Comparator|Subcut. + Sham Subconj. Injection|Patients will undergo standard blepharoptosis repair using an anterior approach, however they will not receive the additional subconjunctival Xylocaine injection. Instead, they will receive a sham injection of Normal Saline to prevent them from knowing which eye received the additional anesthetic.
2491391|NCT02959463|Experimental|Cohort 1 (hemithoracic radiation therapy, pembrolizumab)|Patients undergo hemithoracic radiation therapy. After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2491395|NCT02959463|Experimental|Cohort 2 (palliative radiation therapy, pembrolizumab)|Patients undergo palliative radiation therapy over 1-3 weeks to only the region of palliation (a region that does not include the entire side of the chest or thorax). After radiation therapy, patients receive pembrolizumab IV over about 30 minutes on day 1. Courses repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
2491400|NCT02959255|Active Comparator|10-day concomitant PAMC|40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 10 days
2491401|NCT02959255|Active Comparator|14-day concomitant PAMC|(40mg esomeprazole twice daily, 500mg clarithromycin twice daily, 1gr amoxicillin twice daily, and 500mg metronidazole twice daily for 14 days.
3161236|NCT00439257||Group 1|
3161237|NCT00439322||Group 1|
2491448|NCT02959099||Cases|Patients with acute coronary syndrome (ACS).
3161238|NCT00439348|Experimental|Electronic prescription|Patients receive a prescription for specific over-the-counter medications.
3161239|NCT00439348|Active Comparator|Verbal advice|
3161240|NCT00439361|Experimental|Bortezomib + ICE|"Bortezomib + ICE (Ifosfamide, Carboplatin, Etoposide):~Bortezomib 1.0 mg/m^2 intravenous (IV) over 5 Seconds on Days 1 and 4; + ICE (Ifosfamide 5 Gm/m^2 IV continuous infusion on Day 1, Carboplatin 5 AUC IV over 1 Hour Day 1, Etoposide 100 mg/m^2 IV over 2 Hours Days 1-3) + Mesna 5 mg/m^2 IV continuous infusion Day 1; 2 Gm/m^2 IV continuous infusion over 12 Hours."
3161241|NCT00439400|Active Comparator|A|
3161242|NCT00439400|Placebo Comparator|B|
3161243|NCT00439426|Experimental|1|
3161244|NCT00439439|Sham Comparator|A|Sham Procedure
3161245|NCT00439439|Active Comparator|B|Verum Beamer ablation of heterotopic gastric mucosa
3161246|NCT00439452|Active Comparator|Telemedicine-Based Collaborative Care|Telemedicine-Based Collaborative Care - Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
2490614|NCT02964143|Experimental|Experimental group|Patients from this group will be treated with a combination of platelet-rich plasma (PRP) and hyaluronic acid (HA) prepared with the Cellular Matrix / A-CP HA medical device
2490616|NCT02964143|Active Comparator|Control group 1|Patients from this group will be treated with a well-recognized hyaluronic acid named Ostenil® Plus
2490619|NCT02964143|Active Comparator|Control group 2|Patients from this group will be treated with PRP alone, prepared with RegenKit-BCT-1
2490718|NCT02963688||KGOG 3019|Korean women with HG serous and/or endometrioid epithelial ovarian cancer
2490740|NCT02963480||Sepsis|Patients, who developed postoperative sepsis
2490744|NCT02963480||SIRS|Patients, who developed postoperative SIRS
2490784|NCT02963259||SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system|Subjects will be implanted with SJM Infinity™ DBS IPG or a SJM Brio™ DBS IPG system
2490864|NCT02962856|Experimental|BAY987517|All subjects are patched with the same product.
2490939|NCT02962518|Active Comparator|A Standard Treatment|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months."
2490940|NCT02962518|Experimental|B Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and are additionally treated with a non-customized pressure device."
2490982|NCT02961855|Experimental|Clife1 gel (lidocaine plus diclofenac)|Clife1 gel (lidocaine plus diclofenac) Topical gel containing lidocaine (2%) plus diclofenac (0.5%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
2490983|NCT02961855|Active Comparator|Clife2 gel (lidocaine)|Clife2 gel (lidocaine) Topical gel containing lidocaine (2%) (15 g in total) Application of the gel bid from first day post-surgery to day 3 and once daily from day 4 to day 6
2491040|NCT02961647||Asymptomatic patients|Patients with asymptomatic severe mitral valve regurgitation not undergoing surgical repair of the valve.
2491041|NCT02961647||Symptomatic patients|Patients with symptomatic severe mitral valve regurgitation undergoing surgical repair of the valve.
3161247|NCT00439452|Active Comparator|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
3161248|NCT00439582|Experimental|1|
2491168|NCT02960581|Experimental|Group 1B|HIV-uninfected participants
2491170|NCT02960581|Experimental|Group 1C|HIV-uninfected participants
2491174|NCT02960581|Experimental|Group 2A|HIV-infected on ART, (<50 cp/ml)
2491176|NCT02960581|Experimental|Group 2B|HIV-infected on ART, (<50 cp/ml)
2491177|NCT02960581|Experimental|Group 2C|HIV-infected on ART, (<50 cp/ml)
2491178|NCT02960581|Experimental|Group 3A|HIV-Infected off ART (VL 2x10^3 - 1x10^5 cp/ml)
2491179|NCT02960581|Experimental|Group 3B|HIV-Infected off ART (VL 1x10^2 - 2x10^3 cp/ml)
2491180|NCT02960581|Experimental|Arm 1D|HIV-uninfected participants
2491183|NCT02960542|Experimental|Lifestyle Weight Loss|The Behavioral: HELP Prevent Cancer Intervention is a lifestyle intervention consisting of 24-weekly group meetings led by a community health worker and 3 individual sessions with a nutritionist/diabetes educator
2491290|NCT02960113|Experimental|scopolamine patch|Scopolamine patch will be placed on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery.
3161249|NCT00439582|Experimental|2|
2491295|NCT02960113|Experimental|acupressure point P6|Acupressure point P6 stimulation will be placed on the distal right forearm just above the crest of the wrist.
3161250|NCT00439595|Experimental|1|Hemocue 210 meter
2491300|NCT02960113|Experimental|scopolamine patch + acupressure point P6|Will receive both scopolamine patch and acupressure point P6 stimulation, as described above.
2491362|NCT02959645||Healthy control|Healthy Volunteers
2491423|NCT02959216|Experimental|Aerobic Exercise|Aerobic exercise participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during an initial treadmill test. Participants will be asked to exercise once a day up to 90% of their assigned HRT for a minimum of 20 minutes. Participants will wear a heart rate monitor to track their heart rate during aerobic exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
2491428|NCT02959216|Placebo Comparator|Stretching Exercise|Stretching exercise participants will receive a prescription to complete a standardized physical therapy stretching protocol once a day for approximately 20 minutes. Participants will wear a heart rate monitor to track their heart rate during the stretching exercise. The treatment will continue until the participant is recovered from his/her concussion, as determined by exercise tolerance and a normal symptom count and clinical examination.
3161251|NCT00439595|Experimental|2|Copack HBCS
3161252|NCT00439595|No Intervention|3|Control
3161253|NCT00439621|Experimental|1|
3161254|NCT00439621|Experimental|2|
3161255|NCT00439621|Experimental|3|
3161256|NCT00439621|Placebo Comparator|4|
3161257|NCT00439634|Placebo Comparator|Placebo|
3161258|NCT00439634|Experimental|AVE1625 dose level 1|
3161259|NCT00439634|Experimental|AVE1625 dose level 2|
3161260|NCT00439634|Experimental|AVE1625 dose level 3|
3161261|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(4)|vaccine dose of 1 X 10(4) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
3161262|NCT00439660|Experimental|rotavirus vaccine 116E 1 X 10(5)|vaccine dose of 1 X 10(5) focus-forming units (ffu) in three doses starting at 6 weeks : 4 weeks apart each dose
3161263|NCT00439686|Experimental|Single Arm|
3161264|NCT00439699|Experimental|Memantine|Tremor reduction
3161265|NCT00439712|Experimental|Treatment Group 1|
3161266|NCT00439712|Placebo Comparator|Treatment Group 2|
3161267|NCT00439751|Other|Immediate ADT|
3161268|NCT00439751|Other|Deferred ADT|
3161269|NCT00439764|Active Comparator|1|Routine clinical practice and talk on general health
3161270|NCT00439764|Active Comparator|2|Talk on back health and handout of The Back Book
3161271|NCT00439764|Active Comparator|3|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
2490678|NCT02963779|Experimental|LY2775240 (Part A)|Escalating oral doses of LY2775240 administered in healthy participants
2490684|NCT02963779|Experimental|LY2775240 (Part B)|Oral dose of LY2775240 in healthy participants
2490688|NCT02963779|Placebo Comparator|Placebo (Part A)|Placebo administered orally in healthy participants
2490691|NCT02963779|Active Comparator|Apremilast (Part B)|Oral dose of apremilast in healthy participants
2490751|NCT02963571|Experimental|screw fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw internal fixation.
2490837|NCT02963246|Experimental|Mindfulness group|Mindfulness intervention (12 months). Mindfulness based Cognitive Therapy is an evidence-based psychological program designed to help manage depressive and stress symptoms.
2490842|NCT02963246|No Intervention|Control Group|Treatment-as-usual control
2490957|NCT02962271||Psoriatic Arthritis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
2490960|NCT02962271||Psoriasis|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
2491108|NCT02961049|Active Comparator|Retraction and total-etch|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
2491113|NCT02961049|Active Comparator|No retraction and total-etch|Application of total-etch adhesive system: enamel and dentin etched with 35% phosphoric acid, wash, dry, two layers of primer/bond application with a brush and photoactivated for 20 seconds.
2491118|NCT02961049|Active Comparator|Retraction and self-conditioning|Gingival displacement with a gingival cord (#0, #00 or #000) prior to the restoration. Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
2491119|NCT02961049|Active Comparator|No retraction and self-conditioning|Application of self-conditioning adhesive system: selective enamel etched with 35% phosphoric acid, wash, dry, one layer of acid/pirmer on enamel and dentin with a brush, one layer of bond with a brush and photoactivated for 20 seconds.
2491182|NCT02960737|Experimental|Intervention group|Intensive training with oral screen (intervention group) and traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
2491190|NCT02960737|No Intervention|Control group|Traditional compensatory swallowing training under 3 months with start 6 (±2) weeks after stroke onset.
3161272|NCT00439803|Active Comparator|T1|
3161273|NCT00439803|Placebo Comparator|C1|
3161274|NCT00439803|Active Comparator|T2|
3161275|NCT00439803|Placebo Comparator|C2|
2491369|NCT02959762|Active Comparator|Low-Dose Vitamin K2 (45-mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
3161276|NCT00439803|Active Comparator|T3|
3161277|NCT00439803|Placebo Comparator|C3|
3161278|NCT00439803|Active Comparator|T4|
3161279|NCT00439803|Placebo Comparator|C4|
3161280|NCT00439816|Other|Arm 1|
3161281|NCT00439829|Experimental|1|Initiation of ovarian stimulation therapy on day 1 (i.e., first day of menses)
3161282|NCT00439829|Active Comparator|2|Initiation of ovarian stimulation therapy on day 4 (day 1= first day of menses)
3161283|NCT00439842|Experimental|HF group clinic appointments|HF group clinic appointments Heart failure multidisciplinary group clinic appointments (Arm 1 - HFcareGroup) includes 6 teaching sessions with patients led by nurse practitioner.
3161284|NCT00439842|No Intervention|Standard HF care|Standard HF care Standard heart failure education includes cardiologists instructions and hospital discharge information.
3161285|NCT00439868|Experimental|Treatment Group 1|Subjects in Period 1 of treatment group 1 will receive oral doses of extended release WELLBUTRIN XL tablets for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD. In Period 2 subject will receive placebo for 2 weeks.
3161286|NCT00439868|Experimental|Treatment Group 2|Subjects in Period 1 of Treatment group 2 will receive Placebo for 2 weeks and in Period 2 subject will receive oral doses of extended release WELLBUTRIN XL for 2 weeks, from Days 1-3 subject will receive 150 milligram (mg) tablets once daily (QD) and from Days 4-14 300 mg QD.
3161287|NCT00439894||blood draw|One time blood draw
3161288|NCT00439907|Active Comparator|End-to-end|End-to-end repair
3161289|NCT00439907|Active Comparator|Overlap|Overlap repair
3161290|NCT00439920|Experimental|High-dose anthracycline|
3161291|NCT00439972|Active Comparator|Group 1|Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R)
3161292|NCT00439972|Active Comparator|Group 2|Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
3161293|NCT00439972|Active Comparator|Group 3|Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R)
3161294|NCT00439972|Active Comparator|Group 4|Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R)
3161295|NCT00439972|Active Comparator|Group 5|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R)
3161296|NCT00439972|Active Comparator|Group 6|Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R)
3161297|NCT00439985|Other|Behavioral: Cognitive Behavior Therapy|
3161298|NCT00440024|Experimental|Cell A|Study controlled daily skin care regimen during 'rest period' consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
3161299|NCT00440024|Placebo Comparator|Cell B|Subject controlled normal skin care regimen during 'rest period, followed by study controlled daily skin care regime consisting of Dove Mild Cleanser, Dove Facial Moisturizer with SPF 15 followed by Tazorac
3161300|NCT00440102|Active Comparator|1|ketamine
3161301|NCT00440102|Active Comparator|2|Etomidate
3161302|NCT00440128|Active Comparator|Docetaxel|Docetaxel
3161303|NCT00440128|Experimental|Docetaxel/Casopitant|Docetaxel/Casopitant
3161304|NCT00440141|Experimental|1|
3161305|NCT00440141|Active Comparator|2|
2490719|NCT02963675||Group 1|Prostate cancer patients with bone metastases (mPC)
2490721|NCT02963675||Group 2|Castration-resistant prostate cancer patients with bone metastases (mCRPC)
2490747|NCT02963415|Experimental|Virtual Reality Cognitive Training|Exergame to stimulate cognition
2490802|NCT02963207|Experimental|Modified Sano's Classification|Modified Sano's Classification as described by Singh et al. 2013
2490807|NCT02963207|Active Comparator|NICE classification|NBI International Colorectal Endoscopic Classification as described by Hewett et al. 2012
2490867|NCT02962869|Experimental|BAY987517|All subjects are patched with the same product
2491037|NCT02961660|Experimental|Cohort 1 (Severe Renal Impairment): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
2491038|NCT02961660|Experimental|Cohort 2 (Normal Renal Function): Odalasvir|Participants will receive single oral dose of odalasvir 25 milligram (mg) under fed conditions (standard breakfast) on Day 1.
2491063|NCT02961348|Active Comparator|Early start of NOAC|Day 1 to day 4 after ischemic stroke onset
2491066|NCT02961348|Active Comparator|Late start of NOAC|Day 5 to day 10 after ischemic stroke onset
2491139|NCT02961023|Active Comparator|Training|15 patients are randomised to receive 15 weeks exercise therapy as per study protocol at point of study entry.
2491142|NCT02961023|Other|Control|15 patients are randomised to receive 15 weeks of standard care, acting as a control arm, followed by 15 weeks of exercise therapy.
2491184|NCT02960529||extra-peritoneal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic extra-peritoneal approach repair for inguinal hernia
2491191|NCT02960529||intraabdominal high ligation of hernia|the 150 patients were subjected trans-umbilical single-port laparoscopic intraabdominal approach repair for inguinal hernia
2491232|NCT02960373|Active Comparator|White Bread (Control)|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) at three study visits.
2491235|NCT02960373|Experimental|Dried Fruit - Glycemic Index|Participants will consume a test meal containing one variety of dried fruit (dose: 50g available carbohydrate) per visit for four visits. Varieties include raisins, sultanas, dates, and apricots.
2491242|NCT02960373|Experimental|Catalytic Fructose Dose Effect|Participants will consume a test meal containing white bread (dose: 50g available carbohydrate) and one variety of dried fruit (dose: 7g fructose) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
2491244|NCT02960373|Experimental|High GI Displacement Effect|Participants will consume a test meal containing white bread (dose: 25g available carbohydrate) and one variety of dried fruit (dose: 25g available carbohydrate) per visit for four visits. Varieties of dried fruit include: raisins, sultanas, dates, and apricots.
2491245|NCT02960243|Sham Comparator|Bilateral Thalamic Vim OFF|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2491247|NCT02960243|Experimental|Left Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2491248|NCT02960243|Experimental|Right Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2491251|NCT02960243|Experimental|Bilateral Thalamic Vim ON|"Participants with bilateral thalamic DBS will be tested four times over 90 minutes. The four tests will include the following in a randomized, double-blinded order:~First test: both stimulators on for 15 minutes Second test: left stimulator off, right stimulator on for 15 minutes Third test: left stimulator on, right stimulator off for 15 minutes Fourth test: both stimulators off for 15 minutes~In between switching to each test, there will be a 5 minute washout period."
2491305|NCT02959957|Experimental|Temocillin|Temocillin powder for solution för injection/infusion, per day 6 g (2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
2491309|NCT02959957|Active Comparator|Cefotaxime|Cefotaxime powder for solution för injection/infusion, per day 3-6 g (1-2 g three times per day). Treatment length 7-10 days of which at least 3 days administration with the study drug.
3161306|NCT00440154|Experimental|1|oral administration 5 mg breakfast timing
3161307|NCT00440154|Experimental|2|oral administration 25 mg breakfast timing
3161308|NCT00440154|Experimental|3|oral administration 50 mg breakfast timing
3161309|NCT00440154|Experimental|4|oral administration 100 mg breakfast timing
3161310|NCT00440154|Experimental|5|oral administration 25 mg dinner timing
3161311|NCT00440154|Placebo Comparator|6|oral administration
3161312|NCT00440154|Active Comparator|7|oral administration 10mg breakfast timing
3161313|NCT00440167|Active Comparator|Arm A|
3161314|NCT00440167|Active Comparator|Arm B|
3161315|NCT00440219|Experimental|Prednisone group|Prednisone 50 mg daily for 10 days immediately pre-op
3161316|NCT00440219|Placebo Comparator|Placebo group|Placebo pill for 10 days immediately pre-operative
3161317|NCT00440245|Other|salbutamol|There are two groups, asthma and COPD, which are being compared with respect to bronchoprotection from an active treatment (salbutamol).
3161318|NCT00440323|Experimental|ADBC sequence|In ADBC sequence A is Placebo, B is SB-649868 10 milligram (mg), C is SB-649868 30 mg, and D is Zolpidem 10 mg. Subject will receive placebo tablets, then two 5 mg tablets of SB-649868, then 25 mg and 5 mg tablet of SB-649868. There will be wash-out period of 7 days.
2490652|NCT02964065|Experimental|LAIV|a single dose of Live-Attenuated influenza Vaccine;Dose: 0.2 ml; Each dose contains not less than 6.9 lg EID50 of type A live attenuated influenza virus reassortants(H1N1 and H3N2), and not less than 6.4 lg EID50 of type B live attenuated influenza virus reassortants.
2490654|NCT02964065|Placebo Comparator|Placebo|a single dose of Placebo. Inactivated placebo will be identical to LAIV in appearance, ingredients and concentrations, attenuated influenza virus free.
2490683|NCT02963805|Experimental|High intensity physical activity (HIPA)|Participants attended high intensity vigorous activity after school clubs.
2490685|NCT02963805|Experimental|Fundamental movement skill (FMS)|Participants attended fundamental movement skill based after school clubs.
2490689|NCT02963805|Experimental|Physical activity signposting (PASS)|Participants attended educational physical activity signposting sessions during school hours.
2490692|NCT02963805|No Intervention|Control|Children in the control group received British Heart Foundation leaflets that included information on heart health (given to all groups). Children participated in their usual school curriculum including two hours of physical education and school sport per week, both within and beyond the curriculum.
2490749|NCT02963584|Experimental|intervention group|Patients in this group will receive CTO Choice (decision aid).
2490750|NCT02963584|No Intervention|control group|Patients in this group will receive usual primary care.
2490849|NCT02963220|Experimental|CBT-AR|There is only one arm in this study - all participants will be in the same arm, as all participants will receive CBT-AR. There is no control group.
3194518|NCT00829062|No Intervention|Glucose sensor|Children who have assented to wear a 72 hour physician ordered continuous glucose monitor.
3194519|NCT00829075|Experimental|I|only r-FSH TREATMENT
2490932|NCT02962258|Experimental|Test|Torrent's Olmesrtan Medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg
2490934|NCT02962258|Active Comparator|Reference|Tribenzor of Daichi Sankyo Inc., USA
2490969|NCT02962089|Placebo Comparator|Placebo|Isocaloric isonitrogenous placebo for 4 months (7g, twice daily)
2490971|NCT02962089|Active Comparator|Branched chain amino acids (BCAA)|BCAA mixture for 4 months (7g, twice daily)
3194520|NCT00829075|Experimental|II|only HP-hMG TREATMENT
3194521|NCT00829075|Experimental|III|r-FSH plus HP-hMG TREATMENT
2491189|NCT02960594|Experimental|Arm 1|2 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491194|NCT02960594|Experimental|Arm 2|8 mg INO-1400 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491198|NCT02960594|Experimental|Arm 3|2 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491202|NCT02960594|Experimental|Arm 4|2 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491204|NCT02960594|Experimental|Arm 5|8 mg INO-1400 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491209|NCT02960594|Experimental|Arm 6|8 mg INO-1400 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491211|NCT02960594|Experimental|Arm 7|2 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491214|NCT02960594|Experimental|Arm 8|8 mg INO-1401 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491218|NCT02960594|Experimental|Arm 9|8 mg INO-1401 + 0.5 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491221|NCT02960594|Experimental|Arm 10|8 mg INO-1401 + 2 mg INO-9012 delivered intramuscularly followed by electroporation at Day 0, Weeks 4, 8, and 12
2491253|NCT02960711|Experimental|METFORMIN (1700MG/DAY) + LIFESTYLE|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day) + participation in the life-style intervention activities
2491254|NCT02960711|Placebo Comparator|PLACEBO+ LIFESTYLE|Placebo: (two identical tablets) according to the blind assignment + participation in the life-style intervention activities
2491255|NCT02960711|Experimental|METFORMIN (1700 mg/day) alone|METFORMIN: 2 tablets per day, one at breakfast (or lunch) and one at dinner, of either metformin (two 850 mg tablets/day)
2491256|NCT02960711|Placebo Comparator|PLACEBO alone|Placebo: (two identical tablets) according to the blind assignment
2491294|NCT02959918|Experimental|SEL-037 Pegsiticase LD(low dose) alone|
2491296|NCT02959931|Experimental|High potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~2400 mg of dietary potassium.
2491301|NCT02959918|Experimental|SEL-037 Pegsiticase HD(high dose) alone|
2491302|NCT02959931|Active Comparator|Low potassium meal|In this arm individuals will be provided with a breakfast meal that provides ~540 mg of dietary potassium.
2491304|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (1a)|
2491306|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (1b)|
2491307|NCT02959918|Experimental|SEL-212, Pegsiticase LD & SEL-110 (2a)|
2491312|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (2b)|
2491316|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3a)|
2491323|NCT02959918|Experimental|SEL-212, Pegsiticase HD & SEL-110 (3b)|
3194522|NCT00829101||1 One-stage repair|A consecutive group of children born with unilateral cleft lip and palate from the south region of Sweden, in all 10 children, who have had a primary palatal surgery at 12 months of age.
3194523|NCT00829101||2 Two-stage repair, early closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 12 months of age.
3194524|NCT00829101||3 Two-stage repair, delayed closure|A consecutive group of children born with unilateral cleft lip and palate from the western region of Sweden, in all 10 children, who have have had a two-stage palatal surgery, with soft palate closure at 4-6 months and repair of the hard palate at 36 months of age.
3194525|NCT00829114|Active Comparator|1|ART/COC group
3194526|NCT00829114|Active Comparator|2|COC group
3194527|NCT00829127|Experimental|1|
3194528|NCT00829127|Placebo Comparator|2|
3194529|NCT00829140|Placebo Comparator|Placebo BID|
3194530|NCT00829140|Experimental|Lorcaserin 10mg BID|
3161319|NCT00440323|Experimental|BACD sequence|In BACD sequence subject will receive SB-649868 two tablets of 5 mg each (10 mg, B), Placebo tablets (A), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), and Zolpidem 10 mg (D). There will be wash-out period of 7 days.
2490944|NCT02962180|Experimental|single arm study|Dermabrasion with dermaroller of basal cell layer suspension obtained by soft trypsinisation in vitiligo lesion.
2491024|NCT02961803|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
2491026|NCT02961803|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
2491079|NCT02961309|Experimental|Active THC|5.6% THC via smoked marijuana cigarette
2491080|NCT02961309|Experimental|Placebo|Placebo THC via smoked cigarette
2491203|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2C|ccRCC molecular subgroup 2 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2491208|NCT02960906|Experimental|ccRCC molecular subgroup 2: 2B|"ccRCC molecular subgroup 2 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491210|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3B|"ccRCC molecular subgroup 3 -> randomisation: subjects with ccRCC1 treated with nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses then nivolumab 240mg IV every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~Starting from the Cycle 7 possibility to switch from nivolumab 240 mg every 2 weeks to 480 mg every 4 weeks according to the Investigator's preference."
2491213|NCT02960906|Experimental|ccRCC molecular subgroup 3: 3C|ccRCC molecular subgroup 3 -> randomisation: TKI (sunitinib 50mg daily or Pazopanib 800mg daily) according to investigator's choice until disease progression, unacceptable toxicity or other reasons specified in the protocol.
2491237|NCT02960269|Experimental|Telehealth team assessment|Team assessment for back pain with nurse practitioner and physical therapist via telehealth
3161320|NCT00440323|Experimental|CBDA sequence|In CBDA sequence subject will receive SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), SB-649868 two tablets of 5 mg each (10 mg, B), Zolpidem 10 mg (D) and Placebo tablet (A). There will be wash-out period of 7 days.
3161321|NCT00440323|Experimental|DCAB sequence|In DCAB sequence subject will receive Zolpidem 10 mg (D), SB-649868 two tablets of 25 mg and 5 mg (30 mg, C), Placebo tablet (A), and SB-649868 two tablets of 5 mg each (10 mg, B). There will be wash-out period of 7 days.
2491313|NCT02959879|Experimental|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
2491319|NCT02959879|Experimental|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient. Curative surgery for resectable pancreatic duct adenocarcinoma will be done after neoadjuvant chemotherapy. 8 cycles of adjuvant chemotherapy are administrated following the surgery
2491324|NCT02959879|Active Comparator|standard adjuvant chemotherapy|"Curative surgery for resectable pancreatic duct adenocarcinoma will be done after randomization.~12 cycles of standard adjuvant chemotherapy are administrated following the surgery"
2491374|NCT02959762|Active Comparator|High-Dose Vitamin K2 (90-mcg/d)|The high-dose vitamin K2 group will take two 45-mcg vitamin K2 softgel capsules every day for 8 weeks.
2491382|NCT02959606|Experimental|Sarpogrelate SR 300mg + ASA|"Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Anplone SR"
2491383|NCT02959606|Active Comparator|Clopidogrel + ASA|"Clopidogrel is administrated to patients with PAD for 6 weeks after EVT for femoro-popliteal regions.~Other Name: Plavix"
2491427|NCT02959281|Experimental|Hemodynamic data available|Providing caring physicians with hemodynamic variables measured using the NICAS system.
2491429|NCT02959281|No Intervention|Hemodynamic data not available|Hemodynamic variables measured using the NICAS system will not be provided to the caring physicians.
2491438|NCT02959060|Experimental|BMS-986177 and Rifampin|
2491457|NCT02958852|Active Comparator|Letrozole|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
2491465|NCT02958852|Experimental|Letrozole+Atorvastatin|Confirmed ER positive/HER2 negative metastatic breast cancer, including locally advanced stage IV disease, requiring systemic endocrine treatment, in this case letrozole, 2.5 mg daily, with the addition of atorvastatin, 40 mg daily until progression of disease. Upon progression of first line, patients will receive second line treatment using fulvestrant.
2491469|NCT02958852|Other|Fulvestrant|Fulvestrant will be used as second line endocrine treatment upon progression on first line with letrozole +/- atorvastatin.
2491481|NCT02958800|Experimental|Intervention|The intervention consists of assigning each participant to their own single patient open label trial consisting of a 1:1 randomized sequence of two pre-determined dose reductions of atypical antipsychotics for each participant in order to determine any behavioural issues that arise from atypical antipsychotic dose alteration.
2491503|NCT02958735|Experimental|Hard Exercise|Participants randomly assigned to this arm are made to maintain a heart rate equivalent to 80% of the heart rate observed when VO2 max was achieved in the maximal stress test from the first visit.
2491507|NCT02958657|Experimental|Exercise Training|Patients randomized to the training group will start the supervised regular training program 01 month after the myocardial infarction, and it will last for three months.
3161322|NCT00440362|Active Comparator|T1|
3161323|NCT00440362|Active Comparator|T2|
3161324|NCT00440362|Active Comparator|T3|
3161325|NCT00440362|Active Comparator|T4|
3161326|NCT00440362|Active Comparator|T5|
3161327|NCT00440362|Active Comparator|T6|
3161328|NCT00440362|Active Comparator|T7|
3161329|NCT00440362|Active Comparator|T8|
3161330|NCT00440362|Placebo Comparator|C1|
2490825|NCT02963142||Healthy controls|"Healthy volunteers who undergo bronchoscopy as part of a designated research bronchoscopy list.~Molecular laboratory techniques will be applied to bronchoalveolar lavage samples."
2490863|NCT02962830|Experimental|Sufentanil|
2490954|NCT02962531|Experimental|Treatment A|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fasted conditions
2490958|NCT02962531|Experimental|Treatment B|A single 1600 mg (4 x 400 caplets) oral dose of IX-01 under fed conditions
2490961|NCT02962531|Experimental|Treatment C|A single 1600 mg aqueous dispersion (20 mL) oral dose of IX-01 under fasted conditions.
2490970|NCT02961907|No Intervention|Control|"The usual routine course includes :~a clinico-biological evaluation of infertility causes~a laboratory staff and decision of therapeutic strategy and decision of a therapeutic strategy~collection of blood and sperm samples"
2490972|NCT02961907|Experimental|PEPCI group|In the PEPCI group, the standardized assessment of the periconceptional profile is used to adapt the additional standardized intervention.
2490994|NCT02961777||Time 1|retrospective evaluation of patient record. no intervention
2490996|NCT02961777||Time 2|retrospective evaluation of patient record. no intervention
2490999|NCT02961777||Time 3|retrospective evaluation of patient record. no intervention
2491043|NCT02961595|No Intervention|Inactivated Polio Vaccine (IPV)|The control group received inactivated poliovirus vaccine (IPV) at the age of 6 and 12 months according to the national immunization protocol in Finland at that time.
2491044|NCT02961595|Active Comparator|Oral Polio Vaccine (OPV)|Intervention group were given doses of oral polio vaccine OPV (Polio Sabin®) at the age of 2, 3, 6 and 12 months.
2491085|NCT02961270|Experimental|icotinib|patients will be administered study drug (icotinib) until disease progression or unacceptable toxicity
2491206|NCT02960815|Experimental|Imiquimod and intramuscular vaccine|In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
2491238|NCT02960282||Ancillary-Correlative (gut microbiome analysis)|Patients undergo collection of fecal specimens at baseline, prior to start of each course of chemotherapy or immunotherapy, at the end of weeks 2, 4, 6, and 8, at the end of course 3 and courses thereafter of chemotherapy or immunotherapy, and at the time of disease progression or going off-treatment. Fecal specimens are analyzed via 16S ribosomal RNA gene sequencing, meta-transcriptomics analysis, and meta-proteomics analysis.
2491262|NCT02960165|Experimental|Virtual interface group A|Older adults that started the practice on the virtual interface
2491265|NCT02960165|Experimental|Virtual interface group B|Older adults that started the practice on the virtual interface and then practiced on real task.
2491268|NCT02960165|Active Comparator|Real interface group A|Older adults that started the practice on the virtual interface
2491270|NCT02960165|Active Comparator|Real interface group B|Older adults that started the practice on the real interface and then practiced on virtual task.
3194531|NCT00829153|Experimental|U clip|Anastomosis with U clips
3194532|NCT00829153|Active Comparator|2|Prolene anastomosis
3194533|NCT00829192|Experimental|1|Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months
3194534|NCT00829192|Placebo Comparator|2|Placebo implant administered subcutaneously every 60 days for 24 months
2491358|NCT02959528|Active Comparator|Control|ADHD group treated with visual-perceptual training
2491361|NCT02959528|Experimental|Experiment|ADHD group treated with working memory training
2491387|NCT02959736||National Rehabilitation Hospital Dublin|Music Therapy (MATADOC)
2491389|NCT02959736||Spectrum|Music Therapy (MATADOC)
2491393|NCT02959736||Royal Hospital for Neuro-disability London|Music Therapy (MATADOC)
2491431|NCT02959411|Experimental|Tolvaptan|Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
2491434|NCT02959411|Active Comparator|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients with acute decompensated heart failure
2491462|NCT02959047|Experimental|Alirocumab|Alirocumab 150mg SQ every 2 weeks
2491463|NCT02958917|Active Comparator|Placebo|The placebo will be visually similar to pirfenidone.
2491468|NCT02959047|Placebo Comparator|Placebo|Matched placebo
2491475|NCT02958839||Recurrence Group|In the case control trial, patients who have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
2491477|NCT02958839||Non-recurrence Group|In the case control trial, patients who do not have any episode of atrial fibrillation/atrial flutter/atrial tachycardia after a blanking period of 3 months from the catheter ablation procedure will be assign to the recurrence group
3194535|NCT00829218|Active Comparator|1 - Glutamate challenge|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 1 is the 5 grams of glutamate which will be given in a mixed juice.
3194536|NCT00829218|Placebo Comparator|2- Placebo|Glutamate challenge: After the one month glutamate free diet, subjects will receive 5 grams of glutamate for three days on one week and placebo for three days on the next week. Arm 2 is the placebo arm, which will be juice with nothing added.
2491523|NCT02958540|Experimental|SynGEM low dose|Group 1: 18 subjects receiving SynGEM low dose
3194537|NCT00829231|Experimental|Arm 1|
3194538|NCT00829231|Experimental|Arm 2|
3194539|NCT00829231|Experimental|Arm 3|
3194540|NCT00829257|Experimental|Fine particle steroid inhaler|HFA-BDP plus Fluticasone/Salmeterol Combination
3194541|NCT00829257|Active Comparator|Coarse Particle Inhaler|FP plus Fluticasone/Salmeterol combination
3194542|NCT00829270||mitochondrial diseases diagnosis|
3194543|NCT00829322|Experimental|Treatment group|
3194544|NCT00829322|Placebo Comparator|Control group|
2490830|NCT02963116|Experimental|Treatment B|10 mg rosuvastatin tablet + 200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
2490831|NCT02963116|Experimental|Treatment C|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fasting state)
2490835|NCT02963116|Experimental|Treatment D|200 mg of AZD5718 oral suspension 50 mg/mL (fasting state)
2490839|NCT02963116|Experimental|Treatment E|200 mg of AZD5718 IR tablet (2 x 100 mg tablet) (fed state)
2490862|NCT02962700|Experimental|CVVHF|CVVHF for 48 h interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
2490875|NCT02962700|Active Comparator|IHD for 4 hours|"Intermittent haemodialysis was carried out during the first 4 h at day 1 and day 2 of the study period.~Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis."
2490923|NCT02962440|Experimental|Somapacitan|
2491009|NCT02962154||Coronary Artery Disease (CAD)|"Patients with known coronary artery disease (CAD) as defined by prior PCI, CABG, prior MI, prior abnormal stress test, or invasive coronary angiography (ICA) and who are hemodynamically stable~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
2491010|NCT02962154||Major Depressive Disorder|"Patients with a diagnosis of major depressive disorder and/or a diagnosis of bipolar 1 or bipolar 2 disorder~They will undergo the following:~Radiation: Coronary CT Angiography Other: Mood Symptom Scale Other: Anxiety Symptom Scale Other: Chronic Stress Inventories Other: Psychosocial Function Questionnaires Other: General Health and quality of life questionnaires Other: Magnetic Resonance Imaging"
2491034|NCT02961465||Sacral Neuromodulation (SNM)|
3208730|NCT00977587|Active Comparator|Saccharomyces Cerevisiae CNCM I-3856|2 weeks of treatment with Saccharomyces Cerevisiae CNCM I-3856 1 capsule twice a day, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).
2491144|NCT02960984|Experimental|Neurorehabilitation|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training on an ergometer and 30' of task-oriented training focused on uppper limb rehabilitation.
2491147|NCT02960984|No Intervention|Baseline|No intervention is planned
2491195|NCT02960607|Experimental|Icotinib|250mg, tid until disease progression or unacceptable toxicities occurred
2491207|NCT02960646|Experimental|Treatment (peripheral blood stem cell transplantation)|Patients receive melphalan IV over 30 minutes on day -6 and fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo TBI on day -2 and CD45RA depleted peripheral blood stem cell transplantation on day 0. Patients also receive cyclophosphamide IV over 3 hours on days 3-4. Beginning on day 5, patients receive tacrolimus IV for 2 weeks and PO for at least 4 months. Beginning on day 7, patients receive filgrastim SC daily. Patients with CD20 positive lymphoma may receive rituximab IV on days -13, -6, 1, and 8.
2491241|NCT02960256||Patients admitted to an internal medicine department due to an|
2491276|NCT02960074|Experimental|Non-antibiotics Arm|The first 10 patients will not receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
2491277|NCT02960074|Experimental|Antibiotics Arm|An additional 5 patients will receive antibiotics prior to receiving the investigational agent, which consists of screened-donor inoculum of a biologically active human substance (FMT). We will give oral frozen FMT over 2 days.
2491360|NCT02959502|Experimental|Receive tDCS + CR|Receive tDCS+CR: Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
2491363|NCT02959502|Experimental|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
2491388|NCT02959476|Experimental|Ropivacaine 0.2%|"Naropin® (ropivacaine HCl Injection, USP) bolus + Ropivacaine 0.2% Pre-Filled Dispenser infusion - Ropivacaine Infusion treatment arm"
2491392|NCT02959476|Placebo Comparator|Placebo|"Naropin® (ropivacaine HCl Injection, USP) bolus + placebo infusion (normal saline) - Placebo treatment arm"
2491398|NCT02959450|Experimental|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP.
2491399|NCT02959450|No Intervention|Control Group|Standard treatment consisting of a modified consistency diet with adequate intake of energy and protein and general recommendations on diet prescribed by the treating physician
2491414|NCT02959359|Other|DAA treatment arm|Active DAA treatment ('Ledipasvir 90mg/Sofosbuvir 400 mg plus Ribavirin' ) for HCV-HCC patients after curative resection or ablation.
2491432|NCT02959151|Experimental|CAR-T for liver cancer|A single dose of CART cells will be administered by vascular interventional therapy or by intra-tumor injection with a dose of （1.25~4）×107 CAR positive T cells/cm3 tumor bulk. The volume of cell products and the time of cell perfusion process lasted would depend on the ways of cell perfused. And an interventional radiologist would operate the cell infusion.
2492261|NCT02954120||(PCOS+CP+)|PCOS participants with CP
2490856|NCT02962661|Experimental|Arm I (hMSCs IV)|Patients receive hMSCs IV over 10-20 minutes on days 1, 14, 21, and 28 and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
2490857|NCT02962661|Experimental|Arm II (hMSCs transendocardially)|Patients receive hMSCs transendocardially for a total of 15 injections and standard of care treatment for heart failure in the absence of disease progression or unacceptable toxicity.
2490858|NCT02962661|Active Comparator|Arm III (standard of care)|Patients receive standard of care treatment for heart failure.
2490924|NCT02962388|Active Comparator|Reference therapy arm|Best Available Therapy (BAT) in second line, after hydroxyurea. BAT restricted to anagrelide or IFNα/ PegIFNα in the study, according to the investigator decision
2490926|NCT02962388|Experimental|Investigational therapy arm|"Ruxolitinib JAKAVI® Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing paradigm.~Maximum dose 25 mg BID."
2491004|NCT02962024|Active Comparator|morphine sulphate|10mg locally morphine hydrochloride once betwwen serratus muscle and latissmus dorsi muscle
2491006|NCT02962024|Placebo Comparator|bupivacaine hydrochloride|0.25%locally bupivacaine hydrochloride once
2491054|NCT02961543|Experimental|Group 1.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isokinetic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2491058|NCT02961543|Active Comparator|Group 2.|"The participants randomly allocated to this arm will undergo a muscular rehabilitation program based on the isotonic eccentric exercise for the extensor muscles of the operated knee.~The contralateral non-operated lower limb will be used as control, so it will not undergo any muscular rehabilitation program."
2491095|NCT02961140|Experimental|Cardiac Output Maximization|maximize stroke volume, and maintain cardiac index and stroke volume variation during the whole operation
2491105|NCT02961140|Active Comparator|Cardiac Output Normalization|keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation
2491227|NCT02960386|Other|Machine Learning Algorithm|Single group participants that will use the algorithm to be engaged in using their fitness tracker.
2491261|NCT02960178|Experimental|Perturbation-based training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. While practicing these tasks, the trainer will apply pushes and pulls to the harness at unexpected times, causing a reactive step to be practiced.
2491266|NCT02960178|Active Comparator|Conventional walking training|Participants will practice standing and walking activities while secured in an overhead harness attached to an overhead track. No external perturbations will be applied.
2491293|NCT02960139|Experimental|Test- Treatment with Sylys Surgical Sealant|Standard closure plus treatment with Sylys Surgical Sealant
2491299|NCT02960139|No Intervention|Control- Standard of Care|Control group is standard closure of anastomosis.
2491318|NCT02959905|Experimental|medium dose of preparative regimen|Patients will receive medium dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
2491321|NCT02959905|Experimental|low dose of preparative regimen|Patients will receive low dose of lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by TSA-CTL.
2491325|NCT02959905|Experimental|no preparative regimen|Patients will only receive TSA-CTL.
2491375|NCT02959567|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
2491380|NCT02959554|Experimental|Nivolumab (A)|Nivolumab: 240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
2491381|NCT02959554|Active Comparator|TKI (B)|Sunitinib: According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study) or Pazopanib: According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study)
2491402|NCT02959229|Experimental|Early Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 1 of life and continued for 4-6 weeks.
2491404|NCT02959229|Experimental|Late Lactoferrin Group|Oral Bovine Lactoferrin 100 mg/day once starting on day 3 of life and continued for 4-6 weeks.
2491405|NCT02959229|Active Comparator|Placebo Group|placebo in form of distilled water once starting on day 1 of life and continued for 4-6 weeks.
2491415|NCT02959294|Experimental|Centricyte 1000|Autologous AD-tSVF via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
2491416|NCT02959294|Experimental|Sterile Normal Saline|Re-suspension of AD-cSVF pellet in Normal Saline deployment via IV
2491418|NCT02959372|Experimental|lung ultrasound group|lung ultrasound results
2491422|NCT02959372|Placebo Comparator|control group|The attending physician will not have the result of the lung ultrasound
2491445|NCT02959008||normal|Human without hypertension, diabetes, anemia, liver disease and kidney disease. The group will measure TOI and BP.
2491446|NCT02959008||hypertension|"Human only have hypertension, without diabetes, anemia, liver disease and kidney disease.~Hypertension group will measure TOI and BP."
2491460|NCT02958878|Experimental|A|Tamsulosin 0.4mg given the night before surgery and another dose the day of surgery in the morning.
2491470|NCT02958878|Placebo Comparator|B|Placebo medication given the night before surgery and another dose the day of surgery in the morning
2491494|NCT02958748||ARDS|Patients admitted to ICU with diagnosis of ARDS,which happened in 48hours.
2491498|NCT02958748||Control|Heathy vonlunteers
2491508|NCT02958657|No Intervention|Control Group|Patients in the control group will receive general instructions regarding rehabilitation post-acute myocardial infarction and will be followed for four months after the myocardial infarction.
2491525|NCT02958540|Experimental|SynGEM high dose|Group 2: 18 subjects receiving SynGEM high dose
2490878|NCT02962791|Active Comparator|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy implantation wil be done as usual. Standard Echocardiography will be done at one year
2490973|NCT02962141|Experimental|APERTO OTW group|in the APERTO OTW group the subject will be treated with APERTO OTW balloon (Paclitaxel Releasing Peripheral Balloon Dilatation Catheter)
2490975|NCT02962141|Active Comparator|OHICHO II group|in the OHICHO II group the subject will be treated with OHICHO II balloon (Balloon Dilatation Catheter)
2491045|NCT02961673|Experimental|HU-014 Inj(Phase 1 and 2)|HU-014 Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2491049|NCT02961673|Active Comparator|Botox Inj(Phase 2)|Botox Inj was given an injection to 5 glabellar lines each 4 U/0.1ml (Total 20 U/0.5ml, IM)
2491088|NCT02961283|Experimental|ASN003 Dose Escalation|Multiple ascending doses of ASN003 will be administered to determine the maximum tolerated dose (MTD).
2491099|NCT02961283|Experimental|ASN003 MTD - BRAFv600 melanoma|ASN003 administered at the MTD in subjects with BRAF v600 mutated metastatic melanoma
2491111|NCT02961283|Experimental|ASN003 MTD - BRAFv600 colon or lung cancer|ASN003 administered at the MTD in subjects with BRAFv600 mutated metastatic colorectal or non-small cell lung cancer.
2491116|NCT02961283|Experimental|ASN003 MTD - PIK3 pathway mutated cancers|ASN003 administered at the MTD in subjects who have mutations in PI3 kinase or loss of PTEN.
2491165|NCT02960789|Experimental|Dehydrated Children|"Children between the ages of 2 to 18 years of age presenting to the Emergency Department at Children's Hospital Boston with complaints such as Dehydration, Gastroenteritis, Vomiting, and or Intolerance of POs be approached by study personnel for possible participation in the study.~Interventions:~Undertake and record a formalized clinical assessment of hydration status~Take a measurement of body weight on calibrated scales~RF wristband hydration status measurement~Measure capillary refill time with manual stopwatch~CRT device hydration status measurement"
2491229|NCT02960412|Experimental|furosemide|furosemide 10mg (1mL) IV push for one dose
2491231|NCT02960412|Placebo Comparator|placebo|normal saline 1mL IV push for one dose
2491263|NCT02960152||Anorexia Nervosa|interview and periodontal full-mouth examination
2491264|NCT02960152||Bulimia Nervosa|interview and periodontal full-mouth examination
2491269|NCT02960152||Control|interview and periodontal full-mouth examination
2491310|NCT02960009|Experimental|Anode HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
2491317|NCT02960009|Experimental|Cathode HD-tDCS|The center cathode is fixed on the contralesional primary motor cortex and the 4 surrounding anode electrodes will be placed about 6 cm to the center.
2491322|NCT02960009|Placebo Comparator|Sham HD-tDCS|The center anode is fixed on the ipsilesional primary motor cortex and the 4 surrounding cathode electrodes will be placed about 6 cm to the center.
2491354|NCT02959710|Experimental|Group 1|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2491355|NCT02959710|Experimental|Group 2|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2491356|NCT02959710|Experimental|Group 3|AC-1204 mixed in water, AC-1202 mixed in water, AC-1202 mixed in Ensure®
2491366|NCT02959593|Experimental|Glaucoma patients|To view commercially available content through the VISIOR video goggles for thirty minutes
2491372|NCT02959593|Experimental|Healthy subjects|To view commercially available content through the VISIOR video goggles for thirty minutes.
2491408|NCT02959398|Active Comparator|standard mammography|standard mammography
2491410|NCT02959398|Experimental|standard mammography and tomosynthesis|standard mammography and tomosynthesis
2491419|NCT02959385|Experimental|Definitive Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day."
2491424|NCT02959385|Active Comparator|Neoadjuvant Radiochemotherapy|"Concurrent Radiochemotherapy:~Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later."
2491425|NCT02959333|Experimental|hAEC treatment|hAEC: human amniotic epithelial cells 3-5*10^7 /5 ml
2491459|NCT02959021|Active Comparator|Self-directed treatment|Participants randomly assigned to this arm will receive written and pre-recorded behavioral weight loss intervention materials (i.e., DVDs, online videos), and they will be instructed to work through the materials independently at their own pace. They will have continued physician contact as needed for routine medical care.
3161331|NCT00440362|Placebo Comparator|C2|
2491472|NCT02959021|Experimental|Peer coach treatment|Participants randomly assigned to this arm will receive a combination of in-person, group-based behavioral weight loss sessions plus individual, telephone contacts. Groups and phone calls will be facilitated by a peer coach interventionist. Similar to the self-directed condition, participants will receive written and pre-recorded intervention materials (i.e., DVDs, online videos). They will also have continued contact with their physician for routine medical care.
3161332|NCT00440362|Placebo Comparator|C3|
3161333|NCT00440362|Placebo Comparator|C4|
3161334|NCT00440414|Experimental|1|Alimta
3161335|NCT00440414|Experimental|2|Tarceva
2491482|NCT02958813|Experimental|IMARA|IMARA blends three programs with the most relevance for AA women (SISTA) and girls (SiHLE) and families in psychiatric care (Project STYLE). Separate mother and daughter groups cover parallel content and run simultaneously, and joint activities enhance mothers' credibility as a resource for HIV/STI prevention, practice new communication skills, negotiate conflict, and strengthen the mother-daughter relationship. Activities reinforce the reciprocal impact of mothers and daughters, and enhance safe sex knowledge, attitudes, and skills. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
3161336|NCT00440440|Active Comparator|1|testosterone gel
3161337|NCT00440440|Placebo Comparator|2|placebo gel
3161338|NCT00440453|No Intervention|1|Normal hospital food
3161339|NCT00440453|Experimental|2|Nutritional treatment
3161340|NCT00440479||001|Bortezomib dose as determined (observational study) by treating physician
3161341|NCT00440544|Experimental|1|100 ug H1 antigen alone in BCG naive subjects
3161342|NCT00440544|Experimental|2|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
2490938|NCT02962492|Placebo Comparator|Placebo Arm:|dapagliflozin placebo (oral tablet) and exenatide (5µg acutely)/Exenatide extended release (long term) placebo (subcutaneous injection)
2490941|NCT02962492|Active Comparator|Exenatide extended release & dapagliflozin Arm:|Exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin 10mg
2491000|NCT02961842|Experimental|Combination|500 mL colloid preload and 500 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
2491003|NCT02961842|Active Comparator|Coload|1000 mL crystalloid coload. Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). Ultrasound assessment of the Inferior vena cava diameter. Intravenous ephedrine will be administered.
2491171|NCT02960698|Active Comparator|TREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
2491172|NCT02960698|Active Comparator|UNTREATED PATIENT WITH TOURETTE SYNDROME|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 40 patients
2491175|NCT02960698|Placebo Comparator|Healthy volunteers|comportemental tasks included impulsivity tests will performed at V1 Resting state IRM will be performed at V2 80 subjects
2491239|NCT02960399|Experimental|Antibody Deficient Patients|Zostavax® vaccine administered to antibody deficient patients 60 years of age and older.
2491243|NCT02960399|Active Comparator|Healthy Subjects|Zostavax® vaccine administered per standard of care to healthy adults 60 years of age and older.
2491272|NCT02960048|Active Comparator|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
2491273|NCT02960048|Experimental|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
3194545|NCT00829335||HCC patients|According with the investigators previously reported selection flow-chart , patients suitable for surgical approach were those with HCC without ascites, without or with esophageal varices for which preoperative endoscopic eradication could be carried out successfully, and with serum bilirubin level lower than 1.5 mg/dl. Potential candidates to systematic segmental or subsegmental resection by IOUS-guided finger compression were considered patients with single HCC located in one or 2 adjacent segments without portal thrombosis, and anyway not demanding for its complete removal a sectional resection or wider.
3194546|NCT00829348|No Intervention|Statins, counseling|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
3194547|NCT00829348|Experimental|Statins, Counselling, SMS|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
3194548|NCT00829361|Other|Telemedicine|
3194549|NCT00829374|Experimental|1|Dimebon, 5 mg orally three times daily
2491396|NCT02959489|Active Comparator|Amyloid Brain Imaging Non-Disclosure|Subjects will receive their Alzheimer's disease (AD) risk assessment based on age, gender, family history and ancestry.
2491397|NCT02959489|Experimental|Amyloid Brain Imaging Disclosure|"Subjects will receive both their elevated or not elevated amyloid neuroimaging results based on their brain scan interpretation and Alzheimer's disease (AD) risk disclosure. The AD risk assessment is based on age, gender, family history and ancestry."
2491435|NCT02959112|Active Comparator|Epinephrine sprayed on the papilla and rectal indomethacin|Epinephrine 1 mg/1 mL + 9 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
2491437|NCT02959112|Placebo Comparator|Sterile water sprayed on the papilla and rectal indomethacin|10 mL of sterile water are sprayed on the papilla at the end of the endoscopic retrograde cholangiopancreatography and 100 mg of indomethacin rectal suppository is administered at the beginning of the procedure
3194550|NCT00829374|Experimental|2|Dimebon, 20 mg orally three times daily
3194551|NCT00829374|Placebo Comparator|3|Placebo orally three times daily
3194552|NCT00829400|Experimental|Posit Science|Brain Fitness, Insight, and Aristotle Cognitive Software Training Suites Targeting 100 hours of training
2491485|NCT02958813|Placebo Comparator|FUEL|FUEL Health Promotion Control combines two programs, FUEL and Project Balance Health Promotion. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. FUEL™ does not explicitly address HIV/STI prevention. Investigators will present information from Balance's session about HIV/AIDS, condoms, and other STIs. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
3194553|NCT00829400|Active Comparator|Nintendo Brain Age|Brain Age 2 Nintendo DS Portable Device for home or office use, targeting 100 hours of training
3194554|NCT00829465|Active Comparator|control|
2491509|NCT02958644|Experimental|Synbiotics|Synbiotics - 12g / day fructo-oligosaccharide and probiotics supplemented orally for 90 days.
2491530|NCT02958605|Experimental|Smartphone|Smartphone application
3194555|NCT00829465|Experimental|therapy|
3194556|NCT00829478|Placebo Comparator|1|Usual Care
2490959|NCT02962245|Placebo Comparator|regular treatment group|regular treatment untill recurrence in one year
3194557|NCT00829478|Experimental|2|Intervention
3194558|NCT00829517|Active Comparator|STI kiosk|computer-assisted provision of screening for chlamydia
2491074|NCT02961439||Patient Participants|Patient participants are adult patients in the Epworth Richmond Intensive care Unit. They are not the focus of the research but rather represent a general population of ICU patients that require echocardiography in the management of their critical illness. They will be a mix of medical and surgical patients some of whom are receiving mechanical ventilation, have movement restrictions, high BMI or other impediments to performing echocardiography.
2491075|NCT02961439||Registrar Participants|Registrar participants are doctors in training in ICU. They have completed a formal echo teaching program and completed a logbook of 30 supervised scans. They are the focus of the research and are being assessed on their diagnostic accuracy with echocardiography.
2491136|NCT02961010|Experimental|Intervention Group|The intervention group will receive the Keeping Safe programme between 2016 and 2018. This comprises a blended package of continuing professional development training and support (plus resource materials) for teachers and school staff to enable them teach sensitive preventative education concepts through the formal statutory Personal Development curriculum, and all other informal opportunities that present in the daily life of the school. Following randomisation, intervention schools will receive the package of training and support across a 3 month period and will then implement/teach in their school across 2 school years. The intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
2491138|NCT02961010|No Intervention|Wait-list Control Group|The Wait List Control group will continue with standard practice of teaching the statutory Personal Development curriculum between 2016 and 2018. They will not receive the Keeping Safe intervention until Sept 2018 following completion of the evaluation. The Waitlist control intervention group will collect outcome data for the evaluation between March 2016 and June 2018.
2491162|NCT02960724|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before surgery and compared with the histological findings to evaluate uPAR PET/CT in staging of oral cancer and oropharyngeal cancer.
2491224|NCT02960464|Active Comparator|Active Arm|Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.
2491225|NCT02960464|Sham Comparator|Sham Arm|Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.
3194559|NCT00829517|Experimental|contraceptive kiosk|computer-assisted provision of hormonal contraception
3194560|NCT00829543|Experimental|sacroiliac injection|an open label study designed to evaluate the efficacy and safety of guide-free sacroiliac injection in refractory sacroiliac pain due to spondyloarthropathies
2491286|NCT02960126|Active Comparator|Intervention: Clopidogrel|Case management with clopidogrel 75mg once daily is provided for stroke prevention in AF patient.
2491289|NCT02960126|Experimental|Control: Aspirin|Usual care with aspirin 100mg once daily is provided for stroke prevention in AF patient.
2491351|NCT02959775|Experimental|60 µg dose hepatitis B vaccine|Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6
2491352|NCT02959775|Experimental|20 µg dose hepatitis B vaccine|Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6
2491353|NCT02959775|No Intervention|Control|Receive no vaccination during the study period
2491386|NCT02959541|Other|Calciumfolinat 60 mg/m²|Intravenous infusion of Calciumfolinat 60 mg/m²given to patients with colon cancer at the time for the operation of the colon cancer.
2491390|NCT02959541|Other|Calciumfolinat 200 mg/m²|Intravenous infusion of Calciumfolinat 200 mg/m² given to patients with colon cancer at the time for the operation of the colon cancer.
2491394|NCT02959541|Other|Calciumfolinat 500 mg/ m²|Intravenous infusion of Calciumfolinat 500 mg/ m² given to patients with colon cancer at the time for the operation of the colon cancer.
3194561|NCT00829556|Experimental|1|
3194562|NCT00829556|No Intervention|2|Standard Surgical skin preparation
3194563|NCT00829569|Experimental|Intralipid with/without Omegaven|Lipid infusion with/without marine n-3 fatty acids
3194564|NCT00829582|Experimental|ETI-204|ETI-204, Anthim
3194565|NCT00829582|Sham Comparator|placebo|
3194566|NCT00829595|Experimental|1|IBD, on both an anti-TNF agent and an immunomodulator
3194567|NCT00829595|Experimental|2|IBD, not on any immunosuppressive medications
3194568|NCT00829595|Active Comparator|3|Healthy, non-IBD, not on immunosuppressive medications (control arm)
3194569|NCT00829608|Experimental|Human Papillomavirus Vaccine|There are 9 participants currently being followed in the faculty sponsor's clinic that carry the clinical and histologic diagnosis of RRP. The 9 participants meet one or more of the following criteria: Surgery requirement of more than 4 procedures per year, distal multisite spread of disease, and rapid regrowth of papilloma disease with airway compromise.
3194570|NCT00829634|Other|l-methamphetamine|
3194571|NCT00829647|Experimental|combination dasatinib plus lenalidomide|dasatinib 70 mg po daily plus lenalidomide 2.5 md po daily
3194572|NCT00829660|Active Comparator|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
3194573|NCT00829660|Placebo Comparator|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
3194574|NCT00829699|Experimental|1|Euinsulinemic (low insulin infusion) Euglycemic (normal blood glucose levels) glucose clamp with lipid (fat) infusion
3194575|NCT00829699|Experimental|2|Euinsulinemic Hyperglycemic (high glucose levels) glucose clamp with lipid infusion
3194576|NCT00829699|Experimental|3|Hyperinsulinemic (High dose insulin) euglycemic glucose clamp with lipid infusion
3194577|NCT00829699|Experimental|4|Hyperinsulinemic hyperglycemic (high glucose level) glucose clamp with lipid infusion
2490728|NCT02963662|Experimental|Roux-en-Y gastric bypass group|The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
2490729|NCT02963662|Experimental|sleeve gastrectomy group|The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
2490730|NCT02963662|No Intervention|Normal BMI group|no intervention
3194578|NCT00829725|Active Comparator|screws-internal fixation|3-4-screws-internal fixation
3194579|NCT00829725|Experimental|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
3194580|NCT00829751|Active Comparator|ReNu Multiplus|Purevision lenses will be soaked in ReNu Multiplus
3194581|NCT00829751|Active Comparator|OptiFree RePlenish|PureVision lenses will be soaked in OptiFree RePlenish
3194582|NCT00829816|Experimental|Dimebon|20 mg dimebon by mouth 3 times per day
3194583|NCT00829816|Placebo Comparator|Placebo|20 mg placebo by mouth 3 times per day
2490846|NCT02962986|Active Comparator|norepinephrine 6mcg|norepinephrine, given as 1mL IV boluses, to treat post-spinal hypotension
2490847|NCT02962986|Active Comparator|phenylephrine 100mcg|phenylephrine, given as 1mL IV boluses, to treat post-spinal hypotension
3194584|NCT00829842|Placebo Comparator|1|Placebo
3194585|NCT00829842|Experimental|2|
2490943|NCT02962219|Experimental|Intervention|A pre-operative personalised exercise programme (my-PEP).
2490947|NCT02962219|Other|Control|Standard care
2490974|NCT02961933|Experimental|Apneic oxygenation|
2490976|NCT02961933|Active Comparator|non-apneic oxygenation|
2491047|NCT02961712|Experimental|cell therapy|NK cells and amniotic epithelial cells
3194586|NCT00829855||1|Patients with hypertensive (systolic blood pressure ≥160 mmHg) acute pulmonary edema, evaluated within 120 minutes after admittance.
3194587|NCT00829855||2|The same patients from group 1 followed-up at 48 to 96 hours.
2491228|NCT02960425|Experimental|HI Delivra TM Livsport preworkout cream|7 mL topical creatine cream
2491230|NCT02960425|Experimental|LO Delivra TM Livsport preworkout cream|3.5 mL topical creatine + 3.5 mL placebo cream
3194588|NCT00829881|Placebo Comparator|1|Participants will receive a placebo capsule, administered orally, once per study visit.
3194589|NCT00829881|Experimental|2|Participants will receive a betahistine capsule, administered orally, once per study visit.
3194590|NCT00829894|Experimental|1|Risperidone 1 mg Tablet
3194591|NCT00829894|Active Comparator|2|Risperdal® 1 mg Tablet
2491487|NCT02958761|Experimental|Platelet-rich plasma|Patients in the intervention group will receive three autologous PRP plus calcium gluconate (as activator) intraarticular injections at 4-week intervals. Briefly, at the Immunohaematology and Transfusion Service, on each scheduled visit 20 ml of autologous whole blood will be sampled from each patient, 2 ml ACD-A will be added directly the syringe as anticoagulant; finally the vial will be gently centrifuged at 900rpm for 7 minutes. Platelet-rich plasma was collected. The PRP vials plus activator will be immediately shipped to the rehabilitation unit, where intraarticular injection will be performed by an experienced physiatrist.
2491489|NCT02958761|Active Comparator|hyaluronic acid|Patients in the control group will receive three intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals, by the same study staff.
2491519|NCT02958488|Experimental|Preterm Neonates with Respiratory Distress Syndrome|34 to 36 Weeks Preterm Neonates with Respiratory Distress Syndrome
2491581|NCT02958293||December admission|The elective surgery group of people whose admission was the end of the calendar year (December) corresponding with insurance deductible year-end.
2491582|NCT02958293||Non-December admission|The elective surgery group of people whose admission was between January and November.
2491593|NCT02957994|Experimental|TAF Arm|Tenofovir alafenamide fumarate 25mg, 1 tablet once daily for 24 weeks
2491709|NCT02957825|No Intervention|Control|Routine monitoring
2491715|NCT02957825|Experimental|Continuous wireless monitoring|Continuous wireless monitoring
2522772|NCT02745275|No Intervention|Control|No intervention
3194592|NCT00829907|Experimental|1|Orm-12741
3194593|NCT00829920||Bladder cancer|Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
3194594|NCT00829946|Experimental|2|
3194595|NCT00829959||Genetic Counseling|Women referred to the Clinical Cancer Genetics Program for discussion of Hereditary Breast And Ovarian Syndrome (HBOC).
3194596|NCT00829972||1|children undergoing adenotonsillectomy
3194597|NCT00829972||2|children undergoing elective procedures other than adenotonsillectomy
3194598|NCT00830011|Active Comparator|standard care|Medical care including medication for neuropathic pain
3194599|NCT00830011|Active Comparator|CBT|
3194600|NCT00830050|Experimental|Arm 1|
3194601|NCT00830050|Placebo Comparator|Arm 2|
3194602|NCT00830089|Experimental|TAP block|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
3194603|NCT00830089|No Intervention|Standard care|No TAP block is given. Care is otherwise identical to arm 1
3194604|NCT00830102|Active Comparator|1|"Period 1 Treatment Regimen A: FlutiForm 100/10 ug~Period 2 Treatment Regimen B: FlutiForm 250/10 ug~Period 3 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 4 Treatment Regimen D: Flixotide Evohaler 250 ug"
3194605|NCT00830102|Active Comparator|2|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 3 Treatment Regimen B: FlutiForm 250/10 ug~Period 4 Treatment Regimen A: FlutiForm 100/10 ug"
2491510|NCT02958644|Placebo Comparator|Placebo|"Placebo - polydextrose 12g /day supplemented orally for 90 days.~The study supplements are packed in identical envelopes containing either 12g of oral powder fructo-oligosaccharide and probiotics or placebo to be diluted in water. The powder and the solution were identical in appearance, taste, and smell."
2491645|NCT02957786|Experimental|Cytisine plus behavioural support|"12-week course of cytisine capsules (1.5mg), with a decreasing dosing regimen (9mg/day for days 1-3, 7.5mg/day for days 4-12, 6mg/day for days 13-16, 4.5mg/day for days 17-20, 3.0mg/day from days 21-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
2491646|NCT02957786|Active Comparator|Varenicline plus behavioural support|"12-week course of Varenicline tablets (0.5mg/1mg), with an increasing dosing regimen (0.5mg/day for days 1-3, 1.0mg/day for days 4-7, 2.0mg/day for day 8-week 12).~Participants will be asked to reduce their smoking over the first four days of treatment so that they are not smoking at all by the fifth day, which will be their designated Quit date.~Participants will also receive withdrawal-orientated behavioural support (delivered by cessation advisors), in addition to brief cessation advice from the study-specific doctor (at the point that the prescription is provided) and community pharmacist (at the point the participant redeems their prescription)."
2491671|NCT02957513|Experimental|Text Messaging (TM)|The TM intervention will use an extensive text message library focused on 3 key behavioral areas (diet, exercise, and medication adherence). The TM intervention will incorporate supportive cognitive behavioral strategies such as goal setting, positive reinforcement, self-talk and dealing with barriers to change. Messages will encourage social interaction (social support, problem-solving, and feedback), self-monitoring of diet and exercise, diet modification, physical activity advice and prompting and basic self- regulatory skills. Messages will be tailored based on participant demographics, health literacy, and preferences.
2491673|NCT02957513|Experimental|Health Coaching (HC)|The HC intervention will place emphasis on the coach establishing rapport with the participant and assessing and establishing their initial goals using motivational interviewing, HC program goals, plans for future individual sessions. A written copy of personal health goals will be given to patients at the end of the first session. Coaches will aim to meet with participants for individual HC sessions bi-monthly the first 2-3 months followed by monthly for 8 - 9 months to provide information and support regarding health habits focusing sessions on areas related to patient-identified health goals, needs, and barriers to change. Sessions can occur in person or by phone based on patient preference.
2491676|NCT02957513|Active Comparator|Enhanced Usual Care (EC)|"All participants in all 3 study arms (TM, HC, and EC) will receive enhanced usual care. Usual care in the participating practices will be supplemented through the following key EC resources:~A. Patient-focused Resources including: 1) MODEL Program Toolkit, and 2) low literacy diabetes educational materials.~B. Availability of diabetes support services including: 1) peer group support sessions, 2) diabetes education, 3) MyDiabetesCenter.org resources, and 4) Diabetes Coalition education hub resources.~C. Practice-focused components including: 1) practice training/continuing medical education, and 2) reporting of diabetes performance measures."
3161343|NCT00440544|Experimental|3|50 ug H1 antigen in BCG immunized subjects
3161344|NCT00440544|Experimental|4|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
3161345|NCT00440544|Experimental|5|100 ug H1 antigen in BCG immunized subjects
2491895|NCT02956291|Experimental|Newly Diagnosed Brain Tumors|Participants with newly diagnosed brain tumors will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be performed to visualize recurrence.
2491904|NCT02956291|Experimental|Treated tumors with possible recurrence|Participants with treated brain tumors with possible recurrence will undergo Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans will be added to the repeat MRI studies as determined appropriate by the referring physician/primary care team.
2491936|NCT02955888|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2491938|NCT02955888|Placebo Comparator|Placebo|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2491976|NCT02955563|Experimental|CSDM Tool|Surrogate will complete educational sessions on CSDM tool prior to each family meeting with clinical team.
2491977|NCT02955563|No Intervention|Control|Surrogates will receive augmented usual care. The augmentation is that there will be 2 family meetings scheduled during the first 10 days of enrollment.
2492048|NCT02955238|Experimental|Special Intervention|The Special Intervention (SI) is designed to modify multiple, modifiable CVD risk factors that affect atherosclerosis and can be measured by sonography of the carotid intimal thickness. The SI is designed to address multiple, modifiable CVD risk factors that involve medication therapy, including hypertension, diabetes, and dyslipidemia.
2492049|NCT02955238|No Intervention|Usual Care|Usual care (UC) reflects current practices by the primary care providers in the adult medicine department. Participants randomized into the UC group will continue with their regular medical visits and referrals to the health educator as they were before randomization.
3161346|NCT00440544|Experimental|6|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
3161347|NCT00440583|Experimental|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
3161348|NCT00440609|Active Comparator|0.5mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
3161349|NCT00440609|Active Comparator|1.0 mg transitioning to 2.0mg|Ranibizumab-intravitreal injection
3161350|NCT00440622|Experimental|1|GHer
3161351|NCT00440622|Experimental|2|CapHer
3161352|NCT00440648|Other|1|sevelamer carbonate w(1-8) sevelamer hydrochloride w(9-16)
3161353|NCT00440648|Other|2|sevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
3161354|NCT00440674|Experimental|1|Direct stenting technique
3161355|NCT00440674|Experimental|2|Conventional stenting with pre-dilatation strategy
3161356|NCT00440739|Placebo Comparator|1|1=placebo
3161357|NCT00440739|Active Comparator|2|2= etoricoxib
2491563|NCT02958306|Experimental|platelet rich plasma|autologous blood product
2491570|NCT02958306|No Intervention|no platelet rich plasma|control
2491595|NCT02958085|Experimental|NNC0174-0833|
2491598|NCT02958085|Placebo Comparator|Placebo|
2491657|NCT02957812|Experimental|Orthotics|Custom made orthotic provided for study
2491659|NCT02957812|No Intervention|Control|Wearing own footwear
2491711|NCT02957474|Experimental|Treatment A = single oral dose GED 0301, fasted|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast
2491717|NCT02957474|Experimental|Treatment B = single oral dose GED 0301, fed|Subjects will receive a single oral 160 mg dose of GED-0301 after a 10 hour overnight fast, and within 30 minutes of completely consuming a high fat meal.
2491720|NCT02957474|Experimental|Treatment C = single oral dose GED 0301 fasted|Subjects will receive an oral dose of 160 mg of GED-0301 given as 4 tablets of 40 mg, after a 10 hour overnight fast
2491722|NCT02957474|Experimental|Treatment D = oral omeprazole and GED-0301|Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
2491771|NCT02956993|Active Comparator|Vonapanitase|Vonapanitase administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
2491772|NCT02956993|Placebo Comparator|Placebo|Placebo administered to the distal popliteal, tibial or peroneal artery using a micro-infusion catheter.
2491830|NCT02956590|Active Comparator|Pitavastatin|Study Drug
2491832|NCT02956590|Placebo Comparator|Placebo|Placebo
2491897|NCT02956200|Experimental|fingolimod with standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy with fingolimod.
2491905|NCT02956200|No Intervention|standard therapy|Patients will be treated with standard alteplase bridging and mechanical thrombectomy.
2491935|NCT02955940|Experimental|Ruxolitinib|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
2491942|NCT02955940|Experimental|Ruxolitinib plus background cancer therapy|Study treatment for participants should be the same as the dosage from the parent study at the time the roll over protocol is initiated. Dose modifications are permitted.
2491948|NCT02955940|Experimental|Background cancer therapy alone|Capecitabine and Regorafenib at the same dose provided in the parent study at the time of the rollover.
2492025|NCT02955511|Active Comparator|Blade MAC size 3|"Patient will be intubated using a:~Direct Laryngoscope (DL) Mac size 3 (Sun-Med GreenLine®/D™ Macintosh)"
2492027|NCT02955511|Active Comparator|Blade MAC size 3.5|"Patient will be intubated using a:~DL-blade mac size 3.5 (Sun-Med Greenline®/D™ Macintosh)"
2492029|NCT02955511|Experimental|Inscope Blade size 3.5|"Patient will be intubated using a:~Inscope DL-blade size 3.5"
2492158|NCT02955095|Experimental|Current cigarette smoker|
2492194|NCT02954328|Experimental|tDCS|"The active tDCS condition will consist of 4 visit:~During each visit, subject will receive a single 20-minute session targeting the prefrontal cortices of either real (1.5 mA) or sham tDCS. Total 4 different targets:~Sham~motor M1 area~motor M1 + Dorsolateral Prefrontal cortex~Dorsolateral Prefrontal cortex.~The tDCS condition will be randomized and double blinded"
2492244|NCT02953990|Experimental|MOMS Program|The MOMS Program involves: (1) mindfulness of symptoms and goal-setting through a nurse-participant partnership, and (2) 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home activity. Participants will engage in 12 weeks of weekly community-based group prenatal yoga classes (75 minutes each) and self-directed home practice.
3161358|NCT00440739|Active Comparator|3|3=falvoxate
3161359|NCT00440739|Active Comparator|4|etoricoxib and flavoxate
2492560|NCT02951858|Experimental|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver it and other materials about the harm of substance use.
2492561|NCT02951858|Active Comparator|Control Group|The participants only receive the materials about the harm of substance use.
2492628|NCT02951689|Experimental|Probiotic|Multi-strain probiotic
2492631|NCT02951689|Placebo Comparator|Placebo|Maltodextrin placebo
2492712|NCT02951377|No Intervention|Control|Wait list control - usual care - free to pursue other treatments prescribed by the patients family physician
2492719|NCT02951377|Experimental|MDT +/- TESI|Exercise (MDT approach) and/or Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%). Patients will further classified into centraliser (group 2a) and non-centralising pain responses (group 2b). Group 2a: will continue with exercise (MDT approach). Group 2b: Patients with a non-centralising pain response will be offered Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under fluoroscopic guidance with contrast medium (Omni Pac 240). Two weeks after completion of the MDT or TESI intervention, patients will be reassessed and treated consistent with their response: 1) resolved: advice on remaining active; 2) centralising: daily exercises based on MDT principles; 3) non-centralising but significant less pain: advice to remain active, with respect for worsening leg pain; and 4) persisting high levels of pain and/or disability: advise to remain active as tolerated and consult family physician.
2492790|NCT02950883|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
3161360|NCT00440752||AL|Cohort of study participants receiving treatment with artemether-lumefantrine
3161361|NCT00440765||001|bortezomib dose as determined (observational study) by treating physician
3161362|NCT00440778|Experimental|Gr 1 - intracoronary + infusion|abciximab bolus 0.25 mg/kg ic + 12 hrs iv infusion
3161363|NCT00440778|Experimental|Gr 2 - intracoronary|100% abciximab bolus dose 0.3 mg/kg ic
3161364|NCT00440778|Active Comparator|Gr 3 - intravenous|abciximab bolus dose 0.25 mg/kg iv + 12 hrs iv infusion
3161365|NCT00440778|Experimental|Gr 4 - intravenous|100% abciximab bolus dose 0.3 mg/kg iv
3161366|NCT00440817||Patients with lymphoma|Lymphoma Occurring in Patients with Rheumatoid Arthritis or Crohn's Disease
3161367|NCT00440843|Experimental|OLZ|
3161368|NCT00440843|Active Comparator|Typicals|
2491515|NCT02958722|Active Comparator|physiological solution|Diagnostic hysteroscopy performed with liquid solution (physiologic solution)
2491529|NCT02958332|Experimental|video game program|Participants will play video games during 30 min , all along 5 sessions.
2491689|NCT02957630|Experimental|15 mg E4/3 mg DRSP|15 mg estetrol/3 mg drospirenone combined oral contraceptive
2491696|NCT02957630|Active Comparator|30 mcg EE/150 mcg LNG|30 mcg ethinylestradiol/150 mcg levonorgestrel combined oral contraceptive
2491702|NCT02957630|Active Comparator|20 mcg EE/3 mg DRSP|20 mcg ethinylestradiol/3 mg drospirenone combined oral contraceptive
3194606|NCT00830102|Active Comparator|3|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug~Period 2 Treatment Regimen A: FlutiForm 100/10 ug~Period 3 Treatment Regimen F: Placebo~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug"
3194607|NCT00830102|Active Comparator|4|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 2 Treatment Regimen F: Placebo~Period 3 Treatment Regimen A: FlutiForm 100/10 ug~Period 4 Treatment Regimen B: FlutiForm 250/10 ug"
2491864|NCT02956512|Experimental|Dexibuprofen 300mg - Fed|Fed condition
2491867|NCT02956512|Experimental|Dexibuprofen 300mg - Fasting|Fasting condition
2491944|NCT02956083|Active Comparator|Lipid based artificial tears|Patients use lipid based artificial tears
2491947|NCT02956083|Active Comparator|Non-lipid based artificial tears|patients use non-lipid based artificial tears
2491949|NCT02956083|Placebo Comparator|Saline|patients use saline
2491989|NCT02955602|Experimental|MBX-8025 (2 mg)|MBX-8025 2 mg capsule once daily
2491992|NCT02955602|Experimental|MBX-8025 (5 mg)|MBX-8025 5 mg capsule once daily
2491995|NCT02955602|Experimental|MBX-8025 (10 mg)|MBX-8025 10 mg capsule once daily
2492080|NCT02955108|Experimental|music first then no music|
2492082|NCT02955108|Experimental|no music first then music|
2492131|NCT02954731|Experimental|UP-CBT|"The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is one of the most widely studied transdiagnostic manuals. Here, the investigators apply a group manual that has been modified from the published UP for individual therapy based on recommendations on group delivery from the UP Institute (personal communications) and integrations modifications necessary for the delivery in the Mental Health Service. Group UP-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions."
2492133|NCT02954731|Active Comparator|Standard-CBT|Group CBT following Danish versions of diagnosis specific manuals (Social Anxiety Disorder (SAD) Group; Depression (DEP) Group; Agoraphobia/Panic Disorder (Ag/PD) (standard-CBT). The original elements of psychoeducation, cognitive restructuring, and exposure/activity scheduling are present in the applied manuals. Standard-CBT, consist of 8 treatment modules delivered in 14 group sessions given weekly in 2 hour sessions.
2492217|NCT02954107||Absence epilepsy|Children aged 6-12 years of age primarily presenting with episodes of brief loss of consciousness (absences) in an otherwise normal child in the previous 2 years. With an EEG showing 3 Hz (2.5-4.5 Hz) generalized rhythmic spike-and-wave complexes with a discharge duration of at least 3 seconds on a present or former EEG.
2492220|NCT02954107||Controls|Overall healthy children aged 6-12 years of age following a regular school without major problems.
2492285|NCT02953743|Experimental|Lenvatinib 12 mg|Participants weighing ≥ 60 kg will be enrolled in this arm.
2492286|NCT02953743|Experimental|Lenvatinib 8 mg|Participants weighing < 60 kg will be enrolled in this arm.
3194608|NCT00830102|Active Comparator|5|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 4 Treatment Regimen F: Placebo"
2492400|NCT02953067|Active Comparator|Open reduction and internal fixation|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2492405|NCT02953067|Active Comparator|Primary Arthrodesis|After operative treatment non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2492408|NCT02953067|Active Comparator|Conservative treatment|Non-weightbearing cast immobilisation for 6 weeks. Cast will be changed after 2 weeks. After the 6 weeks cast will be replaced with orthotics. Orthotics will remain for 4 weeks.
2492450|NCT02952729|Experimental|Dose Escalation and Confirmation|XMT-1522 treatment will administered in groups of patients who will receive doses that increase over time. Once the maximum tolerated dose or recommended Phase 2 dose is achieved, new groups of patients will receive XMT-1522 at this fixed dose.
3194609|NCT00830102|Active Comparator|6|"Period 1 Treatment Regimen F: Placebo~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug"
2492611|NCT02951715|Experimental|Zinc|A full medical history assessment was performed, and each patient completed the NIHL questionnaire (Supplementary S1), audiogram, tympanogram, speech discrimination test, distortion product otoacoustic emissions (DPOAE) testing, pitch and loudness match of the tinnitus, Tinnitus Handicap Inventory (THI) and serum zinc level analyses. All tests were repeated after 2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day).
2492662|NCT02951442|Experimental|Renal Transplant|
3194610|NCT00830141||1|50 children with GH deficiency
3194611|NCT00830141||2|50 children with ISS
3194612|NCT00830141||3|50 children with FTT
3194613|NCT00830141||4|50 children with obesity
3194614|NCT00830141||5|50 children without short stature or obesity will serve as controls
3194615|NCT00830154|Experimental|1|0.30 mg pagoclone BID
2522989|NCT02743871|Experimental|Cohort 12|PF-06817024 or placebo
3194616|NCT00830154|Experimental|2|0.60 mg pagoclone BID
3194617|NCT00830154|Placebo Comparator|3|placebo
3194618|NCT00830193|Active Comparator|N-acetylcysteine|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Patients randomized to the experimental arm received intravenous normal saline plus NAC 10 grams IV (5 g pre and 2.5 g at 6 and 12 hours post-exposure) for a total of 3 doses.
2491516|NCT02958696|Active Comparator|HTL0018318 low dose|low dose aqueous solution and/or equivalent low dose capsule
2491517|NCT02958696|Active Comparator|HTL0018318 mid dose|mid dose aqueous solution and/or equivalent mid dose capsule
2491518|NCT02958696|Active Comparator|HTL0018318 high dose|high dose aqueous solution and/or equivalent high dose capsule(s)
2491584|NCT02958228|Experimental|Positive Mental Imagery Training (PMIT)|Computerized Positive Mental Imagery Training (PMIT), a form of mental imagery-based cognitive bias modification adapted from previous experimental (e.g. Holmes, Lang, & Shah, 2009) and clinical (e.g. Blackwell & Holmes, 2010) work. The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
2491586|NCT02958228|Active Comparator|Cognitive Control Training (CCT)|An adaptive Paced Auditory Serial Addition Task (PASAT), adapted from that applied in previous studies (e.g. Siegle et al., 2007; Hoorelbeke et al., 2015). The intervention consists of 8 sessions completed over a period of 2 weeks. The training takes place alongside participants' treatment as usual (TAU) in the inpatient setting.
2491587|NCT02958228|Active Comparator|Treatment as Usual|Participants will receive their treatment as usual (TAU) within the inpatient setting, which may include group/individual psychological therapy, a range of therapeutic activities, and pharmacological treatment.
2491653|NCT02957877|Experimental|LMWH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using low-molecular weight heparin (nadroparin) as anticoagulation
2491655|NCT02957877|Active Comparator|UFH arm|8-hour hemodialysis is performed on alternate day for a week at the dialysis unit (i.e. 3 sessions) by using unfractionated heparin as anticoagulation
2491680|NCT02957448|Experimental|BMS 986141 and Rifampin|
2491743|NCT02957279||Sepsis group|The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).
2491746|NCT02957279||Healthy control group|Healthy volunteers.
2491788|NCT02956850|Experimental|Part I: SAD in Healthy Volunteers|Healthy volunteers will receive single dose of RO7020531 or matching placebo orally on Day 1 of each cohort. A planned dose-escalation sequence for SAD is 3 milligrams (mg), 10 mg, 20 mg, 40 mg, 60 mg, 100 mg, 140 mg, and 170 mg.
2491791|NCT02956850|Experimental|Part I: MAD in Healthy Volunteers|Healthy volunteers will receive RO7020531 (100 mg, 140 mg, and 170 mg as selected based on safety, PK and PD data of SAD cohorts) or matching placebo orally every other day (QOD) from Day 1 through to Day 13.
2491795|NCT02956850|Experimental|Part II: CHB Participants|CHB participants will receive RO7020531 (150 mg and 170 mg as selected based on safety, PK and PD data of MAD cohorts) or matching placebo orally QOD from Day 1 through to Day 41, unless in Cohort 4 in case of QW dosing as dose modification.
2491896|NCT02956213|Experimental|ARM 1 MERV17 first|"This group will receive a portable HEPA air filtering device with MERV17 air filter for the first part of the study. At cross over, this group will receive the placebo or no high-efficiency filter."
2491901|NCT02956213|Active Comparator|ARM 2 MERV17 second|This group will receive a HEPA portable air filter with no high efficiency air filter for the first part of the study. At cross over, this group will receive the high-efficiency MERV17 air filter.
2492008|NCT02955927|Experimental|ortho-k and 0.01% atropine eye drops|participants will receive treatment of ortho-k and 0.01% atropine eye drops
2492011|NCT02955927|Active Comparator|ortho-k|participants will receive treatment of ortho-k alone
2492033|NCT02955264|Experimental|D-Galactose|D-Galactose is an oral powdered supplement to be taken by mouth. For the first 6 weeks galactose will be given at the dose 0.5g per kg, then from weeks 7-12 at 1.0g per kg, lastly from weeks 13 to 18 at 1.5g per kg (with a maximum daily dose of 50g).
2492070|NCT02955134|Experimental|Chinese medicine prescription|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in experimental group use the traditional Chinese medicine application prescription.
2492074|NCT02955134|Placebo Comparator|placebo|On the basis of symptomatic treatment of Talcid® and Compound Azimtamide Entieric-coated Tablets,patients in placebo group use the simulate granule of traditional Chinese medicine application prescription.
3208731|NCT00977587|Placebo Comparator|placebo|"Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
2492272|NCT02953847|Other|sequence 1|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492275|NCT02953847|Other|sequence 2|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492276|NCT02953847|Other|sequence 3|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492277|NCT02953847|Other|sequence 4|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492278|NCT02953847|Other|sequence 5|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492409|NCT02952976|Active Comparator|Abthera|Patients with open abdomen submitted to treatment with the Abthera dressing
3161369|NCT00440856|No Intervention|Control|
2491521|NCT02958566|Experimental|Non-Narcotic|Gabapentin 300 mg PO, orphenadrine 60 mg IV, acetaminophen 1000 mg PO or IV on Morning of surgery. Lidocaine 100 mg prior to incision, lidocaine 1mg/kg/hour during procedure, marcaine in all incisions. Ketamine and methadone per anesthesia. Acetaminophen 1000 mg PO or IV, gabapentin 300 mg PO, tramadol 50 mg PO in PACU. Acetaminophen 600 mg PO Q 6 hours, tramadol 50 mg PO Q 6 hours, gabapentin 300 mg PO Q 6 hours, orphenadrine 60 mg IV Q 12 hours, ketorolac 15 mg IV Q 6 hours for 48 hours post-operatively.
2491656|NCT02957890|Experimental|Twice-annual influenza vaccination|Twice-annual influenza vaccination: administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus inactivated influenza vaccine (Southern hemisphere formulation, SH) prior to the northern hemisphere summer.
2491658|NCT02957890|Placebo Comparator|Once-annual influenza vaccination|Administrations of inactivated influenza vaccine (Northern hemisphere formulation, NH) prior to the northern hemisphere winter, plus placebo prior to the northern hemisphere summer.
2491683|NCT02957435|Experimental|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
3161370|NCT00440856|Experimental|experimental|Participants are given their disc fragments following their operation
3161371|NCT00440869|Experimental|N-acetylcysteine|Active
2491763|NCT02956915||patients with severe symptomatic aortic stenosis|Stable patients with severe symptomatic aortic stenosis undergoing planned Transfemoral Transcatheter aortic valve implantation with the SAPIEN-3 prosthesis will be included. TF-TAVI will be done using a minimalist approach of local anesthesia and conscious sedation.
2491815|NCT02956681|Active Comparator|Delayed Intervention Group|In this arm of the randomized delayed intervention control trial, participants randomized to delayed intervention control group were sent a brochure with information on hereditary breast and ovarian cancer and the phone number to call a cancer risk program for free genetic counseling.
2491824|NCT02956681|Active Comparator|Intervention Group|In this arm of the randomized delayed intervention control trial, those randomized to the intervention group were told that because of their family history, we were able to offer them a free genetic counseling appointment.
2491866|NCT02956330||CLS1003-201|Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.
2491932|NCT02956096|Active Comparator|tDCS device and Treatmill|The stimulation is accomplished with a direct current-tDCS Stimulator Plus device, via two surface electrodes sponge (non-metallic) 5-7 cm2 in saline moistened with a 2mA current during 20 minutes after hemodinamic analysis is performed for 15 minutes and then made only training treadmill for 20 minutes. Placebo tDCS will follow the same procedures, but the tDCS device will only be switched on for 20 seconds. The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve (MACKO , 2005).
2491940|NCT02956096|Sham Comparator|1- tDCS|1. Who received stimulation transcranial direct current active will receive Sham stimulation and who received the placebo stimulation receive active stimulation and then the two groups will do the workout on the treadmill
2492030|NCT02955589|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
2492076|NCT02954939|Active Comparator|MMF-MMF|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus mycophenolate mofetil (MMF) (1g bd) as induction-maintenance therapy
2492079|NCT02954939|Placebo Comparator|CTX-AZA|Class III/IV+V LN patients who receive prednisolone (PRED) (0.8mg/kg/d) plus Cyclophosphamide (CTX) (1.5-2mg/kg/d) followed by Azathioprine (AZA) (1-1.5mg/kg/d) as induction-maintenance therapy
2492124|NCT02954757|Experimental|Treatment arm|HIFU treatment
2492165|NCT02954536|Experimental|Pembrolizumab, trastuzumab,capecitabine/cisplatin|Pembrolizumab 200 mg IV every 3 weeks, trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) IV every 3 weeks with cisplatin IV every 3 weeks with oral capecitabine 2 weeks on/1 week off. Each cycle consists of 21 days. Treatment will be administered on an outpatient basis. In Cycle 1, patients will initiate therapy with trastuzumab 8 mg/kg IV with pembrolizumab 200 mg IV. CT/MRI scan will be performed after the initial 3 weeks (1 cycle) to determine response to pembrolizumab and trastuzumab combination. With subsequent cycles, all patients will begin systemic chemotherapy with the capecitabine/cisplatin regimen in addition to pembrolizumab 200 mg IV with trastuzumab 6 mg/kg maintenance. Patients will receive cisplatin 80 mg/m2 IV on Day 1, and capecitabine 850mg/m2 twice a day on Days 1 through 14, every 3 weeks.
3161372|NCT00440869|Placebo Comparator|placebo|placebo
3161373|NCT00440895|Experimental|1 intracoronary + infusion|Bolus abciximab i.c. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
2492346|NCT02953340|Experimental|Docetaxel +Cyclophosphamide+ SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)~Supplied in prefilled single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle"
2492350|NCT02953340|Active Comparator|Docetaxel +Cyclophosphamide+ Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta®)~Single-dose subcutaneous injection on Day 2 of each cycle."
2492392|NCT02953015|Experimental|Manipulative articulatory and myofascial techniques Group|Manipulative and myofascial techniques
2492398|NCT02953015|Active Comparator|Transcutaneous Electrical Nerve Stimulation Group|Electrical Nerve Stimulation
2492452|NCT02952716|Experimental|intervention group|Human Cord Blood Mononuclear Cell will be slowly infusion three times,at one days, 30 days,at 60days.
2492457|NCT02952716|Placebo Comparator|control group|hyperbaric oxygen
2492496|NCT02952274|Active Comparator|locater attachment|mandibular overdenture retained with single midline implant using locator attachment
2492497|NCT02952274|Active Comparator|ball attachment|mandibular overdenture retained with single midline implant using ball attachment
2492556|NCT02952131|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
3161374|NCT00440895|Active Comparator|2 intravenous|Bolus abciximab i.v. (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
2491524|NCT02958683||Pectus excavatum|Patients with pectus excavatum (funnel chest) condition undergo chest wall motion analysis
2491527|NCT02958683||Pectus carinatum|Patients with pectus carinatum (pigeon chest) condition undergo chest wall motion analysis
2491533|NCT02958683||Chronic obstructive pulmonary disease|Patients affected by COPD undergo chest wall motion analysis
2491537|NCT02958683||Diaphragm abnormality|Patients with abnormal function or structure of the diaphragm. Including diaphragmatic hernia/rupture and diaphragmatic paralysis undergo chest wall motion analysis
2491542|NCT02958683||Healthy control|People who do not have any diagnosed thoracic condition and who do not have symptoms/signs suggestive of undiagnosed thoracic disease undergo chest wall motion analysis
2491550|NCT02958683||Lung cancer|Patients with suspected or confirmed lung malignancy of all histological subtypes undergo chest wall motion analysis
2491555|NCT02958683||Pleural disease|Patients with pleural thickening and/or pleural effusion, pneumothorax, empyema undergo chest wall motion analysis
2491557|NCT02958683||Asthma|Patients diagnosed with asthma clinically or upon spirometry undergo chest wall motion analysis
2491565|NCT02958683||Cystic fibrosis|Patients diagnosed with cystic fibrosis clinically or biochemically undergo chest wall motion analysis
2491573|NCT02958683||Rib or sternal disease|Patients with an abnormality in the chest wall including fractures, osteomyelitis, malignancy of all histological subtypes, chest wall resection/reconstruction undergo chest wall motion analysis
2491633|NCT02957903|Experimental|Treatment A|"Injection around the lateral femoral cutaneous nerve:~8 ml Ropivacaine 0.75 %."
2491637|NCT02957903|Placebo Comparator|Treatment B|"Injection around the lateral femoral cutaneous nerve:~8 ml isotonic Saline."
2491708|NCT02957552|Experimental|Treatment with Mesenchymal Stem Cells|"Two doses of 1 x 10^6 MSCs/kg body weight:~first administration intraoperatively via intraportal infusion~second infusion via intravenous infusion on postoperative day 2 (+/- 1 day)~Standard immunosuppressive treatment consisting of steroids, basiliximab and tacrolimus according to the center's pediatric liver transplantation protocol"
2491740|NCT02957162|Other|Blood samples and Atorvastatin 80mg|All participants are given Atorvastatin 80mg as part of their standard care. The main study intervention is blood samples at days 1-2, 3-4 and 7-8.
2491797|NCT02956889|Experimental|Vismodegib & Radiotherapy|"Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.~Treatment with Vismodegib will start within 4 weeks by the end of radiotherapy and will continue for 6 cycles"
2491879|NCT02956343||AF|Five minutes pulse wave recording in patients with atrial fibrillation at the time of recruitment
2491882|NCT02956343||SR|Five minutes pulse wave recording in patients with sinus rhythm at the time of recruitment
2491933|NCT02955992|No Intervention|standard of care|
2491939|NCT02955992|Experimental|Intervention|"All caregivers will receive a leaflet about the importance of end of life (EOL) communication: key elements and recommendations regarding verbal and non-verbal communication.~A local champion (opinion leader) will be designated by each team in order to help implement the strategy. These physicians will help colleagues to connect external knowledge and requirements of the study to the local context.~Development of a 3-step physician-driven support strategy starting after a decision to withhold or withdraw life-sustaining therapies is implemented:~Preparation for the death : Prepare the relative for the patient's imminent death~During the dying and death process: The physician enters the patient's room at least once to check on the relatives~After the patient's death: the physician and the nurse meet the relative"
2491988|NCT02955576|Placebo Comparator|Control group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
2491990|NCT02955576|Active Comparator|Patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
2491993|NCT02955576|Experimental|Microneedle patch group|All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
2492075|NCT02955121|Active Comparator|Pharmacogenetic Results Available to Provider|Genotyping for CYP2C19 variants is performed. The test results are integrated into the electronic health record and alerts are displayed to the prescriber. The ultimate decision regarding antiplatelet therapy is left to the prescriber
2492078|NCT02955121|No Intervention|Control Arm|No genotyping information is performed as part of clinical care. Standard therapy is followed. Genotyping will be performed at conclusion of study in control arm, and genotyping results will not be incorporated into electronic health record.
2492130|NCT02954835|Active Comparator|Prevena|Subjects randomized to the Prevena dressing will have the dressing in place for 5 to 7 days postoperatively and removed before discharge, or at the first outpatient visit.
2492132|NCT02954835|Active Comparator|Traditional Dressing|Subjects randomized to the traditional dressing will undergo dressing changes as per the standard protocol with the first dressing change at postoperative day 2 or 3, or at the discretion of the attending surgeon.
2492177|NCT02954471||Participants With Breast Cancer|This study will retrospectively collect data from participants with breast cancer in Saudi Arabia.
2492232|NCT02954146|Active Comparator|CBT only|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT only) sessions for anger management.
2492238|NCT02954146|Experimental|CBT + Connectd mobile health app|Veterans will receive 12 weekly individual cognitive behavioral therapy (CBT) sessions for anger management. In addition, veterans in this group will also receive instructions for using Connectd mobile health app with a family member or friend that will provide data for the CBT clinician.
2492282|NCT02953691|Experimental|Galacto-Oligosaccharides (GOS)|Clasado Biosciences Limited will provide Bimuno Pastilles for the clinical trial. Each pastille contains 0.92g GOS and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged GOS pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics. Each subject has an equal chance of receiving GOS or placebo. GOSn will be administered in the hospital when patient reinstitutes oral intake. GOS will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
2492384|NCT02953080|Active Comparator|Call for Life Mobile phone support|"The intervention is Call for life mHealth adherence support tool  through basic mobile phone-based interactive voice response."
2492386|NCT02953080|No Intervention|Standard of Care|No call for life Uganda: Patients are randomized to standard of Care
2491528|NCT02958579||Obesity|Body mass index (BMI) score > 25.2 kg/m2 for women and > 27.3 kg/m2 for men or Waist circumference > 90 cm
2491538|NCT02958579||Pre-diabetics or diabetics|"if any of followings is identified the participant is regarded as diabetics and will be recruited in this arm;~Fasting Plasma glucose (FPG) level ≥ 7.0 mmol/l (126 mg/dL)~Plasma glucose ≥ 11.1 mmol/l (200 mg/dL) two hours after a 75 g oral glucose load as in a glucose tolerance test~Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l (200 mg/dL)~Glycated hemoglobin (A1C) ≥ 6.5% if any of followings is identified the participant is regarded as pre-diabetics and will be recruited in this arm;~1- FPG levels of 100-125 mg/dl (5.6-6.9 mmol/l). 2-Two-h plasma glucose (2HPP) in the 75 g oral glucose tolerance test of 140-199 mg/dl (7.8- 11.0 mmol/l)"
2491544|NCT02958579||Hypertension|Systolic blood pressure (SBP) ≥ 130mmHgand/or diastolic blood pressure (DBP) ≥ 85mmHg or use of anti-hypertensive drugs
2491548|NCT02958579||hypertriglyceridemia|Serum triglyceride ≥150 mg/dL
2491553|NCT02958579||Low high density lipoprotein -cholesterol (HDL-c)|Serum HDL-C of <40 mg/dL for men, <50 mg/dL for women,
2491597|NCT02958033|Experimental|HF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 2.5Gy x18 and SIB 2.88Gy x18)
2491599|NCT02958033|Placebo Comparator|CF WBI-SIB breast radiation|WBI-SIB breast radiation(WBI 1.8Gy x28 and SIB 2.15Gy x28)
2491632|NCT02957838|Experimental|Non-diabetics|Non-diabetic volunteers with HbA1c < 6.5%. Subjects will be treated with C18:0 supplementation or mock.
2491636|NCT02957838|Experimental|Type 2 Diabetics|Type 2 Diabetes according to common definitions, but we exclude insulin-treated Type 2 diabetics because nutritional intervention is more difficult/risky. Subjects will be treated with C18:0 supplementation or mock.
2491688|NCT02957539|No Intervention|No Reward|At enrollment, participants randomized to usual care will be given the MOVE! workbook that serves both as an information resource on diet and exercise, a resource for tools to achieve weight loss goals, and a log of participants' goals, motivations, and outcomes. Each participant will be given a chart with a personalized target weight for a loss of 1lb. per week for 16 weeks. Participants will be given a digital scale or wireless scale and counseled to weigh themselves daily. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
2491699|NCT02957539|Experimental|Financial Reward Arm|Same as usual care, plus financial rewards that are earned in two ways: an assured and random. For the assured reward, they will receive compensation at the end of each month that they are at or below their target weight on the last day of that period. For the random portion, each week that a participant is at or below their target weight, the patient is entered in random drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning.Over the 17-32 week period, Veterans in this group will receive token rewards for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters his/her weight into the portal, he will have a 1-in-8 chance to earn the token reward, such as a t-shirt or movie tickets. Participants will enter their weight weekly into an online portal. They will also complete the surveys in the portal. They will receive text message reminders to enter their weight.
2491703|NCT02957539|Experimental|Non-financial Reward Arm|Procedures for the non-financial rewards arm is identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each week a random drawing will be for 20 points, each monthly weigh in is worth 5 points. Veterans will be given non-financial rewards associated with the number of points they earn.
2491764|NCT02957201|Other|Blood samples|Blood samples taken at baseline, day 1-2, day 3-4 and day 7-8 for Endothelial Progenitor Analysis with flow cytometer
2491792|NCT02956707||No pre-operative steroids|"This is a prospectively enrolling group of 40 subjects.~Our current clinical practice has changed. We no longer administer pre-oeprative steroids to neonates undergoing surgery with cardiopulmonary bypass. These patients still receive their post-operative steroid infusion that starts after termination from bypass. This is their standard of care and does not change due to study enrollment.~Subject's enrolled in this trial have a ACTH stimulation test performed: pre-operative, immediately post-cardiopulmonary bypass prior to the initiation of their clinical steroids, and prior to leaving the cardiac intensive care unit."
2491794|NCT02956707||Pre-operative steroids|This is a retrospective group of 40 subjects who were previously administered pre-operative steroids. These subjects also had ACTH testing performed pre-operative and immediately post-separation from cardiopulmonary bypass.
2492032|NCT02955485||Patients with chronic ankle instability|All patients that develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Experiencing persisting complaints of instability for more than 6 months.
2492037|NCT02955485||Patients without chronic ankle instability|All patients that do not develop chronic ankle instability after an ankle sprain and reporting at the emergency department. Complaints resolve within 6 months.
2492166|NCT02955043|Experimental|Behavioral intervention|Participants will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. The intervention will be delivered in three 45-60 minute face-to-face sessions at approximately 3-4, 8, and 12 weeks post-HSCT with brief telephone coaching calls scheduled between sessions. Participants will be encouraged to use the behavioral strategies from hospital discharge through 18 weeks post-HSCT. Participants will be asked to complete a daily checklist indicating which intervention strategies they used. Participants will also receive standard medical care following HSCT.
2492167|NCT02955043|No Intervention|Usual care|Participants will receive standard medical care following HSCT.
2492178|NCT02954250|No Intervention|Control|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as usual
2492180|NCT02954250|Experimental|Mindfulness Group|The intervention will consist of group, lasting 90 minutes in one session per week for 8 weeks. The exercises will be 5 minutes long alternating between 4 or 5 each session.
2492253|NCT02954120||(PCOS-CP-)|systemically and periodontally healthy participants
2492256|NCT02954120||(PCOS-CP+)|systemically healthy participants with CP
2492257|NCT02954120||(PCOS+CP-)|PCOS participants with periodontally healthy
2491534|NCT02958384|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-LeY-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2491611|NCT02958163|Active Comparator|Trans-Arterial Chemo-embolization (TACE)|"Trans-arterial Embolisation will be performed with drug-eluting beads loaded with Doxorubicin. First session will be given within 4 weeks after randomization.~4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last session of TACE corresponds to the treatment completion date."
2491614|NCT02958163|Experimental|TACE+Stereotactic Ablative Radiotherapy|"The first part of the treatment, which is the DEB-TACE delivery, will be exactly the same than in arm A. The radiotherapy (SABR) will then start within 4 to 6 weeks after.~Afterwards, 4-phase MRI will be performed every 2 months to assess the response. In case of insufficient response according to the MRI performed at 2 or 4 months, a second or third session of DEB-TACE will be allowed, according to the physician's choice.~Once complete response is achieved, the follow-up period will start. The date of the last SABR fraction or the last session of TACE corresponds to the treatment completion date."
2491686|NCT02957591|Experimental|Probiotic Group|Over a period of 4 weeks, depressive patients will ingest a probiotic food supplementation (Vivomixx®) 4 times a day. Primary and secondary endpoints will be assessed before and after the intervention.
2491693|NCT02957591|Placebo Comparator|Placebo Group|Subjects in the placebo group will receive a placebo 4 times a day over 4 weeks. Primary and secondary endpoints will be assessed before and after the intervention.
2491769|NCT02957214|Experimental|Pain education|The patient education provides a basic set of information that includes the explanation of possible pathophysiological mechanisms involved in the development of chronic pain. The main objective is to reduce pain threatening and alarmist interpretation. The patient must understand that the pain is not necessarily a sign of injury, but the consequence of a maladaptive central sensitization. One element of this therapeutic strategy is to help the patient to perform physical activities that involve a gradual exposition to stimuli associated with their pain and promote physical recovery exposure. Pain education also aims to reduce fear-avoidance behavior and the patient's disability.
3194619|NCT00830193|Placebo Comparator|Placebo|Intravenous fluid administration was administered as soon as possible following randomization (not to exceed 12 hours prior to anticipated contrast exposure) and continued for 12 hours post CT. Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g in 100 cc D5W (pre-CT dose) or 2.5 g in 50 cc D5W (post-CT doses). The placebo was D5W and was colour and consistency matched by pharmacy. Patients randomized to placebo received intravenous normal saline plus 3 doses of placebo.
3194620|NCT00830245|Experimental|Erlotinib|Erlotinib 150mg/day (if no negative conversion --> increment to 250mg/day)
3194621|NCT00830271|Experimental|Vicryl plus/Monocryl plus|"Vicryl plus and Monocryl plus is the active comparator arm. These are the active sutures, coated with triclosan antiseptic, being used in the closure of skin and subcutaneous tissues after breast cancer surgery."
3194622|NCT00830271|Placebo Comparator|vicryl/monocryl|"Plain Vicryl or Monocryl suture currently the standard which are not coated with triclosan, serve as the control."
3194623|NCT00830297|Active Comparator|1 Insulatard (long-acting insulin)|
3194624|NCT00830297|Active Comparator|2 Conventional treatment|
3194625|NCT00830323|Experimental|1|
3194626|NCT00830323|Experimental|Arm 2|
3194627|NCT00830323|Active Comparator|Arm 3|
3194628|NCT00830349|Experimental|1|Risperidone 1 mg Tablets
3194629|NCT00830349|Active Comparator|2|Risperdal® 1 mg Tablets
3194630|NCT00830401|No Intervention|1|One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
3194631|NCT00830401|Active Comparator|2|One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
2492145|NCT02954588|Active Comparator|Pyridoxamine (1)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 1), three times daily during 8 weeks.
2492147|NCT02954588|Active Comparator|Pyridoxamine (2)|Subjects will be asked to consume dietary supplements containing pyridoxamine (dosage 2), three times daily during 8 weeks
2492150|NCT02954588|Placebo Comparator|Placebo|Subjects will be asked to consume dietary supplements containing placebo (amylum solani), three times daily during 8 weeks
2492215|NCT02954315|Experimental|Almond arm|The almond dose will be provided as 20% of total energy (20% E) in the diet. This dose was selected based on a previous randomized trial examining lipid parameters in response to 0, 10%, and 20% E as dietary almonds and a recent meta-analysis of intervention trials.
2492216|NCT02954315|No Intervention|Western diet Snack (Granola bar + Pretzels)|The control snack will be a typical western diet snack (see Table 1). The calorie-matched control snack will be commercially available individually wrapped food products such as a small granola bar + pretzels.
3194632|NCT00830414|Experimental|1|
3194633|NCT00830414|Active Comparator|2|DEPO-PROVERA®
2492455|NCT02952651|Experimental|Children with hypovolemic state|Pulse oximeter plethysmography (POP) waveforms are obtained for 90 seconds in children with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Then, intravenous crystalloid fluid 10 mL/kg is infused for 15 min. Delta POP is calculated, and diagnostic power of delta POP for fluid responsiveness will be evaluated.
2492498|NCT02952443||Exercise|EX group will attend multi-component exercise sessions 3 times a week at 45-60 minutes a session for 16 weeks. Each session will include aerobic, flexibility, resistance and balance training but a strong emphasis will be placed on the latter two components.
3194634|NCT00830427|Experimental|PF-00610355|
3194635|NCT00830427|Experimental|PF - 00610355|
3194636|NCT00830427|Placebo Comparator|Placebo|
3194637|NCT00830453|Experimental|Hyperbaric oxygen|Hyperbaric oxygen, 1.5 atmospheres absolute, 60 minutes door-to-door, 60 daily sessions.
3194638|NCT00830466|Experimental|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
3194639|NCT00830479|Active Comparator|Open Surgery|
2491535|NCT02958514|Other|traditional treatment group|Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.
2491541|NCT02958514|Experimental|IPL treatment group|Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.
2491613|NCT02958202|Experimental|BMN 044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
2491618|NCT02958202|Experimental|BMN 044 IV 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
2491621|NCT02958202|Experimental|BMN 044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
2491677|NCT02957604||Specific Evolocumab-Exposed Cohort|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), who were exposed to Evolocumab (Repatha) during pregnancy
2491695|NCT02957604||Comparison Group I|Women diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH) who were not exposed to Evolocumab during pregnancy
2491700|NCT02957604||Comparison Group II|A general comparison group of pregnant women who have not been diagnosed with Atherosclerotic Cardiovascular Disease (ASCVD), or hypercholesterolemia associated with Familial Hypercholesterolemia (FH), and who were not exposed to Evolocumab during pregnancy.
2491704|NCT02957604||General Evolocumab-Exposed Case Series|Women who were exposed to Evolocumab (Repatha) but do not fulfill eligibility criteria for the Specific Evolocumab-Exposed Cohort
2491742|NCT02957175||Patients that develop SIRS|Immunophenotyping of patients that develop SIRS after heart surgery
2491745|NCT02957175||Patients that develop no SIRS|Immunophenotyping of patients that develop no SIRS after heart surgery
2492021|NCT02955615|Experimental|ILT-101|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
2492024|NCT02955615|Placebo Comparator|Placebo|Subcutaneous administrations for 3 to 6 months according to clinical responder status at week 12
2492071|NCT02954926|Experimental|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
2492073|NCT02954926|No Intervention|Control|No intervention
2492136|NCT02954861||Cardiac surgery|Patients who develop delirium following cardiac surgery
2492218|NCT02954484|Active Comparator|PREGABALIN|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive pregabalin 75mg orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
2492219|NCT02954484|Placebo Comparator|PLACEBO|All subjects receive intravenous PCA morphine, paracetamol 1g po six hourly and etoricoxib 120mg po once daily. Subjects receive either placebo tablet (of identical appearance to pregabalin) orally preoperatively followed by 75mg at night for two days. During surgery, patients received general anaesthesia with femoral nerve block on the side of surgery.
3161375|NCT00440895|Placebo Comparator|3 Placebo|Bolus of placebo followed by 12 h infusion (placebo).
3161376|NCT00440973|Other|treatment arm|PI relocated, currently data is no longer available
3161377|NCT00441025|Active Comparator|1|1 Alemtuzumab
3161378|NCT00441038|Active Comparator|1|Education on postural hygiene and handout of The Back Guide
2492404|NCT02953028|Active Comparator|Continuous Positive Airway Pressure|Patients treated With an auto-CPAP-machine which is a compressor Connected to a nose- or face mask which provides increased air pressure, opening the upper Airways during an apnea or hypopnea event.
2492406|NCT02953028|Active Comparator|Mandibular Advancing Splint|Patients treated With a twin block splint (oral appliance) advancing the mandible and thereby opening the upper Airways for easier passage of air during sleep preventing apnea and hypopnea events.
2492454|NCT02952742|Experimental|Black Cohosh Therapy|Black Cohosh will be provided in 250mg capsules. Subjects will take 2 capsules by mouth daily for a total daily dose of 500 mg. Subject's will remain on this study arm for 8 weeks.
2492461|NCT02952742|Placebo Comparator|Placebo|Subjects will take 2 capsules, identical to the Black Cohosh capsules, by mouth each. Subject's will remain on this study arm for 8 weeks.
2492548|NCT02952092|Experimental|ASP1517 Group|Subjects will take the study drug at two- or three-day intervals.
3161379|NCT00441038|Active Comparator|2|Education on active management and handout of The Back Book
3161380|NCT00441038|Active Comparator|3|Education on cardiovascular and general health
3161381|NCT00441155|Experimental|Monotherapy: AMN107|initial dose of imatinib (dose level 1) was 400 mg bid was administered orally on a continuous daily schedule and was not escalated during the study
3161382|NCT00441155|Active Comparator|Combination Therapy: AMN107 + Imatinib|six possible doses of Nilotinib (100 mg once daily (qd), 200 mg qd, 400 mg qd, 200 mg bid, 300 mg bid, and 400 mg bid). four possible doses of Imatinib (0 mg, 400 mg qd, 600 mg qd, and 400 mg bid).the initial dose of nilotinib (dose level 1) was 200 mg qd and could have been escalated up to 400 mg bid
3161383|NCT00441220||A|Patients must have lupus nephritis and previously had therapy with intravenous cyclophosphamide.
3161384|NCT00441220||B|Patients must have lupus nephritis and are currently receiving therapy with intravenous cyclophosphamide.
3161385|NCT00441298|Experimental|1|Tenofovir gel (a reverse transcriptase inhibitor)
3161386|NCT00441298|Placebo Comparator|2|Universal HEC placebo
3161387|NCT00441311|Experimental|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
3161388|NCT00441311|No Intervention|Service-as-Usual|Control Arm
3161389|NCT00441376|Experimental|ThermoDox + RFA|ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation. Dose is determined by dose cohort patient enters study.
3161390|NCT00441454|Active Comparator|A|Retropubic Tension-free Vaginal Tape (TVT)
3161391|NCT00441454|Active Comparator|B|Transobturator Tension-free Vaginal Tape (TVT-O)
3161392|NCT00441597|Active Comparator|1|first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
2491536|NCT02958501|Active Comparator|IU/Day|This is standard dose of the drug (colecalciferol), which is not calculated in relation to patient body weight
2491543|NCT02958501|Active Comparator|IU/Kg/Day|This is dose of the drug (colecalciferol), which is based or calculated in relation to patient actual body weight
2491617|NCT02958150|Experimental|Dexmedetomidine|Dexmedetomidine according to the stablished protocol
2491619|NCT02958150|Active Comparator|Standard Clinical Practice|The physician in charge will decide the treatment to be administered (if deemed necessary) in accordance with the protocol established at the department
2491684|NCT02957656|Experimental|Group 1: H7N9 pLAIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of approximately 10^7.0 FFU of H7N9 pLAIV at study entry (Day 0). They will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
2491697|NCT02957656|Experimental|Group 2: AS03-adjuvanted H7N9 pIIV + AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0) and one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at Day 84.
2491701|NCT02957656|Experimental|Group 3: AS03-adjuvanted H7N9 pIIV|Participants will receive one dose of 15 µg of AS03-adjuvanted H7N9 pIIV at study entry (Day 0).
2491705|NCT02957656|Experimental|University of Rochester URMC 13-001 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
2491706|NCT02957656|Experimental|Johns Hopkins School of Public Health CIR293 Participants|Participants received one dose of 10^7 FFU of H7N9 pLAIV at study entry (Day 0), one dose of 10^7 FFU of H7N9 pLAIV at Day 28, and one dose of 30 µg of unadjuvanted H7N9 pIIV at Day 84.
2491736|NCT02957058|Active Comparator|SERT 0, SCAR (low risk)|Patients with Sydney EMR Recurrence Tool (SERT scoring) score 0. These patients will be invited to return for follow up at 18 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
2491737|NCT02957058|Active Comparator|SERT 1-4, SCAR (high risk)|Patients with Sydney EMR Recurrence Tool score 1-4 (SERT scoring). These patients will be invited to return for follow up at 4-6 months and will have thermal ablation (SCAR technique) of the endoscopic resection defect margin.
2491806|NCT02956941|Experimental|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|Intervention group will be received 12 months on nutrition behavior change communication using two modes (lecture, and posters).
2491818|NCT02956941|No Intervention|Control cluster|Control group will receive routine dietary practices.
2491868|NCT02956356|Placebo Comparator|Control treatment + oral glucose|Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
2491874|NCT02956356|Active Comparator|SATIOSTAT treatment + oral glucose|SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)
2491876|NCT02956356|Placebo Comparator|Control treatment + meal intake|Control treatment as preload followed by a test meal
2491883|NCT02956356|Active Comparator|SATIOSTAT treatment + meal intake|SATIOSTAT treatment as preload followed by a test meal
2491930|NCT02955901|Active Comparator|3-day low residue diet|Group A - 3 day low residue diet prior to the colonoscopy
2491937|NCT02955901|Placebo Comparator|1-day low residue diet|Group B - 1 day low residue diet prior to the colonoscopy
2492041|NCT02955654|Experimental|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
2492043|NCT02955654|Active Comparator|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
2492045|NCT02955654|Other|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
2492069|NCT02955056|Experimental|Teriparatide Intervention|Will be asked to self-administer Teriparatide treatment (self-injection) once a day for 12 weeks
2492072|NCT02955056|No Intervention|Usual care|No intervention, patients will be treated as per local practice but will be followed up identically to the intervention group.
2492137|NCT02954822|Experimental|(Group A)|Evogliptin→Evogliptin+Glimepiride→Glimepiride
2492140|NCT02954822|Experimental|(Group B)|Glimepiride→Evogliptin→Evogliptin+Glimepiride
2492214|NCT02954380|Experimental|ZIO/ILR|THe Zio ILR arm will already have an ILR implanted for standard of care and will receive the Zio patch
3194640|NCT00830479|Active Comparator|Endoscopic Surgery|
2492335|NCT02953379|Experimental|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
2492339|NCT02953379|Active Comparator|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
2492403|NCT02953184|Active Comparator|conventional Doxorubicin plus C-T|AC-T regimen 8 cycles ,60mg/M2 conventional Doxorubicin will be used as active comparator. four cycles of Doxorubicin plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere, every three weeks for one cycle.Dexrazoxane (DZR)will be used for protecting cardiac toxicity.Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
2492407|NCT02953184|Experimental|PLD plus C -T|Pegylated Liposomal Doxorubicin(PLD) plus Cyclophosphamide followed Taxotere 8 cycles.35mg/M2 PLD will be used as experimental medicine. four cycles of PLD plus 600mg/m2 Cyclophosphamide every three weeks followed 4 cycles of 100mg/m2 Taxotere , every three weeks for one cycle.Vitamin B will be used for protecting hand-foot syndrome(HFS).Patients will undergo Modified Radical Mastectomy or Breast Conserved Surgery or Axillary Lymph Node Dissection(ALND) or Sentinel Lymph Node Biopsy（SLNB） after 8 cycles of chemotherapy
2493621|NCT02944721|Other|Transversal study|Patients who had surgery for breast cancer for 2 years or less
2491539|NCT02958605|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
2491616|NCT02958215|Placebo Comparator|Group A|This group will include patients with orthostatic hypotension and will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
2491620|NCT02958215|Active Comparator|Group B|This group will include patients with orthostatic hypotension and will be managed with prophylaxis single dose of phenylephrine, 50 ug IV, will be administered immediately before the spinal block then the patients will be managed with routine spinal anesthesia Ephedrine will be used for management of intraoperative hypotension
2491682|NCT02957643|Placebo Comparator|pregnant women|iron dosage 1 per day for 3 months
2491690|NCT02957643|Experimental|pregnant women with anemia|iron dosage 1 per day for 6 months
2491730|NCT02957253|Experimental|Intervention (CI)|Compensated intervention (CI). Nurse-led clinic one time per year. Focus on Life style and risk factors.
2491731|NCT02957253|No Intervention|Control (CC)|Compensated Control (CC)
2491732|NCT02957253|Experimental|Intervention (DI)|Decompensated intervention (DI). Nurse-led clinic two times every month to every third month. Focus on Lifestyle, risk factors, nutrition, selfcare and psychosocial needs
2491733|NCT02957253|No Intervention|Control (DC)|Decompensated Control (DC)
2491822|NCT02956798|Experimental|Stereotactic ablative body radiation (SABR)|Stereotactic ablative body radiation (SAbR) to all sites of measurable metastases (≤3) will be treated by SAbR. New sites of metastasis will be evaluated for continued treatment if deemed appropriate by both medical and radiation oncologists with SAbR.
2491871|NCT02956369|Placebo Comparator|Control|10 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups. The control granulates consists of maize starch and long-chain fatty acids with powder.
2491875|NCT02956369|Active Comparator|SATIOSTAT|10 obese, non-diabetic candidates will ingest SATIOSTAT as meal replacement at lunch and as first course at dinner over a period of 6 weeks. The SATIOSTAT granulates consists of hydrocolloids (fibers) and long-chain fatty acids with powder.
2492050|NCT02955537|No Intervention|Usual care|Usual care participants will be given a prescription for antihypertensive medications, printed educational materials on hypertension, and a home blood pressure monitor for daily use, but will receive no further intervention.
2492053|NCT02955537|Experimental|MI-BP|MI-BP participants will receive an antihypertensive medication prescription, and be asked to use technology-mediated devices/services linked to positive changes in target behavior/outcome including the MI-BP app, a secure, mHealth platform that will be installed on participant smartphones.
2492102|NCT02954978|Placebo Comparator|Placebo|"Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 1 will receive the placebo (sugar pill) one (1) capsule by mouth once daily (taken without a meal) for 12 months and 3 months follow up."
2492103|NCT02954978|Active Comparator|Nilotinib 150mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
2492104|NCT02954978|Active Comparator|Nilotinib 300mg|Out of seventy five (75) participants that will be recruited and randomly assigned 1:1:1 to the three (3) groups (arms), 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
2492135|NCT02954666|Experimental|Patients with neurally mediated syncope|Tailored radio-frequency ablation of the ARGP (CardNM).
2492139|NCT02954666|Experimental|Patients with sick sinus syndrome|Tailored radio-frequency ablation of the ARGP (CardNM).
2492181|NCT02954406|Experimental|Dose Escalation Phase Cohort A:TAK-659 + Bendamustine|TAK-659 60 milligram (mg), immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 milligram per square meter (mg/m^2), infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492182|NCT02954406|Experimental|Dose Escalation Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492183|NCT02954406|Experimental|Dose Escalation Phase Cohort C: TAK-659 + Gemcitabine|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 21 along with gemcitabine 1000 mg/m^2, infusion, intravenously, over 30 minutes on Days 1 and 8 in a 21-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492184|NCT02954406|Experimental|Dose Escalation Phase Cohort D: TAK-659 + Lenalidomide|TAK-659 60 mg, immediate-release tablet, orally, once daily on Days 1 to 28 along with lenalidomide 25 mg, capsules orally, once daily on Days 1 to 21 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492185|NCT02954406|Experimental|Dose Escalation Phase Cohort E: TAK-659 + Ibrutinib|TAK-659 60 mg, immediate-release tablet, orally, once daily along with ibrutinib 560 mg capsules, orally, once daily on Days 1 to 28 in a 28-day treatment cycle. The TAK-659 will be escalated to 80 mg or 100 mg once daily after safety and tolerability of 60 mg dose is determined. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492520|NCT02952196|Placebo Comparator|placebo|
2492528|NCT02952196|Experimental|cannabinoid dose 1|
2491540|NCT02958475|Experimental|Attention Control|Participants in control arm will receive normal standard messages about infant injury prevention.
2491546|NCT02958475|Active Comparator|Breastfeeding Messages plus Social Support|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action. In addition they will be able to download the MMM app, which will store text messages received. Additionally, participants in this arm will be able to link within the app to a private Facebook page. Participants can access this page through their app or directly via Facebook where they can view, comment, and share in response to posts. The MMM app has three main elements: text messages via push notification are stored and searchable on the app, access to a breastfeeding social support group on Facebook, and access to videos and written material to facilitate knowledge acquisition and skills building.
2491552|NCT02958475|Active Comparator|Breastfeeding Messages only|Participant will receive between 5-7 text messages weekly through push notifications to their phone. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
2491592|NCT02958072|Experimental|LeucoPatch|Treatment with usual ulcer care and LeucoPatch once weekly up til 24 weeks or until healing.
2491594|NCT02958072|Active Comparator|Usual care followed by LeucoPatch|Usual care weekly for 12 weeks, if the ulcer persist after the12 weeks LeucoPatch treatment will be started for up to 12 weeks or until healing.
2491685|NCT02957669|Experimental|Practice Self-Regulation (PS-R)|Practice Self-Regulation (PS-R) is the treatment condition. PS-R is an in-person, individual-level, clinic-based intervention that aims to increase knowledge of sexual health and the impact of trauma on sexual decision-making.
2491698|NCT02957669|Active Comparator|Therapy Practice Group|Therapy Practice Group is the control counterfactual condition. It is an individual-level, therapy as usual in which the therapist addresses mental health concerns of the participant.
2491734|NCT02957266|Active Comparator|Classical treatment|Classical concurrent cisplatin based chemoradiotherapy of cervical cancer. PIK3CA, KRAS, BRAF and RRM1 mutations rates.
2491735|NCT02957266|Experimental|GemInterBraVMAT|"Concurrent chemoradiotherapy of cervical cancer patients treated by VMAT (volumetric arc radiotherapy) based external beam radiotherapy, polyradiosensitization by cisplatin and gemcitabine and interstitial brachytherapy.~PIK3CA, KRAS, BRAF and RRM1 mutations rates."
2491805|NCT02956642|Experimental|Blood Glucose Monitoring System|Participants in this arm will receive the Livongo Health System to manage diabetes. 150 participants will participate in this arm.
2491810|NCT02956642|Active Comparator|Standard Blood Glucose Monitoring|Participants in this arm will receive the iHealth Glucose Meter to take blood glucose measurements that will then be compared to participants from the Livongo Health System arm. 150 participants will participate in this arm.
3194641|NCT00830492|Active Comparator|2|In group A (n=100), the patients were stimulated conventional. They desensitized with buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg and ovarian stimulation would commence with 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
2492051|NCT02955498|Experimental|R-T|First period: administration of reference drug, Second period: administration of test drug
2492054|NCT02955498|Experimental|T-R|First period: administration of test drug, Second period: administration of reference drug
2492084|NCT02954965|Experimental|Reward|A brief, phone-administered intervention designed to help graduate students increase the number of pleasant and rewarding activities in their daily lives.
2492088|NCT02954965|Experimental|Approach|A brief, phone-administered intervention designed to help graduate students block procrastination and avoidance and to approach important activities they are currently avoiding.
2492093|NCT02954965|No Intervention|Monitoring|Participants will monitor their current behaviors, mood, and burnout with no directed intervention to change behavior
2492125|NCT02954783|Experimental|High Intensity Interval Training|The HIIT-group will receive usual care plus a supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes.
2492127|NCT02954783|Active Comparator|Usual Care Observational Control|Patients randomized to usual care control will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.
2492188|NCT02954497|Experimental|Jarvik 2015 Device VAD|New, experimental continuous flow VAD
2492230|NCT02953977|Experimental|Diabetes Intervention|Diabetes Prevention Program
2492235|NCT02953977|Other|Delayed Intervention|Diabetes Prevention Program
2492280|NCT02953730|Experimental|PEG-rhG-CSF|
2492324|NCT02953496|Experimental|vonapanitase|
2492364|NCT02953210|Experimental|GF general free|pre induction midazolam 50ug.kg-1, clonidine 1ug.kg induction dexter ketamine 0.2mg.kg, lidocaine 1.5mg.kg, propofol 2mg.kg,rocuronium 0.6mg.kg maintenance isoflurane 1 CAM, lidocaine 2mg.kg.h
2492365|NCT02953210|Active Comparator|GBal general balanced|pre induction with midazolam 50 ug.kg induction fentanyl 3ug.kg, propofol 2mg.kg, rocuronium 0.6mg.k maintenance isoflurane 1 CAM and fentanyl as needed
2492507|NCT02952404||Before workshop|October 2014 to October 2015 Cohort which is the time frame before the educational workshop
2492514|NCT02952404||After workshop|December 2015 to December 2016 Cohort which is the time after the educational workshop
2492612|NCT02951676||EA - Extraction with antibiotics|"Patients undergoing third molar extraction with antibiotic treatment.~Amoxicillin 250 mg , three times daily for five days."
2492617|NCT02951676||E - Extraction without antibiotics|Patients undergoing third molar extraction with antibiotic treatment.
2492619|NCT02951676||Control|Age and sex matched controls who are not undergoing extractions or antibiotic treatment
2491547|NCT02958436|Experimental|Cohort 1|Dose regimen 1 of REGN3500 (IV) versus placebo
2491551|NCT02958436|Experimental|Cohort 2|Dose regimen 2 of REGN3500 (IV) versus placebo
2491554|NCT02958436|Experimental|Cohort 3|Dose regimen 3 of REGN3500 (IV) versus placebo
2491558|NCT02958436|Experimental|Cohort 4|Dose regimen 4 of REGN3500 (SC) versus placebo
2491568|NCT02958436|Experimental|Cohort 5|Dose regimen 5 of REGN3500 (IV) versus placebo
2491678|NCT02957422|Experimental|Dietary intervention|Participants will receive dietary intervention. Participants will be taking 3 servings of dairy/day.
2491692|NCT02957422|Active Comparator|Control|Participants will receive no additional intervention. Participants will continue on their regular diet, which includes ≤1.5 dairy serving/day.
2491759|NCT02957240|Active Comparator|Standard Care|Four clinic-based intervention sessions where the focus will be on home program competency and advancement and standard home program 3x daily for 15 minutes.
2491761|NCT02957240|Experimental|Standard Care and Motor Representation Techniques|4 clinic-based intervention sessions including 'standard care' intervention in addition to a 'movement representation' intervention. Home Program for Standard Care and Motor Representation 3x daily for 30 minutes.
2491796|NCT02956655|Experimental|Fasting therapy|Fasting therapy, lasting for 14 days, all subjects are isolated from ordinary food. However, drinking water is not limited and they are encouraged to drink more, at least 3 liters. Besides, they need to take some middle intensity exercise for at least 2 hours. They will take some prescribed medications except for hypoglycemic drugs.
2491799|NCT02956655|Active Comparator|Insulin intensive therapy|Insulin intensive therapy, receive continuous subcutaneous insulin infusion. (Human Insulin (Novolin-R, Novo Nordisk) Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland). The insulin dose used will be adjusted everyday according to their glucose by a physician until a target blood glucose level been reached.
3161393|NCT00441597|Active Comparator|2|first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
3161394|NCT00441597|No Intervention|3|3 days treatment with placebo twice
3161395|NCT00441610|Experimental|Gimatecan|
3161396|NCT00441636|Experimental|CPAP treatment|Continuous Positive Airway Pressure (CPAP)for 4 weeks
2492086|NCT02955225|Experimental|Flexible shoe with Active Insole|Subjects will be trained to change the plantar pressure using a flexible walking shoe with an activated pressure-detecting shoe insole (Moticon OpenGO insole).
2492091|NCT02955225|Active Comparator|Flexible shoe with Passive Insole|A flexible walking shoe with a passive pressure-detecting shoe insole will be used for a comparator group.
2492142|NCT02954744|Experimental|Treatment arm|HIFU treatment
3161397|NCT00441636|No Intervention|No CPAP|routine psychiatric care for 4 weeks followed by CPAP titration and initiation after followup measures.
2492304|NCT02953470|Experimental|Individual tailored functional exercise|Receives general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. The intervention group, which is based on a behavioural medicine approach in physiotherapy, also receive individual tailored functional exercise with the goal to enhance the ability to perform everyday activities by reduce pain-related disability and pain-related beliefs and increase physical function. The participants receive 9 visits from a physiotherapist during the 12 weeks period. The participants will also fill in a activity diary to check the compliance to the intervention and to enhance their self-efficacy in relation to perform everyday activities, exercise and physical activity.
2492305|NCT02953470|Active Comparator|Standard care|The participants in the comparison Group will receive standard care which means that they receives one visit from physiotherapist where the participant receive general advice about physical activity with the goal to be physically active at least 30 minutes per day at 5 of 7 days per week. During intervention week 1-8 and 10 the participants receive telephone calls once a week where they will be reminded to follow the advice about physical activity.
2492353|NCT02953301|Experimental|resminostat|3 x 200 mg tablets p.o., 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
2492355|NCT02953301|Placebo Comparator|Placebo|3 tablets p.o. matching verum, 5 days treatment followed by 9 days rest (cycles until progress or unacceptable toxicity)
2492432|NCT02952690|Active Comparator|standard curve group|The style is curved in accordance with the curve of GVL blade in this group.
2492435|NCT02952690|Experimental|tip-manipulated curve group|The style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree) in this group.
3161398|NCT00441636|No Intervention|Control group|No obstructive sleep apnea detected.
3161399|NCT00441675||Salmeterol/Fluticasone|Previous Salmeterol/Fluticasone treatment
3161400|NCT00441675||Fluticasone|Previous Fluticasone propionate treatment
3161401|NCT00441688|Experimental|GI265235|
2492653|NCT02951520|Experimental|SOFT block|Fifty patients will form the study group (one group). All the patients will receive supine ultrasound guided (US) sciatic, obturator, femoral nerve block technique using a single skin puncture (SOFT block).
2492697|NCT02951221|Experimental|Cohort 1|Treatment sub groups A and B
3161402|NCT00441740|Experimental|1|VG
3161403|NCT00441740|Experimental|2|DG
3161404|NCT00441779||1|Traumatic injury
3161405|NCT00441779||2|Elective orthopedic surgery
3161406|NCT00441779||3|Burn injury
3161407|NCT00441896|Experimental|ganaxolone|ganaxolone
3161408|NCT00441896|Placebo Comparator|non-active drug|placebo
3161409|NCT00441909|Experimental|1A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 8 hours
3161410|NCT00441909|Placebo Comparator|1B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 8 hours
3161411|NCT00441909|Experimental|2A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 4 hours
3161412|NCT00441909|Placebo Comparator|2B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 4 hours
3161413|NCT00441909|Experimental|3A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 2 hours
2491556|NCT02958410|Experimental|Lymphocyte Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD30-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2491601|NCT02958098||Myocardial infarction|Individuals with myocardial infarction before age 50 years.
2491602|NCT02958098||Stroke|Individuals with stroke before age 50 years
2491605|NCT02958098||Aortic dissection|Individuals with aortic dissection before age 50 years
2491608|NCT02958098||Systolic heart failure|Individuals with systolic heart failure/dilated cardiomyopathy before age 50 years.
2491610|NCT02958098||Atrial fibrillation|Individuals with atrial fibrillation before age 50 years
2491647|NCT02957773|Experimental|Qigong and art activities|An integrated group of Qigong and art activities for 90 minutes.
2491648|NCT02957773|Experimental|Art activities|Art activities and daily activities group for 90 minutes.
2491649|NCT02957773|Experimental|Qigong|A Qigong and daily activities group for 90 minutes
2491650|NCT02957773|Other|Daily activities|A daily activities group for 90-minutes.
2492007|NCT02956109|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 10 mg finerenone tablet fasting
2492009|NCT02956109|Experimental|Pediatric formulation: 5X 0.25 mg Finerenone ODT_Fasting|Single oral dose of 5 x 0.25 mg finerenone oro-dispersible tablets fasting
2492012|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fasting|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fasting
2492013|NCT02956109|Experimental|Pediatric formulation: 1.25 mg Finerenone ODT_Fed|Single oral dose of 1.25 mg finerenone oro-dispersible tablet fed; 30 minutes after start of an American breakfast
3161414|NCT00441909|Placebo Comparator|3B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 2 hours
3161415|NCT00441909|Experimental|4A|Participants will receive a single application of UC-781 vaginal microbicide, which will be inserted for 0 hours
3161416|NCT00441909|Placebo Comparator|4B|Participants will receive a single application of UC-781 vaginal microbicide placebo, which will be inserted for 0 hours
3161417|NCT00441922|Experimental|1|D
2492367|NCT02953249||Study group|The study group will include 30 subjects with type 1 diabetes mellitus who require extraction of 1 or more erupted teeth
2492371|NCT02953249||Control group|The control group will include 30 healthy subjects, without diabetes mellitus, in need of tooth extraction
2492416|NCT02952937|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 300mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2492417|NCT02952937|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF1 tablet 300mg , 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2492448|NCT02952599||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
3161418|NCT00441922|Experimental|2|V
3161419|NCT00441935||Interstim Neuromodulation|Subjects undergoing implantation of an Interstim device for neuromodulation.
3161420|NCT00442026|Experimental|1|DG
3161421|NCT00442026|Experimental|2|G
3161422|NCT00442039|Experimental|Lithium dosing 1|The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
3161423|NCT00442039|Experimental|Lithium dosing 2|"The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patients response and tolerability."
3161424|NCT00442039|Experimental|Lithium dosing 3|"The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patients response and tolerability."
3161425|NCT00442039|Placebo Comparator|Placebo|
3161426|NCT00442065|Active Comparator|Open label, single arm|A prospective, open label, single-arm (non-randomized) multi-center, international clinical device investigation to collect safety and performance data concerning the Aorfix™ Stent Graft System in the treatment of abdominal aortic aneurysm and aorto-iliac aneurysm where a significant degree of vessel angulation exists
3161427|NCT00442091|Other|10 ml of dandelion juice twice daily|
3161428|NCT00442104|Experimental|ganaxolone|
3161429|NCT00442130|Experimental|GM-K562 Vaccine|"Biological/Vaccine: GM-K562 vaccine The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.~Procedure/Surgery: stem cell transplantation Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation"
3161430|NCT00442156||Laser|People with diabetic macular edema involving the center of the macula (OCT central subfield thickness >250 microns), who were already intended to receive focal photocoagulation
3161432|NCT00442442|No Intervention|1|No treatment control
3161433|NCT00442442|Active Comparator|2|LLIN Nets
3161434|NCT00442442|Experimental|3|Mosquito Coils
3161435|NCT00442442|Experimental|4|Mosquito coils & LLIN
3161436|NCT00442455|Experimental|Erlotinib, radiotherapy.|There are three cohorts of patients in whom the dose of Erlotinib chlorhydrate(100 and 150 mg) and Cisplatin (30 and 40 mg / m2) will be increase, and the doses of Radiation therapy being fixed (63 Gy during 5 days a week during 7 weeks)
3161437|NCT00442494|Other|Study couldn´t start due to investigator|Study couldn´t start due to investigator
3161438|NCT00442520||2|colorectal cancer patients
3161439|NCT00442520||3|head and neck cancer patients
3161440|NCT00442520||1|lung cancer patients
3161441|NCT00442533|Experimental|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
2491559|NCT02958462|Other|Potential Premyeloid Cancer or Bone Marrow Failure Patients|Follow up provided for patients tested using Next Generation Sequencing (NGS) and other relevant functional studies
2491612|NCT02958137||Isolated CMC|Arthroscopic Resection Arthroplasty of isolated CMC joint OA. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
2491615|NCT02958137||Pantrapezial|Arthroscopic Resection Arthroplasty of simultaneous ARA of both the CMC and the STT joints. Please note, this is standard practice of Dr. Cobb's for treatment of CMC and/or STT arthritis.
2491664|NCT02957695|Placebo Comparator|Control group|Control Intervention: Placebo-Neurofeedback, 20 sessions
2491669|NCT02957695|Active Comparator|Intervention group|Experimental Intervention: Active-Neurofeedback, 20 sessions
2491744|NCT02957344||Text without context|
2491747|NCT02957344||Text with context|
2491748|NCT02957344||Map without context|
2491750|NCT02957344||Map with context|
2491807|NCT02956876|Experimental|Nurse practitioner consultation|standard chemotherapy for colorectal cancer
2491814|NCT02956876|Other|Standard consultation|standard chemotherapy for colorectal cancer
2491862|NCT02956252||Spinal anesthesia group|patients underwent laparoscopic cholecystectomy under spinal anesthesia
2491863|NCT02956252||General anesthesia|Patients underwent laparoscopic cholecystectomy under general anesthesia
3194642|NCT00830492|Experimental|clomiphen/gonadotropin/GnRH antagonist|Patients in group B ( n=100 ) were stimulated clomiphene citrate ( ) 100 mg from cycle day three through seven and continuous gonadotropin stimulation with of r_FSH 75 IU daily from cycle day 5. Ultrasound in two group was performed on 8 cycle day. In group B 0.25 mg GnRH antagonist (Ganirelix , Organon ,Netherland ) daily was started with dominant follicle ≥14mm and in this day 75 IU human menopoasl gonadotropin (HMG) (Menogon, ferring, pharmacenticals , Germany ) increased to the initial gonadotropin . LH assessment on the day of starting antagonist was performed and if LH was >15 IU/L , cycle was cancelled. Human chorionic gonadotropin 10000 IU ((pregnyl, Organon, Oss, the Netherlands ) was given when 1 to 3 follicles reached 18 mm
3194643|NCT00830505|Experimental|1: fluticasone/salmeterol|2 puffs twice a day for 2 weeks
2492020|NCT02955472|Other|Group 1|"Period 1: GLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
2492023|NCT02955472|Other|Group 2|"Period 1: GLA5PR GLARS-NF3 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO).~wash-out period: over 7 days.~Period 2: ComparGLA5PR GLARS-NF1 tablet 150mg, 1 tab, once a day(QD), after evening meal(Regular Diet), oral administration(PO)."
3194644|NCT00830505|Active Comparator|2: fluticasone|2 puffs twice a day for 2 weeks
2492143|NCT02954562||Anxiety|"Participants enrolled in study A randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated with a Life-Threatening Illness (NCT02427568) who meet further inclusion criteria for fMRI scan"
2492221|NCT02954367|Experimental|PROTEIN (MEAT + WHEY)|Post workout (training days) or breakfast (non training days) 20g of meat protein (10g meat + 10g whey) mixed with 200ml of orange juice and water
2492224|NCT02954367|Placebo Comparator|CARBOHYDRATE (CHO)|Post workout (training days) or breakfast (non training days) 20g of maltodextrin mixed with 200ml orange juice and water
2492270|NCT02953756||Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery (GKRS)
2492299|NCT02953535|Experimental|T test|Test drug (Magicbuvir)1 tablet contains 400 mg Sofosbuvir
2492300|NCT02953535|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2492301|NCT02953535|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
3194645|NCT00830531|Experimental|1|Standard phenobarbital combined with either 0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the status of the dose escalation design.
3194646|NCT00830531|Placebo Comparator|2|Standard phenobarbital therapy combined with normal saline as placebo for bumetanide
2492437|NCT02952547|Experimental|Test / Reference Drug|DWJ1366 Tab. followed by co-administration of DWC20155 and DWC20156 Tab.
2492445|NCT02952547|Experimental|Reference / Test Drug|Co-administration of DWC20155 and DWC20156 Tab. followed by DWJ1366 Tab.
2492500|NCT02952352|Experimental|Diabetes Intervention|Diabetes Prevention Program
2492510|NCT02952352|Other|Delayed Intervention|Diabetes Prevention Program
2492543|NCT02952105||defibrillation patients|shockable rhythm, defibrillated
2492544|NCT02952105||non defibrillation patients|non-shockable rhythm, non defibrillated
3194647|NCT00830544|Experimental|1|Experimental chemotherapy using neoadjuvant approach
3194648|NCT00830570||1|Historical control group. Patients in this group are drawn from the same plan populations as the intervention group, but they are identified during the 1-year period prior to the start of patient enrollment in the intervention group. The historical control group is closely matched with the intervention group on demographic characteristics, practice patterns, and benefit plan features that may affect resource utilization.
3208732|NCT00977600|Experimental|GT4P-F|GT4P-F (80% GT4P) was supplied as an odorless, colorless, tasteless liquid oil in 125 ml bottles. This formulation was designed to be mixed in water and create a self-emulsifying suspension, thus administered in water for the trial. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-F was mixed in 50 ml of water, taken orally, and then the cup rinsed with 50 ml of water and taken orally. GT4P-F was stored at ambient temperature away from light.
2492962|NCT02949817|Experimental|IMU sensor training group(intervention group)|video-game based rehabilitation therapy system training group
2492966|NCT02949817|Active Comparator|Conventional OT group (control group)|conventional training group (control group)
2493021|NCT02949258|Experimental|SEEOX group|A three-cycle neoadjuvant chemotherapy will be performed in all cases. In every cycle, oxaliplatin 150 mg, etoposide 100 mg and epirubicin 50 mg will be administered from the celiac artery on day 1. Oral S-1 120 mg per day will be given for days 1-14. The second cycle will be scheduled following a 1-week rest after the first cycle.After two courses of neoadjuvant chemotherapy, patients will be reevaluated and receive curative or palliative resection or exploratory laparotomy within 14 days after completing the second course of chemotherapy.
2491560|NCT02958423|Experimental|Transcranial DCS Healthy Volunteers|5 HV will be treated once with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2491569|NCT02958423|Experimental|Transspinal DCS Healthy Volunteers|5 HV will be treated once with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2491575|NCT02958423|Experimental|Transcranial DCS CPP patients|5 chronic pelvic pain patients will be treated with transcranial direct current stimulation (2mA, anodal, 20 minutes) over right primary motor cortex 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2491576|NCT02958423|Experimental|Transspinal DCS CPP patients|5 chronic pelvic pain patients will be treated with transspinal direct current stimulation (2mA, anodal, 20 minutes) over the D10 spinal process 5 days/week for 4 weeks with the Direct Current (DC) Stimulator (NeuroConn. Germany)
2491600|NCT02957981|Experimental|Web-Based Counseling|Genetic information provided via an individually tailored website.
2491603|NCT02957981|Active Comparator|Standard Care|Participants are not provided with web-based education but can choose to pursue genetic counseling and testing.
2491713|NCT02957734|Experimental|LAVA Ultimate restorations|For rehabilitation of the severely worn teeth, teeth are prepared (based on Minimal Invasive procedures), scanned using an intra-oral 3D-scanner (TrueDef, 3M), a digital wax-up model is made and finally restorations are milled from a pre polymerized block of resin (LAVA Ultimate). These indirect restorations are then adhesively cemented on the teeth (Relyx Ultimate, 3M). Teeth on which no indirect restoration could be made/designed a direct composite restoration was made using Filtek Supreme XTE in combination with Scotchbond Universal. Furthermore, all anterior veneer restorations are made of direct composite restorations (Filtek Supreme XTE in combination with Scotchbond Universal).
2491790|NCT02956902|No Intervention|Waiting list control|
2491793|NCT02956902|Experimental|Intervention|Clinician-supported smartphone application intervention
2491892|NCT02956473|Experimental|Supine MRI|"Standard MRI will be performed~Supine MRI will be performed~Participant will receive mammography and ultrasound~Breast Radiologist will take a brief survey.~Patients will undergo upfront surgery or receive Neoadjuvant Therapy per standard of care~Standard of care will be performed"
2491927|NCT02955810|Experimental|CyBorD-DARA|
2491984|NCT02955667|Experimental|invivo microscopy group|patients receive invivo micro-colposcopy examination and do not have to receive the biopsies
2491987|NCT02955667|Other|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
2492065|NCT02955433|Experimental|Rideshare|The intervention arm will receive an appointment reminder and free transportation for one appointment to travel between the patient's home and primary care clinic using a rideshare-based transportation service.
2492066|NCT02955433|No Intervention|Control|The control arm will receive an appointment reminder, but no free transportation offer.
3194649|NCT00830570||2|Concurrent control group. Patients in this group are drawn from different set of plan populations, but they initiate warfarin treatment during the same time period as patients in the intervention group. Outcomes data for the concurrent control group will be used to evaluate whether any differences between the intervention group and the historical control group can be attributed to changes in clinical practice over time. Baseline data for the concurrent control group will help validate the incidence assumptions used in the calculation of statistical power. This use of baseline population norms is an effective means of limiting bias in quasi-experimental studies.
2492202|NCT02954185|Experimental|WellClub Device|Hand held device that patients use for home therapy
2492203|NCT02954185|Active Comparator|Standard Therapy|Standard care therapy for should pain
2492231|NCT02953912|Experimental|Reciproc single-file.|The Reciproc is a single-file nickel-titanium systems used in reciprocating motion, made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue .
2492237|NCT02953912|Active Comparator|One Shape single-file .|One Shape is single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue. with electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
2492312|NCT02953704||Myelofibrosis Cohort|Patients will be categorized as low-risk using Dynamic International Prognostic Scoring System (DIPSS) risk OR intermediate-1 risk by DIPSS by reason of age alone.
2492316|NCT02953704||Essential Thrombocythemia Cohort|Patients will be age ≥ 60 years OR have history of thromboembolic events OR currently receiving ET-directed therapy.
3208733|NCT00977600|Experimental|GT4P-API|GT4P-API was supplied as an odorless, colorless, tasteless oil in 125 ml bottles. The administered dose was calculated to contain the number of moles of PBA equivalent to 3 g/m2 of PBA. GT4P-API was taken orally and washed down with 100 ml of water. GT4P-API was stored at ambient temperature, away from light.
2492841|NCT02950506|Active Comparator|Active tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with active tDCS(transcranial direct current stimulation) andcognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
2492843|NCT02950506|Sham Comparator|Sham tDCS|There will be a total of 14 visits in the study: will complete a screening visit, an initial visit, 10 session visits with sham tDCS and cognitive remediation therapy, and follow--up visits immediately (within 5 days), 1 and 3 months after the last intervention. Subjects will be informed of their group assignment at the end of the study.
2492875|NCT02950116|Active Comparator|Asthma|Asthmatic patients will perform three multiple breath nitrogen washout tests (N2-MBW-test)
2492877|NCT02950116|Active Comparator|Non-CF bronchiectasis|Patients with non-CF bronchiectasis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
2491561|NCT02958449|Experimental|Test - Standard Closure with TissuGlu Surgical Adhesive|Standard closure plus treatment with TissuGlu
2491572|NCT02958449|No Intervention|Control - Standard Closure|Standard closure with no intervention
2491662|NCT02957721|Other|Behavioral self-management|Eligible patients who are registered on the practice EHR linked portal will be invited to join the study. Following informed consent, enrollment and randomization, participants in the treatment group will receive the type 2 diabetes behavioral self-management education intervention; comprised of 9 modules derived from Medline Plus.
2491663|NCT02957721|No Intervention|Usual Care|Usual care includes whatever care and services the patient's clinical provides as well as generic type 2 diabetes education built into the patient's EHR linked portal.
2491721|NCT02957396|Active Comparator|Adult formulation: Finerenone tablet_Fasting|Single oral dose of 20 mg intact finerenone tablet fasting
2491723|NCT02957396|Experimental|Adult formulation: Finerenone crushed tablet_Fasting|Single oral dose of 20 mg crushed and resuspended finerenone tablet fasting
2491724|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fasting|Single oral dose of 20 mg finerenone suspension fasting
2491725|NCT02957396|Experimental|Pediatric formulation: Finerenone suspension_Fed|Single oral dose of 20 mg finerenone suspension fed; 30 minutes after start of an American breakfast
2491765|NCT02956954|Experimental|Patient treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
2491767|NCT02956954|Sham Comparator|Patient no treated with Enzyme replacement therapy|Magnetic Resonance Imaging will be done every 6 months for patient treated with Enzyme replacement therapy (Agalsidase alpha (Replagal®))
3194650|NCT00830570||3|Active study group. For plans participating in the active arm of the study, enrollment is offered to every patient who initiates warfarin therapy during the enrollment period (beginning in July 2007) and who meets the eligibility criteria. Patients are identified for the active study group if they have a warfarin pharmacy claim and no prior warfarin claims during the preceding 180 days. Only patients who remain eligible for the pharmacy benefit throughout the study period are included in the final sample.
3194651|NCT00830583|Other|1|pompe's disease suspected patient
2491893|NCT02956174|Experimental|Co-Cr single crown|Co-Cr single crown
2491903|NCT02956174|Active Comparator|Contralateral sound tooth|Contralateral sound tooth
2491929|NCT02955979||CT scan with iodinated contrast agents|Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
2492016|NCT02955628|Experimental|Ibrutinib-RICE|Patients not achieving a complete remission at time of PET-2 will receive ibrutinib and proceed on to autologous transplant if at least a partial remission is achieved. After transplantation, ibrutinib will be continued for up to 1 year. Autologous transplantation will be with BEAM conditioning.
2492081|NCT02955160|Experimental|Multivalent|Pneumococcal conjugate vaccine
2492083|NCT02955160|Active Comparator|Tdap|Tetanus, diphtheria, and pertussis vaccine
2492157|NCT02954809|Experimental|Experimental|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
2492161|NCT02954809|Active Comparator|Attention Control|Exposure to dim light delivered with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
2492193|NCT02954263|Experimental|TD-1439|Capsule formulation
2492196|NCT02954263|Placebo Comparator|Placebo|Capsule formulation
2492246|NCT02954003|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
2492302|NCT02953613||Cardiac Catheterization with NIRS/IVUS|Cardiac cathetirization with NIRS/IVUS assessment if with blockage of indeterminate severity (greater or equal to 20% to 70%). One day to one week after invasive catheterization a CCTA will be done to correlate result, then CCTA will be repeated at 24 months
2492341|NCT02953327|Experimental|Intervention arm|Intervention arm, these participants will receive BCG vaccination.
2492345|NCT02953327|Placebo Comparator|Placebo arm|The placebo arm will receive BCG solvent.
2492366|NCT02953119|Experimental|Prehabilitation|"The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:~5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively."
2492368|NCT02953119|No Intervention|Controls|The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.
2492414|NCT02952950|Other|Oralstimulation|Infants whose mothers is included in the cohort is randomized to receive oral stimulation when the infant's postnatal age is at least 32 + 0 weeks, as it is the time when the infant is able to coordinate sucking and swallowing reflex
2492415|NCT02952950|No Intervention|Controlgroup|Families in the control group is not seeing the oralstimulation movie, do not receive the script or the supervision of occupational therapists and these infants do not get oral stimulation. Both groups receive instructions after usual practice i.e. guidance and elements that promote breastfeeding example, skin to skin contact and compression.
3194652|NCT00830609|Active Comparator|A|Patients in this arm will receive standard of care (Peginterferon alfa 2A 180 mcg/weeks SC plus ribavirin 800 mg/day for 24 weeks).
2491562|NCT02958618|Experimental|"Duration for 30 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 30 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2491571|NCT02958618|Experimental|"Duration for 60 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 60 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2491574|NCT02958618|Experimental|"Duration for 180 group"|A limited sphincterotomy measuring up to one-third of the size of the papilla was first performed. Dilation with a controlled radial expansion (CRE) balloon (diameter 10, 12, 15, 18 ) was performed after the sphincterotomy. The balloon was centered at the sphincter and gradually filled with diluted contrast under endoscopic and fluoroscopic guidance until waisting was abolished. Once the waist had disappeared, the balloon was kept in position for 180 seconds. The stones were then removed by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
2491681|NCT02957526|Experimental|App|The web-based app will be used to ask participants about their aromatase inhibitor use in the previous 7 days and ask about treatment-related adverse symptoms, or changes in the severity of symptoms. Participants will receive reminders via text or email to use the app once per week. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
2491694|NCT02957526|Active Comparator|Usual Care|Participants will have access to the web-based app, but will not receive reminders. All participants will be followed for a 6-8 weeks (depending on the data of participants' in-clinic follow-up visit) and will be asked to complete a baseline survey at enrollment and a follow-up survey at their 6-8 week in-clinic follow-up visit.
2491766|NCT02957188||Young|Six young (18-30 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
2491768|NCT02957188||Elderly|Six older (≥ 70 yrs old) healthy participants were recruited. The study had three blocks of one month: 13C-EPA follow-up, wash-out and 13C-AA follow-up. Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
2491789|NCT02956694|Experimental|Professional training|Professional e-learning program on shared decision making including two components: (1) a self-directed e-learning activity on shared decision making, lasting about 1 hour, that participants could complete in several sittings; and (2) five evidence summaries named Decision Boxes (DBs).
2491856|NCT02956447|Experimental|Kisspeptin Bolus|Administration of kisspeptin 112-121 0.24 nmol/kg intravenously (IV); 10 boluses in a 10 hour period. One bolus of GnRH at hour 11. Blood sampling every 10 minutes.
2491858|NCT02956447|No Intervention|Baseline|Blood sampling every 10 minutes
2491860|NCT02956447|Experimental|Pulsatile kisspeptin|Administration of kisspeptin 112-121 0.24 nmol/kg IV every 90 minutes over 14 days using a portable pump. One-time bolus of kisspeptin 112-121 2.4 nmol/kg IV (if necessary).
3194653|NCT00830609|Experimental|B1|After a period of 4 weeks with peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day (Induction phase), these patients will be allocated according to negativity or positivity of RNA-HCV at week 4. If RNA-HCV negative, treatment with peginterferon alfa 2 a 180 mcg/week plus RBV 800 mg/day (SOC) will be continued over 20 additional weeks (Arm B1). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
3194654|NCT00830609|Experimental|B2|If RNA-HCV at week 4 remains positive after the induction phase, then peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day will be continued for 20 additional weeks (Arm B2). Epo β (450 IU/kg/week) will be administered as required to maintain hemoglobin > 12g/dL.
3194655|NCT00830622|Experimental|1|Cell Phone Intervention: participant receives weekly SMS text message from the health care worker.
2492089|NCT02955251|Experimental|Arm 1|ABBV-428 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle).
2492094|NCT02955251|Experimental|Arm A, B, and C|Additional participants (with ovarian cancer, NSCLC, etc.) will be enrolled in a dose expansion cohorts that will further evaluate ABBV-428.
2492097|NCT02955251|Experimental|Arm D|Additional participants with NSCLC will be enrolled in an expansion cohort that will further evaluate ABBV-428 plus nivolumab.
2492100|NCT02955251|Experimental|Arm 2|ABBV-428 plus nivolumab.
3194656|NCT00830622|No Intervention|2|SOC: Participant receives standard of care support but not weekly SMS text messages from the health care worker.
3194657|NCT00830648|Experimental|1|
3194658|NCT00830661|Active Comparator|LIFT|those subjects receiving the Ligation of Intersphincteric Fistula Track procedure
3194659|NCT00830661|Active Comparator|Plug|those subjects randomized to the receive the placement of the porcine anal fistula plug
2492255|NCT02953808|Experimental|Cohort 1 Group A|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, GSK2315698 20 mg/hr, and Placebo, respectively, as intravenous infusion over 1 hour.
2492258|NCT02953808|Experimental|Cohort 1 Group B|In dosing sessions 1, 2, and 3, subjects will receive GSK2315698 10 mg/hr, Placebo, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
2492260|NCT02953808|Experimental|Cohort 1 Group C|In dosing sessions 1, 2, and 3, subjects will receive Placebo, GSK2315698 20 mg/hr, and GSK2315698 40 mg/hr, respectively, as intravenous infusion over 1 hour.
2492262|NCT02953808|Experimental|Cohort 2 Group D|In a single dosing session, subjects will receive GSK2315698 20 mg/hr as intravenous infusion over 15 hours.
2492263|NCT02953808|Placebo Comparator|Cohort 2 Group E|In a single dosing session, subjects will receive Placebo as an intravenous infusion over 15 hours.
2492531|NCT02952196|Experimental|cannabinoid dose 2|
2491564|NCT02958358|Experimental|Pulmonary Hypertension|Patients with Group I pulmonary arterial hypertension to undergo CT imaging, functional PET imaging before and after 3 months of treatment with ambrisentan
2491606|NCT02958111|Experimental|Adjuvant capecitabine|Adjuvant chemotherapy with single-agent capecitabine
2491609|NCT02958111|No Intervention|Observation|Clinical follow-up and surveillance only
2491679|NCT02957708|Experimental|mCIMT + SR|modified constraint-induced movement therapy plus self regulation
2491691|NCT02957708|Active Comparator|Control|conventional occupational therapy
2491756|NCT02957227||1|cohort 1: Older adults with memory impairment
2491757|NCT02957227||2|cohort 2: Age matched healthy controls
2491784|NCT02956759|Experimental|Early Intervention|pan-retinal photocoagulation laser treatment applied to the study eye within 2-4 weeks.
2491785|NCT02956759|Active Comparator|Standard Care|pan-retinal photocoagulation laser treatment deferred until the onset of any PDR.
3161442|NCT00442546|Experimental|1|
3161443|NCT00442546|Experimental|2|
3161444|NCT00442546|Placebo Comparator|3|
3161445|NCT00442624||1|Patients with chronic insomnia
3161446|NCT00442624||2|age, sex, bmi matched healthy controls
3161447|NCT00442637|Experimental|1|observation
3161448|NCT00442637|Active Comparator|2|capecitabine plus bevacizumab
3161449|NCT00442676|Experimental|1|Celecoxib, 200 mg/day
3161450|NCT00442676|Placebo Comparator|2|Placebo
3161451|NCT00442741|Experimental|Patupilone + Midazolam|
2491950|NCT02955771|Experimental|PDT-Deuteporfin（6 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 6 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
2491952|NCT02955771|Experimental|PDT-Deuteporfin（9 hour）plus stenting|Deuteporfin (7.5mg/kg) was injected intravenously 9 hours before intraluminal photoactivation (wavelength,630 nm;light dose, 180 J/cm(2)). After PDT, endoscopic or percutaneous stenting will be performed.The second treatment may be given after 3 months.
2491954|NCT02955771|Other|Stenting|Endoscopic or percutaneous stenting alone will be performed.
2491979|NCT02955524|Experimental|Treatment session 1a|"Topical ophthalmic anesthesia to participants (#) on each session (letter) of intra-arterial chemotherapy.~where #1 is the participant identifier and letter-a is the start session with study protocol (most candidates will receive more than 4 sessions in a 6 month period)"
2492046|NCT02955420|Experimental|BC 007 (15, 50, 150, 300, 450, 750, 1350, 1200 mg)|"Part A:~BC 007 at doses of 15, 50 and 150 mg or matching placebo administered as i.v. bolus + infusion of 20 min (Cohorts 1 to 4). The sentinel pair of each cohort will be dosed without bolus.~NaCl 0.9% (matching placebo) administered as i.v. bolus + infusion of 20 min (Part A: Cohorts 1 to 4).~Part B:~BC 007 at doses of 50 and 150 mg administered (Cohort 1) or a single dose < 50 mg or 150 mg (Cohort 2) as i.v. bolus + infusion of 20 min is administered to GPCR autoantibody positive subjects. The first subject in each dosing period of Cohort 1 will be dosed without bolus.~Part C:~BC007 administered at doses of 300 mg (Cohort 1), 450 mg (Cohort 2), 750 mg (Cohort 3), 1350 mg (Cohort 4) as i.v. bolus + infusion of 40 min to GPCR autoantibody positive subjects. The first three subjects in each dosing period of Cohort 1-4 will be dosed without bolus. In Cohort 5 BC007 dose of 1200 mg will be administered as a continuous infusion of 20 min."
2492067|NCT02955017|Active Comparator|Traditional follow-up|
2492068|NCT02955017|Experimental|"Distance follow-up new technologies"|
3161452|NCT00442741|Experimental|Patupilone + Omeprazole|
3161453|NCT00442780|Placebo Comparator|1|Dose Level A of BIIB014
2492935|NCT02949622|Experimental|Multimodal intervention program|The intervention program will be in group format, with a size of 10 to 12 patients per group and with an extension of 12 sessions. The treatment program will feature sessions with psychoeducation of metabolic syndrome and treatment model, problem solving, stress management, anger management, social skills, self-efficacy and social support.
2492937|NCT02949622|Active Comparator|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
2492989|NCT02949466|Experimental|triamcinolone and hyaluronic acid group|combined triamcinolone (Triamcinolone 10 mg 1cc) and hyaluronic acid (2 cc) injections: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
2493001|NCT02949466|Active Comparator|hyaluronic acid group|hyaluronic acid (2cc) injection: one injection per week, for 3 weeks, to compare the additional therapeutic effects of combined triamcinolone and hyaluronic acid injections to hyaluronic acid injections
2493066|NCT02948946||Neuroendocrine Tumor (NET) Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage NET of gastroenteropancreatic (GEP) or lung origin; In the first stage of the study (initial 50 patients) only potential participants with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
2493072|NCT02948946||Non-NET Cohort|Participants with histologically or cytologically proven diagnosis of any grade, any stage gastrointestinal (GI) malignancies.
2493112|NCT02948504||Observation|Aneurysms are left untreated based on patients and family's wishes. These patients will be included in the observation group.
2493120|NCT02948504||Coiling or Clipping|Patients are included in the coiling group if they undergo endovascular coiling, such as single coiling, stent-assisted coiling and balloon-assisted coiling. Or Patients are included in the clipping group if they undergo surgical coiling, such as aneurysm neck clipping, aneurysm isolation or trapping.
2493624|NCT02944721|Other|Longitudinal study|Patients that must be operated for a breast cancer
2494103|NCT02941705|Active Comparator|RECIEVED CELLS|this arm will receive the CDCs /CAP 1002 solution
3161454|NCT00442780|Placebo Comparator|2|Dose Level B of BIIB014
3161455|NCT00442780|Placebo Comparator|3|Dose Level C of BIIB014
3161456|NCT00442780|Placebo Comparator|4|Dose Level D of BIIB014
3161457|NCT00442793|Experimental|1|
3161458|NCT00442793|Active Comparator|2|
3161459|NCT00442806|Placebo Comparator|Placebo|Placebo is injected
3161460|NCT00442806|Experimental|Treatment|ADRC's are injected
3161461|NCT00442832|Experimental|TD-1792|
3161462|NCT00442832|Active Comparator|Vancomycin|
2491566|NCT02958371|Experimental|fMRI|The study consists in a fMRI experiment intended to observe the effect of the presence of choice on brain activity following consumption of a fruit-flavored drink, compared to the brain activity when the same drink is consumed without choice.
2491596|NCT02958046|Experimental|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
3161463|NCT00442871|Experimental|Eltrombopag|Eltrombopag 50 mg oral (single dose)
3161464|NCT00442910|Active Comparator|3% SPL7013|Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
2491775|NCT02956772|Experimental|TACE plus Arsenic Trioxide|Patients in this group are to receive a single dose of TACE treatment on day 1, followed by arsenic trioxide at 10 mg/day for 14 days (day 8-21). TACE treatment is repeated every 9 weeks while arsenic trioxide every 3 weeks for treatment duration of 27 weeks. At least 3 cycles of arsenic trioxide are administrated.
2491776|NCT02956772|Active Comparator|TACE|Patients in this group are to receive a single dose of TACE treatment on day 1. TACE treatment is repeated every 9 weeks for 27 weeks.
2491816|NCT02956525|Experimental|Dexibuprofen 200 mg - Fed|Fed condition
2491825|NCT02956525|Experimental|Dexibuprofen 200 mg - Fasting|Fasting condition
2491907|NCT02956148|Experimental|Radioligand [18F]MNI-659|"All subjects will receive a single intravenous dose of the radioligand [18F]MNI-659 (investigational medicinal product [IMP]) and undergo PET imaging.~The radioligand [18F]MNI-659 will be administered at a dose of less than 5 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
2491943|NCT02955875|Experimental|Pharmaceutical care|Participants received systematically organized pharmaceutical care services, which were provided by pharmacists, in addition to the usual care. The usual care includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
2491946|NCT02955875|No Intervention|Usual care|Participants received the usual care, which includes traditional consultation with pharmacists as well as traditional medical services provided by physicians, nurses, and dietitian.
2491991|NCT02955680|Experimental|Group M|At the end of surgery, patients were stimulated to wake up by recorded mother's voice, which was recorded before the operation.
2491994|NCT02955680|Active Comparator|Group S|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
2492052|NCT02955407||Low back pain patients|Low back pain since more than 3 months Age: 18-65 Caucasian race
2492056|NCT02955407||Controls without low back pain|no low back ain Age: 18-65 Caucasian race
2492085|NCT02954991|Experimental|Glesatinib and Nivolumab|Glesatinib oral tablet administered twice daily in combination with Nivolumab administered as 240 mg IV every 2 weeks
2492090|NCT02954991|Experimental|Sitravatinib and Nivolumab|Sitravatinib oral capsule administered daily in combination with nivolumab administered as 240 mg IV every 2 weeks
2492095|NCT02954991|Experimental|Mocetinostat and Nivolumab|Mocetinostat oral capsule administered three times weekly in combination with nivolumab administered as 240 mg IV every 2 weeks
2492144|NCT02954549|Active Comparator|Healthy control group|Subjects in this arm have a normal serum level of 25(OH)D, >30 ng/mL. Subjects submit to blood draws and biometric tests (DXA, body composition, BP) and questionnaires on 3 occasions. They do not receive vitamin D3 supplementation.
2492148|NCT02954549|Experimental|Low dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of < 30 ng/mL and are randomized to receive vitamin D3 supplementation of 2000 IU daily for 3 months.
2492149|NCT02954549|Experimental|High dose supplementation group|Subjects in this group have been identified as having a level of 25(OH)D of <30 ng/mL and are randomized to receive vitamin D3 supplementation of 5000 IU daily for 3 months.
2492186|NCT02954289|Other|Dietary intervention|Dietary intervention
2492251|NCT02954055|Active Comparator|Arm A|Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
2492252|NCT02954055|Experimental|Arm B|"Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability."
2492333|NCT02953392|Active Comparator|Arm 1|Transcrestal Sinus Floor Elevation using platform switched implant with bone graft material.
2492340|NCT02953392|Active Comparator|Arm 2|Transcrestal Sinus Floor Elevation using platform switched implant with no bone graft material.
2492347|NCT02953392|Active Comparator|Arm 3|Transcrestal Sinus Floor Elevation using platform matching implant with bone graft material.
2492351|NCT02953392|Active Comparator|Arm 4|Transcrestal Sinus Floor Elevation using platform matching implant with no bone graft material.
2492550|NCT02952092|Experimental|Darbepoetin alfa Group|Subjects will take the study drug once a week.
3161465|NCT00442910|Placebo Comparator|Placebo for SPL7013 Gel|Intravaginal application of 3.5 g placebo gel twice daily for 14 days
3161466|NCT00442910|Placebo Comparator|HEC Placebo Gel|Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
3161467|NCT00442923|Placebo Comparator|CTRL|
3161468|NCT00442923|Experimental|TREAT|
3161469|NCT00442949|Active Comparator|2|Catheterization immediate PCI
3161470|NCT00442949|Experimental|1|delayed PCI
3161471|NCT00443014|Experimental|A Cognitive stimulation therapy|Patients with recently diagnosed dementia in five of the study municipality.
2491567|NCT02958397|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with anti-CD33-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2491590|NCT02958059|Experimental|Treatment|The intervention group
2491591|NCT02958059|Placebo Comparator|Comparator|The comparator group
2491798|NCT02956863|Active Comparator|Exercises|Individuals with neck pain will receive a exercises program. Participants will receive treatments during 4 weeks, 1 treatments per week.
2491800|NCT02956863|Experimental|Osteopathic manipulative treatment|Individuals with neck pain in this group will also receive a exercises program and the participants will receive treatments during 4 weeks, 1 treatments per week associated with Osteopathic Manipulative Treatment (OMT)
3161472|NCT00443014|No Intervention|B Care as usual|
3161473|NCT00443027|Experimental|Vaginal Heat Wash-Out Device|
2492113|NCT02954913|Experimental|Simultaneous Resection|Patients will undergo resection of the colon or rectum and liver in the same anesthetic setting. The type of colorectal and liver resection will be decided by the treating physician. The type of liver resection will be described according to the Couinaud classification and the Brisbane terminology of liver anatomy.
2492128|NCT02954627||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
3161474|NCT00443092|Experimental|1|proprietary tart cherry juice blend (8 oz., BID)
2492222|NCT02953925||primary health care users|Subjects with high risk of cardiovascular diseases who lived in the catchment areas of the participating PHC institutions.
3161475|NCT00443092|Placebo Comparator|2|control juice (color matched kool aid blend),(8 oz., BID)
3161476|NCT00443131|Experimental|Group A|
3161477|NCT00443131|Experimental|Group B|
3161478|NCT00443131|Experimental|Group C|
3161479|NCT00443183|Experimental|Brief Negotiation Interview|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
3161480|NCT00443183|Placebo Comparator|Discharge Instructions|Scripted discharge instructions to be read by emergency practitioner and designed to be less than 1 minute in length.
3161481|NCT00443196|Experimental|Experimental|
3161482|NCT00443235|Active Comparator|A|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
3161483|NCT00443235|Experimental|B|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
3161484|NCT00443248|Experimental|Vaginal Heat Wash-Out Device|
3161485|NCT00443287|Placebo Comparator|1|
3161486|NCT00443287|Experimental|2|dose level 1
3161487|NCT00443287|Experimental|3|dose level 2
3161488|NCT00443287|Experimental|4|dose level 3
3161489|NCT00443287|Active Comparator|5|
3161490|NCT00443300||Protective environment|Participants in a Protective environment
3161491|NCT00443300||Not a protective environment|Participants not in a protective environment
3161492|NCT00443326|Experimental|AMG 714|AMG 714 will be given as a multiple dose regimen
3161493|NCT00443365|No Intervention|1|Coronary Artery Bypass Grafting with no Mitral Valve intervention
3161494|NCT00443365|Active Comparator|2|Coronary Artery Bypass Grafting + Mitral Annuloplasty
3161495|NCT00443378|Experimental|1|"Arm 1, CARE+ arm is the study arm that receives the CARE+ computer intervention."
3161496|NCT00443378|No Intervention|2|Arm 2, the control arm, is the study arm that receives computerized risk assessment only.
3161497|NCT00443391|Experimental|1|
3161498|NCT00443404|Active Comparator|1|perioperative epidural analgesia
3161499|NCT00443404|Active Comparator|2|Iv PCA Fentanyl preoperative, Epidural analgesia postoperative
3161500|NCT00443404|Active Comparator|3|perioperative IV PCA Fentanyl, epidural anesthesia
3161501|NCT00443404|Active Comparator|4|perioperative IV PCA Fentanyl general anesthesia
3161502|NCT00443404|Placebo Comparator|5|IV PCA with saline 0.9% and sc saline 0.9%in the L3-L4 area. IM meperidine, po codeine/acetaminophen, IV acetaminophen and IV parecoxib
3161503|NCT00443417|Placebo Comparator|1|
3161504|NCT00443417|Active Comparator|2|200mg qd
3161505|NCT00443417|Active Comparator|3|200mg bid
3161506|NCT00443417|Active Comparator|4|400mg qd
3161507|NCT00443469|Experimental|Magnetic Stimulation|
3161508|NCT00443469|Placebo Comparator|Magnetic Stimulation with tilted coil|Magnetic Stimulation with tilted coil
3161509|NCT00443586|Active Comparator|Developmental Screening|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age.
3161510|NCT00443586|Active Comparator|Screening plus Transportation|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two).
3161511|NCT00443586|Active Comparator|Screening, Transport, Prenatal Visits|Participants received sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy.
3161512|NCT00443586|Experimental|Screen, Transport, Prenatal/Inf Visits|Participants received regular sensory and developmental screening and referral for further evaluation and treatment of suspected problems at 12 and 24 months of age; their mothers received free transportation for regular prenatal and well-child care (through child age two), plus nurse home visiting during pregnancy and through child age two.
3161513|NCT00443612|Experimental|1|"12 weeks on treatment 1~2 week washout period~12 weeks on treatment 2"
2491577|NCT02958280|Experimental|Brief Advice Plus the Fit&Sober App|"Phase 1 (app development & Open Pilot) will consist of: 1) development of the Fit&Sober prototype; 2) series of usability studies with patients with AUDs; and 3) An open pilot of a 12-week trial (n=20) to test the feasibility and acceptability of the Fit&Sober app with patients with AUDs in early recovery.~Phase 2: RCT of the Fit&Sober app with 160 patients with AUD"
2491578|NCT02958280|Active Comparator|Brief Advice for Physical Activity|Phase 2: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
2491634|NCT02957955|Experimental|Interventional|Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
2491639|NCT02957955|No Intervention|Non interventional|Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
2491666|NCT02957565|Experimental|Video 1: No EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2491667|NCT02957565|Experimental|Video 1: No EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2491672|NCT02957565|Experimental|Video 2: With EHR - Physician A|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2491675|NCT02957565|Experimental|Video 2: With EHR - Physician B|"Participant completes 5 questionnaires during an already-scheduled office visit.~Participant then watches 2 short videos. After the first video, participant completes 3 questionnaires. After viewing the second video, participant completes 5 questionnaires."
2491752|NCT02957097|Experimental|Medication - Gabapentin|Participants of this group will be administered either Gabapentin 900 milligram PO 2-3 hours prior to the surgical procedure.
2491753|NCT02957097|Placebo Comparator|Medication - Placebo|Participants of this group will be administered either Placebo PO 2-3 hours prior to the surgical procedure.
2491804|NCT02956785|Active Comparator|Extension of propess+/-second propess|Women will have the initial slow-release Dinoprostone pessary left in place for six more hours (total of 30 hours in place) then removed followed by vaginal assessment 48 hours after the start of labour induction and insertion of a second slow-release pessary if required
2491809|NCT02956785|Active Comparator|Prostin|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of quick-release Dinoprostone tablet (Prostin® 3 mg Dinoprostone vaginal tablet; Pfizer, UK) high in the posterior vaginal fornix immediately after removal of the slow-release pessary. The tablet will be left for 6 hours followed by vaginal reassessment and insertion of a second tablet if ARM is still not achievable.
2491819|NCT02956785|Active Comparator|Dilapan-S|Women will have the initial slow-release Dinoprostone pessary removed followed by insertion of 1-5 Osmotic cervical rods (Dilapan-S® Aquacryl hydrogel rod; HPSRx Enterprises, USA) by a senior obstetrician or a midwife into the cervical canal, immediately after removal of the slow-release pessary using a vaginal speculum and a holder. The rods will be left for 12-24 hours.
2491906|NCT02956226|Experimental|Cannabinoids - 99% pure cannabinoids mix|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months.
2491912|NCT02956226|Placebo Comparator|Placebo|Oral olive oil and flavors that mimic in texture and flavor the cannabinoids' solution.
2491915|NCT02956226|Experimental|Cannabinoids - whole plant extract|Oral cannabinoids mix [cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio] at 1 mg/kg cannabidiol per day, up-titrated until intolerance or to a maximum dose of 10 mg/kg CBD per day, divided to 3 daily doses, for 3 months
2491997|NCT02955706|Experimental|Active|Acetyl-L-carnitine (DongA ST)
2492000|NCT02955706|Placebo Comparator|placebo|Placebo of Acetyl-L-carnitine (DongA ST)
2492200|NCT02954211|Experimental|rTMS/PT|There will be only one group. All participants will receive 10 treatments of active repetitive transcranial magnetic stimulation combined with physical therapy.
2492229|NCT02953964|Experimental|Behavioral: perceptual-based memory encoding training|Participants receive perceptual-based memory encoding training
2492236|NCT02953964|Experimental|Behavioral: Semantic-based memory encoding training|Participants receive semantic-based memory encoding training
2492241|NCT02953964|Active Comparator|Behavioral : control group|Participants receive cognitive stimulation intervention
3161514|NCT00443612|Experimental|2|"12 weeks on treatment 2~2 week washout period~12 weeks on treatment 1"
3161515|NCT00443638|No Intervention|Control Group|Control Group
2492378|NCT02953132|Experimental|Single ascending dose, MT-4129 or Placebo|
2492379|NCT02953132|Experimental|Multiple ascending dose, MT-4129 or Placebo|
3161516|NCT00443638|Experimental|Home visitation through pregnancy|Nurse home visitation through pregnancy
2492433|NCT02952638||Healthy|BMI is between 20 and 25
2492439|NCT02952638||Overweight|BMI is between 25 and 30
2492449|NCT02952638||Obese|BMI is between 30 and 40
2492522|NCT02952482||newborns testing for ALD|newborns testing for ALD
2492701|NCT02951221|Experimental|Cohort 2|Treatment sub groups C and D
3161517|NCT00443638|Experimental|Home visitation through age 2|Nurse home visitation through child age 2.
3161518|NCT00443677|Active Comparator|abvd|
3161519|NCT00443677|Experimental|beacopp|
3161520|NCT00443677|Experimental|coppebvcad|
3161521|NCT00443690|Placebo Comparator|2|placebo control
3161522|NCT00443690|Experimental|1|KW-3902IV
3161523|NCT00443768||1|
3161524|NCT00443768||2|
3161525|NCT00443794|Experimental|1, POLYCAP|Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
3194660|NCT00830674|Experimental|KRN23|Single IV or SC administration on day 1
2491638|NCT02957864|Experimental|Switch to tenofovir alafenamide|Switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide
2491640|NCT02957864|Active Comparator|Switch to abacavir|Switch from tenofovir disoproxil fumarate (TDF) to abacavir
2491665|NCT02957500|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area
2491668|NCT02957500|No Intervention|No treatment|standard treatment for surgery
2491786|NCT02956811|Active Comparator|Active|Dapagliflozin 10mg once daily for 12 months
2491787|NCT02956811|Placebo Comparator|Placebo|Placebo 10mg once daily for 12 months
3194661|NCT00830674|Placebo Comparator|Placebo|Single IV or SC administration on day 1
3194662|NCT00830687|Other|Targon FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
3194663|NCT00830700|Experimental|CATMH intervention|Child telemental health service delivery intervention
3194664|NCT00830700|No Intervention|augmented TAU/PCP|Augmented treatment as usual with primary care physician
2492344|NCT02953431|Placebo Comparator|Sham CPAP|Participants will be randomized to Sham CPAP
2492349|NCT02953431|Active Comparator|CPAP 10|Participants will be randomized to CPAP 10
2492370|NCT02953106|Active Comparator|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
2492373|NCT02953106|Placebo Comparator|Placebos|contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.
2492427|NCT02952911|Experimental|A: MS Participants|MS participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
2492428|NCT02952911|Other|B: Healthy Controls|Healthy participants will perform various active tests (daily, weekly or bi-weekly) and passive monitoring (daily) using smartphone and smartwatch over 24 weeks.
2492467|NCT02952534|Experimental|Rucaparib|Oral rucaparib (monotherapy)
2492578|NCT02951806|Active Comparator|(R) Rapid spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 15 seconds then 10 mg hyperbaric bupivacaine.
2492581|NCT02951806|Active Comparator|(S) Slow spinal fentanyl injection|Patients will receive 25 mic fentanyl spinal ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
2492632|NCT02951585|Experimental|KARTILAGE CROSS|Kartilage® Cross (2.2 mL, 16 mg/g of hyaluronic acid)
2492637|NCT02951585|Placebo Comparator|Placebo|Saline solution (2.2-2.5 mL, NaCl 9 mg/g)
2492706|NCT02951390|Active Comparator|High-definition white-light endoscopy|High-definition white-light endoscopy without indigo carmine instilation
2492715|NCT02951390|No Intervention|High-definition chromoendoscopy|High-definition indigo-carmine chromoendoscopy
2492749|NCT02951091||biomarker group|400 Her-2 (-) metastatic/recurrent gastric cancer patients will be centrally screened for druggable targets [Epstein-Barr virus, Microsatellite instability, HER2, EGFR, c-MET, and PTEN] by immunohistochemistry and in situ hybridization during first line chemotherapy. At the time of second line treatment, patients will be randomized to the biomarker vs control group as 4: 1 ratio. The biomarker group will be offered for entry into a specific protocol based on their molecular cohort and treated with specific targeted agents in combination with weekly paclitaxel; 1) EGFR cohort (EGFR 2+ or EGFR 3+) for pan-ERBB inhibitor (afatinib), 2)PTEN loss cohort (PTEN score less than 100) for PIK3CB inhibitor (GSK2636771), 3) PD-L1 positive, MSI-high, or EBV positive cases for nivolumab, 4) none for weekly paclitaxel.
2492755|NCT02951091||control group|
3194665|NCT00830713|Experimental|MKTP treatment|subject will undergo MKTP
2492873|NCT02950220|Experimental|Arm 1|
2492967|NCT02949778|Active Comparator|Ropivacaine 3.75mg/mL|QL-block using 20 mL ropivacaine 3.75mg/mL
2492969|NCT02949778|Placebo Comparator|Sodium chloride 9 mg/mL|QL-block using 20 mL sterile sodium chloride 9 mg/mL
2492997|NCT02949167|Experimental|MyHealth intervention arm|Nurse-led follow-up
2493006|NCT02949167|No Intervention|MyHealth Control condition|Physician-led follow-up
3194666|NCT00830726||1|Healthy volunteers
3194667|NCT00830726||2|Patients with symptomatic heart failure and EF < 40%
2493235|NCT02947529|Experimental|Hemiarthroplasty|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
2493247|NCT02947529|Experimental|Intramedullary nail|Patients are placed into this arm based on the type of surgery performed, they are randomized to either receive tranexamic acid or a placebo
2493308|NCT02947204|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge.
2493311|NCT02947204|Experimental|Intermittent oxygen monitoring|Oxygen saturation will be measured intermittently, every 4 hours, through the child's hospital stay until discharge.
2493386|NCT02946749||Shanghai First Maternity and Infant Hospital|
2493388|NCT02946749||the Putuo District Maternity and Child Health Care Hospital|
2493390|NCT02946749||the Xinhua hospital affiliated to Shanghai jiaotong University|
2493391|NCT02946749||The Sixth people's hospital of Shanghai|
2493413|NCT02946307|Experimental|small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter>2.00 mm） in small vessel cohort
2493426|NCT02946307|Active Comparator|small vessel cohort:Resolute DES|receiving the treatment with Resolute DES in small vessel cohort
2522992|NCT02743871|Experimental|Cohort 13|PF-06817024 or placebo
3194668|NCT00830726||3|Patients with symptomatic aortic valve stenosis
3194669|NCT00830726||4|Patients with Acute Coronary syndromes prior to surgical intervention
3194670|NCT00830726||5|Patients with refractory stable angina requiring surgical intervention.
3194671|NCT00830726||6|Patients with pulmonary hypertension and preserved systolic left ventricular function.
2491580|NCT02958592||study group|patients with liver tumor intend to perform hepatectomy
3161526|NCT00443794|Active Comparator|2 B|Diuretic antihypertensive
3161527|NCT00443794|Active Comparator|3 C|Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
2491728|NCT02957370||Diagnosed Urinary Bladder Neoplasms|Patients who are being monitored for bladder cancer will be the experimental group to test the electro-phage and aptamer approach to following bladder cancer biomarkers
2491729|NCT02957370||Non-Urinary Bladder Neoplasms|Patients being treated for hematuria will provide a negative control to provide data from testing for biomarkers in patients being treated for other diseases.
2491758|NCT02957032|Experimental|F16IL2 + cytarabine|Patients will be enrolled sequentially in cohorts and treated at different dose levels of F16IL2 and a fixed dose of cytarabine.
2491803|NCT02956733|Active Comparator|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
2491811|NCT02956733|Active Comparator|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
2491854|NCT02956395|Active Comparator|Integrated care group|Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care in three healthcare sectors: Barcelona-Esquerra, Lleida and Badalona.
2491855|NCT02956395|No Intervention|Conventional care group|Patients assigned to the control group will be from other healthcare sectors in Catalonia with similar characteristics.
2491909|NCT02956161|Experimental|Up phase stimulation|Auditory stimulations are delivered in synchrony with the up phase of slow oscillations during N3 sleep stage.
2491913|NCT02956161|Experimental|Random phase stimulation|Auditory stimulations are randomly delivered during N3 sleep stage.
2491917|NCT02956161|Sham Comparator|No stimulation|The device is worn without any auditory stimulations delivered.
2491931|NCT02955849|Experimental|SLT laser group|"selective laser trabeculoplasty for 360 degrees the study eye.~Patients having 1 or 2 quadrants of angle with trabecular meshwork not visible will undergo Laser peripheral iridotomy prior to selective laser trabeculoplasty to maximize the amount of angle visible;~Cataract surgery will be offered if indicated and completed within 3 months of selective laser trabeculoplasty , if accepted by the patient.~Patients will be re-examined every 4 months and selective laser trabeculoplasty performed again according to the above protocol if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)."
2491941|NCT02955849|No Intervention|Standard care group|"Trabeculectomy as usually performed by the operative surgeon in one eye (study eye).~Both Mitomycin and releasable sutures are permitted if indicated in the opinion of the surgeon and s/he can perform and/or has access.~Simultaneous cataract surgery is permitted if indicated in the opinion of the operating surgeon.~Patients will be re-examined every 4 months， and Timolol 0.5% added bid if intraocular pressure exceeds the target (25% reduction from the original intraocular pressure or < 21 mmHg, whichever is lower)"
2491945|NCT02955849|No Intervention|Drug treatment group|Patients not accepting the offered treatment for the study eye within 3 months will receive topical Timolol 0.5% bid at the usual price, with the prescription to be refilled per usual practice at the hospital (usually monthly).
2491996|NCT02955641|Active Comparator|NSAIDs-Placebo|Will receive Nepafenac 0.1%in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
2492001|NCT02955641|Active Comparator|Placebo-NSAIDs|Will receive Hydroxyethylcellulose 0.19% in the first eye, and Nepafenac 0.1%in the second eye
2492003|NCT02955641|Active Comparator|Steroid-Placebo|Will receive Dexamethasone Disodium Phosphate 0.1% in the first eye, and Hydroxyethylcellulose 0.19% in the second eye
2492005|NCT02955641|Active Comparator|Placebo-Steroids|Will receive Hydroxyethylcellulose 0.19%in the first eye, and Dexamethasone Disodium Phosphate 0.1%in the second eye
2492035|NCT02955277|Experimental|TECH protocol|TECH protocol - Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-25 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by six weekly sessions (of 60 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist.
2492038|NCT02955277|No Intervention|standard care|Participants will receive standard medical care with no TECH protocol.
2492039|NCT02955277|Active Comparator|active standard care|Partivipans will receive six weekly group sessions (60 minutes) for cognitive training using puzzle games. The setting will includes small groups of 5-6 participants, with no self training at home.
3194672|NCT00830778|Experimental|PG anastomosis|Pancreaticogastrostomy (PG) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
3194673|NCT00830778|Active Comparator|PJ anastomosis|Pancreaticojejunostomy (PJ) reconstruction/anastomosis after pancreaticoduodenectomy (PD)
3194674|NCT00830843|Active Comparator|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
3161528|NCT00443794|Active Comparator|4 D|Diuretic with Beta blocker combination antihypertensive
3161529|NCT00443794|Active Comparator|5, E|ACE inhibitor plus Beta blocker combination antihypertensive
3161530|NCT00443794|Active Comparator|6, F|Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
3161531|NCT00443794|Active Comparator|7,G|Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
3194675|NCT00830843|Experimental|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
2491999|NCT02955862|Other|Assigned Interventions Antifungals Patients with symptoms|"Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.~For CrAg-positive patients, the initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months."
2492061|NCT02955394|Placebo Comparator|Fulvestrant Without Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
2492063|NCT02955394|Experimental|Fulvestrant With Enzalutamide|500 mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC), plus160mg of Enzalutamide will be given daily.
2492105|NCT02954900|Other|Decision aid|50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.
2492126|NCT02954640|Other|Patient with PID|"For patient with clinical diagnosis of PID, an additional blood sampling will be taken.~The genetic diagnosis will be done via the method of gene-panel in the frame of the study.~A genetic confirmation will, in any case, be done via the reference method (Sanger), in order to establish a final diagnosis for these patients."
2492176|NCT02954523|Experimental|Phase I and Phase II|"Osimertinib (AZD9291) will be given at a 80mg/day dose taken orally across all levels of the dose escalation schedule.~Dasatinib is taken orally and will be given at up to 4 dose levels. Level -2 (50 mg once daily), Level -1 (70 mg once daily), Level 1 (the starting dose - 50 mg twice daily), Level 2 (70 mg twice daily).~Dose escalation will only include 2 dose levels (Levels 1 and 2); in addition there will be 2 dose levels below the starting dose level if dose reductions are necessary (Levels -1 and -2).~There is no limit to the number of cycles a patient can receive.~The phase II portion of the study will use the maximum tolerated dose of dasatinib determined in the phase I portion. Osimertinib (AZD9291) will be given at the same 80mg dose as the phase I portion."
2492254|NCT02953769||Arm 1|Ventral hernia repair using standard wound care.
2492259|NCT02953769||Arm 2|Ventral hernia repair, regarding wound morbidity, post-operative pain and patient comfort to ambulation, with the use of Prevena™
2492310|NCT02953600|Experimental|Standard Dose Spirulina Platensis|Spirulina platensis pill/500mg, 3 pills before each meal /6 pills per day
2492313|NCT02953600|Active Comparator|Zero Spirulina Platensis|Spirulina platensis pill/500mg, 6 pills before each meal /12 pills per day
2492315|NCT02953600|Active Comparator|Double Dose Spirulina Platensis|same as usual, non pill taken
2492402|NCT02953197|Experimental|Single arm radiotherapy dose escalation|FDG-PET guided radiation dose escalation Selective dose escalation
2493195|NCT02947919|Experimental|Intervention|Music in the perioperative period
2493196|NCT02947919|No Intervention|Control|Usual treatment
2493268|NCT02947607||Healthy control|Patients undergoing lower GI endoscopy without any colorectal adenoma or carcinoma.
2493270|NCT02947607||Adenoma|Patients undergoing lower GI endoscopy with presence of colorectal adenoma detected.
2493272|NCT02947607||Colorectal cancer|Patients diagnosed with colorectal cancer and referred to surgical carcinoma resection.
2493392|NCT02946762|Other|Universal Test and Treat|All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
2493422|NCT02946294|Active Comparator|modified pectoral nerves block|Modified pectoral nerves block with general anesthesia. Using the ultrasound, 10 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis major and minor muscles. And another 20 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the pectoralis minor and the serratus anterior muscles.
2493430|NCT02946294|Active Comparator|serratus plane block|Serratus plane block with general anesthesia. Using the ultrasound, 0.4 ml of bupivacaine 0.25% with epinephrine 5 ug/ml will be injected in the plane between the serratus anterior muscle and the underlying ribs.
3161532|NCT00443794|Active Comparator|8,H|Lipid lowering agent
3161533|NCT00443794|Active Comparator|9,A|Antiplatelet
2523348|NCT02741492|Sham Comparator|Sham Group|Continuous Sham Catheter
3161534|NCT00443859||PPHN|Infants with persistent pulmonary hypertension (PPHN)
3161535|NCT00443924|Placebo Comparator|1|Arm 1
3161536|NCT00443924|Experimental|2|Arm 2
3161537|NCT00443924|Experimental|3|Arm 3
3161538|NCT00443924|Experimental|4|Arm 4
3161539|NCT00443924|Experimental|5|Arm 5
3161540|NCT00443963|Experimental|PPI|PPI Medication
3161541|NCT00443963|Experimental|H2RA|H2RA Medication
3161542|NCT00443976|Experimental|AT9283|
3161543|NCT00444002||Hepatitis C - Steatosis|Patients with chronic Hep C infection undergoing liver biopsy with >=5% steatosis on liver biopsy
3161544|NCT00444002||Hepatitis C - no steatosis|Patients with chronic Hep C infection without steatosis on liver biopsy (<5% of hepatocytes involved)
3161545|NCT00444015|Experimental|Dose Escalation|
3161546|NCT00444041|Experimental|Xelox, Bev|
3161547|NCT00444054|Experimental|Dietary modification|Patients are placed on a low carbohydrate diet (<30 grams/day) for 28 days.
3161548|NCT00444093|Experimental|Opii normata treatment|Treamtment with opii normata in case of diarrhea
3161549|NCT00444093|Experimental|Loperamid Treatment|Treatment with Loperamid in case of diarrhea
3161550|NCT00444184|Active Comparator|Travoprost/Timolol therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost/timolol drops
3161551|NCT00444184|Active Comparator|Travoprost therapy|24-hour pressure monitoring after 3 months of chronic dosing with travoprost drops
3161552|NCT00444223|Experimental|fluorine F 18 FEQA + positron emission tomography|
3161553|NCT00444236|Active Comparator|1|
3161554|NCT00444236|Placebo Comparator|2|
3161555|NCT00444249|Active Comparator|1|White Alcon IOL
3161556|NCT00444249|Active Comparator|2|Yellow Alcon IOL
3161557|NCT00444249|Active Comparator|3|White Hoya IOL
3161558|NCT00444249|Active Comparator|4|Yellow Hoya IOL
3161559|NCT00444262|Active Comparator|1|conventional treatment
3161560|NCT00444262|Experimental|2|stroke volume optimisation
2491622|NCT02958189|Experimental|Group 1: Tweet4Wellness+Self-monitoring|This group will receive the Tweet4Wellness intervention: daily theory-based peer-to-peer discussion prompt within the private Twitter-based support group for the entire 6 months of the study. They will also receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component).
2491623|NCT02958189|Active Comparator|Group 2: Self-monitoring|This group will receive the Fitbit triaxial pedometer that will track their daily steps (self-monitoring component) for the first 3 months. For the second three months of the study, they will receive the Tweet4Wellness intervention in addition to their Fitbit self-monitoring.
2491687|NCT02957617|Experimental|BIIB074|BIIB074 orally twice daily
2491971|NCT02955732|Experimental|Intranasal dex|Dexmedetomidine 2-4 µg/kg alone
2492019|NCT02955459|Experimental|VNRX-5133|IV infusion
2492022|NCT02955459|Placebo Comparator|Placebo|IV infusion
2492098|NCT02955199|Experimental|Mothering From the Inside Out|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
2492099|NCT02955199|Active Comparator|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
2492134|NCT02954692|Experimental|Insulin glargine (U300)|Insulin glargine (U300) will be administered daily through subcutaneous injection, and thereafter, dose will be titrated weekly (preferably 3-4 days) as needed. Background non-insulin anti-diabetic drugs approved for use in combination with insulin according to local labelling, will be permitted, with the exception of Thiazolidinediones (TZDs), which must be stopped at the time of basal insulin initiation.
2492195|NCT02954302|Experimental|PrPD with RGA|Patients who will undergo PrPD with proximal Roux-en-y gastrojejunal anastomosis.
2492197|NCT02954302|Experimental|conventional PrPD|Patients who will undergo conventional PrPD.
2492228|NCT02953951||Stored Blood Cells|"Blood transfusion:~Stored blood cells transfused patients"
2492234|NCT02953951||Autologous Salvaged Blood|"Blood transfusion:~Autologous salvaged blood transfused patients"
2492240|NCT02953951||Control|"Blood transfusion:~No transfusion patients"
2492281|NCT02953717|Active Comparator|Stereotactic radiosurgery (SRS)|Gamma Knife radiosurgery
2492283|NCT02953717|Active Comparator|Whole Brain Radiation Therapy (WBRT)|Whole Brain Radiation Therapy
2492387|NCT02953236|Experimental|Instrumented massage|
2492393|NCT02953236|Active Comparator|Manual massage|
2492434|NCT02952846|No Intervention|Before algorithm|Observational
2492438|NCT02952846|Experimental|After algorithm|Algorithm for tapering of analgosedation
2492506|NCT02952391||Parkinson's disease patients|patients with Parkinson's disease, between the ages of 45 and 65, with a disease duration of 3 - 10 years
2492513|NCT02952391||healthy control subjects|Healthy control subjects, between the ages of 45 and 65
2492547|NCT02952079|Active Comparator|BlephEx treatment|Treatment with the BlephEx instrument (lid margin exfoliation)
2492551|NCT02952079|Active Comparator|MiBoFlo treatment|Treatment with the MiboFlo equipment (heat therapy to eyelids)
2492564|NCT02951741||RTHRA group|patients undergoing revision total hip replacement
2492634|NCT02951650|Experimental|Cyberonics VNS|Cyberonics VNS
2492853|NCT02950337|Experimental|Group 1: Peripherally Located Tumors|Peripherally Located Tumors - SBRT
2492855|NCT02950337|Experimental|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Peripherally Located Chest Wall Adjacent Tumors - SBRT
2492856|NCT02950337|Experimental|Group 3: Centrally Located Tumors|Centrally Located Tumors - SBRT
2492895|NCT02950155|Experimental|Rituximab|A single infusion at a dose of 500 mg of Mabthera/Rituximab.
2492896|NCT02950155|Sham Comparator|Sodium Chloride solution|A single infusion with sodium chloride solution.
2492945|NCT02949739|Active Comparator|Intensive lifestyle modification|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study (Index cases). Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Intensive lifestyle modification follows clinically accepted, evidence based strategies to achieve >7% reduction in weight through improved diet and increased physical activity, and is delivered as 9 face-face and 13 telephone contact sessions over 12 months.~Index cases will be followed for three years to identify new-onset T2D."
3161561|NCT00444314|Experimental|A|
2494105|NCT02941705|Placebo Comparator|CONTROL ARM|this arm will receive a solution during randomization but will not receive the CDCs
3161562|NCT00444314|Experimental|B|
3161563|NCT00444379|Active Comparator|PI-based HAART regimen|PI-based HAART regimen (lopinavir/ritonavir plus emtricitabine/tenofovir)
3161564|NCT00444379|Active Comparator|non-nucleoside reverse transcriptase inhibitor|non-nucleoside reverse transcriptase inhibitor (NNRTI)-based HAART regimen (efavirenz plus emtricitabine/tenofovir)
3161565|NCT00444418|Experimental|1|Active medication (Naltrexone) combined with Modified Behavioral Self-Control Psychotherapy
3161566|NCT00444418|Experimental|2|Placebo combined with Modified Behavioral Self-Control Psychotherapy
3161567|NCT00444418|Experimental|3|Active medication (Naltrexone) combined with Brief Behavioral Compliance Enhancement Therapy
3161568|NCT00444418|Placebo Comparator|4|Placebo + Brief Behavioral Compliance Enhancement Therapy
3161569|NCT00444470|Active Comparator|A|Active drug being tested in this study is Tranexamic Acid
3161570|NCT00444470|Placebo Comparator|B|Normal saline was used as the Placebo
3161571|NCT00444509|Experimental|Treatment 1|Subjects will receive GW685698X 800 microgram (mcg) single inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
3161572|NCT00444509|Experimental|Treatment 2|Subjects will receive GW685698X 800 mcg containing magnesium stearate inhaled dose via a DISKUS inhaler. There will be a wash-out period of at least 5 days between doses.
3161573|NCT00444561|Active Comparator|Pramlintide acetate (AC137)|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
3161574|NCT00444574|Active Comparator|Methylphenidate Transdermal System|Methylphenidate 2.7mg, 41.3mg, 55mg, and 82.5mg patches for 7 weeks
3161575|NCT00444574|Placebo Comparator|Placebo|Placebp matching MTS and Concerta for 7 weeks
3161576|NCT00444574|Active Comparator|Concerta|Methylphenidate HCL 18mg tablet 7 weeks
3161577|NCT00444613|Experimental|E0302 25 mg|
3161578|NCT00444613|Experimental|E0302 50 mg|
3161579|NCT00444613|Placebo Comparator|3|
3161580|NCT00444639|Experimental|1|triptorelin 11.25mg given 12 weekly by subcutaneous formulation
2491813|NCT02957409||sacubitril/valsartan|Patients diagnosed with HFrEF being treated with sacubitril/valsartan according to the Canadian product label and treatment initiation with sacubitril/valsartan within the last 3 months. The usual recommended starting dose is one tablet of 49 mg sacubitril / 51 mg valsartan taken twice daily. The target dose is one tablet of 97 mg sacubitril / 103 mg valsartan taken twice daily. Investigator/designated will document sacubitril/valsartan treatment adherence throughout the 3 years study period
2491898|NCT02956187|Experimental|Biofeedback for constipation|Constipation will be treated by correcting functional outlet obstruction.
2491900|NCT02956187|Active Comparator|Fiber supplementation|Constipation will be treated by a fiber supplement
2491960|NCT02955953|Experimental|LY2963016 U-200 Formulation (Test)|LY2963016 test formulation administered as a subcutaneous (SC) injection in one of two or two of four study periods.
2491961|NCT02955953|Experimental|LY2963016 U-100 Formulation (Reference)|LY2963016 reference formulation administered as a SC injection in one of two or two of four study periods.
2491985|NCT02955550|Experimental|PNK-007 and rhIL-2|Melphalan per institutional practices (within Day -5 to 01), ASCT (Day 0), PNK-007 at varying dose levels (within Day 7 to Day 14) and rhIL-2 every other day starting day of PNK-007 administration.
2492138|NCT02954705||Group AAV|Patients recruited from the Nantes University Hospital. 50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
2492141|NCT02954705||Group control|"People recruited from the Etablissement français du sang (French blood establishment ).~10 milliliter of blood are collected from these donors"
2492187|NCT02954419||IgA nephropathy group|Eligible biopsy-proven primary IgA nephropathy patients.
2492233|NCT02954068|Active Comparator|IV Infusion|Oxytocin 10 IU, 500 ml IV infusion within 40 minutes + intra muscular injection of placebo, 10 IU
2492239|NCT02954068|Active Comparator|IM administration|Oxytocin 10 IU via intra muscular injection + Intravenously administered placebo, 10 IU, 500ml
3161581|NCT00444639|Active Comparator|2|triptorelin 11.25mg given 12 weekly by intramuscular injection
2492459|NCT02952833|Experimental|Group 1|5.0 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25 (2 Sentinel subjects will receive intervention prior to remaining 23 subjects), Placebo for 5 subjects
2492463|NCT02952833|Experimental|Group 2|2.5 mcg ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, Placebo for 5 subjects
2492465|NCT02952833|Experimental|Group 3|10 mcg of ZPIV will be administered in a homologous prime-boost regimen on Day 1 and Day 29, n=25, (2 Sentinel subjects will receive intervention prior to remaining 23 subjects) Placebo for 5 subjects
2492504|NCT02952235|Other|SPF50+|SPF 50+ assigned to Left side of face SPF 100+ assigned to Right side of face
2492512|NCT02952235|Other|SPF100+|SPF 100+ assigned to Left side of face SPF 50+ assigned to Right side of face
2492545|NCT02952053|Experimental|Dry Needling into MTrPs.|MTrP Group: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
2492546|NCT02952053|Active Comparator|Dry Needling within Taut Band|TB Group: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band; out of MTrPs).
2492750|NCT02951039||Edoxaban|Patients with established NVAF treated with edoxaban according to package information. Physician's prescribing behaviour will not be influenced; patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2492897|NCT02950064|Experimental|BTP-114|Intravenous (IV) treatment n 21-day cycles
2492947|NCT02949726|Other|Cancer-treated patients receiving NIRFLI|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
2493040|NCT02949284|Experimental|Arm I (androgen receptor ARN-509, radical prostatectomy)|Patients receive androgen receptor antagonist ARN-509 PO daily for 3 months. Patients then undergo radical prostatectomy.
2493041|NCT02949284|Active Comparator|Arm II (ARN-509, abiraterone acetate, GnRH, prednisone, RP)|Patients receive GnRH agonist SC on day 1, androgen receptor antagonist ARN-509 PO daily PO for 4 times, abiraterone acetate PO daily for 4 times, and prednisone PO daily for 3 months. Patients then undergo radical prostatectomy.
2493042|NCT02949284|Active Comparator|Arm III (radical prostatectomy)|Patients undergo radical prostatectomy.
2493102|NCT02948413||Single Group of patients with Cancer|Patients with cancer (lymphoma, leukemia, prostate cancer, and mesothelioma) on clinical trials at the NIH Clinical Center.
2493154|NCT02948270||Adolescents with ADHD|Adolescents who met diagnostic criteria in previous clinical/research assessment are invited to come back to SickKids to participate (ages 13-17)
2493169|NCT02948270||Adolescents without ADHD|Adolescent controls (ages 13-17) are tested through local high schools
3161582|NCT00444743|Active Comparator|1|
3161583|NCT00444743|Placebo Comparator|2|
3161584|NCT00444834|Experimental|1|Egalet carvedilol
3161585|NCT00444834|Active Comparator|2|Coreg
3161586|NCT00444860|Experimental|1|Zostavax
3161587|NCT00444873|Experimental|28 day dose interval|
3161588|NCT00444873|Experimental|42 day dose interval|
3161589|NCT00444873|Experimental|56 day dose interval|
2491651|NCT02958176|Experimental|HRV Biofeedback|At home HRV biofeedback using mobile device
2491652|NCT02958176|Experimental|HRV Biofeedback with Autogenic Training|At home HRV biofeedback using mobile device plus autogenic training recording
2491654|NCT02958176|No Intervention|Wait List|Wait list control
2491712|NCT02957461||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, ocular motor assessment, and clinical symptoms/assessments.
2491716|NCT02957461||Healthy Volunteer Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at a single time point. These subjects will perform the same BrainScope Battery as the injured and matched control subjects.
2491762|NCT02957045|Experimental|Cough|
2491812|NCT02956720|Experimental|single arm|
2491894|NCT02956421|Active Comparator|RABIPUR®|Comparator vaccine RABIPUR® Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14
2491899|NCT02956421|Experimental|PIKA Rabies vaccine|PIKA Rabies vaccine with an accelerated regimen Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)
2491928|NCT02955914||Optimism|Based on quality of life assessment
2491934|NCT02955914||Pessimism|Based on quality of life assessment
2491981|NCT02955693|Other|Sequence A (n=8)|Fumaderm® 120 mg fed (Period 1) - LAS41008 120 mg fasting (Period 2) -Fumaderm® 120 mg fasting (Period 3) - LAS41008 120 mg fed (Period 4)
2491982|NCT02955693|Other|Sequence B (n=8)|LAS41008 120 mg fasting (Period 1) - LAS41008 120 mg fed (Period 2) - Fumaderm® 120 mg fed (Period 3) - Fumaderm® 120 mg fasting (Period 4)
2491983|NCT02955693|Other|Sequence C (n=8)|Fumaderm® 120 mg fasting (Period 1) - Fumaderm® 120 mg fed (Period 2) - LAS41008 120 mg fed (Period 3) - LAS41008 120 mg fasting (Period 4)
2491986|NCT02955693|Other|Sequence D (n=8)|LAS41008 120 mg fed (Period 1) - Fumaderm® 120 mg fasting (Period 2) - LAS41008 120 mg fasting (Period 3) - Fumaderm® 120 mg fed (Period 4)
2492014|NCT02955368|Experimental|DP-R212 group|DP-R212 + C1-R212 placebo + C2-R212 placebo
2492015|NCT02955368|Active Comparator|C1-R212 group|DP-R212 placebo + C1-R212 + C2-R212 placebo
2492018|NCT02955368|Active Comparator|C2-R212 group|DP-R212 placebo + C1-R212 placebo + C2-R212
3194676|NCT00830856|Experimental|1|Early initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and within 72hrs of diagnosis were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
3194677|NCT00830856|Experimental|2|Delayed initiation of antiretroviral therapy. Patients in this treatment group were started on Fluconazole 800mg by mouth every day for Cryptococcal Meningitis, and after completion of high dose fluconazole for 10 weeks, the patients in this group were started on First line antiretroviral therapy per Zimbabwe treatment guidelines which is Stavudine, Lamivudine and Nevirapine.
3194678|NCT00830882|Experimental|1:levosalbutamol|2 puffs four times a day for 2 weeks
2492245|NCT02954042|Experimental|Pelvital probe|Probe to use for incontinence-Pevital is company name of product
2492248|NCT02954042|Placebo Comparator|Placebo Probe|Placebo probe
2492311|NCT02953574|Experimental|daily sleep enhancement nursing protocol|"A 7 step nursing protocol. Each step is daily provided to the demented patient through a nurse by bedtime.~Step 1: serve a late snack Step 2: evening care (brush teeth, get pyjama on, go to toilette) Step 3: note and treat physical circumstances that restrain sleep (pain, obstipation,...) Step 4: ensure comfortable position abed Step 5: assist to eliminate stressful situation (calm, reorientating conversation) Step 6: turn off the light Step 7: care for a silent environment (turn off Television, radio and do not disturb-sign at the door)"
2492314|NCT02953574|No Intervention|usual nursing care|
3194679|NCT00830882|Active Comparator|2: racemic salbutamol|2 puffs four times a day for 2 weeks
3194680|NCT00830882|Placebo Comparator|3: Placebo|2 puffs four times a day for 2 weeks
3194681|NCT00830895|Experimental|RAD001|RAD001 10mg/day
3194682|NCT00830908|Experimental|LaserComb|Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
2492466|NCT02952560||High resolution CT Scan of the head and neck|Patients scheduled for high resolution computerized tomography (CT scan) of the head and neck as part of their medical investigation of thyroid or laryngeal disorders will be recruited for this study.
2492499|NCT02952339|Experimental|RSV LID ΔM2-2 1030s vaccine|Participants will receive a single dose of the RSV LID ΔM2-2 1030s vaccine at Day 0.
2492508|NCT02952339|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine at Day 0.
2492592|NCT02952040|Experimental|ASP1517 alone period preceding group|Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.
2492599|NCT02952040|Experimental|ASP1517+lanthanum period preceding group|Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.
3194683|NCT00830921||1|"Patients will be identified from the Oxford Pleural Clinic and from referrals within the multi-disciplinary team including palliative care and oncology services.~Screening criteria are based on normal practice and consecutive eligible patients will be offered trial entry. The principal investigator or a nominated member of staff will approach participants who fulfil the criteria for inclusion in the study. Screening logs will be kept."
3194684|NCT00830934|Active Comparator|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
2492758|NCT02951000|Active Comparator|platysma suture|running suture of the platysma with 3/0 polyglactin
3194685|NCT00830934|Experimental|Group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
2491660|NCT02957851|Placebo Comparator|Oxygen/Nitrogen (22%/78%)|Medical Air
2491661|NCT02957851|Active Comparator|Nitrous Oxide/Oxygen (50%/50%)|EMONO
2491777|NCT02957318|Experimental|FiberBind|
2491779|NCT02957318|Experimental|RG-I fiber|
2491781|NCT02957318|Placebo Comparator|Placebo|
2491823|NCT02956551|Experimental|cell_therapy|tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times
2491888|NCT02956265|Experimental|Patients - Suffering from carcinomatous or polymorphous skin|
2492002|NCT02956031||HIV pos|those who serologically tested positive for HIV
2492004|NCT02956031||HIV neg|those who serologically tested negative for HIV
2492006|NCT02956031||HIV unk|those with no available serological test for HIV
2492047|NCT02955303|Experimental|TECH protocol|Daily self-training using tablet apps facilitated by weekly group sessions. The self-training will take place independently at participants' home and will include mostly playing puzzle-apps to train different cognitive components. Participants will be requested to play (and log) various apps three to five times a week for 30-60 minutes each time, for a total of 15-20 training sessions. In addition they will use the tablets for a variety of everyday uses. The individual self-training will be accompanied by five weekly sessions (of 60-90 minutes) in a small group setting (5-6 participants) led by an experienced occupational therapist. For initial learning of the tablet's basic use, an individual session for each participant will take place.
2492106|NCT02955030|Experimental|NSV0001(Cohort1)|15 µg of hemagglutinin [HA] antigen per strain with 150 µg of ND002 adjuvant, administration by sublingual route
2492107|NCT02955030|Experimental|NSV0001(Cohort2)|30 µg of hemagglutinin[HA] antigen per strain with 300 µg of ND002 adjuvant, administration by sublingual route
2492108|NCT02955030|Experimental|NSV0001(Cohort3)|60 µg of hemagglutinin[HA] antigen per strain with 600 µg of ND002 adjuvant, administration by sublingual route
2492111|NCT02955030|Placebo Comparator|Placebo|0 µg of hemagglutinin[HA] antigen per strain with 0 µg of ND002 adjuvant, administration by sublingual route
2492116|NCT02955030|Active Comparator|"Influenza HA vaccine Biken HA"|Seasonal quadrivalent influenza vaccine, administration by subcutaneous injection route
2492152|NCT02954614|Experimental|Intervention group|Active play in after school programs (ASP). Training program for ASP staff.
2492154|NCT02954614|No Intervention|Control group|ASP as usual.
2492243|NCT02954029|Experimental|Study group (transradial cohort)|device-assisted compression with ezClot pad
2492247|NCT02954029|Experimental|Study group (transfemoral cohort)|manual compression with ezClot pad
2492249|NCT02954029|Active Comparator|Control group (transradial cohort)|Rotary compression device
2492250|NCT02954029|Active Comparator|Control group (transfemoral cohort)|manual compression with BloodSTOP ix pad
3194686|NCT00830973||Active Study Group|The active study group consists of 50 year or older postmenopausal women taking tamoxifen for the prevention of reoccurrence of breast cancer, do not meet exclusion criteria, meet all inclusion criteria, and are enrolled members for Medco clients agreeing to participate.
2492380|NCT02953054|Active Comparator|DMTS|DMTS applied to the upper arm
2492381|NCT02953054|Placebo Comparator|Placebo|Placebo patches to match DMTS applied to the upper arm
3194687|NCT00830986||1|Computer Assisted Total Knee Arthroplasty
3194688|NCT00830986||2|Conventional Instrumented Total Knee Arthroplasty
3194689|NCT00830999|Experimental|Positive energy balance|Comparison between isocaloric and hypercaloric diets with no exercise performed in any trials
3194690|NCT00830999|Experimental|Energy balance with exercise|Comparison between an isocaloric diet without exercise and a hypercaloric diet with a sufficient amount of exercise performed to match the excess calories consumed resulting in both trials being in net energy balance.
3194691|NCT00830999|Experimental|Negative energy balance|Comparison between isocaloric and hypocaloric diets with no exercise performed in any trials
3194692|NCT00830999|Experimental|Negative energy balance with exercise|Comparison between consuming an isocaloric diet without exercise and consuming the same amount of calories as in the isocaloric trial but with exercise performed resulting in net negative energy balance in the exercise trial.
3194693|NCT00831012|Experimental|Group 1|Group 1 will consist of healthy participants receiving an immunization of 10^3 PFU rDEN3delta30/31-7164
3194694|NCT00831012|Experimental|Group 2|"Group 2A will consist of healthy participants who will receive an immunization of 10^5 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2A participants will be enrolled if less that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42.~Group 2B will consist of healthy participants who will receive an immunization of 10^1 PFU of rDEN3delta30/31-7164 vaccine or placebo. Group 2B participants will be enrolled if more that 90% of Group 1 participants seroconvert to DEN3 by Study Day 42."
3194695|NCT00831025|Experimental|1|Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.
3194696|NCT00831025|Placebo Comparator|2|Placebo for subcutaneous injection.
3194697|NCT00831051|Experimental|Q8003 12mg/8mg|Combination
3194698|NCT00831051|Active Comparator|Morphine sulfate 12 mg|Single component
3194699|NCT00831051|Active Comparator|Oxycodone HCl 8mg|Single component
3194700|NCT00831051|Experimental|Q8003 6mg/4mg|Combination
3194701|NCT00831051|Active Comparator|Morphine sulfate 6mg|Single component
3194702|NCT00831051|Active Comparator|Oxycodone HCl 4mg|Single component
3194703|NCT00831064|Active Comparator|1. 4L PEG only|4L PEG PO
3194704|NCT00831064|Active Comparator|2. 2L PEG plus bisacodyl|2L PEG PO + 4 tablets bisacodyl PO
3194705|NCT00831064|Active Comparator|3. NaP|90 cc NaP PO
3194706|NCT00831064|Active Comparator|4. PSMC plus Mg-citrate|PSMC plus 300 cc Mg-citrate PO
3194707|NCT00831077|Active Comparator|14C-ORM-14540|
3194708|NCT00831077|Active Comparator|14C-ORM-12741|
3194709|NCT00831103|Experimental|EPB-348 1000 mg|EPB-348 1000 mg dosed once daily for seven days
3194710|NCT00831103|Experimental|EPB-348 2000 mg|EPB-348 2000 mg dosed once daily for seven days
3194711|NCT00831103|Experimental|EPB-348 3000 mg|EPB-348 3000 mg dosed once daily for seven days
3194712|NCT00831103|Active Comparator|Valacyclovir|Valacyclovir 1000 mg dosed three times daily for seven days
3194713|NCT00831116||LipiScan|Subjects who have at least one native coronary artery imaged with the LipiScan CIS.
2491719|NCT02957578|Experimental|Solo TTD|Placement of tympanostomy tube with Solo TTD
2491817|NCT02956577||T2|Patients with type 2 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at Odense University Hospital (OUH) Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional Funen Diabetes Database (FDDB). Data on historical invasive procedures due to cardiac disease were registered in Western Denmark Heart Registry (WDHR).
2491826|NCT02956577||T1|Patients with type 1 diabetes without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were invited from the Outpatient Clinic of Endocrinology or The Eye Photo Clinic at OUH Svendborg. Diagnosis of diabetes was classified by trained endocrinologists according to international standards with relevant biochemistry. Historical data on urine- and blood samples as well as micro- and macrovascular diabetic complications have been registered consecutively in patients followed at the outpatient clinic in the regional FDDB. Data on historical invasive procedures due to cardiac disease were registered in WDHR.
2491829|NCT02956577||Non-diabetic subjects|Non-diabetic subjects without myocardial infarction, heart failure and symptoms of cardiac disease at inclusion, were included from The Danish Cardiovascular Screening trial (DANCAVAS). A randomized controlled trial with the primary aim to evaluate the health benefits and costeffectiveness of using non-contrast full truncus computer tomography (CT) scans (to measure coronary artery calcification (CAC) and identify aortic/iliac aneurysms) and measurements of the ankle brachial blood pressure index (ABI) as part of a multifocal screening and intervention program for cardiovascular disease in men aged 65-74.
3161590|NCT00444886|Active Comparator|1|To assess the effect of BOTOX injection to the scalene muscles on the severity of pain from TOS.
3161591|NCT00444886|Active Comparator|2|To assess the effect of BOTOX injection on numbness and tingling and quality of life.
2492087|NCT02955173|Experimental|Open surgery of rectal cancer|Patients undergoing rectal cancer resection in an open approach
2492092|NCT02955173|Experimental|Laparoscopic surgery of rectal cancer|Patients undergoing rectal cancer resection in a laparoscopic approach
2492096|NCT02955173|Experimental|Open surgery of gastric cancer|Patients undergoing gastric cancer resection in an open approach
2492101|NCT02955173|Experimental|Laparoscopic surgery of gastric cancer|Patients undergoing gastric cancer resection in a laparoscopic approach
2492156|NCT02954718|Experimental|1|patient-centered task oriented activity training in real life
2492160|NCT02954718|Experimental|2|patient-centered video-based task oriented activity training
2492191|NCT02954276|Experimental|75 mg Omexa sumatriptan sublingual tablet|
2492192|NCT02954276|Active Comparator|100 mg Imitrex oral tablet|
2492242|NCT02954016|Experimental|ePass|Subjects implanted with the investigational ValenTx Endo Bypass System
2492306|NCT02953626|Experimental|Immediate Treatment Condition (ITC)|Mother Matters Online Postpartum Support Group. Participants will be assigned to begin immediately after randomization.
2492308|NCT02953626|No Intervention|Waitlist Control Condition (WLC)|Mother Matters Online Postpartum Support Group. Participants will receive the intervention after the Immediate Treatment Condition group completes the intervention, and after follow-up data are collected from both groups.
2492352|NCT02953288||Benign thyroid nodules|Benign thyroid nodules
2492354|NCT02953288||Thyroid Carcinoma|Thyroid Carcinoma
2492397|NCT02953145|Experimental|Tisseel applied|In this group, the fibrin sealant Tisseel will be applied as a hemostasis agent in patients undergoing primary palatoplasty
2492401|NCT02953145|No Intervention|No fibrin sealant|In this group, no fibrin sealant will be applied intra-operatively. Standard measures, such as electrocautery, will be used for hemostasis.
2492537|NCT02952456||Bereaved families|Person who have lost a loved one from an epilepsy-related death with interview with a psychologist
2492539|NCT02952456||Patients with épilepsy|Patients with épilepsy with interview with a psychologist
2492541|NCT02952456||Relatives of patients with epilepsy|Relatives (Parents / spouse/ Husband) of patients with epilepsy with interview with a psychologist
2492572|NCT02951845|Experimental|Part 1: Treatment Sequence A1B1C1|Participants in Part 1 will only receive single dose of Treatment A1 oral Suspension (25 milligram [mg], Fasted) then Treatment B1 (Direct Compression Tablets, 5*5 mg Tablets, Fasted) followed by Treatment C1 (Direct Compression Tablets (5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492762|NCT02951000|Active Comparator|no platysma suture|no platysma suture
3161592|NCT00444899|Experimental|Intensive treatment|Submitted to an intensive follow-up by the dietician.
3161593|NCT00444899|Active Comparator|Usual treatment|Subjects will remain under the care of their endocrinologist and/or general practitioner.
3161594|NCT00444977|Experimental|Case-management linkage intervention|"The intervention represents a brief, real world intervention that could easily be adopted by HIV care clinics to facilitate linkage and increase use of oral services by their HIV+ patients (if shown to be effective). We are seeking to compare this intervention to usual practice in these clinics."
3161595|NCT00444977|No Intervention|Standard of Care|Subjects will receive standard of care services.
3161596|NCT00445042|Experimental|A|Intrapatient dose escalation study of sorafenib
3161597|NCT00445055|Experimental|1|Intravenous injection of 0,625 mg Droperidol, 30 min before the end of anesthesia
3161598|NCT00445055|Experimental|2|Intravenous injection of 2,5 mg Droperidol, 30 min before the end of anesthesia
3161599|NCT00445055|Placebo Comparator|3|Intravenous injection of NaCl 9% (Placebo), 30 min before the end of anesthesia
3161600|NCT00445081|Active Comparator|1|
3161601|NCT00445081|Active Comparator|2|
3161602|NCT00445120|Experimental|1|
3161603|NCT00445120|Placebo Comparator|2|
3161604|NCT00445172|Experimental|1|
3161605|NCT00445185|Experimental|1|Henogen Hepatitis B vaccine for uremic patients
3161606|NCT00445185|Active Comparator|2|Fendrix hepatitis B vaccine for uremic patients
3161607|NCT00445198|Experimental|Phase 1 and Phase 2a|
2491726|NCT02957383|Experimental|wavelength|Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
2491727|NCT02957383|Experimental|intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
2491760|NCT02957019|Experimental|L19-IL2 + RTX|"Phase I (Dose definition):~Cohorts of 3-6 patients will receive Rituximab on day 1 and 8 of the first 3-weeks cycle (C1D1 and C1D8, respectively) and on day 1 of the second 3-weeks cycle (C2D1). During two uninterrupted 3-weeks cycles, L19-IL2 will be administered on C1D1, C1D8, C1D15 and C2D1, C2D8, C2D15.~Phase II (Activity Evaluation):~During Phase II, 14 patients will receive Rituximab on C1D1 and C1D8 and on C2D1. Two uninterrupted 3-weeks cycles of L19-IL2 at the RD determined during Phase I will be administered on C1D1, C1D8 and C1D15 and C2D1, C2D8 and C2D15."
2491782|NCT02956668|Experimental|Blindsight training associated to tDCS|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time.~tDCS stimulation start at the beginning of the rehabilitation session, and continue for 30 min, during treatment.~Anode is placed over the parieto-occipital cortex. The cathode is placed in the contralateral supraorbital position."
2491783|NCT02956668|Active Comparator|Blindsight training alone|"During the blindsight training (one-hour time), the patient is asked to maintain central fixation and is exposed to visual stimuli in his blind hemifield. The patient task is detection and/or discrimination of stimuli.~During each session the patient is subjected to around 700 different stimuli variously associated in space and/or time."
2491801|NCT02956538|Experimental|thalidomide|thalidomide 100mg tablet by mouth, every night for 8 weeks
2491802|NCT02956538|Active Comparator|placebo|placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks
2491870|NCT02956304|Other|Group iTBS-cTBS-SHAM|PMv stimulation (iTBS) at session 2, PMv inhibition (cTBS) at session 3, and control (SHAM) at session 4
2491873|NCT02956304|Other|Group iTBS-SHAM-cTBS|PMv stimulation (iTBS) at session 2, control (SHAM) at session 3, and PMv inhibition (cTBS) at session 4
2491878|NCT02956304|Other|Group cTBS-iTBS-SHAM|PMv inhibition (cTBS) at session 2, PMv stimulation (iTBS) at session 3, and control (SHAM) at session 4
2491881|NCT02956304|Other|Group cTBS-SHAM-iTBS|PMv inhibition (cTBS) at session 2, control (SHAM) at session 3, and PMv stimulation (iTBS) at session 4
2491886|NCT02956304|Other|Group SHAM-iTBS-cTBS|control (SHAM) at session 2, PMv stimulation (iTBS) at session 3, and PMv inhibition (cTBS) at session 4
2491890|NCT02956304|Other|Group SHAM-cTBS-iTBS|control (SHAM) at session 2, PMv inhibition (cTBS) at session 3, and PMv stimulation (iTBS) at session 4
2491998|NCT02955784|Experimental|Sinasprite Mobile App|Mobile App
2492042|NCT02955381|Experimental|Restylane Silk, 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Restylane® Silk) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
2492044|NCT02955381|Placebo Comparator|Placebo (Saline), 1.0 ml|Subjects must have at least 1 but up to 3 acne scars ≥3 mm and ≤ 10 mm located on the cheeks or forehead. Subjects will receive one treatment (Placebo (Saline)) in each scar (up to 3 acne scars) at day 0, and Month 1 (2 total treatments per scar during the study). Subjects will remain blinded to the treatment administered to them during these visits.
2492077|NCT02955082|Experimental|Carboplatin|Patients with a germline DNA repair gene mutation identified in part 1 of the study, or who are already known to have a germline mutation will undergo assessment for inclusion in part 2 of the study to receive Carboplatin treatment.
2492129|NCT02954796|Experimental|(Dose Escalation) Cohort -1 - 6|SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.
2492179|NCT02954445|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-BCMA-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2492326|NCT02953457|Experimental|Treatment (olaparib, tremelimumab, durvalumab)|Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2492382|NCT02953041|Experimental|LAMA Treatment|Inhalation of 50mcg glycopyrronium from Breezhaler device 1 hour prior to methacholine challenge
2492383|NCT02953041|Experimental|uLABA Treatment|Inhalation of 75mcg indacaterol from Breezhaler device 1 hour prior to methacholine challenge
2492385|NCT02953041|Experimental|Combo Treatment|Inhalation of 50mcg glycopyrronium from one Breezhaler device, and 75mcg indacaterol from a second Breezhaler device, all one hour prior to methacholine challenge
2492460|NCT02952807|Active Comparator|sequential|sequential use of vaginal misoprotol Plus Foley Catheter for Induction of Labor.
2492464|NCT02952807|Active Comparator|Concurrent|Concurrent Use of Vaginal misoprostol Plus Foley Catheter for Induction of Labor.
3161608|NCT00445367||Case|
2492562|NCT02951910|Experimental|Intervention|Patients receiving zinc-hyaluronate eye drop
2492651|NCT02951663|Experimental|Protein Supplement|Ready to drink blinded protein supplement
2492654|NCT02951663|No Intervention|Control|Control group
3194714|NCT00831142||Prostate Cancer|Males with prostate cancer, referred for biopsy or radical prostatectomy
3194715|NCT00831155|Active Comparator|1|Extinction Based Group (EBT): switch to smoking denicotinized cigarettes while wearing a 21mg/day nicotine patch for one month prior to their quit date.
3194716|NCT00831155|No Intervention|2|Nicotine Replacement Group (NRT): smoke their usual brand of cigarettes up to the quit date.
3194717|NCT00831194|Experimental|Diet plan and PDA|
3194718|NCT00831207||G1|15 HIV-1+ individuals, previously untreated or without HAART for at least six months and CD4+ < 350 cells/mm3.
3194719|NCT00831207||G2|31 HIV-1+ individuals undergoing HAART without virological therapeutic failure (TF).
2524926|NCT02730715||Thymoglobulin|blood specimen collection
3161609|NCT00445367||Control|
2491778|NCT02956980|Experimental|Group 1: non-pubescent children|70 non-pubescent children (25 healthy boys, 25 healthy girls, 10 boys with Klinefelter syndrome and 10 girls with Turner syndrome) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 70 non-pubescent children.
2491780|NCT02956980|Experimental|Group 2: pubescent healthy children|50 pubescent healthy children (25 boys and 25 girls) Two 7 ml tubes of blood will be taken to perform the functional assays as well as the quantification of Blood Plasmacytoid dendritic cells (pDCs) absolute number in this 50 pubescent healthy children.
2491820|NCT02956564|Other|exposure group|subjects in this group are those who accept intrauterine intervention
2491827|NCT02956564|No Intervention|control group|subjects in this group are those who do not accept intrauterine intervention
2491880|NCT02956408|Active Comparator|Conventional|Patients in this arm will be prescribed Vitamin D3 2000 IU once a day
2491885|NCT02956408|Experimental|High Dose|Patients in this arm will be prescribed Vitamin D3 6000 IU once a day
2491978|NCT02955719|Experimental|Enrolled Cases|"Integrated Care Pathway with different treatment interventions~Interventions include:~Sertraline, Venlafaxine, CBT/Psychological therapy, Psychiatric consultation, lifestyle intervention resources"
2491980|NCT02955719|No Intervention|Enrolled Controls|No intervention: Treatment as usual (TAU) will be provided by the primary care practice staff
2492017|NCT02955355|Experimental|HYQVIA|Subjects will continue to receive HYQVIA/HyQvia infusions every 2, or 3, or 4 weeks (±3 days) following the same dose and dosing regimen of the Phase 3 pivotal study (Study 161403).
2492146|NCT02954770||Fitbit® challenger|The residents who participated a Fitbit® challenge study about one year ago
2492173|NCT02954393|Placebo Comparator|Control|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Placebos healing phase TID for 14 days.
2492174|NCT02954393|Active Comparator|Active phase|Scaling and root planing + Metronidazole active phase (400 mg/thrice a day,TID) + Amoxicillin active phase (500 mg/ TID) for 14 days and Placebos healing phase TID for 14 days.
2492175|NCT02954393|Active Comparator|Healing phase|Scaling and root planing + Placebos active phase thrice a day (TID) for 14 days and Metronidazole healing phase (400 mg/TID) + Amoxicillin healing phase (500 mg/TID) for 14 days.
2492223|NCT02954133|Experimental|I7: Control|Subjects assigned to this group receive no OrthoPulse™ treatment, and switch Invisalign aligners every 7 days.
2492225|NCT02954133|Experimental|OP7: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 7 days.
2492226|NCT02954133|Experimental|OP5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 5 days.
2492227|NCT02954133|Experimental|OP3.5: OrthoPulse Treatment|Subjects assigned to this group receive daily OrthoPulse™ treatments, and switch Invisalign aligners every 3.5 days.
2492524|NCT02952183|Experimental|PAMS I|During operation, autonomic nerve monitoring will be performed by PAMS I which is composed of two urodynamic systems.
2492587|NCT02951949||Postmenopausal women|Postmenopausal women attending the outpatient service of a third level hospital for health control.
2492626|NCT02951546|Experimental|Mediterranean diet|"Hypocaloric Mediterranean diet for a 4-month period;~Aerobic exercise training for a 4-month period;"
2492627|NCT02951546|Experimental|Low fat diet|"Hypocaloric low fat diet supplemented by branched and essential amino acids considering the total protein intake for a 4- month period;~Aerobic exercise training for a 4- month period;"
2492709|NCT02951338|Active Comparator|Group aerobic exercise only|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
2492717|NCT02951338|Experimental|PROPEL program|The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
3161610|NCT00445445||Patients|Histologically confirmed breast cancer that was diagnosed between the years 2002-2004
3161611|NCT00445445||Healthy participants|Healthy participant who is receiving routine medical care (e.g., screening mammograms. Healthy participants are frequency-matched by age (± 2 years) and ethnicity.
2492788|NCT02950883|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
3161612|NCT00445471|Other|A|Mifne Approach to PDD
3161613|NCT00445471|Other|B|Treatment as usual
3161614|NCT00445523|Experimental|1|TroVax® alone
3161615|NCT00445523|Experimental|2|TroVax® plus IFN-α
3161616|NCT00445575|Experimental|1|treatment duration: 1 year
3161617|NCT00445575|Placebo Comparator|2|treatment duration: 1 year
2492189|NCT02954406|Experimental|Safety Expansion Phase Cohort B:TAK-659+Bendamustine+Rituximab|TAK-659 TBD, immediate-release tablet, orally, once daily on Days 1 to 21 along with bendamustine 90 mg/m^2, infusion, intravenously, over 10 or 60 minutes (depending on formulation used) on Days 1 and 2 along with rituximab 375 mg/m^2, infusion, intravenously, on Day 1 in a 21-day treatment cycle, for up to 8 cycles in participants with advanced ollicular lymphoma (FL) or marginal zone lymphoma (MZL). The TAK-659 dose will be the MTD / maximally administered dose (MAD)/ RP2D as determined in the dose escalation phase. Participants will continue to receive study treatment for a maximum of 12 months, until they experience PD or unacceptable toxicities.
2492267|NCT02953899|Experimental|Contingency Management|This is a treatment where participants earn points for treatment attendance and for providing evidence of gambling abstinence. These points are added to study accounts that can be redeemed for goods and services available at a variety of on-line businesses (e.g., Amazon, Walmart, etc.). Submission of evidence of gambling behaviour or non-attendance at an on-line counselling session re-sets subsequent points to the starting level. The CM procedure is implemented as part of the CBT counselling session.
2492271|NCT02953899|Active Comparator|Cognitive Behavioural Therapy|"CBT is currently considered best practice for the treatment of problem gambling, as noted in the National Health and Medical Research Council (Australia) endorsed Clinical Guidelines for problem and pathological gambling treatment (Problem Gambling Research and Treatment Centre, 2011). CBT is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling and substance use. Techniques include psychoeducation, behavioural interventions, and cognitive strategies. Participants are expected to attend on-line counselling sessions three times a week for approximately 12 weeks. All participants will receive individual counselling from an experienced counsellor/therapist."
2492289|NCT02953522|Other|191 mcg/day of Folate|Diet with 191 mcg/day of Folate
2492290|NCT02953522|Other|90 mcg/day of Folate|Diet with 90 mcg/day of Folate
2492321|NCT02953353|Active Comparator|Active group|Active transcranial direct current stimulation (tDCS) and hypocaloric diet.
2492329|NCT02953353|Sham Comparator|Control group|Sham transcranial direct current stimulation (tDCS) and hypocaloric diet.
2492390|NCT02953093|Other|Acarbose first|Participants will take acarbose three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take placebo three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
2492395|NCT02953093|Other|Placebo first|Participants will take placebo three times daily for 10 weeks (titration over 4 weeks, maintenance 6 weeks). After a two week washout, participants will take acarbose three times daily for a total of 10 weeks (titration over 4 weeks, maintenance 6 weeks).
2492446|NCT02952768|Other|ultrasound training|The aims were to develop a novel, resuscitative ultrasound-circulation-airway-breathing (US-C-A-B) protocol, to implement a short curriculum for ultrasound training and to assess the feasibility.
2492521|NCT02952430||Frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of greater than or equal to five.~This group will then be observed after intervention to review outcomes."
2492523|NCT02952430||Not frail|"Patients over 65 year old having emergency laparotomy with a Frailty score (Modified Rockwood score) of less than five.~This group will then be observed after intervention to review outcomes."
2492576|NCT02951975||OZURDEX®|Patients prescribed dexamethasone intravitreal implant (OZURDEX®) in clinical practice for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
3194720|NCT00831207||G3|43 HIV-1+ individuals undergoing HAART with TF.
3194721|NCT00831207||G4|20 normal individuals who served as controls for serum cytokines.
2492881|NCT02950129|Other|measurements of gait|all subjects will undergo 6 tests to assess gait before and after SIJ; SIJ pain diagnostic tests
3194722|NCT00831220||1|Patients with a COPD exacerbation
2493027|NCT02949440|Experimental|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein（SMV）and Superior mesenteric artery（SMA）and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein（SMV）. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called caudal-to-cranial approach.
2493031|NCT02949440|Active Comparator|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein（SMV）to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
3161618|NCT00445575|Experimental|3|duration treatment: 3 years
2493168|NCT02948023|No Intervention|Standard Surgical therapy|Includes the control group that fulfills the inclusion criteria
2493179|NCT02948023|Active Comparator|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
2493204|NCT02947711|Experimental|E2027 100 mg alone and in combination with diltiazem ER 300 mg|E2027 100 milligrams (mg) will be administered orally on Days 1 and 12. Diltiazem extended release (ER) 300 mg will be administered alone on Days 7 to 24; however, on the morning of Day 12 it will be coadministered with E2027 100 mg.
2493287|NCT02947464|Active Comparator|Control|Standard clinical practice
2493289|NCT02947464|Experimental|Intervention|Standard clinical practice + Rapid Maxillary Expansion
3161619|NCT00445575|Placebo Comparator|4|treatment duration: 3 years
2524927|NCT02730715||Basiliximab|blood specimen collection
3161620|NCT00445614|Experimental|Marine trout|150 g/day of trout fed on marine based feed
3161621|NCT00445614|Experimental|Vegetable trout|150 g/d of trout fed on vegetable based feed
3161622|NCT00445614|Other|Poultry|150 g/d of poultry (for comparison)
3194723|NCT00831220||2|Patients with stable COPD
3194724|NCT00831220||3|Smokers or former smokers
3194725|NCT00831220||4|Never smokers
3194726|NCT00831246|Experimental|1|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
3194727|NCT00831246|Sham Comparator|2|Patients are given standard post-op care with clear liquid diet as tolerated .
3194728|NCT00831259||1|Incidence of silent stroke in patients with PFO
3194729|NCT00831259||2|Incidence of silent stroke in patients without PFO
2492535|NCT02952170|Experimental|MRI for steatosis assessment|Abdominal MRI for assessment of hepatic steatosis
2492571|NCT02951923|Experimental|Bovine colostrum|8 weeks of Bovine colostrum power, 60g per day
2492573|NCT02951923|Active Comparator|Soy powder|8 weeks of Soy powder, 60g per day
2492629|NCT02951611|Sham Comparator|Sham stimulation|Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.
2492630|NCT02951611|Experimental|Treatment: Acupuncture stimulation|Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.
3194730|NCT00831285|Experimental|tortilla with high amylose flour|
2492827|NCT02950610||Healthy|Healthy volunteer: self-declared healthy individual (no known illness or medications) with Normal BMI
2492830|NCT02950610||Nonalcoholic steatohepatitis|NAFLD without cirrhosis: Metabolic syndrome with known liver disease (NAFLD, excluding other coexisting liver condition) without cirrhosis
2492831|NCT02950610||NAFLD Cirrhosis|NAFLD cirrhosis: well characterised NAFLD compensated cirrhosis (Child's A-B)
2492866|NCT02950259|Experimental|IRX-2 Regimen -Early Stage Breast Cancer|Enrolled subjects with early stage breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
2492869|NCT02950259|Experimental|IRX-2 Regimen -Triple Negative Breast Cancer|Enrolled subjects with triple negative breast cancer will receive a single dose of cyclophosphamide (300 mg/m2) by IV infusion on Day 1. Also starting on Day 1 and continuing until Day 21, subjects will take daily oral indomethacin (25 mg three times each day), daily oral omeprazole (one tablet) and daily oral multivitamin containing 15-30 mg of zinc. On any 10 consecutive day period between Days 4-17, patients will receive two 1 mL subcutaneous periareolar injections of IRX-2.
2492944|NCT02949765|Active Comparator|Iron sulfate 105 mg|Iron sulfate 105 mg: 1 pill/day is administered
2492954|NCT02949765|Experimental|Iron-rich diet|Iron-rich diet recommendations are given
2492986|NCT02949245||Groups/Cohorts|"Surgical treatment~This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity."
2493145|NCT02948231|Experimental|Mistral|
2493199|NCT02947893|Placebo Comparator|Group 1 (placebo)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 1 and given 1 capsule of a placebo drug by mouth every day for the first 6 months followed by 2 capsules once daily for the subsequent 6 months, every time taken without a meal, for the total duration of the study for 12 months.
2493200|NCT02947893|Active Comparator|Group 2 (treated)|Out of 42 total participants with mild to moderate AD (MMSE=17-24 inclusive) and their study partners that will be recruited and 1:1 randomized, 21 (twenty-one) will be assigned to group 2 treated with 1 capsule (150mg Nilotinib) once a day by mouth for the first 6 months followed by dose escalation to 2 capsules (300mg Nilotinib) once daily by mouth for the subsequent 6 months, every time taken without a meal, for the total study duration of 12 months.
2493267|NCT02947555||DM+/AT+|Patients with type 2 diabetes mellitus and atherosclerotic event in history
2493269|NCT02947555||DM+/AT-|Patients with type 2 diabetes mellitus without atherosclerotic event in history
2493271|NCT02947555||DM-/AT+|Non-diabetic patients with atherosclerotic event in history
2493273|NCT02947555||DM-/AT-|Non-diabetic patients without atherosclerotic event in history
2493319|NCT02947126|Experimental|Cystic Fibrosis (HS, IS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive HS dose on first imaging day and IS dose on the second imaging day,~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
2493320|NCT02947126|Experimental|Cystic Fibrosis (IS, HS)|"CF subjects: ages 12 or older with a diagnosis of cystic fibrosis as determined by sweat test or genotype and clinical symptoms who are clinically stable as determined by a physician co-investigator. Subjects receive IS dose on first imaging day and HS dose on the second imaging day.~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml), Inhaled Hypertonic Saline (4ml)"
2493321|NCT02947126|Experimental|Parents of CF subjects|"Ages 18 and older, biological parent of a CF patient who is also enrolled in the study~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)"
2493323|NCT02947126|Experimental|non CF controls|"Ages 18 and older with no history of lung disease~Indium-DTPA (1.5 mCi), Technetium sulfur colloid (8mCi), Inhaled isotonic saline (4ml)."
2493418|NCT02946541|Experimental|evogliptin 5mg|evogliptin 5mg QD
2493434|NCT02946541|Placebo Comparator|placebo|Placebo QD
2493456|NCT02946060|Sham Comparator|Usual Care|Participants in this intervention will receive the minimal standard of care provided at the Cardiac Rehabilitation and Prevention Program at Toronto Rehabilitation Institute. Participants will receive an iPod with a silent track or white noise.
2493459|NCT02946060|Active Comparator|Audiobooks|Participants in this arm will receive iPods with Audiobooks based on their preferred genres.
2494106|NCT02941575|Active Comparator|Control|Implant superstructure crown: All ceramic, IPS Emax
3194731|NCT00831285|Experimental|barley tortilla with low amylose flour|
3194732|NCT00831285|Experimental|barley tortilla with low amylose flour and soluble fibre|
3194733|NCT00831285|Experimental|barley tortilla with low amylose flour and insoluble fibre|
3194734|NCT00831285|Active Comparator|glucose|
3194735|NCT00831285|Experimental|barley tortilla with low amylose flour and low soluble fibre|
2492273|NCT02953834|Experimental|Kisspeptin and Insulin Resistance Test|intravenous administration of kisspeptin 112-121; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
2492274|NCT02953834|Placebo Comparator|Placebo and Insulin Resistance Test|intravenous administration of IV fluids that contain no study drug; eat a standard mixed meal or drink a standard mixed meal or 75 grams of oral glucose
2492307|NCT02953483|Experimental|Acellular first|Lung preservative solution without red blood cells will be used for perfusion in the initial 2 hours followed by addition of red blood cells for the next two hours
2492309|NCT02953483|Experimental|Cellular first|Lung preservative solution will contain red blood cells for the first two hours followed by acellular perfusate for the next two hours
2492359|NCT02953275|Experimental|vedolizumab plus pentoxifylline|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as pentoxifylline 400 mg orally thrice daily.
2492361|NCT02953275|Placebo Comparator|vedolizumab plus placebo|Patients will receive standard induction and maintenance dosing of vedolizumab 300 mg intravenously as well as placebo orally thrice daily.
2492376|NCT02952989|Experimental|SGN-2FF|Dose escalation and dose expansion
2492377|NCT02952989|Experimental|SGN-2FF and Pembrolizumab|Dose escalation and dose expansion
2492442|NCT02952755|Experimental|Study effect of DWC20162 on DWC20155/DWC20156 PK|To study effect of DWC20162 on DWC20155/DWC20156 PK
2492453|NCT02952755|Experimental|Study effect of DWC20155/DWC20156 on DWC20162 PK|To study effect of DWC20155/DWC20156 on DWC20162 PK
2492503|NCT02952378|Experimental|Burn patients|Patients with burns exceeding 6-8 Total Burned Surface Area %
2492509|NCT02952378|Experimental|Healthy individuals|Healthy individuals without allergies.
2492569|NCT02952066|Experimental|TRP1 Density|Bronchial Biopsy: During the biopsy procedure the investigator will collect five bronchial specimens (1-2 cubic millimeters) each the major, lobar and segmental bronchi.
2492636|NCT02951637|Experimental|Group A|Patient will be administrated with Pemetrexed plus carboplatin combined with gefitinib
2492639|NCT02951637|Experimental|Group B|Patient will be administrated with gefitinib
2492698|NCT02951286|Experimental|high pull headgear + OBA|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied with high pull headgear for Orthoclassic ®1300 NE Alpha Drive, McMinnville, OR 97128 USA 866.752.0065.
2492700|NCT02951286|Experimental|OBA (control group)|A modified version of the Open Bite Appliance (OBA),introduced by Erverdi and Usumez, will be applied only.
2492753|NCT02951117|Experimental|Arm A Venetoclax QD + ABBV-838 Q3W + Dexamethasone|ABBV-838 administered at cohort-defined doses every 3 weeks (Q3W; starting dose 4.0 mg/kg) in combination with venetoclax (400 mg or 800 mg once daily [QD]) and dexamethasone (40 mg once weekly [Q1W]); once the maximum-tolerated-dose (MTD) and recommended phase two dose (RPTD) are determined, ABBV-838 in combination with venetoclax and dexamethasone at RPTD will be administered in a dose expansion phase of the study.
2492759|NCT02951117|Experimental|Arm B Venetoclax QD + ABBV-838 Q1W or Q2W + Dexamethasone Q1W|"Dose escalation portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax (400 or 800 mg QD) and dexamethasone (40 mg Q1W).~The dose expansion portion will investigate either the ABBV-838 weekly (Q1W) or bi-weekly (Q2W) dosing interval in combination with venetoclax and dexamethasone at the RPTD combination defined from the Dose Escalation portion."
2492810|NCT02950727|Experimental|3 bicortical screw|1st group:3 bicortical screws will be used to fix the sagittal split ramus osteotomy.
2492812|NCT02950727|Active Comparator|adjustable plate and 2 bicortical screws|adjustable plate and 2 bicortical screws will be used to fix the sagittal split ramus osteotomy.
2492854|NCT02950493|Other|Single group, one arm study group|Compare echocardiograph imaging efficacy of active Definity or Lumason (perflutren lipid microsphere) with compressed Definity or Lumason.
2492884|NCT02950168||Edoxaban|All patients treated with edoxaban with a planned or unplanned diagnostic or interventional procedure
2492972|NCT02949505|Experimental|Intervention arm|12-week home prehabilitation program
2493017|NCT02949206|Experimental|Part 1: Cohort 1 (0.03 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.03 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching placebo on Day 1.
2493019|NCT02949206|Experimental|Part 1: Cohort 2 (0.1 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.1 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2493020|NCT02949206|Experimental|Part 1: Cohort 3 (0.3 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 0.3 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2493022|NCT02949206|Experimental|Part 1: Cohort 4 (1.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2493025|NCT02949206|Experimental|Part 1: Cohort 5 (2.5 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2493026|NCT02949206|Experimental|Part 1: Cohort 6 (5.0 mg/kg of JNJ-64179375 or Placebo)|Participants in a ratio of 3:1 will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching placebo on Day 1.
2493029|NCT02949206|Experimental|Part 1: Cohort 7 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
2493032|NCT02949206|Experimental|Part 1: Cohort 8 (Escalation Dose of JNJ-64179375 or Placebo)|Dose escalation will proceed until the toxicology study exposure limits or a highest tolerable dose will be reached.
2493033|NCT02949206|Experimental|Part 2: Reversal Cohort :(50 IU/kg of 4-factor PCC)|Participants will receive a 2.5 mg/kg of JNJ-64179375 or highest tolerable dose if lower than 2.5 mg/kg followed by administration of a single IV 50 International Unit per kilogram (IU/Kg) dose of a 4 factor prothrombin complex concentrate (PCC) or matching placebo on Day 1.
2493034|NCT02949206|Experimental|Part 3: Subcutaneous Cohort (1.0 mg/kg of JNJ-64179375)|Participants will receive a Single Subcutaneous (SC) dose of 1.0 mg.kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching placebo on Day 1.
2493053|NCT02948738|Experimental|Interactive Education|Interactive asthma education
2493054|NCT02948738|Active Comparator|Standard Education|Standard asthma education
2492279|NCT02953847|Other|sequence 6|"Rifafour e-275®, Sanofi-Aventis /Rimactazid 150/75, Sandoz/ Rimactane® 150 mg capsules, Sandoz~- 24 healthy volunteers will receive single doses of the 3 rifampicin containing products with a washout of 14 days between doses. Each volunteer will be randomised to receive the 3 doses in one of 6 sequences"
2492336|NCT02953366|Experimental|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
2492338|NCT02953366|Active Comparator|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
2492388|NCT02953171|Experimental|Raw sauerkraut+Probiotic capsule|75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
2492391|NCT02953171|Experimental|Raw sauerkraut+placebo capsule|75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.
2492396|NCT02953171|Experimental|Pasteurized sauerkraut+Probiotic capsule|75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.
2492399|NCT02953171|Placebo Comparator|Pasteurized sauerkraut+Placebo capsule|75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.
2492436|NCT02952703|Active Comparator|First Breath|brief pre-natal smoking cessation counseling
2492440|NCT02952703|Experimental|Striving to Quit|Additional pre-natal counseling (in-person and telephonic); post delivery counseling (in-person and telephonic) and incentives
2492495|NCT02952287|Experimental|Study Participants|4D PC MRI acquisition
2492549|NCT02952157|Sham Comparator|Control|Normal saline will be applied to the endotracheal tube.
2492553|NCT02952157|Active Comparator|Lidocaine|Lidocaine jelly will be applied to the endotracheal tube.
2492595|NCT02951793||AUDIT-C > 4|Significant alcohol use within 1 year prior to ICU admission (AUDIT-C>4)
2492600|NCT02951793||AUDIT-C <=4|No significant alcohol use within 1 year prior to ICU admission (AUDIT-C: equal or less than 4)
2492603|NCT02951793||Smoking history positive last year|Who smoke cigarette within 1-year prior to ICU admission
2492606|NCT02951793||Smoking history negative last year|Who did not smoke cigarette within 1-year prior to ICU admission
2492607|NCT02951793||Prior psychotropic medication use - yes|Who used psychotropic medication within 1-year prior to ICU admission
2492608|NCT02951793||Prior psychotropic medication use - no|Who did not use psychotropic medication within 1-year prior to ICU admission
2492659|NCT02951455|Experimental|CD-LC|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Licensed Clinician (LC).
2492660|NCT02951455|Experimental|CBP- LC|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Licensed Clinician (LC)
2492661|NCT02951455|Experimental|QLW- LC|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life Wheel, Licensed Clinician (LC)
2492664|NCT02951455|Experimental|CD & CBP- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2492665|NCT02951455|Experimental|CD & QLW- LC|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2492667|NCT02951455|Experimental|QLW & Capacity Building ProjectCBP- LC|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks. Licensed Clinician (LC)
2492669|NCT02951455|Experimental|QLW & CD & CBP-LC|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Licensed Clinician (LC)
2492672|NCT02951455|Experimental|LC|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes.Licensed Clinician (LC)
2492673|NCT02951455|Experimental|CD- PF|Group behavioral intervention with 9 weekly sessions lasting 2 hours. Critical Dialogue (CD), Peer Facilitator (PF)
2492676|NCT02951455|Experimental|CBP- PF|Group community mobilizing intervention with 9 weekly sessions spread in 15 weeks. Capacity Building Project (CBP), Peer Facilitator (PF)
2492678|NCT02951455|Experimental|QLW-PF|Group intervention where participants learn to develop and implement personal goals that are measurable, attainable, realistic, and time bound. Intervention includes 9 sessions. Quality of Life wheel, Peer Facilitator (PF)
2492681|NCT02951455|Experimental|CD & CBP- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions. Peer Facilitator (PF)
2492682|NCT02951455|Experimental|CD & QLW- PF|Combination of group behavioral intervention and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
2492685|NCT02951455|Experimental|QLW & CBP- PF|Combination of goal development and implementation with community mobilization intervention including 9 weekly sessions spread across 15 weeks.Peer Facilitator (PF)
2492686|NCT02951455|Experimental|CD & QLW & CBP- PF|Combination of group behavioral intervention, goal development and implementation, and community mobilization intervention including 15 weekly sessions.Peer Facilitator (PF)
2492688|NCT02951455|Experimental|PF|This condition will include 3 core sessions that are not a part of the components being tested. These are support sessions to the components being tested and is hypothesized to have the smallest impact on substance use outcomes. Peer Facilitator (PF)
3194736|NCT00831298|Other|1|Behavioral Questionnaire Sleep Recordings Genetic analysis
2492823|NCT02950623|Experimental|patients take titanium dioxide denture|patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) for 1 month in the initial phase of the trial then in the later phase after one month they will receive( rapid heat cured acrylic resin)denture
2492825|NCT02950623|Placebo Comparator|patients take rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles )
2492865|NCT02950324|Experimental|Prehabilitation|Patients in this (intervention) arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'.
2492284|NCT02953691|Placebo Comparator|Maltodextrin (Placebo)|Clasado Biosciences Limited will provide placebo (Maltodextrin) for the clinical trial. Each pastille contains maltodextrin and will be taken 3 times per day. Following informed consent, subjects will be issued prepackaged pastilles to be taken three times daily up until the evening prior to surgery. Subjects will be randomly assigned to receive GOS prebiotics or placebo. Each subject has an equal chance of receiving GOS or placebo. Placebo will be administered in the hospital when patient reinstitutes oral intake. Placebo will be issued to each subject to last until the day of their scheduled follow-up for POCD (approximately 1.5 months post surgery).
2492325|NCT02953444|No Intervention|Wait List Control|Participants receive daily email surveys for two weeks before being given access to the brief-mindfulness-practice training materials.
2492330|NCT02953444|Experimental|Thirty-Second Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a thirty-second mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
2492334|NCT02953444|Active Comparator|Three-Minute Mindfulness Practice|Participants watch a ten minute mindfulness training video then are given electronic access to an audio recording of guidance for a three minute mindfulness meditation practice. Participants are asked to complete this practice using the audio-recorded guidance at least three times a day for two weeks. Participants are sent daily emails that include reminders to complete the practice and a link to a brief online survey.
2492389|NCT02953158|Experimental|Haas Avocado|Haas Avocado commercially available Behavioral: Dietary recommendations Recommendation: a hypocaloric weight loss diet
2492394|NCT02953158|Active Comparator|Dietary Counseling|Behavioral: Dietary Counseling Recommendation: equally hypocaloric usual American diet.
2492458|NCT02952794||ESD|endoscopic submucosal dissection (ESD)for early cancer
2492462|NCT02952794||EMBL|endoscopic mucosal band ligation (EMBL) for early cancer
2492538|NCT02952326|Experimental|XP Endo Finisher|
2492540|NCT02952326|Active Comparator|Conventional needle irrigation|
2492594|NCT02951871||LP: Lymphoma Progression|
2492597|NCT02951871||TRM: Treatment Related Mortality|
2492602|NCT02951871||NHM: Non hematologic malignancy|
2492605|NCT02951871||OC: Other Cause|
3194737|NCT00831337|Experimental|Liver cirrhosis compensated|VSL3 supplemented twice daily for 28 days
3161623|NCT00445718||Observational|Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.
3161624|NCT00445809||1|High Risk population for developing AKI during/after CABG surgery.
2493129|NCT02948322|Experimental|OGTT, CMRI with gadolinium in patients|Patients with acromegaly will be investigated
2493130|NCT02948322|Active Comparator|OGTT, CMRI with gadolinium in volunteers|Age-, sex- and BMI-matched healthy volunteers will be investigated
2493163|NCT02948010|Active Comparator|Auto CPAP + comfort feature A|Auto CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
2493175|NCT02948010|Active Comparator|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
2493177|NCT02948010|Active Comparator|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
2493182|NCT02948010|Active Comparator|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
2493184|NCT02948010|Active Comparator|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
2493187|NCT02948010|Active Comparator|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
2493188|NCT02948010|Active Comparator|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
2493189|NCT02948010|Active Comparator|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
2493190|NCT02948010|Active Comparator|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
3161625|NCT00445809||2|Medium Risk population for developing AKI during/after CABG surgery.
3161626|NCT00445835|Other|BA :Active arm|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
2493274|NCT02947178|Active Comparator|Bupivicaine|Bupivicaine fascial iliaca regional soft tissue infiltration blockade
2493275|NCT02947178|Active Comparator|Bupivacaine plus liposomal bupivacaine|Bupivacaine plus liposomal bupivacaine fascial iliaca regional soft tissue infiltration blockade
2493361|NCT02947061|Experimental|test group|S1 plus Docetaxel ：S-1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
2493365|NCT02947061|Active Comparator|control group|Capecitabine plus Docetaxel ：Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
2493415|NCT02946476||HFrEF|patients with heart failure and reduced ejection fraction
2493429|NCT02946476||HFpEF|patients with heart failure and preserved ejection fraction
3161627|NCT00445835|Other|BC: Conservative arm|Conservative medical approach
3161628|NCT00445913|Experimental|control dendritic cells|autologous dendritic cells that are not treated
3161629|NCT00445913|Experimental|AS ODN dendrtitic cells|autologous dendritic cells treated ex vivo with the mixture of the antisense oligonucleotides
3161630|NCT00445965|Experimental|131I-3F8|This is a phase II single-arm open-label study that will define responses to therapy with weekly intrathecal 131I-3F8 in patients with central nervous system/leptomeningeal GD2-expressing disease.
3161631|NCT00446004|Other|A|On an 18-day schedule, Omeprazole (PPI) once daily on days 10 through 16; and Gleevec® once daily on days 1 and 15 (i.e., Gleevec® alone on day 1, and combination of Gleevec® and PPI on day 15).
3194738|NCT00831337|Experimental|Liver cirrhosis decompensated|VSL3 supplemented twice daily for 28 days
3194739|NCT00831337|Experimental|Control group|VSL3 supplemented twice daily for 28 days
3194740|NCT00831350|Experimental|ranibizumab|
3194741|NCT00831363||1|minimal invasive approach
2492411|NCT02952963|Experimental|Chenodeoxycholic Acid|Chenodeoxycholic Acid (1250 mg) dissolved in 200 ml water. Here after 50 ml clean water.
2492412|NCT02952963|Experimental|Chenodeoxycholic Acid and Colesevelam|Chenodeoxycholic Acid (1250 mg) and Colesevelam (3,75 g) dissolved in 200 ml water. Here after 50 ml clean water.
2492443|NCT02952664|Experimental|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
2492529|NCT02952469|Experimental|(68Ga)PSMA-HBED-CC|Intervention: positron emission tomography / computed tomography (PET/CT) scan using a experimental radiotracer for imaging prostate-specific membrane antigen
2492613|NCT02951897|Active Comparator|IA-CTC-High-enhance|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
2492615|NCT02951897|Placebo Comparator|IA-CTC-High-controls|IA lung adenocarcinoma cases with high abundant CTCs prior to operation will only undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
2492618|NCT02951897|Placebo Comparator|IA-CTC-low-controls|IA lung adenocarcinoma cases with low abundant CTCs prior to operation will only undergo segmentectomy. Postoperative CTC monitoring will be conducted.
2492621|NCT02951897|Active Comparator|IB-CTC-High-enhance|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy plus adjuvant chemotherapy. Postoperative CTC monitoring will be conducted.
2492623|NCT02951897|Placebo Comparator|IB-CTC-High-controls|IB lung adenocarcinoma cases with high abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
2492624|NCT02951897|Placebo Comparator|IB-CTC-low-controls|IB lung adenocarcinoma cases with low abundant CTCs prior to operation will undergo lobectomy&lymphadenectomy. Postoperative CTC monitoring will be conducted.
3194742|NCT00831363||2|traditional transgluteal approach
3194743|NCT00831376|Experimental|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
3194744|NCT00831376|Active Comparator|2: racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
3194745|NCT00831376|Placebo Comparator|3: Placebo|Patients will be asked to take two puffs four times a day for 2 weeks
3194746|NCT00831402|No Intervention|Arm without iodized vitamin (VITAMIN OLIGOBS PREGNANCY)|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
3194747|NCT00831402|Active Comparator|Arm with iodized vitamin|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
3194748|NCT00831467|Experimental|CV9103|CV9103 is applied intradermally into the thigh and upper arm of either side of the body at week 1, week 3, week 7, week 15, week 23
3194749|NCT00831506|Experimental|A|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
2492928|NCT02949986|Experimental|Tablet-based Fall Prevention|The exercise program will be self-administered via a tablet-based version of the fall prevention program and the exercises performed in the home.
2492950|NCT02949583|Experimental|Punica granatum Linn.|The childrens used the mouthwash contain pomegranate 6,25% twice daily for 14 days.
2492957|NCT02949583|Active Comparator|chlorhexidine|The childrens used the mouthwash contain chlorhexidine 0.12% twice daily for 14 days.
3194750|NCT00831506|Experimental|B|digoxin once daily (0.125 mg QD) plus Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
3194751|NCT00831519||Macrosomial, GD|
3194752|NCT00831519||Macrosomial, control|
3194753|NCT00831532|Experimental|Normal|Healthy Volunteers
3194754|NCT00831532|Experimental|Mild Hepatic Impairment|Mild hepatic impairment patients
3194755|NCT00831532|Experimental|Moderate hepatic Impairment|Moderate Hepatic Impairment Patients
3194756|NCT00831532|Experimental|Severe Hepatic Impairment|Severe Hepatic Impairment Patients
3194757|NCT00831545|Experimental|Subjects with melanoma|
3194758|NCT00831545|Experimental|Subjects with breast cancer|
3194759|NCT00831545|Experimental|Subjects with non-small cell lung cancer|
3194760|NCT00831571||All Participants|Patients receiving Oxaliplatin
3194761|NCT00831571||Desensitization|Patients that have experienced a moderate to severe hypersensitivity reaction to oxaliplatin
3194762|NCT00831597|Experimental|Bendamustine with rituximab|All patients received combination bendamustine with rituximab
3194763|NCT00831610|Other|STUDY|"Female healthy volunteers (25 to 55 years old) with normal weight.~Morbid Obese women waiting for bariatric surgery.~Post-bariatric female patients, 25 to 55 years old, MORE than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Skin Evaluation before the abdominoplasty.~Group 3, submitted to anchor-line abdominoplasty without flap undermining."
3194764|NCT00831610|Other|CONTROL|Group 3: Post-bariatric female patients, 25 to 55 years old, LESS than 12 months of weight stability, pendular abdominal wall, clinical conditions to anchor-line abdominoplasty without flap undermining. Who will be submitted to abdominoplasty after the study period.
3194765|NCT00831623|Experimental|Proton radiation therapy|Single arm
3194766|NCT00831636|Experimental|Open label CP-4055|Phase I: Dose escalation Phase II: Fixed dose
3194767|NCT00831649|Experimental|natalizumab|
3194768|NCT00831662|Placebo Comparator|Arm 2|
3194769|NCT00831662|Experimental|Arm 1|
3194770|NCT00831688|Active Comparator|1|Local overpressure treatment
3194771|NCT00831688|Placebo Comparator|2|Placebo treatment
3194772|NCT00831714||Group 1|
3194773|NCT00831714||Group 2|
3194774|NCT00831727|Experimental|Expressive Writing|
3194775|NCT00831727|Placebo Comparator|Control|
3161632|NCT00446004|Other|B|On an 18-day schedule, Omeprazole (PPI) once daily on days -4 through 1; and Gleevec® once daily on days 1 and 15 (i.e., combination of Gleevec® and PPI on day 1, Gleevec® alone on day 15).
3161633|NCT00446069|Experimental|Egalet® morphine|
3161634|NCT00446069|Active Comparator|MST Continus®|
3161635|NCT00446082|Experimental|SOM230 LAR|
3161636|NCT00446173|Experimental|Busulfan + Cyclophosphamide + G-CSF + GM-CSF|
2492468|NCT02952521||Epithelial ovarian cancer|"Whole blood sample collection~Up to 3 fresh tumor tissue core biopsies~Tumor tissue sample taken from tumor tissue already removed from surgery (if surgery is planned)"
2492493|NCT02952209|No Intervention|No Treatment|Tooth extraction with no bone graft.
2492494|NCT02952209|Active Comparator|Alveolar Ridge Preservation Treatment|Tooth extraction followed by alveolar ridge preservation using xenograft bone graft and covered by a resorbable collagen membrane.
2492552|NCT02952144|Experimental|Lixelle® treatment|2 years of Lixelle® treatment in the patients with dialysis related amyloidosis (DRA)
2492555|NCT02952144|No Intervention|natural history|2 years of natural history in the patients with dialysis related amyloidosis (DRA)
3161637|NCT00446212|Active Comparator|1|Propofol based anaesthetic maintenance with propofol effect-site steered target-controlled infusion, in addition to fentanyl and non-opioid analgesics
2492783|NCT02950922|Experimental|RVT-501 0.2% ointment|RVT-501 0.2% ointment BID x 28 days (30 adults, 20 adolescents)
2492784|NCT02950922|Experimental|RVT-501 0.5% ointment|RVT-501 0.5% ointment BID x 28 days (30 adults, 20 adolescents)
2492786|NCT02950922|Placebo Comparator|Vehicle ointment|Vehicle ointment BID x 28 days (30 adults, 20 adolescents)
2492832|NCT02950532||Cases|Retrospective radiological evaluation in cases presenting A3 or A4 TL burst fractures (AOSpine classification) between T11 to L2 with or without suspected PLC injury
2492867|NCT02950246|Experimental|2% alcoholic chlorhexidine group|"Skin preparation Use of 10 ml of 2% alcoholic Chlorhexidine drug for disinfection in place of povidone iodine without scrubing device Wait at least 30 secondes for drying Perineural catheterization implementation Ultrasonography use"
3161638|NCT00446212|Active Comparator|2|Desflurane based anaesthetic maintenance with manually controlled administration in 100% oxygen in addition to fentanyl and non-opioid analgesics
3161639|NCT00446225|Experimental|A|Erlotinib (Tarceva)150 mg /day
3161640|NCT00446225|Active Comparator|B|"4 cycles of Chemotherapy:~Cisplatin / Gemcitabine; Cisplatin /Docetaxel; Carboplatin / Gemcitabine; Carboplatin / Docetaxel."
3161641|NCT00446238|Experimental|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
3161642|NCT00446238|Active Comparator|Standard of Community Care Treatment|Standard of Community Care Treatment
3161643|NCT00446316|Experimental|Gleevec plus antacids|Gleevec® will be administered at a dose of 400 mg, and the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide). Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1.
3194776|NCT00831740|Experimental|Speech Therapy|
3194777|NCT00831740|Active Comparator|ACT NoW Visitor|
3194778|NCT00831818||1|Mothers of healthy infants who breastfeed on demand
3194779|NCT00831818||2|Mothers of healthy infants who do not breastfeed
2492410|NCT02952976|Active Comparator|Barker|Patients with open abdomen submitted to treatment with the Baker dressing
2492429|NCT02952677|Experimental|Experimental|"Participants receive Remind-to-move by means of vibration emitted through sensory cueing wristwatch devices, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period.They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities."
2492430|NCT02952677|Sham Comparator|Sham treatment|Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
2492431|NCT02952677|Other|Control|Participants receive usual care only during the intervention period.
2492533|NCT02952300|Experimental|neolix|single full rotation file (Neolix ® Neolix ,France) the first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan). is passively fit in the canal (most of the canals) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length of the canal
2492536|NCT02952300|Active Comparator|wave one|single reciprocating file (Wave One ® Dentsply , Switzerland) the canal preparation is done by primary file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani Inc., Japan) is passively fit in the canal ( most of canals ) , but in case of K-file (Mani Inc., Japan) size 20 loose in the canal so we choose large large file size 40 taper 8% either of them to the full working length of the canal
2492708|NCT02951299|Experimental|pentoxifylline group|Received oral pentoxifylline (400 mg) three times a day for 14 days.
2492711|NCT02951299|No Intervention|no treatment group|No intervention.
3161644|NCT00446316|Experimental|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
3161645|NCT00446342|Experimental|Dose-escalation of SNS-032 injection|Patients escalated to MTD starting in Cohort 1 of 15 mg/m2 of SNS-032 injection, with 1.5-fold increase each cohort and a maximum loading dose increase of 10 mg/m2. Each dose cohort will have a minimum of 3 patients each with advanced CLL or MM. Dose escalation continues in the absence of Cycle 1 DLT criteria until an MTD is achieved for each disease type to a maximum of 7 cohorts at a high dose of 70 mg/m2. Stage 2 tests at MTD in larger group.
2492860|NCT02950441|Experimental|Nicotinamide Riboside|1000mg (2x250mg tablets twice daily)
2492862|NCT02950441|Placebo Comparator|Placebo|Two tablets twice daily
2492900|NCT02950103|Experimental|Synthetic phosphoethalonamine|Phosphoethanolamine PO daily
2492923|NCT02949752|Experimental|Aripiprazole Adjunct|Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics
2492974|NCT02949492|Experimental|IL-2 arm|Liver recipients <50 years old and 2-6 years after transplantation will receive IL-2 and gradually discontinue their immunosuppressive medication
3161646|NCT00446368|Experimental|RAD001|Subjects will take RAD001 (Everolimus) 10mg by mouth daily.
2493161|NCT02947945|Other|Open-Label|all subjects will receive the study medication- reslizumab.
2493229|NCT02947737|Experimental|Amniotic membrane dressing|One donor site per study participant will be covered with an amniotic membrane dressing.
2493241|NCT02947737|Active Comparator|Gentamicin and xeroform dressing|One donor site per study participant will be covered with a gentamicin and xeroform dressing.
2493340|NCT02946944|Experimental|double drug therapy|
2493348|NCT02946944|Active Comparator|mono drug therapy|
2493552|NCT02945475||obese|Individuals ages 18 to 35 years of age with body mass index (BMI) 30-40 kg/m2
2493558|NCT02945475||lean|Individuals ages 18 to 35 years of age with BMI of 19-24.9 kg/m2
2493562|NCT02945475||overweight|Individuals ages 18 to 35 years of age with BMI of 25-29.9 kg/m2
2493640|NCT02945111|Experimental|Real-time view|Women undergoing Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) will watch the cervical images taken throughout the examination in real-time on a digital screen. The patients' anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
2493647|NCT02945111|Active Comparator|No visual support|Women in this arm will undergo Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) without any visual support. Their anxiety level both before and after the examination will be measured using the Spielberg's State Anxiety Inventory.
2494358|NCT02940015||Anonymous Sample Collection - Adults (ASCA)|Healthy Volunteers ages 18 and older
3161647|NCT00446381|Experimental|1|Patients with Proliferative Diabetic Retinopathy
3161648|NCT00446381|Experimental|2|Patients with Clinically Significant Macular Edema
3161649|NCT00446394|Experimental|1|
3161650|NCT00446394|Active Comparator|2|
3161651|NCT00446407|Experimental|Collaborative Stepped Care|Screening, Antidepressants, Psychosocial interventions (psychoeducation, IPT, adherence management) by Health Counselor, support and supervision by Psychiatrist.
3161652|NCT00446407|Active Comparator|Enhanced Usual Care|
3161653|NCT00446420|Active Comparator|1|These patients will only receive intravenous propofol which will be titrated to an OAA/S score of 3. They will not receive fentanyl, midazolam or any other drugs
3161654|NCT00446420|Active Comparator|2|These patients will receive propofol plus midazolam and/or fentanyl. Midazolam and fentanyl will be given in fixed doses first and propofol will be titrated to effect. All drugs will be given intravenously.
3161655|NCT00446472|Experimental|1|Randomized to Regranex gel
3161656|NCT00446472|Active Comparator|2|Placebo hydrogel will be used for a total of 16 weeks
3161657|NCT00446485|Active Comparator|1|Ginkgo Biloba standardized extract 24/6
3161658|NCT00446485|Placebo Comparator|3|placebo
3161659|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg|Valsartan 80 mg or Amlodipine 5 mg ---> Valsartan + Amlodipine 80 / 5 mg
3161660|NCT00446524|Experimental|Valsartan + Amlodipine 80/5 mg + Diuretic|Valsartan + Amlodipine 80 / 5 mg + Diuretic
2492441|NCT02952625|Other|Single arm imaging study|Single arm study: all patients have 2 PET/MR scans in the radiotherapy treatment position
2492518|NCT02952495|Experimental|Online alcohol educational class|Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults.
2492525|NCT02952495|No Intervention|No intervention|Participants will NOT Participate in the online alcohol education class.
2492584|NCT02951962|Experimental|Twynsta 80/5mg|Day 1 ~ Day 9 : Twynsta 80/5mg / Day 10 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
2492589|NCT02951962|Experimental|Crestor 20mg|Day 1 ~ Day 5 : Crestor 20mg / Day 6 ~ Day 14 : Twynsta 80/5mg + Crestor 20mg
2492648|NCT02951468||Nonunion group|All patients who were treated for clavicular non- or malunion with a locking compression plate and an iliac crest bone graft between January 2010 and December 2014 were included in this retrospective study.
3194780|NCT00831857||Group A|Treatment with sunitinib.
3194781|NCT00831857||Group B|Treatment with bevacizumab and interferon
3194782|NCT00831883|Experimental|Partner Specific IMB|partner-specific HIV risk reduction intervention
3194783|NCT00831883|Placebo Comparator|HLS|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
3194784|NCT00831896|Experimental|1|TAK-701
3194785|NCT00831909||1|All NSCLC patients attending the responsible department of treating this type of patients (e.g. Oncology Department, Pneumology Department) for the first time (regardless of whether the patient is diagnosed with locally, advanced or metastatic disease) at the participating sites from the first of January 2009 to the end of March 2009. Patients diagnosed, or even treated, in other departments within the same hospital or in another hospital are susceptible to be included in the study if full access to the patient's medical record is made available.
3194786|NCT00831922|Experimental|1|masitinib (AB1010) 3 mg/kg/day
2492889|NCT02950428|Experimental|ACURATE neo™TA Delivery System|Patients implanted with ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™ TA Transapical Delivery System
2492964|NCT02949791|Active Comparator|Low Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with low intra-abdominal pressure
2492965|NCT02949791|Experimental|High Intra abdominal pressure HIPEC|Cytoreductive surgery and HIPEC with high intra-abdominal pressure
2492987|NCT02949154||Metastatic melanoma patients|All patients >18 years with histologically proven metastatic melanoma (American Joint Committee on Cancer [AJCC] stage IV melanoma) treated in the UMCG between May 2014 and December 2015.
2493062|NCT02949115|Experimental|70 mL red beetroot juice|70 mL red beetroot juice naturally containing 300 mg nitrate.
2493071|NCT02949115|Active Comparator|70 mL placebo drink plus potassium nitrate|70 mL calorie-matched placebo control drink containing 489 mg potassium nitrate to deliver 300 mg nitrate.
2493074|NCT02949115|Active Comparator|70 mL red beetroot juice without nitrate|70 mL red beetroot juice per day without nitrate.
2493079|NCT02949115|Placebo Comparator|70 mL placebo drink|70 mL calorie-matched placebo control drink devoid of nitrate, vitamins, minerals, and polyphenols.
2493099|NCT02948439|Experimental|Exercise Intervention|The aerobic exercise intervention will consist of a walking program at 50-70% of individual heart rate reserve. This will begin at 16-20 weeks gestation and continue 3-4 times per week until the end of the study (34-36 weeks). The duration of exercise will increase each week up to a maximum of 40 minutes (5 min warm up, 25 minutes exercise, 5 min cool down). Women will have at least one supervised exercise session per week. The investigators will also monitor other activity using questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
2493100|NCT02948439|No Intervention|Control Group|These women will continue regular daily activities. Activity will be monitored periodically with questionnaires and accelerometry. This will occur at baseline (16-20 weeks), mid-intervention (24-26 weeks) and at the end (34-36 weeks).
2493159|NCT02948283|Experimental|Treatment (metformin hydrochloride, ritonavir)|"SINGLE AGENT STAGE : Patients receive metformin hydrochloride PO BID on days 1-7 in the absence of disease progression or unacceptable toxicity.~COMBINATION REGIMEN STAGE: Patients receive metformin hydrochloride PO BID and ritonavir orally PO BID on days 1-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2493244|NCT02947568||CKD|chronic kidney disease
2493249|NCT02947568||DM|diabetes mellitus
2493256|NCT02947568||CKD+DM|chronic kidney disease + diabetes mellitus
2493331|NCT02947230|Experimental|Tailored Knowledge Translation|During the 12-week KT intervention, intervention group participants will have access to the Portal and will receive mobility-focused weekly email alerts including blog posts and evidence summaries relevant to mobility and be invited to follow a Twitter and Facebook feed; a unique hashtag will be created to identify and collate relevant mobility information.
2493333|NCT02947230|No Intervention|Control group|Participants in the control group will have access to the Portal in a 'self-serve' fashion. These participants will be able to browse the Portal, subscribe to email alerts, follow social media, etc. but will not receive the tailored mobility intervention.
2493368|NCT02946671|Experimental|Cohort 1|KW-0761 (Mogamulizumab): 0.1 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2493369|NCT02946671|Experimental|Cohort 2|KW-0761 (Mogamulizumab): 0.3 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2493372|NCT02946671|Experimental|Cohort 3|KW-0761 (Mogamulizumab): 1.0 mg/kg, every week, 4 times ONO-4538 (Nivolumab): 3.0 mg/kg, every two weeks, 3 times
2493443|NCT02946398||elderly patients who visit the ED|elderly patients (65 years and older) who present to the emergency department for internal medicine or gastroenterology
3194787|NCT00831922|Experimental|2|masitinib (AB1010) 6 mg/kg/day
3194788|NCT00831935||Depressed|Depressed individuals, as identified by their referring physician.
3194789|NCT00831935||Non-depressed|Non-depressed individuals, confirmed to be non-depressed by the Centers for Epidemiological Studies Depression Scale (CES-D).
3194790|NCT00831948||Mitochondrial disease|Patients already diagnosed for mitochondrial pathology without mtDNA mutations yet detected by current diagnostic techniques
2493600|NCT02944812|Experimental|Chidamide|Chidamide is given to the patients, the dosage is 30mg,biw,po.
3194791|NCT00831961||1|Patients randomized to gatifloxacin (Zymar)
2492444|NCT02952573|Experimental|FGFR3 wild-type|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
2492451|NCT02952573|Experimental|FGFR3 mutated|"JNJ-42756493: For the first cycle, 8 mg orally (by mouth), once each day for 14 days of each 28-day periods called cycles. Then dose of JNJ-42756493 may then be increased to 9 mg taken orally if no significant side effects related to JNJ-42756493 are seen during the first 14 days.~Dexamethasone: 40 mg, orally, on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly).~Patients over the age of 75 will take a reduced dose of dexamethasone of 20 mg on starting cycle 1 on days 1-4, 9-12, 17-20 for the first two cycles. Starting cycle 3, dexamethasone will be taken on days 1, 8, 15 and 22 (once weekly)."
3194792|NCT00831961||2|Patients randomized to moxifloxacin (Vigamox)
3194793|NCT00831961||3|Patients randomized to ofloxacin (Ocuflox)
2492591|NCT02951832||observational group|Observational Study about Lymphocytes Change during Menstrual Cycle in Women of Child-bearing Age
2492649|NCT02951559|Experimental|Brushing|Patients will undergo nasal brushing as further described additionally to other gold standard practices according to the suspected aetiology (brain MRI, lumbar puncture, plasma tests, etc.)
2492699|NCT02951234|Experimental|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
2492702|NCT02951234|Active Comparator|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside. After fever subsides, low-dose aspirin (3-5mg/kg/day) will be prescribed until 6-8 weeks.
2492754|NCT02950987|Experimental|Whole Body MRI|"Magnetic resonance imaging will be performed on participants~Participants who are two young to tolerate the scans awake, can receive sedation/anesthesia"
2492794|NCT02950805|Experimental|Placebo + AZD5634|Subjects were administered single dose of placebo in period 1 and AZD5634 in period 2.
2492797|NCT02950805|Experimental|AZD5634 + Placebo|Subjects were administered single dose of AZD5634 in period 1 and placebo in period 2.
3194794|NCT00831961||4|Patients randomized to azithromycin (AzaSite)
3194795|NCT00831974|Experimental|2|masitinib (AB1010) 6 mg/kg/day
2493057|NCT02949102|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
2493068|NCT02949102|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
2493167|NCT02948192||Preterm Delivery|African american women who present for prenatal care who experience spontaneous preterm birth
2493178|NCT02948192||Term delivery|African american women who present for prenatal care who experience term birth
2493224|NCT02947815|Experimental|NABOTA|Single-dose
2493236|NCT02947815|Active Comparator|BOTOX|Single-dose
2493309|NCT02947217|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
2493314|NCT02947217|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
2493406|NCT02946814|Active Comparator|essential oils|a single mouthwash with 20 ml of essential oils for 30 seconds.
2493417|NCT02946814|Experimental|essential oils without mouthwash|a single mouthwash with 20 ml of essential oils without alcohol for 30 seconds.
2493432|NCT02946814|Sham Comparator|sterile water|a single mouthwash with 20 ml of sterile water for 30 seconds.
2493495|NCT02946086|Experimental|prismatic adaptation|Including 8 hours of therapy with prismatic adaptation wearing prismatic goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE).
2493498|NCT02946086|Active Comparator|sham goggles|"Including 8 hours of therapy wearing sham goggles during bimanual intensive and locomotor intensive intervention (HABIT-ILE)."
2493548|NCT02945527|Active Comparator|Acetazolamide|750 mg acetazolamide p.o. divided in three dily doses, for 10 days
2493551|NCT02945527|Active Comparator|Dexamethasone|8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
2493557|NCT02945527|No Intervention|No additional anti-edema treatment|No additional treatment
2493606|NCT02945007|Experimental|JNJ-53718678: PART 1|Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and B (novel concept formulation 1), and under fed condition for treatment C (novel concept formulation 1).
2493608|NCT02945007|Experimental|JNJ-53718678: PART 2|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and D (novel concept formulation 2), and under fed condition for treatment E (novel concept formulation 2).~Part 2 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
3194796|NCT00831974|Experimental|1|masitinib (AB1010) 3 mg/kg/day
2494107|NCT02941575|Experimental|Intervention|Implant superstructure crown: Hybrid ceramic, crystal Ultra crown
3194797|NCT00832013|Active Comparator|1|"Propofol 1 % at a dose of 4mg/kg will be administered intravenously via a standard Medex Protégé® 3010 (Medex-A Furon. Healthcare Company, Duluth, GA, USA) infusion pump at a constant rate determined by the randomization schedule. Fresh gas flow will be maintained at 6 l/min throughout the induction procedure with the FiO2 increased to 0.5. Full cardiovascular, respiratory and EEG monitoring will continue during induction of anesthesia.~Once the loading dose of propofol has been delivered the propofol infusion will be maintained at a rate of 200mcg/kg/min or as determined by the attending anesthesiologist whilst the end-point respiratory responses are observed."
3194798|NCT00832013|Active Comparator|2|Same procedure as above. These subjects will be stratified by age and randomized, using the Biased Coin Design (BCD) principle to determine the infusion rate of propofol for delivery of the induction dose.
3194799|NCT00832026||Sleep apnea|Patients with diagnosed obstructive sleep apnea
2492447|NCT02952859||historic control group|Work-up and follow-up of the historic control will be performed through similar means by contacting primary care physicians and/or medical oncologists, if information cannot be received, the patient will be directly contacted. In case the patient cannot be reached and no other information can be received on patients outcome, the death registry will be contacted.
2492456|NCT02952859||comparator group|All patients with potentially and borderline resectable pancreatic cancer are potentially candidates for IRE and will be considered for this treatment. Patient will be recruited/referred through daily clinical practice from the Inselspital Bern. Final inclusion into the study will be performed by the responsible investigators at the Inselspital Bern. Patients will be included according to the inclusion/exclusion criteria mentioned.
2492516|NCT02952417||STEMI and NSTEMI Women|Women with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
2492517|NCT02952417||STEMI and NSTEMI Men|Men with ST-segment elevation myocardial infarction (STEMI) and women non-STEMI (NSTEMI) who survived following acute myocardial infarction and at risk of excess mortality.
2492554|NCT02952027|Experimental|Bell On|Subjects in the Bell On arm will receive a timer where the alarm will sound every hour.
2492557|NCT02952027|Placebo Comparator|Bell Off|Subjects in the Bell Off arm will receive a timer where the alarm will not sound, but still record incentive spirometer usage
2492566|NCT02951754|Experimental|IR-MPH|Immediate-release methylphenidate (IR-MPH) 10 mg two or three times daily with doses increasing weekly until symptom control
2492642|NCT02951598|Other|MCI (Amyloid Positive)|Participants with mild cognitive impairment (MCI) due to AD who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
2492644|NCT02951598|Other|Mild AD Dementia (Amyloid Positive)|Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
2492646|NCT02951598|Other|MCI (Amyloid Negative)|Participants with MCI who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
2492647|NCT02951598|Other|Mild Dementia (Amyloid Negative)|Participants with mild dementia who tested amyloid negative. These participants were not eligible to participate in the 36 month prospective portion of the study.
2492785|NCT02950909|Experimental|Emphasized exercise group|Patients in the emphasized exercise group performed exercises emphasizing the deep cervical extensor muscles applying a resistance at the level of the vertebral arch of C4 either therapeutically with the therapist's fingers or as a home exercise with the aid of a towel or belt. These exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, a dynamic exercise was added moving the head from maximal flexion to maximal extension keeping the gaze fixed at an object lying between both elbows hoping to activate more the extensors in the lower cervical spine.
2492787|NCT02950909|Experimental|General exercise group|Patients in the general exercise group performed exercises targeting all cervical extensor muscles including the superficial ones applying resistance at the head pushing against a wall or the therapist's hand or as a home exercise with the aid of a towel. As in the other group, these exercises were performed in sitting and standing in front of a table propped up on both forearms. In the latter position, the same dynamic exercise was added as in the other group with the only difference that the gaze was fixed at an object lying between both hands hoping to activate all cervical extensors
2492820|NCT02950675||Normal Adult|Control:Normal Adult
2492824|NCT02950675||Burn Patient|The burn patient will be identified according to the diagnoses (ICD-9-CM code: 940-949).
2492848|NCT02950402|Experimental|Two Dried Plums per day|Two Dried Plums per day is approximately 14 g.
2492849|NCT02950402|Experimental|Six Dried Plums per day|Six Dried Plums per day is approximately 42 g.
2492864|NCT02950194||PPAWI|patients with multidisciplinary PPAWI approach
2492898|NCT02950038|Experimental|Ibrutinib + Nivolumab|"Ibrutinib administered by mouth daily in 28 day cycles.~Nivolumab administered by vein beginning with cycle 2, and given on Days 1 and 15 of every 28 day cycle."
2492942|NCT02949687|Experimental|ileal interposition sleeve sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
2492991|NCT02949401|No Intervention|Standard of Care|"No research intervention to be administered.~Participants will have standard preparation for a procedure including discussion of the procedure with the provider the day before the procedure with all questions answered at that time."
2493004|NCT02949401|Experimental|Virtual Reality|The VR interactive module will consist of a 360° visit to the Hospital where patients encounter the various aspects of a procedure from the front door; through the pre-operative area where patients will receive an IV; to the catheterization lab and placement of the anesthesia mask; and back to the post anesthesia care unit. Patients will be accompanied by a child who acts as a guide to the experience. The guide will help explain what the patient is seeing and what to expect along the way. Health care professionals will be enmeshed within the scenarios and will also help with the explanations along the way. Patients will be prompted to enter the relaxation scenarios at different stressful times along the tour to practice relaxation and mindfulness techniques (i.e. before IV start, or upon entering catheterization laboratory). Relaxation scenarios will include a snow scene, tropical beach or other guided imagery scenes.
2493036|NCT02948985||RAS and B-raf wild type mCRC|patients with histologically confirmed RAS and B-raf wild type mCRC treated with FOLFIRI±cetuximab
2493043|NCT02948816|Experimental|Facebook|Participants will spend 30 minutes interacting with a Facebook page that is made up of 20% food-related posts, and 80% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
2493044|NCT02948816|Experimental|Facebook + Food|Participants will spend 30 minutes interacting with a Facebook page that is made up of 70% food-related posts, and 30% non food-related posts (news, sports, etc). They will be provided with bowls of snacks, which will be weighed before and after their session.
2493045|NCT02948816|Active Comparator|Colouring|Participants will spend 30 minutes colouring. They will be provided with bowls of snacks, which will be weighed before and after their session.
2493091|NCT02948699|Experimental|Nutrition support|Nutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
2492781|NCT02950935|Experimental|Progesterone|25 mg of subcutaneous progesterone will be administered twice à day until the 12th week of gestation.
2492782|NCT02950935|Placebo Comparator|Placebo|placebo will be administered twice à day until the 12th week of gestation.
2492811|NCT02950714|Experimental|LIN_NOW|Participants from CaNIOS centres randomized to the NOW group will be provided immediate access to the lupus interactive navigator (LIN), a web-based program developed to promote engagement and self-care in lupus.
2492813|NCT02950714|Active Comparator|LIN_WAIT|Participants from CaNIOS centres randomized to the WAIT group will have usual care for three months prior to crossing over to access to the LIN.
2492890|NCT02950350||radiation and chemotherapy|The patients will receive radiation and chemotherapy
2492892|NCT02950350||removal of pelvic lymph nodes and abdominal aorta lymph nodes|The patients will receive removal of pelvic lymph nodes and abdominal aorta lymph nodes ,and receive concurrent radiation and chemotherapy
2492943|NCT02949934|Active Comparator|Tolcapone|Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days
2492952|NCT02949934|Placebo Comparator|Placebo|Placebo three times per day for eight days
2493002|NCT02949323||children with urinary stones|children with urinary stones
2493009|NCT02949323||children without urinary stones|children without urinary stones
2493038|NCT02948998|No Intervention|control|The participants in control group do not take spironolactone.
2493039|NCT02948998|Experimental|spironolactone|The participants in spironolactone group take 10-20mg spironolactone orally and daily.
3161661|NCT00446589|Experimental|F|HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide
3161662|NCT00446589|Experimental|I|Hemodialysis pts suffering from osteoporosis who received iv ibandronate
2493101|NCT02948452||Anorexia|fMRI: reward task, anxiety provocation
2493103|NCT02948452||Mild anxiety comparison group|fMRI: reward task, anxiety provocation
2493174|NCT02948244|Active Comparator|Group A - Active/Placebo|Participants will receive 3 months of creatine monohydrate followed by a 6 week washout period followed by 3 months of placebo.
2493181|NCT02948244|Active Comparator|Group B - Placebo/Active|Participants will receive 3 months of placebo followed by a 6 week washout period followed by 3 months of creatine monohydrate.
2493263|NCT02947685|Experimental|Arm A|Palbociclib 125 mg daily + AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt) until confirmed disease progression
2493265|NCT02947685|Active Comparator|Arm B|AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant) until confirmed disease progression
2493439|NCT02946502|Experimental|Handheld dynamometry (handgrip strength)|All included patients will have a blinded evaluation of handgrip strength before weaning process.
3161663|NCT00446602|Experimental|001|Epoetin alfa Type=exact unit=units number=80 000 form=solution for injection route=subcutaneous use once every week or once every 2 weeks.
3161664|NCT00446628|Experimental|intervention|Five elementary school received intervention consistin of training in hand and respiratory hygiene, and access to hand sanitizer
2493576|NCT02945241|Experimental|Cystatin C-guided vancomycin dosing algorithm|Cystatin C is an endogenous cysteine proteinase inhibitor produced by all nucleated cells and a biomarker used routinely to estimate glomerular filtration rate either alone or in combination with creatinine. This new dosing algorithm includes patient weight, individualized goal trough concentration, and glomerular filtration rate (expressed with the CKD-EPI creatinine-cystatin C equation in mL/min) to determine dose and frequency.
2493578|NCT02945241|Other|Creatinine clearance guided vancomycin dosing|Historical controls for the quality improvement project had doses based on weight and interval established with the creatinine clearance using the Cockcroft-Gault equation.
2493607|NCT02944877|Experimental|intervention|experimental
2493611|NCT02944877|Other|control|Other
2493677|NCT02944617|Experimental|Arm I (probiotic yogurt supplement)|Patients receive probiotic supplement Activia yogurt QD during weeks 2-13 of VEGF-TKI treatment.
2493678|NCT02944617|Active Comparator|Arm II (no intervention)|Patients avoid any intake of yogurt or yogurt-containing foods and refrain from taking/consuming other probiotic supplements for 3 months.
2493688|NCT02944227|Experimental|Lucentis|Lucentis fixed treatment
2493742|NCT02944123|Other|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose and followed by 75 mg/day as maintenance dose.
2493743|NCT02944123|Experimental|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
2493744|NCT02944123|Experimental|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
2493802|NCT02943785|Experimental|Edoxaban-based Regimen|Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet for transitioning at end of treatment. Dosing must follow the locally approved label.
2493811|NCT02943785|Active Comparator|VKA-based Regimen|VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.
2494083|NCT02941900||Non-melanoma skin cancers (NMSCs)|
2494147|NCT02941601|Experimental|Cohort 1: Necitumumab + Gemcitabine and Carboplatin|Predominately European sites. Gemcitabine administered intravenously (IV) and carboplatin IV plus necitumumab IV.
3161665|NCT00446628|No Intervention|control|Five elementary school received no training or hand sanitizer.
2494303|NCT02940366|Experimental|Pitavastatin 4 mg orally daily|
3161666|NCT00446667|Experimental|1|
3161667|NCT00446680|Experimental|1|
3161668|NCT00446680|Placebo Comparator|2|
3161669|NCT00446693|Experimental|I|Use of EndoFast Reliant System
3161670|NCT00446732|Active Comparator|1|
3161671|NCT00446732|No Intervention|2|
3161672|NCT00446745||Abdominal obesity|60 males were recruited according to waist circumference, from lean to obese values
3161673|NCT00446758|Experimental|Zinc|zinc (as zinc sulphate) 12.5 mg orally per day (6.25 mg in children < 12 mo)
3161674|NCT00446758|Placebo Comparator|Placebo|
2492505|NCT02952443||Control|CON group will be asked to just maintain their normal daily living habits for the duration of the study. The same exercise program will be made available to the CON group upon completion of the study.
2492582|NCT02952014|Experimental|C4 Extreme|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 10 mg synephrine, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
2492586|NCT02952014|Active Comparator|C4 Extreme (without Advantra Z)|One dose of 12 grams (powder mixed with water): 1500 mg beta alanine, 1000 mg creatine nitrate, 1000 mg arginine AKG, 250 mg vitamin C, 150 mg n-acetyle tyrosine, 135 mg caffeine, 7.5 mg l-dopa, 30 mg vitamin B3, 0.5 mg vitamin B6, 0.25 mg vitamin B9, 0.035 mg vitamin B12.
2492590|NCT02952014|Placebo Comparator|Placebo|One dose of flavored placebo (powder mixed with water)
2492652|NCT02951494|Active Comparator|AlterG Anti-gravity treadmill|cont. aerobic exercise training with lower body weight support
2492655|NCT02951494|No Intervention|Exercise without body weight support|cont. aerobic exercise training without lower body weight support
2492703|NCT02951260|Experimental|Metformin|17 days metformin treatment
2492704|NCT02951260|Placebo Comparator|Placebo|17 days placebo treatment
2492744|NCT02951104|Experimental|USCOM|
2492793|NCT02950870|Experimental|group treated|this group will be treated with Ombitasvir-Paritaprevir-Ritonavir (12,5 mg/75 mg/50 mg) and Dasabuvir ( 250 mg) with or without Ribavirina every day , for 12 weeks.
2492798|NCT02950870|No Intervention|group untreated|Control group
3194800|NCT00832039|Active Comparator|SelPCT|Patient receives sodium-selenite; causal therapy is guided by a PCT based algorithm.
3194801|NCT00832039|Active Comparator|SelKon|Patient receives sodium-selenite; causal therapy is not guided by a PCT based algorithm.
2492885|NCT02950077|Experimental|All subjects|Individuals who are under the care of the Yale Liver Center with a diagnosis of autoimmune hepatitis
2492949|NCT02949869|Experimental|Infant Lumbar Punctures|Infants will all be assigned to received two sets of skin markings and sonography exam to assess lumbar puncture landmarks and anatomy.
2492998|NCT02949414|Experimental|Tracheal Replacement|Each patient will receive surgery to implant the cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells and all follow-up procedures.
2493081|NCT02949037|Experimental|Intervention|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, integrated with the mobile health care environment (MHCE) system. The MHCE system will provide tailored behavioral messages triggered by clinical values and survey responses.
2493082|NCT02949037|No Intervention|Control|Use of (4) bluetooth-enabled biomedical devices (i.e. scale, blood pressure cuff, activity monitor, glucose monitor), for use in self care activities, NOT integrated with the mobile health care environment (MHCE) system.
2493166|NCT02948075|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|One 3-weeks course includes 6 doses of Quisinostat 12 mg at Days 1, 3, 5, 7, 9 and 11 and Paclitaxel 175 mg/m2 and Carboplatin (mg/ml x min) x [GFR (ml/min) + 25] on Day 7 up to 6 cycles.
2493293|NCT02947269|Experimental|Intervention group|Patients will receive an oral capsule containing 2mg Prucalopride 2-3 hours preoperatively. Study medication (2mg oral Prucalopride daily) will continue for 6 days postoperatively or until the patient has achieved the study's primary outcome.
2493296|NCT02947269|Placebo Comparator|Placebo group|Patients will receive an oral capsule containing a placebo 2-3 hours preoperatively. Study medication (placebo) will continue for 6 days preoperatively or until the patient has achieved the study's primary outcome.
2493407|NCT02946632|Experimental|Triple combination therapy group|Xigduo (metformin 1000mg + dapagliflozin 10mg), saxagliptin 5mg once daily for 104 weeks
2493423|NCT02946632|Active Comparator|Stepwise add-on therapy group|"Participants were started on metformin 1000mg once daily after screening & assignment~At each visits, FPG and HbA1c are measured. Sequential add-on therapy regimen is described"
2493462|NCT02945982|Placebo Comparator|Entecavir/Carvedilol|Tablet with Entrcavir and Carvedilol
2493468|NCT02945982|Experimental|Entecavir/Carvedilol/ Fuzheng Huayu|Tablet with Entrcavir and Carvedilol+ Tablet with Fuzheng Huayu
2493523|NCT02945735|Experimental|gaze-contingent|Attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
2493525|NCT02945735|Placebo Comparator|non-gaze contingent|Participants will receive non-gaze-continent feedback unrelated to their viewing patterns
2493534|NCT02945358||Prolonged ICU stay|Group 1: adult cardiac surgery with cardiopulmonary pump with prolonged ICU stay Group 2: adult cardiac surgery with cardiopulmonary pump with non-prolonged ICU stay
2493601|NCT02945202|Other|All Eyes|All eyes undergo the same interventions. These are the following examinations: Biometry, Refraction and Corneal Topography. The examinations take place 6 months after surgery
2493691|NCT02944474|Experimental|Cohort 1 (200 mg)|Six subjects received 200 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
2493692|NCT02944474|Experimental|Cohort 2 (500 mg)|Six subjects received 500 mg of lucerastat as a single dose in the morning of Day 1 in fed conditions. After a 5-day washout, they received the same dose twice daily for 7 consecutive days in fasting conditions
2493697|NCT02944474|Experimental|Cohort 3 (500 mg)|Six subjects received 500 mg of lucerastat twice daily for 7 consecutive days in fasting conditions
2492558|NCT02952131|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
2492559|NCT02952131|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2492567|NCT02951728|Experimental|Decitabine plus R-CHOP|"Rituximab 375 mg/m2 IV d6; Cyclophosphamide 750mg/m2 IV d7; Doxorubicin 50mg/m2 IV d7; Vincristine 1.4 mg/m2 IV d7; Prednisone 60 mg/m2 PO d7-11;~Decitabine will be administered intravenously at dose levels as follow in Phase 1:~Dose level 1: Decitabine 10 mg/m2 days 1-5; Dose level 2: Decitabine 15 mg/m2 days 1-5; Dose level 3: Decitabine 20 mg/m2 days 1-5 and determine the maximum tolerated dose.~In phase 2, Decitabine will be administered intravenously at MTD."
2492650|NCT02951507|Active Comparator|Conventional partial denture|Intervention will be O T unilateral attachment
2492656|NCT02951507|Active Comparator|Conventional removal partial denture|Intervention will be new design of extra coronal attachment( O T unilateral attachment)
3194802|NCT00832039|Placebo Comparator|PlacPCT|Patient receives placebo; causal therapy is guided by a PCT based algorithm.
2492819|NCT02950662|Active Comparator|Metal housing|metal housing of ball and socket attachment the intervention will be overdenture
2492822|NCT02950662|Active Comparator|Peek housing|Peek housing of ball and socket attachment the intervention will be overdenture
2492861|NCT02950389|Experimental|Group A|Six bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, followed by 2 weeks of 6 on-line HFR session with HFR17 dialysis filter, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
2492863|NCT02950389|Experimental|Group B|Six on-line HFR session with HFR17 dialysis filter for 2 weeks, followed by 2 weeks of 6 o bicarbonate dialysis session with PMMA dialysis filter for 2 weeks, than 6 bicarbonate dialysis session for 2 weeks with F7 dialysis filter.
2492899|NCT02950090|Experimental|MobilWise|MobilWise will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) via Fitabase to: allow a remote coach to view and collect physical activity data generated by the personal monitor, and use that data to formulate and provide tailored behavioral support, using motivational interviewing. The coach has a phone conversation weekly x 12 using motivational interviewing with participants to set goals and encourage activity. Coaches mention patient use of treatment elements (accountability) and will be positively reinforcing for adherent participants, or will include positive statements for those who are not adherent (supportive).Participants are also encouraged to use all the features of Fitbit (social networking, challenges, email reminders).
2492901|NCT02950090|Active Comparator|Fitbit Only|will use data transmitted from an affordable accelerometer-based personal monitor (Fitbit Flex) to monitor their own progress and physical activity level without coaching support. Participants are again encouraged to use all the features of Fitbit (social networking, challenges, email reminders) to achieve activity levels.
2492902|NCT02950090|No Intervention|Waitlist Control|Participants in the waitlist arm have exposure to the usual wellness supports provided by the company: Motiva is the internal corporate wellness program that is under the direction of the Chief Medical Officer. Initiated in 2000, Motiva is staffed by two full- time health professionals and two full-time healthy lifestyle professionals. Motiva provides wellness programming year round on a BCBSIL intranet web page plus an individual page called myMotiva, where self- assessment of health risks, including weight and physical activity behavior, is encouraged. Participating in myMotiva allows individuals to earn up to $200 per year in an incentive program called Wellness Rewards
2492968|NCT02949713|Experimental|Text messaging-motivational interviewing|Participants will register their phone numbers into an automated SMS software (provided by WelTel.org). Every Monday morning, a text message (SMS) will be sent to participants in the intervention group encouraging participants to continue breastfeeding, and inquire if participants have any problems breastfeeding their infants. Participants will be asked to respond within 48 hours, indicating that they either do not have a problem or they have a problem and require help. In addition to text messaging, participants will have motivational interviews post-delivery at weeks 2, 6, 10, 14, and 24. Motivational interviews will explore and support the participant's commitment to continue breastfeeding.
2492970|NCT02949713|No Intervention|Usual standard of care|Usual standard of care
2493024|NCT02949193|Experimental|evogliptin|evogliptin 5mg qd add-on to metformin
2493028|NCT02949193|Active Comparator|sitagliptin|sitagliptin 100mg qd add-on to metformin
2493059|NCT02948855||Tm group|Simple thymoma group：The patients have suffered thymoma only and have no other complications.
2493067|NCT02948855||Tm+MG group|Thymoma complicated with myasthenia gravis (MG) group: The patients have suffered thymoma and myasthenia gravis in the mean time.
2493073|NCT02948855||Tm+MG+AD group|"Thymoma complicated with myasthenia gravis and other autoimmune diseases (AD) group:~The patients have suffered thymoma, myasthenia gravis and other autoimmune diseases in the mean time."
2493111|NCT02948569|Experimental|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days.
2493164|NCT02948140|Experimental|Stroke|
2493231|NCT02947776|Active Comparator|USUAL|Usual care
2493246|NCT02947776|Experimental|PEER|Usual care + peer-befriending
2493332|NCT02947152|Experimental|Dose escalation part|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma
2493335|NCT02947152|Experimental|Dose expansion part (RCC arm)|Includes patients with clear cell or papillary renal cell carcinoma
2493339|NCT02947152|Experimental|Dose expansion part (ovarian cancer arm)|Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)
2493404|NCT02946567|Experimental|Noisy City|Participant will play the Noisy City game developed by this project.
2493408|NCT02946567|Placebo Comparator|Control|Participant will play a generic game.
2493484|NCT02946190|Experimental|Arm 1: Pertagen® aP + Td-pur®|BioNet-Asia recombinant acellular Pertussis vaccine (Pertagen®) given simultaneously with Td-pur® vaccine (Novartis/GSK) intramuscularly as a single dose on Day 0
2493486|NCT02946190|Active Comparator|Arm 2: Boostrix® dTpa|Licensed Tetanus-diphtheria (reduced dose)-acellular Pertussis vaccine (Boostrix® dTpa; GSK) given intramuscularly as a single dose on Day 0
2493518|NCT02945709|Experimental|Personalized ACT|The personalized attention control training (ACT), comprised of six computerized sessions, in purpose of modulate biases in attention for personalized threat stimuli.
2492568|NCT02951936|Experimental|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
2492570|NCT02951936|Sham Comparator|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment
2492635|NCT02951624|Experimental|Control|Participants will spend 8 hours sedentary. Sedentary time will be spent sitting in a chair, restricted to sedentary behaviors (working on a computer, reading, watching TV, etc.) Participants will only be allowed to stand or walk to go to the toilet.
2492641|NCT02951624|Experimental|Breaker|Participants will spend a total of 7 hours and 12 min sedentary and a total of 48 min breaking sitting time with LPA. Sedentary time will be done in bouts of 18 min with 2 min of light walking.
2492643|NCT02951624|Experimental|Intermediate|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 54 min with 6 min of LPA between each bout.
2492645|NCT02951624|Experimental|Prolonger|Total duration of sedentary time and LPA time will be the same as in Breaker. Sedentary time will be done in bouts of 108 min with 12 min of LPA between each bout.
2492707|NCT02951208|Experimental|Active tDCS + Active VR|Active tDCS over the left DLPFC (30 minutes) combined with active VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
2492716|NCT02951208|Sham Comparator|Sham tDCS + Sham VR|Sham tDCS over the left DLPFC (30 minutes) combined with sham VR motivation training (60 minutes), administered 3 times per week for 4 weeks.
2492802|NCT02950766|Experimental|Neovax in Combination with Ipilimumab|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20~Ipilimumab will be injected within 1 cm of each NeoVax administration"
2492804|NCT02950766|Experimental|NeoVax alone|"Patients will undergo surgery with the intent to resect the primary kidney tumor~Neovax is a combination of Poly-ICLC and Neoantigen Peptides~Priming doses of NeoVax will be administered on days 1, 4, 8, 15, and 22~In the boost phase, vaccine will be administered on days 78 (week 12) and 134 (week 20)"
2492835|NCT02950519|Active Comparator|As needed Cuff Pressure Checks|Cuff pressure checks upon intubation and after any manipulation of ET tube
2492838|NCT02950519|Experimental|Cuff Pressure checks every 8 hrs|Cuff pressure checks upon intubation, after manipulation of ET tube, and minimum of 8 hr interval
2492887|NCT02950233|Experimental|NMDA active + Steroid placebo|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2492891|NCT02950233|Experimental|Steroid active + NMDA placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2492893|NCT02950233|Experimental|NMDA active + Steroid active|"NMDA active: ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).~Steroid active: two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
2492894|NCT02950233|Placebo Comparator|NMDA placebo + Steroid placebo|"NMDA placebo: normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (one capsule BID [first week]; one capsule BID [following three weeks]).~Steroid placebo: two doses of normal saline; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day."
3194803|NCT00832039|Placebo Comparator|PlacKon|Patient receives placebo; causal therapy is not guided by a PCT based algorithm.
3194804|NCT00832052|Experimental|Cohort 1|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
3194805|NCT00832052|Experimental|Cohort 2|Subjects will be randomized to receive either experimental drug (n=6) or placebo (n=2).
3194806|NCT00832052|Experimental|Cohort 3a|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
2493060|NCT02948842|Experimental|Treatment Group|Patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture.
3194807|NCT00832052|Experimental|Cohort 3b|Subjects will be randomized to receive either experimental drug (n=3) or placebo (n=1).
2494108|NCT02941796|Experimental|Sequence 1|"T → R~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
3194808|NCT00832052|Experimental|Cohort 4|
3194809|NCT00832065||Patients With Sleep Apnea and Low Testosterone|Adult male patients between 18-70 years of age with nely diagnosed OSAS documented by all night polysomnography(PSG)
2492574|NCT02951845|Experimental|Part 1: Treatment Sequence B1C1A1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment C1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492575|NCT02951845|Experimental|Part 1: Treatment Sequence C1A1B1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment A1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492577|NCT02951845|Experimental|Part 1: Treatment Sequence A1C1B1|Participants in Part 1 will only receive single dose of Treatment A1 then Treatment C1 followed by Treatment B1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492579|NCT02951845|Experimental|Part 1: Treatment Sequence B1A1C1|Participants in Part 1 will only receive single dose of Treatment B1 then Treatment A1 followed by Treatment C1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492580|NCT02951845|Experimental|Part 1: Treatment Sequence C1B1A1|Participants in Part 1 will only receive single dose of Treatment C1 then Treatment B1 followed by Treatment A1 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492583|NCT02951845|Experimental|Part 2: Treatment Sequence A2B2C2|Participants in Part 2 will only receive single dose of Treatment A2 oral Suspension (25 mg, Fasted) then Treatment B2 (Fluid Bed Granulation Tablets (5*5 mg Tablets, Fasted) followed by Treatment C2 (Fluid Bed Granulation Tablets, 5*5 mg Tablets, Fed) on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492588|NCT02951845|Experimental|Part 2: Treatment Sequence B2C2A2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492593|NCT02951845|Experimental|Part 2: Treatment Sequence C2A2B2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment A2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492598|NCT02951845|Experimental|Part 2: Treatment Sequence A2C2B2|Participants in Part 2 will only receive single dose of Treatment A2 then Treatment C2 followed by Treatment B2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492601|NCT02951845|Experimental|Part 2: Treatment Sequence B2A2C2|Participants in Part 2 will only receive single dose of Treatment B2 then Treatment A2 followed by Treatment C2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492604|NCT02951845|Experimental|Part 2: Treatment Sequence C2B2A2|Participants in Part 2 will only receive single dose of Treatment C2 then Treatment B2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
2492714|NCT02951325|No Intervention|Standard|"Surgery +/- chemotherapy only~Surgery (Standard/routine care) Cysto-prostatectomy and pelvic nodal dissection as part of their standard care.~Chemotherapy All patients following cysto-prostatectomy (inclusive of those received neo-adjuvant chemotherapy) will receive upto 4 cycles of adjuvant chemotherapy if medically fit for the same. The chemotherapy regimen, doses and schedule will be as per standard institutional practice. No concomitant chemotherapy with radiotherapy is recommended.~No radiation therapy will be given."
2492718|NCT02951325|Experimental|Test|"Surgery +/- chemotherapy as per standard arm and Radiation therapy as experimental intervention~Radiation Therapy:~All patients will be treated with conformal radiotherapy technique with intensity modulated radiotherapy with or without image guidance. The radiotherapy will start within 8 weeks from the date of surgery if adjuvant chemotherapy has not been planned. The radiotherapy will start within 4 weeks from the date of last chemo cycle, in patients who will be given adjuvant chemotherapy.~Dose Prescription:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) will be prescribed for the nodal PTV. In case of R1 and/or R2 resection dose to the pelvic nodes and tumour bed may be increased to 54-56 Gy in 28 fractions depending on the constraints achieved during planning.~Patient assessments: Clinical assessment for toxicity evaluation and disease status. QOL evaluation of the patients."
2492756|NCT02951078|Experimental|Thulium Laser en Bloc Resection of bladder tumor|Thulium Laser en Bloc Resection of the Non-muscle Invasive Bladder tumor with thulium laser
2492761|NCT02951078|Active Comparator|Electrical transurethral resection of bladder tumor|Electrical transurethral resection of the Non-muscle Invasive Bladder tumor
2492817|NCT02950688|Experimental|Group 1: Seasonal LAIV|Participants will receive 1 dose of seasonal LAIV on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
2492821|NCT02950688|Placebo Comparator|Group 2: Placebo|Participants will receive 1 dose of placebo on Day 0. They will receive 1 dose of the wild-type A/California/2009-like influenza challenge virus on Day 56.
2492868|NCT02950181|Experimental|Specific Aim|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
3194810|NCT00832143|No Intervention|1|Usual Care
3194811|NCT00832143|Experimental|2|Referral Card with one-to-one counseling
3194812|NCT00832156|Experimental|1|wound 1: the placement of keratinocytes onto a collagen/elastin support after the application of the meshed split skin autograft.
2493069|NCT02949089|Experimental|ACH04|Dosage: 1 capsule, PO, 24/24h for 10 days.
3194813|NCT00832156|Other|2|control wound site; application of mesh graft alone
3194814|NCT00832169|Experimental|1|
3194815|NCT00832182|Experimental|Insulin aspart and neutral protamine Hagedorn insulin|
3194816|NCT00832195|Experimental|1|Footwear with motion controlling elements built into construction in order to reduce pronation of the foot and ankle during running.
3194817|NCT00832195|Active Comparator|2|Footwear with standard neutral stabilization elements for the foot and ankle during running.
3194818|NCT00832208|Active Comparator|Ambisome control:|Ambisome, Total dose 21.0 mg given as 7 x 3mg on days 1,2,3,4,5, and 14 and 21
3194819|NCT00832208|Experimental|Ambisome test|Single dose Ambisome in sequence(7.5 / 10.0/ 12.5 / 15.0mg)
3194820|NCT00832221|Active Comparator|1|
2492596|NCT02952118|Experimental|one night with the device and one night without the device.|"The study duration with each patient will be 48 hours (two nights); at the first night the sleep study will be with PAT device, with snoring recording and without the Forrest epic device. In the second night the sleep study will be with PAT device, with snoring recording and with the Forrest epic device. The order of the sleep studies (with and without the epic device) will be randomly determined by computerized ahead prepared list. The research duration for patients that did not have a sleep study over the last year, will take place for 3 nights; the sleep study will be performed in order to make sure the patient does not suffer from obstructive respiratory disorder during sleep. The sleep studies will take place in a sleep laboratory (Millennium Sleep Labs LTD, Beer Sheva) or as an ambulatory study, at home."
2492633|NCT02951572|Other|Patients with RLD initiating NIV|Patients with RLD initiating NIV according to Belgian Health guidelines are followed-up before and after NIV initiation
2492705|NCT02951403|Experimental|Operative treatment|Patients to whom the elbow arthroscopy will be performed.
2492710|NCT02951403|Other|Conservative treatment|Patients to whom special physiotherapy will be advised.
2492776|NCT02950974|Active Comparator|NSS|NSS 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
2492779|NCT02950974|Experimental|Sterofundin|Sterofundin solution 30 ml/kg (maximum of 2 litres) intravenous load over 1 hour
2492803|NCT02950740||Center 01 (SA)|Toddlers from Santo André Early Childhood Public School
2492805|NCT02950740||Center 02 (POA)|Toddlers from Porto Alegre Early Childhood Public School
2492806|NCT02950740||Center 03 (MG)|Toddlers from Uberaba Early Childhood Public School
2492807|NCT02950740||Center 04 (RN)|Toddlers from Natal Early Childhood Public School
2492826|NCT02950584|Experimental|Patients take titanium dioxide denture|Participants will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) for 1 month in the initial phase of the trial then in the later phase after one month they will receive (rapid heat cured acrylic resin) denture
2492829|NCT02950584|Placebo Comparator|Patients take rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles)
2492903|NCT02950285|Experimental|Baseline alert|For patients randomly selected for the baseline alert arm, their physicians will be alerted via email that a patient(s) under their care has atrial fibrillation, is at high risk of stroke, and is not currently anticoagulated. Physicians will also be asked to complete a survey related to anticoagulation for each patient and will be provided with educational resources and consultation services.
2492905|NCT02950285|No Intervention|3-month alert arm|For patients randomly selected for the 3-month alert arm, their physicians will not be notified during the 3-month study follow-up period. Instead, PCPs will be sent alerts after 3-months via email for these patients.
2492961|NCT02949700|Experimental|Single arm, treatment|"Patients in the Phase I trial will be assigned to a single arm, experimental treatment which will test dose escalation for metformin in the context of chemo-radiation, with toxicity as the primary outcome.~Patients in the Phase II trial will be assigned to a single arm, experimental treatment consisting of metformin plus chemo-radiation."
3194821|NCT00832221|Active Comparator|2|
3194822|NCT00832234|Experimental|BDR|
3194823|NCT00832286|Experimental|Cipro|At Week 12, subjects will receive a 3-day course of oral Ciprofloxacin 500 mg every 12h.
3194824|NCT00832312|Experimental|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml) injected into the knee joint
3194825|NCT00832312|Placebo Comparator|Saline|Injection of 1cc of saline into the knee joint
3194826|NCT00832325||1 individual interviews|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in an individual interview at their convenience.
3194827|NCT00832325||2 Focus Groups|The patient will be asked to come in to the Counseling Center at MSKCC (641 Lexington Avenue, 7th Floor) and participate in a focus group at their convenience.
3194828|NCT00832325||3 Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews scheduled at their convenience.
3194829|NCT00832351|Experimental|1|Early mobilisation within 24 hours after admittance to hospital
3194830|NCT00832351|No Intervention|2|Mobilisation after 24 but within 48 hours from admittance to hospital
3194831|NCT00832364|Experimental|1|U0279 and Injectable Biologic
3194832|NCT00832364|Placebo Comparator|2|Placebo and Injectable Biologic
3194833|NCT00832403||polytetrafluoroethylene|
3194834|NCT00832429|Experimental|Diagnostic (SLN localization and biopsy)|Patients receive technetium Tc 99m sulfur colloid ID and then undergo lymph node mapping and SLN biopsy.
3194835|NCT00832442||Beta blocker|
3194836|NCT00832442||Placebo|
3194837|NCT00832468|Placebo Comparator|sham ear acupressure|
3194838|NCT00832468|Experimental|ear acupressure|
3194839|NCT00832481|Active Comparator|Repaglinide,tablet|
3194840|NCT00832481|Active Comparator|Metformin, tablet|
3194841|NCT00832507|Experimental|Cicletanine 150 mg QD|Cicletanine 150 mg administered once daily (QD)
3194842|NCT00832507|Experimental|Cicletanine 150 mg BID|Cicletanine 150 mg administered twice daily (BID)
3194843|NCT00832507|Experimental|Cicletanine 300 mg QD|Cicletanine 300 mg administered once daily (QD)
3194844|NCT00832507|Placebo Comparator|Placebo|Placebo to match cicletanine administered once daily
3194845|NCT00832546|Placebo Comparator|1|Placebo
3194846|NCT00832546|Experimental|2|Powder in solution
3194847|NCT00832546|Experimental|3|
3194848|NCT00832559|Experimental|CVA21|CVA21
3194849|NCT00832611|Experimental|Experimental: Group A Anastomotic Coupler|Device: ROX Anastomotic Coupler System (ACS). The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
3194850|NCT00832663|Experimental|NSAID|receive NSAID
3194851|NCT00832663|Placebo Comparator|Placebo|receive placebo
3194852|NCT00832689|Experimental|1|
3194853|NCT00832715|Experimental|EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA)
2492880|NCT02950454|Experimental|Intervention|8 weeks of twice weekly high intensity interval training. Session protocol: 2 minute warm up at nominal resistance on cycle ergometer, 6 six intervals of 80-95% heart rate max interspersed with 6 intervals of 1.5 minute working rest. Then 3 minutes cool down.
2492883|NCT02950454|Active Comparator|control|8 weeks of twice weekly continuous moderate intensity exercise. Session protocol: 2 minutes warm up at nominal resistance on cycle ergometer, 20 minutes at 60-70% heart rate max. Then 3 minutes cool down.
2492958|NCT02949843|Experimental|Arm I (nivolumab, pembrolizumab)|Patients receive nivolumab IV over 60 minutes every 2 weeks or pembrolizumab IV every 3 weeks in the absence of disease progression or unacceptable toxicity.
2492960|NCT02949843|Experimental|Arm II (kinase inhibitor, chemotherapy, immunotherapy)|Patients receive tyrosine kinase inhibitor therapy PO targeting the initial oncogenic driver or other treatment for about 3 weeks.
2492963|NCT02949843|Experimental|Arm III (kinase inhibitor, targeted therapy, other treatment)|Patients receive tyrosine kinase inhibitor therapy PO targeting initial oncogenic driver, a drug targeting the secondary mutation, or other treatment for about 3 weeks.
3194854|NCT00832728|Active Comparator|ELAD|ELAD Therapy + Standard of Care
2493110|NCT02948595|Experimental|Video feedback then verbal feedback|Video feedback followed by structured verbal feedback
2493119|NCT02948595|Experimental|Verbal feedback then video feedback|Structured verbal feedback followed by video feedback
2493151|NCT02948153||asthma with bronchial hypersecretion|In a clinical study, participants are often divided into groups. Group one: they were defined as those who expectorated daily for at least three months for a minimum period of two consecutive years, without attribution to any other cause or disease.
2493153|NCT02948153||asthma without hypersecretion|In a clinical study, participants are often divided into groups. Group two: We defined asthma as a history of variable respiratory symptoms and evidence of variable expiratory airflow limitation.
2493225|NCT02947841|Placebo Comparator|Placebo|In the placebo cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks, but they will be blinded to the fact that their group A and group B are equivalent.
2493237|NCT02947841|Active Comparator|Treatment|In the treatment cohort, subjects will alternate their DBS parameters between group A and group B every week for 12 weeks.
2493299|NCT02947321|Experimental|RFA Group|A genicular nerve RFA will be performed prior to planned total knee arthroplasty.
2493301|NCT02947321|Sham Comparator|Control Group|A sham genicular nerve RFA will be performed prior to planned total knee arthroplasty.
3194855|NCT00832728|Other|Standard of Care|Hospital based standard of care for acute liver failure
3194856|NCT00832754|Experimental|RDT+ACT group|RDT+ACT group (ACT offered to RDT positive cases only)
2493411|NCT02946450||Not applicable-observational study|Not applicable-observational study
3194857|NCT00832754|Active Comparator|Clinical judgement+ACT group|Clinical judgement+ACT group (ACT offered to all suspected cases of malaria by clinical judgement)
2493538|NCT02945397|Active Comparator|Individual activity|The individual activity consists of a 3 month membership card at a given gym. This is in addition to regular follow-up from welfare authorities.
2493541|NCT02945397|Active Comparator|Group-based activity|The group-based activity consists of a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services. This is in addition to regular follow-up from welfare authorities.
2493650|NCT02945124|Experimental|Normal children with K Tape|
2493655|NCT02945124|No Intervention|Normal children without K Tape|
2493658|NCT02945124|Experimental|DCD with K Tape|
2493664|NCT02945124|No Intervention|DCD without K Tape|
2493687|NCT02944370|Experimental|PlayFit, Modified exercise games|Subjects will participate in three 60 minute game sessions each week for 12 weeks. During each game session, subjects will be divided randomly into two teams to play a modified game. Research staff will review the instructions of the game and if needed, modify the game rules during play to enhance the experience (ie. keep it fun, keep it to moderate intensity level). The length of play session between breaks increases each week.
2493809|NCT02944149|Active Comparator|assistant medical officer (AMO)|Assistant medical officers (AMO) are currently allowed to provide tubal ligation by minilaparotomy, however government regulations do not allow clinical officers (COs) to provide this service.
2493815|NCT02944149|Experimental|clinical officer (CO)|Experimental: clinical officer (CO) In Tanzania, COs are mid-level providers who offer diagnosis, treatment, and minor surgeries. They are more common in rural areas than medical officers (MOs) and assistant medical officers (AMOs) and are generally considered capable of performing minor surgery. Almost all facilities in Tanzania are understaffed, but COs vastly outnumber MOs and AMOs. COs are more prevalent in poorer and/or rural areas than other higher level cadres; thus, task-shifting to COs would increase access to tubal ligation by minilaparotomy for many women who are most in need.
3194858|NCT00832806|Active Comparator|1|Extended IVR (integrated voice response technology) vs. no extended IVR
2494109|NCT02941796|Experimental|Sequence 2|"R → T~T : HCP1105 4cap R : HGP0918 4cap + HGP0816 4tab"
2494116|NCT02941770|No Intervention|Control group|"Clinic standard care protocol:~Baseline evaluation session with a Pediatrician for initial screening;~Appointment with a Dietitian;~A brochure with physical activity guidelines for youth with examples of physical exercises."
2494140|NCT02941484|Experimental|1 early oral intake|early oral intake since postoperative day 1.
3194859|NCT00832806|Active Comparator|2|Extended IVR (integrated voice response technology) vs. no extended IVR
3194860|NCT00832832|Experimental|Eyelid closure|Eyelids will be closed after administration of eye drop
3194861|NCT00832832|Active Comparator|No eyelid closure|Eyelids will not be closed after eye drop instillation
3194862|NCT00832845|Experimental|CBSST plus treatment as usual|Subject randomized to the CBSST Group arm will attend 2 hour weekly Cognitive Behavioural Social Skills therapy sessions for 9 months. They will also be attending follow-up assessments q 4 months.
3161675|NCT00446810|Active Comparator|A1|Benfotiamine
3161676|NCT00446810|Active Comparator|A2|
3161677|NCT00446836|Other|Single arm|Open label use of Xyotax
3161678|NCT00446875|Experimental|Sucrose|Participants received oral sucrose (0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
3161679|NCT00446875|Placebo Comparator|Placebo|Participants received Placebo (sterile water, 0.6mL/Kg) 2 minutes prior to the combind DTaP, IPV, and Hep B (Hib and PCV7) vaccine.
3161680|NCT00446888|Active Comparator|1|"these subjects will get a standard protein supplement milkshake during thei study."
3161681|NCT00446888|Experimental|2|"these subjects will receive an enhanced protein supplement milkshake during their study. Product 4808."
3161682|NCT00446901|Placebo Comparator|Placebo|Placebo
3161683|NCT00446901|Experimental|Selenium (selenized yeast)|Selenium (selenized yeast) tablets, 300 ug/day
3161684|NCT00446953|Experimental|1|2x 12 mg betamethazone
3161685|NCT00446953|Placebo Comparator|2|no drugs
3161686|NCT00446979|Experimental|1|UC 781 0.1% carbomer gel
3161687|NCT00446979|Experimental|2|UC 781 0.25% carbomer gel
3161688|NCT00446979|Placebo Comparator|3|Placebo vaginal gel
3161689|NCT00447044|Experimental|2|Subjects drink essential amino acid supplement 3x day for 2 days.
2492743|NCT02950948|Experimental|Progesterone|25 mg of progesterone will be administered daily by subcutaneous injection.
2492747|NCT02950948|Placebo Comparator|Placebo|25 mg of progesterone will be administered daily by subcutaneous injection.
2492791|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 0.9 µg/kg|Four weekly subcutaneous injections of 0.9 µg/kg EPEG
2492795|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.2 µg/kg|Four weekly subcutaneous injections of 1.2 µg/kg EPEG
2492796|NCT02950857|Experimental|EPEG (pegylated erythropoietin) - 1.5 µg/kg|Four weekly subcutaneous injections of 1.5 µg/kg EPEG
2492814|NCT02950649|Experimental|Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
2492815|NCT02950649|Active Comparator|No Hemodynamic Monitored Guided Assesment|This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
2492886|NCT02950142|Experimental|CPOE with order sets|Physicians who use CPOE including order sets for large range of indications.
2492888|NCT02950142|Active Comparator|CPOE without order sets|Physicians who use CPOE without order sets.
2492948|NCT02949804||Smoker|Vasovagal tendency will be compared among smokers and non smokers
2492956|NCT02949804||Non-smokers|Vasovagal tendency will be compared among smokers and non smokers
2492993|NCT02949310|Placebo Comparator|Control|Placebo use instead of nefopam
2493003|NCT02949310|Experimental|Nefopam|Intraoperative use of nefopam 40 mg
3161690|NCT00447044|Placebo Comparator|1|Subjects receive inert substance versus protein supplement.
3161691|NCT00447044|Experimental|3|Resistance exercise.
2493192|NCT02947932|Experimental|Pre-ERCP group Oral resveratrol in in all patients.|Oral resveratrol was administrated within 1hour before ERCP in all patients.
2493194|NCT02947932|Active Comparator|Post-ERCP rectal Indomethacin in high-risk patients.|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
2493217|NCT02947620|Active Comparator|Metformin/Atorvastatin|Metformin/Atorvastatin, QD
2493220|NCT02947620|Placebo Comparator|Metformin|Metformin, QD
3161692|NCT00447096|Experimental|Treatment Arm|Treatment arm will receive treatment 5 days a week for 6 weeks. Repetitive transcranial magnetic stimulation (rTMS) treatment.
3161693|NCT00447096|Sham Comparator|Sham Arm|Sham Arm will not receive any stimulation 5 days a week for 6 weeks. Sham transcranial magnetic stimulation.
3161694|NCT00447148|No Intervention|1|Paired comparison of 2 angiographic techniques
3161695|NCT00447161|Experimental|1|Bacillus Clausii Multi ATB Resist
3161696|NCT00447161|Placebo Comparator|2|Placebo
3161697|NCT00447174|Experimental|treatment|treatment manual
3161698|NCT00447174|No Intervention|control group|
3161699|NCT00447187|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
3161700|NCT00447187|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
3161701|NCT00447187|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
3161702|NCT00447213|Experimental|1|
3161703|NCT00447213|Experimental|2|
3161704|NCT00447317|Experimental|A|Intervention
3161705|NCT00447317|Other|B|Attention control, standard dietary education
3161706|NCT00447343||Treatment group|"Patients with cervical myelopathy undergoing decompressive cervical spine surgery will have two scans (pre-operatively and 6 months post-operatively).~A blinded investigator will administer questionnaires at each time point."
3161707|NCT00447343||Control group|"Healthy Volunteers will have two scans 6 months apart.~A blinded investigator will administer questionnaires at each time point."
3161708|NCT00447395||GROUP 1|Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, normal or mild affected sperm, normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
3161709|NCT00447395||GROUP 2|•Recurrent miscarriage, <40 year-old-men, < 38 year-old-women, oligozoospermia (1-5 mill/ml), normal parents karyotype, no thrombophilia, normal uterus, no endocrinopathy
3161710|NCT00447395||GROUP 3|•Oligozoospermia (1-5 mill/ml), < 40 year-old-men, no recurrent miscarriages
2492740|NCT02951065|Experimental|Bristle-less brush|Subjects will be assigned to use a bristle-less manual tooth brush with short, rubbery cones for one year twice daily
2492745|NCT02951065|Active Comparator|Soft bristle brush|Subjects will be assigned to use a soft, nylon-bristled tooth brush for one year twice daily
2492792|NCT02950818|Experimental|Take Heart self-management program|Group and telephone-based educational program to enhance self-management of heart disease and related risk factors.
2492799|NCT02950818|No Intervention|Waitlist control|Control group participants will be offered the opportunity to participate in Take Heart following the conclusion of their study involvement.
2492828|NCT02950636|Experimental|Restorative Yoga|Subjects will participate in a structured restorative yoga program. Subjects will attend a 60 minute restorative yoga class twice a week for 8 weeks in a yoga studio.
2492904|NCT02950051|Active Comparator|Standard chemoimmunotherapy (SCIT)|"Patients up to age 65: 6 cycles (q28d) of Fludarabine + Cyclophosphamide + Rituximab (FCR)~Patients older than 65 years: 6 cycles (q28d) of Bendamustine + Rituximab (BR)"
2492906|NCT02950051|Experimental|Rituximab + Venetoclax (RVe)|6 cycles (q28d) of RVe + 6 cycles (q28d) of Venetoclax (alone)
2492907|NCT02950051|Experimental|Obinutuzumab + Venetoclax (GVe)|6 cycles (q28d) of GVe + 6 cycles (q28d) of Venetoclax (alone)
2492908|NCT02950051|Experimental|Obinutuzumab + Ibrutinib + Venetoclax (GIVe)|"6 cycles (q28d) of GIVe + 6 cycles (q28d) of Ibrutinib plus Venetoclax.~Administration of ibrutinib will be continued for a maximum of 36 months or until MRD negativity, start of new anti-CLL therapy or inacceptable toxicity, whatever occurs first."
3161711|NCT00447395||GROUP 4|•Healthy young sperm donors
3161712|NCT00447408|Active Comparator|A|Education in the hemodialysis diet.
2493162|NCT02948205|Experimental|3D group|infertility patient get TU-LESS by 3D Laparoscopy
2493176|NCT02948205|Other|normal group|infertility patient get normal laparoscopic surgery
2493242|NCT02947828||T2D patients|600 type 2 diabetes (T2D) patients recruited from the DD2 cohort
2493248|NCT02947828||Gender- and age-matched healthy controls|100 healthy subjects
2493291|NCT02947334|Experimental|Bococizumab|Bococizumab Q2wks
2493292|NCT02947334|Placebo Comparator|Placebo|Bococizumab placebo Q2wks
2493355|NCT02946957|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia is delivered by trained sleep therapists in six telephone sessions.
2493358|NCT02946957|Active Comparator|Education Control|Education Only Control is delivered by trained sleep therapists in six telephone sessions.
2493387|NCT02946528|Experimental|urgent-start peritoneal dialysis|All patients in urgent-start peritoneal dialysis arm initiate peritoneal dialysis as urgent-start dialysis modality.
2493389|NCT02946528|Active Comparator|urgent-start hemodialysis|All patients in urgent-start hemodialysis arm initiate hemodialysis as urgent-start dialysis modality.
2493412|NCT02946281|Experimental|Intervention|
2493425|NCT02946281|No Intervention|Care as usual|
2493466|NCT02946112||Shoulder pain|volleyball players with shoulder pain
2493473|NCT02946112||No shoulder pain|volleyball players without shoulder pain
2493502|NCT02945865|Experimental|ITreatment arm: Pain Assessment|Pain assessment by Doloplus-2 pain scale regularly and additional pain assessment in situations where pain is suspected.
2493507|NCT02945865|No Intervention|Control arm: No treatment|Treatment us usual
2493555|NCT02945566|Active Comparator|Standard TME surgery|Radical total mesorectal excision
2493560|NCT02945566|Experimental|Long course concurrent chemoradiation|Capecitabine: 825 mg/m² orally, b.i.d., on radiotherapy days Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
2493563|NCT02945566|Experimental|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
2493631|NCT02944981|Experimental|Gabapentin|Patient receiving oral gabapentin 600 mg preoperatively
2493633|NCT02944981|Placebo Comparator|Placebo|Patient receiving oral placebo tablet preoperatively
2493766|NCT02943707|Experimental|treatment group: ABMSCi & drugs|ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
2493768|NCT02943707|Active Comparator|control group: drugs|drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
3161713|NCT00447408|Experimental|B|Education in the hemodialysis diet. Behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
3161714|NCT00447473|Other|A|GM-CSF given in combination with ketoconazole and mitoxantrone in patients with progressive prostate cancer despite androgen deprivation and prior taxane containing chemotherapy
3161715|NCT00447525|Experimental|1|
3161716|NCT00447525|Active Comparator|2|
3161717|NCT00447551|Experimental|single group|
3161718|NCT00447564|Active Comparator|Group A|
3161719|NCT00447564|Placebo Comparator|Group B|
3161720|NCT00447577|Experimental|Zylet|Loteprednol etabonate and tobramycin ophthalmic suspension, 0.5%/0.3% (Zylet)
3161721|NCT00447577|Active Comparator|Tobradex|Tobradex (tobramycin and dexamethasone ophthalmic suspension, 0.3%/0.1%), US marketed product (Alcon) from commercial lots.
3161722|NCT00447642|Experimental|LX201 0.50 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.50 inch in length
3161723|NCT00447642|Experimental|LX201 0.75 inch implant|LX201 implant contained 30% cyclosporine A by weight and 0.75 inch by length
3161724|NCT00447642|Placebo Comparator|Placebo 0.75 inch implant|Silicone implant not containing cyclosporine A, 0.75 inch in length
3161725|NCT00447668|Experimental|1|
3161726|NCT00447668|Active Comparator|2|Exercise
3161727|NCT00447668|Active Comparator|3|Self-care book recommendations
3161728|NCT00447720|Experimental|PATH counseling|These participants received the PATH intervention
3161729|NCT00447720|Active Comparator|Treatment as Usual|These individuals receive treatment as they normally would receive in the community
3161730|NCT00447733|Experimental|Integrated treatment|Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way.
2492741|NCT02951026||0.03mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.03mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2492746|NCT02951026||0.07mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.07mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2492751|NCT02951026||0.23mg SM04690 (previously injected)|"Subjects in this group received a single intra-articular injection of 0.23mg SM04690 into the target knee during the parent study prior to enrolling in this observational study."
2492757|NCT02951026||Placebo (previously injected)|"Subjects in this group received a single intra-articular injection of placebo into the target knee during the parent study prior to enrolling in this observational study."
2492878|NCT02950311|Experimental|Intranasal xylitol spray|Two sprays each nostril, twice a day.
2492882|NCT02950311|Placebo Comparator|Intranasal saline spray|Two sprays each nostril, twice a day.
2492924|NCT02949895|Experimental|Dose Escalation Dose 1|BMS-986012 Dose Escalation Dose 1
2492925|NCT02949895|Experimental|Dose Escalation Dose 2|BMS-986012 Dose Escalation Dose 2
2492927|NCT02949895|Experimental|Chemotherapy Combination|BMS-986012 + Cisplatin + Etoposide
2492939|NCT02949544|Other|water immersion|patients with heart failure will be immersed to the neck for 15 minutes
2493070|NCT02949050|Experimental|Treatment Group|the treatment -patients underwent SCIT and antihistamine/nasal steroid/use.
2493075|NCT02949050|No Intervention|Control Group|Control patient group only used antihistamines/nasal steroids but no SCIT
2493115|NCT02948491|Experimental|Music therapy|First. Recording of the voice of the mother singing the song to the child. (To choose this option, the song must be sung to the child during pregnancy at least 2 to 3 times per week. Second. The mother's favorite song, obtained externally. (To choose this option, the mother must bring the song that she that she listened to frequently, at least 5 times per week). Third. Pre-determined lullaby. (This option refers only to the lullaby melody or Brahms lullaby, edited to obtain stable volumes and normalization of the audio, with the effect of progressively appearing and fading for the first and last 10 seconds of the intervention with music therapy, so there are no drastic acoustic changes in the intervention. Audacity editing software will be used.)
2493124|NCT02948491|No Intervention|Without sound emission|"The infant does not receive any sound emission because the baffle will be turned off.~One of the three intervention options are chosen. The parents are told that their child may be randomly assigned to either the therapeutic or control group."
2493251|NCT02947867|Experimental|"aganirsen low-dose:"|43µg daily, one drop of 0.86 mg/g emulsion (morning) + one drop of placebo (evening) daily
2493257|NCT02947867|Experimental|"aganirsen high-dose"|86µg daily, one drop of 0.86 mg/g emulsion twice daily (morning and evening)
2493260|NCT02947867|Placebo Comparator|aganirsen placebo (vehicle)|one drop of placebo emulsion (morning) + one drop of placebo emulsion (evening) daily
2493278|NCT02947191|Experimental|Collagen membrane + HUC-MSCs|
2493338|NCT02947074|No Intervention|Control|Waiting list
2493342|NCT02947074|Experimental|Yoga Meditation|Previously naive to yoga and meditation, subjects will receive 2 30min yoga meditation classes for 8 weeks.
2493373|NCT02946645|Active Comparator|Manual Physiotherapy|TMD patients will treat with orofacial physiotherapy by one expert operator according to literature
2493374|NCT02946645|Active Comparator|Neuromuscular Bite|TMD patients will receive an intraoral neuromuscular bite according to literature
2493375|NCT02946645|Placebo Comparator|Placebo|TMD placebo group.
2493395|NCT02946372|Experimental|ILMT|internal limiting membrane autologous transplantation (ILMT)
2493451|NCT02946255|Experimental|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
2493453|NCT02946255|Experimental|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
2493455|NCT02946255|Active Comparator|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
2493491|NCT02945891|Experimental|Study group|Each women recruited for the study belong to the study group. Intervention is performance of HPV testing on Evalyn®Brush and FloqSwab specimens compared to clinician-sampled specimen. Providing an urinary sample (Colli-PeeTM), blood, and a questionnaire data is optional.
2493565|NCT02945579|Experimental|Treatment (whole breast irradiation, EBRT)|Within 12 weeks of completing neoadjuvant systemic therapy, patients undergo whole breast irradiation over 15-25 fractions on consecutive days. Patients then undergo EBRT boost over 7 fractions on consecutive days beginning the day following completion of whole breast irradiation.
2493630|NCT02944786|Experimental|HOPE-model|Four person-centred health dialogue sessions that include pain/stress management and education about stress and pain.
2493635|NCT02944786|No Intervention|Control|Standard care
2493722|NCT02944526|Experimental|Ropivacaine Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of Ropivacaine monohydrochloride 2mg/ml.~3 successive blocks are realized at 1 week interval."
2494162|NCT02941354|Experimental|Turoctocog alfa|
2492801|NCT02950792|Experimental|ViewRay MRI-IGART|"ViewRay MRI-Image-Guided Adaptive Radiation Therapy (IGART):~Daily MRI on ViewRay 5 days per week for 4 weeks in combination with weekly standard of care chemo-radiation.~Daily MRI on ViewRay during Week 5 in combination with Stereotactic Body Radiation Therapy boost for daily for up to 1 week.~Continued standard of care consolidation chemotherapy every 21 days for 3 cycles, beginning 4 - 6 weeks after completion radiation therapy, ."
3194863|NCT00832845|Active Comparator|Treatment as Usual Group|Subjects randomized to the Treatment as Usual Group Arm will continue with their regular psychiatric treatment for 1 year. Like the CBSST Group Arm, they will have follow up assessments q 4 months. After completing the Treatment as Usual Group arm, they will automatically continue on with the CBSST Group Arm.
3194864|NCT00832884|Active Comparator|Group 1A|Lacosamide, IV, 50 mg, once, 30 minutes
3194865|NCT00832884|Active Comparator|Group 2A|Lacosamide, IV, 100 mg, once, 30 min
3194866|NCT00832884|Active Comparator|Group 3A|Lacosamide, IV, 150 mg, once, 30 min
2492911|NCT02949999|Experimental|0.25mg/kg voclosporin|0.25mg/kg voclosporin BID.
2492913|NCT02949999|Experimental|0.5mg/kg voclosporin|0.5mg/kg voclosporin BID
2492915|NCT02949999|Experimental|1.0mg/kg voclosporin|1.0mg/kg voclosporin BID
2492918|NCT02949999|Experimental|1.5mg/kg voclosporin|1.5mg/kg voclosporin BID
2492919|NCT02949999|Placebo Comparator|Placebo voclosporin|placebo BID
2492934|NCT02949609|Experimental|Mirror Therapy (MT)|Standard therapy + 30 min/day of mirror therapy, 5 days/week, for 4 weeks, administered by experienced physical and occupational therapists.
2492936|NCT02949609|Active Comparator|Control Therapy (CT)|Standard therapy + 30 min/day of CT.
2492995|NCT02949453|Experimental|patients after suicidal episode|Patients receiving a telephone-delivered intervention after deliberate self-harm (DSH)
2493201|NCT02947880|Experimental|Bumetanide group|"During 3 months in the double blind, the patient will receive the experimental treatment. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
2493202|NCT02947880|Placebo Comparator|Placebo group|"During 3 months in the double blind, the patient will receive the placebo. For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.~After the 3 months in the double blind trial (bumetanide versus placebo), all the patient will receive (in the open phase of the trial) the bumetanide during 3 months with the posology fitting with their weights."
2493255|NCT02947490|Sham Comparator|Standard BP management|Participants will continue to receive routine measurement of BP and management of treatment from their General Practitioner (GP).
2493259|NCT02947490|Placebo Comparator|Self BP measurement and standard care|Participants in this group (Se-Mo) will be taught to use a validated British Hypertension Society (BHS) approved home BP monitor (with built in memory/printer) by the study nurse along with written information on the procedure and a copy of the BHS Home BP Monitoring DVD. Participants will be contacted before each recording week & arrangements will be made to deliver and demonstrate the use of self BP monitor by the study nurse. Home BP monitoring will be performed over a 7 day period 3 times during the 6 month follow-up and on each occasion the patient will be given a copy of the BP results and asked to inform the GP of the results and the GP will decide if any alteration in therapy is needed.
2493261|NCT02947490|Active Comparator|Self BP measurement and treatment|Participants in this group will undergo exactly the same self BP monitoring training process as the Se-MO group and will undertake monitoring at the same time intervals. However they will be equipped with a validated BP monitor with a Bluetooth interface phone, BP values recorded by the patient will be transmitted automatically via mobile telephone to the trial coordinating centre. The data will be password protected and saved on a secure server and be available only to the trial team (study nurse & supervising physicians). The patient would then be contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels. This will be recorded on the CRF and the GP notified of any treatment changes.
2493285|NCT02947139|Experimental|Study effect of DWC20161 on DWC20155/DWC20156 PK|To study effect of DWC20161 on DWC20155/DWC20156 PK
2493286|NCT02947139|Experimental|Study effect of DWC20155/DWC20156 on DWC20161 PK|To study effect of DWC20155/DWC20156 on DWC20161 PK
2493306|NCT02947048|Experimental|100 mg open|open-label lead-in 100 mg L1-79 t.i.d.
2493307|NCT02947048|Experimental|100 mg blinded|blinded and randomized 100 mg L1-79 t.i.d.
2493310|NCT02947048|Experimental|200 mg open|open-label lead-in 200 mg L1-79 t.i.d.
2493315|NCT02947048|Experimental|200 mg blinded|blinded and randomized 200 mg L1-79 t.i.d.
2493318|NCT02947048|Placebo Comparator|Placebo|placebo t.i.d.
2493492|NCT02946242|Other|General Ultrasound Exam|Each subject may elect to participate in up to five (5) study scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan. Ophthalmic scanning will be limited to no more than 15 cumulative minutes of scan time per eye, per day.
2493569|NCT02945618|Experimental|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
2493573|NCT02945618|Active Comparator|Conventional program with ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
2492816|NCT02950571|Active Comparator|Standard Care|Routine care is comprised of a high level of support from an interdisciplinary team with access to unit-specific and centralized programming
2492818|NCT02950571|Experimental|Digital Picture Frames|"Setup: Over 1-2, approximately 30 minute meetings pictures will be uploaded onto the device from picture files provided by the participant and/or their family or an open online source (e.g., Google Images) that are relevant and of interest to the participant.~Installation: The picture frames are secured to a surface in the participant's room (most typically a table) by facilities staff. Participants are instructed in its use.~Check in: At midpoint (2 weeks) an RA will check in with the participant to informally discuss whether or not it continues to work, is being used, and if they want more pictures uploaded. If the latter is requested step 1 will be repeated."
2492872|NCT02950376||Group1：amphetamine abusers|
2492874|NCT02950376||Group2: health control|
2492876|NCT02950376||Group3: norm of assessment system|
2492926|NCT02949882|Experimental|Probiotic Intervention|130 Elderly participants receiving daily 65ml Yakult for 10 consecutive weeks.
2492929|NCT02949882|Active Comparator|Non-Probiotic Intervention|130 Elderly participants receiving daily 65 ml of Dairy Peach Drink (AH Basic) for 10 consecutive weeks.
2492951|NCT02949570|Experimental|Treatment|
2492990|NCT02949336||Group 1: Traditional UKA|Patients with a traditional Medial Unicompartmental Knee Arthroplasty, SIGMA® High Performance Partial Knee System (functional ACL and tibial posterior slope matching the native bone) will undergo observational use of fluoroscopy to analyze joint kinematics
2492999|NCT02949336||Group 2: ACL deficient UKA|Patients with the same medial UKA implant (SIGMA® High Performance Partial Knee System) in an ACL deficient knee, where the UKA was implanted at a 50% reduced tibial posterior slope relative to the native knee will undergo observational use of fluoroscopy to analyze joint kinematics.
3194867|NCT00832884|Active Comparator|Group 4A|Lacosamide, IV, 200 mg, once, 30 min
3194868|NCT00832884|Active Comparator|Group 1B|Lacosamide, IV, 50 mg, once, 15 min
3194869|NCT00832884|Active Comparator|Group 2B|Lacosamide, IV, 100 mg, once, 15 min
2493363|NCT02946827|Experimental|Low FODMAPs /balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients, low in FODMAPs foods.
2493366|NCT02946827|Active Comparator|Balanced gluten free diet|An expert in nutrition will give a balanced gluten free diet to patients.
3194870|NCT00832884|Active Comparator|Group 3B|Lacosamide, IV, 150 mg, once, 15 min
2493632|NCT02945085|Experimental|Home Based Care Team|Primarily in-home treatment provided by team led by nurse practitioner with geriatrics and geriatric psychiatry expertise.
2493636|NCT02945085|Active Comparator|Telephone Based Care Team|Primarily telephone-based treatment provided by existing care management program offered by collaborating Medicare Advantage insurer.
2493680|NCT02944435|Experimental|CB-839 Capsules|A single dose of 3 x 200-mg capsules of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
2493682|NCT02944435|Active Comparator|CB-839 Tablets|A single dose of 3 x 200-mg tablets of CB-839 will be administered orally with water approximately 5 minutes after consuming an entire meal
2493750|NCT02944175|Experimental|Sugammadex|Patients will receive Sugammadex to antagonise the residual effects of neuromuscular blocking drugs
2493751|NCT02944175|Active Comparator|Neostigmine|Patients will receive Neostigmine to antagonise the residual effects of neuromuscular blocking drugs
2493810|NCT02943720|Placebo Comparator|placebo|5 SC injections in 2 months
2493814|NCT02943720|Experimental|AllerT 50 ug|5 SC injections in 2 months
2493817|NCT02943720|Experimental|AllerT 10 ug|5 SC injections in 2 months
2493871|NCT02943252|Experimental|Apatinib plus S1|Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
2493907|NCT02942992|No Intervention|Control|Usual Care Group
2493908|NCT02942992|Other|Intervention|Intervention Group
2493944|NCT02942732|Other|normal-weight adult subjects|normal-weight adult subjects (n=30, age ≤ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2493947|NCT02942732|Other|overweight adult subjects|overweight adult subjects (n=30, age ≤ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2493950|NCT02942732|Other|normal-weight elderly|normal-weight elderly (n=60, age ≥ 65 years and BMI ≤ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2493952|NCT02942732|Other|overweight elderly|overweight elderly (n=60, age ≥ 65 years and BMI ≥ 25 kg/m²) All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
2494042|NCT02942199|Experimental|MySafeRx Intervention|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents MySafeRx using the MedicaSafe 3000 electronic pill dispenser.
2494096|NCT02941861||recurrence rate of HCC after surgery|There were 33 for Hepatocellular carcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
3194871|NCT00832884|Active Comparator|Group 4B|Lacosamide, IV, 200 mg, once, 15 min
3194872|NCT00832897|Sham Comparator|Eyedrop|
3194873|NCT00832897|Active Comparator|Crosslinking|The patients will be submitted to corneal collagen crosslinking, by use riboflavin eyedrop with UVA light.
3194874|NCT00832910||Rheumatoid Arthritis group1|This group had patients with rheumatoid arthritis
2492940|NCT02949661|Experimental|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block using levobupivacaine
2492946|NCT02949661|Active Comparator|Local wound infiltration|Patients will receive local wound infiltration with levobupivacaine after the conclusion of surgery
2493007|NCT02949375|Placebo Comparator|Placebo Arm|Gel capsule containing Placebo to be taken once per day
2493011|NCT02949375|Active Comparator|4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken once per day
2493012|NCT02949375|Active Comparator|6mg GRI-0621|6mg GRI-0621 gel capsule to be taken once per day
2493048|NCT02948920|Experimental|Ephedrine|Intravenous 9 mg of ephedrine (3 ml) given at finishing local anesthetic administration for spinal anesthesia
2493050|NCT02948920|Placebo Comparator|NSS|Intravenous normal saline 3 ml given at finishing local anesthetic administration for spinal anesthesia
2493107|NCT02948621||Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
2493165|NCT02948101|Experimental|Treatment (PD 0360324, cyclophosphamide)|Patients receive anti-CSF1 monoclonal antibody anti-CSF1 monoclonal antibody PD 0360324 IV over 30 minutes on days 1, 8, 15, and 22. Starting on day 43, patients receive cyclophosphamide PO QD. Courses with cyclophosphamide repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2493214|NCT02947503|Active Comparator|Metformin on top of usual care|"Metformin HCL 850 CF (1-3 times daily) added to usual care from start of the diagnosis GDM.~Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: metformin HCF 850 CF (1-3 times daily) on top of usual care."
2493215|NCT02947503|No Intervention|Usual care|"Usual care from start of the diagnosis GDM. Control group without metformin. Usual care has been defined as intensive counselling for diet and lifestyle plus insulin therapy if needed.~Intervention: usual care."
2493298|NCT02947373|Other|Imaging Arm|Patients will receive a one-time injection of Hyperpolarized Pyruvate prior to a single MR imaging examination that includes the acquisition of HP carbon-13 metabolic data.
2493471|NCT02946164|No Intervention|Comparison: Standard of Care|Standard services available to all men at AHF Wellness Centers.
2493479|NCT02946164|Active Comparator|Intervention: 'Stick To It' Intervention|Behavioral intervention.
2493512|NCT02945813|Experimental|Arm A: Metformin|"Metformin - 850mg PO BID; 48 weeks~Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks"
2493514|NCT02945813|Active Comparator|Arm B: Salvage Radiotherapy|- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks
2493567|NCT02945306|Experimental|Adenotonsillectomy|Removal of tonsils and adenoids under a general anaesthetic
2493571|NCT02945306|Active Comparator|Watchful waiting with supportive care|Reassurance with active medical treatment of conditions associated with Sleep Disordered Breathing such as otitis media with effusion and allergic rhinitis
2493619|NCT02944955|Experimental|BLEX 404 Oral Liquid|"Part I:~Part I-1: Low Dose BLEX 404 Oral Liquid (3 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part I-2: High Dose BLEX 404 Oral Liquid (4.5 mg/kg, BID) is administered in combination with 2 cycles of azacitidine.~Part II:~Recommended Dose Level (RDL) of BLEX 404 Oral Liquid will be determined by results from Part I.~BLEX 404 Oral Liquid at RDL is administered in combination with 6 cycles of azacitidine."
2493679|NCT02944604|Experimental|PEG-rhG-CSF|Patients with breast cancer who were treated with intensive chemotherapy received PEG-rhG-CSF.
2493699|NCT02944266||Hypovolemia group|Those patients who are said to be positive for one or more of the following TTE criteria are grouped under this , them being i.IVC diameter of less than 1 cm , ii.Caval index of > 50%, iii.Left ventricular end diastolic area of < 10 cm2 iv. VTI variation with respiration of < 12.5%, are grouped under the hypovolaemia group .
2493704|NCT02944266||Normovolaemia group|Those patients without the above said TTE findings are hypothesised to be normovolaemic and grouped in here.
2493747|NCT02944019||Edoxaban|Patients with established Non Valvular Atrial Fibrillation (NVAF) treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
3161731|NCT00447733|Active Comparator|Treatment as usual|Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders.
3161732|NCT00447759|Experimental|Celecoxib|Celecoxib. Celebrex 200-400mg daily in divided doses
3161733|NCT00447759|Active Comparator|Diclofenac|continue usual nsNSAID
3161734|NCT00447798|Experimental|Prevention Care Advocate|Prevention Care Advocate (PCA) intervention contains elements based on cognitive-behavioral theories and strengths-based case management. Intervention arm participants will undergo an 8 session intervention comprised of three components: 1) An individual strengths-based case management approach aimed at motivating participants to seek or maintain their engagement with HIV primary care and drug treatment; 2) A cognitive-behavioral, skills-building approach to increase participants' risk reduction knowledge, skills, and perceived self-efficacy as well as intention to change high risk transmission behaviors; and 3) A community placement in which study participants will have the opportunity to practice their advocacy skills in prevention and care setting.
3161735|NCT00447798|No Intervention|Standard of Care|"Standard of Care (SOC) condition involves standard practice, consisting of usual inpatient/hospital services provided within normal clinical practice, plus a brief educational session consisting of the review of the topics in the Living with HIV brochure published by the Centers for Disease Control and Prevention (CDC)."
3161736|NCT00447837|Experimental|1|
3161737|NCT00447837|Experimental|2|
3161738|NCT00447837|Placebo Comparator|3|
3161739|NCT00447915|Experimental|1|
3161740|NCT00447915|Experimental|2|
3161741|NCT00447915|Active Comparator|3|
3161742|NCT00447954|Experimental|1 high dose NT-501 implant|
3161743|NCT00447954|Experimental|2 low dose NT-501 implant|
3161744|NCT00447954|Sham Comparator|3 sham procedure|No implant
3161745|NCT00447967|Experimental|1|IOX
2492870|NCT02950246|Active Comparator|povidon iodine group|"Skin preparation Use of 10 ml of povidone iodine drug for disinfection with scrubing device Wait at least 30 seondes for drying Perineural catheterization implementation Ultrasonography use"
2492955|NCT02949856|Experimental|Tapered|Mallinckrodt, COVIDIEN
2492959|NCT02949856|Active Comparator|Cylindrical|Endotracheal tube, Unomedical
2492994|NCT02949349|Experimental|MMF 500mg|Mycophenolate mofetil 500mg, PO BID
2493005|NCT02949349|Experimental|MMF 750mg|Mycophenolate mofetil 750mg, PO BID
2493010|NCT02949349|Active Comparator|AZA|Azathioprine 1mg/kg, PO BID
2493051|NCT02948894|Experimental|MAD|Mandibular advancement device. A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
2493052|NCT02948894|Placebo Comparator|Sham-MAD|Mandibular advancement device (non-advanced device). A dentist, who is otherwise not involved in HF care, will open a sealed envelope at the time of randomization and program the MAD device accordingly. Each mode will be maintained for 3 months
3194875|NCT00832910||2|
3194876|NCT00832923|No Intervention|Routine IMPACT DC care|Participants receive standard asthma education as routine for IMPACT DC
2493155|NCT02947971|Experimental|OFDI Imaging|Experimental OFDI Imaging
2493211|NCT02947789||Postoperative mortality within 3 days|Group 1: Patients undergoing emergency surgery with postoperative mortality within 3 days Group 2: Patients undergoing emergency surgery without postoperative mortality within 3 days
2493290|NCT02947399|Other|I-124 in thyroid hormone withdrawal|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
2493334|NCT02946853|Active Comparator|CRT-D|Patients will be randomized at enrollment. Patients in this arm of the study will receive cardiac resynchronization therapy with defibrillator (CRT-D).
2493336|NCT02946853|Experimental|CRT-D and AVJ Ablation|Patients in this arm of the study will receive CRT-D and undergo atrioventricular junctional (AVJ) ablation.
2493419|NCT02946606|Experimental|Group 1: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2493435|NCT02946606|Experimental|Group 2: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2493437|NCT02946606|Experimental|Group 3: GX-H9 + Genotropin|GX-H9 (weekly dose), Genotropin (daily)
2493517|NCT02946008|Experimental|SBRT|Stereotactic Body Radiation Therapy (SBRT) will be delivered over 5 treatment sessions for approximately 1.5 weeks total.
2493585|NCT02945163|Experimental|Arm 1|Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die
2493587|NCT02945163|Active Comparator|Arm 2|Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die
2493641|NCT02944825|Active Comparator|Antibiotic|Patients randomized to the intervention arm will be provided a single oral dose of prophylactic oral antibiotic at the time of cystoscopic stent removal
2493646|NCT02944825|Active Comparator|No Antibiotic|Patients randomized to the non-intervention arm will not undergo prophylaxis at the time of cystoscopic stent removal
2493689|NCT02944344|Experimental|Four Conversations Intervention|Subjects in this arm will participate in Reimagine's online Four Conversations program during the initial study period of four weeks.
2493690|NCT02944344|Other|Waitlisted Control|Subjects in this arm will continue to receive standard care from their healthcare providers during the initial study period (i.e. no intervention). After four weeks, subjects will then participate in Reimagine's online Four Conversations program.
2493771|NCT02944110|Active Comparator|Pancreatectomised + LY2409021|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest a dose of 300mg of LY2409021.
2493776|NCT02944110|Placebo Comparator|Pancreatectomised + placebo|During the experimental day the patient will undergo a 75gr-OGTT. On the evening before the experimental day, the patient will ingest placebo tablets.
2493783|NCT02944110|Active Comparator|Healthy + LLY2409021|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest a dose of 300mg of LY2409021.
2493787|NCT02944110|Placebo Comparator|Healthy + placebo|During the experimental day the subject will undergo a 75gr-OGTT. On the evening before the experimental day, the subject will ingest placebo tablets.
2493830|NCT02943512|Experimental|Discharge day of Procedure|Subjects in this arm will be discharged the same day of their cardiac device implant if deemed safe by treating physician.
2493832|NCT02943512|No Intervention|Control|Subjects in this arm will remain in the hospital overnight per standard of care and will be discharged the next day if deemed safe by treating physician.
2493904|NCT02943187|Experimental|Nutrition and Cognitive Training|The intervention includes a physician-directed diet, exercise, and nutritional supplementation regimen, combined with a 60-hour, clinician-delivered cognitive training program created by LearningRx.
3194877|NCT00832923|Experimental|Enhanced care PEPAC Intervention|
3194878|NCT00832962||1|Adult Rh negative pregnant patients from 7 selected centers (SAINT ANTOINE hospital, CHU Marseille, CHU Nantes, CHU Lille, LOUIS MOURIER Hospital, SAINT VINCENT-PAUL Hospital, CH POISSY)
3194879|NCT00832962||2|Adult Rh negative pregnant patients from 6 selected centers (Tenon hospital, Jean VERDIER Hospital, La Pitie-Salpetriere Hospital, Cochin Hospital, Robert Debre Hospital, BICHAT Hospital)
3194880|NCT00832988||Pacemaker patients|Patients who are implanted with a SJM Zephyr™ DR device for a standard pacing indication will be eligible
3194881|NCT00833001||1|GYNECARE PROLIFT+M* Pelvic Floor Repair System
3194882|NCT00833014|Experimental|I|
3194883|NCT00833066|Placebo Comparator|Placebo|
3194884|NCT00833066|Experimental|gpASIT 25|
3194885|NCT00833066|Experimental|gpASIT 100|
3194886|NCT00833066|Experimental|gpASIT 400|
3194887|NCT00833079|Experimental|Tacrolimus 0.1% Taro|Tacrolimus 0.1% manufactured by Taro applied for 14 days
3194888|NCT00833079|Active Comparator|Protopic - Tacrolimus 0.1%|Protopic, Tacrolimus 0.1% applied for 14 days
3194889|NCT00833079|Placebo Comparator|Vehicle|Tacrolimus vehicle applied for 14 days
2492879|NCT02950116|Active Comparator|Cystic fibrosis|Patients with cystic fibrosis will perform three multiple breath nitrogen washout tests (N2-MBW-test)
3194890|NCT00833118||Intubation|
3194891|NCT00833131|Experimental|1|25 Gy in 5 fractions of 5 Gy over 5 days. One week interval. Consolidating chemotherapy of 3 courses of FOLFOX4. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of fluorouracil.
2492932|NCT02949557|Active Comparator|Decortication +DFDBA|After phase 1 therapy patients were assigned for decortication+ DFDBA group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
2492933|NCT02949557|Active Comparator|Decortication+ Xenograft (Cerabone)TM|After phase 1 therapy patients were assigned for decortication+ xenograft (Cerabone)TM group. Mucoperiosteal flaps were reflected. After open flap debridement, decortication was performed and DFDBA graft was placed in the treatment of intrabony defects.
2492988|NCT02949479|Other|Dissociation Investigation in Sex Offenders|The study will be proposed to the subjects after their usual clinical evaluation in the center for sexual offence, and to extend this evaluation by a specific focus on childhood abuse and neglect, trauma and dissociative history
2493063|NCT02949076|Experimental|Exercise|Lung cancer patients will undergo unilateral resistance exercise 3 times per week for 8 weeks during cancer treatment, while the other leg remains unexercised and will serve as a within-subject control.
2493106|NCT02948556||Chronic fatigue syndrome|Participants with chronic fatigue syndrome
2493172|NCT02948218|Active Comparator|Shanghai Longhua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2493180|NCT02948218|Active Comparator|Shanghai Guanghua hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2493183|NCT02948218|Active Comparator|Huadong hospital of Fudan University|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2493186|NCT02948218|Active Comparator|Shanghai Yueyang Integrated hospital|Acupuncture treatments will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
2493264|NCT02947672|Active Comparator|Intravenous dexamethasone|50 patients will receive intravenous dexamethasone
2493266|NCT02947672|Active Comparator|Intra peritoneal dexamethasone|50 patients will receive intraperitoneal dexamethasone
2493294|NCT02947165|Experimental|NIS793|
2493295|NCT02947165|Experimental|NIS793 + PDR001|
2493367|NCT02946840||Solid pancreatic masses|Consecutive patients with solid pancreatic masses, submitted to FNA with 25 G Beacon needle (Medtronic, Newton, MA, USA)
2493536|NCT02945488|Experimental|Exercise and dietary plan|Combination cardiovascular and resistance training and Mediterranean dietary plan
2493539|NCT02945488|Experimental|Exercise and no dietary plan|Combination cardiovascular and resistance training and participants regular diet (control diet)
2493543|NCT02945488|Experimental|Stretching and dietary plan|Flexibility training (control exercise) and Mediterranean dietary plan
2493546|NCT02945488|Active Comparator|Stretching and no dietary plan|Flexibility training (control exercise) and participants regular diet (control diet)
2493602|NCT02945020|Experimental|Dabigatran etexilate mesylate+Odalasvir+Simeprevir|All participants will receive study medications in a fixed sequential order as: a single dose of dabigatran etexilate mesylate 75 milligram (mg) on Days 1, 17 and 26; Odalasvir (ODV) 25 mg once daily from Day 4 to 28; Simeprevir (SMV) 75 mg once daily from Day 20 to 28. The study drugs will be taken orally.
2493639|NCT02945033|Placebo Comparator|Patient with placebo intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
2493675|NCT02944643|Experimental|Active group|Will get the mindfulness and support groups
2493686|NCT02944292|Experimental|All enrolled patients|"Study population:~Adult, mechanically ventilated patients with IAP between 12 and 20 mmHg in at least two consecutive measurements, spontaneous breathing activity of at least 6 breaths/minute, RASS score between 0 and -4, if no contraindications to propofol administration are present and no other immediate interventions to reduce IAP are planned~Intervention: Deepening of sedation Deepening of sedation will be achieved with a bolus of propofol followed by continuous infusion for one hour."
2493710|NCT02944318|Experimental|"The Movement Program"|The intervention program was structured according three main components: (1) training and activities in general curriculum and Physical Education classes; (2) active facilities in the school environment; (3) health education in school community.
2493745|NCT02944058|Active Comparator|Philos plate|Intervention is surgery with Philos plate
2493746|NCT02944058|Active Comparator|Multiloc nail|Intervention is surgery with Multiloc nail
3161746|NCT00447967|Experimental|2|FLOX
3161747|NCT00447980|Experimental|1 NT-501 implant|High Dose
3161748|NCT00447980|Experimental|2 NT-501 implant|Low Dose
3161749|NCT00447993|Experimental|1 NT-501|High Dose Implant
3161750|NCT00447993|Experimental|2 NT-501|Low Dose Implant
3161751|NCT00448045|Experimental|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough peak flow. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough peak flow. Subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
3194892|NCT00833131|Active Comparator|2|Conventionally fractionated chemoradiation with 50.4 Gy total dose in 28 fractions of 1.8 Gy over 5.5 weeks. Surgery 10-11 weeks from beginning of radiation and at least 4 weeks from the last dose of radiation.
3194893|NCT00833144||1|Congestive Heart Failure
2492971|NCT02949531|Active Comparator|21% oxygen|room air will be delivered via Venturi mask during cycle ergometry
2492973|NCT02949531|Active Comparator|28% oxygen|28% oxygen will be delivered via Venturi mask during cycle ergometry
2492975|NCT02949531|Active Comparator|40% oxygen|40% oxygen will be delivered via Venturi mask during cycle ergometry
2493016|NCT02949180||AF|Five minutes puls wave recording will be performed in patients in atrial fibrillation at time of recruitment
2493018|NCT02949180||SR|Five minutes puls wave recording will be performed in patients in sinus rhythm at time of recruitment
2493131|NCT02948309|Experimental|Mistletoe extract (Iscador Qu)|Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg
2493132|NCT02948309|Placebo Comparator|Placebo|isotonic saline solution, subcutaneous use 3 injections/week
3194894|NCT00833144||2|Patients without congestive heart failure
2493203|NCT02947646|Experimental|BabyGentleStick™ ON|Experimental intervention to be compared to the Active Comparator.
2493205|NCT02947646|Active Comparator|BabyGentleStick™ OFF|Active Comparator intervention to be compared to the Experimental Treatment.
2493276|NCT02947438|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
2493277|NCT02947438|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form: Injection Strength: 2000IU, 3000IU, 4000IU~Frequency and Dosage: Intravenously injection 1-3 times a week for a period of 52 weeks."
2493344|NCT02946970|Placebo Comparator|Control|Intragastric infusion
2493349|NCT02946970|Experimental|Quinine hydrochloride|Intragastric infusion
2493409|NCT02946619|No Intervention|Control Condition|Participants in the control group were asked to write for three weeks about facts regarding their cancer and its treatment for three sessions.
2493424|NCT02946619|Experimental|Self-regulation condition|For the self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; in session two, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2493431|NCT02946619|Experimental|Enhanced self-regulation condition|For the enhanced self-regulation condition, each weekly writing assignment covers a different task. During session one, participants will be asked to write about their coping strategies to deal with stressors associated with the cancer diagnosis and treatment, as well as future plans for coping with cancer-related stressors; during session two, participants will be asked to write about their deepest feelings and thoughts regarding their experience with breast cancer as well as its impact on their lives; and in session three, participants will be asked to write about positive thoughts and feelings regarding their experience with breast cancer.
2493483|NCT02946099|Experimental|Reciproc file|Reciproc files in reciprocating motion
2493485|NCT02946099|Active Comparator|ProTaper Next file|ProTaper Next files in continuous rotary motion
2493503|NCT02945722|Active Comparator|Decolonization|persistent carriers will be decolonized. Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days.
2493508|NCT02945722|Placebo Comparator|No decolonization|HD patients in which decolonization is not performed including impersistent carriers.
2493572|NCT02945332|Experimental|Required supervised walking|Device: Fitbit Flexes
2493574|NCT02945332|Active Comparator|Non-required supervised walking|Device: Fitbit Flexes
2493637|NCT02944916|Experimental|IryPump R Set|A new set for transanal irrigation composed by 2 parts : 1 pump and 1 rectal catheter . 1 rectal catheter used per irrigation respecting the patient usual frequency of transanal irrigation
2493696|NCT02944396|Experimental|Veliparib and nivolumab with platinum doublet chemotherapy|Veliparib and nivolumab in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
2493701|NCT02944396|Experimental|Veliparib with platinum doublet chemotherapy|Veliparib in combination with platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed)
3194895|NCT00833157|Experimental|Glucosamine|
2493791|NCT02943863|Active Comparator|HFNC first|"Patients in HFNC first receive oxygen therapy using HFNC in ahead of conventional nasal cannula oxygen therapy. After 20 minutes of HFNC therapy, patients receive conventional nasal cannula oxygen therapy."
3194896|NCT00833157|Experimental|Ibuprofen|
3194897|NCT00833157|Placebo Comparator|Placebo|
3194898|NCT00833183|Active Comparator|25 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
3194899|NCT00833183|Active Comparator|37 J/cm2, with occlusion on right side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
3194900|NCT00833183|Active Comparator|25 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to either 25 J/cm2 of red light starting with the occluded side first.
2492953|NCT02949739|No Intervention|Usual Care|"The investigators will recruit 3,600 South Asian men and women aged 40-70 years with i. central obesity (waist≥100 cm) and/or ii. prediabetes (HbA1c 6.0-6.4%) to the study.~Recruitment will be from the Indian subcontinent (India, Pakistan, Sri Lanka) and Europe (UK). Index cases will receive either i. intensive lifestyle modification (N=1,800); or ii. usual care (N=1,800).~Usual care group will comprise one diabetes prevention session and written material."
2493046|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes, endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological results obtained by EBUS-TBNA."
2493088|NCT02948673|Placebo Comparator|Control|4 placebo tablets/day (2 in the morning and 2 in the evening)
2493090|NCT02948673|Active Comparator|Glutathione|4 oral GSH tablets/day (2 in the morning and 2 in the evening)
2493126|NCT02948361|Experimental|QT Ultrasound breast scan|
2493158|NCT02948166|Active Comparator|Stenting of the femoral artery|A standard endovascular treatment of the steno-occlusive lesion in femoro-popliteal arterial segment.
2493170|NCT02948166|Experimental|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomnyh wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial bed is performed intraoperatively by X-ray angiography.
2493219|NCT02947724|No Intervention|drainage only|50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
2493226|NCT02947724|No Intervention|cystectomy only|50 patients underwent laparoscopic excision of the endometrioma cyst wall
2493238|NCT02947724|Active Comparator|drainage & Surgicel|50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
2493253|NCT02947724|Active Comparator|cystectomy & Surgicel|50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
2493312|NCT02947256|Active Comparator|standard laparoscopic cholecystectomy|This included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery.
2493316|NCT02947256|Experimental|RI approach|"Retroinfundibular laparoscopic cholecystectomy: This included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.~Operative procedure of by RI approach:"
2493376|NCT02946801|Active Comparator|Essential oils mouthwash|20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1).
2493378|NCT02946801|Experimental|essential oils without mouthwash|20 mL rinses for 30 seconds with essential oils without alcohol/2 times daily (1/0/1)
2493381|NCT02946801|Sham Comparator|sterile water mouthwash|20 mL rinses for 30 seconds with sterile water/2 times daily (1/0/1)
2493400|NCT02946346|Experimental|Vaginal and blood sampling|
2493490|NCT02945683|Active Comparator|Reuterin D3|Patients should take 10 drops once a day during meals for 3 months
2493494|NCT02945683|Placebo Comparator|Placebo|Patients should take 10 drops once a day during meals for 3 months
2493542|NCT02945605|Experimental|Early Vestibular Rehabilitation|Participants in this group will receive a customized vestibular rehabilitation program designed and implemented by a vestibular physical therapist. The vestibular physical therapy must be initiated within 72 hours after randomization. Participants in this group will continue to receive standard of care treatment as directed by their physician.
2493545|NCT02945605|Active Comparator|Standard of Care|Participants in this group will receive standard care as directed by their physician.
3161752|NCT00448045|Active Comparator|Incentive spirometry|The active control group will consist of individuals assigned to the oximetry with incentive spirometry group. These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
3161753|NCT00448058|Experimental|GSK372475|flexible-dose design from GSK372475 1.0 mg/day to GSK372475 2.0 mg/day
3161754|NCT00448058|Active Comparator|Venlafaxine|Flexible- dose design from Venlafaxine XR 75 mg/day to Venlafaxine XR 225 mg/day
2493703|NCT02944474|Experimental|Cohort 4 (1000 mg)|Six subjects received 1 g of lucerastat for 7 consecutive days in fasting conditions
2493711|NCT02944474|Placebo Comparator|Placebo cohorts 1 to 4|Twelve subjects received matched placebo (3 subjects per cohort, except for Cohort 3 where 4 subjects received placebo)
2493765|NCT02943759|Experimental|Neem leaf extract|Neem leaf extract (alcoholic solution) used as an anti inflammatory , antibacterial irrigant
2493769|NCT02943759|Active Comparator|Chlorhexidine gluconate|2% chlorhexidine gluconate intracanal irrigant solution used as an antibacterial chemical mean for canal irrigation
2493850|NCT02943538|Experimental|Telemedicine group|In this group, monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
2493853|NCT02943538|Experimental|Telephone support group|A telephone control of their state and evolution will be made through the nursing staff of the unit.
2493857|NCT02943317|Experimental|Part A: VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
2493864|NCT02943538|Active Comparator|Control group|Conventional care provided in the unit to patients with IBD -high moderate complexity.
3161755|NCT00448058|Placebo Comparator|placebo|
3161756|NCT00448097|Other|Data not available PI relocated|No verifiable data available, PI relocated
3161757|NCT00448110|Experimental|A|intravenous diclofenac dosage level 1
3161758|NCT00448110|Experimental|B|intravenous diclofenac dosage level 2
3161759|NCT00448110|Active Comparator|C|intravenous ketorolac
3161760|NCT00448110|Placebo Comparator|D|placebo
3161761|NCT00448149|Experimental|1|To establish the maximally tolerated dose (MTD) of RAD001 in combination with Nexavar®
3161762|NCT00448214|Experimental|1|Low dose
2492983|NCT02949232|Experimental|Prednisolone|Prednisolone will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following treatment guidelines for Inflammatory Bowel Diseases (2008).
2492984|NCT02949232|Placebo Comparator|Placebo Oral Tablet|Placebo will be initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start, following the treatment schedule of the experimental arm
2493035|NCT02948972|Experimental|complete surgery|Prior surgery 3 months before IVF followup 1, 6 12 and 24 month after surgery
2493037|NCT02948972|Active Comparator|In vitro fertilization without surgery|IVF without endometriosis surgery follow up 6, 12 and 24 month after inclusion.
2493056|NCT02948764|Other|single-arm study|This project is designed as a one-armed diagnostic study. Every patient included in the study will undergo the same diagnostic test, the vacuum-assisted biopsy, after NACT and before surgery according to guidelines.
2493104|NCT02948517|Experimental|Time restricted feeding|Time restricted feeding
2493114|NCT02948517|No Intervention|Control|No intervention
2493144|NCT02948114|Active Comparator|Control: Cow milk-based infant formula|Cow milk-based infant formula
2493146|NCT02948114|Experimental|Experimental 1: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics
2493147|NCT02948114|Experimental|Experimental 2: Cow milk-based infant formula|Cow milk-based infant formula with probiotics
2493148|NCT02948114|Experimental|Experimental 3: Cow milk-based infant formula|Cow milk-based infant formula with prebiotics and probiotics
2493149|NCT02948114|No Intervention|Human Milk Reference|Human Milk Reference
2493240|NCT02947802|Experimental|Consumer Support|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale.
2493252|NCT02947802|Experimental|Consumer Support with Effectiveness Info|Participants will be presented with three labels: a calorie label, a textual warning label and a textual warning label with corresponding graphic images and will be asked to rate their support for each label on a 1 (not at all) to 7 (a great deal) scale. Participants will also receive effectiveness information- how each label influenced the purchasing of sugar sweetened beverages- from a recent field experiment.
2493345|NCT02947308||Adolescents with NSSI|12-16 year old females who have a history of non-suicidal self-injury are included in this cohort. No interventions will be administered.
2493350|NCT02947308||Healthy Controls|12-16 year old females with no history of non-suicidal self-injury are included in this cohort.
2493377|NCT02946658|Experimental|Lipoaspiration Arm 1|Acquisition of Adipose-Derived tissue Stromal Vascular Fraction (AD-tSVF) via closed syringe harvest subdermal fat
2493379|NCT02946658|Experimental|AD-cSVF Arm 2|Isolation of cellular stem/stromal cells from subdermal adipose-derived cellular stromal vascular fraction (AD-cSVF)
2493382|NCT02946658|Experimental|Normal Saline IV Arm 3|Normal Saline IV with AD-cSVF cells
2493396|NCT02946333||Patient with MM who are not candidates for ASCT|Patients with newly diagnosed MM who are not candidates for ASCT and who are going to start drug treatment for the study disease and patient who is capable of understanding and filling in the study questionnaires At least 450 patients will be enrolled in a 2-year period. Patients must meet all of the inclusion criteria and none of the exclusion criteria and must have previously granted their informed consent in writing.
2493500|NCT02945696|No Intervention|Local port site injection|
2493505|NCT02945696|No Intervention|Ultrasound-guided nerve blocks|
2493509|NCT02945696|Experimental|Laparoscopic guided nerve blocks|These patients will receive the same volume of local anesthetic as those in the ultrasound-guided arm, but the delivery of the local anesthetic will be guided by laparoscopy.
2493657|NCT02944747|Experimental|Education & paper based calendar|"The participants will be counseled on importance of remembering LMP. In addition, a free calendar will be provided to the participant who will be asked to record menstrual bleeding and spotting dates in each month. The women will be asked to record no bleeding if she did not bleed for any particular month. Likewise, if anybody forgets to record, she will ask to keep a record of it in the subsequent month. Female counselors from the study team will conduct the group or individual education sessions."
2493660|NCT02944747|Experimental|Education & SMS system|Cell-phones will be provided free of cost to participants who will be asked to text the bleeding dates of their menstruation and spotting every month within 3 days of the start of the bleeding. Study team will collaborate with a mobile phone company and the charge of SMS for reporting LMP dates will be free for the user. In situations, where the participant fails to text, she will be provided with several SMS reminders after the due date.
2493665|NCT02944747|Experimental|Education & smart-phone application|Smart phones with an application and an inbuilt reminder system will be provided free of cost to participants who will be asked for recording menstruation dates. Experienced programmer from icddr,b will be involved in developing the application. Again, participants will be asked to record bleeding dates each month and will upload the data in the central server via internet. If participants fail to record the dates and upload the data, an automatic reminder will be sent.
2493668|NCT02944747|No Intervention|Comparison|The participants will not receive any of the interventions that are focused in this study.
2493714|NCT02944318|No Intervention|No intervention|"Schools in the control group will maintain a regular academic year with conventional activities. Thus schools have two weekly Physical Education classes which are organized by according to the perspective of their teachers. Besides that, the Program Saúde na Escola is also performed."
2493738|NCT02944032|Experimental|Cogmed|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
3161763|NCT00448214|Experimental|2|Middle dose
3161764|NCT00448214|Experimental|3|High dose
3161765|NCT00448214|Active Comparator|4|
3161766|NCT00448253|Experimental|1|Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA. And a Fourth Cohort at 840 units TNA with 2 additional product lots.
2493047|NCT02948803|Experimental|Intervention group|smartphone based intervention with Active Coach app: participants in the intervention group will use a newly developed smartphone app in combination with a Fitbit Charge activity tracker for 9 weeks. The app aims to promote an active lifestyle.
2493049|NCT02948803|No Intervention|control group|participants in the control groups only receive a flyer with standard information about an active lifestyle
2493097|NCT02948660|Other|acute consciousness disorders group|"Duration time of coma <= 3 weeks.~This group will receive sleep EEG monitoring, serum melatonin and orexin level testing, and Zolpidem Tartrate Tablets or melatonin treatment."
2493098|NCT02948660|Other|chronic consciousness disorders group|"Duration time of coma > 3 weeks.~This group received sleep EEG monitoring, serum melatonin and orexin testing, and Zolpidem Tartrate Tablets or melatonin treatment."
2493157|NCT02948179|Experimental|Preimplantation genetic diagnosis group|ADPKD patients will complete the whole process of preimplantation genetic diagnosis with healthy baby without pathogenic gene inheritance.
2493173|NCT02948179|No Intervention|Natural pregnancy group|ADPKD patients, pathogenic mutations in PKD1, have natural pregnancy without preimplantation genetic diagnosis.The investigators will perform genetic tests on the blood or umbilical cord blood of infants born between January 2014 and June 2020.
2493210|NCT02947542|Experimental|BLK catheter|Coronary angiography will be performed with the BLK catheter (one-catheter concept).
2493212|NCT02947542|Experimental|Tiger catheter|Coronary angiography will be performed with the Tiger catheter (one-catheter concept).
2493213|NCT02947542|Active Comparator|Judkins catheter|Coronary angiography will be performed with the Judkins catheter (standard catheter).
3161767|NCT00448253|Placebo Comparator|2|Saline (equal volume to 210 U, 420 U, or 840 U TNA dose)
2493352|NCT02946983|Active Comparator|Fructose - Neutral emotion condition|Intragastric infusion of fructose with neutral emotion induction
2493354|NCT02946983|Active Comparator|Fructose - Sad emotion condition|Intragastric infusion of fructose with sad emotion induction
2493357|NCT02946983|Placebo Comparator|Placebo - Neutral emotion condition|Intragastric infusion of distilled water with neutral emotion induction
2493359|NCT02946983|Placebo Comparator|Placebo - Sad emotion condition|Intragastric infusion of distilled water with sad emotion induction
2493421|NCT02946554|Other|Low dose cohort|"Two dose regimens of HepaStem will be given, which differ in the amount of cells per infusion.~The low dose regimen will be given to the first cohort (first 6 patients included in the study)."
2493433|NCT02946554|Other|High dose cohort|The high dose regimen will be given to the second cohort after evaluation of the safety of the 1st cohort (stepwise approach)
2493644|NCT02945189||Peri menopausal|Participants aged 41-55 years
2493651|NCT02945189||post menopausal|participants aged 56-65 years
2493725|NCT02944526|Placebo Comparator|Placebo Suprascapular Nerve Block|"Suprascapular nerve block realized in sterile conditions under live ultrasound guidance: injection of 5ml of physiological /isotonic saline.~3 successive blocks are realized at 1 week interval."
2493726|NCT02944539||Gastric cancer group|300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
2493732|NCT02944539||Control group|The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2493752|NCT02944045|Placebo Comparator|Placebo|Saline serum, same volume as in the Experimental arm.
2493753|NCT02944045|Experimental|Steroids|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
2493777|NCT02943993||Patients treated with Edoxaban|Patients with established acute initial or recurrent VTE treated with edoxaban according to Summary of Product Characteristics (SmPC). Physician's prescribing behaviour will not be influenced, patients may only be included after the treating physician has made the clinical decision to prescribe edoxaban.
2493780|NCT02943694|Experimental|TaTME with CS-Compact (GelPoint Path)|Based on newly-designed devices tailored for transanal TME, CS-Compact, GelPoint and Octoport are employed for the clinical applications.
2493870|NCT02943551|Other|Providers|"Physicians, pediatric nurse practitioners and physician assistants (referred to as providers from here forward) will be recruited from 20 practices, with a maximum of four providers participating from a single practice, for a maximum of 80 providers.~Providers will receive an online tutorials, interactive group webinars, simulated booster sessions as well as feedback reports."
2493876|NCT02943551|Other|Parents|"The number of parents who participate will depend on the number of providers who agree to participate at each of the 20 practices. The total could range from a minimum of 1800 parents to a maximum of 7200 parents.~Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit."
2493978|NCT02942459|Active Comparator|Music Listening|"25 Weekly Hours of Being together with an unknown Care Staff Member listening to Music from selected Play-Lists. Music Therapists at the Music Therapy Research Clinic at Aalborg University Hospital, Psychiatry have developed Play-Lists in a Taxonomy from very Supportive to less Supportive Music including around 100 Hours of Music all together on the Lists.~A Manual is created and trained with the Care Staff Members. Here the Activities are much more limited (only Music Listening to the Play-Lists are allowed). No Therapeutical Conversation is allowed."
2493992|NCT02942537|Experimental|Intervention|Microwave treatment
2493996|NCT02942537|Active Comparator|Control|Uterine artery embolization
2494000|NCT02942602|Experimental|Atorvastatin 20 mg|lipid lowering treatment
2494002|NCT02942602|Experimental|Cholestyramine 8 g|lipid lowering treatment
2494004|NCT02942602|Experimental|Omega-3 (EPA+DHA) 2 g|lipid lowering treatment
3161768|NCT00448266|Experimental|2|1 course ddAc, 2 courses IAA with PBPC support
3161769|NCT00448266|Active Comparator|1|3 courses ddAC
3161770|NCT00448292|Experimental|1|PRX-00023 taken twice daily, escalating from 40 mg to 80 mg to 120 mg
3161771|NCT00448292|Placebo Comparator|2|Placebo taken twice daily, escalating from 40 mg to 80 mg to 120 mg
3161772|NCT00448305|Experimental|1|EndoTAG-1 + Paclitaxel
3161773|NCT00448305|Experimental|2|EndoTAG-1
3161774|NCT00448305|Active Comparator|3|Paclitaxel
2493065|NCT02948842|Placebo Comparator|Control Group|On day of treatment, patients will undergo instillation of local anesthesia (20 mL of 2% urethral lidocaine jelly), the patient will undergo cystoscopy, transurethral injection (via a 70 cm 4.8 Fr flexible cystoscopic needle with a 23 gauge needle tip manufactured by Laborie®, Ontario, Canada) of 0.08ml of injectable normal saline. The depth and location of the needle will be determined pre-procedurally with urethral ultrasonography with the needle in a semi-parallel manner into the plaque as to avoid perforation into nearby structures. Injections will be performed at a single site.
2493160|NCT02947958|Experimental|Teleconsultation|Tele consultation (experimental) - after the randomization the patient is guided to seek primary care under teleconsultation supervision to keep his treatment. One year later the patient's symptoms are reassessed in a medical consultation.
2493171|NCT02947958|Active Comparator|Hospital|Hospital (control) - after the randomization the patient is guided to keep his treatment in the tertiary care as usual. One year later the patient's symptoms are reassessed in a medical consultation.
2493208|NCT02947698||Acute kidney injury patients admitted on weekday|All patients with acute kidney injury requiring dialysis admitted on week day (Monday to Friday) between 1st April 2003 and 31st March 2015
2493209|NCT02947698||Acute kidney injury patients admitted on weekend|All patients with acute kidney injury requiring dialysis admitted on weekend (Saturday or Sunday) between 1st April 2003 and 31st March 2015
2493300|NCT02947451|Experimental|Manual therapy|In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee, in a single application.
2493302|NCT02947451|Experimental|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application.
2493337|NCT02946879||Low dose AAV OPTIRPE65|subretinal administration of a single low dose of AAV RPE65
2493343|NCT02946879||Intermediate dose AAV OPTIRPE65|subretinal administration of a single intermediate dose of AAV RPE65
2493347|NCT02946879||High dose AAV OPTIRPE65|subretinal administration of a single highdose of AAV RPE65
2493416|NCT02946593|Experimental|Treatment|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/problem solving, practice in strategy use, and action planning for safe community mobility.
2493427|NCT02946593|Active Comparator|Control|Participants in the control group will receive written information about preventing outdoor falls.
2493480|NCT02946151|Experimental|Implantation|Implantation of a subcutaneous electrode and connection to the external logging device
2493568|NCT02945293||Study Procedures|Study procedures include a screening visit, a study day visit, and a follow-up phone call. Oxycodone is administered on the study day.
2493599|NCT02944942||Postoperative nausea and vomiting|Group 1: Patients undergoing general anesthesia with postoperative nausea and vomiting Group 2: Patients undergoing general anesthesia without postoperative nausea and vomiting
2493661|NCT02944708|Active Comparator|Conventional chemotherapy|Patients in this arm will only receive 4-8 cycles of cisplatin-based regimen. TPF ( docetaxel, cisplatin and 5-fluorouracil ), TP (docetaxel and cisplatin), GP (gemcitabine and cisplatin) and PF (cisplatin and 5-fluorouracil) regimens are preferred.
2493666|NCT02944708|Experimental|Maintenance chemotherapy 1|Patients in this arm will receive 6 cycles of oral fluoropyrimidine monotherapy as maintenance therapy, in addition to 4-8 cycles of cisplatin-based standard chemotherapy.
2493670|NCT02944708|Experimental|Maintenance chemotherapy 2|Patients in this arm will receive oral fluoropyrimidine maintenance therapy until disease progression or intolerable toxicities, after 4-8 cycles of cisplatin-based standard chemotherapy.
2493693|NCT02944214|Experimental|Febuxostat|take orally,10-80mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
2493698|NCT02944214|Experimental|Benzbromarone|take orally,12.5-100mg per day, for 1 year,start with a low dose, and adjust the dose according to the level of uric acid
2493796|NCT02943876|No Intervention|Control|Serves as a control group, receiving generic information about depression and self-help.
2493803|NCT02943876|Experimental|Intervention|Serves as an intervention group, receiving personalized depression risk information determined by the sex-specific risk calculators, and generic information about depression and self-help.
2493819|NCT02943655|Active Comparator|combined oral contraceptives|oral second generation pills one tablet daily
2493820|NCT02943655|Active Comparator|medroxyprogesterone acetate|oral 5 mg daily
2493821|NCT02943655|Active Comparator|non-steroidal anti-inflammatory|oral 500 mg mefenamic acid three times per day
2493835|NCT02943304||Exposed|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
2493839|NCT02943408|Experimental|person-centered mental health intervention (PCMHI)|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
2493844|NCT02943304||Unexposed|Asymptomatic pregnant women with a negative RT-PCR ZIKV in serum and urine, and a negative specific serology for ZIKV at enrollment into the study and at the time of delivery
2493845|NCT02943408|Active Comparator|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
2493913|NCT02942940|Active Comparator|mobile app|
2493093|NCT02948699|No Intervention|Regular diet|Regular diet without other nutritional intervention.
2493116|NCT02948374||Delirium positive|Patients with a positive CAM-ICU test
2493123|NCT02948374||Delirium negative|Patient without delirium determined with the CAM-ICU test
2493150|NCT02948127|Experimental|RSV LID cp ΔM2-2 Vaccine|Participants will receive a single dose of the RSV LID cp ΔM2-2 vaccine at study entry (Day 0).
2493152|NCT02948127|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
2493227|NCT02947750|Experimental|Exercise training + 6R-BH4|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
2493239|NCT02947750|Active Comparator|Exercise training + 6R-BH4 placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the study drug 6R-BH4.
2493250|NCT02947750|Active Comparator|Stretching + 6R-BH4|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take the study drug 6R-BH4.
2493254|NCT02947750|Placebo Comparator|Stretching + placebo|Participants randomized to this arm will do muscle stretching and toning for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo instead of the active study drug.
2493258|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take histidine and beta-alanine supplementation.
2493262|NCT02947750|Active Comparator|Exercise training + histidine and beta-alanine placebo|Participants randomized to this arm will exercise on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. This arm will also take a placebo to match the histidine and beta-alanine supplementation.
2493324|NCT02947087|Active Comparator|Prolastin-C|Subjects will be given Prolastin-C intravenously at 60mg/kg weekly for 4 weeks.
2493325|NCT02947087|Placebo Comparator|Placebo|Subjects will be given Saline weekly for 4 weeks.
2493380|NCT02946697|No Intervention|Enhanced care and wait-list control group|Participants in the control group will receive enhanced usual care while waiting for the JLA program. Participants will be given information booklets in Chinese developed by the American Cancer Society and cover common issues related to breast cancer, various treatments, and life after treatment. Participants will be asked to read through the booklet individually.
2493383|NCT02946697|Experimental|Social support intervention group|The intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
2493399|NCT02946359|Experimental|Patients with ALK translocation|Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2493401|NCT02946359|Experimental|Patients with ROS1 translocation|Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2493403|NCT02946359|Experimental|Patients with MET amplification|Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
2493465|NCT02946125|Experimental|MDD-administered EYN-1601|EYN-1601 Ophthalmic Solution administered using the Eyenovia MDD
2493474|NCT02946125|Active Comparator|Phenylephrine 2.5% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 2.5% administered as an eyedrop
2493478|NCT02946125|Active Comparator|Phenylephrine 10% Eyedrop|Phenylephrine Hydrochloride Ophthalmic Solution 10% administered as an eyedrop
2493488|NCT02945761|Active Comparator|High concentration of sugar solution|Lavage group of high-concentration sugar solution (HCSS): disinfected the Skin outside wound with conventional PVP. HCSS refers to supersaturated sugar solution made of 50% high-concentration glucose and white sugar. Prior to wound irrigation, dry cotton balls are used to wipe the wound and internal lacuna, to clean some necrotic tissues out of the wound. HCSS is applied on the wound once a day, and whether the lavaging is stopped based on the amount of exudation from the wound.
2493489|NCT02945761|Active Comparator|conventional surgical dressing change|conventional surgical dressing change:separated suture, expanded the wound, placed drainage ribbon gauze and used hydrogen peroxide or(and) PVP to wash the wound; the decision-making power of these operators is determined by a doctor. After the doctor confirms granulation cleaning in the wound, the decision-making power of suture is also determined by a doctor.
2493529|NCT02945644|Placebo Comparator|Placebo|pill filled with inert material
2493530|NCT02945644|Active Comparator|Trazodone 50mg|
2493531|NCT02945644|Active Comparator|Trazodone 100mg|
2493638|NCT02945033|Experimental|Patient with aspirin intake|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines. Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece. If the mutation is detected, patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years. Blood intake will be done every 6 months to evaluate patient compliance to treatment
2494069|NCT02941965|Experimental|ICSI without PGS|Selection of embryos are based on blastocyst morphology criteria on day 5. A maximum of 2 embryos will be transferred for each treatment cycle.
2493105|NCT02948543|Experimental|Treatment (Arm B):Intravesical BCG + MMC|"Induction (weekly x 9); and followed by Maintenance (monthly x 9) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study.~Dosage of Mitomycin (MMC) fixed at 40mg per instillation."
2493113|NCT02948543|Other|Treatment (Arm A): Intravesical BCG|"Induction (weekly x 6); and followed by Maintenance (monthly x 10) beginning 3 months after randomisation.~Dosage of Bacillus of Calmette-Guerin (BCG) dependent on preferred brand of BCG by participating institution. Either 2-8 x 10^8 CFU for OncoTICE or, 81mg for ImmuCYST and TheraCys. Prior to treatment commencement, investigators should nominate which BCG brand will be used. The same brand of BCG must be used for all treatment administered to an individual participant throughout the study."
3194901|NCT00833183|Active Comparator|37 J/cm2 , with occlusion on left side|Subjects will receive MAL cream in a thin layer on both sides of the face (except nose and peri-ocular area) at a concentration of 80 mg/g). Occlusion will be applied to one half of the face. After an incubation time of 90 minutes both sides of the face will be exposed to 37 J/cm2 of red light starting with the occluded side first.
3194902|NCT00833209|Experimental|1|Patients with Medication Overuse Headache (MOH)
2493222|NCT02947477|Experimental|Treatment|The EMA intervention uses twice-a-day interactive questions for emotion tracking including type of emotion, intensity of emotion, trigger to emotion and response to emotion through an Iphone app designed for the study. The study users receive individualized feedback about their daily reporting of emotions, sleep and stress.The study tracking is for 14 days.
2493232|NCT02947477|No Intervention|Control|The control arm does nothing for 14 days and then receives the 14 day emotion tracking listed above.
2493279|NCT02947347|Experimental|(Part 1 : Arm A) ibrutinib + rituximab|"Subjects will receive 560mg of ibrutinib and rituximab 375mg/m^2 weekly x4 with maintenance.~In Part 1, Arm A to Arm B ratio is 3:1"
2493280|NCT02947347|Placebo Comparator|(Part 1 : Arm B) placebo + rituximab|"Subjects will receive placebo and rituximab 375mg/m^2 weekly x4 with maintenance.~In Part 1, Arm A to Arm B ratio is 3:1"
2493281|NCT02947347|Experimental|(Part 2 : Arm A1) ibrutinib|"Subjects will receive 560mg of ibrutinib~Part 1 Arm A subjects will be re-randomized 1:1 into Part 1 Arm A1 or Arm A2"
2493282|NCT02947347|Placebo Comparator|(Part 2 : Arm A2) placebo|"Subjects will receive placebo~Part 1 Arm A subjects will be re-randomized 1:1 into Part 2 Arm A1 or Arm A2"
2493457|NCT02946047|Experimental|Treatment group|Patients will be given at least one treatment cycle of Ixazomib.
2493513|NCT02945852|Experimental|refractory SCLC|Patients receive apatinib 500mg/d until progressive Disease(PD).
2493556|NCT02945436|Active Comparator|SOC + SOC|Participants will receive current standard of care (SOC) for HIV counseling, testing, and referral at both visit 1 and visit 2.
2493561|NCT02945436|Experimental|SOC + SUBI|Participants will receive SOC at visit 1 and the experimental substance use brief intervention (SUBI) at visit 2.
2493564|NCT02945436|Experimental|SUBI + SUBI|Participants will receive the SUBI at both visit 1 and visit 2.
2493566|NCT02945436|Experimental|SUBI + SOC|Participants will receive the SUBI at visit 1 and SOC at visit 2.
2493649|NCT02944929|Experimental|Self-rehabilitation program|Self-rehabilitation program + standard medical care (BTI + conventional physiotherapy)
2493656|NCT02944929|No Intervention|Control arm|Arm with standard medical care ( BTI + conventional physiotherapy) without self-rehabilitation program
2493740|NCT02944032|Active Comparator|MobyMax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
2493741|NCT02944162|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.
2493781|NCT02943850|Experimental|Stem cell implantation|Subjects meeting all Eligibility Criteria and providing Informed Consent will be enrolled in one of two sequential dosing groups (Group A and B). Subjects will be treated sequentially with a minimum of one month interval between surgeries for the first three subjects in each dosing cohort. The remaining subjects in the cohort will be treated with a minimum interval of at least one week between surgeries. There will be 9 subjects in each group. No control group is included. All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
2493782|NCT02943824|Experimental|Machine Learning Planning|Patients will be pre-operatively planned using a machine-learning computer program. An expert radiation oncologist will evaluate the plan prior to implantation. The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
2493786|NCT02943824|Active Comparator|Radiation Therapist Planning|Patients will be pre-operatively planned manually by an expert radiation therapist (> 60 cases planned). An expert radiation oncologist will evaluate the plan prior to implantation.The prescription dose is 145 Gy for monotherapy LDR brachytherapy.
3194903|NCT00833209|Sham Comparator|2|controls suffering from migraine
3194904|NCT00833209|Sham Comparator|3|controls without any neurological disease
2493855|NCT02943525|Experimental|packing|Patients after laparoscopic sacrocolpopexy with a vaginal packing at the end of surgery
2493865|NCT02943525|No Intervention|no packing|Patients after laparoscopic sacrocolpopexy without a vaginal packing at the end of surgery
2493935|NCT02942953||Diaphragmatic Pacer|Patient that have been proposed to diaphragmatic pacer placement at our institution.
2493972|NCT02942563|Experimental|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
2494163|NCT02941432|Other|Black tea|Black tea compress treatment
3194905|NCT00833222||Full Term Infants|Infants born between 37 4/7 weeks and 42 3/7 weeks gestation.
3194906|NCT00833222||Preterm Infants|Infants born between 32 4/7 weeks and 35 3/7 weeks gestation.
2493197|NCT02947906||Study group|Participants with multiple sclerosis who able to walk at least 30 meters independently.
2493198|NCT02947906||Control Group|Healthy participants
2493330|NCT02947412||sleeve gastrectomy|laparoscopic sleeve gastrectomy
2493393|NCT02946723|Experimental|US group|lead implantation surgery for SNM using ultrasound guided technique
2493394|NCT02946723|Sham Comparator|X-ray group|lead implantation surgery for SNM using X-ray guided technique
2493446|NCT02946268|Experimental|Volume of bolus|Ropivacaine 0.2% volume increased or decreased by 1ml based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient, the current patient will receive an increase in volume of bolus by 1ml. If pain is less than 5/10 in the previous patient the current patient will receive a decrease in volume by 1ml.
2493448|NCT02946268|Experimental|Rate of delivery of bolus|Ropivacaine 0.2% rate increased or decreased by 50ml/hr based on previous patient experience. If pain greater than or equal to 5/10 in the previous patient at 30 minutes, the current patient will receive an increase in rate of bolus by 50ml/hr. If the pain is less than 5/10 the rate will be decreased by 50ml/hr.
2493449|NCT02946268|Experimental|Interval between bolus|Ropivacaine 0.2% interval increased or decreased by 1 hour based on previous patient experience. If the previous patient received pain score of 2/10 at 2 hours then the current patient will have an interval of three hours. If the pain is greater than 2/10, the interval will be shortened by 1 hour.
2493496|NCT02945956|Placebo Comparator|Entecavir|Tablet with Entrcavir
2493499|NCT02945956|Experimental|Entecavir + Fuzheng Huayu|Tablet Tablet with Entrcavir+ Tablet with Fuzheng Huayu
2493550|NCT02945449|Experimental|Dose I|Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up.
2493622|NCT02945098|No Intervention|Control group|No intervention. Remained five minutes at rest.
2493626|NCT02945098|Placebo Comparator|Placebo group|Apply Kinesio Taping without tension.
2493628|NCT02945098|Experimental|KT group|Apply Kinesio Taping application with tension.
3161775|NCT00448331||positive screen, negative screen|Positive screens are those who received positive feedback regarding their answers to a mental illness screening assessment. Negative screens received feedback stating that they did not screen positive for any mental illness.
3161776|NCT00448383|Experimental|1|Open-label adalimumab
3161777|NCT00448396|Experimental|Patupilone|
2493831|NCT02943486|Experimental|dac-MSCs and Fitostimoline|Intradermic application of dac-MSCs (1 mL ) in four equidistant points around the ulcer (twice: day 0 and 7) and topical application of fitostimoline every other day
2493837|NCT02943486|Active Comparator|MSCs and Fitostimoline|Intradermic application of MSCs (500,000 cells/mL) in four equidistant points around the ulcer (once: day 0 ) and topical application of fitostimoline every other day
2493841|NCT02943486|Active Comparator|Fitostimoline|Topical application of fitostimoline every other day
2493895|NCT02943109|Experimental|High tech, high touch|Patient receives the full version of MyChart Bedside. Patient receives training/intervention from technology navigator
2493896|NCT02943109|Experimental|Low tech, high touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives training/intervention from technology navigator
2493897|NCT02943109|Experimental|High tech, low touch|Patient receives the full version of MyChart Bedside. Patient receives online training, only
2493898|NCT02943109|Experimental|Low tech, low touch|Patient receives the non-interactional version of MyChart Bedside. Patient receives online training, only
2493925|NCT02942823|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). Additionally, the intervention group will take the game home on a tablet computer to play it with their parents in between session 1 and 2. The game equips the children and their parents with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
2493928|NCT02942823|No Intervention|Control|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors. The parents are not involved.
2493991|NCT02942550|Active Comparator|Methylnaltrexone|Methylnaltrexone bromide (Relistor®). Single intravenous injection of 8 mg (0.4 ml solution) for patients weighing 38-61 kg or 12 mg (0.6 ml solution) patients weighing 62-114 kg).
2493994|NCT02942550|Placebo Comparator|Placebo|Sodium Chloride, 9mg /mL ingle intravenous injection of 0.4 mL solution for patients weighing 38-61 kg or 0.6 mL solution patients weighing 62-114 kg).
3161778|NCT00448409|Experimental|1|TroVax alone
3161779|NCT00448409|Experimental|2|TroVax plus GM-CSF
3161780|NCT00448422|Experimental|1|Tablet
3161781|NCT00448422|Placebo Comparator|2|Tablet
3161782|NCT00448461|Active Comparator|1|heparin
3161783|NCT00448461|Active Comparator|2|bivalirudin
3161784|NCT00448513|Experimental|catechin|catechin capsule group
3161785|NCT00448643|Experimental|Whole-Abdominal Radiation Therapy and Chemotherapy|
3161786|NCT00448721|Experimental|Perifosine|Perifosine will be administered orally at 100mg PO daily with food. One treatment cycle will consist of 42 days (6 weeks).
3161787|NCT00448734|Experimental|1|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
3161788|NCT00448734|Active Comparator|2|Docetaxel
3161789|NCT00448786|Other|Arm C|Arm C - AMG 706 75 mg BID 5-days on and 2-days off
3161790|NCT00448786|Other|Arm B|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
3161791|NCT00448786|Other|Arm A|Arm A = AMG 706 125 mg PO daily continuously
2493206|NCT02947516|Active Comparator|Percutaneous liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol.
2493207|NCT02947516|Experimental|EUS-guided liver biopsy|Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication.
2493341|NCT02946905||SCD participant|No intervention
2493346|NCT02946905||Non-SCD participant|No intervention
2493370|NCT02946684|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
2493371|NCT02946684|Active Comparator|Letrozole 5mg|2 tablets of 2,5mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 IU of recFSH
2493420|NCT02946411||Patients|The glucose of 48 patients will be measured during 5 days after cardiac surgery.
2493469|NCT02946177|Experimental|Influenza Vaccine|O.5 mL single dose influenza vaccine suspension administered intramuscularly
2493477|NCT02946177|Placebo Comparator|Saline Injection|O.5 ml of sterile Saline administered intramuscularly
2493493|NCT02945774|Experimental|(18F)-FEPPA|
2493533|NCT02945631|Experimental|Reduced Dose Radiation|All patients will receive daily radiation treatment with intensity-modulated radiotherapy (IMRT) - PTV56 and PTV50.4. Treatment will be given 5 days per week and will not routinely be delivered on Saturday, Sunday or major holidays unless a treatment is missed during the week due to technical and/or medical reasons. No more than 5 treatments should be given per week.
2493575|NCT02945267|Experimental|Nimotuzumab plus S1|Nimotuzumab Injection:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
2493577|NCT02945267|Active Comparator|Placebo plus S1|Placebo:400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks; S1:40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
2493645|NCT02944838|Active Comparator|Advocacy|"The Senior Change Makers Advocacy Program consists of weekly meetings, 1 hour each, for 8-weeks. The program will be led by graduate level students and will address topics such as how the environment affects walking, potential pedestrian hazards and solutions, how to conduct an audit of the walking environment, what advocates do, local examples of successful advocacy projects, creating an advocacy action plan, creating a fact sheet about the advocacy issue, writing letters to representatives, and making an advocacy presentation. The program will culminate with the presentation of the advocacy issue to a decision maker (e.g., a city planner, engineer, city council member, etc.)."
2493652|NCT02944838|Active Comparator|Physical Activity|The Senior Change Makers Physical Activity Program consists of weekly meetings, 1 hour each, for 8 weeks. The program provides participants with information about safe physical activity, strategies to increase physical activity, and guided walks. Topics will focus on walking, but we will also include information and activities relating to strength training, flexibility, and balance. Behavioral skills such as goal setting, addressing barriers, and social support will also be addressed.
2493681|NCT02944422||Males|Primary school Egyptian boys from 7-10 years.
2493683|NCT02944422||Females|Primary school Egyptian girls from 7-10 years.
2493739|NCT02944201|Experimental|Carvedilol|Carvedilol will be started at 6.25 mg by mouth twice daily. Patients will take carvedilol for 28 days prior to prostatectomy. They will be seen every 7 days and adjustments in the dose will be considered at those visits.
2493775|NCT02943837|Active Comparator|EUS-FNA|Device: 22G FNA needle
2493785|NCT02943837|Experimental|EUS-FNB|Device: 20G FNB needle
2493793|NCT02943863|Active Comparator|LFS first|"Patients in LFS first receive oxygen therapy using conventional nasal cannula in ahead of HFNC therapy. After 20 minutes of conventional nasal cannula oxygen therapy, patients receive HFNC oxygen therapy."
2493836|NCT02943603|Experimental|mFOLFX6 + Pembrolizumab|Subjects will receive mFOLFOX6 every 2 weeks (on Days 1, 15, 29, 43) and Pembrolizumab every 3 weeks (on Days 1, 22, 43).
3194907|NCT00833235||Patients with dry eye|No treatment is prescribed for the study. Patient dry eye progression will be followed for up to 60 months. Patients may use artificial tears to treat their dry eye symptoms.
3194908|NCT00833235||Patients with no history of dry eye|No treatment is prescribed for this control group. Patients will be followed for up to 60 months. If needed, patients may use artificial tears.
3194909|NCT00833274|Experimental|1|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
2493919|NCT02943174|Experimental|MIND Programme for cancer|"MIND programme for cancer is a manualized acceptance, mindfulness and compassionate-based group intervention for cancer patients. It included 8 weekly group sessions, 2h hours each, run in small groups (ranging from 6 to 12 participants).~Participants in this group also receive cancer treatment as usually performed at the Coimbra University Hospital."
2493926|NCT02943174|Other|Treatment as Usual (TAU)|Cancer treatment as usually performed at the Coimbra University Hospital.
2493975|NCT02942459|Experimental|Music Therapy|"25 Weekly Hours of Music Therapy adapted to the Needs of the Participants. Interventions can be Active (playing Music, singing, improvising, Song-writing) or Receptive (Listening to selected Play-lists, or to the Participants´ favored Music).~A Manual is created and trained with the Music Therapists, which distinguishes between~Unique and Essential Principles for Music Therapy with people suffering from Schizophrenia with negative Symptoms,~Essential but not Unique Principles,~Acceptable but not necessary Principles,~Not acceptable and Proscribed Principles. These Principles concern Attitude and Listening Perspectives by the Music Therapist, how to conduct the Musical Interventions and Questions of Frames for the Music Therapy Work."
2494003|NCT02942589|Experimental|100% Portions|Meal portion size: 100%
2494007|NCT02942589|Experimental|125% Portions|Meal portion size: 125%
2493223|NCT02947854|Experimental|Photosensitizer and adjuvant|Run-in cohort for selection of fimaporfin starting dose in the main study. Single intradermal dosing of fimaporfin and adjuvant (Hiltonol [poly-ICLC]) followed by light application.
2493230|NCT02947854|Experimental|Photosensitizer, adjuvant and antigens|Main part: Intradermal dosing of fimaporfin, adjuvant (Hiltonol, poly-ICLC) and antigens (KLH and HPV E7) followed by light application.
2493245|NCT02947854|Experimental|Assessments of time between ID dosing and light|Optional part: Assessment of different time interval between intradermal dosing of fimaporfin, adjuvant/antigens and light application.
2493283|NCT02947113|Experimental|chemotherapy combined with radiotherapy|Patients will be treated with two 3-weekly courses of cisplatin (Day 1: 75mg/m2) and pemetrexed (Day 1: 500mg/m2 for non-squamous) or etoposide (Day1-3 100mg/m2 for squamous), together with hypofractionated radiotherapy (24 daily fractions of 2.42 Gy to the involved mediastinal lymph nodes with an integrated boost of 2.75 Gy to the primary tumor).
2493326|NCT02947035|Experimental|Low Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
2493327|NCT02947035|Experimental|High Risk|Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
3194910|NCT00833300|Active Comparator|1|Haloperidol
3194911|NCT00833300|Active Comparator|2|Olanzapine
3194912|NCT00833326|Experimental|ARRY-334543 + docetaxel + prophylactic growth factors|
3194913|NCT00833339|Experimental|1|mifepristone
3194914|NCT00833339|Placebo Comparator|2|
3194915|NCT00833352|Experimental|1|Right ventricular lead located in Mid Septum
2493598|NCT02945228||Chronic infection of hepatitis C virus (HCV) genotype 2|Participants with confirmed chronic HCV genotype 2, receiving paritaprevir/ritonavir/ombitasvir and ribavirin according to standard of care and in line with the current local label
2493794|NCT02943798|Experimental|Group A|Patients will be administered with etoposide plus carboplatin as first-line treatment.
2493797|NCT02943811||MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy with the use of a uterine manipulator
2493804|NCT02943798|Experimental|Group B|Patients will be administered with paclitaxel plus carboplatin as first-line treatment.
2493808|NCT02943811||NO MANIPULATOR|Patients who were operated for endometrial cancer by laparoscopy without the use of a uterine manipulator
2493854|NCT02943434|Other|Processed Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a processed foods meal to determine changes in diet-induced thermogenesis.
2493856|NCT02943356|Experimental|Tadalafil|Patients will be treated with Tadalafil for 8 weeks.
2493863|NCT02943434|Other|Whole Food|Changes in resting energy expenditure will be measured via indirect calorimetry after consumption of a whole foods meal to determine changes in diet-induced thermogenesis.
2493914|NCT02943083|Experimental|Coached Intervention|Perform prenatal relaxation exercise in the lab with a coach and at home
2493916|NCT02943083|Active Comparator|Home Intervention|Only perform relaxation exercise at home
2493917|NCT02943083|No Intervention|Control Group|Never performs relaxation routine, attends prenatal assessment sessions
2493918|NCT02943083|No Intervention|Postpartum Only|Only attends visits postpartum, never receives prenatal assessments
3194916|NCT00833352|Active Comparator|2|Right ventricular lead located in Apex
3194917|NCT00833378|Active Comparator|Period 2|Treatment B
2494006|NCT02942316|Experimental|Pupil dilation reflex measurement|Four measurements of PDR during surgery at standardized times
2494016|NCT02942641|Experimental|Indwelling urethral catheterization (Foley)|Foley catheter as the intervention.
2494019|NCT02942641|Experimental|Clean intermittent catheterization (CIC)|CIC as the intervention .
3194918|NCT00833378|Active Comparator|Period 1|Treatment A
3194919|NCT00833378|Active Comparator|Period 3|Treatment C
2494062|NCT02942030||ADHD|Children diagnosed with ADHD after a complete psychiatric evaluation.
2494065|NCT02941978|Experimental|Subject on Motivational Interview|"Motivational Interview - Baseline: At hospital discharge, patients assigned to the intervention group will be contacted in person by a study physician for an interactive session and will be given an educational leaflet. Both methods will aim to educate them about the risk for stroke and the importance of adherence to OAC medication. The leaflet will also provide some basic information on how to take OAC medication (doses, food interactions, skipping doses, etc.) and will describe the main clinical manifestations of side effects.~Motivational Interview - Follow-up: Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview at 1 week, 2 months, 6 months and 1 year after discharge. The delegated study personnel will assess whether an intervention is required and provide specific support tailored to the needs of the patient, aiming to improve adherence to OAC."
2494066|NCT02942095|Experimental|Dose Escalation Group - Ixazomib + Erlotinib|"Dose Escalation Phase: Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle starting with Dose Level 1.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2494067|NCT02942030||Non-ADHD|Children diagnosed with other mental conditions after a complete psychiatric evaluation.
3194920|NCT00833391|Experimental|GSK1838262 arm|Each subject will participate in five dosing sessions separated by at least seven days. Subjects will receive a single dose of current formulation of GSK1838262 or one of the four new formulations of GSK1838262 at each dosing session in random sequence.
3194921|NCT00833404|Experimental|Smoking Cessation|8-week nicotine patch regimen
3194922|NCT00833404|No Intervention|Wait List Control|Smoking as usual
3194923|NCT00833456||1|Seroquel SR: Patients whose symptoms are controlled with Seroquel SR and started with the therapy up to 1 month before the inclusion
3194924|NCT00833456||2|Atypical antipsychotics: Patients whose symptoms are controlled with atypical antipsychotic in once daily formulation (excluding Seroquel SR) and started with the therapy up to 1 month before the inclusion
3194925|NCT00833495|Experimental|1|FOV1101-00 concentration 1 and Prednisolone Acetate 0.12% (Pred Mild®)
3194926|NCT00833495|Experimental|2|FOV1101-00 concentration 2 and Prednisolone Acetate 0.12% (Pred Mild®)
3194927|NCT00833495|Experimental|3|Vehicle of FOV1101-00 and Prednisolone Acetate 1% (Pred Forte®)
2493228|NCT02947633|Experimental|Continuous sciatic PNB|If a CPI catheter is placed, the CPI catheter will be placed under ultra-sound guidance, with the tip of the catheter being placed immediately adjacent to the sciatic nerve, after the local anesthesia has been deposited. CPI catheters will only remain in-situ for 48 hours.
2493243|NCT02947633|Active Comparator|Single-injection sciatic PNB|Under ultrasound-guidance, the sciatic nerve can readily be identified in the posterior thigh. The nerve appears hyperechoic and can be traced distally to the popliteal fossa, where it divides into the tibial and common peroneal nerves. Local anesthesia is injected under real-time visualization following a negative aspiration. If a single-injection block is done, local anesthesia is deposited adjacent to the sciatic nerve within the fascial plane, but not within the epineurium. As such, single-injection sciatic PNB, which can last up to 24 hours, should provide adequate analgesia precluding the need for oral narcotic or nonsteroidal anti-inflammatory medications following ACL reconstruction with a hamstring autograft.
2493328|NCT02947282|Active Comparator|Intervention|Educational Workshop
2493329|NCT02947282|No Intervention|Control|They will continue regular prenatal care as planned
2493384|NCT02946736|Experimental|Supervisor Intervention|Supervisors in the intervention group will go through the FSSB/sleep leadership training and receive actigraphy feedback.
2493385|NCT02946736|Experimental|Employee Intervention|Employees in the intervention group will receive actigraphy feedback.
2493450|NCT02946320|Active Comparator|Non-compliant balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2493452|NCT02946320|Experimental|Scoring balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2493454|NCT02946320|Experimental|Cutting balloon|15 patients, before BVS implantation is coronary artery stenosis dilated with this type of balloon
2493554|NCT02945592|Experimental|Intervention|"adaptive, therapeutic cueing during reading tasks~adaptive, therapeutic cueing during visuo spatial tasks"
2493559|NCT02945592|No Intervention|Control|- unspecific neglect treatment
2493591|NCT02945059|Experimental|1|Patients will undergo reversible PVE before major hepatic resection.
2493609|NCT02944851||Prospective observational|The changes of IVC diameter, SpHb and vital signs of blood donors were observed after blood donation
2493672|NCT02944630|Experimental|Experimental:|Receiving psychotherapy and medical treatment.
2493673|NCT02944630|No Intervention|Control|Awaiting group: Receiving medical treatment.
2493694|NCT02944305||Patient with difficult intubation|Group 1: Patient undergoing endotracheal intubation with difficult intubation Group 2: Patient undergoing endotracheal intubation without difficult intubation
3161792|NCT00448825|Experimental|Topiramate|Topiramate + Cognitive Behavioral Therapy
2493798|NCT02943681|Experimental|Measles vaccine|Measles vaccine, 1 dose of 0.5 ml
2493799|NCT02943772|Experimental|Local hypothermia|Local application of a brick cooled to -20(celsius)
2493806|NCT02943681|No Intervention|Control|Nothing
2493807|NCT02943772|Sham Comparator|Control|Local application of a brick in room temperature
2493829|NCT02943382|Experimental|Fingerprick Autologous Blood (FAB)|Assigned treatment with FAB
3194928|NCT00833495|Placebo Comparator|4|Vehicle of FOV1101-00 and vehicle of FOV1101-00
2493953|NCT02942797||NRS 2002 score ≥ 3|
2493954|NCT02942758|Experimental|low-dose AZA / ATRA / Pioglitazone|low-dose azacitidine (75 mg/d), ATRA, pioglitazone
2493955|NCT02942797||NRS 2002 score < 3|
2493957|NCT02942758|Active Comparator|standard-dose AZA|standard-dose azacitidine (75mg/m²/d)
2493984|NCT02942446|Experimental|Headgear|Investigative Headgear with CPAP mask
3161793|NCT00448825|Placebo Comparator|Placebo|Placebo + Cognitive Behavioral Therapy
3161794|NCT00448851|Experimental|1|inhaled allergen challenge
2494009|NCT02942602|Experimental|Atorvastatin 5 mg + Ezetimibe 10 mg|lipid lowering treatment
2494013|NCT02942602|Active Comparator|Life style modification for management of dyslipidemia|
2494035|NCT02942277|Experimental|1a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 on D0, D28, D168
2494040|NCT02942277|Experimental|1b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 on D0, D28, D168
2494046|NCT02942277|Experimental|2a|(n=5), to receive 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
2494048|NCT02942277|Experimental|2b|(n=10), to receive 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
2494051|NCT02942277|Experimental|2c|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 on D0, D28, D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
2494053|NCT02942277|Experimental|2d|(n=60), to receive 40 micrograms Pfs230D1M-EPA/AS01 (500 (Micro)L TBV + AS01) on D0, D28, then 8 micro liters Pfs230D1M- EPA/AS01 (100 (Micro)L TBV + AS01;fractional dose) on D168; all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); 4th vaccination on D476
2494054|NCT02942277|Experimental|3a|(n=5), to receive 16 microgram Pfs25M-EPA/AS01 and 13 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168
2494110|NCT02941731|Experimental|Sequence 1|HIP1403→HGP0919
3161795|NCT00448890|Experimental|GSK729327|Dose escalation from 1.0mg to 6 mg.
3161796|NCT00448890|Placebo Comparator|Placebo|
3161797|NCT00448903|Experimental|A|Bemiparin
3161798|NCT00448903|Placebo Comparator|2|Placebo
3161799|NCT00448929|Experimental|Trabeculectomy with Oculusgen|
3161800|NCT00448929|No Intervention|Trabeculectomy without Oculusgen or antifibrotic agents|
3161801|NCT00449098|Experimental|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
3161802|NCT00449098|Active Comparator|MMC|Trabeculectomy with MMC
3161803|NCT00449124|Experimental|Part I-group 1|Part I/Group 1: Cycle 1-TG4040 10^6 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
3161804|NCT00449124|Experimental|Part IIa-group 1|Part IIa/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
3161805|NCT00449124|Experimental|Part IIa-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
3161806|NCT00449124|Experimental|Part I-group 3|Part I/Group 3: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14; Cycle 3-TG4040 10^8 PFU days 0, 7 and 14.
2493234|NCT02947620|Placebo Comparator|Atorvastatin|Atorvastatin, QD
2493313|NCT02947243|Active Comparator|Standard pharmacological treatment|Standard pharmacological treatment (including Morphine) according to the unit's protocol and adjusted to each participant's age, weight and condition by the anesthetist and pain clinic nurse.
2493317|NCT02947243|Experimental|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention.
2493414|NCT02946788|Experimental|BPX-01 1%|BPX-01 1% minocycline topical gel
2493428|NCT02946788|Experimental|BPX-01 2%|BPX-01 2% minocycline topical gel
2493472|NCT02946138|Experimental|carbon-ion radiotherapy with GM-CSF|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gray(Gy) [relative biological effectiveness (RBE)] in 5 fractions for intrahepatic cases away from gastro-intestinal (GI) tract (>1cm) with concurrent GM-CSF 125ug/m2/d, subcutaneous injection d1-28;
2493504|NCT02945839|Active Comparator|Acute Treatment+ED-initiated preventive medication +PMR|All subjects will be discharged on acute migraine therapy (naproxen, triptan) unless there is a contraindication and will also be started on topiramate (25mg/night) with a plan to increase the dose every week by 25 mg up to 100 mg/night. Subjects will receive medicine along with progressive muscle relaxation therapy
2493506|NCT02945839|Active Comparator|Enhanced Usual Care (EUC)|Subjects will be given a general education session consisting of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. Any migraine treatment decisions on discharge will be left up to the ED attending. The RC will load the APP onto the subjects' smart phones but the PMR component will be blocked on the version of the APP that they receive. All subjects will be asked to track headache frequency, intensity, and acute medication use on the APP.
2493547|NCT02945462|Experimental|autologous mesenchymal stem cells|"Intervention:~Autologous bone marrow derived stem cells will be injected twice intracavernously to enrolled erectile dysfunction patients"
2493588|NCT02945176|Experimental|ARGOS-IO system|"The ARGOS-IO system is a non-European Community (CE) marked investigational medical device composed of the implant and its accessories.~Implant: ARGOS-IO pressure sensor implant for sulcus placement or transcleral fixation~Accessories: MESOGRAPH reading device, Implant Injector"
2493595|NCT02944864|Experimental|TQ-B3395|TQ-B3395 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2493643|NCT02944734|Experimental|Candesartan Cilexetil (CC) 8mg|Candesartan Cilexetil 8mg, once a day for 8 weeks
2493653|NCT02944734|Experimental|CC 16mg|Candesartan Cilexetil 16mg, once a day for 8 weeks
2493654|NCT02944734|Experimental|Amlodipine(AML) 5mg|Amlodipine 5mg, once a day for 8 weeks
2493659|NCT02944734|Experimental|AML 10mg|Amlodipine 10mg, once a day for 8 weeks
2493663|NCT02944734|Experimental|CC 8mg / AML 5mg|Candesartan 8mg and Amlodipine 5mg, once a day for 8 weeks
2493667|NCT02944734|Experimental|CC 8mg / AML 10mg|Candesartan 8mg and Amlodipine 10mg, once a day for 8 weeks
2493669|NCT02944734|Experimental|CC 16mg / AML 5mg|Candesartan 16mg and Amlodipine 5mg, once a day for 8 weeks
2493671|NCT02944734|Experimental|CC 16mg / AML 10mg|Candesartan 16mg and Amlodipine 10mg, once a day for 8 weeks
2493748|NCT02944188|Experimental|LRH plus ERAS|patients undergo Laparoscopic right hemicolectomy plus ERAS
2493749|NCT02944188|Active Comparator|ORH plus ERAS|patients undergo open right hemicolectomy plus ERAS
2493800|NCT02943902|Experimental|Group 1a (1+1, 6 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks and 9 months of age
3161807|NCT00449124|Experimental|Part I-group 2|Part I/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^7 PFU days 0, 7 and 14; Cycle 3-Placebo days 0, 7 and 14.
2493805|NCT02943902|Experimental|Group 1b (1+1, 6 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks and 9 months of age
2493812|NCT02943902|Experimental|Group 2a (1+1, 14 weeks)|PCV10 (Synflorix 0.5ml injection) will be administered at 14 weeks and 9 months of age
2493813|NCT02943902|Experimental|Group 2b (1+1, 14 weeks)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 14 weeks and 9 months of age
2493816|NCT02943902|Active Comparator|Group 3a (2+1)|PCV10 (Synflorix 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
2493818|NCT02943902|Active Comparator|Group 3b (2+1)|PCV13 (Prevenar 13, 0.5ml injection) will be administered at 6 weeks, 14 weeks and 9 months of age, as per EPI schedule in South Africa
2493833|NCT02943330||Hemodialysis|Hemodialysis patients
2493842|NCT02943330||Hepatitis C|Patients receiving interferon treatment for hepatitis C
2493872|NCT02943291|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
2493877|NCT02943291|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
2493899|NCT02942927|Experimental|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
2493900|NCT02942927|No Intervention|Control|Standard of Care as wait list control. Control group will be offered intervention as part of usual clinical care at 6 months.
2494012|NCT02942589|Experimental|150% Portions|Meal portion size: 150%
2494018|NCT02942589|Experimental|175% Portions|Meal portion size: 175%
2494033|NCT02942290|Experimental|Venetoclax + Azacitidine|
2494119|NCT02941770|Experimental|Intervention group I|"Clinic standard care protocol;~Physical activity consultation (Physical activity behavior change);"
3161808|NCT00449124|Experimental|Part IIb-group 1|Part IIb/Group 1: Cycle 1-TG4040 10^8 PFU days 0, 7 and 14; Cycle 2-Placebo days 0, 7 and 14.
3161809|NCT00449124|Experimental|Part IIb-group 2|Part IIa/Group 2: Cycle 1-Placebo days 0, 7 and 14; Cycle 2-TG4040 10^8 PFU days 0, 7 and 14.
3161810|NCT00449137|Experimental|Single Arm|
3161811|NCT00449267|Experimental|1|
2493303|NCT02947009|Experimental|Adolescent athletes with PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Any participant who declares he or she is a competitive athlete and presents to the clinic reporting atypical dyspnea during exertion and associated decrements in athletic performance for more than 2 weeks prior to presentation will be considered for the study. Participants must score at least a 10 out of 40 on the Dyspnea Index"
2493304|NCT02947009|Active Comparator|Adolescent athletes at-risk for PVFMD|"participants must be adolescents (ages 12-18yo) who exercise regularly (at least 40 min 3x/week) and engage in athletic activities competitively by their report.~Participants in the at-risk group must report playing sports in a competitive environment, must report no symptoms of atypical dyspnea over the past 6 months, and must score less than 6 out of 40 on the Dyspnea Index."
2493362|NCT02946866||Cerebral cavernous malformation|Patients with newly diagnosed, cerebral cavernous malformation who will visit one of the study centers during the period from June 2016 to December 2017. Patients would be eligible for enrollment if they were 18 years of age or older and had at least 1 cavernous malformation. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 228 patients.
3161812|NCT00449280|Experimental|A|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
3161813|NCT00449280|Experimental|B|Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
2493589|NCT02945215|Experimental|IBI301|
2493590|NCT02945215|Active Comparator|Rituximab|
2493613|NCT02944773|Experimental|facilitated tucking device (FTD)|20 infants use a FTD in the procedure of daily weight
2493615|NCT02944773|No Intervention|without FTD|20 infants use not a FTD in the procedure of daily weight
2493700|NCT02944279||Peking University Third Hospital|
2493706|NCT02944279||Beijing Friendship Hospital|
2493709|NCT02944279||Beijing Shijitan Hospital|
2493715|NCT02944279||Beijing Xiyuan Hospital|
2493720|NCT02944279||China-Japan Friendship Hospital|
2493755|NCT02944097|Experimental|Vineatrol30 native powder|500 mg Vineatrol30 containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
2493756|NCT02944097|Experimental|Vineatrol30 micelles|500 mg Vineatrol30 micelles containing 30 mg trans-resveratrol and 75.2 mg trans-epsilon-viniferin
2493827|NCT02943395|Experimental|dual cure amine free adhesive resin cement|resin cement that get activated by both light and chemicals
2493828|NCT02943395|Active Comparator|light cured adhesive resin cement|resin cement that only get activated by light
3194929|NCT00833508|Experimental|Test arm|Patients undergoing preoperative chemoradiotherapy will have their exercise capacity measured before and after chemoradiotherapy.
2493861|NCT02943239|Experimental|Panel A|REGN1033 + REGN2477 (Regimen 1) or placebo
2493868|NCT02943239|Experimental|Panel B|Panel B - REGN1033 + REGN2477 (Regimen 2) or Placebo
2493874|NCT02943239|Experimental|Panel C|Panel C - Patients will receive either REGN1033 + REGN2477 (Regimen 3) or Placebo
2493875|NCT02943239|Experimental|Panel D|Panel D - Patients will receive either REGN1033 + REGN2477 (Regimen 4), REGN1033, REGN2477 (high dose) or Placebo
2493878|NCT02943239|Experimental|Panel E|REGN2477 (Regimen 5) or placebo
2493880|NCT02943239|Experimental|Panel F|REGN2477 + REGN1033 (Regimen 6) or placebo
2493881|NCT02943239|Experimental|Panel G|REGN2477 (Regimen 7) or placebo
2493901|NCT02942914|Experimental|LY3209590|LY3209590 administered subcutaneously (SC).
2493902|NCT02942914|Placebo Comparator|Placebo|Placebo (sterile saline) administered SC.
2493903|NCT02942914|Active Comparator|Insulin Glargine (Lantus)|Insulin Glargine administered SC.
2493930|NCT02942875|Experimental|Mirror therapy group|MT group subjects will attend training sessions of bilateral upper limb exercise daily in the presence of the mirror.
2493931|NCT02942875|Active Comparator|Control therapy group|Control group subjects will undergo the same training sessions of bilateral upper limb exercise daily without mirror.
2493936|NCT02942810|Experimental|WCK 5222 (Cefepime and zidebactam combination)|IV infusion over a period of 60 minutes
2493986|NCT02942498|Experimental|Vitamin C 10 mg/Kg + Vitamin E 10 mg/Kg|Vitamin C and Vitamin E supplementation 10 mg/kg/ day
2493990|NCT02942498|Placebo Comparator|Placebo|Placebo solution
2494010|NCT02942524|Experimental|Supportive care (TEPID)|Patients complete the TEPID checklist of items during hospital stay.
2494015|NCT02942329|Experimental|apatinib and SHR-1210|Every patients will received apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks until disease progression or intolerance of side effects.
2494043|NCT02942173|No Intervention|CD45RA-|
2494047|NCT02942173|Experimental|CD45RA+|
2494064|NCT02942043|Experimental|Group A (low dose group)|Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
2494068|NCT02942043|Experimental|Group B (medium dose group)|Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
2494072|NCT02941978|Active Comparator|Subject Control|Patients assigned to the control group will receive usual treatment and will be contacted via telephone for a pre-specified interview at 1 year after discharge for outcome assessment.
2494074|NCT02942043|Experimental|Group C (high dose group)|Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
3194930|NCT00833534|Experimental|Group I (consolidation phase)|Patients receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2493436|NCT02946307|Other|very small vessel cohort:Restore DEB|receiving the treatment with Restore DEB（dimeter:2.00 mm）in very small vessel cohort
2493516|NCT02945943|Experimental|Mobilization|High Velocity Low Amplitude mobilization group. The three joints manipulated included proximal tibiofibular, the distal tibiofibular, and talocrural joints and were mobilized the first three sessions prior to the participants performing the exercise protocol.
2493519|NCT02945943|Active Comparator|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
3194931|NCT00833534|Experimental|Group II (consolidation phase)|Patients receive lenalidomide as in group I. Patients also receive rituximab IV once on the day before the start of lenalidomide and then once between days 25-30, 50-55, and 75-80 for a total of 4 doses in the absence of disease progression or unacceptable toxicity.
3194932|NCT00833573||1|For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD.
3194933|NCT00833573||2|For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD.
2493695|NCT02944487|Experimental|Single ascending doses of lucerastat|Subjects were enrolled sequentially in 4 groups and received a single oral dose of lucerastat from 100 mg to 1000 mg in the morning of Day 1
2493702|NCT02944487|Experimental|B.i.d. Dose Group|Subjects received two doses of lucerastat (2 x 1 g) 12 hours apart on Day 1
2493705|NCT02944487|Placebo Comparator|Placebo for singe ascending doses|These subjects received matching placebo administered orally in the morning of Day 1
2493712|NCT02944487|Placebo Comparator|Placebo for b.i.d.Group|These subjects received matching placebo administered orally in the morning and in the evening of Day 1
2493788|NCT02943967|Active Comparator|CXL + PRK group|"Corneal cross-linking surgery is perfomed in one eye : deepithelization of the cornea and instillation of 0,1% riboflavin (ophthalmos - Brazil) for 30 minutes and UVA for irradiated for 30 minutes with ultraviolet-A of 365nm light with an irradiance of 3 mW/cm2 using Xlink (Opto - São Carlos) Photorefractive keratotomy will be perfomed in the same eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
2493789|NCT02943967|Active Comparator|PRK group|"Photorefractive keratotomy will be perfomed in the fellow eye using excimer laser Ladarvision (Alcon - USA) with 0,02 % mitomicin for 30 seconds (Ophthalmos - Brasil) simultaneously with the other eye.~Both procedures will have the same post operative treatment :~gatifloxacin 0,3% 6/6h for 10 days prednisolone acetate 0,12% 6/6h por 14 days"
3194934|NCT00833599||1: NIRFLI with ICG|1) Persons affected with lymphatic or lympho-vascular disorders, 2) Family members (affected or unaffected) of persons affected with lymphatic or lympho-vascular disorders and 3) Health, normal persons (Controls) that participate at one of the clinical sites in both the lymphatic function imaging with indocyanine green and the Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) system, as well, as the genetic analysis portion of the study.
3194935|NCT00833599||2: Genetic Analysis Only|Family members of an affected subject from Group 1. Subjects in Group 2 can be either affected or unaffected and will provide a blood or saliva sample for the genetic analysis portion of the study, but will not undergo lymphatic function imaging with ICG and the NIRFLI system. Group 2 individuals are not required to travel to one of the clinical sites in order to participate in the study.
2493920|NCT02942888|Active Comparator|Healthy control|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10). Controls will receive sugar pills.
2493929|NCT02942888|Experimental|MCI|Oral administration of NAD precursor, nicotinamide riboside (Niagen; Chromadex Inc.) Dosing will consist of 250mg (week 1), 500mg (week 2), 750mg (week 3), 1g (weeks 4-10).Controls will receive sugar pills.
2494020|NCT02942303|Active Comparator|Technique 1: Lateral orbicularis injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim.
2494021|NCT02942303|Active Comparator|2. Technique 2: Lateral orbicularis and Corrugator injections|5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed into the corrugator at the medial brow
2494028|NCT02942147|Active Comparator|conventional radiofrequency therapy|In the conventional radiofrequency method applied to Group 1 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
2494029|NCT02942147|Active Comparator|conventional TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
2494031|NCT02942147|Active Comparator|pulse radiofrequency therapy|In the pulse radiofrequency method applied to Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position.
2494073|NCT02942095|Experimental|Dose Expansion Group - Non Small Cell Lung Cancer|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2494077|NCT02942095|Experimental|Dose Expansion Group - Pancreatic Ductal Adenocarcinoma|"Dose Expansion Phase : Participants take Ixazomib capsules by mouth on Days 1, 8, and 15 of each 28 day cycle at the maximum tolerated dose from Dose Escalation Phase.~Participants take Erlotinib tablets by mouth on Days 1 - 28 of each 28 day cycle."
2494078|NCT02941913|Experimental|Fixed Dose Palonosetron group|patient will receive a fix dose of 75 μg of palonosetron
2494079|NCT02941939|Active Comparator|Ambient pressure arm|High intensity training will be completed while the subjects are breathing normal air.
2494081|NCT02941913|Experimental|Bodyweight-adjusted Dose Palonosetron|patient will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron
2494082|NCT02941939|Experimental|Hyperoxic-hyperbaric arm|The high intensity training program will be carried out in a hyperbaric chamber.
2494086|NCT02941874||Healthy volunteers IRAP measurement|
2493464|NCT02946060|Experimental|Tempo-pace Synchronized Playlists|Participants in this arm will receive audio playlists synchronized to their exercise pace. Rhythmic enhancements will be added to the playlists during either month 2 or month 3 of the study.
3194936|NCT00833612|No Intervention|Control arm of study|
3194937|NCT00833625|Experimental|PET/CT Scan + Biomarkers Testing|"PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).~Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis."
2493570|NCT02945280|Experimental|patients with acute UEDVT|Patients will receive 10 mg PO apixaban for 7 days and then 5 mg PO for 11 weeks, for a total of 12 weeks of treatment.
3194938|NCT00833651||tacrolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing tacrolimus
2493708|NCT02944253|Experimental|Low energy diet 70 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 70 gram carbohydrates for 8 weeks.
2493716|NCT02944253|Experimental|Low energy diet 100 gram carbohydrates|isocaloric (4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 100 gram carbohydrates for 8 weeks.
2493719|NCT02944253|Experimental|Low energy diet 130 gram carbohydrates|isocaloric 4128 kilojoules/day (1000 kilocalories/day) for men and women, low energy diet containing 130 gram carbohydrates for 8 weeks.
2493760|NCT02943980|Experimental|CMAC Videolaryngoscope|tracheal intubation using CMAC
2493761|NCT02943980|Experimental|Macintosh laryngoscope|tracheal intubation using Macintosh laryngoscope
2493859|NCT02943642|Experimental|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as Total Dose µg/kg given as 1/8 Total Dose µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.
2493866|NCT02943642|Active Comparator|Vorinostat|Subjects in the control arm will receive oral vorinostat capsules at a dose of 400 mg daily up to 12 months in duration until disease progression or uncontrolled side effects take place. Subjects in the vorinostat arm who experience progressive disease may cross over into the experimental arm after 6 months of treatment after a 2-week vorinostat washout period.
2493869|NCT02943317|Experimental|Part A: Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
2493873|NCT02943642|Experimental|Lead-in Dosing single arm|"Dose Group 1: A-dmDT390-bisFv(UCHT1) will be administered as 5 µg/kg given as 0.625 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes.~Dose Group 2: A-dmDT390-bisFv(UCHT1) will be administered as 10 µg/kg given as 1.25 µg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes."
2493909|NCT02943018||anovaginal distance variation|3 measurements
2493910|NCT02943005|Active Comparator|Rotator cuff repair with sling|Patients wear a sling during 4 weeks, they also move passively during this period. Then progressive active mobilization is done.
2493911|NCT02943005|Experimental|Rotator cuff repair without sling|Patients don't wear any sling, they move passively in all axes during 4 weeks. Then progressive active mobilization is done.
2493937|NCT02942719||Shanghai First Maternity and Infant Hospital|
2493940|NCT02942719||Dalian Maternity and Child Health Hospital|
2493943|NCT02942719||Beijing Obstetrics and Gynecology Hospital|
2493945|NCT02942719||Shijiazhuang Obstetrics and Gynecology Hospital|
2493949|NCT02942719||The Children and Women's Healthcare of Laiwu City|
2493951|NCT02942719||Suzhou Municipal Hospital|
2493956|NCT02942719||Wenling Women's and Children's Hospital|
2493958|NCT02942719||First Affiliated Hospital of Kunming Medical University|
2493959|NCT02942719||Changsha Hospital for Maternal and Child Health Care|
2493960|NCT02942719||Xinxiang Maternity and Child Health Hospital|
2493961|NCT02942719||Yanshi People's Hospital|
2493962|NCT02942719||The Maternal and Child Health Hospital of Guangxi|
2493963|NCT02942719||Northwest Women and Children's Hospital|
2493964|NCT02942719||Suining Central Hospital|
2493965|NCT02942719||Inner Mongolia Maternity and Child Health Hospital|
2493966|NCT02942719||Fujian Province Maternity and Child Health Hospital|
2493967|NCT02942719||Qinghai Red Cross Hospital|
2493968|NCT02942719||Xinjiang Maternity and Child Health Hospital|
2493969|NCT02942719||Jiangmen Maternity and Child Health Care Hospital|
2493970|NCT02942719||Gansu Provincial Maternity and Child-care Hospital|
2493982|NCT02942706|Experimental|Cet maintenance|Cetuximab maintenance treatment following induction treatment
2493983|NCT02942706|Active Comparator|Cet+chemo continuation|Cetuximab plus continuation mFOLFOX6/FOLFIRI regimens
2494030|NCT02942212|Experimental|Project HALT II: In-Depth Interviews|"Participants complete a computerized questionnaire to assess demographics and smoking history.~Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program."
2494032|NCT02942212|Active Comparator|Project HALT II: Standard Treatment (ST)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants receive phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
2494038|NCT02942108|Active Comparator|healthy, conventional surgery|Surgical bone removal by conventional rotary burs in healthy patients during third molar surgery
2494044|NCT02942108|Experimental|healthy, piezo surgery|Surgical bone removal by piezoelectric vibrations in healthy patients during third molar surgery
2494090|NCT02941835|Other|radiation|intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy
3194939|NCT00833651||sirolimus|Recipients of primary deceased or living donor renal transplant maintained on immunosuppressive regimen utilizing sirolimus
2493497|NCT02946203|Active Comparator|Flavored Beverage Oral Contrast-Breeza|Pediatric patients that are undergoing awake CT and MR enterography at the Cincinnati Children's Hospital Medical Center (CCHMC) base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
2493501|NCT02946203|Active Comparator|Barium Sulfate Oral Contrast-VoLumen|Pediatric patients that are undergoing awake CT and MR enterography at the CCHMC base (Burnett) campus will be randomized to either VoLumen (current standard of care oral contrast) or Breeza.
3194940|NCT00833651||Healthy controls|Age, gender- and race-matched individuals, not on immunosuppressive medications
2493642|NCT02944760|Experimental|Low-Level Light Therapy Group|The patient was placed supine on a stretcher and the application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. Six points in quadriceps and four points in gastrocnemius, were irradiated, bilaterally, by 30 seconds.
2493648|NCT02944760|Placebo Comparator|Placebo Group|The patient was placed supine on a stretcher and the application of laser therapy occured with apparatus off.
3194941|NCT00833716|Experimental|A|
2493770|NCT02943928|Experimental|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis.
2493774|NCT02943928|Experimental|Traditional method by experience|Operator inserted the double lumen tube by experience
3161814|NCT00449280|Experimental|C|Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.
3194942|NCT00833729|Experimental|etanercept|Single armed study
2493905|NCT02943135|Active Comparator|lidocaine in-situ|Self-administered gel 10 min before intrauterine device insertion
2493906|NCT02943135|Placebo Comparator|placebo|Self-administered gel 10 min before intrauterine device insertion
3194943|NCT00833742|Experimental|1|ISTDP therapy was provided
2493941|NCT02942745|Placebo Comparator|Control|Minimal interaction between participant and facilitator regarding cessation strategies. Participants will only be given a betel nut cessation booklet.
2493946|NCT02942745|Experimental|Experimental|Intensive 5-session intervention program over the span of 22 days, with an additional follow up session after 6 months. The sessions will utilize betel nut cessation social support groups, as well as interactive discussion on how to quit chewing.
2493980|NCT02942420|Experimental|Dose Group A|Bucillamine 300 mg/day
2493981|NCT02942420|Experimental|Dose Group B|Bucillamine 600 mg/day
2494034|NCT02942251|Experimental|Clinical features and medication|A group patients with significant high risk of clinical features and medications.
2494036|NCT02942212|Experimental|Project HALT II: Tailored Treatment (HALT)|"Participants complete a computerized questionnaire to assess demographics and smoking history at baseline.~Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.~Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Participants receive brief advice to quit smoking. Participants scheduled to attend 5 individual, in-person smoking cessation treatment counseling sessions.~Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up."
2494039|NCT02942251|Experimental|Psycho-social|A group patients with significant high risk of psycho-social problems.
2494045|NCT02942251|Experimental|immunology|A group patients with significant high risk of immune disturbance.
2494049|NCT02942251|Experimental|Laboratory abnormality|A group patients with significant high risk of Laboratory abnormalities.
2494050|NCT02942251|Experimental|Comorbidity|A group patients with physical or mental disorders comorbidities.
2494052|NCT02942251|Experimental|Treatment as usual|Control group.
2494076|NCT02941965|Experimental|ICSI with PGS|"PGS will be applied to select embryos on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle."
2494098|NCT02941861||recurrence rate of CCA after surgery|There were 34 patients underwent liver resection for Cholangiocarcinoma between February 2010 to December 2013. All patients were staged according to the tumor-node metastasis (TNM) system and appraised by the hospital tumor board conference. After surgery, an attending physician followed up patients by tumor marker and imaging as standard treatment as well as diagnosed its recurrence. In addition, all recurrence cases had standard treatments till the end of life. The survival was classified as the dates between the operation and the death.
2494112|NCT02941809|Experimental|Open-Label Placebo (OLP)|Participants who are randomly assigned to group OLP will receive placebo pills. In Phase 1 of the study (first two weeks), participants in this group are given one pill, to be taken concomitant with the methadone. In Phase 2 (3 weeks up to 3 months), OLP participants continue to take the single (morning, or AM) pill, and are given a second pill in a bottle as a take-home. OLP participants will meet with the study team at five time points: at baseline (entry into treatment), 2 weeks post-baseline, and 1-, 2- and 3-months post-baseline.
2494115|NCT02941809|No Intervention|Treatment as Usual (TAU)|Participants assigned to TAU will not be given placebo pills, but all interactions with the study team (5 meetings total) will be matched in frequency and length.
2494120|NCT02941770|Experimental|Intervention group II|"Clinic standard care protocol;~Physical activity consultation;~2 exercise sessions per week (≈60 min/session) directed by one Exercise Physiologist."
2494122|NCT02941822|Experimental|Arm 1|"Each patient will self-administer the study drug, ambroxol (60 mg per tablet) at 5 intra-dose escalations (DE) over the duration of 6 months that will be taken three times a day, see below:~Day 1-7, 60 mg~Day 8-14, 120 mg~Day 15-21, 180 mg~Day 22-28, 300 mg~Day 29-186, 420 mg"
3194944|NCT00833742|No Intervention|2|People referred but never seen
3194945|NCT00833768|Active Comparator|Sevelamer carbonate|
3194946|NCT00833768|Placebo Comparator|Placebo|
3194947|NCT00833807|Experimental|Nab-paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
2493520|NCT02945709|Active Comparator|Non personalized ACT|The Non-personalized attention control training (ACT), comprised of six sessions, in purpose of modulate biases in attention for non-personalized threat stimuli.
2493521|NCT02945709|Placebo Comparator|Control training|Computerized control training, comprised of six sessions with a variation of the dot-probe task with neutral stimuli
2493540|NCT02945384|Experimental|Creating Connections|Dual-generation intervention: child component delivered in classroom setting, parent component delivered in small-group setting
2493544|NCT02945384|No Intervention|Head Start as usual|Regular Head Start curriculum
2493596|NCT02944890|Experimental|RESTORE DEB|Conduct Drug Eluting Balloon Catheters(RESTORE DEB）
2493597|NCT02944890|Active Comparator|SeQuent® Please|Conduct Drug Eluting Balloon Catheters(SeQuent® Please）
3194948|NCT00833820|Active Comparator|A|Patients receiving real rTMS
3194949|NCT00833820|Sham Comparator|B|patients receiving sham stimulation
2493757|NCT02944084|Experimental|Rice bran extract|2 g of unprocessed rice bran extract
2493758|NCT02944084|Experimental|Porridge in water|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm water
2493759|NCT02944084|Experimental|Porridge in milk|35 g of porridge containing 2 g of rice bran extract mixed with 95 ml of warm milk (3.8% fat)
2493822|NCT02943629|Experimental|Non-Obese: Apneic Oxygenation: eight minute|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2493823|NCT02943629|Other|Non-Obese: Without Apneic Oxygenation|Non-obese healthy female patients requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for eight minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2493824|NCT02943629|Experimental|Obese: Apneic Oxygenation: five minute|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed and then receive 10 l/minute flow of oxygen through the P blade (apneic oxygenation) for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2493825|NCT02943629|Other|Obese: Without Apneic Oxygenation|Morbidly obese patients (BM I ≥ 40 kg/m2) requiring endotracheal anesthesia for gynecologic (open or laparoscopic) abdominal surgery will have the Pentax AWSTM video laryngoscope with attached P blade placed for five minutes, or earlier if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
2493838|NCT02943278|Placebo Comparator|Sleep Hygiene Group|Participants assigned to the sleep hygiene group you have 1 session with a clinician to learn about different things they can do to improve their sleep.
2493843|NCT02943278|Active Comparator|Intensive Sleep Retraining Group|Participants assigned to this group will spend just over 1 day at our sleep lab, starting around your usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake the participant up after a few minutes if they fall asleep.
2493915|NCT02942940|Active Comparator|in-person|
2493923|NCT02943161|Experimental|L-Citrulline|In this pilot study subjects with asthma that have an increased body mass index compatible with being obese, will be invited to participate in a short open-label treatment with 15g/day of L-citrulline for two weeks. Study participants will be asked to do lung function testing and donate blood before and after taking the supplement. L-citrulline is safe and well tolerated and has been used at much higher doses without significant side effects.
2493971|NCT02942667||Subjects undergoing high quality MRI Scans|
3194950|NCT00833872|Experimental|LEO 22811 solution|
3194951|NCT00833872|Placebo Comparator|placebo solution|
2494055|NCT02942277|Experimental|3b|(n=10), to receive 47 microgram Pfs25M-EPA/AS01 and 40 microgram Pfs230D1M-EPA/AS01 on D0, D28, D168 (Bamako)
2494056|NCT02942277|Active Comparator|4a|(n=10), to receive ENGERIX-B on D0, D28, and D168
2494058|NCT02942277|Active Comparator|4b|(n=10), to receive ENGERIX-B on DO, D28, and Dl68
2494059|NCT02942277|Active Comparator|4c|(n=120), to receive ENGERIX-B on D0, D28, and D168 (start study with Arm 2c and 2d); all subjects will undergo antimalarial drug treatment with Coartem on D-7 (prior to vaccination #1); vaccination with Menactra on D476
2494063|NCT02942082|Experimental|ACP oral care geldesensitizing agent|a desensitizing agent will be applied on tooth before and /or after bleaching.
2494070|NCT02942082|Placebo Comparator|glycrin|glycrin will be applied on tooth before and /or after bleaching.
2494088|NCT02941848|Experimental|Group1|"C → A + B~A : HGP0816 B : HGP1404 C : HCP1306"
2494089|NCT02941848|Experimental|Group2|"A + B → C~A : HGP0816 B : HGP1404 C : HCP1306"
3194952|NCT00833885|Other|1|Control
2494111|NCT02941562|Experimental|Preoperative chemotherapy with short-course radiotherapy|Preoperative treatment:4 course of FOLFOX4 therapy combined with short-course radiotherapy
2494113|NCT02941731|Experimental|Sequence 2|HGP0919→HIP1403
2494114|NCT02941562|Active Comparator|Preoperative neo-adjuvant therapy|Preoperative treatment:neo-adjuvant therapy
2494118|NCT02941744|Experimental|IpNiv|low fixed dose ipilimumab plus low fixed dose nivolumab
2494124|NCT02941679|Experimental|HCP1202|Test
3194953|NCT00833885|Other|2|Masks
3194954|NCT00833885|Other|3|Masks and Hygiene
3194955|NCT00833950|Experimental|narrow band noise|Phase out in narrow band noise tinnitus patients
2493522|NCT02945826|Experimental|uPAR PET/MRI|One injection of 68Ga-NOTA-AE105 followed by PET/MRI.
2493549|NCT02945371|Experimental|IC Training|"The experimental arm (ARM1) is a person-centered inhibitory control training intervention, or PeCIC.~Between the baseline and endpoint sessions, participants come to our lab 12 times to participate in the training sessions. Each participant is randomly assigned to either the PeCIC training or an active control training. The training sessions will take place approx. every other day for 24 days.~Beginning 2-3 days after the baseline session, the experimental group (will come to our behavioral testing lab to receive the PeCIC training. At 11 sessions spaced one every other day, participants will complete one 8-min run of a modified stop-signal task. The cue on each trial (preceding the go signal arrow) will be an image of a personalized risk-cue (PRC) or a neural image."
2493553|NCT02945371|Active Comparator|Control Training|Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
2493629|NCT02944994|Experimental|Unified Protocol|Unified Protocol-psychotherapy
2493634|NCT02944994|Experimental|Routine Care|Routine Care psychotherapy comparison
2493721|NCT02944500|Experimental|Liraglutide followed by placebo|Participants will receive liraglutide with dose titration over 5 weeks (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of placebo for the same amount of time.
2493727|NCT02944500|Experimental|Placebo followed by liraglutide|Participants will receive placebo with dose titration (0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, and 3.0mg for 1 week) followed by a minimum of 3 weeks wash-out and then return for the same dose of liraglutide for the same amount of time.
2493773|NCT02943915|Experimental|Group 1: Ekso GT Rehabilitation Therapy|Participants in this group receive Ekso GT (gait training) PT therapy intervention 3 times per week for 12 weeks (36 sessions). Intervention: Ekso GT Rehabilitation therapy
2493778|NCT02943915|Active Comparator|Group 2: Active controls - BWSTT Therapy|Participants in this group receive a matched number of sessions of standard gait training using body-weight supported treadmill training and overground training. Intervention: Body Weight Supported Treadmill Training
2493784|NCT02943915|No Intervention|Group 3: Passive controls|Participants in this group continue with normal daily activities over 12 weeks.
2493834|NCT02943369|Experimental|Cangrelor|Ticagrelor will be followed by Cangrelor
2493840|NCT02943369|Active Comparator|Ticagrelor|Ticagrelor only
3161815|NCT00449280|Experimental|D|Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.
3161816|NCT00449293|Active Comparator|1|
2493938|NCT02942680|Experimental|Experimental|acetylsalicylic acid started for 24 hours before surgery and determination of platelet function
2493939|NCT02942680|Other|Control|acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function
2494005|NCT02942433|Experimental|Radio Program|Married couple participants will be asked to interact with a radio program and participate in weekly, sex-separate listening and discussion groups (LDG) that each last for between 75 and 120 minutes over the course of 9 months.
2494008|NCT02942615|Experimental|Heart safety management|limit heart dose more frequent follow up of cardiac function professional management of cardiac toxicity
2494011|NCT02942433|Other|Control|The control group participants will be exposed to the radio program only, and will not participate in the LDGs, nor will they or their family members participate in the workshops and community activities.
2494014|NCT02942615|No Intervention|Control group|without any restrict heart dose limitation for RT Follow up of cardiac function Observation and without any special management of cardiac toxicity
2494060|NCT02941991||uniocular subretinal injection of hESC-RPE cells|Cohort 1. 50,000 cells transplanted; Cohort 2. 100,000 cells transplanted; Cohort 3. 150,000 cells transplanted; Cohort 4. 200,000 cells transplanted
2494071|NCT02942056|Experimental|Study Drug|Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile
2494075|NCT02942056|Placebo Comparator|Placebo|Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile
2494101|NCT02941653|Active Comparator|Control: Potassium Nitrate 2% gel|The patient will receive the application of potassium nitrate 2% gel on vestibular surface teeth, for 10 minutes.
2494102|NCT02941653|Experimental|Intervention: Potassium Oxalate 5% gel|The patient will receive the application of potassium oxalate 5% gel on vestibular surface teeth, for 10 minutes.
3161817|NCT00449293|Active Comparator|2|
3161818|NCT00449488|No Intervention|Control|
3161819|NCT00449488|Active Comparator|Epoetin alfa|i.v bolus 60.000 IU epoetin alfa
3161820|NCT00449553||Pioglitazone 15 mg QD + Sulphonylurea|
3161821|NCT00449553||Pioglitazone 30 mg QD + Sulphonylurea|
3161822|NCT00449553||Pioglitazone 15 mg QD + Metformin|
3161823|NCT00449553||Pioglitazone 30 mg QD + Metformin|
3161824|NCT00449592|Experimental|1|Oral zinc therapy, intervention
3161825|NCT00449592|Placebo Comparator|2|oral placebo
3161826|NCT00449605|Experimental|Rimonabant|Rimonabant 20 mg once daily on top of metformin
3161827|NCT00449605|Active Comparator|Glimepiride|Glimepiride from 1 mg up to 6 mg once daily on top of metformin
3161828|NCT00449618|Active Comparator|1|Aspirin 100 mg on awakening
3161829|NCT00449618|Active Comparator|2|Aspirin 100 mg at bedtime
3161830|NCT00449618|Placebo Comparator|3|Placebo on awakening
3161831|NCT00449618|Placebo Comparator|4|Placebo at bedtime
3161832|NCT00449683|Experimental|terazosin|open-label treatment group
3161833|NCT00449774|Experimental|Subjects in Treatment regimen C|Subjects in treatment regimen C will receive 200 milligram (mg) orally disintegrating tablets (ODT) of lamotrigine disintegrate in mouth without water in fasting condition.
2493610|NCT02945007|Experimental|JNJ-53718678: PART 3|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and F (novel concept formulation 3), and under fed condition for treatment G (novel concept formulation 3).~Part 3 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2493612|NCT02945007|Experimental|JNJ-53718678: PART 4|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and H (novel concept formulation 4), and under fed condition for treatment I (novel concept formulation 4).~Part 4 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2493614|NCT02945007|Experimental|JNJ-53718678: PART 5|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and J (novel concept formulation 5), and under fed condition for treatment K (novel concept formulation 5).~Part 5 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2493616|NCT02945007|Experimental|JNJ-53718678: PART 6|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and L (novel concept formulation 6), and under fed condition for treatment M (novel concept formulation 6).~Part 6 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2493617|NCT02945007|Experimental|JNJ-53718678: PART 7|"Participants will receive a single dose of JNJ-53718678 500 mg under fasted conditions on day 1 for treatment A (solution) and N (novel concept formulation 7), and under fed condition for treatment O (novel concept formulation 7).~Part 7 of the study is optional and might be performed depending on the availability of concept formulations and the result of previous part."
2493618|NCT02945007|Experimental|JNJ-53718678: PART 8|"Participants will receive a single dose of JNJ-53718678, 500 mg oral solution under fasted or fed conditions on day 1 for treatment A and P (oral concept formulation 1, 2, 3, 4, 5, 6 or 7) and under fed conditions for treatment Q (oral concept formulation 1, 2, 3, 4, 5, 6 or 7).~Part 8 of the study is optional, might be performed, depending on the interim results of prior parts. One of the concept formulations might be re-evaluated under different feeding conditions."
2493707|NCT02944552|Experimental|low dose group|Patients in the low dose group administrated bicyclol tablet 25mg orally, three times daily for 4-8 weeks.
2493713|NCT02944552|Experimental|high dose group|Patients in the high dose group administrated bicyclol tablet 50mg orally, three times daily for 4-8 weeks.
2493717|NCT02944552|Active Comparator|positive drug control group|Patients in the positive drug control group administrated polyene phosphatidylcholine capsule 456mg orally, three times daily for 4-8 weeks.
2493764|NCT02943889|Experimental|Mesenchymal stem cell transplantation|This group will include 20 patients with liver cirrhosis, autologous bone marrow derived mesenchymal stem cells will be transplanted to them. Every patient will receive 2 million cells per Kg via portal vein once.
2493767|NCT02943889|No Intervention|Control group|This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
2493826|NCT02943616|Experimental|Absorb BVS|Subjects receiving Absorb GT1 Bioresorbable Vascular Scaffold (BVS).
2493858|NCT02943265|Experimental|Complex Care Survivors|Patients eligible for the study who will receive Care Coordination Strategies.
2493912|NCT02943057|Experimental|2% guttae Ganciclovir|2% guttae Ganciclovir 5 times a day for 6 weeks
2493924|NCT02943031|Experimental|IPTP Group|The IPTP Group will receive the Individualized Precision Therapy Programs. After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
2493942|NCT02942693|Experimental|Apatinib with Particle Therapy|Participants will receive apatinib (0.5g, daily) for 6 weekly followed by particle radiotherapy (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
2493948|NCT02942693|Experimental|Particle Therapy|Participants will receive particle radiotherapy alone (proton: 56 GyE/28 Fx, plus carbon: 15 GyE/5 Fx for boost).
2493985|NCT02942628|Experimental|Vegetarian - Meat|4 weeks of vegetarian diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of meat-containing diet
2493987|NCT02942628|Active Comparator|Meat - Vegetarian|4 weeks of meat-containing diet followed by 4 weeks of 'wash out' (no intervention) and 4 weeks of vegetarian diet
2493988|NCT02942381|Active Comparator|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2), 100mg Tid (eGFR45-59 ml/min/1.73m2), 100mg Bid (eGFR 30-44 ml/min/1.73m2) and supportive treatment
2493993|NCT02942381|Placebo Comparator|Placebo|Placebo and supportive treatment
2494024|NCT02942238|Experimental|Complete Mesocolic Excision|the group underwent laparoscopic right hemicolectomy with CME. In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
2494025|NCT02942238|Active Comparator|D3 lymph node dissection|the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 lymph node dissection group(D3), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue. No.6 lymph node should be dissected in this group.
2494037|NCT02942225||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-V criteria
2494041|NCT02942225||TD group|Typically development controls without lifetime diagnosis with ADHD
2494061|NCT02942121|Experimental|LST App|Participants will use the LifeScience Technologies application (LST app) before surgery, and post surgery. Participants will use the app as an educational tool to learn more about their surgery. Participants will also answer questions about themselves in the app.
3161834|NCT00449774|Experimental|Subjects in Treatment regimen D|Subjects in treatment regimen D will receive 200 mg Immediate Release (IR) tablets of lamotrigine with water in fasting condition.
2494087|NCT02941887||Down's Syndrome|Behavior analysis in Down's Syndrome patients
2494100|NCT02941588||non-cardiac surgery after DES|The patients who underwent non-cardiac surgery after percutaneous coronary intervention with drug-eluting stent
2492871|NCT02950324|Active Comparator|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
2492912|NCT02949960|Experimental|DMT210 Topical Gel|DMT210 Topical Gel 5% applied to target lesion twice daily
2492914|NCT02949960|Placebo Comparator|Vehicle Control|Topical Gel vehicle applied to target lesion twice daily
2492938|NCT02949648||Electronic cigarette ever user|Youth Quitline callers who reported ever use of e-cigarette at baseline.
2492941|NCT02949648||Electronic cigarette never user|Youth Quitline callers who reported never use of e-cigarette at baseline.
2492992|NCT02949388|Placebo Comparator|Placebo|Placebo Comparator: Placebo daily Two (2) placebo capsules given twice daily (AM and PM) for 84 (± 2 days
2493000|NCT02949388|Active Comparator|300 mg (150 mg BID)|Active Comparator: 300 mg of Prurisol daily One (1) capsule containing 100 mg Prurisol and one (1) capsule containing 50 mg of Prurisol given twice (AM and PM) for 84 (± 2) days
2493008|NCT02949388|Active Comparator|400 mg (200 mg BID)|Active Comparator: 400 mg of Prurisol daily Two (2) capsule each containing 100 mg Prurisol given twice daily (AM and PM) for 84 (± 2) days
2493084|NCT02948686|Active Comparator|SET (Self-Etching)|55 teeth will receive restorations using Self-Etching Application Strategy
2493086|NCT02948686|Experimental|SEE (Selective Enamel Etching)|55 teeth will receive restorations using Enamel Etching Application Strategy
2493089|NCT02948686|Experimental|SETT (Self-Etching, more time)|55 teeth will receive restorations using Self Etching with Extended time Application Strategy
2493092|NCT02948686|Experimental|SETL (Self-Etching, more layers)|55 teeth will receive restorations using Self Etching with Extended layers number Strategy
2493122|NCT02948348|Experimental|Nivolumab & Ipilimumab(Only Cohort D)|chemoradiotherapy with capecitabine+ Nivolumab + Ipilimumab(Only Cohort D) + surgical therapy
2493156|NCT02948036|Experimental|MMT|Mobile-device, plasticity-based adaptive cognitive treatment
2493221|NCT02947763|Active Comparator|multiple visit|multiple visit root canal treatment with triple antibiotic paste intracanal medication (a mixture of metronidazole, ciprofloxacin, and minocycline)
2493233|NCT02947763|No Intervention|single visit|single visit root canal treatment without any intra-canal medication
2493288|NCT02947360|Experimental|FOVUS|All eligible and consenting patients will receive a focused vascular ultrasound examination of the carotid arteries
2493402|NCT02946437|Experimental|Sevoflurane|"Sevoflurane postconditioning will start after the bleeding source is excluded by coiling or clipping as soon as the patient returns to the ICU and will be continued for 4 hours. 0.5-1.5vol% sevoflurane will be administrated into the ventilation circuit by a MIRUS™System.~The used dose (0.5-1.5vol%) is a lower dose as used for anaesthesia for a surgical intervention (0.5-3vol%), but high enough to provide sufficient sedation."
2493405|NCT02946437|Active Comparator|Propofol or Midazolam|Propofol or midazolam will be administrated intravenously before and after the postconditioning with sevoflurane as in the standard sedation regimen of the Neurointensive Care Unit, University Hospital Zurich (propofol 0.3-4.0mg/kg/h cont. i.v.; midazolam 0.03-0.2mg/kg/h cont. i.v.)
2493410|NCT02946437|Other|MIRUS™System|MIRUS™ is a newly developed device, considered as vaporizer system, which can be used in the setting of operating rooms or in intensive care units. The MIRUS™System is successfully in use in daily clinical practice. This type of device is similar to the well-known AnaConDa® system (AnaConDa®, Sedana Medical, Uppsala, S) with several advantages. Since 2005 the anaesthetic-conserving device AnaConDa® facilitates, from a technical viewpoint, the routine use of volatile anaesthetics in intensive care patients as part of prolonged sedation, using ICU ventilators (Soukup J et al., 2009). The MIRUS™System forms a closed loop. It measures the end-tidal concentration of the anaesthetic gas and governs the application of the anaesthetic gas according to these values and the ventilation parameters.
2493511|NCT02945969|Experimental|Low Sodium Diet|Behavioral modification to decrease dietary sodium intake to ≤2,300 mg/day for 24 weeks. The intervention program consists of two phases. An initial 12-week intensive phase will include weekly individual and group sessions. This will be followed by a 12-week maintenance phase that includes telephone counseling sessions every 2 weeks.
2493515|NCT02945969|No Intervention|Usual Diet|No dietary intervention.
2493535|NCT02945501|Experimental|Subjects Who Received TES SO|Participants will sleep for approximately a two hour period and receive TES SO via the NeuroConn DC Stimulator PLUS during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
2493537|NCT02945501|Sham Comparator|Received SHAM (no TES SO)|Participants will sleep for approximately a two hour period and receive a SHAM (no TES SO) during the second hour of that two hour sleep period. They will then experience a 46 hour period of sleep deprivation, during which cognitive performance, mood and subjective and objective aspects of sleepiness will be assessed approximately every 75 minutes beginning on the night of restricted sleep/treatment.
2493592|NCT02945072|Active Comparator|Sevoflurane group|general anesthesia will be maintained with sevoflurane
2493594|NCT02945072|Experimental|TIVA group|general anesthesia will be maintained with total intravenous anesthesia (propofol and remifentanyl)
3161835|NCT00449774|Experimental|Subjects in Treatment regimen E|Subjects in treatment regimen E will receive 200 mg ODT disintegrate of lamotrigine in mouth without water in fed state.
2493685|NCT02944357|Experimental|Treatment (gemcitabine hydrochloride, cisplatin, AGS-003-BLD)|"NEOADJUVANT PHASE: Patients receive gemcitabine hydrochloride IV on days 1 and 8, AGS-003-BLD ID on day 1, and cisplatin IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive AGS-003-BLD ID on day 1. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo cystectomy during course 8.~ADJUVANT PHASE: Patients continue AGS-003-BLD ID on day 1 of course 9. Treatment repeats every 12 weeks for up to 9 courses in the absence of disease progression or unacceptable toxicity."
2494117|NCT02941718|Experimental|Sleep Advancement Counseling|"Participants will receive a 15-week intervention targeting smoking cessation and sleep counseling intervention.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~Sleep counseling components in the form of CBT for insomnia will be given as part of the smoking cessation counseling."
2494121|NCT02941718|Active Comparator|General Health Intervention|"Participants will receive a 15-week intervention targeting smoking cessation and general health information.~Smoking Cessation intervention components include:~6 individual smoking cessation sessions over 15 weeks (week 1, 3, 4, 7, 11, 15)~12 weeks of the quit-smoking drug chantix. The standard dosing will be used - 0.5 mg once per day for days 1-3, 0.5my twice per day for days 4-7; and 1mg twice per day from week 3 until the end of treatment.~The general health information counseling will be given as part of the smoking cessation counseling and topics include diet, physical activity, oral health, cancer screening and skin protection."
2494172|NCT02941380||Ischemic heart disease|Patients admitted for coronary artery bypass grafting with the use of cardiopulmonary bypass
2494262|NCT02941081|Experimental|IHAT|IHAT arm: novel iron supplement - 1 dose/day single IMP containing IHAT (iron hydroxide adipate tartrate) powder bioequivalent to 12.5 mg elemental iron (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to ferrous sulphate)
2494266|NCT02941081|Active Comparator|ferrous sulphate|Ferrous sulphate arm: clinical standard of oral iron supplementation - 1 dose/day single IMP containing ferrous sulphate (FeSO4 ) powder equivalent to 12.5 mg elemental iron
2494267|NCT02941081|Placebo Comparator|placebo|Placebo arm: 'no iron' arm - 1 dose/day containing saccharose powder
2494304|NCT02940405|Experimental|ketorolac tromethamine|One tablet of Ketorolac tromethamine 10-mg one hour before endodontic treatment
2494309|NCT02940405|Placebo Comparator|placebo tablet|One tablet of a placebo one hour before endodontic treatment
3161836|NCT00449774|Experimental|Subjects in Treatment regimen F|Subjects in treatment regimen F will receive 200 mg ODT of lamotrigine, that subjects will swallow with water in fasting condition.
3161837|NCT00449813|Active Comparator|1.|40 mg Pantoprazole
2494462|NCT02939261|Active Comparator|Control|Families randomized to control will receive monthly emails containing publicly available handouts on general child health.
2494464|NCT02939261|Experimental|Intervention - 4 Home Visits|Families randomized to the intervention will receive: a) 4 home visits from a health educator, b) weekly e-mails, and c) monthly mailed behavioural supports.
2494526|NCT02938923|Experimental|Exercise + Testosterone (EX + T)|Supervised exercise training 2 times per week and topical testosterone 1% gel (12.5 mg per pump depression) daily, both for six months duration.
2494527|NCT02938923|Placebo Comparator|Exercise + Placebo (EX + P)|Supervised exercise training 2 times per week and placebo gel daily, both for six months duration.
2494528|NCT02938923|Other|Enhanced Usual Care (EUC)|Home exercise program 3 times per week and monthly health education modules, both for six months duration.
2494654|NCT02937961|Experimental|Early SLED|
2494657|NCT02937961|Active Comparator|Late SLED|
2494970|NCT02935790|Experimental|ACY-241 combo with Ipi and Nivo|ACY-241 in Combination with Ipilimumab and Nivolumab
2495020|NCT02935491||Transcatheter Aortic Valve Implantation|Lyon and Paris cohorts : 900 patients will be used to test the prognostic value of aortic calcifications and to propose a risk score Clermont and Rouen cohorts (700 patients) will be used to test in an independent group, the predictive value of the risk score
2495102|NCT02935335||Menopur® HP-hMG|Treatment according to routine clinical practice.
2495118|NCT02934867|Experimental|CONTARM|Protocol phone advice
2495121|NCT02934867|Other|CONTHAB|Usual phone advice
2495214|NCT02934360||Non-small cell Lung Cancer|Previously diagnosed stage III or higher non-small cell lung cancer subjects will provide serial plasma specimens and clinical assessment information over time
2495216|NCT02934360||Breast Cancer|Previously diagnosed stage IV breast cancer subjects will provide serial plasma specimens and clinical assessment information over time.
2495277|NCT02933905||Non-PVD subjects|Patients with no PVD on SD-OCT at basal visit
2495279|NCT02933905||PVD subjects|Patients with PVD on SD-OCT at basal visit
2495332|NCT02933632|Active Comparator|Standard Assistance Protocol-SAP|Patients underwent physical therapy once a day. Patients receive intervention by Physical Therapy-SAP.
2495346|NCT02933632|Active Comparator|Accelerated Rehabilitation Protocol-ARP|Patients underwent physical therapy three times a day. Patients receive intervention by Physical Therapy-ARP.
2495381|NCT02933229|Experimental|H. pylori eradication cohort|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
3161838|NCT00449839|Other|A, CSII without bolus|Period A: A constant subcutaneous infusion rate of insulin aspart (0.5 U/hr) is given for 8 hours. Following 3 hours of blood sampling.
3161839|NCT00449839|Other|B; CSII with bolus|Period B: A constant subcutaneous infusion of insulin aspart (0.5 U/hr) is given for 8 hours and upon start a s.c.bolus (1.4 U)of insulin aspart is given. Hereafter follows 3 hours of blood sampling.
3161840|NCT00449839|Other|C; CSII with bolus, optional|A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
3161841|NCT00449852|Experimental|Interactive Voice Response Group|
3161842|NCT00449852|No Intervention|Usual Care Group|
3161843|NCT00449878|Experimental|Liprotamase|"Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units).~Open Label Period: Liprotamase administered orally with each of three meals and two snacks daily for 21 days.~Double Blind Treatment Period: Administered orally with each of three meals and two snacks daily for 6 days.~Second Open Label Period: Administered orally with each of three meals and two snacks daily for 7 days."
3161844|NCT00449878|Placebo Comparator|Placebo|Double Blind Treatment Period: Placebo (microcrystalline cellulose) administered orally with each of three meals and two snacks daily for 6 days.
3161845|NCT00449904|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months.
2494228|NCT02940912|Active Comparator|Apomorphine (5 mg/ml)|Active phase is apomorphine (from 0.5 mg (0.1 ml) to maximum 5 mg (1 ml)/hour of apomorphine), delivered with a pump (subcutaneous administration), during 22 days.
2494235|NCT02940912|Placebo Comparator|Physiologic serum|Physiological serum (from 0.1 ml to maximum 1 ml/ hour), delivered with a pump (subcutaneous administration), during 22 days.
2494287|NCT02940509|Active Comparator|Ketamine plus Magnesium sulfate|Ketamine 0.5mg/kg IV dose with 2g magnesium IV dose
2494294|NCT02940509|Placebo Comparator|Placebo|Normal Saline (NaCl 0.9%)
2494326|NCT02940236||Multimodal analgesia|Patients scheduled for general surgery and requiring multimodal analgesia in preoperative period.
2494360|NCT02939976|Active Comparator|Single Vessel Disease|Standard of care comparator for those subjects with single vessel coronary artery disease. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2494362|NCT02939976|Experimental|Multi-vessel Disease, Culprit Vessel Only|Subjects randomized to revascularization of infarct related artery only. Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2494365|NCT02939976|Experimental|Multi-vessel Disease, Complete Revascularization|Subjects randomized to complete revascularization. Complete revascularization of all diseased arteries with Medtronic Resolute family of stents; Use of Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology to determine which arteries to stent; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
2494583|NCT02938429|Other|Participants with Fontan circulation|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
2494589|NCT02938429|Other|Age and gender matched controlled|"Physical activity measurements: Participants will wear Actigraph GT3X+ accelerometers for 7 consecutive days and complete a physical activity log. Data from the accelerometers and physical activity log will be cross referenced.~Endothelial function measurements: Participants undergo Digital Thermal Monitoring (DTM) via Vendys (VENDYS-6000, Endothelix Inc., Houston, TX). Since DTM is not currently a validated tool and its use has not been published in a paediatric population, we will employ a second assessment of endothelial function, the Endothelial Pulse Amplitude Test (Endo-PAT, Itamar Medical).~Participants will complete a questionnaire to access factors that can affect endothelial function."
2494638|NCT02938182|Experimental|clopidogrel|clopidogrel tablet 75mg daily for three months
2494692|NCT02937805|Experimental|Moisturizing vaginal and vulvar sea buckthorn oil cream|Moisturizing non-hormonal vaginal and vulvar cream containing sea buckthorn oil as active ingredient (medical device product in development). Administered twice or once per day for 5 weeks. Post-menopausal women n= 55 + 45. Pre-menopausal women n=15
2494697|NCT02937805|Active Comparator|Moisturizing vaginal and vulvar cream|Moisturizing non-hormonal vaginal and vulvar cream (commercial medical device cream already on the market, not containing sea buckthorn oil). Administered once - twice per day for 5 weeks. Postmenopausal women n=55
2494698|NCT02937805|No Intervention|Control|No moisturizing vaginal and vulvar cream for 5 weeks. Postmenopausal women n=55
3161846|NCT00449969|Experimental|1. Extended feedback|
3161847|NCT00449969|Active Comparator|2. Limited feedback|
3161848|NCT00450008|Other|A|Combination therapy of GM-CSF, Thalidomide plus Docetaxel in patients with prostate cancer with a rising PSA
3161849|NCT00450034|Experimental|1|
2495023|NCT02935556||post partum pre-eclampsia|women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
2495027|NCT02935556||controls|women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
3161850|NCT00450086|Experimental|A|
3161851|NCT00450086|Experimental|B|
3161852|NCT00450086|Placebo Comparator|C|
3161853|NCT00450099|Experimental|1|Epidural, bupivacaine
3161854|NCT00450125||Six-Minute Walk Test|Two Six-minute walk tests where total distance walked measured. Tests performed within 15 days of an exercise stress test.
3161855|NCT00450138|Experimental|1|Radiation + vandetanib
3161856|NCT00450138|Experimental|2|Radiation + cisplatin + vandetanib
3161857|NCT00450203|Experimental|ECX + Bevacizumab|ECX + Bevacizumab
3161858|NCT00450203|Active Comparator|Epirubicin, Cisplatin and Capecitabine|ECX chemotherapy
3161859|NCT00450203|Experimental|ECX + Lapatinib|ECX + Lapatinib
3161860|NCT00450229|Experimental|Arm I|Patients receive low-dose, nutritional-grade oral diindolylmethane (DIM) twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
3161861|NCT00450229|Experimental|Arm II|Patients receive high-dose, nutritional-grade oral DIM twice daily as in arm I.
3161862|NCT00450229|Placebo Comparator|Arm III|Patients receive oral placebo twice daily for 21-28 days in the absence of disease progression or unacceptable toxicity. Treatment may continue for up to 60 days, if surgery is delayed.
2494129|NCT02941549|Placebo Comparator|Placebo|Participants in this group will receive matching placebo capsules twice daily.
2494131|NCT02941549|Experimental|500 mg DS102|Participants in this group will receive 500 mg DS102 capsules twice daily.
2494133|NCT02941549|Experimental|1000 mg DS102|Participants in this group will receive 1000 mg DS102 capsules twice daily.
2494210|NCT02941133|Experimental|Neural Mobilization Group|Patients in this group will be treated with neural mobilization techniques.
2494211|NCT02941133|Experimental|Standard Care Group|Patients in this group will be treated with standard care (ultrasound, exercise, TENS, massage)
2494241|NCT02940717|Experimental|Vita suprinity|Vita Suprinity is a recent material with glass ceramic enriched with zirconia (approx. 10 % by weight) that offer practices and laboratories a high-strength, zirconia-reinforced lithium silicate ceramic (ZLS).
2494244|NCT02940717|Active Comparator|Emax cad|lithium disilicate glass-ceramic which is etchable and proved to have good success rate if used for laminate venners
2494273|NCT02940587|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
2494274|NCT02940587|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
2494316|NCT02940353|Other|Treatment with Trefoil concept|Treatment
2494331|NCT02940067|Experimental|MedEx|This group will receive nutritional supplementation (based on components of the MEDiterranean diet) and supervised EXercise training for four weeks - hence the trial name, MedEx.
2494332|NCT02940067|No Intervention|Standard Care|This group will follow current standard preoperative care before scheduled pancreatic resection.
2494419|NCT02939534||PD and Controls|50% of the participants will be healthy controls and 50% will be patients diagnosed with Parkinson's disease
2494466|NCT02939248|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
2494467|NCT02939248|Active Comparator|Crushed ticagrelor, morphine,naloxone|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
2494519|NCT02938884|Active Comparator|HidrateSpark Water Bottle|"Patients meeting the eligibility criteria who are interested in participating in the study and randomized to receive the HidrateSpark water bottle be given one at no cost. They will download the associated free software application to their smartphone and be given education in the outpatient setting regarding how to use the system.~All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded."
2494523|NCT02938884|No Intervention|No Smart water bottle|All subjects in both cohorts will be provided the same questionnaire on two occasions, at the beginning and end of the trial, to determine their attitudes about fluids and potentially identify barriers to maintaining adequate hydration status (Appendix A). Additionally, standard information from the medical record including demographics, occupation, medical history and medications will be recorded.
2494559|NCT02938598|Experimental|A|Engagement On - Problem Solving High - Motivation On
2494563|NCT02938598|Experimental|B|Engagement On - Problem Solving Low - Motivation On
2494567|NCT02938598|Experimental|C|Engagement On - Problem Solving High - Motivation Off
2494571|NCT02938598|Experimental|D|Engagement On - Problem Solving Low - Motivation Off
2494576|NCT02938598|Experimental|E|Engagement Off - Problem Solving High - Motivation On
2494580|NCT02938598|Experimental|F|Engagement Off - Problem Solving Low - Motivation On
2494581|NCT02938598|Experimental|G|Engagement Off - Problem Solving High - Motivation Off
2494584|NCT02938598|Experimental|H|Engagement Off - Problem Solving Low - Motivation Off
2494637|NCT02938078|Experimental|Treatment Eye|One eye will be treated with Avenova; the other eye will not be treated. The investigator is masked as to which eye is receiving Avenova product.
2494640|NCT02938078|No Intervention|Non-Treatment Eye|One eye will be treated with Avenova; the other eye will not will be treated. The investigator is masked as to which eye is receiving Avenova product.
2494674|NCT02937831||All Study Participants|
2494711|NCT02937532|Placebo Comparator|GHE + TOBT training|Subjects will receive general health education and task-oriented balance training.
2494713|NCT02937532|Active Comparator|CBT + TOBT training|Subjects will receive group-based cognitive behavioral therapy and task-oriented balance training.
2494751|NCT02937311|Experimental|NMES group|This group of patients received Neuromuscular Electrical Stimulation (NMES) and standardized physiotherapy and rehabilitation protocol
2494754|NCT02937311|Experimental|Kinesiotape Group|This group of patients received standardized physiotherapy and rehabilitation protocol and at the same time kinesiotape was applied to their affected shoulder
2494760|NCT02937311|Experimental|Control|This group of patients received only a standardized physiotherapy and rehabilitation protocol
2494836|NCT02936791||Individuals diagnosed with PKD|Individuals that have been diagnosed and meet the study's definition of early stage PKD.
2494841|NCT02936791||Individuals with a family history of PKD|Unaffected/ undiagnosed family members, preferably siblings, of participants with PKD
2494846|NCT02936791||Normal individuals for the comparison|Normal volunteers with no family history of PKD or other kidney diseases.
2494893|NCT02936427|No Intervention|Control|Control group will receive normal post operative care including intercostal wound catheters however will not receive dexamethasone
2494895|NCT02936427|Experimental|Dexamethasone 4mg|Participants will receive 4mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
2494903|NCT02936414|Experimental|Berberine group|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
3194956|NCT00833963||Participants Treated With Trastuzumab|Participants who are being treated with trastuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3194957|NCT00833963||Participants Treated With Trastuzumab and Pertuzumab|Participants who are being treated with the combination of trastuzumab and pertuzumab during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3194958|NCT00833963||Participants Treated With Ado-Trastuzumab Emtansine|Participants who are being treated with ado-trastuzumab emtansine during pregnancy or within 7 months prior to conception will be evaluated for cancer and pregnancy as determined by their treating physicians' standards of care, and will be observed for up to 12 months after delivery.
3194959|NCT00834015|Other|Experimental|combined strength and aerobic training
3194960|NCT00834028||1|patients with hepatocellular carcinoma receive transcatheter arterial chemoembolization
3194961|NCT00834054||Double-lung transplanted patients|
2494415|NCT02939495|Experimental|Study drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet
2494460|NCT02939300|Experimental|Combination Of Nivolumab with Ipilimumab|"All patients will be treated with the combination regimen of Nivolumab at pre-determine dose with Ipilimumab at a pre-determine dose.This will be followed by Nivolumab Monotherapy.~Each treatment Cycle will last 6 weeks"
2494512|NCT02938910||Healthy Volunteers|Healthy volunteers with normal blood pressure
2494516|NCT02938910||Primary Hyperaldosteronism|Subjects with hypertension and high levels of seric aldosterone.
2494520|NCT02938910||Secondary Hyperaldosteronism|Patient with Gitelman syndrome, with normal blood pressure and high level of aldosterone
2494524|NCT02938910||Essential Hypertension|Patient with hypertension without secondary cause of hypertension
2494547|NCT02938572|Experimental|NNC0143-0406|
2494551|NCT02938572|Active Comparator|Insulin aspart|
2494611|NCT02938312|Active Comparator|Weight Loss Only|24- month weight loss program (year 1: weekly in-person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
2494612|NCT02938312|Experimental|Weight Loss Plus|"Same intervention as Weight Loss Only but includes community-wide interventions to increase access to healthy affordable food and opportunities for safe and convenient physical activity"
2494646|NCT02937987||Group 1|non-obese type 2 DM
2494650|NCT02937987||Group 2|obese type 2 DM
3161863|NCT00450281||Male, Never-smokers|Male subjects who smoked less than 100 cigarettes during their lifetime.
3194962|NCT00834093|Experimental|Biological/Vaccine|'Epstein-Barr Virus Specific Immunotherapy' given intravenously on Days 1 and 14
3194963|NCT00834119|Experimental|Mometasone furoate|
3194964|NCT00834119|Experimental|Mometasone furoate plus an oral antihistamine|
3194965|NCT00834145|Experimental|1|Patients will receive a NormaTec pump and perform active pumping twice daily during hospitalization and thereafter once daily in addition to routine medical therapy.
2494869|NCT02936466|Experimental|Interventional group|Bipolife group
2494873|NCT02936466|No Intervention|Control group|No specific intervention, treatment as usual
2494990|NCT02935972|Active Comparator|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
2494992|NCT02935972|Active Comparator|Local|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
2494995|NCT02935972|Active Comparator|Combined|received intravenous diazepam 5 mg slowly just before TRUS probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
2495055|NCT02935465|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2495057|NCT02935465|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2495072|NCT02935166|Placebo Comparator|Uncharged|Respiratory muscle training: placebo General High Intensity Training (30 minutes in cycle ergometer) and placebo respiratory muscle training: This training group performed with the valve Orygen® uncharged (placebo effect). Performing 10 consecutive inspirations (5 series) two times a day during 3 weeks.
2495076|NCT02935166|Active Comparator|Inspiratory|Respiratory muscle training: Inspiratory General Training (30 minutes in cycle ergometer) and high intensity inspiratory muscle training: The inspiratory training was conducted with the Orygen® valve. Inspiratory training load was defined as maximum and patient tolerance that would perform 10 consecutive inspirations (5 series) two times a day, during 3 weeks.
2495079|NCT02935166|Active Comparator|Inspiratory and expiratory|Respiratory muscle training: Inspiratory and expiratory General High Intensity Training (30 minutes in cycle ergometer) and inspiratory and expiratory training: The inspiratory and expiratory training was conducted with the Orygen® valve. Loading inspiratory and expiratory training was defined as maximum and patient tolerance. This was the optimal load that would allow the patient to perform 10 consecutive inspirations (5 sessions) 2 times a day,during 3 weeks.
2495126|NCT02935023|Experimental|CIRT with systemic therapy arm|Carbon ion radiotherapy combined with systemic therapy
2495207|NCT02934646|Experimental|Subacute stroke patients|Elbow passive/active robotic treatment provided by NEUROExos Elbow Module
3194966|NCT00834145|No Intervention|2|Routine medical treatment
3194967|NCT00834158|Active Comparator|TACE|perform TACE only
3194968|NCT00834158|Experimental|TACE+PVE|perform TACE and PVE sequentially
3194969|NCT00834184|Experimental|A|nikkomycin Z 250 mg BID versus placebo BID x 14 days
3194970|NCT00834184|Experimental|B|nikkomycin Z 500 mg BID versus placebo BID x 14 days
3194971|NCT00834184|Experimental|C|nikkomycin Z 750 mg BID versus placebo BID x 14 days
3194972|NCT00834184|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
3194973|NCT00834223|Other|Aquashunt|Open label, all subjects receive device.
2495494|NCT02932553|Experimental|BVS and OMT|Optimal medical treatment + BVS implantation
3194974|NCT00834262||A|
3194975|NCT00834301|Experimental|Treatment Arm|
3194976|NCT00834314|Experimental|Vacuum-pack|see Interventions
2494224|NCT02941250|Experimental|treatment|patients receiving ISSD emulator
2494285|NCT02940665||Enhanced Recovery After Surgery (ERAS)|ERAS group followed the ERAS protocol. The protocol was implemented 13 months prior to the start of data collection.
2494290|NCT02940665||Conventional|Conventional group received conventional care.
3194977|NCT00834314|Active Comparator|Abdominal dressing|see Interventions
3194978|NCT00834327|Experimental|1|aplindore 0.05 mg MR total daily dose
3194979|NCT00834327|Experimental|2|aplindore 0.1 mg MR total daily dose
3194980|NCT00834327|Experimental|3|aplindore 0.25 mg MR total daily dose (to include short titration)
2494426|NCT02939638|Active Comparator|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
2494429|NCT02939638|Active Comparator|Control diet|Half of the participants will be asked to continue their usual diets for the 16-week study period.
2494494|NCT02939144|Experimental|Liquorice|Participants of the single-arm study will ingest liquorice candy and their blood, saliva and urine samples will be collected. They will be regularly monitored for any potential side effects.
2494533|NCT02938741|Experimental|r-ATG Immunosuppressive agents|"Rabbit Anti-human Thymoglobulin (r-ATG 2.5 mg/kg×4 days) were extra used in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
2494534|NCT02938741|Placebo Comparator|placebo|"Rabbit Anti-human Thymoglobulin (r-ATG) were not used as intervention in the treatment group.~The conditioning include of Busulfex 3.2mg/kg*4d,CTX 60mg/kg *4d."
2494577|NCT02938507|Experimental|Formulation 1 solabegron|Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
2494578|NCT02938507|Experimental|Formulation 2 solabegron|Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
2494615|NCT02938208|Experimental|Jupiter Full Face Mask|Participants to use full face mask in-home for a 14 ± 3 days in-home.
2494679|NCT02937948|Experimental|Adaptative Treatment plans|A Library of treatment plans will be generated for each patient before starting radiochemotherapy (standard treatment). This Library will be created using CT-Scans with variable bladder filling (and hence different uterine positions). Each day of radiotherapy treatment, an appropriate plan is chosen based on Imaging that day.
2494863|NCT02936804|Experimental|Screening Arm|Low Dose Computed Tomography (LDCT) was performed at baseline + 2 rounds of biennial repeated LDCT. Management of positive screening test will be carried out by a pre-specified protocol.
2494936|NCT02936310|Experimental|mindfulness intervention|"The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.The proposed topics include: 1) mindfulness: dealing with stress in a new way, 2) mindful awareness of stress: listening to our body, 3) mindful working with thoughts, 4) mindful working with emotions, 5) mindful interactions, and 6) dealing with obstacles of mindful practices and wrap-up. Mindfulness practices embedded in the program will include mindfulness breathing meditation, sitting meditation, standing meditation, walking meditation, movement meditation (Taichi or Yoga), body scan meditation and daily life meditation.~Data will be collected at pre-intervention (one week before the first session) and post-intervention (one week after the last session) to assess stress, burnout, mindfulness, anxiety,depression,the feedback on the MLWS intervention and the feedback on the influence of MLWS intervention."
2495004|NCT02935855|Active Comparator|Nondiabetics (group 1)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
2495006|NCT02935855|Active Comparator|Diabetics (group 1)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with dabigatran or apixaban or rivaroxaban or edoxaban in randomized way
2495007|NCT02935855|Active Comparator|Nondiabetics (group 2)|Nondiabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
2495008|NCT02935855|Active Comparator|Diabetics (group 2)|Diabetic patients with first diagnosis of non-valvular atrial fibrillation; they will be treated with warfarin or acenocumarole as guidelines suggest
2495071|NCT02935218|Other|Parenting Skills for Mothers with BPD|single-arm study
3194981|NCT00834327|Experimental|4|aplindore 0.5 mg MR total daily dose (to include short titration)
3194982|NCT00834327|Placebo Comparator|5|Placebo
2495218|NCT02934321|Active Comparator|Aspartame Sweetened Beverage|Volunteers will consume a low-calorie, aspartame sweetened beverage (185 mg aspartame in water) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
2495221|NCT02934321|Experimental|Erythritol Sweetened Beverage|Volunteers will consume an isosweet, compared to aspartame, high osmolar, low-calorie erythritol sweetened beverage (50.8 g erythritol in water, 1.66 Molar) after fasting for 10 hours and abstaining from alcohol, caffeine, and strenuous exercise for 24 hours prior to the visit.
2495323|NCT02933853|Experimental|Faster Aspart|
2495337|NCT02933853|Active Comparator|Insulin Aspart|
2495362|NCT02933281|Experimental|Cohort 1: MTBVAC 5 x 10^3 CFU|Quantiferon (QFT) negative, 1 dose on Day 0
2495364|NCT02933281|Experimental|Cohort 2: MTBVAC 5 x 10^4 CFU|QFT Negative, 1 dose on Day 0
2495365|NCT02933281|Experimental|Cohort 3: MTBVAC 5 x 10^5 CFU|QFT Negative, 1 dose on Day 0
2495372|NCT02933281|Experimental|Cohort 4: MTBVAC 5 x 10^6 CFU|QFT Negative, 1 dose on Day 0
2495379|NCT02933281|Experimental|Cohort 5: MTBVAC 5 x 10^3 CFU|QFT Positive, 1 dose on Day 0
2495389|NCT02933281|Experimental|Cohort 6: MTBVAC 5 x 10^4 CFU|QFT Positive, 1 dose on Day 0
2495393|NCT02933281|Experimental|Cohort 7: MTBVAC 5 x 10^5 CFU|QFT Positive, 1 dose on Day 0
3194983|NCT00834353||Pulmonary tuberculosis patients|Freshly diagnosed pulmonary tuberculosis patients who are started with antituberculosis drugs
2494137|NCT02941471|Experimental|Interferential Stimulation|Medical Device: Interferential stimulation. Stimulation parameters: 4 KHz of carrier stimulation, beat frequency between 80-160Hz, amplitude upto 33mA. Delivered via two 100mm x 50mm adhesive pads placed on the anterior abdominal wall
2494142|NCT02941471|Active Comparator|Standard electrical stimulation|Medical Device: Standard electrical stimulation. Parameters set to provide continuous electrical stimulation at a pulse width of 210µs and a frequency of 14Hz and an amplitude upto 33mA.
2494219|NCT02941172|Other|[18F]FMPEP-d2 in warm conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 in standard room temperature conditions.
2494220|NCT02941172|Other|[18F]FMPEP-d2 in cold conditions|PET scan is performed using PET radiotracer [18F]FMPEP-d2 during controlled cold exposure.
2494221|NCT02941172|Other|[18F]FDG in cold conditions|PET scan is performed using PET radiotracer [18F]FDG during controlled cold exposure.
2494282|NCT02940652||Paediatric patients undergoing MRI scanning|All paediatric patients undergoing elective MRI scanning of the brain and/or brain and cervical spine
3161864|NCT00450281||Male, Ever-smokers|Male subjects who have smoked at least 100 cigarettes during their lifetime.
3161865|NCT00450281||Female, Ever-smokers|Female subjects who have smoked less than 100 cigarettes during their lifetime.
2494428|NCT02939625|Active Comparator|muscle training|participants will breathing exercises for 20 min, then 40 min training with Threshold IMT therapy will be held in 7 sessions
2494430|NCT02939625|Active Comparator|bilevel positive airway pressure|participants will breathing exercises for 20 min, then 40 min bilevel (IPAP and EPAP 12 = 8 cm H2O), the therapy will be held in 7 sessions
2494433|NCT02939625|Active Comparator|Continue Positive Airway Pressure|participants will breathing exercises for 20 min, then 40 min CPAP (8 cm H2O) therapy will be held in 7 sessions
2494513|NCT02939001|Experimental|Ophthalmic surgery group|Ophthalmic surgery group (refractive surgery, phakic Intraocular Lens implantation, and cataract surgery)
2494557|NCT02938650|Other|Nitrosomonas eutropha spray|Subjects will receive nitrosmonas eutropha spray that they will apply twice a day.
2494622|NCT02938273|Experimental|Bioimmunoradiotherapy|Concurrent Radiation therapy (i.e. 5 times a week, 7 weeks, total dose 70 Gy) with cetuximab (loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7) and Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months (wk 8,10, 12, 14, 16, 18, 20, 22, 24, 26.
2494677|NCT02937857|Active Comparator|Standard treatment only|Standard treatment only such as antiasthmatic, expectorant and antipyretic
2494680|NCT02937857|Experimental|Standard treatment+Xiyanping injection|Standard Treatment such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection intravenous administration of 0.2-0.4mL/kg/day ,QD for 5 days.
2494813|NCT02937051|Active Comparator|Own Brand Cigarette Condition|
2494815|NCT02937051|Experimental|Original-flavor Black&Mild cigar|
2494819|NCT02937051|Experimental|Apple-flavor Black&Mild cigar|
2494822|NCT02937051|Experimental|Cream-flavor Black&Mild cigar|
2494823|NCT02937051|Experimental|Wine-flavor Black&Mild cigar|
3161866|NCT00450281||Female, Never-smokers|Female subjects who have smoked at least 100 cigarettes during their lifetime.
3161867|NCT00450307|Experimental|3F8 and GM-CSF|One cycle has 5 days of 3F8 treatment. Each day, patients receive GM-CSF subcutaneously ~1.5 hr before the start 3F8 infusion. To limit side-effects, patients receive analgesics, antihistamines, and a small dose (IV, over ~5 minutes) of heat-modified 3F8. Cycles can be repeated after a 2-4 week interval, up to a total of two cycles.
2494916|NCT02936193|Experimental|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy with Pylorus-preservation
2494918|NCT02936193|Active Comparator|Distal gastrectomy|Patients undergo Laparoscopic Gastrectomy procedure detailing in distal gastrectomy with D2 lymphadenectomy
2495080|NCT02935231|Experimental|Nicotine Replacement Therapy|This experimental group receives health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
2495084|NCT02935231|Experimental|Minimal Cessation Advice & Nicotine Replacement Therapy|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet, 1-week free nicotine replacement therapy (gum/patch), a card containing instruction and potential side effects and follow-up intervention if they have the above side effects at 3-, 7- and 10-days.
2495085|NCT02935231|Experimental|Minimal Cessation Advice|This experimental group receives brief smoking cessation advice using AWARD model with a health warning leaflet.
2495087|NCT02935231|Active Comparator|Control|This control group receives a health warning leaflet.
2495122|NCT02934815|Experimental|Intervention group - SEGT|16 weekly sessions, 90 min of Supportive-expressive group therapy
2495128|NCT02934815|No Intervention|Control group|No intervention
2495267|NCT02934217|Experimental|Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
2495272|NCT02934217|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
2495329|NCT02933567|Experimental|CSC OnDemand Pilo|Pilot Intervention
2495385|NCT02933307|No Intervention|Control group|Patients with regular measurements by nurses only (Modified Early Warning Score (MEWS))
2495392|NCT02933307|Experimental|HealthPatch (Intervention)|Patients with HealthPatch and regular MEWS measurements
2495594|NCT02931799|Experimental|Nurse Follow-Up and Electronic Monitoring|
3161868|NCT00450320|Active Comparator|Rapamycin|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen.
3161869|NCT00450398|Experimental|1|YSPSL (rPSGL-Ig)
3161870|NCT00450398|Placebo Comparator|2|
3161871|NCT00450515|Experimental|vinflunine + capecitabine|"Patients receive vinflunine IV over 20 minutes on day 1 and oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every other course, and at the completion of study treatment.~After completion of study treatment, patients are followed periodically for up to 5 years."
3161872|NCT00450541||Fatigue Questionnaire + Interview|
3161873|NCT00450684|Experimental|Group A|Implantation and testing of CRT
3161874|NCT00450684|Experimental|Group B|IImplantation and testing of CRT
3161875|NCT00450697||observation|
2494138|NCT02941445|Experimental|COMBO (sitagliptin and metformin)|metformin 1000 mg BID and sitagliptin 50mg BID for 12 weeks
2494150|NCT02941445|Experimental|MET (metformin)|metformin 1000 mg BID
2494181|NCT02941198|Active Comparator|Gynefix|The GyneFix® 200 IUD(frameless iud) is only 2 cm long. Its small surface area is 1/3 of that of the conventional T-shaped IUDs such as TCu380A
2494184|NCT02941198|Active Comparator|Cu T380a|conventional T-shaped IUDs (TCu380A)which has a frame will be placed into the uterus after placental extraction
2494216|NCT02940964|Experimental|COMSCPR first|Group A will proceed to perform one cycle (two minutes) of COMSCPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
2494217|NCT02940964|Active Comparator|Standard CPR first|Group A will proceed to perform one cycle (two minutes) of Standard CPR. After taking a fifteen minute rest, participants will cross over to perform one cycle of the other method of CPR.
3194984|NCT00834379|Experimental|Pravastatin|Pravastatin 40 mg Tablet (test) dosed in first period followed by Pravachol® 40 mg Tablet (reference) dosed in second period
2494447|NCT02939417|Experimental|using grape seed extract|Grape seed extract as collagen cross-linking agent
2494452|NCT02939417|Active Comparator|without uing grape seed extract|
2494570|NCT02938468|Active Comparator|Surgery|Patients in this arm will receive any form if surgical intervention (i.e. bedside burrhole craniostomy, 2 burrhole washout, craniotomy, endoscopy etc.) for treatment of their chronic subdural hematoma
2494575|NCT02938468|Experimental|Dexamethasone|Patients in this arm will receive Dexamethasone over a 21day period for treatment of their chronic subdural hematoma
2494618|NCT02938195|Experimental|experimental arm|PF regimen (cis-platinum of 25 mg/m2/d, d1-3; 5-fluorouracil of 500mg/m2/d, d1-4) every 4 weeks for 2 cycles concurrently with three-dimensional radiation therapy or intensity-modulated radiotherapy followed by surgery 4-8weeks after neoadjuvant therapy in a standard manner.
2494678|NCT02937909|Experimental|Prospective Data|Use of BSN medical UK range of wound dressings and compression products for 12 weeks treatment period Training and testing of woundcare nursing competencies Quality of Life questionnaire for patients
2494682|NCT02937909|No Intervention|Historical data|Historical data from the three months prior to the study on time needed for nurse training, number of referrals to the Tissue Viability Team, costs of dressings used, number of patients with wounds treated, types of wounds, number of wound closures and duration of treatment .
3161876|NCT00450736|Experimental|Single Arm|
3161877|NCT00450775|Other|1|
2494922|NCT02936141|Experimental|Group psychotherapy|Group psychotherapy sessions includes the following: training of social skills (such as communication, social interaction and assertive behaviors), cognitive stimulation and training of activities of daily living (such as personal hygiene, hygiene of spaces and standardized mealtimes)
2494981|NCT02935959|Active Comparator|nebulized ketamine|patients will be premedicated with nebulized ketamine solution (2 mg/kg)
2494985|NCT02935959|Active Comparator|nebulized dexmedetomidine|patients will be premedicated with nebulized dexmedetomidine solution (2 μg/kg)
2494989|NCT02935959|Active Comparator|nebulized midazolam|patients will be premedicated with midazolam (0.2 mg/kg) nebulized solution
2495022|NCT02935504|Experimental|Program In Support of Moms PRISM|PRISM includes MCPAP for Moms and training, implementation support, and toolkits for Ob/Gyn practices on depression screening, assessment and treatment.
2495024|NCT02935504|Active Comparator|MCPAP for Moms|Consists of access to psychiatric consultation and resources and referrals through MCPAP for Moms - MCPAP for Moms is available free of charge to all Ob/Gyn practices in Massachusetts.
2495105|NCT02935283||OTCD participants|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD who can undergo MRI and behavioral testing
2495106|NCT02935283||Normal controls|Healthy males or females without known medical or metabolic disorder (control group) who can undergo MRI and behavioral testing
2495107|NCT02935283||HA recovery group|Female carriers of ornithine transcarbamylase deficiency (OTCD) or males with late onset presentation of OTCD or participants with CPS-1 who have had a recent hyperammonemic episode who can undergo MRI and behavioral testing
2495108|NCT02935283||Distal UCD|Males and females with ASSD and ASLD who can undergo MRI and behavioral testing
2495201|NCT02934685|Experimental|hypofraction|70 Gy in 28 fractions over 5.6 weeks
2495205|NCT02934685|Active Comparator|convention|80Gy in 40 fractions over 8 weeks
2495251|NCT02934087|Active Comparator|Retrograde Gate Cannulation|All patients undergoing elective EVAR with a standard commercially available stent graft will be randomized after informed consent obtained; gate cannulation method will be attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (snare) will be attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.
2495313|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 300mg)|Healthy elderly participants will receive single dose of 300mg JNJ-54175446.
2495314|NCT02933762|Experimental|Part 1: Cohort A1 (Placebo)|Healthy elderly participants will receive single dose of placebo.
2495395|NCT02933307|Experimental|ViSi Mobile (Intervention)|Patients with ViSi Mobile and regular MEWS measurements
3161878|NCT00450827|Experimental|Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab|Patients will be administered a therapeutic doses of intravenous (IV) 131I-3F8 given in a single dose per the dose escalation regimen on day 0 of study. This will be followed by blood draws for pharmacokinetic and dosimetry studies and by gamma camera scan, where feasible. Bevacizumab will be administered at a fixed dose of 15mg/kg on days 1 and 15. Thyroid protection is commenced 10 days prior to administration of 131I-3F8 and continued for 28 days after the therapeutic dose of 131I-3F8. ASCR will be carried out if ANC < 500/ul on day 28 (blood radioactivity will be confirmed to be <1 uCi/ml prior to ASCR). ASCR will be carried out sooner in the case of life-threatening infection in the setting of neutropenia (ANC<500). G-CSF can be used to maintain ANC>500/ul but should not be used for 24 hours immediately before and after ASCR. Blood product support will be provided with platelet and red cell transfusions as required.
3161879|NCT00450853|Experimental|Granisetron SC-Granisetron IV|Granisetron SC followed by Granisetron IV
2494139|NCT02941510|Experimental|Budesonide|Will participate in all study activities but will receive budesonide.
2494148|NCT02941510|Placebo Comparator|Placebo|Will participate in all study activities but will receive placebo.
2494183|NCT02941224|Experimental|SELUTION DCB|The SELUTION™ DCB (coated with sirolimus) is intended for use as a Percutaneous Transluminal Angioplasty (PTA) balloon catheter to dilate de-novo or restenotic vascular lesions, for the purpose of improving limb perfusion and decreasing the incidence of restenosis.
2494248|NCT02941003|Experimental|OCT treatment|Randomly assigned patients whose small pulmonary nodules are inflated with the diluted OCT medium (2:3) used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS (next-generation sequencing) for driver mutations.
2494252|NCT02941003|Experimental|OCT free|Randomly assigned patients whose small pulmonary nodules are uninflated with OCT used for frozen section, and then detected under microscope for their histopathological characteristics, by immunostaining for specific protein expression, by NGS for driver mutations.
2494295|NCT02940418|Active Comparator|Dose 1 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +1 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
2494299|NCT02940418|Active Comparator|Dose 10 mil/kg|"Adipose mesenchymal cells with bone marrow mononuclear cells.~Two doses with a 6 month interval of allogenic Adipose mesenchymal cells +10 mil/kg of autologous bone marrow mononuclear cells will be injected intravenously."
3194985|NCT00834379|Active Comparator|Pravachol®|Pravachol® 40 mg Tablet (reference) dosed in first period followed by Pravastatin 40 mg Tablet (test) dosed in second period
3194986|NCT00834392|No Intervention|Control|
3194987|NCT00834392|Experimental|Exercise|
2494389|NCT02939612|Experimental|App for Stress management|Participants will get access to two modules per week for five weeks (total 10 modules). The app consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
2494392|NCT02939612|No Intervention|Waitlist control group|Participants will get treatment as usual during the study. After the one year study follow up they will receive the stress management app.
2494473|NCT02939508|Experimental|Colon originated|A history of colon (-innervating) nerve damage, moderate or more severe edema; and without a history of colon (-innervating) nerve damage, with mild or severe edema of colonic wall on CT.
2494477|NCT02939508|Active Comparator|Non-colon originated|"NCOG met one of the two following criteria:~History of nerve damage that could affect colon movement (colon [-innervating] nerve damage), such as pelvic or retroperitoneal operation, spine injury, or cerebral lesion; and non-existing or mild edema of colonic wall on abdominal CT;~Absence of history of colon(-innervating) nerve damage, with no obvious change in the colonic wall visible on the CT scan."
2494539|NCT02938858||ATRA-chimio|according to usual practice center
2494540|NCT02938858||ATRA-ATO|according to usual practice center
3194988|NCT00834457|Active Comparator|2A|co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg po(Trizivir)one tablet twice daily(BID)for 96 weeks
3194989|NCT00834457|Active Comparator|2B|co-formulated abacavir 600mg/3TC 300mg orally (as Kivexa) one tablet daily plus fixed dose lopinavir 133.3mg/ritonavir 33.3mg orally (as Aluvia) four tablets daily for 96 weeks
2494758|NCT02937233|Experimental|4 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 4
2494761|NCT02937233|Experimental|2 Week Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 and Week 2
2494766|NCT02937233|Experimental|Single Vaccination Schedule|Zika Purified Inactivated Vaccine 5 mcg (or placebo) IM at Week 0 only
2494824|NCT02936947|Experimental|tomotherapy (HFPV vs free breathing)|Tomotherapy: locally advanced lung cancer (Stage III) or left breast cancer. High Frequency Percussive Ventilation will be coupled to tomotherapy treatment. The alternative procedure is free breathing.
2494825|NCT02936947|Experimental|linear accelerator (HFPV vs ABC)|"Linear accelerator: breast cancer or pulmonary cancers (Stage I/II) requiring a stereotaxic radiotherapy.~High Frequency Percussive Ventilation will be coupled to linear accelerator. The alternative procedure is Active Breathing Control (ABC)."
2494884|NCT02936557|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2494938|NCT02936167|Experimental|Ringer Lactate|fluid
2494941|NCT02936167|Experimental|Plasmalyte|fluid
2494974|NCT02935777|Experimental|Pomegranate Extract|"POMANOX® pomegranate extract capsules with water by mouth, once. Dosage: 2 capsules~Capsules weigh1.083g and contain: 210mg punicalagin, 328mg other pomegranate polyphenols (e.g. flavonoids and ellagic acid), 0.37mg anthocyanins and maltodextrin."
2494977|NCT02935777|Placebo Comparator|Placebo|Identical placebo capsules by mouth, administered once. Dosage 2 capsules. Each capsule contains maltodextrin to provide PE capsule energy equivalent i.e.6.52 kcal or 27.28kJ.
3194990|NCT00834470|Experimental|Atropine|Atropine 0.01mg/kg IV
2495075|NCT02935114|Experimental|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
3194991|NCT00834470|Placebo Comparator|Normal saline|Same volume of atropine
3194992|NCT00834496||1|"Our experience with the use of Sirolimus is delineated below. About 15% to 20% of our patients are currently switched to Sirolimus.Indications for conversion from calcinurin inhibitors (CNIs) to Sirolimus more than 90 days post liver transplantation include:~CNI renal toxicity.~Hepatic fibrosis on biopsy.~CNI neurologic toxicity.~Post transplant diabetes. Any of the above 4 indications makes a patient a candidate for conversion from CNIs to Sirolimus at or > 90 days after liver transplantation."
3194993|NCT00834509||Obstructive Sleep Apnea (OSA)|OSA participants will be treated with a CPAP/APAP treatment, per standard clinical care.
3194994|NCT00834509||Control|Control participants will not receive APAP/CPAP treatment, if not diagnosed with OSA.
3194995|NCT00834548||1|WB-MRA standard protocol
3194996|NCT00834548||2|WB-MRA hybrid protocol
2494141|NCT02941757|Experimental|Mediterranean Diet Intervention group|"In phase I, Group 1 will receive the MDNI for 12-months. Phase II: Group 1 fire houses will cross-over to self-sustained continuation, a less intense, self-directed, maintenance phase for 12 months to examine longer-term persistence of behavior change after the active 12-month MDNI. During self-sustained continuation access to some environmental changes: such as discounted food access, peer education/support, and online learning will remain; however, the stations will not receive investigator-led educational sessions"
2494152|NCT02941757|No Intervention|Control group|"2) In phase I, Group 2 will receive usual care, consisting of existing IFD health and wellness activities, with no investigator-provided interventions. In Phase II, Group 2 fire houses will cross-over to receive the full active MDNI for 6 months. The Group 2 MDNI will test the efficacy of a shorter, but otherwise identical MDNI. It will be followed by a final 6 months of self-sustained continuation (as described above) to examine the shorter MDNI's effect on persistence of adherence."
2494188|NCT02941211|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
2494202|NCT02940925|Experimental|Drug: Taxol,cisplatin and capecitabine|"Taxol, cisplatin and capecitabine as induction chemotherapy (IC) combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy |(CCRT)."
2494206|NCT02940925|Active Comparator|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
2494255|NCT02940743|Active Comparator|Education (Edu)|
2494257|NCT02940743|Active Comparator|Edu + Self-Monitoring (SM)|
2494263|NCT02940743|Active Comparator|Edu + SM + Social Cognitive Theory (SCT)|
3194997|NCT00834600|Experimental|HCTZ , ARB|Patients randomized to the Experimental Arm have initial drug choice determined by Plasma Renin Activity level. Low renin subjects are assigned to the diuretic hydrochlorothothiazide. Those with PRA >.65 ng/hr are assigned to the angiotensin receptor blocker, olmesartan.
2494385|NCT02939911||Paediatric patients after NMBA administration|Paediatric patients undergoing surgery with neuromuscular blockade
3194998|NCT00834600|Active Comparator|Conventional antihypertensive therapy|All patients randomized to Active Comparator Arm received hydrochlorothiazide 25 mg, which is increased to 50 mg at 3-4 weeks. At 6 weeks, olmesartan may be added if BP > 140 mmHg
2494480|NCT02938988|Experimental|Test group|Scaling and root planning and antimicrobial photodynamic therapy with red laser (658nm; 0.1W; 2229J/cm², 10s per point) and methylene blue dye (100μg/ml). Repetition after 3, 7 and 14 days.
2494484|NCT02938988|Active Comparator|Control Group|Scaling and root planning Repetition after 3, 7 and 14 days.
2494549|NCT02938728||Melanoma|Advanced melanoma treated by immunotherapies
2494614|NCT02938351|Experimental|collaborative care|To test the efficacy of a collaborative care intervention with patients treated with dialysis to reduce depression, pain, fatigue, and improve quality of life
2494681|NCT02937935|Experimental|Protocol Guided-RRT|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
2494683|NCT02937935|Active Comparator|On Demand-RRT|In the protocol guided group patients all patients would be considered for dialysis within 6 hours of randomization After randomization patients would receive dialysis as three sessions per week of at least 4 h with a blood flow >200 mL/min and a dialysate flow >500 mL/min in intermittent group and as 20-25 mL/kg/h of effluent, by filtration and/or diffusion in continuous form until recovery of renal functions
3194999|NCT00834665|Experimental|hTERT/GM-CSF+PCV, T cell infusion|ARM A = hTERT/GM-CSF+PCV, T cell infusion
3195000|NCT00834665|Experimental|GM-CSF+PCV, T cell infusion,GM-CSF+PVC|ARM B GM-CSF+PCV, T cell infusion,GM-CSF+PVC
2494816|NCT02936882|Other|Preoperative gastric ultrasonography|
3195001|NCT00834691||1|Patients with anemia and systolic heart failure
2494931|NCT02936128|Experimental|TruSkin®|Cryopreserved skin allograft
2494933|NCT02936128|Active Comparator|Wound Cover|Active Comparator for Venous Leg Ulcers
2494975|NCT02935829|Experimental|Glucose as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2494979|NCT02935829|Experimental|Carob preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
2494984|NCT02935829|Experimental|White bread as reference food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2494991|NCT02935829|Experimental|Carob snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
3195002|NCT00834691||2|Patients with systolic heart failure but without anemia
3195003|NCT00834691||3|Patients with at least moderate chronic renal failure, with or without anemia and without systolic heart failure.
2494144|NCT02941497|Experimental|Intensive intervention group|The intensive intervention group participates in development and implementation of the social marketing and health promotion campaign and peer-led campus activities and is assessed for their health-related behaviors. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
2494154|NCT02941497|Experimental|Diffuse intervention group|The diffuse intervention group receives the social marketing and health promotion campaign and participates in the peer-led campus activities and is assessed for their health related behaviors, but is not involved in the design and delivery of the intervention materials and activities. This was Wave 1 in colleges in Yr 01-02 and is being repeated as Wave 2 in colleges in Yr 03. This will also be repeated in high schools in Yr 04.
2494191|NCT02941107|Experimental|Rotarix|Rotarix (RV1) vaccine, 1mL liquid suspension administered orally.
2494192|NCT02941107|Placebo Comparator|Placebo|Placebo liquid suspension manufactured to mimic Rotarix (RV1) vaccine, 1ml administered orally
2494249|NCT02940873|Experimental|HARPdoc courses|Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia persisting despite optimised self-care (HARPdoc) - a combination of structured education around hypoglycaemia recognition, avoidance and treatment combined with hypoglycaemia-focussed cognitive behavioural therapy, delivered by diabetes educators, supported by a clinical psychologist, to small groups of eligible adults.
2494251|NCT02940873|Active Comparator|BGAT courses|Blood Glucose Awareness Training is an existing psycho-educational program which coaches adults with type 1 diabetes better to predict and recognise extremes of plasma glucose - hyper- and hypo-glycaemia. It has been shown to reduce severe hypoglycaemia rates.
2494302|NCT02940457|Experimental|Verum tDCS|prefrontal anodal stimulation
2494305|NCT02940457|Experimental|Sham tDCS|sham stimulation, same electrode positions
2494323|NCT02940145|Experimental|intervention 1|"The training group performed the resistance training (RT) program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays, wirh 3 sets of 10-15 repetition maximums.The RT program was performed in the following order: chest press, seated row, triceps pushdown, preacher curl, horizontal leg press, knee extension, leg curl, , and seated calf raise.~Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise"
2494325|NCT02940145|No Intervention|control group|The control group did not perform any type of physical exercise during the intervention period.
2494367|NCT02939963|Experimental|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC
2494369|NCT02939963|Experimental|pressure support 7 cm H2O PEP 4 cm H2O then ATC|ventilator is set to pressure support ventilation mode at set pressure 7 cm H2O above PEEP level of 4 cm H2O
3195004|NCT00834704|Other|1|Dose determination
3195005|NCT00834730|Active Comparator|Ketamine|Ketamine 2mg/kg IV
3195006|NCT00834730|Experimental|N2O gas|50%-70% N2O gas inhalation
2494453|NCT02939313|Experimental|medial prefrontal|Individuals will receive medial prefrontal cortex stimulation
2494455|NCT02939313|Experimental|dorsolateral prefrontal|Individuals will receive dorsolateral prefrontal cortex stimulation
2494456|NCT02939313|Sham Comparator|sham|Individuals will receive sham stimulation to the medial prefrontal and dorsolateral prefrontal cortex
2494517|NCT02938936|Experimental|Scheduling Intervention|Pre-natal visit scheduling
2494522|NCT02938936|No Intervention|Control|
3195007|NCT00834782||IOP|Measuring IOP
3195008|NCT00834821|Experimental|1|Participants will undergo the Child Life and Attention Skills (CLAS) Program.
2494636|NCT02938065|Other|2% Milk|16 participants will drink 10 ounces of 2% milk Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2494639|NCT02938065|Other|Apple Juice|16 participants will drink 10 ounces of apple juice Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2494642|NCT02938065|Other|Ensure Clear|16 participants will drink 10 ounces of ensure clear Ultrasound scan will be performed at the time of beverage administration and then every 30 minutes thereafter until beverage has been cleared from the stomach
2494716|NCT02937675|Experimental|Tomivosertib (eFT-508) Escalation Cohort|This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
2494719|NCT02937675|Experimental|Tomivosertib (eFT-508) Expansion Cohort|This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas
2494764|NCT02937207|Experimental|Hanxiao treatment group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494767|NCT02937207|Placebo Comparator|Hanxiao control group|36 patients of exacerbation group belongs to cold type of asthma will take Ke Chuan Liu Wei Mixture placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494769|NCT02937207|Experimental|Fengtanxiao treatment group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture and Xie Wu Capsule oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494771|NCT02937207|Placebo Comparator|Fengtanxiao control group|36 patients of exacerbation group belongs to wind phlegm type of asthma will take Chuan Xiong Ping Chuan Mixture placebo and Xie Wu Capsule placebo oral therapy twice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494773|NCT02937207|Experimental|Rexiao treatment group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494908|NCT02936414|Placebo Comparator|Placebo group|Accept placebo(300 mg/tid)+SGAs monotherapy.
3195009|NCT00834821|Active Comparator|2|Participants will undergo parent focused training (PFT).
2494145|NCT02941536|Other|Circulating Tumor Cells and Radiotherapy|Circulating tumor cells evaluation before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose and correlate with the local and distant brain progression free survival in patients with metastatic breast cancer
2494185|NCT02941237|Other|Healthcare worker measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
2494187|NCT02941237|Other|Expert measurement of SpO2|Measurement of SpO2 using the Lifebox pulse oximeter probe in children of different ages, stratified by age: 0-1 months, 2-11 months, 12-23 months and 24-59 months
2494231|NCT02940951|Other|Usual home care provided by clinicians|Usual care provided by the home health clinicians. This may or may not include use of some standardized forms of quality of life assessment that were in place prior to the study beginning.
2494237|NCT02940951|Experimental|Use of QPSS by home health clinicians|Usual home care plus the use of the Quality of Life Assessment and Practice Support System (QPSS) to document, monitor and address the quality of life concerns of patients and family caregivers.
2494271|NCT02940548|Active Comparator|Nifedipine GITS|Nifedipine GITS 30~60mg/day
2494272|NCT02940548|Active Comparator|Amlodipine besylate|Amlodipine besylate 5~10mg/day
2494333|NCT02940210|Experimental|Mediclore®|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
2494334|NCT02940210|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
2494398|NCT02939898|Placebo Comparator|Lactose Monohydrate|2 tablets of placebo are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
2494400|NCT02939898|Active Comparator|Letrozole|2 tablets of 2,5 mg Letrozole are administered daily from stimulation start to day before hCG as adjunctive therapy to 150 International Units of recFSH
2494439|NCT02939430|Active Comparator|Control|Reversal of neuromuscular blockade will be performed using classic drugs (neostigmine 80 mic/kg and atropine 40 mic/kg)
2494445|NCT02939430|Experimental|Sugammadex group|Reversal of neuromuscular blockade will be performed using Sugammadex 2mg/kg
2494498|NCT02939092|Experimental|Pomegranate peel extract|Pomegranate is antimicrobial, anti inflammatory and antioxidant
2494502|NCT02939092|Active Comparator|Chlorhexidine|Chlorhexidine mouthwash is antiplaque treatment and effective against gingivitis
3195010|NCT00834821|No Intervention|3|Participants will receive a list of referrals for clinical services as needed, including professional organizations, support groups, and the community mental health system.
3195011|NCT00834847|Experimental|Pravastatin fast|Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
3195012|NCT00834847|Experimental|Pravastatin|Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
2494735|NCT02937376|Experimental|N-acetyl Cystein|NAC supplementation (10 mg/kg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2494738|NCT02937376|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2494857|NCT02936661|Experimental|Tranexamic acid|Tranexamic acid 1 g（10ml） IV in 2 minutes after the baby delivered during ceasarean section
2494859|NCT02936661|Placebo Comparator|placebo|NS 10ml IV in 2 minutes after the baby delivered during ceasarean section
2495064|NCT02935621|Experimental|Mindfulness-Oriented Recovery Enhancement|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2495065|NCT02935621|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2495109|NCT02935101|Experimental|Prednisolon|Participants will receive an oral administration of prednisolone or placebo two times daily for the first five days of opioid detoxification, starting after one day of regular detoxification as baseline. Oral prednisolone will be administered in a dose consistent with standard treatment guidelines for glucocorticoid deficiency (Oelkers, 1996).
2495111|NCT02935101|Placebo Comparator|Placebo|Identical looking capsules like the IMP containing placebo (without active component) for oral administration.
2495160|NCT02934724||Vaccinated|"Women born in 1997, resident to Norway in 2009, vaccinated by the quadrivalent HPV vaccine.~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
2495161|NCT02934724||Un-vaccinated|"Women born in 1997, resident to Norway in 2009, not vaccinated by the quadrivalent HPV vaccine~Interventions:~Self sample from vagina using Rover's Evalyn Brush~Self sample from the oral cavity using COPAN's FloqSwab~Questionnaire"
2495200|NCT02934334||MDD|Major Depressive Disorder
2495265|NCT02934061|Experimental|Tizaspray®|Tizaspray® administered intranasally in patients with acute low back pain
2494149|NCT02941484|Experimental|2 jejunostomy tube feeding (JTF)|jejunostomy tube feeding (JTF) was carried out after PD
2494213|NCT02941185|Other|Devit-3 Oral Drop 400 IU|supplemented with oral Vitamin D 400 IU/day (Devit-3 Oral Drop, 50000 IU/15 ml, Deva Company, Turkey) started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2494214|NCT02941185|Active Comparator|Devit-3 Oral Drop 800 IU|Devit-3 Oral Drop 800 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2494215|NCT02941185|Active Comparator|Devit-3 Oral Drop 1000 IU|Devit-3 Oral Drop1000 IU once daily by oral route started when achieved 75%of total nutrition by enteral feedings and continued until 36 weeks postmenstrual age
2494253|NCT02940704|Experimental|Reciproc|"Reciproc (VDW, Munich, Germany) is a single file reciprocating system for mechanical instrumentation of root canals.~Size: R40 (40/0.06)"
2494258|NCT02940704|Active Comparator|One Shape|"One Shape (MicroMega, Besançon Cedex, France) is a single file system that works by continuous rotation for mechanical instrumentation of root canals.~Size: 25/0.06"
2494310|NCT02940444|Experimental|case group|start heparin sodium (5000IU, BID) upon admission, and continue until discharge
2494311|NCT02940444|Active Comparator|control group|start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
2494351|NCT02940119|Active Comparator|Active PBMT|The volunteers received active phototherapy in each session.
2494353|NCT02940119|Placebo Comparator|Placebo PBMT|The volunteers received placebo phototherapy in each session.
2494390|NCT02939755|Experimental|Stepped collaborative care intervention|The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.
2494393|NCT02939755|Active Comparator|Enhanced Usual Care|Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.
2494437|NCT02939391|Experimental|KW-6356 Low Dose|Oral administration
2494444|NCT02939391|Experimental|KW-6356 High Dose|Oral administration
2494450|NCT02939391|Placebo Comparator|Placebo|Oral administration
2494490|NCT02938975|Placebo Comparator|Placebo|placebo group receiving untreated army combat uniform and placebo lotion. Assigned interventions: Placebo lotion - a liposome lotion with no DEET Army combat uniform - army combat uniform with no permethrin
2494491|NCT02938975|Active Comparator|Combo|"Combined intervention group of receiving Permethrin treated uniform 0.52% w/w and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) One application of Lipo DEET protects for up to 12 hours. DEET is a broad spectrum insect repellent that has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft Permethrin is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings."
2494492|NCT02938975|Active Comparator|Permethrin|"permethrin intervention group receiving Permethrin treated uniform 0.52% w/w and placebo lotion.~Permethrin Factory-Treated Army Combat Uniforms treated by the military apparel contractor Warmkraft~Placebo lotion: liposome lotion with no DEET"
2494493|NCT02938975|Active Comparator|DEET|"DEET intervention group receiving untreated army combat uniform and 30% DEET liposome formula.~Ultra 30 Insect Repellent Lotion (30% Lipo DEET) Army combat uniform with no permethrin"
2494648|NCT02938026|No Intervention|Control|Usual care
2494652|NCT02938026|Experimental|Telephone intensive lifestyle counseling|Telephone intensive lifestyle counseling
2494656|NCT02938026|Experimental|Bariatric surgery|Bariatric surgery
2494672|NCT02937714|Experimental|School mental health training|Teachers Training workshop Workshop based on local adaptation of WHO-EMRO school mental health manual will be conducted in school. The duration of the workshop will be 3 days. Teachers can decline to participate or withdraw at any stage.
2494673|NCT02937714|No Intervention|Wait list control group|Wait list control group of teachers in same schools. Half of teachers in the same school will be the wait list control group.
2494793|NCT02936934|Active Comparator|Morphine|Multimodal analgesia to morphine
2494798|NCT02936934|Experimental|Oxycodone|Multimodal analgesia to oxycodone
2494837|NCT02936739|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
2494838|NCT02936739|Active Comparator|Rotaio|Patients, who receive Rotaio (TM) as cervical disc prosthesis after ventral discectomy.
2494888|NCT02936505|Active Comparator|Arm A:Cyclosporine|Group A: Cyclosporine A, Mycophenolate mofetil (MMF) and corticosteroids according to local practice and approved label.
2494891|NCT02936505|Experimental|Arm B:Tacrolimus|Group B: Tacrolimus (Advagraf), Mycophenolate mofetil (MMF) and corticosteroids.
2494972|NCT02935998|Experimental|ziprasidone|The injection mesylate ziprasidone used in this study have been marketed, manufactured by Pfizer and provided study drug for research purposes.Strength:Each vial contains Ziprasidone 30 mg, Sulfobutyl betadex sodium 441 mg. When reconstituted as directed the solution for injection contains the equivalent of 20 mg per mL of Ziprasidone.The initial dosage of ziprasidone injection：Most patients are suggested with 20mg i.m. Those with first-episode, lower age, emaciated body, or BARS score at 5 are suggest with 10mg i.m. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.
2494155|NCT02941601|Experimental|Cohort 2: Necitumumab + Gemcitabine and Carboplatin|Predominately United States sites. Gemcitabine administered IV and carboplatin IV plus necitumumab IV.
2494212|NCT02941016|Experimental|Lipid lowering|
2494254|NCT02940756|Experimental|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
2494260|NCT02940756|Experimental|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
2494265|NCT02940756|Experimental|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
2494286|NCT02940379|Experimental|Cohort 1|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 1 of Sotagliflozin plus cocktail) after 3 days
2494293|NCT02940379|Experimental|Cohort 2|Participants will initially be given with treatment A (cocktail of metoprolol and midazolam) and then will start with treatment B (Dose 2 of Sotagliflozin plus cocktail) after 3 days
2494341|NCT02940197|Experimental|restricted diet|Mediterrasian diet according to adjusted ideal body weight with 500 calorie restriction
2494344|NCT02940197|Experimental|Non restricted diet|Mediterrasian diet according to adjusted ideal body weight without 500 calorie restriction
2494411|NCT02939846|Experimental|Trametinib|Subjects will be administrated with trametinib 2 mg once daily until disease progression.
3195013|NCT00834847|Active Comparator|Pravachol®|Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
2494485|NCT02938962|Active Comparator|Intravenous TXA|The IV administration group will receive a single 20mg/kg dose of TXA prior to the skin incision.
2494486|NCT02938962|Active Comparator|Topical TXA|The topical administration group will have a 100mL solution (3g TXA in 100cc of normal saline) instilled into the surgical field throughout the operative procedure; 50mL of the solution will be instilled after bony preparation of the acetabulum and/or femur and 50mL of the solution will be instilled prior to closure. The topical TXA solution will be allowed to bathe the wound for 5 minutes at each administration.
2494579|NCT02938793|Experimental|Single Arm|Durvalumab, 1500 mg Q4W (equivalent to 20 mg/kg Q4W) intravenously for 13 doses and Tremelimumab 300mg intravenously as a single dose on cycle 1 day 1 only.
2494623|NCT02938130|Other|Wellness Programs|Community Partners and Community LIFE programs
3195014|NCT00834860|Active Comparator|CHC, HCC|100 naïve CHC patients concomitant with hepatocellular carcinoma without clinical evidence of HCC recurrence more than 3 months after curative treatments.
3195015|NCT00834860|Active Comparator|CHC, LC|100 naïve CHC patients without malignancy
3195016|NCT00834925|No Intervention|standard dose diltiazem|
3195017|NCT00834925|Experimental|low dose diltiazem|
2494714|NCT02937493||Migration Background|Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
2494717|NCT02937493||Non Migration Background|If the following criteria is not fulfilled: Migration background was defined according to current law (MighEV §6, Sozialgesetzbuch). In detail this means that migration background is fulfilled, if (1) the person does not possesses the national citizenship, or (2) the origin of birth is outside the borders of the national country, and emigration to the national territory was after 1949, or (3) origin of birth of one of the two parents is outside the current borders of the national territory plus emigration of one of the two parents occured after 1949.
2494757|NCT02937324|Active Comparator|Clinical Assessment|Motor assessment will be performed by a clinician using the Unified Parkinson's Disease Rating Scale.
2494762|NCT02937324|Experimental|Smartphone assessment|CloudUPDRS smartphone software assessment will be performed.
3195018|NCT00834938||1|Patients with DM2 undergoing RYGB with remission of DM2
2494885|NCT02936531||FXTAS|Patients positive for FMR1 premutation and meet diagnostic criteria for FXTAS
2494890|NCT02936531||FMR1 premutation asymptomatic|Patients positive for FMR1 premutation and do not meet diagnostic criteria for FXTAS
2494921|NCT02936154|Experimental|300 mg|
2494926|NCT02936154|Placebo Comparator|placebo|
2494961|NCT02935920|Experimental|Individual, tailored follow-up|Patient symptoms are evaluated by the use of PRO-data to uncover the needs of a consultation. The outcome of the questionnaire is used to customize the follow-up program to the individual patient.
2494962|NCT02935920|No Intervention|Standard follow-up|Scheduled clinical examination every six months throughout the course of adjuvant treatment. Performed by a doctor or nurse.
2495010|NCT02935647|Experimental|Propofol|Participants will receive intravenous propofol titrated rapidly at 100-200 mcg/kg/min to reach 80% burst-suppression and then maintained there for 15 minutes, after which propofol administration will be discontinued and the participant will be allowed to awaken.
2495093|NCT02935387|Experimental|Taper methotrexate, then golimumab|Taper methotrexate 25>0mg/wk during 24 weeks, then, if still in sustained remission, taper golimumab 50>0mg/month during 24 weeks.
3195019|NCT00834938||2|Patients with DM2 undergoing RYGB without remission of DM2
3195020|NCT00835016|Experimental|Early psychosocial stimulation (LTP)|The 10 session of Early psychosocial stimulation (LTP)will be delivered to depressed mothers in the intervention group
3195021|NCT00835016|Active Comparator|Waiting group|Waiting group will receive standard follow-up by their own LHWs. This group intervention will be documented at baseline, 3 months (end of the trial) and at 6 months. Similar training of Learning through Play will be provided to the mothers in this group at the end of the study.
3195022|NCT00835029|Active Comparator|Clotrimazole varnish|Clotrimazole in a slow release varnish treatment
3195023|NCT00835029|Active Comparator|Clotrimazole troches|Clotrimazole troches 10 mgx5 day for treatment of denture associated candiad infection
3195024|NCT00835094|Experimental|Morning|
3195025|NCT00835094|Experimental|Evening|
2494394|NCT02939872|Experimental|DAPT|Dual antiplatelet therapy : aspirin and clopidogrel
2494396|NCT02939872|Active Comparator|Clopidogrel only|Clopidogrel monotherapy
2494446|NCT02939456|Other|DIR-MRI|Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
2494621|NCT02938247|Experimental|Single-arm study|High caloric, high protein ONS, three portions daily, total dose of 400 kcal/day for 7 consecutive days, oral administration
2494690|NCT02937896|Experimental|Ketorolac|30mg ketorolac administrated intravenous and 4 puffs nasal Normal Saline.
2494695|NCT02937896|Active Comparator|Desmopressin|40 microgram nasal desmopressin administrated and 1cc Normal Saline intravenous
2494736|NCT02937337|Experimental|Videostylet|Laryngeal mask airway insertion using video stylet guided technique
2494741|NCT02937337|Active Comparator|Blind|Laryngeal mask insertion using standard index finger-guided technique
2494803|NCT02937090||Polycystic Ovary Syndrome|"Premenopausal women between 18-40 years of age.~Diagnosed with PCOS using Rotterdam criteria (meet 2 of the 3):~chronic oligo- or amenorrhea (irregular periods during more than a year in combination with a cycle length longer than 35 days);~total or free T levels above the reference interval and/or excessive facial hair, acne;~transvaginal ultrasound with polycystic ovaries.~Exclusion of common medical disorders (normal thyroid function tests and serum prolactin and exclusion of 21-hydroxylase deficiency)."
2494804|NCT02937090||Control|Women matched for age and BMI.
2494870|NCT02936622|Experimental|Stent 1|Zilver® PTX Stent
2494874|NCT02936622|Experimental|Stent 2|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating
2494877|NCT02936622|Experimental|Stent 3|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating
2494947|NCT02936102|Experimental|FAZ053 single agent|
2494948|NCT02936102|Experimental|FAZ053 + PDR001|
3195026|NCT00835107|Experimental|Ziprasidone|
3195027|NCT00835107|Placebo Comparator|Sugar pill|
2495069|NCT02935205|Experimental|Treatment (enzalutamide, indomethacin)|Patients receive enzalutamide PO QD and indomethacin PO BID or QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3195028|NCT00835250|Active Comparator|Laparoscopy|Laparoscopic cholecystectomy
3195029|NCT00835250|Experimental|Transumbilical|Transumbilical endoscopic cholecystectomy
3195030|NCT00835250|Experimental|Transvaginal|Transvaginal endoscopic cholecystectomy
2495165|NCT02934386|Experimental|WinMedical WinPack device|50 volunteers undergoing experimental protocol according to IEEE 1708:2014 standard
2495246|NCT02934295|Experimental|Pregnant women|
2495308|NCT02933788|Experimental|Cilostazol group|Cilostazol Cilostazol 200mg tablet by mouth, once daily for 14 days
2495311|NCT02933788|Active Comparator|Aspirin group|Acetylsalicylic acid Acetylsalicylic acid 100mg tablet by mouth, once daily for 14 days
2495368|NCT02933333|Experimental|GM-CSF|Eligible patients received subcutaneous GM-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
2495376|NCT02933333|Experimental|G-CSF|Eligible patients received subcutaneous G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. G-CSF is given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
2495383|NCT02933333|Experimental|G-CSF + GM-CSF|Eligible patients received subcutaneous a combination of GM-CSF 5 μg/kg per day and G-CSF 5 μg/kg per day when the first time of absolute neutrophil count [ANC] <1.5*10^9/L after chemotherapy. GM-CSF and G-CSF are given daily for at least 5 days and continued until the ANC reached 1.5*10^9/L for two consecutive days.
3195031|NCT00835289|Placebo Comparator|Placebo (corn oil)|Each participant will be taking 3 capsules of a matching placebo (corn oil).
3195032|NCT00835289|Experimental|PUFA (Omax3)|Omax3[TM] (Cenestra Health), or dietary supplement: n-3 polyunsaturated fatty acids, is a 1 gram softgel capsule containing 94.5% omega-3 fatty acids. Each participant will be taking 3 capsules of Omax3[TM].
3195033|NCT00835302|Experimental|Manipulation + Exercise Group|Cervicothoracic manipulation and ROM exercises
2495610|NCT02931656|Experimental|GDM aquatic exercise|GDM Diagnosis criteria accordance with to IADPSG / WHO
2495623|NCT02931656|Active Comparator|Control Group aquatic exercise|No change in blood glucose levels Group, investigated between 24-28 weeks of gestation.
2495725|NCT02931214|Experimental|GMI-1359|Dose escalation
2495726|NCT02931214|Experimental|Placebo|Dose escalation
2495735|NCT02930681|Placebo Comparator|Placebo|Four capsules of placebo to be taken 30 mins before each test meal at the investigator's site
2495737|NCT02930681|Experimental|Glucosanol 1000mg|Two capsules of placebo and two capsules of Glucosanol 500mg capsules to be taken 30 mins before each test meal at the investigator's site
2495739|NCT02930681|Experimental|Glucosanol 2000mg|Four capsules of Glucosanol 500mg to be taken 30 mins before each test meal at the investigator's site
2495787|NCT02930603||Control|Control: Healthy child
2495790|NCT02930603||Experimental|Patients with Developmental Disabilities
2495898|NCT02929914|Experimental|Control|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, dentin washed with sodium 0.9% saline, sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
2495904|NCT02929849|Experimental|300mg SC|300 mg Salacia Chinensis (SC). This will be compared to placebo.
3195034|NCT00835315||3|patients with psoriasis , patients with atopic dermatitis and healthy patients.
3195035|NCT00835393|Experimental|1|
2494161|NCT02941367|Experimental|Lyxumia|Patients will receive Lyxumia once daily as investigational medicinal product (IMP) on top of patient's previous basal insulin with/without metformin. Non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
2494164|NCT02941367|Active Comparator|Sulfonylurea|Patients will continue the treatment with previous Sulfonylurea as IMP on top of patient's previous basal insulin with/without metformin. The IMP and non-IMPs will be administrated as per Investigator's indications according to local labeling, guidelines, and clinical judgment.
2494193|NCT02940977||Prostate cancer patients|Patients diagnosed with prostate cancer, confirmed with needle biopsy, and suitable for radical prostatectomy, and have not received any treatments before.
3195036|NCT00835393|Active Comparator|2|
3195037|NCT00835419|Experimental|1|P276-00 investigational product (small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor)
2494458|NCT02939274|Other|Open Label|Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
3195038|NCT00835445||1|Asthmatics with polyps
3195039|NCT00835445||2|Non-asthmatics with polyps
2494543|NCT02938546|Active Comparator|before therapy|18F-FDG PET/CT performed before therapy
2494544|NCT02938546|Experimental|3 days after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed 3 days after chemotherapy and targeted therapy
2494545|NCT02938546|Experimental|longer time after cisplatin chemotherapy and targeted therapy|18F-FDG PET/CT performed before the third cycle chemotherapy and the 7th week targeted therapy
2494593|NCT02938364|Experimental|Earplugs|The participant will be asked to put plastic earplugs in both ears for 10 minutes and then the impression will be made while they are still on.
2494595|NCT02938364|Experimental|Acupressure|The participant will be asked to wear sea bands on P6 points of both hand wrists for 10 minutes and then the impression will be made while they are still on.
2494598|NCT02938364|Placebo Comparator|Placebo|The participant will be asked to wear non pressure bands on both hand wrists for 10 minutes and then the impression will be made while they are still on.
3195040|NCT00835471|Experimental|1|Erlotinib plus docetaxel (squamous cell NSCLC) or pemetrexed (non-squamous cell NSCLC)
2494718|NCT02937519|Experimental|Melodie group|Induction chrono-chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
2494723|NCT02937519|Other|Routine-Chemotherapy|Induction routine-chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
2494789|NCT02937103|Experimental|Myeloid Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD123-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with myeloid malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2494854|NCT02936817|Other|Aerobika® device|For a period of 15 +/- 3 days all subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily). HRCT scans wil be taken at visit 1 and visit 3.
2494950|NCT02936089|Experimental|Risk Stratification-directed Therapy|AE AML patients first received IA or DA induction therapy, and then received two courses of IDAC (Ara-C 1-2 g/m2 q12 h ×6 cycles). Subsequently, different subgroups of AE AML received different treatment based on risk stratification. For low-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or autologous HSCT. For intermediate-risk AE AML, they randomly received consolidation chemotherapy (two or three courses of IDAC) or allogeneic HSCT. High-risk AE AML all received allogeneic HSCT.
2494963|NCT02935725|Experimental|Low dose AUT00206 800 mg + Ketamine|Low dose AUT00206 (800 mg) + ketamine
2494964|NCT02935725|Experimental|High dose AUT00206 2000 mg + Ketamine|High dose AUT00206 (2000 mg) + ketamine
2494966|NCT02935725|Placebo Comparator|Placebo + Ketamine|Placebo + ketamine
2494968|NCT02935725|Placebo Comparator|Placebo + Saline|Placebo + saline
2495058|NCT02935439|Active Comparator|Cell-Phone Intervention Arm|A standard cell phone system sent web-browser messages daily to ask about their weight and symptoms of heart failure. Participants received up to 3 daily messages 15 minutes apart at a time of their choosing for 90 days. Participants were given a mobile phone for the 90 day period and a weight scale.
2495059|NCT02935439|No Intervention|Usual Care|Usual Care participants continued to receive care in the Heart Failure Clinic. All subjects were enrolled in the study for 90 days. Participants were given a weight scale.
2495074|NCT02935153|Experimental|B Cell Malignancies|Experimental: B Cell Malignancies The trial will be conducted in a manner of simon two-stage design with Anti-CD22-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2495133|NCT02934958|Active Comparator|FIT Positive|Referral to GI or Primary Care. Patients will be referred to MD for pre-colonoscopy vist.Standard of Care.
2495136|NCT02934958|Experimental|FIT Positive Choice|Offered Chioce of Direct referral. Patients will be given a choice to advance to directly having a colonoscopy screening.Colon Cancer Screening Navigation.
2495250|NCT02933983||Control group (healthy)|Participants who do not suffer from acute or chronic airway infections
2495256|NCT02933983||CRS patients|Patients who suffer from chronic rhinosinusitis
2495307|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 30 milligram[mg])|Healthy elderly participants will receive single dose of 30mg JNJ-54175446.
2495310|NCT02933762|Experimental|Part 1: Cohort A1 (JNJ-54175446 100mg)|Healthy elderly participants will receive single dose of 100mg JNJ-54175446.
3195041|NCT00835471|Active Comparator|2|Erlotinib
3195042|NCT00835523||OHSS risk|
3195043|NCT00835562|Experimental|Osteosynthesis|
3195044|NCT00835562|Experimental|Non-surgical|
3195045|NCT00835562|Experimental|Hemiarthroplasty|
3195046|NCT00835627|Active Comparator|sertraline|flexible dose sertraline
3195047|NCT00835627|Active Comparator|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual, 1 hour therapy sessions
2494165|NCT02941419|Experimental|Platelet lysate injection|Injection of platelet lysate intramuscularly in the gastrocnemius muscle
2494292|NCT02940561|Experimental|Methotrexate - Amneal|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
2494298|NCT02940561|Active Comparator|Methotrexate - DAVA|Methotrexate Tablets USP, 2.5 mg, single-dose in each period
2494409|NCT02939703|Active Comparator|Control Western diet|Participants will consume a control western diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period.
2494412|NCT02939703|Experimental|Microbiome Enhancer diet|Participants will consume an experimental microbiome enhancer diet prepared by our metabolic research kitchen for an outpatient period followed by an inpatient period
2494435|NCT02939339|Experimental|real treatment|continuous theta burst stimulation (real) will be delivered
2494443|NCT02939339|Sham Comparator|sham treatment|continuous theta burst stimulation (sham) will be delivered
2494554|NCT02938780|Placebo Comparator|Control|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
2494555|NCT02938780|Experimental|Intervention|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message.
2494625|NCT02938299|Experimental|Arm 1: neoadjuvant + surgery|"Patients in Arm 1 will receive multiple intratumoral administrations into all injectable cutaneous, subcutaneous, and nodal tumors of a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks (or until all injectable tumors have disappeared, or intolerance to study treatment or in the opinion of the investigator immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first).~Newly occurring injectable melanoma lesions within the 4 weeks treatment period will also be treated as described. Surgical resection of all existing metastases will follow within 4 weeks after end of treatment. Surgery will be performed after the safety evaluation carried out at week 5 and, if indicated, may be carried out on the same day of the safety evaluation."
2494627|NCT02938299|Active Comparator|Arm 2: surgery alone|Patients in Arm 2 will receive directly surgical resection of melanoma tumor lesions within 4 weeks after randomization.
2494763|NCT02937285|Active Comparator|Standard care|Interferon alone
2494765|NCT02937285|Experimental|Experimental group|Mitoxantrone for 6 month followed by interferon
2494796|NCT02936973|Experimental|Real catgut implantation|Participants will receive real catgut implantation at acupoints plus lifestyle modification. Participants will receive catgut implantation treatment every two weeks to fulfill a 8-session treatment course.When the acupoints and surrounding skin are disinfected, an absorbable surgical suture of an appropriate length will be embedded into the muscular layer or subcutaneous tissue of the acupoints by the specified disposable embedding needles. The absorbable surgical suture then stimulated those points over a long period.
2494801|NCT02936973|Sham Comparator|sham catgut implantation|Participants will receive sham catgut implantation at acupoints and lifestyle modification every two weeks to fulfill a 8-session treatment course.The operation process will be similar to that applied in the real catgut implantation group. Empty needles without catgut will be pushed into the chosen position, to a depth equivalent to that used for catgut implantation at acupoints. The frequency and duration were the the same as the catgut embedding group.
2494844|NCT02936674|Experimental|Light 1|Light 1 will have an altered color composition as compared with a standard LED bulb.
2494849|NCT02936674|Active Comparator|Light 2|Light 2 will be a standard LED bulb.
2494956|NCT02936011|Other|CTO PCI with Absorb BVS|Single arm observational after successful CTO PCI with Absorb BVS after antegrade or retrograde dissection and re-entry
3161880|NCT00450879|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD for 12-20 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgical resection of tumor between days 13 and 21 (24 hours after completion of pazopanib hydrochloride).
3161881|NCT00450892|Other|arm 1|
2495426|NCT02932826|Experimental|Treg Treatment + Insulin|subjects will be treated with Umbilical Cord Blood Regulatory T cells Therapy and insulin according to routine clinical practice at the discretion of the treating physician
3161882|NCT00450892|Other|arm 2|
3161883|NCT00450892|Experimental|arm 3|
3161884|NCT00450944|Experimental|Combination Therapy with Immunotoxins Imtox 19 Plus Imtox 22|
3161885|NCT00450957|Experimental|Arm I (high-dose lycopene)|Participants receive high-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive high-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days.
3161886|NCT00450957|Experimental|Arm II (low-dose lycopene)|Participants receive low-dose oral lycopene once or twice a day for 14 days. After 2 weeks of a lycopene-free period, participants crossover and receive low-dose lycopene at the alternative daily schedule (once or twice a day) for 14 days
3161887|NCT00450970|Experimental|1|Prednisone and Satraplatin (INN / USAN), also known as JM-216, or OC-6-43-bis(acetato-O)ammine dichloro (cyclohexanamine)-platinum (IV), is a member of a novel class of platinum (IV) compounds that are absorbed by the oral route. The lipophilic properties of these compounds, and hence their absorption, are largely determined by the nature of the axial acetate ligands.
3161888|NCT00450970|Experimental|2|Prednisone (17 alpha, 21-dihydroxypregna-1, 4-diene-3, 11, 20-trione) is commercially formulated as the acetate salt (prednisone 21-acetate). It is a biologically inert glucocorticoid, which is converted to active prednisolone in the liver.
3161890|NCT00451087|Experimental|1|
3161891|NCT00451087|Active Comparator|2|
3161892|NCT00451100|Experimental|Sugammadex|2.0 mg/kg Org 25969 (sugammadex)
3161893|NCT00451100|Active Comparator|Neostigmine|50 ug/kg neostigmine
3161894|NCT00451152|Experimental|Anecortave Acetate Depot|
2494166|NCT02941406||Healthy subjects|"Men and Women aged 18 and older~Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant~Normal ophthalmological findings unless the investigator considers an abnormality to be clinically irrelevant"
2494167|NCT02941406||Age-related macular degeneration patients|"Men and Women aged 18 and older~Presence of a macular disease (such as dry or exudative age-related macular degeneration, diabetic maculopathy, epiretinal membrane)"
2494204|NCT02941094|Active Comparator|angle 30 group|During central line insertion, After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 30-40 degree.
2494207|NCT02941094|Active Comparator|angle 50 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 50-60 degree
2494209|NCT02941094|Active Comparator|angle 70 group|During central line insertion,After choosing the proper position, the skin was infiltrated with %1 lidocaine. The vein will be localized using linear ultrasound probe (PLT-805AT, 8 MHz, Toshiba Tokyo, Japan) attached to ultrasound machine (Xario, Toshiba Tokyo Japan). The needle will be advanced guided by the ultrasound probe with needle skin angle 60-80 degree
3195048|NCT00835627|Active Comparator|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12 individual, 1 hour therapy sessions
3195049|NCT00835627|Active Comparator|Standard care|community care / treatment as usual: routine follow up with existing providers
2494301|NCT02940314|Experimental|sequence 1|HGP1103→HIP1503
2494306|NCT02940314|Experimental|Sequence 2|HIP1503→HGP1103
2494329|NCT02940080|Experimental|Anthocyanins and yellow potato|168 mg of anthocyanins extracted from purple-fleshed potatoes added to 350 g of steam-cooked mashed potatoes in water
2494330|NCT02940080|Experimental|Yellow potato|350 g of steam-cooked mashed potatoes in water
2494382|NCT02939924|Experimental|DCB treatment|Patient treated with Kanshas DCB
2494424|NCT02939586|Active Comparator|Haemodialysis|regular convectional haemodialysis 3times/weekly
2494425|NCT02939586|Active Comparator|Haemodiafiltration|post-dilution haemodiafiltration
2494497|NCT02939196||Group(A)|2.7 mm rigid hysteroscopy.
2494500|NCT02939196||Group(B)|2.9 mm rigid hysteroscopy.
2494548|NCT02938702||Active surveillance|Group with active surveillance of their PTC
2494552|NCT02938702||Surgery|Group who underwent surgery after diagnosis of PTC
2494597|NCT02938377|Active Comparator|No dx of alcohol use disorder, panic or depre|Computerized Brief Intervention (CBI)- a video about alcohol abuse
2494599|NCT02938377|Active Comparator|Risky drinking, no dx of AUD, has panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy
2494600|NCT02938377|Active Comparator|Dx of AUD with or without panic or depression|Computerized Brief Intervention (CBI)- a video about alcohol abuse, plus 4 sessions of counseling called Motivational Enhancement Therapy plus a recommendation for Alcohol Pharmacotherapy (APT). The drugs recommended in the APT are all standard of care drugs for alcohol treatment and are not under study in this protocol.
2494651|NCT02938000|Experimental|Theraband group|This group will be furnished with Thera-band, and link to exercise video, with plans for regular exercise as described previously, in addition to usual post stroke care.
2494655|NCT02938000|Placebo Comparator|Usual Care Group|This group will have usual post stroke care, and will be advised to get regular exercise.
2494675|NCT02937649|Experimental|Laparoscopic sleeve gastrectomy using 48-Fr bougie|Patients will undergo laparoscopic sleeve gastrectomy with a 48-Fr (16 mm) bougie
2494676|NCT02937649|Active Comparator|Laparoscopic sleeve gastrectomy using standard care bougie|Patients will undergo laparoscopic sleeve gastrectomy with a standard care bougie (34, 36 or 38-Fr)
3195050|NCT00835653||1|patients with a carpal tunnel syndrome
2494794|NCT02936908||Ventilatory support|Adult patients presenting a neuromuscular disease, with involvement of respiratory or bulbar muscles
2494842|NCT02936752|Experimental|Treatment (entinostat, pembrolizumab)|Patients receive lower dose entinostat PO on days 1 and 8 or higher dose entinostat PO on days 1, 8, and 15, and pembrolizumab IV over 30 minutes on day 1 of cycle 2 and cycles thereafter. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve an objective response or maintain a SD status after the first 4 cycles may continue to receive entinostat and pembrolizumab for up to 1 year.
2494937|NCT02936284|Experimental|Music Enhancement|37 weekly Music Together classes for one year, then 12 monthly Music Together classes the following year.
2494939|NCT02936284|Active Comparator|Play Date|37 weekly group Play Date sessions for one year, then 12 monthly group Play Date sessions the following year.
3195051|NCT00835653||2|patients without a carpal tunnel syndrome
3195052|NCT00835718|Experimental|Stage I, Arm 1|MK0594 5 mg/day
3195053|NCT00835718|Placebo Comparator|Stage I, Arm 2|Placebo
3195054|NCT00835718|Experimental|Stage II, Arm 2|MK0594 1 mg/day
3195055|NCT00835718|Experimental|Stage II, Arm 3|MK0594 1 mg/week
2495596|NCT02931799|Active Comparator|Minimal Intervention|
3195056|NCT00835718|Placebo Comparator|Stage II, Arm 4|Placebo
3195057|NCT00835744|Placebo Comparator|A|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, an increased dose of 100 mg of clomiphene citrate is administered from day 13 until day 17 of the cycle.
3195058|NCT00835744|Active Comparator|B|Patients undergo a standard treatment with clomiphene citrate from day 3 until day 7 of the cycle at a dose of 50 mg daily. If no reaction on day 13 of the cycle, gonadotropins (75IU) are administered from day 13 until day 17 of the cycle.
3195059|NCT00835757||1|Diabetic peripheral neuropathy
3195060|NCT00835757||2|Healthy controls
3195061|NCT00835783||FUO|Patients with fever of unknown origin undergoing FDG-PET/CT as part of work-up.
2494168|NCT02941393|Active Comparator|Intrauterine pressure catheter|Intrauterine pressure catheter is used during labor to follow up the contractions
2494170|NCT02941393|Active Comparator|External tocodynamometry|External tocodynamometry is used during labor to follow up the contractions
2494203|NCT02941055|Experimental|Fiber diet|50% of daily intake, 5 days a week, a diet rich in fiber, fish and probiotics will be provided to study subjects
2494208|NCT02941055|Active Comparator|Protein diet|50% of daily intake, 5 days a week, a diet rich in protein, red meat and saturated fat will be provided to study subjects
2494223|NCT02940782|Experimental|Reciproc single file system|It is a reciprocating NiTi file used for instrumentation of root canals in endodontic treatment
2494229|NCT02940782|Active Comparator|One Shape single file system|It is a rotary NiTi file used for instrumentation of root canals in endodontic treatment
2494342|NCT02940106|Placebo Comparator|closed device|Standard cryopreservation system.
2494345|NCT02940106|Active Comparator|open device|New cryopreservation system.
2494401|NCT02939729|Experimental|Prehabilitation|This group will receive standard preoperative information and education and be provided with a physiotherapy prehabilitation programme. This programme will be carried out from time of consenting to participate in the study until day of admission to surgery for cardiac or thoracic surgery. The prehabilitation programme consists of: walking programme, deep breathing exercises and tidal volume measurement using the incentive spirometer.
2494403|NCT02939729|No Intervention|Standard Care|This group will receive standard preoperative information and education only.
2494427|NCT02939378|Experimental|ketogenic diet group|Ketogenic diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were kept more than 2mmol/L during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
2494432|NCT02939378|Other|Standard diet group|Standard diet adjuvant to salvage chemotherapy was given to recurrent glioblastoma. Blood glucose and ketone were recorded during salvage chemotherapy. The side effect was observed and recorded. Tumor volume was monitored and the efficacy was recorded.
2494541|NCT02938533|No Intervention|Standard of Care|Standard HIV primary care services available at HIV care and treatment clinics in Tanzania.
2494542|NCT02938533|Experimental|Behavioral Intervention Using Social Norms and Priming|Patients in this arm may have been exposed to the behavioral intervention, which included the following components: 1) visual feedback about clinic-level retention in care through an interactive poster; 2) a self-relevant priming image that appeared on all components; and 3) a take-home item (i.e., pillbox or calendar) with the priming image.
2494587|NCT02938416|Experimental|Isokinetic training|Ten times, three sets of isokinetic strengthening exercise using 30 degree/sec and 120 degree/sec
2494591|NCT02938416|Active Comparator|Isotonic training|Ten times, three sets of isotonic strengthening exercise using consistent resistance of 60% of 1-repetition maximum of hip or knee
2494633|NCT02938117|Experimental|CON : concentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
2494635|NCT02938117|Experimental|EXC : eccentric cycling exercise|Thirty adults will be randomized into 2 groups: CON or EXC. The patients of ECC group will follow habituation sessions (2weeks) to avoid the secondary muscular effects of high intensity eccentric exercise
2494693|NCT02937792|No Intervention|CONTROL|one with intrathecal 12.5 mg bupivacaine
2494696|NCT02937792|Experimental|experimental|one group with intrathecal 15 mg bupivacaine
2494724|NCT02937428|Experimental|Look away and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look away from the needle during vaccination
2494725|NCT02937428|Active Comparator|Look at needle and prefer to look|Participant who is self-identified as preferring to look at the needle is randomized to look at the needle during vaccination
2494726|NCT02937428|Experimental|Look away and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look away from the needle during vaccination
2494727|NCT02937428|Active Comparator|Look at needle and prefer to look away|Participant who is self-identified as preferring to look away from the needle is randomized to look at the needle during vaccination
2494905|NCT02936401|Experimental|MBSR|Participants in this arm enter the 8-week MBSR course immediately after the baseline visit.
2494907|NCT02936401|Experimental|CONTROL|Participants in the waitlist control arm will receive standard of care for 16 weeks after the baseline visit, and then will be offered an identical 8-week MBSR course.
3161895|NCT00451152|Placebo Comparator|Anecortave Acetate Vehicle|
2495040|NCT02935803|Other|Modified TVM operation|Modified Trans-vaginal Mesh operation (mTVM): polypropylene monofilament meshes produced by Aspide® fixed up to the mid urethra by a resolvable suture. 76 participants will be involved.
2495047|NCT02935803|Other|Control group|76 Participants as control group undergo a traditional Trans-vaginal Mesh operation (TVM) with polypropylene monofilament meshes produced by Aspide® . (Sergent et al.)
3161896|NCT00451165||colon|
3161897|NCT00451165||rectum|
3161898|NCT00451295|Placebo Comparator|1|
3161899|NCT00451295|Experimental|2|
3161900|NCT00451308|Experimental|1|Foley balloon wih 60cc fluid
3161901|NCT00451308|Active Comparator|2|Foley balloon with 30cc
3161902|NCT00451412|Experimental|Certoparin|
3161903|NCT00451412|Active Comparator|Unfractionated Heparin|
3161904|NCT00451425|No Intervention|control|standard maternity care
3161905|NCT00451503|Experimental|1|surgery
3161906|NCT00451568|Active Comparator|1|metformin
3161907|NCT00451568|Active Comparator|2|desorelle
3161908|NCT00451568|Active Comparator|3|desorelle + metformin
3161909|NCT00451620|Experimental|2.|GlucoNorm
3161910|NCT00451620|Experimental|1.|Glyburide
3161911|NCT00451646|Experimental|1|SMOFlipid
3161912|NCT00451646|Active Comparator|2|Intralipid
3161913|NCT00451776|Experimental|1|patients who received etomidate
3161914|NCT00451776|Active Comparator|2|patients who received propofol
3161915|NCT00451841||1|Chronic cough caused by GERD
3161916|NCT00451841||2|Chronic cough without GERD
2494169|NCT02941302|Experimental|determine the biological boundaries|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
2494256|NCT02941068|Experimental|Prophylactic group|Patients would received intravenous fluconazole (loading dose 800 mg, then 400 mg/day) or caspofungin (loading dose 70 mg, then 50 mg/day) if patients had organ failure or renal or liver dysfunction during the immediately surgery. The antifungal treatment would continue for 5 to 7 days.
2494261|NCT02941068|No Intervention|Empirical group|
2494317|NCT02940483|Experimental|5-Azacytidine Infusion|12 infusions (once a week) into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle.
2494349|NCT02940054||Patents with suspected Crohn's disease|"Adult patients showing at least one of the following symptoms, from at least 4 weeks:~diarrhea~nocturnal diarrhea~body weight loss (>5%)~abdominal pain~perianal lesions."
2494387|NCT02939833|Experimental|ropivacaine|patients in this group will receive scalp nerve blocks with 0.5% ropivacaine after anesthesia induction and before skull-pin insertion
2494391|NCT02939833|Placebo Comparator|saline|patients in this group will receive scalp nerve blocks with 0.9% saline after anesthesia induction and before skull-pin insertion
2494438|NCT02939521|Experimental|Surgery|Consists of a dorsal flattening of of the bone at the distal phalanx, with a frontal lifting of the distal skin of the toe
2494504|NCT02939222|Other|Routine implant placement|No comparison needed
2494585|NCT02938754|Experimental|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
2494588|NCT02938754|Active Comparator|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
3195062|NCT00835783||BUO|Patients with bacteremia of unknown origin undergoing FDG-PET/CT as part of work-up.
3195063|NCT00835783||VGI|Patients with vascular graft infections undergoing FDG-PET/CT as part of work-up.
3195064|NCT00835809||Acute respiratory diseases.|Patient admit in emergency or intensive care unite with acute respiratory insufficiency.
3195065|NCT00835822|Experimental|A|Arm treated with Investigational product.
2494715|NCT02937597|Active Comparator|National e-learning programme only (HSE)|Active Comparator: National e-learning programme only (HSE) National e-learning programme only Recent successful completion of the National e-learning programme by certificate will be displayed. Students then undergo performance assessment via low fidelity simulation and complete a questionnaire.
2494720|NCT02937597|Active Comparator|eS: eScenarios|Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to an online learning course with 4 scenarios to work through but no requirement to meet a proficiency benchmark. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
2494722|NCT02937597|Experimental|ePBP: eProficiency Based Progression|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to a PBP e-learning course using the same series of cases as S. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks for the cases within the e-learning course to allow progression through the cases. Following training students undergo performance assessment via low fidelity simulation and complete a questionnaire.
2494755|NCT02937246|Experimental|the intervention group|Partial covered double bare metal stent
2494759|NCT02937246|Active Comparator|the control group|Uncovered double bare metal stent
2494808|NCT02937012|Experimental|Bezafibrate & Ursodeoxycholic acid|Bezafibrate 200 mg capsule every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
2494811|NCT02937012|Placebo Comparator|Placebo & Ursodeoxycholic acid|Placebo capsule (for bezafibrate 200 mg capsule) every 12 hours and ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day, for 12 months
2494876|NCT02936570|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2494932|NCT02936271|Active Comparator|Active Vasculera (diosmiplex)|Active Vasculera will be prescribed as one (1) tablet (630 mg) twice a day.
2494934|NCT02936271|Placebo Comparator|Vasculera Placebo|Vasculera Placebo will be prescribed as one (1) tablet twice a day.
2495028|NCT02935582||Enstilar®|Patients for whom a new treatment strategy has been decided which involves start of topical treatment with Enstilar® according to the current local labelling
2495033|NCT02935582||Other topical|Patients for whom a new treatment strategy has been decided which involves start of topical treatment not including Enstilar®
3195066|NCT00835822|Placebo Comparator|B|Arm treated with placebo.
3195067|NCT00835835|Placebo Comparator|Control group|The placebo group did not receive treatment during the matched period yet did undergo all assessments. The MS Placebo group received equal treatment following the study intervention period.
2495328|NCT02933606|Experimental|BNC210 600 mg b.i.d.|Suspension administered orally for 12 weeks.
3195068|NCT00835835|Experimental|Combination Treadmill training group|Subjects randomized to Combination therapy received 20 minutes of Lokomat assisted treadmill training followed by up to 20 minutes of BWS treadmill training (without robotic assistance) twice a week.
3195069|NCT00835848|Active Comparator|Exenatide|25 μg Byetta (Lilly, Exenatide) is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
3195070|NCT00835848|Placebo Comparator|Saline|Isotonic saline infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
3195071|NCT00835887|Experimental|1|Treatment with low dose flavanoids
3195072|NCT00835887|Experimental|2|Treatment with high dose flavanoids
3195073|NCT00835939|Active Comparator|25% Dextrose and 1% Lidocaine|
3195074|NCT00835939|Placebo Comparator|Lidocaine|
3195075|NCT00835952|Experimental|ATX-101|
3195076|NCT00835965|Active Comparator|Active Comparator|Patients receive aprepitant and dexamethasone for prevention of postoperative nausea and vomiting
3195077|NCT00835965|Placebo Comparator|Placebo Comparator|Patients receiving aprepitant and placebo dexamethasone for prevention of postoperative nausea and vomiting
3195078|NCT00836030||A|
2494240|NCT02940899|Active Comparator|Intervention: Syracuse University Fir Families Program (SUFFP)|SUFFP is a randomized control trial comparing two groups of families of children with autism spectrum disorders. 20 families participated in the intervention program
2494243|NCT02940899|Active Comparator|Control: Syracuse University Fir Families Program (SUFFP)|20 families served as a wait-list control group. The control group will fill out the same pre and post measures as the intervention families (membership in the control vs. intervention group will be selected semi-randomly such that the average age of each of the two groups is equal), which will allow us to tease apart the effects of development vs. those related to the intervention.
2494277|NCT02940613|Experimental|Visual feedback of symptom frequency|Participants in this arm receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
2494278|NCT02940613|No Intervention|No visual feedback of symptom frequency|Participants in this arm complete the symptom checklist as is typically done during treatment, but receive no visual feedback of their self-reported symptom frequency over the first 4 weeks of active treatment.
2494289|NCT02940301|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-21 and nivolumab IV continuously over 60 minutes on day 1. Treatment with nivolumab repeats every 21 days for up to 16 courses and treatment with ibrutinib continues in the absence of disease progression or unacceptable toxicity.
2494355|NCT02940093||Stem cell transplant recipient|
2494357|NCT02940093||Stem cell donor|
2494410|NCT02939794|Active Comparator|ferinject|-Patients will receive 1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
2494413|NCT02939794|Placebo Comparator|placebo|Patients will receive a placebo drug intravenous approximately 24 hours before surgery
2494440|NCT02939352|Experimental|Cocaine Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
2494451|NCT02939352|Experimental|Alcohol Users|Participants will receive Real continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex. Participants will also receive Sham continuous Theta Burst Stimulation to the left frontal pole/medial prefrontal cortex.
2494488|NCT02939040|Experimental|Positive Activities Intervention|Patients will note at least one positive event each day, write it down on a slip of paper and then deposit this piece of paper in a piggy bank. After approximately 21 days, the participant reads each one the night before surgery.
2494489|NCT02939040|No Intervention|Usual Care Group|The control group will serve to show the relative benefits of the Positive Piggy Bank intervention. These participants will follow the same questionnaire completion procedures.
2494582|NCT02938806||Obese/overweight children with T1D|No intervention
2494586|NCT02938806||Normal weight children with T1D|No intervention
2494590|NCT02938806||Obese/overweight children, no diabetes|No intervention
2494592|NCT02938806||Healthy, normal weight children|No intervention
2494631|NCT02938104|Experimental|Prehabilitation|"Immediately after randomization, until surgery and to be continued for 8 weeks after surgery, patients in this arm will:~Receive a personalized physical exercise program~Receive nutritional counselling with whey protein isolate powder~Receive relaxation techniques"
2494634|NCT02938104|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patient in the other arm but to be started after surgery.
3195079|NCT00836043||Group 1|
3195080|NCT00836069|Experimental|PD 0332334-α2δ ligand (450mg)|PD 0332334, 450mg/day, for 8 weeks and then 2 weeks of dose tapering.
2494817|NCT02937155||Vaccinated|Patients who have received the HPV vaccine.
2494820|NCT02937155||Vaccine Naive|Patients who have not received the HPV vaccine.
3195081|NCT00836069|Experimental|PD 0332334-α2δ ligand (600mg)|PD 0332334, 600mg/day, for 8 weeks and then 2 weeks of dose tapering.
3195082|NCT00836069|Active Comparator|Paroxetine|Paroxetine, 20mg/daym for 8 weeks and then 2 weeks of dose tapering.
2495066|NCT02935426|Experimental|Cyanoacrylate group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with application of cyanoacrylate tissue adhesive
2495067|NCT02935426|Active Comparator|Suture group|Wound closure after harvesting of connective tissue graft in the donor site will be achieved with polytetrafluoroethylene (PTFE) continuous interlocking sutures
2495127|NCT02934789|Active Comparator|Study group: surgical arm|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
2495137|NCT02934906||Experimental Group|pregnant women with anti-HPA antibody positive
3195083|NCT00836069|Placebo Comparator|Placebo|Inactive Substance (placebo) for 10 weeks.
3195084|NCT00836082|Experimental|Cohort 1 (N=10)|Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days.
3195085|NCT00836082|Experimental|Cohort 2 (N=10)|Placebo-controlled, escalating multiple doses of 1mg per day for 14 days.
3195086|NCT00836082|Experimental|Cohort 3 (N=10)|Placebo-controlled, escalating multiple doses of 4mg per day for 14 days.
3195087|NCT00836082|Experimental|Cohort 4 (N=10)|Placebo-controlled, escalating multiple doses of 8mg per day for 14 days.
3195088|NCT00836108|Sham Comparator|1|spontaneous
3195089|NCT00836108|Experimental|2|coordinating arm elevation with inspiration
3195090|NCT00836108|Experimental|3|coordinating arm elevation with expiration
3195091|NCT00836121||tumor|
3195092|NCT00836134|Experimental|1|rectus sheath block
3195093|NCT00836134|Active Comparator|2|local anesthetic infiltration
3195094|NCT00836147|Placebo Comparator|1|250 ng dose
3195095|NCT00836147|Active Comparator|2|250 ng dose
3195096|NCT00836160||1|
3195097|NCT00836160||2|
2494173|NCT02941328|Experimental|Pyridostigmine|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
2494175|NCT02941328|Placebo Comparator|Placebo|(this is a cross-over trial, in which participants will receive both a placebo and pyridostigmine in different study periods. Both investigators and participants are blinded for what medication is used in what period. All patients will eventually use a placebo for 8 weeks and pyridostigmine for 8 weeks).
2494236|NCT02941029||Evaluate toxicity biomarkers|Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
2494315|NCT02940639||Cohort 1|Participants with advanced/metastatic renal cell cancer (RCC) starting nivolumab monotherapy after prior therapy
2494318|NCT02940639||Cohort 2|Participants with advanced/metastatic RCC starting 1st line therapy with nivolumab and ipilimumab combination therapy, in intermediate/poor risk participants
2494327|NCT02940158|Other|1/2 cup|1/2 cup serving size arm
2494328|NCT02940158|Other|1/4 cup|1/4 cup serving size arm
2494383|NCT02939742|Experimental|Betamethasone|Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
2494384|NCT02939742|Placebo Comparator|Saline Placebo|Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
2494442|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
2494449|NCT02939547|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
2494479|NCT02939027|Experimental|Group 1|For the first 20 patients, a total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days week, 3 weeks or lees at least 2 days apart each fraction.
2494482|NCT02939027|Experimental|Group 2|For the next 20 patients a total dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days week 3 weeks or lees at least 2 days apart each fraction.
2494568|NCT02938832|Active Comparator|Traditional low-fat diet advice|Advice on traditional low-fat diet by dietician
2494573|NCT02938832|Active Comparator|Mediterranean diet advice|Advice on a Mediterranean dietary regime with reduced carbohydrates
2494613|NCT02938221|Experimental|Telemedical video-oculography|Execution of three oculomotor tests using a telemedical video-oculography system
2494649|NCT02937974|Experimental|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
2494653|NCT02937974|Placebo Comparator|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
2494670|NCT02937662|Experimental|IAC regimen|Patients receive IAC regimen including idarubicin, cytarabine and cyclophosphamide.
2494671|NCT02937662|Active Comparator|Control Group|Patients receive physician-directed regimens without cyclophosphamide including FLA±G regimen, AAG regimen, decitabine with AA regimen. Physicians can choose one of these regimens based on their experience and patients' condition.
3161917|NCT00451867|Active Comparator|A|2000 mg per day of CellCept (MMF) divided into 2 equal doses.
2494795|NCT02937181|Experimental|open fractures type II and III|Every patients will receive Ceftaroline in an open label, single arm
2494833|NCT02936765|Experimental|Elastic spine pad|Patients, who receive Elastic Spine Pad (TM) as cervical disc prosthesis after ventral discectomy.
2494834|NCT02936765|Active Comparator|Squale|Patients, who receive Squale (TM) as cervical disc prosthesis after ventral discectomy.
2494878|NCT02936492|Experimental|BAY1003803|Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject
2494882|NCT02936492|Placebo Comparator|Placebo|Topical treatment using matching amount of placebo
2494889|NCT02936492|Active Comparator|Clobetasol propionate|Topical treatment using 16.5 mg of clobetasol propionate per subject
2495162|NCT02934399||Healthy controls (HC)|Definition of the normal circadian and ultradian profiles of pituitary and adrenal hormones in healthy subjects:Each subject (total number 200, anticipated 50 per study centre) will be sampled by the ULTRADIAN sampling device for 27 hours. Day to day hormonal variability:A subgroup of 20 subjects will be asked to undergo sampling on three occasions to assess reproducibility of hormonal levels over time. Comparison of tissue and blood concentrations of hormones: 20 subjects will be asked to participate in the study comparing hormonal tissue level and blood levels.
2495163|NCT02934399||Cushing syndrome (CS)|"Diagnosis of Cushing's syndrome by ULTRADIAN dynamic cortisol measurements The primary objective is to establish circadian and ultradian hormonal profiles of patients with Cushing's from 24 hour ambulatory sampling of subcutaneous fluid.~A secondary aim is to compare the pre and post-operative hormonal profiles of patients with Cushings and to compare these results to age/sex matched control~Study subjects: Subjects with established clinical and biochemical Cushing's syndrome (ACTH-producing pituitary adenoma or ACTH-independent adrenal source)."
2495164|NCT02934399||Adrenal insufficiency (AI)|"Monitoring of adrenal insufficiency (AI) by ULTRADIAN dynamic cortisol and ACTH measurements Aims and objectives: to compare hormonal profiles of patients with Adrenal insufficiency on conventional replacement regimes to age/sex matched controls.~Study subjects: Subjects with established primary (adrenal) AI"
2495184|NCT02934594||Group A|Motor function intact group: received palliative decompression
2495187|NCT02934594||Group B1|motor deficit group: received palliative decompression within 48 hours after symptoms occured
2528136|NCT02709668|Placebo Comparator|placebo|gel cap with placebo
3161918|NCT00451867|Placebo Comparator|B|Placebo
3161919|NCT00451880|Experimental|Arm 1|XL281 administered once a day
3161920|NCT00451880|Experimental|Arm 2|XL281 administered twice a day
3161921|NCT00451880|Experimental|Arm 3|XL281 administered once a day. Subjects in this arm will be dosed under fed conditions, fasted conditions, and with a concomitant single dose of 40 mg famotidine, during the second, third, and fourth week of the first cycle.
3161922|NCT00451893|Active Comparator|Heavy-weight|Lichtenstein operation performed with a heavy-weight mesh.
2494177|NCT02941315|Experimental|with CMR confirmed etiology|Participants who were identified with cardiac magnetic resonance (CMR) in etiology were treated with drug including etiologic treatment,anti-myocardial remodeling.
2494178|NCT02941315|Placebo Comparator|etiology unconfirmed without acute HF|Participants who were not identified with cardiac magnetic resonance (CMR) in etiology and without acute hearts failure (HF) were treated with drug with anti-myocardial remodeling.
2494179|NCT02941315|Placebo Comparator|etiology unconfirmed with acute HF|Participants who were not identified with CMR in etiology but with acute hearts failure were treated with drug with anti-myocardial remodeling,anti-acute heart failure.
2494180|NCT02941315|Experimental|etiology confirmed with acute HF|Participants who were identified with CMR in etiology but with acute hearts failure were treated with drug with Etiological, anti-remodeling and symptom treatment.
2494195|NCT02940938|Experimental|Children under general anesthesia|During general anesthesia without surgical stimuli, pulse oximeter sensor is applied with gradually increased contact force, from 0 to maximal 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds at each contact force. Delta POP will be calculated and compared.
2494247|NCT02940847|Active Comparator|blind technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. The blind technique consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
2494250|NCT02940847|Active Comparator|ultrasound-guided technique|Investigators will perform a medial brachial cutaneous nerve block and an intercostobrachial nerve block with either a blind technique or an ultrasound-guided technique to estimate the effectiveness of each technique. In the ultrasound-guided technique, ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
2494296|NCT02940496|Experimental|Arm A (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
2494300|NCT02940496|Experimental|Arm B (pembrolizumab, elbasvir/grazoprevir, ribavirin)|Patients receive pembrolizumab as in arm A. Patients also receive elbasvir/grazoprevir orally PO QD and ribavirin PO QD on days 1-28. Treatment continues for 12-16 weeks in the absence of disease progression or unacceptable toxicity.
2494370|NCT02940002|Experimental|BAY1003803 0.1% lipophilic cream|BAY1003803 0.1% lipophilic cream (on plaque and healthy skin)
2494371|NCT02940002|Experimental|BAY1003803 0.1% ointment|BAY1003803 0.1% ointment (on plaque and healthy skin)
2494373|NCT02940002|Experimental|BAY1003803 0.01% lipophilic cream|BAY1003803 0.01% lipophilic cream (on plaque and healthy skin)
2494374|NCT02940002|Experimental|BAY1003803 0.01% ointment|BAY1003803 0.01% ointment (on plaque and healthy skin)
2494378|NCT02940002|Active Comparator|Clobetasol propionate|Clobetasol propionate ointment 0.05 % (on plaque and healthy skin)
2494381|NCT02940002|Active Comparator|Betamethasone/calcipotriene|Betamethasone/calcipotriene ointment 0.05 %/0.005% (on healthy skin)
2494395|NCT02939677|Other|Targeted exercise|Targeted exercise intervention
2494397|NCT02939677|No Intervention|care as usual|home based exercises
2494431|NCT02939482|Active Comparator|Group 1: 40 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 0.5 min
2494434|NCT02939482|Experimental|Group 2: 20 ml/min|Triamcinolone acetonide (80 mg)/2 ml and normal saline solution 18 ml infusion in 1 min
2494496|NCT02939209|Experimental|Hydromorphone|Patients will be given 2 mg hydromorphone (immediate release) in the post anesthetic care unit.
2494503|NCT02939209|Placebo Comparator|Placebo|Patients will be given placebo in the post anesthetic care unit.
2494546|NCT02938663||Questionnaires and measurements|assessment of physical activity, dietary intake, psychosocial factors, weight status
2494616|NCT02938143|Experimental|4-stage criteria-based exercise protocol|a progressive 4-stage criteria-based exercise protocol within the limits of pain
2494619|NCT02938143|Active Comparator|Heavy-load eccentric exercise protocol|a 12-week painful heavy-load eccentric exercise protocol
2494688|NCT02937883|Experimental|empowerment intervention|Empowerment intervention
2494694|NCT02937883|No Intervention|regular care|Regular care, care as usual
2494737|NCT02937480|Experimental|Experimental group|Task-specific training
2494743|NCT02937480|Sham Comparator|Control group|Global stretching, memory exercises, health care orientation
2494802|NCT02937064||Controls|Controls
2494805|NCT02937064||ACL subjects|Subjects with anterior cruciate ligament injuries.
2494806|NCT02937064||OA1, doubtful OA|Subjects with doubtful osteoarthritis.
2494809|NCT02937064||OA2, mild OA|Subjects with mild osteoarthritis.
2494812|NCT02937064||OA3, moderate OA|Subjects with moderate osteoarthritis.
2494814|NCT02937064||OA4, severe OA|Subjects with severe osteoarthritis.
2494858|NCT02936700|Other|Control group|Add on relaxation group
2494860|NCT02936700|Experimental|Therapy ACT|Add on ACT group
2494943|NCT02936297|Placebo Comparator|Lactose free placebo|Lactose free placebo pill
2494946|NCT02936297|Active Comparator|Low dose Gluten (0.5g)|Low dose gluten pill
2494949|NCT02936297|Active Comparator|High Dose Gluten (2.0g)|High dose gluten pill
2494965|NCT02935764|Experimental|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
2494967|NCT02935764|Active Comparator|IRINOTECAN|irinotecan
2495026|NCT02935569|Experimental|Compression Headband|a compression headband, placed only at the time of irradiation
2495100|NCT02935322|Active Comparator|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|A mouthrinse combining chlorhexidine and NaF
2495101|NCT02935322|Active Comparator|0.2 % NaF mouthrinse|A mouthrinse containing NaF
2495103|NCT02935322|Active Comparator|0.12% chlorhexidine mouthrinse|A mouthrinse containing chlorhexidine
2495104|NCT02935322|Placebo Comparator|Placebo mouthrinse|A mouthrinse containing all basic ingredients as the other three mouth rinses compared but without chlorhexidine and fluoride
2495149|NCT02934763|Placebo Comparator|Placebo|Saline solution by target controlled infusion
2495151|NCT02934763|Active Comparator|Propranolol at 5ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 5ng/ml
2494182|NCT02941289|Experimental|Alzheimer's patient|Probable diagnosis of Alzheimer's disease with a mild impairment (MMSE 20-26) according to DSM IV diagnosis criteria
2494186|NCT02941289|Active Comparator|Control patient|patient with MMSE score equal or > 27
2494196|NCT02940990|Placebo Comparator|Group A|Participants in the Group A will receive 4-6 cycles of standard two-drug chemotherapy. After that, clinical observation or maintenance chemotherapy will be given.
2494199|NCT02940990|Experimental|Group B|Participants in the Group B will also receive 4-6 cycles of standard two-drug chemotherapy. However, they will receive an additional treatment of SBRT to primary lesions or metastatic lesions combined with GM-CSF.
2494239|NCT02940808|Other|Caffeine first, placebo second|"Caffeine consumption during session 1, placebo consumption during session 2 (after baseline session 0)."
2494242|NCT02940808|Other|Placebo first, caffeine second|"Placebo consumption during session 1, caffeine consumption during session 2 (after baseline session 0)."
2494284|NCT02940535|Experimental|Low Dose GnRHa|Diphereline 0.375mg was administered in the early-luteal-phase. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the day 28.
2494291|NCT02940535|Active Comparator|GnRHa Ultra-short Protocol|Decapeptyl 0.1mg was administered in the menstrual day 2 to 7. Human menopausal gonadotropin/human chorionic gonadotropin (HMG/HCG) was administered start in the menstrual day 2.
2494366|NCT02940184|Experimental|Enteral fructose with DPP-4 inhibition|"Enteral fructose + DPP-4 inhibition (sitagliptin)~After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals."
2494368|NCT02940184|Experimental|Enteral fructose without DPP-4 inhibition|Enteral fructose without DPP-4 inhibition (sitagliptin) After DPP4 inhibition using Tablet Sitagliptin 100mg on the evening before and on the morning of experimentation enteral fructose is given via an intestinal tube (intrajejunal) to either truncally vagotomised and control individuals.
2494399|NCT02939690|Experimental|UVC and surface measurement formula|UVC insertion depth = Umbilicus to nipple distance minus 1cm
2494402|NCT02939690|Active Comparator|UVC and Birth weight based formula|UVC insertion depth=[(3× birth weight (Kg) + 9)/2+1)] cm
3195098|NCT00836173|Experimental|RICE followed by GARD|"RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, for 3 cycles.~GaRD treatment: After RICE treatment, gallium nitrate will be given continuously over a 7 day period. In addition rituximab will be given on day 1 of each cycle. Dexamethasone will be given for the first 4 days of each cycle. The length of each cycle is 21 days."
3195099|NCT00836199|Placebo Comparator|Placebo vaccine|
3195100|NCT00836199|Experimental|NicVAX vaccine|
3195101|NCT00836212|Experimental|LPV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
3195102|NCT00836212|Experimental|EFV|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
3195103|NCT00836225|Experimental|A|50 mg ISIS 388626 vs Placebo, s.c. injection
2494560|NCT02938611||The study population|Persons with stage >=4 chronic kidney disease.
2494617|NCT02938260||Diltiazem|
2494620|NCT02938260||Metoprolol|
2494684|NCT02937922|Active Comparator|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
2494686|NCT02937922|Active Comparator|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 90 seconds between sets and exercises. The weight will be adjusted to 60% of a maximum repetition (1-RM) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
2494687|NCT02937922|Active Comparator|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
2494731|NCT02937402|Experimental|Bronchoscopy with bronchoalveolar lavage|Patients undergo bronchoscopy with bronchoalveolar lavage over 45 minutes
2494750|NCT02937220|Experimental|Monolithic zirconia crowns|New crown material to restore dental implants
2494753|NCT02937220|Active Comparator|metal ceramic crowns|conventional crown material for restoring dental implants
2494807|NCT02937038||Healthy Kids 3-13 y|Healthy boys and girls of 3-13 y of age
2494810|NCT02937038||Parents 20-50 y|One of their Parents 20-50 y of age
2494843|NCT02936713|Experimental|1=Functional Gastro-Intestinal Disorder (FGID)|1=FGID study group: 40 evaluable FGID subjects with a functional gastrointestinal disorder (FGID) complaining of excessive gas evacuation per anus (i.e excessive flatulence), aged from 18 to 75 years that will consume a 3-day specific and controlled mild flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
2494847|NCT02936713|Experimental|2=Non-FGID|2=Non-FGID study group: 60 evaluable non-FGID subjects aged from 18 to 75 years that will consume a 3-day specific controlled high flatulogenic diet twice at 25 days of interval (combined or not with a fermented milk product)
2495082|NCT02935257|Experimental|CD19CAT-41BBZ CAR T-cells|Treatment with the ATIMP: CD19CAT-41BBZ CAR T-cells
2494194|NCT02941159|Active Comparator|SF2000SD|The test product is a Sondashi Formula Spray dried extract (SF2000SD). It is derived from spray drying with water the Sondashi Formula (SF2000), which is a mixture of mixture of 4 plants. SF2000SD is packaged into capsules of 500mg and six capsules are taken twice, daily for 42 days. This drug has anti-HIV properties but in this study we are just looking at safety issues.
2494197|NCT02941159|Placebo Comparator|Placebo|The placebo arm is composed of capsule containing 500mg of inactive ingredient (Microcrystalline Cellulose PH102 -240mg; Starch - 10mg; Magnesium Stearate -10mg; and Maltodextrin Unidry 20 - 240mg).
2494227|NCT02940795|Experimental|Coke cola|Exclusively lactating mothers with infants between 4-6 weeks were investigated. Lactating mothers will be consume a 20 ounce bottle of coke cola.
2494233|NCT02940795|Experimental|Diet Rite|Exclusively lactating mothers with infants between 4-6 weeks were asked to consume a 12 ounce bottle of diet rite.
2494279|NCT02940600|Experimental|Normothermic machine perfusion|Patients undergoing liver transplant with grafts preserved using normothermic machine perfusion
2494280|NCT02940600|Active Comparator|Static cold storage|Patients undergoing liver transplant with statically cold preserved grafts
2494320|NCT02940262|Experimental|Treatment (68Ga-PSMA-11)|Patients receive gallium Ga 68-labeled PSMA-11 IV. Beginning 50-100 minutes after receiving gallium Ga 68-labeled PSMA-11, patients undergo PET imaging.
2494386|NCT02939768|Experimental|Exercise training protocols|Participants will be randomized in one of three groups: HIIT, ST or ST combined with HIIT (ST+HIIT). Each training protocol will last 10 weeks, being the initial two weeks designed to participants' gradual adaptations to respective training protocol, with sessions performed three times per week in non-consecutive days.
2494388|NCT02939768|No Intervention|Control period|Before interventions (exercise training protocols), all participants will participate of a control period lasting one month, where participants will be encouraged to maintain their habitual lifestyle and usual diet habits.
2494441|NCT02939469|Experimental|Experimental: Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
2494550|NCT02938715|Experimental|Feedback group (teledermatology)|
2494553|NCT02938715|No Intervention|Control group (phone only)|
2494601|NCT02938338||Obese patients with BMI above 35|Bariatric surgery
2494644|NCT02938039|Active Comparator|Ambu LMA|Ambu Laryngeal Mask Airway device of different sizes for age
2494645|NCT02938039|Active Comparator|I-Gel LMA|I-Gel Laryngeal Mask Airway device of different sizes for age
2494691|NCT02937779|Experimental|HBs Ag positive|"tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for positive Hbe Ag women.~No treatment for negative HBe Ag women"
2494732|NCT02937363|Experimental|Alpha-lipoic acid|Alpha-lipoic acid supplementation (600 mg/day) for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
2494734|NCT02937363|Placebo Comparator|Placebo|Placebo administration for 4 weeks in a counterbalanced manner to 12 G6PD deficient individuals.
3161923|NCT00451893|Active Comparator|Light-weight|Lichtenstein operation performed with a light-weight mesh.
3161924|NCT00451997|Experimental|Gleevec + Low-Dose Ara-C|
3161925|NCT00452010|Experimental|1|transcutaneous electrical nerve stimulation
2494827|NCT02936856|Experimental|After Hepatic Arteriography|
2494829|NCT02936856|Active Comparator|Before Hepatic Arteriography|
2494880|NCT02936583|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2494923|NCT02936180|Active Comparator|Standard dose influenza vaccine|Patients will receive one dose of FLUZONE® Standard Dose Quadrivalent Inactivated Influenza Vaccine (SD-QIV)
2494928|NCT02936180|Active Comparator|High dose influenza vaccine|Patients will receive one dose of FLUZONE® High Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)
2495038|NCT02935881|Active Comparator|RFA (Stretta Procedure)|Radio Frequency Ablation (RFA) using a Stretta device.
2495046|NCT02935881|Sham Comparator|Placebo Arm|Stretta device used but RFA will not be generated.
3161926|NCT00452010|Placebo Comparator|2|No transcutaneous electrical nerve stimulation
2495117|NCT02934945|Other|patients with CVA(CVA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
2495120|NCT02934945|Other|patients with TA(TA group)|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
2495186|NCT02934607|Active Comparator|Treatment A|2 x 160/4.5 µg Symbicort pMDI administered with no spacer device; no activated charcoal (systemic exposure).
2495189|NCT02934607|Experimental|Treatment B|2 x 160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; no activated charcoal (systemic exposure).
2495193|NCT02934607|Active Comparator|Treatment C|160/4.5 µg Symbicort pMDI administered with no spacer device; with activated charcoal (lung exposure).
2495196|NCT02934607|Experimental|Treatment D|160/4.5 µg Symbicort pMDI administered through AeroChamber Plus Flow-Vu spacer device; with activated charcoal (lung exposure).
2495259|NCT02934113|No Intervention|Control|
2495266|NCT02934113|Experimental|iOTA and HWPP|
2495270|NCT02934113|Experimental|HWPP|
3161927|NCT00452036||Minor head injury|patients with minor head injury
3161928|NCT00452036||minor head injury|patients with minor head injury
3161929|NCT00452075|Experimental|arm 1 medicine|erlotinib daily
3161930|NCT00452088|Experimental|1|15 microgramme candidate vaccine group
3161931|NCT00452088|Active Comparator|2|Hepatitis B comprator group
3161932|NCT00452088|Experimental|3|30 microgrammes candidate vaccine group
3161933|NCT00452088|Active Comparator|4|Hepatitis B vaccine group
3161934|NCT00452127|Experimental|1|
3161935|NCT00452153|Experimental|Characterization Legionnella|Characterization Legionnella by polymerase chain reaction (PCR)
3161936|NCT00452218|Experimental|Open|
3161937|NCT00452244|Experimental|study arm|Iressa (gefitinib) + simvastatin
3161938|NCT00452244|Active Comparator|control arm|Iressa (gefitinib) only
3161939|NCT00452257|Experimental|A|
2494226|NCT02940834||patients with sodium imbalance|
2494230|NCT02940834||patients without sodium imbalance|
2494281|NCT02940431|Experimental|High Autonomy|Children will choose active video games for use during the study.
2494283|NCT02940431|Experimental|Low Autonomy|Children will be assigned active video games for use during the study.
2494335|NCT02940275||Hypertension|
2494336|NCT02940275||Diabetes mellitus|
2494337|NCT02940275||Hypertension and diabetes mellitus|
2494338|NCT02940275||End stage kidney disease|
2494339|NCT02940275||Kidney transplant recipient|
2494343|NCT02940275||Coronary artery disease|
2494346|NCT02940275||Peripheral arterial occlusive disease|
2494416|NCT02939859|Experimental|Microcannula Harvest Adipose|Acquisition AD-tSVF via closed syringe microcannula
2494417|NCT02939859|Experimental|Centricyte 1000|Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) via enzymatic isolation/concentration via Centricyte 1000 Closed System to create AD-cSVF
2494418|NCT02939859|Experimental|Sterile Normal Saline|Re-suspension of Autologous AD-cSVF pellet in Normal Saline deployment via IV
2494459|NCT02939287|Active Comparator|Aprepitant|aprepitant plus standard anti-emetic regimen
2494461|NCT02939287|Experimental|Olanzapine|olanzapine plus standard anti-emetic regimen
2494463|NCT02939287|Experimental|Aprepitant plus olanzapine|aprepitant and olanzapine plus standard anti-emetic regimen
2494518|NCT02938897|Experimental|Telenutrition Intervention|Participants receive diet-related educational materials and self-monitoring tools PLUS registered dietitian nutritionist support.
2494521|NCT02938897|Active Comparator|Enhanced Usual Care Control|Participants receive diet-related educational materials and self-monitoring tools.
3195104|NCT00836225|Experimental|B|100 mg ISIS 388626 vs Placebo, s.c. injection
3195105|NCT00836225|Experimental|C|200 mg ISIS 388626 vs Placebo, s.c. injection
2494756|NCT02937259|Experimental|Self-admission|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
2494799|NCT02937025|Experimental|Left Atrial Appendage Closure Device Group|Device:LAmbre Left Atrial Appendage Occluder（Shanghai Push Medical Device Technology CO.td） to close the left atrial appendage
2494835|NCT02936726|Active Comparator|Exercise and Health Coaching|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)"
2494839|NCT02936726|Experimental|Exercise, Health Coaching and Meditation|"Walking exercise protocol program, carried out by themselves, over 12 weeks.~Health Coach addresses various topics with participant, half-hour sessions on a weekly (12 sessions)~Mindfulness Meditation intervention will incorporate varied types of MBI techniques 3 times per week for 12 weeks, during work hours and/or during their time on campus (after work hours)."
2494886|NCT02936440||critical patients with AKI|Critical patients with AKI will be followed up to 12 weeks after diagnosis
2495009|NCT02935946|No Intervention|Room Temperature Swallows|"Once consented, each participant underwent a video fluoroscopic swallow study (VFSS). Each participant was fed room temperature thin liquid barium (Varibar® Thin Liquid Barium Sulfate for Suspension) from a standard bottle (60ml Similac® Volu-Feeder®) with an attached Similac® Infant Nipple and Ring. The swallows were assessed in real time for any swallowing dysfunction and saved electronically. These swallows were labeled RTS for room temperature swallows. If no swallow dysfunction was observed, the participant became ineligible and the study ended. If swallow dysfunction was observed, the participant became eligible to complete the other arms of the study."
2495011|NCT02935946|Experimental|Cold Liquid Swallows- 5|"Immediately following the RTS condition, a total of 5 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS5 for cold swallows-5."
2495012|NCT02935946|Experimental|Cold Liquid Swallows- 10|"After 10 minutes of feeding a cold liquid, a total of 10 swallows of Cold Liquid Barium was observed under fluoroscopy from an identical bottle and nipple. Images were saved electronically and labeled CS10 for cold swallows-10."
2495081|NCT02935374|Active Comparator|Amoxicillin|The children with acute otitis media will be treated with amoxicillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
2495083|NCT02935374|Active Comparator|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxicillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
2495086|NCT02935374|No Intervention|Wait and see|The children with acute otitis media will be monitored without antimicrobial treatment.
2495088|NCT02935374|Other|Macrolide|The children with acute otitis media with known allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored as a separate group, outside randomization.
2495119|NCT02934880|Experimental|Immediate APA|intervention: 10 sessions of APA within the 5 weeks (2 sessions per week) following the randomization
2495125|NCT02934880|Active Comparator|Delayed APA|intervention: 10 sessions of APA in 5 weeks (2 sessions per week) , 3 months after randomization
2495202|NCT02934490|Experimental|Treatment group|
2495262|NCT02934165|Experimental|Family Safety 123|Parents viewed a website with videos on child injury prevention strategies and received emails for 30 days inviting them to view additional videos.
2495268|NCT02934165|Active Comparator|AAP TIPP sheets|Parents viewed online injury prevention materials developed by the American Academy of Pediatrics and had continuing access to these materials for 30 days.
2495341|NCT02933606|Experimental|BNC210 300 mg b.i.d.|Suspension administered orally for 12 weeks.
2495351|NCT02933606|Experimental|BNC210 150 mg b.i.d.|Suspension administered orally for 12 weeks.
2495354|NCT02933606|Placebo Comparator|Placebo b.i.d.|Suspension administered orally for 12 weeks.
2495396|NCT02933281|Experimental|Cohort 8: MTBVAC 5 x 10^6 CFU|QFT Positive, 1 dose on Day 0
2495401|NCT02933281|Active Comparator|BCG 5 x 10^5 CFU|Both QFT positive and negative, 1 dose on Day 0
2494205|NCT02941120||NOVOCART® Inject patients|Patients who where treated with NOVOCART® Inject autologous chondrocyte implantation in the knee joint.
2494222|NCT02940769|Experimental|light glasses|Study subjects will wear light glasses
2494232|NCT02940769|Sham Comparator|sham glasses (placebo)|Study subjects will wear sham glasses
3195106|NCT00836225|Experimental|D|400 mg ISIS 388626 vs Placebo, s.c. injection
3195107|NCT00836225|Experimental|AA|50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
2494454|NCT02939573|Experimental|Stage 1|Eligible patients will be initially randomized (1:1:1) to receive one of the 3 medications under investigation (colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint is response to treatment at month 6 (stage 1).
2494457|NCT02939573|Experimental|Stage 2|If the patient has to discontinue the study drug within the (stage 1) 6 month study period or during the subsequent follow-up period (up to month 12) because of a lack of response (or failure), flare or side effect, he/she will be randomized again to receive one of the remaining two study drugs (stage 2, with a 1:1 randomization ratio, colchicine 0.6 mg x 2/day; dapsone 150 mg/day; azathioprine 2 mg/kg/day) for 6 months. Endpoint in this second stage will again be the response to treatment at 6 months.
2494531|NCT02938871|Active Comparator|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
2494532|NCT02938871|Placebo Comparator|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
3195108|NCT00836225|Experimental|BB|100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo
3195109|NCT00836225|Experimental|AAA|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3195110|NCT00836225|Experimental|BBB|100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3195111|NCT00836225|Experimental|CCC|200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
2495124|NCT02934828|Experimental|Neoadjuvant chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year. RECIST is used once every 2 cycles. Patients will finish 6 cycles preoperative chemotherapy when CR/partial response(PR)/stable disease(SD) by RECIST without serious adverse events.
2495129|NCT02934828|Active Comparator|postoperative chemotherapy|Postoperative Chemotherapy:Standard chemotherapy regiments according to risk of recurrence: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
2495176|NCT02934542|No Intervention|Control Group|Patients in this group will undergo an elective standard laparoscopic procedure with a designated OR staff to maneuver the laparoscopic camera. The procedures will be performed according to the hospital and OR routine procedure.
2495180|NCT02934542|Experimental|AutoLap Group|Patients in this group will undergo a laparoscopic procedure using the AutoLap system. In this group the surgeon will use the AutoLap system to hold and control the movements of the laparoscopic camera.
2495419|NCT02933073|Experimental|OncoImmunome/Vaccine Phase|Women with Stage III/IV Ovarian Cancer who have received the standard of care treatment (surgical debulking and chemotherapy) for their cancer and are now in clinical remission will be given the experimental drug (vaccine) called OncoImmunome, which has been produced specifically for each participant.
2495488|NCT02932566|Active Comparator|Pirfenidone|Pirfenidone 801mg capsule by mouth, three times a day (target dose) for 12 months
2495492|NCT02932566|Placebo Comparator|Placebo|Placebo capsule by mouth, three times a day (target dose) for 12 months
2495569|NCT02932176||Non-invasive vascular testing|All patients undergoing non-invasive vascular testing will be eligible for this study. The official results will be used to develop the algorithm and to evaluate the accuracy of the algorithm
2495607|NCT02931630|Experimental|HP/HF|Whey protein powder / High fiber bread
2495620|NCT02931630|Experimental|HP/LF|Whey protein powder / Low fiber bread
2495632|NCT02931630|Experimental|LP/HF|Maltodextrin powder / High fiber bread
2495633|NCT02931630|Experimental|LP/LF|Maltodextrin powder / Low fiber bread
2495687|NCT02931331||Observational|Patients undergoing standard of care (PET stress testing followed by mechanical revascularization) are undergoing an additional PET stress test to determine the impact of revascularization.
2495708|NCT02931084||ACL injury|Patients with an acute (not more than 6 weeks old) anterior cruciate ligament (ACL) injury
2495710|NCT02931084||ACL reconstruction|Some of the patients with ACL injury will have reconstruction of the ACL. These will be followed as a new group.
2495767|NCT02930746|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2495794|NCT02930434|Active Comparator|Standard daily vitamin D3|Cholecalciferol 600 IU daily during one year or exit from Antarctica.
2495799|NCT02930434|Active Comparator|Higher weekly vitamin D3|Cholecalciferol 25000 IU once weekly during one year or exit from Antarctica.
2495897|NCT02929901|Placebo Comparator|placebo|placebo (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
3195112|NCT00836225|Experimental|FFF|50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo
3195113|NCT00836238||Questionnaire + Fall Risk Assessment|Physical Function Interview + Physical Function Tests + Symptom Assessment Interview
3195114|NCT00836251||H218O and 2H2O|schizophrenia
3195115|NCT00836264||Morphine T & A|"Subjects ages 4-18 years of age who have a Tonsillectomy and Adenoidectomy and receive morphine for pain control and who have also enrolled in the CAG study at CHOP, A Study of the Genetic Causes of Complex Pediatric Disorders (GCPD study), as approved by the CHOP IRB, 2006-7-4886."
2494312|NCT02940470|Experimental|Calorie restricted diet plus exercise|See Intervention Description
2494314|NCT02940470|Active Comparator|Weight management classes|See Intervention Description
2494350|NCT02940028|Experimental|Expressive writing intervention|The intervention group will participate in a brief expressive writing intervention.
2494352|NCT02940028|Other|Control writing intervention|The control group will receive a control writing condition (fact based writing).
3195116|NCT00836290|Experimental|Pre-release|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
2494436|NCT02939365|Experimental|Belatacept patients|"Forty patients who are previously enrolled in belatacept based regimens with a minimum of 7 years of follow up at 4 transplant centers and who are maintained on belatacept, an antiproliferative ± steroids will be approached for enrollment.~Drug withdrawal of steroids (in patients on steroids) and of antiproliferatives (MPAs or mTor inhibitors). Patients who continue to be stable for 3 months on belatacept monotherapy will be converted from q 4 weeks to q 8 weeks belatacept administrations."
3195117|NCT00836290|Experimental|Post-release|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
3195118|NCT00836290|No Intervention|Control|Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study.
3195119|NCT00836303|No Intervention|Control|Patients of physicians randomly assigned to the control group received usual care
3195120|NCT00836303|Experimental|Intervention Group|This group will receive the behavioral intervention.
2494689|NCT02937727|Experimental|MRI compatible and LFP recordable implantable stimulator|
2494729|NCT02937415|Experimental|Waterpipe smokers group|Three waterpipe cafes located in Ankara were visited. 50 waterpipe smokers aged 18-40 years, enrolled in the study and created the working group. At the same time, there were also cigarette smokers among these people. Breath carbon monoxide, pulmonary function tests were performed both before and after smoking waterpipe and parameters of oxidative stress and antioxidant status were measured in blood samples after smoking waterpipe.
2494733|NCT02937415|Active Comparator|Control group|The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
3195121|NCT00836329|Experimental|Intensive Glucose Management|Participants will receive intensive glucose management.
3195122|NCT00836329|Active Comparator|Traditional Glucose Management|Participants will receive a traditional method of glucose management.
3195123|NCT00836368|Experimental|MaxiGamma|
3195124|NCT00836381|Experimental|Tolterodine ER|Tolterodine ER 4mg once daily
3195125|NCT00836381|Placebo Comparator|Placebo|Placebo once daily
3195126|NCT00836394|Experimental|Intervention Group|Will undergo whole body vibration (WBV) therapy (6 minutes of training on 5 days a week for 3 months)
3195127|NCT00836394|No Intervention|Control|Will follow daily habitual activities
3195128|NCT00836420||liver|patients with acute liver failure
3195129|NCT00836446|Active Comparator|Group 1|20 min. physical activity routine
2495021|NCT02935634|Active Comparator|Nivolumab (nivo) and Ipilimumab (ipi) Combination|
2495025|NCT02935634|Experimental|Nivo and Relatlimab Combination|
2495030|NCT02935634|Experimental|Nivo and BMS-986205 Combination|
2495035|NCT02935634|Experimental|Nivo and Rucaparib Combination|
2495039|NCT02935634|Experimental|Ipi with Rucaparib Combination|
2495045|NCT02935634|Experimental|Nivo with Ipi and rucaparib|
2495131|NCT02934906||Control Group|Pregnant women with anti-HPA antibody negative from the same hospital, the same race, and the same gravidity and parity, who are admitted at the same time.
2528143|NCT02709668|Experimental|enlyte|gel cap of B vitamins brand Enlyte
3195130|NCT00836446|Experimental|Group 2|40 min. aerobic physical activity routine
3195131|NCT00836459|No Intervention|Control|
3195132|NCT00836459|Experimental|Mini Booster|
3195133|NCT00836459|Experimental|Full Booster|
3195134|NCT00836485|Experimental|1|Ketotifen 4.0% Patch
3195135|NCT00836485|Placebo Comparator|2|Placebo Patch
3195136|NCT00836485|Active Comparator|3|Pataday(TM)
3195137|NCT00836485|Placebo Comparator|4|Placebo eye drops
3195138|NCT00836524||1|Pregnant women are included when they attend nuchal transcluency examination and will during their pregnancy be examined 4 times with ultrasound
3195139|NCT00836537|Experimental|1|
3195140|NCT00836537|Active Comparator|2|
3195141|NCT00836550|Active Comparator|Control|The participants spoke with a live counselor prior to answering the knowledge measure
3195142|NCT00836550|Experimental|Video|
3195143|NCT00836563||Forearm Arteriovenous Loop Graft|
3195144|NCT00836576|Experimental|1|
3195145|NCT00836576|Active Comparator|2|
3195146|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 1)|
3195147|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 2)|
3195148|NCT00836602|Active Comparator|BMS-779788 or Placebo (Arm 3)|
3195149|NCT00836628|Experimental|experimental|
3195150|NCT00836654|Active Comparator|1 Catumaxomab|Patient received Catumaxomab and paracentesis
3195151|NCT00836654|No Intervention|2:|Patient treated by paracentesis alone, but after the second paracentesis the patient is able to cross-over in the Catumaxomab-arm
3195152|NCT00836667|Experimental|1|
3195153|NCT00836667|Active Comparator|2|
3195154|NCT00836771|Placebo Comparator|Materna infant formula 1|milk based infant formula powder
2494324|NCT02940132|Experimental|SC10914|SC10914 Dose Escalation： Dose Level 1：30mg(QD) Dose Level 2：60mg(QD) Dose Level 3：120mg(QD) Dose Level 4：200mg(QD) Dose Level 5：100mg(BID) Dose Level 6：300mg(QD) Dose Level 7：150mg(BID) Dose Level 8：400mg(QD) Dose Level 9：200mg(BID) Dose Expansion： Receiving SC10914 in one of three dosage regimens(low, middle or high dose-level and QD or BID) based on the assessment of dose escalation study.
3195155|NCT00836771|Experimental|Materna infant formula 2|Probiotic supplemented infant formula
3195156|NCT00836771|Experimental|Materna infant formula 3|Prebiotic supplemented infant formula
2494421|NCT02939664|Active Comparator|Banded Gastric Bypass|The patient will have done a laparoscopic Roux-en-Y banded (with polypropylene mesh) gastric bypass at the time of the surgical procedure.
2494423|NCT02939664|Active Comparator|Gastric Bypass.|The patient will have done a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
3195157|NCT00836771|Experimental|Materna infant formula 4|Prebiotic+ Probiotic supplemented infant formula
3195158|NCT00836771|Other|Human milk|Human Milk
2494818|NCT02936895|Experimental|Vitamin D3 (Low dose)|vitamin D at a dose of 50,000 IU per day for 2 days
2494821|NCT02936895|Placebo Comparator|Placebo|Placebo (same size and shape) for 2 days
2494855|NCT02936609||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2494856|NCT02936609||Medicaid Non-Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2494909|NCT02936336|No Intervention|Control|without exercise intervention
2494914|NCT02936336|Experimental|Exercise|Subjects with circuit exercise, aerobic dance, or Tai Chi exercise intervention.
2494951|NCT02936063|Experimental|Surgical staples|Skin closure with surgical staples
2494952|NCT02936063|Experimental|Sutures|Skin closure with subcuticular sutures
2494982|NCT02935712|Experimental|Part A|Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)
2494987|NCT02935712|Experimental|Part B|Subjects received 2 treatments (AZD8601+Placebo)
2495032|NCT02935517|Experimental|Group 1: 4.0 x 10^10 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495037|NCT02935517|Experimental|Group 2: 1.2 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495043|NCT02935517|Experimental|Group 3: 3.6 x 10^11 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495049|NCT02935517|Experimental|Group 3a: 3.6 x 10^11 vg/mL of AGTC-402|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495051|NCT02935517|Experimental|Group 4: 1.1 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495052|NCT02935517|Experimental|Group 4a: 1.1 x 10^12 vg/mL of AGTC-402|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495054|NCT02935517|Experimental|Group 5: 3.2 x 10^12 vg/mL of AGTC-402|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGA3 study drug.
2495056|NCT02935517|Experimental|Group 6: MTD of AGTC-402|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGA3 study drug determined by Groups 1-5.
2495110|NCT02935075|Experimental|Reduced dose|Tenofovir 200mg +lamivudine 300mg +efavirenz 400mg PO q.d.
2495112|NCT02935075|Active Comparator|Standard dose|Tenofovir 300mg +lamivudine 300mg +efavirenz 600mg PO q.d.
3195159|NCT00836784|Experimental|1|
2495212|NCT02934308|Experimental|ICU patients|
2495263|NCT02934009|Experimental|Dialysis patients|In this group dialysis patients are measured by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) during their routine dialysis sessions. After a 5 min rest period the arm of the patients is placed onto the NMR-Mouse and measured before the beginning of dialysis. The arm examined is not the shunt arm. The area selected should not display any signs of skin disease or scars from previous surgeries. After the dialysis the same area is measured again in a second measurement. The measurement will be repeated on three different days with each patient.
2495269|NCT02934009|Experimental|Healthy volunteers|"In this group kidney-healthy volunteers will be examined by NMR-Mobile Universal Surface Explorer® (NMR-Mouse) at three different days. The right/left arm or leg will be used for repeated measurement. Altogether 2 measurements per day are reformed in order to evaluate the reproducibility and variability."
2495293|NCT02933671|Experimental|Suprainguinal Fascia Iliaca (SIFI) block|A nerve block technique using a numbing medication called ropivacaine.
2495294|NCT02933671|Placebo Comparator|Sham group|The same nerve block technique as above, however using an inactive solution of salt water.
3195160|NCT00836784|Experimental|2|
3195161|NCT00836797||1 Case with scaffold|This group of patients will be having a placement of PLGA bioscaffold in the alveolar socket after teeth extraction
2495436|NCT02932826|Active Comparator|Insulin|subjects will be treated with insulin according to routine clinical practice at the discretion of the treating physician
3195162|NCT00836797||2 Control without scaffold|The Alveolar socket will be left to heal and no treatment/scaffold placement will be done
3195163|NCT00836823|Experimental|Alpha blocker|Alfuzosin 10mg
3195164|NCT00836836|Experimental|1|Modified Atkins diet arm-In this arm, the children will start the modified Atkins diet after a 4-week baseline period, during which daily seizure log will be maintained. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.
3195165|NCT00836836|No Intervention|2|"No Intervention arm- After the 4-week baseline period, this group will receive their normal diet with no dietetic input, and remain on the same on-going antiepileptic medication for the 3 months. Anti-epileptic medications will remain unchanged during the 3 month trial period, unless the change in AED regimen is medically indicated; e.g. drug side effects or status epilepticus; in which case standard therapy will be provided.~At the end of three months, patients in this arm will be offered the option of the modified Atkins diet treatment.~This group will not receive any dietetic input"
3195166|NCT00836849|Experimental|1|
3195167|NCT00836849|Active Comparator|2|
3195168|NCT00836862||Arteriovenous Fistula|
2494405|NCT02939807|Experimental|advanced HCC, tumor progression with sorafenib|Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.
2494448|NCT02939443|Other|cross-sectional study|
2494529|NCT02938819|Experimental|Experimental group|Patients in the experimental group received a Goal-oriented upper limb intervention.
2494530|NCT02938819|Active Comparator|Control group|Patients in the control group received a standard upper limb intervention
2494537|NCT02938559|Experimental|Cognitive Therapy plus Memory Support|
2494538|NCT02938559|Active Comparator|Cognitive Therapy-as-usual|
2494569|NCT02938442|Active Comparator|Control Arm|Subjects randomized to the control arm will receive SoC neoadjuvant chemotherapy starting on week 1. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
2494574|NCT02938442|Experimental|Chemo+Vaccine Arm|Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
2494630|NCT02938091|Experimental|High-fat diet|The dietary intervention was designed as a typical Western diet (39% total fat, 14% saturated fat, 12% monounsaturated fat, 9.6% polyunsaturated fat, 42% carbohydrate, 8.8 grams fiber/1000 kcal)
2494632|NCT02938091|Experimental|Low-fat diet|The dietary intervention consisted of a Hispanic diet (20% total fat, 5.5% saturated fat, 9.6% monounsaturated fat, 3.7% polyunsaturated fat, 61% carbohydrate, 13.7 grams fiber/1000 kcal). The diet was comprised of typical foods and recipes resembling a traditional Caribbean Hispanic diet and differed from the Western diet in four primary ways: 1) more fruits and vegetables, 2) more beans (e.g. mixed dishes to reduce serving size of white rice while increasing legumes), 3) emphasis on reduced-fat dairy products (e.g., 1% fat milk), and 4) lower total fat and lower animal and hydrogenated fat.
2494685|NCT02937844|Experimental|Anti-PD-L1 CSR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti- PD-L1 CSR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg.
3195169|NCT00836914|Active Comparator|CAL-101|
3195170|NCT00836914|Placebo Comparator|Placebo|
2494910|NCT02936375|Experimental|Iguratimod|Patients will receive iguratimod over the whole follow-up, combined with steroids, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
2494912|NCT02936375|Active Comparator|Cyc+AZA|Patients will receive cyclophosphamide in the first half of study (usually to 24 weeks), followed with azathioprine till the end of follow-up. Patients will also receive steroids as combinational therapy, as well as auxiliary treatment (such as vitamin D, gastrointestinal agents, blood pressure medications, if any)
2495005|NCT02935985||Adults with sICH less than 8h|"Adult patients presenting in one of the study locations and being diagnosed with intracerebral hemorrhage. The onset of the conditions is establised as sonner than 8h.~Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
2495062|NCT02935400||Asymptomatic|Group 1 will have had no symptoms of porphyria in the past year.
2495063|NCT02935400||Symptomatic and treated with hemin|Group 2 will have a history of symptoms within the past year.
2495073|NCT02935127|Experimental|Absorbable Group|In this group of patients absorbable sutures will be used for vascular anastomoses.
2495077|NCT02935127|Experimental|Non-Absorbable Group|In this group of patients non-absorbable sutures will be used for vascular anastomoses.
2495139|NCT02934971||Supervised cohort of 200 chemo-treated patients|cohort of 200 patients undergoing a chemo therapy accordingly to the inclusion criteria patients
2495140|NCT02934971||Age matched control group of 200 normal subjects|200 age matched control group of subjects from the outpatient clinic who are not chemo-treated and who fit the inclusion and exclusion criteria
2495141|NCT02934971||A:machine learning approach (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
2495144|NCT02934971||B: conventional echocardiographic parameters (N=35)|70 female patients undergoing cardiotoxic chemotherapy accordingly to the inclusion criteria will be randomized into two arms (group A and B).
2495271|NCT02934061|Active Comparator|Sirdalud®|Sirdalud® 2 mg tablets administered in patients with acute low back pain
3195171|NCT00836940|Placebo Comparator|1|
3195172|NCT00836940|Experimental|2|GRC 8200-25mg OD
3195173|NCT00836940|Experimental|3|GRC 8200-50mg OD
3195174|NCT00836940|Experimental|4|GRC 8200-50mg BD
3195175|NCT00836940|Experimental|5|GRC 8200-100mg OD
2494481|NCT02939053||Single-arm|All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.
2494535|NCT02938845|Experimental|total laparoscopic hysterectomy(TLH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
2494536|NCT02938845|Experimental|total abdominal hysterectomy(TAH)|Each patient's anxiety was measured using Spielberger's State-Trait Anxiety Inventory immediately before, immediately after the operation.
2494647|NCT02938234|Experimental|Single-arm study|High caloric, high protein ONS, single dose of 400 kcal/day for 7 consecutive days, oral administration
2494781|NCT02937272|Experimental|LY3200882 Schedule 1 Escalation|
2494782|NCT02937272|Experimental|LY3200882 Schedule 2 Escalation|
2494783|NCT02937272|Experimental|LY3200882 Schedule 1 Expansion|
2494784|NCT02937272|Experimental|LY3200882 Schedule 2 Expansion|
2494785|NCT02937272|Experimental|LY3200882 + LY3300054|
2494786|NCT02937272|Experimental|LY3200882 + Gemcitabine + nab-Paclitaxel|
2494787|NCT02937272|Experimental|LY3200882 + Cisplatin + Radiation|
2494788|NCT02937272|Experimental|Japanese Arm LY3200882|
2494881|NCT02936544|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3161940|NCT00452465|Experimental|Intervention|A research nurse will meet with participants, complete a detailed nursing assessment and develop of a care plan to help connect participants with resources to allow them to stay in their homes longer.
3161941|NCT00452465|No Intervention|Control|Usual Care
3161942|NCT00452478|Experimental|1|
3161943|NCT00452491|Experimental|1|
3161944|NCT00452491|Active Comparator|2|
2495092|NCT02935361|Experimental|Treatment (guadecitabine, atezolizumab)|Patients receive guadecitabine SC on days 1-5 and atezolizumab IV over 30-60 minutes on days 8 and 22. Courses repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2495152|NCT02934750|Experimental|Pursed lip breathing|In this arm, patients will be asked to perform a six-minute walking test while continuously using the pursed lip breathing technique.
2495154|NCT02934750|No Intervention|Usual breathing|In this control arm, patients will be asked to perform a six-minute walking test while breathing normally.
2495177|NCT02934438|Active Comparator|Neo40 Supplement|Utilizing intellectual property developed out of the University of Texas Health Science Center in Houston, Neo40 is a GMP certified, over the counter, all natural formulation that provides a system for generating NO in an endothelium-dependent and independent manner. The NEO40™ Daily™ product ingredients list and packaging was submitted to FDA Office of Compliance by Neogenis Labs, Inc. for use as a dietary supplement. It is made up of Beet root extract, hawthorne berry, Vitamin C, L-citrulline and sodium nitrite. The lozenges utilize natural product chemistry activated by the saliva to generate authentic NO gas in the oral cavity through the one-electron reduction of nitrite. This product's formulation was designed to be a quick dissolve that melts in the mouth within four to five minutes.
2495182|NCT02934438|Placebo Comparator|Placebo|A placebo product has been manufactured that looks, tastes and feels like the Neo40 active lozenge without the active ingredients
2495254|NCT02934256|Experimental|Icotinib，treatment effect evaluation|Patients use Icotinib hydrochloride tablets during the course of treatment. The drug dosage is 125mg/m3/d. Every course of treatment lasts three months. Patients are designed to receive total four courses of treatment if there is no disease progression.
2495303|NCT02933736|Experimental|Administration of ribociclib|"Subjects will be administered ribociclib prior to surgical resection of their tumor. All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 following intervals before brain tumor resection:~Cohort 1: last ribociclib dose 2-4 hours prior to craniotomy for tumor resection~Cohort 2: last ribociclib dose 6-8 hours prior to craniotomy for tumor resection~Cohort 3: last ribociclib dose 23-25 hours prior to craniotomy for tumor resection"
2495367|NCT02933398|Active Comparator|Laparoscopic Assisted Partial Nephrectomy|Current standard for partial nephrectomies.
2495375|NCT02933398|Active Comparator|Robotic Assisted Partial Nephrectomy|Possible new standard for partial nephrectomies.
2495458|NCT02933008|Experimental|aNMT Biofeedback|Participants randomized to receive a neuromuscular training intervention that incorporates biofeedback training.
2495461|NCT02933008|Sham Comparator|Sham Biofeedback|Participants randomized to receive a neuromuscular training intervention with sham feedback training.
3161945|NCT00452556|Active Comparator|Standard Radiotherapy Sequence Arm|Standard sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) first, then prostate/prostate bed last
3161946|NCT00452556|Experimental|Experimental Radiotherapy Sequence Arm|Experimental sequence of radiotherapy = whole pelvic lymphatics, proximal seminal vesicles, prostate (or prostate bed) last, prostate/prostate bed first
3161947|NCT00452569|Experimental|A|Oral thalidomide (100mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3161948|NCT00452569|Experimental|B|Oral thalidomide (200mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3161949|NCT00452569|Experimental|C|Oral thalidomide (400mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3161950|NCT00452569|Active Comparator|D|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
3161951|NCT00452582|Experimental|Sildenafil|Orally administered sildenafil in addition to usual care.
3161952|NCT00452582|Active Comparator|Usual post-stroke care|Usual post-stroke treatment including physical, occupational, and speech therapy.
3161953|NCT00452608|Placebo Comparator|amido pill|
3161954|NCT00452608|Experimental|atorvastatina|atrovastatina 80 mg/d by mouth for 10 days
3161955|NCT00452634|Experimental|study arm|
2494483|NCT02939235|Active Comparator|Crushed ticagrelor followed by morphine|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg intravenously
2494487|NCT02939235|Active Comparator|Crushed ticagrelor, morphine,metoclopramide|crushed ticagrelor 180 mg administered orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
2494556|NCT02938767||peritoneal dialysis patients|37 peritoneal dialysis patients followed at the Istanbul Medical Faculty from October 1994 to October 2011
2494561|NCT02938767||renal transplant recipients|20 renal transplant recipients followed at the Istanbul Medical Faculty from October 1994 to October 2011 setted as the control group
2494624|NCT02938286|Experimental|Fractional CO2 laser at 5% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 5% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied to this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2494626|NCT02938286|Experimental|Fractional CO2 laser at 15% density|This test region will be pretreated with a fractional carbon dioxide laser with a 120 μm spot at 15% density and a pulse energy of 2.5 mJ/microbeam (Fractional CO2 laser, 2.5 mJ, 15% density) in a subject blinded fashion. After pretreament Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2494628|NCT02938286|Experimental|Fractional Er:YAG laser at 5% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 5% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 5% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2494629|NCT02938286|Experimental|Fractional Er:YAG laser at 15% density|This test region will be pretreated with a Erbium Yttrium Aluminum Garnet laser with a 225 μm spot at 15% density and a pulse energy of 9 mJ/microbeam (Fractional Er:YAG laser, 9 mJ, 15% density) in a subject blinded fashion. After pretreatment Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region. Fifteen minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at the test region with the Fractional CO2 laser, 50 mJ, 5% density.
2494768|NCT02937298|Experimental|Control Meal|Control meal using standard breakfast foods.
2494770|NCT02937298|Experimental|Berry Treatment|This will consist of standard breakfast foods plus a berry smoothie.
2494772|NCT02937298|Experimental|Sea Buckthorn Treatment|This will consist of standard breakfast foods plus a sea buckthorn berry smoothie.
2494774|NCT02937298|Experimental|Wild Garlic Treatment|This will consist of standard breakfast foods plus a wild garlic dip.
2494790|NCT02936921||Pergravidic maternal infections|proven maternal infections: true seroconversions of profiles of recent infections
2494791|NCT02936921||Subjects free of congenital infection|children who whom all tests performed before birth, at birth and after birth confirmed the absence of congenital toxoplasmosis.
2494792|NCT02936921||Congenitally infected subjects|children for whom at least one test performed before birth, at birth or after birth demonstrated a congenital infection.
2494851|NCT02936830|Placebo Comparator|Control|21 individuals with dentin hypersensitivity will receive a placebo solution of glycerol diluted in water in a 1:1 concentration applied on the sensitive area by the dentist
2494852|NCT02936830|Active Comparator|Fluoride group|21 individuals with dentin hypersensitivity will receive 5% Sodium Fluoride varnish applied on the sensitive area by the dentist
2494853|NCT02936830|Experimental|Nanohydroxyapetite|21 individuals with dentin hypersensitivity will receive 15% nanohydroxyapetite paste applied on the sensitive area by the dentist
2494883|NCT02936362|Other|Sourdough bread, white bread|Consumption of sourdough bread for one week, 2 week washout, consumption of white bread for one week
2494887|NCT02936362|Other|White bread, sourdough bread|Consumption of white bread for one week, 2 week washout, consumption of sourdough bread for one week
2494924|NCT02936115|Experimental|TruSkin®|Cryopreserved skin allograft
2494927|NCT02936115|Active Comparator|Wound Cover|Active Comparator for Diabetic Foot Ulcers
2494980|NCT02935868||Test group|Patients with Type 1 diabetes mellitus
2494986|NCT02935868||Control Group|Patients without systemic diseases
2495240|NCT02934074||Unilateral Lower Limb Loss|Individuals with unilateral lower limb loss will be participants of the group.
2495316|NCT02933827|Experimental|Low dose:|ELIXCYTE 8 mL (ADSC 6.4*10^7 cells in total)
2495319|NCT02933827|Experimental|Middle dose|ELIXCYTE 24 mL (ADSC 19.2*10^7 cells in total)
2495321|NCT02933827|Experimental|High dose|ELIXCYTE 40 mL (ADSC 32.0*10^7 cells in total)
3161956|NCT00452660|Experimental|evaluating the effect of -Exjade|evaluating the effect of -Exjade (Deferasirox)_on oxidative stress parameters of blood cells in patients with Low risk Mylodysplastic syndrome ( MDS) with Iron over load
3161957|NCT00452777|Experimental|BVT.115959|Capsules containing 7 mg BVT.115959 administered orally three times daily
3161958|NCT00452777|Placebo Comparator|Placebo|Placebo capsules administered orally three times daily
3161959|NCT00452803|Active Comparator|study arm|pre-operative chemotherapy (Pac/Cis)
3161960|NCT00452803|Active Comparator|study arm 2|Pre-operative concurrent chemoradiation therapy
3161961|NCT00452816|Experimental|Intervention|Intervention Group - Workplace Solutions Consulting
3161962|NCT00452816|Active Comparator|2|Delayed Intervention
3161963|NCT00452829|Experimental|Study Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD) and 1 g inositol,
3161964|NCT00452829|Placebo Comparator|Control Group|5 mg folic acid (the standard UK supplement for pregnancies at high risk of NTD)and 1 g placebo
3161965|NCT00452881|Experimental|study arm|GemOx
3161966|NCT00452881|Active Comparator|control arm|GemCis
3161967|NCT00452907|Experimental|1|Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
2494775|NCT02937207|Placebo Comparator|Rexiao control group|36 patients of exacerbation group belongs to hot type of asthma will take Dan Ma Jia Tablet placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494776|NCT02937207|Experimental|Xuxiao treatment group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule and Bu Shen Na Qi Granule oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494778|NCT02937207|Placebo Comparator|Xuxiao control group|36 patients of remission phase of Yang deficiency of asthma will take Zhi Chuan Capsule placebo and Bu Shen Na Qi Granule placebo oral therapy thrice everyday for 14 days and background therapy of ICS and beta2-agonist.
2494848|NCT02936778||PICU (= case group)|Children aged 2-18 years admitted to a Paediatric Intensive Care Unit in the Netherlands, with a diagnosis of acute wheeze or SAA.
2494850|NCT02936778||MC (= control group)|Children aged 2-18 years admitted to a Medium Care in the Netherlands, with a diagnosis of acute wheeze or SAA.
2494879|NCT02936518|Experimental|Intervention|
2494915|NCT02936219||Early complementary breast feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
2494917|NCT02936219||Early complementary combined feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
2494919|NCT02936219||Early complementary formula feeding|The EARLY complementary feeding group is defined as the introduction of complementary food <17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
2494920|NCT02936219||Late complementary breast feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like human milk feeding, at the study enrollment.
2494925|NCT02936219||Late complementary combined feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like combined milk feeding, at the study enrollment.
2494929|NCT02936219||Late complementary formula feeding|The LATE complementary feeding group is defined as the introduction of complementary food ≥17th week of life corrected for term. In addition, infants are stratified to the milk regime, like formula feeding, at the study enrollment.
2494953|NCT02935933|Active Comparator|Paravertebral block with bupivacaine|patients received 20 ml of bupivacaine 0.25% paravertebrally in 3 levels, divided into 6-7 ml in each level
2494954|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + morphine|patients received 20 ml of bupivacaine 0.25% +5 mg morphine paravertebrally in 3 levels, divided into 6-7 ml in each level.
2494955|NCT02935933|Active Comparator|Paravertebral block with bupivacaine + dexmedetomidine|patients received 20 ml of bupivacaine 0.25% + 1 μg/kg dexmedetomidine paravertebrally in 3 levels divided into 6-7 ml in each level.
2495036|NCT02935660|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
2495089|NCT02935296|No Intervention|Control|Standard of Care
2495090|NCT02935296|Experimental|Integrated Intervention|Standard of care plus an integrated system of psychosocial counseling and systems navigation for HIV treatment and Substance Use treatment
2495116|NCT02934919|Experimental|nalmefene|
2495203|NCT02934659|Experimental|Investigational|Intervention - Atlas Knee System device for medial knee osteoarthritis
2495248|NCT02934022|Other|Maraviroc|
2495352|NCT02933749|Active Comparator|The sitting|The sitting position Device sCtO2 Device BIS
2495355|NCT02933749|Active Comparator|The prone|The prone position Device sCtO2 Device BIS
2495371|NCT02933190|Other|CSP；transvaginal surgery；UAE and D&C|Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar
2495414|NCT02933086|Experimental|G1: exercises for lumbar stabilization|G1, will perform therapy with specific exercises for lumbar stabilization including the Swiss ball as therapeutic resource
2495416|NCT02933086|Experimental|G2: conventional therapy|G2, will perform conventional therapy including stretching of lower limbs and trunk.
2495467|NCT02932774|Experimental|Cetirizine 10 mg|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive cetirizine HCl syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2495469|NCT02932774|Active Comparator|loratadine 10 mg|Loratadine 10 mg (1 mg/ml) syrup once daily for 2 weeks. Subjects who were randomized to receive loratadine syrup also received placebo syrup. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2495472|NCT02932774|Placebo Comparator|placebo|Placebo syrup once daily for 2 weeks. Both placebo syrups were received by subjects who were randomized to receive placebo. Each subject was instructed to take 2 teaspoons from Bottle A and 2 teaspoons from Bottle B once daily, before 10:00 AM.
2495482|NCT02932371|Experimental|Cardiac Surgery|
2495579|NCT02932254|Active Comparator|Magnesium Sulfate|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution)."
2495581|NCT02932254|Placebo Comparator|Saline Solution|"After anaesthesia induction and calibration of neuromuscular monitoring (acceleromyography) 0,6 mg/kg of rocuronium is given intravenously.~After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) or reappearance of 2 twitches of the train of four (moderate neuromuscular block), 4 mg/kg (deep neuromuscular block) or 2 mg/kg (moderate neuromuscular block) of sugammadex are given intravenously.~INTERVENTION: After 90% of baseline T4 / T1, are injected intravenously 100 mL saline solution over 10 minutes."
2494867|NCT02936453|Experimental|All patients|"Patients will participate during 8-12 months, during which there will be :~Pre-implant evaluations (6-8 weeks)~Device implantation and stimulation optimization (6-8 weeks)~Overground rehabilitation training with EES (5-6 months) In the period after implantation participants need to be present at the CHUV University Hospital in Lausanne 4 days per week for testing and training (lodging can be provided). It is possible to complement the neuro-rehabilitative training at CHUV with a training outside the rehabilitation room by making use of the Home-use system.~An optional extension of the study up to 3 years is offered. During this period, the patient can continue the training with the Home-use system."
2494930|NCT02936258|Other|MRI|Men in Arm A will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI. The unbiopsied men will have a repeat MRI at 2 years.
2494935|NCT02936258|Active Comparator|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
3195176|NCT00836992||Control|Patient's QOL assessments data is not shared with the physician, nurse, and/or nurse practitioner and the patient
3195177|NCT00836992||Active|Patient's QOL assessments data is shared with the physician, nurse, and/or nurse practitioner and the patient immediately prior to the on-treatment visit.
3195178|NCT00837005||1|Patients with suspected CAD
3195179|NCT00837005||2|Patients with known CAD and suspected ischemia.
2495142|NCT02935010|Experimental|Tailored therapy|After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
2495145|NCT02935010|Active Comparator|Empiric therapy|give esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, amoxicillin 1000mg tid and metronidazole 400mg tid for 14 days
2495210|NCT02934373|Active Comparator|A New Sound Processor|Sound Processor is the next generation sound processor.
2495215|NCT02934373|No Intervention|Subject's own sound processor|
2495273|NCT02933996|Experimental|TEAS+GA group|"The patients of TEAS+GA group will receive TEAS therapy in perioperative period.~GA: general anesthesia"
2495275|NCT02933996|Sham Comparator|Sham TEAS+GA group|The patients of Sham TEAS+GA will receive none TEAS in perioperative period.
2495306|NCT02933515|Experimental|Yoga and occupational therapy|twice a week for 8 weeks. one hour of group occupational therapy for fall risk factor management and one hour of yoga for balance
3195180|NCT00837018|Experimental|Physical exercise program|45 min, 3 times a week
3195181|NCT00837044|Active Comparator|1|Treximet, cognitive testing
2495422|NCT02932839|Experimental|Intervention|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
2495486|NCT02932644||Rheumatoid arthritis patients|Participants in the original, parental trial
2495536|NCT02932215|Experimental|All participants|All participants will receive open label lorcaserin
2495585|NCT02931916||healthy group|recruited for evaluation of system reliability
2495588|NCT02931916||Chronic Ankle Instability group|recruited for evaluation of system validity
2495604|NCT02931669||Adult AAC users|Will be accessed via online forums to fill in online anonymous survey link
2495613|NCT02931669||Children who use AAC|Parents at local special schools will be given the opportunity for their child to participate in a face to face symbol based interview. They will give written consent and children's assent will also be obtained.
2495621|NCT02931669||Family members|The paper version of the survey will be distributed among parents at local special schools for them to fill in at home with their families. Online groups of families will also be sent the online survey link.
2495627|NCT02931669||Teachers|Teachers at local special schools will be given the paper survey forms. Online groups of teachers will receive the online link.
2495635|NCT02931669||Health Professionals|Online groups of health professionals will receive the online link
2495658|NCT02931422|Experimental|Low Financial Incentive|Conditional cash transfer upon HIV testing
2495665|NCT02931422|Experimental|Medium Financial Incentive|Conditional cash transfer upon HIV testing
2495672|NCT02931422|Experimental|High Financial Incentive|Conditional cash transfer upon HIV testing
2495698|NCT02931123|No Intervention|standard|
2495699|NCT02931123|Experimental|treatment|rifaximine and lattulose plus low proteine diet
2495905|NCT02929849|Active Comparator|500mg SC|500 mg Salacia Chinensis (SC). This will be compared to placebo.
3195182|NCT00837044|Placebo Comparator|2|Placebo, Cognitive testing
3195183|NCT00837057|Other|early crrt, late crrt|
3195184|NCT00837070|Experimental|1|Percutaneous zygapophyseal cyst rupture
3195185|NCT00837109|Experimental|1|Imagery Rescripting Nightmare Treatment
3195186|NCT00837109|Active Comparator|2|Treatment-as-usual in the Trauma Recovery Program
3195187|NCT00837135|Experimental|All Subjects|Screening for Eligibility into Trial
3195188|NCT00837135|Experimental|ARM A|GI-4000 Vaccine
3195189|NCT00837135|Experimental|ARM B|GI-4000 Vaccine + Activated T Cells
3195190|NCT00837135|Experimental|After GI-4000 Vaccine #4|GI-4000 Monthly - For those with incomplete removal of tumor GI-4000 Monthly + Chemotherapy - For those with complete removal of tumor
3195191|NCT00837174|Experimental|Combination Vorinostat + Bortezomib|Six cycle combination therapy with vorinostat and bortezomib.
3195192|NCT00837187|Active Comparator|Intravenous dexmedetomidine|Dexmedetomidine is administered intravenously
3195193|NCT00837187|Experimental|Intranasal administration|Dexmedetomidine is administered intranasally
3195194|NCT00837226||Study group-Bariatric procedure performed|
3195195|NCT00837226||Control group: No bariatric procedures|
3195196|NCT00837239|Experimental|Gemcitabine + HuaChanSu|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off + HuaChanSu 20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
3195197|NCT00837239|Experimental|Gemcitabine + Placebo|Gemcitabine 1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle) + Placebo 500 ml saline only administered as a 2 hour infusion by central line.
2494897|NCT02936427|Experimental|Dexamethasone 8mg|Participants will receive 8mg of dexamethasone into the intercostal space surrounding the intercostal nerve prior to the first incision. They will then receive routine post operative care including intercostal wound catheters.
2495053|NCT02935478|Experimental|HCC-Left gastric artery embolization|Embospheres Microspheres as artificial embolic agent for left gastric artery embolization
2495148|NCT02934776|Experimental|DTI acquisition|Addition of up to 10 minutes in MRI machine purpose of acquiring additional DTI images
2495230|NCT02934269|Experimental|CC-90006; Dose Level 1|CC-90006 will be administered by subcutaneous injection in the abdomen
2495233|NCT02934269|Experimental|CC-90006; Dose Level 2|CC-90006 will be administered by subcutaneous injection in the abdomen
2495238|NCT02934269|Experimental|CC-90006; Dose Level 3|CC-90006 will be administered by subcutaneous injection in the abdomen
2495242|NCT02934269|Experimental|CC-90006; Dose Level 4|CC-90006 will be administered by subcutaneous injection in the abdomen
2495244|NCT02934269|Experimental|CC-90006; Dose Level 5|CC-90006 will be administered by subcutaneous injection in the abdomen
2495247|NCT02934269|Experimental|Placebo|Placebo will be administered by subcutaneous injection in the abdomen
2495324|NCT02933658|Experimental|Reference1|single(Reference1) -> combination(Reference1+Reference2)
2495336|NCT02933658|Experimental|Reference2|single(Reference2) -> combination(Reference1+Reference2)
2495363|NCT02933242|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy
2495434|NCT02933021||All participants|Nurse visit for blood sample, questionnaire and phone call
2495477|NCT02932488|Experimental|Sumatriptan|"In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects."
3161968|NCT00452907|Active Comparator|2|Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
3161969|NCT00452907|Active Comparator|3|Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
2495964|NCT02929433|Experimental|Cycloergometer group|Training at home with the cycloergometer per 20 minutes twice a day. The protocol suggested a continous use of the cycloergometer for a period of 6 months after 2 weeks of rehabilitation as outpatient.
2495966|NCT02929433|No Intervention|Control group|Usual care after a period (2 weeks) of rehabilitation as outpatient.
2495985|NCT02929160|Experimental|PCN|Percutaneous nephrostomy
2495988|NCT02929160|Experimental|JJ Stent|Retrograde ureteric JJ stent
2496062|NCT02928913||Sedentary|Predominantly engage in sedentary behaviours
2496068|NCT02928913||Non-sedentary|Predominantly engage in non-sedentary behaviours
3161970|NCT00452985||1|"Injection of Docetaxel~3-hour gap~Injection of carboplatin"
3161971|NCT00453037|Active Comparator|group I (early intervention)|"We refer to the results of the DAFNE-study. This study showed the merits of an educational program in diabetics. In accordance to the protocol of DAFNE, we developed a design as follows: For each participating center patients are randomly assigned to two groups. Group I receives an early educational intervention at time of randomization, which should lead to better control of blood pressure after 6 months compared to the control group. The protocol design was chosen for proving an independent effect of the educational program despite optimal management by the GP. Group II is designated to receive the educational intervention 6 months after enrollment into the study.~for further details please see brief description section"
2496276|NCT02927340|Experimental|Lorlatinib|Lorlatinib will be administered orally once daily on a 21 day cycle Blood will be collected for biomarker studies
2496333|NCT02927041||OR-Trauma|Patients presenting with hemodynamic instability with expected intubation greater than 24 hours. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
2496337|NCT02927041||OR-Cardiovascular|Requiring non-isolated cardiac surgery for repair of thoracic aortic aneurysm. Hemodynamic monitoring with transesophageal echo and hemodynamic support/ interventions include volume resuscitation, vasopressors, and positive inotropes. The Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
2496392|NCT02926755|Experimental|Angiography to Assess Vulnerable Plaque|In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
2496419|NCT02926508|Experimental|Prebiotic (Bimuno)|Bimuno (B-GOS, Galacto-oligosaccharides, produced and provided by Clasado BioSciences Ltd)
2496424|NCT02926508|Placebo Comparator|Placebo|Maltodextrin
2497120|NCT02922244|Active Comparator|Centella cream|Apply Centella asiatica cream everyday after radiation therapy on the treatment aria skin.
3161972|NCT00453037|Other|delayed education|"delayed educational intervention~for further details please see brief description section"
3161973|NCT00453076|Experimental|Paclitaxel eluting covered metal stent|Paclitaxel eluting covered metal stent group
3161974|NCT00453076|Active Comparator|Control covered metal stent|Control covered metal stent group
3161975|NCT00453115|Experimental|study arm|GemOx
3161976|NCT00453167|Experimental|study arm|
3161977|NCT00453219||1|Women ages 18-35 years with regular ovulatory menstrual cycles
3161978|NCT00453219||2|Women ages 18-35 years with irregular or absent menstrual periods due to functional hypothalamic amenorrhea (FHA) also called stress-induced anovulation
3161979|NCT00453219||3|Women ages 18-35 years with irregular or absent menstrual periods due to polycystic ovary syndrome(PCOS).
3161980|NCT00453258||Study Subject|Subjects receiving eye examination
3161981|NCT00453271|Experimental|NB-002 0.25% BID|
3161982|NCT00453271|Experimental|NB-002 0.5% QD|
3161983|NCT00453271|Experimental|NB-002 0.5% BID|
3161984|NCT00453271|Sham Comparator|Vehicle control|
2494969|NCT02936024|Experimental|Intervention Group: Two-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in two stages
2494976|NCT02936024|Other|Control Group: One-Stage GSLO Technique|Gubernaculum-sparing laparoscopic orchidopexy will be done in a single stage
2495029|NCT02935530|Experimental|s-LMWH|2125 I.U. subcutaneous injection for 5-10 days
2495034|NCT02935530|Active Comparator|LMWH|4250 I.U. subcutaneous injection for 5-10 days
2495042|NCT02935530|Experimental|Argatroban|20mg, injection for 5-10 days
2495280|NCT02933918|Experimental|Probiotics|
3161985|NCT00453323|Experimental|study arm|
2495360|NCT02933268|Active Comparator|Ad libitum water intake|Ad libitum water intake, defined as intake guided by thirst to achieve a target urine osmolality > 300 mOsmo/kg
2495361|NCT02933268|Active Comparator|High water intake|Personalised daily water intake prescription to achieve target urine osmolality < 270 mOsm/kg.
2495432|NCT02933047|Active Comparator|Outpatient LH|Patients in the intervention group are discharged within 6 to 8 hours after total laparoscopic hysterectomy.
2495439|NCT02933047|Placebo Comparator|Inpatient LH|Patients in the control group follow regular hospitalization and are discharged within 24 hours after total laparoscopic hysterectomy.
2495481|NCT02932631|Active Comparator|CONVENTIONAL PHYSICAL THERAPY group|"physical exercises divided into three phases:~stretching, strengthening and/or mobilization;~functional training of the affected muscles;~functional training of the paretic limb."
2495485|NCT02932631|Experimental|containment therapy induced|healthy side is restricted with splinting and exercises in hemiparetic member: carry out functional tasks individually. Each task will be held for 5 minutes, totaling 60 minutes of service
2495561|NCT02932189|No Intervention|Control|Procedure: Ventilator weaning in the conventional way with a tracheal collar.
2495571|NCT02932189|Experimental|Intervention|"Procedure: Ventilator weaning with a tracheal collar after inspiratory muscle training with an isokinetic device.~Device: K5 Power Breath"
2495611|NCT02931721||MRI Positive|Men with sperm found in MD-TESE
2495619|NCT02931721||MRI Negative|Men with no sperm found in MD-TESE
2495662|NCT02931435|Active Comparator|Nerve Block with Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator activation.
2495668|NCT02931435|Sham Comparator|Nerve Block with Sham Radiofrequency Ablation|A 10 cm 18-gauge RF cannula with a 10 mm active tip will be placed at the superior lateral, superior medial, and inferior medial nerve positions under fluoroscopic guidance.Control patients will undergo the same procedure without RF generator activation. Sensory stimulation at 50 Hz will be performed to identify nerve position and to assure no motor nerves will be ablated. Lidocaine (2 ml of 2%) will be administered in each location prior to RF generator sham activation.
2495700|NCT02931136|Active Comparator|treatment group|Huperzine A treatment.
2495704|NCT02931136|Placebo Comparator|Placebo group|The placebo in 52 weeks.
2495770|NCT02930850|Experimental|Test subjects|All subjects are enrolled and receive Rad-67 Pulse oximeter sensor for measurement of hemoglobin.
2495848|NCT02930239|Experimental|Gait rehabilitation|Will perform 2 weeks of gait rehabilitation using the anti gravity treadmill. Intervention will start 2 weeks post-surgery. This rehabilitation will be performed simultaneously as the patient receives the standardized rehabilitation at Linkoping University Hospital.
2495857|NCT02930239|Active Comparator|Control group|Will only receive the standardized rehabilitation at Linkoping University Hospital.
2495883|NCT02929745|Experimental|10 HLA-Cw6+|HLA-Cw6+ patients will donate blood and skin samples
2495884|NCT02929745|Experimental|10 HLA Cw6-|HLA-Cw6- patients will donate blood and skin samples
2495886|NCT02929745|Experimental|Healthy Skin|Healthy patients will donate blood and skin samples
2495930|NCT02929524|Experimental|Ketamine group|This group was used intranasal ketamine, syringes were made with 4 ml of the drug (50mg/ml), 1 randomized per patient. The validity stability and were 7 days after drawing the solution. The drug began to take effect in 10 minutes and lasted about 40 minutes.
2495932|NCT02929524|Placebo Comparator|Placebo Group|This group was used intranasal saline, syringes were made with 4 ml of liquid 1 per patient randomized. The validity stability and were 7 days after drawing the solution.
2496011|NCT02929225|Experimental|Bifid Triple Viable Capsules|BIFICO(Shanghai Sine Pharmaceutical Laboratories Co.Ltd,S10950032), A biological preparation composed of triple viable microbe(Live combined Bifidobacterium, Lactobacillus and enterococcus capsules)
2496013|NCT02929225|Placebo Comparator|placebo|placebo is also manufactured by Sine Pharmaceutical Laboratories,but only contains starch.And placebo is the same as probiotics in appearance,odor,flavor and color.
2496045|NCT02928731||Children with cancer|"Children met the criteria below were invited to fill in the questionnaires set 1.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, (3) they should have been diagnosed with cancer for at least 2 months and be currently undergoing active treatment, and (4) they should aware of their diseases (cancer)."
2496052|NCT02928731||Healthy children|"Children met the criteria below were invited to fill in the questionnaires set 2.~(1) all children should be ages 9-16 years, (2) they should be able to speak and read Chinese, and (3) they should not have cancer or any other chronic illness."
2496120|NCT02928523|Experimental|Autologous Fecal Microbiota Transplantation|Patients will receive autologous fecal microbiota transplantation (MaaT011- 150 mL rectal enema) - 2 administrations 24 hours apart.
2496160|NCT02928094|Experimental|A: Ad5FGF-4|Ad5FGF-4, administered one time at 6x10e9 viral particles in buffer, and maximally-tolerated medical therapy for angina.
2496162|NCT02928094|Placebo Comparator|B: Placebo|Placebo buffer, administered one time, and maximally-tolerated medical therapy for angina.
3161986|NCT00453375|Experimental|1|BHT-3021
3161987|NCT00453375|Placebo Comparator|2|BHT-Placebo
3161988|NCT00453453|Experimental|Nesiritide|Subjects who come into the ED with CHF will be treated with nesiritide
3161989|NCT00453453|No Intervention|Standard care|Subjects who come into the ED with CHF will receive standard care treatment
3161990|NCT00453531|Experimental|Healthy Volunteers|
2494971|NCT02935907|Experimental|APG-115|APG-115 to be explored sequentially during accelerated dose escalation. This will continue until either the occurrence in Cycle 1 of one DLT or two Grade 2 toxicities (graded as per the National Cancer Institute's Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.0) that are related or possibly related to APG-115. When either of these criteria is fulfilled, dose escalation will be converted to a standard 3+3 escalation scheme,
2495031|NCT02935608|Experimental|BIIB074 high dose|Administered twice daily (BID)
2495041|NCT02935608|Experimental|BIIB074 low dose|Administered BID
2495044|NCT02935608|Placebo Comparator|Placebo|Placebo administered BID
2495157|NCT02934841|Experimental|Conbercept|The patients are followed on a monthly basis until 12 months. Three intravitreal injections of conbercept at a dosage of 0.5 mg are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
2495158|NCT02934841|Sham Comparator|sham|The patients are followed on a monthly basis until 12 months. Three intravitreal sham injections are initiated at inclusion (monthly) with reinjection every month only in case of CNV activity (PRN regimen) until 12 months.
2495172|NCT02934412|Experimental|SHR-1314 20mg|20mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2495178|NCT02934412|Experimental|SHR-1314 40mg|40mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2495183|NCT02934412|Experimental|SHR-1314 80mg|80mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2495190|NCT02934412|Experimental|SHR-1314 160mg|160mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2495192|NCT02934412|Experimental|SHR-1314 240mg|240mg SHR-1314 or placebo is administered subcutaneously to healthy subjects
2495249|NCT02934048|Experimental|7-day triple regimen|Patients in this group received a 7-day triple regimen to eradicate H. pylori. The triple therapy contains proton pump inhibitor (PPI)-clarithromycin plus a susceptible antibiotics will be involved in the study.
2495255|NCT02934048|Experimental|10-day triple regimen|Patients in this group received a 10-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
2495260|NCT02934048|Experimental|14-day triple regimen|Patients in this group received a 14-day triple regimen to eradicate H. pylori. The triple therapy contains PPI-clarithromycin plus a susceptible antibiotics will be involved in the study.
2495297|NCT02933723|Experimental|Blood draw- adjuvanted TIV|individuals who received adjuvanted trivalent influenza vaccine (aTIV, Fluad) and consent to a blood draw
2495302|NCT02933723|Active Comparator|Blood draw - nonadjuvanted TIV|individuals who received nonadjuvanted trivalent influenza vaccine and consent to a blood draw
2495452|NCT02933411||Group A|Adolescent women with heavy menstrual bleeding and low von willebrand factor activity.
2495487|NCT02932397|Active Comparator|Propofol|Active drug given to patients as an intravenous dose of 0.5 mg/kg of propofol
2495491|NCT02932397|Placebo Comparator|Saline solution|Placebo drug given to patients as an intravenous dose of 0.05 mL/kg of saline solution (NaCl 0.9%)
2495570|NCT02932202|Experimental|Longitudinal Nutritional Counseling|The intervention group will be contacted every 2 weeks by medical students over the phone to provide nutrition counseling and complete a verbal survey. During the phone calls, participants will be asked a series of questions regarding their dietary intake over the course of the last 2 weeks. If any deficiencies are identified, participants will be counseled on those topics
2495575|NCT02932202|Placebo Comparator|Standard Care Counseling|Participants in the control group will receive standard counseling, which includes weights at every visit, and counseling on weight gain goals as perceived necessary by the provider.
2495674|NCT02931695|Other|pregnant women|"Women during third trimester of pregnancy and in the first trimester of post partum~ECG~circulating sex hormones levels"
2495681|NCT02931695|Other|women in the first trimester of post partum|"Women (same in first arm) in the first trimester of post partum~ECG~circulating sex hormones levels"
2495727|NCT02931006|Placebo Comparator|control|
2495728|NCT02931006|Active Comparator|experimental|
2495741|NCT02930694|Experimental|Group 1: Treatment Sequence AB|Participants will receive Treatment A [JNJ-54175446, 50 milligram (mg) capsule] on Day 1 of period 1 followed by Treatment B [JNJ-54175446, 50 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2495743|NCT02930694|Experimental|Group 1: Treatment Sequence BA|Participants will receive Treatment B on Day 1 of period 1 followed by Treatment A on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2495746|NCT02930694|Experimental|Group 2: Treatment Sequence CD|Participants will receive Treatment C [JNJ-54175446, 100 mg capsule] on Day 1 of period 1 followed by Treatment D [JNJ-54175446, 100 mg suspension] on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2495748|NCT02930694|Experimental|Group 2: Treatment Sequence DC|Participants will receive Treatment D on Day 1 of period 1 followed by Treatment C on Day 1 of period 2. Both the treatment periods will be separated by washout period of minimum 10 days.
2495783|NCT02930499|Experimental|Hyaluronic Acid ECM (Hyalomatrix)|Hyalomatrix ECM will be applied to the target ulcer once weekly
2495785|NCT02930499|Active Comparator|Non-Adherent wound dressing (Mepilex)|Mepilex wound dressing will be applied to the target ulcer once weekly
2495842|NCT02930148|Experimental|Intervention|Participants will be provided with a smart phone (android, version 5.0), two smart garments, a smart garment sensor and an activity bracelet will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The smart phones will have all apps of the PEGASO ecosystem installed.
2495846|NCT02930148|No Intervention|Comparative|Participants will be asked to continue their routine daily physical and educational activities related to leading a healthy lifestyle.
2495880|NCT02929797|Experimental|AKT + gemcitabine|gemcitabine dose 1000mg/M^2, d1,8,15，q4w ×6 AKT 5*10^8/M^2, d16,q4w ×6 Drug: gemcitabine Biological: AKT, CD8+NKG2D+ AKT Cell
2495881|NCT02929797|Active Comparator|gemcitabine|gemcitabine hydrochloride dose 1000mg/M2 d1,8,15，q4w ×6 Drug: gemcitabine
2495933|NCT02929589|Experimental|Opioid naïve patients-Group A|"Group A: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.~."
2494994|NCT02935829|Experimental|Chocolate cookie snack as test food|Ten healthy, normal-weight subjects (male: 6, female: 4) after 10-14 hr fast, consumed 25g available carbohydrate from white bread and glucose, two times, in different weeks as reference foods along with 250ml water; and 25g available carbohydrates from carob snack and chocolate cookie, one time, in different weeks along with 250ml water. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min. The first glucose sample was taken exactly 15min after the first bite of food or drink.
2494996|NCT02935829|Experimental|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
2495060|NCT02935413|Active Comparator|tDCS|group receiving complete treatment of transcranial direct current stimulation
2495061|NCT02935413|Active Comparator|Standard rehabilitation|Standard rehabilitation procedures
2495147|NCT02934854||Observation|Patients with the Creatine Deficiency Syndromes or high-grade suspicion for the Creatine Deficiency Syndromes
2495173|NCT02934464|Experimental|ARM A|"RAMUCIRUMAB 8 mg/kg on Days 1 and 15 of every 28-day cycle~PACLITAXEL 80 mg/m2 on Days 1, 8, and 15 of every 28-day cycle until progressive disease, unacceptable toxicity, informed consent withdrawal or patient's death."
2495179|NCT02934464|Active Comparator|ARM B|"FOLFOX4: Oxaliplatin 85 mg/m2 + l-Leucovorin 100 mg/m2 + 5-fluorouracil 400/600 mg/m2. Cycle length is 2 weeks +/- 3 days.~mFOLFOX6: Oxaliplatin a 85 mg/m2+ l-Leucovorin 200 mg/m2 + 5-fluorouracil 400 mg/m2 and 2400 mg/m2 46-hours continous infusion. Cycle length is 2 weeks +/- 3 days.~XELOX:Oxaliplatin130 mg/m2 + Capecitabine will be 2000 mg/m2 for 14 days. Cycle length is 3 weeks +/- 3 days."
2495231|NCT02934035||Placebo|The placebo group includes participants in eligible clinical trials who have been assigned to placebo medication.
2495236|NCT02934035||Antidepressant|The antidepressant group includes participants in eligible clinical trials who have been assigned to antidepressant medication.
2495305|NCT02933775|Experimental|CAR-CD19 T cells|Autologous T Cells with a CD19-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection. Lymphodepleting conditioning regimen: A combination of fludarabine and cyclophosphamide will be administered at Day -9 - Day -4.
2495459|NCT02932748|Experimental|Group Phone Conference Call|Delivery: Group Phone Diet: PCMs
2495462|NCT02932748|Experimental|Individual Phone Call|Delivery: Individual Phone Call Diet: PCMs
2495465|NCT02932748|Active Comparator|Enhanced Usual Care|Delivery: Face-to-Face Diet: Conventional Diet
2495509|NCT02932384|Active Comparator|Control-Passport Only|"Complete a needs assessment and develop a written Passport to Wellness, an itemized set of health promoting behaviors and services aligned with lifestyle and goals. Participants are compensated based on the items they complete, services they attend."
2495513|NCT02932384|Experimental|Intervention-Passport and Peer Mentor|"In addition to the Passport to Wellness developed with project staff, study participants will select a peer mentor trained in motivational interviewing. The peer mentor will help guide the participant to complete passport items. Part of passport development will include compensation for meeting with peer mentors to form strategies for meeting goals and addressing barriers/challenges that arise."
2495582|NCT02932033|Active Comparator|Tack fixation|consecutive patients with bilateral inguinal hernias will be recruited for TEP repair. Mesh fixation methods with spiral tack is randomly assigned to one side, then comparative fixation method to the contralateral side. In group of active comparator, after randomization, the target inguinal hernia side of the patient has the mesh fixed with titanium spiral tacks.
2495586|NCT02932033|Experimental|Synthetic glue fixation|The same patient, his contralateral side of inguinal hernia, has the mesh fixed with synthetic glue.
2495647|NCT02931591|Active Comparator|GH+Metformin|The children will be given both Growth Hormone and Metformin for 6 months
2495648|NCT02931591|Placebo Comparator|GH+Placebo|Children will be given both GH and Placebo for 6 months
2495703|NCT02931188||Anacetrapib|Participants who received anacetrapib, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
2495706|NCT02931188||Placebo|Participants who received placebo, in addition to statin on the HPS3/TIMI 55: REVEAL trial.
2495756|NCT02930811|Experimental|Sildenafil|Single Sildenafil oral morning intake (100mg/day) per day for a total duration of 6 months (Sildenafil 100 mg oral morning dose)
2495757|NCT02930811|Placebo Comparator|Placebo|Single Placebo oral morning intake per day for a total duration of 6 months (Placebo oral morning dose)
2495804|NCT02930486|Active Comparator|ZipTight|ZipTight suture endobutton
2495806|NCT02930486|Active Comparator|Syndesmotic screw|Tricortical 3.5 mm syndesmotic screw
3195198|NCT00837265|Experimental|Neugranin Dose Level 1|
3195199|NCT00837265|Experimental|Neugranin Dose Level 2|
2495908|NCT02929615|Experimental|Treatment group|
2495968|NCT02929420|Experimental|Xiaoru Sanjie capsules|a new recipe of traditional chinese medicine； Xiaoru Sanjie capsules,three pills every time,three time a day,PO, last three months.
2495969|NCT02929420|Placebo Comparator|Xiao Yao pills|"a kind of traditional chinese medicine that is efficient and safe to treat hyperplasia of mammary glands.~Xiaoyao pills,three pills every time,three time a day,PO,last three months."
2496088|NCT02928653|Active Comparator|Sucrose Sweetened Beverage|100-140 g sucrose/day
2496090|NCT02928653|Experimental|Aspartame Sweetened Beverage|0.541-0.757 g aspartame Sweetened Beverage/day
2496091|NCT02928653|Experimental|Saccharin Sweetened Beverage|0.300-0.455 g saccharin Sweetened Beverage/day
2496092|NCT02928653|Experimental|Sucralose Sweetened Beverage|0.167-0.233 g sucralose Sweetened Beverage/day
2497266|NCT02920827|Placebo Comparator|Placebo Vaginal Ring|Placebo vaginal ring
3195200|NCT00837265|Active Comparator|Pegfilgrastim|
2495078|NCT02935114|Active Comparator|35% Hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
2495132|NCT02934997||Community-Acquired Sepsis|The Adult ED at UF JAX is a high volume, high acuity ED which treats approximately 90,000 patients per year. All CA-sepsis patients will be recruited from the UF JAX ED. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours presenting to the UF Health Jacksonville Emergency Department (ED) will be approached for enrollment.
2495138|NCT02934997||Hospital-Acquired Sepsis|UFH (Gainesville) is a Level 1 Trauma Center and surgical tertiary care center with 24 trauma intensive care unit (ICU) and 24 surgery ICU beds and are the primary ICUs for almost every surgical patient in the hospital and the location for recruitment for Project #1 of the Sepsis P50. Patients meeting the recently updated definition of sepsis (suspected or confirmed infection plus ≥ 2 SOFA points) OR septic shock (hypotension not responsive to 30 mL/kg IV fluids, vasopressor requirement, and lactate ≥ 2) and being treated with an institutional, evidence-based guideline (EBG) management bundle for sepsis within 24 hours in the UFH Surgical ICU will be approached for enrollment.
2495167|NCT02934620|Experimental|CSD500 Condom|Receive CSD500 condoms with condom counseling to use them for sexual pleasure.
2495169|NCT02934620|Active Comparator|Standard Condom|Receive the standard condom with condom counseling to use them for pregnancy and disease prevention.
2495274|NCT02934230|Experimental|Prehabilitation Group|The intervention will be a home-based total-body exercise training program (prehabilitation) based on a protocol with proven efficacy in improving the function of non-frail surgical patients in less than 4 weeks of preoperative utilization.Prehabilitation will consist of 3 components: 1) strength training; 2) aerobic exercise and 3) flexibility. Prehabilitation will be prescribed as 1-hour sessions performed a minimum of 3 times per week. Intervention group patients will also be provided with nutritional advice. In addition to paper-based materials outlining the prehabilitation program, weekly prehabilitation teaching sessions will be held at our Cancer Centre for patients randomized to the intervention group, and activity logs and weekly phone calls will be used to measure compliance and to answer questions. During the final week of the program, patients will also participate in a brief qualitative interview over the phone to explore their experience with the program.
2495276|NCT02934230|No Intervention|Control Group|Patients randomized to the control group will be provided standard perioperative care as per our institutional standards. They will receive the World Health Organization (WHO) Global Recommendations for Physical Activity for Health for people 60 years and above pamphlet, as well as Canada's Food Guide. In-hospital perioperative care, and postoperative care, will be at the discretion of each patient's surgeon and anesthesiologist.
2495325|NCT02933593|Active Comparator|labetalol|labetalol
2495335|NCT02933593|Active Comparator|hydralazine|Hydralazine
2495343|NCT02933593|Active Comparator|nifedipine|nifedipine
2495380|NCT02933216||VR|The CSD patients are received treatment of vaginal repair.
2495387|NCT02933216||hysteroscope + laparoscope|The CSD patients are received treatment of hysteroscopic combined with laparoscopic excision.
3195201|NCT00837278||1 IVF|Pregnancies conceived with the use of assisted reproductive technologies. This is defined as a pregnancy conceived with all gametes being handled outside of the body.
3195202|NCT00837278||2 Control|Spontaneously conceived pregnancies.
3195203|NCT00837291|Experimental|CF101 1 mg BID|
3195204|NCT00837291|Placebo Comparator|Placebo|Placebo tablets BID
3195205|NCT00837304||UC|Patients with known ulcerative colitis
3195206|NCT00837317|Experimental|1|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
2495608|NCT02931877|Experimental|Sevoflurane|Maintenance of anesthesia with sevoflurane during the cardiac valvular surgery.
2495618|NCT02931877|Active Comparator|Propofol|Maintenance of anesthesia propofol during the cardiac valvular surgery.
3195207|NCT00837343|Experimental|Quetiapine Fumarate arm|Quetiapine Fumarate arm
3195208|NCT00837356|Experimental|Advate®/turoctocog alfa|
2495760|NCT02930902|Active Comparator|Arm A (pembrolizumab, paricalcitol)|Patients receive pembrolizumab IV over 30 minutes on day 1 of each course and paricalcitol IV over 15 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
2495829|NCT02930109|Experimental|PTX-200 and cytarabine|"PTX-200 administered intravenously over 1 hour~Phase I: 4 dose levels: 25 to 55 mg/m2 (with reduction to 15 mg/m2 if needed.~Phase II: maximum tolerated dose. given as a 1 hour infusion~Cytarabine administered by continuous infusion at a dose of 400 mg/m2/day for 4 days."
2497305|NCT02920762||Buprenorphine|
3195209|NCT00837369|Experimental|1|RTPE studies (resting and following Regadenoson 400 ug IV bolus injection) will be performed during a continuous infusion of lipid encapsulated microbubbles (Definity, Lantheus Medical Imaging) to qualitatively and quantitatively examine wall motion and myocardial contrast enhancement.
3195210|NCT00837382|Experimental|1|MEDVAMC Nightmare Treatment
3195211|NCT00837382|Experimental|2|Videoconferencing nightmare Treatment
3195212|NCT00837395||premenstual asthma|women with asthma have an increase in asthma symptoms during the premenstrual or menstrual period
3195213|NCT00837408||Cases|Individuals with Type 2 Diabetes
3195214|NCT00837408||Controls|Individuals without Type 2 Diabetes
3195215|NCT00837421||sepsis|sepsis survivors
3195216|NCT00837460|Experimental|rehabilitation|Bilateral and unilateral prehension oriented rehabilitation to enhance prehension.
3195217|NCT00837499||Mexican Women from Mexico|
3195218|NCT00837499||Mexican-American Women in U.S.|
3195219|NCT00837499||African-American Women in U.S.|
3195220|NCT00837538||Back pain|Persons with back pain and supposed instability of lumbar spine
3195221|NCT00837551|Placebo Comparator|1 Placebo cream|0% cream 12 patients
3195222|NCT00837551|Active Comparator|2. Cream|0.5% WBI-1001 cream 12 patients
3195223|NCT00837551|Active Comparator|3. Cream|1.0% WBI-1001 cream 12 patients
3195224|NCT00837564|Experimental|CBASP|CBASP psychotherapy
3161991|NCT00453544|Experimental|Enhanced consent - A|The intervention was an enhanced consent process, including a multimedia aid for a moderate risk hypothetical protocol
3161992|NCT00453544|Experimental|Enhanced consent - B|The intervention was an enhanced consent process, including multimedia aide for a higher risk hypothetical protocol
2495522|NCT02932670|Active Comparator|costoclavicular inflaclavicular block|costoclavicular block with similar volume
2495525|NCT02932670|Experimental|costoclavicular block|costoclavicular block with decreasing volume
2495580|NCT02931994|No Intervention|Group A Phase 1|50% of sample are randomly assigned to Group A and are to utilise conventional flossing technique in the first phase of 6-weeks
2495583|NCT02931994|Active Comparator|Group B Phase 1|50% of sample are randomly assigned to Group B and are to utilise knotted floss technique in the phase 1 of 6-weeks
2495587|NCT02931994|Active Comparator|Group A Phase 2|After a washout period of 2 weeks, those from Group A will use the knotted floss technique for a period of 6 weeks.
2495589|NCT02931994|No Intervention|Group B Phase 2|After a washout period of 2 weeks, those from Group B will use the conventional floss technique for a period of 6 weeks.
2495646|NCT02931552|Experimental|Nuevo Amancer-II Stress Management Program|Nuevo Amanecer-II (NA-II) is a 10-week peer-delivered cognitive-behavioral stress management program. Participants receive the stress management program as soon as possible after randomization.
2495649|NCT02931552|No Intervention|Wait-list Control Group|Waits six months and at the end of the six months is offered the option of receiving the NA-II program.
2495717|NCT02931240|Experimental|Treatment|Treatment with the Revivent TC System
2495718|NCT02931240|No Intervention|Control Pool|Treatment with Guideline Directed Medical Therapy for Heart Failure Symptoms Only
2495779|NCT02930525|Active Comparator|Standard care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
2495781|NCT02930525|Experimental|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
2495852|NCT02930265|Active Comparator|Liraglutide intervention group|Liraglutide intervention group will accept ischemic cardiomyopathy conventional drugs and Liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
2495859|NCT02930265|No Intervention|Control group|Control group will accept ischemic cardiomyopathy conventional drugs and a placebo
2495887|NCT02929758|Active Comparator|Control Initial Training Group|Healthy Controls will receive initial SOPT training and will be compared against controls in the delayed training group and the PD subjects in the initial training group
2495889|NCT02929758|Active Comparator|Control Delayed Training Group|Healthy Controls will receive delayed SOPT training and will be compared against controls in the initial training group and the PD subjects in the delayed training group
2495892|NCT02929758|Other|PD Initial Training Group|PD subjects will received initial SOPT training and will be compared against PD subjects in the delayed training group and the control subjects in the initial training group
2495895|NCT02929758|Other|PD Delayed Training Group|PD subjects will receive delayed SOPT training and will be compared against PD subjects in the initial training group and the control subjects in the delayed training group
2495945|NCT02929511|Experimental|Reciproc Blue|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit. In this group, intervention will be carried out by the Reciproc motor (VDW, Germany) and Reciproc Blue single-file system (VDW, Germany). The intervention is root canal treatment with the Reciproc Blue single-file system.
2495952|NCT02929511|Experimental|OneShape|In this group, OneShape rotational single-file system (Micro Mega, France) will be used as single-file system according to the manufacturer's instruction.
2495956|NCT02929511|Active Comparator|Protaper|As a control group, Protaper (Dentsply, Mailleffer, Switzerland) will be used according to the manufacturer's instruction.
2495981|NCT02929121|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2495996|NCT02929212|Other|Liquid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as one, 600 kcal, meal
2497308|NCT02920762||Fentanyl|
2497310|NCT02920762||Hydromorphone HCl|
3195225|NCT00837564|Experimental|Escitalopram|Escitalopram pharmacotherapy and clinical management
3195226|NCT00837603|Active Comparator|Training|Ergometer Training
3195227|NCT00837603|No Intervention|2|Counseling
3195228|NCT00837642||ART (Assited reproductive technologies)|In participants born after IVF will be performed a transthoracic echocardiography
3195229|NCT00837642||Control|In participants naturally conceived will be performed a transthoracic echocardiography
3195230|NCT00837655|Experimental|1|Sevelamer intervention
3195231|NCT00837655|Active Comparator|2|Calcium carbonate
3195232|NCT00837668||sarcoidosis|sarcoidosis patients undergoing clinical bronchoscopy
3195233|NCT00837681||lung disease|hematopoietic stem cell transplantation (HSCT)
2495096|NCT02935387|Active Comparator|Taper golimumab, then methotrexate|Taper golimumab 50>0mg/month during 24 weeks, then, if still in sustained remission, taper methotrexate 25>0mg/wk during 24 weeks.
2495123|NCT02934893|Experimental|Intervention Group|Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
2495130|NCT02934893|Active Comparator|Standard Diabetes Management|Patient in standard diabetes management in the Medication Management Clinic
2495134|NCT02934893|No Intervention|Primary Care|Matched cohort managed through their primary care physician (PCP) and standard of care.
2495204|NCT02934633|Experimental|Keeping Baby Safe|Keeping Baby Safe 2-DVD package, designed for parents of children from birth to 24 months. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
2495208|NCT02934633|Active Comparator|AAP TIPP Sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets that parents would typically receive from their pediatrician or general practitioner at well-baby visits.
2495234|NCT02934100|Active Comparator|Group 1 - ESWT Treatment|Patients treated with Extracorporeal Shock Wave Therapy once a week for 10 weeks
2495237|NCT02934100|Active Comparator|Group 2 - Body Wave|Patients treated with electric field diathermy three times a week for 5 weeks
2495241|NCT02934100|Active Comparator|Group 3 - Ultrasound|Patients treated with ultrasound therapy three times a week for 5 weeks
2495243|NCT02934100|Sham Comparator|Group 4 - Control group|Patients treated with sham laser therapy three times a week for 5 weeks
3195234|NCT00837733|Experimental|Biopsy catheter|Biopsy catheter (Pipelle de Cornier, Prodimed, Neuilly-en-Thelle, France
2495373|NCT02933294|Active Comparator|Triportal pulmonary resection surgery|Treated by traditional video assisted thoracoscopic three-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2495378|NCT02933294|Active Comparator|Uniportal pulmonary resection surgery|Treated by minimally invasive video assisted thoracoscopic single-port pulmonary resection in the centers with enough experience in VATS and the volume ≧50 cases each year.
2495421|NCT02932917|Experimental|MapMySmoke|All patients in the study will use the MapMySmoke app to document their smoking and craving behavior
2495475|NCT02932696|Experimental|Exercise training|"Patients in this arm were encouraged to participate in an exercise training program, and they accepted to do so.~Intervention: Cardiac training program"
2495480|NCT02932696|No Intervention|No exercise training|Patients in this arm were encouraged to participate in an exercise training program, and they refused to do so.
3161993|NCT00453544|Active Comparator|Routine consent - A|This was a comparison condition - a routine consent process, including a printed consent document, for a moderate risk hypothetical protocol
2495599|NCT02931747|Placebo Comparator|Placebo|Subjects are received the pill of placebo which has same color, shape and smell like the Bacopa Monnieri once daily for 16 weeks.
2495602|NCT02931747|Active Comparator|Bacopa Monnieri 300 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks
2495615|NCT02931747|Active Comparator|Bacopa Monnieri 600 mg/day|Subjects are received the pill of Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks
2495663|NCT02931461|Experimental|needle Procore ®|
2495671|NCT02931461|Active Comparator|needle Cook®|
2495773|NCT02931201|Experimental|DLBCL patients with 18F-FDG PET/CT|18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria
3195235|NCT00837746||1|Women taking risedronate for 5 years
3195236|NCT00837772|Active Comparator|Arm 1|Usual standard cutting guide for TKA (Total Knee Arthroscopy)
2495906|NCT02929784|Experimental|Intervention|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Affected hemisphere anodal stimulation of the hand area of the primary motor cortex (C3/C4), Intensity of 2 mA (milliampere) for duration of 20 minutes. A total of 10 sessions: 5 sessions a week for 2 weeks.
2495909|NCT02929784|Sham Comparator|Sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
2495910|NCT02929784|No Intervention|no HSP|Patients hospitalized in the Loewenstein department of neurologic rehabilitation after first clinical stroke who do not have hemiplegic shoulder pain.
2495979|NCT02929381|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus)
2495980|NCT02929381|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
2496021|NCT02928978|Experimental|Ruxolitinib|Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
2496022|NCT02928978|Placebo Comparator|Placebo|Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
2497313|NCT02920762||Morphine Sulfate|
2497315|NCT02920762||Morphine Sulfate Beads|
3195237|NCT00837772|Experimental|Arm 2|Otismed MRI generated cutting guide for TKA
3195238|NCT00837785|Experimental|1|240 mg (two 120 mg capsules) twice a day
3195239|NCT00837785|Experimental|2|240 mg (two 120 mg capsules) three times a day
3195240|NCT00837798||No history of AF|Patient should not have had a documented history of AF for a period of 3 months prior to enrollment.
3195241|NCT00837837|Experimental|Chlorpheniramine|Chlorpheniramine dose by body weight.
3195242|NCT00837850|Active Comparator|1|
3195243|NCT00837850|Active Comparator|2|
3195244|NCT00837863|Experimental|1|ALTU-238
3195245|NCT00837863|Experimental|2|ALTU-238
3195246|NCT00837863|Experimental|3|ALTU-238
3195247|NCT00837863|Active Comparator|4|Nutropin AQ
3195248|NCT00837889||decompensated heart failure patients|
2495213|NCT02934477||Hematopoietic Stem Cell Transplant (HCT)|Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
2495217|NCT02934477||Non-HCT|Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
2495227|NCT02933970|No Intervention|Control|Referral-HCV seropositive subjects enrolled for at least 12 months in an opiate agonist treatment (OAT) program will be referred to an off-site liver specialist
2495228|NCT02933970|Other|Intervention|Telemedicine - HCV seropositive subjects enrolled for at least 12 months in an OAT program will be treated on site by a liver specialist via two-way video conferencing. (telemedicine)
3195249|NCT00837889||chronic heart failure patients|
3195250|NCT00837889||healthy controls|
2495435|NCT02933138||Multifactorial Chylomicronemia|no intervention, phenotypic and genotypic study
2495532|NCT02932683|Experimental|MedNav assisted resuscitators|MedNav will be used to perform neonatal resuscitation on a mannequin and assessed after teaching and 7 weeks after intervention, following this a small group will be used as a cross over study.
2495535|NCT02932683|No Intervention|No MedNav resuscitators|Neonatal resuscitation will be performed on a mannequin (without the use of MedNav) and assessed after teaching and 7 weeks after intervention.
2495541|NCT02931942||A: Acute leukemia|Patients that will receive intensive clinical chemotherapy for acute leukemia or high risk myelodysplasia (RAEB2) Blood withdrawn 5-7 x
2495542|NCT02931942||B: Autologous transplantation|Patients that will receive high dose chemotherapy and autologous stem cell rescue for varies hematological malignancies Blood withdrawn 5-7 x
2495543|NCT02931942||C: controls|Healthy controls, found amongst family members of patients of group A and B Blood withdrawn 5-7 x
2495545|NCT02931942||D: lung cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for lung cancer, that will mostly be in the outpatient setting Blood withdrawn 5-7 x
2495547|NCT02931942||E: colon cancer|Patients that will receive relatively mild immunosuppressive chemotherapy for colon cancer, that will mostly be in the outpatient setting and mostly adjuvant Blood withdrawn 5-7 x
2495548|NCT02931942||F: controls|Healthy controls, found amongst family members of patients of group D and E Blood withdrawn 5-7 x
2495643|NCT02931812||Cirrhotic subjects|15 cirrhotic patients in end-stage in waiting a graft
2495644|NCT02931812||Chronic kidney disease subjects|15 chronic kidney disease patients in end-stage in waiting a graft
2495645|NCT02931812||Healthy subjects|30 healthy subjects to compare
3195251|NCT00837915|Experimental|1|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets of Ranbaxy
3195252|NCT00837915|Active Comparator|2|(Claritin-D® 24 hour) Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets
2495742|NCT02930733|Active Comparator|ultrasound guided serratus plane block|Bilateral ultrasound guided serratus plane block with 30 ml %0,25 bupivacaine
2495745|NCT02930733|Placebo Comparator|ultrasound guided sham block|Bilateral ultrasound guided sham block with 2 ml saline subcutaneously
3195253|NCT00837928|Experimental|Bendamustine and Fractionated stereotactic radiotherapy|Bendamustine 40 mg/m2 and will be administered IV on days 1,2,and 3 prior to surgery on each day of SRT (Sterotactic radiation therapy). Laboratory biomarker analysis will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. Pharmacokinetic samples will not be collected from patients who begin SRT on day 1). Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine) Stereotactic fractionated radiation therapy starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri). Concurrent Bendamustine is administered on Days of Stereotactic Radiotherapy (Arm 1: 40 mg/m2/ Day; Arm 2: 50 mg/m2/day).
3195254|NCT00837941|Experimental|1|sequence 1 - Pregabalin, Duloxetine hydrochloride, Diphenhydramine hydrochloride
3195255|NCT00837941|Experimental|2|sequence 2 - Duloxetine hydrochloride, Pregabalin, Diphenhydramine hydrochloride
3195256|NCT00837941|Experimental|3|sequence 3 - Diphenhydramine hydrochloride, Duloxetine hydrochloride, Pregabalin
3195257|NCT00837941|Experimental|4|sequence 4 - Pregabalin, Diphenhydramine hydrochloride, Duloxetine hydrochloride
3195258|NCT00837941|Experimental|5|sequence 5 - Duloxetine hydrochloride, Diphenhydramine hydrochloride, Pregabalin
2495944|NCT02929472|Experimental|Physical Exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
2495951|NCT02929472|Other|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
2495992|NCT02929212|Other|Solid Meal Study Group A|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as one, 600 kcal, meal.
2496094|NCT02928653|Experimental|Rebaudioside A Sweeteened Beverage|0.250-0.350 g rebaudioside A Sweetened Beverage/day
3195259|NCT00837941|Experimental|6|sequence 6 - Diphenhydramine hydrochloride, Pregabalin, Duloxetine hydrochloride
3195260|NCT00837954|Active Comparator|1|distal Anastomosis Lyostypt®, proximal Anastomosis Surgicel®
3195261|NCT00837954|Active Comparator|2|distal Anastomosis Surgicel®, proximal Anastomosis Lyostypt®
3195262|NCT00837954|Active Comparator|3|distal and proximal Anastomosis Lyostypt®
3195263|NCT00837954|Active Comparator|4|distal and proximal Anastomosis Surgicel®
3195264|NCT00837993||Survival Analysis|Survival Analysis Based on Reclassification to a Two-tier Grading System: Review of Pathology Slides for Patients participating on Protocol COG 158.
3195265|NCT00838019|Experimental|Cord blood|
3195266|NCT00838032|Experimental|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
2495135|NCT02934789|Active Comparator|Control group: medical arm|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids
2495174|NCT02934516|Experimental|Disimpaction with lower uterine support|Cesarean section with support of the lower uterine segment
2495181|NCT02934516|Active Comparator|Classic push method|Cesarean section with push method
2495253|NCT02934243||easy Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven easy
2495261|NCT02934243||difficult Laryngeal Mask insertion|patients in whom the insertion of the SIM has proven difficult
2495299|NCT02933697|Active Comparator|Apixaban|2.5 mg apixaban twice daily for 6 to 60 months
2495301|NCT02933697|Active Comparator|Vitamin-K antagonists (Phenprocoumon)|Phenprocoumon by INR (Target: 2.0-3.0) treatment for 6 to 60 months
2495369|NCT02933359||Normal Tissue|Bone fragments and their associated bone marrow will be collected from patients at the time of surgery without any additional dissection or incisions. Bone will be finely minced and then plated in tissue culture flasks as previously reported by other groups [7].
2495430|NCT02933099|Experimental|Aprepitant arm|Aprepitant+palonosetron+dexamethasone
2495438|NCT02933099|Active Comparator|Control arm|palonosetron+dexamethasone
2495497|NCT02932618|Experimental|On-demand Treatment|Participants will receive treatment for non-surgical bleeding episodes over a 12 to 18-month period.
2495498|NCT02932618|Experimental|Elective Surgery|12-24 hours prior to surgery and within 3 hours of surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
2495499|NCT02932618|Experimental|Emergency Surgery|Within 3 hours prior to surgery. Minor surgery: infuse every 12-24 hours for at least 48 hours. Oral Surgery: infuse at least once within first 8-12 hours post-surgery. Major Surgery: infuse every 12-24 hours for at least first 72 hours post-surgery.
2495598|NCT02931760|Active Comparator|subcutaneous pacemaker|The patients who are randomized to receive a subcutaneously implanted pacemaker
2495601|NCT02931760|Active Comparator|intramuscular pacemaker|The patients who are randomized to receive an intramuscular implanted pacemaker
2495664|NCT02931513||PBC patients|Patients with primary biliary cholangitis
2495730|NCT02931058|Active Comparator|Group 2|"Two knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2495731|NCT02931058|Active Comparator|Group 4|"Four knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2495732|NCT02931058|Active Comparator|Group 6|"Six knee-extension exercise sessions per week. Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
2495838|NCT02930044|Experimental|Early glargine dose|Subcutaneous insulin glargine will be administered within two hours of starting the IV insulin infusion.
2495839|NCT02930044|Placebo Comparator|Standard therapy|Retrospective arm that received standard insulin therapy for treatment of DKA
2495921|NCT02929719|Experimental|Test Gel 5%|Topical, twice daily on the face for 84 days.
2495925|NCT02929719|Active Comparator|ACZONE Gel 5%|Topical, twice daily on the face for 84 days
2495926|NCT02929719|Placebo Comparator|Placebo Gel|Topical, twice daily on the face for 84 days
2495994|NCT02929264|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
2495997|NCT02929264|Placebo Comparator|Placebo|Placebo, capsules, single dose
2495999|NCT02929264|No Intervention|Control|No Intervention
2496035|NCT02928900|Experimental|Intervention period|In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.
2496046|NCT02928900|No Intervention|Control period|In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.
2496102|NCT02928445|Experimental|RVT-101 35 mg|RVT-101 35 mg once daily
2496104|NCT02928445|Experimental|RVT-101 70 mg|RVT-101 70 mg once daily
2496222|NCT02927665||Study Subjects|Eligible subjects receiving ReShape Integrated Dual Balloon System treatment in a commercial clinical setting
3195267|NCT00838032|Active Comparator|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
2496461|NCT02926443|Active Comparator|One-on-one Usual Physiotherapy Care (Control)|The Ctl group (n =16) will receive physiotherapy usual care treatments during a 6-week period. The Ctl group will receive 2 physiotherapy treatments (30 minutes) in the clinic per week (total of 12 treatments) as well as an individualized home exercise program (HEP). Treatments will include range of motion exercises, manual therapy treatments, modalities, and strengthening exercises, as determined by the treating physiotherapist. Specific muscle group exercises and parameters will be documented by the treating physiotherapist on a provided summary sheet.
2496464|NCT02926443|Experimental|Group Program (UpEx-NTP) (Exp)|The Exp group (n =16) will partake in a 6-week group Upper Extremity Neuromuscular Training Program that consists of postural education, strength exercises, motor control exercises, and upper extremity functional tasks common for active military personnel. The UpEx-NTP program consists of 35-45 minutes of exercise, three times a week for 6 weeks (18 treatments), supervised by a physiotherapist. The program consists of 11 stations with several variations of difficulty of the same exercise per station. The exercises of each station will be performed in order of difficulty. The participant chooses one exercise to perform per station based on their current ability while respecting their pain levels at 3/10 or less.
2495153|NCT02934763|Active Comparator|Propranolol at 15ng/ml target dose|Propranolol iv by target controlled infusion, to achieve a plasmatic concentration of 15ng/ml
2495198|NCT02934425|Placebo Comparator|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast
2495199|NCT02934425|Experimental|High pork protein breakfast|High pork protein breakfast
2495232|NCT02934152|Experimental|Early eradication|Group A (H pylori eradication timing: early eradication, n=100): Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.
2495235|NCT02934152|Experimental|Late eradication|Group B (H pylori eradication timing: late eradication, n=100): PPI with rabeprazole 20 mg qd for 4 weeks, followed by H pylori eradication with triple therapy for two weeks
2495239|NCT02934152|Active Comparator|Negative Hp|For patients with negative H. p infection documented by UBT (Group C, n=200), No H pylori eradication treatment will be given but PPI with rabeprazole 20 mg qd will be given for 8 weeks.
2495370|NCT02933385|Experimental|Full lifestyle program|Participants receive all the intervention tools that aimed to enhance lifestyle profile.
2495377|NCT02933385|Experimental|High lifestyle program|Participants receive most of the intervention tools that aimed to enhance lifestyle profile.
2495386|NCT02933385|Experimental|Moderate lifestyle program|Participants receive some intervention tools that aimed to enhance lifestyle profile.
2495391|NCT02933385|Experimental|Light lifestyle program|Participants receive little intervention tools that aimed to enhance lifestyle profile.
2495398|NCT02933385|No Intervention|Control group|Participants receive none of the intervention tools that aimed to enhance lifestyle profile.
2495423|NCT02932800|Active Comparator|"Ballerina associated with flap fixation"|"The catheter is anchored to the skin begins by a point U around the catheter insertion site and followed by a series of woven points around the catheter , commonly referred to as  node dancer  to pass the wires on each side of the orifices located at the catheter distal flaps and hold three consecutive nodes . Then, the clamping is carried out of the catheter to the skin by means of a simple point and hold three consecutive nodes in each lateral hole of the fastening flap while leaving, between the fastening flap and the puncture site a space 2 cm distance for viewing the ostium ."
2495425|NCT02932800|Active Comparator|the usual fixation technique|The catheter is attached to the skin with a simple point and holding three we row on each side hole fixing fin while leaving, between the fastening flap and the puncture site , an area of 2 cm away for viewing ostium . The catheter is anchored to the skin by a simple point and holding three consecutive us in each hole of the side flap in the distal region.
2495476|NCT02932605|Experimental|Cannabidiol|Patients will be treated with 600mg CBD daily for 4 weeks (28 days)
2495478|NCT02932605|Placebo Comparator|Placebo|Patients will be treated with placebo daily for 4 weeks (28 days)
3195268|NCT00838045|Experimental|Akreos TL intraocular lens|Bausch & Lomb Akreos TL intraocular lens
3195269|NCT00838058|Experimental|Part1; controlled release formulation 4; 250 mg|one 250 mg controlled release tablet, once in the morning, in fasted state
2495654|NCT02931344|Experimental|Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2495720|NCT02931227|Experimental|Brain-injured group|
2495721|NCT02931227|Experimental|Hypothermia group|
2495723|NCT02931227|Experimental|Hyperthermia group|
2495724|NCT02931227|Experimental|PICCO group|
2495753|NCT02930642|Experimental|Mindful Eating|Participants in this arm will receive a 50 min mindful eating training with four pieces of food. They will practice mindful eating at home with two meals for a one-week duration.
2495754|NCT02930642|Active Comparator|Nutrition Digital Video Disc (DVD)|Participants will watch a 50 min DVD on nutrition and receive four pieces of food. They will receive prompts twice a week to give one-word answers to questions about food.
2495755|NCT02930642|No Intervention|Control|Participants will receive four pieces of food. They will not receive any prompts during the one week.
2495796|NCT02930473|Experimental|Psychotherapeutic Intervention(s) for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will be treated using Nursing Interventions Classification (NIC) psychotherapeutic intervention(s) for anxiety (plus psychopharmaceuticals)."
2495802|NCT02930473|Active Comparator|Treatment-as-Usual for Anxiety|"People diagnosed with Anxiety (according to ICNP/NANDA standardized nursing language) will receive treatment as usual for anxiety (psychopharmaceuticals)."
3195270|NCT00838058|Experimental|Part1; controlled release formulation 4; 500 mg|2x250 mg, once in the morning, in fasted state
3195271|NCT00838058|Experimental|Part 1; controlled release formula 4; 1000 mg|4x250 mg tabs, once in the morning, in fasted state
2496037|NCT02928796||Trainees|Registrar Cardiologists
2496049|NCT02928796||Trainers|Consultant Cardiologists
2496205|NCT02927990||Study group|Percutaneous coronary interventions with additional imaging provided by the new software package
2496207|NCT02927990||Control group|Percutaneous coronary interventions without the new software package
3195272|NCT00838058|Experimental|Part 1; controlled release formulation 4; 500 mg FED|2x250 mg, once in the morning , in fed state
3195273|NCT00838058|Experimental|Part 2; IR formulation 500mg|4x125 mg tab of current formulation , once in the morning in the fasted state. This arm will occur as Part 2, only as needed, pending results of Part 1
2496284|NCT02927236|Experimental|Cocaine - Active (EFS)|designed to implement the iTBS administration parameters established from P1 with a larger sample of treatment seeking CD participants. Though the schedule may change slightly based on the outcome of the pilot, a schedule of 3 daily iTBS sessions with a 20 minute interval between administrations is planned and used throughout the design.
3195274|NCT00838058|Experimental|Part 2; IR formulation, 500 mg FED|4x125 mg once in the morning in the fed state. This arm will occur as part of Part 2,only as needed, pending results of Part 1.
3195275|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FASTED|2x250 controlled release formulation 5 tabs once in the morning in the fasted state. This arm will only occur as part of Part 2, pending results of Part 1.
3195276|NCT00838058|Experimental|Part 2; controlled release formulation 5;500 mg, FED|2x250 mg controlled release formulation 5 tabs once in the morning in the fed state. This arm will only occur as part of Part 2 pending results of Part 1
3195277|NCT00838071|Experimental|IGIV-HB Grifols|
2495166|NCT02934399||Congenital adrenal hyperplasia (CAH)|"Monitoring of congenital adrenal hyperplasia (CAH) by ULTRADIAN dynamic cortisol, ACTH, and androgen measurements Aims and objectives: to compare hormonal profiles of patients with CAH on conventional replacement regimes to age/sex matched controls.~Study subjects: Individuals with established CAH either salt- wasting or simple virilisation forms on glucocorticoid replacement therapy"
2495170|NCT02934399||Primary hyperaldosteronism (PHA)|"Diagnosis of primary hyperaldosteronism (PHA) by ULTRADIAN dynamic aldosterone and renin measurements Aims and objectives: The primary objective is to establish circadian and ultradian profiling of free aldosterone and renin in subcutaneous tissue.~Secondary objectives are (1) to compare pre and post-operative profiles (2) to identify profiles typical for adenoma as opposed to bilateral hyperplasia and (3) to compare profiles to age/sex matched controls.~Study subjects: Subjects with suspected PHA."
2495171|NCT02934399||Growth hormone insufficiency (GHD)|"Diagnosis of growth hormone deficiency (GHD) by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal circadian and ultradian profiles of adult GHD by analysing the growth hormone profile in the subcutaneous tissue fluid.~Study subjects: Adult subjects with established clinical and biochemical GHD."
2495175|NCT02934399||Acromegaly (A)|"Diagnosis and treatment of acromegaly by ULTRADIAN dynamic growth hormone measurements Aims and objectives: The primary objective is to establish hormonal profiles of patients with Acromegaly A secondary objective is to compare pre and post-operative profiles and to compare these profiles to age/sex matched controls.~Study subjects: Patients with established clinical and biochemical Acromegaly by current diagnostic criteria"
2495229|NCT02934126||breast cancer patients|breast cancer patients who have faced a decision on different types of radiotherapy or to leave radiotherapy out of the treatment
2495433|NCT02932852|Active Comparator|GROUP I|lipoaspiration and transplantation of ADAS alone without scaffold
2495440|NCT02932852|Active Comparator|GROUP II|Lipoaspiration and transplantation of scaffold (human corneal decellularized lamina) without ADAS
2495442|NCT02932852|Active Comparator|GROUP III|Lipoaspiration and transplantation of ADAS cellularized on scaffold (the human corneal decellularized lamina)
2495474|NCT02932501||MRONJ|"Patients diagnosed of medication-related osteonecrosis of the jaw (MRONJ). Treatment strategies vary depending on the stage of MRONJ and can be of different nature as:~Conservative treatment Surgical treatment Adjuvant non-surgical treatment"
2495625|NCT02931851|Placebo Comparator|Placebo|Standard Information
2495631|NCT02931851|Active Comparator|Intervention|Professionally developed website for relatives of ICU patients
2495659|NCT02931409|Experimental|Optimal PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O. Optimal PEEP is considered as a PEEP value resulting the highest possible Cstat measured by ventilator. After PEEP titration procedure a lung protective mechanical ventilation will be performed using optimal PEEP and low tidal volumes (6 mL/Kg IBW).
2495666|NCT02931409|Active Comparator|Standard PEEP|Patients submitted to general anesthesia and open radical cystectomy and urinary diversion (20 subjects) will be submitted an alveolar recruitment maneuver using the sustained airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/Kg).
2495707|NCT02931110|Experimental|CBL0137 Dose Escalation|"Dose Level 1: 150mg/m2, IV~Dose Level 2: 180mg/m2, IV~Dose Level 3: 240mg/m2, IV~Dose Level 4: 320mg/m2, IV~Dose Level 5: 400mg/m2, IV~Dose Level 6: 540mg/m2, IV~Dose Level 7: 650mg/m2, IV~Dose Level 8: 780mg/m2, IV~Dose Level 9: 950mg/m2, IV~Dose Level 10: 1150mg/m2, IV~Dose Level 11: 1400mg/m2, IV~Dose Level 12: 1700mg/m2, IV~Dose Level 13: 2000mg/m2, IV~Dose Level 14: 2400mg/m2, IV~Dose Level 15: 2900mg/m2, IV~Dose Level 16: 3500mg/m2, IV"
2495774|NCT02930772|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2495792|NCT02930369|Active Comparator|4PD diameter of ILM peeling in surgery|patients in this group was given 4papillary diameter (PD) diameter of internal limiting membrane (ILM) peeling in surgery
2495798|NCT02930369|Experimental|2PD diameter of ILM peeling in surgery|patients in this group was given 2PD diameter of ILM peeling in surgery
2495845|NCT02930161|Experimental|Runihol 2 tablets x 2 times a day|Intake of 1 tablet of Runihol and 1 placebo tablet orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
2495851|NCT02930161|Experimental|Runihol 1 tablet x 3 times a day|Intake of Runihol, 2 tablets orally, with drinking 100 ml of water, 30 minutes before meals, 2 times a day (morning and evening) for 84 days (12 weeks), and 2 placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals, 1 time a day (afternoon) for 84 days (12 weeks).
2495854|NCT02930161|Placebo Comparator|Placebo|Two placebo tablets orally, with drinking 100 ml of water, 30 minutes before meals three times a day (morning, afternoon and evening) for 84 days (12 weeks).
2495916|NCT02929628|Experimental|Patients with Various Frequency Stimulation|Patients are in the condition of Various Frequency Stimulation
2495920|NCT02929628|Sham Comparator|Patients With Traditional Frequency Stimulation|Patients in the condition of Sham Comparator are Traditional Frequency Stimulation
2496020|NCT02929355||diabetic patients with carotid assessment|Patients with diabetes and a carotid assessment by duplex ultrasonography in 2012 in a monocentric diabetic unit
2496061|NCT02928744|Experimental|COPD|
2496103|NCT02928471||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
3161994|NCT00453544|Active Comparator|Routine consent - B|This was a comparison condition - a routine consent process, including a printed consent document, for a higher risk hypothetical protocol
3161995|NCT00453570|Experimental|1|DTacP IPV// PRP~T combined vaccine at 2, 3 and 4 months of age, and a booster dose at 18-20 months of age.
3161996|NCT00453570|Experimental|2|DTacP-IPV// PRP~T combined vaccine at 3, 4 and 5 months of age and a booster dose at 18-20 months of age.
3161997|NCT00453570|Active Comparator|3|Control vaccines at 3, 4 and 5 months of age and a booster dose at 18-20 months of age
2495222|NCT02934139|Experimental|Cavosonstat (N91115) 400 mg|Every 12 hour oral dosing of N91115 for 7 days
2495223|NCT02934139|Experimental|Cavosonstat (N91115) 600 mg|Every 12 hour oral dosing of N91115 for 7 days
2495224|NCT02934139|Experimental|Cavosonstat (N91115) 1200 mg|Once daily oral dosing of N91115 for 7 days
2495225|NCT02934139|Experimental|Cavosonstat (N91115) 800 mg|Every 12 hour oral dosing of N91115 for 7 days
2495226|NCT02934139|Placebo Comparator|Placebo|Matched placebo. Oral dosing every 12 hour or once daily for 7 days
2495295|NCT02933840|Experimental|AlertWatch|Patients will receive standard monitoring and in addition the AlertWatch software will alert the intensive care physician if there is a value that meets criteria for alerting. The care team will be the orthopedic surgery team in addition to the intensive care physician being involved as a consultant if he/she receives an alert.
2495298|NCT02933840|No Intervention|No AlertWatch|Patients will receive standard monitoring without the AlertWatch software. The care team will be the orthopedic surgery team without the intensive care physician being involved as a consultant.
2495444|NCT02933463|Experimental|embrace wetbond sealant|moisture tolerant resin based, have same properties of other sealant
2495445|NCT02933463|Active Comparator|clinpro sealant|is a dental resin, with low viscosity , fluoride releasing with a unique patented color change.
2495473|NCT02932514|Experimental|Eversense (Senseonics) CGM System|
2495490|NCT02932345||Long-term survivors group (case)|EGFR M+ aNSCLC patients who continuously received gefitinib for at least 3 years
2495495|NCT02932345||Rapid PD group (control)|EGFR M+ aNSCLC patients who had undergone PD after gefitinib treatment≤3 months
3161998|NCT00453635|Experimental|1|Docetaxel + Carboplatin + Herceptin (D/Carbo/Her)
3161999|NCT00453635|Experimental|2|Vinorelbine + Herceptin (VHer)
3162000|NCT00453648|Placebo Comparator|White-fleshed Sweet Potato|0 ug retinol activity equivalents (RAE)/d as boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule, 6d/wk for 10 wk
3162001|NCT00453648|Experimental|Orange-fleshed Sweet Potato (boiled)|600 ug RAE/d as boiled orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
3162002|NCT00453648|Experimental|Orange-fleshed Sweet Potato (fried)|600 ug RAE/d as fried orange-fleshed sweet potato and a corn oil capsule, 6d/wk for 10 wk
3162003|NCT00453648|Active Comparator|White-fleshed Sweet Potato and retinyl palmitate capsule|0 ug RAE/d as white-fleshed sweet potato and 600 ug retinol/d as retinyl palmitate, 6d/wk for 10 wk
3162004|NCT00453661||Intervention Group|Patient Navigator (PN) + Educational Materials + Annual Questionnaires
2495744|NCT02931162|Experimental|Herb-partitioned moxibustion|Drug: Herbal cake, Device: Moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Herbal cakes with moxa cones will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2495747|NCT02931162|Sham Comparator|Sham herb-partitioned moxibustion|Drug: Herbal cake, Device: Sham moxibustion. Herbal cakes formula: Monkshood 10g, Cinnamon 2g, Salvia miltiorrhiza 3g, Flos Carthami 3g, Radix Aucklandiae 2g. Herbs are smashed into powder. Every 2.5g medicine powder is mixed with 3g millet wine and then pressed into herbal cakes using a specific mold. Each cake should be 23mm in diameter and 5mm in height. Then, ignited moxa cones are placed on top of each herbal cake. Small cardboard sheets with the same size as the herbal cakes will be wrapped with aluminum foil and placed under each herbal cake. These herbal cakes will be positioned at acupuncture points ST25 and ST37. The entire treatment will be done once a day for 1 moxa cone every acupuncture point, 30 minutes at a time, 3 times a week, for a total of 12 weeks.
2495778|NCT02930538||Children undergoing surgery|Children ages 3-18 undergoing a surgical procedure at Nationwide Children's Hosp.
2495814|NCT02930304|Experimental|first physiotherapy|cold pack, TENS, exercise
2495815|NCT02930304|Experimental|second physiotherapy|cold pack, TENS, exercise, kinesiotaping
2495817|NCT02930304|Experimental|third physiotherapy|cold pack, TENS, ESWT, exercise
2495860|NCT02929953||Diabetes mellitus type 1|"all T1DM patients in Israel, born during 2000-2013 and diagnosed prior to January 2015.~chart review"
2495865|NCT02929953||Non-diabetic|non-diabetic general population born in Israel during 2000-2013, according to the Israeli Health Ministry's Birth Registry (IHMBR) chart review
2495913|NCT02929706|Experimental|intervention group|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
2495918|NCT02929706|No Intervention|control group|optimize the thiopurine use by coventional strategy without konwing NUDT15 genotype
3162005|NCT00453661||Comparison Group|Educational Materials + Exit Questionnaire
3162006|NCT00453674||Adrenocortical carcinoma|Adrenocortical carcinoma
3162007|NCT00453687|Experimental|Arm 1|Drug
3162008|NCT00453700||serological testing|In Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles, serological testing for Trypanosoma cruzi was performed at enrollment.
3162009|NCT00453765|Experimental|A|montelukast
3162010|NCT00453765|Placebo Comparator|B|placebo
3162011|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 1|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using Metered Dose Inhaler (MDI).
3162012|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 1|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
3162013|NCT00453791|Experimental|Subjects receiving treatment sequence 1: Part 2|Eligible subjects will receive placebo followed by GW805858 with a starting dose of 150 micrograms administered using MDI.
3162014|NCT00453791|Experimental|Subjects receiving treatment sequence 2: Part 2|Eligible subjects will receive GW805858 with a starting dose of 150 micrograms followed by placebo administered using MDI.
2495191|NCT02934594||Group B2|motor deficit group: received palliative decompression 48 hours after symptoms occured
2495264|NCT02934204|Experimental|MTX and Temozolomide|"Induction therapy:~Methotrexate 3.5g/m2 ivgtt d1 2weeks/cycle，total 8 cycles Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 4 cycles~Consolidation therapy:~PCNSL patients achieve CR,Temozolomide 150mg/m2 po d1-5 4weeks/cycle, total 12 cycles"
2495340|NCT02933684|Experimental|DCS|Participants will receive 50mg of Seromycin (aka D-cycloserine) in conjunction with virtual reality exposure therapy once a week for 4 weeks.
2495348|NCT02933684|Placebo Comparator|Placebo|Participants will receive a placebo in conjunction with virtual reality exposure therapy once a week for 4 weeks.
2495382|NCT02933177|Experimental|2 months control condition - 4 months chariot-flash|"200 patient , in 15 nursing homes randomly will be exposed two months in the control condition (usual intervention) and 4 months in the experimental condition (chariot-flash intervention). The experimental condition is to propose the chariot-flash in emergency during the emergence or increase of productive symptoms."
2495388|NCT02933177|Experimental|4 months control condition-2 months chariot flash|200 patient, in 14 other nursing homes will be exposed 4 months in the control condition and 2 months in the experimental condition
2495429|NCT02932969|Experimental|Panel 1 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2495437|NCT02932969|Experimental|Panel 2 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2495441|NCT02932969|Experimental|Panel 3 Arm|BMS-986231 and BMS-986231 Placebo intravenously
2495512|NCT02932540||Healthy controls|healthy controls subjects who have age, sex and Blood pressure matched with the acute ischaemic stroke patient
2495514|NCT02932540||AIS patient-transient arm|transient change of head position from lying flat (0 degree) to sitting up (30 degree)
2495515|NCT02932540||AIS patient - persistent lying flat|lying flat (0 degree) head position for the first 24 hours in the hospital admission
2495516|NCT02932540||AIS patient - persistent sitting up|sitting up ( 30 degree) head position for the first 24 hours in the hospital admission
2495540|NCT02932007|Experimental|Chloroquine Phosphate|Chloroquine Phosphate will be provided at 500 mg dosage strength for oral administration. Patient will be instructed to take 2 tablets per day on the first two days and 1 tablet each day for the next 12 days for a total of 14 days treatment.
2495606|NCT02931864|No Intervention|Usual care group|Usual care is meant the routine medical and health care services at the hospital.
2495617|NCT02931864|Experimental|Experimental group|Five weekly sessions of online symptom management + mindfulness training programme + usual care
2495626|NCT02931864|Active Comparator|Comparison group 1|Five weekly sessions of online symptom management programme + usual care
2495630|NCT02931864|Active Comparator|Comparison group 2|Five weekly sessions of online mindfulness training programme and usual care
2495686|NCT02931370||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks
2495722|NCT02931071|Experimental|plerixafor and filgrastim treatment|to assess the safety and efficacy of CD34+ cells mobilization with plerixafor and filgrastim
2495793|NCT02930707|Active Comparator|Magnesium group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg), on each side of the abdominal wall.
2495797|NCT02930707|Placebo Comparator|control group|patients received ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
2495847|NCT02930096||pulsatility index mesured with doppler ultrasound|
2495924|NCT02929862|Experimental|Single Agent 55716|
2496018|NCT02929095|Experimental|Patients in the dexmedetomidine group|Patients in the dexmedetomidine group are given 1 μg/kg/h of dexmedetomidine for 10 minutes on initiation of the procedure and then 0.2-0.7 μg/kg/h until end of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
2496019|NCT02929095|Active Comparator|Patients in the midazolam group|Patients in the midazolam group are given midazolam 0.02-0.05mg/kg bolus on initiation of the procedure and are given 1.2-7.2 μg/kg/h of remifentanil until end of the procedure
2496064|NCT02928705||telemedicine group|physician operated telemedical prehospital analgesia
2496070|NCT02928705||historical control group|prehospital analgesia by on-scene EMS physicians
3195278|NCT00838084|Experimental|LY2811376 Part 1|LY2811376 (5 mg up to 500 mg); once a day or twice a day for 1 day in up to 3 periods.
3195279|NCT00838084|Placebo Comparator|Placebo Part 1|once a day or twice a day for 1 day in up to 3 periods.
3195280|NCT00838084|Experimental|LY2811376 - Part 2 low dose|Single dose of LY2811376, dose determined by part 1
2496208|NCT02927899|Experimental|Prevention (dietary intervention, survey)|Patients receive 4 tomato-soy beverages and 3 labeled arugula seed powder portions. Patients add 1 arugula seed powder portion to each of 3 tomato-soy beverages immediately prior to consumption, and they consume 1 beverage without the powder. After each beverage tasting, patients complete a survey on the sensory acceptability of the sample.
2496244|NCT02927574||DCB|Treatment with Paclitaxel drug-coated balloon angioplasty (DCB)
2496248|NCT02927574||POBA|Treatment with plain old balloon angioplasty (POBA)
2496269|NCT02927288||Military subjects with mTBI|mTBI/concussion only Group: Participants must have been clinically diagnosed with mTBI/concussion according to criteria outline by the World Health Organization (WHO; Holm et al., 2005) and be at least three month post-injury. Participants in the mTBI/concussion only group must not have a concurrent diagnosis of PTSD and must score below 25 on the Post-traumatic stress Check List for Civilians (PCL-C).
2496271|NCT02927288||Military subjects with PTSD|Participants in the PTSD only group must have a clinical diagnosis of PTSD, following criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV TR). Proof of diagnosis will be obtained from participants via a request for release of pertinent medical records. Participants in this group must not have a history of mTBI or concussion.
2496275|NCT02927288||Military subjects with mTBI and PTSD|Participants in the mixed group must meet criteria for mTBI/concussion and PTSD as outlined above.
2496306|NCT02927249|Experimental|Arm I (aspirin)|Patients receive aspirin PO QD for five years in the absence of disease progression or unacceptable toxicity.
3195281|NCT00838084|Experimental|LY2811376 - Part 2 high dose|Single dose of LY2811376, dose determined by part 1
3195282|NCT00838084|Placebo Comparator|Placebo Part 2|single dose
2495245|NCT02933931||vaccinated with 5 x 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 5 x 10E7 pfu VSV-ZEBOV
2495252|NCT02933931||vaccinated with 10E7 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 10E7 pfu VSV-ZEBOV
2495258|NCT02933931||vaccinated with 3 x 10E5 pfu VSV-ZEBOV|Volunteers vaccinated in 2014 or 2015 with 3 x 10E5 pfu VSV-ZEBOV
2495300|NCT02933814|No Intervention|Control Group|Patients in Group 1 (Plain Bupivacaine) will be treated intra-operatively with injections of 0.25% bupivacaine, with 10 mL (25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the surgical procedure.
2495304|NCT02933814|Experimental|Experimental Group|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
2495390|NCT02933424|No Intervention|Control beverage with no protein powder|Standard breakfast drink with no protein powder added
2495394|NCT02933424|Experimental|Beverage with Rice protein powder 25 grams|Standard breakfast drink with 25 grams of rice protein powder.
2495397|NCT02933424|Experimental|Beverage with Pea protein powder 25 grams|Standard breakfast drink with 25 grams of pea protein powder.
2495400|NCT02933424|Experimental|Beverage with Oats protein powder 25 grams|Standard breakfast drink with 25 grams of Oats protein powder.
2495504|NCT02932319|Active Comparator|Foley catheter|The patient will have an induction at home after 60 mn of fetal heart rate monitoring.
2495505|NCT02932319|Sham Comparator|Expectative|The patient in this arm will have the actual care (expectative until the next day befor starting the induction)
2495537|NCT02932124||1|manual chest compressions
2495538|NCT02932124||2|mechanical chest compression
2495612|NCT02931890|Active Comparator|neo-adjuvant chemotherapy followed by surgery|4 courses of 3 weekly DOC followed by surgery
2495622|NCT02931890|Active Comparator|neo-adjuvant chemo and subsequent CRT followed by surgery|2 courses of 3 weekly DOC and subsequent CRT followed by surgery
2495628|NCT02931890|Active Comparator|neo-adjuvant chemoradiotherapy followed by surgery|chemoradiotherapy followed by surgery
3162015|NCT00453791|Experimental|Subjects receiving GW805858: Part 3|Eligible subjects will receive GW805858 1200 micrograms twice daily administered using MDI.
2495795|NCT02930447|Experimental|Treatment group|Autologous glue will be prepared from the patient's own blood with RegenKit®-Surgery device and applied per-operatively by spraying in the undermining region space between fascia and skin.
2495801|NCT02930447|No Intervention|Control group|Patient from the control group will undergo abdominoplasty according to an identical procedure, but without application of autologous glue or any other treatment product before wound closure.
2495858|NCT02930200|Active Comparator|Treatment as Usual|Behavioral: Treatment as Usual (TAU) is the Tobacco Treatment Research Program (TTRP) which offers all components of an intensive tobacco treatment intervention including: 1) initial assessment of willingness to participate, 2) the use of multiple types of clinicians, 3) at least 4 treatment sessions, in an individual- or group-counseling format, that are greater than 10 minutes in duration, 4) counseling that includes problem-solving, skills training, and social support components, and 5) and the opportunity to use effective medications to aid in tobacco cessation.
2495862|NCT02930200|Active Comparator|NCI QuitGuide|Behavioral: The National Cancer Institute's (NCI's) QuitGuide app is a free smartphone app that is available through the Smokefree.gov website. Participants can track cravings, smoking triggers, and motivations for quitting. Participants who are randomly assigned to the QuitGuide app group will receive a smartphone that is preloaded with the QuitGuide app and a quit date scheduled for 1 week after the baseline visit.
2495867|NCT02930200|Experimental|Smart-T|"Behavioral: The Smart-Treatment (Smart-T) phone based smoking cessation intervention has multiple components (e.g., an on-demand Quit Tips function, an on-demand Medications function/button that offers information about nicotine replacement therapy (NRT), button available 24/7 that offers general smoking cessation advice, daily treatment messages, and an algorithm that uses participant's EMA responses to assess risk of lapse and automatically push relevant messages to help them avoid smoking)."
2495919|NCT02929693|Experimental|combination|YYJD plus gefitinib
2495923|NCT02929693|Placebo Comparator|controll|placebo plus gefitinib
2495995|NCT02929251|Active Comparator|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
2495998|NCT02929251|Experimental|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
2496002|NCT02929251|Experimental|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
2496031|NCT02928861|Experimental|18F-FDG PET/CT-based prognostic model|The new prognostic model is based on 18F-FDG PET/CT scans, and combined with clinical and pathological prognostic factors.
2496114|NCT02928601|Experimental|Ondansetron|
2496116|NCT02928601|Active Comparator|Saline|
3162016|NCT00453791|Experimental|Subjects receiving placebo: Part 3|Eligible subjects will receive placebo administered using MDI.
3162017|NCT00453817|Experimental|Study subjects|One-arm observational study
3162018|NCT00453843|Experimental|proximal to distal training|
3162019|NCT00453843|Experimental|distal to proximal|
3162020|NCT00453843|Experimental|proximal and distal on alternate days|
3162021|NCT00453843|Experimental|proximal and distal same day|
3162022|NCT00453960|Experimental|Genistein|Genistein 54 mg/day
3162023|NCT00453960|Active Comparator|Norethisterone Acetate|Norethisterone Acetate 10mg/day
2495278|NCT02933944|Experimental|TG02-treatment|"Part I: The TG02-treatment consists of an intradermal injection of GM-CSF followed by an injection of TG02. The GM-CSF is to be given 15-30 minutes before TG02. TG02-treatment will be administered on Days 1, 8, 15, 22 and 36. If surgery after week 10, TG02-treatment will also be given at week 10 (Day 64).~Part II: TG02-treatment will be given as described under Part I. In addition pembrolizumab will be administered."
2495523|NCT02932865||MD-TESE (A)|Azoospermic men, MD-TESE operation (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
2495526|NCT02932865||Subfertile men (B)|Subfertile men receiving medication (standard treatment). Semen sample, serum sample and physical examination with testicular ultrasound.
2495528|NCT02932865||Control (C)|Control group, men scheduled for semen analysis. Semen sample, serum sample and physical examination with testicular ultrasound.
2495549|NCT02932020|Experimental|Group A|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection of (a) 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI~Visit: 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
2495550|NCT02932020|Other|Group B|"Randomized 10 subjects~Visit 1:~1st contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine interlaminar epidural injection 2mL 0.5% marcaine and 1mL and 1mL steroid (depomedrol 80mg/ml).~Visit 6 weeks (+7days): 2nd contrast enhanced Magnetic Resonance Imaging (MRI) scan of the lumbar spine"
2495642|NCT02931604|Experimental|Sinus irrigation|Sinus irrigation intervention
2495693|NCT02931292||Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
2495758|NCT02930954|Active Comparator|Gefitinib single agent|Advanced NSCLC patients with EGFR activating mutation (L858R, 19Del) received Gefitinib 250mg Qd orally until progression, intolerable toxicity or death.
2495759|NCT02930954|Experimental|Gefitinib combined with chemotherapy|Gefitinib 250mg Qd combined with pemetrexed or gemcitabine plus carboplatin: Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days, Gemcitabine (1000 mg/m² days 1,d8, intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days
2495762|NCT02930954|Experimental|Gefitinib combined with antiangiogenesis|Gefetinib 250mg Qd combined with bevacizumab 7.5mg/kg per 21 days
2495813|NCT02930395||professional rugby players|
2495844|NCT02929966|Placebo Comparator|standard respiratory care|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy"
2495850|NCT02929966|Experimental|standard respiratory care PLUS a palliative care program|"The patients will receive the usual respiratory care that included both the classical treatments with antifibrotic drugs and oxygen therapy PLUS a palliative care program that includes paid to assessing physical and psychosocial symptoms"
2495900|NCT02929771|Experimental|Intervention Group|In addition to usual care, the intervention group will receive the Samsung GearVR with head mounted display (HMD), controller, and headphones. They will situated in front of the nurse and beside/on the lap of the parent, or they may be lying supine. The VR intervention will use auditory and visual stimuli (simulating the peaceful underwater environment) to distract the child before, during, and after the SCP needle insertion. Children will be allowed to 'try-out' the VR system before the SCP access to familiarize themselves with the equipment. The entire study will be videotaped.
2495901|NCT02929771|Active Comparator|Control Group|In addition to usual care, participants in the control group will be seated with their parent and in front of the nurse, according to preference. Children will watch an age appropriate video selected by an oncology-affiliated child life specialist on an iPad, while wearing the same headphones used in the experimental condition. The RA will hold the iPad and positioned within a meter of the child so that the child can still see the iPad without the RA interfering in the clinical procedure. The entire study will be videotaped.
3162024|NCT00453960|Placebo Comparator|Placebo|Placebo tablets, daily
3162025|NCT00454025||Glaucoma|Patients with Glaucoma
3162026|NCT00454025||Healthy Patients|Patients without glaucoma
2496028|NCT02929082|Experimental|Group 1 : volunteer patient|Group 1 will be constituted of 20 volunteer patients coming for abdominal MRI with no known hepatic disease, in order to determine the feasibility of FRM . A 5-minute- additional sequence to measure FRM will be done for the volunteers.
2496029|NCT02929082|Experimental|Group 2 : patient with resectable HCC|"Group 2 will be constituted of 60 patients with resectable HCC eligible for surgery. This group will enable to evaluate the gold standard.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence."
2496030|NCT02929082|Experimental|Group 3 : patient with HCC eligible for TACE|"Group 3 will be constituted of 50 patients with HCC eligible for transplant with transcatheter arterial chemoembolization (TACE) treatment as pending treatment before transplant. This groups will enable to evaluate the efficiency of TACE through the necrosis percentage in treated HCC.~A 5-minute- additional sequence to measure FRM will be done while MRI sequence"
2496134|NCT02928627||HCC Group|samples obtained from patients with HCC (hepatic tissue and blood)
2496139|NCT02928627||Plasma control Group (PCG)|blood samples obtained from healthy controls
2496178|NCT02928003|Experimental|Lung Surgery|
2496228|NCT02927730||positive retainted placenta histology|base on chorionic villi in the pathalogic sample
2496230|NCT02927730||negative retainted placenta histology|
2496287|NCT02927483|Experimental|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
2496289|NCT02927236|Sham Comparator|Cocaine - Sham (EFS)|To test the efficacy of the iTBS.
2497319|NCT02920762||Oxycodone HCl|
3162027|NCT00454064|Active Comparator|1|cognitive-behavioral treatment
3162028|NCT00454064|Active Comparator|2|cognitive-behavioral treatment with biofeedback elements
3162029|NCT00454155|Experimental|Opebacan|
3162030|NCT00454168|Experimental|Arm I|Patients receive PR1 leukemia peptide vaccine and sargramostim (GM-CSF) subcutaneously.
3162031|NCT00454168|Active Comparator|Arm II|Patients receive placebo vaccine and GM-CSF subcutaneously.
3162032|NCT00454220|Placebo Comparator|Placebo|
3162033|NCT00454220|Experimental|0.01 mg MRrhTSH + 131-I arm|
3162034|NCT00454220|Experimental|0.03 mg MRrhTSH + 131-I arm|
3162035|NCT00454233|Experimental|1|Dose 1
3162036|NCT00454233|Experimental|2|Dose 2
2495257|NCT02934087|Active Comparator|Snare Technique|"All patients undergoing elective EVAR with a standard commercially available stent graft were randomized after informed consent obtained; gate cannulation method was attempted for a period of 15 minutes. If unsuccessful during this time a crossover to the alternative method (retrograde gate cannulation) was attempted. The study will be terminated at 15 minutes in the crossover arm if still unsuccessful.~Antegrade or crossover cannulation involves passing a guidewire from the ipsilateral limb to the contralateral limb gate of the endograft, which can be accomplished with a curved catheter. The wire may be retrieved on the contralateral limb using a snare device."
2495296|NCT02933710||IMOJEV® Vaccine Group|Participants who are 12 months and older and who are given a first dose of IMOJEV® during a routine health care visit
2495384|NCT02933437|Experimental|Healthy Volunteers|Once screened by the investigators, the participants will undergo ajmaline provocation, cardiac magnetic resonance imaging and genotype evaluation
2495428|NCT02932995||DXR stent group|Patients who undergo coronary intervention with DXR stent
2495511|NCT02932592|Experimental|Dysglycemic group|"Patients with dysglycemia (not diabetic patients) will be undergone a monitoring of blood glucose with a device till the discharge of the patient.~Then, an oral glucose tolerance test (OGTT) will be done to categorize the patient as having impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or diabetes mellitus."
2495560|NCT02932111|Experimental|Osteopathic session|The osteopath put fingers on abdominal projection of the junction and sinks deeply into the abdomen until it perceives the trigger zone. Once in contact with the sphincter, it performs friction in the hourly sense, vibration, inhibitions or rebounds.
2495564|NCT02932111|Placebo Comparator|Placebo manipulative session|The Osteopath will touch the patient's limbs at the same place of osteopathic manipulative treatment, but without any intention of treatment and without any known and indexed reproduction techniques to simulate an osteopathic treatment, without its benefits.
2495660|NCT02931383|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg once daily (QD) and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2495667|NCT02931383|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2495701|NCT02931149|Experimental|Submucosal injection with PRP|All participants in the study received submucosal injection of PRP prior to endoscopic resection
2495771|NCT02930863|Active Comparator|Control Non-Automated Group|Participants assigned to this group will receive the standard of care procedures for the monitoring and treatment of hypoxemia. Complete brief post-PACU stay survey.
2495772|NCT02930863|Experimental|Automated Prompt Group|Participants assigned to this group will utilize the automated verbal prompts to enable their ability to improve their current condition by following generated commands. Complete a questionnaire focused around their experience with the pulse oximetry software and its effects on the patient's satisfaction and experience.
2495803|NCT02930330|Experimental|Interval|"2x / week INT~2x / week CONT"
2495807|NCT02930330|Active Comparator|Continuous|4x / week CONT
3195283|NCT00838149|Active Comparator|Glutamine|Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months.
3195284|NCT00838149|Placebo Comparator|Whey Protein|"Whey Protein:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
2496015|NCT02929290|Experimental|BPI-9016M|"Part I：Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M Tablet will be administered orally to patients once daily for each dose cohort.~Part II：400mg BPI-9016M Tablet will be administered orally to patients twice a day."
2496074|NCT02928692|Placebo Comparator|Placebo|Placebo administered before surgery
2496075|NCT02928692|Experimental|Minocycline|Minocycline was administrated before surgery
2496077|NCT02928692|No Intervention|Volunteers|Health people for calculate the incidence of POCD
2496131|NCT02928302|Experimental|TVU CL screening|TVU CL screening: single TVU CL at 18 0/7 to 23 6/7 every week
2496137|NCT02928302|No Intervention|no screening|no TVU CL screening
2496172|NCT02928068|Experimental|Occupational Performance Coaching (OPC)|This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
2496216|NCT02927769|Experimental|Nivolumab + brentuximab vedotin|
2496217|NCT02927769|Experimental|brentuximab vedotin + bendamustine|
2496426|NCT02926495|Active Comparator|Treatment (ON)|
2496428|NCT02926495|Sham Comparator|Control (OFF)|
2496444|NCT02926313|No Intervention|Existing Seating conditions|This group of participants received the standard care - they continue to sit in the seating system (chair and cushion) as provided by the nursing home facility staff; selected from whatever seats the facility had available.
3195285|NCT00838175||1|All pts. who have undergone percutaneous intervention who received a suture-mediated closure of the venous access site will be screened for eligibility for this research trial.
3195286|NCT00838188||1|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3195287|NCT00838188||2|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3195288|NCT00838188||Breast - feeding first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
3195289|NCT00838188||Bottle first|computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
2495315|NCT02933762|Experimental|Part 1: Cohort A2 (JNJ-54175446 D1 mg)|Healthy elderly participants will receive an additional dose D1 mg [less than or equal to (<=) 600 mg] of JNJ-54175446, to be determined.
2495317|NCT02933762|Experimental|Part 1: Cohort A3 (JNJ-54175446 D2 mg)|Healthy young participants will receive a single dose D2 mg (<= 600 mg) of JNJ-54175446, to be determined.
2495318|NCT02933762|Experimental|Part 1: Cohort A3 (Placebo)|Healthy young participants will receive a single dose of placebo.
2495320|NCT02933762|Experimental|Part 2: Cohort B1 (JNJ-54175446 D3 mg)|Healthy elderly participants will receive multiple dose levels D3 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2495322|NCT02933762|Experimental|Part 2: Cohort B1 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1.
2495327|NCT02933762|Experimental|Part 2: Cohort B2 (JNJ-54175446 D4 mg)|Healthy elderly participants will receive multiple dose levels D4 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2495333|NCT02933762|Experimental|Part 2: Cohort B2 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
2495342|NCT02933762|Experimental|Part 2: Cohort B3 (JNJ-54175446 D5 mg)|Healthy elderly participants will receive multiple dose levels D5 mg (<= 450 mg) of JNJ-54175446 determined based on the results from Cohort A1.
2495350|NCT02933762|Experimental|Part 2: Cohort B3 (Placebo)|Healthy elderly participants will receive placebo determined based on the results from Cohort A1
2495404|NCT02933164|Experimental|Arms|Evaluation of the effectiveness of modified Sensor designs on the longevity (up to 180 days) of the Senseonics Continuous Glucose Monitoring (CGM) System. The investigation will also evaluate safety of the Senseonics CGM System usage, while in the clinic and during home use.
2495592|NCT02931903|Experimental|Hybrid superstructure|Vita Enamic is a hybrid ceramic, consisting of composite and ceramic. The ceramic; compatible and high aesthetics while the composite; resilient material with low modulus of elasticity which will absorb stress and therefore decrease load on bone and eventually decrease crestal bone loss
2495593|NCT02931903|Active Comparator|Ceramic superstructure|IPS Emax, is the mostly used ceramic superstructures in implant supported restorations.
2495683|NCT02931526||Group CRRT|Patients who need to treat with tigecycline for bacterial infection, have renal insufficiency and have to treat with CRRT
2495685|NCT02931526||Group non-CRRT|Patients who need to treat with tigecycline for bacterial infection, have normal renal function in ICU and have no need to treat with CRRT
2495751|NCT02930967|Experimental|CSR T cells|"A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors.~CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested."
2495788|NCT02930564|Experimental|a milk fat or gluten challenge|patients will regress to the first stage diet with either a milk fat /emulsifier or a gluten/emulsifier challenge over 7 days.
3162037|NCT00454233|Experimental|3|Dose 3
3162038|NCT00454233|Experimental|4|Dose 4
2496010|NCT02929030||NANO Plus SES|All patients will be treated with NANO plus sirolimus-eluting stent. Patients will be prescribed with clopidogrel and aspirin before the index procedure. The lesions will be predilted if necessary before stent implantation. There are no specific limitations on coronary lesions according the study criteria.
2496044|NCT02928809|No Intervention|TMD control|Patients with diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
2496053|NCT02928809|Experimental|TMD LLL|Patients with diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
2496055|NCT02928809|No Intervention|Without TMD control|Patients without diagnosis of temporomandibular disorder and that are not submitted to pre-fatigue low-level laser therapy
2496057|NCT02928809|Experimental|Without TMD LLL|Patients without diagnosis of temporomandibular disorder and that are submitted to pre-fatigue low-level laser therapy
2496065|NCT02928809|Placebo Comparator|TMD placebo|Patients with diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
2496071|NCT02928809|Placebo Comparator|Without TMD placebo|Patients without diagnosis of temporomandibular disorder and that are submitted to placebo low-level laser treatment
2496097|NCT02928354|Experimental|Treatment A - AZD7594|Treatment A - AZD7594 inhalation powder Particle size Large
2496099|NCT02928354|Experimental|Treatment B - AZD7594|Treatment B - AZD7594 inhalation powder Particle size Medium
2496100|NCT02928354|Experimental|Treatment C - AZD7594|Treatment C - AZD7594 inhalation powder Particle size Small
2496148|NCT02928146|Active Comparator|Lichtenstein technique|Lichtenstein inguinal hernia repair
2496151|NCT02928146|Active Comparator|TAPP|Transabdominal preperitoneal (TAPP) approach for inguinal hernia repair
2496154|NCT02928146|Active Comparator|TEP|Totally extraperitoneal (TEP) approach for inguinal hernia repair
3162039|NCT00454233|Active Comparator|5|
2496292|NCT02927236|Other|Healthy Control-Main (EFS)|Population comparison of acute experimental iTBS.
3162040|NCT00454233|Placebo Comparator|6|
3162041|NCT00454259|Experimental|1|0,5 µg/kg
3162042|NCT00454259|Experimental|2|0,05 µg/kg
3162043|NCT00454259|Experimental|3|0,005 µg/kg
3162044|NCT00454259|Placebo Comparator|4|NaCl 0,9 %
3162045|NCT00454272|Active Comparator|1, Vancomycin|Vancomycin
3162046|NCT00454272|Active Comparator|2, Teicoplanin|Teicoplanin
3162047|NCT00454298|Active Comparator|A|AGG-523 1800 mg QD PO (12 capsules) for 28 days
3162048|NCT00454298|Active Comparator|B|AGG-523 900 mg BID PO (12 capsules) for 28 days
3162049|NCT00454298|Placebo Comparator|C|Placebo QD PO (12 capsules) for 28 days
3162050|NCT00454298|Placebo Comparator|D|Placebo BID PO (12 capsules) for 28 days
3162051|NCT00454311|Active Comparator|One cell biopsy|
3162052|NCT00454311|Other|Two cell biopsy|
3162053|NCT00454337|Experimental|Intensification arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir + enfuvirtide
3162054|NCT00454337|Active Comparator|Standard arm|emtricitabine/TDF + efavirenz or lopinavir/ritonavir
3162055|NCT00454389|Experimental|A|Epi-Rad90™ Ophthalmic System procedure + Lucentis
3162056|NCT00454389|Active Comparator|B|Lucentis only
3162057|NCT00454454||No treatment|
2495326|NCT02933580|Experimental|Cohort A: JNJ-56136379 (25 mg) or Placebo|Participants will receive a single oral dose of 25 milligram (mg) of JNJ-56136379 (1*25-mg tablet) or placebo on Day 1, fasted conditions.
2495334|NCT02933580|Experimental|Cohort B: JNJ-56136379 (150 mg) or Placebo|Participants will receive a single oral dose of 150 mg of JNJ-56136379 (2* 25-mg tablet and 1*100-mg tablet) or placebo on Day 1, fasted conditions.
2495344|NCT02933580|Experimental|Cohort C: JNJ-56136379 (300 mg) or Placebo|Participants will receive a single oral dose of 300 mg of JNJ-56136379 (3*100-mg tablet) or placebo on Day 1, fasted conditions.
2495353|NCT02933580|Experimental|Cohort D: JNJ-56136379 (600 mg) or Placebo|Participants will receive a single oral dose of 600 mg of JNJ-56136379 (6*100-mg tablet) or placebo on Day 1, fasted conditions.
2495420|NCT02933112|Other|AMP test group|All individuals will undergo a test using the auto-titrating mandibular positioner.
2495451|NCT02932722|Sham Comparator|Control|Patients in the control group will be receive remote ischemic preconditioning before anesthetic induction (before exposure to any anesthetic).
2495454|NCT02932722|Active Comparator|Propofol|Patients in the propofol groups will be receive remote ischemic preconditioning after anesthetic induction using propofol, as a main anesthetic.
2495456|NCT02932722|Active Comparator|Sevoflurane|Patients in the sevoflurane groups will be receive remote ischemic preconditioning after anesthetic induction using sevoflurane, as a main anesthetic.
2495500|NCT02932423|Other|1 - Snack|Each subject will consume 6 beverages with varying sugar content at lunch (500 ml) and with a snack in the afternoon (330 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
2495502|NCT02932423|Other|2 - No snack|Each subject will consume 6 beverages with varying sugar content only at lunch (500 ml). The 6 beverages (Test product A, Test product B, Test product C, Test product D, Control product E and Comparative product F) will correspond to the 6 interventions.
2495551|NCT02932098|Experimental|App Notifications|The web-based app will be used to remind patients of discharge instructions, ask questions related to current prescription pain medication use, new symptoms, or changes in the severity of symptoms. Patients will receive reminders via text or email to use the app. Daily reminders will be sent in Week 1, every other day in Week 2, and once per week for Weeks 3-4. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
2495553|NCT02932098|Active Comparator|Usual Care|Patients will have access to the web-based app, but will not receive reminders to use it. All participants will be followed for a minimum of 30 days and will be asked to complete a baseline survey at enrollment and a follow-up survey scheduled 30 days after hospital discharge.
2495605|NCT02931643|Placebo Comparator|High fat challenge breakfast|High fat breakfast without mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2495616|NCT02931643|Experimental|High fat challenge breakfast with mixed-spices|High fat breakfast with mixed-spices (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2495682|NCT02931487|Experimental|Attentional Bias Modification|ABM dot-probe task with image stimuli (faces) of three valences: positive (happy), neutral, or negative (angry and fearful). In the ABM condition, probes were located behind positive stimuli in 87 % of the trials (valid trials), as opposed to 13% with probes located behind the more negative stimuli (invalid trials). Consequently, participants should implicitly learn to deploy their attention toward positive stimuli, and in this way develop a more positive AB when completing the task.
2495684|NCT02931487|Sham Comparator|Sham comparator|Sham condition without modification of attentional bias. These trials are identical in structure to the ABM trials with the exception that target probes replaced negative and positive images with equal frequency.
2495733|NCT02931019|Experimental|neck flexion first|"With specific head posture, intubation is done under flexible fiberoscopy guide.~In this arm, at the position with neck flexion, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck extension, And the laryngeal view is gotten in the same way."
2495734|NCT02931019|Experimental|neck extension first|In this arm, at the position with neck extension, fiberoscopy is pulled into the mouth and get the photo of laryngeal view. After then, neck position is changed to neck flexion, And the laryngeal view is gotten in the same way.
2495808|NCT02930616|Experimental|group 1|Patients in Group 1 will receive probe-based confocal endomicroscopy (pCLE) at first and Wight light endoscopy (WLE) 2 months later
2495809|NCT02930616|Active Comparator|goup 2|patients in Group 2 will receive WLE at first and pCLE 2 months later.
2495840|NCT02929992|Experimental|Home ART initiation|Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
2495841|NCT02929992|Experimental|Hybrid model|Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
2495843|NCT02929992|Active Comparator|Clinic ART initiation, monitoring and resupply|This is the standard of care arm. Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
2495915|NCT02929641||HDWL and OE with magnification|The polyps found will be observed by HDWL and OE with magnicication model and recorded.
2496001|NCT02929394|Active Comparator|investigational treatment|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity.
2496004|NCT02929394|No Intervention|observation|Observation through clinical and radiological follow-up until disease progression (RECIST 1.1).
2496038|NCT02928783|Experimental|Intervention|In interventional group, we arranged individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
2496047|NCT02928783|No Intervention|Control|We didn't arrange individualized rehabilitation programs including home-based cardiac rehabilitation, diet education and management of daily activity for 3 months.
2496108|NCT02928614|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2495330|NCT02933645|Active Comparator|Insulin nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain fast-acting human insulin Actrapid (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
2495347|NCT02933645|Placebo Comparator|Placebo nasal spray|"Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd,Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd,Denmark) over 15 min.~30 min before spray administration a hyperinsulinemic euglycemic clamp will be started and continued for 170 minutes. 40 min after spray administration [18F]-FDG PET-CT scan lasting 100 min is started."
2495402|NCT02933151|Other|Usual Care Protocol|Facility randomized to follow the usual care nutritional supplement protocol
2495403|NCT02933151|Other|Intensive Protocol|Facility randomized to follow the intensive nutritional supplement protocol
2495431|NCT02932956|Experimental|GAP T cells + Fludarabine and Cytoxan|GPC3-Car (GAP T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
2495479|NCT02932527|Experimental|infertile men exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
2495484|NCT02932527|Other|infertile men not exposed to cannabis|Male with isolated teratozoospermia or associated with asthenozoospermia and / or oligozoospermia and / or necrozoospermia defined according to WHO recommendations (WHO guidelines, 2010) and the David amended classification (Auger et al., 2001) with normal constitutional karyotype (46, XY) not exposed to cannabis; The exposure to cannabis is not an intervention in the study but is a pre-condition for inclusion. Blood intake and semen samples collection are done. Questionnaire about cannabis consumption are assessed to patient.
2495670|NCT02931825|Experimental|Reminder letter|A letter is sent for remind the importance of compliance with colonoscopy AND to encourage people to to consult their general practitioner or gastroenterologist (if they haven't done their follow-up in time).
2495677|NCT02931825|No Intervention|Control|No intervention (what is done currently)
2495702|NCT02931175|Experimental|Group 1|Mandatory twice a week (Mondays and Thursdays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
2495705|NCT02931175|Experimental|Group 2|Mandatory thrice a week (Mondays, Wednesdays, and Fridays) treatment with SC ACTH gel 80 U/day starting at BL until month 6. Starting at month 6, the treatment will be administered on as needed basis, based on the retreatment criteria.
2495872|NCT02929927|Experimental|Control group|Rubber dam isolation, tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO, 17% EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, then take the sample again, drying the canal and fill the canal with a commercial calcium hydroxide-based paste. After 2 weeks, the canals were filled with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
2495873|NCT02929927|Experimental|Experimental group|Rubber dam isolation，tooth disinfection，acess to the pulp of the chamber, microbiological sample with two sterile paper points, then mechanical preparation with NITIMTWO to 25#06, and cleaned with 5 ml of 2.5% NaClO between each endodontic file. At the end of the procedure, root canals were ultrasonic irrigated with 2.5% NaClO for 1 min, then 17%EDTA for 1 min followed by irrigation with 0.9% normal saline to remove the smear layer, drying the canal, aPDT, then take the sample again. then dried the canals and filled the canals with AH-Plus sealer and Gutta-percha by vertical condensation. The teeth were take crown restoration. Follow up at 3, 6, 12 and 24 months.
2495958|NCT02929576|Experimental|Double-blind enzalutamide with paclitaxel|
2495960|NCT02929576|Placebo Comparator|Double-blind placebo with paclitaxel|
2495961|NCT02929576|Experimental|Open-label enzalutamide monotherapy followed by paclitaxel|At the time of disease progression, enzalutamide treatment will be discontinued and paclitaxel will be administered if considered to be an appropriate treatment by the treating physician until second disease progression.
2496025|NCT02929043||Dentine hypersensitivity subjects|
2496079|NCT02928679|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2496084|NCT02928679|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2496135|NCT02928341|No Intervention|No intervention|Current water supply access
2496142|NCT02928263||Patients treated with IV agents|Metastatic renal cell carcinoma patients treated with IV agents
2497322|NCT02920762||Oxymorphone HCl|
2495457|NCT02932709||Patients admitted of Psychiatry|Only patients who had a suicide attempt admitted to the Department of Emergency Psychiatry.
2495558|NCT02932059|Experimental|Adult schizophrenic patients (18-45 years)|4 groups formed by the case-control study in two age strata
2495566|NCT02932059|Experimental|Aged patients with schizophrenia (≥ 55 years)|4 groups formed by the case-control study in two age strata
2495568|NCT02932059|Experimental|Adults controls (18-45 years)|4 groups formed by the case-control study in two age strata
2495573|NCT02932059|Experimental|Aged Controls (≥ 55 years)|4 groups formed by the case-control study in two age strata
2495640|NCT02931617|Active Comparator|Physiotherapy w/Positive end expiratory pressure training|Chest Physiotherapy w/Positive end expiratory pressure training; post therapy lung volume measurements
2495641|NCT02931617|Experimental|Physiotherapy w/Inspiratory force training|Chest Physiotherapy w/Inspiratory force training; post therapy lung volume measurements
3162058|NCT00454493|Active Comparator|fish oil|
3162059|NCT00454493|Placebo Comparator|placebo|
2495827|NCT02930057|Experimental|Celestone|all patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed.
2495833|NCT02930057|Other|Control|all patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
2495911|NCT02929810|Experimental|sleep extension|
2495912|NCT02929810|Active Comparator|sleep maintenance|
2496005|NCT02929368|Active Comparator|Fluoroscopy|PICC Implantation under x-ray
2496006|NCT02929368|Active Comparator|Sherlock System (BARD)|PICC Implantation with Integrated Magnetic Tracking and ECG-guided Tip Location System
2496127|NCT02928276|Experimental|All patients|All eligible patients
2496188|NCT02927951|Experimental|pregabalin at 150 mg bid|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
2496192|NCT02927951|Placebo Comparator|Placebo|Each subject was randomized to the treatment for 6 weeks, followed by a 2 week washout period, and then completed the other arm of the study.
2496235|NCT02927626|Experimental|Yang Yin Fu Zheng therapy|
2496237|NCT02927626|Placebo Comparator|Routine medical care|
2496265|NCT02927314|Placebo Comparator|Placebo|Placebo tablets orally q12h
2496267|NCT02927314|Active Comparator|CF102 12.5mg|CF102 tablets orally q12h
2496268|NCT02927314|Active Comparator|CF102 25mg|CF102 tablets orally q12h
2496335|NCT02927054|Other|Internal Medicine Residents|Sepsis education provided to internal medicine residents
2496339|NCT02927054|Other|Emergency Medicine Residents|Sepsis education provided to emergency medicine residents
2496340|NCT02927054|Other|Orthopedic Residents|Sepsis education provided to orthopedic residents
2496342|NCT02927054|Other|Neurosurgery Residents|Sepsis education provided to neurosurgery residents
2496344|NCT02927054|Other|General Surgery Residents|Sepsis education provided to general surgery residents
2496401|NCT02926729|Experimental|Experimental|Standard lumpectomy followed by nonlinear microscopy imaging of excised surgical margins. If invasive cancer or DCIS at or close to the margin is detected, additional excision may be performed.
2496403|NCT02926729|Active Comparator|Control|Standard lumpectomy without nonlinear microscopy imaging.
2496489|NCT02926352|Experimental|Extinction Training with LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear domain. 15 minutes after fear extinction, participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system; to stimulate the vmPFC). Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
2496490|NCT02926352|Active Comparator|Extinction Training with Sham LLLT|Participants will receive one-session of fear extinction training tailored to the participant's specific fear. 15 minutes after fear extinction, participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be directed at two areas on the forehead: bilateral frontal points Fp1 and Fp2 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
2496491|NCT02926352|Experimental|LLLT alone|Participants will receive 8 minutes of Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). F3 corresponds with the left dorsolateral prefrontal cortex and F4 corresponds with the right dorsolateral prefrontal cortex. Each area will be stimulated for 4 minutes. Treatment will consist of alternating between each of these points after each minute.
2496604|NCT02925416|Other|One dose oritavancin, one dose placebo|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, a placebo (D5W) will be administered.
2497327|NCT02920762||Tapentadol|
3162060|NCT00454519|Experimental|A|cytoreductive surgery, IPHC, cisplatin 20 mg/m2/L, Mitomycin C 4 mg/m2/L, postoperative chemotherapy.
3162061|NCT00454519|Active Comparator|B|cytoreductive surgery alone, postoperative chemotherapy.
3162062|NCT00454558|Experimental|Arm 1|
3162063|NCT00454662|Active Comparator|1|olmesartan medoxomil, Calcium channel blockers (amlodipine, azelnidipine)
3162064|NCT00454662|Active Comparator|2|AT1 subtype angiotensin II receptor antagonist/low dose diuretic
3162065|NCT00454688|Placebo Comparator|Placebo|
3162066|NCT00454688|Experimental|Asimadoline 0.15 mg|
3162067|NCT00454688|Experimental|Asimadoline 0.5 mg|
3162068|NCT00454688|Experimental|Asimadoline 1.0 mg|
3162069|NCT00454701||1. Amevive Exposure|Patients treated with alefacept for chronic plaque psoriasis
3162070|NCT00454714|Active Comparator|A|Sildenafil arm
3162071|NCT00454714|Placebo Comparator|B|Placebo arm
3162072|NCT00454740|Experimental|1|
2495413|NCT02933125|Experimental|Intervention group|The youths in the intervention group will participate in a weekly 10-session out-patient motivational enhancement psychotherapy (MEP) program. In addition to this, these youths' caregivers will be referred to simultaneously take part in a weekly 10-session out-patient parenting skill training (PST) program at Kaohsiung Chang Gung Memorial Hospital.
2495415|NCT02933125|Active Comparator|Comparison group|The comparison group consists of substance-using adolescents that receive only standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court. The protection officers provide the adolescents with moral education, as well as counseling in their work or studies.
2495483|NCT02932358|Active Comparator|Flexible Family Visitation Model (FFVM)|In the FFVM, two or fewer family members will be allowed to visit the patient for up to 12 consecutive hours each day. In addition to family visitation, patients will be allowed to receive social visits in specific time intervals (according local ICU regulation). To have access to the FFVM, family members of ICU patients will have to attend a structured meeting at ICU in which they will receive orientations about the ICU environment, common ICU treatments, rehabilitation and basic infection control practices, multidisciplinary work at ICU and palliative treatment. Social visitors will not be required to attend the structured meeting.
2495489|NCT02932358|Active Comparator|Restrictive Family Visitation Model (RFVM)|In the RFVM, patients will be allowed to receive restricted visits according routine ICU practices, but respecting the maximum limit of 4.5 hours of visitation per day. Visitors will not be required to attend the structured meeting. The length of ICU visits will be similar to those of social visits in the FFVM.
2495552|NCT02931955||Venom Group|"The investigators plan to include 15 patients with insect venom allergy and will collect blood at four time points and stool at three time points during the first week of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
2495557|NCT02931955||Pollen Group|"The investigators plan to include 15 patients with pollen allergy and will collect blood at five time points and stool at three time points during the first three months of immunotherapy.~The patients will receive usual standard of care and no intervention. We will, however, include blood draw and stool samples collection from the patients."
2495565|NCT02931955||Control Group|"The investigators plan to include 10 control persons without a clinical history of allergies. Blood and stool samples will be collected at seven/four times respectively.~The patients will receive usual standard of care and no intervention."
2495600|NCT02931734|Active Comparator|Resin modified glass ionomer (RMGI)|Resin modified glass ionomer; an application every 48 hours; 4 sessions.
2495603|NCT02931734|Active Comparator|Potassium Nitrate 2% (KF)|Potassium Nitrate and Sodium fluoride 2%; an application every 48 hours; 4 sessions.
2495614|NCT02931734|Active Comparator|Low level laser therapy - GaAlAs (LLLT)|Low level laser therapy - GaAlAs; an application every 48 hours; 4 sessions.
2495624|NCT02931734|Active Comparator|RMGI and KF|Resin modified glass ionomer and potassium nitrate and sodium fluoride 2%; an application of the two associated products, every 48 hours; 4 sessions.
2495629|NCT02931734|Active Comparator|RMGI and LLLT|Resin modified glass ionomer and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
2495634|NCT02931734|Active Comparator|KF and LLLT|Potassium Nitrate and Sodium fluoride 2% and Low level laser therapy - GaAlAs; an application of the two associated products, every 48 hours; 4 sessions.
2495636|NCT02931734|Active Comparator|RMGI, KF, LLLT|Resin modified glass ionomer, potassium nitrate and sodium fluoride 2% and Low level laser therapy - GaAlAs ; an application of the three associated products, every 48 hours; 4 sessions.
2495715|NCT02930928||Accuracy of weight estimation|Computer based comparison of the two algorithms based on collected patient data
2495775|NCT02930785|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2495786|NCT02930356|Experimental|NSPT-Test group|NSPT was done after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
2495789|NCT02930356|Experimental|Scaling and root planing-Control group|Scaling and root planing was done after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to asses the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
2495831|NCT02930135|Experimental|Antibacterial Bond|"Indirect pulp capping using antibacterial bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply antibacterial light-cure, self-etching bonding agent (Clearfil SE Protect, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
2495836|NCT02930135|Active Comparator|Conventional Bond|"Indirect pulp capping using conventional bond and x-tra fil composite~Local anesthesia administration~Isolation of tooth with rubber dam~Opening of the cavity and the removal of undermined enamel~Caries at the lateral walls of the cavity and at the dentin-enamel junction is completely removed~Partial removal of carious dentin on the pulp wall.~Washing the cavity and dryness~Apply conventional light-cure, self-etching bonding agent (Clearfil SE Bond, Kuraray America, Inc.)~Light-cured bulk fill composite (x-tra fil, VOCO) used as final tooth restoration."
2495888|NCT02929901|Active Comparator|caffeine and chlorogeinc acid|caffeine (200 mg) 1 capsule / day for 6 months plus chlorogenic acid (200 mg) 1 capsule / day for 6 months
2495891|NCT02929901|Active Comparator|caffeine|caffeine (200 mg) 1 capsule / day for 6 months plus placebo (200) mg 1 capsule / day for 6 months
2495894|NCT02929901|Active Comparator|chlorogenic acid|chlorogenic acid (200 mg) 1 capsule / day for 6 months plus placebo (200 mg) 1 capsule / day for 6 months
2495417|NCT02932930|Active Comparator|QLB group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.2% ropivacaine bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Ropivacaine, 0.2 ml/kg of 0.2% ropivacaine"
2495418|NCT02932930|Placebo Comparator|Control group|"Patients will receive at the beginning of the surgery 0.2 ml/kg of 0.9% normal saline bilaterally.~Procedure: Quadratus Lumborum Block type II, local anesthetic injection on the posterior border of the quadratus lumborum muscle Drug: Normal saline, 0.2 ml/kg of 0.9 % normal saline"
2495453|NCT02932761|Experimental|VR + GnRHa|CSD patients were treated with vaginal repair of CSD in combination with GnRHa (Zoladex, 3.6 mg, AstraZeneca, Macclesfield, United Kingdom) as a subcutaneous injection (abbreviated as VR + GnRHa). In the group of VR + GnRHa, 2 doses of GnRHa were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
2495455|NCT02932761|Placebo Comparator|VR|CSD patients were treated with vaginal repair of CSD in combination with 0.01 ml saline as a subcutaneous injection (abbreviated as VR). In the group of VR, 2 doses of saline were administered. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure. The detailed procedure of VR has been described in our previous study (Zhou et al., 2016).
2495519|NCT02932436|Experimental|Empagliflozin|10 mg Empagliflozin daily per os for 12 weeks
2495521|NCT02932436|Experimental|Placebo|amount of Placebo corresponding to empagliflozin 10 mg daily per os for 12 weeks
2495554|NCT02931968||Monolithic zirconia prosthesis|Subjects previously treated with at least one arch (maxilla/mandible) of dental implants restored with a full-arch monolithic zirconia implant supported fixed dental prosthesis will be recalled for clinical and radiographic examination.
2495637|NCT02931773||Control|Probands having normal fasting glucose and having a head up tilt test with Task Force® Monitor.
2495638|NCT02931773||Pre-Diabetes|Patients having normal fasting glucose and abnormal Oral Glucose tolerance test and having a head up tilt test with Task Force® Monitor.
2495639|NCT02931773||Recently diagnosed Diabetic patients|Patients being diagnosed as Diabetics type in the recent five years and having a head up tilt test with Task Force® Monitor
2495689|NCT02931305|Experimental|Epimedium Prenylflavonoids Extract|Single oral doses of EP (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
2495692|NCT02931305|Placebo Comparator|Placebo|Single oral doses of Placebo (370 mg, 740 mg and 1110 mg) capsules would be orally administered.
2495993|NCT02929277|Other|single arm study|
2496218|NCT02927886|Experimental|Per-oral Endoscopy Pyloromyotomy (G-POEM)|
2496219|NCT02927886|Placebo Comparator|Intrapyloric injection of botulinum toxin|
2496475|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1|Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
2496476|NCT02926430|Experimental|Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2|Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
2496479|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
2496480|NCT02926430|Experimental|Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4|Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
2496483|NCT02926430|Experimental|Placebo (Day 1 and Day 365): Group 5|Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
2496531|NCT02925819||SEVERE MITRAL VALVE DISEASE|All patients with symptomatic severe mitral valve disease on a native valve or due to deterioration after surgical valve repair or replacement, and not eligible for surgery according to the heart-team.
2496585|NCT02925442|Experimental|Standard Thermal radiofrequency ablation|Patients randomized to t-RFA will receive standard genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
2496589|NCT02925442|Experimental|Cooled radiofrequency ablation|Patients randomized to C-RFA will receive cooled genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty for postoperative pain management.
2496593|NCT02925442|Sham Comparator|Control:Placebo Sham|Patients randomized to control will receive simulated genicular thermal radiofrequency ablation at least 3 weeks prior to unilateral knee arthroplasty and receive the industry standard of care for unilateral knee arthroplasty pain management.
3162073|NCT00454766||Questionnaire|Questionnaire Regarding Tailored Educational Materials
3162074|NCT00454792|Active Comparator|Exercise and advise to stay active|The exercise group received exercises for the stabilising muscles in the low back and abdomen together with dynamic exercises, exercises for postural instability and light physical fitness training.
3162075|NCT00454792|Experimental|Rest and use of flexible lumbar belt|The rest group was instructed to avoid hard physical activity and to rest twice daily for one hour, by lying down
3162076|NCT00454831|Active Comparator|HEP 400mg TID|HEP-40 400 mg three times a day
3162077|NCT00454831|Active Comparator|HEP 800mg BID|HEP-40 800 mg twice a day
3162078|NCT00454831|Active Comparator|HEP 800mg TID|HEP-40 800 mg three times a day
3162079|NCT00454831|Active Comparator|HEP 2400mg QD|HEP-40 2400 mg once a day
3162080|NCT00454831|Placebo Comparator|Placebo|Placebo, three times a day
3162081|NCT00454883||1 cohort of patients treated with ziprasidone|
3162082|NCT00454896|Experimental|1|
3162083|NCT00454896|Placebo Comparator|2|
3162084|NCT00454922|Active Comparator|1|education
3162085|NCT00454922|Placebo Comparator|2|standard of care
3162086|NCT00455000|Experimental|Active treatment|5 possible active doses
3162087|NCT00455000|Placebo Comparator|Placebo|
3162088|NCT00455026|Placebo Comparator|1|0 ng/ml target effect site concentration remifentanil
3162089|NCT00455026|Active Comparator|2|2 ng/ml target concentration remifentanil
3162090|NCT00455026|Active Comparator|3|4 ng/ml target effect site concentration remifentanil
2495424|NCT02932813|Experimental|Intervention Group|"THINK intervention:~The program will have activity and fitness sessions lasting two hours, three times a week for a total of nine months. Sessions will include theory, clinical laboratory activities, and physically active games to facilitate a fun environment to enhance physical and health-related fitness, improve nutrition and exercise knowledge and behaviors, and exercise enjoyment and self-confidence."
2495427|NCT02932813|No Intervention|Control Group|This group will receive the traditional YMCA SPARK after-school program. They will undergo the same pre, mid, and post testing protocol as the intervention group, but will not receive the THINK program.
2495520|NCT02932293|Experimental|SOF+DCV+SMV 3-4 wks|Patients without cirrhosis will receive sofosbuvir, daclatasvir and simeprevir for (a) 3 weeks if HCV viral load on day 2 is <500 IU/ml or (b) 4 weeks if HCV viral load on day 2 is >500 IU/ml.
2495524|NCT02932293|Experimental|SOF+DCV+SMV 6-8 wks|Patients with cirrhosis and CP-A will receive sofosbuvir, daclatasvir and simeprevir (a) 6 weeks if HCV VL on day 2 is <500 IU/ml or (b) 8 weeks if HCV VL on day 2 is >500 IU/ml.
2495556|NCT02932046||Standardized noon meal|"Patients with anorexia nervosa during in-patient treatment are rating hunger and satiety on a visual analogue scale before and after a standardized and supervised meal. The meal is treatment as usual in a specialized ward. A patient may participate several times, if readmitted."
2495595|NCT02931786|Active Comparator|propofol|body core temperature was measured from tympanic membrane after 1 mg/kg propofol administration, before and after magnetic resonance imaging
2495597|NCT02931786|Active Comparator|ketofol|body core temperature was measured from tympanic membrane after 0,1 ml/kg administration of ketamine propofol mixture of 10 mg/ml both, before and after magnetic resonance imaging
2495729|NCT02931032|Experimental|Patients of Student Dental clinic|"Enrolled patients of the student dental clinic in Hadassah Faculty of Dental Medicine, who came to receive scheduled dental treatment and agreed to participate in the trial.~The patients sampled will originate at the students' clinics, and the samples will be taken as part of their dental treatment, namely: removal of caries and infected dentin for future restoration, and dental calculus and plaque removal for the treatment of periodontal disease."
2495764|NCT02930655|Experimental|Lucerastat group|Ten subjects with Fabry Disease received 1000 mg of oral lucerastat twice daily for 12 weeks in addition to their standard of care treatment (enzyme replace therapy).
2495765|NCT02930655|Experimental|Control group|Four subjects with Fabry Disease under enzyme replace therapy (ERT) as standard of care treatment were included as a control group.
2495784|NCT02930382|Experimental|BAROREFLEX|
2495927|NCT02929875|Experimental|Case (Educational based on TPB)|"Educational intervention delivered to subjects. The content of education includes:~Three training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions."
2495929|NCT02929875|No Intervention|Control (No intervention)|No educational intervention provided to subjects in control group
2496008|NCT02929316|Experimental|Vedolizumab|Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6
2496040|NCT02928822|Experimental|Experimental Group|Virtual reality based sensorimotor aphasia therapy.
2496051|NCT02928822|Active Comparator|Control Group|Conventional aphasia therapy.
2496118|NCT02928484|Active Comparator|Test product|The volunteers, that have been randomly assigned to the Test product arm of the study, will be administered one oral capsule/day of the Probiotic mix CBP-004019/C (Biopolis SL) during the intervention period (1 month). The product contains 1X10Exp9 cfu/capsule of the probiotic mix (Bifidobacterium lactis, Bifidobacterium longum, Lactobacilus casei and Lactobacillus rhamnosus) plus maltodextrin and sugar.
2496121|NCT02928484|Placebo Comparator|Placebo product|The volunteers that have been randomly assigned to this arm of the study will receive one oral capsule per day of the placebo product (Biopolis SL) during the 1 month intervention period. The product contains maltodextrin and sugar.
2496166|NCT02928081|Experimental|Extended lymphadenectomy|In addition to the standard lymphadenectomy, the nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1) must be dissected. Retroperitoneal lymphatic tissue, nerves and connective tissue range from the hepatic portal down to the beginning part of the inferior mesenteric artery, the right to the right renal hilus, left to the left edge of the abdominal aorta is included.
2496171|NCT02928081|Other|Standard lymphadenectomy|Lymph node dissection includes the superior and inferior pyloric nodes (LN5, LN6), anterior and posterior nodes along the common hepatic artery (CHA) (LN8a, 8b), nodes along the common hepatic duct, common bile duct and cystic duct (LN12b1, 12b2, 12c), posterior pancreatoduodenal nodes (LN13a, 13b), nodes along the superior mesenteric artery (SMA) (LN14a, 14b), anterior pancreatoduodenal nodes (LN17a, 17b), but excluding the nerve tissues around common hepatic artery and the superior mesenteric artery.
2496233|NCT02927743|Active Comparator|evidence-based online feedback|During three months GPs will receive weekly feedback about evidence-based management of respiratory tract infections. In order to control that they read the material, there is a questionnaire, they have to fill in every week
2496234|NCT02927743|No Intervention|control|GPs will register data without receiving online feed-back
2496257|NCT02927379|Active Comparator|ketamine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline +1 mg /kg ketamine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
2496258|NCT02927379|Active Comparator|dexmedetomidine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline + 1µg/kg dexmedetomidine (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision.
2496259|NCT02927379|Placebo Comparator|bupivacaine group|intervention: local wound infiltration 30 patients receive local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of incision( control group).
2496326|NCT02927093||Case|neonates with NH reaching exchange transfusion threshold
2496328|NCT02927093||Control|neonates with NH within moderate threshold of the phototherapy charts
2495493|NCT02932579|Active Comparator|Standard of Care|Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
2495496|NCT02932579|Experimental|Pharmacogenomic Group|Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
2495555|NCT02932137|Experimental|Interleukin-2|Interleukin-2 to treat activated SLE.
2495562|NCT02932137|No Intervention|Traditional therapy|Treat activated SLE with glucocorticoid or immunosuppressor.
2495609|NCT02931708|Experimental|DFES group|"Diaphragm Functional Electrical Stimulation:~Each session will last 30 minutes. The parameters selected in the stimulator will be: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance.~The patient will be positioned supine, headboard 30º, knees extended. Furthermore, the electrodes used to perform the electrical stimulation will be adhesive, disposable and hypoallergenic. These will be placed at sixth, seventh and eighth intercostal spaces, axiliar medium line and paraxiphoid both chest sides."
2495676|NCT02931474|Placebo Comparator|Placebo|Salt Water Solution
2495679|NCT02931474|Experimental|Tesamorelin|Growth Hormone-Releasing
2495709|NCT02931097|Active Comparator|Pedunculopontine stimulation|Deep brain stimulation of the pedunculopontine area
2495711|NCT02931097|Active Comparator|Pontomesencephalic stimulation|Deep brain stimulation of the pontomesencephalic area
2495713|NCT02931097|Sham Comparator|Sham stimulation|No deep brain stimulation
2495769|NCT02930759|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2495800|NCT02930421|Experimental|Exercise training (ET)|Patients will enter an 8-week ET program of 3 days per week supervised exercise training at the Rehabilitation Physiotherapy Gymnasium. Exercise training will include high-intensity endurance training at 60-80% of baseline peak work rate and strength training of upper and lower limbs with 3 sets of 6 repetitions at 50% of one repetition maximum. Each session will be 60 min duration, 30 min dedicated to cycle exercise.
2495805|NCT02930421|No Intervention|Usual care (UC)|The UC group will receive usual outpatient care and follow-up.
2495849|NCT02930070||qSOFA(+)SOFA(+)|Infection patients who has a qSOFA>=2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the greatest priority in the competition of inclusion of groups.
2495853|NCT02930070||qSOFA(-)SOFA(+)|Infection patients who has a qSOFA<2 and SOFA>=2 in a same day within 28 day of hospital stay.This group has the secondary priority in the competition of inclusion of groups.
2495864|NCT02930070||qSOFA(+)SOFA(-)|Infection patients who has a qSOFA>=2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the third priority in the competition of inclusion of groups.
2495868|NCT02930070||qSOFA(-)SOFA(-)|Infection patients who has a qSOFA<2 and SOFA<2 in a same day within 28 day of hospital stay.This group has the least priority in the competition of inclusion of groups.
2495882|NCT02929732|Experimental|Willis-Ekbom disease patients (CASE)|
2495885|NCT02929732|Experimental|Healthy volunteers (CONTROL)|
2495914|NCT02929537||Western medicine|Patients in this group only choose conventional medicine treatment based on the classes of medications recommended by 2015 GOLD for COPD.
2495917|NCT02929537||Traditional Chinese Medicine|Patients in this group only choose conventional medicine treatment based on the Chinese Treatment Guidelines for COPD.
2495922|NCT02929537||Integrative Medicine|Patients in this group choose western medicine and Traditional Chinese Medicine.
3195290|NCT00838188||Way of feeding|Each infant is evaluated twice, once after breastfeeding and once after bottle feeding of breast milk using a Premature Nipple & Ring (Ross Products Division, Columbus OH, USA). In this way, each infant serves as its own control. REE is recorded for 20 minutes after each meal
3195291|NCT00838214|Experimental|budesonide|3mg capsules 3x/day for 6 months
2496073|NCT02928991|Experimental|Acquired Aplastic Anemia (AA)|Patients with severe or very severe acquired aplastic anemia (AA). Patients will receive a matched related donor bone marrow transplant following reduced intensity conditioning (RIC) including thymoglobulin (ATG), fludarabine and dose-reduced cyclophosphamide.
2496076|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome + Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes with trilineage aplasia includes those with diagnoses of Fanconi Anemia, Dyskeratosis Congenita, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with fludarabine, cyclophosphamide, thymoglobulin.
2496078|NCT02928991|Experimental|Inherited Bone Marrow Failure Syndrome no Trilineage Aplasia|Patients with inherited bone marrow failure (iBMF) syndromes without trilineage aplasia includes those with diagnoses of Severe Congenital Neutropenia, Diamond-Blackfan Anemia, and related conditions. Patients will receive a matched related donor bone marrow transplant following conditioning with thymoglobulin, busulfan and fludarabine.
2496143|NCT02928315|Active Comparator|magnesium|Five ampules of 500 mg of magnesium sulfate will be dissolved in 100 ml of normal saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
2496145|NCT02928315|Placebo Comparator|control|100 ml of normal saline solution infused intravenously over 4 hours once daily , for 3 days
2496175|NCT02927964|Experimental|Treatment (radiation therapy, TLR9 agonist SD-101, ibrutinib)|Patients undergo radiation therapy on days 1 and 2. Within 12 hours of the completion of radiation therapy, patients receive TLR9 agonist SD-101 IT on day 2 and on days 9, 16, 23, 30 and 37. Patients also receive ibrutinib PO daily beginning on day 9 for 96 weeks or in the absence of disease progression or unexpected toxicity.
2496240|NCT02927600|Experimental|Low GI Rice Breakfast|Intake of low GI breakfast
2496241|NCT02927600|Experimental|High GI rice Breakfast|Intake of High GI breakfast
2496243|NCT02927600|Experimental|Low GI Rice Dinner|Intake of low GI dinner
2496246|NCT02927600|Experimental|High GI Rice Dinner|Intake of High GI dinner
2496420|NCT02926521|No Intervention|Dressing A|Dressing A: a nerve block catheter affixed with Pajunk anchor and covered with Tegaderm.
2496425|NCT02926521|Active Comparator|Dressing B|Dressing B: a nerve block catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
2495517|NCT02932241|Experimental|Computerized DBT skills training|The Computerized Dialectical Behavior Therapy Skills Training (cDBT) intervention includes 4 mindfulness, 6 emotion regulations, 2 distress tolerance, and 4 addiction skills. cDBT will retain the essence of DBT skills by being didactically focused, having a predetermined agenda driven by skills to be taught, emphasizing modeling through video vignettes, incorporating in session practice of skills whenever feasible, reviewing homework at beginning of sessions before teaching new skills, and assigning practice between sessions.
2495518|NCT02932241|No Intervention|Waitlist|A waitlist (WL) control condition was chosen considering the pilot nature of the study, feasibility, and the overall goal of assessing treatment's promise. Participants will be assessed for drinking and suicidal urges in the same manner as in the cDBT condition. After 8 weeks, subjects will be able to enroll in the intervention.
2495544|NCT02932085|Active Comparator|rTMS + Wash-out period + Sham|"Five consecutive daily repetitive transcranial magnetic stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily sham stimulation sessions"
2495546|NCT02932085|Sham Comparator|Sham + Wash-out period + rTMS|"Five consecutive daily sham stimulation sessions (Neurostar TMS Therapy System, NeuroStar XPLOR System)~Two weeks wash-out period~Five consecutive daily repetitive transcranial magnetic stimulation sessions"
2495777|NCT02930551|Active Comparator|Lidocaine|Lidocaine 2 ml injection with 2% Adrenaline
2495780|NCT02930551|Placebo Comparator|Isotonic Saline|Isotonic Saline 2 ml Injection
2495935|NCT02929563|Experimental|pantoprazole|pantoprazole 1 mg/kg (maximum 40 mg) IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until Pediatric Intensive Care Unit (PICU) discharge.
2495939|NCT02929563|Placebo Comparator|placebo (for pantoprazole)|an equivalent volume of normal saline IV once daily until the participants no longer need mechanical ventilation - to a maximum of 30 days or until PICU discharge.
3162091|NCT00455052|Experimental|XMT-1001|XMT-1001 is administered I.V. every 21 days. Groups of 3 patients are given one dose and the dose increases for each group. The first dose level is 17 mg/m^2, the next dose level is 30 mg/m^2, followed by dose levels: 50 mg/m^2, 80 mg/m^2, 120 mg/m^2, 150 mg/m^2, and 190 mg/m^2 until disease progressions or unacceptable side effects are experienced.
3162092|NCT00455104||National Registry|To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
2496107|NCT02928432|Experimental|Steroids switch|CRPC patients with biochemical and/or limited radiological progression after at least 12 weeks of AA + prednisone.
2496150|NCT02928211|Experimental|Experimental|All subjects will receive the ointment and have scans with the Sapphire II device
2496196|NCT02927821|Experimental|ADS Plus|Families in settings assigned to intervention will receive Adult Day Services (ADS) as usual in addition to ADS Plus. ADS Plus has 5 key components: care management, referral/linkage; disease education; counseling/emotional support/stress reduction, and care skills managing daily challenges and behavioral disturbances. The intervention begins with 2 face-to-face sessions with the site interventionist to conduct a needs assessment to identify concerns and needs and develop an agreed upon care plan. The interventionist then meets with caregivers face-to-face at convenient times to implement the care plan, every other week for the first 3 months, and then for monthly reassessments for newly emerging care concerns thereafter. Contact occurs about a minimum of 1 hour per month over 12 months.
2496199|NCT02927821|No Intervention|ADS Usual Care|Caregivers in the 15 sites assigned to serve as the usual care control group will receive Adult Day Services (ADS) as usual. Near completion of the study (project year 05), control group sites will have the option of receiving training in ADS Plus for their setting.
2496245|NCT02927587|Experimental|The induction Cet of propofol 1|The induction Cet of propofol was targeted at 1 ug/ml.
2496247|NCT02927587|Other|The induction Cet of propofol 2|The induction Cet of propofol was targeted at 2 ug/ml.
2496391|NCT02926768|Experimental|Daily dose of CK-101|Daily oral dose of CK-101
2496497|NCT02926053|Experimental|Patient group|"All patients receive the same treatment.~Surgical removal of tumor tissue for T cell production, which takes 4-6 weeks, is performed initially.~All patients are hospitalized during treatment (one week in advance of the T cell product being ready and for approximately 3 weeks in total) and receive treatment only once.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5. Interleukin-2 is administered as high-dose i.v. bolus every eight hour starting approximately 6 hours after TIL infusion and for up to 5 days (maximum of 15 doses)."
2496547|NCT02925663|Experimental|EFI-E|10-session web-based modules to teach about executive functioning with videoconferencing with a therapist
2496635|NCT02925208||Cochlear Implant|Patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
2496653|NCT02925039|Experimental|Experimental|Sit to stand training augmented with technology delivered movement feedback
2496654|NCT02925039|Active Comparator|Control|Sit to stand training as per normal practice
2496693|NCT02924831|Experimental|Moxibustion group|drug:moxa Moxibustion was to stimulate acupoints of Guanyuan(RN4)and the Zusanli(ST36) with burned moxa.
3162093|NCT00455117|Placebo Comparator|1|placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy
3162094|NCT00455117|Active Comparator|2|parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy
3162095|NCT00455156|Experimental|150/15 NES/EE CVR|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
3162096|NCT00455169||1|Premature infants
3162097|NCT00455169||2|Full term infants
3162098|NCT00455182|Placebo Comparator|1|Standard medical care
3162099|NCT00455182|Experimental|2|Acupuncture
3162100|NCT00455182|Sham Comparator|3|Sham acupuncture
2495584|NCT02931929|Other|68Ga-NeoBOMB1|68Ga-NeoBOMB1, 2-vial kit for radiolabelling. I.v. Administration after radiolabelling
2495651|NCT02931578|Active Comparator|Glucose100|Participants in this arm will randomly receive 100% glucose in the OGTT drink 3 out of 9 visits.
2495653|NCT02931578|Active Comparator|Glucose50|Participants in this arm will randomly receive 50% glucose in the OGTT drink 3 out of 9 visits.
2495656|NCT02931578|Active Comparator|Glucose42|Participants in this arm will randomly receive 42% glucose in the OGTT drink 3 out of 9 visits.
2495712|NCT02930993|Experimental|anti-mesothelin CAR T cells|"Dose escalation study aimed to assess the safety and efficacy of anti-mesothelin CAR T cells.~CAR T dosage ranging from 5×10^4 /kg to 1×10^7 /kg will be tested ."
2495782|NCT02930798|Experimental|BAY987516|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2495856|NCT02930252|Experimental|Niti-S Biliary ComVi Stent|"Device:~Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure."
2495863|NCT02930252|Active Comparator|Niti-S Stent (D-type)|"Device:~The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.~The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature."
2495928|NCT02929654|Active Comparator|Control|Subject continue to use their own Blood Glucose Monitoring System ( BGMS) for 12 weeks.
2495931|NCT02929654|Experimental|OneTouch Verio®|Subjects use LifeScan provided BGMS (OneTouch Verio®) for 12 weeks
2495938|NCT02929654|Experimental|Intervention 02|Subjects use LifeScan provided BGMS (OneTouch Verio® Flex ) for 12 weeks.
2496016|NCT02929199|Active Comparator|group A|Pressable E- max, an all ceramic crown
2496017|NCT02929199|Experimental|Group B|BIO-Hpp hybrid crown
2496043|NCT02928718||High risk patients|Patients who are at high risk of post-ERCP pancreatitis, who have at least one of the following factors: clinically suspected sphincter of Oddi dysfunction, history of post-ERCP pancreatitis, pancreatic sphincterotomy, precut sphincterotomy, difficult cannulation, balloon dilatation of intact sphincter, endoscopic ampullectomy, and 2≥minor criteria(an age of less than 50 years and female sex, a history of recurrent pancreatitis (≥2 episodes), three or more injections of contrast agent into the pancreatic duct with at least one injection to the tail of the pancreas, excessive injection of contrast agent into the pancreatic duct resulting in opacification of pancreatic acini,the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush).
2496122|NCT02928575|Experimental|Sunitinib, Temozolomide and Radiation Therapy|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
2496357|NCT02926924|Active Comparator|Wound Vac|Wound vac
2496359|NCT02926924|Active Comparator|Standard Dressing|Standard Dressing
2496466|NCT02926196|Experimental|Arm Avelumab|Avelumab 10 mg/kg I.V. q2w for 1 year (52 weeks)
2496467|NCT02926196|No Intervention|Arm Observation|Observation as per guidelines
2496542|NCT02925676|Experimental|hyposafe H02|All subjects included are assigned to hyposafe H02-testing
2496671|NCT02925104|Experimental|INC280|
3162101|NCT00455221|Experimental|Peptide Vaccine|
3162102|NCT00455299|Active Comparator|a|a: suture anchoring + tackers and approximation of defect
3162103|NCT00455299|Active Comparator|b|b: suture anchoring + tackers without approximation of defect
3162104|NCT00455299|Active Comparator|c|c: only tacker fixation and approximation of defect
3162105|NCT00455299|Active Comparator|d|d: only tacker fixation without approximation of defect
3162106|NCT00455325|Placebo Comparator|Placebo Comparator Limb 1|Chloroquine placebo one tablet daily for 3 weeks
3162107|NCT00455325|Active Comparator|Chloroquine Limb 2|80mg chloroquine or placebo tablet weekly for Weeks 1-3
3162108|NCT00455325|Active Comparator|Chloroquine Limb 3|80mg tablet daily for 3 weeks
3162109|NCT00455325|Active Comparator|Chloroquine Limb 4|250mg tablet daily for 3 weeks
3162110|NCT00455351|Experimental|A I|Study drug
3162111|NCT00455507|Experimental|1|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
3162112|NCT00455507|Experimental|2|40mg KW-6002 per day (two 20 mg KW-6002 tablets orally once daily for 12 weeks)
3162113|NCT00455507|Placebo Comparator|3|Two placebo tablets once daily for 12 weeks
3162114|NCT00455559|Experimental|Perifosine 100 mg/d + imatinib mesylate|Perifosine 100 mg/d x 28 days Oral daily dose of perifosine 100 mg and oral daily dose of imatinib mesylate (current dose at time of progression of disease [PD] without interruption). Both drugs will be taken on a continuous basis and should be taken with food. Each cycle will be defined as 28 days.
3162115|NCT00455559|Experimental|Perifosine 900 mg/d + imatinib mesylate|Perifosine 900 mg/d (300 mg tid), 1 x weekly Oral once-weekly dose of perifosine 900 mg (300 mg tid) + oral daily dose of imatinib mesylate (current dose at time of PD without interruption). Perifosine will be taken on days 1, 8, 15, and 22 of a 28-day cycle. Both medications should be taken with food.
2495675|NCT02931357|Experimental|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day.
2495678|NCT02931357|Active Comparator|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
3195292|NCT00838214|Active Comparator|prednisone|5mg tablet, 40mg starting dose titrated to 10mg over 3 months
3195293|NCT00838227|Experimental|One arm|Study withdrawn due to lack of funds.
2495816|NCT02930317|Experimental|Pharmacokinetic parameters|Pharmacokinetic parameters of rFVIII measured in subset of 10 participants, consisting of:18 Years to 65 Years. In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg rFVIII preceded by a 72 hours washout period.
2495818|NCT02930317|Experimental|On-demand treatment|On-demand treatment with rFVIII for 6 months age 12 Years to 65 Years. In Parts 2 of the study, subjects received repeat injections of rFVIII either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor.
2495825|NCT02929940||PiZZ|Observational
2495828|NCT02929940||PiMZ|Observational
2495834|NCT02929940||Other AATD variants|Observational
2495837|NCT02929940||PiMM (Control)|Observational
3195294|NCT00838240|Experimental|Arm I|Patients receive idarubicin IV over 5 minutes on days 1, 3, and 5, cytarabine IV continuously on days 1-10, and clofarabine IV over 1 hour on days 2, 4, 6, 8, and 10.
3195295|NCT00838240|Experimental|Arm II|Patients receive idarubicin IV and cytarabine IV as in arm I. Patients also receive clofarabine IV by push injection over 10 minutes on days 2, 4, 6, 8, and 10.
3195296|NCT00838253|Experimental|1|
2496054|NCT02929017|Other|Intervention|Group will receive SUPPORT, an intervention that provides information about the disease, self-management strategies, and introduction to advanced care planning in a format with enhanced content available across multiple domains (face-to-face, printed material, and digitally (via use of a tablet) delivered by an interventionist.
2496058|NCT02929017|Other|Usual Care|Group will receive usual standard-of-care, and be provided with currently available printed material for information about their illness.
2496105|NCT02928419|Experimental|Arm 1 (Eltrombopag)|Arm 1 is the active treatment arm
2496106|NCT02928419|Placebo Comparator|Arm 2 (Placebo)|Arm 2 is the control arm
2496223|NCT02927704||case (Aggressive periodontitis)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
2496227|NCT02927704||control (Periodontally healthy subjects)|Single intervention has been performed for each subject. Gingival crevicular fluid sample was obtained in conjunction with clinical measurements in this intervention.
2496261|NCT02927496|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2496264|NCT02927496|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
3195297|NCT00838253|Experimental|2|
3195298|NCT00838253|Experimental|3|
3195299|NCT00838253|Placebo Comparator|4|
3195300|NCT00838266|Experimental|1|Antiplaque mouthrinse containing active component (Grape Seed Extract + nicométhanol fluorhydrate)
3195301|NCT00838266|Placebo Comparator|2|Antiplaque mouthrinse containing non-active component
3195302|NCT00838292|Active Comparator|ART: food|ART + food supplementation + nutrition counseling
3195303|NCT00838292|Active Comparator|ART: no food|ART + nutrition counseling
3195304|NCT00838292|Active Comparator|pre-ART: food|no ART (cotrimoxazole provided) + food supplementation + nutrition counseling
3195305|NCT00838292|Active Comparator|pre-ART: no food|no ART (cotrimoxazole provided) + nutrition counseling
3195306|NCT00838305|Placebo Comparator|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
2496558|NCT02925624|Experimental|CLOSE guided PVI and insertable cardiac monitor|
2496576|NCT02925325|Experimental|Music Therapy|Music therapy 8 weekly sessions
3195307|NCT00838305|Experimental|mdma|drug: mdma subjects also get citalopram and placebo in a 2x2 crossover design
3195308|NCT00838318||Arm 1 Hispanic CRC Patients|
3195309|NCT00838318||Arm 2 FDRs of Hispancic CRC Patients|First-Degree Relatives (FDRs) of Hispanic CRC Patients
3195310|NCT00838318||Arm 3 Key Informants|Key informants from Houston Hispanic Health Coalition.
3195311|NCT00838344|No Intervention|Usual care|Usual prescription refill system and pharmacy care.
3195312|NCT00838344|Experimental|Intervention|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
3195313|NCT00838357|Experimental|Plerixafor|Plerixafor added to a G-CSF Mobilisation regimen
3195314|NCT00838370|Experimental|DPYD*2A|Patients are screened for a DPD-deficiency. Patients with a DPYD*2A mutation are eligible for intervention with capecitabine/5-FU .
3195315|NCT00838383|Experimental|sitaxsentan (1.0 mg/kg)|
3195316|NCT00838383|Experimental|sitaxsentan (2.0 mg/kg)|
3195317|NCT00838383|Placebo Comparator|Placebo|
3195318|NCT00838396|Experimental|XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of XP19986 10, 20, 40 or 60 mg.
3195319|NCT00838396|Placebo Comparator|Placebo for XP19986 CR|On either study Day 1 or study Day 5 (after completion of the minimum 3-day washout period), participants received a single dose of placebo.
3195320|NCT00838409||1|
3195321|NCT00838422||FD-OCT, ORA, USP|
3195322|NCT00838448|Experimental|Cannabis users|Cannabis users
3195323|NCT00838448|Experimental|Cannabis no-users|Cannabis no-users
3195324|NCT00838461|Active Comparator|1|HSD-016
3195325|NCT00838461|Placebo Comparator|2|placebo
3195326|NCT00838474|Other|music therapy|Each infant was randomized to receive music therapy or no music over 2 consecutive days
3195327|NCT00838487|Active Comparator|condroflex and exercise|assent arm
3195328|NCT00838487|Placebo Comparator|sugar pill and exercise|sugar pill arm
3195329|NCT00838500|Active Comparator|Immediate SPA treatment|Immediate spa treatment during 18 days soon after randomization (1 year)
2495890|NCT02929836|Active Comparator|PVI+LA linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI, LA linear ablation (roof line and mitral isthmus)and CFAE ablation.
2495893|NCT02929836|Active Comparator|PVI+linear ablation +CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI,roof line and mitral isthmus,cavotricuspid isthmus abaltion and CFAE ablation.
2495896|NCT02929836|Active Comparator|PVI+CFAE ablation|The ablation procedure for atrial fibrillation guided by CARTO system, including PVI and CFAE ablation.
2495946|NCT02929459|Experimental|Riboflavin Dose 1|100 mg Riboflavin (one capsule) per day for 2 weeks
2495950|NCT02929459|Experimental|Riboflavin Dose 2|50 mg Riboflavin (one capsule) per day for 2 weeks
2495955|NCT02929459|Placebo Comparator|Placebo|100 mg starch plus 0,5% silica (one capsule) per day for 2 weeks
2495987|NCT02929147|Experimental|Morphine 1 mg|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
2495989|NCT02929147|Experimental|Morphine 0.5|In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours
2495991|NCT02929147|Active Comparator|Dexketoprofen & Placebo|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
2496060|NCT02928874|Experimental|Caloric compensation|Twenty-five minutes before breakfast, participants will be asked to consume in full one of two oatmeal preloads that will vary in ED. The order of preload conditions will be randomized across groups of children participating in the visits.
2496067|NCT02928874|Experimental|Eating in the absence of hunger (EAH)|During both study visits, children's EAH will be assessed after lunch and again after dinner. The order of presenting the low and high ED snacks will be counterbalanced across meals.
2496109|NCT02928458|Active Comparator|Omnipaque|Arm 1
2496112|NCT02928458|Active Comparator|MD-Gastroview|Arm 2
2496191|NCT02927912|Experimental|Treatment (IOERT boost)|Patients undergo standard of care lumpectomy and then undergo 1 fraction of IOERT boost to the lumpectomy cavity. Patients then undergo standard of care oncoplastic reconstruction and whole breast radiation therapy.
2496263|NCT02927444|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
2496266|NCT02927444|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
2496327|NCT02927106||Acute Myeloid Leukemia (AML)|AML samples will be collected from individuals with newly diagnosed or relapsed/refractory Acute Myeloid Leukemia (AML) as defined by World Health Organization 2016.
2496351|NCT02926859|Experimental|Cannabidiol|Cannabidiol as add-on to individualized pharmacological treatment
2496361|NCT02926859|Placebo Comparator|Placebo|Placebo as add-on to individualized pharmacological treatment
2496407|NCT02926625|Active Comparator|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, ie. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
2496409|NCT02926625|Experimental|Systematic follow-up arm|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should come back for a systematic follow-up visit after 2 days, even if the child has recovered.
2496453|NCT02926287|Experimental|Ambulatory surgery|All the patients operated for pelvic organ prolapse during the study time will be recruited. All the patient eligible for an Ambulatory surgery will be discharged earlier.
2496470|NCT02926131||Infants|Infants requiring serum bilirubin (SBR) measurement seen in Wang Pha clinic (WPA) clinic.
2496524|NCT02925936|Active Comparator|Cathode|Thyroid facing the cathode end of xray machine
2496527|NCT02925936|Active Comparator|Anode|Thyroid facing the anode end of xray machine
2496615|NCT02925221||ADPKD patients on tolvaptan|ADPKD patients who are newly prescribed with tolvaptan or already treated with tolvaptan will be eligible.
2496670|NCT02924935|Experimental|Treatment|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
2496712|NCT02924805||Telemedicine group|Cases of hypertensive emergencies and urgencies in which the prehospital emergency care was performed by on-scene paramedics, guided by a qualified physician in a teleconsultation center.
2496713|NCT02924805||Control group|Historical cases of of hypertensive emergencies and urgencies in which the prehospital emergency care was carried out by on-scene emergency medical service physicians (conventional care).
2496782|NCT02924480|Active Comparator|Lidocaine Study Group|Intravenous Lidocaine for Cystectomy Procedures: During the surgery, the lidocaine infusion group will receive the lidocaine bolus (1.5mg/kg bolus followed by a 2mg/kg/h infusion) 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
2496783|NCT02924480|Placebo Comparator|Placebo Study Group|Intravenous Saline for Cystectomy Procedures: During the surgery, patients will be randomized to the control group and receive a normal saline bolus 30 minutes prior to skin incision and the infusion will continue until 60 minutes after skin closure.
2496844|NCT02923960|Active Comparator|Standard ONS|liquid oral nutritional supplement
2496847|NCT02923960|Experimental|Diabetes specific ONS 1|liquid oral nutritional supplement with novel carbohydrate blend
2496849|NCT02923960|Active Comparator|Diabetes specific ONS 2|liquid oral nutritional supplement with novel carbohydrate blend
2497121|NCT02922127|Other|Combined Oral Contraceptive|20 women will be randomized to daily use of a combined oral contraceptive pill
3195330|NCT00838500|Sham Comparator|Late SPA treatment|Late spa treatment during 18 days soon after 12 months visit (2nd year)
3195331|NCT00838552||1 Asthma subjects|Children with asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
2495690|NCT02931318|Experimental|Nevsehir|People Living in the City Center of Nevşehir
2495749|NCT02930668|Placebo Comparator|Placebo|"The placebo is identical in shape, colour and size to the active comparator with the active ingredient replaced with microcrystalline cellulose.~Subjects will take 2 capsules three times a day, 30 mins before meals."
2495750|NCT02930668|Experimental|Low dose (Glucosanol 350mg)|"Each capsule contains Glucosanol / Phaselite 350mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
2495752|NCT02930668|Experimental|High dose (Glucosanol 500mg)|"Each capsule contains Glucosanol / Phaselite 500mg~Subjects will take 2 capsules three times a day, 30 mins before meals."
2495791|NCT02930512||patients with idiopathic Parkinson's disease|
2495830|NCT02930031|Experimental|n-acetylcysteine|orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise
2495835|NCT02930031|Active Comparator|Placebo|orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder
2495937|NCT02929888|Experimental|Lysine Acetilsalicilate (LA)|Loading dose (LD) of intravenous LA 450mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
2495942|NCT02929888|Active Comparator|Aspirin|Loading dose (LD) of oral aspirin 300mg plus oral prasugrel 60mg/ticagrelor 180mg in patients with ST-segment elevation myocardial infarction
2496007|NCT02929186|Experimental|Opt-In|Opt-In Outreach
2496009|NCT02929186|Experimental|Opt-Out|Opt-Out Outreach
2496034|NCT02928835|Experimental|Dynasplint group|The experimental group received standardized physical therapy intervention and used the knee flexion Dynasplint orthosis six hours daily during one month, starting at day seven after total knee arthroplasty surgery.
2496042|NCT02928835|No Intervention|Control group|Control group received standardized physical therapy intervention.
2496110|NCT02928549||Black Women with Cancer|In this formative qualitative research study we aim to use one-on-one semi-structured interviews with Black women diagnosed with ovarian cancer to learn about their experiences and their journey to accessing care at a high-volume ovarian cancer care center (HVC).
2496149|NCT02928185||HSCT patients|Individual/dyadic semi-structured interviews between Day +100 to +130
2496152|NCT02928185||HSCT care givers|Individual/dyadic semi-structured interviews between Day +100 to +130
2496153|NCT02928185||HSCT dyads|Individual/dyadic semi-structured interviews between Day +100 to +130
2496155|NCT02928185||HSCT Clinicians|Can include: MD, RN, SW, PharmD and Nutritionist. Individual semi-structured interviews after 14 days to review the Coping Together manuals
2496372|NCT02926898|Experimental|ZX008 - 0.2 mg/kg/day - Cohort 1|"ZX008 0.2 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2496374|NCT02926898|Experimental|ZX008 - 0.4 mg/kg/day - Cohort 1|"ZX008 - 0.4 mg/kg/day is supplied as an oral solution and will be administered twice a day (BID) in equally divided doses with food.~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2496375|NCT02926898|Experimental|ZX008 - 20 mg/day maximum - Cohort 2|"ZX008 - 20 mg/day maximum dose is supplied as an oral solution administered twice a day day (BID) in equally divided doses with food. Dose to be determined based on based on Cohort 1 .~Product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH5"
2496376|NCT02926898|Placebo Comparator|Matching Placebo - Cohort 2|Matching placebo will be administered twice a day (BID) in equally divided doses with food.
2496460|NCT02926326|Other|Period 1 and Period 2|"Period 1 - BCT197 14mg on Day 1~Period 2 - BCT 197 14mg on Day 1 and Azithromycin 500mg on Day 1,2 and 3"
2496512|NCT02925793|Experimental|1% DS107 cream|Participants in this group will receive 1% DS107 cream twice daily.
2496516|NCT02925793|Experimental|5% DS107 cream|Participants in this group will receive 5% DS107 cream twice daily.
2496521|NCT02925793|Placebo Comparator|Vehicle cream|Participants in this group will receive matching placebo cream twice daily.
2496757|NCT02924285|Active Comparator|Procedure|Radiofrequency catheter ablation
2496763|NCT02924285|Active Comparator|Antiarrhythmic Drug|Amiodarone
2496818|NCT02924155|Experimental|SJP002|single/repeated administration
2496823|NCT02924155|Placebo Comparator|SJP002 placebo|single/repeated administration
2496862|NCT02923791|Experimental|Filgrastim Hospira|
2496865|NCT02923791|Active Comparator|US-Approved Neupogen|
3162116|NCT00455572|Experimental|Cohort 1|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will receive chemo-and immunotherapy in parallel.
3162117|NCT00455572|Experimental|Cohort 2|Patients with resected stage IB, II or IIIA tumors who are due for standard chemotherapy with cisplatin and vinorelbine. These patients will first receive chemotherapy and then immunotherapy
3162118|NCT00455572|Experimental|Cohort 3|Patients with resected stage IB, II or IIIA tumors who are not due for chemotherapy. These patients will receive immunotherapy only.
3162119|NCT00455572|Experimental|Cohort 4|Patients with unresectable stage III tumors, following standard chemotherapy and/or radiotherapy. These patients will receive immunotherapy only.
3162120|NCT00455598|Placebo Comparator|A|Sulfonylurea + 100 mg/week ISIS 113715 or placebo
3162121|NCT00455598|Placebo Comparator|B|Sulfonylurea + 200 mg/week ISIS 113715 or placebo
3162122|NCT00455637|Experimental|Dysport 5 units|
3162123|NCT00455637|Experimental|Dysport 10 units|
3162124|NCT00455637|Experimental|Dysport 15 units|
3162125|NCT00455767|Active Comparator|1|Depelestat
3162126|NCT00455767|Placebo Comparator|2|Placebo
3162127|NCT00455780|Experimental|MR-/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy for weight loss maintenance.
3162128|NCT00455780|Experimental|MR+/REDE-|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy and use of meal replacements for weight loss maintenance.
3162129|NCT00455780|Experimental|MR-/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy as well as Reduced Energy Density Education for weight loss maintenance.
2495736|NCT02930876|Experimental|Resistance training at home|Participants will undergo training sessions at their own homes. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
2495738|NCT02930876|Experimental|Resistance training at the hospital|Participants will undergo training sessions at the hospital. The exercise program will be individualized and guided by trained physiotherapists, for 3 months completion, aiming at 2-3 sessions a week (27 to 40 sessions in total), each lasting 45-60 minutes.
2495740|NCT02930876|No Intervention|Controls|Participants will be given an information leaflet with the exercise recommendations of the Portuguese national ministry of health.
2496072|NCT02928939||Multimorbid patients|
2496095|NCT02928393|Experimental|Basmisanil|Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
2496096|NCT02928393|Placebo Comparator|Placebo|Placebo matched to basmisanil orally twice daily for 90 days.
3162130|NCT00455780|Experimental|MR+/REDE+|Weight Loss through cognitive behavioral therapy and meal replacement use, and continued therapy, as well as Reduced Energy Density Education and continued meal replacement use, for weight loss maintenance.
3162131|NCT00455793||1|HIV
3162132|NCT00455793||2|Non-HIV infected controls
3162133|NCT00455845|Active Comparator|1 levonorgestrel IUD|
2496220|NCT02927678||Diabetic patients with osteomyelitis|Patients with a clinical and radiological diagnosis of osteomyelitis were included in two diabetic centers
2496308|NCT02927145|Active Comparator|Group 1-Phase Ia|The study is designed to assess a 'standard' protein-in-adjuvant vaccination regimen- 2µg RH5.1/ 0.5mL AS01- of 3 doses given four weeks apart, with dose escalation to assess the best dose in healthy adults.
2496312|NCT02927145|Active Comparator|Group 2- Phase Ia|"The dose used will be- 10µg RH5.1/ 0.5mL AS01. The total number of volunteers recruited to Groups 1 and 2 will be decided based on the immunogenicity of the vaccines at the 2 µg and 10 µg doses.~If the doses are immunogenic the groups (1 and 2) will be recruited to a total of 12 volunteers."
2496314|NCT02927145|Active Comparator|Group 3-Phase Ia|"Group 3 will receive 50µg RH5.1/ 0.5mL AS0~The ultimate aim is to assess the safety and immunogenicity of giving the 'standard' first two doses of the vaccine followed by a delayed fractional dose (10 µg)."
2496316|NCT02927145|Active Comparator|Group 4-Phase Ia|Group 3 and 4 will be recruited simultaneously. The dose of vaccine for this group is same as that of 3 (50µg RH5.1/ 0.5mL AS01)
2496318|NCT02927145|Active Comparator|Group 5-Phase IIa|The vaccination dose for Group 5 was decided following the analysis of safety and exploratory immunology assays from Groups 1, 2 and 4. The dose of vaccine for this group is the same as that of group 2 (10µg RH5.1/ 0.5mL AS01).
2496319|NCT02927145|No Intervention|Group 6-Phase IIa|"Group 6 volunteers will be infectivity controls, so will not receive any vaccinations.~Groups 5 and 6 will only be recruited once at least 6 volunteers in Group 4 have completed all vaccinations."
2496320|NCT02927145|Active Comparator|Group 7-Phase IIa|Group 7 are Group 5 volunteers who will receive a fourth dose of IMP (10µg RH5.1/ 0.5mL AS01)
2496323|NCT02927145|No Intervention|Group 8 -Phase IIa|Group 8 are infectivity controls who were originally in Group 6.
2496325|NCT02927145|No Intervention|Group 9 -Phase IIa|Group 9 are new infectivity controls
2496377|NCT02926846|Experimental|Lavage arm|Intravenous vancomycin & gentamicin with adjunctive lavage
2496380|NCT02926846|Active Comparator|Standard treatment arm|Intraperitoneal vancomycin & gentamicin
2496395|NCT02926599|Experimental|Personal Optimization Training|"Personal Optimization Training such as positive reinforcement, personalized psycho-physiological relaxation and mental rehearsal (total 5 hours a few weeks before the simulation).~Having 2 min to focus on techniques they were trained, after briefing of the scenario and before the start of the scenario."
2496396|NCT02926599|No Intervention|Control|"No particular training.~Screening of normal labs results during 2 min, after briefing of the scenario and before the start of the scenario."
2496437|NCT02926469|No Intervention|Standard Care|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions. Afterwards they will answer pain and anxiety questionnaires.
2496440|NCT02926469|Experimental|Virtual Reality|For patients presenting in labor and desiring standard care (natural childbirth without pain medications, systematic distraction, or alternative therapies) the patient will experience their contractions while using immersive Virtual Reality.Afterwards they will answer pain and anxiety questionnaires.
2496450|NCT02926222|Experimental|ARM A - Regorafenib|Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
2496451|NCT02926222|Active Comparator|ARM B - Lomustine|Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
3162134|NCT00455845|No Intervention|2 control|
2496544|NCT02925702||Radium-223|Radium-223 55 mBq/Kg every 4 weeks IV
3162135|NCT00455871|Active Comparator|Lucentis plus Reduced Fluence PDT same day|
2497404|NCT02920320|No Intervention|Waiting control group|
3162136|NCT00455871|Active Comparator|Lucentis plus reduced fluence PDT 1-2 weeks later|
3162137|NCT00455897|Experimental|GMCSF-RCHOP|
3162138|NCT00455936|Experimental|study arm|Gefitinib 250mg table/QD, daily every 3 weeks
3162139|NCT00455936|Active Comparator|control arm|gemcitabine 1250mg/m2 iv on D1 & D8 every 3 weeks Cisplatin 80mg/m2 iv on D1 every 3 weeks
3162140|NCT00456105|Active Comparator|1|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician, post operatively until hospital discharge and post discharge in the community.
3162141|NCT00456105|Experimental|2|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team post operatively until hospital discharge and post discharge in the community. The Diabetes Action team will consist of a nurse coordinator who is a Certified Diabetes Educator (CDE) and a team of physicians specialized in the management of diabetes.
3162142|NCT00456105|Placebo Comparator|3|Subjects without diabetes will have their blood glucose levels monitored while in the hospital.
2495763|NCT02930902|Experimental|Arm B (pembrolizumab, paricalcitol, chemotherapy)|Patients receive pembrolizumab and paricalcitol as in Arm A. Patients also receive gemcitabine hydrochloride IV over 30 minutes and nab-paclitaxel IV over 30-40 minutes on days 1, 8, and 15 of course 1 in the absence of disease progression or unacceptable toxicity. Surgical resection is performed within 1 week and up to 4 weeks from last dose of paricalcitol.
2495934|NCT02929550||Well-controlled cohort (LDL-C ≤ 1.8 mmol/L)|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation with well-controlled LDL-cholesterol
2495943|NCT02929550||Non-controlled cohort|Individuals in the Swedish Secondary Prevention after Heart intensive care Admission (SEPHIA) is a sub register within SWEDEHEART collecting data on secondary prevention and cardiac rehabilitation and with not well-controlled LDL-C
2496012|NCT02929238|Experimental|Polypropylene Suture Right Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
2496014|NCT02929238|Experimental|Polypropylene Suture Left Side|Polypropylene suture will be placed over half the wound. There is an equal chance for the suture to be placed on the right or left through randomization. THe other half of the wound will not have the suture placed on it and will act as the control. The wound vac will be placed over entire wound.
2496036|NCT02928757|Experimental|Intervention Group|In addition to standard medical care, participants will be enrolled to be seen as soon as possible in a complex care clinic as part of the CCKO initiative.
2496050|NCT02928757|No Intervention|Wait-list Group|The control group will receive usual care, but will be wait-listed for 1 year to be seen in a complex care clinic as part of the CCKO initiative.
2496093|NCT02928510||Basic Science (biospecimen collection, idelalisib)|Patients receive a physical examination during visit 1. A stool sample, blood sample, and 6 biopsies are collected at visit 2, and patients undergo a flexible fiberoptic sigmoidoscopy. Patients receive idelalisib PO twice daily BID after visit 2. Treatment continues in the absence of disease progression or unacceptable toxicity. A third research visit occurs upon development of idelalisib-associated diarrhea/colitis symptoms. Patients with diarrhea/colitis symptoms undergo a full colonoscopy and collection of stool and blood samples. Control patients with no diarrhea/colitis symptoms undergo all needed tests and assessments including a flexible fiberoptic sigmoidoscopy and collection of stool and blood samples. All patients undergo optional biospecimen collection at the time of disease progression.
2496146|NCT02928237|Active Comparator|Real tDCS|In the active stimulation condition a constant current of active transcranial direct current stimulation (tDCS) of 2mA intensity was applied for 30 minutes,over primary motor cortex M1. The treatment was repeated every day for 10 consecutive days.
2496147|NCT02928237|Placebo Comparator|Sham tDCS|Sham tDCS was applied using the same parameters but only for 30 seconds then the machine is deactivated.
3195332|NCT00838552||2 Non-asthma subjects|Children with other respiratory diseases than asthma undergoing clinically indicated bronchoscopy at National Jewish Health.
2496270|NCT02927275|Experimental|Standing Modality|Performance on computerized cognitive tests while standing at a desk. Experimental: Standing Modality
2496274|NCT02927275|Experimental|Biking Modality|Performance on computerized cognitive tests while biking at user's preferred speed on stationary bicycle. Experimental: Biking Modality
2496277|NCT02927275|Experimental|Walking Modality|Performance on computerized cognitive tests while walking at 1mph. Experimental: Walking Modality
2496283|NCT02927275|Other|Seated Modality|Performance on computerized cognitive tests while sitting. No Intervention: Seated Modality
2496356|NCT02926989|Experimental|Isotonic solution|Plasmalyte Glucos 50 mg/mL; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
2496364|NCT02926989|Active Comparator|Hypotonic solution|0.45% saline in 5% dextrose; total daily fluid requirements are estimated using the Holiday-Segar method plus possible dehydration (according to child's weight loss during acute illness); intravenous fluids are administered using delivery pumps programmed for an hourly infusion rate (mL/hour); intravenous fluids are administered as long as needed during hospitalization, but no longer than seven days after admission.
3195333|NCT00838591|Experimental|1|MN-221 given i.v. 1-hour infusion a total dose of 1200 μg (40 μg/min for 15 min [600 μg] + 13.3 μg/min for 45 min [600 μg]) as an adjunct to the standard of care for acute exacerbation of asthma.
3195334|NCT00838591|Placebo Comparator|Placebo|Placebo (Lot #CLO-095) was packaged in identical vials containing only excipients and administered as an i.v. 1-hour infusion with a regimen as described for MN-221.
3195335|NCT00838617||Participants with ALS|Participants diagnosed with ALS.
3195336|NCT00838643||Allogeneic pts|Adult allogeneic HSCT recipients
3195337|NCT00838656|Experimental|Arm I|Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3195338|NCT00838656|Experimental|Arm II|Patients receive carboplatin IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours and gemcitabine hydrochloride IV over 30 minutes on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2497070|NCT02922465|Experimental|K-877 & Clopidogrel|K-877 & Clopidogrel orally
2497087|NCT02922205||RYGB surgery|Obese patients eligible for laparoscopic Roux-en-Y gastric bypass (RYGB) surgery.
2497126|NCT02922244|Active Comparator|Thunbergia cream|Apply Thunbergia cream everyday after radiation therapy on the treatment aria skin.
2495899|NCT02929914|Experimental|PDT+CH|Local anesthesia, rubber dam isolation, remove caries incompletely, microbiological sample with otoscope curette, disinfect the remaining dentin with antimicrobial photodynamic therapy (DENFOTEX PADplus), sampling again. Indirect pulp treatment with calcium hydroxide(CH). Restoration with resin(Z350,3M). Follow up at 6, 12 and 24 months.
2495936|NCT02929446|Experimental|Mobilisation|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible
2495941|NCT02929446|No Intervention|Control|No mobilisation or breathing exercises until discharge or maximum 6 hours
2495947|NCT02929446|Experimental|Mobilisation and breathing exercises (PEP)|Mobilisation out of bed to sit in an armchair or on the bedside, instructed to sit as long as possible and breathing exercises with PEP
2495982|NCT02929173|Active Comparator|Group 2|E-max is un allceram crown
2495984|NCT02929173|Experimental|Group 1|Bio HPP crown is a hybrid crown
2496063|NCT02928965|Experimental|Minocycline|Participants will receive capsules containing 100mg of minocycline (modified release), two per day for the first two weeks of the trial and then three per day for the remainder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
2496069|NCT02928965|Placebo Comparator|Placebo|Participants will receive placebo capsules entirely matching minocycline, two per day for the first two weeks of the trial and then three per day for the reminder of the 12 month treatment period in addition to antipsychotic drug treatment and other interventions by the responsibel medical officer.
3162143|NCT00456118||repeated miscarriages|60 womens for repeated miscarriages will be included
2496352|NCT02926963|Experimental|Chronic Granulomatous Disease|Sample collection were performed from patients with chronic granulomatous disease linked to X or due to Autosomal Recessive (AR) forms AR220, AR470 and AR670.
2496397|NCT02926703||GTCS patients|Patients with generalized tonic-clonic seizures (GTCS) and whose serum lactate and creatine kinase (CK) concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers
2496399|NCT02926703||Syncope patients|Patients with syncope and whose serum lactate and CK concentrations in blood samples had been measured within 2 hours after the event. In a subgroup of patients follow up blood samples were taken at 10 to 48 hours after the seizure to allow longitudinal the comparison of both markers.
2496448|NCT02926391||Cervical|30 patients who need anterior cervical corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
2496449|NCT02926391||Thoraco-lumbar|30 patients who need anterior thoracolumbar corpectomy and fusion with patient-specific implants (UNiD 3D VBR)
2496477|NCT02926157|Experimental|Life Style and Sleep Group|Participants randomized into this group will undergo a 4 week sleep hygiene course (classes 1x/week for 1.5 hours), followed by a 20 week lifestyle activation program. During the 20 week lifestyle activation program, participants wear a Fit Bit and receive a call from a fitness professional every other week for motivation and recommendations, and receive a bright light therapy program from a sleep expert based on their initial sleep results at the baseline measurement session.
2496478|NCT02926157|No Intervention|Wait-list Control|Participants randomized into this group will complete all measurement sessions. After completion of the final measurement session (6 months), participants will be offered an abbreviated version of the Life Style and Sleep Group intervention including the sleep hygiene course, consultation with sleep expert to go over individual sleep patterns and be given recommendations, along with physical activity recommendations from a fitness expert.
2496515|NCT02925910|Other|softwheels at second round|Begining with regular wheelchair for 2 days and then changing for shock absorbing wheelchair for 2 days
2496520|NCT02925910|Other|softwheels at first round|starting with Shock absorbing wheelchair for 2 days and then changing for regular wheelchair for 2 days
2496571|NCT02925559|Experimental|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
2496577|NCT02925559|Active Comparator|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
2496714|NCT02924792||Reinfusion - Fast1|Case: Autologous reinfusion through Fast1 sternal needle. (Pyng Medical) CE marked/FDA Approved
2496716|NCT02924792||Reinfusion - T.A.L.O.N|Case: Autologous reinfusion through T.A.L.O.N sternal needle. (Vidacare) CE Marked/FDA approved
2496718|NCT02924792||Reinfusion - Intravenous line|Control: Autologous reinfusion through standard intravenous line
3162144|NCT00456118||Preeclampsia|70 women for pre-eclampsia will be included
3162145|NCT00456118||intervillites|20 women for intervillites will be included
3162146|NCT00456131|Experimental|Intervention|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
2496925|NCT02923414|Active Comparator|Standard escalating shocks|Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
2496930|NCT02923414|Active Comparator|High energy shocks|Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA
2497131|NCT02922218||Enzalutamide|Enzalutamide 160 mg/day c/24h
3162147|NCT00456144||Group 1|GnRH agonist for 24 months
3162148|NCT00456144||Group 2|GnRH agonist for 6 months
3162149|NCT00456222||Luteal|
3162150|NCT00456222||Follicular|
3162151|NCT00456235|Experimental|adjument MMF|adjusting the dose according to the MMF AUC of mycophenolic acid
3162152|NCT00456235|Active Comparator|continued treatment|Continued treatment empirically usual
3162153|NCT00456248|Experimental|1|Infergen 15 ug QD plus RBV for 36 weeks
3162154|NCT00456248|Experimental|2|Infergen 15 ug QD plus RBV for 48 weeks
3162155|NCT00456248|Active Comparator|3|
3162156|NCT00456274|Other|1|
3162157|NCT00456313|Active Comparator|arm 1|
3162158|NCT00456326||HIT Patients|Patients at Brigham and Women's Hospital diagnosed with Heparin Induced Thrombocytopenia.
3162159|NCT00456378|Experimental|DIAM™ spinal stabilization system|Implantation of the DIAM Spinal Stabilization System
2495907|NCT02929849|Placebo Comparator|Placebo|The investigators will examine subjects before and during a 3 hour period after subjects consume a Placebo capsule and a fixed breakfast meal.
2495972|NCT02929342|Experimental|Pitolisant|Pitolisant, oral single dose administration, from Day1 to Day7.
2495973|NCT02929342|Experimental|[14C]-Pitolisant|[14C]-Pitolisant, oral single dose administration at Day8.
2496126|NCT02928367||Pneumonia patients|rectal swab (4x) divided over two time points (day 0 and day 28) nasopharyngeal swab (2x) divided over two time points (day 0 and day 28) blood draw (90ml) divided over two time points (day 0 and day 28)
2496128|NCT02928367||Healthy subjects|rectal swab (2x) nasopharyngeal swab (2x) blood draw (70ml)
3195339|NCT00838708|Placebo Comparator|Vehicle cream|
3195340|NCT00838708|Experimental|SRD174 Cream|
3195341|NCT00838734||1|Pre-LASIK
3195342|NCT00838734||2|Post-LASIK
2496297|NCT02927522|Placebo Comparator|Control|Placebo was administrated
2496299|NCT02927522|Experimental|Donepezil|Donepezil (5mg/ day for 7 days) was administrated
2496349|NCT02926976|Active Comparator|risperidone with clozapine|risperidone, dosage form: 1 mg, dosage and frequency:3.0~6.0 mg/d; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
2496350|NCT02926976|Active Comparator|aripiprazole with clozapine|aripiprazole, dosage form: 5 mg, dosage and frequency:15~30 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 8 weeks
2496355|NCT02926976|Active Comparator|sodium valproate with clozapine|sodium valproate, dosage form: 250 mg, dosage and frequency:600~1200 mg/day; clozapine, dosage and frequency:300~600 mg/d; duration: 3 months.
2496363|NCT02926976|Active Comparator|clozapine|only clozapine, dosage and frequency:300~600 mg/d;
2496367|NCT02926976|Active Comparator|Modified electroconvulsive therapy with clozapine|10 times MECT for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
2496369|NCT02926976|Active Comparator|Magnetic seizure therapy with clozapine|10 times MST for 4 weeks, if the PANSS reductive ratio is less 20% in the end of 8th week by the using of risperidone with clozapine, aripiprazole with clozapine, sodium valproate with clozapine, or clozapine.
2496452|NCT02926378|Experimental|Acupuncture Intervention|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
2496581|NCT02925325|Active Comparator|Usual Treatment|It is the usual medical treatment.
3195343|NCT00838747||Gynaecological Cancer|Gynaecological Cancer
3195344|NCT00838773|Experimental|YMSM|Young Men Who Have Sex with Men
3195345|NCT00838773|Experimental|YHA|Young Heterosexual Adults
3195346|NCT00838773|Experimental|ROMA|Gypsies (Bulgarian)
3195347|NCT00838773|No Intervention|Control|All study participants (including those in control condition networks) receive HIV/AIDS/STD risk reduction counseling at baseline, as well as testing and treatment or treatment referral for STDs and HIV infection. STD/HIV testing and treatment or treatment referral are provided at each followup point. This constitutes the control intervention.
3195348|NCT00838812|Other|clindamicin and tretinoin gel|
3195349|NCT00838825|No Intervention|traditional|The traditional arm is composed of primary care physicians who continue the health care delivery model existing for the 5 years prior to the study. The traditional includes the physician, a pool of resources including random assignment of diabetic educators and includes the entire panel of patients assigned to the PCP.
3195350|NCT00838825|Experimental|care management|The care management group is composed of primary care physicians who have been assigned a specific physician extender, the care manager, and an additional medical assistant and form a care manager team working together with registry support, team meetings and instruction in self-management and includes the entire panel of patients assigned to the PCP.
3195351|NCT00838838||Group 1|
3195352|NCT00838851|Experimental|CCRE|
3195353|NCT00838864|Active Comparator|1|ceftrioxone 500mg q12h for 3 days
3195354|NCT00838864|Active Comparator|2|ceftrioxone 500 mg q12h for 7 days
3195355|NCT00838877|Experimental|1|
3195356|NCT00838890|Active Comparator|Cdc7-inhibitor (A)|
3195357|NCT00838890|Active Comparator|Cdc7-inhibitor (B)|
3195358|NCT00838942||1|Patients suffering from both Alzheimer's disease and low vision due to a bilateral impeding cataract.
3195359|NCT00838955|Experimental|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
3195360|NCT00838968|Active Comparator|interferon-alpha (IFN-alpha)|the interferon-alpha is intramuscular injected 3,000,000U three times a week for 18 months
2495940|NCT02929589|Experimental|Non-Opioid naïve patients-Group C|Group C: Subjects will be prescribed ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days, in addition to their preferred opioid medication prescription.
2495948|NCT02929589|Placebo Comparator|Opioid naïve patients-Group B|Group B:Subjects will be prescribed 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain and 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days.
2495953|NCT02929589|Experimental|Non-Opioid naïve patients-Group D|Group D: Subjects will be prescribed or advised to continue to take only their preferred current oral opioid prescription (codeine, hydrocodone, hydromorphone, morphine, methadone, oxymorphone, or transdermal fentanyl).
2495986|NCT02929134|Active Comparator|Doxycycline|The Doxycycline treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg).
2495990|NCT02929134|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
2496023|NCT02928887|Experimental|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480nm) light for the 24 hour photoperiod prior to surgery and for the 24 hour photoperiod immediately after surgery
2496026|NCT02928887|No Intervention|Ambient light|Exposure to ambient, white fluorescent light
2496086|NCT02928666|Experimental|DSS for recommendation interactions|participants may use the DSS for mitigating interactions between recommendations to detect interactions between guideline recommendations and find sets of non-conflicting recommendations. In addition, they may look at the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications.
2496089|NCT02928666|No Intervention|No DSS|participants use only the relevant clinical guidelines and additional medical knowledge sources regarding drug-drug relationships, indications and contraindications to detect interactions between guideline recommendations and find sets of non-conflicting recommendations
2496129|NCT02928289|Active Comparator|VISCO360 ab interno canaloplasty surgery|Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).
2496133|NCT02928289|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Subjects randomized to this arm will undergo the SLT procedure.
2496174|NCT02927977|Active Comparator|Control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
2496176|NCT02927977|Experimental|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks. Participants will receive 4-6 treatments during 4 weeks.
2496298|NCT02927184|Placebo Comparator|Placebo|Placebo capsule
2496301|NCT02927184|Experimental|VK2809 (5mg)|5mg VK2809 capsule
2496302|NCT02927184|Experimental|VK2809 (10mg)|10mg VK2809 capsule
2496303|NCT02927184|Experimental|VK2809 (10mg QOD)|10mg VK2809 capsule
3162160|NCT00456378|Active Comparator|Conservative care|Conservative Care
2496492|NCT02926092||Arm 1|Observation of progression of disease over time.
2496536|NCT02925806||ER/LA opioids included in the class REMS|
2496539|NCT02925806||IR Opioids|
2496541|NCT02925806||Celecoxib|
2496543|NCT02925806||Benzodiazepines|
2496559|NCT02925377|Experimental|Neuromuscular|Neuromuscular warm-up
2496560|NCT02925377|Active Comparator|Control|Standard warm-up
2496621|NCT02925260||Patients with normal ileal pouches|"Inclusion Criteria~Ileal pouch reservoir in situ~Greater than three years since closure of ileostomy~Normal pouch function as defined by Orësland score of <4~Never had a diagnosis of pouchitis~Never had treatment for pouchitis~No evidence of pouchitis on rigid pouchoscopy~CRP <10"
2496663|NCT02925000|Experimental|TLC178|Liposomal Vinorelbine
2496719|NCT02924714|Other|Discontinuation of imatinib|Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
2496752|NCT02924324|Active Comparator|propofol alone|1st Bone Marrow procedure (BM) Intervention A: propofol alone. Crossover for second BM procedure propofol & ropivacaine
2496754|NCT02924324|Experimental|propofol and ropivacaine|1st BM procedure: Intervention B: propofol & ropivacaine. Crossover for second BM procedure propofol alone
2496871|NCT02923804|Experimental|Omega-3|3 capsules of 1g concentrated omega-3 taken daily for 6 months
2496872|NCT02923804|Placebo Comparator|Olive oil|3 capsules of 1g olive oil taken daily for 6 months
2496941|NCT02923505||SDB+COPD|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease
2496943|NCT02923505||SDB+HF|Patients with sleep-disordered breathing and concomitant heart failure
2496948|NCT02923505||SDB+COPD+HF|Patients with sleep-disordered breathing and concomitant chronic obstructive pulmonary disease and heart failure
2497115|NCT02922127|Other|Ulipristal Acetate|20 women will randomized to daily use of 10mg of ulipristal acetate
3162161|NCT00456482|Experimental|Fluocinolone Acetonide 0.59mg|Fluocinolone acetonide intravitreal implant 0.59mg
3162162|NCT00456482|Experimental|Fluocinolone Acetonide 2.1mg|Fluocinolone acetonide intravitreal implant 2.1mg
3162163|NCT00456482|No Intervention|No Intervention|Fellow eye
3162164|NCT00456638|Experimental|Depodur|Depodur arm
3162165|NCT00456638|Active Comparator|Traditional|traditional management
2496136|NCT02928250|Active Comparator|Carnosine oral daily|Intervention group included pediatric patients with diabetic nephropathy receiving oral carnosine daily.
2496140|NCT02928250|Placebo Comparator|Second arm received placebo oral daily|Placebo group or control patients received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
2496253|NCT02927405|Placebo Comparator|TAP Block plus placebo|Patients will only receive a TAP block procedure and then morphine consumption will be recorded.
2496255|NCT02927405|Experimental|TAP Block plus gabapentin|Patients will receive a TAP block procedure and take pre-operative oral Gabapentin and morphine consumption will me recorded after surgery.
2496378|NCT02926807||Atopic Dermatis Subjects|30 subjects with atopic dermatitis
2496379|NCT02926807||Healthy Volunteers|30 subjects without AD that matches for sex, age (± 2 years) and coronary artery disease risk factor with the AD subjects will be included as control case
2496411|NCT02926586|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1500mg/m2/d for 5 days intravenously.
2496412|NCT02926586|Active Comparator|high-dose cytarabine|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
2496457|NCT02926248|Experimental|Colchicine|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral colchicine 0.6 mg twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
2496458|NCT02926248|Placebo Comparator|Placebo|Manipulation under Anesthesia (MUA) will be performed prior to 12 weeks after the index TKA. Patients will be randomized to oral placebo twice daily for 6 weeks. All patients will follow a standardized post-MUA physical therapy protocol.
3162166|NCT00456677|Experimental|Minocycline|Addition of minocycline 150 mg po twice daily to current asthma treatment regimen.
3162167|NCT00456677|Placebo Comparator|Placebos|Addition of placebo capsules po twice daily to current asthma treatment regimen
2496554|NCT02925637|Experimental|FACoT group|treatment group will receive FACoT, that include one to one 10 treatment sessions. the treatment sessions will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
2496555|NCT02925637|No Intervention|control group|control group receiving standard care - cognitive and functional assesment
3162168|NCT00456690|Experimental|1|Thalassemia Mayor Patients
2496691|NCT02924857|Experimental|Test Group (Chocolate Touch)|"The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1.~The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome.~If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation."
2496692|NCT02924857|Active Comparator|Control Group (Lutonix Drug Coated Balloon)|"Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion.~The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of >1:1).~If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit.~Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome."
2496727|NCT02924506|Other|Fixed Core|Cervical arthroplasty with fixed core prothesis
2496736|NCT02924506|Other|Movable Core|Cervical arthroplasty with movable core prothesis
2496785|NCT02924259|Experimental|Foam Roll Group|Subjects will undergo a 2-minute video-guided foam roll intervention on the left quadriceps muscle using the GRID foam roll.
2496819|NCT02924025|Experimental|Case|The women in this group will receive motivational interviews approximately once every 2 weeks for half a year.
2496821|NCT02924025|No Intervention|Control|The women in this group will have the usual guidance in weightloss with a booklet on the seven health tips from the danish government. They will not be contacted ind the half year between study onset and finish.
2496869|NCT02923817|Experimental|Treatment|
2496897|NCT02923557|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
2496900|NCT02923557|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
2496936|NCT02923323|Experimental|Group 1 T1DM aged 12-18 years.|T1DM patients. Receiving regularly insulin. Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
3162169|NCT00456703|Active Comparator|restriction|In this group, the fluids will be restricted compared to a standard procedure
3162170|NCT00456781|Experimental|Augmentation|Rotator Cuff Repair augmented with the Graft Jacket Device
3162171|NCT00456781|Active Comparator|No Augmentation|Rotator Cuff RFepair
3162172|NCT00456833|Experimental|RAD 5mg/day + erlotinib|
3162173|NCT00456833|Active Comparator|erlotinib 150mg/day|
3162174|NCT00456872|Experimental|buffered lidocaine|Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
3162175|NCT00456872|Experimental|unbuffered lidocaine|lidocaine is injected without sodium bicarbonate added
3162176|NCT00456963|Experimental|Diet, exercise and Enalapril|one Enalapril 10mg tablet and one Losartan placebo tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet and one Losartan placebo tablet once daily until the end of the randomized treatment phase. After this one Enalapril placebo tablet and one Losartan placebo tablet once daily for six months.
3162177|NCT00456963|Active Comparator|Diet, Exercise and Losartan|one Losartan 50mg tablet and one Enalapril placebo tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet and one Enalapril placebo tablet once daily until the end of the randomized treatment phase. After this one Losartan placebo tablet and one Enalapril placebo tablet once daily for six months.
3162178|NCT00456963|Placebo Comparator|Diet, exercise and Placebo|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
3162179|NCT00457119|Experimental|Step 1 Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel
2495983|NCT02929121|Placebo Comparator|Placebo|The Placebo treated group will enroll 125 participants. 100 patients with Grades 1-3 lymphedema per study site (based on end point and duration) and up to 25 patients with grade 4-6 lymphedema/per study site. Each patient will receive matching tablets containing no active ingredients.
2496032|NCT02928926||Thrombolysis|Acute ischaemic stroke patients who receive intravenous thrombolysis
2496041|NCT02928926||non thrombolysis|Acute ischaemic stroke patients who admitted to the hospital within the timeframe for intravenous thrombolysis but contraindicate to receive intravenous thrombolysis
2496113|NCT02928562|No Intervention|Control|TKA patients without exercise intervention
2496117|NCT02928562|Experimental|Exercise|TKA patients with exercise intervention ( cyclic exercise, aerobic exercise and resistant training exercise )
2496161|NCT02928172|Other|Depth of Anesthesia|Subjects will have the qCON-qNOX and BIS monitor
2496221|NCT02927782|Active Comparator|Bed Rest|48 hours of strict bed rest after incidental durotomy during lumbar spinal surgery
2496226|NCT02927782|Experimental|Early Mobilization|Immediate Mobilization after incidental durotomy during lumbar spinal surgery
2496252|NCT02927418|Experimental|Strength & Conditioning|Supervised S & C program based on the Long Term Athlete Development Model. Participants will attend 2-3 sessions per week for about one hour each session for 4 months. The comprehensive program will include strength and power training as well as plyometrics, agility and flexibility exercises.
2496254|NCT02927418|Active Comparator|Control|Athletes in the control group will continue with their usual sports and activities but will not receive any type of training.
2496290|NCT02927210|Placebo Comparator|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
2496295|NCT02927210|Experimental|Dimethandrolone Undecanoate|Single doses of DMAU administered via injection intramuscularly (IM - 80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC - 50 mg, 100 mg and 200 mg)
3195361|NCT00838968|No Intervention|control|no interventions were assigned
3195362|NCT00838994|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3208734|NCT00977600|Active Comparator|Ammonul|Ammonul® was supplied as single-use glass vials of 10% sodium phenylacetate and 10% sodium benzoate for intravenous injection. Ammonul® was diluted before use with sterile dextrose injection 10% to a concentration of 9 mg/ml. Once diluted it was kept at room temperature and used within 24 hours. The dose was 2.75 g/m2 and was administered as an intravenous infusion over a 120-minute period. Ammonul® was stored at 25°C, within a range of 15-30°C.
2496535|NCT02926014|Experimental|Lingual Tonsil Hypertrophy participants|"The research group consisted of 50 consecutive adult outpatients suffering from swallowing disorders, examined by otorhinolaryngologist at the Hospital of Lithuanian University of Health Sciences.~Lingual Tonsil Hypertrophy was diagnosed using videolaryngoscopy."
2496538|NCT02926014|Other|Control participants|The control group consisted of 50 healthy adult participants, who were examined using videolaryngoscopy and no pharyngeal pathologies were diagnosed, including lingual tonsil hypertrophy.
2496561|NCT02925351|Experimental|Imaging (fluorine F 18 clofarabine, PET/CT)|Patients receive fluorine F 18 clofarabine IV and undergo a single PET/CT scan for up to 120 minutes.
2496728|NCT02924662||Kellgren and Lawrence classification I|Grade I Kellgren and Lawrence radiographic changes.
2496737|NCT02924662||Kellgren and Lawrence classification II|Grade II Kellgren and Lawrence radiographic changes.
2496740|NCT02924662||Kellgren and Lawrence classification III|Grade III Kellgren and Lawrence radiographic changes.
2496741|NCT02924662||Kellgren and Lawrence classification IV|Grade IV Kellgren and Lawrence radiographic changes.
2496789|NCT02924337|Experimental|Imeglimin therapeutic dose|Tablet, oral, single dose
2496792|NCT02924337|Experimental|Imeglimin supratherapeutic dose|Tablet, oral, single dose
2496795|NCT02924337|Placebo Comparator|Placebo|Tablet, oral, single dose
2496799|NCT02924337|Active Comparator|Moxifloxacin|Tablet, oral, single dose (400 mg)
2496816|NCT02923973|Experimental|TVU CL screening|TVU CL screening: serial TVU CL scan from 16 0/7 to 24 6/7 every week, for a total of nine scans Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
2496820|NCT02923973|No Intervention|No TVU CL screening|no screening Vaginal progesterone 200mg suppository daily from 14 0/7 to 20 6/7 weeks for the history of prior spontaneous preterm delivery
2496926|NCT02923375|Experimental|Cohort A|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 1 million cells/kg (up to a maximum of 100 million cells) by IV infusion on two occasions (Day 0 and Day 7)
2496932|NCT02923375|Experimental|Cohort B|Mesenchymoangioblast-derived mesenchymal stem cells (CYP-001) at a dose of 2 million cells/kg (up to a maximum of 200 million cells) by IV infusion on two occasions (Day 0 and Day 7)
2496994|NCT02923050|No Intervention|Waitlist control|
2496997|NCT02923050|Experimental|10-week family meals program|
2497045|NCT02922790|Active Comparator|Control|"Subjects will review standard health information on the health consequences of smoking.~Subjects will have blood drawn but it will not be tested for DNA damage."
2497047|NCT02922790|Active Comparator|Biomarker feedback|"Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.~Subjects will have blood drawn and the feedback will be presented at Visit 2."
2497062|NCT02922790|Active Comparator|Biomarker feedback plus|"Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.~Subjects will have blood drawn and the feedback and images will be presented at Visit 2."
2497099|NCT02922244|No Intervention|Standard skin care|standard skin care
2497104|NCT02922244|Placebo Comparator|Control|Moisture Cream
2496000|NCT02929212|Other|Solid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive solid meals on study days given as three, 200 kcal, meals.
2496003|NCT02929212|Other|Liquid Meal Study Group B|Patients Pre and Post-GBP who are randomly assigned to receive liquid meals on meal study days, given as three, 200 kcal, meals.
3195363|NCT00838994|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Deltoideus [in the middle of the line insertion of Binao LI 14 and acromion], Forearm [1 inch laterally of the middle point between Shaohai HE3 and Shenmen HE7], Upper arm [1 inch laterally of Tianfu LU 3] and Lower leg [0.5 inch dorsally of Xuanzhong GB39]. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
2496130|NCT02928328|Experimental|GABA oral solution|This study will test if oral administration of GABA containing solutions will reduce the pain and sensitivity induced by application of capsaicin to the tongue of healthy human subjects.
2496132|NCT02928328|Experimental|Intramuscular GABA|This study will test the hypothesis that intramuscular injection of GABA alone will not be painful, but will reduce muscle pain sensitivity in healthy human subjects.
2496138|NCT02928328|Experimental|Pain modulation|This study will test the hypothesis that intramuscular injection of GABA with glutamate will decrease the intensity of glutamate-evoked muscle pain in healthy human subjects.
2496214|NCT02927847|Experimental|BA + VLNC|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during the quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus behavioral activation therapy aimed at increasing reinforcement from non-drug rewards.
2496215|NCT02927847|Active Comparator|VLNC Only|Participants will receive Nicotine Patch, SPECTRUM Nicotine Research Cigarettes (.03), and behavioral treatment prior to quit attempt, followed by standard nicotine replacement therapy with Nicotine Patch during quit attempt. Behavioral treatments in this condition will include standard smoking cessation counseling plus supportive counseling and health education.
3195364|NCT00838994|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
3195365|NCT00839007|Experimental|A|Dose 1 of CD-NP
3195366|NCT00839007|Experimental|B|Dose 2 of CD-NP
3195367|NCT00839007|Experimental|C|Dose 3 of CD-NP
3195368|NCT00839007|Experimental|D|Dose 4 of CD-NP
3195369|NCT00839007|Experimental|E|Dose 5 of CD-NP
2496413|NCT02926547||CCIS|
2496417|NCT02926547||invasive breast cancer|
2496455|NCT02926365|Experimental|ICBT|Therapist-supported internet-delivered CBT
2496494|NCT02926079||Pregnant women diagnosed with gestational diabetes|
2496495|NCT02926079||Pregnant women with normal pregnancy|
2496532|NCT02925728|Experimental|Nutrition with Finger-Food|Nutrition with Finger-Food
2496534|NCT02925728|Active Comparator|Nutrition without Finger-Food|Nutrition without Finger-Food
2496583|NCT02925481|Experimental|Low dose Yoga|12 week online yoga for 60 minutes per week
2496586|NCT02925481|Experimental|Moderate dose Yoga|12 week online yoga for 150 minutes per week
2496590|NCT02925481|Active Comparator|Stretch and toning|12 week online stretching, toning exercises for 60 minutes per week
2496650|NCT02925026|Experimental|Lactoferrin+Lysozyme|lactoferrin and lysozyme in rice flour
2496652|NCT02925026|Placebo Comparator|Placebo|rice flour
2496694|NCT02924844||Observation period before presence of clinical pharmacist|The group of patients was observed between Janary 2013 and December 2013
2496696|NCT02924844||Period with presence of clinical pharmacist|The group of patients was observed between January 2014 and June 2015.
2496755|NCT02924389|Other|Anti-retroviral (ARV) Naïve Males|Males diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
2496759|NCT02924389|Other|Anti-retroviral (ARV) Naïve Females|Females diagnosed with HIV will undergo serial blood and tissue rectal sampling for twelve weeks after initiating ARV therapy as prescribed by their physician. Participants will be treated with either Triumeq or Truvada and dolutegravir.
3195370|NCT00839007|Experimental|F|Dose 6 of CD-NP
2496938|NCT02923323|Active Comparator|Group 2 Healthy aged 12-18 years.|Healthy Interventions: performance of continuous EEG , CGMS, MRI of brain with DTI , actigraph, neurocognitive testing
3195371|NCT00839007|Placebo Comparator|G|Placebo
3195372|NCT00839020|Active Comparator|1|Navigated total knee arthroplasty with a minimally invasive approach
3195373|NCT00839020|Active Comparator|2|Navigated total knee arthroplasty with a conventional approach
3195374|NCT00839033|Experimental|1|patients treated with standard treatment and a mechanical insufflation-exsufflation
3195375|NCT00839033|Active Comparator|2|Patients with standard treatment and standard respiratory physiotherapy
3195376|NCT00839046|Active Comparator|1 Community Health Worker Intervention|This is the active control group, which all 150 participants will receive. It consists of visits from trained community health workers, who will provide asthma education, as well as provision of equipment and supplies to reduce indoor environmental exposures for asthma. These will include: vacuum cleaners, mattress and pillow covers, cleaning supplies.
3195377|NCT00839046|Experimental|2 Air Filter|The 50 families in the Air Filter Arm will receive an air filter in addition to the standard community health worker intervention. The Air Filter will be installed right after baseline measurements in the home.
3162180|NCT00457119|Experimental|Step 1, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel
2497097|NCT02922400|Experimental|Social Cognition Assessment and Training|Assessment and training program to enhance social function
3162181|NCT00457119|Experimental|Step 2, Arm 1|5mg/day RAD001 + Carboplatin + Paclitaxel + Bevacizumab
3162182|NCT00457119|Experimental|Step 2, Arm 2|30mg/week RAD001 + Carboplatin + Paclitaxel + Bevacizumab
2497272|NCT02921100|Other|Conventional cytology|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo a conventional cytology.
2497276|NCT02921100|Other|DNA ploidy test|Patients in this arm will undergo an operation of EUS-FNA . The acquired cytological samples from EUS-FNA will undergo DNA ploidy test.
2497344|NCT02920580|Active Comparator|Extubation|Extubation by removal of endotracheal tube.
2497345|NCT02920580|Active Comparator|Usual care|The usual clinical practice is removal of the endotracheal tube (extubation), or insertion of tracheostomy, timed according to physicians' discretion
2497576|NCT02919397|Experimental|Intervention|If participants are allocated to the intervention group, participants will receive the wearable technology and access to the smartphone application. Motivational messages based on diabetes prevention programme content, and biofeedback messages based on physical activity data provided via the wearable technology, will be received by participants via the application. The diabetes prevention programme educational material will be available via the application.
2497578|NCT02919397|Active Comparator|Control|If participants are allocated to the control group, participants will receive the wearable technology and will be able to access their activity data via the smartphone application. Participants will also have have access to the diabetes prevention programme educational material via the application. Participants will not receive motivational messages related to the education content or activity data.
2497643|NCT02918825|Experimental|Paliperidone|Drug: Paliperidone, 75-150mg/month, once a month, 12 weeks
2497647|NCT02918825|Active Comparator|Olanzapine|Drug: Olanzapine, 20mg/day, twice a day, 12 weeks
2497784|NCT02918110|Experimental|Cytotec|orally administrated solution of misoprostol (Cytotec®)
2497785|NCT02918110|Experimental|Misodel|vaginal slow release misoprostol (Misodel®)
2497828|NCT02917746|Experimental|Imiquimod treatment arm|Treatment by vaginal imiquimod cream during 16 weeks.
2497829|NCT02917746|Active Comparator|Standard treatment arm|Treatment by large loop excision of the transformation zone.
2497864|NCT02917421|Experimental|Cohort 1|"(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.~Radiation therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
2497865|NCT02917421|Experimental|Cohort 2|"In addition to receiving radiation to the original tumor bed, patients will also receive radiation to Level III axillary nodes and Supraclavicular nodes: 3D-CRT or IMRT at 2.7 Gy X 15 fraction (40.50 Gy)~Radiation Therapy : Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost."
2497893|NCT02917200|Active Comparator|MOX + CTRL|Moxifloxacin, 400 mg/day oad, 5 days + Negative control, tid, 7 days
2497894|NCT02917200|Experimental|MOX + DAV132 7.5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g tid, 7 days
2497896|NCT02917200|Experimental|MOX + DAV132 7.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 7.5 g bid, 7 days
2497898|NCT02917200|Experimental|MOX + DAV132 5 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g tid, 7 days
2497899|NCT02917200|Experimental|MOX + DAV132 5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 5 g bid, 7 days
2497900|NCT02917200|Experimental|MOX + DAV132 3.3 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3.3 g tid, 7 days
2497901|NCT02917200|Experimental|MOX + DAV132 3 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 3 g bid, 7 days
2497902|NCT02917200|Experimental|MOX + DAV132 2 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 2 g tid, 7 days
2497903|NCT02917200|Experimental|MOX + DAV132 1.5 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1.5 g bid, 7 days
2497906|NCT02917200|Experimental|MOX + DAV132 1 g tid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g tid, 7 days
2497910|NCT02917200|Experimental|MOX + DAV132 1 g bid|Moxifloxacin, 400 mg/day oad, 5 days + DAV132 1 g bid, 7 days
2497914|NCT02917200|Other|CTRL|Negative control, tid, 7 days
2497974|NCT02916758|Experimental|Let's Go Community Mobility Program|Participation in 4 week program
2497998|NCT02916420|Experimental|Treatment|Pomalidomide plus low-dose Dexamethasone
2498089|NCT02916186|Experimental|Tunnel technique with acellular dermal matrix|the tunnel technique involves separation of the gingiva, then acellular dermal matrix interposed between the flap and the root surface.
2498121|NCT02915718|Experimental|experimental group|protein A immunoadsorption for 5 days
3162183|NCT00457158|Experimental|1|ALN optional filter
3162184|NCT00457158|No Intervention|2|No ALN optional filter
3162185|NCT00457223|Experimental|1Fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®)
3162186|NCT00457223|Active Comparator|2 Suture|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using continuous suture with nylon 10-0
3162187|NCT00457314|Experimental|1|Participants will partake in regular exercise training for 6 months. After 6 months, they will switch to no exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
2496098|NCT02928640|Experimental|ClariCore System|ClairCore System study designed for data collection to build the prostrate tissue classification algorithm.
2496157|NCT02928198|Active Comparator|Fenestration|Fenestration of the Absorb Biovascular Scaffold towards the side-branch
2496163|NCT02928198|Active Comparator|No Fenestration|No fenestration of the Absorb Biovascular Scaffold towards the side-branch
2496225|NCT02927808|Experimental|Intervention group - Motivational Interview|"Patients assigned to the intervention group will be given a leaflet entitled Information leaflet about LDL Cholesterol that will educate them about the risks of high LDL-C and the importance of adherence to lipid-lowering medication. Patients assigned to the intervention group will be contacted via telephone for a pre-specified interview (motivational interview again stressing the importance of adherence to lipid-lowering medication) at 1 month and 6 months after discharge, and for an in-person interview plus lipid profiling at 1 year after discharge."
2496229|NCT02927808|No Intervention|Control group|Patients assigned to the control group will be contacted for a pre-specified in-person interview plus lipid profiling at 1 year after discharge.
2496282|NCT02927470|Experimental|Working memory task|Simple visual stimuli (e.g., dots, colors, lines) will be presented on a computer monitor. The positions of the stimuli must be attended and remembered and decisions about the stimuli and/or their locations must be made. Memory will be probed with a button press or an eye movement towards the remembered locations.
2496331|NCT02927028|Other|Chewing group|50 individuals, both male and female, between the ages of 18 and 60 years old, with a BMI between 18-35 kg/m2 from any ethnic/racial background will be recruited. Participants must have natural dentition and rate the hedonic value of all study foods between 3 and 7 on a 9-point category scale.
2496385|NCT02926794|Experimental|SA and II|Combined self-affirmation and implementations intention arm
2496386|NCT02926794|Experimental|SA and No II|Self-affirmation and control intentions condition
2496389|NCT02926794|Experimental|No SA and II|Implementation intentions intervention and control writing task
2496390|NCT02926794|Experimental|No SA and No II|Control writing task and control intentions condition
2496414|NCT02926534||Smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are currently smoking conventional cigarettes with a minimum of 10 pack-year smoking history
2496415|NCT02926534||Ex-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) with a minimum of 10 pack-year smoking history who stopped smoking cigarettes between 1 and 5 years ago
2496423|NCT02926534||Never-smokers|Individuals (men and women) between the ages of 35 and 59 (inclusive) who are current non-smokers and with no history of smoking (control group)
2496468|NCT02926118|Experimental|Low glycemic load|Low glycemic load
2496469|NCT02926118|Experimental|High glycemic load|High glycemic load
2496500|NCT02925949|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
2496501|NCT02925949|Active Comparator|LifeSteps|A 3-session HIV medication adherence support program for individuals.
2496548|NCT02925650|Experimental|Low Dose|The study drug Posiphen dosage of 60mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2496550|NCT02925650|Experimental|Medium Dose|The study drug Posiphen dosage of 120mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2496552|NCT02925650|Experimental|High Dose|The study drug Posiphen dosage of 180mg is to be taken orally in divided doses, three times per day for a total 23-25 days.
2496553|NCT02925650|Placebo Comparator|Placebo|The Placebo comparator is to be taken orally in divided doses, three times per day for a total 23-25 days.
2496572|NCT02925299|Experimental|24/7 closed loop insulin delivery|The study system includes (1) a CGM that measures glucose levels, (2) a computer program on a smartphone that determines how much insulin is needed, and (3) an insulin pump that delivers the insulin. The name of this closed-loop system used in the US is FlorenceM (Medtronic 640G pump and Guardian3 sensor). The name of this closed-loop system in the UK is FlorenceX (DANA pump and Dexcom sensor). Half of the individuals taking part in the study will use the closed-loop study system for 6 months.
2496578|NCT02925299|Active Comparator|Insulin pump therapy|Half of the Subjects will continue using their own insulin pump for 6 months.
2496665|NCT02924974|Sham Comparator|Control|subcutaneous lidocaïne and intravenous loading dose of morphine
2496667|NCT02924974|Experimental|Intervention|Spinal injection of 4 or 5 ml of bupivacaine/morphine 2,5 mg/ml/60mcg/ml. The reduction to 4 ml is for patients over 75 years of age
2496717|NCT02924701||PBC patients|Patients diagnosed with primary biliary cholangitis
3162188|NCT00457314|Experimental|2|Participants will not partake in regular exercise training for 6 months. After 6 months, they will switch to exercise training for 6 months. Participants will then be encouraged to continue exercise training for an additional 1 year.
3162189|NCT00457353|Active Comparator|1|Administration of oral rehydration therapy with Bacillus clausii probiotic strain (1 vial twice daily, each vial containing 2 billion spores of Bacillus clausii)
3162190|NCT00457353|Placebo Comparator|2|Administration of Oral rehydration therapy
3162191|NCT00457405|Active Comparator|1|first 7 day treatment with dipyridamol and at least two weeks later 7 day treatment with placebo
2496912|NCT02923466|Experimental|VSV-IFNβ-NIS|VSV-IFNβ-NIS will be administered intratumorally as a single dose on day 1.
2496915|NCT02923466|Experimental|Selection of VSV-IFNβ-NIS Monotherapy|VSV-IFNβ-NIS will be administered either intratumorally, intravenously or with a combination of intratumorally and intravenously as a single dose on day 1.
2496919|NCT02923466|Experimental|VSV-IFNβ-NIS and avelumab|"VSV-IFNβ-NIS will be administered as determined in arm 2 as a single dose on day 1.~Avelumab will be administered intravenously every 2 weeks starting on day 1."
2496963|NCT02923128|Active Comparator|Dexmedetomidine+routine PCIA|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
3162192|NCT00457405|Active Comparator|2|first 7 day treatment with placebo and at least two weeks later 7 day treatment with atorvastatin
3162193|NCT00457431|No Intervention|Control|Standard therapy as used in the hospital's ICU
3162194|NCT00457431|Active Comparator|Hypothermia|Standard therapy as used in the hospital's ICU plus Hypothermia
2496111|NCT02928614|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2496156|NCT02928159|Experimental|Low Pulse Amplitude Seizure Therapy|Course of Right Unilateral Ultrabrief LAP-ST using Mecta spectrum 5000Q Device.
2496334|NCT02927132|Experimental|Alcohol-Guilt Condition|"In this condition, participants are asked to write about an incident in which they drank heavily and experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2496338|NCT02927132|Experimental|Distress-Guilt Condition|"In this condition, participants are asked to write about an upsetting incident where they experienced guilt.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2496341|NCT02927132|Experimental|Alcohol-No Guilt Condition|"In this condition, participants are asked to write about a negative drinking incident that they had experienced.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2496343|NCT02927132|Experimental|Distress-No Guilt Condition|"In this condition, participants are asked to write about an upsetting experience that has affected their life.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2496346|NCT02927132|No Intervention|Neutral Control Condition|"In this condition, participants are asked to write about the laboratory room in which they are seated.~Participants in this condition will come into the lab one time each week for three weeks to complete the writing task. They will then complete follow-up surveys remotely, at 1 month, 3 months, 6 months, and 12 months."
2496348|NCT02927132|Experimental|Personalized Normative Feedback|Participants in the PNF condition will be given gender-specific personalized feedback regarding their alcohol use. Participants will be presented with the drinking estimates that they previously gave in addition to average gender-specific drinking estimates provided by 1124 students at the University of Houston. Feedback will be provided for drinking frequency (i.e., number of drinking days per week), and drinking quantity (i.e., the number of drinks consumed per week and number of drinks consumed per typical drinking occasion). Participants will also receive a printed a copy of the feedback for their records. PNF participants will receive feedback immediately after the baseline assessment. We also wanted to control for any differences that might be attributed to attention. Thus, participants will be scheduled to come in to the lab for two more sessions, during which time they will write about the laboratory room in which they are seated.
2496393|NCT02926690|Experimental|OTS167PO|
2496433|NCT02926482|No Intervention|Control|This arm will include 35 organizations who receive access to the Prescriber Recruitment Bundle (PRB) materials online via a secure website.
2496435|NCT02926482|Experimental|PRB: organizations implementing the PRB|This arm will include 35 organizations that will implement the intervention, the Prescriber Recruitment Bundle (PRB) using the NIATx Organizational Change Model (a model developed by our center research team).
3195378|NCT00839046|Experimental|3 Air Filter and Air Conditioner|"Fifty families will be assigned to the Air Filter and Air Conditioner Arm. In addition to the standard community health worker intervention, they will receive an air filter and an air conditioner (for the warmer months)."
3195379|NCT00839059|Experimental|Lenalidomide|
3195380|NCT00839085|No Intervention|1|normal procedure of CABG
3195381|NCT00839085|Active Comparator|2: GSE|100 mg GSE every 6h /Po, starting one day before surgery (4 doses in 24h)
2496618|NCT02925273|Other|Standard|Prospective, grasp techniques will be compared in each patient from the experimental group using a palmar grasp without dorsal stimulation and a standard palmar grasp test with dorsal stimulation on the same patient as the control group
2496659|NCT02924961|Experimental|Triathlon Mobile-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized mobile-bearing
2496661|NCT02924961|Active Comparator|Triathlon Fixed-bearing|Primary total knee replacement with cemented Triathlon posterior stabilized fixed-bearing
3195382|NCT00839085|Active Comparator|3: Vit C|25 mg/kg through pump
3195383|NCT00839111|Experimental|A|Sorafenib plus FOLFIRI regimen
3195384|NCT00839124|Active Comparator|Allergic asthma|subjects with allergic asthma will undergo challenge with 20,000 EU CCRE
3195385|NCT00839124|Active Comparator|healthy control|Healthy volunteers will undergo challenge with 20,000 EU CCRE
3195386|NCT00839150||1|Diabetic patients without diabetic retinopathy : No intervention
3195387|NCT00839150||2|Sex and age-matched control subjects : No intervention
2497251|NCT02920931|Experimental|A|"st period: Tenofovir disoproxil fumarate~nd period: Tenofovir Disoproxil"
2497254|NCT02920931|Active Comparator|B|"st period: Tenofovir disoproxil~nd period: Tenofovir Disoproxil fumarate"
3195388|NCT00839163|Experimental|Arm 1|
3195389|NCT00839163|Experimental|Arm 2|
3195390|NCT00839163|Experimental|Arm 3|
3195391|NCT00839163|Experimental|Arm 4|
3195392|NCT00839163|Active Comparator|Arm 5|
3195393|NCT00839176|Placebo Comparator|Placebo|Placebo (w/o API)
3195394|NCT00839176|Experimental|2|5mg dose of RX-10100
3195395|NCT00839176|Experimental|3|10mg dose of RX-10100
3195396|NCT00839176|Experimental|4|15 mg dose of RX-10100
3195397|NCT00839202|Experimental|FVIII immuno-assay|The study is not designed as a therapeutic evaluation, but an assessment of clotting factor VIII timed responses after the infusion of specified doses of licensed clotting factor VIII concentrates. The purpose of the study is to measure the levels of infused licensed clotting factor VIII by standard assay techniques and comparing these standard assays with an experimental assay. Measurements of possible co-factors that might impact the results were also carried out.
3195398|NCT00839228|Experimental|Perhexiline|perhexiline 100mg o bd for 3 months
2496141|NCT02928341|Experimental|Intervention|Received water supply improvement intervention designed to improve access to tap water, consisting of community managed public taps, improved tap water distribution network, refurbished tap connections and promotion of new household tap connections.
2496184|NCT02928042||Lactobacillus bacteria|Pseudomonas aeruginosa, Acinetobacter baumanii, Staph aureus and Klebsiella pneumoniae will be isolated from tracheal aspiration cultures. 80 isolates associated with pneumonia will be identified and made antibiogram with VITEK. Then antimicrobial effects of Lactobacillus bacteria (LAB) (Lc. lactis subsp. lactis (IL 1403), Lc. lactis subsp. lactis (ATCC 11454), Lactobacillus plantarum (FI8595), Leuconostoc mesenterodies subsp. cremoris (DSMZ 20346), Streptococcus thermophilus (NCFB2392), Pediococcus acidophilus (ATCC 25741)) and nisin bacteriocin will be investigated on the bacteria's growth rate in the laboratory.
2496231|NCT02927691|Experimental|Immediate Treatment|Participants will begin treatment immediately following baseline testing.
2496232|NCT02927691|Other|Delayed Treatment|Following baseline testing, participants will receive no treatment for five weeks, then begin treatment immediately following a second baseline testing session.
3195399|NCT00839228|Placebo Comparator|Placebo|Placebo one tablet bd for 3 months
3195400|NCT00839267||Unstable|Patient with acute myocardial infarction plus severe hemodynamical instability. It means, on mechanical ventilation and catecholamine support
2496537|NCT02925715|Experimental|supraclavicular|ultrasound guided central venous cannulation done by supraclavicular approach
2496540|NCT02925715|Experimental|infraclavicular|ultrasound guided central venous cannulation done by infraclavicular approach
3195401|NCT00839267||Stable|Patients with myocardial infarction hemodynamically completely (Killip I)stable.
3195402|NCT00839280|Experimental|Arm 1|
2496668|NCT02924896|Other|randomization 1|Palm Olein, Interesterified Palm Olein, Soybean Oil
2496673|NCT02924896|Other|randomization 2|Palm Olein, Soybean Oil, Interesterified Palm Olein
2496675|NCT02924896|Other|randomization 3|Interesterified Palm Olein, Palm Olein, Soybean Oil
2496677|NCT02924896|Other|randomization 4|Interesterified Palm Olein, Soybean Oil, Palm Olein
2496679|NCT02924896|Other|randomization 5|Soybean Oil, Interesterified Palm Olein, Palm Olein
2496681|NCT02924896|Other|randomization 6|Soybean Oil, Palm Olein, Interesterified Palm Olein
2496724|NCT02924532||Patients with total thiroidectomy|
2496762|NCT02924363||Single arm (cardiac MRI & hematocrit blood sample)|Patients will undergo a pre- & post- MitraClip procedure cardiac magnetic resonance imaging (CMR) scan with an FDA cleared MRI scanner and with or without an FDA approved contrast dye. The scan and the blood draw to assess the hematocrit is research, the MitraClip procedure is standard of care for these patients.
2496833|NCT02924090|Active Comparator|ECT with Etomidate|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose.
2496837|NCT02924090|Active Comparator|ECT with Ketamine|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose.
2496839|NCT02924090|Active Comparator|ECT with Etomidate and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous etomidate for anesthesia at a dose of 0.3 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
2496841|NCT02924090|Active Comparator|ECT with Ketamine and Hyperventilation|Immediately prior to ECT study patients will be administered intravenous ketamine for anesthesia at a dose of 0.5 -1.0 mg/kg given as a bolus dose. Hyperventilation will be administered (20 breaths in 30 seconds) by face mask immediately prior to ECT.
2496894|NCT02923531|Experimental|X4P-001 Plus Nivolumab|Participants will receive X4P-001 400 milligrams (mg) (as 4 capsules of 100 mg each) orally once daily in combination with nivolumab 240 mg intravenous (IV) infusion (over 60 minutes) every 2 weeks. Study treatment will be administered in 28-day cycles and will continue until treatment-limiting toxicity or disease progression.
3195403|NCT00839280|Active Comparator|Arm 2|
3195404|NCT00839293|Experimental|A|ABT -335 capsules 135mg
3195405|NCT00839293|Experimental|B|ABT-335 capsules 45mg
2497088|NCT02922114|Experimental|Ultrasonography|B-mode and power Doppler Ultrasonography examination
2497157|NCT02921971|Experimental|SAR156597|SAR156597 will be given on a specific time period
2497168|NCT02921971|Placebo Comparator|Placebo|Placebo will be given on a specific time period
2497222|NCT02921243||Stool Sample Collection|
2497226|NCT02921243||Prebiotic|
2497330|NCT02920736||sepsis with acute renal injury group|Based on definition of sepsis with Sepsis 3.0 and AKI was defined using KDIGO（Kidney Disease: Improving Global Outcomes） consensus definition of AKI.The group was the secondary AKI in sepsis patients
2498126|NCT02915718|No Intervention|control group|non intervention
3195406|NCT00839358|Active Comparator|Albumin plus midodrine|Albumin 40 g every 15 days during 1 year or until liver transplantation. Midodrine 5mg/8h. It can be increased according the value of mean arterial pressure. If there is no increase (defined as at least 10mmHGin MAP)midodrine can be increased at a dose of 10mg/8h. This treatment will be given during 1 year or until liver transplantation.
3195407|NCT00839358|Placebo Comparator|salin solution plus pills|Placebo of albumin in the same schedule thats in arm 1; placebo of midodrine in the same schedule thats in arm 1.
3195408|NCT00839371|Active Comparator|Midazolam|i.v. midazolam titration until adequate depth of sedation
3195409|NCT00839371|Active Comparator|Propofol|i.v. propofol titration until adequate depth of sedation
3195410|NCT00839384|Experimental|Implant Advisa IPG|Advisa IPG implant
3195411|NCT00839397|Other|Paroxetine|A 52-week, non-comparative, uncontrolled study (However, the baseline phase is single blind)
3195412|NCT00839449|Experimental|A|Patients in the group A are orally administered eicosapentaenoic acid ethyl ester.
3195413|NCT00839449|No Intervention|B|Patients in the group B (control) are not administered eicosapentaenoic acid ethyl ester.
3195414|NCT00839462|Experimental|Arm 1|
2496144|NCT02928263||Patients treated with oral agents|Metastatic renal cell carcinoma patients treated with oral agents
2496177|NCT02928016|Experimental|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496179|NCT02928016|Experimental|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496180|NCT02928016|Experimental|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496181|NCT02928016|Experimental|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496182|NCT02928016|Experimental|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496183|NCT02928016|Experimental|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment and glycated haemoglobin (HbA1c) <10% consumed three ready-made standardised mixed meals (a dish made with thick pasta, minced meat and béchamel sauce, grilled chicken with vegetables and baked giant beans) with and without the addition of 11 ml of extra virgin olive oil within 20 minutes. No other food or drink (except for water) were consumed until the end of the trial period (total duration 195 minutes). Participants consumed all meals in random order during 6 consecutive visits with one week wash-out period in between visits.
2496236|NCT02927652||Questionnaires for new patients|New patients seen at Duke Clinic for Head and Neck Surgery & Communication Sciences or Duke Raleigh Otolaryngology will be administered questionnaires (BSI-18, CG-CAHPS, and patient control scale).
2496260|NCT02927353|Experimental|DMB-3113|adalimumab biosimilar
2496262|NCT02927353|Active Comparator|adalimumab|adalimumab
2496332|NCT02927119||Non-users|Pregnant women who had not taken dietary iodine supplement before and during pregnancy.
2496336|NCT02927119||Users|Pregnant women who had taken dietary iodine supplement before and/or during pregnancy.
2496384|NCT02926781|Experimental|osteotome technique|transcrestal sinus floor elevation using osteotomes
2496387|NCT02926781|Active Comparator|drills|transcrestal sinus floor elevation using drills
3195415|NCT00839462|Active Comparator|Arm 2|
3195416|NCT00839488|Active Comparator|I|pantoprazole 40 mg iv qd
2496486|NCT02926105|Experimental|T&E Home-based exercise programme|Individually tailored home-based test and exercise programme
2496487|NCT02926105|Experimental|Otago|Individually tailored exercise programme
2496488|NCT02926105|Active Comparator|Helsana booklet|Helsana recommendations and exercises
2496502|NCT02925767|Experimental|The 311-nm Ti:Sapphire laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
2496504|NCT02925767|Active Comparator|The 308-nm excimer laser treatment group|All lesions were treated twice weekly for a total of 12-week period.
3195417|NCT00839488|Active Comparator|II|famotidine 20 mg q12h
3195418|NCT00839501|Experimental|1|Participants will receive either potassium or placebo during six 3-week-long treatments, as randomly determined. Participants will then continue to receive potassium, if tolerated, and also either acetazolamide or placebo during another six 3-week-long treatments, as randomly determined.
3195419|NCT00839566|Experimental|AV ablation|
3195420|NCT00839566|Active Comparator|Rate control|Rate control by drugs
2496829|NCT02924064|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks in combination with metformin
2496830|NCT02924064|Placebo Comparator|Placebo|Placebo for 24 weeks in combination with metformin
2496880|NCT02923739|Active Comparator|Arm I (paclitaxel, bevacizumab)|Patients receive paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 and bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3195421|NCT00839566|No Intervention|Sinus rhythm|
3195422|NCT00839579|Experimental|4x4min|4x4minutes interval group
3195423|NCT00839579|Experimental|1x4min|
3208735|NCT00977600|Active Comparator|Buphenyl|Sodium phenylbutyrate or Buphenyl® was supplied as a white powder in 250 g bottles. The required amount of powder (equivalent to 3 g/m2 of PBA) was weighed out, mixed in 100 ml of water, and administered orally. Doses were calculated on a weight/volume basis and corrected for sodium content and purity. Buphenyl® was stored at ambient temperature.
2496158|NCT02928120||CRC group (exploratory)|"Blood samples from approximately 210 patients diagnosed with colorectal carcinoma collected prospectively and consecutively at the Department of Surgical Gastroenterology, Aalborg University Hospital during the time period 2003-2006 will be used. The blood samples were collected at the time of diagnosis, before and after treatment (surgery and radio-chemo-therapy) and at regular intervals for a time period of two years after treatment. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
2496165|NCT02928120||Control group (exploratory)|"Blood samples (8ml) from patients (n=142) who underwent work-up for lower gastrointestinal malignancy during the time period 2003-2006. Colonoscopy was performed, and no malignancy or premalignant lesions found. Blood samples were collected before/after colonoscopy. These blood samples were collected during a previous PhD-study: Pre- and postoperative Venous Thromboembolism in Patients with Colorectal Cancer - implications of Radiotherapy (ID-number VN 2003/102)."
2496167|NCT02928120||CRC group (validation)|Blood samples from 143 patients were collected prospectively and consecutively for a previous study on the effect of omega 3 fatty acids an postoperative complications after colorectal surgery. All study participants have provided written informed consent (N-VN-20050035).
2496169|NCT02928120||Control group (validation)|There will be recruited approximately 100 control subjects with a positive occult faecal blood but with a normal colonoscopy for blood sampling (28 ml).
2496173|NCT02928120||IBD group (validation)|In collaboration with The Department of Medical Gastroenterology, Aalborg University Hospital, there will be recruited approximately 120 patients with ulcerous colitis for blood sampling (28 ml).
3208736|NCT00977626|Experimental|Part 1 AZD2423 or Placebo|AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days
2496353|NCT02926885|Active Comparator|CONVENTIONAL LIVER RETRACTOR DEVICE|USE OF CONVENTIONAL LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
2496360|NCT02926885|Experimental|FLEXIBLE LIVER RETRACTOR DEVICE|USE OF THE FLEXIBLE LIVER RETRACTOR FOR THE LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
3162195|NCT00457457|Active Comparator|Comparator|Tamsulosin 0.4 mg prolonged release
3162196|NCT00457457|Experimental|Treatment Arm|There are 5 possible UK-369,003 arms as follows: UK-369,003 MR (10mg, 25mg, 50mg & 100mg), UK-369,003 IR (40mg),
3162197|NCT00457496|Active Comparator|A|
3162198|NCT00457509|Experimental|Group 1|Dose 1 with Adjuvant
2496481|NCT02926274||Whole Blood|Adult male trauma patients presenting with systolic blood pressure <100 will receive up to 6 units of whole blood when available.
2496485|NCT02926274||Component therapy|Adult female patients presenting with systolic blood pressure <100, as well as adult male patients with systolic blood pressure <100 during periods when whole blood is not available, will receive component therapy (1:1:1 packed red blood cells: plasma:platelets) for transfusion.
3162199|NCT00457509|Experimental|Group 2|Dose 2 with adjuvant
2496565|NCT02925546|Experimental|GSK2798745 ABCD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496566|NCT02925546|Experimental|GSK2798745 CABD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496567|NCT02925546|Experimental|GSK2798745 ACBD treatment sequence|Subjects will be given 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496568|NCT02925546|Experimental|GSK2798745 BACD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496569|NCT02925546|Experimental|GSK2798745 BCAD treatment sequence|Subjects will be given 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496602|NCT02925416|Experimental|Two doses oritavancin|On Day 1 of the study, subjects will be administered a single 1200-mg IV dose of oritavancin in 1000 mL D5W. On Day 7, an additional 1200-mg IV dose of oritavancin in 1000 mL D5W will be administered.
2497110|NCT02922244|Active Comparator|Cucumber cream|Apply Cucumber cream everyday after radiation therapy on the treatment aria skin.
3162200|NCT00457509|Experimental|Group 3|Dose 3 with adjuvant
3162201|NCT00457509|Experimental|Group 4|Dose 4 with adjuvant
3162202|NCT00457509|Active Comparator|Group 5|Control
3162203|NCT00457652|Active Comparator|1|7 day treatment rosuvastatin
3162204|NCT00457652|Placebo Comparator|2|7 day treatment placebo
3162205|NCT00457756|Active Comparator|I|Cohort I subjects will take supplement for 12 weeks
3162206|NCT00457756|Placebo Comparator|II|Cohort II will take placebo for 12 weeks
3162207|NCT00457769|Experimental|Aricept- A|Half of subjects are randomized to immediate treatment with donepezil 5mg orally daily following baseline testing, with retesting at 12 and 24 weeks.
3208737|NCT00977626|Experimental|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
3162208|NCT00457769|Experimental|A2-12-week waiting period|The remaining nine subjects are randomized to testing followed by a 12-week waiting period. After the 12 week wait, this group of subjects is retested and begins taking donepezil, 5 mg orally daily, with retesting at 24 weeks
3162209|NCT00457782|Experimental|I|Intravenous KW-2478 (ascending dose cohorts)
3162210|NCT00457873|Experimental|A|0.9% saline in 5% dextrose (intravenous)
3162211|NCT00457873|Active Comparator|B|0.45% saline in 5% dextrose (intravenous)
2496251|NCT02927392|Experimental|Pre-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women. We will also explore whether suppression of ovarian hormones in pre-menopausal women (using leuprolide acetate) impairs BAT activity.
2496256|NCT02927392|No Intervention|Post-menopausal women|To determine if natural declines in endogenous E2 contribute to changes in BAT activity, the investigators will compare BAT activity in pre-and post-menopausal women.
2496291|NCT02927197|Experimental|LearningRx Cognitive Training|The intervention is a 60-hour one-on-one cognitive training program
2496294|NCT02927197|No Intervention|Waitlist Control|The treatment-as-usual control group will begin the intervention when the experimental arm has completed the intervention.
2496329|NCT02927002|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the 30-minute stimulation period
2496330|NCT02927002|Sham Comparator|Noninvasive brain: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of 30-minute stimulation period.
2496381|NCT02926820|Experimental|Cognitive training|Participants will undergo five weeks of cognitive training using the Cogmed QM program. All patients complete the same intervention.
2496398|NCT02926612||HCT recipients ages ≤21 years|HCT recipients ages ≤21 years for whom lower respiratory secretions are being collected for direct patient care.
2496459|NCT02926404||Pediatric patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) <18Years old
2496462|NCT02926404||Adult patients operated with Patient-specific rods|Patients with patient-specific rods (UNiD Rods) >18Years old
2496528|NCT02925845|Experimental|Neuromuscular electrostimulation|Patients assigned to the group NMS, following the visit Day Hospital, in the first two hours of each HD session will perform a program of neuromuscular electrostimulation of the limb with the RC-AVF performed in the reference position of the flexors and extensors forearm at the tip intervened in each HD session on the stage previously established in the protocol (duration according to established program).
2496529|NCT02925845|No Intervention|Isometric exercises|They will perform isometric exercises operated limb on an outpatient basis (repeated pressure rubber balls, heavy lifting 1-2 kg).
2496573|NCT02925468|Experimental|Intervention group|A standard initial lateral cephalogram radiograph will be taken of all subjects, unless this is already available within the specified age range. An intra-oral scanner will be used to accurately record the occlusal relationships prior to insertion of the fixed anterior bite plane (bite turbos) (T0) and repeated immediately after placement (T1). Each subject will then be re-scanned on a six weekly basis for a period of six months (T2-T5). Conventional clinical photographs and three-dimensional stereophotogrammetry will be used to assess the vertical facial relationships at T0-T5. A further lateral cephalogram radiograph will be taken at T5.
2496580|NCT02925468|No Intervention|Control group|A control group of subjects from the treatment waiting list who meet the inclusion criteria will be used. An intra-oral scanner will record the baseline occlusal relationship (T0) and will be repeated after six months (T5). The control group will also have a standard pre-treatment lateral cephalogram radiograph taken, as well as conventional and three-dimensional stereophotogrammetry at baseline (T0) and after six months (T5). This will allow changes resulting from growth to be assessed whilst no active orthodontic treatment has taken place.
2496848|NCT02923843|Experimental|intervention|Comprehensive Geriatric Assessment
2496851|NCT02923843|No Intervention|control|Standard care
2496902|NCT02923635|Active Comparator|Standard Wide Local Excision group|Group A (35 patients) have standard curative conservative breast surgery without integration of plastic techniques .
2496904|NCT02923635|Active Comparator|Oncoplastic group|Group B(35 patients) have curative oncoplastic surgery in which plastic techniques integrated with oncological procedures
2496945|NCT02923310|Experimental|Osteoarthrits G II and III|Group of treatment
2496949|NCT02923310|Experimental|Osteoarthrits GIV|Group of treatment
2497004|NCT02922972|Experimental|Platelet Rich Plasma|Interventions: Four injections of PRP: The first injection of A-PRP after complete resection of the keloid scar,Three additional injections were administered with a one-month interval.
2497046|NCT02922699|Experimental|Omeprazole 40mg|Omez 40mg OD
2497055|NCT02922699|Active Comparator|Omeprazole 80 mg|Omez 80mg OD
2497123|NCT02922023|Active Comparator|Chronotherapy|Chronotherapy group automatically receives a shift in 1 anti-hypertensive medication to night-time without assessment of ambulatory blood pressure monitor results.
2497128|NCT02922023|Active Comparator|ABPM|ABPM group will have their ambulatory blood pressure monitor results reviewed prior to deciding to change regimen.
2497142|NCT02921815||Patients with myeloid leukemia|All del(5q) Myelodysplastic syndrome (MDS) patients in the all-case surveillance in whom transformation to acute myeloid leukemia has not been documented at the end of the observation period of the all-case surveillance.
2497189|NCT02921620|Experimental|PRX-102|PRX-102 infusions every 2 weeks
2497190|NCT02921620|Placebo Comparator|Placebo|Placebo infusions every 2 weeks
3162212|NCT00457938|Other|"Low fat diet is the drug"|Diet 10% fat versus 35% fat
3162213|NCT00457964|Experimental|Administration of RAD001|
3162214|NCT00458003|Experimental|Phenylephrine|Subject will receive a phenylephrine infusion to prevent and to treat hypotension associated with spinal anesthesia
3162215|NCT00458003|Active Comparator|Ephedrine|Subject will receive an ephedrine infusion to prevent and to treat hypotension associated with spinal anesthesia
3162216|NCT00458016|Experimental|1|
3162217|NCT00458016|Experimental|2|
3162218|NCT00458016|Experimental|3|
3162219|NCT00458016|Experimental|4|
3162220|NCT00458016|Placebo Comparator|5|
2496278|NCT02927288||Military healthy control|Participants in the military control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above. Participants in this group will include service members on Active Duty and those currently serving with National Guard or Reserve forces.
2496285|NCT02927288||Civilian healthy control|Participants in the civilian control group will meet all general requirements for participation but will not have a history of either mTBI/concussion or PTSD, as described above.
3162221|NCT00458029|Experimental|School based intervention|Integration of activities, events, and programs affecting total school food service environment, physical education class, behavior change, promotion, and communications
3162222|NCT00458029|No Intervention|Control|Observational control
2496607|NCT02925533|Experimental|B-701 and Pembrolizumab|"B-701 will be administered every 3 weeks intravenously~Pembrolizumab will be administered every 3 weeks intravenously"
2496664|NCT02924987|Other|Aflibercept injection|Not applicable. There will be no randomization nor stratification to any to study arms or groups.
2496742|NCT02924727|Experimental|LCZ696 (sacubitril/valsartan)|"Following randomization, patients will receive LCZ696 in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Patients will be required to take a total of two pills, (one tablet from the LCZ696 pack and one capsule from ramipril matching placebo pack) twice a day for the duration of the study.~Patients randomized to LCZ who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will receive a valsartan bridge for one day. These patients will receive two doses of valsartan for 1 day in a blinded manner prior to beginning double-blind LCZ696 treatment."
2496743|NCT02924727|Active Comparator|Ramipril|"Following randomization, patients will receive the Ramipril in titrated doses from level 1 up to level 3 (1.25, 2.5 and 5 mg twice daily).~Patients will be required to take a total of two pills, (one capsule from the ramipril pack and one tablet from LCZ696 matching placebo pack) twice a day for the duration of the study.~Patients randomized to ramipril who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization will immediately start on double-blind ramipril; however, to maintain double blind/double dummy of the valsartan bridge, these patients will receive two doses of matching valsartan placebo for 1 day in a blinded manner prior to beginning double-blind LCZ696 placebo."
2497175|NCT02921698||FRED®|
2497185|NCT02921477|Experimental|Bosutinib Treatment Arm|Subjects will be administered the initial dose of bosutinib, with dosage progressively increased over the course of the study. The initial dose of bosutinib is 100 mg tablet, once per day. The dose will be increased as tolerated up to 300 mg per day. The dose will be increased by 100 mg each month if the lower dose is tolerated without significant side effects. That is to say, the subject will take 100 mg/day every day for the first month, 200 mg/day every day for the second month, and 300 mg/day every day for the third month and for the remainder of the study, provided that adverse reactions do not prohibit continuation at this dosage. Stopping and dose reduction rules for reported adverse reactions have been taken from the package insert of bosutinib. The duration of treatment is 1 year.
2497193|NCT02921269|Experimental|Treatment (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3162223|NCT00458081|Experimental|Rimonabant|
3162224|NCT00458081|Placebo Comparator|Placebo|
3162225|NCT00458094|Experimental|1|Participants will receive the peer-supported physical activity intervention
2497430|NCT02920216|Experimental|eligible patient for a salvage surgery|
2497495|NCT02919748|Experimental|Intervention arm|Choral Singing
2497497|NCT02919748|Active Comparator|Control arm|General Health Education Program and Group Activities
2497631|NCT02918786|Active Comparator|Continuous positive airway pressure|After extubation, patients will receive continuous positive airway pressure (CPAP) delivered by the variable generator WhisperFlow System (control) Intervention:Device : CPAP of 5 cmH2O delivered by the variable generator WhisperFlow System for 48 hours
2497634|NCT02918786|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention) Intervention: Device: Nasal high-flow
2497688|NCT02918539||RAmP Registry Patients|Patients who have a) objectively verified cognitive impairment and etiology diagnosed or suspected to be Alzheimer's disease and b) a positive amyloid scan from either an existing amyloid scan that has been interpreted as positive or a florbetapir F 18 PET scan via protocol addendum
2497831|NCT02917733|Experimental|Radiolabelled LY3039478|Single dose of radiolabelled LY3039478 administered orally.
2498015|NCT02916446|Experimental|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, daily administration
3162226|NCT00458094|Active Comparator|2|Participants will receive physical activity without peer support
3162227|NCT00458120|Experimental|1|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
3162228|NCT00458120|Experimental|2|Participants previously vaccinated with rDEN4delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) into the deltoid region of either arm.
3162229|NCT00458120|Experimental|3|Participants previously vaccinated with rDEN2/4delta30(ME) will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN1delta30 vaccine into the deltoid region of either arm.
3162230|NCT00458120|Experimental|4|Participants previously vaccinated with rDEN1delta30 will receive one subcutaneous vaccination (10^3 dose of vaccine) of rDEN2/4delta30(ME) vaccine into the deltoid region of either arm.
3162231|NCT00458120|Placebo Comparator|5|One subcutaneous vaccination with placebo into the deltoid region of either arm.
3162232|NCT00458133|Experimental|1|We randomly assigned 72 individuals to an aerobic exercise training only group.
3162233|NCT00458133|Experimental|2|We randomly assigned 73 individuals to an resistance exercise training only group.
3162234|NCT00458133|Experimental|3|We randomly assigned 76 individuals to a combination of aerobic plus resistance training group.
3162235|NCT00458133|Placebo Comparator|4|We randomly assigned 41 individuals to a stretching and relaxation group.
3162236|NCT00458146|Experimental|1|MM-093
3162237|NCT00458146|Placebo Comparator|2|Placebo
3162238|NCT00458159|Experimental|1|
2496288|NCT02927483|Active Comparator|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
2496354|NCT02927015|Experimental|Purple Majesty potato chips|Purple Majesty potato chips
2496362|NCT02927015|Experimental|Mountain Rose potato chips|Mountain Rose potato chips
2496366|NCT02927015|Experimental|White potato chips|White potato chips
2496368|NCT02927015|Experimental|Crackers|Crackers
2496482|NCT02926339|Experimental|Teens Against Tobacco Use presentation|Students in the intervention group will receive anti-tobacco presentations from Teens Against Tobacco Use Members
2496484|NCT02926339|No Intervention|Control|Students in this group will receive a control presentation from their physical education teachers on a topic unrelated to tobacco.
2496513|NCT02925897|Experimental|Intervention|participants will receive their usual treatment from nurses who have had some training in behaviour change and motivational interviewing.
2496517|NCT02925897|No Intervention|Control|The participants will receive their usual treatment from nurses who have had no additional training in behaviour change and motivational interviewing.
2496556|NCT02925572|Experimental|Concentric cycling exercise (CON)|40 obese adolescents will be randomized into 2 groups: CON or EXC
2496557|NCT02925572|Experimental|eccentric cycling exercise (EXC)|40 obese adolescents will be randomized into 2 groups: CON or EXC
3195424|NCT00839592|Experimental|Electroacupuncture|"Acupoints will be treated at bilateral Ear Shenmen, Sishencong (EX-HN1), Anmian, and unilateral Yintang (EX-HN3) and Baihui (GV20).~Acupuncture will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (CEFAR Acus II, Lund, Sweden) will be connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.45 ms square wave pulses and constant current. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3195425|NCT00839592|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the same acupoints as stated in the electroacupuncture group. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
2496682|NCT02924909|Experimental|induction carboplatin paclitaxel|carboplatin AUC=6 21 day cycle for 2 cycles paclitaxel 175 mg/m2 21 day cycle for 2 cycles radiotherapy 4500 cGy in 25 fractions carboplatin AUC=2 in a week regimen during radiotherapy paclitaxel 50 mg/m2 in a week regimen during radiotherapy Minimal Invasive Surgery
2496720|NCT02924649|Experimental|Early Intensive mobilisation|As early as possible the experimental group will receive mobilisation on a tilt table for up to 20 minutes 5 days a week for four weeks using an ERIGO tilt table. If orthostatic hypotension occur the patient is moved to supine until parameters are stable again. Hereafter the mobilisation will continue until the patient has completed 20 minutes of standing exercise.
2496731|NCT02924649|No Intervention|Standard care group|The standard care group will receive daily mobilisation to the seated position.
3195426|NCT00839605||Dexmedetomidine|Those requiring thoracic surgery and receiving dex
3195427|NCT00839605||placebo|Group having thoracic surgery and not receiving dex drug
2496903|NCT02923622||Traditional Chinese and Western medicine combined group|
2496905|NCT02923622||Traditional Chinese medicine group|
2496906|NCT02923622||Western medicine group|
3195428|NCT00839644|Active Comparator|2|
3195429|NCT00839644|Active Comparator|3|
2496983|NCT02922933|Active Comparator|Omeprazole|"Treatment A: 5mg entinostat on Day 1~Treatment B: 20mg omeprazole for 5 days with 5mg entinostat on Day 1"
2496987|NCT02922933|Active Comparator|Famotidine|"Treatment C: 5mg entinostat on Day 1~Treatment D: 20mg famotidine on Days -1 and 1 with 5mg entinostat on Day 1"
2496991|NCT02922933|Active Comparator|Acidic Beverage|"Treatment E: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with water~Treatment F: 20mg omeprazole for 5 days with 5mg entinostat on Day 1 taken with an acidic beverage"
2497080|NCT02922426|Experimental|ALKS 3831|Oral, bilayer tablet
2497081|NCT02922426|Active Comparator|Olanzapine|Oral, bilayer tablet
2497082|NCT02922426|Placebo Comparator|Placebo|Oral, bilayer tablet
2497100|NCT02922075|Placebo Comparator|CTL|No soft tissue graft was used. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
2497105|NCT02922075|Experimental|CM|Patient received a collagen matrix graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
3195430|NCT00839644|Active Comparator|1|
3195431|NCT00839657|Experimental|1|Genotype-guided dosing algorithm for warfarin
3195432|NCT00839657|Active Comparator|2|Clinical-guided dosing algorithm for warfarin
3195433|NCT00839670|Active Comparator|Modified Therapy|
3195434|NCT00839670|Active Comparator|Standard Therapy|
3195435|NCT00839683|Active Comparator|simvastatin|
3195436|NCT00839683|Active Comparator|Dapagliflozin + simvastatin|
3195437|NCT00839683|Active Comparator|Dapagliflozin|
3195438|NCT00839683|Active Comparator|valsartan|
3195439|NCT00839683|Active Comparator|Dapagliflozin + valsartan|
3195440|NCT00839709||depletion immunosuppression|
3195441|NCT00839709||no depletion immunosuppression|
3195442|NCT00839722|Experimental|1|fertility after embolization
3195443|NCT00839735||COPD|Chronic obstructive pulmonary disease
3195444|NCT00839735||Asthma|
3195445|NCT00839735||Healthy controls|
3195446|NCT00839748||asthmatics|asthmatics registry for those interested in future asthma studies
3195447|NCT00839761|Experimental|iron fortified rice group|
3195448|NCT00839761|Placebo Comparator|iron drop group|
2496296|NCT02927236|Experimental|Pilot|P1 is designed to establish safety and tolerability criteria for administering iTBS to treatment seeking cocaine users, initially as in-patient followed by an out-patient cohort
3195449|NCT00839774|Experimental|1|Whole yellow pea flour
3195450|NCT00839774|Experimental|2|Fractionated yellow pea flour
2496511|NCT02925988|Other|EEG monitoring|Neonates will receive their aEEG monitoring as soon as the indication for monitoring is established, and cEEG electrodes will be applied in parallel, as soon as an EEG technician is available, which should usually be within less than 16 hours, in many cases within 1-4 hours.
2496595|NCT02925598|Experimental|I-gel LMA|I-gel LMA insertion: I-gel insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2496598|NCT02925598|Experimental|AuraGain LMA|AuraGain insertion:AuraGain LMA insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2496601|NCT02925598|Experimental|Endotracheal tube (ETT)|Endotracheal tube insertion: Endotracheal tube (ETT) insertion was done in supine position and with a standard gel pillow with the patient's head on following anesthesia induction. The insertion was verified with the manual ventilation of the patient and EtCO2 waveform.
2496685|NCT02925052|Experimental|GTG|Gastric tube placement using the Gastric Tube Guide
2496689|NCT02925052|Other|Conventional|Gastric tube placement using a conventional method, according to local protocol.
3162239|NCT00458198|Experimental|1|Participants will receive integrated behavioral therapy
3162240|NCT00458198|Active Comparator|2|Participants will receive integrated behavioral therapy after a 12-week waitlist period
2496855|NCT02923869|Active Comparator|Group L|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine
2496859|NCT02923869|Active Comparator|Group B|Children will receive 0.15 ml/kg of 0.2% Bupivacaine
2496895|NCT02923596||Patients with Ear Keloids|Records of Patients with Ear Keloids will be reviewed. Data and photographs will be analysed.
2496896|NCT02923596||Patients with Neck Keloids|Records of Patients with Neck area Keloids will be reviewed. Data and photographs will be analysed.
2496899|NCT02923596||Patients with Scalp Keloids|Records of Patients with Scalp Keloids will be reviewed. Data and photographs will be analysed.
2496946|NCT02923258|Experimental|Experimental|Concurrent Chemoradiotherapy With Docetaxel and IMRT
2496950|NCT02923258|Active Comparator|Control|Concurrent Chemoradiotherapy With Cisplatinum and IMRT
2497072|NCT02922452|Experimental|BMS-986141 and Dilitazem|
2497102|NCT02922166|Experimental|SRX246|SRX246 oral dosage capsules, daily dose to be taken bid, for up to 7 days
2497107|NCT02922166|Placebo Comparator|Placebo|Placebo oral dosage capsules, daily dose to be taken bid, for up to 7 days
2497147|NCT02921867|Experimental|Intervention group|Simulation-based training in nine modules with optional training times and ending with an obligatory certification test before traditional training is started. Traditional training time unaltered: six weeks.
2497149|NCT02921867|No Intervention|Traditional training|Six weeks focused stay at an ultrasound ward with day to day one-on-one supervision (current practise)
2497184|NCT02921568|Other|All patients|All patients will be imaged on the P200TE and Spectral OCT/SLO devices.
2497351|NCT02920710|Experimental|Experimental: H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 48 weeks on therapy.
2497427|NCT02919917|Experimental|Usual Care Group|"Individuals randomized to the usual care group will receive BP management according to the usual care in current practice in the SCI Rehabilitation Unit.~Will receive treatment only if they experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.).~Treatment to lessen or eliminate these symptoms of low blood pressure will be guided by the attending physician and can include physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.) and/or midodrine ."
2497429|NCT02919917|Experimental|BP Threshold Treatment Group|"Individuals assigned to the BP threshold treatment group will receive BP management, regardless of symptoms, to maintain systolic BP between 111-135 mmHg for males and 101-135 mmHg for females for the duration of their in-patient hospital stay.~This treatment will be started based on your low BP, regardless of if you experience symptoms that are associated with low BP (dizziness, lightheadedness, nausea, blurry vision, loss of consciousness, etc.). Before you start on any medication you will receive physical countermeasures to increase blood pressure (abdominal binders, comperssion stockings, etc.).~If your blood pressure remains low after using these countermeasures you will begin to take midodrine 3 times a day as described in the intervention section. The dosage will increase and be stopped once until your seated SBP is between 111-135 mmHg."
3162241|NCT00458224|Experimental|Parental counseling|Life style counseling
3162242|NCT00458263|Experimental|single arm|
3162243|NCT00458276|Experimental|1|Tezosentan
3162244|NCT00458276|Placebo Comparator|2|Placebo
3162245|NCT00458289|No Intervention|1|P-containing meal alone
3162246|NCT00458289|Active Comparator|2|P-containing meal AND single 1 g oral dose of chewed lanthanum carbonate
3162247|NCT00458289|Active Comparator|3|P-containing meal and single 1 g oral dose of lanthanum carbonate crushed into a fine powder
3162248|NCT00458354|Experimental|Spinal Sealant|Dural repair with the Spinal Sealant System.
3162249|NCT00458354|Active Comparator|Standard Methods|Dural repair with standard methods such as the closing of the dura with stitches.
3162250|NCT00458367||001|Open label risperidone long acting injectable intramuscular injections every 2 weeks for 26 weeks flexible dose 25 to 50 mg
3162251|NCT00458419|Placebo Comparator|A: naloxone; B: normal saline|Arm A: IV naloxone Arm B: IV normal saline
3162252|NCT00458445|Experimental|SPD465 then Placebo|
3162253|NCT00458445|Experimental|Placebo then SPD465|
3162254|NCT00458458|Active Comparator|NA alone|Norethindrone Acetate (NA) 5mg taken 1-3 tabs orally every night for duration of treatment
3162255|NCT00458458|Active Comparator|LD then NA|Lupron Depot(LD) given intramuscularly every 12 weeks for total of 24 weeks then switched to Norethindrone Acetate (NA) taken 1-3 tablets orally every night for remainder of treatment
2496310|NCT02927249|Placebo Comparator|Arm II (Placebo)|Patients receive placebo PO QD for five years in the absence of disease progression or unacceptable toxicity.
2497454|NCT02919865|Other|MRI perfusion imaging|Patients who have received chemoradiation for high grade gliomas and who subsequently developed progressive enhancing lesions on follow-up MR will be asked to participate in this study.
2497501|NCT02919579|Experimental|Part A: Sequence ABC (Placebo+Alcohol+Esketamine)|Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 [Treatment A] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 [Treatment B] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 [Treatment C] in Period 3.
2497504|NCT02919579|Experimental|Part A: Sequence BCA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
2497508|NCT02919579|Experimental|Part A: Sequence CAB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
2497511|NCT02919579|Experimental|Part A: Sequence CBA (Placebo+Alcohol+Esketamine)|Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
2497514|NCT02919579|Experimental|Part A: Sequence ACB (Placebo+Alcohol+Esketamine)|Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
2497516|NCT02919579|Experimental|Part A: Sequence BAC (Placebo+Alcohol+Esketamine)|Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
2497519|NCT02919579|Experimental|Part B: Placebo+Esketamine|Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.
2497596|NCT02919150||Myotonometric and isokinetic measurement|"Myotonometric assessment: into the site of the latent medial myofascial trigger point of the soleus muscle and distal to the lateral medial myofascial trigger point of the soleus muscle but into the same taut band.~Isokinetic assessment: triceps surae muscle tone will be quantified by measuring the passive range of motion for ankle dorsiflexion and the resistance to passive ankle dorsiflexion at slow and fast velocity."
3195451|NCT00839774|Experimental|3|White wheat flour
3195452|NCT00839787|Experimental|Morphine|Morphine Sulfate: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given.
2497754|NCT02918253|Experimental|Tumour visible on MRI|Targeted focal HDR Brachytherapy to dominant lesion +/- whole-gland elective dose
2497755|NCT02918253|Active Comparator|No tumour visible on MRI|Whole-gland HDR Brachytherapy
2497835|NCT02917655|Experimental|Educational Program Associated (EPA)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital on months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; on month 4 for a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
2497838|NCT02917655|Other|Educational Program Isolated (EPI)|"45 patients will participate in two days of lectures two-months apart on the subject of knee OA.~Answer WOMAC, Lequesne, Numerical Rating Scales (NRS), IPAQ, Tampa Scale for Kinesiophobia (TSK); perform the STS30, TUG, six-minute test have calculated BMI and body fat percentage at baseline evaluations, 6, 12 and 24 months."
2497929|NCT02917161|Experimental|Prostatic Artery Embolization (PAE)|PAE is performed 6weeks before RALP
2497987|NCT02916706|Experimental|Teneligliptin 20mg|Teneligliptin (20mg once daily) for 24 weeks
2497988|NCT02916706|Placebo Comparator|Placebo|Placebo for 24 weeks
2497995|NCT02916355|Experimental|Normal BMI|Healthy young men, normal BMI (BMI >18 and ≤28 kg/m2) will receive interventions Anakinra and sodium Chloride (NaCl)
2497996|NCT02916355|Experimental|Overweight|Healthy young men (BMI >30 and ≤35 kg/m2) will receive interventions Anakinra and NaCl
2498069|NCT02916134|Active Comparator|Operative Intervention|Laparoscopic +/- open appendicectomy, with antibiotics at induction and 3 further doses of intravenous antibiotics. Co-amoxiclav, or cefuroxime and metronidazole if previous rash-allergy to penicillin.
2498078|NCT02916134|Experimental|Antibiotic Treatment|Intravenous antibiotics until clinical improvement and then 5 further days of oral antibiotics. Co-amoxiclav, or if rash-allergy to penicillin, cefuroxime and metronidazole.
2498148|NCT02915692||ERASE Silver Coated Foley Catheters|Subjects given silver catheters from an ERASE CAUTI Tray.
2498152|NCT02915692||Comparator Silver Coated Catheter|Comparator silver urinary catheter
2498170|NCT02915211|Experimental|Consumption of Keyo|Participants will consume their normal KD and take Keyo as advised by the lead dietitian.
2498235|NCT02915068|No Intervention|Control|Physicians do not receive focused education and training on patient-centered communication with the EHR
2498236|NCT02915068|Experimental|EHR-PACE|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
2498285|NCT02914626|Experimental|Ranibizumab|Standard of care therapy plus intravitreal ranibizumab injections
2498288|NCT02914626|Sham Comparator|Control|Standard of care therapy
2498319|NCT02914392||Fetal congenital heart disease cases|Gravidas with fetal congenital heart disease diagnosed by fetal echocardiography
2498320|NCT02914392||Matched Controls for fetal congenital heart disease cases|Gravidas without fetal congenital heart disease
2498383|NCT02914145|Other|Participants|Any individual from the study area who participates and is medicated with DHAp in the mass drug administration campaign
2498418|NCT02913820||snowfall >5cm/d|impact of snowfall and its correlation with acute myocardial infarctions is analyzed. Other precipitation (rainfall) changes in atmospheric pressure and temperature will be variables to be corrected for.
2499079|NCT02908971||Healthy control|The control group will included children (at a rate of 2:1) who will be assigned randomly from the healthy population at the initial cohort, and who will agree to participate.
3195453|NCT00839787|Placebo Comparator|Placebo|Normal saline
3195454|NCT00839813|Experimental|Yoga|10 week trauma-sensitive yoga classes
2496358|NCT02926872||Entire Study Population|Male or female patients who are between 2 and 16 years of age (inclusive) will be eligible for the study if they meet all components of Criterion A and/or Criterion B below, provided that these abnormalities are of unknown or unconfirmed etiology and the patient has not previously had a normal LAL enzyme activity result, has not received treatment with sebelipase alfa (Kanuma), and has no evidence of neurological dysfunction within the past year. (Note: Female patients who are of childbearing potential or are pregnant may participate in this study.)
2496465|NCT02926456||Cohort 1|HIV-1-infected patients being in stable ritonavir-boosted Antiretroviral (ARV) treatment with Protease Inhibitors (PIs) (either darunavir 800 milligram [mg] each day -based or not) since at least twelve months and virologically suppressed (HIV-RNA less than [<]50 copies/milliliters) since at least six months.
2496519|NCT02925780|Experimental|Resin infiltration|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated using the resin infiltrant Icon (DMG, Germany). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
2496523|NCT02925780|Active Comparator|Microabrasion|"The labial surface of fluorosed teeth (upper front teeth) that are selected for this group will be treated by microabrasion using the microabrasive material Opalustre (Ultradent, USA). This is a minimally invasive treatment to improve the aesthetics by masking the white spots."
2496596|NCT02925507||Healthy Controls|Healthy patients with no neurologic impairments or disease
2496599|NCT02925507||Stroke Subjects|Patients with new onset stroke for ischemic, hemorrhagic or TIA
2496931|NCT02923362||Laparoscopic Fundoplication Group|This group of patients are surgical candidates based on preoperative testing results for laparoscopic fundoplication antireflux procedure and possible hiatal hernia repair.
2496934|NCT02923362||LINX Antireflux Device Group|This group of patients are surgical candidates based on preoperative testing results for the laparoscopic LINX antireflux device placement and possible hiatal hernia repair.
2497028|NCT02922803|Active Comparator|Vitamin D insufficient|Subjects with Vitamin D level in blood > 25 nmool/L < 50 nmol/L will be treated with 1 combination tablet of Vitamin D3/calcium per day
2497029|NCT02922803|Active Comparator|Vitamin D deficient|Subjects with Vitamin D level in blood < 25 nmol/L (25-OHD) will be treated with 2 combination tablets of Vitamin D3/calcium per day
2497073|NCT02922439|Experimental|Tailored Intervention|Individuals will interact with a chronic disease self-management application that provides information tailored to age, race, language (English or Spanish) and level of health literacy.
2497074|NCT02922439|Active Comparator|Control|Individuals will interact with a chronic disease self-management application that provides the same information as the experimental intervention but is not personally tailored to level of health literacy.
2497116|NCT02922101|Experimental|Audit and Feedback with toolbox|Access to an online dashboard that provides insight into clinical performance on quality indicators for pain management; including a quality improvement toolbox to facilitate planning and executing actions. Participating ICUs will receive one educational outreach visit and brief monthly telephone calls.
2497124|NCT02922101|Active Comparator|Audit and Feedback without toolbox|Same intervention, but without access to the quality improvement toolbox.
3162256|NCT00458497|Experimental|1|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
3162257|NCT00458497|Placebo Comparator|2|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric.
2497213|NCT02921373|Experimental|Prostate Cancer Patients|"Up to 6 Male prostate cancer patients with metastatic, castration resistant prostate cancer will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
2497219|NCT02921373|Experimental|Healthy Volunteers|"Up to 6 male or female healthy volunteers will be enrolled.~19F Cell Sense-labeled PBMC (3 million cells) will be injected intradermally into the upper thigh of each participant above the inguinal lymph node. MRI will be used to image the administration site."
2497388|NCT02920411|Experimental|Combined dermatological treatment|"A combined treatment of two emollient products will be applied:~Pediatopic treatment cream during acute stages of atopic dermatitis and~Pediatopic body lotion during stable stages"
2497452|NCT02920008|Experimental|guadecitabine|Guadecitabine will be given SC at a dose of 60 mg/m2 in 28-day cycles (delayed as necessary to allow blood count recovery).
2497453|NCT02920008|Active Comparator|Treatment Choice (TC)|"High intensity~Low intensity~Best supportive care (BSC)."
2497551|NCT02919137|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497879|NCT02917304|Experimental|GC3110A vaccine group|Participants administered a single dose of GC3110A(Quadrivalent Influenza Vaccine).
3162258|NCT00458510|Experimental|Fentanyl, Open-Label treatment|All patients take NasalFent at effective dose to treat up to four episodes of breakthrough cancer pain per day
3162259|NCT00458549|Experimental|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
3162260|NCT00458549|Placebo Comparator|Corn Oil|Oral 8g once a day for 21 days prior to (biopsy) surgery
3162261|NCT00458562||HIV+, <CIN2|HIV positive women without CIN2-3 or worse
3162262|NCT00458562||HIV-, no >=CIN3 biopsy, HR HPV+|HIV negative women without biopsy-proven CIN3 or worse, and with high risk HPV infection
3162263|NCT00458562||HIV-, <=CIN1, HPV- at screening|HIV negative women who are <= CIN1 and HPV negative at screening
3162264|NCT00458575|Experimental|CNTO 2476|Participants 1 to 4: advanced retinitis pigmentosa (RP) with light perception only (LP); Participant 5: combination visual acuity of LP in the treated eye and no better than hand motion (HM) in the fellow eye; and Participants 6 to 9: advanced RP with hand motion (HM) will receive different dose levels of CNTO 2476.
2496427|NCT02926521|Active Comparator|Dressing C|Dressing C: a nerve block catheter sealed with 2-octyl cyanoacrylate liquid adhesive (Dermabond), trailing catheter affixed with Pajunk anchor, all covered with Tegaderm
2496429|NCT02926521|Active Comparator|Dressing D|Dressing D: a nerve block catheter sealed with 2-octyl cyanoacrylate (Dermabond), trailing catheter affixed with Pajunk anchor, skin treated with gum mastic liquid adhesive (Mastisol), all covered with Tegaderm
2496446|NCT02926235|Experimental|Amino Acid|Patients will be asked to ingest 20g of EAA o two times a day between meals 1 week prior and 2 weeks postoperatively.
2496447|NCT02926235|Placebo Comparator|Placebo|Patients will be asked to ingest 20g of placebo two times a day between meals 1 week prior and 2 weeks postoperatively.
2496472|NCT02926170|Experimental|rivaroxaban|Rivaroxaban 20 mg per day
2496473|NCT02926170|Active Comparator|acenocumarol|INR adjusted dose
2496530|NCT02925884|Experimental|Gunnar OTC Glasses Condition|Intervention: Gunnar Over-The-Counter Glasses with lens (subjects will wear the glasses with lens while performing visual tasks on computers.
2496533|NCT02925884|No Intervention|Control Condition|Subjects will be wearing an identical frame without any lens while performing visual tasks on computers.
3162265|NCT00458601|Experimental|CDX-110 with GM-CSF|
3162266|NCT00458653|Experimental|Group A|Post-transplant vaccination
3162267|NCT00458653|Experimental|Group B|Pre- and post-transplant vaccination
3162268|NCT00458679|Experimental|Vaccine|autologous B-CLL vaccine expressing CD40L and IL2
3162269|NCT00458731|Experimental|Treatment (cediranib maleate and bevacizumab)|"Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of bevacizumab and cediranib maleate until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity."
3162270|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 200 mg/m2
3162271|NCT00458809|Experimental|Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin 250 mg/m2
3162272|NCT00458861|Experimental|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
3162273|NCT00458861|Placebo Comparator|Placebo|Subcutaneous administration of placebo given every other week for 12 weeks
3162274|NCT00458874|Experimental|Receive CIMT Results (R-CIMT)|This group will receive visual feedback of their CIMT results on a weekly basis.
3162275|NCT00458874|No Intervention|Withhold CIMT Results (W-CIMT)|The W-CIMT group will not receive their CIMT results until the end of their study participation.
3162276|NCT00458887||Ancillary/Correlative (ototoxicity assessment)|"Patients undergo hearing tests (conventional, otoscopy, ultrahigh frequency, and otoacoustic emission testing) for management of therapy complications before the first course of planned cisplatin, before each subsequent course of cisplatin, and 4 weeks after the last dose of cisplatin.~Patients who are scheduled to receive hematopoietic progenitor stem cell transplantation undergo hearing tests for management of therapy complications before the transplantation and 4 weeks after transplantation."
3162277|NCT00458900|Experimental|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
3162278|NCT00458978|Experimental|Treatment (enzyme inhibitor)|Patients receive oral cediranib maleate once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3162279|NCT00459030|Experimental|Print Communication|Cancer screening educational information mailed to patient's home one time after signing consent.
3162280|NCT00459030|Experimental|Electronic communication|Cancer screening educational information delivered via a password protected internet site.
3162281|NCT00459030|Active Comparator|No Health Communication|No additional cancer screening education information sent to patient.
3162282|NCT00459160|Experimental|Low MAP Group|Hypotensive Group with a target minimum MAP of 50 mmHg
3162283|NCT00459160|No Intervention|High MAP group|Non experimental group: These patients will have a target minimum MAP of 65 mm Hg
3162284|NCT00459212|Experimental|Arm I|Patients receive GTI-2040 IV continuously on days 1-4 and 15-18.
3162285|NCT00459225|Active Comparator|1|The parent/guardian will be educated on the iron study and provided the opportunity to ask questions. If the parent/guardian chooses to participate in the study, the parent/guardian will give informed consent for the patient to be placed in either Group I or Group II, based upon guardian/parents' choice for participation in the iron arm of the study. Group I will be randomized in a 1:1 ratio in this open label trial to either receive or not receive iron. Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
3162286|NCT00459225|No Intervention|2|Group II will not receive iron but will be a participant in the study and follow the course of the non-iron randomized patients.
3162287|NCT00459264|Active Comparator|1|Folic Acid
3162288|NCT00459264|Placebo Comparator|2|Matching placebo for folic acid
3162289|NCT00459277|Experimental|Nasalfent, Fentanyl Citrate Nasal Spray|
3162290|NCT00459277|Placebo Comparator|Placebo Spray|
3162291|NCT00459407|Experimental|Arm I (green tea catechin extract)|"Patients receive oral defined green tea catechin extract daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
3162292|NCT00459407|Placebo Comparator|Arm II (placebo)|"Patients receive oral placebo daily for 4-7 weeks.~All patients undergo surgery one day after the last dose of study agent."
3162293|NCT00459420|Placebo Comparator|Placebo|
3162294|NCT00459420|Experimental|Caffeine|
3162295|NCT00459433|Experimental|1|psychosocial intervention
3162296|NCT00459433|Active Comparator|2|Usual care
3195455|NCT00839813|No Intervention|Women's Health Education|10 weeks of women's health education classes as an attentional control group
2496770|NCT02924181|Active Comparator|Lt PV CF guided/rt PV CF blinded|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed with contact force information guidance. Then, right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
3195456|NCT00839826|Active Comparator|Arm 2|
3195457|NCT00839826|Experimental|Arm 1|
2496445|NCT02926313|Experimental|Individualized Seating provision|This group of participants were provided with a seating system that was specifically configured to match their individual postural care needs.
2496463|NCT02926183|Experimental|Gemcitabine plus nab-paclitaxel|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
2496508|NCT02925832|Experimental|Group B|Deep Topical Fornix Nerve block anesthesia using bupivacaine and proparacaine
2496510|NCT02925832|Experimental|Group R|Deep Topical Fornix Nerve block anesthesia using ropivacaine and proparacaine
3162297|NCT00459472|Other|Training|laparoscopic training curriculum: all general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
3162298|NCT00459485|Experimental|Zinc supplement (20 mg)|Daily intake of 20 mg supplementary zinc
3162299|NCT00459485|Experimental|Zinc supplement (10 mg)|Daily intake of 10 mg supplementary zinc
3162300|NCT00459485|Placebo Comparator|Placebo supplement|Daily intake of placebo supplement
3162301|NCT00459524||Questionnaire|AML and MDS Patients
2496809|NCT02924168|Experimental|Active Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, at 3.5 to 4 bar air pressure (resulting in an energy flux density [EFD] of approximately 0.07 mJ/mm2) and at 15Hz frequency. A total of 4 sessions will be performed.
2496811|NCT02924168|Sham Comparator|Sham Radial Shockwave|Every patient will receive 5,000 continuous pulses per treatment session, without air pressure (resulting in no EFD) and at 15Hz frequency. A total of 4 sessions will be performed.
3174966|NCT00628784|Experimental|Group 4|Diagnosis of severe dysplasia within esophageal squamous mucosa on pathology review. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). EUS with no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa.
2496886|NCT02923687|Active Comparator|Buccal infiltration of Ketorolac|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, case group will receive a supplemental buccal infiltration of 30 mg/mL of Ketorolac tromethamine (Alborz-Darou Co. Qazvin, Iran).
2496887|NCT02923687|Placebo Comparator|Buccal infiltration of Normal saline|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the control group will receive normal saline as placebo.
2496937|NCT02923401|Experimental|High-Intensity Interval Training (HIIT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2496939|NCT02923401|Experimental|Moderate-Intensity Continuous Training (MICT) Group|"Participants come to the Energy Balance Center to exercise 3 times a week for 12 weeks.~Participants receive written materials and instructions on how to perform their exercises.~Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2496940|NCT02923401|Active Comparator|Control Group|"Participants receive written materials and counseling by an exercise physiologist.~Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals.~Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks.~One (1) time each month, participant attends a motivational session."
2497007|NCT02922946|Experimental|Entinostat 5mg in 2-Way Crossover|"Treatment A: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment B: 5mg entinostat 2 hours after the completion of a meal and followed by a 1-hour fast."
2497014|NCT02922946|Experimental|Entinostat 5mg in 3-Way Crossover|"Treatment C: 5mg entinostat following an overnight fast and followed by a 4-hour fast.~Treatment D: 5mg entinostat following an overnight fast and 1 hour before the start of a meal.~Treatment E: 5mg entinostat 2 hours after the completion of a meal and followed by a 4-hour fast."
2497148|NCT02921880|Experimental|Cardiac Rehabilitation|Patients will return to the out-patient clinic at 4 weeks post - TAVR and research consent will be re-affirmed. Patients will be randomised to receive a programme of cardiac rehabilitation or routine care at this point. Patients randomised to receive cardiac rehabilitation will meet the cardiac rehab team and undergo baseline assessment for the programme. This involves recording height, weight, blood pressure, oxygen saturation and heart rate and rhythm. An individualised programme will be established to meet the needs of each patient. The patients will undergo a 6 week programme of cardiac rehab. Patients who are not allocated to the intervention group will not receive a cardiac programme and will have access to the TAVR nurse specialist team as would be usual care.
2497153|NCT02921880|No Intervention|Standard of care|15 patients will be randomised to receive a programme of cardiac rehabilitation, and 15 patients will receive standard of care which does not include a routine rehabilitation programme.
2497194|NCT02921529|Experimental|TEAS|Patients were given 30min of TEAS(transcutaneous electrical acupoint stimulation) before anesthesia and 1,2,3 day after surgery
2497197|NCT02921529|Sham Comparator|false stimulation|Attach electrodes without electric current
2497281|NCT02921009|Experimental|Crosslinking at different fluence rates|The study will investigate the effectiveness of Transepithelial riboflavin .25% treated with Ultraviolet light at fluence rates of 9mw/cm2 and 18mw/cm2 in the treatment of diagnosed keratoconus, pellucid marginal degeneration or post-LASIK ectasia.
2498019|NCT02916602|Active Comparator|Reference|HCP0605
3195458|NCT00839839|Experimental|Oocyte Vitrification|
3195459|NCT00839865|Experimental|herb ointment dressing change group|This group of patients in the ointment dressing every 2 days until Wound Healing or 6 months
3195460|NCT00839865|No Intervention|Conventional dressing change group|This group of patients in the Conventional dressing every 2 days until Wound Healing or 6 months
2496574|NCT02925247|Other|patient with atrial fibrillation|
2496645|NCT02925195|Experimental|Active Treatment|
2496646|NCT02925195|Placebo Comparator|Placebo|Placebo
2496684|NCT02924870|Active Comparator|Control group|Conventional management. Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
2496690|NCT02924870|Experimental|Intervention group|Conventional management plus health education program. In addition to conventional treatment and follow-up, the patients will be referred to a nursing consultation for perform two health education sessions, at 15 and 30 days after hospital discharge.
2496722|NCT02924558|Experimental|Egg protein/unsaturated fatty acid|8% higher protein energy (from egg protein) and 8% higher fat energy (from unsaturated fatty acids); approximately 42/23/35% kcal from carbohydrate/protein/fat, respectively
2496733|NCT02924558|Placebo Comparator|Control|16% higher carbohydrate energy; approximately 58/15/27% kcal from carbohydrate/protein/fat, respectively
2496753|NCT02924311||Previously treated patient|Already treated with any other treatment such as an anti-VEGF agent (other than IVT aflibercept), macular laser photocoagulation (laser), intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
2496756|NCT02924311||Naïve patient|Not previously treated with an anti-VEGF agent, macular laser photocoagulation (laser) or intravitreal steroid injection or implant (steroids) and initiating treatment with IVT aflibercept
2496761|NCT02924311||Entire study population|Already treated patient with any other treatment such as an anti-VEGF agent (other than intravitreal aflibercept), macular laser photocoagulation, intravitreal steroid injection and initiating treatment with intravitreal aflibercept and not previously treated patients with an anti-VEGF agent, macular laser photocoagulation or intravitreal steroids injection and initiating treatment with intravitreal aflibercept
2496834|NCT02924116|Experimental|Bioboosti|Treatment with the Bioboosti device for two weeks. The device produces a pulsed micro-magnetic field. Subjects will use it once a day for about one hour, before habitual sleep time.
2496838|NCT02924116|Experimental|Sustained Efficacy|"Treatment with Bioboosti device for a year. In order to see if the device has sustained efficacy in treating insomnia.~Subjects will use it once a day for about one hour, before habitual sleep time."
2496840|NCT02924116|Experimental|Insomnia and migraine|Treatment with the Bioboosti device for a month. Subjects will use it once a day for about one hour, before habitual sleep time.
2496888|NCT02923674|Other|Weight loss + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3)."
2496890|NCT02923674|Other|Weight loss + exercise|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
2496892|NCT02923674|Other|Weight loss + exercise + sitless|"All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass.~Participants will be encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).~Participants will be asked to perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week."
2496951|NCT02923336|Other|Smart pill|Single group, before and after, the same group is going to be its own control
2497024|NCT02923037|Experimental|Supportive Care (Yoga)|Patients undergo an initial yoga evaluation for 60 minutes. Patients then undergo their first guided yoga practice session for 30-60 minutes and subsequent guided yoga sessions for 30-90 minutes 3 times a week for 4 weeks, and twice a week for an additional 4 weeks. Patients are also encouraged to complete home yoga practice for 30 to 90 minutes every day for 8 weeks. They will have tape measurement of arms and ldex measurement of arms. Quality-of-Life Assessment will also be made.
2497053|NCT02922556|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training (Moodify) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
2497057|NCT02922556|Active Comparator|Active Comparator|Commercially available computerized training (Games) requiring a total maximum of 50 treatment hours, 3-5 times weekly, 30-45 minutes each session.
2497109|NCT02922270||Patients|Who have received PD as renal replacement therapy (RRT) over a period of 20 years.
2497150|NCT02921906|Experimental|Neonatal diabetes|People with neonatal diabetes due to mutations in the KCNJ11 gene who are treated with sulphonylureas and not on insulin.
2497152|NCT02921906|Active Comparator|Non-diabetic controls|People without diabetes.
2497155|NCT02921906|Active Comparator|Controls with Type 2 Diabetes|People with Type 2 diabetes who are treated with sulphonylurea medication.
3195461|NCT00839878||A|
3195462|NCT00839891|Placebo Comparator|3|"Group 1: 56 subjects to receive active study drug (VI-0521) at steady state, PHEN/TPM 7.5/46 (a potential therapeutic dose), escalating to PHEN/TPM 22.5/138 (a supra-therapeutic dose);~Group 2: 28 subjects to receive placebo preceded by a single oral dose of moxifloxacin on Day 2;~Group 3: 28 subjects to receive placebo followed by a single oral dose of moxifloxacin on Day 24;"
3195463|NCT00839904|Experimental|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
3195464|NCT00839904|No Intervention|control|no intervention
3195465|NCT00839943|Active Comparator|ozone|obese vs non-obese women
2497260|NCT02920827|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25 mg dapivirine
3195466|NCT00839943|Active Comparator|air|obese vs non obese women
2496493|NCT02926352|Sham Comparator|Sham LLLT alone|Participants will receive 8 minutes of Sham Low-Level Laser Therapy stimulation. The laser will be targeted first at the left forehead point F3 and then at the right forehead point F4 (on the EEG electrode placement system). The procedure will consist of alternating between each of these points after each minute. However, each point will receive only a brief (5-second) treatment to the intended site on the forehead, followed by 55 seconds of no treatment, for each one-minute cycle, functioning as a placebo dose of the treatment.
2496575|NCT02925286|Experimental|Intervention group|Five organizations will get the intervention during fall/winter 2016.
2496582|NCT02925286|No Intervention|Wait-list group|Five organizations will be on the waitlist for 12 months and then get the intervention.
2496669|NCT02925156||Ghana|Participants in the Ghana cohort are located at or near the the village of Nkwantakese which is approximately 20 kilometers outside of Kwame Nkrumah University of Science and Technology in Kumasi.
2496674|NCT02925156||South Africa|Participants in the South Africa cohort are located at or near Khayelitsha, the 3rd largest township in South Africa, which is an adjacent town to the city of Cape Town. The population of Khayelitsha is about 500,000 people.
2496676|NCT02925156||Seychelles|Participants in the Seychelles cohort are located at or near The Republic of Seychelles, which is an archipelago with 81,000 inhabitants located approximately 1,500 km east of Kenya in the Indian Ocean and approximately 2,000 km north of the island of Mauritius.
2496678|NCT02925156||Jamaica|Participants in the Jamaica cohort are located at or near Spanish Town, Jamaica which is an urban area 25 km from the center of Kingston. The population of Spanish Town in 1991 was estimated at 92,000 people.
2496680|NCT02925156||United States|Participants in the United States cohort are located at or near Maywood, IL, which is an African-American working class community adjacent to the western border of Chicago, IL. The population of Maywood in 2010 was estimated at 24,090 people.
2496729|NCT02924675|Experimental|pregabalin group|
2496738|NCT02924675|Placebo Comparator|Placebo group|
3162302|NCT00459550|Experimental|Part A|Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
2496813|NCT02923986|Experimental|BP1001 (varying dose) + Dasatinib|Phase 1b: BP1001 (varying dose levels) in combination with Das
2496814|NCT02923986|Experimental|BP1001 (fixed dose) + Dasatinib|Phase IIa: BP1001 (fixed dose based on Phase 1b) in combination with Das
2496875|NCT02923765|Active Comparator|combined training (CT)|additional aerobic training by a stepper : 35 minutes/session, 5 sessions/week and 4-5 weeks
2496876|NCT02923765|No Intervention|usual rehabilitation (UR)|Usual rehabilitation, without additional aerobic training
2496878|NCT02923765|No Intervention|healthy participant (HP)|healthy control
2496924|NCT02923518||Inclusion group|Inclusion group: Those with a positive score in a questionnaire including symptoms and family history and/or high risk-score in the NORRISK-score system.
2496929|NCT02923518||Control group|Those without a positive score on the two scores listed above.
2496960|NCT02923154|Experimental|MT-3995|
2496961|NCT02923154|Placebo Comparator|Placebo|
2496972|NCT02922920|Experimental|Tart cherry juice|Participants consumed 16 fl. oz of tart cherry juice daily for 12 weeks.
2496973|NCT02922920|Placebo Comparator|Placebo juice|Participants consumed 16 fl. oz of placebo daily for 12 weeks.
3173566|NCT00613457|Experimental|Reintensification Arm V|"• Arm V (extended reintensification therapy [triple protocol III] [closed to accrual as of 6/30/2006]): HR patients receive HR therapy elements 3, 2, and 1 following reintensification therapy repeated the therapy element three times with 4-week interim maintenance phases in between. Patients then proceed to maintenance therapy.~Interim maintenance/maintenance therapy: Patients receive MTX once weekly and MP daily until week 104 plus IT MTX every eight weeks.~Radiotherapy: HR patients or patients with T-cell acute lymphoblastic leukemia or CNS disease undergo CNS radiotherapy."
3173567|NCT00613470|Experimental|Citalopram and escitalopram|"Citalopram tablet or solution starting at 20 mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~Escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
2497050|NCT02922543||Relapsed or refractory multiple myeloma (MM) patients|Relapsed or refractory MM patients in the special use-results surveillance (all-case surveillance) (hereinafter referred to as the all-case surveillance) who have received Revlimid treatment for at least 7 cycles at institutions cooperating in performing the all-case surveillance and this surveillance.
2497114|NCT02922335|Experimental|Multisystemic Therapy - Emerging Adults|Multisystemic Therapy for Emerging Adults (MST-EA) is designed to help emerging adults (ages 18-21) with mental illness who have been in trouble with the law. MST-EA is a treatment program specifically for emerging adults, to increase skills and capacities that can help them reduce their antisocial behavior and help reduce problems caused by mental health illness, and alcohol or drug use when present.
2497117|NCT02922335|Active Comparator|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU) emerging adults will get the treatments that they usually receive when they have a mental illness and have been in trouble with the law. They will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
2497151|NCT02921763||Dydrogesterone|Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.
3173568|NCT00613496|Placebo Comparator|2|Placebo treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
3173569|NCT00613496|Active Comparator|1|Irbesartan treatment in each patient during the study (9 weeks) using an intraindividual cross-over design
3173570|NCT00613522||case|Fist ischaemic hemispheric stroke or TIA
3173571|NCT00613522||control|No ischaemic hemispheric stroke or TIA
2496503|NCT02925962|Experimental|Clinical Decision Support System (CDSS)|"PCPs get a notice the CKD Clinical Decision Support System (CDSS) is available.~CDSS overview:~The study MDs order CKD triple marker tests~Patients will go to the lab as per usual clinical care~Lab results are returned to PCPs clinical results folder as per usual clinical workflow with information about CKD and link to KDIGO guidelines~Results will also be sent to the Study MD's for monitoring~At the patient's next visit, if the labs are completed, the full CDSS launches for the PCP~If the labs are not completed by the next visit, a Best Practice Alert (BPA) will launch for the PCP notifying them that the labs have been ordered, but the patient hasn't done them yet"
2496505|NCT02925962|Experimental|Clinic Decision Sup System + Pharmacist|"The Clinical Decision Support System + Pharmacist follow-up call extends beyond the CDSS alone.~CDSS Plus overview:~At the visit in which the CDSS launches, the PCP will hand a study card with pharmacist information to their patient notifying them that a pharmacist will be calling to follow-up after the visit~The pharmacist will use MyChart and/or phone calls to schedule a follow-up call within two weeks of the visit~On the follow-up phone call, the pharmacist will discuss understanding of CKD, medication review and adherence assessment, home BP checks, and the importance of NSAID avoidance~A second follow-up call will only be scheduled if the patient is non-adherent with their medications and makes an active plan for adherence with the pharmacist, or if the patient requests an additional call from the pharmacist"
2496506|NCT02925962|No Intervention|Usual Care|Patients continue to receive usual care by their provider.
2496606|NCT02925585||Pre/post pelvic floor surgery imaging|
2496657|NCT02925065|Experimental|Early-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 1-6 of the study.
2496660|NCT02925065|Experimental|Delayed-start guitar instruction group|A 6 week twice-weekly non-traditional group guitar instruction will be implemented in addition to usual treatment between weeks 8-13 of the study.
2496723|NCT02924766|Experimental|Niraparib + Apalutamide/[Abiraterone Acetate + Prednisone]|Participants will receive initial starting dose of Niraparib 200 milligram (mg) once daily in combination either with Apalutamide 240 mg (4*60 mg) once daily or Abiraterone Acetate 1000 mg (4*250 mg) plus 10 mg Prednisone (5 mg twice daily) for 28 days of cycle 1. Once a safe dose of niraparib is selected with each Andrgen Receptor (AR)-targeted therapy [Apalutamide or Abiraterone Acetate plus Prednisone], then an expansion phase (Part 2) will open to further explore safety and assess antitumor activity.
2496765|NCT02924194|Experimental|nbM stimulation ON for 3 months (GPi also on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation ON for a period of 3 months (GPi also on). No usual treatment is withheld. PD drug doses will be stable unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor Unified Parkinson's Disease Rating Scale (UPDRS) rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
2496768|NCT02924194|Experimental|nbM stimulation OFF for 3 months (GPi is on)|Subjects will undergo activation of GPi and nbM electrodes The GPi's will be stimulated to achieve improvement in motor function. There is a double blind evaluation of DBS-nbM stimulation. Subjects will be those with nbM stimulation OFF for a period of 3 months (GPi is on). No usual treatment is withheld. PD drug doses will be stable during blinded parts of the assessment unless disabling dyskinesias warrants a reduction of medication. After initial 3 months period of stimulation subject will undergo a repeat of neuropsychological testing and Motor UPDRS rating prior to switching group assignment (cross-over). There will be a 2 day wash-out period of nbM stimulation for all subjects (both the On and Off groups) in order to minimize subject bias. Then, the subjects will undergo additional brief neuropsychological testing to asses for carry over effects. The subjects will then be switched to the alternate nbM stimulation group (cross-over) from their previous 3 month period.
2496831|NCT02924103|Active Comparator|Right side|"All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy), will be introduced to both sides of the nose (to the middle meatus); on the RIGHT side by using the Contamination free bacterial swab introduction device.~The Contamination free bacterial swab introduction device is a prototype developed for clinical testing."
2496832|NCT02924103|Active Comparator|Left side|All included participants serve as their own control. A bacterial swab (Eswab 481CE, Copan Diagnostics, Italy) will be introduced to both sides of the nose (to the middle meatus); on the LEFT side using the present day clinical procedure (visually guided introduction).
3173572|NCT00613535|Active Comparator|Lavage debridement to remove loose fragments|Articular cartilage defect left untreated by surgical tool during partial meniscectomy
3173573|NCT00613535|Active Comparator|Mechanical Debridement|Remove large chondral flaps and loose fragments
2497051|NCT02922660|Experimental|Group TIVA|method of anesthesia is total intravenous anesthesia(TIVA) and maintenance with propofol Cp 2-4 μg/ml and remifentanil 2-4 ng/ml in target controlled infusion(TCI) during the procedure
2497056|NCT02922660|Experimental|Group Des|method of anesthesia is inhalation anesthesia and maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
2497091|NCT02922140|No Intervention|control group|will receive standard care by physician in attendance
2497093|NCT02922140|Active Comparator|intervention group|will be supplied by clinical pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.
2497140|NCT02921984|Experimental|Docetaxel arm|Concurrent chemotherapy with Docetaxel if genetic testing show that the patient should be sensitive to this drug.
2497141|NCT02921984|Experimental|Pemetrexed arm|Concurrent chemotherapy with Pemetrexed if genetic testing show that the patient should be sensitive to this drug.
2497143|NCT02921984|Experimental|Cisplatin arm|Concurrent chemotherapy with Cisplatin if genetic testing show that the patient was nor sensitive to neither Pemetrexed nor Docetaxel
2497248|NCT02921217|Experimental|ActivBPL1|Active Probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
2497249|NCT02921217|Experimental|InactivBPL1|Inactivated probiotic Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145)
2496514|NCT02925975|Other|Healthy controls|Healthy volunteers are enrolled as controls to get a normal range of pressure gradient in different sites of hepatic portal system (HPS), such as portal vein, superior mesenteric vein, inferior mesenteric vein and splenic vein. All enrolled healthy subjects should undergo anatomic computed tomographic angiography (CTA) and Doppler ultrasound for only one time, to rebuild a 3D-vHPS by computer.
2496518|NCT02925975|Experimental|Treatment group guided by vPVPG|Enrolled cirrhotic patients with virtual portal vein pressure gradient (vPVPG) above 12mmHg are only treated by oral carvedilol. Once there are visible varies under the endoscopy, participants will be treated with routine endoscopic procedures.
2496522|NCT02925975|Experimental|Follow-up group guided by vPVPG|Cirrhotic patients with vPVPG lower than 12mmHg are followed-up with anatomic CTA and Doppler ultrasound every six months. Once vPVPG is higher 12mmHg or visible varies under the endoscopy, participants will be rescheduled to treatment group guided by vPVPG.
2496525|NCT02925975|Active Comparator|Follow-up group guided by endoscopy|Cirrhotic patients are followed-up by routine endoscopy. Once there are visible varies, participants will be treated according to Baveno V consensus in portal hypertension, such as oral carvedilol and routine endoscopic procedures.
2496588|NCT02925364||No pain|patients who are enrolled in the parent study and report no chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
2496592|NCT02925364||Pain|Patients who are enrolled in the parent study and report chest pain at their 6 month post-cardiac surgery follow-up will undergo functional and anatomical MRI
2496655|NCT02925130|Experimental|Inhaled Salbutamol|Acute inhalation of 800 microgram Salbutamol
2496656|NCT02925130|Experimental|Oral Salbutamol|Acute oral intake of 4 mg Salbutamol
2496658|NCT02925130|Placebo Comparator|Placebo|Acute oral intake of a placebo
2496726|NCT02924740|Active Comparator|control|pelvic floor muscle training
2496735|NCT02924740|Experimental|intervention|vaginal tampon training.
3162303|NCT00459550|Experimental|Part B|"Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:~First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow"
3162304|NCT00459563|Placebo Comparator|Placebo|
2496845|NCT02923999|Experimental|Dose cohort 1|P2G12 0.125g
2496846|NCT02923999|Experimental|Dose cohort 2|P2G12 0.25g
2496850|NCT02923999|Experimental|Dose cohort 3|P2G12 0.5g
2496957|NCT02923219|Experimental|Stem cells separation|Stem cells separation: The adipose-derived stem cells are separated from vacuumed fat obtained through liposuction of abdomen, hip, thigh and so on. It was confirmed the adipose-derived stem cells can be induced differentiation into fat cells under the special condition in the current literature.Stem cells are used to treat wrinkles and facial rejuvenation.
2497037|NCT02922504|Experimental|Music intervention group|For the patients in the Music intervention group, a adjuvant treament by a music intervention will be use before the procedure
2497039|NCT02922504|Active Comparator|Controlled group|"For the patients in the  controlled  group, the use of analgesic will be use if needed during the procedure"
2497077|NCT02922374|Experimental|CS|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
2497180|NCT02921711||LVIS®|
2497200|NCT02921451|Other|Restorelle Smartmesh|Surgical procedure for treatment of uterine prolapse will use the device, Restorelle Smartmesh.
2497253|NCT02921126||High Dose Group|Apixaban - 10 mg/day Rivaroxaban - 20 mg/day Dabigatran - 300 mg/day
2497257|NCT02921126||Low Dose Group|Apixaban - 5 mg/day Rivaroxaban - 15 mg/day Dabigatran - 220 mg/day
2497263|NCT02921126||Other Dose Group|Invalid Doses / Off-Label
2497403|NCT02920320|Experimental|Internet-based self-help|"Internet-based self-help on the basis of the program Mindfulness-Based Compassionate Living (van den Brink & Koster, 2015). The self-help program consists of seven text-based sessions, various exercises (z.B. breathing meditations, diaries,) and tasks. Participants have the possibility for guidance to the program on request."
3162305|NCT00459563|Active Comparator|Cholecalciferol|Cholecalciferol
3162306|NCT00459563|Active Comparator|Calcitriol|Calcitriol
3162307|NCT00459589|Experimental|1|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
3162308|NCT00459589|Active Comparator|2|
3162309|NCT00459602||Laparoscopic incisional hernia repair|Subjects with an incisional, ventral, umbilical, or spigelian hernia no larger tham 15 cm at the largest measurement, who are candidates for laparoscopic repair of the hernia, and who are able to commit to long-term followup. Laparoscopic repair will proceed as per the standard technique, using polyester mesh.
3162310|NCT00459628|Active Comparator|Conventional radiotherapy|Conventional Long schedule Radiotherapy Arm
3162311|NCT00459628|Experimental|Tomotherapy|Short course schedule by tomotherapy
3162312|NCT00459641|Experimental|1|I-040302 doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
3162313|NCT00459641|Active Comparator|2|Standard of care (bone marrow aspirate or steroids)
3162314|NCT00459654|Experimental|Radium-223 dichloride (Xofigo, BAY88-8223)|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of the investigational drug radium-223 (EBR+Radium-223)
3162315|NCT00459654|Placebo Comparator|Saline|Each subject receives local filed external beam radiotherapy (EBR) and repeated injections of saline (EBR+placebo)
3162316|NCT00459680|Experimental|Acupuncture|
3162317|NCT00459680|Experimental|Laser Acupoint|
3162318|NCT00459719|Experimental|1|In combination with steroids
2496570|NCT02925546|Experimental|GSK2798745 CBAD treatment sequence|Subjects will be given 2.4 mg GSK2798745 (milled API with SLS and hypromellose) in fasted state (treatment C), 2.4 mg of GSK2798745 (micronized API with SLS and hypromellose) in fasted state (treatment B), 2.4 mg single oral doses of GSK2798745 (micronized API without SLS and hypromellose) in fasted state (treatment A), and GSK2798745 tablet in fed state (treatment D) in either treatment periods 1, 2, or 3; the three treatment periods will each be separated by a minimum washout period of 7 days
2496686|NCT02924948|No Intervention|Conventional insertion|EUS will be inserted with conventional method.
2496688|NCT02924948|Experimental|Balloon inflated insertion|EUS will be inserted with balloon inflated method
2496730|NCT02924636|Experimental|Intervention|personalized and online intervention. The intervention website will provide secure communication with dietician and lifestyle coaches. Women will receive emails and monthly newsletters with new content and reminder.
2496739|NCT02924636|No Intervention|Control|standard care with oral information about the goal of nutritional needs during pregnancy and gestational weight gain guidelines according to BMI
2496760|NCT02924298|Experimental|Stage 1-2 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate > 60 mL/min/1.73m^2, to undergo SLIMM intervention
2496766|NCT02924298|Experimental|Stage 3-4 Chronic Kidney Disease|Individuals with estimated glomerular filtration rate 15 to < 60 mL/min/1.73m^2, to undergo SLIMM intervention
3162319|NCT00459719|Active Comparator|2|In combination with steroids
3162320|NCT00459745|Active Comparator|Pravastatin|Pravastatin 40 mg
2496908|NCT02923583|Experimental|M834|M834 (abatacept biosimilar candidate)
2496909|NCT02923583|Active Comparator|US Orencia®|US-sourced Orencia® (abatacept)
2496910|NCT02923583|Active Comparator|EU Orencia®|EU-sourced Orencia® (abatacept)
2496954|NCT02923232|Experimental|Accommodative contact lens|The accommodative contact lens is composed of traditional hydrogel lens material but has an internal cavity to allow lens deformation that increases its refractive power at an downward angle.
2496998|NCT02923024|No Intervention|Usual Care|This arm will be usual care and there will be no intervention.
2497000|NCT02923024|Experimental|Information|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent.
2497002|NCT02923024|Experimental|Information and Financial Incentives|In this arm, providers will be sent patient pings after a patient experiences a trigger event. The ping will be a fax sent from Oscar to the physician alerting them of an event their patient had.This trigger event could be an emergency room visit, admission to a hospital, or a hospital discharge event. The patient ping will be sent to the patient's doctor including primary care physicians and specialists. If the patient does not have a doctor, a ping will not be sent. Physicians will be incentivized to see patients immediately via phone call or in office visit. Physicians receive a financial incentive for calling the member within 48 hours of trigger event and will receive a larger financial incentive for seeing the patient for an office visit within 7 days of trigger event.
2497030|NCT02922725|Active Comparator|Depressed patients receiving study drug|Participants diagnosed with MDD
2497031|NCT02922725|Placebo Comparator|Depressed patients receiving placebo|Participants diagnosed with MDD
2497032|NCT02922725|No Intervention|Healthy Control|
3162321|NCT00459745|Active Comparator|Fenofibrate|Fenofibrate 160 mg
3162322|NCT00459745|Experimental|Pravafen (Parvastatin and Fenofibrate)|Combined Therapy of Pravastatin 40 mg and Fenofibrate 160 mg.
2497161|NCT02921932|Active Comparator|Intervention|"In the interventional arm, patients will be given:~A 'Threshold' Inspiratory Muscle Trainer~A nutritional assessment: if needed, dietary supplements prescribed (i.e Ensure, Glucerna).~Cognitive exercise in the form of the 'Memory' card game will be taught to the patients and the caregiver (if available), to be done twice a day.~Patients will be provided with a protocol activities log and a study assistant will be conducting a telephone conversation on day 1, 4 and 7 to encourage compliance to the protocol and answer any queries with regards to the research study."
2497167|NCT02921932|No Intervention|Control|In the control arm, patients will be given the standard education materials regarding surgery and carry out daily activities as usual until the admission of the surgery.
2497229|NCT02921464||Group A|Group A - without known pre-existing SIHD
2497231|NCT02921464||Group B|Group B - with known pre-existing SIHD.
2497292|NCT02920944|Experimental|EUS-FNB with 20-gauge|EUS-FNB with 20-gauge procore needle
2497296|NCT02920944|Active Comparator|EUS-FNB with 22-gauge|EUS-FNB with 22-gauge procore needle
2497337|NCT02920567|Experimental|octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
2497338|NCT02920567|Placebo Comparator|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
2497384|NCT02920359|Experimental|LEUPRORELIN ACETATE|
2497443|NCT02920125|Active Comparator|Trial: Ayurvedic SUVED, REIMMUGEN|"Ayurvedic SUVED formulation comprises of 'Ghana' extract form; Dosage :3 months, 1 BD. Content: (500mg per capsule)Terminalia Arjuna: Withania somnifera; Terminalia chebula; Cyperus rotundus; Apium graveolens; Vitis vinifera; Piper longum; Fagonia Arabica; Emblica officinalis; Terminalia belerica; Nymphaea stellata; Punica granatum; Bacopa Monnieri; and stabilizing herbs.~Reimmugen Cow-colostrum is a total natural product, used as nutritional supplement Dosage: 3months, 1 TDS Contents: IgA, IgE, IgM, IgG, IgD, PRPs, Lactoferrin, Transferrin, Interferons, Cytokines, Growth Factors (bFGF, vFGF, IGF I & II & Angiogenesis growth Factor, Endothelial growth Factor, Nerve growth factor, PDGF), natural Vitamins and Minerals."
2497446|NCT02920125|Placebo Comparator|Control: grain flour|Dummy medication in same packing to mask content given in same dose as active medication. Jowari and ragi flour used in capsules
2529269|NCT02702349|Other|1|penicillin test and challenge
3162323|NCT00459771|Placebo Comparator|Placebo|Placebo
3162324|NCT00459771|Active Comparator|Candesartan|Candasartan
3162325|NCT00459797|Active Comparator|Conventional Glidescope|
3162326|NCT00459797|Experimental|Single-use Glidescope|
3162327|NCT00459823|Experimental|1|
2496647|NCT02924922|Active Comparator|Laparoscopic partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before laparoscopic partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
2496649|NCT02924922|Active Comparator|Robot assisted partial nephrectomy|"Inclusion criteria fulfilled:~Baseline Abdomen CT/MRI~Patient Age, Weight, Height, Co-Medication~Informed Consent~Baseline renal function (eGFR, renal scintigraphy, sCreatinine, creatinine clearance)~During hospitalization, one day before robot assisted partial nephrectomy:~eGFR~sCreatinine~Hemoglobin~After surgery:~Assessment of eGFR 4 days after operation~Hb assessment every 6 H in the first 48 H~Assessment of adverse events~Histological Results~6, 12, 24 months after intervention:~Creatinine Clearance (only performed at 6 months follow-up)~Tc-99m MAG3Dynamic Scintigraphy (only performed at 6 months follow-up)~eGFR~Assessment of adverse events~Assessment of possible recurrence~Assesment of kidney volume variation"
2496711|NCT02924753|Experimental|CART-19|patients will receive a pre-conditioning with cyclophosphamide and fludarabine before infusion of CART-19 cells. The CART-19 cells are to be administered on day0,day1,day2.
2496797|NCT02924467|No Intervention|No intervention: Usual Care|Patients in this group will not receive any influenza vaccine reminder notifications.
2496802|NCT02924467|Experimental|1 Notice|Patients in this group will receive one influenza vaccine reminder notification via autodialer across the 2016 influenza season.
2496805|NCT02924467|Experimental|2 Notices|Patients in this group will receive up to two influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
2496807|NCT02924467|Experimental|3 Notices|Patients in this group will receive up to three influenza vaccine reminder notifications via autodialer throughout the 2016 influenza season.
2496815|NCT02923934|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 3mg/kg every 2 weeks until progression (up to 48 total doses of nivolumab)
3162328|NCT00459914|Active Comparator|1 CPAP|Nasal continuous positive airway pressure
2496976|NCT02922907|Experimental|Arabinoxylan Rice Bran|BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
2496980|NCT02922907|Placebo Comparator|Placebo|Placebo for BRM4 two 500mg capsules thrice daily p.o. for 12 weeks
2497044|NCT02922777|Experimental|BGB324 in combination with docetaxel|The dose of docetaxel will be 75 mg/m2 given IV every 21 days. The dose of BGB324 will be escalated in a standard 3+3 fashion until a maximum tolerated dose is determined.
2497133|NCT02922231||All Study Participants|Participants with congenital hemophilia B (FIX level ≤5%)
2497156|NCT02921659|Placebo Comparator|Placebo|placebo, 500 mg, 2x/day for 6 weeks
2497163|NCT02921659|Active Comparator|Niagen™|Niagen™ (nicotinamide riboside chloride, ChromaDex, Inc.) 500mg, 2x/day for 6 weeks.
2497244|NCT02921503|Experimental|Topical Corticosteroids App Users|Practitioners will asked to use a novel application during their patient encounters over the next three months. This application should not modify treatment, it will only act as a vehicle to present evidence based research. Patients will not be subjects of this research, as the app is only presenting best practice which the physicians should be aware of.
3162329|NCT00459914|No Intervention|2|Pharmacological treatment alone
3162330|NCT00460018|Experimental|Intervention|Women receiving the DEBI Intervention
2497339|NCT02920515|Experimental|GnRHa(Triptorlin or Leuprorelin)|Triptorlin or Leuprelin 100ug/kg per 28 days
2497340|NCT02920515|Active Comparator|Traditional Chinese Medicines|Zhibo dihuang pills: 8 tablets twice a day by mouth for 6 months and Dabu ying pills: 6g twice a day by mouth for 6 months
2497342|NCT02920515|No Intervention|blank group|without therapy
2497390|NCT02920333|Experimental|tDCS+ rehab training|tDCS will be applied 10 days, followed by conventional rehab training. Anodal stimulation will be conducted at the intensity of 2 mA and last for 20 minutes over the affected primary motor cortex of cortical representation of the tibialis anterior muscle.
2497392|NCT02920333|Experimental|rTMS+ rehab training|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
2497393|NCT02920333|Sham Comparator|sham tDCS+ rehab training|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
2497489|NCT02919787|Active Comparator|Surgery and then postoperative adjuvant chemotherapy|Surgery and then postoperative adjuvant chemotherapy
2497494|NCT02919787|Experimental|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy|Neoadjuvant chemotherapy, surgery, adjuvant chemotherapy
2497602|NCT02919189|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497606|NCT02919189|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497608|NCT02919189|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
3162331|NCT00460018|No Intervention|No intervention|Women receiving standard care
3162332|NCT00460057|Placebo Comparator|Alendronate, Placebo|All subjects were given 600 mg of calcium and 400 IU of vitamin D supplements. The subjects were randomized to receive weekly alendronate 20 mg (n = 31) or placebo (n = 32).
3162333|NCT00460083|Active Comparator|Elidel(r)|
3162334|NCT00460083|Experimental|Epiceram(r)|
3162335|NCT00460135|Experimental|RT|resistance training
2496662|NCT02925182|Experimental|test|Recurrent Aphthous Stomatitis were irradiated with Er,Cr:YSGG laser (Waterlase MD, Biolase, Irvine, CA, USA) on hard tissue mode with a mg6 sapphire tip (600 µm diameter, 6 mm length) using non-contact mode at an energy level of 0.25W and a repetition rate of 20 kHz and pulse duration of 140 µs, 0% water and 10% air at 5 J/cm2 energy density. The treatment time was 20 s per surface by scanning the Recurrent Aphthous Stomatitis area.
2496666|NCT02925182|Placebo Comparator|Control|In the placebo group, the same Er,Cr:YSGG laser without laser emission was used.
2496715|NCT02924779||Women during labour|Women receiving lumbar epidural anaesthesia for pain during birth
2496784|NCT02924454|Experimental|Metoprolol-Lipid emulsion|intervention 1: metoprolol Intervention 2: intravenous lipid emulsion
2496787|NCT02924454|Experimental|Metoprolol - normal saline|intervention 1: metoprolol intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
2496790|NCT02924454|Experimental|Normal saline-Lipid emulsion|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: intravenous lipid emulsion
2496794|NCT02924454|Experimental|Normal saline-normal saline|intervention 1: Sodium chloride 0.9% solution - metoprolol dummy intervention 2: Sodium chloride 0.9% solution - lipid emulsion dummy
2496852|NCT02923856|Experimental|Clarithromycin resistance group|Patients who are resistant to clarithromycin in susceptibility test were classified into clarithromycin resistance group.
2496853|NCT02923856|Experimental|7 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 7days standardized treatment.
2496854|NCT02923856|Experimental|7 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 7days standardized treatment.
2496858|NCT02923856|Experimental|10 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 10days standardized treatment.
2496860|NCT02923856|Experimental|10 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 10days standardized treatment.
2496861|NCT02923856|Experimental|14 days Successful treatment|The successful treatment of H. pylori group were treatment successful patients after the 14days standardized treatment.
2496863|NCT02923856|Experimental|14 days failed treatment|The failed treatment of H. pylori group were treatment failure patients after the 14days standardized treatment.
2496928|NCT02923453|Placebo Comparator|Placebo|1g/meal of placebo three times per day (3g/day) for 8-weeks.
2496935|NCT02923453|Active Comparator|Ginseng Extract|CNT2000 (Chai-Na- Ta Corp., Langley, BC) American ginseng extract 1g/meal of placebo three times per day (3g/day) for 8-weeks.
2496982|NCT02923102|Active Comparator|Aloysia citriodora extract|Dietary Supplement: Aloysia citriodora extract
2496984|NCT02923102|Placebo Comparator|Placebo Formulation|Dietary Supplement: Maltodextrin (no active ingredient)
2497041|NCT02922712|Experimental|NISE 100mg|Nise 100mg given BD for 3 weeks
2497112|NCT02922387|Experimental|Varenicline + Behavioral support|varenicline and behavioral support
2497119|NCT02922387|Active Comparator|Behavioral support|behavioral support
2497164|NCT02921802||Patients who received Revlimid|Among relapsed or refractory multiple myeloma and Myelodysplastic syndrome (MDS) with a deletion 5q cytogenetic abnormality patients, all patients who received Revlimid will be targeted in this surveillance.
2497198|NCT02921542||Homogenous Lesions|
2497205|NCT02921542||Heterogenous Lesions|
2497210|NCT02921542||Calcific Lesions|
2497216|NCT02921542||Restenotic Lesions|
2497274|NCT02921035||Relapsing Multiple Sclerosis (RMS) group|Subjects diagnosed with RMS who are prescribed Rebif (Interferon beta-1a)
2497381|NCT02920437|Experimental|Intervention group|Four-week weekly intervention to reduce salt intake.
2497382|NCT02920437|Other|Control group|Usual government pamphlets.
2497442|NCT02920099||Nutrition Literacy|Participants will be asked to completed the Nutrition Literacy Assessment Instrument (NLAI).
2497474|NCT02919722|Experimental|Music interventions|Live music will be provided on the patient's neglected side and patients will be encouraged to play music interactively with a focus towards that side whenever possible
2497582|NCT02919449|Experimental|MV-NIS and Atezolizumab|MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.
2497716|NCT02918578|Experimental|"Phone group"|see intervention description
2497725|NCT02918578|Experimental|"Phone and SMS group"|see intervention description
2497730|NCT02918578|Active Comparator|"single writing group"|see intervention description
2497791|NCT02918032||NLSD / TGCV|Patients who are diagnosed with NLSD / TGCV
2497833|NCT02917551|Active Comparator|Shorter duration (7 days)|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
2497834|NCT02917551|Active Comparator|Longer duration (14 days)|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
2497890|NCT02917343|Experimental|intervention arm|participants received 4 weeks of mirror therapy and repetitive task training
2497943|NCT02916940|Experimental|Diprophos|Patients having had a sprain of the long fingers, within 2 weeks of consultation. This group will receive a single injection of corticoids.
2497946|NCT02916940|No Intervention|Control group|Patients having had a sprain of the long fingers (Eaton classification type I and II), within 2 weeks of consultation. This group will receive the standard of care treatment, without injection of corticoids.
2498070|NCT02916030||Group 1 (hemorrhagic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
2498077|NCT02916030||Group 2 (Ischemic stroke)|All participants will be subjected to thorough history taking, full clinical and neurological examination. Stroke subtype will be classified according to the criteria of Trial of Org 10172 in acute Stroke Treatment (TOAST) classification.
2496695|NCT02924831|Experimental|Acupuncture group|material: stainless steel needle In acupuncture treatment, needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),with manipulations to get Deqi sensation.
2496697|NCT02924831|Placebo Comparator|Placebo group|material: stainless steel needle Needles were applied to acupoints of Guanyuan(RN4)and Zusanli(ST36),but without any manipulations and Deqi sensation.
2496698|NCT02924831|Experimental|Zusanli（ST36)-acupuncture group|material: stainless steel needle Stimulating acupoints of Zusanli(ST36) with acupuncture.
2496699|NCT02924831|Experimental|Guanyuan(RN4)-acupuncture group|material: stainless steel needle. Stimulating acupoint of Guanyuan(RN4) with acupuncture.
2496764|NCT02924415|Experimental|Tele-care support|Online psychoeducation treatment using new technologies
2496767|NCT02924415|Active Comparator|Control group|Standard care
2496842|NCT02924142|Experimental|Intervention|Mandibular removable partial denture with OT Cap attachment
2496843|NCT02924142|No Intervention|Comparator|Mandibular removable partial denture with gingival approaching clasp assembly
2496914|NCT02923661|Experimental|CM LOC attachment group|this group will receive CM LOC attachment and lower overdenture attached to it
2496918|NCT02923661|Active Comparator|Ball attachment|this group will receive Ball attachment and lower overdenture attached to it
2497098|NCT02922192||Rheumatoid arthritis (RA)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2497103|NCT02922192||Inflammatory bowel disease (IBD)|With exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2497108|NCT02922192||Psoriatic conditions|Patients with a psoriasis, psoriatic arthritis, ankylosing spondylitis with exposure to TNF-α antagonists, non-TNFs, DMARD non-biologics
2497227|NCT02921204||Vitamin D status|Subjects are recruited to asses Vitamin D status with no interventions
2497275|NCT02920996|Experimental|NSCLC (Met Exon 14 Mutation)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
2497278|NCT02920996|Experimental|Solid Tumor (NTRK1,2,3 Rearrangement)|Merestinib at the recommended phase II dose of 120 mg by mouth daily.
2497356|NCT02920606|Active Comparator|Endodontic treatment|"The patient will benefit from a conventional treatment : a root canal treatment.~The root canal treatment consists of removing the pulp tissue from all the canals, disinfecting the root canal system with sodium hypochlorite and filling the root with a root canal sealer and gutta percha."
2497358|NCT02920606|Experimental|Pulpotomy|The patient will benefit from an experimental treatment : a pulpotomy. The pulpotomy aims at removing the coronal part of the pulp (the pulp present in the pulp chamber) and filling the pulp chamber with a bioactive material.
2497423|NCT02920268|Experimental|Intervention|Intervention with dance and yoga sessions, two times a week in 8 months.
2497426|NCT02920268|No Intervention|Controls|No intervention
2497488|NCT02919774|Experimental|POMA 40 mg BID|40 mg BID for 10 days
2497492|NCT02919774|Experimental|POMA 160 mg BID|160 mg BID for 10 days
2497496|NCT02919774|Placebo Comparator|Placebo|Placebo BID for 10 days
3162336|NCT00460135|No Intervention|Routine care|General counseling on increasing physical exercise
3162337|NCT00460161|Active Comparator|1|true acupuncture
2497748|NCT02918344||Standard sagittal split osteotomy group|Patients undergoing sagittal split osteotomy without paste application
2497750|NCT02918344||Cohort/Hydroset group|Patients undergoing sagittal split osteotomy with paste application
2497814|NCT02917928|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
2497816|NCT02917928|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
2497836|NCT02917538|Experimental|Intervention group|In the intervention group: The operator will perform the RFA treatment guided by real-time CF parameters.
2497840|NCT02917538|Active Comparator|Control group|In the control group: The Operator will perform the RFA treatment blinded to the real-time CF parameters.
2497880|NCT02917369||Normal lung tissue|Normal lung tissue from LCLC patients
2497883|NCT02917369||LCLC tissues|LCLC tissues from LCLC patients
2497884|NCT02917369||Metastasis tissues|Metastasis tissues from LCLC patients
2497941|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 1|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: visit to out-patient clinic,CT scan of pulmones."
2497944|NCT02916992|Active Comparator|Spontaneous pneumothorax patients 2|"Patients who were treated for spontaneous pneumothorax in Rijnstate hospital. Interventions: withdrawal of blood sample for DNA analyses,"
2498006|NCT02916537|Experimental|Cohort A: Pre-prostatectomy patients|Patients with prostate cancer prior to radical prostatectomy (N = 5). Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort A will undergo radical prostatectomy (plus lymph node dissection) within 12 weeks following CTT1057 PET/MR.
2498022|NCT02916446|Placebo Comparator|Placebo|Placebo patch, daily administration
2498102|NCT02915926|Active Comparator|OT|standard OT
3162338|NCT00460161|Placebo Comparator|2|placebo/sham acupuncture
3162339|NCT00460174|Experimental|Treatment Arm|Concurrent gemcitabine, bevacizumab, and radiation therapy
3162340|NCT00460213|Experimental|Valsartan|
3162341|NCT00460226||lamotrigine|there is only one group.
3162342|NCT00460317|Placebo Comparator|Arm B|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and placebo 125mg QD orally
3162343|NCT00460317|Active Comparator|Arm A|All subjects on this treatment arm will receive a standard paclitaxel and carboplatin chemotherapy regimen (paclitaxel 200mg/m2 and carboplatin at AUC of 6mg/mL x min by Calvert formula) on day 1 of each 3 week cycle + - 3 days for a maximum of 6 cycles and AMG 706 125mg QD orally.
3162344|NCT00460343|Experimental|max|
3162345|NCT00460343|Active Comparator|min|
3173574|NCT00613535|Active Comparator|RF based Debridement|Debridement to remove loose fragments followed by use of Paragon T-2 RF wand to smooth the base of the shoulder of the tear
3173575|NCT00613548|Active Comparator|1|CABG Alone
3173576|NCT00613548|Active Comparator|2|CABG + Mitral repair
2496725|NCT02924597|Experimental|Robot-assisted laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
2496734|NCT02924597|Active Comparator|Robot-Assisted laparoscopic partial nephrectomy|The tumor then will be laparoscopic enucleation without hilar clamping.
2496796|NCT02924246|Placebo Comparator|Control group|Regular cholera vaccination
2496800|NCT02924246|Active Comparator|Raw milk|Cholera vaccination - raw milk
2496803|NCT02924246|Active Comparator|Pasteurized milk|Cholera vaccination - pasteurized milk
2496806|NCT02924246|Active Comparator|UHT milk|Cholera vaccination - UHT milk
2496856|NCT02923882|Experimental|Intervention group|In the intervention group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the '$100Kitchen and improved cookstove'.
2496857|NCT02923882|No Intervention|Control group|In the control group, the pregnant women at 8-12 weeks of gestational age used biomass fuels for cooking in the traditional cookstove.
2496917|NCT02923648||Very/extremely prematurely born with BPD|Very/extremely prematurely born (gestational age [GA]< 32 weeks) with bronchopulmonary dysplasia (BPD) as defined by Jobe and Bancalari 2001, age 18-23 years
2496921|NCT02923648||Very/extremely prematurely born without BPD|Very/extremely prematurely born (GA< 32 weeks) without BPD in the neonatal period, age 18-23 years
2496922|NCT02923648||Asthma full-term control group|Subjects with mild atopic asthma, born at term (GA> 37 weeks), age 18-23 years
2496923|NCT02923648||Healthy full-term control group|Healthy participants, born at term (GA>37 weeks), age 18-23 years
2496970|NCT02923193|Experimental|Lithoplasty System followed by DCB|Shockwave Lithoplasty® Peripheral Lithoplasty System is a lithotripsy-enhanced, low-pressure balloon dilatation of calcified, stenotic peripheral arteries in patients who are candidates for percutaneous therapy. lithoplasty
2496971|NCT02923193|Active Comparator|Medtronic IN.PACT (DCB)|Medronic IN.PACT Drug Coated Balloon (DBS) is indicated for percutaneous transluminal angioplasty (PTA) in patients with obstructive disease of peripheral arteries, including patients with in-stent restenosis (ISR) and arteriovenous (AV) access to help maintain hemodialysis access in patients with end-stage renal disease.
2497054|NCT02922517||patients with obstructive HCM|patients with HCM (obstructive or no obstructive)
2497061|NCT02922517||controls|patients without HCM
2497065|NCT02922517||patients with non obstructive HCM|patients with non obstructive HCM
2497122|NCT02922309|Experimental|experimental|Vocal Training via Telepractice
2497127|NCT02922309|Active Comparator|control|Vocal Training via face-to-face practice
2497144|NCT02921828||Multiple myeloma patients who received Pomalyst|Among relapsed or refractory multiple myeloma patients, all patients who received Pomalyst will be targeted in this surveillance.
2497196|NCT02921607||Observational|One group - all participants will be completing questionnaires and will be followed up with three months post discharge.
2497273|NCT02921152|Other|all|All patients with early breast cancer
2497371|NCT02920684|Active Comparator|Passive legs mobilisation|A physiotherapist performs passive legs movement
2497375|NCT02920684|Active Comparator|Passive cycloergometer|A motorized cycloergometer performs passive legs cycling
2497378|NCT02920684|Active Comparator|Muscular electrical stimulation|Quadriceps neuromuscular electrical stimulation
2497380|NCT02920684|Active Comparator|FES cycling|A motorised cycloergometer performs a quadriceps neuromuscular electrical stimulation during passive
2497438|NCT02920138||Group 5PEEP|Administered 5 cmH2O positive end expiratory pressure group( Group 5PEEP n=30).
2497441|NCT02920138||Group ZEEP|no positive end expiratory pressure group (Group ZEEP n=30)
2497490|NCT02919735|Experimental|CG 428 cutaneous solution|Herbal Medicinal Product, topical use by spray on the scalp
2497493|NCT02919735|Placebo Comparator|Placebo cutaneous solution|Placebo, topical use by spray on the scalp
2497534|NCT02919332||Diagnostic (18F-FDG PET/CT)|Patients receive fludeoxyglucose F-18 IV. Patients then undergo a standard of care PET/CT scan at 60 minutes and a second PET/CT scan at 240 minutes after injection.
2497616|NCT02919046|Experimental|single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times
2497640|NCT02918682|Experimental|Exercise Group|The multimodal intervention protocol is described separated by day (1 to 24) and by weeks (1 to 12). Each session was built to last between 50 and 60 minutes.
2497645|NCT02918682|No Intervention|Control Group|Participants from the control group will not perform any kind of physical exercise.
2497706|NCT02918474|Experimental|Supportive care (decision making tool)|Patients use decision making tool during consultation with breast cancer surgeon and complete questionnaires before and after consultation.
2497782|NCT02918136|Experimental|adipose-derived stem cell injection|ultrasound guided injection of 5cc of adipose-derived stem cells (ADSCs)
2497783|NCT02918136|Active Comparator|cortisone injection|ultrasound guided injection of cortisone
2497854|NCT02917512|Experimental|HU00701|"HU00701(Cyclosporine 0.01% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
2497855|NCT02917512|Experimental|HU007|"HU007(Cyclosporine 0.02% + 3% trehalose)~1 drop b.i.d at 12 hour interval for 12 weeks"
2497857|NCT02917512|Active Comparator|Restasis|"Restasis(Cyclosporine 0.05%)~1 drop b.i.d at 12 hour interval for 12 weeks"
2497860|NCT02917512|Placebo Comparator|Placebo(without main component)|"Placebo~1 drop b.i.d at 12 hour interval for 12 weeks"
2497926|NCT02917005|Experimental|Palbociclib Arm|Palbociclib (Pfizer) 125mg/day orally for 3 weeks followed by 1 week off plus Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
2496744|NCT02924493|Experimental|Low FODMAP diet|This group will follow a exclusion diet called low FODMAP diet, which is a diet with restriction of fermentable carbohydrates. The patients will be guided on how to avoid some foods and how to include others. The patients will follow the diet for four weeks.
2496745|NCT02924493|Placebo Comparator|Control diet|This group will follow a placebo diet, which is designed to imitate the low FODMAP diet by restricting specific foods. However, it is randomly selected foods that will be excluded in this diet, so that it works only as a control diet. The patients in this group will also be guided how to follow the diet for four weeks.
2496786|NCT02924207|Experimental|Intervention|Path Electronic decision support arm
2496817|NCT02924012|Experimental|active video game|An active game session lasting 40 minutes
2496824|NCT02924012|Other|sedentary video game|An sedentary game session lasting 40 minutes
2496828|NCT02924012|Other|walking|An walking lasting 40 minutes
2496927|NCT02923479|Experimental|Experimental: ARBOT Group|"The patients in the ARBOT Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation by ARBOT device"
2496933|NCT02923479|Other|Control Group|"The patients in the Control Group underwent to following interventions:~General Rehabilitation~Specific ankle rehabilitation performed by physiotherapist~Specific ankle rehabilitation by Biodex System 3 dynamometer~Specific ankle rehabilitation by ProKin PK254 platform."
2496986|NCT02923011|Active Comparator|MRgFUS|Magnetic resonance-guided focused ultrasound ablation
2496993|NCT02923011|Active Comparator|CTgRFA|Computed tomography-guided radiofrequency ablation
2497038|NCT02922686|Active Comparator|flucloxacillin + phenoxymethylpenicillin|Flucloxacillin 500 mg four times daily + Phenoxymethylpenicillin 500 mg four times daily for 7 days.
2497040|NCT02922686|Placebo Comparator|flucloxacillin + placebo|Flucloxacillin 500 mg four times daily + Placebo four times daily for 7 days.
3195467|NCT00839969|Sham Comparator|Cystoscopy alone|Women in this arm will undergo saline cystoscopy under general anaesthesia only.
3195468|NCT00839969|Active Comparator|Cystoscopy and urethral dilatation|Women in this group will undergo cystoscopy and urethral dilatation under general anaesthesia
2497223|NCT02921230|Experimental|ELUVIA Stent Implantation|Peripheral stenting
2497224|NCT02921230|Active Comparator|control Bare Metal Stent Implantation|Peripheral stenting
2497267|NCT02920801|Experimental|saxagliptin group|saxagliptin group consumed saxagliptin 5mg per day for 12 week
2497270|NCT02920801|Active Comparator|metformin group|metformin group consumed metformin 1500mg per day for 12 week
2497367|NCT02920671||Mitochondrial Disease|Clinical history consistent with the diagnosis of mitochondrial disease, and molecular genetic diagnosis.
2497373|NCT02920671||Obese|BMI > 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
2497377|NCT02920671||Normal Weight & Overweight|BMI 18.5 - < 30 kg/m2. These will be matched with subjects with mitochondrial disease by age, sex, estrogen status (women), and usual self-reported physical activity.
3195469|NCT00839995||Patients undergoing multi-level spine surgery|
3195470|NCT00840008|Experimental|Educational intervention|see protocol
2497548|NCT02919436|Experimental|Tamsulosin|Subjects in this arm will receive tamsulosin 0.4 mg/day for five days prior to surgery and two days after surgery.
2497549|NCT02919436|Placebo Comparator|Placebo|Subjects in this arm will receive a placebo capsule identical in appearance to the tamsulosin capsule, for five days prior to surgery and two days after surgery.
2497658|NCT02918994|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
3195471|NCT00840008|No Intervention|Standard care|distribution of guidelines and a published algorithm
2497843|NCT02917681|Experimental|MSC injection|Patients will be followed for 3 months before bone marrow aspiration (BMA). Patients will receive 2 intrathecal MSC injections, 1 and 2 months after BMA. The patients will be followed for 6 months after the interventions.
2497866|NCT02917382||Waiting list for liver transplant|Patients on the waiting list for liver transplant treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
2497867|NCT02917382||Undergoing liver transplantation|Patients undergoing liver transplantation treated at ambulatory liver transplant of Hospital of Clinics of the Federal University of Minas Gerais
2497917|NCT02917174|Experimental|mobile management|use mobile management to improve asthma control
2497918|NCT02917174|Other|Traditional management|use Traditional management to improve asthma control
3195472|NCT00840047|Experimental|Participants|Participants who meet the eligibility criteria in the study will receive methionine.
3195473|NCT00840112|Experimental|LCHAD/TFP with peripheral neuropathy|Subjects diagnosed with LCHAD or TFP and with documented peripheral neuropathy
3195474|NCT00840125|Experimental|1|docetaxel + erlotinib
3195475|NCT00840138||1|Patients with common bile duct injury after open cholecystectomy
3195476|NCT00840138||2|Patients with common bile duct injury after laparoscopic cholecystectomy
3195477|NCT00840151|No Intervention|Treatment Group A|Individuals randomized to Treatment Group A will receive standard treatment for study weeks 1-6.
2496773|NCT02924181|Active Comparator|Lt PV CF blinded/rt PV CF guided|Fifteen patients will be allocated to this group. Left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).Then, right side pulmonary veins isolation will be performed with contact force information guidance.
2496776|NCT02924181|Active Comparator|Rt PV CF guided/lt PV CF blinded|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed with contact force information guidance. Then, left side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter).
2496777|NCT02924181|Active Comparator|Rt PV CF blinded/lt PV CF guided|Fifteen patients will be allocated to this group. Right side pulmonary veins isolation will be performed without contact force information (using same catheter named SmartTouch Catheter). Then, left side pulmonary veins isolation will be performed with contact force information guidance.
2496822|NCT02924038|Experimental|IMA950/poly-ICLC subcutaneous (subQ) + Varlilumab IV|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously followed immediately by a Varlilumab 3mg/kg infusion (intravenously) -23±2 days (about 3 weeks) before the date of scheduled standard-of-care surgery to remove the WHO grade II glioma. Patients will continue receiving IMA950/poly-ICLC subcutaneous injections every week leading up to surgery (Days -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every 3 weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). After surgery, patients will continue receiving a Varlilumab infusion every 6 weeks immediately following the IMA950/poly-ICLC injection (Weeks A1, A7, A13, and A19).
2496827|NCT02924038|Experimental|IMA950/poly-ICLC subQ only|IMA950 4.96mg and poly-ICLC 1.4mg administered as one formulation subcutaneously every week leading up to standard-of-care surgery to remove the WHO grade II glioma (Days -23±2, -16±2, -9±2 and 24-48 hours prior to scheduled surgery) and every three weeks after surgery (Weeks A1, A4, A7, A10, A13, A16, A19, A22; defining Week A1 as the first post-surgery vaccine). Patients will not receive Varlilumab.
2496884|NCT02923700|Experimental|Leukocyte-rich PRP group|Three weekly knee intra-articular injections of leukocyte-rich PRP
2496885|NCT02923700|Experimental|Leukocyte-poor PRP group|Three weekly knee intra-articular injections of leukocyte-poor PRP
2496920|NCT02923440|Experimental|Congenital heart defects|
3162346|NCT00460356||Ancillary-Correlative (glycoprotein and glycan profiling)|Primary and metastatic tumor specimens are collected during lymphadenectomy and used for tissue microarray analysis, mutational analysis of T-synthase and Cosmc, immunohistochemical staining of Tn antigen and sialyl Tn antigen, and customized gene expression array analysis of 400 genes associated with glycobiology. Pre-lymphadenectomy blood is collected from patients at baseline for customized glycan array analysis of 300 carbohydrates.
3162347|NCT00460369|Active Comparator|1|sulfadoxine-pyrimethamine
3162348|NCT00460369|Active Comparator|2|artemether-lumefantrine
2497010|NCT02922842|Active Comparator|Tibial Nerve|Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
2497015|NCT02922842|Active Comparator|Parasacral|Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
2497018|NCT02922842|Sham Comparator|Shoulder|Transcutaneous electrical stimulation will be placed on the shoulder.
2497083|NCT02922491|Experimental|Group 1|"400 mg Vitamin E of synthetic source~1 once daily during 2 months"
2497084|NCT02922491|Experimental|Group 2|"400 mg Vitamin E of natural source~1 once daily during 2 months"
2497085|NCT02922491|Placebo Comparator|Group control|"400 mg of starch~1 once daily during 2 months"
2497086|NCT02922491|No Intervention|No intervention|Without intervention
2497113|NCT02922062|Experimental|Low Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO (protein):CHO (carbohydrate):FAT, 18:8:74). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
2497118|NCT02922062|Active Comparator|High Carbohydrate Diet|Half of the participants will be randomly assigned to this diet arm. The macronutrient composition of the diet will be (PRO:CHO:FAT, 18:60:22). There are three diet phases within this arm that use different fats as the primary cooking oil either canola oil, palm oil or butter. Each diet phase lasts for 3 weeks. At the end of each diet phase the testing battery completed at baseline will be repeated followed by a 2 week washout where subjects revert back to their usual diets. Canola oil is the low saturated fat control diet and is administered first. Participants then randomly begin either the palm oil or canola oil diet phases.
2497145|NCT02921724|Experimental|Cancer patients undergoing oral therapy|At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco. Patients are required to manually insert data into the mobile diary app at least once a day. Patients will be visited every 6 weeks. During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
2497217|NCT02921308||With BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
2497220|NCT02921308||Without BPD|No intervention will be administered. After informed consent is obtained, children will undergo ultra-short echo time pulmonary MRI, followed by PFT and completion of questionnaires.
2497242|NCT02921048||omega-3|individuals voluntarily taking at least 3 g/wk of EPA and DHA from dietary sources including fish oil supplements and ocean fish/shellfish consumption for a period of at least 6 months prior to enrollment in the study
2497243|NCT02921048||control|individuals who have consumed no more than 1 serving size (4-6 oz)/month of ocean fish/shellfish, or no more than 1 pill/month of fish oil supplement during the 6 month period preceding enrollment
2497290|NCT02920879|Other|0 CPAP/ 0 PEEP, driving pressure 10|Patients will be preoxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2498100|NCT02915861||EXPa|Scrub typhus patients: Group A
2496808|NCT02924233|Experimental|Sym004 + nivolumab|"Phase 1b, dose-escalation:~Dose Level 1: Sym004 + nivolumab (Q2W)~Dose Level 2: Sym004 + nivolumab (Q2W)~Dose Level -1: Sym004 + nivolumab, if needed"
2496810|NCT02924233|Experimental|Sym004 (RP2D) + nivolumab|"Phase 2b, dose-expansion:~Receiving Sym004 in the RP2D in combination with nivolumab (Q2W)"
2496812|NCT02924233|Active Comparator|Nivolumab|"Phase 2b, dose-expansion:~Receiving nivolumab monotherapy (Q2W)"
3195478|NCT00840151|Experimental|Treatment Group B|Individuals randomized to Treatment Group B will receive contingency management plus standard treatment for study weeks 1-6.
3195479|NCT00840151|No Intervention|Aftercare Group A|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group A will receive standard treatment for study weeks 7-12.
2497042|NCT02922530|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session
2497043|NCT02922530|Active Comparator|Active Comparator|Commercially available computerized training requiring up to a maximum of 80 treatment sessions, up to 7 sessions per week, 15-60 minutes per session.
2497132|NCT02922322|Active Comparator|Pilates Group|The Pilates Group was composed by 15 participants evaluated before and after 16 sessions of intervention with mat Pilates exercises.
2497134|NCT02922322|No Intervention|Control Group|The control group was composed by 15 participants that received no intervention
2497181|NCT02921685|Experimental|Monalizumab|Monalizumab treatment will be initiated 75 to 100 days after hematopoietic stem cells transplantation. Patients will receive a single dose of monalizumab by intravenous route over 1 hour.
2497199|NCT02921360|Experimental|12 hours|Non-contrast CT and CT-angiography are performed in 11 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 12 hours after thrombolysis
2497207|NCT02921360|No Intervention|24 hours|Non-contrast CT and CT-angiography are performed in 23 hours after thrombolysis. In case no haematoma is found, patient would receive 100 mg of acetylsalicylic acid per os daily starting from 24 hours after thrombolysis
3195480|NCT00840151|Experimental|Aftercare Group B|All participants will be re-randomized after study week 6. Those participants assigned to Aftercare Group B will receive contingency management treatment plus standard treatment for weeks 7-12.
3195481|NCT00840190|Experimental|P1446A-05|
2497394|NCT02920372|Experimental|EPOETIN ALFA|
2497433|NCT02920034|Active Comparator|Radiofrequency main renal artery|Renal sympathetic denervation of the main renal artery using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
2497436|NCT02920034|Experimental|Radiofrequency main and branches|Renal sympathetic denervation of the main renal artery, its branches and accessories using the radiofrequency-based Spyral™ catheter (Medtronic, MN, USA)
2497440|NCT02920034|Experimental|Ultrasound main renal artery|Renal sympathetic denervation of the main renal artery using the ultrasound-based Paradise™ catheter (ReCor, CA, USA)
2497469|NCT02919605|Experimental|Single dose of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg will be included, in a single dose.
2497470|NCT02919605|Experimental|Two doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during two weeks.
2497471|NCT02919605|Experimental|Three doses of Pentamidine|Fifty three patients using Pentamidine at a dose of 7 mg/kg, in a weekly dose, during three weeks.
2497575|NCT02919384|Experimental|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
2497579|NCT02919384|No Intervention|Control|Embryos in this arm will be cultured at 5% oxygen (current standard of care) from day 3 until blastocyst developmental assessment.
2497655|NCT02918903|Experimental|Minimal caries removal|the patients in this group will be treated by minimal caries removal technique, where only caries at lateral walls of cavity is removed, stainless steel crown preparation is performed and then stainless steel crown is placed as final restoration.
2497661|NCT02918903|Active Comparator|Complete caries removal|patients in this group will be treated by complete caries removal technique, where all caries will be removed, a base of resin modified glass ionomer is placed and then stainless steel crown is placed as final restoration.
2497703|NCT02918461|Experimental|Emerging from the Haze class|A 6-week psycho-educationally-based, cognitive behavioral program to help patients with subjective cognitive complaints after cancer treatment, titled Emerging from the Haze™ (Haze). Each series meets once a week for 2-2.5 hours for 6 weeks.
2497740|NCT02918188|Experimental|Hydrogen|Patients will receive hydrogen-rich water (4mL/kg three times one day, 0.8 ppm)
2497786|NCT02917980||surgical treatment|patients with structural heart disease received surgical treatment
2497787|NCT02917980||interventional treatment|patients with structural heart disease received interventional treatment
2497788|NCT02917980||surgical combined with interventional treatment|patients with structural heart disease received surgical combined with interventional treatment
2498104|NCT02915861||EXPb|Scrub typhus patients: Group B
3195482|NCT00840229|Experimental|1 capsular & intra-articular|corticosteroid injection (Triamcinolone) in capsule/rotator interval and intra-articular
3195483|NCT00840229|Active Comparator|2 intra-articular|corticosteroid injection (Triamcinolone) intra-articular placebo injection (Lidocaine) in capsule
3195484|NCT00840229|Placebo Comparator|3 placebo|placebo injections (Lidocaine) in capsule and intra-articular
3195485|NCT00840242|Experimental|Nicotine gum|Nicotine gum
3195486|NCT00840242|Placebo Comparator|Placebo gum|Placebo gum
3195487|NCT00840242|Active Comparator|Nicotine inhaler|Nicotine inhaler
3195488|NCT00840242|Placebo Comparator|Placebo inhaler|Placebo inhaler
3208738|NCT00977626|Experimental|Part 3 - AZD2423|AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
3208739|NCT00977652|Active Comparator|Active stimulation|Percutaneous posterior tibial nerve stimulation
3195489|NCT00840255|Active Comparator|Breif Behavioral Treatment of Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
2496889|NCT02923492|Experimental|In-person Therapy by ED Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered by ED staff in-person.
2496891|NCT02923492|Experimental|Remote Therapy by Research Staff|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care delivered remotely (over video) by research staff.
2496893|NCT02923492|No Intervention|Comparison Group|This group will not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
2496913|NCT02923388|Active Comparator|Experimental|"Intervention: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks."
2496916|NCT02923388|Placebo Comparator|Placebo|"Intervention: Injection normal saline (1 ml) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.~Intervention: Oral placebo pill 2 tablets thrice daily for 5 weeks."
2496985|NCT02923089|Experimental|Small Green Lentil Muffin|Muffin: 25g available carbohydrate from small green lentil
2496989|NCT02923089|Experimental|Split Red Lentil Muffin|Muffin: 25g available carbohydrate from split red lentil
2496995|NCT02923089|Placebo Comparator|Wheat Muffin|Muffin: 25g available carbohydrate from wheat
2496996|NCT02923089|Experimental|Small Green Lentil Soup|Soup: 25g available carbohydrate from small green lentil
2497001|NCT02923089|Experimental|Split Red Lentil Soup|Soup: 25g available carbohydrate from split red lentil
2497003|NCT02923089|Placebo Comparator|Potato Soup|Soup: 25g available carbohydrate from potato
2497006|NCT02923089|Experimental|Small Green Lentil Chili|Chili: 25g available carbohydrate from small green lentil
2497009|NCT02923089|Experimental|Split Red Lentil Chili|Chili: 25g available carbohydrate from split red lentil
2497013|NCT02923089|Placebo Comparator|Rice Chili|Chili: 25g available carbohydrate from rice
3195490|NCT00840255|Other|Information Control|This arm of the study does not receive the Brief Behavioral Treatment for Insomnia. This arm will act as the control arm.
3195491|NCT00840268|Experimental|HPGG 0.25%|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
3195492|NCT00840268|Placebo Comparator|HPGG Vehicle|Hydroxypropyl Guar Galactomannan Vehicle, 1 drop per eye twice daily (BID) (in the morning upon awakening and in the evening prior to bedtime) for 21 days (Treatment phase).
3195493|NCT00840320|Experimental|1|Repeat doses of active at escalating doses
2497137|NCT02921997|Experimental|Arm 1|10 Subjects: one dose of 15 µg of A/H3N2v, at Day 1
2497138|NCT02921997|Experimental|Arm 2|10 Subjects: two doses of 3.75 µg of AH7N9 AS03,at Day 1 and at Day 29
2497139|NCT02921997|Experimental|Arm 3|10 Subjects: two doses of 3.75 µg of A/H7N9, at Day 1 and Day 29
2497187|NCT02921633|Experimental|Intervention letter|Centrally-sent behavioural-insight informed invitation letter.
2497188|NCT02921633|No Intervention|Control|No centrally-sent invitation letter.
2497204|NCT02921282||Genotype dopamine|Genotyping will be conducted at the conclusion of the study
2497209|NCT02921282||Genotype cannabinoids|Genotyping will be conducted at the conclusion of the study
3195494|NCT00840320|Placebo Comparator|2|Repeat doses of placebo
3195495|NCT00840333|Experimental|1|CF PATIENTS 6-11 YEARS OF AGE
3195496|NCT00840333|Experimental|2|CF PATIENTS 12-16 YEARS OF AGE
2497395|NCT02920398|Experimental|N8-GP pivotal|
2497396|NCT02920398|Active Comparator|N8-GP commercial|
2497412|NCT02919930|Other|Oronasal - Nasal|Patients undergo polysomnography with oronasal mask during the first night and nasal mask during the second night.
2497415|NCT02919930|Other|Nasal - Oronasal|Patients undergo polysomnography with nasal mask during the first night and oronasal mask during the second night.
2497472|NCT02919800|Experimental|MOD-5014|MOD-5014 longevity is the result of fusion of three consecutive C-terminal peptide (CTP) domains to the C-terminus of FVII. CTP technology is based on a natural peptide, the C-terminal peptide of the beta chain of human chorionic gonadotropin (hCG), which provides hCG with the required longevity to maintain pregnancy (initial half-life [t1/2] ~10 h, terminal t1/2 ~37 h). The beta chain of luteinizing hormone (LH), a gonadotropin that triggers ovulation, is almost identical to hCG but does not include the CTP. As a result, LH has a significantly shorter half-life in blood (initial t1/2 ~1 h, terminal t1/2 ~10 h) (Fares et al., 1992).
2497473|NCT02919800|Placebo Comparator|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
3195497|NCT00840346|Experimental|1|The first patients enrolled in the trial will be successively distributed into three cohorts of patients for each dose level of panobinostat (20 mg, 30 mg, 40 mg) in combination with idarubicin and cytarabine, according to the classical 3+3 schedule
3195498|NCT00840359|Experimental|1 PDT|Leishmania lesion
3195499|NCT00840359|Active Comparator|Cryo|Leishmania lesion
3195500|NCT00840372||1|Chronic hemodialysis patients, native arterio-venous fistula
2497806|NCT02917954|No Intervention|ePRO Control (3 or 6 months)|Control participants will complete surveys at baseline, 3 months, and/or 6 months. Surveys will capture patient demographics, their assessment of quality-of-life, chronic disease management, and primary care experience. A part from completing these surveys, no change to routine care will be seen.
2497895|NCT02917473|Other|Control|"Education and counseling as commonly delivered to the patients in clinical practice.~Brief oral counseling to the patient focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for their first-degree relatives, who should be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examination"
2496881|NCT02923739|Experimental|Arm II (paclitaxel, bevacizumab, emactuzumab)|Patients receive paclitaxel and bevacizumab as in Arm I. Patients also receive emactuzumab IV over 30 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2496942|NCT02923284||Imaged renal mass cohort|Subjects undergoing surgery for an kidney tumor identified radiologically.
2496947|NCT02923284||control cohort|Subjects undergoing surgery for any kind of cancer other than kidney.
2496962|NCT02923141|Active Comparator|Neutral Writing + Contingency Management|Participants will attend four attention-matched control sessions, consisting of face-to-face administration of psychological measures and neutral writing exercises. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
2496964|NCT02923141|Active Comparator|Expressive Writing + Contingency Management|Participants will attend four expressive writing sessions focusing on traumatic or stressful events. Participants will also take part in 36 contingency management sessions in which they provide self-collected urine for toxicology screening and receive financial incentives for each negative drug result.
2496974|NCT02922894|Experimental|Acute episodic hypoxia|To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
2496977|NCT02922894|Experimental|Supplemental oxygen|To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
2496979|NCT02922894|Experimental|Trazodone or placebo|examine the effect of trazodone on breathing during sleep
2497049|NCT02922673|Experimental|Treatment group|7 day treatment with placebo - first LPS challenge - 7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - second LPS challenge
2497060|NCT02922673|Active Comparator|Prophylaxis group|7 day treatment with ASA 80 mg (with a loading dose of 160 mg on the first day) - first LPS challenge - 7 day treatment with ASA (no loading dose on first day) - second LPS challenge
2497063|NCT02922673|Placebo Comparator|Placebo group|7 day treatment with placebo - first LPS challenge - 7 day treatment with placebo - second LPS challenge
2497092|NCT02922179||Diabetes Type 1|Individuals diagnosed with type 1 diabetes exposed to Long- and intermediate- acting insulins
2497094|NCT02922179||Diabetes Type 2|Individuals diagnosed with type 2 diabetes exposed to Long- and intermediate- acting insulins
2497171|NCT02921945|Experimental|SCT800|
3195501|NCT00840372||2|Chronic hemodialysis patients, native arterio-venous fistula
2497264|NCT02920892|Experimental|AFQ056 group with language intervention|12 month treatment phase during which subjects are randomized to AFQ056. The initial dose of AFQ056 will be 25 mg BID. If the subject has no side effects the dose will be titrated (mandatory titration if no side effects) to the next level, 50 mg BID, 75 mg BID and 100 mg BID in order. A flexible dose design will mimic practice, and allow use of maximum tolerated dose (MTD) which is likely to be most effective. The dose can be adjusted weekly through week 7. After 7 weeks the dose will be fixed, and at the 2 month visit all subjects will initiate the language intervention, remaining on a stable AFQ056/placebo dose for the next 6 months.
2497268|NCT02920892|Placebo Comparator|Placebo group with language intervention|12-month treatment phase during which subjects are randomized to placebo. At the 2 month visit (language intervention baseline visit) all subjects will initiate the language intervention, remaining on placebo dose for the next 6 months.
3195502|NCT00840385|Experimental|A|
3195503|NCT00840398|Experimental|1|
3195504|NCT00840398|Active Comparator|2|
2497432|NCT02920047|Experimental|Sequence A|"Period 1(Treatment A) - Period 2(Treatment A) - Period 3(Treatment B)~There will be a washout of 14 days between the each period."
2497435|NCT02920047|Experimental|Sequence B|"Period 1(Treatment A) - Period 2(Treatment B) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
2497439|NCT02920047|Experimental|Sequency C|"Period 1(Treatment B) - Period 2(Treatment A) - Period 3(Treatment A)~There will be a washout of 14 days between the each period."
2497480|NCT02919631|Active Comparator|triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
2497484|NCT02919631|Placebo Comparator|placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day
2497570|NCT02919345|Experimental|Dapagliflozin|Dapagliflozin 10 mg in addition to Metformin 1500 mg
2497574|NCT02919345|Active Comparator|Glibenclamide|Glibenclamide 5mg in addition to Metformin 1500 mg
2497637|NCT02918864|Experimental|ION-ASD|ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training).
2497644|NCT02918864|Active Comparator|Facilitated Play|The active comparison condition is a facilitated play therapy group.
2497709|NCT02918487|Experimental|Active|[Formoterol + Fluticasone] Single maintenance and reliever therapy(SMART) and Active polyherbal capsule
2497714|NCT02918487|Placebo Comparator|Placebo|[Formoterol + Fluticasone] conventional along with inert similar looking placebo capsules
2497802|NCT02918084|Sham Comparator|ARM A|Adjuvant chemotherapy → Aromatase inhibitors x 5 yrs (sequential arm)
2497804|NCT02918084|Experimental|ARM B|Adjuvant chemotherapy + Aromatase inhibitors x 5 yrs (concurrent arm)
2497950|NCT02916862|Experimental|Soluble Corn Fiber (SCF) + Calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
2497951|NCT02916862|Active Comparator|Soluble Corn Fiber (SCF) without calcium|This group will receive 12 g/d of soluble corn fiber (SCF) + 600 mg/d of elemental calcium carbonate, administered twice a day
2497954|NCT02916862|Placebo Comparator|Placebo|This group will receive a similar supplement without SCF or calcium, administered twice a day
2498106|NCT02915861||EXPc|Scrub typhus patients: Group C
2498109|NCT02915861||EXC|Control group
3195505|NCT00840489|Experimental|Ribavirin|Ribavirin 1000-1200 mg qd
3195506|NCT00840489|Active Comparator|Colchicine|Colchicine 0.5 mg bd
2496907|NCT02923609|Experimental|SC Group|In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).
2496944|NCT02923297|Other|Parkinson's disease patients|blood sampling
2497023|NCT02923076|Experimental|Study treatment|Allogeneic transplantation with CCR5 delta32/delta32 hematopoietic cells from cord blood.
2497034|NCT02922595|Active Comparator|Intubation through ILMA®|The ILMA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. The Intervention will be the intubation through ILMA. We will measure the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
2497036|NCT02922595|Experimental|Intubation through ILTS®|The ILTA will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers. It will be proceeded to the intubation through ILTS and the time necessary to insert it, the possibility to ventilate the patient through it and the success rate of tracheal intubation through it will be assessed.
2497101|NCT02922348|Experimental|Hormone Replacement Therapy|Patient will be given hormones in the form of: transdermal estradiol patch (Climara) 100 mcg/24 hours weekly, progesterone (Prometrium) 200 mg per day for first 12 calendar days of each month (If patients insurance plan does not cover transdermal estradiol, they will be prescribed oral estradiol 2 mg daily. If patients insurance plan does not cover Prometrium, they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month).
2497106|NCT02922348|Experimental|Combined Oral Contraceptives|Patients will be given hormones in the form of: monophasic combined oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.25 mg, 1 tablet daily (21 days of active pills and 7 days of inactive pills)
3195507|NCT00840502||Pregnant women|Pregnant women who present at the SMRU antenatal clinics on the Thai Burmese border.
3195508|NCT00840515||Emulsion|
2497233|NCT02921191||Lung cancer|Lung cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF.
2497235|NCT02921191||Breast cancer|Breast cancer patients receiving their first cycle of Grade III and IV myelosuppressive chemotherapy regimen treated prophylactically with G-CSF (filgrastim, TBO-filgrastim or pegfilgrastim)
2497284|NCT02920905|Experimental|lidocaine|• Patients in group A will receive 3 mg/kg of lidocaine 2% diluted with saline to a total volume of 40 ml.
2497286|NCT02920905|Experimental|lidocaine & atracurium|• Patients in group B receive 3 mg/kg of lidocaine 2% + 2 mg atracurium diluted with saline to a total volume of 40 ml.
2497289|NCT02920905|Experimental|lidocaine & atracurium & Mg sulphate|• Patients in group C will receive 3 mg/kg of lidocaine 2% + 2 mg atracurium mixed with 10 mg /kg magnesium sulphate diluted with saline to a total volume of 40 ml.
2497355|NCT02920502|Placebo Comparator|Arm 1: Placebo|Normal Healthy Volunteers without any skin pathology, will receive placebo
2497357|NCT02920502|Experimental|Arm 2: cholecalciferol: 50,000 IU|Normal healthy Volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 50,000 IU.
2497361|NCT02920502|Experimental|Arm 3: cholecalciferol: 100,000 IU|Normal healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 100,000 IU.
2497365|NCT02920502|Experimental|Arm 4: cholecalciferol: 200,000 IU|Normal Healthy volunteers will randomized into one of three groups and receive a one time dose of cholecalciferol at 200,000 IU.
3195509|NCT00840528|Experimental|Ozone exposure|Exposure to ozone at 0.4ppm
3195510|NCT00840541||DR|Type-2 diabetic subjects diagnosed with diabetic retinopathy (DR).
2497526|NCT02919462|Experimental|Treatment Arm A|"Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) + Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles.~Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks)."
2497527|NCT02919462|Active Comparator|Treatment Arm B|"Pemetrexed, 500 mg/m2, day 1 + Cisplatin, 75 mg/m2, day 1 every 3 weeks, for 4 cycles.~Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks).~7-10 days before treatment administration, premedication with vitamin B12 1000µg intramuscular injection (every 9 weeks) and folate 1mg every day should be commenced."
2497585|NCT02919176|Active Comparator|Mirabegron|Mirabegron 50 mg/day
2497589|NCT02919176|Active Comparator|Pioglitazone|Pioglitazone 30 mg/day
2497593|NCT02919176|Experimental|Mirabegron and Pioglitazone|Combination of Mirabegron 50 mg/day and Pioglitazone 30 mg/day
2497659|NCT02918760|Experimental|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
2497664|NCT02918760|Placebo Comparator|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
2497722|NCT02918409|Active Comparator|Standard colistin arm|Subjects initially receive IV colistin 2.5 mg/kg/d divided into three times daily (TID) dosing. Subjects receiving colistin will undergo a 2 day up-titration of dose to an ultimate dose of 4-5 mg/kg/day, for a total treatment of 14 days. The drug is infused over 30 minutes on a TID dosing schedule.
2497728|NCT02918409|Active Comparator|Modified colistin arm|Subjects receiving IV colistin undergo a 2 day up-titration to a maximum dose of 5 mg/kg/day, divided into twice daily (BID) dosing, for a total treatment of 14 days. The drug is infused over 30 minutes BID. Steady state plasma concentrations on day 3 of therapy (on 2nd- 3rd dose once at goal dosing) will be measured; specifically, colistin peak (30 minutes after infusion), midpoint (6 hour) and trough (30 minutes prior to next infusion).
2498108|NCT02915926|Experimental|OT+OPC|occupational performance coaching
3195511|NCT00840554|Active Comparator|Physical Therapy|
3195512|NCT00840554|Experimental|Home Exercise|
2496965|NCT02923128|Sham Comparator|Routine PCIA|Routine patient controlled intravenous analgesia(PCIA) formula is sufentanyl(0.06ug.kg-1.h-1),diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
2497005|NCT02922855|No Intervention|Contemporaneous Control|This group is our 'usual care' control group. They were not contacted for an interview and were not offered an incentive to visit their primary care physician.
2497008|NCT02922855|Active Comparator|$0 group|This group completed a baseline interview but was not offered any incentive if they visited their primary care physician.
2497012|NCT02922855|Experimental|$25 group|This group completed a baseline interview and was offered $25 they visited their primary care physician within 6 months.
2497017|NCT02922855|Experimental|$50 group|This group completed a baseline interview and was offered $50 they visited their primary care physician within 6 months.
2497048|NCT02922647|Experimental|suprapubic catheterization|Intervention:suprapubic catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
2497058|NCT02922647|Active Comparator|transurethral catheterization|Intervention:transurethral catheterization after rectal resection with low anastomosis. Evaluate the urinary tract infection rate on the four days postoperative.
2497095|NCT02922283|Experimental|IL2-PET scan|[18F]FB-IL2 PET scan, Tumor biopsy, CT scan, Biopsy of non-target tissue
2497146|NCT02921854|Experimental|All included patients|3 times Blood withdrawal for each patient (25ml each)
2497182|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard XP|The new Vanguard XP Total knee arthroplasty system is a further development of the Vanguard TKA. The new Vanguard XP system both cruciate ligaments are preserved.
2497183|NCT02921594|Active Comparator|Total knee arthroplasty with Vanguard CR|Total knee arthroplasty system without preservation of the anterior cruciate ligament
2497195|NCT02921334|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation.
2497201|NCT02921334|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
2497283|NCT02921139|Experimental|Arm I|Stereotactic ablative radiotherapy (SABR)
2497287|NCT02921139|Active Comparator|Arm II|Re-transcatheter arterial chemoembolization (re-TACE)
2497352|NCT02920541|Experimental|S 055746|
2497397|NCT02920203||index cases group|unexpected sudden death cases recruited by forensic institutes or pathology departements
2497398|NCT02920203||first degree relatives group|Relatives enrolled of unexpected sudden death index cases
2497455|NCT02919969|Experimental|Pembrolizumab|"Pembrolizumab is administered every 3 week intravenously~Dosage to be determine by physician"
2497477|NCT02919514|Active Comparator|Physical training on hard surface|Subject will participate in exercise training on a firm surface for 50 min/session, 3 days/week for 6 weeks in total.
2497479|NCT02919514|Experimental|Physical training on sand surface|Subject will participate in exercise training on a sand surface for 50 min/session, 3 days/week for 6 weeks in total.
2497481|NCT02919514|Experimental|Physical training on soft surface|Subject will participate in exercise training on a soft surface for 50 min/session, 3 days/week for 6 weeks in total.
2497544|NCT02919293|Experimental|Adjuvant-Free MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant-free MenAC-Hib conjugate vaccine.
2497545|NCT02919293|Active Comparator|Adjuvant MenAC-Hib Conjugate Vaccine Group|Participants randomized to receive adjuvant MenAC-Hib conjugate vaccine.
2497614|NCT02919059|Experimental|Dapagliflozin 10 mg|Dapagliflozin 10 mg once daily during 24 weeks
2497615|NCT02919059|Active Comparator|Glimepiride 4 mg|Glimepiride 4 mg once daily during 24 weeks
3162349|NCT00460369|Active Comparator|3|amodiaquine-artesunate coformulation
3162350|NCT00460473|Experimental|Dexmedetomidine|
2497827|NCT02917798||Genetic Testing in Ovarian ,Prostate or Pancreas Cancer|This study is a prospective single-arm study to examine how an alternative clinical genetics cancer care delivery model affects ovarian, prostate or pancreas cancer patients' cognitions, emotions, and behaviors. Participants will be contacted 1 week (+/- 1 week) (Assessment #2; and 3 months (+/- 2 weeks) (Assessment #3;) following the telephone post-test counseling session to complete the follow-up assessments. These assessments will measure psychological and behavioral study constructs.
2498048|NCT02916797|Experimental|Stepping training with feedback|Subjects stand in a step standing position with placing the affected leg on the load cells of the VWTM and the non-affected leg slightly backward outside the load cells, look forward to light bars of the displayed section which will be set at their eye level. Then subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can. Subjects repetitively practice the task for 30 minutes with a period of sufficient rest as required.
2498049|NCT02916797|No Intervention|Stepping training without feedback|Subjects will be trained and instructed the same as the experimental group but without using the displayed section, for approximately 30 minutes/day (excluding rest periods), 5 days/week, for 4 week. Then, every subject will be trained to walk overground with or without a walking device for 10 minutes in order to promote transferability of the part-task practice to the whole/target task. Subjects still receive routine treatments from other rehabilitation professionals as needed during participation in the study.
3162351|NCT00460473|Placebo Comparator|Placebo (PBO)|
3162352|NCT00460499|Active Comparator|B Low dose GIK|This group will have low doses of glucose and insulin
3162353|NCT00460499|Active Comparator|C High Dose GIK|This group will have high doses of insulin and glucose
3162354|NCT00460499|Active Comparator|A Insulin|This group will receive only an intravenous insulin infusion
3162355|NCT00460512|Experimental|Paliperidone Extended Release (ER)|
3162356|NCT00460538|Placebo Comparator|2|
3162357|NCT00460538|Active Comparator|1|
3162358|NCT00460590|Experimental|1|12 adults with prior BCG
3162359|NCT00460590|Experimental|2|12 adults without prior BCG
3162360|NCT00460590|Experimental|3|12 Adolescents
3162361|NCT00460616||1|Patients already receiving treatment with cabergoline.
3162362|NCT00460616||2|healthy controls sex and age-matched with the patients
2496988|NCT02923063|Experimental|Combined Aerobic and Resistance Exercise|"Exercise will be supervised by exercise trainers 3 days per week for 12 weeks via videoconferencing. Aerobic intervention sessions of 30-minute duration will target 60-80% of the maximal heart rate (or rating of perceived exertion of 13 on a scale of 6-20). We will encourage adherence to 50% ambulatory based and 50% cycling based aerobic exercise each session targeting the same goal heart rate.~Resistance exercises occur 3 times weekly. The load will be adjusted for each exercise as needed on successive sets to ensure that subjects achieved momentary failure in the target repetition range. The load will be increased based on the supervising researcher's assessment of what would be required to reach momentary failure in the desired loading range; if less than 8 repetitions were accomplished, the load was similarly decreased. All routines will be directly supervised by the research team to ensure proper performance of the respective routines."
2496990|NCT02923063|No Intervention|Usual Care|"The control group will receive a one-time counseling session on appropriate dietary and physical activity recommendations. They will receive a Go4Life Workout to go sample exercise routing created by the national institutes on aging (NIA)."
3162363|NCT00460668|Experimental|Pulmonary rehabilitation post-thoracotomy|Pulmonary rehabilitation post-thoracotomy
3162364|NCT00460668|No Intervention|Control|Control
3162365|NCT00460707|Experimental|Cohort 1|All subjects in Cohort 1 will receive ketoconazole 400 milligrams (mg) once daily on Day 1 to 9 and oral casopitant 150 mg on Day 4 and 50 mg on Day 5 and Day 6 of treatment period 1. After a washout period of 21 days, subjects will be administered oral casopitant 150 mg on Day 1 and 50 mg on Day 2 and Day 3 of treatment period 2.
3162366|NCT00460707|Placebo Comparator|Cohort 2, Group A|Subjects will receive placebo once daily on Day 1 to Day 3 in treatment period 1. Subjects will receive ketoconazole 400 mg once daily on Day 1 to Day 9 and oral placebo once daily on Days 4, 5 and 6 in treatment period 2. There will be a 14-day washout period between treatment periods 1 and 2.
3162367|NCT00460707|Experimental|Cohort 2, Group B|In treatment period 1, subjects will receive oral casopitant 150 mg on Day 1 and 50 mg on Days 2 and 3. In treatment period 2, they will be administered ketoconazole 400 mg once daily on Day 1 to Day 9 and oral casopitant 150 mg on Day 4 and 50 mg on Days 5 and 6. There will be a 14-day washout period between treatment periods 1 and 2.
3162368|NCT00460720||001|
2497225|NCT02921399||early eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
2497228|NCT02921399||late eradication group|In the post-endoscopic resection period, patients were grouped by timing (i.e., initiation) of therapy to eradicate H. pylori as follows: 1) early (≤ 2 weeks), 2) late (≥ 8weeks).
2497271|NCT02921074|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2497277|NCT02921074|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.
2497362|NCT02920645||AVM-related ICH patients|patients that suffered intracerebral hemorrhage (ICH) due to a ruptured artery-venous malformation (AVM)
2497400|NCT02920255||Electronic Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with electronic calipers.
2497401|NCT02920255||Conventional Caliper Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with conventional calipers.
2497402|NCT02920255||X-ray Measurements|This arm would be the spinal diagnostic measurements taken at the hips and shoulders of participants with x-rays.
2497458|NCT02919878|Experimental|pre-op Gemcitabine & XRT|"Pre-op chemo: Gemcitabine will be administered as continuous infusion IV over 24 hrs (100 mg/m2) weekly for 6 wks starting on day 1 of Radiotherapy (XRT).~XRT/ Intensity modulated radiotherapy(IMRT): 1.8 Gy/fx, 5 fractions/wk will be delivered. Pelvis will receive 45 Gy/25 fractions/5 wks with a boost dose of 5.4 Gy for T3 and 9 Gy for T4 to a cone down volume. The total tumor dose= 50.4 -54 Gy.~Post-op chemo: Standard 6 cycles of adjuvant Capecitabine (1250 mg/m2) PO twice per day on days 1-14 each cycle, (every 21 days) in patients who have a complete resection of rectal cancer and negative surgical margins."
2497500|NCT02919488|Experimental|Exercise Condition|
2497502|NCT02919488|Active Comparator|Control Condition|
2497536|NCT02919254|Active Comparator|High Dosage|Subjects will receive approximately 8 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
2497537|NCT02919254|Active Comparator|Moderate Dosage|Subjects will receive approximately 0.5 mmol of dietary nitrate per day delivered as a commercially available beetroot juice supplement for 7 days.
2497539|NCT02919254|Placebo Comparator|Placebo|Subjects will receive a placebo beverage containing negligible nitrate for 7 days.
2497605|NCT02919085|Experimental|Mobilization|
2497973|NCT02916810|Active Comparator|Active rTMS stimulation|Real active rTMS stimulation.
2497975|NCT02916810|Sham Comparator|Sham rTMS stimulation|Sham repetitive TMS stimulation.
3162369|NCT00460733|Experimental|1|
3162370|NCT00460733|Active Comparator|2|
3162371|NCT00460759|Experimental|Moxifloxacin and Rifapentine|
3162372|NCT00460837|Active Comparator|1 A|gastrofin & Picolax
3162373|NCT00460837|Active Comparator|2|senna
3162374|NCT00460850|Experimental|1|
3162375|NCT00460902|Experimental|Deep TMS stimulation|
3162376|NCT00460902|Experimental|DTMS with positive cognitive-emotional provocation|
3162377|NCT00460902|Experimental|DTMS with negative cognitive-emotional provocation|
3162378|NCT00460928|Experimental|intravenous immune globulin (IVIG)|
3162379|NCT00460941|Placebo Comparator|Placebo|sc weekly
3162380|NCT00460941|Experimental|Taspoglutide 20mg|sc weekly
3162381|NCT00460941|Experimental|Taspoglutide 20mg-30mg|sc weekly
3162382|NCT00460941|Experimental|Taspoglutide 20mg-40mg|sc weekly
3162383|NCT00460967|Experimental|1|Rheopheresis treatment
3162384|NCT00460967|Sham Comparator|2|Sham treatment
3173577|NCT00613600|Experimental|1|Two 665 mg capsules of glucomannan three times a day for eight weeks
3173578|NCT00613600|Placebo Comparator|2|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
2497033|NCT02922569|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training and mindfulness training requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
2497035|NCT02922569|Active Comparator|Active Comparator|Commercially available computerized training and traumatic brain injury information session requiring a total maximum of 60 treatment sessions, up to 5 sessions per week, 40 minutes per session.
2497211|NCT02921555|Experimental|methylprednisolone & prednisone|Intravenous bolus of methylprednisolone followed by a decreasing conventional course of oral prednisone
2497215|NCT02921555|Active Comparator|prednisone|A decreasing conventional course of oral prednisone
2497259|NCT02920840|Active Comparator|Intermittent theta-burst stimulation|Intervention: application of 200 TMS triplet bursts (at 100 Hz, inter-burst interval 200ms) over left dorsolateral prefrontal cortex
2497265|NCT02920840|Experimental|Negative-peak-triggered-TMS|Intervention: application of 200 brain-state dependent 100 Hz TMS triplet bursts triggered at the negative peak phase of the ongoing endogenous alpha-band oscillation (as detected by surface EEG over left dlPFC)
2497269|NCT02920840|Active Comparator|Open-loop replay TMS|"Intervention: application of the same sequence of TMS pulses as in condition Negative-peak-triggered-TMS, i.e. irrespective of ongoing brain state over left dlPFC"
2497346|NCT02920632|Experimental|Online cognitive training 1 (N=70)|Eight-week, three times a week during 45 minutes cognitive training
2497347|NCT02920632|Active Comparator|Online cognitive training 2 (N=70)|Eight-week, three times a week during 45 minutes cognitive activities
2497348|NCT02920632|No Intervention|Healthy control subjects (N=30)|Reference group to compare cognitive training effects to
2497414|NCT02920307|Experimental|TEP without fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair without mesh fixation
2497418|NCT02920307|Active Comparator|TEP with fixation|Standard totally extraperitoneoscopic preperitoneal (TEP) hernia repair
2497419|NCT02920307|Experimental|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) hernia repair without mesh fixation
2497421|NCT02920307|Active Comparator|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) hernia repair
3162385|NCT00460980|Other|Virtual reality laparoscopic simulator|"Virtual reality laparoscopic simulator training:~Residents will participate in a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience."
2497753|NCT02918227|Experimental|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
2497830|NCT02917902|Experimental|Immediate intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting immediately after randomization. Patients will continue to receive routine medical care at the Free Clinic.
2497832|NCT02917902|Other|Delayed intervention|Intervention: Food boxes. Monthly boxes of food for 6 months, along with brief educational information from food pantry staff regarding eating healthy on a budget, starting 3 months after randomization. Patients will continue to receive routine medical care at the Free Clinic. Participants will be given referrals to local food pantries in their neighborhoods that provide food free of charge as well as referrals for CalFresh (formerly known as food stamps) during the 3 month time frame when patients are waiting to receive food distributions on site at the clinics.
2497870|NCT02917460|Experimental|Enrollees|Enrollment of healthy and affected subjects to collect samples and data for a pediatric genomic Biorepository. Data includes genomic sequencing and resultant molecular diagnostic results, if any.
3162386|NCT00461006|Experimental|Aleglitazar|
2498043|NCT02916264|Active Comparator|a scalp block|A standard scalp block ,with 0.5% bupivacaine total dose < 3 mg/kg, is performed by an anesthesiologist.
2498045|NCT02916264|No Intervention|no scalp block|An anesthesiology will pretend to perform the scalp block,
2498065|NCT02915991||All patients|This is a single-arm study, so all patients enrolled will be in this arm and will undergo diagnostic catheterization procedure as per standard hospital care.
2498130|NCT02915822|Experimental|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique to surgically correct Hallux Valgus
2498131|NCT02915822|Active Comparator|Open Scarf/Akin osteotomy|Open technique to surgically correct Hallux Valgus
2498183|NCT02915315||Baseline survey period|All subjects will continue a normal diet for 3 days in which questionnaire design and anthropometric measurements will be implemented.
2498190|NCT02915315||Low-salt diet|All subjects will be instructed to maintain a low-salt diet for 7 days (3g of salt or 51.3mmol of sodium per day).
2498202|NCT02915315||High -salt diet|After washout period, all subjects will be instructed to maintain a 18g of salt or 307.8mmol of sodium per day.
2498291|NCT02914587|Experimental|ARTAS System|Implantation with the ARTAS System.
2498294|NCT02914587|Active Comparator|Manual Implantation|Implantation manually.
2499517|NCT02905942|Active Comparator|rhG-CSF|Patients in control group received rhG-CSF day +1 after transplantation.
3162387|NCT00461006|Active Comparator|Actos|
3162388|NCT00461019|Experimental|Implantation of the CardioFit system|
3162389|NCT00461058|Active Comparator|Actos|
3162390|NCT00461058|Experimental|Aleglitazar|
3162391|NCT00461071|Active Comparator|Internet-based self-help|Internet-based self-help behavioural
3162392|NCT00461071|Active Comparator|Bibliotherapy|bibliotherapy
3162393|NCT00461084||1|lymphoma follicular
3162394|NCT00461084||2|lymphoma non-follicular
3162395|NCT00461110|Experimental|1|Active
3162396|NCT00461110|Experimental|2|Active
3162397|NCT00461162|Experimental|1: i-DSMP|Internet Dyspnea Self-management Program (i-DSMP)
3162398|NCT00461162|Experimental|2: f-DSMP|Face-to-Face Dyspnea Self-management Program (f-DSMP)
3162399|NCT00461162|Active Comparator|3: AC|Attention Control (AC)
2497096|NCT02922049|Other|pCLE vs. biopsies with histopathology|"The investigators will compare diagnostic accuracy and sensitivity of pCLE with standard biopsies in patients with esophageal and gastric lesions and in patients after completed endoscopic treatment of BORN.~All samples taken by biopsies will be correlated with the images taken by pCLE in the detection of lesions, intestinal metaplasia, dysplasia and buried glands."
2497160|NCT02921919|Experimental|Talazoparib|
3162400|NCT00461240||acromegaly|
3162401|NCT00461240||growth hormone deficiency|
3162402|NCT00461266|Experimental|1|
2497920|NCT02917187|Experimental|Randomized Group 1|After two week run-in, BIIB074 three times a day (TID) followed by placebo (TID) after two week washout period
2497923|NCT02917187|Experimental|Randomized Group 2|After two week run-in, Placebo three times a day (TID) followed by BIIB074 (TID) after two week washout period
2497978|NCT02916732||Module 1|Identification and monitoring of pregnant women who develop clinical signs of acute infection due to ZIKV (standard monitoring report)
2497979|NCT02916732||Module 2|Monitoring of pregnant women with a suspected embryofetopathy (standard monitoring report)
2497982|NCT02916732||Module 3|Trimester biological collection of all pregnant women during the outbreak of Zika (standard monitoring report)
2497983|NCT02916732||Module 4|Biological collection of maternal blood and cord blood collected during the delivery
2497985|NCT02916732||Module 5|Biological collection of maternal blood and fetal tissues of pregnant women whose pregnancies started during the outbreak of Zika , ends in an spontaneous abortion, Induced abortion or intrauterine fetal demise
2498037|NCT02916381|Experimental|PEC block|Ultrasound-guided PEC block after induction of general anaesthesia.
2498040|NCT02916381|Sham Comparator|Control|No ultrasound-guided PEC block; only general anaesthesia will be provided.
3162403|NCT00461266|Active Comparator|2|
2498157|NCT02915471|Experimental|Virtual Peer-to-Peer Support Mentoring|n addition to standard medical care, adolescents in the experimental group will receive the iP2P support program, a manualized peer-mentorship program that will provide mentoring and reinforcement by peers (young adults with cancer aged 16-25 years who have learned to function successfully with their cancer to the mentored participants).
2498159|NCT02915471|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the iP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
2498189|NCT02915185|Experimental|strength training intervention|Strength training of the affected upper limb in chronic stroke survivors
2498194|NCT02915185|Experimental|direct-current brain stimulation (tDCS)|tDCS real of sham will be applied during each session of the strength training intervention
3162404|NCT00461279|Other|1|
3162405|NCT00461279|Other|2|
3162406|NCT00461396||Group 1|
3162407|NCT00461422|Experimental|1|Standard Flexible antagonist protocol Addition of Ganirelix at first 3 days of the cycle
3162408|NCT00461422|No Intervention|2|Standard Flexible antagonist protocol
2498441|NCT02913703|Experimental|Healthy subjects - Preprandial AG (Acyl Ghrelin)|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG (Acyl Ghrelin) bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2498442|NCT02913703|Experimental|Healthy subjects - Preprandial saline|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2499488|NCT02906150|Active Comparator|SoC (chemotherapy and platinum agent)|Arm B: 70 patients (control group) will receive SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
2531078|NCT02689986|Experimental|Treatment arm|Bendamustine, Rituximab
3162409|NCT00461448|Active Comparator|1 Potassium supplement|Patients received an Enriched Grape Juice containing 234.5 mmol microcrystalline KCl (a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily)
3162410|NCT00461448|Placebo Comparator|2 Grape Juice|Patients received same amount of grape juice for 28 days.
3162411|NCT00461487|Experimental|1|Participants will receive sex education information during the physical exam
3162412|NCT00461487|Active Comparator|2|Participants will receive information on hygiene and nutrition during the physical exam
3162413|NCT00461487|No Intervention|3|Passive control participants will not receive any additional information during the physical exam
3162414|NCT00461526|Experimental|125 mg crofelemer|
3162415|NCT00461526|Placebo Comparator|placebo|
3162416|NCT00461539|Active Comparator|2|Participants will receive treatment as usual
3162417|NCT00461539|Experimental|1|Participants will receive the behavioral health intervention
3162418|NCT00461565|Active Comparator|Part A1|
3162419|NCT00461565|Placebo Comparator|Part A2|
3162420|NCT00461565|Experimental|Part B1|
3162421|NCT00461565|Placebo Comparator|Part B2|
3162422|NCT00461617|Active Comparator|2|Nateglinide 120 mg TID
3162423|NCT00461643|Active Comparator|Strategy A|clomiphene followed by clomiphene plus metformin followed by gonadotropins
3162424|NCT00461643|Active Comparator|Strategy B|metformin followed by metformin plus clomiphene followed by gonadotropins
3162425|NCT00461643|Active Comparator|Strategy C|metformin plus clomiphene followed by gonadotropins
3162426|NCT00461695|Other|CMV-seropositive|Cytomegalovirus-seropositive individuals at screening (week 0). Intervention: Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
3162427|NCT00461695|Other|CMV-seronegative|Cytomegalovirus-seronegative individuals at screening (week 0). Intervention: Vaccination against tick-borne encephalitis by intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
3173579|NCT00613613||1|High drug metabolism genotype All receive fenofibrate
2497111|NCT02922075|Experimental|CTG|Patient received a connective tissue graft. It was performed tooth extraction, immediate implant, immediate restoration, bone regeneration, post operative medication and definitive prosthesis.
2497173|NCT02921672|Active Comparator|Cognitively Normal|Persons who are considered to have normal cognitive function. A registered dietician will meet with each person to discuss the Mediterranean Diet.
2497177|NCT02921672|Active Comparator|Mild Cognitive Impairment|Persons diagnosed mild cognitive impairment (MCI). A registered dietician will meet with each person to discuss the Mediterranean Diet.
2497178|NCT02921672|Experimental|Mild to Moderate Alzheimer's Disease|Persons diagnosed with mild to moderate Alzheimer's disease (AD). A registered dietician will meet with each person to discuss the Mediterranean Diet.
2497262|NCT02920814|Experimental|Time Intensive CBT for SPOV|Time intensive CBT for SPOV involving 6 weekly sessions and 2 intensive days of 4 hours each (over 8 weeks in total).
2497350|NCT02920723|Experimental|Training|"For the patients who were allocated in the control group in the EXESAS study. In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
2497353|NCT02920723|Other|Control|For the patients who were allocated in the training group in the EXESAS study. In this group, patients will receive only diets and physical activity counselling
2497399|NCT02920229|Experimental|68Ga- PSMA PET/CT|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
2497541|NCT02919306|Experimental|Ad26.Mos.HIV Vaccine or MVA mosaic Vaccine|Participants will receive adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV) 0.5 milliliter (mL) injection intramuscularly (containing 5 * 10^10 viral particles [vp]) at Weeks 0 and 12 followed by modified Vaccinia Ankara-Mosaic (MVA mosaic) 0.5 mL injection (containing 10^8 Plaque-forming unit [pfu]) at Week 24 and 48.
2497542|NCT02919306|Placebo Comparator|Placebo|0.5 mL Sodium Chloride Injection United States Pharmacopeia (USP) 0.9% will be administered by intramuscular (IM) injection.
2497599|NCT02919072|Experimental|Chloroprocaine|Chloroprocaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
2497600|NCT02919072|Active Comparator|Ropivacaine|Ropivacaine, 20 ml epidural anaesthetic solution administered according to the standard procedures of the hospital. In case of pain or discomfort, a 6 mL epidural top-up will be administered.
2497660|NCT02918747|Experimental|P-Gemoxd|"Pegaspargase+Gemcitabine+Oxaliplatin+Dexamethasone (PEG-ASP+Gemoxd): Patients received the P-Gemoxd chemotherapy regimen every 3 weeks.~Pegaspargase 2000U/m2 im day 1, Gemcitabine 800mg/m2 ivdrip 30min day 1 and day 5, Oxaliplatin 85mg/m2 ivdrip day 1, Dexamethasone 15 mg ivdrip, QD, day 1 to day 5.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions."
2497665|NCT02918747|Active Comparator|P-CHOP|"Pegaspargase+Cyclophosphamide+Doxorubicin+Vincristine +Prednisone (P-CHOP)：Patients received the P-CHOP chemotherapy regimen every 3 weeks. Cyclophosphamide 750 mg/m2，ivdrip day 1； doxorubicin 50mg/m 2，ivdrip day 1；vincristine 1.4 mg/m 2(≤2mg），ivdrip day 1; Pegaspargase 2000U/m2 im，day 2 and prednisone (60 mg/m 2 /day) on days 1 to 5 orally.~IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50-56 grays (Gy) in 25-28 fractions."
3173580|NCT00613613||2|Low drug metabolism genotype All receive fenofibrate
2497808|NCT02917785|Experimental|Karman curettage|after a retained product of interception is observed in ultrasound examination, the women in this arm will undergo Karman curretage.
2497810|NCT02917785|No Intervention|Control|
2497845|NCT02917629|Experimental|Group I (ACTOplus met XR)|Patients receive ACTOplus met XR PO QD for 10-21 days in the absence of disease progression or unacceptable toxicity. Patients may continue ACTOplus met XR PO QD for a maximum of 25 days if end of treatment biopsy/surgical treatment is delayed beyond day 22.
2497846|NCT02917629|Placebo Comparator|Group II (placebo)|Patients receive placebo PO QD daily for 10-21 days.
2497881|NCT02917226|Experimental|Clinical decision support and monitoring system|
2497882|NCT02917226|No Intervention|Control Group|
2497939|NCT02917057||Exenatide once weekly initiators|Type 2 diabetes patients who initiated exenatide once weekly treatment during the index period
2497940|NCT02917057||Basal Insulin initiator cohort|Type 2 diabetes patients who initiated basal insulin treatment in the index period
2498011|NCT02916589|Placebo Comparator|Baseline|The subjects will start with one week eating their normal diet.
2498020|NCT02916589|Active Comparator|Igelosa Diet|After one week the subjects will be provided the Igelosa Diet.
2498083|NCT02916160|Experimental|SACUBITRIL - VALSARTAN|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
2498147|NCT02915601|Experimental|Sodium Bicarbonate|Participants assigned to oral sodium bicarbonate will receive 0.5 mEq/kg-lean body weight (LBW)/day for the entire 12 months. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
2498193|NCT02915198|Placebo Comparator|Placebo|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
2499490|NCT02906085|Placebo Comparator|Placebo|Intravenous infusion of placebo (isotonic saline)
3173581|NCT00613665|Experimental|1|
3173582|NCT00613665|Experimental|2|
3173583|NCT00613665|Experimental|3|
3173584|NCT00613665|Experimental|4|
3173585|NCT00613665|Placebo Comparator|5|
3173586|NCT00613665|Experimental|6|
3173587|NCT00613665|Experimental|7|
3173588|NCT00613678|Active Comparator|1|Exercise + Education: Eight group sessions (8-15 people) during which participants engage in muscular strength and flexibility exercises. In addition, weekly educational lectures on topics germane to osteoarthritis management are included.
3174967|NCT00628797|Other|A UVA1 B no UVA1|half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
3174968|NCT00628797|Experimental|A UVA1|
2497154|NCT02921776|Experimental|Aim 1- VidaTalk post-extubation|"Aim 1 is a two group iterative design preliminary to clinical trial. Group 1 and Group 2 will each consist of five previously mechanically ventilated patients who will be recruited from the ICUs at the OSUWMC (Ohio State University Wexner Medical Center), including discharged patients.~Group 1 will use an initial android prototype of VidaTalk tablet application to be assessed for functionality (ergonomics, ease of use, ease of learning, simplicity, effectiveness and user interface) and usability on customizable communication, picture symbols, and integration with mobile communication devices.~Group 2 will use an improved alpha prototype of VidaTalk tablet application version engineered from observations made during Group 1 sessions."
2497158|NCT02921776|Experimental|Aim 2 - VidaTalk intubated|"Usability testing preliminary to Clinical Trial (Aim 3). Mechanically Ventilated patients will provide feedback on acceptability, will perform test messages with minimal errors, and will rate VidaTalk an overall average score of 4.5 or higher (Likert-type scale; 1 to 7) on usability questions. Prior to implementing these procedures, the company will perform further iterative design assessments and engineer a Vidatalk tablet application prototype. This prototype will be used with a final group of ten (10) intubated patients receiving mechanical ventilation support to field-test the prototype for functionality (human-device interaction factors, feasibility, and usability) and acceptability.~Intervention is usability tasks with the VidaTalk app"
2497162|NCT02921776|Experimental|Aim 3 - VidaTalk tablet app|"Test the clinical efficacy of VidaTalk with MV patients by examining qualitative and quantitative endpoints in a clinical setting. 35 intubated patients (oral endotracheal tube or tracheostomy) will be randomized to the intervention arm and will receive a protocolized instruction in the use of the VidaTalk application including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.~Intervention will be receipt of VidaTalk tablet application."
2497166|NCT02921776|Other|Aim 3 - attention-control|"35 intubated patients (oral endotracheal tube or tracheostomy) will receive the standard of care, which may include primarily writing tools (paper and pen) and, occasionally, picture or alphabet communication charts.~Patients randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk application, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.~Interventions will be Aim 3 - attention-control with non-VidaTalk tablet."
2497170|NCT02921776|No Intervention|Aim 5-VidaTalk Efficacy in Family caregivers|"Aim 5 will test the preliminary efficacy of VidaTalk compared to attention control (AC) on anxiety and depression symptoms in family caregivers during the ICU stay and post-discharge (1-mos; 3-mos; 6-mos) and PTSD-related symptoms post-discharge both qualitatively and quantitatively.~Aim 5.a.) Psychological outcomes (anxiety, depression, and PTSD-related symptoms) between the two groups will be compared at each time point and across time. Aim 5.b.) Family caregivers' perceived communication difficulty will be measured .Aim 5.c.) Family caregivers' experience of communication while they were visiting the patient who received the VidaTalk app in the ICU and their emotional reactions to communication with a patient will be measured."
2497203|NCT02921438||Chest pain patients presenting to the ED|All patients that present to the emergency department with chest pain and potentially other symptoms consistent with ACS and meet all eligibility criteria will undergo VitalScan Magnetocardiograph.
2497279|NCT02921022|Experimental|Patients without a prior thromboembolic event (TE)|Patients without a prior TE will be treated with prophylactic dose and schedule of rivaroxaban (10 mg QD), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
2497280|NCT02921022|Experimental|Patients with a prior thromboembolic event (TE)|Patients with a prior TE will be treated with therapeutic dose and schedule of rivaroxaban (15 mg BID for 21 days for induction if indicated, then 20 mg QD for chronic treatment), together with standard dose and schedule of gemcitabine, nab-paclitaxel and PEGPH20.
2497389|NCT02920489|Experimental|Individualized epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor. Epidural analgesia will begin when asked by parturients and the numeric rating scale of pain is 5 or higher. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
2497391|NCT02920489|Active Comparator|Routine epidural analgesia|Epidural catheterization will be performed after the beginning of the first stage of labor and the cervix is dilated to 1 cm or more. Epidural analgesia will then begin. A loading dose (10 ml mixture of 0.1% ropivacaine and 0.5 ug/ml sufentanil) will be administered through the epidural catheter. After a 20-minute period observation, a patient-controlled analgesia pump (containing a mixture of 0.08% ropivacaine and 0.4 ug/ml sufentanil) will be connected to the epidural catheter and programmed to deliver a 6-ml bolus with a 20-minute lockout interval and a 4 ml/h background infusion. Analgesia will be terminated at the end of the third stage of labor.
2497498|NCT02919501|Experimental|IV vortioxetine|
2497499|NCT02919501|Placebo Comparator|IV placebo|
2497567|NCT02919215|Experimental|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
2497572|NCT02919215|No Intervention|Wait-list Control|These participants will not receive access to the Teacher Help intervention until September of the following academic year. Teachers, students, guardians, and collaborating psychologists are free to access and/or provide usual services. The psychologists will provide Teacher Help access codes to the Wait-list group in September of the following academic year:
2497927|NCT02917005|Active Comparator|Control Arm|Exemestane (Pfizer) 25mg/day orally continuously plus Goserelin (Astrazeneca) 3.6 mg SC given every 28 days
2497186|NCT02921646|Other|energetic expenditure measure|To a standard treatment by chemotherapy, energetic expenditure will be measured 5 times during the study.
3195513|NCT00840567|Other|Healthy Volunteers|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
3195514|NCT00840567|Other|Patients with benign, inherited hematologic disease|To obtain a one time skin sample (4 ml skin punch biopsy) and one time blood sample (1 teaspoon)
3195515|NCT00840580|Experimental|Vigamox|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
2497369|NCT02920463||Critically ill patients with infection|Critically ill adult patients receiving empirical antibiotic therapy for suspected or confirmed infections at the Intensive Care Unit
2497410|NCT02920294|Active Comparator|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
2497413|NCT02920294|Active Comparator|Probiotic 2|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) OD for 14 consecutive days
2497417|NCT02920294|Placebo Comparator|Placebo|Acidified dairy drink without ferments consumed as follows: one bottle (100g) OD for 14 consecutive days
3195516|NCT00840580|Active Comparator|Cravit|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
3195517|NCT00840593|Active Comparator|1. Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
3195518|NCT00840593|Active Comparator|2 Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
3195519|NCT00840606|Experimental|1|
3195520|NCT00840606|Active Comparator|2|
2497713|NCT02918214||echocardiography|Each patient will be hemodynamically assessed using echocardiography: Day1 defines the first echocardiography performed within the first 12 hours (ideally within the first 6 h) following the diagnosis of septic shock, Day2 and Day3 define the examination performed 24 to 36 h and 48 to 72 h later (guidance of treatment during the acute phase), Day end defines the examination performed after vasopressors cessation (end of hemodynamic failure). In addition, echocardiography will be performed on ICU discharge and on Day28 or on hospital discharge (whatever occurs first) to document potential reversibility of LV diastolic dysfunction. Transthoracic echocardiography will always first be performed and transesophageal echocardiography will be limited to ventilated patients without adequate surface echocardiographic image quality, under sedation and during the initial phase of septic shock (D1 to D3), according to the standards of care of participating centers.
2497756|NCT02918058|Active Comparator|McGill University Health Centre|This arm is defined by the geographic cluster of all eligible participants presenting to the McGill University Health Centre (Montreal, Quebec, Canada) Montreal General Hospital or Royal Victoria Hospital during the study period. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2497757|NCT02918058|Active Comparator|University Health Network, Toronto|This arm is defined by the geographic cluster of all eligible participants presenting to the University Health Network (Toronto, Ontario, Canada) at the Toronto General Hospital or Toronto Western Hospital. The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2497760|NCT02918058|Active Comparator|University of Ottawa, Ottawa|This arm is defined by the geographic cluster of all eligible participants presenting to the Ottawa Hospital (Ottawa, Ontario, Canada). The arm will undergo a control and intervention (MedSafer) period. Participants will be enrolled in either the control or intervention period.
2497818|NCT02917837|Active Comparator|Usual QCNL report group|Physicians receive the usual Quality of Care Newfoundland and Labrador utilization report: This reports ranks the physician on a figure of their peers according to the total number of tests ordered in a one-year period.
2497819|NCT02917837|Experimental|Usual QCNL report plus detailing.|This group receives the usual QCNL report described above. Shortly after the reports are sent, this group will be contacted at least three times to attempt to arrange a single in-person detailing session.
2497820|NCT02917837|Experimental|New utilization report|This group will receive a new type of report that shows individual physician ordering per 100 patients compared to the mean of all physicians, adjusted for patient complexity (age, sex, comorbidity, education, income, rurality).
2497823|NCT02917837|Experimental|New utilization report plus detailing|New type of report plus detailing as described above.
2497851|NCT02917486||ECMO piperacillin|patients in intensive care treated with ECMO with antiinfective therapy : piperacillin
2497853|NCT02917486||without ECMO piperacillin|patients in intensive care without ECMO with antiinfective therapy : piperacillin
3195521|NCT00840645|Experimental|1. YM178|
3195522|NCT00840671|Experimental|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
2498036|NCT02916667|Active Comparator|CNdiet|CNdiet includes chrono nutritional dietary guidelines
2498039|NCT02916667|Placebo Comparator|GDMdiet|GDMdiet includes regular GDM diet
2498067|NCT02916004|Other|Measurement of NFR and PDR|Diagnostic intervention: excite NFR and PDR in comparison to behavior pain scale (BPS)
2498125|NCT02915757|Experimental|Depressive patients|EDOR test on depressed patients with or without personal history of suicidal behavior
3208740|NCT00977652|Sham Comparator|sham stimulation|Inefficient percutaneous posterior tibial nerve stimulation
2499518|NCT02906046|Placebo Comparator|placebo Weight in Lower Limbs|placebo Weight in Lower Limbs
2497191|NCT02921347|Experimental|Intervention group|Patients in this group are received ventilator weaning by switching between invasive and noninvasive ventilation
2497192|NCT02921347|No Intervention|Control group|Patients in this group are weaned from ventilator as conventional methods.
2497245|NCT02921165|Active Comparator|Group 1|Non hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
2497246|NCT02921165|Experimental|Group 2|Hypertensive Intervention: On analgesic mouth rinses (dissolved Aspirin)
2497247|NCT02921165|Experimental|Group 3|Non Hypertensive Intervention: On normal saline rinses.
2497288|NCT02920775||Pain|
2497291|NCT02920775||PCP|
2497295|NCT02920775||Dentist|
2497298|NCT02920775||Surgery|
2497302|NCT02920775||Emergency Medicine|
2497306|NCT02920775||Oncology|
2497307|NCT02920775||Hospice and Palliative Medicine|
2497309|NCT02920775||Anesthesiology|
2497311|NCT02920775||Neurology|
2497314|NCT02920775||Nurse Practitioners|
2497317|NCT02920775||Pediatrics|
2497321|NCT02920775||Physical Medicine & Rehabilitation|
2497324|NCT02920775||Physician Assistant|
2497326|NCT02920775||Rheumatology|
2497329|NCT02920775||All Other Specialties|
2497411|NCT02919956||Group I: CBF-I Single Ventricles|The 1st group (cohort group) will be patients who were enrolled in the original NIH CBF grant. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
2497416|NCT02919956||Group II: Prospective Single Ventricles|The 2nd group (cross sectional group) will be prospectively recruited from SV patients after Fontan operation but were not participants in the original study and will be age matched to Group I to enrich the patient population. These patients will undergo a 60-90 minute Magnetic Resonance Imaging scan of the brain and heart. They will also have Neurodevelopmental Testing.
2497420|NCT02919956||Group III: CBF-I Normal Controls|The 3rd group (cohort group) will be normal controls who were enrolled in the original CBF grant. These patients will have Neurodevelopmental Testing. The data from these patients' MRI from CBF-I (original CBF grant) will be used.
2497422|NCT02919956||Group IV: Prospective Normal Controls|The 4th group (cross sectional group) will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for clinically indicated MRIs and found to have structurally normal cardiac and brain anatomy. These patients will have an abbreviated research MRI, lasting 15-20 minutes, added onto their clinically-indicated MRI at CHOP. They will also have Neurodevelopmental Testing.
2497425|NCT02919956||Volunteer Group|There will also be a volunteer group of one to five volunteers that will be enrolled prior to enrollment in the other four study groups. These volunteers will be prospectively recruited from patients who come to Children's Hospital of Philadelphia (CHOP) for a clinically-indicated MRI and consent to have an additional 15-20 minutes of research MRI scanning. The purpose will be to ensure that the brain MRI sequences run correctly and produce useful information before the patient and normal control enrollment begins. The volunteers will not undergo neurodevelopmental testing.
3162428|NCT00461747|Active Comparator|A|"Four alternating cycles of VBMCP/VBAD + Velcade VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalán, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20. The interval between VBMCP and VBAD is 5 weeks and between VBAD and VBMCP is 4 weeks. The patients will received two cycles of VBMCP and two cycles of VBAD. After 4 weeks of last cycle of VBAD, patients will received two cycles of Velcade, 1,3 mg/ m2 iv twice a week (days 1, 4, 8 and 11), followed by 10 days without treatment"
3162429|NCT00461747|Experimental|B|"Six cycles of 4 weeks of Thalidomide/Dexamethasone. Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
3174969|NCT00628810|Experimental|FOLFIRI fort plus bevacizumab|Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
3174970|NCT00628823|No Intervention|A1|Gluten-containing diet
3174971|NCT00628823|Active Comparator|A2|Gluten-free diet
2497657|NCT02918838|Experimental|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
2497663|NCT02918838|Experimental|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
2497666|NCT02918838|Active Comparator|Control Group|Participants do not receive a lottery incentive conditional on adherence. Participants will however, continue to receive weekly messaging with airtime top-up contingent on response.
2532233|NCT02682212|No Intervention|No intervention|Standard care
3174972|NCT00628836|Active Comparator|SE group|surface stimulation
3174973|NCT00628836|Experimental|BE group|BION stimulation
3174974|NCT00628849||1|This group will have 2 mm plates and screws placed according to Champy principles
3174975|NCT00628849||2|This group will have 2 mm plates placed according to modified Champy principles
3174976|NCT00628849||3|This group will have larger (2.3 mm or greater) plates and screws placed according to the AO technique
3174977|NCT00628888|Experimental|Unified Protocol for Adolescents (UP-A)|Participants receive the UP-A intervention for 8-21 weeks immediately following randomization.
3174978|NCT00628888|Experimental|Delayed Treatment/Waitlist|Participants receive an 8-week waitlist condition with some attentional-control via monitoring for clinical deterioration. After a post-waitlist assessment, participants in this condition are offered the UP-A treatment for 8-21 weeks.
2497202|NCT02921516|Experimental|N'ap Grandi|Both Adolescent and Caregiver participate in assessment and intervention groups. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
2497208|NCT02921516|Active Comparator|N'ap Grandi - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
2497214|NCT02921516|Placebo Comparator|Health Promotion - A|Adolescents participate in assessment and intervention groups, Caregivers participate in assessment only. Adolescent assessments will be administered at baseline, 3 months- and 6 months-post intervention. Caregiver assessments will be administered at baseline and 6 months-post intervention.
3195523|NCT00840671|Placebo Comparator|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
3195524|NCT00840697|Active Comparator|Work related rehabilitation|"work related rehabilitation and exercises~The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks.~Exercises comprises of treatment in groups. The treatment includes exercises, both strength and fitness, in addition to cognitive intervention of how to manage pain and work."
2497387|NCT02920385|Experimental|Levothyroxine/SNAC/Placebo/Semaglutide|
2497434|NCT02920021|Experimental|ANB020|ANB020, administration of ANB020
2497437|NCT02920021|Placebo Comparator|Placebo|Placebo, administration of Placebo
3195525|NCT00840697|Active Comparator|Brief intervention|1 consultation at the physiotherapist, which give advise and a summary talk with the physician
3195526|NCT00840697|Active Comparator|Multidisciplinary exercise group|10 days of exercise and cognitive treatment group
2497565|NCT02919202|Experimental|Fluoride Varnish|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.
2497571|NCT02919202|Active Comparator|SEDBA|Self-etching Dentine Bonding Agent. Scotchbond Universal by 3M ESPE. Topical application followed by light curing for 20 seconds.
2497629|NCT02918916|Experimental|Active phototherapy group|"Phototherapy will be applied between sprint and squat training (exactly 10 minutes before squat training).~Active phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin.~The optical power will be calibrated before irradiation in each participant using a Thorlabs thermal power meter (Model S322C, Thorlabs, Newton, New Jersey, USA)."
2497632|NCT02918916|Placebo Comparator|Placebo phototherapy group|"Placebo will be applied between sprint and squat training (exactly 10 minutes before squat training). Placebo phototherapy will be applied by a trained therapist using a MR4 LaserShower 50 4D emitter (Multi Radiance Medical, USA), bilaterally to six sites of the quadriceps (two centrally - rectus femoris and vastus intermedius; two laterally - vastus lateralis; two medially - vastus medially) in direct contact with the skin. To receive active or placebo phototherapy the participant will be placed in the supine position.~The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled."
2497635|NCT02918916|No Intervention|Control group|Passive recovery will be applied between sprint and squat training (exactly 10 minutes before squat training). During the period when the other groups are receiving recovery strategies, the control group participants will remain seated for passive recovery, supervised by an independent therapist.
3195527|NCT00840723||Current smokers|Current cigarette smokers with no other illness
2497856|NCT02917499|Experimental|TMS|The experimental group will be treated with transcranial magnetic stimulation for 4 weeks.
2497858|NCT02917499|No Intervention|noTMS|The control (no intervention) group will be treated as usual (with pharmacotherapy). These patients will receive TMS treatment after data collection is ended.
2498003|NCT02916550|Experimental|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
2498082|NCT02916225|Active Comparator|High intensity interval training|exercise protocol for high intensity/aerobic interval training as described by ESC statement (Mezzani et al.)
2498084|NCT02916225|Placebo Comparator|Moderate Continuous Training|exercise protocol for continuous aerobic training as described by ESC statement (Mezzani et al.)
2498122|NCT02915653|No Intervention|Control|Control: not receiving any intervention
2498127|NCT02915653|Experimental|Intervention 1|Receiving educational materials on a new diagnostic service
2498129|NCT02915653|Experimental|Intervention 2|Receiving educational materials on a new diagnostic service
2498198|NCT02915393||Healthy Volunteers (BC)|Healthy Volunteers with Balanced Constitution(n=10).
2498204|NCT02915393||Healthy Volunteers(QC)|Healthy Volunteers with Qi Deficiency Constitution(n=10).
2498211|NCT02915393||Healthy Volunteers(DC)|Healthy Volunteers with Damp-heat Constitution(n=10).
2498212|NCT02915393||Superficial Gastritis(SDS)|Superficial Gastritis with Spleen-qi Deficiency Syndrome(n=10).
2498214|NCT02915393||Superficial Gastritis(DS)|Superficial Gastritis with Damp-heat Syndrome(n=10).
2498215|NCT02915393||Atrophic Gastritis(SDS)|Atrophic Gastritis with Spleen-qi Deficiency Syndrome(n=10).
2498218|NCT02915393||Atrophic Gastritis(DS)|Atrophic Gastritis with Damp-heat Syndrome(n=10).
2498220|NCT02915393||Gastric Cancer(SDS)|Gastric Cancer with Spleen-qi Deficiency Syndrome(n=10).
2498221|NCT02915393||Gastric Cancer(DS)|Gastric Cancer with Damp-heat Syndrome(n=10).
2498259|NCT02914886|Experimental|Group 1|Daily use of insulin Apidra in insulin pump. The dosis will be according to the patient's former dosing scheme.
2498264|NCT02914886|Active Comparator|Group 2|Daily use of current insulin in insulin pump.The dosis will be according to the patient's former dosing scheme.
2497255|NCT02920853|Experimental|BT-CPR|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback training to provide pain relief when relaxation is achieved.
2497258|NCT02920853|Active Comparator|Biofeedback-Only|Participants will receive training in relaxation and biofeedback to develop skills in relaxation/arousal reduction, and pain reduction. Then they will practice relaxing and reducing their arousal as they view graphical arousal feedback.
2497349|NCT02920697|Experimental|B-cell Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM)|
2497354|NCT02920697|Experimental|Chronic Lymphocytic Leukaemia (CLL)|
2497449|NCT02920112|Experimental|One year post-op Tele-CBT|This group will receive Telephone based Cognitive Behavioral Therapy (Tele-CBT) one year after bariatric surgery.
2497483|NCT02919644|Experimental|vaccine + Interleukin -2 (IL2)|autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by IL-2 given by subcutaneous injection daily for five days (days 3-7)
2497533|NCT02919319|Experimental|Dose group 1|Six subjects received 5 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
2497535|NCT02919319|Experimental|Dose group 2|Three subjects received a single oral dose (25 mg) of ACT-541468 formulation A during Period 1 and a single oral dose (25 mg) of ACT-541468 formulation B during Period 2. Three other subjects Subjects received ACT-541468 formulation B during Period 1 and ACT-541468 formulation A during Period 2. Two additional subjects received the matching placebos in both treatment periods.
2497538|NCT02919319|Experimental|Dose group 3|Six subjects received 50 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 oral tracer for the mass balance and metabolism analyses. Two other subjects received the matching placebos.
2497540|NCT02919319|Experimental|Dose group 4|Six subjects received 100 mg of ACT-541468 (formulation A) as a single oral dose in combination with a [14C]-ACT-541468 intravenous tracer for the absolute bioavailability assessment. Two other subjects received the matching placebos.
2497543|NCT02919319|Experimental|Dose group 5|Six subjects received 200 mg of ACT-541468 (formulation A) as a single oral dose and two subjects received the matching placebo.
2497650|NCT02919020|Experimental|Proprioceptive neuromuscular facilitation (PNF);|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
2497653|NCT02919020|Experimental|resistance exercise|Resistance exercise to strengthen lower limbs
2497687|NCT02918526|Experimental|Laryngeal Mask|laryngeal mask (LMA)
2497689|NCT02918526|Active Comparator|Oro Tracheal Intubation|oro tracheal intubation
2497727|NCT02918240|Experimental|4 week interval|Patients will be seen every 4 weeks to adjust their orthodontic braces
2497733|NCT02918240|Experimental|6 week interval|Patients will be seen every 6 weeks to adjust their orthodontic braces
2497735|NCT02918240|Experimental|8 week interval|Patients will be seen every 8 weeks to adjust their orthodontic braces
2497737|NCT02918240|Experimental|10 week interval|Patients will be seen every 10 weeks to adjust their orthodontic braces
2497764|NCT02918006|Experimental|Oral Vaccine (VXA-A1.1)|Oral enteric coated vaccine tablets. Placebo (saline solution) IM injection will also be administered in this arm.
2497767|NCT02918006|Active Comparator|QIV IM Injection|A commercially available QIV will be administered at the approved dose level as the active comparator. Oral placebo tablets will also be administered in this arm.
2497770|NCT02918006|Placebo Comparator|Oral and IM Placebo|Two forms or placebos (saline IM injection and oral placebo tablets) will be administered in this arm.
2497822|NCT02917772|Experimental|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy~If CR/PR: Nivolumab Maintenance Mono-Therapy~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy"
2497907|NCT02917356|Experimental|Spiritual laying on of hands group|"Spiritist Passe - performed by spiritual healers from the religion Spiritism (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2497911|NCT02917356|Active Comparator|Non-spiritual Laying on of Hands group|"Non-spiritual Laying on of Hands - performed by lay persons (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2497912|NCT02917356|Sham Comparator|Control Group (CG)|"Sham/ Control Group (CG) - performed by lay persons. They will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands (5 min, once a week, for 8 weeks)~Physical therapy: Kinesiotherapy (45 min, twice a week, for 8 weeks)"
2497960|NCT02916888||Care provided by general pediatrician|Standard of care management of atopic dermatitis by general pediatrician. This includes an initial visit with a 2-week follow-up.
2497962|NCT02916888||Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by pediatric dermatologist. This includes an initial visit with a 2-week follow-up.
2498014|NCT02916472|Experimental|CyberCycling - Aerobic Exercise|30-60 mins/week, 3 days/week supervised stationary cycling with exergaming/videogaming for 12 weeks
2498025|NCT02916472|Active Comparator|Control Stretching - Resistance Bands|2 days/week at home for 12 weeks
2498072|NCT02916069|Active Comparator|Group 1 (Multimodal brain monitoring)|Patients will be monitored with combination of brain monitoring; Nearinfrared Spectroscopy (NIRS), Transcranial Doppler (TCD), and Bispectral index (BIS). Interference will be done to optimize the medical condition based on such monitors.
2498079|NCT02916069|No Intervention|Group 2|Patients will be monitored without any interference based on such monitors
2498136|NCT02915627|Active Comparator|Healthy participants|Non chronic kidney disease (CKD) participants. Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2498138|NCT02915627|Active Comparator|CKD patients not on dialysis|CKD 4/5 patients not on Dialysis- Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2497293|NCT02920879|Other|0 CPAP/ 0 PEEP driving pressure 20|Patients will be pre-oxygenated with a CPAP-level of 0 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 20 cmH2O./PEEP-level, driving pressure
2497297|NCT02920879|Other|10 CPAP / 10 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with PEEP 10 cmH2O and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2497303|NCT02920879|Other|10 CPAP/ 0 PEEP, driving pressure 10|Patients will be pre-oxygenated with a CPAP-level of 10 cmH2O and after anesthesia induction, mask-ventilated with ZEEP and a driving pressure of 10 cmH2O./PEEP-level, driving pressure
2497341|NCT02920554|Active Comparator|wedge resection|The extent of hepatic resection is wedge resection of gallbladder fossa
2497343|NCT02920554|Active Comparator|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy
2497444|NCT02920151|Experimental|BALANCE EXERCISES CIRCUIT|balance exercises circuit for three months, twice weekly, 50 minutes per day.
2497445|NCT02920151|No Intervention|CONTROL GROUP|usual routine
3195528|NCT00840723||Healthy controls|Healthy non smokers
3195529|NCT00840736|Active Comparator|1|Laparoscopic adjustable gastric banding
2497550|NCT02919098|Experimental|Intervention|Two schools (all students grades 9-12) will serve as the intervention group.Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based bystander intervention program aimed at teaching students the knowledge and skills to prevent or intervene in instances in sexual harassment and violence among peers. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes. School staff and administrators will be interviewed to gather their insights on the program's feasibility and acceptability.
2497553|NCT02919098|Placebo Comparator|Delayed Control|"One school (all students grades 9-12) will serve as a delayed control group. Participants will complete a baseline survey that will take no longer than 30 minutes. Afterwards, a trained facilitator will delivery a game-based health program unrelated to sexual health, sexual violence, sexual harassment, and bystander behaviors. This will last for 4 class periods (approximately 45 minutes each period, 180 minutes total). Afterwards, participants will complete an immediate post-program survey lasting no more than 30 minutes. Three months later, students will fill out an a follow up survey lasting no more than 30 minutes.~After completing the follow-up survey, this group will follow the same procedures to deliver the bystander program and capture data outlined for the intervention group."
2497630|NCT02919033|Placebo Comparator|Usual care (UC)|Patients are managed by their PCPs at the registered CHCs as usual.
2497633|NCT02919033|Experimental|Self-management|"BP tele-monitor & App based self-management supports~Patient proficiency training"
2497641|NCT02919033|Experimental|PCTM intervention|"BP tele-monitor & App-based self-management supports~Patient proficiency training~PCP & cardiologist training of using Web-based analytics~Proactive and interactive care by PCPs and cardiologists"
2497699|NCT02918422|Experimental|High Carbohydrate No Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO and 25% fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2497700|NCT02918422|Experimental|High Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 55% CHO, 20% PRO 25% and Fat 25% with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2497701|NCT02918422|Experimental|Mod. Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 30% CHO, 20% PRO and 50% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2497702|NCT02918422|Experimental|Low Carbohydrate High Cheese|Intervention: Nutritional and Dietary Manipulation. This arm will be provided food with an approximate macronutrient breakdown of: 10% CHO, 20% PRO and 70% Fat with ~6oz Cheese (gouda or cheddar) per day being used as a fat source.
2497739|NCT02918201|Experimental|topical tranexamic acid|tranexamic acid solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
2497742|NCT02918201|Placebo Comparator|placebo control|Saline solution to be applied on one of two superficial donor wounds on each participant. Potential candidates will be consecutively identified by the trial investigators among patients admitted to the Burn Unit at Haukeland University Hospital.
2497812|NCT02917967|Experimental|BTX injection group|Botulinum toxin injection group
2497868|NCT02917616|Experimental|Alkaline water|Two liters (minimum) daily of alkaline drinking-water (pH=9) for 14 days
2497872|NCT02917616|Active Comparator|Neutral Water|Two liters (minimum) daily of neutral drinking-water (pH=7) for 14 days
2497928|NCT02917109|Experimental|LearningRx cognitive training|The intervention is a 60-hour, clinician-delivered cognitive training program.
3195530|NCT00840736|Active Comparator|2|vertical banded gastroplasty
2498093|NCT02915848||PC+S group|PC+S group gets Medtronic, Activa PC+S DBS device,
2498118|NCT02915562|Active Comparator|Depressive Group|GDS 15 (Geriatric Depression Score) ≥5 at baseline
2498123|NCT02915562|Active Comparator|Non-depressive Group|GDS 15 (Geriatric Depression Score) <5 Points at baseline
2499520|NCT02906046|Other|0,5 kg Weight in Lower Limbs|0,5 kg Weight in Lower Limbs
2499523|NCT02906046|Other|1,0 kg Weight in Lower Limbs|1,0 kg Weight in Lower Limbs
3195531|NCT00840762|Experimental|VircoType HIV-1|Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm
3195532|NCT00840762|Active Comparator|Local Expert review|Local Expert HIV genotypic review, as per Badri, S. et al CID 2003
3195533|NCT00840775|Other|Presillion™ Stent System|
3195534|NCT00840788|Experimental|Skin adhesive|perineal skin repair with octyl-2-cyanoacrylate skin adhesive
3195535|NCT00840788|Active Comparator|subcuticular suture|continuous subcuticular suture of perineal skin using rapidly absorbable polyglactin 910
3195536|NCT00840801|Experimental|1|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
3195537|NCT00840801|Experimental|2|Subjects receive three vaccinations with a paediatric TBE vaccine according to the conventional vaccination schedule.
2497424|NCT02920086|Experimental|Nutrition Education Program|Nutrition education for family members of an elderly critically ill patient
2497428|NCT02920086|Experimental|Decision Support Program|Decision support education for family members of an elderly critically ill patient
2497431|NCT02920086|No Intervention|Usual Care|No intervention
2497503|NCT02919540|Experimental|kangaroo care approach|the kangaroo care approach will be implemented for dyads who agree to participate
2497506|NCT02919540|No Intervention|control group|routine care will be implemented
2497561|NCT02919280||No treatment|This is an observational study. No intervention / treatment involved.
2497638|NCT02918981|Active Comparator|Whey protein|After resistance exercise, participants aged 50-79 years will consume 14g Whey protein dissolved in 200 mL of water
2497642|NCT02918981|Experimental|Whey + Leucine|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine dissolved in 200 mL of water
2497648|NCT02918981|Experimental|Whey + Leucine + Whey peptides|After resistance exercise, participants aged 50-79 years will consume 4 g Whey protein + 1.25 g Leucine + 2.6 g Whey peptides dissolved in 200 mL of water
2497651|NCT02918981|Experimental|Whey + Leucine + Citrulline|After resistance exercise, participants aged 50-79 years will consume 6.6 g Whey protein + 1.25 g Leucine + 0.8 g Citrulline dissolved in 200 mL of water
2497654|NCT02918981|Sham Comparator|Water|After resistance exercise, participants aged either 20-30 or 50-79 years old will consume 200 mL water
3195538|NCT00840853|Experimental|Group A with disease|"CD19+ B-ALL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
2497792|NCT02917850|Active Comparator|Isokinetic|Patients who benefit from the hip flexors isokinetic strengthening rehabilitation program
2497794|NCT02917850|Active Comparator|Control|Patients who benefit from a conventional rehabilitation program
2497847|NCT02917707||normal colorectal tissues (PN)|normal colorectal tissues
2497848|NCT02917707||primary colorectal carcinoma tissues|primary colorectal carcinoma tissues
2497849|NCT02917707||liver metastasis tissues|liver metastasis tissues
2497887|NCT02917252|Active Comparator|Intervention|Subjects drink 3-hydroxybuturate
2497891|NCT02917252|Placebo Comparator|Placebo|Subjects drink saline
3195539|NCT00840853|Experimental|Group A without disease|"CD19+ B-ALL undergoing allogeneic HSCT, without detectable disease post-HSCT.~Patients will receive CD19CAR/virus specific T cells - Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
3208741|NCT00977678||Open access gastroscopy|Patients referred to open access gastroscopy
2498050|NCT02916290|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
2498051|NCT02916290|Active Comparator|Monotherapy|UDCA monotherapy
2498095|NCT02915939|Experimental|Treatment Group|The Residential Care Transition Module (RCTM) includes six in-person consultation sessions over a 4-month period conducted by a trained Transition Counselor (TC) with a primary family caregiver (self-identified as the person most responsible for providing on-going assistance to the care recipient in a residential long-term care setting such (RLTC) such as a nursing home or assisted living memory care unit.
2498098|NCT02915939|No Intervention|Usual Care Group|The usual care control group will adjust for the social engagement provided to the Residential Care Transition Module (RCTM )treatment condition. The Transition Counselor (TC) will provide quarterly contact calls and the research coordinator will send a bi-annual project newsletter to all participants. If caregivers in the control group initiate contact with the TC for care needs, the TC will provide information and referral support.
2498168|NCT02915263|Placebo Comparator|0.9% Sodium Chloride|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The placebo will consist of 0.9% Sodium Chloride per day over 5 days. Participants who are randomized to placebo will receive the same volume as they would if they were randomized to IVIG (i.e.: as if receiving IVIG at 2gm/kg) through a peripheral IV line.
2498169|NCT02915263|Experimental|IGIV-C|The study will include a total 20 individuals. Subjects will be randomized equally to treatment or placebo. The treatment will consist of IVIG administered at 2 grams/kg divided over 5 days, with a follow up treatment 3 weeks (+/-3 days) later of IVIG 1gram/kg administered over 2 day (or placebo).
2498230|NCT02915003|Experimental|E-health website intervention|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
2498232|NCT02915003|No Intervention|Control|usual health insurance navigation, and ACA materials provided by social service agencies and clinics where individuals seek services.
2498269|NCT02914678|No Intervention|Existing treatment|Business as usual: Ambulance personnel use existing treatment approach (a total of 2 μg/kg fentanyl per transport)
2498273|NCT02914678|Experimental|More liberal treatment|Ambulance personnel use a more liberal treatment approach (a total of 3 μg/kg fentanyl per transport)
2499497|NCT02906202|Experimental|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product (autologous CD34+ hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector encoding the human βA-T87Q-globin gene)
3208742|NCT00977678||Conventional outpatient gastroscopy|Gastroscopy after preceding appointment
3208743|NCT00977717||FOLFOX|Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
3208744|NCT00977730|Active Comparator|Protandim|
3208745|NCT00977730|Placebo Comparator|Sugar pill|
2497331|NCT02920736||sepsis non-acute renal injury group|The group was the non-AKI in sepsis patients
2497333|NCT02920736||control group|Approximately 110 persons(18-80years) with healthy physical examination and without liver and kidney dysfunction
2497385|NCT02920424|Experimental|Part A: JNJ-56022473 or Placebo (4:1)|Subjects will receive 3 subcutaneous (SC) administrations of the same dose level of JNJ-56022473 Dose 1, Dose 2, or Dose 3 or placebo every 2 weeks (in the ratio of 4:1 [4 active: 1 placebo]).
2497386|NCT02920424|Experimental|Part B: JNJ-56022473 or Placebo (5:1)|Subjects will receive 3 SC administrations of the same dose level of JNJ-56022473 or placebo every 2 weeks (in the ratio of 5:1 [5 active: 1 placebo]). The dose level(s) will be based upon an interim analysis (IA) of the Part A data.
2497456|NCT02920060|Experimental|Levetiracetam|patient in this group will receive intravenous levetiracetam as loading dose of 30 mg/kg at a rate of 50 mg/min
2497457|NCT02920060|Active Comparator|Sodium valproate|patients in this group will receive intravenous sodium valproate 20 mg/kg as loading dose at a rate of 40 mg/min
2497482|NCT02919527|Experimental|Self-Myofascial-Release|Two 60 seconds bouts of Self-Myofascial-Release performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
2497485|NCT02919527|Active Comparator|Stretching|Two 60 seconds bouts of static stretching performed at the anterior thigh; anticipated intensity of 7/10 on a 10 point numeric rating scale (0 representing no discomfort and 10 representing maximal discomfort)
2497486|NCT02919527|No Intervention|Control|No Intervention
2497577|NCT02919358|Experimental|Music|Exposure to music, twice per day for the study period
2497580|NCT02919358|Other|Control|No intervention; standard care.
2497620|NCT02918929|Experimental|EDP 305 SAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration
2497622|NCT02918929|Experimental|EDP 305 MAD Cohorts|EDP 305 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 oral suspension, once daily for 14 days
2497623|NCT02918929|Placebo Comparator|EDP 305 SAD Placebo Cohort|Matching placebo, oral suspension, once daily in one single administration
2497624|NCT02918929|Placebo Comparator|EDP 305 MAD Placebo Cohort|Matching placebo, oral suspension, once daily for 14 days
2497639|NCT02918643|Active Comparator|Application|7 physicians will receive an application to tablet device with information about potentially inappropriate medications for elderly and access for consultation of the portal of evidence-based health
2497646|NCT02918643|Sham Comparator|Control|7 physicians will receive a tablet with internet access for consultation of the portal of evidence-based health
2497717|NCT02918565|Experimental|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
2497724|NCT02918565|Experimental|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
2497729|NCT02918565|Experimental|Adaptive Goal Support (AGS)|10 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
2497732|NCT02918565|Experimental|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
2497736|NCT02918565|No Intervention|Control|12 weeks of text message assessments without any feedback
2497796|NCT02918019|Experimental|MSTT1041A 210 mg|Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.
2497798|NCT02918019|Experimental|MSTT1041A 490 mg|Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.
2497801|NCT02918019|Experimental|MSTT1041A 70 mg|Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.
2497803|NCT02918019|Placebo Comparator|Placebo|Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.
2497947|NCT02916836||With TDC sheet|Use of therapeutic drug conciliation sheet (TDC) by the hospital and transmitted to the family practitioner with other usual documentation
2497952|NCT02916836||Without TDC Sheet|transmission of usual documentation only to the family practitioner
2497990|NCT02916576|Experimental|Blood glucose measurement|
2498009|NCT02916329|Experimental|68Ga-ZEGFR: EGFR++|Patients in this group had EGFR-activating mutant and EGFR high expression tumors and did not receive any treatment before this study.
2498013|NCT02916329|Experimental|68Ga-ZEGFR: EGFR+|Patients in this group had EGFR-activating mutant and EGFR medium expression tumors and did not receive any treatment before this study.
2498021|NCT02916329|Experimental|68Ga-ZEGFR: EGFR-|Patients in this group had no EGFR expression tumors and did not receive any treatment before this study.
2498026|NCT02916329|Experimental|68Ga-ZEGFR: EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2498027|NCT02916329|Experimental|68Ga-ZEGFR:unknown EGFR status|Patients without the EGFR status measurement results and did not receive any treatments were classified in this group.
2498028|NCT02916329|Experimental|68Ga-ZEGFR: EGFR|Patients in this group had EGFR expression tumors and had receive some treatment before this study.
2498075|NCT02916043||Cardiovascular surgery with cardiopulmonary bypass|Cardiovascular surgery with cardiopulmonary bypass
3208746|NCT00977756||Group G|Participants will receive a medication regimen including RAL + ATV + RTV.
2498252|NCT02914951|Experimental|Cognitive-Behavioral Therapy|CBT is a behavioral intervention where children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger-provoking for their child.
3174979|NCT00628914|Experimental|1|Open label escitalopram plus eszopiclone for 8 weeks
3174980|NCT00628914|Other|2|Escitalopram and eszopiclone for initial 4 weeks, then switch to escitalopram and placebo for final 4 weeks.
3208747|NCT00977756||Group H|Participants will receive a medication regimen including RAL + TDF.
3208748|NCT00977756||Group I|Participants will receive a medication regimen including ETV + DRV + RTV.
3208749|NCT00977756||Group J|Participants will receive a medication regimen including MVC + ATV + RTV.
2497366|NCT02920593|Experimental|Vitamin D Prophylaxis|Participants will be provided Vitamin D 3000 IU daily or Vitamin D 4000 IU daily with and without concurrent use of prenatal vitamins, respectively.
2497372|NCT02920593|No Intervention|No Vitamin D Prophylaxis|Participants will not receive additional Vitamin D in the pregnancy.
2497448|NCT02920190|Experimental|Liraglutide Group|Participants in this group will receive the Liraglutide intervention for 12 months
2497476|NCT02919709|Experimental|thoracic or abdominal aortic aneurysm|
2497566|NCT02919410|Active Comparator|Surgery performed using iodophor-impregnated adhesive drapes|
2497569|NCT02919410|Other|Surgery performed without iodophor-impregnated adhesive drapes|
3195540|NCT00840853|Experimental|Group B with disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, with minimal residual disease or relapse post-HSCT~Patients will receive one of the following dose levels of CD19CAR/virus specific T cells:~Dose Level 1: 1.5 x 10^7/m2~Dose Level 2: 4.5 x 10^7/m2~Dose Level 3: 1.2 x 10^8/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.~If patients with relapse have a partial response or have stable disease they will be eligible to receive up to 6 further doses of CTLs, each of which will consist of the same number or less than as their first injection."
2497719|NCT02918370|Experimental|Aripiprazole|Aripiprazole will be given to the participant beginning at 2 mg per day(QD) then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
2497723|NCT02918370|Placebo Comparator|Placebo|Matching placebo will be given to the participant beginning at 2mg QD then titrating up to 5 mg QD at week 1, 10 mg QD at week 2, 15 mg QD at week 3 until the end of the preliminary phase. If the participant qualifies for the extension phase, then they will be titrated up again at week 12 to 30 mg QD.
3208750|NCT00977756||Group K|Participants will receive a medication regimen including MVC + LPV + RTV.
2497885|NCT02917408||Primary biliary cholangitis during January 2001 to July 2016|
2497932|NCT02917044|Active Comparator|Group A - Standard Care|The operator will attempt to complete the WACA lesion set using standard techniques. These include ablating any obvious gaps in the lesion set, ablating at the WACA line in a location radial to the earliest PV signal measured by the Orion catheter situated within the PV, and guided by amplitude and dV/dt of signals along the WACA lesion set measured using the mapping catheter. If this fails the operator will resort to OSA as per their usual practice.
2497936|NCT02917044|Experimental|Group B - Rhythmia mapping|The operator will form Rhythmia maps focussing on the region of the WACA line surrounding the non-isolated vein(s) whilst pacing from CS. This will be used as a means of targeting RF ablation to gaps in the WACA line (in addition to use of standard observation of signals as per group A). If this fails then the operator will resort to OSA as per their usual practice.
2498031|NCT02916628|Experimental|Group 1|auricular acupressure + group counseling
2498033|NCT02916628|Placebo Comparator|Group 2|placebo acupressure + group counseling
2498035|NCT02916628|No Intervention|Group 3|self-help smoking cessation
2498038|NCT02916628|No Intervention|Group 4|Non-smokers
2498056|NCT02915965|Experimental|DCX and surgery|docetaxol 60mg/m2 iv d1 and cisplatin 30mg/m2 iv d1-2 and capecitabine 850mg/m2 bid po d1-14 repeated every 21 days for 4-6 cycles, followed by surgery of Ivor Lewis Esophagectomy
2498143|NCT02915796|Experimental|G-CSF + CD133(+) cells + PTA|Intramuscular injection of G-CSF along with transarterial infusion of CD133 (+) cells combined with percutaneous transluminal angioplasty
2498145|NCT02915796|Active Comparator|PTA + G-CSF|Percutaneous transluminal angioplasty along with intramuscular injection of G-CSF
2498146|NCT02915796|Placebo Comparator|Only PTA|Only Percutaneous transluminal angioplasty along with placebo infusion of sodium chloride injection
2498179|NCT02915133||MF-MB|Consecutive participants with high myopic foveoschisis are scheduled to macular buckling (MB) surgery.
3208751|NCT00977756||Group L|Participants will receive a medication regimen including MVC + RAL + ETV.
3208752|NCT00977756||Arm M|Participants will receive a medication regimen of DRV
2498384|NCT02914002|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
2498387|NCT02914002|No Intervention|Usual Food Practices - AC|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
2498388|NCT02914002|No Intervention|Usual Food Practices - NAC|These are participants from a community where the intervention is not active.
2498423|NCT02913742|Experimental|monitoring by depth electrode|Subjects will be drawn from refractory mesial temporal lobe epilepsy patients determined to be candidates for LITT. During their LITT surgery, in addition to the placement of the stereotactic LITT probe, subjects will receive a second smaller stereotactic electrode for intraoperative monitoring of epileptic discharges before and after surgery. After surgery, at regularly scheduled follow-ups, patients will receive a QOLIE-31-P questionnaire, in addition to standard post-operative care.
2498453|NCT02913430|Active Comparator|Arm A|fulvestrant administered 500mg IM Q28 days plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
2498456|NCT02913430|Active Comparator|Arm B|Tamoxifen is administered orally, at a dose of20mg PO Qdaily plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
2498499|NCT02913196|Experimental|All patients|Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2
2498569|NCT02912910||Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
2498572|NCT02912910||Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
2498604|NCT02912390|Active Comparator|Cerclage|- Macdonald cerclage placed in standard fashion
2498608|NCT02912390|Active Comparator|Expectant management|- Patient is placed on activity restrictions
2498628|NCT02912169|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Autologous Adipose-derived Stromal Vascular Fraction (AD-SVF infusion) intravenous (IV) and Intranasal.
2499503|NCT02906124||Repatha® exposed|Females with familial hypercholesterolaemia (FH) exposed to Repatha® in the 15 weeks prior to or during pregnancy or during breastfeeding
2497376|NCT02920658|Experimental|NAVS Naphthalan|NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; NAVS oil in adhesive powder in a volume ratio 2:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
2497379|NCT02920658|Active Comparator|0.05% Betamethasone dipropionate|0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 4 weeks for OLP patients; 0.05% Betamethasone dipropionate in adhesive powder in a volume ratio 1:1, to apply on the affected mucosa three times daily during 5 days for RAS patients
2497447|NCT02920164|Active Comparator|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
2497450|NCT02920164|Placebo Comparator|Placebo acupuncture|"Placebo acupuncture with placebo fixed needles"
2497451|NCT02920164|No Intervention|Standard therapy|No intervention, just observation
2497487|NCT02919670|Experimental|Enterade and Standard Supportive Care|"Two 8 oz. bottles of Enterade will be administered daily~Enterade will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
2497491|NCT02919670|Placebo Comparator|Placebo and Standard Supportive Care|"Two 8 oz. bottles of Placebo will be administered daily~Placebo will be given orally from admission until day +14 or until discharge~Standard Supportive Care will be administered according to institution's practice"
2497581|NCT02919228|Experimental|Visible light exposure cognitive Red|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to red LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497583|NCT02919228|Experimental|Visible light exposure cognitive Orange|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to orange LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497584|NCT02919228|Experimental|Visible light exposure cognitive Yellow|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to yellow LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497586|NCT02919228|Experimental|Visible light exposure cognitive Green|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to green LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497587|NCT02919228|Experimental|Visible light exposure cognitive Cyan|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to cyan LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497591|NCT02919228|Experimental|Visible light exposure cognitive Blue|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to blue LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497595|NCT02919228|Experimental|Visible light exposure cognitive Violet|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to violet LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497597|NCT02919228|Experimental|Visible light exposure cognitive White|The participants will be tested for cognitive performance (verbal fluency task, arithmetic task, word repetition task) during exposure to white LED light at a fixed illuminance for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will additionally perform hyperventilation and hypoventilation tasks.
2497667|NCT02918734|Experimental|Endobutton CL BTB|Femoral fixation of the BPTB autograft with the Endobutton CL BTB Fixation System.
2497669|NCT02918734|Active Comparator|Metal interference screw|Femoral fixation of the BPTB autograft with a metal interference screw.
2497711|NCT02918383|Other|Indocyanin Green Dye (ICG)|Once the patient is in the operating room, the operative intervention will take proceed as current standard protocol dictates for the described procedure. No changes in operative technique will be undertaken apart from injection of the dye and visualization with the camera. After the articular surface of the distal femur or proximal tibia has been exposed, 2.5 mg of indocyanin green will be injected intravenously by anesthetist through a pre-existing IV line outside the sterile field. The operating surgeon will grade 6 locations on a standard scale of chondromalacia or cartilage damage.
2497778|NCT02918123|Experimental|Treatment|"FURESTEM-CD Inj. 5.0x10^7 cells~FURESTEM-CD Inj. 1.0x10^7 cells~FURESTEM-CD Inj. 2.0x10^8 cells"
2497800|NCT02917811||ICU patients|
2497886|NCT02917213||StudyGroup|"A cohort of 92 patients with first ST elevation acute myocardial infarction (AMI), sinus rhythm, and LV ejection fraction < 45% in the first 24-72 h after symptoms onset.~In the first 24 hours after enrollment a coagulation blood test, a Doppler echocardiogram exam, a Carotid duplex ultrasound exam, a Transcranial Doppler monitoring and a Reveal LINQ insertable cardiac monitoring system will be 1:1 randomly implanted.~A clinical examination (including neuropsiquiatric evaluation), a Doppler echocardiogram exam, a cardiac MRI and a brain MRI will be performed after a week and after 6 months after enrollment."
2497942|NCT02916914|Other|Q2 feeding|feeding intervals: 2 hours
2497945|NCT02916914|No Intervention|Q3feeding|feeding intervals: 3 hours
2498012|NCT02916602|Experimental|Treatment|HCP1401
2497408|NCT02919891||Participants with Chronic Pain|Questionnaire results will allow the diagnosis of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group without chronic pain.
2497409|NCT02919891||Participants without Chronic Pain|Questionnaire results will reveal the absence of chronic pain. No intervention will be administered. The results of the IENFD will be compared to the group with chronic pain.
2497459|NCT02919852|Other|laparoscopic retrovesical colpopectinopexia|new operative technic
2497475|NCT02919553|Experimental|modified wet-suction technique|Patients in this arm will undergo the modified wet-suction technique. Details in the study description section. After sufficient sampling of the lesion, the needle will be removed and the specimen will be collected.
2497478|NCT02919553|Active Comparator|"Capillary slow pull technique"|"Patients in this arm will undergo the Capillary slow pull technique which will include moving the needle to-and-fro into the lesion. Subsequently the needle will be removed and the specimen will be collected."
2497555|NCT02919371|Experimental|Sunitinib and Bevacizumab Arm|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell carcinoma (CASA)Combined Alternating Sunitinib and Bevacizumab
2497617|NCT02918955|Active Comparator|Arm rA (randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
2497618|NCT02918955|Experimental|Arm rB (randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
2497619|NCT02918955|Active Comparator|Arm oA (non-randomized)|Concomitant chemo-radiotherapy with early salvage neck dissection if less than complete clinical response
2497621|NCT02918955|Experimental|Arm oB (non-randomized)|Up-front neck dissection followed by radiotherapy with concomitant chemotherapy based on the cT pN cM staging after surgery
3162430|NCT00461747|Experimental|C|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose will be increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days."
2497813|NCT02917915|Experimental|New Canadian Standardized PR|"Education Content: exercise, living well with chronic lung disease, breathing management, conserving energy, pulmonary medications, inhaler devices, integrating exercise in your life, management of respiratory infections, management of aggravating environmental factors, management of stress & anxiety, nutrition, leisure & travel, getting a good night's sleep, enjoying intimacy, living in a smoke-free environment, integrating long-term oxygen into your life, keeping a healthy lifestyle.~Delivery style: During group sessions patients engage in active, participatory-based learning of program content. Workbooks are available. During one-on-one interactions motivational communication style (asking for permission before providing information, using open questions, etc.) is used."
2497957|NCT02916862|Placebo Comparator|Placebo + calcium|This group will receive a similar supplement without SCF + 600 mg/d of elemental calcium carbonate, administered twice a day
3162431|NCT00461760|Active Comparator|1|Women with normal cytology at recruitment will be recalled for their next routine screen at 2 years and if negative again, for their exit screen at 4 years, all according to current provincial guidelines.
3162432|NCT00461760|Active Comparator|2|Women with abnormal cytology at recruitment or at the 2 year screen will be followed according to provincial guidelines based on their cytology results.
3162433|NCT00461838||1|All women (n=56) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of colorectal surgeon and/or urologist were selected retrospectively from the list of all patients (n=more than 2000) operated at the Leuven University Fertility Centre (LUFc) between September 1996 and July 2004.
3162434|NCT00461903|Placebo Comparator|Placebo (for perindopril)|Sugar pill manufactued to mimic perindopril
3162435|NCT00461903|Active Comparator|Perindopril|Perindopril (coversyl) 4 mg tablets
3162436|NCT00461955|Experimental|1|autologous peripheral blood stem cell transplantation
3162437|NCT00462007|Experimental|1|Stalevo
3162438|NCT00462098|Experimental|HBO|Subject receives 40 HBO sessions at 2 atmospheres of pressure over 4 weeks
3162439|NCT00462098|Active Comparator|Control|non-HBO comparison group
3162440|NCT00462137||1|control group
3162441|NCT00462137||2|hypnotic group
3162442|NCT00462176||1|All women (n=45) who had undergone CO2 laser laparoscopic radical excision of deep infiltrating endometriosis with active involvement of the colorectal surgeon performing a bowel resection were selected retrospectively from the list of all patients (n=more than 400) operated at the Leuven University Fertility Centre (LUFc) between September 2004 and July 2006.
3162443|NCT00462202|Experimental|Sulodexide|Open label extension to original trial
3162444|NCT00462215|Experimental|1|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
3162445|NCT00462215|Experimental|2|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
3162446|NCT00462215|Experimental|3|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
3162447|NCT00462215|Experimental|4|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
3162448|NCT00462215|Experimental|5|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
3174981|NCT00628914|Placebo Comparator|3|Escitalopram plus placebo for 8 weeks
3174982|NCT00628940|Experimental|1|18F-fluoromethylcholine
3195541|NCT00840853|Experimental|Group B without disease|"CD19+ B cell CLL or NHL undergoing allogeneic HSCT, without detectable disease post-HSCT~Patients will receive CD19CAR/virus specific T cells -~Dose Level 1: 1.5 x 10^7/m2~Patients will be evaluated in the clinic and a single dose of CTL will be administered from day +30 post-HSCT.~Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells."
2497588|NCT02919163|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497592|NCT02919163|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to incandescent light with a red color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497594|NCT02919163|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497598|NCT02919163|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to incandescent light with a blue color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497601|NCT02919163|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497603|NCT02919163|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to incandescent light with a green color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497604|NCT02919163|Experimental|Visible light exposure White 30 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497607|NCT02919163|Experimental|Visible light exposure White 120 lux|The participants will be exposed to incandescent light with no color filter at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497676|NCT02918708|Active Comparator|group 2 (Synflorix then Prevenar13)|PCV10 given at 2 and 4 months of age, PCV13 given at 12 months of age
2497677|NCT02918708|Active Comparator|group 1 (Prevenar13 only)|PCV13 given at 2,4 and 13 months of age
2497752|NCT02918331|Experimental|Daratumumab with Lenalidomide and dexamethasone|"Daratumumab (16 milligram per kilogram [mg/kg]) will be administered by intravenous [IV] infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.~Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle.~Participants will receive dexamethasone 40mg weekly, at day 1, 8, 15, 22 of each cycle."
2497809|NCT02917863|Experimental|Solid L-Thyroxine|"Patients assume L-Thyroxine (tablet, per os) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with hypothyroidism:~0-6 months: 10 mcg/kg body weight/die 6-12 months: 8 mcg/kg body weight/die~1- 5 years: 6 mcg/kg body weight/die 5-10 years: 4 mcg/kg body weight/die~Dosage in adults:~initial dose of 50mcg/die; maintenance dose 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
2497811|NCT02917863|Active Comparator|Liquid L-Thyroxine|"Patients assume L-Thyroxine (oral drops, solution) according to the Summary Product Characteristics for 6 months (then switch to the other formulation).~Dosage in children with acquired hypothyroidism:~initial dose: 12,5-50 mcg/die maintenance dose: 100-150 mcg/m2 body surface area~Dosage in adults:~initial dose: 50 mcg/die; maintenance dose: 100-200 (300) mcg/die (medium dose 2-2,5 mcg/kg body weight/die).~Dosage will be adjusted according to TSH level."
2497876|NCT02917564|Sham Comparator|Control|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, a 3 ml syringe will be placed into the superotemporal conjunctival fornix but no needle is present and no drug injected."
2497878|NCT02917564|Active Comparator|Injection|"Patients placed in a semi supine position. A cotton-tipped applicator saturated with proparacaine 0.5% (Alcaine, Alcon Labs) is placed into the conjunctival fornix of the supero-temporal quadrant for 5 minutes following initial proparacaine drops.~After anaesthetic medication is placed, 1mL of a 40 mg/ml suspension of triamcinolone acetonide is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down."
2497934|NCT02917018|Active Comparator|Dexmedetomidine 1|patients will receive dexmedetomidine 1 mic/kg
2497937|NCT02917018|Active Comparator|Dexmedetomidine 0.75|patients will receive dexmedetomidine 0.75 mic/kg
2497938|NCT02917018|Active Comparator|Dexmedetomidine 0.5|patients will receive dexmedetomidine 0.5 mic/kg
2497984|NCT02916654|Active Comparator|sulphate iron|patients administered with sulphate iron
2497986|NCT02916654|Experimental|sucrosomial iron|patients administered with sucrosomial iron
2498002|NCT02916368||with surgery|
2498005|NCT02916368||with chemotherapy or radiotherapy|
2498057|NCT02916251|Experimental|ZP4207(dasiglucagon)|Intervention: ZP4207(dasiglucagon) glucagon analogue (4 mg/mL) planned doses: 0.03, 0.08, 0.2 and 0.6 mg at euglycemic and hypoglycemic conditions.
2498058|NCT02916251|Active Comparator|Glucagon (Native glucagon)|Intervention: Glucagon (Native glucagon) 1 mg/mL as active comparator planned doses: 0.03, 0.08 and 0.2 mg at euglycemic conditions.
2499544|NCT02905695|Experimental|Group A|Chirocaine
2497590|NCT02919124|Experimental|Echoclip device|Ultrasonography using the echoclip device
2497626|NCT02918812|Experimental|Intracervical lidocaine|This group will comprise of patients that will receive the intracervical block. The study group will receive a total of 60 mg (6 mL) of 1% lidocaine to be injected at four points (12, 4, 6, and 8 o'clock) circumferentially into the cervix (1.5 mL at each point) 5 minutes before proceeding with the hysterosalpingogram.
2497628|NCT02918812|Active Comparator|Intramuscular Diclofenac|This group will comprise of patients that will receive intramuscular diclofenac potassium 75mg 30 minutes before proceeding with the hysterosalpingogram.
2497718|NCT02918513|Experimental|Wellness Intervention|WILD 5 Wellness is an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
3174983|NCT00628953|Experimental|1|
2497869|NCT02917434|Active Comparator|Patients with PsA and obesity|Very Low Energy Diet (VLED)
2497873|NCT02917434|Other|Patients with obesity|Very Low Energy Diet (VLED)
2497921|NCT02917070||Patients|Patients who have chronic kidney diseases
2497922|NCT02917070||Healthy controls|Healthy subjects
2497976|NCT02916784||Sit-to-stand: Pass|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'pass' if the subjects could safely rise from the chair without using their arms and with no more than contact guarding assist.
2497977|NCT02916784||Sit-to-stand: Fail|The subjects seated on a standard armless chair with their back upright at 90 degrees against the backrest of the chair, feet placement on the floor with the heels at 10 cm behind the knees and their arms on their sides. Then they were instructed to stand up from the chair without using the arms. The ability was recorded as 'fail' if the subjects could not rise from the chair without using their arms and/or with more than contact guarding assist.
2498029|NCT02916459|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
2498030|NCT02916459|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
2498191|NCT02915146|Active Comparator|NB-UVB monotherapy|Narrowband ultraviolet B monotherapy will be used
2498203|NCT02915146|Active Comparator|NB-UVB + UVA1|Narrowband ultraviolet B combined with ultraviolet A1 phototherapy will be used
2498253|NCT02914925|Experimental|ArmeoSpring/CIT|Group will receive ArmeoSpring and CIT therapy
2498391|NCT02913989||Doctors from Medical Specialities|Doctors from Medical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
2498392|NCT02913989||Doctors from Surgical Specialities|Doctors from Surgical Specialities A voluntary and anonymous questionnaire was distributed to all physicians for a period of 4 months. The questions included sociodemographic data, smoking habits characterization, attitudes towards smoking, importance attribute to smoking cessation programme in the hospital and knowledge of the 2008 country law.
2498454|NCT02913469|Experimental|morphine+metoclopramide|administrated intravenous morphine 5mg and metoclopramide 10mg
2498458|NCT02913469|Active Comparator|morphine|avenous morphine 5mg and 0.9%normal saline 2ml
2498460|NCT02913469|Sham Comparator|metoclopramide|intravenous metoclopramide 10mg and 0.9%normal saline 2ml
2498461|NCT02913469|Placebo Comparator|placebo|intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml
2498508|NCT02913131|Experimental|Part A: Feasibility Run-In|Patients with advanced solid tumor malignancies with at least one liver metastasis will be enrolled with iterative adjustment of coil design to optimize imaging parameters including spatial resolution and signal-to-noise ratio (SNR) of hyperpolarized pyruvate / lactate within the target metastatic lesion(s).
2498510|NCT02913131|Experimental|Part B: Biomarker Cohort|Patients with advanced solid tumor malignancies and the presence of at least one liver metastasis amenable to hyperpolarized C-13 pyruvate metabolic MR imaging who are planning on being treated with agent targeting PI3K/mTOR pathway will be enrolled.
2498552|NCT02912884||PV|Patients with a diagnosis of polycythaemia vera.
2498553|NCT02912884||ET|Patients with a diagnosis of essential thrombocythaemia.
2498573|NCT02912598|Active Comparator|Mallinckrodt™ Endobronchial Tube|Usage of a left-sided Mallinckrodt™ double-lumen tube (DLT) to achieve lung isolation and one lung ventilation.
2498576|NCT02912598|Active Comparator|Fuji Uniblocker™|Usage of a Fuji Uniblocker™ in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
2498585|NCT02912598|Experimental|ETView VivaSight™-SL+EB|Usage of a ETView VivaSight™-EB endobronchial blocker in a ETView VivaSight™-SL single-lumen tube to achieve lung isolation and one lung ventilation.
2498588|NCT02912598|Active Comparator|COOK© Arndt Endobronchial Blocker|Usage of a COOK© Arndt Endobronchial Blocker in a generic single-lumen tube to achieve lung isolation and one lung ventilation.
2498639|NCT02912325|Other|FaseMetS ® a food supplement|Daily administration: 2 tablets FaseMETS a day
2498670|NCT02912000|Experimental|Intervention|The intervention group will receive the TEACH intervention - an electronic tablet screening in waiting room for the modifiable risk factors
2498672|NCT02912000|No Intervention|Control|Care as usual: No electronic tablet in waiting room
2499529|NCT02905955|Other|Prevena|
2499545|NCT02905695|Placebo Comparator|Group B|Placebo
3174984|NCT00628953|Placebo Comparator|2|
3174985|NCT00628979|Other|1|CBT
3174986|NCT00628992|Other|1|
3174987|NCT00628992|Active Comparator|2|
3174988|NCT00628992|Active Comparator|3|
3174989|NCT00628992|Active Comparator|4|
3174990|NCT00629005|Experimental|Arm 1|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus 1 hour of strength training for the arms and hands 3x/week
3174991|NCT00629005|Active Comparator|Arm 2|Constraint-Induced Movement Therapy (wear a mitt on non-paretic hand for 90% of waking hours + functional task practice for 3 hours) plus non-resisted arm and hand movements for 1 hour 3x/week
3195542|NCT00840892|Experimental|Intercom|INTERdisciplinary COMmunity-based COPD management (INTERCOM)
3195543|NCT00840892|No Intervention|Usual Care|
2497668|NCT02918604|Other|B : veinsite access|infrared technology vein access
2497670|NCT02918604|Active Comparator|A: control group|conventional vein access
2497704|NCT02918448|Experimental|Taining group|training group that performed the resistance program. All participants were personally supervised by physical education professionals with substantial RT experience. The sessions were performed 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. Participants of the TG performed 3 sets of 10-15 repetition maximums. Participants were afforded a 1 to 2 min rest interval between sets and 2 to 3 min between each exercise. The training load was consistent with the prescribed number of repetitions for the three sets of each exercise
2497705|NCT02918448|No Intervention|control group|control group that did not perform any type of physical exercise
2497789|NCT02918175|Other|mHealth Intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected. In addition, they will receive personalized feedback on activity goals based on prior week step counts and participate in coaching sessions using the Pillbox medication tool.
2497790|NCT02918175|No Intervention|No intervention|Subjects in this study arm will have data on activity levels, quality of life, medication adherence, and blood samples collected.
2497888|NCT02917395|Experimental|echo|"Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.~Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide."
2497955|NCT02916979|Other|Conditioning Regimen|Fludarabine, Busulfan, Rabbit ATG, Methotrexate
3195544|NCT00840905||1|HIV seropositive women from an HIV Antiretroviral therapy clinic in Johannesburg South Africa
3195545|NCT00840905||2|A cohort of HIV seropositive women from Gabarone Botswana
3195546|NCT00840905||3|A cohort of HIV seropositive women from Rio De Janeiro Brasil
3195547|NCT00840918|Active Comparator|1|Intravenous Lidocaine group
2498229|NCT02914990|Experimental|BPI-15086|BPI-15086, orally administered daily
2498276|NCT02914691|Active Comparator|Active|Dapagliflozin 10 mg once daily tablet treatment
2498280|NCT02914691|Placebo Comparator|Placebo|Identical once daily tablet treatment
2498318|NCT02914405|Experimental|Treatment|"The dose and schedule of 131-I mIBG will be constant, and the doses of ch14.18/ CHO and Nivolumab determined by cohort:~Cohort I: 3 mg/kg Nivolumab (100% adult dose). No ch14.18/CHO. (3-6 patients)~Cohort II: 50mg/m2/cycle ch14.18/CHO (50% established Long Term Intervention (LTI) dose) and 3 mg/kg Nivolumab (100% adult dose) (3-6 patients)~Cohort III: 100mg/m2/cycle ch14.18/CHO (100% established LTI dose) and 3 mg/kg Nivolumab (100% adult dose) (initial 3-6 patients, expanded to 15 patient cohort if tolerated)"
2498380|NCT02914054|Active Comparator|Conventional Prednisone receiving group|Patients in PDN arm received PDN
2498381|NCT02914054|Active Comparator|Dxamethasone receiving group|In HD-DXM arm, DXM was administered
2498424|NCT02913781|Experimental|polar body removal|polar body removal by zona drilling with laser then suction by injecting pipette then ICSI procedure is done
2498515|NCT02913404|Experimental|ACL Reconstruction|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia."
2498516|NCT02913404|Experimental|ACL Recon. extra-articular-tenodesis|"Surgical Protocol~Standard single bundle anatomic ACL reconstruction will be performed for all subjects. Quadrupled hamstring tendon will be used with cortical fixation on femur and tibia. ACL-R+EAT will be performed as described by Marcacci with doubled hamstring tendon left attached at the pes anserinus, an anatomic tibial tunnel, staple fixation in the over the top position, routing of the graft superficial to the LCL, and staple fixation at Gerdy's tubercle. Concomitant tears to the menisci and their roots will be repaired as indicated."
2498562|NCT02912871|Experimental|MRIgHIFU unilateral subthalamotomy|Unilateral Subthalamotomy performed by MRI guided High intensity focused ultrasound in a single session.
2498630|NCT02912520||Patients with antibiotic therapy|Patients with antibiotic therapy for 2 weeks.
2498641|NCT02912520||Patients without antibiotic therapy|Patients without any antibiotic therapy in the last 3 months.
3195548|NCT00840918|Placebo Comparator|Placebo|Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
3195549|NCT00840931|Experimental|Immunotherapy|Participants will take two 5 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Participants will receive 4 treatment cycles with 28 days in each cycle. Those participants showing a clinical response after 4 cycles of treatment may continue to receive lenalidomide as a single agent for additional cycles at the treating Physicians discretion. During each 28 day cycle participants will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
3195550|NCT00840944|Experimental|ZOMATRIP|GnRH agonist triptorelin plus somatropin
3195551|NCT00840957||A|Rhumatoid arthritis patient currently receiving infliximab
3195552|NCT00840983|No Intervention|1-Immediate Cord Clamping|infants received the routine care of immediate clamping of the umbilical cord
3195553|NCT00840983|Experimental|2-Delayed Cord Clamping|after birth, cord clamping was delayed 30 to 45 seconds while infant was held lower than the level of the placenta.
3195554|NCT00841022|Experimental|1|Information of children with comic leaflet
3195555|NCT00841022|No Intervention|2|
3195556|NCT00841048|Experimental|1|AZD4017 in ascending doses (start dose 75mg od)
3195557|NCT00841048|Placebo Comparator|2|Placebo
3195558|NCT00841061|Active Comparator|Cereal L|Rice cereal with electrolytic iron
3195559|NCT00841061|Active Comparator|Cereal M|Rice cereal with ferrous fumarate
3195560|NCT00841074|Experimental|1|Peridex mouthwash
3195561|NCT00841074|Placebo Comparator|2|Placebo mouthwash
3195562|NCT00841113|Experimental|1 Abarelix|Investigative drug
3195563|NCT00841113|Active Comparator|2 Goserelin plus bicalutamide|Standard therapy
2497554|NCT02919137|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497558|NCT02919137|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497560|NCT02919137|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497562|NCT02919137|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497564|NCT02919137|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497568|NCT02919137|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497573|NCT02919137|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 45 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness. The participants will perform cognitive tests (verbal fluency task, arithmetic task, word repetition task) during the colored light exposure and hyperventilation and hypoventilation tasks .
2497636|NCT02918799|Other|Community cohort|Beirut community will receive the multi-component intervention Mpowerment; the community cohort of YMSM will be used to evaluate the effects of the intervention on the community, as the cohort participants may or may not have participated in the intervention.
2497707|NCT02918591|Experimental|Empagliflozine|All type 2 diabetic participant will be treated during 2 month with Empagliflozine 10 to 25 mg daily during 2 month.
2497793|NCT02918149|Other|Palpation Landmark Technique LP|Traditional landmark palpation technique will be used to perform LP
2497795|NCT02918149|Experimental|Ultrasound-Assisted Technique LP|Bedside ultrasonography exam will be used for identification of anatomic landmarks before performing LP
2497837|NCT02917668|Active Comparator|Group A|15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
2497841|NCT02917668|Active Comparator|Group B|15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
3162449|NCT00462215|Experimental|6|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
3162450|NCT00462241|Experimental|chiropractic treatment|Individualised chiropractic treatment, pragmatic approach
2497991|NCT02916641|Experimental|Fuzhenghuayu+UDCA|Regular UDCA treatment combination with Fuzhenghuayu
2497992|NCT02916641|Active Comparator|Monotherapy|UDCA monotherapy
2497999|NCT02916303||Patients|Patients followed up at least during 3 years at PAFIP clinic
2498064|NCT02916238|Experimental|Measurement Based Care|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
2498073|NCT02916238|Active Comparator|Enhanced Usual Care|Depression symptoms monitored at 3 month interval; results from PHQ-9 available to ART clinic physicians.
2498346|NCT02914262|Experimental|Experimental:Cohort 1-6 Experimental|Intervention AKB 4924 Six subjects per cohort will receive single doses of 20 to up to 480 mg of AKB 4924 orally in a dose escalation format
2498347|NCT02914262|Placebo Comparator|Placebo:Cohort 1-6|"Intervention Placebo:~Two subjects per cohort will receive single oral doses of placebo"
2498425|NCT02913625|Experimental|Ultrasound guided retroclavicular block|Patients assigned to this group will receive an ultrasound guided retroclavicular brachial plexus block
2498426|NCT02913625|Active Comparator|Ultrasound guided infraclavicular block|Patients assigned to this group will receive an ultrasound guided infraclavicular brachial plexus block
2498489|NCT02913378|Experimental|Locking plate|Surgical treatment with open reduction and osteosynthesis with locking plate
3162451|NCT00462241|Sham Comparator|self-management|Self-management: Minimal intervention - practice as usual.
3162452|NCT00462254|Other|A|Day 1-3: placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: continue placebo.
3162453|NCT00462254|Other|B|Day 1-3: Placebo run-in - 8 mg of placebo orally 30 minutes before bedtime. Days 4-11: continue placebo. Days 12-14: crossover - 8 mg of placebo orally 30 minutes before bedtime. Days 15-22: true drug - 8 mg of Ramelteon orally 30 minutes before bedtime.
3162454|NCT00462267|No Intervention|Usual care|
2497609|NCT02919189|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497610|NCT02919189|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497611|NCT02919189|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497612|NCT02919189|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white fluorescent light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2497613|NCT02919189|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white fluorescent light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
3195564|NCT00841126|Experimental|Magnesium iron hydroxycarbonate|
3195565|NCT00841126|Active Comparator|Lanthanum carbonate|
3195566|NCT00841126|Placebo Comparator|Placebo|
3195567|NCT00841139|Experimental|Perhexiline|perhexiline 100mg bd for 1 month duration
3195568|NCT00841139|Placebo Comparator|Placebo|placebo one tablet bd for 1 month duration
2497933|NCT02917135||Angel® Catheter|All consecutive, hospitalized patients in whom the Angel® Catheter is placed, or there has been an attempt to place, at selected Registry sites.
2498007|NCT02916615|Active Comparator|High nitrate vegetables|During 5 weeks subjects receive 100-150 g of a leafy green vegetable (High nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
2498017|NCT02916615|Placebo Comparator|Low nitrate vegetables|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and placebo pills containing 300 mg KCl (2 x 150 mg).
2498024|NCT02916615|Active Comparator|Low nitrate vegetables + nitrate|During 5 weeks subjects receive 100-150 g of tomatoes/sweet pepper (Low nitrate vegetables) per day and nitrate pills containing 300 mg KNO3 (2 x 150 mg).
2498074|NCT02916082||Prolonged pregnancy|Pregnancies with 41 weeks or more of gestation determined by a reliable last menstrual period or early fetal ultrasound.
3195569|NCT00841152||Hand lesions|Stratum I: comparison of three interventions (autograft, bioactive glass and beta-tricalcium phosphate)
3195570|NCT00841152||Long-bone lesions|Stratum II: comparison of three interventions (bioactive glass, beta-tricalcium phosphate, allograft)
2498393|NCT02913976|Experimental|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2498394|NCT02913976|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2498471|NCT02913300|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
2498473|NCT02913300|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during EBUS-TBNA
2498534|NCT02912988|Experimental|Letrozole group|"Letrozole + standard treatment:~Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration."
2498537|NCT02912988|No Intervention|Control group|"Standard treatment:~Daily 150-300 IU HMG/FSH cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) until the day before hCG administration. GnRH antagonist 0.25 mg daily from stimulation day 5 until the day of hCG administration."
2498555|NCT02912728|Active Comparator|CGM + Family Behavioral Intervention|CGM training for CGM groups using a standard curriculum will take place at the 1, 3 and 6 week visits in addition to the training at baseline. The family behavioral intervention will be delivered by a study coordinator (separate coordinator from the CGM instruction) at the 1, 3, 6, 13 and 19 week visits and is expected to take approximately 30 minutes.
2498557|NCT02912728|Active Comparator|Standard CGM|"Each participant will be asked to use a CGM sensor on a daily basis, inserting a new sensor as needed with a maximum of 7 days of wear per sensor.~A home BGM will be used for calibration of the CGM sensor. Additional BGM glucose measurements may be performed by the participant at any time, particularly prior to making a real-time management decision based on the CGM glucose reading.~Participants will be instructed to use the CGM as per the FDA labeling."
2498559|NCT02912728|No Intervention|BGM - usual care control group|A BGM will be used for a finger stick blood glucose check with a recommendation of at least 4 times a day. BGM data will be downloaded and reviewed with the participant at each visit.
2498614|NCT02912494|Experimental|JR-131|
2498616|NCT02912494|Active Comparator|Darbepoetin alfa|
2499531|NCT02906163|Experimental|Thymalfasin biw plus SoC (tyrosine kinase inhibitor)|Twice weekly thymalfasin
3195571|NCT00841165|Experimental|1|Participants in this arm are treated with Continuous Positive Airway Pressure at 5cm H2O and 100% oxygen
3195572|NCT00841165|Active Comparator|2|Participants in this arm receive standard of care therapy- oxygen via a non-rebreather mask
3195573|NCT00841178|Active Comparator|Surgery|Patients undergo Surgery under a general anaesthetic.
3195574|NCT00841178|Experimental|EVLT|Patients undergo EVLT under a local anaesthetic.
3195575|NCT00841191|Experimental|Siltuximab 2.8 mg/kg (Cohort 1)|
3195576|NCT00841191|Experimental|Siltuximab 5.5 mg/kg (Cohort 2)|
3195577|NCT00841191|Experimental|Siltuximab 11 mg/kg (Cohort 3)|
3195578|NCT00841191|Experimental|Siltuximab 15 mg/kg (Cohort 4)|
3195579|NCT00841191|Experimental|Siltuximab 15 mg/kg (Expansion Cohort 5)|
2497797|NCT02917889|Experimental|Caffeine protocol|300 mg in pills
2497799|NCT02917889|Experimental|Placebo protocol|300 mg in pills
2497850|NCT02917590|Experimental|Dual-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are instructed to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device. During walk over obstacles, subjects asked to perform simultaneously with a color word stroop task which requires subjects to see and answer the color of the name of a color words in the monitor (ignore the meaning) as quickly as possible, and loudly.
2497852|NCT02917590|Sham Comparator|Single-task obstacle crossing training|The four obstacles in the sizes of 4cm wide, 8cm wide, 4cm high, and 8cm high are randomly placed along a 10-meter walkway in 2-meter intervals. Subjects are asked to walk continuously over obstacles at their comfortable speed, as good as they can without contact the obstacles by their leg or device.
2497904|NCT02917291|Experimental|FAB117-HC (Ph 1)|Patients with acute traumatic spinal cord injury grading AIS A (8 patients)
2497909|NCT02917291|Other|Control group (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
2497913|NCT02917291|Experimental|FAB117-HC (Ph 2)|Patients with acute traumatic spinal cord injury grading AIS A or B (up to 20 patients)
2497964|NCT02916849|Experimental|Safe Step - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Safe Step exercise program as intervention, participants will be given a green prescription for exercise using the application Safe Step. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
2497966|NCT02916849|Active Comparator|OEP - Health Care Centre|Participants will be recruited informed and asked for participation in the study by health care professionals. If included in the study, and choosing the Otago Exercise Program as intervention in the study participants will be given a green prescription for exercise with the Otago Home Exercise Programme-booklet. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
2497969|NCT02916849|Experimental|Safe Step - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises in the Safe Step application. During the four month intervention the participants will create weekly exercise plan, keep a digital exercise diary, and receive motivational feed-back within the system. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time
2497970|NCT02916849|Experimental|Safe Step mentors- Advertising|This arm is exactly the same as the Safe Step Advertising group except the participants will be invited to attend group meetings with peer mentors, once a month during the intervention. The peer mentors are older adults earlier involved in the research project . They will act as role models and encourage the participants throughout the four months of exercise.
2497972|NCT02916849|Active Comparator|OEP - Advertising|Participants are recruited through meetings at senior citizens organisations and interviewed by telephone for background data and choice of intervention before inclusion. After an introduction meeting in small groups and pre-assessments the participants will create an individual exercise programme containing ten balance and leg strengthening exercises using the Otago booklet for guidance. During the four month intervention the participants will keep a paper-based exercise diary that will be sent to the researchers on a monthly basis. The participants will be recommended to exercise at least three times per week and for at least 30 minutes at a time.
3195580|NCT00841191|Experimental|Siltuximab 15 mg/kg (Ovarian Cancer Cohort 6)|
3195581|NCT00841191|Experimental|Siltuximab 15 mg/kg (KRAS Mutant Tumors Cohort 7)|
2498092|NCT02915913|Experimental|High Intensity Interval|One session for 30-60 minutes of high intensity aerobic exercise
2498094|NCT02915913|Experimental|Resistance training|One session for 30-60 minutes of resistance exercise
2498099|NCT02915913|Experimental|Plus: High Intensity Interval + Resistance Training|One session for 30-60 minutes of high intensity aerobic exercise and resistance exercise
2498101|NCT02915913|Placebo Comparator|Non-exercise|Non-exercise
2498150|NCT02915510|Experimental|GMP|Single arm designed, 3 day baseline, 28day on GMP
2498185|NCT02915198|Experimental|Metformin|Participants are randomly assigned in a 1:1 ratio to treatment with metformin XR 500 mg or matching placebo.
3195582|NCT00841217|Placebo Comparator|1|placebo group
3195583|NCT00841217|Active Comparator|2|GW501516, 2.5mg
3195584|NCT00841230|Placebo Comparator|Lactose placebo|1x/day
3195585|NCT00841230|Experimental|Deanxit|
3195586|NCT00841243|Active Comparator|nutritional advise/support|Nutritional advise and support
3195587|NCT00841243|No Intervention|control|Control
3195588|NCT00841256|Experimental|Immunotherapy|Grass pollen allergens in a water/glycerol solution
3195589|NCT00841256|Placebo Comparator|Placebo|Water/glycerol solution with phosphate buffered saline
3195590|NCT00841282|Active Comparator|1|Water Infusion in lieu of Air Insufflation Colonoscopy
3195591|NCT00841282|Placebo Comparator|2|Air Insufflation Colonoscopy
3195592|NCT00841295|Experimental|Carnitine|Intervention 'Parenteral L-carnitine supplementation' Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
3195593|NCT00841295|Placebo Comparator|Controle|Intervention 'Parenteral supplementation with sterile water'
2497731|NCT02918409|Active Comparator|Standard tobramycin arm|Subjects receive IV tobramycin 8-10 mg/kg/day with once daily dosing for 14 days. Peaks and troughs are drawn with the second dose of tobramycin, and the drug is infused over 30 minutes
2497773|NCT02918045|Experimental|Hemcon Dental Dressing|The HemCon® Bandage is an FDA-cleared chitosan-based flat bandage that controls severe arterial bleeding from traumatic injuries. In comparison to traditional bandages, the HemCon® Bandage provides superior control of bleeding, wound site adhesiveness, multiple injury site usage, biocompatibility and provides a barrier to infective agents.
2497774|NCT02918045|Active Comparator|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions involves the placement of an absorbable oxidized cellulose gauze Surgicel (Ethicon, Inc, San Angelo, TX) into the extraction socket. This treatment was chosen as the study control to compare the HemCon Dental Dressing to the standard local hemostatic care for oral surgery subjects.
2497821|NCT02917824|Experimental|High-intensity IMT|Participants enrolled in this arm received high-intensity IMT
2497824|NCT02917824|Active Comparator|Low-intensity IMT|Participants enrolled in this arm received low-intensity IMT
2497859|NCT02917525|Experimental|Vitamin K2|22 patients will receive 360ug Vitamin K2 daily during 18 months.
2497862|NCT02917525|Placebo Comparator|Placebo|22 patients will receive placebo during 18 months.
3162455|NCT00462267|Experimental|Enriched lifestyle intervention|
3162456|NCT00462358|Experimental|ARRY-520|
3162457|NCT00462358|Experimental|ARRY-520 + G-CSF support|
2498097|NCT02915887|Experimental|cervical taping|Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
2498117|NCT02915549|Experimental|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
2498120|NCT02915549|Active Comparator|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
2498171|NCT02915367|Experimental|SMS Reminders|Participants will receive regular SMS reminders regarding PrEP. All participants will receive adherence monitoring through a WisePill device.
2498172|NCT02915367|No Intervention|No Reminders|Participants will not receive SMS reminders. All participants will receive adherence monitoring through a WisePill device.
2498233|NCT02915042|Experimental|Experimental group|Intervention group 1: pre-operative administration of IV dexmedetomidine 1mcg/kg
2498234|NCT02915042|Placebo Comparator|Placebo group|Intervention group 2: placebo
3162458|NCT00462553|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 OR on days 1, 8, and 15. Patients also receive oral sunitinib malate once daily on days 1-21 OR days 1-28. Treatment repeats every 21 days OR every 28 days in the absence of disease progression or unacceptable toxicity.
3162459|NCT00462592|Active Comparator|1|montelukast - montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
3162460|NCT00462592|Active Comparator|2|budesonide - inhaled budesonide turbuhaler 200ug (& matching placebo) taken 1 puff morning & 1 puff evening.
3162461|NCT00462592|Placebo Comparator|3|placebo
3174992|NCT00629031|Active Comparator|2|Paromomycin for 21 days @ 11mg/kg
2498802|NCT02911051|Experimental|Actreen Hydrolite Cath|a new hydrophilic coated catheter for Urinary Intermittent Catheterisation
2498924|NCT02909985|Experimental|Visual response to IR|"15 healthy participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~10 colorblind participants will describe IR light passing through narrow bandpass filters over a broad spectrum light source~For both groups, as intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band Tungsten halogen light with narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see."
2498927|NCT02909985|Experimental|Electroretinography|"5 healthy participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an ERG with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
2498930|NCT02909985|Experimental|Visual Evoke Potential Test|"5 healthy participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR~A total of 15 participants, or five per retinal disease, will be recruited . Retinal diseases include retinitis pigmentosa, age related macular degeneration, congenital stationary night blindness, cataracts. Participants will undergo an VEP with standard baseline tests followed by similar tests using IR, with standard baseline tests followed by similar tests using IR"
2498969|NCT02909712|Active Comparator|sulfadoxine-pyrimethamine (SP)|"Group 1 (50 CareStart™ RDT-positive women)~Group 2 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy and molecular analysis, and receive SP on day 0. On days 7, 14, 21, and 28 women will provide blood for microscopy and molecular analysis."
2499532|NCT02906163|Experimental|Thymalfasin plus SoC (tyrosine kinase inhibitor)|5 times a week thymalfasin
3174993|NCT00629031|Experimental|1|Paromomycin for 14 days @ 11mg/kg
3195594|NCT00841308|Active Comparator|Usual care|
3195595|NCT00841308|Active Comparator|Home blood pressure monitoring|
3195596|NCT00841334|Experimental|1|ACTION
3195597|NCT00841334|Active Comparator|2|Usual care
3195598|NCT00841347|No Intervention|1|Study of habitual sleep length on non obese teen group
3195599|NCT00841347|Experimental|2|Study of habitual sleep length period followed by extended sleep length period on obese teen group
3195600|NCT00841347|Experimental|3|Study of extended sleep length period followed by habitual sleep length period on obese teen group
3195601|NCT00841360||HIV Positive|"Participant self-discloses as HIV positive.~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
2499546|NCT02905682|Experimental|Desmopressin|Desmopressin ODT
3195602|NCT00841360||HIV Negative|"Participant self-discloses as HIV negative (based on receiving a negative HIV test within 12 months prior to study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
3195603|NCT00841360||HIV Status Unknown|"Participant self-discloses as HIV negative (no history of prior HIV testing, or HIV screening more than 12 months prior to date of study consent).~Sexually experienced females between the ages of 13 and 24 years old and of African American race, Hispanic/Latina ethnicity, or mixed-race/ethnicity, which must include African American race and/or Hispanic/Latina ethnicity."
3195604|NCT00841360||Friendship Network Members|Friendship network members will also consist of sexually experienced females, aged 13 years and older. Although most members are expected to be of African American race and/or Hispanic/Latina ethnicity, all races and ethnicities will be included.
3195605|NCT00841373|Active Comparator|1|Panretinal Photocoagulation
3195606|NCT00841373|Active Comparator|2|Ranibizumab Supplementing Panretinal Laser Photocoagulation
3195607|NCT00841386|Experimental|Cross-linking treatment|Topical anesthesia (lidocaine jelly 2%) will be used. The central 9 mm of corneal epithelium will be removed cautiously with an Amoils brush. Riboflavin 0.1% solution will be applied (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) to the cornea every 2-3 minutes for 15 minutes and then every 5 minutes thereafter. The UV source will be from the CBM VEGA X-linker (CSO, Florence, Italy). A wavelength of 370 nm will be used to direct 5.4 J/cm2 to the area of cornea debrided for 30 minutes. The distance from the UV source to the cornea will be 1.5 to 5.4 cm.
3195608|NCT00841386|Sham Comparator|Sham treatment group|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and a 2% methylcellulose solution combined with 1% fluorescein dye will be applied to the cornea every 5 minutes for 30 minutes. The patient will be placed under the UV device, but instead of the UV light, the LED aiming beam will be applied for 30 minutes.
3195609|NCT00841399|Experimental|E75 + GM-CSF vaccine|The dose escalation scheme is for three patients to receive each of the doses, 100, 500, and 1,000 mcg of peptide + 250 mcg GM-CSF each month for 6 months until the maximum tolerated dose is determined. Patients who receive the vaccine are HLA-A2+ and/or HLA-A3+. Responses to the vaccine are measured via immunologic assays.
3195610|NCT00841399|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients do not receive the E37 + GM-CSF vaccine, but are instead enrolled to the control arm for observation.
3195611|NCT00841425||Swimmers|
3195612|NCT00841438|Active Comparator|Provisional use of Clotinab|Provisional use of clotinab
3195613|NCT00841438|Experimental|Upstream use of clotinab|early upstream use of clotinab
3195614|NCT00841477|No Intervention|A1|standard behavioral intervention, standard HB vaccine schedule (0,1,6month)
3195615|NCT00841477|Active Comparator|A2|standard behavioral intervention, accelerated HB vaccine schedule (0,1,2month)
3195616|NCT00841477|Active Comparator|B1|enhanced behavioral intervention, standard vaccine schedule
3195617|NCT00841477|Active Comparator|B2|enhanced behavioral intervention, accelerated vaccine schedule (0,1,2MONTH)
3195618|NCT00841490||1|Intellectually & Developmentally Disabled Adults
3195619|NCT00841490||2|Control Group of Adults without Intellectual & Developmental Disabilities
3195620|NCT00841503||12 healthy volunteers|Healthy volunteers are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
3195621|NCT00841503||12 Participants with Type 2 diabetes|Volunteers with type 2 diabetes are randomized to 1 of 4 products over 4 weekly visits: i)buckwheat crackers;ii)crackers without buckwheat; iii)oral glucose; iv) oral sugar substitute, followed by 7 days of buckwheat crackers.
3195622|NCT00841516|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
3195623|NCT00841516|Experimental|80 µg rBet v1-FV Immunotherapy|All randomized patients were treated with either placebo or 80 µg rBet v1-FV (maintenance dose) for 2 years.
3195624|NCT00841581|Experimental|Lucentis|"All patients receive iL for for first 6 months of study. At 6 months - patients are classified as responders or non-responders. Responders receive iL PRN based on OCT,clinical exam etc. Non-responders are seen again at 12 months for repeat investigations."
3195625|NCT00841594|Active Comparator|1|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the hand."
3195626|NCT00841594|Active Comparator|2|"MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.~Applied to the chest."
3195627|NCT00841607|Experimental|Pancreaticojejunostomy|Pancreaticojejunostomy reconstruction used following Whipple surgery.
3195628|NCT00841607|Active Comparator|Pancreaticogastomy|Pancreaticogastomy reconstruction used following Whipple surgery.
3195629|NCT00841620|Active Comparator|1|Haemorrhoidectomy a.m. Milligan for grade 3-4 haemorrhoids
3195630|NCT00841620|Active Comparator|2|Stapled anopexy for grade 3-4 haemorrhoids
3195631|NCT00841633|No Intervention|1|No induced hypertension (reference group)
3195632|NCT00841633|Experimental|2|Induced hypertension with a MAP of 30 mmHg above the average MAP on the previous day; during 24-36 hours, until a perfusion CT scan has been performed
3195633|NCT00841646|Other|1|
3195634|NCT00841685|Experimental|1|Goldlock
3195635|NCT00841685|Active Comparator|2|Visicoil smallest size
3195636|NCT00841685|Active Comparator|3|Visicoil larger size
2497948|NCT02916966||ALS Patients in Case-Control|ALS patients enrolled by Cleveland Clinic Foundation (CCF)
2497953|NCT02916966||Non-neurodegenerative patients in case control|Non-neurodegenerative patients enrolled by CCF
2497956|NCT02916966||Non-neurodegeneration population in population control|Non-neurodegenerative general population enrolled by ABS mailing system from DHMC
2497958|NCT02916966||ALS Patients in State of OH|ALS registry of all cases in Ohio
2498008|NCT02916524|Experimental|Model-based|Semantic Feature Analysis training will be provided in the language that was selected by the computational model.
2498018|NCT02916524|Active Comparator|Model-opposite|Semantic Feature Analysis training will be provided in the language opposite to that which was selected by the computational model.
2498023|NCT02916524|No Intervention|Sub-Study: Computational Modeling for Bilingual Dementia and Semantic Decline|This is a sub-study aimed at building a computational model to simulate bilingual dementia and semantic decline.
2498060|NCT02916095|Experimental|Kanitinib|Subjects will be enrolled in cohorts at different dose levels in order to evaluate the safety,tolerability and determine the maximum tolerated dose and recommended phase II dose of kanitinib.
2498134|NCT02915809|Experimental|GC3110B Vaccine Group|Participants randomized to receive a single dose of GC3110B vaccine (Biological: GC3110B vaccine).
2498139|NCT02915809|Active Comparator|GCFLU Quadrivalent Inj.|Participants randomized to receive a single dose of GCFLU Quadrivalent Inj. vaccine (Biological: GCFLU Quadrivalent Inj. vaccine).
3195637|NCT00841685|Active Comparator|4|Bard goldmarker smallest size
3195638|NCT00841685|Active Comparator|5|Bard goldmarker larger size
2498267|NCT02914652|Experimental|Operated VSD's|Through the use of Electronic Patient Journal (EPJ), the investigators have identified a total of 182 children who underwent surgical closure of a congenital VSD at Aarhus University Hospital, Denmark between 1990 and 1995. After thorough review of all charts, 117 patients were excluded from participation. Exclusion criteria were coexistence of other congenital heart defects (n=89), associated syndromes, e.g. Down's (n=14), operation through a ventricular approach (n=7), missing chart (n=6) and documented arrhythmia requiring pacemaker (n=1). The remaining 68 patients represent a homogeneous group comparing surgeons, anaesthetists, surgical procedure and post-surgical period. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
2498271|NCT02914652|Experimental|Un-operated VSD's|Using EPJ, this project identified a total of 481 children born between 1985 and 1998 who had a small VSD, confirmed through diagnosis codes, that was not closed, neither spontaneously nor surgically. Exclusion criteria were lack of medical record, suffering from coronary disease, other congenital cardiac abnormalities than VSD, spontaneous closure of the ventricular septal defect at inclusion date, magnetic implants, pregnancy, lack of Danish language skills, suffering from lung disease requiring continuous medical treatment. The remaining patients represent a homogenous group of patients with isolated persistent ventricular septal defects. A fraction of this group will be randomly selected for this trial, and receives salbutamol or norflouran, blinded.
2498278|NCT02914652|Experimental|Healthy controls|Will function as a control group. Controls will be recruited through www.forsoegsperson.dk and www.sundhed.dk. Current group receives salbutamol or norflouran, blinded.
2499505|NCT02906176|Experimental|SLCO2B1 wild type|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
3195639|NCT00841711|Other|Behavioral counseling|
3195640|NCT00841724|Active Comparator|Busilvex, Fludara, Thymoglobuline|D-6: Fludara D-5: Fludara + Busilvex D-4: Fludara + Busilvex D-3: Fludara + Busilvex D-2: Fludara + Thymoglobuline D-1: Thymoglobuline D0: graft infusion
3195641|NCT00841737|Experimental|Psychoeducational group intervention|Psychoeducational group received weekly a psychoeducational intervention during a period of 12 weeks run by a nurses.
3195642|NCT00841737|Active Comparator|Control group|Individual conventional care
3195643|NCT00841750|Experimental|No chest tube|No chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
3195644|NCT00841750|Active Comparator|Chest tube|Chest tube left in the pleural cavity at the end of a VATS pulmonary wedge resection.
3195645|NCT00841789|Experimental|Arm 1 -Etanercept|Drug - Treatment with Etanercept as adjunct to standard treatment with IVIG and aspirin
3195646|NCT00841789|Placebo Comparator|2|Placebo
3195647|NCT00841802|Experimental|Prednisone|Steroid medication
3195648|NCT00841802|No Intervention|No Intervention|No Intervention
3195649|NCT00841841|Experimental|Dipyrone|"Analgesic affectiveness using Dipyrone (500mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
3195650|NCT00841841|Experimental|Acetaminophen|"Analgesic affectiveness using Acetaminophen (750mg) as a postoperative drug for pain relief.~Intervention: Drug: dipyrone and acetaminophen"
3195651|NCT00841854|Active Comparator|PBMT7|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 7 days
3195652|NCT00841854|Active Comparator|PBMT14|pantoprazole 40mg bid, bismuth 300mg qid, metronidazole 500mg tid,tetracycline 500mg qid for 14 days
3195653|NCT00841867||1|Subjects 18-80 years of age who have previously undergone partial pancreatectomy due to a benign lesion
3195654|NCT00841867||2|Healthy control subjects, 18-80 years of age, who have not had partial pancreatectomy.
3195655|NCT00841880|Experimental|1|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril + Felodipine
3195656|NCT00841880|Active Comparator|2|2 weeks run-in of Ramipril 5 mg followed by 8 weeks of Ramipril 10 mg
3195657|NCT00841893|Experimental|1|Mustard
3195658|NCT00841893|Experimental|2|Placebo
3195659|NCT00841919|Active Comparator|2|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
2497807|NCT02917954|Experimental|ePRO intervention (12 or 9 months)|"During the ePRO Tool intervention participants will complete surveys at every 3 months intervals starting month at 4 or month 7, for study duration. Surveys capture patient demographics, assessment of quality-of-life, chronic disease management, primary care experience, and Electronic Patient Reported Outcome (ePRO) Mobile Application tool usability.~Participants will also meet with their provider to setup and monitor a health goal to track during the study via the ePRO application. During the study, participants will meet with their primary care providers 4-5 times to discuss their health goal monitoring. Post-study participants will discuss their experience using the ePRO app in an interview or focus group setting."
2497949|NCT02916953|Experimental|Treatment|All subjects who meet the inclusion and exclusion criteria will receive the AGN1 Femoral Local Osteo-Enhancement Procedure (LOEP™) treatment
2497997|NCT02916511|Experimental|Chemo-radiation group|"A total dose of 45Gy will be delivered in 25 fractions at 1.8Gy/fraction, 5 fractions per week in 5 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and celiac nodes.~Paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; Carboplatin AUC=2, ivgtt, d1; qw*5"
2498061|NCT02916173|Experimental|Human chorionic gonadotrophin group|Patients will receive Human chorionic gonadotrohpin injection 5000 unit
2498066|NCT02916173|Active Comparator|Human chorionic gonadotrophin + agonist group|patients will receive both Human chorionic gonadotrophin (2500 unit) and gonadotrophin releasing hormone agonist 1mg leuprolide acetate
2498114|NCT02915770|Experimental|participants receive cholangiojejunostomy|participants will receive hepatectomy、cholangiojejunostomy and T-tube Drainage
2498115|NCT02915770|Active Comparator|participants receive no cholangiojejunostomy|participants will receive hepatectomy and T-tube Drainage
2498227|NCT02915055||Patients with pain following knee arthroscopic meniscectomy|
2498249|NCT02914704|Experimental|Patients treated with MRI-HIFU|
3162462|NCT00462592|Active Comparator|4|montelukast budesonide combination - montelukast 5mg ( < 15 years) or 10 mg (& matching placebo)will be taken 1 tab in the evening together with inhaled budesonide turbuhaler 200 ug (& matching placebo) taken 1 puff morning & 1 puff evening.
3162463|NCT00462618|Active Comparator|CBT|
3162464|NCT00462631|Experimental|1|paclitaxel eluting balloon followed by bare metal stent
3162465|NCT00462631|Active Comparator|2|Paclitaxel eluting stent
3162466|NCT00462787|Experimental|Clofarabine|This is a single arm phase I clinical trial to assess safety (morbidity and mortality) of a novel leukemia re-induction regimen. The first component of this trial is a phase I dose escalation study to determine the maximum tolerated dose (MTD) of the novel agent Clofarabine, when used in combination with topotecan, vinorelbine, thiotepa and dexamethasone. A total of three dose levels will be explored in this study.
2498651|NCT02912130|No Intervention|Control|No Intervention
2498653|NCT02912130|Experimental|Exercise|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Resistance Exercise i.e. 60 minutes per week of progressive resistance training"
2498655|NCT02912130|Experimental|Exercise+Nutrition|"Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise~Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day"
2498657|NCT02912130|Experimental|Nutrition|Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day
2498729|NCT02911584|Active Comparator|Sacral colpopexy|Laparoscopic procedure
2498731|NCT02911584|Active Comparator|POPS|Laparoscopic procedure: Pelvic Organs Prolapse Suspension
2498812|NCT02910778|Experimental|Atorvastatin|80 mg atorvastatin for 14 days with a loading dose of 180 mg ticagrelor on day 15
2498814|NCT02910778|Placebo Comparator|Placebo|Placebo for 14 days with a loading dose of 180 mg ticagrelor on day 15
2498844|NCT02910492|Experimental|Investigational Enlighten Device|Laser treatment for facial skin rejuvenation with the experimental enLighten Laser
2498936|NCT02909933|Experimental|liraglutide|liraglutide 3 mg QD for 12 weeks
2498937|NCT02909933|Experimental|metformin and liraglutide|metformin 1000 mg BID and liraglutide 1.2 mg QD for 12 weeks
3162467|NCT00462891|Experimental|IT System|IT system to send reminder letters to patients overdue for breast cancer screening.
3162468|NCT00462891|No Intervention|Usual Care|
3162469|NCT00462956|Experimental|lapatinib 1500mg daily|Subjects will self-administer lapatinib 1500 mg orally once daily.
3162470|NCT00462969|Experimental|1|pre-surgical SHG
3162471|NCT00462995|Active Comparator|Erlotinib|Erlotinib 150mg once a day p.o
3162472|NCT00463086|Experimental|1.Isoniazid (INH)|A self-administered daily dose of 5mg/kg of Isoniazid (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
3162473|NCT00463086|Placebo Comparator|2. Placebo|A self-administered daily dose of 5mg/kg of placebo for 12months (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
3162474|NCT00463242|Experimental|Agomelatine|Dosing for each subject in this extension study began with the same dose (25 mg or 50 mg of agomelatine orally once daily) the subject was receiving at the end of Week 8, the week before this study began.
3162475|NCT00463242|Active Comparator|2|
3162476|NCT00463242|Placebo Comparator|3|
2499014|NCT02909166|Active Comparator|aliskiren|Aliskiren 300 once a day (q.d)
2499016|NCT02909166|Placebo Comparator|placebo|Placebo once a day (q.d)
2499090|NCT02909114|Experimental|Experimental group|SBRT for oligometastatases from colorectal cancer objectives
2499325|NCT02907125|Experimental|TSM arm|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
3162477|NCT00463268|Active Comparator|1|Alendronate 70 mg every 2 weeks
3162478|NCT00463268|Placebo Comparator|2|Alendronate 70 mg placebo tablet every 2 weeks
3162479|NCT00463294|Active Comparator|On Pump Arm|
3162480|NCT00463294|Experimental|Off Pump Arm|
2497815|NCT02917915|Active Comparator|Traditional PR|"Education Content: Exercise, anatomy, pulmonary diseases, healthier breathing, pulmonary medications, pulmonary devices, exercise action plan, allergies & pulmonary function tests, health and air quality, healthier eating, travel, stress management & relaxation, tips to remember/summary of content.~Delivery style: During group sessions, patients engage in passive learning of program content delivered in a lecture-style approach. Patients also receive one-on-one education regarding: dyspnea management/pacing, inhaler technique, exercise maintenance."
2497842|NCT02917577|Active Comparator|Avaxim Pediatric®|2 doses (0.5 mL each) six months apart of Avaxim Pediatric®
2497844|NCT02917577|Active Comparator|Avaxim ® (adult)|2 doses (0.5 mL each) six months apart of Avaxim ® (adult)
2497871|NCT02917330|Experimental|Strength and stretching intervention|Treatment as usual + a strength and stretching intervention together with a physiotherapist
2497874|NCT02917330|No Intervention|Control group|Treatment as usual
3162481|NCT00463398||Patients operated at the LUFc|All patients operated at the Leuven University Fertility Centre (LUFc) between september 2006 and August 2008.
2498059|NCT02915900|Experimental|Intervention|Hormone dosage is calculated by using the new method Gonadotropin removal test.
2498062|NCT02915900|Active Comparator|Routine IVF method|Hormone dosage is chosen by the clinician according to standard clinical routine.
2498186|NCT02915445|Experimental|CAR-T cells recognizing EpCAM|Autologous T cells from patient are engineered to expressing a special chimeric antigen receptor to recognizing EpCAM by lentiviral vector. The engineered T cells were then endowed cytotoxicity to the tumor cells and hold the potential to inhibit the advance of tumors.
2498260|NCT02914964|Experimental|Swank Diet|Individuals randomized to this arm will follow a low saturated fat diet starting at week 12.
2498263|NCT02914964|Experimental|Wahls Elimination Diet|Individuals randomized to this arm will follow a modified paleolithic diet that eliminates all grains, dairy, eggs, legumes, and nightshade vegetables/spices starting at week 12.
2498493|NCT02913339|Experimental|Intervention|Community health workers (CHWs) will conduct screening for CVD risk using a mobile phone application to assess risk and to schedule appointments at primary care centers (PCCs). The screening process will be non-invasive and no surgical, pharmaceutical, or other testing procedures will be utilized for screening of CVD risk by CHWs. If the CHW calculates the risk of CVD to be > 10%, s/he will schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment. An automatic reminder messaging system will send reminder messages about upcoming appointments to the participants.
2498496|NCT02913339|Active Comparator|Control|"The protocol will be identical to that implemented in the intervention arm with the following difference:~If the CHW calculates the risk of CVD to be > 10%, s/he will verbally advise the study participant of her/his increased risk and recommend that s/he schedule a clinical visit with a health professional at one of the PCCs for further assessment and/or appropriate treatment."
2498529|NCT02913001|Experimental|Low Glycemic Load Diet|Participants received a diet education to follow a low glycemic load diet and received some low glycemic load staple foods.
2498532|NCT02913001|Active Comparator|Usual Eating Plan|Participants received a diet education to continue with their usual diet.
2498581|NCT02912754|Experimental|Ibrutinib plus Ruxolitinib|Patients taking ibrutinib for relapsed CLL will add ruxolitinib twice per day at the dose identified in a preliminary phase I trial for 7 cycles (3 weeks on/2 weeks off).
2498584|NCT02912754|No Intervention|Ibrutinib alone|Patients will continue to take Ibrutinib for the equivalent period of time.
2498629|NCT02912286|Active Comparator|conventional needle irrigation|side-vented needle used for endodontic irrigation
2498640|NCT02912286|Experimental|passive ultrasonic irrigation|IrriSafe ultrasonic tip used for irrigation agitation in endodontic treatment
2498644|NCT02912286|Experimental|sonic irrigation|Vibringe is a sonic irrigation system used to irrigate and activate the irrigant at same time
2498667|NCT02912026|Experimental|Intravenous|Intravenous AUC0-infinity
2498669|NCT02912026|Experimental|Oral|Oral AUC0-infinity
2498713|NCT02911792|Experimental|Dapagliflozin|Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day, Subjects who are taking Metformin at time of randomization we will add Dapagliflozin to current metformin.
2498715|NCT02911792|Active Comparator|Metformin|Subjects who Drug naïve we will give Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).Subject who are on metformin at time of randomization we will add Glipizide 5 mg( to be increased to 10 mg at Visit 5), Subject who are on Glipizide at time of randomization we will add Metformin- XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).
2499533|NCT02906163|Active Comparator|SoC (tyrosine kinase inhibitor)|12 months
3162482|NCT00463450|Experimental|Arm 1|
3162483|NCT00463450|Active Comparator|Arm 2|
3162484|NCT00463489|Active Comparator|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
3162485|NCT00463489|Experimental|Individualized Lifestyle Intervention|Women randomized to the individualized lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
3162486|NCT00463541|Experimental|1|
3162487|NCT00463593||2|children enrolled in formal schools and children not enrolled in formal schools
3174994|NCT00629044|Active Comparator|G|
3174995|NCT00629044|Active Comparator|AMD|
3174996|NCT00629044|Active Comparator|Healthy subjects|
3174997|NCT00629057|Experimental|1|Lowest dose level
3162488|NCT00463658|Experimental|1|Subjects in the interdisciplinary group received home care services from a team of professional service providers (CCAC Case Manager, Registered Nurse, Occupational Therapist, Physiotherapist, Registered Dietician) with experience and training in falls prevention. The team provided a comprehensive, coordinated and evidence based approach to falls prevention through regular home visits, weekly case conferencing, a single accessible fall prevention plan,and joint client visits.
2497919|NCT02917148||aGVHD|Patient who undergo allogeneic transplant with clinical and/or biopsy-proven diagnosis of aGVHD within the first 100 days post-transplant.
2497924|NCT02917148||non aGVHD|Patients who undergo allogeneic transplant but do not develop aGVHD.
2497980|NCT02916771|Experimental|Ixazomib|"Cycles 1-9~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Dexamethasone is administered orally on days 1, 8, 15, 22 on a 28 days cycle~Cycle 10-24~Ixazomib is administered orally on days 1, 8, 15 on a 28 days cycle~Lenalidomide is administered orally on days 1-21 on a 28 days cycle~Supportive measures consistent with optimal patient care may be given throughout the study"
2498001|NCT02916342|Active Comparator|Interscalene brachial plexus block|An ultrasound-guided interscalene brachial plexus block will be performed prior to surgery.
2498004|NCT02916342|Experimental|Supraclavicular-axillary nerve blocks|A dual supraclavicular-axillary nerve blocks will be performed prior to surgery.
2498086|NCT02916199|Experimental|Needle knife fistulotomy|"Device: Needle knife fistulotomy Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
2498087|NCT02916199|Active Comparator|conventional cannulation|"Device: conventional canulation catheter Disease: Common bile duct stone, Malignant biliary stricture, Benign biliary stricture, Benign pancreatic disease, biliary sphincter of Oddi dysfunction Indication: High risk of post-endoscopic retrograde cholangiopancreatography pancreatitis~- Intervention: canulation of ampulla of Vater Intervention: canulation of ampulla of Vater"
2498149|NCT02915588|Active Comparator|Primary Active|Early postoperative isometric activation of the rotator cuff
2498154|NCT02915588|Active Comparator|Primary Passive|Standard postoperative passive movement rehabilitation protocol
2498192|NCT02915224||Obinutuzumab|Participants will receive obinutuzumab as per Summary of Product Characteristics in daily practice along with chlorambucil for 24 months.
2498245|NCT02914769|Placebo Comparator|placebo|patients receiving a passive placebo
2498247|NCT02914769|Experimental|Ayahuasca|patients receiving Ayahuasca
2498413|NCT02913911|Experimental|Feedback|Subjects will be trained using the sit-to-stand weight-taking machine. Prior to the training, subjects sit in a standard sitting position. Then they will be instructed to take most of their body-weight onto the legs while they standing up where the light bars will be gradually lightened from the red, yellow and green zones according to the level of LLL. Then they stand up, hold a standing position for 3-5 seconds and sit-down with always maximize their body-weight onto their legs during performing the task in which the green zone will always be lightened.
2498416|NCT02913911|Sham Comparator|No feedback|Subjects will be trained using the same instruction and protocol as the experimental group, but without the provision of external feedback.
3162489|NCT00463658|No Intervention|2|Participants allocated to the control group received standard home care services arranged by the CCAC. These include routine follow-up by the CCAC case manager whose focus is on assessing client's eligibility for in-home health services, arrangement and coordination of professional (i.e. nursing, occupational therapy, physiotherapy, social work, speech-language pathology, nutrition) and non-professional HSS, information and referral to community agencies, and ongoing monitoring and evaluating the plan of care through in-home assessments with clients.
3162490|NCT00463697|Experimental|GW642444M 25mcg|Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning.
2498506|NCT02913118|Experimental|standard antibiotic treatment +AS injection|Andrographolid Sulfonate Injection (AS Injection) plus one of 3 antibiotics in China CAP Guideline
2498509|NCT02913118|Placebo Comparator|standard antibiotic treatment + AS placebo|AS placebo (NS injection) plus one of 3 antibiotics in China CAP Guideline
2498579|NCT02912689|Experimental|Neurally adjusted ventilator assist|Neurally adjusted ventilator assist (NAVA) during NIV for exacerbation of COPD.
2498586|NCT02912689|Active Comparator|Pressure support ventilation|Pressure support ventilation (PSV) during NIV for exacerbation of COPD.
2498623|NCT02912312|Experimental|Arm I: Hypofractionated Regional Nodal Irradiation (RNI)|Patients undergo hypofractionated RNI in 15 fractions 5 consecutive days a week for 3 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
2498638|NCT02912312|Active Comparator|Arm II: Standard Regional Nodal Irradiation (RNI)|Patients undergo standard RNI in 25 fractions 5 consecutive days a week for 5 weeks. Patients also undergo additional boost dose of radiation therapy in 5 or 7 fractions on consecutive days following completion of RNI.
3162491|NCT00463697|Experimental|GW642444M 100mcg|Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning.
3162492|NCT00463697|Experimental|GW642444M 400mcg|Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning.
3162493|NCT00463697|Experimental|GW642444H 100mcg|Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning.
3162494|NCT00463697|Placebo Comparator|placebo|Subject will inhale single dose of Placebo via a DISKUS device in morning.
3162495|NCT00463736|Active Comparator|Magnesium sulfate|x 48 hours IV
3162496|NCT00463736|Placebo Comparator|Normal saline|x 48 hours IV
3162497|NCT00463749|Active Comparator|1|High-dose N-Acetylcystein during percutaneous coronary intervention and for 2 days post intervention 2 x/day
3162498|NCT00463749|Placebo Comparator|2|Placebo (NaCl)
3162499|NCT00463827|Active Comparator|2|Atorvastatin 40
3162500|NCT00463827|Placebo Comparator|placebo|matched placebo
3162501|NCT00463853|Experimental|Arm 1|direct intramyocardial injection of cells as adjunct to CABG
3162502|NCT00463905|No Intervention|1|Current management for identifying postmenopausal women with osteoporotic vertebral fractures in primary care i.e. nothing
2497897|NCT02917473|Experimental|Intervention group|"Education and counseling as commonly delivered to the patients in clinical practice and written advice for their first-degree relatives.~In addition to oral counseling to the patient, written advice will be provided to patients for their relatives focusing on sun protection, self-skin examination, medical skin examination, increased risk of melanoma for first-degree relatives, who should also be informed orally by the patients to protect themselves from UV radiation, perform self-skin examination and ask their GP or dermatologist to perform annual skin examinations."
2497959|NCT02916901|Experimental|CKD-519 200mg|CKD-519 tab(formulation II) 200mg (100mg X 2tabs)
2497961|NCT02916901|Placebo Comparator|Placebo|placebo
2498010|NCT02916485|Experimental|Bioresorbable scaffold|Percutaneous coronary intervention (PCI) with a sirolimus-eluting resorbable coronary magnesium scaffold
2498112|NCT02916147|Experimental|volatile anesthesia|Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
2498113|NCT02916147|Active Comparator|intravenous anesthesia|Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
2498162|NCT02915484|Experimental|tDCS stimulation A|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
2498165|NCT02915484|Experimental|tDCS stimulation B|Intervention: Transcranial Direct Current Stimulation (tDCS) Up to 20 minutes of tDCS applied to the prefrontal cortex.
2498228|NCT02914847|Experimental|Immediate Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery training (FIT) immediately.
2498231|NCT02914847|No Intervention|Delayed Functional Imagery Training (FIT)|Participants in this arm receive Functional Imagery Training (FIT) after a 3 month delay.
2498270|NCT02914665|Experimental|20 mg elamipretide|20 mg elamipretide once daily for 7 consecutive days
2498275|NCT02914665|Placebo Comparator|Placebo|Placebo once daily for 7 consecutive days
2498407|NCT02914028|Active Comparator|Tramadol and paracetamol|subjects were administered intravenous analgesia (control group) Tramadol 100 mg and paracetamol 1000 mg at the end of the surgery
2498408|NCT02914028|Active Comparator|transversus abdominis plane block|patients that applied transversus abdominis plane block at the end of the surgery after given intravenous analgesia
2498432|NCT02913547|Experimental|Treatment group|"Each subject will serve as his/her own control, while comparing results before treatment, and after 6 weeks of treatment.~Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual."
3208753|NCT00977756||Arm N|Participants will receive a medication regimen of DRV
3208754|NCT00977756||Arm O|Participants will receive a medication regimen of unboosted ATV
2498561|NCT02912637||CF patients|Hyperpolarized Xenon MRI
2498565|NCT02912637||Healthy volunteers|Hyperpolarized Xenon MRI
3208755|NCT00977756||Arm P|Participants will receive a medication regimen of RPV
3208756|NCT00977756||Arm Q|Participants will receive a medication regimen of RPV
2498721|NCT02911623|Experimental|Lithoplasty Treatment|Patients in this group will receive treatment with the Shockwave Lithoplasty® System which uses lithotripsy-enhanced, low-pressure balloon dilation of calcified stenotic peripheral arteries.
2498761|NCT02911389|Active Comparator|Home PT via web-based platform|unsupervised, home rehabilitation delivered by a web-based platform
2498765|NCT02911389|Active Comparator|Home PT via paper manual|unsupervised, home rehabilitation delivered by a paper manual
2498766|NCT02911389|Active Comparator|outpatient PT|outpatient physical therapy
2498794|NCT02910947|Experimental|quadratus lumborum|
2498795|NCT02910947|Experimental|TAP(Transversus abdominis plane)|
2498855|NCT02910661||Patients|Focus groups (n=6-8/group) will be conducted at 4 sites selected to maximize racial diversity and to ensure availability of adequate numbers in each age group (Montreal (incl. the McGill University Health Centre (MUHC), Centre Hospitalier Universitaire-Ste. Justine & CHUM ), Pittsburgh, Seattle, and St. Louis). Separate focus groups will be conducted with patients clustered by patient age to maximize homogeneity in developmental stage. Purposive sampling will be employed to ensure that each focus group includes patients with combinations of characteristics that are likely to account for variation in perspectives, including the major racial and ethnic groups, both sexes, time since transplant, and level of adherence.
2498860|NCT02910661||Parents|Focus groups (n=6-8/group) will be conducted at Pittsburgh & Seattle. Focus groups will be conducted with parents clustered by patient age (12-14 y. & 15- 17 y.)
2498865|NCT02910661||Healthcare professionals|One focus group of healthcare professionals (HCP) representing the variety of multidisciplinary transplant team members at each center will be convened. We will aim for 4-8 HCP per group; however, the number will be dictated by the composition and size of the transplant team at each site. We expect variability in the organization of care across the 7 sites, which represent 2 countries and small to large program sizes; including all sites will capture this variability.
3208757|NCT00977795|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
2499535|NCT02905877||Functional neurological disorders|Initially especially patients diagnosed with a functional tremor.
3208758|NCT00977821|Active Comparator|fresh|Embryo transfer with fresh oocytes
2497981|NCT02916719|Experimental|Neo-adjuvant radiotherapy|Group of women having undergone a neo-adjuvant radiotherapy for early breast cancer.
2498042|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+++|Patients in this group had IGF-1R overexpression tumors and did not receive any treatment before this study.
2498044|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R++|Patients in this group had IGF-1R moderate expression tumors and did not receive any treatment before this study.
2498046|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：IGF-1R+|Patients in this group had IGF-1R low expression tumors and did not receive any treatment before this study.
2498047|NCT02916394|Experimental|68Ga-NODAGA-ZIGF-1R:4：40：healthy volunteers|Patients in this group who are healthy volunteer.
2498063|NCT02915952|Active Comparator|Zip Closure Device|The Zip device is a non-invasive, single use, sterile medical device for closure of the skin layer for surgical incisions or laceration repair.
2498068|NCT02915952|Active Comparator|Conventional Sutures|Conventional subdermal (subcuticular) absorbable sutures
2498128|NCT02915666|Experimental|Digoxin combination for Melanoma|Drugs: Dabrafenib 150mg PO 2x daily, Trametinib 2 mg PO daily, and Digoxin 0.25 mg PO daily for 8-week cycles.
2498180|NCT02915250|Experimental|BioChaperone® Combo|Individualised single subcutaneous of BioChaperone® Combo + injection of placebo (0.9% NaCl) to ensure the double dummy
2498181|NCT02915250|Active Comparator|Humalog® Mix25|Individualised single subcutaneous of Humalog® Mix25 + injection of placebo (0.9% NaCl) to ensure the double dummy
2498184|NCT02915250|Active Comparator|Humalog® and Lantus®|Individualised simultaneous subcutaneous injections
3208759|NCT00977821|Experimental|Frozen|Embryo transfer with vitrified oocytes
2498367|NCT02914015|Experimental|Continuous QLB+postoperative IPCA|Single-injection of QLB (quadratus lumborum block) is given preoperatively followed with continuous infusion+ postoperative IPCA (intravenous patient control analgesia)
2498371|NCT02914015|Active Comparator|IPCA|Postoperative IPCA (intravenous patient control analgesia) is given alone
2498419|NCT02913768|Active Comparator|Ondansetron|Intravenous Ondansetron 4 mg diluted in 10 mL of normal saline over 1 min, 5 min before spinal anaesthesia
2498421|NCT02913768|Placebo Comparator|control|Normal Saline 10 mL over 1 min, 5 min before spinal anaesthesia
2498455|NCT02913443|Experimental|Introductory Cohort - 400 μg RO7051790|Introductory cohort to ensure participant safety, prior to the dose escalation study. 400 μg of RO7051790 was administered to two (2) participants followed by a 21-day DLT observation period.
2498457|NCT02913443|Experimental|Dose Escalation - 1000 μg RO7051790|1000 μg of RO7051790 was administered to six (6) participants once every 3 weeks (Q3W).
2498459|NCT02913443|Experimental|Dose Escalation - 1300 μg RO7051790|1300 μg of RO7051790 was administered to seven (7) participants once every 3 weeks (Q3W).
2498462|NCT02913443|Experimental|Dose Escalation - 1900 μg RO7051790|1900 μg of RO7051790 was administered to three (3) participants once every 3 weeks (Q3W).
2498504|NCT02913170|Experimental|Nattokinase group|A nattokinase group composed of 50 individuals who consumed a 300mg nattokinase capsule (100mg of nattokinase and 200mg of maltodextrin) daily after meal.
2498507|NCT02913170|Placebo Comparator|Placebo group|A placebo group composed of 50 individuals who consumed a 300mg placebo capsule (300mg of maltodextrin) daily after meal.
2498548|NCT02912936|Experimental|Ketogenic medium chain triglyceride drink|Lactose-free skim milk drink containing 25 g of MCT oil per 250 ml.
2498550|NCT02912936|Placebo Comparator|Placebo|Lactose-free skim milk drink containing high-oleic sunflower oil in the equivalent amount of energy as the active arm.
2498563|NCT02912663|Experimental|Verapamil and Magnesium Sulfate|10mg of verapamil in 10 cc of normal saline and 1000mg of magnesium sulfate in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
2498566|NCT02912663|Placebo Comparator|Placebo|Control group will receive saline only
2498601|NCT02912403||Postpartum Cesarean Section|We will be including postpartum women as this study idea is pertaining to recent pregnancy
2498615|NCT02912221|No Intervention|Control|Participants will be reimbursed for participation in the study but will not receive other encouragements for meeting fitbit and step count goals
2498617|NCT02912221|Active Comparator|Incentive|An incentive will be used for this arm to encourage participants to meet their step goals
2498678|NCT02912052|Experimental|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.
2498680|NCT02912052|Active Comparator|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.
2498718|NCT02911662|Experimental|3-day treatment|Three-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
2498723|NCT02911662|Active Comparator|7-day treatment|Seven-day treatment with Cephalexin or Nitrofurantoin for diagnosis of asymptomatic bacteriuria in pregnancy.
2498754|NCT02911337|Experimental|Lifestyle modification|Lifestyle modification
2498848|NCT02910596|Experimental|A|"Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~In bethanechol chloride arm arm should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5thpostoperative day. Void volume and postvoid residual urine were record. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
3208760|NCT00977834||Group 1|Patients with lymphoma or lung cancer
3208761|NCT00977834||Group 2|Caregivers
2498000|NCT02916680|Experimental|Pancreatic islet transplantation|Pancreatic islet transplantation in the anterior chamber of the human eye
2498091|NCT02916212|Experimental|Experimental|Hospital units where alarms have been optimized
2498096|NCT02916212|No Intervention|Control|Hospital units where alarms remain unchanged
2498151|NCT02915614|Active Comparator|PiMM patients|"COPD patients with the Alpha-1 antitrypsin genetic variant PiMM (Smoking-related COPD)"
2498155|NCT02915614|Experimental|PiZZ patients|COPD patients with alpha-1 antitrypsin deficiency (genotype PiZZ)
2498182|NCT02915237|Experimental|Low Dose - Concord grape juice|Daily dietary supplementation with 4 oz. of a commercially available Concord grape juice.
2498187|NCT02915237|Experimental|Moderate Dose - Concord grape juice|Daily dietary supplementation with 8 oz. of a commercially available Concord grape juice.
2498196|NCT02915237|Experimental|High Dose - Concord grape juice|Daily dietary supplementation with 16 oz. of a commercially available Concord grape juice.
2498201|NCT02915237|Placebo Comparator|Low dose - placebo beverage|Daily dietary supplementation with 4 oz. of a placebo beverage
2498207|NCT02915237|Placebo Comparator|Moderate Dose - placebo beverage|Daily dietary supplementation with 8 oz. of a placebo beverage
2498209|NCT02915237|Placebo Comparator|High Dose - placebo beverage|Daily dietary supplementation with 16 oz. of a placebo beverage
3195660|NCT00841919|Experimental|1|"The study group will receive Insulin Glargine as basal insulin and bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff"
3195661|NCT00841932||Fractional Flow Reserve|Patients with suspected coronary artery disease undergoing FFR to assess physiological significance of stenosis
2498321|NCT02914379|Experimental|[¹⁴C]-LY3337641|Oral dose of LY3337641 containing 120 microcuries of radioactivity.
2498349|NCT02914158|Experimental|Goserelin and aromatase inhibitors|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.~AI: no restriction of specific drugs, oral by standard dose of post-menopause breast cancer, for 5 years."
2498352|NCT02914158|Active Comparator|Goserelin and tamoxifen|"Goserelin: GnRH analogues goserelin 3.6 mg administered intravenously every 28 days, for 5 years.~Tamoxifen: 20mg oral for every day, for 5 years."
2498492|NCT02913365||Patients presenting with hemoptysis|Patients over 18 years of age presenting with hemoptysis at the Centre Hospitalier Universitaire de Sherbrooke (CHUS) between the periods of 2005 to 2010.
2498518|NCT02913027|No Intervention|Observational|ARM: Normal Pelvic Exam Exposures: External Exam followed by speculum exam, followed by bimanual exam
2498520|NCT02913027|Active Comparator|Experimental Pelvic Exam|Arm: Changing the order of Pelvic Exam Intervention: External exam, Bimanual Exam, Speculum Exam
2498587|NCT02912572|Experimental|Pole Mutated Endometrial Cancer|Participants with Pole mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
2498591|NCT02912572|Experimental|MSS Endometrial Cancer|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle
2498592|NCT02912572|Experimental|MSS Avelumab/Talazoparib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Talazoparib will be administered one time per day by mouth
2498593|NCT02912572|Experimental|MSS Avelumab/Axitinib Combination Arm|Participants with MSS mutated endometrial cancer Avelumab will be administered intravenously twice per cycle Axitinib will be administered twice per day by mouth
2498652|NCT02912247|Experimental|monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection 40mg administered subcutaneously once
2498654|NCT02912247|Active Comparator|adalimumab|adalimumab 40mg administered subcutaneously once
3195662|NCT00841945|Active Comparator|1|"Chemotherapy + Radiotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone~Radiotherapy 40 gray on initial nodes"
3195663|NCT00841945|Experimental|2|"Chemotherapy~- 4 or 6 R CHOP courses regimen every 14 days R CHOP = Rituximab, Doxorubicin, Vincristine and prednisone"
2498759|NCT02911454|Experimental|Healthy infants: fully or partly formula fed|
2498800|NCT02910895|Other|single arm|single tumor biopsy
2498843|NCT02910609||Management at PN 3-7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
2498852|NCT02910609||Management after PN 7 days|Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
2498897|NCT02910310|No Intervention|Baseline period|The baseline period will involve data collection on study outcomes before uterine balloon tamponade (UBT) is introduced at study sites.
2498898|NCT02910310|Experimental|Uterine balloon tamponade|The UBT period will involve data collection on study outcomes after providers at sites are trained on UBT use and UBT is introduced into PPH management practice at study sites.
2498979|NCT02909530|Active Comparator|First pass EZ Shot 3Plus then EZ Shot 2|Olympus EZ Shot 3Plus will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 3Plus first), then the 19G and EZ Shot 2 will be used to puncture the pancreatic mass.
2498982|NCT02909530|Active Comparator|First pass EZ Shot 2 then EZ Shot 3Plus|Olympus EZ Shot 2 will be used to puncture the mass first (Intervention EUS-FNB with EZ Shot 2 19G first), then the EZ Shot 3Plus will be used to puncture the pancreatic mass.
2499018|NCT02909322|Active Comparator|Continuous Epidural Analgesia|Analgesic medications will be given via epidural, the standard of care.
2499030|NCT02909322|Experimental|Paravertebral Block Analgesia|Analgesic medications will be given via the paravertebral space.
2499074|NCT02908971||Soy based formula|"soy group will include children from the children who had milk allergy, and consumed a soy-based substitute formula for longer than three months and agreed to participate in this study."
3195664|NCT00841984||1|patients with complex neurological disease of unknown cause
2498016|NCT02916537|Experimental|Cohort B: Metastatic prostate cancer|"Patients with evidence of metastatic castration-resistant prostate cancer (N = 15).~Single IV dose (370 MBq, or 10 mCi). Combined PET/MR imaging (prostate + whole body) will be performed following tracer injection. Patients in cohort B (metastatic prostate cancer) will have the option for metastatic tumor biopsy following CTT1057 PET imaging."
2498081|NCT02916121|Experimental|folic acid 5 mg/cap|folic acid 5 mg/d and vitamin B12 500 ug/d
2498085|NCT02916121|Placebo Comparator|placebo|placebo
2498132|NCT02915640|Experimental|Remote technology|Remote technology will be used for an initial patient assessment after being contacted by phone from the peripheral center to transfer an acutely ill pediatric patient as assessed by the referral centre care provider.
2498141|NCT02915640|No Intervention|Control|A Nurse Practitioner or General Practitioner from a remote site has a pediatric acute care referral and arranges a transportation. There is an initial call to obtain a patient history, to provide advice to the remote caregiver to initiate specific therapies and to mobilize the specialized team to the patient.
2498188|NCT02915289|Active Comparator|Povidone Iodine|10% povidone iodine solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to the manufacture guidelines with a minimum of four completed minutes of drying time before placement of surgical drapes. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
2498195|NCT02915289|Active Comparator|Chlorhexidine gluconate|4% chlorhexidine gluconate solution will be used for vaginal cleansing prior to non-emergent cesarean section. The preparation will be applied according to manufacture guidelines. The group will receive standard obstetrical care, continuous fetal monitoring, and pre-operative prophylactic antibiotics at least one hour prior to skin incision.
2498255|NCT02914860|Experimental|Volunteers|Healthy volunteers
2498256|NCT02914860|Active Comparator|PAF|Patients with paroxysmal atrial fibrillation
2498257|NCT02914860|Active Comparator|Pers AF|Patients with persistent atrial fibrillation
2498261|NCT02914860|Active Comparator|L-s Pers AF|Patients with long-standing persistent atrial fibrillation
2498329|NCT02914366|Experimental|Ambroxol high dose (1050 mg)|Participants randomized to the 1050 mg/day group will begin with a dose of 225mg (3 mg/kg/day), increasing bi-weekly by ~3mg/kg to a dose of 1050 mg/day (~l5 mg/kg/day).
2498332|NCT02914366|Placebo Comparator|Placebo|Participants receive capsules visually identical to the experimental groups but without active ingredients.
2498389|NCT02914041||Kyphosis group|Subjects are community-dwelling elderly with different degrees of kyphosis, aged at least 60 years with a body mass index between 18.5-29.9 kg/m2 and OWD >0 cm.
2498415|NCT02913833|Experimental|Daily pain evaluation|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
2498417|NCT02913833|No Intervention|Control|Patients recruited in a sequential order within the chronic revalidation unit of the CHU Brugmann hospital, Queen Astrid site.
2498465|NCT02913508|Experimental|Vedolizumab 300 mg IV Q8W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, and then every 8 weeks (Q8W) (Weeks 6 and 14).
2498468|NCT02913508|Experimental|Vedolizumab 300 mg IV / 160 mg SC Q3W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously (SC), every 3 weeks (Q3W) (Weeks 6, 9, 12, 15 and 18).
2498472|NCT02913508|Experimental|Vedolizumab 300 mg IV / 108 mg SC Q2W|Vedolizumab 300 mg, intravenously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Q2W) (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
2498475|NCT02913508|Experimental|Vedolizumab 480 mg SC / 160 mg SC Q3W|Vedolizumab 480 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 160 mg, subcutaneously, every 3 weeks (Weeks 6, 9, 12, 15 and 18).
2498477|NCT02913508|Experimental|Vedolizumab 324 mg SC / 108 mg SC Q2W|Vedolizumab 324 mg, subcutaneously, at Weeks 0 and 2, then vedolizumab 108 mg, subcutaneously, every 2 weeks (Weeks 6, 8, 10, 12, 14, 16, 18 and 20).
2498527|NCT02913053|Active Comparator|Aerobic exercise|
2498531|NCT02913053|Active Comparator|Stretching and Toning|
2498533|NCT02913053|No Intervention|Usual care: Control Group|
2498570|NCT02912741|Experimental|Vanish xt Extended Contact Varnish|Vanish xt Extended Contact Varnish is a resin modified glass ionomer cement and fluoride varnish used to treat white spot lesions to be more resistant to early caries progression.
2498577|NCT02912741|Active Comparator|Resin infiltration|Resin infiltration is a low viscous resin infiltrates into small pores of white spot lesions to block entrance of bacteria into dentinal tubules of the tooth and more resistant to early caries progression.
2498752|NCT02911350|Experimental|Hormone Suppressors, Paclitaxel & Radiation therapy|"Hormone Suppressors: Patients may take any of the following combinations for a period of 6 months:~Lupron / Flutamide~Zoladex/ Flutamide~Lupron/ Casodex~Zoladex/ Casodex~Paclitaxel: 30 mg/m2 twice a week administered as a one hour infusion either Monday & Wednesday or Tuesday & Thursday for eight consecutive weeks will be started within the first week of radiation therapy. Following the first 3 dose levels, the dose of Paclitaxel will be escalated to 35 mg/m2 (dose level IV), 40 mg/m2 (dose level V) & 45 mg/m2 (dose level VI).~Radiation Therapy: 5 days a week for 8 weeks to a total dose of 66.6 to 73.8 Gray depending on when patient enter the study."
3195665|NCT00841984||2|positive controls : patients with already known metabolic disease for whom we already have CSF or urines
3195666|NCT00841984||3|negative controls: patients with non metabolic neurological disorders of known cause hospitalized for a lumbar puncture
2498964|NCT02909660|Experimental|Support-seeking intervention|Cognitive-behavioural therapy intervention that guides participants to seek support rather than reassurance; participants' significant others are asked to provide support rather than reassurance.
2498966|NCT02909660|Active Comparator|Family accommodation reduction intervention|Cognitive-behavioural therapy intervention that guides participants' significant others to withhold reassurance when it is requested; participants are asked to refrain from seeking reassurance.
3195667|NCT00842010||HND|Patients with hyperglycemia, without previous diagnosis of diabetes
3195668|NCT00842010||DH|Patients that have previous diagnosis of Diabetes Mellitus
3195669|NCT00842010||NHND|Patient with NO previous diagnosis of diabetes, and no hyperglycemia
2498119|NCT02915679|Other|Study participant|"All the participants performed blood sample for genetic purpose, psychiatric assessment and pain investigation:~81 depressed patients admitted after a recent suicidal act (<8 days)~81 depressed subjects with a past history of suicidal act (>1month)~80 depressed subjects without any personal history of suicidal behaviour"
2498199|NCT02915419|Active Comparator|group A|prp revascularization
2498205|NCT02915419|Experimental|group B|treatment of affected teeth using platelet rich fibrin by applying prf in steril root canal
3162503|NCT00463905|Experimental|2|Intervention arm: simple clinical assessment to identify high risk 30% (approximately) who will then be offered lateral thoraco-lumbar X-rays
3162504|NCT00463970|Active Comparator|1|Brief Intervention
2498344|NCT02914197|Experimental|Full information|"The intervention arm will receive full information on the risks and benefits of mammography through:~Decision aid~YouTube video~Group information session"
2498345|NCT02914197|No Intervention|Control|Standard information leaflet for breast screening from Cancer Care Ontario
2498395|NCT02913963|Active Comparator|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2498396|NCT02913963|Placebo Comparator|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
2498435|NCT02913716|Experimental|Defactinib treatment|Single dose of 400 mg [14C]-defactinib, oral suspension
3162505|NCT00463970|Experimental|2|Cognitive Behavioural Therapy
3162506|NCT00463970|Experimental|3|Seal oil
3162507|NCT00463970|Placebo Comparator|4|Soy oil
3162508|NCT00463983|Experimental|octreotide|octreotide SR 30 mg intra muscularly every 4 weeks
3162509|NCT00464009|Active Comparator|A|Group A practices (n=39) received didactic training and course materials in oral health screening, referral, counseling and application of fluoride varnish.
3162510|NCT00464009|Active Comparator|B|Group B practices (n=41) received the same as Group A and were offered weekly conference calls providing advice and support.
2498556|NCT02912767||SLN cohort|Patients who underwent hysterectomy only or with SLN mapping alone.
2498558|NCT02912767||LND cohort|Patients who underwent hysterectomy with standard lymphadenectomy, with or without SLN mapping.
2498625|NCT02912533|Experimental|JR-131|
3162511|NCT00464009|Active Comparator|C|Group C practices (n=41) received the same as Group B and were also offered in-office follow-up visits providing hands-on advice and support.
3162512|NCT00464061|Experimental|Volinanserin|
2498767|NCT02911480|Experimental|oxytocin intravenous 0.1 IU|single dose of 0.1 International Units (IU) intravenous (IV) oxytocin
2498768|NCT02911480|Experimental|oxytocin intravenous 1 IU|single dose of 1 IU IV oxytocin
2498770|NCT02911480|Experimental|oxytocin intravenous 10 IU|single dose of 10 IU IV oxytocin
2498772|NCT02911480|Experimental|oxytocin tablet 20 IU|single dose of 20 IU tablet oxytocin
2498774|NCT02911480|Experimental|oxytocin tablet 200 IU|single dose of 200 IU tablet oxytocin
3162513|NCT00464061|Placebo Comparator|Placebo|
2498940|NCT02910245|Active Comparator|Mercaptopurine (Purinethol)|Mercaptopurine (Purinethol),1-1.5 mg/kg/day oral, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
2498941|NCT02910245|Placebo Comparator|Placebo|Placebo, 1-1.5 mg/kg/day, 52 weeks & Prednisone, 40 mg/day oral, 2 weeks, followed by fixed tapering over 6 weeks OR budesonide (cortiment) 9 mg/day during 8 weeks & Mesalamine, 2 g/day oral, 52 weeks.
2499027|NCT02909426||Women aged 40-59|"Asymptomatic women aged 40-59 who participate in the National Cancer Screening Program in Korea and agreed with participating in this study will be the cohort.~The participants' digital mammography and ultrasonography will be interpreted combinedly by radiologists who perform the screening sonography and the participants' digital mammography will be interpreted independently by other radiologists who do not perform the screening sonography."
2499071|NCT02909010|Active Comparator|BIS™ Brain Monitoring System|BIS monitoring to adjust sedation in order to maintain values between 50-60
2499076|NCT02909010|Placebo Comparator|RASS Monitorization|sedation was adjusted with the exclusive useof Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2.
2499123|NCT02908711|Active Comparator|Patients receiving ACB before primary TKA|"Patients receiving adductor canal block (ACB) before primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block prior to incision after induction of general anesthesia"
2499132|NCT02908711|Active Comparator|Patients receiving ACB after primary TKA|"Patients receiving adductor canal block (ACB) immediately after primary total knee arthroplasty (TKA).~Patients randomized to this group will receive the block at the end of the surgery."
3162514|NCT00464113|Experimental|1|once-weekly dosing
3162515|NCT00464113|Experimental|2|twice-weekly dosing
3162516|NCT00464126|Active Comparator|Colloid|5% albumin for volume resuscitation
3162517|NCT00464126|Placebo Comparator|Crystalloid|Saline for volume resuscitation
3162518|NCT00464139||1|"The electronic files of all patients who consulted the LUFC since 2003 were searched to select women with at least 1 year of infertility, a regular cycle (variation 21 - 35 days), whose partner had normal sperm according to World Health Organization (WHO) criteria (n = 304).~After exclusion of 83 (27,3%) patients with a previous laparoscopic diagnosis of endometriosis before referral to our centre, 221 (72,7%) infertile women were included in our study."
3162519|NCT00464178|Experimental|Bortezomilb and bevacizumab|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
3162520|NCT00464243|Experimental|Volinanserin|2 mg volinanserin tablets orally once daily
2498090|NCT02916186|Active Comparator|subepithelial connective tissue graft|Tunnel is prepared and sub-epithelial connective tissue graft is harvested from the palate and placed under the flap.
2498116|NCT02915575|Other|Control Arm (usual care)|Participants will be discharged as per usual ward discharge protocols.
2498124|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
2498254|NCT02914977|Experimental|Low-dose daunorubicin (DNR)|Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
2498305|NCT02914483|Other|Enhanced Usual Care (EUC)|
2498308|NCT02914483|Other|Stress Management|
2498365|NCT02914093|Experimental|IMT-feasibility|Single arm intervention
2498434|NCT02913677|Active Comparator|group 1|prolonged minimal enteral nutrition
2498436|NCT02913677|Placebo Comparator|group 2|slowly advancing enteral nutrition
2498467|NCT02913287|Placebo Comparator|Placebo|Maltodextrin
2498470|NCT02913287|Experimental|Aquamin/Aquamin MG|Aquamin/Aquamin MG mix
2498498|NCT02913183|Experimental|young Fresh Frozen Plasma|"Drug: young plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Drug: young plasma exchange over a course of 3 consecutive days after stroke onset."
2498501|NCT02913183|Placebo Comparator|old Fresh Frozen Plasma|"Old plasma will be administered as 2 unit /day over a course of 3 consecutive days after stroke onset.~Old plasma exchange over a course of 3 consecutive days after stroke onset.~Patients will receive usual care and drug use in hospital."
2498535|NCT02912949|Experimental|Part 2 Pancreatic cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
2498538|NCT02912949|Experimental|Part 2 NSCLC cancer harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
2498540|NCT02912949|Experimental|Part 2 Solid tumour (basket) harboring NRG1 fusion|Participants will receive intravenous infusion of 750 mg of zenocutuzumab (MCLA-128) (the recommended Phase 2 dose (RP2D)) every 2 weeks.
2498619|NCT02912442||Infertile women study 1|
2498632|NCT02912442||Infertile women study 2|
2498642|NCT02912442||Repeated pregnancy loss|
2498722|NCT02911701|Experimental|Acetaminophen|Study participants randomized to the acetaminophen group will receive 650mg of acetaminophen orally every 6 hours during their postpartum hospital stay.
2498727|NCT02911701|Active Comparator|Ibuprofen|Study participants randomized to the ibuprofen group will receive 600mg of ibuprofen orally every 6 hours during their postpartum hospital stay.
2498751|NCT02911363|Active Comparator|Capitvator Cassette|The EMR specimen will be processed using the Captivator Cassette.
2498755|NCT02911363|Active Comparator|Standard of Care Processing|The EMR specimen will be prepared per Standard of Care.
2498807|NCT02911012||Study Group|The identified population will be assessed on VTE risk according to the risk score PADUA, CAPRINI, KHORANA, and IMPROVE for BLD risk.
2498932|NCT02910050|Experimental|bicalutamide+ Aromatase Inhibitor|ER(+)/AR(+)/HER2(+) metastatic breast cancer patients that previously treated by an aromatase inhibitor
2498957|NCT02909699||Dose 1|1,000mg of resveratrol per day (1 pill 3 times per day). This ancillary study will be observational without drug administration.
2498960|NCT02909699||Dose 2|1,500mg of resveratrol per day (1 pill 3 times per day)
2498962|NCT02909699||Placebo|Alike looking 1 pill 3 times per day
2499031|NCT02909478|Experimental|Aprepitant arm|Aprepitant + Tropisetron
2499036|NCT02909478|Active Comparator|Control arm|Dexamethasone+ Tropisetron
2499085|NCT02909023||Hepatitis B infected patients or cured|blood samples are performed to measure active T cellular immune response during a routine visit
3162521|NCT00464243|Placebo Comparator|Placebo|tablets orally once daily
3162522|NCT00464321|Experimental|Cohort A|Dose Group
3162523|NCT00464321|Experimental|Cohort B|Dose Group
3162524|NCT00464321|Experimental|Cohort C|Dose Group
3162525|NCT00464321|Experimental|Cohort D|Dose Group
3162526|NCT00464373|Experimental|1|Botulinum Toxin Type A 200 U in 4ml NaCl 0.9%
2499438|NCT02906462|Other|Early consideration of vulnerability|Strategy promoting early consideration of patients' vulnerability
2499547|NCT02905682|Placebo Comparator|Placebo|Placebo ODT
3162527|NCT00464373|Placebo Comparator|2|4ml NaCl 0.9%
3162528|NCT00464386|No Intervention|POC Glucose Testing|Hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
3162529|NCT00464386|Experimental|Continuous Glucose Monitoring|Continuous arterial glucose monitoring with Guardian sensor + hourly blood glucose monitoring with point of care glucometer (i.e., current standard of care).
3162530|NCT00464425|Experimental|Electroacupuncture (EA)|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
3162531|NCT00464425|Sham Comparator|Sham Acupuncture (SA)|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
3162532|NCT00464425|No Intervention|No Acupuncture (NA)|Control
3162533|NCT00464451|Experimental|1|Dexmedetomidine sedated pediatric patients undergoing EEG study.
3162534|NCT00464451|Active Comparator|2|Chloral hydrate sedated pediatric patients undergoing sedated EEG study.
3162535|NCT00464516|Experimental|estetrol|
3162536|NCT00464516|Placebo Comparator|placebo|
3162537|NCT00464555|Experimental|Islet Transfusion and LSF|Participants assigned to this group will receive an islet transfusion and an immunosuppressive medication regimen containing LSF.
3162538|NCT00464633|Experimental|Alvocidib|Cycles with 4-week treatment with alvocidib followed by 2-week rest period for up to a maximum of 6 cycles
3162539|NCT00464659|Experimental|Effective CPAP treatment|Effective Continuous Positive Airway Pressure treatment (CPAP) applied for 6 weeks
3162540|NCT00464659|Sham Comparator|Sham CPAP treatment|Ineffective Continuous Positive Airway Pressure treatment (sham CPAP) applied for 6 weeks
3162541|NCT00464724|Experimental|3T MRSI Prostate|3T Magnetic Resonance Spectroscopic Imaging
3162542|NCT00464763|Experimental|Dexmedetomidine|
3162543|NCT00464763|Placebo Comparator|Placebo (PBO)|
2498133|NCT02915523|Active Comparator|Entinostat plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with Entinostat administration on D1 and D8 of each cycle at the Maximum tolerated Dose (MTD)/RP2D as determined in the Phase Ib (Dose Determination) part of the study.
2498140|NCT02915523|Placebo Comparator|Placebo plus Avelumab|Avelumab is administered intravenously (IV) on Day 1 of each 14-day cycle in combination with placebo administered on D1 and D8 of each cycle.
2498217|NCT02915107|Experimental|Biofreedom|Experimental: Biofreedom BioFreedom stent at index procedure
2498219|NCT02915107|Active Comparator|Orsiro|Active comparator: Orsiro Orsiro stent at index procedure
3162544|NCT00464776|Experimental|1|Various sequences of 3 doses of Aliskiren plus placebo
3162545|NCT00464776|Experimental|2|Various sequences of 3 doses of Aliskiren plus placebo
3162546|NCT00464776|Experimental|3|Various sequences of 3 doses of Aliskiren plus placebo
3162547|NCT00464776|Experimental|4|Various sequences of 3 doses of Aliskiren plus placebo
2498792|NCT02910973|Active Comparator|Vagus Nerve Stimulation|Device: Vagus nerve stimulation Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
2498793|NCT02910973|Sham Comparator|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes.
2498956|NCT02909673|Experimental|Fourth R|Fourth R: 27 lesson curriculum addressing youth risk and health promoting behaviors
2498959|NCT02909673|No Intervention|Control|Control: Treatment as usual (standard health class curriculum)
2499019|NCT02909491||Cases|Inpatient with severe behavioural disorders
2499022|NCT02909491||Controls|Inpatients without severe behavioural disorder and taking no antipsychotics
2499087|NCT02909127||Cerebral palsied children|The inclusion criteria are age above 18 months, fed orally, referred due to parent complaints about their child's swallowing function and not admitted a swallowing center before. Swallowing evaluation will be performed. The Functional Independence Measure and PEDI-EAT-10 will be filled.
2499091|NCT02909127||Healthy children|Healthy children above the age of 18 months with no medical history of voice, swallowing, reflux, airway, neurologic, rheumatologic, or neoplastic disorders will be included for normative data generation. The PEDI-EAT-10 will be filled.
2499148|NCT02908555||no intervention|Descriptive study without groups
2499175|NCT02908230|Placebo Comparator|Active Control|Active Control: exposure to a non-nutrition, physical activity, or mental health curriculum/program
2499190|NCT02908230|Active Comparator|Standard Care|Standard Care: exposure to a nutrition and physical activity curriculum/program
2499196|NCT02908230|Experimental|Enhanced Care|Enhanced Care: exposure to a nutrition, physical activity, and mental health curriculum/program
2499302|NCT02907645|Experimental|Local educational|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
2499305|NCT02907645|Experimental|National educational|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
2499310|NCT02907645|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
2499404|NCT02906631||patients admitted to the ICU for AE|Adult patients with all-cause encephalitis admitted to an intensive care unit.
2499431|NCT02906423||Allina health patients|
2499477|NCT02906215|Experimental|Care Coordination Intervention|The care coordination intervention will consist of a mobile application designed for treatment providers, an interagency communication protocol, and a series of cross-training in HIV and addiction issues.
2499507|NCT02905929|Experimental|Sitting Less group|The 'reduce sitting' intervention group will receive three in-person health coaching sessions followed by five counseling phone calls. Participants will wear a thigh worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. At each in-person health coaching session participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. In addition to the three initial in-person counseling sessions using the ActivPAL feedback, participants will receive phone calls from the health educator biweekly to help overcome barriers, to work on self-monitoring and planning skills, and to prepare relapse prevention. Tools to help prompt standing, including a standing desk, will also be provided.
2499511|NCT02905929|Active Comparator|Attention Control|Participants in the attention control condition will receive a healthy aging educational intervention developed and tested by the investigators in previous studies. This group will receive one in-person coaching session followed by seven phone coaching sessions.
2499564|NCT02905630|Experimental|Exercise training|High intensity aerobic exercise training
2499567|NCT02905630|No Intervention|No training|No exercise training, only ordinary daily life activities.
3162548|NCT00464841|Experimental|1|Tsui test for combined spinal-epidural
3162549|NCT00464841|Experimental|2|Tsui test for intrathecal catheter
3162550|NCT00464893|Active Comparator|catumaxomab arm|Patients will get first the chemotherapeutic regimen (Epirubicin, Cisplatin and Capecitabine or 5-Fluorouracil) consisting of three 21-day cycles, starting on the weeks 1, 4 and 7. Four weeks after CTx the D2 surgery will take place. Treatment with catumaxomab will consist of an initial dose of 10µg given intraoperatively as in intraperitoneal bolus and of four postoperative ascending doses.
3162551|NCT00464919|Experimental|A|
3162552|NCT00464958|Experimental|Sublingual tizanidine|Once nightly dosing of 12 mg sublingual tizanidine tablet
3162553|NCT00464984|Active Comparator|ILI-group|Intensive lifestyle intervention at a tertiary care rehabilitation center. Treatment included changes in both dietary habits (calori restriction) and physical activity with particularly high intensity the first 3 months.
3162554|NCT00464984|Active Comparator|MLI|Moderate lifestyle intervention at a secondary care outpatient center. Treatment included moderate changes in dietary habits (calori restriction) and physical activity.
3162555|NCT00465023|Experimental|Proton Beam Radiation|Proton radiation therapy
3162556|NCT00465049|Experimental|primary closure|suture after I&D
3162557|NCT00465049|Placebo Comparator|SECONDARY CLOSURE|LEAVE TO HEAL BY SECONDARY INTENTIN AFTER I&D
3162558|NCT00465153|Experimental|1|Flax oil
3162559|NCT00465153|Placebo Comparator|2|corn oil
3174998|NCT00629057|Experimental|2|Middle level dose
2498137|NCT02915497|No Intervention|Treatment As Usual + Resilience-Based Supportive Therapy|Routine psychosocial management of trauma patients, including Manualized Resilience-Based Therapy.
2498142|NCT02915497|Experimental|Abbreviated Early Prolonged Exposure Therapy|AEPET, including Manualized Resilience-Based supportive Therapy.
2498173|NCT02915328|Experimental|Stent Roadsaver® +Filterwire EZ™|The arm assess the efficacy of the combination of the stent Roadsaver® with the Filterwire EZ™ protection
2498174|NCT02915328|Experimental|Stent Roadsaver® + MO.MA Ultra|The arm assess the efficacy of the combination of the stent Roadsaver® with the MO.MA Ultra protection
2498175|NCT02915328|Experimental|Carotid Wallstent +MO.MA Ultra|The arm assess the efficacy of the combination of the Carotid Wallstent with the MO.MA Ultra protection
2498177|NCT02915328|Experimental|Carotid Wallstent + Filterwire EZ™|The arm assess the efficacy of the combination of the Carotid Wallstent with the Filterwire EZ™ protection
3195670|NCT00842036|Active Comparator|ANft|12- step Al/Nar-Anon Facilitation
3195671|NCT00842036|Experimental|TEnT|Treatment Entry Training
2498358|NCT02914171|Experimental|Treatment arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention using an add-on procedure delivering autologous bone marrow-derived mononuclear cells into the right ventricle.
2498359|NCT02914171|Other|Control arm|Individuals with Ebstein anomaly and underlying myopathic right ventricle undergoing planned surgical intervention without cell delivery.
2498411|NCT02913846||Hospital revalidation units|The study will take place within the CHU Brugmann hospital (Brussels) who has 4 revalidation units (104 beds). All patients coming within these units during the study duration will be included.
2498541|NCT02912962|Experimental|Intervention Group|"Cognitive testing 1, 12 intervention sessions, Cognitive testing 2, Approximately a 12 week wait (no intervention), Cognitive testing 3.~The intervention is a 12 week, individualized, one-on-one self-regulation intervention where adolescents will learn to attain, change, or maintain an appropriate level of alertness ."
2498542|NCT02912962|Experimental|Waitlist|Cognitive testing 1, Approximately a 12 week wait (no intervention), Cognitive testing 2, 12 intervention sessions, Cognitive testing 3
2498574|NCT02912702|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin hydrochloride liposome injection 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
2498578|NCT02912702|Active Comparator|HLH-94 regimen|Etoposide 150 mg/m2 twice weekly for 2 weeks and then weekly; dexamethasone initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
2498620|NCT02912260|Experimental|MGL-3196|Study Drug
2498631|NCT02912260|Placebo Comparator|Placebo|Matching Placebo
2498709|NCT02911831|Experimental|Tranexamic Acid: Abdominal Hysterectomy|"Agent/Device: Tranexamic acid. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 1g in solution to be given intravenously, within 1 hour prior to procedure"
2498711|NCT02911831|Placebo Comparator|Sodium chloride (placebo): Abdominal Hysterectomy|"Agent/Device: 0.9% sodium chloride solution. Patients undergoing abdominal hysterectomy who consent to the study may be randomized to this arm.~· Protocol dose: 100ml to be given intravenously, within 1 hour prior to procedure"
2498750|NCT02911441|Experimental|Treatment Group|Receives 8-12 weeks of one-on-one Cognitive Behavioral Therapy sessions
2498753|NCT02911441|No Intervention|Control Group|Receives no intervention during data-collection phase. Participants in this group will receive the intervention post-data collection.
2498810|NCT02911103|Experimental|Active|single arm study
2498874|NCT02910531|Experimental|ALA supplement|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one supplement tablet containing 1200 mg of alpha lipoic acid orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
2498880|NCT02910531|Placebo Comparator|Placebo|"Clinical data including medical history, plain KUB x-ray and renal ultrasound, routine blood work and 24-hour urine collections for all subjects will be collected as part of normal clinical care at routine clinical visit every 4 months.~Subjects in this study arm will be taking one placebo tablet containing 10 mg of sucrose orally once daily for three years.~At the end of the three years of study drug treatment, all subjects will undergo a low dose non-contrast CT scan to look for a silent change in stone size."
2498911|NCT02910115|Other|Control Group|Following delivery of the fetus patients in the control group will have Pitocin® administered to them intravenously according to the usual protocol. The uterus may be wrapped lap sponges soaked in room-temperature saline while the uterine incision is closed per the attending obstetrician's usual practice. At the discretion of the attending obstetrician additional uterotonic medications (Pitocin®, Methergine® Cytotec® and/or Hemabate®) may be given to improve uterine contraction.
2498913|NCT02910115|Experimental|Study Group|"Following delivery of the fetus, patients in the study group also will have Pitocin® administered to them according to the usual protocol.~Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in cold laparotomy sponges saturated in sterile, iced normal saline. The skin of the abdomen will be draped to prevent contact with the cold towels. Additional uterotonic medications may be given at the discretion of the attending obstetrician."
2498942|NCT02909803|Experimental|Lentil Variety|Each participant will consume a serving of one of eight lentil varieties (Greenland; Improve; Impower; Imigreen; Asterix; Redberry; Redcliff; Redbow) containing 25g available carbohydrate at separate study visits
2498944|NCT02909803|Active Comparator|White Bread|Each participant will consume a serving of white bread containing 25g available carbohydrate on two separate visits
2498995|NCT02909595|Experimental|Balloon catheter group|Bile duct stones extraction was carried out with a balloon catheter.
2498998|NCT02909595|Active Comparator|Basket catheter group|Bile duct stones extraction was carried out with a basket catheter.
3195672|NCT00842036|Experimental|CRAFT|Community Reinforcement and Family Training
3195673|NCT00842049|Experimental|Study|Insertion of lumbar drain
2498144|NCT02915627|Active Comparator|CKD patients on Dialysis|Patients having haemodialysis treatment at least 3 times per week at a London Health Sciences Centre facility-Intervention: Application of antishock garment. Participants will be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
2498166|NCT02915276|Active Comparator|Blastocentisis|The blastocoelic fluid will be aspirated from the embryonic cavity on day 5 or 6 of development and will be subjected to genetic analysis
2498167|NCT02915276|Active Comparator|Trophectoderm biopsy|Throphectoderm cells will be removed from the embryo on day 5 or 6 of development and will be subjected to genetic analysis
2498222|NCT02915081|Experimental|Blue light|Subjects will be exposed to 24 hours of bright (1700 lux) blue (peak 442 nm) spectrum light the day prior to operative intervention and for the 24 hours after the operative intervention.
2498223|NCT02915081|No Intervention|Ambient light|Subjects will be exposed preoperatively to the lighting conditions of their living environment and postoperatively to the standard, white fluorescent lighting environment of the hospital.
2498238|NCT02914821|No Intervention|"Business as Usual (No Tax)"|Baseline data where business 'as usual' will be conducted and no price increases will be implemented on SSBs.
2498239|NCT02914821|Experimental|"General Tax (without named beneficiary)"|In the general tax condition investigators will introduce a 3 cent/ounce tax on the five SSB flavors the café offers. An example of this sign would be 'Pepsi, $2.29, includes 60 cent sugary drink surcharge.'
2498242|NCT02914821|Experimental|"Pre-K Tax"|"In the Pre-K tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Pre-K education."
2498246|NCT02914821|Experimental|"Childhood Healthy Eating Tax"|"In the Childhood Healthy Eating tax condition investigators will institute a 3 cent/ounce tax but will label the tax as proceeds going to Pre-K education. An example of this sign is, Pepsi, $2.29, includes a 60 cent sugary drink surcharge to fund Childhood Healthy Eating education."
2498298|NCT02914574|Other|healthy control|Healthy control group will attend one visit and functional performance, muscle strength and flexibility, quadriceps AMI, patellar position and posture will be measured. No intervention will be applied.
2498333|NCT02914353|Experimental|Experimental - EP-7041|"Single Ascending Dose: Single IV dose for each cohort; dose range 0.01 mg/kg to 1.0 mg/kg~Multiple Ascending Dose: 0.01 mg/kg/h - 5 x 24 h continuous infusion up to 0.6 mg/kg/h - 5 x 24 h continuous infusion"
2498334|NCT02914353|Placebo Comparator|Placebo - Sterile Saline|"Single Ascending Dose: Single IV dose for each cohort;~Multiple Ascending Dose: 5 x 24 h continuous infusion for each cohort"
3162560|NCT00465166||1|Patients who had a documented, accidental dural puncture during placement of their labor epidural.
3162561|NCT00465205|Experimental|I|
3162562|NCT00465218||1|High dose aspirin (325 mg)
2498420|NCT02913755|Experimental|Intervention group|Repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
2498422|NCT02913755|Active Comparator|Lagged Control Group|2 week period of treatment as usual followed by repeated viewing of a short Preparatory video about ABI rehabilitation; viewed every 2-3 days over a 4 week period
2498452|NCT02913456||HER2-positive unresectable LA/mBC|Participants with HER2-positive unresectable LA/mBC diagnosed up to 6 months prior to enrollment will be included in the study. Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LA/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site.
2498551|NCT02912897|Experimental|Cellular therapy with EBV specific autologous CTL infusion|
2498580|NCT02912611|Other|Moderate and High risk for AKI|
2498700|NCT02911727|Experimental|Fast-track discharge|Intention to discharge within 28 hours after elective cesarean section including a home visit by a nurse or midwife from the postnatal ward.
2498702|NCT02911727|No Intervention|Standard discharge|Discharge at least 48 hours after elective cesarean section.
2498732|NCT02911597|Experimental|A: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase A and B. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase A will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
2499439|NCT02906345|No Intervention|Control Group|Patients with septic shock, no therapeutic plasma exchange, BMC standard treatment
2499554|NCT02905773|Other|postoperative pain|postoperative pain
2499556|NCT02905773|Other|intensity|intensity
3162563|NCT00465218||2|Low dose aspirin (81 mgs) plus warfarin
3162564|NCT00465231|Active Comparator|1|Epidural
3162565|NCT00465231|Placebo Comparator|2|Epidural - saline solution
3162566|NCT00465244|Experimental|1|Levetiracetam 1 g IV + Lorazepam 2 mg IV
3162567|NCT00465244|Other|2|Placebo + Lorazepam 3 mg IV
3162568|NCT00465283|Active Comparator|Donepezil|
3162569|NCT00465283|Placebo Comparator|placebo|
3162570|NCT00465426||1|HIV Positive men and women 18-65 years of age
3162571|NCT00465426||2|HIV negative men and women 18-65 years of age
3162572|NCT00465465|Active Comparator|1|Dose of 1 x 10^7
3162573|NCT00465465|Active Comparator|2|Dose of 1 x 10^8
3162574|NCT00465491|Experimental|1|Picoplatin
3162575|NCT00465491|Other|2|BSC
3162576|NCT00465517|Experimental|ganaxolone|active study drug
3162577|NCT00465517|Placebo Comparator|non-active drug|placebo
3162578|NCT00465543|Placebo Comparator|II|Arm 2 receives 4 weeks of placebo mint tea (consumed twice a day) followed by 4 weeks of washout and then a further 4 weeks of treatment with study mint tea (consumed twice a day).
3162579|NCT00465543|Placebo Comparator|I|Arm 1 receives 4 weeks of treatment with mint tea high in rosmarinic acid, consumed twice a day. Treatment is followed by a 4 week wash-out phase. Subjects then enter a 4 week phase of placebo mint tea (low in rosmarinic acid), to be consumed twice a day.
2498153|NCT02915601|Placebo Comparator|Placebo|Subjects randomly assigned to placebo will take the same number of capsules as if they were assigned to receive 0.5 mEq/kg-LBW/day of sodium bicarbonate. Participants will take ½ the daily dose in the morning and the other ½ in the evening. The number of capsules will be rounded to the nearest whole capsule. To reduce pill burden and increase compliance the maximum number of pills per day will be six.
2498216|NCT02915172|Experimental|Lenvatinib + Capecitabine|"Phase 1 Study Escalation: Group consists of participants with various solid tumors.~Dose of Lenvatinib received depends on when joining study. First group of participants receive lowest dose level of Lenvatinib. Each new group receives a higher dose of Lenvatinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Lenvatinib found.~All participants receive the same dose of Capecitabine.~Phase 2 Study Expansion: Group consists of participants with advanced breast cancer and any solid tumors with confirmed FGFR abnormalities.~Participants receive Lenvatinib at the highest dose that was tolerated in Dose Escalation Phase.~All participants receive the same dose of Capecitabine."
2498240|NCT02914756||Sepsis|Patients suffering from Severe sepsis or Septic chock at the ICU.
2498244|NCT02914756||Non-Sepsis|Patients being treated at ICU but not suffering from severe sepsis/septic chock
2498283|NCT02914613|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
2498286|NCT02914613|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
2498335|NCT02914327|Experimental|SNX-5422 plus ibrutinib|Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
2498397|NCT02913898|Experimental|IBLT (information bias learning task)|Computerised task in which most information is provided by positive outcomes. Completed for 10 mins per day every day for 2 weeks.
2498400|NCT02913898|Placebo Comparator|IBLT control|Computerised task in which information is provided by both positive and negative outcomes. Completed 10 mins per day every day for 2 weeks
2498500|NCT02913248|Experimental|Conventional periodontal treatment|35 subjects diagnosed with manifest periodontitis, which will all receive standardized treatment according to protocol. In brief, this treatment includes professional tooth cleaning and thorough instruction in self-performed oral hygiene procedures. Clinical registrations and collection of microbiological samples (subgingival and saliva) will performed at baseline and 2, 6 and 12 weeks after treatment.
2498521|NCT02912975|Experimental|Mirror treatment|Five minutes treatment period twice a day for three weeks
2498522|NCT02912975|Active Comparator|Tactile treatment|Tactile massage twice a day for three weeks
2498554|NCT02912832|Experimental|TBDx|"All samples were tested with TBDx and compared with smear microscopy and Xpert MTB/RIF using solid and liquid culture as gold standard.~Operators were blinded to all other results for a sample upon data entry."
3162580|NCT00465556|Experimental|1|Dove Intervention
3162581|NCT00465556|Active Comparator|2|Intimate Partner Violence (IPV) Protocol
2499960|NCT02902601|Experimental|Group A: JNJ-54175446|Participants will receive a loading dose of JNJ-54175446, 600 milligram (mg) on Day 1 followed by JNJ-54175446, 150 mg once daily until Day 10.
2499961|NCT02902601|Experimental|Group B: Placebo + JNJ-54175446|Participants will receive placebo on Days 1 to 3 followed by a loading dose of JNJ-54175446, 600 mg on Day 4 followed by JNJ-54175446, 150 mg once daily until Day 10.
2499963|NCT02902601|Placebo Comparator|Group C: Placebo|Participants will receive placebo from Day 1 until Day 10.
2499978|NCT02902315|Active Comparator|1ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2499979|NCT02902315|Active Comparator|2ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2500301|NCT02900131|Experimental|trial group 1|Participants will receive Jaungo and placebo once a day for three weeks.
3162582|NCT00465608|Experimental|1|propranolol
3162583|NCT00465686|Experimental|A|
3162584|NCT00465712|Experimental|A|Transabdominal amnioinfusion performed before external cephalic version
3162585|NCT00465712|No Intervention|V|Without transabdominal amnioinfusion
3162586|NCT00465725|Experimental|1|two-period crossover, open label study in which a single dose (Cycle 1) of picoplatin will be given either IV or PO, followed 4 weeks later by a single dose (Cycle 2) of picoplatin given by the route not used for Cycle 1. Subjects subsequently may continue to receive IV picoplatin commencing with Cycle 3 in a Continuation Study.
3162587|NCT00465751|Active Comparator|A|chenodeoxycholic acid treatment
2498274|NCT02914639|Experimental|SF0166 low dose BID|SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
2498277|NCT02914639|Experimental|SF0166 high dose BID|SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
2498328|NCT02914301|Active Comparator|Babyscripts Prenatal App|For patients allocated to the study group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients who were allocated to the intervention arm, the clinician will told that they are in intervention group and therefore will be receiving regular app-based education and clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
2498331|NCT02914301|Placebo Comparator|Placebo|For patients cared for by clinicians allocated to the usual care arm, the clinician will discuss the management options and scheduling procedures with the parent in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.
2498363|NCT02914106||Control group|Sixty-90 year-old subjects were randomly selected and distributed in two experimental groups: 1) a control group, involving subjects without physical or psychiatric illness, and 2) an Acute Ischemic Stroke group (AIS group).
2498368|NCT02914106||Acute Ischemic Stroke group|Patients with diagnosis of AIS within the 24 hours of their neurovascular event.
2498409|NCT02913859|Experimental|pelvic radiotherapy|long-term hormonal therapy (LHRH agonist and/or antiandrogens) plus radiotherapy to the pelvis and prostate
2498410|NCT02913859|Active Comparator|No pelvic radiotherapy|long-term hormonal therapy ( LHRH agonist and/or antiandrogens) alone
2498517|NCT02913391|Experimental|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group (RG) used noninvasive ventilation (NIV) associated with recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV until 30 minutes with pressure support for a tidal volume of 6 mL/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen (FiO2) for a peripheral oxygen saturation (SpO2) ≥ 95%.
2498519|NCT02913391|Active Comparator|control group (CG)|After extubation the patient who was randomized to the Control Group (CG) used noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, FiO2 for a SpO2 ≥ 95%.
2498571|NCT02912858|Experimental|geko plus R-2|neuromuscular electrostimulation
2498598|NCT02912507|Experimental|Investigational Enlighten Device|Tattoo removal treatments with the investigational Cutera enlighten laser
2498599|NCT02912507|Active Comparator|Cynosure PicoSure 755 nm laser|Tattoo removal treatments with the Cynosure PicoSure 755 nm laser
2498656|NCT02912234|Experimental|Apixaban and Clarithromycin|
2498786|NCT02911155||US Nuclear Medicine Technologist|radiologic technologists certified in nuclear medicine
2498799|NCT02910869||Successful weight loss|Patients who have lost =>5% of their weight after completing MOVE! or TeleMOVE!
2498806|NCT02910869||Unsuccessful weight loss|Patients who have lost <5% of their weight after completing MOVE! or TeleMOVE!
2498870|NCT02910570|Experimental|Liraglutide 3 mg|Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.
2498879|NCT02910570|Placebo Comparator|Liraglutide 3 mg placebo|Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.
2498918|NCT02910206|Experimental|etomidate|etomidate is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
2498920|NCT02910206|Experimental|propofol|propofol is given for maintenance of general anesthesia,combined with sufentanil and cisatracurium
2498949|NCT02909725|Experimental|Limit accumulation of sedentary time|Group 1 (SR): Participants will be asked to limit the accumulation of prolonged bouts ( >50 minutes) of sedentary time.
2498950|NCT02909725|Experimental|Walk 30 minutes most days of the week|Group 2 (WALK): Participants will be asked to walk 30 minutes per day on most days of the week.
2498953|NCT02909725|Active Comparator|Normal daily routine; Usual Care|Group 3 (UC): Participants will be asked to continue on with their normal daily routine. The usual care group will receive no form of intervention.
2499038|NCT02909452|Active Comparator|ENT 1mg daily with pembro every 3 weeks|Entinostat daily in combination with pembrolizumab every three weeks
2499039|NCT02909452|Active Comparator|ENT 5mg weekly with pembro every 3 weeks|Entinostat once weekly in combination with pembrolizumab every three weeks
2499040|NCT02909452|Active Comparator|ENT 10mg bi-weekly with pembro every 3 weeks|Entinostat once every other week in combination with pembrolizumab every three weeks
3162588|NCT00465751|Placebo Comparator|B|placebo treatment
3162589|NCT00465764|Experimental|Protein formula|Feed as per HCP direction
2499188|NCT02908152|Active Comparator|curcumin|curcumin
2499197|NCT02908152|Placebo Comparator|placebo|
2532883|NCT02678091|Experimental|Patients|Patients with an orbital mass
3162590|NCT00465764|Active Comparator|Standard infant formula|Feed as per HCP instructions
3162591|NCT00465803|Other|DuoTrav|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months, as recorded by dosing aid
3162592|NCT00465803|Other|Travatan/Timolol|One drop Timolol in the study eye(s) once daily at 8 AM; one drop of Travatan in the study eye(s) once daily at 8 PM. Both products dosed for twelve months, as recorded by separate dosing aid for each product.
3162593|NCT00465842||A - Normal Volunteers|"Normal volunteers without any history of liver disease and with normal liver functions test (LFT), including total protein/Albumin, LDH, ALT, AST, GGT, total bilirubin, direct and indirect bilirubin and do not belong to group B.~Volunteers will be screened using questionnaires. Those deemed suitable will then be asked to have the blood test done. All blood tests are done free of charge to subjects."
3162594|NCT00465842||B - Hepatitis B or C carriers with normal liver functions|
3162595|NCT00465842||C - Hepatitis B or C carriers with abnormal liver functions|
3162596|NCT00465842||D - Liver Cirrhosis|Liver cirrhosis, proven by liver biopsy or on clinical evidences, such as varices on CT scan indicative of portal hypertension.
2498197|NCT02915354|Experimental|Etanercept, AS|The patients were diagnosed with ankylosing spondylitis and obtained the ASAS20 response after etanercept treatment. Then they were discontinued to etanercept and received no treatment except DMARDs or NSAIDs which had used before.
3195674|NCT00842049|Other|Control|Normal clinical management without lumbar drain
2498474|NCT02913690|Placebo Comparator|Control group|Control group will be supplemented with placebo for 12 months.
2498476|NCT02913690|Active Comparator|Intervention group|The intervention arm will be supplemented with TRF for 12 months.
2498523|NCT02913092|Experimental|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed and responded to (e.g. outreach worker contacts the participant for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide asthma education over the phone
2498526|NCT02913092|No Intervention|Usual Care|Usual care group will receive the electronic tracker but the sensor-generated alerts will not be delivered. If the usual care group rescue inhaler data reveals frequent use of rescue medication (daily use for >3 days) investigators will reach out (via app or phone call) to advise the participant to see their physician
2498575|NCT02912845|Experimental|20 IU/kg KamRAB + Active Anti-Rabies Vaccine|
3195675|NCT00842062|Experimental|MyoScience Tissue Remodeling Device|
3195676|NCT00842088|Experimental|Active|
2498798|NCT02910843|Experimental|Regorafenib & Capecitabine|"Regorafenib dose level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dose level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table.~Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.~External beam Radiotherapy~Surgery"
2498836|NCT02910414|Experimental|Treated with Peregrine System Kit|The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.
2498841|NCT02910414|Sham Comparator|Renal Angiography Only (Sham Procedure)|The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).
2498901|NCT02910076|Experimental|Healthy volunteers|
2498902|NCT02910076|Experimental|Diabetes patients|
2498952|NCT02909920|Experimental|Telerehabilitation|The Telerehabilitation group receives a standardized and customized exercises through a web application that allows the Physiotherapist generate videos, images and parameters of each exercise program and send them via email for each patient. Patients are initially supervised by a physiotherapist who will conduct videoconference sessions to ensure proper execution of exercises and encourage patient adherence.
2498954|NCT02909920|Active Comparator|Traditional Physiotherapy|Traditional Physiotherapy group receives assistance in a physiotherapy center through the usual procedure of rehabilitation in Spain consisting in personalized therapy 1 to 1 with a physical therapist and exercise programs for home.
2499010|NCT02909465|Placebo Comparator|placebo|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections of distilled water (one 2 ml and the other 0.05 cc/kg) 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2499011|NCT02909465|Experimental|midazolam|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. one will be 2 ml of distilled water and the other 0.05 mg/kg midazolam, 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2499012|NCT02909465|Experimental|haloperidol|To do procedural sedation and analgesia in this group, the patients will receive 2 intravenous injections. One will be 0.05 cc/kg of distilled water and the other 5 mg of haloperidol (in 2 cc syringes), 5 minutes before receiving a sedative dose of 1 mg/kg IV ketamine.
2499065|NCT02908984|Experimental|Specific neck rehabilitation|The intervention includes specific neck rehabilitation as described by Jull and Falla over a period of 4 weeks and recommendations for further training.
2499069|NCT02908984|Active Comparator|Standard primary health care|This represents individualized therapy administered by the primary physician.
2499110|NCT02908724||ERT receiving patients|Patients that were receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 47).
2499113|NCT02908724||non-ERT receiving patients|Patients that were not receiving specific treatment for FD (ERT, enzyme replacement therapy, Fabrazyme or Replagal) during the observational time (n= 19).
2499441|NCT02906345|Active Comparator|TPE-Filtration Group|Patients with septic shock, therapeutic plasma exchange, plasma separation using a filter (Fresenius MultiFiltrate, Kit 16 MPS P2 dry), BMC standard treatment
2499578|NCT02905513|Experimental|Intervention|App plus the contraceptive instant messages
3195677|NCT00842088|Placebo Comparator|Placebo|
3195678|NCT00842101||pressure monitor|Tibial Fracture
3195679|NCT00842114|Experimental|R+CVP+IFN|8 cycles of Rituximab plus CVP chemotherapy (Bagley's et al) associated with Interferon for 12 weeks
2498304|NCT02914496|Experimental|Diabetes in Balance|"The intervention consists of the manual-based CBT-group intervention Diabetes in Balance. It is given in a group format with six to ten participants and consists of 7 sessions. The sessions are given bi-weekly for two hours. Each session has a specific theme such as Stress and acceptance The life-compass; what is important in my life. The participants also conduct assignments related to the themes between the sessions. A licensed psychologist specialised in CBT and a diabetes specialist nurse, both trained in ACT-stress management will be leading the intervention group."
2498307|NCT02914496|No Intervention|Control|The control group receives regular care including regular visits at the out-patient clinic, 3-4 times per year.
2498357|NCT02914223|Experimental|Treatment and observation period|On Day 1, subjects will receive a single oral dose of 2 mg 14C-radiolabeled cenerimod. Subjects will be followed for 21 days during which blood, urine, feces, and expired air samples will be collected
2498360|NCT02914223|Experimental|Extended observation period|In case, radioactivity recovery does not meet the stopping criteria described in the protocol, the subjects will have to come for a maximum of 7 24-h in-clinic visits during which blood, urine, feces, and expired air samples will be collected
2498399|NCT02913885|Active Comparator|Group 2|curodont repair is a biomimetic regeneration scaffold for remineralization
2498402|NCT02913885|Experimental|Group 1|fluoride varnish inhibit progression of white spot lesion
2498450|NCT02913651||Idiopathic hypersomnia|Drug-free patients diagnosed with idiopathic hypersomnia from 01/01/11 to 15/09/15
2498451|NCT02913651||Controls|Patients with no sleep complaints, having a 24-h ambulatory ad libitum polysomnography
2498497|NCT02913209||Multiple Sclerosis Fatigue (MSF) Cohort|Participants will complete study assessments over 4 visits to the DC VAMC. Disease severity will be assessed by the EDSS, and a cognitive battery will be completed. Peak torque assessment for the knee flexors and extensors will be performed on an isokinetic dynamometer (Biodex System 4). Muscle morphology measures of the rectus femoris will be obtained using diagnostic musculoskeletal ultrasound. The sonographic measures will include muscle thickness and echogenicity. Isokinetic and isoinertial mode fatigue measures for the knee extensors will be assessed on separate visits (at least 48 hours apart). Performance-based measures of function will include an assessment of patient mobility and the 25-foot walk test. Muscle power will be estimated by the timed sit to stand test. Subjective measures of fatigue and quality of life include the MSQoL, MFIS, and Neurology Quality of Life Adult Fatigue Bank (AFB).
2498544|NCT02913040|Experimental|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
2498546|NCT02913040|Active Comparator|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
2498622|NCT02912546|Active Comparator|Control group|Eighteen healthy subjects and eighteen hypertensive patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
2498633|NCT02912546|Active Comparator|Stroke patients|Eighteen stroke patients (men and women) will be enrolled. A 1.5 Tesla MRI device with a large magnet bore (70 cm) will be used, allowing positions change. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and Cerebral Blood Flow (CBF) maps will be reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers). Differences in CBF values (in mL/100g/min) will be analyzed using SAS 9.3 software for Windows (SAS Institute, Cary North Carolina, USA).
2498664|NCT02912013|Experimental|Me mini|Subjects treated with Me mini device
2498690|NCT02911805|Active Comparator|Aerobic Exercise|Exercise 3 times a week
2498691|NCT02911805|Placebo Comparator|Balance Training|Group balance training 3 times a week
2498724|NCT02911610|Experimental|Arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
2498728|NCT02911610|Other|volar plate|surgery of wrist fractures with volar plate
2498872|NCT02910453||VATS group|Pulmonary lobectomy via VATS. VATS starts with a utility incision, approximately 4 cm in length, anterior to the latissimus dorsi muscle at the 4th intercostal space. Muscle fibers are split without cutting and a wound protector is regularly placed in site. The camera port is placed in the 6th or 7th intercostal space at the anterior axillary line and a third 10-mm access is made at the same intercostal space at the posterior axillary line. The hilum is approached anteriorly
2498881|NCT02910453||Open group|Pulmonary lobectomy via posterolateral thoracotomy (PLT). PLT consists in a standard 10-15 muscle-sparing incision at 4th intercostal space, rib divaricators are utilized and the hilum is approached posteriorly as previously described
2498894|NCT02910193||alcohol-dependent patients|
2498895|NCT02910193||first-degree relatives|Parents, children, siblings of alcohol-dependent patients
2498896|NCT02910193||healthy control subjects|
2499584|NCT02905513|Placebo Comparator|Control|App only
2498429|NCT02913807|Placebo Comparator|Traditional Reconstruction|This cohort will be reconstructed using hand contoured osteotomies and reconstruction bars
2498430|NCT02913807|Experimental|Computerized Custom|This cohort will be reconstructed using customized computer-modeled titanium locking customized jigs and plates for the osteotomies.
2498466|NCT02913352|Active Comparator|Latarjet procedure|Open Latarjet-Patte procedure. Surgery. Anterior glenoid bone graft from coracoid. Fixation with 2 screws.
2498469|NCT02913352|Experimental|Modified Eden-Hybinette Procedure|Surgery. Modified Eden-Hybinette surgery, with capsular repair on the iliac bone Anterior glenoid bone graft from iliac bone. Fixation with 2 screws.
2498505|NCT02913157|Experimental|Hydroxychloroquine|Oral Hydroxychloroquine, 200mg BID
2498547|NCT02912923|Experimental|Start with Visual + Force|Participants will complete a set of trials while receiving Visual + Force Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force + Game Scores Feedback.
2498549|NCT02912923|Experimental|Start with Visual + Force + Game Scores|Participants will complete a set of trials while receiving Visual + Force + Game Scores Feedback. After finishing, participants will continue to a new set of trials while receiving Visual + Force Feedback.
3162597|NCT00465842||E - Hepatocellular Carcinoma (HCC) with Resection|HCC patients with resection.
3162598|NCT00465842||F - Unresectable HCC|Unresectable HCC patients with treatment
2499684|NCT02904967|Experimental|patients with recurrent VTE|
2499687|NCT02904967|Active Comparator|patients with only one episode of VTE|
3162599|NCT00465842||G - Malignant HCC|HCC patients with active malignant disease and only palliative care are offered.
2499837|NCT02903459||Males|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration, using perimetry; evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in males aged between 18 and 26.
2499841|NCT02903459||Young Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in young adults females aged between 18-26.
2499848|NCT02903459||Adults|Evaluation of abdominal thickness, percentage of abdominal fat and photogrammetry (to evaluate the lumbar lordosis degree) in adult females aged between 40-60.
2499854|NCT02903459||Females|Evaluation of body mass index, determination of waist-to-hip ration and waist-to-height ration using perimetry, evaluation of 7 skinfold according to the model 7-site-skinfold Equation, by Jackson and Pollock, and photogrammetry (to evaluate the lumbar lordosis degree) in females aged between 18 and 26.
2499882|NCT02903199|Experimental|Whey Protein|Whey protein (18g) experimental supplement
2499886|NCT02903199|Experimental|Hydrolysed Protein|Hydrolysed whey protein (19.1g) experimental supplement
2499889|NCT02903199|Placebo Comparator|Placebo|Water placebo supplement
2499921|NCT02902874|Experimental|Patients treated for anaplastic large cell lymphoma ( ALCL )|
2499992|NCT02902627|Experimental|Metastatic cancer|
3162600|NCT00465855|Active Comparator|Hyperbaric Oxygen (HBO2) - 3 sessions|Subjects undergo 3 hyperbaric oxygen sessions within 24 hours following carbon monoxide poisoning.
2500183|NCT02900989|Other|ASQ-Fr|Adolescents undergo the ASQ-Fr questionnaire composed of 5 items.
2500184|NCT02900989|Other|SIQ-Fr|Adolescents undergo the SIQ-Fr questionnaire composed of 30 items if >=15 yo and the SIQ-Fr Junior composed of 15 items if <15 yo
2500224|NCT02900690||recombinant activated factor VII (NovoSeven®)|Group using the Novoseven
2500226|NCT02900690||Standard care|without use of the Novoseven
2500379|NCT02899247|Experimental|No Surface Sealant|Resin composite only
2500386|NCT02899247|Active Comparator|With surface Sealant|Resin composite with surface sealant application
2500430|NCT02899091|Experimental|CB-AC-02|Subjects with Alzheimer's disease Intervention: CB-AC-02
2500432|NCT02899091|Placebo Comparator|Placebo|Subjects with Alzheimer's disease Intervention: Placebo
2500510|NCT02898610|Active Comparator|Colchicine treatment|Colchicine 0.5mg/day plus usual care for 60 months
2500511|NCT02898610|No Intervention|Usual Standard of care alone|Normal standard of care remains for these patients
2500623|NCT02897843|Sham Comparator|sham tDCS|Sham tDCS sessions will last 20 minutes, but a real stimulus of 2 milliamps (mA) will be applied only during the first minute
2500631|NCT02897843|Experimental|tDCS|20 minute tDCS sessions
3162601|NCT00465855|Sham Comparator|Hyperbaric Oxygen (HBO2) - 1 session|Subjects undergo 1 hyperbaric oxygen session and then 2 sham chamber sessions within 24 hours of carbon monoxide poisoning.
3162602|NCT00465907|Experimental|Paclitaxel, Carboplatin and Irinotecan|Study of Weekly Paclitaxel, Carboplatin and Irinotecan in patients with Non-Small Cell Lung Carcinoma
3162603|NCT00465959|Experimental|400 mg TrIP|
3162604|NCT00465959|Experimental|800 mg TrIP|
3162605|NCT00465959|Placebo Comparator|Placebo|
3162606|NCT00466024|Experimental|1|Health coach and 2 HEPA air cleaners
3162607|NCT00466024|Active Comparator|2|Standard asthma education and 2 HEPA air cleaners
3162608|NCT00466024|Active Comparator|3|Standard asthma education and delayed receipt of 2 HEPA air cleaners
3162609|NCT00466063||ICL670|ICL670
3162610|NCT00466089|Experimental|1|RT + Tarceva
3162611|NCT00466089|No Intervention|2|RT
3162612|NCT00466102|Active Comparator|1|Patients with stable disease after 8 week run in randomized to RAD001 (blinded)
3162613|NCT00466102|Placebo Comparator|2|Patients with stable disease after 8 week run in receive placebo (blinded)
3162614|NCT00466232|Experimental|1|Weekly Topetecan in combination with Sorafenib
3162615|NCT00466245|Experimental|A|Previously vaccinated for smallpox, 1x10-8 dose
3162616|NCT00466245|Experimental|B|Smallpox vaccine naive, 1x10-8 dose
3162617|NCT00466245|Experimental|C|Previous smallpox vaccination, 1x10-7 dose
3162618|NCT00466245|Experimental|D|Smallpox vaccine naive, 1x10-7 dose
3162619|NCT00466245|Experimental|E|Previous smallpox vaccination, 1x10-6 dose
3162620|NCT00466245|Experimental|F|Smallpox vaccine naive, 1x10-6 dose
3162621|NCT00466245|Experimental|G|Previous smallpox vaccination, placebo dose
3162622|NCT00466245|Experimental|H|Smallpox vaccine naive, placebo dose
2498237|NCT02914743|Experimental|Dental Cleaning and MI Arm|Subjects in this arm will receive a dental cleaning by the hygienist as well as a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
2498241|NCT02914743|Experimental|MI only Arm|Subjects in this arm will not receive a dental cleaning but the hygienist will provide a motivational interviewing (MI) session to explore the subject's motivations to pursue oral health treatment.
2498243|NCT02914743|No Intervention|Control Arm|Subjects in this arm of the study will not receive any oral health intervention while hospitalized. A medical record review will be completed, and patients will be contacted via telephone at 3, 6, and 12 months post-hospitalization to assess their oral health-related quality of life and oral health care-seeking behaviors.
3195680|NCT00842140|Active Comparator|1|This group will receive an oral contraceptive containing 0,03mg ethynylestradiol and 2mg chlormadinone acetate
3195681|NCT00842140|Experimental|2|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
3195682|NCT00842140|Experimental|3|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg metformin.
3195683|NCT00842179||Manual Closure|Patients who received vascular closure with manual compression after percutaneous coronary intervention (PCI)
3195684|NCT00842179||Perclose Device|Patients who received vascular closure with the Perclose VCD after percutaneous coronary intervention (PCI)
3195685|NCT00842192||A|
3195686|NCT00842205|Active Comparator|1 HCV positive pts|"Patients with chronic HCV infection undergoing liver biopsy followed by antiviral treatment.~peg-IFN alfa 2a 180ug s.c. QW + ribavirin 1000-1200mg p.o. daily 48weeks or peg-IFN alfa 2b 1.5 ug/kg s.c. QW + ribavirin 100-1200mg p.o. daily 48 weeks"
3195687|NCT00842205|No Intervention|2 Other liver disease|pts. with NASH (or other liver disease) undergoing liver biopsy.
3195688|NCT00842270|Experimental|2|4,5 mg/kg/day
3195689|NCT00842270|Experimental|3|6 mg/kg/day
3195690|NCT00842270|Placebo Comparator|4|matching placebo for AB1010 3, 4,5 and 6 mg/kg/day
3195691|NCT00842270|Experimental|1|AB1010 3 mg/kg/day
3195692|NCT00842283||dermatologic diseases|skin tissue sample
3195693|NCT00842322|Experimental|High fluid intake|fluid intake of 4 litres per day
2499017|NCT02909179|Experimental|mCARE-II|mCARE-II supported service provision through existing community health workforce.
2499028|NCT02909179|No Intervention|Comparison|Standard of care, paper-based service provision through existing community health workforce.
2499105|NCT02909049|Active Comparator|CONTROL|Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy
2499107|NCT02909049|Experimental|EXPERIMENTAL|Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.
2499135|NCT02908425|Other|Healthy taking statin|healthy subjects currently taking cholesterol lowering statin
2499164|NCT02908256|Experimental|PVI group|Monitoring of the PVI during the surgical intervention
2499166|NCT02908256|Active Comparator|Delta PP group|Monitoring of the deltaPP during the surgical intervention
2499224|NCT02908074|Experimental|Experimental: Regimen 1|Drug: BGS649 Dose 1 weekly
2499227|NCT02908074|Experimental|Experimental: Regimen 2|Drug: BGS649 Dose 2 weekly
2499229|NCT02908074|Experimental|Experimental: Regimen 3|Drug: BGS649 Dose 3 weekly
2499286|NCT02907476|Experimental|Iyengar Yoga|Twelve-week Iyengar Yoga protocol with two 90-minute classes per week and three 30-minute homework assignments. Classes consist of approximately 60-minutes of yoga postures, 10-minutes of rest and transition, and 20-minutes of Coherent Breathing at 5 breaths per minute. Homework consist of 15-minutes of yoga postures and 15-minutes of Coherent Breathing. Coherent Breathing is CD guided. Yoga classes are taught by certified Iyengar Yoga instructors.
2499298|NCT02907476|Active Comparator|Walking|Twelve-week walking intervention will consist of two 60-minute group-walking sessions per week and three 15-minute homework walking sessions at 2.5 miles per hour on flat surface. Walking classes are conducted by research staff.
2499338|NCT02907164|Active Comparator|Group 1: Control|People receive emails encouraging them to sign up for the challenge. The email does not mention the number of people who have signed up.
2499602|NCT02905357||MINOCA|OCT and CMR imaging
3195694|NCT00842322|Experimental|normal fluid intake|Fluid intake of 2 litres per day
3195695|NCT00842374||Non-STEMI ACS|
3195696|NCT00842387||1|Patients with symptoms suggestive of GERD, managed according to a new structured and implemented pathway
3195697|NCT00842387||2|Patients with symptoms suggestive of GERD, managed according to usual clinical practice.
3195698|NCT00842413||1|The study compares brain-damaged patients with healthy ones on two psychophysical tasks.
3195699|NCT00842413||2|The study does not intervene on the brain-damaged patients, it merely compares their behaviour with that of healthy patients on a range of psychophysical tasks.
3195700|NCT00842426|No Intervention|Usual Care|Usual Care
3195701|NCT00842426|Experimental|Self-Management Program|Online Self-Management.
3195702|NCT00842426|Experimental|Care Management Program|Care management lifestyle modification program with intensive intervention phase with exercise and nutrition specialist. Followed by a online self-management phase.
3195703|NCT00842439|Experimental|Cognitive Behavioral Intervention (CBI)|Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.
3195704|NCT00842439|Experimental|Nutritional Supplements (NUT)|Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.
3195705|NCT00842439|Experimental|CBI + NUT|Participants will receive both the cognitive behavioral intervention and the nutritional supplements.
3195706|NCT00842439|No Intervention|No intervention|Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.
3195707|NCT00842452|Experimental|Oral Topotecan|
3195708|NCT00842465||1|benign breast diseases
3195709|NCT00842465||2|breast cancer
2498314|NCT02914431|Experimental|3D Printing Personalized Titanium Plate|After the LeFort I osteotomy, the intraoperative repositioning and fixation of the maxilla is accomplished using 3D printing personalized titanium plates.
2498317|NCT02914431|No Intervention|CAD/CAM Surgical Splint|After the LeFort I osteotomy, the intraoperative repositioning of the maxilla is accomplished using CAD/CAM surgical splints and the fixation of the maxilla is accomplished using commercialization titanium plates.
3162623|NCT00466375||A|Patients with a hemangioma.
3162624|NCT00466375||B.|Patients with a vascular anomaly.
3195710|NCT00842465||3|control
2498590|NCT02912676|Experimental|6TG/6MP/MTX|Single arm feasibility study aiming to demonstrate the applicability of combining incremental doses of oral 6-Thioguanine with oral daily 6-Mercaptopurine and oral weekly Methotrexate in order to achieve mean levels of DNA-TG above 500 fmol/mikrogram DNA.
2498618|NCT02912273||Fall Risk Assessment Group|-Participants will complete baseline primarily self-administered cancer-specific geriatric assessments and measures of neuropathy and pain, an abbreviated geriatric assessment with each follow-up clinic visit (generally every 3-4 weeks in patients receiving systemic therapy) for 6-months of follow-up and a final end-of-study assessment.
2498673|NCT02911935|Active Comparator|Oral azithromycin|Oral Azithromycin
2498675|NCT02911935|Placebo Comparator|Placebo|Oral Placebo
2498699|NCT02911714|Experimental|CEUS and Delayed Graft Function|On the first post-operative day after kidney transplantation, recipients enrolled in the study will undergo CEUS using Lumason to quantify microvascular perfusion within the cortical and medullary zones of the kidney allograft for comparison to the concentration of neutrophil gelatinase-associated lipocalin (NGAL, an early biomarker of acute kidney injury) measured from recipient urine simultaneously collected on the first post-operative day.
2498701|NCT02911714|Experimental|CEUS and Biopsy-Proven Acute Rejection|We will identify and enroll kidney transplant recipients in need of clinically-indicated duplex ultrasounds and possible biopsy to evaluate allograft dysfunction during hospital admissions and outpatient follow-up. Immediately after the duplex ultrasound, we will perform CEUS using Lumason for allograft perfusion measurements to determine its potential association with biopsy-proven acute rejection according to the most recent Banff criteria.
2498769|NCT02911415||the dosage of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.25 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015.
2498771|NCT02911415||the dosage of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac-Combi in the dosages of 0.5 ml, during the study under Protocol 01-COMBI-2015 in October-November 2015
3162625|NCT00466388|Experimental|Cevimeline|Evoxac tid for xerostomia
3162626|NCT00466388|Placebo Comparator|Placebo|sugar pill
3162627|NCT00466466|Experimental|Daily dosing RAD001|
2498899|NCT02910154|Experimental|Weight loss, training, medication|"The intervention program consists of a comprehensive 24-week treatment period of: 1) Body weight loss without significant loss of muscle mass, through low energy diet combined with 2) Exercise training based on interval training and resistance exercise and 3) Optimal medical treatment for hypertension and hypercholesterolemia (with statin and ACE-inhibition). Further, participants in this allocation group receive nutrition counselling.~The diet products are sponsored by Cambridge Weight Plan. No persons with interest in Cambridge Weight Plan will take part in the intervention phase, analyzing phase, data processing, or publication of data in this study."
2498900|NCT02910154|No Intervention|Control|The control group receives 24 weeks of usual care according to guidelines of Danish Cardiology Society. Treatment of angina pectoris in absence of coronary artery disease is normally provided by the patient's general practitioner and does not comprise intensive lifestyle intervention or medical treatment. If control group participants in this study need medical therapy for hypertension or hypercholesterolemia, this will be effectuated by the researcher, MD. Then, control participants will be monitored with blood pressure and LDL blood samples and receive medicine adjustments according to National Prevention Guidelines during the full study period.
2498963|NCT02909855||Participants|Parents of children aged 2-4 who will receive the child flu vaccine from their general practitioner (GP)
2499445|NCT02906449|Experimental|Mindfulness Training|Daily Mindfulness Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
2499680|NCT02904850||group of patients|Plasma dosage of erlotinib and OSI-420
3162628|NCT00466466|Experimental|Weekly dosing RAD001|
3162629|NCT00466492|Other|No sedatation intervention|The intervention group is the normal care in our institution, the control group is the golden standard
3162630|NCT00466518|Experimental|1|
3162631|NCT00466609|Experimental|Quetiapine (fluoxetine plus quetiapine)|fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks
3162632|NCT00466609|Active Comparator|Clomipramine (fluoxetine plus clomipramine)|Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks
3162633|NCT00466609|Placebo Comparator|Placebo (fluoxetine plus placebo)|Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks
3162634|NCT00466622|Experimental|1|Metformin 1000mg x 2 daily. Orally. From Weifa
3162635|NCT00466622|Placebo Comparator|2|Placebo 2 tablets x 2 daily. Orally From Weifa
3162636|NCT00466674|Experimental|Allogenic Transplant|
3162637|NCT00466765|Experimental|Single Arm|Use Brava system for pre-expansion of breast prior to fat grafting
3162638|NCT00466791|Active Comparator|Methylphenidate Transdermal System|Transdermal patch, 27.5mg, 41.3mg, 55mg, and 82.5mg, daily for 11 weeks
3162639|NCT00466791|Placebo Comparator|Placebo|Transdermal patch, 0mg, daily for 11 weeks
3162640|NCT00466804||Heart Transplant Recipients|People who will have a heart transplant
3162641|NCT00466843|Experimental|1|Participants will be treated with ATG
3162642|NCT00466856|Experimental|Sir-Spheres|
3162643|NCT00466882||Inamed Lap-Band System|The LAPBAND is positioned laparoscopically around the stomach and requires an overnight hospitalization and an upper GI swallow the next morning. The device can be gradually adjusted to increase stomach constriction by the physician in an office setting so that the patient loses approximately 1-2 pounds per week over two years.
2498327|NCT02914314|Experimental|Perampanel up to 12 or 16 mg/day|Pediatric participants, ranging from 1 month to less than 4 years of age, will receive perampanel oral suspension once a day in titration period starting at Week 0 at a dose of 0.50 mg per day (mg/day) titrated up to 4 mg/day (for participants taking non-EIAED) or up to 8 mg/day (for participants taking EIAED). Depending on participants clinical response, tolerability and investigator's decision, dose can be up titrated to 6 mg/day (for participants taking non-EIAED) and up titrated to 8 mg/day (for participants taking EIAED). Dose titration must not exceed 12 mg/day (non-EIAED) and 16 mg/day (EIAED). Participants will continue taking the perampanel oral suspension at dose level achieved at end of titration period through maintenance period of core study and maintenance period of extension phase (Up to Week 52).
3195711|NCT00842478|Experimental|Raspall|
3195712|NCT00842478|No Intervention|Control|
2498447|NCT02913417|Experimental|hepatic radiation followed by immunotherapy|SIR-Spheres Yttrium 90 will be given by injection into the hepatic artery in two treatments, one for each lobe. 3-5 weeks later patients receive concurrent ipilimumab 1mg/kg q 3 wk x 4 and nivolumab 3mg/kg q 3 weeks x 4, all followed by nivolumab 240mg/kg q 2 weeks or 480 mg q 4 weeks until progression or 3 years
2498488|NCT02913235|Experimental|Oral hygiene discontinuation group|The intervention of the present study is discontinuation of regular oral hygiene procedures for a period of 10 days. Discontinuation of oral hygiene will allow undisturbed biofilm formation (supragingival dental plaque) along the gingival margin of the teeth. After 10 days all individuals will resume regular oral hygiene. Clinical registrations and collection of microbiological samples (supragingival and saliva) will be performed at baseline and 4, 7 and 10 days after discontinuation of regular oral hygiene, and will be repeated 14 days after regular oral hygiene has been resumed.
2498524|NCT02913079|Experimental|Sit-stand desk|During this condition, participants will sit or stand as much as they like throughout a workday.
2498528|NCT02913079|Placebo Comparator|Sitting|During this condition, participants will work in the sitting position only.
2498560|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2498564|NCT02912793|Active Comparator|Hydroxy-propyl-beta-cyclodextrin IV 2000 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2498567|NCT02912793|Active Comparator|Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg|Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
2498646|NCT02912338|Experimental|Resistant Training Group|sandbag 2-5lb, grip ball, twice/week, Duration:12 weeks
2498649|NCT02912338|Active Comparator|Control Group|not change lifestyle
2498665|NCT02911974|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2498666|NCT02911974|Active Comparator|Expect EUS Aspiration Needle|All patients will undergo sampling of pancreatic masses using the Expect EUS Aspiration Needle. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types
2498712|NCT02911779|Other|change of medilateral angle line|change of medilateral angle line during crowning of the head
2498779|NCT02911194|Experimental|Treatment|a2 milk intervention period
2498781|NCT02911194|Placebo Comparator|Control|a1 containing milk (normal) intervention period
2498813|NCT02910882|Experimental|Single Arm|"Cohort I (PEGPH20 Dose Escalation + Gemcitabine and Concurrent Radiotherapy), First 3 Patients:~An abbreviated sequential dose escalation schema for the first 3 patients (each subsequent patient will be accrued only after no dose limiting toxicities are found in the first 2 weeks of concurrent therapy for the previous patient).~Intravenous (IV) PEGPH20, per dose escalation guidelines for first 3 patients; Intravenous (IV) Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);~Cohort II (PEGPH20 + Gemcitabine and Concurrent Radiotherapy), Patients 4 - 10:~IV PEGPH20, per dosing level determined in dose escalation (Cohort I); IV Gemcitabine (Standard Regimen); Radiotherapy (Standard Regimen);"
2498875|NCT02910440|Experimental|DCL-101|
2498877|NCT02910440|Active Comparator|GoLytely|
2498905|NCT02910128|Experimental|School intervention|chiquichefs education innovation
2498907|NCT02910128|No Intervention|control school|A primary schools will function as control schools.
2498973|NCT02909894|Experimental|Prolonged Sitting|
2498976|NCT02909894|Active Comparator|Light intensity arm ergometry breaks|
2499025|NCT02909374|Experimental|Balance training|"The program includes exercise with dual- and multi task performance and is progressive as the exercises can be performed at different levels (basic, moderate, and advanced). The 12-week balance training program will be performed two times per week for one hour each. The training will be lead by physiotherapists or trained leaders. After the balance training the participants will get recommendations for continued physical activity and training, i.e. Physical activity on prescription."
2499083|NCT02909062||Electronic Activity Monitoring (EAM)|This is a prospective, observational study. The study aims to examine the role of EAM as an objective, assessment of patient fitness in patients receiving chemotherapy for gastrointestinal malignancy. Physical activity level measured by EAM will be compared with standard measurement tools used by the oncology community to predict chemotherapy tolerability.
2499084|NCT02909075||PET/CT scans and MRI|Eligible patients will be enrolled onto the study, and will undergo 3 limited field of view (FOV) FDG-PET/CT scans and MRI of the chest: at baseline (within 4 weeks prior to transplantation), and approximately 3 months (+/-2 weeks) and 6 months (+/-2 weeks) after transplant. PET/CT and MR imaging can be completed on the same day. We will also offer the exams on other days if this is easier for the patient. The PET/CT and MR should be performed within 2 weeks of each other.
2499122|NCT02908607|Experimental|experimental|3 groups of patients will be participated: women with cancer, women with premalignant lesions and women with a normal cervix. All patients will undergo the same examination
2499140|NCT02908646|Experimental|microcoil|patients who plan for microcoil localization
3195713|NCT00842491|Experimental|endostar+chemotherapy|
3195714|NCT00842504|Other|Micafungin|3 mg/kg given once
3195715|NCT00842517|Experimental|Extended|36-week duration contingency management program
2498330|NCT02914340|Experimental|Treatment|The treatment algorithm is complete occlusion of one lobe of the lung by using valves to occlude all segments of the lobe. The lobe will be selected based on imaging with high resolution computed tomography (HRCT). The lobe to be treated will have severe heterogeneous emphysema based on visual exam. The selected lobe will also have an intact fissure separation with the ipsilateral lobe. An intact fissure will be estimated visually to be ≥ 90% complete after viewing the HRCT in 3 dimensions. If more than one lobe meets criteria, the investigator will determine a primary lobe to treat based on fissure completeness, heterogeneity, disease severity, and the anatomy of the airways that will be treated.
3195716|NCT00842517|Active Comparator|Standard|12-week duration contingency management program
2498448|NCT02913573|Experimental|GA + Pec Block|Following induction of general anesthesia, the patients in the intervention group will undergo an ultrasound-guided pectoral block. With the patient in proper position, the infraclavicular and axillary regions are prepped with chlorhexidine. An US probe is placed below the third of the clavicle over the pectoralis major muscle. After identifying the appropriate anatomical structures, a 21-gauge echogenic needle is advanced under US visualization to the tissue plane between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie and 15 mL of 0.25% bupivacaine will be deposited. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
2498449|NCT02913573|No Intervention|GA only|Patients will receive standard general anesthesia.
3195717|NCT00842556|Active Comparator|Dapagliflozin|
3195718|NCT00842556|Active Comparator|Glimepiride|
2498582|NCT02912585|Experimental|Own mother's colostrum|Oropharyngeal administration of own mother's colostrum.
2498583|NCT02912585|Placebo Comparator|Placebo|Oropharyngeal administration of sterile water.
2498589|NCT02912585|Active Comparator|Donor human milk|Oropharyngeal administration of donor human milk.
2498627|NCT02912299||Septic patients|Patients admitted to the ICU that fulfill the criteria for the systemic inflammatory response syndrome in the presence of a(n expected) new infection. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2498635|NCT02912299||CABG patients|Patients admitted to the ICU after coronary artery bypass grafting. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2498643|NCT02912299||Patients before hip replacement|Patients that will undergo a hip replacement because of arthrosis. 2 3mm skin biopsies will be taken, blood and urine analysis will take place and also blood collection for RNA-investigation.
2498707|NCT02911883||Normal|Not having glaucoma or retinal pathology
2498708|NCT02911883||Glaucoma|Having glaucoma.
2498710|NCT02911883||Retina|Having retinal pathology
2498746|NCT02911493|Experimental|Sedentary Group-Experimental|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
2498747|NCT02911493|Active Comparator|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
2498773|NCT02911207|Experimental|Intervention arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during the following six months
2498775|NCT02911207|Active Comparator|control arm|patients choose one creative activity (evolutive art-therapy, writing workshop, theatre, singing) and one physical activity (pilates, mindfulness meditation, shiatsu, ayurvedic massage) that they will practice during six months but they will start 6 months later after randomization
2498821|NCT02910934|Experimental|IRS|This arm is comprised of village clusters that have received indoor residual spray with Actellic CS.
2498823|NCT02910934|No Intervention|non-IRS|This arm is comprised of village clusters that will not receive indoor residual spray
2498845|NCT02910479|Experimental|temperature measurements with 4 devices|temperature measurements with e-device Celsius, esophageal probe and a rectal probe and vital sense capsule
2498947|NCT02909777|Experimental|CUDC-907|"CUDC-907 orally administered~CUDC-907 once daily for 5 consecutive days per week followed by two days without dosing~Dose level assigned at registration~Pre-dose pharmacokinetic blood sample will be collected~Dose escalation will follow a standard 3+3 design"
2499004|NCT02909569|Experimental|INCB039110|INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
2499062|NCT02909231||Foothills Medical Centre|Patients admitted to the Foothills Medical Centre trauma service (Calgary, AB) over four months.
2499064|NCT02909231||Vancouver General Hospital|Patients admitted to the Vancouver General Hospital trauma service (Vancouver, BC) over four months.
2499136|NCT02908802|Active Comparator|Probiotic|Probiotic capsules: two capsules twice a day
2499446|NCT02906436|Experimental|ExVivo lung reconditioning|
3195719|NCT00842556|Active Comparator|Dapagliflozin + Glimepiride|
3195720|NCT00842556|Active Comparator|Sitagliptin|
3195721|NCT00842556|Active Comparator|Dapagliflozin + Sitagliptin|
3195722|NCT00842569||Normal weighted|BMI<25
3195723|NCT00842569||Obese|BMI>30
3195724|NCT00842582|Experimental|Single group assignment|Patients will receive Azacitidine at 20, 40, or 75 milligrams per meter squared subcutaneous once daily for 7 days.
3195725|NCT00842595|Experimental|R NIMP|(Mabthera®) Rituximab IV 375 mg/m²day 1 (Navelbine ®)Vinorelbine IV 25mg/m² day 1 and day 5 (Novantrone®)Mitoxantrone IV 10 mg/m² day 1 (Holoxan®)Ifostamide IV 1000 mg/m²day 1 to day 5 (Cortancyl®)prednisone oral day 1 to day 5
3195726|NCT00842621||1|Pediatric participants with severe sickle cell disease (HbSS or Hb S/β°-thalassemia) who are not receiving treatment, e.g., hydroxyurea or chronic transfusions
3195727|NCT00842621||2|Pediatric participants with other forms of SCD or severe sickle cell disease patients (HbSS or Hb S/β°-thalassemia) being treated with hydroxyurea or chronic transfusions
3195728|NCT00842621||3|Pediatric and adult participants with other non-sickling hematological disorders
3195729|NCT00842634|Experimental|Cohort 1|Patients who have failed two more HAART regimens
3195730|NCT00842634|Experimental|Cohort 2|Patients doing well on a stable antiretroviral medication
3195731|NCT00842634|Experimental|Cohort 3|Patients who have an undetectable viral load on HAART who have exhibited suboptimal CD4+ T cell gains during long term antiretroviral therapy. This group will not participate in the structured treatment interruption.
3195732|NCT00842660|Experimental|Gemzar,survival|
3195733|NCT00842673|Experimental|1|30 mg ST101
3195734|NCT00842673|Experimental|2|90 mg ST101
3195735|NCT00842673|Experimental|3|180 mg ST101
3195736|NCT00842673|Placebo Comparator|4|Placebo
3195737|NCT00842699||1|patients receiving IL-2 receptor antagonist (Simulect) as induction treatment
3195738|NCT00842699||2|patients receiving Thymoglobulin as induction treatment
3195739|NCT00842738|Active Comparator|Mindfulness meditation|Women with mild dysplasia offered mindfulness meditation
3195740|NCT00842738|Other|No meditation|Women with mild dysplasia offered health care services as usual
3195741|NCT00842738|Other|Controls|Women with normal cervical cells
3195742|NCT00842777|Experimental|Parent group treatment|Manualized group treatment of parents. Allocation of 4-6 parental couples of children with similar age.
3195743|NCT00842777|Active Comparator|Parent self-help groups|Professionals initiate and organize the self-help groups initially. The groups will not receive any teaching or counseling concerning eating and physical activity.
3195744|NCT00842803|No Intervention|Control Group|Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
2498919|NCT02910024|Active Comparator|Real-rTMS|Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex in the lesioned hemisphere using the intermittent theta-burst-stimulation protocol (iTBS; application of 3 pulses with a frequency of 50 Hz, in a theta-rhythm of 5 Hz for 2 seconds, repeated every 10 seconds, duration of one session: about 3,5 minutes) before physiotherapy for 8 days
2498921|NCT02910024|Sham Comparator|Sham-rTMS|Repetitive transcranial magnetic stimulation (rTMS) in sham position (tilted coil over parieto-occipital vertex) before physiotherapy for 8 days
2498958|NCT02909751|Active Comparator|Neoadjuvant chemotherapy|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv"
2498961|NCT02909751|Experimental|Neoadjuvant chemotherapy + tocotrienol|"HER2 negative:~Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv followed by Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3~HER2 positive:~Four cycles of taxane, i.e. 3-weekly docetaxel 100 mg/m2 iv or weekly paclitaxel 80 mg/m2 iv + 3-weekly trastuzumab (8 mg/kg iv saturation, then 6 mg/kg iv) and possibly pertuzumab (840 mg saturation, then 420 mg iv) followed by Four cycles of 3-weekly epirubicin 90 mg/m2 iv and cyclophosphamid 600 mg/m2 iv.~Daily: Tocotrienol 300 mg x 3"
2499095|NCT02908854|Experimental|School Lunch Participants|School lunch participants will be given vegetables with and without additional spices and herbs to determine if intake will increase with the addition of spices and herbs.
2499115|NCT02908789|Other|Antimicrobial photodynamic therapy (aPDT)|The technique consists of a basic protocol of two steps: the use of a photosensitizer and the laser application. In the first step, the cavity was dried and then 0.01% methylene blue solution (Formula & Ação, São Paulo, Brazil) was applied to the entire cavity using a carpule in order to keep in contact with all the walls. It remained in the cavity for a pre-irradiation period of 5 minutes. In the second step, the excess of 0.01% methylene blue solution was removed and the cavity was irradiated with an Indium Gallium Aluminum Phosphorus diode laser (InGaAlP) (Laser DUO®, MM Optics, São Carlos, São Paulo, Brazil) with a wavelength of 660 nm (visible red), a spot area of 3mm2, and fixed output power of 100 mW. We adopted the following parameters: energy of 9 J with 90 seconds of exposure time. The irradiation was applied in continuous mode and the laser array was positioned, in contact, directly over the central part of the cavity.
3195745|NCT00842803|Experimental|Albumin group|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
3195746|NCT00842816|Experimental|1|10 mg ST101
2499173|NCT02908373||Case group|Nursing homes benefiting first the implementation of the coaching model (methodological help for professionals on the patient safety culture): just after the first measure (overview of the situation)
2499184|NCT02908373||Control group|Nursing homes benefiting the implementation of the coaching model (methodological help for professionals on the patient safety culture): after the second measure (impact of the device on case group)
3195747|NCT00842816|Experimental|2|60 mg ST101
3195748|NCT00842816|Experimental|3|120 mg ST101
3195749|NCT00842816|Placebo Comparator|4|Placebo
3195750|NCT00842842|Active Comparator|1: tacks|mesh fixation with tacks
3195751|NCT00842842|Experimental|2: glue|mesh fixation with glue
3195752|NCT00842855||1|274 GERD patients, partial responders to PPI treatment
3195753|NCT00842881|No Intervention|a|healingstone
3195754|NCT00842881|No Intervention|b|stone powder
3195755|NCT00842894||Insulin detemir|
3195756|NCT00842894||Biphasic insulin aspart 30|
3195757|NCT00842907|Active Comparator|oral isotretinoin|Twelve subjects will be treated with oral isotretinoin 20.0 mg, once a day, every other day, for 24 weeks.
3195758|NCT00842907|Active Comparator|tretinoin|Twelve patients will be treated with 0,05% tretinoin cream applied on face and forearms at night and moisturizer broad-spectrum sunscreen twice a day.
3195759|NCT00842920|Placebo Comparator|Placebo|Placebo or 20 mg Simvastatin (stratified by prior use of statins)
3195760|NCT00842920|Experimental|Simvastatin 60 mg|Simvastatin 60 mg once daily
3195761|NCT00842920|Experimental|Simvastatin 20 mg|Simvastatin 20 mg once daily
3195762|NCT00842933|Experimental|Experimental group|Corticosteroids discontinued 24 hours after cessation of vasopressor therapy or 7 days, which ever comes first.
3195763|NCT00842933|Active Comparator|Standard of care group|Standard corticosteroid therapy given for 7 days as treatment for adrenal insufficiency during septic shock.
3195764|NCT00842959|Other|ZO|XL Stabi ZO or Invent ZO
2498355|NCT02914249|Experimental|Orange juice|Orange juice: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) plus 100% orange juice (500 mL/d) during 12 weeks.
2498356|NCT02914249|No Intervention|Control|Control: thirty-nine obese individuals were submitted to a low-caloric diet (500 kcal/d of energy restriction) during 12 weeks.
2498405|NCT02913937|Active Comparator|Needle irrigation|Endodontic irrigation will be done using an endodontic needle.
2498406|NCT02913937|Experimental|Passive ultrasonic irrigation|Endodontic passive ultrasonic irrigation will be done using an endodontic needle followed by passive ultrasonic agitation.
3162644|NCT00466895|Experimental|Stratum 1 Acute Leukemias|Patients must have a diagnosis of Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia(ALL)according to the WHO (World Health Organization) classification.
3162645|NCT00466895|Experimental|Stratum 2 Chronic lymphocytic leukemia|Patients must have diagnosis of B-Cell, Chronic Lymphocytic Leukemia(CLL) or Small Lymphocytic Leukemia (SLL) (including Waldenstrom's Macroglobulinemia) requiring therapy (see eligibility criteria for definition of this) and have previously received treatment with one or more prior chemotherapy regimens.
3162646|NCT00466973|Active Comparator|Dry bipolar radiofrequency (RF) clamp|used for ablation during surgical procedure
3162647|NCT00466973|Active Comparator|Unipolar microwave antenna|used for ablation during surgical procedure
2498600|NCT02912429|Other|Inlay|specific technical type of patellofemoral arthroplasty
2498603|NCT02912429|Other|Onlay|specific technical type of patellofemoral arthroplasty
2498624|NCT02912156|Experimental|Vaway FC Tablets|Vaway FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
2498636|NCT02912156|Active Comparator|VFEND FC Tablets|VFEND FC Tablets 200mg (Voriconazole) Dosing Regimen: Single dosing
2498674|NCT02911987|Experimental|the 'cardio' HIT group|Group 1 receives HIT exercise, aimed only at improving cardiovascular endurance (the 'cardio' HIT group).
2498676|NCT02911987|Experimental|the 'general' HIT group|Group 2 receives HIT exercise aimed at improving both cardiovascular and general muscle condition (the 'general' HIT group ).
2498677|NCT02911987|Experimental|the 'lumbar' HIT group|Group 3 receives HIT exercise, aimed at improving both cardiovascular condition and specific trunk muscle condition (the 'lumbar' HIT group).
2498679|NCT02911987|Experimental|the 'combined' HIT group|Group 4 receives HIT exercise which is a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'combined' HIT group). These trainings will take place in the REVAL Rehabilitation Research Center on the campus of Hasselt University in Diepenbeek.
2498681|NCT02911987|Active Comparator|control group|Group 5 receives MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group)
2498719|NCT02911675||Standard of Care Group|Study Group 1: Standard EVD/IVC management with therapeutic CSF drainage as appropriate and hourly EVD/IVC ICP measurements per standard of care with simultaneous IPM/Camino ICP measurements collected.
2498726|NCT02911675||Experimental Group|Study Group 2: Therapeutic CSF drainage as appropriate, with EVD/IVC closure and ICP assessment approximately every 12 hours with simultaneous IPM/Camino ICP measurements collected.
2498757|NCT02911428||dosages of 0.25 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.25 ml, during the study under Protocol 02-E-2015 in October-November 2015.
2498758|NCT02911428||dosages of 0.5 ml|Blood sampling collection: 12, 18 and 24 months after the vaccination. The study will enroll up to 30 healthy volunteers of both genders aged 18-55 inclusive who had been earlier immunized with medicinal product GamEvac in the dosages of 0.5 ml, during the study under Protocol 02-E-2015 in October-November 2015.
2498805|NCT02910999||NSCLC patients with squamous tumor histology|
2498811|NCT02910999||NSCLC patients with non-squamous tumor histology|
2498840|NCT02910622||Oncogramme breast|Taking a fragment of breast tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
2498849|NCT02910622||Oncogramme ovarian|Taking a fragment of ovarian tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme
2498925|NCT02909946|Active Comparator|Intervention Arm|NHs randomized to the Intervention Arm will implement a new multi-modal infection control program.
2498929|NCT02909946|No Intervention|Control Arm|NHs randomized to the Control Arm will continue their current standard infection control practices.
2499147|NCT02908568|Experimental|Spring device|Brisk dilatation of fhe mouth.
2499149|NCT02908568|Sham Comparator|Mandible stimulator|Stimulation of fhe mouth.
2499176|NCT02908191|Experimental|ABI-H0731 or Matching Placebo|ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
2499189|NCT02908191|Experimental|ABI-H0731 or Placebo and ETV or TDF|ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
3162648|NCT00466973|Active Comparator|Unipolar cryothermic probe|used for ablation during surgical procedure
3162649|NCT00466973|Active Comparator|Irrigated unipolar RF antenna|used for ablation during surgical procedure
3162650|NCT00466973|Active Comparator|Irrigated bipolar RF clamp|used for ablation during surgical procedure
3162651|NCT00466973|Active Comparator|Hi-intensity focused ultrasound wand|used for ablation during surgical procedure
3162652|NCT00466999|Active Comparator|surgery|standard surgical treatment (either dilation and curettage or manual vacuum aspiration)
3162653|NCT00466999|Active Comparator|misoprostol|400 mcg misoprostol
3162654|NCT00467012|Experimental|step 1|6 enrollment for 1 cycle(4 weeks)
3162655|NCT00467012|Experimental|step 2|114 enrollment through to meet the stopping criteria
3162656|NCT00467025|Experimental|Arm A|
3162657|NCT00467025|Experimental|Arm B|
3162658|NCT00467025|Active Comparator|Arm C|
3162659|NCT00467064|Experimental|Arthritis self-management workshop|Comparison of two-week, lay led, scripted self-management workshop emphasizing action planning, problem-solving, and content specific to arthritis.
3174999|NCT00629057|Experimental|3|Highest dose level
2498443|NCT02913703|Experimental|Healthy subjects - Prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 5 hour fast, they will receive a prandial AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2498444|NCT02913703|Experimental|Healthy subjects - Preprandial & prandial AG|Control group of healthy subjects. Subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive another AG bolus over 1 minute starting at the same time as the liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2498445|NCT02913703|Experimental|Diabetic subjects - Preprandial AG|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial AG bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2498446|NCT02913703|Experimental|Diabetic subjects - Preprandial Saline|Type 2 diabetic subjects will eat standardized, provided breakfast at home; then after a 4 hour fast, they will receive a preprandial saline bolus over 1 minute. Sixty minutes later, they will receive a liquid mixed meal (Ensure: 2 cans/474 ml). Venous blood samples will be taken over the entire 245 minutes.
2498494|NCT02913261|Active Comparator|Ruxolitinib|Ruxolitinib 10 mg Bis In Diem (BID)
2498495|NCT02913261|Active Comparator|Best Available Therapy (BAT)|As selected by the investigator
2498607|NCT02912377|Experimental|Arm 1; B12019 / Neulasta|2 single doses of B12019 followed by one dose of Neulasta
2498611|NCT02912377|Experimental|Arm 2; Neulasta / B12019|2 single doses of Neulasta followed by one dose B12019
2498647|NCT02912182|Placebo Comparator|Placebo|Day 1: Intravenous sodium-chloride 2ml Day 2-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
2498648|NCT02912182|Active Comparator|Short treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-3: 10 tablets prednisolone 5 mg Day 4-6: 10 tablets placebo Day 7: 8 tablets placebo Day 8: 6 tablets placebo Day 9: 4 tablets placebo Day 10: 2 tablets placebo Day 11: 1 tablet placebo
2498650|NCT02912182|Active Comparator|Standard treatment|Day 1: Intravenous betamethasone 8mg (2ml of 4mg/ml) Day 2-6: 10 tablets prednisolone 5 mg Day 7: 8 tablets prednisolone 5 mg Day 8: 6 tablets prednisolone 5 mg Day 9: 4 tablets prednisolone 5 mg Day 10: 2 tablets prednisolone 5 mg Day 11: 1 tablet prednisolone 5 mg
2498687|NCT02911870|Experimental|Part A, SNAC|Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
2498688|NCT02911870|Placebo Comparator|Part A, placebo|Single dose at corresponding dose levels.
2498689|NCT02911870|Experimental|Part B, SNAC, Placebo, Moxifloxacin|Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.
2498714|NCT02911636|Experimental|Arm 1|Pelvic SABR with intra-prostatic SABR
2498742|NCT02911467|Experimental|MR imaging with hyperpolarized 13C pyruvate of men with CRPC|75 men with castration-resistant prostate cancer (CRPC) will undergo MR imaging with hyperpolarized 13C pyruvate of a pre-selected target lesion at baseline and after 1 month of treatment with an androgen signaling inhibitor. Patients with CRPC that is not primarily refractory (defined as disease progression by PCWG2 criteria within 6 months of treatment initiation) to Androgen Signaling Inhibitors (ASI) treatment will undergo a third metabolic MR scan at the time of disease progression. Patients may undergo optional MR- or CT-guided tumor biopsies at baseline and at the time of disease progression.
3195765|NCT00842998|Experimental|1 - Trastuzumab|Day1 Week1: 8 mg/kg iv in 90 min. Following 1st week: 2 mg/kg once/weekly for 8 weeks
2498878|NCT02910401|Active Comparator|Asthmatic|Asthmatic subjects will be infected with Rhinovirus (GMP RV16 human (H)RV-16)
2498883|NCT02910401|Active Comparator|Allergic rhinitis|Allergic rhinitis subjects will be infected with Rhinovirus (GMP RV16 HRV-16)
2498886|NCT02910401|Active Comparator|Healthy control|Healthy controls will be infected with Rhinovirus (GMP RV16 HRV-16)
3195766|NCT00842998|Experimental|2 - Lapatinib|1500 mg/die orally
3195767|NCT00843011|Experimental|Arm 1|Orvepitant 60 mg
2499024|NCT02909387|Experimental|Stratum A|This group will be the first to receive the Project UPLIFT intervention, a distance-delivered mindfulness-based cognitive therapy intervention. The intervention is conducted by phone for one hour once a week for 8 weeks.
2499034|NCT02909387|Active Comparator|Stratum B|This group will also receive the Project UPLIFT intervention at crossover, after a 10-week waiting period.
2499059|NCT02908932|Experimental|Phospholipid-bound omega-3 supplement|2.3g/d omega-3 HUFAs (with the EPA to DHA ratio of approximately 2:1), delivered in 8 capsules/day in Krill oil concentrates (Aker BioMarine Antarctic AS, Norway). Participants will receive supplements for the duration of IBOLC (19 weeks) and up until entry in Ranger. Time between completion of IBOLC and entry in Ranger is variable, ranging from 1 weeks to 10 weeks (4 weeks typical). Total duration on supplement thus ranges from 20 to 30 weeks.
2499061|NCT02908932|Placebo Comparator|Placebo supplement|Matching placebo capsules, substituting macadamia nut oil and appropriate colorant for krill oil. Macadamia nut oil has not been associated with psychological, cognitive, or health benefits. Furthermore, it is not typically consumed in large quantities and is therefore useful in tracking blood serum levels to assess compliance within the placebo arm. Placebo capsules have been produced by Aker Biomarine. As with the experimental arm, participants will take 8 capsules daily for the duration of the study (20-30 weeks).
2499129|NCT02908633|Active Comparator|canaloplasty ab externo and phacoemulsification|As soon as the two scleral flaps: deep and superficial -similar to deep sclerectomy are dissected, the phacoemulsification with PCIOL insertion is performed. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and guided for 360 degrees within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. Then a suture is tied to the distal tip and the microcatheter is withdrawn. As it appears at the other ostium of canal the microcatheter it separated from the suture.Then suture loop is tightened to tension the trabecular meshwork. The superficial flap is sutured watertight to prevent bleb formation
2500600|NCT02897687|Experimental|Facebook Group|Social skills training within an online group.
3195768|NCT00843063|Active Comparator|pantoprazole|pantoprazole 20 mg om and matching placebo nocte
2498491|NCT02913378|Active Comparator|Conservative|Conservative treatment with sling and rehabilitation
2498525|NCT02913014|Active Comparator|Arm 1- No AAD post Ablation|Subjects will not resume their Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation.
2498530|NCT02913014|No Intervention|Arm 2-Resume AAD post Ablation|Subjects will resume their pre-ablation Anti Arrhythmic Drugs after cryoballoon-ablation for paroxysmal atrial fibrillation, during the 90 day blanking period following the ablation.
2498605|NCT02912481|Experimental|Posterior tibial artery|real time ultrasound guided arterial catheterization on the posterior tibial artery
2498609|NCT02912481|Active Comparator|Radial artery|real time ultrasound guided arterial catheterization on the radial artery
2498610|NCT02912481|Active Comparator|Dorsalis pedis artery|real time ultrasound guided arterial catheterization on the dorsalis pedis artery
2498645|NCT02912143||newly diagnosed children with hemophilia|no intervention
2498668|NCT02911961|Experimental|Acetaminophen|Subjects will take extra strength acetaminophen (4g/day) for the three days prior to the embolization procedure.
2498671|NCT02911961|No Intervention|Observational - No Acetaminophen|Subjects will take no acetaminophen containing products prior to the embolization procedure.
2498776|NCT02911168|Active Comparator|Proximal Intercostal Block|See Intervention Section
2498782|NCT02911168|Active Comparator|Paravertebral Block|See Intervention Section
2498847|NCT02910635|Experimental|Volanesorsen, Intravenous (IV)|300 mg of volanesorsen (ISIS 304801) administered Intravenous (IV) single dose
2498853|NCT02910635|Experimental|Volanesorsen, Subcutaneous (SQ)|300 mg of volanesorsen (ISIS 304801) administered Subcutaneous (SQ) single dose
2498857|NCT02910635|Active Comparator|Moxifloxacin Hydrochloride|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
2498863|NCT02910635|Placebo Comparator|Placebo Intravenous (IV) single dose|Administered as normal saline (0.9% Sodium Chloride)
2498867|NCT02910635|Placebo Comparator|Placebo Subcutaneous (SC) single dose|Administered as normal saline (0.9% Sodium Chloride)
2498922|NCT02910180||Repository Group|The Repository Group consists of patients which have donated tissue to the repository.
2498946|NCT02909790|Experimental|CURVE LLLT treatment|Up to 20 subjects are randomly selected to receive Curve Low Level Laser Therapy
2498948|NCT02909790|Sham Comparator|SHAM device treatment|Up to 20 subjects assigned to the sham group will be treated with a device that is designed to have the same physical appearance as the treatment group, except that the interlock fuse (grey fuse holder back of device) will be removed prior to treatment. The laser screen will still be active and show to the subject that the treatment time will still be counting down, but will not activate lasers in the treatment paddles
2498987|NCT02909608||Controls|
2498990|NCT02909608||Children With Pulmonary Hypertension|
2499057|NCT02909283||Sickle cell disease patients|Physical exams and blood analyzes
2499099|NCT02908815|Experimental|4 weeks active treatment|4 weeks of rTMS active treatment applied using an active rTMS coil.
2499100|NCT02908815|Experimental|2 weeks active treatment|2 weeks of rTMS active treatment applied using an active rTMS coil.
2499101|NCT02908815|Sham Comparator|4 weeks sham treatment|4 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
2499102|NCT02908815|Sham Comparator|2 weeks sham treatment|2 weeks of rTMS sham treatment applied using a modified rTMS coil which does not stimulate the brain.
3162660|NCT00467064|Other|Delayed treatment control|After 4 month delay, participants in Control Group receive Experimental intervention.
2499203|NCT02908126|Experimental|Oxytocin intravenous|single dose of intravenous (IV) oxytocin
2499205|NCT02908126|Experimental|Oxytocin tablet|single dose of oxytocin tablet
2499242|NCT02907866||Patients undergoing bronchoscopy|All patients presenting for bronchoscopy (These patient are expected to have normal pleural sliding sign identified by ultrasound)
2499245|NCT02907866||Patients with pneumothorax|Patients with pneumothorax requiring chest tube(This group of patient is expected to have residual pneumothorax for identification of absence of lung sliding, B lines and lung point)
2499249|NCT02907866||Patients on mechanical ventilation|Patients with respiratory failure on mechanical ventilation(This group of patient is expected to have alveolo-interstitial findings such as B lines)
2499253|NCT02907853|Experimental|Contingency Management|In exchange for consecutive urine samples documenting methamphetamine abstinence, participants receive increasingly valuable reinforcers.
2499283|NCT02907632|Experimental|Metoclopramide|Blind and randomized allocation to the experimental treatment: Metoclopramide
2499287|NCT02907684|Experimental|Almonds|Almond snacks
2499295|NCT02907632|Placebo Comparator|Placebo|Blind and randomized allocation to placebo
2499296|NCT02907684|Placebo Comparator|Control muffins/crackers|Muffin/Cracker snacks
2499512|NCT02906176|Experimental|SLCO2B1 variant|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h (Day 1) - washout period - Vfend (voriconazole) 200 mg tablet once (Day 8)
3162661|NCT00467103||Chronic Stroke patients with Nonfluent Aphasia|patients with left hemisphere (LH) stroke who have chronic nonfluent aphasia
3162662|NCT00467116|Experimental|Therapeutic Intervention|
3162663|NCT00467194|Experimental|Phase I study of rapamycin and bevacizumab|"Rapamycin (available as 1mg per tablet; Wyeth) will be given orally once in the morning before meal. The starting dose of rapamycin will be 1mg administered once daily. All doses of rapamycin will be preceded by an oral loading dose three times the maintenance dose on day 1. The dose of rapamycin will be increased at each dose level.~Bevacizumab (100mg/4ml; Roche) will start concurrently with rapamycin. It will be diluted in a total of 100ml of 0.9% sodium chloride given via intravenous injection. The first dose will be infused over 90 minutes. If the first infusion is tolerated without any adverse infusion-related events (fever and/or chills), the second infusion may be delivered over 60 minutes. If the 60- minute infusion is well tolerated, the subsequent doses may be delivered over 30 minutes."
3162664|NCT00467207|Active Comparator|BoNT A|Botulinum toxin A injections in muscles of the arm (biceps brachii and brachialis)
3162665|NCT00467207|Experimental|Resistance training|8 weeks resistance training
3162666|NCT00467220|No Intervention|Control|Subjects will follow all study tasks but will not be required to follow a calorie-restricted meal plan.
3195769|NCT00843063|Active Comparator|famotidine|Famotidine 40 mg om and nocte
3195770|NCT00843089|No Intervention|1|Standard care
2498703|NCT02911740|Experimental|Urine LAM Ag test|Patients will be enrolled prospectively and tested for TB using the urine LAM Ag test
2498704|NCT02911740|No Intervention|Retrospective arm|Charts of retrospectively selected patients from the Hospital Santo Tomas database who presented within the last five years meeting inclusion criteria will be used as controls
2498730|NCT02911571|Experimental|MMprofiler SKY92|Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature
2498778|NCT02911272|Active Comparator|2-hour group|Augmentation of labour at 2-hour action line on the labour partograph
2498784|NCT02911272|Experimental|4-hour group|Augmentation of labour at 4-hour action line on the labour partograph
2498815|NCT02910817|Experimental|Metformin-treated group|51 overweight and obese women (BMI>24) with PCOS underwent their first fresh autologous IVF-embryo transfer cycle
2498817|NCT02910817|Placebo Comparator|Placebo|A cohort of fifty-one cross matched PCOS women
2498837|NCT02910518|Experimental|Insulin glulisine (U300) - Test formulation|Insulin glulisine (U300) will be given as a single subcutaneous (SC) dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
2498846|NCT02910518|Active Comparator|Insulin glulisine - Reference formulation|Insulin glulisine (U100) will be given as a single SC dose on Day 1 of each period under fasting conditions according to the random list and assigned sequence. Glucose, insulin aspart (IV) and heparin will be used for clamp procedure. NPH insulin (if necessary) and insulin aspart (SC) will be handed out at screening to change insulin regimen and glucagon at Day 1 to treat cases of severe hypoglycemia.
3195771|NCT00843089|Experimental|2|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
2499000|NCT02909582|No Intervention|Pfannenstiel Incision|This curved incision is approximately 10-15 cm long and 2 cm above the pubic symphysis. If a pannus is present, the pannus should be retracted up (see diagram) to allow placement of the Pfannenstiel incision.
2499003|NCT02909582|Experimental|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
2499043|NCT02909218|No Intervention|National HIV Treatment Guidelines|HIV-positive individuals are offered ART per Swaziland's national treatment guidelines
2499045|NCT02909218|Experimental|Early Access to ART for All|HIV-positive individuals are initiated on ART regardless of client's immunological and clinical staging
2499070|NCT02908919|Active Comparator|Fortrans pulv. sol|Polyethylene glycol solution. Used 4 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
2499075|NCT02908919|Active Comparator|Picoprep pulv. sol.|Natrium picosulfate/ magnesium citrate solution. Used 2 l before colonoscopy. bowel preparation interval: QD/BID or one day.
2499082|NCT02908919|Active Comparator|Moviprep pulv. sol.|Polyethylene glycol + ascorbic acid solution. Used 2 l before colonoscopy. Bowel preparation interval: QD/BID or one day.
2499139|NCT02908633|Active Comparator|canaloplasty ab interno and phacoemulsification|This variant of canaloplasty spares conjunctival surface. First phacoemulsification and PCIOL placement is performed. The Schlemm's canal is reached through goniotomy through anterior chamber. Similarly microcatheter is inserted and viscodilatator applicated. The key difference, is that no tensioning suture is left after the catheter is withdrawn. phacoemulsification is performed.
2499142|NCT02908633|Active Comparator|minicanaloplasty and phacoemulsification|The dissected conjunctival flap is of minimal size. The scleral flaps are sized: superficial flap 3x1mm, and deep flap: 1x1 mm- with no removal of the deep flap. Afterwards phacoemulsification part is performed. The microcatheterization and viscodilatation are conducted as in the traditional procedure.The conjunctiva is closed with one suture or coagulation
2499155|NCT02908412|Experimental|Digital nerve block in left hand|Patients in this group will receive DNB in left hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
2499157|NCT02908412|Experimental|Digital nerve block in right hand|Patients in this group will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
2499180|NCT02908165|Experimental|Group A- continuous schedule|Subjects with HCC randomized to group A
2499192|NCT02908165|Active Comparator|Group B- sequential schedule|Subjects with HCC randomized to group B
2499208|NCT02908113|Other|preterm infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
2499209|NCT02908113|Other|term infants|physiological data collection, behavioral, cerebral hemodynamics, physical environmental newborns studied in response to visual stimuli / auditory or visual-auditory calibrated
2499218|NCT02907957|Active Comparator|Caudal|Participants receiving a caudal neuraxial blockade, as clinically indicated.
2499222|NCT02907957|Sham Comparator|No Caudal|Participants not receiving a caudal neuraxial blockade, as clinically indicated.
2499257|NCT02907840|Experimental|Recruitment|Lung aeration monitored by Swisstom BB2 during PEEP steps and recruitment maneuver
3195772|NCT00843128|Experimental|1: RAGT|Following randomization, 20 patients will be treated with RAGT, 12 sessions over three weeks
3195773|NCT00843128|Active Comparator|2: Control|The control group will be treated by CWT, 12 sessions in three weeks.
3195774|NCT00843141|Experimental|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
3195775|NCT00843141|Active Comparator|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
3195776|NCT00843154|Experimental|Candesartan QD|
3195777|NCT00843154|Active Comparator|Standard chronic heart disease therapy|
3195778|NCT00843219||PET/CT Scan|
3195779|NCT00843232||Elderly T2DM|Elderly T2DM subjects 65 to 80 years old
2498756|NCT02911220|Other|blood sample for genetic evaluation|a blood sample is collected once for genetic analysis
3162667|NCT00467220|Other|Alternate Day Fasting Arm|Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
2498851|NCT02910583|Experimental|MRD Cohort Randomized ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity
2498856|NCT02910583|Placebo Comparator|MRD Cohort Randomized Placebo to match ibrutinib (blinded)|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-negative will be randomized to receive matching ibrutinib placebo capsules orally once daily on a continuous schedule until MRD-positive relapse, clinical disease progression or unacceptable toxicity.
2498862|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules and venetoclax 400 mg tablets orally once daily on a continuous schedule until clinical disease progression or unacceptable toxicity.
2498868|NCT02910583|Experimental|MRD Cohort Randomized open-label ibrutinib|Subjects will receive 420 mg capsules of single-agent ibrutinib for the first 3 cycles followed by ibrutinib plus venetoclax combination treatment for at least 12 cycles (a cycle is defined as 28 days) prior to randomization. Subjects that are MRD-positive will be randomized to receive ibrutinib 420 mg capsules orally once daily on a continuous scheduled until clinical disease progression or unacceptable toxicity.
2498869|NCT02910583|Experimental|Fixed Duration Cohort - Open Label ibrutinib + venetoclax|Subjects will receive 420 mg capsules of single agent ibrutinib for first 3 cycles followed by ibrutinib plus venetoclax combination treatment for 12 cycles (a cycle is defined by 28 days) or until disease progression or unacceptable toxicity.
2499056|NCT02908945|Experimental|Group 1|Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2499058|NCT02908945|Experimental|Group 2|Participants randomized to group 2 will receive a 0.25 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 5 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2499060|NCT02908945|Other|Group 3|Participants randomized to the control group will receive an equivalent anesthetic, without the addition of ketamine. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
2499125|NCT02908763|Experimental|Pegylated interferon group|Low replicative chronic HBV infection patients with HBsAg <1000 IU/ mL and HBV DNA<2000 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
2499133|NCT02908763|No Intervention|Observing Group|Only observing and following up in this group.
2499143|NCT02908802|Placebo Comparator|Placebo|Probiotic capsules without the active ingredient: two capsules twice a day
2499171|NCT02908243||Prophylaxis|Severe hemophilia A patients who receive factor VIII with dose of 15-25 IU/Kg, 2-3 times/week Severe hemophilia B patients who receive factor IX with dose of 30-50 IU/Kg, 1-2 times/week
2499174|NCT02908217|Experimental|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
2499181|NCT02908243||On-demand|Severe hemophilia A patients who receive factor VIII injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH); Severe hemophilia B patients who receive factor IX injection when bleeding occurs with the dose according to the criteria of World Federation of Hemophilia (WFH)
2499185|NCT02908217|Placebo Comparator|Placebo|6 Intravenous infusions of placebo (sterile sodium chloride solution) every 4 weeks
2499193|NCT02908243||Collection of baseline data in all hemophilia A and B patients|All severe, moderate and mild types of hemophilia A and B patients
2499341|NCT02907294|Experimental|PBF-999|
3162668|NCT00467220|Other|Calorie Restriction|Subjects in this arm will be asked to follow a calorie-restricted meal plan, daily, for three months.
3162669|NCT00467376|Experimental|1|Administration of Insulin Glulisine
3162670|NCT00467376|Active Comparator|2|Administration of Lispro
3162671|NCT00467402|Experimental|1|
3162672|NCT00467402|Experimental|2|
3162673|NCT00467402|Placebo Comparator|3|
3162674|NCT00467454|Active Comparator|1|Naltrexone
3162675|NCT00467454|Placebo Comparator|2|Placebo
3162676|NCT00467493|Experimental|Anastrozole - A|Treatment for 26 consecutive days
3162677|NCT00467493|Experimental|Anastrozole -B|Treatment for 7 consecutive days early in menstrual cycle
3162678|NCT00467493|Experimental|Anastrozoe - C|Treatment for 7 consecutive days mid follicular phase
3162679|NCT00467493|Experimental|Anastrozole - D|Treatment for 7 consecutive days - mid cycle
3162680|NCT00467493|Experimental|Anastrozole - E|Treatment for 7 consecutive days - luteal
3162681|NCT00467493|Placebo Comparator|Anastrozole - F|Treatment with placebo for 26 consecutive days
3175000|NCT00629070|Experimental|ST|Traditional strength training
2498695|NCT02911766|Active Comparator|Corsodyl, 0.2% mouthrinse|"The comparator solution was Corsodyl, 0.2% Chlorhexidine mouthrinse,~Intervention Rinsing 60 sec with Comparator solution twice daily for 21 days"
2498697|NCT02911766|Experimental|FluxProKlorhexidine 0.12% mouthrinse|"The experimental solution was FluxProChlorhexidine 0.12% mouthrinse~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
2498698|NCT02911766|Experimental|Corsodaily 0.06% mouthrinse|"The second experimental solution was Corsodaily, 0.06% chlorhexidine mouthrinse.~Intervention Rinsing 60 sec with test solution twice daily for 21 days"
2498740|NCT02911532|Experimental|Optical Coherence tomography|
2498762|NCT02911259|Experimental|Group 1|Post-operative suction is set to -2 cmH2O.
2498764|NCT02911259|Active Comparator|Group 2|Post-operative suction is set to -10 cmH2O (standard treatment).
2498797|NCT02910986|No Intervention|Usual Care|Breast density notification using standard language reporting for dense and non-dense breasts within the mammogram results notification letter
2498804|NCT02910986|Active Comparator|Enhanced|Usual Care plus a written educational brochure
2498808|NCT02910986|Active Comparator|Interpersonal|Usual Care plus Enhanced plus interaction with a promotora (lay health educator)
2498838|NCT02910505|Experimental|Treatment|Treatment with investigational Cutera enlighten laser for tattoo removal
2498908|NCT02910336||Cases|Orofacial Pain patients under went to quantitative sensory test
2498910|NCT02910336||Control|Volunteers and presented neither previous diagnostic of orofacial pain nor generalized pain, under went to quantitative sensory test
2498970|NCT02909881|Experimental|Endurance trained male cyclists|8 male endurance trained male cyclist will consume varying amounts (0, 1, 1.5 and 2 g/min) of PhytoSpherix (sweet-corn derived sugar) during a 150 min . cycling exercise
2499049|NCT02909270|Experimental|Mediclore|adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy
2499051|NCT02909270|No Intervention|No treatment|No treatment, standard treatment for thyroidectomy
2499086|NCT02908867||Therapeutic strategies group|To know the main therapeutic strategies used by men with spinal cord injury in sexual dysfunctions, mainly medicinal plants.
3195780|NCT00843232||Middle-age T2DM|Middle-age T2DM subjects 35 to 50 years old
3195781|NCT00843245||heart failure|Heart failure attending a HF clinic with or without clinical decompensation
2499146|NCT02908646|Placebo Comparator|hookwire|patients who plan for hookwire localization
2499168|NCT02908204||Endoscopic treatment|Patients underwent endoscopic treatment including Endoscopic Mucosal Resection (EMR), Endoscopic Submucosal Dissection (ESD), Multiband Mucosectomy (MBM), Endoscopic Mucosal Band Ligation(EMBL) and so on.
2499169|NCT02908204||Traditional surgery|Patients underwent traditional surgery
2499244|NCT02908061|Active Comparator|Surgery (Usual approach group)|standard surgery
2499247|NCT02908061|Experimental|Surgery + Mesh Placement|prophylactic mesh at the time of standard surgery
2499282|NCT02907567|Active Comparator|Active Treatment-Low|6 subjects randomized to 280 mg (Low) CT1812
2499292|NCT02907567|Active Comparator|Active Treatment-High|6 subjects randomized to 560 mg (High) CT1812
2499303|NCT02907567|Placebo Comparator|Placebo|4 subjects randomized to matching placebo of CT1812
2499323|NCT02907112|No Intervention|Control|Participants to continue on their habitual diet for 4 weeks
2499326|NCT02907112|Experimental|Meat Reduction|Participants asked to reduce their red and processed meat intake by 50% for 12 weeks
2499331|NCT02907125|Experimental|SM arm|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
2499334|NCT02907125|Active Comparator|Comparison arm Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
2499369|NCT02907034|Experimental|Group 1|First,Virtual reality approach (VR), then classical narrative approach (CN)
2499370|NCT02907034|Active Comparator|Group 2|First, classical narrative approach (CN), then virtual reality approach
2499391|NCT02906995|Experimental|Sublingual tablet 4 mg|The 24 study participants will be administered the sublingual 4 mg nicotine tablet on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
2499392|NCT02906995|Active Comparator|Nicorette lozenge 4 mg|The 24 study participants will be administered the Nicorette lozenge containing 4 mg of nicotine on one occasion. Blood samples will be obtained for 4 hours for analysis of nicotine plasma levels.
2499436|NCT02906462|Other|Usual Practices|Usual Practices
3195782|NCT00843258|No Intervention|Active Sonographic surveillance|Follow-up at 1.5 and 3 months (Ultrasound,Clinical examination), at 6 and 12 months (clinical examination, pelvic X-ray)
3195783|NCT00843258|Experimental|Abduction treatment|Treatment (abduction splint) from 0-6 weeks, follow-up at 1.5 and 3 months (clinical examination and ultrasound) and at 6 and 12 months (clinical examination and pelvic x-ray)
3195784|NCT00843271||MESA Lung|MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
3195785|NCT00843297|Active Comparator|CG|Coolgard: invasive Cooling
3195786|NCT00843297|Active Comparator|AS|ArcticSun: Surface-Cooling
3195787|NCT00843297|Sham Comparator|UnCOOL|No Cooling-Therapy due to non-operational cooling-devices
3195788|NCT00843336|Experimental|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that measures urinary estrogen and LH and provides users with low, high, or peak fertility readings.
2498734|NCT02911597|Experimental|B: Ketamine + Naltrexone or placebo|"Patients will receive two infusions of Ketamine 0.5mg/kg divided into two phases Phase A and Phase B, which are separated by 30 days.~Patients will be randomly assigned to receive either Naltrexone 50 mg or a matched placebo in both Phase B and A. The Naltrexone or placebo will be given 45 min prior to the administration of ketamine 0.5 mg/kg (e.g. patient X assigned to arm X. Arm X is assigned to Ketamine 0.5mg/kg plus Naltrexone 50 mg during Phase A then when transitioning to Phase B they would receive Ketamine 0.5mg/kg plus a matched placebo). In Phase B will then be followed for 30 days with study assessments to examine the durability of Ketamine effects then once at day 30 for transition."
2498748|NCT02911298|Experimental|Mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation is administered to subject in fasted state
2498749|NCT02911298|Active Comparator|Non-mucoadhesive formulation|A single dose of 100 mg Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation is administered to subject in fasted state
3162682|NCT00467571|Experimental|I|Drug: lansoprazole, clarithromycin, amoxycillin
2498825|NCT02910804|Experimental|68Ga-BBN-IRDye800CW PET/NIRF|The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.
2498859|NCT02910388|Experimental|LLETZ with colposcopy|The LLETZ procedure will be performed under direct colposcopic vision
2498866|NCT02910388|Active Comparator|LLETZ without colposcopy|The LLETZ procedure will be performed without colposcopy
2498912|NCT02910232||1|The groups were orthopedic patients and neurosurgical patients. The samples to fill the voiding space of bone and skull same as autografts.
2498971|NCT02909842|Experimental|study group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of yoghurt drink, unlabelled drinking fermented milk containing probiotic, Lactobacillus paracasei (IMULUS)
2498975|NCT02909842|Placebo Comparator|control group|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB) and 100 ml bottle of placebo, unlabelled acidified milk with similar physical and sensory appearance to the experimental one
2499052|NCT02909361||Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
2499094|NCT02908828|Experimental|Calanus oil|4 capsules of 500 mg Calanus oil once every day
2499096|NCT02908828|Placebo Comparator|Placebo|4 capsules of 500 mg dietary oil once every day
2499163|NCT02908321|Active Comparator|CBT|
2499165|NCT02908321|No Intervention|WL|
2499223|NCT02908048||Hepatocellular Carcinoma|Blood samples will be collected at entry into the study and at varying intervals over a two to three year period.
2499225|NCT02908048||Biliary Tract Cancer|Blood samples will be collected at entry into the system and at varying intervals over a two to three year period.
2499226|NCT02908048||Cirrhosis|Blood samples will be collected during regular intervals over a three year period.
2499228|NCT02908048||Chronic Liver Disease without Cirrhosis|A single blood sample will be collected at entry into the study
2499236|NCT02908087|Active Comparator|Victoza® (liraglutide)|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30 years, and treated with insulin are treated with Victoza®
2499239|NCT02908087|Placebo Comparator|Placebo|Subjects with early diagnosis of type 1 diabetes (no symptoms, diagnosis in OGTT) aged 10-30, and treated with insulin are treated with placebo
2499260|NCT02907671|Active Comparator|Group A|carpal tunnel corticoanesthetic injection between the flexor tendons
2499262|NCT02907671|Active Comparator|Group B|carpal tunnel corticoanesthetic injection next to the median nerve with hydrodissection
2499276|NCT02907710|Experimental|concurrent chemoradiotherapy + endostar|"Drug: Endostar~Endostar 7.5mg / m2,3 cycles of intravenous infusion for ten days, and 2 cycles of maintenance therapy after radiotherapy~Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
2499277|NCT02907710|Active Comparator|concurrent chemoradiotherapy|"Drug: DDP~DDP 100mg / m2, intravenous infusion over 2 hours , for 2-3 cycles~Radiation: IMRT~IMRT:70-74Gy"
2499293|NCT02907424|Active Comparator|BP-100|standard treatment
2499301|NCT02907424|Experimental|Num Trey|locally produced RUTF
2499337|NCT02907333|Active Comparator|Intervention group|Women who are advised to use condom during the time period between diagnosis and follow-up
2499343|NCT02907164|Experimental|Group 2: Norm|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up.
2499344|NCT02907333|No Intervention|Control group|Women who are not contacted with advise to use condoms
2499346|NCT02907164|Experimental|Group 3: Norm and health motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay fit in a fun way.
2499349|NCT02907164|Experimental|Group 4: Norm and reward motive|People receive emails encouraging them to sign up for the challenge. The email mentions the number of people who have signed up AND highlights that the challenge helps people to stay active and earn rewards.
2499353|NCT02907242|No Intervention|Concealment|Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
2499358|NCT02907242|Other|Revealment|Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5
2499407|NCT02906943||Advanced cancer|Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.
3162683|NCT00467636|Experimental|Insulin Glulisine|Blood glucose monitoring and treatment of hyperglycaemia with insulin. Insulin to be with-held if pre meal blood glucose < 4 mmol/l.
3162684|NCT00467636|Active Comparator|2|Blood glucose monitoring for comparison with treatment arm (1)
3162685|NCT00467688|No Intervention|A,1|Real time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
3162686|NCT00467688|No Intervention|A,2|Retrospective analysis of glucose values
3162687|NCT00467714|No Intervention|1|2.5 cm Cartilage as columella strut
3162688|NCT00467727|Experimental|1|Phase Contrast Mammography Exam
3162689|NCT00467883|Experimental|amphotericin B|Treatment with high dosage of amphotericin B liposomal 10 mg/kg/day during 4 weeks
3162690|NCT00467974|Experimental|1|TEA with LEM
3162691|NCT00467974|Active Comparator|2|TACE
3162692|NCT00467987|Experimental|androgel|androgel
2499172|NCT02908399|Experimental|Thermal Imaging|Imaging using a thermal camera
2499195|NCT02908191|Experimental|ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys|ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days
2499240|NCT02908022|Experimental|Interaction|"Phase 1:~Prior to the MRI sessions, the clinician will be introduced to the patient and do a general intake of physical examination.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
2499241|NCT02908022|Experimental|No Interaction|"Phase 1:~The clinician and the patient will first be introduced at the MRI sessions.~During the MRI sessions, the patient will receive experimental pressure pain via the Hokanson Rapid Cuff Inflator and electroacupuncture analgesia to the leg for pain relief."
2499243|NCT02908022|Experimental|Longitudinal|"Phase 2:~Prior to first MRI session, both clinician and patient will go through a training visit.~During the first MRI session, the patient will receive experimental pressure pain to the left leg via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief.~Following the first MRI session, the patient will attend biweekly acupuncture treatment sessions with the clinician (6 treatments total). During the first session the clinician will be introduced to the patient and do a general intake in addition to the acupuncture treatment.~The final MRI session will be identical to the first. The patient will receive experimental pressure pain via Hokanson Rapid Cuff Inflator and electroacupuncture to the same leg for pain relief."
2499250|NCT02907827|Experimental|stage IV melanoma CR>3years|Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging
2499252|NCT02907827|Experimental|Stage III Melanoma|AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging
2499271|NCT02907593|Experimental|0.025 mg/kg Budesonide|0.025 mg/kg Budesonide in Calfactant
2499272|NCT02907593|Experimental|0.050 mg/kg Budesonide|0.050 mg/kg Budesonide in Calfactant
2499273|NCT02907593|Experimental|0.10 mg/kg Budesonide|0.10 mg/kg Budesonide in Calfactant
2499274|NCT02907593|Experimental|0.15 mg/kg Budesonide|0.15 mg/kg Budesonide in Calfactant
2499328|NCT02907320|Experimental|CYCLO 3 ® FORT and placebo MPFF|MPFF = Micronized Purified Flavonoid Fraction
2499335|NCT02907320|Active Comparator|MPFF and placebo CYCLO 3 ® FORT|MPFF = Micronized Purified Flavonoid Fraction
2499339|NCT02907320|Placebo Comparator|placebo|MPFF = Micronized Purified Flavonoid Fraction
2499345|NCT02907294|Placebo Comparator|Placebo|
2499389|NCT02906904|Experimental|CASE (adult sleepwalking patients)|
2499390|NCT02906904|Experimental|CONTROL (adult healthy volunteers)|
2499416|NCT02906618|Experimental|LY3039478 - Oral|LY3039478 given once, orally
2499417|NCT02906618|Experimental|13C 15N 2H-LY3039478 - IV|13C 15N 2H-LY3039478 given once, IV
2499424|NCT02906527||Non-exposed group|Non-exposed group / Patients receiving VKA
2499427|NCT02906527||Exposed group|Exposed group / Patients receiving DOAC
2499447|NCT02906345|Active Comparator|TPE-Centrifugation|Patients with septic shock, therapeutic plasma exchange, plasma separation using a centrifuge (Fresenius COM-TEC, PL1 Erythrozytapherese/Plasmabeutel Set) BMC standard treatment
2499463|NCT02906293||Healthy Participants|Potential participants will self-refer.
2499468|NCT02906254||ECIL-4 guidelines group|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st February 2014 to 30th November 2014, antibiotics were stopped when patients had been afebrile for more than 48 hours, as recommended by the ECIL-4 guidelines"
2499473|NCT02906254||short-course antibiotic therapy|"For the FUO group, antibiotics were stopped based on two procedures, irrespective of the neutrophil count or expected duration of neutropenia:~- From 1st December 2014 to 30th September 2015, antibiotics were stopped on day 5 in febrile or afebrile patients (short-course antibiotic therapy)."
3162693|NCT00467987|Placebo Comparator|placebo|placebo gel
3162694|NCT00467987|No Intervention|no treatment|eugonadal comparison arm
3162695|NCT00468000|Experimental|Ixmyelocel-T|The treatment arm of the study will receive injections of the study cellular product.
3162696|NCT00468000|Placebo Comparator|Placebo|The control arm of the study will receive placebo injections.
3162697|NCT00468013|Experimental|1|Computer-based exercises to be executed at home.
3162698|NCT00468013|Sham Comparator|2|Computer-based exercises to be executed at home.
3162699|NCT00468039|Experimental|vildagliptin + metformin|
3162700|NCT00468065|Experimental|A|TO use Veinviewer to improve the effectiveness of IV starts in children
3162701|NCT00468065|No Intervention|B|Standard approach to placing IV s in children
3162702|NCT00468078|Experimental|A|Parkinson's disease
3162703|NCT00468078|Active Comparator|B|ET+Normal
3162704|NCT00468091|Placebo Comparator|saline-saline|"saline IV~+ saline IV"
3162705|NCT00468091|Active Comparator|saline-exendin(9-39)amide|"saline IV~+ exendin(9-39)amide IV"
3162706|NCT00468091|Active Comparator|saline-atropine|"saline IV~+ atropine IV"
3162707|NCT00468091|Active Comparator|exendin(9-39)amide-atropine|"exendin(9-39)amide IV~+ atropine IV"
3162708|NCT00468117|Experimental|Islet transplantation|Up to three separate islet transplants will occur and a regimen of immunosuppressive medications consisting of antithymocyte globulin (ATG) and etanercept throughout study.
3162709|NCT00468130|Experimental|Aripiprazole|Subjects in the experimental group will receive Aripiprazole
3162710|NCT00468130|Placebo Comparator|Placebo|Subjects in the control group will receive sugar pill
3162711|NCT00468156|Active Comparator|1|written materials only
3162712|NCT00468156|Experimental|2|written materials plus asked to form implementation intentions
3162713|NCT00468156|Experimental|3|same as arm 2 plus telephone support
3175001|NCT00629070|Experimental|VT|Velocity-enhanced training
3195789|NCT00843336|Active Comparator|Cervical mucus monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
2498826|NCT02910765|Active Comparator|M methylene blue and ozone|intravenous methylene blue and blood mixed with ozone ozone injection in early sepsis patients
2498827|NCT02910765|Placebo Comparator|P Placebo|saline and oxygen mixed blood injection in early sepsis patients
2498842|NCT02910375|Other|Cohort A|Patients starting golimumab therapy Week 0: 200 mg Week 2: 100 mg Week 6, 10, 14, and 18: 50 mg (<80 kg) or 100mg (>80 kg body weight)
2498850|NCT02910375|Other|Cohort B|Patients already on golimumab therapy will continue their actual treatment 50 mg every 4 weeks (<80 kg) or 100mg every 4 weeks (>80 kg body weight)
2498906|NCT02910219|Experimental|Treatment|Patients on the treatment arm will take one tablet of crofelemer twice a day (each tablet is 125 mg), to be swallowed whole without chewing or crushing, during cycles 1-2 of chemotherapy with THP or TCHP. Patient will be monitored off crofelemer during cycle 3 of chemotherapy.
2498909|NCT02910219|No Intervention|Control|Patients on the control arm will be on the study for cycles 1-3 of THP or TCHP. Patients on the control arm will not receive crofelemer at any time on this study.
2498965|NCT02909829|Experimental|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
2498967|NCT02909829|Experimental|Closed Loop Delivery with Meal Detection Module|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm. Participants will eat breakfast and bolus, then eat lunch and not bolus.
2498968|NCT02909829|Active Comparator|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate. Participants will eat breakfast and bolus as per usual, then eat lunch and not bolus.
2499026|NCT02909400|Experimental|Treatment A|Oral administration of 100 mg KH176 twice daily
2499035|NCT02909400|Placebo Comparator|Treatment B|Oral administration of matching placebo twice daily
2499066|NCT02908958|Experimental|PEG-somatropin|Low dose group, PEG Somatropin 0.14mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
2499068|NCT02908958|Experimental|PEG-Somatropin|High dose group, PEG Somatropin 0.2mg/kg/week, subcutaneous use, inject once a week, the duration is 26 weeks.
2499112|NCT02908503|Other|1 x 2 inch PVA based film|1 x 2 inch polyvinyl acetate (PVA) based vaginal film
2499116|NCT02908503|Other|2 x 2 inch PVA based film|2 x 2 inch polyvinyl acetate (PVA) based vaginal film
2499117|NCT02908503|Other|1 x 2 cellulose based film|1 x 2 cellulose based vaginal film
2499119|NCT02908503|Other|2 x 2 cellulose based film|2 x 2 cellulose based vaginal film
2499177|NCT02908334|No Intervention|Standard of Care|standard of care treatment for disseminated or meningeal coccidioidomycosis
2499186|NCT02908334|Experimental|Standard of Care + Sertraline|Standard of care treatment with the addition of sertraline for the treatment of disseminated or meningeal coccidioidomycosis
3195790|NCT00843362|Experimental|1|24-hours vaginal dinoprostone pessary
3195791|NCT00843362|Active Comparator|2|Vaginal dinoprostone gel
2499256|NCT02907801|Experimental|Perception-Action Approach|Perception-Action Approach (P-AA) intervention components include environmental set-up for activity and participation in play, manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions, and caregiver education in modifications to everyday activities consistent with the P-AA. All components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing the environmental supports and therapist's hands to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
2499278|NCT02907697|Experimental|LifeSteps-Drug Use|The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach. The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions. While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
2499281|NCT02907697|Active Comparator|Health Education|The health education condition is a time-matched, active control arm. It will consist of two in-person sessions and two telephone sessions. Each session will cover a general health education topic.
2499285|NCT02907502|Experimental|Experimental formula|Young-child formula with low protein content
2499300|NCT02907502|Active Comparator|Control formula|Young-child formula with protein content similar to that of cow's milk
2499327|NCT02907190|Experimental|Bean Type|Beans (black; cranberry; great northern; navy; pinto; red) soaked overnight and boiled. 1/2 cup serving eaten by participants at study visit
2499333|NCT02907190|Active Comparator|Starchy Foods|1/2 cup serving of rice or paste or potato or corn will be eaten by participants on different study visit
2499342|NCT02907229|Experimental|Treatment group|neuroendovascular therapy(NCVC-CS1)
2499386|NCT02906956|Experimental|Preferred Music Playlist|All participants will have this phase twice in the protocol. See description in intervention section.
2498796|NCT02910960|Active Comparator|Acquire EUS Biopsy Device|All patients will undergo sampling of pancreatic masses using the Acquire EUS Biopsy Device. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2498803|NCT02910960|Active Comparator|SharkCore Biopsy System|All patients will undergo sampling of pancreatic masses using the SharkCore Biopsy System. Both needles will be used, but the needle to be used first will be based on randomization. A minimum of at least one pass and a maximum of 8 passes will be performed using both needle types.
2498871|NCT02910544||Intensive dietary intervention|Supervised dietary weight loss program lasting 8 weeks.
2498999|NCT02909556|Experimental|ACURATE neo AS|
2499063|NCT02909205|Other|control|First phase : before training / sensitization / booklet delivery
2499067|NCT02909205|Other|post intervention|Second phase : after training / sensitization / booklet delivery
2499109|NCT02908776|Experimental|Dietary supplement - Probiotics|4 sachets of Ecoviesel (probiotics) per day for at least 2 weeks before undergoing a coronary angiography with possible ad hoc angioplasty; and 2 sachets of probiotic per day after angioplasty, if performed.
2499114|NCT02908776|Placebo Comparator|Placebo|Sachets with inactive substance indistinguishable from Ecoviesel
2499178|NCT02908360||Patients with allergic rhinitis|Patients with rhinitis and / or allergic conjunctivitis duly diagnosed according to the ARIA criteria
2499187|NCT02908360||Patients with atopic dermatitis|The patient has moderate classified atopic dermatitis (SCORAD 25 to 50) or severe (SCORAD> 50).
2499194|NCT02908360||Patients with allergic asthma|The patient has allergic asthma diagnosed according to the criteria GINA21
2499215|NCT02907905|Other|Population homeless or living in slum|Population homeless or living in slum realizing realizing a capillary sampling
2499217|NCT02907931|Experimental|Subjects|Lower Body Negative Pressure
2499264|NCT02907749|Active Comparator|Carvedilol|Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
2499266|NCT02907749|Experimental|Spironolactone and carvedilol|"Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose~Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose"
2499279|NCT02907515|Experimental|cm-loc attachment|cm-loc attachment is a new attachment for dental implants and connect to the denture with resin matrix as housing
2499280|NCT02907515|Active Comparator|ball attachment|ball attachment is the most common attachment for dental implants and connect to the denture by nylon cap and metal housing
2499289|NCT02907411|Experimental|Quadrivas Therapy|Hands on therapy to improve all aspects of fat tissue including the vessels within. Each of 7 subjects receive 12 treatments in one month time.
2499354|NCT02907255|Experimental|Oximetry monitor|"Standard care plus~Wireless respiratory monitoring~Covidien~Alarm triggers:~SpO2 ≤89% (heart rate) HR < 50 or > 120"
2499357|NCT02907255|No Intervention|Standard of Care|"• Standard care:~1:4 patient to nurse ratio~Vital signs every 4 hours~Respiratory rate and sedation scores every 2 hours for patients on the Acute Pain Service"
2499372|NCT02906982|Experimental|Gum health formulation in intra-oral device|The interventional gum health formulation is applied to the participant's mouth by means of an intra-oral device for a single eight-minute application, daily. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night.
2499375|NCT02906722|Experimental|Experimental group|Patients receive simultaneously nebulized colimycin every 8 h and intravenous placebo administered once, twice or 3 times per day according to renal function
2499377|NCT02906982|Experimental|Gum health formulation on toothbrush|The interventional gum health formulation is applied to the participant's mouth by means of a toothbrush and toothpaste, plus the gum health formulation, for two-minute applications, twice daily, morning and night.
2499379|NCT02906722|Active Comparator|Control group|Patients receive simultaneously intravenous colimycin administered once, twice or 3 times per day according to function renal and nebulized placebo every 8 h
2499380|NCT02906982|No Intervention|Control group (split-mouth design)|The control group did not receive the interventional gum health formulation. Participants instructed to brush their teeth with a toothbrush and toothpaste twice daily, morning and night. In addition, participants instructed to floss only half of their mouth daily, and the non-flossed half serves as the untreated comparative control receiving no intervention.
2499425|NCT02906501||Group I (n=15)|Male children and adolescents diagnosed with ADHD not treated with risperidone or any other antipsychotic treatment.
2499426|NCT02906501||Group II (n=15)|Male children and adolescents diagnosed with ADHD intended to start risperidone or any other antipsychotic treatment due to behavioral problems.
2499428|NCT02906501||Group III (n=15)|Male children and adolescents diagnosed with ADHD treated with risperidone or any other antipsychotic treatment due to behavioral problems.
2499444|NCT02906553|Experimental|Glyceryl Trinitrate|Glyceryl Trinitrate, sublingual spray, 3 x 0.4mg dose, once per day for 3 days in total.
2499448|NCT02906553|Placebo Comparator|Placebo|The formulation composition of the placebo will be the same as the active spray minus the Glyceryl Trinitrate.
2499513|NCT02905916|Experimental|PEG-rhG-CSF|
3195796|NCT00843388|Active Comparator|1|60 days treatment with tablet hexalacton 25 mg OD.
3195797|NCT00843388|Placebo Comparator|2|Inactive drug of 25 mg OD
3195798|NCT00843427|Experimental|Aphasia - CIAT|Patients with aphasia >1 year after left MCA stroke who will be randomized to receive CIAT
3195799|NCT00843427|No Intervention|Aphasia - observation|Patients with aphasia >1 year after left MCA stroke who will be randomized to no intervention (observation)
3175002|NCT00629096|Experimental|1|All included patients are assigned to arm 1, in which they are treated by the intervention
2498873|NCT02910427|Placebo Comparator|Na salt|regular salt
2498882|NCT02910427|Active Comparator|K salt|potassium-enriched salt
2498885|NCT02910427|Active Comparator|K/Mg salt|potassium and magnesium-enriched salt
2498989|NCT02909647|Active Comparator|Plan group|3D preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
2498992|NCT02909647|Active Comparator|Control group|Conventional preoperative planning for the distal radius fracture was performed prior to the osteosynthesis.
2499050|NCT02909244||Patients with PID|Biological sampling: collection of feces. In case of blood samples availability in hospital biobank : analyzes of these samples in the frame of this research
2499053|NCT02909244||Control patients, with no PID|Biological sampling: collection of feces.
2499261|NCT02907658|Experimental|PROTECT intervention group|The PROTECT intervention group receives the preventive intervention PROTECT (4 modules in 4 subsequent weeks à 90 min). Participants are assessed at T1 (baseline), T2 (post treatment, 1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
2499263|NCT02907658|No Intervention|Assessment-only control group|The assessment-only control group is an observational condition without intervention. Participants are assessed at T1 (baseline), T2 (1-month follow-up), T3 (4-months follow-up), and T4 (12-months follow-up).
2499383|NCT02906748|Experimental|new site for parathyroid auto-graft|choose the site fairly close to the antecubital vein for parathyroid auto-transplantation
2499384|NCT02906748|Active Comparator|traditional parathyroid autograft|choose not intensely close to antecubital vein for parathyroid auto-transplantation
2499432|NCT02906488||Patients with Parkinson's Disease|
2499450|NCT02906449|Active Comparator|Relaxation Meditation Training|Daily Relaxation Meditation Training - both in-class lectures (weekly) and self-study (daily) over 3 weeks
2499467|NCT02906228|Experimental|GSM 900 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
2499469|NCT02906241|Other|Physicians|Physicians receive the intervention approximately halfway through data collection for a within subjects, pre-post intervention comparison
2499514|NCT02905942|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day +1 after transplantation.
3175003|NCT00629135|Experimental|1|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 1: Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily.
3175004|NCT00629135|Active Comparator|2|For adult patients with intra-abdominal abscesses matching the criteria to be included will and enrolled in the study arm 2: Piperacillin / Tazobactam 4,5 g administered intravenously three times daily
3175005|NCT00629148|Active Comparator|combination chemotherapy|Simultaneous use of Vinorelbine and Capecitabine
3175006|NCT00629148|Experimental|sequential chemotherapy|Sequential use of Vinorelbine and Capecitabine
3175007|NCT00629161|Experimental|A|
3175008|NCT00629161|Placebo Comparator|B|
3175009|NCT00629174|Experimental|1|Exercise
3175010|NCT00629174|Experimental|2|Mental training (computer lessons)
3175011|NCT00629174|No Intervention|3|
3175012|NCT00629187|Experimental|1|
3175013|NCT00629200|Experimental|SSG + Intron A|Sodium Stibogluconate (SSG) 400 mg/m^2 intravenous (IV) daily on days 1-5 + Interferon Alfa-2b (Intron A) 3x10^6 units subcutaneously three times weekly
3175014|NCT00629213|Active Comparator|1|
3175015|NCT00629213|Placebo Comparator|2|
3175016|NCT00629226|Experimental|Group I|Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, 43, and 50. Patients also receive bortezomib IV over 3-5 seconds on days 1, 4, 8, 11, 22, 25, 29, 32, 43, 46, 50, and 53. Beginning on day 8 or 9, patients undergo standard intensity-modulated radiotherapy (IMRT) once daily, 5 days a week, for up to 8 weeks.
3175017|NCT00629226|Experimental|Group II|Patients receive cetuximab, bortezomib (beginning at one dose level below the MTD determined in group I), and IMRT as in group I. Patients also receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, and 57.
3175018|NCT00629252|Experimental|1|Schizophrenic patients treated with sertindole
3175019|NCT00629252|Active Comparator|2|Schizophrenic patients treated with risperidone
3175020|NCT00629252|No Intervention|3|Healthy controls without any treatment.
3175021|NCT00629291||1|Sickle cell anemia patients
3175022|NCT00629291||2|Sickle cell β thalassemia
3175023|NCT00629304|Placebo Comparator|1|standard visit at 3 and 6 months
3175024|NCT00629304|Active Comparator|2|PDA-FIT system + standard visit at 3 and 6 months
3175025|NCT00629304|Active Comparator|3|PDA-FIT system + 12 telephone visits + standard visit at 6 months
3175026|NCT00629317|Active Comparator|A|
3175027|NCT00629317|Placebo Comparator|B|
3175028|NCT00629330|Experimental|Multi-component Academic Detailing|Includes an interactive, digitized CDROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients.
3175029|NCT00629343|Experimental|Treatment|
3175030|NCT00629369|Experimental|A|subjects with Occlusion Support Device with active pushing in the second stage of labor
3175031|NCT00629369|No Intervention|2|Subjects without Occlusal Support Device with active pushing in the second stage of labor
3175032|NCT00629382|Experimental|1|
3175033|NCT00629382|Other|2|
3175034|NCT00629395|Experimental|1|Participate in 12 week computer program.
3175035|NCT00629434|Experimental|1|This arm will receive diabetes education via telemedicine
3175036|NCT00629434|Active Comparator|2|diabetes education in-person
3175037|NCT00629447|Experimental|1|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
2498854|NCT02910596|Experimental|B|"Early bladder training Start on 3rd - 5th postoperative day~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
2498858|NCT02910596|Experimental|C|"Early bladder training and Ucholine(Bethanechol chloride, 10 mg) 2 tablets oral tid, ac Start on 3rd - 5th postoperative day~should be vital signs were monitored every 30 minute on first hour then every 4 hours on first day. Any adverse event were recorded.~Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative"
2498864|NCT02910596|Other|D|-Remove urethral catheter on 5th postoperative day. Void volume and postvoid residual urine were recorded. Intermittent urethral catheterization was used to measure postvoid residual urine. If postvoid residual urine was more than 100 cc in two consecutive measurement, the urethral catheter was reinserted, and medication would be continue until the catheter cloud be removed but medication were not given for more than 1 month. Postvoid residual urine, urinalysis were evaluated at 1 month postoperative
2498903|NCT02910141||CSII (subcutaneous insulin infusion)|People with Type 2 diabetes treated by continuous subcutaneous insulin infusion (CSII)
2498904|NCT02910141||MDI (multiple daily insulin injections)|People with type 2 diabetes treated by multiple daily insulin injections
3195800|NCT00843440|Experimental|Bevacizumab|Study using a Gehan design, 7 patients will be included in the first phase and 18 additional patients will enter the second phase.
3195801|NCT00843453|Other|1|Comparison of serum vitamin and B12 concentrations of PPI and non-PPI groups
3195802|NCT00843453|Experimental|2|Comparison of baseline and end of treatment serum vitamin B12 and MMA concentrations.
3195803|NCT00843505|Experimental|1|Participants will take part in a telemedicine smoking cessation program.
3195804|NCT00843505|Active Comparator|2|Participants will take part in a telephone quitline smoking cessation program.
2499124|NCT02908594|Experimental|exercise group|Using the Medical Exercise Peddler 3000, Medi-Bike, Taiwan as an exercise tool. Exercise group received routine care and 3- months exercise. The exercise was performed during the first 2 hr of each haemodialysis session (30 min per session, 3 sessions per week for 3 months).
2499138|NCT02908594|No Intervention|control group|The control group received routine care
2499179|NCT02908282|Other|PUFA (polyunsaturated fatty acids)-group|REMOGEN OMEGA: Usage according to instructions for use.
2499191|NCT02908282|Other|C (control)-group|Povidone: Usage according to instructions for use.
2499220|NCT02907879||Ultrasound perfusion imaging|Measuring methods of UPI with phase inversion harmonic imaging
2499246|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery High Dose|High-Dose Group: 0.4 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2499248|NCT02908035|Active Comparator|Active Comparator: Temsirolimus Delivery Low Dose|Low-Dose Group: 0.1 mg/mL temsirolimus (including 20% contrast) Patients qualifying for enrollment will be randomized 2:1 for inclusion in either the treatment (low-dose or high-dose) or the control group. The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2499251|NCT02908035|Placebo Comparator|Placebo Comparator: Saline Delivery|Control Group: Saline/contrast (80% normal saline for injection:20% non-ionic contrast) The first 20 patients randomized to treatment will receive low-dose. After the first 30 patients (20 low-dose and 10 control) are enrolled in the trial, enrollment will be held until 30-day safety endpoints are met, at which point the dosage will be escalated to the high dose and the trial will resume, with the remaining 30 patients randomized 2:1 for high-dose or control.
2499288|NCT02907554|Placebo Comparator|control group|control group receives a placebo
2499299|NCT02907554|Experimental|intervention group|the intervention group receives 2.5 mg/kg of cyclosporine
2499347|NCT02907151||pre-consultation survey group|The group completing a pre consultation survey filled the same questionnaire in post consultation but the doctor will see the result in the consultation.
2499350|NCT02907151||Group absence of pre-consultation survey|This group will be a control group to see if there is a difference between completing a pre-consultation survey before or not.
2499515|NCT02905968|Experimental|TTPLAR|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
3195805|NCT00843544|Experimental|Integrative Medicine|
3195806|NCT00843544|No Intervention|Control|
3195807|NCT00843557||all ICU admissions|patients admitted to the ICU for greater then 72hrs
3195808|NCT00843570|No Intervention|1|Natural FER (frozen embryo replacement)
3195809|NCT00843570|Active Comparator|2|HRT-FER (Down regulated frozen embryo replacement)
3195810|NCT00843583||resistant hypertension subjects|subjects with resistant hypertension
3195811|NCT00843596|Experimental|vacuum device - suction cup|
3195812|NCT00843609|Experimental|Continuous glucose monitoring|Continuously wearing the FreeStyle Navigator continuous glucose monitor, displaying real-time glucose values and sounding alarms
3195813|NCT00843609|No Intervention|Control|Using SMBG with standard routine instructions
3195814|NCT00843648||preterms|mother and preterm babies
3195815|NCT00843648||term-bfing|term breastfed babies and mothers
3195816|NCT00843648||term-PIF|term non breastfed babies and mothers
2499020|NCT02909413|Experimental|Group Desflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into Desﬂurane for maintenance. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
2499029|NCT02909413|Active Comparator|Group Sevoflurane|Anesthesia maintenance: After endotracheal intubation, patients will be randomized into sevoﬂurane for maintenance. The gas flow rate of Sevoflurane group is 2L/ min, include 50％O2 and 1.7-2.0% Sevoflurane.
2499089|NCT02909036|Experimental|Melphalan|Test Dose CE Melphalan 10mg/m2 with PK studies Day -12 to Day-3, CE Melphalan Dose of Target AUC 13 mg/L/h infused with PK studies Day -2, 3-10 x 10^6 CD 34+ cells/kg reinfused Day 0, Pegfilgrastim 6mg injection Day +1
2499108|NCT02908581|Active Comparator|Placebo|21 Patients Placebo Each tablet by mouth once daily for 12 weeks
2499111|NCT02908581|Experimental|Iron 150 mg and Folic acid 0.5 mg|21 Patients Iron 150 mg and Folic acid 0.5 mg Each tablet by mouth once daily for 12 weeks
2499290|NCT02907450|Experimental|Clinical evaluation of the tolerance of the orthosis|
2499309|NCT02907359|Experimental|Guadecitabine|Guadecitabine 60 mg/m2 given subcutaneously daily on Days 1-5 in 28-day cycles. The total amount (in mg) of guadecitabine to be administered is determined by body surface area.
2499312|NCT02907359|Active Comparator|Treatment Choice|"Best Supportive Care.~Low dose cytarabine.~Standard Intensive Chemotherapy."
2499329|NCT02907307|Experimental|LactiSal vaginal gel 1%|5g of 1%LactiSal Gel vaginal gel once daily for 6 days
2499336|NCT02907307|Experimental|LactiSal vaginal tablet 50 mg|50 mg of LactiSal vaginal tablet daily for 6 days
2499340|NCT02907307|Active Comparator|Clotrimazole vaginal tablet 100mg|100 mg Clotrimazole vaginal tablet daily for 6 days
2499387|NCT02906891|Experimental|Usual Care Patients on MDI or CSII|Usual Care Patients on MDI or CSII Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
2499393|NCT02906787|Experimental|BAS+|Participants will attend 8 counseling sessions and receive a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+).
2499394|NCT02906787|Placebo Comparator|SC|Participants will attend 8 counseling sessions and receive standard smoking cessation counseling (SC).
2499403|NCT02906800|Experimental|DIGHANC|Patients meeting all inclusion /exclusion criteria, will be given 3 cycles of the following regimen: 1) digoxin (0.25 mg/day) for a 7-day period (digitalization time) from Day 1 to Day 7; 2) chemotherapy regimen TPF protocol from Day 8 to D12 (continuous perfusion of fluorouracil for 120h, Cisplatin at Day 10 and Docetaxel at Day 11) administered in combination with digoxin 0.25 mg/day from Day 8 to Day 9; 3) a 15-day period off treatment.
2499433|NCT02906514|Experimental|Hydroxyethyl starch 130/0.4|
2499434|NCT02906475|Other|Intervention: standardized skin care regimen|Intervention: The milk lotion will be applied once daily on the total body including the face by the parents or care givers at home. If bathing is needed, the bathing addendum is used in addition to water.
2499435|NCT02906514|Placebo Comparator|Sodium Chloride 0.9%|
2499437|NCT02906475|No Intervention|Control|In the control group no predetermined or standardized skin care regimen is prescribed.
2499458|NCT02906371|Active Comparator|Tocilizumab low tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with low pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
3162714|NCT00468182||1|MS patients or patients with CIS (Clinically isolated syndrome) who decided to be treated with IFN-beta for 3 months (with the option to continue Rx)
2499472|NCT02906228|Experimental|TETRA 385 MHz|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
2499475|NCT02906228|Experimental|Sham Exposure|Radiation: Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law
3162715|NCT00468182||2|MS patients or patients with CIS(Clinically isolated syndrome)who decided to postpone the treatment with IFN-beta
3162716|NCT00468247|Active Comparator|1|Device , Navigator used for guiding haemodynamic care
3162717|NCT00468247|Placebo Comparator|2|Conventional care
3162718|NCT00468273|Experimental|Intravenous Immune Globulin|Subjects with primary humoral immunodeficiency
3162719|NCT00468325|Active Comparator|Multi-slice Computed Tomography|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to a multi-slice computed tomography arm where they will receive a CT scan of their heart.
3162720|NCT00468325|Active Comparator|Standard of Care|Patients admitted to the ED with chest pain and/or anginal equivalent symptoms are randomized to the Standard of Care arm and receive rest-stress nuclear myocardial perfusion imaging test.
3162721|NCT00468338||BIS monitor used for all subjects|BIS monitor applied to all subjects
3162722|NCT00468403|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplantations and continuous immunosuppressive therapy including belatacept
3162723|NCT00468442|Experimental|Allogeneic Pancreatic Islet Cells|Participants will receive up to three islet transplants and maintenance immunosuppressive therapy.
3162724|NCT00468468|Experimental|CHESS Condition|Subjects who receive the CHESS (Comprehensive Health Enhancement Support System)
3162725|NCT00468468|Experimental|Mentor Condition|Subjects who receive access to a Human Cancer Mentor only
3162726|NCT00468468|Experimental|CHESS + Mentor|Subjects who receive the CHESS system plus a Human Cancer Mentor
3162727|NCT00468468|No Intervention|Internet Only|Subjects receive routine care and nothing else
3162728|NCT00468572|Experimental|1|Participants will receive treatment with affectionate writing
3162729|NCT00468572|Active Comparator|2|Participants will receive treatment with meaningless writing
3162730|NCT00468611|Experimental|1|
3162731|NCT00468611|Placebo Comparator|2|
3175038|NCT00629460||1|there is only one group/cohort. This is a non-therapeutic study.
3175039|NCT00629473|Experimental|Arm AM: advanced malignancies|Dose Escalation - 9 dose cohorts NPI-0052 on Days 1, 8, 15 every 28 days NPI-0052 doses ranging from 0.1 to 0.9 mg/m2
2498926|NCT02909972|Experimental|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days
2498928|NCT02909972|Experimental|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
2498951|NCT02909738||Volunteers|Healthy volunteers willing to pedal a bike for 30 minutes.
2499005|NCT02909517||Choroidal nevus|Requires distinction from melanoma through diagnostic testing (low-risk features)
2499006|NCT02909517||Choroidal indeterminate melanocytic lesion|Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features)
2499007|NCT02909517||Choroidal melanoma|Requires confirmation of diagnosis and evaluation for potential metatstases
2499008|NCT02909517||Suspected metastatic tumour|Requires identification of primary tumour (ie, primary tumour elsewhere)
2499009|NCT02909517||Locally treated ocular tumour|Requires followup to evaluate response to treatment and potential change or repeat therapy
2499013|NCT02909192|Active Comparator|Bright light therapy|Participants will be treated twice daily with bright light therapy.
2499015|NCT02909192|Active Comparator|Dim-Red light therapy|Participants will be treated twice daily with dim-red light therapy.
2499088|NCT02909088|Experimental|Ecopipam 50mg|50mg of ecopipam at bedtime for the first two weeks. If there is deemed improvement by the investigator, the subject will remain on the same dose. If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
2499092|NCT02909088|Experimental|Ecopipam 100mg|If there is no improvement, then the subjects' dose will be increased to 100mg at bedtime beginning on day 14.
2499126|NCT02908451|Experimental|AbGn-107|AbGn-107 will be administered every 14-days or 28-days via intravenous infusion. Patients with a complete response (CR), partial response (PR), or stable disease (SD), or with evidence of clinical benefit may be treated every continuously every 14-days or 28-days..
2499182|NCT02908139||Patients before kidney transplantation|The study included who had been admitted to the TransplantClinic before kidney transplantation
2499219|NCT02907944|No Intervention|Usual Care- Control|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The first phase for all clinics is a control phase where clinic staff and patients engage in usual care. The time to implementation is randomly assigned. Each clinic is then followed prospectively to determine their outcome status.
2499221|NCT02907944|Experimental|Implementation Facilitation|We will use a stepped wedge design to evaluate the effect of the Implementation Facilitation on the outcomes. The time to implementation in a stepped wedge design is randomly assigned. Clinics are then followed prospectively to determine their outcome status..
3162732|NCT00468715|Experimental|bicalutamide|This is a multicenter, open-label, phase II study to evaluate the antitumor activity and safety of bicalutamide administered orally daily to patients with ER(-)/PR(-)/AR(+) metastatic breast cancer. Eligible patients who have consented to trial participation will receive bicalutamide at a dose of 150mg PO daily.
3162733|NCT00468741|No Intervention|1|subjects receive internet access and computer
2499275|NCT02907723|Experimental|Continuous Sleep Recording|Continuous Sleep Recording in Patients
2499321|NCT02907047|Active Comparator|Tourniquet|These subjects will have their tourniquet inflated during key portions of the total knee arthroplasty procedure
2499322|NCT02907047|Other|No tourniquet|These subjects will not have their tourniquet inflated during key portions of the total knee arthroplasty procedure
2499374|NCT02906735||Study group|Patients with knee surgery undergo plantar foot pressure measurement pre- and postoperatively
3162734|NCT00468741|Experimental|2|CHESS informational services only
3162735|NCT00468741|Experimental|3|CHESS social support and informational services
2499418|NCT02906605|Experimental|JNJ-809 plus Apalutamide (Group A)|JNJ-809 given as an infusion and Apalutamide 240 milligram (mg) daily.
3162736|NCT00468741|Experimental|4|Full CHESS
3162737|NCT00468754|Experimental|A|
3162738|NCT00468754|Experimental|B|
3162739|NCT00468767|Experimental|1|Atrial fibrillation (AF) duration of 3 hours to 7 days.
3162740|NCT00468767|Experimental|2|AF duration of >7 days to <45 days
3162741|NCT00468793|Active Comparator|2|Fluid therapy guided by blood pressure and urine production
3162742|NCT00468793|Experimental|1|ScvO2 guided fluid therapy
3162743|NCT00468832||Ongoing Duchenne Muscular Dystrophy (DMD) Cohort|340 patients currently enrolled participants with DMD.
3162744|NCT00468832||New Young Duchenne Muscular Dystrophy (DMD) Cohort|Additional 100 confirmed DMD participants aged 4-7 years old to be recruited.
3162745|NCT00468832||Typically Developing Control Cohort|Up to 370 typically developing male children and adults aged 6-30 years old to be recruited.
3162746|NCT00468871|Experimental|Fluocinolone acetonide|Intravitreal fluocinolone acetonide implant
3162747|NCT00468871|Active Comparator|Standard care|Standard of Care
3162748|NCT00468897|Experimental|Treatment Arm AB|A will be a single tablet RSG XR 8 milligram (mg) manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm AB subject will receive A regimen in Period 1 and B regimen in Period 2.There will be wash-out period of 5 days between doses.
3162749|NCT00468897|Experimental|Treatment Arm BA|A will be a single tablet RSG XR 8 mg manufactured in Harlow administered in the fasted state and B will be a single tablet RSG XR 8 mg manufactured in Crawley administered in the fasted state. In Arm BA subject will receive B regimen in Period 1 and A regimen in Period 2. There will be wash-out period of 5 days between doses.
3162750|NCT00468923|Placebo Comparator|Rosuvastatin|Rosuvastatin 10 mg vs placebo
3162751|NCT00468923|Placebo Comparator|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 mg vs placebo
3162752|NCT00468936|No Intervention|1|Usual medications (Cellcept)
3162753|NCT00468936|Active Comparator|2|Patients taking Myfortic
3162754|NCT00468949||1|Patients undergoing excision surgery for their dupuytren's contracture
3162755|NCT00468949||2|Patients not undergoing surgery for their excision surgery
3162756|NCT00469027|Experimental|eNOS transfected EPCs|eNOS transfected EPCs will be delivered by injection via a PA line, incremental doses over three days
2498972|NCT02909712|Experimental|dihydroartemisinin-piperaquine (DHA-PQP)|"Group 3 (50 CareStart™ RDT-positive women)~Group 4 (50 CareStart™ RDT-negative women)~These 100 women will have an ECG exam, provide blood for microscopy, molecular, and PK analysis, and receive DHA-PQP day 0. On day 1, women will receive dose 2. On day 2, women will have an ECG exam, begin Holter monitoring, provide blood for PK analysis, and receive dose 3. Blood for PK analysis will be drawn at 4, 5, and 6 hours following dose 3. An ECG exam will be conducted during this period and, again, on day 7. On days 7, 14, 21, and 28, women will provide blood for microscopy and molecular analysis."
2499032|NCT02909335|Active Comparator|Tacrolimus group|Tacrolimus + mycophenolate mofetil + corticosteroids
2499037|NCT02909335|Experimental|Everolimus group|Everolimus + mycophenolate mofetil + corticosteroids
2499072|NCT02908893|Experimental|Salient|"Messages in the salient arm highlight the number of incentives (points) received by getting a flu shot and recording it through the wellness program app.~Additionally, messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy."
2499077|NCT02908893|Active Comparator|NonSalient|"Messages in the non-salient arm highlight the benefits of getting vaccinated against flu, but make no mention of incentives received for getting vaccinated.~Incentives would still be earned through the wellness program if the vaccination is recorded. Messages mention that flu shots can be received at the pharmacy while picking up an Rx.~Users in the arm are matched up with a second user from the same arm, randomly. For each pair, the messages are sent to both users at the same time within the specified time window. Such time is picked to be the day in which the first user is most likely to pick up an Rx from a pharmacy"
2499081|NCT02908893|No Intervention|Control|Users in this group will not receive any message promoting flu vaccination. Incentives would still be earned through the wellness program if the vaccination is recorded.
2499127|NCT02908737|Experimental|Bass and Treble controls|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively.
2499170|NCT02908295|Experimental|A|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
2499183|NCT02908295|Placebo Comparator|B|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
3195817|NCT00843648||c-section|c-section babies and their mothers
2499265|NCT02907775|Active Comparator|Transcutaneous Electric Nerve Stimulus|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
2499267|NCT02907775|Active Comparator|Sensory Barrage Stimulation|Researcher 1 who is blind to patients' allocation group will perform the baseline assessments. The researcher 2 will determine the maximum tolerable level of stimulation. The researcher 2 will demonstrate to the participant how to apply the stimulation and will instruct the participant. The participant will revive the first intervention in the Royal Hallamshire Hospital under supervision of researcher 2. The researcher 2 will then issue the participants in Group-2 (SBS) with Shefstim and six multichannel electrodes. They will instruct each participant to change the electrode once every 3 days. On the 15th day the researcher 2 will visit them at home and issue further 6 multichannel electrodes and collect back the previous set. At the end of week 4, the patient will come to Hospital.
2499304|NCT02907437|Active Comparator|Minocycline treatment|Intervention: Drug: Minocycline (200 mg/day)
2499307|NCT02907346|Experimental|Reinforcement for wearing CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
2499308|NCT02907437|Placebo Comparator|Placebo treatment|Placebo Intervention: Drug: Placebo (200 mg/day)
2499352|NCT02907086||colorectal cancer|
2499356|NCT02907086||melanoma|
2499371|NCT02907021|Experimental|Heart failure|Treat the HER-2 positive breast cancer patients experiencing mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
3195818|NCT00843661|Experimental|Ezetimibe and fenofibrate|
3195819|NCT00843661|Active Comparator|Pravastatin|
3195820|NCT00843700|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy, 16 individual sessions within 32 weeks
3195821|NCT00843700|Active Comparator|Individual Psychotherapy|Individual Psychotherapy, 16 individual sessions within 32 weeks
3195822|NCT00843739|Experimental|EMST|Four week device driven strength training program
3195823|NCT00843739|Sham Comparator|sham|Four week sham device driven training program
2499413|NCT02906683|Experimental|TAS-303 3mg|
2499414|NCT02906683|Experimental|TAS-303 6mg|
2499415|NCT02906683|Placebo Comparator|Placebo|
2499454|NCT02906371|Active Comparator|Tocilizumab high tumor burden|This is a two cohort, open-label, pilot study to describe the efficacy of administration timing of tocilizumab on CART19 (CTL019) associated CRS safety events in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia with high pre-infusion tumor burden following redirected autologous T cells transduced with the anti-CD19 lentiviral vector (CART19/CTL019).
2499462|NCT02906267|Other|Manual-controlled|Patient in the manual ventilation group will receive facemask ventilation to get a tidal volume of 8-10ml/kg with a respiratory rate of 15/min. The pop-off valve will be set to 20 cm H2O.
2499516|NCT02905968|No Intervention|NORLAR|Tranditional low anterior resection without transanual tube placement or ileostomy.
3195824|NCT00843739|No Intervention|Control|Four weeks of no intervention
3195825|NCT00843765|Active Comparator|TCM integrated group|800 patients with acupuncture, massage and basic Chinese medicine treatment
2499023|NCT02909257|Experimental|same dose|patient is exposed to the same previously successful dose
2499033|NCT02909257|Experimental|lower dose|patient is exposed to a lower concentration dose
2499073|NCT02908997|Experimental|5 week baseline|5 week baseline data collection followed by 6 week MindMate intervention
2499078|NCT02908997|Experimental|6 week baseline|6 week baseline data collection followed by 6 week MindMate intervention
2499080|NCT02908997|Experimental|7 week baseline|7 week baseline data collection followed by 6 week MindMate intervention
2499137|NCT02908698|Experimental|Prednisone Treatment|"Prednisone will be administered orally for 15 days at the following doses:~0.75 mg/kg of body weight for 5 days 0.5 mg/kg of body weight for 5 days 0.25 mg/kg of body weight for 5 days"
2499145|NCT02908698|Placebo Comparator|Placebo Control|Placebo will be administered orally for 15 days in a capsule identical to the experimental treatment.
2499268|NCT02907580|Experimental|Local educational data|Local-based educational handout
2499269|NCT02907580|Experimental|National educational data|National-based educational handout
2499270|NCT02907580|No Intervention|Usual care|No educational information other than provided as usual care by health care providers
2499284|NCT02907385|Experimental|LifeSeal™ Kit|Stapled Anastomosis is performed according to Standard of Care (SoC) with the addition of LifeSeal™ Kit application during surgery.
2499297|NCT02907385|No Intervention|Standard of Care|Stapled Anastomosis is performed according to SoC without LifeSeal™ reinforcement.
3162757|NCT00469040|Experimental|GW642444M 25mcg|In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.
3162758|NCT00469040|Experimental|GW642444M 50mcg|Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.
2499324|NCT02907060|Experimental|Mechanical cervical ripening|mechanical cervical ripening with a Cook® Cervical Ripening Balloon
2499330|NCT02907060|Active Comparator|Pharmacological cervical ripening|pharmacological cervical ripening with a 10mg slow releasing system of Dinoprostone (Propess®)
2499385|NCT02906839|Experimental|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
2499388|NCT02906839|No Intervention|Control group|No SAS screening will be performed in this group before the end of the 2 year follow up period.
2499419|NCT02906605|Experimental|Apalutamide (Group B)|Apalutamide 240 mg orally daily.
2499429|NCT02906540|Experimental|Transpubic symphysis reset therapy group|Transpubic symphysis reset therapy will be conducted once a day for 7 consecutive days.
2499430|NCT02906540|Experimental|Physiotherapy group|Physiotherapy and a sham reset treatment will be performed once a day for 7 consecutive days.
2499440|NCT02906306|Experimental|Individual Occupational therapy|In Individual Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT).
2499442|NCT02906306|Experimental|Group Occupational therapy|In group Occupational Therapy treatment the activities included personal independence training (ADLs), sensory-motor stimulation activities, cognitive stimulation (attention, memory, language and executive function) and animal-assisted therapy (AAT) and psychosocial skills training.
2499452|NCT02906384|No Intervention|routine PCI|PTV:25Gy/10F. Radiation technique: VMAT.
2499455|NCT02906384|Experimental|HA-PCI|"PTV 25Gy/10F. Hippocampus avoidance: decrease the dose to HAZ as the following criteria: Dmin<9Gy Dmax<16Gy.~Radiation technique: VMAT."
2499464|NCT02906280|Experimental|19 Ga EBUS-TBNA needle|needle aspiration by a flexible 19 Ga needle (Olympus)
2499466|NCT02906267|Other|Volume-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Tidal volume will be set to 8-10 ml/min.
2499470|NCT02906267|Other|Pressure-controlled|mechanical breath will be delivered by a Primus ventilator (Dräger, Lubeck, Germany) at a frequency of 15 breath/min. Pressure will be adjusted to obtain a tidal volume of 8-10 ml/min.
2499474|NCT02906280|Active Comparator|22 Ga EBUS-TBNA needle|needle aspiration by a 22 Ga needle (Olympus)
2499485|NCT02906150|Experimental|Thymalfasin (Thymosin alpha 1, Ta1)|Arm A: 70 patients will receive Thymosin alpha 1 in 1mL SC injection five times a week (first four months); then two times a week for eight months. SoC chemotherapy and cisplatin (or carboplatin) for twelve months.
2499487|NCT02906085|Experimental|Endothelin-1|Intravenous infusion of pharmaceutical grade human endothelin-1
3162759|NCT00469040|Experimental|GW642444M 100mcg|In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.
3162760|NCT00469040|Experimental|GW642444M 200mcg|Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.
3162761|NCT00469040|Experimental|GW642444M 400mcg|Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.
3162762|NCT00469105|Active Comparator|Control|Control Arm receives standard diabetes disease management
3162763|NCT00469105|Experimental|Intervention Arm|Receives numeracy/literacy sensitive diabetes management
3162764|NCT00469118|Experimental|DRX Treatment|20 treatments of spinal decompression over a six week period. Each session lasts about 45 minutes and consists of a 28-minute treatment on the DRX9000™ machine followed by 15 minutes of cold therapy to the lumbar paravertebral muscles.
3162765|NCT00469118|No Intervention|Conservative Care|Conservative non surgical therapy for 6 weeks prior to beginning DRX9000 treatment
3162766|NCT00469131|Active Comparator|1 Drug:|tacrolimus + steroid
3162767|NCT00469131|Active Comparator|2 Drug:|tacrolimus + mycophenolate mofetil
3162768|NCT00469157|Other|1.|
3162769|NCT00469170|Experimental|A|vaginal ring first 12 weeks & observational safety last 12 weeks
3162770|NCT00469170|Experimental|B|observational safety first 12 weeks & vaginal ring last 12 weeks
3162771|NCT00469235|Placebo Comparator|1|50ng dose group
3162772|NCT00469235|Placebo Comparator|2|200ng dose group
3162773|NCT00469261|Experimental|Doxycycline|Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
3195826|NCT00843765|Active Comparator|Western Medicine group|400 patients with modern rehabilitation techniques and Western Medicine basic treatment
3195827|NCT00843791|Placebo Comparator|Placebo|Treatment with placebo for 3 months before spectroscopy, hyperinsulinemic-euglycemic clamp, control diet, blood sampling.
3195828|NCT00843791|Active Comparator|2|Treatment with pioglitazone for 3 months before hyperinsulinemic-euglycemic clamp, control diet with blood sampling and spectroscopy.
3195829|NCT00843817|Experimental|DRUG|PULMOZYME
3195830|NCT00843869||Chronic Rhinosinusitis|Participants with chronic rhinosinusitis
3195831|NCT00843908|Active Comparator|TVT|Women in this arm will undergo the Tension Free Vaginal Tape procedure
2499291|NCT02907541|Experimental|QI4U Group|Group 1 - Learners who will learn QI methods using eLearning through QI4U
2499294|NCT02907541|Active Comparator|Facilitated Learning Group|Group 2 - Learners who will learn QI methods by facilitated teaching
2499306|NCT02907541|Active Comparator|QI4U and Facilitated Learning Group|Group 3 - Learners who will learn QI methods using a combination of QI4U and facilitated teaching
2499315|NCT02907528|Placebo Comparator|BONE Group|bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
2499316|NCT02907528|Active Comparator|BONE+EMD Group|mixture of enamel matrix derivative proteins (EMD) (Emdogain® Straumann, Basel, Switzerland) and bone substitute consisting of βTCP/HA (Bone Ceramic® Straumann, Basel, Switzerland);
2499317|NCT02907528|Experimental|EMD Group|enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland)
2499332|NCT02907099|Experimental|Treatment (CXCR4 antagonist BL-8040, pembrolizumab)|Patients receive CXCR4 antagonist BL-8040 SC on days 1-5 and 8-12 of cycle 1 and days 1, 4, 8, and 11 of subsequent cycles. Beginning cycle 2, patients also receive pembrolizumab IV over about 30 minutes on day 1. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
2499348|NCT02907138|Experimental|Medical Yoga|Medical Yoga Group therapy for eight weeks, 60 minutes per week, with the guidance of a physical therapist.
2499351|NCT02907138|Active Comparator|Treatment as Usual (physical therapy)|Treatment as Usual provided by physical therapist
2499378|NCT02906969|Experimental|Colonoscopy educational Video|Brief educational video of colonoscopy to determine comprehension and quality of bowel preparation.
2499381|NCT02906969|Placebo Comparator|Control|Non-colonoscopy video as a control.
2499400|NCT02906826|No Intervention|Reported adherence|During a 4 month period the investigators will measure adherence to therapy as reported in a daily diary by participants against actual adherence which will be measured by a digital manometer attached to the participants therapy device which uploads real time data to the cloud.
2499402|NCT02906826|Active Comparator|Adherence with a video game|During the second 4 month period, participants will be given a video game on a tablet which is operated through the digital manometer by their performing their therapy correctly.Actual adherence will be measure again during this time and be compared to the no intervention arm
3195832|NCT00843908|Experimental|Miniarc|Women in this group will undergo the Miniarc suburethral sling procedure
3195833|NCT00843921|Experimental|Carbaglu|Investigate whether a 3-day treatment with NCG can improve or restore urea genesis capacity in patients with NAGS, CPSI, or OTC deficiency or PA or MMA using surrogate markers: [13C] label incorporation into urea and plasma levels of ammonia, urea nitrogen (BUN) and amino acids
2499443|NCT02906410|No Intervention|Control 1|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for numeric labeling conditions.
2499449|NCT02906410|Experimental|Numeric individual|Features Item-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices.
2499451|NCT02906410|Experimental|Numeric individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Numeric calorie labels will be featured on individual items, along with prices. Additionally, an aggregated numeric calorie count for the entire meal will be dynamically updated as items are added or removed from the meal.
2499453|NCT02906410|No Intervention|Control 2|Participants in this group will see a menu labeled with prices, but will not observe calorie information. Used as a comparator for light labeling conditions.
2499456|NCT02906332|Experimental|Pembrolizumab + lenalidomide|"This is an open label study.~Pembrolizumab 200 mg IV every 3 weeks and lenalidomide 25 mg po daily x 14 days and dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles.~This is followed by pembrolizumab 200 mg every 3 weeks and lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for a total of 4 cycles."
2499457|NCT02906410|Experimental|Light individual|Features Item-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices.
2499459|NCT02906410|Experimental|Light individual + aggregate|Features Item-Level Calorie information and Meal-Level Calorie information. Traffic light calorie labels will be featured on individual items, along with prices. Additionally, an aggregated traffic light label for the entire meal will be dynamically updated as items are added or removed from the meal.
2499460|NCT02906241|Experimental|Patients--Intervention|Patients are randomized to an intervention group. They participate in all aspects of the study and also receive the intervention, which consists of a booklet.
2499465|NCT02906241|No Intervention|Patients--Usual Care|Patients are randomized to the standard of care arm and participate in all aspects of the study but receive no intervention.
3195834|NCT00843934|Experimental|anti-cancer agent|
3195835|NCT00843960|Active Comparator|1|intervention group
3195836|NCT00843960|No Intervention|2|control group
3195837|NCT00843973||iliac crest bone graft|Bone graft harvested via iliac crest bone graft procedure
3195838|NCT00843973||Reamer Irrigator Aspirator|Bone graft harvested via the Reamer Irrigator Aspirator (RIA) Procedure
3195839|NCT00844012|Experimental|Experimental group|
3195840|NCT00844012|Active Comparator|Control|
3195841|NCT00844025|Experimental|Pharmacist intervention|Patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including medication review, medication reconciliation, patient education and recommended actions.
3195842|NCT00844025|No Intervention|Usual care|Patients randomized to usual care group will receive routine review of medication by ward-based pharmacist and nurse.
3195843|NCT00844038||1|Sick
2498315|NCT02914418|Experimental|Active iTBS|iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. The hand representation of the primary motor cortex will targeted using a circular coil held over the vertex of skull. Intensity will be set to 80% of Resting Motor Threshold (RMT), which will be determined visually by the lowest percentage of stimulator output which can cause upper limb motor twitch in at least 5 out of 10 attempts.
2498316|NCT02914418|Sham Comparator|Sham iTBS|Sham iTBS will be delivered using the 50Hz, 600 pulses protocol for 10 sessions over a period of two weeks. Intensity will be set at 80% RMT. Circular coil will be held over vertex of skull but angled away to ensure no neural stimulation.
2498536|NCT02913066|Experimental|Single drug|S-1 concurrent Radiotherapy
2498539|NCT02913066|Active Comparator|Double drug|S-1 plus cisplatin concurrent Radiotherapy
2498568|NCT02912715|Experimental|Paclitaxel releasing angioplasty balloon|Intervention treatment of balloon angioplasty with Paclitaxel releasing angioplasty balloon(Passeo-18 Lux) in new and non-stented re-stenotic lesions in the superficial femoral artery (SFA) and proximal popliteal artery (PPA)
2498602|NCT02912416|Experimental|Probiotics|Capsule with probiotics
2498606|NCT02912416|Placebo Comparator|Placebo|Capsule with placebo
2498716|NCT02911649|Experimental|Wearable Device Only|Participants will be allowed to choose one of three wearable devices (FitBit, Garmi or Polar), for the wearable technology intervention. Once the participant has chosen their wearable device they will be oriented to their chosen device, platform to obtain information from the device, as well as a guide with ideas for reducing sedentary behaviour. Participants will be asked to wear the devices every day during waking hours.
2498717|NCT02911649|Experimental|Online Educational Workshop Only|The Online Educational Group will be asked to participate in 6 online workshops that will occur during the 12-week intervention. Adobe connect software will be used to implement these workshops which allows for interaction between participants and leader. Workshops will focus on specific aspects related to reducing sedentary behaviours and increasing PA time. Each workshop will be developed by study coordinator/author (MO) and constructed using Social Cognitive Theory (SCT), ensuring the themes such as self-efficacy, self-control and reinforcements are within each topic. EDU topics will include motivation, goal setting, and activities and ways to reduce sedentary behaviour.
2498720|NCT02911649|Experimental|Wearable Device+Online Edu Workshop|Both the wearable technology intervention and Online Educational Group intervention simultaneously.
2498725|NCT02911649|No Intervention|Control Group|Participants in this group will receive usual care
2498777|NCT02911311|Experimental|IVC group|intravitreal injection of conbercept (IVC) group：all study eyes randomised to receive conbercept will receive an intravitreal injection of conbercept 2 mg/ 0.05 mL at baseline and at 1 and 2 moths. Further treatment since months 3 is determined by the degree of regression of neovascularization (NV) of disc and elsewhere on clinical examination
2498783|NCT02911311|Active Comparator|PRP group|panretinal photocoagulation (PRP) group:all study eyes randomised to receive PRP will receive an fill-in PRP in 1-2 two weekly sessions as per routine clinical practice with emphasis on targeting retinal nonperfusion areas
2498839|NCT02910687||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
2498943|NCT02910323||Experimental group|Patients with a history of Cluster Headaches and other TACs, or Trigeminal Neuralgia.
2498945|NCT02910323||Family/Healthy Controls|Healthy volunteer controls and family members may be enrolled for identification of genetic mutations.
2498978|NCT02909621|Active Comparator|Group A|Group A: FLEXOFYTOL® high dosage
2498981|NCT02909621|Active Comparator|Group B|Group B: FLEXOFYTOL® low dosage
2498984|NCT02909621|Placebo Comparator|Group C|Group C: PLACEBO
2499021|NCT02909309|Other|ALL INCLUDED PATIENTS|"A single arm for this study. All the patients benefit of both systems. The participants are their own control.~Non invasive sensors are used to monitor and record data of those two systems in a synchron way ( JAWAC / Capnoline + Spo2)."
2499131|NCT02908438|Experimental|GnRHa group|Intervention: additional GnRHa for routine LPS GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
2499141|NCT02908438|No Intervention|control group|Control group receive only the routine LPS.
2499162|NCT02908308|Active Comparator|Normothermia|Standard care with early treatment of fever. Active temperature control with a device will be used if the patient develops a temperature greater than or equal 37.8°C.
2499167|NCT02908308|Experimental|Hypothermia|Targeted temperature management to 33°C for up to 28h.
2499355|NCT02907281||Multiple sclerosis patients|Multiple sclerosis patients
2499359|NCT02907281||Healthy volunteers|Healthy volunteers
3162774|NCT00469261|Active Comparator|Standard Therapy|Pts with AMI treated with Primary PCI and current medical therapy
3162775|NCT00469326|Active Comparator|atorvastatin|atorvastatin pre-treatment group (80mg atorvastatin two days before PCI)
3162776|NCT00469326|No Intervention|control|PCI without atorvastatin pretreatment
3162778|NCT00469378|Experimental|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
3162779|NCT00469430|No Intervention|Op|traditional surgery
3162780|NCT00469430|Experimental|Ab|antibiotic treatment
3162781|NCT00469443|Experimental|1|FOLFIRI/Avastin
3162782|NCT00469443|Experimental|2|XELIRI/Avastin
3162783|NCT00469482|Active Comparator|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS Targeted)
3162784|NCT00469482|Active Comparator|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring.
3162785|NCT00469547|Experimental|1|62% ethanol in emollient gel
3162786|NCT00469547|Placebo Comparator|2|15% ethanol in emollient gel
3162787|NCT00469560|Experimental|Deferasirox|
3162788|NCT00469573|Other|1.|
3162789|NCT00469586|Experimental|A|
3162790|NCT00469586|Experimental|B|
3162791|NCT00469586|Active Comparator|C|
3162792|NCT00469599|Active Comparator|1|alfacalcidol 16 weeks, 6 weeks wash out, paricalcitol 16 weeks
3162793|NCT00469599|Active Comparator|2|paricalcitol ´16 weeks, 6 weeks wash out, alfacalcidol 16 weeks
3195844|NCT00844064|Experimental|AP 12009|
3195845|NCT00844077||Barrett's metaplasia|Barrett's intestinal metaplasia, confirmed via pathology, undergoing standard of care endoscopic screening.
3195846|NCT00844103|Experimental|1|
3195847|NCT00844103|Placebo Comparator|2|
3195848|NCT00844116|Active Comparator|Conventional Spirometry|personal spirometry
3195849|NCT00844116|Experimental|Telematic Spirometry|"performed remotely on line"
3195850|NCT00844129||Neurofibromatosis Type 1|Children with Neurofibromatosis Type 1
2499592|NCT02905461|Experimental|Intervention|Contraceptive text messages
2499599|NCT02905461|Placebo Comparator|Control|Text messages not about contraception
2499642|NCT02905097||Arthroplasty cohort|A cohort of patients who will undergo knee replacement surgery and will receive Triathlon Tritanium (cementless) tibial implant.
2499685|NCT02904746|Experimental|Intervention|Participants receiving the Make It! intervention
2499688|NCT02904746|No Intervention|Control|Care as usual
2499707|NCT02904564|Experimental|MMP with 5-FU infusion|MMP with 5-FU infusion using tattoo device
2499709|NCT02904564|Placebo Comparator|MMP with saline infusion|MMP with saline infusion using tattoo device
3195851|NCT00844142|Other|1|etanercept 25mg twice weekly
3195852|NCT00844142|Active Comparator|2|Sulfasalazine 2000- 3000mg daily
3195853|NCT00844155|Active Comparator|A.Oseltamivir 75 mg dose|Patients will be randomized to two groups (group A) to receive oseltamivir at 75 mg, or (group B) to receive the drug at 150 mg in the fasting or fed state.
3195854|NCT00844155|Active Comparator|B. Oseltamivir 150mg|Patients will be randomized to groups (group A) to receive oseltamivir at 75 mg, or group B to receive the drug at 150 mg in the fasting or fed state.
2499953|NCT02902744|Experimental|ILUVIEN 0.19 MG|
2499972|NCT02902406||normal oral mucosa|
2499975|NCT02902406||oral precancerous lesion or oral cancer|
2500016|NCT02902224|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
2500017|NCT02902224|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
2500018|NCT02902224|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
2500040|NCT02901847|Other|Intervention|PAD tailored care
2500102|NCT02901730|Experimental|532nm laser group|LPI with 532nm laser.
2500105|NCT02901730|Experimental|561nm laser group|LPI with 561nm laser.
3195855|NCT00844168|Experimental|Treatment (adjuvant sorafenib tosylate after liver transplant)|Patients receive sorafenib tosylate PO twice daily on days 1-28. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
2500206|NCT02900612|Experimental|WA (Water Aerobics Training)|Water aerobics training.
2500207|NCT02900612|Experimental|WR (Water Resistance Training)|Resistance aquatic training.
2500208|NCT02900612|Active Comparator|CG (Control Group)|Control Group.
2500275|NCT02900469|Experimental|Denosumab & surgery|"denosumab: 120 mg subcutaneous injection~Surgery: 2-4 weeks after denosumab"
2500316|NCT02899923||Autoimmune bullous dermatoses|Patients with autoimmune bullous dermatoses
3195856|NCT00844181||0|white women
3195857|NCT00844181||1|Black women
3195858|NCT00844207|Experimental|Treatment A|Two of the fixed combination tablets each containing 250 mg of azithromycin and 155 mg of chloroquine base.
3195859|NCT00844207|Active Comparator|Treatment B|A single tablet containing 500 mg of azithromycin and a single tablet containing 300 mg of chloroquine base.
3195860|NCT00844220|Experimental|CT/MR|CT/MRI-directed clinical management strategy
3195861|NCT00844220|Active Comparator|Catheterization|Standard clinical management
3195862|NCT00844233|Experimental|1|Irinotecan Bead
3195863|NCT00844246|Experimental|SRS|School Readiness Specialist (SRS) will administer the screening questionnaire to the subject during the intervention period, at the subject's 9, 18, 24 and 30 month visits. They will then see their PCP for a well child visit in which the results of the test will be interpreted, developmental counseling and/or anticipatory guidance provided as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
3195864|NCT00844246|Experimental|Provider|Primary Care Physician (PCP) will do the developmental screening at the subject's 9, 18, 24 and 30 month well child visits. Once the screening questionnaire is complete the PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI (Early intervention) referral will be completed, at the discretion of the providers, if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
3195865|NCT00844246|No Intervention|Routine|Subjects randomized to routine surveillance will receive routine preventive care as well as developmental surveillance at all well child visits, including the 9, 18, 24 and 30 month visits. EI referral will be completed, at the discretion of the provider, if the PCP observes a developmental delay during surveillance or the caregivers raise a specific concern about the child's development.
3195866|NCT00844259||Research Group|15 children with Down syndrome, observed in two interaction conditions: playing with their therapist (A) and playing with their caregiver (B).
3195867|NCT00844272|Experimental|Psychoeducation|"PE group sessions lasted 60 minutes and were carried out under continuous supervision. The manualised program was especially tailored to (former) IDUs in HCV treatment, containing the following aspects:~Module 1: HCV infection and symptoms, course of illness, interaction with opioid dependence, further problems and risk factors~Module 2: HCV treatment, side effects, psychiatric and somatic comorbidities, reinfection and drug use, risk behaviour~Module 3: Coping strategies, resources and self-help, effective use of health-care support, the role of social environment, healthy living & nutrition"
3195868|NCT00844272|No Intervention|Treatment as usual|Control group did not received no intervention.
3195869|NCT00844285||Cimzia Cohort:|Patients about to receive treatment with Cimzia® as part of pre-existing management plan for Crohn's disease or has already been receiving treatment with Cimzia® for ≤12 months. Patients must also receive a Cimzia dose within 2 months following enrollment.
2499498|NCT02906098|Experimental|Patient centered oral health education|The program is based on cognitive behavioral theory and principles. Hence, the intervention is adapted to each individual's problem, capacity and goals were the dental hygienist use motivational interviewing skills in communication and act as a guiding resource during the process of behavioral change. The program follows a specific structure including components such as formulation of personal goals, continuous self-monitoring by diary and planning of behavior. The initial intervention phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
2499501|NCT02906098|Active Comparator|Standard educational intervention|The subjects in the control group receive educational intervention by a dental hygienist in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
2499560|NCT02905799|Experimental|Oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
2499561|NCT02905799|Placebo Comparator|Oral Placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months.
2499619|NCT02905305|Experimental|CA with dexamethasone base|Contour Advance electrode with controlled dose of dexamethasone base
2499624|NCT02905305|Active Comparator|Contour Advance|Standard Contour Advance electrode array
2499739|NCT02904343|Experimental|Group of domestic hemodialysis machine|
2499740|NCT02904343|Active Comparator|Group of imported hemodialysis machine|
2499775|NCT02903849|Experimental|Control|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will receive standard reminders generated by Wellness Connection.
2499779|NCT02903849|Experimental|Treatment|On the 20th, 50th, and 90th day of the Challenge, Wellness Connection will email employees who participate in this survey. Employees will see the motivating messages they wrote at the beginning of the Challenge, in addition to Wellness Connection's standard reminders.
2499853|NCT02903615|Experimental|Novel type 1 diet|Experimental diet to be examined: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
2499857|NCT02903615|Placebo Comparator|Standard therapy|Standard dietary therapy, as promulgated by Australian standards
2499866|NCT02903225|No Intervention|Usual Care|usual care and no changes in their previous physical activity
2499869|NCT02903225|Active Comparator|Cardiac Rehabilitation|Exercise Training program on a 3-days/week basis during 24 weeks (68-74 sessions). Each session started with a 10-min warm-up walking period followed by 20-min of breathing exercises and free non-resistance movements of limbs. This stage was followed by pedaling during 20-minutes at a circuit resistance training protocol using a stationary cycle-ergometer. Each session ended with a cool down period (5-minutes) including diverse stretching maneuvers of engaged muscle groups. The initial bicycle-ergometer workload (WL) was defined as 50% of the maximum achieved in the previous stress testing
2499934|NCT02903017|Active Comparator|Tranexamic acid 5%|Tranexamic acid 5%, 2000 mg (40 mL) in 60 mL normal saline (0.9%) solution (total 100 mL)
2499939|NCT02903017|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
2500004|NCT02902471|Experimental|Group A|Patients with bronchiolitis obliterans syndrome after bone marrow transplantation
2500025|NCT02902029|Experimental|Arm A|"After a 3 months run-in period with vemurafenib and cobimetinib [960 mg vemurafenib twice daily (BID), 28/0; 60 mg cobimetinib daily (QD), 21/7], all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7).~After progression of disease patients in Arm A will subsequently receive atezolizumab treatment (1200 mg/ q3w)."
2500028|NCT02902029|Experimental|Arm B|"After a 3 months run-in period with vemurafenib and cobimetinib (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7), all patients who do not show disease progression or definite treatment interruption (e.g. due to unacceptable toxicity) for more than 28 days will be randomized.~Further treatment with atezolizumab. Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on day 1 of each 21 day-cycle.~After progression of disease patients in Arm B will cross back to vemurafenib and cobimetinib treatment (960 mg vemurafenib BID, 28/0; 60 mg cobimetinib QD, 21/7)."
2500162|NCT02901145|Experimental|progressive/relapsed solid tumors|patient with progressive/relapsed solid tumors who failed first line therapy
2500321|NCT02899936|Active Comparator|2 drug dose - DA|Drug treatment with two-drug regimen diethylcarbamazine and albendazole (DA)
2500325|NCT02899936|Experimental|3 drug dose - IDA|Triple-drug regimen Ivermectin, diethylcarbamazine and albendazole (IDA)
2500419|NCT02899104||Radium-223 dichloride|Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC), at least 18 years of age, must have received at least one intravenous injection of Radium-223.
2500464|NCT02898701|Active Comparator|No Overpractice (NoOVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the NoOVP group will cease practicing.
2500466|NCT02898701|Experimental|Overpractice (OVP)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) according to the practice schedule until they reach a performance plateau on the repeated sequence. At that time, members of the OVP group will continue to practice as part of the overpractice phase until they have completed 100% overpractice.
2500469|NCT02898701|Active Comparator|Standard of Care (SoC)|Subjects will perform the intervention (i.e., motor practice of a standing serial reaction time task) until they have performed 144 practice trials over the course of one day. At that time, members of the SoC group will cease practicing.
2500493|NCT02898376|Experimental|combination tocopherol/pentoxifylline + spa care|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months AND skin-oriented spa care (18 days)
2500496|NCT02898376|Active Comparator|combination tocopherol/pentoxifylline|pentoxifylline (400 mg bid) + tocopherol (500 mg x bid) during at least 6 months
2499499|NCT02906072|Experimental|Low fat plant-based diet|Low fat plant-based diet with conventional meals and supplemented with plant-based meal replacements and participants attend the lectures on health effects of a low fat plant-based diet.
2499500|NCT02906072|Other|Control group|Control participants attend the lectures on health effects of a low fat plant-based diet.
2499638|NCT02905136||Patient with confirmed diagnosis of autoimmune encephalitis by|"Patient with confirmed diagnosis of autoimmune encephalitis by French rare disease reference center on PNS with :~with detection in CSF of characterized antibodies against neuronal synaptic receptor or protein (anti-NMDAr, anti-LGI1, anti-CASPR2, Anti-AMPAr, anti-mGluR5, anti-GABAbr)~or uncharacterized antibodies"
2499675|NCT02904824|Experimental|ADRC, adipose derived regenerative cells|Biological: Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
2499679|NCT02904824|Active Comparator|CAF, centrifuged autologous fat|Biological: Autologous fat tissue processed by centrifugation. Route of administration: Injection inside a paralyzed vocal cord.
2499704|NCT02904525|Experimental|7T MRI + high resolution spectroscopy|Next to routine imaging, patients undergo an additional 7 tesla MRI for high resolution spectroscopy
2499776|NCT02903862|Experimental|Intervention Arm|Participants will receive the intervention, Mindoula plus DANA, which involves working with a case manager via an app for 12 weeks. The case manager will help the participant cope with the stresses of caregiving as well as remind them to use the DANA cognitive assessment app. This arm will also take the study's psychological surveys.
2499783|NCT02903862|Other|Waitlist Control Arm|These participants will take psychological surveys and a usability questionnaire for the first 12 weeks of participation, then, for the 12 weeks following, take the psychological surveys along with DANA and a usability questionnaire.
2499834|NCT02903576|Active Comparator|injection of hESC-RPE in suspension|6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
2499846|NCT02903576|Active Comparator|injection hESC-RPE seeded in a substrate|15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
2499870|NCT02903212|Experimental|Rheumatoid arthritis|Patients with rheumatoid arthritis. An injection of autologous apoptotic cells is performed on the D0.
2499942|NCT02903069|Experimental|Stage 1: Concomitant Treatment|"MRZ + TMZ + RT~Patients who complete Concomitant Treatment may continue on to Adjuvant Treatment."
2499945|NCT02903069|Experimental|Stage 1: Adjuvant Treatment|MRZ + TMZ
2499949|NCT02903069|Experimental|Stage 2: Dose-Expansion|"MRZ + TMZ + RT followed by MRZ + TMZ~In Stage 2 (dose-expansion): a minimum of 12 and up to approximately 18 additional evaluable patients will be enrolled in a cohort in which Concomitant Treatment (MRZ + TMZ + RT) is followed by Adjuvant Treatment (MRZ + TMZ) to confirm the MTD for each treatment regimen as determined in the Dose-Escalation (Stage 1), and to assess preliminary activity of the recommended Phase 2 dose (RP2D)."
2499950|NCT02903069|Experimental|Optune Arm|MRZ + TMZ + Optune
2499970|NCT02902328||MRI data collection|A group of 30 subjects will be scanned on a 3 Tesla (T) and on a 7T MRI scanners. The images will be compared.
2500064|NCT02901821||Control|No intervention. Collection of medical/demographic info and salivary RNA in children 5-21 years without history of mild traumatic brain injury (mTBI).
2500066|NCT02901821||Concussion|Collection of medical/demographic info and salivary RNA in children 5-21 years with history of mild traumatic brain injury (mTBI). Collection of PCSI concussion assessment interview tool and balance/cognition testing at time of injury, 1-2wks post injury, and 4wks post injury.
2500082|NCT02901522|Active Comparator|Control|Spirometry (baseline) Spirometry (20 - 22weeks)
2500084|NCT02901522|Experimental|Telemedicine|Spirometry (baseline) Telemonitoring Teleconsultation Spirometry (20 - 22weeks)
3162794|NCT00469638|Experimental|Agilis sheeth group|
3162795|NCT00469638|Active Comparator|Non-steerable sheeth group|
2500262|NCT02900209||COPD frequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced 2 or more exacerbations requiring oral steroids/antibiotics treatment and/or hospitalisation in the previous 12 months.
2500264|NCT02900209||COPD infrequent exacerbators|Aged 65-85 years with a diagnosis of COPD according to Global Initiative for Chronic Obstructive Lung Disease criteria (post bronchodilator FEV1/FVC ratio <0.70). Moderate to severe airflow limitation (FEV1 30-80% predicted). Patients have experienced no more than 1 course of oral steroids/antibiotics and none exacerbations requiring hospital admission in the previous 12 months.
3162796|NCT00469651|Experimental|1|15 microgramme candidate vaccine
3162797|NCT00469651|Active Comparator|2|Hepatitis B vaccine
3162798|NCT00469651|Experimental|3|30 microgramme MSP3 candidate malaria vaccine
3162799|NCT00469651|Active Comparator|4|Hepatitis B control vaccine
3162800|NCT00469690|Other|1|
3162801|NCT00469690|Other|2|
3162802|NCT00469729|Experimental|StemEx|
3162803|NCT00469755|Active Comparator|1|Differin® Gel, 0.1% for 12 weeks
3162804|NCT00469755|Active Comparator|2|Tazorac® Cream, 0.1% for 12 weeks
3162805|NCT00469755|Active Comparator|3|Differin® Gel, 0.1% for 6 weeks switched to Tazorac® Cream, 0.1% for 6 weeks
3162806|NCT00469768|Experimental|A|
3162807|NCT00469768|Experimental|B|
3162808|NCT00469768|Placebo Comparator|C|
3162809|NCT00469781|Active Comparator|1|
3162810|NCT00469781|Other|2|
3162811|NCT00469872|Active Comparator|Child Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to improve child functioning
3162812|NCT00469872|Experimental|Context Focused|Occupational and physical therapy focused on improving child's skills and abilities through rehabilitation to change the task or environment around a child
3162813|NCT00469885|Other|1|Usual care
3162814|NCT00469885|Other|2|Reduction
2499502|NCT02906059|Experimental|AZD1775 & Irinotecan|"Group AZD1775 (study drug); Irinotecan (chemotherapy)~1) 125 mg two times a day (BID) for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2A) 150 mg BID for 3 days every 2 weeks; 180mg/m2 every 2 weeks~2B) 125 mg BID for 5 days every 2 weeks; 180mg/m2 every 2 weeks~3) 150 mg BID for 5 days every 2 weeks ; 180mg/m2 every 2 weeks"
2499553|NCT02905838|Active Comparator|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
2499555|NCT02905838|Active Comparator|CAD/CAM CARES Abutment|Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
3195870|NCT00844285||Comparison cohort|Patient must be about to receive treatment with any other medication as part of a pre-existing management plan for Crohn's disease or has already been receiving treatment (previous Cimzia® treatment is prohibited).
2499698|NCT02904642|No Intervention|Control|"All enrolled caregivers will receive a congratulatory text message at enrollment which indicates who is conducting the study and which also includes a general-health related saying, The greatest wealth is health. No additional text messages or travel subsidies will be sent to caregivers randomized to the control arm."
2499700|NCT02904642|Experimental|SMS reminder|At enrollment, participants will be told to expect 2 SMS reminders for measles vaccine; first, at 3 days before and second, on the day before the scheduled measles vaccine at 9 months of age. At most, enrolled caregivers will receive three text messages (two for the measles vaccine and one for welcoming mother to the study). Text messages will be sent in English, Kiswahili or Dholuo language, according to the mother's preference. These reminders will have information about the child's scheduled immunization date.
2499702|NCT02904642|Experimental|SMS reminder + Unconditional Incentive|Participants will receive SMS reminders as described in the SMS reminder arm. Additionally, participants will be sent a 150 Kenyan Shillings (KES) incentive to the mobile phone number they provided at enrollment. The incentive will be delivered three days before the child turns nine months (i.e. sent on the same day as the first SMS reminder). Caregivers will receive the mobile-money incentive unconditionally. The intent of the incentive is to help offset the costs associated with transportation to the clinic. The transaction costs associated with mobile-money transactions will be borne by the study such that mothers will receive the full 150 KES.
2499876|NCT02903329|Active Comparator|Protocol A|In program A, patients underwent detoxification without any acute medication during a two months period (complete stop of acute medication intake).
2499879|NCT02903329|Active Comparator|Protocol B|In program B, patients were allowed to take up to 2 days a week with analgesics or migraine medication during the two months detoxification period (restricted acute medication intake).
2499927|NCT02902978|Experimental|Cohort 1 to 7|Participants will receive a single dose of E6130 or placebo, administered in a dose-ascending manner under the fasted condition.
2499933|NCT02902978|Experimental|Cohort 8|Participants will receive a single dose of E6130 (determined in Cohort 1 to 7), administered in the specified order (fed/fasted or fasted/fed) to evaluate the food effect.
2500035|NCT02902133|Other|Acetazolamide Arm|Acetazolamide 500 mg twice per day for 5 consecutive days post standard-of-care endoscopic skull base surgery
3195871|NCT00844311|Active Comparator|Control arm|150 iu/day of rFSH alone
3195872|NCT00844311|Experimental|hCG low dose|150 iu/day of rFSH + 50 iu/day of hCG from stimulation day 1
3195873|NCT00844311|Experimental|hCG medium dose|150 iu/day of rFSH + 100 iu/day of hCG from stimulation day 1
3195874|NCT00844311|Experimental|hCG high dose|150 iu/day of rFSH + 150 iu/day of hCG from stimulation day 1
3195875|NCT00844324|Experimental|A|Candesartan cilexetil 1mg/mL
2500244|NCT02900560|Active Comparator|Cohort 1|CC-486 100 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2500247|NCT02900560|Active Comparator|Cohort 2|CC-486 100 mg twice a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2500249|NCT02900560|Active Comparator|Cohort 3|CC-486 300 mg once a day, 14 days on and 14 days off combined with Pembrolizumab 200 mg IV every 21 days
2500250|NCT02900560|Active Comparator|Cohort 4|CC-486 300 mg once a day, 21 days on, 7 days off combined with Pembrolizumab 200 mg IV every 21 days
2500280|NCT02900183|Experimental|ARC-AAT Injection|Intravenous administration of ARC-AAT Injection (4 mg/kg or 6 mg/kg) every 28 days for a total of 7 doses
3195876|NCT00844324|Experimental|B|Candesartan cilexetil 1.6mg/mL
3195877|NCT00844337|Active Comparator|1|One study arm will receive injectable gentamicin once daily and oral amoxicillin twice daily for seven days by comparison to other study arms.
2500442|NCT02898831|No Intervention|Control/No Intervention|Standard clinical procedure with intrauterine device insertion involving no heated/cold compresses on the abdomen during insertion.
2500443|NCT02898831|Experimental|Cold Compress/Experimental|Cold compress (intervention) placed on abdomen just before IUD insertion and remains throughout insertion. Pain scale and survey completed following insertion regarding pre-procedure and intra-procedure pain.
2500475|NCT02898571|Placebo Comparator|Placebo|360ml water based drink containing 50g mix of glucose and fructose plus flavouring
2500477|NCT02898571|Experimental|Vitamin C|360ml water based drink containig 60mg vitamin C and 50g mix of glucose and fructose plus flavouring
2500478|NCT02898571|Experimental|Epicatechin|360ml water based drink containig 80mg epicatechin and 50g mix of glucose and fructose plus flavouring
2500490|NCT02898337||Methadone-induced QTc interval prolongation|
2500491|NCT02898337||Methadone-treated patients, no QT interval prolongation|
3195878|NCT00844337|Active Comparator|2|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days
3195879|NCT00844337|Active Comparator|3|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days (COMPARISON ARM)
3195880|NCT00844350|No Intervention|letrozole+hCG|
2499504|NCT02906111|Active Comparator|Study Group on estriol vaginal gel|Drug: 1 g/daily of vaginal gel containing 50 μg of estriol (0.005%) for 3 weeks and then twice weekly for 9 weeks, for a complete cycle of treatment of 12 weeks
2499509|NCT02906111|Active Comparator|Control group, no estriol treatment|Procedure: vaginal surgery
2499576|NCT02905760|Experimental|Furosemide|Furosemide and Placebo filling (Glucose 5%).
2499582|NCT02905760|Active Comparator|Fluid expansion|"Placebo furosemide (Glucose 5%) and Vascular filling~The vascular filling is the gold standard in the treatment of acute myocardial infarction"
2499643|NCT02905162||HIV positive individuals incarcerated at Lusaka Central Prison|Cohort of individuals scheduled for release within 30 days will be followed for 6 months post release
2499672|NCT02904798|Experimental|Polypodium Leucotomos Extract (PLE)|"Patient will serve as their own control and will be exposed to 4 doses of visible light on one side of their back prior to receiving PLE.~PLE 240mg will be dispensed to patient after evaluation of Pre-PLE visible light doses are evaluated to be taken by the patient for a total of 28 day followed by exposure of the opposite side of the back with the same 4 doses of visible light as above"
2499712|NCT02904616|Experimental|Healthy volunteers|"Healthy volunteers wash their hands with a traditional soap. Every healthy volunteers pose with palm of hand three times on the device in order to measure basal level of fluorescence of the skin.~Healthy volunteers repeated three times this procedure in order to assess the reproducibility of the measurement."
2499785|NCT02904213|Experimental|Pentavalent vaccine|3 Dose, interval for each dose is 4 weeks. The first dose will be received at 8-10 weeks of age
2499835|NCT02903641|No Intervention|Control|All households in the study were given general child nutrition educational messaging, immediately after the baseline survey and prior to any treatments. This messaging focused on appropriate feeding habits complemented by breastfeeding and ways to maintain proper hygiene during food preparation and consumption.
2499843|NCT02903641|Experimental|Personalized information only|Household received the personalized information about the index child's height.
2499847|NCT02903641|Experimental|Labeled cash transfer only|Household received the labeled cash transfer.
2499849|NCT02903641|Experimental|Personalized information and labeled cash transfer|The household received both the personalized information intervention and labeled cash transfer intervention.
3195881|NCT00844350|No Intervention|letrozole+oxytocin|
3195882|NCT00844350|No Intervention|letrozole+oxytocin+hCG|
2500011|NCT02902367|Experimental|Intervention:|Outdoor walking and strength exercise, Three months, daily SMS.
2500013|NCT02902367|Other|Control group|Usual care; no restriction for exercise, Three months
2500042|NCT02901925|Experimental|ABY-029|ABY-029 will be administered prior to surgery. Probe will be used in vivo to determine if signal is detectable, and ex vivo tissue pathology will measure extent of binding with EGFR positive tumor tissue.
2500094|NCT02901639|Experimental|counseling group|will receive counseling about contraceptive methods using illustrations through postpartum interview with the study
2500098|NCT02901639|No Intervention|NO counseling|will not receive any counseling about contraceptive methods
2500155|NCT02901327|Experimental|Lumbar Stabilisation Exercise|30 minute lumbar stabilization exercise, 3 times per week for 8 weeks.
2500172|NCT02901327|Active Comparator|Treadmill walk exercise|Walking exercise on a treadmill for a maximum of 30 minutes with increasing speed and inclination. 3 times/week for 8 weeks.
2500225|NCT02900755|Experimental|Epilepsy|Epilepsy patients (focal onset seizure with or without secondary generalization)
3195883|NCT00844350|No Intervention|clomiphene citrate +oxytocin|
3195884|NCT00844350|No Intervention|clomiphene citrate +oxytocin+hCG|
2500622|NCT02897505|Experimental|Women enrolled in Empower Clinic|Women who are enrolled in the Empower Sanctuary will be asked to participate in a Music Workshop
2500690|NCT02897336|Experimental|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
2500692|NCT02897336|Active Comparator|interlaminar|interlaminar epidural corticosteroid injection
3195885|NCT00844363|Other|NB-UVB|Regular, monitored NB-UVB treatment. Patients will be treated 3 times per week, and a full course of therapy is 12 weeks. NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
3195886|NCT00844389|Active Comparator|NIR light|Group of patients stimulated with near to infrared light daily stimulation
2500880|NCT02896088|Other|test tooth groups|test tooth groups
2500883|NCT02896088|Other|control tooth groups|control tooth groups
2500946|NCT02895633|Experimental|Patients with bone or peripheral soft-tissue tumor|
2500970|NCT02895061|Experimental|A: Daily|A: oral daily alfacalcidol treatments total 6 microgram/week
2500972|NCT02895061|Experimental|B: Pulse|B: pulse (trice a week) alfacalcidol treatments total 6 microgram/week
3195887|NCT00844389|Placebo Comparator|Green light|Group of patients stimulated with green light.
3195888|NCT00844402|Experimental|Atorvastatin|Atorvastatin 10 mg per day for 48 weeks
3195889|NCT00844454|Experimental|QFEA|multi-pronged ethanol ablation
3195890|NCT00844454|Active Comparator|RFA|radiofrequency ablation
3195891|NCT00844480|Experimental|zoledronic acid|
3195892|NCT00844480|Placebo Comparator|placebo|
3195893|NCT00844493|Experimental|H10407 challenge 1|7 or 8 logs of E. coli strain H10407 with CeraVacx buffer
3195894|NCT00844493|Experimental|H10407 challenge 2|7 or 8 logs of E. coli strain H10407 with bicarbonate buffer
3195895|NCT00844493|Experimental|H10407 challenge 3|6 logs of E. coli H10407 with bicarbonate buffer
3195896|NCT00844493|Experimental|H10407 challenge 4|5 logs of E. coli H10407 with bicarbonate buffer
3195897|NCT00844571||E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
3195898|NCT00844571||control group|
3195899|NCT00844584|Other|ablation|patients with atrial fibrillation underwent radiofrequency ablation with totally thoracoscope.
3195900|NCT00844636|Active Comparator|Sharp Needles|Sharp needles to close uterus, fascia and skin during cesarean section
3195901|NCT00844636|Active Comparator|Blunt Needles|Assignment to blunt needles to close uterus, fascia and skin during cesarean section
3195902|NCT00844662|Experimental|1|
2499506|NCT02906124||Non exposed to Repatha®|Pregnant females with familial hypercholesterolaemia (FH) not exposed to Repatha® and enrolled into this study, overall and stratified by lipid lowering therapy use
3195903|NCT00844662|Active Comparator|2|
3195904|NCT00844675|Experimental|rabeprazole|rabeprazole
2499795|NCT02903875||laryngectomised patients since 1 month|laryngectomised patients since 1 month and their close relative
2499797|NCT02903875||laryngectomised patients since 3 months|laryngectomised patients since 3 months and their close relative
2499800|NCT02903875||laryngectomised patients since 6 months|laryngectomised patients since 6 months and their close relative
2499803|NCT02903875||laryngectomised patients since 12 months|laryngectomised patients since 12 months and their close relative
2499825|NCT02903498|Experimental|UFT treatment|Uracil and Tegafur
2499831|NCT02903498|No Intervention|comparator|no treatment, follow-up at regular time
2499877|NCT02903316||Fluid Therapy|Systematisation of fluids during CABG surgery
2500103|NCT02901509||CHIK +|People with chikungunya diagnosis (serodiagnosis)
2500106|NCT02901509||CHIK -|People without chikungunya diagnosis (negative serology)
2500166|NCT02901301|Experimental|4 combination|pembrolizumab 200mg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 capecitabine 1000mg/m2, PO, BID, Day 1-14 cisplatin 80mg/m2 (level 1), IV, q3weeks, Day 1
2500254|NCT02900742|Experimental|TCM granules plus Chemotherapy|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day until progression or unacceptable toxicity; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
2500255|NCT02900742|Placebo Comparator|Placebo granules plus Chemotherapy|Placebo granules: oral granules, oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day; Chemotherapy: Gemcitabine® 1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days or Pemetrexed® 500 mg/㎡, ivgtt 30 min, day 1, every 21 days or Docetaxel® 75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity.
2500410|NCT02899468|Experimental|Active Treatment Group|Active treatment will consist of the BrightBrainer Virtual Reality (BBVR) Rehabilitation System therapy intervention (3 sessions per week x 6 weeks). Standard validated outcome measures which assess various domains of function, will be obtained at baseline and then at 3 and 6 weeks for those randomized to the Active Treatment group.
2500411|NCT02899468|Other|Wait-List Control Group|Subjects randomized to the Wait-List Control (WLC) group will wait 3 weeks before beginning the Active Treatment program intervention (3 sessions per week x 6 weeks) using the BrightBrainer Virtual Reality (BBVR) Rehabilitation System. For those randomized to the WLC group, outcome measures will be assessed at baseline, completion of waiting period (3 weeks), then at 3 and 6 weeks after initiating active treatment.
2500565|NCT02897908||liver fibrosis and steatosis|measurements of liver fibrosis and steatosis will be obtained using Vibration controlled transient elastography FDA approved device- FibroScan for the purpose of building a data base of potential subjects for future research.
2500602|NCT02897661|Experimental|Early WMT and EEN|WMT (day1), EEN (day1-15)
2500610|NCT02897661|Experimental|Late WMT and EEN|WMT (day8), EEN (day1-15)
2500693|NCT02897362||Adolescents with ADHD|Adolescents, male or female, ages 13-17, confirmed diagnosis of Attention Deficit Hyperactivity Disorder (inattentive, hyperactive/impulsive, or combined presentations), medically healthy, no comorbid psychiatric diagnosis other than ODD, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
2500697|NCT02897362||Healthy Control Adolescents|Adolescents, male or female, ages 13-17, medically healthy, no psychiatric diagnoses, intelligence within normal limits. Participants will complete 3 nights of ambulatory polysomnography at home and a neuropsychological assessment in the lab.
2500866|NCT02895958|Other|Administration of Zepatier|
2500932|NCT02895750|Experimental|normal to mild renal impairment|(12 subjects): eGFR ≥ 60 (normal renal function to mild renal impairment, CKD stages 1-2) METFORMIN
2500937|NCT02895750|Experimental|mild to moderate renal impairment|(12 subjects): eGFR 59-45 (mild to moderate renal impairment, CKD stage 3a) METFORMIN
2500944|NCT02895750|Experimental|moderate to severe renal impairment|(12 subjects): eGFR 44-30 (moderate to severe renal impairment, CKD stage 3b) METFORMIN
2500982|NCT02895113|Experimental|Aspirin|Patients will be treated with aspirin 100 mg/day for one year
2500985|NCT02895113|Placebo Comparator|Placebo|Patients will be treated with placebo for one year
2501154|NCT02894281||Measure of pupillary light reflex|patients without optic neuritis
2501156|NCT02894281||patients with optic neuritis|clinical database of 22 patients (measurement of pupillary light reflex already performed for the same purpose, in a former study)
2501214|NCT02893566|Experimental|Mi Band Step Challenge|
3162815|NCT00469924|Experimental|Alerting system ON|Alerting system is ON
3162816|NCT00469924|No Intervention|Alerting system OFF|Alerting system is OFF
2501412|NCT02892071|Active Comparator|22% TCA peel|22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
2501620|NCT02890823|Experimental|EIAEDs-6000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
3162817|NCT00469937|Experimental|Therapeutic Intervention|
3162818|NCT00469963|Experimental|SIR-SPHERES|
3162819|NCT00470015|Experimental|MART1 Analog, gp100 and Survivin|
3162820|NCT00470080|Experimental|1|venepuncture
3162821|NCT00470119|No Intervention|Control|
3162822|NCT00470119|Other|Caloric Restriction|Nutritionist-delivered weight loss intervention though diet modification with an aim of 10% weightloss over a year long intervention based on the DPP and LookAHEAD interventions. Participants meet with a nutritionist individually and in small groups. Participants receive general information about diet and behavior strategies such as self-monitoring, goal-setting, stimulus-control, problem-solving, and relapse-prevention training. Participants learn to set a calorie goal and a fat gram goal and how to achieve the goal calorie reduction. Meetings are held weekly during the first 6 months of the diet program but taper off over the course of the study.
2499508|NCT02906137|Experimental|HIV-1 infected subjects|"40 subjects will be recruited in the Department of Infectious Diseases of Toulouse University Hospital, France:~15 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~15 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
2499510|NCT02906137|Other|Uninfected-controls|"30 subjects will be recruited in the Department of Internal Medicine of Toulouse University Hospital, France:~10 subjects will have an upper endoscopy (gastroscopy) with duodenal sampling~10 subjects will have a lower endoscopy (coloscopy) with colonic and ileal sampling~10 subjects will have both a gastroscopy and a coloscopy"
2499562|NCT02905747|Experimental|Medical Exercise Therapy|Medical Exercise Therapy (MET) developed by Oddvar Holten
2499606|NCT02905396|Experimental|Spinal cord stimulation|implantation of spinal cord stimulator
2499652|NCT02905019|Active Comparator|Standard Dose x3 (Group 1)|R21 with Matrix-M1. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0, 28 and 56.
2499653|NCT02905019|Active Comparator|High Dose (Group 2)|R21 with Matrix-M1. Two vaccinations with 50µg R21/50µg Matrix-M1 on days 0 and 28 and one vaccination with 10 µg R21/ 50 µg Matrix M1 on day 56.
2499654|NCT02905019|Active Comparator|Combination (Group 3)|R21 with Matrix-M1, ChAd63 ME-TRAP and MVA ME-TRAP. Three vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 , 28 and 56. Plus one vaccination with ChAd63 ME-TRAP on day 7 and one vaccination with MVA ME-TRAP on day 63.
2499655|NCT02905019|No Intervention|Control Group 4a|These volunteers will not be vaccinated and will serve as infectivity controls when groups 1-3 undergo challenge.
2499657|NCT02905019|No Intervention|Control Group 4b|These volunteers will not be vaccinated and will serve as infectivity controls when group 5-7 and sterilely protected volunteers from groups 1-3 undergo challenge.
2499659|NCT02905019|No Intervention|Control Group 4c|These volunteers will not be vaccinated and will serve as infectivity controls if any volunteers from groups 5 and 7 are rechallenged.
2499660|NCT02905019|Active Comparator|Fractional Dose (Group 5)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28 and one vaccination with 2µg R21/ 50 µg Matrix-M1 on day 56.
2499661|NCT02905019|No Intervention|Long-term Efficacy (Group 6)|Volunteers in this group have received vaccinations in a different malaria vaccine trial. These volunteers will not receive any vaccinations in this trial, but will undergo controlled human malaria infection as part of this study.
2499662|NCT02905019|Active Comparator|Standard Dose x2 (Group 7)|R21 with Matrix-M1. Two vaccinations with 10 µg R21/ 50 µg Matrix-M1 on days 0 and 28.
2499710|NCT02904486|Experimental|change behavior|Modified Health Belief Model Based Intervention and study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
2499711|NCT02904486|Experimental|lifestyle behavior|study health topic in classroom to change behavior for Reduce Body Mass Index for Age in Overweight Junior High School Students.
2499782|NCT02904187|Other|Profound deaf patients|Profound deaf patients with bilateral cochlear implants: Cortical brain activation pattern obtained by PET and EEG
2499786|NCT02904187|Other|Healthy volunteers|Healthy volunteers: Cortical brain activation pattern obtained by PET and EEG
2499885|NCT02903433|Experimental|High Intake Group|"Throughout the entire study, this group will be provided with 14 avocados per week and will receive 12 bi-weekly home visits over a 6-month period during which they will receive specific brochures offering diet tips. This group will be given specific advice on avocado consumption. Each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
2499888|NCT02903433|Active Comparator|Low Intake Group|"This group will receive 3 avocados per week, as well as 12 bi-weekly home visits over a 6-month period during which they will be provided with the same educational materials (i.e., Diet Tips) as those assigned to the High intake group. Participants in this group will be encouraged to improve the quality of their diets, but will not be given specific advice on avocado consumption. However, each month throughout the study, we will provide opportunities for families to visit the study kitchen at the SYHC to observe the staff preparing recipes with avocado, participate in preparing recipes, and taste recipes."
2499917|NCT02902861|Active Comparator|methotrexate|Once weekly (every 7 days) s.c. administration of 17.5 mg MTX. If PASI50 is not reached after 8 weeks (week 8) or PASI75 is not reached after 24 weeks, the dosing will be increased to 22.5 mg MTX/week. If patients were already dosed with 22.5 mg MTX/week in week 24 and PASI50 is not reached, patients will be excluded from treatment. Primary endpoint after 16 weeks.
2499919|NCT02902861|Placebo Comparator|Placebo (NaCl-Solution)|Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
2500003|NCT02902575|Experimental|Laparoscopic-assisted Gastrectomy|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
2500044|NCT02902055|Active Comparator|Rocuronium 1 mg/kg i.v.|Neuromuscular blocking agent
2500054|NCT02902055|Active Comparator|Isotonic saline|
2500087|NCT02901626|Experimental|Pessary|Arabin pessary. Participants where local standard of care includes vaginal progesterone will also receive progesterone.
2500090|NCT02901626|No Intervention|No Pessary|Participants that do not receive a pessary will receive the usual standard of care, including vaginal progesterone if that is the local standard.
2500175|NCT02901041|Experimental|Zonisamide & Computerized Psychotherapy|Zonisamide capsules (with a target maintenance dose of 400 mg daily) and a seven module computerized psychotherapy for alcohol use disorders called Take Control (9 sessions) will be administered over the course of 12 weeks, followed by a two week medication taper.
2500178|NCT02901041|Active Comparator|Placebo & Computerized Psychotherapy|Placebo capsules (for zonisamide) and a seven module computerized psychotherapy for alcohol use disorders called Take Control will be administered over the course of 14 weeks.
2500215|NCT02900703||PATIENT|
2539911|NCT02631278|Other|single arm|Intraoperative radiofrequency ablation
2499519|NCT02905994|Experimental|Volasertib with chemotherapy|"Patients enrolled on this trial will receive induction chemotherapy with 7+3~Cytarabine continuous infusion days 1-7~Idarubicin IV bolus on days 1, 2, and 3.~Patients will receive Volasertib as an intravenous infusion over approximately 1 hour, according to dosing level, on day 8~Patients will receive Standard Anti Fungal and Standard Antibiotic during induction~A bone marrow biopsy will be performed according to standard practice on day 14"
2499558|NCT02905604|Experimental|dmPFC iTBS|Repetitive transcranial magnet stimulation (rTMS) over the dorsomedial prefrontal cortices at 90% of the resting motor threshold of the foot flexors. The rTMS is given in 20 trains to the left and right dmPFC, respectively. Each train consists of 10 bursts at 5 Hz (theta-frequency), and each burst consists of 3 pulses at 50 Hz. The stimulation is intermittent with 2 seconds of stimulation, 8 seconds off. After a 15 minute break the whole protocol i applied again, resulting in 2400 pulses/day. Treatment is delivered daily at 10 week days.
2499559|NCT02905604|Sham Comparator|dmPFC Sham iTBS|A sham treatment protocol by using a sham coil with two identical sides where one side give active treatment as described above while on the other side the coil is insulated so very little magnetic energy is delivered. The coil has a built in positioning sensors and a software handling the randomization codes prompts the operator which side of the coil that should be directed towards the patient. Superficial transcutaneous electrical nerve stimulation (TENS) is applied over the stimulation site of the dmPFC synchronous wiht the TMS pulses to further mimic the sensation of the active stimulation.
2499742|NCT02904369|Experimental|F/TAF 200/10|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/10 mg)
2499744|NCT02904369|Experimental|F/TAF 200/25|Emtricitabine (FTC) + Tenofovir Alafenamide (TAF) (200/25 mg)
2499745|NCT02904369|Active Comparator|F/TDF 200/300|Emtricitabine (FTC) + Tenofovir Disoproxil Fumarate (TDF) (200/300 mg)
2499778|NCT02903901|Placebo Comparator|Placebo|Individuals who are randomized to the control arm will receive liquid placebo sublingually 60-90 minutes prior to surgery.
2499787|NCT02903901|Active Comparator|Melatonin|Individuals who are randomized to the treatment arm will receive 10 mg liquid IR-SL melatonin 60-90 minutes prior to surgery
2499828|NCT02903602|Experimental|CHW training method-Sharing Histories|"Experimental clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing the experimental teaching methodology, Sharing Histories.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
2499840|NCT02903602|Active Comparator|CHW training method-Standard|"Control clusters of primary health care facilities provided training to Community Health Workers (CHW) from their communities utilizing a standard CHW teaching methodology.~CHW in both study groups made home visits to pregnant women and mothers of children under two years of age to teach mothers, monitor behaviors and danger signs in pregnant women, newborns, and children, and refer cases when needed for preventive and curative care."
2499875|NCT02903303|Other|Treatment|There will be only one arm for this pilot study. All participants will follow 4 hypnosis sessions, and then the facet block.
2499906|NCT02903056||Rett Syndrome|Rett Syndrome is a neurodevelopmental disease that primarily affects girls. Clinically, patients are normal before six months to one and half years old, and then develop progressive severe problems with communication, learning, co-ordination and neurodevelopment, with loss of motor skills around the age of two. At the same time, stereotyped hand movement typically appears.
2499907|NCT02903056||Control-normal|Healthy people
3195905|NCT00844675|Experimental|placebo|placebo
3195906|NCT00844688|Other|sorafenib/gemcitabine|
3195907|NCT00844701||Non-smoker|Non-smoking control
2500038|NCT02901873|Active Comparator|Thyroid surgery|Electrical Impedance Spectroscopy in Thyroid surgery
2500041|NCT02901873|Active Comparator|Parathyroid surgery|Electrical Impedance Spectroscopy in parathyroid surgery
2500117|NCT02901678|Active Comparator|Intrusion by 200 g|Applying 200 g intrusive force for the maxillary posterior segment intrusion using miniscrews
2500120|NCT02901678|Experimental|Intrusion by 400 g|Applying 400 g of Intrusive force for the maxillary posterior segment intrusion using miniscrews
2500153|NCT02901132||Cancer group 1|Colorectal cancer patients, under 18 years old, no inflammatory disease, weight loss greater 10% habitual body weight, sarcopenic.
2500173|NCT02901132||Control group|No cancer patients, under 18 years old, no inflammatory disease, no weight loss, no sarcopenic.
2500276|NCT02900443|Experimental|Mycophenolate mofetil|The intervention group will receive oral mycophenolate mofetil for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
2500277|NCT02900443|Active Comparator|Azathioprine|. The control group will be treated with azathioprine (standard of care) for 24 weeks. Both groups will be treated with steroid induction which will closely follow the schedule from the recent EASL Clinical Practice Guidelines.
2500326|NCT02899858|Experimental|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
2500374|NCT02899364|Experimental|Sodium thiosulfate|25 gram sodium thiosulfate is given intravenously in two doses of 12.5 gram (50mL) dissolved in 250 ml sodium chloride 0.9%. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15 mL/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he will receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
2500427|NCT02898922|Experimental|HCV group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
3195908|NCT00844701||Nicotine Dependent Smoking Group|current smokers
3195909|NCT00844727|Active Comparator|1|Rofexocib 25 mg OD, 1 year treatment
2499524|NCT02905890|Experimental|Norethisterone enanthate plus condoms|200 mg Norethisterone enanthate intramuscularly every eight weeks at enrolment, 2 and 4 months. Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
2499526|NCT02905890|Active Comparator|Condoms only|Counseling and condoms will be provided at enrolment, 1, 2, 3 and 4 months.
2499551|NCT02905617||Primary Augmentation|
2499552|NCT02905617||Revision Augmentation|
2499590|NCT02905487||GDM|Mother-child pairs from mothers with GDM diagnosis (ADA, 2012)
2499595|NCT02905487||No GDM|Mother-child pairs from mothers without GDM diagnosis (ADA, 2012)
2499621|NCT02905123|Experimental|Check Your Drinking (CYD)|The CYD is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
2499626|NCT02905123|No Intervention|Control|No Intervention Control
3195910|NCT00844727|Placebo Comparator|2|Placebo
3195911|NCT00844740|Experimental|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood and urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
2499747|NCT02904330|Experimental|Single dose|The intervention is K1-70 intramuscular or K1-70 intravenous. This is a single, ascending, intramuscular or intravenous dose, sequential group study.
2499852|NCT02903771|Experimental|Part A and Part B|"Part A (Dose Escalation):~Part A is a Dose Escalation study to determine the Maximum Tolerated Dose of Cantrixil as a monotherapy.~The tolerance of Cantrixil in combination with standard chemotherapy agents will also be examined.~Part B (Expansion Cohort):~An expansion cohort of an additional 12 patients will be recruited at the MTD."
2499891|NCT02903147|Experimental|Functional Meta-Cognitive Intervention|The intervention is aimed to improve human factors of professional bus drivers
2499893|NCT02903147|Active Comparator|Control group|The control group had the employer's training - The company holds routine covert inspections, summons to conversations with the security offices and records in the drivers' personal files.
2499929|NCT02902900||Imnovid|Patients relapse/ refractory multiple myeloma who initiated pomalidomide in routine clinical practice
2500086|NCT02901782|Experimental|Personalized titanium plate|Ten males and two females with a mean age of 22.8 years were recruited. They all had bone tumor around the knee.
2500141|NCT02901379|Experimental|Atorvastatin 80mg|Subjects who will receive atorvastatin 80mg for two weeks
2500143|NCT02901379|Active Comparator|Atorvastatin 10mg|Subject who will receive atorvastatin 10mg
2500160|NCT02901002||Patient|Patients suffering from CRPS of the lower limb Patients with sensory testing in the two hand and neuropsychological evaluation
2500170|NCT02901002||Control|Healthy controls match by age, gender, Body Mass Index Healthy volunteers with sensory testing in the two hand and neuropsychological evaluation
2500213|NCT02900729|Experimental|Renal Denervation plus Medications|Renal denervation procedure after randomization plus maintenance of baseline standardised triple anti-hypertensive medications for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days
2500222|NCT02900729|Active Comparator|Medications|Maintenance of baseline standardised triple antihypertensive medications after randomization for 90 days and then medically necessary adjustment of antihypertensive medications for another 90 days, after which, subjects will be allowed to cross over to perform renal denervation if they still meet the inclusion criteria for the study.
2500258|NCT02900196|Experimental|1 - Test|
2500259|NCT02900196|Placebo Comparator|2 - Placebo|
3195912|NCT00844779||T|(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.
2500382|NCT02899533||FES PET/CT scan|All subjects will receive an [18F]FES PET/CT scan.
3195913|NCT00844779||A|(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).
3195914|NCT00844779||B|(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).
2500485|NCT02898324|Experimental|KiVa program full|The schools allocated in this arm will receive the Chilean adaptation of KiVa program with all its universal and indicated actions.
2500486|NCT02898324|Experimental|KiVa program w/o the digital component|The schools allocated in this arm will receive the Chilean adaptation of KiVa program without the digital component (online game)
2500487|NCT02898324|No Intervention|Control group|The schools allocated in this arm will not receive the KiVa program. If successful, these schools will receive the program the following academic year.
3195915|NCT00844792|Experimental|1|This group of men will be on active treatment (antioxidants)for 6-8 weeks prior to their radical prostatectomy.
2500633|NCT02897622|Other|Case management|Case management
2500678|NCT02897245||Patient with intentionally stop|
2500777|NCT02896985||Participants with Crohn's disease|Participants who have developed LOR to adalimumab after a minimum of 16 weeks of treatment.
3195916|NCT00844792|Placebo Comparator|2|This group of men will be on placebo for 6-8 weeks prior to their radical prostatectomy.
3195917|NCT00844818|No Intervention|Control|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
3195918|NCT00844818|Experimental|Intervention Group|Moms and dads who were current smokers (1 cigarette, even a puff, in past 30 days) or recent quitters (smoked since one month prior to conception)
2500882|NCT02895893|Experimental|Smartphone app condition|"Men who are at risk for HIV and already prescribed and taking Truvada will be asked to use an application on their smart phones called PrEP Smart."
2500957|NCT02895685|Experimental|Dyad training|Participants randomized to train in pairs during the whole 6-week course
3195919|NCT00844870|Active Comparator|1|stabilization training group
3195920|NCT00844870|Experimental|2|auditory response training group
3195921|NCT00844922|Experimental|Org 34517|Org 34517 titrated to 900 mg daily for 2 weeks
3195922|NCT00844922|Placebo Comparator|Placebo|
2499577|NCT02905526|Experimental|Intervention|App plus the contraceptive instant messages
2499586|NCT02905526|Placebo Comparator|Control|App only
2499620|NCT02905253|Experimental|AC-084, single ascending dose (Part A)|AC-084 administered at different single dose levels in a sequential manner, and in a maximum of 7 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
2499623|NCT02905253|Placebo Comparator|Placebo,single ascending dose (Part A)|Matched placebo administered as single ascending doses in parallel to AC-084
2499627|NCT02905253|Experimental|AC-084, multiple ascending dose (Part B)|AC-084 administered in a twice daily (b.i.d.) dosing regimen at multiple dose levels. The starting dose will be between 1 and 30 mg and will be selected on the basis of the safety and pharmacokinetic results of the part A. Each dose level will be investigated in a new group of at least 8 healthy male subjects (6 on active drug and 2 on placebo)
2499631|NCT02905253|Placebo Comparator|Placebo,multiple ascending dose (Part B)|Matched placebo administered as multiple ascending doses in parallel to AC-084
2499633|NCT02905253|Experimental|AC-084, single dose (Part C)|Up to 6 subjects in part C will receive AC-084 administered at a single dose (foreseen to be 100 mg)
2499683|NCT02904785|Experimental|Extracorporeal Shock Waves|Focused shock waves delivered by an electromagnetic generator with a focus of 5.0cm deep on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks.
2499686|NCT02904785|Sham Comparator|Sham Extracorporeal Shock Waves|Sham focused shock waves delivered by an electromagnetic generator on the affected knee in three different positions. A total of 7000 pulses will be delivered on a weekly session for four weeks. A foam will be placed in the probe as to stop the energy to be transmitted to the patient's knee, so no focused shockwaves will be delivered.
2499750|NCT02904174|Experimental|Healthy Living Programme|6 weeks program, with 45 minutes weekly session over 6 weeks.Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies.
3175040|NCT00629473|Experimental|Arm MM: multiple myeloma|Dose Escalation - 8 dose cohorts NPI-0052 on Days 1, 4, 8, 11 every 21 days NPI-0052 doses ranging from 0.075 to 0.6 mg/m2 Dexamethasone 20 mg oral or IV day before and day after NPI-0052 dosing.
2500068|NCT02901938|Experimental|cemented femoral stem group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo implantation of cemented femoral stem.
2500070|NCT02901938|Experimental|cannulated compression screws group|The patients with avascular necrosis of the femoral head complicated by osteoporotic femoral neck fracture will be randomly assigned to undergo percutaneous internal fixation with cannulated compression screws.
2500125|NCT02901496|Experimental|Endurance exercise + infusion of Tocilizumab|Endurance exercise training + monthly infusion of Tocilizumab
2500128|NCT02901496|Experimental|Endurance exercise + infusion of placebo|Endurance exercise training + monthly infusion of placebo
2500134|NCT02901496|Experimental|No exercise + infusion of Tocilizumab|No exercise + monthly infusion of Tocilizumab
2500137|NCT02901496|Placebo Comparator|No exercise + infusion of placebo|No exercise training + monthly infusion of placebo
2500139|NCT02901496|Experimental|Resistance exercise + infusion of placebo|Resistance exercise training + monthly infusion of placebo
2500195|NCT02900937|Experimental|Coronary Scaffold Implantation|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
2500260|NCT02900313|Other|Patients having cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
2500335|NCT02899741|Experimental|Omega-3|One group of this study. Omega-3 will be administered for thee months.
2500384|NCT02899403|Experimental|healthy subjects|
2500453|NCT02899039|Experimental|IgG4-related disease|Subjects suffering from IgG4-related disease
3175041|NCT00629486|Experimental|cytokines were determined|prevalence of genetic polymorphisms of interleukin 1B was measured in HBV-related hepatocellular carcinoma
3175042|NCT00629512|Experimental|1|20mg oral daily
3175043|NCT00629512|Experimental|2|40mg oral daily
3175044|NCT00629512|Placebo Comparator|3|
3175045|NCT00629551|Experimental|Saredutant 100mg and Paroxetine 20 mg|combined saredutant 100mg and paroxetine 20mg once daily for a maximum of 8 weeks
3175046|NCT00629551|Experimental|Saredutant 30mg and Paroxetine 20mg|combined saredutant 30mg and paroxetine 20mg once daily for a maximum of 8 weeks
3175047|NCT00629551|Active Comparator|Paroxetine 20 mg and saredutant placebo|paroxetine 20mg and saredutant placebo once daily for a maximum of 8 weeks
3175048|NCT00629551|Placebo Comparator|Placebo|Saredutant placebo and paroxetine placebo once daily for one week during screening period and maximum of 8 weeks for the active phase
3175049|NCT00629564|Active Comparator|1|20mg oral
3175050|NCT00629564|Active Comparator|2|15 minute intravenous infusion
3175051|NCT00629590|Experimental|1|
3175052|NCT00629590|No Intervention|2|
3175053|NCT00629603|Experimental|cytokine polymorphisms, HCV infection|Relate the fibrosis cytokine gene polymorphisms with disease severity of HCV-related chronic liver disease
3175054|NCT00629616|Experimental|Arm A|Anastrozole
3175055|NCT00629616|Experimental|Arm B|Fulvestrant
3175056|NCT00629629|Other|I, Intervention|
3175057|NCT00629642|Experimental|I.Solifenacin succinate 10mg (2x5mg 1/day)|Oral
3175058|NCT00629642|Experimental|II.Solifenacin succinate 5mg (5mg 1/day)|Oral
3175059|NCT00629642|Active Comparator|III.Oxybutynin hydrochloride 15mg (5mg 3/day)|Oral
3175060|NCT00629642|Placebo Comparator|IV. Placebo|Oral
3175061|NCT00629655||1|healthy people, male
3175062|NCT00629655||2|male patients with cerebral infarction, chronic stage
3175063|NCT00629681|Experimental|1|
3175064|NCT00629694|Active Comparator|A-T|
2499528|NCT02905903|Other|Trichloroacetic Acid|Intervention-Apply 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study. Comparisons will be made using Investigators Global Assessment scoring of hyperpigmentation and erythema, colorimetry, photography, and biopsies
2499557|NCT02905643||Study subjects|Patients who have or might have a brain tumor which may be a glioblastoma.
2499591|NCT02905409|Active Comparator|4PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 4PD (papillary diameter) group, patients were given 4PD diameter of ILM (internal limiting membrane) peeling in surgery.
2499597|NCT02905409|Experimental|2PD diameter of ILM peeling in surgery|Patients were stratified according to the macular hole closure index(MHCI) measured by OCT into 3 subgroup (MHCI<0.5, 0.5≤MHCI<0.7, MHCI≥0.7 ). And then randomized into 2 different intervention groups. If randomized into 2PD (papillary diameter) group, patients were given 2PD diameter of ILM (internal limiting membrane) peeling in surgery.
2499639|NCT02905071|Experimental|Study 1 Group 1 G1 (n =50)|filling of Serenat at baseline (T1)
2499641|NCT02905071|Experimental|Study 1 Group 2 G2 (n=50)|Serenat at baseline T1 and 3 others questionnaires
2499645|NCT02905071|Experimental|Study 1 Group 3 G3 (n =50)|filling of Serenat at baseline T1 and T2 (one week after baseline).
2499646|NCT02905071|Experimental|Study 2 Ancillary study (n=50)|filling of Serenat, HADS, STAY-Y and BDI at baseline T1
2499733|NCT02904421||Group 1|the placebo group
2499735|NCT02904421||Group 2|the low-dose treatment group with 600mg calcium + 400IU Vit-D3/day
2499737|NCT02904421||Group 3|the high-dose treatment group with 600mg calcium + 800IU Vit-D3/day
2499770|NCT02904044||Injured/Case|Secondary school pupil injured during a physical activity lesson between 2012-2014 in south of Reunion Island
2499773|NCT02904044||Control|Same age and gender than case in the same classroom and during the same physical activity lesson
2499850|NCT02903719|Other|Group A|"st intervention: A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml~nd intervention (approx. 15 minutes after 1st intervention): A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml"
2499856|NCT02903719|Other|Group B|"st Intervention: A single ultrasound guided perineural injection of isotonic saline solution 9 mg/ml, 3 ml~nd Intervention (approx. 15 minutes after 1st intervention):A single ultrasound guided perineural injection of Ropivacaine 7,5 mg/ml, 3 ml"
2499874|NCT02903173||Women who undergo cesarean delivery|
2499910|NCT02903082||Case|Patient hospitalized in intensive care for sepsis evolving for less than 48 hours with two criteria of systemic inflammatory response syndrome
2499911|NCT02903082||Control|10 Patients hospitalized for a hematologic pathology workup considered normal by two haematologists and 10 patients hospitalized for a preoperative workup.
2499954|NCT02902692|Experimental|Brief Mindfulness|45 minute brief mindfulness intervention (lead by study investigator) on day 1 followed by 7 days of 30 minute mindfulness practice at home (without study investigator)
2500007|NCT02902380|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
2500010|NCT02902380|Placebo Comparator|Control Group|0.9% saline infusion
2500023|NCT02901990||GMT-low-level group|low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
2500029|NCT02901990||GMT-high-level group|high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study
2500109|NCT02901769|Experimental|Depressed suicide attempters|20 subjects
2500112|NCT02901769|Experimental|Depressed patients with past history of|20 subjects
2500116|NCT02901769|Experimental|Depressed patients with no history of|20 subjects
2500119|NCT02901769|Placebo Comparator|Healthy controls|20 subjects
2500149|NCT02901158||Critical care patients|Mechanically ventilated patients in the critical care unit
2500150|NCT02901158||OR-patients|Mechanically ventilated patients in the operating room
2500266|NCT02900352|Experimental|Zonisamide|Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind (Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose). Subjects may increase their dose to 600mg daily during the target treatment period if it is thought to be beneficial.
2500271|NCT02900352|Placebo Comparator|Placebo|Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group)
2500317|NCT02899975|Other|Validation Swiss|20 german talking elderly and the non-professional caregiver will validate a Fitness and Information software
2500337|NCT02899598|Experimental|Pregnant women|
2500377|NCT02899390|Experimental|Lifestyle Intervention|All the participants will be offered group and individual sessions to help them accomplish weight loss and also increase physical activity.
2500420|NCT02899000|Experimental|Acne treatment|"Topical adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel (one application daily for 12 weeks)~Oral doxycycline hyclate, 200 mg per day (two 50-mg tablets twice daily for 12 weeks)"
2500467|NCT02898688|Other|Control Site + Control Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to the control group.
2500470|NCT02898688|Experimental|Control Site + Intervention Patient|The obstetric practice site is randomized to be a control site and the patient is randomized to receive the intervention.
2500471|NCT02898688|Experimental|Intervention Site + Control Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to the control group.
2500472|NCT02898688|Experimental|Intervention Site + Intervention Patient|The obstetric practice site is randomized to be an intervention site and the patient is randomized to receive the intervention.
2500518|NCT02898285|Active Comparator|Personal time condition|"People randomized to this group will be asked to go on a night out with no kids (i.e. dinner, or a movie) once a month."
2500606|NCT02897687|Active Comparator|Book Club Group|An in-person Book Club discussing material related to Autism Spectrum Disorder.
3175065|NCT00629694|Experimental|A-M|
2499570|NCT02905578|Experimental|Ascorbate group|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Pharmacological ascorbate: 75 grams, three times weekly for 4 weeks"
2499574|NCT02905578|Active Comparator|Control|"Each cycle is 4 calendar weeks~Gemcitabine: 1000 mg/m2, once weekly for 3 weeks nab-paclitaxel: 125 mg/m2, once weekly for 3 weeks Each cycle has 1 rest week"
2499703|NCT02904473|Experimental|GROWell|GROWell incorporates 4 elements: phone coaching, goal setting, self-monitoring of behavior and skills training. These interactions take place on a study subject's cell phone, through text messaging, and phone calls with a dietician coach. At study initiation, the subject takes a short survey, after which the intervention algorithm assigns up to 4 tailored behavior change goals from the GROWell library. Goals are tailored to the subject's needs as indicated by the initial survey. Subjects self-monitor adherence weekly via text, responding to prompts from the system regarding their level of success with a given goal. Via text they receive immediate tailored feedback regarding their current adherence and long-term progress.
2499706|NCT02904473|No Intervention|Attention Support Control (ASC)|The ASC control arm of the study involves one coaching call at baseline, regarding prenatal diet. Weekly text or IVR messages will focus on pregnancy, labor, delivery, and early infancy education.
2499708|NCT02904473|No Intervention|Usual Care (USC)|The USC will receive no intervention. They will simply complete baseline and follow-up CASI and blood draw.
2499951|NCT02902679|Experimental|End Stage Renal Disease Subjects|Subjects given a single oral dose of BMS-986177 before (Period 1) and after (Period 2) a hemodialysis session
2500002|NCT02902445||Case group|250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit for diagnosed rotavirus acute gastroenteritis: rotavirus rapid screen test and oral swab for polymorphism exploration
2500006|NCT02902445||Control group|"250 children from Nantes University Hospital and 150 children from Guyana Hospital admitted in paediatric emergency unit without signs of infection and / or digestive clinical picture evocative of gastroenteritis.~Paired with a case upon ethnicity or origin if impossible to match the ethnicity of the case.~oral swab for polymorphism exploration"
2500046|NCT02901964|Experimental|Group Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
2500052|NCT02901964|Active Comparator|Group Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
2500081|NCT02901613|No Intervention|Retrospective|Standard dry sterile dressing
2500083|NCT02901613|Experimental|Prospective|Negative-pressure wound therapy
2500131|NCT02901392||Artificial urinary sphincter AMS-800®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AMS-800®
2500133|NCT02901392||AdVance/AdvanceXP®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with AdVance/AdvanceXP®
2500138|NCT02901392||VIRTUE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with VIRTUE®
2500140|NCT02901392||INVANCE®|Male patients with stress urinary incontinence after prostatectomy or radiotherapy treated with INVANCE®
2500188|NCT02901015|Other|Schizophrenic patients group 1|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
2500189|NCT02901015|Other|Schizophrenic patients group 2|80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).
2500242|NCT02900638|Experimental|Intervention (Mentor/Mentee)|
2500246|NCT02900638|No Intervention|Wait list control|
2500309|NCT02900105|Experimental|Letrozole|Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
2500396|NCT02899182|Placebo Comparator|conventional group|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
2500399|NCT02899182|Experimental|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
2500421|NCT02898896|Other|HIV-infected patients|HIV-infected patients >= 45 years with 2 or more CV risk factors currently on ART and HIV-RNA < 50 copies >= 12 months (one blip allowed) As part of this research, three additional tubes of blood (EDTA) will be taken from patients (21 mL) during blood tests performed as part of a scheduled consultation for the management of their pathology
3175066|NCT00629733|Experimental|Ro-14|
3175067|NCT00629746|Experimental|NIM (Nerve Integrity Monitor)|
3175068|NCT00629759|Experimental|1|1e8 pfu (plaque forming units)total dose each treatment day
3175069|NCT00629759|Experimental|2|3e8 pfu (plaque forming units) total dose each treatment day
3175070|NCT00629759|Experimental|3|1e9 pfu (plaque forming units) total dose each treatment day
3175071|NCT00629759|Experimental|4|3e9 pfu (plaque forming units) total dose each treatment day
3175072|NCT00629824|Active Comparator|A|110 naïve CHC patients who are 65 to 80 years of age
3175073|NCT00629824|Active Comparator|B|140 naïve CHC patients who are 50 to 64 years of age
3175074|NCT00629824|Active Comparator|C|40 HCV-1 infected patients with an RVR who are 65-80 years of age will receive 24 weeks of treatment
3175075|NCT00629837|Experimental|Arm 1|
3175076|NCT00629837|Experimental|Arm 2|
3175077|NCT00629837|Active Comparator|Arm 3|
3175078|NCT00629837|Active Comparator|Arm 4|
3175079|NCT00629876|Experimental|Peginesatide|
3175080|NCT00629889|Active Comparator|Levetiracetam|Patients assigned to Levetiracetam are treated with the initial dose of 2 x 250mg per day up to one year
3175081|NCT00629889|Active Comparator|Pregabalin|Patients assigned to Pregabalin are treated with the initial dose of 2 x 75mg per day up to one year
3175082|NCT00629902||A1|Patients with prosthesis-patient mismatch after mitral valve replacement
3175083|NCT00629902||A2|Patients without prosthesis mismatch after mitral valve replacement
3175084|NCT00629928|Experimental|1|20mg capsule once daily
3175085|NCT00629928|Experimental|2|40mg capsule daily
3175086|NCT00629928|Placebo Comparator|3|
2499536|NCT02906020|Experimental|GZ/SAR402671|Part 1: Increasing dose of GZ/SAR402671 will be administered once per day. Part 2: A dose of GZ/SAR402671 (determined in Part 1) will be administered once per day.
2499538|NCT02906020|Placebo Comparator|Placebo|A matching placebo for Parts 1 and 2 will be administered once per day.
3195923|NCT00844948||Young adults (18-25 years old)|Young adults (18-25 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
2499768|NCT02904109|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo.
2499771|NCT02904109|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
2499829|NCT02903628|Experimental|eye health education|
2499880|NCT02903355|Placebo Comparator|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
2499883|NCT02903355|Experimental|D-methionine, oral liquid suspension|D-methionine liquid suspension also contains sorbitol, orange flavor and purified water Intervention: Drug: D-methionine, oral liquid suspension.
2499918|NCT02902939|No Intervention|Uncomplicated cardiac surgery patients|Patients after scheduled cardiac surgery procedures
2499920|NCT02902939|Active Comparator|Complicated cardiac surgery patients|MECC systems Cytokines modulation by CytoSorb and PMMA membranes
2499988|NCT02902588|Experimental|ICG washout kinetics assessment|Intravenous administration of 5-10 mg indocyanine green (ICG-PULSION), once per subject
2499991|NCT02902588|Other|Pulse oximeter monitor|Monitoring of a person's oxygen saturation (SO2), peripheral oxygen saturation
2499995|NCT02902588|Experimental|Gadolinium washout kinetics assessment|20 mL of gadolinium (Gadovist, Bayer, Germany) injection at 5 mL/s, once per subject
2500036|NCT02902016|Experimental|Lactase expression induction by GED|
2500111|NCT02901717|Active Comparator|Standard of Care|Antibiotic lock + standard of care antibiotics. The standard of care antibiotic will be chosen by the investigator at the time of the infection.
2500115|NCT02901717|Experimental|Mino-Lok Therapy (MLT)|Standard of care plus MLT. MLT contains minocycline with EDTA and ethanol.
2500194|NCT02900976|Experimental|Arm I (RTX)|Patients with newly diagnosed PTLD who achieve a complete response (CR) after induction receive additional rituximab or biosimilar as in induction.
2500198|NCT02900976|Experimental|Arm II (LMP-TC)|Patients with newly diagnosed PTLD who do not achieve a CR to induction, all relapsed patients after induction, and all patients with refractory disease who received rituximab or biosimilar within 90 days according to institutional guidelines, receive allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes IV over 1- 2 minutes on days 0 and 7. Cycle continues for up to 42 days in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after first cycle of cycle allogeneic LMP1/LMP2-specific cytotoxic T-lymphocytes receive an additional cycle.
2500329|NCT02899819|Experimental|meconium|The meconium will be sampled in the first 2 days of life
2500462|NCT02898779|Experimental|Cohort 1 ( Primaquine Low Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period."
2500463|NCT02898779|Experimental|Cohort 2 (Primaquine High Dose)|"Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.~Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each."
2500502|NCT02898415||Training set|Consecutive patients who underwent liver transplantation for HCC at Italian transplant centers
2500535|NCT02898051||Venous Thromboembolism and cancer|"Patients hospitalized for Venous Thromboembolism and having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: three tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
2500536|NCT02898051||Venous Thromboembolism and non cancer|"Patients hospitalized for Venous Thromboembolism and not having a cancer. Inclusion (as soon as the diagnosis of venous thromboembolism is confirmed). One tube of blood taken before the start of treatment (at the time of another blood sample) for determination of heparanase. After the start of treatment: 3 tubes of blood drawn for determination of anti-Xa activity.~Assays will be centrally performed, blinded from the clinical data and from the group knowledge of the group patient."
2500599|NCT02897817||Oral to Injectable|Patients treated with oral MTX and requiring a switch to injectable MTX
2500609|NCT02897817||Injectable to Injectable|Patients treated with injectable MTX and eligible for a change in MTX injection device.
2500684|NCT02897206|Experimental|Imipenem group|Imipenem 3 x 500 mg i.v. daily ideally for 10 days (minimum 7 days, maximum 21 days)
2500688|NCT02897206|Placebo Comparator|Placebo group|Identical placebo administered in identical dosage, timing and duration.
2500695|NCT02897401|Experimental|Smocker|Cigarette consumption in the context of their habit (not related to the particiapion under study).
2500705|NCT02897219|Placebo Comparator|Part 1 Placebo|Placebo will be administered for 24 weeks under double blind conditions.
2499537|NCT02905877||Organic neurological disorders.|Initially especially patients diagnosed with a an organic action tremor (e.g. essential tremor or dystonic tremor).
2499539|NCT02905877||Healthy control|Healthy age matched controls
2499550|NCT02905591|Experimental|ChemoRT + Ascorbate|Radiation therapy, intravenous paclitaxel, intravenous carboplatin, intravenous ascorbic acid (pharmacological ascorbate)
2499644|NCT02905201||mCRPC participants|Participants will not receive any intervention as a part of this study. Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) who have adequate response to treatment (abiraterone Acetate + prednisone) will be observed to collect data for ECOG performance status, safety assessments (as described above), the collection of PROs (BPI-short form, Pain VAS, HCU questionnaire), the assessment of disease status and parameters, and the assessment of participant compliance to treatment.
2499689|NCT02904863|Experimental|patients with HUS|
2499794|NCT02904005|Other|Depressed patients|Depressed patients with a recent suicide attempt or without any personal history of suicide attempt
2499851|NCT02903537|Experimental|5 * 10 ^6 tolDC-VitD3|5 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)
2499855|NCT02903537|Experimental|10 * 10 ^6 tolDC-VitD3|10 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
2499858|NCT02903537|Experimental|15 * 10 ^6 tolDC-VitD3|15 million autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3).
2499859|NCT02903537|Experimental|Interferon-beta|Additional group (patients treated with beta-interferon) will receive the selected dose of those 3 previously cohorts studied
2499894|NCT02903134||Newborn from obese and nonobese pregnant|Obese (BMI>30) or normal weight (BMI<25) women at their first antenatal visit were invited to participate in the study at the moment of delivery at Sotero del Rio Hospital, Santiago. Information regarding birth outcomes, parental history, as well as environmental conditions was collected at recruitment. Follow-up questionnaires by phone were completed every 6 months. Umbilical cord blood samples were collected to measure IL-12, TNF-α, IL-10, IL-4; to evaluate metabolic status; to isolated monocytes and macrophage differentiation; and for DNA methylation status of the promoter regions of the genes coding for TNF-α, IL-12, IL-10, and IL-4Rα. Also, fasting blood samples of the mothers within 48 hours after delivery; and blood samples and skin prick test were collected.
2499969|NCT02902354|Other|Nifedipine for tocolysis|Only women receiving nifedipine (as standard of care) for tocolysis
2500056|NCT02902211|Experimental|Ankle foot orthosis|Patients will wear an off-the-shelf, carbon composite AFO that is adjusted for them for three months. The patients will be asked to wear the AFO at all times except when they are in bed or showering/bathing. The instructions given to the patients about walking will be to follow the instructions from their doctor regarding risk factor management and exercise.
2500058|NCT02902211|Active Comparator|Control|Patients will be asked to follow the instructions from their doctor regarding risk factor management and exercise for three months.
3162823|NCT00470119|Other|Exercise Intervention|Participants exercise 3 days per week under the supervision of a physiologist and 2 days per week independently at home, for a total of 5 exercise sessions (at least 45 minutes of moderate-intensity exercise per session) weekly over 12 months
2500192|NCT02900963|Other|Nutrition state determination|"Determination of nutritional state and inflammatory status:~weekly assessment of patient's weight biological parameters (albumin, transthyretin, orosomucoid) and weekly assessment of patient's weight"
2500216|NCT02900677|Experimental|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks.
2500221|NCT02900677|No Intervention|Control|usual care
2500312|NCT02900001|Active Comparator|Early invasive strategy|Patients undergo coronary angiography within 24 hours after admission and have percutaneous coronary intervention or coronary artery bypass grafting as soon as possible during the index hospitalization if appropriate.
2500315|NCT02900001|Experimental|Deferred invasive strategy|Patients undergo coronary angiography and appropriate revascularization after at lest 72 hours from admission in the index hospitalization.
2500355|NCT02899559|Experimental|Control|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The control group will read only summary information about the David Pottruck Health and Fitness Center.
2500356|NCT02899559|Experimental|Nudge Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. The nudge message encourages participants to make a plan for when they will exercise at the gym during the next week.
2500359|NCT02899559|Experimental|Boost Message|Participants will fill out a brief Qualtrics survey which will expose them to one of three message conditions. Those in the Boost condition will also have summary information about the Pottruck gym but will also be given information about why an implantation intention is an effective way to attain long term goals. They will also be given a prompt to form an implementation intention.
2500383|NCT02899221|Experimental|Treatment (high dose rate brachytherapy, hyperthermia)|Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.
2500457|NCT02899039|Active Comparator|Sjögren syndrome|Subjects suffering from Sjôgren syndrome
3162824|NCT00470119|Other|Caloric Restriction AND Exercise Intervention|Combined caloric restriction & exercise intervention
3162825|NCT00470197|Experimental|Arm I|Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.
3162826|NCT00470210|Experimental|1|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week Ribavirin (Copegus®) 1600 mg/day Epoetin β (450 UI/kg/week)
3162827|NCT00470223|Experimental|Chemotherapy + zoledronic acid|
3162828|NCT00470223|Active Comparator|chemotherapy|
3162829|NCT00470236|Active Comparator|Arm 1 (Standard WB Fractionation)|Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)
3162830|NCT00470236|Experimental|Arm 2 (Shorter WB Fractionation)|Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)
3175087|NCT00629941|Experimental|1|
3175088|NCT00629954||I|
2499540|NCT02905851|Placebo Comparator|Non Feedback|No feedback given to this group regarding their antibiotic use Subjects take images and answer questions during the study like the feedback group, but in this group no feedback re dosing is given.
2499541|NCT02905851|Active Comparator|Feedback group|"Feedback given to this group regarding their antibiotic use after baseline.~If the subject is in the feedback group, after this visit, a dermatologist will review all images and the survey results and give the patient information about whether they should:~Continue current dose~Reduce dose if there is at least a one point improvement in both the investigator acne global assessment AND the patient acne global assessment scores: A dose reduction will be such that the dose is halved from the previous dose. For example if the subject is on minocycline or doxycycline 100 mg twice daily, they will be reduced to minocycline or doxycycline 100 mg daily.~Increase dose if had been previously reduced, dose will not be increased beyond the initial starting dose."
2499587|NCT02905565|Placebo Comparator|Placebo|Interventions: Placebo (NBP placebo softgel capsules, 0 mg NBP, BID)
2499589|NCT02905565|Active Comparator|800 mg of NBP daily|Interventions: 800 mg NBP softgel capsules daily (400 mg BID)
2499650|NCT02905032|No Intervention|Standard Care|Observations in clinical encounter via video, audio or observational notes.
2499651|NCT02905032|Active Comparator|Standard Care + Decision Aid|Observation of clinical encounter using the decision aid via video, audio, or observational notes.
2499729|NCT02904707||Questionary EQ-5D|"The EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.~Finally, a pain assessment questionnaire by Numeric Evaluation Scale before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient."
3195924|NCT00844948||Elderly (60-80 years old)|Elderly (60-80 years old). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started treatment or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
2499830|NCT02903485|Experimental|nurses (intervention arm)|for patients without risk factors, the anesthetic team is not involved in patients' care
2499845|NCT02903485|Active Comparator|anesthetic team (control arm)|the anesthetic team is involved in every patient's care (with or without risk factors)
2499864|NCT02903251|Experimental|oxytocin|"intranasal oxytocin spray Day 1-3: Twice daily intranasal oxytocin spray administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily intranasal spray without oxytocin"
2499867|NCT02903251|Placebo Comparator|Placebo|"intranasal spray without oxytocin Day 1-3: Twice daily intranasal spray without oxytocin, administered by health personnel.~Day 3-30: Self-administered intranasal spray as needed, max thrice daily"
2499928|NCT02902952|Experimental|Physical Exercise Condition|An eight week physical exercise intervention
2499935|NCT02902952|Active Comparator|Control Condition|An eight week control condition consisting of sedentary activities
2499989|NCT02902458|Experimental|Psychological follow-up|Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
2499994|NCT02902458|No Intervention|Control|Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.
2500126|NCT02901483|Experimental|PEP503+Cisplatin+Radiotheraphy|"Phase 1b: There are 6 levels (L1- 5% + 40mg/m2 weekly cisplatin, L2- 10% + 40mg/m2 weekly cisplatin, L3- 15% + 40mg/m2 weekly cisplatin, L4-22% + 100mg/m2 tri-weekly cisplatin, L3a- 15% + 100mg/m2 tri-weekly cisplatin, and L5- 33% + 100mg/m2 tri-weekly cisplatin) in this phase 1b study. Only primary tumor will receive PEP503 implementation via intratumor injection. A 3 + 3 dose escalation study design will be adopted in this phase to identify the recommended intratumor injection volumes of PEP503.~Phase 2: The recommended volume identified from phase 1b will be applied in phase 2 for both primary tumor and ≥ 3 cm lymph node lesions."
2500211|NCT02900768|Experimental|Exercise Group|Patients in the intervention group will receive supervised and unsupervised exercise program after their bone marrow transplant.
2500214|NCT02900768|No Intervention|Control Group|Patient will receive standard of care within the hospital as an inpatient and outpatient after their bone marrow transplant.
2500279|NCT02900404||NVAF Patients|Adult female and male patients with non-valvular atrial fibrillation (NVAF) treated with rivaroxaban before and after surgery
2500282|NCT02900404||VTE/PE Patients|Adult female and male patients with venous thromboembolism/pulmonary embolism (VTE/PE) treated with rivaroxaban before and after surgery
2500319|NCT02899871||Control|patients treated with anti-TNF not presenting any joint symptoms.
2500323|NCT02899871||case|aetiology of joint symptoms
2500388|NCT02899520|Active Comparator|Group A|Reference method
2500391|NCT02899520|Experimental|Group B|CMP ® method (Knowledge and Control of Perineum)
2500435|NCT02898961|Experimental|The study population|"ICU patients with severe sepsis treated with aminoglycosides were recruited.~Intervention: 30 mg/kg amikacin or 8 mg/kg gentamicin"
2500588|NCT02897726|Experimental|NVP-1402|NVP-1402 was administered once a day for 24 hours
2500591|NCT02897726|Active Comparator|NVP-1402R|Active comparator was administered twice a day for 24 hours
2500699|NCT02897453||The Spinal Tethering System group|Patients with adolescent idiopathic scoliosis that have been implanted with the Spinal Tethering System in an anterior vertebral body tethering construct.
2500766|NCT02896868|Experimental|LY3041658|LY3041658 administered intravenously (IV) once every two weeks over 6 weeks (four doses).
2500768|NCT02896868|Placebo Comparator|Placebo|Placebo administered IV once every two weeks over 6 weeks (four doses).
2500856|NCT02896465|Active Comparator|ORS+ZINC|Oral rehydration solution + Zinc
2500858|NCT02896465|Experimental|ORS+ZINC+HMO|Oral rehydration solution + Zinc + Human milk oligosaccharides
2500859|NCT02896465|Placebo Comparator|ORS+ZINC+Breastfeeding|Oral rehydration solution + Zinc + Breastfeeding
2499542|NCT02905864|Experimental|Liraglutide 3 mg|"Arm description: Subjects will be up titrated to liraglutide 3 mg QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg QD administered in a 6 mg/mL, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks."
2499543|NCT02905864|Placebo Comparator|Liraglutide 3 mg placebo|"Arm description: Subjects will be up titrated to liraglutide 3 mg placebo QD and stay on that dose for the remainder of the 52-week drug intervention period.~Drug: Liraglutide 3 mg placebo QD administered in a 6 mg/mL drug equivalent volumes, 3 mL pen for subcutaneous injection.~Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks."
2499569|NCT02905539|Experimental|Iron Isomaltoside 1000|Subjects receive Iron Isomaltoside 1000 solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
2499571|NCT02905539|Active Comparator|Ferric Carboxymaltose|Subjects receive Ferric Carboxymaltose solution intravenously. Dosage: A unique dose of 20 mg per kilogram bodyweight, but total dose is not more than 1000 mg.
2499635|NCT02905058|Experimental|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
2499636|NCT02905058|Placebo Comparator|Placebo|women will take one placebo tablet one hour before the procedure
2499682|NCT02904876|Experimental|Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
2499759|NCT02904304|Experimental|Desloratadine+Phenylephrine+Ibuprofen|"It's a tablet manufactured by Aché S.A., composed of desloratadine 2,5mg, Phenylephrine hydrochloride 20mg and Ibuprofen 400mg.~Tablet will be dispensed in a cartridge containing 10 tablet to 75 participants."
2499760|NCT02904304|Placebo Comparator|Placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo will be dispensed in a cartridge containing 10 tablet to 75 participants. The participants shall administer the placebo tablets to enable the double-blind study.~The use of placebo comparator is important in this type of pathology because with this design will be able to evaluate the response of the pure treatment, rapid relief of symptoms, or 03 hours after the first administration of study drug."
2499802|NCT02903797||Endometrial Hyperplasia|The first group was formed of the patients diagnosed endometrial hyperplasia histopathologically
2499804|NCT02903797||Control group|The control group was formed of the patients who were healthy women admitted to the clinic just for annual examination without any complain and symptoms
3162831|NCT00470236|Active Comparator|Arm 3 (Standard WB fractionation+Boost)|Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)
3162832|NCT00470236|Experimental|Arm 4 (Shorter WB fractionation + Boost)|Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)
2500256|NCT02900508|Experimental|Exergaming training|Participants in the exergaming training group received a 4-week exergaming intervention.
2500257|NCT02900508|Active Comparator|Control training|Participants in the control training group received a 4-week conventional training.
2500305|NCT02900144|Experimental|Modified CBIT Treatment Arm|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
2500308|NCT02900144|Active Comparator|Standard CBIT Treatment Arm|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
2500341|NCT02899624|Experimental|Bicuspid aortic valve (BAV)|patient with bicuspid aortic valve
2500343|NCT02899624|Active Comparator|healthy subjects related patients with BAV|healthy control, related to patient with bicuspid aortic valve, at the 1st, 2nd or 3rd degree
2500344|NCT02899624|Active Comparator|Tricuspid aortic valve (TAV)|patient with aortic stenosis on tricuspid valve
2500424|NCT02899143|Experimental|Group 5-days|5-days targeted antibiotic therapy
2500428|NCT02899143|Other|Group 10-days|10-days targeted antibiotic therapy
2500506|NCT02898584|Other|BP Track|The study participants will be asked to monitor their blood pressure twice daily at home for twelve weeks, and sync the data to the mobile intervention so that a clinical pharmacist can review and incorporate the data into ongoing hypertension management.
2500537|NCT02898038|Experimental|Experimental|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PARIS for a period of 9 days.
2500616|NCT02897830|Experimental|Study treatment|Ixazomib, Lenalidomide, Dexamethasone Induction and extended Consolidation followed by Lenalidomide Maintenance
3162833|NCT00470249|Experimental|Patients with (HER-2)-negative and anthracycline- and taxane-resistant|Patients with human epidermal growth factor 2 (HER-2)-negative locally advanced or metastatic breast cancer that was anthracycline- and taxane-resistant
3162834|NCT00470340|Experimental|1|Oxaliplatin, gemcitabine, cisplatin, lipiodol
3162835|NCT00470340|Experimental|2|Oxaliplatin, gemcitabine, cisplatin, lipiodol
3162836|NCT00470379|Experimental|Immunization with NY-ESO-1b|Efficacy of maximal dose of topical resiquimod as immune adjuvant to intradermally administered NY-ESO-1b peptide vaccine.
3162837|NCT00470405|Experimental|Therapeutic Intervention|
3162838|NCT00470444|Active Comparator|1|Liberal transfusion strategy
3162839|NCT00470444|Active Comparator|2|Restrictive transfusion strategy
3162840|NCT00470483|Active Comparator|arm 1|Paroxetine treatment during 8 weeks
3162841|NCT00470483|Placebo Comparator|arm 2|Placebo treatment during 8 weeks
3175089|NCT00629967|Active Comparator|A|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
2499548|NCT02905708|Active Comparator|Forced Air Warming Device|"Active Comparator: Forced Air Warming Device first group will have the warming devices started in the pre-operative area. You will receive a full body forced air warming. Device is non experimental and FDA approved, used within the hospital to keep patients warm.You will then have your temperature taken and documented by the staff at various prescribed times.~Warming in the operating room: You will receive the same or a similar warming device known as a Bair Hugger and warmed IV fluids once you are in the operating room. Bair Paws or Bair Hugger will also be used in the post-anesthesia care area."
2499549|NCT02905708|Active Comparator|Air-Activated heating packs|The second group will receive the study warming device which consists of a jacket, pants, gloves and socks with integrated Air-Activated heating packs. Device is supplied vacuum packed, heat packs of iron powder/activated charcoal activated by air. Device applied at least twenty minutes prior to surgery. The same device will be maintained in place throughout the surgery and the post-anesthesia period.
2499593|NCT02905422|No Intervention|Waitlist Control Group|Six month delayed access to the H.E.A.L.T.H. II Intervention - Intensive intervention (wait-list control)
2499598|NCT02905422|Active Comparator|Active Intervention Group|Immediate access to the H.E.A.L.T.H. II Intervention - Intensive intervention
3162842|NCT00470496|Experimental|Treatment (intraoperative PDT)|Patients receive HPPH IV over 1 hour on day 1. Patients undergo surgery followed by laser light exposure to the entire tumor bed on day 2.
2499697|NCT02904733|Experimental|mHealth platform|Stable HIV-1 infected subjects will be followed-up using an mHealth platform. The platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to healthcare providers. The minimum length of follow-up will be 12 months and the maximum 35 months.
2499736|NCT02904408|Experimental|Experimental|experimental group (receiving psychotherapy and medical/surgical treatment)
2499738|NCT02904408|No Intervention|Control|control group (awaiting group) (receiving medical/surgical treatment)
2499761|NCT02904031|Experimental|FOLFOX plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
2499762|NCT02904031|Experimental|5FU/LV plus panitumumab|"Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;~L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;~5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal."
2499826|NCT02903667|Experimental|bone grafting|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing bone grafting material in the fresh extraction sites.
2499833|NCT02903667|Sham Comparator|natural healing|ridge modelling after multiple tooth extractions.
2499908|NCT02903095|Experimental|TD-1439|Capsule formulation
2499909|NCT02903095|Placebo Comparator|Placebo|Capsule formulation
2499930|NCT02902705|Experimental|Chronic Kidney disease patients - stage V|Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
2499937|NCT02902705|Other|Non Chronic Kidney Disease patients|Non CKD male adults matched for age, gender and body mass index (BMI) with CKD patients. All the non - CKD patient will recruited from Department of recruited at the Department of Urology of Edouard Herriot University Hospital (Lyon, France).
2499982|NCT02902523|Active Comparator|Viread ® tablet 300mg|Tenofovir disoproxil fumarate
2499987|NCT02902523|Experimental|HUG116 tablet 245mg|Tenofovir disoproxil
2500304|NCT02900118||Group 1|Patients with breast cancer bone metastasis at the initial diagnosis.
2500306|NCT02900118||Group 2|Patients with breast cancer bone metastasis in a metastatic bone relapse.
2500310|NCT02900118||Group 3|Patients with breast cancer bone metastasis with a progression of bone metastasis.
2500416|NCT02899117|Experimental|Yoga intervention|Patients in the yoga intervention group will have 4 yoga sessions with a certified yoga instructor while they are in the cancer clinic or on the inpatient floor.
2500498|NCT02898467||diabetics|Type 2 diabetic patients exhibiting fasting glycemia value over 7 mmol/L or glycated hemoglobin value over 6.5% or type 2 diabetic patients under oral anti-diabetic treatment or type 2 diabetic patient under insulin treatment and in which diabetes has been diagnosed after the age of 45 y
3162843|NCT00470509|Experimental|Adalimumab|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
3162844|NCT00470509|Placebo Comparator|Placebo|2 placebo injections on day 0 and 7
3162845|NCT00470561|Active Comparator|Aspirin|
3162846|NCT00470561|Placebo Comparator|Placebo|
3162847|NCT00470613|Experimental|SGT-53|SGT-53 (2.4mg DNA/infusion) will be administered in a standard 3x3 dose escalation design in combination with docetaxel 40mg/m2 starting dose, cohort 1, cycle 1. This protocol will allow for both inter- and intra-patient dose escalations. SGT-53 will be administered weekly, day 1 except weeks 1, 4 & 7 when it will be administered biweekly on days 1 & 4. Docetaxel will be administered every 3 weeks (weeks 1, 4 & 7) on day 3. Patients completing cohort 1, cycle 1 without DLT at docetaxel 40mg/m2 will be allowed to dose escalate to 60mg/m2 in cycles 2 and 3. Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60mg/m2. Cohort 3 (3.6mg DNA/infusion; 75mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4mg DNA/infusion and docetaxel 75mg/m2. If necessary, the dose of docetaxel in cycle 2 and 3 may be reduced to 60mg/m2.
3162848|NCT00470652||1|Pre-intervention patients admitted to our ED in the month prior to the intervention, before the 'computer-assisted decision support' is turned on (the intervention)
3162849|NCT00470652||2|Short-term post-intervention cohort of patients admitted in the month following the initiation of the 'computer-assisted decision support' for pain management
2499563|NCT02905656|Placebo Comparator|Brief Advice|Participants will receive brief advice to quit smoking, and be provided psycho-education citing health consequences and the positive impact on mortality and morbidity.
2499568|NCT02905656|Experimental|Motivational Interviewing (MI)|Motivational interviewing (MI) is a collaborative conversation style for strengthening a person's own motivation and commitment to change. MI attempts to avoid a confrontational style and, instead, guides participants toward choosing to make a change in their behavior.
2499572|NCT02905656|Experimental|Rate Reduction (RR)|Participants will be informed of the strong medical evidence of systematic reductions in smoking behavior can lead to long-term smoking cessation. This condition will receive Nicotine Replacement Therapy in the form of gum.
2499575|NCT02905656|Experimental|MI + RR|In this intervention, participants receive both the skills based rate reduction intervention and the more motivationally based MI intervention. This condition will receive Nicotine Replacement Therapy in the form of gum.
2499617|NCT02905188|Experimental|GLYCAR T cells + Fludarabine and Cytoxan|GPC3-CAR (GLYCAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with hepatocellular carcinoma.
2499673|NCT02904837|Experimental|Experimental Group (EG)|The Experimental training (ET) consists of 10 sessions with 4 blocks of MP (GMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2499677|NCT02904837|Active Comparator|Control Group|The Control training (CT) consists of 10 sessions with 4 blocks of MP (nGMP) intercalated with 4 blocks of gait physical practice (GPP), under single (ST) and dual-task (DT) conditions.
2499699|NCT02904551|Experimental|Experimental|Free gingival grafts
2499701|NCT02904551|Active Comparator|Control|Oral prophylaxis
2499790|NCT02904252||Study group|Population : The participants are thalassemia patients who regularly visit Hematology Clinic, Department of Medicine, Faculty of Medicine Siriraj Hospital Clinical data, Laboratory data (Blood samples) and Transient elastography data will be collected from all participants, as previously described.
2499922|NCT02902718|Experimental|mē device|The subjects will perform treatments with the mē device at the clinic under the supervision of the study personnel at the baseline visit, 1 week and 2 week visits, and 1 month and 2 month visits. In addition the subject will be expected to perform treatments at home according to the following schedule: daily treatments at home for 5 days a week during the first month, followed by 2 treatments a week during the 2nd month, and optionally 1 time a week during the 3rd month.
2499990|NCT02902562|Other|Study Visit|You will have a Contrast Enhanced Ultrasound (CEUS) and contrast Magnetic Resonance Imaging (MRI) which will take about 2 hours.
2500043|NCT02902068||Parturients undergoing cesarean section|Healthy parturients, hypertensive parturients and parturients suffering from preeclampsia above 18 undergoing cesarean section deliveries .
2500092|NCT02901652|Active Comparator|NIPPV|"noninvasive respiratory support devices~This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment."
2500095|NCT02901652|Active Comparator|BİPAP|"noninvasive respiratory support devices~This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment."
2500164|NCT02901262||qEEG patients|All the patients with continuous EEG (>24 hours) in teh two study units
2500212|NCT02900820|Experimental|Novel intervention group|Discontinuing antibiotic therapy.
2500218|NCT02900820|Experimental|Usual intervention group|Usual strategy of continuing antibiotic treatment.
2500267|NCT02900326|Placebo Comparator|Control patients with no intervention|group without intervention
2500270|NCT02900326|Experimental|Endurance training program (8 weeks) group|only physical training group
2500273|NCT02900326|Experimental|MBSR group (mindfulness-based-stress-reduction)|only mental training group(8 weeks)
2500274|NCT02900326|Experimental|Endurance training program combined with MBSR sessions|Endurance training program combined with MBSR sessions, during 8 weeks (mindfulness-based-stress-reduction)
2500327|NCT02899832||NIRS|Near Infra Red Spectroscopy.
2500376|NCT02899494|Other|Group A|Antenatal classes
2500380|NCT02899494|Experimental|Group B|Physical and psychic preparation
2500412|NCT02899065|Experimental|Intervention|The intervention arm will receive pharmacist-led education and stewardship intervention and a procalcitonin test to aid in the decision of how to treat the patient. This intervention will include direct delivery of education from the pharmacist to the treating clinician about interpreting the Roche Cobas Liat Flu/RSV and procalcitonin test results, recommendations for antiviral-treatment for high-risk patients and information about infection control precautions for patients being hospitalized with a positive RSV or influenza test.
2500413|NCT02899065|No Intervention|Standard of care|The second arm will be usual care (i.e. Roche Cobas Liat Flu/RSV test only). Results will be delivered via standard of care.
3162850|NCT00470652||3|long-term post-intervention cohort of patients admitted on the 6th month following the initiation of the 'computer-assisted decision support' for pain management
3162851|NCT00470678|Experimental|1|Ranibizumab
3162852|NCT00470691|Experimental|complete plaster cast|reduction and a complete plaster cast,
3162853|NCT00470691|Active Comparator|dorsal plaster splint|reduction and a dorsal plaster splint.
3162854|NCT00470704|Other|Lapatinib and Herceptin|1000 mg daily Lapatinib and 2 mg/kg weekly or the 6 mg/kg every 3 week dose of trastuzumab
2500483|NCT02898428||New mothers|New mothers with type 1 diabetes
2500484|NCT02898428||Control group|Non-pregnant, non-breastfeeding women with type 1 diabetes matched for age and BMI
3162855|NCT00470743|Experimental|Ibuprofen|Compare ibuprofen
3162856|NCT00470743|Placebo Comparator|Normal saline|Compared against ibuprofen -- placebo
3162857|NCT00470756||evertors, invertors|
3162858|NCT00470795|Experimental|A|Acupuncture - 2 treatments weekly, 4 weeks (8 treatment)
3162859|NCT00470795|Placebo Comparator|B|Placebo/sham treatment; twice weekly for 4 weeks (total 8 treatments)
3162860|NCT00470821|Placebo Comparator|A - placebo|Identical tablets without the active principles. Each evening, nurses are requested to give 2 tablets at 8 PM and 12 PM
3162861|NCT00470821|Active Comparator|B - melatonin|Identical tablets containing melatonin 3 mg Nurses are requested to give two tablets daily, at 8 PM and 12 PM.
3162862|NCT00470873||Group 1|
3162863|NCT00470886||Group 1|
3162864|NCT00470899|Experimental|placental drainage|
2499565|NCT02905721|Experimental|Spectral cardiac CT scan|All patients will undergo cardiac CT scan with spectral mode acquisition
2499615|NCT02905344||1|Control, no anatomical model used for description
2499618|NCT02905344||2|Anatomical model used for description
3195925|NCT00844948||Chinese speakers|Chinese speakers (Mandarin or Cantonese). Major Depressive - eligible subjects will meet a baseline depression severity score of 10 or greater on the QIDS-C & QIDS-IVR, will have recently started or about to start receiving treatment for MDD. Exclusion: subjects with suicidal ideation; subjects who have a history or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, other than alcohol, active within the last 12 months; subjects with a history or current diagnosis of dementia or diagnosis or history of hypothyroidism.
3195926|NCT00844961|Experimental|Internet CBT|10 weeks of internet delivered cognitive behaviour therapy
3195927|NCT00844961|No Intervention|Waiting list|Waiting list which is offered treatment after completion of post intervention assessments
3195928|NCT00844974|Other|1|
3195929|NCT00845026|Experimental|LY2140023|
3195930|NCT00845026|Active Comparator|aripiprazole|
2499941|NCT02902731|Placebo Comparator|placebo|PLACEBO + Usual use of tapering doses of oral prednisone
2499947|NCT02902731|Experimental|anakinra|"ANAKINRA : dose of anakinra is 100 mg/day by subcutaneous injection from day 1 until the end of week 16 (W16). The dose of Anakinra will be adapted to that recommand according to renal function.~Intervention Anakinra in add on Therapy."
2499996|NCT02902432|Placebo Comparator|SCCHN|patients with advanced squamous cell carcinoma of the head and neck.IMRT.
2499998|NCT02902432|Experimental|SCCHN-Endostar|patients with advanced squamous cell carcinoma of the head and neck.Endostar will be continuously intravenous pumped (7.5 mg/m2) for 14 days (d1-d14) during chemotherapy and for 5 days/week(d-5-d-1, d3-d7, d10-d14, d17-d21)during IMRT.
2500021|NCT02902042|Experimental|Arm A: Triple therapy|Encorafenib, binimetinib and pembrolizumab. Doses as determined in phase I
2500022|NCT02902042|Experimental|Arm B: Pembrolizumab alone|Pembrolizumab with a dose of 200 mg every 3 weeks.
2500099|NCT02901535|Active Comparator|Control|Spirometry in baseline Spirometry - 20 weeks
2500104|NCT02901535|Experimental|Intervention|Spirometry in baseline Teleconsultation Telemonitoring Spirometry - 20 weeks
2500146|NCT02901119|Experimental|Whey protein|Patients are instructed to consume 20g of whey protein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
2500147|NCT02901119|Active Comparator|Casein|Patients are instructed to consume 20g of casein in the morning and 20g at night, during 15 days, as a supplement. Their regular usual diet is maintained.
2500228|NCT02900898|Experimental|Dynamic exercise and Mediterranean diet|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part.~MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation."
2500230|NCT02900898|Experimental|Dynamic exercise|"DE: divided in stretch: arms, hands, legs, knees, for 20 seconds (s), resting 5, warming and flexion: making small circles forward and backward for 20 s, resting 5, DE: resistance (contraction, twisting) using therapeutic leagues with 20 repetitions, resting 10 s. Aerobic part will perform in a treadmill by 20 minutes (monitoring blood pressure and heart rate) and relaxation: involved the stretching part."
2500231|NCT02900898|Experimental|Mediterranean diet|MD: Individualized diet (energy expenditure) according to age, ideal weight and height. Distribution of macronutrients will be 50% carbohydrates, 30% lipids and 20% of proteins. This diet is according to the Mediterranean diet patterns and consist in five meals: breakfast, snack, principal meal, snack and dinner. All recommended meals include type of food and method of preparation.
2500234|NCT02900898|Active Comparator|Control|This group will not carry out interventions.
2500263|NCT02900235|Experimental|MT-3995|[14C]-MT-3995 after a single oral dose
2500300|NCT02900079||travelers|persons intending to travel for 3 weeks or longer to South-East Asia, Sub-Saharan Africa or South-/ Central America; they will be trained to use a rapid diagnostic test for malaria antigen when febrile. Upon a positive test result they are recommended to use standby emergency treatment (SBET)
3195931|NCT00845026|Active Comparator|olanzapine|
3195932|NCT00845026|Active Comparator|risperidone|
2500473|NCT02898766|Active Comparator|Enteral Nutrition Formula 1|Enteral Nutrition Formula
2500474|NCT02898766|Active Comparator|Enteral Nutrition Formula 2|Enteral Nutrition Formula
2500538|NCT02898168|Experimental|WA|
2500539|NCT02898168|Active Comparator|Control|
2500627|NCT02897557|Experimental|Single Cohort in CRC|This study is a single-arm, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting.
2500745|NCT02896816|Experimental|Parkinson's subjects|"The participants with Parkinson's disease should have symptoms only on one side of the body, and they should not be taking any dopamine replacement medication such as levodopa or dopamine agonists.~Surface EMG, MRI and PET scan will be performed at baseline."
2500746|NCT02896816|Active Comparator|Control subjects|Participants not affected by neurological disorders. Surface EMG will be performed at baseline.
2500789|NCT02896556|Experimental|Resin infiltrate|This is a single-arm study. Resin infiltration technique will be performed to all patients.
2500900|NCT02895854|Active Comparator|LDR-brachytherapy with I125 seeds|Low-dose rate-brachytherapy with I125 permanent seeds in prostate cancer.
2500929|NCT02895672||Daily GLP-1 therapy liraglutide|Patients receiving daily liraglutide
3195933|NCT00845052||First group of house staff|First group of house staff to be surveyed
3195934|NCT00845052||Second group of house staff|Second group of house staff to be surveyed
3195935|NCT00845052||Thirst group of house staff|Third group of house staff to be surveyed
2499573|NCT02905669|Experimental|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device.
2499824|NCT02903524|Active Comparator|control group|Pirarubicin combination with cyclophosphamide,4 cycles (each cycle is 21days) of chemotherapy
2499832|NCT02903524|Experimental|Experimental group|Doxorubicin Hydrochloride Liposome Injection combination with cyclophosphamide, 4 cycles (each cycle is 21 days) of chemotherapy
2499872|NCT02903290|Other|cerebellar ataxia|Evaluation ataxia according SARAs; measuring the quality of life through SF36 Questionnaire; quantifying the severity of fatigue perceived by FSS questionnaire quantifying the severity of physical tiredness by VAS before and after physical activity; quantified analysis of walking on walking track GAITRite® (with score calculation FAP and GVI) before and after physical activity; physical activity like walking on a treadmill (with measurement of maximal voluntary quadriceps by manual dynamometer before and after physical activity to ensure the induction of fatigue). Patients will be provided with a portable device for analyzing gas exchange FitMateMED® (COSMED, Rome, Italy) during walking analyzes GAITRite®
2499926|NCT02903043||COPD patients|Quadriceps biopsies will be done. No drug administration.
2499932|NCT02903043||Healthy controls|Quadriceps biopsies will be done. No drug administration.
2500001|NCT02902536||Myasthenia Positive Antibodies|Patients with Acetyl choline receptor (AChR) or muscle-specific kinase (MuSK) Positive Myasthenia
2500005|NCT02902536||Myasthenia Double Negative|Patients without AChR or MuSK antibodies
2500009|NCT02902536||Normal Controls|Patients without myasthenia
2500045|NCT02901977|Experimental|ACE inhibitor|Ramipril tablets 10 mg od for 12 weeks
2500053|NCT02901977|Active Comparator|Alpha receptor blocker|Doxazosin tablets 8 mg od for 12 weeks
2500110|NCT02901561|Experimental|misoprostol 200|misoprostol 200 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
2500114|NCT02901561|Active Comparator|misoprostol 400|misoprostol 400 microgram placed into the vagina 3 hours prior to having the intrauterine device inserted
2500152|NCT02901197|Active Comparator|Education and Reminder|This arm will consist of participants in a location that receive with web based training and exposure to reminder posters in the workplace.
2500163|NCT02901197|Active Comparator|Policy Change|This arm's participants will not receive an active intervention (education and reminders), however, policy change will take place in this location.
2500278|NCT02900417|Experimental|sitagliptin|All the patients will receive sitagliptin 100mg daily.
2500357|NCT02899572|Experimental|Sexology consultation|specialized sexology consultation planned in the 15 days after inclusion. Randomisation is performed at D7 during a phone call to the patient.
2500360|NCT02899572|No Intervention|Leaflet concerning erectile disorders|leaflet explaining erectile disorders related to type 2 diabetes will be sent by post to the patients. Randomisation is performed at D7 during a phone call to the patient.
2500381|NCT02899260|No Intervention|Control|Subjects who are randomized to to the control group will labor without the use of the peanut ball in labor.
2500387|NCT02899260|Experimental|Experimental/Peanut Ball|Subjects randomized to the intervention (peanut ball) arm will have the peanut ball planed between their upper legs for at least 30minutes during their labor. Time on the peanut ball will be quantified by the bedside nursing staff.
3162865|NCT00470899|No Intervention|no drainage of fetal blood|
2500515|NCT02898389||Group 1: With cardiovascular risk factors|Patients fall within this group when they have at least one of the cardiovascular risk factors listed in the eligibility criteria section.
2500519|NCT02898389||Group 1: Without cardiovascular risk factors|Patients fall into this group when they do not have any of the cardiovascular risk factors listed in the eligibility criteria section.
2500548|NCT02898012|Experimental|Temozolomide and Bevacizumab|Single experimental arm with two drugs : Temozolomide and Bevacizumab
2500583|NCT02897752|Experimental|WalkAide|
2500586|NCT02897752|Active Comparator|Usual gait Training|
2500671|NCT02897193|Active Comparator|Dental implant with bone augmentation|patients will be installed with ICE Dental implant 4.2 mm diameter with Alpha-Bio's grafts horizontal bone augmentation
2500676|NCT02897193|Experimental|narrow implant|patients will be installed with NICE Dental implant 3.2 mm diameter
2500848|NCT02896699|Experimental|PrEP Intervention Group|Group training session including HIV Education, PrEP Education, Following the training session Booster phone calls HIv and syphillis testing
2500849|NCT02896699|Active Comparator|Control Group|Group HIV risk vignettes
2500901|NCT02895841|No Intervention|Standard of Care|Patients will continue with their normal Standard of Care for their condition
2500905|NCT02895854|Active Comparator|Hypofractionated RT 5 x 7,25 Gy|Hypofractionated stereotactic radiotherapy 5 x 7,25 Gy delivered every second day in prostate cancer.
2500911|NCT02895503|Experimental|Arm I (yoga)|Patients undergo traditional medical treatment, participate in yoga comprising basic postures and breathing exercises 3-4 times per week, and attend yoga class once weekly over 30-60 minutes for 12 weeks.
3162866|NCT00470925|Experimental|Access [123I]MZINT and SPECT Imaging|
3162867|NCT00470951|Active Comparator|open rectal resection|conventional open resection
3162868|NCT00470951|Active Comparator|laparoscopic rectal resection|laparoscopic rectal resection
3162869|NCT00470977|Experimental|(Ranibizumab) Lucentis|(Ranibizumab)Lucentis 0.5%
3162870|NCT00471003||Arm 1|
3162871|NCT00471055|Experimental|A|Capsaicin and placebo controlled,Cross-over design study
3162872|NCT00471055|Placebo Comparator|B|Capsaicin and placebo controlled,Cross-over design study
3162873|NCT00471094|Experimental|Ilaprazole 5 mg QD|
3162874|NCT00471094|Experimental|Ilaprazole 20 mg QD|
3162875|NCT00471094|Experimental|Ilaprazole 40 mg QD|
3162876|NCT00471094|Active Comparator|Lansoprazole 30 mg QD|
3162877|NCT00471120|Experimental|P2x7 Assay|Compare assay results with biopsy
3162878|NCT00471133|Experimental|Xenogeneic Tyrosinase|
3162879|NCT00471185|Experimental|A|Subjects will receive progressively increasing doses of 10, 20 and 40 mg of oral acyline, on 3 occasions, each separated by 1 week
3162880|NCT00471224||Patients who have received drug.|Patients who have received drug.
2499579|NCT02905812|Active Comparator|RGI & Massage|"relaxation and guided imagery with background music (RGI) (40 min, headphones)~a brief moderate pressure massage session (massage: 15 min)"
2499585|NCT02905812|No Intervention|Control|Sham intervention: Silent headphones to mask the audio component, and presence of an intervention nurse at the bedside with drawn curtains.
2499601|NCT02905279|Active Comparator|Biofeedback|Biofeedback Relaxation Training
2499604|NCT02905279|Active Comparator|Standard Exposure|Exposure Therapy
2499607|NCT02905279|Experimental|Exposure with Threat-Relevant OAs.|Exposure with Threat-Relevant Opposite Actions
2499608|NCT02905279|Experimental|Exposure with Threat-Irrelevant OAs|Exposure with Threat-Irrelevant Opposite Actions
2499666|NCT02904993|Other|L2 paravertebral block|regional anesthetic nerve blocks using an L2 paravertebral block with ropivacaine
2499668|NCT02904993|Active Comparator|periarticular injection group|periarticular local injection into the periarticular soft tissues at the time of hip replacement using a combination of ropivacaine, epinephrine, ketorolac and morphine sulphate (periarticular injection group).
2499715|NCT02904655|Active Comparator|healthy diet|Participants were provided all meals and snacks for four weeks. Menus were created to target a healthy diet high in unsaturated fats.
2499719|NCT02904655|No Intervention|control diet|Participants were instructed to consume their usual diet.
2499792|NCT02903810|Experimental|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
3162883|NCT00471289|Experimental|1|PTA with primary placement of Drug (paclitaxel) Eluting Stent
2499924|NCT02902887|Experimental|Monitored CIAO therapy|Participants wear 3-hour CIAO therapy
2499925|NCT02902887|No Intervention|Observation|No intervention, just observation
2500027|NCT02902159|Experimental|BWW|Free access to online peer support through BWW for 6 months
2500031|NCT02902159|Experimental|MZ|Access to NHS Moodzone Information Only
2500118|NCT02901743|Active Comparator|GroupI (Test)|20 patients with renal insufficiency chronic and chronic periodontitis underwent scaling and root planing. Clinical parameters( GI,PD,CAL) were assessed at baseline and after 3 months. 2ml blood was drawn to assess serum creatinine levels and urine analysis was done at baseline and after 3 months for urinary albumin: creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema Denticola and Tannerella Forsythia by PCR.
2500121|NCT02901743|Active Comparator|Group II- (Control)|20 patients with chronic periodontitis who underwent scaling and root planing.Clinical parameters(GI,PD,CAL)were assessed at baseline and after 3 months. 2ml blood was drawn to assess seum creatnine levels and urine analysis was done at baseline and after 3 months for serum urinary Albumin:Creatinine ratio.Pooled plaque samples were taken at baseline and after 3 months to assess the microbial activity of Treponema denticola and Tannerella Forsythia by PCR.
2500193|NCT02901171|Experimental|Combined Treatment|ACT group treatment combined with smartphone application
2500196|NCT02901171|Active Comparator|Acceptance and Commitment Therapy (ACT)|ACT group treatment
2500197|NCT02901171|Active Comparator|Behavioural Support Programme|Group based Behavioural Support Programme
2500284|NCT02900482||case group|Patients with a history of congenital hip dislocation
2500286|NCT02900482||control group|Patients with no history of congenital hip dislocation
2500288|NCT02900482||parents of case group|Parents of patients with a history of congenital hip dislocation
2500570|NCT02898129|Experimental|Tube houses|Tube Houses. Group of 75-100 houses, with 4 inhabitants per house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2500575|NCT02898129|Experimental|Apartment|Apartments. Group of 75-100 apartments, with 4 inhabitants per apartment. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2500577|NCT02898129|Experimental|Rental Houses|Rental Houses. Group of 150-200 rental houses, with 2 inhabitants per rental house. Expected number of participants: 300-400. Predicted number of non-smoker chronic respiratory disease of 18-24.
2500579|NCT02898129|Experimental|Rural houses|Rural Houses. Group of 40-60 rural houses, with 5 inhabitant per rural house. Expected number of participants: 200-300. Predicted number of non-smoker chronic respiratory disease of 12-18.
2500608|NCT02897609||A simple questionary filled|
2500664|NCT02897440||Full Repairing of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
2500665|NCT02897440||Partial Repairing of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting
2500821|NCT02896257|Other|Proactive patient-tailored electronic consult (E-consult)|Primary care clinicians receive patient-tailored guideline concordant treatment recommendations, including orders and rationale to discontinue inhaled corticosteroids.
2500924|NCT02895529|Experimental|Itraconazole|
3162884|NCT00471289|Active Comparator|2|PTA
3162886|NCT00471471|Experimental|Peptide Vaccine + GM-CSF + Pfizer 3512676 in-ISA Oil|"The water-in-oil emulsion will consist of peptide (100 mcg/0.1 mL), GM-CSF (80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water), Pfizer PF3512676 (0.6 mg/0.04 mL using 15mg/mL vial) and 0.20 mLl of sterile saline.~Vaccination will be given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year)."
3162887|NCT00471510|Experimental|1|NEOSH101 2%
3162888|NCT00471510|Experimental|2|NEOSH101 1%
3162889|NCT00471510|Experimental|3|NEOSH101 0.5%
3162890|NCT00471510|Placebo Comparator|4|
3173589|NCT00613678|Experimental|2|Exercise + Activity Strategy Training: 7/8 sessions will be in a group format in which participants engage in muscular strength & flexibility exercises and listen to education lessons on management strategies for osteoarthritis. The remaining session includes a home assessment by an occupational therapist to facilitate adequate participation in daily living and leisure activities.
3173590|NCT00613691|Experimental|SPI-1620|SPI-1620 an endothelin B agonist
2499580|NCT02905734|Experimental|nicotine replacement patch|Single administration of a nicotine patch (14 mg or 21 mg, according to the Heaviness of Smoking Index)
2499583|NCT02905734|Placebo Comparator|placebo patch|Single administration of a placebo patch
2499625|NCT02905175||Rheumatoid arthritis|blood sample specimen and synoviocytes from synovial tissue
2499629|NCT02905175||Osteoarthritis|blood sample specimen and synoviocytes from synovial tissue
2499674|NCT02904889|Experimental|Stay Active at Home|One group of homecare professionals receives a training programme. In this training they learn to motivate their clients to be more active in daily and physical activities.
2499678|NCT02904889|Active Comparator|Usual care|Second group of homecare professionals will get no training and their clients will receive usual homecare.
2499713|NCT02904629|Experimental|RCL Intervention|"Respecting the Circle of Life (RCL) includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. RCL lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total RCL duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which RCL youth will receive one lesson each day. The investigators will evaluate RCL's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
2499714|NCT02904629|Other|Control|"The control program includes peer-group & youth-parent components. The peer-group component has 8 educational lessons, each lasting 90-120 minutes, delivered to self-selected same-sex peer groups of 8-10 AI teens. Control lessons are delivered once/day during an 8-day summer basketball camp. The youth-parent component is one educational lesson lasting 90-120 minutes delivered within 3 months after camp to a teen and parent together at home. Total control duration is 810-1,080 minutes over 3 months. All 8 days of the camp are study days, in which control youth will receive one lesson each day. The investigators will evaluate the control program's impact on key sexual and reproductive health risk factors at 3-, 9-, 12-, 24-, and 36-month post-intervention follow-up time points."
2499752|NCT02904122|Other|Teleconsultation|Teleconsultation using a specific camera SoproCare®6
3162891|NCT00471601|Experimental|Interviews/Questionnaires|The primary intervention in part 1 includes the interview for item generation with 50 women and the pilot-testing with a separate group of n = 30 women. The primary intervention in part 2 and 3 is the administration of the questionnaire. In part 3, along with the questionnaire being developed, the Body Image Scale (BIS), the Life Orientation Test-Revised (LOT-R), and the upcoming MSKCC BREAST-Q will be given to determine convergent and discriminant construct validity. No other therapeutic or diagnostic agents will be administered.
3162892|NCT00471614|Experimental|1|NucleomaxX
3162893|NCT00471614|Placebo Comparator|2|Placebo
3162894|NCT00471640|Active Comparator|1|dexamethasone
3162895|NCT00471640|Placebo Comparator|2|Placebo
3162896|NCT00471679|Experimental|Ethanol-Lock Treatment|Ethanol instillation and removal will be carried out by one of the investigating physicians, a pediatric surgical nurse practitioner, or a dedicated research nurse. Syringes containing a 70% ethanol solution will be pre-filled in the PDH pharmacy and dispensed to the nurse caring for a particular patient. The volume of ethanol to be administered into each lumen of the central line will be specific to each patient's catheter and will be determined at enrollment.
3162897|NCT00471692|Placebo Comparator|placebo|Normal saline placebo
3162898|NCT00471692|Active Comparator|Ropivocaine|Ilioinguinal nerve block with ropivocaine
2499904|NCT02903108|Active Comparator|Boric acid group|Oral prophylaxis followed by 0.75% boric acid drug in gel form placed in intrabony defects
2499905|NCT02903108|Placebo Comparator|Placebo group|Oral prophylaxis followed by placebo gel placement in intrabony defects
2499914|NCT02902783||Consented deceased organ donors|Data will be collected on deceased donors, declared by neurological determination of death (DND) and by circulatory determination of death (DCD).
2500008|NCT02902614|Experimental|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from opposite side to the 2nd polar body or from vegetal pole.
2500012|NCT02902614|Experimental|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage: Blastomere collection from and side around the 2nd polar body and not the vegetal pole.
2500024|NCT02901912||Active|Women who perform at least 3h of physical activity per week
2500026|NCT02901912||Sedentary|Women who did not perform any kind of exercise
2500079|NCT02901808||NOMI|Patients suffering from NOMI
2500080|NCT02901808||No-NOMI|Patients not suffering from NOMI
2500129|NCT02901418||control group|In this group,these children born in about two hours, we injected HBIG 200 iu and 10 micrograms of hepatitis b vaccine in their left and right thigh respectively, then injected 10 micrograms again in 1 and 6 months.
2500135|NCT02901418||experimental group|In this group,about 2 hours after birth, respectively injecting HBIG 200 IU and 10 micrograms of hepatitis b vaccine in the right and left thigh, and in 1 and 6 months again taking 10 micrograms of standard solution, in addition, offering the additional injection of 200 IU HBIG within 24 hours.
2500158|NCT02901067|Experimental|Experimental|Administration of 325mg Aspirin and 20mg of Rosuvastatin mixture in a single capsule daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
2500272|NCT02900209||Healthy controls|Aged 65-85 years and do not have any symptoms of lung disease and have normal spirometry.
2500302|NCT02900014|Experimental|Children with cleft|
3162899|NCT00471770||1|1.Core group: enrolled subjects who have isolated pneumococcal
3162900|NCT00471770||2|2.SPN group:enrolled subjects who have no isolated pneumococcal
3162901|NCT00471770||3|3.DCF group: Subjects screened but not enrolled
3162902|NCT00471952|Experimental|1|Maxalt 10mg with Caffeine 75mg
3162903|NCT00471952|Active Comparator|2|Maxalt 10mg plus Placebo
3162904|NCT00471952|Placebo Comparator|3|Double placebo
3162905|NCT00471965|Experimental|A|Oxaliplatin + 5-Fluorouracil/Leucovorin
3162906|NCT00471965|Active Comparator|B|Doxorubicin
3162907|NCT00471991|Active Comparator|Arm 1|
3162908|NCT00471991|Experimental|Arm 2|
3173591|NCT00613717|Experimental|a|pre- and early postnatal iron
2499581|NCT02905552||Case group|Patient developing a first episode of infection since diagnosis of high-risk MDS (index case)
2499588|NCT02905552||Control group|"Patient with no infection since diagnosis of MDS~Patient will be paired to index case by:~Hospital site~Age~Sexe Control patient is eligible if he has been seen in consultation within 15days before or after date of first infection of index case If matching fails, control patient can be found in another site and/or within 30days before or after date of first infection of index case"
2499614|NCT02905240|Experimental|nSTRIDE APS|Autologous Protein Solution prepared using the nSTRIDE APS Kit
2499616|NCT02905240|Other|Saline|Saline control
2499746|NCT02904148|Experimental|Shoulder mobilisation|The shoulder mobilisation is performed daily by a physiotherapist for 45 days.
3162909|NCT00472004|Active Comparator|1|17B Estradiol (1mg) / (0.125 mg) Trimegestone (TMG) Continuous combined, 1 Daily, 1 year duration
2499839|NCT02903472||Acute to first year after SCI|Individuals sustained SCI within a 1-year period
2499844|NCT02903472||Chronic|Individuals sustained SCI more than1 year ago
2499865|NCT02903264||GDM group|Gestational diabetes mellitus patients under treatment of an endocrinologist
2499868|NCT02903264||Control|Healthy non-pregnant females
2499984|NCT02902302|Experimental|Ibuprofen 400 mg/10 mL oral suspension|Single dose of 1 ibuprofen 400 mg/10 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2499986|NCT02902302|Active Comparator|MOMENT 400 mg coated tablet|Single dose of 1 MOMENT 400 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2500047|NCT02902094|Experimental|Experimental|Drug eluting angioplasty balloons
2500051|NCT02902094|Active Comparator|Control|Non-drug eluting balloons
2500096|NCT02901587|Experimental|Lu AF35700 (10 mg/day)|Lu AF35700 10 mg/day for 6 weeks
2500097|NCT02901587|Experimental|Lu AF35700 (30 mg/day)|Lu AF35700 30 mg/day for 6 weeks
2500100|NCT02901587|Experimental|Quetiapine (Seroquel XR® 800 mg/day)|Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks
2500154|NCT02901184|Active Comparator|Spironolactone treatment|Spironolactone will be prescribed by the Investigator and filled by patient at conventional pharmacies as 25 mg tablets. The treatment will be on top of standard care. Initial dose is 25 mg/day, which will be increased to target dose 50 mg/day if tolerated. Eplerenone can be prescribed if spironolactone is not tolerated.
2500165|NCT02901184|Placebo Comparator|Standard care alone|Patients in the control arm will get the standard care alone
2500281|NCT02900157|Experimental|MEDI9090|
2500320|NCT02899845|Experimental|elderly people with walking difficulties|subjects with proven gait disturbance and balance will be recruited from a walking speed test and a standardized geriatric assessment by a geriatrician
2500324|NCT02899845|Active Comparator|elderly people without walking difficulties|subjects with no gait disturbance and balance disorders will be recruited from a walking speed test and a standardized geriatric assessment, once the subjects with gait disturbance and balance disorders have been recruited in order to make a match on the age criterion
2500390|NCT02899481|Experimental|Study group|The study group will be constituted by pregnant women in whom the operative delivery will be preceded by a transabdominal and transperineal ultrasound to evaluate fetal head position and fetal head station, by means of determination of the 'angle of progression'.
2500392|NCT02899481|No Intervention|Control group|The control group will be constituted by pregnant women in whom the operative delivery will be carried out based solely on clinical criteria, namely transvaginal digital examination.
2500651|NCT02897596|Experimental|Genotype 1b|Grazoprevir 100 mg/d during 8 weeks. Elbasvir 50 mg/d during 8 weeks.
2500653|NCT02897596|Experimental|Genotype 1a and 4|Grazoprevir 100 mg/d during 12 weeks. Elbasvir 50 mg/d during 12 weeks.
2500767|NCT02896920||Participants receiving adalimumab/ Humira®|Participants with HS for whom a change in treatment to Humira® is made by the treating physician
2500795|NCT02896413|Experimental|Dexmedetomidine Group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
2500796|NCT02896413|Placebo Comparator|Control Group|0.9% saline infusion
2500873|NCT02896179|Experimental|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
2500879|NCT02896179|Active Comparator|Robot-assisted gait training group|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
2500925|NCT02895672||Weekly GLP-1 therapy: exenatide|Patients receiving weekly exenatide
3162910|NCT00472004|Active Comparator|2|Tibolone 2.5 mg 1 daily, 1 year duration
3162911|NCT00472017|Experimental|Pediatric Diffuse Brainstem Glioma Patients|Patients with newly diagnosed diffuse brainstem gliomas receive vandetanib.
3162912|NCT00472069|Experimental|A|transplantation of the squeletic muscular cells
3162913|NCT00472095|Experimental|diabetes fotonovela|spanish language comic book describing diabetes care and consequences
3162914|NCT00472095|Placebo Comparator|placebo fotonovela|
3162915|NCT00472121||1: AMG|
3162916|NCT00472121||2: MMG|
3162917|NCT00472134|Active Comparator|Bupivicaine via Elastomeric pump|Bupivicaine via elastomeric pump
3162918|NCT00472134|Placebo Comparator|Placebo via elastomeric pump|Placebo via elastomeric pump
3162919|NCT00472160|Experimental|1|Non Invasive Ventilation
3162920|NCT00472173|Active Comparator|Calcium hydroxide|
2499594|NCT02905474|Experimental|eKidneyCare|The eKidneyCare mobile app has an active interface with the renal clinic pharmacy system to allow for updated medication profiles to be sent directly to the patient's smartphone for the renal clinic pharmacy information system.
2499596|NCT02905474|Active Comparator|My MedRec (Commercial App)|My MedRec is a commercially available mobile app which allows a user to have a personal health record along with keeping track of their medications. The My MedRec mobile app allows users to track blood pressure and medication information through manual data entry with the app. It is a stand alone mobile app which stores specified medical information on the native smartphone device and does not connect to any other servers or databases.
2499637|NCT02905045|Active Comparator|Ketoprofen|women will take one tablet 150 mg one hour before the procedure
2499640|NCT02905045|Placebo Comparator|Placebo|women will take one tablet placebo one hour before the procedure
2499690|NCT02904759|Experimental|Desmopressin 25 µg|Desmopressin ODT
2499691|NCT02904759|Experimental|Desmopressin 50 µg|Desmopressin ODT
2499693|NCT02904759|Placebo Comparator|Placebo|Placebo ODT
2499705|NCT02904434||Voriconazole|Children (2-17 years old) will receive oral voriconazole as prescribed by their physicians as standard of care for the duration of the study.
2499741|NCT02904278|Experimental|Teen Pocket PATH® Mobile Application|"Participants in this group will receive the mobile application for improving adherence to their post-transplant medications, along with standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken. Additionally, the mobile app. will inform the investigators, by way of automated text messaging, of treatment adherence.~Duration of participation: up to 12 months post heart transplantation."
2499743|NCT02904278|Other|Control Group: Standard of Care|"Participants in the control group will receive standard post-transplant care, in accordance with the CTOTC-10 Cardiac Consortium Clinical Care Guidelines.~Duration of participation: up to 12 months post heart transplantation."
2499763|NCT02903888||BAY86-5028|Women aged 18 to 29 years that use Jaydess for contraception
2499836|NCT02903784|Other|grade 2 glioma|Patient with grade 2 glioma use a neuropsychological examination and brain imaging (fMRI and tractography)
2499842|NCT02903784|Other|healthy volunteers|healthy volunteers use a neuropsychological examination and brain imaging (fMRI and tractography)
2499931|NCT02902835|Active Comparator|Referral to treatment (Control)|The control group will receive a referral to buprenorphine treatment by the research staff.
2499936|NCT02902835|Experimental|BUP-FAST Intervention|Thirty-six participants will each be paired with a trained peer mentor who will provide the BUP-FAST intervention.
2500000|NCT02902484|Experimental|Nintedanib Monotherapy|"One cycle of Nintedanib monotherapy followed by a total of eight cycles of both Nintedanib and the chemotherapeutic agents, or until disease progression, whichever comes first.~Nintedanib dose escalation: 150, 200 mg PO BID~Nab-paclitaxel: 125 mg/m2 day 1,8,15 every 28 days~Gemcitabine: 1000 mg /m2 day 1,8,15 every 28 days"
2500048|NCT02902003|No Intervention|Control|Not eligible for program services
2500055|NCT02902003|Active Comparator|Empowering Families|"These couples will be eligible to participate in the Empowering Families program."
2500091|NCT02901665|No Intervention|Pre-FCC Intervention|Pre-intervention group. No intervention will be administered.
2500093|NCT02901665|Active Comparator|Post-FCC Intervention|Following unit-wide implementation of FCC intervention consisting of communicating to families an expectation that they spend 4 hours per day in the NICU with their infants.
2500161|NCT02901288|Experimental|experimental group1|"The experimental group1 all oral regimen is consisted of isoniazid,rifampin, pyrazinamide, ethambutol and levofloxacin for 4.5 months.~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily), levofloxacin 600mg(less than 50kg,given once daily) or 800mg(more than 50kg,once daily)."
2500171|NCT02901288|Experimental|experimental group2|The experimental group2 all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol for 4.5 months. The dosage of isoniazid,rifampin, pyrazinamide, and ethambutol is as same as that of control regimen.
2500174|NCT02901288|Active Comparator|Control regimen group|"The control all oral regimen consisted of isoniazid,rifampin, pyrazinamide, and ethambutol during the intensive phase of treatment (2 months), followed by isoniazid and rifampin during the continuation phase (4 months).~Dosage: isoniazid 300mg(given once daily), rifampin 450mg(less than 50kg,given once daily)or 600mg(more than 50kg,given once daily), pyrazinamide 1500mg((less than 50kg,given once daily)or 30mg/kg(more than 50kg,once daily), ethambutol 750mg (less than 50kg,once daily) or 1000mg (more than 50kg,once daily).~."
2500268|NCT02900339|Experimental|MR parameters optimization|The study will be conducted on the MRI of the Neurinfo platform, in the radiology department of the University Hospital of Rennes.
2500292|NCT02900040||patients with kidney transplantations|patients with kidney transplantations
2500348|NCT02899676|Experimental|Healthy subjects aged 18 to 24|Subjects without neurological or psychiatric history
2500349|NCT02899676|Experimental|Healthy subjects aged 8 to 11|Subjects without neurological or psychiatric history
2500351|NCT02899676|Experimental|Healthy subjects aged 12 to 14|Subjects without neurological or psychiatric history
2500378|NCT02899234|Active Comparator|Nicotine-free e-cigarette|Subjects will actively inhale nicotine-free vapor prior to blood samples and various non-invasive cardiopulmonary tests.
2500385|NCT02899234|Active Comparator|Nicotine e-cigarette|Subjects will actively inhale nicotine containing vapor prior to blood samples and various non-invasive cardiopulmonary tests.
2500431|NCT02899026|Experimental|Part A: Sirukumab 100 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 100 mg subcutaneously (SC) every 2 weeks (q2w) for 52 weeks plus a 6-week oral prednisone taper regimen
2500459|NCT02899039|Active Comparator|Healthy controls|Healthy subjects
2500928|NCT02895529|Active Comparator|Caspofungin|
2499600|NCT02905448|Experimental|Low fat plant-based diet|Low fat plant-based nutrition: low fat plant-based diet supplemented with plant-based meal replacements
2499663|NCT02904941|Experimental|Amniotic Membrane Dressing|Children allocated to this arm will receive skin dressings made out of human amniotic membrane. Dressings will be replaced every 72 - 96 hours.
2499665|NCT02904941|Active Comparator|Synthetic Dressing|Children allocated to this arm will receive skin dressings made out of silicone as part of their wound care. Dressings will be replaced every 72 - 96 hours.
2499721|NCT02904499||VKA|First Initiators of VKA for non-valvular atrial fibrilation
2499723|NCT02904499||Dabigatran|First Initiators of Dabigatran for non-valvular atrial fibrilation
2499769|NCT02904083|Experimental|specific training of professionals|patients from centers where professionals have received specific training
2499772|NCT02904083|Active Comparator|control training of professionals|patients from centers where professionals have received control training
2499827|NCT02903680|Active Comparator|Dexamethasone group|Dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED.
2499838|NCT02903680|Placebo Comparator|Placebo group|The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
2499884|NCT02903186|Experimental|Nutrition messages|The intervention will focus on reinforcing the WIC breastfeeding messages, preventing overfeeding (i.e. using spoon to feed baby, not adding baby food or cereal to bottle, not placing their babies to sleep with a bottle, feeding their babies without distractions, etc), delaying introduction of solid foods, and delaying and reducing baby juice consumption. Constructs in the transtheoretical model such as self-efficacy and decisional balance will be used to address key determinants of behavior change to ensure relevance to the audience, and will target individuals both at the earlier and later stages of change. The messages are written at a grade 5 level in Spanish (PR site) and English (Hawaii site) and will be sent on different days and times of the week.
2499887|NCT02903186|Active Comparator|General health messages|The control group will receive weekly SMS about general infant's health issues, such as placing the infant on his/her back to sleep, the timeline for immunizations, the proper use of car seats, asthma and other respiratory conditions common among small children, and other health information relevant to infants. The investigators will follow the same protocol (schedule, length, language, etc.) as for the intervention messages.
2499940|NCT02902926|Experimental|Low FODMAPs Diet|"Instructed to low FODMAPs diet when patients signed the informed consent.~Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food."
2499946|NCT02902926|Placebo Comparator|Diet Instruction|1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
2499973|NCT02902419|Active Comparator|1|Wound dressing removal was performed between 12-30 hours postoperatively.
2499976|NCT02902419|Active Comparator|2|Wound dressing removal was performed between 30-48 hours postoperatively.
3195936|NCT00845078||1|Immediate reconstruction followed by radiation therapy
3195937|NCT00845078||2|Radiation therapy followed by delayed reconstruction
2500127|NCT02901457|Experimental|Healthy Body Image|Students receive the Healthy Body Image intervention containing 3x90 minutes of interactive workshops with the addition of related homework after each workshop.
2500130|NCT02901457|No Intervention|Control group|Students do not receive the intervention program.
2500148|NCT02901106|Experimental|Patient with recurring-remitting MS|
2500204|NCT02900911|Experimental|Early rehabilitation|Early intervention consisting in standard swallow therapy and instructions to train respiratory muscles starting 2 weeks before Radiotherapy during 6 months
2500205|NCT02900911|Active Comparator|Later rehabilitation|Late intervention consists of standard swallow therapy and instructions to train respiratory muscles starting after completing Radiotherapy
2500269|NCT02900222|Experimental|Choroid Plexus Coagulation|Patients with communicating hydrocephalus will be treated with endoscopic choroid plexus coagulation.
2500294|NCT02900053|Active Comparator|Arm 1|Cerebral modulation using tDCS (transcranial Direct-Current Stimulation) associated with repetitive traumatic exposure using a personal traumatic script
2500298|NCT02900053|Placebo Comparator|Arm 2|Placebo cerebral modulation using sham-tDCS associated with repetitive traumatic exposure using a personal traumatic script
2500345|NCT02899637|Experimental|Spinal Cord Injury (Active Group)|Active high-frequency Transcranial Magnetic Stimulation
2500346|NCT02899637|Sham Comparator|Spinal Cord Injury (Control group)|Sham high-frequency Transcranial Magnetic Stimulation
2500397|NCT02899169|Experimental|Oral Realgar-Indigo naturalis formula(RIF) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: RIF（60mg/kg/d) and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: RIF and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
2500401|NCT02899169|Active Comparator|Intravenous Arsenic Trioxide(ATO) Group|Induction therapy: ATO and ATRA, which will maintain until complete hematologic remission. Hydroxyurea should be administrated until WBC count decrease <10x109/L. Consolidation therapy: ATO and ATRA 4 weeks on and 2 weeks off, until the fusion gene expression is negative. Maintenance therapy: ATO and ATRA 2 weeks on and 2 weeks off for a total of 6 courses.
2500422|NCT02898844|No Intervention|Control Condition|Neither roommate dieted.
2500423|NCT02898844|Experimental|Mixed Diet Condition|Low-calorie diet: One roommate in each pair was randomly assigned to a 1200-calorie/day diet, while the other roommate was instructed to eat normally.
2500426|NCT02898844|Experimental|Both Diet Condition|Low-calorie diet: Both roommates in each pair were randomly assigned to a 1200-calorie/day diet.
3195938|NCT00845091|Experimental|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
3195939|NCT00845091|Active Comparator|Heart Healthy Education|Educational topics on heart health (e.g., nutrition, smoking, sleep)
2500626|NCT02897531|Active Comparator|ES anastomosis|Stapled end-to-side anastomosis
2500636|NCT02897531|Active Comparator|SS anastomosis|Stapled side-to-side anastomosis
2500701|NCT02897219|Experimental|Part 1 ASP1941|ASP1941 will be administered for 24 weeks under double blind conditions.
2500733|NCT02896829||Imatinib treatment ending|Interruption of the treatment by Imatinib
3195940|NCT00845104|Experimental|Arm I|See Detailed Description
2499605|NCT02905357||MI-CAD|Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
2499717|NCT02904538|Experimental|Perineural group|1cc (4mg) of dexamethasone will be administrated in perineural injection. 2.5cc of isotonic saline solution will be administrated in systemic injection.
2499720|NCT02904538|Experimental|systemic group|1cc of isotonic saline will be administrated in perineural injection. 2.5cc (10mg) of dexamethasone will be administrated in systemic injection.
2499774|NCT02904070|Experimental|Threat of premature delivery|"Perform detection test of Placental Alpha-Microglobulin-1, fetal Fibronectin and phosphorylated Insulin-like Growth Factor Binding Protein-1ph by vaginal swabbing;~Collection of clinical data, laboratory data and treatment of obstetric care in the delivery room during childbirth for all included subjects"
3195941|NCT00845117|Experimental|Limbal Stem Cell Transplant|The cornea is debrided of all superficial fibrovascular tissue and the cultivated stem cell graft is glued onto the cornea.
2499966|NCT02902822|Active Comparator|Screening|This arm includes all subjects randomized to regular dermatological follow-up visits on annual basis.
2499967|NCT02902822|Experimental|Tele-dermatology|This arm includes all subjects randomized to the use of a tele-dermatology system for the evaluation of newly onset non-widespread skin lesions.
3195942|NCT00845156|Active Comparator|Anti-Oxidant|Alpha Lipoic Acid
2500142|NCT02901366|Experimental|14C-FYU-981|14C-FYU-981, (Oral single dosing)
2500177|NCT02901028|Experimental|Collar Device|The Device is a standard hockey neck guard, adapted for the purposes of this study. The Device incorporates two bulges localized over the site of the internal jugular veins bilaterally. Experiments performed with jugular Doppler ultrasound demonstrate that while wearing the Device, flows within the jugular veins are reduced, while flow within the carotid arteries and all portions of the cerebrum are preserved (JA Fisher, unpublished data). Thus, application of the Device to the subject will not cause any untoward health risks. The pressure exerted by the Device on the region of the neck superficial to the internal jugular vein is akin to the pressure felt when a person yawns or wears a snugly fitting necktie.
2500180|NCT02901028|Sham Comparator|Arm Device|the subject is wearing a sham arm device, which will be placed on the upper arm and not cause venous engorgement. The subject will undergo the same testing as when wearing the collar device (strength, Vo2, vision, blood, urine, etc)
2500209|NCT02900716|Experimental|Phase Ia|DTRMWXHS-12: oral capsules, daily x 21 days every 28 days
2500217|NCT02900716|Experimental|Phase Ib, DTRM-505|DTRMWXHS-12 oral capsules and everolimus oral tablets: daily x 21 days every 28 days
2500220|NCT02900716|Experimental|Phase Ib, DTRM-555|"DTRMWXHS-12 and pomalidomide oral capsules, everolimus oral tablets:~daily x 21 days every 28 days"
3195943|NCT00845156|Placebo Comparator|Placebo|Placebo
3195944|NCT00845169|Experimental|Diesel Exposure|1 hour exposure to diesel exhaust at 300 µg/m3 during intermittent exercise
3195945|NCT00845169|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
3195946|NCT00845208|Active Comparator|Case Management|
2500673|NCT02897427||Screening (specimen collection, HPV testing)|"STAGE I: Participants fill out a survey and undergo collection of blood and oral rinse samples.~STAGE II: Participants complete a head and neck exam by using brushing of the oropharyngeal mucosa, a thorough oropharyngeal exam including narrow band imaging, collection of oral rinse sample, transcervical ultrasonography of the neck lymph nodes and oropharynx, anoscopy, penile exam, and complete Papanicolaou/HPV testing. Participants undergo repeat oropharyngeal screening, oral HPV DNA test, oral HPV integration testing, ultrasound, and blood sample collection once every year for 5 years. Select participants will provide oral rinse sample by mail every six months."
2500731|NCT02896764|Experimental|Eligible patients for cone-beam CT|A cone-beam CT will be offered to the patient undergoing a CT scan of the middle ear
2500792|NCT02896673|Experimental|ventilatory conditions and measures with scanner and EIT|"The patient is installed on the scanner bed, EIT electrodes are connected to the acquisition device of the EIT signal.~Esophageal pressure signals, pressure and flow in the airways will be acquired continuously"
2500824|NCT02896205|Experimental|Mycophenolate mofetil|Subjects will be started on Mycophenolate Mofetil 500mg twice a day and increased by 500mg every 2 weeks, if tolerated, to a target dose of 2gram per day.
2500825|NCT02896205|Placebo Comparator|Placebo|Subjects in this arm will be given matching placebo, made of lactulose, starting at two tablets per day and increased by one tablet every 2 weeks to a target of 4 tablets per day.
2500888|NCT02895932|Experimental|Case|Patients with diagnosed Parkinson's disease
2500896|NCT02895932|Experimental|Control|Healthy adults
2500967|NCT02895269|Experimental|Collaborative shared care|Conventional primary health care providers (PHCP) are trained to collaborate with and support traditional and faith healers (complementary alternative providers, CAPs) in the care of patients with psychosis. The PHCP are purposively trained to deliver evidence-based treatment for psychosis and to conduct scheduled and on-request visits to the facilities of the CAPs to collaborate in the treatment of patients with psychosis through joint decision making and clinical management. The overall care of the patients remains the responsibility of the healers. The role of the PHCP is to support the healers deliver safe and acceptable care to patients, including the promotion of and respect for human rights and avoidance of harmful practices in the care of patients.
2500969|NCT02895269|Active Comparator|Usual care|Complementary alternative providers deliver intervention for patients with psychosis without active or formal collaboration with conventional primary health care providers. The primary health care providers in this arm nevertheless receive training on evidence-based treatment of psychosis.
2501027|NCT02894944|Experimental|Theragene arm|Patients who were treated with Theragene®,Ad5-yCD/mutTKSR39rep-ADP and chemotherapy
3195947|NCT00845208|Experimental|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
2499611|NCT02905383|Experimental|Exercise|This group will perform a multi-component exercise program twice a week for 16 weeks. The multi-component exercise program consists of endurance training, progressive strength exercises and balance exercises. The intervention will be individualised, but performed in groups of four to ten patients. The participants are also expected to do exercises on their own, at least once weekly.
2499613|NCT02905383|No Intervention|Control|The participants in the control group will be encouraged to exercise on their own, according to the World Health Organization recommendations on physical activity for adults aged 65 and above.
2499664|NCT02904980|Experimental|Technical Training Group|15 children diagnosed with DCD
2499667|NCT02904980|Experimental|Quiet Eye Training Group|15 children diagnosed with DCD
2499716|NCT02904668|Experimental|Experimental group|Patients allocated to the experimental group were included in a self-management program and manual therapy program
2499718|NCT02904668|Active Comparator|Control group|"The intervention consisted of 45-minute manual therapy sessions. Manual therapy included hands-on muscular mobilization techniques (aimed at improving soft tissue function), specific articular mobilization techniques (to improve overall joint function and decrease any restrictions in movement at single or multiple segmental levels in the cervical spine), and coordination or stabilization techniques (to improve postural control, coordination, and movement patterns by using the stabilizing cervical musculature)"
2499748|NCT02904161||first stage|For the first stage, 60 healthy volunteers, 10 patients with stage 4 breast cancer and 10 patients with other types of cancer will be recruited.
2499749|NCT02904161||second stage|For the second stage, approximately 65 breast cancer patients will be recruited.
2499764|NCT02903979|Experimental|HVGIC|Restorations with only HVGIC in deep caries lesion of primary teeth.
2499766|NCT02903979|Active Comparator|Indirect pulp capping|Indirect pulp capping with calcium hydroxide cement, restored with HVGIC:
2499871|NCT02903342|Experimental|Intervention|Parents will be asked to read a leaflet. They will then complete a survey and re-complete the survey via telephone two weeks later.
2499878|NCT02903342|No Intervention|Control|Parents will be asked to complete a survey and re-complete the survey via telephone two weeks later.
2499912|NCT02903004|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)
2499913|NCT02903004|Other|Standard Treatment|Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
2499974|NCT02902510|Experimental|Experimental|The experimental group is the group that received yoga. The individuals originally assigned to the WLC who completed the yoga intervention AFTER the 8 weeks WLC period also are considered part of the experimental group.
2499977|NCT02902510|No Intervention|Wait List Control|There was no intervention during the WLC.
2500033|NCT02902185|Experimental|Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
2500034|NCT02902185|Placebo Comparator|Placebo-controlled|Placebo with the same taste and appearance like Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.
2500101|NCT02901691|Experimental|Deaf children|
2500107|NCT02901691|Placebo Comparator|healthy volonteer children|
2500159|NCT02901223|Active Comparator|Quadrantectomy group|35 female patients with non metastatic breast cancer who had standard conservative breast surgery by general breast surgeons.
2500167|NCT02901223|Active Comparator|oncoplastic group|35 female patients with non metastatic breast cancer who had oncoplastic techniques for tumor resection by well trained oncoplastic breast surgeons.
2500285|NCT02900495|Experimental|Suprapubic TENS|electrodes, 'transcutaneous electric nerve stimulation' placed onto the lower abdomen in the suprapubic region directly over the bladder
2500287|NCT02900495|Experimental|Posterior Tibial TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the posterior tibial nerve behind the medial malleolus of the ankle and another electrode on the bottom of the foot
2500289|NCT02900495|Experimental|Parasacral TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the S3 foramen on the sacrum on each side of the midline in the lower back/upper buttocks
2500290|NCT02900495|Placebo Comparator|Shoulder TENS|electrodes, 'transcutaneous electric nerve stimulation' placed over the scapula on the shoulder/back
2500332|NCT02899780|Experimental|Ultraviolet arm|This arm will have their dialysis catheters treated with an ultraviolet light emitting optical fiber.
2500398|NCT02899455|Experimental|Experimental|HGP0904 + HGP0608 + HGP0816, once daily
2500400|NCT02899455|Active Comparator|Active Comparator1|HGP0904 placebo + HGP0608 + HGP0816, once daily
2500402|NCT02899455|Active Comparator|Active Comparator2|HGP0904 + HGP0608 + HGP0816 placebo, once daily
2500446|NCT02898883|Experimental|Intervention group|Early intervention Program The early intervention program (EIP) will consist of 4 sessions with one parent/guardian of the injured child and a clinical psychology graduate student therapist. All sessions are one on one for one hour. The first session will be conducted in the hospital within an average of 24- 48 hours after the traumatic event. The subsequent three sessions will be conducted electronically via web-based video chat once per week. In general, the EIP will utilize psychoeducation, skills implementation, and daily monitoring to facilitate communication regarding the traumatic event, maintain daily and sleep routines, increase child's access to social support and mitigate the impact of life stress.
2500447|NCT02898883|No Intervention|Treatment as Usual (TAU)|As part of routine hospital protocol, all participants who screen positively for PTSD risk are provided with a packet of educational materials and potential referrals for behavioral healthcare.
2500503|NCT02898558|Experimental|Magnification hand size|magnifying lenses used for 30 minutes daily for 14 days while completing a jigsaw puzzle
2500546|NCT02897986|Experimental|patients with refractory/relapsing solid tumors|
2500657|NCT02897791|Experimental|Impaired Rt. Hemisphere patients|20 first stroke patients
2500659|NCT02897791|Experimental|control|20 healthy adults without any known damage to the right hemisphere. The two groups will be matched concerning sex, age, educational level and socio-economic status.
2500667|NCT02897180|Placebo Comparator|Placebo|Subjects will receive a total of 14 capsules with Placebo
2500668|NCT02897180|Experimental|Nyaditum resae(R)|Subjects will receive a total of 14 capsules with Nyaditum resae(R)
2499630|NCT02905227|Experimental|Adult Asthmatics|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult asthmatics
2499632|NCT02905227|Experimental|Adult Smokers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult smokers.
2499634|NCT02905227|Experimental|Adult Healthy Volunteers|Two doses of CVT-427, 2 hours apart. 3.0 mg zolmitriptan capsule administered via CVT-427 breath-actuated inhaler in adult healthy volunteers.
2499669|NCT02904772|Other|alipogene tiparvovec with IS|Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration. The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day). Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
2499671|NCT02904772|Other|alipogene tiparvovec without IS|Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks. Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
2499754|NCT02904317||Misprostol vaginal insert for labour induction|69 patients matching the inclusion criteria and received MVI for labour induction
2499755|NCT02904317||Oral misoprostol for labour induction|69 patients matching the inclusion criteria and received OM for labour induction
2499765|NCT02903927|Experimental|CT LUCIA|
2499767|NCT02903927|Active Comparator|Acrysof IQ Sn60WF|
2499881|NCT02903381|Experimental|Nivolumab, Lenalidomide, Dexamethasone|"A treatment cycle is defined as 28 consecutive days.~Participants will receive 6 cycles of induction therapy followed by 6 cycles of maintenance therapy with lower doses of lenalidomide and no dexamethasone for a total of 12 months."
2499959|NCT02902653|Experimental|Oral misoprostol|"Administration of oral misoprostol according to a 3x1 diagram, that is,3 oral doses (1 per hour) and then 1 hour without treatment"
2499962|NCT02902653|Active Comparator|Vaginal misoprostol|vaginal misoprostol, 25 microgs every 4 hours
2499964|NCT02902653|Active Comparator|Vaginal dinoprostone|vaginal dinoprostone, 10 mg during 24 hours (maximum)
2499981|NCT02902341|Active Comparator|Control|Standard protocol nutrition.
2499985|NCT02902341|Experimental|Nutrition Therapy|Resting energy expenditure was measured using indirect calorimetry or calculated. A dietician assessed daily caloric intake during the entire hospitalization. Caloric deficits were calculated. According to a predefined flow-chart protocol, nutritional interventions were launched on different time points. Interventions varied from nutritional modifications to oral supplementation, tube feeding, and parenteral nutrition.
3162921|NCT00472173|Experimental|MTA|
2500122|NCT02901574|Active Comparator|tDCS plus computerized naming therapy|Anodal or cathodal tDCS, 2 milliamps (mA) plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks.The electrical current will be administered to the right cerebellum. The stimulation will be delivered at an intensity of 2 mA for a maximum of 20 minutes. Language therapy will be a computer delivered naming +picture matching task.
2500123|NCT02901574|Sham Comparator|Sham plus computerized naming therapy|Sham tDCS plus computerized naming treatment for 15 sessions (20 minutes per each 45 minute treatment session) over the course of 3-5 weeks. Current will be administered in the in a ramp like fashion for 15-30 seconds but then the current is gradually decreased and drop to 0 mA. Language therapy will be a computer delivered naming +picture matching task.
2500451|NCT02898857||down-staging of a KRAS|Six with demonstrated down-staging of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2500456|NCT02898857||no down-staging of a KRAS|Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2500460|NCT02898857||non-staging and triple negative adenocarcinoma|Six with or without non-staging and triple negative adenocarcinoma who underwent biopsie The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches
2500505|NCT02898480|Experimental|Remote ischemic conditioning|
2500630|NCT02897544|Experimental|Health Education Intervention|Study participants will attend Health Education sessions led by health educators over the course of 6 months. The emphasis in the sessions will be to provide engaging educational information on common survivorship issues.
2500757|NCT02896946|Experimental|diffusion-weighted nuclear magnetic resonance imaging|detection of liver metastasis on diffusion-weighted nuclear magnetic resonance imaging in patients with potentially resectable pancreatic adenocarcinoma
2500892|NCT02895867|Experimental|Full fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
2500898|NCT02895867|Experimental|Low fat dairy group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietitian and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
2500903|NCT02895867|Other|Control group|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
2501142|NCT02894060|Experimental|blood|blood tests
3162924|NCT00472212|Experimental|Spectacles|Spectacles with hyperopic lenses
3162925|NCT00472212|Placebo Comparator|Control|Spectacles with placebo lenses
3162926|NCT00472225|Experimental|1|Rituximab treatment arm
3162927|NCT00472238|Experimental|1, Training|Group for training therapy
3162928|NCT00472238|Active Comparator|2, Control|
3173592|NCT00613717|Experimental|b|iron prenatal only
3173593|NCT00613717|Experimental|c|iron early postnatal only
2499726|NCT02904590||IBD patients|Incidental patients with IBD controlled (including Crohn's disease, Ulcerative colitis and unclassified colitis)
2499781|NCT02903940|Experimental|CRT+NAVH|Surface ECG recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings.
2499915|NCT02902796|Active Comparator|Treatment group A|Group A will consist of sequence of treatment with 3 stimulation modes. They are, in order, 1000 hertz, standard, and burst stimulation. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
2499916|NCT02902796|Active Comparator|Treatment group B|Group B will consist of sequence of treatment with 3 stimulation modes. They are, in order, burst stimulation, standard, and 1000 hertz. Each stimulation modes will last 3 weeks, with 4 days of wash off between them. Each group treatments will take about 3 months, and subject will cross over into the other treatment group. Burst stimulation sends packets of electrical pulses, composed of pulse and packet frequency. 1000 hertz stimulation delivers tonic, sub perception stimulation. The standard stimulation mode, which will serve as the control, will be below 100 hertz, and its pulse strength will be above threshold, where patients will feel the tingling from the electrical pulses generated by the spinal cord stimulator.
2499965|NCT02902640||Acute Bronchitis Participants|Participants with acute bronchitis for whom the treating physician has decided to initiate treatment with Balsamic Bactrim, will be observed. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling. The study protocol does not enforce any treatment.
2500014|NCT02902289|Experimental|Ibuprofen 200 mg/5 mL oral suspension|Single dose of 1 ibuprofen 200 mg/5 mL stick administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2500015|NCT02902289|Active Comparator|MOMENT 200 mg coated tablet|Single dose of 1 MOMENT 200 mg coated tablet administered under fasting conditions in two consecutive periods, with a wash-out interval of at least 7 days between consecutive administrations.
2500050|NCT02901886|Experimental|Intensive smoking cessation intervention|"The intervention includes 1) Individual motivational counseling in combination with 2) nicotine replacement therapy.~The intervention consists of five individual motivational counselling sessions, each lasting 20 to 40 minutes over a period of six weeks with a trained smoking cessation counsellor. The principles of motivational counselling are based on the trans theoretical model of change. The smoking cessation counsellor has also been trained in motivational counselling techniques specific to this intervention.~2. Nicotine replacement therapy The participants in the intervention group will be offered nicotine replacement therapy (NRT) free of charge and if accepted it will be tailored individually according to the Fagerström's Test for Nicotine Dependence.~The participants will note their tobacco and NRT consumption in a smoking diary."
2500057|NCT02901886|No Intervention|Control|The control group will receive the standard treatment and care in the rheumatology outpatient clinic. The participants will be encouraged to write a diary describing their tobacco use during the trial period. If participants in the control group express an interest in receiving smoking cessation counselling, they will be informed about municipal programs.
2500085|NCT02901600||Patients with colorectal cancer|Fresh tissue samples from individuals with colorectal carcinoma taken from the tumor as well as from resection margins will be used for the detection of a potential marker of carcinogenesis.
2500088|NCT02901600||Patients with adenomatous polyps|Fresh tissue samples from individuals with adenomatous polyps will be used for the detection of a potential marker of carcinogenesis.
2500089|NCT02901600||Control patients|Fresh tissue samples from individuals without colorectal carcinoma will be used as control.
2500144|NCT02901340||Borderline isolated oligohydramnios|"Borderline idiopathic isolated oligohydramnios was defined according to the four quadrants technical with ultrasound examination and diagnosed with amniotic fluid index>5.0 and ≤8.0cm.~The borderline idiopathic isolated oligohydramnios group was formed of the patients who meets the inclusion criteria and between 34-37 weeks gestation (n:40)"
2500145|NCT02901340||Control group|The control group was formed of the patients who had normal amniotic volume and 34-37 weeks gestation who meets the inclusion criteria (n:100)
2500187|NCT02900950|Experimental|Arm A-Multicolour inking specimen|"After performing the pancreaticoduodenectomies, the surgeon intraoperatively inked the surfaces/margins of the specimen with different colours. The surfaces/margins inked were the following:~Anterior surface of the pancreas (yellow);~Posterior surface of the pancreas (orange);~Superior mesenteric/portal vein groove (blu);~Superior mesenteric artery margin (retroperitoneal margin) (red);~Transection margin of the bile duct (green) The trans-section pancreatic and gastric margins were not inked."
2500190|NCT02900950|Other|Arm B-Monocolour inking specimen|In arm B, only the superior mesenteric artery margin and the pancreatic margin were intraoperatively indicated by the surgeon in the specimen: a single stitch to identify the transection pancreatic margin and a continuous suture to identify the superior mesenteric artery margin. Monochromatic inking of the superior mesenteric artery margin was subsequently carried out by the pathologist.
2500227|NCT02900664|Experimental|PDR001+canakinumab in TNBC|
2500229|NCT02900664|Experimental|PDR001+CJM112 in TNBC|
2500232|NCT02900664|Experimental|PDR001+trametinib in TNBC|
2500233|NCT02900664|Experimental|PDR001+EGF816 in TNBC|
2500236|NCT02900664|Experimental|PDR001+canakinumab in NSCLC|
2500237|NCT02900664|Experimental|PDR001+CJM112 in NSCLC|
2500239|NCT02900664|Experimental|PDR001+ trametinib in NSCLC|
2500240|NCT02900664|Experimental|PDR001+EGF816 in NSCLC|
2500241|NCT02900664|Experimental|PDR001+canakinumab in CRC|
2500243|NCT02900664|Experimental|PDR001+ CJM112 in CRC|
2500245|NCT02900664|Experimental|PDR001+trametinib in CRC|
2500248|NCT02900664|Experimental|PDR001+ EGF816 in CRC|
2500251|NCT02900664|Experimental|canakinumab in TNBC|
2500252|NCT02900664|Experimental|canakinumab in NSCLC|
2500253|NCT02900664|Experimental|canakinumab in CRC|
2499777|NCT02904135||first stage|During the first stage, the patient's baseline blood sample will be mainly used for validating and troubleshooting our instrument with clinical samples.
2499780|NCT02904135||second stage|During the second stage, 40 patients will be followed for up to three years after their baseline blood draw to obtain data on their survival status. The CTC results and follow-up data obtained from these samples will help to analyze any correlation with the patient's clinical outcome and further validate the prognosis ability of MiCareo's CTC platform for mBC patients.
2499955|NCT02902666|Experimental|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|"A single dose of the experimental drug will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 1) or after (treatment arm 2) a wash-out interval of at least 7 days between the active comparator administration.~Test formulation will be administered as a single dose of one paracetamol 1000 mg/codeine 30 mg tablet."
2499956|NCT02902666|Active Comparator|paracetamol 500mg/codeine phosphate hemihydrate 30mg 2 tablets|A single dose of active comparator will be administered to healthy male and female volunteers under fasting conditions before (treatment arm 2) or after (treatment arm 1) a wash-out interval of at least 7 days between the experimental drug administration. Reference formulation will be administered as a single dose of two 500 mg/30 mg tablets.
2499971|NCT02902393||Success of revascularisation|
2500069|NCT02902198|Placebo Comparator|Placebo preoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
2500071|NCT02902198|Placebo Comparator|Placebo postoperative|Single intragastric instillation of 200ml tap water via nasogastric tube
2500072|NCT02902198|Active Comparator|Glucose preoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
2500073|NCT02902198|Active Comparator|Glucose postoperative|Single intragastric instillation of 200ml tap water with 25g glucose via nasogastric tube
2500074|NCT02902198|Active Comparator|Monosodium glutamate preoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
2500075|NCT02902198|Active Comparator|Monosodium glutamate postoperative|Single intragastric instillation of 200ml tap water with 1g monosodium glutamate via nasogastric tube
2500076|NCT02902198|Active Comparator|Quinine preoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
2500077|NCT02902198|Active Comparator|Quinine postoperative|Single intragastric instillation of 200ml tap water with 17mg quinine via nasogastric tube
2500156|NCT02901210|Experimental|Modified Delorme|Modified technique for delorme procedure done in mild to moderate rectal prolapse as the investigator destroy use the electrocautery to peal the mucosa with less intraoperative bleeding ,avoiding stripping of the mucosa done in classic delorme that induce major bleeding intraoperative .
2500261|NCT02900534|Experimental|Internet-based self-help|The self-help programme consists of 10 text-based sessions and one supportive E-Mail a week. The programme employs cognitive-behavioural interventions. The theoretical background is the Dual Process Model by Stroebe and Schutt (1999).
2500265|NCT02900534|No Intervention|Waiting control group|
2500293|NCT02900027|Experimental|IONIS-APOC-III-LRx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
2500297|NCT02900027|Placebo Comparator|Placebo (Normal Saline)|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
2500336|NCT02899793|Experimental|Pembrolizumab|Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
3162929|NCT00472264||Single arm study (Healthy volunteers & COPD subjects)|A single arm study PET imaging is carried out twice during the first week of the study and again 4 weeks later in both Healthy volunteers and COPD subjects.
2500440|NCT02898805|Experimental|LopiGLIK®|first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet
2500441|NCT02898805|Active Comparator|Armolipid Plus|first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet
2500495|NCT02898532|Active Comparator|Intervention group|The intervention is organised in collaboration between the local school, the Danish Shooting Association, and the national DGI (The Danish Gymnastics and Sporting Organization). The intervention is available geographical nationwide. The children will practise target-shooting sport in local Shooting Association once a week during school hours for a period of 6 months. Selected schools are either special schools or municipal schools with special educational programmes for children diagnosed with either ADHD or severe difficulties of hyperactivity, inattention and impulsivity. Teachers accompany the children to the Shooting Association where the instructors meet them.
2500497|NCT02898532|No Intervention|Control group|The same target group as children in the intervention group. In the control group children are not practicing target shooting sport, neither in school or free time.
2500598|NCT02897856|Active Comparator|Buccal midazolam|Study subject will receive buccal midazolam and intramuscular placebo. The dose of buccal midazolam is 0.3 mg/kg
3162930|NCT00472329|No Intervention|Fludarabine and 400cGY TBI|
3162931|NCT00472368|Experimental|LBH589|
3162932|NCT00472381|Experimental|2|Insulin
3162933|NCT00472472|Placebo Comparator|1|PTA
3162934|NCT00472472|Active Comparator|2|PTA with Paccocath
3162935|NCT00472498||1|"Case:~Patients resuscitated after 2001"
3162936|NCT00472498||2|"Control:~Patients who suffer cardiac arrests after 2001."
3162937|NCT00472589||1|Healthy women
3162938|NCT00472589||2|Women with breast cancer
3162939|NCT00472654|Placebo Comparator|WL|
3162940|NCT00472654|Experimental|WL + D|
3162941|NCT00472654|Placebo Comparator|WM|
3162942|NCT00472654|Active Comparator|WM + D|
3162943|NCT00472667|Experimental|1|Procalcitonin guided strategy
3162944|NCT00472680|Experimental|1|High Dietary Protein
3162945|NCT00472680|Active Comparator|2|Normal Dietary Protein
3162946|NCT00472693|Experimental|Bevacizumab and ABI-007 (Abraxane)|Bevacizumab and ABI-007 (Abraxane)
3162947|NCT00472706|Active Comparator|1|Excision
3162948|NCT00472706|Active Comparator|2|Photodynamic therapy
3162949|NCT00472719|Experimental|1|Participants in this group will receive an injection of the adenoviral vector vaccine VRC-HIVADV027-00VP at study entry and an injection of VRC-HIVADV038-00-VP at Month 3. There will be 9 study visits for this arm.
2499980|NCT02902315|Active Comparator|3ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2499983|NCT02902315|Active Comparator|4ª Session of resistance exercises|Exercise session are based on previous studies (TEIXEIRA et al., 2012; TEIXEIRA et al., 2014) and will be randomized according to the sequence of exercises (extensor bench, squat and leg press) and the interventions by drawing sealed brown envelopes. Forty minutes before basal blood collection and of the exercise session the volunteers will receive placebo (two pills wheat flour) and the remaining procedures will be conserved. The exercise sessions were comprised of four series of 10 maximum repetitions, with an interval of one minute between series and two minutes between exercises. Before the 10 maximum repetitions test and data collection, standard instructions will be given concerning the experimental procedure and execution technique of the exercises.
2500037|NCT02901860||Traditional workers|"Individuals who work 'traditional work hours, i.e., 9a-5p."
2500039|NCT02901860||Non-traditional workers|Individuals who have work hours outside the usual daytime period
2500108|NCT02901704|Experimental|renal denervation|Iberis Multielectrode Renal Denervation System (AngioCare)
2500113|NCT02901704|Sham Comparator|Sham procedure|Renal anigography
2500176|NCT02901236|Active Comparator|Mitomycin C|Standard Guarded Trabeculectomy will be performed. In this arm 0.02% of mitomycin C (Kyowa, Japan) will be applied on bare sclera under the conjunctiva for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
2500179|NCT02901236|Active Comparator|Bevacizumab|Standard Guarded Trabeculectomy will be performed. In this arm at the end of the case and after conjunctival closure 1.25mg of bevacizumab (Avastin; Genentech, San Francisco, CA) will be injected into the the anterior chamber through a paracentesis.
3162950|NCT00472719|Experimental|2|Participants in this group will receive an injection of VRC-HIVADV038-00-VP at study entry and an injection of VRC-HIVADV027-00-VP at Month 3. There will be 9 study visits for this group.
2500283|NCT02900248||Provider Determined Treatment|Participants with advanced solid or hematologic malignancy or myelodysplasia (MDS), will have their tumor or tissue tested by a standardized next generation sequencing (NGS) panel. They will be treated by physician determined treatment including FDA approved or compendia-listed biomarker directed therapy. All patients will be followed for time to progression by line of therapy, overall survival by line of therapy.
2500318|NCT02899910|Experimental|Yoga with health education|12 week yoga program coupled to standardized health education for weight loss
2500322|NCT02899910|Active Comparator|Health education|Standardized health education for weight loss
2500358|NCT02899507|Experimental|Prophylactic antibiotic|Amoxicillin-Clavulanic acid 1.2g every 8h
2500361|NCT02899507|No Intervention|Clinically-driven antibiotics|Administration of antibiotics in clinically-driven group was at the discretion of attending intensivist. Selection of antibiotic in clinically-driven group was empirical or based on the results of bacterial cultures if already available.
2500445|NCT02899078|Experimental|Treatment (ibrutinib, nivolumab)|Patients receive ibrutinib PO QD on days 1-28 and nivolumab intravenously IV over 60 minutes on days 1 and 15. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3195948|NCT00845208|Experimental|Network Support + Contingency Mgmnt|12 weekly sessions intended to help patients change their social networks to be more supportive of abstinence. Contingency management component added to reinforce efforts to make network changes.
3195949|NCT00845221|Experimental|Imatinib|
3195950|NCT00845234|No Intervention|Standard of Care Group|Received the current standard of care as operationally defined by the investigators- Q&A session + Video
2500807|NCT02896374|Experimental|Patients|Treated or hospitalized patients for schizophrenia.
2500809|NCT02896374|Experimental|Control|No schizophrenic participants, comparable to schizophrenia patients in age, gender, education level and socio premorbid verbal IQ.
2500890|NCT02896010|Active Comparator|Sweetch App + DBWS|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app plus weight monitoring via digital body weight scale (DBWS).
2500894|NCT02896010|Active Comparator|Sweetch App Alone|Participants receive usual care for prediabetes management. In addition, participants will be randomized to receive the Sweetch app alone.
2500933|NCT02895516|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
2500984|NCT02895243|Experimental|Prehabilitation|
2501033|NCT02894892|Active Comparator|(A)Bismuth|(A)Bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
2501036|NCT02894892|Active Comparator|(B)Bismuth|(B)Bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
2501039|NCT02894892|Active Comparator|(C)Bismuth|(C)Bismuth (120mg/tab) q.i.d. and endoscopy the next day
2501042|NCT02894892|Active Comparator|(D)Esomeprazole and Bismuth|(D)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose prior 1 hr before endoscopy
2501043|NCT02894892|Active Comparator|(E)Esomeprazole and Bismuth|(E)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) 1 dose in the morning and endoscopy in the afternoon
2501046|NCT02894892|Active Comparator|(F)Esomeprazole and Bismuth|(F)3 days esomeprazole (40mg/tab) q.i.d. followed by bismuth (120mg/tab) q.i.d. and endoscopy the next day
2501049|NCT02894892|Other|(G)Control|(G)These patients underwent endoscopy due to abdominal discomfort or other symptoms and did not have cancers in the digestive tract after series of workup.
2501157|NCT02894320||Parkinson's disease|
2501320|NCT02892812|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
3195951|NCT00845234|Experimental|Intervention Group|Intervention group- Patients will receive the brief educational CBT intervention + video and Q&A session
2500169|NCT02901067|Placebo Comparator|Control|Administration of the placebo, which is identical-looking to the Aspirin and Rosuvastatin single capsule mixture, daily either orally or via a feeding tube for the duration of the patient's stay in the ICU.
2500219|NCT02900794|Other|Contrast Arm (Microdebridement)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
2500223|NCT02900794|Other|Treatment Arm (Gold Laser)|Typical pre-operative intervention including injectable local anesthetic into the inferior and middle turbinates followed by topical anesthetic on soaked cottonoids or pledgets placed in the nasal cavity floor, medial to the middle turbinate, behind the uncinate process will be performed. Using endoscopy, the nasal passage is located. Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary. If the Investigator determines that the sinus is not sufficiently dilated or cannot be accessed, the need for and the type of additional treatment will be at the discretion of the Investigator.
2500296|NCT02900365|Experimental|Early cataract surgery group|"Eyes which presented with cataract and underwent surgery within 1 week were included in the early procedure group. They underwent early cataract surgery & IOL implantation"
2500299|NCT02900365|Experimental|Late cataract surgery group|"Eyes which presented with cataract and underwent surgery at least 1 month after trauma were included in the secondary procedure group.They underwent Late cataract surgery & IOL implantation."
2500333|NCT02899806|Placebo Comparator|Paper|Information about epidural analgesia by oral and paper sheep given by anesthesist in programed consultation
2500338|NCT02899806|Experimental|Video|Video information in addition to oral and written information gave by anesthesist in programed consultation
2500394|NCT02899351||Infants less than 12 months|intubated infants in ICU
2500682|NCT02897375|Experimental|Arm A (palbociclib, cisplatin)|Patients receive cisplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2500686|NCT02897375|Experimental|Arm B (palbociclib, carboplatin)|Patients receive carboplatin IV over 30-60 minutes on day 1 and palbociclib PO QD on days 2-22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2500784|NCT02896660|Experimental|ActiGraph Link|Study participants will wear an actigraphy device, the ActiGraph Link, continuously for 90 days
3162951|NCT00472719|Experimental|3|Participants in this group will receive an injection of the VRC-HIVDNA044-00-VP vaccine at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV027-00-VPat Month 6. There will be 13 study visits for this group.
2500931|NCT02895477|Experimental|Intervention group|Hearing aid
2500940|NCT02895477|Experimental|Test group|Hearing aid
2500963|NCT02895191|Experimental|Cohort 1|Cohort 1- Ulinastatin 4.8 million units per day
2500965|NCT02895191|Experimental|Cohort 2|Cohort 2- Ulinastatin 2.4 million units per day
2500966|NCT02895191|Experimental|Cohort 3|Cohort 3- Ulinastatin 1.2 million units per day
2500968|NCT02895191|Placebo Comparator|control group|Placebo
3162952|NCT00472719|Experimental|4|Participants in this group will receive an injection of VRC-HIVDNA044-00-VP at study entry and Months 1 and 2, followed by an injection of VRC-HIVADV038-00-VP at Month 6. There will be 13 study visits for this group.
2501235|NCT02893553|Experimental|Study 1|Study 1: is a dose escalation to determine the individualized dose of each of 3 medications (midodrine, pyridostigmine, mirabegron) that increases SBP into the normal range (111-139 mmHg). The investigator will be using midodrine hydrochloride, pyridostigmine bromide and mirabegron.
2501247|NCT02893553|Experimental|Study 2|Study2: is a randomized placebo-controlled double-blinded investigation to determine the effect of the normalization of SBP on cerebral blood flow, cognitive function (memory and attention processing) and quality of life. The investigator will be using midodrine hydrochloride, pyridostigmine bromide, mirabegron and placebo.
2501318|NCT02892812|Experimental|LBVE013|13-valent pneumococcal conjugate vaccine
2501319|NCT02892812|Experimental|LBVE014|14-valent pneumococcal conjugate vaccine
3162953|NCT00472745|Experimental|WL|weight loss (WL) with nutrition/behavior modification counseling
3162954|NCT00472745|Active Comparator|WM|Weight Maintenance (WM)
3162955|NCT00472758|Active Comparator|1|MEDI 545
3162956|NCT00472758|Placebo Comparator|2|Placebo IV
3162957|NCT00472810|Experimental|1|20 patients will be recruited according to the enrollment acceptance criteria.Randomisation is performed using a sealed envelope system, where 40 shuffled envelopes designating the surgery to either trabeculectomy with mitomycin-C (MMC) and trabeculectomy with ologen™ Collagen matrix must be open before surgery. Then, patients are allocated and trabeculectomy is performed.If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
3162958|NCT00472810|Active Comparator|2|Following ethics committee approval, 20 patients with uncontrolled glaucoma will be randomised to trabeculectomy with mitomycin -C. Randomisation is performed. Then, trabeculectomy is performed
3162959|NCT00472823|Experimental|vitamin D3 400 IU daily|vitamin D3 400 IU daily
3162960|NCT00472823|Experimental|vitamin D3 800 IU daily|vitamin D3 800 IU daily
3162961|NCT00472823|Experimental|vitamin D3 1600 IU daily|vitamin D3 1600 IU daily
3162962|NCT00472823|Experimental|vitamin D3 2400 IU daily|vitamin D3 2400 IU daily
3162963|NCT00472823|Experimental|vitamin D3 3200 IU daily|vitamin D3 3200 IU daily
3162964|NCT00472823|Experimental|vitamin D3 4000 IU daily|vitamin D3 4000 IU daily
3162965|NCT00472823|Experimental|vitamin D3 4800 IU daily|vitamin D3 4800 IU daily
3162966|NCT00472823|Placebo Comparator|placebo|matched to vitamin D tablet
3162967|NCT00472836|Experimental|Normal renal function|
3162968|NCT00472836|Experimental|Severe renal impairment|
3162969|NCT00472862|Experimental|2|Cognitive training
2500291|NCT02900430||Patients without antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
2500295|NCT02900430||Patients with antifungal prophylaxis|Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
2500330|NCT02899702|Experimental|IVIG|PRIVIGEN (CSL Behring) NORMAL HUMAN IMMUNOGLOBULINS L-PROLINE, Water for injection
2500331|NCT02899702|Placebo Comparator|control|"Single administration of Albumin 4% diluted albumin (LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
2500372|NCT02899442|No Intervention|individual prevention|"The individual preventive advice will be delivered to the control group by occupational physicians during routine medical examinations (defined by law, each 6 months), in occupational medical centres. The type and time spent to explain this advice will be collected in case report form.~To ensure each night workers included in the control group received the same advice, a booklet was provided outlining the content under 5 main headings:~Information about health risks for night workers~Dietetic intake~Leisure physical activities~Sleep and alertness~Lifestyle behaviors (Tobacco, alcohol and psychoactive drugs consumption)~That's a current practice in France for Occupational physicians."
2500373|NCT02899442|Experimental|individual and collective prevention|In addition to this individual prevention, the night workers from the experimental group will benefit from implementation of preventive actions in the workplace (collective prevention in workplace ). These collective preventive measures will be dispensed by the occupational health team (occupational physicians and technician of occupational risks prevention).
2500414|NCT02899130|Experimental|Polyherbal|Combination of 3 whole herbs in a capsule
2500415|NCT02899130|Placebo Comparator|Matching placebo|Similar looking inert capsules
2500449|NCT02898792|Experimental|targeted infusion of remifentanil untreated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2500452|NCT02898792|Experimental|targeted infusion of remifentanil CPAP treated OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2500455|NCT02898792|Experimental|targeted infusion of remifentanil No OSA|Stepped-dose, targeted infusion of remifentanil with measurement of miosis, respiratory rate, end-expired CO2, and thermal analgesia and plasma drug concentrations. Remifentanil dose will be based on ideal body weight.
2500582|NCT02897882|Experimental|Lung transplant|Pain evaluation
2500625|NCT02897518|Experimental|endotracheal intubation with Imago V-blade|Patients in this arm will receive endotracheal intubation with the Imago V-Blade videolaryngoscopes.
2500635|NCT02897518|Active Comparator|endotracheal intubation with Glidescope|Patients in this arm will receive endotracheal intubation with the glidescope videolaryngoscopes.
2500687|NCT02897258||Without anticoagulant/antiplatelet|
2500691|NCT02897258||Treated with antiplatelet only|
2500698|NCT02897258||Treated with anticoagulant only|
2500706|NCT02897258||With antiplatelet/anticoagulant|
2500739|NCT02896894|Experimental|Immediate Treatment Group|The Immediate Treatment Group will receive access to the study intervention - the Big White Wall, immediately after consenting for a total duration of 3 months.
2500741|NCT02896894|Other|Delayed Treatment Group|The Delayed Treatment Group will have no access to the study intervention - the Big White Wall for the first 3 months, then receive access to the BWW for 3 consecutive months.
2500742|NCT02896894|Experimental|Immediate Treatment Group - Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to the The Immediate Treatment Group - Extension, will receive access to the Big White Wall for an additional 3 months (months 4-6), immediately after receiving the initial 3 months of access.
2500743|NCT02896894|No Intervention|Immediate Treatment Group - No Extension|Immediate Treatment Group participants who opt in to the nested study and are randomized to The Immediate Treatment Group - No extension, will not receive extended access to the Big White Wall.
2500788|NCT02896582|Experimental|Induction - ASCT - maintenance|Induction : 4 cycles of GA-DHAP every 21 days - Conditioning regimen and ASCT: GA-BEAM + Autologous transplantation - Maintenance : Obinutuzumab every 2 months for 3 years then every month for patients with positive MRD
2500861|NCT02895984|Experimental|Brief Motivational Intervention (BMI)|The intervention recipients in the BMI group will receive a 1-hour single-session alcohol intervention (BMI) with personalized normative feedback.
2500863|NCT02895984|No Intervention|Natural History Control (NHC)|Students in the NHC group will receive no contact.
2500915|NCT02895789||spinal muscular atrophy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with laboratory documentation of homozygous deletion of SMN1 exon 7
2500919|NCT02895789||mitochondrial myopathy|ambulatory children and adults ages between 8 and 55 years old by the time of enrollment with genetic confirmation or evidence from muscle biopsy confirming the diagnosis
2500921|NCT02895789||control|The healthy control group will be age and gender-matched to the SMA and mitochondrial myopathy groups as best as possible.
3195952|NCT00845247|Placebo Comparator|Control|Control group patients will receive usual medical plus usual supportive treatment.
3195953|NCT00845247|Active Comparator|Case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
3195954|NCT00845260|Experimental|Internet CBT|Internet-based cognitive behavior therapy (CBT).
3195955|NCT00845260|Experimental|Group CBT|Group cognitive behavior therapy (CBT).
3195956|NCT00845273||Pegaptanib sodium|Patients administered Pegaptanib sodium.
3195957|NCT00845299|Experimental|1|Latanoprost punctal plug and use of artificial tears containing Benzalkonium Chloride
2500303|NCT02900131|Experimental|trial group 2|Participants will receive Jaungo twice a day for three weeks.
2500307|NCT02900131|Placebo Comparator|control group|Participants will receive placebo twice a day for three weeks.
2500353|NCT02899585|Experimental|Group A|Elaboration of the questionnaires
2500354|NCT02899585|Experimental|Group B|Patients taken care for more less than 6 days by the health care team palliatives EIVA and they eventual family caregiver. Score
2500389|NCT02899273||Dentistry students|Dentistry students of the University of Göttingen
2500393|NCT02899273||Psychology students|Psychology students of the University of Hildesheim
3195958|NCT00845299|Experimental|2|Latanoprost punctal plug only
3195959|NCT00845312||Complicated hospitalization|"Patients 60 years old or younger, who were diagnosed with community acquired pneumonia (CAP) between March 1, 2005 and December 31, 2008 were retrospectively analyzed for risk factors for severe morbidity or mortality.~was defined as at least one of the following parameters: hospitalization longer than ten days, admission to intensive care unit and in- hospital mortality. Otherwise, the hospitalization was defined uncomplicated .The Rambam hospital Institutional Review Board approved the study."
2500488|NCT02898506|Active Comparator|Liraglutide|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with Victoza®
2500489|NCT02898506|Placebo Comparator|Placebo|Subjects with multiple islet autoantibodies and dysglycemia and aged 10-30 years are treated with placebo
2500522|NCT02898246||Patients with chronic heart failure|"Fear of physical activity (exposure) will be assessed in adult outpatients with diagnosed, chronic heart failure (with reduced ejection fraction or with preserved ejection fraction).~Hospitals provide medical data to assess patients' disease severity. Additional measures assessed via questionnaire include demographic characteristics, State and Trait depression and anxiety, heart failure related symptom distress, and coping dispositions relevant for coping with physical threat.~Fear of physical activity (FActS-HF 15) is reassessed after 4 weeks to evaluate the instrument's retest reliability.~After questionnaire completion, a subsample of participants will wear the MOVE III accelerometer for one week to objectively assess everyday physical activity and fill in an activity diary."
2500544|NCT02897947||treated in Norway included in NORspine|patients having had surgery for lumbar spinal stenosis in Norway and are included in the national register NORspine
2500549|NCT02897947||treated in Sweden included in Swespine|patients having had surgery for lumbar spinal stenosis in Sweden and are included in the national register Swespine
2500551|NCT02897947||treated in Denmark included in Danespine|patients having had surgery for lumbar spinal stenosis in Denmark and are included in the national register DANEspine
2500589|NCT02897739||TTC Patients|Patients diagnosed with Tako-tsubo cardiomyopathy.
2500590|NCT02897739||Health Volunteers|Participants who have normal hearts.
2500683|NCT02897310||critically ill patients|critically ill patients with acute kidney failure requiring renal replacement therapy
2500771|NCT02896972|Active Comparator|Inverted ILM flap group|Eyes underwent vitrectomy with inverted internal limiting membrane technique
2500774|NCT02896972|Active Comparator|ILM peeling group|Eyes underwent vitrectomy with internal limiting membrane peeling
2500817|NCT02896166|Experimental|microwave ablation|The procedure is performed similar to a needle biopsy of the lung, under CT guidance. Placement of the needle-electrode is similar to needle placement for CT-guided biopsy. Appropriate positioning of the microwave ablation antenna is confirmed by CT imaging.
2500881|NCT02896023|Active Comparator|pregnant|women with positive pregnancy test after induction of ovulation and ICSI
2500884|NCT02896023|Active Comparator|Not pregnant|women with negative pregnancy test after induction of ovulation and ICSI
3195960|NCT00845325|Active Comparator|Group One|"The first group (early motion) will have a bulky dressing placed at the time of surgery. They will be instructed to remove the dressing on the first postoperative day and to place a band-aid over the incision. A set of non-weight bearing stretching exercises will be explained on the day of surgery and instructions with diagrams sent home with the patient. They will begin these exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work."
3195961|NCT00845325|Other|Behavorial Control Group Two|The second group will have wrist immobilization splints placed at the time surgery. The thumb and fingers will not have limited motion in this splint. Due to the splint placement, the patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
2501151|NCT02894346||Teachers|Public school teachers in Denmark - across age, gender, subject, class and experience.
2501176|NCT02893696|Active Comparator|Immediately Supine Position|Women placed in supine position within 30 seconds after spinal injection of local anesthetic drug.
2501177|NCT02893696|Active Comparator|Delayed Supine Position|Women placed in supine position after three minutes of seating after spinal injection of local anesthetic drug.
2501224|NCT02893215||Heart failure|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with heart failure, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
2501234|NCT02893215||Diabetes mellitus II|Screening for silent AF with Zenicor thumb-ECG: Patients older than 65 years, diagnosed with diabetes mellitus II, without any history of atrial fibrillation, ongoing OAC treatment, implanted device or recent stroke/TIA.
2501313|NCT02892825|Experimental|music group|music listening
2501316|NCT02892825|Active Comparator|no music group|no music listening
2501428|NCT02891837|Experimental|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
2501429|NCT02891837|Placebo Comparator|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
2500395|NCT02899286|Experimental|PEG-BCT-100|PEG-BCT-100 (PEGylated recombinant human arginase)
2500476|NCT02898649|Experimental|IRE|The intervention group
2500512|NCT02898350|Active Comparator|Pulsed Dye Laser treatment|Pulsed Dye Laser treatment after suture removal (3 sessions)
2500513|NCT02898350|Active Comparator|CO2 laser treatment|CO2 laser (3 treatment sessions) after suture removal
2500516|NCT02898350|Active Comparator|Combined PDL and CO2 Laser treatment|Combined PDL and CO2 Laser resurfacing (3 treatment sessions) after suture removal
2500520|NCT02898350|Active Comparator|Split PDL and CO2 Laser treatment|Half of the scar was not treated and served as a control, while the other half was treated with CO2 ablative fractional resurfacing immediately after surgery, in addition to the three combined PDL and CO2 treatment sessions after suture removal
2500567|NCT02897921||Carriers of recessive gene mutations of myopathies|"Patients with several different kinds of recessively inherited myopathy genes, such as for example Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, Limb Girdle limb girdle muscle dystrophy (LGMD) type 2A and 2L etc.~Investigated by blood sampling, Biodex 4 Isokinetic Dynamometer, MRI analysis, ECG, Holter monitoring, and echocardiography."
2500573|NCT02897921||Healthy controls|Healthy controls, investigated by blood sampling, Biodex 4 Isokinetic Dynamometer and MRI analysis.
2500643|NCT02897700|Experimental|Mono-chemotherapy|"A mono-chemotherapy (a single chemotherapeutic agent out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic cancer-associated chemotherapy.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
2500645|NCT02897700|Experimental|Combined chemotherapy|"Combined chemotherapy (random combination of two breast cancer chemotherapeutic agents including cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate, or CDEFM) was performed 30~60 days prior to surgery for patients who had no history of receiving either local or systemic chemotherapy for cancer.~Interventions: cyclophosphamide, doxorubicin, epirubicin, fluorouracil or methotrexate."
2500647|NCT02897700|Placebo Comparator|Placebo treatment|No chemotherapeutic regimes using any cytotoxic agent was done for patients who have infiltrating ductal carcinoma of breast. Placebo was used instead.
2500712|NCT02897076|Active Comparator|12mg betamethasone+12mg betamethasone|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
2500717|NCT02897076|Placebo Comparator|12 mg betamethasone+ placebo|"A betamethasone course consists in 2 intramuscular injections of 12 mg betamethasone 24 hours apart for a total dose of 24 mg.~In the BETADOSE trial, the first injection will be unmasked in both groups. In both groups, women will received a first 12 mg injection of betamethasone according to local protocols.~Randomization will be performed after the first injection. Women will then received either a blinded placebo injection (50% reduced dose regimen, 12 mg only from the first injection) or a second blinded 12 mg betamethasone injection (standard full dose regimen, 12 mg from the first injection and 12 mg from the second injection=24 mg)."
2500750|NCT02896790||Stage 1|Patients without therapeutic education
2500753|NCT02896790||Stage 2|Patients with therapeutic education
2500855|NCT02896309|Experimental|Sodium bicarbonate|Oral sodium bicarbonate tablets three times daily 1000mg
2500857|NCT02896309|Active Comparator|Sodium chloride|Oral sodium chloride capsules two times daily 1000mg
2500860|NCT02896309|No Intervention|No treatment|No treatment
2500922|NCT02895802|Other|Verbal instructions with picture diagram|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a picture diagram of handwashing.
2500927|NCT02895802|Other|Verbal instructions with video of ADSC|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and a video of the adult down syndrome center
2500938|NCT02895802|Other|verbal instructions w. video of w/o DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and viewing an educational video depicting a person without down syndrome washing their hands.
2500941|NCT02895802|Other|verbal instructions w.video w/DS|hand washing is scored prior and after educational intervention with verbal instructions of handwashing and watching an educational video depicting a person with down syndrome washing their hands.
2500974|NCT02895048||Chronic heart failure|
2500976|NCT02895048||CCM treatment|Subjects with heart failure receiving OPTIMIZER system implant
2501006|NCT02894957|Experimental|Gradual smoking cessation|"Gradual cessation Patients randomized to the gradual cessation group will receive varenicline (0,5 mg once daily for 3 days, 0,5 mg twice daily for 4 days, and 1,0 mg bid thereafter) as an aid for smoking reduction. This pre-treatment phase will last 6 weeks at the end of which all participants must stop smoking altogether. After quitting, they will continue to receive varenicline 1,0 mg bid for a further 12 weeks.~Smoking reduction: Participants will be recommended to reduce their smoking by 25% in the first two weeks, 50% in weeks 3-4, and 75% in weeks 5-6; however, this will be given only as an indication and every subject will be allowed to chose his/her own goal and rate of progress."
2501009|NCT02894957|Active Comparator|Abrupt smoking cessation|Patients in this group will be asked to smoke as usual for 6 weeks after enrolment then stop altogether. However, those feeling ready will be allowed to quit as of week 4. Thereafter, they will receive the standard 12-week varenicline treatment, starting with a 1 week titration period as described above.
2501103|NCT02894697|Active Comparator|Angiography-guidance|
2501107|NCT02894697|Experimental|OCT-guidance|
2501133|NCT02894112|Experimental|Oral glucose tolerance test|100 g of glucose in a fruit punch flavored 8 oz drink
2500347|NCT02899611|Experimental|ICV Valproate|Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
3195962|NCT00845338|Experimental|Arm 1|
3195963|NCT00845351|Experimental|Bexarotene|Bexarotene 300 mg/m2/day times 5 days
2500524|NCT02898233|Active Comparator|Deprexis and active LLLT|Participants will have access to Deprexis and will receive active low-level light therapy (4 days X 8 minutes of active LLLT)
2500525|NCT02898233|Sham Comparator|Deprexis and sham LLLT|Participants will have access to Deprexis and will receive sham low-level light therapy (4 days X 5 seconds of active LLLT and 55 seconds of sham LLLT)
2500527|NCT02898233|Other|Deprexis only|Participants will have access to Deprexis but will not receive real or sham LLLT
2500569|NCT02897895|Experimental|new strategy of immunosuppression monitoring|evaluation of calcineurin activity (CN-a) in combination with CNI blood levels
2500574|NCT02897895|Active Comparator|strategy of reference|CNI (inhibitor of Calcineurin) blood levels alone
2500584|NCT02897635|Experimental|Integrative Medicine Intervention|Study participants will attend 14 visits with an integrative medicine clinician over the course of 6 months followed by a 6 month maintenance phase. The treatment modalities employed in the study will include nutrition and lifestyle recommendations.
2500681|NCT02897167||PAFIP patients (1)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between June 2011 and February 2016.~Retrospective study of frozen samples: samples at baseline and 3 months will be analyzed."
2500685|NCT02897167||PAFIP patients (2)|"Individuals included in the First Episode Psychosis Clinical Program (PAFIP) between September 2016 and September 2017.~Prospective study of fresh samples: samples at baseline and 3 months will be analyzed."
2500689|NCT02897167||Controls|Healthy subjects without psychotic disorder.
2500749|NCT02896842|No Intervention|Control Arm|cohort 3: Imatinib through dosage ≥ 1000 ng/ml
2500755|NCT02896842|Active Comparator|Active comparator|Cohort 2 : Imatinib standard dose Imatinib through dosage < 1000 ng/ml
2500759|NCT02896842|Experimental|Experimental arm|Cohort 1 : dose adjustment based on trough plasmatic level value Imatinib through dosage < 1000 ng/ml
2500800|NCT02896426|Experimental|Collaborative Problem Solving|Participants will attend parent group sessions led by trained group leaders and learn the Collaborative Problem Solving approach.
2500803|NCT02896426|Active Comparator|Positive Solutions For Families|Participants will attend parent group sessions and learn the Positive Solutions for Families approach, a group that is usually offered by Head Start.
3195964|NCT00845364|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
3195965|NCT00845364|Placebo Comparator|Placebo|Pre-operative administration of placebo tablets according to dosing schedule
2500996|NCT02894983|Other|Arm 1|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
2500998|NCT02894983|Other|Arm 2|Conservative treatment chosen by physician on-call for dorsally displaced radius fracture.
2501063|NCT02894736|Experimental|Active tDCS|Soterix tDCS machine is used to administer active stimulation
2501086|NCT02894489|Experimental|corneal lenses|patients that wear corneal lenses ( Hiclear Rigid Gas Permeable Lenses)
2501091|NCT02894489|Experimental|large diameter lenses|patients that wear scleral lenses (Paragon Normaleyes)
2501140|NCT02894151|Active Comparator|LNG-IUS|"LNG IUS was hormonal containing IUD relased LNG at constant rate through out 5 year period.~It was inserted only first time entry in the study."
2501145|NCT02894151|Active Comparator|DMPA|DMPA was given in trimonthly intramuscular injection.
2501204|NCT02893891|Active Comparator|Laparoscopic sleeve gastrectomy|Patients undergoing bariatric surgery procedure of laparoscopic sleeve gastrectomy.
2501207|NCT02893891|Active Comparator|Laparoscopic gastric plication|Patients undergoing bariatric surgery procedure of laparoscopic gastric plication.
2501211|NCT02893891|Active Comparator|Intragastric balloon|Patients undergoing bariatric surgery procedure with intragastric balloon implantation.
2501228|NCT02893163|Experimental|CHANGE Intervention|The CHANGE intervention is a personalized approach to nutrition and exercise modification supported by a interdisciplinary team. The FD will recruit patients, complete baseline measurements and stabilize medication. The RD will create a diet plan tailored to the individual patient based on the intervention protocol. The ES will create an exercise plan tailored to the individual patient based on the intervention protocol. At the start, patients will meet weekly with the RD and ES in order to monitor progress, ascertain barriers and facilitators to change, and ensure adherence for the first 12 weeks of the intervention. Meetings will then occur monthly for the remaining 9 months of the intervention. Visits with the FD will occur every 3 months for the 12 month intervention to monitor progress, encourage behaviour change. A follow-up visit with the Research Coordinator will take place at 18 months.
2501238|NCT02893163|Active Comparator|Usual Care|The usual care arm of the study will involve regular care from the patients' FD. This may involve discussions regarding nutrition and exercise. The FD will still recruit patients, complete baseline measurements and stabilize medication. Visits to the FD will occur as usual care dictates. Participating PCNs randomized to usual care will still have interdisciplinary team members available but the referral arrangements are and will continue to be ad hoc. For the study, we will mandate that control patients have follow-up with the Research Coordinator at 3, 12 and 18 months for the purpose of assessing outcomes. At these time points, appointments will not be scheduled with the FD to manage their disease; rather, the purpose of the visit is to just conduct the outcome assessment.
2501296|NCT02893033|Experimental|Real stimulation|Real repetitive transcranial magnetic stimulation + swallowing training
2501298|NCT02893033|Sham Comparator|Sham stimulation|Sham repetitive transcranial magnetic stimulation + swallowing training
2501347|NCT02892630||Pregnant ITP women|Pregnant women more than 18 years old, with primary ITP diagnosis before pregnancy
2501349|NCT02892630||Control ITP Women (Non pregnant)|Primary ITP women more than 18 years old, at more than one year from a precedent pregnancy
2501351|NCT02892630||De novo ITP pregnant women|Pregnant women more than 18 years old, with newly diagnosed thrombocytopenia during pregnancy
2501430|NCT02892006|Experimental|Intervention|All participants in the study will participate a 6 week improv intervention.
3195966|NCT00845377|Experimental|Counseling|
2500375|NCT02899364|Placebo Comparator|Sodium chloride 0.9%|50 ml Sodium chloride 0.9%, added to 250ml sodium chloride 0.9% is administered twice. Upon arrival at the cath-lab, after confirming in- and exclusion criteria and obtaining verbal informed consent the first dose, will be administered in 20 minutes (infusion rate 15ml/min). After infusion the patient will receive primary percutaneous coronary intervention. Post-PCI the patient will be admitted to the coronary care unit where he receive the second dose, 6 hours after start of the first dose. The second dose is administered in 30 minutes (infusion rate 10 mL/min). At 4 months infarct size is assessed by LGE cardiac magnetic resonance imaging.
2500417|NCT02898909|Experimental|16 pieces fragmentation|
2500418|NCT02898909|Active Comparator|8 pieces fragmentation|
2500461|NCT02898727|Other|Local Therapy|"The local therapy offered will be determined by the participant's doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases.~Neurosurgery: The surgery may be performed up to 6 weeks before participant being registered on the trial or up to 4 weeks after registration.~Sometimes stereotactic radiosurgery is required to be delivered to the cavity left after the metastasis has been removed (Cavity Boost).~Stereotactic Radiosurgery: Treatment is to commence within 4 weeks of study registration. The size, number and location of the brain metastasis will determine the dose and fractionation schedule of radiotherapy."
2500504|NCT02898441|Active Comparator|Screening Arm|LDCT was performed at baseline + 2 biennial repeated LDCT rounds
2500509|NCT02898441|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care
2500540|NCT02897973||Transtibial lower limb amputation|unilateral amputation below knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
2500542|NCT02897973||Transfemoral lower limb amputation|unilateral amputation above knee resulting from traumatic injuries (with no upper-extremity amputations), evaluation took place at least 6 months post-injury, no assistive device use (e.g., canes, walkers, crutches), no other documented injuries, such as musculoskeletal impairments in the contralateral limb, neurologic disorder or traumatic brain injury that would affect gait and movement.
2500545|NCT02897973||Controls|Able-bodied individuals without amputation
2500593|NCT02897778|Active Comparator|Entinostat|15 patients will be randomized to receive a single, supratherapeutic dose of entinostat
2500595|NCT02897778|Placebo Comparator|Placebo|15 patients will be randomized to receive a single dose of placebo
2500679|NCT02897388|No Intervention|Pre-intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from January 2015 through March 2015 (which is the period before any intervention started)who meet the enroll criteria
2500680|NCT02897388|Experimental|intervention|all very low birth weight infants admitted to the NICU at Fudan University Children's Hospital from April 2015 through June 2016 who meet the enroll criteria. A series of breast milk consume promotion interventions would implemented during this intervention period, which including build local lactation team, set breast milk feeding room, train NICU staff etc.
2500752|NCT02896998|Other|Control group|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
2500756|NCT02896998|Experimental|Intervention|The syndesmotic screw will only be removed in case of symptomatic implants (e.g. implants causing pain or restricted range of motion)
2500867|NCT02896036|Experimental|Veress needle entry with concomitant CO2|For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
2500872|NCT02896036|Active Comparator|Veress needle entry with subsequent CO2|For the other group of participants who will be randomized to subsequent CO2 insufflation; the Veress needle will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by insertion of the Veress needle. The gas insufflation will be started and the opening pressure will be noted. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the Veress needle will be withdrawn and reinserted up to 3 times. Each time the needle is to reinserted, the CO2 insufflator will be switched off until the location of the Veress needle is felt to be adequate.
3162970|NCT00472862|Active Comparator|1|OPUS psychosocial treatment alone
3162971|NCT00472953|Experimental|A|
3162972|NCT00472953|Active Comparator|B|
2501222|NCT02893202|Experimental|Ride On Center for Kids (ROCK) facility|8-week therapeutic horseback riding
2501232|NCT02893202|Experimental|Triple H Equitherapy Facility|8-week therapeutic horseback riding
2501242|NCT02893202|Experimental|Rainer Therapeutic Riding facility|8-week therapeutic horseback riding
2501252|NCT02893202|Experimental|REACH Therapeutic Riding facility|8-week therapeutic horseback riding
2501263|NCT02893202|Experimental|Courtney Cares Riding facility|8-week therapeutic horseback riding
2501309|NCT02892890|Experimental|patients with CIDP|
3162973|NCT00472966|Other|1|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
3162974|NCT00473031|Experimental|1|High Protein
3162975|NCT00473031|Active Comparator|2|Normal Protein
3162976|NCT00473109|Experimental|Dialysis without systemic heparinization|Dialysis without systemic heparinization
3162977|NCT00473122|Other|Delayed-Immediate Breast Reconstruction|Delayed-Immediate Reconstruction: If radiation therapy (XRT) not needed, immediate reconstruction. If XRT is needed, delayed reconstruction until XRT complete.
3162978|NCT00473135|Experimental|1|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 120.
3162979|NCT00473135|Experimental|2|Two subcutaneous vaccinations with rDEN1delta30 into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on Day 180.
3173594|NCT00613717|Active Comparator|d|no iron pre- or postnatal
2500429|NCT02898922|Active Comparator|Healthy control group|Three doses of hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae (20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China) were given intramuscularly in the deltoid region to all participants at 0, 1 and 6 months respectively.
2500499|NCT02898675|Experimental|Platelet Rich Fibrine|Platelet Rich Fibrine was applied with open flap debridement in test group.
2500500|NCT02898675|Active Comparator|Open Flap Debridement|Platelet Rich Fibrin was not applied to control groups. Only open flap debridement was applied to control groups.
2500533|NCT02898064|Other|Standard care + brace|Spinal brace (thoracolumbosacral orthosis or cervico-thoraco-lumbar orthosis) to be fitted to the participant in addition to receiving standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
2500534|NCT02898064|Other|Standard care|Participant will receive standard of care treatment which can include radiotherapy, chemotherapy or surgery including vertebral augmentation and also medication including bisphosphonates
2500601|NCT02897869|Experimental|Treatment sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, POL7080; Period 2, Amikacin; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
2500607|NCT02897869|Experimental|Treatment sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, Amikacin; Period 2, POL7080; Period 3,POL7080+Amikacin. Each period is separated by a wash-out period of at least 12 days between last dose and start of next treatment.
3195967|NCT00845390||ICD Patients|ICD patients
3195968|NCT00845455||1. Harm Avoidance|Personality type
3195969|NCT00845455||2. Reward Dependence|Personality type
2500958|NCT02895438|Experimental|gluten|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
2500961|NCT02895438|Active Comparator|Placebo|One group had a introduction of gluten followed by a wash-out period, then a placebo introduction, whereas the other group had the placebo first, then the wash-out and the gluten introduction.
2501004|NCT02895022|Experimental|Lidocaine 2% adrénalinée|The main objective is to determine the ED95 dose of 2% lidocaine with epinephrine injected into the epidural catheter for which it does not arise from failure to surgical anesthesia for cesarean during labor.
2501113|NCT02894684|Experimental|AZLI then Standard Care|Upon first exacerbation this arm will receive AZLI, on their second they will receive standard care
2501116|NCT02894684|Active Comparator|Standard Care then AZLI|Upon first exacerbation this arm will receive standard care, on the second exacerbation this arm will receive AZLI
2501159|NCT02893995|Experimental|Slow Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 1.25 ng/kg/min of subcutaneous treprostinil with dose increases of approximately 1.25 ng/kg/min once every seven days for the first 4 weeks, then approximately 2.5 ng/kg/min every seven days thereafter according to clinical response and tolerability.
2501160|NCT02893995|Experimental|Rapid Dose Titration Group of Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump. While hospitalized, initiation will begin at approximately 2.0 ng/kg/min with dose increments of 1-2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate should be increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min has been achieved the dose increments can be increased up to 4 ng/kg/min with dose increments separated by at least 24 hours. The aim is to achieve a dose rate of at least 10, 20, 30 and 40 ng/kg/min by the end of Weeks 1, 4, 8 and 12, respectively.
2501213|NCT02893605||Cases|Patients have a sporadic form of Amyotrophic Lateral Sclerosis.
2501215|NCT02893605||Controls|Controls correspond to spouses/partners of patients.
2501249|NCT02893228|Experimental|Group S (saline group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected. This will be followed by repositioning of the needle between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
2501261|NCT02893228|Active Comparator|Group C (control group)|In plane posterior approach will be used with a 50mm short bevel block needle (Braun), advanced through the middle scalene muscle. The needle tip will be positioned between roots C5 and C6 where 20 ml of 0.25% levobupivicaine will be injected in 5ml increments with intermittent aspiration.
2501306|NCT02892877||Complete Hydatidiform mole and Partial Hydatidiform mole|
2501308|NCT02892877||Invasive mole|
2501310|NCT02892877||Choriocarcinoma|
2501311|NCT02892877||Post-molar neoplasia|
2501312|NCT02892877||Placental Site Trophoblastic and Epithelioid Tumor|
2501333|NCT02892578|Experimental|electrocardiogram|Patient will take an electrocardiogram in order to detect atrial fibrillation
2501370|NCT02892396||COPD patients & conventional cigarettes|COPD patients regular smokers of conventional cigarettes with no desire to quit smoking habit.
2501372|NCT02892396||COPD patients & electronic cigarettes|COPD patients who had been users of electronic cigarettes for at least 8 weeks. They will be provided with an specific type of electronic cigarette and the same dosage of inhaled nicotine.
2501396|NCT02892097|Active Comparator|Parietal tDCS plus RTP|Single session of bilateral parietal tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP).
2502356|NCT02885103|Placebo Comparator|inhalation with nebulizer|inhalation with an nebulizer via mouth
3195970|NCT00845455||3. Novelty Seeking|Personality type
3195971|NCT00845468||No treatment|
3195972|NCT00845494|Other|medication history education|Four hospital unit nurses asked to participate in the study. Two nursing units will receive the cognitive behavioral intervention.
2500434|NCT02899026|Experimental|Part A: Sirukumab 50 mg SC + prednisone (6-week taper)|Eligible subjects will receive blinded Sirukumab 50 mg SC q4w (with placebo SC injections q2w between sirukumab injections) for 52 weeks plus a 6-week oral prednisone taper regimen
2500437|NCT02899026|Placebo Comparator|Part A: Placebo SC + prednisone (52 week taper)|Eligible subjects will receive blinded placebo SC q2w for 52 weeks plus a blinded 52-week oral prednisone taper
2500492|NCT02898545|Other|SEEQ monitor|Subjects will be monitored via use of the SEEQ monitor
2500494|NCT02898545|No Intervention|Standard of care|Subjects will not wear the SEEQ monitor or may have a pre-existing implanted device capable of detecting atrial fibrillation
2500597|NCT02897674|Experimental|Normal weight|Participants will BMI 18.5-24.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
2500603|NCT02897674|Experimental|Overweight|Participants will BMI 25-29.9 kg/m2 will consume 20% of their calories from one of the three dietary fats Intervention: palm olei Intervention: interesterified palm olein Intervention: soybean oil
2500765|NCT02897011|Sham Comparator|Group 1: MTX continue|Group will continue MTX after vaccination
2500769|NCT02897011|Experimental|Group 2: MTX hold|will hold MTX for 2 weeks after vaccination
2500801|NCT02896452||Women diagnosed with PCOS without IIH|Women diagnosed with polycystic ovary syndrome without idiopathic intracranial hypertension
2500805|NCT02896452||Women diagnosed with PCOS and IIH|Women diagnosed with polycystic ovary syndrome and idiopathic intracranial hypertension
2500806|NCT02896452||Women diagnosed with IIH without PCOS|Women diagnosed with idiopathic intracranial hypertension without polycystic ovary syndrome
2500811|NCT02896452||Women without PCOS or IIH|Women age and body mass index match controls without polycystic ovary syndrome or intracranial hypertension
2500818|NCT02896153||Adult population going to a pharmacy|Adult population going to a pharmacy will be asked to complete a questionnaire.
2500870|NCT02896062|Experimental|Treatment group|In the treatment phase subjects receive a sleep-coaching
2500875|NCT02896062|Active Comparator|Waiting group control|The waiting group receives the treatment after a waiting period of up to 6 weeks
2500951|NCT02895698|Active Comparator|Treatment group|Dry cupping + active dorsiflexion exercise + stretching exercise
2500952|NCT02895698|Other|Control group|stretching exercise + active dorsiflexion without cupping
3162980|NCT00473135|Placebo Comparator|3|Two subcutaneous vaccinations with placebo into the deltoid region or either arm. One vaccination is given on Day 0 and one vaccination is given on either Day 120 or 180, depending on arm assignment.
3162981|NCT00473148|Experimental|1|BNP-guided treatment (Furosemide)
3162982|NCT00473148|No Intervention|2|
2501132|NCT02894359||CD patients|10 patients with a cervical dystonia
2501136|NCT02894359||control subjects|10 healthy patients
2501180|NCT02893904|Experimental|Propofol|General anesthesia by TCI Propofol and Remifentanil guided by BIS EEG monitoring intervention
2501185|NCT02893904|Experimental|Sevoflurane|General anesthesia by Sevoflurane and Remifentanil guided by BIS EEG monitoring intervention
2501223|NCT02893332|Active Comparator|TKI without SBRT|"Newly diagnosed Patients will be placed on EGFR-TKI, ,Gefitinib 250mg po qd or Tarceva 150mg po qd for their metastatic EGFR-mutant stage IV oligometastatic disease.~The oligometastatic disease will not receive SBRT"
2501231|NCT02893332|Experimental|TKI with SBRT|"experimental: Oligometastatic Non-Small Cell Lung Cancer Newly diagnosed patients will be placed on EGFR-TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, for their metastatic EGFR-mutant stage IV oligometastatic disease. All patients will TKI, Gefitinib 250mg po qd or Tarceva 150mg po qd, and SBRT at the same time.~SBRT to up to 5 sites. The SBRT dose range from 5 Gy per fraction to 8 Gy per fraction. SBRT deliver within 5 fractions."
2501300|NCT02892942|Active Comparator|Control Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®."
2501303|NCT02892942|Experimental|NATOS Group|"Background therapy which is the usual COH treatment:~Recombinant FSH (Gonal-F®, 225 to 450 IU/d; MerckSerono Pharmaceuticals) from day 2 of their menstrual cycle onward,~GnRH antagonist (Cetrotide®, MerckSerono Pharmaceuticals) 0.25 mg/day, S.C., starting on day 6 of Gonal-F®.~GnRH antagonist treatment (Cetrotide®, MerckSerono Pharmaceuticals) will be reinforced and patients will receive 1.5 mg/day (6 ampoules of 0.25 mg), S.C., starting on day 1 (S1) of Gonal-F® treatment until dhCG"
2501403|NCT02892279|Experimental|Diesel exhaust exposure|A single arm study in which first a baseline muscle sympathetic nerve activity (MSNA) is recorded with and without an exposure mask. When measurements have been secured exposure to dilute diesel exhaust will start.
2501466|NCT02891421|Other|Therapeutic Horseback Riding|Therapeutic Horseback Riding: Veterans were matched to a horse by the instructor and occupational therapist for best fit and the same horse was ridden each week
2501467|NCT02891421|Other|Standard Care|Participants received standard care.
2501513|NCT02891330|Experimental|Dietary and nutritional recommendations|Postoperative personalized approach based on dietary and nutritional recommendations conducted by a nurse
2501514|NCT02891330|No Intervention|Standard of care|Postoperative standard of care
2501556|NCT02890979|Experimental|Screening (cytology collection)|Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.
2501656|NCT02890589|Experimental|SYNERGY Stent|The SYNERGY™ stent is a Device marked CE (European Conformity), platinum chromium coronary stent, currently developped by Boston Scientific™. This stent has been designed with the goal of providing optimal and rapid healing within the vessel using a bioabsorbable polymer to elute everolimus.
2501658|NCT02890589|Experimental|BVS device|The ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold (BVS 1.1, Abbott Vascular, California, USA, CE approved) is Device marked CE, currently the most studied PLA (Polylactic acid) based scaffold. It consists of PLLA (Poly I-lactic acid) backbone with 1:1 PDLLA (Poly-DL Lactic Acid) drug surface coating and a total strut thickness of 156 μm.
2500479|NCT02898753|Experimental|VAL-1221 3 mg/kg|"Part 1: Participants will receive VAL-1221 3 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 3 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 3 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 10 mg/kg and further to 30 mg/kg (after at least 12 weeks of dosing at 10 mg/kg), depending upon the pharmacodynamics, efficacy, and safety data."
2500480|NCT02898753|Experimental|VAL-1221 10 mg/kg|"Part 1: Participants will receive VAL-1221 10 mg/kg IV infusion every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 10 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 10 mg/kg IV infusion every other week. The dose can be increased by the Investigator to 30 mg/kg IV infusion, depending upon the pharmacodynamics, efficacy, and safety data."
2500481|NCT02898753|Experimental|VAL-1221 30 mg/kg|"Part 1: Participants will receive VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive, for a total of 7 infusions.~Part 2: Participants from Part 1 of the study who were randomized to VAL-1221 30 mg/kg can enter Part 2 of the study and receive VAL-1221 at a dose of 30 mg/kg IV inufsion every other week."
2500482|NCT02898753|Active Comparator|rhGAA|"Part 1: Participants will be maintained on their current dose and regimen of Myozyme or Lumizyme.~Part 2: Participants from Part 1 of the study who were randomized to rhGAA can enter Part 2 of the study and receive VAL-1221 either 3 mg/kg, 10 mg/kg, or 30 mg/kg (based on the dose of VAL-1221 in respective cohorts to which they were randomized in Part 1) IV infusion every other week."
2500507|NCT02898298|Experimental|Immediate|Immediate group receives the Positive Emotion Regulation training immediately.
2500508|NCT02898298|Active Comparator|Waitlist control group|Waitlist control group receives the Positive Emotion Regulation training 4 weeks later.
2500629|NCT02897765|Experimental|Drug: NEO-PV-01 + Nivolumab + Adjuvant|Nivolumab at a dose of 240 mg administered by intravenous (IV) infusion over 30 minutes every two weeks. At Week 12, all patients, regardless of their disease status, will receive NEO-PV-01 + adjuvant administered subcutaneously (one vial of pooled peptides per injection site) in up to four distinct sites (each extremity or flanks) while continuing therapy with nivolumab.
2500815|NCT02896322|Experimental|Cyberknife|APBI with cyberknife after breast conserving surgery in breast cancer
2500878|NCT02896049||Hyperthermia|treatment with the Celsius42 Hyperthermia System
2500956|NCT02895724|Experimental|HBOT receivers|Participants in a post breast cancer surgery randomized controlled trial detected with lymphedema 1 year postoperatively are invited to 40 consequtive treatments of hyperbaric oxygen therapy to reduce lymphedema. The experimental drug is 100% medical oxygen given in a pressure chamber of 2,4 bar,every treatment lasting approximately 100 minutes.
2500959|NCT02895724|No Intervention|blodsample comparison|Matched Lymphedema free participants from LYCA Exercise recruited to donate blood samples for comparison on important blod biomarkers and collagen levels.
3162983|NCT00473174|Active Comparator|1|Ramipril on awakening
3162984|NCT00473174|Active Comparator|2|Ramipril at bedtime
2501111|NCT02894710|Experimental|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
2501114|NCT02894710|Placebo Comparator|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
2501187|NCT02893943|Active Comparator|Probiotics|1 capsule per day containing probiotics
2501195|NCT02893943|Placebo Comparator|Placebo|1 capsule per day without probiotics
2501397|NCT02892227|Experimental|JET ECHO|Transmitral flow estimation
2501398|NCT02892227|No Intervention|NO JET ECHO|no bedside echocardiography
2501501|NCT02891356||Anorexia patient|Dual Energy X-ray Absorptiometry (DEXA)
2501533|NCT02891148|Experimental|BI 690517|
2501558|NCT02890927|Experimental|Cardio-geriatric co-management|A geriatric co-management intervention will be implemented on the cardiology units of the University Hospitals Leuven. Geriatric co-management is defined as a shared responsibility and decision making between the cardiology team and the geriatric team who provides complementary medical care in the prevention and management of geriatric problems. Patients included in the co-management program will undergo a comprehensive geriatric assessment within 24 hours of hospital admission.
2501561|NCT02890927|No Intervention|Standard of care|The control group will receive the standard of care on the cardiology units. This includes multidisciplinary care with a one weekly multidisciplinary team meeting. Team members include a cardiology resident (supervised by a cardiologist), ward nurses, a physical therapist, a social worker and a dietician. A geriatric consultation team is available for consultation services if requested by the cardiology team.
2501609|NCT02890745|Experimental|Empagliflozin|One tablet 25 mg empagliflozin every morning for 14 days
2501611|NCT02890745|Placebo Comparator|Placebo|One tablet placebo every morning for 14 days
2501684|NCT02890394|Experimental|2 minutes Group|The group was perform the technique inhibition suboccipital two minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
3162985|NCT00473200|Active Comparator|S-adenosylmethionine|S-adenosylmethionine
3162986|NCT00473200|Placebo Comparator|Placebo|Placebo
3162987|NCT00473239|Experimental|cholecalciferol|A single dose of 100,000 IU vitamin D
3162988|NCT00473239|No Intervention|Control|No drug was given
3162989|NCT00473252||Hemodialysis patients|
3162990|NCT00473252||Renal transplant patients|
3162991|NCT00473291||Patients with pleural effusion|Patients diagnosed with pleural effusion and presenting for treatment
3162992|NCT00473317|Experimental|1|All subjects in this study will be in the active arm
3162993|NCT00473356|Active Comparator|1|to receive amino acid supplement
3162994|NCT00473356|No Intervention|2|no amino acid supplement
3162995|NCT00473460|Experimental|Arm 1|
3162996|NCT00473460|Placebo Comparator|Arm 2|
3162997|NCT00473473|Experimental|1|potassium bichromate
3162998|NCT00473473|Placebo Comparator|2|placebo
2500501|NCT02898467||non-diabetics|patients without diagnosed diabetes exhibiting fasting glycemia value under 7 mmol/L
2500541|NCT02897999|Experimental|SAD Cohort 1|Single dose of 0.05 mL QBKPN or Placebo
2500543|NCT02897999|Experimental|SAD Cohort 2|Single dose of 0.10 mL QBKPN or Placebo
2500547|NCT02897999|Experimental|SAD Cohort 3|Single dose of 0.20 mL QBKPN or Placebo
2500550|NCT02897999|Experimental|SAD Cohort 4|Single dose of 0.40 mL QBKPN or Placebo
2500553|NCT02897999|Experimental|SAD Cohort 5|Single dose of 0.80 mL QBKPN or Placebo
2500555|NCT02897999|Experimental|SAD Cohort 6|Single dose of 1.2 mL QBKPN or Placebo
2500557|NCT02897999|Experimental|MAD Cohort 1|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
2500560|NCT02897999|Experimental|MAD Cohort 2|5 doses of QBKPN or Placebo administered every other day (using one of the dose from the SAD Cohort)
2500561|NCT02897999|Experimental|MAD Cohort 3|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
2500563|NCT02897999|Experimental|MAD Cohort 4|5 doses of QBKPN or Placebo administered every day (using one of the dose from the SAD Cohort)
2500640|NCT02897583|Experimental|YAG vitreolysis|A Karickoff lens with goniosol will be used to perform the YAG vitreolysis. The number of shots will be determined at the discretion of the treating physician. A focus offset may be used at investigator discretion. Single shot mode will be used. The maximum energy per pulse will be 7 mJ. The endpoint of treatment is the vaporization of the Weiss ring into gas, as well as the disruption of it into smaller fragments as well as any other vitreous opacities deemed visually significant by the treating physician. Only one treatment session will be performed.
2500644|NCT02897583|Sham Comparator|Sham YAG vitreolysis|Sham laser treatment will be applied under the same procedure used for laser treatment but by turning the laser power down to 0.3 mJ and using a separate lens covered by a filter that absorbs the power, so no laser enters the eye.
2500674|NCT02897232||Community Group Survey|Community members coming into the University Health Shreveport Ambulatory Care Facility.
2500677|NCT02897232||Physician Group Survey|Physicians affiliated with LSU Health Shreveport School of Medicine
2500735|NCT02896959|Experimental|25mmHg pressure|Pump pressure of 25mmHg during rotator cuff repair
2500736|NCT02896959|Experimental|45mmHg pressure|Pump pressure of 45mmHg during rotator cuff repair
2500737|NCT02896959|Experimental|65mmHg pressure|Pump pressure of 65mmHg during rotator cuff repair
2500819|NCT02896270|Experimental|single arm|"Patients will start study treatment on Day1 and will be treated with a dose of 250mg twice daily of the valproic acid slow release formulation (Depakine Chrono© - Sanofi Pharma Belgium).~Control of valproic acid serum levels after 4 to 7 days. The dose will be progressively increased targeting valproic acid serum levels in the target range for use of the drug as an anti-epileptic (50-100µg/ml).~During the study, visits will be performed every month and at the end of treatment. The duration of the study is 12 months. Continuation of valproic acid after completion of the study will be at the investigators discretion."
2500871|NCT02895997|Experimental|Clinical Operations Room Staff|Clinicians and critical care nurse volunteers from the clinical operations room (COR) staff at Emory University Hospital will travel to Sydney Australia to deliver telemedicine.
2500948|NCT02895737|Other|balloon-expandable TAVI without cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement without cerebral protection
2500950|NCT02895737|Other|balloon-expandable TAVI with cerebral protection|Patient receives a balloon-expandable transcatheter aortic valve replacement with cerebral protection
2500953|NCT02895737|Other|self-expandable TAVI without cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement without cerebral protection
2500954|NCT02895737|Other|self-expandable TAVI with cerebral protection|Patient receives a self-expandable transcatheter aortic valve replacement with cerebral protection
2500977|NCT02895009|Other|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. In control group, TR Band deflation is commenced at the 2nd hour with successive 5 mL air released at 2 hours intervals until the bladder was empty at the 6th hour, and the TR Band is removed at the 24th hour.
2500978|NCT02895009|Experimental|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. In experimental group, TR Band deflation is commenced at the 1st hour with 3 mL air released, and at the 2nd hour with 5ml, and at the 3rd hour with the remainder air in the bladder, and the TR Band is removed at the 12th hour.
2501048|NCT02894905|Experimental|AL-335 (Cohort 1)|Participants with mild impaired renal function will receive a single oral dose of AL-335 800 milligram (mg) (given as 2*400-mg tablets).
2501052|NCT02894905|Experimental|AL-335 (Cohort 2)|Participants with moderate impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2501056|NCT02894905|Experimental|AL-335 (Cohort 3)|Participants with severe impaired renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2501059|NCT02894905|Experimental|AL-335 (Cohort 4)|Participants with normal renal function will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
2501092|NCT02894554|Placebo Comparator|lamivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy.
2501097|NCT02894554|Active Comparator|telbivudine|HBsAg (+) patients received renal transplant and under lamivudine therapy and then switch to telbivudine 6 months later.
2501143|NCT02894229|No Intervention|No intervention wait-list|This arm will receive no intervention for approximately the first 4 months. At the conclusion of the 4-month period, this group will receive a 6-week cognitive-behavioral therapy (CBT) group
2501147|NCT02894229|Active Comparator|Mindfulness Based Stress Reduction(MBSR)|This arm will receive 6 weekly, 2-hour groups that focuses on mindfulness meditation for stress reduction
2501148|NCT02894229|Active Comparator|Cognitive Behavioral Therapy (CBT) Group|This are will receive 6 weekly, 2-hour groups that focus on cognitive-behavioral skills for stress
2501182|NCT02893852|Active Comparator|standard CO-OP Approach|Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents.
2501332|NCT02892552|Experimental|Cone Beam|Patients included will have first a MultiSlice Computed tomography (MSCT) as usual and then a Cone Beam Computed Tomography (CBCT)
2500521|NCT02898285|Experimental|Individual sport condition|People randomized to this group will select an individual sport. They will be asked to participate in this individual sport for three months.
2500523|NCT02898285|Experimental|Team sport condition|People randomized to this group will select a team sport. They will be asked to participate in the team sport for three months (length of the team sport season).
2500592|NCT02897804|Experimental|Knowledge alone|Participants will have access to the knowledge module for a period up to 3 weeks.
2500594|NCT02897804|Experimental|Self-efficacy alone|Participants will have access to the knowledge module plus the self-efficacy module for a period up to 3 weeks.
2500596|NCT02897804|Experimental|Perceived benefits alone|Participants will have access to the knowledge module plus the perceived benefits module for a period up to 3 weeks.
2500604|NCT02897804|Experimental|Benefits and self-efficacy|Participants will have access to the knowledge module plus the perceived benefits and self-efficacy modules for a period up to 3 weeks.
2500611|NCT02897804|Experimental|Injunctive norms alone|Participants will have access to the knowledge module plus the injunctive norms module for a period up to 3 weeks.
2500612|NCT02897804|Experimental|Injunctive norms and self-efficacy|Participants will have access to the knowledge module plus the injunctive norms and self-efficacy modules for a period up to 3 weeks.
2500613|NCT02897804|Experimental|Injunctive norms and perceived benefits|Participants will have access to the knowledge module plus the injunctive norms and perceived benefits modules for a period up to 3 weeks.
2500614|NCT02897804|Experimental|Injunctive norms, perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500615|NCT02897804|Experimental|Descriptive norms alone|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
2500617|NCT02897804|Experimental|Descriptive norms and self-efficacy|Participants will have access to the knowledge module plus the descriptive norms and self-efficacy modules for a period up to 3 weeks.
2500618|NCT02897804|Experimental|Descriptive norms and perceived benefits|Participants will have access to the knowledge module plus the descriptive norms and perceived benefits modules for a period up to 3 weeks.
2500619|NCT02897804|Experimental|Descriptive norms,perceived benefits,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms module for a period up to 3 weeks.
2500620|NCT02897804|Experimental|Descriptive norms and injunctive norms|Participants will have access to the knowledge module plus the descriptive norms and injunctive norms modules for a period up to 3 weeks.
2500621|NCT02897804|Experimental|Descriptive norms, injunctive norms,self-efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2500624|NCT02897804|Experimental|Descriptive and injunctive norms, benefits|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2500632|NCT02897804|Experimental|Descriptive and injunctive norms, benefits,efficacy|Participants will have access to the knowledge module plus the descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500637|NCT02897804|Experimental|Expectancies alone|Participants will have access to the knowledge module plus the expectancies module for a period up to 3 weeks.
2500639|NCT02897804|Experimental|Expectancies and self-efficacy|Participants will have access to the knowledge module plus the expectancies and self-efficacy modules for a period up to 3 weeks.
2500642|NCT02897804|Experimental|Expectancies and perceived benefits|Participants will have access to the knowledge module plus the expectancies and perceived benefits modules for a period up to 3 weeks.
2500646|NCT02897804|Experimental|Expectancies, perceived benefits, self-efficacy|Participants will have access to the knowledge module plus the expectancies, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500648|NCT02897804|Experimental|Expectancies and injunctive norms|Participants will have access to the knowledge module plus the expectancies and injunctive norms modules for a period up to 3 weeks.
2500649|NCT02897804|Experimental|Expectancies, injunctive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2500650|NCT02897804|Experimental|Expectancies, injunctive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2500652|NCT02897804|Experimental|Expectancies, injunctive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500654|NCT02897804|Experimental|Expectancies and descriptive norms|Participants will have access to the knowledge module plus the expectancies and descriptive norms modules for a period up to 3 weeks.
2500655|NCT02897804|Experimental|Expectancies, descriptive norms, and self-efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and self-efficacy modules for a period up to 3 weeks.
2500656|NCT02897804|Experimental|Expectancies, descriptive norms, and benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and perceived benefits modules for a period up to 3 weeks.
2500658|NCT02897804|Experimental|Expectancies,descriptive norms, benefits, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500660|NCT02897804|Experimental|Expectancies, descriptive and injunctive norms|Participants will have access to the knowledge module plus the expectancies, descriptive norms, and injunctive norms modules for a period up to 3 weeks.
2500661|NCT02897804|Experimental|Expectancies, descr& injun norms, efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and self-efficacy modules for a period up to 3 weeks.
2500662|NCT02897804|Experimental|Expectancies, desc & injun norms, benefits|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, and perceived benefits modules for a period up to 3 weeks.
2500702|NCT02897284|Experimental|Mindfulness 8 weeks|Mindfulness-based intervention with 8 weekly sessions
2500552|NCT02898142|Experimental|Isolated HTG without metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
2500556|NCT02898142|Experimental|HTG with metabolic syndrome|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting.
2500585|NCT02897713|Experimental|intensive EN|Intensive enteral nutrition is to performed until discharge with max during of 7 days
2500587|NCT02897713|Active Comparator|routine EN|Routine enteral nutrition is to performed until discharge with max during of 7 days
3162999|NCT00473486|Active Comparator|1|Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC
2500700|NCT02897063|Experimental|Droxidopa and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
2500707|NCT02897063|Experimental|Midodrine and Placebo|Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
2500751|NCT02896751|Experimental|3D Printed NIV Mask|3D imaging and use of a custom mask from 3D printer
2500885|NCT02895919||Control group - blood culture bottles|Standard of care group for control - will inoculate all samples in blood culture bottles for ascitic fluid culture
2500886|NCT02895919||Study group - sample to lab for culture|Study group - will send a sample of ascitic fluid to lab for inoculation in addition to control sample
2500923|NCT02895646||Beta-lactam antibiotic allergy|Diagnosis based on clinical symptomatology and skin test positive for allergen and negative for other drugs and substances. Skin tests are performed 6 weeks after allergic reaction.
2500926|NCT02895646||Control|No specific clinical investigation for control subjects
2501061|NCT02894827||EMS|
2501062|NCT02894827||Control|
2501139|NCT02894177|Experimental|tcPCO2 measurement arm|Patients will be monitored by tcPCO2 during spontaneous breathing trials
3163000|NCT00473486|Placebo Comparator|2|Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC
3163001|NCT00473499|Experimental|DEBlue stent|Paclitaxel coated balloon with CoCr stent mounted on it
3163002|NCT00473499|Active Comparator|Cypher stent|
3163003|NCT00473499|Placebo Comparator|Coroflex Blue stent|
3163004|NCT00473525|Placebo Comparator|Placebo|
2501315|NCT02892864|Active Comparator|Control arm|Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
2501317|NCT02892864|Experimental|Experimental Virtual Arm|Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
2501366|NCT02892487|Experimental|Early active swallowing therapy|
2501368|NCT02892487|No Intervention|Usual care|
2501484|NCT02891486||Incidence of surgical site infection|The number of spinal surgery patients with surgical site infections.
2501548|NCT02891239|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
2501616|NCT02890823|Experimental|EIAEDs-1000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
2503347|NCT02878070|Experimental|Peer Health Coaching|Calls from a Peer Health Coach for 6 months
3163005|NCT00473525|Experimental|PF-00734200 10 mg QD|
3163006|NCT00473525|Experimental|PF-00734200 20 mg QD|
3163007|NCT00473525|Experimental|PF-00734200 5 mg QD|
3163008|NCT00473525|Experimental|PF-00734200 2 mg QD|
3163009|NCT00473551|Experimental|Anti-Third Party T Lymphocytes + Nonmyeloablative SCT|"Anti-Third Party CTL (Cytolytic T-lymphocytes) with Nonmyeloablative SCT (Stem Cell Transplantation)~Rituximab 375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8; + Cyclophosphamide 50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine; + Fludarabine 40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6; + Radiation 2Gy Total body radiation day before transplantation + Stem Cell Transplantation + Intravenous infusion of Anti-third Party CTLs."
3163010|NCT00473603|Experimental|LHI|to perform an i.v. lipid heparin infusion for 4 h
3163011|NCT00473603|Sham Comparator|SHI|to perform an i.v. saline heparin infusion for 4 h
3163012|NCT00473616|Experimental|1|AZD7762 monotherapy followed by AZD7762 + irinotecan
3163013|NCT00473707|Active Comparator|1|Active management of the third stage of labor- oxytocin infusion after delivery of fetus, gentle cord traction, and fundal massage
3163014|NCT00473707|Other|2|Expectant management of the third stage of labor
3163015|NCT00473720|Experimental|satraplatin abraxane|Satraplatin and abraxane will be given in escalating cohorts on a 3 + 3 design from satraplatin 40mg/m2 and abraxane 80mg/m2
3163016|NCT00473772|Active Comparator|Cypher Stent|
3163017|NCT00473772|Experimental|DEBlue Stent|
3163018|NCT00473798||A|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3163019|NCT00473798||A'|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3163020|NCT00473798||B|Patients who have consented to participate in a randomized trial of optical spectroscopy.
3163021|NCT00473798||C|Women who are eligible to participate in a study of the technical feasibility of optical spectroscopy will be invited to participate in this study.
3163022|NCT00473798||D|Health care providers.
3195973|NCT00845546|Experimental|1|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets of Ranbaxy
3195974|NCT00845546|Active Comparator|2|(Claritin_D® 24 hour) 10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets
2500703|NCT02897089|No Intervention|acid-etch|Acid etch+fissure sealant
2500711|NCT02897089|Other|All Bond universal adhesive|Acid etch+ All Bond universal adhesive agent+fissure sealant
2500716|NCT02897089|Other|All Bond universal|All Bond universal adhesive agent+fissure sealant
2500718|NCT02897089|Other|Scotchbond universal adhesive|Acid etch+ Scotchbond universal adhesive agent+fissure sealant
2500721|NCT02897089|Other|Scotchbond universal|Scotchbond universal adhesive agent+fissure sealant
2500722|NCT02897089|Other|Clearfil universal adhesive|Acid etch+ Clearfil universal adhesive agent+fissure sealant
2500723|NCT02897089|Other|Clearfil universal|Clearfil universal adhesive agent+fissure sealant
2500725|NCT02897089|Other|Total-etch Dental Adhesive|Acid etch+ Single Bond adhesive agent+fissure sealant
2500738|NCT02896725|Experimental|Keratin dressings|Wool-derived keratin matrix dressing applied with each change of the compression bandage until healing
2500740|NCT02896725|Active Comparator|Usual care dressings|Dressing chosen from study centres' formulary of non-medicated moist wound dressings applied with each change of the compression bandage until healing
2500785|NCT02896621|Experimental|Chlorthalidone plus amiloride|"Chlorthalidone plus amiloride group received 25 mg of chlortalidone and amiloride, 5 mg.~A capsule with both drugs was taken once daily in the morning for eight weeks."
2500786|NCT02896621|Active Comparator|Amlodipine|Amlodipine group received 10 mg. A capsule was taken once daily in the morning for eight weeks. Capsules of amlodipine had identical presentation of that the intervention drug.
2500889|NCT02896218||Pharmacist consulting group|When physicians make the decision that patients need to prescribe vancomycin or need dose adjustment, they will call for a pharmacist consultation. Pharmacists will provide the initial regimen based on PPK methods if applicable, otherwise give the suggestion of the initial dosage according to guidelines. Also, pharmacists will give suggestions on the time of sampling for serum concentration measurement. For dosage adjustment, pharmacists will be informed the results of serum vancomycin concentration, and then make a calculation using Bayesian estimation to determine whether there is a necessity to change the dosing regimen. Pharmacists will follow the patients until they discharge.
2500895|NCT02896218||Usual care group|Empirical use of vancomycin without pharmacists consultation.
3195975|NCT00845559|Experimental|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide.
3195976|NCT00845559|No Intervention|No Treatment|
3195977|NCT00845572|Experimental|Consta Club|
2501248|NCT02893540|Experimental|Metronomic|accept capecitabine metronomic chemotherapy (500mg, twice per day, everyday)
2501259|NCT02893540|Active Comparator|Conventional|accept capecitabine conventional chemotherapy (1000mg/m2, twice per day for 14 days, every 21 days)
2501295|NCT02892903|No Intervention|Conventional angiography|Routine angiography will be performed according to local best practice
2501299|NCT02892903|Experimental|Routine Measurement of FFR|Additional investigation with the measurement of FFR in all major vessels
3195978|NCT00845585|Active Comparator|Owniflow II|
3195979|NCT00845585|Active Comparator|PTFE|
3195980|NCT00845598|Experimental|Azelastine Fluticasone|
2501635|NCT02890524|Experimental|Night guard|the night guard made of EVA
2501639|NCT02890524|Placebo Comparator|Placebo night guard|Placebo night guard made of EVA
2501679|NCT02890160|Experimental|Firesorb|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
2501685|NCT02890160|Active Comparator|XIENCE|Implantation of the XIENCE Everolimus Eluting Coronary Stent System
3195981|NCT00845598|Active Comparator|Fluticasone propionate|
2501835|NCT02889302|Experimental|KPS-0373|
2501836|NCT02889302|Placebo Comparator|Placebo|
2501881|NCT02888951||Diabetic Group|A group of diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
2501885|NCT02888951||Non-Diabetic Group|A group of non-diabetic patients who have fasted for at least 8 hours undergoing an elective surgical procedure.
2501931|NCT02888574|Experimental|Intranasal Oxytocin|Oxytocin nasal spray delivered bi-daily over a 14-day period at 24-IU per dose
2501932|NCT02888574|Placebo Comparator|Placebo|Placebo nasal spray containing the same ingredients as the active nasal spray minus the oxytocin and packaged in an identical bottle. To be delivered bi-daily over a 14-day period at 24-IU per dose
3195982|NCT00845624||1|Preterm infants <1500 grams or 32 weeks gestation.
3195983|NCT00845637|Active Comparator|Eggplant extract|
3195984|NCT00845637|Placebo Comparator|Placebo|
3195985|NCT00845689|Placebo Comparator|1|liver resection with Pringle + placebo
3195986|NCT00845689|Active Comparator|2|liver resection with Pringle + adenosine preconditiong
3195987|NCT00845689|Active Comparator|3|liver resection with Pringle + adenosine pre- and postconditioning
3195988|NCT00845715|Other|Early motion|
3195989|NCT00845715|Other|Standard motion|
3195990|NCT00845754|Placebo Comparator|1|Placebo
3195991|NCT00845754|Active Comparator|2|Ketorolac
3195992|NCT00845767|Experimental|Diesel Exposure|1 hour exposure to dilute diesel exhaust at a concentration of 300 µg/m3 with intermittent exercise
3195993|NCT00845767|Experimental|Air Exposure|1 hour exposure to filtered air during intermittent exercise
3195994|NCT00845780|Experimental|withdrawal amiodarone|withdrawal amiodarone afer at least 6 months of sinus rhythm maintenance on amiodarone therapy
3195995|NCT00845780|Active Comparator|continuation amiodarone|continuation of amiodarone after 6 months of sinus rhythm maintenance on amiodarone therapy
3195996|NCT00845806||Arabic Speakers|All subjects must be male native arabic speakers who can read and speak english.
2500566|NCT02898025|Active Comparator|G1 (Active IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G1) will receive the treatment of Active Interferential Current and Active Laser for 12 sessions.
2500571|NCT02898025|Active Comparator|G2 (Active IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G2) will receive the treatment of Active Interferential Current and Placebo Laser for 12 sessions.
2500576|NCT02898025|Active Comparator|G3 (Placebo IFC and Active Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. This group (G3) will receive Placebo Interferential Current and Active Laser for 12 sessions.
2500578|NCT02898025|Placebo Comparator|G4 (Placebo IFC and Placebo Laser)|42 patients with knee (s) osteoarthritis. All patients will receive guidance on the disease and on joint protection and energy conservation over a period of 50 minutes in a single session. The placebo group (G4) will receive Placebo Interferential Current and Placebo Laser for 12 sessions.
2500628|NCT02897570|Active Comparator|Glucose|EEG_pre + Oral glucose tolerance test (50-g OGTT) + EEG_post
2500634|NCT02897570|Experimental|Milk + Cereals|EEG_pre + B1: milk (125ml) and cereals (30g) + EEG_post
2500638|NCT02897570|Experimental|Milk + Apple + Snack|EEG_pre + B2: milk (220ml), apple (200g) and cream chocolate filled sponge cake (30g) + EEG_post
2500641|NCT02897570|Experimental|Milk + Apple + Bread w/ cream|EEG_pre + B3: milk (125ml), apple (150g), and bread (50g) with hazelnut chocolate cream (15g) + EEG_post
2500669|NCT02897102|Active Comparator|Control group|The individuals in the control group chose to participate in different group activities: ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants). The activities were offered once per week in 2 hours classes for 35 weeks and were held between April and November of 2013.
2500670|NCT02897102|Experimental|Training group|was offered in one weekly class for 2 hours for 35 weeks between April and November of 2013. The first 50 minutes were spent performing exercises with the abacus, with increasing difficulty. One or two of the following activities followed the abacus training: playing games, neurobic and group dynamics.
2500744|NCT02897050|Experimental|T+mCX followed by FEC|Docetaxel 75mg/m2, iv, d1 + CTX 50 mg/d, po, d1-d21 + capecitabine 1200mg/m2/d, po, d1-d21 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
2500748|NCT02897050|Active Comparator|T followed by FEC|Docetaxel 100mg/m2, iv, d1 * 3 cycles (21 days per cycle) followed by fluorouracil 500mg/m2,iv,d1 + epirubicin 100mg/m2,iv,d1 + cyclophosphamide 500mg/m2,iv,d1 * 3 cycles (21 days per cycle)
3195997|NCT00845819|Active Comparator|EGF|rhEGF + povidone iodine, chlorhexidine, & nystatin
3195998|NCT00845819|Placebo Comparator|Placebo|Placebo + povidone iodine, chlorhexidine, & nystatin
3195999|NCT00845884|Experimental|AVDCF|Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
3196000|NCT00845910|Experimental|1|
3196001|NCT00845923|Other|Civamide Patch 0.015%|All subjects in study will receive the Civamide Patch 0.015%
3196002|NCT00845936|Experimental|1|850 mg of Metformin bid
3196003|NCT00845936|Placebo Comparator|placebo|Tablets Identical to Metformin, bid
3196004|NCT00845962|Active Comparator|Chloroprocaine|
3196005|NCT00845962|Active Comparator|Bupivacaine|
3196006|NCT00845988|Active Comparator|treatment as usual|patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine
3196007|NCT00845988|Experimental|switch to aripiprazole|aripiprazole
3196008|NCT00846001|Active Comparator|CABG alone|Standard coronary artery bypass grafting according guidelines
3196009|NCT00846001|Experimental|CABG+CRT|Standard coronary artery bypass grafting according guidelines with concomitant three bipolar epicardial leads implantation for cardiac resynchronization therapy
3196010|NCT00846014|Experimental|Asthmatics|All subjects will be asthmatics that have had an exacerbation (asthma attack) no more than 48 hours before the imaging session.
2501021|NCT02895178|Experimental|Exercise in breast cancer survivors|Combined aerobic and strength exercise training for 12 weeks under supervision
2501026|NCT02895178|No Intervention|No exercise in breast cancer survivors|Lifestyle counseling and standard of care follow up for 12 weeks
2501028|NCT02895178|Sham Comparator|Exercise in healthy subjects|Age-matched healthy subjects. Combined aerobic and strength exercise training for 12 weeks under supervision
2501102|NCT02894606||Thymoglobulin Induction|Patient receiving thymoglobulin as an induction therapy for renal transplant
2501106|NCT02894606||Basiliximab Induction|Patient receiving basiliximab as an induction therapy for renal transplant
2501186|NCT02893774|Experimental|cancer quality of life|All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis
2501292|NCT02893098|Experimental|Humia inj.|Participants with symptomatic Primary Osteoarthritis of Knee received a single injection of 3ml Humia inj.
2501293|NCT02893098|Active Comparator|High Hyal Plus inj.|Participants (Control Group) with symptomatic Primary Osteoarthritis of Knee received single injection of 2ml High Hyal Plus inj. given weekly for 3 weeks
2501339|NCT02892695|Experimental|CAR-NK Cell immunotherapy|Enrolled patients will receive CAR-NK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2501460|NCT02891655||surgery for keratoconus|
2501461|NCT02891655||refractive surgery (control patients)|
2500605|NCT02897856|Active Comparator|intramuscular midazolam|Study subject will receive intramuscular midazolam and buccal placebo. The dose of intramuscular midazolam is 0.25 mg/kg.
2500694|NCT02897414||Overall group of all ER/LA opioid excluding hydrocodone|
2500696|NCT02897414||Each type of opioid that has an ER/LA opioid formulation|
2500704|NCT02897414||Overall group that includes all prescription opioids except|
2500713|NCT02897414||Comparator Group taking benzodiazepines|
2500720|NCT02897414||Comparator Group taking IR hydrocodone|
2500761|NCT02896777|Experimental|Transfer embryos from 7.20±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.2±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2500763|NCT02896777|Experimental|Transfer embryos from 7.3±0.02 pH|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.3±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2500764|NCT02896777|Experimental|Transfer embryo from 7.4±0.02|In this arm, the intervention is to culture the inseminated oocytes in vitro in a pH of 7.4±0.02 from day 0 to 5/6 post IVF/ICSI. Then according to the result of the randomization, women will receive their embryos that will be cultured in this pH on either Day 3 or Day 5/6 post IVF/ICSI.
2500798|NCT02896439|Experimental|Neurophysiological monitoring|
2500868|NCT02896192|Experimental|Setmelanotide|Setmelanotide subcutaneous injection once daily
2500874|NCT02896192|Placebo Comparator|Placebo|Placebo subcutaneous injection once daily
2500918|NCT02895620|Other|NMIBC patients Xpert bladder test|Xpert bladder test of urine of patients with NMIBC treated with BCG therapy
2500992|NCT02895334|Experimental|MyHeartBaby|Caregivers will complete Telehealth Psychosocial Sessions and 4 follow up assessments.
2500994|NCT02895334|No Intervention|Standard of Care|Caregivers will complete 4 follow up assessments.
2501070|NCT02894814|Active Comparator|Basic intervention|Elements of One-Stop Dispensing (use of own medication, placed in bedside locker, partly or self-administration of medication during hospitalization)
2501071|NCT02894814|Active Comparator|Extended intervention|Elements of One-Stop Dispensing and focused dialogue with the patients about their medication during the hospitalization.
2501072|NCT02894814|No Intervention|Observational part of the study|Data collection on patients under the traditional medication system
2501110|NCT02894411||No ocular motility disorders|Patients without ocular motility disorders, with normal orbital and brain MRI.
2501117|NCT02894411||superior oblique muscle palsy|Clinical features compatible with unilateral paralysis of the SO muscle Atrophy of the SO muscle on the orbital MRI without other orbital or cerebral anomaly
2501153|NCT02894125||old subject|
2501203|NCT02893709|Experimental|Omeprazole|A course of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
2501230|NCT02893306|Experimental|DMT1+MSCs|type 1 diabetic patients receiving a single dose of allogeneic ex vivo expanded mesenchymal stem cells
2501290|NCT02893046||Population at Risk|Population with at least one risk factor of being infected with hepatitis C; MSM population; people in precarious situations and / or attending support from addictions care structures.
2501294|NCT02893046||Prison population|"Proposal of participation to a  consultation arrivants  by the staff of medical units correctional"
2501341|NCT02892617||Group 1|Patients with low back pain lasting for more than 6 months, debilitating, with the presence of type 1 Modic disc disease on MRI at the operated disc, eligible for a disc prosthesis or arthrodesis anterior approach
2501342|NCT02892617||Group 2|Patients underwent surgery for nerve root pain by disc herniation on MRI viewable with a radio-clinical concordance with or without Modic 1 disc disease in the operated disc
3321438|NCT02018848|Experimental|Attention Training Program|"The Attention Training consists of a modified dot-probe task. In this task pairs of pictures (OCD-relevant/neutral) are presented for 500 ms on a computer screen. Next, a probe appears on one of the two former picture locations. Participants have to react to that probe by pressing the corresponding button on the keyboard. One training session takes approximately 10 minutes in which 160 stimulus pairs are shown.~In the experimental group the probe always appears at the location of the neutral picture so as to train attention away from OCD-relevant stimuli.~Participants are asked to complete at least 2 training sessions per week over a period of 5 weeks. The first and last session are bias assessment sessions (see outcome measures), but participants stay blind to this."
2501605|NCT02890550||30 Patients Alström syndrome|
2501606|NCT02890550||60 Related patients Alström syndrome|
2502439|NCT02884557|Other|PSC + IBD group|collection of gut biopsies collection of blood samples in patients with PSC and IBD
2502443|NCT02884557|Other|IBD alone group|collection of gut biopsies collection of blood samples in patients with IBD alone
2502512|NCT02884167||Patients with constipation|
2502513|NCT02884167||Healthy individuals without constipation|
2502536|NCT02883634|Experimental|specific manipulation|"Participants allocated to group specific manipulation, will have their lumbar spine manipulated according to the previous clinical examination."
2502538|NCT02883634|Experimental|non-specific manipulation|"Participants allocated to group non-specific manipulation will have their upper thoracic spine manipulated (also known as global manipulation) regardless of the previous clinical examination."
2502612|NCT02883413|Experimental|CRT +Teach the Parent|The Teach the Parent (TtP) addition to CRT is designed to increase parental understanding of their adolescents' thinking styles. We hypothesize that by doing so, parents will be more likely to challenge eating disorder behaviors and be less likely to accommodate behavioral symptoms of the eating disorder (e.g., make something low-fat for dinner because it will be easier). In this arm, adolescents will explain what they learned during CRT and walk their parents though at least 4 tasks during each TtP session. Parents and child will not be permitted to speak about the eating disorder during these sessions. TtP sessions will occur 3-4 times during hospitalization and will be guided by the adolescent.
2502621|NCT02883127||The study group|Receives lifestyle intervention with motivational interviewing focusing on following the recommended diabetes diet and gestational weight gain recommendations in addition to routine care
2503352|NCT02878070|No Intervention|Usual Care|
2500663|NCT02897804|Experimental|Expectancies,desc & injun norms,benefits,efficacy|Participants will have access to the knowledge module plus the expectancies, descriptive norms, injunctive norms, perceived benefits, and self-efficacy modules for a period up to 3 weeks.
2500747|NCT02897024|Active Comparator|Usual weekly|Usual weekly physical therapy is 1 hours of therapy one day per week for 40 weeks.
2500754|NCT02897024|Experimental|High intensity periodic|High intensity periodic physical therapy is 2 hours of therapy 5 days a week for 2 weeks, followed by an 18 week break, followed by another bout of high intensity therapy for 2 hours of therapy every weekday for two 10-consecutive-weekdays, followed by another 18 week break from therapy.
2500782|NCT02896543||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attacks. They will all undergo coronary angiography.The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had obvious blood system diseases,severe liver dysfunction, severe renal insufficiency,severe heart failure (NYHA class 3 and 4), acute or chronic infectious diseases, disease of immune system, asthma, malignant tumor, other advanced disease are excluded.
2500783|NCT02896543||Control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are enrolled as Control group.
2500808|NCT02896348|Experimental|SynPhNe therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes with SynPhNe platform, over 6 weeks. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. Over the next 4 to 5 weeks, 10 sessions following exercises prompted by the SynPhNe system will be done unsupervised at home (or under limited supervision at the hospital), 2 sessions will be done at Spaulding Rehabilitation Hospital to review exercises with the SynPhNe system."
2500810|NCT02896348|Active Comparator|Conventional therapy|"Subjects will be asked to participate in a program of 18 upper-extremity rehabilitation sessions of 60 minutes under therapist supervision over two weeks at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The sessions will emphasize on the wrist and fingers movements, including functional activities.~During week the two first weeks, 6 sessions will be done under therapist supervision at the Motion Analysis Laboratory at Spaulding Rehabilitation Hospital. The remaining 10 sessions will be done unsupervised at home, over approximately 4 weeks, and following the therapist home treatment plan. Over that time, 2 visits to Spaulding Rehabilitation will be made to review home treatment plan. Over the course of the study, participants will wear GeneActiv sensors to gather information about upper-extremity usage."
2500865|NCT02896101|Experimental|Pimecrolimus Cream, 1%|Pimecrolimus Cream, 1 % (Glenmark Pharmaceuticals Ltd) topical application
2500869|NCT02896101|Active Comparator|Elidel®|Elidel® (Valeant Pharmaceuticals North America LLC) topical application
2500876|NCT02896101|Placebo Comparator|Placebo|Placebo of Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) topical application
3163023|NCT00473811|Active Comparator|ADA diet|Patients will be encouarged to consume foods consisted with ADA dietary recommendation
3163024|NCT00473811|Experimental|Low-GI|a low GI dietary education
2501035|NCT02895152|Experimental|Feedback|Those randomised to the feedback arm will receive weekly feedback on their activity levels and tailored advice on how to improve activity levels.
2501038|NCT02895152|No Intervention|Control|Control arm will wear the activity monitor as specified in the protocol but will not receive feedback on activity levels
2501084|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2501088|NCT02894593|Active Comparator|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2501093|NCT02894593|Placebo Comparator|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2501099|NCT02894593|Experimental|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
2501130|NCT02894021|Active Comparator|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
2501135|NCT02894021|Experimental|padding|areas of padding and stiching between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h.
2501173|NCT02893839|Other|Prick to prick|
2501245|NCT02893514|Placebo Comparator|Screening Only (SO)|
2501253|NCT02893514|Experimental|Substance Use Screening and Intervention Tool (SUSIT)|
2501279|NCT02892994|Experimental|Ultrasound|Subjects will receive 5 minutes of ultrasound treatment at 0.4 W/cm^2 and 100% duty cycle on each masseter muscle.
2501282|NCT02892994|Placebo Comparator|Placebo|Subjects will receive 5 minutes of ultrasound treatment at zero power on each masseter muscle.
2501407|NCT02892084|Experimental|Uphill COMa training|Walking on an inclined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
2501410|NCT02892084|Experimental|Downhill COMa training|Walking on a declined treadmill, thus manipulating the permissive environment to elicit COMa adaptation, while receiving either tDCS or sham tDCS.
2501483|NCT02891460|Experimental|40 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.
2501491|NCT02891460|Experimental|80 mg MMC in 40 mL TC-3.|TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 40 ml of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.
3163025|NCT00473863|Experimental|intervention|Receives CCTA
3163026|NCT00473863|No Intervention|Control|
2500672|NCT02897466|Experimental|Direct Antimicrobial Susceptibility Testing|"At day 0: Direct antibiotic susceptibility testing performed directly (DAST) on the respiratory sample At day 1: both results of isolated GNB identification using mass spectrometry and DAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to change antimicrobial therapy in case of differences between CAST and DAST (2nd switch to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems)"
2500675|NCT02897466|No Intervention|Conventional Antimicrobial Susceptibility Testing|"At day 1 identification of isolated GNB bacilli using mass spectrometry will be given to the physician in charge (usual care in ICU involved) to adapt antibiotic regimen. Conventional antibiotic susceptibility testing (CAST) performed on isolated GNB.~At day 2-3: results of CAST will be given to the physician in charge in order to switch antimicrobial therapy to an antibiotic with a spectrum as narrow as possible with the main objective to avoid whenever possible carbapenems."
2500732|NCT02896933||patients with multiple sclerosis|recruited in a former study
2500734|NCT02896933||healthy control subjects|
2500793|NCT02896686|Active Comparator|Control|Abdominal wall closure will be done by continuous polydioxanone (PDS) suture following a SL:WL ratio of 4:1, and the skin will be closed using a subcutaneous purse-string closure
2500794|NCT02896686|Experimental|Reinforcement with Mesh|"Abdominal wall closure will be done by continous polydioxanone (PDS) suture following a SL:WL ratio of 4:1.~The incision is reinforced with onlay placement of a light polypropylene mesh (3 cm wide and the length corresponding to the incision), fixed to the aponeurosis with interrupted polyglactin (Vycril) suture.~The skin will be closed using a subcutaneous purse-string closure"
2500891|NCT02896140||Type 2 diabetes in WhyWAIT Program|Patients with type 2 diabetes who are participating in Joslin Diabetes Center's 12-week intensive diabetes weight management program (WhyWAIT).
2501064|NCT02894775||included in a clinical trial|
2501065|NCT02894775||not included in a clinical trial|
2501190|NCT02893969|Experimental|Experimental group|Gradual reintroduction of non-contact physical activity at 72 hours post-concussion.
2501198|NCT02893969|Sham Comparator|Control Group|Physical and cognitive rest post-injury until fully asymptomatic. Once asymptomatic participants can gradually reintroduce physical activity.
2501218|NCT02893345|Experimental|Safe@Home Intervention Group|Participants receive: (1) computer-generated, personalized assessment of abilities, risk, and recommended next steps; (2) 2 person-family education visits to develop a shared understanding of client strengths and risks, set goals, develop better ways to work as a team, and problem-solve; (3) 8 in-home visits in which personal transition trainer/life skills coach provides training, compensatory strategies, and social/technological supports on self-selected activities. The ten visits last 90-120 minutes and ideally take place over a three month period.
2501226|NCT02893345|Active Comparator|Usual Care Group|Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
2501284|NCT02893007|Experimental|Brief family-centered care program|The Brief family-centered care (BFCC) program was developed and provided for hospitalized patients with BPD and their family caregivers.The BFCC protocol is outlined as 4 treatment sessions, specific goals, and example questions. Four 90-minute in-depth sessions for each dyad were initially held in a quiet interview room to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
2501286|NCT02893007|No Intervention|treatment-as-usual (TAU)|All patients were given the standard hospital-provided services: psychiatric nursing care, occupational therapy, and pharmacotherapy. All of the family caregivers were only to attend a routine 60-minute family discussion group about violence and suicide prevention without any specific patient-family dyad interview.
2501323|NCT02892721|No Intervention|Control group|The control group will not receive the one-day training course or access to the online educational module. Test sets will be administered in the same manner as for the intervention group, but the control group will not receive any feedback on performance during the 12 month assessment phase. Feedback on test performance will only be provided after the 12 month period has ended.
2501326|NCT02892721|Other|Training with feedback|See intervention description
2501384|NCT02892435|Experimental|Prevena arm|patients underwent to contaminated/dirty surgery who positioned incisional negative pressure wound therapy and kept for six days
2501386|NCT02892435|Active Comparator|Control arm|patients underwent to contaminated/dirty surgery who positioned conventional dressing
2501441|NCT02891941||Mild Traumatic Brain Injury|This cohort will have sustained a closed head injury, defined as externally inflicted trauma without skull fracture within the last month.
2501504|NCT02891616|Experimental|FDG-PET/CT + FLT-PET/CT + PET/MR|"-Baseline, Week 3 (between days 14-20), Week 6 (between days 35-41)~FDG-PET/CT - Patients required to fast for at least 4 hours prior to FDG administration. Roughly 60 minutes prior to PET/CT imaging, FDG will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~FLT-PET/CT - Patients required to fast for at least 4 hours prior to FLT administration. Roughly 80 minutes prior to PET/CT imaging, FLT will be administered via IV bolus injection. A CT will be performed immediately before PET imaging. Whole body PET imaging will be performed for a total of about 30 minutes.~PET/MR - A limited whole body scan performed immediately following PET/CT imaging when possible. Should be performed at least once at each time-point. This scan will be of a more limited area and be performed for no more than 30 minutes."
2501536|NCT02891057|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2501575|NCT02890888|Experimental|Hyperbaric oxygen treatment|HBO for 1 hour at 2 ATA 10 times, administered 5 times per week over 2 consecutive weeks
2501629|NCT02890563|No Intervention|No Compression|Patients in this group will not receive any compression after treatment.
2503853|NCT02874456|Experimental|virus detection|detection of ZIKA virus in blood and sperm
2500708|NCT02897284|Active Comparator|Mindfulness 2 weeks|Mindfulness-based intervention with 2 weekly sessions
2500715|NCT02897284|No Intervention|Control|waiting list
2500760|NCT02896803|Experimental|Experimental|mFLOX
2500862|NCT02895906|Experimental|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as capsules for oral administration.
2500947|NCT02895776||General Sedation|Case patients: Endovascular Acute Stroke Therapy scheduled to be performed under local sedation and finally performed under General anesthesia
2500949|NCT02895776||local sedation|Control patients: Endovascular Acute Stroke Therapy scheduled to be performed, and actually performed under conscious Sedation
2501024|NCT02895204|Experimental|Test group (F-MRP)|Fermented Maillard reacted whey protein (F-MRP) supplementation
2501030|NCT02895204|Placebo Comparator|Placebo group|Placebo supplementation
2501079|NCT02894632|Experimental|Healthy volunteers|Volunteers without cardiac, hepatic or renal pathology
2501171|NCT02894268|Experimental|Regimen A|esomeprazole (E) 20 mg, doxycycline (D) 100mg, furazolidone (F) 100 mg, and colloidal bismuth subcitrate (B) 100 mg
2501172|NCT02894268|Active Comparator|Regimen B|two sensitivity antibiotics based on antibiotic sensitivity of helicobacter pylori culture, colloidal bismuth subcitrate (B) 100 mg, esomeprazole (E) 20 mg
2501244|NCT02893293|Active Comparator|Ferumoxytol-enhanced MRI|Patients receive a ferumoxytol injection (Feraheme, AMAG, 5mg Fe/kg, single administration) prior to routine decompression surgery and autologous stem cell transplant. Follow-up imaging with magnetic resonance imaging will be conducted in regular intervals for evaluation of the response to treatment.
2501256|NCT02893293|Sham Comparator|Non-ferumoxytol enhanced MRI|Patients scheduled for routine decompression surgery and autologous stem cell transplant will receive follow-up magnetic resonance imaging in regular intervals for evaluation of the response to treatment.
2501314|NCT02892851|Experimental|Deep brain stimulation (DBS)|Deep brain stimulation of the subthalamic nuclei (STN-DBS)
3321439|NCT02018861|Experimental|Parsaclisib|escalating doses given every day (QD)
3321440|NCT02018861|Experimental|Parsaclisib in combination with itacitinib (INCB039110)|Starting dose of parsaclisib determined in Part 1 of the study in combination with itacitinib (INCB039110)given QD
2501422|NCT02891967|Other|Bulk full composite (3M)|bulk fill composite in posterior class one cavities
2501427|NCT02891967|Other|Incremental packing composite resin|Nano resin composite (K Z350 xt) restoration in class one cavities
2501458|NCT02891668||Hypothyroid|Levothyroxine treatment
2501459|NCT02891668||Healthy volunteers|Matched on age and BMI 18 persons
2501509|NCT02891447|Experimental|Treatment (mitomycin, cisplatin)|Patients undergo HIPEC comprised of mitomycin and cisplatin given intraperitoneally over 60 minutes during standard of care cytoreduction and gastrectomy.
2501617|NCT02890771|Active Comparator|Tooth Brushing|Tooth brushing with dentifrice
2501618|NCT02890771|Experimental|Turmeric massaging|Tooth Brushing,massaging with whole turmeric powder
2501621|NCT02890771|Experimental|SRP with turmeric massaging|SRP with turmeric massaging on half arch
2501657|NCT02890173|Experimental|CS-3150 2.5 mg|CS-3150 2.5 mg, orally, once daily after breakfast for 12 weeks
2501659|NCT02890173|Experimental|CS-3150 5.0 mg|CS-3150 5 mg, orally, once daily after breakfast for 12 weeks
2501660|NCT02890173|Active Comparator|Eplerenone|Eplerenone 50 mg, orally, once daily after breakfast for 12 weeks
2501713|NCT02890043|Experimental|Robot|Intervention: Surgery: robot-assisted spine surgery, device: TiRobot surgery system
2501714|NCT02890043|Active Comparator|Free-hand|Intervention: Surgery: free-hand surgery
2501766|NCT02889718|Experimental|anaesthesia with CONCERT-CL® station|During the surgery, 3 drugs usually used for anaesthesia will be administered by the CONCERT-CL® station
2501817|NCT02889497|Experimental|300 subjects receive the first batch vaccine|300 subjects will be randomly received the first batch vaccine
2501819|NCT02889497|Experimental|300 subjects receive the second batch vaccine|300 subjects will be randomly received the second batch vaccine
2501821|NCT02889497|Experimental|300 subjects receive the third batch vaccine|300 subjects will be randomly received the third batch vaccine
2501897|NCT02889042|Experimental|Volunteers repeated drug poisoning|performing MRI and a biological assessment
2501903|NCT02889042|Other|Volunteers single drug poisoning|performing MRI and a biological assessment
2501909|NCT02889042|Other|alcoholic|performing MRI and a biological assessment
2501912|NCT02889042|Other|volunteers|performing MRI and a biological assessment
2501991|NCT02888392|Experimental|Kiwifruit intervention|4 week intervention treatment with 2 fresh, whole green kiwifruit per day
2501993|NCT02888392|Active Comparator|Psyllium intervention|4 week intervention treatment with psyllium, matched for fibre content of 2 green kiwifruit / day for 4 weeks
2502047|NCT02887755|Experimental|Amputee Group|In this study n=20 returning US military combatants between 18 and 45 years of age who have unilateral transtibial or transfemoral amputation will be asked to perform two aerobic exercise tests while we4aring the NIRS sensor. Subjects must be medically cleared and able to complete approximately 30 minutes of physical activity.
2502086|NCT02887391||Conventional Hemodialysis|Control group 4 hours of hemodialysis 3x per week (12 hours hemodialysis/week)
2502087|NCT02887391||In-Centre Nocturnal Hemodialysis|8 hours of hemodialysis 3x per week (24 hours hemodialysis/week)
2502146|NCT02887066||Patients with thoracic pain and suspicion of ACS|
2502187|NCT02886676|Experimental|Spirulina capsules and scaling & root planing|Patients in test group will be provided with Spirulina capsules 2gm daily, after meals for 1 month
2502193|NCT02886676|Active Comparator|Placebo capsules and scaling & root planing|Patients in test group will be provided with placebo capsules after meals for 1 month
2502218|NCT02886195|Experimental|PC plus erlotinib|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1; concurrent erlotinib 150mg/d d1-21, per 3 week, for 4-6cycles, then erlotinib 150mg/d maintain therapy
2502219|NCT02886195|Active Comparator|erlotinib|"erlotinib 150mg/d until progress disease"
2502221|NCT02886195|Active Comparator|PC|pemetrexed 500mg/m2 d1 plus cisplatin 80mg/m2 d1 for 4-6 cycles
2502362|NCT02885103|Active Comparator|inhalation with nebulizer and NHF|inhalation with combination of nebulizer and nasal high flow (NHF) via nasal cavity
2500709|NCT02897401|Experimental|Electronic cigarette|Electronic cigarette consumption in the context of their habit (not related to the particiapion under study).
2500714|NCT02897401|Experimental|Nicotine replacement therapy|Nicotine replacement therapy (only patch) consumption in the context of their habit (not related to the particiapion under study).
2500719|NCT02897401|Placebo Comparator|Without nicotine|No consumption in the context of their habit (not related to the particiapion under study).
3163027|NCT00473941|No Intervention|1|Writing in a journal 15 minutes a day
3163028|NCT00473941|No Intervention|2|Control Writing in a journal 15 minutes a day
3163029|NCT00473954|Experimental|EGEN-001|
3163030|NCT00473967|Experimental|10 mcg Na-ASP-2/Alhydrogel|Na-ASP-2 Hookworm Vaccine
3163031|NCT00473967|Active Comparator|Butang hepatitis B vaccine|Hepatitis B Vaccine - comparator vaccine
3163032|NCT00473980|Experimental|Drug|Treatment with indomethacin or celecoxib
2500820|NCT02896283|Experimental|low-level laser therapy|Low-level laser (Diode, 66o nanometer, power:200 milli Watt (mW), Continuous wave, time of irradiation:32 seconds)is irradiated in donor site
2500822|NCT02896283|Placebo Comparator|Turned-off laser|The same protocol is applied in te donor site, unless the laser is remained off.
3163033|NCT00473980|Sham Comparator|SHAM|Sham treatment
2500935|NCT02895490|Experimental|Arm I (DVD)|Patients receive a DVD containing educational information about patients' legal rights in the workplace and communication skills demonstrated through four scenarios depicting a variety of employer-employee communication challenges for patients, provided by LINC group.
2500942|NCT02895490|Active Comparator|Arm II (control)|Patients receive information about the LINC group.
2501002|NCT02894996|Other|Pediatric patient for general anesthesia|Pediatric patients for general anesthesia elected for scheduled surgery Patients weight between 8 and 30 kilograms
2501077|NCT02894723|Active Comparator|l-arginine|Patients will receive L-arginine 30 ml twice a day for 8 weeks.
2501081|NCT02894723|Placebo Comparator|syrup|Patients will receive placebo, 30 ml twice a day for 8 weeks.
2501131|NCT02894099|Experimental|Prolonged Sitting Time (PST)|Uninterrupted sitting time of 5 hours
2501134|NCT02894099|Experimental|PST+Light intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of light physical activity
2501141|NCT02894099|Experimental|PST+Moderate intensity Short bouts PA|Sitting prolonged interrupted with breaks of 2 minutes of moderate physical activity
2501146|NCT02894099|Experimental|PST+Moderate intensity Long bouts PA|Sitting prolonged interrupted with breaks of 10 minutes of moderate physical activity
2501227|NCT02893397|Experimental|Group I (supervised exercise)|Patients wear a fitbit and undergo supervised physical therapy exercise sessions over 40 minutes 3-5 times a week for at least 4 weeks.
2501236|NCT02893397|Experimental|Group II (fitbit)|Patients wear a fitbit.
2501302|NCT02892916|Experimental|Ketamine|Patients in this experimental group will receive a bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
2501305|NCT02892916|Placebo Comparator|Placebo|Patients in this control group will receive a bolus of an intravenous normal saline solution following induction of anaesthesia.
2501345|NCT02892526||Vital wounds|from abdominoplasty of alive persons
2501348|NCT02892526||Post-mortem wounds|from autopsy of deceased persons
2501469|NCT02891707|Active Comparator|Control Group|The investigators will recruit 20 healthy subjects at Walter Reed National Military Medical Center (WRNMMC) with the goal of consenting and enrolling 15 healthy subjects to assess the reliability and validity the wearable Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD) system.
2501470|NCT02891707|Active Comparator|Amputee Group|The investigators will recruit a total of 130 subjects (65 at WRNMMC and 65 at the Miami VA) with the goal of consenting and enrolling 100 subjects (50 and WRNMMC and 50 at the Miami VA) with lower limb amputation to utilize the ReLOAD system.
2501539|NCT02891304||Quarterly Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive objective feedback every 3-months on trainee overall performance including learning curves on ACE tool performance, performance relative to de-identified anonymous peers on each of the individual skills (e.g. fine tip control), and the global assessment for technical and cognitive skill achievement. For those skills which are not advanced/superior - trainees will additionally receive links to online didactic videos which teach these skills.
2501540|NCT02891304||Annual Feedback|In addition to each center's traditional endoscopic feedback for trainees, centers/trainees will receive learning curves at the end of each training year. Learning curves, relative to de-identified anonymous peers will be provided to program directors annually (June).
2501576|NCT02890862||20 healthy volunteers|
2501577|NCT02890862||Dupuytren disease|10 patients dupuytren disease
2501578|NCT02890862||Tendon pathology|10 patients with tendon pathology
2501579|NCT02890862||wrist osteoarthritis|10 patients with wrist osteoarthritis
2501634|NCT02890628||pregnant/post-natal adolescents (<20 years)|12-24 individual with pregnant or postnatal adolescent girls (<20 years) will be interviewed.
2501638|NCT02890628||non-pregnant female adolescents (<20 years)|1 Focus group discussion of 6-10 non-pregnant female adolescents (<20 years)
2501642|NCT02890628||male adolescents (<20 year)|1 Focus group discussion of 6-10 adolescent men (<20 years)
2542250|NCT02615795|No Intervention|Control|Best practice
3163034|NCT00474006|Active Comparator|arm I|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days
3163035|NCT00474019|Experimental|1|Based on age and/or weight dose of esomeprazole IV qd in milligrams 20,40,10,20,10, 1.0 mg/kg, 0,5 mg/kg
3163036|NCT00474110|Experimental|1|Ketamine and hydromorphone for patient-controlled relief in children's mucositis.
3163037|NCT00474136|Experimental|1|
3163038|NCT00474136|Experimental|2|
3163039|NCT00474136|Active Comparator|3|
3163040|NCT00474227|Experimental|A|behavioral intervention, group therapy including nutritional guidance and physical exercise
3163041|NCT00474227|No Intervention|B|comparison group, one time explanation of importance of proper nutrition. This group receives no group therapy or organized exercise sessions or nutritional guidance. They are wait listed for this program.
2500710|NCT02897219|Experimental|Part 2 ASP1941|ASP1941 will be administered for 28 weeks under open label conditions.
2500850|NCT02896634||group with inflammation|Selection of samples from biobank with groups with inflammation
2500851|NCT02896634||group with denutrition|Selection of samples from biobank with groups with denutrition
2500852|NCT02896634||group with none|Selection of samples from biobank with groups with none
2500854|NCT02896634||group with both|Selection of samples from biobank with groups with both.
2500906|NCT02895828|Experimental|Core Stabilization Exercise (CSE)|The participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
2500907|NCT02895828|Experimental|General Strengthening Exercise (GSE)|The participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks.
2500917|NCT02895464|Experimental|Exercise group|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
2500920|NCT02895464|Other|Control group|The participants will receive ordinary preoperative information, but will also be encouraged to follow the recommendation of 150 minutes/week of moderate physical activity.
2500991|NCT02895321|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity. The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense and Colgate Protection Caries and Placebo gel.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The effectiveness will be evaluated: immediately after application and after 2, 4, 8 weeks."
2501138|NCT02894294||Intervention district|implementation of the seasonal malaria chemoprevention
2501144|NCT02894294||Control district|no implementation of the seasonal malaria chemoprevention
3196011|NCT00846092|Experimental|Device|"The study will require 20 subjects.~Each subject will have one study eye that will be designated for treatment.~Subjects will be exposed to light emitted from Warp 10 LED's (Quantum Devices, Barneveld, WI) at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily.~Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study.~• This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group."
2501810|NCT02889640|No Intervention|Control group|These youth will receive standard mathematics instruction and support (including possibly other tutoring interventions), but not the daily, intensive, during-the-school-day math tutoring provided by SAGA.
2501814|NCT02889640|Experimental|Scale-up SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with scale-up tutors. Tutors will be hired using the randomization process, and will be randomly assigned to youth.
2501815|NCT02889640|Experimental|Standard SAGA math tutoring|These youth will receive intensive, daily mathematics tutoring, and students will be paired with tutors hired via SAGA's standard process, which does not involve randomization. Tutors will be randomly assigned to youth.
2501974|NCT02888236|Experimental|LEO 32731 tablet|LEO 32731 30 mg two times daily for 16 weeks
2501978|NCT02888236|Placebo Comparator|LEO 32731 Placebo tablet|LEO 32731 placebo two times daily for 16 weeks
2502092|NCT02887469|Active Comparator|Intermittent bolus group|"<<Within 6hr>>~Moderately Severe : 3% saline 2ml/kg over 20min *1 (unknown bwt 100ml)~Severe :3% saline 2ml/kg over 20min *2 (unknown bwt 100ml)~<additional treatment> Repeat 3% saline 2ml/kg over 20min at every sample time point (at 1/6hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 6-24hr>>~- Moderately Severe or Severe~: Repeat 3% saline 2ml/kg over 20min at every sample time point(at 12/18/24hr) till Na 5-9 mmol/L inc from initial Na and sx relief~<<During 24-48hr>>~Moderately Severe or Severe : Repeat 3% saline 2ml/kg over 20min at every sample time point (at 30/36/42/48hr) till Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief"
2502094|NCT02887469|Active Comparator|slow continuous infusion group|"<<Within 24hr>>~- Moderately Severe: 3% saline 0.5ml/kg/hr (unknown bwt 25ml/hr)~- Severe: 3% saline 1ml/kg/hr (unknown bwt 50ml/hr)~Infusion protocol modification as below by Na at every sample time point (at 1/6/12/18/24 hr)~If Na 5-9 mmol/L inc from initial Na and sx relief : stop 3% saline infusion regardless of △ Na~if △ Na inc <0.5mmol/hr or △ Na inc <3mmol/6hr : add 0.25ml/kg/hr, restart 0.5ml/kg/hr if previously stopped~if △ Na inc ≥0.5mmol/hr or △ Na inc ≥ 3mmol/6hr~: maintain infusion rate~<<During 24-48hr>>~- Moderately Severe and Severe~Infusion protocol modification as below by Na at every sample time point (at 30/36/42/48hr)~If Na 10-17 mmol/L inc from initial Na or Na ≥ 130mmol and sx relief~: stop 3% saline infusion regardless of △ Na~if △ Na inc <1.5mmol/6hr~: add 0.25ml/kg/hr or restart 0.25ml/kg/hr if previously stopped~if △ Na inc ≥ 1.5mmol/6hr~: maintain infusion rate"
2502118|NCT02886988|Experimental|Botulinum toxin type A|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.100U Botulinum toxin type A(BTA) will be reconstituted with 2mL of normal saline for a concentration of 50U/mL. 0.1ml(5 units) of BTA will be injected along the wound edges. The injections will be administered within 14 days of median sternotomy with a 30G needle.
2502119|NCT02886988|Placebo Comparator|Normal Saline|The entire median sternotomy wound was divided into the upper half and the lower half. Both halves of the wound were randomized to receive treatment with either BTA or 0.9% normal saline.0.1ml normal saline will be injected along the wound edges.
2502145|NCT02886832|Experimental|Prostate Health formulation|Prostate Health formulation
2502188|NCT02886598||Firmagon®|Treatment according to standard clinical practice.
2543754|NCT02605889|Experimental|Group A|Laser acupuncture
2500758|NCT02897037|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
2500762|NCT02897037|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
2500837|NCT02896491|Experimental|GSM 900 MHz exposure|Radiation: Exposure with non-ionizing electromagnetic fields exposure with GSM 900 MHz (2W/kg)
2500839|NCT02896491|Experimental|TETRA 400 MHz exposure|"Radiation: Exposure with non-ionizing electromagnetic fields:~exposure with TETRA (6W/kg)"
2500841|NCT02896491|Sham Comparator|Sham exposure|Radiation: Exposure with non-ionizing electromagnetic fields: exposure with 0 W/kg
2500893|NCT02895880||usual care|first 25 participants will receive usual care (i.e. no risk communication tool)
2500899|NCT02895880||risk communication tool|next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
2500930|NCT02895555|Active Comparator|Allograft group, standard treatment|Control group, standard treatment. Aprox 50 g pr level fused.
2500936|NCT02895555|Experimental|i-FACTOR|i-FACTOR putty in the operation site. Fda approved. Aprox 5 ml pr level fused.
2500971|NCT02895139|Experimental|Additive Manufactured Orthotic Device|Device will be produced via additive manufacture to the specification of a Health and Care Professions Council (HCPC) registered orthotist based on a digital foot scan.
2500973|NCT02895139|Other|Moulded Orthotic Device|Historic control collected using same protocol. Intervention was a moulded orthotic device produced from an impression box of the foot shape.
2500975|NCT02895139|Other|Milled Orthotic Device|Historic control collected using same protocol. Device will be produced via Computer Aided Design/Computer Aided Manufacture (CAD/CAM) milling to the specification of a HCPC registered orthotist based on a digital foot scan.
2501051|NCT02894918|Experimental|Combination group|Maintain NAs treatment while add 48-week standard treatment by Peginterferon alfa 2a 180µg/week
2501053|NCT02894918|No Intervention|Mono NA group|Maintain NAs mono-therapy oral-daily for 48 weeks.
2501083|NCT02894528|Experimental|Ridge Preservation (Test Group)|
2501087|NCT02894528|Active Comparator|Ridge Preservation (Control Group)|
2501152|NCT02894255|Experimental|PCI and CABG|
2501174|NCT02893748|Active Comparator|1: HyGIeaCare Prep and Colonoscopy|"Patients will receive:~HyGIeaCare Prep~Colonoscopy"
2501175|NCT02893748|Active Comparator|2: Split-dose PEG Prep and Colonoscopy|"Patients will receive:~Split-dose PEG~Colonoscopy"
2501243|NCT02893423|Active Comparator|Group 1 - 0.5% Ropivacaine|Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin
2501254|NCT02893423|Active Comparator|Group 2 - 0.25% Ropivacaine|Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin
2501265|NCT02893423|No Intervention|Group 3 - No Tap Block|Patients will not receive a TAP BLOCK
2501280|NCT02892955|Experimental|HeartMate 3 LVAS (HM3 LVAS)|The study will be a single-arm, prospective, multi-center, study for continued evaluation of safety and clinical performance of the HM3 LVAS.
3163042|NCT00474318||Adolescents with severe obesity|Adolescents and young adults with severe obesity
3163043|NCT00474357|Experimental|1|Bipolar patients participating in psychoeducation intervention
2501464|NCT02891720|Active Comparator|ARM A: Proteus Sensor System (PSS) First|ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
2501465|NCT02891720|No Intervention|ARM B: SOC First|ARM B will 12 weeks of FTC/TDS standard of care (SOC) first. At 12-week intervals participants will crossover to the next condition.
3163044|NCT00474357|No Intervention|2|bipolar patients who do not participate in psychoeducation group
3163045|NCT00474357|No Intervention|3|Therapists will complete questionnaires regarding myths about bipolar patients, no intervention
2502490|NCT02884115|No Intervention|Control group|Absence of any retreatment
3163046|NCT00474370|Experimental|Test Arm|Vicriviroc 30 mg QD
3163047|NCT00474370|Placebo Comparator|Placebo Control Arm|Placebo
3163048|NCT00474461|Experimental|Treatment group|Patients in this arm received intracoronary expanded autologous c-kit positive cardiac stem cells.
3163049|NCT00474461|No Intervention|Control group|Patients in this arm did not receive any intervention.
3163050|NCT00474552|Experimental|1|Experimental-Placebo Comparator
3163051|NCT00474669|Experimental|Docetaxel|Intraperitoneal Docetaxel administered with heat
3163052|NCT00474695||1|Active approved treatment
3163053|NCT00474799|Experimental|A|MNS075 7.5mg q1h
3163054|NCT00474799|Experimental|B|MNS075 15mg q3h
3163055|NCT00474825|Active Comparator|1|Hyperbaric Oxygen twice weekly (Monday & Friday) with Radiation and Chemotherapy
3163056|NCT00474825|Active Comparator|2|Hyperbaric Oxygen three times per week (Monday, Wednesday & Friday) with Radiation and Chemotherapy.
3163057|NCT00474825|Active Comparator|3|Hyperbaric Oxygen Five times per week (Monday through Friday) with Radiation and Chemotherapy
3163058|NCT00474838|Active Comparator|Oral AntiDiabetic Drug|glimepiride and metformin and/or once daily glargine
3163059|NCT00474838|Experimental|intensive insulin group|insulin glargine insulin glulisine
3163060|NCT00474916|Experimental|KRN5500|KRN5500 escalating dose of .6, 1.2, 1.8, or 2.2 mg/m2 in IV infusion of normal saline
3163061|NCT00474916|Placebo Comparator|Normal Saline|Placebo consists of IV infusion of normal saline
3163062|NCT00474981|Experimental|1|IMNCI
3163063|NCT00474981|No Intervention|2|Control
3163064|NCT00475007|Experimental|1|The experimental group will have an investigational medical device implanted in their lungs with an instrument known as a bronchoscope. This procedure is done without an incision
3173595|NCT00613743|Placebo Comparator|1|D1-D3 receive placebo
3173596|NCT00613743|Active Comparator|2|receive D1 D3 morphine
2500787|NCT02896504||Chemotherapy|Breast Cancer patients undergoing conventional postsurgical adjuvant chemotherapy treatment
2500790|NCT02896504||Hormonal Therapy|Breast Cancer patients undergoing conventional postsurgical adjuvant hormonal therapy treatment (with no Chemotherapy)
2500791|NCT02896504||Healthy Control|Healthy age, height and body-mass matched healthy controls
2500864|NCT02896231|Experimental|PLB1001|There are 5 dose cohorts, including 50mg BID, 100mg BID, 150mg BID, 200mg BID and 275mg BID in the dose escalation stage and PLB1001 will be administered orally to patients twice daily for each dose cohort.
2500934|NCT02895763||Neuro Muscular disease patients|French Patients, young adults and adults, with a diagnosed neuromuscular disease, of any known form.
2500979|NCT02895230||Men with prostate cancer with androgen-deprivation therapy|Using the French Health Reimbursement Agency database and French hospital discharge database, the investigators will identify all men with prostate cancer who had either, at least one dispensation in a 1.5-year period (1st July 2010 to 31st December 2011) of an androgen-deprivation therapy or a hospitalization for orchiectomy. The French Health Insurance System covers the entire French population (65.3 million inhabitants in 2012).
2501011|NCT02894879|Experimental|Modify group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 4 modify techniques and receive cardiac rehabilitation phase 1 in postoperative period.
2501013|NCT02894879|Sham Comparator|Conventional group|For 2 days pre-surgery and continuous post-surgery repeated for 5 sets a day. The patients in Modify group will be taught 3 conventional techniques and receive cardiac rehabilitation phase 1 in postoperative period.
2501101|NCT02894671||male under 45y|blood exams performed on males under 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2501105|NCT02894671||male over 45y|blood exams performed on males over 45years (in a range of 20-90 years) not wearing articular devices, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2501108|NCT02894671||fertile female|blood exams performed on fertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2501109|NCT02894671||infertile female|blood exams performed on infertile females (in a range of 20-90 years) not wearing articular devices, no pregnant, without fractures, and without these diseases: oncologic, hemochromatosis, hepatic, thalassaemia, diabetes, anemia (Hb<9)
2501150|NCT02894073|No Intervention|control group|PVC placement performed in the usual manner: visual inspection of the patient's anatomy
2501155|NCT02894073|Experimental|visualisation group|a skin transilluminator (such as the VeinViewer®Vision) is used to guide PVC placement
2501169|NCT02893735|Active Comparator|Charisma-Diamond|Charisma Diamond was randomly applied for diastema closure.
2501170|NCT02893735|Active Comparator|Filtek-Z550|Filtek-Z550 was randomly applied for diastema closure.
2501216|NCT02893527|Experimental|"Group intervention"|Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
2501217|NCT02893527|No Intervention|"Group standard"|conventional support
2501276|NCT02893137|Experimental|Craniectomy and Optune|Patients will receive best physician's choice chemotherapy along with Optune therapy and craniotomy surgery. Optune therapy will be administered in the standard configuration and in accordance with current guidelines with the exception of the surgical intervention.
2501324|NCT02892747|Experimental|Educational Program for prevention of malnutrition|In addition to the usual nutritional assessment, the patients in the experimental arm benefit of a personalized educational program for prevention of malnutrition. This program aims to monitor energy and protein intake in addition to managing sodium intake, notably by offering personalized menu ideas and recipes.
2501327|NCT02892747|No Intervention|Control|In the control arm, patients are followed-up by the cardiologist and the nutritionist, and did not benefit of the personalized educational program for prevention of malnutrition.
2501480|NCT02891590|Experimental|DTRMWXHS-12|DTRMWXHS-12 only: oral capsules (50 mg and 150 mg strengths), successive administration, dose escalation from 50mg to 100, 200, 400, 600, 800mg daily until MTD. During successive administration, orally once a day, 28 days as a cycle.
2501511|NCT02891252|Active Comparator|outpatient|outpatient
2501512|NCT02891252|No Intervention|inpatient|inpatient
2501571|NCT02891044|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2501589|NCT02890693|Experimental|interdisciplinary lifestyle/psychosocial|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions.
2501590|NCT02890693|No Intervention|treatment as usual|Usual clinical follow-up and treatment is based on the current American Diabetes Association, the Endocrine Society guidelines, and the NICE guidelines.
2501646|NCT02890446|Experimental|External Focus (EF)|"Participants received arm training using the InMotion2 robot under external focus practice conditions and instructions. Participants practiced arm reaching by playing a simple video game.~EF instructions: Focus on moving the yellow ball on the screen in a smooth, straight line at a constant speed; Move the yellow ball toward the blinking red/orange light; and Hit the center of the target and try not to overshoot the target"
3175090|NCT00629967|Active Comparator|B|Eligible patients will be randomized into two groups with a ratio of 1:1 (Arm A & B)
3175091|NCT00629980|Experimental|1|
3175092|NCT00629980|No Intervention|2|
3175093|NCT00629993|Experimental|Multi-component Academic Detailing|"Multi-component, academic detailing regarding ACS guidelines on cervical cancer screening approaches.~Includes an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients."
3175094|NCT00630019|Experimental|1|
3175095|NCT00630019|Active Comparator|2|
2500823|NCT02896257|No Intervention|Usual care|Standard practice (usual care). Primary care providers treat their patients as usual.
2500908|NCT02895815|Experimental|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 microliter (mcL) given by subretinal delivery system.
2500909|NCT02895815|Experimental|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system.
2500910|NCT02895815|No Intervention|Control Group|Participants will undergo observations without surgery.
2500955|NCT02895412|Experimental|Transplant Recipient|"The T cell product administration is personalized cellular therapy product, individually prepared for each participant.~Donor-derived WT1-CTL and P-CTL.~It's exact make up and effect is dependent on both donor and recipient characteristics and as such variability is expected in the response. These variations will be adjusted for by multiple samplings over time and collation and analysis of response in both individuals an the group as a whole.~One infusion of 2 x 107/m2 P-CTLs prophylactically on or after day 28 post-allogeneic peripheral blood haemopoietic stem cell transplant (HSCT), combined with up to four infusions of 2x107/m2 WT1-CTLs."
2500962|NCT02895126|Experimental|"Appui Parental program (44 cases)"|
2500964|NCT02895126|Other|Regular parental support (44 cases)|Usual intervention
2501007|NCT02894970||Healthy adults|Healthy adults for checking feasibility of Pulmonary PPG
2501008|NCT02894970||Healthy children|Healthy children for checking feasibility of Pulmonary PPG
2501012|NCT02894970||Healthy neonates|Healthy neonates for checking feasibility of Pulmonary PPG and in order to be a control group for neonates with pulmonary hypertension.
2501014|NCT02894970||Healthy preterm neonates|Healthy preterm neonates for checking feasibility of Pulmonary PPG and in order to be a control group for premature neonates with patent ductus arteriosus (PDA).
2501017|NCT02894970||Preterm neonates with PDA|Preterm neonates with hemodynamic significant PDA. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
2501019|NCT02894970||Neonates with pulmonary hypertension|Neonates with pulmonary hypertension. Intervention: evaluate Pulmonary PPG and oxygen saturation as compared to normal newborns.
2501167|NCT02893787||Patients treated with anthracyclines in childhood|
2501168|NCT02893787||Healthy volunteers|
2501205|NCT02893579|Experimental|Early Intervention|Stress reduction intervention 1 time a month
2501209|NCT02893579|Experimental|Delayed Intervention|Wait list Control
2501258|NCT02893254|Experimental|IBI303|IBI303 40mg administered subcutaneously every other week, 12cycles
2501267|NCT02893254|Active Comparator|Adalimumab|Adalimumab 40mg administered subcutaneously every other week
2501297|NCT02892929|Experimental|Motivational Interviewing|The motivational interview is a style of care that evokes the patient their motivations to make behavioral changes in the interests of their own health. It is a technique centered in patient to explore and resolve their ambivalence to modify unhealthy behavior.
2501301|NCT02892929|Active Comparator|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation. In this type of consultation the health professional who plans the action plan for the patient and determines how it will be the patient's lifestyle modification.
2501354|NCT02892591|Experimental|Cannabis|Medium dose THC, single administration, vaporized
2501356|NCT02892591|Active Comparator|Oxycodone|5-10 mg oxycodone hydrochloride, single administration, oral
2501358|NCT02892591|Placebo Comparator|Placebo|No active study drug
2501408|NCT02892149|Experimental|Vadadustat|
2501411|NCT02892149|Active Comparator|darbepoetin alfa|
2501666|NCT02890316|Experimental|Radiation therapy with Homeopathy|Patients in this arm will receive the homeopathy remedy during the adjuvant radiation therapy period, from treatment number 16 until the last assessment, 3 times every day.
2501669|NCT02890316|Placebo Comparator|Radiation therapy with placebo|Patients in this arm will receive the placebo remedy during the adjuvant radiation period, from treatment number 16 until the last assessment, 3 times every day.
2501816|NCT02889627|Experimental|FMT with microbiota suspension|Participants undergo repeated FMT with ~50ml microbiota suspension.
2501842|NCT02889081||infants from birth cohort with AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of suffering from atopic dermatitis
2501843|NCT02889081||infants from birth cohort without AD|maternal biological folate level and maternal biological vitamin D level and offspring's incidence of not suffering from atopic dermatitis
2501880|NCT02888860||Group 1|Patients with candidemia
2501882|NCT02888860||Group 2|Patients without colonization during follow up
2501887|NCT02888860||Group 3|Patients without colonization at admission, with subsequent colonization during hospitalization
2501891|NCT02888860||Group|Patients colonized at admission, and during the whole hospitalization
2501893|NCT02888860||Group 5|Patients who develop colonization during hospitalization and become negative at discharge
2501933|NCT02888366||1|Breath samples taken, no treatment given.
2501994|NCT02888210|Experimental|MD-15|Investigational intraocular lens
2502049|NCT02887508|Experimental|HINTS Intervention|The HINTS intervention consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills related to a specific topic relevant to online partner seeking and transmission risk reduction, including Internet safety and communication, condom negotiation, and serostatus disclosure.
2502050|NCT02887508|Active Comparator|Healthy Living Control|The Healthy Living Control condition consisted of an online four-session group intervention for 45 minutes, twice a week for two weeks. In each session, facilitators presented information, motivational skills, and behavioral skills to address non-sexual health-related topics particularly relevant to individuals living with HIV, such as nutrition, healthy eating, portion control, exercise and staying active, and stress reduction.
2502098|NCT02887326||age 15-25 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2502099|NCT02887326||age 25-35 years|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2502101|NCT02887326||age 35-45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2500904|NCT02895841|Experimental|SMART app wearable device|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
2500913|NCT02895542||Oral Anti-Cancer Agent|No intervention
2500989|NCT02895373|Experimental|Alprostadil|heparin (dose adjusted to aptt 50-60s) + Alprostadil (=PGE1) 5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
2500990|NCT02895373|Placebo Comparator|Placebo|heparin (dose adjusted to aptt 50-60s) + 0.9% sodium chloride infusion, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
2501080|NCT02894385|Experimental|Part 1 - Subjects with severe renal impairment|Subjects with severe renal impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
2501090|NCT02894385|Experimental|Part 1 - Subjects with moderate hepatic impairment|Subjects with moderate hepatic impairment received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
2501095|NCT02894385|Experimental|Part 1 - Healthy subjects|Healthy subjects received a single oral dose of darolutamide 600 mg (2 x 300 mg tablets).
2501127|NCT02894138|Experimental|Alteplase|40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel
2501128|NCT02894138|Placebo Comparator|Placebo|40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel
2501129|NCT02894138|No Intervention|Observational|10 patients with IMR <30 will undergo the same follow-up as the randomised patients
2501183|NCT02893982|Experimental|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
2501240|NCT02893436||Curarized patients|
2501344|NCT02892799|Active Comparator|Standard of Care|Patients randomized to the usual care arm will be treated almost the same as if they do not enroll in the study. They will be managed in accordance with best ICU (intensive care unit) practices, with treatment decisions made by the treating team. Often this will include blood draws (often 2 teaspoons once or twice per day, but sometimes exceeding this), assessments of cardiac function, assessments of fluid status, and other measures as dictated by the presenting illness (this is broad and will include antibiotics, diuretics, cardiac medications, ventilator and oxygen management, etc.). Patients in the usual care arm will not have diuresis managed by NICOM.
2501346|NCT02892799|Experimental|NICOM-Guided Diuresis|"Within 4 hours, patients will have their blood pressure obtained, a NICOM-based assessment of PLR (passive leg raise)-induced change in cardiac index, hourly urinary output, and quantization of the total input and output from the beginning of the morning shift (7 am). This will allow determination of the fluid goal over the next 4 hours. Patients will receive furosemide to achieve the goal fluid balance, if needed as described in the accompanying protocol. Monitoring of electrolytes and renal function will be at the discretion of the treating physician.~Following the initial evaluation, at set times spaced every 4 hours apart, patients will have an ongoing evaluation of the day's fluid balance, hourly urinary output, and PLR/NICOM values. This diuresis protocol will continue for a total of seven 24-hour periods or until the primary means of oxygenation/ventilation has been withdrawn, whichever occurs first. Patients will be followed for a total of 60 days to evaluate outcome data."
2501404|NCT02892201|Experimental|All subjects|"for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation~Pembrolizumab will be given at a constant dose of 200 mg every three weeks, for four cycles. Patients with resectable disease can then go on to surgery, and patients with unresectable disease can continue on pembrolizumab until progression or for up to 1 year."
3196012|NCT00846105|Experimental|Rapid PCR screen|Rapid PCR screen test for detection of MRSA carriers upon hospital admission
3196013|NCT00846105|Active Comparator|Conventional culture|Conventional culture screen for detection of MRSA carriers upon hospital admission
3196014|NCT00846118|Active Comparator|Pitavastatin|Pitavastatin in addition to optimal standard care
3196015|NCT00846118|No Intervention|optimal standard care|
3196016|NCT00846131|Active Comparator|A: Y-90 alone|Patients randomized to Arm A will proceed to Y-90 treatment alone in the Northwestern standard of care procedure
3196017|NCT00846131|Experimental|B: Sorafenib + Y-90|Patients randomized to Arm B will start sorafenib at a dose of 400 mg twice daily for bilirubin ≤ 1.5 x ULN and 200 mg twice daily for bilirubin > 1.5 x ULN to ≤ 3 x ULN. After 14 days of sorafenib therapy (+/- 3 days) patients will proceed to Y-90 in the Northwestern standard of care procedure
2501619|NCT02890823|Experimental|EIAEDs-3000|Patients receiving EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
3196018|NCT00846157|No Intervention|control|Rituximab 375mg/m2 IV administered on day 1. Cyclophosphamide 750mg/m2 IV for 2hours,Adriamycin 50mg/m2 ,Vincristine 1.4mg/m2 IV respectively. Prednisone 60mg P.O. per day for 5 days.
3196019|NCT00846157|Active Comparator|Active|R-CHOP plus Natural Killer Cell therapy
3196020|NCT00846170|Active Comparator|probiotics|patients with IBS that will receive investigational treatment for 4 weeks
3196021|NCT00846170|Placebo Comparator|Placebo|cross over of patients from arm 1
3196022|NCT00846183|Active Comparator|local ingury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed.
3196023|NCT00846183|No Intervention|control|in 60 patients routine IVF are performed
3196024|NCT00846196|Experimental|2|one commercial risedronate 35 mg DR tablet
3196025|NCT00846196|Active Comparator|1|one Phase III risedronate 35 mg DR tablet
3196026|NCT00846222|Experimental|Mild theraputic hypothermia|
3196027|NCT00846235|Experimental|Moisturising cream|
3196028|NCT00846248|Active Comparator|1|Chromium picolinate
3196029|NCT00846248|Placebo Comparator|2|2 sugar pills taken twice daily
3196030|NCT00846261|Experimental|Ilzarov|
3196031|NCT00846274|Active Comparator|Antithrombin III|
3196032|NCT00846274|Experimental|SK Antithrombin III|
2500912|NCT02895503|Active Comparator|Arm II (emotional support group therapy)|Patients undergo traditional medical treatment and participate in emotional support group therapy with a chaplain to work on mind-body therapies comprising guided imagery and spirituality once weekly for 12 weeks.
2500983|NCT02895386|Active Comparator|Treatment Group A|ROX Coupler implantation and continuing antihypertensive medications.
2500986|NCT02895386|Sham Comparator|Control Group B|Sham procedure and continuing current antihypertensive medications.
2501073|NCT02894788||ICU|patients postoperatively admitted to ICU
2501074|NCT02894788||no ICU|patients who didn't required ICU admission postoperatively
2501122|NCT02894372|Experimental|Subjects with oral spray 1|Research subjects, who got oral spray 1. Spray was used 3 times a day 3 sprays a time for seven days. Spray 1 was Faringomoss or simple oily oral spray (unknown because of double blind method).
2501123|NCT02894372|Experimental|Subjects with oral spray 2|Research subjects, who got oral spray 2. Spray was used 3 times a day 3 sprays a time for seven days. Spray 2 was Faringomoss or simple oily oral spray (unknown because of double blind method).
2501163|NCT02894008|Experimental|ChAd63- KH|Single intramuscular dose of ChAd63-KH, 1 x10(10)vp or, following safety review, 7.5 x 10(10)vp in adults
2501165|NCT02894008|Experimental|ChAd63-KH|Single intramuscular dose of ChAd63-KH, 1x10(10)vp or, following safety review, 7.5 x 10(10)vp in adolescents
2501178|NCT02893618|Experimental|DCCR 75 mg fasted|Administered a single 75 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2501179|NCT02893618|Experimental|DCCR 150 mg fasted|Administered a single 150 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2501184|NCT02893618|Experimental|DCCR 300 mg fasted|Administered a single 300 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2501189|NCT02893618|Experimental|DCCR 450 mg fasted|Administered a single 450 mg dose of DCCR after an overnight fast followed by 4 hours of fasting
2501194|NCT02893618|Experimental|DCCR 300 mg fed|Administered a single 300 mg dose of DCCR after a standardized meal
2501220|NCT02893319|No Intervention|Breastfeeding|control group
2501229|NCT02893319|Active Comparator|5 oz bottle|Subject will feed infant with 5oz medela bottle
2501241|NCT02893319|Active Comparator|8 oz bottle|Subject will feed infant with 8oz medela bottle
2501283|NCT02893085||patients with malignant biliary stricture|
2501291|NCT02893085||patients with benign biliary diseases|
2501329|NCT02892682|Other|Arm 1 AE-Bk|Arm of the recurring angiodeme medié by the bradykinine: blood test
2501335|NCT02892682|Other|Arm 2 AE-Mast|Superficial nettle rash group recurring angiodemes associated with superficial nettle rash: blood test
2501337|NCT02892682|Other|ARM 3 AEI|Arm recurring angiodemes isolate idiopathique not hostaminergique: blood test
2501338|NCT02892682|Other|ARM 4 US|Arm of superficial nettle rashes: blood test
2501387|NCT02892305||PAC with LVLM|Patients with pancreatic cancer and low-volume liver metastasis
2501432|NCT02891928|Experimental|with rocker sole|patient were wearing the rocker soles shoes during investigation
2501435|NCT02891928|Placebo Comparator|without rocker sole|patient were wearing normal shoes during investigation
2501494|NCT02891603|Experimental|Pacritinib with Sirolimus and Tacrolimus|"Pacritinib added to standard treatment with Sirolimus and Tacrolimus (PAC/SIR/TAC).~Pacritinib will begin the day of the participant's transplant (Day 0) and will continue until 70 days after the transplant.~Sirolimus will be given the day before transplant and continued daily for at least one year.~Tacrolimus will begin 3 days before transplant and will be given for at least 50 days."
3196033|NCT00846313|Active Comparator|Dietary counseling|Patients receive dietary advice at an individual level and are offered contact with clinical dietitian every second week if necessary.
3196034|NCT00846313|No Intervention|Control|
2501652|NCT02890420||Female children|Female children in third year of preschool in Thionville (north-eastern France)
2501655|NCT02890420||Male children|Male children in third year of preschool in Thionville (north-eastern France)
2501738|NCT02889757|Experimental|NAC 1200 mg|patients with add NAC (600) 1# bid use per day during the study period
2501739|NCT02889757|Experimental|NAC 2400 mg|patients with add NAC (600) 2# bid use per day during the study period
2501740|NCT02889757|Placebo Comparator|NAC 0 mg|patients with add NAC (600) 0# (placebo) use per day during the study period
2501790|NCT02889523|Experimental|DLBCL cohort|"RCHOP + tazemetostat:~- RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1): Phase I : 8 cycles, every 21 days Phase II : 6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, doses according to dose cohorts for phase I, and at RP2D for phase II: continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID"
2501791|NCT02889523|Experimental|FL cohort|"RCHOP + tazemetostat:~Induction~RCHOP: rituximab (IV, 375 mg/m², day 1), Prednisolone (PO, 40 mg/m² in the morning, day 1 to day 5), doxorubicine (IV, 50 mg/m², day 1), cyclophosphamide (IV, 750 mg/m², day 1), vincristine (IV, 1.4 mg/m², day 1):~6 cycles, every 21 days~Rituximab (IV, 375 mg/m², day 1) Phase II : 2 cycles, every 21 days~Tazemetostat: PO, RP2D, continuous: Cycle 1: 2 to 21 BID, Cycle 2-8: 1 to 21 BID~Maintenance~Tazemetostat : 6 months (every 8 weeks)~Rituximab : 24 months (every 8 weeks)"
2501901|NCT02888808||Erosive GERD|Gastroscopy examination.
2501906|NCT02888808||Control population|Gastroscopy examination.
3196035|NCT00846326|Experimental|Oxymetazoline-Fluticasone Propionate|Combination nasal spray with oxymetazoline 0.05% and fluticasone propionate 0.05%
3196036|NCT00846326|Placebo Comparator|Oxymetazoline-placebo|oxymetazoline 0.05% w/v and placebo fluticasone propionate
2502081|NCT02887430|Experimental|intervention|Participants will be received 8 sessions of foot reflexology therapy, 30 minutes each (2 sessions per week of 4 weeks) and low back pain standard care
2502085|NCT02887430|No Intervention|control|participants will be received standard care in general practice
2502248|NCT02886169|Experimental|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
2502525|NCT02884011||No chronic antihypertensives|not on either a chronic β-blocker or ACE-Inhibitor
3196037|NCT00846339|Experimental|1|DRD2 Taq1A1 allele
2500914|NCT02895659|Active Comparator|Ringer lactate|Fluid resuscitation will be performed with lactated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
2500916|NCT02895659|Active Comparator|Ringer acetate|Fluid resuscitation will be performed with acetated Ringers during the perioperative period. Perioperative hemodynamic management will be performed according to a specified treatment protocol.
2500980|NCT02895308|Experimental|Online|The Online psychoeducation is presented on on a webpage.
2500981|NCT02895308|Active Comparator|Face-to-face|The face-to-face psychoeducation is provided by psychologist and psychology master students.
2501029|NCT02894866|Experimental|hyperbaric oxygen|Newborns with hypoxic ischemic encephalopathy treated with intensive care and hyperbaric oxygen
2501034|NCT02894866|No Intervention|control|Newborns with hypoxic ischemic encephalopathy treated with intensive care only
2501098|NCT02894515|Experimental|Test/Reference|Single dose of commercial tablet Treatment A (Test) in period I. Followed by single dose of clinical tablet Treatment B (Reference) in period II. First and second dose administration will be separated by a washout period of at least 7 days
2501100|NCT02894515|Experimental|Reference/Test|Single dose of clinical tablet Treatment B (Reference) in period I. Followed by single dose of commercial tablet Treatment A (Test) in period II. First and second dose administration will be separated by a washout period of at least 7 days
2501201|NCT02893722|Experimental|atosiban|"Give drugs 30 minutes before the start of the embryo transfer. First step: give a 37.5 mg Atosiban (Ferring, Germany) to take 0.9 ml, that is, 6.75 mg, conduct intravenous injection in one minute.~Second step: for the remaining 4.1 ml, namely 30.75 mg, dilute to 41 ml, use the venous pump to adjust to 24 ml/h, infuse for 1 hour, namely 18 mg.~Third step: for the remaining 17 ml, use the venous pump to adjust to 8 ml/h, infuse 2.1 hours, namely 12.75 mg. Total administration time is 3 hours, total dose is 37.5 mg."
2501202|NCT02893722|Placebo Comparator|0.9% salain|intravenous injection of 0.9% saline in one minute before transfer. Then use the same dose of normal saline for intravenous infusion to set the same infusion rate with experimental group, complete the infusion in 3 hours.
3163065|NCT00475007|Sham Comparator|2|The sham comparator group will be tested, treated and followed in an identical manner as the experimental group, except that no valves will be placed during the diagnostic bronchoscopy, the sham procedure.
3163066|NCT00475059|Experimental|1|patients who received cimétidine
3163067|NCT00475072|Experimental|1|
2501322|NCT02892773|Other|Incentive Spirometry Group|"Participant will be asked to take 10 deep breaths through the mouthpiece of an incentive spirometer, followed by a 60 second pause.~This cycle will be repeated two more times.~A Respiratory Therapist will coach participants three times per day.~Each duration of Incentive Spirometry will last about 15 minutes."
2501325|NCT02892773|Active Comparator|EzPAP® Positive Airway Pressure Group|"Participant will be coached by a Respiratory Therapist to breathe through the mouthpiece of an EzPAP® device for 10 breaths, followed by a 60 second pause.~This cycle will be repeated two more times.~The Respiratory Therapist will coach participants three times per day.~Each duration of EzPAP® therapy will last about 15 minutes."
2501439|NCT02891811|Experimental|Induction Arm A|"Carfilzomib + Thalidomide + Dexamethasone (KTd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
2501443|NCT02891811|Active Comparator|Induction Arm B|"Carfilzomib + Lenalidomide + Dexamethasone (KRd) for 9 cycles (day 1-28) Followed by second randomisation: maintenance arm with carfilzomib monotherapy versus observation only arm"
2501502|NCT02891382|Experimental|Individual incentives - Arm 1|This arm receives diabetes education + goal setting + individual rewards
2501505|NCT02891382|Experimental|Mixed incentives (Altruism) - Arm 2|This arm receives diabetes education + goal setting + companion support + individual rewards
2501507|NCT02891382|Experimental|Mixed Incentives (Cooperation) - Arm 3|This arm receives diabetes education + goal setting + companion support + shared rewards
2501543|NCT02891018|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
2501545|NCT02891018|Experimental|paclitaxel release coronary balloon catheter|Patients treated with paclitaxel release coronary balloon catheter
2501580|NCT02890849|Experimental|a prospective, open, self-controlled phase I clinical study|The project is planned to explore the consistency analysis of PD-L1 expression level detected in cancer tissues and pExo.We have designed to detected the expression levels of PD-L1 mRNA and protein in cancer tissue and detected the expression levels of PD-L1 mRNA in pExo.by using variance analysis of repeated measures design information.
2501625|NCT02890654||Teenagers with scoliosis|"Patients will be evaluated at three times during the study :~First time measure : 1 month before the scoliosis surgery~Second time measure : 3 months after the scoliosis surgery~Third time measure : 1 year after the scoliosis surgery"
2501697|NCT02890082|Experimental|Tamoxifen stim in early follicular phase|Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
3163068|NCT00475098|Active Comparator|A|
3163069|NCT00475098|Experimental|B|
3163070|NCT00475111|Experimental|1|People in Group 1 will participate in CBT for Pain (CBT-P), which will focus on altering thought processes as a way to cope more effectively with pain.
3163071|NCT00475111|Experimental|2|People in Group 2 will participate in Mindfulness Medication for Emotion Regulation (MM-ER), a type of CBT that focuses on being more aware of one's emotions and regulating them.
3163072|NCT00475111|Experimental|3|Group 3 participants will serve as controls and receive educational information on the causes of, course of, and treatment for RA.
3163073|NCT00475124|Experimental|1|Home Monitoring ON
3163074|NCT00475124|Active Comparator|2|Home Monitoring OFF
3163075|NCT00475137|Experimental|Lamotrigine Plus Antidepressant|Subjects will be randomized to one of two study arms at baseline. Those in the first treatment arm will be prescribed lamotrigine in addition to the antidepressant medication they were prescribed prior to study entry.
3173597|NCT00613769|Active Comparator|ordinary per operative prophylaxis|cefuroxime(1500mg) i.v.+ metronidazole (1500mg)i.v.given at the time point of induction of anesthesia
3173598|NCT00613769|Experimental|Per oral alternative|Trimethoprim-sulfamethoxazole(160mg/800mg)p.o.+metronidazole (1200mg)p.o.given 06.00 am on the day of operation
3173599|NCT00613782|Active Comparator|1|Reandron 100 treatment
2500960|NCT02895685|No Intervention|Control group: individually training|If randomized to train individually, participants will be instructed to do all the training individually. Participants will be instructed not to practice with others when practising at home and will only receive feedback from the expert during the expert-guided self-training. At the training at CAMES, participants will sit at separate tables.
2501022|NCT02895074|Experimental|femtosecond laser-assisted cataract surgery group|
2501031|NCT02895074|Experimental|conventional phacoemulsification surgery group|
2501078|NCT02894541|Experimental|CKD-519 tablet 100mg|CKD-519 tablet(formulation Ⅱ) 100mg(100mg X 1Tab) Period 1: CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
2501082|NCT02894541|Experimental|CKD-519 tablet 200mg|CKD-519 tablet(formulation Ⅱ) 200mg(100mg X 2Tabs) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
2501089|NCT02894541|Experimental|CKD-519 soft capsule 100mg|CKD-519 soft capsule(formulation Ⅲ) 100mg(100mg X 1Cap) Period 1:CKD-519 100mg in fasted state Period 2:CKD-519 100mg with a standard meal Period 3:CKD-519 100mg with a high fat meal
2501096|NCT02894541|Experimental|CKD-519 soft capsule 200mg|CKD-519 soft capsule(formulation Ⅲ) 200mg(100mg X 2Caps) Period 1:CKD-519 200mg in fasted state Period 2:CKD-519 200mg with a standard meal Period 3:CKD-519 200mg with a high fat meal
2501196|NCT02893956|Experimental|echocardiography with postural support then standard condition|the first echocardiography (ultrasound) is performed with a postural support then the second echocardiography is performed with standard condition
2501200|NCT02893956|Active Comparator|echocardiography with standard condition then support postural|the first echocardiography (ultrasounds) is performed with standard condition (usual) and the second echocardiography is performed with a postural support
2501289|NCT02893072|Experimental|Individualized medical nutrition therapy|A comparison of normal lifestyle and medical nutrition therapy after intervention in the same individual
2501367|NCT02892266||Adolescent Transplant Recipients|"Questionnaire battery at enrollment (Participants and their parents/guardians)~Clinical data from patient's chart (6 months of retrospective data & 6 months of prospective tacrolimus trough level data)"
2501423|NCT02892045||MMG versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus Mechanomyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg.
2501426|NCT02892045||TOFWatch versus Mindray NMT|24 patients where Mindray NMT is monitoring one hand versus TOF-Watch Acceleromyograph on the other hand accessible in supine position, alternately right and left hands monitoring neuromuscular block of rocuronium neuromuscular blocking agent 0.6 mg/kg
2501488|NCT02891694||recurrent corneal erosion|
2501493|NCT02891694||control patients (refractive surgery)|
2501537|NCT02891226|Experimental|Mirikizumab Dose Level 1|"Period 1 (Weeks 0 -12) Mirikizumab dose level 1~Period 2 (Weeks 12 - 52) Mirikizumab dose level 1 or dose level 4 or dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2501538|NCT02891226|Experimental|Mirikizumab Dose Level 2|"Period 1 (Weeks 0 -12) Mirikizumab dose level 2~Period 2 (Weeks 12 - 52) Mirikizumab dose level 2 or dose level 4 or dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2501541|NCT02891226|Experimental|Mirikizumab Dose Level 3|"Period 1 (Weeks 0 -12) Mirikizumab dose level 3~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3 or dose level 4~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
2501542|NCT02891226|Placebo Comparator|Placebo|"Period 1 (Weeks 0 -12) Placebo~Period 2 (Weeks 12 - 52) Mirikizumab dose level 3~Period 3 (Weeks 52 - 104) Mirikizumab dose level 4"
3196038|NCT00846339|Experimental|2|DRD Taq1 A2 homozygote2
2501829|NCT02889601||Fronto-temporal lobar degeneration|DAPHNE score building and internal validation through Fronto-temporal lobar degeneration patients.
2501833|NCT02889601||Control|External validation of DAPHNE score among patients with Alzheimer's disease, progressive supranuclear palsy and bipolar disorder with cognitive disorders.
2501875|NCT02889003|Experimental|CML patients following molecular response loss|
2501923|NCT02888600|Active Comparator|Mindfulness Training|The Mindfulness Meditation Program consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily mindfulness meditation homework.
2501926|NCT02888600|Active Comparator|Health Education|The Health Education Program also consists of eight weekly 2- 2.5 hour group sessions, a day-long retreat in the sixth week, and daily health practice homework
2501997|NCT02888119|Active Comparator|High Risk for Osteoarthritis|"High risk of developing knee OA has been defined by having knee pain but normal radiographs (Kellgren-Lawrence score 0 i.e. KL0) on both knees but at least one abnormal finding on clinical MR protocol such as overweight, prior knee injury (ligaments or menisci) or traumatic bone marrow edema lesions."
2502001|NCT02888119|Active Comparator|Mild Osteoarthritis|
2502002|NCT02888119|Active Comparator|Healthy Controls|Controls will be age/gender matched to patients within 2 years of age.
2502048|NCT02887768|Experimental|Treatment|Epicardial Infarct Repair with CorMatrix-ECM in addition to coronary artery bypass grafting
2502088|NCT02887365|Experimental|tegafur-uracil|tegafur-uracil treatment in patients with stage II MSI-L or MSS colon cancer
2502090|NCT02887365|No Intervention|Observation|Observation for one year
2502121|NCT02887040|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
2502250|NCT02886169|Placebo Comparator|unsupplemented group|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
2502527|NCT02884011||β-blocker|on chronic β-blocker
2502529|NCT02884011||ACE-Inhibitor|on chronic ACE-Inhibitor
3196039|NCT00846352|Active Comparator|Early Bronch|This group will receive bronchoscopy within 36 hours of enrollment into the study.
3196040|NCT00846352|Active Comparator|Late bronch|This group will receive bronchoscopy within 5 days of enrollment.
2501010|NCT02894931|Sham Comparator|Control|Dietary Interventions: Control- water, Flavered Chilled water, will be administered once after O.N fasting.
2501015|NCT02894931|Active Comparator|Glucose|Dietary Interventions: Glucose, Monosaccharides, at the dose of 50 g, based on oral loading tests, once.
2501016|NCT02894931|Experimental|Fructose|Dietary Interventions: Fructose, Monosaccharides, at the dose of 50 g, once.
2501020|NCT02894931|Experimental|Galactose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
2501025|NCT02894931|Experimental|Mannose|Dietary Interventions: Monosaccharides, at the dose of 50 g, once.
2501032|NCT02894931|Experimental|Maltose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2501037|NCT02894931|Experimental|Sucrose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2501040|NCT02894931|Experimental|Lactose|Dietary Interventions: The dose of the disaccharides - 50 g, once.
2501041|NCT02894931|Experimental|Saccharin|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2501044|NCT02894931|Experimental|Aspartame|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2501045|NCT02894931|Experimental|Sucralose|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2501047|NCT02894931|Experimental|Steviol|Dietary Interventions: The dose of the different artificial sweeteners - 300 mg, is based on an average adult male body weight of 75 kg and is set not to exceed the acceptable daily intakes of saccharin, aspartame, sucralose and steviol that were reported at 15, 50, 5, and 4 mg/kg body weight/day by the USA Food and Drug Administration, once.
2501050|NCT02894931|Experimental|Leucine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2501054|NCT02894931|Experimental|Isoleucine|Dietary Interventions: The dose of the different BCAAs Amino acids - 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2501057|NCT02894931|Experimental|Valine|Dietary Interventions: The dose of the different BCAAs Amino acids- 5 g, is set not to exceed the mean daily intakes of leucine, isoleucine and valine for adult males that were reported at 8.64, 5.01 and 5.63 g/day, respectively, once.
2501149|NCT02894242|Experimental|F&P Deimos Nasal Pillows Mask|Participants to use nasal pillows mask in-home for 2 weeks.
2501191|NCT02893800|Other|Himatic locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
2501197|NCT02893800|Other|ReSOS locating system|Locating system watch with GPS-technology (free available) Main functions: telephone function and location upon request via smartphone
2501251|NCT02893384|Experimental|Local Anesthetic Injection|"The intervention involves injection of local anesthetic (0.25% bupivacaine with 1:200,000 epinephrine) under direct vision in the serratus anterior muscle plane at the end of surgery.~Local Anesthetic Injection above the serratus anterior"
2501264|NCT02893384|No Intervention|Control Arm|Retrospective control group who have not had the new injection technique.
2501328|NCT02892786|Experimental|experimental|
2501431|NCT02891980|Experimental|Group 2|MVA-BN®-Filo Day 1, Ad26.ZEBOV Day 29 and MVA-BN®-Filo Day 366
2501433|NCT02891980|Experimental|Group 3|Ad26.ZEBOV Day 1, MVA-BN®-Filo Day 29 and MVA-BN®-Filo Day 366
2501436|NCT02891980|Experimental|Group 4|Ad26.ZEBOV Day 1, Ad26.ZEBOV Day 29
2501438|NCT02891980|Experimental|Group1|MVA-BN®-Filo Day 1 and MVA-BN®-Filo Day 29
3173600|NCT00613782|Placebo Comparator|2|Placebo
3173601|NCT00613795|Active Comparator|1|Lactobacillus
2501563|NCT02891213||LE (Lupus Erythematosus) group|"Samples of the LE (Lupus Erythematosus) group from a specimen collection : Lupus BioBanque du Rhin Supérieur (LBBR UF 9882).~It's a historical cohort of lupic patients which samples have been collected from many centers in France and Germany and stored in a biobank Lupus BioBanque du Rhin Supérieur (project : LBBR UF 9882)."
2501585|NCT02890758|Experimental|Cytokine Arm|Two infusions of Natural Killer (NK) cells and ALT803
2501586|NCT02890758|Active Comparator|No Cytokine Arm|Two infusions of Natural Killer (NK) Cells
2501677|NCT02890108|Experimental|Sugar sweetened beverages|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a sugar sweetened beverage, that contain 38,7 grams of carbs and 154 kcal, separated by at least 1 week each one
2501682|NCT02890108|Experimental|Artificially sweetened beverage|Subjects will receive, in 3 different ocassions, 350cc (1 can) of a artificially sweetened beverage, that contain 84 mg of Aspartame, 56 mg of Acesulfame K and 0,7 kcal, separated by at least 1 week each one
2501734|NCT02889874|No Intervention|A: Radiation Therapy & endocrine therapy|Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care).
2501741|NCT02889926|Experimental|a swab according to the method of Levine|
3173602|NCT00613795|Placebo Comparator|2|placebo
3173603|NCT00613808|No Intervention|A - Standard of Care (control)|Standard of care - dressings and sustained compression only for the two week screening period and then for 20 weeks thereafter
2501018|NCT02895217|Experimental|Cycling exercise in water|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
2501023|NCT02895217|Experimental|cycling exercise on dryland|The aim of this project is to investigate energetic response (energy expenditure and food intake) of a single bout of cycling exercise in water vs on dryland in normal weight and overweight premenopausal women.
2501118|NCT02894645|Other|Standard Risk (SR)|
2501119|NCT02894645|Other|Intermediate Risk (IR)|
2501120|NCT02894645|Other|High risk (HR)|
2501199|NCT02893670|Other|Tailored re-evaluation|"Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation:~Following enrollment each patient will undergo a structured re-evaluation and transition process which will include radiologic intervention (MRE) for Crohn's patients and endoscopic intervention (sigmoidoscopy) for UC patients"
2501278|NCT02893124|Experimental|PEG-IFN group|HBeAg-negative CHB patients with HBsAg <1000 IU/ mL and HBV DNA<100 IU/mL are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for at most 96 weeks.
2501281|NCT02893124|No Intervention|NAs group|CHB patients do not need to change their NAs treatment.
2501388|NCT02892318|Experimental|Cohort A1: Safety Cohort (Relapsed/refractory AML)|An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2501391|NCT02892318|Experimental|Cohort A2: Expansion Cohort (Relapsed/refractory AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2501392|NCT02892318|Experimental|Cohort A3: Safety Cohort (Previously Untreated AML)|If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2501394|NCT02892318|Experimental|Cohort A4: Expansion Cohort (Previously Untreated AML)|If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.
2501449|NCT02891785|Experimental|ANtiPain intervention|ANtiPain is a cancer pain self-management support intervention administered by nurses in an intervention session while the patient is still hospitalized and via phone calls after discharge. ANtiPain is based on three key strategies: information, skill building and nurse coaching.
2501451|NCT02891785|No Intervention|standard care|Standard care will be described as part of the study.
2501495|NCT02891499|Experimental|LLLT + immediate force|Use of Low-level laser therapy and not mediate orthodontic force application (150 gF the day of the implantation).
2501496|NCT02891499|Experimental|LLLT + mediate force|Use of Low-level laser therapy and mediate orthodontic force application (150 gF 4 weeks after the day of the implantation).
2501498|NCT02891499|No Intervention|Immediate force application|Not mediate orthodontic force application (150 gF the day of the implantation), without use of Low-level laser therapy.
2501503|NCT02891499|Experimental|Mediate force application|Mediate orthodontic force application (150 gF 4 weeks after the day of the implantation), without use of Low-level laser therapy.
2501521|NCT02891109||patients group|Adults patients with chronic immune thrombocytopenia
2501526|NCT02891109||control group|Adults without immune thrombocytopenia
2501568|NCT02890953|Placebo Comparator|Control|Control group receives placebo medication (normal saline)
2501569|NCT02890953|Experimental|MSC group|MSC group receives mesenchymal stem cells transplantation (Pneumostem)
2501633|NCT02890563|Active Comparator|Compression|Patients in this group will use compression stockings for seven days after treatment (2 days continuously and 5 days during daytime).
2501644|NCT02890628||SMRU health staff of antenatal clinics (ANC)|1 Focus group discussion of 6-10 Shoklo Malaria Research Unit antenatal clinic staff
3175096|NCT00630045|Experimental|1|2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
2501075|NCT02894749|No Intervention|2D Angiography (2DA)|Standard of care - Patients benefit from a 2D completion angiogram at the end of the procedure, and from a angioCT-scan before discharge. If any technical issues is depicted on the CT-scan, a new intervention needs to be scheduled.
2501076|NCT02894749|Experimental|3D rotational angiography (3DRA)|New strategy - Patients benefit from a 3D rotational acquisition at the end of procedure, which offers CT-like reconstructions. If any technical issues is depicted on the 3DRA, it can be treated during the same operating time. A contrast-enhanced ultrasound is performed for each patient before discharge to confirm that no technical issue was missed by the 3DRA.
2501161|NCT02894333||Patients with Parkinson's disease|
2501221|NCT02893449|Other|SICRPPD group|(Specific Individual Cognitive Remediation Program in Parkinson's Disease). Group of patients profiting from a structured program of preoperative cognitive remediation
2501233|NCT02893449|Other|ICM group: Intensive Care Management|Group of patients profiting from a preoperative non structured support
2501239|NCT02893449|Other|CG group: Control Group|No supplementary support
2501304|NCT02892838|Experimental|mobile bearing knee prosthesis|use of the Scorpio mobile bearing knee system for total knee arthroplasty
2501307|NCT02892838|Active Comparator|fixed bearing|use of the Scorpio fixed bearing knee system for total knee arthoplasty
2501330|NCT02892565|Experimental|Cases|Patients with SLE and/or APL and first vein thrombosis episode
2501334|NCT02892565|Other|Controls|age-matched; Patients with SLE and/or APL
2501360|NCT02892370|Experimental|SHR0302 fasted to fed|SHR0302 tablets (10 mg) administered on day 1 fasting, and day 7 with high fat, high calorie breakfast
2501361|NCT02892370|Experimental|SHR0302 fed to fasted|SHR0302 tablets (10 mg) administered on day 1 with high fat, high calorie breakfast, and day 7 fasting
2501405|NCT02892162|Experimental|With additional LAAW linear ablation|Patients who undergo CPVI+LA roof linear ablation+/ MI linear ablation, and additional LAAW linear ablation using ThermoCool SmartTouch catheter.
2501406|NCT02892162|Active Comparator|Without additional LAAW linear ablation|Patients who undergo CPVI+LA roof +/ MI linear ablation using ThermoCool SmartTouch catheter, without LAAW linear ablation.
2501442|NCT02891824|Placebo Comparator|Arm A: Placebo + Avastin + platinum-based chemotherapy|"The placebo arm:~Placebo 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by placebo 1200mg q3wk until progression"
2501445|NCT02891824|Experimental|Arm B: Atezolizumab + Avastin+ platinum-based chemotherapy|"The atezolizumab arm:~Atezolizumab 1200 mg x 6 cycles q3wk or 800mg x 6 cycles q4wk during treatment with chemotherapy and Avastin, followed by atezolizumab 1200mg q3wk until progression~."
2501535|NCT02891278|Experimental|Sertraline with cytosine arabinoside|"All subjects will receive the following:~Induction phase~Sertraline, twice daily at one of the pre-defined dose levels~Cytosine arabinoside, on days 1 and 10~Consolidation phase~Patients who achieve complete remission (CR) or complete remission with incomplete count recovery (CRi) and are eligible for allogeneic stem cell transplantation will receive one of the following:~Allogeneic SCT and off study~Repeat cycle of oral sertraline and cytosine arabinoside IV infusion~Maintenance phase with sertraline for cycles of 28 days in length"
2501587|NCT02890810|Experimental|Verum Electroacupuncture|Active Intervention
2501588|NCT02890810|Placebo Comparator|Placebo Electroacupuncture|Validated Control
2501641|NCT02890472||prenatal diagnosis of a fetal 22q11 deletion syndrome|
2501670|NCT02890277|Experimental|Treatment group|
2501715|NCT02889978||Cancer arm|Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.
2501717|NCT02889978||Non-cancer arm|Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.
2501849|NCT02889016||PANS group|500 children, 1-18 years old at onset with a strict diagnosis of PANS/PANDAS will be recruited
2501850|NCT02889016||Health Controls|100 healthy children age- and gender- matched to the PANS group will be recruited
2501890|NCT02888834||Adverse drug reaction|Patients aged over 65 years who presented a serious adverse drug reaction notified to the Regional Pharmacovigilance Center of Champagne-Ardenne between January and May 2013 were included in the study.
2501945|NCT02888548|Experimental|Arm cross over 1|botulinum toxins alone then botulinum toxins + orthos
2501948|NCT02888548|Experimental|Arm cross over 2|botulinum toxins + orthosis then botulinum toxins alone
2502117|NCT02887118||Common arm|Children with sickle cell anemia will be included. Blood samples of all the included patients will be collected during a day-hospitalization for a planned chek-up. For all these patients the number of dense erythrocytes will be evaluated
2502148|NCT02886858|Experimental|tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
2502150|NCT02886858|Sham Comparator|Sham tDCS|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
2502185|NCT02886572|Experimental|Stereotactic Radiosurgery|All subjects will receive stereotactic radiosurgery(SRS) following the RTOG Stereotactic Radiotherapy Guidelines available at http://dx.doi.org/10.1016/j.prro.2011.06.014
3175097|NCT00630045|Active Comparator|2|no neoadjuvant chemotherapy, resect the liver metastasis directly
2502279|NCT02885896||Experimental period (active platform)|During the experimental period, the eligible calls will be transferred to the platform by SAMU regulator doctors, and callers will be subject to health advice by specially trained nurses. The nurse conduct the call by holding the conversation guide, giving advice for a home care, answering questions from the circle (caller, family,..) and ensuring the proper understanding of these tips. An information leaflet for the theme of the call will be sent in the days following the call to the caller of the experimental group having given their consent.
3175098|NCT00630084|Active Comparator|A|40 naïve CHC patients concomitant with malignancy other than hepatocellular carcinoma
3175099|NCT00630084|Active Comparator|B|80 naïve CHC patients without malignancy
3175100|NCT00630110|Active Comparator|docetaxel|docetaxel (75 mg/m2)
2501104|NCT02894567|Experimental|spiderSTN|It is an Intraoperative test during a deep brain stimulation surgery. The spiderSTN lead is implanted in a selected track in the brain, and is tested for stimulation and recording.
2501162|NCT02894203|Experimental|Mindfulness|
2501164|NCT02894203|Active Comparator|Hatha Yoga|
2501166|NCT02894203|No Intervention|Wait-list|
2501219|NCT02893189|Experimental|4G7-CARD T-cells|All patient will receive modified CAR19 T-cells.
2501277|NCT02893111|Experimental|Bortezomib (Velcade)|A proteasome inhibitor
3196041|NCT00846378|Experimental|Post conditioning|After 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. The balloon should be inflated to only occlude the coronary artery. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
3196042|NCT00846378|Active Comparator|Usual Care|Usual care for treatment of thrombolysis in myocardial infarction (TIMI) 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
3196043|NCT00846404||Case|Patients with Diastolic Dysfunction
2501510|NCT02891343|Experimental|Healthy volunteers|
2501550|NCT02891031|Active Comparator|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
2501552|NCT02891031|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
2501651|NCT02890784|Active Comparator|A. Standard arm|100mg dasatinib (SPRYCEL®) daily dose (QD) (7x100) (Standard therapy)
2501654|NCT02890784|Experimental|B. Study arm|100mg dasatinib (SPRYCEL®) (QD) weekdays (1-5) only (5x100+2x0) (overall dose reduction per week)
2501759|NCT02890017|Experimental|Hotel-Ambu|Outpatient surgery with a patient-hotel night
2501772|NCT02890017|Other|conventional hospitalization|conventional hospitalization
2501876|NCT02889068||Intellectual disability|
2501944|NCT02888678|Experimental|ES + HIV Prevention|"Economic Strengthening + HIV prevention education combined intervention consists of 2 parts.~Impumelelo: This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.~Vhutshilo 2.2: . This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy."
2501949|NCT02888678|Experimental|ES only|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
2501951|NCT02888678|Experimental|HIV only|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
2501954|NCT02888678|No Intervention|No intervention (control)|The control group will not receive the ES or HIV prevention interventions. They will receive the basic package of services available to all beneficiaries of Future Families.
2502015|NCT02888041|Experimental|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
2502017|NCT02888041|Active Comparator|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
2502068|NCT02887586|Experimental|Auricular Needling group|Patients will receive auricular needling for 4 weeks .
2502071|NCT02887586|No Intervention|control group|This group will receive no treatment. Subjects will be assessed at baseline and the 2th, 4th and 8th week.
2502120|NCT02887209|Experimental|CBT-I|This is a single arm study in which all participants receive the intervention (cognitive behavioural therapy for insomnia)
2502154|NCT02886845||Chinese Breast Cancers|Woman with breast cancer that have been diagnosed in clinic
2502156|NCT02886845||healthy controls|Woman without breast cancer
3196044|NCT00846404||Control|Patients without Diastolic Dysfunction
2502304|NCT02885597|Experimental|Juanbi group|participants should administrate both Juanbi pill and Methotrexate
2502308|NCT02885597|Placebo Comparator|placebo group|participants should administrate both Juanbi pill placebo and Methotrexate
2502328|NCT02885168|Experimental|Shock + Treatment|Patients treated with activated protein C
2502330|NCT02885168|Other|Shock|Patients not treated with activated protein C
2502405|NCT02884921|Active Comparator|Preemptive Paracetamol|Preemptive Paracetamol
2502406|NCT02884921|Active Comparator|Post surgery Paracetamol|Post surgery Paracetamol
2502407|NCT02884921|Placebo Comparator|Placebo|Placebo
2502416|NCT02884583|Experimental|Pulmonary function test|Patients hospitalized for Oral Food Challenge realize pulmonary function test
2502438|NCT02884440|Experimental|TAP block ropivacaine|Bilateral ultrasound guided with 15 ml ropivacaine 5mg/ml on each side under general anesthesia at the end of the intervention
2502445|NCT02884440|Placebo Comparator|TAP block placebo|Bilateral ultrasound guided with 15 ml saline on each side under general anesthesia at the end of the intervention
2502505|NCT02884076||Symptomatic Hemorrhoid|Consecutive patients with symptomatic hemorrhoids presenting to our clinic
2502533|NCT02883699|Active Comparator|Endurance Training Group 1|Standard endurance training
2502535|NCT02883699|Experimental|Endurance Training Group 2|Polarized endurance training
2502537|NCT02883699|Active Comparator|Resistance Training Group 1|Standard resistance training
2502539|NCT02883699|Experimental|Resistance Training Group 2|Daily undulating periodization resistance training
2502615|NCT02883296|Experimental|Patients with perianal fistulizing Crohn's disease|
2503855|NCT02874079|Experimental|bullous pemphigoid|patients with bullous pemphigoid
2501137|NCT02894112|Experimental|High fat tolerance test|single high fat load determined by body weight.
2501208|NCT02893826|Experimental|EG-1962 Group|1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
2501212|NCT02893826|Active Comparator|Enteral Nimodipine Group|Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)
2501246|NCT02893176|Placebo Comparator|Placebo|10mg will be administered one time daily
2501255|NCT02893176|Active Comparator|Active|10mg macitentan will be administered one time daily
2501288|NCT02892981|Other|Pulmonary hypertension patients|All Pulmonary hypertension patients enrolled in the study underwent a cardiopulmonary exercise test and hypoxia and hypercapnia tests
3163076|NCT00475137|Active Comparator|2. Lamotrigine Monotherapy|Subjects in the second treatment arm will discontinue their antidepressants and will be prescribed lamotrigine monotherapy. Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily.
2501401|NCT02892253|Experimental|NIR+ group|"Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND).~Parathyroid identification was done with the use of NIR (intervention group, NIR+ group)"
2501402|NCT02892253|No Intervention|NIR- group|Patients who undergo conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only (no intervention group, NIR- group)
2501551|NCT02891083|Experimental|Adjuvant chemotherapy group|Surgery followed by adjuvant chemotherapy,with Paclitaxel and Cisplatin.
2501553|NCT02891083|Experimental|Adjuvant radiotherapy group|Surgery followed by 50Gy adjuvant radiotherapy
2501554|NCT02891083|Other|Control group|Surgery alone
2501612|NCT02890680|Experimental|Platelet-rich fibrin group|Use platelet-rich fibrin after mandibular third molar extraction
2501615|NCT02890680|Placebo Comparator|Control group|mandibular third molar extraction
3163077|NCT00475189|Active Comparator|1|
3163078|NCT00475189|Active Comparator|II|loestrin 1/20 given 1 tab 21/7
3163079|NCT00475280|Other|Geriatric assessment|
3163080|NCT00475293|Experimental|1|
3163081|NCT00475371|Experimental|1|MKC253 Inhalation Powder
3163082|NCT00475410|Experimental|ASCs|
3163083|NCT00475410|Experimental|ASCs+fibrin glue|
2501898|NCT02888782|Experimental|Pharmacist Consultation|Meet with pharmacist for consultation in addition to regular physician follow up
2501904|NCT02888782|No Intervention|Control|Receive regular physician follow up
2502000|NCT02888067|Active Comparator|Moderate neuromuscular blockade (MNB)|"The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
2502005|NCT02888067|Active Comparator|Deep neuromuscular blockade (MNB)|"The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent)."
2502042|NCT02887664||Blood test in Mothers of SGA Infants|In mothers of Small for Gestational Age (SGA) Infants, maternal and cord blood test will be performed
2502043|NCT02887664||Blood test in Mothers of AGA infants|In mothers of Appropriate for Gestational Age (AGA) Infants, maternal and cord blood test will be performed
2502078|NCT02887417||patients|glioblastoma patients
2502080|NCT02887417||controls|healthy controls
2502152|NCT02886962|Experimental|No anticoagulation|No oral anticoagulation, and no monitoring of the INR.
2502153|NCT02886962|Active Comparator|Oral anticoagulation with vitamin K antagonists|"VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.~Antiplatelet therapy will be provided only if recent acute coronary syndrome (< 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population."
2502280|NCT02885896||Control period (inactive platform)|During the control periods, the call center will not be active, eligible calls can not receive advice from nurses, but will be subject to the usual care: the regulator doctor will treat the call as its current practice.
2502325|NCT02885402|Experimental|Osteoarthritis patient|
3163084|NCT00475410|Active Comparator|Fibrin glue|
3163085|NCT00475436|Experimental|Arm 1|
3163086|NCT00475475|Experimental|1|Fructose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% fructose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3163087|NCT00475475|Experimental|2|Glucose-sweetened beverage Subjects will be asked to drink 4 servings of a beverage sweetened with 100% glucose per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3163088|NCT00475475|Placebo Comparator|3|Beverage sweetened with a non-caloric sweetener Subjects will be asked to drink 4 servings of a beverage sweetened with a non-caloric sweetener per day for 8 days, while consuming an ad libitum diet (same solid food for all three diet periods).
3163089|NCT00475488|Other|Group 1|Radial Artery versus Right Internal Thoracic Artery when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
3163090|NCT00475488|Other|Group 2|Radial Artery versus Saphenous Vein when used as a coronary conduit in patients undergoing multi-vessel coronary artery bypass grafting.
3163091|NCT00475527|No Intervention|iron only|Only iron therapy
3163092|NCT00475527|Experimental|iron + HP therapy|Iron + 'omeprazole,clarithromycin,amoxicillin (or metronidazole)
2501158|NCT02894320||Healthy subjects|gender and age matched with Parkinson's disease patients, whose data will be extracted from an existing database
2501262|NCT02893488|Experimental|SEQUENCE ABCDE|Participants will receive treatment A in period 1, treatment B in period 2, treatment C in period 3, treatment D in period 4 and treatment E in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with zero mineral content (ZMC) water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 milliliter (mL) stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 minutes(mins), re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2501268|NCT02893488|Experimental|SEQUENCE BCDEA|Participants will receive treatment B in period 1, treatment C in period 2, treatment D in period 3, treatment E in period 4 and treatment A in period 5 (one treatment per period). Where A= EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2501271|NCT02893488|Experimental|SEQUENCE CDEAB|Participants will receive treatment C in period 1, treatment D in period 2, treatment E in period 3, treatment A in period 4 and treatment B in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2501273|NCT02893488|Experimental|SEQUENCE DEABC|Participants will receive treatment D in period 1, treatment E in period 2, treatment A in period 3, treatment B in period 4 and treatment C in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2501275|NCT02893488|Experimental|SEQUENCE EABCD|Participants will receive treatment E in period 1, treatment A in period 2, treatment B in period 3, treatment C in period 4 and treatment D in period 5 (one treatment per period). Where A=EPZICOM (ABC 600 milligrams (mg)/3TC 300 mg) plus four TIVICAY (DTG 10 mg) tablets with ZMC water. B=Four TRIUMEQ (ABC 150mg/DTG 10 mg/3TC 75 mg) tablets dispersed in 40 mL stock solution 1 and consumed immediately. C=Four TRIUMEQ tablets dispersed in 40 mL stock solution 1, held for 30 mins, re-dispersed, and then consumed. D=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2 and consumed immediately. E=Four TRIUMEQ tablets dispersed in 40 mL stock solution 2, held for 30 mins, re-dispersed, and then consumed.
2501321|NCT02892669||patients admitted to the intensive care department|
2501374|NCT02892474||Hybrid Coronary Revascularization (HCR)|Patients who are scheduled to have the hybrid coronary revascularization (HCR) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
2501375|NCT02892474||Coronary Artery Bypass Grafting (CABG)|Patients who are scheduled to have the coronary artery bypass grafting (CABG) procedure for treatment of multi-vessel coronary artery disease. The treatment plan is determined by the patient's doctor.
2501420|NCT02892032|Experimental|Attention Modification Training|ABMT is a newly emerging intervention that trains patients to override their tendency to focus on threatening aspects of an event and to interpret events as more neutral and therefore less stressful
2501424|NCT02892032|Placebo Comparator|No Attention Modification Training|There is no disengagement of attention from a target stimulus. Attention is divided equally between two stimuli on the screen.
3196045|NCT00846417||Case|Patients with ICDs who attend the ICD Support Groups.
3196046|NCT00846417||Control|Patients with ICDs who do not attend the ICD support groups.
2501508|NCT02891395|Experimental|open-label|"Induction phase: Imatinib mesylate - starting with 100 mg/day with increase of 100 mg/day each other week up to maximum tolerable dose or 400 mg/day whichever occurred first. For the responders and in absence of toxicity, the treatment will be maintained up to one year.~Salvage phase:~Nilotinib - starting with 200 mg/day with increase of 200 mg/day each other week up to maximum tolerable dose or 800 mg/day whichever occurred first. In absence of toxicity, the treatment will be maintained up to one year."
2501562|NCT02891005|Experimental|paclitaxel controlled release balloon catheter|Patients treated with paclitaxel controlled release balloon catheter
2501565|NCT02891005|Experimental|common balloon catheter|Patients treated with common balloon catheter
2501613|NCT02890706|Other|Patients|Each patient undergo the same CT protocol. Theobservers will observe the detection of the perfusion defects in two different techniques.
3196047|NCT00846430|Experimental|Open-Label Intervention|This is a phase II single arm study with sequential treatments available by response where all participants begin therapy with a combination of celecoxib and interferon alpha-2b (CI, treatment-1). Response to CI therapy will be assessed at six months by clinical and radiographic evaluations. Those patients who have achieved a partial response (improvement in pain, improvement in functioning, or ≥50% reduction in tumor size) or complete response (resolution of pain, and normalization of functioning with a ≥ 90% reduction in tumor size) will continue with the same CI therapy for up-to two years on study.
3196048|NCT00846443|Experimental|1|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
3163093|NCT00475540|Active Comparator|Prolift mesh|vaginal prolapse repair with mesh
2501600|NCT02890485|Experimental|Glute Dry Needling|Receives dry needling to their gluteal muscles in addition to standard physical therapy treatment.
2501601|NCT02890485|Experimental|Quad Dry Needling|Receives dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
2501602|NCT02890485|Sham Comparator|Glute Sham Dry Needling|Receives sham dry needling to their gluteal muscles in addition to standard physical therapy treatment.
2501603|NCT02890485|Sham Comparator|Quad Sham Dry Needling|Receives sham dry needling to their quadriceps muscles in addition to standard physical therapy treatment.
2501604|NCT02890485|Active Comparator|Control|Receives only standard physical therapy treatment.
3163094|NCT00475540|Active Comparator|Prolapse repair without mesh|vaginal prolapse repair without mesh
3163095|NCT00475553|Other|Group 2|Subject will use the nuvaring and if they developed breakthrough bleeding or spotting for more than 5 days on the 6th day the ring would be removed and would leave it out for 3 full days and reinsert the same ring the next day. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
3163096|NCT00475553|Other|Group 1|Subject is using the nuvaring continuously and it would be changed out monthly. If she develops breakthrough bleeding or spotting she does not remove the ring until it is her time to change it. All subjects would be filling out a daily diary or calendar which would rate their blood flow, pelvic pain, headaches, moods, how many pain pills were taken and how many pads, liners or tampons would be used.
3175101|NCT00630110|Experimental|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
2501968|NCT02888496||PMR patients|Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
2501972|NCT02888496||Healthy controls|Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease
2502022|NCT02887924|Active Comparator|group 1|SLI group In this group the preterm infants will receive sustained lung inflation (SLI) via short binasal prongs in the delivery room.
2502023|NCT02887924|Placebo Comparator|group 2|Preterm infants will be assisted in the delivery room without sustained lung inflation.
2502089|NCT02887625|Experimental|Combination Therapy|pioglitazone (actos) 30 mg per day and exenatide (bydureon) 2 mg per week
2502091|NCT02887625|Active Comparator|Insulin Therapy|"insulin glargine (lantus) will be started every morning and the dose will be weekly increase to achieve fasting plasma glucose (FPG) <110 mg/dl.~and Aspart insulin will be started before meals and the dose is adjusted to maintain HbA1c <7.0% and postprandial plasma glucose (PPG) <140 mg/dl"
2502134|NCT02887027|Experimental|Exercise Group 1|Participants assigned to this group will complete a baseline period of 8 days and an Exercise4Mood Intervention period of 21 days.
2502137|NCT02887027|Experimental|Exercise Group 2|Participants assigned to this group will complete a baseline period of 11 days and an Exercise4Mood Intervention period of 18 days.
2502140|NCT02887027|Experimental|Exercise Group 3|Participants assigned to this group will complete a baseline period of 15 days and an Exercise4Mood Intervention period of 14 days.
2502180|NCT02886663|Experimental|immediate rehabilitation|
2502182|NCT02886663|Other|delayed rehabilitation|
2502236|NCT02886273||Group 1|SCA with first MI (n = 43)
2502240|NCT02886273||Group 2|SCA with AMI and previous MI (n = 10)
2502243|NCT02886273||Group 3|SCA without AMI and without former heart disease (n = 3)
2502245|NCT02886273||Group 4|SCA without AMI and with known heart disease (n = 18)
2502259|NCT02885675||ARDS|
2502264|NCT02885675||Healthy control|
2502342|NCT02885376|Experimental|Dentoxol|Dentoxol® is a proprietary mouthrinse that has anti-inflammatory, antimicrobial and analgesic effects. Subjects will use Dentoxol® mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
2502347|NCT02885376|Placebo Comparator|Placebo|The placebo rinse will be identical in color, taste and consistency as the Dentoxol rinse and will be packaged in identical bottles with the same labels. Subjects will use placebo mouthrinse 5 times each day, starting on the first day of radiation therapy and ending on the last day of radiation therapy.
2502423|NCT02884895|Experimental|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
2502427|NCT02884895|Active Comparator|Direct Laryngoscopy|Direct Laryngoscopy
2502448|NCT02884349|Experimental|RoM assessment|All patients recruited to the study.
2502503|NCT02884141||Patients|"Patients with documented fibromuscular dysplasia (see inclusion criteria).~Non-usual care added acts:~blood sampling~urine sampling~renal echography"
2502597|NCT02883257|Experimental|Cognitive Behavioral Therapy|"20 individual 60-minute appointments over the course of 16 weeks~Consistent with Beck, Rush, Shaw, and Emery (1979)"
2502697|NCT02882607|Experimental|Intervention group|Reproductive Health Peer Groups
2502698|NCT02882607|No Intervention|Control group|no intervention
2502750|NCT02882321|Experimental|Treatment (oxidative phosphorylation inhibitor IACS-010759)|"INDUCTION PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 1-7.~MAINTENANCE PHASE: Patients receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and on days 1, 8, and 15 of subsequent courses. Treatment repeats every 21 days for subsequent courses for up to 12 courses in the absence of disease progression or unacceptable toxicity. Patients may receive additional courses of oxidative phosphorylation inhibitor IACS-010759 at the discretion of study doctor."
2502828|NCT02882048|Experimental|Medication management & NADA Protocol|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens, and NADA protocol administered biweekly
2502831|NCT02882048|Active Comparator|Medication management|Standard of care medication management defined by opioid weaning protocol with specific, symptomatic medication regimens.
2503710|NCT02875119|Experimental|Griffithsin Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer Griffithsin Gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
2503876|NCT02874105|Active Comparator|control group|Conventional physiotherapy
2501193|NCT02893852|Experimental|standard CO-OP Approach plus coaching parents|"Task oriented and client-centred intervention with 12 sessions (10 interventional and 2 assessment sessions) with children and parents with a boost of 4 group sessions of coaching for parents in groups."
2501250|NCT02893358|Active Comparator|Active treatment|Treatment will be started with allisartan isoproxil 80mg once daily taken in the morning during 8:00-9:00. After 2 months, to achieve the target BP (24h BP<130/80 mmHg, and daytime BP <135/85 mmHg, and nighttime BP <120/70 mmHg), allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan Isoproxil.
2501260|NCT02893358|Placebo Comparator|Placebo|Placebo tablets are identical to the active study drugs, with a similar schedule of administration.
2501285|NCT02892968|Experimental|U/S Guided Regional Anesthesia|"Fascia-Iliaca Block(FIB) Femoral Nerve Block(FNB)~All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. EPs will then be trained to use two approaches to ultrasound (U/S) guided regional anesthesia, the fascia iliaca and femoral nerve blocks. Which block that will be used will be randomly determined at the individual patient level"
2501287|NCT02892968|No Intervention|Current Local Standard Analgesia|"All participating emergency physicians (EPs) will be randomly assigned to the order they receive training in a stepped wedge design. Thus all EPs will begin the trial as control physicians. Physicians who are in the control group will provide current local standard of analgesic care for hip fracture patients such as the use of IV opiods with supplemental acetaminophen and non-steroidal anti-inflammatory agents until they receive training."
2501331|NCT02892643|Experimental|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
2501336|NCT02892643|Active Comparator|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
2501390|NCT02892214||Hypertonic pelvic muscle dysfunction|In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.
2501393|NCT02892214||Hormonally mediated PVD|The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.
2501395|NCT02892214||Neuroproliferative PVD|In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.
2501468|NCT02891642||Malignancy, Serous effusion|Analysis of serous effusion through immunomagnetic detection device
2501522|NCT02891317||Cataract Surgery Only|Twenty-five participants with mild or moderate open angle glaucoma (OAG) controlled by medication with a visually significant cataract that meets clinical criteria for cataract surgery will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery only (Group 1) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2501528|NCT02891317||Cataract Surgery with iStent|Twenty-five participants with mild or moderate open angle glaucoma (OAG) that meets clinical criteria for cataract surgery with implantation of an iStent trabecular micro-bypass shunt will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for cataract surgery with iStent (Glaukos Corp., Laguna Hills, CA) implantation (Group 2) will be recruited to this group. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2501530|NCT02891317||Glaucoma Drainage Device|Twenty-five participants with moderate or severe open angle glaucoma (OAG) that meets clinical criteria for implantation of a glaucoma drainage device (Group 3) will be recruited from the glaucoma clinics at the UNC Kittner Eye Center. Patients who are consented for implantation of a glaucoma drainage device (Group 3) will be recruited to this group. There will be 25 participants in each of the groups. Each procedure will be completed in a standardized fashion with standardization of the post-operative medications. An effort will be made to gender and age match each surgical group as well as provide reasonable racial and ethnic diversity.
2501555|NCT02890966|Experimental|Cohort 1|1mg SHR4640 or placebo
2501559|NCT02890966|Experimental|Cohort 2|2.5mg SHR4640 or placebo
2501566|NCT02890966|Experimental|Cohort 3|5mg SHR4640 or placebo
2501567|NCT02890966|Experimental|Cohort 4|10mg SHR4640 or placebo
2501630|NCT02890576||telemedicine|Setting up of a new organization of medical monitoring (ussing telemedicine) of patient having a cochlear implant
2501665|NCT02890290|Active Comparator|Intervention|Marine protein hydrolysate pills (3000mg)
2501668|NCT02890290|Placebo Comparator|Control|Placebo pills (gum arabicum)
2501746|NCT02889965||Radiologically Isolated Syndromes (RIS)|
2501754|NCT02889965||Clinically Isolated Syndromes (RIS)|
2501764|NCT02889965||Primary progressive MS (PPMS)|
2501803|NCT02889549|Experimental|Ticagrelor 22.5 mg|Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
2501807|NCT02889549|Experimental|Ticagrelor 45 mg|Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
2501808|NCT02889549|Experimental|Ticagrelor 90 mg|Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
2501812|NCT02889549|Active Comparator|Clopidogrel|Clopidogrel (75mg, once daily, oral) treatment for 1 month.
2501851|NCT02889094||HIV-HBV co-infected individuals|No interventions will be administered. Individuals will be undergoing routine care.
2502326|NCT02885402|Placebo Comparator|Healthy volunteers|
2501362|NCT02892357|Experimental|Treatment group|Participants in this group take the herbal compound of Jianpi Qinghua granules and half-dose omeprazole tablet.Jianpi Qinghua granule:one bag after 1 hour of breakfast and supper(twice a day) for 4 weeks.Half-dose omeprazole tablet:1 tablet of real omeprazole (10mg) and 1 tablet of Sham(10mg),once a day before breakfast for 4 weeks.
2501363|NCT02892357|Active Comparator|Control group|Participants in this group take the sham herbal granules twice a day as treatment group and two pieces of real omeprazole tablet(10mg each) once a day before breakfast for 4 weeks.
3196049|NCT00846443|Experimental|2|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
3196050|NCT00846443|Experimental|3|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
2501564|NCT02890940|Experimental|Pet Therapy|
2501614|NCT02890732|Experimental|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
2501699|NCT02890368|Experimental|TTI-621 Monotherapy Escalation|TTI-621 Escalation phase of single or multiple doses of TTI-621 delivered by intratumoral injections (various dose cohorts).
2501701|NCT02890368|Experimental|TTI-621 Monotherapy (Single Lesion)|TTI-621 Single Lesion Injection Expansion Cohort
2501703|NCT02890368|Experimental|TTI-621 Monotherapy (Multiple Lesions)|TTI-621 Multiple Lesion Injections Expansion Cohort
2501705|NCT02890368|Experimental|TTI-621 + PD-1/PD-L1 Inhibitor|Combination Therapy Expansion Cohort of TTI-621 plus PD-1/PD-L1 Inhibitor
2501706|NCT02890368|Experimental|TTI-621 + Pegylated Interferon-α2a|Combination Therapy Expansion Cohort of TTI-621 plus Pegylated Interferon-α2a
2501707|NCT02890368|Experimental|TTI-621 + T-Vec|Combination Therapy Expansion Cohort of TTI-621 plus T-Vec
2501708|NCT02890368|Experimental|TTI-621 + Radiation|Combination Therapy Expansion Cohort of TTI-621 plus Radiation Therapy
2501743|NCT02889692|Experimental|TCM granules plus EGFR-TKIs|"TCM granules: oral granules, YiQiFang or YangYinFang or YiQiYangYinFang, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day，until progression or unacceptable toxicity."
2501753|NCT02889692|Placebo Comparator|Placebo granules plus EGFR-TKIs|Placebo granules: oral granules, which the taste and smell are similar to experimental TCM granules and has no therapeutic effect, four packages, twice a day, until progression or unacceptable toxicity; EGFR-TKIs: oral tablet, Gefitinib® 250mg daily or Erlotinib® 150mg daily or Icotinib® 125 mg three times a day until progression or unacceptable toxicity.
2501822|NCT02889367|Experimental|Treatment A|Participants will receive odalasvir 100 milligram (mg) or odalasvir matching placebo once on Day 1.
2501827|NCT02889367|Experimental|Treatment B|Participants will receive odalasvir 500 mg or odalasvir matching placebo once on Day 1.
2501830|NCT02889367|Experimental|Treatment C|Participants will receive odalasvir (dose to be determined based on pharmacokinetic data from treatment A and B but no more than 1000 mg) or odalasvir matching placebo once on Day 1.
2501870|NCT02888886|Experimental|COPD|
2501956|NCT02888275|Experimental|DEX|dexmedetomidine 1mcg/kg for 10min. loading and continuous infusion during the surgery 0.5mcg/kg/hr.
2501957|NCT02888275|Active Comparator|no_DEX|Normal saline 1mcg/kg for 10min. and continuous infusion during the surgery 0.5mcg/kg/hr.
3196051|NCT00846443|Experimental|4|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
3196052|NCT00846469|Experimental|chest pain|CCTA (Coronary computed tomography angiography)
2502082|NCT02887651|No Intervention|observation|patients in the observation arm receive no adjuvant local radiation therapy after complete surgical resection of a cerebral metastasis
2502084|NCT02887651|Active Comparator|cavity boost radiation therapy|patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
2502125|NCT02887105||Patients with cerebrovascular accident|
3196053|NCT00846508|Experimental|ciaplantin,cancer,survival|
3196054|NCT00846534||Post operative atrial fibrillation|To evaluate the ability of oxidative stress markers to predict postoperative atrial fibrillation in subjects undergoing cardiac surgery.
3196055|NCT00846560||1 ALS patients|
3196056|NCT00846560||2 Healthy subjects|
2503042|NCT02880345|Active Comparator|Cohort 1 - 8 Gy x 3 fractions|8 Gy x 3 fractions
2503044|NCT02880345|Active Comparator|Cohort 2 - 17 Gy x 1 fractions|17 Gy x 1 fraction
3196057|NCT00846599||1|High omega-3
2503138|NCT02879539|Experimental|MP3000-ACE strategy|MP3000 sound coding strategy or ACE strategy with lower stimulation rate
2503196|NCT02879357|Experimental|Trained Clinicians|Training in Serious Illness Communication Guide
2503200|NCT02879357|No Intervention|Untrained Clinicians|No training in Serious Illness Communication Guide
3196058|NCT00846599||2|High saturated fat
2503341|NCT02878135|Experimental|fast vulsellum|rapid ratchet of the vulsellum
2503344|NCT02878135|Active Comparator|slow vulsellum|Placement of the tenaculum over 7-10 seconds and not allowing the vulsellum to ratchet audibly.
3196059|NCT00846612|Experimental|Avastin-Doxil|
3196060|NCT00846625|Experimental|1|Ranibizumab (0.5 mg)
2503482|NCT02877056||Colorectal Cancer|Participants undergo standard endoscopy before therapy. Tissue samples taken from the tumor and normal colorectal tissue.
2503517|NCT02876705|Experimental|Pain Patterns|In this vein, we tend to study and delineate individualized pain and discomfort patterns in exercise.
3196061|NCT00846625|Active Comparator|2|Triamcinolone (4 mg/0.1 ml)
3196062|NCT00846638|Experimental|1|Diagnostic assessment with brief intervention and 3, 6, and 12 month follow-up
3196063|NCT00846638|Active Comparator|2|Diagnostic assessment with 12 month follow-up
3196064|NCT00846664|Experimental|Group 1|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
3196065|NCT00846677|Experimental|1|Vitamin D quick dissolve strip
3196066|NCT00846677|Active Comparator|2|Vitamin D syrup
3196067|NCT00846690|Active Comparator|Benzocaine|"serves as active control"
2501364|NCT02892461|Experimental|Umbilical cord milking|The cord will be cut at 25 cm from the umbilical stump within 30 seconds after the infant is taken out from the uterus and its blood will be milked to the infant gently and thoroughly in 30 seconds during resuscitation on the radiant warmer, and then the cord will be cut at 2 to 3 cm from the umbilical stump.
2501365|NCT02892461|No Intervention|Routine clinical treatment and care|The cord will be dealt with routine clinical method, which means it will be cut twice within 1minute after the infant is taken out from the uterus, the first cut is on the operating table, while the second cut is on the radiant warmer.
2501409|NCT02892123|Experimental|ZW25 (Zanidatamab) Monotherapy and ZW25 Combination Therapy|
2501475|NCT02891512|Experimental|ELF and Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® is a dietary supplement containing alpha-lipoic acid, N-acetyl-L-carnitine, turmeric, vitamins B, E and C. They have an antioxidant and anti-inflammatory action on nervous system and they act on cellular energy metabolism.
2501479|NCT02891512|Placebo Comparator|ELF and Placebo Xinepa®|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues. Xinepa® without its specific activity for the condition being treated.
3196068|NCT00846690|Experimental|TAC|serves as comparator
3196069|NCT00846703|Active Comparator|Protocol A (MM)|
2501663|NCT02890511|Experimental|DHP107(Oral paclitaxel)|"Phase I (determining MTD) The patients diagnosed with either advanced or metastatic solid cancers were enrolled. The administered dose was escalated in a step-wise manner by an increment of 2 x 50 mg/m2 at each dose level. Three patients were treated for toxicity evaluation for each dose level.~Phase IIa (efficacy evaluation) The safety and efficacy of the corresponding dose was investigated more closely by increasing the patient number to 6 or more patients in the dose tentatively determined as recommended dose for phase IIa clinical trial."
2501782|NCT02889536||Focus group interview, stoma clinics|Qualitative data collection. Patients attending stoma clinics in the capital region
2501783|NCT02889536||Focus group interview, referred|Qualitative data collection. Patients referred to repair surgery at a specific hospital in the capital region
2501823|NCT02889341|Placebo Comparator|Placebo|Placebo
2501825|NCT02889341|Active Comparator|500 mg DHA/day|500 mg DHA/day
2501828|NCT02889341|Active Comparator|1g DHA/day|1g DHA/day
2501832|NCT02889341|Active Comparator|2g DHA/day|2g DHA/day
2501884|NCT02888964|Experimental|ACTOS treatment|Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events
2501955|NCT02888431||Arterial blood sample|0.5 mL blood sample from arterial line which is clinically indicated
2501958|NCT02888431||peripheral venous blood sample|0.5 mL blood sample drawn simultaneously with arterial sample from clinically indicated peripheral line
3196070|NCT00846703|Experimental|Protocol B (MM/VD)|
3196071|NCT00846716|Experimental|Pioglitazone add on to SU or biguanide|
3196072|NCT00846716|Active Comparator|SU or Biguanide|
3196073|NCT00846755|Active Comparator|Levothyroxine, Propylthiouracil|Drugs for the treatment of thyroid disease, are administered, when necessary, in high risk women, either in case finding, or in Universal Screening Group
3196074|NCT00846755|No Intervention|clinical checks|Low risk women whose sera are tested postpartum. Then patients with undiagnosed thyroid disease, are not treated
3196075|NCT00846781|Experimental|Denufosol tetrasodium Inhalation Solution|
2502255|NCT02885974|Experimental|Celecoxib plus Gemcitabine/Cisplatin chemo|Celecoxib plus Gemcitabine/Cisplatin neoadjuvant chemotherapy
2502281|NCT02885662|Experimental|CS-3150|CS-3150 2.5 to 5.0 mg , orally, once daily after breakfast for 12 weeks.
2502357|NCT02885077|Experimental|High-intensity IMT + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). Training will progress to 80% maximal inspiratory pressure (PiMax). IMT will perform for 12 weeks with two sessions per week. The training protocol will consists of five series with ten repetitions with two minutes or according to patient feedback using the modified Borg scale.The initial charge of training will be 50% of PiMax in the first 2 weeks, with an increase of 55% of PiMax in the 3 week, 60% of PiMax in the 4 week, 65% of PiMax in the 5 week, 70% of PiMax in the 6 week, 75% of PiMax in the 7 week and 80% of PiMax in the 8 week. After the 9 and 12 week training period, the PiMax measurements will be performed weekly to keep 80% of the new PiMax.
2502359|NCT02885077|Sham Comparator|H-IMT sham + combined exercise|Participants will perform 12 weeks of IMT strength training is achieved with a device with linear load pressure with a device with linear load pressure (POWERbreathe Medic Plus ®, SP, BR). The sham group will perform for 12 weeks with two sessions per week. The protocol will consists of five series with ten repetitions with two minutes and will train at a constant inspiratory load of no more than 10% of their initial Pimax.
2502420|NCT02884830|Placebo Comparator|Sham CPAP|Sham continuous positive airway pressure is a CPAP given at too low pressure to have any physiological effect on upper airways patency and on lung volumes
2502424|NCT02884830|Active Comparator|Efficace CPAP|Continuous positive airway pressure is a CPAP given at effective pressure to decrease the work of breathing in COPD patients
2502435|NCT02884375||Elderly cancer patient cohort|Patients aged 70 years or older, who had diagnosis of cancer in participating sites (including hematologic malignancies), and referred to a geriatrician for geriatric assessment (GA)
2502507|NCT02884180|Active Comparator|Treatment A|Dexamethasone 24 mg i.v. after start of anaesthesia
2502510|NCT02884180|Placebo Comparator|Treatment B|Saline isotonic i.v. after start of anaesthesia
2502550|NCT02883556|Experimental|Pembrolizumab 200 mg|Pembrolizumab 200 mg administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
2502623|NCT02883127||The control group|Was given the same routine care with the same treatment goals, but without motivational interviewing.
3196076|NCT00846794||1 Asymptomatic|students with conditions being studied
3196077|NCT00846794||2 Symptomatic|students without conditions being studied
3196078|NCT00846833|Experimental|Cyclophosphamide, high-dose interleukin-2, NK cell|
3196079|NCT00846859|Experimental|varenicline|
2501369|NCT02892331|No Intervention|Control|This group does not change physical activity during the intervention period, but will receive exercise training after the study is complete
2501371|NCT02892331|Experimental|MOD-INT|The Moderate intensity exercise training (MOD-INT) group will exercise at a moderate aerobic exercise intensity for 24 weeks
2501373|NCT02892331|Experimental|HIGH-INT|High Intensity exercise training (HI-INT) group will exercise at a high aerobic intensity for 24 weeks
2501455|NCT02891772||Hypotension after anesthetic induction group|Patients with hypotension after anesthetic induction
2501626|NCT02890459|Active Comparator|Aim 1 - Fixed Incentive|Fixed Incentive - Prize Prize incentive - Low Prize incentive - High
2501627|NCT02890459|Experimental|Aim 1 - Loss Aversion|Loss Aversion - Prize Prize incentive - Low Prize incentive - High
2501631|NCT02890459|Experimental|Aim 1 - Lottery|Lottery - Prize Prize incentive - Low Prize incentive - High
2501636|NCT02890459|Active Comparator|Aim 2 - Standard Care|Standard care Travel voucher
2501640|NCT02890459|Experimental|Aim 2 - Enhanced Care (Intervention)|Escalating payment incentive Travel voucher
2501643|NCT02890459|Experimental|Aim 3 Pilot - Loss Aversion|Loss Aversion - Deposit
2501645|NCT02890459|Experimental|Aim 3 Pilot - Fixed Incentive|Fixed Incentive - Voucher
2501647|NCT02890459|No Intervention|Aim 3 Pilot - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
2501649|NCT02890459|Experimental|Aim 3 Trial - Loss Aversion|Loss Aversion - Deposit
2501650|NCT02890459|Experimental|Aim 3 Trial - Fixed Incentive|Fixed Incentive - Voucher
2501653|NCT02890459|No Intervention|Aim 3 Trial - No incentive|Participants will be encouraged to come for repeat HIV testing, but no incentive will be offered.
2501745|NCT02889744|Active Comparator|36-TH|Core temperature 36℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
2501752|NCT02889744|Active Comparator|33-TH|Core temperature 33℃ of targeted temperature management (36-TH) for 24 hours in cardiac arrest victims using Arctic Sun.
2501809|NCT02889432|Experimental|Melatonin|Oral Melatonin 10mg Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
2501813|NCT02889432|Placebo Comparator|Placebo|Placebo tabs Taken 30 minutes before bedtime for 3 weeks First dose starts the night before surgery
2501855|NCT02889133|Active Comparator|Iron repletion|Subjects will donate blood donation and undergo 24-hour PTR and receive IV iron-dextran. After 5 months, subjects will donate blood again, receive IV saline and undergo 24-hour PTR.
2501857|NCT02889133|Placebo Comparator|Placebo|Subjects will donate blood donation and undergo 24-hour PTR and receive IV saline. After 5 months, subjects will donate blood again, receive IV iron-dextran and undergo 24-hour PTR.
2501913|NCT02888704|Experimental|intervention: Biological: ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once for the duration of the study."
2501943|NCT02888405|Experimental|High-carbohydrate diet|Single day of 9 g/kg body weight consumption of carbohydrate. Isocaloric to very low-carbohydrate condition.
2501946|NCT02888405|Experimental|Very low-carbohydrate diet|Single day of 1 - 1.5 g/kg body weight consumption of carbohydrate. Isocaloric to high-carbohydrate condition.
2502040|NCT02887898|Active Comparator|Carb counting and bolus calculator|Education in carb counting and the use of an automated bolus calculator
2502041|NCT02887898|Placebo Comparator|Carb counting|Education in carb counting and manual calculation of insulin bolus
2502051|NCT02887456|Active Comparator|Vitapex|Endodontic treatment using Vitapex
2502052|NCT02887456|Experimental|MTA paste|Endodontic treatment using MTA paste
2502113|NCT02887313|Experimental|Locally advanced rectal cancer|Locally advanced rectal cancer receiveing total neoadjuvant treatment
2502142|NCT02886884|Experimental|20 million allogeneic hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
2502143|NCT02886884|Experimental|100 million hMSCs|Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)
2502223|NCT02886143|Experimental|Active Voiding Trial (instillation of sterile saline)|Patients randomized to receive an active voiding trial will have the bladder filled with 250-400 cc of sterile saline (or until the bladder was full) via the lumen of the urinary catheter before the urinary catheter is removed. The patient will then be immediately assisted to void. Physician teams will follow a standardized algorithm for the management of urinary retention arising during the study.
2502224|NCT02886143|Active Comparator|Passive Voiding Trial|For patients randomized to receive a passive voiding trial, the urinary catheter will be removed, the bladder will fill with urine naturally, and the patient will be assisted to void when he or she reports the urge. To ensure uniformity in the intervention, all voiding trials in the study will be supervised by an experienced nurse who will ensure that the protocol is followed.
2502309|NCT02885558|Experimental|L + T-type|8 weeks treatment with efonidipine (1 week 1x20mg, 7 weeks 2x20mg)
2502310|NCT02885558|Active Comparator|L-Type|8 weeks treatment with nifedipine (1 week 1x20mg, 7 weeks 2x20mg)
2502338|NCT02885194|Other|Patients who underwent Deep Brain Stimulation (DBS)|Patients who underwent Subthalamic Nucleus (STN)-DBS at Lyon
2502368|NCT02884999||severe trauma patients|Severe trauma patients admitted to the site in the first 24 hours
2502415|NCT02884739||schizophrenia|
2502418|NCT02884739||chronic psychiatric disorder other than schizophrenia|
2502434|NCT02884388|Experimental|experimental group|Combined nerve block will be used, involving lower lumbar plexus, sciatic nerve, and paraspinal nerve L1-2.
2502442|NCT02884388|Experimental|control group|General anesthesia will be used in this group.
2502485|NCT02884115|Active Comparator|Retreatment group|Serofast early syphilis cases retreated with three doses benzathine penicillin
2501399|NCT02892097|Active Comparator|Primary motor cortex tDCS plus RTP|Single session of bilateral primary motor cortex tDCS (2.0 mA for 30 minutes) paired with repetitive task-specific practice (RTP)
2501400|NCT02892097|Sham Comparator|Sham tDCS plus RTP|Single session of sham tDCS (for 30 minutes) paired with repetitive task-specific practice (RTP)
2501490|NCT02891551||Patients receiving Azacitidine per daily clinical practice|
2501532|NCT02891265|No Intervention|Group A|Group A - smoking cessation with no assistance
2501534|NCT02891265|Placebo Comparator|Group B|Group B - smoking cessation with the addition of a smoking cessation patch
2501673|NCT02890667||Beneficiaries|Incident cancer for Beneficiaries present in the EGB on January 1, 2012.
2501765|NCT02889991|Experimental|High Intensity Dry Needling|Maneuver of Input-Output with the acupuncture needle, until the disappearance of local twitch responses or patient tolerance.
2501771|NCT02889991|Experimental|Low Intensity Dry Needling|Maximum 10 input-output maneuvers with acupuncture needle or maximum 3 local twitch responses or patient tolerance.
2501773|NCT02889991|Experimental|Fascial mechanotransduction Dry needling|Maneuver of input, screwing and pulling out of the needle acupuncture.
2501777|NCT02889991|Sham Comparator|Placebo Dry Needling Technique|"Technique is performed with the Park´s Sham device."
2501834|NCT02889380||Cetrotide|This study will retrospectively collect the data from the subjects who had been treated with 0.25 milligram (mg) of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available assisted reproductive technology (ART) outcome.
2501908|NCT02888938||Patients suspected of SpA|
2501929|NCT02888379|Experimental|TOP1288 200 mg Rectal Solution|TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks
2501930|NCT02888379|Placebo Comparator|Placebo Rectal Solution|Placebo (for TOP1288) Rectal Solution Once Daily for 4 Weeks
2501984|NCT02888158|Active Comparator|Pelvic Trainer without robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart.~Intervention: Pelvic Trainer"
2501986|NCT02888158|Experimental|Pelvic Trainer with robotic assistance|"Interns randomized to this arm will have two Pelvic Trainer training sessions three months apart but with robotic assistance.~Intervention: Robotic assistance~Intervention: Pelvic Trainer"
3196080|NCT00846859|Placebo Comparator|placebo|
3196081|NCT00846872|Active Comparator|Low dose GHRP-3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
2502181|NCT02886520|Active Comparator|PVDF transobturator tape|Transobturator tension-free suburethral tape made of polyvinylidene fluoride.
2502183|NCT02886520|Active Comparator|PP transobturator tape|Transobturator tension-free suburethral tape made of polypropylene.
2502213|NCT02886182||group A|pregnants who were positivity for serum HBsAg for more than 6 months and HBeAg , HBV DNA >106IU/mL, alanine aminotransferase (ALT) below 35 IU/mL (ULN=40IU/mL) and no received nucleoside analogue antiviral therapy were enrolled into group A
2502215|NCT02886182||group B|the CHB infection pregnants with undetectable HBVDNA were enrolled into group B(control group)
2502275|NCT02885935|Experimental|Recommended protein intake|Subjects consumed diets with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat for 4 weeks.
2502276|NCT02885935|Experimental|Elevated protein intake|Subjects consumed diets with a macronutrient distribution of 20% protein, 45% carbohydrates and 35% fat for 4 weeks.
2502327|NCT02885233|Active Comparator|Free From Falls|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
2502331|NCT02885233|Placebo Comparator|Waitlist|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
2502453|NCT02884479|Experimental|PT-112 + Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
2502476|NCT02883998|Active Comparator|Outpatient Physical Therapy Group|Once the patient is cleared for discharged from the hospital, the patient will be given a prescription for outpatient physical therapy to attend 3 times per week for 6 weeks.
2502479|NCT02883998|Experimental|Home Base Physical Therapy Group|Patients will be provided a packet of exercises and equipment to perform the home based physical therapy program. Patients will attend a single session of outpatient physical therapy prior to surgery no more than 4 weeks prior to the procedure to teach the patient how to perform the exercises.
2502542|NCT02883686|Experimental|Alma Mentoring plus usual care|Alma peer-mentoring
2543762|NCT02605889|Sham Comparator|Group B|Simulation Laser acupuncture
2501413|NCT02892071|Active Comparator|CO2 laser|CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
2501414|NCT02892071|Active Comparator|Qs-NdYAG laser|Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
2501450|NCT02891746||Premature infants|premature infants ≤ 34 weeks of gestation
2501454|NCT02891746||Term infants|neonates ≥ 37 weeks gestation
2501477|NCT02891525|Active Comparator|50g glucose intragastric|50g glucose dissolved in 250mL tap water given via nasogastric tube
2501481|NCT02891525|Active Comparator|25g fructose intragastric|25g glucose dissolved in 250mL tap water given via nasogastric tube
2501486|NCT02891525|Active Comparator|220mg acesulfame-K intragastric|220mg acesulfame-K dissolved in 250mL tap water given via nasogastric tube
2501492|NCT02891525|Placebo Comparator|250mL tap water intragastric|250mL tap water given via nasogastric tube
2501520|NCT02891187|Active Comparator|Outpatient Clinic Visits|Outpatient clinic visits for postoperative care is currently the standard of care. Patients who undergo surgery for a pelvic floor disorder will be scheduled appointments in the outpatient clinic at 1-2 weeks, 6 weeks, and 3 months where they will be evaluated by a physician.
2501525|NCT02891187|Active Comparator|Telephone Follow-up|Patients will be called instead of returning to clinic for postoperative care at 1-2 weeks, 6 weeks, and 3 months.
2501573|NCT02890914|No Intervention|Standard Education|These residents received their standard residency education and experience.
2501574|NCT02890914|Experimental|DVD Intervention|These residents received a one-hour long DVD lecture in addition to standard residency education and experience.
2501637|NCT02890602|Experimental|Darbepoietin alfa|Hemoglobin level will be checked at every cycle's day 0 or 1(1cycle is 21days) after starting Darbepoietin alfa. It will be applied to chemotherapy until increment of hemoglobin 12.0 g/dL.
2501694|NCT02890199|Active Comparator|Lidocaine group|0.5% lidocaine mixed with 1:200,000 epinephrine 70 milliliters (mL) will be used for local injection at the sacrospinous ligament and for anterior / posterior colporrhaphy
2501696|NCT02890199|Experimental|Bupivacaine liposomal group|1.3% bupivacaine liposomal (20 mL) injected at the sacrospinous ligament 0.5% lidocaine mixed with 1:200,000 epinephrine 50mL for the anterior / posterior colporrhaphy
2501744|NCT02889835|Active Comparator|Universal Composite|Supreme Universal Restorative
2501751|NCT02889835|Experimental|Flowable Composite|Supreme Flowable Restorative
2501757|NCT02889835|Experimental|Bulk Fill Flowable Composite|Bulk Fill Flowable Restorative
2501804|NCT02889406|Experimental|Motivational intervention|"Following the motivational interviewing schema, structured in 2 phases of treatment (motivational and intervention) and organised in 11 visits (one each month). The first and last visits will be performed in consultations of endocrinology unit from referral hospitals; the other visits will be held in paediatric primary care setting. Visits will be scheduled monthly and each one will last between 15 and 20 minutes.~In addition to individualized visits, three group workshops focused in nutrition education for families will be organized. Each workshop will last 45 minutes and will target parents/mothers and obese children, separately."
2501806|NCT02889406|No Intervention|Control group|Children who are assigned to the control group will follow the usual treatment performed in paediatrics, what is following the Clinical Practice Guideline on the prevention and treatment of child and adolescent obesity. Monthly visits will be conducted in which weight, height and waist circumference will be measured and compliance with the initial advice will be reviewed.
2501859|NCT02889172|Experimental|Problem Solving Therapy|Will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City. The aim is evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
2501861|NCT02889172|No Intervention|Control|This group will receive the usual treatment , without intervention with Brief Intervention ( PST )
2501917|NCT02888743|Experimental|Arm A (tremelimumab, durvalumab)|Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.
2501919|NCT02888743|Experimental|Arm B (tremelimumab, Durvalumab, RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive high dose radiation therapy QD over 10 days for up to 3 fractions.
2501920|NCT02888743|Experimental|Arm C (tremelimumab, durvalumab, and RT)|Patients receive tremelimumab and durvalumab and as in Arm A. Beginning at week 2, patients receive low dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.
2501995|NCT02888223|Experimental|Group A|a single dose administration of SCT800 followed by Xyntha (50 IU.kg-1, based upon the manufacturer's labeled potency)
2501999|NCT02888223|Experimental|Group B|a single dose administration of Xyntha followed by SCT800(50 IU.kg-1, based upon the manufacturer's labeled potency)
2502155|NCT02886871|Experimental|Personalized Steps Goal|Step Goal Delivery by Smartphone
2502157|NCT02886871|Active Comparator|Constant Steps Goal|Step Goal Delivery by Smartphone
2502175|NCT02886507|Active Comparator|NSK-SD (nattokinase)|One capsule (100 mg) nattokinase/day for the 8-week study duration.
2502176|NCT02886507|Placebo Comparator|Placebo|One capsule placebo/day for the 8-week study duration.
2502204|NCT02886364|Other|Women delivered at AAC Hospital|The intervention is only being implemented at the Ángel Albino Corzo Hospital due to limited funding. The site was selected by the Ministry of Health in Chiapas as a hospital that would benefit from improved quality of care around childbirth. There are no other arms in this study.
2502258|NCT02885961|Other|Dabigatran|"All patients will be entered into the arm, i.e. this is a single arm study. All patients will complete 2 FDG PET scans. All patients will receive dabigatran (direct thrombin inhibitor) at a dose of 110mg twice daily (oral).~The drug will be given for 24 days (+/-3 days). The variation in duration reflects that scans are completed Monday to Friday only."
2502290|NCT02885649|Experimental|Treatment (enzalutamide, nephrectomy)|Patients receive enzalutamide PO daily for 90 days in the absence of disease progression or unacceptable toxicity. Patients then undergo partial or radical nephrectomy.
2543805|NCT02605720|Experimental|Dihydroartemisinin-piperaquine|
2501452|NCT02891759|Experimental|Group A: Alloderm RTU|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group A will receive Alloderm RTU~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
2501456|NCT02891759|Experimental|Group B: Cortiva 1mm Allograft Dermis|"Prior to the date of mastectomy, the BREAST Q patient-reported outcome survey will be administered for routine clinical care purposes. It may occur before or after enrollment.~On the day of surgery, patients will receive standardized preoperative care, a skin- or nipple-sparing mastectomy from an experienced surgical breast oncologists and immediate tissue expander breast reconstruction with Dr. Myckatyn or Dr. Tenenbaum. Uniform operative techniques will be used in both treatment groups. All patients will receive either a 16x8 cm (128 sq cm) ADM graft for postpectoral reconstruction or 16x20 cm (320 sq cm) for prepectoral reconstruction. Patients randomized to Group B will receive Cortiva 1mm Allograft Dermis~A post-operative version of the Breast Q validated in patients who have received tissue expanders will be administered between 1 and 3 months after tissue expander insertion, and again prior to exchange for an implant or flap (or at time of patient-requested removal"
2501471|NCT02891434|Experimental|Acquisition on TouchScreen|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2501472|NCT02891434|Experimental|Acquisition on Kinect|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2501474|NCT02891434|Experimental|Acquisition on LeapMotion|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2501478|NCT02891434|Active Comparator|Acquisition on TouchScreen Control Group|Subjects practice the task and retention TouchScreen, transfer 1 on LeapMotion and transfer 2 on Kinect
2501482|NCT02891434|Active Comparator|Acquisition on Kinect Control Group|Subjects practice the task and retention Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
2501487|NCT02891434|Active Comparator|Acquisition on LeapMotion Control Group|Subjects practice the task and retention LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
2501557|NCT02891135|No Intervention|Standard|Patients randomized to the standard arm will receive standard procedures for initiating antiretroviral therapy for HIV.
2501560|NCT02891135|Experimental|Intervention|Patients randomized to the intervention arm will be offered immediate treatment initiation under the intervention algorithm (SLATE).
2501607|NCT02890719|Experimental|Genotype 1B|treatment 12 weeks
2501610|NCT02890719|Experimental|Genotype 1A and 4|treatment 16 weeks
2501711|NCT02890056|Experimental|H2GO! intervention|H2GO! is a community-based behavioral intervention to reduce sugar-sweetened beverage consumption and promote water intake among school-age youth and parents.The intervention consists of 6 weekly group-based sessions (1-hour sessions twice a week) that target beverage knowledge, attitudes, and behaviors through interactive activities, youth-produced narratives, and parent-child activities. The intervention is delivered through a youth-based community setting (Boys and Girls Clubs of America) by trained Boys and Girls Club staff.
2501712|NCT02890056|No Intervention|Comparison|Usual care will take place at the comparison site (standard programming at the Boys and Girls Club comparison site).
2501838|NCT02889198|Experimental|Intervention group|Centers in this group will be granted immediate access to the Go NAP SACC website following randomization with minimal support from a local technical assistance provider. The center director will have 4 months to use Go NAPSACC tools.
2501839|NCT02889198|No Intervention|Control group|During the study, centers in this group will receive no intervention. However, they will be granted delayed access to the Go NAP SACC website and technical assistance support after post-intervention measures are collected.
2501914|NCT02888925|Other|Epilepsy|Patients do face specific tests during conventional pre-lobectomy intercritical assessment hospitalization (inclusion, day 0) and after 6 and 18 months from anterior temporal lobectomy
2501915|NCT02888925|Other|Control|Control individuals do face specific tests during inclusion visit (day 0) and after X months (X = time from day 0 and lobectomy of matched patient + 6 months)
2501942|NCT02888301||Basic science (18F-clofarabine biodistribution)|Patients receive 18F-clofarabine IV and undergo PET/CT scan at baseline and 2-4 weeks after completion of immunotherapy.
2502004|NCT02887976|Experimental|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid)
2502058|NCT02887690|Experimental|Modular Prosthetic Limb|The Defense Advanced Research Projects Agency's (DARPA) advanced upper limb prosthesis, the Modular Prosthetic Limb (MPL)
2502177|NCT02886689||1|patients will be those receiving any biotherapy
2502178|NCT02886689||2|patients will be those not receiving biotherapy : non indication, refusal, contraindication.
2502209|NCT02886351|Experimental|nitrous oxide|Administration of high concentration of nitrous oxygen in pediatric dentistry
2502256|NCT02886026|Active Comparator|Inpatient TUR-BT|Transurethral bladder tumor resection in operating theatre as inpatient.
2502257|NCT02886026|Experimental|laser bladder tumor destruction|Outpatient laser mediated destruction of bladder tumors (LMD-BT)
2502430|NCT02884713|Experimental|Levofloxacin and Doxycycline and Esomeprazole|The rescue treatment was given for ten days consisting of levofloxacin 500 mg once daily, doxycycline 100 mg twice daily, and esomeprazole 20 mg twice daily
2502456|NCT02884271||cardiac arrest group|patients who develop intraoperative cardiac arrest
2502457|NCT02884271||without cardiac arrest group|patients who don't develop intraoperative cardiac arrest
2502530|NCT02884011||Both β-blocker and ACE-inhibitor|on both chronic β-blocker and ACE-inhibitor
2501497|NCT02891473|Experimental|Mézières Method group|Sessions of exercises for the recovery of midline symmetry, diaphragmatic breathing exercises, stretching of the latissimus dorsi respecting the global elongation according to the Mézières Method.
2501500|NCT02891473|Active Comparator|Home based exercise program group|Sessions of home based exercises performed by the patients at their domicile after a training session about the exercise program made by a physiotherapy. The exercises aimed at promoting trunk control in static and dynamic position according to the specific guidelines for Parkinson's disease and proprioceptive exercises for the recovery of balance. An illustrated exercises booklet was given to the patient.
2501583|NCT02890836||Pregnant women with pre-existing diabetes|Inclusion of 400 women is anticipated.
2501584|NCT02890836||Healthy pregnant women|Inclusion of 100 women is anticipated
2501672|NCT02890537|Experimental|Core decompression/PREOB® implantation|Core decompression/autologous osteoblastic cells (PREOB®) implantation
2501678|NCT02890537|Active Comparator|Core decompression/BMC implantation|Core decompression/bone marrow concentrate (BMC) implantation
3196082|NCT00846872|Active Comparator|High dose GHRP -3|Subjects will receive the infusion for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
2501841|NCT02889250|Experimental|Open Label DBS|6 months of DBS
2501871|NCT02888899|Experimental|Standard treatment|
2501874|NCT02888899|Experimental|PTNS in addition to standard treatment|
2501961|NCT02888509||healthy control|Well mathed with patients in age, gender, education
2501962|NCT02888509||major depression disorder|patients with major depression disorder
2501963|NCT02888509||anxiety disorder|patients with anxiety disorder
2501964|NCT02888509||bipolar depression disorder|patients with bilopar depression disorder
2501996|NCT02888015|Other|Upper extremity exercise|Five upper extremity exercises will be provided to each of the 10 participants to complete on a daily basis. Exercises included shoulder flexion, elbow flexion/extension, shoulder abduction, internal/external rotation
2502027|NCT02887794|Experimental|30 patients with schizophrenia|Measure the correlation between the score on the scale psychometric AHRS (Auditory Hallucination Rating Scale) to measure HAV and performance scores discrimination test psychoacoustic Tone Matching Task in subjects suffering from schizophrenia and HAV.
2502077|NCT02887560|Experimental|All patient|Only one arm has been specified for the protocol. This arm included all study patient (33) for which the intervention is to be administered
2502386|NCT02884856||Females observers (F)|those with female gender characteristics
2502388|NCT02884856||Male observers (M)|those with male gender characteristics
2502431|NCT02884674|Active Comparator|active Transcranial Magnetic Stimulation|Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, Using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
2502432|NCT02884674|Placebo Comparator|Placebo|Placebo comparator, using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using Transcranial Magnetic Stimulation navigator and robot
2502482|NCT02884245|Experimental|Arm E2: With estrogens pretreatment|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
2502489|NCT02884245|No Intervention|Arm S: without estrogens pretreatment|No estrogen pretreatment will be delivered
2502541|NCT02883595|Experimental|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
2502544|NCT02883595|Placebo Comparator|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
2502676|NCT02883062|Active Comparator|Arm A (carboplatin, paclitaxel, mastectomy, lumpectomy)|Patients receive carboplatin IV over 30 minutes Q3W and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2502681|NCT02883062|Experimental|Arm B (atezolizumab, carboplatin, paclitaxel, breast surgery)|Patients receive atezolizumab IV over 30-60 minutes and carboplatin IV over 30 minutes Q3W, and paclitaxel IV over 1 hour QW. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2502778|NCT02882100|Experimental|aTIV|NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents
2502780|NCT02882100|Active Comparator|TIV|NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents
2502857|NCT02881359||LifeSeal® Kit|creation of a coloanal or colorectal anastomosis
2502924|NCT02881268||Patient with sepsis|Patient hospitalized in intensive care unit
2502925|NCT02881268||Patient without sepsis|Patient hospitalized in intensive care unit
2503072|NCT02880046||Melanoma (LyteloMel)|
2503076|NCT02880046||Lung cancer (TeloCap)|
2503079|NCT02880046||Renal carcinoma (EMIR)|
2501523|NCT02891161|Experimental|Arm A: Safety Run In Phase Ib|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
2501529|NCT02891161|Experimental|Arm B: Investigational Treatment Phase II|Subjects will receive durvalumab 1500mg Q4 weekly with RT to gross disease over 36 fractions. Durvalumab will start on Day 1. RT to start on Day 1 or 2.. Subjects will receive adjuvant durvalumab monotherapy Q4 week, up to 12 months. Adjuvant durvalumab monotherapy to start 4 weeks post completion of durvalumab and RT.
2501570|NCT02890875|Active Comparator|Ethanol lock|70% ethanol
2501572|NCT02890875|Active Comparator|Heparin lock|Heparinized saline (100 U/mL)
2501608|NCT02890641||drug resistant epilepsy|Sequencing of paired blood-brain DNA samples
2501691|NCT02890095|Experimental|Arm A = Breast Cancer surgery|Arm A : women undergoing breast cancer surgery.
2501695|NCT02890095|Other|Arm B = Control (plastic surgery)|Arm B : women undergoing breast surgery for the purpose of plastic surgery
3196083|NCT00846872|Placebo Comparator|Saline Infusion|Subjects will receive Placebo for 14 ± 2 days. On day 1 of the test period, patients will report to the CTRC in a fasting state stay there for 3 - 4 hrs after the initiation of the infusion. Blood will be drawn in a fasting state and urine sample will be collected prior to insertion of the OmniPod and the CGMS. On day 7 +/- 2 days and on day 12 +/- 2 days, patients will report to the CTRC for blood draw and CGMS insertion. On day 14 +/- 2 days, patients will again report to CTRC for 24 hour admit. They will undergo urine sample collection, periodic blood draws and BP monitoring. After the 24 hour period, the CGMS will be disconnected and the patient will undergo FMD after which the test period will be terminated. There will be a washout period of 2 weeks between each test period.
3196084|NCT00846898|Experimental|cinnamon|Subjects in this group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
3196085|NCT00846898|Placebo Comparator|Control|Subjects in this group will receive placebo capsules (starch flour) for 12 weeks period. The 2 g dose of starch capsules will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
3196086|NCT00846911||Group 1|
3196087|NCT00846924|Active Comparator|repeat 24-hour Holter monitor|
3196088|NCT00846924|Experimental|30-day ambulatory cardiac event monitor|
2502377|NCT02884960|Experimental|Embozene Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embozene Microspheres as the embolic agent.
2502379|NCT02884960|Active Comparator|Embosphere Microspheres|Patients will undergo the uterine fibroid embolization procedure with Embosphere Microspheres as the embolic agent.
2502433|NCT02884700||Severe legionellosis cases|Patients admitted to Grenoble University Hospital for severe legionellosis between 2006 and 2011.
2502497|NCT02884193|Experimental|Brief Cooling (Quick Icing)|Group receiving the application of cold on the ventral side of the dominant forearm for 30 seconds, using the technique of ice beakers dynamically.
2502504|NCT02884193|Active Comparator|Prolonged Cold|"Group receiving the intervention of ice bag for a period of 5 and a half minutes from 1 minute, on the ventral side of the dominant forearm"
2502509|NCT02884193|Sham Comparator|Control|"Group receives a placebo application through an ice bag empty. The bag will be applied from 1 minute to 6 and a half minutes, as the group of prolonged cold"
2502551|NCT02883543|Experimental|icotinib plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy.
2502554|NCT02883543|Active Comparator|icotinib|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib monotherapy.
2502557|NCT02883543|Active Comparator|chemotherapy plus radiotherapy|Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive chemotherapy plus concurrent radiotherapy.
2502598|NCT02883218||Comunity-acquired severe sepsis patients|Patients with new-onset community-acquired severe sepsis within 24h without confounding factors in immune status
2502602|NCT02883218||Non-severe sepsis patients|Patients between 18 and 90 years of age and be admitted to the ICU without a diagnosis of severe sepsis.
2502607|NCT02883218||Healthy controls|Heathy vonlunteers between 18 and 90 years of age.
2502631|NCT02883023|Experimental|Electrosclerotherapy|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will be treated with electrosclerotherapy
2502632|NCT02883023|Active Comparator|Intralesional bleomycin injections|One region of interest in the capillary malformation will be treated with intralesional bleomycin injections without electroporation
2502633|NCT02883023|No Intervention|No treatment|One region of interest in the capillary malformation (approximately 1.5x1.5cm)will not be treated.
2502812|NCT02881853|Experimental|Part A1|XmAb7195 for IV infusion; dose level 1; 4 once-weekly doses
2502814|NCT02881853|Experimental|Part A2|XmAb7195 for SC injection; dose level 1; 4 once weekly doses
2502817|NCT02881853|Experimental|Part A3|XmAb7195 for SC injection; dose level 2; 4 once weekly doses
2502819|NCT02881853|Experimental|Part A4|XmAb7195 for SC injection; dose level 3; 4 once weekly doses
2502820|NCT02881853|Experimental|Part A5|XmAb7195 for SC injection; dose level 4; 4 once weekly doses
2502822|NCT02881853|Experimental|Part B6|XmAb7195 or placebo for SC injection; dose level 5; 4 once-weekly doses
2502826|NCT02881853|Experimental|Part B7|XmAb7195 or placebo for SC injection; dose level 6; 4 once-weekly doses
2502830|NCT02881853|Experimental|Part B8|XmAb7195 or placebo for SC injection; dose level 7; 4 once-weekly doses
2502832|NCT02881853|Experimental|Part B9|XmAb7195 or placebo for SC injection dose level 8; 4 once-weekly doses
3175102|NCT00630123||1|Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
3196089|NCT00846950|Experimental|healthy volunteers|
3196090|NCT00846963|Experimental|Ursodiol|Participants assigned in this arm receive an ursodiol suspension at 20mg/ml.
3196091|NCT00846963|Placebo Comparator|placebo|A placebo suspension that looks like the ursodiol suspension used.
3196092|NCT00846976|Experimental|200 mg Casodex|
2501800|NCT02889328|Experimental|regorafenib|regorafenib 100 mg po od daily, every 4 weeks (28 day)
2501863|NCT02889224|Active Comparator|Obese|Subjects with BMI between 30 - 40 kg/m2 and no alteration of corticotrope axis.
2501864|NCT02889224|Experimental|Hypercortisolism|Subject with BMI between 18 - 40 kg/m2 and presenting a hypercortisolism defined by HAS (Haute Autorité de Santé).
2501865|NCT02889224|Experimental|Hydrocortisone|Subject with BMI between 18 - 30 kg/m2 and with adrenal or corticotrope failure
2501866|NCT02889224|Experimental|Control|Subject with BMI between 18 - 30 kg/m2 and with a pituitary or adrenal tumor without effect on corticotrope axis.
2501910|NCT02888717|Experimental|OSNA stadification during surgery|The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and will be analysis both by histological analysis and OSNA analysis
2501969|NCT02888457|Other|AOM (acute otitis media)|Infants (6-30 months of age) with acute otitis media
2501971|NCT02888457|Other|DCC (day-care centers)|Healthy infants (6-30 months of age) attending day-care centers
2502024|NCT02887911||Asthmatic, not taking inhaled steroids|Men/Women, ages 18-75 who are not currently taking corticosteroids.. No intervention; this is a prospective observational study.
2502025|NCT02887911||Asthmatic, taking inhaled steroids|Men/Women, ages 18-75 who are already taking corticosteroids prescribed by their physician. No intervention; this is a prospective observational study.
2502028|NCT02887911||Healthy, non-asthmatic without allergies|Men/Women, ages 18-75 without a current diagnosis of asthma and no allergies. No intervention; this is a prospective observational study.
2502030|NCT02887911||Healthy, atopic non-asthmatic|Men/Women, ages 18-75 with allergies but without a current diagnosis of asthma. No intervention; this is a prospective observational study.
2502053|NCT02887573|Experimental|Free-residue nutrients+PEG|"Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm.~Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy."
2502056|NCT02887573|Experimental|Low fiber diet+PEG|"Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given.~Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test.~Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists.~Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy."
2502127|NCT02887053|Experimental|All subjects|All subjects will have an MRI examination
2502159|NCT02886767|Experimental|skin-to-skin contact (SSC)|Experimental: a daily skin-to-skin contact (SSC) at least 15 minutes in length
2502162|NCT02886767|No Intervention|Control: hospital routine care|As the hospital routine. Allow the father to visit the neonate, touching the neonate
2502189|NCT02886442|Experimental|Cohort 3|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two kinds of visits:~Visit 1:~Two adhesive strips (standard adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:~Two adhesive strips (new adhesive strip) are applied on the peristomal skin; one strip is exposed to real output (contained in a sleeve) and the other strip is not.~Visit 2:"
2502214|NCT02886156|Experimental|CPAP plus BSC|Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center.
2502216|NCT02886156|Active Comparator|BSC intervention|Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
2502273|NCT02885831||A - Abduction splintage|Treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients.
2502274|NCT02885831||B - Surveillance|No treatment by abduction splintage. Sonographic, clinical and radiographic surveillance. 45 patients
2502282|NCT02885493||Falls is <or = 1 year|Patients whose number of falls is <or = 1 year
2502284|NCT02885493||falls is> 1 year|Patients whose numbers falls is> 1 year
2502565|NCT02883725||Esophageal atresia|
3196093|NCT00846989|Experimental|1|
3196094|NCT00846989|Experimental|2|
3196095|NCT00846989|Active Comparator|3|
3196096|NCT00847028|Experimental|1|glucose 10%
3196097|NCT00847028|Experimental|2|glucose 20%
3196098|NCT00847028|Experimental|3|glucose 30%
3196099|NCT00847028|Placebo Comparator|4|placebo: sterile water
3196100|NCT00847054|Experimental|MORAb-004|
3196101|NCT00847067|Active Comparator|Block|
3196102|NCT00847067|Sham Comparator|Sham injection|Skin injections with Normal Saline
3196103|NCT00847080|Experimental|Sitagliptin|
3196104|NCT00847080|Placebo Comparator|Placebo|
3196105|NCT00847093|Experimental|Cream|Experimental group receiving either medicated topical cream or placebo cream
3196106|NCT00847119|Experimental|Bevacizumab & capecitabine & radiotheraphy|"Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.~Radiotherapy 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.~Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period."
3196107|NCT00847158|Active Comparator|1|phacoemulsification alone
2501622|NCT02890823|Active Comparator|non-EIAEDs-1000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 1000 IU once daily
2501623|NCT02890823|Active Comparator|non-EIAEDs-3000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 3000 IU once daily
2501624|NCT02890823|Active Comparator|non-EIAEDs-6000|Patients receiving non-EIAEDs who were randomly assigned to receive vitamin D3 6000 IU once daily
2501676|NCT02890225|Other|3|Patients in 3 days
2501681|NCT02890225|Other|10|Patients in10ys
2501687|NCT02890225|Experimental|30|Patients in10ys
2501728|NCT02889848|Sham Comparator|Saline only|Injection of saline to assess the injection procedure
2501730|NCT02889848|Experimental|1.16 mg EN3835|Injection of maximum marketed dose of EN3835 regardless of fibroid size
2501732|NCT02889848|Experimental|Dose 1|Injection of 0.05 mg EN3835 per cm3 fibroid
2501735|NCT02889848|Experimental|Dose 2|Injection of 0.1 mg EN3835 per cm3 fibroid
2501737|NCT02889848|Experimental|Dose 3|Injection of 0.2 mg EN3835 per cm3 fibroid
2501748|NCT02889666|Experimental|Carboplatin|Carboplatin-based chemotherapy (Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Carboplatin was done for 3 cycles with 30 days after last surgery.
2501755|NCT02889666|Experimental|Docetaxel|Docetaxel-based chemotherapy (Docetaxel 120mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Docetaxel was done for 3 cycles with 30 days after last surgery.
2501763|NCT02889666|Experimental|Gemcitabine/Cisplatin|Gemcitabine/Cisplatin-based combinational chemotherapy (Gemcitabine 200mg + Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2501770|NCT02889666|Experimental|Cisplatin|Cisplatin-based chemotherapy (Cisplatin 60mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy using Cisplatin was done for 3 cycles with 30 days after last surgery.
2501776|NCT02889666|Experimental|Docetaxel/Oxaliplatin|Docetaxel/Oxaliplatin-based chemotherapy (Docetaxel 120mg + Oxaliplatin 200mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2501778|NCT02889666|Experimental|Docetaxel/Carboplatin|Docetaxel/Carboplatin-based chemotherapy (Docetaxel 120mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2501779|NCT02889666|Experimental|Gemcitabine/Carboplatin|Gemcitabine/Carboplatin-based chemotherapy (Gemcitabine 200mg + Carboplatin 400mg) was performed 30 days before surgery for patients who had previous surgery to remove the primary non-small cell lung carcinoma but suffered from the recurrent disease. The same chemotherapy was done for 3 cycles with 30 days after last surgery.
2501780|NCT02889666|Placebo Comparator|Placebo|No Adjuvant chemotherapy using CCODG was done for patients who had previous surgery to remove the primary non-small cell lung carcinoma but subject to tumor relapse. Instead, placebo was supplied to these patients as a comparator Arm.
2501852|NCT02889107|No Intervention|standard care|Patients received standard listening strategies for 10 weeks
2501853|NCT02889107|Experimental|intervention|Patients received an assistive listening device (personal frequency modulated systems) for 10 weeks
2501888|NCT02888795|Experimental|hypertonic dextrose prolotherapy|
2501927|NCT02888587||Control group|no gastrointestinal symptoms
2501928|NCT02888587||Symptomatic group|Patients with Visceral hypersensitivity
3196108|NCT00847158|Active Comparator|2|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
3196109|NCT00847184|Active Comparator|1. Airtraq|Intubation with the use of the Airtraq technique
2502054|NCT02887534|Experimental|Arm 1|three times medication; SPARC1401-low dose
2502055|NCT02887534|Experimental|Arm 2|three times medication; SPARC1401-mid dose
2502057|NCT02887534|Experimental|Arm 3|three times medication; SPARC1401-high dose
2502059|NCT02887534|Active Comparator|Active comparator|Reference1401; To be administered 3 times a day
2502060|NCT02887534|Placebo Comparator|Arm 5|Placebo1401 - 3 three times a day
3196110|NCT00847184|Active Comparator|2. MacIntosh|Intubation using the standard MacIntosh blade
3196111|NCT00847223|Experimental|ZARNESTRA (Tipifarnib)|
3196112|NCT00847236||Subjects with Polymyalgia Rheumatica|50 subjects with Polymyalgia Rheumatica, both acute and chronic
2502239|NCT02885987|No Intervention|Standard Colonoscopy|AmplifEYE will not be used.
2502242|NCT02885987|Experimental|Colonoscopy with AmplifEYE|AmplifEYE accessory device will be attached to the colonoscope prior to starting the procedure
2502261|NCT02885779||Patient having an operating indication of adnexa surgery|Patient having an operating indication of adnexa surgery : unilateral or bilateral adnexectomy
2502320|NCT02885571|Active Comparator|MAD for subjective compliance|MAD for subjective compliance group wears the same SomnoDent Flex with DentiTrac to objective group, but they are subjected to be prescribed based on the subjective compliance data, which are acquired from patient's explanation. Compliance (average daily time,
2502324|NCT02885571|Experimental|MAD for objective compliance|MAD for objective compliance group wears the same SomnoDent Flex with DentiTrac to subjective group, but they are subjected to be prescribed based on the objective compliance data, which are acquired from data recorded within SomnoDent Flex with DentiTrac.
2502579|NCT02883465|Other|Single arm|
3196113|NCT00847236||Subjects w/o Polymyalgia Rheumatica|50 subjects with Rheumatic Disease other than polymyalgia Rheumatica
3196114|NCT00847236||Subjects w/o Rheumatic Disease|50-Non Rheumatic disease subjects
2501628|NCT02890615|Experimental|Depression Self-care Intervention (SCI)|"Intervention group participants will receive the Depression Self-Care Toolkit for Cancer Survivors and will be supported by telephone by a coach who will help to activate them, guide them through the materials, help in selecting appropriate tools, and provide positive reinforcement. Coach contacts will be made every week for 3 months followed by 3 monthly contacts, up to a maximum of 15 contacts, lasting 10-20 minutes each.~The coach uses a stepped approach (i.e. educate about depression, initiate mood monitoring, determine participant's goals with respect to reducing depressive symptoms, and help with the use of specific tools). A suggested script is provided for the coach as a framework for each call. Tailoring of the SCI to different participants will be based on problems, depressive symptoms (from the PHQ-9), or concerns a participant may raise during the call."
2501632|NCT02890615|No Intervention|Control group|"Members of both groups will continue to receive usual care for their depression. We will not interfere with usual care beyond recommending that participants discuss their depressive symptoms with their doctor. If participants consent, a short progress report will be send to their treating physician at the end of the study. At each follow-up, we will ask participants about specific treatment they have received for depression since entering the study (antidepressant medication initiation, discontinuation, change of dose, or psychotherapy) and use of community resources. The Intervention group will receive the Depression SCI. The Control group will receive only usual care for 6 months after randomization; they will be given the Toolkit with a single coaching call upon completion of the final interview, to ensure their access to depression treatment."
2501758|NCT02890030||Case-Control|Patients with testicular germ cell tumor who were treated with surgery and not cisplatin-based chemotherapy
2501811|NCT02889419|Experimental|Evaluation of underwear Selfia®|Every patient is his own control.
2501867|NCT02889146|Active Comparator|Control group|Conventional Physical Therapy: motor physical therapy delivered by the intensive care unit physical therapists, according to his own criteria, without following any protocol. Respiratory therapy.
2501868|NCT02889146|Experimental|Protocol group|Early and progressive mobilization program: motor physical therapy delivered by a trained physical therapist according to the mobilization protocol, in which patient progress according to his performance. Respiratory therapy.
3196115|NCT00847249|Experimental|1|Solution for nebulisation, inhaled
3196116|NCT00847249|Placebo Comparator|2|Solution for nebulisation, inhaled
2502100|NCT02887300|No Intervention|Passive control group|"After randomisation, 30 consenting, eligible study participants will be allotted a place in the passive, parallel control group. Participants will work as usual in the ED. Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
2502103|NCT02887300|Experimental|Planned intervention - mantra meditation|"After randomisation, 30 randomly chosen, ED staff members will be taught mantra meditation by an experienced meditator. Each 4 hour session will occur once every two weeks for 8 weeks (total of 4 sessions) and consist of guided meditation as well as discussions around prescribed texts on the meaning of health care.~In addition, participants will be asked to engage in home work (20 minutes of a guided mantra meditation on a twice daily basis). Biological and survey samples will be obtained from both groups of participants on the same days:~T1 - one week before session one T2 - one week after session 4 T3 - three months following T2"
2502149|NCT02886975|Experimental|low protein diet plus α-keto acid|A comparison of normal diet and low protein diet plus α-keto acid after intervention in the same individual
2502202|NCT02886559|Experimental|DCCAG|Chidamide 30mg twice for one week decitabine 20mg/m^2 for 5 days
2502234|NCT02886078|Experimental|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
2502237|NCT02886078|Active Comparator|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
2502315|NCT02885766|Experimental|PF-114|"PF-114 From 50 mg up to the MTD. Dose escalation for each next cohort is conducted by increasing the dose by 20 % (or the closest lower level, which is a multiple of 25 mg) if there are Grade 3 ADRs according to NCI CTC AE v.4 without reaching а MTD. An increase of the dose by 40 % is applied if there were Grade 2 ADRs. In the absence of Grade 2 or 3 ADRs an increase of 100 % is applied.~When the dose reaches 400 mg/day, the following increase in dose can be made after discussing results of safety findings of PF-114 between the Investigators and the Sponsor.~Orally, once daily"
2502341|NCT02885142|Experimental|Transanal endoscopic microsurgery group|
2502349|NCT02885142|Active Comparator|endoscopic submucosal dissection group|
2502449|NCT02884531|Experimental|Patient Education and BBAT|Patients will participate in Patient Education and Basic Body Awareness Therapy
2502452|NCT02884531|Active Comparator|Patient Education|Patients will only participate in Patient Education
2502492|NCT02884024||lean|healthy subject undergoing routine screening colonoscopy, BMI< or = 25
2502499|NCT02884024||mildly obese|healthy subject undergoing routine screening colonoscopy, BMI 30-33.9
2502506|NCT02884024||moderate-to-severe obese|healthy subject undergoing routine screening colonoscopy, BMI 34+
2502532|NCT02883621|Active Comparator|Group A|subjects receive standard upper endoscopy
2502534|NCT02883621|Experimental|Group B|subjects receive cap assisted upper endoscopy
2502606|NCT02883426|Experimental|Group 1: H3N2v Seronegative Adults: H3N2v LAIV|Participants will receive one dose of H3N2v LAIV on Day 0 (study entry). They will then receive one dose of H3N2v IIV on Day 84.
2502608|NCT02883426|Experimental|Group 2: H3N2v Seropositive Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2502609|NCT02883426|Placebo Comparator|Group 2: H3N2v Seropositive Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2502610|NCT02883426|Experimental|Group 3: H3N2v Seronegative Adolescents: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2503809|NCT02874573|Active Comparator|Treatment Group|Subjects in the tocilizumab group will receive a 4 mg/kg infusion at baseline, and weeks 4 and 8, as per the recommended starting dosing for rheumatoid arthritis
2501648|NCT02890446|Experimental|Internal Focus (IF)|"Participants received arm training using the InMotion2 robot without the video game interface. Participants were instructed to think about how they were moving their arm while completing the arm training tasks.~IF instructions:~think about how you're moving your arm; push your arm away from you; pull your arm toward you; move your arm to the right/left"
2501854|NCT02889159|Other|Candida albicans antigen|useful in measuring the capacity of a person to manifest a delayed-type hypersensitivity response
2501856|NCT02889159|Other|histamine phosphate|useful to assess type I IgE-mediated hypersensitivity reactions
2501858|NCT02889159|Other|imiquimod 5% cream|direct stimulator of TLR-7, a key component of the innate immune response with downstream signaling effects involving the adaptive immune response
2501860|NCT02889159|Other|tape stripping|to create alterations in key inflammatory mediators involved in both the innate and adaptive immune responses
2501862|NCT02889159|No Intervention|Control|control sample from both sun exposed and non-sun exposed skin
2501916|NCT02888730|Experimental|Tobramycin nebulized nasally|Nebulized Tobramycin, one bulb (tobramycin 300 mg and sodium chloride 11.25 mg) nasally twice a day for 15 days
2501918|NCT02888730|Placebo Comparator|Physiologic serum nebulized nasally|Nebulized sodium chloride 0.9%, one bulb twice a day nasally for 15 days
2501935|NCT02888340|Experimental|Acupuncture|One session of acupuncture prior to receiving pain medications after arriving to the emergency department with pain as a symptom.
2501937|NCT02888340|No Intervention|Usual Care|Usual care for pain, without intervention, after arriving to the emergency department with pain as a symptom.
2502045|NCT02887677|Active Comparator|Dapagliflozin|Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
2502046|NCT02887677|Placebo Comparator|Placebo|Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.
2502061|NCT02887378|Experimental|hot clamps|reusable hot biopsy forceps
2502062|NCT02887378|Active Comparator|normal clamps|normal clamps
2502167|NCT02886793|Experimental|FDG|all patients will undergo a PET scan and will receive 18F fludeoxyglucose
2502199|NCT02886429|Active Comparator|Group A|Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
2502201|NCT02886429|Active Comparator|Group B|Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
2502241|NCT02886052|Experimental|ICBT for insomnia|Therapist guided Internet-CBT for insomnia
2502244|NCT02886052|Active Comparator|Active control|Written information on sleep, insomnia, and sleep hygiene
2502288|NCT02885753|Experimental|Experimental arm with oxaliplatin intra-arterial|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intra-arterially Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
2502295|NCT02885753|Active Comparator|Reference arm with oxaliplatin intravenous|Panitumumab (6 mg/kg if RAS wild) or Bevacizumab (5 mg/Kg if RAS mutated) Oxaliplatin (85 mg/m²) intravenously Folinic Acid (400 mg/m²) intravenously 5Fu: 400 mg/m² in bolus of 10 minutes 5Fu: 2400 mg/m² intravenously over 46 hours
3196117|NCT00847262|Experimental|Telmisartan Group|Telmisartan intervention group
3196118|NCT00847262|Active Comparator|Amlodipine Group|Amlodipine intervention group
2502522|NCT02883868||patients treated with CXL|
2502562|NCT02883569|Active Comparator|HIVD-OP|open or endoscopic discectomy
2502564|NCT02883569|Experimental|HIVD-NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2502566|NCT02883569|Active Comparator|LSS w/o instability -OP|decompression, instrumentation and fusion
2502568|NCT02883569|Experimental|LSS w/o instability -NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2502571|NCT02883569|Active Comparator|LSS w/ instability - OP|decompression, instrumentation and fusion
2502572|NCT02883569|Experimental|LSS w/ instability - NonOP|epidural block, epidural adhesiolysis, exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2502575|NCT02883569|Active Comparator|No intervention group|exercise, ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac, codeine, oxycontine, IRcodone, Tramadol
2502576|NCT02883569|Experimental|Intervention group|epidural block, epidural adhesiolysis
2502662|NCT02882984|Active Comparator|WBRT along with TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~3750Gy/15F~Other Name: WBRT"
2545084|NCT02597465|Experimental|SPARC1507|SPARC1507
3196119|NCT00847275|Placebo Comparator|1|"Exclusive nephrology follow-up arm"
3196120|NCT00847275|Experimental|2|"Geriatric follow-up arm"
3196121|NCT00847314||Group 1|
2501661|NCT02890238|Active Comparator|sildenafil citrate|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd - 7th day of the cycle and sildenafil citrate 20mg tab from 7th-11th day of the same cycle orally 3times/day
2501662|NCT02890238|Placebo Comparator|placebo group|50 women who will be given clomiphene citrate 50mg (clomid,) orally 2times/day from 2rd- 7th day of the cycle and placebo tablets from 7th-11th day of the same cycle orally 3 times/day
2501742|NCT02889939|Other|UC + ETT|"An enriched comprehensive task-specific therapy (ETT) program combining intensive and task-specific therapy with the sensory-motor, social, and cognitive stimulation inherent to environmental enrichment.~The intervention was preceded by a baseline period of usual care (UC) for 3 weeks, which also served as a control."
2501872|NCT02888873|Active Comparator|Charisma|applied randomly
2501873|NCT02888873|Active Comparator|Charisma classic|applied randomly
2501975|NCT02888444|Active Comparator|Varenicline plus behavioural support|12 weeks extended treatment with varenicline, plus relapse prevention-orientated behavioural support
2501979|NCT02888444|Placebo Comparator|Placebo plus behavioural support|12 weeks extended treatment with placebo, plus relapse prevention-orientated behavioural support
2502032|NCT02887807|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
2502033|NCT02887807|Placebo Comparator|Control|Single intravenous bolus of placebo (2.5 mg/kg) at the onset of resuscitation
2502093|NCT02887339|Experimental|Intervention Group|Tissue requesters from participating OPOs are randomly assigned to complete additional informed consent training through an interactive online training website.
2502095|NCT02887339|Experimental|Control Group|The control group of tissue requesters receive the standard training offered by their OPO and GTEx partners.
2502130|NCT02887001|Other|BMO|
2502190|NCT02886780|Experimental|Concentrated Exposure Treatment (cET)|Please refer to:Havnen, A., Hansen, B., Öst, L.-G. & Kvale, G. Concentrated ERP delivered in a group setting: An effectiveness study. Journal of Obsessive Compulsive and Related Disorders 3, 319-324 (2014)
2502194|NCT02886780|Active Comparator|Self-help|"The self-help condition (SH):~Foa, E.B. & Kozak, M.J. Mastery of obsessive-compulsive disorder: Client workbook, (Graywind Publications, New York, 1997)."
2502198|NCT02886780|No Intervention|Wait list|
2502226|NCT02886130|Placebo Comparator|Placebo|Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
2502230|NCT02886130|Experimental|Alpha-GPC|Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
3173604|NCT00613808|Active Comparator|B Same treatment for 6 weeks, 200ppm NO gas|Subjects were treated by topical application of 200ppm Nitric Oxide gas delivered to the wound area for 8 hours per day for 6 weeks
3173605|NCT00613847|Active Comparator|1|Patients with invasive solid tumors
2502354|NCT02885090|Experimental|RTT patient|Blood sampling
2502361|NCT02885090|Experimental|Parents|Blood sampling. To distinguish between inherited polymorphic variants and potentially deleterious new imbalances.
2502493|NCT02883907||Healthy volunteers|
2502500|NCT02883907||Osteoarthritis patients|
2502577|NCT02883777|Experimental|High Protein and Low Glycemic Index Diet|A protocol of a high protein and low glycemic index diet.
2502578|NCT02883777|Active Comparator|Conventional Diet|A protocol of a conventional diet.
2502649|NCT02882815|Other|IrisFIT PFO Occluder|Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device.The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.
2502693|NCT02882659|Experimental|Dendritic Killer Cell (DKC)|All enrolled patients received one treatment cycle of DKC cell therapy, which consists of 5 infusion cycles approximately 23 days apart. There were 3 dose levels: 5 x 10^6, 1 x 10^7, and 5 x 10^7 cells, and the protocol followed a traditional 3+3 dose escalation design.
2502733|NCT02882412||patient group|
2502840|NCT02881762|Active Comparator|Immediate start maraviroc|To start maraviroc immediately after randomization.
2502841|NCT02881762|Active Comparator|Delayed start maraviroc|To start maraviroc 8 weeks after enrollment.
2502892|NCT02881437|Experimental|IgHy10 (HyQvia)|"Open-label, one arm study conducted in France in subjects with PI to IgG trough level at steady state after standard SCIG dosing and after IgHy10 (HyQvia) administered every other week and every 3-4 weeks at equivalent dose. The study will have three periods:~The first period is a one-week ramp-up period. The first administration of IgHy10 (HyQvia) will be with a one-week dose~During the first three-month follow-up period, IgHy10 (HyQvia) will be administered, every other week at a dose equivalent to the dose administered with the previous treatment (standard SCIG).~At the end of this first follow-up period, the dose of IgHy10 (HyQvia) will be increased for the next infusion to reach a 3-4 week equivalent dose."
2503877|NCT02874222||Caucasian|surveys completed by subject n=600, nationally
3173606|NCT00613847|Active Comparator|2|Patients with advanced solid tumors that express HER2 with tumors that are HER2 1+ by IHC or FISH.
3173607|NCT00613873||1|Women participating in a community based mammography or cervical screening program will also participate in colonoscopy screening. Participation will be measured by stating an interest in colorectal cancer screening and then following through with colonoscopy screening. Furthermore we will assess whether those complying with colonoscopy will also recommend colonoscopy screening for their spouses or household members.
3173608|NCT00613899|Other|Telesurveillance|"At time of discharge from hospital, 40 ALS patients willbe enrolled in a telesurveillance program (TP) for the management of cought at home.~Two hours of an in-hospital educational training will be provided to patients and caregivers on the use of:~air stacking with Ambu balloon~manual manoeuvres and~in-Exoflator device indications and use"
3173609|NCT00613912||A|Ambulant patients with major depression
3173610|NCT00613964|Placebo Comparator|Standard Therapy|Standard heart failure therapy excluding carperitide administration
3173611|NCT00613964|Active Comparator|Carperitide Therapy|Addition of carperitide administration to standard heart failure therapy
3173612|NCT00614003|Experimental|1|decision support
2501664|NCT02890212|Experimental|selenium|subjects resistant to treatment of major depression with sertraline who were randomized and ingest selenium pills (400 microgram) during six weeks
2501667|NCT02890212|Placebo Comparator|placebo|subjects resistant to treatment of major depression with sertraline who were randomized and ingest placebo pills
2501747|NCT02889952||NIR-|All consecutive patients (n=174) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) without the use of NIR - parathyroid identification was done by naked eye only- by surgeon 1, from January 2015 to January 2016 (period 1)
2501750|NCT02889952||NIR|All consecutive patients (n=63) who underwent conventional total thyroidectomy (TT)+/- lymph node dissection (LND) with intraoperative use of NIR - surgical field was examined with NIR before any thyroid dissection- by surgeon 1, from February 2016 to May 2016 (period 2)
2501756|NCT02889952||Control1|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by another surgeon in the unit (surgeon 2), during period 1.
2501769|NCT02889952||Control2|Patients (n=30) patients randomly selected among the patients who underwent TT+/- LND without the use of NIR, by surgeon 2, during period 2.
2501799|NCT02889471|Experimental|ERCP with nasobiliary catheter|
2501801|NCT02889471|Active Comparator|ERCP only|
2501840|NCT02889185|Experimental|Adaptative optics retinal camera|
2501878|NCT02888912|Active Comparator|EQUIA|randomly applied
2501879|NCT02888912|Active Comparator|Gradia Direct Posterior|randomly applied
2501981|NCT02888028|Active Comparator|ICD remote monitoring|Active Comparator: ICD remote monitoring additionally to regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement
2501985|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
2502076|NCT02887846|Active Comparator|group 1|Heated humidified high-flow nasal cannula therapy device for post extubation
2502083|NCT02887846|Active Comparator|group 2|Nasal continuous positive airway pressure for post extubation
2502114|NCT02887131|Experimental|Healthy volunteers|
2502115|NCT02887131|Experimental|Arthritis|
2502116|NCT02887131|Experimental|Instability|
2502131|NCT02886910|Experimental|Clinical observation|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. They will receive a limited evaluation (blood culture, complete blood count), and a clinical observation. Antibiotics will be started only if sepsis-related signs or symptoms are present.
2502133|NCT02886910|Active Comparator|Standard management|Asymptomatic newborns born at term to mothers with suspected chorioamnionitis. The will receive a limited evaluation (blood culture, complete blood count), a clinical observation and antibiotics at birth.
2502191|NCT02886637||Acinetobacter baumannii infection|Critically ill patients infect with Acinetobacter baumannii
2502317|NCT02885610|Placebo Comparator|Placebo Comparator|Placebo SC plus standard therapy; placebo once weekly ,and total of 48 doses
2502318|NCT02885610|Experimental|RC18 80 mg plus standard therapy|RC18 80 mg/kg SC plus standard therapy RC18 80 mg SC once weekly X 48 doses
2502319|NCT02885610|Experimental|RC18 160 mg plus standard therapy|RC18 160 mg/kg SC plus standard therapy RC18 160 mg SC once weekly X 48 doses
2502321|NCT02885610|Experimental|RC18 240 mg plus standard therapy|RC18 240 mg/kg SC plus standard therapy RC18 240 mg SC once weekly X 48 doses
2502358|NCT02885116|Placebo Comparator|oxygen supplementation|right heart catheterization will be done in hypoxemic patients with supplemental oxygen
2502363|NCT02885116|Active Comparator|Nasal high flow (NHF) supplementation|right heart catheterization after during NHF (20 min) use with 35 l/min
2502450|NCT02884843|Active Comparator|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction Disposable
2502454|NCT02884843|Active Comparator|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
2502549|NCT02883816|Experimental|cystic fibrosis|assessment of lung function in newborns screened for cystic fibrosis
2502673|NCT02882750||Surgical Patients|Early stage NSCLC patients submitted to Surgical Resection
2502679|NCT02882750||SABR Patients|Early stage NSCLC patients submitted to SABR
2502711|NCT02882373|Experimental|Group I (arginine)|Patients receive arginine PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
2502712|NCT02882373|Placebo Comparator|Group II (placebo)|Patience receive placebo PO QID. Treatment continues for up to 3 months in the absence of disease progression or unacceptable toxicity.
2502823|NCT02882230||exposition to the drugs|patients treated with at least one of the following drugs: dolutegravir, elvitegravir and rilpivirine
2502827|NCT02882230||patients non exposed to the drugs|
2502890|NCT02881619|Placebo Comparator|Placebo|Placebo - (inert content)
2502895|NCT02881619|Experimental|Experimental -|400 mg of NAISE etodolac
2502955|NCT02881034||Hepatitis C patients|Hepatitis C virus (HCV) infected patients with a previous non-response to pegylated-interferon/ribavirin therapy and re-treated with pegylated-interferon/ribavirin and telaprevir
2502979|NCT02880787|Other|Adult population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
2502980|NCT02880787|Other|Adult population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
2502981|NCT02880787|Other|Pediatric population 1|TOF-Watch SX® on nondominant arm and TOFScan® on dominant arm
2502983|NCT02880787|Other|Pediatric population 2|TOF-Watch SX® on dominant arm and TOFScan® on nondominant arm
2503713|NCT02875119|Placebo Comparator|Placebo Gel|In the randomized period, duration of treatment will be 14 days; each of the 30 subjects will self-administer placebo gel once daily for 14 consecutive days, with 5 doses administered under clinical supervision and the remaining 9 doses administered at home.
3173613|NCT00614016|Experimental|single|8 subjects total (6 active and 2 placebo)
3173614|NCT00614029|Experimental|A|IMITREX -abd. to Intraject-abd. to IMITREX -thigh to Intraject-thigh
3173615|NCT00614029|Experimental|B|Intraject-abd. to IMITREX -abd. to Intraject-thigh to IMITREX -thigh
3173616|NCT00614029|Experimental|C|Intraject-abd to IMITREX -abd to Intraject-arm. to IMITREX -arm.
3173617|NCT00614029|Experimental|D|IMITREX-abd to Intraject-abd to IMITREX-arm. to Intraject-arm.
3173618|NCT00614029|Experimental|E|IMITREX-arm to Intraject-arm to IMITREX-thigh to Intraject-thigh
2501686|NCT02890394|Experimental|4 minutes Group|The group was perform the technique inhibition suboccipital four minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
2501688|NCT02890394|Experimental|8 minutes Group|The group was perform the technique inhibition suboccipital eight minutes, collecting data by measuring with algometer and test repositioning of the head before and after the technique.
2501689|NCT02890394|No Intervention|not intervention Group|The not intervention group will be asked to lie supine on the table for ten minutes, collecting data by measuring with algometer and test repositioning of the head before and after laying.
2501760|NCT02889887||preterm|infants who born before 37 completed weeks
3196122|NCT00847327|Experimental|Parental Support|
3196123|NCT00847327|Active Comparator|Diabetes Education|
2501883|NCT02888847|Active Comparator|Philips Zoom! White Speed whitening lamp|Philips Zoom! White Speed whitening lamp
2501889|NCT02888847|Sham Comparator|Philips Zoom! Advanced power lamp|Philips Zoom! Advanced power whitening lamp
2501982|NCT02888054|Experimental|Sequence ABBA|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
2501987|NCT02888054|Experimental|Sequence BABA|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 22: lesinurad/allopurinol 200/300 FDC tablet (Sequence A)
2501988|NCT02888054|Experimental|Sequence ABAB|Day 1: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 8: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
2501989|NCT02888054|Experimental|Sequence BAAB|Day 1: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B) Day 8: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 15: lesinurad/allopurinol 200/300 FDC tablet (Sequence A) Day 22: coadministered lesinurad 200 mg + allopurinol 300 mg tablets (Sequence B)
2502144|NCT02887261|Other|Power Port|patients who received power injectable port
2502147|NCT02887261|Active Comparator|Conventional Port|patients who received conventional port ( not power injectable)
2502195|NCT02886585|Experimental|Previously Untreated Brain Metastases-Cohort A|"- Previously Untreated Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2502197|NCT02886585|Experimental|Progressive Brain Metastases-Cohort B|"- Progressive Brain Metastases~Baseline Brain MRI and PET CT~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2502200|NCT02886585|Experimental|Neoplastic Meningitis-Cohort C|"Neoplastic Meningitis~Histologically confirmed solid malignancy~Positive Cytology~Baseline Brain MRI~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. Treatment will be administered on an outpatient basis.~Brain MRI and PET/CT"
2502203|NCT02886585|Experimental|1-4 Brain Metastases from Melanoma Cohort D|"1-4 Brain Metastases from Melanoma~Clinical indication for stereostatic radiosurgery~Evaluable extracranial focus~For all cohorts, pembrolizumab will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle. In Cohort D, cycle 1 and 2 of pembrolizumab will be administered 3 weeks apart and stereotactic radiosurgery will be administered between cycles. Treatment will be administered on an outpatient basis.~Brain MRI and PET CT"
2502263|NCT02885909|Active Comparator|Insulin protocal with CGM|Insulin protocal with continue glucose monitor
2502268|NCT02885909|Active Comparator|Insulin protocal|Insulin protocal with convential glucose monitor
2502270|NCT02885909|No Intervention|Convential treatment|Convential insulin treatment and glucose monitor
3196124|NCT00847366|Experimental|Perifosine 201|"Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer.~Perifosine dosage:~Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week."
3196125|NCT00847366|Experimental|Perifosine 206|"Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab.~Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle.~Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle."
3196126|NCT00847366|Experimental|Perifosine 207|Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food.
3196127|NCT00847366|Experimental|Perifosine 208|Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule.
3196128|NCT00847366|Experimental|Perifosine 209|Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval).
3196129|NCT00847392|Experimental|Ultrasound|Bladder ultrasound prior to catheterization
3196130|NCT00847392|No Intervention|Standard catheterization|No ultrasound prior to bladder catheterization
3196131|NCT00847418|Experimental|Esketamine|
3196132|NCT00847431||STN DBS Group|PD patients with deep brain stimulators in the subthalamic nucleus. Subjects within this group will be placed into either a 1 contact group, or 2 contact group, depending on contact location requirements for this study.
2502459|NCT02884297|Experimental|surgical termination of pregnancy|Contrast agent: SonoVue®: Hexafluoride (SonoVue®, injectable solution to solubilisate, 8µg/mL) is injected in all patients for ultrasound angiography during the termination of pregnancy. 2,4 mL are administrated per patient, divided into two injections of 1,2 mL.
2501690|NCT02890186|Experimental|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
2501693|NCT02890186|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
2501761|NCT02889822|Experimental|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
2501792|NCT02889484||Disc hernia patients treated in Sweden|Individuals undergoing lumbar disc hernia surgery and included in the Swespine register
2501793|NCT02889484||Disc hernia patients treated in Norway|Individuals undergoing lumbar disc hernia surgery and included in the NORspine register
2501795|NCT02889484||Disc hernia patients treated in Denmark|Individuals undergoing lumbar disc hernia surgery and included in the Danespine register
2501894|NCT02889211|Active Comparator|Metabolically Healthy - Non-depressed|Overweight individuals without metabolic syndrome and free of psychiatric illness
2501896|NCT02889211|Experimental|Metabolically Healthy - Depressed|Overweight individuals without metabolic syndrome and with active major depression
2501900|NCT02889211|Experimental|Insulin Resistant - Depressed|Overweight individuals with metabolic syndrome and active major depression
2501905|NCT02889211|Experimental|Insulin Resistant - Non-depressed|Overweight individuals with metabolic syndrome and free of psychiatric illness
2501934|NCT02888418|Experimental|One dose of HPV vaccine in women aged 18 to 30|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 18 to 30.
2501936|NCT02888418|Placebo Comparator|Placebo in women aged 18 to 30|Placebo in women aged 18 to 30.
2501938|NCT02888418|Experimental|One dose of HPV vaccine in women aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in women aged 9 to 17.
2501939|NCT02888418|Placebo Comparator|Placebo in women aged 9 to 17|Placebo in women aged 9 to 17.
2501940|NCT02888418|Experimental|One dose of HPV vaccine in men aged 9 to 17|One dose of Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha) in men aged 9 to 17.
2501941|NCT02888418|Placebo Comparator|Placebo in men aged 9 to 17|Placebo in men aged 9 to 17.
2501977|NCT02888132|Experimental|Hypertrophic Obstructive Cardiomyopathy|
2502026|NCT02887872|Experimental|Pilot data|Four participants with chronic stroke participated in a 45-minute combined electrical stimulation-dynamic hand orthosis regimen using the affected upper extremity (UE) 5X/week for 6 weeks.
3196133|NCT00847431||Control Group|PD patients without deep brain stimulator surgery, with similar symptoms to the study group.
3196134|NCT00847444|Active Comparator|AA|Drug intervention
2502129|NCT02886936|Experimental|iFIT Group|This is a feasibility and effectiveness study to assess the iFIT transtibial and transfemoral prosthesis as a viable alternative to a traditional prosthesis. We also hope to gain information that will influence future design iterations.
2502160|NCT02886741|Other|Quality Improvement Campaign|"IHI designed and encouraged implementation of a five-component enhanced surgical site infection (SSI) prevention bundle with three relatively new evidence-based practices and two Surgical Care Improvement Program (SCIP) practices.~The campaign recruited state organizations to share information about evidence-based practices and publicize IHI activities and intervention materials (a How-to Guide, evidence reviews, a summary of the business case for interventions, and tip sheets for surgeons, other providers, patients and families). A project website and email listserv offered learning opportunities including webinar calls, faculty-led office hours, and town hall meetings."
2502163|NCT02886741|No Intervention|Comparison|Matched state pairs received no campaign intervention and experienced usual care
2502186|NCT02886455|Experimental|Cohort 4|"This is a sub-study testing the effect of real output applied under two adhesive strips on the skin at two different time points (4 and 24 hours).~There are two visits:~Visit 1:~Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 4 hours before being removed~Visit 2: Two adhesive strips (standard adhesive strip and new adhesive strip)contaminated with the subjects own output are applied on the peristomal skin and allowed to sit for 24 hours before being removed"
2502217|NCT02886208|Experimental|Intervention|This study has a single arm. All participants in a summer employment program at an urban farm in Indianapolis, IN are invited to participate.
2502314|NCT02885454|Experimental|OC + AL-335 + ODV + 3-DAA combination|Participants will receive single dose of 3 milligram (mg) drospirenone/0.02 mg ethinylestradiol [OC] on Day 1, AL-335 800 mg once daily on Days 5 and 6, a single dose of AL-335 800 mg + a single dose of OC on Day 7, ODV 25 mg once daily on Days 12 to 24, followed by a single dose of ODV 25 mg and a single dose of OC on Day 25, followed by ODV 25 mg + AL-335 800 mg + simeprevir (SMV) 75 mg [3-DAA combination] once daily on Days 26 to 31, followed by a single dose of 3-DAA combination and a single dose of OC on Day 32.
2502336|NCT02885155||Patients with pulmonary arterial hypertension|
3196135|NCT00847444|Active Comparator|BA|Lifestyle intervention
3196136|NCT00847444|No Intervention|BB|No individualized lifestyle intervention program.
3196137|NCT00847457|Experimental|Aerobic exercise|Participants will perform aerobic exercise regularly for 12 weeks.
3196138|NCT00847457|Active Comparator|Stretch|Participants will stretch regularly for 12 weeks.
3196139|NCT00847483|Active Comparator|Latanoprost|
3196140|NCT00847483|Active Comparator|Travoprost|
3196141|NCT00847483|Active Comparator|Bimatoprost|
3196142|NCT00847496|Experimental|1|AWBAT
3196143|NCT00847496|Active Comparator|2|BIOBRANE(R)
3196144|NCT00847548|Experimental|combined treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
3196145|NCT00847548|Active Comparator|control condition|Cognitive behavioral therapy addressing partner violence
3196146|NCT00847574|Experimental|Moderate-fat|35% of calories from fat
3196147|NCT00847574|Experimental|Lower-fat|20% of calories from fat
3196148|NCT00847600|Experimental|1 Pregnenolone|50 mg/day
2501698|NCT02890082|Other|Tamoxifen stim in late follicular phase|Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
2501700|NCT02890082|Other|Tamoxifen stim in luteal phase|Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
2501762|NCT02889679|Experimental|Underwater resection|All eligible lesion identified in a patient will be resected by the underwater technique. Excluded lesions will be resected by standard polypectomy.
2501768|NCT02889679|Active Comparator|Conventional resection|All eligible lesion identified in a patient will be resected by the conventional (gas distended colon) resection techniques. Excluded lesions will be resected by standard polypectomy.
3196149|NCT00847600|Placebo Comparator|2 Placebo|1 caps.
3196150|NCT00847639|Experimental|Lenalidomide|Lenalidomide maintenance therapy will start within 60 to 180 days after allogeneic HCT at a starting dose of 10mg PO once daily. Dose escalation and de-escalation are performed depending on tolerability of lenalidomide. The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days).
2501869|NCT02888990|Experimental|Treatment Arm|standard treatment + dasatinib
2501966|NCT02888262||Patients with bipolar disorder|Patients with newly diagnosed bipolar disorder
2501967|NCT02888262||Healthy first generation relatives|Healthy first generation relatives to the included patients
2501970|NCT02888262||Healthy individuals|Healthy individuals without a family history of psychiatric disorders
2502018|NCT02887937||Breast Mass 4a-cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2502019|NCT02887937||Breast Mass 4a- non cystic|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4a-non cystic breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration..
2502020|NCT02887937||Breast Mass 4b|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4b breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2502021|NCT02887937||Breast Mass 4c|Contrast Enhanced UltraSound (CEUS) exams will be performed on a ultrasound machine for the 4c breast masses recommended for biopsy. An intravenous line (IV) line will be inserted into the vein in the arm for the administration of the contrast agent, Definity (10 µL/kg) The patient will be asked to lie on a table for the 4DCT and unenhanced CT procedure and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into the IV line. The CEUS will be performed and the images will be recorded. The contrast agent may be administered two to three more times as needed. Scanning will then be repeated with 30 and 90 seconds delay after the IV contrast administration.
2502073|NCT02887599|Other|Patient Group|Pancreatic cancer patients
2502074|NCT02887599|Other|Control Group|Healthy people without evidence of malignancy
3196151|NCT00847678|Experimental|1|Mycograb + Amphotericin B + 5 flucytosine
2502231|NCT02886013||Mexican adolescents|"Students without known disease, between 14 and 18 years from the Lic. Adolfo Lopez Mateos Preparatory school of the Autonomous University of the State of Mexico (UAEMex)."
2502277|NCT02885844|Experimental|INVERTED VISION|inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
2502278|NCT02885844|Active Comparator|NORMAL VISION|During normal vision trials, subject's field of view will be restricted by goggles without lenses (see below) in order to be equivalent to the inverted vision one.
2502296|NCT02885441|Experimental|Ketorolac|Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment
2502301|NCT02885441|No Intervention|Control|The standard medical treatment
2502329|NCT02885298||Supine intubations (0-10 degrees)|Intubations performed with patient positioned 0-10 degrees. Patient supine.
2502332|NCT02885298||Inclined (11-44 degrees)|Intubations performed with 11-44 degrees of elevation.
2502333|NCT02885298||Upright (45 degrees or greater)|intubations performed with patient elevated to 45 degrees or greater
3196152|NCT00847678|Placebo Comparator|2|Placebo + Amphotericin B + 5 flucytosine
3196153|NCT00847678|Experimental|3|Mycograb + Amphotericin B
2502469|NCT02884232||Workers exposed to wood dust|
2502516|NCT02883920||workers of Champagne vineyard|
2502569|NCT02883517||Aggressive primary cutaneous lymphomas|"Mycosis fungoides ≥ T2b~Primary cutaneous T helper follicular lymphoma ≥ T2~Primary cutaneous diffuse large B-cell lymphoma, leg type Genetic: Cytogenetic and molecular studies Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome."
3196154|NCT00847691||Sarcoma|patients with biopsy or excision of sarcoma (suspected or diagnosed)
3196155|NCT00847717|Experimental|1|IIb preserving neck dissection
3196156|NCT00847717|Other|2|Conventional neck dissection
3196157|NCT00847756||rAOM|Children 0-5 years of age suffering from recurrent acute otitis media and waiting for tympanostomy tube insertion.
3163097|NCT00475566|Other|1|This is a prospective, non-randomized, single-arm, multi-center study. A projected 100 patients will receive the stent(s) in this study at approximately 10-15 European sites. The primary objective is to evaluate the safety and performance of the Dynalink®-E everolimus eluting peripheral stent system for the treatment of patients with atherosclerotic de novo or restenotic native superficial femoral or proximal popliteal lesions.
3163098|NCT00475592|Experimental|Capsule Endoscopy|
3163099|NCT00475592|Active Comparator|Upper Gastrointestinal Endoscopy|
3163100|NCT00475605||1. Protopic Exposure|Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus ointment exposure
3163101|NCT00475618|Experimental|Fluoride Varnish|Professional cleaning + education + fluoride vanish
3163102|NCT00475618|Active Comparator|Fluoride Toothpaste 500 ppm|Professional cleaning + education + fluoride toothpaste 500 ppm
3163103|NCT00475618|Active Comparator|No fluoride toothpaste|Professional cleaning + education + no fluoride toothpaste
3163104|NCT00475683|Sham Comparator|regular measurments|Mouth wash with chlorexidin
3163105|NCT00475683|Experimental|Curucmol|mouth wash with curcumol and mouth wash with chlorexidin
2501824|NCT02889354|Experimental|Cognitive-behavioral therapy|
2501877|NCT02889029|Experimental|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
2502010|NCT02887950|Active Comparator|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
2502013|NCT02887950|Experimental|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
2502016|NCT02887950|Experimental|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
2502063|NCT02887638|Experimental|headache|Patients diagnosed (neurologist - anesthesiologist - manual therapist) with tension-type and/or cervicogenic headache. During a first phase the sitting-posture, dura mater profile and pain-profile of the Headache-group will be analyzed. In a second phase, the patients will be sub-classified according to the data-analysis and receive intervention (Individual Profile Analysis +Physical therapy Intervention)
2502065|NCT02887638|No Intervention|asymptomatic controls|Asymptomatic controls, matched for gender and age. During a first phase the sitting-posture, dura mater profile and pain-profile of the control-group will be analyzed.
2502104|NCT02887248|Experimental|nab-paclitaxel+gemcitabine|"Induction Phase: nab-paclitaxel (125 mg/m²) and gemcitabine (1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle. Responding or stable patients will be treated with a minimum of 3 cycles and up to 6 cycles before starting the single agent maintenance therapy.~Maintenance Phase: Patients completing 3-6 cycles of induction therapy with an objective response (complete or partial response) or stable disease will continue treatment with single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
2502220|NCT02886221|Other|HV patients|patients with symptomatic Hallux Valgus treated my Reverdin-Isham Osteotomy
2502292|NCT02885883|Active Comparator|a control group|
2502302|NCT02885883|Experimental|patients with paroxysmal or persistent AF|
2502307|NCT02885883|Experimental|patients with permanent AF|
2502346|NCT02885311|Other|At-Risk Drinkers (AR)|AR will receive feedback about their drinking and brief advice along with follow up assessments.
2502348|NCT02885311|Other|Problem Drinkers (PD)|PD will be offered a choice of either an evidence-based behavioral intervention(Motivational Enhancement Therapy) or medication (Naltrexone) plus medication management. These participants will also receive follow up assessments.
2502350|NCT02885311|Other|AD with physiological withdrawal (AD-W)|AD-W will referred to outpatient detoxification as part of standard care, unless medically contraindicated, and will be offered medication (naltrexone) plus medication management as or an evidence-based behavioral intervention (Modified Behavioral Self-Control Therapy [MBSCT]) adapted from our two prior protocols. These participants will also receive follow up assessments.
2502351|NCT02885311|Other|AD with complex presentation (AD-CMPLX)|AD-CMPLX will receive a referral to specialty substance use disorder treatment and also receive follow up assessments.
2502413|NCT02884726|Experimental|BMS-986148 intravenous infusion|
2502458|NCT02884453|Experimental|ibrutinib|ibrutinib delivered orally at a dose of 560mg once daily continuously on a 4 weekly cycle until disease progression or unacceptable toxicity occurs.
2502495|NCT02883972|Experimental|Intervention letter and reminder|Behavioural insights informed invitation letter and SMS/email reminder message
2502502|NCT02883972|Experimental|Intervention letter|Behavioural insights informed invitation letter only
2502508|NCT02883972|Experimental|Control letter and reminder|Control invitation letter and SMS/email reminder message
2502511|NCT02883972|Active Comparator|Control letter|Control invitation letter only
2502540|NCT02883530||Biomarker optimised patients|Optimised biomarker/Th2 low n=40
2502543|NCT02883530||non -optimised/Th2 low patients|Patients identified in clinic with FeNO <30 ppb. Those who at screening demonstrate FeNO <30 ppb and blood eosinophil count ≤0.20 x109/L will be considered to be non-optimised biomarker-low patients (Th2-low) and will proceed to bronchoscopy n=80
2502547|NCT02883530||corticosteroid-resistant biomarker|Patients identified in clinic with FeNO >45 ppb who have failed to suppress their FeNO during FeNO suppression testing. These patients are considered adherent to inhaled corticosteroids. Those who at screening also demonstrate blood eosinophils of >0.3x109/L n=40
2503840|NCT02874365|Experimental|Crohn disorder|arm composed by 30 patients with Crohn disorder
3163107|NCT00475839|Active Comparator|Tension-free Vaginal Tape|
3163108|NCT00475839|Active Comparator|Monarc Sub-fascial hammock|
3163109|NCT00475917|Experimental|1|
2501736|NCT02889874|Experimental|B: No Radiation Therapy (ET only)|Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only.
2501826|NCT02889276|Active Comparator|Control|Unsupervised activity
2501831|NCT02889276|Experimental|Functional Resistance Training (FRT)|Supervised, group-based functional resistance training
2501921|NCT02888613|Other|Mini laparotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with transperitoneal approach
2501924|NCT02888613|Other|Mini lumbotomy|Patients with surgical indication to mini invasive aortic repair will be operated after randomisation with retroperitoneal approach
2501947|NCT02888327|Other|Oseltamivir and AL-794|Oseltamivir alone and with AL-794 over fourteen days.
2501950|NCT02888327|Other|Digoxin, Midazolam, and AL-794|Single doses of Digoxin and Midazolam with and without AL-794 over seventeen days.
2501952|NCT02888327|Other|Pitavastatin and AL-794|Single doses of Pitavastatin with and without AL-794 over seventeen days.
2501953|NCT02888327|Other|JNJ-63623872 and AL-794|JNJ-63623872 alone and with AL-794 over fourteen days.
2502031|NCT02887820|Other|Pilot Arm|All subjects enrolled in the trial will be in the pilot group. These subjects will have traditional laboratory coagulation and blood transfusion tests (baseline arterial blood gas (ABG), complete blood count (CBC), fibrinogen, platelet count, aPTT, PT, anti-Xa, ACT), as well as thromboelastograph (TEG). Pertinent TEG results will include: heparinase-kaolin TEG maximum amplitude (MA) in millimeters (mm), heparinase-kaolin TEG r-time in seconds, heparinase-kaolin TEG alpha angle in degrees, and TEG functional fibrinogen (FLEV) MA in mm.
2502067|NCT02887482|Experimental|Placebo|Placebo at 0 mg DNA/dose
2502069|NCT02887482|Experimental|GLS-5700|GLS 5700 at 2 mg DNA/dose. GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
2502124|NCT02887144|Experimental|SenSura test product 1pc|"Subjects randomized to treatment sequence 1test:~SenSura test product~SenSura"
2502126|NCT02887144|Experimental|SenSura 1pc|"Subjects randomized to treatment sequence 2 test:~SenSura~SunSura test product"
3196158|NCT00847756||COME|Children 0-5 years of age suffering from chronic otitis media with effusion and waiting for tympanostomy tube insertion.
3196159|NCT00847756||CSOM|Children 0-5 years of age suffering from chronic suppurative otitis media and waiting for tympanostomy tube insertion. Note: Only 3 patients with CSOM were recruited and therefore not suitable for publication.
3196160|NCT00847769|Experimental|High velocity, low amplitude stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
2502262|NCT02885857|Experimental|Shenyan kangfu Tablets|Shenyan Kangfu Tablets；Each weighing 0.48g；Oral；Once five, three times a day
2502352|NCT02885363|Experimental|Patients with newly diagnosed Left Ventricular Non Compaction|Patient newly diagnosed with Left Ventricular Non Compaction (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
2502353|NCT02885363|Active Comparator|Patients with Idiopathic Dilated Cardiomyopathy|Patient newly diagnosed with Idiopathic Dilated Cardiomyopathy (diagnose < 6 months), confirmed by echocardiography associated or not with MRI, after centralized review
2502417|NCT02884778|Experimental|NoL index in response to stimulation|"There is only one arm in this study. The intervention is not a drug, but it is the stimulus applied to the patient such as intubation and a standardized electrical stimulus applied on the forearm of the anesthetized patient. There are several stimuli that are the so-called interventions and the NoL index and the classical vital signs (heart rate, mean blood pressure, BISspectral index) are registered in response to these stimuli in an observational manner."
2502517|NCT02883881||No eye rubbing|
2502520|NCT02883881||with eye rubbing|
2502559|NCT02883608|Experimental|Initial cap assisted endoscopy|undergo initial cap assisted forward-viewing endoscope then side-viewing duodenoscope
2502563|NCT02883608|Active Comparator|Initial standard endoscopy|undergo initial side-viewing duodenoscope then cap assisted forward-viewing endoscope
2502627|NCT02883101|Active Comparator|Pulmonary rehabilitation group|"Participants randomised to the PR group will receive exercise training and regular instruction in self-management of ACT along with standard care. Patients will be enrolled into the pulmonary rehabilitation programme, in the Department of Pulmonary Medicine and Sleep disorders, All India Institute of Medical Sciences.~The total duration of the programme would be 8 weeks, with thrice weekly sessions of exercise training of 1 hour duration each. Of these sessions, at least 2 will be supervised while one will be at home. The patient will be asked to maintain a personal log recording the date, time, duration and type of exercise performed to ensure compliance, and these will be regularly reviewed and monitored.~The Rehabilitation Programme will include the following:~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
2502628|NCT02883101|No Intervention|Standard care group|"Candidates randomized to the standard care group will receive standard care for bronchiectasis according to current guidelines. These participants will receive instruction and review of airway clearance therapy (ACT). Each participant will be provided with written information about bronchiectasis and education regarding self-management of the condition. Participants who have not been previously instructed in any ACT will be taught the active cycle of breathing technique. These participants will not receive any supervised exercise training."
2502687|NCT02882776|Other|Ginger drink once daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water once a day for continuous 5 days.
2502689|NCT02882776|Other|Ginger drink twice daily|this group will receive ginger drink made by dissolving 4g ginger powder in plain water twice a day for continuous 5 days.
2502732|NCT02882438|Active Comparator|Infected group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Ginkgo Biloba in different dosage forms.
2502739|NCT02882438|Placebo Comparator|Control group|A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo without Ginkgo Biloba.
2502815|NCT02882074|Other|Human albumin|Human albumin 5% during surgery.
2501797|NCT02889458||Case|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)~Able to speak Cantonese~Newly diagnosed with breast cancer or DCIS in 24 weeks~Exclusion Criteria~- Undergoing treatment for any non-breast cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood, normal breast tissue and tumour tissue will be collected."
2501798|NCT02889458||Control|"Inclusion Criteria~Female~aged 18 or above~Chinese~Usually residing in Hong Kong~Able to speak Cantonese~Exclusion Criteria~- History of any cancer~Subjects will complete a structured interview with a questionnaire with research assistants' aid. Specimen of blood will be collected."
3196161|NCT00847769|Active Comparator|Slow, mobilization stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
2502265|NCT02885870|Experimental|Patient|"Patient with :~Spinal muscular atrophy (n=25)~X-linked spinobulbar muscular atrophy (n=25)~Amyotrophic lateral sclerosis (n=25)"
2502267|NCT02885870|Experimental|Healthy subject|Subject without any neurologic or spine affection Subject matched for sex and age with patient arm
2502313|NCT02885545|Experimental|Left atrial appendage occlusion|Patients receiving the Watchman device will have it placed via a percutaneous trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance. Patients will be anticoagulated for at least 45 days after the procedure.
2502316|NCT02885545|Active Comparator|Continuation of prescribed anticoagulant|Patients continuing medical therapy will continue to take their previously prescribed oral anticoagulation (vitamin K antagonist, apixiban or rivaroxaban) for the duration of the study unless a medical reason to alter therapy occurs.
3321441|NCT02018861|Experimental|Parsaclisib rituximab, ifosfamide, carboplatin, and etoposide|Starting dose of parsaclisib determined in Part 1 given in combination with: rituximab on Days 1 and 2 of Cycle 1, and Day 1 of Cycles 2 and 3; ifosfamide and carboplatin given on Day 3 of each Cycle; and etoposide given on Days 3 to 5 of each Cycle.
2502472|NCT02884219|Active Comparator|Early Treatment with cyclooxygenase inhibitors|Treatment of PDA that starts within the first 3 days of life using cyclooxygenase-inhibitors (Ibuprofen or Indomethacin)
2502473|NCT02884219|Sham Comparator|Expectative Treatment|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
2502558|NCT02883504|Experimental|Echocardiography|
2502664|NCT02882945||Group A|150 healthy blood donors without a family history of diabetes mellitus
2502666|NCT02882945||Group B|200 cases of type 2 DM without complications (group B), there were 62 males and 108 females, aged 29-53, with an average age of 42 ± 9 years
2502667|NCT02882945||Group C|120 cases of type 2 DM with macroangiopathy complication (group C), there were 70 males and 50 females, aged 40-53, with an average age of 47 ± 6 years. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD
2502763|NCT02882516|Experimental|Visible light exposure Red 30 lux|The participants will be exposed to red LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502766|NCT02882516|Experimental|Visible light exposure Red 120 lux|The participants will be exposed to red LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502768|NCT02882516|Experimental|Visible light exposure Blue 30 lux|The participants will be exposed to blue LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502770|NCT02882516|Experimental|Visible light exposure Blue 120 lux|The participants will be exposed to blue LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502772|NCT02882516|No Intervention|darkness|The participants will not be exposed to any light but stay in darkness for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502788|NCT02881931||Pre-Manifest HDGEC Participant|
2502789|NCT02881931||Early-Manifest HDGEC Participant|
2502790|NCT02881931||Corresponding HDGEC participant Companion|
2502873|NCT02881788||Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a traumatic brain injury. We are hoping to find patterns that may indicate a TBI in the data we collect.
2502876|NCT02881788||Non-Traumatic Brain injury|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have sustained a non-trauma related brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as healthy controls.
2502878|NCT02881788||Control|There will be no intervention necessary. We will analyze the eyetracking data from subjects who have not recently sustained any brain injury. We are hoping to find patterns that we may compare this data to subjects who have sustained a TBI as well as subjects who have had a non-trauma related brain injury.
2502926|NCT02881242|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD. Treatment continues in the absence of disease progression or unacceptable toxicity.
2503004|NCT02880696|Experimental|Test (Regular)|Regular stimulation sequence & DCS
2503009|NCT02880696|Active Comparator|Control (Random)|Random stimulation sequence & DCS
2503074|NCT02880072|Experimental|refeeding syndrome|6 patients with head and neck cancer and refeeding syndrome, 4 different of preparations of phosphate orally
2503077|NCT02880072|Experimental|no refeeding syndrome|6 patients with head and neck cancer without refeeding syndrome, 4 different of preparations of phosphate orally
2503155|NCT02879773||Lung cancer|Patients undergoing thoracic surgery for suspected or confirmed lung cancer; including wedge resection, segmentectomy, lobectomy, bilobectomy or pneumonectomy. CTPVe will be modelled to predict postoperative lung function.
2501886|NCT02888769|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week.
2501892|NCT02888769|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
2501959|NCT02888288|Experimental|Mental Health Intervention|This arm was designed based on mental health needs of HIV-infected youth in Tanzania. It incorporates principles of cognitive behavioral therapy, interpersonal psychotherapy, and motivational interviewing built into 10 group sessions, approximately 90 minutes each (2 sessions with caregiver participation) and 2 individual sessions. Groups are age and gender matched and facilitated by lay counselors with a mix of lived experience and prior mental health research experience.
2501960|NCT02888288|Active Comparator|Standard of Care|This arm includes standard medical care and adherence counseling with routine education prior to the start of the HIV youth clinic from which participants are recruited.
2502006|NCT02888002|Experimental|Internet-based treatment|"Guide to better alcohol habits online. An Internet-based treatment program with online counselor support."
2502007|NCT02888002|Experimental|Face-to-face treatment|"Guide to better alcohol habits F2F: Face-to-face treatment with 5 individual counselor sessions at the clinic."
2502064|NCT02887703|Experimental|Sensory Augmentation Group 1|Each subject in Group 1 will undergo 6 weeks of balance training with sensory augmentation followed by 6 weeks of balance training without sensory augmentation.
2502066|NCT02887703|Experimental|Sensory Augmentation Group 2|Each subject in Group 2 will undergo 6 weeks of balance training without sensory augmentation followed by 6 weeks of balance training with sensory augmentation.
2502106|NCT02887222|Active Comparator|PIEB volume of 7 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 7mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502108|NCT02887222|Active Comparator|PIEB volume of 8 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 8mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502109|NCT02887222|Active Comparator|PIEB volume of 9 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 9mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502110|NCT02887222|Active Comparator|PIEB volume of 10 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502111|NCT02887222|Active Comparator|PIEB volume of 11 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 11mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502112|NCT02887222|Active Comparator|PIEB volume of 12 mL|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 12mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2502123|NCT02886897|Experimental|D-CIK and anti-PD-1 Immunotherapy|D-CIK was incubated with anti-PD-1 antibody before infused back into participants
2502161|NCT02886754|Active Comparator|National e-learning programme only (HSE)|National e-learning programme only Recent successful completion the National e-learning programme by certificate will be displayed. Students then complete a student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
2502164|NCT02886754|Active Comparator|Simulation (S)|Simulation Recent successful completion of the National e-learning e-learning programme by certificate will be displayed. Students will proceed to standard simulation using the same series of paper cases as PBP which prompt simulated phone calls but no requirement to meet a proficiency benchmark. 4 hours will be allotted to this training. Following training participants will complete the student satisfaction survey and will then proceed directly for performance assessment to the high-fidelity simulation suite.
2502165|NCT02886754|Experimental|Proficiency-Based Progression (PBP)|Recent successful completion of the National e-learning programme by certificate will be displayed. Students will proceed to PBP simulation using the same series of paper cases as S which prompt simulated phone calls. PBP students will be scored according to predefined metrics and will be required to reach proficiency benchmarks. Following training participants will complete the student satisfaction survey and proceed directly for performance assessment to the high-fidelity simulation suite.
2502207|NCT02886403|Experimental|Cohort 02|"This is a sub-study testing how the adhesion of two adhesives is influenced by exposure to real output.~There are two visits:~The first visit:~Two adhesive strips (standard adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not.~The second visit:~Two adhesive strips (new adhesive strip) are applied to the peristomal skin and one of these strips is exposed to real output (contained in a sleeve) and the other strip is not."
2502253|NCT02886065|Experimental|PVX-410 + Citarinostat|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat"
2502254|NCT02886065|Experimental|PVX-410 + Citarinostat + Lenalidomide|"Participants will receive:~6 biweekly doses of PVX-410~6 biweekly doses of Hiltonol~3 monthly cycles of Citarinostat~3 monthly cycles of Lenalidomide"
2502287|NCT02885584|Experimental|Transpulmonary pressure controlled mechanical ventilation|transpulmonary pressure will be used for ventilation settings
2502294|NCT02885584|No Intervention|Conventional pressure-controlled mechanical ventilation|transpulmonary pressure will not be used for ventilation settings
2502344|NCT02885324|Experimental|Cabozantinib|Cabozantininb will be taken daily at a dose of 40 mg/m2. Drug cycles will last 28 days and be continuous for up to 12 months of therapy on study.
3321442|NCT02018874|Experimental|LY2780301|
2502029|NCT02887833||XRT for Cancer induced bone pain|Will have community based assessment before and after radiotherapy to assess feasibility of using a clinical biomarker (thermal sensory testing) to predict treatment response
2502075|NCT02887547|No Intervention|Control|Control group, with traditional orthodontic mechanics for anterior retraction. Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
2502079|NCT02887547|Experimental|Acceleration|Group with micro-osteoperforation for accelerated tooth movement during anterior retraction, Crevicular fluid will be collected during anterior retraction mechanics to identified biomarkers in the inflammatory process
2502105|NCT02887235|No Intervention|Standard of Care (SOC) Meals|Patient assigned in this arm will receive standard of care nutritional services including nutrition consult, evaluation, and as needed follow-ups.
2502107|NCT02887235|Active Comparator|Medically tailored meals|Patient assigned in this arm will receive home delivered, medically tailored meals (HDMTM) in addition to the standard nutritional care.
2502158|NCT02886819|Experimental|WBV group|whole-body vibration (WBV) group
2502174|NCT02886468|Experimental|ultrasound images|ultrasound images of the anterolateral aspect of the mid-right thigh
2502205|NCT02886377||NMOSD-ON|NMOSD-ON included patients who met the established diagnostic criteria for NMO or NMOSD published by Wingerchuk et al,with AQP4 seropositive according to the results of the AQP4-Ab test.
2502206|NCT02886377||MS-ON|MS-ON group patients included typical acute demyelinating ON with brain lesions fulfilling the revised McDonald criteria or clinical isolate syndrome (CIS), with AQP4 seronegative according to the results of the AQP4-Ab test.
2502208|NCT02886377||Healthy controls|Age- and gender- matched healthy controls.
2502249|NCT02886039|Other|patients|Patient with cardiac arrest benefiting an electroencephalogram
2502297|NCT02885701|Experimental|No splint|
2502303|NCT02885701|Experimental|Removable Splint|
2502306|NCT02885701|Experimental|Non-removable Splint|
3196162|NCT00847769|Sham Comparator|Passive positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
2502496|NCT02884037||1|Rifaxmin group
2502501|NCT02884037||2|placebo group
2502524|NCT02883647||retreatment|"Patients with HBV DNA > 2000 IU/ml and ALT ≥ 5×ULN;~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have clinical symptoms.~Intervention: Patients of this group will receive Entecavir 0.5mg/d or Tenofovir 300mg/d again."
2502526|NCT02883647||non-retreatment|"Patients with HBV DNA ≤ 2000 IU/ml;~Patients with HBV DNA > 2000 IU/ml and ALT ≤ 2×ULN;~Patients with HBV DNA > 2000 IU/ml and 2×ULN < ALT ≤ 5×ULN, but have no clinical symptoms."
2502600|NCT02883439|Experimental|Investigational product|MP29-02 137
2502603|NCT02883439|Active Comparator|Non-investigational product|fluticasone propionate
2502651|NCT02882893|Experimental|DWP450|Single-dose
2502654|NCT02882893|Active Comparator|Botox|Single-dose
2502694|NCT02882646|Experimental|Stroke/CP survivors & healthy subjects|"Part A: Stroke and CP survivors greater than 18 years of age with hemiplegia and varying levels of impairment. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. Healthy persons over the age of 18 with no upper limb impairment.~Part B: Low to mid functioning CP and stroke survivors greater than 18 years of age with hemiplegia. The subject's stroke must have occurred at least 3 months prior to enrollment in the study. All will be asked to use the Bi-ADLER system."
2502735|NCT02882347|Experimental|somatostatin group|The investigators administrate somatostatin at a rate of 3.5ug/kg/hour to PHLF patients (prothrombin time < 50% and serum total bilirubin > 2.9mg/dl after liver resection) until recovery from liver failure.
2502777|NCT02882139||Electrical storm|Documentation of 3 or more episodes of sustained ventricular arrhythmia within 24h or documentation of sustained ventricular tachycardia lasted at least 12h
2502880|NCT02881463|Experimental|Home Exercise Program|8- week therapeutical exercise program performing at home for women with knee joint osteoarthritis
2502998|NCT02880735|Experimental|Non Invasive Ventilation.|"It will provide noninvasive mechanical ventilation with the following specifications:~Bilevel devices: Pressurized bilevel mode Spontaneous/Time. Interface: Facial mask Usage: During sleep Frequency: Daily Duration: Three months."
2503033|NCT02880410|Experimental|LITT Treatment w/radiation therapy and temozolomide|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System in combination with radiation therapy and temozolomide
2503119|NCT02879565|Other|qualitative and neuroimaging research|
2503147|NCT02879422|Other|Diabetic patients with proliferative diabetic retinopathy|
2503154|NCT02879422|Other|Diabetic patients with non proliferative diabetic retinopathy|
2503184|NCT02879266|Experimental|TetraVax-DV TV005|Participants will receive a subcutaneous injection of TetraVax-DV TV005 at study entry (Day 0).
2503186|NCT02879266|Placebo Comparator|Placebo|Participants will receive a subcutaneous injection of placebo at study entry (Day 0).
2503218|NCT02879006|Active Comparator|Chinese Herbal Medication|
2503220|NCT02879006|Placebo Comparator|Placebo|
2503275|NCT02878564|Experimental|Praziquantel treatment|Participants will be HIV-uninfected women with asymptomatic Schistosoma mansoni infection; the study will examine the impact of standard praziquantel therapy (40 mg/kg po single dose) on genital immunology and HIV susceptibility.
2503718|NCT02875145||Keratoplasty with cataract surgery|Patients who underwent keratoplasty who also underwent a cataract surgery during follow up.
2503721|NCT02875145||Keratoplasty without cataract surgery|Patients who underwent keratoplasty who never underwent cataract surgery.
2503841|NCT02874365|Experimental|FAP (familial adenomatous polyposis )|arm composed by 30 patients with FAP disorder
2502102|NCT02887326||> age 45 year|Ophthalmic examination, VA measure, contrast vision, pentacam measurement, Tear fluid, saliva and blood samples
2502135|NCT02887014|Experimental|Group A|Participants getting SPECIFIC VERBAL INSTRUCTIONS before starting bowel preparation (Group A).
2502138|NCT02887014|No Intervention|Group B|Participants getting ordinary instructions as usual in each of the participating centers (Group B).
2502184|NCT02886650|Experimental|Thermocoagulation|
2502233|NCT02886286|Experimental|Bupivacaine + Opioid|Intrathecal solution has bupivacaine with an opioid (hydromorphone, fentanyl or morphine). Patients will administer PTM bolus of bupivacaine with opioid. The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10. The bupivacaine dosage would range between 0.4 and 1.5 mg per bolus. The opioid dose will vary depending on the concentration of the opioid in the solution.
2502238|NCT02886286|Active Comparator|Opioid|Intrathecal solution has only an opioid (hydromorphone, fentanyl or morphine) and no bupivacaine. Patients will administer PTM bolus of opioid without bupivacaine. This opioid bolus dose would be the same as they would have received prior to enrolling in the study (with bupivacaine). The bolus will be administered over 2 minutes and will have a variable frequency depending on patient's need but the number of boluses should be >2 and <10.
2502260|NCT02885727|Experimental|Durvalumab + Radiation therapy|"Durvalumab (MEDI4736) 750 mg (or 10mg/kg if the patient weighs <30 kg) IV Q2W over 1 hour for all patients + Radiation therapy~First lesion to receive 25 Gy / 5 daily consecutive fractions of 5 Gy~Second lesion to receive15 Gy / 5 daily consecutive fractions"
2502289|NCT02885519|No Intervention|Control|Standard treatment and standard vocational rehabilitation
2502298|NCT02885519|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
2502305|NCT02885519|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
2502355|NCT02885285|Experimental|Spinning Class|Subjects randomly selected for the spinning group will participate in spinning classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2502360|NCT02885285|Experimental|Yoga Class|Subjects randomly selected for the yoga group will participate in yoga classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2502364|NCT02885285|Experimental|Dance Class|Subjects randomly selected for the dance group will participate in dance classes, twice a week for six weeks. Subjects will complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2502365|NCT02885285|Active Comparator|No Exercise Class|Subjects randomly selected for the no class group will not participate in the study exercise classes. Subjects will still complete questionnaires at screening, each week during the class sessions, and for 1 month follow-up.
2502414|NCT02884765||Bicondylar Fracture|Patients presenting a bilateral condylar fracture of the mandible with or without additional symphyseal fracture. Bilateral condylar fractures will be treated non-surgical, surgical or combining both.
3163110|NCT00475930|Experimental|1|2% chlorhexidine gluconate impregnated cloths, self applied three times weekly
3163111|NCT00475930|Placebo Comparator|2|Comfort Bath cloths, self applied three times weekly
2502645|NCT02882685|Active Comparator|RYGB|Roux-en-Y gastric bypass
2502647|NCT02882685|Active Comparator|SAGB|Single anastomosis gastric bypass
2502774|NCT02882594||CIBA Study Cohort|Patients aged 1 to 13 years undergoing inhalation inductions for general anesthesia
2502834|NCT02881918||squamous cell carcinoma|Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment
2502865|NCT02881528|Experimental|Metformin Hydrochloride|"Metformin Hydrochloride Ph Eur oral solution (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
2502868|NCT02881528|Placebo Comparator|Placebo|"Placebo (100mg/1ml) Starting Dose 10mg/Kg body weight once daily for 2 weeks, increasing to 10mg/Kg body weight twice daily if tolerated, increasing to target dose of 20mg/Kg body weight twice daily (max 1000mg twice daily) at Month 1 (4 weeks post randomization).~Down-titration to 10mg/kg twice daily if target dose not tolerated. Stage 1: Dosing for up to 15 months (option to extend to Stage 2: 36 months)"
3163112|NCT00475956|Experimental|1|AZD2171 Monotherapy
2503011|NCT02880800|Experimental|Analgesia, patient controlled|Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of either morphine or hydromorphone.
2503013|NCT02880800|Active Comparator|Analgesia, as per needed|Patients will receive intravenous (IV) opioids as per needed.
2503039|NCT02880306||RA cohort|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria.
2503041|NCT02880306||Non-RA cohort|Participants who were ≥18 years of age, without a RA diagnosis
2503075|NCT02880033|Active Comparator|Parkinson's disease|ex vivo analysis of lymphocytes from 30 patients with Parkinson's disease with deferiprone and placebo treatment
2503078|NCT02880033|Active Comparator|Amyotrophic lateral sclerosis|ex vivo analysis of lymphocytes from 30 patients with Amyotrophic lateral sclerosis with deferiprone and placebo treatment
2503081|NCT02880033|Placebo Comparator|healthy age and sex matched controls|ex vivo analysis of lymphocytes from 30 healthy age and sex matched controls with deferiprone and placebo treatment
2503719|NCT02875158|Experimental|Diode laser using modified settings|The cyclophotocoagulation protocol is used with the modified cyclophotocoagulation settings of 1250 mW for 4 seconds.
3163113|NCT00475956|Experimental|2|AZD2171 + AZD0530
3163114|NCT00476060|Experimental|A|
3163115|NCT00476060|Placebo Comparator|B|
3163116|NCT00476099|Experimental|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|
3163117|NCT00476099|Active Comparator|Budesonide 200 µg plus formoterol 6 µg DPI|
3163118|NCT00476099|Active Comparator|Formoterol 12 µg DPI|
3163119|NCT00476112|Experimental|1|Atrial flutter duration of 3 hours to <45 days
3163120|NCT00476125|Experimental|3 day ketogenic diet|
3163121|NCT00476125|Experimental|12 day ketogenic diet|
2502122|NCT02887040|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for 104 weeks. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week for 6 weeks overall, to a total radiation dose of 5400cGy.
2502166|NCT02886806|Experimental|high risk vascular surgery|Patients scheduled for high risk vascular surgery under automated total closed loop intravenous anesthesia and fluid management
2502271|NCT02885948|Experimental|Naloxone|"The naloxone arm of the study will receive naloxone at a rate of 5mcg/kg/hr which equates to 0.25ml/kg/hr. Each 1 ml ampoule of solution contains 400 micrograms (0.4mg) naloxone hydrochloride present as naloxone hydrochloride dihydrate.~Excipients: each 1ml contains 3.55mg sodium. This will be diluted to a concentration of 20mcg/ml with 0.9% NaCl. Presented as solution for injection or infusion. Clear colourless sterile solution."
2502272|NCT02885948|Placebo Comparator|Saline|The placebo arm of the study will receive an infusion of normal saline at a rate of 0.25ml/kg/hr.
2502311|NCT02885467|Active Comparator|Control|Standard total knee arthroplasty performed through medial parapatellar approach
2502312|NCT02885467|Experimental|Intervention|Total knee arthroplasty performed through medial parapatellar approach with identification, ligation, and burial of saphenous nerve branches
2502337|NCT02885207|Other|Focal epilepsy of unknown cause|
3163122|NCT00476125|Experimental|16 hour fast|
3163123|NCT00476164|Experimental|Rituximab|Infusion of 2 x 1g of rituximab, 14 days apart
3163124|NCT00476164|Sham Comparator|2|
3163125|NCT00476190|Experimental|Arm A|Complete remission achieved after Induction Phase
2502498|NCT02883946||hairy-cell leukemia|Patients with hairy-cell leukemia.
2502528|NCT02883660||Cases|"patients who had empirically defined increased AEs on one of the specified antidepressants (SSRIs/ SNRIs). This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
2502531|NCT02883660||Controls|"patients who did not have empirically defined increased AEs with an index antidepressant (one of the specified SSRIs/ SNRIs) AND were nonresponders to that antidepressant. This group will get the Genecept Assay, which is a battery of pharmacogenetic tests relevant to psychiatry."
2502745|NCT02882568|Other|investigational|Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
2502816|NCT02882126|Experimental|Subcutaneous Treprostinil|Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
2502929|NCT02880891|Experimental|splinted|splinted crown
2502932|NCT02880891|No Intervention|non-splinted|single crown
2503024|NCT02880462|Active Comparator|high dose sulforaphane|The goal of the study is to investigate whether adding high doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
2503025|NCT02880462|Active Comparator|low dose sulforaphane|The goal of the study is to investigate whether adding low doses of sulforaphane will benefit the clinical symptoms and cognitive function in individuals who have schizophrenia.
2503026|NCT02880462|Placebo Comparator|placebo|The purpose of including placebo is to judge if the outcome is related to the study medication rather than other reasons.
2503085|NCT02880202|Other|Massage Therapy|Massage therapy for hospice patients.
2503172|NCT02879734|No Intervention|Without Omentopexy|Patients that did not undergo prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter
2503173|NCT02879734|Experimental|With Omentopexy|Patients that underwent prophylactic omentopexy during laparoscopic insertion of peritoneal dialysis catheter. Intervention = Prophylactic laparoscopic omentopexy
2503197|NCT02879201|Active Comparator|Slow efficiency dialysis|SLED is a kind of hemodialysis technique performed using Fresenius 4008B dialysis machine with FDX 120 GW (NIKKISO Japan) dialyzer. SLED sessions were 6-8 hour duration, three times per week (except Sunday), In case of severe volume overload, the session could be increased to meet clinical situation. Blood flow was maintained between 150-200 mL/hr and the dialysate flow of 300 mL/hr. Both the groups use unfractionated heparin as anticoagulant to prevent clotting of the extracorporeal circuit .the target partial thromboplastin time( PTT) was not more than twice the control level.
2503199|NCT02879201|No Intervention|Continuous renal replacement therapy|CRRT is a kind of therapy involved continuos dialysis throughout 24 hours by using Edward Delivery system (Edward Life Science) as continuous venovenous hemodiafiltration (CVVHDF) mode using Aquamax HF 12 dialyzer. Blood flow rate was kept from 100-200 mL/hr and target effluent rates of 20 mL/hr . The substitution fluid was infused at a rate of 1,000 ml/hr with ultrafiltration rate at 100-300 mL/hr.Intervention here is the different mode of dialysis
3163126|NCT00476190|Experimental|Arm B|Failure to achieve complete remission after the Induction Phase
3163127|NCT00476203|Experimental|1|Immediate yoga classes offered
3163128|NCT00476203|Other|2|Delayed yoga classes (after 6 months) offered [wait list control group]
3163129|NCT00476216|Experimental|Combination of Arixtra with chemotherapy|Carboplatin 6 AUC q 21 days; Paclitaxel 200 mg/m2 q 21 days. Cohort I: Arixtra 2.5 mg SQ qd x 21 days; Cohort II: Arixtra weight-based dose (D1-2)followed by Arixtra 2.5 SQ q day (D3-21)
3163130|NCT00476255|Active Comparator|Enhanced Standard Care|Instructional materials
3163131|NCT00476255|Experimental|Motivational Intervention|Motivational interview
3163132|NCT00476268|Experimental|beclometasone /formoterol|beclomethasone dipropionate 100 µg plus formoterol 6 µg pMDI
3163133|NCT00476268|Active Comparator|Beclomethasone|Beclomethasone dipropionate (BecotideTM) 250 µg/unit dose pMDI aerosol via CFC propellant.
3163134|NCT00476268|Active Comparator|Formoterol powder 12 µg/unit dose|Formoterol powder 12 µg/unit dose (Foradil™)
3163135|NCT00476281|Other|abnormal glucose tolerance|abnormal glucose tolerance
3163136|NCT00476294||Group 1: G + Placebo|G-CSF plus Placebo Arm (G + Placebo)
3163137|NCT00476294||Group 2: G + AMD3100|G-CSF plus AMD3100 Arm (G + AMD3100)
3163138|NCT00476346|Active Comparator|Calcium|Daily calcium supplementation Intervention: Calcium 2000mg / daily
3163139|NCT00476346|Experimental|Vitamin D|Daily Calcium and Vitamin D supplementation Intervention: Vitamin D 800IU / daily
2502136|NCT02887157||Specific Aim 1B|"Specific Aim 1B (implement technical innovations to improve OCT imaging in non-sedated infants in the ICN: (1B) extend imaging to the vascular-avascular junction via a wide-field lens).~Aim 1B only: 50 participants (25 healthy adult volunteers and 25 pediatric participants under going examination under anesthesia~Healthy adult volunteers will have SSOCT imaging of both eyes with the novel ultralight handpiece up to 10 times.~Pediatric participants undergoing examination under anesthesia will have SSOCT imaging of both eyes with the novel ultralight handpiece once during their EUA in the Duke Eye Center Operating Rooms (OR). These participants will be enrolled into the study at DUHS including the Duke Eye Center clinics and OR for testing the custom widefield lens."
2502139|NCT02887157||Specific Aim 2|"Specific Aim 2 (distinguish elements of retinal microanatomy that predict maldevelopment of visual pathway and poor neurodevelopment that may impact vision in preterm infants) includes 68 very preterm infants undergoing the following during evaluation for ROP.~Swept Source OCT imaging of both eyes with the novel ultralight handpiece before or after ROP examination, timed with each examination. The axial length of the eye may be measured after the ROP exam.~Non-sedated research brain Magnetic Resonance Imaging will be obtained in 68 participants prior to discharge from the nursery whenever possible (as close to term age as possible). In the case of an early infant discharge to another hospital, every effort will be made to obtain brain MRI prior to transfer or an outpatient non-sedated brain MRI at near term age.~Scavenged blood collection: Residual samples of serum/plasma in the laboratory will be collected for neuroinflammatory marker testing."
2502141|NCT02887157||Specific Aim 3|"Specific Aim 3 (delineate which elements and regions (posterior) or (peripheral) of preterm infant OCT-derived retinal microanatomy best inform us about severity of disease and visual outcomes in infants with ROP will include the same 68 participants plus an additional 42 very preterm infants undergoing evaluation for ROP and visual function but who will not be in the neurodevelopmental study and thus will not have brain MRI, 2-year Bayley Scales testing or neuroinflammatory marker testing on scavenged blood. The Specific Aim 3 subjects will undergo the following:~Swept Source OCT imaging of both eyes with the novel ultralight handpiece as described in Aim 2. The axial length of the eye may be measured after the ROP exam.~After imaging with the original lens (ultralight handpiece) both eyes will be imaged with the widefield OCT lens. before or after the ROP exam.~Ocular and systemic health data will be extracted from the study participant's medical record."
2502232|NCT02886299|Active Comparator|Fenofibrate group|Group I (30 patients): Patients receiving fenofibrate (100 mg) taken on dialysis days after the dialysis session (three times per week).
2502235|NCT02886299|Active Comparator|Simvastatin group|Group II (30 patients): Patients receiving simvastatin (20 mg) taken on dialysis days after the dialysis session (3 times per week).
2502285|NCT02885805|Experimental|SPF evaluation + Control|Fair-skinned subjects in good health with Skin Types I, II or III.
2502340|NCT02885337|Active Comparator|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the physiotherapist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
2502345|NCT02885337|Experimental|Multi-Modal Frailty Intervention|"Exercise: A physiotherapist will develop an individualized exercise program and schedule appointments with patients at a physiotherapist clinic. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20-40 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
2502422|NCT02884869|Experimental|Intubating laryngeal Mask|Intubating laryngeal Mask
2502426|NCT02884869|Active Comparator|Direct laryngoscopy|Intubating laryngeal Mask
2502556|NCT02883842|Experimental|Intervention-Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week.
2502561|NCT02883842|No Intervention|Control|Participants in the control group will receive 2 thank-you messages per month and undertake routine clinical practice.
3196163|NCT00847782|Other|Blood draw (Group 1)|"Normocholesterolemic Subjects~Normal Healthy Volunteers"
3196164|NCT00847782|Other|Blood draw (Group 2)|Hypercholesterolemic Subjects
2502702|NCT02882672|Experimental|Experimental|experimental group did 8 weeks exercise training
2502704|NCT02882672|Experimental|Control|Control group did not do any exercise training.
2502723|NCT02882308|Experimental|Monotherapy with olaparib|Patients in the monotherapy arm will be treated with olaparib until the 21st -28th day depending on the day of surgery, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
2502725|NCT02882308|Experimental|Combination of cisplatin and olaparib|Patients in the cisplatin - olaparib combination arm will receive treatment until the 5th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day.
2502727|NCT02882308|No Intervention|No treatment arm|"Patients in the no treatment arm will wait to be operated or have a second biopsy on the 23rd - 29th day.Optionally, patients who have a baseline FDG-PET/CT scan may be re-examined on the 22nd -28th day by the same modality to assess metabolic response."
2503810|NCT02874651|Placebo Comparator|Placebo|In the phase IIb part of this trial, patients in this arm will take oral placebo until disease progression, intolerable toxicity, death or to a maximum of 2 years.
2502192|NCT02886390|Experimental|RIC group|The upper limb ischemic conditioning is composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which is induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation. This therapy started within 2 hours after r-tPA thrombolytic therapy. In addition, all participants receive a standard clinical therapy.
2502196|NCT02886390|No Intervention|Control group|The participants received r-tPA thrombolytic therapy after diagnosed ischemic stroke. In addition, all participants receive a standard clinical therapy.
2502227|NCT02886104|Active Comparator|CRLM resection group|Resection of both primary and secondary tumors in SCRLM and resection of MCRLM. Interventions: Simultaneous resection of both primary and secondary tumors in SCRLM and resection of MCRLM.
2502228|NCT02886104|Experimental|CRLM ablation group|"Ablation of CRLM after resection of primary tumor in SCRLM and ablation of MCRLM.~Interventions: Ablation of liver metastasis within 30 days after resection of primary tumor in SCRLM and ablation of MCRLM."
2502266|NCT02885740|Experimental|Atrial fibrillation in normal heart|Patients having atrial fibrillation in normal heart
2502269|NCT02885740|Active Comparator|Control|Patients having a junctional supraventricular tachycardia in normal heart
2502366|NCT02885051|Experimental|preterm newborn|Newborns hospitalized in the neonatal or Neonatal Resuscitation unit of Brest University Hospital and born before 36 weeks of gestation who will have recording of skin conductance and heart rate variability.
2502389|NCT02884791|Experimental|Fasting (Healthy)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
2502392|NCT02884791|Experimental|Fasting (metabolic syndrome)|Participation in this study involves fasting overnight, drinking a sweet beverage, and several blood draws through an IV line. Each subject may drink up to10 different sweet beverages, separated by 2 weeks.
2502410|NCT02884661||Hospitalization in Cardiology department|Patients cared by the Cardiology department
2502411|NCT02884661||Hospitalization in Geriatric unit|Patients cared by the Geriatric unit
2502436|NCT02884505||Patients with Hypersomnolence|Patients referred for polysomnography and multiple sleep latency test
2502481|NCT02884063||NGS reading for Media Free DNA|Ability to read the DNA product available in embryo culture media using NGS to have valuable diagnostic image for genetic composition of embryo before implantation.
2502487|NCT02884063||NGS reading for blastomer DNA|DNA extracted from Blastomere used for aneuploidy screening.
2502580|NCT02883374|Experimental|Chidamide|Patients of advanced cephalic and cervical adenocystic carcinoma are given Chidamide 30mg,biw, then the efficacy and safety will be accessed.
2502629|NCT02883114|Experimental|single cohort|single dose of PF-06648671 in period 1 and 14-day dose of itraconazole plus single dose of PF-06648671 in period 2
2502703|NCT02882763|Experimental|Parents As Teachers (PAT)|c.f. intervention
2502705|NCT02882763|No Intervention|control group condition|Families in the control group condition did not receive the home visiting program PAT, but were informed about support services in their community. The use of these services was permitted for ethical reasons; however, parents were regularly asked about the nature and intensity of the retrieved services. Additionally, all parents received incentives, such as greeting cards, small birthday presents, and monetary reimbursements.
2502748|NCT02882282|Active Comparator|Arm A (observation)|Patients undergo observation.
2502749|NCT02882282|Experimental|Arm B (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2502795|NCT02881905|Active Comparator|ball attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the conventional ball attachment
2502800|NCT02881905|Experimental|CM LOC attachment|completely edentulous patients having single median mandibular implant to retain mandibular overdenture.the attachment used is the cm loc attachment
2502852|NCT02881697||Obese insulin-resistant subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; insulin-resistant, scheduled for elective bariatric surgery
2502853|NCT02881697||Lean insulin-sensitive controls|Adipose tissue sampling in normal weight patients (BMI < 27kg/m2) aged 18- max. 60 years, males and females; insulin-sensitive, scheduled for elective surgery
2502854|NCT02881697||Obese diabetic subjects|Adipose tissue sampling in obese volunteers (BMI > 35kg/m2) aged 18- max. 60 years, males and females; diabetic, scheduled for elective bariatric surgery
2502891|NCT02881372|Experimental|Oral food desensitization|All of the children enrolled in the study will receive oral food desensitization with his or her specific EoE flare-inducing food antigen (e.g. cow's milk protein). The food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C) to stabilize and preserve the solution. This oral spray will need to be administered twice a day, every day for a total of 4 months.
2502939|NCT02881021|Experimental|Rehabilitation program and kinesiotaping.|"Each patient will attend 10 physiotherapy sessions over six. Patients from the Experimental group (KT group) will receive the same standardized rehabilitation program as control group (No-KT group) including manual therapy, movement training, stretching, muscular strengthening, and patient education.~Only KT-group (experimental) will receive therapeutic KT added to the rehabilitation program.~Kinesio® Tex Classic will be applied using a combination of techniques designed for RCTe and underlying symptoms following the instructions and principles described by Kase et al (2003).~Kinesiotaping strips will be weaned gradually, according to the individual improvements of deficits evaluated weekly by the physiotherapist treating."
2502948|NCT02881021|Active Comparator|Rehabilitation program.|"Each patient will attend 10 physiotherapy sessions over six. Patients allocated at the control group (No-KT group) will receive only the rehabilitation program, including manual therapy, movement training, stretching, muscular strengthening, and patient education.~The rehabilitation program will be exactly the same applied to the experimental group (KT group)."
2503036|NCT02880384|Experimental|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent for FilmArray LRTI v.2.0 IUO Panel testing.
2503156|NCT02879721|No Intervention|no drug|No drug and no intervention
2503161|NCT02879721|Active Comparator|AT1R-antagonist|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily
2502283|NCT02885792|Experimental|Debuting and chronic schizophrenia|"ILLNESS HISTORY:~Existing psychiatric and somatic diagnosis and treatment~Charlson co-morbidity~MEASURE OF SOCIAL CONDITIONS~- For example Lubben Social Network Scale-6 and Brief Trauma Questionnaire.~MEASURE OF PSYCHIATRIC CONDITION::~Positive and Negative Syndrome Scale (PANSS)~Clinical Global Impression Scale (CGI)~Columbia Suicide Severity Rating Scale (C-SSRS)~Beck Cognitive Insight Scale~Birchwood Insight Scale~CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
2502286|NCT02885792|Active Comparator|Matched controls|"CARDIOVASCULAR MEASUREMENT:~CT Coronary angiography (CT-CAG)~Echocardiography~Heart rate variability (HRV)~Pulmonary function test (PFT)~Toe blood pressure (TBP)~Blood test~Body composition analysis~CT scan of upper abdomen~Cardiovascular magnetic resonance imaging (CMR)~Adipose tissue biopsy"
2502334|NCT02885220|Active Comparator|Conventional Program|The aim of our study is to determine if a goal directed program improves weight loss outcomes after sleeve gastrectomy. In the conventional weight loss program, patients will only be given their ideal weight to strive toward after surgery. Routine dietary and physiotherapy/exercise counseling are provided and patients would be educated on their ideal weights based on a BMI of 23. The target weight loss over a 12 month period would be 100% excess weight loss.
2502335|NCT02885220|Experimental|Goal Directed Program|For the goal directed program, patients would be given an additional sheet to show expected weight loss goals to strive towards at each consultation after surgery (3, 6, 9 and 12 months post operation). Bariatric patients in this modified program will be counselled prior to laparoscopic sleeve gastrectomy (LSG) and EWL (excess weight loss) targets will be set for patients to achieve at fixed intervals post LSG. These targets are charted in a graph, with the patient's actual weight charted on the graph at each clinic consultation, providing a strong visual aid counselling and motivation.
2502399|NCT02884986|Active Comparator|Etoricoxib|120mg of oral Etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
2502402|NCT02884986|Placebo Comparator|Placebo|120mg of oral Placebo the same amount as the drug administrated one hour prior to spinal anaesthesia induction
2502412|NCT02884622|Other|CF patients|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added and blood sampling will be collected for this study
2502441|NCT02884401|Other|osteoporotic women with a missing tooth|Post-menopausal osteoporotic women with a missing tooth and willing to replace it with a dental implant
2502477|NCT02884154|Other|Arm who will undergo EUS-FNB|
2502567|NCT02883829|Experimental|Peer-Based Delivery|The Peer-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a peer will be the spokesperson delivering the intervention content.
2502570|NCT02883829|Experimental|Provider-Based Delivery|The Provider-Based Delivery Arm will receive a brief health information intervention (delivered as video content) about diabetes self-management and alcohol use risks, measuring effects on health knowledge. For this arm, a healthcare provider will be the spokesperson delivering the intervention content.
2502586|NCT02883179|Active Comparator|lidocaine injection|5 mL of 2% lidocaine anhydrous solution (Depocaine) will be injected slowly along the lines of the edges of the perineal tears after delivery, with frequent aspirations to avoid intravascular injection.
2502590|NCT02883179|Experimental|lidocaine-prilocaine cream|5-g dose of Lidocaine-prilocaine cream will be applied to the intact tissue around each tear for 5 minutes before suturing
2502658|NCT02883036||Patients with chronic myeloid leukemia|100 adult patients(age>18 years),with chronic myeloid leukemia defined by the World Health Organization(WHO) criteria
2502661|NCT02883036||Healthy volunteers|Healthy volunteers
2502699|NCT02882555|Experimental|Children|"12 concentrations of caspaicin are administered: - 0.6, 1.2, 2.4, 4.8, 9.8, 19.5, 39, 78.1, 156.2, 312.5, 625, 1250 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
2502700|NCT02882555|Active Comparator|Adults|"As reference for more precise assessment of effects of development.~12 concentrations of caspaicin are administered: 0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500, 1000 μmol/l. Capsaicin concentration eliciting at least 2 coughs (C2) or 5 coughs (C5) is determined.~At least 1-hour-interval from capsaicin dose titration (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls (normal saline) in random order at baseline~At least 1-hour-interval (in order to minimize tachyphylaxy)~Administration of 4 inhalations at 1-min-interval: 2 C5 and 2 controls in random order during exercise, when heart rate is maximum"
2502756|NCT02882269|Active Comparator|Postoperative chemotherapy|Patients receive 6 months of chemotherapy after surgery.
2502762|NCT02882269|Experimental|Neoadjuvant chemotherapy|Patients receive 3-4 cycles of chemotherapy before surgery. Preoperative and postoperative chemotherapy will be given for a total of 6 months.
2502844|NCT02881983||STA group|Short-term alcohol abstinent patients (after 1 month of withdrawal)
2502846|NCT02881983||LTA group|Long-term alcohol abstinent patients (at least 6 months of abstinence)
2502848|NCT02881983||Control group|Healthy subjects
2502888|NCT02881385||E5 Esense 10%|PSV mode using E5 ventilator with Esense 10%
2502894|NCT02881385||E5 Esense 30%|PSV mode using E5 ventilator with Esense 30%
2502898|NCT02881385||E5 Esense 50%|PSV mode using E5 ventilator with Esense 50%
2502902|NCT02881385||Servo-I Esense 10%|PSV mode using Servo-I ventilator with Esense 10%
2502905|NCT02881385||Servo-I Esense 30%|PSV mode using Servo-I ventilator with Esense 30%
2502906|NCT02881385||Servo-I Esense 50%|PSV mode using Servo-I ventilator with Esense 50%
2502908|NCT02881385||E5 Esense autocycle|PSV mode using E5 ventilator with Esense Auto cycle
3196165|NCT00847782|Other|Blood draw (Group 3)|Hypercholesterolemic Subjects with Statin Treatment
3196166|NCT00847795|Experimental|1|5ng Avotermin
3196167|NCT00847795|Experimental|2|50ng Avotermin
2502293|NCT02885688|Other|Standard-of-Care Treatment for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment alone for up to 7 days.
2502300|NCT02885688|Experimental|Standard-of-Care Treatment Plus Liquid Nutrition for Sepsis|Participants with diagnosis of septic shock in MD Anderson Cancer Center ICU receive standard of care treatment plus plus liquid nutrition for up to 7 days.
2502339|NCT02885259|Experimental|HyQvia|human immunoglobulin and one vial of recombinant human hyaluronidase (rHuPH20
2502440|NCT02884635|Experimental|ASP1707|ASP1707 will be orally administered for 12 weeks.
2502446|NCT02884635|Placebo Comparator|Placebo|Placebo will be orally administered for 12 weeks.
2502484|NCT02883894||bullous pemphigoid|Patients with bullous pemphigoid.
2502552|NCT02883738|Experimental|upper limb tremor|
2502599|NCT02883387|Experimental|Preoperative CT Angiography|Patients will receive preoperative CT angiography to map the blood vessels potentially used for reconstruction
2502604|NCT02883387|Active Comparator|No Imaging Preoperatively|No preoperative vessel mapping will be done
2502761|NCT02882529|Experimental|Visible light exposure Green 30 lux|The participants will be exposed to green LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502764|NCT02882529|Experimental|Visible light exposure Green 120 lux|The participants will be exposed to green LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502767|NCT02882529|Experimental|Visible light exposure Yellow 30 lux|The participants will be exposed to yellow LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502769|NCT02882529|Experimental|Visible light exposure Yellow 120 lux|The participants will be exposed to yellow LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502771|NCT02882529|Experimental|Visible light exposure Violet 30 lux|The participants will be exposed to violet LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502773|NCT02882529|Experimental|Visible light exposure Violet 120 lux|The participants will be exposed to violet LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502845|NCT02881879|Experimental|Allergovac depot with HDM extract|Extract of mixture of Dermatophagoides pteronyssinus and Dermatophagoides farinae (50:50) adsorbed onto aluminum hydroxide 0.33%.
2502896|NCT02881411|Active Comparator|Self-soft tissue therapy|Intervention group: Fibromyalgia coping skills programme plus self-soft tissue therapy (SSTT) SSTT consists of MTrP therapy on TrP sites in either the lower leg/foot or forearm/hand. MTrP therapy will be administered by the researcher for only two sessions which will include training to teach the participant how to do SSTT on themselves. All participants in the intervention group will also receive an advice booklet for SSTT.
2502899|NCT02881411|Active Comparator|Fibromyalgia coping skills programme|Control group:Fibromyalgia coping skills programme only. The FCSP is a non-pharmacological, multidisciplinary exercise and education group programme. Its main aims are to provide condition-specific, patient centred, self-management education and advice, in line with national drivers for long-term conditions and international FMS clinical guidelines.
2502931|NCT02880982|Active Comparator|Intervention|Softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3) to be taken orally once per week for 3 years
2502942|NCT02880982|Placebo Comparator|Placebo|Softgel capsule of identical taste and appearance to active comparator, but containing no cholecalciferol, to be taken orally once per week for 3 years
2503003|NCT02880813|Experimental|Gastric|gastric infusion
2503008|NCT02880813|Experimental|Duodenal|Duodenal infusion
2503098|NCT02879916|Placebo Comparator|Placebo|NaCl 0.9% 3ml perineural stellate ganglion injection
2503100|NCT02879916|Active Comparator|Stellate ganglion block|Levobupivacaine 3ml perineural stellate ganglion injection
2503160|NCT02879656|Other|Cohort 1|"Early ustable fracture:~Phase 1:~After closed reduction, if satisfactory reduction is not achieved fulfilling the inclusion criteria, the patient is allocated to Cohort 1. The patient is randomized to either non-operative (=Arm 1) or operative treatment (=Arm 2). Patients allocated to non-operative treatment will undergo a standard treatment protocol. Patients allocated to operative treatment will undergo a surgery with volar locking plate with modified Henry's volar approach."
2503167|NCT02879656|Other|Cohort 2|"Early stable fracture:~Phase 1:~After closed reduction, if satisfactory position is achieved, the patient is allocated to Cohort 2 and conservative treatment is performed as usually.~Phase 2:~Patients allocated to Cohort 2, will visit orthopedic outpatient clinic in 1 week in the hospital where the treatment was initially started. If reduction is maintained the patient will undergo standard follow-up visits. If reduction is lost to fulfill the inclusion criteria for surgery the patient is asked to participate to phase 2 of this study. After the patient´s enrollment has been confirmed and informed consent is signed, the patient is randomized to either non-operative (=Arm 3N) or operative treatment (=Arm 3O). If allocated to non-operative treatment patient will undergo the same protocol as those in the Arm 1. Patients allocated to operative treatment will undergo surgery with volar locking plate with standard volar approach."
2503211|NCT02879136|Active Comparator|Physical Therapy|Physical Therapy (PT) will consist of two weekly sessions over a 12 week period using the Mellen center protocol PT for PD.
2502343|NCT02885272|Experimental|Diagnostic (PET/CT)|Patients receive fluorodeoxyglucose F-18 IV over 1 minute and then undergo PET/CT scans over 30 minutes at 1 hour, 4-5 hours, and 7-8 hours after injection. Patients also undergo a standard of care MRI scan over 45 minutes if not already completed as part of standard of care.
2502428|NCT02884518|Experimental|patient group|The patient group recruits subjects diagnosed with first episode psychosis which occurred within 2 years and having been treated with antipsychotics for 1 year. Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity. And patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
2502429|NCT02884518|Other|healthy control group|Screening tests for healthy volunteers included physical examination, vital signs, laboratory will test (hematology, blood chemistry, and urinalysis), and a 12-lead electrocardiograms. A psychiatric interview with the Structured Clinical Interview for text revision of the Diagnostic and Statistical Manual of Mental Disorders -IV(DSM-IV-TR) Axis I disorders, Research Version, Nonpatient Edition (SCID-I/NP) (First et al. 2002) will be conducted. Subjects with any medically significant abnormality on investigations and/or psychiatric disease will be excluded. Also, healthy control group will take a PET scan at 0, 2, 4, 6, and 8 week and clinical scales at baseline.
2502466|NCT02884258||Bariatric surgery group|Women undergoing IVF (IVF or ICSI) with a history of bariatric surgery (surgery procedures include sleeve gastrectomies and by-passes). No intervention is involved.
2502468|NCT02884258||Control Group|1. Women undergoing IVF with no history of bariatric surgery and matched to bariatric surgery patients for weight, parity and age. 2. non-operated severely obese women
2502483|NCT02883959|Experimental|music therapy|Music therapy
2502488|NCT02883959|No Intervention|control arm|No music
2502545|NCT02883803|Experimental|MSC|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 10^6/kg heterologous mesenchymal stem cells in 250 ml albumin 4%, infused for 30 minutes in central venous line.
2502548|NCT02883803|Sham Comparator|Placebo|Patients hospitalized in recovery unit and having a very severe septic shock with community origin (≥ 2 organ failures other than hemodynamic) since less than 12 hours, will receive 250 ml albumin 4%, infused for 30 minutes in central venous line.
2502595|NCT02883270|Experimental|RAGT treatment group|Robotic-assisted gait training （RAGT）is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation after some neuropathy. The investigators use LokoHelp for training, which is provided to the feet and the patient actively controls the knee and hip joints. The participants of RAGT treatment group receive 30 min conventional rehabilitation and 30 min robotic-assisted gait training daily for 8 weeks.
2502596|NCT02883270|Placebo Comparator|controls|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
2502701|NCT02882932|Other|Super Oxidized Solution|Procedure/Surgery: Super Oxidized Solution(SOS) in group I - SOS with normal saline solution was used
2502706|NCT02882932|Other|normal saline|"Procedure/Surgery: normal saline~In group II - patients underwent normal saline wash and bacterial load was noted."
2502721|NCT02882295||writer's cramp|patients assessed without, then with Botulinum Neurotoxin injections
2502722|NCT02882295||control|age and gender matched
2502863|NCT02881502||healthy control group|Mainly from students, family members of patients without chronic lung disease, healthy population, age 18-75 years old, the gender is not limited.
2502866|NCT02881502||mild and moderate asthma group|Patients diagnosed with asthma in the outpatient clinic, in accordance with the inclusion criteria and exclusion criteria.
2502869|NCT02881502||severe asthma group|Outpatient patients with severe asthma diagnosis, in accordance with the inclusion criteria and exclusion criteria.
2502970|NCT02881229||Women in the Vulvar Specialty Clinic|Information will be collected from all patients presenting with vulvar complaints who have been seen by Dr. Schlosser in the Vulvar Mucosal Specialty Clinic at Northwestern Medical Group.
2502995|NCT02880722||IBS patients|IBS according to Rome IV criteria.
2503001|NCT02880722||Healthy control group|Healthy volunteers without abdominal complaints fulfilling Rome IV criteria for IBS.
3196168|NCT00847795|Experimental|3|100ng Avotermin
3196169|NCT00847795|Placebo Comparator|4|Placebo
2503117|NCT02879591|Experimental|Patients with schizophrenia|Patients with schizophrenia
2503118|NCT02879591|Placebo Comparator|Healthy volunteers|Healthy volunteers
2503134|NCT02879448|Experimental|Amulet|Amulet left atrial appendage occluder
2503136|NCT02879448|Active Comparator|WATCHMAN (Control)|WATCHMAN left atrial appendage closure device
2503276|NCT02878512|Active Comparator|PCNL under General Anesthesia|Patients were premedicated with Inj. Atropine 0.06 mg intramuscularly half an hour prior to surgery, IV ranitidine 1mg kg-1, IV ondansetron 0.08mg kg-1 IV midazolam 0.02mg kg-1 and Pentazocine 0.3 mg/kg. Anaesthesia was induced with IV Thiopentone sodium 3-5 mg kg-1 and Vecuronium 0.1mg kg-1.and then intubated. Anaesthesia was maintained on 50 %:50% nitrous oxide and oxygen, vecuronium and propofol infusion . At the end of the surgery postoperative analgesia was given with IV tarmadol and local nfiltration with 0.25% bupivacaine at the surgical site. Patients were reversed with IV glycopyrrolate 0.008mg kg-1 and IV neostigmine 0.06mg kg-1 and extubated.
2503405|NCT02877550|Experimental|Part A - dose escalation and part B - dose expansion|"Part A: dose escalation:~Combination therapy N= 4-18 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to dose level (DL)~Part B - dose expansion:~Combination therapy N= up to 25 pts Cycle 1-6 (1 cycle = 28 days) Obinutuzumab: 1000 mg, i.v. infusion d1, 8, 15 C1 and d1 C2-6 Venetoclax: p.o. once daily according to MTD~Part A and part B are followed (in case of no PD) by an obinutuzumab maintenance therapy for 2 years"
2503458|NCT02877160|Experimental|Reference Formulation Fasted|150 mg of AL-794 study drug in suspension dosed in a fasted condition
2503862|NCT02874196|Experimental|Patients with painful prosthesis|
3196170|NCT00847795|No Intervention|5|Standard Care
3196171|NCT00847821||Bazedoxifene 10 mg/CE 0.625 mg|
3196172|NCT00847821||Bazedoxifene 20 mg/CE 0.625 mg|
3196173|NCT00847821||Bazedoxifene 40 mg/CE 0.625 mg|
3196174|NCT00847821||Bazedoxifene 10 mg/CE 0.45 mg|
3196175|NCT00847821||Bazedoxifene 20 mg/CE 0.45 mg|
3196176|NCT00847821||Bazedoxifene 40 mg/CE 0.45 mg|
3196177|NCT00847821||Raloxifene 60 mg|
2502474|NCT02884466|Experimental|Intervention group|The intervention group will receive a multidisciplinary rehabilitation intervention consisting of: 1) a pre-admission day, 2) two weeks of home-based activities, 3) two-week inpatient period, 4) four weeks of home-based activities, 5) 1st two-days inpatient follow-up, 6) six weeks of home-based activities and 7) 2nd two-days inpatient follow-up.
2502478|NCT02884466|Active Comparator|Usual care group|The usual care group will receive a four-week inpatient multidisciplinary rehabilitation intervention.
2502585|NCT02883322||Initial|Patients answering the initial translation
2502589|NCT02883322||Committee-only|Patients answering the translation modified by an expert committee
2502591|NCT02883322||BT-only|Patients answering the translation modified with the use of a back-translation
2502593|NCT02883322||Both|Patients answering the translation modified by an expert committee with the use of a back-translation
2502643|NCT02883049|Experimental|DS HR B-ALL (RER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
2502644|NCT02883049|Experimental|DS HR B-ALL (SER)|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
2502646|NCT02883049|Experimental|Group I Arm A (HR B-ALL)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2502648|NCT02883049|Experimental|Group I Arm B (HR B-ALL) (CLOSED 03/19/2018)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2502650|NCT02883049|Active Comparator|Group II Arm A (VHR B-ALL - Control Arm)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2502652|NCT02883049|Experimental|Group II Arm B (VHR B-ALL - Exp Arm1) (CLOSED 02/15/2017)|"Patients receive consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2502655|NCT02883049|Experimental|Group II Arm C (VHR B-ALL - Exp Arm 2) (CLOSED 09/12/2014)|"Patients receive induction, consolidation, interim maintenance, delayed intensification and maintenance therapies.~See outline for details."
2502657|NCT02883049|Experimental|Group III PH-like predicted TKI-sensitive kinase mutation|"Patients receive induction, consolidation, interim maintenance, delayed intensification, interim maintenance and maintenance therapies.~See outline for details."
3196178|NCT00847821||Placebo|
2503402|NCT02877511|Experimental|Arm 1|2/3 of subjects testing the test article
2503408|NCT02877511|Active Comparator|Arm 2|1/3 of subjects testing the marketed control
2503456|NCT02877277|Experimental|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
2503457|NCT02877277|Placebo Comparator|Placebo|Oral intake of placebo tablet daily for 56 days
3196179|NCT00847834|Experimental|1|"4 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by:~If DBP<85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg~If DBP≥85mmHg: 4 weeks of one tablet of Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet of Irbesartan 150mg"
3196180|NCT00847834|Experimental|2|"2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg followed by 2 weeks of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg followed by:~If DBP<85mmHg: 4 weeks of of one tablet Irbesartan 150mg / Hydrochlorothiazide 12.5mg + one tablet Irbesartan 150mg~If DBP≥85mmHg: 4 weeks of two tablets Irbesartan 150mg / Hydrochlorothiazide 12.5mg"
3196181|NCT00847847|Other|2|control subjects with muscle biopsy
3196182|NCT00847847|Other|1|ALS patients with muscle biopsy
2503706|NCT02875665|Experimental|geko device arm|geko™ devices (acting on the posterior tibial nerve) to be used on alternate days over seven days, for an hour per day
3196183|NCT00847860|Experimental|1|Cilostazol
3196184|NCT00847860|Active Comparator|2|Asprin
3196185|NCT00847873|Experimental|Combined SU/IPV treatment|A combined treatment containing cognitive behavioral therapy addressing partner violence and cognitive behavioral therapy addressing substance abuse
2503782|NCT02874612||Young Adults with Type 1 Diabetes Mellitus|All YA (ages 18-24) who are seen in the Cincinnati Children's Hospital Medical Center Diabetes Clinic and have recently (< 4 months) completed the Transition Readiness assessment tool as part of their standard clinical care is eligible for the study.
2503817|NCT02874560||Schizophrenia|350 patients will be included in the study. The centers selection is planned with 100 hospital-based psychiatrists, in centers for preventive medicine (CMP) or in private settings. Each investigator should consecutively enroll patients fulfilling the selection criteria to participate in the study (mean expected number of participants per center is around 10).
2503864|NCT02874261|Experimental|Whole Body Periodic Acceleration|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation is 120 cycles/minute; cpm) as well as a distance traveled 16 mm."
3196186|NCT00847873|Active Comparator|control condition|Cognitive behavioral therapy addressing substance abuse
2504056|NCT02873117||5 alpha reductase inhibitor|
2504057|NCT02873117||Any other drug for benign prostate hyperplasia|
2504114|NCT02872688|Experimental|GanedenBC30|
2545087|NCT02597465|Experimental|Chemotherapy|Chemotherapy
3196187|NCT00847899|Active Comparator|1|AR9281
3196188|NCT00847899|Active Comparator|2|AR9281
3196189|NCT00847899|Placebo Comparator|3|Placebo
3196190|NCT00847899|Placebo Comparator|4|Placebo
3196191|NCT00847925|Other|A|50ng Avotermin/100ul
3196192|NCT00847925|Other|B|20ng Avotermin/100ul
3196193|NCT00847925|Other|C|5ng Avotermin/100ul
3196194|NCT00847925|Other|D|100ng Avotermin/100ul
3196195|NCT00847925|Other|E|500ng Avotermin/100ul
3196196|NCT00847925|Other|F|0.25ng Avotermin/100ul
3196197|NCT00847925|Other|G|1ng Avotermin/100ul
3196198|NCT00847925|Other|H|20ng Avotermin/100ul
3196199|NCT00847925|Other|I|50ng Avotermin/100ul
3196200|NCT00847951|Other|Renal perfusion in Neonates|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys.
2502462|NCT02884323|Experimental|geko device arm|
2502475|NCT02883985|Experimental|Radiation Therapy: 6 Gy/ fraction|All patients will be treated with 6 Gy /fraction delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
2502555|NCT02883790|Experimental|Somnage|Group A-Melatonin 1mg, Zinc, Magnesium Oral administration o.d.
2502560|NCT02883790|Placebo Comparator|Placebo|Oral administration o.d.
2502653|NCT02882880|Other|Started|Intervention: Treatment with the Luco Hybrid OSA Appliance (LHOA) Group 1, fitted with LHOA Group 2: LHOA removed for 48 hours
2502656|NCT02882880|Active Comparator|Completed|Intervention: The LUco Hybrid OSA APpliance The subjects that actually completed the study in both groups. Group 1 n = 32, in Group 2 n=19
3196201|NCT00847964|Experimental|Algisyl-LVR implants|Algisyl-LVR implants to the left ventricular wall
3196202|NCT00847977|Active Comparator|1|Heafusine - Physiologic serum
2502797|NCT02881866|Active Comparator|Air Hunger|"Previous studies have shown that inhaled furosemide relieves 'air hunger'.~Each volunteer has 3 mists per visit. The mists are either in the order of Furosemide-Saline-Furosemide or Saline-Furosemide-Saline. The furosemide mist is 40mg (10mg/ml) nebulised and the saline mist is 4ml nebulised.~Induced air hunger (hypercapnia with constrained ventilation) is the active comparator and will be the type of breathlessness induced, before and after each mist inhalation on one day. ."
2502799|NCT02881866|Experimental|Work Effort|Induced sense of breathing effort (raised ventilation with external resistive load) is the 'experimental arm' and will be the type of breathlessness induced, before and after each mist inhalation on the other day. .
3196203|NCT00847977|Experimental|2|Isofundine - Tetraspan
3196204|NCT00847990||Pregnant women|Pregnant women who are scheduled to undergo an amniocentesis or CVS procedure and will receive the fetal FISH and/or karyotype results from the procedure.
3196205|NCT00848003|Active Comparator|1. Active|"Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12)~Probiotic, BB-12, supplemented yogurt, 4 ounces taken orally for 10 days"
3196206|NCT00848003|Placebo Comparator|2. Placebo|Strawberry flavored yogurt
2503130|NCT02879825|Experimental|Group A|Mitral valve prolapse without mitral regurgitation
2503131|NCT02879825|Experimental|Group B|Mitral valve prolapse with trivial mitral regurgitation
2503135|NCT02879825|Experimental|Group C|Mitral valve prolapse with moderate or mild mitral regurgitation and asymptomatic
2503137|NCT02879825|Experimental|Group D|Mitral valve prolapse with severe mitral regurgitation or symptomatic
3196207|NCT00848029|Experimental|1|
3196208|NCT00848055|Experimental|arm 1|AbGn168 cohort 1
2503273|NCT02878395||Crohn's disease|
2503441|NCT02877394|Experimental|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
2503444|NCT02877394|Sham Comparator|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
2503519|NCT02876913||Group Nasotracheal Intubation|Patients who are scheduled for nasotracheal intubation for general anesthesia
2503574|NCT02876471|No Intervention|OSA group|100 severe OSA patients without hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS),demographic and anthropometric data The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated
2503577|NCT02876471|Other|OSA with hypertension|100 severe OSA patients with hypertension were enrolled. Primal evaluations including office blood pressure, Epworth sleepiness scale score(ESS), antihypertensive medicine demographic and anthropometric data. The full night polysomnogram was performed, recording nocturnal blood pressure, oximetry, beat-to-beat BPV, AHI, BP event was calculated.Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood pressure control, the investigators would give one-night CPAP.
2503608|NCT02876029|Other|Reference|White wheat bread
2503613|NCT02876029|Other|Test product|Pasta
2503631|NCT02875743|Experimental|Posaconazole|
2503642|NCT02875574||All participants|
2503842|NCT02874365|Experimental|ulcerative colitis|arm composed by 30 patients with ulcerative colitis
3196209|NCT00848055|Experimental|arm 2|AbGn168 cohort 2
3196210|NCT00848055|Experimental|arm 3|AbGn168 cohort 3
3196211|NCT00848055|Experimental|arm 4|AbGn168 cohort 4
3196212|NCT00848055|Experimental|arm 5|AbGn168 cohort 5
3196213|NCT00848055|Experimental|arm 6|AbGn168 cohort 6
3196214|NCT00848055|Experimental|arm 7|AbGn168 cohort 7
3196215|NCT00848055|Experimental|arm 8|AbGn168 cohort 8
3196216|NCT00848068|Other|OD (Right Eye)|FID 114657 or OPTIVE
3196217|NCT00848068|Other|OS (Left eye)|FID 114657 or OPTIVE
3196218|NCT00848094|Other|arm 1|Arm I: tumor diameter more than 5 cm and less than 10 cm.
3196219|NCT00848094|Other|arm 2|Arm II: tumor diameter no less than 10 cm.
3196220|NCT00848133|Active Comparator|mini-midvastus|
3196221|NCT00848133|Active Comparator|mini-subvastus|
3196222|NCT00848146|Experimental|NOTES-Assisted Lap Chole|These patients will undergo an experimental surgical procedure that uses a combination of laparoscopic instruments (i.e., inserted through the skin into the abdominal cavity) and flexible endoscopic instruments (i.e., inserted through the mouth).
3196223|NCT00848159||1|Group 1 was composed of six women with a densitometric diagnosis of osteoporosis in column (DP =- 2.70 to -4.97), with an average weight of 57.5 (+6.9) kg, mean height of 1 , 4 (+ 0.07) my body mass index (BMI) of 26.1 (+1.8) Kg/m2
3196224|NCT00848159||2|Group 2 consists of six women with a densitometric diagnosis of osteopenia in column (DP =- 1.07 to -2.09), with an average weight of 62.1 (+9.9) kg, mean height of 1, 5 (+0.03) I BMI 25.3 (3.3) kg/m2, both compared with young adults
3196225|NCT00848224|Experimental|2|
3196226|NCT00848263|Active Comparator|DVR|Volar plate
2502408|NCT02884882|Other|Emotional induction in stroke population|Six films are presented, each after a relaxation period after which the basal score is measured.
2502409|NCT02884882|Placebo Comparator|Emotional induction in healthy volunteers|Six films are presented, each after a relaxation period after which the basal score is measured.
2502444|NCT02884544|Experimental|HLD100 10mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (10mg)
2502447|NCT02884544|Experimental|HLD100 20mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (20mg)
2502451|NCT02884544|Experimental|HLD100 30mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (30mg)
2502455|NCT02884544|Experimental|HLD100 40mg|HLD100 (dextroamphetamine sulfate) DR/ER capsules (40mg)
2502486|NCT02884050|Experimental|Topiramate|single, 100mg oral dose of topiramate
2502491|NCT02884050|Placebo Comparator|Placebo|matched inactive placebo
2502553|NCT02883673|Experimental|Intervention|Jada System for Postpartum Hemorrhage will be administered to subjects who are diagnosed with postpartum hemorrhage.
2502614|NCT02883166|Other|group 1|1000mg abiraterone fasted followed by 500 mg with breakfast
2502618|NCT02883166|Other|group 2|500 mg abiraterone with breakfast followed by 1000mg fasted
2502805|NCT02882204||First Episode Patients|First episode patients new to the PEPP program.
2502807|NCT02882204||Chronic Patients|Existing patients who have been enrolled in the PEPP program for >3 years
2502809|NCT02882204||Healthy Controls|Healthy controls who are not currently in treatment for any major mental illness defined using DSM-V criteria.
2502810|NCT02882204||Cliniucal High Risk patients|Patients who are accessing PEPP services during the prodromal phase of psychotic illness.
2502850|NCT02881684|Experimental|Treatment|"Intervention:~Device: Aspiration Therapy (AspireAssist)~- Subjects randomized to the treatment group will undergo an endoscopic procedure to have the experimental device (i.e. the A-tube) inserted. This will be followed by regular follow up visits and lifestyle therapy matched to the control group. The device will be removed at the end of one year and this group will be observed for one year more to determine if there is any legacy effect.~Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy"
2502851|NCT02881684|Active Comparator|Control|"Intervention:~(1) Behavioral: Lifestyle Therapy Lifestyle therapy is a behavioral, diet and physical activity education program Other Name: Lifestyle Behavioral Therapy~- Subjects randomized to the control group will receive lifestyle management matched to the treatment group in the first year. At the end of one year, they will be crossed over to treatment and the A-tube will be inserted. They will then follow up the same follow up schedule of the treatment group during the first year."
2502858|NCT02881346||Enstilar®|Patients with psoriasis vulgaris plaques on body and/or extremities will apply Enstilar® (calcipotriol /betamethasone dipropionate (50 micrograms/g + 0.5 mg/g) cutaneous foam) once daily for up to 4 weeks, according to the approved labelling of Enstilar® in Germany.
2502914|NCT02881294|Active Comparator|Food Effect|SUVN-G3031 tablets single dose
2502918|NCT02881294|Active Comparator|Gender Effect|SUVN-G3031 tablets single dose
2502921|NCT02881294|Active Comparator|Age Effect|SUVN-G3031 tablets single dose
2502937|NCT02880956|Experimental|Group 2|Dose 2 ABBV-8E12
2502949|NCT02880956|Experimental|Group 3|Dose 3 ABBV-8E12
2502951|NCT02880956|Experimental|Group 1|Dose 1 ABBV-8E12
2502953|NCT02880956|Placebo Comparator|Group 4|Placebo for ABBV-8E12
2503125|NCT02879461|Active Comparator|Lumbar Decompression plus Physical Therapy|First group will be submitted to lumbar decompression L3 to S1 and physical therapy with exercise Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
2503126|NCT02879461|Active Comparator|Physical Therapy|Second group physical therapy alone, with exercises Application of questionnaires Oswestry Rolland moris Sf 36 Of 6minutos walk test Likert scale Use of paracetamol
2503179|NCT02879370|Experimental|TICRANT|Transanal Inspection and management of low ColoRectal Anastomosis
2503214|NCT02879097|Experimental|CBT124 arm|CBT124 plus carboplatin and paclitaxel
2503215|NCT02879097|Active Comparator|EU Sourced Avastin® arm|EU-sourced Avastin® plus carboplatin and paclitaxel
2503261|NCT02878772|Active Comparator|vinpocetine group|Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
2503262|NCT02878772|Placebo Comparator|Control group|Patients will receive aspirin only.
2503297|NCT02878356|Active Comparator|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
2503298|NCT02878356|Active Comparator|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
2503299|NCT02878356|Active Comparator|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
2503342|NCT02878031|Experimental|Oral amoxicillin for CI pneumonia|Community management of chest indrawing pneumonia using oral amoxicillin by CHWs
2503401|NCT02877693|Other|Thoracic MRI Scan|Subjects will be enrolled at least 60 days post successful St. Jude Medical™ MR Conditional ICD System implant. Enrolled subjects will undergo an elective MRI scan within 30 days post enrollment. Post MRI visit all subjects will be followed up at 1-Month post MRI visit.
3163140|NCT00476359|Other|double-boosted PI|double-boosted protease inhibitor combination
3163141|NCT00476372||Parkinson's disease|Pt with parkinsons disease
3163142|NCT00476385|Experimental|somatropine|
3163143|NCT00476398|No Intervention|Diagnostic capsule endoscopy|Patient with non-cardiac chest pain will undergo capsule endoscopy
3163144|NCT00476411|Experimental|1|HBV vaccine
3163145|NCT00476424|Active Comparator|1|400 mg EFV
3163146|NCT00476424|Active Comparator|2|600 mg EFV
3163147|NCT00476463|Active Comparator|1|AZT+FTC+EFV
3163148|NCT00476463|Active Comparator|2|TDF+FTC+EFV
3163149|NCT00476502||1|patients involved in structured interruption therapy
3163150|NCT00476515|Experimental|Rituximab|this study has only one arm as treatment group.
3163151|NCT00476541|Experimental|1|Gemtuzumab 5 mg / m2 two courses with three week interval
2502419|NCT02884817|Experimental|Listerine prof.gum.ther|"The test solution was the commercially available mouthwash product EOELA that contains essential oils and ELA in 21.6% alcohol (Listerine Professional Gum Therapy®, Johnson & Johnson,USA).~Intervention; Rinsing 30 sec with test solution twice daily for 21 days"
2502421|NCT02884817|Placebo Comparator|21.6% hydroalcoholic|"a hydro-alcohol solution made from 96% ethanol diluted with sterilized water to the final concentration of 21.6%.~Intervention: Rinsing 30 sec with placebo comparator twice daily for 21 days"
2502425|NCT02884817|Sham Comparator|Plain sterile water|"Plain sterile water.~Intervention: Rinsing 30 sec with sham comparator twice daily for 21 days"
2502465|NCT02884310|Experimental|SPI group|"Remifentanil titration before tracheal intubation and skin incision according to the SPI gradient obtained after a nociceptive test using a tetanic stimulus of 100 Hz, 60 milliamperes during 30 seconds performed at a 3 ng/ml level of the remifentanil concentration.~During surgery, the effect site remifentanil concentration was either increased or decreased by 1 ng/ml to maintain SPI below 40 or above 20, respectively."
2502467|NCT02884310|Active Comparator|Control group|"The remifentanil concentration before tracheal intubation and skin incision was fixed at 4 ng/ml.~During surgery, the remifentanil concentration was adapted according to the hemodynamic answer of the patient. It was changed by 1 ng/ml stepwise variations to maintain heart rate and mean blood pressure within 20% of the patient reference hemodynamic values."
2502480|NCT02883933||melanoma|Patients with melanoma.
2502584|NCT02883751|Active Comparator|Control group|Control group - gold standard: Conventional ulcer treatment with Rayon® and essential fatty acids (Dersani®). Cleaning of the surgical wound will be performed with saline solution. The wound will then be covered with a sterile polyethylene film, over which the LED plate will be positioned for placebo treatment (emission of sound, but with the device switched off). After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
2502588|NCT02883751|Experimental|LED group|LED group: Cleaning of the surgical wound will be performed with saline solution and the wound will be covered with a sterile polyethylene film, over which the LED plate will be positioned for active treatment with the device switched on. After 10 minutes, the LED plate and polyethylene film will be removed and the surgical wound will be covered with rayon moistened with essential fatty acids (following the standard protocol of the hospital), followed by the application of gauze and finalization with a crepe bandage.
2502686|NCT02883010|Experimental|PICO|Single use NPWT (PICO Softport V1.6)
2502691|NCT02883010|Other|Standard care|Gauze dressing, Film dressing, foam dressing, skin glue, no dressing
2502751|NCT02882425|Experimental|Intravenous selexipag (Pilot phase)|Subjects received a 20-minute intravenous (i.v.) infusion of 50 µg selexipag
2502752|NCT02882425|Experimental|Sequence A-B (Main phase)|Subjects received a 80-minute i.v. infusion of 200 µg selexipag during Period 1, and 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 2. A washout period of 7 to 10 days separated the i.v. infusion from the oral administration.
2502753|NCT02882425|Experimental|Sequence B-A (Main phase)|Subjects received 2 tablets of oral selexipag (total dose of 400 µg) as a single administration during Period 1, and a 80-minute i.v. infusion of 200 µg selexipag during Period 2. A washout period of 7 to 10 days separated the oral administration from the i.v. infusion.
2502835|NCT02881944|Experimental|Low FODMAP (modified healthy) Diet|Low FODMAP diet for 3 weeks. Veterans will be provided a diet containing foods low in FODMAP.
2502837|NCT02881944|Experimental|High FODMAP (typical healthy) Diet|High FODMAP diet for 3 weeks. Veterans will be provided a typically healthy diet following US Dietary Guidelines, containing foods high in FODMAPs
2502861|NCT02881515|Experimental|Blood Pressure Reactivity|Blood Pressure Responses to a cold pressor test and acute exercise will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
2502862|NCT02881515|Experimental|Blood Pressure Variability|Twenty four hour blood pressure variability will be assessed. This will be performed while subjects are on a low sodium diet (1000 mg/daily), medium sodium diet (2300 mg/daily), and high sodium diet (7000 mg/daily).
2502971|NCT02881164|Experimental|Low glycemic index breakfast|Low glycemic index breakfast (GI=45)
2502974|NCT02881164|Active Comparator|High glycemic index breakfast|High glycemic index breakfast (GI=80)
2503082|NCT02880150|Other|Elite climbers|Elite climbers selected in a national group for their previous performances at high altitude
2503084|NCT02880150|Other|Sea level sportsmen|Control group with similar anthropometric, age, gender and maximal normoxic oxygen consumption that the elite climber group
2503114|NCT02879708|No Intervention|Control|40 (of 120) randomly selected villages receive no intervention
2503115|NCT02879708|Other|Information Only|"40 randomly selected villages are assigned to the information only arm where households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village."
2503116|NCT02879708|Other|Information and Facilitation|The remaining 40 villages will receive similar information as the villages in the Information Only Arm, but will also have facilitators present that ensure the existence of the VHSNC at the village level as well as the occurrence of VHSNC monthly meetings.
2503152|NCT02879474||Patient with melanoma|
2503231|NCT02879045|Experimental|elasticity Belly® oil|Volunteer's abdomen skin are divided two parts through medioventral line, half of the abdomen skin will apply the elasticity Belly® oil
2503324|NCT02878291|Experimental|High dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,40μg/dose
2503325|NCT02878291|Experimental|low dose Group|Received Vaccine: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine,20μg/dose
2503374|NCT02877875|Experimental|Child STEPS|Child STEPs includes (1) a treatment protocol, Modular Approach to Therapy for Children with Anxiety, Depression, Trauma or Conduct Problems (MATCH-ADTC;Chorpita & Weisz, 2009), and (2) a youth monitoring and feedback system (MFS).
2503375|NCT02877875|Active Comparator|Usual Care|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective, and researchers will not influence their work.
2503843|NCT02874365|Sham Comparator|witness|arm composed by 30 patients with no intestinal disorders
2502494|NCT02884128|Experimental|PEP02 + 5-FU/LV|The initial starting dose of PEP02 is 60 mg/m2, and was escalated by increments of 20 mg/m2 between dose levels. 5-FU and LV were given as 24-hour infusion via an implanted central venous catheter, with dose fixed at 2000 mg/m2 and 200 mg/m2, respectively. PEP02 was administered on Day 1; 5-FU/LV was started after the end of PEP02 infusion on Day 1 and also on Day 8.
2502573|NCT02883582|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA)with or without ICS)+ hydrogen/ oxygen inhaled
2502574|NCT02883582|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
2502620|NCT02883153|Experimental|Zirconium-89 girentuximab PET/CT|A Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq).
2502669|NCT02882841|Other|Single-arm study|
2502754|NCT02882451|Experimental|pinaverium bromide|take 50 mg pinaverium bromide three times a day 1 days before and then 100 mg 1 hour before the examination orally
2502755|NCT02882451|Placebo Comparator|Vitamin C|take 50 mg Vitamin C three times a day 1 days before and then 100 mg 1 hour before the examination orally
2502824|NCT02882022|Experimental|CPAP|All participants will be included in this arm, and CPAP will be administered using a full face mask at incrementally increasing pressures. This will occur during a single session lasting no more than one hour.
2502900|NCT02881645||Best practices|Assessment of critical incidents linked to nursing with a best practices protocol
2502903|NCT02881645||Common practices|Assessment of critical incidents linked to nursing in common practices
2502930|NCT02880995|Experimental|patient group|"50 Drug-naïve patients with first episode psychosis (We anticipate the non-responder rate will be 30% of the patients)~Drug-naïve~Diagnosed as first episode psychosis~The total score of PANSS>70~No co-morbid psychiatric illness (including drug dependence/abuse)~They will also undergo PET scan at the baseline. And the investigators are going to determine treatment response after 6 weeks of treatment with amisulpride. Also they should complete clinical scales at 0, 2, 4, 6, and 8 week."
2502941|NCT02880995|Other|healthy control group|"12 healthy volunteers~No history of psychiatric disorder (including drug dependence/abuse)~No history of physical illness~No contra-indication to scanning~They will also undergo PET scan at the baseline"
2502992|NCT02880670|Experimental|Single dose of radiolabeled BMS-986142|
2503035|NCT02880527||patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis will be used:~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
2503083|NCT02880111||group 1|CF patients with Pseudomonas aeruginosa chronic colonization.
2503087|NCT02880111||group 2|CF patients without a Pseudomonas aeruginosa chronic colonization.
2503133|NCT02879760|Experimental|Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab|"Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.~MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.~Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22."
3163152|NCT00476541|No Intervention|2|No further therapy
2503569|NCT02876276|Active Comparator|HA filler group|6 weeks after the initial therapy, patients were scheduled for the procedure.16 Local Anesthetic solution (2% Lignocaine HCl with adrenaline 1:80000) was administered.17 About 0.2 ml of a commercially available hyaluronic acid based gel was injected 2-3 mm coronal to the apical tip of the receded interdental papilla . Injections were performed using 23 gauge X 25mm intraoral injection needles . The concentration of HA gel used was 20 mg/ml.6 The area was gently massaged to ensure that the filler was uniformly distributed. Care was taken to fill each papilla to full correction (100% of defect). After the treatment the individual patient syringes were capped and stored in a refrigerator with patient names and details. The needle was discarded. Patients were seen three weeks after the initial treatment and if augmentation was still deemed necessary, another injection of 0.2ml was injected up to three times
2503570|NCT02876276|Placebo Comparator|saline filler group|with saline same protocol was performed as mentioned in test group
2503863|NCT02874170|Experimental|drepanocytose affected patient|
3163155|NCT00476567|Experimental|exercise|Regular exercise 45-60 minutes minimum three times per week
3163156|NCT00476567|Active Comparator|control|standard antenatal care
3163157|NCT00476580||Sri Lankan Sinhalese|Sri Lankan Sinhalese adults (18 years of age or older) living in the greater Houston area, but born in Sri Lanka.
3163158|NCT00476580||Siblings or Cousins in Sri Lanka|Siblings or the first cousins of the study participants living in Sri Lanka of same sex and of an age plus or minus 10 years.
3163159|NCT00476606||Long-term pediatric cohort|Long-term follow-up cohort since 2003
3163160|NCT00476619|Placebo Comparator|Erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
3163161|NCT00476632||Control|Person with no history of cancer.
3163162|NCT00476671||1|HIV infected adults with viral load < 50 copies/ml on NNRTI based HAART
3163163|NCT00476684|Experimental|radiofrequency neurotomy|Radiofrequency-neurotomy of the medial branch at 80 degr. C for 70 seconds, after diagnostic blocks
3173619|NCT00614029|Experimental|F|Intraject-thigh to IMITREX-thigh to Intraject-arm to IMITREX-arm
2502583|NCT02883478|Active Comparator|Treatment group A|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 3 milliwatt/cm² (mW/cm²) for 30 minutes.~Device: UV-X 1000 irradiator (3 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
2502587|NCT02883478|Active Comparator|Treatment group B|"Corneal collagen cross-linking using riboflavin with hydroxypropyl methylcellulose solution and ultraviolet-A (UVA) irradiation at 9 mW/cm² for 10 minutes.~Device: UV-X 2000 irradiator (9 mW/cm²) Drug: riboflavin with hydroxypropyl methylcellulose"
2502707|NCT02882620|Experimental|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2502708|NCT02882620|Experimental|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2502709|NCT02882620|Experimental|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
2502775|NCT02882256|Experimental|Intervention|Patients will receive video discharge instructions in addition to standard written discharge instructions.
2502776|NCT02882256|No Intervention|Control|Patients will receive standard written discharge instructions.
2502859|NCT02881736|Experimental|Pateint with chronic stroke|
2502860|NCT02881736|Active Comparator|Healthy volunteer|
2502916|NCT02881281|Other|Education|Education program
2502919|NCT02881281|Other|Control Group|no intervention
2502946|NCT02880969|Experimental|Patient with end stage renal disease undergoing dialysis|
3163164|NCT00476684|Sham Comparator|sham controls|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
3163165|NCT00476697|Experimental|UVA1 Irradiation|UVA1 irradiaton up to 5 times per week, for up to 16 weeks using German manufactured UVA1 emitting light system. UVA1 dose will be applied with up to 130 J/cm2.
2503159|NCT02879617|Experimental|durvalumab|1500 mg of durvalumab will be administered intravenously (IV) on day 1 of every 28 day cycle.
2503255|NCT02878863|Experimental|Paeoniflorin + phosphatidylcholine or silymarin|Paeoniflorin tablets(600mg, tid)combination of phosphatidylcholine or silymarin
2503257|NCT02878863|Active Comparator|Phosphatidylcholine or silymarin|Phosphatidylcholine or silymarin
2503277|NCT02878447|Experimental|External Beam Radiotherapy|Patients will receive radiotherapy (3.5Gy weekly for 5 fractions to a maximum of 17G) prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue
2503278|NCT02878447|No Intervention|Control|Patients will receive best medical care.
2503327|NCT02878161|Experimental|A group|Infliximab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2503329|NCT02878161|Experimental|B group|Etanercept plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2503333|NCT02878161|Experimental|C group|Adalimumab plus Methotrexate , Leflunomide and NSAIDs and Glucocorticoids are permitted but not necessary included.
2503396|NCT02877524|Experimental|Adaptive support ventilation|Adaptive support ventilation during NIV for acute exacerbation of COPD
2503398|NCT02877524|Active Comparator|Pressure support ventilation|Pressure support ventilation during NIV for acute exacerbation of COPD
2503442|NCT02877264|Experimental|Vapendavir Capsule, 264 mg|Vapendavir phosphate salt administered orally as a single dose of two 132 mg hard gelatin capsules
2503446|NCT02877264|Experimental|Vapendavir Tablets, 264 mg|Vapendavir free base tablets containing 264 mg of vapendavir
2503448|NCT02877264|Experimental|Vapendavir Oral Suspension, 264 mg|Vapendavir free base as a 24 mg/mL oral suspension
2503532|NCT02876835|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
2503533|NCT02876835|Active Comparator|Darbepoetin alfa|Participants will be administered darbepoetin alfa subcutaneously (SC).
2503888|NCT02874014|Experimental|Hypofractionation Proton beam therapy|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes
3163166|NCT00476710||Normal Glucose Metabolism|Overweight and obese individuals that have normal glucose metabolism and their response to Colesevelam HCl
3163167|NCT00476710||Impaired Glucose Tolerance|Overweight and obese individuals that have impaired glucose tolerance and their response to Colesevelam HCl
3163168|NCT00476710||Frank type 2 diabetes|Overweight and obese individuals that have frank type 2 diabetes and their response to Colesevelam HCl
3163169|NCT00476723||1|HIV/Hepatitis coinfected patients who use at least one hepatitis activity drug or medications
3163170|NCT00476775|Experimental|After school ethnic dance and home-based screen time reduction|After school ethnic dance classes and home-based screen time reduction intervention
3163171|NCT00476775|Active Comparator|Health and Nutrition Education|Health and nutrition education active placebo control intervention
3163172|NCT00476801|Experimental|UVA1 irradiation|The dose and scheduling will be similar to those being successfully used in Germany: up to 130J/cm2 from a UVA1 Sellamed irradiation device (German manufactured UVA1 light emitting device) with irradiations up to 5 times per week for up to 14 weeks on one side of the face. Then a cross-over treatment an equal length of time.
3163173|NCT00476801|No Intervention|Control|No treatment on the opposite side of the face as the UVA1 treatment for up to 14 weeks. Then a cross-over treatment an equal length of time.
2502546|NCT02883686|No Intervention|Enhanced Usual Care|Usual care for depression within the Kaiser Permanente of Colorado healthcare system plus study monitoring of depression symptoms and feedback.
2502581|NCT02883361|Experimental|Treatment|Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
2502582|NCT02883361|Placebo Comparator|Control|Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
2502640|NCT02883075|Sham Comparator|Supine position|Supine position Supine position after placement of spinal anesthetic
2502641|NCT02883075|Active Comparator|Right lateral position|Right lateral position Right lateral after placement of spinal anesthetic
2502642|NCT02883075|Active Comparator|Left lateral position|Left lateral position Left lateral after placement of spinal anesthetic
2502685|NCT02882698|Experimental|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
2502688|NCT02882698|Experimental|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
2502690|NCT02882698|Active Comparator|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
2502692|NCT02882698|Active Comparator|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
2502719|NCT02882334|Experimental|Finger individuation training|Finger Force Manipulandum
2502720|NCT02882334|Active Comparator|control|conventional physiotherapy
2502798|NCT02882191|Experimental|LevoCept IUD|LevoCept IUD placement
2502864|NCT02881606|Active Comparator|Naso-alveolar molding (NAM)|Active plates and nasal stents (Grayson method)
2502867|NCT02881606|Active Comparator|Computer aided design NAM (CAD/NAM)|Computer aided design active plates and nasal stents
2502928|NCT02881255|Other|Subcutaneous ICD|Patient will receive a subcutaneous implantable cardioverter defibrillator (Boston Scientific EMBLEM)
2502933|NCT02881255|Other|Transvenous ICD|Patient will receive a single-chamber, transvenous implantable cardioverter defibrillator (from any manufacturer) which as the capability for remote monitoring.
2503043|NCT02880332|Active Comparator|Usual care + Extra care|This group will receive usual care and one additional session; extra care.
2503045|NCT02880332|Experimental|Usual care + PNE|Next to usual care, this group will also receive pain neuroscience education.
2503068|NCT02879955|Experimental|10 gastric bypass operated patients|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
2503069|NCT02879955|Experimental|10 healthy control subjects|4 different carbohydrate loads ingested at separate study days will be tested against each others ability to induce GLP-1 secretion.
3163174|NCT00476853|Active Comparator|1|NVP 400 mg
2503239|NCT02879019|Sham Comparator|Stretching exercise group|Patients will receive two session per week of stretching classes.
2503241|NCT02879019|Experimental|Walking training group|Patients will perform two walking sessions per week.
2503269|NCT02878577||EEG fMRI TBI Mild/Moderate-Severe severity|patient population who suffered a brain trauma (traumatic brain injury, TBI). with a Glasgow Coma Scale between 3-15
2503270|NCT02878577||EEG fMRI Control group|healthy subjects with out a traumatic brain injury
2503319|NCT02877992|Active Comparator|Donors|Oocyte donors without infertility problems
2503320|NCT02877992|Experimental|PCOS|Patients with Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria
2503321|NCT02877992|Experimental|Endometriosis|Patients with endometriosis (I-IV)
2503322|NCT02877992|Experimental|Age|Patients with advanced maternal age (38 years or more)
2503323|NCT02877992|Experimental|Low ovarian response|Patients with low ovarian response according to Bologna criteria
2503370|NCT02877888|Experimental|drug fluoride varnish /strength 22600ppm|intervention: drug :fluoride varnish 22600ppm topical application every 6 months for a total period of 2 years
2503371|NCT02877888|No Intervention|placebo comparator|placebo:use of routine dental advice
2503390|NCT02877537|Experimental|Asthma child|
2503394|NCT02877537|Experimental|Control adult|
2503397|NCT02877537|Experimental|Control child|
2503445|NCT02877199||HCV triple therapy|Cohort of HCV patients who received first-generation protease inhibitor-based triple therapy
2503509|NCT02876965|Active Comparator|Physical Exercise|Aerobic physical exercise protocol of moderate intensity, for 12 weeks, 3 sessions per week, about 12 minutes. Physical activity chosen will be pedaling on a static bike.
2503510|NCT02876965|Experimental|Muscle Stretching|Stretching program on the main muscle groups of the body, for 12 weeks, 1sessions per week, about 45 minutes.
2503582|NCT02876497|Experimental|Study arm|
2503681|NCT02875379|Experimental|HME|Passive humidification with heat and moisture exchanger, Y-piece circuit.
2503682|NCT02875379|Experimental|HH33|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
2503684|NCT02875379|Experimental|HH37|Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
2503685|NCT02875379|Experimental|NoH|Passive humidification, double tube circuit
2503716|NCT02875158|Active Comparator|Diode laser using conventional settings|The cyclophotocoagulation protocol is used with the conventional cyclophotocoagulation settings of 2000 mW for 2 seconds.
2503865|NCT02874170|Other|Healthy volunteers|
3163175|NCT00476853|Active Comparator|2|NVP 600 mg
3163176|NCT00476879|Experimental|1|12 hours of fasting and a GH bolus
3163177|NCT00476879|Experimental|2|36 hours of fasting and a GH bolus
3163178|NCT00476879|Experimental|3|36 hours of fasting and Pegvisomant
3163179|NCT00476879|Experimental|4|36 hours of fasting and NaCl injection
3173620|NCT00614042|Experimental|1|Dose escalation and expansion cohorts
3173621|NCT00614068|Experimental|A|Participants will receive 12 sessions of trauma-focused cognitive behavioral therapy over 3 months.
3173622|NCT00614068|Active Comparator|B|Participants will receive 12 sessions of treatment as usual over 3 months.
3173623|NCT00614081|Experimental|1|Renal transplant recipients
3173624|NCT00614133|Experimental|1|Preoperative nutrition.
3173625|NCT00614133|Active Comparator|2|Preoperative fasting.
2502601|NCT02883283|Active Comparator|Epidural Catheter Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural catheter following catheter placement. (Current standard practice) Epidural loading dose via epidural catheter.
2502605|NCT02883283|Experimental|Epidural Needle Administration|Participants will receive the 10 mL epidural loading dose in 5 mL increments via the epidural needle prior to catheter placement. Epidural loading dose via epidural needle.
2502765|NCT02882503|Experimental|EUS-RFA|monopolar radiofrequency probe (1.2 mm Habib endoscopic ultrasound - radiofrequency ablation (EUS-RFA) catheter) and 19 or 22 gauge fine needle aspiration (FNA) needle
2502829|NCT02882009|Experimental|Gantenerumab + Placebo|Participants will be randomized to receive gantenerumab HCLF and placebo solution via SC injection according to different sequences for the site of administration and different injection speeds.
2503251|NCT02878733||Albumin|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) with any volume of 5% albumin
2503252|NCT02878733||Crystalloid Only|patients that had received at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.) without any volume of 5% albumin
2503268|NCT02878499|Other|ASD|
2503328|NCT02878265|Placebo Comparator|Vitamin A|A single dose of 20,000IU Vitamin A for the whole study period
2503331|NCT02878265|Active Comparator|Vitamin A and zinc|A single dose of 20,000IU Vitamin A and 10mg of elemental zinc each day for 5 months
2503336|NCT02878265|Active Comparator|Vitamin A , Zinc and Multivitamin|A single dose of 20,000IU Vitamin A , 10mg of elemental zinc each day and 0.5ml/kg multivitamin syrup for 5 months
2503404|NCT02877654|Experimental|Irritable Bowel Syndrome|
2503459|NCT02877303|Experimental|Treatment (blinatumomab, inotuzumab, combination chemotherapy)|See detailed description.
2503731|NCT02875431||ACDF or cervical vertebral body replacement|
2503883|NCT02874300|No Intervention|Control|The control arm will comprise the offer of an assessment by a standard community falls prevention service.
2503892|NCT02874300|Other|High intensity supervision arm|high-intensity supervision
2503894|NCT02874300|Other|Moderate intensity supervision arm|Moderate intensity supervision
2503951|NCT02873741||Validation Study|Participants will undergo a perianal and digital anorectal exam, a high resolution anoscopy, and cervical and anal swabs to determine the best method to identify women at high risk for anal cancer.
2503987|NCT02873312|Experimental|StimRouter Treatment|The Treatment group will receive therapeutic level StimRouter electrical stimulation. At the end of the Month 3 visit the Treatment group will continue to receive therapeutic level StimRouter electrical stimulation for an additional 3 months.
2503988|NCT02873312|Sham Comparator|StimRouter Control|The Control group will receive sham (sub-therapeutic level only) StimRouter stimulation. At the end of the Month 3 visit the Control group will be allowed to receive therapeutic level StimRouter electrical stimulation for 3 months.
2504067|NCT02872870||Control adults|lexical tests and electroencephalogram (EEG).
2504070|NCT02872870||Dyslexic patients|lexical tests
2504073|NCT02872870||Dysphasic patients|lexical tests
2504164|NCT02872506|Active Comparator|medical treatment by Anti TNF|The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time
2504169|NCT02872506|Active Comparator|ileocecal resection|The surgical treatment group are the patients operated on for the first time by means of ileocecal resection laparoscopic or laparotomy
2504197|NCT02871934|Experimental|PGx+|Patients in the PGx+ (intervention) arm will have their SLCO1B1 results reported to their ordering provider immediately.
2504198|NCT02871934|Experimental|PGx-|Patient in the PGx- (control) arm will have their SLCO1B1 results reported to their ordering provider at the end of the study (after 12 months).
2504253|NCT02871687|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
2504257|NCT02871687|Active Comparator|Simvastatin|Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
2504260|NCT02871687|Active Comparator|Pravastatin|Subjects in the pravastatin arm will receive pravastatin 40 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of pravastatin is increased to 80 mg daily for the following 6 weeks.
2504291|NCT02871310|Experimental|IQP-AS-118|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
2504294|NCT02871310|Placebo Comparator|Placebo|To be taken once daily dosing of 1 tablet in the morning with 250 mL of water. The tablets should not be chewed, but swallowed whole.
3173626|NCT00614146|Experimental|1|
2504683|NCT02868736||Suspected Periprosthetic Joint Infection|Individuals who are suspected of having Periprosthetic Joint Infection (PJI)
2504736|NCT02868411|Experimental|Patients admitted for traveller's fever|
3173627|NCT00614146|Active Comparator|2|
3173628|NCT00614159||GI Endoscopy|
3173629|NCT00614172|Experimental|Proton Radiotherapy|Two week course of proton radiotherapy to the breast.
3173630|NCT00614211|Active Comparator|1|Total Abdominal Radical Hysterectomy
3173631|NCT00614211|Experimental|2|Total Laparoscopic or Robotic Radical Hysterectomy
3173632|NCT00614224|Experimental|A|Treadmill training group (TAEX)
3173633|NCT00614224|Active Comparator|B|Attention control group (CON)
3173634|NCT00614250|Experimental|Dose Level 1|
3173635|NCT00614250|Experimental|Dose Level 2|
3173636|NCT00614250|Experimental|Dose Level 3|
3173637|NCT00614250|Experimental|Dose Level 4|
3173638|NCT00614250|Placebo Comparator|Placebo|12 subjects: 3 subjects per dose level
3173639|NCT00614263||Blinded Group|SEDline output is unknown to anesthesiologist.
2502611|NCT02883426|Placebo Comparator|Group 3: H3N2v Seronegative Adolescents: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2502613|NCT02883426|Experimental|Group 4: Children: H3N2v LAIV|Participants will receive two doses of H3N2v LAIV, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2502616|NCT02883426|Placebo Comparator|Group 4: Children: Placebo|Participants will receive two doses of placebo, the first dose on Day 0 (study entry) and the second dose on Day 28. They will then receive one dose of H3N2v IIV on Day 84.
2502672|NCT02882737|Experimental|Exercise and glucagon before exercise|"120 minutes after breakfast; a single subcutaneous bolus of 200µg glucagon is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~When exercise is ended a single subcutaneous bolus of 0.2 ml saline is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
2502680|NCT02882737|Active Comparator|Exercise and glucagon after exercise|"120 minutes after breakfast; a single subcutaneous bolus of 0.2 ml saline is administered by the primary investigator. However, the patient do, not know whether placebo or a glucagon injection is administered.~Exercise: Immediately thereafter, the patient will bicycle for 45 minutes at 50% of the heart rate HR reserve.~Low-dose glucagon phase: When exercise is ended or when hypoglycemia occurs (≤3.9 mmol/l); a single subcutaneous bolus of 200μg glucagon is administered and the exercise session will be suspended. Again, the patient do not know whether placebo or a glucagon is administered."
2502683|NCT02882737|Active Comparator|Resting and glucagon after resting|"120 minutes after breakfast; a single subcutaneous bolus of 200μg placebo is administered.~Resting: After placebo injection the patient will be resting on a hospital bed for 45 minutes. The patient do not know if placebo or glucagon is administered.~Low-dose glucagon phase: After 45 minutes of resting or when hypoglycemia occurs, a single subcutaneous bolus of 200μg glucagon is administered.~Safety issues: If plasma glucose drops < 2.5 mmol/l at two consecutive measurements with 5 min interval or the patient experiences unbearable symptoms of hypoglycemia even after glucagon administration, 20 g carbohydrate is given orally. If plasma glucose drops< 2.3 mmol/l or doesn't raise sufficient after oral glucose, we will give intravenøs glucose to the patient. The study will then end and a new study day will be planned."
2502724|NCT02882360|Experimental|Elective LSCS--Kerlix AMD|Kerlix-AMD applied to wound site pre-operatively (3 days) and post-operatively for 2 weeks
2502726|NCT02882360|Placebo Comparator|Elective LSCS--Placebo|Normal gauze applied to wound site pre-operatively for 3 days and post-operatively for 2 weeks
2502730|NCT02882360|Experimental|Labouring LSCS--Kerlix AMD|Kerlix-AMD applied to wound post-operatively for 2 weeks
2502737|NCT02882360|Placebo Comparator|Labouring LSCS--Placebo|Normal gauze applied to wound post-operatively for 2 weeks
2502842|NCT02882087|Experimental|Placebo Comparator|Placebo SC plus MTX. Patients received placebo SC weekly administered subcutaneously for 24 times.All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
2502843|NCT02882087|Experimental|Experimental: RC18 160 mg plus MTX|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times. All patients had a foundation MTX therapy, MTX dose should be stable, not to adjust the dose.
2502871|NCT02881398|Experimental|mHealth|Each participant randomized to a mHealth assessment were evaluated with: (1) structural abnormalities with handheld-echocardiography (Vscan®, General Electric Healthcare); (2) vital signs with smartphone-connected oxymetry and blood pressure monitors (iHealthLabs®); (3) functional assessments on a 6-minute walk test with a trial-axial activity monitor (Ozeri®); (4) cardiac rhythm abnormalities with smartphone-connected- iECG (AliveCor®) and; (5)point-of-care testing with fingerstick B-type natriuretic peptide (Alere). All study participants then underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
2502875|NCT02881398|Active Comparator|Standard-Care|Each participant randomized to a standard-assessment were evaluated with the resource available at the institution including a physical examination,12 lead-ECG, radiographic, laboratory testing as clinically required. All study participants underwent a comprehensive transthoracic echocardiogram for anatomical assessments of the severity of rheumatic and structural heart disease prior to percutaneous valvuloplasty or a surgical valve replacement.
2502963|NCT02881138|Experimental|RC48-ADC|Participants will be allocated to one of the following dose groups: 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC48-ADC followed by 28 days of dose limited toxicity (DLT) observation period.
2502996|NCT02880748|Experimental|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum.
2503006|NCT02880748|Active Comparator|Air insufflation (AI) method|Air insufflation (AI) method was used for insertion to the cecum.
2503030|NCT02880397|Active Comparator|Garcinia Mangostana|The constituents of mangostana containing gel were prepared under the following proportions: Mangostana powder - 4gm, Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml.
2503032|NCT02880397|Placebo Comparator|Placebo gel|The placebo gel was prepared with Gelatin - 12gm, Glycerin (wetting agent) - 0.2ml, Peppermint oil (flavouring agent) - 0.1ml, sodium saccharine (sweetening agent) - 0.1ml and purified water q.s 100ml excluding the active ingredient mangostana powder - 4 mg and maintaining same physical properties such as color and taste.
3196227|NCT00848263|Active Comparator|DNP|Dorsal nail plate
3196228|NCT00848276||1|Hypogonadal Men before and after starting testosterone replacement therapy
2503146|NCT02879526|Experimental|C-CPT|
2503413|NCT02877784||Screening|Participants enrolled will undergo testing of the swallowing mechanism
3196229|NCT00848276||2|Post-menopausal women before and after starting Estrogen Replacement Therapy
3196230|NCT00848289||Participants with Bladder Cancer|Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
2502617|NCT02883413|Active Comparator|CRT + Family Fun Time|In order to assess for any non-specific effects of spending non-eating disorder driven time with family, adolescents in the CRT+ Contact Control condition will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). We refer to this condition as CRT + Family Fun Time (CRT+FFT). Adolescents will be asked to complete a series of fun tasks (some standardized, some are choice driven) with their parents. During these sessions, they will not be permitted to discuss CRT or the eating disorder.
2502619|NCT02883413|No Intervention|Treatment as Usual (TAU)|Adolescents in this condition will not receive any additional treatment. They will have a standard hospital stay with all normal contact with health professionals.
2502671|NCT02882789|Experimental|LCB01-0371 200mg|LCB01-0371 IV 200 mg
2502678|NCT02882789|Experimental|LCB01-0371 400mg|LCB01-0371 IV 400 mg
2502684|NCT02882789|Experimental|LCB01-0371 800mg|LCB01-0371 IV 800 mg
2502713|NCT02882386|Placebo Comparator|Milk 1%|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2502714|NCT02882386|Experimental|Whey protein concentrate 80 (WPC-80)|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2502715|NCT02882386|Experimental|Microparticulated whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2502716|NCT02882386|Experimental|Hydrolyzed whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2502717|NCT02882386|Experimental|Native whey|Participants performed a bout of strength training and consumed 636 ml of a protein supplement
2502779|NCT02882113|Experimental|Expressor|CYP3A5 expressor; containing CYP3A5*1 wild-type allele(*1/*1 type & *1/*3 type) intervention: Advagraf conversion
2502781|NCT02882113|Active Comparator|Non-expressor|CYP3A5 non-expressor: without CYP3A5*1 allele( *3/*3 type) intervention: Advagraf conversion
2502801|NCT02881827|Active Comparator|Infrared Laser|Using a laser in the infrared wave spectrum (780 nm)
2502803|NCT02881827|Active Comparator|Red Laser|Using laser red wave spectrum (662 nm)
2502806|NCT02881827|Placebo Comparator|Placebo|Simulation of treatment with the device switched off
2502808|NCT02881827|Active Comparator|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two ( statistically ) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug , which serves to prevent bias and isolating effects of such drugs."
2502874|NCT02881671||Patients with congenital atrioventricular block|Patient with congenital atrioventricular block
2502879|NCT02881671||relatives with congenital atrioventricular block|Normal relatives of patients with congenital atrioventricular block
2502881|NCT02881671||Patients with progressive Cardiac Conduction Disease|Patients with progressive Cardiac Conduction Disease,
2502882|NCT02881671||relatives with progressive Cardiac Conduction disesae|Normal relatives of patients with progressive Cardiac Conduction Disease
2502966|NCT02881073|No Intervention|Control|"Eligible women at participating centres prior to roll-out of PlGF testing (as per stepped wedge trial design) will be managed according to HSE/Institute of Obstetrician and Gynaecologists' National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia or by NICE guidelines for Management of Hypertension in Pregnancy for those in Northern Ireland."
2502969|NCT02881073|Active Comparator|Maternal plasma PlGF quantification|"Women in the interventional arm will have an additional point of care test performed at the time of enrolment for immediate PlGF quantification. The PlGF measurement will be reported as the absolute value in pg/ml with the following ranges given:~PlGF <12 pg/ml: Very low~PlGF ≥12 and <100 pg/ml: Low~PlGF ≥100 pg/ml: Normal~All hospitals will follow National Guidelines for 'The management of hypertensive disorders during pregnancy' & The management of Pre-eclampsia with the additional integration of PlGF results as indicated in the algorithm."
2503034|NCT02880592|Experimental|Fresh amniotic membrane/standard of care|This group will receive the Affinity Allograft and standard of care.
2503037|NCT02880592|Active Comparator|Standard of Care|This group will receive standard of care for diabetic foot ulcers that includes offloading of the diabetic foot ulcer, debridement, and infection management using the appropriate dressings.
2503094|NCT02880007|Experimental|ARM A|Dose Optimization in 3D Pulsed Dose Rate Brachytherapy
2503151|NCT02879552||Traditional upper blepharoplasty|Patients with an odd total number of letters in their first name received traditional upper blepharoplasty.
2503162|NCT02879552||Brassiere suture with blepharoplasty|The rest of the patients received orbicularis oculi muscle fixation to periosteum (brassiere sutures)
2503192|NCT02879227|Active Comparator|Arm Cisplatin|Radiotherapy 50 Gy with cisplatin 75 mg/2 Day 1 and day 22 (2)
2503194|NCT02879227|Experimental|Arm Oxaliplatin|Radiotherapy 50Gy Oxaliplatin 85mg/m2 every 2 weeks, (6)
2503253|NCT02878980|Experimental|Arm I (exercise intervention)|Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
2503287|NCT02878421|Active Comparator|tobacco cigarette|Intervention: tobacco cigarettes min 15/day
2503288|NCT02878421|Active Comparator|e.cigarettes + 16mg nicotine & flavor|Intervention: One flavoured electronic cigarette 16mg nicotine/day
2503290|NCT02878421|Active Comparator|e.cigarettes + 0mg nicotine & flavour|Intervention: One electronic cigarette with flavour +0mg nicotine/day
2503326|NCT02878083|Experimental|VEDOLIZUMAB|300 mg IV
2503380|NCT02877719||Children from low-income families|Children from low-income families were invited to fill in a set of questionnaires.
2503382|NCT02877719||Children from high income families|Children from high-income families were invited to fill in a set of questionnaires.
2503848|NCT02874469|No Intervention|Control group (first period)|Patients treated as recommended with usual care in a center.
2502630|NCT02883088||LAD-group|Subjects over 18 years who are undergoing Frequency Domain - Optical Coherence Tomography (FD-OCT) evaluation of the native left anterior descending artery during clinically indicated coronary angiography regardless of the clinical syndrome (silent ischemia, effort angina or acute coronary syndrome).
2502668|NCT02882724|Experimental|Exercise training|
2502675|NCT02882724|Experimental|Control|Control group did not do any exercise training.
2502741|NCT02882477|Experimental|Deferiprone and Acetylcystein|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200 mg divided in 2 doses 5 months duration
2502743|NCT02882477|Experimental|Deferiprone and Acetylcystein with Sitagliptin and Metformin|PO Deferiprone 20 mg/kg divided in 2 doses PO Acetylcysteine 200mg divided in 2 doses PO Januet 50/500 if BW < 30kg and 50/850 if BW> 30kg *2/D 5 months duration
3196231|NCT00848302|Experimental|L-arginine|Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography
3196232|NCT00848315|No Intervention|1|Usual Care that the Type 2 Diabetes Patients usually receive at the health centers.
2502877|NCT02881476|Experimental|Allogeneic WJ-MSCs injection|Intervention: Biological: Cell-based therapy of allogeneic Wharton's jelly-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
2502938|NCT02881190|Experimental|RC48-ADC|The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.
2502997|NCT02880839|Experimental|Partial cervical lamina excision group|Patients in the cervical lamina partial excision group underwent partial cervical lamina excision and cervical pedicle screw internal fixation.
2503005|NCT02880839|Experimental|Pipeline-dredge discharge group|Patients in the pipeline-dredge discharge group underwent pipeline-dredge discharge and cervical pedicle screw internal fixation.
2503010|NCT02880839|Experimental|Digital navigation group|Patients in the digital navigation group underwent digital navigation-assisted cervical pedicle placement.
2503049|NCT02880371|Experimental|Phase 1b/Part A|Patients in Part A will receive escalating doses of single-agent ARRY-382 in combination with 2 mg/kg pembrolizumab.
2503051|NCT02880371|Experimental|Phase 2|Patients in Phase 2 will receive the MTD/RP2D dose of ARRY-382 determined during Part A in combination with 200mg pembrolizumab.
2503210|NCT02879162|Experimental|Durvalumab + Tremelimumab|Durvalumab 1500 mg IV 60 min Day 1 every 4 weeks Tremelimumab 75 mg IV 60 min Day 1, cycles 1-4
2503245|NCT02878785|Experimental|Phase 1: Decitabine and Talazoparib Combo|"Phase 1:~Decitabine by IV daily for 5 days every 28 days. Talazoparib orally daily days 1-28.~The 'outer layer' of this nested dose escalation trial will escalate the dose of the two drugs by sequentially going through dose levels 1-6 in the table found in the protocol. The standard algorithm of the 3+3 design will be applied."
2503247|NCT02878785|Experimental|Phase 2: Decitabine and Talazoparib Combo|"Phase 2:~Recommended Phase 2 Dose (RP2D) The MTD of the combination of decitabine with a dose of talazoparib of at least 0.25 mg is defined as the maximal tolerated dose of decitabine studied - and for that dose level, combined with the maximum dose of talazoparib for which the incidence of DLT was less than 33% in 6 participants treated and this will be chosen as the recommended Phase 2 dose (RP2D). Among potential combined dose levels at MTD, available pharmacodynamic data (PARP trapping) will also be considered in the choice of RP2D, as will any significant indications of differences in clinical efficacy"
2503248|NCT02878785|Active Comparator|Phase 2 Arm A|Adult patients with AML who are thought not to be likely to tolerate or respond to standard chemotherapy
2503249|NCT02878785|Active Comparator|Phase 2 Arm B|Adult patients with AML that has not responded to previous treatment or has come back after responding to previous treatment
2503250|NCT02878785|Active Comparator|Phase 2 Arm C|Adult patients previously treated with a DNA methyltransferase inhibitor (decitabine, azacitidine or guadecitabine)
2503289|NCT02878408|Other|acute Bipolar disorder|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
2503291|NCT02878408|Other|acute Schizophrenia|blood sampling and data collection Following visit at end of hospitalisation (blood sampling and data collection)
2503293|NCT02878408|Other|stable Bipolar disorder|blood sampling and data collection (only one visit)
2503294|NCT02878408|Other|stable Schizophrenia|blood sampling and data collection (only one visit)
2503295|NCT02878408|Other|healthy control|blood sampling and data collection (only one visit)
3196233|NCT00848315|Experimental|2|Cognitive Behavioral Intervention
3196234|NCT00848341||Control|
3196235|NCT00848380||1|Patients with hypertension and hyperlipidemia and other CV risk factors
3196236|NCT00848406||1|30 individuals ≤ 40 years, who currently smoke ≥ 10 cigarettes/day and > 10 packyears
3321443|NCT02018900|Placebo Comparator|Placebo|Placebo
3321444|NCT02018900|Experimental|Ecologic 825/scFOS|Ecologic 825/scFOS
2502659|NCT02882828|Experimental|DBS (dried blood spots) collection|In this study, we make a switch from Prograf® to Envarsus®. Patients will be trained to collect their blood from a finger prick on filter paper. DBS will be done at home, collected on filter paper and mailed by the patients to a centralized laboratory (Department of Pharmacology, Toxicology and Pharmacovigilance at Limoges University Hospital), where tacrolimus concentration will be determined by HPLC-MS/MS
2502758|NCT02882490|Experimental|Parent training (PT)|The PT arm receives a 10-week therapist-guided behavioral group treatment. The treatment is based on existing literature for training parents in child behavior management skills (Barkley 1999). Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
2502759|NCT02882490|Experimental|Supportive Therapy (ST)|The ST arm receives a 10-week supportive group treatment. Parents are invited to discuss relevant problems that have occurred during the previous week. A therapist moderate the discussion but does not provide information about the behavioral techniques included in the PT group. Parents attend weekly sessions, which last 90 minutes and are held at the Hospital Clinic of Barcelona. Parents are given homework assignments to complete between sessions.
3196237|NCT00848406||2|30 individuals ≤ 40 years, who have not smoked during the last year, have never smoked for as long as a year (i.e. at least one cigarette per day or one cigar per week, AND have < 0.5 packyear.
3196238|NCT00848406||3|30 individuals above 40 years, who currently smoke ≥ 10 cigarettes per day, and > 20 packyears.
2502889|NCT02881424||alcohol-dependent patients|a group of 34 alcohol-dependent patients, currently abstinent
2502893|NCT02881424||healthy controls|a group of control subjects, without neurologic or psychiatric disease, matched for age and sex with the alcohol-dependent participants
2502936|NCT02881060|Active Comparator|Ethanol|Drinking a cocktail of ethanol (0.8 g ethanol per kg body weight), diet lemonade and water of 1:1:1 (volume distribution).
2502943|NCT02881060|Placebo Comparator|Non-ethanol|Drinking a cocktail of diet lemonade and water of 1:2 (volume distribution).
2502982|NCT02880774|Experimental|Mandibular Nonspecific mobilization|GA: Mandibular Nonspecific mobilization on the region of the face with presence of TMD.
2502985|NCT02880774|Placebo Comparator|ultrasound detuned|Group B: Used ultrasound equipment detuned on the region of the face with presence of TMD.
2503038|NCT02880501|Experimental|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.
2503121|NCT02879786|Experimental|Phonological dyslexia|Children with phonological dyslexia
2503123|NCT02879786|Experimental|Visuo-attentional dyslexia|Children with visuo-attentional dyslexia
2503124|NCT02879786|Other|Control|Control children, age-matched
3196239|NCT00848406||4|30 individuals above 40 years, who have not smoked during the last year, have never smoked for as long as a year, and have < 0.5 packyear.
3196240|NCT00848419|Active Comparator|Methadone|Epidural methadone bolus 4mg
2503260|NCT02878759|Experimental|Wristbot|WristBot will be used as diagnostic tool to evaluate the novel technology and the associated protocol for proprioception quantification during rehabilitation. The main objective is to provide clinicians with a reliable instrument able to overcome the limitations in proprioceptive measurement by current clinical methodologies.
3196241|NCT00848419|Active Comparator|Morphine|Epidural morphine 4mg bolus
3196242|NCT00848419|Active Comparator|Fentanyl|Epidural fentanyl 200 microgram bolus
2503366|NCT02877901|Active Comparator|tolterodine-treated group|they will receive long acting tolterodine 4 mg at bedtime for 4 weeks. After that re-evaluation. then stop medication for two weeks (washout period).
2503367|NCT02877901|Placebo Comparator|placebo-control group|they will receive placebo at bedtime for 4 weeks. After that re-evaluation. then stop for two weeks (washout period). Then re-evaluate the nocturnal incontinence status and crosed over to receive long acting tolterodine 4 mg for 4 weeks. at the end the nocturnal incontinence status will be evaluated
2503409|NCT02877576|Experimental|Epileptic patient|micro-electrode recordings interventions: Implantation of mixed intracerebral electrodes Face detection Face individualization
2503435|NCT02877238|Active Comparator|Group A|Sevoflurane plus remote ischemic preconditioning anesthesia will be induced and maintain with sevoflurane in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
2503436|NCT02877238|Active Comparator|Group B|anesthesia will be induced and maintain with total intravenous anesthesia (propofol, midazolam plus fentanyl) during plus remote ischemic preconditioning in addition to remote ischemic preconditioning which will be done after induction and before cardiopulmonary bypass by inflating the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3 cycles
2503474|NCT02877017|No Intervention|Pre-intervention arm|This arm is the pre-intervention arm of parents and providers before the family safety reporting bundle has been implemented.
2503476|NCT02877017|Experimental|Post-intervention arm|This arm is the post-intervention arm of parents and providers after the family safety reporting bundle has been implemented on the study units.
3196243|NCT00848419|Placebo Comparator|Saline|Epidural saline bolus
2503544|NCT02876536|Experimental|TNES with sending electrical impulses|The MS patients will receive electrical impulses by TENS device for 30 minutes a day, for 5 days a week and in 6 weeks
2503545|NCT02876536|Sham Comparator|TENS without sending electrical impulses|The MS patients will use the TENS device for 30 minutes a day, for 5 days a week and in 6 weeks without receiving any electrical impulses
2503597|NCT02876237|Experimental|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later.~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
2504895|NCT02867436|Experimental|Gluten-free diet|Gluten-free diet
2502665|NCT02882984|Experimental|HFSRS with EGFR TKI|"Drug: EGFR-TKI~Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid~Other Name: Gefitinib/Tarceva/Icotinib~Radiation: whole brain radiotherapy~25 to 40 Gy/5F~Other Name: HFSRS"
2502736|NCT02882542|Experimental|Visible light exposure Orange 30 lux|The participants will be exposed to orange LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502740|NCT02882542|Experimental|Visible light exposure Orange 120 lux|The participants will be exposed to orange LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502742|NCT02882542|Experimental|Visible light exposure Cyan 30 lux|The participants will be exposed to cyan LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502744|NCT02882542|Experimental|Visible light exposure Cyan 120 lux|The participants will be exposed to Cyan LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502746|NCT02882542|Experimental|Visible light exposure White 30 lux|The participants will be exposed to white LED light at a illuminance of 30 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502747|NCT02882542|Experimental|Visible light exposure White 120 lux|The participants will be exposed to white LED light at a illuminance of 120 lux at eye level for 15 minutes. The colored light exposure will be preceded by sitting 8 minutes in darkness and followed by sitting 20 minutes in darkness.
2502791|NCT02882061|Experimental|CTDT positive|All subjects with a positive cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
2502792|NCT02882061|Active Comparator|CTDT negative|All subjects with a negative cervicothoracic differentiation test will be assigned to this arm. All subjects will then receive thoracic spinal manipulation to a level between T1 and T4.
2502839|NCT02881749|Experimental|TSEBT & mechlorethamine gel 0.016%|All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
2502872|NCT02881489|Experimental|Autologous BM-MSCs injection|Intervention: Biological: Cell-based therapy of autologous bone marrow-derived mesenchymal stem cells which are transplanted intrathecally (via a standard lumbar puncture) into the ALS subjects.
2502922|NCT02881216|Other|Common DES|Group of Patients with narrowed coronary artery disease, who were treated with an implantation of currently established drug-eluting stents (Xience Prime, Promus Element plus, Resolute Integrity).
2502923|NCT02881216|Other|Synergy Stent|Group of Patients with narrowed coronary artery disease, who were treated with Synergy stent implantation
2502927|NCT02880917|Active Comparator|Cognitive training + tDCs-Active|tDCs active left dorsolateral prefrontal cortex (2mA,20 min) and Cognitive training (20min) at the same time.
2502934|NCT02880917|Sham Comparator|Cognitive training+ tDCs-Sham|tDCs Sham dorsolateral prefrontal cortex ((2mA,20 min) and Cognitive training (20min) at the same time.
3173640|NCT00614263||Unblinded Group|SEDline output is known to anesthesiologist.
3173641|NCT00614276||Phase I - Focus Groups|
2503090|NCT02879981||Pediatric Participants With Acute Bronchitis|Pediatric participants receiving treatment for acute bronchitis with Balsamic Bactrim according to standard of care and in line with the current summary of product characteristics (SPC) / local labeling and who have no contraindication to Balsamic Bactrim as per the local label will be observed for safety.
2503120|NCT02879630||Obese Patients|Obese patients (patients whose weight is >190% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by adjusted body weight as part of their routine care.
2503122|NCT02879630||Non-obese Patients|Normal weigh patients (patients whose weight is 80-120% of ideal body weight) will be receive a single dose of I.V. acyclovir sodium 5mg/kg dosed by total body weight as part of their routine care.
2503175|NCT02879396|Experimental|Study Participants|A maximum of 50 participants will be enrolled in the study per the inclusion and exclusion criteria. The participants will be residents of SLH who are 55 years old or older. They will have had one or more EMS calls made, ED visit or hospital admission in the past year, as determined by the incidence report at SLH. The study participants will receive PA4LE program.
2503206|NCT02879149||Group 1|Standard Rigid Fixation plus autograft
2503207|NCT02879149||Group 2|Standard rigid fixation plus AUGMENT® Bone Graft
2503878|NCT02874222||African-American|surveys completed by subject n=200, nationally
3173642|NCT00614276||Phase II TENDRILS|Phase II - TENDRILS Program only.
3173643|NCT00614276||Phase II TENDRILS + Counseling|Phase II - TENDRILS + Sexual Counseling Sessions.
3173644|NCT00614328|Active Comparator|1|Naltrexone (50 mg once a day) + placebo baclofen + behavioral therapy (n=10)
3173645|NCT00614328|Active Comparator|2|Placebo naltrexone + baclofen (10 mg t.i.d) + behavior therapy (n=10)
3173646|NCT00614328|Active Comparator|3|Baclofen (10 mg t.i.d) + naltrexone (50 mg once per day) + behavior therapy (n=10)
3173647|NCT00614328|Placebo Comparator|4|Placebo baclofen + placebo naltrexone + behavior therapy
3173648|NCT00614341|Active Comparator|1, 2|"Pulse MedRelief SE 55~Continuous MedRelief SE 55"
3173649|NCT00614354|Experimental|1|
3173650|NCT00614419|Active Comparator|1|The Lichtenstein tension-free hernioplasty with polypropylene mesh
3173651|NCT00614419|Experimental|2|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
3173652|NCT00614471|Active Comparator|1|
2502670|NCT02882919|Experimental|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
2502677|NCT02882919|No Intervention|Usual care|In the usual care group, patients are asked to complete health risk screening on a computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors
2502729|NCT02882464|Experimental|2PRF+CAF|"Two tubes of blood samples were centrifuged by PC-02 Centrifuged device. This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France). PRF were prepared for patients in 2 layer platelet rich fibrin membrane with coronally advanced flap group (2PRF+CAF).~Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 2PRF+CAF group: two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flpa is positioned coronally."
2502734|NCT02882464|Experimental|4PRF+CAF|Four tubes of blood samples were centrifuged by PC-02 Centrifuged device,four layers of PRF membranes were prepared for patients in 4 layer platelet rich fibrin membrane with coronally advanced flap.(4PRF+CAF). This centrifuged device is used with 2700 rpm and for 12 minutes( PC-02 Centrifuge, Process,France) Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In 4PRF+CAF group: four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ and flap is coronally positioned.
2502738|NCT02882464|Active Comparator|CTG+CAF|"The surgical technique in coronally advanced flap with subepithelial connective tissue graft (CTG+CAF) group was envelope technique as described by Raetzke. The papillae were dis epithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. The connective tissue graft was harvested from the palate using trap-door technique described by Edel. Epithelial layer was elevated with a horizontal and two vertical incisions. The connective tissue graft was harvested as 1 mm by using a standard caliper, then epithelial layer was sutured by resorbable suture. The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ."
2502796|NCT02881970|Experimental|Neonatal hypoxic-ischaemic encephalopathy|
2502855|NCT02881723|Experimental|Treatment for oropharyngeal cancer by surgery|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by surgery
2502856|NCT02881723|Experimental|Treatment for oropharyngeal cancer by radio-chemotherapy|Disease-free patients treated for locally advanced oropharyngeal cancer for over 12 months by radio-chemotherapy
3163180|NCT00476892|Other|1|"It consists of five outpatient appointments (weeks 0, 2, 6, 11 and 16) with a local trial physiotherapist at a trial centre. At the first appointment a standardised history is taken from the woman, anatomy and function of the pelvic floor muscles are taught, and types of prolapse described, using diagrams and a model pelvis. Women are taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Pelvic floor muscles are assessed by vaginal examination and recorded on a dedicated form at each appointment thus determining the content of a single set of exercises for each woman. At least three sets of exercises daily is recommended. Women use an exercise diary to record compliance. Tailored advice is given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise."
3163181|NCT00476892|No Intervention|2|Women allocated to the control group will be sent a lifestyle advice leaflet only, and will have no planned contact with the centre until their consultant review appointment at six months. The leaflet gives instructions on seeking advice where appropriate about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause prolapse to worsen.
3163182|NCT00476905||Spectral-Diagnosis|Method for noninvasive detection of cutaneous malignancies
3163183|NCT00476931|Experimental|1|SB-509
3163184|NCT00476931|Placebo Comparator|2|
3163185|NCT00476970|Experimental|Patient Navigation Intervention|Participants randomized to this arm will receive language-concordant patient navigation in the form of an introductory letter with educational material followed by phone or in-person contact to provide individually tailored interventions.
3163186|NCT00476970|No Intervention|Usual Care|Participants randomized to this arm will receive no additional navigation beyond the usual care for the duration of the 9-month intervention. Participants will be offered navigation services after the completion of the intervention period.
3163187|NCT00476983|Experimental|1|SQV/r 1500/100 mg OD + Truvada OD
2502976|NCT02880878|Experimental|Early Surgical Hematoma Evacuation|Subjects will receive early surgical hematoma evacuation using Minimally Invasive Parafascicular Surgery (MIPS).
2502977|NCT02880878|No Intervention|Medical Management|Subjects will receive standard of care medical management for ICH.
2503108|NCT02879877|Experimental|UCB7858 (intravenous)|Various single doses, administered to various cohorts.
2503110|NCT02879877|Placebo Comparator|Placebo (intravenous)|Single dose placebo comparator for each cohort of iv administration.
2503111|NCT02879877|Experimental|UCB7858 (subcutaneous)|Various single doses, administered to various cohorts.
2503112|NCT02879877|Placebo Comparator|Placebo (subcutaneous)|Single dose placebo comparator for each cohort of sc administration.
2503880|NCT02874222||Asian|surveys completed by subject n=200, nationally
3163188|NCT00477009|Experimental|1|Adjustable mandibular repositioning appliance
3163189|NCT00477009|Placebo Comparator|2|Placebo device in upper jaw
3163190|NCT00477035|Experimental|Autologous Cytokine-induced Killer Cells|
3163191|NCT00477048|Other|1|Replace Indinavir with SQV in patients with indinavir toxicity
3163192|NCT00477100||Observational (biospecimen and medical data collection)|Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
2502674|NCT02882802|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format. MBSR groups will be delivered virtually.
2502682|NCT02882802|Active Comparator|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions. TREC groups will be delivered virtually.
2502718|NCT02882399|Experimental|Shortystrap|
2502784|NCT02882217|Active Comparator|XC8 10mg|Cohort 1: 8 subjects will be randomized in a 3:1 ratio to be treated either with 10mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
2502785|NCT02882217|Active Comparator|XC8 50mg|Cohort 2: 8 subjects will be randomized in a 3:1 ratio to be treated either with 50mg XC8 (6 subjects) or placebo (2 subjects, see placebo arm)
2502786|NCT02882217|Active Comparator|XC8 200mg|Cohort 3: 16 subjects will be randomized in a 3:1 ratio to be treated either with 200mg XC8 (12 subjects) or placebo (4 subjects, see placebo arm)
2502787|NCT02882217|Placebo Comparator|Placebo|Placebo comparator arm consists of 2 subjects in the cohorts 1 and 2 each and 4 subjects in the cohort 3.
3196244|NCT00848432|Experimental|1|Optimal therapeutic doses of risperidone continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months in clinically stable schizophrenia patients
3196245|NCT00848432|Experimental|2|Optimal therapeutic doses of risperidone continued for 26 weeks followed by a 50% dose reduction for at least another 6 months in clinically stable schizophrenia patients
2502913|NCT02881307|Experimental|Dietary Supplement|
2502915|NCT02881307|Active Comparator|Dietary Counseling|
2502940|NCT02880943|Experimental|Group A|"Group A: patients with bone disease mainly will be treated with XOFIGO® alone.~Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A."
2502947|NCT02880943|Experimental|Group B|Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
2503012|NCT02880683|Experimental|Single arm, transvenous cardiac autonomic nerve stimulation|
2503028|NCT02880423|Other|salpingectomy group I|salpingectomy during cesarean section for sterilization
2503031|NCT02880423|Active Comparator|tubal ligation group II|tubal ligation in cesarean section
3196246|NCT00848432|Experimental|3|Optimal therapeutic doses of risperidone continued for at least 1 year in clinically stable schizophrenia patients
3196247|NCT00848445|Experimental|APP and VRR on|APP and VRR turned on at 2 week visit
3196248|NCT00848445|Active Comparator|APP and VRR off|APP and VRR turned off
3196249|NCT00848458|Experimental|Azelaic Acid Iontophoresis|
2503229|NCT02878915|Active Comparator|Ultrasound guided femoral puncture|
2503232|NCT02878915|No Intervention|palpation guided femoral puncture|
2503355|NCT02878122||Patients with epithelial ovarian cancer|Cancer treatment
2503399|NCT02877667|Experimental|Open label device treatment|Up to four passes with Q-Switched laser alternating with acoustic wave device
2503416|NCT02877498|Experimental|Adaptive support ventilation|adaptive support ventilation mode during invasive mechanical ventilation
2503417|NCT02877498|Active Comparator|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
2503438|NCT02877225|Experimental|Treatment Sequence 1 : ABAB|Participants will receive 140 milligram (mg) of ibrutinib administered as one IMBRUVICA 140-mg oral capsule (Treatment A) in Period 1, 140 mg of ibrutinib administered as one ibrutinib 140-mg oral tablet (Treatment B) in Period 2, then Treatment A in period 3 and then followed by Treatment B in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2503439|NCT02877225|Experimental|Treatment Sequence 2 : BABA|Participants will receive (Treatment B) Period 1, then Treatment A in Period 2, then Treatment B in Period 3 and then followed by Treatment A in Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2503467|NCT02877329|Experimental|Internet-delivered ACT|Guided Internet-delivered Acceptance and commitment therapy for 8 weeks
2503469|NCT02877329|No Intervention|Wait list control|No treatment during 8 weeks
2503516|NCT02876978|Experimental|CAR-GPC3 T cells|"Intravenous infusion with escalating dose is adopted in this study.~Total dosage: 1 x 10^5 - 2 x 10^9 CAR-GPC3 T cells/kg~The next dose and interval depends on the response of the subject to previous dose.~Lymphodepletion:~Fludarabine: 30 mg/m^2/day x 4 days; Cyclophosphamide: 500 mg/m^2/day x 2 days. Adjustment is in discretion of the investigator based on individual response."
3196250|NCT00848458|Active Comparator|Azelaic acid topical|
2503571|NCT02876341||No chronic antihypertensives|Not on either a chronic β-blocker or ACE-Inhibitor
3196251|NCT00848471|Experimental|1|Quark RMR calorimeter (Cosmed)
3196252|NCT00848471|Active Comparator|2|Deltatrac II (GE health Care Clinical Systems)
3196253|NCT00848562|Experimental|Nicorandil|
3196254|NCT00848575||Group 1 - Device|The principal Investigator and sub-investigators of this study will identify potential participants that attend the gynecologic oncology or gynecology clinics of UAMS. These subjects will have been scheduled for diagnostic or therapeutic laparoscopy. Based on the Inclusion Criteria and Exclusion Criteria of this study, women who are eligible for the study will be approached to participate.
3196255|NCT00848588||1|Full and part-time 9-1-1 call takers employed at Ambulance Communication Centres in the Canadian provinces of Ontario, Nova Scotia, New Brunswick, as well as the city of Montreal, Quebec, Canada.
3196256|NCT00848627||Males|60 years of age or older Smokers or history of smoking
3196257|NCT00848640|Experimental|Sorafenib|
2502731|NCT02882308|Experimental|Combination of durvalumab and olaparib|Patients in the durvalumab - olaparib combination arm will receive treatment until the 21th-28th day, will be reassessed by imaging (tumour objective response by RECIST) on the 22nd -28th day and then will have a second biopsy or be operated on the 23rd - 29th day. If surgery is delayed, olaparib will be continued until the day before surgery.
2502802|NCT02882035|Experimental|OFA (opioid free anesthesia)|"All drugs were given IV. Induction in the opioid free group began with a loading dose of clonidine (0.2 mcg kg-1), a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1) (adapted according to hemodynamic stability).~Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups. A bolus of ketamine (0.2mg kg -1) was given if necessary in the opioid free group (up to three bolus max. were permitted).~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
2502804|NCT02882035|No Intervention|OA (opioid anesthesia)|"All drugs were given IV. Induction in the opioid group began with remifentanil TCI, a bolus of ketamine (0.3 mg kg -1) lidocaine (1.5 mg kg -1) and a bolus of propofol (2-3 mg kg -1).~General anesthesia was maintained with sevoflurane (MAC: 1). Upon the incision, acetaminophen (1000 mg) and diclofenac (75 mg) were given in both groups.~A bolus of piritramide (0.03 mg kg -1) was administered upon subcutaneous closure.~Postoperative pain was treated with IV acetaminophen (1000 mg) every 6 h for the first 24 hours and IV diclofenac (75 mg) every 12 h for the first 24 hours. Patients received a PCIA (patient-controlled intravenous analgesia) pump of piritramide."
2502885|NCT02881541|Experimental|Patients having Enhanced Support|"A preoperative consultation with a nurse. This time will be dedicated to the preparation of returning home: explanation of the clinical pathway, realization of postoperative wound care, information on pain management and answer any questions the patient.~A nurse call on D + 1, the day after the operation to ensure the smooth running of returning home, assess postoperative pain, the correct performance of local care, answer questions from the patient, and provide advice to to limit pain .. A reminder to J2 / J3 will be produced at the request of the patient or on FDI initiative if particular difficulties are reported"
2502886|NCT02881541|Experimental|Patients having usual care|no intervention will be made for this group. Patients will receive usual care respecting intern procedure
2502972|NCT02881099||Recent diagnosis (P3)|Primary cohort; participants recruited if diagnosed within the last three years
2502975|NCT02881099||Early diagnosis (P50)|Participants recruited if diagnosed before the age of 50 years old
2502978|NCT02881099||Relatives (R)|Siblings of existing participants
2502994|NCT02880657|Experimental|SODB®-physical training|This arm receives daily two capsules of SODB® 40mg containing 560 UI of superoxide dismutase, associated with standardized physical training
2502999|NCT02880657|Experimental|Placebo-physical training|This arm receives daily two capsules of Placebo containing excipients only, associated with standardized physical training
3196258|NCT00848666|Experimental|I|Patients with tinea pedis
3196259|NCT00848679|Active Comparator|Epidural lidocaine|30 women to receive 5 x 5mL boluses of epidural lidocaine 2%. 10 pre-eclampsia, 10 term pregnancy, 10 non-pregnant.
2503185|NCT02879240|Other|Group animated cartoon-black screen (AB)|In this group, children will be exposed to a animated cartoon during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to a black screen in the same conditions for one other week.
2503187|NCT02879240|Other|Group black screen - animated cartoon (BA)|In this group, children will be exposed to a black screen during the delivery of their inhaled treatment twice a day during one week, then they will be exposed to an animated cartoon in the same conditions for one other week.
2503244|NCT02878993||Intubated infants|Recording of diaphragm EMG
2503302|NCT02878538|Active Comparator|deferiprone|Deferiprone will be administered three times a day (25mg/kg). Total dose per day will depend on participants' body weight for one, three month block.
2503303|NCT02878538|Placebo Comparator|Placebo Phase|Placebo tablets with inactive substance will be used. Total number of placebo tablets will be equivalent to the active tablets administered depending on participants' body weight for two, three month blocks.
2503346|NCT02877979|Experimental|DS003 vaginal tablet|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
2503349|NCT02877979|Placebo Comparator|placebo|participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17.
2503387|NCT02877771|Experimental|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses CGM values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
2503424|NCT02877472|Experimental|Experimental group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression and porous tantalum rod implantation (experimental group).
2503425|NCT02877472|Experimental|Control group|Patients with avascular necrosis of the femoral head after femoral neck fracture surgery will undergo core decompression (control group).
2503426|NCT02877433|Active Comparator|Roxolid short implant, 4 mm length (4)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
2503428|NCT02877433|Experimental|Roxolid short implant, 4 mm length (2)|Straumann Tissue Level Ø4.1 mm RN SLActive Roxolid Standard Plus Implants available in lengths 4mm, 10mm, 12mm and 14mm
2503450|NCT02877108||Adasuve|These patients will receive Adasuve for treatment of agitation.
2503453|NCT02877108||Haloperidol/Lorazepam|These patients will receive haloperidol/lorazepam for treatment of agitation.
2503483|NCT02877030|Experimental|Test control group|Start the sensorimotor exercises protocol with video game immediately after the first evaluation
2503484|NCT02877030|Active Comparator|Control test group|Start of sensorimotor exercises with video game protocol after ten weeks
2503486|NCT02877030|No Intervention|comparison group|No intervention
2503523|NCT02876679|Experimental|Cyclophosphamide|50mg/Kg/day cyclophosphamide (day +3 and +4)
2502818|NCT02882074|Other|Hydroxyethyl starch|Hydroxyethyl starch 6% (130/0.4) solution during surgery
2502884|NCT02881632||Healthy infants aged 0-2|Healthy infants aged 0-2 year with no respiratory diseases to provide a reference values. A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person.
2502887|NCT02881632||Infants aged 0-1 with Bronchiolitis|Infants admitted to hospital within last 24hrs (AVB participants only). A structured light pattern (Structured Light Plethysmography (SLP) - Pneumscan) will be projected onto the chest and abdominal wall and the movement of this pattern as the patient breathes will be recorded for 2 min. The total period of testing per session should take approximately 30 minutes per person
2502950|NCT02881086|Other|Stratification I - Standard Risk (SR)/ High Risk (HR)|Induction and consolidation I therapy for standard and high risk patients, PH/BCR-ABL-negative Chemotherapy, immunotherapy, intrathecal prophylaxis, CNS irradiation according to randomisation I Drugs: Rituximab, Vincristine, Daunorubicin, Dexamethasone, Cyclophosphamide, Cytarabine, Mercaptopurine, PEG-Asparaginase, Methotrexate, Vindesine, VP16
2502952|NCT02881086|Other|Stratification I - Philadelphia (PH)+|Induction and consolidation I therapy for PH+ patients Chemotherapy, immunotherapy, intrathecal prophylaxis Drugs: Rituximab, Vincristine, Imatinib, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, VP16
2502956|NCT02881086|Active Comparator|Rand I - B-Lin + CNS Rad + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: CNS irradiation 24 Gy, intrathecal Methotrexate
2502957|NCT02881086|Experimental|Rand I - B-Lin + i.th. MTX|Chemotherapy according to Stratification I SR/HR CNS prophylaxis: intrathecal Methotrexate
2502958|NCT02881086|Other|Stratification II - SR + MRD-neg|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine, Dexamethasone
2502959|NCT02881086|Other|Stratification II - HR + MRD-neg|Chemotherapy or stem cell transplantation according to randomisation II
2502960|NCT02881086|Other|Stratification II - SR/HR/PH+ + MRD-pos|Chemotherapy or targeted therapy, followed by stem cell transplantation Drugs: Fludarabine, Idarubicin, Cytarabine, Nelarabine
2502964|NCT02881086|Active Comparator|Randomisation II - HR + MRD-neg-SCT|Stem cell transplantation
2502968|NCT02881086|Experimental|Randomisation II - HR + MRD-neg-SR-chemo|Chemotherapy, immunotherapy, intrathecal prophylaxis, consolidation II, reinduction, consolidation III - VI, maintenance Drugs: Rituximab, Dexamethasone, PEG-Asparaginase, Cytarabine, Methotrexate, Vindesine, Adriamycin, Prednisolone, Cyclophosphamide, Nelarabine
2503103|NCT02879838||Occupational Asthma|
2503104|NCT02879838||Work Aggravated Asthma|
2503105|NCT02879838||Non-Work-Related Asthma|
2503145|NCT02879487|Active Comparator|Coagulation mode|Colpotomy will be performed by monopolar needle electrode using coagulation mode
2503158|NCT02879487|Active Comparator|Cut mode|Colpotomy will be performed by monopolar needle electrode using cut mode
2503193|NCT02879279|Experimental|Robotic rehabilitation|In the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
2503195|NCT02879279|Active Comparator|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
2503236|NCT02878954|Other|No intervention|160 men and women with PAD will be recruited.
2503237|NCT02878954|Other|Control session|40 patients (men and women) will complete this session.
2503238|NCT02878954|Other|Exercise session|40 patients (men and women) will complete this session.
2503305|NCT02878525|Experimental|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
2503307|NCT02878525|Active Comparator|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
2503339|NCT02877953|No Intervention|Control group|The conventional care was performed for the patients of control group
2503340|NCT02877953|Experimental|Intervention group|the prevention of complications post-TIPS
2503389|NCT02877810|Experimental|Telemedicine|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telemedicine, a live, interactive, audiovisual teleconferencing system, from a pediatric critical care physician.
2503393|NCT02877810|Active Comparator|Telephone|A consultation will be given for the care of a critically ill pediatric patient to a remote hospital emergency department physician by telephone, from a pediatric critical care physician..
2503460|NCT02877160|Experimental|Test Formulation Fasted|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fasted condition
2503462|NCT02877316|Experimental|MYPLAN app|MYPLAN app (safety plan) as part of treatment
2503463|NCT02877160|Experimental|Test Formulation Fed|150 mg of AL-794 tablet formulation (3 x 50 mg tabs) dosed in a fed condition
2503466|NCT02877316|Active Comparator|Safety plan on paper|Safety plan on paper as part of treatment
2503514|NCT02876874||the patients group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
2503522|NCT02876861|Active Comparator|Surgery alone|"Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
2503524|NCT02876874||the health group|0.1ml, 5mg/ml indocyanine green(ICG) will be injected subcutaneously to aid visualization in NIR
2502870|NCT02881554|Experimental|Diagnostic (SC SPECT/CT)|"There are 2 cohorts of patients: Those receiving radiation therapy per standard of care (Cohort A) and those undergoing surgery per standard of care (Cohort B). All patients have a total of 3 SPECT/CT imaging with 99mTc-SC. The first scan in both cohorts is routine medical care (not experimental) and takes place prior to initiation of RT or surgery. Two follow up scans are part of the protocol.~In cohort A, the first follow up scan occurs at mid-RT, and the second one at 1 month post-RT.~In cohort B, the first follow-up scan occurs 3-5 days postoperatively, and the second one at 1 month post-operatively. An additional IV contrast enhanced CT scan (70 second delay) will be obtained immediately following the SPECT/CT scan for all 3 SPECT/CT scans."
2502962|NCT02880930|Experimental|Vitamin D supplement (Cholecalciferol)|Participants will be given oral Fultium-D3 drops (Internis) contain 400 IU cholecalciferol/day for a period of 3 months. Daily vitamin D3 supplementation dose will be increased to 1,000 IU for an additional 3 months if plasma 25(OH)D still below 75 nmol/L.
2503002|NCT02880709|Experimental|Special diet|Special diet with taste, energy-and protein content adjusted according to previous finding
2503007|NCT02880709|No Intervention|Usual diet|Patients habitual diet
2503141|NCT02879682|Active Comparator|nTMS|presurgical motor mapping by nTMS and fusion with intraoperative neuronavigation
2503148|NCT02879682|Sham Comparator|non-nTMS|presurgical motor mapping by nTMS without access of the surgeon to these data
2503343|NCT02878239||Early OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with early knee osteoarthritis because their Kellgren-Lawrence Scores were Grade I.
2503345|NCT02878239||Moderate OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade II.
2503350|NCT02878239||Severe OA|All patients (>35 years) have been diagnosed with medial knee osteoarthritis according to the American College of Rheumatology criteria. Those are classified as patients with moderate knee osteoarthritis because their Kellgren-Lawrence Scores were Grade III/IV.
2503357|NCT02878239||Asymptomatic Participants|The asymptomatic participants（>35 years） has no history of knee pain, trauma, surgery, or obvious gait abnormalities. They are set as controls in the study.
2503392|NCT02877589||solid tumor|Patients receiving chemotherapy for solid tumors in Ambulatory Medicine Unit of the Reims University Hospital (France) between May 14, 2012 and July 31, 2013.
2503464|NCT02877381|Active Comparator|Single IV Dose|• 1 gram IV TXA administered at time of prepping and draping
2503468|NCT02877381|Active Comparator|Double Dose IV|"1 gram IV TXA administered at time of prepping and draping~1 gram IV TXA administered prior to tourniquet deflation"
2503470|NCT02877381|Active Comparator|IV + Topical|"1 gram IV TXA administered at time of prepping and draping~1 gram topical TXA injected intra-articular following closure of the arthrotomy"
2503471|NCT02877381|Active Comparator|Repeated Oral Dose|• Three 650 mg tablets of TXA administered two hours prior surgery with a second dose given 6 hours postoperatively and a final dose given the morning of postoperative day 1
2503478|NCT02877186|Experimental|Diet Soda|Consumption of diet soda three times daily for one week
2503480|NCT02877186|Placebo Comparator|Carbonated Water|Consumption of plain, unsweetened, carbonated water three times daily for one week
2503507|NCT02876770|Experimental|Melatonin|
2503508|NCT02876770|Placebo Comparator|Placebo|
2503521|NCT02876718||Rivaroxaban, BAY59-7939|It is a single-arm study in which only patients who switched from a VKA to a NOAC treatment will be included.
2503556|NCT02876523||Patients with a hilar biliary stricture requiring a drainage|Drainage performed by endoscopy, echo-endoscopy or percutaneously
2503609|NCT02876185||Patients with glaucoma|Patients presenting an open-angle glaucoma or ocular hypertension
2503614|NCT02876120|Other|Pre- and post-implementation phases|"Pre-implementation phase: during the pre-implementation period persons with hip or knee osteoarthritis will receive usual care as it is currently delivered by physiotherapists and general practitioners.~Post-implementation phase: during the post-implementation phase the GPs and PTs will treat persons with hip or knee osteoarthritis according to the START treatment model including providing information/patient education program, supervised exercise and advice/support to loose weight and other non-surgical evidence based treatments modalities prior to being referred to an orthopaedic surgeon"
2503627|NCT02875756|Experimental|10 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
2503628|NCT02875756|Active Comparator|20 revolutions|In this group, 10 revolutions will be made with the EBUS-TBNA needle
2503635|NCT02875808||patients|patients with an external ventricular drainage
2503644|NCT02875535|No Intervention|Usual Care|Standard school nurse care for suicide prevention.
2503645|NCT02875535|Experimental|RLAS|Through the RLAS, the investigators will train school nurses statewide. Using the Dynamic Adaptation Process, the nurses will then convene and lead Implementation Resource Teams (IRTs). With the assistance of RLAS coaches, the school nurse-led IRTs will engage in an iterative process of assessment and planning to build school capacity and implement up to six evidence-base strategies to reduce adolescent suicide.
2503671|NCT02875496||Healthy aging|Subjects meeting criteria for healthy aging No intervention administered
2503674|NCT02875496||Early Alzheimer Disease|Subjects meeting criteria for Early Alzheimer Disease No intervention administered
2503675|NCT02875496||Depression|Subjects meeting criteria for Depression No intervention administered
2503676|NCT02875496||MCI-Mild Cognitive Impairment|Subjects meeting criteria for MCI-Mild Cognitive Impairment No intervention administered
2503678|NCT02875496||General Arm|Subjects not meeting criteria for any of the other arms (Healthy, Early Alzheimer's, Depression, or MCI)
3196260|NCT00848679|Placebo Comparator|Epidural saline|30 women to receive 5 x 5 mL boluses of epidural saline. 10 pre-eclamptics, 10 normal term pregnancy, 10 non-pregnant
3196261|NCT00848692|Experimental|1|Rituximab
2503724|NCT02875236|Placebo Comparator|Control|Ringer-acetat
2503725|NCT02875236|Active Comparator|Intervention|OctaplasLG®
2503728|NCT02875106||Atrial Fibrillation Patients|Adult female and male patients with diagnosed atrial fibrillation
2503729|NCT02875106||Sinus Rhythm Patients|Adult female and male patients with diagnosed sinus rhythm
2502967|NCT02881125|Experimental|Treatment (paclitaxel, nortriptyline hydrochloride)|Patients receive paclitaxel IV on days 1, 8, and 15. Patients also receive nortriptyline hydrochloride PO QD on days 1-7, BID on days 8-14, and TID on days 15-28 of course 1 and TID on days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2503047|NCT02880280|Experimental|Human Menopausal Gonadotropin|Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
2503052|NCT02880280|Experimental|Human Chorionic Gonadotropin|Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation
2503107|NCT02879942||Case cohort|Patients with pregnancies complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
2503109|NCT02879942||Control cohort|Patients with pregnancies not complicated by placental insufficiency (preeclampsia and/or intrauterine growth restriction) will be included in this cohort.
2503142|NCT02879513|Active Comparator|Switch to CEF|Epirubicin 75 mg/m² IV push on day 1 every 3 weeks for 4 cycles. Cyclophosphamide 500 mg/m² IV push on day 1 every 3 weeks. 5-fluoruracil 500 mg/m² IV push on day 1 every 3 weeks.
2503153|NCT02879513|Experimental|Continue the neoadjuvant regimen|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
2503164|NCT02879513|Experimental|Pathological complete response group with chemotherapy|Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.
2503169|NCT02879513|No Intervention|Pathological complete response group with no chemotherapy|
2503225|NCT02878889|Experimental|Arm 1|S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
2503280|NCT02878707|Experimental|DEX|Intraoperative intravenous infusion of dexmedetomidine
2503283|NCT02878707|Placebo Comparator|Control|Intraoperative intravenous infusion of 0.9% saline
2503330|NCT02878174|Active Comparator|conventional ultrasound (US)-guided group|internal jugular vein catheterization using conventional US-guided internal jugular vein (IJV) cannulation
2503337|NCT02878174|Experimental|rotational Prelocation group|internal jugular vein catheterization using landmark approach based on the rotation-adjusted US screen
2503473|NCT02877212|Experimental|Study subjects|Steroid refractory ITP patients will be given Eltrombopag to investigate the association of treatment outcome with Fc Receptor polymorphism and THPO expression in responders and non responders following comparison correlation with ITP patients treated with standard IST as control group
3163193|NCT00477126|Active Comparator|1|start generic product cross over to reference product
3163194|NCT00477126|Active Comparator|2|start reference product cross over to generic product
3163195|NCT00477178||chronic non-malignant pain codeine|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - on long-term codeine therapy
3163196|NCT00477178||chronic non-malignant pain|patients having chronic non-malignant pain, living in Trondheim or the four adjacent counties and treated at the Center for Pain and Complex Disorders at St. Olav University Hospital - NOT on long-term codeine therapy
3163197|NCT00477178||healthy|healthy controls
2503596|NCT02876484|Experimental|Placebo|"Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM.~25 ml water"
2503599|NCT02876484|Experimental|Chenodeoxycholic Acid|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Chenodeoxycholic acid (1250 mg) mixed in 25 ml yoghurt
2503600|NCT02876484|Experimental|Colesevelam|Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
2503881|NCT02874118|Experimental|HIV Patient population over 50 years old|
3163198|NCT00477217|Other|1|
3163199|NCT00477243||Palliative Care Clinic Patients|Department of Symptom Control and Palliative Care Center Patients
3163200|NCT00477256||Child|Children between 6 and 17 years diagnosed with, and treated for, any type of cancer.
3163201|NCT00477256||Parent|Parent(s) or caregiver(s) of children with cancer.
3163202|NCT00477256||Medical Staff|Medical staff (i.e., physicians, nurse practitioners) involved in the children's medical decision-making.
3163203|NCT00477282|Experimental|Karenitecin|
3163204|NCT00477282|Active Comparator|Topotecan|
3163205|NCT00477308|Other|salvage therapy|Children with drug resistance were treated using the drug resistant profile
3163206|NCT00477321|Experimental|CYT107|CYT107 vs Placebo (4:1 ratio)
3163207|NCT00477347|Active Comparator|1|Manual administration
3163208|NCT00477347|Experimental|2|Closed-loop administration
3163209|NCT00477360|Experimental|1|C.A.P
3163210|NCT00477373|Experimental|1|If the daily dose does not exceed 1000 mg, Depakine CHRONO can be administered once a day. If the dose is greater than 1000 mg/day, Depakine CHRONO will be administered in a bid regimen: one tablet in the morning and one tablet in the evening.
3173653|NCT00614471|Experimental|2|
3173654|NCT00614471|Experimental|3|
3173655|NCT00614536||001|
3173656|NCT00614549||Levetiracetam|Patients treated with Levetiracetam
3173657|NCT00614562|Experimental|NAVA|
3173658|NCT00614588||observation group|Patients undergoing laparoscopic surgery requiring general anesthesia and a bladder catheter.
3173659|NCT00614601|Experimental|1|Vaccine + chemo + chemoradiation therapy
3173660|NCT00614601|Experimental|2|Vaccine Only
3173661|NCT00614640|Experimental|1|One 0.8 ml vaccine-containing patch and 1 placebo patch placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
2503020|NCT02880566|Experimental|Treatment|Full scalp block performed with a total of 30 ml of levobupivacaine 0.33 %.
2503021|NCT02880566|Placebo Comparator|Control|Full scalp block performed with a total of 30 ml of normal saline.
2503048|NCT02880267|Other|CGM Users|Glucose challenge during a clinic sessions to assess performance of CGM compared to reference measurement
2503070|NCT02879968||Head and Neck squamous cell carcinoma|"A single measurement of serum squamous cell carcinoma antigen level is performed in the eligible Head and Neck squamous cell carcinoma patients.~The study tool measuring serum squamous cell carcinoma antigen level is ARCHITECT SCC (Abbott).~The gross tumor volume in the cross sectional imaging obtained within 2 weeks of each patient is calculated with the typical ellipsoid formula."
2503143|NCT02879799|Experimental|Implement Family Integrated Care|Dynamic education and support intervention for families of preterm infants.
2503150|NCT02879799|No Intervention|Monitor Standard Practices|Standard nursing care of preterm infants and their families.
2503202|NCT02879110|Experimental|Sulforaphane group|The patients will take sulforaphane for 12 weeks.
2503204|NCT02879110|Placebo Comparator|Placebo group|The patients will take placebo for 12 weeks.
3163211|NCT00477412|Experimental|Treatment (combination chemotherapy)|"Participants receive Drug Combination I during courses 1, 3, 5, and 7 (if needed) and Drug Combination II during courses 2, 4, 6, and 8 (if needed) in the absence of disease progression or unacceptable toxicity.~Drug Combination I: Participants receive rituximab IV over 6 hours on day 1, cyclophosphamide IV over 3 hours BID on days 2-4, doxorubicin IV over 15-30 minutes on day 5, vincristine IV over 15-30 minutes on days 5 and 12, dexamethasone PO or IV on days 2-5 and 12-15, and bortezomib IV over a few seconds after the first dose of cyclophosphamide and immediately after vincristine and doxorubicin have been given on day 5.~Drug Combination II: Participants receive rituximab IV over 6 hours on day 1, methotrexate IV over 24 hours on day 2, and cytarabine IV over 2 hours every 12 hours on days 3-4."
3163212|NCT00477477|Experimental|1|Low glycemic load diet
3163213|NCT00477477|Active Comparator|2|Low fat diet
3163214|NCT00477503|Active Comparator|Group A|Ga-67 citrate injection alone for individuals with cancer cells in cerebral spinal fluid (CSF), no earlier treatment for disease.
2503485|NCT02877342||Pre-intervention|All injured patients arriving by ambulance (to the four intervention sites) and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving without notification buy ambulance service
2503487|NCT02877342||Post-Intervention|All injured patients arriving by ambulance, and allocated to a red (1st) or yellow (2nd) priority category will be eligible for inclusion. Patients arriving with and without notification by the ambulance service using the pre-hospital notification application.
3163215|NCT00477503|Active Comparator|Group B|Ga-67 + In 111 DTPA injection for individuals who have cancer cells in CSF, no earlier treatment for disease.
2503502|NCT02876666|Experimental|Coach Intervention|
2503504|NCT02876666|No Intervention|Usual Care|
2503540|NCT02876562|Experimental|root coverage with collagen matrix|evaluation of root coverage achieved by collagen matrix in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
2503542|NCT02876562|Active Comparator|root coverage with connective tissue graft|evaluation of root coverage achieved by connective tissue graft in conjunction with modified coronally advanced tunnel in patients with multiple gingival recession
3163216|NCT00477503|Active Comparator|Group C|Individuals with tumors in the CSF that have been treated and are now cleared from the CSF, receive standard follow-up care (baseline injection of Ga-67 citrate and In-111 DTPA).
3163217|NCT00477516|Experimental|1|
3163218|NCT00477529|Experimental|ABI-008|
3163219|NCT00477581|Experimental|Sequence A|
3163220|NCT00477581|Experimental|Sequence B|
2503651|NCT02875769|Experimental|Test: Mouthwash CPC+Zn+F|To rinse with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2503655|NCT02875769|Active Comparator|Positive control: Mouthwash CHX|To rinse with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2503656|NCT02875769|Placebo Comparator|Negative control A: No rinsing|No rinsing with pre-procedural mouthwash + full mouth dental prophylaxis using ultrasonic scaler.
2503661|NCT02875769|Placebo Comparator|Negative control B: Water|To rinse with pre-procedural mouthwash containing water from a three-way syringe (for one minute and 20 ml of solution) + full mouth dental prophylaxis using ultrasonic scaler.
2503704|NCT02875730|Experimental|CMRI Pulse Sequence|Patients will have late gadolinium cardiac magnetic resonance images of the individual pulmonary veins acquired with the standard and the cylindrical navigator preparatory pulse sequences for comparison.
2503730|NCT02875171||Anthracycline therapy|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
2503868|NCT02874027||TBI Patients with depression|All the patients should be diagnosed by CCMD-3(evaluation of depression)
3163221|NCT00477646|Experimental|Prevention Care Management|Telephone support over 18 months from trained Prevention Care Managers, to help women overcome barriers to colon, breast, and cervical cancer screening
3163222|NCT00477646|No Intervention|Usual Care|Usual Care. A sample of patients receive a single telephone call to validate claims data and collect basic demographic information.
3163223|NCT00477711|Experimental|C225+Chemotherapy|
3163224|NCT00477724|Placebo Comparator|sedentary control group|patients are treated by conventional rehabilitation
3163225|NCT00477724|Active Comparator|exercise and respiratory therapy|rehabilitation with exercise and respiratory therapy
3163226|NCT00477763|Active Comparator|1|
3163227|NCT00477763|Placebo Comparator|2|
3163228|NCT00477776|Active Comparator|a|Mother with diet-controlled diabetes receive Metoclopramide 10 mg 3 times a day for the first 7 days, and 2 times a day for day 8 to 10, and once a day from day 11 to day 12
3163229|NCT00477776|Placebo Comparator|b|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day for day 11 to 12
3163230|NCT00477776|Active Comparator|c|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, and once a day from day 11 to 12
2503027|NCT02880449|Experimental|Intervention|The intervention will be conducted in pre-existing older women's groups based in community centres. The intervention will consist of three educational sessions, encouragement to enlist the support of a partner or 'buddy' (e.g. a spouse, partner or friend), an information pack (containing information on the local area, walking routes, points of interest) and the option of weekly telephone contact. Participants will be given the opportunity to discuss their progress and share feedback with the rest of the group at weekly meetings.
2503029|NCT02880449|No Intervention|Control|Due to the stepped wedge design of the study, one group in each centre will not receive the intervention procedure detailed above until week seven. The control groups shall be given information about the study at baseline and informed that they will receive the intervention 6 weeks later.
2503065|NCT02880215|Experimental|Attention Bias Modification|Behavioral intervention designed to improved negative attention bias.
2503066|NCT02880215|Experimental|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
2503067|NCT02880215|No Intervention|Assessment Only|Assessment only with no active intervention.
3196262|NCT00848692|Placebo Comparator|2|Placebo (saline)
3196263|NCT00848705|Active Comparator|Measurement Only|
2503216|NCT02879058|No Intervention|Without Ultrasound|Laparoscopic or robotic myomectomy will be performed without aid of intraoperative contact ultrasonography
2503217|NCT02879058|Experimental|With Ultrasound|Laparoscopic or robotic myomectomy will be performed with aid of intraoperative contact ultrasonography
2503304|NCT02878720|Experimental|Robotic therapy and real tVNS|This group receives REAL vagus nerve stimulation during robotic rehabilitation.
2503306|NCT02878720|Active Comparator|Robotic therapy and sham tVNS|This group receives SHAM VNS during robotic rehabilitation. Sham VNS is not effective. Both groups receive the same amount of robotic rehabilitation.
2503354|NCT02877966|Experimental|Arm A|Amixea- patented stoechiometrical mixture of EAA & AA
2503360|NCT02877966|Placebo Comparator|Arm B|Placebo
2503381|NCT02877615|Experimental|S 44819 150 mg twice a day|
2503383|NCT02877615|Experimental|S 44819 300 mg twice a day|
2503384|NCT02877615|Placebo Comparator|Placebo|
2503527|NCT02876679|Active Comparator|Anti-Thymocyte Globulin|2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1)
2503566|NCT02876432|Experimental|Device: Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
2503567|NCT02876432|Sham Comparator|Device: Sham Electroacupuncture|In sham electroacupuncture (Sham) the investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
2503568|NCT02876432|Active Comparator|Drug: Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
2503607|NCT02876289||patients treated with Perampanel|
2503612|NCT02876016|Experimental|awake brain surgery|Exploration of the cortical area of the brain awake surgery
3196264|NCT00848705|Experimental|Internet Intervention|
3196265|NCT00848731|Experimental|iNO|gaseous NO is delivered by facemask
3196266|NCT00848757|Experimental|Lifestyle Counseling|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
2503733|NCT02875314|Experimental|Induction|"The 5 chemotherapy drugs used in the Induction part of treatment are vincristine, cisplatin, cyclophosphamide, etoposide and high-dose methotrexate.~Three medications are also given to help reduce the side effects of the chemotherapy drugs. Filgrastim will be given through a vein or through a tiny needle into the tissue just under the skin to help blood counts recover after the chemotherapy. Mesna will be given through a vein with cyclophosphamide to help prevent bleeding in the bladder. Leucovorin will be given through a vein after the methotrexate to protect the body from the side effects of the methotrexate."
2503734|NCT02875314|Experimental|Single Cycle Intensive Chemotherapy|"The three drugs to be used in this research study are thiotepa, etoposide and carboplatin. These drugs will be given over 6 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Carboplatin is given by vein over 4 hours. Thiotepa is given by vein over 3 hours. Etoposide is given by vein over 3 hours. The schedule for these drugs is as follows:~Day -8: Carboplatin Day -7: Carboplatin Day -6: Carboplatin Day -5: Thiotepa, Etoposide Day -4: Thiotepa, Etoposide Day -3: Thiotepa, Etoposide Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells"
2503735|NCT02875314|Experimental|Tandem 3 Cycle Intensive Chemotherapy|"The 2 drugs to be used in this treatment are thiotepa and carboplatin. These drugs will be given over 2 days to help kill the cancer cells. After 72 hours from getting these drugs, previously collected and frozen blood cells will be thawed and returned through the venous catheter.~Day -4: Thiotepa, Carboplatin Day -3: Thiotepa, Carboplatin Day -2: Rest Day -1: Rest Day 0: Re-infusion of blood cells.~Following recovery from the first cycle of this chemotherapy, about 28 days following the Day 0 reinfusion of blood cells, the same cycle will be repeated again. A total of 3 cycles of this therapy will be administered, over the course of 12 weeks."
2503745|NCT02875860|Other|Standardized postnatal care (Expectant)|Mothers will be expectantly managed during pregnancies and babies receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website.
2503807|NCT02874651|Experimental|Apatinib|In the phase IIb part of this trial, patients in this arm will take oral apatinib until disease progression, intolerable toxicity, death or to a maximum of 2 years.
2503869|NCT02874144|Experimental|AZ Compound|40 mg 12 weeks TID po
2503873|NCT02874144|Placebo Comparator|Placebo|40 mg 12 weeks TID po
2503086|NCT02880124|Experimental|Maple syrup|A maple syrup solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2503088|NCT02880124|Experimental|Maple sap|A maple sap solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2503091|NCT02880124|Active Comparator|Glucose|A glucose solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2503093|NCT02880124|Active Comparator|Sport drink|A Gatorade (TM) solution of 6% carbohydrate per volume labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2503095|NCT02880124|Placebo Comparator|Trace|A solution containing stevia (sugar substitute) and trace amounts of glucose (3g) labeled with 13C-sucrose will be ingested 30 min prior to starting exercise and every 30 min thereafter (solution ingestion), until 2h of the constant load cycling exercise is completed. Starting 4 min before each solution ingested over the protocol, indirect respiratory calorimetry, expired gas sampling, blood sampling will occur. After completing the 2h of exercise, subjects will be given a few minutes of rest (5-min) during which the catheter will be removed, after which the 20-km time trial will be initiated on the same ergometer. Palatability of the solution will be assessed after the first ingestion and after ingesting the last solution. Gastrointestinal symptoms will be assessed after the time trial.
2503129|NCT02879435|Experimental|bupivacaine|Intervention
2503132|NCT02879435|Placebo Comparator|Placebo|Control
2503183|NCT02879344|Other|Patient undergoing ECMO|
2503292|NCT02878551|Experimental|Prehabilitation program|Multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
2503334|NCT02878109||Post-treatment phase group|29 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before and after transarterial chemoembolisation (TACE).
2503338|NCT02878109||Pre-treatment phase group|11 patients will undergo: 4D-THRIVE and 4D-FLOW sequences during magnetic resonance imaging (MRI) before treatment (if any).
2503376|NCT02877745||no SDB|apnea-hyponea index <15/hour
2503378|NCT02877745||SDB|apnea-hyponea index >=15/hour
2503427|NCT02877459|Experimental|AeriSeal System|Subjects will be treated with AeriSeal Foam.
2503447|NCT02877147|Experimental|$60 SEBTC Benefit Group|Households received $60 per summer month when school was not in session for each eligible child (Summers 2011-2013).
2503451|NCT02877147|Experimental|$30 SEBTC Benefit Group|Households received $30 per summer month when school was not in session for each eligible child (Summer 2013 only).
2503455|NCT02877147|No Intervention|No Intervention Group|Households with eligible children were not issued SEBTC benefits (Summers 2011 and 2012)
2503528|NCT02876861|Experimental|Neoadjuvant chemotherapy and Surgery|"Experimental: Neoadjuvant chemotherapy group~Neoadjuvant chemotherapy(Gemcitabine and Cisplatin):~Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.~Surgery:~2-3weeks after Neoadjuvant chemotherapy~Surgeons: the operation shall be performed by senior urologic surgeons. Try to achieve the consistency of operation quality.~Operation: Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff or distal ureterectomy."
2503530|NCT02876939|Experimental|HSAN III|
2503531|NCT02876939|Active Comparator|Control Subjects|
2503564|NCT02876315|Experimental|Redoxon VI|2 film coated tablets Redoxon VI oral intake daily for 12 weeks
2503565|NCT02876315|Placebo Comparator|Placebo|2 film coated tablets placebo oral intake daily for 12 weeks
2503575|NCT02876354|Experimental|Menaquinone 360|All patients in the study will be assigned to receive menaquinone 360 μg /d for 4 weeks.
2503610|NCT02875990|Experimental|patients with invasive cervical cancer|Blood sample
2503630|NCT02875678|Experimental|ABX-1431|ABX-1431, capsules, 40 mg, single dose
2503634|NCT02875678|Placebo Comparator|Placebo|Placebo, capsules, single dose
2503648|NCT02875847|Active Comparator|HMO1|Daily bolus of HMO1
2503652|NCT02875847|Active Comparator|HMO2|Daily bolus of HMO2
2503658|NCT02875847|Placebo Comparator|Dextropur|Daily bolus of dextropur
2503669|NCT02875457|Experimental|Arm A|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and apatinib 250mg/d , repeated every 21 days, a total of 6 cycles, and then continue to take apatinib 250mg/d until progressive Disease(PD).
2503871|NCT02874027||TBI Patients without depression|
2503127|NCT02879669|Experimental|ONCOS-102+cyclophosphamide+pemetrexed/cisplatin (carboplatin)|ONCOS-102 will be administered in a priming cycle (Cycle 1) comprising injections on Days 1, 4, 8 and 36, followed by two treatment cycles at intervals of 6 weeks (Cycle 2, Day 78 and Cycle 3, Day 120). Pre-treatment with an i.v. bolus of cyclophosphamide (CPO) will be given 1 to 3 days before the first administration of ONCOS-102 (Cycle 1, Day 1) and before administration of Cycle 2 of ONCOS-102 (Day 78). Patients will also receive pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 22 and continuing as applicable during the study period of 6 cycles of pemetrexed/cisplatin (carboplatin) in combination with ONCOS-102.
2503128|NCT02879669|Active Comparator|Pemetrexed/cisplatin (carboplatin)|Patients will be treated with pemetrexed/cisplatin (carboplatin) in 21-day cycles starting on Day 1, and continuing as applicable during the study period of 6 cycles of chemotherapy. Patients will be monitored regularly for immunological assessment (PBMCs) including Month 9 and Month 12 (i.e., after the end of study visit), and will be followed up for survival every 3 months until end of life.
2503190|NCT02879331|Active Comparator|10 coils in upper lobes|10 coils in upper lobes
2503191|NCT02879331|Experimental|15 coils in upper and lower lobes|15 coils in upper and lower lobes
2503230|NCT02878941|Other|Elbow Fracture|Patients with an intraarticular elbow fracture and/or dislocation. Synovial fluid from the injured elbow will be obtained during the subject's emergency department encounter by one of the Chief Residents or Attending surgeon as part of standard of care procedures for pain control-related injection and aspiration. Patients with an intraarticular elbow fracture and/or dislocation receive an intraarticular elbow injection with anesthetic (i.e. lidocaine or marcaine) to provide analgesia for elbow range of motion testing and orthopaedic reduction maneveuers as the current standard of care. The patients would be asked to consent for 2 elbow joint aspirations: 1.Aspiration of the injured elbow at time of surgical fracture fixation; 2.Aspiration of the uninjured elbow at time of surgical fracture fixation.
2503281|NCT02878694|Experimental|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections
2503377|NCT02877862|Experimental|Intervention|Receive 7-day mAGIC app intervention and handout
2503379|NCT02877862|No Intervention|Control|Handout only
3196267|NCT00848757|No Intervention|Usual Care Control|Women with pre-diabetes randomized to usual care will be offered 30 minute appointments with a medical provider to review their diagnosis, risk for diabetes, and stress the importance of lifestyle changes to prevent diabetes, including weight loss and exercise and setting individual goals for these. Usual care participants will be encouraged to achieve goals equivalent to the ILI group: to reduce their weight by 7%, and to increase their physical activity to approximately 150 minutes moderate intensity exercise per week. They will be offered a consultation with an FHCHC nutritionist to achieve dietary/weight loss objectives. Participants are offered printed educational materials which are language and literacy-appropriate.
3196268|NCT00848770|Active Comparator|1, 140 to 160 mmHg|Esmolol, NPS or NOR
2503475|NCT02877043||patients undergoing lung resection|
2503518|NCT02876796|Experimental|50 mg GS-0976 (Cohort 1)|"Sequence 1:~Period 1 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 2:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 50 mg (1 x 50 mg capsule) + IV infusion 1-13C acetate and fructose solution"
2503525|NCT02876796|Experimental|200 mg GS-0976 (Cohort 2)|"Sequence 3:~Period 1 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 4:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 200 mg (1 x 200 mg capsule) + IV infusion 1-13C acetate and fructose solution"
2503529|NCT02876796|Experimental|20 mg GS-0976 (Cohort 3)|"Sequence 5:~Period 1 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): placebo + IV infusion 1-13C acetate and fructose solution~Sequence 6:~Period 1 (2 days): placebo + IV infusion 1-13C acetate and fructose solution; Washout Period (minimum of 5 days); Period 2 (2 days): 20 mg (2 X 10 mg capsule) + IV infusion 1-13C acetate and fructose solution"
3196269|NCT00848770|Active Comparator|2, 161 to 180 mmHg|Esmolol, NPS or NOR
3196270|NCT00848770|Active Comparator|3, 181 to 200 mmHg|Esmolol, NPS or NOR
3196271|NCT00848796|Other|Heparin|Compare two market brands of Heparin
2503581|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 1: SRP)|Stage 1 Safety Run-in Phase (SRP): Approximately 12 participants will receive cobimetinib 60 milligrams (mg) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 milligrams per kilogram (mg/kg) administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Upon determination of the safety and tolerability of the treatment regimen, the study will proceed to Stage 2: dose expansion phase. If the results from the safety run-in phase require dose reduction in cobimetinib, then an additional Stage 1 cohort will be opened. Treatment will continue until the participant has disease progression according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2503615|NCT02876198||Patients treated with anti-VEGF|
2503629|NCT02875704||Stargardt disease, AMD, DR patients|Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
2503632|NCT02875704||Controls|Patients without retinal disease who will be undergoing cataract surgery
2503641|NCT02875483|Placebo Comparator|Standard Scheduling|Group allocated to follow standard surgical scheduling practices
2503643|NCT02875483|Experimental|Expedited Scheduling|Group allocated to expedited scheduling practices
2503687|NCT02875405|Experimental|Received pericardiotomy|Patient will receive a posterior left pericardiotomy at the time of surgery
2503689|NCT02875405|No Intervention|No Pericardiotomy|Patient will not receive posterior left pericardiotomy.
3196272|NCT00848809||1|Slow-low efficiency daily dialysis group
3196273|NCT00848809||2|Intermittent Hemodialysis group
3196274|NCT00848835||control|all patients in the control group
3196275|NCT00848848|Active Comparator|1|
3196276|NCT00848848|Active Comparator|2|
2503166|NCT02879773||Emphysema|Patients undergoing assessment of emphysema/chronic obstructive pulmonary disease (COPD) for potential surgical intervention; including lung volume reduction surgery, endobronchial valve insertion or endobronchial coil insertion. CTPVe will be modelled to predict postoperative lung function.
2503170|NCT02879773||Interstitial lung disease|Patients undergoing assessment or treatment of suspected or confirmed interstitial lung disease. CTPVe will be modelled to aid diagnosis of the subtype of interstitial lung disease confirmed by histological diagnosis.
2503203|NCT02879188|Experimental|Ambulation|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
2503205|NCT02879188|Active Comparator|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
2503221|NCT02878824||HK-Children|This is a group of typically-developing children ages 7-12 years old who are of Chinese ethnicity, born and raised in Hong Kong (n=32).
2503223|NCT02878824||FHK-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity; either born, migrated and/or raised in Hong Kong (n=32).
2503224|NCT02878824||FU-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in an urban area in the Philippines (n=32).
2503227|NCT02878824||FR-Children|This is a group of typically-developing children ages 7-12 years old who are of Filipino ethnicity, born and raised in a rural area in the Philippines (n=32).
2503348|NCT02878278|Experimental|Chidamide BIW|Chidamide is given 30mg,5mg/pill,twice a week, for at least 6 weeks
2503353|NCT02878278|Experimental|Chidamide QD|Chidamide is given 10mg,5mg/pill, everyday,for at least 6 weeks.
2503418|NCT02877641|Active Comparator|Control arm (multivitamin, placebo)|Patients receive a placebo and multivitamin orally each day for 52 weeks.
2503420|NCT02877641|Experimental|Supplementation arm (multivitamin, cholecalciferol)|Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.
3196277|NCT00848848|Active Comparator|3|
3196278|NCT00848848|Active Comparator|4|
3196279|NCT00848848|Active Comparator|5|
3196280|NCT00848848|Active Comparator|6|
3196281|NCT00848848|Active Comparator|7|
3196282|NCT00848848|Active Comparator|8|
3196283|NCT00848848|Active Comparator|9|
2503593|NCT02876133|Experimental|Narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
2503594|NCT02876133|Placebo Comparator|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
2503625|NCT02875691|Active Comparator|green tea extract|Patients were given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules (500 mg) for three months.
2503626|NCT02875691|Placebo Comparator|Placebo|Patients in placebo group received daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
2503638|NCT02875561|Active Comparator|Sonopet Ultrasonic Aspirator|Treatment of VIN dysplasia with sonopet ultrasonic aspirator: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
2503639|NCT02875561|Experimental|CO2 Laser Ablation|Treatment of VIN dysplasia with CO2 Laser Ablation: to evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
2503647|NCT02875938|Experimental|Music and reading lyrics|A single-subject adapted alternating treatment design will be used to compare two music conditions, using music with sung lyrics simultaneously with silent reading of the lyrics, and priming with music and sung lyrics followed by reading of the lyrics, with a control condition using reading materials without music.
2503668|NCT02875444||"group abdominal aortic aneurysm"|Patients with non-operated abdominal aortic aneurysm with angio-CT realized between 01/01 2010 au 04/15/2012
2503737|NCT02875054|Active Comparator|Continued Casting|Participants with 24 hour cast wear (continued casting) for the entire duration of the constraint portion of camp (2 initial weeks).
2503738|NCT02875054|Active Comparator|Intermittent Casting|Participants who wear a univalve cast for 3 hours of constraint camp with home exercise program of 2 hours cast wear on the weekends (intermittent casting).
2503740|NCT02875353|Other|Standard endoscopy (not experimental)|For Standard treatment group, the Doppler probe will not be used, nor will hemoclip closure of post-polypectomy ulcers be attempted. Standard published guidelines will be followed for management of blood thinners (anti-coagulants) and/or aspirin like drugs (anti-platelet drugs) before and after the colonoscopic polypectomies. This is the standard of care at the investigators' medical centers and part of written instructions that are given to the participants and their referring physicians during the scheduling process and prior to their preparation for screening or surveillance outpatient colonoscopies.
3196284|NCT00848848|Active Comparator|10|
3196285|NCT00848861|Active Comparator|1 propofol|
3196286|NCT00848861|Active Comparator|2 midazolam plus meperidine|
3196287|NCT00848874|Experimental|PVGS User|
3196288|NCT00848887|Experimental|1|
3196289|NCT00848900|No Intervention|Control|
3196290|NCT00848900|Experimental|Outdoor activity|Adding 1 hour outdoor time into school curricula
3196291|NCT00848913|Active Comparator|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
3196292|NCT00848913|Experimental|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of fractured limb every day during admission.
3196293|NCT00848939|Experimental|treprostinil diethanolamine|
3196294|NCT00848978|Experimental|2|The experimental group will participate in the aerobic and strength training program.
3196295|NCT00848978|No Intervention|1|The usual care group will receive general physical activity guidelines.
2503168|NCT02879721|Active Comparator|ACE-inhibitor|Angiotensin converting enzyme inhibitor, (enalapril) 5 mg once daily
2503219|NCT02878837|Active Comparator|DEX|Patients undergoing surgical procedures under regional anesthesia sedated with a loading dose of 1 µg/Kg of Dexmedetomidine over 10 minutes followed by continuous infusion at 0.2 to 0.8 µg/Kg/h, along with 0.5µg/Kg bolus breakthrough doses of Fentanyl as necessary to achieve a RASS score between -3 and -1.
2503222|NCT02878837|Active Comparator|MDZ|Patients undergoing surgical procedures under regional anesthesia sedated with a 0.05mg/Kg bolus dose of Midazolam, along with 0.02 mg/Kg bolus doses of Midazolam plus 0.5µg/Kg bolus doses of Fentanyl as necessary to achieve a RASS score between -3 and -1
2503282|NCT02878681|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab for six months
2503285|NCT02878681|Experimental|Group 2|Monthly intravitreal injections of 2 mg aflibercept for the initial three months followed by monthly intravitreal injections of 0.5 mg ranibizumab for the next three months.
2503286|NCT02878681|Experimental|Group 3|Monthly injections of 2 mg aflibercept for six months
2503358|NCT02878148|Experimental|Patients with suspected acute uncomplicated renal colic|Diagnostic imaging
3196296|NCT00848991|Active Comparator|Precedex|In the operating room routine anesthesia monitors will be placed and vital signs will be recorded continuously using data collection software. A routine propofol anesthetic will be administered to subjects randomized to the control group or a Precedex infusion with propofol for subjects randomized to the treatment group. Precedex infusion will be started after induction of general anesthesia. Vital signs (SBP, DBP, MAP) will be recorded continuously throughout the surgery. At the end of the case subjects will be extubated and the blinded observer will assess emergence from anesthesia based on hemodynamic stability and tolerance of the endotracheal tube. Videotaping of emergence will be used to assist in the evaluation of emergence of anesthesia and extubation.
3196297|NCT00848991|Active Comparator|Propofol|Propofol for emergence from anesthesia
3196298|NCT00849004|Active Comparator|Gel vs. Sheet|One group will act to compare the effectiveness between silicone gel and silicone sheet.
3196299|NCT00849004|Active Comparator|sheet vs. paper tape|The second group between silicone sheet and paper tape.
2503561|NCT02876367||Acute scrub typhus (Group 1)|Participants presenting with a fever will be verbally consented for a scrub typhus RDT, using <1ml of blood that is likely to be taken as part of routine clinical assessment. If the RDT tests positive, the patient will be informed about the study and asked to give written informed consent. If they agree to join the study, participants will be asked to give a further blood sample of 10mls (2 teaspoons) for ELISA, PCR and culture testing to confirm the presence of scrub typhus.
2503563|NCT02876367||Scrub typhus serosurvey (Group 2)|Villagers who are living in an identified scrub typhus environment will be informed about the study and asked to give written informed consent. If they agree to join the study they will be asked to give a finger prick dried blood spot (DBS) test on which scrub typhus ELISA and IFA will be performed.
2503611|NCT02876094|Experimental|Open-label|All patients will be treated at each dose of oral once daily celecoxib (40, 80 and 160 mcg/kg) for a period of two weeks, for a total of 6 weeks (42 days) of treatment.
2503619|NCT02876146|Other|Hepatic alveolar echinococcosis|"Follow-up of standardized clinical, biological, and imaging characteristics (according to the WHO-expert consensus). Albendazole treatment, 400 mg x 2/d (or mebendazole if adverse effects)~Standardized earlier withdrawal of benzimidazole :~Patients with non operable hepatic AE lesion : Withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after at least 4 years when viability markers became negative (PET-CT, serological markers)~Curative hepatectomy : Earlier withdrawal of benzimidazole treatment for patients without metastasis or neighbouring lesions (PxN0M0) after one year (WHO guidelines : 2 years), if viability markers became negative. Close prospective follow-up after withdrawal (PET-CT, serological markers)"
2503633|NCT02875652|Experimental|Blood sampling|
2503636|NCT02875821|Experimental|Group IMP|Group IMP (Ipragliflozin with Metformin with Pioglitazone)
2503637|NCT02875821|Active Comparator|Group MP|Group MP (Metformin with Pioglitazone)
2503665|NCT02875522|Experimental|Patients with COPD|Stable patients with COPD participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
2503667|NCT02875522|Active Comparator|Healthy Controls|Age, sex, BMI and activity matched controls participated in an 8-week (24 session) individualized, non-linear aerobic exercise training program consisting of upper and lower body cycle ergometry.
2503677|NCT02875470|Experimental|Intensiv Perio Set|Root planing with diamond burs
2503679|NCT02875470|Active Comparator|Gracey curette|Root planing with Gracey curettes
2503715|NCT02875262|Experimental|Treatment|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day. duration 3 days
2503717|NCT02875210|Experimental|Patient with anterior cruciate ligament rupture|Anterior laxity of patient was measure with 4 laximeters:Telos, reference laximeter and with three other instruments called, KT-1000, GnrB and Rolimeter.
2503720|NCT02875262|Placebo Comparator|placebo|NaCl 0.9% in similar dosis to treatment arm
2503742|NCT02875353|Experimental|Doppler treatment (experimental)|A colon length catheter (probe) will be used to check the non-bleeding post-polypectomy ulcer with shallow and medium depth Doppler probe settings (< 4 mm deep) for arterial blood flow. If arterial flow is found, treatment through the colonoscope (either hemoclipping or multipolar electrocoagulation probe) will be used to stop the arterial flow. This will be confirmed by rechecking with Doppler probe after endoscopic treatment. Tatoos (Spot method) will be placed on two sides of the ulcer so treated.
2503767|NCT02874885||Ancillary-Correlative (biospecimen collection)|Patients and healthy participants undergo collection of blood sample at baseline. Patients may also undergo collection of blood sample collections during tumor surgery, 4 weeks after surgery or after completion of treatment if you are not surgery, 8 weeks after the last dose of chemotherapy, 1 year after surgery or 1 year after completion of treatment if not having surgery, 2 years after surgery or 2 years after completion of treatment if not having surgery, and within 6 years after treatment or at the end of the 6 year follow-up if the disease gets worse with treatment or comes back.
2503773|NCT02874989|Experimental|Dasatinib + Quercetin|
2503774|NCT02874989|Placebo Comparator|Placebo|
2503176|NCT02879409|Experimental|Treatment arm 1|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >140mg/dl~Intervention: intensify treatment until their FBG is <90mg/dl, using whatever treatment is clinically appropriate for them using different interventions (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin), and only intensify it further if their FPG rises to >140mg/dl again."
2503178|NCT02879409|Experimental|Treatment arm 2|"75 Type 2 diabetic patients with a gender balance who will have the intervention if/when their FBG >115mg/dl~Intervention: intensify treatment until FBG is <=115 mg/dl and intensify further if >115 mg/dl again, using what ever clinical treatment is necessary (Metformin, Gliclazide, Sitagliptin, Dapagliflozin, Liraglutide, Pioglitazone, human insulin)."
2503240|NCT02878902||Before implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2012 to December 31, 2013"
2503242|NCT02878902||Post implementation|"Patients registered in monitoring French registry of renal patients Réseau Epidémiologie et Information en Néphrologie (REIN) from January 1, 2014 to December 31, 2015"
2503272|NCT02878616|Experimental|LFG316 + IVIG|
2503274|NCT02878616|Experimental|LFG316 alone|
2503312|NCT02878200|Experimental|reactive treatment|Household members; defined as those sharing the same sleeping area, in the intervention villages, will be treated with a full course of dihydroartemisinin-piperaquine (DHAP)
2503314|NCT02878200|No Intervention|standard care|In control villages, no household treatment will be done
3196300|NCT00849004|Active Comparator|gel vs. paper tape|One group will act to compare the effectiveness between silicone gel and paper tape.
3196301|NCT00849030|Active Comparator|1|Arimidex 1mg + Nolvadex placebo
2503429|NCT02877420|Experimental|Non-Technical Skills Training Curriculum|This group will receive 4 hours of small-group and hands-on sessions and 1 hour of didactic NTS sessions. Participants will watch a video that demonstrates ideal endoscopic performance. They will use the E-NTS Checklist during the integrated scenario training. This checklist targets NTS. The group will be given 7 hours of expert-assisted instruction on the low-fidelity simulator (1 hour) and the high-fidelity VR simulator (6 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist who will demonstrate techniques, answer questions and provide individualized performance feedback with a focus on NTS. The last three hours on the high fidelity simulator will be an integrated scenario (IG) featuring standardized patient (SP) and standardized nurse (SN). Feedback will be given after each IG by the instructor, SP and SN. Participants can view the E-NTS Checklist before and after each case.
2503430|NCT02877420|Active Comparator|Conventional Simulation Training Group|This group will receive 4 hours of small-group and hands-on sessions on colonoscopy theory from an expert endoscopist. The core curriculum is designed on the basis of the American Society for Gastrointestinal Endoscopy colonoscopy curriculum and an endoscopic training textbook. This curriculum has been shown to be effective when compared to self-regulated learning on the simulator. The sessions will be interlaced with eight hours of expert-assisted instruction on both the low-fidelity simulator (1 hour) and on the high-fidelity VR simulator (7 hours). Six modules of increasing difficulty in colonoscopy and polypectomy will be taught with feedback from an expert endoscopist. The expert will demonstrate techniques, answer questions and provide feedback on global performance. Feedback, in the form of performance metrics, will be provided by the simulator upon completion/failure of each module.
3196302|NCT00849030|Active Comparator|2|Arimidex placebo + Nolvadex 20mg
2503499|NCT02876731|Other|single group|PET-CT MRI
2503541|NCT02876588|Active Comparator|Unrestricted|"Users have unrestricted access to open up to a maximum of 4 patient records at a time in the EHR"
2503543|NCT02876588|Active Comparator|Restricted|"Users have restricted access to open a maximum of 1 patient record at a time in the EHR"
2503572|NCT02876341||Chronic antihypertensives|On a chronic β-blocker, on chronic ACE-Inhibitor, or on both chronic β-blocker and ACE-inhibitor
2503595|NCT02876250|Experimental|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
2503598|NCT02876250|Placebo Comparator|Control|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
2503624|NCT02875951||ER positive, HER2 negative breast cancer patients|Postmenopausal patients with hormone receptor positive, HER2 receptor negative breast cancer
2503659|NCT02875626|Experimental|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
2503698|NCT02875717||Control|
2503699|NCT02875717||Acetylsalicylic acid|Patients that were on medication with Acetylsalicylic acid on the date of shockwave lithotripsy
2503700|NCT02875717||Low Molecular weight heparin|Patients that were on medication with low molecular heparin on the date of shockwave lithotripsy
3196303|NCT00849030|Active Comparator|3|Arimidex 1mg + Nolvadex 20mg
2503736|NCT02875093|Other|ADI-PEG 20 Plus Low Dose Cytarabine|This is a phase 1, open label trial of ADI-PEG 20 (18 and 36 mg/m2) weekly in combination with low-dose cytarabine (20 mg BID [twice daily] for 10 days, every 28 days)
2503748|NCT02875860|Experimental|Prenatal Intervention (FETO)|Patients will undergo fetoscopic endoluminal tracheal occlusion and ideally prenatal reversal of the occlusion followed by standardized postnatal care as in the expectant . In this study FETO (where GoldBal2 detachable balloon and Baltaccidbpe100 Delivery Catheter are used) is to be done between 30 weeks plus 0 day and 31 weeks plus 6 days and removal of the balloon at 34 weeks plus 0 day to 34 weeks plus 6 days.
2503791|NCT02874833|Experimental|Exercise Group|Experimental arm type will assess whether a newly developed, supervised 8-week individualized, internet-based exercise therapy is effective in reducing depressive symptoms.
2503794|NCT02874833|No Intervention|Treatment as usual group|Treatment as usual. Other form of therapy (e.g. antidepressive medication) will not be affected.
2503812|NCT02874573|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the tocilizumab group) at baseline, and weeks 4 and 8.
2503814|NCT02874729||Healthy donors|No interventions
2503816|NCT02874729||Cancer patients|No interventions
2503820|NCT02874677|No Intervention|Control|Routine activities
3196304|NCT00849043||Provent|Provent Professional Sleep Apnea Therapy device
3196305|NCT00849069|Experimental|Group A|
2503226|NCT02878876|Experimental|Sequence A1-A2|Dietary Supplement: Oral consumption of milk with sequence A1-A2
2503228|NCT02878876|Experimental|Sequence A2-A1|Dietary Supplement: Oral consumption of milk with sequence A2-A1
2503332|NCT02878018||TCM intervention|Participants with HSPN of the Heat-Toxin type will take the Qi-Ji Shen-Kang formula. HSPN patients of the Wet-Heat type will take the Zhu-Bai formula. Those of Qi-Deficiency with Blood-Stasis type will take the Yu-Shen formula.
2503335|NCT02878018||WM conventional intervention|The WM conventional intervention, recommended by the Chinese Medical Association's (CMA) Scientific Statement, includes angiotensin-converting enzyme (ACE) inhibitor, adrenergic receptor binder (ARB), adrenal cortical hormone, Tripterygium wilfordii polyglycosidium and an immunosuppressant.
2503403|NCT02877758|Experimental|Experimental|Tomorrowlabs cosmeceutical formulation is applied to the face of the subjects twice daily for 3 consecutive months.
2503411|NCT02877758|Sham Comparator|Control|Tomorrowlabs cosmeceutical formulation without the active ingredient is applied to the face of the subjects twice daily for 3 consecutive months.
2503477|NCT02877251||Deep venous thrombosis|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis
2503479|NCT02877251||Deep venous thrombosis and Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with deep venous thrombosis and pulmonary embolism
2503481|NCT02877251||Pulmonary embolism|To identify clinical characteristics, treatment trends, in-hospital and 3, 6, and 12 months follow-up outcome through major adverse cardiovascular events (MACE) of patients diagnosed with pulmonary embolism
2503573|NCT02876510|Experimental|IMA101 product only (Cohort 1)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2"
2503578|NCT02876510|Experimental|IMA101 product + atezolizumab (Cohort 2)|"Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide~Infusion of the IMA101 T-cell product(s)~Post-infusion administration of low-dose recombinant human interleukin-2~Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year"
2503580|NCT02876445|Other|Caregiver Evaluation|ZARIT Burden Interview
2503620|NCT02875964|Experimental|registration of intracerebral activity|epileptic patient receiving implantation of intracranial electrodes
2503662|NCT02875925|Experimental|MTM|Patients will receive MTM at an individualized frequency for 1 year.
2503663|NCT02875925|No Intervention|Control|Patients enrolled in the control group will not experience any change in their medical care.
2503701|NCT02875639|Experimental|tonifying qi group|tonifying qi group:which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng,and so on)
2503702|NCT02875639|Experimental|activating blood group|which treated by a kind of Chinese patent medicine (major components: Honghua,Taoren,Danggui，and so on)
2503703|NCT02875639|Experimental|qi and blood group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，Honghua,Taoren,Danggui，and so on)
2503705|NCT02875639|Active Comparator|QISHEN YIQI DRIPPING PILLS group|which treated by a kind of Chinese patent medicine (major components: Huangqi,Dangsheng，and so on)
2503707|NCT02875639|Sham Comparator|placebo group|which treated by the simulation of Chinese patent medicine (major components:excipient)
2503723|NCT02875301|Experimental|150 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 150 minutes of exercise per week.
2503726|NCT02875301|Experimental|225 Minutes Week|Participants engage in supervised 12 month moderate intensity aerobic exercise intervention with goal of maintaining 225 minutes of exercise per week.
2503727|NCT02875301|Active Comparator|Stretch and Tone|Participants engage in supervised 12 month non-cardiorespiratory activity intervention. This group has focus on improving balance, flexibility, and strength.
2503752|NCT02875015|Experimental|Liposomal Bupivacaine|20mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
2503757|NCT02875015|Active Comparator|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
2503770|NCT02875002|Experimental|All subjects|Subjects have relapsed and refractory aggressive B- and T-cell lymphomas and will receive both Belinostat and Volasertib.
2503785|NCT02874625|Active Comparator|Treatment 1|Dental restoration performed with glass-ionomer materials.
2503786|NCT02874625|Experimental|Treatment 2|Dental restoration performed with resin-based composites.
2503797|NCT02874755|Experimental|Tuberculosis Program (PPIA)|Half of the 300 participants were randomly selected to be sensitized and engaged into the program, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if networked into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free and/or subsidized diagnostic testing and referrals to providers for free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests; training opportunities, and access to a referral network.
2503800|NCT02874690|Placebo Comparator|Placebo|Placebo pill received
2503801|NCT02874755|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining half of the sample in Mumbai selected randomly will be phased into the program at least a year after the PPIA arm. However, during the year of the study, they will not be networked into the program.
2503805|NCT02874690|Experimental|Methylphenidate|
2503813|NCT02874911|Experimental|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
2503874|NCT02874105|Experimental|experimental group|Dynamic Humeral Centering
3196306|NCT00849069|Active Comparator|Group B|
2503212|NCT02879136|Active Comparator|Physical Therapy plus Methylphenidate|Methylphenidate 20 mg daily in combination with PT
2503213|NCT02879136|Active Comparator|Physical Therapy plus Atomoxetine|Atomoxetine 10 mg daily in combination with PT or PT alone.
2503254|NCT02878746|Experimental|Robotic mirror therapy|For 30 min per day for two weeks (10 sessions)
2503256|NCT02878746|Active Comparator|Conventional mirror therapy|For 30 min per day for two weeks (10 sessions)
2503264|NCT02878460|Experimental|monitoring with ORI + SpO2|"Patients receive the regular monitoring with SpO2, but in this group, the ORI parameters is shown on the scope.~Lower and upper SpO2 limits are prescribed for each patient."
2503266|NCT02878460|Other|monitoring with SpO2|"Patients receive the regular monitoring; the ORI parameters is not shown (but it is recorded each time a blood gas is drown).~Lower and upper SpO2 limits are prescribed for each patient."
2503296|NCT02878317||Malnourished participants|"Presence of malnutrition will be assessed by using the Subjective Global Assessment.~Once the identified malnourished participants have given their informed consent, they will receive intensive dietitian supervised nutritional support with the aim of improving their malnutrition. In addition, participants will receive standard dietary advice for people on dialysis based on the Nutritional Guidelines in CKD published by the Renal Association in March 2010 in the UK (Wright and Jones, 2010) and will include the following: energy (35 kcal/kg/day) and protein intake (1.2 g/kg/day), as well as potassium, phosphate and sodium restriction, according with biochemical blood parameters."
2503361|NCT02878096|Experimental|[14C]-SK-1404|
2503388|NCT02877602||Experience of liver disease|This is defined as either those who have had direct experience of liver disease as sufferers, or the carers of those who have had liver disease. Each individual receives an MRI (LiverMultiScan), with many also receiving a FibroScan.
2503472|NCT02877368||gastrointestinal stromal tumours|Patients with advanced or high-risk resected gastrointestinal stromal tumours (GIST) .
2503576|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
2503579|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
2503584|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: BC)|Stage 2 Biopsy Cohort (BC): Approximately 7 evaluable participants in the biopsy cohort in expansion phase will receive bevacizumab 5 mg/kg IV on Cycle 1 Days 1 and 15 (tumor biopsy on Cycle 1 Day 8) and cobimetinib (at dose determined during safety run-in phase) orally on Cycle 1 Day 15 to Cycle 2 Day 14 (tumor biopsy on Cycle 1 Day 22). From Cycle 2 onwards, participants will follow the same treatment regimen for bevacizumab and atezolizumab (optional tumor biopsy on Cycle 2 Day 22) as those in the safety run-in phase and expansion cohort, and for cobimetinib cycles start at Day 15 and will continue 21 days to Day 7 of next cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Biopsies must be collected before the initiation of cobimetinib and atezolizumab. Treatment will continue until disease progression according to RECIST v1.1, unacceptable toxicity, death, decision to withdraw, or pregnancy, whichever occurs first.
2503588|NCT02876224|Experimental|Cobimetinib + Bevacizumab + Atezolizumab (Stage 2: EC)|Stage 2 Expansion Cohort (EC): Approximately 14 participants will receive cobimetinib (at dose determined during safety run-in phase) orally once daily for Days 1-21 with atezolizumab 840 mg and bevacizumab 5 mg/kg administered by IV infusion on Days 1 and 15 of each 28-day cycle. Atezolizumab will be administered first, followed by bevacizumab, with a minimum of 60 minutes between dosing. Treatment will continue until the participant has disease progression according to RECIST v1.1, unacceptable toxicity, death, participant or physician decision to withdraw, or pregnancy, whichever occurs first.
2503606|NCT02876003|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
2503649|NCT02875873|Experimental|Plasma-Lyte, Slow Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
2503650|NCT02875886|Active Comparator|Diuretic treatment|Patients receive amiloride and hydrochlorothiazide
2503653|NCT02875886|Active Comparator|Low-sodium diet|Patients are put on a low-sodium diet (60 mmol/day)
2503654|NCT02875873|Experimental|Plasma-Lyte, Fast Infusion|Plasma-Lyte will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
2503657|NCT02875873|Experimental|Saline 0.9%, Slow Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h.
2503660|NCT02875873|Experimental|Saline 0.9%, Fast Infusion|Saline 0.9% will be used for fluid expansion and maintenance whenever needed and when there is no contraindication either for Plasma-Lyte or normal saline. Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h.
3163231|NCT00477776|Placebo Comparator|d|Placebo 10 mg 3 times a day for 7 days, 2 times a day for day 8 to 10; and once a day from day 11 to 12
2503739|NCT02875275|No Intervention|Glucose Solution only|Control drink containing 50 g carbohydrate
2503741|NCT02875275|Active Comparator|Glucose with grass jelly solution|Control drink plus 3.12 g grass jelly powder
2503743|NCT02875275|Active Comparator|Glucose with grass jelly (solid)|Control drink plus 3.12 g grass jelly powder in solid form
2503746|NCT02875275|No Intervention|Porridge and juice only|Control breakfast containing 50 g carbohydrate.
2503750|NCT02875275|Active Comparator|Porridge and juice with coconut oil|Control breakfast, plus 25g coconut oil
2503754|NCT02875275|Active Comparator|Porridge and juice with coconut oil gel|Control breakfast, plus 25g coconut oil gel
2503755|NCT02875288|Active Comparator|Plain Bupivicaine|"Post procedure, infiltrate wounds with plain bupivicaine~Plain Bupivacaine 0.25%, volume of 30 mL~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
2503789|NCT02874703||HIV-positive|
2503792|NCT02874703||HIV-negative|
2503821|NCT02874820|Experimental|Patient Group|Baseline PET scan followed by a blocked PET scan
2503233|NCT02878928|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|Medical providers for IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
2503234|NCT02878928|No Intervention|Control Group|Medical providers for the Control Group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
2503263|NCT02878473|Experimental|Liver transplantation|The intervention will consist of liver transplantation
2503308|NCT02878343|Active Comparator|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
2503309|NCT02878343|Active Comparator|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
2503311|NCT02878343|Active Comparator|Incentive and environmental strategies|A combination of incentives and environmental strategies
2503315|NCT02878343|No Intervention|Usual care|Standard employee wellness benefits
2503362|NCT02877940|Active Comparator|ProSeal Laryngeal mask airway|ProSeal will be inserted in mechanically ventilated patients undergoing elective surgeries.
2503364|NCT02877940|Active Comparator|Laryngeal Tube Suction- Disposable|LTS-D will be inserted in mechanically ventilated patients undergoing elective surgeries.
2503365|NCT02877940|Active Comparator|Group I|i-gel will be inserted in mechanically ventilated patients undergoing elective surgeries..
2503410|NCT02877563||Patients with PAD|Patients with PAD who are to undergo surgical or percutaneous revascularization.
2503440|NCT02877290|Experimental|cycling test first with NIV, then without NIV|patients in this arm will perform their first constant work rate test while using NIV and the second constant work rate test without NIV
2503443|NCT02877290|Experimental|cycling test first without NIV, then with NIV|patients in this arm will perform their first constant work rate test without NIV and the second constant work rate test with NIV
2503511|NCT02876952|Active Comparator|Attention Control Group (AC)|Moderate to high- intensity physical activity and Mediterranean Diet recommendations
2503512|NCT02876952|Experimental|HV-HIIT|"Supervised high volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity [heart rate (HR) values up to second ventilatory threshold (VT2) to peak intensity] interval training and high-volume increasing gradually from 20 to 40 min and alternating high and moderate [HR values between first ventilatory threshold (VT1) and VT2] intensities at different protocols."
2503513|NCT02876952|Experimental|LV-HIIT|"Supervised low volume and high intensity interval training exercise group with Mediterranean Diet recommendations.~High-intensity (HR values up to VT2 to peak intensity) interval training and low-volume (20 min) alternating high and moderate (HR values between VT1 and VT2) intensities at different protocols."
3163232|NCT00477802|Experimental|Botox|Randomized into receiving Botox first. At cross-over, patients will receive placebo.
3163233|NCT00477802|Placebo Comparator|Placebo|Randomized to receive placebo first. At cross-over, patients will receive the active Botox.
3163234|NCT00477815|Experimental|Rituximab + Zevalin|Determine the dose level that is both tolerable and achieves the greatest B cell recovery in patients with multiple myeloma.
2503601|NCT02876484|Experimental|Colesevelam x 2|plus (on another study day) 3,75 g colesevelam administered the evening before the experiment. Morning meal: brown bread, margarine, cheese, yoghurt, oatmeal, raisins, almonds, water, PCM. Colesevelam (3,75 g) dissolved in 25 ml water and mixed in 25 ml yoghurt.
2503664|NCT02875782|Experimental|DM intervention|Subjects will receive a patient-centered motivational intervention with two components: (1) the stage-matched smoking cessation intervention and (2) the relationship between smoking and diabetic complications. All subjects will receive a self-help cessation manual with DM components and take the exhaled carbon monoxide test. The total counseling process will take about 20 minutes. Three consecutive (3-, 6- and 12-month) follow ups will be conducted. Also, the counselor will further the progress of their action plan and barriers encountered in the behavioral change process as well as engage them in the process, enhance their self-efficacy, and identify individual barriers and facilitators.
2503666|NCT02875782|Placebo Comparator|Control group|Subjects will receive usual care provided at the DM clinic. All subjects will receive a self-help cessation manual and take the exhaled carbon monoxide test. Counselor will give follow-up calls to the patients to assess their smoking status and other health-related lifestyle practices. Three consecutive (3-, 6- and 12-month) follow ups will be conducted with all participants. The total counseling process will take about 20 minutes.
2503744|NCT02875912|No Intervention|Usual Care|Family members are surveyed at enrollment, day 5 (if patient is still in ICU), and 90 days post ICU discharge for symptoms of PTSD, depression, and anxiety as well as for concordance of care at enrollment and ICU day 5. Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed to establish baseline data
2503747|NCT02875912|Experimental|Family Care Rituals Intervention|At enrollment, family members are given a handout/pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so. The families are then surveyed in the same way as they were during the usual care, with nursing completing the same surveys as well to compare against the baseline data
2503749|NCT02875288|Experimental|Liposomal Bupivicaine arm|"Post procedure, infiltrate wounds with liposomal bupivacaine~Liposomal Bupivacaine (Brand name Exparel) 266 milligram (mg)/20 mL to be diluted to 30 mL with normal saline~10 mL of study drug to be injected at each 10-12 millimeter (mm) trocar site and 5 mL of study drug to be injected at the 5 mm trocar sites. Typically there are two 10 mm trocar sites and three 5 mm trocar sites."
2503765|NCT02874898|Active Comparator|Heavy marijuana use|Heavy marijuana users with PTSD
2503766|NCT02874898|Active Comparator|No marijuana use|Non-marijuana users with PTSD
2503908|NCT02873845||PATIENT|Patients with colon cancer
3163235|NCT00477854|Experimental|Visual Analogue Scale Ratings|Food intake data and its coefficients, including total food intake, food not eaten, duration of the meal, and bite rate. A mixed model analysis of variance will also be conducted on ratings of food cravings and eating atttudes. Changes in hunger and satiety ratings between, before, and after the meals will be compared for difference across treatment conditions.
2503235|NCT02879214|Experimental|SIDE cervical trial|To Maximal downstage locally advanced squamous cell cervical cancer before minimal invasive surgical resection. The SIDE study is to use both RT dose escalation to the biological target defined by PET and Chemo dose escalation composited with two drugs to achieve maximal reduction of tumor burden, providing feasibility of minimal invasive surgical resection.
3196307|NCT00849095|Experimental|as needed medication|patients assigned to this arm will take bid inhaled placebo plus prn inhaled 160/4.5 mcg budesonide/formoterol combination
2503318|NCT02878044|Experimental|Implementation Arm|
2503406|NCT02877797|No Intervention|standard Esophagogastroduodenoscopy|standard Esophagogastroduodenoscopy
2503412|NCT02877797|Experimental|cap assisted Esophagogastroduodenoscopy|cap assisted Esophagogastroduodenoscopy
2503461|NCT02877355|Experimental|Semaglutide|
2503520|NCT02876848|Experimental|Intervention Site|"The hospital that will be the intervention site will have access to the OPTIMUM e-health tool. The intervention site cancer care team will receive the following OPTIMUM e-health alerts:~An electronic alert of increased Adjuvant Endocrine Therapy discontinuation risk.~An adherence to Adjuvant Endocrine Therapy monitor.~An electronic discontinuation occurrence alert"
2503526|NCT02876848|No Intervention|Control Site|The hospital that will be the control site will not have access to the OPTIMUM e-health tool. The cancer care team will continue to deliver care according to standard processes.
2503560|NCT02876380||Prospective cohort|These are women who are currently pregnant and who have a LQTS mutation. This also includes women whose partner/father of the baby has a LQTS mutation. If the father of the child has the LQTS mutation, the father will also be enrolled.
2503562|NCT02876380||Retrospective cohort|In this cohort the investigators will collect information about previous pregnancies affected by the LQTS mutation. Parents may enroll in both retrospective and prospective cohorts
2503646|NCT02875600|Experimental|Nutri drink|MRI flow measurements of mesenterial vessels and portal vein before and after stimulation with nutritional drink
2503693|NCT02876107|Experimental|Group A (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 1 hour on day 1 of cycle 0 and over 30 minutes on days 1, 8, and 15 of cycles 1-4. Patients also receive paclitaxel IV over 1-3 hours on days 1, 8, and 15 of cycles 1-4, and carboplatin IV over 30 minutes on day 1 of cycles 1-4. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
2503696|NCT02876107|Experimental|Group B (paclitaxel, carboplatin)|Patients receive paclitaxel, carboplatin, doxorubicin, and cyclophosphamide as in Group A. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unexpected toxicity.
3196308|NCT00849095|Active Comparator|guideline treatment|bid inhaled 160/4.5 mcg budesonide/formoterol combination plus prn 500 mcg terbutaline
3196309|NCT00849134|Placebo Comparator|Cohort 1,2 & 3|This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing the study drug. Effects will be compared to those seen when a placebo is taken. Up to 3 groups of 8 healthy male and female volunteers may be enrolled.
3196310|NCT00849134|Active Comparator|Cohort 4|If an investigation of food effect is not possible in Cohorts 2 or 3, this Cohort will be used to check if there is a difference in the blood levels of the study drug when taken with or without a high fat meal.
2503778|NCT02874976|Experimental|Experimental: Group A|"Active and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before aerobic training, and the same program 1 after training"
2503779|NCT02874976|Experimental|Experimental: Group B|"Active and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before aerobic training, and program 2 after training."
2503780|NCT02874976|Experimental|Experimental: Group C|"Placebo and Active Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before aerobic training, and program 1 after training."
2503781|NCT02874976|Experimental|Experimental: Group D|"Placebo and Placebo Phototherapy The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
2503798|NCT02874586|Experimental|Plasma exchange combination of immunosuppressive regimens|Plasma exchange(once) ,with the following standard immunosuppressive regimens for the remission of auto-immune hepatitis
2503799|NCT02874716|Experimental|Tuberculosis Program (PPIA)|In Patna, 171 of the 321 participants were randomly selected to be sensitized and engaged into the program in Phase 1, and subsequently to receive the benefits of the PPIA intervention. Providers in the PPIA arm if engaged into the program will receive the benefits of the program, including but not limited to: ability to provide presumptive TB patients and TB cases vouchers for free or subsidized diagnostic testing and free first line anti-TB treatment (TB cases only); reimbursements for subsidized tests and anti-TB treatment; financial incentives to providers based on certain indicators; training opportunities, and access to a referral network.
2503804|NCT02874716|No Intervention|No Tuberculosis Program (Non-PPIA)|The remaining part of the sample in Patna selected randomly will be phased into the program at least a year after the PPIA arm in Phase 2. However, during the year of the study, they will not be engaged into the program.
3196311|NCT00849160|Experimental|Darunavir/r|
2503818|NCT02874547|Experimental|Intervention|Patients will receive five visits with a CHW during a 6 month period (two in-person and three by telephone). At the first visit, patients will meet the CHW who is trained in motivational interviewing techniques to deliver coaching to work on behavioral changes and introduce a 60 minute Digital Video Disc of five patient stories of individuals who have managed to control their hypertension.
3196312|NCT00849199||High risk of breast or ovarian cancer|
2503825|NCT02874547|Other|Delayed Intervention|Patients will receive print materials at time of consent and randomization. Four to six months after randomization, DI patients will receive an invitation to schedule an in-person visit at the health center to begin receiving the intervention protocol.
2503279|NCT02878512|Experimental|PCNL under Segmental epidural Anesthesia|epidural space was located at T12 -L1 or L1-L2 space .The epidural catheter was inserted cephalad 5 cm upwards in the epidural space (tip approximately at T8 to T9). and test dose of 3 ml of 2% Adrenalized Lignocaine was administered..loading dose of 0.5% Bupivacaine, approximately 8 to 10 ml was injected epidurally with regular negative aspiration to block T6- T12 segments, if desired level was not achieved then additional dose of 1 to 1.5 ml 0.5% bupivacaine per spared segment was given to achieve the desired level.Motor blockade of the lower limbs was checked and noted before lithotomy, before prone and at the end of the surgery using Bromage scale. After two segment regression of sensory level epidural top up with 1/4th of initial dose 2 to 3 ml of 0.5% Bupivacaine was given. At the end of the surgery 8ml of 0.125% Bupivacaine was administered for postoperative analgesia and the catheter was removed.
2503300|NCT02878187||placenta previa|all women managed by conservative surgical techniques during cesarean section after intraoperative hemorrhage due to placenta previa/accreta
2503301|NCT02878187||healthy controls|women delivered by Cesarean for any other indication with no intraoperative hemorrhage or any additional surgical techniques performed during Cesarean
2503356|NCT02878005|Active Comparator|Intubating laryngeal Tube Suction|Intubating laryngeal Tube Suction
2503359|NCT02878005|Active Comparator|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
2503433|NCT02877407|Other|laparoscopic/robotic-assisted hysteropexy|patient who undergo laparoscopic/robotic-assisted hysteropexy
2503434|NCT02877407|Other|vaginal hysterectomy|patient who undergo vaginal hysterectomy
2503437|NCT02877069|Experimental|VYC-12 Injectable Gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection on Day 0 in the face and if applicable neck areas. Participants are eligible to receive up to 3 treatments including an optional top-up and an optional second treatment.
2503495|NCT02876991|Other|Sodium fluoride PET|"Before inclusion, patients undergo choline PET to assess an occult recurrence of prostate cancer.~After inclusion, they undergo sodium fluoride PET."
2503503|NCT02876653|Other|Severe OSA|Patients with severe OSA (AHI > 30)
2503505|NCT02876653|Other|Moderate OSA|Patients with moderate OSA (5 < AHI ≤ 30)
2503506|NCT02876653|Other|Healthy volunteers|Healthy volunteers (AHI ≤ 5)
2503536|NCT02876549|Experimental|G6PD Normal|
2503539|NCT02876549|Experimental|G6PD Deficient|
2503672|NCT02875457|Placebo Comparator|Arm B|Patients receive etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, and placebo, repeated every 21 days, a total of 6 cycles, and then continue to take placebo until PD.
2503694|NCT02876263||Study group|Elective and emergency surgery for aneurysm or dissections of the ascending aorta, operated under extracorporeal circulation, protective deep therapeutic hypothermia and circulatory arrest.
2503695|NCT02876263||On-pump CABG Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease under extracorporeal circulation
2503697|NCT02876263||OPCAB Group|Elective coronary artery bypass grafting (CABG) for coronary heart disease with a beating heart
2503722|NCT02875132|Experimental|pembrolizumab|
3196313|NCT00849264|Experimental|A|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar
3196314|NCT00849264|Active Comparator|B|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with CBP and 5-FU
3196315|NCT00849264|Experimental|C|PLC patients with PVTT underwent hepatectomy and portal thrombectomy followed by portal vein chemotherapy with endostar, CBP and 5-FU
2503783|NCT02874963|Active Comparator|Surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (without initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Intervention:~Procedure: Surgery (Tooth Extraction)"
2503784|NCT02874963|Active Comparator|Surgical and non-surgical periodontal treatment|"Type 2 Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Non-Diabetes Patients with periodontitis (with initial non-surgical periodontal therapy) at least one tooth extraction will be performed.~Interventions:~Procedure: Surgery (Tooth Extraction)~Procedure: Non-surgical periodontal therapy-full mouth scaling and root planing (FM-SRP) with ultrasonic device and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus, post operative rinsing thrice a day for 3 weeks."
2503803|NCT02874807|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg once daily for four days
2503806|NCT02874807|Placebo Comparator|Placebo|Treatment with Placebo once daily for four days
2503819|NCT02874521|Experimental|Intra-dialytic LF-EMS|Performed twice weekly whilst seated on a standard dialysis chair. Delivered by adhesive electrodes in a neoprene garment, applied bilaterally to the quadriceps and hamstrings. Cardiovascular stimulus via rapid, rhythmical, sub-tetanic contractions. Short bursts of four pulses repeatedly delivered by stimulator at a frequency of 4Hz. Current amplitude adjustable from 40 - 200 mA with inbuilt controller. Conducted for one hour at the maximum tolerable intensity. Five minute warm-up and cool down at a lower frequency (3 Hz).
2503824|NCT02874521|Experimental|Intra-dialytic cycle training|Semi-recumbent cycling performed twice weekly whilst seated on a standard dialysis chair. Performed for up to one hour per session, initially at a workload (Watts) equivalent to that achieved at 40-60% VO2 reserve during cardiopulmonary exercise test. Exercise intensity regulated using a combination of heart rate and rating of perceived exertion (12-14). Workload adjusted weekly and controlled with a combination of pedal resistance and cadence to provide a personalised exercise prescription. Five minute warm-up and cool down each session.
2503826|NCT02874677|Experimental|Experimental|Effort reeducation program : 3 sessions of 20 minutes per week during 6 weeks
2503827|NCT02874521|No Intervention|Usual care|Continuation of dialysis treatment without the addition of an intra-dialytic exercise intervention.
2503829|NCT02874482||Patients with schizophrenia|30 patients with schizophrenia (diagnosis based on the standard DSM criteria)
2503831|NCT02874482||Controls|30 healthy controls without any psychiatric or neurological diagnosis
2503837|NCT02874378|Placebo Comparator|control group|0.9%NaCl solution 0.1ml/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
3196316|NCT00849303|Experimental|earlier gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
2503385|NCT02877849||Individuals with Alcohol Use Disorder|Individuals with Alcohol Use Disorder will be recruited from Lodging Plus treatment program (Fairview Riverside Hospital, Minneapolis, MN). All patients will have between 2-3 weeks of abstinence from alcohol use. We will collect brain imaging data, this is an observational study.
2503386|NCT02877849||Healthy Volunteers|Healthy volunteers with comparable age and gender to the patient group will be recruited through community advertisements. We will collect brain imaging data, this is an observational study.
2503449|NCT02877173|Experimental|Alprostadil Liposomes for Injection|Alprostadil Liposomes for Injection at low dose:20ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at medium dose:40ug,once a day,continuous administration for 3 weeks; Alprostadil Liposomes for Injection at high dose:60ug,once a day,continuous administration for 3 weeks;
2503454|NCT02877173|Active Comparator|Alprostadil Injection|Alprostadil Injection:10ug,once a day,continuous administration for 3 weeks;
2503515|NCT02876822|Experimental|Vitamin D|Enrolled subjects will receive one observed oral vitamin D dose (based on current vitamin D status and rounded to the nearest 5000IU) within 2 weeks prior to their HSCT.
2503554|NCT02876393||Cases|Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
2503557|NCT02876393||Control definition|Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
3196317|NCT00849303|Active Comparator|later gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.
2503670|NCT02875587|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
2503673|NCT02875587|Experimental|Calcium gluconate infusion group|Calcium gluconate is administered starting on the day of HCG administration.
2503683|NCT02875418|Experimental|EUM and tocodynamometry|Pregnant women with gestational age 24+0/7 to 33+6/7 weeks of gestation and contractions, cramping, pelvic pressure or backache.
2503712|NCT02875197||Healthy Controls|"Males and females 18-50 years old~Up to 20 able-bodied sex, age, height, and weight-matched subjects"
2503714|NCT02875197||Lower Extremity Amputees|"Males & females 18-50 years old~Must have a unilateral, transtibial amputation & must have been prescribed a running-specific prosthesis~Subject with amputations resulting from trauma, congenital reasons, or cancer treatment unless cancer is in remission or treatments do not impact gait function~Physician approval to run~4 months experience using a running-specific prosthesis"
2503768|NCT02874950|Experimental|Office exercise training|A package of exercise raining was defined by the researcher and one of the intervention group did it for 6 months.
2503769|NCT02874950|Experimental|Ergonomic modification|The ergonomic group, followed 6 months ergonomic modification.
2503771|NCT02874950|Experimental|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months ergonomic modification.
2503772|NCT02874950|Experimental|Control|Control group did not do any exercise and did not follow any ergonomic modification.
2503787|NCT02874599|Experimental|Patients|Patients who require multiple dental restorations. Teeth will be restored with commercial restorative composites
2503788|NCT02874638|Experimental|BASE egg protein|0.8 g/kg/d of BASE protein provided as crystalline amino acid made after egg protein.
2503790|NCT02874638|Experimental|BCAA-enriched egg protein|branched-chain amino acid-enriched egg protein
2503793|NCT02874638|Experimental|small amount of essential amino acids|small amount of essential amino acids made after egg protein, which is equivalent to the amount of essential amino acids in BASE
2503795|NCT02874638|Experimental|large amount of essential amino acids|large amount of essential amino acids made after egg protein, which is equivalent to the amount of amino acids in BCAA
2503808|NCT02874872|Experimental|OASIS Collaborative|The nursing homes in this arm will receive facilitated implementation of two tools aimed at minimizing unnecessary antibiotic use. Facilitated implementation includes coaching of the nursing home staff on use of the tools. In addition, nursing home management will be coached on how to monitor implementation fidelity, antibiotic utilization, and consequences to over- and under-utilization of antibiotics as feedback on the effectiveness of the intervention. Finally, nursing home management will receive coaching on how to develop and implement a sustain plan for the OASIS intervention.
2503811|NCT02874872|No Intervention|Control|The nursing homes in this arm will continue care as usual, with no tools or facilitated implementation.
3196318|NCT00849316||A|
3196319|NCT00849329|Experimental|Period 1|1250mg lapatinib once daily in the morning
2503830|NCT02874495||Healthy volunteers|22 persons.
2503832|NCT02874664|Experimental|Rovalpituzumab Tesirine|0.3 mg/kg rovalpituzumab tesirine intravenously on Day 1 of every 6-week treatment cycle for 2 cycles omitting every third cycle
2503833|NCT02874495||Patients with Crohn's disease|22 patients.
3196320|NCT00849329|Experimental|Period 2|1250mg lapatinib once daily in the morning in combination with esomeprazole 40mg once daily at bedtime.
2503836|NCT02874378|Experimental|study group|Dexmedetomidine will be pumped at 0.3μg/kg•h during the operation till 30 minutes before the operation complete. Standard anaesthesia and standard cure are given for all patients.
2503844|NCT02874391||AV fistula group|
2503845|NCT02874391||Control group|
3196321|NCT00849342||A|
3196322|NCT00849355|Experimental|unique|RCOMP-14 with Rituximab
3196323|NCT00849368|Experimental|Azathioprine / Allopurinol|Single arm study: Dose escalations as described.
3196324|NCT00849394||1|Shortened infusions of bevacizumab
3196325|NCT00849407||1|melanoma patients
2502660|NCT02882997|Experimental|Duck Duck Punch|"Community dwelling stroke survivors: Stroke survivors will install an interactive computer game in their home. Subjects will be instructed to play the computer game as much as you want to every day for 7 days. Inpatient stroke patients: The interactive computer game will be installed at a local inpatient stroke rehabilitation hospital. Subjects will be instructed to play this game as much as you want to during non-therapy hours (evenings and weekends) over the next 7 days."
2502663|NCT02882997|Active Comparator|Standard activities|"Community dwelling stroke survivors: Subjects will receive a hard-copy handout of an arm home exercise program and given the instructions to do these exercises as many times as you can daily. Inpatient stroke patients: Subjects will be encouraged to participate in standard evening/weekend recreational activities and to remember to use the paretic arm as much as you can."
2502728|NCT02882581|Experimental|11C-metformin|All participants allocated to the study will be included in this arm
2502821|NCT02882165|Experimental|Intervention arm|Participants receive a comprehensive medical review by a Respiratory Clinical Fellow.
2502825|NCT02882165|No Intervention|Control arm|Participants receive usual care as required via their primary care practice.
2502961|NCT02881177|Experimental|Oxytocin|Oxytocin 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
2502965|NCT02881177|Placebo Comparator|Placebo|Placebo 40 International Units (IU) intranasal administration prior to six Motivational Interviewing Group Therapy (MIGT) sessions.
2503015|NCT02880605||appropriate in appropriate indications|
2503016|NCT02880605||inappropriate in appropriate indications|
2503018|NCT02880605||appropriate in inappropriate indications|
2503019|NCT02880605||inappropriate in inappropriate indications|
3163236|NCT00477854|Experimental|Consuming less Lunch allows consumption of more dinner|Test whether chromium picolinate supplementation affects food cravings, eating attitudes, and satiety in healthy, overweight and/or obese, adult women who are determinded to be carbohydrate cravers. Whether participants who eat less at a lunch test meal consume more food at an ad lib dinner test meal with a diversity of foods.
2503089|NCT02879903|Experimental|biofilm tobacco effect|Group smokers - patients will receive periodontal treatment and biofilm will be collected.
2503092|NCT02879903|Experimental|biofilm non smoker effect|Group Non Smokers - patients will receive periodontal treatment and biofilm will be collected.
2503144|NCT02879643|Experimental|Cohort A: Marqibo and UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~Dexamethasone orally twice daily on days 1-5 and 15-19.~Mitoxantrone: given by intravenous (IV) infusion on days 1 and 2.~PEG-asparaginase: given as an injection into the muscle on says 3 and 17.~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
2503149|NCT02879643|Experimental|Cohort B: Marqibo and lower intensity UK ALL R3 backbone|"Marqibo®: given by intravenous (IV) infusion on days 1, 8, 15 and 22.~Dexamethasone orally twice daily on days 1-5 and 15-19.~PEG-asparaginase: given as an injection into the muscle on days 3 and 17.~Methotrexate IT: given intrathecally (used to treat the brain and spinal cord and is given using a needle inserted into the spinal canal) on days 1 and 8."
2503163|NCT02879643|Experimental|Cohort C: Marqibo and maintenance regimen|"Marqibo®: given by intravenous (IV) infusion on day 1~Dexamethasone orally twice daily on days 1-5~Methotrexate: given orally on days 1 and 8~Mercaptopurine: given orally daily on days 1-13"
2503243|NCT02878850|Experimental|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
2503246|NCT02878850|No Intervention|Conventional Blood Pressure|Subjects will have their blood pressure kept in a normal range.
2503265|NCT02878434||Study group|
2503267|NCT02878434||control group|
2503537|NCT02876627|Experimental|breast cancer|Effect of exercise training on breast cancer patient
2503602|NCT02876211|Experimental|paricalcitol plus epoetin beta|Paricalcitol 2 capsules /three times per week & epoetin
2503603|NCT02876211|Placebo Comparator|placebo plus epoetin beta|Placebo 2 capsules/three times per week & epoetin
2503708|NCT02875795|Experimental|speech intelligibility|speech intelligibility is registered by an automatic speech processing tool
2503751|NCT02875041|Experimental|Transcranial Magnetic Stimulation (TMS) MAGSTIM Rapid2 Therapy|TMS is a non-invasive device that employs the use of a magnet on the scalp to measure and potentially modulate cortical excitability. The use of TMS for Parkinson's treatment is experimental.
2503756|NCT02875041|Active Comparator|MAGSTIM Rapid2 Therapy System|MAGSTIM Rapid2 Therapy System has been FDA cleared for the treatment of refractory depression.
2503796|NCT02874768|Experimental|dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
2503802|NCT02874768|Active Comparator|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
2503882|NCT02874352|Other|intensive care patients|intensive care patients with tracheostomy/ high resolution impedance manometry with Automated Impedance Manometry analysis
2503889|NCT02874352|Other|healthy volunteers|control group with healthy volunteers/ high resolution impedance manometry with Automated Impedance Manometry analysis
2504036|NCT02873130|Experimental|Behavioral: Telepractice Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) through West Chester University's Desire 2 Learn (D2L) software program. Synchronous and asynchronous learning opportunities are provided through D2L over a four week period. The GVPM includes vocal hygiene, vocal education, and vocal training.
2504157|NCT02872220|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products compared to that of a negative control [0.9% NaCl] were tested simultaneously on each subject.
3163237|NCT00477880|Experimental|Cetuximab|Cetuximab lV weekly at an initial loading dose of 400 ml/m2, followed by three weekly maintenance doses of 250 mg/m2. Four infusions of C225 will be defined as a course of therapy.
3163238|NCT00477893|Placebo Comparator|Placebo|
3163239|NCT00477893|Active Comparator|Adalimumab|
3163240|NCT00477906|Experimental|1|"MVax + BCG + cyclophosphamide + IL2~2:1 randomization - MVax:Control"
3163241|NCT00477906|Placebo Comparator|2|Placebo Vaccine + BCG + cyclophosphamide + IL2
3173662|NCT00614640|Experimental|2|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 42, and 84
2503875|NCT02874053||Healthy|Healthy Volunteers
3173663|NCT00614640|Experimental|3|Four 0.8 ml vaccine-containing patches placed on upper back or upper thigh for 24 hours on Days 0, 7, 42, 49, 84, and 91
3173664|NCT00614653|Experimental|Bevacizumab, Erlotinib + Capecitabine|Bevacizumab intravenous (IV) every 2 weeks at 5 mg/kg, Erlotinib 100 mg orally (PO) daily + Capecitabine 400 mg/m2 PO twice daily (BID) only on days of radiation. Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy.
2504022|NCT02873143||The APA2011 cohort|In September 2011, students at 4 upper secondary schools in Aalborg were invited to answer an online questionnaire and to be part of the APA2011 cohort. From 2846 potential responders, 2200 adolescents responded to the questionnaire, corresponding to a response rate of 77%. A total of 504 adolescents indicating knee pain at least monthly were successfully contacted (a response rate of 83% of those who reported their telephone numbers) and were asked standardized questions on the telephone. This forms the cohort of 504 adolescents with knee pain. In addition a random selected group of adolescents without knee pain in 2011 will be contacted and asked the same questions as those with knee pain.
2504060|NCT02873000|No Intervention|Routine Care Group|Routine Care (R): Standard of care therapy based on admitting diagnosis
2504062|NCT02873000|Experimental|Experimental Group|"Intervention 1 (E1): addition of incentive spirometry every hour while awake;~There will be a computerized protocol with specific instructions documenting:~compliance~patient position while using [sitting up vs laying flat in bed]~inspiratory volume attained~effort, motivation and compliance will subjectively be documented using a visual analogue 0-5 point scale."
2504104|NCT02872636|Experimental|Treatment Group|
2504146|NCT02872350|Experimental|Premature with necrotizing enterocolitis|
2504202|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 2 doses (Escalation Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
2504203|NCT02872025|Experimental|Pembrolizumab intralesionally (IL) x 4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 4 doses of pembrolizumab injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 4th dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
2504204|NCT02872025|Experimental|Pembrolizumab intralesional (IL) x 2 doses + intralesional mRNA 2752 x 2-4 doses (Expansion Phase)|Subjects, upon diagnosis with high risk DCIS, will be offered 2 doses of pembrolizumab and intralesional mRNA 2752 injected intralesionally (IL) 3 weeks apart (+/- 1 week) with surgery 3 weeks (+/- 2 weeks) after the 2nd dose. The subject will then undergo the surgical treatment as determined by the surgeon and the subject (partial mastectomy or mastectomy).
2504205|NCT02872025|No Intervention|No active treatment|The control group will proceed to surgery alone within a 4 month timeframe following the diagnosis of high risk DCIS.
2504435|NCT02870608|Experimental|preterm labor group|Pregnant women hospitalized for preterm labor
2504442|NCT02870608|Other|control group|Pregnant women with a normal pregnancy
2504556|NCT02869685|Other|a prospective, open,phase I clinical study|We have designed five kinds of radiation-division with bioequivalent doses, and detected the expression levels of PD-L1 in pExo after 24h, 48h of each stage of radiotherapy.
2504590|NCT02869373|Experimental|Exercise|spinal stabilization exercise program was applied
2504591|NCT02869373|No Intervention|Control|
2504624|NCT02869100|Experimental|Spondyloarthritis Patients|
2504678|NCT02868801|Placebo Comparator|Placebo|placebo, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2504679|NCT02868801|Experimental|Pregabalin SR tablet 165mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2504685|NCT02868801|Experimental|Pregabalin SR tablet 330mg/day|1pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2504689|NCT02868801|Experimental|Pregabalin SR tablet 660mg/day|2pills once ,one time a day in an hour after meals, oral administration for 14 weeks (2 week titration and 12-week fixed dose)
2504757|NCT02868268||Relapsed/Refractory Neuroblastoma Pts|History of high risk neuroblastoma (NBL) according to Childrens Oncology Group (COG) risk classification with relapsed/progressive, refractory or persistent neuroblastoma. Archival or biopsied tumor specimens are provided for gene panel sequencing to subjects with potentially targetable genetic and/or immunologic biomarkers. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receiving this clinical report.
2504856|NCT02867839|Experimental|A: postoperative Oxaliplatin plus S-1|"Patients in arm A will receive standard distal gastrectomy with D2 lymphadenectomy first, and 8 cycles of adjuvant Oxaliplatin plus S-1 (SOX) later.~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3W S-1: 40~60mg bid, po, d1~14, q3W (6 months)"
2504858|NCT02867839|Active Comparator|B: postoperative S-1 only|"Patients in arm B will receive standard distal gastrectomy with D2 lymphadenectomy first, and 16 cycles of adjuvant S-1 later.~S-1: 40~60mg bid, po, d1~14, q3W (12 months)"
2504884|NCT02867137||Mild TBI patients|
2504941|NCT02867033|Other|Study procedure|Tumor biobank realization (biopsy...) and biobank constitution. coloscopy associated with colonic chromoscopy. Blood sampling (facultative). Pain evaluation
2505065|NCT02866201|Experimental|Patient suffering from traveler's diarrhoea|Patient suffering form traveler's diarrhoea during a stay (up to 3 months) outside metropolitan France
2505117|NCT02865850|Experimental|Vadadustat|
2505124|NCT02865850|Active Comparator|darbepoetin alfa|
2545963|NCT02591602|No Intervention|CONTROLLI|X-ray hospital department
3173665|NCT00614666|Experimental|A|nikkomycin Z 50 mg BID versus placebo BID x 14 days
3173666|NCT00614666|Experimental|B|nikkomycin Z 250 mg BID versus placebo BID x 14 days
3173667|NCT00614666|Experimental|C|nikkomycin Z 500 mg BID versus placebo BID x 14 days
3173668|NCT00614666|Experimental|D|nikkomycin Z 750 mg TID versus placebo TID x 14 days
3173669|NCT00614679|Experimental|1|single arm trial of experimental catheter lock solution
3173670|NCT00614705|Experimental|1|
2503846|NCT02874417|Experimental|Psychoeducation|The program was designed to dispel exaggerated thoughts surrounding the danger of the experience of anxiety symptoms, specifically focusing on fears regarding feelings of cognitive dyscontrol. The psychoeducation portion contains video animation and audio narration throughout, as well as some interactive features . Participants are provided with corrective information about the experience of anxiety-related sensations, with a particular focus on dispelling myths commonly held by individuals with high anxiety sensitivity cognitive concerns . Participants are taught that anxiety-related sensations are not dangerous and that they may have developed a conditioned fear to these symptoms of arousal.
2503847|NCT02874417|Placebo Comparator|Health and Wellness|The controlled condition consisted Physical Health Education Training (PHET), a computerized presentation which focuses on information on general healthy living. The PHET program contains information on nutrition, alcohol, water consumption, exercise, sexual health, hygiene, stress management, life organization, social support, positive outlook, and sleep.
2503917|NCT02873637|Experimental|under sartorial catheter|catheter under sartorial
2503918|NCT02873637|Other|femoral catheter|femoral catheter
2503976|NCT02873533|Other|A-Elderly patients with cancer|geriatric care and longitudinal follow up
2504001|NCT02873234||Traditional Chinese Medicine|Including Zishui Qinggan Yin,Xiaoyao San, Longdan Xiegan Tang, Guipi Decoction, Ningshen Dingzhi Wan, HuangLian-EJiao decoction and Jiaotai Wan.
2504010|NCT02873234||TCM plus antidepressants|This is a integrative therapy that refers to a new treating system including TCM and antidepressants.
2504017|NCT02873234||Antidepressants|Antidepressants include Selective serotonin reuptake inhibitors (SSRIs), Norepinephrine-reuptake inhibitors and other antidepressants, such as Paroxetine, Citalopram, Venlafaxine, Sertraline, Trazodone, Maprotiline and so on.
2504075|NCT02872896|Experimental|ClearSight device|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the ClearSight device second by second throughout surgery.
2504079|NCT02872896|Sham Comparator|Non-ClearSight|Patients having orthopedic, urologic or general surgery will have blood pressure monitored by the Non-ClearSight (the clinical team) every 5 minutes throughout surgery.
2504109|NCT02872584||Prednisone|Patients with dermatological conditions requiring high dose long term glucocorticoid treatment
2504154|NCT02872259|Experimental|BGB324 + pembrolizumab|"BGB324 capsules, 200 mg once daily + pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
2504158|NCT02872259|Experimental|BGB324 + dabrafenib and trametinib|"BGB324 capsules: Dose finding part of the study will determine if 100 mg once daily should be used for main part of the study or if 200 mg once daily once daily should be used.~Dabrafenib capsules: 150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
2504162|NCT02872259|Active Comparator|pembrolizumab|"Pembrolizumab 2 mg/kg IV every 3. week~Treatment until disease progression, or unacceptable toxicity"
2504168|NCT02872259|Active Comparator|dabrafenib and trametinib|"Dabrafenib capsules:150 mg twice daily Trametinib tablets: 2 mg once daily~Treatment until disease progression, or unacceptable toxicity"
2504252|NCT02871765|Experimental|education group|In education group, each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department by researchers. Three months later, participants in the education group received a follow-up phone call in order to clarify any questions related to the brochure. All participants completed posttest at 6-month follow-up.
2504256|NCT02871765|No Intervention|control group|The control group received the brochure only.
2504282|NCT02871427|Experimental|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
2504343|NCT02871063||High altitude ARDS|ARDS diagnosed at altitudes greater than 1500 meters above sea level
2504345|NCT02871063||Sea level ARDS|ARDS diagnosed at altitudes below 1500 meters above sea level
2504476|NCT02870582|Experimental|Donafenib|Donafenib 300mg bid on 1-21 days of each 28 days cycle.
2504479|NCT02870582|Placebo Comparator|Placebo|Placebo 300mg bid on 1-21days of each 28 days cycle.
2504509|NCT02869906||FFR and iFR|The investigators compare FFR and iFR values in the acute phase of STEMI and in the subacute phase, 5-7 days after STEMI.
3173671|NCT00614705|Placebo Comparator|2|
3173672|NCT00614718||1|Total number of patients receiving an ICD between 1993 and 2004 and not having re interventions due to malfunctioning leads.
2504606|NCT02869243|Experimental|hrBMP4|Intra-tumour and interstitial convection enhanced delivery (CED) as a continuous infusion via intracranial catheters of hrBMP4 solution and gadolinium
2504645|NCT02868879||Schizophrenia|
2504646|NCT02868879||Normal controls.|
2504727|NCT02868619|Other|Healthy controls|Non obese adolescents without Binge Eating Disorder (BED)
2504729|NCT02868619|Other|Patients with BED|Obese adolescents with BED with Binge Eating Disorder (BED)
2504785|NCT02867982|Other|Subcrestal|implants that are placed below the alveolar ridge
2504786|NCT02867982|Other|Paracrestal|implants that are placed flush to the alveolar ridge
2504913|NCT02867111|Other|ICSI Control|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with no intervention of the Sperm Selection Assay
2504914|NCT02867111|Placebo Comparator|ICSI + SSA placebo|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with control solution (culture medium)
2504916|NCT02867111|Experimental|ICSI + SSA Attractant substance|Intracytoplasmic sperm injection (ICSI), an in vitro fertilization procedure in which a single sperm is injected directly into an egg, with intervention of the Sperm Selection Assay with attractant solution (attractant diluted in culture medium at 10 pM)
2504931|NCT02866747|Active Comparator|Arm A: radiation therapy alone|Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.
3173673|NCT00614718||2|Patients with ICD lead failure receiving a new ICD lead
3173674|NCT00614718||3|Patients with ICD lead failure but intact shock-coil of the ICD lead receiving only an additional pace/sense lead.
3175103|NCT00630123||2|Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
2503849|NCT02874469|Experimental|Group with diary (second period)|Intervention group = On top of usual care, an intensive care unit diary will be implemented for patients within the first 8 hours following their admission.
2503885|NCT02874040|Experimental|Experimental|endoresection of the tumor scar or, when surgery is not possible, transpupillary thermotherapy on the tumor scar
2503936|NCT02873715|Active Comparator|Usual Care (UC)|Usual Care will consist of the care typically delivered by the family's primary care provider for children with overweight or obesity. The implementations of UC may vary between providers but typically includes and assessment of the child's weight, help remove barriers to weight loss and introductions of goals for better weight management.
2503938|NCT02873715|Experimental|Family-based treatment (FBT)|Family- Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two yeart study
2504005|NCT02873364|Active Comparator|Vitamin D3 (Low dose)|Daily 600 unites of vitamin D + Cetirizine 10mg twice a day
2504012|NCT02873364|Experimental|Vitamin D3 (High dose)|Daily 4000 unites vitamin D + Cetirizine 10mg twice a day
3196326|NCT00849407||2|controls
3196327|NCT00849433||1|30 patients with asthma
2504145|NCT02872363|No Intervention|Control|The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment.
2504148|NCT02872363|Experimental|Intervention A - Behavioural Regulation|Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
2504151|NCT02872363|Experimental|Intervention B - Priority|Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment.
2504225|NCT02871908|Experimental|L reuteri DSM 17938|L reuteri DSM 17938 2 x 10^8 twice daily
2504227|NCT02871908|Placebo Comparator|Controls|Identically appearing placebo twice daily
2504315|NCT02871531|Experimental|Pneumatic retinopexy|Patients with retinal detachment allocated to pneumatic retinopexy
2504318|NCT02871531|Experimental|Vitrectomy|Patients with retinal detachment allocated to vitrectomy
2504366|NCT02870946|Experimental|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced.
2504367|NCT02870946|Experimental|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
2504456|NCT02870569|Experimental|Donafenib1|This is the lower dose group. Donafenib 200mg bid
2504463|NCT02870569|Active Comparator|Donafenib2|This is the higher dose group. Donafenib 300mg bid
2504519|NCT02869958|Active Comparator|1: Written action plan|Written action plan
2504521|NCT02869958|Experimental|2: Digital action plan|Written action plan + Digital action plan for asthma exacerbations Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
2504595|NCT02869568||Patients with ovarian cancer diagnosis|
2504648|NCT02869035|Experimental|Treatment of MDD patients|Treatment of MDD patients with escitalopram
2504650|NCT02869035|No Intervention|Healthy controls|No treatment.
2504652|NCT02869035|Experimental|Shift of treatment for MDD patients|Treatment of MDD patients with duloxetine
2504734|NCT02868528|Experimental|PGS group|After blastocyst culture, blastocyst embryo trophoblast biopsy will be performed and chromosome screening with NGS technology, at the same time, the blastocysts will be frozen, then the blastocysts with normal chromosome will be thawed and transferred.
2504740|NCT02868528|No Intervention|control group|After blastocyst culture, blastocysts will be transferred
2504772|NCT02868008|Experimental|fMRI guided AVM resection|fMRI guided microsurgical resection of brain AVMs
2504828|NCT02867774|Experimental|Intervention|This pilot study will enroll 25 women age 18-65 with greater than six months of noncyclic pelvic pain. Subjects will participate in an 8-week physical activity program specifically designed for patients with chronic pain and supervised by personal trainers and exercise physiologists in a rehab-focused, medically-based fitness center. Subjects will complete web-based assessment tools at the start of the program, immediately after completion of the 8-week program and four weeks after the conclusion of the program (at the 12-week time point).
2504890|NCT02867423|Other|A - CK boost radiation|CK boost radiation
2504942|NCT02867020|Active Comparator|Abiraterone acetate + Prednisone + ADT (Goserelin)|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250-mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~Goserelin administered as subcutaneous injections of 10.8mg every 3 months"
2504944|NCT02867020|Experimental|APALUTAMIDE monotherapy|o APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)
2504951|NCT02867020|Experimental|Abiraterone acetate + Prednisone + APALUTAMIDE|"Abiraterone administered at a single 1000 mg daily oral dose (4 x 250 mg tablets)~Prednisone administered at a 5 mg twice daily oral dose~APALUTAMIDE administered at a single 240 mg daily oral dose (4 x 60 mg tablets)"
2505018|NCT02866331|Experimental|CB + G-CSF|
2505022|NCT02866331|Placebo Comparator|CB + placebo|
2505026|NCT02866331|Experimental|G-CSF|
2505027|NCT02866331|Placebo Comparator|Placebo|
2505091|NCT02865902|Experimental|Test Group|In Test group, the free gingival graft donor sites of each experimental group received low-level laser therapy by Ezlase; Biolase® at doses of 8.6 J/cm2.
2505094|NCT02865902|Sham Comparator|Control Group|In Control Group, the low-level laser therapy by Ezlase; Biolase® was performedin a same manner with test group at free gingival graft donor sites. However, no irradiation was occurred because of not pushing the start button.
2545986|NCT02591394|Active Comparator|Usual Care|
3196328|NCT00849433||2|30 patients with COPD
3196329|NCT00849446||Activity monitoring in CVA patients|
3196330|NCT00849446||Activity monitoring in healthy persons|
3196331|NCT00849459|Experimental|adenovirus-mediated human interleukin-12|starting dose of ADV-hIL12 - 1 x 10 to the 10th power vp (virus particles) per patient, escalating in half-log increments up to 1 x 10 to the 13th power vp per patient, after which dose escalation will be at lower increments of 2 x 10 to the 13th power vp, to a maximum of 3.0 x 10 to the 13th power vp per patient.
3196332|NCT00849511|Active Comparator|Placebo first|Placebo 8 weeks, 6 weeks washout, extended-release melatonin 2 mg vesper for 8 weeks
3196333|NCT00849511|Active Comparator|Melatonin first|Extended-release melatonin 2 mg vesper for 8 weeks, 6 weeks washout, placebo 8 weeks
2503914|NCT02873793||7/8 cases pure seminomas|
2503915|NCT02873793||5 cases of non-seminoma|
2503916|NCT02873793||3 cases of composite tumours seminoma/non-seminoma.|
2503950|NCT02873546|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 minutes for 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
2503955|NCT02873546|Sham Comparator|sham tDCS on left DLPFC (F3)|Sham tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 minutes - 10 sessions. Anode is placed on the scalp facing on left DLPFC (F3) and cathode between Fp2-F8 EEG-repair.
2504003|NCT02873299|No Intervention|Treatment as usual|Treatment as usual, wait list control group
2504009|NCT02873299|Active Comparator|rTMS at 10Hz|10 Hz rTMS of the right dorsolateral prefrontal cortex
2504015|NCT02873299|Active Comparator|rTMS at 20Hz|20 Hz rTMS of the right dorsolateral prefrontal cortex
2504077|NCT02872974||Exposed|Offspring of woman with GDM
2504078|NCT02872974||Not exposed|Offspring of woman without GDM
2504170|NCT02872155|Experimental|Oral hydratation|
2504172|NCT02872155|Active Comparator|Endovenous hydratation|
2504193|NCT02871830|Experimental|Physical activity intervention group|
2504194|NCT02871830|No Intervention|Control group|
2504236|NCT02871726|Experimental|TRUS-Robot and TRUS|TRUS and TRUS-Robot will be used during prostate biopsy
2504245|NCT02871726|Active Comparator|Routine TRUS/Fusion biopsy|Just Uronav will be used during prostate biopsy
3196334|NCT00849537|Experimental|Triamcinolone|Injection of intravitreal Triamcinolone
3196335|NCT00849550|Experimental|XELOX-A-Ev|
3196336|NCT00849563|Active Comparator|SRA+genetic test|patients randomized to receive genetic test for type 2 diabetes risk will be followed and surveyed and will be counseled based on SAR and genetic risk for type 2 diabetes
2504421|NCT02870647|Other|Single arm study|only 1 arm - no comparison nor randomization in this study
2504437|NCT02870296|No Intervention|Control|The control group will receive usual care; no interventions will be administered.
2504444|NCT02870296|Experimental|Intervention|Interventions will be administered to this group. Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
2504501|NCT02870179||Healthy volunteer|Smoker or non-smoker
2504554|NCT02869607||Patients with breast cancer diagnosis|
2504610|NCT02869412|Experimental|Group I (BCG website)|Patients use the BCG website which will collect personal information including individual health priorities/goals, demographics (i.e. age, ethnicity), health information (i.e. weight, height, cancer history, other health conditions), individual capabilities, physical activity level, and exercise preferences. Patients then receive a report with a personalized physical activity plan.
2504615|NCT02869412|Active Comparator|Group II (passive website)|Patients use a passive website (American Cancer Society Guidelines on Nutrition and Physical Activity for Cancer Survivors).
2504695|NCT02868827|Experimental|Cholecalciferol|This group of patients will receive single high dose of vitamin D (Cholecalciferol) dissolved in 45 ml of fresh milk (Nestle)
2504697|NCT02868827|Placebo Comparator|Placebo|This group of patients will receive placebo - 45 ml of fresh milk (Nestle) so that the amount, color, smell, taste etc will be the same as that of experimental drug)
2504720|NCT02868320|Experimental|Intervention group|This group received a diabetes instruction booklet in addition to daily educational SMS messages and weekly reminders
2504724|NCT02868320|Active Comparator|Control group|This group only received a diabetes instruction booklet
2504817|NCT02867865|Active Comparator|Chemotherapy arm|"Post staging laparoscopy, all patients will receive chemotherapy using Injection Gemcitabine 1000 mg/m2 delivered day 1 and 8 every 3 weeks.~In addition, Injection Cisplatin 25 mg/m2 for and 4 cycles week 1 to week 11."
2504818|NCT02867865|Experimental|Chemoradiation arm|"Post staging laparoscopy in Experimental arm The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2). Radiotherapy will be for 5 weeks which will be followed by 2 cycles of chemotherapy with Injection Gemcitabine (Gemcite,Gemzar) 1000 mg/m2 delivered day 1 and 8 every 3 weeks and cisplatin (Cisplat, Cytoplatin) 25 mg/m2from week 7 to week 11.~During week 12-13 patients will undergo repeat PETCECT scan. If the scan shows partial or good response then patients will be evaluated for surgery. Surgery if possible will be done between weeks 13-15. In case of inoperable disease patients will receive further chemotherapy"
2503854|NCT02874183|Experimental|Pharmacist intervention group|"The intervention group will receive:~A phone call 48h-72h after discharge from the hospital to ensure that the patient filled their prescriptions and started taking their medication.~A phone call five to seven days after discharge to reinforce the education using the teach back technique1. Patients will be asked about their medications, what are they for, how to use them, and what side effects to watch for, based on the education and information that was provided to them at discharge."
2503856|NCT02874183|No Intervention|usual care group|The control group will receive the usual standard care available at West Kendall Baptist Hospital.
2503903|NCT02873988||patients with COPD|patients with COPD
2503904|NCT02873988||patients without COPD|patients without COPD
2503952|NCT02873663|Experimental|heavy drinkers|Plasma and head hair collection
2503957|NCT02873663|Experimental|teetotalers|Plasma and head hair collection
2503992|NCT02873403|Experimental|KNEEMO knee brace & Popular knee brace|Patients having medial knee osteoarthritis
2503994|NCT02873403|Experimental|Popular knee brace &KNEEMO knee brace|Patients having medial knee osteoarthritis
2504065|NCT02873078|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of cognitive behavior therapy (CBT). Parents will also receive 10 weekly modules. Main components in the children's modules are exposure for abdominal symptoms, feared stimuli and situations in which the children are afraid of having symptoms. The parental receive information on how they can support their children in the treatment and how to reinforce health y behaviors and decrease attention to pain behaviors. Therapist support is provided through written messages within the secure platform.
2504072|NCT02873078|No Intervention|Waiting list|This is a wait-list control where the children and parents are allowed to carry on with any contacts within the health-care system, exempt for psychological treatments.
2504103|NCT02872623|Experimental|experimental group|patients clinically suspected of having a tumor of the small intestine
2504136|NCT02872389|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2504143|NCT02872389|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2504231|NCT02871973|Experimental|SDP|Families randomized to intervention group will receive Sit Down and Play while they wait in the waiting room to be seen by their primary care provider at current and subsequent well-child visit.
2504242|NCT02871973|Active Comparator|CDC Handout|Families in the control group will receive the Center for Disease Control and Prevention (CDC) Handout at enrollment.
3196337|NCT00849563|No Intervention|SRA only|Patients randomized to not get genetic testing will be followed and surveyed and will be counseled based on SRA only
3196338|NCT00849563|No Intervention|no testing control|Patients not interested in genetic testing will be followed and surveyed. Counseling will be based on SRA only
2504427|NCT02870595|Active Comparator|Parallel lidocaine injection|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
2504432|NCT02870595|Sham Comparator|Parallel|In the sham comparator, the device will be placed on the skin, but not turned on. Digit block anesthesia will progress in usual fashion as with active comparator, except without the vibratory device engaged.
2504563|NCT02869672|Experimental|age of 18-50 years old, experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504565|NCT02869672|Active Comparator|age of 18-50 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504566|NCT02869672|Experimental|age of 7-17 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504568|NCT02869672|Active Comparator|age of 7-17 years old, control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504569|NCT02869672|Experimental|age of 2-6 years old,experimental|0.5 ml of Tiantan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504570|NCT02869672|Active Comparator|age of 2-6 years old,control|0.5 ml of Hualan Biology ACYW135 meningococcal polysaccharide vaccine will be given.
2504597|NCT02869282||Prospective cohort|Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
2504656|NCT02868970|Other|Community (2 in NB, 2 from NS)|There are four communities involved in the study, two in New Brunswick and two in Nova Scotia. All pharmacies in each community will be allocated to one intervention. Interventions include: High-Dose TIV, Meningococcal B Vaccine, Meningococcal ACWY vaccine, Tdap, Herpes Zoster vaccine and Travel Health vaccines (Hepatitis A, Hepatitis B, Typhoid Fever).
2504766|NCT02868190|Other|Two micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
2504811|NCT02867826|Experimental|Cap-assisted endoscopy|forward-viewing endoscope with a Cap attached at the tip
2504859|NCT02867592|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib-s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2504961|NCT02866708|Experimental|Intermittent negative pressure (INP) therapy|"At baseline, the participants will be randomized into 2 groups: 1) INP therapy or 2) control with no INP therapy.~The 1) patients randomized to INP therapy will start with 8 weeks INP therapy two hours per day divided into timed sections (1-3 times per day or use the device as many times as practical for the individual as long as the total time is two hours). After 8 weeks of INP therapy, final measures will be performed at the Vascular lab before the participants starts their 8-week control period."
2504971|NCT02866708|No Intervention|Control|The participants randomized to control will continue their usual wound care for 8 weeks without INP therapy. The control group will start INP therapy after 8 weeks. After 8-weeks without intervention, the participants allocated to the control-group will be asked to start with INP therapy for 8 weeks before a final examination. The participants in the control group will receive vascular assesment at baseline, week 8 (end of control).
2505002|NCT02866513|Other|Patient mechanically ventilated with APRV mode|
2505030|NCT02866162||patients with neutropenia|
2503857|NCT02874079|Active Comparator|no bullous pemphigoid|patients with basal cell carcinoma or squamous cell carcinoma and without inflammatory skin disease
2503905|NCT02873975|Experimental|Homologous Repair (HR) Deficiency|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2503906|NCT02873975|Experimental|Replicative Stress|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2503907|NCT02873975|Experimental|CCNE1 Amplification|Prexasertib (LY2606368) will be administered as an IV infusion on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour.
2503930|NCT02873650|Experimental|Group 1 - Control group|
2503940|NCT02873650|Experimental|Group 2-Moderate hepatic impairment|
2503944|NCT02873650|Experimental|Group 3-Severe hepatic impairment|
3196339|NCT00849576|Active Comparator|Regular Human Insulin|Single Injection
3196340|NCT00849576|Active Comparator|Inuslin Lispro (90%)|Single Injection
2504083|NCT02872779|Experimental|Patients Treated for Metastatic Colorectal cancer|Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer
2504111|NCT02872493||RYGB|Roux-en-Y Gastric Bypass - these are patients that undergo a Roux-en-Y gastric bypass operation for their bariatric operation.
2504112|NCT02872493||VSG|Vertical Sleeve Gastrectomy - these are patients that undergo a vertical sleeve gastrectomy operation for their bariatric operation.
2504152|NCT02872233|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
2504183|NCT02871999|Active Comparator|Control group|This group receives normal treatment after surgery,with no acupuncture.
2504184|NCT02871999|Experimental|Experimental group|This group receives acupuncture therapy besides normal treatment after surgery. The acupuncture therapy starts after 24 hours of surgery, 1 time a day, 30 minutes every time, until the fifth day.
2504220|NCT02871752|Experimental|MBSR (Mindfulness condition)|MBSR (mindfulness-based stress reduction) is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations. Lesson activities include the following: (1) mindful meditation (e.g., awareness of breathing, body scan, sitting, walking); (2) yoga; and (3) group discussion.
2504221|NCT02871752|Active Comparator|HealthPro (Control Matched Condition)|HealthPro is a health promotion program designed by Dr. David Victorson of Northwestern University Medical Social Sciences Department and his research team to function as a matched control for the MBSR intervention in this research study. The program teaches and promotes healthy behaviors, skills, and lifestyles. Major learning themes include: (1) health behavioral change readiness and self-assessment; (2) physical activity, movement, and non-sedentary lifestyles; (3) dietary and nutritional considerations for optimal health; (4) emotional wellness and coping with difficulties; (5) social engagement, relationships intimacy, and health; (6) managing bodily pain; (7) weight management and weight loss strategies; (8) health behavior maintenance over the long-term.
3196341|NCT00849576|Experimental|Insulin VIAject™ (75%)|Single Injection
3196342|NCT00849576|Experimental|Insulin VIAject™ (90%)|Single injection
3196343|NCT00849589|No Intervention|1|Treatment as Usual (TAU)
2504429|NCT02870257|Experimental|Progressive overload strengthening group|"Strengthening protocol with progressive load~Strengthening muscle exercises for the shoulder and scapular with progressive increase of load during 10 weeks (20 sessions)"
2504438|NCT02870257|Active Comparator|Strengthening group|"Strengthening protocol without progressive load~Strengthening muscle exercises for the shoulder and scapular without increase of load (minimal load) during 10 weeks (20 sessions)"
2504498|NCT02870153|Experimental|SOX(oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
2504500|NCT02870153|Active Comparator|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
2504593|NCT02869542||Patients with lymphoma diagnosis|
2504670|NCT02869048||ALS patients|Patients diagnosed with ALS will be included in this group. Blood and spinal fluid samples will be stored in biobank and later analyzed. A subset of this group (20 ALS patients) will give blood and spinal fluid every 6 months during progression of the disease. A subset of 10 will donate a muscle biopsy.
2504671|NCT02869048||Control group with patients with other neurological disease|Patients referred to hospital with symptoms of acute or chronic headache.
2504673|NCT02869048||Neurologically healthy control group|Patients having orthopaedic surgery performed in spinal anaesthesia.
2504737|NCT02868437|Active Comparator|Group 1|The patients who are having curettage for retained product after second trimester abortion will also receive an intervention of intrauterine self-cross-linked hyaluronic acid gel after the procedure
3196344|NCT00849589|Experimental|2|Computerized Screening and Brief Physician Advice (SBA)
3196345|NCT00849589|Experimental|3|Computerized screening and brief physician advice with technological extenders (SBA/TE)
3196346|NCT00849602|Placebo Comparator|1|
3196347|NCT00849602|Active Comparator|2|
3196348|NCT00849615|Experimental|FLOT|
3196349|NCT00849628||1|Constipation
3196350|NCT00849641||1|patients with decompensated liver cirrhosis admitted to the medical ICU
3196351|NCT00849641||2|critically ill patients without liver cirrhosis, matched to group 1
3196352|NCT00849641||3|healthy control group
3196353|NCT00849654|Experimental|PCI-32765|
3196354|NCT00849667|Active Comparator|1|Carboplatin and taxane with MORAb-003 1.25 mg/kg
3196355|NCT00849667|Active Comparator|2|Carboplatin and taxane with MORAb-003 2.5 mg/kg
3173675|NCT00614731|Experimental|ID immunizations (100 mcg)|Participants will receive a total of two 100 mcg intradermal (ID) KLH carrier-protein immunizations with 1 mg/ml KLH per immunization. Immunizations will be given 21 days apart at Visits 5 and 6.
3196356|NCT00849667|Placebo Comparator|3|Carboplatin and taxane with Placebo
2503931|NCT02873949|Other|1. Periodontitis patients|30 patients consulting at Odontology department for periodontal treatment
2503941|NCT02873949|Other|2. Control|10 patients not affected by periodontitis consulting at Odontology department for checkup of teeth state and/or scaling
2504020|NCT02873351|Experimental|carbidopa-levodopa 25-100 mg|Treatment with carbidopa-levodopa 25-100 mg tablets dosed once daily at bedtime for 45 +/- 5 days followed by carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
2504021|NCT02873351|Placebo Comparator|Placebo for carbidopa-levodopa 25-100 mg|Treatment with placebo for carbidopa-levodopa 25-100 mg in identical tablets dosed once daily at bedtime for 45 +/- 5 days followed by placebo for carbidopa-levodopa 25-100 mg tablets dosed 3 times daily for 45 +/- 5 days.
3196357|NCT00849706||Study group|Medical staff personal, doctors and nurses, working night shifts.
2504119|NCT02872376||Anemic|Anemic patients
2504156|NCT02872181|Experimental|BMI <30|Pregnant women undergoing C/S with BMI <30
2504161|NCT02872181|Experimental|BMI 30-40|Pregnant women undergoing C/S with BMI 30-40
2504166|NCT02872181|Experimental|BMI >40|Pregnant women undergoing C/S with BMI >40
2504224|NCT02871817||Normal Vision|Patients without significant vision deficit (20/20 vision), when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2504226|NCT02871817||Age-related macular degeneration|Patients presenting with dry AMD or neovascular (wet) AMD, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2504228|NCT02871817||Diabetic retinopathy|Patients presenting with Diabetic Retinopathy, when eligible and providing informed consent, assigned to evaluation with Paxos Checkup Study Mobile Medical Application
2504297|NCT02871362|Experimental|IQP-AS-118|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
2504300|NCT02871362|Placebo Comparator|Placebo|To be taken once daily with a glass of water. The tablets should not be chewed, but swallowed whole.
2504340|NCT02871050||Castleman Disease Patients|Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease.
2504402|NCT02870777|Experimental|MRD-directed therapy|
2504428|NCT02870426||Group 1A:|Donors after brainstem death (DBDs) undergoing solid organ donation
2504436|NCT02870426||Group 1B:|Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
2504445|NCT02870426||Group 2:|Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
2504581|NCT02870062|Experimental|Chlorhexidine|Intervention: daily baths with chlorhexidine wipes, oral spray and shampoo. This arm will receive daily bathing with chlorhexidine wipes at 2% (CLORHEXI-WIPES ONE-STEP, G70 Antisepsis, León, México) plus an oral spray application of chlorhexidine chlorhydrate at 0.12%. For scalp washing, a chlorhexidine shampoo at 0.12% concentration will be applied.
2504585|NCT02870062|Placebo Comparator|Placebo|Intervention: daily baths with placebo wipes, oral spray and standard shampoo. This arm will receive wipes with the same components as arm #1 plus an oral spray application with the same components except chlorhexidine. For scalp, a standard shampoo will be used. These products will have the same labels and smell as the products in arm #1.
2504625|NCT02869126|Experimental|Patients|Patients with abnormalities of myocardial perfusion detected with stress tomoscintigraphy, undergo double isotope myocardial tomoscintigraphy using Thallium-201 and 99mTc-sestamibi and traditional myocardial tomoscintigraphy using 99mTc-sestamibi with a semiconductor camera
2504677|NCT02868814|Experimental|330mg/day|330 mg QD taken orally,1 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2504680|NCT02868814|Experimental|495mg/day|495 mg QD taken orally,2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2504684|NCT02868814|Placebo Comparator|Placebo|1 or 2 pills once ,one time a day in an hour after meals, oral administration for 15 weeks (3 week titration and 12-week fixed dose)
2504781|NCT02867969|Other|Motor training|The motor training comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
2504844|NCT02867735|Experimental|LKA651|
2504846|NCT02867735|Sham Comparator|Sham Comparator|
2504915|NCT02867241|Experimental|Intervention|"Motivational interviews (3 visits) + supportive phone calls~Feedback of child hair nicotine levels~Feedback of home air quality (PM2.5)~New Media (Website and/or Facebook with information and parental forum)"
2504917|NCT02867241|Other|Control Regular|This group will get no intervention during the study period. Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
2504918|NCT02867241|Other|Control Expanded|This group will get no intervention during the study period. However, participants will fill out a detailed questionnaire on parental perceptions of exposure and risk, as well as questions on social norms, self-efficacy, and knowledge Following the close of the study, participants in this group will receive a shortened version of the intervention (1 motivational interview, with feedback on child hair nicotine levels and feedback on home air quality (PM2.5))
2504952|NCT02866825|Active Comparator|IFX-1|dose escalating single i.v. administration of IFX-1 (verum)
2504959|NCT02866825|Placebo Comparator|Placebo|dose escalating mimicing single i.v. administration of placebo
2505036|NCT02866383|Experimental|Nivolumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT and then every 2 weeks (q2w), for a maximum of 52 weeks
2505149|NCT02865486|Experimental|Lipid emulsion: visit 2|One of four randomly assigned lipid emulsions
2505150|NCT02865486|Experimental|Lipid emulsion: visit 3|One of four randomly assigned lipid emulsions
2503860|NCT02874209|Experimental|Patient with amyotrophic lateral sclerosis|ALS patients with, spinal and bulbar form, certain or probable diagnosis according to the revised El Escorial criteria will go through the MRI sodium
2503861|NCT02874209|Placebo Comparator|Healthy volunteer|Healthy Volonteer apparied for sexe and age with selected ALS patients will go through the MRI sodium
3196358|NCT00849719|Experimental|1|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient.
3196359|NCT00849719|Active Comparator|2|Patients in this arm will be administered with only boluses of 1.5 mg/bolus of MO, by request.
3196360|NCT00849732|Experimental|1|V520 (1x10^9 vp/d)
2504308|NCT02871245|Active Comparator|Comparator Group|Patients received gastrointestinal neoplasms laparoscopic surgery but no acupuncture therapy.
2504310|NCT02871245|Experimental|Acupuncture Therapy Group|Patients received gastrointestinal neoplasms laparoscopic surgery and acupuncture therapy. Finish surgery up to 24 hours electricity acupuncture treatment, treatment 1 times a day, every time lasted 30 minutes, 5 days in a row
2504338|NCT02870998|Experimental|Active learning|Educational strategies will be used to foster active learning.
2504339|NCT02870998|Active Comparator|Passive learning|Traditional educational strategies (lecture) will be used.
2504408|NCT02870764|Active Comparator|Dan-shen extract|Based on the standard medical care, 200mg of Danshenduofensuanyan, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours, once a day during the patients' hospitalization. Danshen drop spill (30 pill/day) taken orally for 60 days after discharge.
2504409|NCT02870764|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 200mg of glucose, added into 250ml of 0.9% saline injection, given by continuous IV infusion at 2.5ml/min within 2 hours.
2504450|NCT02870322|Active Comparator|Fruit and Vegetable CSA Prescription|"Study participants randomized to the CSA group will be expected to pick up their weekly CSA box at University Health Services and to commit to using and consuming as much of the produce as they are able. CSA group participants will also be required to attend two cooking and food preparation classes coordinated by Slow Food UW. The classes will teach study participants how to properly clean and prepare the fruits and vegetables from a weekly CSA box, and also offer techniques and show them how to cook the foods in a healthy manner. These classes will also educate study participants on the benefits of eating fruits and vegetables and buying them from local farmers. These two classes will only exist for study participants in this fruit and veggie CSA group. Participants in the CSA group will also be required to take a field trip to the farm providing their CSA share, which will offer the opportunity for participants to gain a better understanding of from where their food comes."
2504461|NCT02870322|Active Comparator|Bikeshare Prescription|"Study participants randomized to the bikeshare group will be expected to use B-cycle bikes for transportation and/or recreation as much as is safe and appropriate. Bikeshare group participants will be required to attend one bicycle use/safety course. This course will introduce the B-cycle program, demonstrate use of the B-cycle station, provide information use of helmets and safety gear, and provide information on the basics of cycling and keeping yourself safe and comfortable while riding in traffic. The study participants in this group will also be required to attend a class on the benefits of exercise, including bicycling, among other forms of physical activity. This class will be offered by the University Health Services Wellness program. B-cycle usage, including estimated distance traveled and frequency of use, will be tracked via the B-cycle Madison website."
2504468|NCT02870322|No Intervention|Control|"Study participants in the control group will receive continued usual care from University Health Services providers, which includes educational brochures on healthy eating and exercising, plus a cash payment. Control group participants are not part of a wait-list group."
2504520|NCT02869945|Other|COMT HH|COMT HH gene
2504524|NCT02869945|Other|COMT HL|COMT HL gene
2504530|NCT02869945|Other|COMT LL|COMT LL gene
2504587|NCT02869464||Patients presenting with IA|These patients will undergo an abdominal ultrasound (Imaging - Ultrasound) to test for abdominal aortic aneurysm(s). RNA, DNA testing will be planned on banked samples
2504588|NCT02869464||Patients presenting with AAA|These patients will undergo a non-contrast enhanced magnetic resonance angiogram (MRA) (Imaging - MRA) to test for intracranial aneurysm(s). RNA, DNA testing will be planned on banked samples
2504635|NCT02869074||VWD Spanish Cohort|"Patients with previously diadnosis of VWD from approximately 38-40 different centers from Spain.~Samples from these patients will be analyzed locally, and also centrally for VWF and VWFgene"
2504674|NCT02868723|No Intervention|Control; standard of care|All the subjects enrolled in this arm will receive counseling as the usual standard of care by the stroke neurologists. These will include procedures and guidelines as approved by American Heart Association (AHA), follow up and guidance as offered by Hamad General Hospital's policies.
2504675|NCT02868723|Active Comparator|Intervention; Lifestyle counselling: Behavioural|Subjects in this group will receive a more detailed guidance on rigorous management of stroke and will be provided assistance from a stroke trained nurse and pharmacist additional to the counseling offered by the Stroke Neurologist.
2504749|NCT02868424|Experimental|fRPE cells|Subretinal transplantation of fRPE cells in experimental eye
2504796|NCT02867943||respiratory rate is 10 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2504800|NCT02867943||respiratory rate is 12 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2504802|NCT02867943||respiratory rate is 14 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
2504806|NCT02867943||respiratory rate is 16 breaths/min|"GapCO2=Pv-aCO2 = PvCO2 - PaCO2;~Effects of venous-to-arterial CO2 tension difference after increased respiratory rate."
3196361|NCT00849732|Experimental|2|V520 (1x10^10 vp/d)
3196362|NCT00849732|Placebo Comparator|3|Placebo to V520
2504955|NCT02866968|Experimental|Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|All patients included will undergo FLAPS in one eye.
2503866|NCT02874430|Experimental|Treatment (metformin hydrochloride, doxycycline)|Patients receive metformin hydrochloride orally daily on days 1-3 and twice a day starting on day 4. Patients also receive doxycycline orally every 12 hours starting on day 1. Treatment repeats every 7 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2504059|NCT02873065|Experimental|Ilaprazole|Ilaprazole -based quadruple therapy for 7days：Ilaprazole -based quadruple therapy for 7days: Ilaprazole 5mg bid.
2504063|NCT02873065|Active Comparator|Esoprazole|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid.
2504117|NCT02872597|Experimental|Treatment|Inhaled ipratropium bromide 250mcg given via nebulization every 6 hours for up to 5 days
2504118|NCT02872597|Placebo Comparator|Placebo|Inhaled normal saline 1.25mL given via nebulization every 6 hours for up to 5 days
2504289|NCT02871271|Experimental|IQP-AS-121|To be taken once daily dosing of 1 tablet in the morning.
2504350|NCT02871141||ECT group|Patients with a major depressive episode treated with ECT. Patients will be investigated (i) prior to the 1st ECT session, (ii) after the 4th ECT session, (iii) after the 12th ECT session, and (iv) 6 months after the 1st ECT session.
2504356|NCT02871141||Antidepressant group|Patients with a major depressive episode treated with antidepressants. Patients will be investigated (i) prior to treatment, (ii) after 10 days of treatment, (iii) after 4 weeks of treatment, and (iv) after 6 months.
3173676|NCT00614731|Experimental|Scarification by 3 jabs|Participants will receive two scarification immunizations by 3 jabs containing 20 mg/ml of KLH carrier-protein. The immunizations will occur 21 days apart at Visits 5 and 6.
3173677|NCT00614731|Experimental|ID immunizations (250 mcg)|Enrollment will begin after the safety data for Groups 1A and 2A have been reviewed. Participants in this group will receive two 250 mcg ID KLH vaccinations containing 10 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
2504410|NCT02870543|Placebo Comparator|Placebo|Placebo
2504411|NCT02870543|Active Comparator|Phytolacca decandra|The Phytolacca decandra with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2504412|NCT02870543|Active Comparator|Melissa officinalis|The Melissa officinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2504413|NCT02870543|Experimental|Phyt.decandra + Melissa offic.|The combination of Phytolacca decandra with Melissa offcicinalis with 12CH dosage will be administered (one drop per age of the child) once a day during 30 days.
2504517|NCT02869828|Other|monitoring by arterial catheter and Spot-on|
2504525|NCT02869828|Other|monitoring by oesophagus tube and Spot-on|
2504553|NCT02869620||Patients with thyroid cancer diagnosis|
2504582|NCT02869386|Experimental|STEMO deployment|STEMO is a specialized stroke ambulance providing prehospital neurovascular expertise, a CT scanner, point-of-care testing, and telemedical support.
2504583|NCT02869386|Active Comparator|Regular care|Regular prehospital care consists of an ambulance. In suspected life-threatening cases an emergency physician is sent to the emergency scene in parallel.
2504628|NCT02869113|Experimental|Sunscreen agent A + control|Application of control and test product into one of the subjects two eyes.
2504630|NCT02869113|Experimental|Sunscreen agent B + control|Application of control and test product into one of the subjects two eyes.
2504632|NCT02869113|Experimental|Sunscreen agent C + control|Application of control and test product into one of the subjects two eyes.
2504642|NCT02868749|Experimental|Hyaluronic Acid filler 1 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 1, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 1, 5 to 9 days before the surgery"
2504898|NCT02867436|No Intervention|Conventional diet|Conventional diet
3173678|NCT00614731|Experimental|Scarification by 15 jabs|Enrollment will begin after the safety data from groups 1A and 2A has been examined. Participants in this group will receive a total of two scarification immunizations by 5 needles used to administer 15 jabs, each containing, 20 mg/ml of KLH carrier-protein. Immunizations will occur 21 days apart at Visits 5 and 6.
3173679|NCT00614757|No Intervention|2|One half of the patients will take not medication for 30 days and then have labs redrawn
3173680|NCT00614757|Experimental|1|one half of the patients with insulin resistance will take 4ml of 20% N-acetylcysteine BID for 30 days
3173681|NCT00614770|Experimental|1|Standard White Light Colonoscopy
3173682|NCT00614770|Experimental|2|High Definition White Light Colonoscopy
3173683|NCT00614770|Experimental|3|Narrow Band Imaging Colonoscopy
3173684|NCT00614796|Experimental|1|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
3173685|NCT00614796|No Intervention|2|daily physical activity is assessed at baseline, 3 months, 9 months and 15 months. No counseling.
3173686|NCT00614809|Experimental|1|non-randomized open-label uncontrolled phase II trial
3173687|NCT00614835|Experimental|1 patients with completely resected uterine leiomyosarcoma|Docetaxel plus Gemcitabine
3173688|NCT00614848|Experimental|1|Endeavor Drug Eluting Coronary Stent
3173689|NCT00614848|Active Comparator|2|Driver bare-metal coronary stent
3173690|NCT00614861||001|
3173691|NCT00614887||2|Patients scheduled for elective cerebral aneurysmal surgery
3173692|NCT00614887||1|Patients with subarachnoid hemorrhage
3173693|NCT00614952|Experimental|PR|
3173694|NCT00614952|Active Comparator|PSG|
3173695|NCT00614965|Experimental|1|IC
3173696|NCT00614965|Experimental|2|PC
3173697|NCT00614978|Experimental|I|Lapatinib plus temozolomide
3173698|NCT00615004||1-SSA|All patients receiving first-line depot SSA treatment, with either octreotide-LAR or lanreotide, achieving control of the disease, and with available follow-up after 12 months of treatment.
3173699|NCT00615004||2-Surgery|All patients treated with first-line surgery via trans-sphenoidal route by microscopic and/or endoscopic approach, who did not require any additional therapy for acromegaly and with available follow-up after 12 months of treatment
3173700|NCT00615043||TURBT group|Subjects undergoing transurethral resection of bladder tumor or other transurethral biopsy procedure who agree to provide bladder tissue specimens
3173701|NCT00615082|Experimental|Mindfulness-Based Stress Reduction|
2503867|NCT02874326|Experimental|Active comparator: Octreotide LAR|Sandostatin LAR Sandostatin LAR 20 mg will be administered once every 4 weeks as a intramuscular injection
2503929|NCT02873858|Active Comparator|1.independent patients|
2503932|NCT02873858|Experimental|2. less mobile patients|
2503939|NCT02873858|Experimental|patient in a residence|
2503943|NCT02873858|Experimental|patients in a home for the elderly (EHPAD)|
2503998|NCT02873494||PHYSIOFLOW PF05 Lab1TM|Impedance cardiography
2504159|NCT02872298|Experimental|Treatment|Treatment: Targeted Lung Denervation (TLD)
2504222|NCT02871791|Experimental|Palbociclib, Everolimus, Exemestane|"Palbociclib will be administered orally, once daily for 21 consecutive days followed by a 7-day rest (28-day cycle)~Everolimus will be administered orally, once daily on a 28 day schedule~Exemestane will be administered orally, once daily on a 28 day schedule~Participants will be treated with increasing/decreasing doses of palbociclib and everolimus to establish MTD(s)/RP2D for both drugs in the setting of the triple combination of palbociclib, everolimus and exemestane"
2504321|NCT02871505|Experimental|Molecular subtyping (14d/f) of Treponema pallidum|Benzathine Penicillin G treatment
2504323|NCT02871505|Experimental|Molecular subtyping (others) of Treponema pallidum|Benzathine Penicillin G treatment
3173702|NCT00615082|Active Comparator|Caregiver Education & Social Support|
3173703|NCT00615095||1|Cases will be patients 18 years or older with a histologically confirmed, second or multiple primary melanoma.
2504455|NCT02870231|Experimental|NNC9204-0530 / Placebo and Liraglutide 1.8|
2504464|NCT02870231|Active Comparator|NNC9204-0530 /Placebo and Liraglutide 3.0|
2504667|NCT02869022|Experimental|Custodiol-N|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
2504668|NCT02869022|Active Comparator|Custodiol|comparison of two perfusion solutions, Custodiol-N versus Custodiol, in heart transplantation
2504739|NCT02868450|Experimental|Patients with HLA-DQB1 06 and/or HLA-DRB 13|
2504774|NCT02868021|Placebo Comparator|NO-EX group|Subjects allocated to the No Exercise (NO-EX) group will undergo: Strength testing, Short Physical Performance Battery (SPPB), Six-minute walk (SMW), Numerical pain scale, Self-assessed function and Six-minute walk (SMW) test. Intra-op muscle biopsies.
2504778|NCT02868021|Experimental|EX-BFR group|Subjects allocated to the EX-BFR group will undergo baseline strength testing, Short Physical Performance Battery (SPPB), Numerical pain scale, Six-minute walk (SMW), Self-assessed function, and determination of 1 Repetition Maximum (1-RM). Blood flow restriction exercise, Borg Category Ratio 10 (Borg CR10) scale. Intra-op muscle biopsies.
2504868|NCT02867475|Other|A|Physical activity motivation
2504908|NCT02867189|Experimental|atlas of micro-instrument|anterior chamber cell counts and visual and intraocular pressures on postoperative days 1,3,7,14 by atlas of micro-instrument training method.
2504912|NCT02867189|No Intervention|traditional training|anterior chamber cell counts and visual and intraocular pressures on postoperative days1,3,7,14 by traditional training method.
2504930|NCT02866916|Experimental|Dose escalation|"The standard method 3+3 will be used for dose escalation: the first 3 patients will be treated at level 1; consecutive cohorts of 3 to 6 patients will be treated with increasing doses of SXL01.~Treatment will be administered until patient experiences unacceptable toxicity, PSA raising, progressive disease and/or treatment is discontinued at the discretion of the investigator or withdrawal of consent.~Additional patients will be included at the Recommended Phase II Dose (RP2D) in the expansion phase."
2504996|NCT02866669|Active Comparator|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
2504998|NCT02866669|Experimental|Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
2505000|NCT02866669|Experimental|Peer coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
2505001|NCT02866669|Experimental|Peer coach and Practice facilitation|Practices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. The patients will also be matched with peer advisors who will work with the participants for 12 months.
2505114|NCT02866097|Experimental|Intervention|mHealth inventory management and referrals via text messaging plus supportive supervision of CHWs via an mHealth strategy
2505122|NCT02866097|Placebo Comparator|Control|ICCM current standard of care with CHWs operating under standard conditions without enhanced inventory management or supportive supervision by mHealth
2505186|NCT02865421|Experimental|Stem cells|adipose tissue derived stromal vascular fraction was used
2505189|NCT02865421|Experimental|platelet rich plasma|platelet rich plasma isolated after centrifugation from the pt was transplanted
2505261|NCT02864966|Other|Other|This is a safety study where a marketed product will be placed on healthy adult skin.
2505323|NCT02864641|Experimental|TX Group: Planet K Treatment|Participants in the TX Group will receive access to Planet K. Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Adolescent and young adult participants will then receive a mobile phone preloaded with the Planet K app and a brief orientation to the app and associated website.
2505328|NCT02864407||Vahelva group|Korean patients with COPD who are newly prescribed with Vahelva Respimat
3173704|NCT00615095||2|Controls will be patients 18 years or older with a histologically confirmed first primary melanoma diagnosed no earlier than 12 months prior to the study start date.
2503870|NCT02874443|Experimental|Intervention centers|"Application of a knowledge translation strategy, of new clinical practice guidelines on labor management, to physicians and nurses caring for women in labor.~Intervention centers will receive knowledge translation of labor management guidelines"
2503872|NCT02874443|No Intervention|Control centers|No intervention at control centers
2503924|NCT02873910|Experimental|IQP-AS-119|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
2503933|NCT02873910|Placebo Comparator|Placebo|One tablet to be taken daily with any meal, with a glass of water. They should not be chewed, but swallowed whole.
2504007|NCT02873520|Experimental|Precision Cells combined with Chemotherapy treatment:|Precision cells combined with Chemotherapy treatment: Chemotherapy: once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
2504011|NCT02873520|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
3175104|NCT00630136||A|Adult parent or legally authorized representative (LAR) of child who has consented to undergo an out-patient endoscopy at Children's Mercy Hospital as a diagnostic procedure
3175105|NCT00630149|Experimental|1|
2504120|NCT02872454|Experimental|Text Messaging|
2504230|NCT02872077|Active Comparator|Auricular Acupuncture|Study subjects randomized to this group will receive auricular acupuncture: the investigator will evaluate the infant using an ear point locator to determine active sites, and will place acupuncture needles in the active sites found in one ear. Acupuncture sites will be alternated every 3 days between right and left ear.
2504235|NCT02872077|No Intervention|Control|The subjects randomized to the control group will have NO interventions, and will continue to receive routine care for NAS, pharmacologic and non-pharmacologic, per NICU protocol.
2504299|NCT02871518|Experimental|Two cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22)combine with IMRT
2504301|NCT02871518|Active Comparator|Three cycle CCRT|Concurrent cisplatin(100mg/m2,D1,D22 and D43)combine with IMRT
2504328|NCT02871024|Experimental|Intervention arm|Usual care with two sessions of 2-hour hemoperfusion with Toraymyxin in 24 hours apart
2504393|NCT02870907|Experimental|Low risk group|
2504394|NCT02870907|Experimental|Intermediate risk sub group 1|2 cycles (4 courses): 2 courses of etoposide and Carboplatin from D1 to D5 and Vincristin at D22 and D26- Cyclophosphamide from D22 to D26.
2504396|NCT02870907|Experimental|Intermediate risk sub group 2|2 courses of Vincristin and Carboplatin
2504398|NCT02870907|Experimental|High risk group|"Orbital irradiation~3 cycles of two different types of alternating chemotherapy courses (id 6 courses) :~Etoposide (100 mg/m²/d) and Carboplatin (160 mg/m²/d) with intrathecal Thiotepa injection.~Vincristin (1,5 mg/m²/d) - Cyclophosphamide (1000 mg/m²/d)~Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamide.~High dose chemotherapy :~Carboplatin (AUC : 7/d) - etoposide (250 mg/m²/d) - Thiotepa (300 mg/m²/d)~Peripheral bood stem cell transplantation."
2504496|NCT02870088|Active Comparator|Prolonged Sitting|Participants sat on a chair during the trial.
2504497|NCT02870088|Experimental|Breaking Sitting|Participants walked regularly during the trial.
2504654|NCT02868983|Experimental|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
2504659|NCT02868983|No Intervention|Co-Location|A Behavioral Health Clinician (BHC) such as a psychologist or counselor is housed in or near the primary care practice.
2504747|NCT02868567|Experimental|Ampyra|Ampyra open label
2504810|NCT02867904|Placebo Comparator|Group A|After arthroscopic surgery the control group (Group A) will undergo a subacromial marcaine injection (standard of care).
2504812|NCT02867904|Experimental|Group B|After arthroscopic surgery the experimental group (Group B) will undergo a subacromial corticosteroid injection+marcaine.
2504849|NCT02867540|Experimental|experimental group|Patient's with Crohn's disease who have had ileocolic resection
2504879|NCT02867267|Experimental|thymosin alpha 1|1ml subcutaneous injection with 1.6 mg thymosin alpha 1, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
2504886|NCT02867267|Placebo Comparator|Placebo|1ml subcutaneous injection with placebo, every 12±2 hours for not more than 7 days depending on the change of the subjects' condition
2504967|NCT02866786|Active Comparator|OCP only arm|OCP containing 35 microgram ethinyl estradiol and 2 milligram cyproterone acetate to taken from the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill. OCP to be taken for 6 months.
2504974|NCT02866786|Active Comparator|Metformin arm|Metformin 500mg bid in morning and evening after meals to be taken for 6 months.
2505044|NCT02866461||Fibromyalgia|No treatment
2505107|NCT02866045|Active Comparator|EUS-guided Fine Needle Biopsy|EUS-FNB is performed using a 22 or 25 G SharkCore biopsy needle with a minimum of 3 passes into the lesion.
2505110|NCT02866045|Experimental|Single incision needle knife biopsy|SINK biopsy is performed under direct endoscopic visualization via EGD with a minimum of 3 biopsy samples obtained.
2505245|NCT02865148|Experimental|Cognitive behavioral therapy (CBT) group|Participants will receive 4 sessions that lasts approximately 50 mins. The sessions will teach patients to manage their symptoms.
3175106|NCT00630188|Experimental|1|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with physician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
3175107|NCT00630188|Active Comparator|2|Highway Safety video
3175108|NCT00630201|Experimental|Probuphine|buprenorphine implant
3175109|NCT00630214|No Intervention|C|No supplements after total thyroidectomy and central neck dissection
3175110|NCT00630214|No Intervention|D|No central neck dissection group (total thyroidectomy alone)
3175111|NCT00630214|Active Comparator|A|Oral calcium plus vitamin D supplements after total thyroidectomy and central neck dissection
2503884|NCT02874287|Other|Hydroxychloroquine|Subjects are treated with hydroxychloroquine sulfate tablets.All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
2503891|NCT02874287|Other|placebo|Subjects are treated with placebo tablets. All the subjects are treated with guideline-based secondary prevention of coronary heart disease medications.
2503947|NCT02873676|Experimental|nutritional intervention|This group received multi-dimensional intensive nutritional intervention for 3 month, which included whey (30g/d,plus three times every week ),vitamin D (1000IU) and omega-3 fatty acid (DHA 1200mg and EPA 800mg).
2503956|NCT02873676|Experimental|resistance training program|This group received resistance training program which is made up warm-up exercise, muscle strength training and relaxing.
2503959|NCT02873676|Experimental|lifestyle modification project|This group receive multi-dimensional intensive nutritional intervention and resistance training program.
2503961|NCT02873676|Placebo Comparator|control|This group receive nutritional consulting,which involve dietary pattern modification and protein intake standardization.
2504006|NCT02873260|Experimental|TetraVax-DV-TV005 + rDEN3Δ30|Participants will receive the TetraVax-DV-TV005 vaccine at Day 0 and the rDEN3Δ30 virus at Day 180.
2504013|NCT02873260|Placebo Comparator|Placebo + rDEN3Δ30|Participants will receive placebo at Day 0 and the rDEN3Δ30 virus at Day 180.
2504050|NCT02872883|Experimental|Expectant management and minimal vaginal examinations|Expectant management up to approximately 96hours and vaginal examinations only when necessary during active labour
2504051|NCT02872883|Experimental|Expectant management and routine vaginal examinations|Expectant management up to approximately 96hours and routine vaginal examinations during active labour
2504053|NCT02872883|Experimental|Active management and minimal vaginal examinations|Induction of labour at approximately 24hours and vaginal examinations only when necessary during active labour
2504054|NCT02872883|Active Comparator|Active management and routine vaginal examinations|Induction of labour at approximately 24hours and routine vaginal examinations
2504107|NCT02872610|Experimental|Self-help Online|6 weeks of internet-based self-help intervention
2504108|NCT02872610|No Intervention|Wait-list|Waiting list control condition
3196363|NCT00849745|Experimental|Systemic Lupus Erythematosus|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Satisfy the American College of Rheumatology (ACR) criteria for the diagnosis of SLE~Have Lupus nephritis, refractory and severe seizures or encephalopathy, severe pulmonary involvement, transfusion-dependent cytopenias, catastrophic antiphospholipid syndrome or vasculitis and/or immune complex deposition causing end-organ signs or symptoms.~Have received a trial of corticosteroids equivalent to prednisone greater than or equal to 0.5 mg/kg/d for at least one month~Have received a trial of IV cyclophosphamide pulse greater than 500 mg/square meter at least once within the previous 6 months, unless contraindicated because of severe cytopenias or intolerance."
2504238|NCT02871921|Experimental|Conversational Engagement|Participants engage in 30-minute face-to-face communications with study staff through internet/webcam 4 times per week for 24 weeks (6 months). Under an exploratory aim, a limited number of participants will be further followed by sustaining dose of 2 times per week of 30 minutes session for additional 24 weeks (6 months). Conversational staff will facilitate content-standardized but naturalistic-style social engagement. Staff and participants will engage in conversation about a wide variety of topics that are culturally and personally relevant and interesting to participants. Each day, participants will be able to choose from topic options. Participants will also receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions.
2504246|NCT02871921|No Intervention|Control Group|Participants will receive a phone call once per week that lasts approximately 10 minutes; interviewers ask brief questions to monitor participant social activities and health conditions
2504316|NCT02871466|Experimental|stem cells infusion|
2504373|NCT02870712|Experimental|suture directed|The suture of the perineum is headed by obtaining hemostasis by digital compression 5 minutes; If hemostasis is obtained, the perineum will not be sutured. In case of failure of hemostasis, suture of the perineum will be realized.
2504374|NCT02870712|Active Comparator|systematic suture|systematic suture tears following current recommendations
2504422|NCT02870517|Experimental|Relaxing Music|Participants will listen to relaxing music through noise-cancelling headphones during induction.
2504423|NCT02870517|Active Comparator|No Music|Participants will wear noise-cancelling headphones during induction but no music will be played through them.
2504503|NCT02870192|Experimental|Rectal Prolapse|Patients with rectal prolapse, who will underwent laparoscopic ventral mesh rectopexy. The implemented mesh may be synthetic or biological.
2504576|NCT02869698|Experimental|Evaluation of cognitive functions by Spectral Dynamic Imaging|Evaluation of cognitive functions by SDI will be conducted during the exploration SEEG (which usually lasts from 1 to 3 weeks), and started a few days after implantation of intracranial electrodes
2504621|NCT02869217|Experimental|Cohort B (retreatment)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 at a dose of 5x10^9 cells.~*Patients will only enter into this cohort if they have already been enrolled in another cohort prior"
2504623|NCT02869217|Experimental|Cohort C (double infusion)|"Cyclophosphamide will be given intravenously (by vein) at a fixed dose of 750mg/m^2/d for 2 days.~Fludarabine will be given intravenously at a fixed dose of 30mg/m^2/d for 2 days.~TBI-1301 cells will be infused on Day 0 and Day 14 at a dose of 5x10^9 cells."
2504653|NCT02868788|Other|high fat high calorie|Subjects in this arm will receive high fat high calorie meal
2504657|NCT02868788|Experimental|high fat high calorie plus fiber|Subjects in this arm will receive high fat high calorie meal plus dietary fiber supplementation
2504814|NCT02867878|Experimental|Adenosine|Patients in this arm will receive systemic infusion of adenosine at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
2504919|NCT02867098|Experimental|Cohort 1|Dose Level 1 XmAb5871 given SC Q14days X 3
2503886|NCT02874339|Experimental|Optiflow Group|High flow nasal oxygen therapy
2503893|NCT02874339|Active Comparator|NIV group|
3321445|NCT02018926|Experimental|Mocetinostat and azacitidine|"Drug: Mocetinostat (MGCD0103) Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5 for 10 doses in each 28 day cycle~Drug: Azacitidine (Vidaza) Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle"
2504071|NCT02873026|No Intervention|Standard care|The patient will receive the standard care given to all patients that have received a vitrectomy following open globe trauma.
2504076|NCT02873026|Experimental|Triamcinolone acetonide|Triamcinolone Acetonide 4mg/0.1ml intravitreal cavity and 40mg/1ml subtenons to be injected at the time of the vitrectomy. Patients will then receive standard care following operation.
2504128|NCT02872545|Experimental|forward tilted|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in forward tilted position
2504134|NCT02872545|Other|semi sitting|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in semi sitting
2504137|NCT02872545|Other|dorsal decubitus|Patients with abnormal results at stress myocardial perfusion tomoscintigraphy will undergo a rest tomoscintigraphy. Acquisition will be done in dorsal decubitus
2504195|NCT02871882|Active Comparator|Ox bile extract|Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
2504196|NCT02871882|Placebo Comparator|Placebo|Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
2504240|NCT02871674|Experimental|Intervention group|Participants in the intervention group will receive behavioural training by psychologists in three sessions over three weeks
2504243|NCT02871674|No Intervention|Control group - usual care|Participants in the control group will receive usual care. They will also attend their usual appointments with the psychiatrists. They will not receive any intervention.
2504303|NCT02871544|Sham Comparator|Low BNP and Low NGAL Group|BNP≤100pg/ml and NGAL≤153pg/ml
2504304|NCT02871544|Active Comparator|High BNP and Low NGAL Group|BNP>100pg/ml and NGAL≤153pg/ml
2504305|NCT02871544|Active Comparator|Low BNP and High NGAL Group|BNP≤100pg/ml and NGAL>153pg/ml
2504307|NCT02871544|Active Comparator|High BNP and High NGAL Group|BNP>100pg/ml and NGAL>153pg/ml
2504451|NCT02870400|Experimental|REGN2477|Cohorts 1 - 5 will receive REGN2477
2504462|NCT02870400|Experimental|Placebo|Cohorts 1 - 5 will receive placebo
2504506|NCT02870023|Experimental|Balance training|"All sessions will start with a ten minute warm-up on either a treadmill or a cycle.~The balance intervention will be conducted in stations/domains where balance is challenged in the five different functions: standing, walking, sit to stand, stepping, and a station that exercises vestibular and gaze control.~Progression is achieved by adding exercises with increased balance requirements and by adding additional motoric and cognitive tasks to the exercises-dual-tasking.~Intensity of the exercises is defined from an error-rate where an adequate level is 20-40 percent.~The intervention is conducted according to a standardized framework that describes examples of exercises and progressions."
2504511|NCT02870023|Experimental|Strength training|"All sessions will start with a ten minute warm-up on a stationary bicycle, followed by strength training of primary muscle synergies in the lower extremities. All exercises will be performed on machines with patients sitting or lying, adequately supported. The exercises are leg press, knee extension, hip flexion, hamstring curl, and hip extension. Exercises are performed with a fast concentric phase and a slow eccentric phase..~Set, repetition, and load:~Weeks 1 and 2, 3 sets of 10 repetitions at a load of 15 repetitions maximum (RM)~Weeks 3 and 4, 3 sets of 12 repetitions at a load of 12RM~Weeks 5 and 6, 4 sets of 12 repetitions at a load of 12RM~Weeks 7 and 8, 4 sets of 10 repetitions at a load of 10RM~Weeks 9 and 10, 4 sets of 8 repetitions at a load of 8RM."
2504515|NCT02870023|No Intervention|Control group|On a waitlist. After ten weeks of waiting, and intervention that contains 50 percent strength training and 50 percent balance training begins.
2504578|NCT02869581||Patients with diagnosis of Pancreatic neoplasms|
2504598|NCT02869204|Experimental|Leucocyte - Platelet rich Plasma and Dietary Supplements|"An application of an autologous platelet concentrate (20 ml). This is injected once, locally in the muscle after closure of the inner fascia and before closure of the outer fascia.~A daily dietary supplement of Vitamin C, Zinc and L-Arginine. Provided from POD2-3 until POD30"
2504600|NCT02869204|No Intervention|Treatment as usual|Patients are treated as usual.
2504660|NCT02868957|Active Comparator|Impression data from reference scanner|desktop scanner was used as a reference scanner. According to the data of the manufacturer, the accuracy is less than 20 µm and the scan points more than 100,000.
2504661|NCT02868957|Experimental|Trios|"Trios is a scanner with real time rendering type adopting the confocal principle, and scans the object while showing the scanned area on a screen.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of Trios intra-oral scanner."
2504664|NCT02868957|Experimental|iTero|"iTero captures teeth and periodontal soft tissue using a red laser beam and parallel confocal imaging technology. This system with a focal depth of 300 can capture up to 100,000 of laser points, and each of such laser points is separated at a 50 mm gap.~Interventions: Assigned intervention to participants in this clinical study was in the form of repetitive learning of iTero intra-oral scanner."
2504745|NCT02868502||Trabeculectomy|Subjects with OAG s/p Trabeculectomy. IOP measurement in different positions.
2504746|NCT02868502||Ahmed Glaucoma Valve implantation|Subjects with OAG s/p Ahmed valve implantation. IOP measurement in different positions.
2504748|NCT02868502||Cyclophotocoagulation|Subjects with OAG s/p Cyclophotocoagulation. IOP measurement in different positions.
2504750|NCT02868502||Ocular hypotensive eye drops|"Subjects with OAG treated with ocular hypotensive eye drops and no ocular surgical hypotensive treatments.~IOP measurement in different positions."
2504752|NCT02868502||Ocular Hypertension|"Subjects with no evidence of glaucomatous damage, but with IOP measurements above 21 mmHg..~IOP measurement in different positions."
2503887|NCT02874235|Experimental|Music therapy treatment|35 patients receiving each 16 sessions of Receptive music therapy
2503890|NCT02874235|Active Comparator|Standard treatment|35 patients receiving each 16 sessions of Psychological treatment
2503925|NCT02873728|Experimental|RIC|In the study group, a blood pressure cuff will be inflated to 50 mmHg above systolic blood pressure while the performing investigator examines the radial pulse to ensure complete blood flow obstruction. Ischemia will be performed for 3 cycles of 5 min each and 10 min resting between cycles.
2503934|NCT02873728|Sham Comparator|Control|In the control group, a blood pressure cuff will be inflated to 10 mmHg (Sham procedure) for 3 cycles of 5 min each and 10 min resting between cycles.
2503999|NCT02873507|Experimental|MRI of donor liver|MRI evaluation of graft steatosis in donor liver prior to transplantation
3196364|NCT00849745|Experimental|Systemic Sclerosis|"Nonmyeloablative allogeneic stem cell transplant~Patients must:~Have diagnosis of SSc as defined by American College of Rheumatology and at high-risk for fatal outcome.~Have (1) both a and b below and (2) at least one of c, d, or e.~Diffuse cutaneous scleroderma with skin score of >= 16~Duration of systemic sclerosis <= 3 years from the onset of first non-Raynaud's symptom.~Presence of interstitial or pulmonary vascular lung involvement (FVC or DLCO <70% of predicted) especially with evidence of alveolitis (abnormal bronchoalveolar lavage or high-resolution chest CT scan).~Presence of myocardial disease~History or presence of proteinuria > 500 mg/24 hrs or serum creatinine > the upper limit of normal."
3196365|NCT00849758||1|chemotherapy: elderly patients receiving 4x adjuvant taxotere cyclophosphamide adjuvant for breast cancer
2504132|NCT02872402|Experimental|Intervention group|"At 2-mo postpartum, women will start the 1-yr lifestyle intervention that will consist of 7 face-to-face individual sessions of 1-hr (at 2, 3, 4, 5, 6, 9, 12 mo postpartum and a follow-up at 18 mo). Metabolic and anthropometric measurements will be assessed at 2,6,12 and 18 mo postpartum. In addition, 7 individual sessions of 30 min between face-to-face sessions will be carried out on the phone.~Benefits of exclusive breastfeeding, healthy eating and physical activity will be portrayed at each visit ."
2504141|NCT02872402|Active Comparator|Active control lifestyle intervention|Women in the control group will come to the testing unit at 2, 6, 12 and 18 mo postpartum for metabolic and anthropometric measurements and at 3, 4, 5, 9 mo for weight measurements only. They will receive standard lifestyle recommendations in the form of written information at each visit.
2504237|NCT02871986||Individuals with hypogonadism|Individuals with hypogonadism requiring pubertal induction. Participants will receive oestrogen therapy in the form of transdermal oestrogen patch, which is standard care.
2504285|NCT02871453|Experimental|Acupuncture combined rehabilitation|"Scalp acupuncture treatment~Rehabilitation treatment"
2504286|NCT02871453|Experimental|Rehabilitation|Rehabilitation treatment
2504365|NCT02871089|Experimental|24/7 Closed loop delivery|Unsupervised home use of day and night automated closed-loop insulin delivery system FlorenceM (Medtronic 640G insulin pump, guardian 3 CGM and Android smartphone) of CamAPS FX (Dana insulin pump, Dexcom G6 CGM and App on Android smartphone) until 24 months after diagnosis
2504368|NCT02871089|Active Comparator|Multiple Daily Injections|Participants will apply standard insulin therapy using multiple daily injections via insulin pens during the 24 months control period
2504434|NCT02870504|Experimental|corneoscleral limbus group|Laser spot locates on the corneoscleral limbus.
2504440|NCT02870504|Experimental|One spot group|Laser spot locates on one spot away from the corneoscleral limbus
2504446|NCT02870504|Experimental|Two spots group|Laser spot locates on two spots away from the corneoscleral limbus
2504493|NCT02870075|Active Comparator|Fed exercise|Fed prior to exercise
2504494|NCT02870075|Active Comparator|Fasted exercise|Fasted prior to exercise
3196366|NCT00849758||2|adjuvant hormone therapy: 40 patients receiving adjuvant aromatase inhibitor without chemotherapy
2504693|NCT02868580|Experimental|Single arm open label|All subjects will receive open label Triumeq following a lead-in phase. Triumeq is abacavir 600mg, lamivudine 300mg, dolutegravir 50mg
2504717|NCT02868307|Experimental|Patient prsenting schizophrenia|
2504764|NCT02868177|Experimental|Totum-63|The studied active product is a food supplement formula in shape of capsule which contains Totum-63 (a patented mixture of dry extracts from 5 plants), active ingredient of Valedia
2504765|NCT02868177|Placebo Comparator|Placebo|The comparative product is a placebo with the same characteristics of appearance and packaging in which all ingredients are replaced by maltodextrin.
2504840|NCT02867748|Experimental|1|TVT-Abbrevo
2504845|NCT02867748|Experimental|2|Serasis
2504896|NCT02867280|Experimental|Sorafenib|Sorafenib (Nexavar) 200mg tablet, 2 tablets oral daily for 2 years, starting within 4weeks after hepatectomy. Regular treatment combined.
2504899|NCT02867280|No Intervention|Control|No use of Sorafenib (Nexavar). Regular treatment.
2504938|NCT02866903|Experimental|Patients with peritoneal carcinosis|Patients with peritoneal carcinosis of colorectal origin and uncertain resectability with an indication for systemic chemotherapy compatible with the FOLFIRI + bevacizumab combination.
2505034|NCT02866435|Experimental|Euglycemia pre-conditioning|Participants will undergo two euglycemia (normal blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where the target glucose during the clamp will be 95 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
2505039|NCT02866435|Experimental|Hypoglycemia pre-conditioning|Participants will undergo two hypoglycemia (low blood sugar) clamps (8-10 am and 1-3 pm) on day 1, where target glucose during the clamp will be 50 mg/dl. For each clamp, participants will be given intravenous insulin for two hours and blood glucose will be maintained at target by the infusion of 20% dextrose, the rate of which will be adjusted based on measured blood glucose values collected every 5 minutes. Potassium phosphate will also be infused during each clamp. On next day (day 2), participants will undergo MRI session during experimental hypoglycemia, i.e., while their blood sugar is clamped from normal value to low value.
2505096|NCT02865837|Experimental|ARM 1|
3196367|NCT00849771||1|Operative Treatment (Open Reduction Internal Fixation)
3196368|NCT00849771||2|Non-operative/Conservative Care
2503895|NCT02874248|Active Comparator|Group 1: 15 mg E4/3 mg DRSP (n=10)|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
2503896|NCT02874248|Placebo Comparator|Group1: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2503897|NCT02874248|Active Comparator|Group 2: 30 mg E4/6 mg DRSP (n=10)|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
2503898|NCT02874248|Experimental|Group 2: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2503899|NCT02874248|Active Comparator|Group 3: 60 mg E4/12 mg DRSP (n=10)|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
2503900|NCT02874248|Placebo Comparator|Group 3: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2503901|NCT02874248|Active Comparator|Group 4: 75 mg E4/15 mg DRSP (n=9)|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
2503902|NCT02874248|Placebo Comparator|Group 4: Placebo (n=4)|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
2503993|NCT02873442|Experimental|Precision cells combined with TACE|"Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
2503995|NCT02873442|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
2504131|NCT02872649|Experimental|study medication|Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate >80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
2504139|NCT02872649|Active Comparator|control group|Phenprocoumon dosage according to INR
2504185|NCT02871960|Experimental|Robotic colectomy|Patients undergoing robotic colectomy for colorectal cancer
2504186|NCT02871960|Active Comparator|Laparoscopic colectomy|Patients undergoing laparoscopic colectomy for colorectal cancer
3196369|NCT00849823|Active Comparator|Male Sexual Health Program|
3196370|NCT00849823|Experimental|Focus on the Future Program|
3196371|NCT00849836||Acute exacerbation|
3196372|NCT00849836||Stable disease|
2504311|NCT02871219|Experimental|Treatment (obinutuzumab, lenalidomide)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 8, and 15 of course 1 and day 1 of cycles 2-6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, and 30. Treatment repeats every 28 days for up to 30 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with CR or CRu may receive up to an additional 12 cycles of lenalidomide.
2504362|NCT02870985|Experimental|BIOTRONIK Orsiro SES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the experimental arm will be implanted with BIOTRONIK sirolimus eluting coronary stent(Orsiro).
2504364|NCT02870985|Active Comparator|Abbott Xience Prime™ EES|Preparation and percutaneous access should be performed according to the standard hospital practice. Both femoral and radial accesses are accepted. The procedure begins once percutaneous access has been made.Following intracoronary injection of nitroglycerin or isosorbide dinitrate, a baseline angiography of the target vessel must be performed according to the QCA corelab guidelines.The subjects randomized to the comparator arm will be implanted with Abbott everolimus eluting coronary stent(Xience Prime™).
2504417|NCT02870673|Active Comparator|Injection of Shincort 0.5 ml and Xylocaine 0.5ml mixture|"In the first week of recruitment, this group will receive the local injection around the distal wrist crease with mixture of Shincort Inj(10mg/ml) 0.5 ml and xylocaine(20mg/ml) 0.5 ml only one time.~The ultrasound-guided procedure is performed by the orthopedic physician."
2504419|NCT02870673|Experimental|sham electroacupuncture|"In this group, the participants receive acupuncture treatment and only 2 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant. After 2 minutes, the stimulator will turn off spontaneously and the participant will not be informed.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
2504644|NCT02868749|Active Comparator|Hyaluronic Acid filler 2 for deep injection|"Injection Session 1 of Hyaluronic Acid filler 2, 3 weeks to 4 months before the surgery~Injection Session 2 of Hyaluronic Acid filler 2, 5 to 9 days before the surgery"
2504718|NCT02868632|Experimental|Cohort A: MEDI4736 + SBRT|MEDI4736 10 mg/kg IV every 2 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
2504826|NCT02868593|Experimental|Patient with clinical meningitis or meningo-encephalitis|
3196373|NCT00849836||Healthy control|
3196374|NCT00849849||Postpartum GDM OGTT|200 women with prior GDM in their index pregnancies will undergo postpartum screening assessment. This program will follow these women who are at a high risk of developing DM2 after delivery for 1 year.
3196375|NCT00849888|Experimental|Atypical Complete DiGeorge|Thymus Transplantation with Immunosuppression
3196376|NCT00849888|Experimental|Typical Complete DiGeorge|Thymus Transplantation without Immunosuppression
3196377|NCT00849914||1|Patients with actinic keratoses of the skin
2503909|NCT02873845||THE SPOUSE/PARTNER|The spouse/partner of patients with colon cancer
2503946|NCT02873611|Experimental|MRI scanning and the genicular ablation|patients undergoing both MRI scanning and the genicular ablation procedure. additional MRI testing of apprx. 0.5-1 hour
3196378|NCT00849914||2|Patients with basal cell carcinoma of the skin
3196379|NCT00849914||3|Patients with squamous cell carcinoma of the skin
2504061|NCT02872818|Active Comparator|Control group|Medicated with only 4mg/kg 17β estradiol hemihydrate for 20 days to develop endometrial hyperplasia
2504064|NCT02872818|Active Comparator|Metformin group|Having been obtained hyperplasia, the investigators continued medication with 50 mg/kg metformin in addition to 17β estradiol hemihydrate for 10 days
2504068|NCT02872818|Active Comparator|Medroxyprogesterone acetate group|Having been obtained hyperplasia, the investigators continued medication with 1mg/day medroxyprogesterone acetate in addition to 17β estradiol hemihydrate for 10 days
2504163|NCT02872207|Experimental|Suncare agent 1 + control|Application of control and test product into one of the subjects two eyes.
2504167|NCT02872207|Experimental|Suncare agent 2 + control|Application of control and test product into one of the subjects two eyes.
2504212|NCT02871869|Active Comparator|Control group A|Control group A was treated with single R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2504213|NCT02871869|Experimental|Trial group A|Trial group A was treated with Cinobufacini Tablets combined with R-CHOP protocol[Rituximab 375mg/㎡,one day before CHOP protocol, CHOP protocol included vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2504214|NCT02871869|Active Comparator|Control group B|Control group B was treated with single CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2504215|NCT02871869|Experimental|Trial group B|Trial group B was treated with Cinobufacini Tablets combined with CHOP protocol[vindesine 3 mg/㎡ (maximum dosage: <4mg) d1 plus cyclophosphamide 750 mg/㎡ d1 plus Epirubicin 60 mg/㎡ d1 plus prednisone tablets 100 mg, d1～5], 21 d as a cycle, for 4～6 cycles.
2504287|NCT02871323|Experimental|Treatment (durvalumab)|Patients receive durvalumab IV over approximately 1 hour on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with SD, no new inter-current illness, and no unacceptable toxicity, may continue treatment beyond 3 courses.
2504334|NCT02871076|Experimental|Verum Acupuncture|Patients will receive verum acupuncture twice weekly for twelve weeks.
2504336|NCT02871076|Placebo Comparator|Sham Placebo Acupuncture|Patients will receive sham placebo acupuncture twice weekly for twelve weeks.
2504470|NCT02870348|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg administered weekly via intravenous administration
2504510|NCT02869880|Active Comparator|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial.
2504516|NCT02869880|Experimental|Enhanced Pre-consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision-parent, patient, healthcare provider and research staff.
3163242|NCT00477919||Weekly assessment by E-MOSAIC|Patients complete a weekly assessment comprising visual analogue scales (VAS) of pain, fatigue, drowsiness, nausea, anxiety, depression, shortness of breath, loss of appetite, and overall well-being; up to 3 optional symptoms selected by the patient; and an estimated nutritional intake using an electronic tool for monitoring symptoms and syndromes associated with advanced cancer (E-MOSAIC). Nurses record the patient's weight, KPS score, body mass index, and assessment of current medication for pain (i.e., morphine-equivalent daily dose), fatigue, and anorexia/cachexia syndromes weekly. A Longitudinal Monitoring Sheet (LoMoS) is printed (comprising VAS of pain, pain medication, fatigue, KPS, medication for fatigue [i.e., methylphenidate hydrochloride or epoetin alfa], anorexia, weight change, nutritional intake, medication, supplements, counseling for anorexia, VAS of individually selected symptoms) and stored.
2504594|NCT02869308|Other|Myocardial angioscintigraphy|
2504682|NCT02868905|Other|Control group|Control group
2504688|NCT02868905|Other|Obese group|Obese group
2504692|NCT02868905|Other|Non-obese AD group|Non-obese AD groups
2504694|NCT02868905|Other|Obese AD group|Obese AD group
2504719|NCT02868385|Active Comparator|Control group (A)|1x praziquantel: Children assigned to group A receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive no further treatment until the final visit (week 8).
2504723|NCT02868385|Experimental|Intervention group (B)|4x praziquantel: Children assigned to group B receive a standard single oral dose of praziquantel (40 mg/kg) at baseline (week 0) and will receive three consecutive praziquantel treatments (40 mg/kg) in the following six weeks with 2 weeks intervals.
3163243|NCT00477919||Palm-based monitoring tool|Patients complete a weekly symptom assessment and nutritional intake using a Palm-based monitoring tool. Nurses record weight and Karnofsky performance status (KPS) scores weekly. A proof of electronic transfer sheet is printed and stored.
3196380|NCT00849953||FinESS Treatment|Subjects undergoing treatment with the FinESS Sinus Treatment System
3196381|NCT00849966|Experimental|A|Celebrex suspension
3196382|NCT00849966|Placebo Comparator|B|Placebo
2503911|NCT02873819|Experimental|GL-0817|Subjects in active treatment will be vaccinated with GL-0817 with the adjuvants Poly-ICLC (Hiltonol®) and GM-CSF (Sargramostim, Leukine®) 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at Week 18. Patients will receive IV Cyclophosphamide 1 day prior to the first 3 vaccinations.
2503913|NCT02873819|Placebo Comparator|Placebo|Subjects in placebo arm will receive placebo to cyclophosphamide (normal saline solution) followed by Poly-ICLC/GM-CSF/placebo vaccine injections on the same schedule as the GL-0817 cohort.
2503963|NCT02873559|No Intervention|Controls|A control group, which is 20 weeks with placebo injections without training.
2503964|NCT02873559|Experimental|Testosterone|A testosterone group given 20 weeks on testosterone injections without training
2503965|NCT02873559|Experimental|Training|A Training Group, which is 20 weeks with placebo injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
2503967|NCT02873559|Experimental|Testosterone and training|A combination group that is 20 weeks with testosterone injections and 16 weeks of progressive resistance training supplemented with vitamin D and protein supplements
3196383|NCT00849979|Other|Questionnaire|
3196384|NCT00849979|Other|Questionnaire + Interview|
2504125|NCT02872675|Experimental|HOST-DM059 (Prebiotic)|HOST-DM059 is the only Second Generation Prebiotic, manufactured by Clasado Biosciences/HOST Therabiomics. HOST-DM059 consists of a specific type of carbohydrate/dietary fibre (GOS), and an enzyme extracted from species of Bifidobacteria (e.g. The β-Galacotosidase Enzyme, & Bifidobacterium Bifidum). The enzyme from which HOST-DM059 is developed provides a highly selective source of energy for certain species of Bifidobacteria. HOST-DM059 encourages the growth and development of Bifidobacteria. Certain species of Bifidobacteria have been demonstrated to exert prominent immunomodulatory effects in terms of regulating systemic inflammation.
2504126|NCT02872675|Placebo Comparator|Maltodextrin|Maltodextrin will be administered as a taste/appearance-matched sugar/carbohydrate.
3196385|NCT00849992|Other|Imiquimod 5%|Patients randomized to this arm will receive treatment with imiquimod 5%
3196386|NCT00849992|Other|Photodynamic therapy|Patients will be randomized to receive photodynamic therapy twice at a 2 week interval to the affected area.
2504258|NCT02871648|Placebo Comparator|Placebo|Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital
2504263|NCT02871648|Active Comparator|Fludrocortisone|Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.
2504265|NCT02871648|Active Comparator|Epleronone|Subjects will receive 100 mg of epleronone on one of three study days.
2504292|NCT02871284|Experimental|Sensorimotor training (EI)|The participants of the experimental intervention arm will take part in a 45 minutes sensorimotor training class two times a week for a maximum of 24 weeks at the NCT (National Center for Tumor Diseases). Highly qualified exercise therapists will guide the class. Class size will be no bigger than 8 patients to ensure adequate individual supervision and guidance. Additionally, participants will be asked to perform one weekly 15 minutes home-based sessions without supervision. Participants who are not able to come to the NCT Heidelberg 2x/week will be offered a home-based sensorimotor program including the same exercises. At the beginning, participants will receive an appointment for an individual face-to-face counseling session at the NCT. During this appointment, the patient will receive an exercise manual for individualized home-based sensorimotor training and a practical introduction by the exercise therapist.
2504295|NCT02871284|Active Comparator|machine-based resistance training (AC)|Participants of the active control arm will receive machine-based resistance training. The supervised resistance exercise program will be undertaken twice weekly in small groups (not more than 12 people per group) of participants and will be guided by an exercise physiotherapist over a maximum of 24 weeks. All sessions will start with a warm-up and finish with a cool-down (comprising exercise on a cycle ergometer or treadmill at a relatively low intensity and stretching activities) and will take approximately 45 minutes. Additionally, participants will be asked to perform a weekly 15 minutes home-based resistance training session without supervision
2504296|NCT02871284|No Intervention|usual care|Participants will receive usual care with no additional exercise training or intervention
2504333|NCT02871102|Experimental|Intervention Arm|
2504389|NCT02870855|Experimental|HCG group|intrauterine injection of HCG before blastocyst transfer
2504392|NCT02870855|No Intervention|Control group|blastocyst transfer
2504458|NCT02870465||CRIF in operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed in the operating room.
2504465|NCT02870465||CRIF outside of operating room|Patients who present with a hand fracture amendable to closed reduction internal fixation (CRIF) who are managed outside of the operating room (i.e.: in clinical setting, the emergency department or minor procedures area).
2504514|NCT02869854|Active Comparator|PAP only|This group will follow the referral scheme for three months, and after this period they will leave new blood samples and answer surveys. They will get a new PAP with follow up after another 3 months.
2504526|NCT02869854|Active Comparator|Mindfulness only|Mindfulness. This group will receive a group course in mindfulness during 8 weeks once a week, and with 20 minutes of daily personal training. Three and six months after inclusion they will answer a new set of surveys and fasting blood samples.
2504528|NCT02869854|Experimental|Combination of the two groups|Mindfulness and physical activity prescription. This group will get a combination of the two other groups. PAP will be prescribed during the first meeting and another one after 3 months. During the first 8 weeks once a week they will participate in a mindfulness training group and also preform 20 minutes of daily training. The same surveys as the other groups and fasting blood samples
2504592|NCT02869529||Chronic lymphatic leukemia diagnosis|
2504634|NCT02869087|Experimental|Single Group|Single Arm study, study subjects are assigned to treatment with the Akesys Prava Scaffold
3196387|NCT00850005|Experimental|IVIG|Active treatment will be intravenous immunoglobulin G (Gamunex, immune globulin intravenous [human], 10%), at a dose of 2 g/kg divided over five days (0.4 g/kg/day).
3196388|NCT00850005|Placebo Comparator|Placebo|The placebo treatment will be intravenous normal saline and will be infused in a similar manner.
3196389|NCT00850018|Experimental|1|Participants will receive monthly blood transfusions.
3196390|NCT00850018|Active Comparator|2|Participants will receive usual care.
3196391|NCT00850044|Active Comparator|1|ABT-450
2503919|NCT02873572|Experimental|online poker gamblers|Recruitment by forums of online poker gamblers: an explanation of the research is sent with the dedicated link of the research.
2503921|NCT02873572|Experimental|casino gamblers|Recruitment to the casino gates: an explanation of the research is sent with the dedicated e-link of the research and they could answer directly to the questionnaire (1st step) on sites.
2503922|NCT02873572|Experimental|MMORPG gamers|Recruitment by forums of MMORPG (as guilds): an explanation of the research is sent with the dedicated link of the research.
2503923|NCT02873572|Experimental|no gamer subjects|Recruitment by poster.
2504000|NCT02873390|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
2504058|NCT02873013||Prostate Cancer|About 20,000 patients who have received a histopathological diagnosis of prostate cancer from ten countries in Asia.
3163244|NCT00477958|Experimental|Geriatric Assessment Tool|
3163245|NCT00477984|Experimental|A|alcohol and placebo
3163246|NCT00477997|Placebo Comparator|1|Saline bolus + OGTT
2504266|NCT02871609||Patients with longterm ureteral stent|
2504290|NCT02871258|Other|The MetaNeb® System Treatment|Treatment with The MetaNeb® System for a minimum of 48 hours, or until hospital discharge, if discharge is within 48 hours from initial treatment.
2504504|NCT02870049|Experimental|Inreach strategy|This consists of a community health worker-delivered in clinic education regrading CRC screening with a fecal immunochemical test (FIT) kit, and telephone reminders.
2504507|NCT02870049|Experimental|Outreach strategy|This consists of mailed invitations to complete screening with an enclosed fecal immunochemical test (FIT) kit and telephone reminders.
2504512|NCT02870049|Experimental|Both Inreach and Outreach strategies|This is a combination of the above two strategies: Inreach and Outreach combined.
2504518|NCT02870049|Active Comparator|Usual care|Usual care in the clinic using the fecal immunochemical test (FIT) kit.
2504575|NCT02869555||Patients with multiple myeloma diagnosis|
2504655|NCT02868996|Experimental|Low dose (Part A)|Recombinant human tissue kallikrein
2504658|NCT02868996|Experimental|Medium low dose (Part A)|Recombinant human tissue kallikrein
2504662|NCT02868996|Experimental|Medium high dose (Part A)|Recombinant human tissue kallikrein
2504663|NCT02868996|Experimental|High dose (Part A)|Recombinant human tissue kallikrein
2504665|NCT02868996|Experimental|Subcutaneous (Part B)|Recombinant human tissue kallikrein
2504666|NCT02868996|Experimental|IV (Part B)|Recombinant human tissue kallikrein
2504731|NCT02868515|Experimental|Oatmeal containing beta-glucan|43 g cereal containing 3g fiber per serving
2504780|NCT02868047||Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination with suspected chronic pancreatitis
2504782|NCT02868047||NOT Suspected Chronic Pancreatitis|Included patients will be those scheduled for an upper endoscopic ultrasound examination without suspected chronic pancreatitis.
2505009|NCT02866305|Experimental|HRCT with bullae, treatment conservative|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
2505010|NCT02866305|Experimental|HRCT no bullae, treatment conservative|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to conservative treatment with conventional chest-tube drainage.
2505011|NCT02866305|Experimental|HRCT with bullae, treatment VATS.|Patients undergo High-resolution CT scan, and significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
2505012|NCT02866305|Experimental|HRCT no bullae, treatment VATS.|Patients undergo High-resolution CT scan, and no significant bullae are identified (i.e. > 1 cm). Afterwards randomised to active treatment with VATS bullectomy and mechanical pleurodesis.
2505111|NCT02865967|Experimental|Block1_Intervention|Usual care + a-GPS
2505120|NCT02865967|Other|Block1_Control|Usual Care
2505123|NCT02865967|Experimental|Block2_Intervention|Usual care + a-GPS
2505125|NCT02865967|Other|Block2_Control|Usual care
2505126|NCT02865967|Experimental|Block3_Intervention|Usual care + a-GPS
2505127|NCT02865967|Other|Block3_Control|Usual care
3163247|NCT00477997|Other|2|GH-bolus and OGTT
3163248|NCT00477997|Other|3|GH-bolus
3163249|NCT00478049|Active Comparator|1|Docetaxel
3163250|NCT00478049|Experimental|2|Gefitinib
3163251|NCT00478088|Experimental|1|NeoDisc
3163252|NCT00478088|Active Comparator|2|ACDF
3163253|NCT00478114|Experimental|1|Sorafenib
3163254|NCT00478270|Experimental|1|
3163255|NCT00478309|No Intervention|Arm I|Participants receive standard primary care.
3163256|NCT00478309|Experimental|Arm II|Participants receive standard primary care followed by the Genetic Epidemiology and Risk Assessment (GERA) intervention. Participants also participate in a discussion session regarding the GERA including the rationale behind methylenetetrahydrofolate reductase mutation detection and folate assessment and its relationship to colorectal cancer risk.
3163257|NCT00478322|Experimental|INCB013739|
3163258|NCT00478322|Placebo Comparator|Matching Placebo|
3163259|NCT00478348|Other|Drain|
3163260|NCT00478348|Other|No drain|
3163261|NCT00478374|Experimental|1|
3163262|NCT00478400||Participants who have had a TBI|"(recruited by invitation only)~Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
3163263|NCT00478400||Participants with No history of TBI|"(Recruited by invitation only)~No history of TBI~Must have an informant (friend, spouse, child etc.)"
3163264|NCT00478400||Veterans with History of TBI|"Must be between 1- and 6-years post-injury~Closed head injury~Evidence of loss of consciousness~Must have an informant (friend, spouse, child etc.)~Audit-C < 7, PCL < 65 and PHQ-9 < 15"
3163265|NCT00478400||US Veterans with No history of TBI|"No history of TBI~Must have an informant (friend, spouse, child etc.)"
3163266|NCT00478439|Placebo Comparator|Placebo Comparator|
3163267|NCT00478452|Experimental|DC Ova|DC Ova vaccine administered day 2 and week 3,6,9
3196392|NCT00850044|Placebo Comparator|2|Placebo for ABT-450
3196393|NCT00850044|Active Comparator|3|ABT-450/ritonavir
3196394|NCT00850044|Placebo Comparator|4|Placebo for ABT-450/placebo for ritonavir
3196395|NCT00850083||Children in the ED|
3196396|NCT00850122|Experimental|Cefazolin|"Dosage Number of Infants~≤28 days of age 25 mg/kg IV q12 6 29-120 days of age 25 mg/kg IV q8 6"
3196397|NCT00850148|Experimental|Melles|
2504175|NCT02872116|Experimental|Nivolumab + Ipilimumab|"Nivolumab + Ipilimumab for 4 doses, followed by Nivolumab monotherapy~Enrollment is closed for this arm"
2504177|NCT02872116|Active Comparator|XELOX (Oxaliplatin + Capecitabine)|
2504178|NCT02872116|Active Comparator|FOLFOX (Oxaliplatin + Leucovorin + Fluorouracil)|
2504179|NCT02872116|Experimental|Nivolumab + XELOX|
2504180|NCT02872116|Experimental|Nivolumab + FOLFOX|
2504377|NCT02870868|Experimental|Slow breathing with exhale greater than inhale|
2504380|NCT02870868|Experimental|Slow breathing with exhale equal to inhale|
2504453|NCT02870530|Experimental|division-less gastric bypass|
2504459|NCT02870530|Active Comparator|mini-gastric bypass|
2504488|NCT02870010|Experimental|non-metastatic hepatocellular carcinoma|"Radiation : Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection~Biological : blood samples (5 ml) will be taken"
2504696|NCT02868710|Experimental|Individualized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: HR > VT1; 5.6 kcal/kg/wk Week 2: HR > VT1; 8.4 kcal/kg/wk Week 3: HR > VT1; 11.2 kcal/kg/wk Week 4: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 5-6: HR ≥ VT1 to <VT2; 11.2 kcal/kg/wk Week 7: HR ≥ VT1 to <VT2; 12.6 kcal/kg/wk Week 8: HR ≥ VT1 to <VT2; 14 kcal/kg/wk Week 9-10: HR ≥ VT2; 14 kcal/kg/wk Week 11-12: HR ≥ VT2; 15.4 kcal/kg/wk"
2504698|NCT02868710|Experimental|Standardized method|"3 days a week of exercise at the following intensity and energy expenditure:~Week 1: 40-45% HRR; 5.6 kcal/kg/wk Week 2: 40-45% HRR; 8.4 kcal/kg/wk Week 3: 40-45% HRR; 11.2 kcal/kg/wk Week 4: 50-55% HRR; 11.2 kcal/kg/wk Week 5-6: 55-60% HRR; 11.2 kcal/kg/wk Week 7: 55-60% HRR; 12.6 kcal/kg/wk Week 8: 55-60% HRR; 14 kcal/kg/wk Week 9-10: 60-65% HRR; 14 kcal/kg/wk Week 11-12: 60-65% HRR; 15.4 kcal/kg/wk"
2504699|NCT02868710|No Intervention|Control|"non-exercise control group~Testing at baseline and post-program (12 weeks)"
2504735|NCT02868346|Experimental|Patients admitted for sexually transmitted infection|
3196398|NCT00850148|Experimental|Anwar|
3196399|NCT00850161|Experimental|Nasulin™|Intranasal insulin spray
2504851|NCT02867514|Active Comparator|anodal tDCS on left DLPFC (F3)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
2504853|NCT02867514|Sham Comparator|sham tDCS on left DLPFC (F3)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on left DLPFC and cathode on right DLPFC.
2504857|NCT02867514|Active Comparator|anodal tDCS on right DLPFC (F4)|tDCS is a non-invasive neuromodulation method, which delivers a constant current of low intensity (1 mA) during 30 min for 10 sessions. Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
2504860|NCT02867514|Sham Comparator|sham tDCS on right DLPFC (F4)|tDCS differs from active tDCS by the interruption of stimulation after 15 sec and reactivation of the stimulation 15 sec before the end of the session (30 min - 10 sessions). Anode is placed on the scalp facing on right DLPFC and cathode on left DLPFC.
3196400|NCT00850161|Active Comparator|aspart|Subcutaneous administration
2504937|NCT02866877||Subarachnoid Hemorrhage|
3196401|NCT00850187|Experimental|Bone marrow mesenchymal stem cells|
3196402|NCT00850213||Endeavor Resolute Stent|Patients implanted with the Medtronic Endeavor Resolute stent
2505074|NCT02866123|Experimental|patient with insertion of an NGT|
2505090|NCT02865785|Active Comparator|Study Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of intralipid 20% (100 mL of intralipid 20% diluted in 250 mL sterile i.v. saline administered i.v. over two hours), once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
2505093|NCT02865785|Placebo Comparator|Placebo Group|This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
2505156|NCT02865655||CSD-TVU|Cesarean Section Scar Evaluation by TVU
2505157|NCT02865655||CSD-MRI|Cesarean Section Scar Evaluation by MRI
2505158|NCT02865655||CSD-MRI with saline|Cesarean Section Scar Evaluation by MRI with saline
2505159|NCT02865655||CSD-Hysteroscopic|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy
2505174|NCT02865239|Placebo Comparator|Supine position|3.0 tesla MRI in supine position
2505175|NCT02865239|Active Comparator|Prone position|3.0 tesla MRI in prone position
3196403|NCT00850226|Experimental|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
3196404|NCT00850226|Experimental|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
3196405|NCT00850239|Experimental|1|dutogliptin/PHX1149T
2503927|NCT02873598|Experimental|FOLFIRINOX or gemcitabine/abraxane followed by SBRT|SBRT will be administered in 3 fractions, every other day, on an outpatient basis, following chemotherapy with either FOLFIRINOX or gemcitabine/abraxane
3196406|NCT00850239|Placebo Comparator|2|Plabeco
3196407|NCT00850252|Experimental|Lifeline blood vessel|
2504094|NCT02872792|Experimental|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer in addition of Standard physiotherapy during sepsis for patient with sepsis in ICU
2504096|NCT02872792|Active Comparator|Standard physiotherapy|Standard physiotherapy during sepsis for patient with sepsis in ICU
2504129|NCT02872441|Experimental|diagnosis of disease associated with IgG4|patients suffering from organ initially compatible with a diagnosis of a disease associated with IgG4
2504216|NCT02872090|Experimental|Arm 1|The patients receive once a week during 4 weeks, in the order: indacaterol, tiotropium, glycopyrronium and placebo
2504217|NCT02872090|Experimental|Arm 2|The patients receive once a week during 4 weeks, in the order: tiotropium, glycopyrronium, placebo and indacaterol
2504218|NCT02872090|Experimental|Arm 3|The patients receive once a week during 4 weeks, in the order: glycopyrronium, placebo, indacaterol and tiotropium,
2504219|NCT02872090|Experimental|Arm 4|The patients receive once a week during 4 weeks, in the order: placebo, indacaterol and tiotropium and glycopyrronium
2504317|NCT02871414|Experimental|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
2504319|NCT02871414|Experimental|REST - Late Group|Control - No treatment for 7 weeks, then provided 7 weeks of sleep skills education provided in group and one-on-one format
3196408|NCT00850265|Experimental|Spacer|Extrafine formoterol plus beclomethasone with spacer
3196409|NCT00850265|No Intervention|No Spacer|Extrafine formoterol plus beclomethasone without spacer
3196410|NCT00850278|Experimental|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
3196411|NCT00850291||1|Electrosurgical vessel sealing device
3196412|NCT00850291||2|traditional surgical methods:stitches and ligations
2504542|NCT02869815||ICG+Methylene Blue|"ICG+Methylene Blue:~Sentinel Lymph Node (SLN) identification and resection using dual tracer technique with the sub-areolar injection of ICG+Blue dye, before surgery."
2504584|NCT02869516||Patient with new diagnosis of Acute Leukemia|
2504619|NCT02869152|Experimental|Intraoperative sentinel lymph node mapping|Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
2504712|NCT02868606||Historical control group (H)|Winthrop patients with diabetes hospitalized between August 1, 2010 and March 31, 2011
2504713|NCT02868606||Intervention group (I)|Winthrop patients with diabetes hospitalized between August 1, 2011 and March 31, 2012
2504714|NCT02868606||Parallel control group (P-sub-H)|Patients with diabetes hospitalized between August 1, 2010 and March 31, 2011 at 7 control hospitals located in the New York City metropolitan region
2504715|NCT02868606||Parallel control group (I-sub-H)|Patients with diabetes hospitalized between August 1, 2011 and March 31, 2012 at 7 control hospitals located in the New York City metropolitan region
2504760|NCT02868164|Experimental|Fecal Microbiota Transplantation (FMT)|
2504761|NCT02868164|Active Comparator|Weight Reduction|
2504834|NCT02867852|Experimental|Abiraterone acetate|Abiraterone acetate 1 g/day must be taken as four 250-mg tablets daily on an empty stomach. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least 1 hour after the dose of abiraterone acetate is taken. Prednisone (prednisolone when prednisone is not available) 5 mg will be given orally twice a day.
2504905|NCT02867332|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2504909|NCT02867332|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment."
3196413|NCT00850304|Experimental|Arm one|
3196414|NCT00850330||Hospitalized patients|Patients elder than 65 years old hospitalized for any reason.
3196415|NCT00850356||Bariatric Surgery Patient (Sx)|Participants who are patients in an Adult Weight Management Clinic (AWMC) and undergo bariatric surgery.
3196416|NCT00850356||Medical Treamtent (Mx)|Participants who are patients in the same AWMC as above and are currently undergoing a medical treatment program that includes intensive lifestyle counseling (diets, exercise, behavioral modification).
3196417|NCT00850356||Wait-List (Wx)|Participants who are on the Wait-List for the AWMC, and waiting to undergo medical treatment program and/or bariatric surgery.
2503942|NCT02873806|Other|2 micro-bypass stents & travoprost|"Two iStent inject micro-bypass stents and topical travoprost~Intervention:~Implantation of two iStent inject micro-bypass stents~Tobramycin~Dexamethasone"
3163268|NCT00478452|Active Comparator|DC Ova with Cyclophosphamide|Cyclophosphomide administered at day 0 prior to administration of DC Ova vaccine administered day 2 and week 3,6,9
3163269|NCT00478478||Acute Ischemic Stroke patients|Patients presenting with signs and symptoms consistent with a diagnosis of Acute Ischemic Stroke, who are treated with the Merci Retrieval System during a Mechanical Thrombectomy procedure.
3163270|NCT00478491||1|Persons with a parent with Alzheimer's disease
2504171|NCT02872428|Experimental|Valproic acid (Depacon)|Valproic acid by IV infusion over one hour
2504173|NCT02872428|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
2504259|NCT02871804|Active Comparator|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
2504264|NCT02871804|Experimental|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
2504371|NCT02871180|Other|With late night snack|At 10 p.m. a late night snack (one slice of whole meal rye bread containing approximately 20 g of carbohydrate) was eaten from Type 1 diabetic patients on an intensified conventional treatment regimen.
2504372|NCT02871180|Other|Without late night snack|Not nutrients (No late night snack) were consumed at 10 p.m. from Type 1 diabetic patients on an intensified conventional treatment regimen..
2504430|NCT02870556|Experimental|EP, Cervical epidural group|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive cervical epidural analgesia in addition to the standard general anesthesia (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) Cervical epidural technique: epidural needle will be inserted at C 6-C7 or C7-T1 under fluoroscopy in prone position, 6 ml of 0.125% bupivacaine and fentanyl 2 mic/ ml will be administered before skin incision followed by 4 ml of the same injectate, will be infused continously for 2 days
2504441|NCT02870556|Active Comparator|GA, General anesthesia|patients undergoing salvage laryngectomy (failed radiotherapy to treat laryngeal cancer) will receive standard general anesthesia only (induction with propofol 2 mg / kg, endotracheal intubation facilitated by cis-atracurium 0.3 mg / kg and 0.15 mg /kg on demand and maintained with inhalational anesthetic sevoflurane) in addition to postoperative analgesia through patient controlled intravenous morphine analgesia (PCA), that involve 1 mg continuous infusion and 2 mg boluses with lockout interval 10 min
2504499|NCT02870140|Experimental|SUPRAFLEX|Percutaneous Coronary Intervention with the SUPRAFLEX Sirolimus Eluting Bioabsorbable Polymer Coronary Stent System. It is a balloon expandable sirolimus eluting stent with an bioabsorbable polymer coating.
2504505|NCT02870140|Active Comparator|XIENCE|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
2504602|NCT02869425|Experimental|Arbaclofen ER Tablets|AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by AERT 15 mg BID (30 mg/day) for 7 days
2504604|NCT02869425|Placebo Comparator|Placebo for Arbaclofen ER Tablets|Matching placebo AERT 10 mg twice daily (BID) (20 mg/day) for 7 days, followed by matching placebo AERT 15 mg BID (30 mg/day) for 7 days
2504647|NCT02868918|Experimental|biodentine|bioactive dentin substitute used to act like natural dentin in insulating the pulp against external stimuli intervention
2504649|NCT02868918|Active Comparator|glass ionomer cement|high viscosity glass ionomer used as a base material comparator other name : - fuji ix
2504732|NCT02868541||Haaj pilgrim|Patient that are showing at the traveler hospital health center requiring the mandatory Meningococcal vaccine ACYW135
2504773|NCT02868099|Placebo Comparator|Placebo|Subjects received placebo for injection treatment will be administered subcutaneously once a week
2504777|NCT02868099|Experimental|Drug|Subjects received Romiplostim for injection treatment will be administered subcutaneously once a week
3163271|NCT00478491||2|Persons whose parents survived to old age without memory problems
3163272|NCT00478491||3|Persons with diagnosed mild cognitive impairment
2504869|NCT02867176|Other|Corneal collagen CXL epi-off|For the epithelium-off procedure, the corneal epithelium is removed with a 10-minute soak time with isotonic riboflavin 0.1% solution and 4 minutes of exposure with 30 mw/cm2 ultraviolet-A irradiation.
2504870|NCT02867176|Other|Corneal collagen CXL epi-on|For the epithelium-on procedure, riboflavin is applied for a total soak of 4 minutes; the cornea is then completely rinsed with additional riboflavin for a total of 6 minutes. The ultraviolet-A irradiation is performed for 2 minutes and 40 seconds at 45mw/cm2.
3163273|NCT00478491||4|Persons without memory problems
3163274|NCT00478504|Active Comparator|Clomiphene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
3163275|NCT00478504|Active Comparator|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
3163276|NCT00478543|Experimental|Diuretic|Furosemide
3163277|NCT00478595|Experimental|Rimonabant|Rimonabant 20 mg once daily
3163278|NCT00478595|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily
3163279|NCT00478621|Experimental|Group A|
3163280|NCT00478621|Experimental|Group B|
3163281|NCT00478621|Experimental|Group C|
3163282|NCT00478621|Experimental|Group D|
3163283|NCT00478621|Experimental|Group E|
3163284|NCT00478621|Active Comparator|Group F|
3163285|NCT00478634|Experimental|A1: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2, loading i.v. (250mg/m2 for subsequent weekly dose i.v.), 350mg/m2 every 3 weeks i.v.
3163286|NCT00478634|Experimental|B1 dose: RAD001 + cetuximab + irinotecan|RAD001 30mg weekly oral, 400mg/m2 loading i.v (250mg/m2 for subsequent weekly dose i.v.), 250mg/m2 every 3 weeks i.v.
2503948|NCT02873767|Placebo Comparator|Placebo|Single dose placebo comparator for each active arm
2503954|NCT02873767|Experimental|UCB4019 Dose 1|Dose 1 calculated based on body weight
2503958|NCT02873767|Experimental|UCB4019 Dose 2|Dose 2 calculated based on body weight
2503960|NCT02873767|Experimental|UCB4019 Dose 3|Dose 3 calculated based on body weight
2503962|NCT02873767|Experimental|UCB4019 Dose 4|Dose 4 calculated based on body weight
2503986|NCT02873273|Experimental|Dexamethasone delivery system|
2504024|NCT02873156|Experimental|E2027|"Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:~Part A Cohort 1: 50 mg (1 × 50 mg capsule)~Cohort 2: 100 mg (2 × 50 mg capsules)~Cohort 3: 200 mg (4 × 50 mg capsules)~Cohort 4: 400 mg (8 × 50 mg capsules)~Cohort 6: 25 mg (5 × 5 mg capsules) Part B~Cohort 5: 400 mg (8 × 50 mg capsule)~Part C:~• Cohort 7: 50 mg (1 × 50 mg capsules)~Part D:~Cohort 8: 5 mg (1 × 5 mg capsules)~Cohort 9: 10 mg (2 × 5 mg capsules)"
2504025|NCT02873156|Placebo Comparator|Placebo|Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.
2504052|NCT02872961||SIBO Positive|Positive small bowel aspirate culture and/or positive glucose breath test
2504055|NCT02872961||SIBO Negative|Negative small bowel aspirate culture and negative glucose breath test
2504100|NCT02872740|Experimental|Embolization of Left Gastric Artery|These patients will have their left gastric artery embolized
2504102|NCT02872740|Experimental|Embolization of Gastroepiploic Artery|These patients will have their gastroepiploic artery embolized
2504113|NCT02872415|Experimental|The forearm as blood puncture site|The child receives a puncture blood on the forearm
2504115|NCT02872415|Placebo Comparator|Fingers like blood puncture site|Premature receiving a puncture blood on the finger
2504147|NCT02872194|Experimental|Suncare agent A + control|Application of control and test product into one of the subjects two eyes.
2504150|NCT02872194|Experimental|Suncare agent B + control|Application of control and test product into one of the subjects two eyes.
2504153|NCT02872194|Experimental|Suncare agent C + control|Application of control and test product into one of the subjects two eyes.
2504229|NCT02871843|Experimental|Escalation of RRx-001 with TMZ + RT|Dose escalation of RRx-001 with fixed doses of Temozolomide and radiation followed by Temozolomide maintenance therapy
2504283|NCT02871401|Experimental|Valganciclovir|Valganciclovir 450 mg, 2 pills by mouth one time per day x 12 weeks
2504284|NCT02871401|Placebo Comparator|Placebo|Placebo, 2 pills by mouth one time per day x 12 weeks
2504341|NCT02871154|Experimental|Delay|Delaying oocyte pick up beyond 39 hours post hCG
2504382|NCT02870829|Experimental|Vitamin K2|Vitamin K comes in various isoforms and we have elected to use the K2 isoform - menaquinone-7. We have chosen a dose of 360mcg 3x/week as previous studies using menaquinone-7 demonstrated an increasing dose efficacy relationship up to this strength. Vitamin K2 is manufactured by Nattopharma
2504384|NCT02870829|No Intervention|Standard Therapy|Subjects randomised to standard therapy will continue to receive dialysis and chronic kidney disease-metabolic bone disease (CKD-MBD) management in accordance to current best practise guidelines
2504433|NCT02870491|No Intervention|Control|Existing standard of care.
2504443|NCT02870491|Experimental|Free Distribute+Preemptive Delivery|Community health workers (CHWs) will deliver oral rehydration salts (ORS) and zinc for free to all households in their catchment area with a child under 5-years-old at the beginning of the study.
2504447|NCT02870491|Experimental|Cost Sharing + Preemptive Delivery|CHWs will visit all households with a child under 5-years-old at the beginning of the study and offer to sell ORS and zinc to caretakers at the time of the visit for them to store in their homes.
2504448|NCT02870491|Experimental|Free Distribution Upon Retrieval|CHWs will visit all households with a child under 5-years-old at the beginning of the study and inform caretakers that they have ORS and zinc available for free that caretakers can retrieved from the CHWs home if needed.
2504558|NCT02869750||Obese PCOS|PCOS patients with BMI more than 25 kg/m2
2504559|NCT02869750||Lean PCOS|PCOS patients with BMI less than 25 kg/m2
2504561|NCT02869750||PCOS with normal HOMA2-1R|PCOS without Insuline resistance
2504564|NCT02869750||PCOS with elevated HOMA2-IR|PCOS with Insuline resistance
2504605|NCT02869360||Multiple Sclerosis (MS) patients|4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
2504611|NCT02869360||Healthy Controls|4 Healthy volunteers aged between 18-60 years of age
2504669|NCT02869009|Experimental|clopidogrel plus aspirin group|the group will receive a 300mg loading dose of clopidogrel plus aspirin 100 mg, followed by clopidogrel 75 mg/d and aspirin 100 mg/d from day 2 to day 14, and followed by clopidogrel 75 mg/d or aspirin 100 mg/d from day 15 to day 90.
2504672|NCT02869009|Experimental|aspirin group|the group will receive 100-300 mg aspirin from day 1 to day 14, followed by aspirin 100 mg/d from day 15 to day 90.
2504755|NCT02868255||Ascites|"30 inflammatory ascites of HCC patients (Collection of human samples ) Ascites will be selected only from HCC patients with an elevated protein level (ie inflammatory ascites) Puncture of ascites will be collected by paracentesis on HCC or ovarian cancer patients during their routine care These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2504756|NCT02868255||Resections|"30 HCC resections (Collection of human samples ) Fragment of resected HCC will be obtained after surgery and histological analysis will be performed by the anatomo-pathology service These biological samples are affiliated with the biobank hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2504758|NCT02868255||blood samples|"blood samples (Collection of human samples )will be collected prospectively for complementary functional analysis of peripheral These biological samples are affiliated with the biocollection hépato-gastroentérologie du CHU de Nantes (declared under the reference DC-2011-1399)."
2504920|NCT02867098|Experimental|Cohort 2|Dose Level 2 XmAb5871 given SC Q14days X 3
2503949|NCT02873884||case-management|Patients will meet the case-manager 5 times per month during 1h30 in community living
2503953|NCT02873884||traditional nursing|Patients will meet the case-manager 2 times per month during 1h00 in hospital
2503996|NCT02873416|Experimental|Precision cells combined with Chemotherapy treatment:|Once a week with a total of six times before 60 days prior to the start of drawing blood. Precision cells：once per 3 weeks with a total of three periods.
2503997|NCT02873416|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
2504074|NCT02872987||B-ALL/NHL|
2504080|NCT02872987||ALL/ Lymphoblastic Lymphoma (LBL)|
2504135|NCT02872337|Experimental|Experimental (Intervention): PreopPT Group|This group will undergo the group preoperative education session. Following this session (intervention) this group underwent a one-time, one-on-one preoperative PT session. They also were given access to a web-based microsite which was customized to surgeon
2504142|NCT02872337|Placebo Comparator|Control (standard of care): No PreopPT Group|This group underwent the current of standard of care at our institution. This only includes the group preoperative education session. No further preoperative education was given.
2504223|NCT02872064|Experimental|Treatment with PDT|A single intravenous injection of Verteporfin (0.4mg/kg) will be administered, at least 60minutes and up to 90 minutes before laser activation. A 690nm red laser light will be delivered with a diffuser laser fibre inserted through the skin into the breast tissue, with light dose escalation after every three patients. All patients will have fixed dose of the photosensitizer but variable light dose.
2504331|NCT02871167|Experimental|Oocyte/embryo cryopreservation|"Controlled ovarian hyperstimulation (COH)~Oocyte/embryo freezing"
2504452|NCT02870439|Experimental|patients with at least 20% of wounded burns body|
2504460|NCT02870439|Experimental|patients with at least 5% of wounded burns body|
2504467|NCT02870439|Experimental|patients with post-surgical wounds with skin resection|
2504502|NCT02869971|Experimental|Embolization|Prostatic Arteries Embolization
2504508|NCT02869971|Active Comparator|Combined Therapy|Combodart® : dutasteride 0.5 mg/tamsulosin 0.4 mg per day
2504567|NCT02869490||Patients with cervical cancer diagnosis|
3196418|NCT00850369|Experimental|1|All subjects wil receive monthly RBC transfusions for 6 months
3321446|NCT02018939|Experimental|Pharmacokinetic profiling in Hemodialysis|Patients with chronic intermittent hemodialysis receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
3321447|NCT02018939|Experimental|Pharmacokinetic profiling in CVVH|Patients receiving continuous venovenous renal replacement therapy in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
2504707|NCT02868671|Experimental|real acupuncture|Participants will receive treatment four times a week for two weeks and three times a week for two weeks. Participants will be treated with major points: Yintang, Du20 (Bai Hui), LI4 (He Gu), LR3 (Tai Chong), RN4 (Guan Yuan), ST36 (Zusanli) (front treatment) or Du20, GB20 (Feng Chi), SP6 (Sanyinjiao), BL15 (Xin Shu), BL18 (Gan Shu), BL23 (Shen Shu) (back treatment). The position of the treatment will alternate between sessions such that the first session will be on the back, with the next session on the front. In addition to the 6 required points, acupuncturist will be allowed to choose 4 more points. The 4 supplemental points may be chosen from the following: LR2 (Xin Jian), HT7 (Shenmen), PC6 (Neiguan), GB34 (Yang Ling Quan), GB39 (Xuan Zhong), SI3 (Hou Xi), RN6 (Qi Hai), RN24 (Cheng Jiang),KI 3 (Taixi), KI 6 (Zhao Hai), ST40 (Feng Long), SP10 (Xue Hai), BL14 (Jue Yin Shu), BL17 (Ge Shu), BL19 (Dan Shu), BL20 (Pi Shu), BL60 (Kun Lun). Auricular acupuncture will be employed.
2504708|NCT02868671|Sham Comparator|sham acupuncture|Participants randomized to sham acupuncture will receive a 'placebo' acupuncture session. In the sham procedure, a needle guiding tube will be tapped on the surface of the skin near, but not on, each of the 10 acupuncture points that would have been selected for true acupuncture. The needle guiding tube will be used to create sensations that mimic needle manipulation.
2504709|NCT02868671|No Intervention|No Intervention|All participants in this study will receive usual care. For those assigned to true acupuncture and sham acupuncture, the usual care will be in addition to their acupuncture.
2504751|NCT02868203|Active Comparator|OCT at 3 months|OCT at 3 months and 12 OCT at 3 months
2504753|NCT02868203|Active Comparator|OCT at 6months|OCT at 6 months and 12 OCT at 3 months
2504827|NCT02867917|Other|Total group|Volcolon sugar free & Metamucil Orange & Psyllium Orange in a randomized order.
2504894|NCT02867358|Active Comparator|High dose of KT07 capsule|It will assess about 140 subjects with influenza at high dose KT07 (6 capsules each time, bid).
2504897|NCT02867358|Active Comparator|Low dose of KT07 capsule|It will assess about 140 subjects with influenza at low dose KT07 (4 capsules of KT07 + 2 capsules of placebo each time, bid).
2504900|NCT02867358|Placebo Comparator|Placebo|It will assess 140 subjects with influenza using 6 capsules of placebo each time, bid as control.
2505045|NCT02866500|Experimental|oral cancer|
2505102|NCT02866006|Experimental|BVAC-C mono(High dose)|BVAC-C IV injection at 0, 4, 8th weeks.(HIgh dose)
2505106|NCT02866006|Experimental|BVAC-C mono(Intermediate dose)|BVAC-C IV injection at 0, 4, 8, 12th weeks.(Half dose)
2505108|NCT02866006|Experimental|BVAC-C + Topo Combi|BVAC-C IV injection at 0,4,8,12th weeks.(Half dose) Topotecan IV injection at 2, 6, 10, 14th weeks
2505182|NCT02865447||PRESERVE total hip arthroplasty implant|Subjects to be prospectively implanted with the PROFEMUR PRESERVE total hip arthroplasty implant
2505264|NCT02865044|Active Comparator|Wax Ester Marine Oil|Active: Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules)
2505269|NCT02865044|Other|Ethyl Ester Marine Oil|Control: Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule)
2505335|NCT02864524|Experimental|Manipulative and Massage Therapy|"Ten sessions (2/week):~High speed and low amplitude technique to lower cervical spine (C3-C4).~Dog technique flexion for high thoracic area (T1-T4).~Dog technique flexion for mid-thoracic area (T5-T8).~Dog technique flexed to low thoracic (T6-T12).~Classic Massage Therapy during 40 minutes (2 time / week):"
2505341|NCT02864524|Active Comparator|Exercise Program|Ten sessions (2 time/ week): Initial heating and continuing with aerobic and muscle stretching exercises.
2505893|NCT02860715|Experimental|Cohort 2|GX-I7 SC 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
2503975|NCT02874131|Experimental|Behavioral Activation + CPT|Behavioral Activation, an evidence-based treatment for depression, is combined with Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, to address symptoms of PTSD and comorbid MDD.
2503978|NCT02874131|Active Comparator|Cognitive Processing Therapy|CPT is an evidence-based treatment for PTSD that has also been shown to reduce depression symptoms.
3196419|NCT00850382|Experimental|Dasatinib|"Induction cycle(s):~Patients will receive in cycle 1 induction therapy with daunorubicin 60 mg/m2/day administered on days 1 through 3 and cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7). Patients will receive dasatinib 100 mg QD on days 8-21. Patients not achieving CR or CRi at the end of cycle 1 will be evaluable to receive a second induction cycle identical in schedule and dosage to the first induction cycle.~Consolidation Cycles 1, 2, 3, 4:~Patients achieving CR or CRi at the end of cycle 1 will receive consolidation therapy for 4 cy-cles. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours. Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
3196420|NCT00850408|Experimental|Real rTMS|Real rTMS - subjects receiving real repetitive TMS - 1Hz over unaffected hemisphere
3196421|NCT00850408|Sham Comparator|Sham rTMS|Sham rTMS
2504174|NCT02872129||166 women with FM/CWP|166 women with Fibromyalgia (FM) or Chronic Widespread Pain (CWP) that participated in an Randomised Controlled Trial called GAU in western Sweden 2004-2005.
2504329|NCT02871193|Sham Comparator|Group C（Control）|Group C received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml combined with general anesthesia and intravenous patient controlled analgesia pump.
2504330|NCT02871193|Experimental|Group R(Ropivacaine)|Group R received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20 ml combined with general anesthesia and intravenous patient controlled analgesia pump.
2504332|NCT02871193|Experimental|Group D(Dexamethasone)|Group D received ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg combined with general anesthesia and intravenous patient controlled analgesia pump.
2504407|NCT02870751|Experimental|ST-only ETEC strain TW11681 or TW10722|Oral inoculum of several doses of bacteria to establish range to achieve diarrhea attack rate in around 70% of volunteers.
2504424|NCT02870361|Active Comparator|Insulin nasal spray|160 Units of human insulin as nasal spray
2504425|NCT02870361|Placebo Comparator|Placebo nasal spray|Nasal spray containing placebo solution
3196422|NCT00850434|Experimental|modified autoset|the modified AutoSet responds to different breathing patterns than the standard AutoSet, to treat OSA. Participants in this arm will trial the modified AutoSet for one night, and the standard AutoSet for one night, in a randomised order
3321448|NCT02018939|Experimental|Pharmacokinetic profiling in MARS|Patients receiving liver replacement therapy (MARS) in an ICU setting receiving doripenem therapy are included in this arm. Pharmacokinetic samples are drawn.
2504636|NCT02869061|Experimental|ADRC injection|Subjects will be undergone liposuction under local anesthesia. Adipose-derived regenerative cells (ADRC) will be isolated from lipoaspirate by enzymatic digestion. Transurethral bladder neck resection followed by the injection of ADRC suspension will be performed. This is a single arm study with no control. All patients receive cell therapy.
2504702|NCT02868697|Active Comparator|A|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of of all Hemodialysis sessions and during all interdialytic periods
2504703|NCT02868697|Experimental|B|We will lock the dialysis catheter post HD with TauroLock Hep500 at the end of the first two session only per week and during first two interdialytic periods then TauroLock U 25000at the end of third session before week end, (over the week end).
2504871|NCT02867228|Other|Single Observational Group|Patients receiving mechanical ventilation and subject to the intervention: changes in ventilator settings.
2504921|NCT02867085||Group 1 (MDS group)|
2504924|NCT02867085||Group 2 (control group)|
2505028|NCT02866630||Cardiopulmonary bypass (Sevoflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of sevoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
2505029|NCT02866630||Cardiopulmonary bypass (Desflurane)|All patients who scheduled for an elective heart surgery in University Malaya Medical Centre using a heart-lung machine and the administration of desflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being six additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
2505113|NCT02866058||Cesarean|Mothers delivered by cesarean section
2505118|NCT02866058||Vaginal|Mothers delivered by vaginal delivery
2505163|NCT02865564|Active Comparator|Intervention group|The intervention group will receive 5 drops, a minimum of 100 million live Lactobacillus reuteri DSM 17938 a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
2505164|NCT02865564|Placebo Comparator|Placebo group|Placebo group will receive 5 drops of maltodextrin in the some oil suspension a day during antibiotic treatment (empirical treatment for neonatal sepsis with ampicillin and gentamicin) and 6 consecutive weeks after finishing the antibiotic treatment.
2503980|NCT02874313|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin plus continuous positive airway pressure (CPAP)
2503981|NCT02874313|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with oral antidiabetic drugs or insulin
2504066|NCT02872831|Active Comparator|22G SharkCore™ needle|Covidien has recently released a novel SharkCore™ Fine Needle Biopsy (FNB) system for EUS-guided tissue acquisition of solid gastrointestinal lesions. With its unique bevel design, this needle has shown promising results to acquire histologic tissue as per oral communication with physicians around the country
2504069|NCT02872831|Active Comparator|22G BNX EUS-FNA needle|The standard 22G BNX Endoscopic Ultrasound Fine needle aspiration (Beacon Endoscopic, Newton, MA) needle is routinely used for the evaluation of solid mass lesions in the pancreas and gastrointestinal tract.
2504110|NCT02872571|Experimental|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
2504149|NCT02872246|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
3196423|NCT00850434|Active Comparator|standard AutoSet|The standard autoset treat OSA by using pressure increases to overcome abnormal breathing patterns. Patients in this arm will use the standard AutoSet for one night and the modified AutoSet for one night, in a randomised order
3196424|NCT00850447|Experimental|Cognitive Remediation Therapy|
3196425|NCT00850447|Placebo Comparator|Videogames|
3196426|NCT00850512|Experimental|CHOP21|4 cycles CHOP21-R plus Zevalin
3196427|NCT00850551|Active Comparator|Usual Care|Usual Care
3196428|NCT00850551|Other|Intervention|Twice weekly home spirometry and symptom assessment
2504267|NCT02871596|Experimental|Placebo,Flavonoids,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504268|NCT02871596|Experimental|Placebo,Flavonoids+Prebiotics,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504270|NCT02871596|Experimental|Flavonoids,Placebo,Flavonoids+Prebiotics|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504272|NCT02871596|Experimental|Flavonoids,Flavonoids+Prebiotics,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504273|NCT02871596|Experimental|Flavonoids+Prebiotics,Placebo,Flavonoids|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504274|NCT02871596|Experimental|Flavonoids+Prebiotics,Flavonoids,Placebo|Participants will receive three treatments, for three weeks each, with 21 day washout period between each product.
2504306|NCT02871232||Intentional exposures among adolescents and adults|
2504309|NCT02871232||Unintentional exposures among infants and children|
2504342|NCT02871037|Experimental|Part 1_Cohort 1_Active|Single, escalating dose of PF-05221304
2504344|NCT02871037|Placebo Comparator|Part 1_Cohort 1_Placebo|Single dose of Placebo
2504346|NCT02871037|Experimental|Part 1_Cohort 2_Active|Single, escalating dose of PF-05221304
2504348|NCT02871037|Experimental|Part 1_Cohort 2_Placebo|Single dose of Placebo
2504351|NCT02871037|Experimental|Part 2_Active|Repeated, escalating doses of PF-05221304
2504354|NCT02871037|Placebo Comparator|Part 2_Placebo|Repeated doses of placebo
2504358|NCT02871037|Experimental|Part 3|Single dose of PF-05221304 with and without food
2504399|NCT02870686|Active Comparator|ERCP without the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to the EUS guided ERCP without fluoroscopy clear all of the bile duct stones.
2504400|NCT02870686|Active Comparator|ERCP with the use of fluoroscopy|Patients with uncomplicated bile duct stones detected by EUS was assigned to underwent ERCP with the use of fluoroscopy to clear all of the bile duct stones.
2504475|NCT02870413|Experimental|Telelactation support|Participants in the experimental group will receive unlimited, free telelactation visits with lactation consultants (IBCLCs) as demanded up to 12 weeks post-partum. Services will be available through mobile phone app.
2504478|NCT02870413|No Intervention|Usual care|Participants in the control arm will receive care as usual.
2504489|NCT02869919||Patients with AKI|critically ill patients with acute kidney injury
2504490|NCT02869919||Patients without AKI|critically ill patients without acute kidney injury
2504544|NCT02869776|Experimental|Rapid finger stick|HIV and HCV testing through rapid finger stick. Behavioral questionnaires will also be administered.
2504547|NCT02869776|Experimental|Standard venipuncture|HIV and HCV testing through venipuncture. Behavioral questionnaires will also be administered.
3196429|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/CT-322|
2505894|NCT02860663|Active Comparator|25OHD|10 ug/ of 25OHD for 6 weeks
3196430|NCT00850577|Active Comparator|Paclitaxel/Carboplatin/Bevacizumab/Placebo|
3196431|NCT00850590|Experimental|Low Dose|NRL001 at 5, 7.5, and 10 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
3196432|NCT00850590|Experimental|High Dose|NRL001 at 10, 12.5, and 15 mg administered in a dose escalating manner with placebo in a random position in the sequence. NRL001 is contained in either a 1 g or a 2 g slow release rectal suppository.
3196433|NCT00850616|Experimental|1|MRKAd6 Trigene 0.5x10^9 Ad6 vg
3196434|NCT00850616|Experimental|2|MRKAd6 Trigene 0.5x10^10 Ad6 vg
3196435|NCT00850616|Experimental|3|MRKAd6 Trigene 0.5x10^11 Ad6 vg
3196436|NCT00850616|Experimental|4|MRKAd5 Trigene 0.5x10^10 Ad5 vg
3196437|NCT00850616|Experimental|5|MRKAd5 Trivalent 1.5x10^10 Ad5 vg
3196438|NCT00850616|Experimental|6|MRKAd5+6 Trigene 1x10^9 Ad vg
3196439|NCT00850616|Experimental|7|MRKAd5+6 Trigene 1x10^10 Ad vg
3196440|NCT00850616|Placebo Comparator|8|Placebo
3196441|NCT00850629|Placebo Comparator|placebo|Placebo
3196442|NCT00850629|Experimental|lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
3321449|NCT02018952|Other|Ultrasonography assessment|
2503982|NCT02874274|Active Comparator|100 Non-Homebound Subjects|outpatient healthcare utilization and self-reported illness.
2503983|NCT02874274|Active Comparator|60 Homebound Subjects|Will test the feasibility of offering influenza and pneumococcal vaccinations, as appropriate, to the homebound individuals in our HVP cohort
3196443|NCT00850668|Active Comparator|EMP-123|Participants who are not allergic to peanuts will receive four escalating doses of study product on a weekly basis
2504087|NCT02872766|Experimental|Corneal cross linking (CXL)|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.
2504106|NCT02872519|Experimental|Experimental|Patients receive (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) PET scans. Patients undergo PET imaging scans during 0-45 minutes, 60-75 minutes, and 105-120 minutes after injection and within 4 weeks prior to surgery (Cohort A) or within 4 weeks of SOC imaging at diagnosis and prior to subsequent treatment (Cohort B).
3196444|NCT00850668|Experimental|EMP-123 in Peanut Allergics|Participants who are allergic to peanuts will receive weekly dose escalation of the study product for 10 weeks followed by administration every 2 weeks for 6 weeks
3196445|NCT00850681|Experimental|1|PEP005 (ingenol mebutate) Gel
3196446|NCT00850694||1|Obese female adolescents
3196447|NCT00850707||1|220 hemodialysis patients with Arterovenous fistula (AVF group)
3196448|NCT00850707||2|58 hemodialysis patients with Arterovenous graft (AVG group)
3196449|NCT00850707||3|180 hemodialysis patients with Tunneled cuffed catheters (TCC group)
3196450|NCT00850707||4|60 healthy subjects as controls
2504376|NCT02870842|Placebo Comparator|Control|Perform recruitment maneuver with fraction of inspired oxygen (FiO2) of 1.0 after intubation under lung ultrasound guidance and maintain FiO2 of 0.6 during the general anesthesia.
2504379|NCT02870842|Active Comparator|Low FiO2|Perform recruitment maneuver with low FiO2 of 0.3 after intubation under lung ultrasound guidance and maintain FiO2 of 0.3 during the general anesthesia.
2504414|NCT02870478|Active Comparator|0.01% atropine daily|Nightly dosing of 0.01% atropine
2504415|NCT02870478|Experimental|0.01% atropine twice per week|Atropine dosed twice per week
2504457|NCT02870335|Experimental|Manual Therapy|The objective of treatment is to restore esta possible limitation of global mobility to major lower limb joints and remove any tensions from the musculature involved in a relevant way in this sport.
2504466|NCT02870335|Active Comparator|Proprioceptive neuromuscular facilitation|It is a stretching technique with the aim of increasing the ROM. It includes passive static stretching and contract-relax.
2504491|NCT02869984|Experimental|Treatment|ramosetron treatment for 4 weeks from 1mo after anterior resection for rectal cancer
2504492|NCT02869984|No Intervention|Control|No treatment
2504543|NCT02869763|Experimental|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
2504546|NCT02869763|Experimental|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
2504548|NCT02869763|Placebo Comparator|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
3196451|NCT00850746|Placebo Comparator|A. Placebo|
3196452|NCT00850746|Experimental|B. Ym443 Lower Dose|
2504783|NCT02868086|Experimental|Tested patients|Patients treated with anti-angiogenics for ARMD : monitoring using optical coherence tomography angiography
2504784|NCT02868086|Active Comparator|Control patients|Patients treated with anti-angiogenics for ARMD : monitoring during common practice via optical coherence tomography B scans
2504821|NCT02867696|Active Comparator|Standard Care|Standard Care serves as the no treatment control in this project. Participants in this group will receive the typical care from their surgeon following bariatric surgery. No additional interventions will be given to participants randomized to this group.
2504823|NCT02867696|Experimental|Technology-based Intervention (TECH)|TECH is the experimental group in this project. A minimal-contact technology-based intervention for weight management will be given to this group in addition to the standard or typical care received from their surgeon following bariatric surgery.
2504902|NCT02867449|Experimental|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
2504903|NCT02867449|Experimental|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
2504928|NCT02866864||Subjects with animal allergy|Subjects who suffer from allergic symptom during contact with animal
2504929|NCT02866864||Subjects without animal allergy|Subjects who do not suffer from allergic symptom during contact with animal
2504992|NCT02866656|Experimental|control group|patients were given Conventional conservative treatment；
2504993|NCT02866656|Experimental|therapeutic ultrasound group|patients were given Conventional conservative treatment and low intensity ultrasonic treatment ；
2505053|NCT02866240|Experimental|Single arm|Cathodal Transcranial Direct Current Stimulation (tDCS)
3196453|NCT00850746|Experimental|C. YM443 Higher Dose|
3196454|NCT00850746|Active Comparator|D. Moxiflocxacin|
3196455|NCT00850772|Experimental|Early post-operative enteral feeding|Standard post-operative care and diet together with early post-operative enteral feeding
3196456|NCT00850772|No Intervention|Standard post-operative care and diet|Standard post-operative care and diet only
3196457|NCT00850798|Experimental|1|Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
3196458|NCT00850798|Active Comparator|2|Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
3196459|NCT00850811|Experimental|1|
3196460|NCT00850824|Experimental|Behavioral|Community Health Worker home visits
3196461|NCT00850824|Active Comparator|Usual Care|Usual Care, Wait List Control
3196462|NCT00850837|Experimental|1|Participants will apply Acidform lubricant twice daily for 14 consecutive days between menses
2503985|NCT02873871|Experimental|Intervention group|Hemostasis with TerumoBand®
2504028|NCT02873182|Experimental|Autonomic nervous system monitoring|During standard intraoperative neuromonitoring, additional smooth muscle free-running and stimulated EMG will be recorded from corporal tissues (corpus spongiosum) of male and female genitalia from all patients who consent to participate in the study. EMG data and additional demographics and clinical data (e.g. operative time, adverse events) will be collected for each patient.
2504047|NCT02872922|Active Comparator|Endothelial function after CWUT|Endothelial function of the all patients before and after application continuous waveform of ultrasound therapy (CWUT) measured by technique flow-mediated dilation (FMD).
2504048|NCT02872922|Active Comparator|Endothelial function after PWUT|Endothelial function of the all patients before and after application pulsed waveform of ultrasound therapy (PWUT) measured by technique flow-mediated dilation (FMD).
2504049|NCT02872922|Active Comparator|Endothelial function after PLACEBO|In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off. Endothelial function of the all patients before and after application placebo waveform of ultrasound therapy measured by technique flow-mediated dilation (FMD)
2504084|NCT02872753|Experimental|ACP GROUP|Patients will receive a single intra-op ACP injection following a procedure of arthroscopic partial meniscectomy (medial or lateral)
2504089|NCT02872753|Other|CONTROL GROUP|Patients will be treated by standard meniscectomy alone (medial or lateral)
2504155|NCT02872467|Experimental|Syntocinon treatment|Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
2504160|NCT02872467|Placebo Comparator|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
2504279|NCT02871583|Active Comparator|lichtenstein|lichtenstein procedure
2504280|NCT02871583|Active Comparator|Kugel|Kugel procedure
2504281|NCT02871583|No Intervention|control|healthy volunteers
2504324|NCT02871206|Experimental|Adjuvanted Influenza Vaccine|Fluad
2504325|NCT02871206|Active Comparator|Quadrivalent Influenza Vaccine|Fluzone
2504469|NCT02870452|Experimental|Hypnosis|Hypnosis for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
2504471|NCT02870452|Experimental|Cognitive-Behavioral Therapy|Cognitive Behavioral Therapy for the prevention and management of pain, emotional regulation and promotion of quality of life in people with Haemophilia
2504472|NCT02870452|No Intervention|Control Group|No psychological intervention - standard Haemophilia care
2504513|NCT02869932|Other|Atypical and classic cystic fibrosis|Lung CT scan without injection
2504560|NCT02869659|Active Comparator|Control/Delayed Weight Loss Group|"Control/Delayed Weight Loss Group: (18 weeks) Participants randomized to the delayed weight loss intervention (n=100) will serve as a no-weight loss control to the weight loss group during the first 18 weeks of the study. During the control (18 weeks) phase these participants will receive a monthly phone call visit from staff to maintain contact and interest in the study. At the end of the initial 18 weeks participants will complete all follow up assessments prior to being offered the opportunity to participate in a weight loss program.~No outcome data will be collected at the end of the delayed weight loss phase."
2504562|NCT02869659|Experimental|Weight Loss Group|"Weight Loss group: Phase 1 (18 wks): Participants assigned to this group will undergo a dietary intervention for the first 18 weeks of the study.~This level of weight loss will be achieved through the combination of a partial meal replacement (MR) program and individual and group nutrition/behavioral counseling. Participants will be provided with and asked to consume 4 Medifast® MR per day.~Phase 2 (8 wks): After completion of the active weight loss phase, participants in this group will attend bimonthly group meetings to discuss increasing their activity.~Phase 3 (26 wks): After completion of phase 2, participants will be called monthly for 26 weeks and then asked to return for a maintenance visit at the end of the 52 weeks from study start."
2504596|NCT02869321|Experimental|Fentanyl|"Administration of Morphine Sulfate Placebo and Fentanyl~Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~+~Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
2504599|NCT02869321|Placebo Comparator|Morphine Sulfate|"Administration of Morphine Sulfate and Fentanyl Placebo~Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy~+~Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy~Administration 1+2 if pain after 4 hours from gastrostomy"
2504687|NCT02868840|Experimental|Tai Chi group|Tai Chi exercise, twice a week, one hour per session. participated in Tai Chi either while seated or standing upon their comfort level.
2504691|NCT02868840|Active Comparator|Symptom management group|manage stroke symptom through phone and text message along with other rehabilitation therapy.
2504791|NCT02867891||Chemotherapy alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
2504795|NCT02867891||Chemotherapy/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
2504798|NCT02867891||Sorafenib alone|The specific interventions to the subjects of the study are assigned by the individual transplant center
2504801|NCT02867891||Sorafenib/DLI|The specific interventions to the subjects of the study are assigned by the individual transplant center
2504819|NCT02867657|Experimental|Mindfulness in nature|A five day mindfulness retreat in nature
2504820|NCT02867657|Active Comparator|Mindfulness indoor|A five day mindfulness retreat indoor
2504822|NCT02867657|No Intervention|Wait list control|A wait list control group, that 6 months later is offered a two-day mindfulness retreat in nature
2504889|NCT02867384|Active Comparator|Obinutuzumab|"Obinutuzumab or will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
2504922|NCT02867098|Experimental|Cohort 3|Dose Level 3 XmAb5871 given SC Q14days X 3
2504004|NCT02873455|Experimental|watching video|Short video clip including the circumstance of operation theater, and surgeon's interview
2504044|NCT02873091|Active Comparator|CEI|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of CEI: 10 ml/h, beginning immediately after the initial dose
2504045|NCT02873091|Active Comparator|PIEB 1|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil.The basal infusion of PIEB1: 5 ml per 30 min, beginning 30 min after the initial dose
2504046|NCT02873091|Active Comparator|PIEB 2|Initial loading dose:10 ml (0.125% ropivacaine with 0.4 μg/ml sufentanil) Epidural infusion with maintain dose: 0.08% ropivacaine with 0.4 μg/ml sufentanil. The basal infusion of PIEB2: 10 ml per 60 min, beginning 60 min after the initial dose
2504105|NCT02872701|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
2504144|NCT02872272|Experimental|Treatment with Amikacin|Dressing impregnated by administration of amikacin
2504199|NCT02872051|No Intervention|Control|Standard treatment and standard vocational rehabilitation
2504200|NCT02872051|Experimental|IBBIS MHC|IBBIS mental health care and standard vocational rehabilitation
2504201|NCT02872051|Experimental|IBBIS integrated MCH and VR|Integrated mental health care and vocational rehabilitation
2504234|NCT02871661|Active Comparator|Amitriptyline|This group will be treated with medication alone (amitriptyline hydrochloride, 25 mg) for chronic vulvar pain (vulvodynia).
2504247|NCT02871661|Active Comparator|Amitriptyline plus kinesiotherapy|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus pelvic floor exercises such as Kegel contractions and stretching of pelvic floor muscles with patients own hands.
2504250|NCT02871661|Active Comparator|Amitriptyline plus IC (Quark)|This group will be treated with medication (amitriptyline hydrochloride, 25 mg) plus electrical stimulation with Interferential Current (manufacturer: Quark Medical; Model: Dualpex 961 - program number 42): two electrodes put into the perineal surface area emitting interferential current, once a week for twenty minutes each, for eight weeks long.
2504405|NCT02870634|Experimental|Cu(II)ATSM|Cu(II)ATSM capsules, administered orally once daily
2504431|NCT02870387|Active Comparator|Usual Inpatient Care|Usual Inpatient Care: High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
2504439|NCT02870387|Experimental|Comprehensive Care with Inpatient Consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
3196463|NCT00850837|Placebo Comparator|2|Participants will apply HEC gel twice daily for 14 consecutive days between menses
2504613|NCT02869165|Experimental|Conjugated equine estrogen topical cream|The conjugated equine estrogen topical vaginal cream 0.5 grams per vagina two times per week at nights for 3 months.
2504616|NCT02869165|Experimental|Apricot kernel oil|One teaspoonful per vagina every night for 3 months.
2504640|NCT02868775||Interstitial cystitis/bladder pain syndrome|These are the patients that will be evaluated in this study.
2504706|NCT02868658|Experimental|Health-care workers|Health-care workers recruited in the study will have blood sampling and naso-pharyngeal bottle-brush sampling
3196464|NCT00850850|Active Comparator|Physostigmine|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 mg of physostigmine.
2504852|NCT02867683|Experimental|Vibrotactile Feedback|Balance exercises completed while vibration was applied to the trunk (anterior, posterior, right, and left) if postural sway exceeded a pre-determined threshold during the exercise.
2504855|NCT02867683|No Intervention|Without Vibrotactile Feedback|Balance training without feedback
2504874|NCT02867254||Groups1|15 patients with type 2 diabetes mellitus with periodontal endodontic lesions
2504877|NCT02867254||Groups 2|15 non-diabetics with periodontal endodontic lesions
2504923|NCT02867072|Active Comparator|Open appendectomy|Subjects that underwent open surgery for appendicitis
2504926|NCT02867072|Active Comparator|Laparoscopic appendectomy|Subjects that underwent laparoscopic surgery for appendicitis
2504954|NCT02866773|Experimental|PA1:Education sessions, Reminders, Whataps group|The intervention includes Physical activity knowledge enhancement session, Physical activity anti-inertia Reminders , Physical activity ambassadors' electronic communication group.
2504963|NCT02866773|Active Comparator|PA2:Education sessions, Reminders|The intervention includes Physical activity knowledge enhancement session and Physical activity anti-inertia Reminders
2504972|NCT02866773|Active Comparator|PA3:Education sessions, Whataps group|The intervention includes Physical activity knowledge enhancement session and Physical activity ambassadors' electronic communication group.
2504976|NCT02866773|Active Comparator|PA4:Education sessions|The intervention includes Physical activity knowledge enhancement session only.
3196465|NCT00850850|Placebo Comparator|NaCl|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo).
2504037|NCT02873130|Experimental|Behavioral: In-person Global Voice Prevention Model|Participants will complete the Global Voice Prevention Model (GVPM) at West Chester University in-person. The GVPM will meet for 2 hours once a week for four weeks. The GVPM includes vocal hygiene, vocal education, and vocal training.
2504038|NCT02873130|Sham Comparator|Behavioral: Telepractice, Vocal Hygiene and Vocal Education|Participants will complete Vocal Hygiene and Vocal Education through West Chester University's Desire 2 Learn (D2L) software program. Asynchronous learning opportunities are provided through D2L over a one week period.
2504088|NCT02872805|Active Comparator|PEPFAR Enhanced Standard of Care (PESCA)|This arm reflects an enhanced standard of care comparison group for PEPFAR supported sites. We will provide standardized materials to be used by current clinical staff to help support whatever the site specific activities are related to transition from pediatric to adult medical care
2504093|NCT02872805|Experimental|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
2504130|NCT02872480|Experimental|ACTIVE Training|Healthy participants will be progressed from 60-80% of their VO2max as determined by the progressive exercise test over the course of 6 30-minute training sessions. Concussed participants will begin 30-minute training sessions at 60% of the VO2 achieved at symptom exacerbation of the exercise test. Intensity will be progressed as tolerated by the participant and training sessions will continue until the participant is asymptomatic for 24 consecutive hours (total number of sessions variable based on clinical recovery).
2504138|NCT02872480|No Intervention|Control|Healthy controls will be asked to follow their normal routine for rest and physical activity. Concussed controls will be asked to follow the guidance for rest and activity as prescribed by the physicians and athletic trainers overseeing their clinical care.
2504254|NCT02872038|Experimental|Treatment|Cefepime intraperitoneal continuous dosing
2504262|NCT02872038|Active Comparator|Control|Cefazolin plus Ceftazidime intraperitoneal continuous dosing
2504320|NCT02871388|Experimental|CONECT|12 week program with additional follow up at 24 weeks.
2504322|NCT02871388|No Intervention|Control|Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
3196466|NCT00850863||A|20 healthy individuals not susceptible for COPD (age 18-40 years, 0 < pack years > 10, FEV1/FVC >70% , FEV1 >85% predicted)
3196467|NCT00850863||B|30 healthy individuals susceptible for COPD (age 40-75years, pack years >20, FEV1/FVC > 70%, FEV1 > 85% predicted)
2504454|NCT02870244|Experimental|Escalating Doses|Three patients will be treated at the first & each subsequent dose level. Patients will be observed for 30 days post T cell infusion. If there was one DLT in the first 3 patients, an additional 3 patients will be treated at that level. If no additional DLTs are observed (for a total of 1 DLT in 6 patients) then the dose will be escalated. If two patients in the first 3 patients at a dose level experience a DLT, the dose will be de-escalated to the previous level & an additional 3 patients will be enrolled at that level if 6 have not yet been treated at that level. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a DLT. If 2 or 3 patients in the first 3 patients experience a DLT at the first dose level, the study will terminate.
2504495|NCT02869997|Experimental|Single arm|arm wherein all patients Suppression Ratio evaluated by BIS will be collected
2504574|NCT02869724|Active Comparator|Weekly divided delivery|Hospitalized for voluntary drug intoxications.
2504577|NCT02869724|Active Comparator|Monthly divided delivery|Hospitalized for voluntary drug intoxications.
2504609|NCT02869230|Other|Radioguided occult lesion localization|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
2504614|NCT02869230|Experimental|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
2504638|NCT02868944|Experimental|experimental group|sequential combined spinal epidural with local anesthetic injection associated with morphine
2504639|NCT02868944|Active Comparator|control group|sequential combined spinal epidural with local anesthetic injection alone
2504700|NCT02868684||mild traumatic brain injury|
2504701|NCT02868684||Healthy controls|
2504733|NCT02868294|Experimental|Patient receiving the Fassier-Duval Nail|Implementation of a telescopic system intramedullary
2504790|NCT02868060|Experimental|1 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
2504793|NCT02868060|Experimental|3 mcg/kg AMG531|The administration of Romiplostim will be performed on Day 1 and 8
2504842|NCT02867631|No Intervention|Enhanced control|Regular care as provided by the community based organization from which the convenience sample is recruited with one year of assessments only
2504843|NCT02867631|Experimental|Intervention|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
2504880|NCT02867306|Experimental|ASP1707 and methotrexate (MTX)|On day 1 patients will receive prescribed dose of MTX. On Days 3 through 8, patients will receive ASP1707 (twice daily). On Day 9, patients will receive a single dose in the morning. A single dose of MTX will be coadministered on Day 8.
2504956|NCT02866955|Other|GROUP E (Estramustine)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by estramustine
2504958|NCT02866955|Other|GROUP T (Tamoxifen)|Patients with HER2-/RH+ breast cancer progressing after having already undergone a first line adjuvant treatment by tamoxifen
2505055|NCT02866318||Novice practitioners|Residents in Emergency department who has no experiences of echocardiography prior to the study.
2505112|NCT02866071|Active Comparator|Ketamine|50mg IN Ketamine Hydrochloride
2504165|NCT02872324|Experimental|Sessions of Mindfulness Based Cognitive Therapy (MBCT)|
2504251|NCT02871713|Active Comparator|Intrathecal morphine|Intrathecal morphine 100 mcg
2504255|NCT02871713|Experimental|Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg)
2504261|NCT02871713|Experimental|Intrathecal morphine + Quadratus lumborum block|Bilateral QLB with 20 ml of 0.5% ropivacaine per side (maximum total dose 3 mg/kg) + Intrathecal morphine 100 mcg
2504326|NCT02871349|Experimental|Propanolol and MRI|Participants will receive propranolol via oral capsule, crushed tablet, or liquid daily. The drug dosage will be titrated slowly to ensure the drug is tolerated well. Those aged 15-24 will have an MRI before starting drug.
2504327|NCT02871349|Placebo Comparator|Placebo and MRI|Participants will receive placebo via oral capsule, crushed tablet, or liquid daily. Those aged 15-24 will have an MRI before starting drug.
2504426|NCT02870790|Experimental|treatment|A single open-label arm. All participants receive daily oral pill containing TDF/FTC
2504523|NCT02869867|No Intervention|Qutenza® without refrigerated cushion|Qutenza® without refrigerated cushion
2504529|NCT02869867|Experimental|Qutenza® with refrigerated cushion|Qutenza® with refrigerated cushion
2504555|NCT02869594||Patients with prostate cancer diagnosis|
2504603|NCT02869399|Experimental|Experimental arm|The experimental arm is based on a dietary intervention in addition to standard recommendations.The diet will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare).
2504608|NCT02869399|No Intervention|Control arm|Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group will not receive any of the recipes or educational materials given to the intervention group and they will not have kitchen classes.
2504686|NCT02868853|Experimental|Photo App|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile dietary tracking application(Photo App). This Photo App allows participants to track meals by taking photos.
2504690|NCT02868853|Active Comparator|Diet App|Participants in this group will receive podcasts twice weekly in conjunction with an app (Diet App) to track their diet by entering in foods and beverages consumed.
2504738|NCT02868359||Pregabalin / Other analgesics|Patients will be treated for 8 weeks with pregabalin in primary care: no intervention
2504741|NCT02868359||Other analgesics|Patients will be treated for 8 weeks with other analgesics in usual care: no intervention
2504836|NCT02867722|Experimental|Daylight PDT|Patients will receive daylight-PDT treatment (aminolevulinic acid)
2504888|NCT02867371|Experimental|-Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
3321450|NCT02018965|Other|ER niacin followed by ART alone|For Arm 1, ER niacin administration begins Week 0 and ends Week 24 (defined as 'immediate use' arm).
2505031|NCT02866344|Experimental|Microwave ablation|Patients will be given general anesthesia. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. Once the operating surgeon determines that the lesions as evaluated on intraoperative ultrasound remain amenable to MWA, ablations will be performed with a 2.45-gigahertz (GHz) generator with a 1.8-mm-diameter transcutaneous antenna (Acculis pMTA Accu2i; AngioDynamics Inc., Denmead, Hampshire, UK). Additional ablations will be performed sequentially. Laparoscopic core needle biopsy of lesions will be performed and submitted for permanent pathologic sectioning per current treatment standards. At the conclusion of the ablation, a collapsed titanium clip will be inserted into the microwave antenna tract as a radiographic fiducial marker. Hemostasis of the ablation track will be ensured using a combination of microwave energy, monopolar electrocautery, and/or topical hemostatics.
2505033|NCT02866344|Active Comparator|Hepatic resection|General anesthesia will be induced. A laparoscopic trocar and additional ports will be placed under direct visualization and pneumoperitoneum will be established. The liver will be evaluated with intraoperative ultrasound (BK Medical A/S, Herlev, Denmark). Laparoscopic core needle biopsy of lesions will be performed. Partial hepatectomy may be carried out with parenchymal precoagulation with radiofrequency electrosurgical devices such as the LigaSure™ (Covidien, Medtronic; Minneapolis, MN), Harmonic® (Ethicon Endosurgery; Cincinnati, OH), or saline-coupled radiofrequency ablation device (Aquamantys™; Covidien/Medtronic; Minneapolis, MN); hepatic parenchymal transection can be performed as above or with the use of stapling devices to ligate and divide parenchyma. Hepatic vascular inflow occlusion will be performed at the surgeon's discretion. A topical hemostatic may be used along the transected hepatic parenchyma. Resected specimens will be preserved in formalin for pathology.
2505116|NCT02865993|Other|Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
2505121|NCT02865993|Other|No Betadine Group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
2505165|NCT02865473|No Intervention|primary open angle glaucoma patients|
2505166|NCT02865473|No Intervention|patients with primary angle closure|
2505168|NCT02865473|No Intervention|patients with neovascular glaucoma|
2505169|NCT02865473|No Intervention|PEX glaucoma patients|
2505171|NCT02865473|No Intervention|glaucoma patients with filtering bleb|
2505172|NCT02865473|Experimental|healthy volunteers|instillation of antiglaucoma treatment in the study eye
2505214|NCT02865161||NISELAT|Amtolmetin guacil should be taken in fasting conditions. The recommended dose is 600 mg b.i.d. Maximum daily dose - 1800 mg
2505252|NCT02864875|No Intervention|Control|Not to receive an early replacement of fibrinogen
2505253|NCT02864875|Experimental|Intervention|Receive early replacement through fibrinogen concentrate (50mg per kg of body weight)
2505286|NCT02864693|Active Comparator|Configuration A (Kinnex)|
2505290|NCT02864693|Active Comparator|Configuration B (Pacifica LP)|
2504233|NCT02871700|Experimental|Action observation therapy (AOT)|Action observation therapy (AOT)
2504241|NCT02871700|Experimental|Mirror therapy (MT)|Mirror therapy (MT)
2504248|NCT02871700|Active Comparator|Control group|Customary bilateral UE training
3196468|NCT00850863||C|20 healthy individuals very susceptible for COPD (age 18-40 year, 0 < pack years > 10, FEV1/FVC > 70%, FEV1 > 85% predicted)and high prevalance of COPD in smoking family members older than 45 years
3196469|NCT00850863||D1|30 COPD patients with GOLD stage I (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 > 80% predicted)
2504401|NCT02870699|Experimental|ARM A|"Evonail film forming solution : 1 daily application on the left hand~Placebo excipient : 1 daily application on the right hand"
2504403|NCT02870699|Active Comparator|ARM B|"Evonail film forming solution : 1 daily application on the right hand~Placebo excipient : 1 daily application on the left hand"
2504481|NCT02870218|Active Comparator|0.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 0.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
2504482|NCT02870218|Active Comparator|1.40mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 1.40mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
2504483|NCT02870218|Active Comparator|2.50mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 2.50mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
2504484|NCT02870218|Active Comparator|5.60mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 5.60mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
2504485|NCT02870218|Active Comparator|16.9mg Nicotine Cigarette w/ e-Cigarette|"Participants will be assigned to smoke 16.9mg nicotine Spectrum cigarettes for 12 weeks with unlimited access to JUUL e-cigarettes.~Smoking research cigarettes with e-cigarette"
2504486|NCT02870218|Experimental|Halo G6 & Tribeca e-liquid|"Difference detection assessments.~Nicotine discrimination thresholds"
2504487|NCT02870218|Experimental|Spectrum Research Cigarette|"Difference detection assessments.~Nicotine discrimination thresholds"
2504527|NCT02869841|Active Comparator|Continuous rectus sheath analgesia|Local anesthetic continuous infusion with infusion pumps
2504534|NCT02869841|Active Comparator|Bolus rectus sheath analgesia|Bolus administration of local anesthetic
2504537|NCT02869841|Active Comparator|Single dose rectus sheath analgesia|single dose administration of local anesthetic
2504539|NCT02869841|Placebo Comparator|Placebo|no rectus sheath analgesia
2504573|NCT02869477||Patients with cardia cancer diagnosis|
2504607|NCT02869269||Early stage|patients who diagnosed as TNM stage 1 and 2
2504612|NCT02869269||Late stage|patients who diagnosed as TNM stage 3 and 4
3196470|NCT00850863||D2|30 COPD patients with GOLD stage II (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 50-80 predicted)
2504704|NCT02868489|Experimental|Proprietary Blend - LactoWise®|After being randomized into two groups, the assigned experimental group, prior to surgery and after consenting, will be asked to complete the Gastrointestinal Quality of Life Index. In addition the experimental group will be given their supply of LactoWise®. They will be required to take 1 capsule per day (300 mg of bacillus coagulans and galactomannans at 4.5 billion live cells) at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
2504705|NCT02868489|Placebo Comparator|Control|For the control group, prior to surgery and after consenting to enroll in the study participants will also be asked to complete the Gastrointestinal Quality of Life Index. Participants of the control group will be administered their supply of a matching placebo. They will be required to take 1 capsule per day at breakfast consistently for 3 months. There will be three follow up visits (Week-2, Week-6 and Month-3) where participants will be asked to complete the gastrointestinal quality of life index.
3196471|NCT00850863||D3|30 COPD patients with GOLD stage III (age 40-75 years, Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30-50% predicted)
3196472|NCT00850863||D4|30 COPD patients with GOLD stage IV (age 40-75 years,Pack years > 10, FEV1/FVC ≤ 70%, FEV1 30% predicted)
2505132|NCT02865746|Active Comparator|Group betamethasone|Active Comparator: betamethasone disodium phosphate at a concentration of 4 mg / ml - dosage of 0.05 mg / kg
2505135|NCT02865746|Placebo Comparator|Group placebo|sterile saline solution (sodium chloride 0.9% - 1 ml ampoules) - dosage of 0.05 mg / kg
2505184|NCT02865369||Daclatasvir plus Asunaprevir treatment|Among patients taking Daclatasvir and Asunaprevir combined treatment and having advanced liver fibrosis assessed by transient elastography
2505276|NCT02864797|Experimental|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software.
2505349|NCT02864537|No Intervention|Conventional treatment|Conventional anticoagulation treatment Before enrolment
2505352|NCT02864537|Experimental|Self-management|Trained to monitor INR and dose warfarin
2505394|NCT02864043|Other|EGD with NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe following standard of care endoscopy
2505448|NCT02863406|Experimental|Healthy volunteers|Bronchoalveolar lavage in healthy volunteers
2505449|NCT02863406|Experimental|Patients suffering from sarcoidosis|Bronchoalveolar lavage in patients suffering from sarcoidosis
2505485|NCT02863250||Massively transfused patients|Patients (18+ years) who have had a critical bleeding event that necessitated a massive transfusion (defined as 5 or more units of red cells in any 4 hour period)
2505557|NCT02862847||gastroenteritis|
2505560|NCT02862847||control|
2505670|NCT02861963|Experimental|Right ventricle outflow tract reconstruction|RVOT reconstruction used femoral allogenic vein valve conduit through ventricular fibrillation and without VSD closure
3163287|NCT00478686||Severe Toxicity|Patients who experienced severe toxicity (at least one grade 4 side effect) with capecitabine chemotherapy
2504416|NCT02870725|No Intervention|Control Group (Treatment As Usual)|Individuals randomized into the control condition will not receive any active treatment but will have access to customary, community-based supportive services. These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of comparison for those in the other arm of the study.
2504418|NCT02870725|Experimental|CBT Individual Psychotherapy (Treatment)|Behavioral Intervention (Individual Psychotherapy). These individuals will complete the pre-, post- and 4-week post-intervention outcome assessment measures and will serve as a means of determining whether or not the intervention was effective compared to the control arm.
3163288|NCT00478686||Dose-Limiting Toxicity|Patients who experienced dose-limiting toxicity (at least one grade 3, or recurrent grade 2, side effect)with capecitabine chemotherapy
2504522|NCT02869802||Biopsy Cohort|"Participants will undergo a tumour biopsy at baseline and an optional tumour biopsy at disease progression.~Participants will undergo serial collection of plasma and serum samples."
2504531|NCT02869802||Archival Cohort|"Genomic analyses will be performed on participants' archival tumour samples.~Participants will undergo serial collection of plasma and serum samples."
2504586|NCT02869503||Patients with colorectal cancer diagnosis|
2504618|NCT02869139|Experimental|Package of mentholated measures|Package of mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
2504620|NCT02869139|Active Comparator|Package of non-mentholated measures|Package of non-mentholated measures (mentholated Ice Popsicle and lip moisturizing) Group.
2504676|NCT02868866|Experimental|Immediate intervention|Training of church committee followed by 12 months of technical assistance phone calls.
2504681|NCT02868866|No Intervention|Delayed intervention|20 churches are followed but receive no intervention.
2504716|NCT02868372|Active Comparator|Betadine group|Subcutaneous tissues of cesarean section wounds are swabbed with10% undiluted Povidone Iodine solution without mobbing before closure of subcutaneous tissues
2504721|NCT02868372|No Intervention|No intervention group|No swabbing of subcutaneous tissue of cesarean section wounds
2504767|NCT02868151|No Intervention|GROUP A|Standard treatment followed in the regional cancer center for prevention and treatment of oral mucositis during chemo radiotherapy of cancers. 20% Benzocaine 15grms. twice daily for the entire treatment period
2504770|NCT02868151|Experimental|GROUP B|"Ascorbic acid oral supplementation 1g four times daily for the entire treatment period of 30 days and after treatment by tapering the dose of the drug to half for another month. The drug has to be started 2 days prior to initiation of treatment of cancer.~Subdivided into 2 groups , 30 patients in each : sub group 1: only radiotherapy patients, subgroup 2 includes concurrent chemo-radiotherapy patients."
2504771|NCT02868151|Experimental|GROUP C|Zinc acetate tablets 50mg orally
2504825|NCT02867787|Experimental|Botox arm|intramuscular injection of botulinum toxin
2504878|NCT02867462|Other|A-Standard Care|standard care
2504882|NCT02867462|Experimental|B-manipulator consultation radiotherapy added to standard care|manipulator consultation radiotherapy added to standard care
2504953|NCT02867007|Experimental|KHK2455 + Mogamulizumab|"Part 1 (Dose Escalation Part): Will identify the MTD for the KHK2455 monotherapy run-in and for the combination regimen (KHK2455 monotherapy [Cycle 0] followed by KHK2455 +mogamulizumab combination [Cycle 1]).~Part 2 (Expansion Part): Subjects with a selected tumor type will be enrolled and treated with the recommended dose of KHK2455 established in Part 1 in combination with mogamulizumab."
2505019|NCT02866422||OCD|
2505021|NCT02866422||Healthy Controls|
2505115|NCT02866084|Experimental|Device|Neuromodulation
2505260|NCT02864849|Experimental|TNT|"Patients with MRI defined high-risk rectal cancer will receive chemotherapy before and after chemoradiation, and will not receive adjuvant treatment. This arm is called total neoadjuvant treatment (TNT). The neoadjuvant chemotherapy regimen is designed as 3 cycles of CapeOX (Capecitabine+Oxaliplatin) over a period of approximately 8 weeks. Tumor response will be evaluated after chemotherapy. Then patients will undergo 22f-IMRT (Intensity modulated radiotherapy) with capecitabine. Patients will receive two more cycles of consolidation CapeOX if tolerable when there was no progressed disease in induction CapeOX.~Finally, patients will receive TME (Total mesorectal excision) following TNT if no metastasis occurs."
2505422|NCT02864160|Experimental|Health Coaching|The health coaching intervention group (n=100) will receive written educational materials on diabetes self-management in Spanish and the diabetes self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish). In addition, patients in the intervention group will be assigned a health coach who will provide health coaching over the course of 6 months with 14 phone calls.
2505423|NCT02864160|Active Comparator|Comparison group|The comparison group (n=100) will receive the standard diabetes care that is offered at Heart of Ohio clinics including consultations with a primary care provider, a dietician, a pharmacist, and a diabetes educator. The comparison group will receive written educational materials on diabetes self-management in Spanish and diabetes self-management tools including a stretch band, a glucometer, and a diabetes cookbook in Spanish.
2505479|NCT02863523|Experimental|Integrated Behavioral Intervention|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
2505486|NCT02863523|No Intervention|Usual Care|Patients receive usual care
2505508|NCT02862964||identify L4-5|Level marked as L4-5 using Accuro and palpation
2505559|NCT02862860|Experimental|patients with type-1 diabetes|
2505562|NCT02862860|Placebo Comparator|Controls|
2505649|NCT02862366||Primary Myelofibrosis (PMF)|Blood sampling during routine visit
2505650|NCT02862366||Essential thrombocytosis (ET)|Blood sampling during routine visit
2505652|NCT02862366||Polycythemia vera (PV)|Blood sampling during routine visit
2505805|NCT02860936|Experimental|Lenvatinib|24 mg of lenvatinib will be administered daily to patients until progression of disease or intolerable toxicity or other criteria for discontinuation is met.
3163289|NCT00478686||Low/No Toxicity|Patients who have experienced low/no toxicity (none or only side effects at grade 1 & 2) with capecitabine chemotherapy.
3163290|NCT00478699|Active Comparator|1|
3163291|NCT00478699|Experimental|2|
2504420|NCT02870673|Experimental|electroacupuncture|"In this group, the participants receive acupuncture treatment and 20 minutes electrical stimulation.~Each needle insertion depth and position are confirmed by the ultrasound. The procedure makes sure that needle pin is directly placed on the median nerve and prevent nerve penetration. Then the electrical stimulator is connected to the needles as cathode and anode and is turned on to the intensity which can induce thenar muscle contraction or reach the upper limit of the participant.~The whole course will cost 20 minutes after needles are pulled out. Every participant is asked to receive 1 treatment per week in the consecutive 3 months(total 12 times)."
2504449|NCT02870270||Head and neck cancer patients|Patients with head and neck cancer who were ≥ 18 years old and had ≥ 16 teeth and no removable prosthesis or dental implants consisting of more than one teeth were included
2504532|NCT02870036|Experimental|Pharmacokinetic data investigation of Simmitecan|To further determine the pharmacokinetic (PK) characteristics of Simmitecan monotherapy in patients with advanced solid tumors
2504535|NCT02870036|Experimental|Dose escalation study of Simmitecan combined therapy|To determine the maximum tolerated dose (MTD) of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced solid tumor
2504536|NCT02870036|Experimental|Dose extension study of Simmitecan monotherapy|To preliminarily evaluate the anti-tumor activity of Simmitecan monotherapy in patients with advanced solid tumors, and to determine the recommended phase II dose (RP2D)
2504538|NCT02870036|Experimental|Dose extension study of Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with 5-fluorouracil/Leucovorin Calcium in patients with advanced/metastatic colorectal cancer (CRC), and to determine RP2D
2504540|NCT02870036|Experimental|Dose escalation&extension Simmitecan combined Thalidomide|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with gastrointestinal tumors, and to determine RP2D and MTD
2504541|NCT02870036|Experimental|Dose extension study of Simmitecan combined therapy|To preliminarily evaluate the anti-tumor activity of Simmitecan combined with thalidomide in patients with specific tumors
2504579|NCT02869347|Active Comparator|Conestat alfa|Intravenous injection of Conestat alfa, for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U (2 vials, each diluted in 14ml sterile water).
2504580|NCT02869347|Placebo Comparator|Sodium chloride 0.9%|Intravenous injection of sodium chloride 0.9%.
2504617|NCT02869191||blood cultures|Admitted patients in critical care who need blood cultures
2504622|NCT02869191||blood cultures Getafe|Data collection of patients included in study
2504641|NCT02868931|Experimental|INPUT|INPUT consists of 12 lessons comprising all relevant information in order to treat diabetes with an insulin pump. Patients learn to effectively use the different features of their pump in order to improve not only glycemic control but also to improve the implementation of pump therapy in daily life. Psychological and motivational aspects of living with diabetes and living with an insulin pump are addressed as well.
2504643|NCT02868931|No Intervention|Waiting list|Patients are randomly assigned to the waiting list. After completion of the 6-month follow-up, these patients will also receive training with INPUT.
2504710|NCT02868645|Experimental|Patients with bone fibrous dysplasia|Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum
2504711|NCT02868645|No Intervention|Control subjects|Control subjects will have no intervention
3196473|NCT00850863||E|20 healthy individuels very susceptible for COPD ( Age 18-40 years,0 < Pack years > 10, FEV1/FVC >70%, FEV1 > 85% predicted, and one of the smoking family members has severe early onset COPD or mild COPD with very low smoke exposure
3196474|NCT00850863||F|30 COPD patients who are highly susceptible (age > 53 years with Pack years > 10 , FEV1/FVC ≤ 70% and FEV1 < 40% predicted) or (age >18 years with 0 < pack years > 5, FEV1/FVC ≤ 70% and FEV1 < 80% predicted)
2504847|NCT02867800|Experimental|Standard GVHD Prophylaxis + Abatacept|"Subjects will receive~premedication (Diphenhydramine, Acetaminophen, Methylprednisolone; and Meperidine as needed)~immunosuppression (Alemtuzumab, or Thymoglobulin)~conditioning regimen (Fludarabine, Thiotepa, and Melphalan)~GVHD prophylaxis: calcineurin inhibitor (Cyclosporine,Tacrolimus, Sirolimus or Mycophenolate Mofetil with permission of the sponsor) and Methotrexate plus Abatacept on days -1, +5, +14 and +28, and a marrow infusion on day 0."
2504901|NCT02867124|Experimental|Vivitrol at place of residence|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at the participants's place of residence utilizing mobile medical treatment
2504904|NCT02867124|Active Comparator|Vivitrol at opioid treatment program|One injection of long-acting naltrexone (XR-NTX) in prison, followed by 6 monthly injections post-release at a community opioid treatment program.
2504932|NCT02866799|Experimental|Multi-PAP intervention|Complex intervention with general practitioners and patients
2504935|NCT02866799|Active Comparator|Usual care|Patients will receive the usual clinical care
2504991|NCT02866591|Experimental|Arm A|Patients have a mammography performed by themselves according to auto-compression procedure. The radiologist leads the compression at a minimum threshold of 40 Newton, then leaves the control of the compression to the patient. The radiologist treats only the positioning of the breast on the sensor.
2504994|NCT02866591|Active Comparator|Arm B|Patients have a mammography performed by the radiologist according to standard procedure.
3196475|NCT00850902|Active Comparator|Moderate Humidity (MH)|
3196476|NCT00850902|Experimental|High Humidity|
2505304|NCT02864680|Other|Cannabis users|
2505305|NCT02864680|Other|Healthy volunteers, not cannabis/tobacco users|
2505306|NCT02864680|Other|Healthy volunteers, tobacco users|
2505308|NCT02864680|Other|Schizophrenia patients|
2505364|NCT02864238||Pre intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2013 prior to the institution of the electronic milestone pathway
2505371|NCT02864212||Depth of anesthesia monitoring|Depth of anesthesia will be monitor in patients undergoing cardiac surgery.
3196477|NCT00850915|Other|1|in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
3196478|NCT00850915|Other|2|no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
2504722|NCT02868632|Experimental|Cohort B:Tremelimumab + SBRT|Tremelimumab 10 mg/kg IV every 4 weeks plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 10 Subjects
2504725|NCT02868632|Experimental|Cohort C: MEDI4736 + Tremelimumab + SBRT|MEDI4736 + Tremelimumab (recommended phase 2 IV dose for combination) plus Stereotactic Body Radiation (SBRT) 6 Gy x 5 Days, 16 Subjects
2504804|NCT02867956|Experimental|Apatinib + Etoposide|"Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.~Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles."
2504833|NCT02867566|Experimental|IBI301|IBI301, 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2504835|NCT02867566|Active Comparator|Rituximab|Rituximab,375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2504872|NCT02867319|Experimental|age of 18-50 years old|
2504876|NCT02867319|Experimental|age of 7-17 years old|
2504881|NCT02867319|Experimental|age of 2-6 years old|
2504939|NCT02867046|Experimental|medial approach group|
2504940|NCT02867046|Active Comparator|lateral approach group|
2504997|NCT02866617|Experimental|Conventional|T1-T2 : VFR constructed on conventional study model T2-T3 : VFR constructed on 3D reconstructed study model
2504999|NCT02866617|Experimental|3D|T1-T2 : VFR constructed on 3D reconstructed study model T2-T3 :VFR constructed on conventional study model
2505016|NCT02866214|Experimental|Group I|This Group of Patients will receive Febuxostat Drug along with their Standard Treatment.
2505017|NCT02866214|Placebo Comparator|Group II|This Group of Patients will receive Placebo along with their standard Treatment.
2505084|NCT02866110|Experimental|Treatment group|25 patients with BPD. In a diagnostic session, diagnostics of psychiatric disorders are conducted. For BPD diagnosis, the International Personality Disorder Examination (IPDE) is used and symptom severity is assessed with the Borderline Symptom List. The Treatment group will receive fMRI amygdala neurofeedback training (3 sessions within 2 weeks). Patients in regular psychotherapeutic treatment (treatment-as-usual) will not be excluded.
2505144|NCT02865681|Active Comparator|Conventional IVF|Conventional ovarian stimulation consist of ovarian stimulation with daily gonadotropins injections daily starting in the early follicular phase (cycle day 3). The final maturation of oocytes will be induced with the standard hCG trigger when at least two follicles reached 18 mm or greater. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
2505147|NCT02865681|Experimental|IVF protocol using nasal gonadotropins|Instead of injectable gonadotropins, nasal human menopausal gonadotropins (hMG; menopur) and oral clomiphene citrate and/or oral letrozole starting in the early follicular phase (cycle day 3). When at least two follicles reached 18 mm or greater, Synarel (Nafarelin) will be used instead of the injectable HCG trigger. Oocyte retrieval will be performed by either local or general anesthesia depending on the ovarian response, i.e., the number of mature follicles. Retrieved oocytes will be fertilized by IVF/ICSI and subsequently cultured until the blastocyst stage. All blastocysts will be vitrified. A single thawed blastocyst will be transferred in a subsequent natural or artificially prepared cycle.
2505200|NCT02865304|Experimental|endostar; taxane|Endostar was administered at 7.5 mg/m2, d1-14, q21d and was continued until progressive disease, unacceptable toxicity, consent withdrawal, or completion of 24 months. In the same time,Taxane-based chemotherapy was continued until progressive disease, unacceptable toxicity, consent withdrawal, or up to 8 cycles.
2505222|NCT02865005|Active Comparator|Dapsone 5.0% Gel (Allergan)|Dapsone 5.0% Gel applied twice daily for 84 days
2505224|NCT02865005|Experimental|Dapsone 5.0% Gel (SEEGPharm)|Dapsone 5.0% Gel applied twice daily for 84 days
2505226|NCT02865005|Placebo Comparator|Placebo|Vehicle of Experimental Gel applied twice daily for 84 days
2505340|NCT02864615|Experimental|Stereotactic Body Radiation Therapy|Patients with stable disease on targeted or IO therapy will receive SBRT on first metastasis of clear cell renal cell carcinoma. Second metastasis will be as a control. In case of safety and 50% reduction in size of first metastasis, up to 10 metastasis will be treated with SBRT.
2505482|NCT02863380|Experimental|Individualized rTMS (transcranial magnetic stimulation)|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 38). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The procedure will be repeated twice a day for 10 days over 2 weeks."
2505488|NCT02863380|Active Comparator|Classical rTMS (transcranial magnetic stimulation)|rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil on F3, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.
2505490|NCT02863380|Active Comparator|Classical tDCS (transcranial direct current stimulation)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and right shoulder. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
2505536|NCT02862886|Other|N°1|
2505551|NCT02862704|Experimental|MG7-CART|A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance. The dose is 1-6x108 MG7-CAR positive T cells. The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
2505592|NCT02862483|Experimental|Experimental|Tamsulosin 0.2mg and Tadalafil 5mg
2505595|NCT02862483|Active Comparator|Comparator|placebo for Tamsulosin 0.2mg and Tadalafil 5mg
2505622|NCT02862158|Experimental|Experimental|FDT visual field will be compared to standard HVF in detecting glaucomatous visual field loss
2504742|NCT02868437|No Intervention|Group 2|The patients who are having curettage for retained product after second trimester abortion will receive no intervention
2504787|NCT02868034|Experimental|SMT Only|Patients receive 2 sessions on SMT during week 1, no additional treatment.
2504788|NCT02868034|Experimental|SMT extended|2 sessions of SMT in week 1 and 6 additional sessions of SMT during weeks 2-4.
2504789|NCT02868034|Experimental|SMT with Activation Exercises|2 sessions of SMT during week 1 and 6 additional sessions of lumbar multifidus activating exercises during weeks 2-4.
2504792|NCT02868034|Experimental|SMT with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of spinal mobilizing exercises during weeks 2-4.
2504794|NCT02868034|Experimental|SMT with Mobilizing and Activation Exercises|2 sessions of SMT during week 1; 6 sessions of lumbar multifidus activating exercises and spinal mobilizing exercises during weeks 2-4.
2504797|NCT02868034|Experimental|SMT extended with Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and spinal mobilizing exercises during weeks 2-4.
2504799|NCT02868034|Experimental|SMT extended with Activation Exercises|2 sessions of SMT during week 1; 6 sessions of SMT and lumbar multifidus activating exercises during weeks 2-4.
2504803|NCT02868034|Experimental|SMT extended with Activation and Mobilizing Exercises|2 sessions of SMT during week 1; 6 sessions of SMT, multifidus activating and spinal mobilizing exercises during weeks 2-4.
2504864|NCT02867501||Aneurysmatic disease|Patients with dilatative arteriopathy (DA) the aortic diameter must be > 3 cm or the popliteal artery diameter > 1.5 cm
2504866|NCT02867501||Peripheral arterial occlusive disease|Patients with arterial occlusive disease (PAOD) defined with an Ankle brachial index (ABI) < 0.9 and positive criteria in the Edinburgh questionnaire.
2504867|NCT02867501||Healthy|Control group of age matched persons without PAOD (ABI > 0.9) and without DA.
2504891|NCT02867215|Active Comparator|Barley bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
2504893|NCT02867215|Active Comparator|Wheat bread|Two loaves, 2 x 120 g loaf/day for 3 weeks.
2504948|NCT02866981|Experimental|Observation|Patients that meet all inclusion and exclusion criteria are monitored every 2 months for two years or until a therapeutic intervention is warranted.
2504986|NCT02866552|Placebo Comparator|PLACEBO|Patients will receive an injection of placebo
2504987|NCT02866552|Experimental|DRUG : Stromal Vascular Fraction|Patients will receive an injection of Stromal Vascular Fraction injection
2505057|NCT02866279|Experimental|Postplacental|contraceptive implant placed within 30 minutes of placental delivery
2505060|NCT02866279|Experimental|Immediate Postpartum|Contraceptive Implant placed 1-3 days postpartum
2505063|NCT02866279|Active Comparator|Delayed|Contraceptive Implant placed 6 or more weeks postpartum
3196479|NCT00850928||Subjects|65 years and older scheduled for spine surgery will be undergoing serial assessments preoperatively and postoperatively over 6 time-points.
3196480|NCT00850941||Questionnaire|Prognostic factors and outcome for patients treated with radiation with curative intent for rising Prostate Specific Antigen (PSA) post-prostatectomy.
2505201|NCT02865317||Study group|Patients with obstetrical brachial plexus injury involving upper trunk (C5-6)
2505301|NCT02865057||3rd year Residents|3rd year Ob, Gyn Residents
2505303|NCT02865057||4th Year Residents|4th year Ob, Gyn Residents
3196481|NCT00850954|Experimental|Group I (smoking cessation)|Participants receive smoking cessation intervention materials based on TTM.
3196482|NCT00850954|Experimental|Group II (informational)|Participants receive fotonovelas and other materials on secondhand smoking and how to assist the smoker in quitting.
2505439|NCT02863809|Experimental|Active Treatment Arm|De-epithelialized corneas cross-linked with riboflavin 0.1% and dextran 20% solution AND ultraviolet A light (UVA Light Source).
2505443|NCT02863809|Active Comparator|Control Treatment Arm|De-epithelialized corneas will be exposed to only riboflavin 0.1% with dextran 20% solution (NO ultraviolet A light).
2505480|NCT02863302|Experimental|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment until the end of hospitalization.
2505521|NCT02862977|Experimental|EMS association|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h.
2505526|NCT02862977|Active Comparator|Miosan Caf®|The patient will take 2 tablets (combination of Cyclobenzaprine and caffeine), oral, per day, each 12h.
2505575|NCT02862639|Experimental|injection of viscosupplementation and corticosteroid|experimental group
2505576|NCT02862639|Active Comparator|injection of corticosteroid|control group
2505630|NCT02862301|Other|Control group|Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
2505638|NCT02862301|Experimental|CIS group|patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.
2505712|NCT02861872||IP Patients|women, aged younger than 70 years, who will receive standard IP chemotherapy for advanced epithelial ovarian cancer, who are in an adequate physical and biochemical state to receive chemotherapy will be studied.
2505757|NCT02861326|Other|Patients|Non-surgical periodontal treatment has performed to patients. Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
2505811|NCT02861001|Active Comparator|bronchoscopic guidance|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
2505812|NCT02861001|Experimental|tube mounted camera guidance|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
2505845|NCT02860780|Experimental|Part A: prexasertib + ralimetinib|"Cohort 1: 60 milligrams (mg) prexasertib (LY2606368) given intravenously (IV) and 100 mg ralimetinib given orally.~Cohort 2: 60 mg prexasertib (LY2606368) given intravenously (IV) and 200 mg ralimetinib given orally."
2505849|NCT02860780|Experimental|Part B1: prexasertib + ralimetinib (colorectal cancer)|60 mg prexasertib (LY2696368) given IV and 200 mg ralimetinib given orally. Participants receive prexasertib IV on Days 1 and 15 and ralimetinib every 12 hours (Q12H) Days 1 and 14 of a 28 day cycle.
2505869|NCT02860442|Experimental|Smartphone brief intervention (SP-BI)|
3196483|NCT00851019|Experimental|DDR|"Dance Dance Revolution (DDR) Exergaming"
3196484|NCT00851019|Active Comparator|Treadmill|Treadmill exercise
2504754|NCT02868502||Control|"Subjects with healthy eyes, apart for refraction errors, post cataract surgery, strabismus or amblyopia.~IOP measurement in different positions."
2504850|NCT02867644|Active Comparator|standard care|
2504854|NCT02867644|Experimental|standard care+conversational hypnosis|
2504947|NCT02866734|Active Comparator|Free screening group|Subjects in this group receive free diabetic retinopathy screening.
2504960|NCT02866734|Active Comparator|Pay screening group ($150)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$150.
2504969|NCT02866734|Active Comparator|Pay screening group ($300)|Subjects in this group receiving diabetic retinopathy screening will be charged HK$300.
2505048|NCT02866487||Asthmatics|"0-5 years of age: Intermittent cough, wheeze, chest symptoms AND one or more of the following: Eczema Eosinophilia Elevated total IgE Positive family history~6-17 years of age: Physician diagnosis Current treatment with one or more asthma medications Recurrent episodes of cough, wheeze, chest discomfort, pain"
2505050|NCT02866487||Age-Similar Non-asthmatic Controls|Age-similar controls will undergo diagnostic bronchoscopy for clinical indications in the absence of known asthma, including recurrent pneumonia, congenital lung anomalies, prolonged cough, suspected laryngeal abnormalities, and suspected aspiration syndromes. Inclusion in the final set to be determined post-procedure based on BAL granulocyte profiles. To be included as a control, participants must have pauci-granular BAL counts (less than 2 percent eosinophils and less than 4 percent PMN), no positive allergen sensitization, and no positive viral or bacterial studies from analysis of BAL fluid.
3163292|NCT00478712||Families with Hirschsprung Disease|Individuals with Hirschsprung disease and their affected and unaffected relatives.
3163293|NCT00478725|Experimental|Part A|Absorption, Distribution, Metabolism and Elimination of a Single Oral [14C] Labeled Dose of GW786034
2505177|NCT02865512|Active Comparator|supine position|thoracic epidural catheterization with supine position
2505181|NCT02865512|Active Comparator|flexed lateral position|thoracic epidural catheterization with flexed lateral position
2505220|NCT02865031|Experimental|Decorin|Intravitreal injection of 200-400 ug of Decorin.
2505291|NCT02864771||1|Derivation cohort (n=474); may be analyzed separately or combined with cohort #2 to enhance statistical power
2505292|NCT02864771||2|Validation cohort (patient #475 and after); may be combined with cohort #1 to enhance statistical power
2505348|NCT02864498|Experimental|1g Oral DS107|1g Oral DS107 to be administered once-daily for 8 weeks.
2505353|NCT02864498|Experimental|2g Oral DS107|2g Oral DS107 to be administered once daily for 8 weeks.
2505360|NCT02864498|Placebo Comparator|Placebo|Placebo orally administered once-daily for 8 weeks.
2505380|NCT02863965||High definition endoscopy and optic enhancement|All the patients underwent routine preparation before the procedure. The detected lesions in high definition endoscopy were observed with optic enhancement mode. The endoscopist was required to give the real-time descriptions of surface pit patterns of the lesions, based on surface pattern classification. After that, biopsy specimens will be obtained respectively by forceps from each detected lesion recorded for histologic diagnosis.
2505392|NCT02863900|Experimental|Experimental arm|subtypes of BC (namely luminal A and luminal B, HER2+, TN)
2505442|NCT02863757||CHB Group|Patients with chronic hepatitis B
2505445|NCT02863757||CHB/NAFLD Group|Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease
2505446|NCT02863757||NAFLD Group|Patients with nonalcoholic fatty liver disease
2505453|NCT02863367|Experimental|Treatment group|Apatinib：500 mg，po，qd, d1-14, every 3 week Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
2505625|NCT02862353||patients with thrombocytopenia drug|
2505660|NCT02861989||Osteoporotic women|women over 50 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2505662|NCT02861989||At risk women|women over 50 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2505664|NCT02861989||Osteoporotic men|Men over 60 years with a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2505665|NCT02861989||At-risk men|Men over 60 years without a diagnosis of osteoporosis or history of fragility fracture /osteoporosis treatment
2505668|NCT02861989||General practitioners|General practitioners from the Rhône area, France
2505698|NCT02861625||Group A|letter of condolence offering to the reliable person a post-death consultation with the reference physician (sent between J15 and J30 post death)
2505699|NCT02861625||Group B|no intervention, i.e without a letter of condolence proposing a consultation with the reference physician
2505748|NCT02861456|Active Comparator|Standard Care Group|Patient in the treatment arm will receive the Standard Model of Care as prescribed for their condition by their physician including but not limited to Advanced imaging, Rest, Bracing, Physical Therapy, and Medication.
2505750|NCT02861456|Experimental|Functional Progression Group|Patients who are randomized to the alternative model of care to guide treatment will not have advanced imaging done and will be referred directly to physical therapy care . If the patient is able to functional progress through phase I and II of physical therapy within 3 weeks and phase III within 5 weeks then they return to sport. If patient are unable to progress the are put on rest as a presumed vertebral injury (spondylolysis).
3163294|NCT00478725|Experimental|Part B|characterize the pharmacokinetics of a single IV dose of GW786034
3163295|NCT00478738|Other|GSK961081|GSK961081
3163296|NCT00478790|Experimental|1|ologen™ collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy. After operation with ologen™ Collagen Matrix, anti-inflammatory eye-drops will be prescribed
3163297|NCT00478803|Experimental|1, preservation|aortic valve surgery(Remodeling associated with a subvalvular aortic ring annuloplasty or double sub and supra valvular aortic annuloplasty)
2504775|NCT02868073|Experimental|H1N1 (high dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (high dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
2504776|NCT02868073|Experimental|H1N1 (low dose) Oral Vaccine Tablet|Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
2504779|NCT02868073|Placebo Comparator|Placebo Tablets|Singe dose of VXA Placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
2504829|NCT02867670||Transcranial Magnetic Stimulation of Motor Cortex|All study participants will receive real TMS stimulation over the primary motor cortex in order to collect physiological measures which will later be correlated with measures of neuroplasticity. There is NO placebo stimulation.
2504831|NCT02867670||Transcranial Magnetic Stimulation of Language Cortex|All study participants will receive real TMS stimulation over the language cortex and a control site (i.e. vertex). Transient changes in speech production will be recorded and compared to measures of neuroplasticity. There is NO placebo stimulation.
2504907|NCT02867345||Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/ day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2504911|NCT02867345||Comparable group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 wild-type T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third. Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
2504945|NCT02866812|Experimental|patient with endovascular treatment for intracranial aneurysm|
2504985|NCT02866565|Experimental|Diabetic foot ulcer|
2505007|NCT02866292||non-pregnant nulliparous|Nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
2505008|NCT02866292||primigravid|Pregnant women on her first pregnancy and gestational age above 14 weeks. Pelvic floor muscle evaluation by means of vaginal palpation and vaginal squeeze pressure (perineometer), and evaluation of the sexual function by the Female Sexual Function Index (FSFI) questionnaire.
2505061|NCT02866136|Other|(IV)Intravenous chemotherapy, laser diode|"Group 1 - Multicentric non randomised, phase II study for patients with retinoblastoma (unilateral group A,B according to age, group C according to the age and the vitreous seeding or bilateral groups A,B and C excluding the bilateral groups D or patients with bilateral macular threat).~Treatment by chemoreduction (VP16, carboplatin) followed by Carboplatin + laser day 1 (chemothermotherapy) without laser treatment at day 8 (decreasing laser sessions) combined to local treatments from third course (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
2505064|NCT02866136|Other|(IA) Intraarterial Melphalan|"Group 2 - Multicentric non randomised, phase II study for the patients with bilateral very asymmetric disease (group D retinoblastoma on one of the eye, and the other amenable to a local treatment without chemotherapy) or unilateral presentation group D and groups B/C according to the age and vitreous seeding.~Treatment by Melphalan chemotherapy administered by superselective catheterization of the ophthalmic artery and combined to local treatments (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan)."
2505067|NCT02866136|Other|(IV-PM) Intravenous 3 drugs chemotherapy|Group 3 - Multicentric non randomised, phase II study for the patients with bilateral group D retinoblastoma or with a group D retinoblastoma on the only remaining eye. Treatment by 6 cycles of three drugs (VP16, carboplatin, vincristin) regimen combined to local treatments from the third cycle (laser, cryoapplication, I125 radioactive plaques or intravitreal Melphalan).
2505133|NCT02865759|Experimental|Mindfetalness|The pregnant woman will be informed about the possibility of practicing Mindfetalness verbally, in a brochure and at a website. The practice is described as spending 15 minutes every day from gestational week 28 to get to know the fetal movement pattern. The fetus must be awake when she practice Mindfetalness and the woman is suggested to lay on her left side when she observe the fetal movements. In the brochure as well at the website the woman can write down something about the nature, frequency or strength of the fetal movements. If the woman experiences decreased frequency of fetal movements or weaker movements she is instructed to seek health-care without unnecessary delay.
2505136|NCT02865759|No Intervention|Routine Care|No activities will take place in the antenatal clinics randomized to routine care.
2505199|NCT02865408|Active Comparator|Group 1: Peptamen 1.5% via enteral only|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard EN Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d
2505208|NCT02865408|Active Comparator|Group 2: Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive the same enteral feeding as group 1 (Peptamen 1.5) but in addition will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/d
2505210|NCT02865408|Active Comparator|Group 3: Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids (Prosol 20%) in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/day.
2505257|NCT02864823|Experimental|Perichondrium|Perichondrium Autografts
2504807|NCT02867930|Active Comparator|Group D|Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
2504809|NCT02867930|Active Comparator|Group KF|Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
2504824|NCT02867579|Other|women with denial pregnancy|women with denial pregnancy
2504830|NCT02867579|Other|women without denial pregnancy|women without denial pregnancy
2504885|NCT02867397|Other|Teysuno (S1) in combination with epirubicin and oxaliplatin|
2505013|NCT02866409|Experimental|Bupivacaine,dexmedetomidine scalp block|Bupivacaine (0.25%) and Dexmedetomedine (1 µg/kg). Maximum dose of bupivacaine kept < 2 mg /kg for scalp block
2505014|NCT02866409|Active Comparator|bupivacaine dexmedetomidine infiltration|The incision site was infiltrated with 15-20 ml bupivacaine (0.25%) and dexmedetomedine (1 µg/kg). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
2505015|NCT02866409|Active Comparator|bupivacaine infiltration|The incision site was infiltrated with 15-20 ml of bupivacaine (0.25%). {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}. Maximum dose of bupivacaine kept less than 2 mg /kg.
2505097|NCT02865954|Experimental|iball intervention|Use of iball pelvic floor training mhealth application for 16 weeks.
2505101|NCT02865954|No Intervention|Standard Care|Standard Care - control group
2505173|NCT02865616|Experimental|MET-2 Capsules|"Patients will be on vancomycin to control symptoms up until the time of the treatment.~Initial Loading Dose: Patients will be given an initial daily loading dose of 5 g MET-2 over 2 days followed by a maintenance dose of 1.5 g over 8 days. Patients who do not experience treatment failure between Day 14 and Day 40 will be monitored until Day 130.~Second Loading Dose: Patients experiencing treatment failure after the first dose may be offered a second, higher loading dose 10 g of MET-2 in the form of 20 MET-2 capsules per day for two days, there will not be additional daily dosing beyond the first 10 days.~Colonoscopy: Patients failing the second loading dose of MET-2 may be offered 15 g of MET-2, equivalent to a 30 MET-2 capsule loading dose by weight, via colonoscopy..~All patients will be followed up for 120 days after the last treatment has been received."
2505251|NCT02865135|Experimental|DPX-E7 Vaccine|Subjects will 2 priming doses of DPX-E7 at a pre-determine dosage 3 weeks apart followed by a predetermine booster dose every 8 weeks until clinical progression.
3163298|NCT00478803|Sham Comparator|2, Bentall|Mechanical aortic valve replacement(isolated or composite valve and graft replacement);actual surgical standard for dystrophic aortic roots
2505677|NCT02862041|Active Comparator|Group Echogenic|Ultrasound guided infraclavicular brachial plexus block with Pajunk sonoplex echogenic needle
2505680|NCT02862041|Placebo Comparator|Group Nonechogenic|Non echogenic needle group, ultrasound guided infraclavicular brachial plexus block with Stimuplex Braun non echogenic needle
2505737|NCT02861612||Nerve Transfer|This is an observational study that looks at function and quality of life in patients before and after nerve transfer surgery.
2505815|NCT02861066|Experimental|Mindfulness-based Intervention|6 week, abbreviated group MBI treatment for depression and anxiety
2505888|NCT02860715|Experimental|Cohort 1|GX-I7 SC 20㎍/㎏ (8 subjects) / Placebo (2 subjects)
3163299|NCT00478816|Active Comparator|Group 1|Primed subject with pandemic Vaccine
3163300|NCT00478816|Active Comparator|Group 2|Non Primed subject with pandemic Vaccine
3163301|NCT00478842|Experimental|1|Deep brain stimulation
3163302|NCT00478946|Experimental|1|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
3163303|NCT00478946|Active Comparator|2|FOLFOX Oxaliplatin 85 mg/m2, as a 2-hour infusion Leucovorin (400 mg/m2 in D5W) and Oxaliplatin. Leucovorin + oxaliplatin will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
3163304|NCT00478959|Experimental|Lenalidomide|Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma.
3163305|NCT00478972|Experimental|Rimonabant|Rimonabant 20 mg once daily in addition to diet and exercise
3163306|NCT00478972|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily in addition to diet and exercise
3163307|NCT00478985|Experimental|1|Imatinib treatment ending
3163308|NCT00479024||observation|patients enrolled in previous trial IOP 104; collecting clinical outcome data on these same patients
3163309|NCT00479063||Cases|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Cases had been referred for a lumbar MRI for LBP lasting > 90 days.
3163310|NCT00479063||Controls|All subjects screened for this study were aged 30 to 50 years, had been referred to participating Radiology services, and underwent a lumbar MRI. Controls were headache patients who had been referred for a cranial MRI, which turned out to be normal, and who either had no history of LBP or had only experienced one episode in their life, which had lasted for less than 7 days.
3163311|NCT00479128|Experimental|Bortezomib + Gemcitabine + Doxorubicin|Starting dose of Bortezomib 0.8 mg/m^2 IV Over 3-5 Seconds. Starting dose of Gemcitabine 225 mg/m^2 IV Up to 90 Minutes. Starting dose of Doxorubicin 12.5 mg/m^2 IV Over 15-30 minutes.
3163312|NCT00479141|Experimental|1|HIV infected participants and their families
3163313|NCT00479141|Experimental|2|Popular Opinion Leaders (POL) participants
3163314|NCT00479180|Experimental|AVG1|Vascugel
3163315|NCT00479180|Placebo Comparator|AVG2|Gelfoam
3163316|NCT00479180|Experimental|AVF3|Vascugel
3163317|NCT00479180|Placebo Comparator|AVF4|Gelfoam
3175112|NCT00630214|Active Comparator|B|Oral calcium alone supplement after total thyroidectomy and central neck dissection
2504816|NCT02867878|Placebo Comparator|Saline solution|Patients in this arm will receive systemic infusion of saline solution at 140μg/kg/min for 3 minutes plus standard therapy according to current guidelines
2504838|NCT02867553|Experimental|Rituximab by intravenous|attack treatment (4 slow intravenous perfusions of rituximab at a dose of 375 mg / m2 on day 1, day 8, day 15 and day 22) and maintenance treatment (intravenous perfusions of rituximab at a dose of 375 mg / m2 every 2 months for 2 years).
2504841|NCT02867553|Active Comparator|multi-field radiotherapy|multi-fields radiotherapy with a dose between 20 and 30 gray and a fractionated dose over 2 at 3 weeks.
2504873|NCT02867293|Active Comparator|Preop-drainage|ascites drained over the pre-operative week through multiple ultrasound guided paracentesis
2504875|NCT02867293|Active Comparator|Op-drainage|ascetic fluid drained through an abdominal incision after anesthesia
2504966|NCT02866994|Experimental|Project Connect Online (PCO)|Creation of personal website to share breast cancer experience with friends and family
2504975|NCT02866994|Experimental|PCO PLUS|Creation of personal website to share breast cancer experience with friends and family, as well as other women diagnosed with breast cancer
2504990|NCT02866474|Other|- Puteaux or Paris for elderly persons|
2504995|NCT02866474|Other|-Two EHPAD in Lyon for elderly persons living|
2505070|NCT02866266||All commercially insured patients in the HIRD|
2505071|NCT02866266||All Medicaid patients in a participating state Medicaid plan|
2505086|NCT02865824|Active Comparator|Continue thienopyridine|Patients continue dual antiplatelet therapy (DAT) before colonoscopy and all polyps are removed by cold snare polypectomy.
2505089|NCT02865824|Experimental|Discontinue thienopyridine|Patients discontinue thienopyridines for 1 week before colonoscopy and all polyps are removed by cold snare polypectomy.
2505152|NCT02865668|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with one Extended Release (XR) tablet of metformin of 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with one metformin (XR) tablets of 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2505153|NCT02865668|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2505154|NCT02865668|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2505155|NCT02865668|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2505204|NCT02865226|Experimental|experimental group|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)
2505206|NCT02865226|Active Comparator|control group|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual)
3175113|NCT00630227|Experimental|Single|all patients are treated with the experimental therapy
3175114|NCT00630240||1|only one arm for study
2505326|NCT02864550|Experimental|Doxycycline arm|Participants in this intervention group will receive doxycycline 100mg orally daily, which is available as a 100mg capsule. This single daily dose was chosen to maximize adherence, given the common use of once-daily Human Immunodeficiency Virus (HIV) pre-exposure prophylaxis (PrEP), as well as its efficacy as once-daily prophylaxis against malaria and its utility as dosing as infrequent as once weekly for another spirochete infection, leptospirosis.
2505329|NCT02864550|Placebo Comparator|Placebo arm|Participants in this control group will receive a placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group.
2505400|NCT02864121|Experimental|arm 1|all patients included in IDAHO study
2505450|NCT02863744|Experimental|CAF+SCTG|
2505500|NCT02863237||weaning failure group|Patients reconnected to the ventilator within 48 hours after SBT will be designated the weaning failure group
2505503|NCT02863237||weaning success group|Patients who pass the SBT and breathing without ventilator support within 48 hours are designated the weaning success group
2505594|NCT02862509|Experimental|Budesonide nasal instillation|budesonide(0.5mg/2ml) 1 respule plus normal saline solution 120ml instilled in vertex to floor position daily
2505596|NCT02862509|Placebo Comparator|Normal saline nasal instillation|Normal saline solution instilled in vertex to floor position daily
2505895|NCT02860715|Experimental|Cohort 3|GX-I7 IM 60㎍/㎏ (8 subjects) / Placebo (2 subjects)
2505914|NCT02860312|Active Comparator|Exercisers|Intradialytic exercise on stationary bicycles
3175115|NCT00630279|Placebo Comparator|1|
3175116|NCT00630279|Experimental|2|
3175117|NCT00630279|Experimental|3|
3175118|NCT00630279|Experimental|4|
3175119|NCT00630370|Placebo Comparator|1|2 Placebo tablets, TID, orally, 58 days
3175120|NCT00630370|Experimental|2|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
3175121|NCT00630370|Experimental|3|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
3175122|NCT00630370|Experimental|4|2 ATI 40mg tablets, TID, orally, 58 days
3175123|NCT00630383|Experimental|1|Patients will receive 25 live hookworm larvae.
3175124|NCT00630383|Placebo Comparator|2|Patients will receive 0.01 % histamine solution.
3175125|NCT00630422||64|All Patients
3175126|NCT00630435|Experimental|1|
3175127|NCT00630435|Experimental|2|
3175128|NCT00630435|Experimental|3|
3175129|NCT00630435|Active Comparator|4|
2504892|NCT02867384|Sham Comparator|Placebo|"Placebo will be administered at a pre- determine dose, intravenously, at 3, 6, 9 and 12 months from transplantation.~Premedication with histamine blockers and acetaminophen will be provided~All subjects will undergo allogeneic stem cell transplantation according to locally approved clinical trials"
2504943|NCT02866851|Experimental|Monitoring by Web application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
2504988|NCT02866604|Active Comparator|Strerofundin|Days of intervention: 3 days
2504989|NCT02866604|Active Comparator|0.9% saline|Days of intervention: 3 days
2505049|NCT02866253|Experimental|DHEA Group|DHEA 25mg t.i.d. for more than 12weeks
2505052|NCT02866253|No Intervention|Control Group|patients without any DHEA
2505085|NCT02865941|Experimental|5 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed five times per week, of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
2505087|NCT02865941|Experimental|1 milk analysis|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed once per week of native breast milk batches which had been prepared for 24 hours feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
2505142|NCT02865629|Experimental|N-acetyl cysteine|Following the screening and review of all laboratory studies, patients will be scheduled to receive N-acetylcysteine.
3196485|NCT00851032||Molecular Profiling Analyses|Participants seen in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center in Houston, Texas
3196486|NCT00851045|Active Comparator|Arm 1|Irinotecan/5-Fluorouracil (bolus)/5-Fluorouracil (infusional)/Leucovorin calcium/CT-322
2505217|NCT02865174|Active Comparator|Topical tranexamic acid|Intraarticular application of tranexamic acid Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
2505218|NCT02865174|Active Comparator|Floseal®|"Floseal® was applied on potential bleeding sites before prosthesis implantation.~Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay"
2505219|NCT02865174|Placebo Comparator|Control group|No intervention before closure of joint capsule. Enoxaparin for venous thromboembolism prophylaxis in the duration of hospital stay
2505274|NCT02864758||Group 1|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with rivaroxaban
2505275|NCT02864758||Group 2|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with vitamin k anatognists
2505277|NCT02864758||Group 3|Adult patients with nonvalvular atrial fibrillation (NVAF) treated with dabigatran
2505319|NCT02864472|Other|combination Tx|combination Tx(vPDT +ranibizumab) (M0) + ranibizumab PRN (M3-6)
2505320|NCT02864472|Other|mono Tx|Ranibizumab (at 4 weeks interval) *3 (M0-2) + ranibizumab PRN (M3-6)
2505343|NCT02864277|No Intervention|No Intervention Conventional Strategy|Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.
2505344|NCT02864277|Experimental|ERAS Group|ERAS (enhanced recovery after surgery)
2505412|NCT02864056|No Intervention|Control|Usual care
2505419|NCT02864056|Experimental|Tai Chi|Completes 50 hours of Tai Chi, a combination of in-class and at-home practise.
2505451|NCT02863562|Experimental|Group 1|"This group included 16 subjects. They received kinesio taping for both ankle joints and and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training."
2505452|NCT02863562|Experimental|Group 2|"This group received placebo kinesio taping for ankle joint (no tension) and performed proprioceptive exercises.~Proprioceptive exercises were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed. Kinesio taping technique was used on both ankles on the first day of training in the same way as before but with no tension. It was removed on the second day of training."
2505454|NCT02863562|Experimental|Group 3|This group received kinesio taping for ankle joint. Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training.
2505530|NCT02863120|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 10cc of normal saline and 30cc of bupivacaine HCl administered prior to cementation of knee implants
2505534|NCT02863120|Active Comparator|Adductor canal and tibial nerve block|Preoperative tibial nerve block with 15cc bupivacaine HCl and adductor canal block with 20cc adductor canal block. Postoperative continuous adductor canal block with 550cc ropivacaine at 8cc per hour
2505573|NCT02862587|Experimental|Precision Cells|"precision cells combined with Chemotherapy treatment:~Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. precision cells：once per 3 weeks with a total of three periods."
2505574|NCT02862587|Active Comparator|Chemotherapy|Once a week with a total of six times before 60 days prior to the start of drawing blood.
2505628|NCT02862249|Experimental|Faecal microbiota transplantation|Faecal microbiota transplantation.
2505635|NCT02862249|Placebo Comparator|Placebo|Placebo solution.
2505679|NCT02861846|Other|Presence of biomarkers of AD in cerebrospinal fluid|Patients older than 60 years, with normal brain MRI and with normal cognitive functioning who demonstrate a profile of CSF biomarkers of AD suggestive of biological AD
2505714|NCT02861508|Active Comparator|Usual care|Usual care as determined by treating team. Ultrasound may still be part of the workup per the treating team's discretion.
3196487|NCT00851045|Active Comparator|Arm 2|Irinotecan/5-Fluorouracil(bolus)/5-Fluorouracil(infusional)/Leucovorin calcium /Bevacizumab/Bevacizumab Placebo(saline solution)
2504925|NCT02867098|Experimental|Cohort 4|Dose Level 4 XmAb5871 given IV Q14days X 3
2504927|NCT02867098|Experimental|Cohort 5|Dose Level 5 XmAb5871 given SC Q7days X 3
2504949|NCT02866721|Experimental|Human Allogeneic Mesenchymal Stem Cells|"One time IV Infusion of up to 5 x 10^6 allogeneic hMSCs/kg of body weight. A dose escalation using the 3+3 design will be employed. The three doses are 1 x 10^6, 3 x 10^6, and 5 x 10^6 hMSCs/kg. There is no placebo group. All study participants will receive stem cells."
2505020|NCT02866526||group1|adolescents (14-17 years old)
2505023|NCT02866526||group 2|young adults (20-29 years old)
2505131|NCT02865707|Experimental|Prebiotic|Prebiotic group will take 15 grams of prebiotic product Synergy-1 per day for 6 months. Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1). During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
2505134|NCT02865707|Placebo Comparator|Placebo|Placebo group will take 15 grams of maltodextrin per day for 6 months. Maltodextrin is a sugar adsorbed in the small bowel with no effect on the colonic intestinal microbiota. During the first two weeks the patient is advised to take 7.5 g of the product at breakfast only. Starting in week 3 until the end of the treatment the participant will take 7.5 g at breakfast and 7.5 g at dinner for a total of 6 months, or until you experience a flare.
2505179|NCT02865356|Experimental|Cyclosporine 5% Solution|"SP14019-F-01 Cyclosporine solution, 5%. Cyclosporine solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
2505187|NCT02865356|Placebo Comparator|Placebo|"SP14019-F-02 vehicle-control placebo solution. Vehicle-control placebo solution will be applied twice daily for four complete weeks (28 days) in all affected areas.~A randomized list will be created to determine in which side of the body (left or right) the subject will apply each medication"
2505278|NCT02864862|Active Comparator|Immediate implant|Immediate implant alone
2505282|NCT02864862|Active Comparator|Immediate implant combined with SCTG|Subepithelial connective tissue graft (SCTG)
2505289|NCT02864862|Active Comparator|Immediate implant combined with ADM|Acellular dermal matrix (ADM)
3196488|NCT00851058|Experimental|Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
3196489|NCT00851058|Active Comparator|Community Counseling|Four session of group counseling and six hours of volunteering in a local not for profit community agency.
2505424|NCT02863822|Experimental|Low FODMAP|Subjects will be given dietary education in the low FODMAP diet, which they will continue for 4 weeks. Subjects will then followup with the dietician and subjects with a symptomatic response will be given instructions for reintroduction.
2505427|NCT02863822|Active Comparator|Choose My Plate|Subjects will receive dietary counseling in the choose my plate diet as defined by choosemyplate.gov. Subjects will also receive 2 dietician visits, 4 weeks apart.
2505455|NCT02863510|Experimental|Renal Denervation|Participation receiving renal sympathetic denervation
2505546|NCT02863185|Experimental|Pitavastatin group|Use of 2mg or 4mg Pitavastatin
2505547|NCT02863185|Active Comparator|Atorvastatin group|Use of 10mg or 20mg Atorvastatin
3196490|NCT00851058|Placebo Comparator|Prototypic Community Service|Four hours of education about road safety and 16 hours volunteering at a local not for profit community service.
3196491|NCT00851071|Active Comparator|Cognitive Behavioral Therapy|Three individual 45 minute cognitive behavioral therapy sessions over a 3 month period
3196492|NCT00851071|No Intervention|Usual Care Arm|The Usual Care Arm will be the control arm. These patients will not be scheduled with any CBT sessions.
3196493|NCT00851123|Experimental|1. Modified Constraint-Induced Movement therapy|Modified Constraint-Induced Movement Therapy at the rehabilitation unit or in an outpatient clinic.
3196494|NCT00851123|Experimental|2.Task-specific bimanual training|Task-specific bimanual training at the rehabilitation unit or in an outpatient clinic.
3196495|NCT00851136|Experimental|1|
3196496|NCT00851149||1/10|Abdominal aortic surgery patients
3196497|NCT00851149||2/10|Total hip replacement patients
3196498|NCT00851162|Experimental|Trinity|Trinity multipotent stem cells
3196499|NCT00851162|Active Comparator|Demineralized bone matrix|Demineralized bone matrix
2505725|NCT02861300|Experimental|CB-839 + capecitabine|Patients will receive CB-839 orally twice daily for 21 days (continuous administration) and capecitabine orally twice daily for 14/21 days. In the phase I portion of the study, patients will receive escalating doses of CB-839 and capecitabine and will have day 15 blood samples drawn and archived for as needed assessment of CB-839 pharmacokinetics. In the phase II portion of the study, patients will receiving 800mg CB-839 and 1000mg/m^2 capecitabine as were determined to be safe doses during the phase I portion of the study. They will also undergo pre-treatment and post-treatment blood samples and tissue biopsies for evaluation of pharmacodynamic biomarkers.
2505809|NCT02861040|Experimental|Treatment (volasertib, vincristine sulfate liposome)|Patients receive volasertib IV over 1 hour on day 1 and vincristine sulfate liposome IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression, development of an inter-current illness that prevents further administration of treatment, unacceptable toxicity, patient decides to withdraw or treating investigator determines that the patient should be taken off treatment for any reason.
2505882|NCT02860663|Active Comparator|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
2505891|NCT02860663|Active Comparator|Vitamin D2|10 ug/d of vitamin D2 for 6 weeks
3196500|NCT00851175|No Intervention|1|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia
3196501|NCT00851175|Active Comparator|2|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
3196502|NCT00851175|Experimental|3|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg
3196503|NCT00851175|Active Comparator|4|forearm bloodflow after 2,3, and 5 minutes of forearm ischemia after 7 days oral treatment with rosuvastatin 1dd 20mg with concommitant administration of caffeine (90 ug/min/100ml forearm volume) into the brachial artery of the experimental (=non dominant) arm
2504933|NCT02866747|Experimental|Arm B: combined treatment|"hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.~* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I."
2505047|NCT02866396||Pregabalin patients|Same dose of preoperative pregabalin 1h after surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration (PACU if NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
2505051|NCT02866396||Naive patients|Pregabalin 150mg PO initiated 1h before surgery and associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
2505109|NCT02865889||Uterine oncologic Indications for surgery|
2505198|NCT02865200|Experimental|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique. The needles were kept on the body for 20 minutes and at the 10th minute, the needle was rolled and re-stimulation was enabled. The treatment was applied twice a week, which is equal to 6 sessions in total.
2505207|NCT02865200|Experimental|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again. The period of treatment was 6 sessions in total with 25 minutes of each.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
2505270|NCT02864992|Experimental|Tepotinib|
2505413|NCT02863887|Experimental|Weight loss intervention|Churches randomized to the intervention condition will receive the community health coach delivered church based intervention for 6 months followed by 6 months of weight maintenance.
2505417|NCT02863887|Experimental|Delayed Treatment Control Group|Churches in the delayed treatment control condition will receive information on various health topics relevant to African Americans, such as strokes, lupus, sickle cell, etc. via text message during the first six months. Participants in this group will not receive any behavioral strategies designed to alter weight, physical activity, or diet during this time. They will receive the community health coach delivered church based weight loss intervention after 6 months.
2505437|NCT02863640||Exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA above the 59th percentile of the population
2505441|NCT02863640||Non exposed patients|Patients treated for Parkinson's disease with a cumulative dose of L-DOPA below the 41th percentile of the population
2505468|NCT02863341|Experimental|naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
2505471|NCT02863341|No Intervention|naive Wait-list Control arm|
2505476|NCT02863341|Experimental|non-naive Deprescribing arm|Team-based deprescribing practice, Deprescribing Guide
2505477|NCT02863341|No Intervention|non-naive Wait-list Control arm|
2505513|NCT02863042|Experimental|Deltoid Tendon Repaired|Repair Deltoid Tendon
2505517|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|
2505581|NCT02862756|Experimental|patient with endovascular treatment|
2505633|NCT02862288|Experimental|Renal tumor|Microwave ablation of renal tumor
2505641|NCT02862288|Experimental|Lung tumor|Microwave ablation of lung tumor
2505645|NCT02862288|Experimental|Bone tumor|Microwave ablation of bone tumor
2505700|NCT02861833||Patients with a cancerous wound|major patients followed in a cancer ward and holders of a cancerous wound.
2505823|NCT02861196|Experimental|Therapy Arm|Patients who have response to neoadjuvant chemotherapy will be separated into two groups (GI cT0-1 and G2 ≥cT2). G1receive concurrent radiochemotherapy, and G2 receive partial resection of the bladder+lymphadenectomy+adjuvant radiotherapy.Patients who have no response to neoadjuvant chemotherapy or disagree to receive the sequential treatment will receive the radical resection of bladder.
2505860|NCT02860676|Experimental|Cirmtuzumab|
2505884|NCT02860377|Active Comparator|stranger's voice|At the end of surgery, patients were stimulated to wake up by recorded stranger's voice, which was recorded before the operation.
2505889|NCT02860377|Experimental|maternal voice|At the end of surgery, patients were stimulated to wake up by recorded maternal voice, which was recorded before the operation.
2505937|NCT02860143||studying ventilation during sedation|Comparing ventilation during sedation with capnography
2505944|NCT02859857|Experimental|Rising dose; safety and tolerance|Sequential cohorts of patients with advanced solid tumors and recurrent high-grade gliomas will be be treated with escalating doses of BXQ-350 until the MTD is established, or in the absence of a MAD, the highest planned DL is reached.
2505945|NCT02859857|Experimental|Solid tumor patients|Cohort of patients with advanced solid tumors administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
2505946|NCT02859857|Experimental|Glioblastoma Multiforme patients|Cohort of patients with recurrent high-grade gliomas administered BXQ-350 at the MTD determined in Part 1 or at the highest planned DL if the MAD is not reached.
2505947|NCT02859857|Experimental|Gastrointestinal tumor patients|Cohort of patients with Gastrointestinal tumors as defined in the protocol and administered BXQ-350 at the 2.4 mg/kg dose level.
2505948|NCT02859857|Experimental|Ependymoma tumor patients|Cohort of patients with ependymoma administered BXQ-350 at the 2.4 mg/kg dose level.
2504946|NCT02866890|Experimental|Laryngeal Tube Suction size 1|Measurement of leak pressure
2504964|NCT02866890|Experimental|Laryngeal Tube Suction size 2|Measurement of leak pressure
2504970|NCT02866890|Experimental|Laryngeal Tube Suction size 2.5|Measurement of leak pressure
2505038|NCT02866539|Active Comparator|Polyherbal capsule|Polyherbal capsule contains leaves of 3 herbs namely C. indica, B. spectabilis and C. rosea.
2505042|NCT02866539|Placebo Comparator|Placebo|Placebo will contain an inert substance
2505088|NCT02865980|Experimental|inflammation|The effect of washing with betadine and clove extract on incidence of inflammation place logging shaldon catheter in the hemodialysis patients
2505092|NCT02865980|Experimental|infection|The effect of washing with betadine and clove extract on incidence of infection place logging shaldon catheter in the hemodialysis patients
2505146|NCT02865642|Experimental|Serotonin Uptake Inhibitors|"Treatment 1: Starting with Escitalopram 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage increase of 5mg/day till target dose of Escitalopram 20mg/day.~Subjects will remain on Escitalopram 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by dosage reduction of Escitalopram 10mg/day for one week."
2505148|NCT02865642|Placebo Comparator|Placebo|"Treatment 2: Starting with Placebo 5mg/day at the baseline-visit (day 14 (+-7) post stroke) for 7 days followed by a weekly dosage of 5mg/day till target dose of Placebo 20mg/day.~Subjects will remain on Placebo 20mg/day until visit 3 (day 90 (+-14) post stroke) followed by Placebo 10mg/day for one week."
2505265|NCT02864953|Experimental|BIIB093|BIIB093 administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
2505271|NCT02864953|Placebo Comparator|Placebo|Placebo administered as a bolus followed by continuous intravenous (IV) infusion over 72 hours.
2505484|NCT02863315|Experimental|tsDCS|In the tsDCS group, anodal tsDCS will be applied for 20 minutes.
2505489|NCT02863315|Placebo Comparator|sham|In sham tsDCS group, the current of anodal tsDCS will be discontinued after 30 s while the power indicator remained on for 20 minutes.
2505512|NCT02862925|No Intervention|Pre-Intervention|A consecutive sample of 350 patients will be collected. After informed consent, data will be abstracted from the patient's record including day and time of delivery, method of delivery, parity, gestational age, meconium presence, heart rate abnormality and induction methods. For CD, the following data will be collected: decision-to-delivery time, Partogram adherence, time of each FSST, Apgar score, date and time of delivery and Comorbidities such as: Hypertension-spectrum disorders, Malaria, Postpartum Hemorrhage, Macrosomia, History of CD, Diabetes, Sickle Cell, and HIV status.
2505518|NCT02862925|Experimental|Post-intervention|The study will take place on the labor ward at KCMC in Moshi, Tanzania. It will involve women who present to the labor ward in labor or who undergo an induction of labor. A consecutive sample of 350 patients will be collected. Study investigators will be present for 24 hours a day, 7 days a week on a rotating schedule during the enrollment period. All patients who fit inclusion and exclusion criteria will be approached if they are deemed medically stable.
2505591|NCT02862769|Experimental|Lidocaine infusion|first group (lidocaine group) will include those who receive a intraoperative lidocaine infusion (Induction bolus dose of 1.5 mg/kg body weight followed by a continous lidocaine infusion
2505593|NCT02862769|Placebo Comparator|Saline Infusion|The second group will include those who receive a intraoperative placebo i(Induction bolus dose of 1.5 mg/kg body weight of lidocaine followed by a continous saline infusion at the same rate as the lidocaine infusion.
2505617|NCT02862171|Experimental|Dapivirine Vaginal Ring-004|Dapivirine Vaginal Ring, 25 mg.Each participant will engage in the screening process for up to 45 days prior to enrolment and will use the monthly Dapivirine Vaginal Ring for a period of up to 12 months. IPM will have the option to extend this trial period.
2505658|NCT02862054|Experimental|Splenectomy|Splenectomy as a treatment for patient with relapsed haemophagocytic lymphohistiocytosis of unknown etiology
2505720|NCT02861703|Experimental|Online lifestyle intervention|"A weekly psychosocial intervention (Online Lifestyle Intervention) delivered in an online group format, to promote positive changes in physical (eating habits, physical activity) and mental health (body image, self-esteem, self-efficacy)."
2505775|NCT02861248|Experimental|Laser treatment|Fractional micro-plasma radiofrequency treatment given to 95 patients with non-hypertrophic burn scar.
2505816|NCT02860975|Experimental|Inhaled Nitrogen|A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
2505919|NCT02860702|Experimental|Exclusive Human Milk|All infants randomized to this arm will receive exclusive human milk diet with addition of human milk derived fortifier from birth to 30 days post initiation of feedings after initial palliative cardiac surgery
2505921|NCT02860702|Active Comparator|Human/Bovine Milk|All infants randomized to this arm will receive exclusive human milk diet prior to randomization and will use either human and/or bovine milk and fortifier per the institution's standard practice 30 days post initiation of feedings after initial palliative cardiac surgery
2505951|NCT02859844|Experimental|TTNS ON|Transcutaneous tibial nerve stimulation
2505953|NCT02859844|Sham Comparator|TTNS OFF|Sham/placebo stimulation
2506002|NCT02859701|Experimental|AK002|AK002 will be administered as an intravenous (IV) infusion in 8 cohorts of single escalating doses and two cohorts with multiple doses
2506004|NCT02859701|Placebo Comparator|Placebo|Placebo administered as anl IV infusion
2506130|NCT02858817|Experimental|51,200 PfSPZ|Three injections of 51,200 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2506133|NCT02858817|Experimental|150,000 PfSPZ|Three injections of 150,000 PfSPZ Challenge (P. falciparum strain: NF54) under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2506135|NCT02858817|Placebo Comparator|Placebo|Three injections of NaCl 0,9% solution under chemoprophylaxis with atovaquone/proguanil 250mg/100mg (A/P) at 4 week intervals
2506199|NCT02858284|Experimental|TUG Device|1 time external application - device powered on
2506200|NCT02858284|Sham Comparator|Sham|1 time external application - device powered off
2504950|NCT02866929|Active Comparator|Conventional orthodontic treatment|Patients that will receive conventional orthodontics
2504962|NCT02866929|Experimental|Orthodontics with decortication|Patients that will receive orthodontic treatment with selective alveolar decortication
2504968|NCT02866929|Experimental|Orthodontics decortication and Mucograft|Orthodontic treatment, selective alveolar decortication and Mucograft® on the mandibular anterior segment
2504973|NCT02866929|Experimental|Orthodontics and Mucograft®|Patients that will receive orthodontic treatment and Mucograft® on the mandibular anterior segment
2505037|NCT02866370|Experimental|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously
2505043|NCT02866370|Active Comparator|Chemotherapy|"Ovarian Cancer Patients:~Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days Topotecan (4mg/m2) IV Day 1, 8, 15 every 28 days~Endometrial Cancer Patients:~Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days Doxorubicin IV (60mg/m2) every 21 days~Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
2505129|NCT02865772||observational|healthy newborns
2505176|NCT02865460|Experimental|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
2505180|NCT02865460|Placebo Comparator|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x 200 mg for 4 months) with food each morning-upon waking
2505266|NCT02864901|Experimental|KSL-W 30 mg|3 times per day over 4 treatment days
2505268|NCT02864901|Placebo Comparator|Chewing Gum Placebo|3 times per day over 4 treatment days
2505307|NCT02864602|Experimental|Dexamethasone 2mg|The experimental intervention in this arm will be an IV infusion of 2mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
2505309|NCT02864602|Experimental|Dexamethasone 4mg|The experimental intervention in this arm will be an IV infusion of 4mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
2505310|NCT02864602|Experimental|Dexamethasone 8mg|The experimental intervention in this arm will be an IV infusion of 8mg of dexamethasone. Volunteers will also have a cross-over placebo comparator (saline infusion).
3163318|NCT00479193|Other|1|There is one arm to the study. The same subjects are their own control. One of the investigators will identify two sites that appear to be the same depth on each patient [1 site Polymen and 1 site bacitracin/xeroform )]. One site will be identified for bacitracin/xeroform and one site for Polymen. All burns will be initially debrided and cleaned according to burn unit protocol. Laser Doppler will be utilized to determine burn depth at both the trial and control sites. On each subsequent visit, patients will rate the pain of the dressing change on a 1-10 pain intensity scale.The study will end for each patient when the investigator determines that 95% of their burn has re-epithelized.
3163319|NCT00479219|Experimental|A|
2505411|NCT02863926|Experimental|Day 7|BKA performed at 7 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2505420|NCT02863926|Experimental|Day 14|BKA performed at 14 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2505421|NCT02863926|Experimental|Day 21|BKA performed at 21 days post autologous cBMA injection. Injection of cBMA aspirate into the index leg
2505461|NCT02863536|Other|Polybactum®|"Polybactum® ovules are administered intravaginally on 3 cycles, 1 cycle per month.~Polybactum is a medical device Class IIa used and marketed for the recurrence of Bacterial Vaginosis."
2505539|NCT02863159|Active Comparator|Treatment Group 1|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +3.25D (ZLB00) in their non-dominant eye.
2505544|NCT02863159|Active Comparator|Treatment Group 2|50 qualified study patients will receive the +2.75D (ZKB00) in their dominant eye and the +4.00D (ZMB00) in their non-dominant eye.
3163320|NCT00479219|Placebo Comparator|B|
3163321|NCT00479245|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
2505738|NCT02861352|Experimental|diet zinc|3 dietary zinc levels: 6 mg/d, 10 mg/d and 25 mg supplemental zinc/d
2505992|NCT02859961|Experimental|PRO 140 SC 350 mg weekly injection (Group A)|PRO 140 350 mg (175 mg/mL) SC injections per week
2505993|NCT02859961|Experimental|PRO 140 SC 525 mg weekly injections (Group B)|PRO 140 525 mg (175 mg/mL) SC injections per week
2505994|NCT02859961|Experimental|PRO 140 SC 700 mg weekly injections (Group C)|PRO 140 700 mg (175 mg/mL) SC injections per week
2506056|NCT02859350|Experimental|Group 6a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 9.0x10^5 PfSPZ Vaccine. Group 6a will start 7 weeks after Group 1a.
2506842|NCT02854085|Experimental|Music Reminiscence Activity|Music Reminiscence Activity, 24 sessions
3163322|NCT00479271|Active Comparator|Home Care|"A flexible home-care program tailored to the needs of the individual and the family. The components of the intervention will include:~Basic education about dementia (what is the disease, its course, its features etc)~Education about common behaviour problems and how they can be managed~Support to the carer, for example for an elderly carer living alone with the patient, in activities of daily living~Referral to specialists when behaviour problems are severe and warrant medication intervention (sedatives)."
3163323|NCT00479271|Other|Wait-list|This group will be put on a waiting list to receive the intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
3163324|NCT00479323|Other|1|Immunize healthy volunteers with pneumococcal vaccine (Pneumovax 23) to obtain a pool of hyperimmune sera in a quantity sufficient to generate reference sera.
3163325|NCT00479349|Active Comparator|1|SAM 531 + placebo
3163326|NCT00479362|Experimental|1 Warfarin Uninterrupted|Warfarin therapy is continued without interruption prior to cardiac pacing device implantation
3163327|NCT00479362|Active Comparator|2 Warfarin Interrupted|Warfarin therapy is discontinued 2 days prior to cardiac pacing device implantation
3163328|NCT00479362|Sham Comparator|3 Aspirin Group|Patients with aspirin therapy during implantation
3163329|NCT00479362|Other|4 No Antithrombotic Group|No antithrombotic treatment during operations
2504977|NCT02866773|Experimental|HD1:Education sessions, Reminders, Whataps group|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , Health diet ambassadors' electronic communication group.
2504979|NCT02866773|Active Comparator|HD2:Education sessions, Reminders|The intervention includes Health diet knowledge enhancement session, Health diet anti-inertia Reminders , and Health diet ambassadors' electronic communication group.
2504980|NCT02866773|Active Comparator|HD3:Education sessions, Whataps group|The intervention includes Health diet knowledge enhancement session and Health diet ambassadors' electronic communication group.
2504981|NCT02866773|Active Comparator|HD4:Education sessions|The intervention includes Health diet knowledge enhancement session only.
2505024|NCT02866227|Experimental|BV and/or VVC infection - Gel Treatment|Randomized 1:1 to gel nightly for 7 days. N = 40
2505025|NCT02866227|Experimental|BV and/or VVC infection - Vaginal Insert Treatment|Randomized 1:1 to insert nightly for 7 days. N = 40
2505100|NCT02866032|Experimental|MOB015B|
2505105|NCT02866032|Active Comparator|Ciclopirox 80 mg/g|
2505167|NCT02865551|Experimental|Extended catheterization|Participants in which a foley catheter will be inserted adjacent to epidural anesthesia during labor.
2505170|NCT02865551|Experimental|Intermittent catheterization|Participants in which a short term catheter will be inserted every 4 hours during labor after epidural anesthesia until delivery.
2505481|NCT02863276|Experimental|Intensified insulin group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving tight blood glucose control with intensified insulin therapy (blood glucose target<6 mmol*l-1) via an continuous insulin infusion.
2505487|NCT02863276|No Intervention|Control group|Patients undergoing elective colorectal surgery will receive standard anesthesia including epidural analgesia and nutritional support with an intravenous amino acid solution while receiving standard blood glucose control (blood glucose target <10 mmol*l-1) via subcutaneous insulin boluses
2505541|NCT02862990||Pre menopausal women with breast cancer|Pre menopausal women with breast cancer prior treatment in face of infertility evoked by chemotherapy
2505556|NCT02862561|Experimental|Precision Cell Immunotherapy|"Precision Cells combined with Chemotherapy treatment: Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood. Precision Cells：once per 3 weeks with a total of three periods."
2505558|NCT02862561|Active Comparator|Chemotherapy|"Chemotherapy:~once a week with a total of six times before 60 days prior to the start of drawing blood."
2505618|NCT02862431|Experimental|Cohort 1 (JNJ-64565111 2.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 2.5 Nanomole Per Kilogram (nmol/kg) JNJ-64565111 or placebo.
2505619|NCT02862431|Experimental|Cohort 2 (JNJ-64565111 3 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.0 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
2505620|NCT02862431|Experimental|Cohort 3 (JNJ-64565111 3.5 nmol/kg or Placebo)|Participants in ratio of 3:1 will receive 3.5 nmol/kg JNJ-64565111 or placebo. Dose may be escalated based on review by Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29 but dose will not exceed 3.5 nmol/kg.
2505621|NCT02862431|Experimental|Cohort 4 (JNJ-64565111 Repeat or Lower Dose or Placebo)|Participants in ratio of 3:1 will receive a dose of JNJ-64565111 or placebo that would be a repeat or lower dose level previously assessed as well-tolerated.
2505669|NCT02861950|Active Comparator|Caudal block|Patients will receive a caudal block with 0.75-1ml/kg of 0.2% ropivacaine.
2505671|NCT02861950|Active Comparator|Penile Nerve Block|Patients will receive a dorsal penile nerve block with up to 0.75ml/kg of 0.25% bupivacaine.
3163330|NCT00479427|Experimental|Overall study|overall study population
3163331|NCT00479479|Experimental|Cobalamin|An intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
2505843|NCT02860806|Experimental|Part 1: Period 1 (JNJ-63623872 100 mg or Placebo)|Participants will receive a single intravenous (IV) infusion of JNJ-63623872 100 milligram (mg) [3 milligram per milliliters (mg/mL) solution] (Treatment A) or matching placebo (Treatment D) over 120 minutes.
3163332|NCT00479479|No Intervention|No intervention|No intervention
3163333|NCT00479492|Experimental|1|
3163334|NCT00479492|Experimental|2|
3163335|NCT00479492|Experimental|3|
3163336|NCT00479492|Placebo Comparator|4|
3163337|NCT00479505|Experimental|Active|
3163338|NCT00479505|Placebo Comparator|Placebo|
3163339|NCT00479570|Experimental|Study period 1, 2 or 3|
3163340|NCT00479570|Placebo Comparator|Placebo Study period 1, 2 or 3|
3163341|NCT00479583|Active Comparator|A|
3163342|NCT00479583|Active Comparator|B|
3163343|NCT00479609|Placebo Comparator|1|Placebo gel
3163344|NCT00479609|Active Comparator|2|Transdermal testostrone therapy
3163345|NCT00479622|Experimental|1|
3163346|NCT00479622|Experimental|2|
3163347|NCT00479635|Experimental|TPI 287|
3163348|NCT00479648|Active Comparator|1|Inactivated trivalent influenza vaccine
3163349|NCT00479648|Experimental|2|CSL412 formulation
3163350|NCT00479648|Experimental|3|CSL412 formulation
3163351|NCT00479648|Experimental|4|CSL412 formulation
3163352|NCT00479661|Experimental|1|Dexmedetomidine
3163353|NCT00479661|Active Comparator|2|Propofol
3163354|NCT00479739|Experimental|Arm 1|
3163355|NCT00479752|Active Comparator|A|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m²."
3163356|NCT00479752|Active Comparator|B|"FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
2505095|NCT02866019|Experimental|CLS2702C/CLS2702D|
2505185|NCT02865577||Adult asthma|"Adult asthma subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2505188|NCT02865577||Adult COPD|"Adult COPD subjects with airflow limitation (FEV1% predicted < 80%) will be recruited for this study.~Participants will undergo following study assessments:~Clinical History~Health status and disease control questionnaires~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2505191|NCT02865577||Healthy participants|"Healthy participants with no past history of cardiovascular or respiratory disease.~Participants will undergo following study assessments:~Clinical History~Focused physical examination~Electrocardiogram (ECG)~Blood test~Spirometry~Echocardiogram~Cardiac magnetic resonance (CMR) imaging~CMR survey"
2505393|NCT02863861|Experimental|Group PK|Propofol-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV propofol 1mg.kg-1 for induction with added doses of propofol 1mg.kg-1 when needed.
2505399|NCT02863861|Experimental|Group DK|Dexmedetomidine-Ketamine group: patients in this group will receive IV ketamine at a dose of 1mg.kg-1 in addition to IV dexmedetomidine 0.5 mcg.kg-1 for induction with additional doses of dexmedetomidine 0.5mcg.kg-1 when required
2505459|NCT02863705|Experimental|COMBIGAN®|One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months
2505470|NCT02863705|Experimental|COMBIGAN® + LUMIGAN® 0.01%|LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.
2505509|NCT02862951||Term pregnancy (>37 weeks gestation)|Term pregnancy (>37 weeks gestation)
2505584|NCT02862873|Experimental|Ondansetron|
2505586|NCT02862873|Placebo Comparator|Saline solution|
2505654|NCT02862210|Experimental|Lithium carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
2505655|NCT02862210|Placebo Comparator|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels provided by an unblinded study team member.
2505713|NCT02861716|Experimental|fentanyl and dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl and dexmedetomidine in 2ml volume will be injected slowly over 20 seconds.
2505715|NCT02861716|Active Comparator|dexmedetomidine and placebo for fentanyl|intrathecal bupivacaine (0.5%) 0.4mg/kg plus dexmedetomidine 0.2 μg/kg in 2ml volume and placebo (for fentanyl 0.2 μg/kg) it will be injected slowly over 20 seconds.
2505717|NCT02861716|Active Comparator|fentanyl and placebo for dexmedetomidine|intrathecal bupivacaine (0.5%) 0.4mg/kg plus fentanyl 0.2 μg/kg in 2ml volume and placebo (for dexmedetomidine 0.2 μg/kg) it will be injected slowly over 20 seconds.
2505736|NCT02861274|Active Comparator|electrophysiological testing|Patients will receive a pacemaker.
2505744|NCT02861274|No Intervention|control group|These subjects will receive cardicor® (beta blockers).
2505827|NCT02861170|Experimental|Brief Mindfulness-Based Intervention|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety as well as a 10-minute mindfulness-based intervention called a body scan at 3 different time-points (T1 - 1 week prior to surgery, T2 - within 4 hours before surgery, and T3 - approximately 24 hours after transfer from recovery to the orthopedic floor).
2505830|NCT02861170|No Intervention|Education|Participants in this arm will be provided with an educational brochure and links to videos containing strategies for coping with pain and anxiety.
2505873|NCT02860611||Type 1 Diabetes|Patients with type 1 diabetes
2505874|NCT02860611||Type 2 Diabetes|Patients with type 2 diabetes
2505875|NCT02860611||Control|Healthy volunteers
2505915|NCT02860260|Experimental|Patients with fibrinolysis|
2505920|NCT02860260|Placebo Comparator|Patients without fibrinolysis|
3163357|NCT00479817|Experimental|Arm A|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 10 mg/kg IV QW
3163358|NCT00479817|Experimental|Arm B|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 3 mg/kg IV QW
2506066|NCT02859285|Active Comparator|Estradiol vulvar cream|"The estradiol cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
2506067|NCT02859285|Placebo Comparator|Placebo cream|"The placebo cream 0.5 grams will be placed on the clitoris/vestibule every night for 2 weeks, then 3 times a week thereafter on Monday, Wednesday, and Friday, for a total of 12 weeks.~In addition estradiol 10mcg tablet will be placed in the vaginal every night for 2 weeks, then 2x a week on Tuesday and Thursday, for a total of 12 weeks."
2506084|NCT02858960|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO~Constant Treadmill Load Test (CTLT) using HFNCO"
2506087|NCT02858960|Active Comparator|The Venturi Mask|"Incremental Load Treadmill Test (ILTT) using venturi mask~Constant Treadmill Load Test (CTLT) using venturi mask"
3163359|NCT00479817|Active Comparator|Arm C|Paclitaxel 80 mg/m2 IV QW (3 on/1 off) + AMG 386 placebo
3163360|NCT00479830||Group 1|South Asian, Subgroup: Asian Indian, population in the Greater Houston area.
3163361|NCT00479830||Group 2|South Asian, Subgroup: Bangladeshi, population in the Greater Houston area.
3163362|NCT00479830||Group 3|South Asian, Subgroup: Pakistani, population in the Greater Houston area.
3163363|NCT00479830||Group 4|South Asian, Subgroup: Sri Lankan, population in the Greater Houston area.
3163364|NCT00479895|Other|1|Occlusion with pre-oxygenated HBOC-201 followed by dry occlusion
3163365|NCT00479895|Other|2|Dry occlusion followed by occlusion with pre-oxygenated HBOC-201
3163366|NCT00479934|Experimental|1|6 month treatment with Imtinib 400mg/day
3163367|NCT00479934|Placebo Comparator|2|6 month treatment with Placebo 400mg/day
2505003|NCT02866578|Experimental|Open lung protective ventilation|"Recruitment maneuvers (30 cmH2O during 30 seconds) after intubation, after CPB initiation, before aortic declamping and at ICU arrival.~PEEP at 8 cmH2O.~Ultraprotective ventilation during CPB: PEEP 8 cmH2O, Tidal volume 3mL/kg, Respiratory rate 12 cycles per minute, FiO2 40%.~Assigned intervention - Procedure: patients are randomized and ventilated with the open lung strategy from intubation to detubation."
2505004|NCT02866578|No Intervention|Conventional strategy|No recruitment maneuvers. PEEP at 2 cmH2O. During CPB: continuous positive pressure at 2 cmH2O.
2505054|NCT02866149|Other|"Cohort 1 - Anti checkpoint"|"Monitoring of patients with tumours treated by immune therapy.~Timing of blood sampling:~inclusion~after #8 weeks on therapy~at progression or 6 months from inclusion for patient without progressive disease~if toxicity grade 3 or 4, or grade 2 until 1 month."
2505056|NCT02866149|Other|"Cohort 2 - Oncoscan®"|"Monitoring of patients with HER 2+/- breast cancer and correlation with genome-wide copy number, loss of heterozygosity detection, as well as identification of frequently tested somatic mutations (Oncoscan® assays).~Timing of blood sampling:~inclusion~after 1 cycle of therapy (weeks 3-4)~up to 2 other samples, timepoints decided by the investigator"
2505058|NCT02866149|Experimental|"Cohort 3 - CirCe-PLA"|"Feasibility of Proximity-Ligation Assay (PLA) to study membrane proteins dimerisation by on isolated tumour cells in patients with HER2+/- breast cancer (HER 2+/-).~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2505059|NCT02866149|Other|"Cohort 4 - CDX PDX"|"Establishment of xenografts from tumor (PDX) and from Circulating Tumour Cell (CDX) by tumour and blood sampling.~One tumor sampling.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2505062|NCT02866149|Other|"Cohort 5 - Post-TP53"|"Follow-up of patients previously treated by neoadjuvant chemotherapy for triple negative breast cancer.~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2505066|NCT02866149|Other|"Cohort 6 - Palbociclib"|"Monitoring of patients treated with palbociclib~Timing of blood sampling:~Inclusion day (2 samples)~after #2 weeks of therapy~after #4 weeks of therapy~at progression."
2505068|NCT02866149|Other|"Cohort 7 - CTC_PD-L1_Breast"|"Detection of PD-L1 in metastatic breast cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2505073|NCT02866149|Other|"Cohort 8 - CTC_PD-L1_Broncho-Pulmonary"|"Detection of PD-L1 in metastatic lung cancer patients~Timing of blood sampling:~Inclusion~up to 3 other samples, timepoints decided by the investigator."
2505075|NCT02866149|Other|"Cohort 9 - NSCLC"|"Monitoring of patients with Non-Small Cell lung Cancer treated by immune therapy.~Blood sampling at 4 timepoints."
2505076|NCT02866149|Other|"Cohort 10 - Palbociclib II"|"Monitoring of patient with a metastatic breast cancer treated by palbociclib.~Timing of blood sampling:~Inclusion~after #4 weeks of therapy~at the first tumoral evaluation (month 3 or 4)~at progression."
2505077|NCT02866149|Other|Cohort 11 - Sarcomas|The cohort includes all patients with bone or soft tissue sarcoma. Timing of blood sampling depending on disease staging.
2505078|NCT02866149|Other|Cohort 12 - Faslorad|"Monitoring of patient with a metastatic breast cancer initiating a treatment by Faslodex-Afinitor.~Timing of blood sampling:~Inclusion~after #3-5 weeks of therapy~at the first tumoral evaluation (month 2 or 3)~at progression."
2505079|NCT02866149|Other|Cohort 13 - MUm|"The cohort concerns patients with uveal melanoma in the 1st systemic line at the metastatic stage (may have had prior adjuvant therapy or surgery/radiofrequency).~Timing of blood sampling:~J1C1~J2C1~J1C2~J1C5 (first tumoral evaluation)."
2505080|NCT02866149|Other|Cohort 14 - CNBC Snipe|"This cohort concerns patients with metastatic Non-Small Cell lung Cancer receiving anti-PD-1/PD-L1.~One tumour sampling.~Timing of blood sampling:~before treatment~at W8 of treatment (after radiological examination)~at W12 of treatment~at progression or 18 months after the beginning of treatment"
2505081|NCT02866149|Other|Cohort 15 - Breast CLI|"This cohort concerns patients with metastatic lobular breast cancer One tumour sampling.~Timing of blood sampling:~At inclusion~After biopsy post inclusion (or in 15 days after)~after 1 or 2 months of treatment~at progression or 18 months after inclusion"
3196504|NCT00851188|Experimental|internet CBT self-help|CBT via the internet
3196505|NCT00851188|Experimental|CBT self-help booklet|
2505211|NCT02865213|Experimental|Miniplates + OBA|"The intrusion of posterior teeth using Miniplates + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniplates.~The miniplates are for Jeil Dual top® anchor system, Jeil medical corporation, #702,kolon science valley 2nd, 811, Guro-Dong, Guro-Gu, Seoul, 152-050, Korea. Tel: 82.2.850.3500. Fax: 82.2.850.3537. homepage: www.jeilmed.co.kr/ E-mail: mktg@jeilmed.co.kr"
2505212|NCT02865213|Experimental|Miniscrews + OBA|"The intrusion of posterior teeth using Miniscrews + OBA will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth and miniscrews.~The miniscrews are for Denxy ® dental orthodontic products, Denxy technology co, limited . 404,Lihuabuilding,Furongroad, Changsha, Hunan, China. Tel: 0086-731-89717339. Fax: 0086-731-82237315. Homepage: www.denxy-orthodontic.com/email: DENXYDENTALBOSS@126.COM"
2505213|NCT02865213|Experimental|Only OBA|The intrusion of posterior teeth using OBA only will be performed. The investigators will apply a modified version of the OBA (Open Bite Appliance), by Erverdi and Usumez, for all patients in upper posterior teeth only.
2505279|NCT02864836||Patients with head or neck cancer|Samples collection
2505283|NCT02864836||Patients with lymphoma|Samples collection
2505288|NCT02864836||Patients without tumoral pathology|Samples collection
2505325|NCT02864433||Controls for non-cholera diarrhea cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
2505330|NCT02864433||Non-cholera diarrhea cases|- Cases of acute watery diarrhea that present for healthcare at the study sites, but that test negative for cholera
2505334|NCT02864433||Controls for cholera cases|- Community members that did not have diarrhea between date of study commencement, and time of presentation of the case
2505337|NCT02864433||Cholera cases|- Those with cholera-related diarrhea who present to healthcare at the study sites.
2505370|NCT02864212||Glucose monitoring|Glucose will be monitor in patients using fast-acting insulin.
3196506|NCT00851188|Active Comparator|Waiting list|
2505032|NCT02866448|Placebo Comparator|Vehicle control|"Subjects will consume~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
2505035|NCT02866448|Experimental|Isoquercetin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid~1 x 75mg cellulose pill"
2505041|NCT02866448|Active Comparator|Aspirin|"Subjects will consume~1 x 75mg dispersible aspirin~4 x 250mg cellulose capsules containing 250mg cellulose, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg Folic Acid"
2505046|NCT02866448|Experimental|Isoquercetin plus Aspirin|"Subjects will consume~4 x 250mg isoquercetin capsules containing 250mg isoquercetin, 62mg Ascorbic acid (Vitamin C), 5mg Nicotinic acid (Vitamin B3) and 0.25mg folic acid~1 x 75mg dispersible aspirin"
3196507|NCT00851201|Active Comparator|Standard Intervention|
2505178|NCT02865278|Experimental|Polyphenol-rich drink|The participants consume the polyphenol-rich drink. After 3 hours they consume a standard meal to evaluate whether the metabolic response may be influenced by polyphenols.
2505183|NCT02865278|Placebo Comparator|Placebo drink|The participants consume the control drink.After 3 hours they consume a standard meal to evaluate the metabolic response after a placebo.
2505221|NCT02865070||2 infants (ages 1-6mo) non-NICU setting|
2505223|NCT02865070||10 babies (full term, ages 37-42 weeks)|
2505225|NCT02865070||5 babies (premature, ages 34-37 weeks)|
2505227|NCT02865070||5 babies (premature, ages 31-34 weeks)|
2505228|NCT02865070||5 babies (premature, ages 28-31 weeks)|
2505229|NCT02865070||5 babies (premature, ages 25-28 weeks)|
2505231|NCT02865070||5 babies (premature, ages 23-25 weeks)|
2505232|NCT02865070||30 babies (any gestational age under 6 months)|
2505234|NCT02865070||25 neonates (ages 24-29 weeks for sub-study)|
3196508|NCT00851201|Experimental|Intensive lifestyle|
3196509|NCT00851214||Acute CHF/COPD|Patients presenting with shortness of breath secondary to acute exacerbation of CHF/COPD
2505388|NCT02864017|Experimental|L-Citrulline group|Enteral nutrition 5-day L-citrulline treatment (10 grams/day)
2505389|NCT02864017|Placebo Comparator|Control group|Enteral nutrition 5-day placebo treatment
2505458|NCT02863731|Experimental|Alternating postures: first day|Alternating body postures on the first day of measurement. Sitting body posture on the second day of measurement.
2505467|NCT02863731|Experimental|Alternating postures: second day|Alternating body postures on the second day of measurement. Sitting body posture on the first day of measurement.
2505472|NCT02863731|No Intervention|Control group|Sitting body posture on both days of measurement.
2505514|NCT02863055|Experimental|Nintedanib|200 mg twice a day per os
2505522|NCT02863055|Placebo Comparator|Placebo|Placebo match twice a day per os
3196510|NCT00851214||Acute Trauma|Acute trauma patients with a trauma ISS>15
3196511|NCT00851214||Sepsis|Patients presenting with a suspicion of acute sepsis (fever, tachycardia, tachypnea)
3196512|NCT00851214||Stroke|Patients presenting with symptoms and signs of acute stroke (thrombotic or hemorrhagic)
2505656|NCT02862093|Active Comparator|Deep rTMS|The intervention consisted of deep rTMS of dorsolateral prefrontal cortex through the Brainsway Deep TMS System using an H-shaped coil . The motor threshold was measured by delivering a single pulse to the motor cortex. The site of stimulation was located 5.5 cm anterior to the point at which maximum stimulation of the abductor pollicis brevis muscle was reached. Each patient received a total of 12 rTMS sessions (three sessions per week): 20 trains per session at an intensity of 100% of the motor threshold, 50 pulses per train at a frequency of 10 Hertz, an inter-train interval of 15 seconds.
2505657|NCT02862093|Placebo Comparator|Placebo|The sham stimulation consisted of rTMS sessions without an effective instrument operation.
2505706|NCT02861768|Experimental|diagnosis of M.tuberculosis infection|
2505741|NCT02861391|Experimental|CO2 AcuPulse Laser treatment|Subjects with USI as diagnosed in urodynamic testing intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
2505793|NCT02861079|Experimental|Propess with Foley balloon catheter|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix
2505794|NCT02861079|Active Comparator|Propess vaginal ovule|10 mg PGE2 vaginal ovule will be inserted to the posterior fornix
2506052|NCT02859649|Experimental|healthy volunteers|
2506090|NCT02859103|Active Comparator|Treatment|Patients in this arm will receive treatment with desvenlafaxine for 8 weeks.
2506101|NCT02859103|No Intervention|Healthy Control|Patients in this arm are healthy controls and will not receive any medication.
2506159|NCT02858700|Experimental|umbilical cord blood procalcitonin|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
2506525|NCT02856087|Placebo Comparator|group LR|low dose remifentanil (1 ng/ml of Ce) with normal saline infusion
3196513|NCT00851227|Experimental|1. Mildly Hepatic Impaired Subjects|
3196514|NCT00851227|Experimental|2. Moderately Hepatic Impaired Subjects|
3196515|NCT00851227|Experimental|3. Subjects with Normal Hepatic Function|
3196516|NCT00851240|Experimental|BTT1023|
3196517|NCT00851240|Placebo Comparator|Placebo|
3196518|NCT00851266|Experimental|1|V512
3196519|NCT00851266|Placebo Comparator|2|Placebo to V512
3196520|NCT00851292|Active Comparator|Side-firing|prostate biopsies obtained with side-firing probe
3196521|NCT00851292|Active Comparator|End-firing|
3196522|NCT00851305|Experimental|1 confocal laser endomicroscopy|Targeted biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by confocal laser endomicroscopy.
3196523|NCT00851305|Active Comparator|2 Conventional endoscopy|Routine biopsies are performed when the lesion was considered as IM, dysplasia or carcinoma by conventional endoscopy.
3196524|NCT00851344|Active Comparator|GSK835726 (10mg)|10mg oral dose
3196525|NCT00851344|Active Comparator|GSK835726 (50mg)|50mg oral dose
2505040|NCT02866383|Experimental|Nivolumab & Ipilimumab & Radiotherapy|Patients will receive nivolumab 3 mg/kg over 60 minutes as an IV infusion on day 1 just after RT. Thirty minutes after the completion of nivolumab infusion patients will receive ipilimumab 1 mg/kg over 90 minutes IV as an IV infusion. Nivolumab will be given every 2 weeks (q2w) and ipilimumab every 6 weeks (q6w), respectively for a maximum of 52 weeks
2505098|NCT02865863|Experimental|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
2505103|NCT02865863|Placebo Comparator|Placebo|
3196526|NCT00851344|Active Comparator|GSK835726 (100mg)|50mg oral dose
3196527|NCT00851344|Active Comparator|Cetirizine 10mg|10mg cetirizine as active comparator
3196528|NCT00851344|Placebo Comparator|placebo|placebo tablet
3196529|NCT00851370|Experimental|Omalizumab|
3196530|NCT00851370|Placebo Comparator|Placebo|
2505462|NCT02863497|Active Comparator|Mindfulness Intervention|For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
2505469|NCT02863497|No Intervention|No Intervention|For those who are not in the intervention group they will simply be asked to fill the initial questionnaire and the 3 month post questionnaire. They will not participate in any other questionnaires.
2505538|NCT02863133|Experimental|Easyx Liquid Embolic|embolization of intracranial malformations and fistulas and brain tumours with Easyx Liquid Embolic
2505590|NCT02862652|Experimental|children with acute lymphoblastic leukemia|
2505643|NCT02862223|Experimental|Neoprinol|
2505663|NCT02861885||Lesion SSL|Patient cohort referred by colonoscopy screening indication, digestive syndrome or monitoring, with ascendant colon macroscopic SSL suspicion throughout white light during colonoscopy
2505710|NCT02861547||Traumatic brain injury|
3196531|NCT00851383|Experimental|Group A|Ad35-GRIN/ENV: 2x10^9 vp
3196532|NCT00851383|Experimental|Group B|Ad35-GRIN/ENV: 2x10^10 vp
2505899|NCT02860390|No Intervention|Adolescent - Control|Usual care arm of subjects aged 13-19 years old
2505903|NCT02860390|Experimental|Adolescent - SMS|Subjects aged 13-19 years and receiving Denver Health Asthma Management Program (text messaging intervention)
2505908|NCT02860390|Experimental|Adolescent - SMS plus support person|Subjects aged 13-19 years, Denver Health Asthma Management Program (text messaging intervention) sent to subjects and subjects' chosen Person of Support.
2505910|NCT02860390|No Intervention|Adult - Control|Usual care arm of subjects aged 20-40 years old.
2505911|NCT02860390|Experimental|Adult - SMS|Subjects aged 20-40 years and receiving Denver Health Asthma Management Program (text messaging intervention).
2505973|NCT02859987|Active Comparator|Landmark Technique|Blinded method for catheter placement
2505981|NCT02859987|Experimental|Ultrasound-guided Technique|Use sonography for catheter placement
2506021|NCT02859532|Experimental|Diagnosis of deep vein thrombosis|All subjects with proximal DVT will have quantitative elastography SWIRE, thrombin generation test and rotational thromboelastometry test.
2506098|NCT02859194|Experimental|Veno-veno-arterial ECMO group|
2506160|NCT02858752|Experimental|Healthy Children|Memory and Attention in healthy children will be assessed non-invasively through behavioral and electrophysiological measures while participants will perform passive or active computer task involving auditory and/or visual perception.
2506209|NCT02858219|Experimental|Botulinum toxin|"Injection of 50 units (50U) botulinum toxin type A (powder), reconstituted in 1 mL physiologic saline solution in each perineal muscle (100 units in total).~First injection at day 1 and. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale)."
2506213|NCT02858219|Placebo Comparator|Saline solution|Injection of 1 mL physiologic saline solution in each perineal muscle. A second injection is scheduled at 3 months, only if there is a 50% or more pain improvement compared to baseline (pain measured with Visual Analogic Scale).
2506259|NCT02857959|Experimental|single dose benzathine penicillin G.|single dose benzathine penicillin G.
2506260|NCT02857959|Active Comparator|three doses of benzathine penicillin G.|three doses of benzathine penicillin G.
2506286|NCT02857660|Experimental|Whole-Body Electromyostimulation and Protein|16 weeks of whole-body intervention 1.5 x 20 min week with bipolar current up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
2506287|NCT02857660|Active Comparator|Protein supplementation|up to 1.5 - 1.7 g/kg body mass/d of protein supplements up to 800 IU/d Vitamin D-Supplementation
2506288|NCT02857660|No Intervention|sedentary Control Group|No protein supplementation or WB-EMS-application, but up to 800 IU/d Vitamin D-Supplementation
2506381|NCT02857075||Rhesus positive individuals|Red cell concentrates from RH1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
2506385|NCT02857075||Rhesus negative individuals|red cell concentrates from RH-1 individuals from each ABO group is used for the study. Red cell concentrates derived from blood donation.
2506416|NCT02856698|Experimental|midazolam|The dose of midazolam intravenously will be of 1 mg which may be repeated until a total dose of 3 mg.
2506417|NCT02856698|Active Comparator|morphine|The dose of morphine intravenously is of 2-4 mg which may be repeated until a total dose of 8 mg if the patient continue suffering from severe anxiety or distress caused by APE
2506570|NCT02855957|Other|Blood sample|A blood collection is carry out in the three populations of patients during the day of their enrolment.
3196533|NCT00851383|Experimental|Group C|Ad35-GRIN/ENV: 2x10^11 vp
3196534|NCT00851383|Experimental|Group D|Ad35-GRIN at 1x10^10 vp
3321451|NCT02018965|Other|ART alone followed by ER niacin|For Arm 2, ER niacin administration begins after the Week 24 Visit and ends Week 48 (defined as 'deferred use' arm).
2506727|NCT02854618|Experimental|Everolimus treatment|
2506776|NCT02854397||patients with hereditary angioedema|A blood sample will be performed in crisis and 7 days after the crisis.
2505082|NCT02865876|Experimental|Accelerated Corneal Cross-linking|Cross-linking in the management of microbial keratitis is an adjunctive therapy.This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. The corneal epithelium on the edge of the ulcer is cautiously removed using a microsponge. As photosensitizer, riboflavin 0.1% (Vibex, Avedro Inc, Waltham, USA) is used for 10 minutes. After impregnation, the participant´s cornea is irradiaded with UVA-light (370 nm) using 30 mW/cm2 for 3 minutes (which corresponds to a total dose of 5.4J/cm2) with accelerated cross-linking (Avedro Inc., Waltham, USA). After procedure, conventional treatment for keratitis remains unchanged.
2505083|NCT02865876|Sham Comparator|Sham Accelerated Corneal Cross-linking|"Placebo surgery. This procedure is conducted under sterile conditions in the operating room. Tetracaine hydrochloride 0.5% (Ponti Ofteno, Sophia, Mexico) eye drops is apply for topical anesthesia. Investigators do not perform removal of the corneal epithelium in edge of the ulcer. The researchers conducted the impregnation phase applying drops of saline solution for 10 minutes. After impregnation fase, a device is placed in Avedro equipment off (Avedro Inc, Waltham, USA) this device emits white light for 3 minutes. After procedure, conventional treatment for keratitis remains unchanged."
2505128|NCT02865733|Experimental|Remodulin Injection|Drug: Remodulin Injection Dosage:5 ng/kg/min-80ng/kg/min(0.15ml/hr-2.4ml/hr) Frequency: intravenous maintenance increase at a rate of 10ng/kg/min (0.3ml/hr)every 30 minutes Durations:48 hours
2505130|NCT02865733|Placebo Comparator|Distilled water group|Drug:distilled water Dosage:0.15ml/hr-2.4ml/hr Frequency:increase at a rate of 0.3ml/hr every 30 minutes Durations:48 hours
2505197|NCT02865382|Active Comparator|Group A|white light was used for both insertion and withdrawal of the colonoscope
2505203|NCT02865382|Experimental|Group B|Insertion to cecum was performed under white light and once the cecum was reached,the OE mode was swithed on during withdrawal of endoscope for complete colonic examination
2505263|NCT02864888|Experimental|Radiation|Study subjects receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
2505267|NCT02864888|Experimental|Antineoplaston therapy + Radiation|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 24 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.Study subjects also receive a single daily radiation fraction of 180cGy, 5 days a week, for the 2 weeks of the QT/QTc study and for 6 weeks overall to a total radiation dose of 1600 cGy and 5400cGy, respectively.
2505346|NCT02864485|Experimental|transplantation|Live donor liver transplantation for the treatment of unresectable colorectal cancer liver metastases
2505401|NCT02864030|Other|Single arm with Eribulin mesylate|
2505465|NCT02863471|Experimental|Gemcitabine|1000 milligram (mg)/ square meter (m²) body surface, intraperitoneal use, unique intraoperative application for 60 minutes
2505520|NCT02863016||Concentrate SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution: first of all concentrate SelectBag One (with 3 mM of acetic acid and 0 mM of citrate)
2505527|NCT02863016||Concentrate SelectBag Citrate|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution, then with SelectBag Citrate (with 0 mM of acetic acid and 1 mM of citric acid)
3196535|NCT00851396||Obese female adolescents|Obese adolescents will be screened for vitamin D deficiency through an existing study. Those found to be vitamin D deficient will be given standard treatment of vitamin D deficiency. In this study, patients who self report that they had taken the treatment for vitamin D will be screened for serum 25 OH D level and will undergo OGTT. The OGTT results as well as insulin resistance indices will be compared to their initial values.
3196536|NCT00851435|Experimental|KBPA-101, a monoclonal antibody|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
3196537|NCT00851448|Experimental|1|Oral nutritional supplement containing n-3 fatty acids, amino acids, antioxidants
3196538|NCT00851448|Placebo Comparator|2|isocaloric, isonitrogenous
2505672|NCT02862015|Experimental|Oncothermia|Patients with oncothermia treatment and palliative chemotherapy
2505676|NCT02862015|Active Comparator|Control|Patients with palliative chemotherapy only
2505708|NCT02861521|Experimental|Corrective shoe lift|Participants will be given an external shoe lift to correct post-operative leg length discrepancy (LLD).
2505709|NCT02861521|Sham Comparator|Sham shoe intervention|Participants will be given a sham shoe intervention that does not correct post-operative leg length discrepancy.
2505729|NCT02861313|Experimental|CM LOC attachment|CM LOC attachment other names: resin matrix attachment
2505735|NCT02861313|Active Comparator|ball attachment|ball attachment other names metallic ball attachment
2505829|NCT02861053|Experimental|chronic quiet inflammatory bowel disease patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with regular and moderate physical activity
2505831|NCT02861053|Sham Comparator|chronic quiet inflammatory bowel disease Patient (IBD)|Patient with chronic quiet inflammatory bowel disease patient (IBD) with no regular and moderate physical activity more than usual
2505863|NCT02860559|Experimental|TBX-1400 treatment|Single intravenous infusion of TBX-1400
2505898|NCT02860364|Experimental|Mild Hypothermic Circulatory Arrest|During aortic hemiarch surgery, mild hypothermia (32°C) will be used during circulatory arrest.
2505900|NCT02860364|Active Comparator|Moderate Hypothermic Circulatory Arrest|During aortic hemiarch surgery, moderate hypothermia (26°C) will be used during circulatory arrest.
2505952|NCT02860000|Experimental|Arm I (alisertib)|Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
3196539|NCT00851487|Experimental|Amoxicillin|Oral amoxicillin in the dose of 15 mg/kg/dose 8 hourly was given as an active drug
3196540|NCT00851487|Placebo Comparator|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
3196541|NCT00851500|Experimental|low dose K-604|
3196542|NCT00851500|Experimental|high dose K-604|
3196543|NCT00851500|Placebo Comparator|placebo|
3196544|NCT00851513|Experimental|Group B|local anesthetics (lidocaine) associated with local steroids (depo-medrol)
2505151|NCT02865486|Experimental|Lipid emulsion: visit 4|One of four randomly assigned lipid emulsions
2505192|NCT02865252|Active Comparator|MWM treatment|"Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.~MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range."
2505194|NCT02865252|Sham Comparator|MWM sham|The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).
2505254|NCT02864927|Experimental|Menactra Group 1|Participants aged 9 to 23 months will receive 2 doses of Menactra
2505255|NCT02864927|Experimental|Menactra Group 2|Participants aged 2 to 55 years will receive 1 dose of Menactra
2505313|NCT02864628|Experimental|Group 1|≥55 year old healthy subjects, receiving either 5x10E7 TCID50 MVA-BN-RSV or Placebo intranasal application
2505315|NCT02864628|Experimental|Group 2|≥55 year old healthy subjects, receiving either 1x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
2505316|NCT02864628|Experimental|Group 3|≥55 year old healthy subjects, receiving either 5x10E8 TCID50 MVA-BN-RSV or Placebo intranasal application
2505317|NCT02864628|Experimental|Group 4|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intranasal and intramuscular application
2505318|NCT02864628|Experimental|Group 5|≥55 year old healthy subjects, receiving 5x10E8 TCID50 MVA-BN-RSV intramuscular application
2505386|NCT02863874|Active Comparator|Vicryl®|The vaginal or and perineal tear is sutured continuously with Vicryl®. The instruments for suturing and the bedcover are clean whereas the gloves are sterile.
2505387|NCT02863874|Active Comparator|VicrylPlus®|The vaginal or and perineal tear is sutured continuously with VicrylPlus®. The instruments for suturing and bedcover are clean whereas the gloves are sterile.
3163368|NCT00479973|Active Comparator|Cinnamonforce|Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
2505537|NCT02862899|Experimental|Heating cable|
2505587|NCT02862691|Active Comparator|Oral analgesic|2 tablets of acetaminophen 325 mg/ oxycodone 5 mg orally once
2505589|NCT02862691|Experimental|Injectable local anesthetic|local injection or nerve block with bupivicaine 0.5%
2505623|NCT02862197||study group|hemodialysis treated patients as described in the inclusion of the study
2505674|NCT02862028|Experimental|HerinCAR-PD1 cells|Patients will receive 3 cycles of HerinCAR-PD1 cells treatment.
3163369|NCT00479973|Placebo Comparator|Placebo|
3163370|NCT00479986|Experimental|Pioglitazone|
3163371|NCT00479986|Active Comparator|placebo|
3163372|NCT00480038|Other|1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
3163373|NCT00480090|Experimental|Cytarabine|eligible patients will receive cytarabine, starting at 075g/m2 and escalating to a maximum of 1.25g/m2, BID IV for 2 days every three weeks for 6 or more cycles if tolerated.
3163374|NCT00480116|Active Comparator|1|
3163375|NCT00480116|Active Comparator|2|
3163376|NCT00480116|Active Comparator|3|
3163377|NCT00480155|Active Comparator|1|FluMist
3163378|NCT00480155|Placebo Comparator|2|Placebo
3163379|NCT00480181|Experimental|Active|
3163380|NCT00480181|Placebo Comparator|placebo|
3163381|NCT00480207|Experimental|omega-3, folic acid, vitB12|folic acid (1600 mcg per day), and omega-3 (2000 mg per day: active docosahexaenoic acid (DHA) and eicosapentanoic acid (EPA), proportion 1:1), vitamin B12 (1000 mcg per day)
3163382|NCT00480207|Experimental|omega-3, folic acid placebo, vit B12|omega-3,folic acid placebo (starch), vitamin B12 (1000 mcg per day)
3163383|NCT00480207|Experimental|omega-3 placebo, folic acid, vit B12|folic acid, omega-3 placebo(canola oil),vitamin B12 (1000 mcg per day)
3163384|NCT00480207|Experimental|omega-3 placebo, folic acid placebo, vit B12|omega-3 placebo (canola oil),folic acid placebo (starch), vitamin B12 (1000 mcg per day)
3163385|NCT00480220|Experimental|1|Specific Intervention as Global care and support program
3163386|NCT00480220|No Intervention|2|'No specific intervention'
3163387|NCT00480259|Active Comparator|Standard Nutrition|
3163388|NCT00480259|Experimental|Hyperprotein Nutrition|
3163389|NCT00480272|Experimental|group A|"adalimumab 40 mg subcutaneous injections every other week from baseline to month 12~methotrexate orally weekly at initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~prednisone orally 50 mg daily, gradually tapered up to 6.25 mg at week 7 and stopped at month 6"
3163390|NCT00480272|Placebo Comparator|group B|"adalimumab 40 mg subcutaneous injections every other week from baseline to the end of month 12~methotrexate orally oweekly at an initial dose of 10 mg rising to 20 mg weekly over 4 weeks in 2.5 mg increments, continued up to month 24.~placebo orally, stopped at month 6"
3163391|NCT00480311||1|Measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
3163392|NCT00480363|Experimental|1|Lenalidomide + Dexamethasone for 9 cycles and maintenance
3163393|NCT00480363|No Intervention|2|Observation
3163394|NCT00480389|Experimental|Sorafenib|"All patients on study will be accrued to this arm. Sorafenib (200 mg tablets x 2) will be administered orally twice a day for 12 weeks (full daily dose of 800 mg). Patient visits for safety will be conducted at least every 4 weeks. Sorafenib dose reductions for drug-related toxicity will be applied based on considerable prior clinical experience. Surgery will be performed at the completion of the 13th week, allowing for a one-week washout period. Sorafenib will be continued post operatively (around 6 weeks post surgery or when complete wound healing has occurred) until patient progresses or unacceptable toxicity occurs."
3163395|NCT00480402|Experimental|400 mg Progesterone|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 400 mg Progesterone Group vaginal pessaries arm.
2505162|NCT02865265||Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral PaB was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
2505280|NCT02864745|Experimental|Early rehabilitation arm|These patients will receive very early (<48 hours after ICU admission), protocolised, intensive rehabilitation, which will include functional electrical stimulation-assisted cycle ergometry.
2505284|NCT02864745|Active Comparator|Standard-of-care|These patients will receive standard rehabilitation delivered by non-study physiotherapist.
2505350|NCT02864420|Active Comparator|Inpatient hospitalization|Control / usual care arm. Patients are admitted per usual to an inpatient service. Patients' medical records will be closely monitored. Patients will wear a vitals and activity monitor whose data is used only retrospectively. On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
2505355|NCT02864420|Experimental|Home hospitalization|Intervention arm. Patients will return home after triage, diagnosis, and the beginning of treatment in the emergency department with a set of specialized patient-tailored services (listed above). On discharge and 30 days after discharge, they will be interviewed regarding their hospitalization and health.
3163396|NCT00480402|Experimental|200 mg Progesterone Group|Approximately one third of the bichorionic biamniotic twin pregnant women randomized to the 200 mg Progesterone Group vaginal pessaries arm.
3163397|NCT00480402|Active Comparator|Placebo|Approximately one third of the bichoronic biamniotic twin pregnant women were randomized to the placebo vaginal pessaries arm.
2505516|NCT02863224||Healthy control|
2505525|NCT02863224||Ocular hypertension|
2505532|NCT02863224||Primary open angle glaucoma|
2505533|NCT02863224||Normal tension glaucoma|
2505639|NCT02862340|Other|Autistic disorder|Children over 4 years with an autistic disorder of unknown etiology with the techniques currently available and accessible in routine diagnostics.
3163398|NCT00480454|Active Comparator|1|Stage 1 would require 12 per group low dose and 12 per group high dose (total 72)
2505962|NCT02859922|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
2505964|NCT02859922|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
2506119|NCT02858921|Experimental|Sequential D + T, THEN Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day for 1 week, then followed by treatment with Pembrolizumab 2mg/kg delivered intravenously at weeks 1, 3, and 6, then once every 3 weeks from week 6 for 46 weeks.
2506120|NCT02858921|Experimental|Concurrent D + T AND Pembrolizumab|Dabrafenib 150mg orally twice a day + Trametinib 2mg orally once a day + Pembrolizumab 200mg intravenously once every 3 weeks for 6 weeks, the Pembrolizumab alone for 46 weeks
2506121|NCT02858921|Experimental|Pembrolizumab ONLY|Pembrolizumab 200mg intravenously once every 3 weeks alone for 52 weeks.
2506179|NCT02858505|Active Comparator|27 mg elemental iron group|received 27 mg elemental iron once daily starting at 12 weeks until 36 weeks
2506184|NCT02858505|Active Comparator|54 mg elemental iron group|received 54 mg elemental iron once daily starting at 12 weeks until 36 weeks
2506223|NCT02858193|Experimental|1.35 g SCMC- lys powder|1.35 g of SMC L-lysine monohydrate salt powder for solution
2506226|NCT02858193|Experimental|Fluifort® syrup|Fluifort® syrup 90 mg SCMC-lys/mL
2506292|NCT02857829|Placebo Comparator|Placebo|
2506296|NCT02857829|Active Comparator|Caffeine-alone|The effects of the combination will be compared to both placebo and caffeine-alone, to test the hypothesis that the blend of ingredients will enhance cognitive measures greater than the most commonly used cognitive enhancer, caffeine.
2506299|NCT02857829|Experimental|CAF+|
2506333|NCT02857335|Other|study group|patients with benign intracranial hypertension ages 8-16 years
2506387|NCT02857114|Other|massage|
2506426|NCT02856711|Experimental|Trauma-informed group|These groups will use the enhanced Centering Pregnancy curriculum.
2506429|NCT02856711|No Intervention|Control group|These groups will use the standard CenteringPregnancy curriculum.
2506486|NCT02856386|Experimental|polyphenol supplement|Dietary supplement administered 8 mL once daily
2506588|NCT02856009|Experimental|patient|
2506625|NCT02855307|Active Comparator|Unannounced exercise|The target blood glucose of the algorithm will be as usual. A pre-meal full insulin bolus will be given.
2508313|NCT02843165|Active Comparator|CBI|Checkpoint blockade immunotherapy (CBI)
3163399|NCT00480454|Active Comparator|2|Stage 2 would require 48 per group (total 144)
3163400|NCT00480558|Active Comparator|1|Group 1: M. tb
3163401|NCT00480558|Active Comparator|2|Group 2: HIV (not on antiretrovirals [ARV])
3163402|NCT00480558|Active Comparator|3|Group 3: M. tb and HIV (not on ARV)
3163403|NCT00480558|Active Comparator|4|Group 4: M. tb and HIV (on ARV)
3163404|NCT00480571|Experimental|1|BL 1020 low dose
3163405|NCT00480571|Experimental|2|BL 1020 High Dose
3163406|NCT00480584|Experimental|GemCap-T Dose Escalation|GemCap-T, capecitabine in combination with gemcitabine. Dose Escalation 6 Cycles @ 28 Days.
3163407|NCT00480610|Experimental|1|
3163408|NCT00480610|Placebo Comparator|2|
3163409|NCT00480649|Active Comparator|Sal/FP 50/250mcg|SERETIDE 50/250
3163410|NCT00480649|Active Comparator|Sal/FP 50/500mcg|SERETIDE 50/500
3163411|NCT00480675|Experimental|1|Trochanteric bursa injections done into the bursa under fluoroscopic guidance
3163412|NCT00480675|Active Comparator|2|Trochanteric bursa injection done with sham fluoroscopy using only landmarks as guidance.
3163413|NCT00480701|Experimental|[123I]-IBVM|To assess [123I] IBVM and SPECT imaging
3163414|NCT00480727|Placebo Comparator|Control|No fortnightly re-tensioning. Placebo treatment utilises the re-tensioning procedure, pt experiences clicking sensation, however, the pin is not tightened.
3163415|NCT00480727|Experimental|Treatment (Re-tensioning) Group|Pins are re-tensioned fortnightly back to initial fitting tension of 8lb/inch.
3163416|NCT00480792|Active Comparator|A|GenHevac-B 20 microgramme Intramuscular use at M0, M1, M6
2505202|NCT02865291|Experimental|ForConti device|Use the device up to 12 hours/day for 4 weeks
2505262|NCT02865018|Experimental|cetirizine|10mg oral each day
2505314|NCT02864563|Experimental|Prospective cohort|Experimental arm, prospective cohort
3163417|NCT00480792|Experimental|B|GenHevac-B 40 microgramme Intramuscular use at M0, M1, M2, M6
3163418|NCT00480792|Experimental|C|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
3163419|NCT00480831|Experimental|1|
3163420|NCT00480831|Placebo Comparator|2|
3163421|NCT00480844|Experimental|Sertindole|
3163422|NCT00480844|Active Comparator|Risperidone|
2505416|NCT02863835|Experimental|Intervention 1|"A 1:1 randomisation will be performed to decide the order of the administration of salbutamol and CPAP. All participants will receive both interventions in a cross-over fashion. Salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure.~Each participant will then have continuous assessment of the following whilst self venting:~Spirometry - FEV1, FVC, MVV~Muscle strength measurements: MIP, MEP, SNIP~Borg scale, mMRC, Visual Analogue Scale for breathlessness~Electrical impedance tomography~EMGpara~Transcutaneous measurement of CO2 and 02 level~End-tidal CO2 monitoring~Pneumotachography"
2505435|NCT02863588|Experimental|seropositive for Toxoplasma gondii|
2505758|NCT02861755|Experimental|Arm 1|The MARIGOLD positive emotions course plus a blend of enhancements to include: 5-minutes of weekly facilitator contact, online discussion board, or gamification through virtual flower badges.
2505770|NCT02861755|Experimental|Arm 2|Emotion reporting control condition. Reporting daily emotions for the same duration of the online emotions course.
2505806|NCT02860923|Experimental|Exenatide|Treatment with exenatide at the initial dose of 5 µg x 2/day (subcutaneously administered) during 4 weeks, and treatment with 10 µg x 2/day during 5 months.
2505808|NCT02860923|Placebo Comparator|Placebo|Patients will be maintained on placebo (injected subcutaneously, twice a day) with the same dose and frequency than exenatide arm.
2505862|NCT02860650|Experimental|Group 1: AD26.Filo/MVA-BN-Filo or Placebo|Participants will receive Ad26.Filo or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
2505864|NCT02860650|Experimental|Group 2: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 57.
2505865|NCT02860650|Experimental|Group 3: MVA-BN-Filo/AD26.Filo or Placebo|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.Filo or placebo on Day 15.
2505866|NCT02860650|Experimental|Subset of Group 3: AD26.Filo or Placebo|The first 8 participants in Group 3 who are willing to enroll in the subset for third vaccination, will receive a third vaccination at Day 92. Participants who previously received placebo will receive placebo a third time and participants who previously received MVA-BN-Filo/Ad26.Filo vaccination will receive Ad26.Filo as third vaccination. After enrollment of the 8 participants, the unblinded monitor and unblinded pharmacist will assess whether 7 participants who previously received MVA-BN-Filo/Ad26.Filo vaccination have been enrolled. If less than 7 participants of the active vaccine regimen have been enrolled, 2 additional participants will be enrolled. If at least 7 participants of the active vaccine regimen have been enrolled, no further will be enrolled. The aim is to enroll 7 or 8 participants who will receive Ad26.Filo as third vaccination.
2505868|NCT02860650|Experimental|Group 4: Ad26.ZEBOV/MVA-BN-Filo or placebo|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 57.
2506015|NCT02859311|Experimental|Withdrawal of therapy|Gradual, supervised withdrawal of medical therapy over 4-16 weeks
2506032|NCT02859311|No Intervention|Control|Continuation of usually prescribed pharmacological therapy
2506096|NCT02859233|No Intervention|Control group|Routine advices about the interest of increase fluid after lumbar puncture to prevent PDPH will be transmitted: 2 liters will be provided to be drunk in 2 hours.
2506102|NCT02859233|Experimental|Interventional group|Lack of hyperhydration : no particular advices will be transmitted about the interest of oral hyperhydration. 500 milliliters will be provided in case of thirst, according to patient's convenience.
2506152|NCT02858661|Experimental|Patients diagnosed with clinical meningitis|Patients admitted in emergency rooms for clinical meningitis, for which a nasopharyngeal swab will be performed in order to confirm the etiological diagnosis of meningitis
2506340|NCT02857452||Lupus|
2506371|NCT02857036|Experimental|responder|responder to antidepressant treatment
2506373|NCT02857036|Experimental|non responder|non responder to antidepressant treatment
2506425|NCT02856789||Healthy volunteers (HV)|"HV without any known treatment, without any coagulation trouble and with normal hemostasis results.~FS and TEG will be processed to define the most relevant parameters for normal range and the correlation between both assays.~Tests performed on HV :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)~Specialized hemostasis tests"
2506526|NCT02856087|Active Comparator|group HR|High dose remifentanil infusion (4ng/ml of Ce) with normal saline infusion
3163423|NCT00480870|Experimental|A|Donepezil treated Alzheimer patients
3163424|NCT00480870|Placebo Comparator|B|Placebo treated Alzheimer patients
3163425|NCT00480883|Active Comparator|1|injection meglumine antimoniate 20 mg/kg/day/intramuscular for 21 days.
3163426|NCT00480883|Experimental|2|injection meglumine antimoniate 10 mg/kg/day/intramuscular plus tablet allopurinol 1200 mg/day/6hourly divided doses.
3163427|NCT00480896|Experimental|1|
3163428|NCT00480896|Placebo Comparator|2|
3163429|NCT00480922|Experimental|1|A low glycemic load diet
3163430|NCT00480922|Active Comparator|2|Low fat diet
3163431|NCT00480935|Experimental|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 2 week rest period to comprise a complete cycle of 6 weeks. Patients will then continue on Sutent for another cycle of 4 consecutive weeks
3163432|NCT00480948|Active Comparator|1|Infant formula with InFat™ oil(containing ~49% of C16:0 at sn-2 position).
3163433|NCT00480948|Placebo Comparator|2|Standard vegetable oil based infant formula
3163434|NCT00480974||1|Patients with Sickle cell anemia treated by Hydroxyurea
3163435|NCT00481000|No Intervention|1|Waitlist; Treatment as usual
3163436|NCT00481013|Placebo Comparator|1a|For six months, half of patients are randomized into placebo . After 6 months, all patients are on treatment.
2505205|NCT02865603|Experimental|PAX Good Behavior Game|The intervention is delivered by teachers within the normal school curriculum. Teachers from intervention classes completed 3-day training and were supported by the mentor, who visited their class during the 2016/17 school year and provided counseling via e-mail and phone. During the second year (2017/18) teachers could use the PAX GBG methods, but they did not receive additional support from the mentors.
2505209|NCT02865603|No Intervention|Waitlist control group|Control group continue their normal activities without intervention. After a post-test assessment in spring 2018 the control group teachers will be trained and supported to implement PAX GBG.
2505256|NCT02864940|Experimental|Intervention Arm|Using the cognitive exercises on Lumosity for 10 weeks
2505258|NCT02864940|Active Comparator|Control Arm|Using online crossword puzzles for 10 weeks.
2505311|NCT02864589|Experimental|I-HRT|Internet-delivered habit reversal training
2505312|NCT02864589|Experimental|I-ERP|Internet-delivered exposure and response prevention
2505327|NCT02864264|Experimental|Single Ascending Dose (SAD) - IV Panel|Single intravenous (IV) dose of BMS-986184 or placebo matching BMS-986184
2505333|NCT02864264|Experimental|Single Ascending Dose (SAD) - SC Panel|Single subcutaneous (SC) dose of BMS-986184 or placebo matching BMS-986184
2505338|NCT02864264|Experimental|Multiple Ascending Dose (MAD) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
2505342|NCT02864264|Experimental|Proof of Mechanism (POM) - IV Panel|Multiple IV doses of BMS-986184 or placebo matching BMS-986184
2505396|NCT02863978|Experimental|Digi-NewB Cohort|Multimodal signal acquisitions
2505438|NCT02863627|Experimental|Newborn Care Pathway|two telephone interviews conducted after the emergency department visit will be used to gather data to meet the objectives of this study.
2505483|NCT02863393|Experimental|Diaphragmatic breathing exercise|The aim of this study is to ameliorate hepatic inflammation by using diaphragmatic breathing exercises instead of aerobic exercise to reduce the fat in liver inflammation.
2505510|NCT02863081||Healthcare providers|All healthcare providers working in the participating LTACH will be asked to complete 2 surveys and invited to participate in focus group meetings
2505511|NCT02863081||Patients|81 LTACH patients will be enrolled over the course of a 9 month period. Each patient and their LAR will be interviewed at the time of LTACH admission to garner information about their pre hospitalization physical, functional, and cognitive health status. Each day enrolled patients will undergo daily symptom assessments and medical record reviews. At the time of LTACH discharge all enrolled patients will be interviewed again to garner information about their discharge physical, functional, and cognitive health status.
2505578|NCT02862743|Experimental|patients with metastatic melanoma|patients with metastatic melanoma (stage III unresectable or stage IV)
3163437|NCT00481013|Active Comparator|1b|Cohort 1b patients are randomized onto treatment. After 6 months, all patients are on drug.
2505721|NCT02861677|No Intervention|Control group|The control group will receive the usual medical care by physicians and nurses
2505722|NCT02861677|Experimental|Intervention group|the intervention group will receive clinical pharmacy services
2505756|NCT02861235|Experimental|1. stress thallium-201 tomoscintigraphy|
2505768|NCT02861235|Experimental|2. stress technetium-99m tomoscintigraphy 1|
2505776|NCT02861235|Experimental|3. stress technetium-99m tomoscintigraphy 2|
2505781|NCT02861235|Experimental|4. stress technetium-99m tomoscintigraphy 3|
2505784|NCT02861235|Experimental|5. rest thallium-201 tomoscintigraphy|
2505786|NCT02861235|Experimental|6. rest technetium-99m tomoscintigraphy|
2505818|NCT02860858|Experimental|Aflibercept|
2505867|NCT02860728|Experimental|Resistance training|Patients with COPD will participate in 4 weeks (12 sessions) of individualized, non-linear, lower body resistance training.
2505918|NCT02860338||GROUP 1- CNS Protocol|"Patients in a specialized dementia practice. Evaluated and treated for hypoxia, elevated BNP, hyperhomocysteinemia, B 12 deficiency as measured by elevated methymalonic acid, Vitamin D 25-OH deficiency, elevated CRP, and decreased IGF-1, and other metabolic abnormalities.~Treated with maximal doses of acetylcholinesterase inhibitors, memantine, methylfolate/methylB12/N-acetylcysteine, dextromethorphan/quinidine, and SSRI's; dose and duration based on protocol."
2505923|NCT02860338||GROUP 2- Community Care|Patients referred to a neuropsychology practice for cognitive evaluation and treated for MCI or dementia by their primary care clinician or non-dementia specialist according to specific provider's usual practice pattern.
2505966|NCT02859935|No Intervention|Control group|The control group will receive standard care - 3 monthly STI screening, motivational interviewing and counselling. Both groups will get questionnaires on mental health problems: ADHD, depression, anxiety disorder, alexithymia and sex and drug addiction.
2505969|NCT02859935|Other|Intervention group|The intervention group will receive -besides standard care- additional questionnaires depending on their baseline questionnaires and in case of an indication for mental health problems, feedback and referral to relevant mental health and addiction care will be provided.
2506059|NCT02859610|Other|cirrhotic patients|We prospectively included 90 cirrhotic patients .
2506063|NCT02859610|Other|healthy volunteers|The pilot cohort was compared with 10 healthy volunteers.
3163438|NCT00481026|Sham Comparator|Placebo|Placebo tDCS
3163439|NCT00481026|Active Comparator|active tDCS|active tDCS
3163440|NCT00481039||1|Patients diagnosed as having abnormal hemoglobin like hemoglobin S and thalassemia in a bedouin village
2506193|NCT02858427|Experimental|depressed with suicide attempt (SA)|elderly depressed patients with a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
2506194|NCT02858427|Experimental|depressed without a history of SA|elderly depressed patients without a history of suicide attempt. interventions: eye tracking, neuropsychological assessment, psychiatric assessment and sociological interview.
2506527|NCT02856087|Experimental|group HR-N|remifentanil infusion at 4ng/ml of Ce with naloxone infusion
3163441|NCT00481091|Experimental|Phase 1: Dose Escalation Portion|Participants will receive escalating doses of ABT-263 to determine the recommended phase 2 dose (RPTD). Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
3175130|NCT00630448||Group 1|Control Group. Normal (healthy) individuals without Von Willebrand Disease.
3196545|NCT00851513|Experimental|Group C|local anesthetics (lidocaine) associated with local steroids (depomedrol) and important volumes of physiological serum
3196546|NCT00851513|Active Comparator|Group A|only local anesthetic (lidocaine)
3196547|NCT00851526||Coronary bifurcation lesion|
3196548|NCT00851539|No Intervention|Control|Participants received counseling from a live counselor.
3196549|NCT00851539|Experimental|Video|Behavioral Intervention Video
3196550|NCT00851565|Active Comparator|1|Patients with Crohn's disease with secondary loss of response to infliximab.
2505410|NCT02863939|Other|NICAS|There is only one arm - a single cohort. All patients undergoing the nuclear stress test will also have the NICAS evaluation.
3196551|NCT00851565|Active Comparator|2|Patients with Crohn's disease with secondary loss of response to infliximab.
3196552|NCT00851578|Experimental|WATCHMAN|non-valvular atrial fibrillation patients contraindicated to warfarin
2505761|NCT02861742|Other|Study procedure|Delivery of questionnaires, Questionnaire T1 to fill, Questionnaire T2 to fill, Questionnaire T3 to fill, Questionnaire T4 to fill, Questionnaire T5 to fill
3196553|NCT00851604||1|Patients with malignant neuroendocrine tumors
2505958|NCT02860078|Active Comparator|Ultrasound|The group I will be subjected to epidural infiltration using methylprednisolone acetate diluted in ropivacaine 0.1%. Initially the sacral hiatus is identified by palpation. After, the ultrasound device is used (USG) for the puncture, with a linear transducer of high frequency. At the end of corticosteroid administration, the placement of the needle tip will be checked with fluoroscopy and noted.
2505960|NCT02860078|Active Comparator|Radioscopy|The group II will be subjected to infiltration using methylprednisolone acetate diluted in ropivacaine 0.1% . However, only radioscopy be used to guide the puncture.
2506089|NCT02859116||Collection of digestive tissues|Digestive tissues will be collected from participants undergoing scheduled (non-emergent) gastrointestinal surgery.
2506145|NCT02858778|Experimental|Interventional group (Ig)|The interventional group (Ig) will have an early palliative care consultation ordered during their stay in the emergency department.
2506148|NCT02858778|No Intervention|Control group (Cg)|The control group will be treated as standard of care. Palliative care consultations may or may not be ordered at the attending physician's discretion.
3196554|NCT00851617|Experimental|IMT Group|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
3196555|NCT00851617|No Intervention|Control Group|Patients were evaluated until weaning without interventions
3196556|NCT00851669|Experimental|IPT|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
2506343|NCT02857257|Experimental|Treatment arm|Only one treatment arm. Patients are allocated under disease condition and later treated with ACHIM. The post-treatment disease progression is monitored.
2506402|NCT02857023|Experimental|Cogmed intervention|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
2506403|NCT02857023|Experimental|Cogmed-waitlist control|Cogmed RM Children and adolescents with SCD between the ages of 7 and 16 years old (n = 80) will be recruited to complete a randomized (intervention or waitlist-control) home-based computerized CT program (Cogmed)
3196557|NCT00851669|Active Comparator|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
3196558|NCT00851695||Asthma|All 1024 participants of the Childhood Asthma Management Program, who provided blood samples.
3196559|NCT00851695||Asthma in Hispanics|All 616 subjects in the Genetic Epidemiology of Asthma in Costa Rica who have serum.
3196560|NCT00851695||Lung function and lung function decline|626 subjects from the Normative Aging Study who have serum and lung function.
3196561|NCT00851708|Active Comparator|NAC|treatment
3196562|NCT00851708|No Intervention|control|
3196563|NCT00851734|Experimental|LX214 0.02%|LX214 ophthalmic solution 0.02%
3196564|NCT00851734|Experimental|LX214 0.2%|
3196565|NCT00851734|Placebo Comparator|placebo|placebo
3196566|NCT00851760|Experimental|1 Combined Surgery|
3196567|NCT00851760|Active Comparator|2 consecutive surgery|
3196568|NCT00851773|Experimental|A|
3196569|NCT00851773|Experimental|B|
3196570|NCT00851773|Experimental|C|
3196571|NCT00851773|Experimental|D|
3196572|NCT00851773|Experimental|E|
3196573|NCT00851773|Placebo Comparator|F1|
3196574|NCT00851773|Placebo Comparator|F2|
3196575|NCT00851773|Placebo Comparator|F3|
3196576|NCT00851773|Placebo Comparator|F4|
3196577|NCT00851773|Placebo Comparator|F5|
3196578|NCT00851812|Other|Arm 1|Usual Care: Standard care monitoring
3196579|NCT00851812|Experimental|Arm 2|Progressive walking and resistance exercise treatment
3196580|NCT00851838|Experimental|PD solution|
3196581|NCT00851864|Experimental|A|Women requiring therapeutic anticoagulation, singleton pregnancy,<30weeks
3196582|NCT00851916|Other|CyberKnife Radiosurgery|Single arm study using CyberKnife radiosurgery to treat recurrent prostate cancer patients that have already received external beam radiotherapy.
3196583|NCT00851929|Experimental|sarcoidosis associated pulmonary hypertension|sarcoidosis associated pulmonary hypertension
3196584|NCT00851942|Experimental|Synacthen 250 micrograms|IV injection of 250 micrograms of Synacthen in 1m
3196585|NCT00851955||1. Normal pancreas patients|Patients with no documented clinical history of pancreatic diseases supported by at least 1 negative imaging test (EUS, CT scan or MRI).
2505247|NCT02865148|No Intervention|Waitlist control (WLC) group|The WLC group receives standard usual care before being offered the same CBT protocol and assessment thereafter.
2505287|NCT02864719|Experimental|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
2505331|NCT02864511|Experimental|Intervention group|
2505390|NCT02864186|Active Comparator|control|Women wont use support bra for six months
2505397|NCT02864186|Active Comparator|surgical support bra|Women will use surgical support bra 24 hours a day for six months
2505403|NCT02864186|Active Comparator|common support bra|Women will use common support bra 24 hours a day for six months
2505436|NCT02863614|Experimental|Ibuprofen+Lorazepam|Oral ibuprofen (600 mg) + lorazepam (1 mg); one hour before endometrial scratching.
2505440|NCT02863614|Active Comparator|Ibuprofen|Oral ibuprofen (600 mg) + Placebo; one hour before endometrial scratching.
2505444|NCT02863614|Placebo Comparator|Placebo|Placebo + Placebo; one hour before endometrial scratching.
2505569|NCT02862678|Experimental|Patients with head and neck squamous cell carcinoma|
2505627|NCT02862379|Experimental|Elderly patients that fall|Personalized rehabilitation program for elderly patients that fall for the first time. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors.
2505675|NCT02862002|Experimental|"Therapeutic Patient Education (E.T.P)of type caratif"|Patients in arm E.T.P benefit of the nursing consultation E.T.P,
2505678|NCT02862002|Active Comparator|standard care|patients receiving standard care of cancer pain.
3163442|NCT00481091|Experimental|Phase 2a: Dose Expansion Portion|Participants will receive ABT-263 at the RPTD determined in Phase 1 portion. Eligible participants can continue to receive ABT-263 for 11 years in the extension portion.
3163443|NCT00481143|Experimental|deferasirox|
2505941|NCT02860273|Experimental|High Flow Nasal Cannula Oxygen|"Incremental Load Treadmill Test (ILTT) using HFNCO at 21%~Constant Treadmill Load Test (CTLT) using HFNCO at 21%"
2505942|NCT02860273|Other|Control Group|"Incremental Load Treadmill Test (ILTT) at Room Air~Constant Treadmill Load Test (CTLT) at Room Air"
2505971|NCT02859740||permanent prosthesis|
2505983|NCT02859740||Temporary prosthesis|
2506062|NCT02859571|Active Comparator|Continuous oxytocin|oxytocin will be used at a starting dose of 1-2 mIU/min and the dose will be increased by 2 mIU/min at every 15 minutes until regular contractions will be obtained at a rate of 3-5 contractions in a 10-minute period. The maximum dose of oxytocin will 40 mIU/min and oxytocin will be administered until delivery.
2506065|NCT02859571|Experimental|intermittent oxytocin|oxytocin will be discontinued when cervical dilation will 5 cm and 2 hours after discontinuation oxytocin will be reused at a starting dose of 1-2 mIU/min and will be increased as the same protocol will be used for continuation oxytocin group.
2506093|NCT02858999|Experimental|treatment|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles PAD-VCD
2506144|NCT02858622|Active Comparator|dual TAB group|22 patients will receive unilateral dual transversus abdominis plane (TAB) block USING bupivacaine 0.25% at a dose of 2 mg/kg
2506149|NCT02858622|Sham Comparator|control group|22 patients who will not receive dual TAB block
2506222|NCT02858245||Commercial MitraClip® patients|Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
2506297|NCT02857842|Experimental|Blood eosinophil guided prednisolone treatment|Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood <0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.
2506300|NCT02857842|Active Comparator|Standard of care|Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days
2506332|NCT02857322|Other|subjects with documented psychiatric pathology|
2506393|NCT02857127|Experimental|Intervention Group|A group of people who participated in the walking program during a six month period. This group also received an educational material and attended meetings for behavioral change strategies.
2506396|NCT02857127|No Intervention|Control Group|A group of people who did not receive the educational material and did not participated in any of the activities offered by the research team, such as walking classes and meetings for behavioral change.
2506536|NCT02856022|Experimental|Electrical ilioinguinal nerve stimulation|
2506537|NCT02856022|Active Comparator|Intravesical Irrigation|
3163444|NCT00481156|Experimental|Patients: Cognitive Remediation|Patients in the cognitive REM condition attended up to 25 h of training in small groups over 4-6 weeks based on the approach to cognitive remediation described by Wexler and Bell (2005). Patients performed tasks designed to train attention and memory from the battery available within a computerized software package (CogPack Marker Software). This training protocol has been shown to improve memory and executive functioning in patients with schizophrenia (Sartory et al, 2005) and tasks chosen were designed to produce improved working memory and attention capacity in the treated group. In addition, patients in the REM group trained on the word N-back one to two times a week and on N-back tasks using a variety of other stimuli (such as faces) one to two times a week to support the generalization of working memory improvements.
3163445|NCT00481156|Active Comparator|Patients: Cognitive-Behavioral Social Skills Training|Patients in the CBSST group also attended up to 25 h of treatment but followed a manualized group therapy protocol (Granholm et al, 2005) using cognitive and behavioral therapy methods to increase patients' skills in symptom recognition, communication, problem solving, and relapse prevention. In both conditions, the facilitators interacted with the clients throughout small group (B4 patients) sessions: in the REM group, this mostly involved brief one-on-one discussions regarding task performance; in the CBSST condition, this interaction was in the context of the group milieu.
2505259|NCT02864810|Experimental|[18F]GP1 PET/CT imaging|"Maximally 10 patients with deep vein thrombosis, pulmonary embolism, or arterial thromboembolism, respectively will be enrolled in the study (plus replacements for drop-outs).~Intravenous injection and PET/CT scanning of [18F]GP1"
2505373|NCT02864225|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
2505425|NCT02863913|Experimental|Test group|Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will be knocked out by CRISPR Cas9 in the laboratory (PD-1 Knockout T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion. A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant). Patients will receive a total of 2, 3, 4 cycles of treatment.
2505426|NCT02863913|Placebo Comparator|Comparable group|"Peripheral blood lymphocytes will be collected and Programmed cell death protein 1(PDCD1) gene will not be knocked out by CRISPR Cas9 in the laboratory (PD-1 Wild-type T cells). The lymphocytes will be selected and expanded ex vivo and infused back into patients. Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~A total of 2 x 10^7/kg PD-1 Knockout T cells will be infused in one cycle. Each cycle is divided into three administrations, with 20% infused in the first administration, 30% in the second, and the remaining 50% in the third.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
2505464|NCT02863484|Active Comparator|Conventional surgery intra-dural|This arm will be surgically operated by direct attack of the tumour after opening the dura
2505474|NCT02863484|Experimental|Pealing surgery extra-dural|This arm the pealing of the outer layer of the lateral wall of the cavernous sinus will be done before the dura is opened. After the pealing is completed, the middle meningeal artery will be divided at the foramen spinosum. Then, the dura will be opened and the tumour attacked.
2505524|NCT02863029|Other|Flexible Sigmoidoscopy|Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
2505572|NCT02862795|Other|HPV detection in anal canal samples|
2505631|NCT02862327|Active Comparator|intravenous dexamethasone|intravenous injection of 8mg (2ml) of dexamethasone during regional anesthesia
2505637|NCT02862327|Placebo Comparator|intravenous placebo|intravenous injection of 2ml of NaCl 0.9% during regional anesthesia
2505759|NCT02861222|Experimental|MYOCET|2 treatments of doxorubicin are administered at 60 mg/m²/day or 75 mg/m²/day in single dose in 1-hour perfusion each 21 days. A maximum of 6 treatments/patient is administered.
2505807|NCT02860949|Experimental|LAI with PCI|Local anesthetic infiltration with posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area, Lateral gutter area and Posterior capsular area)
2505810|NCT02860949|Active Comparator|LAI without PCI|Local anesthetic infiltration without posterior capsular injection (Drug inject at Anterior soft tissue, Medial gutter area and Lateral gutter area)
2505881|NCT02860455|Other|SpCO and COHb measurement|"SpCO measurement (Experimental) : Non invasive pulse CO-oximetry will be carried out in all patients simultaneously with venous blood sampling for standard laboratory blood gas analysis, at time of prehospital management by emergency medical services~COHb measurement (Active comparator) : Blood carboxyhemoglobin testing will be carried out in all patients"
2505934|NCT02860104|Other|microwave ablation|microwave ablation
2505959|NCT02859818|Other|adolescents with type 1 diabetes|adolescents with type 1 diabetes following their participation in therapeutic education program
2506091|NCT02859155|Other|Multiviceral resection colorectal cancer|Multiviceral resection surgery of 2 or more intrabdominal organs en bloc with colorectal cancer
2506157|NCT02858791||Healthy Controls|"Subjects are made up of healthy adults~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
2506164|NCT02858791||Affected|"Subjects have Pulmonary Hypertension Subjects have Pulmonary hypertension with Interstitial lung disease Subjects have Interstitial lung disease~Interventions:~Venous blood drawn before and after cardiopulmonary exercise test Will have a resting 12 lead EKG Undergo pulmonary function test"
3163446|NCT00481156|Other|Controls: Retest control group|Estimate of normal brain functioning and retest effects
3163447|NCT00481221||1|Screened pregnant women
2506372|NCT02857192|Experimental|Horton|
2506374|NCT02857192|Placebo Comparator|control|
2506554|NCT02855762|Other|Dietary Intervention Group|Subject will be guided to eat a high polyunsaturated fatty acid diet.
3163448|NCT00481286|Experimental|Group Clinic|Patients in Group Clinic arm will meet every 3rd week for 12 weeks, for a total of 4 visits. At each visit, BP will be measured, home BP and glucose measurements collected. Each visit will include group-based education and feedback sessions, with an individualized process of selecting and modifying process of care goals for systolic BP, H1C, and LDL cholesterol. Short-term health behavior change goals will also be discussed.
3163449|NCT00481286|Placebo Comparator|Uusual Care|Older diabetes patients will attend regular clinician visits and one targeted primary care physician visit during the 12 weeks post-enrollment. They will be enrolled in a diabetes education class. Blood pressure, H1C and lipids will be measured at enrollment, 6 weeks , and 12 weeks.
3163450|NCT00481312|Active Comparator|1|Dexmedetomidine
3163451|NCT00481312|Active Comparator|2|Midazolam
3163452|NCT00481325|Experimental|A1|
2505281|NCT02864784|Experimental|Amorphous calcium carbonate|Subjects in this arm of the study will receive AMOR-1 tablets, containing 200 mg elemental calcium in addition to the standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
2505285|NCT02864784|Placebo Comparator|Placebo|Subjects in this arm of the study will receive Placebo tablets in addition to standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab)
2505345|NCT02864459|Experimental|Muscular ultrasound|
3163453|NCT00481325|Active Comparator|A2|
3163454|NCT00481325|Placebo Comparator|A3|
2505523|NCT02862938|Experimental|NT-501 ECT Implant|"On eligible participants that are randomized to this group, the NT-501 Investigational product will be implanted in the study eye, and participants will be followed for 24 months.~The investigational treatment, NT-501 ECT, provides intravitreal sustained release of soluble ciliary neurotrophic factor (CNTF) receptor after intraocular implantation."
2505529|NCT02862938|Sham Comparator|Sham|To maintain masking, participants randomized to this group receive sham surgery and will be followed for 12 months. Following analysis of the 6 month data, if the open label extension (OLE) is not triggered, patients in the control group will continue on the original study schedule timeline trough month 24. If OLE is triggered participants will be offered the NT-501 ECT investigational product and will followed for additional 12 months.
2505566|NCT02862782|Experimental|hCG|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono)
2505568|NCT02862782|Experimental|hCG + GnRH agonist|Injection of hCG - Human Chorionic Gonadotropin (Ovitrelle 250 mcg mcg - Merck Serono) and GnRH agonist - Gonadotropin - releasing hormone (Decapeptyl 0.2mg - Ferring Gmgh)
2505629|NCT02862405||Patients with loss of central vision|Patients coming in ophthalmic consultation will be selected for the study. The diagnosis of this disease is based on clinical examination, and imaging of the retina.Patients with only loss of central vision will be selected.
2505636|NCT02862405||Patients with loss of peripheral vision|Patients coming in ophthalmic consultation will be selected for the study. Patients with loss of peripheral vision will be selected on the bases of presence of tunnel vision.
2505644|NCT02862405||Control group|Patients without loss of vision.
2505694|NCT02861859|Placebo Comparator|Placebo Comparator|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle,), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine placebo (PO OD days 1-4)."
2505697|NCT02861859|Active Comparator|Olanzapine|"Eligible patients at high personal risk of CIVN will receive Standard of Care Regimen: Aprepitant (125 mg PO, OD day 1, 80mg OD days 2-3), ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4).~Eligible patients at low personal risk of CIVN will receive Standard of Care Regimen: Ondansetron (8mg PO, BID on Day 1 of each cycle), dexamethasone (12 mg IV x1 before chemotherapy and 4mg PO BID days 2-3) and olanzapine (5 mg PO OD days 1-4)."
2505727|NCT02861469||Main carers|Individual semi-structured interviews
2505733|NCT02861469||General practitioners|Individual semi-structured interviews
2505826|NCT02861183|Experimental|OVT (Sodium Hyaluronate)|Sodium hyaluronate is supplied as a 2 mL unit dose in a 3 mL glass syringe.
2505828|NCT02861183|Placebo Comparator|Saline|0.9% sterile saline is supplied as a 2 mL unit dose in a 3 mL glass syringe.
2505870|NCT02860598||Group 1|Patient with AML de novo or secondary myelodysplasia, in Complete Remission (CR) after induction and / or salvage therapy and candidate to receive a consolidation therapy
2505872|NCT02860598||Group 2|Patient with hematologic malignancies (ALL, AML, chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma, myeloma, myeloproliferative syndrome (MDS)) and candidate for blood marrow or stem cell or placental blood transplantation.
2505901|NCT02860325|Experimental|NIV-NAVA|Patients allocated to non-invasive NAVA
2505906|NCT02860325|Active Comparator|Conventional|Patients allocated to nasal CPAP or non-synchronized nasal IPPV
2505963|NCT02860039|Experimental|Group 1 - High Dose HD-TIV|Patients receive HD-TIV intramuscularly (IM) on day 0 and day 28.
2505968|NCT02860039|Active Comparator|Group 2 - Standard Dose QIV|Patients receive standard dose QIV IM on day 0 and day 28.
3163455|NCT00481338|Experimental|Study specific procedure|X-rays, biological samples and medical information about osteoarthritis
2506177|NCT02858557|Experimental|Group A|Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
2506180|NCT02858557|Experimental|Group B|Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
2506261|NCT02857946|Experimental|A Test|Test drug (Prevaglip) 1 tablet contains 5 mg linagliptin
2506262|NCT02857946|Active Comparator|B Reference|Reference drug (Trajenta) 1 tablet contains 5 mg linagliptin
2506315|NCT02857595|Active Comparator|Online Weight Loss Program|
2506317|NCT02857595|Experimental|Online Weight Loss Program + Nomogram|
2506319|NCT02857595|Experimental|Online Weight Loss Program + Nomogram + Bite Counter|
2506357|NCT02857244|Other|Open-Label Treatment Arm|"Each patient will take Duloxetine 30mg for 1 week, followed by 60mg qam for 1 week, 90mg qam for 1 week, and 120mg qam for 1 week, if tolerated. The patient will be taking Duloxetine for a total of 4 weeks. The dose of Duloxetine will be reduced if the patient cannot tolerate. Donepezil will then be added to Duloxetine 120mg qam (or the highest dose the patient can tolerate) by 5mg qd for 1 week, followed by 10mg qd for 1 week.~After a 4-week washout period, each patient will take Modafinil 100mg qam for one week, followed by 200mg qam for 1 week.~Patients will come into the medical center on 5 occasions, 1 for screening/baseline, 1 after completion of duloxetine, 1 after completion of duloxetine+donepezil, 1 after four-week washout, 1 after completion of modafinil."
3163456|NCT00481364|Active Comparator|Statin|Atorvastatin 40 mg/day
3163457|NCT00481364|Placebo Comparator|Placebo|placebo
3163458|NCT00481390||HIV-1 infected adults|HIV-1 infected adults
3163459|NCT00481429||1|Rosiglitazone
3163460|NCT00481429||2|Diet control +/- metformin
2505324|NCT02864641|No Intervention|CO Group: Treatment-as-usual|A national sample of CKD participants will be recruited. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet K app and website but will receive email reminders to complete surveys online at each time point.
2505382|NCT02864199|Experimental|Group A: Moderate Renal Impairment|Participants with CrCl 30 to 50 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 micrograms (mcg) via subcutaneous (SC) injection once weekly, in combination with ribavirin, 600 milligrams (mg) orally (PO) daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2505383|NCT02864199|Experimental|Group B: Severe Renal Impairment|Participants with CrCl <30 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 400 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2505384|NCT02864199|Experimental|Group C: Hemodialysis/ESRD|Participants requiring hemodialysis will receive 12 weeks of peginterferon alfa-2a, 135 mcg via SC injection once weekly, in combination with ribavirin, 200 mg PO every morning. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2505385|NCT02864199|Experimental|Group D: Normal Renal Function|Participants with CrCl >80 mL/min will receive 12 weeks of peginterferon alfa-2a, 180 mcg via SC injection once weekly, in combination with ribavirin, 800 to 1200 mg PO daily in two divided doses. Those with Genotype 2 or 3 disease may receive an additional 12 weeks of the same regimen, and those with another genotype may receive an additional 36 weeks.
2505542|NCT02863211||Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|One-thousand women 55 years of age or older will be recruited to be screened through the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol. This involves the cardiovascular assessment of resting blood pressure, blood pressure response to 3-min of moderate intensity exercise and large and small arterial elasticity. The participants will be classified into risk categories based on these measures. The incidence of the following adverse cardiovascular outcomes will be assessed in the five-year period after screening in both groups: Ischemic heart disease, acute myocardial infarction, stroke, percutaneous coronary intervention, coronary bypass surgery, congestive heart failure, and hypertension.
2505564|NCT02862665|Experimental|IV iron|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
2505567|NCT02862665|Placebo Comparator|Control|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
2505600|NCT02862418||Pulmonary disease|UTE MRI
2505602|NCT02862418||Control|UTE MRI
2505616|NCT02862145|Experimental|Treatment with MRX34|Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.
2505704|NCT02861729|Experimental|Suprinity|Vita Suprinity® (VITA Zahnfabrik H. Rauter GmbH & Co.KG- Germany) Zirconia reinforced lithium silicate PCRs
2505705|NCT02861729|Active Comparator|e.max|IPS-e.max® CAD (Ivoclar Vivadent AG, Schaan - Liechtenstein) lithium disilicate PCRs
2505763|NCT02861378|Experimental|Phentolamine mesylate|Once anesthesia is confirmed, subjects in the Phentolamine mesylate group will receive 1 injection of 1ml of a solution containing 0.24 mg of phentolamine mesylate in the same site that was previously anaesthetized (not as a part of the study).
2505769|NCT02861378|Placebo Comparator|Water|Once anaesthesia is confined, the subjects in the water group will receive 1 injection of 1 ml of sterile physiological water in the same site that was previously anaesthetized (not as a part of the study).
2505813|NCT02860962|Active Comparator|Dextromethorphan|2 doses of Dextromethorphan 75mg oral (PO), separated by 4 hours
2505814|NCT02860962|Placebo Comparator|Placebo|2 doses of placebo (oral/PO), separated by 4 hours
2505841|NCT02860754|Other|Six-minute walk test|All patients will perform six-minute walk test before surgery, in the preoperative clinic
2505887|NCT02860494|Experimental|Topical everolimus 0.1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2505892|NCT02860494|Experimental|Topical everolimus 0.5%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2505896|NCT02860494|Experimental|Topical everolimus 1%|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2505897|NCT02860494|Placebo Comparator|Topical placebo|Topical placebo will be identical to the everolimus topical formulation. Topical placebo will be applied to the affected areas, once daily, in the evening, for 6 months by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
2505955|NCT02860065|Experimental|CPC-201|combination of solifenacin and high doses of donepezil
2506000|NCT02859688||SRS patient|
2506003|NCT02859688||father SRS patient|
2506005|NCT02859688||control patient|
2505332|NCT02864576|Experimental|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program, performed 3 days per week, lasting 40 minutes."
2505339|NCT02864576|Active Comparator|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~12 weeks of systematic cognitive training (REHACOP), performed 3 days per week in a 90-minutes-long sessions.~Health Promotion:~12 weeks of health promotion sessions, performed 3 days per week, lasting 40 minutes each."
3163461|NCT00481455|Experimental|1|
3163462|NCT00481481|Experimental|1|
3196586|NCT00851955||2. Chronic pancreatitis patients|Patients with documented diagnosis of moderate to advanced chronic pancreatitis supported by at least 1 positive imaging test (EUS,CT scan or MRI).
3196587|NCT00851955||3. Pancreatic cancer patients|Patients with documented tissue diagnosis (or clinical suspicion) of Pancreatic Cancer.
2505579|NCT02862496||hyperemesis gravidarum|hyperemesis gravidarum group consisting of 30 pregnant women between 7-20 weeks of gestation with diagnosed hyperemesis gravidarum.
2505582|NCT02862496||Control group|control group consisting of 30 health pregnant women between 7-20 weeks of gestation with excluded hyperemesis gravidarum.
2505632|NCT02862262|Experimental|Blinded, Prospective Arm (1)|Clinical performance of the ARIES Bordetella Assay for the detection of B. pertussis and B. parapertussis will be evaluated in prospectively collected, de-identified, left-over, clinical specimens.
2505640|NCT02862262|Experimental|Blinded, Pre-selected Arm (2)|In the event that an insufficient number of positive specimens are acquired for B. pertussis / B. parapertussis in Arm 1, clinical performance of the ARIES Bordetella Assay will be tested using banked, pre-selected, positive clinical specimens.
2505646|NCT02862262|Experimental|Blinded, Contrived Arm (3)|Contrived specimens will be tested using the ARIES Bordetella Assay to evaluate detection of B. parapertussis in the event that an insufficient number of positive specimens are acquired in Arm 2.
2505701|NCT02861781||Type 2 diabetes|Type 2 diabetes according to ADA criteria
2505702|NCT02861781||Insulin resistance non diabetes|HOMA-IR criteria ≥ 3
2505703|NCT02861781||Insulin sensitivity non diabetes|HOMA-IR criteria < 3
2505762|NCT02861404||Salicylate ointment|patients included in VRAIE study, treated with salicylate ointment (VRAIE study, NCT01059110)
2505774|NCT02861404||Imiquimod|patients included in VRAIE study, treated with Imiquimod (VRAIE study, NCT01059110)
2505780|NCT02861404||5-Fluoro-Uracil|patients included in VRAIE study, treated with 5-Fluoro-Uracil (VRAIE study, NCT01059110)
2505782|NCT02861404||Cryotherapy|patients included in VRAIE study, treated with cryotherapy (VRAIE study, NCT01059110)
2505785|NCT02861404||placebo|patients included in VRAIE study, receiving placebo (VRAIE study, NCT01059110)
2505848|NCT02860910|Experimental|Cognitive Behavioral Group Therapy|"The six CBGT sessions are outlined in the manual entitled: Managing Hot Flushes with Group Cognitive Behaviour Therapy: An Evidenced-Based Treatment Manual for Health Care Professionals (Hunter & Smith, 2015) as follows:~Session 1: Psycho-education and the cognitive behavioural model Session 2: Stress management, improving wellbeing and identifying precipitants Session 3: Managing hot flushes using a cognitive behavioural approach Session 4: Managing night sweats and improving sleep (part one) Session 5: Managing night sweats and improving sleep (part two) Session 6: Review and maintaining changes (One alteration: Open discussion about mood disorders, anxiety and the psychological impact instead of the psychological impact of breast cancer)"
2505885|NCT02860468|Experimental|Cranberry juice consumption|participants in this arm will be provided cranberry juice to consume for 21 days in total
2505890|NCT02860468|Placebo Comparator|Placebo juice consumption|participants in this arm will be provided placebo juice to consume for 21 days in total
3196588|NCT00851968|Active Comparator|Pringle's Maneuver|Patients with HCC received Pringle's Maneuver in hepatectomy.
3196589|NCT00851968|Experimental|Hemihepatic vascular Clamping|Patients with HCC received Hemihepatic vascular Clamping in hepatectomy
2506131|NCT02858570|Experimental|MenCC-BIO Vaccine|Vaccine against meningococcus serogroup C conjugated to tetanus toxoid produced by Bio-Manguinhos / FIOCRUZ (MenCC-Bio). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old)For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
2506134|NCT02858570|Active Comparator|combined - CRM197|Adsorbed vaccine meningococcal C (combined - CRM197) produced by the Foundation Ezequiel Dias (FUNED). Stratum I - 11-19 years; Stratum II - 1 to 10; Stratum III - less than 1 year old). For the age groups I and II are applied 2 doses ideal interval of 6 months between them. In stratum III, are recommended 3 doses of the vaccine, at ages 3, 5 and 12 months of age, according to calendar of the National Immunization Program.
2506555|NCT02855632|Experimental|G-CSF|G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
3163463|NCT00481520|Experimental|1|
3163464|NCT00481520|Placebo Comparator|2|
3163466|NCT00481572|Experimental|1|Terlipressin
3163467|NCT00481572|Experimental|2|Vasopressin
3163468|NCT00481572|Active Comparator|3|titrated norepinephrine
3163469|NCT00481624|Experimental|Epoetin Alfa plus Iron|
3163470|NCT00481637||Cancer patients|SCLC and gynecological cancer patients and unrelated cancer patients with presence of PND-specific CTLs.
3163471|NCT00481637||Normal|Normal volunteers
3163472|NCT00481663|Experimental|Sitagliptin 25 mg once daily|Sitaglipin (MK-0431), 25 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
3163473|NCT00481663|Experimental|Sitagliptin 50 mg once daily|Sitagliptin, 50 mg, once daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
3163474|NCT00481663|Experimental|Sitaglipin 100 mg once daily|Sitagliptin, 100 mg, once daily for 158 weeks, orally
2505336|NCT02864654|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate Adipose-derived regenerative cells (ADRC). After isolation 10 mL of autologous ADRC suspension will be injected intramuscularly, close to the site of muscle injury. 10 to 20 injections will be performed so as to infiltrate the injured muscle
2505407|NCT02864095|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
2505414|NCT02864095|Experimental|Topical epinephrine|Topical epinephrine
2505418|NCT02864095|Active Comparator|Control|No epinephrine
3196590|NCT00851968|Experimental|portal vein occlusion|Patients with HCC received portal vein occlusion in hepatectomy
3196591|NCT00851981|Placebo Comparator|1|
2505561|NCT02862821|Experimental|validation of EEfRT task|20 healthy volunteers will be recruted to validate motivation EEfRT task which is adaptated to HR-EEG
2505563|NCT02862821|Experimental|biomarkers identification|20 addict online poker gamblers and 20 non-addict online poker gamblers will be recruted : After standardized questionnaires to define the socio-demographic data, the diagnosis of gambling addiction (Diagnostic and Statistical Manual of Mental Disorder 5th edition DSM-5), screening for comorbidities addictive, the level of anxiety and impulsivity, brain acvtivity will be registred (by randomisation between the 2 tasks) with HR-EEG: during the performance of a task of motivation evaluation laboratory (EEfRT) adaptated for high-resolution electroencephalography AND during a laboratory task that assesses decision making in conditions of uncertainty (IGT) with its version for high-resolution electroencephalography has already been validated in a previous study (Giustiniani et al., 2015).
2505565|NCT02862821|Experimental|biomarkers validation|13 online poker gamblers will be recruted, independently of their dependance profile and they will realize the same task that in precedent arm (quaestionnaires and 2 tasks adaptated to HR-EEG).
2505659|NCT02861924|Experimental|microcirculatory responses|"Measure microcirculatory responses after localized ischemia obtained by local application of pressure (laser speckle).~A pressure is applied to the subject's arm. this causes a localized ischemia. the measures responses to this ischemia will be made by the imager speckle (LSCI) give the microvascular perfusion data."
2505724|NCT02861690|Experimental|Treatment group|patients received Liposomal Paclitaxel and Nedaplatin every 21 days until the presence of progressive disease or unacceptable toxicity
2505791|NCT02861105|Active Comparator|LMWH supplementation|40 mg of enoxaparin injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
2505792|NCT02861105|Placebo Comparator|0.9% saline solution|0.9% saline injected subcutaneously every 24 hours starting the day of ovum pick-up to the documentation of fetal life by ultrasound at 7 weeks of gestation
3196592|NCT00851981|Active Comparator|SAMe|
3196593|NCT00851994||1|Patients having surgery
2505904|NCT02860403|Experimental|C6-C7 patients|C6-C7 patients able to recover tenodesis grasp.
2505907|NCT02860403|Experimental|C5-C6 patients|C5-C6 patients for whom surgery for rehabilitation of an upper limb is indicated with a upper limit of one year after trauma, and after complete clinical and functional evaluation
2505909|NCT02860403|No Intervention|Control group|a control group (n=6) matched on age and sex to C6-C7 without medical history or neurological disorder
2505988|NCT02860026|Active Comparator|Control|Marketed cow's milk-based infant formula
2505991|NCT02860026|Experimental|Investigational|Cow's milk-based infant formula with added nutrients
2506008|NCT02859350|Experimental|Group 1a (PfSPZ Vaccine)|18-35 years; n= 20; 3 doses of 2.7x10^6 PfSPZ Vaccine given eight weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2506009|NCT02859350|Placebo Comparator|Group 1a (normal saline)|18-35 years; n=6; 3 doses of normal saline given 8 weeks apart. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2506011|NCT02859350|Experimental|Group 1b (PfSPZ CVac)|18-35 years; n=20; 3 doses of 1.0x10^5 PfSPZ Challenge given every four weeks. Group 1b will start 8 weeks after Group 1a. Volunteers in Group 1b will receive their first immunization after the loading dose of chloroquine has been administered. Volunteers will receive CHMI between 10 and 14 weeks post last vaccination (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2506013|NCT02859350|Placebo Comparator|Group 1b (normal saline)|18-35 years; n=6; 3 doses of normal saline given 4 weeks apart. Group 1b will start 8 weeks after Group 1a. Volunteers will receive CHMI between 10 and 14 weeks post last dose of NS (with a window of +/-7 days on each side) and will be followed for 8 weeks following CHMI.
2506029|NCT02859350|Experimental|Group 2 (PfSPZ Vaccine)|36-65 years; n=12; 3 doses of 2.7x10^6 PfSPZ Vaccine given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
2506043|NCT02859350|Placebo Comparator|Group 2 (normal saline)|36-65 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 2 will start 3 weeks after Group 1a.
2506047|NCT02859350|Experimental|Group 3 (PfSPZ Vaccine)|11-17 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
2506048|NCT02859350|Placebo Comparator|Group 3 (normal saline)|11-17 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 3 will start 3 weeks after Group 1a.
2506049|NCT02859350|Experimental|Group 4 (PfSPZ Vaccine)|6-10 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
2506050|NCT02859350|Placebo Comparator|Group 4 (normal saline)|6-10 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 4 will start 4 weeks after Group 1a.
2506051|NCT02859350|Experimental|Group 5 (PfSPZ Vaccine)|1-5 years; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
2506053|NCT02859350|Placebo Comparator|Group 5 (normal saline)|1-5 years; n=4; 3 doses of normal saline given 8 weeks apart. Group 5 will start 7 weeks after Group 1a.
3196594|NCT00852007|Experimental|DC-Tn-MUC|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1. 1.2 x 10e7 dendritic cells per dose. 5 administrations (doses)may be given in total.
3196595|NCT00852020|Experimental|1|oral nutritional supplement containing n-3-fatty acids, amino acids and antioxidants
3196596|NCT00852020|Placebo Comparator|2|oral nutritional supplement (isocaloric, isonitrogenous)
3196597|NCT00852033|No Intervention|1|Assessment Group (no intervention)
2505365|NCT02864238||post intervention|This cohort consists of patients who underwent cardiac valve surgery during calender year 2014 after the electronic milestone pathway had been instituted
2505395|NCT02863991|Experimental|ONC201|Single agent ONC201.
2505457|NCT02863718|No Intervention|Watch & wait|Watch & wait
2505466|NCT02863718|Placebo Comparator|Placebo 420 mg/d|Placebo 420mg/d
2505473|NCT02863718|Active Comparator|Ibrutinib 420mg/d|Ibrutinib 420mg/d
2505550|NCT02862834||patients with poikiloderma|
2505552|NCT02862522||Women With CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
2505553|NCT02862522||Women Without CED|All subjects had blood work with included measurement of C-reactive protein, complete blood count with differential, basic chemistry panel, and uric acid level. All subjects completed a standardized questionnaire to assess baseline characteristics. All subjects underwent comprehensive coronary endothelial function assessment. Subjects completed a questionnaire of overall health several years after the index coronary angiogram and endothelial function study.
2505624|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 250 mg)|
2505626|NCT02862236|Experimental|Hypericum perforatum (Remotiv, 500 mg)|
2505739|NCT02861638|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
2505743|NCT02861638|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 30 minutes twice a day, 5 days a week for 2 weeks.
2505824|NCT02861027|Active Comparator|PPTHA|Control Group performs the PPTHA.
2505825|NCT02861027|Experimental|FES and PPTHA|The Intervention Group performs the PPTHA associated with FES.
2505880|NCT02860624|Experimental|10 mg ilaprazole|
2505883|NCT02860624|Active Comparator|40 mg esomeprazole|
3196598|NCT00852033|Active Comparator|2|Brief Motivational Intervention (BMI)
3196599|NCT00852033|Active Comparator|3|Parent Based Intervention (PBI)
2505972|NCT02859779|Other|mediterranean adolescents with type 1 diabetes|
2506054|NCT02859584|Other|no serious acute hepatitis|
2506058|NCT02859584|Other|Serious acute hepatitis|
2506061|NCT02859584|Other|Healthy volunteers|
2506064|NCT02859584|Other|Surrenal insufficiency|
2506094|NCT02858986|Experimental|3D laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 3D laparoscopic system
2506104|NCT02858986|Experimental|4K laparoscopy|Patients will undergo laparoscopic cholecystectomy using a 4K laparoscopic system
2506274|NCT02857933|Other|Frequency Level 1 - Daily Therapy|Level 1 daily physical therapy is 2 hours of one-on-one physical therapy per day for 20 straight weekdays
2506276|NCT02857933|Other|Frequency Level 2 - Intermediate Therapy|Level 2 intermediate physical therapy is 2 hours of therapy per day 3 days per week for 6.6 weeks
2506277|NCT02857933|Other|Frequency Level 3 - Usual Therapy|Level 3 usual weekly physical therapy is 2 hours of therapy one day per week for 20 weeks.
2506314|NCT02857556|Other|group with stage 3 kidney failure (diabetic or not)|
2506318|NCT02857556|Other|group with stage 5 kidney failure (diabetic or not)|
3196600|NCT00852033|Active Comparator|4|BMI and TBI
3196601|NCT00852046|Experimental|1. Low dose dexmedetomidine|Dexmedetomidine 0.2 mcg/kg/hr added to fentanyl & propofol.
2506458|NCT02856451||Patients Treated with Nivolumab followed by Encephalitis Event|Case series reported to the sponsor from various health care facilities
2506509|NCT02856191|Other|Septic shock|
2506576|NCT02855840||systemic lupus erythematous|
2506577|NCT02855840||systemic sclerosis|
2506578|NCT02855840||inflammatory myopathy|
3196602|NCT00852046|Experimental|2. High dose dexmedetomidine|Dexmedetomidine 0.6 mcg/kg/hr added to fentanyl & propofol.
3196603|NCT00852046|Placebo Comparator|3. Placebo|Placebo added to fentanyl & propofol.
3196604|NCT00852059|Experimental|Immediate release|Treatment with immediate release (IR) methylphenidate (Medikinet®) in the morning and 3-4 h later (twice a day)
3196605|NCT00852059|Active Comparator|Extended release|Treatment with extended release (ER) methylphenidate (Medikinet reatard®) applied with breakfast(once daily)
2506771|NCT02854410|Experimental|Sodium nitrate supplementation|Patients will receive Sodium nitrate supplementation from 7 days before radiotherapy to one month after the end of radiotherapy
2506773|NCT02854410|Placebo Comparator|Placebo Comparator(sodium chloride)|Patients will receive placebo from 7 days before radiotherapy to one month after the end of radiotherapy
2506815|NCT02854137|Experimental|Sunscreen / Arm 1|Subjects will be escorted to a separate room for instillation of the test materials. Test materials will be instilled in immediate succession and with a randomized order of presentation. A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the eyes of the subject forming sacs in the conjuntival tissue, apply one test product to one eye.
2506816|NCT02854137|Other|Control|A trained technician will use the thumb and forefinger of one hand to retract the lower eyelid from the other eyes of the subject forming sacs in the conjuntival tissue, apply control materials to this eye, follow the same procedure, using a new pipet tip or steriled dropper.
2547412|NCT02582086|Placebo Comparator|Placebo Cream|Placebo Cream
3196606|NCT00852072|Active Comparator|Single-operator cholangioscopy guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
3196607|NCT00852072|Active Comparator|Balloon sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
2505372|NCT02864212||Blood pressure monitoring|Invasive blood pressure will be monitor in patients undergoing cardiac surgery.
2505381|NCT02863952|Other|EARLY POST-STRESS EF CHANGE|There is only a single arm. All patients undergoing the routine myocardial perfusion SPECT study will also have additional (earlier) image acquisition in order to assess the relation of early wall motion abnormalities to the severity of myocardial ischemia.
2505391|NCT02863848|Placebo Comparator|Placebo|Maltodextrin 2g, twice per day, 6 weeks
2505398|NCT02863848|Active Comparator|Inulin-type fructans|Orafti inulin-type fructans 2g, twice per day, 6 weeks
2505456|NCT02863679|Experimental|Tetracaine hydrochloride gel group|Patients in getracaine hydrochloride gel group were covered with a gauze with tetracaine hydrochloride gel on the cervix after hysteroscopic insertion of utrauterine balloon stent.
2505463|NCT02863679|Placebo Comparator|Control group|Patients in control group were covered with a gauze with saline on the cervix after hysteroscopic insertion of utrauterine balloon stent.
2505535|NCT02863094|Active Comparator|Real Stimulation|The continuous theta burst stimulation (cTBS) protocol lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. In the cTBS session, this 40s protocol was repeated for three times (1800 pulses in total) separated by two 15 min breaks (controlled by a stopwatch). MRI dataset should be acquired before the first cTBS session and after the last cTBS session.
2505543|NCT02863094|Sham Comparator|Placebo Stimulation|The procedure of this protocol was performed by a placebo coil. Each session lasted 40 s and consisted of burst of 3 pulses delivered at 50 Hz, with bursts being repeated every 200 ms (at 5 Hz) for a total of 600 pulses. No actual magnetic stimulation was applied on the head of the volunteers. MRI dataset should be acquired before the first sham TBS session and after the last sham TBS session.
2505570|NCT02862613|Experimental|Precision Cells|"Precision Cells combined with Transcatheter Arterial Chemoembolization:~Transcatheter Arterial Chemoembolization:~patients will receive MMC,EADM hepatic arterial infusion,6 cycles. Precision Cells：After accepting concurrent TACE treatment,patients will receive 3 cycles of Precision Cells treatment"
2505571|NCT02862613|Active Comparator|Transcatheter Arterial Chemoembolization|patients will receive MMC,EADM hepatic arterial infusion,6 cycles.
2505634|NCT02862314|Experimental|procalcitonin group|The procalcitonin concentration is measured at inclusion.
2505642|NCT02862314|No Intervention|control group|Concentrations of procalcitonin are not measured. .
2505666|NCT02861911|Sham Comparator|Control group|The current intensity is generally defined between the sensory and motor threshold (patients feel the power but no visible muscle contraction will be obtained).
2505667|NCT02861911|Active Comparator|Active NMES group|Tthe current intensity must always meet and exceed the motor threshold (patients feel the current and quadriceps muscle will contract a visible and quantifiable if possible).
2505711|NCT02861482|Experimental|Bakri Ballon|All the enrolled patients who would undergo the laying of Bakri Balloon
2505753|NCT02861261|Experimental|Group A|
2505764|NCT02861261|Experimental|Group B|
2505772|NCT02861261|Experimental|Group C|
2505779|NCT02861261|Placebo Comparator|Group D|
2505832|NCT02860897|Experimental|Vaginal estrogen cream|
2505834|NCT02860897|Experimental|Vaginal estrogen tablet|
2505876|NCT02860572|Experimental|follow-up without intervention|No intervention to increase the urine output within 2 hours will be done.
2505878|NCT02860572|Active Comparator|Standard group - fluid bolus|Patient will receive 500mL of balanced crystalloid intravenously over 30 minutes.
2505985|NCT02860156||HIV+/DD+|Subjects are HIV positive and have diastolic dysfunction
2505987|NCT02860156||HIV+/DD-|Subjects are HIV positive and do not have diastolic dysfunction
2505989|NCT02860156||HIV-/DD+|Subjects do not have HIV and have diastolic dysfunction
2506014|NCT02859428||Patients with hereditary spastic paraplegia (HSP)|Patients with hereditary spastic paraplegia types 3A, 4 and 31.
2506100|NCT02859259|Experimental|Treatment A: reference extended-release (ER) 1 tablet at 600mg|A single dose of BMS-663068 administered orally as specified
2506110|NCT02859259|Experimental|Treatment B: low-dose ER 4 tablets at 150mg|A single dose (4 tablets) of BMS-663068 administered orally as specified
2506153|NCT02858674|Experimental|Active Alerting Mechanism|Traditional Pop Up Alert used in Epic
2506156|NCT02858674|Active Comparator|Passive Alerting Mechanism|Noninterruptive alert that sits in the checklist
2506211|NCT02858271|Experimental|AKB-9778|Single dose of [14C]-radiolabeled subcutaneous (SC) injection of AKB-9778 in the morning of Day 1
3196608|NCT00852085|Experimental|Group MI|Four group counseling sessions and a directed observational visit to the emergency department of a busy urban hospital
3196609|NCT00852085|Active Comparator|Enhanced community service|
2506310|NCT02857647|Experimental|The experimental group|"Participants who will assigned to the experimental group will be asked to watch an information video of 30 minutes 1-2 weeks prior to the surgery date.~n=100."
2506311|NCT02857647|No Intervention|The control group|"Participants who will assigned to the control group will receive standard care and will not asked to watch a videotaped lecture prior to the surgery.~n=100."
2506355|NCT02857361|Experimental|Treatment A: Simultaneous Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered simultaneously at T=0 minute.
2506358|NCT02857361|Experimental|Treatment B: Sequential Administration|Sublingual ketamine 50mg (2 x 25mg wafers) administered sequentially, one 25 mg wafer at T=0 minute and one 25 mg wafer at T=3 minutes.
2506377|NCT02856919|Other|Mirvaso® gel|Mirvaso® gel (5 mg/g brimonidine tartrate)
2506434|NCT02856776|Experimental|Arm 1: 600 IU vitamin D|Subject will receive 600 IUs of vitamin D3/day for 24 weeks.
2506436|NCT02856776|Experimental|Arm 2: 4,000 IU vitamin D|Subject will receive 4,000 IUs of vitamin D3/day for 24 weeks
2506438|NCT02856776|Experimental|Arm 3: 10,000 IU vitamin D|Subjet will receive 10,000 IUs of vitamin D3/day for 24 weeks
2506443|NCT02856776|Experimental|Arm 4: Mixed vitamin D dosages|Subject will receive 600 IUs of vitamin D3/day for the first 8 weeks, 4,000 IUs of vitamin D3/day for the next 8 weeks, and 10,000 IUs of vitamin D3/day for the final 8 weeks.
3196610|NCT00852098|Active Comparator|1|dividing short gastric vessels
3196611|NCT00852098|Active Comparator|2|non-dividing short gastric vessels
2505406|NCT02864147|Experimental|imiquimod + 9-valent HPV vaccine|Participants randomized to the imiquimod + 9-valent HPV vaccine group will receive instruction on imiquimod self application (16 week course) at the baseline visit. In addition, all women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
2505408|NCT02864147|Active Comparator|imiquimod only|Participants randomized to the imiquimod only group will receive instruction on imiquimod self application (16 week course) at the baseline visit.
2505415|NCT02864147|No Intervention|observation only (control)|Participants randomized to the control group will only be observed and will receive no intervention.
3196613|NCT00852163|Experimental|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
3196614|NCT00852176||On-label treatment|"Patients treated in routine clinical practice following FDA Pre-Market Approval of the Beta-Cath(TM) 3.5F System within the parameters of the approved indications for use for the System (on-label)."
3196615|NCT00852215|Active Comparator|1|Taxus stent group
2505751|NCT02861417|Experimental|Group I (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
2505755|NCT02861417|Experimental|Group II (matched donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.
2505766|NCT02861417|Experimental|Group III (haploidentical donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score > 3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
2505773|NCT02861417|Experimental|Group IV (matched donor transplant, chemotherapy)|Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, > 60 years old, or patients with comorbidity scores > 3 will go in Group 3 or 4. If patients with comorbidity score >3, then the principal investigator is the final arbiter of eligibility for comorbidity score > 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.
2505777|NCT02861417|Experimental|Group V (haploidentical donor transplant, chemotherapy)|Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
2505783|NCT02861417|Experimental|Group VI (matched or haploidentical transplant, chemotherapy)|Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.
2505950|NCT02860208||3 years follow-up|all patients who received surgical treatment for peri-implantitis during a Randomized and Controlled Trial registered in ClinicalTrials.gov NCT NCT01857804
3196616|NCT00852215|Active Comparator|2|Vision stent group
2506012|NCT02859363||Young stroke|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing for the 26 common Fabry mutation types in Taiwan.
2506107|NCT02859220|Other|group 1|group 1 : Roche Elecsys intact PTH
2506112|NCT02859220|Other|group 2|group 2 : PTH 1-84 complete (PAC) report and CAP / PTH 7-84 (CIP), Duo PTH IRMA Scantibodies
3196617|NCT00852228|Experimental|chronomodulated HAI chemotherapy|
3196618|NCT00852228|Experimental|conventional HAI chemotherapy|
3196619|NCT00852267|Active Comparator|High CHO, High SatFat Diet|
3196620|NCT00852267|Experimental|Low CHO, High SatFat Diet|
2506376|NCT02856984||ZIKV infected women|The study will prospectively enroll pregnant women up to 17 weeks and 6 days gestation and follow them through their pregnancy for clinical evidence of acute ZIKV infection while controlling for potential confounders. All pregnant women will be followed throughout the pregnancy, delivery, and 6 weeks postpartum. Outcomes in women, the developing fetus, and infants will be assessed.
2506378|NCT02856984||Control (uninfected women)|The women who remain uninfected will serve as the internal comparison group. The infants who remain uninfected at delivery and throughout the follow-up period will serve as the internal comparison group.
2506441|NCT02856685|Experimental|PLM60|Mitoxantrone Hydrochloride Liposome
2506467|NCT02856256|Experimental|RedBull® energy drink|
2506505|NCT02856113|Experimental|Alogliptin 25 mg|Alogliptin 25 mg tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
2506585|NCT02855671||Healthy volunteers|
2506586|NCT02855671||Sepsis|
3196621|NCT00852267|Experimental|Low CHO, Low SatFat Diet|
3196622|NCT00852293||study group|Patients with liver disease followed at the liver unit at Hadassah Medical Center.
3196623|NCT00852306|Experimental|slow freeze|these recipients will have their first embryo transfer with oocytes frozen via the slow freeze method.
3196624|NCT00852306|Experimental|vitrification|these recipients will have their first attempt at an embryo transfer with oocytes frozen via the vitrification method.
2505554|NCT02862717||Hemodialysis (HD)|HD patients in MOH dialysis centres notified to NRR.
2505555|NCT02862717||Continuous ambulatory peritoneal dialysis (CAPD)|CAPD patients in MOH dialysis centres notified to NRR.
2505615|NCT02862444||intervention group|Culturally Appropriate Intervention
3163475|NCT00481663|Experimental|Sitagliptin 50 mg twice daily|Sitagliptin 50 mg, twice daily for 12 weeks, orally. Due to interim analysis of this study and another Phase IIB study, participants in this arm were switched into the 100-mg once daily arm during either the first or initiation of the second extensions study periods.
2505728|NCT02861560|Experimental|dHACM|Dehydrated human amnion/chorion membrane (dHACM)
2505796|NCT02861157|Experimental|TX Condition: Planet T1D Intervention|Families participating in the TX condition will be asked to attend a one-hour orientation session, during which study expectations and tasks will be explained. Families will be asked to watch a short 2-minute study overview video that summarizes study requirements and expectations. Parents and their children will then have the opportunity to provide informed consent/assent prior to their participation in the study. Youth participants will then receive a mobile phone preloaded with the Planet T1D app and a brief orientation to the app and associated website. Participants in the TX condition will receive immediate access to the Planet T1D application and website following the orientation session and will have four months to freely use the application. The TX group will be provided with a mobile phone for the full 2-months of the study.
2505798|NCT02861157|No Intervention|CO Condition: Treatment-As-Usual|A national sample of type 1 diabetes participants will be recruited through a partnership with Medikidz Ltd. Because of the inability to meet with remotely located participants for orientation and distribution of phones, these participants will be assigned to the treatment-as-usual, online control (CO) condition. For recruitment of the online control group, youth and parents interested in participating will be asked to complete a brief eligibility survey. Participants in the treatment-as-usual CO condition will not receive access to the Planet T1D app and website but will receive email reminders to complete surveys online at each time point.
2505836|NCT02860819|Experimental|Gemcitabine, Carboplatin, Veliparib|Gemcitabine 800mg/m2 day 1 and 8 every 3 weeks; Carboplatin AUC = 4, day 1, every 3 weeks, Veliparib 250mg bid day continuously.
2505930|NCT02860117|Active Comparator|Ketatamine|Ketamine continuous infusion 0,2mg/kg/h
2505932|NCT02860117|Placebo Comparator|Placebo|Placebo in continuous infusion
2505986|NCT02859831||with construction work|
2505990|NCT02859831||without construction work|
2506025|NCT02859519|Experimental|MOB015B|Subjects will treat all affected fingernails and/or toenails with MOB015B for 48 weeks once daily at bedtime.
2506039|NCT02859519|Placebo Comparator|MOB015B Vehicle|Subjects will treat all affected fingernails and/or toenails with MOB015B Vehicle for 48 weeks once daily at bedtime.
3163476|NCT00481663|Placebo Comparator|Placebo to Sitagliptin → Metformin|Placebo to Sitagliptin, once daily, orally for 12 weeks. Participants randomized to the placebo treatment group during the base study were reallocated to treatment with metformin 850 mg twice daily (b.i.d., initiated with 850 mg q.d. for 4 weeks then force titrated to 850 mg b.i.d.) during either the first or initiation of the second extensions study periods.
3163477|NCT00481715|Experimental|1|Web-based weight loss program
2506132|NCT02858596|Experimental|Semi-solid feed group|Given semi-solid feed protocol
2506137|NCT02858596|Placebo Comparator|Liquid feed group|Given liquid feed protocol
2506290|NCT02857738|Experimental|SPF evaluation|Subjects with Good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were included for SPF testing.
2506344|NCT02857465|Experimental|Epidural analgesia + DEXAMETHASONE|Single epidural injection of Dexamethasone Mylan (8 mg) concomitant to epidural analgesia (ropivacaine+ sufentanil)
2506347|NCT02857465|Placebo Comparator|Epidural analgesia + PLACEBO|Single epidural injection of sodium chloride (0.9%) Lavoisier concomitant to epidural analgesia (ropivacaine + sufentanil)
2506388|NCT02856867|Active Comparator|mFOLFOX6 + Nintedanib|"Patients will receive nintedanib in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of nintedanib and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
2506391|NCT02856867|Placebo Comparator|mFOLFOX6 + Placebo|"Patients will receive placebo in combination with mFOLFOX6 (5-Fluorouracil 400 mg/m2 bolus on day 1, 5-Fluorouracil 2400 mg/m2 continuous infusion over 46 hours starting on day 1, Leucovorin 400 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1) via IV infusions every 2 weeks (14 days).~Dose modification of placebo and mFOLFOX6 is allowed. Patients may continue to receive protocol therapy as long as they have not experienced any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression."
3163478|NCT00481715|Experimental|2|Cash incentive weight loss program
3163479|NCT00481715|Experimental|3|Web-based program plus the cash incentive program
2506675|NCT02854969|No Intervention|epinephrine auto-injector|3 months using the epinephrine auto-injector alone, and after that 3 more months using the epinephrine auto-injector + medical device
2506677|NCT02854969|Experimental|epinephrine auto-injector + medical device|"Device: Anapphylaxis is a medical device with a case for an epinephrine autoinjector that connects via Bluetooth to a mobile application~3 months using the epinephrine auto-injector + medical device , and after that 3 more months using the epinephrine auto-injector alone"
2506721|NCT02854761|Experimental|SC administration|Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
3163480|NCT00481715|No Intervention|4|No intervention
3163481|NCT00481728|Experimental|Tolterodine|
3163482|NCT00481754||Females with ovarian cancer|Recruited from Magee Women's Hospital
3163483|NCT00481819|Experimental|1|In combination with MMF and steroids
3163484|NCT00481819|Active Comparator|2|In combination with MMF and steroids
3163485|NCT00481884|Experimental|RadiaPlexRx Gel|RadiaPlexRx Gel for application to one half of irradiated breast skin, determined by a randomization process.
2505601|NCT02862457|Experimental|Epacadostat (Epacad)|Cycle 1 is a dose escalation study in which participants will receive 25 or 100 mg of epacadostat orally twice daily (BID) alone on Days 1-5 of Cycle 1 with a washout on Days 6 and 7. On Day 8 of Cycle 1 participants will receive a one-time intravenous (IV) infusion of 200 mg pembrolizumab while continuing to receive 25 or 100 mg of epacadostat orally BID on Days 8-28. For Cycles 2 through 35 participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25 or 100 mg of epacadostat orally BID on Days 1-21.
2505603|NCT02862457|Experimental|Epacad+Pembrolizumab (Pembro)|For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and receive 25 or 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles.
2505605|NCT02862457|Experimental|Epacad+Pembro+Cisplatin+Pemetrexed|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of 75 mg/m^2 Cisplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, cisplatin and pemetrexed."
2505607|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Pemetrexed|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of Area Under the Curve (AUC) 5 Carboplatin and 500 mg/m^2 Pemetrexed on Day 1 for the first 4 cycles.~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, carboplatin and pemetrexed."
2505610|NCT02862457|Experimental|Epacad+Pembro+Carboplatin+Paclitaxel|"For each 21-day cycle, participants will receive a one-time IV infusion of 200 mg pembrolizumab on Day 1 and 100 mg of epacadostat orally BID on Days 1-21 for a maximum of 35 cycles. Participants will also receive a one-time IV infusion of AUC6 Carboplatin and 200 mg/m^2 Paclitaxel on Day 1 for the first 4 cycles.~With protocol amendment 02, treatment with epcadostat stopped, and participants continued treatment with pembrolizumab, carboplatin and paclitaxel."
3196625|NCT00852319|Experimental|Central Mississippi group|Participants from central Mississippi are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
3196626|NCT00852319|Experimental|Mississippi Delta group|Participants from 18 counties of the Mississippi delta are provided with 24 months of interpregnancy care. The results from this arm are compared to a historical control group (who were not given interpregnancy care) from the same geographical area in Mississippi.
3196627|NCT00852332|Experimental|Curcumine|With curcumin capsules
3196628|NCT00852332|Active Comparator|Drug taxotere only|Without curcumin
2505723|NCT02861339|Experimental|Keratoconus and IBD|Opthalmologic measure with DM OPD scan III (Nidek)
2505787|NCT02861209|No Intervention|Non-care pathway|"This arm comprises patients before the implementation of the care pathway. Patients starting with an oral anticancer therapy participate in the current care process. Outcomes are assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
2505788|NCT02861209|Experimental|Care Pathway|"This arm comprises patients after the implementation of the care pathway. Patients starting with an oral anticancer therapy in this arm, receive care as is described by the novel designed care pathway. Outcomes are again assessed at start of treatment, after 1 and after 3 months.~The decision to start with an oral anticancer therapy depends solely on the treating physician."
2505817|NCT02860884||simple fatty liver|patients with fatty liver disease
2505820|NCT02860884||NASH|patients with nonalcoholic steatohepatitis
2505922|NCT02860234||Group A:Clinical complete response (cCR)|Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).
2505924|NCT02860234||Group B:Near-cCR|Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).
2505925|NCT02860234||Group C:Residual tumor|Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Total Mesorectal Excision(TME).
2505976|NCT02859766|Experimental|Abicipar Pegol_Repeat Dose|Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]
2505979|NCT02859766|Experimental|Abicipar Pegol_Single Dose|Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.
2506027|NCT02859376|Active Comparator|sucrose24% 2 minutes before|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure
2506040|NCT02859376|Experimental|sucrose24% 2minutes before and during|sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure
3196629|NCT00852358|Experimental|intrathecal laronidase|The Experimental treatment group will receive study assessments and intrathecal laronidase (1.74 mg laronidase) treatments every 1-3 months beginning at start of study.
3196630|NCT00852358|Other|Control Group|During the first 11 months, the control group will receive study assessments but will be unblinded with no intrathecal treatment or placebo administered. Beginning at month 12, the control group will receive intrathecal laronidase (1.74 mg) treatment every 3 months (months 12, 15, 18, and 21).
3196631|NCT00852371|Active Comparator|Combination of Amodiaquine +sulfadoxine-pyrimethamine|Combination of Amodiaquine (Camoquin, Parke-Davis, 200 mg tablets, 10 mg/kg on days 0 and 1, and 5 mg/kg on day 2) + sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
3196632|NCT00852371|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets targeting a total dose of 6.4 and 51.2 mg/kg of dihydroartemisinin and piperaquine, respectively, given in 3 equally divided daily doses to the nearest ¼ tablet)
3196633|NCT00852371|Placebo Comparator|Placebo|Placebo (had no active ingredients, produced by Cosmos Limited, Nairobi, Kenya)
2505673|NCT02861963|Active Comparator|Systemic-to-pulmonary artery shunts|systemic-to-pulmonary artery shunts (modified Blalock-Taussig shunt)
2505754|NCT02861599|Experimental|proprioceptive therapy|
2505765|NCT02861599|Placebo Comparator|speech therapy|
3196634|NCT00852371|Active Comparator|Sulfadoxine-pyrimethamine alone|sulfadoxine-pyrimethamine (Fansidar, Roche, 500 mg/25 mg tablets, 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine per treatment as a single dose) given as oral tablets
2505926|NCT02860299|Experimental|Citrate lock|
2505927|NCT02860299|Active Comparator|Heparin lock|
3175131|NCT00630448||Group 2|Case Group. Individuals with known Von Willebrand Disease.
2506178|NCT02858882||Swimmers|Screening of elite athletes
2506205|NCT02858232|Experimental|solid tumor|Multiple Target Antigen Stimulating Cell Therapy (MASCT-I)
2506237|NCT02858024|Active Comparator|Cohort I|In Cohort I, eligible participants will be randomly assigned to one of two treatment sequences (ABE or BAE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
2506241|NCT02858024|Active Comparator|Cohort II|In Cohort II, eligible participants will be randomly assigned to one of two treatment sequences (CDE or DCE). During two consecutive 28-day treatment periods (treatment periods 1 and 2), separated by a washout period of 28 days, the participants will receive each of the following treatments according to their assigned treatment sequence
2506360|NCT02857530|Experimental|rhTPO|rhTPO injection
2506361|NCT02857530|Placebo Comparator|control|without rhTPO injection
2506459|NCT02856295|Active Comparator|clexane according to weight group|clexane dose adjusted for woman's weight according to: weight < 90 kg - 40mg, 91-130kg - 60 mg, 131-170kg - 80mg, >170kg-100mg.
2506463|NCT02856295|Active Comparator|clexane mg per kg|clexane dose of 1mg/kg up to 120 mg
2506497|NCT02856100||Patients with CRPC, evidence of metastases, planned treatment|
2506557|NCT02855879||CAD patients|
2506604|NCT02855489|Experimental|Attitudes Only|The attitudes condition targeted cognitive and affective attitudes by pairing attitudinal messages with pictures, and included an evaluative conditioning task.
2506608|NCT02855489|Experimental|Norms Only|The norms condition utilized a group-affirmation exercise, personalized feedback, and group norms in an attempt to greater condom use norms.
2506609|NCT02855489|Experimental|Perceived Behavioral Control Only|The PBC condition included a condom application video, lubrication instructions, condom negotiation videos, and a detailed description regarding purchasing condoms.
2506610|NCT02855489|Experimental|Intentions Only|The intentions condition utilized implementation intentions in order to create condom use intentions.
2506612|NCT02855489|Experimental|Three Constructs|A three construct condition, which included attitudes, norms, and perceived behavioral control represented the core components of the TPB that are thought to work through intentions to result in behavior change.
2506613|NCT02855489|Experimental|Four Constructs|"A four construct condition (i.e., attitudes, norms, PBC, and intentions) was designed to represent the full TPB model intervention which we expected would be more successful than either the three-construct intervention or any of the single construct interventions."
2506617|NCT02855489|No Intervention|No-Treatment, Control|A no-treatment control condition, which solely consisted of pretest and posttest assessments, was included. This allowed us to obtain important information about how the theoretical constructs in the TPB change over time (or do not) in the absence of an experimental manipulation.
2506658|NCT02855099|Active Comparator|CR group|patients will be referred to our rehabilitation centre at the following week after the procedure, and assigned to a personalized rehabilitation program for duration of 3 month.
2506660|NCT02855099|No Intervention|conservative group|No intervention
2506685|NCT02854878|Experimental|treatment|
2506699|NCT02854657|Experimental|skin self-examination|"Participants from the treatment arms of the original RCT. It is anticipated that 228 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study. These subjects received Skin Self- examination structured training.~The subject are being followed for an additional period of time after receiving an educational intervention."
2506702|NCT02854657|Experimental|Skin Self- examination:Distance (remote) learning|Participants receive the Skin Self- examination structured training with partner assistance educational intervention via mailed workbook while under the customary care of their own dermatologists. It is anticipated that 50 new participant dyads will be recruited and randomized to this group.
2506706|NCT02854657|Active Comparator|Active control|"Participants from the control arm of the original RCT. It is anticipated that 100 participant dyads that are 18-70 years old from the original study will be invited to continue in the ongoing study.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the Skin Self- examination structured training with partner assistance."
2506723|NCT02854761|Experimental|IM administration|Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
2506844|NCT02854085|No Intervention|Control|Participants will not participate in either of the interventions and will continue life as usual.
3175132|NCT00630474|Active Comparator|1|nasal application of xylometazoline
3175133|NCT00630474|Placebo Comparator|2|nasal application of placebo
3175134|NCT00630500|Active Comparator|Memantine|Active treatment with memantine
3175135|NCT00630500|Placebo Comparator|Placebo|Placebo matching active study drug
3175136|NCT00630513|Experimental|E|3 days regimen with Ertapenem
3175137|NCT00630513|Active Comparator|AS|3 days treatment with Ampicillin-Sulbactam
3175138|NCT00630552|Placebo Comparator|Placebo + Gemcitabine|
3175139|NCT00630552|Experimental|AMG 655 + Gemcitabine|
3175140|NCT00630552|Experimental|AMG 479 + Gemcitabine|
3175141|NCT00630565|Experimental|Bone Marrow Transplant (2-70 Years old)|Patients over the age of two will receive a cytoreductive regimen of total-body irradiation and cyclophosphamide (TBI/CY) as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
2505693|NCT02861820||Substance Use Disorder (SUD)|"Participants in the SUD group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline, 1 month and 2 month time points.~Complete MRI brain imaging data collection at the baseline, 1 month and 2 month time points.~Complete 9 follow-up phone calls to assess for relapse."
2505696|NCT02861820||Healthy Control (HC)|"Participants in the HC group will:~Complete a diagnostic screening interview at baseline.~Complete questionnaires and computer tasks at baseline and 2 month time points.~Complete MRI brain imaging data collection at the baseline and 2 month time points."
2505732|NCT02861495|Experimental|humeral nail|Surgical fixation with a humeral compression/distraction nail.
2505819|NCT02861144|Other|Intervention|"Patient participants in the intervention arm will receive diabetes self-management program, Ma ka hana ka ̒ike which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 4.5 months. After 4.5 months, the patient will receive 4 monthly boosters by mail that will reinforce information from the Ma ka hana ka ̒ike program. Completion of diabetes process and glycemic outcomes will trigger the modest financial incentives.~Health care provider participants in the intervention arm will receive educational resources, Hanapū Provider Toolbox to guide their patients to optimal glycemic control.They will receive modest financial incentives when their patients complete clinical tests and achieve glycemic target."
2505821|NCT02861144|No Intervention|Usual Care|"Patient participants in the usual care arm will receive 5 mail-out diabetes self management education booklets endorsed by the American Diabetes Association (ADA) and the National Institute for Diabetes, Digestive and Kidney disease for 4.5 months. Patients will see their doctor according to usual care practice. After 4.5 months, the patients will receive 4 monthly boosters in mail reinforcing the previous mail-out diabetes self-management program materials.~Health care provider participants in the usual care arm will receive the latest ADA guidelines to use in their treatment plan of their patients."
2505938|NCT02860221|Experimental|Intravenous epinephrine|Intravenous (IV) low dose epinephrine
2505939|NCT02860221|Experimental|Topical epinephrine|Topical epinephrine
2505940|NCT02860221|Active Comparator|Control|No epinephrine
2505997|NCT02859753|Experimental|RFA|
2505998|NCT02859753|Active Comparator|MCT|
2506026|NCT02859402|Experimental|Experimental Arm|Conditioning chemotherapy: Fludarabine and Busulfan followed by Allogeneic stem cell transplantation
2506074|NCT02859051|No Intervention|control|No intervention
2506080|NCT02859051|Experimental|robot|Humanoid robot interacts with child, teaching breathing and coping strategies.
2506127|NCT02858908|Experimental|Cohort 1 - Tideglusib|1000 mg tideglusib, orally, once daily
2506128|NCT02858908|Experimental|Cohort 2 - Tideglusib|400 mg tideglusib, orally, once daily
2506182|NCT02858466|Experimental|peripheric nervous lesion|MRI scan
2506185|NCT02858466|Experimental|medullar or encephalic lesion|MRI scan
2506189|NCT02858466|Other|control group|MRI scan
2506293|NCT02857764||Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users|Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2506295|NCT02857764||Canagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.
2506301|NCT02857764||Dapagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2506304|NCT02857764||Empagliflozin New Users|Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
2506308|NCT02857764||First-time Non-SGLT2i AHA New Users|Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.
3163486|NCT00481884|Active Comparator|Aquaphor Gel|Aquaphor Gel for application to one half of irradiated breast skin, determined by a randomization process.
3163487|NCT00481936|Experimental|Dose Escalating|"Patients will be treated with VB6-845 as a monotherapy IV infusion, once weekly in 4-week cycles. Patients will continue to receive treatment up until the treatment stopping criteria or patient withdrawal criteria are met.~Dose escalation will begin at a dose level of 1.00 mg/kg. Doses will be escalated according to the modified Fibonacci design with dose multipliers of 2.00, 1.67, 1.50, 1.40, and 1.33."
3163488|NCT00482027|Active Comparator|1 AAV-2 HIV Vaccine|64 volunteers receiving AAV-2 HIV vaccine tgAAC09 at 3 dosage levels, dose escalation and dose optimization
3163489|NCT00482027|Placebo Comparator|2|16 volunteers receiving formulation buffer consisting of a buffered salt solution with potassium phosphate, calcium chloride, magnesium chloride, and HEPES
3163490|NCT00482066|Active Comparator|1|Abatacept (Orencia)
2506665|NCT02855177|Placebo Comparator|Placebo|Placebo will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
2506668|NCT02855177|Experimental|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared suspension every 8 hours for 14 days
2506873|NCT02853643|Experimental|25 mg Dose|Single dose of 25 mg ASN002
3163491|NCT00482066|Placebo Comparator|2|saline placebo
3173705|NCT00615095||3|Healthy controls will be subjects 18 years or older recruited from the general population through random digit dialing. These subjects will have no history of melanoma. They will also be frequency matched to cases on the basis of sex and 10-year age group.
3173706|NCT00615121||arteries from PAD patients|peripheral arteries from patients undergoing amputation for end stage peripheral arterial occlusive disease
3196635|NCT00852410|Active Comparator|1% lidocaine with 1:100000 adrenaline|high dose adrenaline
2505760|NCT02861430||Patients|
2506024|NCT02859545|Experimental|Validation Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to validate which is provided by the research assistant.
2506038|NCT02859545|Placebo Comparator|Education Training|In this arm, the romantic partner of the individual with chronic pain receives training on how to ask questions about treatments, which is provided by the research assistant.
2506077|NCT02859129|Experimental|Rosuvastatin|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
2506081|NCT02859129|Experimental|Epanova®|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova® QD for 10 consecutive days (Days 4 to 13)
2506085|NCT02859129|Experimental|Epanova® + Crestor®|Epanova® multiple oral doses of 4 g (4 x 1 g capsules) QD for 13 consecutive days (Days 14 to 26) with coadministration of single 40 mg (1 x 40 mg tablet) oral dose of rosuvastatin (Crestor®) with the 11th dose of 4 g Epanova® on Day 24
2506086|NCT02859129|Active Comparator|Vascepa®|Vascepa® multiple oral doses of 2 g (2 x 1 g capsules) every 12 hours for 20 consecutive days (Days 1 to 20).
2506335|NCT02857517|Experimental|intravitreal 0.05ml conbercept for ICNV|0.05ml conbercept ,1 injection with PRN
2506394|NCT02857088|Experimental|depressed patients|patient with a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
2506398|NCT02857088|Experimental|non depressed subject|subject without a current unipolar major depressive disorder intervention: olfactory assessment, image visualization and psychophysiological assessment
2506422|NCT02856516|Experimental|Boost Glucose Control (A)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
2506423|NCT02856516|Experimental|Boost Glucose Control (B)|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption in people with Diabetes.
2506424|NCT02856516|Active Comparator|Boost Original|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption.
2506534|NCT02856165|Experimental|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (Fisher&Paykel (F&P), NZ)
2506535|NCT02856165|Active Comparator|Low-flow oxygen therapy|Low-flow oxygen therapy with standard nasal canula
2506611|NCT02855658|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
2506615|NCT02855658|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
2506669|NCT02855112|No Intervention|Control|A group of 10 patients only will be subjected to electro-myogram test every 3 month and then follow up for their survival time without any cell therapy intervention.
2506672|NCT02855112|Experimental|Adipose derived Mesenchymal Stem cell|A group of 10 patients will be take stem cells intra-thecally Dose: 1 million cells/kg for three times Intervals: Every 3 weeks.
2506763|NCT02854774|Active Comparator|Knee muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of knee extensor muscles.
2506766|NCT02854774|Active Comparator|Hip muscle activation/strengthening|4 weeks of exercises focused on activation and strengthening of hip extensor muscles.
2506829|NCT02854176|Experimental|Somatosensory electrical stimulation|
2506833|NCT02854176|Sham Comparator|Control|
2506883|NCT02853734|Experimental|SEVERE PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
2506887|NCT02853734|Other|NO PERIODONTITIS|Periodontal examination Biological samples collection: periodontal, saliva, blood, fecal, visceral adipose tissue
2506907|NCT02853292||amoxicillin crystalluria|
2506923|NCT02853188|Experimental|cancer of lung|
3163495|NCT00482105|Other|A|"This research study proposes to use a non-invasive method to capture superficial cells on pigmented skin lesions that are suspected of being early melanomas. This non-invasive biopsy technology has been developed and patented by DermTech International. RNA in skin cells captured by this method will be profiled in order to diagnose the nature of the lesion (i.e. malignant melanoma or not). A successful outcome of this proposal would create a candidate non-invasive diagnostic assay based on a gene expression profile for identifying early stage melanomas"
3163496|NCT00482118||Cases|Non smoking women with lung cancer
3163497|NCT00482118||Controls|Non smoking women without lung cancer
3163498|NCT00482144|Active Comparator|Treatment: PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
3163499|NCT00482144|Active Comparator|Treatment: PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
2507127|NCT02851979|Experimental|S0 - S1 - S2|S0 = no stimulation; washout; S1 = vehicle; washout; S2 = olfactory stimulation
2507128|NCT02851979|Experimental|S0 - S2 - S1|S0 = no stimulation; washout; S2 = olfactory stimulation; washout; S1 = vehicle
2507129|NCT02851979|Experimental|S1 - S0 - S2|S1 = vehicle; washout; S0 = no stimulation; washout; S2 = olfactory stimulation
2507131|NCT02851979|Experimental|S1 - S2 -S0|S1 = vehicle; washout; S2 = olfactory stimulation; washout; S0 = no stimulation
2507133|NCT02851979|Experimental|S2 - S0 - S1|S2 = olfactory stimulation; washout; S0 = no stimulation; washout; S1 = vehicle
2508450|NCT02842281|Placebo Comparator|Maltodextrin|Maltodextrin will be provided for 72 hours.
3163500|NCT00482144|No Intervention|Control|The scar will be randomly divided into three equal fields. One third of the scar will not receive treatment
3163501|NCT00482209|Active Comparator|1|200mg mifepristone followed by 400mcg misoprostol
3163502|NCT00482209|Active Comparator|2|200mg mifepristone followed by 800mcg misoprostol
3163503|NCT00482222|Active Comparator|OxMdG / IrMdG chemotherapy|OxMdG / IrMdG chemotherapy for 12 weeks Followed by surgery OxMdG / IrMdG chemotherapy for 12 weeks
2505716|NCT02861508|Experimental|Early POCUS|Point-of-care ultrasound protocol will involve cardiac views (for pericardial effusion, left ventricular function, left and right ventricular equality, aortic root dilation, and inferior vena cava status), lung views (for pneumothorax, signs of alveolar interstitial syndrome), abdominal views for free fluid, and a view of the abdominal aorta for aneurysm.
2505730|NCT02861287||Study cohort|patients with Multiple Myeloma who underwent PBSC mobilization since December 2009 and who received plerixafor in line with inclusion criteria
2505734|NCT02861287||Historical cohort|patients with Multiple Myeloma who underwent PBSC mobilization immediately prior to marketing authorization and clinical utilization of Plerixafor which is before December 2009 (over the 2007-2009 period)
2505842|NCT02860793|Experimental|AML patients at diagnosis|
2505877|NCT02860481|Other|first cohort : first 100 patients|first cohort : first 100 patients 10 patients with ovarian and/or endometrial cancer 10 patients with colorectal cancer 10 patients with head and neck cancer 10 patients with uveal melanoma 40 patients with invasive breast cancer 10 patients with breast ductal carcinoma in situ 10 patients with other tumor type
2505879|NCT02860481|Other|second cohort : 100 patients|Patients with breast cancer of with ovarian and/or endometrial cancer
2505916|NCT02860195|Experimental|healthy volunteers|
2505975|NCT02859909|Experimental|2 day treatment schedule|Patients will receive a dosage of 1 g/kg bw per day of BT595 for 2 consecutive days
2505980|NCT02859909|Experimental|5 day treatment schedule|Patients will receive a dosage of 0.4 g/kg bw per day of BT595 for 5 consecutive days
2506141|NCT02858531||patients < 24 months or 60 years with bronchiolitis or ARF|ARF = Acute Renal Failure
2506221|NCT02858167|Experimental|FDG-PET|
2506257|NCT02857907||ATG group|Patients who received T cell depleting ATG therapy (blood sample one year after transplantation)
2506258|NCT02857907||anti-CD25 group|Patients who received nondepleting anti-CD25 (blood sample one year after transplantation)
2506279|NCT02857673|Experimental|Intervention Group|The intervention group will receive Child Abuse Prevention Problem Solving (CAPPS), a one-on-one, workbook-based intervention of six sessions, each lasting approximately 30-60 minutes. CAPPS is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. Sessions will be delivered at the medical home by bachelor level providers, whose availability and level of training mimic those of existing medical home care coordinators.
2506280|NCT02857673|Active Comparator|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers. The study team member will not be trained in CAPPS and will adhere to a case management model consistent with resources available in the medical home, checking in with control families and offering to help identify existing clinic and community resources as needed.
2506341|NCT02857504|Other|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
2506346|NCT02857504|Other|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
2506404|NCT02857010|Experimental|Allogenic Mesenchymal stem cells|Intravenous allogenic bone marrow derived mesenchymal stem cells: 4 doses of 2 x 106/kg administered on days 1, 4, 11 and 18
2506406|NCT02857010|Placebo Comparator|Placebo|Solution without cells on days 1, 4, 11 and 18
2506472|NCT02856503|Experimental|Phase 1 - Group A - VD 3 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 3 weeks.
2506475|NCT02856503|Active Comparator|Phase 1 - Group B - VD 4 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 4 weeks
2506476|NCT02856503|Active Comparator|Phase 1 - Group C - VD 5 Weeks|Weekly oral dose of 50,000 IU Vitamin D3 (VD) for 5 weeks.
2506478|NCT02856503|Experimental|Phase 2 - VD|Weekly oral dose of 50,000 IU Vitamin D3 (VD) therapy for the duration selected from the phase I part of the study.
2506552|NCT02855983|Experimental|A (Fat grafting initially)|"A PATHWAY -~Intervention: autologous fat grafting to the foot, occur first~Fat graft study intervention procedure to occur first, next post-operative follow up visits (V1-V4). The Subject will after Month 6 (V4) crossover to Pathway B to complete Observation visits V1 (Month 2) and V2 (Month 6). After completion of V2 (Month 6), the subject will have completed study participation."
2506553|NCT02855983|Other|B (Standard of care initially)|"B PATHWAY -~Intervention: standard of care (observation) for the first year, followed by autologous fat grafting to the foot~Observation visit will occur first, next the subject will have two Observation visits V1 (Month 2) and V2 (Month 6). The subject will then crossover to Pathway A. The subject will be assessed by the PI his/her for continued study eligibility. Once the continued eligibility has been determined, the subject will have the interventional fat graft procedure and subsequent post-operative follow up visits (V1-V4). After completion of Post-op V4 (Month 6), the subject will have completed study participation."
2506587|NCT02855502|Active Comparator|Prednisolone|dose: 15 mg per day(divided 5 mg TDS) dosage form: tablet duration administration: 30 days
2506590|NCT02855502|Placebo Comparator|Placebo|placebo given to patient: 3 tablet (divided TDS) dosage form: tablet duration administration: 30 days
3163504|NCT00482222|Experimental|OxMdG / IrMdG chemotherapy with cetuximab|OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks Followed by Surgery OxMdG / IrMdG chemotherapy with cetuximab for 12 weeks
3173707|NCT00615121||arteries from Free Fib transfers|peripheral arteries from patients without evidence of peripheral arterial occlusive disease
2506744|NCT02854696|Experimental|Islet graft|Patients who receive islet graft Intervention : Procedure/Surgery
2506748|NCT02854696|Active Comparator|Best medical care|Patients who continue their optimal medical treatment (insulin pump therapy coupled with real time continuous glucose monitoring) Intervention : insulin treatment
3173708|NCT00615134|Experimental|1|
3173709|NCT00615134|Active Comparator|2|
3163505|NCT00482261|Experimental|len-dex|Drug: Lenalidomide 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards; Drug: dexamethasone 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
3163506|NCT00482287|Other|1|Dose level 0.3 mg/kg with 6 active and 2 placebo
3163507|NCT00482287|Other|2|Dose level 0.6 mg/kg 6 patients active and 2 placebo
2505886|NCT02860533|Experimental|Blood pressure measurement|six repetitive blood pressure measurements with iPhone and conventional oscillometric cuff device during stress testing will be performed
2505931|NCT02860182||experimental|patients with acute type A dissection
2505933|NCT02860182||control|patients without any pathology of the ascending aorta, but having the same characteristics as the sick patients, in terms of age and vascular risk factors including high blood pressure
2506023|NCT02859480|Experimental|Rosuvastatin 5mg|Patients are treated with Rosuvastatin 5mg/day for 30 months after percutaneous coronary intervention
2506036|NCT02859480|Active Comparator|Rosuvastatin 20mg|Patients are treated with Rosuvastatin 20mg/day for 30 months after percutaneous coronary intervention
2506105|NCT02859077|Experimental|EGFR-TKI and Chemotherapy|NSCLC patients
2506129|NCT02858635|Experimental|Suicide attempters|Clinical and neuropsychological assessment. Blood and saliva samples in order to answer objectives study.
2506188|NCT02858453|Experimental|AQX-1125 100 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
2506190|NCT02858453|Experimental|AQX-1125 200 mg|2 tablets, by mouth, once per day for 12 weeks; followed by a 52-week Extension Period
2506191|NCT02858453|Placebo Comparator|Placebo|2 placebo tablets, by mouth, once per day for 12 weeks; followed by randomization to 100 mg or 200 mg AQX-1125 for a 52-week Extension Period
2506345|NCT02857439|Other|MD as first examiner|Patients will be examined according to a standardized physical examination item list
2506348|NCT02857439|Other|Triage nurse as first examiner|Patients will be examined according to a standardized physical examination item list
2506399|NCT02856997|Experimental|Chidamide with ICE regimen|"Drugs:Chidamide and ICE regimen (ifosfamide, Mesna,Carboplatin and etoposide): Chidamide 20mg on d1,4,8,11;ifosfamide 1.2g/ m2，d1-4,ivg during 4 hours; Mesna 0.4g, 0,4,8 hours during Ifosfamide transfusion, ivg, d1-4; Carboplatin AUC=4, d2,ivg; etoposide 65mg/m 2, d1-4, ivg. 3 weeks as 1 course, for 6 courses.~if the effect is PR or better than PR, go to auto-stem cell transplantation, no further treatment with Chidamide is needed.~If the effect is PR or better than PR and no auto-stem cell transplantation available,Chidamide 20mg orally, twice every week, till the end of the trial."
2506450|NCT02856620||Moderate AS with HF|
2506451|NCT02856620||Severe AS with HF|
2506452|NCT02856620||Moderate AS without HF|
2506454|NCT02856620||Severe AS without HF|
2506455|NCT02856620||HFpEF without AS|
2506457|NCT02856620||Normal age-matched controls|
2506487|NCT02856178|Experimental|F901318 + Caspofungin|"Patients will receive F901318 intravenously, starting 24 - 72 h after last chemotherapy infusion:~Day 1: 4.0 mg/kg i.v. b.i.d.~Day 2 until resolution of neutropenia (max. until day 14): 2.0 mg/kg i.v. b.i.d.~Day after last i.v. application: 2.0 mg/kg oral q.d.~Concomitant medication:~For Candida prophylaxis, concomitant caspofungin will be administered from the 4th day of chemotherapy until end of neutropenia:~Chemo day 4: Caspofungin 70 mg i.v. q.d.~Chemo day 5 until resolution of neutropenia or until end of F901318 treatment (day 15): Caspofungin 50 mg i.v. q.d.~All patients will undergo chemotherapy for acute leukaemia according to local clinical standard."
2506620|NCT02855385||Patient group|This are patients who have current or previous history of rectal bleeding
2506622|NCT02855385||General Practitioner group|This are General practitioner who are in public or private hospitals who treat patients with rectal bleeding
2506657|NCT02855190|Experimental|68Ga-citrate and 18F-FDG PET scans|The recruited subject with surgery/pathology proved periprosthetic joint infection will undergo total four PET scans at two different stages. At first stage, subsequent FDG PET/CT and Ga68 citrate PET/CT scans on different two days will be arranged before infective prosthesis is removed. Eight to twelve weeks after the 1st stage operation, patient will receive two subsequent PET/MR scans using Ga-68 Citrate and FDG on different two days, respectively. For the subject without surgery/pathology proved infection, PET/MR scans will NOT be applied.
2506719|NCT02854865||Echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
2506765|NCT02854462|Experimental|Language comprehension intervention|The intervention will run for 4 weeks. Caregivers will be provided with storybooks (e.g., Percy the Park Keeper) that have been amended to include inference-eliciting questions. Caregivers will be trained (with a video) to ask these questions and respond to their children's answers during shared reading sessions. They will be asked to read one book per day. Caregivers will keep a reading diary.
2506778|NCT02854397||patients with angioedema resulting of mast cell activation|A blood sample will be performed in crisis and 7 days after the crisis.
2506780|NCT02854397||healthy patients, without angioedema|A quantity of additional blood was taken from eligible patients who had a scheduled blood sample.
3163508|NCT00482287|Other|3|Dose level 1.2 mg/kg 6 active and 2 placebo
3163509|NCT00482287|Other|4|Dose level 2.4 mg/kg 6 active and 2 placebo
3163510|NCT00482313|Experimental|Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
3163511|NCT00482313|Placebo Comparator|Sugar pill|Placebo given orally once daily for 5 weeks.
3163512|NCT00482352||Ancillary-Correlative (marker identification, molecular test)|Patients undergo blood collection and bone marrow biopsies at baseline and at the end of induction therapy for immunophenotyping for marker identification; molecular testing for translocations; trisomy analysis by fluorescence in situ hybridization (FISH); and DNA ploidy. Immunophenotype results obtained on this study are used to determine the patient's assignment to specific treatment clinical trials (consistent with acute lymphoblastic leukemia).
3163513|NCT00482378|Experimental|Sm 153 lexidronam|
3163514|NCT00482430|Other|1|MK0557 10mg tablet qd, crossing over to MK0557 Pbo tablet qd.
3163515|NCT00482430|Other|2|MK0557 Pbo tablet qd, crossing over to MK0557 10mg tablet qd.
3163516|NCT00482443|Experimental|1|To assess the efficacy of a Diabetes Interactive Diary in Diabetes Management.
3163517|NCT00482443|Active Comparator|2|Control Arm. Patients will receive standard education programme.
3163518|NCT00482482|Experimental|Yoga|Yoga was offered twice a week for 8 weeks, 1.5 hours per session
2505961|NCT02860052|Experimental|SB208 2%|Apply once daily to one or both feet for 14 days
2505965|NCT02860052|Experimental|SB208 4%|Apply once daily to one or both feet for 14 days
2505967|NCT02860052|Experimental|SB208 16%|Apply once daily to one or both feet for 14 days
2505977|NCT02860052|Placebo Comparator|Vehicle Gel|Apply once daily to one or both feet for 14 days
2506022|NCT02859467|Experimental|Kinesio Taping and Inhibitory Treatment Techniques|"During each session participants will receive the application kinesio taping in trapezius, infraspinatus and paravertebral muscles.~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
2506033|NCT02859467|Active Comparator|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
3163519|NCT00482482|Active Comparator|Psychoeducation|Psychoeducation was offered twice a week for 8 weeks, 1.5 hours per session
3163520|NCT00482521|Experimental|CC-4047|
2506162|NCT02858895|Experimental|MDNA55|"Single infusion of MDNA55 via convection enhanced delivery (CED).*~*Subjects may be eligible to receive a second administration of MDNA55."
2506250|NCT02858206|Experimental|Neoadjuvant nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
2506251|NCT02858206|Active Comparator|Neoadjuvant chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity.~Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
2506253|NCT02858206|Experimental|Radical nimotuzumab|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent nimotuzumab: Patients may receive nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
2506255|NCT02858206|Active Comparator|Radical chemotherapy|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy: Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks after enrollment in the absence of disease progression or unacceptable toxicity."
2506306|NCT02857608|Experimental|Lymphoseek - 0.5 mCi, 50 ug|A single dose of 50 µg Lymphoseek radiolabeled with 0.5 millicurie (mCi) (18.5 MBq) 99m Tc
2506349|NCT02857400|Other|Arm A (standard)|
2506350|NCT02857400|Experimental|Arm B (experimental)|
2506447|NCT02856737|Experimental|Earplugs and eye masks (to be used concurrently)|Group will include patients consented to the use of earplugs and eye masks. Patients will participate in the intervention nightly
2506519|NCT02856230|Experimental|Ranger SL DEB angioplasty|patients filling general and angiographic inclusion/exclusion criteria will have an BTK angioplasty using one or several Ranger SL drug-eluting balloons
3163521|NCT00482573|Experimental|Group LE|Seventeen (54.8%) patients, composed group LE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution with epinephrine 1:100,000. Their ages were ranging from 18 to 44 years (mean:29.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 28 to 36 weeks (mean:31.8), and the BMI from 18.7 to 32.9 (mean:23.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
3163522|NCT00482573|Active Comparator|Group LNE|Fourteen (45.2%) patients, composed group LNE, were randomly assigned for the infusion of 1.8 mL (one cartridge) by the modified anesthesia into the periodontal ligament (PDLm injection) of 2% lidocaine solution without epinephrine. Their ages were ranging from 22 to 33 years (mean:26.6), they were diagnosed as having rheumatic valve disease, in a functional class I or II according to classification of the NYHA. Gestation age ranged from 29 to 37 weeks (mean:32.1), and the BMI from 18.5 to 38.1 (mean:22.8) kg/m2. All the patients had the restauration done in their inferior premolar and/or molar teeth.
3163523|NCT00482586||Image-guided Therapy|Patients undergoing Image-guided Therapy of Hepatic Neoplasms.
3163524|NCT00482599|Active Comparator|Normal renal function|Org 25969 given to subjects with normal renal function
3163525|NCT00482599|Experimental|Impaired renal function|Org 25969 given to subjects with impaired renal function
3163526|NCT00482651|Experimental|UAP, SAP|
3163527|NCT00482664|Experimental|1 mg|
3163528|NCT00482664|Experimental|10 mg|
2505847|NCT02860806|Experimental|Part 1: Period 2 (JNJ-63623872 200 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 200 mg (3 mg/mL solution) (Treatment B) or matching placebo (Treatment D) over 120 minutes.
2505850|NCT02860806|Experimental|Part 1: Period 3 (JNJ-63623872 300 mg or Placebo)|Participants will receive a single IV infusion of JNJ-63623872 300 mg (3 mg/mL solution) (Treatment C) or matching placebo (Treatment D) over 120 minutes.
2505852|NCT02860806|Experimental|Part 2: Group 1 (EFG)|Participants will receive a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over x minutes (Treatment E) followed by a single IV 300-mg infusion of JNJ-63623872 (3 mg/mL solution) over y minutes (Treatment F), then a single oral 600-mg dose (2* 300 mg tablets) of JNJ-63623872 under fasted conditions (Treatment G). Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505854|NCT02860806|Experimental|Part 2: Group 2 (FGE)|Participants will receive Treatment F, then Treatment G followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505855|NCT02860806|Experimental|Part 2: Group 3 (GEF)|Participants will receive Treatment G, then Treatment E followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505856|NCT02860806|Experimental|Part 2: Group 4 (GFE)|Participants will receive Treatment G, then Treatment F, followed by Treatment E. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505857|NCT02860806|Experimental|Part 2: Group 5 (FEG)|Participants will receive Treatment F, then Treatment E followed by Treatment G. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505858|NCT02860806|Experimental|Part 2: Group 6 (EGF)|Participants will receive Treatment E, then Treatment G followed by Treatment F. Study drug administration in subsequent treatment periods will be separated by a washout period of at least 7 days.
2505859|NCT02860806|Experimental|Part 3: JNJ-63623872 300 mg|Participants will receive multiple IV infusions of JNJ-63623872 300 mg (3 mg/mL) solution every 12 hours on Days 1 to 10, with only a morning dose on Day 10. Duration of infusion and dose will be selected after Part 2 of this study is completed.
2505902|NCT02860429|Experimental|Cinobufacini injection|"Capsule Dosage and frequency:This group receives cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.~Duration:6 chemotherapy cycles."
2505905|NCT02860429|Other|Control group|Only receive the same chemotherapy with the experimental groups.No Cinobufacini injection.And have the same adjuvant treatment with the experimental groups.
2505936|NCT02859974|Experimental|Respiratory retraining for PVFMD|Single arm study
2506017|NCT02859675||Crohn and anti-TNF treatment|Tests at 3 or 4 weeks after the beginning of anti-TNF treatment
2506030|NCT02859675||Crohn and without anti-TNF treatment|tests performed according to patient availability
2506044|NCT02859675||Control|tests performed according to patient availability
2506106|NCT02858973|Experimental|Q203|Q203 tablets
2506111|NCT02858973|Placebo Comparator|Placebo|Placebo tablets
2506143|NCT02858687|Experimental|Patients with clinical diagnosis of tonsillitis|
2506206|NCT02858388|Active Comparator|SN45|Sinuclean Nebules 45
2506210|NCT02858388|Placebo Comparator|Sal|Saline solution
2506240|NCT02857985|Experimental|Patient with Myocardial Infarction|
2506281|NCT02857751||Surf therapy cohort 1|The first cohort of participants to enroll in the study (i.e., participants in the first 6-week program)
2506282|NCT02857751||Surf therapy cohort 2|The second cohort of participants to enroll in the study (i.e., participants in the second 6-week program)
2506283|NCT02857751||Surf therapy cohort 3|The third cohort of participants to enroll in the study (i.e., participants in the third 6-week program)
2506284|NCT02857751||Surf therapy cohort 4|The fourth cohort of participants to enroll in the study (i.e., participants in the fourth 6-week program)
2506285|NCT02857751||Surf therapy cohort 5|The fifth cohort of participants to enroll in the study (i.e., participants in the fifth 6-week program)
2506342|NCT02857478|Experimental|Safety of a Sunscreen product|Sunscreen product safety evaluation under supervised out-door conditions on sport users.
2506375|NCT02857049|Experimental|Geriatric patients administered with ONS|Oral nutritional supplements (ONS) degustation
3196636|NCT00852410|Active Comparator|1% lidocaine with 1:200,000 adrenaline|low dose
3196637|NCT00852423|Experimental|DHAPQ|Three-day treatment with dihydroartemisinin-piperaquine
2506468|NCT02856360|Experimental|Moderate Stiffness|Shoe condition that has moderate stiffness
2506471|NCT02856360|Active Comparator|High Stiffness|Shoe condition that has high stiffness
3196638|NCT00852423|Experimental|MQAS|Three-day treatment with mefloquine artesunate
2506546|NCT02855723|Active Comparator|GS strategy|sentinel node biopsy
2506547|NCT02855723|Other|Classic strategy|systematic lymphadenectomy
2506641|NCT02855528|Experimental|Reduction of radiation dose and diagnostic accuracy|Reduction of radiation dose during coronary artery calcium scoring with the use of a tin filter system.
3196639|NCT00852423|Active Comparator|AQAS|Three-day treatment with artesunate-amodiaquine
3196640|NCT00852423|Active Comparator|AL|Three day treatment with artemether-lumefantrine (Coartem(R)
2506756|NCT02854579|Experimental|Neural progenitor cell|Three doses of Neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
2506759|NCT02854579|Experimental|Paracrine factors|Three doses of concentrated paracrine factors of human mesenchymal stem cell （0.5ml） intrathecally at 12h,24h,48h after birth.+routine therapy
2506881|NCT02853643|Experimental|50 mg Dose|Single dose of 50 mg ASN002
3196641|NCT00852436|Active Comparator|1|Pregabalin capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
3196642|NCT00852436|Placebo Comparator|2|Placebo capsules in 75 mg, administered orally one (or two, or four) capsule(s), twice daily. Dosing increment from 150, 300, to 600mg/day at weekly intervals.
3196643|NCT00852449|Experimental|restrictive fluid|Restrictive fluid administration: 6 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
2505917|NCT02860312|Placebo Comparator|Non Exercisers|No intradialytic exercise
2505970|NCT02859948|Experimental|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
2506117|NCT02858934|Experimental|preoperative tomotherapy|This study is an open study investigating the effect on quality of life of a very short preoperative radiotherapy for early breast cancer, including approximately 24 women. Radiotherapy will be performed in 1 week and before the surgery in stead of following surgery.Preoperative radiotherapy has the advantage that the tumor is visible on imaging. This can result in smaller boost volumes. The surgery will follow shortly after termination of the radiotherapy, resulting in a very short treatment period.
2506181|NCT02858583|Experimental|Intervention (CC+SI)|"Infants randomized into the CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression. The SI will be delivered over a period of 45 seconds. This will be followed by PEEP of 5-8 cm water to perform an assessment of the newborn's heart rate. If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 45sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI."
2506186|NCT02858583|Active Comparator|Control (3:1 C:V)|"Infants randomized into the 3:1 C:V group will receive CC at a rate of 90/min and 30 ventilations/min in a 3:1 C:V ratio as recommended by the current resuscitation guidelines."
2506236|NCT02857998|Experimental|HMPL-523|Oral administration, at dose of 200, 400, 600 and 800 mg once daily;at dose of 200,300, 400mg twice daily at Dose-escalation stage; At Dose-expansion stage, if patients dosing at 600mgQD.
2506298|NCT02857777|Experimental|Cohort 1: Japanese elderly subjects (Esketamine)|Subjects will receive Treatment A (28 milligram [mg] of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0) in Period 1, Treatment B (56 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0 and 5 minutes) in Period 2 and then Treatment C (84 mg of esketamine, administered as 1*14 mg spray of esketamine in each nostril at Time 0, 5, and 10 minutes) in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
2506303|NCT02857777|Active Comparator|Cohort 2: Japanese healthy subjects (Esketamine)|Subjects will receive Treatment A in Period 1, Treatment B in Period 2 and then Treatment C in Period 3. A washout period of 5 to 14 days will separate each intranasal esketamine treatment regimen.
2506336|NCT02857374|Experimental|Diagnostic (intravital microscopy)|Patients receive indocyanine green and fluorescein sodium injection IV and then undergo intravital microscopic observation over 15-20 minutes during standard of care sentinel node biopsy.
2506386|NCT02856932|Experimental|Glass Ionomer with Glass Hybrid technology|Intervention
2506390|NCT02856932|Active Comparator|Conventional high viscosity Glass Ionomer|Comparator
2506489|NCT02856607||Group I|patient for whom diagnosis and medical care are realized in a referent center with cardiac surgery
2506490|NCT02856607||Group II|patients secondary addressed to a referent center with cardiac surgery
2506491|NCT02856607||Group III|patients for which the totality medical care are performed in non-referent health center
2506528|NCT02855892|Placebo Comparator|Control Group|- Placebo, two-week interval, intradermal administration
2506529|NCT02855892|Experimental|Study Group 1|- GV1001 0.4 mg, two-week interval, intradermal administration
2506530|NCT02855892|Experimental|Study Group 2|- GV1001 0.56 mg, two-week interval, intradermal administration
2506531|NCT02855892|Experimental|Study Group 3|"- GV1001 0.56 mg, four-week interval, intradermal administration~: Should be visited every two weeks (GV1001 0.56 mg or placebo is administered alternately at every visit.)"
2506579|NCT02855645|Experimental|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
2506580|NCT02855645|Placebo Comparator|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
2506638|NCT02855333||Merendino Group (MER)|Patients who underwent merendino procedure for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
2506640|NCT02855333||Control Group (CON)|Patients who underwent alternative surgery for benign or early malignant lesions of the distal esophagus/gastroesophageal junction Perioperative data and EORTC and QLQ-C30 / QLQ-OES24 questionnaire
2506673|NCT02855034|Other|Blood sample|All the patients performed the same blood samples for dosage: copeptin, S-100B, GFAP, NFL and UCHL-1 proteins
2506733|NCT02854748|Experimental|Empagliflozin / Lobeglitazone / Empa.+Lobe.|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
2506736|NCT02854748|Experimental|Empagliflozin / Empa.+Lobe. / Lobeglitazone|Period 1: Empagliflozin 25 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
2506740|NCT02854748|Experimental|Lobeglitazone / Empagliflozin / Empa.+Lobe.|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days
2506742|NCT02854748|Experimental|Lobeglitazone / Empa.+Lobe. / Empagliflozin|Period 1: Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
2506743|NCT02854748|Experimental|Empa.+Lobe. / Empagliflozin / Lobeglitazone|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Empagliflozin 25 mg QD for 5 days Period 3: Lobeglitazone 0.5 mg QD for 5 days
3163529|NCT00482664|Experimental|3 mg|
2505974|NCT02859792|Placebo Comparator|Placebo|
2505982|NCT02859792|Experimental|Experimental|
2506018|NCT02859493|Active Comparator|Saccharomyces cerevisiae|Inactivated whole yeast Saccharomyces cerevisiae presented in vaginal capsules. 1 capsule a day for 14 days.
2506034|NCT02859493|Placebo Comparator|Maize starch and magnesium stearate|Placebo presented in a vaginal capsule. 1 capsule a day for 14 days
2506092|NCT02859181|Experimental|Active, Adolescent males|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2506154|NCT02858804|Experimental|Etoposide|50 mg/m2, IV, d1-4
2506155|NCT02858804|Experimental|Doxorubicin|10 mg/m2, IV, d1-4
2506161|NCT02858804|Experimental|Dexamethasone|30 mg/d, d1-5
2506163|NCT02858804|Experimental|Vincristine|0.4 mg/m2, IV, d1-4
2506166|NCT02858804|Experimental|Cyclophosphamide|750 mg/m2 ,d5
2506168|NCT02858804|Experimental|Cytarabine|2g/m2, q12h, d1
2506170|NCT02858804|Experimental|Cisplatin|100mg/ m2,IV, d1
2506173|NCT02858804|Experimental|Rituximab|375 mg/m2 IV, d1
2506175|NCT02858804|Experimental|Thalidomide|50-150mg/d, po, d1-28
2506176|NCT02858804|Experimental|Prednisone|0.5mg/Kg, po, qod
2506256|NCT02857972|Experimental|Wondaleaf®|This is a single arm clinical trial, all female subjects will be recruited to the arm using investigational device only.
2506278|NCT02857712|Experimental|Axitinib|Axitinib will be administered at 5 mg BID (starting dose); in case of no adverse events above CTCAE version 4.0 Grade 2 for a consecutive 2-week periods, the dose may be increased to 7 mg BID and further to 10 mg BID using the same criteria until tumor progression, unacceptable toxicity or other criteria for discontinuation is met.
3163530|NCT00482664|Placebo Comparator|Placebo|
3163531|NCT00482742|Other|Lifestyle counseling|
3163532|NCT00482742|Other|Metformin|
2506356|NCT02857218|Experimental|Diagnostic (ferumoxytol, MRI)|Patients receive ferumoxytol IV over 15 minutes and then undergo ferumoxytol-enhanced MRI (Magnetic Resonance Imaging) after 24-36 hours and before surgery at week 12.
2506407|NCT02856841||optimum cytoreduction|without any gross tumor residue after surgery
2506408|NCT02856841||Suboptimum cytoreduction|with any gross tumor residue after surgery
2506453|NCT02856594|Experimental|Dexmedetomidine-induced sleep|Precedex (Dexmedetomidine) intervention: Intravenous administration of 1mcg/kg over 40 minutes.
2506456|NCT02856594|Placebo Comparator|Placebo|Placebo of normal saline: Intravenous administration of normal saline over 40 minutes.
2506494|NCT02856204||Diagnostic (collection of blood samples)|Patients undergo collection of blood samples before and during the episode of febrile neutropenia for up to 6 weeks.
2506567|NCT02855866|Experimental|cryotherapy|
2506571|NCT02855866|Active Comparator|Cortisone aerosol|
2506574|NCT02855866|Placebo Comparator|Management|
2506646|NCT02855320|Experimental|PE (patient education)|Nurse-led self-management education intervention : The intervention group will benefit from the nurse intervention in addition to usual care : follow up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
2506647|NCT02855320|No Intervention|Standard|The control group will be followed up by their rheumatologist in hospital or private care according to usual management of biologics treatment.
2506720|NCT02854956|Other|X-linked Mental retardation|This is an observational study which will allow to precisely describe the phenotype associated to each X-linked mental retardation gene.
2506722|NCT02854956|Other|Control Group|This group will be compared to X-linked mental retardation group in order to obtain a baseline on some cognitive tests.
3163533|NCT00482768|Experimental|1|Intervention clinics will receive practice facilitation visits at regular intervals over a 12-month period.
2506903|NCT02853500|Experimental|TACE Procedure With Surefire|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Surefire.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
2506904|NCT02853500|Active Comparator|TACE Procedure Traditional Delivery|"Patients will receive a single administration of intra-arterial chemotherapy (Doxorubicin) during the TACE procedure via Traditional Delivery.~Patients will undergo structural follow-up for a timeframe of one year post treatment~Post-procedural, contrast-enhanced Magnetic Resonance Imaging (MRI) will be performed one month after trial entry, and at regular intervals thereafter for a total of one year to assess tumor response"
2506939|NCT02853214|Experimental|Identification of genetic factors in dysglobulinemia cases|
2507078|NCT02852356|No Intervention|Control Incubator|Standard Incubator
2507079|NCT02852356|Experimental|MIRI-TL Timelapse Incubator|Timelapse incubator
2507080|NCT02852356|Experimental|Culture Coin Dish|Culture Coin dish for embryo culture
2507082|NCT02852356|No Intervention|Control dish|Control Dish for embryo culture
2507123|NCT02851927|Experimental|Mini Thoracoscopy|Thoracoscopy procedure shall be performed using the Rigid Mini Thoracoscope
2507124|NCT02851927|Active Comparator|Semirigid Thoracoscopy|Thoracoscopy procedure shall be performed using the SemiRigid Thoracoscope
2507141|NCT02851589|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2507206|NCT02851381|Other|FG-3019|Treatment of Pancreatic Cancer with FG-3019
2507297|NCT02850952|Experimental|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
2508465|NCT02842177|Active Comparator|Group I (classic method)|
3163534|NCT00482768|No Intervention|2|Control clinics will deliver usual care for patients with diabetes.
3163535|NCT00482794||1|Individuals with APS who also have one or more of their family members affected specifically by APS
3163536|NCT00482794||2|Individuals with APS who also have one or more of their family members affected by another type of autoimmune disorder, such as lupus or rheumatoid arthritis.
3163537|NCT00482794||3|Individuals with APS and no family or no family affected with APS or another autoimmune disorder
2505949|NCT02859857|Experimental|Solid tumor patients other than HGG|Cohort of patients with advanced solid tumors other than HGG administered BXQ-350 at the 2.4 mg/kg dose level.
2506001|NCT02859714||colorectal adenoma|
2506169|NCT02858544||Group1 - Validation Group|n=890 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
2506174|NCT02858544||Group 2 - Cross Validation Group|n=900 patients seen and evaluated for possible concussion after a motor vehicle accident. Patients with qualifying scores on the Concussion Identification Index will also complete the ImPACT.
2506305|NCT02857634||Bladder tumor resection|
2506351|NCT02857387|Experimental|acute coronary syndrome|
2506401|NCT02856958|Experimental|Operative|Peroneal nerve decompression
2506405|NCT02856958|Active Comparator|Non-operative|Physical therapy
2506445|NCT02856568|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, ricolinostat)|Patients receive cisplatin IV followed by gemcitabine hydrochloride IV on days 1 and 8, and ricolinostat PO on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2506566|NCT02855970|Experimental|patient|
2506678|NCT02855021|Other|Parkinson disease|Patients with a Parkinson disease with clinical diagnosis made for at least 5 years
2506749|NCT02854709|No Intervention|Control|Continue with habitual sleep duration
2506751|NCT02854709|Experimental|Intervention|Sleep extension
2506807|NCT02854332|Active Comparator|MRI by rTMS|Patients which received an MRI study of cortical plasticity by rTMS.
2506808|NCT02854332|Active Comparator|MRI by tDCS|Patients which received an MRI study of cortical plasticity by tDCS.
2506823|NCT02853864|Placebo Comparator|Propofol and 0.0 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2506824|NCT02853864|Experimental|Propofol and 0.4 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2506825|NCT02853864|Experimental|Propofol and 0.6 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2506826|NCT02853864|Experimental|Propofol and 0.8 ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2 ug/ml until the patient's consciousness disappears.
2506870|NCT02853669|Experimental|group (A) lumber plexus block|Ultrasound-guided Lumber plexus Block (30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation.
2506871|NCT02853669|Experimental|Group (B) adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
2507118|NCT02852018||Appropriate treatment|Patients who have a rhythmic event (before or after inclusion) appropriately treated either by administering an electric shock or by antiarrhythmic stimulation
2507119|NCT02852018||No event|Patients who have never received treatment or electrical antiarrhythmic stimulation and with a minimum follow-up of three years before inclusion and did not receive appropriate treatment during the follow up period of the study.
2507162|NCT02851576|Experimental|Infusion of ADV specific T cells|This one arm study consists in ADV-specific T cell infusion after HSCT from a (M)MUD or, for the first time, from a haploidentical donor for patients having undergone previous UCB transplantation, in the event of refractory ADV infection or disease. Specific anti-ADV immune reconstitution was observed in all patients, and viral load clearance in all but one.
2507215|NCT02851277|Experimental|Low dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses. After participants complete the Low dose arms, the Dose Escalation Committee (DEC) will determine if the study can progress to the parallel higher dose arms.
2507218|NCT02851277|Experimental|High dose ASP0892 Intradermal|Participants will receive study drug once every 2 weeks for a total of 4 doses.
2507219|NCT02851277|Placebo Comparator|Placebo Intradermal|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
2507220|NCT02851277|Experimental|High dose ASP0892 Intramuscular|Participants will receive study drug once every 2 weeks for a total of 4 doses.
2507230|NCT02851277|Placebo Comparator|Placebo Intramuscular|Participants will receive comparable Placebo once every 2 weeks for a total of 4 doses.
3163538|NCT00482820|Experimental|1|attention training away from threat
3163539|NCT00482820|Placebo Comparator|2|placebo attention training
3163542|NCT00482846|Experimental|Palifermin & Melphalen|"Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3~Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
3163543|NCT00482924||Overweight/obese|"The cohort consists of age and sex matched normal weighted controls and overweight/obese persons.~Definition for overweight: BMI >90th and <97th percentile, if under 18 years of age, and BMI >25 and <29.9 kg/m2 if over 18 years of age.~Definition for obese: BMI >97th percentile, if under 18 years of age, and BMI >30kg/m2, if over 18 years of age."
3163544|NCT00482924||Interventional branch|A lifestyle intervention following a holistic schedule was done in a subgroup of obese juveniles.
3163545|NCT00482963|Experimental|levonorgestrel, efavirenz|healthy HIV-negative women of reproductive age were given levonorgestrel, efavirenz
2505954|NCT02860000|Experimental|Arm II (alisertib, fulvestrant)|Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2506020|NCT02859506|Experimental|liver transplant|
2506035|NCT02859506|Active Comparator|kidney transplant|
2506041|NCT02859506|Placebo Comparator|control|
2506046|NCT02859506|Active Comparator|stable liver damage|
2506076|NCT02859012|Experimental|axitinib|Axitinib 5 mg twice (10mg) daily po medication until progression or development of unacceptable toxicity (4 weeks is considered as one cycle).
2506079|NCT02859012|Active Comparator|observation|Observation. if disease progression is detected, cross-over will be permitted.
3163546|NCT00482989|Experimental|1|MEDI-545
3163547|NCT00482989|Other|2|Placebo
3163548|NCT00483054|Experimental|Efavirenz|Efavirenz 600 mg/day + stavudine +lamivudine
2506291|NCT02857920|Experimental|Bevacizumab and NK immunotherapy|In this group, the patients will receive regular Bevacizumab treatment in combination with multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2506294|NCT02857920|Active Comparator|Bevacizumab|In this group, the patients will receive regular Bevacizumab treatment to control the tumor growth. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2506330|NCT02857348|Experimental|Adventure video game|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for one hour.
2506331|NCT02857348|Active Comparator|Educational Module|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least one hour on the combined tasks.
2506397|NCT02857153|Experimental|Low-level MAP|According to grouping, MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
2506400|NCT02857153|Experimental|High-level MAP|According to grouping, MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
2506435|NCT02856477|Experimental|adapted treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
2506439|NCT02856477|Experimental|non-adaptated treatment|the treatment dose is adapted to the metabolic capacity of the patient. intervention: urine analysis
2506469|NCT02856334||Chronic pelvic pain|Women with chronic pelvic pain
2506473|NCT02856334||Control group|Healthy women
2506500|NCT02856048|Experimental|Triptorelin (GnRHa) + Chemotherapy|Triptorelin LP 3 mg (DECAPEPTYL LP 3 mg, IPSEN) 3 mg every 28±3 days, intramuscular during chemotherapy
2506506|NCT02856048|No Intervention|Chemotherapy alone|Patient having a chemotherapy without drug injection for fertility preservation
2506558|NCT02855801|Experimental|constant exercise without cryotherapy|constant exercise without cryotherapy
2506561|NCT02855801|Experimental|constant exercise with cryotherapy|constant exercise with cryotherapy
2506564|NCT02855801|Experimental|intermittent exercise, no cryotherapy|intermittent exercise without cryotherapy
2506565|NCT02855801|Experimental|intermittent exercise and cryotherapy|intermittent exercise with cryotherapy
2506616|NCT02855424|No Intervention|control|traditional rehabilitation merely, no ergocycling training
2506619|NCT02855424|Experimental|the low-intensity exercise group|traditional rehabilitation plus the low-intensity ergocycling exercise training
2506621|NCT02855424|Experimental|the moderate-intensity exercise group|traditional rehabilitation plus the moderate-intensity ergocycling exercise training
2506692|NCT02854852||Patients undergoing general anesthesia|Patients ASA 1-3, undergoing different types of general anesthesia, in supine position, with standard or advanced hemodynamic monitoring.
2506753|NCT02854553|Experimental|TAP|Transversus abdominis plane block
2506755|NCT02854553|Experimental|TAP and rectus sheath block|Transversus abdominis plane block with rectus sheath block
2506757|NCT02854553|No Intervention|control|no truncal blocks, conventional analgesia
2506794|NCT02854215|Other|Ovarian cancer|Patient undergoing primary surgery for a newly diagnosed ovarian, tubal or peritoneal malignancies; Stage IIIc or IVa with extrapelvic carcinomatosis according to the International Federation of Gynecology and Obstetrics classification 2014
2506878|NCT02853981|Active Comparator|Harmonic scalpel group|group of donors whom will undergo liver transection using harmonic scalpel.
2506884|NCT02853981|Active Comparator|clamp-crush group|group of donors whom will undergo liver transection using Kelly clamp.
3163549|NCT00483054|Experimental|Nevirapine|Nevirapine 400 mg/day + stavudine +lamivudine
3163550|NCT00483067|Experimental|2-CdA + Ara-C + G-CSF|2-CdA 12 mg/m^2/day by vein (IV) Continuous Infusion and Ara-C 1 gm/m^2/day IV for 5 Days with G-CSF 5 mcg/kg/day subcutaneously starting Day 9
2507081|NCT02852109||experimental group|patients who was firstly diagnosed as diffuse axonal injury
2507084|NCT02852109||control group|patients negative for magnetic resonance examination with no trauma
2507132|NCT02851966|Other|TEX101|This is a single arm study. All patients will be asked to provide multiple semen samples and all samples will be tested with TEX101 ELISA assay. Timing of mTESE maybe changed according to the assay results.
2507169|NCT02851524|Experimental|posturography|
3163551|NCT00483080|Experimental|A: NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every 3 weeks or weekly
3163552|NCT00483093|Experimental|A|
3163553|NCT00483106|Active Comparator|Ritalin|
3163554|NCT00483106|Placebo Comparator|Placebo|
3163555|NCT00483145|Active Comparator|1|Long-pulsed dye laser (Candela)
3163556|NCT00483145|Active Comparator|2|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)
3163557|NCT00483158|Placebo Comparator|A|Rising Single Dose
3163558|NCT00483158|Placebo Comparator|B|Rising Multiple Dose
3163559|NCT00483158|Experimental|C|Open Label H. pylori cohort
3163560|NCT00483171|Placebo Comparator|Placebo|
3163561|NCT00483171|Other|Non-pharmacological weight loss program (NPP)|
3163562|NCT00483171|Other|Low Calorie Diet|
2505956|NCT02860013|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling heart failure in general. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
2505957|NCT02860013|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with heart failure are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). Heart failure patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing heart failure. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in heart failure and definitely not on call
2506097|NCT02859090|Experimental|patient|
2506122|NCT02858765|Experimental|white polychromatic light A|
2506123|NCT02858765|Experimental|white polychromatic light B|
2506124|NCT02858765|Experimental|white polychromatic light C|
2506125|NCT02858765|Experimental|white polychromatic light D|
2506146|NCT02858518||patients with atrial fibrillation with anticoagulant treatment|
2506216|NCT02858297|Experimental|Glucosamine/Corticosteroid 4|Topical steroid (triamcinolone acetonide 0.1 %) four times per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
2506217|NCT02858297|Experimental|Glucosamine/Corticosteroid 2|Topical steroid (triamcinolone acetonide 0.1 %) twice per day and (glucosamine sulfate 500 mg) orally three times per day for 8 weeks
2506218|NCT02858297|Active Comparator|Corticosteroid|Topical steroid (triamcinolone acetonide 0.1 %) four times per day for 8 weeks
2506326|NCT02857569|Experimental|Experimental IT Arm|"ipilimumab: 0.3mg/kg IT injection every 3 weeks until complete response, eradication of all injectable sites, disease progression or toxicity, for a maximum of 4 doses (to compare back to back to IV standard of care and marketing authorization).~nivolumab: 1mg/kg, IV injection every 3 weeks during IT ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IT ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
2506328|NCT02857569|Active Comparator|Standard Arm|"ipilimumab: 3mg/kg, IV injection every 3 weeks for a maximum of 4 doses as per standard of care and marketing authorization.~nivolumab: 1mg/kg, IV injection every 3 weeks during IV ipilimumab treatment period and 3mg/kg, IV injection every 2 weeks after IV ipilimumab treatment interruption. Treatment should be continued as long as clinical benefit is observed or until treatment is no longer tolerated by the patient for a maximum of 12 months."
2506354|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
2506395|NCT02856906|Experimental|Occlusal adjustment group|Patients in this group will receive treatment of occlusal adjustment based on the clinical and lab examination results.
2506460|NCT02856633||Vitaliti System|
2506522|NCT02856139||1 (MB- and VL-)|without mottled fluorescent band (MB) and vascular leakage (VL)
2506523|NCT02856139||2 (MB+ and VL-)|with mottled fluorescent band (MB), without vascular leakage (VL)
2506524|NCT02856139||3 (MB-/+ and VL+)|with or without mottled fluorescent band (MB), with vascular leakage (VL)
2506614|NCT02855775|Experimental|Bevacizumab|Bevacizumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
2506618|NCT02855775|Experimental|Trastuzumab|Trastuzumab in monotherapy or in association to other anticancer agents pharmacokinetic assessment with blood sample with additional blood sample
3196644|NCT00852449|Experimental|liberal fluid|Liberal fluid administration: 12 ml kg-1 h-1 of crystalloids (lactated Ringer's solution)
3196645|NCT00852462|Experimental|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
3196646|NCT00852462|No Intervention|Usual Care|Symptom assessment and management follows customary procedures in each study site.
3196647|NCT00852488|Experimental|Catheter|Cohort undergoing catheter placement using the new technique being studied
2506970|NCT02853006|Other|Group 1 lung cancer in stage 1-2|Group 1 : patient with lung cancer in stage 1-2, lung cancer of all histology kind eligible for surgery
2506978|NCT02853006|Other|Group 2 lung cancer in stage 3-4|Group 2 : patient with lung cancer in stage 3-4 (no adenocarcinoma or squamous) receiving classical or targeted chemotherapy on genetic anomalies.
2506983|NCT02853006|Other|Group 3 : control patients|Group 3 control patients : carriers of non-cancerous radiological anomalies : benign nodules, cicatricial lesions, infectious or inflammatory, paired with the two other groups by age, sex or tobacco.
2507029|NCT02852564|Experimental|Enrolled Participants|Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor [TURBT])
2507090|NCT02852369|Experimental|Task Oriented Training|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
2507253|NCT02851446||DS|
2507255|NCT02851446||no DS|
2507295|NCT02850666|Experimental|Interdisciplinary Process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
2507781|NCT02847286|Active Comparator|Treatment B|Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
3163563|NCT00483249|Experimental|Interventional|Endovascular Branched Stent-Graft: The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents).
3163564|NCT00483314|Experimental|1|
3173710|NCT00615147||1|Patients to have a CT pulmonary angiogram for suspected pulmonary embolism will have a d-dimer drawn as is routinely done.
2506095|NCT02859025|Active Comparator|A:Iiac|Treated with anterior iliac crest spongy bone to fill defects, followed by coverage with collagen membrane.
2506103|NCT02859025|Experimental|B:MSCs+LRCP|Treated with lateral ramus cortical bone plate (LRCP) to create a protected healing space by fixing it to adjacent walls of the cleft defect. BFPScs were loaded on NBBM and delivered to the defect
2506109|NCT02859025|Experimental|C:MSCs+liac|Treated with anterior iliac crest spongy bone as in Group 1, but BFP-derived mesenchymal stem cells (MSCs ) cultured over NBBM were put over the spongy bone and covered with a collagen membrane.
2506158|NCT02858648|Experimental|Behavior intervention with smart phone based self-monitoring|Patients in this group were asked to attend 11 group and 1 individual session over 6 months, and received a smartphone with two downloaded applications to monitor diet, physical activity, weight, and blood glucose (connected with a blue tooth glucometer) throughout 6 months.
2506165|NCT02858648|Experimental|Behavior intervention with paper diary based self-monitoring|Patients in this group were asked to attend 11 group sessions and 1 individual session over 6 months, and received paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer to monitor diet, physical activity, weight, and blood glucose throughout 6 months.
2506167|NCT02858648|No Intervention|Usual care|Patients in this group received no intervention, they continue to receive usual diabetes care and education from the recruitment clinic.
2506204|NCT02858258|Active Comparator|Standard Arm A|"R-CHOP/R-DHAP: Alternating 3 cycles of R-CHOP in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM"
2506208|NCT02858258|Experimental|Experimental Arm A+I|"R-CHOP+Ibrutinib/R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days 1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~ASCT conditioning (ASCT: autologous stemm cell transplantation) Drug: THAM or BEAM~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenace)"
2506212|NCT02858258|Experimental|Experimental Arm I|"R-CHOP+Ibrutinib / R-DHAP: Alternating 3 cycles of R-CHOP + Ibrutinib at Days1-19 in cycle 1,3,5 and 3 cyles of R-DHAP in cycle 2,4,6; each 21 day cycle~Drug: R-CHOP/R-DHAP Drug: Ibrutinib (Induction)~2 years Ibrutinib Maintenance Drug: Ibrutinib (Maintenance)"
2506492|NCT02856425|Experimental|NSCLC of adenocarcinoma tumor hist|
2506493|NCT02856425|Experimental|NSCLC of squamous cell tumor histo|
2506495|NCT02856425|Experimental|Urothelial cancer|
2506496|NCT02856425|Experimental|Renal Cell cancer (RCC)|
2506498|NCT02856425|Experimental|Colo Rectal Cancer|
2506499|NCT02856425|Experimental|Ovarian cancer (OC)|
2506504|NCT02856425|Experimental|Hepatocellular (HCC)|
2506508|NCT02856425|Experimental|Mesothelioma (MPM)|
2506542|NCT02855736|Experimental|Intervention group|Positive Psychology (gratitude journal)
2506543|NCT02855736|Placebo Comparator|Control group|Alimentary list
2506603|NCT02855554|Experimental|Additional 5 minute research MR scan of heart.|The purpose of this is to evaluate new, faster MR scans
2506655|NCT02855216|Experimental|Manual technique of sub-occipital inhibition|"The technique applied to Manual Group was performed with the patient supine position. Physiotherapist in a sitting position at the head of the subject with forearms resting on the table . Suboccipital region was located , and flexing the metacarpophalangeal joints 90º a pressure was made ventrally , relaxing the rest of the head in the heel of the hand.~The technique was performed for 5 minutes"
2506656|NCT02855216|Experimental|Self-treatment by way of Occipivot®|The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
2506750|NCT02854566||periprosthetic fractures of the femur|periprosthetic fractures of the femur treated by osteosynthesis
2506795|NCT02854267||group without guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all registered situations of brain death patients on the database (nationwide) minus the situations occuring in the group with guide (22 intensive care units forming the 'RESEAU NORD FRANCILIEN' network). The period before the diffusion of the guide is from 1st of july 2012 to 30th of june 2014
2506796|NCT02854267||group without guide, after guide's diffusion|For this group, only the primary objective (refusal rate) will be assessed, using the French Biomedicine Agency database; The group without guide is made up by all the registered situations of brain death patients on the database minus the situations occuring in the group with guide ('RESEAU NORD FRANCILIEN'). The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
2506797|NCT02854267||Group with guide, before guide's diffusion|For this group, only the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database; The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018.
2506799|NCT02854241|Experimental|LC group|LC group under surveillance of biannual ultrasonography and annual noncontrast liver MRI. Six month after the last MRI, contrast enhanced liver CT is performed to investigate presence of HCC.
3173711|NCT00615160|Experimental|A|PTK787/ZK 222584 (PTK-ZK) taken orally with a daily flat dose of 1250 mg on days 1 to 28 (= 1 cycle)
3173712|NCT00615160|Experimental|B|combined treatment with DTIC 850 mg/m² on day 1 + PTK-ZK 1250 mg flat dose on days 1 to 28
3173713|NCT00615173|Experimental|1|tacrolimus(fk506) treatment in induction and maintenance phase
2506028|NCT02859298|Experimental|Suspicion of threat of premature delivery|10 consecutive patients arriving at the Brugmann maternity with suspicion of a threat of premature delivery will be encouraged to participate in this study, before the onset of any tocolytic treatment. The patient will receive an standard examination of the cervix and at the same time a polarimetric measurement.
2506045|NCT02859298|Active Comparator|Normal pregnancy|10 control patients, with the same term of pregnancy, will be benefit from the same measurements.
2506075|NCT02859207|Experimental|Cohort 1|Participants with mild hepatic impairment (Child-Pugh class A).
2506078|NCT02859207|Experimental|Cohort 1C|Healthy participants (control) matched to participants in Cohort 1.
2506083|NCT02859207|Experimental|Cohort 2|Participants with moderate hepatic impairment (Child-Pugh class B)
2506088|NCT02859207|Experimental|Cohort 2C|Healthy participants (control) matched to participants in Cohort 2
2506138|NCT02858856|Experimental|A group|Take Sipjeondaebo-tang on 0~2 week, 3~5 week of clinical trial period, total of 4 weeks
2506140|NCT02858856|Experimental|B group|Take Sipjeondaebo-tang on 6~8 week, 9~11 week of clinical trial period, total of 4 weeks
2506207|NCT02858414|Experimental|blood sample|
2506239|NCT02858011|Active Comparator|Control and comparison group -cash transfer program|The program is implemented during 48 months. During the first 36 months the control group does not receive any intervention. During the last 12 months eligible beneficiaries receive cash transfer and accompanying information sessions on health, child nutrition, household economics every three months (identical to experimental group).
2506242|NCT02858011|Experimental|Jigisemejiri cash transfer program|Unconditional cash is distributed every 3 months to beneficiaries of the Jigisemejiri program. During cash handouts, information sessions on health, child nutrition, households economics and education are organized by local NGOs.
2506244|NCT02858011|Experimental|Jigisemejiri - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women receiving rations of fortified flour (PNP) during the last 12 months of the project
2506246|NCT02858011|Active Comparator|Control and comparison group - Preventive Nutrition packages|Households belonging to the experimental group who previously received Cash transfer and information sessions on health, child nutrition, households economics and education for 36 months, with children and/or pregnant/lactating women
2506313|NCT02857686|Active Comparator|arm intravenous regional anesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
2506316|NCT02857686|Experimental|forearm intravenous regional anesthesia|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
2506448|NCT02856672|Active Comparator|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
2506449|NCT02856672|Active Comparator|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
2506501|NCT02856217|Active Comparator|tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal tunneling in SCP: creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum.
2506503|NCT02856217|Active Comparator|non-tunneling|Placement of mesh between vaginal apex and sacrum is retroperitoneally placed in peritoneal non-tunneling group in SCP: incised and sutured peritoneum between vaginal apex and sacrum
2506670|NCT02855073|Experimental|ReJoinTM Group|Subjects in this Group will receive ReJoinTM injections on day 1 and day 22, and Sodium Hyaluronate injection on day 8 and day 15.
2506671|NCT02855073|Active Comparator|Sodium Hyaluronate Group|subjects in this group will receive Sodium Hyaluronate injections on day 1, 8, 15, 22.
2506737|NCT02854722|Experimental|Deferasirox and calcium-vitamin D3|"Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and Vitamin D3 800 IU should also be taken daily as a basic therapy."
2506741|NCT02854722|Placebo Comparator|Calcium-vitamin D3|Calcium 500 mg and Vitamin D3 800 IU are taken daily as a basic therapy.
2506784|NCT02854254|Experimental|PICC|peripherally inserted central catheter
2506785|NCT02854254|Other|Control|peripherally venous access
3163565|NCT00483366|Other|Imatinib/Gemcitabine/Capecitabine|"Patients will be accrued on cohorts of three per dose level starting at dose level 0. Accrual to higher dose levels will depend on toxicity occurrence.~Dose limiting toxicity (DLT) will be determined after cycle two for each patient.~Schema: Imatinib days 1 - 5 and days 8 - 12 Gemcitabine on days 3 and 10 Capecitabine on days 1 - 14~Doses: Imatinib 400 mg/d fixed dose Gemcitabine 450 mg/m2; 550 mg/m2; 675 mg/m2; 825 mg/m2; 1000 mg/m2 Capecitabine 500 mg/m2; 600 mg/m2 bid; 725 mg/m2; 850 mg/m2~Treatment cycle: 21-days~Treatment duration: Until disease progression or unacceptable toxicity defined in protocol."
3163566|NCT00483431|Placebo Comparator|PLACEBO|MK7 dosage 0 mcg, 4 capsules, orally, daily for 12 weeks.
3163567|NCT00483431|Active Comparator|MK7_10|MK7 dosage 10 mcg, 1 capsule of 10 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
2506949|NCT02853136|Experimental|Reference Treatment (pilot phase)|BI 409306 low dose
2506950|NCT02853136|Experimental|Test Treatment (pilot phase)|Fluvoxamin and low dose of BI 409306
2506951|NCT02853136|Experimental|Reference Treatment (main phase)|BI 409306 medium or high dose
2506952|NCT02853136|Experimental|Test Treatment (main phase)|Fluvoxamin and medium or high dose of BI 40930
2506999|NCT02852824|Experimental|BI 655130|
2507002|NCT02852824|Placebo Comparator|Placebo|
2507047|NCT02852577|Active Comparator|Clonazepam|Treatment with clonazepam
2507054|NCT02852577|Active Comparator|Paroxetine|Treatment with paroxetine
2507094|NCT02852187|Active Comparator|MOBIS PEEK|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS PEEK Cage
2507095|NCT02852187|Active Comparator|MOBIS II ST|Transforaminal Lumbar Interbody Fusion (TLIF) with the SIGNUS MOBIS II ST Cage
3163568|NCT00483431|Active Comparator|MK7_20|MK7 dosage 20 mcg, 2 capsules of 10 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
3163569|NCT00483431|Active Comparator|MK7_45|MK7 dosage 45 mcg, 1 capsules of 45 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
3163570|NCT00483431|Active Comparator|MK7_90|MK7 dosage 90 mcg, 2 capsules of 45 mcg and 2 placebo-capsules, orally, daily for 12 weeks.
2506057|NCT02859350|Experimental|Group 6b (PfSPZ Vaccine)|6-11 months; n=12; 3 doses of 1.8x10^6 PfSPZ Vaccine given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
2506060|NCT02859350|Placebo Comparator|Group 6b (normal saline)|6-11 months; n=4; 3 doses of normal saline given 8 weeks apart. Group 6b will start 11 weeks after Group 1a.
2506116|NCT02858947|Active Comparator|Aelite Flo|Microhybrid flowable composite
2506118|NCT02858947|Active Comparator|x-tra base|Bulk-fill flowable composite
2506151|NCT02858609|Experimental|Patients with Diarrhoea|Patients admitted in emergency room with Diarrhoea
2506329|NCT02857725|Experimental|SPF evaluation|Subjects with good health as determined from the CRO Subject History Form (SHF) and Fitzpatrick Skin Type I, II and/or III were considered for SPF testing.
2506379|NCT02857062|Experimental|E45 Eczema Repair Emollient|Open label, single arm study to evaluate the skin tolerance of E45 Eczema Repair Emollient in babies and children
2506432|NCT02856724|Experimental|Early amniotomy and PGE2|10 mg PGE2 vaginal ovul(Propess) Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
2506433|NCT02856724|Active Comparator|PGE2|10 mg PGE2 vaginal ovul(Propess)
2506488|NCT02856347|Other|PET 18-FDOPA|"18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).~PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).~Other series of images will be done 50 min after tracer injection. Images will be interpreted."
2506562|NCT02855905|Experimental|Coronary artery disease patients|Coronary artery disease patients are exposed to brief cold exposure (-15 C for 30 min) mainly subjected to facial region during which their cardiovascular responses are registered. Exposure was repeated 4 times: rest and exercise in 22 C and rest and exercise in -15 C.
2506591|NCT02855476||Early Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD
2506593|NCT02855476||Late Pre-manifest HD|Huntington's disease gene expansion carriers who not have clinical diagnostic motor features of HD, but who have a higher burden of disease compared to the Early Pre-manifest HD cohort
2506595|NCT02855476||Early Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage I or Stage II HD
2506598|NCT02855476||Moderate Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage III HD
2506599|NCT02855476||Late Manifest HD|Huntington's disease gene expansion carriers who have clinical diagnostic motor features of HD defined as Stage IV-V HD
2506600|NCT02855476||Controls|Have no known family history of HD; or have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD.
2506700|NCT02854826||UCLA Ronald Reagan Medical Center|"Site 1 (UCLA Regan Medical Center): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2506703|NCT02854826||Huntington Hospital|"Site 2 (Huntington Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research Council/ Evidence Based Practice will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2506707|NCT02854826||Torrance Memorial Hospital|"Site 3 (Torrance Memorial Hospital): Leaders from nursing, pharmacy, social work/case management, physician, administration, performance improvement, information systems and the Nursing Research/ Evidence Based Practice Council will implement, monitor and evaluate the SAFE Care model of care. Two nursing units will be identified for staff training in screening at-risk older adults. One units will be randomly selected to initiate the SAFE Care program. The comparison unit staff will screen for at-risk patients and continue usual high standard of care assessments and care planning. Both units will be closely followed with formative and summative evaluation data presented for local and all-site findings."
2506762|NCT02854501||Uncomplicated pregnancies|
2506769|NCT02854501||Preeclampsia|
2506772|NCT02854501||Isolated IUGR|
2506774|NCT02854501||Any complication|
2506811|NCT02854189|Other|patients with genu recurvatum|The medial osteoarthritis knees with genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
2506812|NCT02854189|Other|patients without genu recurvatum|The medial osteoarthritis knees without genu recurvatum were included in this study. Patients had been treated with cemented minimally invasive surgery Oxford unicompartmental knee arthroplasty and had had a minimum of 24 months of follow-up.The incidence of postoperative genu recurvatum, postoperative hyperextension angle, and the knee society score were recorded.
2506827|NCT02853903|Experimental|Allogenic NK immunotherapy|In this group, the patients will receive more than 4 times of allogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2506830|NCT02853903|Active Comparator|Autogenic NK immunotherapy|In this group, the patients will receive more than 4 times of autogenic NK immunotherapies in 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507474|NCT02849262|Experimental|Omiganan (CLS001)|CLS001 Topical Gel, 2.5%
3196648|NCT00852501||Non-functioning pituitary macroadenoma|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
3196649|NCT00852514|Experimental|Monthly BIA|monthly BIA to monitor fluid status
3196650|NCT00852566|Active Comparator|Imatinib|Standard treatment Imatinib 400mg OD
3196651|NCT00852566|Experimental|dasatinib|Dasatinib 100mg OD
2506382|NCT02857166|Experimental|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 0.3mg/kg or 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2506512|NCT02856269|Active Comparator|45 mg daily|Participants in this arm will take a daily 45 mg dose of zinc gluconate.
2506515|NCT02856269|Active Comparator|90 mg daily|Participants in this arm will take a daily 90 mg dose of zinc gluconate.
2506573|NCT02855788|Experimental|POLF regimen|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly
2506624|NCT02855346|Experimental|200 mg of DPV|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
2506626|NCT02855346|Experimental|200 mg of DPV + 320 mg LNG|Each participant will receive a VR containing either 200 mg DPV or 200 mg DPV + 320 mg LNG. Participants will be randomized in a 1:1 ratio. The VR should be worn for approximately 14 consecutive days +/-1 day. The ring will be removed by the participant (or clinician/designee, if necessary) at the Product Use End Visit (PUEV)/Early Termination Visit. The participant will be followed for approximately 2 days following VR removal
3196652|NCT00852579|Experimental|1|Active treatment.
3196653|NCT00852579|Placebo Comparator|2|Placebo control group.
2506732|NCT02854592||rtPA|Intravenous rt-PA thrombolysis shall be administered within 4.5 h after symptom onset, at a dose of 0.9 mg/kg body weight (maximum, 90 mg), with 10% of the dose given as a bolus over 1 min and the remaining 90% infused over 60 min.
2506735|NCT02854592||urokinase|1,000,000-1,500,000 units of urokinase intravenous infused over 30 minutes within 4.5 h of stroke onset .
2506800|NCT02854280|Active Comparator|Chronic Obstructive Pulmonary Disease (COPD)|18 patients
2506802|NCT02854280|Active Comparator|Sleep Apnea Obstructive (OSA)|18 patients
2506805|NCT02854280|Active Comparator|Healthy Volunteers|36 control patients
2506854|NCT02853851||France|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2506857|NCT02853851||Italy|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2506860|NCT02853851||spain|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2506863|NCT02853851||montreal|10 senior physicians, 10 interns, 10 experienced nurses (with more than one year of experience in the service) and 10 inexperienced nurses (with less than one year of experience in the service)
2506910|NCT02853487||Cluster headache patients|Episodic cluster headache patients in- and outside of bout will wear an actigraph and fill out a diary for 2 weeks.
2506913|NCT02853487||Control group|Healthy, headache-free controls will wear an actigraph and fill out a diary for 2 weeks.
2506975|NCT02853058|Active Comparator|normal PI|Uterine artery PI expresserd in MoM is <95e percentile
2506982|NCT02853058|Active Comparator|pathological PI|Uterine artery PI expressed in Multiple of Mediane (MoM) is >=95e percentile
2507022|NCT02852655|Experimental|Pre-surgery MK-3475|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK3475) pre-surgery at pre-determine dosage followed by Pembrolizumab at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
2507026|NCT02852655|Active Comparator|No MK-3475 at Pre-Surgery|"-After a screening phase of 14 days, eligible subjects will be randomized into two groups.~Pembrolizumab (MK-3475) at pre-determine dosage every 3 weeks post surgery.~MK-3475 will be administered intravenously"
3196654|NCT00852605|No Intervention|Oxygen|Conventional Treatment including Oxygen-support
3196655|NCT00852605|Experimental|NIV|Conventional Treatment plus intermittent Non-Invasive-Ventilation
3196656|NCT00852618||A|Participants undergoing treatment with raltegravir (RAL) in the main study
3196657|NCT00852618||B|Participants undergoing treatment with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in the main study
3196658|NCT00852657|Active Comparator|Surgical treatment|Open or mini-open tendon repair with acromioplasty
3196659|NCT00852657|Active Comparator|Physiotherapy|Physiotherapy by exercises
3196660|NCT00852670|Experimental|A|
3196661|NCT00852670|Placebo Comparator|B|
3196662|NCT00852683|Active Comparator|A|
3196663|NCT00852683|Placebo Comparator|B|
3196664|NCT00852696|Placebo Comparator|Placebo Group|Placebo Orally 9 weeks once daily.
3196665|NCT00852696|Experimental|Solifenacin Group|Solifenacin Orally 9 weeks once daily.
3196666|NCT00852722|Experimental|1. Low fat study diet|The low fat study diet arm will receive low fat diet training and followed for 12 months on the diet.
3196667|NCT00852722|No Intervention|2. Regular diet group|The regular diet arm will be a wait-listed group that will receive no training in diet and will be advised to continue their regular (usual) diet as was prior to entry into the study, for the duration of the study. They will have a similar clinic follow up schedule as the treatment group. The regular diet group will be given identical instructions to exercise regularly similar to the treatment group.
3196668|NCT00852774||1|Endometrial Cancer Patients Hysterectomy Robotic Surgery
3196669|NCT00852774||2|Endometrial Cancer Patient Hysterectomy Laparotomy Surgery
3196670|NCT00852787|Experimental|Low|0.1mg/kg
3196671|NCT00852787|Experimental|Medium|0.4mg/kg
2506126|NCT02858843|Experimental|Lumacaftor-ivacaftor|Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.
2506183|NCT02858479|Other|patients with pain allodynic peripheral|
2506187|NCT02858479|Other|patients with pain allodynic central|
2506225|NCT02858115||one lung ventilation lung|patients requiring one lung ventilation lung resection.
2506321|NCT02857881|Experimental|Evolutive keratoconus|
2506359|NCT02857270|Experimental|LY3214996 Dose Escalation|LY3214996 given orally once a day (or twice a day) for 21 days.
2506362|NCT02857270|Experimental|LY3214996 + Midazolam|"(Preliminary Drug-Drug Interactions [DDI])~LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days)."
2506365|NCT02857270|Experimental|LY3214996 Dose Expansion|LY3214996 given orally (once a day) during each 21 day cycle.
2506366|NCT02857270|Experimental|LY3214996 + Abemaciclib|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.
2506367|NCT02857270|Experimental|LY3214996 + Nab-Paclitaxel + Gemcitabine|Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.
2506368|NCT02857270|Experimental|LY3214996 + Encorafenib + Cetuximab|Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.
2506369|NCT02857270|Experimental|Japan Part 1|LY3214996 given orally.
2506370|NCT02857270|Experimental|Japan Part 2|LY3214996 given orally and abemaciclib given orally.
2506440|NCT02856581|Experimental|Intervention group (varenicline and behavioral intervention)|Patients receive varenicline PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
2506444|NCT02856581|Placebo Comparator|Control group (placebo and behavioral intervention)|Patients receive placebo PO QD on days 1-3 and BID on days 4-84 for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete behavioral intervention consisting of no smoking message from surgical team member and how to use NCI quitline at surgical consult.
2506828|NCT02854098||with functional constipation|n = 200 patients with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
2506831|NCT02854098||without functional constipation|n = 200 patient with functional constipation examined for BHJS age 3 -18 years meet inclusion criteria, do not fulfill exclusion criteria
2506917|NCT02853396|Experimental|Cognitive behavioural therapy|Cognitive behaviour therapy
2506918|NCT02853396|Active Comparator|Psychoeducation|psychoeducation
2506953|NCT02853110|Experimental|Hypo-FLAME|External beam radiotherapy, 5 additional MRI scans, blood sampling
2507033|NCT02852759|Experimental|intervention group|Add Selective Cold and Electroacupuncture treatment to the existing treatment for patients with insulin resistance.
2507034|NCT02852759|No Intervention|Intensive Care group|continue the existing management of insulin resistance in these patients. They will receive the same follow up, examinations etc as intervention group.
3196672|NCT00852787|Experimental|High|1.6 mg/kg
2507163|NCT02852031||Hypoplastic Left Heart Syndrome|Infants diagnosed with Hypoplastic Left Heart Syndrome (HLHS)
2507267|NCT02850627|Experimental|Tongguan capsule|Tongguan capsule (0.5 g tid. for 6 months)
2507284|NCT02850627|Placebo Comparator|placebo capsule|same volume/day of placebo capsule (0.5 g tid. for 6 months)
2507343|NCT02850341|Experimental|Intervention group|Patients receive a pedometer and instructions how to raise their physical activity
2507350|NCT02850341|No Intervention|Control group|Patients receive treatment-as-usual
2507405|NCT02849808||Keratoplasty patients|All patients who underwent one or more keratoplasties since january 1983.
2507446|NCT02849470|Active Comparator|ARM 1|Control: 1) HD-PRP + Matristem Matrix (ACell) (Current Standard of Care); 2) Intradermal injections of hair loss 3) Platelet Rich Plasma 4) Matristem Matrix (ACell)
2507452|NCT02849470|Active Comparator|ARM 2|"Experimental: HD-PRP + Emulsified AD-tSVF;~Intervention:~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Intradermal injections of hair loss"
2507458|NCT02849470|Experimental|ARM 3|"Experimental: HD- PRP + Emulsified AD-tSVF + Emulsified AD-cSVF; Intervention: Intradermal injections of hair loss~Platelet Rich Plasma~Adipose Derived Stem/Stromal Cells~Stem/Stromal Cell Isolation~Intradermal injections of hair loss"
2507549|NCT02848898|Experimental|Equistasi Group|arm treated with application of devices
2507554|NCT02848898|Placebo Comparator|Placebo Group|arm treated with application of inactivated devices
2507601|NCT02848378||Chronic periodontitis group|Subjects who have moderate to severe alveolar bone loss and clinical attachment level (CAL) ≥5 mm and probing depth (PD) ≥6mm in multiple sites of all four quadrants of the mouth but with no evidence of rapid progression
2507611|NCT02848378||Gingivitis group|Subjects who show gingival inflammation that is based on the presence of bleeding on probing (BOP) at >50% of sites in the whole mouth, no clinical and radiographic signs of periodontitis
2507619|NCT02848378||Periodontally healthy group|Subjects who have no sites with PD >3mm and CAL >0 mm, a BOP score of <15% at the examination and no alveolar bone loss.
2507666|NCT02848053||Tianqi group|used Tianqi Capsule in the REDUCES study
2507668|NCT02848053||Placebo group|used placebo in the REDUCES study
3196673|NCT00852787|Placebo Comparator|Placebo|
3196674|NCT00852800|Active Comparator|Standard regimen|Albumin in standard regimen (1.5 g/Kg IV on day 1 and 1 g/kg IV on day 3)with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
3196675|NCT00852800|Experimental|Dose reduced regimen|Albumin in dose reduced regimen (1 g/kg IV on day 1 and 0.5 g/kg IV on day 3) with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3
3196676|NCT00852826|Sham Comparator|1|Standard axillary lymphadenectomy
3196677|NCT00852826|Experimental|2|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
2506228|NCT02858102|Active Comparator|Active treatment group|Physical activity program: 36 sessions of physical activity lasting between 30-60 minutes for 12 weeks, three days per week.
2506229|NCT02858102|No Intervention|Control group|No physical activity program
2506273|NCT02857855|Experimental|80% fraction of inspired oxygen|80% fraction of inspired oxygen delivered either by a nonrebreathing facemask with a reservoir with oxygen flow of 14 l/min and air flow of 2 l/min or by a respirator for first 6 postoperative hours
2506275|NCT02857855|Active Comparator|28% fraction of inspired oxygen|28% fraction of inspired oxygen delivered either by a Venturi facemask or by a respirator for first 6 postoperative hours
2506323|NCT02857582|Active Comparator|Vancomycin|Secondary treatment for relapse of Clostridium difficile infection.
2506324|NCT02857582|Experimental|Cultured human intestinal microbiota1|Cultured intestinal microbiota is experimental treatment for relapse of Clostridium difficile infection.
2506327|NCT02857582|Experimental|Cultured human intestinal microbiota2|Cultured intestinal microbiota is thirdly experimental treatment for second relapse of Clostridium difficile infection.
2506437|NCT02856750|Experimental|gabapentin|gabapentin 300 mg three times daily x 30 d
2506442|NCT02856750|No Intervention|placebo|no gabapentin administered to this arm.
3196678|NCT00852839|Experimental|552-02|
2506540|NCT02855853|Experimental|serious game|
2506541|NCT02855853|Placebo Comparator|control|
2506596|NCT02855593||Physicians|Physicians who perform acupuncture
2506597|NCT02855593||Patients|Patients who have received acupuncture treatment in the past
2506752|NCT02854982||Prostate Cancer|Group drawn of the case group of the case control study, entitled EPICAP
2506754|NCT02854982||No Prostate Cancer|Group drawn of the control group of the case control study, entitled EPICAP
2506810|NCT02854319|Experimental|LOTUS Edge Valve System|Transcatheter aortic valve implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
2506856|NCT02853916|Active Comparator|500 mg InSea2®|
2506859|NCT02853916|Active Comparator|250 mg InSea2®|
2506862|NCT02853916|Placebo Comparator|Placebo|
2506899|NCT02853539|Experimental|Denosumab|One per 6 months subcutaneous injection of Denosumab (2 doses in total)
2506901|NCT02853539|No Intervention|No Denosumab|No intervention, just observation of HPN patients
2506922|NCT02853253|Experimental|SMOF|parenteral nutrition using SMOFlipid® (FreseniusKabi France, Sèvres, France)
2506928|NCT02853253|Active Comparator|Medialipide®|parenteral nutrition using Medialipide® 20% (B Braun Medical, Boulogne, France)
2506954|NCT02852980||gestational diabetes women|Women who had childbirth in the Hospital center Rene Dubos and who had gestational diabetes.
2507009|NCT02852772||PLHIV with microalbuminuria|Patient infected with HIV and well controlled by treatments, with microalbuminuria for at least 5 years
2507010|NCT02852772||PLHIV without microalbuminuria (control)|Patient infected with HIV and well controlled by treatments, without microalbuminuria, matched for age +/- 5 years
2507049|NCT02852499||Mothers|Pregnant women.
2507055|NCT02852499||Fathers|Futur fathers.
2507060|NCT02852499||Children|Children after childbirth.
2507098|NCT02852096|Experimental|Dual or Multiple Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with Dual or Multiple Tumor Tissue Paraffin Blocks
2507100|NCT02852096|Active Comparator|One Paraffin Blocks|Assessing Her2/neu Expression in Gastric Cancer with One Tumor Tissue Paraffin Blocks
2507144|NCT02851719|Experimental|BF group|24 outpatient sessions of the PFMT (twice a week) using manometric-based BF equipment and daily home PFMT exercises.
2507149|NCT02851719|Active Comparator|PFMT group|24 outpatient sessions (twice a week) of PFMT without BF and daily home PFMT exercises.
2507212|NCT02851303|Active Comparator|Morphine|"Dose given q 3 - 4 hrs with feeds; do not exceed 4 hrs between doses Morphine (0.04mg/0.1ml)~Score Dose For Initiation 0-8 0 None 9-12 0.04 mg/dose 13-16 0.08 mg/dose 17-20 0.12 mg/dose 21-24 0.16 mg/dose 25 or above 0.20mg/dose~Morphine Maintenance/Escalation~Maintain dose if score 0-8~Increase dose by 0.02 if score is 9-12 (rescore before dosing) • Increase dose by 0.04 if score 13-16~Increase score by 0.06 if score 17-20~Weaning Instructions:~Maintain on dose 48 hrs before starting weaning~Wean 0.02 mg morphine every day for a score is 0-8 • Defer wean for score 9-12~Re-escalation~If neonate scores 9-12 re-score as described for initiation,~If second score is in 9-12 increase morphine 0.01 mg q3-4 hrs • If 2 consecutive scores 13-16, increase 0.02 mg q3-4 hrs~If 2 consecutive scores in 17-20, increase 0.04 mg q3-4 hrs etc"
2507213|NCT02851303|Active Comparator|Methadone|Step 1: 0.7 mgs/Kg/24 hrs. divided by into six doses (q 4 hrs) is starting dose Step 2: Decrease dose by half, which is 50% of starting dose, EVERY 4 hours. Step 3: Same dose which is 50% of starting dose EVERY 6 hours. Step 4: Same dose which is 50% of starting dose EVERY 8 hours. Step 5: Same dose which is 50% of starting dose EVERY 12 hours. Step 6: Decrease dose by half, which is 25% of starting dose EVERY 12 hours. Step 7: Same dose which is 25% of starting dose q 24 hours
2507290|NCT02850835|Experimental|Video Decision Aid|This group will be shown a video decision aid along with their standard of care.
2507293|NCT02850835|No Intervention|Standard Care|This group will not see the video decision aid and will only receive standard of care.
2507341|NCT02850367|Active Comparator|Acute intake|Evaluation after acute intake of the food supplement.
2507349|NCT02850367|Active Comparator|Chronic intake|Evaluation before and after chronic intake of the food supplement.
2507399|NCT02849756||older in intensive care unit|older (age superior at 85 years) hospitalized in intensive care unit. A follow-up until 6 months after hospitalization will determine the evolution of the quality of life and others secondary outcomes.
2507425|NCT02849483|Experimental|Ramosetron|2 ml of normal saline iv before induction, ramosetron 0.3 mg iv at the end of surgery, ramosetron 0.6 mg added to the iv PCA(Patient-Controlled Analgesia)
2507427|NCT02849483|Placebo Comparator|Control|dexamethasone 10 mg iv before induction, 2 ml of normal saline iv at the end of surgery, 4 ml of normal saline added to the iv PCA
3196679|NCT00852839|Placebo Comparator|Placebo|
2506230|NCT02858063||Pending chemotherapy +/- trastuzumab|In the 1st group (chemotherapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2506231|NCT02858063||pending trastazumab +/- hormone therapy|In the 2nd group (trastazumab), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2506232|NCT02858063||pending hormone therapy alone|In the third group (hormone therapy), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2506233|NCT02858063||pending afercare period|In the last group (aftercare), 25 couples will answer to kalicou questionnaire (KALI), 25 couples to KALI plus QLQC-30 and QLQBR-23 questionnaires for patients and SF-36 questionnaire for their partners. 25 couples will answer to KALI plus STAI plus CES-D questionnaires and 25 couples will ansmwer twice to KALI questionnaire, with a delay of 15 days between each other
2506289|NCT02857868|Experimental|ABL001|
2506334|NCT02857491|Experimental|ranibizumab|Intravitreal Injection of 0.5 mg ranibizumabone week before vitrectomy.
2506337|NCT02857491|Sham Comparator|control|Sham intravitreal injection one week before vitrectomy.
2506514|NCT02856152|Experimental|Treatment A Then B Then D Then C|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment A on Day 1 of first intervention period, followed by Treatment B on Day 1 of second intervention period, followed by Treatment D on Day 1 of third intervention period, and then Treatment C on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2506516|NCT02856152|Experimental|Treatment B, Then C, Then A, Then D|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment B on Day 1 of first intervention period, followed by Treatment C on Day 1 of second intervention period, followed by Treatment A on Day 1 of third intervention period, and then Treatment D on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2506517|NCT02856152|Experimental|Treatment C, Then D, Then B, Then A|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment C on Day 1 of first intervention period, followed by Treatment D on Day 1 of second intervention period, followed by Treatment B on Day 1 of third intervention period, and then Treatment A on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2506518|NCT02856152|Experimental|Treatment D, Then A, Then C, Then B|Treatment A: a single dose of three 90-mg capsules of GDC-0276 administered orally after at least an 8-hour fast. Treatment B: a single dose of three 90-mg tablets GDC-0276 administered orally after at least an 8-hour fast. Treatment C: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized FDA high-fat meal. Treatment D: a single dose of three 90-mg tablets of GDC-0276 administered orally within 30 minutes of eating a standardized low-fat meal. Participants will receive Treatment D on Day 1 of first intervention period, followed by Treatment A on Day 1 of second intervention period, followed by Treatment C on Day 1 of third intervention period, and then Treatment B on Day 1 of fourth intervention period. A washout period of 6 days will be maintained between each intervention period.
2506548|NCT02855749|No Intervention|landmark group|percutaneous tracheostomy with traditional landmark technique
2506550|NCT02855749|Active Comparator|ultrasound-guided long axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided in plane technique
2506551|NCT02855749|Active Comparator|ultrasound-guided short axis group|percutaneous tracheostomy will be implemented In the real-time ultrasound-guided out of plane technique
3196680|NCT00852852|Experimental|Intervention|Patient participants in the intervention arm can access educational information about self-care strategies, track and share reports of their symptoms and quality of life issues over time, and receive coaching on how to discuss these issues with their care team.
2506705|NCT02854943||Critically ill patients|Male and female critically ill patients admitted to the Charité - University Medicine Berlin during 2000 and 2018.
3196681|NCT00852852|No Intervention|Control|Participants in the control arm access the ESRA-C from home or clinic to self-assess only.
3196682|NCT00852865|Experimental|1|24 healthy volunteers consuming L.farciminis during three weeks
3196683|NCT00852865|Placebo Comparator|2|24 healthy volunteers consuming placebo during three weeks
3196684|NCT00852878|Active Comparator|Biofeedback|heart rate variability biofeedback
2507134|NCT02851979|Experimental|S2 - S1 - S0|S2 = olfactory stimulation; washout; S1 = vehicle; washout S0 = no stimulation
2507155|NCT02851797|Active Comparator|givinostat|Givinostat oral suspension (10 mg/mL) twice daily in a fed state
2507159|NCT02851797|Placebo Comparator|placebo|Placebo oral suspension (10 mg/mL) twice daily in a fed state
2506238|NCT02858037|Experimental|HIV Open-label Prevention|"Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women~MTN-020:NCT01617096 MTN-025: NCT02858037"
2506302|NCT02857803|Experimental|Virtual Reality|The Virtual Reality group will perform personalised activities of daily living in the context of a simulated city (Reh@City). The interaction with the virtual environment will be through a natural user interface.
2506307|NCT02857803|Active Comparator|Paper and Pencil|The paper and pencil group will perform a set of cognitive paper and pencil tasks personalised to their deficits and generated automatically through a Task Generator.
2506309|NCT02857803|Active Comparator|Conventional Therapy|The Conventional Therapy group will perform the activities offered by the public health system, which are motor-focused.
2506338|NCT02857309|Other|Device implant|Patients randomized to the treatment group will receive optimal medical therapy for heart failure. and implantation of the OPTIMIZER System.
2506339|NCT02857309|Active Comparator|Optimal medical therapy|Patients randomized to the control group will receive optimal medical therapy for heart failure.
2506383|NCT02856893|Experimental|Osimertinib till progression|Osimertinib until PD according to RECIST 1.1
2506389|NCT02856893|Experimental|Gefitinib till + blood test/progression than Osimertinib|"Gefitinib until emergence of positive T790M status (cfDNA T790M positive progression) followed by Osimertinib until second PD according to RECIST 1.1"
2506392|NCT02856893|Active Comparator|Gefitinib till progression than Osimertinib|Gefitinib until PD according to RECIST 1.1 followed by Osimertinib until PD according to RECIST 1.1
2506428|NCT02856464|Experimental|Experimental|
2506431|NCT02856464|Other|Control|
2506470|NCT02856373|Other|CPVT|catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
2506474|NCT02856373|Other|long QT syndrome|long QT syndrome patients
2506477|NCT02856373|Other|ARVC|arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
2506479|NCT02856373|Other|HCM|hypertrophic cardiomyopathy (HCM) patients
2506481|NCT02856373|Other|DCM|dilated non-ischemic cardiomyopathy (DCM) patients
2506483|NCT02856373|Other|ICM|ischemic cardiomyopathy (ICM) patients
2506538|NCT02855996|Experimental|Intervention|"Fathers will be randomly assigned to participate in the Fathers in Action/Padres Activos (FA/PA) intervention program to support fathers' healthy relationships with their children and support their co-parenting skills."
2506539|NCT02855996|No Intervention|Control|"Fathers waitlisted for participation in the Fathers in Action/Padres Activos (FA/PA) program."
2506556|NCT02855619|Active Comparator|Martin|A threshold-based IMT is performed like used by Martin in a randomized trial in 2011, in a view of inspiratory strength increase.
2506560|NCT02855619|Active Comparator|Cader|A threshold-based IMT is performed like used by Cader in a randomized trial in 2012, in a view of inspiratory endurance increase.
2506563|NCT02855619|Experimental|EDRIC|A new threshold-based IMT is performed, in a view of both inspiratory strength and endurance increase.
3196685|NCT00852878|Active Comparator|Behavioral|Behavioral intervention will provide parent and child with a variety of pain management techniques such as relaxation, distraction, contingency management, and coping statements
3196686|NCT00852904||NCS Vanguard cohort|Women of child bearing potential, children born to women enrolled in the study, the children s biological and/or social fathers, and primary caregivers (if other than parent)
2506730|NCT02854735||Head and neck neoplasm|Patients with stage III-IV head and neck cancer (squamous cell carcinoma) patient undergoing CCRT
2506813|NCT02854384||Epilepsy Patients|males and females whose age more than 18 years, diagnosed with epilepsy, regardless of whether symptomatic,idiopathic ,focal or generalized
2506814|NCT02854384||Healthy Control|males and females whose age more than 18 years
2506996|NCT02852850||Molecular Imaging With IFX-FITC|Endoscopic examination with the fluorescent antibody (IFX-FITC) was performed in patients with active ulcerative colitis before infliximab therapy was initiated. Labeled infliximab was applied topically via a standard spray catheter onto the most inflamed region of the bowel during colonoscopy, followed by CLE. In vivo imaging of inflamed areas of the intestinal mucosa showed a specific fluorescence signal of mTNF+ cells after topical application of labeled adalimumab. These specific fluorescence signals were recorded.
2507043|NCT02852642|Experimental|Exercise|Power training model based in the potentiation of the stretch-shortening cycle.
2507051|NCT02852642|No Intervention|Control|Maintaining daily activities
2507105|NCT02852291|Experimental|Parents Make the Difference|Parents Make the Difference (Caregivers attend 10 group parent training sessions)
2507106|NCT02852291|Experimental|Parents Make the Difference Plus|Parents Make the Difference Plus (Caregivers attend 10 group parent training sessions and receive 3 home visits)
2507107|NCT02852291|No Intervention|Waitlist Control|No parenting intervention until the end of the study period
3196687|NCT00852956|Experimental|Treatment|Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
3196688|NCT00852956|Active Comparator|Control|Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
3196689|NCT00852982|Experimental|Exercise|Five hours of Nordic walking per week, during four months
2507334|NCT02850172|Experimental|Walk, eat, & breathe group|"Participants in the experimental group will receive Walk, Eat, & Breathe at initiation of CCRT and ends before curative surgery."
2507344|NCT02850172|No Intervention|Control group|Participants in the control group received usual care.
3196690|NCT00852982|No Intervention|Control|Control group asked not to alter lifestyle during study
3196691|NCT00853034|Active Comparator|FOS-IN|prebiotic fructo-oligosaccharide enriched inulin
2507445|NCT02849301|Experimental|Cervical pessary|Arabin cervical pessary
2507454|NCT02849301|No Intervention|Standard care|No treatment
2507788|NCT02847286|Active Comparator|Treatment C|Clotrimazole, 5 g per day for 7 days
3196692|NCT00853034|Experimental|AXOS|arabinoxylan-oligosaccharides (AXOS)
3196693|NCT00853086||A|
3196694|NCT00853138|Experimental|CBT|Cognitive-behavioral therapy delivered via the internet in eight treatment modules for children (education, stress and negative emotions, deep breathing and relaxation, distraction, cognitive skills, sleep hygiene and lifestyle, staying active, relapse prevention) and eight treatment modules for parents (education, stress and negative emotions, operant strategies I, operant strategies II, modeling, sleep hygiene and lifestyle, communication, relapse prevention).
3196695|NCT00853138|No Intervention|SMC|The standard medical care wait-list control group continued with the treatment recommendations proscribed by their pain care team.
3196696|NCT00853164|Experimental|aerobic exercise|Subjects who are randomly assigned to this arm will be assigned a walking program to participate in 3 times a week for eight weeks
3196697|NCT00853164|Experimental|resistence training|Subjects who are randomly assigned to this arm will be assigned a weight training program to participate in 3 times a week for eight weeks
3196698|NCT00853164|Active Comparator|Usual Care|Subjects who are randomly assigned to this arm will not participate in any exercise program and will continue with usual care treatment
3196699|NCT00853177|Experimental|nitrous oxide|"N2O of 50% and 50% O2~MEOPA"
2506892|NCT02853617|Experimental|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
2506893|NCT02853617|Experimental|AV0328 - Cohort 2|Cohorts 2 will receive 30 µg to be given as an IM injection
2506894|NCT02853617|Experimental|AV0328 - Cohort 3|Cohorts 3 will receive 75 µg to be given as an IM injection
2506896|NCT02853617|Experimental|AV0328 - Cohort 4|Cohorts 4 will receive 150 µg to be given as an IM injection
2506912|NCT02853240|Experimental|Children with spastic CP receiving toxin injections|Children with spastic cerebral palsy receiving toxin injections
2506946|NCT02853149|Experimental|Spinal Cord Injury (SCI)|Experimental: Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) for Spinal Cord injury individuals enrolled with their caregivers, can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
2506947|NCT02853149|Active Comparator|Caregiver Intervention(CCC)|Lifestyle Intervention This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life using a 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
2506948|NCT02853149|Placebo Comparator|Caregiver Control (CC)|Placebo: This arm will examine whether a twelve month treatment program (one year) enrolled with their Care-receivers( SCI individuals) can lower body weight, reduce body fat, reduce risk factors for developing heart disease and diabetes, and improve the quality of life. The control group intervention will test benefits of exercise alone while controlling for investigator contact.
2507000|NCT02852837|Experimental|Part 1: Dose Escalation Part|Participants will receive single dose of daratumumab from Week 1 till Week 3 (Period 1 - single dosing period) followed by 6 weekly doses of daratumumab until Week 9 (Period 2 - weekly dosing period) and every 2 weeks for 8 infusions and then once every 4 weeks from Week 26 until disease progression, intolerability, or other reasons for treatment discontinuation (Period 3 - less intense dosing period). A dose of 8 milligram per kilogram (mg/kg) will be chosen as the starting dose and will be escalated to 16 mg/kg if the 8 mg/kg is determined safe and tolerated by study evaluation team (SET).
2507003|NCT02852837|Experimental|Part 2: Pharmacokinetic (PK) Expansion Part|Participants will receive daratumumab at 16 mg/kg in 3 periods as given in the Part 1.
2507004|NCT02852837|Experimental|Part 3: Safety Expansion Part|Participants will receive daratumumab 16 mg/kg every week for 8 weeks followed by every 2 weeks for an additional 16 weeks, and then every 4 weeks thereafter. Participants will be treated with daratumumab until disease progression, intolerability, or any other reasons for treatment discontinuation.
2507052|NCT02852473|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP) will be administered using FDA-approved equipment.
2507096|NCT02851992|Other|GTS cementless stem|Total Hip arthroplasty with GTS cementless stem (standard and lateralized) with different cup and bearing options (metal-on-polyethylene or ceramic-on-polyethylene)
2507211|NCT02851368|Other|Near Infrared Fluorescence Imaging with Indocyanine Green|Patients will receive an injection of indocyanine green (ICG) 1 day prior to surgery. Near infrared fluorescence imaging (NIFI) will be used to identify pulmonary nodules during the surgical biopsy and/or resection procedure.
2507269|NCT02850887|Active Comparator|general endotracheal anesthesia|an inhalation anesthetic (substance that blocks pain) technique in which anesthetic and respiratory gases pass through a tube placed in the trachea (throat) via the mouth or nose
2507278|NCT02850887|Active Comparator|deep sedation without endotracheal intubation|local anesthesia together with sedation (drug that produces sleep) and analgesia (drug that treats pain) only.
2507320|NCT02850458||implant retained-overdentures with the attachment of bar|patients treated with implant-retained overdentures,and the attachment is bar
2507323|NCT02850458||implant retained-overdentures with the attachment of magnet|patients treated with implant-retained overdentures,and the attachment is magnet
2507397|NCT02850055|Experimental|Specific Manual Therapy Group|Conventional Physiotherapy and Specific manual therapy, six one hour treatment sessions. An hour for week.
2507400|NCT02850055|Active Comparator|Multimodal Group|Conventional Physiotherapy, six one hour treatment sessions. An hour for week.
2507431|NCT02849431|Experimental|Mindfulness-based intervention|
2507482|NCT02849236|Placebo Comparator|Control group|PECS block performed with Saline solution instead of local anesthetic
2507484|NCT02849236|Experimental|PECS group|PECS block performed with Ropivacaine 3.75mg/mL
2507542|NCT02848885|Experimental|Active TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere parietal (P3 cathodal, P4 anodal) stimulation daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
2507620|NCT02848352|Placebo Comparator|Placebo control group|Participants receive a nasal spray that is a placebo and are told that it is a placebo. Participants watch a film sequence that is supposed to induce sadness.
3196700|NCT00853177|Active Comparator|lidocaine|Injection solution 1%
2506380|NCT02856854|Experimental|EMB-001 (oral)|EMB-001 will be orally administered for 7 consecutive days, twice daily for 6 days followed on the last day by one EMB-001 oral dose (QD) in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
2506384|NCT02856854|Placebo Comparator|Placebo (oral)|PLB-to-match EMB-001 will be orally administered for 7 consecutive days, BID for 6 days, followed on the last day by one PLB oral dose in the morning. Three hours later Cocaine IV or Saline IV will be administered followed 2 hours by the other (saline or cocaine).
2506462|NCT02856529|Experimental|Intervention|A BICSL certified trainer conduct the intervention. It includes hand on training session standardized in a scientific way. The participants trained on hand hygiene and use of PPE. Also, it includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator.
2506464|NCT02856529|Active Comparator|Control|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
2506520|NCT02856126|Experimental|HAIC plus sorafenib|Procedure/Surgery: Hepatic arterial infusion chemotherapy Drug: HAIC Regimen Drug: Oral Sorafenib
2506521|NCT02856126|Active Comparator|TACE plus sorafenib|Procedure/Surgery: Transarterial chemoembolization Drug: TACE regimen Drug: Oral Sorafenib
2506549|NCT02855697|Experimental|Olaparib +/- cediranib|Patients are administered two courses of maintenance olaparib following chemotherapy. It is possible for patients to take cediranib during the second course of olaparib if recommended as per the protocol.
2506644|NCT02855255|Active Comparator|NHS smoking cessation|NHS 1-1 smoking cessation programme. One thirty minute session followed by up to five shorter sessions (approx.10/15minutes) comprising Cognitive Behavioural Therapy/Motivational Interviewing to assist with smoking cessation.
2506645|NCT02855255|Active Comparator|Allen Carr's Easyway smoking cessation|Group smoking cessation programme. One 5/6 hour group session (plus one or two 3 hour booster sessions over the following 3 months for those who require them) comprising of Allen Carr's Easyway method being delivered in a spoken form.
2506688|NCT02854995|Other|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce.
2506689|NCT02854995|Other|preputioplasty with intralesional injection of triamcinolone|(ii) preputioplasty with intralesional injection of triamcinolone: longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile.
3196701|NCT00853190|Experimental|A|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule
3196702|NCT00853190|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
3196703|NCT00853203||Part 1|Interviews + Questionnaire + Electronically Activated Recorder (EAR)
2506846|NCT02854020||An asian airline|
2506874|NCT02853682||presence of a vascular dysfunction|plasma
2506877|NCT02853682||absence of vascular dysfunction|plasma
3196704|NCT00853203||Part 2, Expressive Disclosure Group|Group Meetings + Written Materials
2507103|NCT02852200||SEGAm|Elderly community-dwelling people
2507161|NCT02851758|Experimental|Autologous mitochondria injection|All subjects will have autologous mitochondria injected into ischemic areas of the myocardium (via injection or infusion).
2507186|NCT02851238|No Intervention|Protective Ventilation|The control arm receives existing conventional protective ventilation with tidal volume of 6mL/kg of ideal body weight and positive end expiratory ventilation of 5cmH2O during one-lung ventilation
2507187|NCT02851238|Experimental|Driving Pressure Limited Ventilation|The intervention arm receives driving pressure limited ventilation during one-lung ventilation
2507199|NCT02851095|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 50 milligram (mg) along with two Extended Release (XR) tablet of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D of (1 XR fixed dose combination [FDC] tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 50 mg and 1 metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg along with 2 metformin (XR) tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507201|NCT02851095|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507202|NCT02851095|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507204|NCT02851095|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507272|NCT02850757|Experimental|U shaped Guedl's airway|
2507282|NCT02850757|Experimental|Modified William's airway(Fekry airway )|
2507322|NCT02850445|Experimental|Integrated Treatment|
2507328|NCT02850445|Active Comparator|antipsychotic medication alone treatment|
2507386|NCT02850016|Experimental|Group A|Two treatment cycles each consisting of 3BNC117 infusions (30mg/kg) + three romidepsin infusions (5mg/m2). 3BNC117 will be administered on Days 0 and 56. Romidepsin will be administered on days 2, 9, 16, 58, 65, and 72 .
2507391|NCT02850016|Experimental|Group B|Two treatment cycles each consisting of three romidepsin infusions (5mg/m2). Romidepsin will be administered on days 0, 7, 14, 56, 63, and 70 .
3196705|NCT00853203||Part 2, Standard Care Control Group|Written Materials
3196706|NCT00853216|Experimental|A|Oxycodone hydrochloride tablet 30 mg
3196707|NCT00853216|Active Comparator|B|Roxicodone™ tablet 30 mg
3196708|NCT00853255|Experimental|1|Participants will receive 0.5 mL of vaccine intranasally via an Accuspray device (0.25 mL in each nostril)
2506409|NCT02856815|Experimental|Immuncell-LC group|Adjuvant adoptive immune therapy using a CIK cell agent(Immuncell-LC) 12 times(5 treatments at a frequency of once per week, followed by 5 treatments every 2 weeks, and finally 2 treatments every 4 weeks.
2506410|NCT02856815|No Intervention|Non-treatment group|Non-treatment
2506532|NCT02855931|Experimental|Middle turbinate resection|Resection of one middle turbinate
2506533|NCT02855931|No Intervention|Middle turbinate preservation|Preservation of one middle turbinate
2506568|NCT02855684|Experimental|Toujeo - insulin glargine (U300)|Toujeo - Insulin glargine (U300) will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
2506572|NCT02855684|Active Comparator|Lantus - insulin glargine|Lantus - Insulin glargine will be administered subcutaneously once in the evening on top of the non-insulin antihyperglycemic drugs for 29 weeks
2506679|NCT02855008|Experimental|STEPS|Experimental: Individuals with ID and residential staff in group homes receive 6 one-hour STEPS sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games to build group cohesiveness, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice social problem-solving skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
2506680|NCT02855008|Active Comparator|Food for Life|Active Comparator: Individuals with ID and residential staff in group homes receive 6 one-hour Food for Life sessions over 12 weeks and a booster in week 18 following a standardized manual. Sessions include interactive games regarding food and nutrition followed, along with interactive discussion and practice. Participants are given session materials and 1-2 worksheets to practice learned skills and are asked to return the worksheets at the next session. Residential staff are given additional materials with tips on how to help residents practice Food for Life skills between sessions. Highlights of each session using a standardized format are brought to the following session to help with engagement and provide cues for retention of materials.
2506728|NCT02854683|Experimental|Normal Saline|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
2506729|NCT02854683|Experimental|Oral rehydration solution|Subjects will receive 1 liter of intravenous normal saline over 1 hour and on an alternate day Subjects will drink ORS solution 1 liter total by mouth over 20 minutes.
2506803|NCT02854293||Booklet-Question List (BQL) group|76 patients
2506804|NCT02854293||control group|"Conventional palliative management~76 patients"
2506839|NCT02853942|Experimental|Stem cell therapy group|Using the international standard 14G (diameter 1.54mm) needle inject autologous adipose derived mesenchymal stem cells 2ml to facial nerve, the effective release of the concentration is 100 million stem cells / ml.
2506843|NCT02853942|Experimental|Neurotrophic drugs treatment group|Patients were treated with routine drug therapy，do not inject stem cell to the facial nerve of patient
2506985|NCT02853045|Experimental|period with drug (trade name) then period with generic|Period of 6 weeks.
2506986|NCT02853045|Experimental|period with generic then period with drug (trade name)|Period of 6 weeks.
2507050|NCT02852551|Experimental|PAT-1251 Single Dose|Oral solution of PAT-1251, 150 - 4000 mg administered once
2507056|NCT02852551|Placebo Comparator|Placebo Single Dose|Matching placebo solution administered once
2507059|NCT02852551|Experimental|PAT-1251 Multiple Dose|Oral tablet(s) of PAT-1251 up to 2000 mg administered daily for 7 days
2507061|NCT02852551|Experimental|Placebo Multiple Dose|Matching placebo tablets administered daily for 7 days
2507101|NCT02852148|Experimental|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
2507145|NCT02851745|Experimental|Linagliptin|Linagliptin 5 mg daily for 48 weeks
2507150|NCT02851745|Placebo Comparator|Placebo|Placebo 5 mg daily for 48 weeks
2507242|NCT02851186|Experimental|Electroacupuncture (EA) and Auricular Acupuncture (AA)|Subjects in the treatment group will receive EA combined with AA two hours before operation, immediately post-operation and once a day for the subsequent 5 days.
2507245|NCT02851186|Sham Comparator|Sham acupuncture|Subjects in the control group will receive non-invasive sham procedure in the same schedule as the treatment group.
2507258|NCT02850744|Other|Single-arm|Open label, single arm including patients with progressive glioblastoma during or after temozolomide chemotherapy obtaining PQR309 80mg capsules.
2507338|NCT02850549|Other|physical therapy|Physical Therapy intervention provided by therapists in phase one without training in following a neck classification system and in phase two after being trained to follow a neck pain classification system.
2507421|NCT02849652|Experimental|ATTOC|Addressing Tobacco Through Organizational Change is a multi-phase organizational intervention to promote the treatment of tobacco dependence
2507424|NCT02849652|Other|Usual Care|Usual Care is the typical guideline based smoking cessation intervention
2507471|NCT02849288|Experimental|Intervention|Use of the Investigational Bigfoot Type 1 Diabetes Management System (T1DMS)
2507483|NCT02849028||TBI Patients with sleep disorder|All the patients should be diagnosed by polysomnographic (PSG)
2507485|NCT02849028||health people|The people have a normal sleep
2507560|NCT02848872||NSCLC patients|Resected patients
2507617|NCT02848287|Placebo Comparator|Normal Saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
2507622|NCT02848287|Experimental|Ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
2507644|NCT02847910|Experimental|experimental group|device： High-tech disposable tissue suction set for uterine cavity tissue is produced by Xi'an Mejiajia Medical Equipment Company ; The participants will be use the disposable tissue suction set during the induced abortion procedure.
2506427|NCT02856789||Patients without coagulation disorder|"Hospitalized patients without coagulation disorder or abnormal hemostasis and hematological results and witout ongoing treatment (mainly anticoagulant treatment). FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
2506430|NCT02856789||Patients with coagulation disorders|"Hospitalized patients with coagulation disorders, mainly trauma patients or abnormal hemostasis and hematological results, mainly decreased fibrinogen level . FS and TEG will be processed to determine the most relevant parameters to discriminate patients from normal range and the correlation between assays.~Tests performed on patients :~Routine hemostasis tests~Fibrin structure (FS)~Thromboelastography (TEG)"
2506461|NCT02856308|Experimental|Hairstetics hair implant device|Subjects will undergo the Hairstetics prosthetic hair implantation starting with a test of up to 100 fibers and up to 2 additional implantation sessions with up to 1500 fibers overall per subject. The implantation will be carried out according to the device IFU.
2506502|NCT02856061|Other|PRT|Children with ASD who are currently receiving PRT treatment.
2506507|NCT02856061|No Intervention|Wait List / Non-Treatment Control|Children with ASD who are not currently receiving PRT treatment.
2506511|NCT02856061|No Intervention|Typically Developing|Children without ASD or developmental delay.
2506592|NCT02855580||PGX Testing Based Treatment|Treatment will be administered based on the results that are obtained from the pharmacogenomics testing. Results from testing will be provided two weeks after specimen collection.
2506594|NCT02855580||Standard of Care Treatment|Treatment will be based off of the standard of care. Results from pharmacogenomics testing will be provided at the end of the study.
2506745|NCT02854787|Active Comparator|Phenylephrine|A bolus of 100 mcg
2506746|NCT02854787|Active Comparator|Norepinephrine|A bolus of 0,2 mcg/kg
2506832|NCT02854072|Experimental|GV1001 + gemcitabine/capecitabine|
2506835|NCT02854072|Active Comparator|gemcitabine/capecitabine|
2506973|NCT02853084|Experimental|HL2351|
2507038|NCT02852707||Unilateral overhead throwing athletes|Volleyball attackers involved in competitive events ≥ 2 years, ≥18 years of age
2507042|NCT02852707||Bilateral overhead athletes|Swimmers involved in competitive events ≥ 2 years, ≥18 years of age
2507044|NCT02852707||Non-athletes|Persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers), ≥18 years of age
2507097|NCT02852135|Experimental|LMA Proseal group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Prosealgroup,LMA Proseal was inserted into each patient after anesthesia induction.
2507099|NCT02852135|Experimental|LMA Supreme group|The patients were randomly allocated to two groups by using computer-generated numbers.In LMA Supreme group,LMA Supreme was inserted into each patient after anesthesia induction.
2507146|NCT02851771|Experimental|Pneumonia Patients|Patient admitted at hospital with pneumonia, who need a microbiological diagnosis
2507207|NCT02851394|Active Comparator|Levobupivacaine group|
2507209|NCT02851394|Experimental|Levobupivacaine + tramadol group|
2507270|NCT02850913|Active Comparator|Doxycycline|"115 participants will be randomized to oral Doxycycline 100 mg daily for six weeks.~Each capsule contains doxycycline hyclate equivalent to 100 mg of doxycycline base.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
2507283|NCT02850913|Placebo Comparator|Placebo|"115 participants will be randomized to the placebo arm for matching capsules containing no active ingredients daily for six weeks.~Placebo will be initiated in hospital but will be continued at home.~Scheduled study clinic and home visits will be conducted at 6, 12, 24 months and at 2, 4 and 6 weeks respectively for adherence monitoring and assessment of safety."
2507311|NCT02850302|Other|FDG PET + exome analysis before treatment and after|Participants will performed one PET with FDG an tumor exome analysis before treatment is started.After 6 cycles of chemotherapy a second PET with FDG and a second tumor exome analysis will be performed
2507363|NCT02850120||Unconfounded|"All hospital admissions including Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with:~no concomitant procedures,~any concomitant procedures which were considered unlikely to have an effect on outcomes from their mesh insertion, or~only other concomitant procedures which were considered likely to be rescue procedures treating complications caused by the mesh insertion procedure itself."
2507364|NCT02850120||Confounded|All hospital admissions for insertion of Tension-free Vaginal Tape (TVT), Trans-obturator tape (TOT) or suprapubic sling (SS) procedures with concomitant procedures likely to affect outcomes.
2507403|NCT02849743|Experimental|Syntocinon (= Oxytocin), then Placebo|"Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks) *Dose Escalation, as appropriate, at 2 Weeks"
2507404|NCT02849743|Experimental|Placebo, then Syntocinon (= Oxytocin)|"Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)~Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)"
2507448|NCT02849392|Experimental|Pistachio|Pistachio added 20% of kcals to diet
2507451|NCT02849392|No Intervention|No Pistachio|No pistachios in diet (control)
2507624|NCT02848352|Other|No-treatment control group|Participants do not receive the nasal spray. Participants watch a film sequence that is supposed to induce sadness.
3196709|NCT00853268|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
2506510|NCT02856113|Placebo Comparator|Placebo|Alogliptin placebo-matching tablets, orally, once daily for 52 weeks and background antidiabetic therapy (metformin and/or insulin), if applicable, maintained at the same dose throughout the first 26 weeks of the treatment period.
2506709|NCT02854644|Experimental|glioma|1 additional blood sample for patients with glioma and without treatment
2506711|NCT02854644|Experimental|breast cancer|2 additional blood samples for patients with localized brest cancer, metastatic breast cancer in 1st line of treatment and breast cancer in second line of treatment.
2506713|NCT02854644|Experimental|breast cancer HER2+|1 additional blood sample for patients with metastatic breast cancer with HER2 surexpression
2506715|NCT02854644|Experimental|Breast Cancer HER 2+ or HER2 triple -|1 additional blood sample for patients with breast cancer HER2 + or HER2 triple negative treated by neo adjuvant
2506731|NCT02854475|Experimental|Proband group|Raman spectroscopy and venous blood collection
2506817|NCT02854358|Active Comparator|control|In the control group, patients received Hypozalix (artificial saliva)spray three times per day for a period of four weeks.
2506819|NCT02854358|Experimental|intervention|Patients in intervention group received sachets containing 4 grams of mixed powder of A. digitata and M. sylvestris (in a proportion of 1:1), three times per day for a period of four weeks
2506876|NCT02853825|No Intervention|Wait List Control Group|No interventions given, this is a wait list control group.
2506880|NCT02853825|Experimental|Intervention Group|Receive relationship skill enhancement classes with access to parenting, employment services, and financial services.
3196710|NCT00853268|Active Comparator|B|OxyContin® 40 mg tablet
3196711|NCT00853281|Experimental|Hammocks with LLIN|Locally-made hammocks covered with long-lasting insecticidal net (LLIN)- Olyset(R), used in addition to the standard vector control measures
2507046|NCT02852460|Experimental|Experimental group|rapid recovery
2507057|NCT02852460|No Intervention|Controlled group|non-rapid recovery
2507172|NCT02851498|Experimental|Novel high-protein pasta and cereal|High-protein pasta (orzo and fusilli) enriched with gluten and egg white protein (%energy: 27/30/43 for protein/fat/carbohydrate) and high-protein flaked breakfast cereal enriched with gluten (%energy: 30/35/35 for protein/fat/carbohydrate) were manufactured by Zone Inc.(Boston, MA). The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as control meals.
2507174|NCT02851498|Sham Comparator|Control pasta and cereal|Commercial gluten-free pasta (Barcilla orzo and fusilli; %energy: 13/24/63 for protein/fat/carbohydrate) and commercial flaked cereal (Post Honey Bunches of Oats; %energy: 6/18/76 for protein/fat/carbohydrate) were used as the control foods. The study foods provided an average of 945 kcal/day (one aliquot of cereal and two pasta dishes daily). Pasta meals were prepared in a metabolic kitchen and were identical in appearance and basic taste as experimental foods.
2507247|NCT02851199|Active Comparator|study group 1|1. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the prone position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. Finally the participants will performed additional 3 minutes of hyperventilation in the sitting position
2507248|NCT02851199|Active Comparator|study group 2|2. A group of 15 children who will undergoe an electroencephlaography recording with 3 minutes of hyperventilation in the sitting position, followed by 5 minutes of rest, then after another 5-10 minutes of recording with normal breathing. . Finally the participants will performed additional 3 minutes of hyperventilation in the
2507266|NCT02850731|Experimental|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
2507273|NCT02850731|No Intervention|supervision by a therapist|an adapted physical activity program under supervision of a therapist
2507317|NCT02850510|Experimental|Brief Incredible Years parent training|Parent training
2507318|NCT02850510|No Intervention|No parent training|No parent training
2507365|NCT02850107|Other|Non-randomized|"Directional Atherectomy + Drug Coated Balloon: DA followed by DCB will be performed in all enrolled subjects.~DA includes the use of Intervention 'Medtronic HawkOne® or TurboHawk™.~Medtronic Spider™ Distal Protection Device (DPD) is recommended for use according to IFU.~Medtronic IN.PACT® Admiral® DCB will be used after DA.~Volcano Visions® PV .014 IVUS catheter required to assess lesion in each procedure.~Nitinol Stent Placement: Only FDA approved nitinol stents can be used if provisional stenting is required."
2507406|NCT02849691||Quartile 1|Quartile 1 of plasma DPP4 activity
2507408|NCT02849691||Quartile 2|Quartile 2 of plasma DPP4 activity
2507409|NCT02849691||Quartile 3|Quartile 3 of plasma DPP4 activity
2507411|NCT02849691||Quartile 4|Quartile 4 of plasma DPP4 activity
2507436|NCT02849444||Moderate kidney failure|30 ≤ CrCl < 50 mL/min/1.73 m2
2507440|NCT02849444||Severe kidney failure|CrCl < 30 mL/min/1.73 m2
2507537|NCT02848911|Experimental|AFM11|IV (intravenous) infusion, dose escalation
2507584|NCT02848209|No Intervention|Control|No peeling applied on the skin flap
2507588|NCT02848209|Experimental|Drug: TCA 20% Peeling|Trichloroacetic acid 20% applied on the skin flap until even frosting for 2-4 minutes.
2507591|NCT02848209|Experimental|Drug: TCA 40% Peeling|Trichloroacetic acid 40% applied on the skin flap until even frosting for 2-4 minutes.
2507592|NCT02848209|Experimental|Drug: Phenol/croton oil Peeling|Phenol/croton oil applied on the skin flap occluded with silicone tape for 24 hours and not neutralized.
2507657|NCT02847936|Active Comparator|VICRYL PLUS|triclosan-coated sutures
2507661|NCT02847936|Active Comparator|VICRYL|non antibacterial coated sutures
2507824|NCT02846610||regional anesthesia|surgical patients (age: 0-100 years) having regional anesthesia along with the procedure and postoperative course
2507832|NCT02846610||systemic analgesia|surgical patients (age: 0-100 years) having systemic analgesia along with the procedure and post procedure course
3196712|NCT00853281|Active Comparator|ITN|Standard vector control measures (insectice-treated net or ITN)
2506559|NCT02855632|Placebo Comparator|Normal saline|equal volume of normal saline(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
2506623|NCT02855372||Lung transplanted patients|
2506664|NCT02855138|Active Comparator|study group|The study group consisted of 40 volunteers women with PCOS (aged 18- 40 years, BMI, 18-44kg/m2) who attended the obstetrics and gynecology clinic for the treatment of menstrual irregularities and hirsutism.The patients were treated with 0.6-0.8 mg/kg oral isotretinoin up to a total dose of 120-150 mg/kg. Treatment was started at 20 mg/day and gradually increased to the maximum of 40 mg/day. The patients were monitored monthly during isotretinoin treatment.
2506666|NCT02855138|No Intervention|control group|The control group of this study was pretreatment period of the same volunteer patients.
2506683|NCT02854813||Group 1|Patients with a OAB-V8 score ≥8
2506684|NCT02854813||Group 2|Patients with a OAB-V8 score <8
2506697|NCT02854670|Experimental|Capsaicin patch|Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.
2506767|NCT02854514||aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated with endometrial secretion then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
2506848|NCT02854163|Experimental|Secukinumab|"Secukinumab will be given to all 20 patients registered (Secukinumab group). All doses will be given subcutaneously using the following schedule: 4 weekly injections of 150 or 300 mg subcutaneous injections depending the severity of skin involvement, followed by 11 monthly subcutaneous injections of 150mg.~Patients will continue to use their normal DMARDs treatment."
2506933|NCT02853578|Experimental|Busonid (budesonide 200mcg and 400mcg)|"It´s a capsule with inhalatoin powder composed of budesonide 200mcg or 400mcg. The experimental drug will be dispensed in a cartridge containing 60 capsules of 200 mcg or 400 mcg and an inhaler. It should be stored at room temperature (between 15 and 30°C) and protected from moisture.~Regarding the dosage, the 80 study participants will perform an inhalation 200mcg every 12 hours (400 mcg / day). During follow-up visits (V1 and V2) the attending physician will assess the need for increased PSI dose to 400 mcg every 12 hours (800mcg / day). Study participants should rinse the mouth with water and / or brush your teeth immediately after use of the drug.~The duration of treatment may be 12 weeks."
2507036|NCT02852746||Asympt. athletes / scapular dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2507039|NCT02852746||Symptom. athletes / scapular dyskinesis|Symptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2507120|NCT02851914|Active Comparator|Arm 1 - TCA|"The Tricyclic Antidepressant (TCA) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
2507122|NCT02851914|Active Comparator|Arm 2 - SSRI|"The Selective Serotonin Reuptake Inhibitor (SSRI) group will receive medication for 12 weeks. Patients will be evaluated every 4 weeks and phone call will be made in between visits to assess the effectiveness and side effects of the medication. Questionnaires will be repeated in the clinic visits and will be used in the data analysis to look for improvements and to compare the two classes of medication in this study."
2507157|NCT02851602|Experimental|Obese|
2507160|NCT02851602|Placebo Comparator|control|
2507208|NCT02851316|Experimental|Whole Body Vibration|The WBV intervention consists of 6 bouts of 60 seconds vibration with 2 minutes of rest in between (30Hz, 2g acceleration) while participants stand on a vibrating platform with their knees bent.
2507210|NCT02851316|No Intervention|Control|The control intervention consists of 6 bouts of 60 seconds with 2 minutes of rest in between while participants stand with their knees bent (no vibration applied).
2507274|NCT02850926|Experimental|Soccer head gear|Subjects who are wearing soccer head gear during the practices and games during the soccer season.
2507287|NCT02850926|No Intervention|Control|Subjects who are not wearing soccer head gear during the practices and games during the soccer season.
2507319|NCT02850471|Experimental|TEAS group|Before anesthesia, patients in this group treated with Transcutaneous Electric Acupoint Stimulation (TEAS) which is an electroacupuncture on Feishu, Hegu, Chize half an hour before the surgery, using the device Hua Tuo SDZ-II Acupoint Stimulator. The stimulus parameters set as 2/100Hz, 2V, 30min.
2507325|NCT02850471|No Intervention|controlled group|Patients in controlled group treated without TEAS or other placebo.
3196713|NCT00853294|Active Comparator|B|Tussionex® Pennkinetic® Extended Release Oral Suspension
2507429|NCT02849379|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507430|NCT02849379|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507524|NCT02849197||Primary Closure|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: primary closure. Technical details: An elliptical incision was made, and the excision included sinus openings at the median line and extended down to the pre-sacral fascia. One suction drain was placed in the wound cavity. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and skin was closed with interrupted 2-0 silk suture."
2507545|NCT02848885|Experimental|Sham TDCS|Participants who are randomly assigned to this arm will receive dual hemisphere sham stimulation with electrodes placed on the parietal lobes (P3 and P4) daily for 10 days. Each participant will have two MRI scans and their degree of illness awareness assessed at baseline and after 10 days of tDCS. Illness awareness will be assessed weekly thereafter for 4 weeks.
2507597|NCT02848391|Experimental|healthy subjects|three hour flight simulation
3196714|NCT00853294|Experimental|A|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
3196715|NCT00853320|Experimental|A|Oxycodone hydrochloride tablet 15 mg
2506607|NCT02855515|Experimental|Short-time diagnostic anaesthesia|The study population will consist of patients with obstructive sleep apnoea, which will be classified as mild, moderate, severe (patients who failed or refused primary CPAP treatment). The patients will undergo a short-time general anaesthesia in order to diagnose OSA when relaxed.
2506659|NCT02855203|Experimental|SABR + Pembrolizumab|SABR treatment (18Gy-20Gy/1#) followed by 200mg pembrolizumab IV once every 3 weeks for a total of 8 cycles
2506686|NCT02854839|No Intervention|The Control Group|Patients will be randomized 1:1 to the control group and the treatment group. Patients who had allocated control group will not receive adjuvant treatment.
2506687|NCT02854839|Experimental|The Treatment Group (MG4101)|Patients will be randomized 1:1 to the control group and the treatment group. The treatment group will receive 6 times of MG4101(allogeneic natural killer cells) on week 0, 1, 2, 5, 6, 7.
2506932|NCT02853279|Experimental|Interval exercise training|Supervised exercise training undertaking interval exercise twice per week for 30 min each visit over 12 weeks.
2506934|NCT02853279|Active Comparator|Continuous exercise training|Supervised exercise training undertaking continuous exercise twice per week for 30 min each visit over 12 weeks.
2507005|NCT02852941||Patients after kidney transplantation|The study included who had been admitted to a nephrology-transplantation outpatient clinic 0.5 to 30 years after kidney transplantation.
2507006|NCT02852941||Healthy subjects|Medical staff: medical doctors, nurses
2507062|NCT02852486|Experimental|Pioglitazone|Pioglitazone will be given 30 mg/day, orally, for 3 months, before imatinib discontinuation
2507087|NCT02852122|Experimental|C-11 choline|
2507113|NCT02851888|Experimental|Iliac Fascia Block (Ropivacaine)|These patients will receive a preoperative iliac fascia block performed as a single shot in the standard fashion prior to hip arthroscopy with general anesthesia.
2507114|NCT02851888|Sham Comparator|Control (Normal Saline Sham Injection)|These patients will receive a preoperative sham block of normal saline in the same fashion as a standard singl shot iliac fascia block prior to hip arthroscopy with general anesthesia.
2507165|NCT02851628|Experimental|Alternative sizing model trial mask|In this arm participants who are randomized to the alternative sizing model based mask will be given the alternative sizing model based mask to use in home for the duration of this arm.
2507167|NCT02851628|Active Comparator|Prototype Full Face Mask (PFFM)|In this arm, participants who are randomized to the PFFM will be given the PFFM to use in-home for the duration of this arm.
2507228|NCT02851212|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with two Extended Release (XR) tablets of metformin of each 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 Extended Release (XR) fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin XR two tablets of each 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507236|NCT02851212|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507243|NCT02851212|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507246|NCT02851212|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507339|NCT02850432|Active Comparator|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
2507348|NCT02850432|Active Comparator|Conservative treatment|rehabilitation with medical therapy
2507395|NCT02849834|Active Comparator|healthy volunteers|
2507396|NCT02849834|Experimental|Patients with resistant pain|
3163571|NCT00483431|Active Comparator|MK7_180|MK7 dosage 180 mcg, 4 capsules of 45 mcg, orally, daily for 12 weeks.
3163572|NCT00483431|Active Comparator|MK7_360|MK7 dosage 360 mcg, 1 capsule of 360 mcg and 3 placebo-capsules, orally, daily for 12 weeks.
2507565|NCT02848508|Experimental|moderate impairment, CKD stage 3a|(12 subjects): GFR 59-45 (moderate impairment, CKD stage 3a) Metformin : 1500mg/day
2507568|NCT02848508|Experimental|moderate impairment, CKD stage 3a)|(12subjects): GFR 44-30 (moderate impairment, CKD stage 3b) Metformin : 1000mg/day
2507569|NCT02848508|Experimental|severe impairment|(12 subjects): GFR 29-15 (severe impairment, CKD stage 4) Metformin : 500mg/day
2507699|NCT02847533|Other|non resistant depression|patients in remission from unipolar depressive disorder
2507778|NCT02847286|Active Comparator|Treatment A|Dapivirine Ring-004 for 28 days
3163573|NCT00483444|No Intervention|2|Control group were recruited in the emergency department after concussion and received standard care as directed by the ED physician and PCP.
3163574|NCT00483444|Experimental|1|Persons with concussion recruited in the emergency department received 5-6 scheduled telephone counseling calls focused on symptom management and self-management.
3163575|NCT00483470|Experimental|1|
3163576|NCT00483470|Active Comparator|2|
3163577|NCT00483483|Experimental|1|Healthy Relationships Intervention (HRI)
3163578|NCT00483483|Active Comparator|Attention-control group|health education & support
3163579|NCT00483522|Experimental|1|Scheduled telephone counseling over 2 years time.
3163580|NCT00483522|No Intervention|2|This control group will receive standard care after hospital rehabilitation discharge as directed by their physician.
3173714|NCT00615173|Active Comparator|2|intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
2506627|NCT02855307|Active Comparator|Announced exercise with pre-meal full bolus|The target blood glucose of the algorithm will be increased and a pre-meal full bolus will be given
2506628|NCT02855307|Active Comparator|Announced exercise with reduced insulin bolus|The target blood glucose of the algorithm will be increased and the pre-meal insulin bolus will be reduced by 33%.
2506694|NCT02854904|Experimental|Dexmedetomidine intervention|Dexmedetomidine (1 ug/kg/hr) during anesthesia.
2506696|NCT02854904|Placebo Comparator|Placebo|Infusion of normal saline during anesthesia.
2506734|NCT02854488||Women Exposed to Yervoy (ipilimumab) During Pregnancy|Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
2506820|NCT02854345|Experimental|Tomoscintigraphic parathyroid imaging on a CZT camera|Tomoscintigraphic parathyroid imaging on a CZT camera
2506849|NCT02853786|Experimental|LENA and advices|With the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
2506851|NCT02853786|Active Comparator|LENA without advices|Regular speech therapy follow blindly the results of LENA
2506908|NCT02853591|Active Comparator|Standard High Pressure (15mmHg)|Pneumoinsufflator mode and setting: standard at 15mmHg
2506909|NCT02853591|Experimental|AirSeal High Pressure (15mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 15mmHg
2506915|NCT02853591|Experimental|Standard Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: standard at 9mmHg
2506916|NCT02853591|Experimental|AirSeal Low Pressure (9mmHg)|Pneumoinsufflator mode and setting: pressure-barrier at 9 mmHg
2506967|NCT02853071|Experimental|Estramustine|560 mg per day
2506971|NCT02853071|Active Comparator|Standard practice center|"Standard treatment center choice.~Excepted: anthracyclines, taxanes, capecitabine and eribulin"
2507016|NCT02852681|Other|15 mg E4/3 mg DRSP without food|Treatment A (Reference): a single 15 mg E4/3 mg DRSP tablet without food (fasted).
2507019|NCT02852681|Other|15 mg E4l/3 mg DRSP with food|Treatment B (Test): a single 15 mg E4/3 mg DRSP tablet with food (fed)
2507088|NCT02852408||Study|liver cauterized during laparoscopic cholecystectomy.
2507089|NCT02852408||Control|liver not-cauterized during laparoscopic cholecystectomy.
2507148|NCT02851862||Late Onset GM2 Gangliosidosis|10-15 subjects with Late Onset GM2 Gangliosidosis
2507214|NCT02851407|Experimental|Defibrotide|Defibrotide is administered intravenously at a dose of 25 mg/kg/day in addition to best supportive care on the day before the first day of the conditioning regimen and will continue (for those patients without a VOD diagnosis) for a recommended minimum of 21 days and end no later than Day +30 post HSCT
2507216|NCT02851407|Other|Best Supportive Care|Best supportive care alone (without the addition of defibrotide) according to institutional guidelines and patient need, is administered on the first day of conditioning and will continue until Day +30 post HSCT or hospital discharge, whichever is sooner, or diagnosis of VOD, if applicable
2507337|NCT02850185|Experimental|oxyhydrogen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ hydrogen/ oxygen inhaled
2507346|NCT02850185|Experimental|oxygen|conventional treatment (bronchodilator (LABA,LAMA) with or without ICS)+ oxygen inhaled
2507415|NCT02849795|Experimental|Psoriasis and arthritic psoriasis|additional blood sample for biological analyses bone densitometry questionnaires
2507465|NCT02849327|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507469|NCT02849327|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507486|NCT02849067|Experimental|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
2507491|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
2507531|NCT02848807|Active Comparator|NUTRIDRINK Compact Protein|NUTRIDRINK Compact Protein Oral nutritional supplement Dietary advice
2507532|NCT02848807|No Intervention|without oral nutritional supplements|Dietary advice alone
2507550|NCT02848586|Active Comparator|ECIGS|Subjects will receive e-cigarettes for a total of 4 weeks. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. After 4 weeks, subjects will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks after transition to ECIG (Visit 4) and again 2 weeks after stopping ECIG (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
2507553|NCT02848586|Active Comparator|Usual brand|Subjects will receive their usual brand of combustible cigarettes for a total of 4 weeks. A mobile contingency management mCM procedure will be used. Respiratory assessments will occur at study arm assignment (Visit 1) to establish baseline measures of lung function, oxidative stress, and systemic inflammation, repeated again 4 weeks later (Visit 4) and again 2 weeks later (Visit 5). Neuro-cognitive and behavioral assessments will occur at Visits 2, 3, 4 and 5.
2507599|NCT02848261|Experimental|Developmental Demands|Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
2507609|NCT02848261|Experimental|Distress Reduction|Identify and reduce parent distress symptoms and worries. Provide strategies for obtaining social support.
2507616|NCT02848261|Experimental|Remote Monitoring|Optimize the use of remote monitoring by focusing on situational demands and problem solving.
2507621|NCT02848261|Experimental|Fear of Hypoglycemia|Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
2507626|NCT02848261|Placebo Comparator|No Intervention|Serves as the control group comparator. No intervention provided.
2507649|NCT02847793|Active Comparator|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial
3196716|NCT00853320|Active Comparator|B|Roxicodone™ tablet 15 mg
2506738|NCT02854917||Memantine Alone|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine for a period of 28 weeks."
2506739|NCT02854917||Memantine plus Individualized Management of AD|"10 subjects who previously participated in the Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial study will be enrolled in this cohort. These subjects received memantine plus individualized management of AD for a period of 28 weeks."
2506818|NCT02854371|Experimental|CLD and LC|Patients with underlying chronic liver disease. Gadoxetic acid enhanced liver MRI and ICG R15 are performed in this group.
2506852|NCT02853799|Other|Continuous Enteral Feeding|"Crossover Study:~Randomized to continuous enteral feeding first then crossed over to receive versus intermittent enteral feeding next."
2506853|NCT02853799|Other|intermittent enteral feeding|"Crossover Study:~Randomized to intermittent enteral feeding first then crossed over to receive versus continuous enteral feeding next."
2506900|NCT02853526|Experimental|TIPS arm|Transjugular intrahepatic portosystemic shunt(TIPS) is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension.TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (also called p-TIPS or modified TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
2506902|NCT02853526|Active Comparator|conservative treatment arm|Conservative treatment including endoscopic therapy，non-selective beta blockers (propranolol)and anticoagulation therapy (warfarin).
2506935|NCT02853227||BCS|Photographs og consecutive group of 346 patients operated with breast conserving surgery were used to investigate cosmetic outcomes.
2506936|NCT02853227||DIEP|Photographs og consecutive group of 30 patients operated with DIEP-flap were used to assess cosmetic results
2506956|NCT02852954||study group1|20 paraffin embedded blocks which was diagnosed endometrial cancer
2506958|NCT02852954||control group|20 paraffin embedded blocks of healthy women
2506960|NCT02852954||study group2|20 paraffin embedded blocks which was diagnosed endometrial hyperplasia
2507025|NCT02852785||Asymptomatic volleyball attackers|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
2507028|NCT02852785||Asymptomatic bilateral overhead athletes|Asymptomatic swimmers involved in competitive events ≥ 2 years and no signs of postural and movement impairments of the upper body quadrant
2507030|NCT02852785||Asymptomatic non-athletes|Asymptomatic persons not regularly involved in sports activities or occupational overhead tasks (e.g. construction workers),
2507031|NCT02852785||Asympt. athletes / scapula dyskinesis|Asymptomatic volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis
2507032|NCT02852785||Symptom. athletes / scapula dyskinesis|Volleyball attackers involved in competitive events ≥ 2 years and with clinical evidence of scapula dyskinesis and complaints of shoulder pain and disability
2507071|NCT02852083|Experimental|A: Biomodulatory treatment|treosulfan 250 mg p.o. twice daily, pioglitazone 45 mg p.o. once daily, clarithromycin 250 mg p.o. twice daily until progression or no clinical benefit observed, whichever comes first.
2507072|NCT02852083|Active Comparator|B: Standard Treatment|Nivolumab, 3 mg per kilogram of body weight every 2 weeks until disease progression according to RECIST 1.1 or unacceptable toxicity
3196717|NCT00853346|Experimental|1|Patients randomized to the immediate arm will be given 12 weeks of CBT starting one week after randomization
3196718|NCT00853346|Active Comparator|2|Patients in the delayed arm will receive 12 weeks of CBT, starting 12 weeks after randomization.
2507223|NCT02851173|Experimental|LLLT|Six weekly sessions of LLLT. The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). Each laser stimulation session will consist of total 8 min, with eight 1 min/cycle treatments alternating between two locations on the right forehead.
2507238|NCT02851173|Active Comparator|Placebo|The control group will undergo the same procedure as the treatment group, but will receive brief (5-s) stimulation to the intended site on the forehead, followed by 55 s of no stimulation, for each 1-min cycle. Thus the control group will receive approximately 1/12th of the cumulative energy density as the treatment group. This is sufficient to provide a brief sensation of slight heat (as active placebo) at the onset of each one-minute cycle, using a fraction of the energy received by the experimental group.
2507294|NCT02850796|Experimental|Kg-Free|Kg-free is a manualized acceptance, mindfulness & compassionate-based group intervention for women struggling with their weight. It comprises 10 weekly group sessions plus 2 booster fortnightly sessions (31/2months) 2h30 hours each, run in small groups (ranging from 10 to 12 participants).
2507300|NCT02850796|Other|Treatment as Usual (TAU)|nutritional treatment for weight loss in primary care units and Hospitals from Coimbra's district that includes dietary and physical activity support
3196719|NCT00853398|Experimental|Minimal Invasive Surgery,|
3196720|NCT00853398|Active Comparator|Standard Surgical Technique|
3196721|NCT00853424|Active Comparator|M|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
3196722|NCT00853424|Experimental|I|subjects receive an islet cell transplant in addition to all recommended medical treatment for diabetes and diabetic eye disease
3196723|NCT00853450|Experimental|1|AZD6482 on top of ASA
3196724|NCT00853450|Active Comparator|2|Clopidogrel on top of ASA
3196725|NCT00853463|No Intervention|No Alert|The responsible physician of a patient randomized to the control arm will not be contacted regarding the increased VTE risk of the patient.
3196726|NCT00853463|Other|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
3196727|NCT00853502|Active Comparator|testosterone cypionate|
3196728|NCT00853502|No Intervention|bone monitoring|
3196729|NCT00853515|Experimental|1|Goal-directed fluid resuscitation with lactated Ringer's solution
2506653|NCT02855294|Active Comparator|Oral contraceptive pills users|The participants received treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of ring/pill treatment followed by a 1-week pill-free period. The women were randomized in a 1:1 ratio to receive the COC containing 30 μg of EE and 3mg of drospirenone (Yasmin; Schering AG, Berlin, Germany)
2506654|NCT02855294|No Intervention|control|no drugs
2506806|NCT02854306|Active Comparator|Surgery|Obese patient without mindfulness program in parallel.
2506809|NCT02854306|Active Comparator|Surgery with mindfulness program|Obese patient following a mindfulness program in parallel.
2506837|NCT02853877|Experimental|Weekly Incentive|Participants in the Weekly Incentive arm will be asked to weigh in each week during a 12 week intervention period. They will receive tailored messages and have an opportunity to win a financial reward each week they meet their weight loss goal. Participants will be asked to complete a final weight measurement at week 24.
2506841|NCT02853877|No Intervention|Weekly Weigh-In|Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
2506872|NCT02853721|Experimental|Experimental group|iPTH at 6 hours after surgery
2506882|NCT02853721|Other|Control group|no dosage of iPTH
2506927|NCT02853370|Experimental|Bendamustine and Rituximab|"Induction Phase (Cycle 1 to Cycle 3 ):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1**~Extended Phase (Cycle 4 to Cycle 6):~Bendamustine 90 mg/sqm i.v. d1 & d2* Rituximab 375 mg/m2 i.v. d1~From Cycle 4 to Cycle 6, every 4 weeks, depending on the response after the first 3 Cycles~*Or days 2-3 according to institutional/patient/physician preference~**Administration of Rituximab during cycle 1 and cycle 2 can be postponed to day 8 or 14 in case of risk of tumor lysis syndrome (TLS)"
2506993|NCT02852811|Other|group education|To measure improvement of menopause symptoms and depression all participating women answered a baseline questionnaire and a follow-up questionnaire four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
2506997|NCT02852811|No Intervention|control group|The control group did not obtain any group education or any other intervention. Women answered at baseline questionnaire and four month later. The questionnaires who were used: The Menopause Rating Scale (MRS) and The Montgomery-Asberg Depression Rating Scale (MADRS). MRS were used for reflecting menopause symptom and MADRS for depression symptoms.
2507017|NCT02852616|Active Comparator|Narrative Exposure Therapy|Participants with a PTSD diagnosis
2507021|NCT02852616|No Intervention|no / standard treatment|Participants with a PTSD diagnosis / other mental health problems / no mental health problems
2507091|NCT02852382|Active Comparator|scalp block|In this arm, after general anesthesia, before surgery and head pin placement, scalp block will be applied. Scalp block will be performed with bupivacaine (Marcaine 5 mg/mL, 0,5% bupivacaine); nervus supraorbitalis, nervus supratrochlearis, n. auriculotemporalis, nervus zygomaticotemporalis, nervus occipitalis majoris and minoris will be bilaterally blocked with 2-3 ml bupivacaine.
2507092|NCT02852382|Active Comparator|local infiltration|In this arm, after general anesthesia, before surgery, 20 ml 0,5% bupivacaine (Marcaine 5 mg/ml, 0,5% bupivacaine) will be infiltrated to head pin points and skin incision area.
2507093|NCT02852382|Placebo Comparator|control|In this arm, neither scalp block, nor local infiltration will be performed.
2507151|NCT02851784|Active Comparator|MWA only|The HCC patients will be treated only by MWA.No adoptive immunotherapy will be used.
2507153|NCT02851784|Experimental|MWA combined with immunotherapy|The HCC patients will be treated firstly by MWA, and then treated by courses of adoptive immunotherapy.
2507227|NCT02851225|Experimental|telemedicine transmission|telemedicine transmission of biological results in the treatment of transfusion supportive care
2507235|NCT02851225|No Intervention|without telemedicine transmission|no telemedicine transmission of biological results in treatment in the treatment of transfusion supportive care
2507299|NCT02850848|Experimental|Entigin Film Coated Tablet 0.5mg|Entigin Film Coated Tablet 0.5mg Dosing Regimen: Single dosing of two tablets
2507302|NCT02850848|Active Comparator|Baraclude 0.5mg Tablets|Baraclude 0.5mg Tablets Dosing Regimen: Single dosing of two tablets
2507332|NCT02850380|Other|spatial orientation in weightlessness|"subjects will be asked to flip a series of switches into the off position. On Earth, the off position corresponds to down in all three reference frames: the visual allocentric, the non-visual allocentric as well as the egocentric frames. We expect that flip direction will be dominated by visual allocentric cues when those are available, will be delayed and more variable when confirmatory gravitational cues are absent, and will be biased towards the egocentric reference when tactile cues are added"
2507385|NCT02850003|Experimental|IDP-120 Gel|Gel
2507450|NCT02849353|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507457|NCT02849353|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507517|NCT02849119|Experimental|Transperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through transperitoneal approach
2507520|NCT02849119|Experimental|Retroperitoneal approach|Laparoscopic or Robotic Partial Nephrectomy through retroperitoneal approach
3196730|NCT00853515|Experimental|2|Goal-directed fluid resuscitation with normal saline
2507691|NCT02847741|Other|Major depressive episode|Depressive patients will be assessed by interview (psychiatrists), questionnaires and blood sampling, as the inpatients's routine care
2507706|NCT02847429|Experimental|Crenolanib Arm|Investigational product (crenolanib)
2507711|NCT02847429|Placebo Comparator|Placebo Arm|Matching placebo
2507844|NCT02846493|Active Comparator|bromocriptine group|Rectal bromocriptine (2.5 mg, qd) for 7 days
2507846|NCT02846493|Experimental|dexamethasone group|Oral take dexamethasone(3mg,qd)for 7 days
2547476|NCT02581579|Placebo Comparator|Placebo|MANITOL CAPSULES
3196731|NCT00853515|No Intervention|3|Standard fluid resuscitation with lactated Ringer's solution
2506710|NCT02854657|Placebo Comparator|Assessment-only control|"Participants who receive customary care from their own dermatologists. It is anticipated that 150 new participant dyads will be recruited and randomized to this group.~These subjects are controls and do not receive the structured training in skin self-examination with partner assistance at the beginning of the study. After completing the 18 month online survey, the subjects may request the structured training in skin self-examination with partner assistance."
2506712|NCT02854657|No Intervention|Observational study 1|"Feasibility of wearing 2 sensors No intervention. At the conclusion of the study, participants receive a report of their UV exposure and physical activity over the 7 days of the study.~N= 10"
2506714|NCT02854657|No Intervention|Observational study 2|"Feasibility of completing online daily survey. The research team will strive to integrate event level data in real -time No intervention. At the conclusion of the study, participants receive an event level reports of their daily UV exposure and physical activity over the 7 days of the study.~N= 30"
2506716|NCT02854657|No Intervention|Relationship Factors Study Observational Study|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~No intervention- Control group. n=144 Results pending*"
2506717|NCT02854657|Active Comparator|Relationship Factors Study- Skin Self Examination|"Identification of how shared responsibility for SSE (i.e., being in this together) contributed to SSE frequency and provide dermatologists with practical information they can efficiently communicate to patients with a history of melanoma to increase SSE.~Intervention= Skin self-examination training n=197 Results Pending*"
2506718|NCT02854657|Active Comparator|Comparison of distance (remote) learning vs in-person learning|Controls re-enrolled from the original study (n=38) and newly enrolled in the distance (remote) learning (n=106) are compared with participants receiving the workbook in-person in the original study and re-enrolled (n=134) and participants newly enrolled in distance (remote) learning, who had the workbook mailed to them (n=63). Online surveys assessed SSE knowledge, confidence, anxiety and performance. Electronic health record review identified biopsies of concerning moles and the number of melanomas identified.
2506764|NCT02854423||biodegradable polymer|
2506768|NCT02854423||durable-polymer|
2506789|NCT02854202|Experimental|Arm 1-Whey protein|In the Arm 1-Whey protein Breakfast the participant will consume 42 g protein at breakfast mainly from whey
2506791|NCT02854202|Active Comparator|Arm 2 Breakfast- other proteins|In the Arm 2 Breakfast- other proteins sources (No Whey) the participants will consume 42 g protein from other sources (no Whey) at breakfast
2506793|NCT02854202|Placebo Comparator|Arm 3 Breakfast- low protein|In the Arm 3: breakfast with low proteins content, the participant will consume 22 g protein at breakfast
2506868|NCT02854007||Coronary stenosis treated with Absorb|Patients with ischemic heart disease who have undergone percutaneous coronary revascularization with Absorb according to standard clinical practice. One thousand revascularized patients will be recruited at 40 siteS.
2506941|NCT02853175||Patients with both CF and ABPA|"Patients with both cystic fibrosis and allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
2506943|NCT02853175||Patients with CF and no ABPA|"Patients with both cystic fibrosis and no allergic broncho-pulmonary aspergillosis (ABPA).~The diagnosis of ABPA (Gold Standard) rely on routine dosage of total immunoglobulin E (IgE), specific to Aspergillus IgE, specific to aspergillus Immunoglobulin G, eosinophilia on blood cell count, and imaging (infiltrate, mucoid impaction, central bronchiectasis)"
2506977|NCT02852915|Experimental|Laparoscopic surgery for T4 colon cancers|Laparoscopic surgery for T4 colon cancers
2506984|NCT02852915|No Intervention|Conventional open surgery for T4 colon cancers|Conventional open surgery for T4 colon cancers
2507018|NCT02852694|Active Comparator|High Risk Group|subcutaneous methotrexate versus subcutaneous adalimumab
2507023|NCT02852694|Active Comparator|Low risk group|subcutaneous methotrexate versus oral dose of azathioprine / 6 mercaptopurine
2507027|NCT02852694|Other|Ancillary|the ancillary study is planned to analyse of Adalimumab treated patients from inclusion (TOP-Down) versus patients switched to Adalimumab due to failure of immunomodulator therapy (STEP-Up).
3196732|NCT00853515|No Intervention|4|Standard fluid resuscitation with normal saline
2507268|NCT02850939|Experimental|Mobile phone app + patient navigation|Patients assigned to the intervention group (60) will: 1) use the personalized mobile phone app in their preferred language for a duration of 6 months; and 2) receive assistance from a patient navigator. They will also continue to receive the usual EHT care provided at the MCC's breast clinic.
2507280|NCT02850939|No Intervention|Usual care|Patients assigned to the control (usual care) group (60) will receive the usual EHT care and materials offered at the MCC's breast clinic.
2507312|NCT02850393|Experimental|patients with obsessive compulsive disorder|Functional magnetic resonance imaging behavioral measures physiological measurements
2507313|NCT02850393|Experimental|healthy participants|Functional magnetic resonance imaging behavioral measures physiological measurements
2507374|NCT02850094|Experimental|Financial Bonuses|For two weeks following enrollment, subjects are monitored via their FitBit accelerometer to monitor their pre-intervention physical activity levels. For a twenty-four week period following the observational period, participants are eligible for financial bonuses based on their increased activity. Participants enroll as teams and are eligible for additional financial bonuses based on their team's performance.
2507417|NCT02849665|Experimental|Kangaroo Position|The newborn remains in a vertical position, with limbs flexed, dressed in light clothes, maintaining skin-to-skin contact and the face on the adult's thorax.
2507418|NCT02849665|No Intervention|Not Kangaroo Position|The newborns will be not placed in the position Kangaroo.
2507475|NCT02849262|Placebo Comparator|Vehicle|Vehicle Topical Gel
2507604|NCT02848391|Experimental|COPD normocapnic|three hour flight simulation
2506747|NCT02854748|Experimental|Empa.+Lobe. / Lobeglitazone / Empagliflozin|Period 1: Empagliflozin 25 mg + Lobeglitazone 0.5 mg QD for 5 days Period 2: Lobeglitazone 0.5 mg QD for 5 days Period 3: Empagliflozin 25 mg QD for 5 days
2506845|NCT02854111|Active Comparator|oral glucose tolerance test|75-g glucose A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink a sweet liquid containing 75 g-glucose. Blood samples will be collected at timed intervals of 1 and 2 hours after you drink the glucose. This is a standard method for diagnosis of diabetes mellitus that called oral glucose tolerance test or OGTT.
2506847|NCT02854111|Experimental|ice cream|A blood sample will be collected when the participants arrive. This is a fasting blood glucose value. Then the participants will be asked to drink ice cream that contained carbohydrate 73.9 g. Blood samples will be collected at timed intervals of 1 and 2 hours after you eat the ice cream.
2506890|NCT02853630|Active Comparator|Metformin|Tablet Metformin 1000 - 2500 mg/day for 96 weeks
2506891|NCT02853630|Experimental|Vildagliptin|Tablet Vildagliptin 100mg/day for 96 weeks
2506921|NCT02853266||patients KD|adults with a history of KD in childhood
2506926|NCT02853266||control group|healthy adults volunteers
2506969|NCT02853019|Sham Comparator|Healthy volunteers|Healthy volunteers
2506976|NCT02853019|Experimental|Patients with schizophrenia|Patients with schizophrenia
2507063|NCT02852603||thoracic aortic aneurysm and dissection|Patients with thoracic aortic aneurysm and/or dissection are recruited in the study.
2507102|NCT02852161|Experimental|MACE|MACE procedure
2507104|NCT02852161|Active Comparator|OGD|Clinically indicated gastroscopy
2507136|NCT02851732|No Intervention|Control|"Clusters randomized to the control group will keep their usual practice standards. Patient screening will be performed at the outpatient clinics and primary care centers. Both groups must complete the following forms: Admission, 06 months, and 12 months. Data collection will be performed from medical records by an independent professional not involved in patient care. Furthermore, study coordinator and data collectors from the sites, when asked, must provide appropriate documents for adjudication purposes."
2507137|NCT02851732|Experimental|Intervention|Educational multifaceted intervention can increase the evidence based prescriptions. If this is the case, this tool package may be offered as a quality improvement intervention for all hospitals. Health care professionals from each institution one being a physician (acting as a local leader) and the other being a research nurse (acting as a case manager) must attend the training course for high cardiovascular risk patients that will take place at HCor.
2507173|NCT02851511|Experimental|Cognitive Training + Active Stimulation|This arm receives cognitive training combined with active tDCS.
2507175|NCT02851511|Experimental|Cognitive Training + Sham Stimulation|This arm receives cognitive training combined with sham tDCS.
2507177|NCT02851511|Experimental|Educational Training + Active Stimulation|This arm receives educational training combined with active tDCS.
2507178|NCT02851511|Experimental|Educational Training + Sham Stimulation|This arm receives educational training combined with sham tDCS.
2507239|NCT02851134||Crohn disease subject|Crohn disease affected subject
2507244|NCT02851134||family control subject|family control unaffected subject
2507257|NCT02850718|Experimental|Period 1: Sublingual wafer|Subjects receive receive a single dose of 50 mg sublingual sildenafil followed by plasma sampling for 14 hours.
2507260|NCT02850718|Active Comparator|Period 2: Oral comparator|Subjects receive a single dose of 50 mg oral sildenafil (Viagra) followed by plasma sampling for 14 hours.
3196733|NCT00853528|Experimental|Single-fraction radiosurgery; 16 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 16 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
2507383|NCT02849873|Experimental|IDp-123 Lotion|Lotion
2507387|NCT02849873|Active Comparator|Tazorac Cream|Cream
2507511|NCT02849158|Experimental|Biopsy|Patients will have new biopsy before starting RT-CT and samples will be taken on rectum surgery at the level of the tumor and away from the rectum.
2507558|NCT02848703|Experimental|healthy volunteers|
3196734|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 21 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 21 Gray
3196735|NCT00853528|Experimental|Single-fraction radiosurgery; 18 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 18 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
3196736|NCT00853528|Experimental|Single-fraction radiosurgery; 20 Gray|Subjects able to achieve the spinal cord dose constraints for single-fraction SRS stereotactic radiosurgery Radiation: stereotactic radiotherapy at 20 Gray Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging
2507794|NCT02846961||Crohn's disease|Patients with moderate to severe Crohn's disease who need to get a biosimilar CT-P13
2507798|NCT02846961||Ulcerative colitis|Patients with moderate to severe ulcerative colitis who need to get a biosimilar CT-P13
2507860|NCT02846454|Experimental|inulin|Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)
2507862|NCT02846454|No Intervention|non inulin and arabinoxylan|investigating the satiating effects of a control drink (2.6g/d maltodextrin)
2507865|NCT02846454|Experimental|arabinoxylan|Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)
2508004|NCT02845544|Experimental|Experimental group - Pilates|A Pilates-based exercises program of 6 weeks' duration
2508005|NCT02845544|No Intervention|Control group - no exercises|
2508042|NCT02845310|Experimental|Restricted fluid therapy group|Patients will receive restricted fluid management guided by concomitant SVV monitoring. GDT protocol
2508044|NCT02845310|Placebo Comparator|Control group|Patients will receive standard fluid management.
2506760|NCT02854579|Experimental|Progenitor cell and paracrine factors|Three doses of concentrated paracrine factors 0.5ml intrathecally at 12h,24h,48h after birth.And three doses of neural progenitor cell (4*10^6) intrathecally at 48-72h, 5d and 10d after birth.+routine therapy
2506761|NCT02854579|No Intervention|Routine therapy|neonates only receive routine therapy
2506801|NCT02854124||Patients with stage Ib and II melanoma|Melanoma and peritumoral skin excision
2506861|NCT02853968||Castleman's Patients|Castleman's patients with HHV8 negative multicentric MCD
2506865|NCT02853968||Related Disease Controls|Controls with inflammatory diseases similar to idiopathic multicentric Castleman's: i.e. HHV8+ MCD, HLH, Hodgkin disease
2506866|NCT02853968||Healthy Donor Controls|Healthy subjects used for controls. These healthy subjects have no history of autoimmune disorders.
2507251|NCT02851004|Experimental|BBI608 + Pembrolizumab|BBI608 and Pembrolizumab
2507321|NCT02850562|Active Comparator|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
2507324|NCT02850562|Experimental|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
2507373|NCT02850042|Experimental|Occupation-based practice|Occupation-based intervention (OBP) is a form of activity-based therapy consisting of client-directed occupations that match client-identified goals. OBP group will participate in activities such as wood working, scrap booking, higher level dressing (don/doffing a bra, zipping coat), hair care, opening doors, using bathroom stalls, typing, cooking, tying shoes, washing dishes, carrying dirty dish carts, clearing dirty dishes and raking. Repetition of the tasks are not the focus in the OBP group. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
2507375|NCT02850042|Active Comparator|Modified-constraint induced therapy|Modified-constraint induced therapy (m-CIT) group will target functional goals (eg, activities of daily living) or goal subcomponents (eg, pinching, grasp/release, or functional reach patterns). Tasks were repeated at rate of approximately 10 to 50 repetitions each session according to the demands of the task. No physical constraint of the less-affected UE will be applied, but training compelled highly repetitive use of the more-affected upper extremity. Subjects will attempt tasks with progressive difficulty. Each session lasted 55-minute and it was delivered twice a week for 4 weeks (8 sessions).
3163581|NCT00483535|Experimental|Sequence ABC|All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
3163582|NCT00483600|Experimental|no arms/one group|
2507472|NCT02849275|Placebo Comparator|Lactose free 1% milk|Diet will be recorded with a 7-day diet record and participants will include an isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
2507473|NCT02849275|Experimental|Probiotic treatment|Diet will be recorded with a 7-day diet record and participants will include an isocaloric fermented milk (probiotic), consumed once daily, over 4-5 weeks.
2507502|NCT02849015|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive liver cryosurgery first to destroy big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507612|NCT02848391|Experimental|COPD hypercapnic|three hour flight simulation
3163583|NCT00483678|Experimental|Intimacy-Enhancing Couples Therapy|Patients and their partners receive Intimacy-Enhancing Couples Therapy over 6 weeks comprising the following four 90-minute sessions: the Story of Cancer; Understanding the Couple, Ways of Relating and Key Influences; Intimacy; and Coping, Support, and Adaptation. Patients and their partners complete treatment satisfaction questionnaires after completion of study intervention.
3163584|NCT00483678|Active Comparator|standard psychosocial care|Patients and their partners receive standard psychosocial care. All participants complete questionnaires assessing psychological distress, intimacy, communication patterns, and overall relationship adjustment/satisfaction at baseline and at 1 month after completion of study intervention
3163585|NCT00483743|Experimental|TPI 1020|TPI 1020 500 mcg BID x 42 days
3163586|NCT00483743|Active Comparator|Budosenide cortico|Budesonide 800 mcg BID x 42 days
3163587|NCT00483743|Placebo Comparator|Placebo|Placebo inhaler
3163588|NCT00483808|Experimental|Denervation|Renal denervation using the Symplicty Catheter
3163589|NCT00483834|Experimental|Bevacizumab, Irinotecan and Capecitabine|Evaluate the efficacy and toxicity of bevacizumab, irinotecan and capecitabine as first-line treatment for patients with metastatic colorectal cancer
3163590|NCT00483860|Experimental|Topotecan|once a day
3163591|NCT00483886|Active Comparator|1|Prucalopride 2 mg
3163592|NCT00483886|Placebo Comparator|3|Placebo
3163593|NCT00483886|Active Comparator|2|Prucalopride 4 mg
3163594|NCT00483899|Experimental|Cohort 1: Part A|Subjects in Cohort 1 will be randomized to receive 0.5, 2 and 6 mg GW870086X and placebo.
3163595|NCT00483899|Experimental|Cohort 2: Part A|Subjects in Cohort 2 will be randomized to receive 3 mg GW870086X or placebo.
3163596|NCT00483899|Experimental|Part B|Subjects will be randomized to receive 1 and 3 mg of GW870086X or placebo.
3163597|NCT00483951||Patients with known or suspected cardiovascular disease|Patients referred to protocol with known or suspected cardiovascular disease for further evaluation.
3163598|NCT00483964|Experimental|A|The group getting the study drugs, Bacopa monnieri and Nardostachys jatamansi
3163599|NCT00483964|Active Comparator|B|The group getting Olanzapine
3163600|NCT00483977|Active Comparator|Oxycodone|
3163601|NCT00483977|Placebo Comparator|Placebo|
3163602|NCT00483977|Experimental|PF-00592379|
3163603|NCT00484029|Experimental|1|Nasal Carbon Dioxide
3163604|NCT00484029|Placebo Comparator|2|Air
2506770|NCT02854462|Active Comparator|Counting intervention|The intervention will run for 4 weeks. Caregivers will be provided with a book 'At home with counting' that is made up of age appropriate maths exercises. Caregivers will trained (with a video) to work through one page of the book per day. This should take the same amount of time as the activity in the language intervention condition. Caregivers will keep a counting diary.
2506855|NCT02853890||pregnant woman|
2506940|NCT02853565|Experimental|CAN008|CAN008 administered as a 30 min intravenous infusion once a week until disease progression or unacceptable toxicity.
2506974|NCT02852889||fluid responders|Patients whose stroke volume index increase by >10% in response to a 500-ml fluid bolus was defined as fluid responders.
2506980|NCT02852889||fluid non-responders|Patients whose stroke volume index increase by <10% in response to a 500-ml fluid bolus was defined as fluid non-responders.
2507020|NCT02852720|Experimental|Pharmacokinetics|A bilateral TAP block will be performed with 20 ml levobupivacaine 0,25% and epinephrine (5ug/ml). After the blockade, venous blood samples will be taken on predefined times.
2507115|NCT02852174|Experimental|Mindfulness group|The treatment groups will participate in a mindfulness intervention training that will meet for 2 hours once a week for eight weeks. The 8-week program provides participants with 2-hour weekly instruction designed to teach specific skills and how to apply them during stressful situations (e.g., when caring for or advocating for the veteran).Mindfulness training also requires that participants engage in daily home practice for 30 to 40 minutes. Participants will be required to record the duration of the meditation in log sheets.
2507116|NCT02852174|No Intervention|Control|Participants in the control may receive the mindfulness training after the wait period ends at which point they may receive the treatment as described above.
2507130|NCT02851654||Dry eye syndrome|Meibomian gland dysfunction responsible of moderate to severe dry eye syndrome
2507189|NCT02851264||Optical enhancement technology examination|After routine examination by white-light endoscopy,the imaging mode will be switched to optical enhancement.Suspicious area will be recorded in detail. Then all enrolled patients will have their esophagus sprayed with iodine solution. Suspicious area will be also recorded in detail.After that biopsy specimens will be obtained respectively by forceps from each suspicious lesion recorded for histologic diagnosis.
2507305|NCT02850588||TCAR treatment|All high risk surgical patients undergoing transcarotid revascularization with a carotid stent during carotid artery flow reversal in hospitals that participate in the Carotid Artery Stent Registry of the Society for Vascular Surgery Patient Safety Organization
2507306|NCT02850588||CEA treatment|All patients undergoing carotid endarterectomy in hospitals that participate in the Carotid Endarterectomy Registry of the Society for Vascular Surgery Patient Safety Organization
2507371|NCT02850029||critically ill patients|Critically ill patients admitted in intensive care units and receiving one of the following aminoglycosides: gentamicin, tobramycin and amikacin as part of their usual care.
2507515|NCT02849223|Experimental|Transcranial Direct Current Stimulation|Participants will receive 24 sessions (3 times a week) of anodal transcranial direct current stimulation concurrent with working memory training. Stimulation will be administered at 2 milliamps (mA) for 20 minutes over the left dorsal lateral prefrontal cortex.
2507518|NCT02849223|Sham Comparator|Sham|Participants will receive 24 sessions of working memory training. The experience of transcranial direct current stimulation will be simulated by administering 30 seconds of stimulation at the beginning of the session.
2507546|NCT02848677|Active Comparator|intervention group|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
2507552|NCT02848677|Sham Comparator|control group|usual care of hypertensive patients.
2507600|NCT02848365|Active Comparator|Glidescope|
2507610|NCT02848365|Active Comparator|Macintosh laryngoscope|
2507618|NCT02848365|Active Comparator|Bonfill's rigid scope|
2507623|NCT02848365|Active Comparator|Air traq|
2507625|NCT02848365|Active Comparator|C -Mac scope|
2507627|NCT02848365|Active Comparator|flexible fiberoptic scope|
2507687|NCT02847845|Experimental|Red ginseng powder capsule|People in this group take a red ginseng powder capsule.
2507690|NCT02847845|Placebo Comparator|Placebo powder capsule|People in this group take a placebo powder capsule.
2507730|NCT02847390||Pre-implementation group|"The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes education intervention to our staff over a 6-month time frame from August 2016-January 2017. The investigators will use a before and after study design to assess the impact of the educational intervention on hospital-wide hypoglycemia and hyperglycemia.~Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/16 to 6/30/16)."
2507738|NCT02847390||Post-implementation group|Adult (>18 years), non-obstetrical patients admitted to the medical services where housestaff and hospitalist superusers have been trained, with Type 1 diabetes, Type 2 diabetes, or individuals with hospital-related hyperglycemia who do not carry a prior diabetes diagnosis (4/1/17 to 6/30/17).
2507785|NCT02847130||Observational (chart review, focus group, interviews)|"AIM 1 (CHART REVIEW): Patients are separated for each CPG evaluated (fever and neutropenia [FN], chemotherapy induced nausea and vomiting [CINV], fertility preservation [FP]) and are randomly selected for medical chart review. Patients with eligible episodes of FN, CINV or FP within the health records are selected and have the data from their records abstracted and reviewed by COG for adherence to COG endorsed CPGs.~AIM 2 (FOCUS GROUPS): Health care providers who provide direct care to pediatric oncology patients are identified and separated to participate in three types of focus groups: physician-only, non-physician, and mixed.~AIM 3 (INTERVIEWS): Health care providers undergo one-on-one interviews consisting of think aloud technique (TAL) of cognitive interviewing."
3196737|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 24 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 24 Gray
3196738|NCT00853528|Experimental|Hypo-fractionated radiosurgery; 27 Gray|Subjects unable to achieve the spinal cord dose constraints for single-fraction radiosurgery (SRS), based on tumor location and expected tolerance dose to the adjacent normal tissue, will be offered hypo-fractionated SRS (3 fractions) Radiation: stereotactic radiotherapy Questionnaire administration diffusion tensor imaging functional magnetic resonance imaging hypo-fractionated radiation therapy at 27 Gray
2506905|NCT02853604|Placebo Comparator|Reference Treatment Group (Arm A)|Placebo Arm A
2506906|NCT02853604|Experimental|Experimental Treatment Group (Arm B)|"ADXS11-001~1:2 Arm A to Arm B"
2507024|NCT02852525|Other|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction. Photographs will be taken and digitally stored. Biopsies (which are part of the routine diagnosis and surveillance of Barrett's) will be targeted based on the microscopic images. The histologic findings on the biopsy specimens will be compared to the microscopic images to determine the accuracy of the probe-based microscopy in predicting pathology.
2507073|NCT02852395|Experimental|Part 1 Single Dose|Part 1 single daytime oral dose of JNJ-48816274 or placebo. Doses of JNJ-48816274 will start at 5 milligram (mg) and increase sequentially to a maximum dose of 250 mg.
2507074|NCT02852395|Experimental|Part 2 Crossover Sleep Study|Part 2 single nighttime oral dose of JNJ-48816274 or placebo administered during each of 3 or 4 crossover periods separated by 7-9 days. The doses of JNJ-48816274 will be selected based on data from Part 1 (not to exceed 250 mg).
2507075|NCT02852395|Experimental|Part 3 Repeated Dose (Optional)|Part 3 daytime oral dose of JNJ-48816274 or placebo administered once daily for 7 consecutive days. Doses will be determined based on data from Part 1, and may increase sequentially (not to exceed 250 mg/day).
2507108|NCT02851940|Experimental|A (Rubber Band Ligation)|15 patients
2507109|NCT02851940|Experimental|B (Hypertonic Saline Infusion)|15 patients
2507139|NCT02851680|Experimental|Fongitell test|
2507140|NCT02851680|Active Comparator|serum galactomannan|
2507195|NCT02851459|Experimental|Morally Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations.
2507196|NCT02851459|Experimental|Morally Non-Congruent Message|Participants randomized to this arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations.
2507197|NCT02851459|Sham Comparator|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
2507252|NCT02850991|Experimental|High-dose|"concurrent chemoradiotherapy High-dose RT:59.4 Gy in 33 fractions, 1.8 Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
2507254|NCT02850991|Active Comparator|Standard-dose|"concurrent chemoradiotherapy Standard-dose RT:50.4 Gy in 28 fractions, 1.8Gy per fraction, 5days/week; CT: Paclitaxel 50 mg/m2 D1+carboplatin AUC (area under curve) =2 D1, weekly for 6 weeks.~After that, patients receive consolidative platinum-based 3-week chemotherapy for 2 cycles."
2507279|NCT02850653|Other|Endophthalmitis sufferers|Patients hospitalized for diagnostic and therapeutic evaluation of a post-operative acute endophthalmitis.
2507288|NCT02850653|Other|Healthy control patient|Patients hospitalized in the context of a scheduled surgery with sampling of aqueous humour.
2507327|NCT02850289||Pegylated Interferon (PEG-IFN) alfa-2a and Ribavirin|Participants with hepatitis C who were to be treated with combination of pegylated interferon (PEG-IFN) alfa-2a and ribavirin, within 7 days of baseline, with ongoing management at investigator's discretion.
3196739|NCT00853541||heart failure with renal impairment|Heart Failure patients with renal impairment
3196740|NCT00853554|Experimental|A|Hydromorphone Hydrochloride tablet 8 mg
2507488|NCT02849002|Experimental|Interventional Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the brain motion caused by pulsatile blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile blood flow. The system is powered by rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
2507551|NCT02848820|Experimental|Augmentin + Gentamicin|"Initial non-operative treatment strategy reserving an appendectomy for those not responding or with recurrent disease. It consist of:~Clinical observation for 48 hours with administration of Intravenous administration of amoxicillin/clavulanic acid 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) and gentamicin 7mg/kg once daily for 48 hours. If after 48 hours the patient fulfils the predefined discharge criteria, the antibiotics will be switched to oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days and discharge. An appendectomy is reserved for those patients with clinical deterioration, non-improvement after 72 hours or recurrent appendicitis.~Pain medication according to national protocol."
2507614|NCT02848352|Experimental|Negative placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it sensitizes for experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
3196741|NCT00853554|Active Comparator|B|Dilaudid® tablet 8 mg
3196742|NCT00853619|Experimental|Services Demo at PHS and RI|Service based CDS intervention at PHS.
3196743|NCT00853619|Active Comparator|Normal CDS interventions at PHS and RI|Normal CDS intervention at both PHS and RI hospitals
2506798|NCT02854267||Group with guide, after guide's diffusion|For this group, the primary endpoint (refusal rate) will be assessed, using the French Biomedicine Agency database. The secondary endpoints (level of anxiety of the caregivers before the meeting with the next of kins as measured by the french short version of Spielberger test and compliance to the guide) will be assessed by the datasheet prospectively filled by the caregivers. The group with guide is made up by all the registered situations of brain death patients on the database occuring in the 22 intensive care unit forming the 'RESEAU NORD FRANCILIEN' network. The period after the diffusion of the guide is from 1st of january 2017 to 31st of december 2018
2506875|NCT02853773|Experimental|Artificial sweetener|Effects of co-ingestion of artificially sweetened beverage on the response to a test meal
2506879|NCT02853773|Active Comparator|Sugar|Effects of co-ingestion of sugar-sweetened beverage on the response to a test meal
2506885|NCT02853773|Active Comparator|Water|Effects of co-ingestion of water on the response to a test meal
3196744|NCT00853632|Other|Device - CEP Mitral Valve|
3196745|NCT00853684|Experimental|oxaliplatin, capecitabine plus endostar|
3196746|NCT00853697|Experimental|testosterone with the 5α-reductase inhibitor dutast|This trial is a multi-center, open-label, phase II trial of the combination of exogenous testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride in patients with castration-resistant metastatic prostate cancer.
3196747|NCT00853710|Experimental|rapid PSA assay on whole blood|
2507147|NCT02851693|Experimental|Optical Coherence Tomography (OCT)|
2507190|NCT02851342||MS|patients with multiple sclerosis
2507192|NCT02851342||CO|matched control subjects
2507221|NCT02851082|Experimental|Haemophilia A patients|Patients will perform endurance training program on 6 consecutive weeks
3196748|NCT00853736|Experimental|A|Oxycodone hydrochloride tablet 30 mg
3196749|NCT00853736|Active Comparator|B|Roxicodone™ tablet 30 mg
2507310|NCT02850406|Experimental|Voxelotor|"Subjects to receive daily oral dosing of voxelotor according to which Part (A, B, C, or D), the subject is participating in:~Part A: Subjects to receive daily oral dosing of voxelotor for 1 day (single dose)~Part B: Subjects to receive daily oral dosing of voxelotor for up to 24 weeks (multiple dose)~Part C: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)~Part D: Subjects to receive daily oral dosing of voxelotor for up to 48 weeks (1500mg or 1500mg equivalent dose)"
2507366|NCT02849964||First time renal replacement therapy|Patients beginning renal replacement therapy by renal dialysis or preemptive kidney transplant.
3196750|NCT00853775||African American Families|Families with 2 parents and 2 children - no intervention, observational study
3196751|NCT00853775||Caucasian Families|Families with 2 parents and 2 children - no intervention, observational study
2507481|NCT02849041|Experimental|Screening program|Who consults or is hospitalized in a medical services or vascular surgery 'Paris Saint Joseph Hospital Group' (GHPSJ) or 'the European Hospital Georges Pompidou' (HEGP) for occlusive arterial disease or aneurysm the abdominal aorta. This population should accept to have a medical imaging Low-dose CT-scanner and an Identification of Circulating Tumor Cells on their blood. 30 first patients will be proposing to particpate to the psychologic sub-study by answering to a Psychological Questionnaires
2507544|NCT02848846|Experimental|Robotic Hand|The two patient enrolled will perform the task requiring the use of the robotic hand.
2507582|NCT02848417|Experimental|Curcumin|12 weeks 400mg orally twice a day
2507587|NCT02848417|Experimental|Liposomal Glutathione|12 weeks 630mg orally twice a day
2507590|NCT02848417|Experimental|Placebo Liquid or Capsules|"Placebo liquid for Glutathione 120 ml per/ bottle 420 mg/5 ml~Placebo capsules for Curcumin 60 capsules per bottle 400 mg /cap"
2507658|NCT02847988|Active Comparator|Neuro-muscular electrical stimulation|"Intervention:Neuromuscular electrical stimulation (NMES)~NMES stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering NMES"
2507663|NCT02847988|Sham Comparator|Sham stimulation|"Intervention: sham stimulation~Sham stimulation will be applied to lower extremity muscle groups up to 5 days a week until discharge. Standard physical therapy will also be administered by a therapist distinct from the therapist administering sham-NMES"
2507698|NCT02847533|Other|resistant depression|patients suffering from resistant unipolar depression (at least 2 failed antidepressant treatments for the current episode)
3196752|NCT00853801|Experimental|1|Lifestyle modification education and counseling for intervention patients. Diagnosis and treatment education and feedback on performance for providers of intervention patients.
3196753|NCT00853814|Experimental|Reduced access to sedentary behaviors, High park access|
3196754|NCT00853814|Experimental|Usual access to sedentary behaviors, High park access|
3196755|NCT00853814|Experimental|Reduced access to sedentary behaviors, Low park access|
3196756|NCT00853814|Experimental|Usual access to sedentary behaviors, Low park access|
3196757|NCT00853853|Active Comparator|1. EnSeal Device|The EnSeal device cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding. The device is able to seal blood vessels up to 7mm and hemorrhoidal vessels are much smaller than this size.
3196758|NCT00853853|Active Comparator|2. Ferguson Hemorrhoidectomy|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced.
3196759|NCT00853866|Experimental|1|reboxetine + tDCS verum
3196760|NCT00853866|Experimental|2|reboxetine + sham tDCS
3196761|NCT00853866|Experimental|3|placebo drug + verum tDCS
3196762|NCT00853866|Experimental|4|placebo drug + sham tDCS
3196763|NCT00853879|Active Comparator|Arm 1. B6, B12, folate|Triple therapy with folate. Intervention #1.
3196764|NCT00853879|Active Comparator|Arm 2. B6, B12, L-methylfolate|Triple therapy with L-methylfolate. Intervention #2
3196765|NCT00853879|Placebo Comparator|Arm 3. B6, B12, Placebo|Triple therapy with placebo. Intervention #3.
3196766|NCT00853892|Experimental|A|Controlled-Release Oxycodone Hydrochloride 40 mg tablet
2506858|NCT02853838|Experimental|Prolonged slow expiration+provoked coughing+ST|Prolonged slow expiration+provoked coughing+Standard Therapy
2506864|NCT02853838|Active Comparator|Manual chest wall vibration+ST|Manual chest wall vibration+Standard Therapy
2507048|NCT02852538|Experimental|NEW FED TR for Anorexia|NEW FED TR
2507110|NCT02852226|Experimental|Study Intervention|Assess PrEP among women in the study. Assess the characteristics of women who enroll in the PrEP study. Assess the referral sources of women who enroll in the PrEP study
2507143|NCT02851641||Nasolacrimal duct obstruction|
2507188|NCT02851420|Placebo Comparator|control|
2507191|NCT02851420|Experimental|patient|
3173715|NCT00615186|Experimental|A|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
2507277|NCT02850783|Experimental|SLN identification with 89-zirconium-nanocoll|Submucosal injection of 2.5 mBq, 0.4 ml 89-Zirconium-Nanocoll and subsequently SLN identification
2507355|NCT02850484|Active Comparator|Reference 1 Symbicort Inhaler 160/4.5μg|Reference 1: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2507356|NCT02850484|Experimental|SYN010 HFA Inhaler|SYN010 HFA (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2507358|NCT02850484|Active Comparator|Reference 2 Symbicort Inhaler 160/4.5μg|Reference 2: Symbicort Inhaler (Budesonide/ Formoterol, 160/4.5μg), Single dose, 8 puffs
2507389|NCT02849782|Experimental|Fampridine responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner."
2507393|NCT02849782|Active Comparator|Fampridine non responder|"Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner."
2507432|NCT02849561|Active Comparator|Favourable neurological evolution after cardiac arrest|MGOS 4-5
2507435|NCT02849561|Active Comparator|Unfavourable neurological evolution after cardiac arrest|MGOS 1-3
2507499|NCT02848963|Active Comparator|ketamine-propofol mixture 5/1|Ketamine-propofol mixture will be compare for every groups.
2507506|NCT02848963|Active Comparator|ketamine-propofol mixture 10/1|Ketamine-propofol mixture will be compare for every groups.
2507510|NCT02848963|Active Comparator|Ketamine-propofol mixture 6,7/1|Ketamine-propofol mixture will be compare for every groups
2507535|NCT02848690|Experimental|Educational Intervention Group|Participants assigned to the educational intervention group will have dietitian consultation to receive a dietary planning based on diet rich of fruits, vegetables, low fat, low processed foods and high nonfat dairy. During six months they will have monthly dietitian appointments including educational sessions to stimulate sodium restriction and enhance to follow the dietary planning. Each 15 days they will be contacted by phone to reinforce adherence to sodium restriction diet.
2507536|NCT02848690|Sham Comparator|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
3196767|NCT00853892|Active Comparator|B|OxyContin® 40 mg tablet
3196768|NCT00853918|Experimental|$20 Cash|
2507726|NCT02847663|Experimental|Whole-body cryotherapy|The effects of whole-body cryotherapy (-135°C for 2 minutes) are investigated after a muscle damage protocol.
2507736|NCT02847663|Other|Cold-water immersion|The effects of cold-water immersion (10°C for 15 minutes) are investigated after a muscle damage protocol.
2507760|NCT02847104||dynamic insulin protocol|patients received intravenous insulin infusion according to a dynamic insulin protocol
2507761|NCT02847104||static insulin protocol|patients received intravenous insulin infusion according to a static insulin protocol
2507770|NCT02846935|Experimental|Decitabine + Tetrahydrouridine|"oral THU dosed by weight, followed by oral decitabine dosed by weight for 60 minutes (± 10 minutes) after the THU, twice weekly on consecutive days.~Treatment on protocol monitoring continues for 52 weeks."
2507823|NCT02846675|Experimental|SVF treatment (random knee)|A random knee (left or right) of subjects will be treated with autologous SVF.
2507828|NCT02846675|Placebo Comparator|placebo treatment (the other knee)|The other knee of subjects will be treated with placebo.
3196769|NCT00853918|Experimental|$50 Cash|
2549513|NCT02568280|Experimental|Faster aspart|
3196770|NCT00853918|Experimental|$50 Check|
3196771|NCT00853918|Experimental|$100 Check|
3196772|NCT00853931|Experimental|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
3196773|NCT00853944|No Intervention|P|subjects take 1 tablet of placebo daily
3196774|NCT00853944|Experimental|S|subjects take 1 tablet of sitagliptin 100 mg daily
3196775|NCT00854009|Experimental|1|BLI-489
3196776|NCT00854009|Placebo Comparator|2|Placebo
2506867|NCT02854046||Calciphylaxis Cases|Adult patients with advanced chronic kidney disease (DFG estimation < 30 ml/min/1.73m² - beyond 3B stage) with/without substitute therapy who has presented a case of calciphylaxis (Calcific Uremic Arteriolopathy) between 2006 and 2016 in the Regions of Pays de la Loire, Centre Val de Loire, Bretagne and Poitou-Charentes
2506869|NCT02854046||Witness cases|"Selected anonymously in French national register REIN. Matched to Calciphylaxis Cases according to gender, age, treatment by extrarenal purification at the timepoint onset of the lesions and REIN regions belonging"
2506944|NCT02853162|Experimental|ARREST-study|SBRT renal cell carcinoma 5 times 7Gy
2506955|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group A (Fasting)|Participants will receive single dose of ASP2151 assigned to Group A on day 1
2506957|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group B (Fasting)|Participants will receive single dose of ASP2151 assigned to Group B on day 1
2506959|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group C (Fasting)|Participants will receive single dose of ASP2151 assigned to Group C on day 1
2506961|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group D (Fasting)|Participants will receive single dose of ASP2151 assigned to Group D on day 1
2506962|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group E (Fasting)|Participants will receive single dose of ASP2151 assigned to Group E on day 1
2506963|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group F (Fasting)|Participants will receive single dose of ASP2151 assigned to Group F on day 1
2506964|NCT02852876|Placebo Comparator|Part 1: Placebo Single Ascending Dose (Fasting)|Participants will receive single dose of matching placebo on day 1
2506965|NCT02852876|Experimental|Part 2: ASP2151 (Fasting)|Participants will receive a single dose of ASP2151 under fasted conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
2506966|NCT02852876|Experimental|Part 2: ASP2151 (Fed)|Participants will receive a single dose of ASP2151 under fed conditions on day 1 in the first treatment period (period 1). Following a wash-out period of at least five days, the treatment will be repeated in the reverse orientation (period 2)
2506972|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group G (Fasting)|Participants will receive single dose of ASP2151 assigned to Group G on day 1
2506979|NCT02852876|Experimental|Part 1: ASP2151 Single Ascending Dose Group H (Fasting)|Participants will receive single dose of ASP2151 assigned to Group H on day 1
2507053|NCT02852512|Active Comparator|Laparoscopic sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be laparoscopic
2507058|NCT02852512|Active Comparator|Robotic assisted Sacrocolpopexy|The surgical technique will be the same between the two approaches, in this arm the approach will be robotic assisted
3163605|NCT00484055|Active Comparator|treatment|"Use of local CollagenGentamicin and enhanced sternal fixation according to the Clinical routine introduced 4 years earlier as a result of a previous RCT on 2000 patients. In that sense these patients did not receive any intervention but just the standard treatment introduced 4 years earlier.~The aim of the study was to PROSPECTIVELY include a defined number of patients to compare their complication rate with that from aControl Group of patients från a previous RCT to verify that the effect of the treatment was stable over time.~As the study did not include any intervention compared to the present standard treatment at that time ethical approval was Exempt."
2507142|NCT02851667|Experimental|Training group|Resident training programs such as talks, day camp and thematic activities were delivered in training group.
2507198|NCT02851433|Experimental|Sevoflurane Group|
2507200|NCT02851433|Active Comparator|Propofol Group|
2507367|NCT02849977||Cohort 1|If the subject has a history of hyperphagia, early onset obesity and/or clinical characteristics known to be related to mutations in the MC4R pathway and related to obesity (1.4 times 95th percentile in children).
2507368|NCT02849977||Cohort 2|If the subject has exponentially high BMI (≥50 to 59), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.5 - 1.6 times 95th percentile in children).
2507369|NCT02849977||Cohort 3|If the subject has exponentially high BMI (≥60), without hyperphagia and early onset obesity, whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.6 times 95th percentile in children).
2507370|NCT02849977||Cohort 4|If the subject has had or is undergoing bariatric surgery, who represents a refractory population of severely obese individuals whose obesity may be driven by an MC4R pathway mutation in the absence of other clear history or clinical characteristics (1.4 times 95th percentile in children and adolescents aged 12 and older).
2507434|NCT02849457|Placebo Comparator|Vigabatrin or Placebo|Vigabatrin or Placebo is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
2507437|NCT02849457|Other|Vigabatrin|Vigabatrin open label is given for administration, the entire content of one sachet (500 mg active drug) is dissolved in 10 ml water for oral administration that is dosed according to body weight 50-150 mg/kg/day divided BID. Dosing will follow established recommended guidelines (50 mg/kg/day and increased as needed by 50 mg/kg/day every 3 days up to a maximum dose of 150 mg/kg/day, divided BID).
2507441|NCT02849457|No Intervention|Control Group|Enrolled subjects who never develop EEG abnormalities or clinical seizures
2507500|NCT02848950|Active Comparator|treatment|drug: metformin
2507505|NCT02848950|No Intervention|control|without metformin
2507605|NCT02848352|Experimental|Positive placebo group|Participants receive a nasal spray that is a placebo. However, they are told that it protects from experiencing negative emotions. Participants watch a film sequence that is supposed to induce sadness.
2507762|NCT02847156|Other|cystic fibrosis infants|1 year follow-up in CF infants
2508469|NCT02842424|Experimental|Ramipril Treatment|6 months treatment with the medication Ramipril
3163606|NCT00484120|Experimental|1|3% Diclofenac NE cream
3163607|NCT00484120|Placebo Comparator|2|
3163608|NCT00484211|Experimental|A|
3163609|NCT00484263|Active Comparator|1|
2506886|NCT02853643|Experimental|100 mg Food effect cross over|100 mg single dose under both fasted and fed conditions in a cross over fashion
2506925|NCT02853357|Sham Comparator|Control|The control group includes randomized participants that will receive a sham manipulation. Participants will also complete the standard set of core strengthening exercises.
2506931|NCT02853357|Experimental|Manipulation|The manipulation group includes randomized participants that will receive a thoracic spine thrust manipulation. Participants will also complete the standard set of core strengthening exercises.
2506994|NCT02852863|Experimental|Ultrasound (case only)|Subjects will fast for a minimum of 8 hours. Ultrasound assessment of gastric volume and content will determine basal conditions. Next, subjects will chew gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
3196777|NCT00854022||Healthy|Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
3196778|NCT00854022||RCC|Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
2507125|NCT02852044|Active Comparator|Rest|Remain rested prior to the oral glucose tolerance test
2507126|NCT02852044|Experimental|Exercise|Complete exercise prior to the oral glucose tolerance test
2507226|NCT02851290|Experimental|Caudal block|Local anesthetic will be administered into the caudal space
2507233|NCT02851290|Active Comparator|Dorsal penile nerve block|Local anesthetic will be administered around the dorsal penile nerve
2507276|NCT02850770|Other|Control|Pedometers and walking logs
2507281|NCT02850770|Experimental|Phone Messaging|Phone Messaging
2507289|NCT02850770|Experimental|Phone Messaging + Family/Friend Support|Phone Messaging + Family/Friend Support
2507360|NCT02850133|Experimental|Spinal cord injury|Cardio-pulmonary exercise testing and aerobic exercise training
2507381|NCT02849821|Other|hypobaric pressure chamber|The healthy volunteers and IBD patients will have a 3-hour exposure to hypoxic conditions simulating an altitude of 4,000 meters above sea level (m.a.s.l.) in a hypobaric pressure chamber. Before and after the pressure chamber sigmoidoscopy will be performed. During stay in the pressure chamber repetitive measurements of bladder volume will be performed by sonography.
2507449|NCT02849613|Experimental|Adipose derived Stem Cells ADSC|ADSC, single IV, 1.106 cells/kg
2507456|NCT02849613|Sham Comparator|Vehicle media|IV infusion of cell excipients, 1ml/kg
2507490|NCT02849106|Experimental|biopsy to obtain a chemogram|
2507533|NCT02848859|Active Comparator|Intervention: Go! to Sleep|We are using a web-based cognitive behavioral therapy program called Go! to Sleep. Go! to Sleep is an interactive online program developed by specialists in Cleveland Clinic's Wellness Institute and Sleep Disorders Center. The program is a 6 week self-help program that uses cognitive behavioral therapy techniques that have been proven to be effective in decreasing symptoms of insomnia.
2507534|NCT02848859|Placebo Comparator|General Sleep Hygiene Education|General Sleep Hygiene Education is the first step in the treatment of any sleep disorder. Both arms will have access to a Harvard sleep education web site that provides general information about sleep as well as sleep hygiene.
2507579|NCT02848443|Experimental|S 95005 + oxaliplatin (+/- bevacizumab or nivolumab)|
2507660|NCT02847962|No Intervention|Control (No FBF)|FBF provided after the intervention period
2507662|NCT02847962|Active Comparator|Corn Soy Blend Plus (CSB+)|Consumed Corn Soy Blend Plus (CSB+)
2507664|NCT02847962|Experimental|Corn Soy Blend 14 (CSB14)|Consumed Corn Soy Blend 14 (CSB14)
2507669|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 1|Consumed White Sorghum Cowpea Blend Variety 1
2507671|NCT02847962|Experimental|White Sorghum Cowpea Blend Variety 2|Consumed White Sorghum Cowpea Blend Variety 2
2507674|NCT02847962|Experimental|Red Sorghum Cowpea Blend|Consumed Red Sorghum Cowpea Blend
2507677|NCT02847962|Experimental|White Sorghum Soy Blend|Consumed White Sorghum Soy Blend
2507733|NCT02847416|Experimental|Inspiratory group|the subjects will be instructed to inspire as deeply as possible with steady flow rate for 3 seconds with end-inspiratory pause for 2-3 seconds through the inspiratory circuit and follow by passive exhalation
2507739|NCT02847416|Experimental|expiratory group|the subjects will be instructed to inspire as deeply as possible through the nose with end-inspiratory pause for 2-3 seconds and partially forced exhalation with reach to 1/3 of expiratory reserve volume (ERV) for at least 3 seconds through expiratory circuit
2507768|NCT02847091|Experimental|Ipragliflozin Group|Ipragliflozin will be administered orally for 24 weeks.
2507816|NCT02846597|No Intervention|Control|Infants in this group will not receive sustained lung inflation in the delivery room and will be put immediately on CPAP at a pressure of 5 cm H2O.
2507818|NCT02846597|Active Comparator|High pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2507820|NCT02846597|Active Comparator|High pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 20 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2507821|NCT02846597|Active Comparator|Low pressure for long duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 20 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2507822|NCT02846597|Active Comparator|Low pressure for short duration|Infants in this group will receive sustained lung inflation in the delivery room at a pressure of 15 cm H2O for a duration of 10 second for a single intervention followed by CPAP at a pressure of 5 cm H2O.
2507876|NCT02846389|Experimental|Moderate Exercise|Moderate exercise - 15 minutes a day using a pedal box before or after radiation at the hospital (75 minutes a week).
2507878|NCT02846389|No Intervention|Control Group|No exercise
2507900|NCT02846155|Placebo Comparator|clear water group|the patients only drink 1000ml clear water before checking
2549514|NCT02568280|Active Comparator|Insulin aspart|
3196779|NCT00854035|Experimental|E|
3196780|NCT00854035|Placebo Comparator|P|
2506981|NCT02852993||Transfused patients|A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.
2507035|NCT02852733||Residents in end-of-life situation|"Residents in end-of-life situation the day of the survey, as determined by the physician coordinator of nursing homes (we will use the definition of terminal condition contained in the guide of the CNSA (coding PATHOS - April 2011))."
2507040|NCT02852733||dead residents|dead residents in the quarter preceding the date of the survey
2507066|NCT02852317||Spina bifida patient|
2507067|NCT02852317||Patients with multiple sclerosis|
2507068|NCT02852317||Patients with spinal cord injury|
2507069|NCT02852317||Patients with overactive bladder|
2507135|NCT02852070|Active Comparator|control group|Bronchoscopy examination with 120ml sterile saline solution for bronchoalveolar lavage
2507138|NCT02852070|Experimental|observation group|Bronchoscopy examination with 60ml sterile saline solution for bronchoalveolar lavage
2507193|NCT02851472|Experimental|Inhaled Nitric Oxide|iNO will be given at 20 ppm, continuous, via inhalation before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
2507194|NCT02851472|Active Comparator|Placebo|Placebo gas (nitrogen) will be given continuous, via inhalation at the same ppm, before (1 hour), during (3 hours) and after (2 hours) elective blood transfusion and NIRS monitoring
2507224|NCT02851017|Experimental|Exergaming group (XBOX Kinect|Kinect™ exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total).
2507232|NCT02851017|Experimental|Traditional gym based exercise group|Traditional gym based (TGB) exercise group performed sessions on three non-consecutive days per week for 4 weeks (12 sessions in total). Those in the TGB group performed exercises that were matched for sequence, intensity, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading as required in the Kinect™ group.
2507275|NCT02850861|Experimental|The experimental group|In this group, the condylar reductor was applied in the surgical treatment of mandibular condylar fractures.
2507286|NCT02850861|No Intervention|The control group|In this group, traditional surgical instruments were applied in the surgical treatment of mandibular condylar fractures.
2507333|NCT02850497|Active Comparator|CRE8 stent|Treatment with CRE8 stent implantation and evaluated with optical coherence tomography at 6 months
2507336|NCT02850497|Active Comparator|Biomatrix stent|Treatment with Biomatrix stent implantation and evaluated with optical coherence tomography at 6 months
2507347|NCT02850497|Active Comparator|patients treated with Xience stent|Treatment with Xience stent implantation and evaluated with optical coherence tomography at 6 months
2507401|NCT02849899|Active Comparator|Vildagliptin|Group 1 will be treated with Vildagliptin 50 or 100 mg/day for 2 months, then 25 or 50 mg/d for 1 month depending on their creatinine assay.
2507402|NCT02849899|Placebo Comparator|Placebo|Group 2 will be treated with placebo according to the same dosage.
3196781|NCT00854074|No Intervention|2|Subject will be observed until recovery of normal GI function
3196782|NCT00854074|Experimental|1|Spinal neurostimulation
2507694|NCT02847715|No Intervention|Audit phase|In the audit-phase, a group of 59 patients will be recruited and followed over a 12 month period. Data will be collected on clinical and patient outcomes in an audit in order to be able to compare to the intervention (after-phase) group.
2507696|NCT02847715|Experimental|Intervention (pilot-phase)|In the pilot-phase, a group of 59 patients will be recruited and followed over a 6-12 month period. Patients in this group will be assigned to the new remote monitoring follow-up pathway (ePRIME), whereby instead of attending routine outpatient appointments they are monitored remoted via a online symptom monitoring questionnaire and related clinical tests undertaken remotely. All information is collated in the patient's electronic patient record, and clinicians will review/respond to the data as necessary.
2507720|NCT02847351|Placebo Comparator|Control Diet (CD)|Period 1(the first 4 weeks): 10 subjects were randomly assigned to Control Diet: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with a normal white grain flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day (bread, pasta, runks) with crackers produced with Arabinoxylan-enriched flour.
2507764|NCT02847013|Placebo Comparator|Placebo- Tap block w normal saline|After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
2549515|NCT02568202||Survey|
3196783|NCT00854126|Experimental|1|
3196784|NCT00854139|Experimental|Bone marrow and renal transplant|Cyclophosphamide, anti-thymocyte globulin, thymic irradiation conditioning and kidney transplant and bone marrow transplant from a related donor for patients with multiple myeloma and end stage renal disease with cyclosporine for graft versus host disease prophylaxis
3196785|NCT00854152|Experimental|1|
3196786|NCT00854178|Experimental|2|
3196787|NCT00854191|Experimental|1|4 half-day of simulator ERCP practice and usual training
3196788|NCT00854191|Active Comparator|2|Usual training
3196789|NCT00854217|Placebo Comparator|placebo, hemodilution|
3196790|NCT00854230|Experimental|1|Naltrexone
3196791|NCT00854230|Placebo Comparator|2|
3196792|NCT00854256|Experimental|Canaloplasty|
3196793|NCT00854256|Active Comparator|Trabeculectomy with mitomycin C|
3196794|NCT00854295|Other|1|Follow-up of existing IDE study subjects
3196795|NCT00854295|Other|2|Newly enrolled study subjects
3196796|NCT00854321||patients with active RA|drug, follow-up
3196797|NCT00854334||1.|Children with both obesity and obstructive sleep apnea
3196798|NCT00854334||2|Children without the presence of both obesity and obstructive sleep apnea
3196799|NCT00854386|Active Comparator|1|liberal fluid administration group
3196800|NCT00854386|Experimental|2|Restrictive fluid administration group
3196801|NCT00854425|Experimental|L-asp|
3196802|NCT00854438|Experimental|Active treatment arm|Reduction of anticholinergic drug effects by pharmacist review
2506968|NCT02853097||Ancillary-Correlative (blood collection)|Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.
2507037|NCT02852668|Experimental|Power Training Group|Physical exercises. Strength training performed quickly
2507041|NCT02852668|Experimental|Strength Training Group|Physical exercises. Strength training performed in moderate speed
2507045|NCT02852668|No Intervention|Control Group|This group maintained the same physical activity level during the intervention period.
2507083|NCT02852239|Experimental|Group 1 - Normal renal function|Subjects with normal renal function defined as GFR ≥ 90 mL/min at baseline and matching to the renal impaired subject based on gender, race, age, and weight.
2507085|NCT02852239|Experimental|Group 2 - Severe renal function|Subjects with severe renal impairment defined as GFR of 15-29 mL/min at baseline.
2507086|NCT02852239|Experimental|Group 3 - End stage renal disease (ESRD)|Subjects with end stage renal disease (ESRD), defined as GFR of <15 mL/min at baseline.
2507152|NCT02851849|Active Comparator|LGD-6972-5 mg|5 mg LGD-6972 QD
2507154|NCT02851849|Active Comparator|LGD-6972-10 mg|10 mg LGD-6972 QD
2507158|NCT02851849|Active Comparator|LGD-6972-15 mg|15 mg LGD-6972 QD
2507164|NCT02851849|Placebo Comparator|Placebo|Placebo QD
2507229|NCT02851043|Experimental|pneuRIP(breathing with resistance)|Testing the subjects breathing with resistance
2507237|NCT02851043|No Intervention|Respitrace system (Carefusion) (breathing without resistance)|Testing subjects breathing without resistance
2507296|NCT02850822||Therapy pre-transplantation|Chemotherapy regimen and/or demethylation drugs(such as decitabine) were given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
2507301|NCT02850822||No Therapy pre-transplantation|No therapy (chemotherapy or demethylation drugs) was given pre-transplantation for patients with RAEB-1, REAB-2 and AML Secondary to MDS (bone marrow blast cells less than 50%).
3163610|NCT00484276|Experimental|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every 3 weeks or weekly
3163611|NCT00484302|Experimental|CapOpus|
3163612|NCT00484302|Active Comparator|Treatment as usual|
2507379|NCT02850081|No Intervention|Observational - Maximal Dose - ARM 1|Patients on a pre-existing maximal dose of either Simvastatin (40mg) with/without currently taking amlodipine (Norvasc) and those on Simvastatin 20mg while currently on amlodipine; Atorvastatin (80mg), or Rosuvastatin (20mg) regimen will be observed for ~2 weeks before their CEA.
2507380|NCT02850081|Experimental|Less Than Maximal Dose - ARM 2|Patients on a pre-existing statin regimen at a lower dose (less than maximal) of Simvastatin <40mg without amlodipine and <20mg with amlodipine; Atorvastatin (<80mg) or Rosuvastatin (<20mg) will be randomized to maintain their current dose plus placebo or be increased to the maximal dose of their current statin for ~2 weeks before their CEA.
2507382|NCT02850081|Experimental|Statin Naive - ARM 3|Patients on no pre-existing statin regimen will be randomized to Atorvastatin 10 mg or Atorvastatin 80 mg for ~2 weeks before their CEA
2507477|NCT02849405|Other|Arteriosclerosis|Hyperspectral camera for arteriosclerosis Diagnostic
2507478|NCT02849405|Other|Healthy controls|Hyperspectral camera for healthy control Diagnostic
2507653|NCT02848066||Gastric Cancer patients|This arm is composed of the gastric cancer patients. It is perfomed a blood sampling to them after the research registration.
2507655|NCT02848066||Cancer-free healthy volunteers|This arm is composed of the cancer-free healthy volunteers. It is perfomed a blood sampling to them after the research registration.
2507725|NCT02847611|Experimental|Jamar then Labin|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
2507732|NCT02847611|Experimental|Labin then Jamar|"The order of the using of the dynamometers Jamar then Labin or Labin then Jamar is chosen by randomization"
2507811|NCT02847117|Other|Mastiha|
3163613|NCT00484328|Experimental|1|
2507901|NCT02846155|Experimental|simethicone group|the patients drink 950ml clear water and 15ml simethicone before checking
3163614|NCT00484328|Experimental|2|
3163615|NCT00484341|Experimental|A: low-dose NGR-hTNF|0.8 mcg/m² of NGR-hTNF
3163616|NCT00484341|Experimental|B: high-dose NGR-hTNF|45 mcg/m² of NGR-hTNF
3163617|NCT00484341|Experimental|C: low-dose NGR-hTNF + doxorubicin|0.8 mcg/m² of NGR-hTNF + doxorubicin
3163618|NCT00484341|Experimental|D: high-dose NGR-hTNF + doxorubicin|45 mcg/m² of NGR-hTNF + doxorubicin
3163619|NCT00484367|Active Comparator|1 AGT|
3163620|NCT00484367|Active Comparator|2 TFT|
3163621|NCT00484432|Experimental|A: NGR-hTNF + doxorubicin|NGR-hTNF plus doxorubicin
3163622|NCT00484458|Experimental|1|Wallis Stabilization System
3163623|NCT00484458|Active Comparator|2|Total Disc Replacement
3163624|NCT00484471|Experimental|1|
3163625|NCT00484471|Placebo Comparator|2|
3163626|NCT00484484|Experimental|1|Ketamine
3163627|NCT00484484|Experimental|2|Ketamine
3163628|NCT00484510|Experimental|Ascorbic Acid|
3163629|NCT00484510|Placebo Comparator|Placebo|
3163630|NCT00484536|Experimental|CDP323 1000 mg/day|
3163631|NCT00484536|Experimental|CDP323 500 mg/day|
3163632|NCT00484536|Placebo Comparator|Placebo|
3163633|NCT00484562|Active Comparator|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
3163634|NCT00484562|Active Comparator|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
3163635|NCT00484562|Active Comparator|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
3163636|NCT00484562|Active Comparator|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
3163637|NCT00484575|Active Comparator|propofol|propofol for sedation minimum 2 hours in CTICU after CABG
3163638|NCT00484575|Experimental|sevoflurane|Sevoflurane via AnaConDa for minimum 2 hours in CTICU after CABG
3163639|NCT00484601|Experimental|Ifosfamide and Doxorubicin|Single arm treatment with Ifosfamide and Doxorubicinin patients with Refractory Nasopharyngeal Carcinoma
2507076|NCT02852421|Active Comparator|Multiple injection paravertebral blocks|"Patients in this group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
2507077|NCT02852421|Experimental|Single injection paravertebral block|"Patients in single injection group will receive single injection paravertebral blocks at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections."
2507121|NCT02851953|Experimental|Aqueduct 100 dilation|Uterine cervix dilation through Aqueduct-100 device
3196803|NCT00854438|No Intervention|Control|No intervention
3196804|NCT00854451|Active Comparator|1 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 500mg qid 2wk
2507241|NCT02851121|Other|Healthy volunteers|
2507352|NCT02850523|Experimental|Experimental|After an initial assessment, the experimental group will receive 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety (n=6 per group) for perinatal anxiety. They will then be re-assessed at post-treatment and 3 months post-treatment to determine the effectiveness of the treatment and whether these effects are maintained 3 months after treatment.
2507354|NCT02850523|No Intervention|Waitlist Control|After an initial assessment, the wait-list control group will not receive any treatment for 6 weeks. They will then be re-assessed after 6 weeks and this data will be used to compare this group to the experimental group to determine the effectiveness of the treatment. After this re-assessment they will be offered the same treatment as the experimental group: 6 weekly sessions (2 hours long) of group Cognitive Behavioural Therapy for Perinatal Anxiety
2507378|NCT02849860|Experimental|IDP-121 Lotion|Lotion
3196805|NCT00854451|Active Comparator|2 omeprazole plus amoxicillin|omeprazole 20mg bid 2wk + amoxicillin 250mg qid 2wk
2507682|NCT02847767|Experimental|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution.
2507704|NCT02847455|Experimental|5 mg ilaprazole|
2507708|NCT02847455|Experimental|10 mg ilaprazole|
2507709|NCT02847455|Active Comparator|10mg Rabeprazole|
2507852|NCT02846727||Sepsis Group|This group will consist of surgical intensive care patients with diagnosis of sepsis, severe sepsis, or septic shock.
2507855|NCT02846727||Control Group|This group will consist of patients that serve as controls who do not have diagnosis of sepsis, severe sepsis, or septic shock.
3196806|NCT00854451|Active Comparator|3 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 500mg qid 2wk
3196807|NCT00854451|Active Comparator|4 omeprazole plus amoxicillin|omeprazole 20mg qd 2wk + amoxicillin 250mg qid 2wk
2508079|NCT02845024|Active Comparator|oral doxycycline|Oral capsules of doxycycline 100 mg were used
2508082|NCT02845024|Placebo Comparator|oral placebo capsule|oral placebo capsule were used
2508147|NCT02844686|Experimental|Cardiac Dynamic SPECT|
2508197|NCT02844309|Experimental|Thalidomide|thalidomide 50-150mg per night
2508255|NCT02843815|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508256|NCT02843815|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508315|NCT02843256||Patients receiving intravenous nutrition|Patients will blow into a bag that will capture 500 mL of their exhaled air daily for 7 days or the length of the parenteral nutrition, whichever is shorter. The Isomark Canary will analyze the air to generate a breath delta value.
2508395|NCT02842892|Other|Squat Jump|
2508397|NCT02842892|Other|Drop Jump|
2508404|NCT02842892|Other|Countermovement Jump|
2508442|NCT02842385|Active Comparator|Nonsubmerged thick group|Nonsubmerged type of implants placed with thick (>3 mm) soft tissue
2508444|NCT02842385|Active Comparator|Nonsubmerged thin group|Nonsubmerged type of implants placed with thin (<3 mm) soft tissue
2508446|NCT02842385|Active Comparator|Submerged thick group|Submerged type of implants placed with thick (>3 mm) soft tissue
2508451|NCT02842385|Active Comparator|Submerged thin group|Submerged type of implants placed with thin (<3 mm) soft tissue
2508487|NCT02842112||CD34+ CD38-|A first cell population, which expressed the CD34 antigen and lacked CD38 (CD34+ CD38-), and often contained very few events requiring to be tightly clustered in a forward light scatter /side light scatter (FSC/ SSC) and CD45/SSC plot;
2508493|NCT02842112||CD34+ CD38low|A second population characterized by expression of the CD34 antigen and by a low density of CD38 antigen (CD34+ CD38low)
3196808|NCT00854503|Active Comparator|Simvastatin|Simvastatin 20 mg/day
3196809|NCT00854503|Active Comparator|Rosuvastatin|Rosuvastatin 20 mg/day
3196810|NCT00854529|Experimental|1|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 1 week after the surgery
3196811|NCT00854529|Active Comparator|2|20 patients who had an uneventful trabeculectomy with usage of mitomycin C, will receive subconjunctival bevacizumab 2 weeks after the surgery
2507176|NCT02851485|Experimental|GLPG1972 600 mg oral solution fasted|600 mg GLPG1972 administered as oral solution after overnight fasting
2507179|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fasted|600 mg GLPG1972 administered as oral tablet after overnight fasting
2507180|NCT02851485|Experimental|GLPG1972 600 mg oral tablet fed|600 mg GLPG1972 administered as oral tablet after a high-fat high-calorie breakfast
2507222|NCT02851160||Patients requiring lung cancer chemotherapy|30 major Patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment having a semi-structured interview conducted by a clinical psychologist
2507231|NCT02851160||Family of lung cancer patients receiving chemotherapy|30 Family of lung cancer patients receiving chemotherapy having a semi-structured interview conducted by a clinical psychologist
2507240|NCT02851160||doctors caring for lung cancer patients receiving chemotherapy|15 doctors caring for lung cancer patients receiving chemotherapy 15 have a semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
2507292|NCT02850809||patients|Treated by percutaneous image-guided radiofrequency for renal tumor
2507359|NCT02850146|Experimental|18F-AV-1451|50 individuals who are cognitively normal, older, Aβ not elevated and enrolled in the LEARN study will undergo 18F-AV-1451 imaging procedures at 4 time points over a 4.5 year period.
2507398|NCT02849769||Patients implanted with an MR-conditional Tachy device system|Patients implanted with an MR-conditional Tachy device system in the routine care
2507461|NCT02849522||PAE patients|Men who have undergone PAE and are in the UK ROPE Register
2507466|NCT02849522||Comparator treatment patients|Men who have undergone TURP, Open Prostatectomy or laser ablation/enuclation of the prostate, and are on the UK ROPE Register.
2507489|NCT02848976||IA group|EDSS (Expanded Disability Status Scale) below 6 with RE
2507493|NCT02848976||IB group|EDSS (Expanded Disability Status Scale) below 6 with no RE
2507496|NCT02848976||IIA group|EDSS (Expanded Disability Status Scale) betwin 6 and 8 with RE
2507497|NCT02848976||IIB group|EDSS (Expanded Disability Status Scale) below 6 with RE
2507548|NCT02848781|Experimental|ICD with Ablation|Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.
2507555|NCT02848781|Active Comparator|ICD Only|Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.
2507557|NCT02848781|Active Comparator|Ablation Only (Registry)|The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.
2507583|NCT02848183|Experimental|Pediatric de novo acute myeloid leukemia|"I. Chemotherapy Induction-1: Cytarabine + idarubicin Induction-2: High dose (HD) cytarabine + mitoxantrone Consolidation-1: Cytarabine + idarubicin Consolidation-2: HD cytarabine + etoposide Consolidation-3: HD cytarabine + mitoxantrone Consolidation-4: HD cytarabine + etoposide~II. Allogeneic hematopoietic stem cell transplantation (HSCT) Favorable prognosis group: chemotherapy only Intermediate prognosis group: chemotherapy or HSCT with reduced intensity conditioning Poor prognosis group: HSCT with myeloablative conditioning"
2507651|NCT02847897|Experimental|CO2 AcuPulse Laser treatment|Subjects with vulvovaginal atrophy intended to receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
2507836|NCT02846818|Experimental|Low mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were randomized to usual range MAP (40 to 60 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
2507839|NCT02846818|Experimental|High mean arterial perfusion pressure|5 patients undergoing primary, elective coronary artery bypass grafting were blindly randomized to intervention group MAP (60 to 80 mmHg) during CPB. Microdialysis catheters were positioned in a retrograde direction in the internal jugular vein.
2507972|NCT02846012|No Intervention|CSCM Control|Control medium
2507979|NCT02846012|Experimental|CSCM2|New Formulation medium
2508043|NCT02845414|Experimental|Intravenous Infusion of dCD133KDEL|
2508114|NCT02844933|Experimental|Cannabidiol|Cannabidiol oral solution (40 mg/kg/day) divided into two daily doses with a standard meal
2508117|NCT02844933|Placebo Comparator|Placebo|Matching placebo solution divided into two daily doses with a standard meal
2508151|NCT02844465|Experimental|Treatment|Visualase MRI-guided laser ablation procedure
2508199|NCT02844101|Other|non-blinded group|The non-blinded subjects will be informed that the accelerometer device (GT3X Actigraph accelerometer) is an accelerometer that assessed physical activity levels and patterns
2508202|NCT02844101|Other|blinded group|The blinded subjects will be informed that they will test the reliability of a new device for body posture assessment and these youngsters will not receive any information with regards to physical activity.
2508257|NCT02843828|Experimental|Samsung Hip Assist v1|gait rehabilitation with Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
2508258|NCT02843828|Active Comparator|Conventional gait training|gait rehabilitation without Samsung Hip Assist v1 10 sessions (5sessions - treadmill gait training / 5sessions - overground gait training), 30 min per session
2508335|NCT02843347||Biorepository substudy participants|Participants from the main study who give consent for the genetic testing substudy.
2508475|NCT02842320|Experimental|Additional biological samples|Bone marrow sample and blood collected at J0 (screening visit), and at 3, 6, 12, 18 and 24 months and at each additional consultations (relapse ...)
2508532|NCT02841488|Active Comparator|Continuous nerve block|Continuous peripheral sciatic nerve block through popliteal perineural catheter with ropivacaine
2508534|NCT02841488|Active Comparator|Systemic analgesia|Intravenous fentanyl patient controlled analgesia device
2508604|NCT02841345|Other|Bipolar|bipolar patients type I or II (DSM-IV TR), euthymic phase
2508607|NCT02841345|Other|Schizophrenic|schizophrenic loss or paranoid or undifferentiated patients
2508609|NCT02841345|Other|Control|control group (paired in age and sex for patients)
2508678|NCT02840773|Active Comparator|Test group-baseline|Press-fit implant connection was monitored at baseline
2549531|NCT02568306|Experimental|NNC0165-1562|
3196812|NCT00854529|No Intervention|3|20 patients after an uneventful trabeculectomy with usage of mitomycin C, will not receive any bevacizumab injection.
3196813|NCT00854542|Active Comparator|TCSCT|
3196814|NCT00854542|Placebo Comparator|Usual Care|
2507335|NCT02850198|Experimental|Scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
2507345|NCT02850198|Sham Comparator|Sham scalp electroacupuncture group|Select a 1.5 cun long disposable sterile filiform needle NO.30.Divide the Anterior oblique line of the vertex-temporal in ipsilesional into three equal parts to accept acupuncture.Insert the needle subcutaneously at a 30°angle to the scalp.The depth of insertion is 1 cun.The needle is twirled continuously at a frequency of about 170 times per minute.When the acupuncture sensation is obtained,connect the positive and negative outputs of the electroacupuncture to the handle of the needle in the Anterior oblique line of upper 1/3 and the middle 1/3. with shame electroacupuncture. Select an sparse-dense wave .Use the low frequency electroacupuncture which the frequency is 2Hz. Every session lasts for 30 min per day.The treatment must be given once daily and 5 sessions constitute one therapeutic course.There is 2 days for relaxation between the two therapeutic courses.The participants must be treated for 4 weeks.
2507388|NCT02849925|Experimental|Glass Ionomer Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of Glass ionomer sealant, EQUIA (GC) in first permanent molars.
2507392|NCT02849925|Active Comparator|Resin Sealant|Sealants to arrest microcavitated caries. 75 microcavitated ICDAS 3 lesions will be sealed by the use of resin sealant, Clinpro (3M-ESPE) in first permanent molars
2507494|NCT02849145|Experimental|Biological/Vaccine|
3196815|NCT00854555|Experimental|robot|30 persons with incomplete SCI who live within driving distance to Oslo and who meet the inclusion/exclusion criteria will be selected for randomization to robotic assisted training or control (conventional treatment). Intervention consists of locomotor training with robot for 60 days during 6 months period in an out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
2507685|NCT02847728||Single Arm Design|The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.
2507805|NCT02846857|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
2507806|NCT02846857|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
2507808|NCT02846857|Active Comparator|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon mini-boluses will be infused using two separate subcutaneous infusion pumps to regulate glucose levels (MiniMed® Paradigm® Veo™, Medtronic). Participant's usual fast-acting insulin analog and Glucagon (Eli Lilly) will be used. Every 10 minutes, the glucose level as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Newly reconstituted glucagon will be used every 24 hours.
2507847|NCT02846506|Experimental|Treatment Sequence ADBC|Participants will receive Treatment A (1 canagliflozin tablet 100 milligram (mg) and 1 canagliflozin tablet 50 mg along with 1 Extended Release (XR) tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, then Treatment D (1 XR fixed dose combination [FDC] tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, then Treatment B (1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, followed by Treatment C (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg and metformin (XR) 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507849|NCT02846506|Experimental|Treatment Sequence BACD|Participants will receive Treatment B on Day 1 of treatment period 1, then Treatment A on Day 1 of treatment period 2, then Treatment C on Day 1 of treatment period 3, followed by Treatment D on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507850|NCT02846506|Experimental|Treatment Sequence CBDA|Participants will receive Treatment C Day 1 of treatment period 1, then Treatment B on Day 1 of treatment period 2, then Treatment D on Day 1 of treatment period 3, followed by Treatment A on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507903|NCT02846155|Experimental|simethicone combined with pronase group|the patients drink 900ml clear water and 15ml simethicone and 20，000iu pronase before checking
2507225|NCT02851030|Experimental|Move, Play, Learn! Intervention|This arm will receive the 10-week Move, Play, Learn! intervention immediately.
2507234|NCT02851030|No Intervention|Waitlist Control|This arm will receive the 10-week intervention once follow-up measures on the primary outcome have been collected for both groups.
2507303|NCT02850874|Experimental|HIPEC|Immediately following laparoscopy for diagnosis and staging of disease, closed neoadjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) will be performed using the anatomical site of the laparoscopic procedure in the same operative encounter. Perfusion will be initiated with 4-6 L of 1.5% dextrose at a 500 mL/min flow rate with manual agitation of the abdominal wall. Once the temperature in the abdomen becomes stable above 40°C, perfusate volume will be reduced to 1.5 L/m sq, and gemcitabine (GEMZAR®) will be instilled into the abdomen (1000 mg/m sq) for 90 min. Neoadjuvant chemotherapy with gemcitabine will be administered prior to open pancreaticoduodenectomy by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy with gemcitabine will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional protocol.
2507304|NCT02850874|Other|Historical Control|Case-matched historical controls will have received neoadjuvant chemotherapy with gemcitabine prior to open pancreaticoduodenectomy (PD) by the standard Whipple or pylorus-preserving approach. Adjuvant systemic chemotherapy (SCT) with gemcitabine will be administered for 6 mo (including period of neoadjuvant therapy) according to established institutional protocol.
2507340|NCT02850224|Experimental|Motivational interviewing to elicit PCO in pediatrics|"Providers will be randomized into a patient-centered outcomes (PCO) education course or standard of care. The PCO education course will educate and test providers on patient-centered outcomes of interest and appropriate methods to deliver PCO care.~Providers randomized into the intervention arm will be required to take a brief, one-hour, webinar describing the background, problem, results from focus groups we conducted, and a training program on motivational interviewing. After completing the course, providers will be required to complete an evaluation."
2507351|NCT02850224|No Intervention|No Intervention|Standard care
2507459|NCT02849535|Experimental|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
2507463|NCT02849535|No Intervention|Standard of care|In the group with standard of care, patients will have interviews with a hospital pharmacist only dedicated to the record of data for outcomes assessment. These sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion , and at the end at month 6 after the final physical session.
2507503|NCT02848937||Bath with citrate|"Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM.~•Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study"
2507508|NCT02848937||Bath with citrate and Ca_eq|"Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials:~Filter high permeability (Kuf> 20ml/mmHg);~Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.~All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study."
2507598|NCT02848170|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 12 weeks
2507608|NCT02848170|Active Comparator|olmesartan medoxomil|olmesartan medoxomil 10 to 20 mg, orally, once daily after breakfast for 12 weeks
2507650|NCT02847923|Experimental|Group Experimental|All the volunteers will use the software and then answer the questionnaire. They will be familiar with the software interface, performs an initial test to learn how to use the software, run a test script and answer the questionnaire.
2507787|NCT02847299|Experimental|Astral ventilator|instrumental increase of cough peak flow with air stacking
2507793|NCT02847299|Experimental|Astral ventilator - mode kiné|instrumental increase of cough peak flow with hyperinsufflation
2507882|NCT02846337|Experimental|ULTRAFILTRATION|The ultrafiltration sodium-overload extraction will be chosen by the patient nephrologist and the patient himself (according to his comorbidities) among the following one: peritoneal dialysis (at least a daily contact), hemodialysis (>1 session per week) or isolated ultrafiltration (>1 session per week). Ultrafiltration technique could change throughout the care
2507883|NCT02846337|Other|ENHANCED MEDICAL TREATMENT|"The control group called enhanced medical treatment will not benefit of ultrafiltration (except refractory pulmonary edema, or terminal kidney failure requiring extra renal depuration). These situations will not be considered as protocol violation, because they are scientifically indicated for extra renal depuration."
2507941|NCT02846064|Other|Ovarian tissue cryopreservation|
2508006|NCT02845635||Relapsing Remitting Multiple Sclerosis|Those who document during the study on-boarding process that they suffer from relapsing-remitting multiple sclerosis.
2508007|NCT02845635||Primary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from primary progressive multiple sclerosis.
2508008|NCT02845635||Secondary Progressive Multiple Sclerosis|This who document during the on-boarding process that they suffer from secondary progressive multiple sclerosis.
2507291|NCT02850614|Active Comparator|Control|Fifty participants in the control condition will each receive a FitBit to track their physical activity. Instead of interfacing with a gaming app on their Chromebooks to track physical activity, control condition participants will interface with a minimalist activity tracker showing them only how many minutes of MVPA they've done over the course of the day. It is expected that after several weeks of baseline use, control condition participants will no longer find the FitBit novel. In order to encourage control condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
2507298|NCT02850614|Experimental|Intervention|Fifty participants will be randomized to the intervention condition, which will use a gaming application to encourage physical activity, as physical activity goal achievement will translate into rewards in the game. Physical activity will be tracked using a FitBit activity monitor and in order to encourage intervention condition participants to wear their FitBits at school daily, they will receive one entry into a weekly lottery for each day they wear the FitBit that week.
2507353|NCT02850328|Other|high-load resistance training for long term space flights|"Short duration electrical will be delivered and the resulting EMG will be recorded. Intensity of electrical stimulation will be progressively increased until we observed a maximal EMG response.~Finally an ultrasound probe (similar to that used for prenatal diagnostic imaging) will be fixed behind your calf in order to visualize muscle."
2507376|NCT02849951|Experimental|LT-02|1.6 g PC in LT-02 BID
2507377|NCT02849951|Placebo Comparator|LT-02 Placebo|0 g PC in LT-02 Placebo BID
2507444|NCT02849314|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507455|NCT02849314|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507487|NCT02849093||Dry Eye Syndrome Patients|Patients who have been diagnosed clinically with Sjögren's will have an OCT image of their lacrimal glands and buccal mucosa taken. Imaging from patients found to have Sjögren's clinically diagnosed following examination of buccal mucosa under the microscope will be compared with images from patients without dry eye syndrome to see of any obvious differences can be identified.
2507492|NCT02849093||Epiphora Patients|Pre and post-operative OCT images of patients undergoing punctoplasty or conjunctivoplasty will be compared to images of the same structures in people without watery eyes.
2507495|NCT02849093||Asymptomatic Patients|OCT images will be captured of the cornea, conjunctiva, lacrimal gland and buccal mucosa to establish normal appearance in asymptomatic patients.
2507543|NCT02848794|Experimental|Apatinib+Irinotecan|Apatinib and irinotecan in treating patients with recurrent high-grade glioma,who have progressed on temozolomide, or radiotherapy alone, or combined with chemotherapy within 3 months after surgery .
2507606|NCT02848404|Experimental|Categorical Language Fluency Smartphone Application|Smartphone game application specifically aimed at training categorical language fluency
2507680|NCT02848040|Experimental|Single Arm|All patients will receive the same interventions. Single are only
2507721|NCT02847468|Experimental|FDG and FCH PET|Patients will performed a TEP with 2 different radiotracer before treatment is started and 1 month after treatment has been started.
2507786|NCT02847143|Experimental|secure|healthy adult male with secure attachement
2507792|NCT02847143|Experimental|avoidant|healthy adult male with avoidant attachement
2507797|NCT02847143|Experimental|enmeshed/fearfull|healthy adult male with enmeshed/fearfull attachement
2507799|NCT02847143|Experimental|dual style|healthy adult male with dual attachement style
2507851|NCT02846532|Experimental|Rivaroxaban|
2507854|NCT02846532|Experimental|Acetylsalicylic Acid|
2507958|NCT02845908|Experimental|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days. The combined chemotheraphy will be treated for 9 circle. then，the capetabine was allowed
2507961|NCT02845908|Experimental|FOLFOX plus PAC(ip)|The regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2) plus paclitaxel (80 mg/m2) intra-peritoneally.Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
2507965|NCT02845908|Active Comparator|FOLFOX|The FOLFOX regimen consisted of oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
3163640|NCT00484614|Active Comparator|1 PEM|
3163641|NCT00484614|Active Comparator|2 MRI|
2508142|NCT02844868|Experimental|Active tDCS|During the first 20 min of training program, patient will have active tCDS (2 mA )
2508146|NCT02844868|Sham Comparator|sham tDCS|During the first 20 min of training program, patient will have sham tCDS
2508236|NCT02844244|Experimental|training group|Two two-hour training sessions for the participants. It aimed to train lay resident leaders to be peer health promoters. The peer health promoters were taught either to independently implement or to assist social workers to conduct a series of community-based family well-being activities.
2508267|NCT02843594|Active Comparator|LEEP Intervention C1|Cataract surgery with micro-interventional LEEP technology lens fragmentation (non-randomized cohort 1)
2508269|NCT02843594|Active Comparator|LEEP Intervention C2|Cataract surgery with micro-interventional LEEP technology lens fragmentation (randomized cohort 2)
2508271|NCT02843594|Placebo Comparator|Control Phaco C2|Cataract surgery with conventional phaco-assisted lens fragmentation (randomized cohort 2)
2549532|NCT02568319|Experimental|LIPO-202|Experimental arm
3163642|NCT00484705|Experimental|Low-frequency electro-acupuncture|
3163643|NCT00484705|Experimental|Physical exercise|
3163644|NCT00484705|Active Comparator|Untreated control|
3163645|NCT00484731|Placebo Comparator|Injection with Saline|Injection with Saline instead of Bupivacain
3163646|NCT00484731|Active Comparator|Injection with Bupivacaine|Injection with Bupivacaine
3163647|NCT00484744|Experimental|Acetaminophen|
2507259|NCT02850692|Experimental|Cystic fibrosis with portal hypertension|Mucoviscidosis with portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
2507261|NCT02850692|Experimental|Muco without portal hypertension|Mucoviscidosis without portal hypertension. Blood sample (21ml). Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
2507262|NCT02850692|Experimental|Portal hypertension without muco|Portal hypertension without Mucoviscidosis. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®). Injected abdominal CT scan.
2507263|NCT02850692|Experimental|Healthy volunteers|Healthy volunteers. Blood sample (21ml) . Hepatic elastography (Fibroscan®). Measure of endothelial function (Endopat®).
2507326|NCT02850211|Experimental|Celecoxib|1 capsule of 200mg Celebrex twice a day for 14 days
2507329|NCT02850211|Active Comparator|Traditional NSAIDs|1 tablet of 385mg Ibuprofen twice a day for 14 days
2507330|NCT02850211|Active Comparator|Opioid drug|1 tablet of 50mg Tramadol twice a day for 14 days
3196816|NCT00854555|Experimental|manual assistance|30 persons with incomplete SCI who live outside driving distance to Oslo and who meet inclusion/exclusion criteria will be selected for manually assisted training in Tromsø or control (conventional treatment). Intervention consists of 60 days locomotor training with manual assistance during 6 months period in an in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
2507504|NCT02849210|Experimental|Allergovac depot|Allergovac depot with Olea europaea pollen extract
3196817|NCT00854568|Experimental|CEOP regimen|CEOP regimen
3196818|NCT00854568|Active Comparator|CHOP regimen|CHOP regimen
2507631|NCT02848105|Experimental|VPA+Methyl|VPA added to standard methylpredisonlone treatment for aGVHD
2507683|NCT02847806|Experimental|Estradiol|dosage used in the study: 1 patch / 3-4 days dosed at 25, 37.5 or 50 mg / 24h titration according to the plasma level, with the objective of a physiological level of estradiol (25-40 pg / ml ) - During 4 weeks
2507686|NCT02847806|Experimental|Testosterone|dosage used : from 25 to 75 mg / day of testosterone (ie 2.5 to 7.5 g / day transdermal gel) according to the plasma level, with the goal of a physiological level of testosterone (5-8 ng / ml) - During 4 weeks
2507689|NCT02847806|Experimental|Testosterone + Estradiol|Testosterone + Estradiol During 4 weeks
2507710|NCT02847403|Experimental|exenatide|long-acting exenatide 2 mg subcutaneously once-weekly
2507713|NCT02847403|Placebo Comparator|placebo|no drug assigned
2507763|NCT02847195|Experimental|pediatric intensive care|"When aspiration is planned, pain assessment will be performed thrice :~3-5 minutes before aspiration, during aspiration, and 3-5 minutes after aspiration.~Pain assessment will be performed with both methods:~COMFORT B scale (routinely performed by nurses, and lasts less than one minute)~Simultaneously pupillometry is assessed using the device (Neurolight) (one measurement per eye, this also lasts less than one minute) These measurements can occur at any time during stay in ICU, and can be repeated."
2507802|NCT02846870|Active Comparator|Standard Education|Patients receive standard-of-care prostate cancer radiation oncology consultation.
2507804|NCT02846870|Experimental|Visually Enhanced Education|Patients receive a visually enhanced prostate cancer educational Powerpoint presentation including prostate anatomy, pathologic results, surgical options, radiation therapy, and prognosis with pictographs during radiation oncology consultation.
2507841|NCT02846584|Experimental|CD19 or CD20 CAR T cells briging HSCT|lentiviral transfection and transfuse anti-CD19 or anti-CD20 CAR T cells into patients. Six months later, select appropriate patients to transplant hemopoietic stem cells.
2507888|NCT02846311||Group with support that will be usually performed|"During the first phase (before), the assumption will be that usually achieved.~The doctor continues to support according to information it has and according to good practice and service protocols."
2507889|NCT02846311||Group with a flu test|"During the second phase (after), a flu test is routinely performed within the home emergency department by the doctor who supports the patient.~The doctor continues to support according to information it has and according to good practice and service protocols."
2507980|NCT02845986|Experimental|No.10 lymph node dissections|Patients with locally advanced upper third gastric carcinoma will performed laparoscopic spleen-preserving No.10 lymph node dissections.After the surgery the patients will be treated with oxaliplatin or platinum-based chemotherapy.
2508072|NCT02845167|No Intervention|Usual-care only|Patients will receive usual-care only during the preoperative period.
2508075|NCT02845167|Experimental|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods.
2508109|NCT02844764|Experimental|StroMed + Platelet Rich plasma [PRP]|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product by direct injection to affected joints.
3196819|NCT00854633|Experimental|1|Talactoferrin
2508218|NCT02844127|Other|Apex First|Patients born in odd-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the apex and then in the septum. Final lead position will be determined at the discretion of the implanting physician.
2508219|NCT02844127|Other|Septum First|Patients born in even-numbered years will receive an implantable cardioverter defibrillator (ICD). Defibrillation threshold determined with the right ventricular lead placed first in the septum and then in the apex. Final lead position will be determined at the discretion of the implanting physician
3196820|NCT00854633|Placebo Comparator|2|Placebo
3196821|NCT00854646|Experimental|ON 01910.Na|The starting dose is 650 mg/m2 per day for 3 continuous days every 2 weeks. In successive courses, infusion time may be increased by 1 day up to 7 days every two weeks and/or drug dose may be increased (650, 1050, 1700 mg/m2/day, etc.). After 4 2-week cycles, cycle length may be extended to 3 or 4 weeks. Treatment continues until evidence of disease progression, intolerable adverse events or withdraw of consent.
3196822|NCT00854659|Active Comparator|1|ABT-102 Tablets, 4 mg BID
2507309|NCT02850419|Experimental|ThermoDox (40mg/m2)+hyperthermia+RT|Treatment will consist of up to six cycles of LTLD combined with hyperthermia every 21 days with the first day of each cycle being Day 1. ThermoDox will be administered at a dose of 40 mg/m2. Thermal dose is a one-hour treatment at a temperature between 40 and 43°C at the target site. At Cycle 1, radiotherapy will begin and will be combined with hyperthermia. A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
3196823|NCT00854659|Active Comparator|2|ABT-102 Tablets BID, escalating dose
3196824|NCT00854659|Active Comparator|3|ABT-102 Tablets BID, escalating dose
2507426|NCT02849730||Young adults|Patients aged 20 to 39 who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
2507428|NCT02849730||Elderly patients|Patients aged 70 and over who had used fentanyl/ropivacaine based Epi-PCA for postoperative pain.
2507528|NCT02849249|Active Comparator|One day schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in one day schedule. The maintenance dose (0.5 mL) is reached in one day.
2507530|NCT02849249|Active Comparator|Rapid schedule|Allergovac polimerized with a mixture of 2 pollen extracts (100:100): Olea europea and Phleum pratense, administered in a rapid Schedule.The initation phase includes 3 weekly increasing doses till the maintenance dose of 0.5 mL is reached.
2507566|NCT02848482|Active Comparator|Control group|Plastic curette will be used to perform the mechanical debridement. Then, irrigation (2% chlorhexidine) will be performed at contaminated sites.
2507567|NCT02848482|Experimental|Test group|Plastic curette will be used to perform the mechanical debridement. Then, the addition photodynamic therapy (PDT) will be performed. This will be performed with a set-up for PDT (HELBO Photodynamic Systems, German).
2507594|NCT02848235|No Intervention|Group 1 (Standard of Care)|Participants in group 1 will receive the standard of care for the Prevention of Mother to Child Transmission (PMCTC) of HIV from the clinic's Mentor Mothers.
2507603|NCT02848235|Experimental|Group 2 (Standard of Care + EMMA)|Participants in group 2 will receive the standard of care for Prevention of Mother to Child Transmission (PMCTC) of HIV plus study-specific enhanced care interventions from the clinic's Mentor Mothers.
2507712|NCT02847598|Experimental|Part A: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with systemic lupus erythematosus [SLE] with active skin manifestations and joint involvement.
2507714|NCT02847598|Placebo Comparator|Part A: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional dose at Week 2 for a total of 7 doses (Weeks 0, 2, 4, 8, 12, 16, and 20) in participants with [SLE] with active skin manifestations and joint involvement.
2507715|NCT02847598|Experimental|Part B: BIIB059 50 mg|BIIB059 50 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active cutaneous lupus erythematosus [CLE] with or without systemic manifestations.
2507717|NCT02847598|Experimental|Part B: BIIB059 150 mg|BIIB059 150 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2507718|NCT02847598|Experimental|Part B: BIIB059 450 mg|BIIB059 450 mg administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2507719|NCT02847598|Placebo Comparator|Part B: Placebo|BIIB059 matching placebo administered subcutaneously (SC) every 4 weeks (Q4W) with an additional loading dose at Week 2 for a total of 5 doses (Weeks 0, 2, 4, 8, and 12) in participants with active [CLE] with or without systemic manifestations.
2507870|NCT02846467|Experimental|Portable video media|Patients who receive informed consent trough portable video media around 10 minutes
2507874|NCT02846467|Active Comparator|Traditional IC|Patients who receive traditional IC (written consent) during 10 to 15 minutes
2507937|NCT02846077||College students|College students will be monitored and will complete online surveys, install apps on their mobile phones, wear physiological sensors and provide saliva samples for later assay.
2507971|NCT02845687||Participants|All participants are patients within the Quit at Duke Smoking Cessation Program. This is an observational study with no interventions.
2508035|NCT02845466|Experimental|Becaplermin/Promagran Dressing|Topical Becaplermin with a protease inhibitor wound dressing.
2508038|NCT02845466|Active Comparator|Becaplermin/Placebo Dressing|Topical Becaplermin with a placebo wound dressing.
2508089|NCT02844907|Experimental|Hyperglycemic clamp + Exendin (9-39)|During the 2-hour procedure, a variable infusion of 20% dextrose and blood glucose will be clamped at basal + 3mM. Participants will receive an infusion of the GLP-1 receptor antagonist Exendin (9-39) between the 60-120 minute time-points of the clamp. The amount of Ex-9 infused will be 750 pmol/kg/min for 60 minutes.
2508091|NCT02844907|Experimental|Dexamethasone|Subjects will be asked to take 4 mg once daily between Visit-2 and Visit-3.
2508137|NCT02844608|Other|Quality of Life|Administration of Quality of Life questionnaires
2508181|NCT02844348|No Intervention|Standard pain control|Classical pain assessment and drug treatment at each dialysis session.
2508182|NCT02844348|Experimental|Hypnosis|Besides the classical pain assessment and drug treatment, hypnosis sessions during 2 periods of one week of dialysis sessions.
2508217|NCT02843971|Experimental|Healthy volunteers|
2508268|NCT02843672|Active Comparator|TWO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Triple´s Weil osteotomy is performed."
2508270|NCT02843672|Active Comparator|DMMO|"Patients with metatarsalgia and without response to non-operative treatment after six months, needing surgical treatment for relief of their symptoms.~Distal metatarsal minimally invasive osteotomy is performed."
2508318|NCT02843230||Avastin Combine with MRI, DSC and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2549533|NCT02568306|Placebo Comparator|Placebo|
2507357|NCT02850354|Experimental|anti-g maneuvers|"Before the first parabola, pulmonary function will be evaluated. Then during each weightlessness period the subject will be instructed either to stay at rest (control condition) or to perform anti-g maneuvers (4 times each): intermittent exhalation on exertion, lower limbs and abdomen muscular contraction, combined maneuver ('intermittent exhalation on exertion' + 'muscle contraction'). Before, the exhalation on exertion, the subject will close the airway after the mouthpiece by pushing on a button actuating a pneumatic valve.~Each subject will be tested during 15 parabola where the anti-g maneuvers will be performed in randomized order. After the 15th parabola, pulmonary function will be again evaluated."
2507384|NCT02849886|Experimental|LT icasp9 ΔCD19 (cohort1)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 Gene Modified Cells (GMC)/kg).
2507390|NCT02849886|Experimental|LT iCASP9 ΔCD19 & GvHD (cohort2)|Injection T lymphocytes iCASP9 ΔCD19 (2.10e6, 5.10e6 and 10.10e6 GMC/kg). Patients who develop GVHD after administration of Gene Modified Cells (GMC) will be treated with dimerizer drug (AP1903)
2507462|NCT02849548|Experimental|suvorexant|10 to 20 mg to be administered after an evening written trauma narrative exposure session.
2507468|NCT02849548|Placebo Comparator|Placebo pill|A pill without active ingredients
2507498|NCT02849054|Experimental|4, 5, 6ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 5ml/kg, 6ml/kg. Measurement of PTPdi
2507507|NCT02849054|Experimental|4, 6, 5ml/kg targetted tidal volume|Randomised to receive TTV at 4ml/kg, 6ml/kg, 5ml/kg. Measurement of PTPdi
2507512|NCT02849054|Experimental|5, 4, 6ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 4ml/kg, 6ml/kg. Measurement of PTPdi
2507514|NCT02849054|Experimental|5, 6, 4ml/kg targetted tidal volume|Randomised to receive TTV at 5ml/kg, 6ml/kg,4ml/kg. Measurement of PTPdi
2507516|NCT02849054|Experimental|6, 5, 4ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 5ml/kg, 4ml/kg. Measurement of PTPdi
2507519|NCT02849054|Experimental|6, 4, 5ml/kg targetted tidal volume|Randomised to receive TTV at 6ml/kg, 4ml/kg, 5ml/kg. Measurement of PTPdi
2507562|NCT02848560||Treatment|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients homozygous for F508del CFTR mutation as they age into the FDA approved treatment window for the CFTR modulator orkambi. Subjects will be observed at 2 time points before starting clinically prescribed treatment (orkambi) and 2 time points while on orkambi.
2507564|NCT02848560||Control|Observation of lung changes over time by hyperpolarized xenon MRI on CF patients heterozygous for F508del CFTR mutation at similar timepoints to treatment group. Control subjects are not be eligible to be clinically prescribed orkambi based on FDA approval.
2507586|NCT02848248|Experimental|SGN-CD123A|SGN-CD123A every 3 weeks
2507665|NCT02847975|Experimental|Sodium nitrate|Sodium nitrate will be administered orally and functional sympatholysis assessed before and after treatment
2507703|NCT02847572|Other|Surgery Patient|All patients to be implanted bilaterally with a Tecnis Extended Range Lens in the Dominant eye and a Low Add Multifocal in the non dominant
2507813|NCT02846844||Group A|"Whole body vibration training~manuelle therapy~exercises for power and coordination~performance training as needed"
2507815|NCT02846844||Group B|"manuelle therapy~Exercises for power and coordination~Performance training as needed"
2507826|NCT02846545|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may enter in an open-label (OL) extension period to receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area).
2507830|NCT02846545|Placebo Comparator|Group 2: Placebo|Participants will receive a matching placebo to golimumab.
2507925|NCT02846103|Experimental|Biological samples|"Blood samples will be collected at baseline, after the first-line therapy and at 12 months.~Tumor tissues will be collected if available."
3196825|NCT00854659|Placebo Comparator|4|Placebo Tablets, BID
3196826|NCT00854672||sarcoidosis patients|Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
2508048|NCT02845141|Experimental|Actifuse|Actifuse to fill bone tunnel
2508050|NCT02845141|Active Comparator|bone graft|bone graft to fill bone tunnel
2508105|NCT02844855|Active Comparator|patients with Alzheimer disease|Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2508106|NCT02844855|Active Comparator|patients with Parkinson disease|Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2508115|NCT02844725|Placebo Comparator|Placebo|Placebo group will receive an water for injection the same volume and period of experimental group.
2508173|NCT02844504|Experimental|Low Intensity Exercise Training 1|Cancer survivors will receive low intensity handgrip exercise training.
2508600|NCT02841306|Active Comparator|> 12 hours|Duration between oral UDCA intake and surgery of >12 hours.
3196827|NCT00854685|Experimental|1|
3196828|NCT00854685|Experimental|2|
3196829|NCT00854685|Experimental|3|
3196830|NCT00854685|Experimental|4|
3196831|NCT00854685|Placebo Comparator|5|
3196832|NCT00854685|Placebo Comparator|6|
3196833|NCT00854698|Experimental|Group with MVA|
3196834|NCT00854698|Other|group without MVA|
3196835|NCT00854711|Experimental|nitric oxide|inhaled nitric oxide 80 ppm and oxygen
3196836|NCT00854711|Placebo Comparator|standart of care|no intervention
3196837|NCT00854737|Active Comparator|1|Omega-3 fatty acid and cytidine supplementation
3196838|NCT00854737|Active Comparator|2|omega-3 fatty acid supplementation
2507581|NCT02848196|Experimental|Stereotactic body radiation therapy|Oligometastatic patients with adrenal gland metastases are treated with high dose of Stereotactic Body Radiation Therapy delivered with VMAT/Rapid Arc technique.
2507743|NCT02847364|Experimental|Chewing gum group|The patients will be asked to chew on a regular chewing gum starting morning of post-operative day 1 until the first bowel movement.
2507745|NCT02847364|No Intervention|Control group|These patients will not be offered any food/beverage orally. Patients will be asked not to eat or chew anything till the first bowel movement.
3163648|NCT00484744|Experimental|Ibuprofen|
3163649|NCT00484744|Placebo Comparator|Avicel|
2507996|NCT02845557||Control subjects without diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
2508001|NCT02845557||Subjects with type 2 diabetes|"(i) 2-hour 75g OGTT with sampling of glucose, insulin, C-peptide and GLP-1 hormone, with sampling at fasting (time zero) and 30, 60, 90, 120 min after the glucose load.~(ii) 1-hour IVGTT, with sampling at time 10 and 1 min, after which glucose (300 mg/kg body weight) infused in a contralateral vein within 30 s, starting at time zero. Blood further sampled for glucose, insulin and C-Peptide with sampling schedule: 3, 5, 6, 8, 10, 15, 20, 25,30 ,40 ,50 ,60 min;~(iii) computed tomography scan, (CT) for abdominal subcutaneous and visceral fat quantification."
2508025|NCT02845284|No Intervention|Routine Care|Group education/counseling from Antenatal clinic midwives, routine PMTCT, HIV C&T and family planning C&T services on request.
2508027|NCT02845284|Experimental|Routine Care plus group support|Routine Care plus enhanced group support
2508029|NCT02845284|Experimental|Routine Care plus individual support|Routine Care plus enhanced individual support
2508175|NCT02844166|Experimental|viscoelastic group|viscoelastic surface support
2508177|NCT02844166|Active Comparator|pyramidal foam group|pyramidal foam surface support
2508214|NCT02843984|No Intervention|A - untreated|The patients will be not treated with vaginal lactoferrin
2508215|NCT02843984|Active Comparator|B - 4 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
2508216|NCT02843984|Active Comparator|C - 12 hrs treatment|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 12 hours prior to mid-trimester genetic amniocentesis.
2508325|NCT02843269|Active Comparator|Multi-component lifestyle intervention 1|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2508326|NCT02843269|Active Comparator|Multi-component lifestyle intervention 2|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2508327|NCT02843269|Active Comparator|Multi-component lifestyle intervention 3|A multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
2508383|NCT02842814|Experimental|Full withdrawal|Intervention: 'Drug free'.
2508385|NCT02842814|Experimental|GC withdrawal|Intervention: 'HCQ' .
2508386|NCT02842814|Experimental|No withdrawal|Intervention: 'GC+HCQ' .
2508441|NCT02842372||Ectoin Dermatitis Cream 7%|Cream for symptomatic treatment and relief of skin redness and itching experienced with various types of inflammatory dermatoses.
2508499|NCT02842138|Experimental|CD19 CAR T cells|A standard dose escalation approach aimed to assess the safety and efficacy of autologous anti-CD19 CAR T cells will be applied.
2508565|NCT02841761|Experimental|Treatment A (Midazolam)|Single dose of Midazolam 8 mg on Day 1
2508568|NCT02841761|Experimental|Treatment B1 (ACT-132577)|Single dose of ACT-132577 150 mg on Day 2; single dose of ACT-132577 50 mg on Day 3, Day 4, and Day 5.
2508572|NCT02841761|Experimental|Treatment B2 (Midazolam + ACT-132577)|Single dose of Midazolam 8 mg and single dose of ACT-132577 50 mg on Day 6
2508632|NCT02841176|Experimental|Experimental|Thermography and Golimumab (solution for subcutaneous injection, 50 or 100 mg, monthly)
2508669|NCT02840669|Other|Friedreich's Ataxia|
2508670|NCT02840669|Other|Healthy Volunteers (Controls)|
2508720|NCT02840305|Other|Expérience 1|Brain bases of spatial frequencies treatment 30 young adults, 20 old adults 20 children between 4 and 6 years, 20 children between 6 and 12 years and 20 young adults
3163650|NCT00484770|Other|Congestion Score Strategy|
3163651|NCT00484770|Other|BNP Strategy|
3163652|NCT00484783|Experimental|Prospective|Subjects scheduled to receive procedure
3163653|NCT00484783|Other|Historical|Chart review control group
3163654|NCT00484796||1|Patients undergoing carotid surgery
3163655|NCT00484822|Experimental|1|Brazo 1: Bemiparina Sódica 3.500 UI/día.
3163656|NCT00484822|Placebo Comparator|2|Brazo 2: Heparina Cálcica 10.000 UI/día.
3163657|NCT00484926|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3163658|NCT00484926|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
3163659|NCT00485004|Experimental|Cutting balloon|Cutting balloon
3163660|NCT00485004|Active Comparator|Sirolimus-eluting stent|Sirolimus-eluting stent
3163661|NCT00485017|Experimental|1|THR-4109: 115 mg orally in am, 115 mg orally in pm for 24 weeks
3163662|NCT00485017|Experimental|2|THR-4109: 100 mg orally in am, 100 mg orally in pm for 24 weeks
3163663|NCT00485017|Experimental|3|THR-4109: 15 mg orally in am, 15 mg orally in pm for 24 weeks
3163664|NCT00485017|Placebo Comparator|4|
3163665|NCT00485030|Experimental|Cypher|sirolimus-eluting stent
3163666|NCT00485030|Active Comparator|Xience-V|everolimus-eluting stent
3163667|NCT00485056|Placebo Comparator|Placebo|Crossover arm
3163668|NCT00485056|Active Comparator|Pioglitazone|Pioglitazone 45mgs daily
3163669|NCT00485108|Active Comparator|1|Prednisolone 1% eye drop
2507447|NCT02849340|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507453|NCT02849340|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507501|NCT02849132|Experimental|Treatment group|entecavir oral，0.5mg daily for 8 years
3196839|NCT00854737|Placebo Comparator|placebo|placeno or sugar pill
3196840|NCT00854750|Experimental|ACTHAR- placebo first|Placebo, 20 mg, 40 mg, 80 mg
2507628|NCT02848118|Experimental|A nasal-oral cannula of capnography|Start bronchoscopy when the nasal-oral capnography shows hypoventilation during bronchoscopic sedation.
2507629|NCT02848118|Active Comparator|Sedation scale|Start bronchoscopy when Observer Assessment of Alertness and Sedation scale (OAAS)=3~2 during bronchoscopic sedation.
2507656|NCT02847780|Active Comparator|C-Mac video laryngoscope.|Active Comparator: C-Mac Videolaryngoscope for vocal cord movement assessment.
2507659|NCT02847780|Experimental|Airway Ultrasound|Experimental: Airway Ultrasound for vocal cord movement assessment.
2507756|NCT02847312|Active Comparator|High avenanthramide, phenolic acid|66.8g Pepsico Oatmeal + 60g Oat cake
2507758|NCT02847312|Active Comparator|Low avenanthramide, medium phenolic acid|17g Oatwell + 63.6g Cream of Rice + 60g Melba Toast
2507759|NCT02847312|Placebo Comparator|Control|69.8g Cream of Rice + 8.1g Cellulose + 4.8g Pectin + 60g Melba Toast
2507771|NCT02846909|Active Comparator|Vaginal progesterone group|Will receive progesterone pessaries 400 mg once daily vaginally
2507773|NCT02846909|No Intervention|No progesterone group|Will receive nothing
2507833|NCT02846766|Experimental|Lenvatinib|The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.
2507881|NCT02846363||Patients included in the Rhône region from France|public awareness campaign
2507884|NCT02846363||Patients included in the control region (Isère, France)|
2507921|NCT02846142|Active Comparator|SAD PTI-428|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
2507922|NCT02846142|Placebo Comparator|SAD placebo|The safety, tolerability, and pharmacokinetic profile of PTI-428 will be evaluated following a single dose of PTI-428. Three cohorts are planned for evaluation where subjects will be randomized to PTI-428 or placebo.The subjects will be followed for 7 days post dose.
2507923|NCT02846142|Active Comparator|MAD PTI-428|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
2507926|NCT02846142|Placebo Comparator|MAD placebo|Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult female subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 cohorts. Subjects will be randomized to either PTI-428 or placebo. Each dose will be administered once daily (QD) for a total of 7 days. Follow up visits will occur on Days 12 and 14.
2507928|NCT02846142|Experimental|OC (ethinyl estradiol and levonorgestrel) DDI Period A|Treatment period A will consist of once daily oral contraceptive (OC) for 28-days (21-day hormonal active + 7 days off).
2507929|NCT02846142|Active Comparator|OC (ethinyl estradiol and levonorgestrel) DDI Period B|Treatment period B will randomize subjects to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
2507931|NCT02846142|Placebo Comparator|OC (ethinyl estradiol and levonorgestrel) DDI|Treatment period B will randomize subjects 4:1 to PTI-428 or placebo in combination with once daily OC daily for 28 days (21-day hormonal active + 7 days off).
2507973|NCT02845609|Experimental|Intervention|Sialic acid-Extended release 2000 mg, three times per day (TID) for 3 months
2508047|NCT02845440|Active Comparator|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services. Participants in this arm will receive no other study-related intervention.
2508054|NCT02845440|Experimental|AD + CHW|"Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. The aim of AD is to help clinicians understand and adopt targeted evidence-based practices.~Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers."
2508056|NCT02845440|Experimental|AD Alone|Participants who are randomized to this condition will only not be offered additional Community Health Worker services; however, the participant's primary care clinic will receive Academic Detailing as described above.
2508059|NCT02845440|Experimental|CHW Alone|Community Health Worker (CHW) will offer to support patients and prescribers to implement smoking cessation treatments that may be requested by patients and/or recommended by prescribers.
2508113|NCT02844725|Experimental|VVZ-149 injection|VVZ-149 injections will be mixed with saline, then intravenous infusion for 10hr. The drug product will be administrated with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 9.5 hours.
3196841|NCT00854750|Experimental|ACTHAR- placebo second|20mg, Placebo, 40 mg, 80mg
3196842|NCT00854750|Experimental|ACTHAR- placebo third|20 mg, 40 mg, Placebo, 80 mg
3196843|NCT00854750|Experimental|ACTHAR- placebo fourth|20 mg, 40 mg, 80 mg, Placebo
3196844|NCT00854763||Hypertension|
2507464|NCT02849366|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors and then receive multiple NK immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507470|NCT02849366|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to clear all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507748|NCT02847338|Experimental|Mono-therapy group|"The monotherapy group will be treated with the following treatments:~A) 1 to 2 weeks of Amlodipine 5mg followed by 6 to 7 weeks of Amlodipine 10mg B) 1 to 2 weeks of Lisinopril 10mg followed by 6 to 7 weeks of Lisinopril 20mg C) Approximately 8 weeks of 25mg Chlortalidone~Participants will be randomly allocated to one of six possible sequences of treatments of the three-treatment-three period Williams design: ABC, ACB, BAC, BCA, CAB, and CBA."
2507749|NCT02847338|Experimental|Dual-therapy arm|"The dual-therapy group will be treated with the following treatments:~A) Approximately 8 weeks of Amlodipine 5mg and Lisinopril 20mg B) Approximately 8 weeks of Amlodipine 5mg and Chlortalidone 25mg C) Approximately 8 weeks of Lisinopril 20mg and Chlortalidone 25mg D) Approximately 8 weeks of Amiloride 10mg and Chlortalidone 25mg~Participants will be randomly allocated to one of four possible sequences of treatments of the four-treatment four-period Williams design: ABDC, BCAD, CDBA, and DACB."
2507783|NCT02846922||catheter ablation group|atrial fibrillation patients with heart failure who received catheter ablation for rhythm control
2507791|NCT02846922||rate control group|atrial fibrillation patients with heart failure who received pharmacological approaches for rate control
2507943|NCT02845895||Neuroscience pole|Patient hospitalized in the department of medicine-surgery-obstetric of the neuroscience pole department
2507944|NCT02845895||Respiratory tracts pole|Patient hospitalized in the department of medicine-surgery-obstetric of the respiratory tracts pole department
2507968|NCT02845583||Retrospective cohort|150 oncologic patients belonging to major complexity DRGs
2507975|NCT02845583||Perspective cohort|150 oncologic patients belonging to major complexity DRGs
2508039|NCT02845479|Experimental|Integrative Care Intervention|Broad-based, multi-agent integrative care program delivered by naturopathic doctors (ND) in conjunction with standard surgical and oncologic care.
2508127|NCT02844595|Active Comparator|Standard cognitive-behavioural smoking cessation treatment|
2508129|NCT02844595|Active Comparator|Standard smoking cessation treatment and behavioral activation|
2508130|NCT02844595|No Intervention|Control group|It will be a delayed treatment control group for a period of 3 months.
2508180|NCT02844374|Other|Partial Epilepsy Drug Resistant|Patients with partial Epilepsy Drug Resistant , justifying a SEEG exploration.
2508213|NCT02843958|Other|Healthy volunteers and patients under Vitamin K antagonist|
2508262|NCT02843698|Experimental|Dexmedetomidine group|Patients will receive either, Dexmedetomidine (Precedex, Hospira, Lake forest, IL, USA) in a dose of (1ug/Kg LBW) bolus followed by 0.5ug/Kg continuous infusion for one hour
2508264|NCT02843698|Placebo Comparator|Control group|Patients will receive normal saline
2508301|NCT02843282|Experimental|Cognitive training|Advanced reasoning training
2508333|NCT02842996||Patient and carer study group|Patients having undergone hip fracture surgery and their care givers.
2508379|NCT02842840|Experimental|Patients based intervention|A multifaceted intervention program will use to improve adherence and clinical outcomes in Stroke patients. This intervention focus on behavioral treatment in the patients.
2508380|NCT02842840|Experimental|Family based intervention|Patients and their families will receive a series of educational/motivational interventions.
2508382|NCT02842840|Active Comparator|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 30 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
2508429|NCT02842463||Prospective observational cohort|"Every patient referred to pulmonary rehabilitation program will be eligible. They will perform cardiopulmonary exercise testing prior to join rehabilitation program.~During the first session of pulmonary rehabilitation, they will perform 2 6-minute stepper test with a rest of 20 minutes minimum between each test."
2508492|NCT02842164|Other|Foley Catheter Balloon with Tension group|a 16 French transcervical Foley catheter balloon will be advanced to or past the internal os and the balloon will be filled. Then catheter will be placed on gentle traction by taping the distal tip to the medial thigh for maximum 24 hours. To maintain gentle traction, periodic repositioning of the distal tip on the thigh will be necessary.
2508494|NCT02842164|Other|Foley Catheter Balloon without tension group|The Foley catheter balloon will be just supported by simple taping to the thigh.
2508545|NCT02841722|Other|Biological samples|Only one arm in this pilot study. All patient will have a follow up and treatment as per standard care for this pathology. Specifically for the study all patients will have 8 additional blood samples to be drawn during the first 2 cycles of treatment (1 cycles is 21 days).
2508586|NCT02841371||chronic kidney disease (CKD)|chronic kidney disease (CKD) is defined as abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for more than 3 months.
2508590|NCT02841371||no CKD|Suspected chronic kidney disease but no chronic kidney disease after screening by abnormalities of kidney structure (markers of kidney damage) or function (decreased GFR by 99mTc-DTPA renal clearance and/or eGFR), present for less than 3 months, or no abnormalities of kidney structure or function.
2508646|NCT02840903||Setting 1 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2507509|NCT02849015|Active Comparator|Cryosurgery|In this group, the patients will receive liver cryosurgery to destroy big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
3163670|NCT00485108|Active Comparator|2|ketorolac 0.5% eye drop
3163671|NCT00485108|Placebo Comparator|3|Artificial Tears (methyl cellulose eye drop)
2507574|NCT02848456|Active Comparator|Spinal Manipulation SM|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2507575|NCT02848456|Active Comparator|Max Voluntary Isometric Contraction MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2507576|NCT02848456|Active Comparator|SM+MVIC|In a repeated measures, crossover design, all subjects received one of three randomized treatments during three separate sessions: SM; a 10 second plantar flexion maximal voluntary isometric contraction (MVIC) or the manipulation immediately preceding the contraction (SM+MVIC).
2507585|NCT02848144|Other|Children with infectious shock|Children aged from 1 month to <18 years. In 3 stratified groups : <2 years, 2-8 years, and >8 years. About one third of the patients are expected in each age-group.
2507589|NCT02848144|Other|Control group: healthy children|Healthy children aged-matched to cases (same stratification group, about 20 per age group); They will be hospitalized for an elective surgery (dental, ENT, maxillofacial, urologic, hernia surgery, neurosurgery without massive hemorrhage) and without any infection.
2507667|NCT02848014|Experimental|Expectation|Participants are asked to think and write about ways how they can positively influence/control the stress during stress induction. They also can think of strategies they used in their past. The purpose of this arm is to improve participants' personal control expectations.
2507673|NCT02848014|Experimental|Emotion|Participants in this group are asked to write a gratitude-letter to a person they want to thank. The purpose of this arm is to foster positive emotions.
2507675|NCT02848014|Active Comparator|Control|Participants in this group are asked to do a neutral writing task. The task is to write a protocol of yesterday's to-dos.
2507772|NCT02846987|Experimental|Abemaciclib (LY2835219)|Patients will be treated with abemaciclib 200 mg bid.
2507906|NCT02846220|Experimental|Health coaching|"Two-hour in-person group counseling session led by health coach, involving development of personalized immunity maps that lay out adherence goal, behaviors that distract from goal, hidden motives that compete with achieving goal, and underlying assumptions~Eight 50-minute individual telephone counseling sessions every three weeks with a health coach, focusing on uncovering hidden motives and challenging assumptions with the goal of overturning nonadherence mindsets"
2507907|NCT02846220|No Intervention|Usual care|
2507954|NCT02845843|Experimental|Combination of Lopinavir /Ritonavir and IntErferon Beta 1B|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
2507955|NCT02845843|Placebo Comparator|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
2508065|NCT02845453|Experimental|Quetiapine|Quetiapine
2508067|NCT02845453|Placebo Comparator|Placebo|Placebo
2508133|NCT02844751|Experimental|Cohort 1|Interventions assigned by Principal Investigator
2508135|NCT02844751|Experimental|Cohort 2|Interventions assigned by Principal Investigator
2508191|NCT02844283|Experimental|treatment group|Single dose of Ad-HGF given by investigator via intracoronary injection into infarct-related artery
2508192|NCT02844283|Sham Comparator|control group|0.9% sodium chloride (NaCl) injection of same volume given by investigator via intracoronary injection into infarct-related artery
2508245|NCT02843880||Septic shock patients|Septic shock patients staying over 3 days mechanically ventilated in the ICU
2508265|NCT02843516||patients with stroke|patients with stroke
2508266|NCT02843516||patients without stroke|patients without stroke
2508343|NCT02843295|Experimental|Population of the study|3 stratification groups: Group 1: High immunologic risk Patients receiving a ≥ 2nd graft and/or Panel Reactive Antibody ≥ 30% and/or Human Leukocyte Antigen (HLA) mismatches ≥ 4 Group 2: High non-immunologic risk Donors over 60 years of age and/or Donor between 50 to 59 years of age who have died of stroke, or had a history of high blood pressure, or at the time of death had a creatininemia ≥ 135 µmol/L Group 3: Low risk Patients not included in Groups 1 or 2
2508531|NCT02841930|Experimental|Member|"The member group will be able to join ActionHealth NYC program, where they are assigned a primary care physician and have a standardized fee scale for services obtained in network. Laboratory, diagnostic, and specialty services can be obtained at network H+H locations. They will be offered recommended USPSTF A+B tests/screenings, HIV and TB screening (if indicated), and care coordination. If they are deemed high risk, enhanced care coordination services will be offered."
2508533|NCT02841930|No Intervention|Study|The study group will be counseled on their options to access health care, including at public hospitals and community health centers. They will receive no additional services from the study.
2508592|NCT02841293|Active Comparator|Arm with primary perineal wound closure|The intervention consists of perinal reconstruction by primary perineal wound closure
3163672|NCT00485186||1|
3163673|NCT00485186||2|
3163674|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 1|
3163675|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 2|
3163676|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 3|
3163677|NCT00485225|Experimental|Transdermal patch (EN3270) - Titration 4|
3163678|NCT00485251|Active Comparator|1|hand assisted right hemicolectomy
3163679|NCT00485251|Active Comparator|2|laparoscopic right hemicolectomy
3163680|NCT00485329|Experimental|Low dose papain|Ratio of drug to placebo treated patients will be 4:1
3163681|NCT00485329|Experimental|Medium dose papain|Ratio of drug to placebo treated patients will be 4:1
3163682|NCT00485329|Experimental|High dose papain|Ratio of drug to placebo treated patients will be 4:1
2507513|NCT02848989|Experimental|Qigong Mind-Body Exercise (QMBE)|"After the screening procedures confirm that you are eligible to participate in the research study:~Breast cancer survivors with persistent post-surgical pain (PPSP) into a 12-week program of Qigong mind-body exercise (QMBE).~Outcome assessments related to pain, function, and quality of life"
2507559|NCT02848742|Experimental|Treatment with cryotherapy device|To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.
2507684|NCT02847819||Vocal cords movement assessment by airway USG.|Preoperatively patients undergoing thyroid surgery will be scanned by airway ultrasound and graded for vocal cord movement, the same group of patients will be again scanned and graded by airway ultrasound at 4th post operative hours.
2507724|NCT02847481|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
2507731|NCT02847481|Placebo Comparator|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
2507737|NCT02847481|Experimental|FMT after antibiotic pretreatment v1|fecal microbiota transplantation after antibiotic pretreatment
2507741|NCT02847481|Experimental|FMT after antibiotic pretreatment v2|fecal microbiota transplantation after antibiotic pretreatment
2507774|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2507775|NCT02847026|Active Comparator|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a full dose IPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2507776|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2507777|NCT02847026|Active Comparator|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2507779|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2507780|NCT02847026|Active Comparator|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of IPV at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
2507789|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. Rotarix will also be given at 6 and 10 weeks of age.
2507796|NCT02847026|Active Comparator|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive fractional doses of IPV (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. RotaTeq will also be given at 6, 10, and 14 weeks of age.
3196845|NCT00854776|Active Comparator|1|Upper GI tract symptoms are evaluated. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
3196846|NCT00854776|Placebo Comparator|2|Upper GI tract symptoms are evaluated at each visit. Patients are asked to report to gastroenterologist if they have persistent ulcer symptoms and to report to the emergency room if they have evidence of GI bleeding or ulcer complications (melena, hematemesis, or sudden onset of severe epigastric pain). Endoscopy will be undergone to document any gastroduodenal ulcers with or without ulcer complications. An ulcer is defined as a circumscribed mucosal break at least 3 mm in diameter. If the hemoglobin level has decreased by 2g/dL or more, or stool check shows occult blood at each visit, endoscopy will be undergone to check the presence of gastroduodenal ulcers with or without bleeding. Patients without persistent ulcer symptoms or without evidence of ulcer complications will be invited to undergone scheduled endoscopy at the 3-month end of follow-up in each subjective.
3196847|NCT00854789|Experimental|Vaccine|HLA-A2+ and HLA-A3+ patients are administered the E75+GM-CSF vaccine.
3196848|NCT00854789|No Intervention|Control/observation|HLA-A2- and HLA-A3- patients are prospectively followed for disease recurrence. Control patients are not vaccinated.
2507952|NCT02845856|Experimental|Cetuximab and NK immunotherapy|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2507953|NCT02845856|Active Comparator|Cetuximab|In this group, the patients who have EGFR mutation of lung cancer will receive regular Cetuximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508013|NCT02845505||IVUS-CAMS|patients who undergo coronary computed tomography angiography, invasive coronary angiography and IVUS
2508062|NCT02845128||HFNC failure|requiring intubation and invasive mechanical ventilation
2508064|NCT02845128||HFNC success|not requiring intubation nor invasive mechanical ventilation
2508145|NCT02844803|Other|Active drug-> Placebo|Metformin + S. Baicalensis --> Metformin + Placebo
2508148|NCT02844803|Other|Placebo -> Active drug|Metformin + Placebo --> Metformin + S. Baicalensis
2508184|NCT02844231|Other|Sleepwalker, SW episode|Sleepwalker patients undergo single-photon emission computed tomography during a sleepwalking episode.
2508186|NCT02844231|Other|Sleepwalkers, slow wave sleep|Sleepwalker patients undergo single-photon emission computed tomography during slow-wave sleep.
2508188|NCT02844231|Other|Control group|Control subjects undergo single-photon emission computed tomography during slow-wave sleep.
2507561|NCT02848547||Intervention - SMS|Participants in the intervention group received periodic text messages on healthy lifestyle throughout the study period.
2507563|NCT02848547||Control - Standard Care|Participants in the control group received standard one time advice at entry in the study.
2507596|NCT02848300|Experimental|All Participants|Bimatoprost 1% Formulation A solution applied to the left side of the scalp and trunk area and Bimatoprost 1% Formulation B solution applied to the right side of the scalp and trunk area once daily for 14 days.
3163683|NCT00485342|No Intervention|standard dose|"the reference strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg)"
3163684|NCT00485342|Experimental|adjusted dose|individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.
2507729|NCT02847377|Experimental|[18F]-ODS2004436|Two TEP will be performed with the radiotracer [18F]-ODS2004436
2507908|NCT02846194|Experimental|brief guided imagery|The study group of our research will go through six Brief Guided Imagery sessions. These sessions will be completed within two months and will last one hour each.
2507909|NCT02846194|No Intervention|control group|
2507945|NCT02845804||Alpine|The patients who received percutaneous coronary intervention with Xience Xpedition™/Alpine™
2508116|NCT02845102|Experimental|Pre-Post Feasibility Testing|The pre-post feasibility testing/ intervention includes the use of tablet technology and cognitive behavioral therapy (CBT) for depression and self-management education for patients with chronic illness and/or chronic pain and depression. The pre-post feasibility testing phase will include 25 subjects. The total duration of pre-post feasibility testing will be 6 weeks upon the retrieval of the RA-CBT tablet and the inclusion of follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview.
2508166|NCT02844517|Experimental|Artificial Pancreas|The primary outcome is a qualitative assessment of the system's suitability for use in a large-scale in-home clinical trial based on the results of the Technology Acceptance questionnaire and feedback from clinical staff.
2508240|NCT02844114|Experimental|Ganoderma lucidum spore & Chemotherapy|Ganoderma lucidum spore 1500mg tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
2508242|NCT02844114|Placebo Comparator|Placebo & Chemotherapy|Placebo tablet by mouth, every 8 hours for 7 days; Gemcitabine 1000mg intravenously on days 1 and 8 every 3 weeks(iv.over 30 minutes) or cisplatin 75mg intravenously on days 2 and 3 every 3 weeks (iv.15-30 minutes).
2508298|NCT02843412||group 1|choose one tumor tissue paraffin blocks
2508299|NCT02843412||group 2|choose two tumor tissue paraffin blocks
3163685|NCT00485355|Active Comparator|1|Conventional Laparoscopic Hysterectomy
2508377|NCT02842710|Experimental|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
2508432|NCT02842528|Experimental|Alcohol-dependent patients|
2508433|NCT02842528|Active Comparator|First-degree relatives of alcohol-dependent probands|
2508435|NCT02842528|Active Comparator|Healthy Controls|
2508470|NCT02842034|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 120% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 50 stimuli each (i.e., 3000 stimuli) and an intertrain interval of 10 sec. Treatment will be applied in sequential order to the dorsomedial prefrontal cortices (DMPFC).
2508471|NCT02842034|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the same site of active treatment, but the coil will be reversed. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
2508521|NCT02841826|Other|Group I: IUD without uterine sound group|Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding.
2508523|NCT02841826|Other|Group II: IUD with uterine sound|Intrauterine contraceptive device inserted by classic method
2508548|NCT02841579|Experimental|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily. Patients will receive study treatment until disease progression or occurrence of unacceptable side effects up to 78 weeks from the time of the first administered dose.
2508595|NCT02841306|Active Comparator|3-5 hours|Duration between oral UDCA intake and surgery of 3-5 hours.
2508598|NCT02841306|Active Comparator|6-8 hours|Duration between oral UDCA intake and surgery of 6-8 hours.
2508599|NCT02841306|Active Comparator|9-12 hours|Duration between oral UDCA intake and surgery of 9-12 hours.
3163686|NCT00485355|Active Comparator|2|Robotic Assisted Laparoscopic Hysterectomy
3163687|NCT00485394|Experimental|1|OT-551 0.3% ophthalmic solution
3163688|NCT00485394|Experimental|2|OT-551 0.45% ophthalmic solution
3163689|NCT00485394|Placebo Comparator|3|vehicle placebo
3163690|NCT00485420|Active Comparator|Usual Care|Member with recurrent or chronic depression receives usual specialty mental health care
3163691|NCT00485420|Experimental|Internet-based disease managment program|Usual care is augmented with internet based education, self monitoring and clinical monitoring
3163692|NCT00485615|Experimental|1|OMEGA 3
3163693|NCT00485667|Active Comparator|Moxifloxacin tablet|
3163694|NCT00485667|Experimental|Placebo tablet|
3163695|NCT00485667|Experimental|SKY0402 300mg|
3163696|NCT00485667|Experimental|SKY0402 450mg|
3163697|NCT00485667|Placebo Comparator|Placebo injection|
3163698|NCT00485719|Experimental|1|Twice daily (bid) dosing
3163699|NCT00485719|Experimental|2|Once daily (qd) dosing
3163700|NCT00485784|Sham Comparator|control group|control group
3163701|NCT00485784|Experimental|prééclampsies group|prééclampsies group
2507526|NCT02849171|Experimental|high-grade glioma|Eligible patients must have undergone standard radiation (typically 60Gy in 30 fractions), with or without concurrent drug therapy, and have MRI findings consistent with tumor progression and/or pseudoprogression within 24 weeks after completion of radiation. Eligible patients will undergo an 11C-CH PET study within 2 weeks of the standard of care MRI that shows changes concerning for tumor progression vs. pseudoprogression. All patients will then be followed with surveillance brain MRI with and without contrast as per standard of care for a period of 11 months, to assess further progression or stabilization of the lesion. Initial MRI changes are considered to represent pseudoprogression/treatment related changes if the lesion stabilizes or becomes smaller without a change in tumor-related therapy. Otherwise, it will be considered a recurrence should there be progessive radiographic changes.
2507538|NCT02848625|Experimental|Group A|Patients randomized to 12 weeks of twice weekly yoga sessions. The yoga exercises have been designed specifically for patients with IPF.
2507540|NCT02848625|No Intervention|Group B|Patients who are not randomized to yoga sessions will continue with their usual care and usual activities
2507577|NCT02848469|Active Comparator|Omega-3 fatty acids|Subjects will receive food supplements in the form of 200ml juice drinks, containing either the active component, 1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid, or matching placebo for a duration of six months. Neither the active nor the placebo food supplements taste of fish, so the subject will be blind to whether he/she is receiving the active intervention or placebo.
2507578|NCT02848469|Placebo Comparator|placebo 200ml juice drinks|200ml juice drinks
2507607|NCT02848157|Experimental|DR|dexmedetomidine 0.3mcg/kg and 0.25% ropivacaine 0.3ml/kg
2507615|NCT02848157|Placebo Comparator|PR|0.25% ropivacaine 0.3ml/kg
2507692|NCT02847702|Experimental|VM902A 200 mg|VM902A 200-mg Capsules
2507693|NCT02847702|Experimental|VM902A 400 mg|VM902A 400-mg Capsules (2 x 200-mg capsules)
2507695|NCT02847702|Active Comparator|Naproxen|Naproxen 500-mg Capsules
2507697|NCT02847702|Placebo Comparator|Placebo|Placebo
3196849|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
2507967|NCT02845882|Other|Low risk group|Stage I or II: Induction I followed by extracompartmental Protocol M, and maintenance therapy for up to a total therapy duration of 96 weeks. Twenty triple intrathecal injections.
2507974|NCT02845882|Other|Intermediate risk group|Stage III or IV or receiving steroids within one week prior to the diagnosis: Induction protocol I followed by the extracompartmental protocol M, reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
2507978|NCT02845882|Other|High risk group|Failure to qualify a PR, or >5% BM blasts, or with CNS disease on d33 of induction: Induction protocol I followed by 6 intensive polychemotherapy blocks (HR1'-HR2'-HR3'-HR1'-HR2'-HR3'), reintensification protocol II, and maintenance therapy for up to a total therapy duration of 104 weeks. Twenty-two triple intrathecal injections.
2508049|NCT02845154|Active Comparator|Control (bolus purge)|The portal vein clamp will be totally released after end of portal vein anastomosis and all graft and portal blood contents are allowed free and complete access to the systemic circulation via the inferior vena cave
2508052|NCT02845154|Experimental|Intermittent Purge|The portal clamp will be released in situ for 5 seconds to allow purge of the graft and portal contents into the systemic circulation, followed by 30 seconds of portal clamping again. This will be followed by another two cycles of 5 seconds declamping and 30 seconds clamping , then, the portal clamp will be completely released.
2508110|NCT02844777|Placebo Comparator|Placebo|Excipeint alone
2508111|NCT02844777|Experimental|5% VDA-1102|Active study medication
2508112|NCT02844777|Experimental|10% VDA-1102|Active study medication
2508155|NCT02844491||Cohort A|"In Cohort A, patients will be included either in the group sustainable responseor in the short / refractory response group.~- sustainable response group : patient with NHL diffuse large B cells, and persistent complete response for at least 6 months after first-line treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease in complete response or partial stable response for at least 1 year after first line treatment with Rituximab~short / refractory response group : patient with NHL diffuse large B cells, refractory or relapsed in less than 6 months after at least one line of treatment with Rituximab OR patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstrom's disease refractory or relapsed / progression within less than 1 year after at least one line of treatment with Rituximab"
2508156|NCT02844491||Cohort B|"For Cohort B patients will be included either in the group B hematologic therapeutic abstention or in the group any blood disease not treated with anti-CD20 antibodies.~B hematologic therapeutic abstention group : patient with hematological malignancy whatever the initial expansion stage~any blood disease not treated with anti-CD20 antibodies group : patient with follicular NHL, mantle NHL, NHL marginal zone or Waldenstorm disease without treatment criteria at diagnosis and with stable disease for at least 6 months"
2508221|NCT02844049|Active Comparator|Deep Brain Stimulation|DBS surgical procedure scheduled and realized
2508225|NCT02844049|No Intervention|Control group|medical treatment (psycho- and pharmaco-therapy) will continue to be given and optimized according to the defined BMT strategies and criteria
2508287|NCT02843438|Other|Subjects suspected of toxoplasmosis chorioretinitis infection|Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
2508421|NCT02842684|Experimental|Traumacad software|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise . The recent TraumaCad system ( Brainlab® ) allows adjustment of the scales for each patient and the virtual positioning of implants to simulate the response to the return of geometric hip parameters
2508425|NCT02842684|No Intervention|without digital planning|Preoperative planning of hip prothesis is practiced by layer on radiographs whose scaling is imprecise
2508588|NCT02841293|Experimental|Arm with biological mesh|The intervention consists of perinal reconstruction using biological mesh (Cellis prosthesis from Meccellis Biotech, reference C1015E size 10x15cm)
2507527|NCT02849197||Limberg Flap Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Limberg Flap Technique. Technical details: A rhomboid incision was made as to include all sinus openings, and an excision was made down to the pre-sacral fascia. A bisector drawn in the rhombohedron was extended laterally to a length similar to that of a corner of the rhombohedron. Then, the flap was prepared by removing gluteal muscle with its fascia. One suction drain was placed at the wound cavity. The base of the flap was approximated with the presacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable sutures, and the skin was closed with interrupted 3-0 prolene suture."
2507529|NCT02849197||Modified Limberg Technique|"Patients with pilonidal sinus disease treated with surgery for pilonidal sinus disease.~Technique: Modified Limberg Flap Technique. Technical details: As in Limberg flap technique, a rhomboid incision was made. Upper and lower corners of the excision were lateralized 2 cm away from the midline in order to keep the suturing line at the inferior from overlapping the midline. An excision was made down to the pre-sacral fascia. One suction drain was placed at the wound cavity, and the base of the flap was approximated with the pre-sacral fascia at the excised area with interrupted 2-0 absorbable sutures. Subcutaneous tissue was approximated with interrupted 2-0 absorbable suture, and the skin was closed with 3-0 prolene."
2507595|NCT02848430|Experimental|Humulus lupulus|Spent hop extract; 2 gelatin capsules (59.5 mg extract) per day for 14 days
2507647|NCT02848027|Experimental|Regenexx-SD procedure|Measure components of knee synovial fluid collected 2-4 days before and after Regenexx SD procedure
3163702|NCT00485784|Experimental|RCIU group|RCIU group
3163703|NCT00485784|Experimental|MFIU group|MFIU group
2507910|NCT02845869|Experimental|Light Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Light Therapy treatment with the THOR laser LX2 system.
2507911|NCT02845869|Sham Comparator|Sham Therapy|Subjects from this group will receive 8 biweekly physiotherapy treatment and in addition Sham Therapy.
2507988|NCT02845778|Experimental|melatonin niosomes oral gel 2.5 mg|apply onto oral mucosa as single use
2507990|NCT02845778|Experimental|melatonin niosomes oral gel 5 mg|apply onto oral mucosa as single use
2507994|NCT02845778|Experimental|melatonin niosomes oral gel 10 mg|apply onto oral mucosa as single use
2508019|NCT02845232||Intensive chemotherapy|First group: 68 patients receiving a combination of intermediate-dose cytarabine and an anthracycline. One patient with acute promyelocytic leukaemia (APL) also received all-trans retinoic acid (ATRA).
2508021|NCT02845232||Lower-intensity treatments|The second study group comprised 70 patients who were treated on frontline by lower-intensity treatments [LD-AraC(39 patients), azacitidine (16 patients), decitabine (11 patients),tipifarnib (3 patients), or ATRA (1 patient)]. Patients received LD-AraC 20 mg once or twice daily (according to physician'schoice) by subcutaneous injection for 10 consecutive days. Azacitidine was given at the dose of 75 mg/m2/day for 7 consecutive days by sc injection. Decitabine was administered by intravenous route once daily at 20 mg/m2 for 5 consecutive days. Tipifarnib was given at 600 mg administered orally twice daily for 21 consecutive days in 4-week cycles. ATRA was given at 45 mg/m2until CR achievement followed by maintenance combining 6-mercaptopurine with methotrexate.
2508022|NCT02845232||Best Supportive Care|The last study group comprises 76 patients: 31 patients received supportive care, while 36 patients also received hydroxyurea and 9 patients received 6-mercaptopurine.
2508124|NCT02845050|Experimental|Vinflunine+Cisplatin+radical cystectomy|neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
2508193|NCT02844400||Adjuvant and Curative Chemotherapy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with adjuvant or curative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
2508194|NCT02844400||Palliative Chemoteraphy|30 participants. Primarily older (60+ years in age) cancer patients receiving cytotoxic chemotherapy with palliative intent. Will undergo both the Physical Performance Testing and Biometric Devices interventions.
2508248|NCT02843789|Experimental|Adiponectin evaluation|Patients evaluated for serum adiponectin level and for body composition before each infusion of Tocilizumab
2508331|NCT02843477||Fluid loading group|Spontaneously breathing patients before induction of general anesthesia who receive fluid loading
2508387|NCT02842827|Experimental|Multiple ascending dose|MAD Cohorts using IMG-7289 alone
2508388|NCT02842827|Experimental|Combination Therapy|IMG-7289 in combination with all-trans retinoic acid (ATRA)
2508389|NCT02842827|Experimental|Ascending duration|Treatment duration extension Cohorts using IMG-7289 alone
2508436|NCT02842450||training with typical definitions established + photos|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
2508438|NCT02842450||Training only with definitions|Interns will receive typical definitions of LAP stages
3163704|NCT00485888|Active Comparator|1|
3163705|NCT00485888|Placebo Comparator|2|
3163706|NCT00485914|Experimental|On-site work evaluation|Participants will receive one-to-one contact with an occupational therapist and an individualized work plan
3163707|NCT00485914|Active Comparator|Educational material|Participants will receive educational materials to develop strategies to compensate for limitations caused by their condition
3163708|NCT00485940|Active Comparator|1|Prucalopride 2 mg
3163709|NCT00485940|Placebo Comparator|3|Placebo
3163710|NCT00485940|Active Comparator|2|Prucalopride 4 mg
3163711|NCT00485979|Experimental|Arm A1|Cohort 1: Her2-ve breast cancer
3163712|NCT00485979|Active Comparator|Arm B1|Cohort 1: Her2-ve breast cancer
3163713|NCT00485979|Experimental|Arm A2|Cohort 2: Her2+ve breast cancer
3163714|NCT00485979|Active Comparator|Arm B2|Cohort 2: Her2+ve breast cancer
3163715|NCT00486135|Experimental|1|Daily dosing for 21 days/7 days off
3163716|NCT00486135|Experimental|2|Continuous daily dosing
3163717|NCT00486135|Experimental|3|Continuous daily dosing
3163718|NCT00486148|No Intervention|"group S"|Breast milk
3163719|NCT00486148|No Intervention|"group A"|Control Infant formula
3163720|NCT00486148|Experimental|"group B"|Infant formula supplemented with 0.4 g/100 ml of oligosaccharides
2507556|NCT02848820|Active Comparator|Operative treatment strategy|Clinical observation and semi-urgent appendectomy. Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics. Discharge if the patient fulfils the predefined discharge criteria. Pain medication according to national protocol.
2507602|NCT02848131|No Intervention|Group 1: Observational|Observational Only
2507613|NCT02848131|Active Comparator|Group 2: Dasatinib & Quercetin|The drugs dasatinib and quercetin will be used in this arm
2507645|NCT02847871|Other|Multimodal Intervention|The multimodal intervention on mobility will consist of the implementation of a care pathway dedicated in primary care. It will include awareness and training of general practitioners for easy identification, a care associating a dedicated geriatric consultation to rule out underlying pathology, teaching exercises by MAPA (+/- taken care in the presence of MAPA) and nutritional counseling by a dietician. Close collaboration between general practitioners, geriatrician, MAPA and dietician will be established.
2507652|NCT02847871|No Intervention|Non interventional|Patients received treatment as part of their standard care: at the discretion of the general practitioner patients
2507716|NCT02847624||ADPKD|
2507750|NCT02847208||cystic fibrosis women|It was a cohort of 155 CF women attending the Lyon adult centre. Women attending the CF adult centre in 2014 completed a written questionnaire about their contraceptive choices, frequency of gynaecological follow-up and cervical screening. Other clinical data were collected from the CF adult centre registry.
2507790|NCT02846974||Calibration cohort|In this cohort, approximately 30 subjects will be put through a controlled desaturation study with controlled hypoxia until they arrive at approximately SpO2 = 70%. Measurements will be taken via arterial catheterization to resolve proper values to calibrate the device
2507795|NCT02846974||Validation cohort|In this cohort, approximately 250 patients will have a single pulse oximetry reading taken using the novel device and a gold standard device to ensure accurate validation.
2507861|NCT02846649|Experimental|PIER Intervention|The program will help participants learn to recognize the presence of craving and how it can be reduced through environmental, self-regulatory and mood management. Each day, the PIER1 program sends (1) a morning reflection focused on positive thinking, (2) two random prompts assessing severity of craving, (3) feedback specific to managing withdrawal symptoms, mood management, and environmental triggers that are affecting craving, (4) evening assessments of drug use with feedback, (5) goal commitment prompt with feedback, and (6) user-triggered craving assessments with feedback
2507898|NCT02846207|Experimental|Yiqi huoxue group|Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
2507902|NCT02846207|Experimental|Yiqi group|Astragalus 60g. Oral administration, twice one day, for 12weeks.
2507904|NCT02846207|Experimental|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
2507905|NCT02846207|Placebo Comparator|placebo group|dextrin, Oral administration, twice one day, for 12weeks.
2507985|NCT02845739|Experimental|kidney transplanted patient|
2508034|NCT02845388|Active Comparator|estradiol valerate|estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
2508036|NCT02845388|Active Comparator|Sildenafil citrate and estradiol valerate|Sildenafil citrate 25 mg every 6 hours orally in combination with estradiol valerate 2mg every 12 hours orally starting from the second day of the menstrual cycle till reaching trilaminar endometrial pattern and endometrial thickness 8 mm or more
3163721|NCT00486174|Active Comparator|1|standard sepsis therapy plus Methylene Blue
3163722|NCT00486174|No Intervention|2|standard sepsis therapy
2508183|NCT02844322|Experimental|Bortezomib|Patients in this group will receive bortezomib+ cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to RCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
2508185|NCT02844322|Experimental|rituximab|Patients in this group will receive rituximab+cyclophosphamide+ dexamethasone as introduction chemotherapy regimen. Chemotherapeutic response will be evaluated after 3 cycles. If a PR or better response achieves, addition 3 cycles will be given. If not, patients will cross to BCD group for another 3 cycles. If a PR or better response comes out, addition 3 cycles will be given, otherwise, the patient will quit this study.
2508277|NCT02843321|Experimental|T-cell infusion|Infusion of donor-derived T cells. Non randomised, prevention study arm
2508309|NCT02843139||Children group|Children recruiters were categorized into three groups: obesity, overweight and normal control based on World Health Organization child growth standards.
2508312|NCT02843139||Adults group|Adults with type 2 diabetes were defined if the individual had a fasting plasma glucose (FPG) level ≥ 7.0 mmol/L.
2508344|NCT02842918|Active Comparator|Spinal Manual Therapy|Supine thoracic spine manipulation located between the levels of T4-T7
2508345|NCT02842918|Sham Comparator|Spinal Range of Motion|Supine thoracic spine sham manipulation located between the levels of T4-T7; identical procedure as the active treatment intervention but without the delivery of high velocity low amplitude thrust
2508394|NCT02842671|Experimental|Assigned Ambassador (Intervention Group)|Patients who were consented, completed the accommodations survey, and for whom a medical student was available during the time of the the procedure will serve as our intervention group. The participants will be assigned an Ambassador throughout the procedure and will complete a patient satisfaction survey afterwards. The investigators hope to enroll 25 controls.
2508399|NCT02842671|No Intervention|Control Group|Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
2508601|NCT02841306|No Intervention|Control|No medication
2507646|NCT02847949|Experimental|Extension arm|IGN002 study drug will initially be administered at the same dose level and schedule that the subject was receiving at the conclusion of the other Spectrum sponsored IGN002 study, IGN002-101.
2507734|NCT02847676||No previous surgery, adhesions present.|Patients have had no previous abdominal surgery. Inspection shows peritoneal adhesions.
2507740|NCT02847676||No previous surgery, no adhesions present.|Patients have had no previous abdominal surgery. Inspection shows no peritoneal adhesions.
2507742|NCT02847676||Previous surgery, adhesions present.|Patients have had previous abdominal surgery. Inspection shows peritoneal adhesions.
2507744|NCT02847676||Previous surgery, no adhesions present.|Patients have had previous abdominal surgery. Inspection shows no peritoneal adhesions.
2507829|NCT02846662|Experimental|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an applicative for smartphones (CONEMO), which encourages them to be more active and to incorporate more activities in their everyday life.~Primary care nurses will train participants to use the CONEMO app, monitor patients' adherence to CONEMO, calling patients when they are non-adherent, and give technical support when necessary. They will be supervised by clinical psychologists.~Primary care teams are informed of participants' depression level and deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication."
2507835|NCT02846662|No Intervention|ENHANCED USUAL CARE|The primary care teams are informed of the participants' depression level and can deliver usual care according to clinical protocols, including the assessment for the need of antidepressant medication. This is considered enhanced usual care because the teams are notified about participants' level of depressive symptomatology, which otherwise might go undetected, and then decide about the best way to handle with patients' needs related to their depressive symptomatology.
2507866|NCT02846376|Experimental|Group A - Nivolumab|"Nivolumab for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Dose level 1: 1 mg/kg~Dose level 2: 3 mg/kg"
2507868|NCT02846376|Experimental|Group B - Ipilimumab|"Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 1.0 mg/kg~Dose level 3: 3.0 mg/kg"
2507872|NCT02846376|Experimental|Group C - Nivolumab + Ipilimumab|"Nivolumab 3 mg/kg for 12 doses, on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34~Ipilimumab for 6 doses on day 1 of weeks 1, 4, 7, 10, 13, 16~Dose level 1: 0.3 mg/kg~Dose level 2: 0.6 mg/kg~Dose level 3: 1.0 mg/kg"
2507915|NCT02846051|Other|intensive sport practice|"intensive sport practice~the subject must practice for more than six months a drive of at least 8 hours / week, intense, above the ventilatory threshold, or 60-70% of maximum consumption oxygen or 70-80% of maximum heart rate, ie beyond a moderate slowdown. If stopping the intensive sport practice, the duration of the stop at the time of the study should be less practice time.~volunteers,~from 18 to 80 years,~free to consent.~covered by social security.~reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
2507918|NCT02846051|Other|control group|"&) Volunteers who do not have intensive sport practice as it is defined in the group intensive sport practice 2) from 18 to 80 years, 3) free to consent. 4) covered by social security. 5) reported in the national register of healthy volunteers.~The intervention is a lower limb venous examination = venous mapping"
3196850|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 weeks + peg-IFNα2a 180 µg sc once weekly for 24 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 weeks.
3196851|NCT00854802|Experimental|Debio 025 600 mg + peg-IFNα2a + ribavirin - 24 or 48 weeks|Participants receive Debio 025 600 mg orally twice daily for 7 days (loading dose) followed by Debio 025 600 mg orally once daily for 23 or 47 weeks + peg-IFNα2a 180 µg sc once weekly for 24 or 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 24 or 48 weeks. Participants who achieve a rapid viral response, defined as having undetectable hepatitis C virus RNA at week 4, are treated for 24 weeks; other patients are treated for 48 weeks.
2508081|NCT02845089||Advanced/Metastatic NSCLC patients from UAE and KSA|A random sample of patients diagnosed with advanced/metastatic non-small cell lung cancer (NSCLC) from select oncology centers in Kingdom of Saudi Arabia (KSA) and United Arab Emirates (UAE)
2508371|NCT02842879|Experimental|Outpatient Foley cervix priming|Patients randomized to outpatient cervix priming will have the insertion of the catheter in the same conditions defined by the Department protocol for inpatient cervix priming. They will be discharged after a reassuring cardiotocogram following the introduction of the Foley catheter. When discharged, the patients will be instructed to apply manual traction to the catheter every 6 hours and they will be given a written document with all the information that should bring them back to hospital.
2508373|NCT02842879|No Intervention|Inpatient Foley cervix priming|The introduction of a deflated catheter (Foley catheter nº 16F) through the outer cervix orifice is preceded by iodine disinfection of the cervix. The intracervical catheter is distended with 40mL of a saline solution. The end of the catheter is taped to the medial portion of the thigh and manual traction is applied to the catheter every 6 hours. If it is not spontaneously extruded it is removed after 24h. Cervix priming occurs in an inpatient setting.
2508454|NCT02842554|Other|DPA|Drug Placebo Administration
2508455|NCT02842554|Other|C|Control
2508456|NCT02842554|Other|EPT|Evoked Pain Training
2508481|NCT02842021|Active Comparator|S2G6T-1|Topical cream
2508485|NCT02842021|Active Comparator|S2G6T-2|Topical Cream
2508488|NCT02842021|Active Comparator|S2G6T-3|Topical Cream
2508491|NCT02842021|Placebo Comparator|S2G6T-4|Topical Cream
2508682|NCT02840708|Active Comparator|125mcg|SK-1401 125mcg single inhalation
2508685|NCT02840708|Active Comparator|250mcg|SK-1401 250mcg single inhalation
2508687|NCT02840708|Active Comparator|500mcg|SK-1401 500mcg single inhalation
2508744|NCT02840292||Cases|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal hemoglobin < 11gm/dl
2508749|NCT02840292||Controls|Late preterm neonates (>34weeks but <37weeks of gestation) with maternal haemoglobin ≥ 11gm/dl
2508768|NCT02840006|Active Comparator|General anesthesia only|Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1
2510432|NCT02828397|Experimental|Reference Drug|REGN2222 Reference Formulation
2507648|NCT02847910|Experimental|control group|device： Traditional metal instruments for induced abortion procedure; The participants will be use traditional metal instruments during induced abortion procedure.
3196852|NCT00854802|Placebo Comparator|Debio 025 placebo + peg-IFNα2a + ribavirin - 48 weeks|Participants receive Debio 025 placebo orally twice daily for 7 days followed by Debio 025 placebo orally once daily for 47 weeks + peg-IFNα2a 180 µg subcutaneously (sc) once weekly for 48 weeks + ribavirin 1000 or 1200 mg (weight based) orally daily for 48 weeks.
3196853|NCT00854815|Active Comparator|Irrigation|Irrigation of the area with at least 500ml normal saline using the power suction/irrigator
3196854|NCT00854815|Active Comparator|No Irrigation|Only suction with the power suction/irrigator without saline attached
3196855|NCT00854854|No Intervention|Control|"Oxaliplatin infusion (100mg/m2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16~LV infusions (200 mg/m2) on days 1, 2, 15 and 16"
2507934|NCT02845973||test cohort|The test cohort was from Fudan University Shanghai Cancer Center (August 2016 to December 2016) and ECRJ-East Campus of Renji hospital (January 2012 to March 2017);
2507938|NCT02845973||validation cohort|The validation cohort was from Shanghai Tenth People's Hospital (October 2015 to November 2016) and WCRJ-West Campus of Renji hospital (July 2016 to March 2017)
3196856|NCT00854854|Active Comparator|Active|"Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times~and chemotherapy schedule"
2508032|NCT02845206|Experimental|Patient Specific Cutting Blocks|For the bespoke individualised cutting blocks to be manufactured, the patients will undergo a preoperative CT scan under a set protocol. The CT radiation dose will be considerably less than a conventional diagnostic CT scan.
2508033|NCT02845206|Active Comparator|Conventional Cutting Blocks|The patients in this arm will be operated on using conventional instruments.
2508069|NCT02844985||Addict Group|In-patient and out-patient adult men and women who meet diagnostic criteria for sexual addiction.
2508071|NCT02844985||Control Group|Individuals from the general community and college student populations who have no history of identifiable psychopathology.
2508138|NCT02844673|Active Comparator|Standard monitoring (SM) arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) with standard monitoring. Standard monitoring is defined as a follow-up visit two weeks after initiation of therapy and monthly follow-ups thereafter
2508141|NCT02844673|Experimental|mDOT arm|Participants will receive fixed dose hydroxyurea therapy (15 mg/Kg/day) and Mobile Directly Observed Therapy (mDOT) consisting of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Participants will receive alerts on their cell phone at pre-arranged times to remind them to take their medications. Participants will be followed-up at two weeks after initiation of therapy and monthly thereafter.
2508222|NCT02843932|Experimental|Psychogenic disorders|Psychogenic movement disorders and seizures
2508278|NCT02843633|Experimental|BioFreedom™ Drug Coated Stent|
2508412|NCT02842593|Experimental|Resistance exercise training|Whole-body resistance exercise training 4x/week for 12 weeks. Either 'lower-repetition, heavier-load' or 'higher-repetition, lighter-load' intervention.
2508414|NCT02842593|No Intervention|Non-exercising control|Continue habitual physical activity for 12 weeks.
2508473|NCT02842307|Active Comparator|A(senior acupuncturists)|Manual acupuncture implemented by senior acupuncturists (clinical experience >15 years)
2508484|NCT02842307|Active Comparator|B(junior acupuncturists)|Manual acupuncture implemented by junior acupuncturists (clinical experience <5 years)
2508489|NCT02842307|Active Comparator|C(P6 points)|Manual acupuncture on P6 points by junior acupuncturists (clinical experience <5 years)
2508490|NCT02842307|No Intervention|D(no acupuncture)|No acupuncture treatment
2508596|NCT02841410|Other|Healthy Volunteer|
2508616|NCT02841020|No Intervention|Control SOC|Standard of care is followed
2508618|NCT02841020|Experimental|Experimental additional biopsy|Additional biopsy
2508690|NCT02840799|Experimental|Potassium Nitrate (KNO3)|Potassium nitrate (KNO3) capsules, providing 6 millimoles of inorganic nitrate per capsule, to be taken three times daily for 6 weeks.
2508693|NCT02840799|Placebo Comparator|Potassium Chloride (KCl)|"Potassium Chloride (KCl) is the placebo (control drug) in this trial.~Potassium Chloride (KCl) capsules administered at a dose of 6 millimoles (1 capsule) three times daily for 6 weeks."
2508714|NCT02840227|Experimental|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
2508717|NCT02840227|Experimental|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous PCA opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
2508785|NCT02840071|Experimental|Intervention|Psychological therapy.
2508958|NCT02839070|Experimental|Regular Schedule|Participant will be on a regular sleep/wake schedule
2508960|NCT02839070|Experimental|Irregular Schedule|Participant will be on an irregular sleep/wake schedule
2509018|NCT02838342|Experimental|Metronomic cyclophosphamide and interferon-alpha|
2509042|NCT02837900|Placebo Comparator|Previous LT TX knee and right placebo|Previous left treated knee will have placebo treatment in this protocol.
2509045|NCT02837900|Placebo Comparator|Previous RT TX knee and left placebo|Previous right treated knee will have placebo treatment in this protocol.
2509047|NCT02837900|Active Comparator|Both TX with Active|Both knees with receive Active
2509123|NCT02837770|Active Comparator|Pacebo pill and Diclofenac Eye Drops|Pacebo pill will be administered 4 hours before the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
2509192|NCT02837003||Experimental: Aspirin|Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.
2507654|NCT02847793|Placebo Comparator|Placebo intervention|Using a matching procedure (i.e., yoked control group), participants are required to maintain their gaze in a given picture (e.g., a happy face), for the same average time that their counterparts in the Gaze training group (i.e. Experimental group)
2507700|NCT02847585|Experimental|Open label|water-soluble ubiquinol
2507746|NCT02847325|Experimental|AC0058TA|Drug: 50 mg AC0058TA Drug: 100 mg AC0058TA Drug: 200 mg AC0058TA Drug: 400 mg AC0058TA
2507747|NCT02847325|Placebo Comparator|Placebo capsules|Drug: Placebo capsules
2507784|NCT02847039||Early repolarization syndrome|Patients with an aspect of early repolarization syndrome or belonging to a family in which the diagnosis of early repolarization was identified.
2507827|NCT02846701|Other|patient treated by duloxetine|
2507856|NCT02846428|Active Comparator|5-Fluorouracil + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of 5-FU + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
2507857|NCT02846428|Experimental|Capecitabine + Epirubicin + Cyclophosphamide|Neoadjuvant treatment (Period 1): Participants will receive 4 cycles (cycle length = 21 days) of capecitabine + epirubicin + cyclophosphamide. Surgery will be performed 5 (+/- 1) weeks after the last cycle. Adjuvant treatment (Period 2): Participants will receive 4 cycles (cycle length = 21 days) of docetaxel.
2507899|NCT02845934|Experimental|Mucormycosis|blood sample
2507991|NCT02845830||Participants in early stage of dementia|Subjects with any type of dementia at an early phase diagnosed in the last 12 months with MMSE score 20-25 points
2507993|NCT02845830||Participants without dementia|Subjects without dementia with MMSE score 26-30 points
2508046|NCT02845349|Experimental|Drug-Vortioxetine|The treatment group will receive vortioxetine 10 mg per day, which will be increased to 20 mg or decreased to 5 mg, if deemed clinically necessary, at week 4 or 8.
2508051|NCT02845349|Placebo Comparator|Placebo|Matching placebo will be used.
2508134|NCT02844829|Other|MRI and biomarkers|Prostate MRI. Blood and urine biomarkers. Both prior to biopsy. Tissue samples during prostatectomy.
2508200|NCT02844361|Experimental|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
2508203|NCT02844361|Active Comparator|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
2508272|NCT02843373||rTMS|rTMS will be delivered for 20 sessions over 4 weeks. Active 10 Hz rTMS will be delivered to the left DLPFC as assessed by either the 5cm rule or F3 site. Daily treatment regiments will last 36.5 minutes and rTMS will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS sessions for adverse events and/or side effects.
2508351|NCT02843204|Experimental|Pembrolizumab and NK immunotherapy|In this group, the patients will receive regular Pembrolizumab first to control tumor burden; then NK immunotherapy will be given. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508356|NCT02843204|Active Comparator|Pembrolizumab|In this group, the patients will receive regular Pembrolizumab to control tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508401|NCT02842619|Experimental|Intervention Arm|1 Arm - IMP treatment arm
2508477|NCT02842411||chronic constipation|patients with chronic constipation based on Rome Ⅳ
2508518|NCT02841813||The normal mothers group|No intervention
2508522|NCT02841813||The normal full-term infants group|No intervention
2508524|NCT02841813||The preterm mothers group|No intervention
2508526|NCT02841813||The preterms group|No intervention
2508573|NCT02841501||Candidemia patients|These patients are included in the study after the reception of a positive blood culture for Candida sp.
2508574|NCT02841501||Control patients|"These patients are matched on case patients on the following criteria:~Age+/-5 years~length of hospitalisation~type of ward~type of surgery for surgical patients~IGS2 for intensive care patients"
2508644|NCT02841150|Experimental|Treatment Sequence 1|Participants will receive treatment A, on Day 1 of Intervention Period 1 followed by treatment B , on Day 1 of Intervention Period 2 followed by treatment A, Day 1 of Intervention Period 3 and then followed by treatment B, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2508645|NCT02841150|Experimental|Treatment Sequence 2|Participants will receive treatment B, on Day 1 of Intervention Period 1 followed by treatment A, on Day 1 of Intervention Period 2 followed by treatment B, Day 1 of Intervention Period 3 and then followed by treatment A, on Day 1 of Intervention Period 4. Each intervention Period will be separated by a washout period of 7-9 days.
2508701|NCT02840565|Experimental|BIA 5-453 25 mg or placebo|Multiple oral doses of BIA 5-453 25 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2508703|NCT02840565|Experimental|BIA 5-453 50 mg or placebo|Multiple oral doses of BIA 5-453 50 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2508704|NCT02840565|Experimental|BIA 5-453 100 mg or placebo|Multiple oral doses of BIA 5-453 100 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2508705|NCT02840565|Experimental|BIA 5-453 200 mg or placebo|Multiple oral doses of BIA 5-453 200 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2508706|NCT02840565|Experimental|BIA 5-453 400 mg or placebo|Multiple oral doses of BIA 5-453 400 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2508707|NCT02840565|Experimental|BIA 5-453 600 mg or placebo|Multiple oral doses of BIA 5-453 600 mg or placebo were administered once daily for 10 days to subjects in fasting conditions.
2507681|NCT02847754|Experimental|A|A patients in arm A carry out daily physical Training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home. exercise tailored isometric physical exercise
2507688|NCT02847754|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min progressive muscle relaxation starting from day one of radiotherapy.
2507701|NCT02847442|Experimental|Opicapone (BIA 9-1067) 50 mg|Total duration of trial participation and treatment: three months. All subjects will start treatment with 50 mg opicapone (OPC) once daily for a 3-month period in addition to their current treatment with levodopa/dopa decarboxylase inhibitor (L-dopa/DDCI)
2507769|NCT02847247|Experimental|CCRE|20,000 EU of CCRE (Clinical Center Reference Endotoxin)
2507838|NCT02846753|Experimental|Implantation of Venus P-Valve™|Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
3196857|NCT00854867|Experimental|Whole brain radiotherapy (WBRT) with concomitant Depocyte|Subjects will receive a total of 38.4 Gray (Gy) WBRT given over 4 weeks. Subjects will receive 3 GyWBRT on Days 1 and 2 and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 3 (or Day 4 or 5) of Week 1, i.e. the third day of radiotherapy treatment when the dosage is reduced to 1.8 Gy. The second dose will be administered on Day 17(+2 days); the third dose will be administered on Day 31 (+2 days); the fourth dose will be administered on Day 45 (+2 days) to complete the induction phase of the protocol. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
3208762|NCT00977847|Experimental|Interactive Voice Response Practice|"The introductory letter to patients will allow them an opportunity to opt-out of the study using a toll-free number. If they do not opt-out within 2 weeks of receiving the letter, the IVR system will make up to 15 call attempts over a 2 week period to reach the patient. The system will make outbound calls during preset hours. The system continuously checks the call list for the next scheduled call. Once contact is made, the spoken script greets the patient by name, authenticates identify, and will ask the patient the programmed questions. The IVR server will send completed family history assessments to the patients EHR as an HL7 compliant summary note as well as transmitting the separate coded responses for each condition/ family member to coded family history fields in the EHR."
2507946|NCT02845817|Other|Qualitative research|Semi-structured interviews
2507999|NCT02845570|Experimental|68Ga-DOTANOC PET/MRI|Comparison between 68Ga-DOTANOC PET/MRI and 18F-FDG PET/MRI scans
2508092|NCT02845037|Experimental|2 mg or placebo|BIA 5-453 or placebo
2508093|NCT02845037|Experimental|10 mg or placebo|BIA 5-453 or placebo
2508095|NCT02845037|Experimental|20 mg or placebo|BIA 5-453 or placebo
2508097|NCT02845037|Experimental|50 mg or placebo|BIA 5-453 or placebo
2508099|NCT02845037|Experimental|100 mg or placebo|BIA 5-453 or placebo
2508100|NCT02845037|Experimental|200 mg or placebo|BIA 5-453 or placebo
2508101|NCT02845037|Experimental|400 mg or placebo|BIA 5-453 or placebo
2508102|NCT02845037|Experimental|600 mg or placebo|BIA 5-453 or placebo
2508103|NCT02845037|Experimental|900 mg or placebo|BIA 5-453 or placebo
2508104|NCT02845037|Experimental|1200 mg or placebo|BIA 5-453 or placebo
2508311|NCT02843191|Active Comparator|Adjuvant chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive surgery followed by eight cycles of chemotherapy.
2508314|NCT02843191|Experimental|Consolidation chemotherapy|After neoadjuvant chemoradiotherapy, patients will receive three cycles of chemotherapy. Thereafter, they will receive surgery followed by five cycles of chemotherapy.
2508407|NCT02842788||ARDS patients receiving invasive mechanical ventilation in ICU|"ARDS criteria (Berlin definition) fulfilled the day of the study, whatever the ARDS stage. The onset of ARDS could have been established at any time between ICU admission and study day but ARDS criteria must be still present the day of the study. The ARDS criteria are listed below~Within 1 week of a known clinical insult or new or worsening respiratory symptoms~Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or nodules~Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (eg, echocardiography) to exclude hydrostatic edema if no risk factor present~PaO2/FIO2 ≤ 300 with Positive end-expiratory pressure (PEEP) ≥ 5 cmH2O~Age ≥ 18 years~Intubated or tracheotomized and mechanically ventilated"
2508497|NCT02842047|Experimental|End of Life Care with Meditation|The intervention has two content components: end of life planning education (using end of life planning videos) and strategies and kindness based meditation (using the Stop, Breathe & Think™ app). The activities comprising these components work together to improve both analytic neural processing (e.g. improving knowledge about goal setting and EOL planning, learning self-monitoring of EOL values and goals of care, and self-regulation skills of monitoring symptoms of distress and anxiety) and emotional neural processing (e.g. teaching participants to experience the moment non-judgmentally and directing thoughts to think positive thoughts and feel positive feelings like kindness and compassion.
2508501|NCT02842047|Active Comparator|Meditation Only|This arm has the single content component of kindness based meditation delivered by using the Stop, Breathe & Think™ application. This group will also be instructed to view 3 caregiver wellness videos.
2508553|NCT02841683|Active Comparator|Lifestyle counseling|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
2508558|NCT02841683|No Intervention|Current practices|Current practices of smoking cessation in France
2508866|NCT02839447||Normal Semen|"Semen that meet the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
2508870|NCT02839447||Abnormal Semen|"Semen that fail to achieve one or more of the criteria for normal on sperm number, motility, and morphology as described by the current WHO manual."
2508952|NCT02838940|Experimental|cesarean in different indications|Women that are about to undergo an elective cesarean in different indications.
2510434|NCT02828397|Experimental|Test Drug|REGN2222 Test Formulation
2507705|NCT02847559|Experimental|Treatment (bevacizumab, electric field therapy)|Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 of courses 1-4. Beginning on day 1 of course 5, patients may choose to receive bevacizumab IV every 3 weeks or remain on the every 2-week schedule. Patients also undergo electric field therapy using Optune (formerly NovoTTF-200A System) daily over 18 hours. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2507782|NCT02847000|Experimental|Decitabine + Tetrahydrouridine|Tetrahydrouridine (THU) is supplied as 250 mg/capsule, Decitabine (Dec) as 5 mg/capsule.
2507817|NCT02846623|Experimental|Cohort I (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 3, patients also receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 14 cycles in the absence of disease progression or unacceptable toxicity.
2507819|NCT02846623|Experimental|Cohort II (obinutuzumab, atezolizumab, venetoclax)|Patients receive obinutuzumab intravenously IV over 4-6 hours on days 1, 2, 8, and 15 of cycle 1 and on day 1 of cycles 2-9 and atezolizumab IV over 30-60 minutes on days 3-4 of cycle 1 and on days 1-2 of cycles 2-9. Treatment repeats every 28 days for 9 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 2, patients receive venetoclax PO on days 1-28. Treatment repeats every 28 days for 25 cycles in the absence of disease progression or unacceptable toxicity.
2507942|NCT02846181|Experimental|Healthy|
2507963|NCT02845622|Experimental|30g peeled hazelnuts cream|Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2507966|NCT02845622|Experimental|30g unpeeled hazelnuts cream|Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2507970|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts|Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2507977|NCT02845622|Experimental|snack w/ 2.5g cocoa powder|Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2507981|NCT02845622|Experimental|snack w/ 30g peeled hazelnuts+2.5g cocoa|Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2507982|NCT02845622|Placebo Comparator|empty snack|Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
2508066|NCT02845193|Experimental|Modified Nasoalveolar molding group|This group will receive nasoalveolar molding appliance in addition to taping for 3 Months with follow-up every 2 weeks.
2508068|NCT02845193|Experimental|Taping group|Tape will be used alone in this group on the upper lip segments for 3 months with follow-up every 2 weeks.
2508070|NCT02845193|No Intervention|Control group|This group will not receive any treatment.
2508073|NCT02845193|Experimental|CAD/NAM group|Computer Aided Designed Nasoalveolar molding and 3D printed.
2508123|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
2508206|NCT02844452|Experimental|Verum Acupuncture 1|The participants with atopic dermatitis in the acupuncture group 1 will attend twelve acupuncture sessions over 4 weeks: 3 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
2508209|NCT02844452|Experimental|Verum Acupuncture 2|The participants with atopic dermatitis in the acupuncture group 2 will attend eight acupuncture sessions over 4 weeks: 2 days a week. Once the 4-week treatment period was ended, the additional follow-up period will be conducted. The subjects will stand a final visit 4 weeks from the end of treatment period. Any other intervention will not be allowed during this study period.
2508211|NCT02844452|Sham Comparator|Sham Acupuncture|The participants in the sham acupuncture group will visit eight acupuncture sessions over 4 weeks. The acupuncture treatment will be conducted on six control points. The acupressure will be applied with ring-sham press tack needles on three control points. Unlike the acupuncture group 2, partially-individualized manual acupuncture according to the patient's symptoms will not be given but the questions about symptoms will be questioned to patients.
2508212|NCT02844452|No Intervention|Healthy Control|The participants will go through the screening test. The included subjects will complete questionnaires and their blood sample will be obtained.
2508254|NCT02843711||Adenocarcinoma|Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.
2508275|NCT02843386|Experimental|A : Chemotherapy|Adjuvant chemotherapy by Fotemustin 100mg/m²
2508276|NCT02843386|Other|B : Surveillance|Intensive surveillance
2508511|NCT02841982|Experimental|single-injection QLB(quadratus lumborum block)|Single-injection of QLB is given preoperatively + postoperative IPCA(intravenous patient controlled analgesia)
2508512|NCT02841982|Active Comparator|IPCA|postoperative IPCA is given alone
2508540|NCT02841631||Post-Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
2508591|NCT02841358|Other|Psychiatric adults patients presenting psychologic disorders|
2507722|NCT02847351|Experimental|Arabinoxylan Diet (AXD)|Period 1(the first 4 weeks): 9 subjects were randomly assigned to Arabinoxylan-Diet: they replaced for 4 weeks all the carbohydrates consumed in day with crackers baked with an Arabinoxylan-enriched flour. After this period they crossed to period 2 (the second 4 weeks of treatment) without any wash out: they replaced for 4 weeks all the carbohydrates consumed in day with crackers produced with a normal white grain flour
2507755|NCT02847078|Experimental|Smart phone app|The app contains education materials for secondary prevention of coronary artery disease. So patients can access them very easily. The app pushes heath management recommendation information on the timeline after percutaneous coronary intervention, and also provides health care lecture to help patients to improve their secondary prevention. And online or telephone consultation ways are integrated into the App to provide convenience for patients to communicate with health care professionals.
2507757|NCT02847078|Other|Control group|Participants allocated to the control group will receive a booklet with general advice on secondary prevention of coronary artery disease.
2507766|NCT02846948|No Intervention|Non-echo group|Patients get the standard monitoring and treatment based on Good medical practice. Extended monitoring by focused echocardiography is not applied for this group.
2507767|NCT02846948|Experimental|Focussed echocardiography group|The extended cardiac monitoring by focused assessed transthoracic echocardiography is applied.
2507831|NCT02846831|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
2507834|NCT02846831|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
2507887|NCT02846272|Experimental|Observational cohort|Observing MRI changes in subjects.
2507962|NCT02845999|Experimental|Allogenic NK cells transfer|Patients will be treated with a conditioning chemotherapy including 60 mg/kg intravenous cyclophosphamide, 25 mg/m2 intravenous fludarabine for 5 consecutive days and cetuximab. A lymphapheresis from an haploidentical related donor will be performed and T cells will be depleted . Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol (three doses with at least three patients per cohort)to define the dose-limiting toxicity (DLT). T
3196858|NCT00854867|Active Comparator|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|Subjects will receive a total of 38.4 Gy WBRT given over 4 weeks. Subjects will receive 3 Gy (WBRT on Day 1 and Day 2) and then 1.8 Gy on the third fourth and fifth days of WBRT treatment during Week 1. Subjects will then receive 1.8 Gy WBRT per day; 5 days out of seven, each week for the next 3 weeks. A total of 4 doses of DepoCyte (50 mg of liposomal ARA-C) will be administered intrathecally. The first dose will be administered on Day 29 (+2 days); the second dose will be administered on Day 43(+2 days); the third dose will be administered on Day 57 (+2 days); the fourth dose will be administered on Day 71 (+2 days) to complete the induction phase of the protocol. DepoCyte should never be administered more frequently than every 14th day. Subjects will continue to receive an additional 6 doses of DepoCyte one dose every 28 days (+2 days) during the maintenance period. The first dose will be given 28 days after the last dose in the induction phase.
3196859|NCT00854893|Experimental|anodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
3196860|NCT00854893|Experimental|cathodal|anodal stimulation: 20 min during language learning, intensity: 1 mV, cathodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
2508235|NCT02844036|Experimental|Patients with a pulmonary hypertension|Pulmonary hypertension group 4 of Dana point, chronic thromboses lesions, thromboembolic.
2508293|NCT02843425|Experimental|Regular Diet + Beans, Then Regular Diet - Beans|
2508297|NCT02843425|Active Comparator|Regular Diet - Beans, Then Regular Diet + Beans|
2508328|NCT02842983|Experimental|Esmolol|After, at least six hours of hemodynamic optimization, patients with a hyperdynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 10% reduction in heart rate. This infusion is maintained for 72 hours.
2508329|NCT02842983|No Intervention|Control|Patients received conventional management of septic shock
2508408|NCT02842775|Experimental|Dynamic balance exercise group|balance perturbation training
2508409|NCT02842775|No Intervention|Control group|No intervention
2508474|NCT02842333|Experimental|Additional biological samples|"Blood samples will be realized at inclusion and 6 months after inclusion (optional).~Peripheral Blood Mononuclear Cells (PBMC) will be collected."
2508566|NCT02841748|Experimental|Pembrolizumab|200mg, every three weeks, iv, x 1 year
2508569|NCT02841748|Experimental|Placebo|iv, every 3 weeks, x 1 year
2508626|NCT02841124|Other|Qualitative research|Semi-structured interviews
3163723|NCT00486187|Experimental|1|"Treatment-naive subjects randomly assigned to rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking metformin before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day force titrated to 8 mg/day).~Subjects taking glyburide before randomization were randomly assigned to the addition of rosiglitazone (4 mg/day)."
2510133|NCT02830594|Experimental|Treatment (pembrolizumab, RT)|"INITIAL TREATMENT: Patients undergo palliative external beam RT daily. On day 1, patients undergo the first RT fraction and then receive pembrolizumab intravenously (IV) over 30 minutes. Cycles repeat every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.~SECOND PHASE: Patients who achieve a complete response, stop study treatment, and then experience radiographic disease progression may be eligible for the second phase at the discretion of the investigator if no cancer treatment was administered since the last dose of pembrolizumab and trial eligibility safety parameters are met. Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 17 cycles in the absence of disease progression or unacceptable toxicity."
2507765|NCT02847013|Experimental|Intervention-Tap block w Liposomal bupivacaine|After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm
2507837|NCT02846805|No Intervention|complete dentures|complete dentures will be provided for all subjects according to the standardized treatment protocol
2507842|NCT02846805|Experimental|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible ,and continue wearing their complete denture in the maxilla
2507930|NCT02846025|Other|Folate|diet rich in folate
2507932|NCT02846025|Other|placebo|placebo
2507935|NCT02846025|Other|diet antioxidant|diet antioxidant
2507939|NCT02846025|Other|Hazelnut Oil|hazelnut oil capsule
2507969|NCT02845596|Active Comparator|Immunosuppressive Therapy|Patient will receive standard immunosuppressive therapy combination of drugs: horse anti-thymocyte globulin (ATG) and cyclosporine.
2507976|NCT02845596|Active Comparator|Matched Unrelated Stem Cell Transplant|Patient will under go matched unrelated donor transplant of hematopoietic stem cells as their therapy using fludarabine, cyclophosphamide, rabbit anti-thymocyte globulin (ATG), and low-dose total body irradiation (TBI) as preparative regimen and cyclosporine and methotrexate for graft versus host disease (GVHD) prevention.
2508076|NCT02845115|Other|control|standard care : usual technique for implanting
2508078|NCT02845115|Experimental|laser velocimetry|optimized implantation of laser velocimetry
2508152|NCT02844738|Experimental|StroMed + platelet rich plasma (PRP)|Because no enzymes or drugs are added with this mechanical process, the resulting (StroMed) cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to affected joint.
2508201|NCT02844218||Intensive chemotherapy group|Group 1: Patients' age ≥ 70 years treated from 1985 to 1999 with intensive induction chemotherapy.
2508204|NCT02844218||Lower intensity treatment group|Group 2: patients treated from 2000 to 2006 with intensive chemotherapy plus improved supportive care and a follow-up protocol systematically performed at the university hospital.
2508207|NCT02844218||personalized treatment group|"Group 3: patients who had received, starting in 2007, more personalized treatment with either intensive chemotherapy or lower-intensity therapy determined by the clinical judgment of the treating physician."
2508244|NCT02843750|Experimental|Inspiratory Muscle Training-Rehabilitation|Patients will start the IMT-R, following their consent and within 2 weeks of their scheduled surgery: 10 sessions lasting about 90 minutes. Participants who completed their initial IMT greater than 2 weeks prior to surgery will have an additional visit prior to surgery. Participants will receive a Participant Manual demonstrating and explaining the rehabilitation process. Participants will also receive a log for recording their efforts and notes. A DVD of the rehabilitation is available to the participant. Participants will complete questionnaires at baseline and 3 months.
2508284|NCT02843490|Experimental|Ranibizumab treatment of nAMD patients|nAMD patients will be treated with Ranibizumab (0.5 mg injection) 3 times within three months followed by individual therapy interval based on the clinical progress (PRN) up to 7 times. Analysis of specific biomarker.
2508288|NCT02843490|No Intervention|healthy subjects|Analysis of specific biomarker.
3163724|NCT00486187|Active Comparator|2|"Treatment-naive subjects randomly assigned to metformin (250 mg twice per day [BID] titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%).~Subjects taking metformin before randomization were randomly assigned to the addition of glyburide (2.5 mg BID titrated to 5 mg BID if baseline A1C ≥7.5% and ≤8.0%, or 5 mg BID titrated to 10 mg BID if baseline A1C >8.0%).~Subjects taking glyburide before randomization were randomly assigned to the addition of metformin (250 mg BID titrated to 500 mg BID if baseline A1C ≥7.5% and ≤8.0% or 500 mg BID titrated to 1 g BID if baseline A1C >8.0%)."
3163725|NCT00486200|Active Comparator|1|Oral administration of active comparator
3163726|NCT00486200|Placebo Comparator|2|Oral administration of placebo
3163727|NCT00486200|Experimental|3|Dosing regimen 1
2508392|NCT02842905|Active Comparator|Control Group|Fitting Audiologist completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
2508393|NCT02842905|Experimental|Test Group|Participant's physician completion of the Client Outcome Scale of Improvement at a post fitting follow up visit.
3163728|NCT00486200|Experimental|4|Dosing regimen 2
3163729|NCT00486200|Experimental|5|Dosing regimen 3
3163730|NCT00486200|Experimental|6|Dosing regimen 4
3163731|NCT00486213|Active Comparator|Pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
3163732|NCT00486213|Placebo Comparator|Placebo|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
3163733|NCT00486304|Experimental|Antioxidant-deficient diet (ADD)|
3163734|NCT00486304|Placebo Comparator|Placebo|
3163735|NCT00486343|Experimental|1|Zileuton CR
3163736|NCT00486343|Placebo Comparator|2|Placebo
3163737|NCT00486356|Experimental|Capecitabine, Epirubicin, and Carboplatin|
3163738|NCT00486382|Experimental|Low dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3163739|NCT00486382|Experimental|Medium dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3163740|NCT00486382|Experimental|High dose|Biological/Vaccine: Leish-111f + MPL-SE Adjuvant
3163741|NCT00486395|Active Comparator|1|Mechanical ventilation
3163742|NCT00486395|Experimental|2|CPAP
3163743|NCT00486408|Experimental|1|MRKAd5 HIV-1 gag/pol/nef vaccine administered as 1 ml in either deltoid at study entry and Weeks 4 and 26
3163744|NCT00486421|Experimental|PRED & RITUX|
3163745|NCT00486486|Active Comparator|Bimatoprost/Timolol AM therapy|
3163746|NCT00486486|Active Comparator|Bimatoprost/Timolol PM therapy|
3163747|NCT00486512|Experimental|Active Treatment (calcitriol+ASA+CaCO3)|Daily dose of 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol, Rocaltrol; Roche, Basel, Switzerland), 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). The daily dose was administered as 1 capsule containing 0.5 mg calcitriol (Rocaltrol; Roche) and 2 tablets containing a 37.5-mg ASA core with a 625-mg calcium carbonate shell (tablet-in-tablet) that was made expressly for this study. Patients should take 1 capsule and 2 tablets daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
3163748|NCT00486512|Placebo Comparator|Placebo to calcitriol+ASA+CaCO3|Daily dose of matching placebo to 0.5 mg calcitriol, 75 mg acetylsalicylic acid (ASA), and 1250 mg calcium carbonate (CaCO3). Patients should take 1 capsule and 2 tablets of placebo daily, together or separately. Timing of the intake is not important; study medication can be taken with or without food. The daily dose should not be exceeded. Before randomization, patients were given the placebo and followed up for a 3-week run-in period. Only patients who showed a placebo medication compliance rate of at least 80% were eligible for randomization. The primary outcome was the proportion of patients with recurrence of any adenomas as detected by colonoscopy after 3 years of treatment.
3163749|NCT00486538|Experimental|Single arm|One oral dose daily
2507845|NCT02846519|Experimental|Esketamine|Participants in Cohort 1 (Han Chinese participants), Cohort 2 (Korean participants) and Cohort 3 (Japanese participants ) will receive 100-microliter (mcL) spray of 14 percent (%) esketamine solution (14 milligram [mg]) into each nostril at Time 0 and 5 minutes later for a total dose of 56 milligram (mg) in Period 1.
2507848|NCT02846519|Experimental|Esketamine+Rifampin|Participants in Cohort 4 (Caucasian participants) will receive a 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 1 followed by rifampin from Day -6 to Day -1 of treatment Period 2 and followed by 56-mg intranasal esketamine dose regimen on Day 1 in treatment period 2.
2507947|NCT02845921|Placebo Comparator|Group C Control|Patient will be shifted to operation theatre. Electrocardiography (ECG), pulse oximeter and non-invasive blood pressure (NIBP) monitors will be attached. Baseline vitals will be noted. Intravenous access will be secured and crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs will be neither elevated or wrapped. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube.
2507948|NCT02845921|Experimental|Group E Leg elevation|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl 2µg/kg body weight. Lower limbs are elevated and supported on a stand making an angle of 30 degree to the horizontal. Vitals will be recorded again. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol 2mg/kg body weight injected over 30 seconds. Muscle relaxation will be achieved by inj. vecuronium 0.1mg/kg body weight. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Stand will be removed and legs will be brought to horizontal position 10 minutes after intubation.
2507949|NCT02845921|Experimental|Group W Leg wrapping|Patient will be shifted to operation theatre. Crystalloids at 100ml/hr will be given. Analgesia will be given by inj fentanyl. Each lower limb will be elevated alternately and wrapped from toe to mid-thigh with Esmarch bandage. Care will be taken to avoid compressing the legs to greater than arterial pressure by confirming the presence of pulse using a saturation probe. Following wrapping, the lower limbs will be brought to horizontal position. 3 minutes of pre-oxygenation will be done. Anaesthesia will be induced with inj. propofol injected over 30 seconds. Muscle relaxation by inj. vecuronium. Patient will be ventilated with oxygen for 5 minutes. Orotracheal intubation will be performed with appropriate sized endotracheal tube. Esmarch bandage will be removed 10 minutes after intubation.
2508011|NCT02845518|Experimental|no arms|"All patients included will undergo a cardiac Magnetic Resonance Imaging (cMRI) at the baseline visit (V1), at 3- or 6-month follow up visit (V2 or V3), at 24-month follow up visit and in case of clinical worsening during the first 24-month of follow up.~All patients will complete a questionnaire on the acceptability and tolerability of cMRI and right heart catheterization at V1, V2 or V3 and V9, right heart catheterization being performed as a routine test in pulmonary arterial hypertension.~Depending on patient agreement, 22 ml of peripheral venous blood will be taken at visits V1, V2 or V3 and V9. On one of these 3 visits a blood sample of 5 ml will be taken from the pulmonary artery during the right cardiac catheterization."
2508026|NCT02845180|Experimental|3 Mo. Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 3 months.
2508030|NCT02845180|Experimental|6 Month Post AAM Injection|Injection. Adipose Allograft Extracellular Matrix (AAM). Panniculectomy post injection, 6 months.
2508094|NCT02845011|Experimental|Audiovisual compression feedback|Cardiopulmonary resuscitation according to international guidelines with chest compressions performed with real-time audiovisual feedback using the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) device.
2508096|NCT02845011|Active Comparator|Standard chest compression|Cardiopulmonary resuscitation according to international guidelines with standard manual chest compression
2508131|NCT02844621|Experimental|Healthy subjects|
2508178|NCT02844387|Experimental|Arginine|In the Arginine arm patients will receive 10 mg of L-arginine hydrochloride solution oral supplementation (in 200 ml of flavoured drinking water solution) administered twice a day prior to the radiation therapy fraction
2508310|NCT02843165|Experimental|CBI plus SBRT|Checkpoint blockade immunotherapy (CBI) plus stereotactic body radiation therapy (SBRT)
3163750|NCT00486577|Experimental|1|
3163751|NCT00486577|Experimental|2|
3163752|NCT00486629|Experimental|Intervention|Lifestyle intervention
3163753|NCT00486629|No Intervention|Control|No intervention
3163754|NCT00486668|Active Comparator|Group 1: AC then paclitaxel + trastuzumab|AC followed by paclitaxel plus trastuzumab
3163755|NCT00486668|Experimental|Group 2: AC then paclitaxel + lapatinib|AC followed by paclitaxel plus lapatinib
2507853|NCT02846506|Experimental|Treatment Sequence DCAB|Participants will receive Treatment D on Day 1 of treatment period 1, then Treatment C on Day 1 of treatment period 2, then Treatment A on Day 1 of treatment period 3, followed by Treatment B on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
2507933|NCT02846038||Patient|Patients at St. Jude Children's Research Hospital who meet the eligibility criteria and consent to participate.
2507936|NCT02846038||Primary oncologist|Primary pediatric oncologists who meet the eligibility criteria and consent to participate.
2507940|NCT02846038||Parents of patient|Parents of the enrolled patient who meet eligibility criteria and consent to participate.
2508037|NCT02845427|Active Comparator|A(drain group)|patients of primary THA will have closed suction drain introduced intraoperative at surgical site
2508040|NCT02845427|Placebo Comparator|B(No drain group)|patients of primary THA will have the surgical wound be closed with no suction drain
2508168|NCT02844478|Active Comparator|SBP ENGLISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in English
2508170|NCT02844478|Experimental|SBP SPANISH|Caregivers will complete the 9 -week Stress-Busting Program for Family Caregivers in Spanish
2508224|NCT02844062|Experimental|anti-EGFRvIII CAR T cells|Patients will receive lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide, followed by intravenous infusion of autologous anti-EGFRvIII CAR T cells. A standard 3+3 escalation approach will be used to obtain the safe dosage of CAR T cells. The tested CAR T cell dosage ranges from 5×10^4 /kg to 1×10^7 /kg
2508260|NCT02843568|Active Comparator|Standard of Care|"Subjects undergo four-dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning. Subjects undergo laboratory biomarker analysis, including spirometry, diffusion capacity (DLCO), and lung volumes (FEV, FEV1). Subjects complete a self-assessment, RTOG defined acute evaluation toxicity evaluation, RTOG late toxicity evaluation, and constitutional assessment.~Radiation doses between 60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation schemes are utilized. Treatment volumes are at the discretion of the treating radiation oncologist and should follow standard of care."
2508263|NCT02843568|Experimental|Pulmonary Function Damage Reduction|All criteria and specifications in the standard of care arm are applicable for this arm, including the same 4DCT scans, and laboratory biomarker analysis. Subjects randomized to this arm of the trial will have the same prescribed radiation dose to the tumor volume and held to the same radiation dose criteria as the subjects in the standard of care arm (60-66 Gy using standard fractionation (1.8-2.0 Gy/fx) and 40-60 Gy stereotactic body radiation therapy (SBRT) hypofractionation). The fundamental difference will be radiation doses for these subjects will be redistributed away from regions predicted to cause the greatest reduction in pulmonary function if damaged.
2508308|NCT02843217|Experimental|Text Messaging|
2508372|NCT02842931|Active Comparator|R-DA-EPOCH-21|Protocol involves 6 cycles.
2508374|NCT02842931|Active Comparator|R-DA-EPOCH-21 + auto-SCT|Protocol involves 6 cycles. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
2508375|NCT02842931|Active Comparator|R-mNHL-BFM-90|"Course A:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Ifosfamide 800 mg/m2/day 1 h IV 1 - 5 days, Etoposide 100 mg/m2/day IV 4, 5 days, Doxorubicin 25 mg/m2/day IV 1, 2 days, Vincristine 2 mg IV 1 day, Cytarabine 100 mg/m2/day IV 1 h 4, 5 days.~Course B:~Rituximab 375 mg/m2 IV 0 day, Dexamethasone 10 mg/m2/day IV 1 - 5 days, Cyclophosphamide 200 mg/m2/day IV 1 h 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day, Doxorubicin 25 mg/m2/day IV 4, 5 days, Vincristine 2 mg IV 1 day. Protocol involves 6 cycles : A-B-A-B-A-B. One cycle continues 21 days."
2508376|NCT02842931|Active Comparator|R-mNHL-BFM-90 + auto-SCT|Protocol involves 6 cycles R-mNHL-BFM-90: A-B-A-B-A-B. Patients with complete remission undergo auto-SCT after 6 cycles and patients with partial remission after 6 cycles undergo auto-SCT after 2 cycles of R-DHAP
2508426|NCT02842489|Experimental|left lateral tilt-down position|patients will be positioned on left lateral tilt-down position during colonoscopy until sigmoid-descending junction were examined, and then patients will be positioned on the left lateral horizontal position during colonoscopy
2508427|NCT02842489|Active Comparator|left lateral horizontal body position|patients will be positioned on the left lateral horizontal position during colonoscopy insertion
2508529|NCT02841891|Experimental|Test|Test group will receive Sylys® Surgical Sealant as an adjunct to standard closure of stapled anastomosis in colectomy procedure.
2508530|NCT02841891|Active Comparator|Control|Control group will receive standard of care closure of stapled anastomosis in colectomy procedure without Sylys® Surgical Sealant.
2508570|NCT02841462|Experimental|Bursitis|Intra-bursal thermal ablation
2508667|NCT02840617|Experimental|ICG injection group|ICG will be intravenously administered over a 10 second period immediately after the patient was anesthetized. The fluorescence will be performed during and after the surgery, respectively.
3163756|NCT00486668|Experimental|Group 3: AC then paclitaxel + trastuzumab + lapatinib|AC followed by paclitaxel plus trastuzumab plus lapatinib
3163757|NCT00486681||1|period I (warning of the Accu-Check Inform glucose meter on glucose levels not activated)
2508900|NCT02839252|Experimental|Intervention Group|After the baseline tools have been completed, the child will be given the Iggy Comic Book and trading cards. Parents and their children will then watch a 12-minute Iggy Video. At the completion of the video and prior to going home, the child and parent will complete the same 2 measures on asthma knowledge and self-efficacy. At 1-month after this clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
2508994|NCT02838680|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
2509060|NCT02838108||patients with COPD|
3163758|NCT00486681||2|period II (warning activated).
3163759|NCT00486707||Patients with ovarian cancer|
3163760|NCT00486733|No Intervention|Standard of Care|Standard of Care Treatment; no study treatment
3163761|NCT00486733|Experimental|Standard of Care plus Study Treatment|Standard of Care Treatment plus study treatment
2507867|NCT02846402|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2507877|NCT02846402|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2507880|NCT02846402|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
2507956|NCT02845661|Experimental|group 1|patients in group 1, aged 20~60, were accepted an initial dose of 0.9μg/kg dexmedetomidine over 15 min.
2507957|NCT02845661|Experimental|group 2|patients in group 2, aged 20~60, were accepted an initial dose of 1.0μg/kg dexmedetomidine over 15 min.
2507960|NCT02845661|Experimental|group 3|patients in group 3, aged 20~60, were accepted an initial dose of 1.1μg/kg dexmedetomidine over 15 min.
2508018|NCT02845401|Experimental|HBeAg-CHB patients who stop NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that stop treatment.~Intervention: Cases will stop antiviral therapy"
2508020|NCT02845401|No Intervention|HBeAg-CHB patients continue NA Therapy|"Patients with early antigen negative form of disease (HBeAg-CHB) who are already taking standard oral HBV antiviral therapy for at least 192 weeks that continue to stay on treatment.~Intervention: None. Controls will continue antiviral therapy."
2508077|NCT02845076|Active Comparator|Decrease in duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered. When a patient reaches without the presence of any reinstitution criteria, the duration of NIV use as 4 hours per 16 hours during daytime, it will be liberated definitively from NIV.
2508080|NCT02845076|Active Comparator|Decrease in pressure and duration|Weaning will be started with the liberation of patient from NIV during day-time and then nighttime support will be gradually reduced. The level of pressure support will be decreased by 2-4 cmH2O per 4 hours during daytime in patients with good tolerance, with no change at night time. From day 2 the daytime NIV will be gradually decreased in steps of at least 2 hours/day at the attending discretion. At day 2, nighttime discontinuation will be considered, based on the vitals and ABGs recorded at 8 pm (see above), with gradual decrease of at least 2 hrs/night. When a patient reaches without the presence of any reinstitution criteria, the level of PS of 8 cmH20, it will be liberated definitively from NIV.
2508083|NCT02845076|Active Comparator|Abrupt discontinuation of NIV|Patients will be disconnected from NIV and oxygenated with a nasal cannula. Oxygen flow will be limited to a maximum of 5L/min.
2508143|NCT02844647|Experimental|MRI w/ Hyperpolarized Pyruvate (13C)|"Hyperpolarization of low natural abundance species such as 13C, when injected offers the potential of extracting metabolic information by real-time MR imaging of biochemical reactions within the body. The biochemical reactions, including lactate production, will be measured using MRI."
2508205|NCT02844270|Experimental|Galaxy stent|The galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System will be implanted in all subjects.
2508247|NCT02843763|Other|Renal transplant with 1rst cancer|"Renal transplant patients with first cancer (all cancer excepting skin cancer including in group 2).~Intervention : blood sample"
2508249|NCT02843763|Other|Renal transplant patients without cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status.~Intervention : blood sample"
2508250|NCT02843763|No Intervention|Patient with cancer|Patient with cancer from oncology departement matched for cancer type and stade and CMV/EBV status.
2508251|NCT02843763|Other|Renal transplant with first skin cancer|Renal transplant patients with first epidermoid skin cancer. Intervention : blood sample
2508252|NCT02843763|Other|RT with several skin cancer|Renal transplant patients with several epidermoid skin cancer. Intervention : blood sample
2508253|NCT02843763|Other|Rt patients without cancer apparied to RT skin cancer|"Renal transplant patients without cancer matched for age, transplantation duration and CMV/EBV status with renal transplant patients with skin cancer.~Intervention : blood sample"
2508282|NCT02843399||Exenatide once weekly (EQW)|EQW cohort includes patients with one or more outpatient prescription claims for EQW between 2012 and 2015.
2508285|NCT02843399||Insulin Glargine (IG)|IG cohort includes patients with one or more outpatient prescription claims for IG between 2012 and 2015
2508347|NCT02843113|Experimental|4 Your Child Program|Program integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
2508349|NCT02843113|Experimental|4 Your Child + Case Management|Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
2508350|NCT02843113|No Intervention|Waiting list control|Individuals who are randomly assigned to this condition will receive no treatment for a period of months in parallel with the experimental intervention conditions. Data will be gathered from them, and they will be randomly assigned to a treatment condition when possible.
2508396|NCT02842632|Other|A virtual teaching|Group A will be introduced to the virtual TEE online (http://pie.med.utoronto.ca/TEE/)
2508400|NCT02842632|Other|B simulator|Group B will be introduced to the simulator (CAE Vimedix Simulator)
2508403|NCT02842632|Other|C hands on OR|group C will be introduced to the TEE training in the operation room.
2508448|NCT02842281|Active Comparator|Fructan|Fructans will be provided for 72 hours.
2507869|NCT02846480|Experimental|surgical treatment+behavior therapy+physical therapy|Including POP surgical treatment, and pre- post physical therapy to aim the posture, PFM awareness and the strengthening. They will be also informed and instructed on hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
2507873|NCT02846480|Experimental|surgical treatment+behavior therapy|Including POP surgical treatment, and information and instruction about hygienic and behavioral education to prevent POP and urinary incontinence (behavior therapy).
2507912|NCT02846090|Experimental|D50 Dexmedetomidine 50 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
2507914|NCT02846090|Experimental|D25 Dexmedetomidine 25 micrograms group|peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine + 4.5 ml of 2% lidocaine +0.5ml of 25 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
2507919|NCT02846090|Placebo Comparator|control|peribulbar block was given using 10 ml of a mixture of local anesthetics without Dexmedetomidine. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml with 150 IU hyaluronidase.
2507987|NCT02845726||Patients with temporary ureteral stent|Assessment of patients transiently undergoing ureteral stenting.
2508061|NCT02845362|Experimental|Dysphagia assessment|
2508118|NCT02844842||1 day initiation schedule|The initiation Schedule consists in administering 0.2 mL and 0.3 mL with 30 minutes of interval in the same day. Thus, the patient will reach the maintenance dose of 0.5 mL in one day.
2508119|NCT02844842||Rapid initiation schedule|The patient will receive 3 increasing doses (0.1 mL + 0.3mL + 0.5 mL) weekly doses till the maintenance dose (0.5 mL) is reached.
2508158|NCT02844426|Placebo Comparator|Placebo|patients allowed to take maltodextrin by the experienced doctor.
2508160|NCT02844426|Experimental|synbiotic|patients are allowed to take synbiotic (BIFICOPEC) contained 0.63g bifid triple viable capsule (BIFICO) and 8g soluble dietary fiber (Pectin) .
2508172|NCT02844153||6 groups, for each CKD stage (1, 2, 3a, 3b, 4, 5)|All patients with type 2 diabetes seen for the first time by a nephrologist.
2508229|NCT02844010||patients with pneumonia|
2508259|NCT02843607|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508261|NCT02843607|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508303|NCT02843308|Experimental|Immediate Treatment|Facilitated group therapy with behavioral practice; 18 weeks
2508305|NCT02843308|Experimental|Delayed Treatment|Facilitated group therapy with behavioral practice; 18 weeks (after a 18-20 week delay)
2508307|NCT02843308|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment.
2508354|NCT02842957|Experimental|Lifestyle intervention|Behavioral: The Lifestyle arm is the experimental group that will be exposed to an intensive, individualized approach aimed at assisting these CKD patients to adhere to lifestyle changes that are expected to be beneficial to their health and wellbeing. Patients will receive direction to implement a plant based diet, along with more physical activity in their lives. They will be assisted with the optimal use of their prescribed medications by pharmacy professionals and they will receive behavioral counseling by experts in that area.
2508358|NCT02842957|No Intervention|Usual Care|The Usual Care arm will continue to receive the current standard of care involving all the services provided at a contemporary nephrology practice in Western Massachusetts
2508430|NCT02842645||Control|Children born at term and not exposed to drugs during pregnancy
2508431|NCT02842645||Case|Case = Children exposed to drugs during pregnancy
2508458|NCT02842190|Active Comparator|NIPPV|NIPPV after ekstubation
2508460|NCT02842190|No Intervention|BIPAP|BIPAP after ekstubation
2508517|NCT02841969|Active Comparator|Normal care - Prontosan|Patient wounds will be irrigated using the in-use product (Prontosan)
2508520|NCT02841969|Experimental|Investigational arm - Electrolysed water|Patient wounds will be irrigated using electrolysed water
2508536|NCT02841540|Experimental|H3B-8800 (Dose Escalation and Expansion)|H3B-8800 Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes/ Low Risk Myelodysplastic Syndromes/ Chronic Myelomonocytic Leukemia.
2508628|NCT02841137|Experimental|progesterone 5 mg|progesterone 5 mg tablet
2508633|NCT02841137|Experimental|progesterone 10 mg|progesterone 10 mg tablet
2508636|NCT02841137|Experimental|progesterone 20 mg|progesterone 20 mg tablet
2508638|NCT02841137|Active Comparator|progesterone 100 mg|progesterone 100 mg capsule
2508762|NCT02840123|Experimental|Autologous dendritic cells|
2508807|NCT02839837|Experimental|Depressed and non-depressed controls|All participants will participate in three different conditions: Low intensity aerobic exercise and paired associative stimulation, high intensity aerobic exercise and paired associative stimulation, no exercise control and paired associative stimulation. The order of conditions will be randomized.
2508879|NCT02839395|Active Comparator|base line|First night is the base line- no exposure to computer screen illumination.
2508884|NCT02839395|Experimental|Acute|Second night is the acute exposure to computer screen illumination.
2508890|NCT02839395|Experimental|Chronic|Chronic is the effect after five nights of exposure to computer screen light illumination.
3196861|NCT00854893|Experimental|sham (placebo)|sham stimulation (placebo condition): 30 seconds during language learning, intensity: 1 mV, anodal electrode over primary motor cortex of language-dominant hemisphere, reference electrode over contralateral supraorbital area
3196862|NCT00854919|Experimental|CBT|All subjects received cognitive-behavioral therapy (CBT) during the study period.
2509033|NCT02838186|Active Comparator|right colon in retroflexion|"polyp/adenoma detection~feasibility"
3196863|NCT00854919|Experimental|1|Drug; Paroxetine (30-50mg/D)or Fluvoxamine (150-250mg/D), 1-year administration
2507924|NCT02846116|Active Comparator|lithium disilicate|The intervention will be: Prosthetic crown
2507927|NCT02846116|Active Comparator|Vita suprinity|The intervention will be: Prosthetic crown
2507997|NCT02845713|Active Comparator|Single IDA dose W. bancrofti positive|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) W. bancrofti infections positive
2508002|NCT02845713|Active Comparator|Single IDA dose W. bancrofti negative|Single oral dose of Ivermectin, Diethylcarbamazine Albendazole (IDA) in 40 individuals who are free of W. bancrofti infection.
2508028|NCT02845271|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
2508031|NCT02845271|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
2508087|NCT02844894|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine in 20 ml normal saline will be infused in 5 minutes before intubation
2508088|NCT02844894|Experimental|Esmolol|0.5 mg/kg esmolol in 20 ml normal saline will be infused in 5 minutes before intubation
2508090|NCT02844894|Placebo Comparator|Placebo|20 ml normal saline infused in 5 minutes before intubation
2508167|NCT02844634|Experimental|Immediate doxycycline 100mg PO daily|"Individuals will receive tenofovir/emtricitabine one tablet daily in an open-label fashion.~Subjects are randomized to immediate (12 months duration) doxycycline 100mg PO daily."
2508169|NCT02844634|Active Comparator|Deferred doxycycline 100mg PO daily|Individuals will receive daily tenofovir/emtricitabine one tablet daily and will begin doxycycline 100mg PO daily after 6 months for a total duration of 6 months
2508187|NCT02844023|Other|Patient with giant gells arteritis|50 patients with giant gells arteritis
2508190|NCT02844023|Other|Control patients|50 control patients : blood from French national blood service (EFS)
2508238|NCT02843802|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508239|NCT02843802|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508413|NCT02842801|Other|Hip Manipulation|Hip manipulation: high velocity low amplitude thrust mobilization
2508447|NCT02842294||irinotecan based chemotherapy|patients having a 1st line doublet chemotherapy including irinotecan
2508452|NCT02842294||oxaliplatin based chemotherapy|patients having a 1st line doublet chemotherapy including oxaliplatin
2508453|NCT02842294||triplet chemotherapy|patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy
2508556|NCT02841592|Active Comparator|Non-rebreather|This group will have a non-rebreather mask applied to the face and they will receive the flush rate oxygen intervention
2508559|NCT02841592|Active Comparator|Bag-valve-mask|With each inspiration from the subject, the ventilation bag will be gently squeezed to provide positive pressure and augment the amount of oxygen that is received by the subject for each breath. This group will receive the flush rate oxygen with assist intervention.
2508721|NCT02840500||Breakthrough Cancer Pain|No intervention (Non-interventional study)
2508907|NCT02839135|Experimental|Reformulated scopolamine patch|Participants will receive reformulated scopolamine Transdermal Delivery System (TDS) patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
2508909|NCT02839135|Active Comparator|Marketed scopolamine patch|Participants will receive currently marketed scopolamine TDS patch 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area, with delivery of approximately 1.0 mg over 72 hours.
3163762|NCT00486746|Experimental|Lifestyle intervention|
2508996|NCT02838485|Experimental|Amputees|The subjects will receive both mirror and imagery treatments in a cross-over design.
3163763|NCT00486746|Active Comparator|General health counseling|
3163764|NCT00486785|Experimental|1|
3163765|NCT00486876|Placebo Comparator|1|Placebo
3163766|NCT00486876|Experimental|2|100 mg BID
3163767|NCT00486876|Experimental|3|200 mg BID
3163768|NCT00486876|Experimental|4|300 mg BID
3163769|NCT00486915|Active Comparator|Left Atrial Appendage Exclusion|
3163770|NCT00486915|No Intervention|Control|
3163771|NCT00486928||AVR|All consecutive patients in the study period
3163772|NCT00486967||Heart Failure|CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.
3163773|NCT00486967||Controls|A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.
3163774|NCT00486993||asuriesgo|unselected outpatient population
3163775|NCT00487006|Active Comparator|At risk for CIH/with CIH|In hyperglycemic patients who will be starting insulin infusions to control hyperglycemia, blood will be drawn just prior to initiation of insulin infusion for the following levels: insulin, glucose, and C-peptide. These levels will be re-drawn upon achieving euglycemia, at 24 hours following that, then every three days. Levels will be again drawn once the insulin infusion is stopped/when CIH has resolved, and 24 hours following discontinuation of insulin infusion. At each timepoint the patient's clinical status will be documented and significant interval changes (intubation/extubation, change in pressor need), amount of dextrose (mg/kg/hour) supplied, and other concurrent medicines and doses will be recorded.
3196864|NCT00854919|Active Comparator|2|Either risperidone (1-5mg/D), olanzapine (1-5mg/D) or quetiapine (25-100mg/D) was added to ongoing SSRI, the combination trial was continued at least for half a year.
2507959|NCT02845960||Experimental group|rapid recovery
2507964|NCT02845960||Controlled group|no rapid recovery
2508055|NCT02845492|Experimental|Qigong intervention|Qigong meditative exercise intervention meets three times a week for 10 weeks. The qigong group (n=30) will meet at the Women's Medicine Collaborative, Miriam Hospital (146 W. River St., Providence, RI) for Qigong classes. The lesson will be taught by a validated Qi Gong master with over forty years of experience and the interventional protocol will be validated. Two and a half hours of weekly outside personal practice will also be required of participants.
2508058|NCT02845492|Active Comparator|CHIP healthy wellness-exercise class|The Complete Health Improvement Program is a validated set of weekly classes designed to promote gentle exercise and wellness related activities in a supportive group setting led by an experienced trainer.
2508108|NCT02844790|Experimental|IDegAsp|
3196865|NCT00854932|Experimental|PCT group|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PCT values are within the normal range.Antibiotic therapy can be continued despite fulfilled criteria at the discretion of the attending physician. These divesions from the stopping rules will be reported for further analysis.
2508208|NCT02844088|Experimental|vaccinated group|evaluation of immunity's level against meningococcus C among people vaccinated in 2002 in Puy-de-Dôme
2508210|NCT02844088|Other|unvaccinate group|Duration of vaccinal immunity, compare vaccinal immunity to possible natural immunity among unvaccinated people
2508243|NCT02843724|Active Comparator|Control (Conventional) Arm|Treatment of Type 2 Diabetes according to the Canadian Diabetes Association guidelines. Participants' other health concerns to be addressed as per usual care by practitioners at Wise-Elephant Family Health Team.
2508246|NCT02843724|Active Comparator|Integrative (Naturopathic + Conventional) Arm|In addition to conventional care, participants will receive free naturopathic care at Brampton Naturopathic Teaching Clinic (located within the Brampton Civic Hospital). Senior student clinicians will provide care under the direct supervision of licensed naturopathic doctors. A naturopathic menu of treatment options have been designed to reflect naturopathic practice and vetted by 3 licensed naturopathic doctors and experts in the field. Participants' other health concerns will be addressed as per naturopathic doctors' discretion.
2508281|NCT02843451|Experimental|Silymarin (Milk Thistle)|Each subject will have a 4 week treatment phase with milk thistle.
2508286|NCT02843451|Placebo Comparator|Placebo|4 week placebo phase before or after milk thistle phase depending on randomization.
2508340|NCT02843022|Active Comparator|Usual care|Participant will receive the usual care provided by the nursing staff at Catholic Medical Center. A lactation consultant or childbirth educator attempts to call each patient within 2-3 weeks prior to discharge. Only one call is made, and a message left if the patient would like to call back.
2508341|NCT02843022|Experimental|Message Only|Participant will receive the usual care, and in addition, will receive four standardized electronic messages weekly for six months postpartum. These will be one-way messages without the option to respond.
2508342|NCT02843022|Experimental|Message and Nurse|"Participant will receive the usual care as well as the four standardized electronic messages/week for 6 months. Two of these weekly messages will be two-way, providing the option for the participant to respond yes to an offer to have a nurse call them. A nurse phone call if requested will be provided with a week."
2508410|NCT02842658|Active Comparator|A high-intensity interval exercise group|Supervised exercise training with be carried out at the Mayo Clinic Cardiac rehabilitation center on cycle ergometers using EKG telemetry. Treatment will begin one week prior to chemotherapy and is tailored around 8 weeks.
2508411|NCT02842658|Other|An attention-control group|Patients will receive counseling regarding physical activity during chemotherapy. Patients will receive a weekly phone call to maintain physical activity during chemotherapy and compliance will be verified using physical activity diaries and pedometers.
2508496|NCT02842268|Experimental|BAY987517|Subject will self-apply the test sunscreen formula to his/her face with the goal of applying 0.65 to 0.85 grams.Subject should sweat profusely.
2508571|NCT02841800|Experimental|Intra-luminal radiofrequency ablation|Intra-luminal radiofrequency ablation Admission for endoscopic retrograde cholangiopancreatography (ERCP) and stent placement after radiofrequency ablation. ERCP should be performed for 2 times with an interval of two months.
2508620|NCT02841202|Active Comparator|oral contraceptive pills group|healthy women using oral contraceptive pills for only contraception for more than one year was called OCP group
2508622|NCT02841202|No Intervention|control group|The second group was called control group consisting 20 healthy women and using no drug
2508681|NCT02840760|Active Comparator|tardive dyskinesia group|tardive dyskinesia group will be delivered at an intensity that is 80% of the resting motor threshold (RMT). Stimulation will be delivered at 10 Hz with 60 stimulation trains of 30 stimuli each (i.e., 1800 stimuli) and an intertrain interval of 12 sec in primary motor cortex（M1）.
2508684|NCT02840760|No Intervention|Healthy control group|
2508752|NCT02840318|Experimental|Compassion Intervention|Coordinated by the ICL who co-ordinates key activities at each site to address the two core components of the Intervention. Component 1 activities include: (a) person-centred assessment of residents, focussing on their physical, psychological, emotional and social needs, (b) meetings of the core care team (General practitioner, care home nurse and/or manager and ICL) and (c) meetings of the wider multidisciplinary care teams (including care home staff, ICL, and external healthcare professionals such as geriatrician, palliative care, mental health etc). Activities to facilitate component 2 include: (d) staff training sessions, education and support for staff and family carers. Training sessions are run by the ICL and logistics of training is planned at core meetings.
2508864|NCT02839226|Active Comparator|AR/101|AR/101 will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 28 days, or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
2508899|NCT02839187|Experimental|Patients with Alzheimer Disease|Patients will have Neuroimaging by Florbetapir (AV-45)-positron emission tomography
2509036|NCT02838186|Active Comparator|right colon in forward view|polyp/adenoma detection
2507917|NCT02846246|Experimental|Intervention|The experimental group will be introduced to a person-centred care model that involves shared decision making where the person with home care service and family together with contact nurse prioritise care content and make rearrangements to make sure the provided home care service maximises health.
2507920|NCT02846246|Sham Comparator|Control|A usual care paradigm will guide the control units, i.e. a continuation with practice as usual.
2507998|NCT02845765||Patients with erectile dysfunction|Patients with erectile dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual activity. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline and 6 months after therapy with Phosphodiesterase type 5 Inhibitor (PDE5I).
2508003|NCT02845765||Subject healthy volunteers|Patients without erectile dysfunction or ocular disease. Patients will be examined with Dynamic Vessel Analyzer (DVA) at baseline
2508016|NCT02845245|Active Comparator|Standard of Care|Standard of care imaging techniques (3D CT scan and plain film radiographs) will be obtained for the surgeon to pre-operatively plan the surgery.
2508017|NCT02845245|Experimental|Intervention|A 3D printed plastic model prototype will be developed for the surgeon to use, in addition to the standard of care imaging techniques (3D CT scan and plain film radiographs), to pre-operatively plan the surgery.
2508053|NCT02845063|Experimental|concentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2508057|NCT02845063|Experimental|eccentric cardiovascular rehabilitation|Heart patients under ACE inhibitor intake will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2508060|NCT02845063|Active Comparator|concentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'concentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2508063|NCT02845063|Active Comparator|eccentric cardiovascular training|Healthy subjects will be enrolled in the intervention 'eccentric cardiovascular training' and evaluated by the intervention 'ACE genotyping'
2508125|NCT02844660|Experimental|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
2508126|NCT02844660|Active Comparator|Standard of Care|Weekly application of moist wound therapy and offloading
2508233|NCT02844296|Experimental|exercise group|"A free handgrip (strength 15 kg) will be given to the subject and some short-bout exercise will be introduced to the subjects for reliving the cravings for smoking through a short video. After the video, the counselor will install a smartphone application which is about exercise in the subject's mobile phone to set up exercise reminder schedule for 4 weeks. 20-30 reminders on exercise and quitting tips via the App for 4 weeks. Subjects will be requested o record a daily diary on smoking.~A leaflet with exercise instruction and motivation messages based on the Health Action Process Approach (HAPA) will be given to the participant. 2-month, 6 -month and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
2508234|NCT02844296|Experimental|diet group|"Subjects will view a short video on healthy diet only. After the video, the counselor will also install another smartphone application which is about healthy diet in the subject's mobile phone to set up healthy die reminder schedule for 4 weeks.~A leaflet on healthy diet will be given to the subjects, and 20-30 reminders on healthy diet and quitting tips via the App for 4 weeks.2-,6- and 12-month telephone interview will be conducted. Biochemical validation will be conducted at 6-month follow up. And hand grip strength will be measured the next time when the participant comes back to CISI."
2508279|NCT02843464|Experimental|long-term RIPC group|routine treatment + once RIPC/day for a year. Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
2508283|NCT02843464|No Intervention|control group|routine treatment.
2508337|NCT02843126|Experimental|Trastuzumab and NK immunotherapy|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508339|NCT02843126|Active Comparator|Trastuzumab|In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508384|NCT02842723|Experimental|Protontherapy|
2508428|NCT02842502|Experimental|Skin graft pellet|This group concerns patients who are recruited for skin graft procedure leading to the collection of supernumerary biopsies.
2508542|NCT02841904|Other|CLE|CLE assessed by the pathologist
2508543|NCT02841904|Active Comparator|Biopsy|Histology assessed by the pathologist
2508597|NCT02841332|Experimental|Patients with glioblastoma|"Patient with histologically proved glioblastoma diagnostic will receive the following interventions :~Cerebral magnetic resonance imagery~Tomography emission positron with F-MISO~Bevacizumab administration~Clinical examination"
2508619|NCT02840955|Active Comparator|Staphefekt SA.100|Staphefekt SA.100 cream, twice daily on (lesional) skin during 12 weeks
2508623|NCT02840955|Placebo Comparator|Placebo|Placebo (Gladskin cream without the Staphefekt protein), twice daily on (lesional) skin during 12 weeks
2508694|NCT02840695||AS patients|Patients registered in the Swedish Patient Registry with active AS treated with or without biological DMARD according to the Swedish Prescribed Drugs Registry, with or without spinal fractures
2508722|NCT02840214|Active Comparator|tDCS rescue group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp half-way through the 3-hour fatigue task.
2508726|NCT02840214|Placebo Comparator|Sham Treatment Group|Subjects assigned to this arm will initially receive current of the same intensity for a period of 30 seconds and then gradually turned off.
2508730|NCT02840214|Active Comparator|tDCS prevent group|Subjects assigned to this arm will receive transcranial direct current stimulation (tDCS) that delivers a constant, small current (2 milliAmp) across specific regions of the brain through electrodes placed on the scalp at the beginning of the task.
2508903|NCT02839187|Active Comparator|Controls patients|Controls will have neuroimaging by AV45-positron emission tomography
2507984|NCT02845791|No Intervention|Control|The control participants will not receive the educational intervention but will be provided with a detailed advice leaflet for themselves and their parents/guardians.
2507989|NCT02845791|Other|Intervention|The educational intervention participants will receive the eight 90 minute sessions of an interactive family based lifestyle programme.
3196866|NCT00854932|No Intervention|Standard group|The duration of antibiotic treatment in the standard group is based on the attending physician's assessment of the risk of classification: infection unlikely for 36-72 hours, infection possible for 5-7 days, infection probable of proven for 7-21 days depending on clinical course, laboratory values and positive cultures.
3196867|NCT00854945|Experimental|ON 01910.Na|1800 mg/day of ON 01910.Na administered as a 24-hour continuous intravenous infusion on days 1, 2 and 3 of 14-day cycle.
2508122|NCT02844881|Experimental|Apatinib+MASCT|Apatinib+Multiple Antigens Specific Cellular Therapy(MASCT) in patients with advanced solid tumors,excluding T cell lymphoma
2508157|NCT02844413|Experimental|study group|implementation of aerobic interval training
2508159|NCT02844413|No Intervention|control group|control group
2508198|NCT02844179|Experimental|dose escalation|Single dose administration of (+)-alpha-Dihydrotetrabenazine (HTBZ), escalating dosage amounts 7.5 - 30 mg orally
2508220|NCT02843841|Other|ATG group|"Renal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of polyclonal antilymphocyte globulin (ATG-Fresenius®) as recommended.~Intervention = blood and fecal sample"
2508223|NCT02843841|Other|Anti-CD25 group|"PRenal transplant Patients from Nephrology department of the University Hospital of Besancon receiving induction immunosuppressive therapy of anti-CD25 monoclonal antibodies (basiliximab SIMULECT®) as recommended.~Intervention = blood and fecal sample"
2508273|NCT02843646|Experimental|Walk Aide training|This group of children will receive six weeks of Walk Aide training. During training, children will wear the Walk Aide. This device triggers ankle dorsiflexion, and controls the timing and duration of personal nerve stimulation during the swing phase of gait. The duration of the stimulus is gradually increased along with the wearing of the Walkaide. Subjects will begin by wearing the prosthesis for 30 minutes. The wearing time will be increased to waking hours of the subject, depending on their age. The electrodes will be placed on the client before the session is to begin, and taken off immediately after WalkAide usage. The skin will be checked before and after WalkAide electrode usage. The skin will be cleaned with an alcohol wipe before the electrodes are applied.
2508274|NCT02843646|Placebo Comparator|Delayed Walk Aide training|This group of children will not receive Walk Aide training during the first six weeks of enrollment. This group will serve as a comparator group to Arm 1. After six weeks, children in this group will be given the option to complete the 6-week Walk Aide training protocol that is given in Arm 1.
3196868|NCT00854971|No Intervention|control|Oxaliplatin infusion (85mg/m2) on days 1 and 15 (every 2 weeks) 5-FU bolus + infusions (400 mg/m2) on days 1, 2, 15 and 16 LV infusions (200 mg/m2) on days 1, 2, 15 and 16
3196869|NCT00854971|Active Comparator|Active|FOLFOX-4 regimen + Infusion of TKCell(autologous activated lymphocyte) over 2x10^9 cells, IV route, 7 times
3196870|NCT00854984|Experimental|Self-help CBT|A nurse supported self-help CBT intervention in addition to usual care.
3196871|NCT00854984|No Intervention|Usual care|
2508462|NCT02842437|Experimental|Dexmedetomidine|25 patients receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
2508463|NCT02842437|Placebo Comparator|Placebo|25 patients receive matching placebo （normal saline）
2508555|NCT02841566||Problem glambers|The group of problem gamblers will consist of patients already included in the cohort EVALADD [favorable opinion of GNEDS 06/09/2012; CNIL authorization No. 912631 of 10.09.2013], and the data will be extracted directly from the database EVALADD
2508562|NCT02841566||Non-problem gamblers|The subjects of this group will be matched on sex, age and education level with the group problem gamblers. They will be recruited over the Internet and using the volunteer base [normal declaration with the CNIL: No. 1761543 of 21/05/2014].
2508593|NCT02841280|Experimental|Chlorthalidone|Subjects with stage 4 chronic kidney disease (CKD) and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home blood pressure (BP) results.
2508594|NCT02841280|Placebo Comparator|Placebo|Subjects with stage 4 CKD and poorly controlled hypertension confirmed by 24 hour ambulatory blood pressure monitoring will be randomized into two groups, one receiving placebo and one receiving a diuretic called chlorthalidone (12.5 mg at randomization). Doubling of the dose of the diuretic (up to 50 mg) or placebo will occur every 4 weeks if required by home BP results.
2508610|NCT02840994|Experimental|CV301 + Pembrolizumab|CV301 + Pembrolizumab (Phase 1b portion of the trial)
2508614|NCT02840994|Experimental|CV301 + Nivolumab|CV301 + Nivolumab (Phase 1b portion of the trial)
2508710|NCT02840591|Experimental|Drug Treatment|"First 5 consecutive subjects: Ramelteon 8 mg daily at 8 pm for 5 days~Next 5 consecutive subjects: Citicoline 250 mg daily at 8 pm for 2 days, followed by citicoline 500 mg daily at 8 pm for 3 days~All subjects: Standard medical care"
2508712|NCT02840591|No Intervention|Observation-Only|Standard medical care
2508766|NCT02840110||Post-ACTR|Subjects who have previously been treated with an ACTR T cell product
2508853|NCT02839473|Experimental|Hydrosorb® arm|Hydrogel Hydrosorb®
2508854|NCT02839473|Placebo Comparator|Placebo arm|Castalie water spray
3196872|NCT00854997||1|AMI with OSA
3196873|NCT00854997||2|AMI without OSA
2508009|NCT02845635||Control|This who document during the on-boarding process that they do not suffer from multiple sclerosis.
2508074|NCT02845219|Experimental|Oral contraceptive/SNAC/Oral Trial drug|
2508139|NCT02844699|Experimental|Mobilan (M-VM3) on both Day 1 and on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Investigational Drug Product (Mobilan (M-VM3)) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2508140|NCT02844699|Experimental|Placebo on Day 1 and Mobilan (M-VM3) on Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) first on Day 1 and Investigational Drug Product (Mobilan (M-VM3)) in two weeks on Day 15. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2508144|NCT02844699|Placebo Comparator|Placebo on both Day 1 and Day 15|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 3) treated with Placebo (Glucose 5%) administered 2 weeks apart. All subjects will subsequently undergo planned prostatectomy, ideally within 2 weeks following the final study drug injection and will remain under observation thereafter.
2508241|NCT02843919|Other|Healthy volunteers|Adults healthy volunteers
2508304|NCT02843542|Other|Control Group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT)
2508306|NCT02843542|Other|Study group|primary hyperthyroidism patients that will be refered to the routine exams (PET-CT) and in addition will also undergo the PET-MR
2508336|NCT02842944|Experimental|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
2508338|NCT02842944|Active Comparator|Routine care|"Connect and start Beacon with advice disabled~Standardized routine care"
2508398|NCT02842762|Sham Comparator|Non-paced|"cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (off)"
2508402|NCT02842762|Experimental|Paced|"The patient is randomized to the order of measurements taken, and serves as his own control.~cardiac surgery~3D TEE measurements of systolic dyssynchrony~right ventricular epicardial pacemaker lead (on)"
2508464|NCT02842255|Experimental|Healthy volunteers|
2508513|NCT02841956|Experimental|Electronic Screen + Education (Phase 1)|Electronic screening of participants and targeted education of providers according to standard EDAPT model.
2508514|NCT02841956|Active Comparator|Targeted Provider Education (Phase 1)|Targeted education of providers according to standard EDAPT model.
2508515|NCT02841956|Experimental|Community Mobile Engagement (Phase 2)|Clinical intake interviews take place via videoconference at a location in the community convenient for the participant.
2508516|NCT02841956|Active Comparator|Clinic based Engagement (Phase 2)|Clinical intake interviews take place at the EDAPT clinic.
2508546|NCT02841605|Other|AD group|AD group: rectosigmoidospcopy with biopsies of colon
2508547|NCT02841605|Other|PD group|PD group: rectosigmoidospcopy with biopsies of colon
2508549|NCT02841605|Other|PSP group|PSP group: rectosigmoidospcopy with biopsies of colon
2508550|NCT02841605|Other|Patient eligible for colorectal cancer screening|Patient eligible for colorectal cancer screening: colonoscopy with biopsies of colon
2508605|NCT02841319|Experimental|Intervention|Virtual reality exercises using Hand Tutor for 8 weeks
2508606|NCT02841319|No Intervention|Control|Home exercises for 8 weeks
2508689|NCT02840812|Experimental|Renal function impaired|Subject with Severe Impaired Renal Function. Nemonoxacin Malate Capsules 500mg single dose oral
2508692|NCT02840812|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
2508715|NCT02840240|Experimental|Gabapentin enacarbil|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive Gabapentin enacarbil for 5 days
2508716|NCT02840240|Placebo Comparator|Placebo|Patients going through elective hip or knee replacement surgery with spinal anesthesia will receive placebo for 5 days
2508781|NCT02840084|Experimental|Treatment Patients|In stage I, 10 women aged 22 years or older who have received silicone or saline breast implants for subglandular or submuscular breast augmentation, and who subsequently developed Baker Grade III capsular contracture, will be invited to participate. In Stage II, the study group will be expanded to include an additional 50 patients who have received saline or silicone gel implants, placed in either the subglandular or submuscular position, with Grade III capsular contracture of the breast. The intervention will be treatment with the Aspen(TM) Ultrasound System.
2508844|NCT02839590||HiFu (ultrasound)|Manufacturer Name Eyehope Principle intended use Surgical treatment of uncontrolled glaucoma and OHT The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study.
2508845|NCT02839590||Baerveldt implant|"Manufacturer Name Abbott Medical Optics Inc., Abbott Laboratories Inc., Abbott Park, Illinois, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2508846|NCT02839590||Ahmed Implant|"Manufacturer Name New World Medical, Inc., 10763 Edison Court, Rancho Cucamonga, CA 91730, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2508848|NCT02839590||STARflo|"Manufacturer Name iSTAR Medical SA, Parc Créalys, Rue Phocas Lejeune, Bâtiment Regain 25/3, 5032 Isnes, Belgium.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2508947|NCT02838914|Experimental|patients with AF|Before radiofrequency ablation (RFCA)
2508957|NCT02838914|Experimental|Assigned Comparisons|After radiofrequency ablation (RFCA)
2508107|NCT02844855|Sham Comparator|healthy controls|Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
2508132|NCT02844556|Other|SMILE surgery|Small incision lenticule extraction (SMILE) has become a novel and effective method for the correction of myopia and myopic astigmatism. It is a micro-invasive and flapless refractive procedure that has been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
2508136|NCT02844556|Other|FS-LASIK surgery|FS-LASIK surgery is femtosecond laser assisted- conventional refractive surgery and has also been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
2508195|NCT02844335|Experimental|Cryosurgery and NK immunotherapy|In this group, the patients will receive comprehensive cryosurgery first to destroy all big tumors, then receive multiple NK immunotherapy (intensive treatment: 6 times in first 3 months; then interval treatment: once every 3 months). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508196|NCT02844335|Active Comparator|Cryosurgery|In this group, the patients will receive comprehensive cryosurgery to destroy all big tumors. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets, circulating tumor cell).
2508292|NCT02843503|Experimental|Arterialized-venous reference YSI|CGM monitoring performance per arterialized venous reference measurement (YSI)
2508296|NCT02843503|Experimental|Venous reference samples YSI|CGM monitoring performance per venous reference measurement (YSI)
2508330|NCT02843035|Experimental|Open label (OL) venglustat|Administered once a day orally for 260 weeks. Patients will continue their usual dose of Cerezyme throughout study.
2508378|NCT02842697|Experimental|Single arm study|"Patients will receive CTA, Doppler ultrasound, HVPG measurement, and vHVPG per protocol.~Intervention: Procedure: HVPG measurement"
2508443|NCT02842476||Disposable Sensor|Adhesive based Pulse Oximeter Probes, Model S0136J
2508445|NCT02842476||Reusable Sensor|Reusable Pulse Oximeter Probes, Model S0080D
2508449|NCT02842476||Control Pulse Oximetry|Reference CO-Oximeters ABL80 Flex OSM (Radiometer), # 302125, 307205 IL682 (Instrumentation Laboratories), # 012511B (ILH), #012511A (ILG)
2508480|NCT02842099|Experimental|TA or TAC plus X|Standard chemotherapy (TA or TAC) followed by capecitabine 2.5g, po, qd for one year.
2508486|NCT02842099|Active Comparator|TA or TAC|Standard chemotherapy (TA or TAC) followed by no more chemotherapy
2508554|NCT02841774|Active Comparator|Moderate Intensity Group|pravastatin 40mg daily for 12 weeks
2508560|NCT02841774|Experimental|High Intensity Group|rosuvastatin 20 - 40 mg daily for 12 weeks
2508608|NCT02841163||Lumbar/cervical disc herniation group|Lumbar and cervical intervertebral disc herniation patients are administered integrative Korean medicine treatment consisting of herbal medicine, acupuncture, pharmacopuncture, bee venom pharmacopuncture, and Chuna manipulation.
2508662|NCT02840656||healthy adult subject|oropharyngeal and rectal swabbing to collect Gram-negative bacilli
2508787|NCT02840019|Experimental|60 minute research full MRI scan|"Pregnant women who are able to have an MRI are eligible for the 60 minute research full MRI scan. Pregnant women may have a healthy pregnancy, a concern for fetal/placental abnormalities with a clinical fetal MRI ordered by their doctor, or a concern for fetal/placental abnormalities without a clinical fetal MRI ordered by their doctor.~The investigational MRI coil designed for pregnant women and research MRI sequences will be tested during the 60 minute research scan."
2508791|NCT02840019|Experimental|15 minute research add-on MRI scan|"Pregnant women with a concern for fetal/placental abnormalities with a clinical fetal MRI at Boston Children's Hospital are eligible for the 15 minute research add-on MRI scan.~The research MRI sequences will also be tested during the add-on research MRI scan."
2508842|NCT02839460||subjects with sarcopenia|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
2508843|NCT02839460||healthy, physically-active controls|"Screening Procedures (Physical Exam, Height & Weight, Vitals, Medical History, CHAMPS, DXA Scan, Physical Performance Testing, Muscle Strength Testing, Blood Collection)~Day 1 (target +/- 2 days) Outpatient Muscle Biopsy (Vitals, Blood Collection, Muscle Biopsy, update Concomitant Therapy and Procedure-Related AEs/SAEs)~Day 14 (target +/- 2 days) Safety Follow-up Visit (Vitals, Blood Collection, update Concomitant Therapy and Procedure-Related AEs/SAEs)"
3196874|NCT00855023||Asymptomatic Volunteers|healthy volunteer athletes and excluded those who had any of the following criteria: 1) counter-indications to magnetic resonance imaging (e.g., pregnancy or postsurgical hardware [plates, screws, aneurysm clip, implanted cardiac pacemaker, etc.]); (2) relevant medical problems (e.g., connective tissue problems, paralyzed hemidiaphragm, morbid obesity, claustrophobia, etc.); (3) clinical signs of an impairment or abnormality in the knee (e.g., abnormal range of motion, muscle weakness, or malalignment); (4) injury to the knee that required medical attention; (5) previous surgery on the knee; or (6) current pain in the knee.
3196875|NCT00855036||Renal Injury|All patients who have a discernable injury to the renal parenchyma on CT scan from blunt trauma
3196876|NCT00855049|Experimental|1|Intranasal acetaminophen administration
3196877|NCT00855049|Active Comparator|2|Oral acetaminophen administration
2509040|NCT02838212||Drug-related deaths|fatal adverse drug reactions
2509041|NCT02838212||non drug-related deaths|deaths for other causes different as drugs
2509048|NCT02837848|Experimental|Coactivation strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
2509164|NCT02837172||Parkinson's disease from UAB|MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, Diffusion Weighted Imaging (DWI), and neurological examination.
2508161|NCT02844530|Experimental|RIT|The experimental treatment will consist on 2 injections of 370 MBq/m2 of 90Y-epratuzumab tetraxetan fractionated RIT at day 1 and day 8. The first infusion of 90Y-epratuzumab tetraxetan will be co-injected for the six first patients in Nantes with 111In-epratuzumab tetraxetan for dosimetry purpose.
2508162|NCT02844530|Active Comparator|chemotherapy/ immunotherapy|"chemotherapy/ immunotherapy regimen will be assigned per investigator's choice to one of the following chemotherapy/ immunotherapy regimens:~FLAG +- anthracycline based regimen For subject's >60 years : idarubicin 5 mg/m2 day 1,3, fludarabine 20 mg/m2 days 1-5, cytarabine 1 g/m2 days 1-5.~Clofarabine or clofarabine based regimens. Clofarabine use as a single agent should follow the recommended prescribing information. Clofarabine combination based regimens should use >=20mg/m2/day for up to 5 days.~Hyper-C-VAd regimen: hyperfractionated cyclophosphamide 300 mg/m2 intravenously(i.v.) every 12 hours for 6 doses Days 1 to 3 + vincristine 2 mg i.v.Days 4 and 11; doxorubicin 50 mg/m2 i.v. over 24 hours via central venous catheter Day 4; and dexa-methasone 40 mg daily Days 1 to 4 and 11 to 14.~Blinatumomab (Blincyto®) : 28-day continuous infusion (9µg/d for days 1-7; 28µg/d thereafter, followed by 2 weeks of rest for up to 2 cycles."
2508171|NCT02844140|Experimental|Scans|Patients included in the trial will receive DE-CT in stead of SE-CT's.
2508189|NCT02844075|Experimental|pembrolizumab|
2508228|NCT02843906|Active Comparator|BD/CD +|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2508230|NCT02843906|Active Comparator|BD/CD -|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2508232|NCT02843906|Active Comparator|a-MCI|Lombar punction, RMI, TEP/FDG, ApoE detection, psychiatric tests, neuropsychological tests
2508280|NCT02843334||Population of adult patients undergoing chronic renal dialysis|Population of adult patients undergoing chronic renal dialysis for end stage kidney disease in 5 French areas (Rhône-Alpes-Auvergne, Ile de France, Aquitaine, Picardie and department of Gard)
2508316|NCT02843048|Experimental|Exercise training|Exercise training plus standard medical follow-up care
2508319|NCT02843048|Active Comparator|Standard medical care|Standard medical follow-up care only
2508625|NCT02841098|Experimental|Carotid endarterectomy combined with optimal medical therapy|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)
2508630|NCT02841098|Active Comparator|Optimal medical therapy (OMT)|Optimal medical therapy (OMT)
3163776|NCT00487006|Active Comparator|At risk for CIH/without CIH|"For comparative controls, insulin, C-peptide, and glucose levels will be drawn from ICU patients aged 2-12 years at similar risk (mechanical ventilation or vasoactive medications) but without CIH. The above labs will be drawn and data gathered near the time of risk, 24 hours later, then in 3 days following, for a total of three timepoints."
2508934|NCT02838862||Response to Therapy|
2508937|NCT02838862||No therapy response|
2509121|NCT02837575|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 4 doses
2509125|NCT02837575|Placebo Comparator|Phosphate-buffered saline, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 4 doses
2509154|NCT02837055|Experimental|VivaSight intubation|Patients are intubated with the VivaSight-SL endotracheal tube
2509160|NCT02837055|Active Comparator|conventional intubation|Patients are intubated with a conventional endotracheal tube
2509234|NCT02836912|No Intervention|Regular education|Regular education for COPD, including percussion and posture drainage.
2509237|NCT02836912|Experimental|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group.
2509320|NCT02836431|Experimental|DEX 1 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2510438|NCT02828228|Placebo Comparator|Placebo|Placebo once a day for 26 weeks
3163777|NCT00487006|Active Comparator|Not at risk for CIH/without CIH|"In addition, other ICU patients aged 2-12 years that are deemed NOT at risk for critical illness hyperglycemia will also be evaluated to serve as a group not at risk but admitted to the PICU as a further control population. Like Group B, the above labs will be drawn and data gathered at the time consent is obtained, 24 hours later, then in 3 days following, for a total of three timepoints"
3163778|NCT00487019||1|Neonates aged <72 h and needing antibacterial therapy for early onset neonatal sepsis
3163779|NCT00487019||2|Same as group 1
3163780|NCT00487032|Experimental|1|Prazosin 1mg challenge to block alpha 1 adrenoreceptors
3163781|NCT00487032|Placebo Comparator|2|Placebo to Prazosin
3163782|NCT00487045|Experimental|1|Hem-Avert Perianal Stabilizer, single use, disposable, sterile, individually packaged instrument
3163783|NCT00487045|No Intervention|2|
3163784|NCT00487071|Experimental|Anal fistula plug|
3163785|NCT00487097|Experimental|Study Group|Enteral Nutrition with Omega 3 (Eicosapentanoic acid, docosahexaenoic acid)
3163786|NCT00487097|No Intervention|Control Group|Patients in control group will receive nutritional support composed of a standard formula
3163787|NCT00487136|Active Comparator|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
3163788|NCT00487136|Experimental|Warfarin plus ABT-335 plus Rosuvastatin|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
3163789|NCT00487136|Experimental|Warfarin plus ABT-335 mg plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
3163790|NCT00487227|Placebo Comparator|Placebo|
3163791|NCT00487227|Experimental|2.5mg caffeine|
3163792|NCT00487227|Experimental|5mg caffeine|
3163793|NCT00487227|Experimental|10mg caffeine|
3163794|NCT00487253|Active Comparator|Group 1|"Oral administration of Miltefosine, doses: 1,5mg to 2,5mg/kg/day, during 28 days.~presentation: capsulas 10mg and 50mg Miltefosine (Impavido®)"
2508174|NCT02844504|Experimental|Low Intensity Exercise Training 2|Cancer survivors will receive low intensity handgrip exercise training different than other arm.
2508176|NCT02844504|No Intervention|Control|This group will receive no training.
2508231|NCT02843997|Other|Healthy volunteers|Members of a family
2508290|NCT02843581|Experimental|Cryosurgery and NK immunotherapy|We use comprehensive cryosurgery to destroy big tumors, and use multiple (more than 6 times) NK immunotherapy to destroy small tumors
2508294|NCT02843581|Active Comparator|Cryosurgery|We use comprehensive cryosurgery to destroy big tumors
2508332|NCT02843009|Placebo Comparator|Safflower Oil plus Resistance Exercise Training|3.0g of safflower oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
2508334|NCT02843009|Active Comparator|Fish Oil plus Resistance Exercise Training|3.0g of fish oil taken daily alongside twice weekly resistance exercise training sessions for 18 weeks
2508381|NCT02842749|Experimental|everolimus (single arm)|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
2508434|NCT02842515||Patients requiring dental avulsion|Patients requiring dental avulsion
3196878|NCT00855075||Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
3196879|NCT00855088|Experimental|Darunavir, ritonavir, etravirine|Single arm trial looking at the pharmacokinetics of darunavir, ritonavir, etravirine in healthy volunteers.
3196880|NCT00855101|Experimental|voriconazole|
3196881|NCT00855114|Experimental|Patients Treated with Everolimus|Breast cancer patients treated with Everolimus by mouth, 5 mgs/day x 7 days, followed by surgery.
2508611|NCT02840942|No Intervention|Non-robot|Patients will interact with Child Life as per usual routine, no robot condition
2508615|NCT02840942|Experimental|Coping Robot|Robot will play coping game with children. Robot will speak and child will respond by touching tablet. Child life still present.
2508617|NCT02840942|Experimental|Non-coping Robot|Robot will play distraction only game, in addition to Child Life and routine cares
2508688|NCT02840786|Active Comparator|Intervention: Stents|Stents group
2508691|NCT02840786|Active Comparator|Intervention: Atherectomy|directional atherectomy group
2508770|NCT02839993|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2508771|NCT02839993|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
2508811|NCT02839668|Experimental|Sevoflurane|The patients enrolled in this arm will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
2508813|NCT02839668|Active Comparator|Sevoflurane+Lidocaine|The patients enrolled in this group will receive general anesthesia in which the hypnosis will be maintained with Sevoflurane. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia
2508816|NCT02839668|Experimental|TIVA-TCI|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine. The bispectral index- BIS will be monitored throughout the anesthesia.
2508817|NCT02839668|Active Comparator|TIVA-TCI+lidocaine|The patients enrolled in this group will receive total intravenous anesthesia with propofol using a target controlled infusion technique for the maintenance of hypnosis throughout the surgery. At the induction of anesthesia the patients will receive a bolus of lidocaine 1% 1.5 mg/kg. A continuous infusion of lidocaine 1% of 2 mg/kg/h will be associated throughout the surgical procedure and 1mg/kg/h until 24 h postoperative. Postoperative analgesia will be assured by the administration of tramadol and acetaminophen.A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery. A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine.The bispectral index- BIS will be monitored throughout the anesthesia.
2508863|NCT02839213|Active Comparator|group A (Hyoscine Butyl bromide group)|The women will be given Hyoscine Butyl bromide
2508867|NCT02839213|Active Comparator|group B (Saline group)|The women will be given saline
2508961|NCT02839031|Experimental|"CBT group"|
2508962|NCT02839031|Sham Comparator|Control group|
2509067|NCT02838160|Experimental|booklet Group|
2509070|NCT02838160|Experimental|Oral presentations group|
2509074|NCT02838160|Experimental|Clinical teaching in bedside Group|
2509128|NCT02837523||Observation|Patients with a Cystinosis disease or high-grade suspicion for Cystinosis disease
2510441|NCT02828046|Experimental|M281|M281
3196882|NCT00855127||Liver transplant recipients|
3196883|NCT00855140|Placebo Comparator|Sham acupuncture|Sham acupuncture at non-active acupuncture points, using the Park Sham Device
3196884|NCT00855140|Experimental|Verum Acupuncture|Acupuncture following a specific TCM-based protocol
2508179|NCT02844387|Placebo Comparator|Placebo|In the Placebo arm patients will receive 200 ml of flavoured drinking water oral solution administered twice a day prior to the radiation therapy fraction
2508227|NCT02843945|Experimental|Directional Brachytherapy Source Implant|Patients undergoing a pancreatic cancer resection will receive a CivaSheet LDR directional brachytherapy implant at the time of surgery. The directional nature of the FDA cleared CivaSheet is expected to allow physicians to increase the radiation dose given to the surgical margin safely, reducing risk of recurrence without increasing radiation side effects.
2508289|NCT02843555||Leukodystrophy of unknown etiology|Subjects who may have an undiagnosed form of leukodystrophy
2508346|NCT02843100|Experimental|Group 1|Modified Exclusive Enteral Nutrition including two weeks of Exclusive Enteral Nutrition (EEN) using Modulen followed by Partial Enteral Nutrition (PEN) along with the Crohn's Disease Exclusion Diet (CDED) phases 2 & 3 for 24 weeks
2508348|NCT02843100|Active Comparator|Group 2|Standard Exclusive Enteral Nutrition for 8 weeks using Modulen, followed by free diet with gradual reduction of Modulen to 25% of energy needs by week 24.
2508457|NCT02842541|Experimental|Single dose arm|Subjects will receive a single intravitreal dose of EBI-031
2508459|NCT02842541|Experimental|Repeat dose arm|Subjects will receive an intravitreal dose of EBI-031 monthly for 3 months
2508498|NCT02841995|Experimental|belumosudil 200 mg QD|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil once daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal.
2508500|NCT02841995|Experimental|belumosudil 200 mg BID|Two 100 mg capsules or one 200 mg tablet (200 mg) of belumosudil twice daily. Subjects should take 2 capsules or 1 tablet with their morning meal or within 5 minutes of completing a meal and 2 capsules or 1 tablet with their evening meal or within 5 minutes of completing a meal.
2508502|NCT02841995|Experimental|belumosudil 400 mg QD|Four 100 mg capsules or two 200 mg tablets (400 mg) of belumosudil once daily. Subjects should take 4 capsules or 2 tablets with their morning meal or within 5 minutes of completing a meal.
2508587|NCT02841436|Experimental|irreversible electroporation (IRE)|IRE (AngioDynamics, NY) To use 2 to 6 unipolar electrodes in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
2508612|NCT02841085||Genetic sample|Blood sample or saliva collection to genetic research
2508671|NCT02840851||Healthy young women|Healthy young women between the age of 20-34 years.
2508672|NCT02840851||Healthy young men|Healthy young men between the age of 20-34 years.
2508674|NCT02840851||Healthy older women|Healthy older women between the age of 50-64 years.
2508676|NCT02840851||Healthy older men|Healthy older men between the age of 50-64 years.
2508708|NCT02840279|Experimental|BPN14770|An oral dose of BPN14770
2508709|NCT02840279|Placebo Comparator|Placebo|An oral dose of placebo matching BPN14770
2508874|NCT02839499|Experimental|mixed food|experimental group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
2508881|NCT02839499|Other|normal texture food|control group with RU sleeping®, autonomy scale (ADL and AGGIR) and various activity scale (IADL)
2508938|NCT02838875|Experimental|Pregnant women at risk population|women who arrived to the delivery room at Lis hospital and which the newborn is about to undergo glucose levels follow-up after birth regardless the study, because of their affiliation to the at-risk population.
2508999|NCT02838667|No Intervention|Standard of Care|If participants are randomized into the non-intervention group, the participants' information during the study period will be collected. Participants will be managed by a care provider as per the standard of care. Participants may receive nephrology consultation as indicated clinically.
2509001|NCT02838667|Experimental|Standard of Care plus Nephrology Care|If participants are randomized into the intervention group, participants' information will be checked by the study investigators daily for 7 days (2 days pre-op and 5 days post-op). When appropriate, investigators may give suggestions to minimize the participants' risk(s) for AKI. Participant's primary care providers may take the suggestions into consideration. Participants' primary care providers are not obligated to carry out the suggestions that are given.
2509072|NCT02838082|Experimental|Sleep Hygiene Protocol|Participants in this arm will undergo a 4 week sleep hygiene protocol
2509075|NCT02838082|Active Comparator|Standard of Care Protocol|Participants will undergo 4 weeks of current inpatient standard of care procedures in a rehabilitation facility
2509106|NCT02837653|Experimental|Experimental|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home, and a personalized Physical Activity Counseling based on the Cardiovascular Risk of Each Patient
2509107|NCT02837653|Active Comparator|Control|Usual Care in Primary Health Care in Low back pain patients, consisting in Therapeutic Exercise and Superficial Thermotherapy at home.
2509213|NCT02836951||Patient|This group consists of patients that are hospitalized due to a head injury. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
2509214|NCT02836951||Healthy controls|This group consists of healthy volunteers. Samples of blood, urine and plasma will taken from these subjects and the fluids will be analyzed for novel biomarkers using a biochemical assay.
2509268|NCT02836574|Experimental|Immediate Treatment|Renal Autologous Cell Therapy (REACT) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
2509272|NCT02836574|Active Comparator|Delayed Treatment|Renal Autologous Cell Therapy (REACT) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT product is made available before receiving 2 injections of REACT.
2509351|NCT02836067|Other|Smokers|"HIV-positive smokers will be enrolled in a smoking cessation program including the following procedures:~Counseling Smoking cessation drugs Questionnaires Blood Draw Bronchoscopy"
2509353|NCT02836067|Other|Non-Smokers|"HIV-positive non-smokers will be enrolled as a comparison group to HIV-positive smokers and will have the following procedures:~Questionnaires Blood Draw Bronchoscopy"
2508226|NCT02843893|Other|Intubated and Mechanically Ventilated Patients|Intubated and Mechanically Ventilated Patients receiving by continuous intravenous an hypnotic sedation (midazolam or propofol) associate with a morphine type drug (fentanyl, sufentanil, rémifentanil, or morphine) since at least 6 hours and for a predictable duration over 24 hours.
2508291|NCT02843620|Placebo Comparator|Placebo|The placebo arm will take a pill each day containing only excipients
2508295|NCT02843620|Experimental|b-2Cool|The b-2Cool arm will take a pill each day containing 40 mg of b-2Cool and excipients
2508352|NCT02843061|Experimental|Rituximab and NK immunotherapy|In this group, the patients will receive regular Rituximab treatment accompanied with multiple NK immunotherapy. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508355|NCT02843061|Active Comparator|Rituximab|In this group, the patients will receive regular Rituximab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
2508405|NCT02842606|Experimental|Fiber-enriched pasta|The participants consume whole wheat pasta with added fiber (fiber 12 g fiber/100 g).
2508406|NCT02842606|Active Comparator|Control pasta|The participants consume pasta made from durum wheat semolina (fiber 2.7g/100g).
2508437|NCT02842359|Experimental|Rovelito|Fixed-dose combination of irbesartan/atorvastatin will be given orally daily for 28 days
2508439|NCT02842359|Active Comparator|Irbesartan|Irbesartan will be given orally daily for 28 days
2508440|NCT02842359|Active Comparator|Atorvastatin|Atorvastatin will be given orally daily for 28 days
3163795|NCT00487253|Active Comparator|Group 2|Administration of Parenteral meglumine antimoniate, Glucantime® Amp 5ml (83mg/ml). Dosage:20mg/kg/day, during 20 days.
3163796|NCT00487305|Experimental|Biological/Vaccine|"Biological/Vaccine: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.~--------------------------------------------------------------------------------"
3163797|NCT00487318|Experimental|Arm 1 Plus statin|The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
3163798|NCT00487318|Active Comparator|2|Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
2508661|NCT02840877|Other|DOT Adherence Monitoring|Daily adherence monitoring by study-employed directly observed therapy (DOT) worker on weekdays throughout the course of TB therapy
2508711|NCT02840513|Experimental|Smartphone app/CO self-monitoring|The app offers a coaching function where users receive personalized messages to encourage smoking cessation and advice for behavioural changes. For the first 4 weeks of the intervention, individuals will also be asked to blow daily into a breath carbon monoxide monitor before going to sleep. Depending on the results of the breath test, individualized messages will be delivered by the Smokelyzer feedback app to either enhance maintenance of abstinence or increase the motivation to quit. After the first 4 weeks, participants will use the breath carbon monoxide monitor at least twice a week until the end of the 6-month study. The app will react with positive feedback in individuals doing well with smoking cessation and messages to encourage individuals with difficulties quitting to smoke.
2508713|NCT02840513|No Intervention|Control|Participants in the control group will be managed according to usual care as regularly provided by their SHCS physicians. Physicians will motivate patients to quit, emphasise the advantage of quitting, and provide patients with an information card that contains short advices how to quit and addresses of stop smoking clinics. The Swiss HIV Cohort Study study nurse will enter past or current use as well as of nicotine replacement therapy or use of other pharmaceutical support to quit smoking in the online study form
2508767|NCT02840149|Other|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan performed on Neuro-endocrine tumor patients
2508796|NCT02839785|Experimental|Ibuprofen|Active ibuprofen
2508802|NCT02839785|Placebo Comparator|Placebo|Placebo of ibuprofen
2508883|NCT02839382|Active Comparator|Coaching|External facilitation by a practice coach for 15 months
2508887|NCT02839382|Active Comparator|Educational Outreach|Academic detailing phone calls to support implementation of a cardiovascular risk calculator/estimator in each clinic
2508889|NCT02839382|Active Comparator|Site Visit|"Site visits made by practices to 'exemplar practices to learn innovative approaches to quality improvement"
2508892|NCT02839382|Active Comparator|Educational Outreach and Site Visit|In this arm of the study, practices will be offered both educational outreach and an opportunity for a site visit
2508963|NCT02838758|Experimental|Cryoablation|Ultrasound guided perineural cryoablation. The mechanism of therapeutic cryoablation involves using short and repeated cycles of freezing and thawing to cause axonal degeneration and disrupt neuronal activity without damage to epineurium and perineurium.
2508965|NCT02838758|Active Comparator|Lidocaine|Ultrasound guided perineural lidocaine injection. Under ultrasound guidance, roughly 3cc of 2% lidocaine will be injected near the neuroma.
2508968|NCT02838758|Placebo Comparator|Saline|Ultrasound guided perineural normal saline injection. Under ultrasound guidance, roughly 3cc of normal saline will be injected near the neuroma.
3163799|NCT00487331|Experimental|Acupuncture|Acupuncture sessions 1-3 times per week. 2 pain questionnaires + satisfaction survey completed at beginning and end of treatment.
2509082|NCT02837874|Active Comparator|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
2509087|NCT02837874|Experimental|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
2509140|NCT02837536|Active Comparator|Horizontal iCare|In the horizontal iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the horizontal position first and then their IOP measured with the iCare tonometer held in the vertical position.
2509141|NCT02837536|Active Comparator|Vertical iCare|In the vertical iCare arm, these patients were randomized to have their IOP measured with the iCare tonometer held in the vertical position first and then their IOP measured with the iCare tonometer held in the horizontal position.
2509243|NCT02836548|Experimental|vorinostat|Vorinostat 360 mg once daily
2509292|NCT02836340|Experimental|2-Iminobiotin|Increasing dosage of study drug
2508321|NCT02843230||Avastin and Temozolomide Combine with DSC, MRI and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Temozolomide treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 8 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2508323|NCT02843230||Avastin and Lomustine Combine with MRI, DSC, and MRS Scan|"Study subjects will have an MRI exam including MRS and DSC imaging prior to bevacizumab/ Avastin and Lomustine treatment (baseline scan).~Subsequently, patients will receive their follow-up MRI exams every 6 weeks as standard of care.~Advanced imaging will be added to the patients' regular follow-up scans including MRS and DSC MRI."
2508422|NCT02842580|Active Comparator|Standard arm (escalation strategy - arm A)|LV5FU2 (5 FLUOROURACYL)+avastin. After progression: FOLFIRI + avastin. after the 2nd progression:FOLFOX4 (eloxatine)+ avastin.
2508424|NCT02842580|Experimental|Experimental arm (de-escalation strategy -arm B)|(4 cycles of FOLFOXIRI (campto) + avastin and 4 cycles of FOLFIRI + avastin) is followed by maintenance with capecitabine
2508478|NCT02842008|Experimental|Exercise group|Wheelchair basketball players participating in home therapeutic exercise program that use the protocol of postural hygiene.
2508483|NCT02842008|No Intervention|Control group|Wheelchair basketball players that not participate in home therapeutic exercise program and use a protocol of postural hygiene provided.
2508519|NCT02841839|Experimental|2-step system|Subjects are to brush with 2-step system for 4 weeks; stannous fluoride
2508535|NCT02841618|Experimental|High Linoleic Acid Healthy Cookies|High Linoleic Acid Healthy Cookies (10g grapeseed oil) 1 per day for 2 weeks
2508538|NCT02841618|Placebo Comparator|High Oleic Acid Healthy Cookies|High Oleic Acid Healthy Cookies (10g safflower oil) 1 per day for 2 weeks
2508613|NCT02841007|Experimental|geko device arm|Patients consenting to take part will receive the geko device prior to surgery to internally fixate their fractured ankle, to reduce and prevent oedema
2508665|NCT02840864|Experimental|Arm 1|Sonographically assisted breast surgery
2508666|NCT02840864|Active Comparator|Arm 2|Conventional breast surgery
2508723|NCT02840435|Active Comparator|North Carolina Quit Line: Quit for Life|Participants will be connected to the 'Quit for Life' program offered through the North Carolina Quit Line.
2508725|NCT02840435|Experimental|Sit to Quit|Participants will be connected to the 'Sit to Quit' program offered through the Duke Smoking Cessation Program.
2508795|NCT02839980||orthopedics (gr1) surgery|parient admitted to the orthopedics (gr1) surgery ward for an elective or semi-emergent surgical procedure.
2508799|NCT02839980||thoracic (gr2) surgery|parient admitted to the thoracic (gr2) surgery ward for an elective or semi-emergent surgical procedure.
2508803|NCT02839980||abdominal (gr3) surgery|parient admitted to the abdominal (gr3) surgery ward for an elective or semi-emergent surgical procedure.
2508808|NCT02839980||ICU (gr4)|patients admitted to the ICU with an antcipated length of stay of 3 days or more
2508835|NCT02839538|Active Comparator|local Infiltration|"Induction of General Anesthesia with Propofol(2mg/Kg) and Atracurium(0,5mg/Kg) . Pulmonary ventilation with laryngeal mask and Propofol infusion ( 100mcg/Kg/min.) After , Infiltration of 0.75% ropivacaine (10 ml) each side block injection of local anesthetic at perianal.~If necessary, fentanyl endovenous injection (50 mcg)."
2508838|NCT02839538|Other|Subarachnoidal block|"Sedation with midazolam 2 mg. After , Spinal block with 10 mg of hyperbaric 0.5% bupivacaine. Injection of anesthetic at subarachnoidal space with Quincke needle 27G.~If pain, local infiltration with lidocaine 1% (5 ml) in wound."
2508897|NCT02839291|Experimental|quality of life questionaries|Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)
2508940|NCT02838849|Sham Comparator|Fiber|Participants were treated with 2 sachets of fiber orally a day for 14 days, after baseline characterization of bowel habit and stool features.
2508942|NCT02838849|Active Comparator|Fiber and Water|Participants were treated with 2 sachets of fiber orally a day and ingested 2 liters of water a day for 14 days, after baseline characterization of bowel habit and stool features.
2509016|NCT02838615|Active Comparator|epidural steroid injection|TF epidural steroid (dexamethasone) injection
2509024|NCT02838615|Active Comparator|IL epidural steroid injection|PS interlaminar epidural steroid(dexamethasone) injection
3196885|NCT00855153|Experimental|treatment|Subjects receive 50mg DCS prior to 90 min session with graded VRE treatment
2509157|NCT02837081|Active Comparator|Preauthorization group|Strategy 1 of antimicrobial stewardship: Prescriptions of antimicrobial agents are done real-time by infectious diseases physician consultant. Use restricted without real-time authorization.
2509161|NCT02837081|Experimental|Prospective audit|Strategy 2 of antimicrobial stewardship: Prescription of antimicrobial agents are audited 48-72 hours later by infectious diseases physician consultant. Use allowed without authorization for 72 hours.
2509226|NCT02836834|Experimental|Dose Escalation Cohort|JS001
2509227|NCT02836834|Experimental|Expanded cohort 1|The subjects of expanded cohort 1 will use repeated doses every 2 weeks like multiple dose cohorts
2509228|NCT02836834|Experimental|Expanded cohort 2|The subjects of expanded cohort 2 will use repeated doses every 2 weeks like multiple dose cohorts
2509293|NCT02836418|Experimental|ATYR1940|All patients will receive ATYR1940 at the highest tolerated dose received in the parent study for 12-weeks. After 12 weeks, if the patient is demonstrating good tolerability, theATYR1940 dose may be increased on a patient-specific basis at the Investigator's discretion, in consultation with the Sponsor and Medical Monitor. ATYR1940 dose increases to >3.0 mg/kg are not permissible.
2509425|NCT02835547||Systemic lupus erythematosus|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2509426|NCT02835547||Rheumatoid arthritis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2509428|NCT02835547||Psoriasis|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
3163800|NCT00487357||MATCh Parents' Supplemental Survey|Parent/Guardian Survey
3163801|NCT00487409|Other|Group A|Standard of Care
3163802|NCT00487409|Other|Group B|Standard of Care
3163803|NCT00487422|Active Comparator|1|Prucalopride
3163804|NCT00487422|Active Comparator|2|Prucalopride
3163805|NCT00487422|Placebo Comparator|3|Placebo
2508415|NCT02842567|Experimental|TREATED GROUP|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks.
2508417|NCT02842567|Placebo Comparator|PLACEBO GROUP|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
2508479|NCT02842229||Patients with Haematologic Neoplasms|"Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01).~Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).~Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01)."
3163806|NCT00487474||Sculptra|
3163807|NCT00487500|Experimental|Ultrabrief, Right Unilateral ECT|Right unilateral ECT administered with an ultrabrief pulse width (0.3 ms), at a dose 6 times the initial seizure threshold
3163808|NCT00487500|Experimental|Ultrabrief, Bilateral ECT (2.5 X ST)|Bilateral (frontotemporal) ECT with an ultrabrief pulse width with dosage 2.5 times the initial seizure threshold
3163809|NCT00487500|Active Comparator|Brief Pulse, Right Unilateral ECT|Right unilateral ECT, with a standard brief pulse (1.5 ms), with dosage 6 times the initial seizure threshold
3163810|NCT00487500|Active Comparator|Brief Pulse, Bilateral ECT|Bilateral (frontotemporal) ECT with a standard brief pulse (1.5 ms), with dosage 2.5 times the initial seizure threshold
3163811|NCT00487591||Simva+Omacor|
3163812|NCT00487591||Simva + Placebo|
3163813|NCT00487617|Experimental|fruit juice|300 mL of fruit juice
3163814|NCT00487617|Placebo Comparator|placebo|300 mL of fruit juice without polyphenols
3163815|NCT00487656|Experimental|ART-123|6 mg/ml ampule solution for injection
3163816|NCT00487656|Placebo Comparator|Placebo|6 mg/mlampule of solution for injection
3163817|NCT00487682|Experimental|1|ASP2151 low dose
3163818|NCT00487682|Experimental|2|ASP2151 middle dose
3163819|NCT00487682|Experimental|3|ASP2151 high dose
3163820|NCT00487682|Active Comparator|4|Valacyclovir hydrochloride
3163821|NCT00487708|Experimental|1|ACZ885
3163822|NCT00487734|Experimental|1|Subjects in this arm will receive testosterone gel
3163823|NCT00487734|Placebo Comparator|2|
3163824|NCT00487773|Active Comparator|1|budesonide
3163825|NCT00487773|Active Comparator|2|D3 vitamin
3163826|NCT00487773|Active Comparator|3|montelukast sodium
3163827|NCT00487773|Active Comparator|4|salbutamol
3163828|NCT00487786|Experimental|A|Each patient receives OGX-427
3163829|NCT00487851|Active Comparator|1|Endoscopic treatment strategy
3163830|NCT00487851|Active Comparator|2|Surgical treatment strategy
3163831|NCT00487929|Experimental|CPAP|Continuous positive airway pressure
3163832|NCT00487929|Sham Comparator|Sham CPAP|Sham nasal continuous positive airway pressure
3163833|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD|
3163834|NCT00487994|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin 10 mg QD|
3163835|NCT00487994|Active Comparator|Atorvastatin 10 mg QD|
3163836|NCT00488007|Experimental|Active Hearing aids|Active
3163837|NCT00488007|Placebo Comparator|Inactive Hearing aids|Hearing aids turned off
3163838|NCT00488046|Experimental|1|Two, 0.5 ml doses of vaccine in nasal spray form administered at study entry and sometime between 4 and 8 weeks after initial vaccination
3163839|NCT00488072|Experimental|Mirtazapine|Mirtazapine 15 mg by mouth (PO) daily for 15 days; Day 22-29, increased to 30 mg PO daily.
3163840|NCT00488072|Placebo Comparator|Placebo|One placebo tablet by mouth daily.
3163841|NCT00488111|Active Comparator|1|Participants were treated with normal Ringer's solution 15 min before the operation.
3163842|NCT00488111|Active Comparator|2|6% Starch was used 15min before operation followed epidural anesthesia.
3163843|NCT00488137|Active Comparator|1|Prucalopride 2 mg
3163844|NCT00488137|Placebo Comparator|3|Placebo
3163845|NCT00488137|Active Comparator|2|Prucalopride 4 mg
3163846|NCT00488163|Active Comparator|Atomoxetine|Atomoxetine 40 mg compounded into capsules.
3163847|NCT00488163|Placebo Comparator|Placebo|Inactive matching compounding of placebo capsules
3163848|NCT00488176|Active Comparator|1|monteluksat sodium
3163849|NCT00488176|Active Comparator|2|cetirizine
3163850|NCT00488176|Active Comparator|3|montelukast sodium and cetirizine
3163851|NCT00488176|Placebo Comparator|4|placebo
3163852|NCT00488189|No Intervention|1|baseline, collecting rectal swab samples
3163853|NCT00488189|Active Comparator|2|use pipercill/tazobact to replace 3rd generation cephalosporin and collect rectal swab
3163854|NCT00488215|Active Comparator|1|Prucalopride
3163855|NCT00488215|Placebo Comparator|2|Placebo
3163856|NCT00488228|Experimental|1|Participants in the behavioral self-regulation intervention will receive a modified standard treatment that incorporates daily weighing and training in self-regulation methods for weight loss. All treatment modules are adapted for a young adult age group.
3163857|NCT00488228|Experimental|2|Participants in the Standard group will receive a brief version of standard behavioral weight loss treatment with treatment modules tailored to better meet the needs of young adults.
3163858|NCT00488241|Active Comparator|1|Topically applied daily for 2 weeks
3163859|NCT00488267|Experimental|Thermoprofen|ThermoProfen™ (ketoprofen matrix/Controlled Heat Assisted Drug Delivery [CHADD™] patch)
3163860|NCT00488267|Placebo Comparator|Placebo Matrix|Placebo matrix with CHADD patch.
3163861|NCT00488267|Placebo Comparator|Ketoprofen matrix/placebo CHADD|Ketoprofen matrix with placebo CHADD patch (no heat)
2508466|NCT02842398|Experimental|Balance Master Training|Children receive one weekly Balance Master training session, in addition to their weekly physical therapy sessions. During Balance Master training, children practice balance on a Balance Master device that simulates crossing a city street.
2508468|NCT02842398|Active Comparator|Customary Care|Children received their customary scheduled physical therapy sessions, without Balance Master training
2508537|NCT02841917||Transcatheter Aortic Valve Replacement|ROS Post TAVR
2508539|NCT02841917||Surgical Aortic Valve Replacement|ROS Post SAVR
2508602|NCT02841423|Experimental|INTRAVENOUS ANESTHESIA|neuropsychological test battery
2508603|NCT02841423|Experimental|CLOSED LOOP ANESTHESIA|neuropsychological test battery
2508651|NCT02840890|Experimental|experimental|Patients will have a visceral osteopathic technique perform with continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
2508653|NCT02840890|Placebo Comparator|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
2508679|NCT02840552|Experimental|FCH-PET/CT|18F-Fluoromethylcholine (18F-FCH) PET/CT
2508740|NCT02840331|Experimental|St. John's Wort & PDD, PDT|St. John's Wort 900 milligram once oral preoperative & intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
2508775|NCT02839941|Experimental|experiment|
2508779|NCT02839941|Sham Comparator|Control|
2508847|NCT02839577|Active Comparator|High Volume injection (HVI) with corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~20 mg of Depomedrol (40 mg/ml methylprednisolonacetat)~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI without corticosteroid."
2508849|NCT02839577|Active Comparator|High Volume injection (HVI) without corticosteroid|"10 mls 0.5% bupivacaine hydrochloride~40 mls saline (NaCl)~HVI with corticosteroid is injected one time at baseline and compared to HVI with corticosteroid."
2508951|NCT02839005|Active Comparator|suture with polyglecaprone 25|
2508956|NCT02839005|Active Comparator|suture with polyamide (nylon)|
2508981|NCT02838537||Triptan Arm|"Users of triptan defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
2508982|NCT02838537||Ergot Arm|"Users of ergot derivative defined as at least one recorded dispensing of any drug during the follow up, with no recorded of any of these drugs during the previous 6 months (new or incident users)"
2508997|NCT02838277||Lipedema|Women with all stages of lipedema
2508998|NCT02838277||Dercum's disease|Men and women with nodular, mixed and diffuse Dercum's disease
2509000|NCT02838277||Control|Sex, age and BMI matched controls.
2509002|NCT02838277||Familial Multiple Lipomatosis|Women and men with multiple lipomas and/or angiolipomas
2509005|NCT02838277||Madelung's disease|Men and women with different types of Madelung's disease.
2509063|NCT02838056|Experimental|epidural injection|epidural injection of 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
2509116|NCT02837718|Other|Bupivacaine 0,5% Single arm study|Bupivacaine 0,5% Single arm study
2509175|NCT02837341|Other|Volunteers|Monitoring of respiratory rates via camera-based System Monitoring of respiratory rate by Philips®Vital Sign Device - Camera-based system (Prototype) and capnography simultaneously.
2509317|NCT02836132|Active Comparator|Weight Watchers Online|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform.
2509322|NCT02836132|Experimental|Weight Watchers Online + Experience Success|Participants will receive 6 months of no-cost access to the Weight Watchers Online platform. They will also receive 6 months of no-cost access to the Experience Success online platform, with 4 virtual reality scenarios for training in behavioral weight loss skills.
2509356|NCT02835833|Experimental|Nintedanib 150 mg + Bevacizumab 15 mg/kg|"The first three patients on study will be treated with 150 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.~If one dose limiting toxicity occurs in the first cohort, then three more patients will be treated at that same starting dose and assessed for toxicity after cycle two. If two or more patients have dose limiting toxicity, then dose escalation will end and the maximum tolerated dose will be reached."
2509358|NCT02835833|Experimental|Nintedanib 200 mg + Bevacizumab 15 mg/kg|If no patients experience dose limiting toxicity, then three additional patients will be treated with 200 mg orally of Nintedanib two times daily plus 15 mg/kg of Bevacizumab administered intravenously on day one of each three week cycle.
2509433|NCT02835391|Active Comparator|PerClot|PerClot® Polysaccharide Hemostatic System (PerClot) is a medical device composed of absorbable polysaccharide particles (AMPs) and delivery applicators. Investigators will have the option to choose 3g or 5g dependent on the requirements of the patient
2509438|NCT02835391|Active Comparator|Usual Care|Usual care will consist of any other haemostat the Investigator would normally use in the control of bleeding i.e arista, Floseal, surgical, surgiflo. If the Investigator would not normally use a haemostat to control bleeding then electrocautery or diathermy may be used in this arm
2509531|NCT02834962|Experimental|single bundle ACLR|patients undergo single bundle ACL reconstruction
2509537|NCT02834962|Active Comparator|double bundle ACLR|patients undergo double bundle ACL reconstruction
3163862|NCT00488280|Experimental|Kids Step Study: Locomotor Training|All children who participate will be in the experimental cohort, KSS-#, and receive 60 sessions of daily locomotor training. This experimental cohort will also undergo clinical and neurophysiological testing pre, during, and post 60 sessions of locomotor training.
3163863|NCT00488332||OCT + FS + Questionnaire|Optical Coherence Tomography (OCT) + Fluorescence Spectroscopy (FS) and Questionnaire
3163864|NCT00488384|Other|a|single arm only. Only open label treatment anticipated
3163865|NCT00488397||1|
3163866|NCT00488423|Active Comparator|Lap-band|Patient undergoing Lap-band Bariatric Surgery
3163867|NCT00488423|Active Comparator|Gastric Bypass|Patient's undergoing Laparoscopic Roux-N Y Gastric Bypass surgery.
3163868|NCT00488462|No Intervention|Control|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the control arm, half of the study clinics will not use the NASG but the NASG will be available at the referral hospital for patients transported there.
2508472|NCT02842125|Experimental|Ad-p53 with Xeloda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and daily metronomic Xeloda (capecetabine), at a dose of 625 mg/m2 BID continuously.
2508476|NCT02842125|Experimental|Ad-p53 with Keytruda 33.3% of patients|Up to 12 patients, in 3+3 cohorts, all patients treated with Intra-arterial Ad-P53 once weekly, dosing dependent on DLT and MTD findings, and infusions of pembrolizumab every 3 weeks.
2508482|NCT02842125|Experimental|Ad-p53 with Opdivo 33.3% of patients|Up to 12 patients treated with intra-tumoral Ad-P53 3 times week 1 of each cycle, dose determined by tumor size, in combination with IV nivolumab (Opdivo) 480 mg, every 4 weeks.
2508564|NCT02841696||Hypertensive people|Hypertensive people recruited 10 years ago before any anti-hypertensive treatment
2508627|NCT02841228|Experimental|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction, SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
2508695|NCT02840747||Patients with CTCL|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with CTCL (according to World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) criteria).
2508696|NCT02840747||Patients with benign dermatoses|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from patients with benign dermatoses, including but not limited to conditions such as eczema, psoriasis, and dermatitis.
2508697|NCT02840747||Healthy Controls|Skin biopsies, blood samples, skin swabs, nasal swabs, cheek epithelium swabs, fecal samples and urine samples may be collected from healthy volunteers.
2508794|NCT02840045|Experimental|Alzheimer patients|Cerebral measurements from high-density electroencephalography are recorded in Alzheimer patients. The same protocol is applied in the 3 arms
2508800|NCT02840045|Experimental|patients with a depressive disorder|Cerebral measurements from high-density electroencephalography are recorded in patients with a depressive disorder. The same protocol is applied in the 3 arms
2508804|NCT02840045|Active Comparator|Healthy controls|Cerebral measurements from high-density electroencephalography are recorded in healthy controls
2508857|NCT02839408|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
2508858|NCT02839408|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months.
2508860|NCT02839408|Experimental|Periodontal treatment, Antibiotic|Periodontal treatment (scaling and root planning) and one tablet containing 500mg Azithromycin
2508948|NCT02839057||Surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated with surgical fracture stabilisation
2508953|NCT02839057||Non-surgical treatment|Patients ≥70 years with C2 fracture coded in patient registry (ICD-10: S12.1) treated non-surgically
2508993|NCT02838511||Non-cardiac surgery|Hopkins Frailty Score (HFS) or Modified Frailty Index (MFI) will be obtained during during pre anesthesia evaluation
3196886|NCT00855179|Active Comparator|Antistax film-coated tablets 360 mg|Patient to receive 2 tablets daily as a morning dose, each containing 360 mg Antistax
3196887|NCT00855179|Placebo Comparator|Placebo|Patient to receive 2 tablets identical to those containing 360 mg Antistax daily as a morning dose
2509144|NCT02837406||Doctors|specialists and general practitioners by ich territory
2509146|NCT02837406||Health professionals|"pharmacists~nurses~physiotherapists~Medical and social professionals: social workers, psychologists, educators ..."
2509148|NCT02837406||Medical-social institutes|"Hospital,~Healthcare structure,~Local Centre of Information and Gerontological Coordination ..."
2509181|NCT02837094|Experimental|C19-A3 GNP (Gold Nanoparticles)|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold. Solution For Injection The dose given will be equivalent to 10ug of C19A3 peptide at 3 dispensing visits, which are 4 weeks apart. Total 30ug.
2509219|NCT02836730||Lumbar disc herniation|Patients with surgery for lumbar disc herniation;
2509221|NCT02836730||Spinal stenosis|Patients with surgery for lumbar spinal stenosis
2509222|NCT02836730||No surgery|Patients with no surgery for lumbar disc herniation; patients with no surgery for lumbar spinal stenosis;
2509265|NCT02836509|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
2509266|NCT02836509|Experimental|Ibuprofen group|Second Group: 800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
2509298|NCT02836171|Experimental|Treatment|subjects receiving a single 250 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then Itraconazole capsules 100 mg/day orally for 6 days with a single 250 mg oral dose of apatinib mesylate tablets co-administered on day 4 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
2509337|NCT02835937|No Intervention|Transfuse|Patients will receive a transfusion under standard care
2509345|NCT02835937|Experimental|No-Transfuse|Patients will not receive a transfusion
2509403|NCT02835664|Experimental|Nicotinamide Riboside|Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
2509414|NCT02835664|Placebo Comparator|Placebo|Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.
2509467|NCT02835053||Emergency General Surgery|All patients having emergency general surgery procedures as defined by Scott et al (JAMA Surgery 2016)
2509519|NCT02834767|Experimental|Group 1 Primary Snoring Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2510401|NCT02828423|Active Comparator|Control group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) alone
2508495|NCT02842112||CD34+ CD38+|A third population characterized by a large density of CD38 and CD34 antigens (CD34+ CD38+). Antigens were expressed as percent positively stained cells as well as intensity of the fluorescence signal quantified as mean fluorescence intensity (MFI) from CD34+ gated cells and from CD45low/SSC total immature cells
2508525|NCT02841735||Smartphone breathalyzer device & app|This is a small device that attaches to a smartphone with an accompanying app that produces accurate breath alcohol readings when a user blows into a small tube attached to the device. Participants randomized to this study condition will have the opportunity to use this device and app during an alcohol drinking session in a simulated laboratory.
2508527|NCT02841735||BAC estimator app|This is an app that produces estimated blood alcohol content (eBAC) readings based on sex, weight, number of drinks and time taken to consume drinks. Participants randomized to this study condition will have the opportunity to use this app during an alcohol drinking session in a simulated laboratory.
2508528|NCT02841735||Text Messaging|A procedure whereby one sends a text message to the phone one is using after each alcoholic drink. Participants randomized to this study condition will have the opportunity to the text messaging procedure during an alcohol drinking session in a simulated laboratory.
2508541|NCT02841514|Experimental|treatment group|the operator will administer the Y10 whitening toothpaste in to the attachable mouthpiece and place it in the subject's mouth and turn on the device RF. After treating the patients for 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
2508544|NCT02841514|Placebo Comparator|placebo group|the operator will administer an off the shelf regular toothpaste in to the attachable mouthpiece and place it in the subject's mouth. At this point the operator will switch on the device but the RF will not be activated. After 30 minutes the operator will turn off the device and retrieve the mouthpiece from the mouth.
2508585|NCT02841384|Other|Group taping McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
2508589|NCT02841384|Other|Group placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
2508631|NCT02841059||Laparoscopic subtotal hysterectomy|women with benign gynecology disease and decided to receive laparoscopic subtotal hysterectomy (LSH) after discussion with her surgeon.
2508635|NCT02841059||Laparoscopic CLSH|women with benign gynecology disease and decided to receive laparoscopic cervical ligament sparing hysterectomy (CLSH) after discussion with her surgeon.
2508637|NCT02841059||Laparoscopic AVH|women with benign gynecology disease and decided to receive laparoscopic assisted vaginal hysterectomy (LAVH) after discussion with her surgeon.
2508731|NCT02840370|Experimental|transcranial direct current stimulation|tDCS
2508737|NCT02840370|Sham Comparator|Sham tDCS|S-tDCS
2508777|NCT02839954|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
2508819|NCT02839629||Cohort 1: National patient cohorts in Scandinavia|Scandinavian countries: Denmark, Norway and Sweden Cohort 1 will include all patients with a diagnosis of NSCLC between 2005 and 2013
2508823|NCT02839629||Cohort 2: Electronic Medical Records based cohort (Sweden)|Patient as data is available (~2010) to 2013
2508873|NCT02839369||children|post Traumatic Brain Injury With Cerebral Palsy Typically developed
2508941|NCT02838992|Experimental|ATG, Cy and cord blood transfusion group|"ATG 3mg/kg/d for 5 days Cy 50mg/kg/d for 2 days CSA Started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml One unit of cord blood having no more than 3 HLA-A,B and DRB1 mismatches is transfused 24h after last dose of ATG administration.~Intervention:~Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus Cyclophosphamide plus CSA Biological: Cord blood transfusion"
2508943|NCT02838992|Active Comparator|ATG and CSA group|ATG 3mg/kg/d for 5 days CSA started from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-400ng/ml Intervention: Drug: Rabbit ATG, Thymoglobuline (Genzyme) plus CSA
2509011|NCT02838355|Active Comparator|Standard Respiration Monitoring|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring throughout their stay in the ICU.
2509012|NCT02838355|Experimental|Standard Respiration Monitoring + Continuous ETCO2-NC|Participants scheduled for mechanical circulatory support device (MCSD) implant or who have been readmitted to an intensive care unit (ICU) with a continuous flow left ventricular assist device (CF-LVAD) will receive standard respiratory monitoring and continuous end-tidal capnography monitoring via nasal cannula (ETCO2-NC) throughout their stay in the ICU.
2509066|NCT02837965||diagnosed bullous pemphigoid|
2509098|NCT02837614|Active Comparator|Group A (intramuscular dexamethasone)|In Group A patients, 1 ml of dexamethasone (4mg) administered in the deltoid muscle before commencement of surgical procedure
2509099|NCT02837614|Experimental|Group B (submucosal dexamethasone)|In Group B patients, 1 ml of dexamethasone was administered in submucosa after local anesthesia
2509100|NCT02837614|Placebo Comparator|Group C (control)|Group C patients continued without receiving any preoperative medication.
2509223|NCT02836847|Experimental|target therapy|The patients wil receive conventional chemotherapy(GEMOX) combined with target agents according to the result of genomic and proteomic profiling of tumor tissue.
2509224|NCT02836847|Other|GEMOX|The patients wil receive conventional chemotherapy(GEMOX).
3196888|NCT00855192|Experimental|mindfulness-based therapy|mindfulness-based meditation
3196889|NCT00855192|Experimental|interpersonal therapy|psycho-educational
3196890|NCT00855205|Experimental|Treatment|Treatment with rituximab
2509378|NCT02835703|Active Comparator|Deep hypothermic arrest|Surgical repair of coarctation of aorta under deep hypothermic circulatory arrest
2509380|NCT02835703|Active Comparator|Selective antegrade cerebral perfusion|Surgical repair of coarctation of aorta using selective antegrade cerebral perfusion
2509383|NCT02835703|Active Comparator|Double arterial cannulation|Surgical repair of coarctation of aorta using cerebral antegrade perfusion with descending aortic cannulation
3196891|NCT00855244|Other|BMT survivors|Diagnostic exams
3196892|NCT00855257|Experimental|1|treatment by acid nicotinique
3196893|NCT00855257|Placebo Comparator|2|Treatment by placebo
2508639|NCT02840929|Experimental|Second-look OGD group|"Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)"
2508641|NCT02840929|Active Comparator|Standard care group|Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present
2508668|NCT02840604||patient with all types of solid malignant tumors not treatable|In the treatment or assessment of metastatic solid tumor malignancies not curable it can be offered to patients to establish the profile of their tumor by next generation sequencing (NGS). This technique permits the sequencing of millions of fragments in parallel in a short time and allows to identify rapidly somatic or constitutional mutations known or yet unknown. The establishment of the genetic profile of the tumor coupled to the available clinical data can help clinicians to predict patient outcome in terms of survival or progression to disease, but may also provide key clues to adapt the management and patient treatment.
2508700|NCT02840396|Experimental|rTMS|
2508702|NCT02840396|Sham Comparator|Sham rTMS|
2508755|NCT02840162|Active Comparator|Celecoxib|Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
2508757|NCT02840162|Placebo Comparator|Placebo|Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth
2508902|NCT02839148|Experimental|Dietary supplementation|In case of dietary supplementation, we will provide milk and egg 6 days a week for 3 months to stunted children.
2508905|NCT02839148|Experimental|psychosocial stimulation|In case of psychosocial stimulation, we well provide PS weekly for first month, fortnightly for 2nd and 3rd months and then monthly for next 3 months. The total number of visits will be 11 over a period of 6 months.
2508927|NCT02838823|Experimental|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2508991|NCT02838693||APT-2D (Normoglycemic)|800 Normoglycemic
2508992|NCT02838693||APT-2D (Pre-Diabetic)|1,500 Pre-Diabetic
2509020|NCT02838199|Experimental|TAVR|Transcatheter aortic valve replacement with SAPIEN 3
2509027|NCT02838199|Active Comparator|SAVR|Surgical aortic valve replacement
2509051|NCT02837887|Experimental|Group I (immediate treatment)|Patients undergo computerized cognitive behavior therapy consisting of 45-60 minute sessions once per week for 8 weeks. Patients also complete the PHQ-9 and GAD7 at weeks 1, 3, 5, 7 and 8 and complete other questionnaires for 15-30 minutes each that assess psychosocial and physical symptoms.
2509053|NCT02837887|Experimental|Group II (wait-list)|Patients are placed on an 8-week wait-list and then undergo computerized cognitive behavior therapy and receive questionnaires as in Group I.
2509111|NCT02837757|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting everolimus treatment), and then 3 months and 9 months (or at disease progression if occurs first) after initiation of everolimus treatment Peripheral blood mononuclear cell (PBMC) and serum will be collected.~Available tumor tissues samples will be collected."
2509179|NCT02837302|Active Comparator|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
2509186|NCT02837302|No Intervention|General nutritional support|General nutritional support
2509231|NCT02836808|No Intervention|Control|Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area
2509235|NCT02836808|Experimental|CAIPaDi|Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day
2509359|NCT02835885|Experimental|Active tVNS Stimulation|Stimulating electrode will be placed on left tragus of subject. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied.The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
2509365|NCT02835885|Sham Comparator|Sham tVNS Stimulation|Stimulating electrode will be placed on left ear lobe of subject for sham tVNS stimulation condition. Current will be held constant (200% perceptual threshold) while pulse width and frequency are varied. The intervention used to keep current constant is Digitmer High Voltage Stimulator model DS7A TENS unit. Each stimulation period (9 randomized stimulation parameters varying in pulse width and frequency) will last 1 minute with a 3 minute break between each parameter. Physiological data (O2 saturation, blood pressure, breathing rate, and Electrocardiogram (EKG) to measure heart rate ) will be collected continuously.
2509448|NCT02834988||SLND Patients|Patients scheduled to have their sentinel lymph nodes removed, as part of standard of care.
2510402|NCT02828423|Experimental|Test group|Regeneration therapy of non-contained intrabony defects with enamel matrix derivate (EMD) and Biphasic Calcium phosphate (BC)
3196894|NCT00855270|Placebo Comparator|saline|An IV injection of saline will be administered to the control group in a double blind, randomized manner.
3196895|NCT00855270|Experimental|Hydrocortisone|IV hydrocortisone will be given in a double blind random manner as the active treatment group
2508557|NCT02841527|Active Comparator|Gastric Band|The procedure will involve an operation in which a gastric Band and port will be fitted using a laparoscopic technique.
2508561|NCT02841527|Active Comparator|Gastric Bypass|The procedure will involve a laparoscopic operation in which a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
2508563|NCT02841527|Active Comparator|Sleeve Gastrectomy|The procedure involves an operation which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach using a laparoscopic technique.
2508718|NCT02840357|Experimental|Treatment Group|Purple Wheat Convenience Bars The treatment group will consume 4 servings /day of bran-enriched purple wheat convenience bars (40g/ serving)
2508719|NCT02840357|Placebo Comparator|Control Group|Control Wheat Convenience Bars The control group will consume 4 servings /day of bran-enriched ordinary wheat convenience basr (40g/ serving)
2508772|NCT02840058|Experimental|Biological samples|"Blood samples will be realized specifically to the study at inclusion (baseline before starting anti PD1/PDL1 treatment), and then 1 month, 3 months and 12 months after initiation of anti-PD1/PDL1 treatment.~Peripheral blood mononuclear cells (PBMC) and plasma will be collected.~Available tumor tissues will be collected."
2508815|NCT02839655|Experimental|Da Vinci Xi|
2508859|NCT02839434||Treated with oral anticoagulants|Ex vivo study using blood samples from patients treated with oral anticoagulant (direct oral anticoagulants or AVK) at curative dose, taken in the usual cardiac monitoring.
2508925|NCT02838784|Experimental|Artacent Human Amniotic Membrane|Patients randomized to the Artacent group will receive standard of care (off-loading with a removable cast walker and non-adherent dressings in addition to debridement and use of moisture retentive dressing) and the application of the Artacent amniotic allograft once every two weeks for up to 5 applications or until the ulcer has healed.
2508926|NCT02838784|Active Comparator|Lower Extremity Ulcer Standard of Care|Patients randomized to standard of care will receive off-loading with a removable cast walker and non-adherent dressings (e.g. Adaptic) in addition to debridement and use of moisture retentive dressings. An outer dressing will also be applied.
2508987|NCT02838550|Experimental|MOI and PEDOMETER|Accessing to a motivational online intervention and wearing an unblinded pedometer (in order to receive feedback of the steps taken).
2508989|NCT02838550|Experimental|MOI (without PEDOMETER)|Accessing to a motivational online intervention and wearing a blinded pedometer (in order to not receive feedback of the steps taken).
2508990|NCT02838550|No Intervention|CONTROL|Wearing a blinded pedometer (in order to not receive feedback of the steps taken).
2509007|NCT02838238|Experimental|X|Capecitabine 1250mg/m², bid, po, d1-14, every 3 weeks for 6 cycles
2509010|NCT02838238|Placebo Comparator|Placebo|Placebo, bid, po, d1-14, every 3 weeks for 6 cycles
2509083|NCT02838030|Experimental|acetylsalicylic acid and L-arginine|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and L-arginine 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
2509086|NCT02838030|Placebo Comparator|acetylsalicylic acid and placebo|acetylsalicylic acid 75 mg every 24 hours from the 12th week of pregnancy and placebo 3 gr every 8 hours from the 20th week of pregnancy to pregnancy termination
2509137|NCT02837497|No Intervention|Control|Standard ICU resuscitation practices
2509139|NCT02837497|Experimental|ICU-RESUS CPR Improvement Bundle|ICU-RESUS bundle implementation: 1) point-of-care bedside CPR training; and 2) post-cardiac arrest debriefings.
2509158|NCT02837146|Experimental|Tocilizumab (TCZ) + Methotrexate (MTX)|"Induction phase:~From week 0 to week 24, all subjects will receive TCZ and MTX~Maintenance phase:~From week 24 to week 54, all subjects will receive MTX"
2509245|NCT02836886||Sézary syndrome|Patients diagnosed with Sézary syndrome diagnosed according to the WHO-EORTC criteria.
2509315|NCT02836379||Breakthrough Cancer Pain|No intervention (Non-interventional study)
2509340|NCT02835807|Experimental|Health Chat including Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image) with 25% of all of the content being about indoor tanning. Indoor tanning-related content was developed by the investigators and a social media marketing expert using information from published literature on IT risk factors, evidence-based intervention content from published trials targeting IT reduction, public health campaigns from major non-profit organizations (e.g., CDC, Skin Cancer Foundation, etc.), and investigator-developed video-recorded interviews of local mothers and professionals about the risks of indoor tanning, experiences with skin cancer, and mother-daughter communication role modeling.
2509348|NCT02835807|Active Comparator|Health Chat excluding Indoor Tanning|Facebook group, Health Chat, which provides information via posts within the private group about a wide variety of health topics (e.g. tobacco use, body image), but does not include any content about indoor tanning. The designated number of posts (25%) assigned to the indoor tanning content in the intervention group will be assigned to prescription drug use in the control arm. In order to keep number and frequency of posts standardized between the two groups, prescription drug use was selected to replace the indoor tanning content for the control arm.
2509412|NCT02835521|Experimental|Intervention Group|Patients will receive the reception treatment before the joint injection
2509421|NCT02835521|Active Comparator|Control Group|patient will receive a joint injection
2509518|NCT02834715|Experimental|Stevia|Once-daily oral intake of 240 mg of Stevia liquid extract for 30 days as food supplement.
2509524|NCT02834715|No Intervention|Control|No intervention, similar follow up as experimental arm to control for trial effect
2509601|NCT02834429||endoscopy patients|We will recruit patients (n=1000) from the endoscopy department at the Royal Hallamshire Hospital, Sheffield, United Kingdom (UK).
3196896|NCT00855283|Experimental|Arm 1|SCI
3196897|NCT00855322|Experimental|1|Gym group exercise intervention
2509775|NCT02833116|Experimental|Group Betamethasone|One ampule containing 12 mg of betamethasone in a syringe of 10 ml
2509778|NCT02833116|Active Comparator|Group Dexamethasone|One ampule containing 4 mg of dexamethasone in a syringe os 10 ml
2509832|NCT02832700|Active Comparator|Casein glycomacropeptide (CGMP)|During 4 weeks a daily oral intake of CGMP-protein-shake.
3196898|NCT00855322|Experimental|2|Hydrotherapy group exercise intervention
3196899|NCT00855322|No Intervention|3|Control group
2508567|NCT02841878|Other|analysis on colorectal biopsy|"Proteases activity (cystein and serin proteases)~Proteases inhibitors genes expression (Serpins A1 / E1)~Colonic biopsies permeabilityTight junctions genes expression~Cytokines genes expression (TNFalpha, interleukines)~Cellularity on histologic sections"
2508663|NCT02840643|Experimental|Constraint Therapy and Bimanual Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy). During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
2508664|NCT02840643|Experimental|Bimanual Therapy and Constraint Therapy|Children in this arm will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Bimanual Hand Therapy (bimanual therapy), followed by 90 hours (6 hrs/day, 5 days/week, 3 weeks) of Intensive Hand Therapy (constraint therapy). During bimanual therapy, children will actively use both hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements. During constraint therapy, children will wear a mitt over their less-impaired hand and actively use their more-impaired hand in therapy. Therapy will involve playing games, practicing activities of daily living, doing arts and crafts, and practicing repetitive hand movements.
2508739|NCT02840409|Active Comparator|Arm A|68 weeks of single agent Vinblastine administered once weekly IV
2508742|NCT02840409|Experimental|Arm B|68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks.
3163869|NCT00488462|Other|Intervention|Clinics will collect data on patients experiencing shock due to obstetrical hemorrhage. In the intervention arm, half of the study clinics will use the NASG on patients before transporting to the referral hospital.
3163870|NCT00488527|Experimental|1|
3163871|NCT00488540|Active Comparator|Paracetamol (Acetaminophen)|Paracetamol (Acetaminophen) given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
2509078|NCT02838095|No Intervention|No nap|After each night with a 5-hour sleep opportunity, participants did not have a daytime nap opportunity, but instead watched documentaries.
2509084|NCT02838095|Experimental|Nap|After each night with a 5-hour sleep opportunity, participants had the chance to take a daytime nap from 14:00 to 15:00.
2509096|NCT02837588|Active Comparator|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
2509097|NCT02837588|No Intervention|CONTROL|No intervention with radiofrequency treatment, only evaluation to usual drug treatment
3163872|NCT00488540|Placebo Comparator|Placebo|Placebo given at 2 and 8 hours post birth, measurement of EDIN-Score on day one of life, measurement of stress response after Guthrie-test on day 4 of life.
3163873|NCT00488553||Cases|Participants of study with newly diagnosed lymphoma.
2509165|NCT02837068|Experimental|Wheelchair handrail compensator|When a patient sitting on the wheelchair, the physiotherapist put the paralysis upper limb on the handrail compensator and keep the limb in normal position for at least 60 minutes one day.
2509167|NCT02837068|Active Comparator|Ordinary wheelchair|When a patient sitting on the wheelchair, the paralysis upper limb was put on the ordinary handrail for at least 60 minutes one day.
2509233|NCT02836860|Other|Healthy Controls|Effects of tactile stimulation on lumbar multifidus activation in healthy adults without LBP.
2509236|NCT02836860|Other|Low Back Pain|Effects of tactile stimulation on lumbar multifidus activation in adults with LBP.
2509300|NCT02836405||Autism Spectrum Disorder (ASD)|Individuals diagnosed with an Autism Spectrum Disorder (ASD) will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
2509307|NCT02836405||Healthy Control|Typically developing individuals without a history of autism will receive transcranial magnetic stimulation (TMS) to measure brain plasticity.
2509334|NCT02835950|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
2509407|NCT02835352|Experimental|Essential oils then oil massages|Essential oils massages will be done as needed during a period of 7 days, then oïl massages as needed will be done during a follow-up period of 7 days
2509415|NCT02835352|Experimental|Oil then essential oils massages|Oil massages will be done as needed during a period of 7 days, then essential oïl massages as needed will be done during a follow-up period of 7 days
2509457|NCT02835118|Experimental|Surotomycin 0.5 g|Two oral doses of 0.25 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2509459|NCT02835118|Experimental|Surotomycin 1 g|Two oral doses of 0.5 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2509462|NCT02835118|Experimental|Surotomycin 2 g|Two oral doses of 1 g surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
2509463|NCT02835118|Placebo Comparator|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, taken at least 8 hours apart, for 14 days
3163874|NCT00488553||Control|Participants of study from matched control group.
3163875|NCT00488566|Other|Part 1|Single dose escalation
3163876|NCT00488566|Other|Part 2|Pharmacodynamic assessment
3163877|NCT00488579|Active Comparator|routine iron prophylaxis|giving 60 mg ferrous sulphate daily (+folic acid)
3196900|NCT00855348||Adults > 50 Years Scheduled for Colonscopy|Average to increased risk adults older than 50 years without symptoms indicative of CRC and designated for colonoscopy.
3196901|NCT00855361|Experimental|Rabeprazole sodium|
2508673|NCT02840630|No Intervention|Non-diabetic group|Non-diabetic volunteers will be recruited for baseline data. They will only be required to provide dried blood samples (DBS) samples and information at week 0. They have to collect finger prick DBS, weigh themselves and fill in food frequency questionnaire only at one time point.
2508675|NCT02840630|No Intervention|Diabetic control intervention group|The diabetic control group will provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16. This group will not be receiving tinned mackerel and will be asked to continue with their habitual diet and lifestyle.
2508677|NCT02840630|Active Comparator|Diabetic fish intervention group|This intervention group will receive two 125 g portion of tinned mackerel fish (containing 7.8 g n-3 LCPUFA) per week from week 0 until 16 and a mackerel recipe book each. They will be required to provide finger prick DBS at week 0, 8 and 16, fill in food frequency questionnaire at week 0 and 16 and weekly weighing from week 0 until 16.
2508763|NCT02840344|Experimental|Couples MBSR|"Young breast cancer survivors and their partners take part in an 8-week Couples Mindfulness-Based Stress reduction (C-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor and partner will be asked to watch a video module, together, each week for a total of 8 weeks. The C-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
2508765|NCT02840344|Active Comparator|Individual MBSR|"Young breast cancer survivors take part in an 8-week Individual Mindfulness-Based Stress reduction (I-MBSR) intervention. The course will be taught through recorded videos of a trained MBSR instructor. The young breast cancer survivor will be asked to watch a video module each week for 8 weeks in a row. The I-MBSR course consists of practicing mindful stress reduction techniques and filling out handouts.~Both members of the couple will be asked to complete surveys assessing primary and secondary outcome measures administered at baseline and after final session. Participants will be asked to provide a Salivary Cortisol sample at baseline and after the 8th session. Follow up Surveys will be administered at one and three months after intervention."
2508885|NCT02839512|Experimental|Jejunal to Ileal Diversion|All subjects who receive jejunal to ileal diversion endoscopic procedure
2508944|NCT02839018||Central nervous system (CNS) group|n=50 patients with presumed low prevalence of ICU-AW
2508945|NCT02839018||Severe sepsis/shock group|n=50 patients with presumed high prevalence of ICU-AW
2509008|NCT02838394|Experimental|Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be dry needled; presence of muscle twitching (which would signify appropriate needle insertion) will be documented.
2509009|NCT02838394|Sham Comparator|Sham Dry Needling|Trigger points found in the gluteal region of one side (e.g. right) will be SHAM dry needled with blunted needles, no actual penetration through the skin will occur.
3196902|NCT00855387||Costs|Patients collected consecutively for undergoing major surgical procedures(liver, bile duct, pancreas, small bowel, colo-rectal, gastric bypass resections).
3196903|NCT00855400|Experimental|Transplant|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
2509129|NCT02837458|Experimental|High-Frequency|"Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2509136|NCT02837458|Sham Comparator|Sham Stimulation|Electrodes are placed over the arm for a 30 minutes in the same manner as experimental group but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
2509178|NCT02837185|Experimental|Cervical Dystonia|'Botulinum Toxin injection' will be done and 'physiological measures' will then be collected.
2509184|NCT02837185|Other|Healthy controls|No Botulinum toxin is injected, 'physiological measures' will be collected as a healthy comparator.
2509259|NCT02836704|Active Comparator|Standard initial dose of insulin glargine|Dose 1 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
2509262|NCT02836704|Experimental|Higher initial dose of insulin glargine|Dose 2 of insulin glargine will be administered subcutaneously once a day at the same time every day. Previous non-sulfonylurea OADs (eg, metformin, acarbose) are background treatment and will be continued at the same dosage and dosing frequency as before.
2509291|NCT02836197|Experimental|Experimental group|This group of 30 physicians will immediately attend the intervention communication skills training program (experimental group).For this experimental group, the first assessment will take place before the first training session and the second recording after the last session. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
2509295|NCT02836197|No Intervention|Waiting-list group|This group of 30 physicians will attend the intervention communication skills training in a delayed manner (control group). For this control group, the first and the second recording will take place with a four-month interval. This assessment involves the analyses of communicational, physiological and psychological variables recorded in the context of an encounter with a simulated advanced stage cancer patient.
2509343|NCT02835976|Experimental|Olesoxime|Participants will receive a single dose of liquid suspension of 14C-labeled olesoxime containing an equivalent of 600 milligrams (mg) of the compound. The total amount of administered radiocarbon will be 93 microcuries (mcCi), or 3.447 megabecquerels (MBq).
3196904|NCT00855478|Experimental|1|Cypher drug-eluting stent
3196905|NCT00855491|Experimental|1. MYOPIA|axial length > 26.00 mm
3196906|NCT00855491|Active Comparator|2. Emmetropia|emmetropic eyes- eyes with an axial length of 21.00 to 23.99 mm
3196907|NCT00855504||Subjects|All the consecutive primigravidae who register in the antenatal clinic before 20 weeks of gestation
2508727|NCT02840526|Experimental|PVB group|Thoracic paravertebral blockade PVB (preoperatively) Bupivacaine WZF Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
2508733|NCT02840526|Other|GEN group|Sopodorm Propofol WZF Fentanyl WZF Nimbex Sevorane Intubation Oxynorm Ketonal Paracetamol Kabi
2508805|NCT02839759|Experimental|TELLYHealth Group|Subjects will receive the standard of care in hearing aid education and the TELLYHealth intervention for use over an 8 to12-week period and will be followed by their audiologist for 8 to 12 weeks.
2508810|NCT02839759|No Intervention|Standard of Care Group|Subjects will receive the standard of care in hearing aid education and will be followed by their audiologist for 8 to 12 weeks.
2508839|NCT02839421|Experimental|Scaling and Root Planing plus moxifloxacin|The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.The experimental treatment group consist of SRP combined with systemically administered MOX at the dosage of 400 mg once daily for 7 days.One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the MOX group will be extensively informed about the intake of the prescribed medication.
2508840|NCT02839421|Active Comparator|Scaling and Root Planing plus amox-metro|"The active comparator is Scaling and Root Planing (SRP) combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days. The active comparator group consist of SRP combined with systemically administered Amoxicillin (amox) + Metronidazole (metro) 500 mg tid each one for 7 days.~One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The adjunctive agent will start at the SRP visit. Subjects in the amox-metro group will be extensively informed about the intake of the prescribed medication."
2508841|NCT02839421|Placebo Comparator|Scaling and Root Planing plus placebo|Scaling and Root Planing (SRP) + placebo once daily for 7 days. The placebo comparator group consist of SRP combined with systemically administered placebo once daily for 7 days. One-stage full-mouth SRP under local anesthesia will be performed (using manual instruments and ultrasonic debridement) in approximately 2 h and half by the same experienced clinician.The endpoint of SRP will be a tactile smooth root surface. The placebo agent will start at the SRP visit. Subjects in the placebo group will be extensively informed about the intake of the prescribed medication.
2508861|NCT02839239|Experimental|Drops with lactobacilli and vitamin D3|Exclusive breast feeding plus L. rhamnosus 19070-2 and L. reuteri DSM 12246 in a dose of 125 x 106 CFU (both strains) with 1,667 mg fructooligosaccharides and 2,5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
2508862|NCT02839239|Placebo Comparator|Drops with vitamin D3|Exclusive breast feeding plus 2.5 mcg (100 IU) vitamin D3 (in sunflower oil) per 6 drops. One dose (6 drops) in the first morning (from 6 AM) breastfeeding, and one dose (6 drops) in one of the evening (6 PM-12 PM) breast feedings for 28 days.
2508950|NCT02839044|Experimental|Vitamin K|One group receives tablets of 360 microgram menaquinone-7 daily
2508955|NCT02839044|Placebo Comparator|Placebo|One group receives placebo tablets daily
2508977|NCT02838498|Experimental|Intensive EMS training group|"Device: ERCP mechanical simulator training EMS group was coached (by JWL) on how to use the EMS, and then practiced with supervision by a senior surgeon biliary endoscopist (WBM). Trainees practiced for a total of 20 hours performing basic maneuvers including scope insertion 2 hours, scope positioning 6 hours, selective guide wire cannulation of common bile duct (CBD) stricture or pancreatic duct (PD) 10 hours and placement of a biliary stent 2 hours.~All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over."
2508978|NCT02838498|No Intervention|Routine ERCP training group|Other: Routine ERCP training group All trainees received hands-on supervised clinical ERCP practice on patients. Time taken to perform ERCP procedures was documented. Trainees received verbal instructions, hands-on assistance from the trainer in performing the clinical procedure. If the trainee still failed after 20 minutes, the trainer took over.
2509015|NCT02838329|Active Comparator|room temperature - RT|Ropivacaine used for Epidural top-up administered at room temperature
2509019|NCT02838329|Experimental|body temperature BT|Ropivacaine used for Epidural top-up administered warmed to body temperature
3196908|NCT00855517|Experimental|Punctal Plug|
3196909|NCT00855530|Experimental|1|
2509104|NCT02837484|Other|NuTech Affinity™ Membrane|Sharp dissection of the defect will be performed being careful not to violate the subchondral bone sparing the calcified cartilage layer. After hemostasis is reached, the defect will be treated with an Affinity™ patch stabilized with fibrin glue.
2509174|NCT02837380|Experimental|FF/UMEC/VI|Subjects will receive single combination dose of FF/UMEC/VI 100/62.5/25 mcg via a DPI in the morning for 7 days.
3196910|NCT00855569||1|Each donor site will act as it own control - both dressings will be applied to the donor site and assessments will be made
2509296|NCT02836223|Experimental|Interdental device|Water Flosser
2509305|NCT02836223|Other|Toothbrush|Control
2509341|NCT02835924|Active Comparator|Arm A|160 mg/day 3w on/1w off
2509347|NCT02835924|Experimental|Arm B|120 mg/day 3w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
2509349|NCT02835924|Experimental|Arm C|160 mg/day 1w on/1w off 1st cycle; 160 mg/day 3w on/1w off 2nd cycle on
2509410|NCT02835586|Experimental|paclitaxel delivery in femoropopliteal artery|
2510420|NCT02828150|Experimental|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements
3196911|NCT00855608|Experimental|adalimumab arm|intravitreal mode of delivery
3196912|NCT00855621|Active Comparator|Single microelectrode|Surgical procedure performed using single microelectrode recording guidance intraoperatively
2508647|NCT02840903||Setting 2 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
2508648|NCT02840903||Setting 3 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2508649|NCT02840903||Setting 4 of Iopromide|Craniocervical CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
2508650|NCT02840903||Setting 5 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2508652|NCT02840903||Setting 6 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.65 ml/kg BW, tube voltage = 80 kvp
2508654|NCT02840903||Setting 7 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 3.2 ml/s, concentration of iopromide = 300 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 80 kvp
2508656|NCT02840903||Setting 8 of Iopromide|Coronary CTA under below setting: injection rate of iopromide: 4 ml/s, concentration of iopromide = 370 mgI/ml, injection dose of iopromide: 0.8 ml/kg BW, tube voltage = 100 kvp
2508699|NCT02840539|Experimental|Experimental|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim
2508753|NCT02840175|Experimental|Experimental|"Day 0 at Weeks 24 : Increase the interval between 2 doses of the biological agent (etanercept, adalimumab, tocilizumab, abatacept)~Weeks 24 at Weeks 72: Stop the biological agent if inactive disease is maintained."
2508754|NCT02840175|Active Comparator|Control|"Day 0 at Weeks 24: Maintain the biological agent (etanercept, adalimumab, tocilizumab, abatacept) at the same dose.~Weeks 24 at Weeks 48 : Increase the interval between 2 doses of the biological agent.~Weeks 48 at Weeks 72: Stop the biological agent if inactive disease is maintained."
3196913|NCT00855621|Active Comparator|Multiple microelectrode|Surgical procedure performed using multiple microelectrode recording guidance intraoperatively
3196914|NCT00855634|Active Comparator|1|"COHORT 1 (minimal metastatic disease):~Arm 1 (intervention): resection of the primary tumor, followed by resection of the liver metastasis/metastases~Arm 2 (control): exploration and/or gastroenterostomy and/or hepaticojejunostomy/choledochojejunostomy"
2508971|NCT02838797|Placebo Comparator|Placebo|"For the single ascending dose study, subjects will receive a single dose of oral acetate buffer on a single day.~For the multiple ascending dose study, subjects will receive a single daily dose of oral acetate buffer each day for 14 days."
2508975|NCT02838797|Experimental|RQ-00000010|"For the single ascending dose study, subjects will receive a single dose of either:~2 micrograms, 50 micrograms or 200 micrograms of RQ-00000010 on a single day.~For the multiple ascending dose study, subjects will receive single daily doses of either 10 micrograms, 50 micrograms or 100 vs. 200 micrograms of RQ-00000010 each day for 14 days."
2509004|NCT02838381|Other|Additional biological samples|"Additional blood samples will be realized at the inclusion of patients. Two optional blood samples could be realized if necessary with at least 3 months apart.~Peripheral Blood Mononuclear Cells (PBMC) will be collected. Tissue tumor will be collected if available."
2509076|NCT02838043|Experimental|Participant|All participants will be experimental and receive Probio'Stick.
3196915|NCT00855634|Active Comparator|2|"COHORT 2 (venous infiltration):~Arm 1 (intervention): resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV)~Arm 2 (control): resection of the primary tumor with dissection of the portal vein (and/or superior mesenteric vein/splenic vein (SMV/SV) plus tumor masses adjacent to these veins; no venous resection"
2509220|NCT02836639|Experimental|Busulfan, Etoposide, Bendamustine|All patients will receive the conditioning regimen followed by autologous stem cell transplantation.
3196916|NCT00855660|Active Comparator|Riociguat|Subjects received multiple doses of riociguat (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
3196917|NCT00855660|Placebo Comparator|Placebo|Subjects received placebo (thrice a day) with concomitant administration of ranitidine (once daily) for 14 days
3196918|NCT00855673|Experimental|Active|Active group receiving intermittent compression
3196919|NCT00855673|Active Comparator|Control|Standard Medical Treatment
2509486|NCT02834897|Experimental|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
3196920|NCT00855686|Experimental|Memantine|
2509610|NCT02834130|Other|children from 2 to 10 years with haemophilia or allied HBD, wh|
2509641|NCT02833883|Experimental|Enzalutamide plus CC-115|The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. The doses will continue to increase for every group of study participants until the maximum tolerated dose is identified. Participants at each site will participate in the dose escalation phase of the study. During the dose escalation phase, study participants will be assigned sequentially to three dose levels in groups (cohorts) of 3 to 6 subjects per dose level: Cohort 1: CC-115 at 5 mg dose twice a day & enzalutamide at 160 mg once a day. Cohort 2: CC-115 at 10 mg dose twice a day & enzalutamide at 160 mg once a day. The protocol has been amended to accrue an additional in the expansion phase treated at 7.5 mg BID. Amended to treat expansion group with 5mg BID of CC-115.
2509744|NCT02833584|Experimental|Paracetamol|Eligible patients will be randomised to receive Paracetamol prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
2509745|NCT02833584|Placebo Comparator|Placebo|Eligible patients will be randomised to receive Placebo prn for fever at maximum dosage of 500 mg PO q 4 hr (3 gm/day)
2509812|NCT02832895|Experimental|Transcranial Doppler examination|Transcranial Doppler examination
2509848|NCT02832544|Experimental|Rivaroxaban (20 mg)|Rivaroxaban 20 mg od (n ~ 2250); 15 mg od (once daily) in patients with creatinine clearance (CrCl) 15-49 ml/min
2509850|NCT02832544|Active Comparator|Vitamin K antagonists (VKA)|Any approved VKA in the participating country (n ~ 2250); VKA titrated to achieve an INR of 2.0-3.0
2509961|NCT02831517|Experimental|Part 1|48 participants: Cohorts 1,2 and 3 (Single Ascending Dose of BIIB074 or placebo) in a 6:2 ratio
3196921|NCT00855686|Placebo Comparator|Placebo|
3196922|NCT00855712|Experimental|Organ Care System|
2508680|NCT02840773|Active Comparator|Test group-12 month|Press-fit implant connection was monitored at 12 month after prosthesis delivered.
2508683|NCT02840773|Active Comparator|Control group-baseline|Screw-retained connection was monitored at baseline
2508686|NCT02840773|Active Comparator|Control group-12 month|Screw-retained connection was monitored at 12 month after prosthesis delivered.
2508745|NCT02840188||Radius tilt angle|Children 0-16 years of age positive for distal forearm fracture and positive history of goalkeeper's fracture (to catch a ball).
2508748|NCT02840188||Normal control group|Children 0-16 years of age without radius fracture and no history of catching a ball.
2508776|NCT02839915|Experimental|Folinic Acid|Subjects randomized to receive Folinic Acid will take Liquid levo-leucovorin via oral route. The target dose is 1 mg/kg/day with a maximum of 25 mg/day, divided in two daily doses. A two- to four-week supply of 15 ml vials will be dispensed in line with the visit schedule. With the exception of children in the lowest weight group (≥ 15 - < 20 kg) from days 1-14, parents will administer the prescribed dose twice a day at the same time each day.
2508778|NCT02839915|Placebo Comparator|Placebo Control|Subjects randomized to receive placebo will take placebo twice a day (Exception: children in the lowest weight group ( ≥ 15 - < 20 kg) will start once a day for Days1-13). The pattern of dose escalation will be the same as the active compound. After 12 weeks, the blind will not be broken and subjects will be offered treatment for a 12-week open-label extension phase.
2508831|NCT02839564|Experimental|Adhesiolysis group|Patients underwent laparoscopic adhesiolysis
2508832|NCT02839564|Placebo Comparator|Placebo group|Patients underwent diagnostic laparoscopy alone
2508876|NCT02839304|Experimental|Catheter Ablation Treatment|Cryoablation System: Atrial Fibrillation Ablation
2508936|NCT02838979|Experimental|Oral L-Glutamine (0.4mg/kg/day)|Subjects will receive 0.4 g/kg/day of L-glutamine (Nutrestore, EMMAUS Life Sciences, Inc Torrance, CA) in three divided daily doses. Duration 2 weeks
2508939|NCT02838979|Placebo Comparator|Maltodextrin|Identical appearing maltodextrin powder.
2508983|NCT02838589|Active Comparator|Byetta|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2508984|NCT02838589|Placebo Comparator|Isotonic saline|"Pre- and post treatment investigations:~Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler~Cerebral cortical oxygination by near infrared spectroscopy (NIRS)~Endothelial function/response by the methods:~Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA)~EndoPAT2000~Ankle-brachial index"
2509081|NCT02838004|Experimental|Single arm receiving Mini WELL Ready IOL|IOL implantation for cataract
2509110|NCT02837601|Other|LOW AIS Pressure AirSeal®|AIS with an insufflation pressure target of 9mmHg ±1mmHg
2509112|NCT02837601|Other|HIGH AIS Pressure AirSeal®|AIS with an insufflation pressure target of 15mmHg ±1mm
2509176|NCT02837289|Other|Treatment|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
2509182|NCT02837289|Other|Placebo|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
2509242|NCT02836743|Experimental|Circadin 2mg|low-dose (2mg) slow-release melatonin for 1 month.
2509246|NCT02836743|Experimental|Circadin 6mg|high-dose (6mg) slow-release melatonin for 1 month.
2509250|NCT02836743|Placebo Comparator|Placebo|Administer placebo pills with identical morphology
2509299|NCT02836275|Experimental|Perfusion and diffusion-weighted MRI|
2509404|NCT02835612|Experimental|Early stimulation|skin-to skin care by mother (kangaroo care) plus massage therapy by mothers.
2509416|NCT02835612|Active Comparator|Conventional care|skin-to skin care by mother (kangaroo care).
2509451|NCT02835105|Experimental|Surotomycin 0.5 g|A single oral dose of 0.5 g surotomycin in hard gelatin capsules
2509453|NCT02835105|Experimental|Surotomycin 1 g|A single oral dose of 1 g surotomycin in hard gelatin capsules
2509455|NCT02835105|Experimental|Surotomycin 2 g|A single oral dose of 2 g surotomycin in hard gelatin capsules
2509456|NCT02835105|Experimental|Surotomycin 4 g|A single oral dose of 4 g surotomycin in hard gelatin capsules
2509460|NCT02835105|Placebo Comparator|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
3196923|NCT00855712|Active Comparator|Cold cardioplegia solution|
3196924|NCT00855764|Experimental|Paclitaxel|
2509561|NCT02834182|Experimental|Bipolar Disorder patients and Schizophrenic patients|
2509568|NCT02834182|Active Comparator|Healthy Controls|
3196925|NCT00855777|Experimental|Etoricoxib|Etoricoxib 120 mg/day x 3 days
2509771|NCT02833038|Experimental|Magnesium group|Intravenous administration of Magnesium Sulfate
2509776|NCT02833038|Placebo Comparator|Control group|Intravenous administration of normal saline
2509828|NCT02832713|Experimental|Intra-articular injection of botulinum toxin A|
2509830|NCT02832713|Active Comparator|Intra-articular injection of hyaluronic acid|
2509865|NCT02832388||Primary aldosteronism patients for cardiac MRI|A subgroup of primary aldosteronism (PA) patients perform a cardiac MRI, including stress-testing with adenosine, and are compared to a sex- and age-matched group of healthy controls who perform the same MRI procedure
2509867|NCT02832388||Healthy controls|Healthy controls that are age-and sex-matched to the subgroup of PA patients performing cardiac MRI, perform MRI including adenosine as stress-test.
2509868|NCT02832388||Primary aldosteronism patients diagnosed from 2013 onwards|"All PA patients diagnosed or subtyped at Haukeland University from 2013 onwards are asked for inclusion in the main observational PA-study.~From 2020 onwards, PA patients diagnosed or subtyped at Oslo University hospital will also be included."
3196926|NCT00855777|Active Comparator|Ibuprofen|Ibuprofen 1800 mg/day x 3 days
3196927|NCT00855790|Active Comparator|RJ3 Biopsy Forcep|use of RJ3 Biopsy forcep for the polypectomy
3196928|NCT00855790|Active Comparator|RJ4 Biopsey Forcep|Use of RJ$ biopsy forcep for polypectomy
3196929|NCT00855803|Experimental|Group 1 radiation|"Intervention:~Patients had prior radiotherapy will undergo 5 fractions of stereotactic body radiotherapy (SBRT) over 30-90 minutes each."
2508724|NCT02840305|Other|Expérience 2|Brain bases of Computer to Film (CtF) analysis 30 young adults, 20 old adults
2508729|NCT02840305|Other|Expérience 3|Part of parahippocampal gyrus in Computer to Film (CtF) analysis 30 young adults, 20 old adults.
2508774|NCT02839928|Experimental|Treatment|The experimental arm consists of children given intranasal Ketamine 1 mg/kg, once
2508871|NCT02839317||Biological in pediatric CD|75 pediatric-onset CD Biological
2508877|NCT02839317||Biological in pediatric controls|75 pediatric controls matched on gender, age and area of residence Biological
2508882|NCT02839317||Biological in elderly CD|75 elderly-onset CD Biological
2508886|NCT02839317||Biological in elderly controls|75 elderly controls matched on gender, age and area of residence Biological
2508949|NCT02838771|Experimental|Research group participants|"Research group consisted of 171 elderly nursing home residents and 82 outpatients of the Hospital of Lithuanian University of Health Sciences.~The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening)."
2508954|NCT02838771|Other|Control group participants|Community-dwelling elderly healthy individuals. The participants were given the dysphagia screening questionnaire, consisted of 16 questions and the several sips of water to drink (clinical water drinking test for dysphagia screening).
2509077|NCT02838173|Experimental|SPB|Serratus Plane Bloc with Ropivacaine 2mg/ml (0,3ml/kg) and tissue infiltration with placebo made once, by the anesthetist in the operating theater before surgical incision
2509079|NCT02838173|Active Comparator|tissue infiltration|tissue infiltration with Ropivacaine 2mg/ml (0,3ml/kg) and Serratus Plane Bloc with placebo made once, by the anesthetist in the operating theater before surgical incision
2509122|NCT02837510|Other|Standard smoking cessation counseling|Participants will receive a standard treatment program consisting of smoking cessation counseling.
2509166|NCT02837224||Preimplementation: Situate Locate System|Subjects/surgeries performed before implementation of the Situate Detection System.
2509171|NCT02837224||Implementation|Subjects/surgeries performed after implementation of the Situate Detection System.
2509279|NCT02836210|Active Comparator|Angled incision|Patients in this arm will undergo 27-gauge vitrectomy wound construction using angled (tunnel-like) incisions for trocar entry.
2509282|NCT02836210|Active Comparator|Straight Incision|Patients in this arm undergo 27-gauge vitrectomy wound construction using straight (perpendicular) incisions for trocar entry.
2509362|NCT02836093||evaluations/assessments|
2509471|NCT02835014||Adolescents with T1DM|Adolescents with type I Diabetes Mellitus diagnosed for at least one year will be screened for mental health symptoms with the PHQ9, SCARED and UCLA PTSD. Self-efficacy regarding self-care and diabetes management will be assessed by using the SEDM. Parenting styles will be assessed by administering the Parenting Styles and Dimensions Questionnaire (PSDQ).
2509520|NCT02834572|Experimental|All About Me|assessment and algorithm to provide participants with a tailored recommendation of their optimal HIV testing approach
2509525|NCT02834572|Active Comparator|Control|HIV testing information
3196930|NCT00855803|Experimental|Group 2 radiation|"Intervention:~Patients has no prior radiotherapy will undergo 1 fraction of SBRT over 30-90 minutes."
3196931|NCT00855829|Active Comparator|Miniature Actilady device active|one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
2509709|NCT02833506|Active Comparator|Cohort I (NY-ESO-1 protein with MIS416)|Patients receive NY-ESO-1 protein with MIS416 vaccine SC on days 1, 15, 29, 57, 85, and 113 in the absence of disease progression or toxicity.
2509712|NCT02833506|Experimental|Cohort II (NY-ESO-1 protein with MIS416, sirolimus)|Patients receive NY-ESO-1 protein with MIS416 vaccine as in Cohort I. Patients also receive sirolimus PO daily for 2 weeks followed by 2 weeks off starting on days 1, 29, 57, and 85.
2509802|NCT02832999|Experimental|sub cutaneous liraglutide|once daily add-on subcutaneous injection of Liraglutide at 0.6mg/day for 1 week increased to 1.2mg the second week
2509806|NCT02832999|Active Comparator|Oral Vildagliptin|Once daily oral 100mg of Vildagliptine for two weeks
2509879|NCT02832505||Non-CKD (Control)|"Patients without CKD (eGFR ≥ 60 ml/min/1.73 mm2) (non-CKD controls).~No intervention but only observational."
2509882|NCT02832505||CKD (chronic kidney disease)|"Patients with Patients with moderate to severe CKD (eGFR ranging from 26 to 44 ml/min/1.73 mm2).~No intervention but only observational."
2509885|NCT02832505||ESRD (end-stage renal disease)|"Patients with advanced CKD (eGFR < 15 ml/min/1.73 mm2), preparing for or undergoing the standard thrice-weekly HD or standard PD treatment (end-stage renal disease (ESRD) patients).~No intervention but only observational."
2509931|NCT02832011|Active Comparator|olive oil|After randomization, Investigators will give human milk fortiﬁed with olive oil
2509941|NCT02832011|Active Comparator|Eoprotin|After randomization, Human milk fortiﬁed with Eoprotin according to the recommendations of the manufacturer (1g per 30ml milk)
2509964|NCT02831595||Patients undergoing unilateral TKA|
2510007|NCT02831426|Active Comparator|ADM two-stage reconstruction|Two-stage with Acellular Dermal Matrix (CELLIS® Breast). Tissue Expander A, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by ADM
2510008|NCT02831426|Experimental|TCPM two-stage reconstruction|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra). Tissue Expander B, Pre-pectoral, subcutaneous, two-stage reconstruction by means of TE supported by TCPM
3196932|NCT00855829|Sham Comparator|Miniature Actilady device not active|Sham Comparator: one miniature Actilady device tested for all patients during a 4 months period. The device is active in 3 months out of the 4, and the patients are blinded to the action of the device (sham comparator).
3196933|NCT00855855||Hib vaccine|Participants has received at least one dose of an Hib vaccine
3196934|NCT00855881|Experimental|Treatment arm|Treated with tegafur-uracil for 1 year
2508728|NCT02840734|Experimental|Kinesio taping|All subjects wore an eye mask and the taped leg was covered by clothes for preventing subjects and researchers from identifying different tapings due to double-blinding. Subjects layed down on the mat in a supine position with the hip flexed 30º and the knee flexed 60º. Y type tape was applied from a point 10 cm below the anterior superior iliac spine, bisected at the junction between quadriceps femoris tendon and the patella, ending at its inferior side. And another Y type tape was applied from the tibial tuberosity, bisected at the junction between patella tendon and the patella, ending at its superior side. The first 5 cm tape was not stretched and acted as the anchor. I type tapes were applied downward and inward to the superior and inferior meniscus of the patella respectively.
2508732|NCT02840734|Placebo Comparator|Placebo taping|Placebo tapes (3M tape) were applied with same method with Kinesio taping.
2508735|NCT02840734|No Intervention|No taping|In case of the no taping condition, the subject was treated along the same procedure which was closed subject's eyes with eye mask and covered the legs with clothes although applied anything on their legs. It might be able to minimize the error, because the researchers did not realize which condition the subject had.
2508820|NCT02839642|Active Comparator|Rivastigmine|"Subject will receive a treatment of Rivastigmine twice daily during 24 weeks of treatment.~Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit"
2508825|NCT02839642|Placebo Comparator|Placebo|Subject will receive a placebo twice daily during 24 weeks of treatment. Study drug will be administered orally. Sufficient test drug will be dispensed to subjects or their caregivers at each study visit to allow twice daily dosing until the next scheduled study visit
3196935|NCT00855907||cases|IBD patients above the age of 18 years old, suffering from the disease for at least one year.
3196936|NCT00855985|Active Comparator|1|Pancreaticojejunostomy for reconstruction after pancreaticoduodenectomy
3196937|NCT00855985|Active Comparator|2|Pancreaticogastrostomy for reconstruction after pancreaticoduodenectomy
3196938|NCT00855998||1|With BRCA1 or BRCA2 mutations
2509021|NCT02838290|Experimental|Induction|
2509028|NCT02838290|Other|Control group|
2509088|NCT02837991|Experimental|CDX-014|"During the treatment phase of the study, patients will receive CDX-014 treatment every 3 weeks (RCC or OCCC) or every 2 weeks (RCC) as long as they remain eligible. Patients may be discontinued from CDX-014 treatment based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~The planned dose of CDX-014 depends on the cohort assigned at enrollment."
2509095|NCT02837549|Experimental|Occupational therapy treatment|"Participants will undergo the following as appropriate:~Thermal Modalities Hot packs, focused on areas with limitations Paraffin, focused on digital limitations~Application of the Physiotouch (a low-intensity negative pressure device)~Passive Range of Motion~Active Range of Motion~Functional Activities"
2509163|NCT02837016|Experimental|Experimental 1|Wearable biofeedback device + Relaxation Training
2509169|NCT02837016|Active Comparator|Experimental 2|Relaxation Training only
2509269|NCT02836899|Placebo Comparator|Control|Inhaled nitrogen will be administered via the cardiopulmonary bypass (CPB) machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the Intensive Care Unit (ICU). Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours.
2509271|NCT02836899|Experimental|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Once patients are extubated they will breathe test gas via a facemask or nasal cannula. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
3196939|NCT00855998||2|Without BRCA1 or BRCA2 mutations
3196940|NCT00856011||1|Diabetic patients with carpal tunnel syndrome
2509515|NCT02835287|Experimental|Protocol-based Integrated Care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by care team (trained primary care physicians, health managers, and nurses supported by diabetes specialists) and assisted by a clinical decision support systems.
2509521|NCT02835287|Active Comparator|Enhanced Control|A usual team-based care delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
2509597|NCT02834377|Experimental|Treatment algorithm|Patients allocated to the study group will be connected to a cardiac output monitor. An initial haemodynamic assessment will be performed at the beginning of surgery and at regular time intervals (every 15 minutes) during surgery. The personal cardiac output value is targeted.
2509598|NCT02834377|No Intervention|Standard of Care|Patients allocated to the control group will receive the standard care of the hospital.
2509626|NCT02833896||endometrial cancer|
2509627|NCT02833896||Control|
2509808|NCT02833168||1|Patients with proven neuromuscular disorders known to be potentially associated with significant diaphragmatic weakness, e. g. ALS, myotonic dystrophy type 1, limb-girdle muscular dystrophy, Duchenne and Becker muscular dystrophy. Patients already receiving home ventilatory support will not be included in the study.
2509810|NCT02833168||2|Patient with proven obstructive sleep apnea syndrome prior to CPAP initiation.
2509811|NCT02833168||3|Patients with sleep disorders other than sleep-related breathing disorders, e. g. narcolepsy, hypersomnia, parasomnia or sleep-related movement disorders.
2509887|NCT02832401|Active Comparator|Caffeine|200 mg of caffeine powder administered in capsules
2509889|NCT02832401|Placebo Comparator|Placebo|Cellulose powder administered in capsules
3196941|NCT00856011||2|Non-diabetic patients with carpal tunnel syndrome
2508734|NCT02840487|Experimental|Group 1|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 8.
2508738|NCT02840487|Experimental|Group 2|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0 and Week 12.
2508743|NCT02840487|Experimental|Group 3|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0, Week 4 and Week 8.
2508746|NCT02840487|Experimental|Group 4|ZIKV DNA vaccine administered IM at a dosage of 4mg, as two 0.5ml injections on Day 0,Week 4 and Week 20.
2508967|NCT02839083|Placebo Comparator|Thoracic Paravertebral group|Ultrasound guided thoracic paravertebral block
2508970|NCT02839083|Active Comparator|Pecs II group|Ultrasound guided Pecs II block
2509103|NCT02837705||carriers of a mutation in the Prion gene|Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status.
2509105|NCT02837705||family members of carriers of a mutation in the Prion gene|Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
2509190|NCT02837315|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS was described to participants as the College Adjustment Session and the session was conducted using an MI plus personalized feedback approach."
2509193|NCT02837315|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce marijuana use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students were asked about their reaction to the relaxation techniques and were provided with relaxation training handouts.
2509195|NCT02837315|No Intervention|Assessment|Participants fill out a battery of measures and receive no intervention.
2509379|NCT02835729|Experimental|Phase 1a|"Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (freebase formulation). These patients will additionally receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.~All current subjects will transition from indoximod freebase capsules over to indoximod HCL F2 tablets. All new subjects enrolled will also receive indoximod HCL F2 tablets."
2509381|NCT02835729|Experimental|Phase 1b (CLOSED TO ACCRUAL)|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy (7+3) with Indoximod (HCL F1 formulation). These patients will receive maintenance therapy with indoximod for 6 months after consolidation therapy. The indoximod dose will be studied in up to 4 dose levels.
2509399|NCT02835326|Experimental|Exercise and Dietary Weight Loss|For the first 6 months, participants will meet at a community center for 3 group-based sessions and 1 individual session each month. Sessions include a 45 minute exercise component and a 45 minute dietary weight loss component. Exercise will consist of progressive aerobic and strength training. The dietary component will focus on decreasing caloric intake, while being nutritionally safe. All diets will be monitored by a Registered Dietitian. During months 7-12, participants will meet for 1 group session and 1 individual session per month. The final 12-24 months, bimonthly phone calls are provided to the participants to aid in retention efforts.
2509405|NCT02835326|Active Comparator|Walk with Ease|The Arthritis Foundation's (AF) WWE is a self-management program for symptoms of arthritis (pain, fatigue, stiffness,etc.) through exercise. It is a 6 week program involving 3 sessions per week each lasting about 60 minutes. The WWE sessions are comprised of walking, stretching and strengthening exercises, and health education lectures. These group classes will be lead by an AF instructor. Each participant will complete 2 consecutive WWE classes for a total of 12 weeks in the program. During the final week of the program, participants will be trained and transitioin to the self-directed version of WWE for maintenance of exercise. To aid in retention efforts, phone contacts are provided to participants on a monthly basis from 4-12 months and bi-monthly from 12 to 24 months
3163878|NCT00488579|Active Comparator|screening and therapy|doing Hb measurement on each visit, Hb>9g/dl giving only folic acid, Hb<9g/dl giving 60-120 mg of ferrous sulphate daily (+folic acid)
3163879|NCT00488605|Active Comparator|Treatment Arm A|
2509509|NCT02834585||Ultrasound|Patients undergoing Ultrasound
3163880|NCT00488605|Experimental|Treatment Arm B|
3163881|NCT00488657|Experimental|1|In the ear device to provide altered auditory feedback
3163882|NCT00488696|Experimental|Interventional|Endovascular Bifurcated Stent Graft: The investigational operation involves placing a stent-graft over the aortic aneurysm.
3163883|NCT00488748|Experimental|MST|Magnetic Seizure Therapy (MST)
3163884|NCT00488748|Active Comparator|ECT|Electroconvulsive Therapy (ECT)
3163885|NCT00488787|Experimental|A|Intranasal ketamine low dose
3163886|NCT00488787|Experimental|B|intranasal ketamine medium dose
3163887|NCT00488787|Experimental|C|intranasal ketamine high dose
3163888|NCT00488787|Placebo Comparator|D|placebo
3163889|NCT00488839|Other|IPX056 20 mg - OLE|A single dose of IPX056 20 mg, Placebo IPX056 40 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3163890|NCT00488839|Other|IPX056 40 mg - OLE|A single dose of IPX056 40 mg, Placebo IPX056 20 mg and Placebo Baclofen Tablet (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3163891|NCT00488839|Other|Baclofen 20 mg - OLE|A single dose of Encapsulated Baclofen 20 mg, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design, IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3163892|NCT00488839|Other|Placebo - OLE|A single dose of Placebo Baclofen Tablet, Placebo IPX056 20 mg and Placebo IPX056 40 mg (Part 1), 9 week Open label extension of IPX056 (flexible dose design,IPX056 10 mg, IPX056 20 mg, IPX056 30 mg, IPX056 35 mg, or IPX056 40 mg)
3196942|NCT00856037|Experimental|Treatment (doxorubicin hydrochloride, topotecan hydrochloride)|Patients receive doxorubicin hydrochloride IV over 3-5 minutes on day 6 of course 1 and on days 6, 13, and 20 of courses 2-5. Patients also receive topotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
3196943|NCT00856076||VTE case group 1/2|Women with first time venous thromboembolism in pregnancy. VTE data validated from medical records.
2508878|NCT02839486||vancomycin and cefoxitin pharmacokinetics|This is surgical prophylaxis and cefoxitin/vancomycin have to be administered to each patient of the study, before surgery
2508928|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 1|1 can per day for 5 days prior to surgery
2508929|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 2|2 cans per day for 5 days prior to surgery
2508930|NCT02838966|Active Comparator|Nestle IMPACT Advanced Recovery 3|3 cans per day for 5 days prior to surgery
2508933|NCT02838966|Active Comparator|Nestle Boost High Protein Drink - Control Arm|4 cans per day for 5 days prior to surgery
2509003|NCT02838602|Experimental|Carbon ions therapy|Radical and exclusive carbon ions radiotherapy
2509006|NCT02838602|Active Comparator|Conventional radiotherapy|Radical radiotherapy by Xrays and / or protons
2509091|NCT02837822|Active Comparator|Stimulation Off|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn Off during the experiment."
2509092|NCT02837822|Active Comparator|Stimulation On|"Patients receiving the intervention implantation with a spinal cord stimulator. The system is turn On during the experiment."
2509132|NCT02837471|Experimental|Intervention group, PiezoRx device|Participants will use the PiezoRx pedometer at leisure for 12 weeks, and receive the standard care of the FrancoForme cardiac prevention and rehabilitation program.
2509138|NCT02837471|No Intervention|Control group, Standard care|Participants will receive the standard care of the FrancoForme Cardiovascular disease prevention and rehabilitation program.
2509155|NCT02837159|Experimental|mHealth application|The assessment of the end points will be made at three moments: at baseline, at 8 weeks (at the end of the program) and at 12 months of follow-up. The intervention will consist in: 1)Feedback daily or weekly of physical exercise and diet through the application (notice) according to the records of diet and exercise and following recommendations of International Organizations 2) Participation in three sessions of seminars (1 hour each every 15 days) on habits of life healthy and cancer and the self-regulation through measurements performed by the application 3) Calls weekly to the patients of way individual to comment possible errors or doubts about the application, of 10 min of duration (8 calls).
2509159|NCT02837159|No Intervention|Usual care|Usual care
2509209|NCT02836964|Active Comparator|Loading of Dental Implants after 4 weeks|"A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar. for this group.~After 4 weeks definitive crown will be placed."
2509210|NCT02836964|Active Comparator|Loading of Dental Implants after 3 months|A total of 12 titanium implants with a modified SLA surface (BLT SLActive®, Institute Straumann AG, Basel, Switzerland) will be placed in the mandibular first molar for this group. After 3 months definitive crown will be placed
2509229|NCT02836587|Experimental|interventional|Experimental group will undergo balance training for 8 weeks.
2509232|NCT02836587|No Intervention|control|Control group will have no assigned intervention.
2509314|NCT02836158|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
2509339|NCT02835898||Test Group|Patients with periodontal disease that need conventional periodontal treatment
2509346|NCT02835898||Control Group|Periodontally-healthy individuals.
3196944|NCT00856076||VTE control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
3196945|NCT00856076||VTE control group 2|Randomly drawn from group 1 (using the Norwegian Birth Registry), but matched for time of delivery. Without history of venous thromboembolism, and with validated data from medical records.
3196946|NCT00856076||VTE case group 3|Subjects from VTE case group 1/2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3196947|NCT00856076||VTE control group 3|Subjects from VTE control group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3196948|NCT00856076||IUFD group 1|Women who have experienced IUFD - data verified from medical records.
2509988|NCT02831504||Myotonic Dystrophy type 1 (DM1) patients|Natural History Study
2510033|NCT02831335||Group 1|normal 21-35 years old participants
3196949|NCT00856076||IUFD group 2|Subjects from IUFD group 2 invited to meet for investigation, donation of biological material and to answer a questionnaire.
3196950|NCT00856076||IUFD control group 1|All pregnancies of source population - clinical data from the Norwegian Birth Registry and the Norwegian Patient Registry.
3196951|NCT00856076||IUFD control group 2|Subjects from VTE control group 1/2 with validated data from medical records.
3196952|NCT00856076||IUFD control group 3|Subjects from VTE control group 3 invited to answer a disease specific questionnaire for IUFD.
3196953|NCT00856089|Experimental|Retapamulin|
3196954|NCT00856102|Experimental|Exercise|
3196955|NCT00856102|No Intervention|Control|
3196956|NCT00856115||African American Female|
3196957|NCT00856115||African American Male|
3196958|NCT00856115||Caucasian Female|
3196959|NCT00856115||Caucasian Male|
3196960|NCT00856141|Experimental|1. High fluidic parameters|Bottle height varied from 90-110cms, fixed aspiration flow rate 40cc/min, vacuum upto 650mmHg depending on the grade of cataract
3196961|NCT00856141|Active Comparator|2. Low fluidic parameters|Bottle height varied from 70-90cms, fixed aspiration flow rate of 25cc/min, vacuum upto 400mmHg, depending on the grade of cataract
3196962|NCT00856167|Active Comparator|TCM|Whole systems traditional Chinese medicine, including individually tailored herbal formulas, acupuncture, tuna (Chinese massage), lifestyle recommendations
3196963|NCT00856167|Active Comparator|Self-care|Self-care for TMD developed by Dworkin, LeResche et al.
3196964|NCT00856219|Active Comparator|Enteral Continuous|Continuous tube feeding for 72 hours.
2508769|NCT02840006|Active Comparator|General anesthesia associated spinal anesthesia|spinal anesthesia using bupivacaine 0,5% hyperbaric 20 mg, morphine 200 mcg, set trendeleburg for 10 minutes, sensitive test in T1. Anesthetic induction with etomidate 0,3 a 0,4 mg.kg-1, citrate fentanyl 5 mcg.kg-1 and atracurium 0,5.kg-1.
2508786|NCT02839694|Experimental|Dose escalation cohort|dose escalation cohort
2508792|NCT02839694|Experimental|Expansion cohort|expansion cohort at MTD
2508793|NCT02839694|Active Comparator|expansion cohort with celecoxib|expansion cohort at MTD with celecoxib
2508855|NCT02839356|Experimental|Drug: epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
2508856|NCT02839356|Placebo Comparator|Drug: normal saline|20-mL irrigation with physiological saline over the entire papilla
2508906|NCT02839122|Experimental|Dutasteride, Tadalafil|
2508908|NCT02839122|Experimental|Tadalafil, Dutasteride|
2508922|NCT02838810|Experimental|Experimental|CHB patients with low level HBsAg.Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1000 IU/mL and Hepatitis B virus DNA <100 IU/mL, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. The longest course of treatment is 96 weeks. After treatment, patients will be followed up for 24 weeks. During the 96 weeks course of treatment, HBsAg level will be monitored. When HBsAg level is less than 0.05 IU/mL, peginterferon treatment will be stopped and patients will receive 24 weeks follow up.
2508923|NCT02838810|Other|Control|Patients do not need to change their NAs treatment.
2508969|NCT02838706||Elderly with hip fracture|The subjects are patients age ≥ 65 years requiring surgery for a hip fracture
2508979|NCT02838446|Experimental|Cognitive Therapy|Graded motor imagery program was applied in only intervention group for 8 weeks.
2508980|NCT02838446|Active Comparator|Control|Rehabilitation program applied in both groups for 8 weeks. Frequency of the treatment was 2 days in per week and its duration was approximately one hour in one session.
2509017|NCT02838303|Other|Group A|Initial spray session: organophosphate. Crossover spray session: placebo
2509022|NCT02838303|Other|Group B|Initial spray session: placebo. Crossover spray session: organophosphate
2509044|NCT02837926|Experimental|women attending for cervical cancer screening|
2509101|NCT02837809|Experimental|Intervention|Low Dose CT, annual or biennial, associated with primary prevention and pulmonary function test evaluation.
2509102|NCT02837809|No Intervention|Control|Program of primary prevention with pulmonary function test evaluation
2509152|NCT02837393||History of Kidney Stones|Participants with a history of kidney stones who will be undergoing kidney surgery.
2509153|NCT02837393||No History of Kidney Stones|Participants without a history of kidney stones who will be undergoing kidney surgery.
3163893|NCT00488878||Observational (electronic health record review)|Patients' medical records are reviewed for retrospective and prospective data collection. Patients may also have residual tissue samples collected and stored.
2509572|NCT02834351|Active Comparator|Peripheral artery diseased group|pad Patients referred for femoro popliteal bypass Muscle biopsy during surgery
2509582|NCT02834351|Sham Comparator|Cardiac group|Patients referred for saphenous withdrawal for coronary bypass Muscle biopsy during surgery
2509631|NCT02834052|Experimental|Phase 1|"This Run In phase is aimed to determine if poly-ICLC can be safely combined with standard dosages of pembrolizumab:~i. Pembrolizumab will be administered 200 mg intravenously (IV) every 3 weeks (q3w)~ii. Poly-ICLC will be administered intramuscularly (IM) twice weekly at one of two dose levels: 1 mg or 2 mg~Each dose level will enroll 3-6 participants, up to 12 participants total, depending on the occurrence of dose limiting toxicities (DLT) at each dosing level.~Participants may receive treatment for 1 year (~17 cycles)."
2509634|NCT02834052|Experimental|Phase 2|"In Phase 2, all participants will receive the standard pembrolizumab dose (200 mg IV q3w) in addition to the maximum tolerated dose of poly-ICLC (either 1 mg or 2 mg), as determined by the Phase 1 arm.~Up to 30 participants will be treated in Phase 2. Participants may receive treatment for 1 year (~17 cycles)."
2509688|NCT02833558|Experimental|PuraStat®|Interventional arm: PuraStat® applied through a catheter delivery system via the endoscope is used to stop bleeding during ESD.
2509691|NCT02833558|Other|Standard Electrocautery|Control arm where standard electrocautery delivered via the endoscopic knife tip or coag grasper is used to achieve haemostasis during ESD
2509814|NCT02832869|Experimental|short message service|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
2509818|NCT02832869|Experimental|Wechat|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
3163894|NCT00488891||Paliperidone extended release (ER)|Drug: Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
3163895|NCT00488891||Atypical antipsychotics agent (AAP)|AAP includes quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
3163896|NCT00488904|Experimental|a|
3163897|NCT00488904|Placebo Comparator|b|
3163898|NCT00488969|Active Comparator|Modified-release morphine then Placebo|up to a ceiling dose of 120 mg
3163899|NCT00488969|Placebo Comparator|Placebo then modified-release morphine|Matching placebo
3163900|NCT00489008|Experimental|Cohort 1|Stereotactic Body Radiation Therapy (SBRT) Stage I NSCLC
3163901|NCT00489008|Experimental|Cohort 2|Stereotactic Body Radiation Therapy (SBRT) Selective Stage II NSCLC
3163902|NCT00489008|Experimental|Cohort 3|Stereotactic Body Radiation Therapy (SBRT) Isolated Peripheral Lung Recurrent NSCLC
2508789|NCT02839967|Experimental|Photobiomodulation group|For the purposes of photobiomodulation is used a portable cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), and 1 905 nm diode LASER, 4 875 nm LED diodes and 4 670 nm diodes LED, 4 cm2 beam, emitting an energy of 39.27 J.
2508790|NCT02839967|Placebo Comparator|Photobiomodulation placebo group|"To provide the blinding of the participants of the study we will use two identical photobiomodulation equipment supplied by the manufacturer, being an active and another a placebo, but both have identical light and sound device (do not send energy and heat, non-coherent light without biological effect). The devices are named in X and Y for a researcher who does not participate in treatment and assessments."
2508830|NCT02839525|Placebo Comparator|Omega 3|"3000mg of olive oil~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2508833|NCT02839525|Placebo Comparator|Isolate whey protein|"23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2508836|NCT02839525|Placebo Comparator|Omega 3 and Isolate whey protein|"3000mg of olive oil and 23g of maltodextrin~Eccentric exercise: 100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series"
2508901|NCT02839278|Experimental|Immune-mediated inflammatory disease|Patients with an immune-mediated inflammatory disease. A blood sample is achieved at T0 (no follow-up).
2508959|NCT02838927||Hypoparathyroidism|No intervention.
2509059|NCT02838121|Experimental|Aclasta|Aclasta IV once annual for 2 years
2509062|NCT02838121|Placebo Comparator|Placebo|Placebo group
2509119|NCT02837692|Experimental|Cohort 1|Participants assigned to Cohort 1 group A (elderly non-Asian), group B (young healthy non-Asian) and group C (healthy Japanese) will receive JNJ-42847922 10 mg, 3 hours after completing dinner.
2509120|NCT02837692|Experimental|Cohort 2|Participants assigned to Cohort 2 group A, group B and group C will receive JNJ-42847922 20 mg, 3 hours after completing dinner.
2509124|NCT02837692|Experimental|Cohort 3|Participants assigned to Cohort 3 group A and group C will receive JNJ-42847922 40 mg, 3 hours after completing dinner. Participants in group B will receive JNJ-42847922 40 mg, 3 hours after completing dinner in Period 1, followed by at least 7 days washout period, further followed by JNJ-42847922 40 mg, immediately after completing dinner.
2509131|NCT02837692|Experimental|Cohort 4|Participants assigned to Cohort 4 group B will receive JNJ-42847922 60 or 80 mg, 3 hours after completing dinner.
2509162|NCT02837133|Experimental|other techniques group|theory and practice of pair massage with tapping, stretching of the ankle and neck, and autogenic training
2509206|NCT02836977|Experimental|maintenance therapy|Patients will receive oral tegafur-uracil 400mg/day (100mg/Cap., 2 capsules each time, twice a day), combined with oral folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day), and continue for one year.
2509208|NCT02836977|Active Comparator|observation arm|Patients will be observed following adjuvant oxaliplatin-based regimen.
2509301|NCT02836470|Experimental|LB1148|Active
2509306|NCT02836470|Placebo Comparator|Placebo|Placebo
2509369|NCT02835768|Experimental|Intervention|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Participants will be given an additional leaflet about the domestic safety website with address link and brief introductory information.
2509373|NCT02835768|No Intervention|Control|Each participant will be provided an information package - the parenting booklet from Maternal and Child Health Centres (MCHCs) about domestic safety tips. Only this booklet serves as the anticipatory guidance to mothers about domestic safety.
2509408|NCT02835508|Experimental|Treatment A|Participants will receive a single dose of 1 tablet of JNJ-56021927, 60 milligram (mg) on Day 1.
2509419|NCT02835508|Experimental|Treatment B|Participants will receive a single dose of JNJ-56021927, 120 mg (2 tablets*60 mg) on Day 1.
2509424|NCT02835508|Experimental|Treatment C|Participants will receive a single dose of JNJ-56021927, 240 mg (4 tablets*60 mg) on Day 1.
2509511|NCT02834871|Other|patients with cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients with cervical dystonia
2509514|NCT02834871|Other|patients without cervical dystonia|Computerized assessment of the cervical muscular force and with electromyogram in patients without cervical dystonia
2509557|NCT02834481|Other|: ventilated children|ventilated children admitted in PICU postoperative of cardiac surgery with extracorporeal circulation with ANI/NIPE
2509677|NCT02833779|Active Comparator|Group Therapy Exercises|Patients will be taught exercises in groups of six persons, on a daily basis for twelve sessions.
2509678|NCT02833779|Active Comparator|Individual Manual Therapy Exercises|Patients will be taught the same exercises as in a Group 1, individually, and will receive manual therapy consisting of muscular and joint re-centering
2509692|NCT02833480|Experimental|Fluticasone group|Advair (fluticasone) 250 mcg to be administered twice daily via Diskus for 12 weeks
2509695|NCT02833480|Experimental|Budesonide group|Symbicort (budesonide) 400 mcg to be administered twice daily via Turbuhaler for 12 weeks
2509696|NCT02833480|Active Comparator|Formoterol group|Oxeze (formoterol) 12 microg to be administered twice daily via Turbuhaler for 12 weeks
2509743|NCT02833272|Experimental|EMPOWER Educational Brochure|This is the only arm of the study. All participants will undergo the intervention, which is an educational brochure (EMPOWER educational brochure) to explain the possible harms of benzodiazepine and non-benzodiazepine sedative drugs.
2509796|NCT02832921|Experimental|VR cognitive tasks + treadmill|This is the primary group of interest, in which the investigators hypothesize the greatest cognitive gains since motor activity will augment cognitive activity.
2509797|NCT02832921|Active Comparator|VR cognitive tasks - treadmill|This group will be an active control, receiving the VR cognitive training without treadmill walking, to examine whether the motor component augments the effect of the VR in the experimental group.
2510435|NCT02828228|Experimental|Vitamin D 1200 IU|Supplementation with vitamin D (1200 IU) once a day for 26 weeks
2508850|NCT02839590||Hydrus Microstent implant|"Manufacturer Name Ivantis, Inc., 38 Discovery, Suite 150, Irvine, CA 92618, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2508851|NCT02839590||iStent implant|"Manufacturer Name Glaukos Corporation, 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653, USA.~Principle intended use Surgical treatment of uncontrolled glaucoma and OHT~The device is currently routinely used in the department for the treatment of uncontrolled glaucoma and OHT, and will be used in accordance with usual clinical practice. It is not anticipated that there will be any changes to the device or its usage during the course of the study."
2508852|NCT02839590||Kahook Dual Blade|Manufacturer: New World Medical. Inc. Single use, ophthalmic blade Utilizes ab interno approach through a clear cornea micro incision Dual blades positioned for precise parallel incisions of the trabecular meshwork with minimal residual leaflets Maintains natural physiologic outflow pathways
2508910|NCT02839096|Other|Once Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and placebo in the evening
2508911|NCT02839096|Other|Twice Daily Dosing|Randomized to 325mg of ferrous sulfate in the morning and 325mg of ferrous sulfate in the evening
2508946|NCT02838745|Experimental|Pemetrexed and Cisplatin|• Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
2508986|NCT02838563||Patient living in nursing home|Patient with an Alzheimer Disease or related disorder living in nursing home.
2509031|NCT02838264|Experimental|Cohort 1|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2509032|NCT02838264|Experimental|Cohort 2|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2509035|NCT02838264|Experimental|Cohort 3|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive PF-06463922 Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2509038|NCT02838264|Experimental|Cohort 4|All subjects in this cohort will receive the same dose of PF-06463922 in both periods. Subjects will receive the highest safe dose (mg) of PF-06463922 as a single-dose Alone in Period 1 followed by PF-06463922 with Itraconazole in Period 2.
2509080|NCT02837835|Experimental|continuous administration of ceftazidime|
2509085|NCT02837835|Experimental|intermittent administration of ceftazidime|
2509130|NCT02837562||Interventional Cardiology/Cath Lab Staff|"This is considered to be the case or group under study. These are Interventional Cardiology/ Cardiac Cath lab staff that are exposed to radiation as a result of their role as Cardiac Cath lab staff.~Intervention: Slit lamp eye examination"
2509135|NCT02837562||Non-Interventional Cardiology/ Controls|"This is considered to be the control or comparison group. These are non-interventional cardiology/ non-cardiac cath lab staff that are not exposed to radiation as they do no operate/ work in the Cardiac Cath Lab.~Intervention: Slit lamp eye examination"
2509180|NCT02837198|Experimental|Uric acid-overproduction Type|FYU-981
2509185|NCT02837198|Experimental|Uric acid- underexcretion Type|FYU-981
2509188|NCT02837198|Experimental|Uric acid-overproduction Type (combination)|FYU-981 , Topiroxostat
2509191|NCT02837198|Experimental|Uric acid- underexcretion Type2|FYU-981
2509217|NCT02836665|No Intervention|A: Control group|Patients of group A wait routinely until the dermatological investigator in charge arrives at the emergency room. Once the dermatological investigator is on site, he gives a diagnosis and proposes a therapy.
2509218|NCT02836665|Experimental|B: Telemedicine for dermatological emergency patients|"For Patients of group B study-related photographs of the skin lesion and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal."
2509252|NCT02836535||patients with complications|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential. The interview will examine the impact of complications utilizing a semi-structured script specific to each group
2509257|NCT02836535||patients without Complications (control group)|Each subject will participate in an audio-recorded interview, either in-person or by telephone, expected to last 30 to 60 minutes. Subjects' responses to the interview questions and basic demographic data will remain confidential.
2509280|NCT02836301|Active Comparator|Testimonials-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2509281|NCT02836301|Active Comparator|Testimonials-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2509284|NCT02836301|Active Comparator|Testimonials-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2509288|NCT02836301|Experimental|Documentary-Uplifting|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2509289|NCT02836301|Experimental|Documentary-Negative|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
2509290|NCT02836301|Experimental|Documentary-Unresolved|2x3 matrix for the RCT comparing the control genre of only testimonials (G0) versus the experimental genre (G1) of a documentary with live footage along with the testimonials. The story ending (E) will serve as the cofactor.
3196965|NCT00856219|Active Comparator|Enteral Intermittent|Intermittent tube feedings for 72 hours
2508868|NCT02839161|Experimental|Low-dose (0,2,4 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2508872|NCT02839161|Experimental|Low-dose (0,2,6 months)|10 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 10 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2508875|NCT02839161|Experimental|Medium-dose (0,2,4 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2508880|NCT02839161|Experimental|Medium-dose (0,2,6 months)|30 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 30 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2508888|NCT02839161|Experimental|High-dose (0,2,4 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2508891|NCT02839161|Experimental|High-dose (0,2,6 months)|100 µg Na-APR-1 (M74) plus 5 µg GLA-AF delivered by IM injection in the deltoid muscle, with 100 µg Na-GST-1 administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2508894|NCT02839161|Active Comparator|Comparator (0,2,4 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 4 months.
2508895|NCT02839161|Active Comparator|Comparator (0,2,6 months)|Hepatitis B vaccine delivered by IM injection in the deltoid muscle, with sterile saline solution administered IM in the alternate arm. Injections at 0, 2, and 6 months.
2508973|NCT02838732|Experimental|vegetarian|oral L-carnitine for one month
2508976|NCT02838732|Sham Comparator|omnivore|oral L-carnitine for one month
3196966|NCT00856219|Active Comparator|Parenteral|Parenteral continuously for 72 hours
2509197|NCT02837367|Experimental|Adult intervention|"The intervention will consist Administration of supplements containing methyl-donors (as capsules) containing: 2 g betaine, 800 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 1000 ug (micrograms) Vitamin B12, 500 mg choline bitartrate, 1 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 280 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2509199|NCT02837367|Placebo Comparator|Adult placebo|"The intervention will consist of the Administration of supplements containing methyl-donors (as capsules) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2509200|NCT02837367|Experimental|Children intervention|"The intervention will consist of the Administration of supplements containing methyl-donors (as syrup) containing: 1 g betaine, 400 ug (micrograms) 5-MTHF (L-5-methyltetrahydrofolate) + 500 ug (micrograms) Vitamin B12, 250 mg choline bitartrate, 0.5 g ALA (alfa-linolenic acid), 700 mg EPA (eicosapentaenoic acid), 140 mg DHA (docosahexaenoic acid).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2509201|NCT02837367|Placebo Comparator|Children Placebo|"The intervention will consist of Administration of supplements containing methyl-donors (as syrup) containing inactive ingredients with low glycemic index (usually starch-based), and one capsule containing corn oil (1 g).~Every week the participants will receive a weekly amount of supplements, in opaque pharmaceutical-grade plastic bottles, adequately coded. Participants will be instructed to consume the daily amounts in 2-3 administrations, immediately after a meal,for a duration of 3 months"
2509202|NCT02837367|No Intervention|Adults genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in adult people with obesity.
2509203|NCT02837367|No Intervention|Children genetic assessment|Establishing a genetic signature model in the 1-carbon and omega-6/3 fatty acids metabolic pathways, with high predictive value for dyslipidemia and insulin resistance classification in children with obesity.
3196967|NCT00856258|Placebo Comparator|Cohort 1|Cohort 1 completed.
3196968|NCT00856258|Placebo Comparator|Cohort 2|Cohort 2 not studied
2509350|NCT02836028|Experimental|talazoparib|Cohorts 1A (PARP inhibitor naïve), 2A (PARP inhibitor sensitive), and 3A (PARP inhibitor refractory)
2509352|NCT02836028|Active Comparator|talazoparib + temozolomide|Cohorts 1B (PARP inhibitor naïve), 2B (PARP inhibitor sensitive), and 3B (PARP inhibitor refractory)
2509402|NCT02835573||Sepsis-induced myocardial injury group|Patients admitted to the hospital with the diagnosis of Sepsis-induced myocardial injury
2509413|NCT02835573||Blank control group|Patients admitted to the hospital without the diagnosis of Sepsis-induced myocardial injury
2509468|NCT02835248||Primary|Older adult study participants will be recruited from the cohort of participants in the STRIDE Study at the Boston trial site (http://www.stride-study.org/).
2509543|NCT02834754|Experimental|Vedolizumab|Vedolizumab infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
2509546|NCT02834754|Placebo Comparator|placebo|Placebo infusions at weeks 0, 2, and 6 weeks, then every 8 weeks for 52 weeks
2509565|NCT02834312|Experimental|2.5 mg estetrol|
2509574|NCT02834312|Experimental|5 mg estetrol|
2509583|NCT02834312|Experimental|10 mg estetrol|
2509587|NCT02834312|Experimental|15 mg estetrol|
2509590|NCT02834312|Placebo Comparator|placebo|
2509666|NCT02833909|Experimental|HS|
2509669|NCT02833909|Experimental|Controls|
2509679|NCT02833545|Experimental|OZONE|injection of ozone gas
3196969|NCT00856258|Placebo Comparator|Cohort 3|Cohort 3 not studied
3196970|NCT00856258|Placebo Comparator|Cohort 4|Cohort 4 not studied
3196971|NCT00856271|Experimental|1|olmesartan medoxomil
3196972|NCT00856271|Active Comparator|2|losartan potassium
2508869|NCT02839226|Placebo Comparator|Placebo|placebo will be administered topically once daily for up to 28 days concomitantly with standard of care as advised by treating physician. After randomization, patients will be treated for up-to 14 days or until granulation tissue formation has reached maximal score on the granulation scale, or until the wound is ready for skin grafting, whichever occurs first.
2508932|NCT02838953|Experimental|COPD patients|COPD patients submitted to Pulmonary Rehabilitation according to the ATS/ERS statement.
2508935|NCT02838953|No Intervention|Control|"Healthy individuals who will undergo the same COPD's evaluation protocol. As healthy individuals they will not participate to the Pulmonary Rehabilitation."
2509034|NCT02838654||cervical epidural injection group|cervical epidural injection group
2509049|NCT02837978|Experimental|Tacrolimus group|RA patients treated with tacrolimus, without MTX
2509052|NCT02837978|Active Comparator|Tacrolimus + MTX group|RA patients treated with tacrolimus and MTX
3196973|NCT00856310|Active Comparator|Cohort 1|Dose 1 REGN475
3196974|NCT00856310|Active Comparator|Cohort 2|Dose 2 of REGN475
2509238|NCT02836626|Experimental|Deep Fascial Mobilization|
2509239|NCT02836626|Experimental|Superficial Fascial Mobilization|
2509357|NCT02836015|Experimental|Shared Medical Visit Groups|All patients will be enrolled in the experimental group and will be involved in shared medical visits.
2509411|NCT02835534|Experimental|rhTNK-tPA|rhTNK-tPA; Dose:16mg; Mode of admin: Single bolus Dose:50mg; Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
2509420|NCT02835534|Active Comparator|rt-PA|Drug:alteplase;Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
2509446|NCT02835040|Experimental|CAP Service|
2509449|NCT02835040|Active Comparator|Usual care|
2509544|NCT02834845|Experimental|Sevoflurane|
2509545|NCT02834845|Experimental|Desflurane|
2509563|NCT02834325||exit|HFNC with no need for mechanical ventilation
2509571|NCT02834325||failure|HFNC with need for mechanical ventilation
2509623|NCT02834078|Experimental|BGG|Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
2509624|NCT02834078|Placebo Comparator|Placebo|Matching placebo capsules [for BGG tablet] composed of micro crystalline cellulose and added colors and odors. Dose: 01 tablet three times daily just before all major meals (breakfast, lunch and dinner)
2509711|NCT02833701|Experimental|Treatment (bevacizumab and ascorbic acid)|Patients receive ascorbic acid IV over 90-120 minutes three times per week (at least 24 hours apart) and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2509792|NCT02832947|Other|Rivaroxaban Arm|
2510018|NCT02831439|Experimental|Intervention|Participating health systems in Wisconsin. Interventions include: Basic public reporting and the enhanced intervention (app)
2510019|NCT02831439|Other|Control|Health systems in comparison states. Control includes: Cost savings comparison
3163903|NCT00489034||Index Participants|HIV-infected females, ages 13- 23 years, recruited from ATN sites in New York, Chicago, Miami, Los Angeles, and New Orleans will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic and/or gender interviewing.
3163904|NCT00489034||Network Participants|Closest friends of index participants s and parents/guardians of index participants who know the index participant's HIV status will undergo quantitative interviewing. A sub-sample of the group will undergo ethnographic interviewing.
3163905|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot A|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot A administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
2510131|NCT02830360|Active Comparator|VT catheter ablation|Catheter ablation of ventricular tachycardia
2510132|NCT02830360|Active Comparator|Antiarrhythmic Drug Therapy|Patients will be prescribed either oral amiodarone or sotalol daily (dosage and frequency to be determined based on patient's clinical presentation at the time of the qualifying arrhythmia).
3163906|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot B|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot B administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3163907|NCT00489099|Experimental|V232 Modified Process Hepatitis B Vaccine: Lot C|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) modified process Lot C administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
2510352|NCT02828969|Other|Children and adolescents with conduct disorders|Girls and boys having less than 18 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
2510392|NCT02828592|Experimental|Flu/Cy/TBI|Fludarabine, Cyclophosphamide, TBI followed by bone marrow transplantation. Post-transplant Cyclophosphamide will be on Days 3 & 4.
2510483|NCT02827955|Experimental|bilateral thalamotomy radiosurgery|Gamma Knife radiosurgery bilateral
2510520|NCT02827539|Other|Research|If the patient is randomized to the Research Arm, the physician will begin the procedure utilizing LessRay enhanced fluoroscopic images.
2510525|NCT02827539|Other|Control|For patients in the control arm standard fluoroscopy will be used with the C-arm set to the conventional full dose setting
2510531|NCT02827318|Active Comparator|75g glucose|75g of glucose dissolved in 500ml provided in a clear plastic tumbler.
2510537|NCT02827318|Experimental|75g isomaltulose|75g of isomaltulose dissolved in 500ml provided in a clear plastic tumbler.
2510539|NCT02827318|Placebo Comparator|Sweetened water|500ml water sweetened with sucralose provided in a clear plastic tumbler.
2510580|NCT02827123|Experimental|Mcgrath group|Orotracheal intubation with McGrath MAC videolaryngoscopy
2510581|NCT02827123|Placebo Comparator|Macintosh group|Orotracheal intubation with Macintosh laryngoscopy
2510638|NCT02826876|Placebo Comparator|Ropivacaine|Topical use of Ropivacaine
2510642|NCT02826876|Placebo Comparator|Placebo|Topical use of placebo
2510698|NCT02826304|Active Comparator|VH|Vaginal Hysterectomy for uteri larger than 280gm
2510699|NCT02826304|Active Comparator|LAVH|Laparoscopic assisted vaginal hysterectomy for uteri larger than 280gm
2508904|NCT02839252|No Intervention|Control Group|After the baseline tools have been completed, the parent and child will go home. At 1-month after the initial study clinic visit, the parent will be sent an email with a link to a Qualtrics survey that will contain a few supplemental questions to assess use of the intervention and the same 2 measures that the parent and the child completed at the initial visit.
2508924|NCT02838888||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
2508964|NCT02838719|Experimental|Perineural group|Group 1: perineural dexamethasone acetate added to bilateral transverse abdominis plane block with levobupivacaine
2508966|NCT02838719|Active Comparator|Intravenous group|Group 2: Intravenous dexamethasone acetate added with bilateral transverse abdominal plane block with levobupivacaine
2508995|NCT02838433|Experimental|Biological samples|"Blood samples will be collected :~at baseline,~6 months after the first-line therapy or at disease progression (if occurs first).~In particular case of patient with immunotherapy or targeted therapy, 3 blood samples will be collected :~at baseline~3 months after the initiation of immunotherapy or targeted therapy~at disease progression Tumor tissues will be collected if available."
2509058|NCT02838147|Experimental|Normal OGTT (Oral Glucose Tolerance Test)|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
2509061|NCT02838147|Experimental|Pathological OGTT - 1 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
2509068|NCT02838147|Experimental|Pathological OGTT - 2 abnormal value|Patients will pathological OGTT (either one or more abnormal values) will be randomly allocated to the antenatal care plus FreeStyle group or the SMBG group by a computer generated random number table
2509108|NCT02837666|Active Comparator|Exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group with exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
2509109|NCT02837666|Active Comparator|No exercise group and supplementation|Supplementation with Spirulina maxima Supplementation with placebo Group without exercise program and supplementation with Spirulina maxima or placebo (4.5 g/d) in capsules during 6 weeks, then a 2 weeks washout, to finally proceed to the other treatment during 6 more weeks. During the 14 weeks of study duration every participant will have a personal isoenergetic diet.
2509183|NCT02837107|Active Comparator|Supplement|The supplement (Mind Master) were custom prepared and donated by LR Healthy and Beauty Systems LTD. The supplement contained per 80ml, aloe barbadensis miller gel (USA/Mexico 36%), grape juice, Polygonum cuspidatum extract (that contain 10% resveratrol), green tea extract, 1.1 mg vitamin B1 (100% RDA), 2.5 µg vitamin B12 (100% RDA), 12 mg vitamin E (α - ΤΕ) (100% RDA), coenzyme Q10, 200 µg folic acid (100% RDA), ascorbic acid, 27.5 µg selenium (100% RDA), 4.2 mg iron (100% RDA).
2509187|NCT02837107|Placebo Comparator|Placebo|A look-alike placebo were prepared and donated by LR Healthy and Beauty Systems LTD. The placebo contained Aloe barbadensis Miller Gel (USA/Mexico 3.6%), ascorbic acid, and some excipients.
2509267|NCT02836457||Population with Exposure to ELIQUIS (APIXABAN)|
2509297|NCT02836184|Active Comparator|control group|Group treated with calcium carbonate for 6 weeks first,then switch to nicotinic acids treatment after 2 week of wash-out.
2509308|NCT02836184|Experimental|nicotinic acids group|Group treated with nicotinic acids for 6 weeks first,then switch to calcium carbonate treatment after 2 week of wash-out.
3196975|NCT00856310|Active Comparator|Cohort 3|Dose 2 of REGN475
3196976|NCT00856310|Active Comparator|Cohort 4|Dose 1 of REGN475
3196977|NCT00856310|Active Comparator|Cohort 5|Dose 2 of REGN475
2509482|NCT02834923|Active Comparator|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change. CTH utilizes web-based interactive behavior change technology, based on a logic model of behavior and maintenance that is informed by social-cognitive and social ecological theories. Prior to diabetes visits with a clinician, health educator, or care manager, patients complete a pre-visit CTH assessment at their practice through a tablet computer or computer kiosk. CTH assesses multiple diabetes management behaviors (diet, physical activity, medication adherence, alcohol and tobacco use, stress, mood) using brief assessment measures, each with cut-points highlighting areas of deficit. Action planning plays a central role, through a web-based platform that allows the patient and health care team to select and set goals collaboratively.
2509483|NCT02834923|Experimental|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
3196978|NCT00856310|Active Comparator|Cohort 6|Dose 1 REGN475 subcutaneous administration
3196979|NCT00856310|Active Comparator|Cohort 7|Dose 2 REGN475 subcutaneous administration
3196980|NCT00856362|Experimental|1|
2510448|NCT02827994|Experimental|Education and exercise|The intervention included neurophysiology of pain education and exercises.
3196981|NCT00856401|Experimental|PTH1-84 in parent study|In the RELAY, RACE, and HEXT study participants utilize PTH1-84. In the REPLACE Study participants utilize PTH1-84 or placebo of PTH1-84.
3196982|NCT00856427|Experimental|Diagnostic|Patients undergo implantation of radio-opaque markers into the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo routine 4D CT, 4D CBCT, fluoroscopy, and x-ray imaging during standard stereotactic radiation therapy (early stage tumors) or conventionally fractionated radiation therapy (advanced stage tumors).
3196983|NCT00856440||1|SCI
3196984|NCT00856440||2|Able-bodied
3196985|NCT00856453|Experimental|Yoga classes plus home yoga practic|
3196986|NCT00856453|Experimental|home yoga practice alone|
3196987|NCT00856479|Active Comparator|1 Infuse|The patient will receive BMP 2 with allograft
2508985|NCT02838576|Experimental|Conjugated Equine Estrogen|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive 0,625 mg/day conjugated equine estrogen (CEE) for 12 weeks. These 1 active pill containing conjugated equine estrogen, 0,625 mg will be provided by a laboratory with no trademark identification.~The bottles will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of conjugated equine estrogen, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug."
2508988|NCT02838576|Placebo Comparator|Placebo|"Thirty-six healthy postmenopausal women aged between 45 and 55 years will receive placebo pills, identical in size, shape and color to the active drug, via oral administration, for 12 weeks.~The bottles, without trademark identification, will be numbered in code by a pharmaceutist not involved directly in study and they will donated to volunteers.~During the intervening period, use of placebo, there will be blinding. After this phase, blinding will be interrupted in order to identify volunteers who used the active drug and placebo."
2509025|NCT02838225|Experimental|DA|docetaxel 75 mg/m², iv, day 1, doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1, every 3 weeks for 6 cycles
2509029|NCT02838225|Active Comparator|DAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
2509064|NCT02837939|Experimental|Active|Drug: Human derived Transfer factor applied by subcutaneous injection in specified time points.
2509069|NCT02837939|Placebo Comparator|Control|Aqua pro injectione 4 mL ampules for subcutaneous administration in the same time points as in the active arm
2509127|NCT02837679|Experimental|Intervention|Geriatric follow up
2509134|NCT02837679|No Intervention|Control|Usual care
2509196|NCT02837211|Experimental|Tapered Diet|
2509198|NCT02837211|Active Comparator|Traditional Low Calorie Diet|
2509248|NCT02836678|Active Comparator|Control group|Ridge splitting, immediate implantand PRF.
2509251|NCT02836678|Experimental|Test group|Ridge splitting, immediate implant, Nanobone with PRF.
2509310|NCT02836327||Multiple sclerosis|Multiple sclerosis patients confirmed by neurologist according to the 2010 revised Mcdonald criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
2509313|NCT02836327||Neuromyelitis optica spectrum disorders|Neuromyelitis optica spectrum disorders confirmed by neurologist according to the 2015 revised diagnostic criteria without other nervous system diseases.All patients performed magnetic resonance imaging.
2509318|NCT02836327||Health control|Health control is defined as no other nervous system diseases such as ischemic stroke, alzheimer disease and so on. The baseline data(age,education background etc.) is similar to multiple sclerosis and neuromyelitis optica spectrum disorders patients.All participants performed magnetic resonance imaging.
2509367|NCT02835872|Placebo Comparator|Cellulose control|3 g Insoluble Fiber (Cellulose)/d contained within drinks and crackers
2509372|NCT02835872|Active Comparator|Soluble fiber treatment|3 g soluble dietary fiber test ingredient contained within drinks and crackers
2509395|NCT02835456|Active Comparator|Group A: Sharklet Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
2509401|NCT02835456|Active Comparator|Group B: Silicone Foley Catheter|Patient requiring indwelling urinary catheter will be randomised into Group A or Group B
2509476|NCT02835196||Optical Elastography Assessment of Skin Thickness|
2509481|NCT02835196||Visual Assessment of Skin Thickness|
2509494|NCT02834702|Experimental|Sinew acupuncture|Sinew acupuncture
2509498|NCT02834702|Sham Comparator|Sham acupuncture|Sham acupuncture
2509602|NCT02834520||oral lichen planus|30 patients suffering from reticular, erosive and atrophic oral lichen planus
2509606|NCT02834520||control subjects|30 individuals age, gender and periodontal status matched with oral lichen planus patients and not suffering from any oral mucosal lesions or periodontal disease.
2509630|NCT02833935|Experimental|Physical Activity Intervention Group|Participants will complete a baseline questionnaire (week 1) about their demographic information, self-determination theory variables, their current physical activity, and other psychological indicators. They will complete the same questionnaire at two additional time points. First, about halfway through the intervention (week 6), and then at the end (week 10). Participants in the physical activity intervention group will also receive 8 1-hour physical activity sessions over 2 months (1/week) with a trained physical activity counselor through a video-based internet platform.
2509633|NCT02833935|No Intervention|Control Group|Control Group: For participants assigned to the control group, they will be asked to continue with their regular routine for the next two months. Otherwise, the participants in this group will be asked to complete the follow-up baseline questionnaires at 6 and 10 weeks post-baseline. They will be contacted by a physical activity counsellor at the end of the 10-week period.
2509680|NCT02833662|Other|Patients suspected to present a Sleep Apnea Syndrom|"Record nocturnal respiratory and cardiac parameters before and after surgery :~Severity of sleep respiratory disorders and relationship with cardiac rhythm abnormalities will be assessed in patients suspected to present Sleep Apnea, before and after surgery under general anesthesia."
2509718|NCT02833402||UUI patients undergoing SNM|Urine specimens, questionnaire, and medical data will be collected from subjects that have UUI and are undergoing InterStim placement (SNM).
2509757|NCT02833090|Other|Group 1|Control group had biomarkers.
2509759|NCT02833090|Experimental|Group 2|Biomarkers
2509761|NCT02833090|Experimental|Group 3|Biomarkers
2509763|NCT02833090|Experimental|Group 4|Biomarkers
2509822|NCT02832804|Experimental|anodal stimulation|10 person The patients treated by anodal stimulation (2mA) for 20 minutes
2509823|NCT02832804|Active Comparator|cathodal stimulation|10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
2509824|NCT02832804|Sham Comparator|sham stimulation|10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
2509858|NCT02832414|No Intervention|Regular program|
2509862|NCT02832414|Active Comparator|Intensive weight loss program|
2510000|NCT02831465|Experimental|healthy subjects|Subjects with normal lung function between 40 and 70 years old.
2510074|NCT02831231|Active Comparator|Xanomeline plus placebo|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Placebo, TID
2509043|NCT02837861|Experimental|Experimental Group|Routine Nutritional Support plus supplemental IV amino acids, to begin within 24h of injury. (Target approximately 1.5-2g protein/kg/day)
2509046|NCT02837861|Active Comparator|Control Group|Routine Nutritional Support (i.e. enteral nutrition as tolerated, to begin as early as medically feasible)
2509156|NCT02837263|Experimental|SBRT + Pembrolizumab|Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
2509225|NCT02836821|Experimental|Apatinib|subjects receiving a single 750 mg oral dose of apatinib mesylate tablets and wash-out for 3 days,then rifampicin capsules 600 mg/day orally for 10 days with a single 750 mg oral dose of apatinib mesylate tablets co-administered on day 8 . apatinib mesylate tablets was administered in the morning after an overnight fast of at least 10 h
2509270|NCT02836483|Experimental|Group 1|LCB01-0371 800mg, QD
2509273|NCT02836483|Experimental|Group 2|LCB01-0371 400mg, BID
2509274|NCT02836483|Experimental|Group 3|LCB01-0371 800mg, BID
2509275|NCT02836483|Active Comparator|Group 4|Tubes 3~5Tablet, QD
2509276|NCT02836483|Active Comparator|Group 5|Zyvox 600mg, BID
2509277|NCT02836483|Experimental|Group 6|LCB01-0371 1200mg, QD
2509338|NCT02835989|Experimental|CP@Home Intervention|"The experimental group will receive the CP@Home program. The main elements of this program include BP assessment, diabetes risk assessment, falls risk assessment, heart failure risk assessment, neurologic assessment, psychiatric assessment, depression screening, health-related quality of life analysis (including pain, mobility, anxiety/depression, ADLs), social isolation screening, and food and income security. The program is targeted at referrals to appropriate community resources, identification and referral of high-risk patients to their family physician (FP), as well as regular communication of participants' health information to their physician.~The intervention will be implemented by community paramedics from the local paramedic service who have undergone a structured training program (4 hours of online, interactive training modules, including case studies and the observation of an intervention visits led by another paramedic) to assure intervention fidelity."
2509344|NCT02835989|No Intervention|Control|Usual Care
3196988|NCT00856479|Active Comparator|2 Iliac crest autograft|Autograft from Patients Iliac Crest and allograft
3196989|NCT00856505|Experimental|Everolimus and mycophenolate sodium|Combination of experimental immunosuppressants for GvHD prophylaxis
3196990|NCT00856531||1|
3196991|NCT00856531||2|
2509484|NCT02834910||Case group|patients with Extended-Spectrum Beta-lactamase producing Enterobacteriaceae carrying a qnr gene isolate
2509485|NCT02834910||control-group|patients with Enterobacteriaceae isolate without qnr gene
2509501|NCT02834637|Active Comparator|3 doses 2valent|3 doses of bivalent HPV vaccine (Cervarix) given at M0, M1 and M6
2509507|NCT02834637|Active Comparator|2 doses 2valent|2 doses of bivalent HPV vaccine (Cervarix) given at M0 and M6
2509510|NCT02834637|Active Comparator|1 dose 2valent|1 dose of bivalent HPV vaccine (Cervarix) given at M0
2509513|NCT02834637|Active Comparator|3 doses 9valent|3 doses of nonavalent HPV vaccine (Gardasil9) given at M0, M2 and M6
2509516|NCT02834637|Active Comparator|2 doses 9valent|2 doses of nonavalent HPV vaccine (Gardasil9) given at M0 and M6
2509528|NCT02834637|Active Comparator|1 dose 9valent|1 dose of nonavalent HPV vaccine (Gardasil9) given at M0
2509611|NCT02834286|Experimental|Rituximab, eltrombopag and dexamethasone|Each patient will receive Rituximab 100 mg weekly days 1, 7, 14, 21 Eltrombopag 50 mg PO days 1-28 Dexamethasone 40 mg IV/PO days 1-4
2509647|NCT02833805|Experimental|Bone marrow transplant|Non-myeloablative bone marrow transplant with a Thymoglobulin (ATG), fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis.
2509721|NCT02833441|Experimental|Peer Support Intervention|Adolescents/young adults in the Peer Support Intervention arm will be referred to a Peer Support Intervention support group within their own or nearby community. This support group will meet monthly and will be facilitated by a professional HIV counsellor together with a Peer Support Intervention counselor. The Peer Support Intervention counsellors will provide regular counselling to their allocated participants through home visits and SMS messages. Each participant will be visited once a week in their home. Whatsapp messages will be delivered daily to each participant by the Community Adolescent Treatment Supporters. The agreed messages will briefly enquire about the participant's well-being without specifically making reference to HIV or ARVs. In addition, participants' caregivers will be invited to a 3-session intervention to build knowledge, skills and confidence to better support their adolescents.
2509725|NCT02833441|No Intervention|Standard of Care Practice|"Participants in the standard of care group will receive adherence evaluations and counseling at the clinic as per the current standard of care. Current procedures involve a group counseling session given on Monday morning during which topics are discussed that are relevant to adolescents. In general children aged between 13-19 years attend these sessions. After the group counseling, adolescents also receive an individual counseling session before being evaluated by the clinic doctor. Youth are also encouraged to complete a self reported adherence questionnaire and may periodically undergo pill counts by the clinic counselors.~The adolescents may belong to peer support groups in their communities, however these activities are not part of the clinic program. No interventions are typically targeted at their caregivers."
2510444|NCT02828072|Experimental|Sky|Sky treatment foe 15 days
3196992|NCT00856531||3|
3196993|NCT00856531||4|
3196994|NCT00856531||5|
3196995|NCT00856531||6|
3196996|NCT00856531||7|
3196997|NCT00856531||8|
3196998|NCT00856531||9|
3196999|NCT00856531||10|
3197000|NCT00856531||11|
3197001|NCT00856531||12|
3197002|NCT00856531||13|
2509050|NCT02837848|Active Comparator|Regular strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
2509113|NCT02837796|Active Comparator|inside-outside group|inside-out transobturator tape approach
2509117|NCT02837796|Active Comparator|outside-inside group|outside-in transobturator tape approach
3197003|NCT00856531||14|
3197004|NCT00856531||15|
2509254|NCT02836561|Experimental|Intervention Message|Participants who are randomized to the intervention message will receive contraception information in advance of their appointment that may be helpful in their decision-making.
2509258|NCT02836561|No Intervention|Control Message|Participants who are randomized to the control message will receive appointment logistic information that may be a helpful reminder.
2509312|NCT02836353|No Intervention|Observational only|Oral glucose tolerance test, neurocognitive questionnaire tasks only.
2509321|NCT02836353|Experimental|Somatostatin|Oral glucose tolerance test after 100mcg Somatostatin
2509326|NCT02836353|Experimental|Antibiotics|Oral glucose tolerance test after treatment of small intestinal bacterial overgrowth
2509361|NCT02835859|Experimental|Group 1- Oral solution|Participants will be randomly assigned to drink two oral solutions made of different combinations of saccharin, lactisole, acetaminophen, 3-O-methyl glucose, or glucose.
2509398|NCT02835469||Menopur® Multidose|Treatment according to routine clinical practice.
2509477|NCT02835235|Experimental|NNC9204-0530|Dose-escalation within the cohort before reaching final dose
2509480|NCT02835235|Placebo Comparator|Placebo|
2509493|NCT02834611|Experimental|Ceramide NanoLiposome|Dose escalation of Ceramide NanoLiposome
2509613|NCT02834494|Other|3D Shear Wave Elastography (SWE)|
2509650|NCT02833818|Experimental|CAKE-intervention|Increased nutrition and dietary consultations. Growth rate followed by clinical nutritionists that supply high protein and energy if growth rate deviates from 17g/kg/day
2509654|NCT02833818|Active Comparator|CAKE-control|nutrition according to established procedures in the neonatal intensive care unit (NICU)
2509700|NCT02833623|Experimental|Short-message-based Re-education group|"Patients receive oral and written education before H. pylori eradication therapy at first, then they receive short message re-education twice per day during therapy.~Both the content of the oral and written education and the short message re-education are same."
2509702|NCT02833623|Active Comparator|conventional education group|Patients only receive oral and written education before H. pylori eradication therapy.
2509772|NCT02833155|Experimental|Entinostat and Exemestane|"Patients receive entinostat PO on days 1, 8, 15, and 22. Entinostat in combination with exemestane will be repeatedly administered every 28 days in the absence of disease progression or unacceptable toxicity.~Exemestane wil be orally administered once daily for up to six months."
3197005|NCT00856596|Other|Males and females with athlete's foot|Male and female subjects with athlete's foot inbetween their toes without nail involvement
2509984|NCT02831634|Other|Blood sampling|
2510004|NCT02831374|Experimental|Use of platelet rich plasma (Group A)'|Local anesthesia, surgical extraction of impacted third molar, Preparation of PRP gel, Placing platelet Rich plasma and suturing, Postoperative medication
2510006|NCT02831374|Placebo Comparator|surgical extraction (Group B)|Local anesthesia, surgical extraction of impacted third molar, Suturing, Postoperative medication
2510020|NCT02831140|Other|Common arm : for both groups :|"In preoperative phase~In peroperative phase~In postoperative phase"
2510022|NCT02831140|Experimental|FTR protocol group (A)|"A. Experimental : FTR protocol group :~Early exercises after a thoracic surgery : removing urinary probe and all catheters as well as alimenting ."
2510026|NCT02831140|No Intervention|Control group (B)|Traditional, conventional care group with first get up and alimentation permission in 24 hours at the postoperative.
2510111|NCT02830945|Other|Control Brochure Arm|Control Arm households receive a culturally tailored Stroke and CVD brochure for prevention.
2510114|NCT02830945|Experimental|Motivational Interviewing Intervention Arm|The MI intervention households receive three aspects of the intervention: digital stories, motivational interviewing talking circle and the option to receive text messages to adhere to the action plan.
3197006|NCT00856622|Experimental|Fixed combination of latanoprost 0.005% and timolol 0.5%|
3197007|NCT00856622|Active Comparator|timolol 0.5% ophthalmic solution|one drop in the morning and evening
2510279|NCT02829476|Experimental|patients with AIS|Patients will have 'Osteoblast sample'
2510282|NCT02829476|Experimental|control patients|
2510338|NCT02829060|Active Comparator|1a: Indwelling drains (48 hr)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510343|NCT02829060|Active Comparator|1b: Indwelling drains (7d)|"This group has indwelling urinary tubes/drains and a negative urine culture~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510345|NCT02829060|Active Comparator|2a: +UCx with Oral Options (48hr)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510411|NCT02828163|Experimental|Autologous Platelet rich plasma|Autologous platelet-rich plasma (PRP) is autologous plasma that has platelet concentration above the baseline. 1 millilitre of autologous platelet-rich plasma will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
2510450|NCT02827994|No Intervention|No intervention|This group received no intervention as participants were students that were not seeking treatment for their pain.
3197008|NCT00856622|Active Comparator|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
3197009|NCT00856648||Group 1|SCI
3197010|NCT00856648||Group 2|Able-bodied
3197011|NCT00856687|Experimental|PF-03893787|
2509114|NCT02837640|Experimental|Treatment|"This is a single armed study. All patients included will receive treatment. Control will happen with data from the same patients before they received treatment.~patients will receive sinemet 200/50 1/2 tablet (levodopa-carbidopa 100/25) b.i.d for two days and then will be increased to t.i.d. for 6 months."
2509173|NCT02837250|Experimental|Pos4Health|Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.
2509177|NCT02837250|Active Comparator|Patient Education|Patient Education is a static (unchanging) website that presents accurate information about the same topics in Pos4Health, but without personalization, peer videos, or interactivity.
2509283|NCT02836782||Naive patients|Patients who begin their first antiretroviral regimen. Blood sample withdrawal
2509286|NCT02836782||Experienced patients|"Patients with a history of antiretroviral treatment, switching to a new regimen.~Blood sample withdrawal"
2509335|NCT02836080|Experimental|Integrated Collaborative Care Team|Integrated Collaborative Care Team (ICCTs) are housed in the local community to improve youth access, in three neighborhoods across Toronto (East Metro Youth Services [EMYS]-Scarborough, EMYS-Southeast Toronto, and Delisle Youth Services-Central Toronto). Each ICCT will include a variety of service providers and coordinated patient care delivering evidence-informed interventions in a stepped-care model.
2509336|NCT02836080|Active Comparator|Treatment as Usual (TAU)|"The comparator arm consists of out-patient TAU in a hospital setting and will occur at one of four outpatient hospital sites across Toronto.~Partners include the following four hospitals: Hospital for Sick Children (SickKids), the Centre for Addiction and Mental Health (CAMH), Michael Garron Hospital (formerly the Toronto East General Hospital), and Sunnybrook Hospital."
2509417|NCT02835560|Experimental|Experimental|Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid
2509423|NCT02835560|Active Comparator|Active Comparator|"Esoprazole~Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid"
2509473|NCT02835183|Experimental|Insulin pump followed by iDECIDE|Participants will be randomly assigned to 4 weeks of using their insulin pump to decide insulin boluses and then 4 weeks of using iDECIDE to receive recommendations for insulin dosing.
2509478|NCT02835183|Experimental|iDECIDE followed by insulin pump|Participants will be randomly assigned to 4 weeks of using iDECIDE to receive recommendations for insulin dosing and then 4 weeks of using their insulin pump to decide insulin boluses.
2509495|NCT02834676||Chemonucleolysis by Gelified Ethanol|Patients visiting the pain clinic of the hospital who had cervical discogenic or radicular pain that did not resolve after the use of conventional therapy and ozone-oxygen therapy. Written informed consent was obtained from all participants.
2509552|NCT02834468|Experimental|Treatment group|DEX Combined With RTX, CSA and IVIG All patients are assigned to receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
2509604|NCT02834208|Experimental|Schizophrenia subjects|35 patients suffering from schizophrenia
2509609|NCT02834208|Other|Healthy siblings|35 healthy siblings of the patients suffering from schizophrenia
2509612|NCT02834208|Other|Healthy controls|"35 healthy controls patients"
2509673|NCT02833766|Experimental|anti-EGFR-IL-dox|Metastatic, non resectable, EGFR positive TNBC patients treated in first-line
2509716|NCT02833428|Experimental|patients with acute spinal cord injury|The study will be performed on patients with acute spinal cord injury between the cord next to the C2 vertebra and marrow next to the T12 vertebra. This is usually hospitalized patients in an emergency situation, brought by EMS (emergency medical services) and taken care of immediately in the recovery room by intensivists. Patients who accepted to participate to this study will got the installation bedside biomedical equipment for the project (Eclipse Nim, Medtronic®). The aim of this work is to analyze using an artificial intelligence engine (IA, Biomedical equipment (Eclipse Nim, Medtronic®)) the influence of the physiopathological environment (set of parametric data monitoring, imaging, biology etc.) of the traumatized spinal cord on spinal pain.
2509770|NCT02833103|Experimental|Pinaverium Bromide group|Able to improve the spasms of SO; literature showed that it treated biliary disorders effectively.
2509774|NCT02833103|Active Comparator|Danshu group|Contains the active pharmaceutical ingredient (API) and has the effects of fighting infection, alleviating pain, promoting bile secretion and lifting muscle spasms; literature showed that Danshu Capsules effectively improved the symptoms of biliary disorders, such as pain, nausea and abdominal distension.
2509902|NCT02832128|Experimental|AUT00063 - Placebo|AUT00063 (800 mg/day) for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with placebo
2509905|NCT02832128|Experimental|Placebo - AUT00063|Placebo for 28 days, followed by a 2 to 4 week washout period before commencing the second 28-day dosing period with AUT00063 (800 mg/day)
2509935|NCT02831829|Active Comparator|Water-based exercise training group|"Intervention: Patients randomized to the water-based exercise training group will undergo water-based exercise training. The immersed exercise will include two session of aerobic (water-based) and calisthenic exercise per day, six days of a week, each lasting 30 minutes."
2509971|NCT02831517|Experimental|Part 2|16 participants: Multiple Ascending Dosing of BIIB074 or placebo in a 6:2 ratio; 3 times daily [TID] in cohort 4 for 6 days and one time (QD) for 1 day and 2 times daily [BID] in cohort 5 for 6 days and QD for 1 day
2509126|NCT02837770|Active Comparator|Oral Diclofenac and Diclofenac Eye Drops|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI and one drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
2509133|NCT02837770|Placebo Comparator|Pacebo pill and Artificial Tears|Pacebo pill will be administered 4 hours before the IVI and one drop Artificial Tears will be instilled 45' prior to the IVI.
2509170|NCT02837042|Experimental|Pembrolizumab 200 mg|Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.
2509261|NCT02836795|Experimental|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody is to be injected intravenously 1mg/kg or 3mg/kg or 10mg/kg until disease progresses or unacceptable tolerability occurs.
2509302|NCT02836288|Experimental|Ketamine|Oral ketamine 1.0 mg/kg mixed with syrup
2509304|NCT02836288|Placebo Comparator|Placebo|Oral placebo (syrup)
2509309|NCT02836288|Experimental|Ketamine after placebo|Optional oral Ketamine 1.0 mg/kg mixed with syrup for patients on placebo arm after 12 week treatment is completed.
2509333|NCT02835794|Experimental|Arm 1|Omacetaxine - escalating doses subcutaneous twice daily on Days 1-5 and 8-12 Azacitidine 50 mg/m2 subcutaneous/intravenous daily on Days 8-12 G-CSF 5mcg/kg subcutaneous daily on Days 15-19 and 22-26
2509370|NCT02835742|Active Comparator|Group1|Treatments for Group 1 include GM-CSF inhalation with 250 mcg/day/body of sargramostim (125 mcg BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
2509375|NCT02835742|Placebo Comparator|Group2|Treatments for Group 2 include placebo inhalation (Placebo BID on Days 1-7, none on Days 8-14) for twelve 2-week cycles.
2509400|NCT02835430|Experimental|Coronally advanced flap and PRF with DFDBA|Coronally advanced flap and platelet-rich fibrin membrane with demineralized freeze-dried bone allograft.
2509406|NCT02835430|Active Comparator|Coronally advanced flap and PRF without DFDBA|Coronally advanced flap and Platelet-rich fibrin membrane without demineralized freeze-dried bone allograft.
2509474|NCT02835144|Experimental|TIQAAM_therapy|Individuals in this group will receive units from the TIQAAM treatment program
2509479|NCT02835144|Active Comparator|active_control|Individuals in this group will receive units of psychoeducation
2509500|NCT02834689|Experimental|Walking|Walking on a treadmill at 3.5 metabolic equivalents (METS) for 50 minutes
2509508|NCT02834689|Experimental|Seated Control|Sitting for 50 minutes
2509553|NCT02834507|Placebo Comparator|Placebo|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2509554|NCT02834507|Experimental|Nebicapone 75 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2509555|NCT02834507|Experimental|Nebicapone 150 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2509556|NCT02834507|Active Comparator|Entacapone 200 mg|In each treatment period, patients received, in a double-blind manner, 1 capsule of investigational product (nebicapone 75 mg, nebicapone 150 mg, entacapone 200 mg or placebo, according to the treatment sequence), concomitantly with each levodopa/carbidopa (Sinemet®) dose patient used to take.
2509566|NCT02834156|Other|LP in a seated position then LP in a lying position|Patients will have first a lumbar puncture (LP) in a seated position then a LP in a lying position
2509576|NCT02834156|Other|LP in a lying position then LP in a seated position|Patients will have first a lumbar puncture (LP) in a lying position then a LP in a seated position
2509625|NCT02834039|Active Comparator|Tidal volume 6 ml/kgBW|Tidal volume 6 ml/kgBW was given to patients after endotracheal tube was inserted properly
2509628|NCT02834039|Active Comparator|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to patients after endotracheal tube was inserted properly.
2509714|NCT02833688|Experimental|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
2509715|NCT02833688|Placebo Comparator|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
3197012|NCT00856687|Placebo Comparator|Placebo|
3197013|NCT00856687|Active Comparator|Montelukast|
2509857|NCT02832362|Experimental|Carbomer 980|Participants will be administered test product (nasal spray) containing 0.5% carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
2509861|NCT02832362|Placebo Comparator|Placebo|Participants will be administered reference product (nasal spray) containing vehicle without carbomer 980, 4 times per day (i.e. 3 actuations per nostril per dose; each actuation will be 140 mcL, equivalent to 140 mg).
3197014|NCT00856700|Experimental|GLP-1 infusion|Patients with metabolic syndrome
2509978|NCT02831582|Active Comparator|Arm I (omega-3 fatty acid)|Patients receive omega-3 fatty acid supplementation PO QD for 6 months.
2509982|NCT02831582|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 6 months.
2510009|NCT02831205|Experimental|ABSORB BVS|
3197015|NCT00856713|Experimental|1 YM|Healthy young males
3197016|NCT00856713|Experimental|2 EM|Healthy elderly males
3197017|NCT00856713|Experimental|3 YF|Healthy young females
3197018|NCT00856713|Experimental|4 EF|Healthy elderly females
3197019|NCT00856713|Experimental|5 CTP-A|Patients with hepatic cirrhosis CTP-class A
3197020|NCT00856713|Experimental|6 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
3197021|NCT00856752|Experimental|T1|Pre-treatment with rifampicin
3197022|NCT00856752|Experimental|T2|Pre-treatment with cyclosporin
3197023|NCT00856752|Experimental|Reference|Administration of NRL001 alone: no pre-treatment
2509168|NCT02837172||Parkinson's disease from PPMI dataset|Obtain retrospective and prospective de-identified data from the The Parkinson's Progression Markers Initiative (PPMI) dataset on Parkinson's disease (PD) subjects that have the following characteristics: within 2 years of diagnosis, positive DaTscan, and not (at study entry) on any PD related medication.
2509172|NCT02837172||Controls from PPMI dataset|Obtain retrospective and prospective de-identified DTI imaging and data from the PPMI dataset
2509255|NCT02836938||Severe|Severe chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 3
2509256|NCT02836938||Mild|Mild chronic lung allograft dysfunction (CLAD), bronchiolitis obliterans syndrome (BOS), stage 1-2
2509260|NCT02836938||Control|Bronchiolitis obliterans syndrome (BOS), stage 0
2509285|NCT02836314|Experimental|PRF and ABBM|Intervention: Anorganic Bovine Bone Mineral and Platelet Rich fibrin is applied to the periodontal intrabony defects
2509287|NCT02836314|Active Comparator|Anorganic Bovine Bone Mineral|Intervention: Anorganic Bovine Bone Mineral is applied to the periodontal intrabony defects
2509354|NCT02836054|Other|Patients with cognitive disorders|lumbar punction + brain MRI
2509355|NCT02836054|Other|Patients without cognitive disorders|lumbar punction + brain MRI
2509475|NCT02835209||Work of breathing during SBT|Ventilated premature infants born 24 to 34+6 weeks gestational age.
2509502|NCT02834728||Frail elderly people|A group of elderly people hospitalised in medical wards via emergency department
2509558|NCT02834546||Patients with HCC treated with sorafenib|
2509567|NCT02834117|Other|Natural cycle|Ovulation is not induced by drugs
2509577|NCT02834117|Experimental|Moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
2509667|NCT02833987||Treated with direct oral anticoagulants (DOACs)|Patients who received a new prescription for a DOAC (apixaban, dabigatran, or rivaroxaban) in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
2509668|NCT02833987||Treated with warfarin|Patients who received a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis, and did not have a previous prescription for a DOAC or warfarin in the year prior to the date of the new prescription.
3197024|NCT00856765|Experimental|1|Drug eluting balloon followed immediately by implantation of bare metal stent
3197025|NCT00856765|Active Comparator|2|Drug eluting stent
3197026|NCT00856765|Active Comparator|3|Bare metal stent
3197027|NCT00856804|Experimental|1|thalidomide added to peg-interferon + ribavirina
3197028|NCT00856817|Experimental|1|L-arginine treatment first, heme arginate treatment second
3197029|NCT00856817|Experimental|2|Heme arginate treatment first, L-arginine treatment second
2510010|NCT02831205|Active Comparator|XIENCE EES|
2510065|NCT02831127|Experimental|short message service group|Patients in this arm received conventional instructions plus short message reminder.
2510068|NCT02831127|Active Comparator|conventional group|Patients in this arm just received conventional instructions.
3197030|NCT00856869|Experimental|1 YM|Healthy young males
3197031|NCT00856869|Experimental|2 EM|Healthy elderly males
3197032|NCT00856869|Experimental|3 YF|Healthy young females
3197033|NCT00856869|Experimental|4 EF|Healthy elderly females
3197034|NCT00856869|Experimental|5 NASH|Patients with presumed NASH
3197035|NCT00856869|Experimental|6 CTP-A|Patients with hepatic cirrhosis CTP-class A
3197036|NCT00856869|Experimental|7 CTP-BC|Patients with hepatic cirrhosis CTP-class B and C
3197037|NCT00856882|Experimental|soy protein and isoflavones|
3197038|NCT00856882|Experimental|milk protein and isoflavones|
3197039|NCT00856882|Placebo Comparator|milk protein only|
3197040|NCT00856895||Hispanic|
3197041|NCT00856895||Non-Hispanic|
3197042|NCT00856947|Active Comparator|Vitamin D|Dietary supplement: 2400 IU Vitamin D3 (2 tablets of 1200 IU) from week 24 of gestation to 1 week after delivery
3197043|NCT00856947|Placebo Comparator|Placebo|Placebo: 2 placebo tablets with no active substance, identical to the active tablets, from week 24 of gestation to 1 week after delivery
3197044|NCT00856960|Active Comparator|1|Aliskiren 600 mg
3197045|NCT00856960|Active Comparator|2|Aliskiren 150 mg
3197046|NCT00856960|Active Comparator|3|Losartan 100 mg
3197047|NCT00856960|Placebo Comparator|4|Placebo
3197048|NCT00857012||All patients|treated with Anastrozole as per SPC
3197049|NCT00857025|Experimental|Treatment (beta-glucan MM-10-001)|Patients receive oral beta-glucan MM-10-001 once or twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3197050|NCT00857038|Experimental|1|Doxycycline 100mg daily
3197051|NCT00857038|Placebo Comparator|2|Placebo
3197052|NCT00857051|Experimental|1|A 22 minute DVD that discusses common stressor in the early postpartum.
3197053|NCT00857051|Experimental|2|A 24 hour hotline available for the first 3 months postpartum.
3197054|NCT00857051|Experimental|3|Both the film and the hotline will be given to this arm.
3197055|NCT00857051|No Intervention|4|A CD of children's music will be given to mothers in this arm.
3197056|NCT00857077|Placebo Comparator|1 Placebo|
3197057|NCT00857077|Active Comparator|2 Sulfadoxine-pyrimethamine (SP)|
3197058|NCT00857090|Experimental|1|Drug
3197059|NCT00857090|Placebo Comparator|2|Vehicle
3197060|NCT00857103|No Intervention|1|Standard care
3197061|NCT00857103|Experimental|2|Use of Choice intervention to support consultations
3197062|NCT00857116|Active Comparator|Albendazole|Albendazole 400mg per os once daily for three consecutive days
3197063|NCT00857116|Placebo Comparator|Placebo|Placebo 400mg per os for three consecutive days
2509194|NCT02837003||Experimental: Thienopyridine|Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.
2509244|NCT02836691|Active Comparator|EKG to Control subjects|healthy controls without asthma or other respiratory disease.
2509247|NCT02836691|Active Comparator|EKG monitoring Mild asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2509249|NCT02836691|Active Comparator|EKG monitoring severe control asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2509253|NCT02836691|Active Comparator|EKG monitoring severe uncontrolled asthma|The clinical grade of asthma is assessed in terms of the type of current asthma control (as GEMA Guide 4.0)
2509278|NCT02836262|Experimental|HIT Hip Replacement System (HRS)|Single group assignment with historical controls.
2509331|NCT02836106|Experimental|Healthy|Lean subjects (BMI<25) with a waist circumference of <94 cm for men and<80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
2509332|NCT02836106|Experimental|Obese|Overweight and obese subjects (BMI≥25) with a waist circumference of ≥94 cm for men and ≥80 cm for women. Subjects will be randomly assigned to eat butter, cheese, whipped cream and sour cream in a cross-over design.
2509368|NCT02835755|Active Comparator|Group I (Control)|Patients receive standard information about HPV and HPV vaccine, such as the VIS, on a mobile-friendly website study portal.
2509374|NCT02835755|Experimental|Group II (mHealth HPV vaccine)|Patients receive the mHealth HPV vaccine intervention consisting of content about HPV and HPV vaccine on the study portal for 15 minutes and vaccination reminders sent by the portal via text or e-mail.
2509434|NCT02835378||Bilateral upper limb amputation|Bilateral upper limb amputees, with amputation from the short transverse hand (hand completely non-functional) to complete arm, whatever their age
2509444|NCT02835001|Other|Patient with severe emphysema|Patients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
2509523|NCT02834858|Experimental|Umbilical Cord Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells Infusion.
2509532|NCT02834858|Placebo Comparator|saline|saline injection
2509564|NCT02834338|No Intervention|Laparoscopic surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
2509575|NCT02834338|Active Comparator|Laparoscopic surgery, intervention|activity tracking for autofeedback
2509584|NCT02834338|No Intervention|Open surgery, control|The control group is wearing an activity tracker wristband with covered display, so that the step count can't be read out.
2509588|NCT02834338|Active Comparator|Open surgery, intervention|activity tracking for autofeedback
2509646|NCT02834026|Experimental|Intervention|The intervention group held two months of training in hemodialysis a physical therapy protocol with cycle ergometer
2509656|NCT02834026|Experimental|Control|The control group was reassessed after two months of the initial evaluation
2509685|NCT02833610|Experimental|Denosumab Injection|Patients will be administered Denosumab Q4W at a pre-determine dose for 12 cycles. Denosumab Q4W is administered by subcutaneous injection.
2509731|NCT02833298|Experimental|Automated reminders|Patient will be contacted for automated reminders within one month before the six-month interval indicating they are due for HCC screening.
2509732|NCT02833298|Experimental|Patient navigation|The patient navigator will coordinate with the provider and subject to schedule the appropriate office visit and imaging for HCC screening as needed within one month before the test is due.
2509767|NCT02832986||Patients in frailty consultation|Patients consulting in frailty consultation, at this occasion they will complete a medical questionary for the collection of study data
2509790|NCT02832778|Experimental|Stage 1 London|"Stage 1, London:~Phase 1 (2 weeks): tenofovir/emtricitabine or tenofovir/lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily~Phase 2 (12 weeks): tenofovir/emtricitabine or tenofovir /lamivudine or zidovudine/lamivudine) plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)"
2509794|NCT02832778|Experimental|Stage 2 Kampala|Tenofovir/emtricitabine or lamivudine or zidovudine/lamivudine plus efavirenz (Sustiva/Stocrin) 400 mg once daily plus Rifinah or local generics once daily (rifampicin 600 mg and isoniazid 300 mg if ≥ 50 kg or rifampicin 450 mg and isoniazid 300 mg if <50kg).
2509877|NCT02832349|Experimental|EA group (Educational Actions)|Epileptic patients participating to the educational actions program
2509881|NCT02832349|No Intervention|Control group|Epileptic patients with standard follow-up
2509919|NCT02832063|Active Comparator|B244 arm|B244 dose administered in a 1:1 (active vs placebo) ratio
2509922|NCT02832063|Placebo Comparator|Placebo arm|Placebo dose administered in a 1:1 (active vs placebo) ratio
2509976|NCT02831738|Experimental|Active Treatment|Polydextrose 12 g
2509981|NCT02831738|Placebo Comparator|Control Treatment|No polydextrose
2510039|NCT02831348||Uncontrolled asthma|Indicated by an asthma control test (ACT) score of <20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
2510046|NCT02831348||Controlled asthma|Indicated by an ACT score of >19, or spirometry results within 10% of year's best value (based on FEV1).
2510050|NCT02831348||Pneumonia|Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
2510054|NCT02831348||Controlled allergic rhinitis|Indicated by a rhinitis control assessment test (RCAT) score of >= 21.
2510057|NCT02831348||Uncontrolled allergic rhinitis|Indicated by an RCAT score of <21.
2510060|NCT02831348||Cystic fibrosis (exacerbated)|Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
2510061|NCT02831348||Cystic fibrosis (stable)|Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
2510062|NCT02831348||Control|Indicated by a negative history of any of the conditions characterizing the other groups.
2509325|NCT02836431|Experimental|DEX 2 mcg/kg Intranasal|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2509328|NCT02836431|Experimental|DEX 1 mcg/kg Intravenous|Standard anesthesia care for a patient presenting for cardiac surgery includes induction of general anesthesia , placement of an endotracheal tube and an arterial line. Once these are accomplished, dexmedetomidine is administered according to group assignment.
2509342|NCT02835781||Acellular dermal matrix arm|The females undergoing breast reconstruction surgery after breast removal because of breast cancer. The breast reconstruction will be performed using acellular dermal matrix implantation.
2509392|NCT02835651|Experimental|Palmitic acid|Diet rich in palmitic acid
2509394|NCT02835651|Experimental|Stearic acid|Diet rich in stearic acid
2509470|NCT02835170|Experimental|Autologous immunoglobulin|Intramuscular injection of autologous immunoglobulin (IgG)
2509472|NCT02835170|Placebo Comparator|Placebo|Intramuscular injection of normal saline
2509492|NCT02834650|Experimental|Group 1a|Group 1a comprises healthy volunteers who will complete a Cardiac MRI without contrast. A subset of healthy volunteers will have a repeat MRI at Children's Hospital of Orange County.
2509496|NCT02834650|Experimental|Group 1b|"Group 1b comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test.~A subset of boys with DMD will have a repeat MRI with contrast at Children's Hospital of Orange County."
2509497|NCT02834650|Experimental|Group 2|Group 2 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a repeat MRI scan with contrast at 6 Months.
2509503|NCT02834650|Experimental|Group 3|Group 3 comprises boys with DMD who will complete a Cardiac MRI with contrast, a blood test, a heart rate test and a pulmonary function test and a genetic testing.
2509570|NCT02834221|Experimental|Real-time ultrasound-guided puncture|Cannulate each femoral veins with two wires with real-time ultrasound-guided method.
2509581|NCT02834221|Other|Anatomical landmark guided puncture|Cannulate each femoral veins with two wires with the anatomical landmark guided method.
2509639|NCT02833961|Experimental|ISCHEMIC STROKE|ischemic stroke admitted in the Pitié Salpêtrière Stroke unit in Paris
2509644|NCT02833961|Active Comparator|HEALTHY SUBJECTS|Age and gender-matched healthy volunteers
2509698|NCT02833649|Experimental|Toric Implantable contact Lens|The Visian implantable collamer lens (Staar Surgical AG, Nidau, Switzerland), is a monoblock single-piece plate haptic lens made of collamer (an extremely hydrophilic and highly biocompatible flexible collagen copolymer with a refractive index of 1.452 that is permeable to oxygen and nutrients
2509749|NCT02833207|Experimental|EDD Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
2509750|NCT02833207|Experimental|EDD Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 1 (EDD) (described in Intervention section).
2509751|NCT02833207|Experimental|ROV Obese|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible obese subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
2509752|NCT02833207|Experimental|ROV Lean|On study visit after screening. Brachial artery catheter in the non-dominant arm + infusion drugs (IND approval) to test basic vascular function and associated mechanisms in healthy volunteers. Eligible lean subjects will undergo Drug Trial 2 (ROV) (described in Intervention section).
2509815|NCT02832843||NTM lung disease|Patients with NTM lung disease satisfying American Thoracic Society guidelines
2509817|NCT02832843||Healthy control|The age-, sex-matched control subjects without pulmonary diseases
2509835|NCT02832531|Experimental|Rivaroxaban (15 mg)|Rivaroxaban 15 mg od (n ~ 1000)
2509836|NCT02832531|Active Comparator|Aspirin (ASA)|Aspirin 100 mg od (n~1000)
2509886|NCT02832271|Active Comparator|green tea group|green tea extract SUNPHENON EGCg for women with ultrasound confirmed endometriosis
2509890|NCT02832271|Placebo Comparator|placebo group|placebo fro women with ultrasound confirmed endometriosis
2509932|NCT02831972|Experimental|Period 1|A single oral dose of AG-120 will be administered at Hour 0 followed by PK sampling for 504 hours (21 days).
2509939|NCT02831972|Experimental|Period 2|In Period 2, multiple oral doses of itraconazole will be administered once daily (QD) for 18 consecutive days (Days -4 to 14) with a single oral dose of AG-120 coadministered at Hour 0 on Day 1. PK sampling for AG-120 will be taken for 504 hours (21 days) following AG-120 dosing on Day 1. PK sampling will also be collected for itraconazole and its metabolite, hydroxy-itraconazole, from Day -2 up to Day 13.
2509975|NCT02831647|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES PRAGUE for a period of 9 days.
2510040|NCT02831400|Experimental|IFABP assessment (1 study group)|30 elderly volunteers
2510099|NCT02830997||Conventional guidance|The conventional guidance will undergo TKA surgery with use of the Investigator's usual precision guided technique based on conventional instrumentation (mechanical and simple computer-assisted guidance techniques). For participants of the conventional guidance arm, the Investigator will employ the established technique he currently employs for all routine TKA procedures and would employ if the patient were not a participant in the study.
2510104|NCT02830997||Stereotactic guidance|The stereotactic guidance group will undergo their TKA surgery with use of a stereotactic guidance system.
2510152|NCT02830620|Other|groupe1|cancer of the pancreas WITH syndrome of anorexia-cachexie Dosage of chimiokines
2510153|NCT02830620|Other|groupe2|cancer of the pancreas WITHOUT syndrome of anorexia-cachexie Dosage of chimiokines
2510154|NCT02830620|Other|groupe3|pure food limitation typifies restrictive anorexia nervosa Dosage of chimiokines
2510456|NCT02828033|Experimental|Rilonacept|A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
2509363|NCT02836002|Experimental|Group 1 - SP low/SP high|"Group 1 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 1 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2509366|NCT02836002|Experimental|Group 2 - SP low/Pip high|"Group 2 will be treated with a course of subcurative sulfadoxine-pyrimethamine (SP) (SP low, 500mg/25mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 2 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2509371|NCT02836002|Experimental|Group 3 - Pip low/Pip high|"Group 3 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (Pip high) volunteers will receive a treatment with piperaquine (960mg).~Group 3 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2509376|NCT02836002|Experimental|Group 4 - Pip low/SP high|"Group 4 will receive piperaquine (Pip) in a low-dose (Pip low, 480 mg) as treatment 1.~As treatment 2 (SP high) volunteers will receive a treatment with sulfadoxine-pyrimethamine (1000mg/50mg).~Group 4 will receive a malaria challenge infection, P. falciparum 3D7 -infected mosquito bites Final treatment with a curative regimen of atovaquone/proguanil (malarone)."
2509391|NCT02835313|Experimental|FAST+SAM|Subjects participate in fast walking training in combination with a step activity monitoring program
2509393|NCT02835313|Active Comparator|FAST|Subjects participate in fast walking training
2509396|NCT02835313|Active Comparator|SAM|Subjects participate in a step activity monitoring program
2509466|NCT02835079|Other|open label study|one arm open label study
3197064|NCT00857129|No Intervention|1|Low risk women with expected normal birth are being Randomized to The Midwife-led Unit, with low amount of intervention, No epidural is offered, no medical augmentation available, unless for the active phase of the second stage. If extended surveillance is necessary or if the birth no longer is considered to be normal and needs to be taken over by a doctor, the woman will be transferred to either the Normal Unit or the Special Unit
2509614|NCT02834273|Experimental|Therapeutic Workshop|Therapeutic Workshop (patients following therapeutic education workshops during their hospitalization)
2509616|NCT02834273|No Intervention|Usual care|
2509629|NCT02833831|Experimental|Part 1: Group 1|Participants will receive Treatment A (a single dose of ALS-008176 1,500 mg) or Treatment B (a single dose of placebo) under fasted conditions.
2509632|NCT02833831|Experimental|Part 1: Group 2|Participants will receive Treatment C (a single dose of ALS-008176 2,500 mg) or Treatment D (a single dose of placebo) under fasted conditions.
2509635|NCT02833831|Experimental|Part 1: Group 3|Participants will receive Treatment E (a single dose of ALS-008176 3,000 mg) or Treatment F (a single dose of placebo) under fasted conditions.
2509636|NCT02833831|Experimental|Part 2: Sequence GHI|Participants will receive Treatment G (a single dose of ALS-008176 3,000 mg + a single dose of moxifloxacin placebo under fasted conditions) then Treatment H (a single dose of ALS-008176 placebo + a single dose of moxifloxacin 400 mg under fasted conditions) then Treatment I (a single dose of ALS-008176 placebo + a single dose of moxifloxacin placebo under fasted conditions). There will be a washout period of at least 14 days between subsequent treatments.
2509637|NCT02833831|Experimental|Part 2: Sequence HIG|Participants will receive Treatment H then Treatment I and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
2509643|NCT02833831|Experimental|Part 2: Sequence IGH|Participants will receive Treatment I then Treatment G and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
2509652|NCT02833831|Experimental|Part 2: Sequence IHG|Participants will receive Treatment I then Treatment H and then Treatment G. There will be a washout period of at least 14 days between subsequent treatments.
2509657|NCT02833831|Experimental|Part 2: Sequence HGI|Participants will receive Treatment H then Treatment G and then Treatment I. There will be a washout period of at least 14 days between subsequent treatments.
2509659|NCT02833831|Experimental|Part 2: Sequence GIH|Participants will receive Treatment G then Treatment I and then Treatment H. There will be a washout period of at least 14 days between subsequent treatments.
2509801|NCT02832765|Experimental|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions
2509804|NCT02832765|Experimental|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis
2509807|NCT02832765|Experimental|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions
2509809|NCT02832765|Experimental|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis
2509844|NCT02832453|Other|Lifestyle counseling|This group will receive lifestyle counselling but not supervised exercise training sessions
2509845|NCT02832453|Experimental|Aerobic interval training|This group will receive lifestyle counselling plus supervised high intensity (80%VO2max) interval exercise training sessions
2509846|NCT02832453|Active Comparator|Traditional continous training|This group will receive lifestyle counselling plus supervised moderate intensity (60%VO2max) continous exercise training sessions
2509884|NCT02832206||hybrid ablation|60 patients with stand-alone, persistent or long-standing persistent atrial fibrillation
2510072|NCT02831075|Experimental|Adipose-derived stem cell|Mesenchymal stem cells derived from adipocyte transplantation
2510073|NCT02831075|Placebo Comparator|saline|saline injections
2510126|NCT02830828||Patients|Patients fulfilling inclusion/exclusion criteria referred to the PI with suspected carpal tunnel syndrome.
2510128|NCT02830828||Controls|"Healthy volunteers fulfilling inclusion/exclusion criteria with no symptoms of carpal tunnel syndrome.~Mid-study, it was elected to also match patients to their own contralateral disease-free hand to act as a control."
2510453|NCT02827916|Experimental|All patients|Measure of painful neuropathy for al patients with thermotest and sudoscan Devices and Neuropathic Pain Symptom Inventory.
2509397|NCT02835365||patients treated with baclofen|Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled
2509465|NCT02835066||Ancillary-Correlative (HRQOL, fitness and psychosocial health)|Patients scheduled for surgery, radiation therapy, or chemotherapy complete the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-core 30 (C30) and QLQ-Lung Cancer 13 (LC13) in addition to psychosocial health and smoking status questions from baseline up to 2 weeks prior to the start of treatment, 5-6 weeks after treatment begins, and 5-6 months from the start of treatment. During the same time points, patients also undergo function/fitness assessments including standard health measurements, short physical performance battery (SPPB), 6 minute walk test (6MWT), and a grip strength test.
2509499|NCT02834598|Experimental|Rocking movement|Participant is lying in a hammock with a rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2509504|NCT02834598|Active Comparator|Lying position|Participant is lying in a hammock with no rocking motion. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2509506|NCT02834598|Active Comparator|Seated position|Participant is sitting on a chair. Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
2509559|NCT02834533|Active Comparator|column heading in tables.|The group 1 (G1, n=20) underwent Lokomat-Nanos training. Each patient underwent 40 1h-training sessions (for 3 times a week). Both the study groups were treated by Lokomat (Hocoma Inc., Zurich, Switzerland), which includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . The overall duration of Lokomat therapy, including the time to get on and off, was 60min, while the robotic gait training lasted around 40min.
2509560|NCT02834533|Active Comparator|row and column in table|The group 2 (G2, n=20) underwent Lokomat-Pro training, with the same G1 sessions. The Pro device offers instead a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
2509622|NCT02834104|Experimental|Myocardial fibrosis|
2509676|NCT02833753|Experimental|Dose Escalation|"Single arm dose finding for intraperitoneal Oxaliplatin. All patients will receive experimental treatment.~The first cohort of 3 patients will receive dose level 1. The second cohort of 3 patients will receive dose level 2. The Third cohort of 3 patients will receive dose level 3. The fourth cohort of 3 patients will receive dose level 2."
2509746|NCT02833220||Healthy volunteers|"Healthy adults between the ages of 18-65 are eligible.~Participants will receive non-invasive brain stimulation by way of single-pulse transcranial magnetic stimulation to the motor cortex"
2509803|NCT02832908|Other|Patients + parents|Patients with severe head trauma
2509833|NCT02832583|Experimental|Mesotherapy of PRP-HA into the cheeks|Three sessions of PRP-HA prepared with RegenKit BCT-HA Cellular Matrix into each cheek separated by 1 month interval.
2509855|NCT02832336|Experimental|Caffeine|"Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakefulness state.~Generic name :Vivarin(1,3,7-trimethylxanthine), 200 mg/day for one week, Form of Administration:Oral in veg white capsule form (size 1) Drug Class:Central nervous system (CNS) stimulants."
2509859|NCT02832336|Placebo Comparator|Fiber|Fiber powder will be used as placebo, Form of Administration:Oral in veg white capsule form (size 1)
2509900|NCT02832089|Experimental|active arm|single arm study with one group given oral carvedilol.
2509914|NCT02831868|Experimental|EXP|Implantation of a HAVAI device to correct HVA without osteotomy
3163908|NCT00489099|Active Comparator|V232 Current Process Hepatitis B Vaccine|Recombivax HB™ (Hepatitis B Vaccine [Recombinant]) current process administered as a 1 mL intramuscular injection on Day 1, Month 1, and Month 6.
3163909|NCT00489138|Experimental|1|Noradrenalin infusion
2510032|NCT02831322|Experimental|radial artery occlusion|Radial artery occlusion was the absence of a flow signal by Doppler ultrasound examination.
2510036|NCT02831322|Other|radial artery normal|Radial artery normal was blood flow signal by Doppler ultrasound
2510096|NCT02831010||encephalopathy of prematurity|infants with encephalopathy of prematurity showed on MRI at term-equivalent age
2510102|NCT02831010||no encephalopathy of prematurity|infants with no encephalopathy of prematurity showed on MRI at term-equivalent age
2510173|NCT02830230|Experimental|Intervention group/Case|"women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.~women with clinical cervicitis or cervicovaginitis as per NACO Guidelines will be enrolled in intervention group.A cervico-vaginal swab shall be taken for Lab diagnosis of RTIs along with HPVDNA test on day 1.Women shall be treated with Tab Azithromycin 1gm and Tab Cefixime 400mg stat along with barrier contraception advised.The women will be followed up after 7-14 days .A repeat cervicovaginal swab and HPVDNA shall be repeated."
2510174|NCT02830230|No Intervention|Control group|Women without signs and symptoms of cervicitis or cervico-vaginitis.No intervention will be done in this group
2510181|NCT02829801|Experimental|AAT arm|AAT and cognitive stimulation and rehabilitation of social tie.
2510188|NCT02829801|Other|control group|Cognitive stimulation and rehabilitation of social tie.
3163910|NCT00489138|No Intervention|2|No adrenalin infusion
3163911|NCT00489177|Active Comparator|A|QuickOpt
3163912|NCT00489177|Placebo Comparator|B|Usual care
3163913|NCT00489203|Experimental|Arm I|Patients receive oral beclomethasone dipropionate 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
3163914|NCT00489203|Active Comparator|Arm II|Patients receive oral placebo 4 times daily beginning at the start of the conditioning regimen and continuing through day 75 post-transplant. Patients also receive a standard immunosuppressive regimen comprising tacrolimus and methotrexate post-transplant.
2509427|NCT02835404|Experimental|Concurrent radiochemotherapy Group|Concurrent radiochemotherapy with Nedaplatin Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f with 8mv-X rays (SSD) 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations; Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
2509429|NCT02835404|Active Comparator|Radiotherapy Group|patients received Radiotherapy only Pelvic External Radiotherapy: patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X Linear Accelerator SSD 252-Cf Neutron Intracavitary Brachytherapy: total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations.
2509447|NCT02834949|Experimental|BMI + SFAS|"Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the College Adjustment Session and the session will be conducted using an MI plus personalized feedback approach."
2509450|NCT02834949|Active Comparator|BMI + Relaxation Session|Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive a relaxation training session. In the relaxation training session, the clinician leads the student through a diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
2509452|NCT02834949|No Intervention|Assessment|Participants will fill out a battery of measures and receive no intervention.
2509530|NCT02834832||Control|The patients will be given removable dentures with no coatings. These dentures are part of the standard of care to treat their edentulism.
2509535|NCT02834832||PECVD Coatings|The patients will be given removable partial dentures with PECVD coatings on both the tissue surface of the dentures and the acrylic denture teeth.
2509603|NCT02834455|Active Comparator|CE-CT scanning|Contrast-enhanced CT scan of the thorax and abdomen.
2509607|NCT02834455|Active Comparator|PET-CT scanning|Positron-emission-CT scanning (low dose without contrast) of the thorax and abdomen.
3197065|NCT00857129|Experimental|2|Low-risk women are randomised to this Low-risk maternal unit, The Normal Unit.The unit is organised for low-risk women with expected normal birth. The unit has access to extended surveillance, epidural and operative vaginal deliveries. If extended surveillance is necessary for a woman randomised to this unit, she does not have to be transferred to a higher level of care. Instrumental vaginal deliveries can be carried out at this unit.
3197066|NCT00857129|Experimental|3|Women with expected normal births are being randomised to this Special birth unit designed to take care of women before, under and after birth. The Special Unit cares for women with extended need for surveillance, but does also handle low-risk women.
2509827|NCT02832856|Placebo Comparator|Control|"Control group members will receive a job readiness curriculum entitled Beginning to Work it Out (BWIO) that assists at-risk youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
2509829|NCT02832856|Experimental|Full Relationship Smarts Curriculum|This group receives the behavioral intervention of the healthy relationship education in the form of the full, 12-lesson RS+ curriculum over approximately 12 weeks.
2509831|NCT02832856|Experimental|Abridged Relationship Smarts Curriculum|"This group receives the behavioral intervention of the healthy relationship education in the form of the summary 8-lesson version of the RS+ curriculum - as well as four lessons on career planning and job readiness over approximately 12 weeks."
3197067|NCT00857142|Experimental|1|Oxymorphone hydrochloride 40 mg extended release tablets (Sandoz)
3197068|NCT00857142|Active Comparator|2|Opana 40 mg extended release tablets
3197069|NCT00857155|No Intervention|Aspirin only|Continue aspirin until surgery
3197070|NCT00857155|Other|Clopidogrel and Aspirin|
2510035|NCT02831335||Group 2|normal 36-50 years old participants
2510042|NCT02831335||Group 3|normal 51-65 years old participants
2510048|NCT02831335||Group 4|normal 66- 80 years old participants
3197071|NCT00857168|Active Comparator|Group 1|
3197072|NCT00857168|Active Comparator|Group 2|
3197073|NCT00857168|Active Comparator|Group 3|
2510164|NCT02830295|Experimental|Basic Body Awareness Therapy|The Basic Body Awareness Therapy is usual therapy of physiotherapy in health mental in nord of europe. BBAT is based in twelve movements and massage that improve the movement quality of patient, also BBAT improves others movement qualities like biomechanical, physiologic, socio-cultural and existential.
2510165|NCT02830295|No Intervention|control|the patients which below receive the treatment as usual, according the clinic guidelines of Health government
2510175|NCT02829931|Experimental|Combination Therapy|"Safety Cohort: The first 6 participants will receive Hypofractionated Stereotactic Irradiation (HFSRT) followed by Ipilimumab + Nivolumab + Bevacizumab.~Dose Expansion Cohort: All 26 participants will be treated with Hypofractionated Stereotactic Irradiation (HFSRT), followed by Ipilimumab + Nivolumab +Bevacizumab"
3197074|NCT00857168|Active Comparator|Group 4|
3197075|NCT00857168|Active Comparator|Group 5|
3197076|NCT00857168|Active Comparator|Group 6|
3197077|NCT00857181||Liver Cirrhosis|Single cohort of patients with liver cirrhosis to be investigated in the study. Two-monthly measurements of serum cytokines.
3197078|NCT00857194||Group 2|Chronic, stable spinal cord injury
3197079|NCT00857298|Active Comparator|HIV-MS|HIV-positive obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
3197080|NCT00857298|Active Comparator|MS only|HIV-negative obese women with metabolic syndrome will be studied before and after losing 6-8% of body weight
3197081|NCT00857324|Experimental|ZMP|Combination with Vorinostat, Melphalan and Prednisone
3197082|NCT00857350||HIV+, opiod dependent|
3197083|NCT00857363||Constipated|Adult subjects with functional constipation as define by Rome II criteria
3197084|NCT00857376|Placebo Comparator|placebo|Placebo 2 tabs three times daily
2509430|NCT02835547||Scleroderma|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2509432|NCT02835547||Hematopoietic stem cells transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2509436|NCT02835547||Kidney transplants|Data collection of risk factors (collected retrospectively - 5 years) and cardiovascular events (collected prospectively - 2 years).
2509454|NCT02834975|Experimental|Pembrolizumab, Paclitaxel + Carboplatin|"The following therapy will be administered during each 21-day cycle for a maximum of eight (8) cycles:~Pembrolizumab 200mg intravenously (IV);~Paclitaxel 175 mg/m2 IV in a neoadjuvant setting (NACT);~Paclitaxel same as NACT, OR 80 mg/m2 IV dose dense option in an adjuvant setting (ACT);~Carboplatin IV area under the curve (AUC) of 6."
3163917|NCT00489372|Placebo Comparator|Arm I (placebo)|Participants receive oral placebo on day 1.
3163918|NCT00489372|Experimental|Arm II (Se-methyl-seleno-L-cysteine)|Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity.
2510047|NCT02831114|Experimental|Intervention|The nine participants in the intervention arm will receive 18 acupuncture treatments over the course of 12 weeks (2 treatments per week for 6 weeks and 1 treatment per week for 6 weeks). They will undergo assessments at baseline, 6 weeks, and 12 weeks through the use of questionnaires and blood tests. The participants will also be allowed to continue their conventional therapy for TIPN.
2510051|NCT02831114|No Intervention|Control|The nine participants in this arm will undergo the same assessments as the intervention arm at baseline, 6 weeks, and 12 weeks. They will not receive any acupuncture treatments during this time, but will be allowed to continue their conventional therapy. The control arm will be offered the same 18 acupuncture treatments after a wait of at least 12 weeks.
2510110|NCT02830971|Other|Clinical specific education|Providing clinical skills conditions
2510150|NCT02830633|Experimental|LNTME|Laparoscopy-assisted nerve-preserved TME (LNTME) is conducted in rectal cancer patients
2510151|NCT02830633|Active Comparator|OTME|Open TME (OTME) is conducted in rectal cancer patients
2510197|NCT02830100|Other|Healthy volunteers|
2510262|NCT02829424|Active Comparator|Experimental group|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the control group and according to the Summary of Product Characteritics (SmPC) MTX: 15 mg a week orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX will be initiated within 7 days after the start of the anti TNF alpha agent
2510263|NCT02829554||Respondents|US residents recruited to an on-line questionnaire through Amazon mTurk.
2510266|NCT02829424|Placebo Comparator|Control group|"Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication: etanercept- Enbrel®, adalimumab- Humira ®, infliximab -Remicade ®, infliximab's biosimilar- Inflectra®, Remsima®, or any other biosimilar or branded biological agent~All anti TNF alpha agents will have to be prescribed in the same administration modality and dosing regimen than in the experimental group and according to the SmPC Placebo-MTX orally: on a fixed day of the week defined for each patient In patients receiving an anti TNF alpha according to the SmPC, MTX-placebo will be initiated within 7 days after the start of the anti TNF alpha agent"
2510299|NCT02829229|No Intervention|Usual care (UC)|Usual postpartum WIC care
2510300|NCT02829229|Experimental|Community-based obesity treatment (PP)|The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook.
2510336|NCT02828904||Primary Cases|"Primary cases are women~aged 15 to 49 years~with a new VTE diagnosis within the study period~current user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
2510339|NCT02828904||Secondary Cases|"Secondary cases are women~aged 15 to 49 years~with a new VTE diagnosis within the study period~using any HC other than CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg, or not using any HC at all"
2510342|NCT02828904||Primary Controls|"Primary controls are women~aged 15 to 49 years~matched to a primary case by age (+/- 1 year) and region of residence~current or recent past user of CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg categorized as new-starter or incident user"
2510346|NCT02828904||Secondary Controls|"Secondary controls are women~aged 15 to 49 years~matched to a primary case by age (+/- 1year) and region of residence~current or recent past user of other COCs (not containing CMA 2mg / EE 30µg or LNG 0.15 mg / EE 30µg)"
2510364|NCT02828670||patient|
2510367|NCT02828670||control|
2510413|NCT02828163|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide is an effective treatment for oral erosions of pemphigus vulgaris patients. 10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
2510423|NCT02828449|Experimental|therapeutic education program|therapeutic education program which aims is to improve the adherence to the treatment and management of adverse effects of this treatment in patients taking an oral chemotherapy for active cancer
2510451|NCT02828462||Experimental|Patients using the device
2510452|NCT02828462||Control|Patients not using the device
3163919|NCT00489515||patients with gastrointestinal cancer scheduled for surgery|
3163920|NCT00489567||Group A|Children hospitalised with community-acquired severe RV GE and children acquiring nosocomial severe RV GE.
3163921|NCT00489593|Experimental|Olanzapine|Olanzapine 2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
3163922|NCT00489632||Questionnaire|Children with leukemia and their families/caregivers.
3163923|NCT00489645|Placebo Comparator|1|Placebo, euglycemia
2509440|NCT02835300|Experimental|CampAir Intervention|Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
2509441|NCT02835300|Active Comparator|Information and Referral Control|Adolescents assigned to the information-and-referral control condition will be provided access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will receive access to CampAir.
2509445|NCT02834936|Experimental|pyrotinib treatment|
2509522|NCT02834741|Placebo Comparator|SAD Phase|"Up to 36 subjects: 50 - 1200 mg NYX-2925, Up to 12 subjects: placebo~6 additional subjects will receive a fed dose of NYX-2925, 2 additional subjects will receive a fed dose of placebo (Food Effect Cohort)~6 additional subjects will receive 1 dose of 50 mg NYX-2925 followed by a lumbar puncture at 1 and 4 (3 subjects) or 2 and 8 (3 subjects) hours post dose"
2509526|NCT02834741|Placebo Comparator|MAD Phase|"Up to 24 subjects : 150 - 600 mg NYX-2925 daily for 7 days, up to 6 subjects : placebo daily for 7 days~6 additional subjects will receive 300 mg NYX-2925 daily for 7 days and undergo lumbar puncture on Day 6 in order to have two CSF samples taken (CSF Cohort)."
2509579|NCT02834416|Experimental|Group-Supervised|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
2509586|NCT02834416|Experimental|Home-Based|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as the supervised group). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
3197085|NCT00857376|Experimental|Alpha lipoic acid 1|Alpha lipoic acid 600 mg daily
3197086|NCT00857376|Experimental|Alpha lipoic acid 2|Alpha Lipoic acid 1200 mg daily
2509697|NCT02833363||patients with non-atrophic gastritis|
2509699|NCT02833363||Patients with gastritis|
2509701|NCT02833363||Patients with intestinal metaplasia|
2509705|NCT02833363||Patients with intrepithelial neoplasia|
2509708|NCT02833363||Patients with non-cardia gastric cancer|
2509769|NCT02833194||Leiden Group|Women with an isolated F5 rs6025 polymorphism or an isolated F2 rs1799963 polymorphism.
2509773|NCT02833194||aP1Ab-positive|"Inclusion in the aP1Ab Group:~Initially positive for aP1Ab~Second positive aP1Ab test six months later"
2509777|NCT02833194||Thrombophilia-negative|Women with completely negative thombophilia screening results.
2509837|NCT02832726|Active Comparator|cyano-hydroxo B12|Absorption of 3 doses of 9 ug cyano-B12 and 9 ug hydroxo-B12 for two days (the CobaSorb test). No drugs given.
2509838|NCT02832726|Active Comparator|Cyano-B12 doses|Absorption of 3 doses of 3 ug, 6 ug, and 9 ug cyano-B12 for two days (the CobaSorb test). No drugs given.
2510075|NCT02831231|Experimental|Xanomeline plus trospium|Drug: Xanomeline tartrate 75 mg TID, for 225 mg total daily dose Drug: Trospium chloride 20 mg BID, for a 40 mg total daily dose
3197087|NCT00857376|Experimental|Alpha lipoic acid 3|Alpha lipoic acid 1800 mg daily
2510135|NCT02830412|Experimental|PONV Reminder|After patient has non-cardiac surgery, the subject will have Post-Operative Nausea and Vomiting Reminder display
2510136|NCT02830412|No Intervention|No PONV Reminder|After patient has non-cardiac surgery, the subject will not have Post-Operative Nausea and Vomiting Reminder display
2510155|NCT02830529|Experimental|MAD DASH|Mindfulness based stress reduction and diet education delivered in 8 sessions lasting 2.5 hours each. Mindfulness conducted by a certified trainer. Participants were given homework and meditation CD. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
2510158|NCT02830529|Experimental|DASH diet education|Dietary approaches to stop hypertension sessions were delivered by a registered dietitian in 8 sessions lasting 1 hour each. Dietitian delivered diet education and conducted interactive food demonstrations. Participants were given option complete weekly diet diary for the dietitian to provide feedback.
2510159|NCT02830529|No Intervention|Usual Care-DASH Pamphlet Only|Dietary approaches to stop hypertension pamphlet was mailed to each participant. They continued receiving usual care from their health care provider.
2510177|NCT02830217||STEMI patients having primary PCI|Patients with STEMI receiving primary PCI in Wuhan Aisa Heart Hospital are included in this study. All patients are the first time to have STEMI, and primary PCIs are performed according to 2013 ACCF/AHA guideline for the management of STEMI. Patients with previous stroke, pneumonia, cirrhosis, autoimmune diseases are excluded from this study.
2510182|NCT02830035|Active Comparator|Anatomical Landmark Technique|Traditional anatomical landmark technique based paramedian spinal anesthesia
2510187|NCT02830035|Active Comparator|Real-time Ultrasound-guided Technique|Ultrasound-guided paramedian spinal anesthesia Intervention: Ultrasound-guided Technique
2510200|NCT02829788||Digestive peritoneal carcinomatosis staging|All patients underwent laparoscopic followed by laparotomic surgical staging.
2510238|NCT02829580|Experimental|Sickle group|Children with major sickle cell syndrome will have an usual Echocardiography
2510239|NCT02829580|Active Comparator|Control group|Children recruited in a previous study and who had an usual Echocardiography
3197088|NCT00857402|Active Comparator|Peanuts|
3197089|NCT00857402|Active Comparator|Daboqolo|
3197090|NCT00857428|Experimental|1|Oxymorphone ER 40 mg tablets Sandoz
3197091|NCT00857428|Active Comparator|2|Opana ER 40 mg tablets Eon Pharmaceuticals
2509605|NCT02834364|Experimental|single arm|Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
2509640|NCT02833792|Experimental|Stem Cells|Stem cells
2509651|NCT02833792|Placebo Comparator|Placebo|Lactated Ringer's Solution
2509795|NCT02832791|Active Comparator|QUADRICEPS TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING QUADRICEPS TENDON
2509798|NCT02832791|Active Comparator|HAMSTRING TENDON|ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION USING HAMSTRING TENDON
2509839|NCT02832518||patients under hemodialysis|
2509880|NCT02832297|Other|Vectra DA (Arm A)|Treatment intensification with non-biologic DMARDS guided by Vectra DA
2509883|NCT02832297|Other|Usual care (Arm B)|Treatment intensification by usual care without using Vectra DA
2509993|NCT02831478|Experimental|BAY987517|2/3 of subjects testing the test article
2509995|NCT02831478|Active Comparator|Sunscreen Lotion|1/3 of subjects testing the marketed control
2510011|NCT02831270||Control Group|Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB
2510012|NCT02831270||Active Comparator: Acute normovolemic hemodilution group|Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
2510037|NCT02831101|Experimental|Sufentanil|Sufentanil intravenously, continuously with effect-site concentration of 0.3 ng/ml until the end of the study
2510043|NCT02831101|Other|Placebo|Saline intravenously, continuously with the same effect-site concentration as sufentanil (recorded on administration device) until the end of the study
2510049|NCT02831101|No Intervention|Propofol|Open administration using a separate target controlled infusion system and the PK/PD model by Schnider. Initial effect-site concentration 0.5 mcg/ml increased by 0.5 mcg/ml until LOC
2510083|NCT02830854|Experimental|Molecular Hydrogen|Molecular hydrogen: 20 min per day of 3% H2 during 4 weeks
2510095|NCT02830958|Experimental|Kinesiotaping Group|applied next to the lymphatic system from the validated methods Kinesiotaping®.
2510101|NCT02830958|Placebo Comparator|Ordinary tape Group|Installation of an ordinary tape (not having the characteristics of Curetape®).
2510120|NCT02830724|Experimental|1/Phase I|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + escalating doses of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
2510121|NCT02830724|Experimental|2/Phase II|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + MTD of anti-hCD70 CAR transduced PBL + high-dose aldesleukin
2510144|NCT02830347||Amoxicillin|No randomization is performed. Patients who are prescribed antibiotics by the clinician performing the tooth extraction ( based on case complexity and intra operative judgement) are recruited into this group.The principal investigator is not involved in the decision to prescribe antibiotics or not.
2510147|NCT02830347||No Amoxicillin|Patients who do not receive antibiotics after extractions are recruited into this group.
2510149|NCT02830607|Experimental|Xiaomi Mi Band|participants will wear Xiaomi Mi Band .the device measures their daily steps number before and after epidural steroid injection for treatment of low back pain.
2510167|NCT02830113|Experimental|non-surgical periodontal treatment|One session of non-surgical periodontal treatment consisting of a complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution.
2510201|NCT02830139|Sham Comparator|Radical colorectal resection without HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and postoperative chemotherapy (XELOX)
3163924|NCT00489645|Experimental|2|Pramlintide, euglycemia
2510207|NCT02830139|Experimental|Radical colorectal resection with HIPEC|Patients will be treated with a radical colorectal resection for locally advanced colorectal cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (XELOX)
2510253|NCT02829450||PD|"Patients with CHF and chronic renal disease which started the treatment with peritoneal ultrafiltration.~The patients will be follow up every 3 months for assesment of symptoms, QOL questionary, routine blood and urine tests and also for assesment of residual renal function and peritoneal membrane function: monitoring of clinical symptoms of fluid overload, hospital admissions, UF rate, peritoneal membrane damage parameters (cell-free DNA in peritoneal effluent, peritoneal equilibration test) and residual renal function markers (eGFR creatinine or cystatin C based , KT/V, urinary markers) at the start of the treatment, each 3 months during the treatment and at each change of prescription. Complications of all kinds will be recorded."
2510330|NCT02828852|Experimental|Pregnancy|Blood sample
3163925|NCT00489645|Placebo Comparator|3|placebo, hyperglycemia
3163926|NCT00489645|Experimental|4|pramlintide, hyperglycemia
3163927|NCT00489671||pre cancerous condition (pancreatitis)|
3163928|NCT00489697|Experimental|1 (single arm)|patient with histologically confirmed colorectal tumor treated in first line by a bevacizumab based chemotherapy
2509490|NCT02834793|Experimental|Perampanel up to 8 mg/day|"During the Randomization Phase, participants will receive perampanel at a starting dose of 2 milligrams per day (mg/day). Thereafter, the dose will be increased to a maximum target dose of 8 mg/day according to individual tolerability and efficacy for up to 18 weeks. Participants who enter into Extension A will continue to receive perampanel at the dose last received during randomization phase. Participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion.~Participants who continue in Extension B will continue to receive perampanel at the dose last received at the end of Extension A."
2509491|NCT02834793|Placebo Comparator|Matching placebo|"During the Randomization Phase, participants will receive matching placebo for up to 18 weeks.~During the Extension A, participants who received placebo during the Randomization Phase will begin treatment with perampanel in a blinded manner in double-blind Conversion Period, starting at 2 mg/day and then up-titrated to a maximum target dose of 8 mg/day according to individual tolerability and efficacy. After the Conversion Period, participants can be titrated up to 12 mg/day (at 2-week intervals) per the investigator's discretion."
2509580|NCT02834169||pseudomyxoma peritonei|Data from pseudomyxoma peritonei cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509585|NCT02834169||peritoneal mesothelioma|Data from peritoneal mesothelioma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509589|NCT02834169||desmoplastic small round cell tumor|Data from desmoplastic small round cell tumor cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509591|NCT02834169||psammocarcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509592|NCT02834169||primary peritoneal serous carcinoma|Data from primary peritoneal serous carcinoma cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509593|NCT02834169||diffuse peritoneal leiomyomatosis|Data from diffuse peritoneal leiomyomatosis cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509594|NCT02834169||appendiceal mucinous neoplasms|Data from appendiceal mucinous neoplasms cases will be used to generate descriptive statistics on demographics, clinical characteristics including prevalence and incidence of co-morbidities, treatment patterns, and patient outcomes (resulting from treatment or disease).
2509710|NCT02833636||Successful CTO-PCI group|low ACEF score <1.215 (n = 79), intermediate ACEF score from 1.215 to 1.493 (n=70), and high ACEF score≥1.493 (n=72)
2509713|NCT02833636||Failed/non-attempted CTO-PCI group|low ACEF score<1.215 (n=45), intermediate ACEF score from 1.215 to 1.493 (n=57), and high ACEF score≥1.493 (n=54).
2509791|NCT02832739|Experimental|SENACA - self-management support system|Use of enhanced SENACA - ICT based self-management support system prototype by study participants at home for 75-100 days
2509875|NCT02832609|No Intervention|sitting position|measurement in the sitting position
2509876|NCT02832609|Active Comparator|supine position|measurement in the sitting position
2509925|NCT02832076|Experimental|group a|This arm will receive subcutaneous negative suction drain for the midline wound for 10 days.
2509926|NCT02832076|Active Comparator|group b|This arm will receive closure of the midline wound without a subcutaneous drain.
2509966|NCT02831530|Experimental|Abemaciclib|Patients randomized to the treatment arm will start treatment from 15 days before the surgery (day 1 of the study) to receive the last dose of treatment the day before the surgical procedure (day 14 of the study). Abemaciclib will be taken orally at a dose of 150 mg/ twice a day (Every 12h +/- 2h) on day 1 to day 14. The treatment should be taken in the morning and evening with a big glass of water (250ml) at approximately the same time.
2509973|NCT02831530|No Intervention|No treatment|
2510041|NCT02831413|Placebo Comparator|Control|Control group members will receive an alternate curriculum that is not related to relationship education. Family Bridges has identified a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
2510044|NCT02831413|Experimental|RS+|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
2510053|NCT02831413|Experimental|RS+ with enhanced facilitator support|The RS+ curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making. Affiliates assigned to this enhanced treatment group will participate in enhanced facilitator training and support activities.
2510089|NCT02830919|Experimental|Glucosamine and chondroitin sulfate combination (Eurofarma)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Eurofarma Laboratórios S.A., administered once a day for 24 weeks.
2510091|NCT02830919|Active Comparator|Glucosamine and chondroitin sulfate combination (Zodiac)|Glucosamine sulfate 1500mg plus chondroitin sulfate 1200mg combination, manufactured by Zodiac Produtos Farmacêuticos S.A. (Condroflex®), administered once a day for 24 weeks.
2510122|NCT02830932|Experimental|VXA-RSV-f Tablets (high dose)|Singe dose of orally administered VXA-RSV-f Tablets (high dose). VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
2510124|NCT02830932|Experimental|VXA-RSV-f Tablets (low dose)|Singe dose of VXA-RSV-f Tablets (low dose).VXA-RSV-f is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of respiratory illness caused by RSV. The vaccine vector encodes for a full-length F protein gene from RSV.
2509512|NCT02834585||Magnetic Resonance Imaging|Patients undergoing Magnetic Resonance Imaging
2509595|NCT02834442|Experimental|Single ascending dose, MT-7117 or Placebo|
2509599|NCT02834442|Experimental|Multiple ascending dose, MT-7117 or Placebo|
2509649|NCT02833870|Experimental|Musical intervention|
2509655|NCT02833870|Experimental|Non-musical (cooking) intervention|
2509661|NCT02833870|Active Comparator|Control with no intervention|
2509733|NCT02833246|Experimental|SMS/MMS text messaging|Patients will be able to tailor their SMS/MMS reminders with respect to when (i.e., what time of day) they wish to receive the reminders, as well as how often the messages are sent (e.g., morning and evening).
2509735|NCT02833246|Active Comparator|usual care|This includes physician and nursing assessment and intervention for any identified AEs. Of note, there is not currently standard follow-up that patients receive from nursing or physician staff while on an OAM treatment. Patients are encouraged to call their physician's office with any questions or changes in their medical status but are not called routinely by MSK staff.
2509779|NCT02832973|Experimental|Spironolactone, Furosemide Amiloride|Spironolactone 25 mg qd, Furosemide 20 mg qd, Furosemide 40 mg qd, Amiloride 5 mg qd
2509782|NCT02832973|Active Comparator|Ramipril, Bisoprolol|Ramipril 5 mg qd, Ramipril 10 mg qd, Bisoprolol 5 mg qd, Bisoprolol 10 mg qd
2509863|NCT02832596|No Intervention|Control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
2509864|NCT02832596|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
2509903|NCT02832102||Retrospective cohort|"A total of 1000 SCCHN patients will be enrolled in a retrospective observational study treated in the period 2008-2014.~Standard treatment of SCCHN patients The patients will be managed as foreseen by best clinical practice and international guidelines for SCCHN."
2509907|NCT02832102||Prospective cohort|"A total of 450 SCCHN patients will be enrolled in a study. Each participating Center will select consecutive patients according to the selection criteria (inclusion/exclusion criteria) for one year and will be followed up for two years or more.~Standard treatment of SCCHN patients: patients will be administered current best clinical practice treatments."
2510017|NCT02831491|Experimental|Ramucirumab + Docetaxel|Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.
2510076|NCT02831062|No Intervention|ad lib diet|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients will be asked to continue on their regular diet and the protein and caloric ingestion will be recorded at each visit.
2510077|NCT02831062|Experimental|Low Protein Diet + Ketosteril|Patients who have an episode of Stage 2/3 AKI and are followed in a focused post-AKI clinic. Patients in this arm will be prescribed a low protein diet (LPD) and +Ketosteril supplementation, containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose). Protein and caloric ingestion will be recorded.
2510094|NCT02830802|Experimental|Group A|Active Agent
2510098|NCT02830802|Placebo Comparator|Group B|Placebo
2510127|NCT02830932|Placebo Comparator|VXA Placebo Tablets|Singe dose of matching placebo tablets. The placebo tablets are small off-white tablets that are similar in size and number to the active vaccine dose being delivered.
3163929|NCT00489710|Experimental|Talabostat|Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles
2510176|NCT02830243|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2510178|NCT02830243|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2510190|NCT02829970|Experimental|SUCCEEDS Program|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will be engaged about personalized alcohol feedback and identify life values and specific activities important to those values.
2510193|NCT02829970|Active Comparator|Living a Healthy College Lifestyle|Participants will meet individually with a research team member for three weekly sessions, two bi-weekly sessions, and complete 1-month and 3-month post treatment follow-ups. Participants will engage in discussion focused on experiences as an emerging adult.
2510251|NCT02829606|Active Comparator|small scotoma using Head Mounted Display No re-mapping|patients with scotoma smaller than 5 degrees NO re-mapping PLUS re-mapping
2510255|NCT02829606|Active Comparator|Large scotoma using Head Mounted Display PLUS re-mapping|patients with scotoma larger than 5 degrees NO re-mapping PLUS re-mapping
2510260|NCT02829762|Experimental|Interventional arm PS-DR|The interventional arm (PS-DR) will include the implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance (in connection with a call center 24h/24).
2510265|NCT02829762|No Intervention|Reference Arm|In the reference arm, patients will have a conventional oncological care, social support measures will be left to the discretion of the clinician and the paramedical team.
2510269|NCT02829359|Experimental|Entecavir therapy|Patients who received entecavir (zhengda Tianqing Co., Ltd, Lianyungang, Jiangsu Province, China; 0.5 mg/d) were submitted to antiviral group. Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month. No immunological therapy in perioperative period will be submitted to any included patients.
2510273|NCT02829359|No Intervention|No antiviral therapy|Patients who did not receive any antiviral therapies were submitted as non-antiviral group. Patients in the non-antiviral group who underwent HBV reactivation will receive entecavir therapy. No immunological therapy in perioperative period will be submitted to any included patients.
3163930|NCT00489801|Other|Exercise intervention|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
3163931|NCT00489814||1|Patients who are planned to undergo local proton radiotherapy for biopsy-proven, untreated, prostate adenocarcinoma.
3163932|NCT00489840|Experimental|anecortave acetate|
3163933|NCT00489957||Normals|
3163934|NCT00489957||Cardiomyopathy|
3163935|NCT00490074|Experimental|3 DNA-C + 1 NYVAC-C|
3163936|NCT00490074|Active Comparator|2 DNA-C + 2 NYVAC-C|
3163937|NCT00490087|Experimental|Hysteroscopic resection plus IUD|
3163938|NCT00490087|No Intervention|Hysteroscopic resection without IUD|
2509529|NCT02834767|Placebo Comparator|Group 2 Primary Snoring Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2509533|NCT02834767|Experimental|Group 3 Primary OSA Treatment|Intervention: Eight weeks of supervised use of the genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2509540|NCT02834767|Placebo Comparator|Group 4 Primary OSA Placebo|Intervention: Eight weeks of supervised use of the placebo genioglossus muscle strength trainer. Training will occur 5 days per week for 8 weeks. Each daily training regimen to consist of 5 sets of 5 repetitions (25 repetitions total daily) of tongue contractions using the device.
2509562|NCT02834299|Experimental|DBT Guided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and receive six brief therapy sessions via video-calling."
2509569|NCT02834299|Experimental|DBT Unguided Self-Help|"Participants will be provided with the DBT self-help manual Dialectical Behavior Therapy for Binge Eating: A Self-Help Program by Safer, Adler & Masson (2016) and asked to follow the manual on their own."
2509578|NCT02834299|Active Comparator|Self-Esteem-Focused Unguided Self-Help|"Participants will be provided with the self-help manual Self-Esteem by McKay & Fanning (2016) as asked to follow the manual on their own."
2509642|NCT02834000|No Intervention|Standard Care|We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. The control group will compose of patients supervised in a standard way.
2509648|NCT02834000|Experimental|LiDCO rapid™ CNAP monitoring|Young, healthy adult patients (ASA I and II) undergoing elective orthopaedic surgery under general anaesthesia will be included in to this study. We will compare the standard monitored group of patients with the LiDCO rapid™ monitored group. We will use in the LiDCO rapid™ CNAP monitoring group, the continuous real time haemodynamic monitoring through non-invasive arterial pressure waveform. The monitor LiDCO rapid™ CNAP permits, through analysis the arterial blood pressure trace, to acquire information about CO, SVR, HR variability, SV and BIS.
2509681|NCT02833675||bradykinin angioedema|Hereditary angioedema with or without C1Inhibitor Drug induced angiodema
2509683|NCT02833675||Histaminergic angioedema|Allergic and non allergic angioedema
2509684|NCT02833675||Control group|Patients with abdominal pain
2509717|NCT02833376|Experimental|Alcohol group|Patients allocated to this group will receive skin antisepsis with alcohol 70% prior spinal anesthesia
2509723|NCT02833376|Experimental|Chlorhexidine group|Patients allocated to this group will receive skin antisepsis with alcoholic solution of chlorhexidine 0.5% prior spinal anesthesia
2509825|NCT02832752|Active Comparator|ECPR Region|The ECPR region has incorporated ECPR therapy into the out-of-hospital cardiac arrest algorithm. Within the ECPR Protocol, full standard advanced cardiac life support treatments will continue up until the time of ECMO initiation. The anticipated enrolment in this group is 70 patients. All eligible patients in the region will be enrolled, regardless of whether the ECPR protocol is activated or whether the patient is actually treated with ECPR.
2509826|NCT02832752|No Intervention|Control Region|"The control region will continue usual care as per current protocols which include standard advanced cardiac life support. Patients will be enrolled in the control region group at the same juncture of study eligibility. The anticipated enrolment in this group is 350 patients.~Within BCEHS practice, transport to hospital without prior return of spontaneous circulation is rare. Termination of resuscitation must be approved by an on-call physician and cannot occur prior to 30 minutes of resuscitation efforts."
2509873|NCT02832258||Children with urinary tract infection due to E-ESBL|In this prospective observational study between March 2013 and March 2017, children (0 to 18 years) with E-ESBL UTI (febrile UTI or cystitis) were enrolled in 24 pediatric departments in France. Clinical and biological characteristics, risk factors of infection of E-ESBL, first and second lines of antibiotic therapies were analyzed. We used the Kaplan-Meier method to estimate the time to apyrexia and length of hospital stay, and Log-rank test to assess equality of survivor functions. We also analyzed the resistance patterns and molecular characterization of ESBL types in the isolates.
2509928|NCT02831907||Cardiac surgery patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
3163939|NCT00490113|Experimental|1|
3163940|NCT00490126||Laparoscopic Surgery Database|
2510142|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC
2510170|NCT02830165|Experimental|Treatment (SBRT)|Patients undergo 3 fractions of SBRT over 1-2 weeks, 2-4 weeks prior to radical prostatectomy.
2510205|NCT02829814|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 12 weeks
2510208|NCT02829827|Experimental|Radiprodil|Each subject will enter an individualized dose titration schedule.
2510210|NCT02829814|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
2510274|NCT02829736|Active Comparator|Chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with a standard post-operative chest tube.
2510278|NCT02829736|Experimental|No chest tube group|Participants undergoing video-assisted thoracoscopic wedge resection with a positive intraoperative sealing test are treated with intraoperative chest tube removal.
2510415|NCT02828540|Placebo Comparator|Placebo|three times a day dosing schedule 3 tablets per dose
3163941|NCT00490152||1|Participants use Vivagel™, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3163942|NCT00490152||2|Participants use VivaGel™ Placebo, applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3163943|NCT00490152||3|Participants use HEC Placebo Gel (HEC Gel), applied vaginally twice daily for 14 days, and report their experiences via phone diary and teleconference.
3163944|NCT00490230|Experimental|WR 279,396|CL lesions treated with WR 279396
3163945|NCT00490230|No Intervention|Natural Healing|CL lesions healed naturally
3163946|NCT00490230|Placebo Comparator|vehicle control|CL lesions were treated with the vehicle alone
3163947|NCT00490295||newborn cardiac surgical study group|
2509573|NCT02834260|Experimental|ozurdex group|Subconjunctival injection of the absorbable implant of Dexamethasone immediately at the end of penetrating keratoplasty. The injection is made at the 12 O'Clock position is a bubble created by subconjunctival injection of balanced salt solution.
2509645|NCT02834065|Active Comparator|Deep Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius
2509653|NCT02834065|Active Comparator|Low Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius
2509660|NCT02834065|Active Comparator|Moderate Hypothermia|Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius
2509703|NCT02833519|No Intervention|control group|Standard care, mentally vulnerable women
2509706|NCT02833519|Active Comparator|group exercise|Supervised Group training
2509780|NCT02833142|Experimental|BIIB033-A|Staggered single dosing schema
2509781|NCT02833142|Experimental|BIIB033-B|Staggered single dosing schema
2509891|NCT02832193||Study group|"POCD data of study patients of the following studies:~Phydelio - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 ReCosa - EA1/056/13 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 Pain-Long-EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
2509894|NCT02832193||Control group I|"POCD data of prospective control subjects/patients (ASA I+II+III) and POCD data of control subjects/patients of the following studies:~Neuprodex - Eudract-No.: 2013 -000823-15 - 13/0491 ZSEK11 Phydeliostudie - Eudract.-No.: 2008-007237-47 - 08/0618 ZS EK11 BioCog - EA2/092/14 Cognitive Outcome after two stage liver operation - EA1/296/12 Hypnoc - EA1/273/11 Sudoco - EA1/242/08 Peratecs - EA1/241/08 Hipster - Eudract.-No.: 2009-016043-19 100/10 ZS EK15 BioCog-Studie - EA2/092/14 REACT-Studie - EA2/091/15 PAINLONG-Studie - EA2/041/17 PCI - EA2/024/18 PODSPA - EA4/138/18, PRÄP-GO -EA1/225/19, ANA-PRÄP-Go (EA1/266/20) Further studies from the Department of Anesthesiology and Operative Intensive Care Medince (CCM/CVK), Charité - Universitätsmedizin Berlin"
2509915|NCT02831985|Experimental|general practice follow-up|post-surgery follow-up by general practitioner
2509916|NCT02831985|Active Comparator|ENT specialist follow-up|post-surgery follow-up by ear-nose-throat (ENT) specialist
2509972|NCT02831686|Experimental|Selinexor (KPT-330), Ixazomib, and Dexamethasone|"Patients with relapsed and/or refractory MM will be treated with ixazomib, selinexor, and dexamethasone, all of which will be administered orally.Ixazomib will be given on Days 1, 8, and 15 on a 28 day cycle.~Selinexor will be given twice weekly for three weeks, then there will be 1 week off (Days 1,3, 8,10, 15, 17) This study will follow a 3-by-3 dose escalation design.~Dexamethasone will be given on all days of Selinexor but will also be given on the week off from Selinexor (Days 1, 3, 8, 10,15, 17, 22, 24)."
2510034|NCT02831244|Other|Agili-CTM|Intervention
2510103|NCT02830984|Experimental|EST+LBD+ENBD group|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
2510106|NCT02830984|Active Comparator|EST+LBD group|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
2510130|NCT02830516||Lung elastance - transpulmonary pressure|Lung elastance and transpulmonary pressure measured by tidal esophageal pressure variations and by performing a PEEP step
2510157|NCT02830620|Other|groupe4|unhurt individual of any appetite-suppressing evolutionary disease and cachectisante Dosage of chimiokines
2510198|NCT02830061||TYAC|Teenagers and young adults who have received a cancer diagnosis which puts them at moderate-to-high risk of fertility impairment. Semi-structured interviews will take place with each individual participant.
3197092|NCT00857441|Experimental|1|Use of Dior balloon and implant of Liberté Bare Metal Stent
3197093|NCT00857441|Active Comparator|2|Use of standard balloon and implant of Liberté Bare Metal Stent
2510234|NCT02829645|Other|Eating disorders|
2510245|NCT02829411|Active Comparator|Employment Services only|'Workforce Readiness Program'. job readiness workshop, organized into ten daily sessions over two weeks. The main content of these sessions will be a program-developed workforce readiness training, developed with funding from a DOL Career Pathways Bridge grant.
2510248|NCT02829411|Experimental|Employment Services with HMRE content|'Workforce Readiness Program supplemented with Relationship Education': job readiness workshop, organized into ten daily sessions over two weeks. Program will add approximately 17 hours of content from the Within My Reach relationship education curriculum to the two-week job readiness workshop - and add up to eight additional one-hour relationship skills education sessions that customers can attend in the five weeks after completing the initial two-week job readiness workshop
2510271|NCT02829346|Experimental|Peri-articular group|Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
2510277|NCT02829346|Active Comparator|Intravenous group|Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.
3163948|NCT00490334||Cancer patients|Children with cancer aged 8 to 16 years
3197094|NCT00857441|Active Comparator|3|Use of standard balloon and implant of Taxus Liberté Drug Eluting Stent
3197095|NCT00857467|Experimental|1 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository
3197096|NCT00857467|Experimental|2 g suppository|Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
2509734|NCT02833233|Experimental|Cryoablation and Immune Therapy|Patients will undergo breast biopsy with cryoablation 7-10 days prior to the planned surgery, and ipilimumab with nivolumab administration 1-5 days before cryoablation. All patients will undergo surgery at the pre-determined day defined at the initial surgical consultation. Women will receive ipilimumab and nivolumab 1-5 days prior to US or MRI-guided core biopsy and cryoablation date. Intravenous ipilimumab will be administered as a single 1 mg/kg dose to be infused intravenously over 90 minutes. Intravenous nivolumab will be administered as a single 3 mg/kg dose to be infused intravenously over 60 minutes.
2509755|NCT02832960|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2509756|NCT02832960|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
2509793|NCT02832830|Experimental|A|intensity modulated radiotherapy (IMRT) 10 x 3 Gy
2509799|NCT02832830|Active Comparator|B|fractionated conventional external beam RT 10×3 Gy
2509872|NCT02832570|Experimental|Sildenafil|Single sildenafil oral intake (100 mg) approximately 2 hours before the treadmill test.
2509874|NCT02832570|Placebo Comparator|Placebo|Single placebo intake approximately 2 hours before the treadmill test.
2509929|NCT02832050|Experimental|Intervention|"The play therapy intervention consists of a standard of care delivered by a play specialist. The play specialist delivers interventions aimed in assisting the child through the process of undergoing procedures. The intervention is semi-structured in order to facilitate a systematic approach which remains individualised and child-centred.~The intervention requires patients to be classified as 'high risk' or 'low risk' for procedure-related anxiety. This is assessed for all patients at baseline based on parent and clinician opinion. The play specialist may re-classify patients at the initial assessment or at any point whilst working with the child. If this occurs, clear documentation of the rationale for this will be recorded. Patients classified as high risk receive additional preparation sessions as detailed in the standard of care."
2509933|NCT02832050|Placebo Comparator|Comparator|The comparator group will receive standard care of patients having blood tests within the Trust, which does not include the specific intervention of a play therapist routinely. As part of standard care if a child becomes particularly distressed a clinician may make a decision to refer the child for play therapy. If this occurs during the study period the child will be referred to the play specialist delivering the intervention for the study. The child will then receive play therapy as in the described intervention. They will be excluded from the main analysis but data will still be collected and analysed descriptively.
3197097|NCT00857480|Experimental|Reference|No pre-treatment
3197098|NCT00857480|Experimental|T1|Cloxacillin pre- and co-treatment
2510143|NCT02830542|Experimental|SER-262|SER-262 [Single dose: 10(4), 10(5), 10(6), 10(7) or 10(8) SCFUs; Multiple dose 10(6), 10(7), or 10(8) SCFUs]
2510146|NCT02830542|Placebo Comparator|Placebo|Placebo
2510160|NCT02830321||case|"Pregnant women who suffered from hyperemesis gravidarum and admitted in the hospital~Age: 18-40 years old~Gestational age: less than 16 weeks confirmed by pelvic u/s~Excessive pregnancy - related nausea and /or vomiting that prevent adequate intake of food and fluids.~All pregnant (case and control) were asked to bring a stool sample in a clean container. Collected samples were tested in a laboratory (Ain Shams Univerisity hospital).~Stool samples were be tested by using one step H.pylori stool antigen test (CER TEST BIOTEC) for the detection of H. pylori antigen."
2510162|NCT02830321||control|Control patients which are selected from pregnant women presenting to the outpatient clinics for routine antenatal care of the same gestational age, same age range and same socioeconomic standard as cases.
2510180|NCT02830009|Other|Primary Hyperoxaluria patient|
2510189|NCT02830009|Other|Primary Hyperoxaluria patient's siblings|
2510192|NCT02830009|Other|Idiopathic hypercalciuria patients|
2510194|NCT02830009|Other|Healthy volunteers|
2510455|NCT02827903|Active Comparator|Group II|Metformin + placebo, Dosing to Type II DM with Dyslipidemia
3197099|NCT00857480|Experimental|T2|UDCA pre-treatment
3197100|NCT00857519|Experimental|Chemotherapy|Chemotherapy using Melphalan, Carboplatin.
3197101|NCT00857558|Experimental|1|OPC-262 1mg
3197102|NCT00857558|Experimental|2|OPC-262 2.5mg
3197103|NCT00857558|Experimental|3|OPC-262 5mg
3197104|NCT00857558|Placebo Comparator|4|
3197105|NCT00857571|Experimental|Suspension|PF-02413873 suspension
3197106|NCT00857571|Experimental|Tablet|PF-02413873 Phase 2 Tablets
3197107|NCT00857597|Experimental|EsophyX|
3197108|NCT00857597|Active Comparator|Proton Pump Inhibitors|
3197109|NCT00857610||1|Subjects using 0.1% retinol one day per week
3197110|NCT00857610||2|Subjects using 0.1% retinol three days per week
3197111|NCT00857610||3|Subjects using 0.1% retinol seven days per week
3197112|NCT00857610||4|Subjects using 0.5% retinol one day per week
3197113|NCT00857610||5|Subjects using 0.5% retinol three days per week
3197114|NCT00857610||6|Subjects using 0.5% retinol seven times per week
3197115|NCT00857636|Experimental|Health Literacy|
3197116|NCT00857662|Experimental|Onyx|
3197117|NCT00857662|Active Comparator|TRUFILL|
3197118|NCT00857675|Experimental|Adefovir Dipivoxil|ADV 10mg tablets once daily
3197119|NCT00857675|Placebo Comparator|Adefovir Dipivoxil matched placebo|Adefovir Dipivoxil matched placebo one tablet once daily
2509671|NCT02833740|Other|Click-MUAC & regular MUAC tape screening|"Each child will have nutritional status classified 11 times:~3 times with each of the 3 Click-MUAC prototypes by the mother/caregiver~1 time with a regular MUAC tape by the mother/caregiver~3 times with each of the 3 Click-MUAC prototypes by the case-finding/programme staff~1 time with a regular MUAC tape by the case-finding/programme staff~3 times with a regular MUAC tape by the data collection team (gold standard)"
2509704|NCT02833532|Experimental|Volus|Maxium: 22ml
2509707|NCT02833532|Active Comparator|Powerfill|Maxium: 22ml
2509758|NCT02833181||Awake patients|Awake patients
2509760|NCT02833181||Sedated patients|
2509762|NCT02833181||Sedated and curarized patients|
2509895|NCT02832557||MCHAT-R Positive|Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
2509937|NCT02831933|Experimental|Experimental|"ADV/HSV-tk (5 x 1011 viral particles) in a 2-mL total volume will be injected intratumorally on day 0 of the study.~Valacyclovir will be orally administered at a dose of 2 g three times daily for 14 days. Valacyclovir treatment will be administered 24 hours after the gene vector injection from day 1 to day 15 of the study.~SBRT of 30 gray (Gy; 6 Gy X 5 fractions) will be administered over 2 weeks from day 2 to day 16 of the study.~Nivolumab (480 mg) will be administered intravenously over 30 minutes every 4 weeks starting on day 17 of the study and continuing until disease progression, unacceptable toxicity, or up to 12 months in patients without disease progression."
2509989|NCT02831556||Emergency Department Subjects|Subjects that present to the Emergency Department with complaints necessitating abdominal or pelvic imaging.
2509990|NCT02831556||Non-patient volunteers|Duke employees that will voluntarily have an abdominal or pelvic ultrasound for with the sole purpose being for the study.
2510023|NCT02831296||Affected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy (SMA)~The affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy."
2510025|NCT02831296||Unaffected Subjects <36 Mos. of Age|"Infants and children 36 months of age and younger who are not affected with SMA~The unaffected group will undergo the same assessments as the affected group."
2510028|NCT02831296||Unaffected Family Members|"Parents and siblings of any age, without genetic diagnosis of SMA, who have family members enrolled in either of the Affected Infants/Children/Adults cohorts.~The unaffected siblings will undergo the same assessments as the affected group, where age-appropriate. Unaffected parents' participation will be limited to blood sample collection and optional research skin biopsy."
2510029|NCT02831296||Affected Subjects >36 Mos. of Age|"Children and adults >36 months at time of enrollment who have been genetically diagnosed with Spinal Muscular Atrophy.~The older affected cohort will receive coordinated, multidisciplinary care including dietary intervention, respiratory monitoring, physical therapy, and genetic counseling. They will also undergo assessment of motor function, muscle action potential measurement, and body composition, as well as blood sample collection for DNA and biomarkers, and optional research skin biopsy. Where applicable, these participants will be considered Affected Control Subjects."
2510090|NCT02831036|Experimental|trial group|subjects in trial group will be following the experimental protocol (VO2max tests and spatial orientation tests) while performing a training program during the trial (3 months).
2510092|NCT02831036|Other|control group|following the experimental protocol (VO2max tests and spatial orientation tests)without performing additional exercise.
2510134|NCT02830568||couples kidney living donor - receiver|"Three groups for each technique of taking of kidney :~open donor nephrectomy~standard and hand-assisted laparoscopic donor nephrectomy~laparoscopic robotic-assisted nephrectomy"
2510168|NCT02830152|Experimental|Left Atrial Appendage Occlusion (LAAO)|The intervention is implantation of Amplatzer Amulet LAAO device within two months after randomization. Device implantation comprises a catheterization procedure using venous access and a transseptal puncture to obtain access to the left atrium (LA). Procedural imaging guidance is left to the physician's discretion and may include several techniques such as angiography/fluoroscopy, transesophageal echocardiography (TEE) and/or intracardiac echocardiography (ICE). Recommended post-implant antithrombotic therapy includes ASA therapy for at least 6 months, which may be combined with clopidogrel for the first 45 days after implantation.
2510169|NCT02830152|Active Comparator|Medical Therapy|The optimal medical therapy of stroke prevention in non-valvular atrial fibrillation (NVAF) after intracerebral hemorrhage (ICH) is not known. Therefore, it will be left to the discretion of the treating physician to decide if, when, and which pharmacological therapy will be prescribed. Available options include anticoagulation with oral anticoagulation (OAC) or novel oral anticoagulants (NOAC), antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
2510199|NCT02829853||sporadic cases (SP)|Sporadic cases are defined as patients diagnosed for sarcoidosis, for which the familial history did not reveal any other cases, whatever the relative degree is: 1, 2, 3 or 4. The clinical follow-up and the genetic studies performed in the frame of this project are the same as for the familial group. During the regular follow-up, patients are regularly questioned about the putative occurrence of the disease in their family, and if such a situation occurred, the patient (and his relative) may change from the SP to the familial (FAM) group. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
2510202|NCT02829957|Active Comparator|Rivaroxaban|
2510204|NCT02829853||familial cases (FAM)|Familial cases are defined as patients diagnosed for sarcoidosis with a first and/or second degree relative parent also affected by a well-proven sarcoidosis syndrome. More than 70% of SARCFAM families included two first-degree affected individuals, with both a vertical or horizontal transmission. The Mendelian trait seems to be autosomal dominant. 20 to 30% of the families consists of 3, 4 or more cases, with a subset of families including more than 5 cases. Patients are managed as for the sporadic one, and in such families, an informed consent was also provided with a clear explanation on the complexity of the genetic background of the disease. In blood samples, genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING will be done.
2510209|NCT02829957|Active Comparator|Apixaban|
2509682|NCT02833545|Active Comparator|control|injeciton of steroids intra articularly
2509720|NCT02833389|Experimental|Cohort A - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 1|Participants with 0.8-6.0 centimeters square (cm^2) index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 1 for 12 weeks (a total of 4 doses).
2509722|NCT02833389|Experimental|Cohort B - UTTR1147A, 0.8-6.0 cm^2, No Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and no infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2509726|NCT02833389|Experimental|Cohort C - UTTR1147A, 0.8-6.0 cm^2, Mild Infection - Dose 2|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2509728|NCT02833389|Experimental|Cohort D - UTTR1147A, 1.5-6.0 cm^2, Mild Infection - Dose 2|Participants with 1.5-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 2 for 12 weeks (a total of 4 doses).
2509729|NCT02833389|Experimental|Cohort E - UTTR1147A, 0.8-6.0 cm^2, No infection - Dose 3|Participants with 0.8-6.0 cm^2 index ulcer area at screening and mild infection in index ulcer will receive UTTR1147A SC at Dose Level 3 for 12 weeks (a total of 4 doses).
2509730|NCT02833389|Placebo Comparator|Placebo|Participants will receive UTTR1147A matching placebo SC in each cohort for 12 weeks (a total of 4 doses).
2509813|NCT02832934|Experimental|1|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2509816|NCT02832934|Placebo Comparator|2|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
2509842|NCT02832440|Other|Intradialytic exercise|Exercise during hemodialysis
2509843|NCT02832440|Other|Home-based exercise|Exercise at home
2509852|NCT02832219|Experimental|Molecular hydrogen|Molecular hydrogen, tablet, 2 g/day, 4 weeks
2509853|NCT02832219|Placebo Comparator|Placebo|Cellulose, tablet, 2 g/day, 4 weeks
2509908|NCT02832180|Experimental|Daily single dose of OC containing EE and NET|Daily single dose of OC Containing EE and NET alone.
2509909|NCT02832180|Experimental|Daily single dose of OC in combination with BMS-986142|Daily single dose of OC containing EE and NET in combination with BMS-986142.
2509936|NCT02831803|Experimental|Intervention|All participants will receive an 8-week supply of walnuts and Extra Virgin Olive Oil (EVOO). Study supplements will consist of 28 gm of walnuts and 32 gm of EVOO per day. Participants will be instructed how to consume the proper amount of walnuts and EVOO and to report their consumption using a compliance diary. The walnuts are pre-packaged in daily servings (one 28 g packet per day) and measuring spoons will be provided with the olive oil to assist participants in consuming it appropriately. Participants will also receive recipes and other written information that will assist them in incorporating both the nuts and olive oil into their existing dietary patterns.
2509960|NCT02831712|Other|Iron supplement|Ferrous Fumarate tablet 200 mg
2510118|NCT02830737|Active Comparator|Traditional RFA|Using Traditional RFA for the treatment of small hepatocellular carcinoma
2510119|NCT02830737|Experimental|No-touch RFA|Using No-touch RFA for the treatment of small hepatocellular carcinoma
2510139|NCT02830399|Active Comparator|active rTMS-ECT|5 active high frequency rTMS before 5 bilateral ECT
2510141|NCT02830399|Placebo Comparator|sham rTMS-ECT|5 sham rTMS before 5 bilateral ECT
2510185|NCT02830126|No Intervention|Anesthesiology Control Tower Control|Patients managed by anesthesia teams without feedback alerts from the ACT
2510191|NCT02830126|Experimental|Anesthesiology Control Tower Feedback|Patients managed by anesthesia teams with feedback alerts from the ACT
2510235|NCT02829632|Experimental|Experimental: Group Sessions|Participants will be asked to attend 3 group meetings over a 12 week period. Groups will meet for approximately 1 hour on weeks 2, 4 and 8. At each of the group meetings, the participant will be weighed and a group leader will present information on topics related to eating and exercise.
2510236|NCT02829632|Experimental|Active Comparator: Self-Monitoring|Active Comparator: Self-monitoring Participants will record diet, activity and weight as described above in the participant's smartphone app to assist the participant in losing weight.
2510237|NCT02829632|Experimental|Experimental: Feedback|"Participants will be sent via the participant's smartphone between~1 and 4 feedback messages a day about whether the participant has been self monitoring, or the amount of calories, fat or sugar the participant has consumed."
3163949|NCT00490334||Control (non-cancer)|Normal children aged 8 to 16 years, age- and gender-matched to the cancer cohort
2510315|NCT02829281|Experimental|Botulinum toxin group|Patients will receive a intervention with joint injection of 100 units of botulinum toxin
2510318|NCT02829281|Active Comparator|Corticosteroid group|Patients will receive a intervention with joint injection of 40mg of triamcinolone hexacetonide (corticosteroid)
2510319|NCT02829281|Placebo Comparator|Saline Group|Patients will receive a joint injection of 2ml of normal saline
2510324|NCT02829242||Prostatic Surgery|Patient scheduled for a robotic assisted laparoscopic prostatic surgery.
3163950|NCT00490412|Experimental|A: tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group A (who are already taking Tenofovir) once every four weeks during study visits.
3163951|NCT00490412|Placebo Comparator|B: tenofovir/placebo|A placebo will be administered orally to subjects in Group B (who are already taking Tenofovir).
3163952|NCT00490412|Experimental|C: no tenofovir/vitamin D|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Group C (who are not taking Tenofovir) once every four weeks during study visits.
2509687|NCT02833727||Asthmatic smokers (AS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a provocative concentration of methacholine inducing a 20% fall in FEV1 (PC20) < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Smokers or ex smokers will be defined by a smoking history of ≥ 10 pack/year."
2509689|NCT02833727||Asthmatic non-smokers (ANS)|"Asthmatics will fulfill the following definition of asthma: reversible airflow obstruction and/or a PC20 < 8 mg/ml with a diagnosis of asthma made by a respirologist.~Never smokers will have a life-long history without smoking."
2509747|NCT02833324|Experimental|Fitbit with ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. In addition to being educated on the importance of postoperative ambulation, this arm will have 5 alarms every day reminding them to ambulate.
2509748|NCT02833324|Active Comparator|Fitbit without ambulation reminder alarms|Study participants who are postoperative for colorectal surgery will wear a Fitbit (a wireless activity tracking device) to count steps taken during their postoperative hospitalization. Participants will be educated on the importance of postoperative ambulation but will not have ambulation reminder alarms.
2509819|NCT02832882|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
2509820|NCT02832882|Active Comparator|Conventional tumor puncture RFA arm|Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
2509840|NCT02832492||PNR+|Patients who will show pupil near response during PNR assessment.
2509841|NCT02832492||PNR-|Patients who will not show pupil near response during PNR assessment.
2509866|NCT02832232|Experimental|Mobilization Group|translational dorsal glide mobilization technique grade III and Protocolized Physiotherapy
2509869|NCT02832232|Experimental|Maintained pressure Group|pressure maintained suboccipital inhibition technique and Protocolized Physiotherapy
2509871|NCT02832232|Other|Control Group|Protocolized Physiotherapy
2509901|NCT02832024|Active Comparator|Intervention: Stents|Stents group
2509904|NCT02832024|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
2509906|NCT02832024|Active Comparator|Intervention: Balloon|Balloon group
2509944|NCT02831842||mCRC Participants|Data of mCRC participants who received first-line treatment with bevacizumab-containing regimen or with chemotherapy alone and had KRAS-mutant status and mCRC participants who received first-line treatment with bevacizumab-containing regimen or an anti-epidermal growth factor receptor (EGFR)-containing regimen and had KRAS wild type status, will be collected retrospectively.
2510013|NCT02831218|Experimental|QCA and Aspirin alone|
2510014|NCT02831218|Experimental|QCA and Clopidogrel alone|
2510015|NCT02831218|Active Comparator|Imaging guided and Aspirin alone|
2510016|NCT02831218|Active Comparator|Imaging guided and Clopidogrel alone|
2510066|NCT02831088|Experimental|Neu2000KWL High-dose group|
2510067|NCT02831088|Experimental|Neu2000KWL Low-dose group|
2510070|NCT02831088|Placebo Comparator|Placebo|
2510109|NCT02830763|Experimental|Medium-chain Fatty Acid (CNT-02)|
2510184|NCT02829892|Other|Light therapy|Innovative ambient lighting
2510213|NCT02829840|Experimental|Cohort #3|"Cohort #3: Participants with relapsed/refractory FLT3-mutated AML, that have received previous FLT3 inhibitor therapy (including, but not limited to, quizartinib, crenolanib, sorafenib, other FLT3 inhibitors).~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant will continue on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2510284|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 2.5 mL|Perineural injection of ropivacaine 0.2 %, 2,5 mL
2510286|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
2510288|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
2510289|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
3163953|NCT00490412|Placebo Comparator|D: no tenofovir/placebo|A placebo will be administered orally to subjects in Group D (who are not taking Tenofovir).
2510291|NCT02829697|Active Comparator|Peroneal nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
3163954|NCT00490503||MRI + MRS|Patients with newly diagnosed stage II A-B or III A-C breast cancers who are scheduled to start systemic chemotherapy.
2510293|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 5 mL|Perineural injection of ropivacaine 0.2 %, 5 mL
2510294|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 10 mL|Perineural injection of ropivacaine 0.2 %, 10 mL
2510295|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 15 mL|Perineural injection of ropivacaine 0.2 %, 15 mL
3163955|NCT00490516|Experimental|1|
3163956|NCT00490516|Experimental|2|
3163957|NCT00490516|Placebo Comparator|3|
3163958|NCT00490581|Experimental|Study group|These patients are assigned to the intervention of early supportive housing with case management integrated into the medical system. These subjects are offerred respite care/interim housing upon discharge from enrolling hospitalizations, followed by stable housing within 90 days. They have a case manager at each stage (hospital, respite/interim housing, and stable housing)
3163959|NCT00490581|No Intervention|Usual Care|These patients receive usual social services for hospital discharge planning.
3163960|NCT00490620|Placebo Comparator|1|blinded placebo control
3163961|NCT00490620|Active Comparator|2|Antiretroviral therapy
3163962|NCT00490633|Experimental|Facemask and hand hygiene|Facemask and hand hygiene provided for participants.
3163963|NCT00490633|Experimental|Facemask only|Facemask only provided for participants.
3197120|NCT00857688|Experimental|1 - Test|Patients will recieve the association.
3197121|NCT00857688|Placebo Comparator|2|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
3197122|NCT00857701|No Intervention|1|Patient will receive post-surgical standard of care treatment with standard Physical therapy and NSAIDs.
3197123|NCT00857701|Experimental|2|Patients will be treated with the Standard of Care physical therapy and NSAIDs as well as a Knee Extension Dynasplint that includes tension chambers.
3197124|NCT00857753|Experimental|1|Fentanyl patch 25 ug/hr Sandoz
3197125|NCT00857753|Active Comparator|2|Duragesic Patch 25 ug/hr
2510270|NCT02829372|Experimental|GBR 1302|Dose escalation
2510276|NCT02829749|Experimental|NeoChord DS1000 Artificial Chordae Delivery System|Subjects randomized to the experimental group will undergo the NeoChord implantation
2510281|NCT02829749|Other|Control|traditional mitral valve repair performed under cardiac arrest
2510296|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 20 mL|Perineural injection of ropivacaine 0.2 %, 20 mL
2510297|NCT02829697|Active Comparator|Sciatic nerve: Ropivacaine 0.2%, 30 mL|Perineural injection of ropivacaine 0.2 %, 30 mL
2510325|NCT02829021|Other|Thermography and mammography|"All participants will be examined with~Dynamic infrared thermography (FLIR ThermaCAM P-65)~Mammography, clinical examination and if necessary breast tissue biopsy to diagnose breast cancer."
2510344|NCT02829047|Other|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
2510347|NCT02829060|Active Comparator|2b: +UCx with Oral Options (7d)|"This group has a positive pre-operative urine culture with oral antibiotic options~Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery~If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin > sulfamethoxazole-trimethoprim > doxycycline> ciprofloxacin > cephalexin > cefpodoxime.~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510349|NCT02829060|Active Comparator|3a: +UCx No Oral options (48hr)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510351|NCT02829060|Active Comparator|3b: +UCx No Oral options (7d)|"This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities~7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)~Gentamicin (80 mg) preferred if sensitive~All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time."
2510354|NCT02828930|Experimental|Idasanutlin|On Day 1, 300 milligram (mg) idasanutlin tablet orally and 100 mg [14C]-radiolabeled idasanutlin capsule orally (2, 50 mg capsules containing approximately 100 microcurie of radioactivity). After 5 hours and 45 minutes of the oral dose, 100 microgram (mcg) of [13C]-radiolabeled idasanutlin will be administered over a 15-minute intravenous (IV) infusion. On Day 11, idasanutlin matching placebo aqueous dispersion orally and approximately after 1 hour, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. On Day 19, 400 mg idasanutlin tablet will be administered orally in the form of an aqueous dispersion. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days, and no treatment during 23 days of 28-day cycle, until the development of progressive disease, unacceptable toxicity, consent withdrawal or any other criteria for removal.
2510373|NCT02828826|Experimental|telephone coaching|"Patients randomized to the experimental group will benefit from the telephone coaching , with 5 phone calls programmed by the physiotherapist according to the most convenient times for the patient, due to appointments per month.~The telephone coaching conducted by the physiotherapist with patients is to assess the number of exercises performed, the number of falls may have occurred, assess the fear of falling and overall assessment of the patient's general condition and a self-assessment of their physical ability (one leg balance, fear of falling, FTSST). With this information, the therapist may encourage patients to practice more diligently exercises can even strengthen the practice of some based on its evaluation.~Data from the telephone coaching will be recorded in the eCRF."
2510375|NCT02828826|No Intervention|Without telephone coaching|
2510381|NCT02828618|Active Comparator|Arm I PDS and chemotherapy|PDS with maximum effort to achieve the goal of complete gross resection then followed by 6 cycles of standard chemotherapy
2510382|NCT02828618|Experimental|Arm II Timing of surgery after 3 cycles of SOC CTX|3 cycles of standard NACT followed by IDS with maximum effort to achieve the goal of complete gross resection followed by 3 more cycles (for a total of 6) of standard chemotherapy
2510385|NCT02828553||Control Group - Usual Care|At the start of the study, subjects will be enrolled in usual care when admitted to the heart failure unit following standard protocols.
2510388|NCT02828553||Intervention Group - Aggressive Ambulation|After a washout period and transition to a new aggressive ambulation protocol, subjects will be enrolled to usual care + aggressive planned ambulation with a trained mobility aide.
2510399|NCT02828332|Other|Patient with autism disorder|Interview with a psychologist who do Vineland II (VABS -II) and evaluate Quality of life and comorbidities
2510407|NCT02828280||NuMask|Pt's randomized to Numask first will be ventilated for 10 breaths with the NuMask device first, followed by 10 breaths with the traditional face mask
2510408|NCT02828280||Traditional mask|patients randomized to traditional mask first will receive 10 breaths by traditional mask, followed by 10 breaths with NuMask
2510410|NCT02828696|Other|No prep|"No prep treatment of worn dentition with CAD-CAM composite (PICN)"
2510416|NCT02828293||GMK Sphere|Patients who underwent total knee replacement using GMK Sphere implants. Patients underwent surgery before the inclusion in the study.
2510440|NCT02828046|Placebo Comparator|Placebo|Placebo
3197126|NCT00857779|Active Comparator|subcutaneous immunotherapy|subcutaneous immunotherapy using a slow updosing schedule
3197127|NCT00857779|Active Comparator|subcutaneous injections|subcutaneous immunotherapy using a fast updosing schedule
3197128|NCT00857805|Active Comparator|Transarterial Chemoembolization|Transarterial Chemoembolization
3197129|NCT00857805|Active Comparator|Proton Beam Radiotherapy|Proton Beam Radiotherapy
2509785|NCT02833064||Acute Liver Failure|"biological sampling~MRI scanning for patients with paracetamol induced acute liver failure"
2509786|NCT02833064||Acute Liver Injury|- biological sampling
2509787|NCT02833064||Acute on Chronic Hepatic Injury|- biological sampling
2509788|NCT02833064||Stable Cirrhotics|- biological sampling
2509789|NCT02833064||Non-cirrhotic liver disease|- biological sampling
2509851|NCT02832635|Experimental|WBRT|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy without avoidance of hippocampus applied.
2509854|NCT02832635|Experimental|WBRT with avoidance of hippocampus|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus applied.
2509856|NCT02832635|Experimental|WBRT with TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with concurrent TMZ chemotherapy applied.
2509860|NCT02832635|Experimental|WBRT with avoidance of hippocampus and TMZ|Patients with brain metastases (>3 lesions) ; Whole-brain radiotherapy with avoidance of hippocampus and concurrent TMZ chemotherapy applied.
2509923|NCT02831920|Experimental|Single Arm|every patient undergoes mpMRI and targeted biopsies, CEUS and targeted biopsies and systematic biopsies. Every patient is therefore its own control.
2509965|NCT02831699||Febrile Rash|
2509974|NCT02831699||Household|
2509983|NCT02831699||Guillain-Barré prospective|
2509986|NCT02831699||Prior Guillain-Barré|
2510045|NCT02831309|Sham Comparator|Sedentary Condition|Forty minutes of screen time. Standardized meals provided.
2510052|NCT02831309|Active Comparator|Light-Intensity Condition|Forty minutes of light-intensity activity. Standardized meals provided.
2510055|NCT02831309|Active Comparator|Moderate-Intensity Condition|Forty minutes of moderate-intensity activity. Standardized meals provided.
2510058|NCT02831309|Active Comparator|High-Intensity Condition|Forty minutes of high-intensity activity. Standardized meals provided.
2510123|NCT02830685|Active Comparator|Direct-To-Implant A|DTI with Acellular Dermal Matrix (CELLIS® Breast), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of an Acelluar Dermal Matrix (ADM)
2510125|NCT02830685|Experimental|Direct-To-Implant B|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra), pre-pectoral, subcutaneous direct-to-implant breast reconstruction with the aid of a titanium coated polypropylene mesh
2510179|NCT02830048|Experimental|Glibenclamide dose titration|Increasing doses of glibenclamide oral suspension from 0.3mg/day to 6mg/day.
2510304|NCT02829177|Active Comparator|Allopurinol|400 mg once daily, tablet treatment
2510306|NCT02829177|Placebo Comparator|Placebo|Identical tablet treatment
2510314|NCT02828878|Experimental|ApoGraft|ApoGraft is a mobilized peripheral blood cell (MPBC) product derived from peripheral blood. There will be 4 cohorts, each differ in the amount of apoptotic mediator Fas Ligand (APO010) to which the graft is exposed during incubation prior to ApoGraft transplant, ranging from 10 ng/ml APO010 in Cohort 1, 25 ng/ml APO010 in Cohort 2, 50 ng/ml APO010 in Cohort 3, and 100 ng/ml APO010 in Cohort 4
2510350|NCT02828891|Experimental|Experimental|Intervention: transcranial Doppler device will be utilized to measure CSF pressure.
2510357|NCT02828839|Experimental|Treatment Arm|Subjects will receive standard of care prostate biopsies through the use of a trans-rectal ultrasound probe for needle placement and guidance. The intervention for all patients receiving a prostate biopsy will include the use of an investigational single use, disposable stainless steel access needle and a single use, disposable polymeric needle guide.
3163964|NCT00490633|No Intervention|Control|Control, no intervention.
3163965|NCT00490672|Other|Control Arm|Conventional Patient Management on Hypertension, Diabetes Mellitus and Hyperlipidaemia by Malaysian GP
2510371|NCT02828631|Active Comparator|Macintosh laryngoscope|Nasotracheal intubation by Macintosh laryngoscope
2510376|NCT02828631|Experimental|McGrath videolaryngoscope|Nasotracheal intubation by McGrath videolaryngoscope
2510378|NCT02828631|Experimental|Pentax videolaryngoscope|Nasotracheal intubation by Pentax videolaryngoscope
2510384|NCT02828605|Experimental|Experimental Group|Receive VIP Transplant App and surveys.
2510400|NCT02828306||Patients with skull defects|Patients with skull defects after craniotomy for example tumor resection, head trauma, stroke which need a Patient Specific Implant.
2510405|NCT02828566|Experimental|IN ketamine and IV saline|Ketamine, single dose, 10 mg/kg (0.1 mL/kg) of 100 mg/mL solution delivered intranasally using an atomizer and divided to both nares to a maximum of 800 mg (8 mL) AND 0.9% normal saline (NS) 0.02 to 0.03 mL/kg delivered intravenously to a maximum of 2.4 mL
2510406|NCT02828566|Active Comparator|IV ketamine and IN saline|Ketamine, single dose, 1 to 1.5 mg/kg (0.02 to 0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 120 mg (2.4 mL) AND 0.9% normal saline (NS) 0.1 mL/kg delivered intranasally using an atomizer and divided to both nares, to a maximum of 8 mL
2510417|NCT02828293||GMK PS Fixed Bearing|Patients who underwent total knee replacement using GMK PS Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
3163966|NCT00490672|Active Comparator|CORFIS Arm|Community based Multiple Risk Factor Intervention Strategies
3163967|NCT00490737|Experimental|Hemodialysis (HD) Participants|Participants will receive daptomycin 6 mg/kg by intravenous infusion (i.v.) at 48-hours intervals (with dialysis) for a total of 3 doses.
3163968|NCT00490737|Experimental|Continuous Ambulatory Peritoneal Dialysis (CAPD) Participants|Participants will receive daptomycin 6 mg/kg, i.v., at 48-hours intervals for a total of 3 doses.
3163969|NCT00490750|Active Comparator|Laparoscopic Dor fundoplication|Heller myotomy followed by Dor fundoplication
3163970|NCT00490750|Active Comparator|Laparoscopic Toupet fundoplication|Heller myotomy followed by Toupet fundoplication
3163971|NCT00490763||Active Surveillance|Patients with low-risk prostate cancer who choose to undergo active surveillance.
3163972|NCT00490828|Placebo Comparator|A|
3163973|NCT00490828|Active Comparator|B|Stress doses of hydrocortisone
3163974|NCT00490854|Experimental|1|
3163975|NCT00490854|Experimental|2|
3163976|NCT00490906||1|Patients receive Copaxone
3163977|NCT00490906||2|Patients receive interferons
3163978|NCT00490997|Active Comparator|1|Ketamine only arm
3163979|NCT00490997|Active Comparator|2|Ketamine-Propofol arm
2509800|NCT02832921|Sham Comparator|scientific TV documentary + treadmill|This group will watch a scientific TV documentary while walking on the treadmill. This control group will permit examination of whether the VR cognitive training, which requires an especially active cognitive effort while walking on the treadmill, is more advantageous than passively watching a scientific TV documentary while performing the same motor task as the experimental group.
2509805|NCT02832921|No Intervention|Passive control|This group of participants will not receive any intervention but will be assessed with the same battery of assessments as the other three groups, permitting comparisons of the cognitive and neurobiological outcomes of the intervention groups to that of the natural course of decline/deterioration of these at-risk individuals.
2509930|NCT02832141||Group A|Group A: immediate effects: T0, Grade 3 central thoracic mobilization from posterior-to-anterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3 central thoracic mobilization from anterior-to-posterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
2509938|NCT02832141||Group B|Group B: immediate effects: T0, 3 central thoracic mobilization from anterior-to-posterior on thoracic vertebrae from T5 to T12, immediate (T1), after 2 (T2), 4 (T3), 6 (T4), 8 (T5) and 10 (T6) minutes, 1 days wash-out period; T7, a grade 3-4 central thoracic mobilization from posterior-to-anterior on all thoracic vertebrae, immediate T8, after 2 (T9), 4 (T10), 6 (T11), 8 (T12) and 10 (T13) minutes.
2509963|NCT02831608|Experimental|Drug: influenza vaccine|Standard influenza vaccine administered as a deep subcutaneous injection at one occasion per subject.
2509969|NCT02831608|Placebo Comparator|Drug: placebo|Saline administered as a deep subcutaneous injection at one occasion per subject.
2510056|NCT02831166|Active Comparator|Transradial approach|Transradial approach primary percutaneous coronary intervention using the TR Band device to obtain hemostasis (n=125).
2510059|NCT02831166|Active Comparator|Transfemoral approach|Transfemoral approach primary percutaneous coronary intervention using a vascular closure device to obtain hemostasis (n=125).
2510085|NCT02830906|Experimental|ramosetron group|Patients received 0.3 mg of intravenous ramosetron before spinal anesthesia and intrathecal morphine
2510086|NCT02830906|Active Comparator|ondansetron group|Patients received 8 mg of intravenous ondansetron before spinal anesthesia and intrathecal morphine
2510129|NCT02830386||LVIS stents group|The patients with ruptured intracranial saccular aneurysm wil be treated with a LVIS stent without coils.
2510183|NCT02830022|Experimental|Patients|Children from 8 to 18 years with autism without without intellectual disabilities (IQ > 70), verbals and responding to classification CIM 10-DSM IV.
2510186|NCT02830022|Experimental|Healthy volunteers|Paired for age, gender, IQ and and the practice of a physical activity strictly within the school context.
2510231|NCT02829528|Experimental|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a New York based organization dedicated to making the tools of yoga and mindfulness available to all children and teens. Their Teacher Training Program focuses on the physical, mental emotional, and social wellbeing of students. Teachers are trained to use the five elements format (connect, breathe, move, focus, relax). Implementation of the Little Flower Yoga for Kids curriculum will be manualized prior to the start of the study with Ms. Love, and will be presented as a series of activities (e.g., poses) throughout the school year. The emphasis in these yoga and mindfulness activities is exploration not competition, which allows the child to learn and develop at her own pace with the support of Ms. Love. The children participate in the Little Flower Yoga for Kids intervention at school for 40 minutes per class, 3 to 5 times per week, for the entire academic school year (9 months).
2510247|NCT02829385|Experimental|Apatinib combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
2510268|NCT02829658||Psychiatric patients group|Patient groups were composed with: BPD, other PD and assessed Psychologic test
2510272|NCT02829658||Control group|Matched controls (age, sex) composed the 3rd and 4th group (BPD control and other PD control). They were randomly chosen in the health database insurance previously used. They had no intervention.
3163980|NCT00491036|Active Comparator|Intraaortic balloon pump|Patients in cardiogenic shock get an intraaortic balloon pump in the cath lab
2510327|NCT02829203||No-Frailty|Patients without frailty score submitted to a cardiac surgery
2510331|NCT02829203||Pre-Frailty|Patients with pre-frailty score submitted to a cardiac surgery
2510332|NCT02829086|Experimental|Group I|Participants in Group I will receive the following interventions: Intro to Relationship Enhancement (8 hours), Family Stress and Conflict Management (8 hours), and case management
2510337|NCT02829086|Experimental|Group II|Participants in Group II will receive the following interventions: Intro to Relationship Enhancement (8 hours), RE & Financial Management (8 hours), and case management
2510340|NCT02829086|No Intervention|Group III|Participants in Group III will receive the the standard care of all participants, case management ONLY
2510355|NCT02829008|Experimental|low-dose-bevacizumab/Pemetrexed|Low-dose-bevacizumab is given at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and every three weeks are a treatment cycle .Pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too. The pretreatment of pemetrexed should be conducted within the study.
2510356|NCT02829008|Active Comparator|Treatment of physician' choice|Treatment of physician's choice can be any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. It can be drugs like taxanes,capecitabine, gemcitabine, cisplatin, everolimus or even nutrient solution,et al.
2510360|NCT02828735|Other|Respiration assessment|
2510412|NCT02828540|Experimental|HT047 High-dose group|three times a day dosing schedule 3 tablets per dose
2510414|NCT02828540|Experimental|HT047 Low-dose group|three times a day dosing schedule 3 tablets per dose
3163981|NCT00491036|No Intervention|No intraaortic balloon pump|Patients in cardiogenic shock in this group get no intraaortic balloon pump
3163982|NCT00491062|Active Comparator|Control|
3163983|NCT00491062|Experimental|Parkinson stade 1|
3163984|NCT00491062|Experimental|Parkinson stade2|
3163985|NCT00491062|Experimental|Parkinson stade 3|
3163986|NCT00491101||1|Children with asthma, both genders, from 7-18 years old.
2509821|NCT02832869|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
3197130|NCT00857831|Experimental|Arm 1|Vitamin D & Calcium supplementation in FES
2509911|NCT02831894|Sham Comparator|0% Hypnotic Medication Taper|In this condition patients will be maintained on their baseline hypnotic medication dosage throughout a 20-week double-blinded tapering period.
2509912|NCT02831894|Active Comparator|25% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 25% every 2 weeks throughout a 20-week double-blinded tapering period.
2509913|NCT02831894|Active Comparator|10% Hypnotic Medication Taper|In this condition patients will have their current hypnotic medication dosage reduced by 10% every 2 weeks throughout a 20-week double-blinded tapering period.
2509957|NCT02831790|Experimental|Educational Intervention|Participants in the intervention group will have access to the 3 teaching videos, ~3:30-5:00 minutes in duration each, beginning several weeks prior to the preadmission clinic (as soon as written consent is obtained).
2509958|NCT02831790|No Intervention|Usual Care|Participants in the usual care will not be offered an intervention and will not be made aware of the existence of the teaching videos.
2509997|NCT02831452||non-pregnant nulliparous|nulliparous without previous gestation. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
2509999|NCT02831452||primigravid on 1º trimester|"nulliparous women on her first pregnancy and gestational age until 13 weeks and 6 days.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
2510001|NCT02831452||primigravid on 2º trimester|"nulliparous women on her first pregnancy and gestational age between 14 weeks and 27 weeks.~Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer."
2510002|NCT02831452||primigravid on 3º trimester|nulliparous women on her first pregnancy and gestational age above 28 weeks. Pelvic floor muscle evaluation by means of vaginal palpation, vaginal squeeze pressure (perineometer), and pelvic floor muscle strength using a proper vaginal dynamometer.
2510038|NCT02831192|Experimental|MST（microtransplantation）|
2510113|NCT02831023|Active Comparator|SP-AQ only|Subjects will receive sulphadoxine-pyrimethamine (SP) as single dose and administered in combination with amodiaquine (AQ), which will be given once daily for 3 days.
2510115|NCT02831023|Experimental|SP-AQ plus PQ|Participants in this arm will receive SP-AQ in combination with a single low dose of primaquine at the World Health Organization (WHO) recommended dose of 0.25 mg/kg.
2510116|NCT02831023|Active Comparator|DP only|Participants in this arm will be treated with dihydroartemisinin-piperaquine (DP), which will be administered once a day for three days.
2510117|NCT02831023|Experimental|DP plus MB|Study participants in this arm will receive DP as described above combined with once-daily methylene blue (MB) for 3 days, at 15 mg/kg/day (45 mg/kg total over 3 days).
2510138|NCT02830373||LVIS stents group|patients with unruptured intracranial saccular aneurysms which located in the internal carotid artery or vertebra-basilar artery will be treated with a LVIS stent with coils
2510171|NCT02830178||Any Paracetamol|Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
2510172|NCT02830178||Ibuprofen|Participants with age 18 and over who received a first prescription of single-ingredient ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
2510206|NCT02829840|Experimental|Cohort #1|"Cohort #1: Participants with no previous leukemia therapy (including no previous FLT3 inhibitor therapy) for either: a) front-line treatment of elderly (age 65 and greater) FLT3-mutated AML patients, or b) patients unable or unwilling to receive standard intensive therapy.~Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2510211|NCT02829840|Experimental|Cohort #2|"Cohort #2: Participants with relapsed/refractory FLT3-mutated AML that have not received prior FLT3 inhibitor therapy.~Part 1: Participants receive Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle. If disease does not respond to ponatinib alone, participant continues on to Part 2 of study.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle. 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle. 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
2510240|NCT02829593|Experimental|type 1 diabetes|type 1 diabetes >5 years duration
2510241|NCT02829593|Placebo Comparator|healthy controls|
2510313|NCT02829268|Experimental|Pediatric|Pediatric patients treated with dantrolene sodium
2510317|NCT02829268|Experimental|Adult|Adult patients treated with dantrolene sodium
2510418|NCT02828293||GMK UC Fixed Bearing|Patients who underwent total knee replacement using GMK UC Fixed Bearing implants. Patients underwent surgery before the inclusion in the study.
2509834|NCT02832700|Placebo Comparator|Placebo|During 4 weeks a daily oral intake of placebo-shake consisting of milk powder.
3197131|NCT00857844||Group 1|Normal GFR (>90ml/min/1.73m2). Stage I CKD
3197132|NCT00857844||Group 2|GFR between 30-59ml/min/1.73m2. Stage III CKD
3197133|NCT00857844||Group 3|GFR between 15-29ml/min/1.72m2. Stage IV CKD
2509970|NCT02831543|Experimental|Motireb 5/100 mg t.i.d|Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
2509977|NCT02831543|Active Comparator|Mosapride citrate t.i.d|Placebo of Motireb 5/100 mg t.i.d + Mosapride citrate t.i.d
2509980|NCT02831543|Placebo Comparator|Placebo t.i.d|Placebo of Motireb 5/100 mg t.i.d + Placebo of Mosapride citrate t.i.d
2510064|NCT02831283|Experimental|Cognitive impairment|Alzheimer's disease, Preclinical Alzheimer's disease or Impairment due to suspected non-Alzheimer's disease pathophysiology
2510069|NCT02831283|Active Comparator|No cognitive impairment|Normal aging
2510093|NCT02830789|Experimental|Calcium Carbonate|1 tablet Unikalk Forte + 1 placebo tablet by mouth three times daily equal to 1200 mg elementary calcium and 57 µg Vitamin D3
2510097|NCT02830789|Experimental|Calcium Citrate|2 tablets Unikalk Citrat by mouth three times daily equal to 1200 mg elementary calcium and 60 µg Vitamin D3
2510195|NCT02829879|Experimental|arginine|25 volunteers with dentin sensitivity
2510196|NCT02829879|Active Comparator|potassium nitrate|25 volunteers with dentin sensitivity
2510232|NCT02829567|Experimental|Oral hygiene counseling and motivational interviewing|This group will receive a session of oral hygiene counseling and a single session of motivational interviewing to increase the readiness of change.
2510233|NCT02829567|No Intervention|Oral hygiene counseling|
2510244|NCT02829541|Experimental|Cohorts 1|6 participants randomized (4:2) to receive a single-ascending dose (SAD) administered orally in tablet
2510246|NCT02829541|Experimental|Cohort 2|6 participants randomized (4:2) to receive a SAD administered orally in tablet(s)
2510249|NCT02829541|Experimental|Cohort 3|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
2510250|NCT02829541|Experimental|Cohort 4|8 participants randomized (6:2) to receive a SAD administered orally in tablet
2510252|NCT02829541|Experimental|Cohort 5|8 participants randomized (6:2) to receive a SAD administered orally in tablet(s)
2510256|NCT02829541|Experimental|Cohort 6|14 participants (all active) to receive a SAD administered orally in tablet(s)
2510285|NCT02829333|Other|Group GA|22 patients receive general anesthesia and patient controlled intravenous analgesia
2510287|NCT02829333|Other|Group SA|22 patients receive spinal anesthesia and continuous postoperative epidural analgesia
2510310|NCT02829073|Experimental|Oasis™ device|Treatment using the Neuromonics Tinnitus Treatment Program and the Neuromonics Oasis™ treatment device.
2510311|NCT02829073|Placebo Comparator|Placebo device|Treatment using the Neuromonics Tinnitus Treatment Program and an identical-appearing placebo device.
3197134|NCT00857870|Active Comparator|Metformin|
3197135|NCT00857870|Active Comparator|Insulin glargine|
3197136|NCT00857883|Placebo Comparator|Part A|Part A: This part of the study will start with a very low dose of study drug, which will then be gradually increased in subsequent doses. This is known as dose-rising and is the way to assess safety and tolerability (i.e. possible presence of any side effects that make taking the drug unpleasant) of increasing doses of the study drug. Effects will be compared to those seen when a placebo is taken. Up to 4 groups of 6-9 healthy male or female volunteers will be enrolled.
2510358|NCT02828943|Active Comparator|IMT with Low Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. For the comparator group, EMT will be set to 5 cm H2O, the lowest setting on the device. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with low resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training.
2510359|NCT02828943|Experimental|IMT with High Resistance EMT|The pressure loads can be adjusted at 2 cm H2O intervals for the Threshold IMT, up to 41 cm H2O, and 1 cm H2O intervals for the Threshold PEP, up to 20 cm H2O. EMT training loads in the experimental group will be set to 30% of maximal expiratory pressure. IMT training loads will be set to 30% of maximal inspiratory pressure for both groups. The patient will be blinded to the valve titration. Each training session will include one set of 10 repetitions with IMT followed by one set of 10 repetitions with high resistance EMT. Patients will be instructed to maintain a respiratory rate of 15-20 breaths/min without rest between repetitions. Participants will be monitored daily by phone and by self-reported log for completion of each training. At two weeks, participants will have a follow-up office visit to monitor progress and those that have completed 80% of their training sessions will increase their training to 40% of maximum inspiratory and expiratory pressures as tolerated.
2510386|NCT02828501|Experimental|Lumbar manipulation group|Spinal Manipulation
2510387|NCT02828501|Experimental|Cervical manipulation group|Spinal Manipulation
2510389|NCT02828501|No Intervention|Control group|This group will receive a 2 minute supine rest between measurements
2510393|NCT02828787|Experimental|Urticaria|15 patients with urticaria
2510394|NCT02828787|Experimental|Psoriasis|15 patients with psoriasis
2510395|NCT02828787|Other|healthy|15 healthy control subjects
3197137|NCT00857883|Active Comparator|Part B|Part B: A dose selected from Part A that was well tolerated will be used to check if there is a difference in the pharmacokinetics (blood levels) of the study drug when taken without food in liquid form, or as a capsule, or as a capsule together with a high fat meal to assess the effect of food. One group of 12 healthy male or female volunteers will be enrolled.
2510409|NCT02828579||Group 1|Patient with morbid obesity defined as a BMI above 40kg/m2 or 35kg/m2 with comorbidities who are qualified for bariatric surgery.
2509917|NCT02831946|Experimental|MODIFIED VICRYL PLUS|The intra-cuticular layer will closed with with VICRYL PLUS suture
2509918|NCT02831946|Experimental|DERMABOND GLUE|The intra-cuticular layer will closed with with DERMABOND GLUE
2509959|NCT02831751|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
2509967|NCT02831751|Experimental|60 µg/strain of Quadrivalent VLP Vaccine|
2509979|NCT02831751|Active Comparator|FluLaval® Tetra (15 µg/strain)|
2509985|NCT02831751|Active Comparator|Fluzone® High-Dose (60 µg/strain)|
2510071|NCT02831179|Experimental|Treatment (capecitabine, temozolomide, veliparib)|Capecitabine PO BID on days 1-14, temozolomide PO BID on days 10-14 and veliparib PO BID on days 10-14.
2510137|NCT02830672|Active Comparator|Open surgical release A1 Pulley|
2510140|NCT02830672|Active Comparator|Ultrasound guided close release A1 pulley|
2510166|NCT02830204|Experimental|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
2510254|NCT02829398|Experimental|Patients with subarachnoid hemorrhage|Patients with subarachnoid hemorrhage will have CerebroSpinal fluid and plasma sample.
2510257|NCT02829398|Active Comparator|Control subjects|healthy controls from a previous study with a CerebroSpinal fluid and plasma sample
2510261|NCT02829671|Other|Patients with major depressive disorders|
2510305|NCT02829190|Experimental|Healthy volunteers|Magnetic Resonance Imaging (MRI)
2510307|NCT02829190|Experimental|Patients treated by radiotherapy|Magnetic Resonance Imaging (MRI)
2510308|NCT02829190|Experimental|Patients treated by embolization|Magnetic Resonance Imaging (MRI)
2510309|NCT02829190|Experimental|Patient operated on with free flap|Magnetic Resonance Imaging (MRI)
2510328|NCT02829242||Colorectal Surgery|Patient scheduled for a robotic assisted laparoscopic colorectal surgery.
2510361|NCT02828748|Experimental|active UC|patients with clinically active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2510365|NCT02828748|Experimental|remission UC|patients with clinically non active ulcerative colitis undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2510366|NCT02828748|Experimental|active CD|patients with clinically active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2510368|NCT02828748|Experimental|remission CD|patients with clinically non active crohns disease undergoing colonoscopy not for study purpose, biopsy will be taken from inflamed and normal mucosa and treated with either cannabinoids or will be used as a control
2510369|NCT02828709|Experimental|Irreversible electroporation (IRE)|"IRE is based on high current electric pulses, transferred between two or more placed needle electrodes. Charging the cell membrane causes holes in the cell membrane called nanopores, resulting in increased permeability of the cell and subsequent cell death."
2510390|NCT02828683|Experimental|Ultimaster, Drug Eluting Stent|Primary PCI in patients with ST segment elevation myocardial infarction with a new Drug Eluting Stent, Ultimaster
2510391|NCT02828683|Active Comparator|Kaname, Bare metal stent|Primary PCI in patients with ST segment elevation myocardial infarction with a Bare Metal Stent - Kaname
2510398|NCT02828319|Experimental|Z-213|
2510403|NCT02828384|Active Comparator|low fodmap diet|Subjects receive formalized teaching in low fodmap diet by a dietician
2510404|NCT02828384|Active Comparator|psyllium|subjects receive 7.1 g of psyllium daily
2510419|NCT02828475||CALYPSO-augmented|Patients' postoperative care will be augmented with the CALYPSO platform.
2510421|NCT02828371|Experimental|Erigo|Single daily sessions of verticalization, using a tilt table with an integrated robotic stepping device (Erigo. Hocoma AG, Switzerland) located in the ICU room. Sessions were performed five times per week (Monday-Friday) for three consecutive weeks (a total of 15 sessions per patient). On the same days the patients received conventional physiotherapy for 30 minutes a day. Before the verticalization period the experimental group received conventional in-bed physiotherapy for 60 minutes a day.
2510422|NCT02828475||Historical Control|Patients' postoperative care was performed using standard practice, before adopting the CALYPSO platform
2510424|NCT02828371|Active Comparator|Conventional|treated with conventional in-bed physiotherapy for 60 minutes a day, from Monday to Friday, throughout the ICU stay.
2510425|NCT02828189|Active Comparator|Physical Exercise|"The protocol consists in:~Physical Exercise according to their preferences.~Therapeutic Education related to Health Habits and Physical Exercise."
2510426|NCT02828189|Experimental|Therapeutic Exercise-Physiotherapy|"The protocol consists in:~Cardiovascular exercise.~Force-Resistance Exercises of the principals muscle groups of the lower limbs, upper limbs and trunk.~Muscle Stretches.~Therapeutic Education related to Health Habits and Physical Exercise."
3197138|NCT00857883|Placebo Comparator|Part C|Part C: A well tolerated dose selected from Parts A & B will be used to test whether the drug has an effect on individual preferences for sugary and high fat food, when compared to placebo. Up to 32 healthy overweight male volunteers will be enrolled.
3197139|NCT00857909|Active Comparator|Randomisation 1|Amiloride 5 mg twice daily for 28 days, later compared with spironolactone and placebo
3197140|NCT00857909|Active Comparator|Randomisation 2|Spironolactone 25 mg twice daily, to be compared with placebo and amiloride
3197141|NCT00857909|Placebo Comparator|Placebo|calcium tablet
3197142|NCT00857922||Neurosurgical patient|Neurosurgical patient of the Mischer Neuroscience Institute, 18 years and over
2510439|NCT02828410|Experimental|SBI|Serum bovine immunoglobulin protein isolate (SBI)
2510454|NCT02827903|Experimental|Group I|Metformin + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
3197143|NCT00857922||Family members|Family members of specific vascular, trauma, brain tumor and functional disorder cohorts
3197144|NCT00857935|Experimental|1|NatrOVA Creme Rinse - 1%
3197145|NCT00857935|Active Comparator|2|NIX Creme Rinse
3197146|NCT00857974|No Intervention|Usual Care|No physical activity intervention will be prescribed for the Usual Care Arm.
3197147|NCT00857974|Active Comparator|Physical Activity|
3197148|NCT00857987|Experimental|1|Guaifenesin, doxylamine succinate and hydrochloride etafedrine syrup
3197149|NCT00857987|Placebo Comparator|2|Vehicle
2509942|NCT02831829|Active Comparator|Land-based exercise training group|"Patients randomized to the land-based exercise training group will undergo exercise training which will include two aerobic and calisthenic exercise session per day, six days of a week, lasting 30 minutes"
2509943|NCT02831829|No Intervention|Control group (usual care)|Control group: patients randomized in control group will have usual care with no exercise
2509962|NCT02831621|Active Comparator|diet (usual care)|All participants will receive a hypocaloric diet based on the individual resting metabolic rate. Resting metabolic rate (RMR) will be estimated using the WHO formula or measured using indirect calorimetry. Total energy expenditure will be calculated by multiplying RMR with a physical activity level (PAL). The used physical activity level will be 1.3. A hypocaloric diet with an energy deficit of 500 kcal/day will be prescribed. Participants will see a skilled dietician two-weekly the first month and on a monthly basis the next five months to discuss problems and solutions or coping strategies. The first consultation will have a duration of 60 minutes, the next consultations will have a duration of approximately 30 minutes. Each visit, nutritional compliance will be recorded on a 0 to 10 numeric rating scale. The usual care group will be asked to continue with their normal physical activity during the six-month intervention period.
2509968|NCT02831621|Experimental|diet+exercise|"For participants of this group, usual care will be supplemented with a prescribed exercise program. For this exercise program the participants will be referred to a local fitness club near home, free of charge. Aerobic training will be done at an intensity of 90-95% of the heart rate achieved at the RCP. Aerobic training will have a duration of 30 to 45 minutes, according to the training stage. Cardio training will be performed on different cardio devices and strength training will be done on isotonic strength training devices. Each training day, core stability training will be completed with four strength exercises for large muscle groups. Each exercise will be done in two sets of 15 repetitions with the goal to achieve better muscular strength endurance.~This combined training will be done individually during six months, three times/week.~In this study, an effort is made to reach a uniform manner of guidance to the physical activity program."
2510003|NCT02831361|Experimental|Gemigliptin 50mg|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
2510005|NCT02831361|Placebo Comparator|Gemigliptin 50mg placebo|the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total
2510021|NCT02831153|Active Comparator|normal coronary anatomy|coronary angiography will be performed by transfemoral or transradial route.
2510024|NCT02831153|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
2510027|NCT02831153|Active Comparator|slow coronary flow|coronary angiography will be performed by transfemoral or transradial route.
2510030|NCT02831153|Active Comparator|nonobstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2510031|NCT02831153|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
3197150|NCT00858000||Group A|No intervention
2510242|NCT02829710||group 1 : pre implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between January 2013 and December 2013.~Prior to implementation of the protocol, analgesia and sedation were managed by the attending physician's order."
2510243|NCT02829710||group 2 : post implementation group|"All children aged less than 18 years, requiring mechanical ventilation for at least 24 hours and admitted in PICU between May 2014 and March 2015.~Nurses managed analgesia and sedation following an algorithm, including COMFORT-B scale."
2510258|NCT02829450||Control|Patients with CHF and chronic renal disease which preferred to continue their regular treatment or choose other then peritoneal ultrafiltration type of renal replacement therapy (data from medical records): clinical symptoms of fluid overload, hospital admissions, urine volume,residual renal function markers (eGFR creatinine)
2510301|NCT02829151|Experimental|Triple antiplatelet therapy group|Patient group with triple antiplatelet therapy using aspirin, clopidogrel, and cilostazol
2510302|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) A|Patient group with dual antiplatelet therapy using aspirin and clopidogrel
2510303|NCT02829151|Active Comparator|DAP (Dual antiplatelet therapy) B|Patient group with angioplasty using aspirin and cilostazol
2510312|NCT02829255|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
3197151|NCT00858026|Other|1|Breastfed babies
3197152|NCT00858026|Active Comparator|2|Weaning with the standard milk
2510348|NCT02828865|Experimental|irreversible electroporation (IRE)|irreversible electroporation (IRE) (AngioDynamics, NY) To use 2 to 6 unipolar electrodes of IRE in a predetermined grid pattern. 90 pulses of 2,000 - 3,000 V were applied with a pulse generator (AngioDynamics, NY) across the gap between the electrodes for 100 microseconds (0.1 msec) per each ablation.
2510370|NCT02828813||Normal|healthy subjects
2510372|NCT02828722|Experimental|Controlled light, noise and nutrition|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the nutrition protocol corresponding to the daily rhythm will be applied.
2510374|NCT02828813||CogImpair|persons with cognitive impairments
2510377|NCT02828722|Experimental|Controlled light and noise|Simultaneously with the standard treatment performed at the clinical trial site environmental simulation of night time and daytime alternation as well as the continuous nutrition (in accordance with the clinical trial site's standard practice) will be applied.
2510379|NCT02828813||MotorDeficits|persons with motor deficits
2510380|NCT02828722|No Intervention|Control|The treatment of the study subject will be performed based on the clinical trial site's standard practice without environmental simulation or changes in the nutrition protocol.
2510383|NCT02828605|No Intervention|Control Group|Only receive surveys.
3197153|NCT00858026|Experimental|3|Weaning with the fermented milk
3197154|NCT00858039||Her-2 positive ESBC|
3197155|NCT00858052|Experimental|breast augmentation|breast implant
3197156|NCT00858065|Active Comparator|RCT FM|Random control trial- Family Matters. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Family Matters program.
2509364|NCT02836041||Pediatrics cancer patients|Eligible patients will be approached for enrollment after their first night in the hospital (i.e.: not on day of admission). Patient/parent will be asked to complete a brief questionnaire describing the child's general sleep habits prior to admission. The parent and/or child will then be asked to complete a questionnaire describing sleep while in the hospital; this in-hospital sleep questionnaire will be obtained for 3 consecutive nights after enrollment, or until discharge, whichever is soonest. A subgroup of patients (between the ages of 5 and 18) will be invited to participate in an additional aspect of the study, where they wear an actigraph (a small device that looks like a watch) for up to 72 hours. This device reliably measures sleep by monitoring the child's motion. This will be used to relate sleep perception to more objective measures of sleep as provided by actigraphy.
2509409|NCT02835482|Experimental|Patient with glaucoma|Patient eligible for bilateral cataract surgery, with glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with phacoemulsification for the other eye.
2509418|NCT02835482|Other|Patient without glaucoma|Patient eligible for bilateral cataract surgery, without glaucoma. Each patient is his own control. The patient is treated with femtolaser surgery for one eye and with the phacoemulsification for the other eye.
2509549|NCT02834559|Active Comparator|Adjuvant therapy with 5-FU and LMWH|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
2509551|NCT02834559|Placebo Comparator|Standard of care|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV) in high-risk patients for proliferative vitreoretinopathy (PVR) with primary rhegmatogenous retinal detachment (RRD).
2509608|NCT02834234||Peritoneal mesothelioma specimens|"The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.~The CGH arrays will be realized on frozen samples (for the comparative genomic analysis)."
2509686|NCT02833454|Active Comparator|direct insertion single bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using single bundle technique.
2509690|NCT02833454|Experimental|anatomical double bundle ACLR|Patients with ACL rupture undergo double bundle anterior cruciate ligament reconstruction.
2509693|NCT02833454|Experimental|anatomical single bundle ACLR|Patients with ACL rupture undergo single bundle anterior cruciate ligament reconstruction.
2509694|NCT02833454|Active Comparator|direct insertion double bundle ACLR|Patients with ACL rupture undergo direct insertion anterior cruciate ligament reconstruction using double bundle technique.
2509719|NCT02833311|Active Comparator|Computer Tablet Group|A computer tablet application to set goals,self-monitor healthy behaviors, record condition-related symptom impact, and self-manage a problematic symptom.
2509724|NCT02833311|Active Comparator|Paper and Pencil Group|Use of paper and pencil diaries and worksheets to set goals, record condition-related symptom impact, and self-monitor behaviors.
2509727|NCT02833311|Active Comparator|Standard Treatment Control Group|Participants are prescribed an exercise program and given information on healthy eating.
2509764|NCT02833012|Experimental|Group 1|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2509765|NCT02833012|Experimental|Group 2|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2509766|NCT02833012|Experimental|Group 3|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2509768|NCT02833012|Experimental|Group 4|Caprylic Triglyceride Oil, AC-1202, Axona, AC-1204
2509888|NCT02832648|Experimental|selenase 200mcg|selenium as selenase 200mcg once daily, oral
2509893|NCT02832648|Experimental|selenase 50mcg|selenium as selenase 50mcg once daily, oral
2509896|NCT02832648|Placebo Comparator|placebo|matched placebo, once daily, oral
3163987|NCT00491140||Observation|Colorectal cancer patients
3163988|NCT00491257|Experimental|Study Group 1|Participants aged 18 to 60 years at enrollment
2510100|NCT02830841|Experimental|DR-RIPC (donor and recipient RIPC group)|Both donors and recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm(donor) or right lower limb(recipient) and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2510105|NCT02830841|Sham Comparator|S-RIPC (sham RIPC)|Patients had a deflated cuff placed on the right upper arm or right lower limb for 30 min
2510107|NCT02830841|Experimental|R-RIPC (recipient RIPC group)|Recipients receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right lower limb and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2510108|NCT02830841|Experimental|D-RIPC (donor RIPC group)|Donors receive remote ischemic preconditioning, with three 5-min cycles of remote limb ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 15 mmHg above systolic pressure, with an intervening 5 min of reperfusion during which the cuff was deflated.
2510145|NCT02830503|Experimental|Intervention|Feeding tube daily replacement
2510148|NCT02830503|No Intervention|Control|Feeding tubes replaced as normal practice in the department (normally once a week).
2510333|NCT02828995||Comprehensive Diabetes Stigma Survey|Participants in the END STIGMA study will be adult patients who have been receiving diabetes-related medical care for a minimum of 12 months in the Vanderbilt University Medical Center Diabetes Clinic and who take at least 1 medication to manage their diabetes.
3163989|NCT00491257|Experimental|Study Group 2|Participants aged 61 years or older at enrollment.
3163990|NCT00491309|Active Comparator|exercise training group|exercise and respiratory therapy with specific program for pulmonary hypertension (respiratory therapy, dumbbell training, ergometer training, mental training)
3163991|NCT00491309|No Intervention|Control group without exercise training|continuation of sedentary lifestyle without advice for specific exercise training
3163992|NCT00491426||<26 weeks|Subjects <26 weeks gestational age
3163993|NCT00491426||26-29 weeks|Subjects 26-29 weeks gestational age
3163994|NCT00491426||30-32 weeks|Subjects 30-32 weeks gestational age
3163995|NCT00491439||Corneal wounds after Epi-LASIK|Corneal wounds after Epi-LASIK
2510437|NCT02828085|Other|Infective Pericarditis|In patient prescribed with a pericardite kit for an etiological diagnosis of a pericardial syndrome, an additional nasal swab will be performed in order to perform a specific diagnosis with PCR technique.
2510570|NCT02827851|Experimental|SVF injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate stromal vascular fraction of cells (SVF). After SVF isolation autologous cells suspension will be injected intraarticularly into knee joint.
2510651|NCT02826837|Experimental|LEAC-102 and FOLFOX+Bevacizumab/Cetuximab|"The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
2510702|NCT02826330||case Crohn disease|60 cases with Crohn's Disease
2510703|NCT02826330||first relative healthy|2 healthy relatives per CD case (total 120)
2510704|NCT02826330||controls|60 controls matched on gender and age with CD cases
2510755|NCT02825862|No Intervention|Replication group|Replication group - this group will complete the entire questionnaire, in order to replicate the findings of O'Carroll et al (2011)
2510759|NCT02825862|Active Comparator|Omit affective attitudes|Omitting affective attitudes The intervention is the omission of all questions on affective attitudes. This group will complete a similar questionnaire to the replication group, with the same number of questionnaire items, but affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
2510760|NCT02825862|Active Comparator|Omit negatively-worded items|Omitting negatively-worded affective attitudes. This intervention is the omission of a subset of negatively-worded affective attitudinal items. This group will complete a similar questionnaire to the replication group, with the same number of items, but all negatively-worded affective attitudes will be omitted. Dummy questions (e.g. about politics) will be substituted for these deleted questions.
2510832|NCT02825628|Experimental|Osteodex 3.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2510835|NCT02825628|Experimental|Osteodex 6.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2510838|NCT02825628|Experimental|Osteodex 9.0 mg/kg|formulation: solution for infusion route of administration: intravenous infusion
2510892|NCT02825030|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2510926|NCT02824731|Active Comparator|supratentorial, grade III/IV, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
2510939|NCT02824731|Experimental|supratentorial, grade III/IV, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
2510946|NCT02824731|Active Comparator|supratentorial, grade I/II, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
2510952|NCT02824731|Experimental|supratentorial, grade I/II, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients, bening tumors.
2510956|NCT02824731|Active Comparator|infratentorial, photon|Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients.
2510957|NCT02824731|Experimental|infratentorial, proton|Radiation with protons normofractionated 54-60 Gy(RBE). Not pre-irradiated patients.
2510959|NCT02824731|Active Comparator|pre-radiation, photon|> 40Gy in the region of recurrence. Radiation with photons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
2510961|NCT02824731|Experimental|pre-radiation, proton|> 40Gy in the region of recurrence. Radiation with protons normofractionated 54-60 Gy(RBE) or 5 Gy(RBE)/fraction until 30 Gy(RBE) or normofractionated 36 Gy(RBE).
2510974|NCT02824120|Experimental|Comedy|patients in this group will watch a comedy film that will not exceed 30 minutes
2510978|NCT02824120|Experimental|Documentary|patients in this group will watch a documentary film that will not exceed 30 minutes.
2511089|NCT02823535|Experimental|Iwin: Individual Well-Being Navigator|Iwin intervention during 6-month intervention period plus study assessments at baseline, 6, and 9 months.
2511093|NCT02823535|No Intervention|Control group|Study assessments at baseline, 6 months, and 9 months, plus two short surveys unrelated to the study behaviors at 4 and 5 months.
2511120|NCT02823158|Experimental|GPi DBS and best medical treatment|
2511124|NCT02823158|Active Comparator|Best medical treatment|
2511188|NCT02822898|Active Comparator|Isotonic Maintenance Fluid|Isotonic Maintenance Fluid
2511190|NCT02822898|Active Comparator|Hypotonic Maintenance Fluid|Hypotonic Maintenance Fluid
2511254|NCT02822417||patients after general anesthesia|Laparoscopic surgery, orthopedics surgery or open surgery patients after general anesthesia
2511315|NCT02822027|Experimental|human gamma globulin|human gamma globulin for infants with encephalopathy of prematurities
2511319|NCT02822027|Active Comparator|non-human gamma globulin|non-human gamma globulin for infants with encephalopathy of prematurities
2511342|NCT02821520|Experimental|Initial PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT: PDT with verteporfin is administered at baseline and then PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
2511377|NCT02821650|Experimental|Intervention|Intervention arm will be administered with improved cook stoves (TEJ- Traditional stove to Efficient stove in Jhuggi).
2511385|NCT02821650|No Intervention|control|control arm will continue using traditional cook stoves (chulha) or a combination of the traditional stove and the kerosene/diesel stove.
2510445|NCT02828098|Experimental|Part 1: BO-112 IT|BO-112 dose 1 (starting dose) intratumoral injection. BO-112 dose 2, 3 and 4 are expected to be tested, upon confirmation of the safety profile of the starting dose.
2510447|NCT02828098|Experimental|Part 2: BO-112 IT|"Combination treatment of BO-112 intratumoral injections with standard of care nivolumab intravenous treatment~Or Combination treatment of BO-112 intratumoral injections with standard of care pembrolizumab intravenous treatment"
2510519|NCT02827682|Experimental|study group|Using Angel-6000D Multiparameter Anesthesia Monitor to maintain the Hemodynamic stability during surgery. Keep IoC1 40 to 60 while IoC2 30-50.Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when IoC1<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when IoC2>50 but was decreased by 1 ng/ml per adjustment when IoC2<30, with the maintenance value between 30 and 50.
2510522|NCT02827682|Placebo Comparator|control group|Using BIS VISTA Monitor to maintain the Hemodynamic stability during surgery. Keep BIS 40 to 60.The doses of propofol and remifentanil were adjusted by the anesthetists according to BIS. Target concentration of propofol was decreased by 0.5 μg/ml per adjustment when BIS<40, with a maintenance value between 40 and 60. The target concentration of remifentanil was increased by 1 ng/ml per adjustment when BIS>60 but was decreased by 1 ng/ml per adjustment when BIS<40, with the maintenance value between 40 and 60.
2510534|NCT02827253||Predialysis|Patients with CKD (4 and 5 stages by KDOQI guidelines) underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A MRI 6 months after starting haemodialysis will be performed to analyze changes in gray and white matter of the brain.
2510538|NCT02827253||Haemodialysis|Patients with end stage of renal disease (ESRD) in haemodialysis underwent MRI to obtain in vivo images of brain anatomy that were subsequently analyzed by the data processing package FreeSurfer (version 5.3). A one year follow up MRI will be performed to analyze the changes in gray and white matter of the brain.
2510636|NCT02826538|Experimental|patient specific guides|fracture fixation with 3D planning and use of patient-specific instruments
2510640|NCT02826538|Active Comparator|standard procedure|standard procedure of fracture Fixation without 3D planning and without use of patient-specific instruments
2510687|NCT02826382|Experimental|Dynamic imaging group|Dynamic imaging of suspected bone metastases with the investigation drug [68Ga]P15-041
2510689|NCT02826382|Experimental|Whole body dosimetry group|Determination of human dosimetry of the investigation drug [68Ga]P15-041
2510705|NCT02826109|Experimental|Interventional: Cyanoacrylate Application|Application of cyanoacrylate adhesive to one quadrant of mouth
2510709|NCT02826109|No Intervention|Control: Absence of Cyanoacrylate Application|No application of cyanoacrylate adhesive to the other quadrant of mouth
2510772|NCT02825875||adenocarcinoma of the prostate|
2510966|NCT02824458|Experimental|Gefitinib + Apatinib|"(Part A) Phase I, Open-label, Dose-escalation Study Escalating doses(500mg, 750mg, or 250mg) of Apatinib in combination with 250mg Gefitinib daily orally. Participants may continue to receive treatment until progress or intolerable.~(Part B)Multicenter, Randomized, Double-Blind Study Apatinib (dose determined from Part A of study) in combination with 250mg Gefitinib."
2510967|NCT02824458|Placebo Comparator|Gefitinib + Placebo|"(Part A) Not Applicable~(Part B) Placebo in combination with 250mg Gefitinib. Participants may continue to receive treatment until progress or intolerable."
2511045|NCT02823886|Experimental|STEMI patients|
2511090|NCT02823444||Peripheral Vascular Disease|Gender distribution will be approximately equal. The age range is 18-95, with increased prevalence in the elderly population.
2511094|NCT02823444||Control|In the initial sequence optimization stage, healthy volunteers will also be recruited.
2511123|NCT02823184||Patients|ET or PV patients diagnosed before acceleration phase and treated by hydroxyurea with a follow up period of at least 6 months following treatment start, with a RNA sample of total leukocytes before start of treatment available
3197157|NCT00858065|Active Comparator|Choice SFP|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Strengthening Families Program (SFP).
2511265|NCT02822274|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511275|NCT02821936|Experimental|Parametric Imaging|"one parametric PET at the inclusion and one at 42 Gray after the beginning of radiotherapy.~Two PET scans at 3 months and one year after inclusion"
2511338|NCT02821494|Experimental|Hespecta|Four dose groups of Hespecta
2511374|NCT02821364|Other|Advanced Life Support|ALS providers are trained and able to perform certain procedures such as intubation with endotracheal tubes and placement of intravenous catheters. Endotracheal intubation is often performed by pre-hospital providers in critically ill trauma patients because it is believed that it allows for protection of the airway and better delivery of oxygen. However, most studies actually show that intubation does not provide a survival advantage to this patient population and actually could result in worse outcomes. Intravenous catheter placement and administration of intravenous fluids is also routinely performed however, studies have shown that it is also not helpful.
2511383|NCT02821364|No Intervention|Basic Life Support|Subjects randomized to the study group will receive basic life support (BLS) level care. This means that pre-hospital procedures such as endotracheal intubation and intravenous fluid administration will not be carried out. However, passive oxygen and needle thoracostomy, if required for tension pneumothorax, will be permitted if medically necessary.
2511457|NCT02821247||Aflibercept|Adult wet Age Related Macular degeneration (AMD) treatment naïve partcipants were treated with intravitreal aflibercept injection
2511483|NCT02820610|Active Comparator|Dexmedetomidine|2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
2511485|NCT02820610|Active Comparator|Magnesium sulfate|2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
2511487|NCT02820610|Placebo Comparator|Control group|2 mg/kg bupivacaine 0.5% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
2511573|NCT02819999|Experimental|Rovalpituzumab Tesirine|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
2510449|NCT02828007|Experimental|Treatment/Intervention|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
2510496|NCT02827721||COPD|Patients with known or suspected COPD Patients with known or suspected obstructive ventilation disorder
2510502|NCT02827721||pulmonary healthy controls|Patients without known or suspected pulmonary disease
2510541|NCT02827344||Stage IV non-small cell lung cancer|"Intervention to be done are :~- Blood sample collection for CTC and MDSC analysis"
2510608|NCT02827110|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope
2510610|NCT02827110|Experimental|fiberoptic bronchoscope with pentax-AWS|Tracheal intubation in patients with semi-rigid collar immobilization of the cervical spine using fiberoptic bronchoscope with pentax-AWS
2510618|NCT02826564|Experimental|Sequential|Stereotactic body radiotherapy prior to pembrolizumab treatment
2510620|NCT02826564|Experimental|Concurrent|Stereotactic body radiotherapy concurrent with pembrolizumab treatment
2510706|NCT02826473|Experimental|Intervention-Group|
2510708|NCT02826473|No Intervention|Control-Group|
2510717|NCT02825901|Active Comparator|Djulis-Buckwheat & Placebo|Ingest Djulis-Buckwheat or placebo drink 100ml/day for 8 weeks
2510722|NCT02825901|Active Comparator|Buckwheat & Placebo|Ingest Buckwheat or placebo drink 100ml/day for 8 weeks
2510727|NCT02825901|Experimental|Djulis-Buckwheat & Buckwheat|Ingest Djulis-Buckwheat or Buckwheat drink 100ml/day for 8 weeks
2510763|NCT02825771|Experimental|Usual Care + Caring Contacts messages|Usual care services plus caring contacts messages
2510764|NCT02825771|Active Comparator|Usual Care|Usual care services provided in that community following identification of suicidal ideation or behavior.
2510782|NCT02825472|Active Comparator|Exercise training program|Six-months sports participation, three times per week for 30 minutes in the target heart rate zone
2510784|NCT02825472|No Intervention|No exercise training program|no exercise training program, usual care
2510834|NCT02825368|Experimental|Homeopathic vaccine group|"Diphtheria (Diphtherinum®), pertussis (Pertussinum®), tetanus (Tetanotxicum®), measles (Morbilinum®) and mumps (Ourlianum®) nosodes.~Two sterile saline injections (0.5ml each, intramuscular and subcutaneous) as placebo."
2510836|NCT02825368|Active Comparator|Conventional vaccine group|"One intramuscular dose of Tdap (tetanus, diphtheria, acellular pertussis)~One subcutaneous dose of MMR (measles, mumps, rubella)~Sugar pellets as placebo."
2510840|NCT02825368|Placebo Comparator|Control group|"Sugar pellets oral dose~Two sterile saline injections (0.5 ml each, intramuscular and subcutaneous) as placebo"
2510870|NCT02824991|Experimental|Deep Dry Needling|"Deep Dry Needling (DN) with the purpose of obtaining local twitch responses (LTRs). Description: Latent MTrPs were identified in both MG using according the presence of a palpable taut band and hypersensitive spot in the palpable taut band as diagnostic criteria.~The deep DN was administered by a physical therapist with three years of experience in the technique. The ultrasound video (SonoSite Titan; Sonosite, Bothell, WA, USA) was recorded at 60 frames per second captured through an external capture device from Epiphan Systems Inc. (Ottawa, Ontario, Canada). According to the perception of the physical therapist and the ultrasound assessment, the filament needle was inserted into the MTrP to achieve three LTRs. Posterior to DN application, the ROMs of the MG and HA were measured"
2510925|NCT02824861|Experimental|Text Intervention|Participants receive text messages to a personal cell phone over 8 weeks, wear a fitbit to monitor physical activity, and communicate with a health coach intermittently over 2 weeks
2510932|NCT02824861|Active Comparator|Active Control|Participants receive and wear a fitbit only for 8 weeks
2510995|NCT02824380|Experimental|Sequence A|Period 1: DA-4001 H(High dose) Period 2: DA-4001 L(Low dose)
2511002|NCT02824380|Experimental|Sequence B|Period 1: DA-4001 L(Low dose) Period 2: DA-4001 H(High dose)
2511034|NCT02823821|Active Comparator|137mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 137mmol/l
2511038|NCT02823821|Active Comparator|140mmol/l|Participating dialysis sites will be randomised to a default dialysate sodium concentration of 140mmol/l
2511257|NCT02822300|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511278|NCT02821988|Experimental|Nonstress test|"Subjects will undergo weekly nonstress tests beginning at 32 weeks until delivery in addition to monitoring fetal kick counts.~A nonstress test is a test in which an external fetal monitor is placed on the mother to defect the fetal heart rate for 20 to 40 minutes. A test is considered reactive if there are more than 2 accelerations in fetal heart rate defined as an increase of at least 15 beats per minute lasting at least 15 seconds in a 20 minute period."
2511279|NCT02821988|Experimental|Biophysical profile|Subjects will undergo weekly biophysical profile testing beginning at 32 weeks until delivery in addition to monitoring fetal kick counts. A Biophysical profile is a test using real time ultrasonography to determine the presence of absence of certain components of fetal well being. There components include: an episode of fetal breathing lasting at least 30 seconds, 3 or more discrete body movements, 1 or more episodes of extension of a fetal extremity with return to flexion, and determination of amniotic fluid volume to detect a maximum vertical pocket of >2cm. The duration of this test is no more than 30 minutes.
2511280|NCT02821988|No Intervention|Kick counts only|Subjects will monitor fetal kick counts only.
3163996|NCT00491439||penetrating keratoplasty|Corneal wound after penetrating keratoplasty
2511356|NCT02821481|Experimental|Beta-alanine and muscular endurance exercise|Receive 3.2 g/day beta-alanine and 3 days per week of endurance resistance training for 12 weeks
2511366|NCT02821481|Experimental|Beta-alanine without muscular endurance training|Receive 3.2 g/day beta-alanine with no endurance resistance training for 12 weeks
2511370|NCT02821481|Placebo Comparator|Placebo and muscular endurance exercise|Receive similar dextrose placebo and 3 days per week of endurance resistance training for 12 weeks
2511382|NCT02821481|Placebo Comparator|Placebo without muscular endurance training|Receive similar dextrose placebo with no endurance resistance training for 12 weeks
2510457|NCT02827903|Active Comparator|Group III|Placebo + Rosuvastatin, Dosing to Type II DM with Dyslipidemia
2510499|NCT02827513|Experimental|Arm 1|Participants will receive sustained release (SR) Tablet Formulation 1 (SR1) containing 100 mg of Centanafadine (CTN) (2 x 100 mg tablets taken orally by mouth [PO] in the morning at starting at approximately 7 am and 2 x 100 mg tablets PO 5 hours later) for a total daily dose (TTD) of 400 mg on Days 1, 4, 7, and 10.
2510507|NCT02827513|Experimental|Arm 2|Participants will receive extended release (XR) Tablet Formulation 1 (XR1) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2510509|NCT02827513|Experimental|Arm 3|Participants will receive XR Tablet Formulation 2 (XR2) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2510511|NCT02827513|Experimental|Arm 4|Participants will receive XR Tablet Formulation 3 (XR3) containing 400 mg of CTN (1 x 400 mg tablet PO in the morning) on Days 1, 4, 7, and 10.
2510554|NCT02827331||Patients exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to hypnotics or anxiolytics benzodiazepines"
2510556|NCT02827331||Patients not exposed to benzodiazepines|"Data to be collected are :~Administrative and medical data~Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics"
2510558|NCT02827331||Control group|"Data to be collected are :~Administrative and medical data~Medical consultation without prescription of interest"
2510614|NCT02826668|No Intervention|Control|Baseline ultrasound only, with no markings placed. No ultrasound prior to epidural placement.
2510615|NCT02826668|Experimental|Ultrasound|Baseline and pre-puncture ultrasound with markings placed.
2510655|NCT02826525|Experimental|Treatment|Subjects in this arm will receive AZD4076
2510657|NCT02826525|Placebo Comparator|Control|Subjects in this arm will receive placebo
2510714|NCT02826291||RD-100i, OSNA|SLNM and OSNA assessment of sentinel lymph nodes compared to ultrastaging
2510776|NCT02825836|Experimental|TL-895 80/160 mg QD|Participants received TL-895 80 mg powder in capsule (PiC) orally once daily (OD) for 3 days followed by TL-895 160 mg OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510778|NCT02825836|Experimental|TL-895 300 mg QD|Participants received TL-895 300 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510780|NCT02825836|Experimental|TL-895 600 mg QD|Participants received TL-895 600 mg PiC orally OD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510781|NCT02825836|Experimental|TL-895 300 mg BID|Participants received TL-895 300 mg PiC orally twice daily (BID) in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510783|NCT02825836|Experimental|TL-895 900 mg QD|Participants received TL-895 900 mg PiC orally QD in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510785|NCT02825836|Experimental|TL-895 100 mg BID|Participants received TL-895 100 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510787|NCT02825836|Experimental|TL-895 150 mg BID|Participants received TL-895 150 mg BID orally BID with food for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
2510865|NCT02825186|Experimental|Loteprendol|Topical Loteprendol used after strabismus surgery
2510869|NCT02825186|Experimental|Dexamethasone|Topical Dexamethasone used after strabismus surgery
2510983|NCT02824419|Experimental|C11-methionine|To compare FDG and C11-methionine in the detection of sarcoidotic lesions.
2510992|NCT02824419|Experimental|68Ga-Dotanoc|To compare FDG and 68Ga-DOTANOC in the detection of sarcoidotic lesions.
2511033|NCT02823808|Experimental|ALO+PIO|Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.
2511037|NCT02823808|Active Comparator|GMPD+MET|Group who takes Glimepiride 2mg+Metformin 500mg, once daily.
2511078|NCT02823483|Experimental|Arm 1|All subjects are patched.
2511108|NCT02823236|Active Comparator|Intralesional Triamcinolone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months.
2511110|NCT02823236|Experimental|Topical Pirfenidone|Dosage commensurate with scar surface to be treated. After washing and drying the affected area, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
2511113|NCT02823236|Experimental|Triamcinolone + Pirfenidone|A dosage of 4mg/cm2 of intralesional triamcinolone will be injected in the keloid scar every 4 weeks during 6 months. Simultaneously, a thin layer of 8% pirfenidone will be applied on the scar, three times a day, for 6 months.
2511164|NCT02822989|Active Comparator|Vagus Nerve Stimulation|Subjects randomized to this arm will receive transcutaneous vagus nerve stimulation for 5 minutes on 4 consecutive days.
2511165|NCT02822989|Sham Comparator|Sham Vagus Nerve Stimulation|Subjects randomized to this arm will receive sham stimulation for 5 minutes for 4 consecutive days.
2511227|NCT02822638||STEMI PATIENT Cohort|STEMI PATIENT Cohort
2511292|NCT02822209|Experimental|Coordinating nurse added to the personalized care program|"The coordinating nurse (CN) is dedicated to the newly diagnosed patient to optimize their personalized care program.~The CN is the connection between the medical team and the patient. They act according to the instructions from the multidisciplinary staff in charge of bronchopulmonary cancer patients.:~e.g. Schedule an exam or an hospitalization, collect and share results of useful information to correct treatment's side effects etc~Main contact of the patient, the general practitioner and the patient's relatives, they give practical information for the patient's case~Quality of life questionnaires - EORTC QLQ-C30 and EORTC QLQ-LC13 - completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
2511387|NCT02821702|Active Comparator|Normal Vaginal Delivery - no suspected accreta|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
2511413|NCT02821312|Active Comparator|Active in Group B1~B4|In each of Groups B1 to B4, 8 subjects will receive DA-8010.
2511414|NCT02821312|Placebo Comparator|Placebo in Group B1~B4|In each of Groups B1 to B4, 2 subjects will receive placebo.
2510458|NCT02827890|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Januvia Tab. 100mg)*1T/day for 5 days, QD, PO.~Period 2: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
2510460|NCT02827890|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Januvia Tab. 100mg + Duvie Tab. 0.5mg)*1T/day for 5 dyas, QD, PO.~Period 2: Treatment A(Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO.~Each treatment period was separated by a washout period of at least 10 dyas."
2510524|NCT02827617||TP53 mutated CLL|
2510559|NCT02827240|Experimental|Direct Distribution|The direct distribution arm consists of peer educators directly distributing HIV self-test kits to participants. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2510560|NCT02827240|Experimental|Fixed Distribution|The fixed distribution arm consists of peer educators distributing coupons to participants. The participants can then use the coupon to collect an HIV self-test kit at a participating distribution point, including drug stores, pharmacies, and health posts. Peer educators will briefly describe HIV self-testing to participants but will not provide extensive training on the use of the test kit. Peer educators also provide referral to existing services for HIV testing.
2510561|NCT02827240|No Intervention|Referral to Existing Services|Peer educators will not provide HIV self-tests to participants. Peer educators will only provide referral to existing services for HIV testing.
2510601|NCT02826967|Experimental|Colonic Irrigation|A designated health professional will administer to the patient the colonic irrigation procedure -using the Hydro-San Plus colon therapy system, an FDA approved and ISO certified device for colonic irrigation and cleansing before endoscopic procedures (FDA #2027347).
2510671|NCT02826655|Active Comparator|Healthy Controls|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
2510674|NCT02826655|Experimental|Subjects with diabetic retinopathy|Study participants will undergo imaging of both eyes with the WF-AO-OCT unit, per standard operating protocol. Imaging is noncontact. Study participants will undergo only a single imaging session on a single day.
2510738|NCT02826213||Kidney : perfusion device lifeport|Each donor (n=140) will provide one kidney for pulsatile perfusion.
2510742|NCT02826213||Kidney : perfusion device waves|Each donor (n=140) will provide one kidney for continuous perfusion.
2510795|NCT02825667|Experimental|Experimental group|"Patients included in this group will receive treatment over a period of three weeks, receiving 3 physiotherapy sessions lasting approximately 30 minutes each.~The treatment program includes 8 maneuvers that must be administered bilaterally: maneuver longitudinal sliding on the fascial surface plant, maneuver induction of the plantar fascia, maneuver longitudinal surface sliding on the anterolateral compartment of the leg, induction maneuver ankle anterior compartment, maneuver pressure and sliding on the posterior region of the leg, technical release of the popliteal fascia, maneuver induction sural triceps, and lower extremity telescopic technique."
2510797|NCT02825667|No Intervention|Control group|Patients included in this group will not receive any physiotherapy treatment. However, will be evaluated under the same conditions that patients in the experimental group (pretreatment evaluation, post-treatment and follow-up).
2510874|NCT02825316|Experimental|Group A|Patients with active Crohn's disease that will be allocated to the Mediterranean diet group.
2510876|NCT02825316|Experimental|Group B|Patients with active Crohn's disease that will be allocated to the low residue diet group.
2510905|NCT02824770|Active Comparator|Usual Care|After a major abdominal surgery, the control group will receive the usual postoperative care including continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) in the surgical intensive care unit.
2510908|NCT02824770|Experimental|Dimming of lights and decreasing noise|After a major abdominal surgery, the patients in the experimental group will be screened in the side-rooms where normally the patients who either have infections or are at risk of infection, are nursed and will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour and infusion of Tramadol HCl (Tramosel®) via PCA (Gemstar®) as in the control group. The study intervention will include dimming of lights and decreasing noise. The lights will be dimmed to 40 lux. The doors of the side-rooms will be closed decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m.
2511030|NCT02824016|Active Comparator|with supraclavicular irradiation|Patients received supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
2511031|NCT02824016|Active Comparator|without supraclavicular irradiation|Patients did not receive supraclavicular irradiation according to local policies. Biological samples were obtained in order to evaluate hypothyroidism during the follow-up period
2511079|NCT02823496|Experimental|Arm 1|All subjects are patched with the same product
2511132|NCT02823262|Experimental|Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~The Decision Aid Group (workbook and CD) explains each treatment including its benefits and risks.~-- The DA asks women 10 questions about their health;the response to each question is associated with a point value and women are asked to tally their points. The DA groups women into 4 health categories based on their health score.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
2511136|NCT02823262|Active Comparator|No Decision Aid|"Post Initial Surgical Consultation~Including background questionnaire and randomization into Decision Aid Group or Control Group:~Participant will receive Usual Care assistance when making treatment decisions.~Assessment at One week after participants surgical consultation and five months after surgical consultation"
2511206|NCT02822820|Active Comparator|Advanced bipolar (Ligasure-Covidien)|Devices with advanced bipolar energy (Ligasure-Covidien) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
2511208|NCT02822820|Active Comparator|Conventional bipolar (RoBi forceps-Karl Storz)|Devices with conventional bipolar energy (RoBi rotating bipolar forceps-Karl Storz) will be used during laparoscopic hysterectomy and pelvic lymphadenectomy
2511410|NCT02821312|Active Comparator|Active in Group A1~A7|In each of Groups A1 to A7, 8 subjects will receive DA-8010.
3197158|NCT00858065|Active Comparator|RCT SFP|Random control trial- Strengthening Families Program. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to Strengthening Families Program.
3197159|NCT00858065|No Intervention|RCT Control|Random control trial- Control Group. Half the families were assigned to the RCT condition, in which they were assigned to one of two prevention programs or to a control group. This arm was assigned to the control group and received no prevention program. However, this group and all groups received an informational pamphlet about youth alcohol and other drug use.
3197160|NCT00858065|Active Comparator|Choice FM|Half the families were assigned to the choice condition in which they can choose between two prevention programs. This arm chose the Family Matters (FM) program.
2510612|NCT02826941|Experimental|Hypothermia|If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.
2510613|NCT02826941|Placebo Comparator|Normothermia|If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.
3197161|NCT00858104|Active Comparator|1|Laser thermal ablation
3197162|NCT00858104|No Intervention|2|Follow-up
2510749|NCT02826044|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2510752|NCT02826044|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2510754|NCT02826044|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 10 healthy volunteers.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2510804|NCT02825706|Experimental|Experimental group|The patients in experimental group received 60-minute educational sessions every two weeks about the pathophysiology of hemophilia, clinical manifestations, postural advice and prevention advice to avoid recurrent bleeding. Likewise, doubts on the clinical progress of hemophilic arthropathy, functional limitations and management of joint pain were resolved. In parallel with the educational sessions, patients followed a 15-week home exercise program performed once a day, 6 days a week. The program included muscle stretching exercises; isometric exercises; proprioceptive exercises on one leg with visual support; and a 20-minute walk. Low-intensity exercises with 20-25 repetitions were included.
2510806|NCT02825706|No Intervention|Control group|The patients in the control group did not receive any educational sessions and did no exercise at all at home.
2510884|NCT02825303|Experimental|Novel workplace - first half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the first half of the study. Traditional workstation within the second half of the study.
2510887|NCT02825303|Experimental|Novel workplace - second half|Intervention: A novel two-desk sit-to-stand workstation for 23 weeks; provided within the second half of the study. Traditional workstation within the frist half of the study.
2510891|NCT02825303|No Intervention|Control group|Control group subjects did not encounter any changes in their regular office environments. Traditional workstation for both halves of the study.
2510942|NCT02824523||High-dose aspirin|
2510985|NCT02824315|Experimental|AL-335+Simeprevir (SMV)+Odalasvir (ODV)|Participants will receive AL-335 800 milligram (mg) once daily from day 1-3; SMV 75 mg once daily from Day 4-13; loading dose of ODV 150 mg on Day 14, followed by ODV 50 mg once daily from Day 15 to 23; ODV 50 mg once daily + AL-335 800 mg once daily from day 24-26; ODV 50 mg once daily + SMV 75 mg once daily from Day 27-33 and ODV 50 mg once daily + SMV 75 mg once daily + AL-335 800 mg once daily from Day 34 to 36.
2511151|NCT02823314|Experimental|Intervention group|One piece of a special hypoallergenic adhesive tape, called Cure Tape®, they will have a size of 12-20 cm and will be attached in the front and back torso area on the T7- T8 dermatomes.
2511156|NCT02823314|Placebo Comparator|Placebo group|Two piece of a special hypoallergenic adhesive tape, called Cure Tape®, have a size of 2.5 cm x 2 cm and they will have to be placed near the greater trochanter area.
2511174|NCT02822703|Experimental|Active 20Hz|The rTMS device used in this study is the Mastim Super Rapid2 Stimulator with a 70mm Double Air Film Coil. Guidelines indicate that the maximum safe duration of a single train of 20Hz at 110% of the Motor Threshold (MT) is 1.6 seconds. In this study, the stimulator and the coils will be used to stimulate neurons in the left dorsolateral prefrontal cortex (DLPFC), the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment in depression, in order to examine the feasibility of testing this intervention for efficacy in the treatment of tobacco dependence.
2511175|NCT02822703|Sham Comparator|Sham|The rTMS sham coil used in this study is manufactured by Magstim and currently classified as an investigational device. There is no intention to treat or prevent a disease and/or alter a function in the body with the sham stimulation provided by the sham coil. In this project, the sham coil will be placed in the same location in the brain as that stimulated in the studies supporting the efficacy of this treatment for depression.
2511211|NCT02822560|Active Comparator|pEVAR|percutaneous femoral access using a suture-mediated closure system
3197163|NCT00858182|Experimental|Group A|
3197164|NCT00858182|Experimental|Group B|
3197165|NCT00858195|Experimental|1|Indomethacin 75mg ER Capsules
3197166|NCT00858195|Active Comparator|2|Indocin 75mg SR Capsules
3197167|NCT00858260||hemodialysis patients|Adult patients undergoing maintenance dialysis since at leat three months
3197168|NCT00858273|Active Comparator|Antioxidant Supplement|Vitamin C 250 mg; beta-carotene 6 mg; vitamin E 30 mg; selenium 100 mcg; zinc 20 mg
3197169|NCT00858273|Placebo Comparator|Placebo|
2510461|NCT02827968|Experimental|KN035|Cohorts of 3-6 subjects will be enrolled sequentially at escalating doses of 1, 2.5, 5 and 10 mg/kg weekly.
2510494|NCT02827643|Active Comparator|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
2510495|NCT02827643|Other|TDF/3TC or FTC/EFV|the subjects in this arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
2510526|NCT02827435|Experimental|Rocuronium bolus|rocuronium bromide 1st bolus 0.1mg/kg, rocuronium bromide 2nd bolus 0.4mg/kg
2510625|NCT02826707|Experimental|SPPAC intervention|Smartphone-delivered peer-led physical activity counselling
2510626|NCT02826707|No Intervention|Control group|Pragmatic no-contact control group
2510683|NCT02826447||Patients|500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
2510685|NCT02826447||Healthcare workers|50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
2510777|NCT02825498|Experimental|Operator guided by contact force|Operator has full access to contact force parameters including force time integral (FTI).
2510779|NCT02825498|No Intervention|Operator blinded to contact force|Operator is blinded to contact force with ablation guided by standard markers of effective ablation.
2510881|NCT02825004|Experimental|Psychological Intervention|All the professionals workers involved in the experimental group will attend three intensive psychological meetings about emotional exhaustion, depersonalisation, low personal accomplishment and how to improve coping skills.
2510889|NCT02825004|No Intervention|Control Group|There is not any intervention.
2510915|NCT02824718|Experimental|rh PTH(1-34)|40 µg/day rhPTH(1-34) (teriparatide or FORSTEO® 20 µg twice daily) over 7 to 8 weeks (52±3 days).
2510916|NCT02824718|Active Comparator|Thiazide + potassium sparing diuretic|hydrochlorothiazide 25 mg/day (ESIDREX®) + amiloride 5 mg/day (MODAMIDE®) + 0.5 µg/day alfacalcidol (ALFACALCIDOL®) over 7 to 8 weeks (52±3 days).
2511008|NCT02824237|Experimental|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
2511054|NCT02823912|Experimental|Capsaicin|75 mg capsaicin every 12 hours for 90 days
2511056|NCT02823912|Placebo Comparator|Control|75 mg magnesia calcinada every 12 hours for 90 days
2511104|NCT02823405|Experimental|X4P-001 + Pembrolizumab|X4P-001 alone, then adding pembrolizumab
2511272|NCT02822131|Other|low phosphate|low phosphate will be induced by low phosphate diet and additional treatment with oral phosphate binder sevelamer.
2511274|NCT02822131|Other|high phosphate|high phosphate diet will be induced by oral supplementation with sodium phosphate.
3163997|NCT00491439||corneal epithelial debridement|Corneal wound after pars plana vitrectioy with corneal epithelial debridement for diabetic retinopathy
3163998|NCT00491517|Experimental|Sirolimus|
3163999|NCT00491517|Active Comparator|conventional therapy|
2511358|NCT02821442|Experimental|Acupuncture|Acupuncture will consist of acupuncture points ST36, LR3, LI4 bilaterally x 30 minutes, once a week over 6 weeks. ST36 will have EA with 2Hz at the maximum tolerated intensity (ES-130 Portable Japanese Electro-Acupuncture Device, UPC Medical Supplies Inc. South El Monte, CA, USA).
2511365|NCT02821442|Sham Comparator|Sham Acupuncture|Sham acupuncture (Streitberger Placebo Needles, Asiamed) uses the same points and treatment parameters but the placebo needle does not penetrate the skin and the current for EA is not turned on.
2511435|NCT02821208||One cohorte : patient psychogenic nonepileptic seizures|The Psychogenic nonepileptic seizures (PNESs) are paroxysmal episodes type of abnormal movements, behavior modification or alteration of the contact-like seizures. These episodes are involuntary and underpinned by an unconscious psychological processes. In the International Classification of Disease-10 (ICD-10), they are classified as dissociative phenomena as conversing syndromes in the Manual of Diagnostic and Statistical Mental Disorders-IV (DSM-IV). The participants of the study only receive the usual care they would have if they were not included (no new/different intervention allocated in the study).
2511497|NCT02820779|Experimental|WILLIS|Patients undergo WILLIS intracranial covered stent interventional treatment
3164000|NCT00491582|No Intervention|Athletes, controls, patients|Sedentary controls: age, BMI, Gender and waist matched (to the growth hormone deficient patients) healthy control subjects Endurance trained athletes: minimal >50 mlO2/KG body weight
3164001|NCT00491621|Other|1|surgery or biopsy of the kidney tumor
3164002|NCT00491634|Experimental|1|treosulfan
3164003|NCT00491673|Active Comparator|Uncemented|Uncemented primary bipolar hemiarthroplasty of the hip
3164004|NCT00491673|Active Comparator|Cemented|Cemented primary bipolar hemiarthroplasty of the hip
3164005|NCT00491790|Sham Comparator|1|Sterile Water
3164006|NCT00491790|Active Comparator|Montelukast|Dissolved granules in sterile water
3164007|NCT00491803|Active Comparator|1|Sildenafil 20mg
3164008|NCT00491803|Active Comparator|2|Sildenafil 40mg
2510464|NCT02827864|Experimental|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1 lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
2510465|NCT02827864|Experimental|apply tDCS concurrently|"For the participants in the CON group, sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS.~Similar to the SEQ group, the participants will also practice functional tasks for 30 minutes after MT."
2510466|NCT02827864|Sham Comparator|MT with sham tDCS|For the SHAM group, the training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
2510600|NCT02827071||Retina abnormalities|Subjects with various retina vascular disorders
2510660|NCT02826720||HP+|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2510661|NCT02826720||HP-|Subjects with plasma Triglyceride or Total cholesterol levels > 200 mg/dl and low density lipoprotein-cholesterol levels > 130 mg/dl were included in the hyperlipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2510663|NCT02826720||NP+|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and having periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2510667|NCT02826720||NP-|Subjects with plasma Triglyceride or Total cholesterol levels < 200 mg/dl and low density lipoprotein-cholesterol levels < 130 mg/dl were included in the normolipidemic group and do not have periodontitis which were further evaluated for clinical periodontal parameters as well as to define the effects of the patient's habits on plasma lipid levels.
2510732|NCT02826226||obstructive ventilation disorder|patients with known or suspected obstructive ventilation disorder and clinical indication for bronchodilator testing
2510841|NCT02825784|Experimental|Renastart|"Compared to cows' milk and/or standard pediatric enteral feeds, Renastart has the following additional nutritional features that are beneficial in children with CKD: lower phosphorus, calcium and vitamin A. The powder presentation allows flexibility with dilutions to facilitate the provision of adequate energy and protein to support growth in children with CKD.~For each subject, the recommended daily intake of Renastart is determined by the dietitian in collaboration with the local PI and primary nephrologist based on individual nutritional requirements, specifically dietary intake of potassium and serum potassium levels.~Renastart is to be given by the clinician and based on clinical and nutritional needs. Standard preparation guidelines can be found on the Renastart label."
2510852|NCT02825108|Experimental|experimental group|The patients who receive 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
2510853|NCT02825108|Placebo Comparator|placebo group|The patients who receive only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
2510855|NCT02825108|Other|control group|The patients for whom the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups
2510910|NCT02824900|Experimental|Vibration stimuli to neck|Vibration stimuli to contralesional neck muscles, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
2510911|NCT02824900|Active Comparator|Vibration stimuli to hand|Vibration stimuli to contralesional hand, 5 days per week, for 2 weeks, 20 minutes per day + structured (conventional exercises) daily physiotherapy ~ 45 minutes.
3197170|NCT00858286|Experimental|Stable dosing with SERETIDE, short acting B-2agonist as needed|Regular treatment with SERETIDE in a stable dosing with short acting beta-2 agonists as needed
3197171|NCT00858286|Experimental|Maintenance treatment with SYMBICORT and SYMBICORT as needed|Maintenance treatment with SYMBICORT and using the same inhaler with SYMBICORT as needed
2511087|NCT02823587|Experimental|Bronchiectasis Pulmonary Rehabilitation|The volunteers will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
2511091|NCT02823587|Experimental|Healthy Pulmonary Rehabilitation|In this arm, the volunteers healthy will receive supervised physical training twice a week and will be instructed to adopt a routine of home exercises, for 12 weeks.
2511096|NCT02823587|Sham Comparator|Bronchiectasis Group Control|The volunteers with bronchiectasis will be informed only about the benefits of physical activities
2511098|NCT02823587|Sham Comparator|Healthy Group Control|Volunteers healthy will be informed only about the benefits of physical activities
2511142|NCT02823106|Experimental|Verapamil and Citicoline|10mg of verapamil in 10 cc of normal saline and 1000mg of citicoline in 10cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot to the treatment group
2511145|NCT02823106|Placebo Comparator|Placebo|The control group will receive saline only.
2511183|NCT02822755|Experimental|Video Recording Group|The experimental group participants will be recorded on their personal smartphone performing their prescribed exercises with individualized instruction from the participating physical therapist. The prescribing therapist will record participants on their own smartphones doing the exercise program in the clinic so that participants can have that video recording of the exercises to help remind them how to do the exercises properly at home. Participants will not be asked to record themselves performing future exercise sessions as documentation of improvement. Intervention: Home Exercise Program and Adherence Logs
2511218|NCT02822560|Active Comparator|open femoral access|cutdown to femoral artery and surgical closure
3197172|NCT00858299|Experimental|valsartan|
3197173|NCT00858312|Experimental|1|Diet with 3-4 servings of dairy-rich foods/day
2510467|NCT02827812|Experimental|Participants Telemedicine Care (PTE)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months~C. Home-Based telemedicine program:"
2510468|NCT02827812|Active Comparator|Participants Usual Care (PUC)|"A. Comprehensive evaluation at baseline (T0) and at the end of the study (T1).~B. Physical Intervention at home for 60 minutes 3 days/week for three months"
2510516|NCT02827578|Experimental|Tamsulosin + Solifenacin|Tamsulosin and Solifenacin
2510518|NCT02827578|Active Comparator|Tamsulosin + Solifenacin Placebo|Tamsulosin and Solifenacin placebo
2510533|NCT02827292|Experimental|Laparoscopic Surgery without music|Intervention: Headphones without music (Silent). A headphone will be applied peroperatively but no music will be played. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
2510535|NCT02827292|Experimental|Laparoscopic Surgery with music|Intervention: peroperative music via head phones. A headphone will be applied peroperatively and music will be played for the entire duration of the surgical procedure. Blood samples to assess the biomolecular inflammatory response and the post operative monitoring will be done as per the protocol.
2510583|NCT02827097|Experimental|Rectus sheath block group|"administration of denogan~rectus sheath block with 0.375% ropivacaine"
2510585|NCT02827097|Placebo Comparator|Control group|just administration of denogan
2510688|NCT02826434|Experimental|PVX-410 and Durvalumab|"Each patient will receive 6 PVX-410 vaccine injections and 2 infusions of Durvalumab.~The injection of PVX-410 will be co-administered with Hiltonol every 2 weeks for 6 injections.~The infusion of Durvalumab will be given on the day of the 4th and 6th PVX-410 injection, for a total of 2 infusions."
2510713|NCT02826005|Experimental|cirrhotic patients|if positive for 3 bio-markers- will be followed by MRI for HCC diagnosis
2510716|NCT02826005|No Intervention|non cirrhotic patients|control group - 3 bio-markers will be measured only
3197174|NCT00858312|Placebo Comparator|2|Low Dairy < 1 serving of dairy food/day
3197175|NCT00858351|Experimental|Thermal Biofeedback Assisted Relaxation|
2510846|NCT02825433||Patients receiving procedural sedation|The investigators collected ventilation data for each breath (respiratory rate, tidal volume, and end-tidal CO2) for all patients receiving procedural sedation for endoscopy.
2510886|NCT02825017|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2510944|NCT02824757||known diabetes|Participants have been diagnosed diabetes.
2510953|NCT02824757||known prediabetes|Participants have been diagnosed impaired glucose tolerance or impaired fasting glucose before.
2510954|NCT02824757||normal glucose tolerance|Participants have done the oral glucose tolerance test and been confirmed the normal glucose tolerance.
2510958|NCT02824757||unclear glucose tolerance condition|Participants who have not done oral glucose tolerance test or been diagnosed diabetes before.
2511006|NCT02824276|Experimental|Oral Opioid Medication|The primary study medication will be oxycodone, with morphine sulfate immediate release (MSIR) as a backup in case of side effects
2511009|NCT02824276|Placebo Comparator|Placebo Treatment|Placebo medications will be encapsulated in an opaque blinding capsule to ensure adequate blinding of study medications
2511035|NCT02823769|Experimental|SI-R21204 resin composite|Fillings made with a new dental filling material
2511044|NCT02823769|Active Comparator|Nanohybrid resin composite|Fillings made with nanohybrid resin composite (Clearfil Majesty)
3197176|NCT00858351|Active Comparator|Discussion|
2511118|NCT02823119|Experimental|Mini-hysteroscopy|A rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm.
2511121|NCT02823119|Active Comparator|Conventional Office Hysteroscopy|A rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm
2511185|NCT02822937|Experimental|Placebo, Methylphenidate, Triazolam|The participants will receive placebo on the first day, 40mg Methylphenidate on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2511186|NCT02822937|Experimental|Placebo, Triazolam, Methylphenidate|The participants will receive placebo on the first day, 0.375mg Triazolam on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2511187|NCT02822937|Experimental|Methylphenidate, Placebo, Triazolam|The participants will receive 40mg Methylphenidate on the first day, placebo on the second day, and 0.375mg Triazolam on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2511189|NCT02822937|Experimental|Methylphenidate, Triazolam, Placebo|The participants will receive 40mg Methylphenidate on the first day, 0.375mg Triazolam on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2511191|NCT02822937|Experimental|Triazolam, Placebo, Methylphenidate|The participants will receive 0.375mg Triazolam on the first day, placebo on the second day, and 40mg Methylphenidate on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2549535|NCT02568319|Placebo Comparator|Placebo|Placebo comparator
3197177|NCT00858377|Experimental|Arm 1- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
3197178|NCT00858377|Experimental|Arm 1- Dose Escalation|The dose escalation part of the study is aimed at determining the maximum tolerated dose (MTD) of AMG 900 and if necessary, the MTD with prophylactic GCSF support (MTD-G).
3197179|NCT00858416|Experimental|AB|First active then Sham
3197180|NCT00858416|Sham Comparator|BA|First sham then active
2510512|NCT02827565|Experimental|CircuLOR-1|KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (exon 15) mutations
2510566|NCT02827370|Experimental|Precision Nutrition (dietary intervention)|During chemotherapy, patients will receive dietary counseling based on the molecular pathways driving their specific breast cancers found through genetic testing. Nutritional recommendations will seek to down-regulate the dominant molecular drivers of an individual's breast cancer while they are receiving standard chemotherapy as outlined by their treating medical oncologist.
2510602|NCT02826928|Experimental|patients with small-intestine neuroendocrine tumors|
2510603|NCT02826928|Experimental|control subjects with irritable bowel syndrome|
2510630|NCT02826642|Experimental|Arm 1: Medically fit for induction|IDH305 + Standard of care for patients that are medically fit for induction.
2510633|NCT02826642|Experimental|Arm 2 Medically unfit for induction|IDH305 + Standard of care for patients that are medically unfit for induction.
3197181|NCT00858429|Experimental|Cohort 1 (capecitabine, Y90)|2,000mg/m2 capecitabine +110 Y90
3197182|NCT00858429|Experimental|Cohort 2 (capecitabine , Y90)|2,000mg/m2 capecitabine + 130 Y90
3197183|NCT00858429|Experimental|Cohort 3 (capecitabine, Y90)|2,000mg/m2 Capecitabine + 150 Y90
3197184|NCT00858429|Experimental|Cohort 4 (capecitabine, Y90)|2,000 mg/m2 capecitabine = 170 Y90
2510720|NCT02825953|Active Comparator|Nebulized surfactant|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV), and than premature babies with RDS breathing spontaneously will be administered surfactant by nebulizer.
2510725|NCT02825953|Active Comparator|Endotracheal bolus application|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The investigators will administer surfactant via fundamental method.
2510729|NCT02825953|Active Comparator|Minimally invasive surfactant therapy|For randomisatio, each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). After randomisation, the investigators will administer surfactant via minimally invasive surfactant therapy (MIST) method which is recently very popular method
2510808|NCT02825589|Experimental|BIA-guided|Assessment of target dry weight guided by using bioelectrical impedance analysis (BIA).
2510809|NCT02825589|No Intervention|Standard clinical guided|Assessment of target dry weight guided by clinical evaluation eg. jugular venous pressure, blood pressure, edema etc.
3197185|NCT00858455|Experimental|Healthy Volunteers|4 period cross over
3197186|NCT00858481|Placebo Comparator|1|Vehicle control
3197187|NCT00858481|Active Comparator|2|0.5% Spinosad creme rinse
3197188|NCT00858481|Active Comparator|3|1.0% Spinosad Creme Rinse
2511388|NCT02821624|Experimental|Cohort 1|G1T38 or placebo
2511389|NCT02821624|Experimental|Cohort 2|G1T38 or placebo
2511390|NCT02821624|Experimental|Cohort 3|G1T38 or placebo
2511391|NCT02821624|Experimental|Cohort 4|G1T38 or placebo
2511392|NCT02821624|Experimental|Cohort 5|G1T38 or placebo
2511393|NCT02821624|Experimental|Cohort 6|G1T38 or placebo
2511394|NCT02821624|Experimental|Cohort 7|G1T38 or placebo
2511397|NCT02821624|Experimental|Cohort 8|G1T38 or placebo
2511400|NCT02821624|Experimental|Cohort 9 - Food Effect|G1T38
2511402|NCT02821624|Experimental|Cohort 10|G1T38 or placebo
2511403|NCT02821624|Experimental|Cohort 11|G1T38 or placebo
2511404|NCT02821624|Experimental|Cohort 12|G1T38 or placebo
2511454|NCT02820948|Experimental|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
2511458|NCT02820948|No Intervention|No Vitamin E ointment application|No vitamin E ointment was performed.
2511551|NCT02820220||Students,nursing|"Pursuing Bsc Nursing(in their final year) or intern of college of nursing LHMC~Written informed consent to participate in the study"
2511554|NCT02820220||In-service nurses|"Posted in Department of Paediatrics indoor/OPD/well-baby clinics/immunisation clinics or Department of Gynaecology and Obstetrics indoor/OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
3197189|NCT00858481|Active Comparator|4|2.0% Spinosad Creme Rinse
2549558|NCT02568085|Experimental|1|thyroidectomy + Arista
3197190|NCT00858520||Smoking controls|Smokers without lung cancer and without COPD
3197191|NCT00858520||COPD patients|Smokers with COPD but without lung cancer
3197192|NCT00858520||Lung cancer patients|smokers - never smokers with lung cancer
2510472|NCT02827877|Experimental|Treatment (trastuzumab, copper Cu 64-DOTA-trastuzumab PET)|Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
2510543|NCT02827461||MZ|Monozygotic twins
2510547|NCT02827461||DZ|Dizygotic twins
2510595|NCT02827162||Case D1|Subject having experienced a Virologically confirmed dengue infection, from the first injection until the end of the active phase, excluding Case D3 subjects
2510597|NCT02827162||Case D3|Subject having experienced a Virologically confirmed dengue infection, from 28 days after the third injection until the end of the Active Phase of the proof of concept (PoC) efficacy study
2510598|NCT02827162||Control I|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and belonging to the PoC efficacy study immunogenicity subset
2510599|NCT02827162||Control E|Subject having not experienced a Virologically confirmed dengue infection in the Active Phase of the PoC efficacy study, and not belonging to the PoC efficacy study immunogenicity subset
2510672|NCT02826681|Active Comparator|Injectafer|750 mg undiluted slow IVpush (100 mg/minute) of Injectafer® (Ferric Carboxymaltose - FCM)
2510675|NCT02826681|Placebo Comparator|Normal Saline|Placebo (15 ml of Normal Saline [NS]) IV push at 2 ml/minute on Day 0 and 7.
2510770|NCT02826135|Experimental|Pediatric patients with hypovolemic state|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output or decreased central venous pressure. Changes of blood pressure during abdominal compression is continuously recorded.
2510786|NCT02825459|Experimental|Abstinence from e-cigarettes|Participants abstain from e-cigarettes and other nicotine/tobacco products for 6 days
2510788|NCT02825459|No Intervention|E-cigarette use|Participants use e-cigarettes and continue to abstain from tobacco/nicotine products as they normally would.
2510867|NCT02825355||Patients with cervical cancer|All patients receive sentinel node mapping as the conventional treatment.
2510872|NCT02825355||Patients with endometrial cancer|All patients receive sentinel node mapping as the conventional treatment.
2510968|NCT02824471||Minor SCD Group, Ages 12-17|No Intervention. Use of discarded blood/tissue only
2510969|NCT02824471||Adult SCD. Ages 18+|No Intervention. Use of discarded blood/tissue only
2510975|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 15 mg; then RO5545965 5mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2510979|NCT02824055|Placebo Comparator|Placebo first; then RO5545965 5 mg; then RO5545965 15 mg|Participants will receive placebo matched to RO5545965 capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2510982|NCT02824055|Experimental|RO5545965 15 mg first; then Placebo; then RO5545965 5 mg|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 5 mg capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2510989|NCT02824055|Experimental|RO5545965 15 mg first; then RO5545965 5 mg; then Placebo|Participants will receive RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 5 mg capsules orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2510999|NCT02824055|Experimental|RO5545965 5 mg first; then Placebo; then RO5545965 15 mg|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then placebo matched to RO5545965 capsules orally daily from Weeks 6 to 8 in second intervention period; followed by RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2511004|NCT02824055|Experimental|RO5545965 5 mg first; then RO5545965 15 mg; then Placebo|Participants will receive RO5545965 5 mg capsules orally daily from Weeks 1 to 3 in first intervention period; then RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily from Weeks 6 to 8 in second intervention period; followed by placebo matched to RO5545965 capsules orally daily from Weeks 11 to 13 in third intervention period. A washout period of minimum 14 days will be maintained between each period.
2511074|NCT02823613|Experimental|Healthy male test subjects 1-5|High salt diet followed by low salt diet
2511075|NCT02823613|Experimental|Healthy male test subjects 6-10|Low salt diet followed by high salt diet
2511130|NCT02823301|Experimental|VAMOS group|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
2511133|NCT02823301|No Intervention|Control group|Group that will not receive the VAMOS program as intervention.
3197193|NCT00858533|Other|workplace health advice|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances.
3197194|NCT00858533|No Intervention|GP sickness absence consultation|Routine general practitioner care for workplace sickness absence.
3197195|NCT00858546|Experimental|Active repetitive transcranial Stimulation|Active repetitive transcranial Stimulation
3197196|NCT00858559|Experimental|1|Home Monitoring
3197197|NCT00858559|Active Comparator|2|Home Monitoring not used
3197198|NCT00858572|Experimental|Cohort|
3197199|NCT00858598||Pro Osteon|All patients in this pilot study will receive pro osteon as a bone void filler and will be enrolled according to the same inclusion / exclusion criteria.
3197200|NCT00858624|Active Comparator|Chronic Cough Patients|
2510650|NCT02826746|Experimental|Magnesium group|intravenous administration of Magnesium Sulfate
2510653|NCT02826746|Placebo Comparator|Control group|intravenous administration of normal saline
2510733|NCT02825940|Experimental|Atezolizumab Monotherapy: PK and Extension Phases|Participants during the PK and extension phases of the study will receive atezolizumab alone at a dose of 1200 milligrams (mg) IV every 3 weeks (q3w) (in 21-day cycles) continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
2510734|NCT02825940|Experimental|Atezolizumab and Chemotherapy: Extension Phase|Participants during the extension phase of the study will receive atezolizumab at a dose of 1200 mg IV on Day 1 in combination with gemcitabine at a dose of 1250 milligrams per square meter (mg/m^2) on Days 1 and 8 and cisplatin at a dose of 75 mg/m^2 on Day 1 (four or six 21-day cycles at the discretion of the investigator), followed by atezolizumab as a single agent at a dose of 1200 mg IV q3w on Day 1 of a 21-day cycle) as maintenance treatment continuously until loss of clinical benefit, disease progression, unacceptable toxicity, participant or physician decision to discontinue, or death. Study treatment may continue beyond disease progression based on the investigator's discretion.
3197201|NCT00858624|Active Comparator|Healthy Volunteers|
3197202|NCT00858650||Standard of Care|Hypogonadal males treated by standard of care, with or without testosterone replacement therapy
3197203|NCT00858663|Experimental|Chemoradiation|"IMRT, 1 fraction/day, over approximately 33 treatment days~RAD001 per oral or PEG, per dose escalation scheme (Days 1 - 42)~Cisplatin IV weekly, per dose escalation scheme (Days 1, 8, 15, 22, 29, 36)"
3197204|NCT00858676|Active Comparator|Acarbose|
3197205|NCT00858715|Active Comparator|1|75 mg clopidogrel + 100 mg aspirin
2510996|NCT02824081|Other|Depressive patients|Blood samples (inflammatory biomarkers and genetic purpose) on depressive patients with or without story of suicidal behavior
2511020|NCT02823977|Experimental|Ketamine / Dexmedetomidine|Ketamine 0.25 mg/kg bolus followed by 0.5 mg/kg per hour AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
2511021|NCT02823977|Placebo Comparator|Placebo / Dexmedetomidine|Normal saline, as a 500 mL infusion bag, to represent placebo AND Dexmedetomidine by continuous infusion at a fixed rate of 0.6 µg/kg per hour, both administered for up to 72 hours
2511029|NCT02823678||Pancreatectomy|Patients scheduled to undergo a pancreatectomy
2511088|NCT02823574|Experimental|Nivolumab and Ipilimumab|Specified dose on specified days
2511095|NCT02823574|Active Comparator|Nivolumab and Ipilimumab-placebo|Specified dose on specified days
2511195|NCT02822521|Experimental|Mobile Application + Population Manager|This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.
2511197|NCT02822521|No Intervention|No Mobile Application|This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.
2511412|NCT02821312|Placebo Comparator|Placebo in Group A1~A7|In each of Groups A1 to A7, 2 subjects will receive placebo.
3197206|NCT00858715|Active Comparator|2|150 mg clopidogrel + 100 mg aspirin
3197209|NCT00858741|Experimental|8 Gy arm|8.0 Gy in 1 fraction to 8.0 Gy total dose.
3197210|NCT00858741|Active Comparator|30 Gy arm|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
3197211|NCT00858754|Experimental|Group 1 Active Drug|Methylnaltrexone
3197212|NCT00858754|Placebo Comparator|Group 2 Non-Active Drug|Placebo
3197213|NCT00858767|Active Comparator|1|2 casein capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
3197214|NCT00858767|Active Comparator|2|2 arabic gum capsules per day existing of 90 µg menaquinone-7 per day for 8 weeks
3197215|NCT00858767|Active Comparator|3|2 linseed capsules existing of 90 µg menaquinone-7 per day for 8 weeks
3197216|NCT00858793|Experimental|A|
3197217|NCT00858806|Experimental|Intermittent Imatinib|"Imatinib will be given with the following schedule:~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
3197218|NCT00858819||AS|Patients with AS attending three different rheumatology clinics in Western Sweden have been invited to participate.
3197219|NCT00858871|Active Comparator|Brivanib|
3197220|NCT00858871|Active Comparator|Sorafenib|
2510485|NCT02827669|Experimental|One Drop Experts Program|Participants will be able to use the One Drop mobile app and One Drop Experts program on their smartphones. The One Drop mobile app is a diabetes management platform that allows users to track and log their blood glucose levels, medications, food, and activities. One Drop Experts is a diabetes education and coaching program delivered entirely through the One Drop mobile application.
2510487|NCT02827669|Experimental|One Drop Experts Program + Apple Watch|An Apple Watch will be provided to study participants in this arm. In addition to using the One Drop mobile app and One Drop Experts program on their smartphones, participants will also be able to engage with the app and program on their Apple Watch.
2510622|NCT02826863|Experimental|Experimental: ZX008 - 0.8 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2510623|NCT02826863|Experimental|Experimental: ZX008 - 0.2 mg/kg/day|ZX008 is supplied as an oral solution in concentrations of 0.2 mg/kg/day ZX008 will be administered twice a day (BID) in equally divided doses with food.
2510624|NCT02826863|Placebo Comparator|Placebo Comparator: Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
2510711|NCT02826252||Ventavis|The study will be conducted in patients who are enrolled in the German Ventavis patient support program Ventaplus.
2510842|NCT02825810|Experimental|Cervical motor control group|
2510844|NCT02825810|No Intervention|Control group|
2510866|NCT02825095|Active Comparator|Talc Pleurodesis|"For patients in this group, chest tube type PIGTAIL 10 - 14 Fr will be inserted by by chest ultrasound guided and under local anesthesia, allowing good draining of the hemithorax, in case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed, chest tube will be removed 24 - 48 hours later on. the patient will be admitted in the hospital during the whole procedure course.~If the patient developed non expanded - trapped lung post chest tube insertion, or if he had persistence high chest tube output for more than 10 days, then the patient will remain with the PIGTAIL as an Indwelling Pleural Catheter."
2510871|NCT02825095|Active Comparator|Indwelling Pleural Catheter|"All patients from this group will have Indwelling Pleural Catheter insertion type PLEURAX inserted by ultrasound guided and under local anesthesia.~the patient and his/her family will be instructed and educated about the proper way of using the catheter, and how to perform pleural draining at home.~the duration of treatment with the Pleurax depends on the rate and amount of pleural effusion draining."
2510914|NCT02824666|Experimental|0.5 mg/kg|• Cohort 1: ATI-9242 - Single IV bolus dose of 0.5 mg/kg
2510917|NCT02824666|Experimental|ATI-9242 1.0 mg/kg|• Cohort 2: ATI-9242 - Single IV bolus dose of 1.0 mg/kg
2511022|NCT02824393|Experimental|Mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
2511023|NCT02824393|No Intervention|Control patients|The patients who treated with the conventional therapy for urticaria, but not treat with mesenchymal stem cell.
2511070|NCT02823652|Experimental|Group I (internet-based intervention)|Patients receive web-based genetic education consisting of general information about testing tumors for genetic mutations.
2511072|NCT02823652|Active Comparator|Group II (usual care control)|Patients receive standard genetic education consisting of conversations with the treating physicians, interaction with and information from the clinical staff, and information from usual resources about testing for genetic mutations.
2511073|NCT02823652|Experimental|Group III (genetic counseling)|Patients who meet the criteria for the remote counseling substudy will receive genetic counseling over the telephone and undergo germline testing.
2511109|NCT02823249|Active Comparator|1.56 g L-Tryptophan|"1.56 g L-Tryptophan in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2511112|NCT02823249|Active Comparator|1.56 g L-Leucine|"1.56 g L-Leucine in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2511114|NCT02823249|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water given via nasogastric tube
2511115|NCT02823249|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water given via nasogastric tube
2511116|NCT02823249|Placebo Comparator|75 g Glucose and mixed liquid meal|"75 g Glucose in 300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2511117|NCT02823249|Placebo Comparator|Tap water and mixed liquid meal|"300 mL tap water given via nasogastric tube~+ after 60 min: 500ml of a mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate) given via nasogastric tube"
2511176|NCT02822729|Experimental|DE-117 ophthalmic solution (Group1)|Monotherapy
2511177|NCT02822729|Experimental|DE-117 ophthalmic solution (Group2)|Monotherapy
2511179|NCT02822729|Other|DE-117 ophthalmic solution + Timolol (Group3)|Concomitant Use
2511235|NCT02822508|Experimental|BLI801 Laxative (high dose)|BLI801 Laxative (high dose)
2511238|NCT02822508|Experimental|BLI801 Laxative (mid dose)|BLI801 Laxative (mid dose)
2511242|NCT02822508|Experimental|BLI801 Laxative (low dose)|BLI801 Laxative (low dose)
2511244|NCT02822508|Placebo Comparator|BLI801 Placebo|BLI801 Placebo
3164009|NCT00491816|Experimental|erlotinib with neoadjuvant chemotherapy|Study drug, erlotinib, is administered along with neoadjuvant chemotherapy. Adjuvant therapy given at discretion of treating physician. Once adjuvant therapy is completed, all patients will receive erlotinib 150 mg daily for 1 year.
2511420|NCT02820987|Active Comparator|MEROPENEM|After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.
2511440|NCT02821143|Experimental|Intervention group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive intervention with a follow-up with Telemedicine consultation
2510527|NCT02827487|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) and an oral placebo similar to Celecoxib 2 hours before IUD insertion.
2510528|NCT02827487|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg (Celebrex® 200, Pfizer, USA) and an oral placebo similar to Tramadol 2 hours before IUD insertion.
2510529|NCT02827487|Placebo Comparator|Placebo 1|Women will receive a placebo similar to Tramadol and a placebo similar to Celecoxib orally 2 hours before IUD insertion.
2510591|NCT02827136|Experimental|Patch group|Lidocaine patch and Hypafix
2510592|NCT02827136|Placebo Comparator|Control group|Just Hypafix
2510631|NCT02826733||Normal|"Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI).~EEG NIRS MRI"
2510635|NCT02826733||cerebral neurological disease|"Group of children meeting the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological (ETF , Scanner, MRI) The children present either convulsions or a cerebrovascular accident or a neurological pain . Each condition being verified by a pathological electroencephalogram .~EEG NIRS MRI"
2510700|NCT02826083|Experimental|XXS|
2510701|NCT02826083|Placebo Comparator|Placebo|
2510774|NCT02825914|Active Comparator|Casein glycomacropeptide (CGMP)|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of CGMP-protein-shake during 12 weeks.
2510775|NCT02825914|Placebo Comparator|Placebo|As add-on to the standard medical treatment of active ulcerative colitis the patients will receive a daily oral intake of placebo-shake consisting of milk powder during 12 weeks.
2510815|NCT02825394||apixaban initiation|N=20
2510818|NCT02825394||apixaban on-treatment|N=20
2510820|NCT02825394||dabigatran initiation|N=20
2510821|NCT02825394||dabigatran on-treatment|N=20
2510823|NCT02825394||rivaroxaban initiation|N=20
2510824|NCT02825394||rivaroxaban on-treatment|N=20
2510826|NCT02825394||edoxaban initiation|N=20
2510827|NCT02825394||edoxaban on-treatment|N=20
2510849|NCT02825147|Experimental|MESA|stage I/II: methotrexate 1000mg/m2,d1 dexamethasone 40mg,d2-d4 etoposide 100mg,d2-d4 pegaspargase 2500U/m2,d5 a cycle of every 21 days with totally 4 cycles Radiotherapy at least 50Gy in dose for the involved local focus is sandwiched after 2 cycles.
3197221|NCT00858884|No Intervention|No intevention|No intervention
2510906|NCT02824601|Experimental|One-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
2510909|NCT02824601|Experimental|Two-visit treatment PDT|Intervention: Chemo-mechanical preparation (CMP) was performed by using the single-file reciprocating technique + 2.5% NaOCL and a final rinse with 17% EDTA. In the following, 14-day inter-appointment medication with Ca(OH)2 + SSL was placed in the root canal. After 14 days with intracanal medication, the tooth was isolated for surgery and disinfection, including removal of provisional restoration. Next, the root canals were irrigated with 10 mL of saline solution, with calcium hydroxide medication being neutralized with 0.5% citric acid. Afterwards, the photosensitizer agent (methylene blue 10 mg/mL) was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP in the one-visit treatment
2511014|NCT02824445|Sham Comparator|Sham|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
2511015|NCT02824445|Experimental|Treatment|The double-blind is used during the first 2 weeks. From week 3 and on, the study becomes open label. Subjects in Group I (active MeRT treatment group) will continue receive active MeRT treatment for W3/4; subjects in Group II (placebo/sham group) will receive active MeRT treatment from W3 to W6 for 4 weeks. All subjects will receive 4 weeks active MeRT treatment. The study ends in 8th wk. The data collection points are baseline, weeks of 2, 4, 6, and 8. The data from weeks 1-2 (Phase I) will be utilized to analyze the safety and any effect of MRT procedure may have over placebo. The data from weeks 3 on (Phase II) will be used to address if any benefit of longer MeRT treatment (4 vs 2 weeks). The study design offers both groups 4 weeks of the experimental therapy in a row. This will provide potentially equal benefit to those participants assuming that MeRT helps to improve PTSD symptoms.
2511060|NCT02823743|Experimental|Low dose aspirin|75 mg aspirin orally daily from gestational week 7-35
2511062|NCT02823743|Placebo Comparator|Placebo|Placebo pill orally daily from gestational week 7-35
2511126|NCT02823379|Experimental|Physical Activity|A culturally relevant physical activity promotion program delivered using a Smartphone application.
2511128|NCT02823379|Active Comparator|Wellness Contact Control|A wellness contract control condition delivered using a Smartphone application.
2511226|NCT02822378|Experimental|Ca2+/VitD Control|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).
3197222|NCT00858897|Experimental|1|Normoglycemia (80-140 mg/dL)
2510489|NCT02827695|Experimental|SMASK|Subjects will receive electronic pill tray with reminder functions activated and Bluetooth blood pressure monitor and phone app.
2510490|NCT02827695|Other|EnhancedSC|Subjects will receive daily attention control texts with healthy lifestyle information and continue to use the pill tray without reminder functions.
3197223|NCT00858897|Experimental|2|Hyperglycemia (200-250 mg/dL)
3197224|NCT00858910|Experimental|EG1: embedded MI|"Experimental group 1:~Participants receive motor imagery (MI) training included in 45min physiotherapy, 3 times per week for 2 weeks."
2510611|NCT02826785|Experimental|Cognitive strategy training|The cognitive strategy training intervention consists of 6 weekly ~1 hour sessions. It is delivered in an individual, face-to-face format in the client's home. It is a behavioral intervention that teaches people metacognitive, problem-solving and other compensatory strategies to address self-identified cognitive performance problems, and it uses practice and homework to promote strategy learning, retention and transfer.
3197225|NCT00858910|Experimental|EG2: added MI|"Experimental group 2:~Participants receive a 15 minutes motor imagery (MI) training added to a 30 min physiotherapy session, 3 times a week for two weeks."
3197226|NCT00858910|Placebo Comparator|CG|"Control group:~Participants receive a 15 min control intervention added to their 30 min physiotherapy session, 3 times a week for two weeks."
2510907|NCT02824536|Experimental|Group 1|Participants will be randomized in a 3:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
2510912|NCT02824536|Experimental|Group 2|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 3 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
2510913|NCT02824536|Experimental|Group 3|Participants will be randomized in a 3:1 ratio to receive three intravenous infusions of 3BNC117 and three intravenous infusions of 10-1074, each dosed at 10 mg/kg OR placebo (sterile saline), on day 0, week 8, and week 16.
2510972|NCT02824146|No Intervention|Control group|Patients received standard protective mechanical ventilation during all surgery, with tidal volumen 6 ml/kg and positive end-expiratory pressure (PEEP) level of 5 (centimeter of water) cmH2O.
2510973|NCT02824146|Experimental|Recruitment maneuver group|"Patient received a lung recruitment maneuver after pneumoperitoneum insufflation.~The recruitment maneuver consists in 10 breaths at 30/15 cmH2O of plateau pressure and PEEP, respectively. Then, the ventilatory settings back to protective ventilation but adding 8 cmH2O of PEEP to keep the lungs open."
2511084|NCT02824042|Experimental|Anetumab ravtansine|The evaluation of multiple ECG parameters and the drug-drug interaction (DDI) potential of anetumab ravtansine parameters when administered alone and together with itraconazole 100 mg oral capsules will be conducted in 2 sequential parts. On Cycle 1 Day 1, anetumab ravtansine will be given alone at a dose of 6.5 mg/kg in Part 1 and Part 2. On Cycle 2 Day 1, anetumab ravtansine will be given together with itraconazole at a dose of 0.6 mg/kg in Part 1, and at a dose of 6.5 mg/kg (planned) in Part 2.
2511225|NCT02822690||University Medical Center Groningen|all patients that died on one of the wards with the exception of children; on several wards the Hospice care will be introduced as an intervention
2511229|NCT02822690||Martini Ziekenhuis|all patients that died on one of the wards with the exception of children
2511234|NCT02822690||Ommelander ZorgGroep|all patients that died on one of the wards with the exception of children
2511289|NCT02822170|Experimental|IV amino acids and in-bed cycle ergometry|"Beginning within 96 hours of ICU admission, participants will receive the following combined intervention:~IV amino acids (15% solution) delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day.~In-bed cycle ergometry exercise delivered in 45-minute sessions 5 days per week according to a detailed specific protocol that includes a safety check and gradual increases in resistance if the participant is actively cycling."
2511339|NCT02821728|Experimental|Normal diet|No dietary intervention
2511340|NCT02821728|Experimental|Dietary intervention|3 portions of broccoli soup per week
2511372|NCT02821351|Experimental|DiamondTemp|Bilateral pulmonary vein isolation by RF ablation using DiamondTemp temperature controlled catheter and RF generator/pump system
2511453|NCT02821130||Cystic Fibrosis Patients|Participants diagnosed with cystic fibrosis
2511476|NCT02820636|Experimental|InVita|Participants receive the Socio-Cognitive Behavior Therapy (S-CBT) treatment.
2511480|NCT02820636|Active Comparator|Treatment as Usual|Intensive outpatient therapy of standard care for adolescents and their parents
2511528|NCT02820285|Other|Morbid obese patients|
2511531|NCT02820285|Other|Control patients|
2511533|NCT02820285|Other|Patients with overweight, steatosis and steatohepatitis|
2511746|NCT02818907|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, after neoadjuvant chemotherapy (if applicable) and before surgery, 1 month after surgery and 1 month after the last adjuvant chemotherapy cycle.~Peripheral blood mononuclear cell (PBMC), plasma and circulating tumor DNA and RNA will be collected.~Tumor tissue will be collected during surgery."
2511789|NCT02818647|Active Comparator|COLD-DISSECTION|Cold Dissection Technique
2511792|NCT02818647|Active Comparator|HOT-DISSECTION|Needle Electrocautery Dissection Technique
2511823|NCT02818361|Experimental|topical TwHF gel group|Topical TwHF gel recipe composes Tripterygium wilfordii Hook F, Mangxiao (Mirabilite), Chuanxiong (Rhizoma Ligustici), Ruxiang (Olibanum), Moyao (M yrrh) (prescription proportion is 4:4:2:2:1).Each gel is 20 gram(g). TwHF gel is applied for 1st to 5th metacarpophalangeal joints, 1st to 5th proximal interphalangeal joints, wrists, knees and ankles 20g for 1 hour, once per day from week 0 through week 4 and 10g for 1 hour, once per day from week 5 through week 8.
2511827|NCT02818361|Placebo Comparator|placebo group|Placebo recipe composes viscous agent which matches by the sucrose. The usage and dosage of topical TwHF and placebo are the same.
2511898|NCT02818075|Experimental|Mobile Phone Based Peer Support|Mobile phone-based peer support (MPPS)
2511902|NCT02818075|Active Comparator|Usual Care|Standard community prenatal and postpartum support services
2512108|NCT02816593|Experimental|Group 1 - HP 6%|Group 1: Experimental: Office; hydrogen peroxide 6%,
2510491|NCT02827630|Active Comparator|DH-4|Subjects will use Proteus Discover, the digital health offering (DH) for 4 weeks
2510492|NCT02827630|Active Comparator|DH-12|Subjects will use Proteus Discover, the digital health offering (DH) for 12 weeks
2510493|NCT02827630|Other|Usual Care|Subjects received usual medical care including all normal interventions such as medication titration, adherence counseling, lifestyle coaching, and additional clinic visits per their providers' discretion.
2510571|NCT02827084|Experimental|Kinesio Taping|Apply the Kinesio Taping with tension in the vatus mediallis
2510573|NCT02827084|Placebo Comparator|Placebo|Apply the Kinesio Taping without tension in the vatus mediallis
2510574|NCT02827084|No Intervention|Control|It will not apply Kinesio.
2510629|NCT02826850|Sham Comparator|Genicular nerves|Neurotomy by radiofrequency of genicular nerves knee guided by fluoroscopy
2510632|NCT02826850|Active Comparator|Saphenous Nerve|Neurotomy of saphenous nerve by radiofrequency on the distal third of the thigh, guided by ultrasound
2510723|NCT02826070|Other|Off-treatment|Patients who had stopped treatment during EFFORT extension study could receive 2-year off-treatment follow-up. All the patients in Part I will be followed up at the interval of 12 weeks. For these patients, if they have hepatitis flare during follow-up, they will be re-treated with telbivudine combined with adefovir for the left study period ( the total study period is 2 years) and followed up at the interval of 12 weeks. Hepatitis flare is defined as HBV DNA>4 Log10 copies/mL with either ALT≥5 times upper limit of normal (ULN) or TBIL≥2×ULN，or 2 ≤ALT ≤5 ×ULN (at two consecutive visits at least 2 weeks apart) and total bilirubin (TBIL) <2×ULN.
2510728|NCT02826070|Other|On-treatment|Patients with continuous treatment during EFFORT extension study will continue treatment, without off-treatment rule in the further extension study. The treatment strategy is depended on the HBV DNA level of each individual, that is, for patients with negative HBV DNA level (defined as HBV DNA <20 IU/mL) will continue their previous treatment strategy; and for patients with positive HBV DNA level (defined as HBV DNA>=20 IU/mL) will receive the combination therapy of telbivudine and adefovir, irrespective of their previous treatment strategy. All the patients in Part II will be followed up at the interval of 24 weeks until they complete the 2-year on-treatment follow-up. Patients will be conducted liver biopsy at the sixth year of treatment. All the patients with telbivudine monotherapy will be switched to telbivudine plus adefovir once confirmed HBV DNA breakthrough developed.
2510810|NCT02825602||Vietnam War Theater Veterans|Vietnam War Theater Veterans are defined for this protocol as those who served in the U.S. Armed Forces on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos between February 28, 1961 and May 7, 1975, inclusive. The investigators based this definition on legal dates of service set forth in 38 Code of Federal Regulations (CFR) 3.2 - Periods of war, but broadened the definition of sites of military service that constituted war zones based on written historical accounts and input from Vietnam Veterans.
2510812|NCT02825602||Blue Water Navy Vietnam Veterans|Blue Water Navy Veterans are defined as Veterans who served aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975 and who never served ashore or on inland waterways of Vietnam.
2510816|NCT02825602||Vietnam era Veterans|Vietnam era Veterans served in locations around the world OTHER than on the ground, in the air, or on the inland waters of Vietnam, Cambodia, and/or Laos or aboard deep-water naval vessels in waters offshore North or South Vietnam between February 28, 1961 and May 7, 1975.
2510819|NCT02825602||Non-military U.S. public|Non-military U.S. public are individuals who were born before 1958, never served in the U.S. military, and are age- and gender-matched (by the study investigators) to Vietnam War Theater Veterans.
2510885|NCT02825264||STARflo|Patients who have been implanted with STARflo implant
2510938|NCT02824640|Active Comparator|Patient Navigation|"The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.~Health Promotion Sessions: PNs will deliver 4 standardized health promotion sessions to all patients either individually or within a group.~Optional Weekly Support Groups: Subjects randomized to the PN arm will be offered weekly support groups led by Peers."
2510949|NCT02824640|Active Comparator|modified Directly Observed Therapy|"OAT clinic setting: Observation of HCV medications will be linked to methadone visits among patients receiving methadone. Patients will be receiving methadone as part of routine clinical care for opioid addiction and not as an intervention related to this study. The schedule of five days per week will be considered modified DOT (mDOT). Subjects will initiate HCV treatment on Mondays if feasible. Take home medications will be packed in a weekly electronic blister pack.~Community health clinic setting: This intervention is considered modified DOT (mDOT) since between 3-5 weekly doses will be directly observed. A minimum of one dose will be observed in person by clinic/study staff. For the remaining observed doses, the research staff and provider will present the participant with a menu of options and determine what will work best for that participant."
2510984|NCT02824250|Experimental|MBSR + Usual Care|8-week standard Mindfulness-Based Stress Reduction (MBSR) course + standard of care
2510993|NCT02824250|No Intervention|Usual Care|Standard of care
3197227|NCT00858936|Experimental|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
2511153|NCT02823067||Nursing home patients|Nursing home patients aged 65 years or above. One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
2511181|NCT02822768|Active Comparator|Packing|The patient is to have a long piece of gauze within the abscess cavity in an attempt to keep it open and allow purulent material to continue to drain after the initial incision and release of purulent material has been performed.
2511182|NCT02822768|Placebo Comparator|No packing|The patient is not to have packing of the abscess as part of the incision and drainage procedure
2511231|NCT02822482|Experimental|Copanlisib + Cetuximab|All patients will be treated by Copanlisib in association with Cetuximab.
2511303|NCT02822053|Experimental|US-guided laser ablation for refractory neoplasms|The investigators used percutaneously US-guided laser ablation for patients with small hepatocellular carcinoma (single or multiple nodules of less than 3 cm in diameter), Child-Pugh A/B, PLT ≥ 50*10E9/L and PT ≤ 20s. Then the investigators estimated the safety and efficacy of this treatment through follow-up of US/CEUS/CT/MRI and the tumor markers every three months.
2510498|NCT02827656|Experimental|Decapeptyl support|S.C single luteal Decapeptyl 0.1 mg on days 3, 6,9 post ovulation triggering
2510506|NCT02827656|Active Comparator|hCG luteal support|S.C single luteal S.C recombinant hCG 50 micrograms on days 3 ovulation triggering
2510532|NCT02827383|Experimental|Stair Climbing 4x/day|Participants use the stair climber 4 times per day, for 4 minutes at a time. Total dose = 16 minutes.
2510536|NCT02827383|Experimental|Stair Climbing 8x/day|Participants use the stair climber 8 times per day, for 2 minutes at a time. Total dose = 16 minutes.
2510590|NCT02827175|Experimental|fevers of the travelers|
2510637|NCT02826772|Experimental|Phase 1 GT0918 level 1|generic name: not applicable dosage form: tablet dosage: oral dosage to be determined dosage frequency: daily dosage duration: 6 months
2510696|NCT02826343|Other|COPD Advair|"Subjects will undergo hyperpolarized xenon MRI with perfusion imaging, before and after a 90 day course of Adair.~All subjects belong to one arm and will receive same treatment. Then they are compared at baseline and 3 month post intervention (described below) for within same-subject changes.~Subjects will be administered with~Hyperpolarized Xenon129 inhalation during MRI twice (at baseline and post 3 month Advair)~Gadolinium intravenous contrast during MRI twice (at baseline and post 3 month Advair)~Advair diskus: strength 250mcg/50mcg, one puff twice a day for 3 months."
2510741|NCT02825979|Active Comparator|Cryoballoon-based PVI|"Sinus rhythm control via a pulmonary vein isolation (PVI) (first-line) procedure utilizing the the Arctic Front Cryoballoon Procedure."
2510746|NCT02825979|Active Comparator|Anti-Arrhythmic Drug Therapy|"Sinus rhythm control via the use of anti-arrhythmic drug (AAD) therapy (first-line) based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF."
2510790|NCT02825537|Experimental|With use of compression stocking|Use of compression stocking during 3 consecutives days
2510792|NCT02825537|Other|Without use of compression stocking|No use of compression stocking during 3 consecutives days
2510882|NCT02824965|Experimental|Pembrolizumab+1x10^9 TCID50 CVA21|CVA21 will be administered IV on days: 1, 3, 5, 8 29, 50, 71, 92, 113 134, and 155. 200mg Pembrolizumab will be administered as per normal dosing frequency at Q3W IV, and will continue for up to 24 months. Should dose limiting toxicities be observed participants may be transferred a lower dosage of CVA21.
2510987|NCT02824406||Patients|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
2510998|NCT02824406||Controls|CVR assessment consists of CBF measurement with arterial spin labelling (ASL)-MRI before and after intravenous administration of 16mg/kg acetazolamide (Diamox)
2511024|NCT02823847|Experimental|Oral Screening|Participants given a screening interview at baseline. Carbon monoxide testing given to participants at baseline. Participants who want to stop smoking are given referral information for a tobacco cessation program. Participants undergo an oral examination using conventional light, and oral examination using a fluorescence light-based hand held device at baseline, and again two weeks later. Oral lesions still present after two weeks are biopsied. Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation.
2511067|NCT02823639|Active Comparator|Transcranial direct current stimulation|tDCS with varying intensity, location and polarity
2511071|NCT02823639|Placebo Comparator|Sham stimulation|Double blind sham stimulation with sham mode of neuroConn device
2511119|NCT02823353|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
2511125|NCT02823353|Active Comparator|Monotherapy|UDCA alone
2511166|NCT02822924|Other|Prostate artery embolization treatment|Prostatic artery embolization (PAE) as a new treatment technology is a potentially promising, minimally invasive alternative procedure for BPH, which has been shown to be safe and effective in both animal models and clinical trials.
2511246|NCT02822573|Active Comparator|Donepezil|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5 mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
2511248|NCT02822573|Placebo Comparator|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
2511472|NCT02820584|Experimental|GSC-loaded autologous dendritic cells|DC-GSC immunotherapy. Six vaccinations are envisaged. The first three vaccinations will be performed every two weeks; subsequent three vaccinations every month. The first vaccination will be performed using 20 million DC, the second and third with 10 million DC; and from the 4th vaccine 5 million DC
2511511|NCT02820441|Experimental|ZOPICLONE|Zopiclone 3.5 mg capsule by mouth daily for 2 weeks
2511514|NCT02820441|Placebo Comparator|PLACEBO|Placebo 3.5 mg capsule by mouth daily for 2 weeks
2511575|NCT02820090||Success with SBT|The patient have a success in SBT.
2511577|NCT02820090||Success with mechanical ventilation|Weaning from mechanical ventilation is successful
2511580|NCT02820090||failure with SBT|The patient have a failure in SBT.
2511583|NCT02820090||failure with mechanical ventilation|Weaning from mechanical ventilation is failed
2511649|NCT02819713|Placebo Comparator|ultrasound gel|
2511652|NCT02819713|Active Comparator|Instillagel|
2511699|NCT02819362||Prospective cohort - MRI|Patients with pathological nipple discharge
2511739|NCT02819037|Experimental|Gas chromatography and stool analysis|gas chromatography and stool analysis for detection of malabsorption
2511772|NCT02818686|Experimental|TD-1473 low dose|10 subjects will be randomized to receive low-dose TD-1473 orally daily for 28 days
2511773|NCT02818686|Experimental|TD-1473 mid dose|10 subjects will be randomized to receive mid-dose TD-1473 orally daily for 28 days
2511777|NCT02818686|Experimental|TD-1473 high dose|10 subjects will be randomized to receive high-dose TD-1473 orally daily for 28 days
2511783|NCT02818686|Placebo Comparator|Placebo|10 subjects will be randomized to receive placebo orally daily for 28 days
3197228|NCT00858936|Placebo Comparator|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
3197229|NCT00858949||Post surgery monitored group|Outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids
3197230|NCT00858975|Experimental|Cryotherapy|The patients who receive cryotherapy for their renal tumors
2510500|NCT02827799|Placebo Comparator|Heart Failure Self-Management Education|This treatment includes participation in 4 one hour biweekly face-face sessions of education on heart failure self-management, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
2510505|NCT02827799|Experimental|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
2510593|NCT02827188|Experimental|Treatment group|Subjects randomly assigned to this arm will train on the Mega Team video game.
2510596|NCT02827188|No Intervention|Control-waitlist group|Subjects randomly assigned to this arm will be the wait-list group. They are allowed to play the video games that they usually play.
3197231|NCT00859001|Experimental|FM+R|4 cycles of FM+R plus Zevalin
3197232|NCT00859066||Control Group|"First year University of Michigan Radiology residents will take call as scheduled without a buddy call experience.~(Enrollment completed for the control group)"
2510756|NCT02826148|Other|Patients with autism disorder|The RAADS-R scale is a self-administered questionnaire completed by the patient himself assisted by a clinician
2510868|NCT02825693|Active Comparator|Femtosecond laser cataract surgery|Cataract surgery with femtosecond laser treatment for corneal incisions, astigmatic keratotomies, capsulotomy and nuclear fragmentation
2510873|NCT02825693|Active Comparator|Conventional phacoemulsification surgery|Conventional phacoemulsification surgery
2510955|NCT02824835||adenoma group|Patients with adenoma. Biopsies are taken before endoscopic resection.
2510960|NCT02824835||cancer group|Patients with colorectal cancer. Biopsies are taken before surgical resection.
3197233|NCT00859066||Experimental Group|2009 class of first year Radiology residents who will be assigned two 5 hour shifts working side by side with a more senior resident (who has experience taking call).
3197234|NCT00859079|Active Comparator|GLP-1|Intravenously administered GLP-1
2511069|NCT02823626||Intervention|Spironolactone and patiromer
2511111|NCT02823340|Experimental|Fractional Microneedle Radiofrequency Treatment|Fractional Microneedle Radiofrequency Treatment
2511157|NCT02823054|No Intervention|Standard group|bi lung ventilation usual practice
2511159|NCT02823054|Experimental|EZ-Blocker group|one lung ventilation 'EZ-Blocker'
2511178|NCT02822742|Other|DE-117 ophthalmic solution and Latanoprost|DE-117 is Experimental. Latanoprost is Active Comparator.
2511243|NCT02822534|Experimental|SP2086 50mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2511245|NCT02822534|Experimental|SP2086 100mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2511247|NCT02822534|Experimental|SP2086 200mg|there were 3 groups in the study: 50mg ,100mg and 200mg ,each group including 8 Type 2 diabetes patients.All subjects were administrated the medicine at Day 1 and Day 5 to Day 9.During the test,collecting the blood samples were needed before and after taking medicine.
2511317|NCT02822066|Experimental|IRE for refractory neoplasms in liver and pancreas|To evaluate the safety and efficacy of irreversible electroporation (IRE) for refractory neoplasms in liver and pancreas, the investigators used preoperative and postoperative US/CEUS/CT/MRI to assess lesions, and laboratory tests including the tumor markers to evaluate the general condition of patients. Intraoperative US/CEUS/CT would be applied to monitor ablation lesions.
2511376|NCT02821611|Experimental|Meditation Group|Participants in the experimental group are practicing a mantra-based meditation twice daily for 20 minutes over the 8 week intervention period to reduce stress and blood pressure and enhance quality of sleep.
2511384|NCT02821611|No Intervention|Control Group|Control group participants will continue their normal activities and not add any form of meditation during the study period.
2511442|NCT02821234|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of at least 3 nights a week, for at least 3 months, affected daytime functioning, objectified low sleep quality (SE <85%) with 10 days actigraphy occurred in the last 2 months
2511443|NCT02821234|Experimental|Control group|Volunteer without sleep problems either self-reported or objectified through actigraphy (SE ≥85%)
2511490|NCT02820714|Experimental|BLI801 Laxative|BLI801 oral laxative
3197235|NCT00859079|Active Comparator|Insulin intravenously|Insulin intravenously according to the Munich registry
3197236|NCT00859092|Experimental|Thickening of feeds|
3197237|NCT00859092|No Intervention|Removal of thickener|
3197238|NCT00859105|Experimental|Imiquimod 5%|Manufactured by Apotex
3197239|NCT00859105|Active Comparator|Adara 5 % Cream US|Manufactured by 3M, US.
2511688|NCT02819570|Experimental|cefuroxime|I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d in addition to P.O roxithromycin 150 mg*2/d for 7 days
2511691|NCT02819570|Active Comparator|ampicillin|I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for 5 days in addition to P.O roxithromycin 150 mg*2/d for 7 days
2511744|NCT02818959|Experimental|Transcatheter Aortic Valve Replacement|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended for use in subjects with severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using a delivery system.
2511784|NCT02818751|Experimental|Escitalopram|Patients being randomized to receive escitalopram, at an initial dose of 5 mg (oral) daily for 2 days. On day 3, escitalopram will be increased to 10 mg daily and continued for 7 days. Then, on day 10, escitalopram will be increased to 15 mg. At the week 4 visit, the dose of escitalopram may be increased to 20 mg, based on the investigator's clinical judgment and if significant anxiety symptoms are still present.
3197240|NCT00859105|Active Comparator|Adara 5% Cream Canada|Manufactured by 3M, Canada
3197241|NCT00859105|Placebo Comparator|Vehicle|Manufactured by Apotex
2510503|NCT02827747|Placebo Comparator|Placebo with Dietary Sources of Vitamins|Persons assigned to placebo, who obtain Vitamins A, C, E and Glutathione from dietary sources alone, and have not been on oral RDA supplementation, in the 1 month leading up the time of enrollment and throughout the study period.
2510508|NCT02827747|Active Comparator|Antioxidants(Vitamins A,C,E) plus GSH, plus Centrum|Persons assigned to the study medication, and are continuing the take an oral RDA supplementation, in the form of Centrum.
2510510|NCT02827747|Active Comparator|Antioxidants (Vitamins A,C, E) plus GSH|Persons assigned to the study medication alone, without oral RDA supplementation in the 1 month leading up the time of enrollment and throughout the study period.
2510513|NCT02827747|Active Comparator|Placebo plus Centrum|Persons assigned to placebo, who have been on oral RDA supplementation, who would continue to do so throughout the study.
2510553|NCT02827305|Experimental|group 1|scaling and Gotukola mouthwash intervention- 1.Scaling 2.Gotukola mouthwash , 10ml twice daily to be rinsed for 60 seconds
2510555|NCT02827305|Active Comparator|group 2|Scaling
2510557|NCT02827305|Active Comparator|group 3|Intervention- Gotukola mouthwash only is advised to be used two times a day, each time 10ml rinsed for 60 seconds (morning and evening ) after the food.
2510617|NCT02827006|Active Comparator|Bone graft|Bone graft from iliac crest as gapfiller
2510621|NCT02827006|Experimental|Calcium phosphate bone cement|CaP bone cement as gapfiller
2510677|NCT02826499|Active Comparator|Fluoroscopy|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy.
2510679|NCT02826499|Experimental|Fluoroscopy and Pediguard|Vertebral instrumentation with pedicular screwing, performed under fluoroscopy, with the Pediguard system.
2510744|NCT02826174|Experimental|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
2510747|NCT02826174|Active Comparator|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
2510748|NCT02826174|Other|Anti-Rejection Agents|Anti-Rejection Agents for both groups
2510750|NCT02826174|Other|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
2510794|NCT02825576|Active Comparator|Sugammadex group|Sugammadex 2mg/kg intravenously at completion of surgery.
2510796|NCT02825576|Active Comparator|Neostigmine/Glycopyrrolate group|Neostigmine 50mcg/kg plus Glycopyrrolate 10mcg/kg intravenously at completion of surgery.
2510843|NCT02825277|Other|pathological group|pregnant women with preeclampsia and/or IUGR pregnancy with a planned or semi-urgent caesarean section or vaginal delivery will be recruited into this study.
2510845|NCT02825277|Other|physiological group|pregnant women with normal pregnancy with a planned caesarean section or vaginal delivery will be recruited into this study
2510893|NCT02825056|Active Comparator|Bupivacaine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%).
2510895|NCT02825056|Experimental|Bupivacaine + Morphine|Intrathecal 8 ml single dose of 0.5% heavy Bupivacaine (Anawin heavy 0.5%) and 250 microgram of preservative free Morphine (VERMOR).
2510924|NCT02824627|Experimental|Oxytocin|Subjects weighing >40kg will receive a total of 24 IU of oxytocin delivered as 2- 6 IU puffs to each nostril once daily. Subjects weighing < 40kg will receive a total of 12 IU of oxytocin delivered as 1- 6 IU puff to each nostril daily. Subjects will receive 14 to 21 days of daily oxytocin administration.
2510934|NCT02824627|Placebo Comparator|Placebo|Subjects weighing>40kg will 2 puffs of placebo to each nostril daily. Subjects weighing <40kg will receive 1 puff per day. Subjects will receive 14-21 days of placebo administration.
2510977|NCT02824211|Experimental|Right Dose System|Use of automated oxygen titration during exertion
2511080|NCT02823418||No neuraxial labor analgesia|For patients who do not accept neuraxial labor analgesia, analgesics will be prescribed by obstetricians according to routine practice.
2511082|NCT02823418||Neuraxial labor analgesia|For patients who accept neuraxial labor analgesia, epidural analgesia or combined spinal-epidural analgesia will be provided when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
2511169|NCT02823223|Experimental|ELVR with Endobronchial Valves|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Endobronchial Valves (Zephyr valve) inserted into the target lobe of the lung with the aim of complete lobar exclusion.
2511170|NCT02823223|No Intervention|Standard of Care|Patients will receive optimal drug therapy and medical management according to clinical practice
2511213|NCT02822625|Experimental|arm 1|Patients, followed in the institut and for whom a new application of QUTENZA® is required, will receive standard care.
2511220|NCT02822625|Active Comparator|arm 2|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a standardized hypnotic message"
2511223|NCT02822625|Placebo Comparator|arm 3|"Patients, followed in the institut and for whom a new application of QUTENZA® is required.~Patients will receive QUTENZA® according to standard procedure with a music therapy"
2511294|NCT02822144|Experimental|general anesthesia|General anesthesia with etomidate, succinylcholine, propofol and remifentanil
2511299|NCT02822144|Experimental|sedation|Sedation with remifentanil and local anesthesia with lidocaine
2511379|NCT02821559|Experimental|triweekly then biweekly|The arm A consisted of 2 cycles of triweekly TOMOX (standard dose 3mg/m2 of Raltitrexed in 15-minutes infusion, and 130mg/m2 of oxaliplatin in 2h infusion, every 3 weeks), followed by 2 cycles of biweekly TOMOX (2mg/m2 of Raltitrexed in 15-minutes infusion, and 85mg/m2 of oxaliplatin in 2h infusion, every 2 weeks).
2511386|NCT02821559|Experimental|biweekly then triweekly|The arm B consisted of the reserve sequence starting with 2 cycles of biweekly TOMOX followed by 2 cycles of triweekly TOMOX regimen.
2511425|NCT02821078|Experimental|Participants|"In addition to the standard clinical MR protocol, 2 added sequences:~4D flow imaging sequence~standard 2D-PhaseContrast at portal trunk level as reference"
2511475|NCT02820857|Experimental|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
2511477|NCT02820857|Active Comparator|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
2511607|NCT02819791|Active Comparator|Control group|
2510504|NCT02827760|Active Comparator|Prebiotic Synergy1|Effective prebiotic
2510540|NCT02827409|Active Comparator|Short Delay Cord Clamping|Subject will have umbilical cord clamped and cut by 1 minute of life.
2510545|NCT02827409|Active Comparator|Extended Delay Cord Clamping|Subject will have umbilical cord clamped and cut after at least 5 minutes of delayed cord clamping. Duration of cord clamping after 5 minutes will depend on if the subject is breathing and/or if the cord has stopped pulsating
2510582|NCT02827045||Depressive phase|Vestibular test
2510584|NCT02827045||Maniac phase|Vestibular test
2510586|NCT02827045||Euthimic phase|Vestibular test
2510588|NCT02827045||Healthy subject|Vestibular test
2510712|NCT02826239||pulmonary healthy controls|patients without known pulmonary disease
2510715|NCT02826239||pulmonary disease|patients with known or suspected pulmonary disease
2510771|NCT02825823|Experimental|Ketone Salts|Acute dose of beta-hydroxybutyrate potassium/sodium salt (0.2g beta-hydroxybutyrate/kg, 0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
2510773|NCT02825823|Placebo Comparator|Placebo|Acute dose of taste-matched placebo (0.01g Potassium/kg, 0.01g Sodium/kg with 1 g Steviol Glycoside and 30 ml of lemon juice per dose)
2510833|NCT02825407|Experimental|main study|
3197242|NCT00859118|Experimental|Schedule A Cohort 1|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
2510920|NCT02824874|Experimental|Group 1(Treatment A/Treatment B)|"Period 1: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Period 2: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
2510928|NCT02824874|Experimental|Group 2(Treatment B/Treatment A)|"Period 1: Treatment B(Duvie Tab. 0.5mg + Januvia Tab. 100mg)*1T/day for 5 dyas, QD, PO~Period 2: Treatment A(Duvie Tab. 0.5mg)*1T/day for 5 days, QD, PO~Each treatment period was separated by a washout period of at least 10 dyas."
2511081|NCT02823691|Experimental|Lanreotide and Metformin|"Dose and Treatment Regimen:~LANREOTIDE ATG 120 mg/28 days (equivalent to 1 cycle), deep subcutaneous injection (SC) in combination with METFORMIN 2550 mg daily (maximum dose), oral administration (OS).~Metformin starting dose 850 mg/day to be increased up to 1700 mg/day at day 14, 2550 mg/day at day 28, (maximum dose), if well tolerated."
2511205|NCT02822963||A|Non anticoagulant and/or antiplatelet users.
2511207|NCT02822963||B|Anticoagulant and/or antiplatelet users that hold their drugs during perioperative periods.
2511209|NCT02822963||C|Anticoagulant and/or antiplatelet users that doesn't hold their drugs during perioperative periods.
2511252|NCT02822339|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511305|NCT02822040||Experimental group|All patients who have initial and final records qualify in the experimental group.
2511335|NCT02821663|Experimental|Vocal intervention|Vocal intervention
2511398|NCT02821390|Active Comparator|Nepafenac 0.1% Eye Drops|One drop of Nepafenac 0.1% Eye Drops will be instilled to the eye's cul de sac prior to the intravitreal injection.
2511401|NCT02821390|Placebo Comparator|Artificial Tears|One drop of Artificial Tears will be instilled to the eye's cul de sac prior to the intravitreal injection.
2511505|NCT02820480||Patients/health professionals|Stroke AND cerebral palsy PATIENTS: greater than 18 years of age, who are more than 3 months post stroke, as well as health professionals who have considerable experience in stroke rehabilitation will be asked to evaluate the design of the Rehab in a Crate system. The aim is to survey stroke survivors and healthcare professionals on the design, ease of use, utility, and various features of, both existing and those yet-to-be-developed.
2511612|NCT02819856|Placebo Comparator|SPI-1000 Capsule 0mg Ebselen Placebo|0mg Ebselen SPI-1000 bid po x 21d
2511617|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x1|200mg SPI-1005 bid po x 21d Low Dose Arm
2511619|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x2|400mg SPI-1005 bid po x 21d Mid Dose Arm
2511621|NCT02819856|Experimental|SPI-1005 Ebselen 200mg Capsule x3|600mg SPI-1005 bid po x 21d High Dose Arm
2511678|NCT02819349|Experimental|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. The intervention will include an online interface for clinicians and an automated text messaging program for patients. Firstly, patients and providers will meet in an intake session, to identify the patient's personal early warning signs from a pre-identified list. Using the online interface, providers will enter additional warning signs or personalize the wording of the messages as requested by the patient. The patient also will determine the threshold at which the provider will be alerted about a possible relapse and whether additional contact people should be alerted.
2511679|NCT02819349|No Intervention|Treatment-As-Usual Control|The control group will be a treatment as usual comparison group. For the majority of individuals with schizophrenia/SAD in care at JHCPP, this involves meeting with their therapist every 2 to 4 weeks and meeting with their psychiatrist at least once every 90 days or more frequently as clinically indicated. All routine appointments are scheduled, but individuals can walk in or call if they do not feel well between sessions.
2511740|NCT02819180||Healthy adults group|Healthy men and women between 18 and 59 years of age.
2511743|NCT02819180||Elderly group|Elderly over 60 years old.
2511760|NCT02818712||Patients with IPF|
2511801|NCT02818530|Experimental|IOP by tomoneter and ultrasound|Intraocular pressure will be measured by electronic tomometer (tonopen) at different point of time after induction of anaesthesia in patients undergoing robotic assisted surgery under steep Trendelenberg position. Anterior chamber depth will be measured by ultrasound at the same time intervals.
2511831|NCT02818309|Experimental|Lesogaberan|Lesogaberan
2510515|NCT02827734||interstitial lung disease|patients with known or suspected ILD such as idiopathic pulmonary fibrosis, non-specific interstitial pneumonia, sarcoidosis, granulomatosis with polyangiitis
2510517|NCT02827734||pulmonary healthy controls|patients without known or suspected pulmonary disease
2510569|NCT02827058|Experimental|G25 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 25 gauge pencil point needle
2510572|NCT02827058|Active Comparator|G27 pencil point needle|healthy pregnant women who at (vaginal or cesarean section) delivery get spinal anesthesia administered with use of a 27 gauge pencil point needle
2510606|NCT02826902|Active Comparator|TIVA group|
2510607|NCT02826902|Active Comparator|Inhalation anesthesia group|
2510616|NCT02826590|Experimental|Neck passive mobilizations|Neck passive mobilizations
2510619|NCT02826590|Placebo Comparator|Manual contact|Manual contact
2510662|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®)|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 three times a week"
2510665|NCT02826486|Experimental|BL-8040 plus pembrolizumab (Keytruda®) plus Onivyde chemo|"BL-8040 monotherapy 1.25 mg/kg subcutaneous(SC) injections daily on days 1-5 of week 1 of treatment.~Combination therapy period begins following monotherapy treatment and consists of:~IV Onivyde® 70 mg/m2 over 90 minutes followed by IV leucovorin (LV) 400 mg/m2 over 30 minutes or according to local standard, followed by IV fluorouracil (5-FU) 2400 mg/m2 over 46 hours, every 2 weeks.~Pembrolizumab 200mg once every three weeks.~Beginning on Day 10, BL-8040 twice a week and following the chemotherapy dosing."
2510736|NCT02826018|Active Comparator|ALN-HBV|
2510739|NCT02826018|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
2510802|NCT02825654||Post-9/11 Gulf War Era Veterans|Military personnel who deployed to Central Asia, Southwest Asia, and Africa during the Post-9/11 Gulf War Era
2510862|NCT02825238|No Intervention|Control|Control group, did not undergo intervention.
2510864|NCT02825238|Experimental|Exercise group|Experimental, exercise group, underwent intervention
2510945|NCT02824848|Active Comparator|Passive Stretching|Passive Stretching intervention components include static passive stretching, active assistive range of motion, assisted stretching of the involved cervical musculature, and associated strengthening activities aimed to elicit head righting in developmentally appropriate positions and during developmentally appropriate movement transitions. Intervention is progressed by increasing head tilt angles, duration of head righting, and frequency and number of repetitions.
2510951|NCT02824848|Active Comparator|Perception-Action Approach|P-A Approach intervention components include environmental set-up for activity and participation in play, and manual guidance in the form of light pressure applied to the infant's body in developmentally appropriate positions. Both components are designed to promote spontaneous exploration of the environment by the infant by suggesting small, incremental changes in his/her perceptual-motor orientation and contact with the support surface. Intervention is progressed by gradually removing environmental supports provided to the infant's body parts, and by removing the therapist's hands from the infant's body to allow for spontaneous exploration of a newly found contact with the support surface or new body configuration.
2510980|NCT02824159||Patient with haematologic malignancies|"Interventions to be administrated are :~Clinical examinations~Biological statement~Blood samples for pharmacokinetics exploration~Imagery with positron emission tomography scan or resonance magnetic imagery~Saliva samples for genetics analyses~Blood samples for treatment mutation resistance search~Quality of life scale questionary~Detection of adverse events"
2511135|NCT02823288|Experimental|Sonke CHANGE intervention condition|This arm (n=9 clusters) will receive the Sonke CHANGE intervention for 12 months.
2511138|NCT02823288|No Intervention|Control condition|In this arm (n=9 clusters), no activities will take place during the trial period outside of data collection.
2511215|NCT02822430||Patients|"Patients with psychiatric disorders will be assessed using five evaluation of pain scales :~Visual analogic scale pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Global Clinical Impression (GCI) for severity and improvement~Mini International Neuropsychiatric Interview (MINI)"
2511268|NCT02822248|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511288|NCT02821897|Experimental|Target-controlled Intravenous Anaesthesia|Patients have a target controlled intravenous anaesthesia to implant the spinal cord stimulation lead with active cooperation during the surgery.
2511296|NCT02821897|Active Comparator|Total anesthesia|Patients have a total anaesthesia to implant the spinal cord stimulation lead without active cooperation during the surgery.
2511353|NCT02821702|Experimental|Post surgery and embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2511360|NCT02821702|Active Comparator|Control group|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2511367|NCT02821702|Active Comparator|Post surgery with accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH) Vaginal ultrasound to estimate antral follicle count ( AFC)
2511373|NCT02821702|Active Comparator|Post surgery without accreta without embolization|Blood sample for hormonal profile: estrogen , progesterone, anti mullarian hormone ( AMH)
2510530|NCT02827266|Experimental|Epoetin beta|Participants will receive epoetin beta over an 8-week correction phase and a 4-week extension or continuation phase, for a total exposure of up to 12 weeks.
2510669|NCT02826629|Other|Schizophrenia|40 patients with diagnosis of schizophrenia (25 medicated - 15 non-medicated)
2510673|NCT02826629|Other|Healthy sibling|25 healthy siblings
2510676|NCT02826629|Other|Ultra high risk for developing Schizophrenia|15 patients with ultra high risk for developing Schizophrenia
2510678|NCT02826629|Other|Controls|-25 age and gender-matched healthy controls
2510751|NCT02826031|Experimental|Sodium Hyaluronate Injection + DICL-SR|"Each syringe (2.5mL) contains 25mg of sodium hyaluronate, and one Artz® will be administered via intra-articular injection into the target knee at the baseline and Weeks 1, 2, 3 and 4 respectively for the combination group.~From the run-in period to the end of study, both groups will receive DICL-SR 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID） daily"
2510753|NCT02826031|Active Comparator|DICL-SR|From the run-in period to the end of study, both groups will receive Diclofenac Sodium Sustained-release Tablets(DICL-SR) 75mg, which is administered on demand for treatment of knee pain. If the knee pain is relieved or has disappeared, DICL-SR may be withdrawn. However, if the pain occurs again and requires treatment, the drug may be resumed. If a dose of 75mg daily fails to control the knee pain, it may be increased to the maximum dose 150mg daily upon the approval of the investigator, that is, 75mg bis in die（BID daily）. A subject is allowed to withdraw from this study prematurely if unable to tolerate the adverse effects.
2510822|NCT02825615|Active Comparator|Conventional method (CM)|Radial artery cannulation has been done using the conventional method. Cannulation failure with this technique were tried with USG technique secondarily.
2510825|NCT02825615|Experimental|Ultrasound guided method (USG)|Radial artery cannulation is done with ultrasound guidance for this group of patients. Cannulation failure with this technique were tried with Conventional technique secondarily.
3197243|NCT00859118|Experimental|Schedule A: Cohort 2|"Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.~Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans."
2510896|NCT02824926|Experimental|Dapaconazole|(cream; 2%; topical)
2510899|NCT02824926|Active Comparator|Ketoconazole|(cream; 2%; topical)
2510919|NCT02824653|Experimental|Mesenchymal Stem Cells|The experimental arm is comprised of GVHD patients receiving allogenic bone marrow mesenchymal stem cells
2511005|NCT02824367|Other|Parkinsonian|Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
2511007|NCT02824367|Other|Dystonic|Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
2511032|NCT02823834||PROFEMUR® Gladiator Plasma Femoral Stems|Single study group either previously implanted with the following combination of components: PROFEMUR® Gladiator Plasma Femoral Stems, PROCOTYL® L Beaded Acetabular Shells, Polyethylene or Ceramic Liners, and Metal or Ceramic Femoral Heads.
2511092|NCT02823548|Experimental|Droglican|Patients take one sacchet of Droglican (Chondroitin Sulfate 1,500mg + Glucosamine Hydrochloride 1,200mg) Once a day during 6 months.
2511097|NCT02823548|Placebo Comparator|Placebo|Patients take one sacchet of Placebo once a day during 6 months.
2511134|NCT02823171|Experimental|Sequence I|Sequence I: treatment A/B
2511137|NCT02823171|Experimental|Sequence II|Sequence II: treatment B/A
2511201|NCT02822807|Other|Q fever without valvular disease|Q fever without valvular disease
2511202|NCT02822807|Other|Q fever with valvular disease|Q fever with valvular disease
2511203|NCT02822807|Other|Q fever infective endocarditis|Q fever infective endocarditis
2511204|NCT02822807|Other|Other Coxiella burnetii infections (including pregnant women)|Other Coxiella burnetii infections (including pregnant women)
3197244|NCT00859144|Experimental|BART|Participants will complete the Becoming a Responsible Teen (BART) program.
2511313|NCT02821871|Active Comparator|SP2086|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
2511318|NCT02821871|Other|high fat diet|All subjects were ransomed to A and B sequence.In A sequence,subjects take SP2086 100mg once in fasting the first day,and the B sequence subjects need to take SP2086 100mg after the high fat diet.In Day 8，the medicine strategy of two sequence subjects were alternately.
2511348|NCT02821598|Experimental|Upper limb pattern|Upper Limb pattern with flexion - abduction - external rotation
2511350|NCT02821598|Experimental|Lower limb pattern 1|Lower Limb pattern with flexion - adduction - external rotation with knee flexion;
2511352|NCT02821598|Experimental|Lower limb pattern 2|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion;
2511364|NCT02821598|Experimental|Lifting to the right|
2511369|NCT02821598|Active Comparator|Sit to Stand|Sit to Stand task
2511429|NCT02821091|No Intervention|Control young adults|Healthy adults, age between 20 to 59 yeas old
2511432|NCT02821091|No Intervention|Control old adults|Healthy adults, age between 60 to 80 yeas old
2511434|NCT02821091|Experimental|Exercise old adults|Healthy adults, age between 60 to 80 yeas old received interactive dynamic balance training
2511503|NCT02820805|Experimental|Meal skipping|No meal given
2511504|NCT02820805|Experimental|Mashed potatoes|Carbohydrate Test Meal (50 g of available carbohydrates)
2511506|NCT02820805|Experimental|French fries|Carbohydrate Test Meal (50 g of available carbohydrates)
2511512|NCT02820805|Experimental|Hash browns|Carbohydrate Test Meal (50 g of available carbohydrates)
2511515|NCT02820805|Experimental|Rice|Carbohydrate Test Meal (50 g of available carbohydrates)
2511518|NCT02820805|Experimental|Beans|Carbohydrate Test Meal (50 g of available carbohydrates)
2510546|NCT02827474||Patient Participants|Patient participants will participate in two patient interviews.
2510548|NCT02827474||Physician Participants|Provider participants will participate in one provider interview.
2510594|NCT02827032|Experimental|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
3197245|NCT00859144|Experimental|Reducing the Risk|Participants will complete the Reducing the Risk program.
2510697|NCT02826278||Healthy female newborns|Healthy female newborns 24 to 41 weeks of pregnancy without sexual development disturbances
3197246|NCT00859144|Active Comparator|Be Proud Be Responsible|Participants will complete the Be Proud! Be Responsible! program.
2510798|NCT02825563|Experimental|Anlotinib(In the fasting state)|In the fasting state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
2510801|NCT02825563|Experimental|Anlotinib(In the high fat diet state)|In the high fat diet state, Anlotinib po only once and after 14 days it could be continued by Qd po.until disease progression or intolerable toxicity or patients withdrawal of consent
2510850|NCT02825290|Experimental|Study group|hCG (Choriogonadotropin alfa; Ovitrelle 250 mcg) on day of embryo transfer & GnRH-agonist (Triptorelin acetate; Decapeptyl 0.1 mg) after 4 days In addition to the usual progesterone luteal support.
2510851|NCT02825290|No Intervention|Control group|The usual progesterone only luteal phase support.
2510890|NCT02824939|Experimental|Transversus Abdominis Plane group|
2510894|NCT02824939|Experimental|Quadratus Lumborum group|
2510897|NCT02824939|No Intervention|Control group|
2510976|NCT02824289|Experimental|Sun Safe Workplaces Program|Program promoting the adoption of occupational sun protection policies by the local government organization comprised of personal visits with senior managers and in-person training of outdoor workers by research staff over two years.
2510981|NCT02824289|Active Comparator|Attention Control|Program promoting occupational sun protection practices by employees in local government organizations through two mailings containing educational materials and presentations at state professional meetings by project staff.
2511048|NCT02823899|Experimental|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
2511049|NCT02823899|Active Comparator|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
3197247|NCT00859157||Group 1|Patients undergo standard mastectomy.
3197248|NCT00859157||Group 2|Patients undergo tumescent mastectomy.
2511162|NCT02823015||Study population|The study population consists of adult surgery patients, scheduled for breast cancer surgery at St-Luc University Hospital.
2511241|NCT02822547|Experimental|Peginterferon alfa-2a|
2511271|NCT02822118|Experimental|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe for 8 weeks.
2511273|NCT02822118|Placebo Comparator|Placebo|Patients in this group were administered the placebo for 8 weeks.
3197249|NCT00859170|Experimental|Accordion use|Use of an Accordion device during the lithotripsy.
3197250|NCT00859170|No Intervention|Control Group|Patients who will not have an Accordion device used during lithotripsy.
3197251|NCT00859183|Active Comparator|1|cumulative loading dose of 8 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
2511460|NCT02820909|Experimental|Ultrasound guidance|46 patients in the experimental ultrasound group
2511461|NCT02820909|Active Comparator|Anatomical guidance|46 patients in the anatomical group
2511559|NCT02820077|Experimental|Hemospray|Patients treated with hemostatic powder
2511560|NCT02820077|No Intervention|Clinical support|Patients treated with optimal clinical management, as it is been advised by the latest guidelines
3197252|NCT00859183|Active Comparator|2|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
2511697|NCT02819245|Other|Age before and after 18 years old|Surgical treatment before and after skeletal maturity
2511725|NCT02819128|Other|Homeless people|Populations of homeless households in Marseille.
2511797|NCT02818855|Experimental|Collagen Matrix plus coronally advanced flap (CAF)|A new collagen matrix (Mucograft) associated to coronally advanced flap
2511803|NCT02818855|Active Comparator|Subepithelial connective tissue graft plus CAF|Subepithelial connective tissue graft associated to coronally advanced flap
3197253|NCT00859183|Placebo Comparator|3|oral placebo
3197254|NCT00859196|Experimental|Arm 1|
3197255|NCT00859196|Placebo Comparator|Arm 2|
3197256|NCT00859235|Active Comparator|1|
3197257|NCT00859235|Placebo Comparator|2. Plain water|
3197258|NCT00859261|Experimental|Breast imaging using Ultrasound and Photoacoustic|Evaluating 3D ultrasound for breast abnormalities/masses/cysts. This includes ultrasound imaging and possibly photoacoustic imaging.
3197259|NCT00859274|Experimental|Budesonide|All patients receive this treatment to induce a change in asthma control
3197260|NCT00859300||1|500 patients with ventricular fibrillation at the acute phase of myocardial infarct
3197261|NCT00859300||2|500 patients without ventricular fibrillation at the acute phase of myocardial infarct.
3197262|NCT00859352|Experimental|1|AZD1981 100mg and Midazolam
3197263|NCT00859352|Experimental|2|AZD1981 500mg and Midazolam
3197264|NCT00859365|Experimental|Acupuncture|Real Acupuncture
3197265|NCT00859365|Placebo Comparator|2 Placebo acupuncture|
3197266|NCT00859365|No Intervention|3 No treatment|No treatment performed
3197267|NCT00859378|Active Comparator|1 - cemented|Patients are treated with a cemented semiendoprosthesis
2510550|NCT02827396|Experimental|Psycho-social intervention|Experimental group: The intervention group will get Psycho social Training Intervention which will be developed during the third phase of the study.
2510552|NCT02827396|No Intervention|TAU intervention|Wait-list (controlled) group: The waiting list (control) group will continue getting the general health education (TAU) that is done at disability clinics in the existing sites.
2510649|NCT02826759||serum sphingolipid metabolites in healthy subjects|Healthy subjects are classified according to BMI into three subgroups: healthy normal weight subjects, healthy overweight subjects and healthy subjects with obesity. Age and sex are matched among three subgroups. serum sphingolipid metabolites including sphingosine-1-phosphate will be compared.
2510652|NCT02826759||serum sphingolipid metabolites in diabetic subjects|Diagnosed diabetic patients are divided into three subgroups: diabetic patients with normal weight, overweight and obesity. age and sex are matched.
2510654|NCT02826759||serum sphingolipid metabolites in the progression of diabetes|serum sphingolipid metabolites are compared among three age-, sex- and body mass index-matched subgroups: healthy subjects, subjects with pre-diabetes, subjects with diabetes
2510656|NCT02826759||serum sphingolipid metabolites and HbA1c|diabetic subjects are divided by HbA1c level. the cut-offs are 7% and 9%. serum sphingolipid metabolites will be tested among diabetic patients with HbA1c <7%, 7%-9% and >9%
2510658|NCT02826759||serum sphingolipid metabolites in insulin-resistant subjects|comparison of serum sphingolipid metabolites in newly diagnosed insulin-resistant subjects and age-, sex- and BMI-matched healthy controls.
2510691|NCT02826265||pulmonary disease|patients with known or suspected pulmonary disease
2510719|NCT02826057|Active Comparator|24 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 24 hours of targeted temperature management (33 degree Celsius)
2510724|NCT02826057|Experimental|48 hour of targeted temperature management|Patients resuscitated after cardiac arrest and treated with 48 hours of targeted temperature management (33 degree Celsius)
2510799|NCT02825797|Experimental|Group 1A|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion of 10-1074), each dosed at 10 mg/kg OR placebo (sterile saline), on day 0.
2510800|NCT02825797|Experimental|Group 1B|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be randomized in a 2:1 ratio to receive one intravenous infusion of 3BNC117 and one intravenous infusion 10-1074, each dosed at 30 mg/kg, OR placebo (sterile saline), on day 0.
2510803|NCT02825797|Experimental|Group 1C|HIV-infected individuals, off ART will be administered one infusion of 3BNC117 and one infusion 10-1074, each dosed at 30 mg/kg, on day 0.
2510805|NCT02825797|Experimental|Group 2|HIV-infected individuals, on ART with HIV-1 RNA < 20 copies/ml will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg, on days 0, 21 and 42. Participants enrolled in Group 2 will undergo an analytical treatment interruption and they will discontinue their antiretroviral (ART) regimen on day 2.
2510807|NCT02825797|Experimental|Group 3|HIV-infected individuals, off ART who will be administered three infusions of 3BNC117 and three infusions of 10-1074, each dosed at 30 mg/kg on days 0, 14 and 28.
2510875|NCT02825121|Experimental|Monitoring Neuromuscular Blockade|Monitoring Neuromuscular Blockade the Flexor Hallucis and adductor of the thumb.
2510923|NCT02824796|Experimental|Schema Parent Behavioral Training|An enhanced protocol which combines a Schema Focused Therapy (SFT) and Behavioral Parent Training (PBT)
2510933|NCT02824796|Active Comparator|Parent Behavioral Training|Usually medication & The usual PBT treatment
3197268|NCT00859378|Active Comparator|2 - non-cemented|Patients are treated with a non-cemented semiendoprosthesis
2511146|NCT02823366|Experimental|Fenofibrate + UDCA|Fenofibrate in combination with ursodeoxycholic acid
2511148|NCT02823366|Active Comparator|Monotherapy|UDCA alone
2511173|NCT02822716|Other|IRE treatment|Irreversible electroporation (IRE) is a form of non-thermal local ablation for solid tumors, it induces apoptosis of tumor cells by creating irreversible damage in the cell membrane using electric current. IRE treatment is given for a therapeutic purpose as a non-surgical alternative to those patients with an inoperable condition.
2511251|NCT02822586|Experimental|Cohort A (Stage IB and Stage IIA to IIIB [if N0-1])|"(Eligible patients with Stage IB, IIA, IIB, and IIIA [if N0-1])~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week."
2511255|NCT02822586|Experimental|Cohort B(Stage IIA to IIIB; IVA;transformed CTCL)|"(Eligible patients with Stage IIA, IIB, IIIA [if N2-3]; IIIB; Stage IVA; and transformed CTCL)~Brentuximab Vedotin 1.8 mg/kg IV every 3 weeks for 3 doses beginning 3 weeks prior to initiation of TSEB.~TSEB 12 Gy in 6 fractions at 2 Gy/fraction treated twice/week.~Continuation of brentuximab every 3 weeks until disease progression or unacceptable toxicity or for up to 2 years as a study participant, (whichever occurs first)."
3197269|NCT00859391||1 - Active|This group received gluten pre-treated with ALV003
3197270|NCT00859391||2 - Placebo|This group received Gluten pre-treated with placebo.
3197271|NCT00859404|Experimental|1. oglemilast|
2511451|NCT02821052||insulin degludec/insulin aspart|
2511479|NCT02820675|Other|intervention|all hospitals participating in the icosmos trial will be supported in implenatation of the two main interventions.
2511540|NCT02820363|Experimental|Test|"Tibial fracture fixation with IM Nail. Apply CERAMENT™|G applied to bony void(s)."
2511541|NCT02820363|Active Comparator|Control|Tibial fracture fixation with IM nail.
2511626|NCT02819661|Active Comparator|women BMI<30 POD 1|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
2511628|NCT02819661|Active Comparator|women BMI≥30 POD 1|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 1 after elective cesarean section.
2549561|NCT02568085|No Intervention|2|Thyroidectomy
3197272|NCT00859404|Experimental|2. oglemilast|
3197273|NCT00859404|Experimental|3. oglemilast|
3197274|NCT00859404|Placebo Comparator|4. placebo|
3197275|NCT00859417|Active Comparator|1|Traditional surgical method without prosthesis
2510562|NCT02827227||Primary HIV- Infected patients|Primary HIV- Infected patients with a minimum of 2 years of effective cART.
2510577|NCT02826993|Experimental|CCE in incomplete Colonoscopies|Patients in which colonoscopy is not possible are invited for CT colonography and those patients are examined by Camera Capsule Endoscopy the day before the CT colonography and the two different examinations are compared.
2510609|NCT02826889|Experimental|Fluid loading group|
2510634|NCT02826577|Active Comparator|Pregnenolone 175mg|- Single dose of 175mg
2510639|NCT02826577|Active Comparator|Pregnenolone 400mg|- Single dose of 400mg
2510641|NCT02826577|Placebo Comparator|Placebo|- Single dose of placebo
2510643|NCT02826577|No Intervention|Matched healthy controls|- No intervention
2510695|NCT02826369|Experimental|3.0 Tesla in Magnetic Resonance Imaging|
2510707|NCT02826096|Experimental|biofeedback group|biofeedback therapy
2510710|NCT02826096|No Intervention|medication group|only medication treament
2510735|NCT02825888||Non-obese|Body Mass index less than 30 kg/m2
2510740|NCT02825888||Obese|Body Mass index more than 30 kg/m2
2510762|NCT02825758|Experimental|ZestiVits|"Supplement for use in ketogenic and restricted therapeutic diets, from the age of 11.~Daily use for 7 days. Daily intake level for each subject will be determined and prescribed by a dietitian."
2510831|NCT02825524|Experimental|Endobiliary radiofrequency|
2510847|NCT02825173|Experimental|Seal-G|A surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.
2510918|NCT02824588|Experimental|Intervention|Working Memory Training
2510929|NCT02824588|Active Comparator|Control|Internet use
2510994|NCT02824354|Placebo Comparator|placebo|"The placebo will have the same composition as the active treatment (without the drug substance) and an identical appearance. White, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side."
2511001|NCT02824354|Experimental|Nalmefene|"Drug : 'Nalmefene (Selincro®) 18 mg tablet is a white, oval, biconvex, 6.0 x 8.75 mm film-coated tablet engraved with S on one side. It contains 18.06 mg nalmefene (in the form of hydrochloride dihydrate).~Nalmefene must be taken as-needed: on each day the patient perceives a risk of drinking alcohol, one tablet should be taken, preferably 1-2 hours prior to the anticipated time of drinking. If the patient has started drinking alcohol without taking nalmefene, the patient should take one tablet as soon as possible.~The maximum dose of nalmefene is one tablet per day. Nalmefene can be taken with or without food."
2511041|NCT02823782|Experimental|Laminar HP|Structural and functional MRI markers
2511047|NCT02823782|Experimental|Complex HP|Structural and functional MRI markers
2511050|NCT02823782|Experimental|ADHD|Structural and functional MRI markers
2511051|NCT02823782|Other|Control|Structural and functional MRI markers
2511194|NCT02822833|Experimental|Sentinel lymph node mapping|Sentinel lymph node mapping with indocyanine green injection to cervix in endometrial cancer patients operated laparoscopically
2511221|NCT02822391||Stroke-group|Screened and recruited from the Division of Neurorehabilitation, Department of Clinical Neurosciences, University Hospital and University of Geneva, Geneva, Switzerland by a senior consultant neurologist (BL). Patients were included if they were hospitalized for stroke rehabilitation, were able to undergo psychophysical testing and presented with a facial impairment according to the House-Brackmann criteria ≥2 15. They were excluded if they presented with acute pain in the oro-facial sphere (nominal question) or an additional neuro-muscular disease.
2511224|NCT02822391||Control-group|Similar to stroke group in regard to age, gender and dental state. no stroke
3197276|NCT00859417|Experimental|2|Surgical method with Perigee prosthesis
3197277|NCT00859599|Active Comparator|1|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
2511449|NCT02821013|Active Comparator|Arm 1: Intermittent PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
2511452|NCT02821013|Active Comparator|Arm 2: Continuous PD-1 Inhibitor therapy|Any PD-1 inhibitor that is commercially available, government approved and publicly funded. Dose as recommended by the manufacturer.
2511508|NCT02820467|Experimental|patients with suspicion of CLI|patients presenting with peripheral artery disease and suspicion of critical limb ischemia as assessed by TASK II consensus 30 patients will be enrolled and will benefit of measures of TcPO2, too systolic blood pressure and skin perfusion pressure and in the same time angiography with fluorescence (Indocyanine grey 0.05 mg/kg by intravenous injection
2511549|NCT02820155|Placebo Comparator|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511553|NCT02820155|Experimental|RGN1016_50mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511555|NCT02820155|Experimental|RGN1016_100mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511556|NCT02820155|Experimental|RGN1016_200mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511557|NCT02820155|Experimental|RGN1016_400mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511558|NCT02820155|Experimental|RGN1016_800mg|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
2511608|NCT02819752|Experimental|HPV-ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
2511613|NCT02819752|Experimental|HPV+ve stage IVA/IVB SCCHN|Pembrolizumab and Chemoradiotherapy
2511722|NCT02818972|Experimental|RelayPro|Endovascular treatment with the investigational device.
2511791|NCT02818751|Placebo Comparator|Placebo|Patients will receive placebo (sugar pill) at an initial dose of 5 mg daily for 2 days. On day 3, placebo will be increased to 10 mg daily and continued for 7 days to match the experimental group.
2510565|NCT02827929|Experimental|educated group|Subjects who is diagnosed as COPD or asthma by their physicians were recruited from 43 primary clinic and had been visiting each primary clinic over one year or more will be provided education of 3 times for one months about disease, inhaler use technics and action plans about exacerbation
2510604|NCT02826954||COPD patients|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
2510605|NCT02826954||Healthy subjects|"Self administered questionnaires regarding sinonasal and lung symptoms, quality of life as well as symptoms of depression and anxiety.~Lower airway assessment using Spirometry with reversibility Upper airway assessment using Acoustic Rhinometry, Rhinomanometry and Peak nasal Inspiratory Flow Nasal biopsy using a nasal brush Nasal endoscopy Allergic prick-test"
2510627|NCT02826616|Experimental|Trimetazidine group|Trimetazidine 60 mg 30 min before PCI and 20 mg for 12 months after surgery
2510628|NCT02826616|No Intervention|The control group|placebo 60 mg 30 min before PCI and 20 mg for 12 months after surgery
2510664|NCT02826408|Active Comparator|Active group|Will receive Rabeprazole sodium (Proton pump inhibitor 20 mg once daily)
2510666|NCT02826408|Placebo Comparator|Placebo group|Will receive Folic acid 5 mg once daily
2510721|NCT02826200|Experimental|Group 1 (SOC+OAT)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving single antiplatelet therapy plus oral anticoagulant therapy.
2510726|NCT02826200|Active Comparator|Group 2 (SOC)|Patients with reduced leaflet motion or with prosthetic heart valve thrombosis receiving standard of care therapy.
2510767|NCT02825745|Other|Betashot|"Children:will take Betashot as a proportion of their daily energy requirements calculated from the dietary information obtained during Visit A for up to 12 weeks.~Adults:will introduce Betashot and increase the amount taken in ml incrementally for up to 12 weeks."
2510789|NCT02825485|Other|Control Group|The control patients will be the patients with antenatal hydronephrosis who get a routine VCUG to evaluate for vesicoureteral reflux, as part of routine care.
2510791|NCT02825485|No Intervention|Observation Group|Receives no intervention
2510854|NCT02825342|No Intervention|GERD with PPI's therapy|Patients will abnormal distal acid esophageal exposure will receive PPI twice daily for 8 weeks .
2510856|NCT02825342|Active Comparator|PPI's and SSRI's therapy|Patients with positive symptom index for chest pain will receive citalopram 20 mg once daily and PPI once daily for 8 weeks.
2510857|NCT02825342|Active Comparator|SSRI's therapy|Patients with a negative symptom index for chest pain will receive citalopram 20mg once daily for 8 weeks
2510901|NCT02824887||Exposed group|Long term curative effect of electroacupuncture treatment of lumbar intervertebral disc herniation in exposure group
2510902|NCT02824887||control group|Long term efficacy of conventional treatment of lumbar disc herniation in the control group
2510964|NCT02824484|Experimental|Guided Written Disclosure Protocol|GWDP consists of three 20-minutes writing sessions. Participants write every two weeks at home following the specific instructions for each session.
2510965|NCT02824484|Placebo Comparator|Control|Control condition consists of three 20-minutes writing sessions. Participants write every two weeks at home following the instructions. Their task is constructed to be emotionally neutral.
2511039|NCT02824003|Experimental|ISIS-GCGRRx|ISIS-GCGRRx once weekly dosing for 13 weeks
2511043|NCT02824003|Placebo Comparator|Placebo|once weekly dosing for 13 weeks
3197278|NCT00859599|Placebo Comparator|2|"At the study start, the patient will be given a subject number according to a fixed randomisation list. The investigator/study nurse will be instructed to log in at the Biolight® website to get the patient-number and treatment code, with the information which treatment model (i.e. marked A & B, E & F, X & Y) the randomised patient shall receive.~Up to 44 monochromatic Phototherapy treatment sessions (Biolight® or placebo) will be given, additional to standard care treatment. The treatment session schedule compromise of three times weekly during the first four weeks and twice weekly during the following weeks or until the ulcer is completely healed."
3197279|NCT00859625|Experimental|1|Nurse participation during colonoscope withdrawal
2511171|NCT02822976||Critically Ill Patient HbA1c<6.5|Patients admitted to an intensive care unit with a HbA1c <6.5.
2511172|NCT02822976||Critically Ill Patient HbA1c≥6.5|Patients admitted to an intensive care unit with a HbA1c ≥6.5.
3197280|NCT00859625|No Intervention|2|usual colonoscopy practice
3197281|NCT00859664||Neuroleptics|Children with autistic spectrum disorder, treated with neuroleptics
3197282|NCT00859677||1|HIV-positive and MRSA negative
3197283|NCT00859677||2|HIV-positive and MRSA infected (skin/soft tissue)
2511290|NCT02821858|Experimental|Panel 1: Treatment A|Participants will receive odalasvir (ODV) 50 milligram (mg) (n=8) or placebo (n=2) on Day 1.
2511297|NCT02821858|Experimental|Panel 1: Treatment B|Participants will receive ODV 100 mg (n=8) or placebo (n=2) on Day 1.
2511300|NCT02821858|Experimental|Panel 1: Treatment C|Participants will receive ODV 300 mg (n=8) or placebo (n=2) on Day 1.
2511301|NCT02821858|Experimental|Panel 2: Treatment D|Participants will receive AL-335 400 mg (n=8) or placebo (n=2) on Day 1 of Period 1. Each treatment period will be separated by a washout period of 7 days.
2511302|NCT02821858|Experimental|Panel 2: Treatment E|Participants will receive AL-335 800 mg (n=8) or placebo (n=2) on Day 1 of Period 2. Each treatment period will be separated by a washout period of 7 days.
2511306|NCT02821858|Experimental|Panel 2: Treatment F|Participants will receive AL-335 1,200 mg (n=8) or placebo (n=2) on Day 1 of Period 3. Each treatment period will be separated by a washout period of 7 days.
3197284|NCT00859677||3|HIV-positive and MRSA colonized
2511427|NCT02821117|Experimental|Intervention|FreeStyle Libre Flash Glucose Monitoring System
2511502|NCT02820740|Other|NeuroBlate LITT Treatment|This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
2511548|NCT02820220||Patient/patient attendants|"Study subjects will be females.~Age at enrolment should be more than 18 years.~Attending Department of Paediatrics OPD/emergency/well-baby clinics/immunisation clinics OR Department of Gynaecology and Obstetrics OPD/emergency/Ante-natal clinics/Post-natal clinics of Lady Hardinge Medical College and associated hospitals.~Written informed consent to participate in the study."
2510567|NCT02827942|Experimental|Dual therapy|Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
2510568|NCT02827942|Active Comparator|Triple therapy|Patients assigned to this group are treated with the triple therapy with vonoprazan 20 mg bid, clarithromycin 200 mg bid and amoxicillin 750 mg bid for 1 week as the first line therapy or the triple therapy with vonoprazan 20 mg bid, metronidazole 250 mg bid and amoxicillin 750 mg bid for 1 week as the second line therapy. The eradication rates attained with these regimens are measured.
3197285|NCT00859677||4|HIV-negative and MRSA negative
3197286|NCT00859677||5|HIV-negative and MRSA infected (skin/soft tissue)
3197287|NCT00859677||6|HIV-negative and MRSA colonized
3197288|NCT00859690||Sleep Disorder - Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have Obstructive Sleep Apnea (OSA).
3197289|NCT00859690||Sleep Disorder - Not Sleep Apnea|Subjects determined by a clinically indicated overnight sleep study (Nocturnal Polysomnography) to have a sleep disorder other than Obstructive Sleep Apnea (OSA).
3197290|NCT00859703|Placebo Comparator|2|"Patients receive placebo 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
2510828|NCT02825511||A cohort of basal cell carcinoma|A cohort of surgically treated BCC, primitive clinically suspected or previously biopsied on a 4-month period, an expected number of 3 200 cases. The management of the BCC will be consistent with current recommendations. BCC recurrence and those who received prior medical treatment will be excluded.
2510858|NCT02825069|Experimental|Intervention group|Early introduction of solid foods starting at the age of 4 months, with foodstuff from all major groups in diet by the age of 6 months (vegetables and fruits, wheat and other grains, meat, fish, egg, dairy products). Babies presenting with mild symptoms are encouraged to continue the symptom-eliciting food.
2510859|NCT02825069|No Intervention|Control group|Families are advised to follow the official Finnish Nutrition Recommendations, including exclusive breastfeeding until the age of 6 months.
3197291|NCT00859703|Active Comparator|1|"Patients receive risedronate 35 mg once a week plus a calcium and vitamin D supplementation.~Measure of bone density, bone markers, clinical examination and questionnaire regarding fractures will be assessed at 12 and 24 months of treatment"
2510986|NCT02824107|Experimental|patients with myocardial infarction|
2510997|NCT02824107|Experimental|patients with stroke|
2511040|NCT02823873||Normotensive|Normotensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
2511046|NCT02823873||Hypertensive|Hypertensive pregnant and postpartum women will have blood pressure measurements administered with standard clinical equipment and the Pulsewave oscillometric wrist cuff blood pressure monitor.
2511129|NCT02823275|Active Comparator|Functional mobilisation|
2511131|NCT02823275|Experimental|plaster cast fixation|
2511210|NCT02822859|Active Comparator|Wright|Methacholine challenge performed using the Wright nebulizer
2511212|NCT02822859|Active Comparator|Bennett-Twin|Methacholine challenge performed using the Bennett-Twin nebulizer
2511217|NCT02822859|Active Comparator|Aeroneb Solo|Methacholine challenge performed using the Aeroneb Solo nebulizer
2511327|NCT02822157|Experimental|Olaparib|olaparib 300mg oral tablets twice daily for 28 days in 28-day cycles
2511328|NCT02822157|Active Comparator|Chemotherapy|physician's choice chemotherapy
2511355|NCT02821468|Experimental|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochoride 1,500mg
2511361|NCT02821468|Experimental|Control|Untreated arm
2511491|NCT02820649|Experimental|Exercise training|7 weeks of exercise training
2511496|NCT02820649|Sham Comparator|Control|Sedentary group
2511529|NCT02820272|Experimental|NPWT with cold water|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change.
2511532|NCT02820272|Active Comparator|NPWT with normal saline room temp|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was the intervention with injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change.
2511538|NCT02820272|Placebo Comparator|NPWT without other intervention|Each patient will be randomized for dressing method sequence, and each of them would be treated for total of three times of NPWT dressing changes over study period. This arm was no injection of any liquids into sponge before dressing change.
2511585|NCT02819986|Experimental|Progressive Goal Attainment Program|10 one hour weekly therapy sessions focused on behavioural interventions
2511705|NCT02819388|Experimental|Intervention|Contraceptive counseling
2511707|NCT02819388|No Intervention|Control|Control group without counseling
2511719|NCT02819024|Experimental|Treatment (dexamethasone, 18F-FLT PET)|Patients receive dexamethasone PO BID on days 1-5. Patients undergo 3 18F-FLT PET scans. One scan within 7 days prior to the start of dexamethasone, one scan on day 3 after the 5th dose of dexamethasone, and one scan 6-9 days after the last dose of dexamethasone.
2511808|NCT02818556|Other|Restylane Right, Belotero Left|Patients will receive one treatment with Restylane® Silk (right side of the face) and one treatment of Belotero Balance® (left side)
2511810|NCT02818556|Other|Restylane Left, Belotero Right|Patients will receive one treatment with Restylane® Silk (left side of the face) and one treatment of Belotero Balance® (right side)
2511855|NCT02818231||NON EXPOSED|"Male, >50 years, unexposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
2511859|NCT02818231||EXPOSED|"Male, >50 years, exposed to wood dust, without any nasal pathology, without known tumor~-> Brushing of the olfactory cleft"
2511939|NCT02817659|Experimental|Glucagon Infusion|Glucagon infusion in escalating manner at 12.5, 25, 37.5 and 50 ng/kg/min (each step for 60 min). At 30 and 60 mins of each infusion rate, we will administer a previously established questionnaire to assess overall nausea intensity.
2510575|NCT02827773|Experimental|Received Talking Pill Bottles|Patients received anti-hypertensives over 90 day period in Talking Pill Bottle which contained summary of pharmacy counselling session.
2510579|NCT02827773|No Intervention|Usual Care|Patients received oral summary of pharmacy counselling session.
2510680|NCT02826460||Liver Transplant Recipients|
2510718|NCT02826187||Patients with acetabular implant|"Data to be collected are :~Early complications data related to implant or procedure of implantation~Late stage complications data~Efficacity of treatment with HIP score~Patient satisfaction~Radiographic evaluation during standard follow-up"
2510765|NCT02825719|Experimental|Ulipristal|Patients will be prescribed Ulipristal acetate 5mg daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
2510766|NCT02825719|Placebo Comparator|Placebo|Patients will be prescribed placebo pills daily for 12 weeks before operation. If the patients have anaemia with haemoglobin less than 10g/dL, ferrous sulphate 300mg three times a day will be prescribed as well. Tranexamic Acid 500mg four times a day will be prescribed on request basis.
2510837|NCT02825446|Active Comparator|angioplasty tibial arteries|
2510839|NCT02825446|Experimental|radio frequency denervation popliteal artery by the use|"radio frequency denervation popliteal artery Vessix Renal Denervation System Balloon"
2510877|NCT02825134|Experimental|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
2510879|NCT02825134|Active Comparator|Surgical aortic valve replacement|Surgical aortic valve replacement
2510931|NCT02824575|Experimental|Arm A1-2: Paclitaxel plus Rebastinib.|"Arm A1 (Dose Escalation Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm A2 (Expansion Cohort): Paclitaxel 80 mg/m2 weekly x 12 weeks. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
2510941|NCT02824575|Experimental|Arm B1-2: Eribulin plus Rebastinib.|"Arm B1 (Dose Escalation Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days plus Rebastinib (50 mg PO BID or 100 mg PO BID) beginning on cycle 1, day 1 and given continuously.~Arm B2 (Expansion Cohort): Eribulin Mesylate 1.4 mg/m2 day 1 & 8 q21 days. Patients will be randomized to receive Rebastinib (at RP2D) beginning on cycle 1, day 1 OR cycle 2, day 1."
2510991|NCT02824133|Experimental|AZD4547|AZD4547: intake of 80mg bd (160mg/day), on a continuous schedule.
2511052|NCT02823951||Rebif - 1 year MRI cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline and at 12 months
2511053|NCT02823951||Rebif - 1 year clinical cohort|Treatment naive patients starting with Rebif, 1 year follow-up available, MRI scan available at baseline
2511055|NCT02823951||Rebif - early discontinuation cohort - tolerability|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
2511057|NCT02823951||Rebif - early discontinuation cohort - adverse events|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
2511058|NCT02823951||Rebif - early discontinuation cohort - disease activity|Treatment naive patients starting with Rebif, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
2511059|NCT02823951||Tecfidera - 1 year MRI cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline and at 12 months
2511061|NCT02823951||Tecfidera - 1 year clinical cohort|Treatment naive patients starting with Tecfidera, 1 year follow-up available, MRI scan available at baseline
2511063|NCT02823951||Tecfidera - early discontinuation cohort - tolerability|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to tolerability
2511065|NCT02823951||Tecfidera - early discontinuation cohort - adverse events|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to adverse events
2511068|NCT02823951||Tecfidera - early discontinuation cohort - disease activity|Treatment naive patients starting with Tecfidera, MRI scan available at baseline, discontinuation within the first treatment year due to disease activity
2511122|NCT02823132||patients who develop a fungal infection|
2511127|NCT02823132||patients without fungal infection|
3197292|NCT00859716|Experimental|1|vaccination with ACE393 followed by challenge with campylobacter jejuni
2511236|NCT02822443|Experimental|TAU - EFT|This arm integrates emotion focused components (EFT; Greenberg, 2010) into psychological therapy (PT) as treatment-as-usual (TAU), aiming at clarifying and transforming maladaptive emotions. 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
2511239|NCT02822443|Experimental|TAU - SR|This arm focuses on the training of self-regulation strategies (SR; Carver & Scheier, 2000) in the context of psychological therapy (PT) as treatment-as-usual (TAU). 25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions.
2511283|NCT02822105|Experimental|H3N2 M2SR monovalent influenza vaccine|This group will receive a low, medium or high dose of the H3N2 M2SR monovalent influenza vaccine administered intranasally. It will be compared with placebo in a 3:1 ratio.
2511285|NCT02822105|Experimental|placebo|This group will receive saline administered intranasally.
2511375|NCT02821676|Experimental|PEC1/SPB Block|
2511381|NCT02821676|Active Comparator|Intercostal Block|
2511436|NCT02821169|Placebo Comparator|saline solution 0.9%|injection of saline solution in the sphenopalatine area in both nasal fossa
2511437|NCT02821169|Active Comparator|ropivacaine (2mg/ml)|injection of ropivacaine in the sphenopalatine area in both nasal fossa
2511574|NCT02819999|Experimental|Rovalpituzumab Tesirine followed by Cisplatin, Etoposide|Rovalpituzumab Tesirine 0.3 mg/kg IV infusion followed by Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion
2511576|NCT02819999|Experimental|Rovalpituzumab Tesirine with Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion and Rovalpituzumab Tesirine 0.1 mg/kg IV infusion
3197293|NCT00859716|Placebo Comparator|2|Placebo vaccination followed by challenge with campylobacter jejuni
3197294|NCT00859729|Experimental|Cohort I|50 µg DNA/dose, 3 patients
2510730|NCT02826122|Active Comparator|FitBit APP|FitBit Zip APP registers and give feed-back on number of steps per day, distance and calories burned.
2510731|NCT02826122|Experimental|Pai APP|Mio Pai APP registers duration and intensity of the Activity and give feed back as activity Points.
3197295|NCT00859729|Experimental|Cohort II|150 µg DNA/dose, 3 patients
2510861|NCT02825225|Experimental|20 core-biopsy fragments|Patients submitted to experimental intervention (extended sextant biopsy with 20 cores) compared to current standard biopsy protocol (extended sextant biopsy with 12 cores) guided by transrectal ultrasound.
2510863|NCT02825225|Experimental|Base and apex local anesthesia|Patients submitted to experimental intervention in prostate-biopsy anesthetic protocol (prostate base and prostate apex bilateral local anesthetic injection) compared to participants submitted to current standard anesthetic protocol in institution (prostate base bilateral local anesthesia) guided by transrectal ultrasound. guided by transrectal ultrasound.
2510922|NCT02824822||High SUDEP risk cohort|Patients with epilepsy who have a high SUDEP-7 risk score and/or a blood-relative with epilepsy, seizure, cardiac arrest, sudden death, drowning/near-drowning, syncope or arrhythmia.
2510930|NCT02824822||Low SUDEP risk cohort|Patients with epilepsy and a low SUDEP-7 score.
2510990|NCT02824341|Other|Parkinson's disease patients with RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2511000|NCT02824341|Other|Parkinson's disease without RBD|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2511003|NCT02824341|Other|Healthy volunteers|The investigators hypothesize that PD patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD, explaining their susceptibility to ICD when exposed to high doses of dopaminergic treatment.
2511042|NCT02823860|Other|Biospecimens and Quality of Life (QoL)|Only if patient's consent is obtained, biospecimens, including tumor and/or peripheral blood are collected.
2511086|NCT02823509|Experimental|Arm 1|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511147|NCT02823197|Experimental|active transport lesson|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations.
2511149|NCT02823197|Experimental|active transport lesson and Facebook group|Participants receive a 2-hour lesson (at school) promoting active transport for short distance travel to various destinations. Furthermore, they are asked to join a Facebook group on active transport in which 3 messages per week are posted during an eight-week period. The Facebook posts aim to promote the use of active transport for short distance travel.
2511150|NCT02823197|No Intervention|control group|Participants in the control group do not receive the active transport lesson or the Facebook group.
3197296|NCT00859729|Experimental|Cohort III|400 µg DNA/dose, 3 patients
3197297|NCT00859729|Experimental|Cohort IV|1000 µg DNA/dose, 3 patients
2511395|NCT02821429||Patient with mechanical ventilation|Patient will be followed with combined Thoracic Echography Record
2511513|NCT02820493|Other|single arm study|Vedolizumab 300 mg iv at week 0, week 2 and week 6, than every 8 weeks.
2511545|NCT02820194|Active Comparator|Stereotactic body radiation therapy|Patients are treated with Stereotactic Body Radiation Therapy, a methodology for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule.
2511547|NCT02820194|Active Comparator|Microwave Ablation|Patients are treated with Microwave Ablation,a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis.
2511589|NCT02819817|Experimental|Aloe Vera Gel|Experimental gel placed in identical opaque tube as placebo gel.
2511591|NCT02819817|Placebo Comparator|Ultrasound Gel|Placebo placed in identical opaque tube as experimental gel.
2511595|NCT02819817|No Intervention|Standard care|Standard care
2511674|NCT02819583|Experimental|PCAR-019|Enrolled patients will receive PCAR-019 with a novel specific chimeric antigen receptor targeting CD19 antigen by infusion.
2511695|NCT02819258|Other|Endodontic treatment for a tooth with a periapical pathology|
2511729|NCT02819115||Healthy adults group|Healthy adults aged 18 to 59 years
2511733|NCT02819115||Elderly group|Elderly over 60 years old.
2511781|NCT02818816|Experimental|Brimonidine Tartrate 0.2% (2mg/mL)|One (I) drop of brimonidine tartrate 0.2% (2mg/mL) will be placed in the randomized eye preoperatively thirty minutes before robotic-assisted radical laparoscopic prostatectomy (RALP)
2511788|NCT02818816|Placebo Comparator|Carboxymethylcellulose Eye Drops|One drop of Carboxymethylcellulose eye drops will be placed in the randomized eye half an hour before RALP
2511847|NCT02818374|Experimental|Disabled People with behavioral trouble|
2511891|NCT02817867|Active Comparator|tDCS|Patients who will be treated with Transcranial direct-current stimulation (tDCS) in the ipsilesional motor cortex.
2511893|NCT02817867|Active Comparator|rTMS|Patients who will be treated with Magnetic brain stimulation (rTMS) in the contralesional motor cortex.
2511895|NCT02817867|Experimental|tDCS + rTMS|Patients who will be treated with the association between Transcranial direct-current stimulation (tDCS) and magnetic brain stimulation (rTMS), in the ipsilesional and contralesional motor cortex, respectively.
2511955|NCT02817646||Intensive care patients|Patients admitted to the intensive care unit for 4 days or more with a computed tomography scan made for clinical reasons early during intensive care stay and who receive enteral and/or parenteral nutrition as per hospital protocol
2512113|NCT02816515||Ectoin mouth wash|The treatment will be started after oral mucositis development in patients receiving radio- and/or chemotherapy
2512127|NCT02816593|Active Comparator|Group 3 - CP 10%|Group 3: Control: Homemade; Carbamide Peroxide 10%,
3197298|NCT00859729|Experimental|Cohort V|Optimal dose to be determined, 6 patients
3197299|NCT00859742|Experimental|EBUS-TBNA|
3197300|NCT00859755|Experimental|ARRY-403|
2510757|NCT02825927|Experimental|Intervention group|Intensive training with oral screen for 5 weeks.
2510758|NCT02825927|No Intervention|Control group|The control group is not offered any intervention.
3164010|NCT00491855|Experimental|Bevacizumab + Oxaliplatin + Paclitaxel|One cycle of treatment is 21 days. Bevacizumab starting dose level 2.5 mg/kg given intravenously on day 1. Oxaliplatin starting dose level 25 mg/m^2 given intraperitoneally on day 2. Paclitaxel starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
3164011|NCT00491868|Experimental|1|
3164012|NCT00491868|Experimental|2|
3164013|NCT00491868|Active Comparator|3|
2510878|NCT02825199|Experimental|Caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received caffeine capsule (300mg). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
2510880|NCT02825199|Placebo Comparator|Non caffeine group|All participants underwent otoscopy and tympanometry, responded to the Profile of Mood State (POMS), submitted to the cVEMP, oVEMP and caloric tests in that order. After that they received placebo capsule (maize starch). After 45 minutes they again responded to the POMS, repeated the cVEMP, oVEMP and caloric test.
2510903|NCT02824744|Active Comparator|treatment by 2l/min/kg in HFNC|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
2510904|NCT02824744|Experimental|treatment by 3l/min/kg in HFNC|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC) during the initial management of severe bronchiolitis in infants (0-6 months years old)
2510936|NCT02824510|Active Comparator|Patients under insulin pump therapy.|Patients under insulin pump therapy. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart).
2510947|NCT02824510|Active Comparator|Patients under MDI.|Patients under multiple daily injection regimen. Intervention= 2 treadmill exercises to evaluate the efficacy of algorithmic changes in insulin therapy (insulin aspart and glargine or detemir).
2510988|NCT02824185|Experimental|FCH-PET/MRI|FCH-PET/MRI exam performed in addition to the usual examinations for monitoring hepatocellular carcinoma.
2511026|NCT02823795|Experimental|sPATH|Motivational Interviewing in five sessions post hospital discharge
2511027|NCT02823795|No Intervention|Control|Care as usual
2511099|NCT02823561|Active Comparator|Garcinia mangostana (treatment group)|Balanced low-calorie diet and regular exercise in combination with integration
2511102|NCT02823561|Other|Control group|balanced low-calorie diet and regular exercise
2511152|NCT02823145|Experimental|ZX008|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
2511199|NCT02822469|Experimental|Manual Therapy Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Manual Therapy Treatment
2511200|NCT02822469|Placebo Comparator|Placebo Ultrasound Treatment Group|Severe and Moderate TMD patients who filled the inclusion criteria who will receive the Placebo Treatment.
2511228|NCT02822352|No Intervention|High Definition White Light|Surveillance colonoscopy using High Definition White Light alone
2511233|NCT02822352|Active Comparator|High Definition Virtualchromoendoscopy|High Definition Virtualchromoendoscopy
2511307|NCT02822196|Experimental|Serratus Anterior Muscle Plane Block|The US probe will be placed in the mid-axillary line at the level of the 5th intercostal space. The latissimus dorsi, teres major and serratus muscles will be identified. Using in-plane approach, the block needle (22 G, 50 mm) will be inserted until the tip is visualized between the serratus anterior muscle and the intercostal muscles. As an extra reference point thoracodorsal artery will be used which aids in the identification of the plane superficial to the serratus muscle. After negative aspiration of blood, local anesthetic (20 ml of 0.25 % bupivacaine) will be injected and visualized in real-time.
2511309|NCT02822196|Active Comparator|Thoracic Paravertebral Block|The spinous processes of T1- T5 will be identified and at parasagittal plan at 2.5 cm, skin wheel will be raised using 1% lidocaine. A 20-gauge, bevel needle will be advanced until the transverse process is located. The depth from skin to transverse process will be marked/identified by needle marking. The needle will be withdrawn 1-2 cm and angled down.The needle will be re-advanced 1cm past the initial marking. After negative aspiration, 4-5 ml of 0.25% bupivacaine will be slowly injected. The same procedure will be repeated at each level from T2 to T6 ensuring total dose of bupivacaine does not exceed the maximum dose recommended.
2511345|NCT02821572||patient|
2511346|NCT02821572||control|
2511444|NCT02821273|Experimental|Modified INSURE|Modified INSURE is intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
2511445|NCT02821273|Active Comparator|INSURE|INSURE technique meas surfactant administration through intubation-surfactant-extubation. And noninvasive ventilation is immediately used after surfactant.
2511474|NCT02820688|Active Comparator|Concentrated|Infraclavicular nerve block under guidance of ultrasonography will be performed using an undiluted solution of 45mg bupivacaine and 180mg prilocaine (bupivacaine 0.25% and prilocaine 1%, 18mL in total) to patients in this group
2511478|NCT02820688|Active Comparator|Diluted by 33%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 33% (bupivacaine 0.167% and prilocaine 0.66%, 27mL in total) to patients in this group
2511481|NCT02820688|Active Comparator|Diluted by 50%|Infraclavicular nerve block under guidance of ultrasonography will be performed using a solution of 45mg bupivacaine and 180mg prilocaine diluted by 50% (bupivacaine 0.125% and prilocaine 0.5%, 36mL in total) to patients in this group
2512252|NCT02816151|Experimental|Group 1|
3164014|NCT00491868|Active Comparator|4|
3164015|NCT00491985|Experimental|Study Group 1|Subjects aged 9 to 17 years
3164016|NCT00491985|Experimental|Study Group 2|Subjects aged 3 to 8 years
3164017|NCT00491985|Experimental|Study Group 3|Subjects aged 6 to 35 months
3164018|NCT00491998|Experimental|2-hourly dosing|6 Doses of IMP at 2-hourly intervals
3164019|NCT00491998|Experimental|3-hourly dosing|4 doses of IMP at 3-hourly intervals
3164020|NCT00491998|Active Comparator|3-hourly dosing plus Entacapone|4 doses of IMP plus Entacapone at 3-hourly intervals
2510937|NCT02824614|No Intervention|Control|20 obese, non-diabetic candidates will serve as control-group. All assessments are carried out just as in the intervention groups.
2510948|NCT02824614|Active Comparator|E967-Xylitol|20 obese, non-diabetic candidates will receive a daily dose of 24g of xylitol.
2510950|NCT02824614|Active Comparator|E968-Erythritol|20 obese, non-diabetic candidates will receive a daily dose of 36g of erythritol.
2511010|NCT02824263|No Intervention|CPAP (Usual care)|Continuation of established CPAP therapy. CPAP will be worn during a metabolic sleep study in the research laboratory.
2511011|NCT02824263|Experimental|CPAP withdrawal;|Cessation of established CPAP therapy for 3 nights. CPAP will NOT be worn during this period, and a metabolic sleep study off CPAP is performed in the research laboratory on the third night.
2511025|NCT02823756|Experimental|Physical Therapy|Treatment arm: manipulation, exercise, and education
3197301|NCT00859755|Placebo Comparator|Placebo|
2511140|NCT02823028|Active Comparator|NRT + Web Guide|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges)
2511141|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Coed|NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a coed Tweet2Quit group
2511144|NCT02823028|Experimental|NRT + Web Guide + Tweet2Quit-Women|Experimental: NRT + Web Guide + Tweet2Quit-Women NCI Smokefree.gov plus 8 weeks of combination NRT (nicotine patch plus gum/lozenges) plus assignment to a women-only Tweet2Quit group
2511230|NCT02822664|Other|Pedophiles patients|Adults diagnosed with pedophilia
2511237|NCT02822664|Other|Healthy subjects|Healhy subjects (not diagnosed with pedophilia)
2511291|NCT02822092||Patients with Psychotic Disorders taking Risp. or Arip.|Risperidone or aripiprazole will be administered. Subjects will start risperidone 1 mg qhs or 5mg qhs aripiprazole; on day 4 the daily dose will be increased to 2 mg risperidone or 10mg aripiprazole and to 3 mg risperidone or 15mg aripiprazole at day 7. The target dose is 3 mg risperidone or 15 mg aripiprazole daily but patients who remain psychotic can be increased to 4 mg risperidone or 20mg aripiprazole at week 4; 5 mg risperidone or 25 mg aripiprazole at week 6 and 6 mg risperidone or 30 mg aripiprazole at week 8. Study Psychiatrists will be able to increase faster if symptoms don't improve as well as decrease for side effects. These dose ranges conform with standard clinical practice and are within the FDA approved dosing ranges for schizophrenia, and schizoaffective disorder. Subjects advance in the risperidone titration schedule until they respond or develop dose-limiting side effects.
2511298|NCT02822092||Healthy Volunteers|Healthy Volunteers will participate in MR imaging, Electroencephalogram , and cognitive testing.
2511362|NCT02821637|Other|Effort rehabilitation program|"An effort rehabilitation program designed for obese and overweight children or teens : 13 weekly sessions of 1hour30 then 1 session 2 months, 6 months and 12 months later.~This program is part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse.~Child Health Questionnaire (CHQ) of quality of life are completed by parents and children on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session.~Eurofit tests of Physical Fitness performed on the 1st and the 13th session, then 3 more times : 2, 6 and 12 months after the 13th session."
2511433|NCT02821182|Experimental|Anti-PD1 treatment in combination with SBRT|Patients receiving anti-PD1 treatment will be treated with high-dose radiotherapy to one lesion in 3 fractions prior to the second cycle of systemic therapy.
2511509|NCT02820428|Other|Healthy participants|Submission of the scale 'Evaluation of behaviour in Parkinson's Disease' to healthy subjects
2511542|NCT02820246||hospitalised patients|all patients present in a hospital ward during the morning shift
2511620|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC with radiotherapy|Patients will receive 3 radiotherapy treatments (one treatment every 3-5 days) during weeks 3 and 4. The first treatment will occur 6 (+/- 2) hours after the Talimogene Laherparepvec administration at week 3.Talimogene Laherparepvec will be administered at weeks 0, 3, 5, 7, 9, 11, 13 and 15. The first dose of Talimogene Laherparepvec will be 10^6 plaque forming units (PFU)/mL, followed three weeks later by a dose of 10^8 pfu/mL.
2511623|NCT02819843|Experimental|Intralesional TALIMOGENE LAHERPAREPVEC without radiotherapy|Patients will receive Talimogene Laherparepvec alone, as described above, without radiotherapy.
2511676|NCT02819414|Placebo Comparator|Control Group|Treatment with placebo at a volume of 2.25 cc/kg/dose x 4/day to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
2511677|NCT02819414|Active Comparator|Treatment Group|Treatment with paracetamol drops at 15 mg/kg/dose x 4/day. Drops will be diluted 1:15 in order to reduce osmolality. This will yield a dose of 2.25 ml/kg/dose, to be given with feeds, or in place of feed when baby is receiving <2 cc/kg/feed.
2511720|NCT02819193||exposed group : early raw mother's own milk|"The use of raw MOM is considered as early when it begins before day 7."
2511721|NCT02819193||unexposed group : no use of raw mother's own milk|Neonates who receive, or not, raw MOM before day 7.
2511749|NCT02818894|Active Comparator|Lidocaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Lidocaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
2511752|NCT02818894|Active Comparator|Bupivacaine prior to THA|Participants receiving Total Hip Arthroplasty through anterior approach with Bupivacaine spinal anesthesia and completing telephone questionnaires to see how they are feeling post-operation.
2511800|NCT02818621|Active Comparator|Group Dex|"The Dex group received 1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure.~Interventions:~◦Drug: Dexmedetomidine"
2511805|NCT02818621|Placebo Comparator|Group Placebo|"The Placebo group received equal amount of normal saline.~Interventions:~◦Drug: Normal saline"
2511833|NCT02818270|Experimental|Drug depositions|Aerosol drug deposited delivered on the inhaled and exhaled filters and protective filters were evaluated. Salbutamol and Acetylcysteine were delivered by a jet nebulizer through a mechanical ventilator.
2511979|NCT02817438|Experimental|Online Intervention|Participants randomized to the online intervention arm will be given access to the Good Days Ahead program for 12 weeks.
2511984|NCT02817438|No Intervention|Waitlist|Participants randomized to the waitlist arm will wait for 12 weeks without doing an online intervention.
3164021|NCT00492011|Experimental|Ramelteon 1 mg QD|
2511018|NCT02824172|Experimental|Cast immobilization|36 patients in the experimental cast immobilization
2511019|NCT02824172|Active Comparator|complete sport rest|36 patients in the complete sport rest group
2511064|NCT02823665|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
2511066|NCT02823665|Experimental|Atropine|to evaluate the effect of neural activation on insulin secretion and glucose metabolism
2511105|NCT02823327||Chart review, RNA sequencing, microarray|Laboratory Biomarker Analysis. Medical chart review is performed and patient information is collected regarding human immunodeficiency virus HIV/AIDS medical history, staging of AIDS related malignancy, and type of treatment. Previously collected tissue samples are analyzed via RNA sequencing and microarray.
2511139|NCT02823041|Experimental|Cognitive Training & Exercise|This arm involves a combination of systematic computerized cognitive training plus 150 minutes per week of aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as Individual Placement and Support.
2511143|NCT02823041|Active Comparator|Cognitive Training|This arm includes the same systematic computerized cognitive training as the experimental condition, but without the additional aerobic exercise. All participants will also receive individual case management and supportive psychotherapy as well as and Individual Placement and Support.
2511214|NCT02822651|Experimental|Vitamin D status|The 2500 subjects included in this unique arm will complete a self-administered questionnaire and will have a blood sampling to measure vitamin D blood concentration.
2511267|NCT02822261|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511284|NCT02821923|No Intervention|Control|no treatment
2511286|NCT02821923|Active Comparator|E967-Xylitol|24g xylitol/d
2511293|NCT02821923|Active Comparator|E968-Erythritol|36g erythritol/d
2511336|NCT02821689|Experimental|pirfenidone|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on. Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. Investigators were allowed to adjust the dose according to the participants' tolerance.
2511337|NCT02821689|No Intervention|Blank|Eligible participants for clinical trial were randomized in a 2:1 ratio to pirfenidone/blank add-on.
2511419|NCT02821377|Experimental|intravenous furosemide|intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge Intervention: drug: furosemide ; other name: lasix
2511421|NCT02821377|Experimental|intravenous hypertonic saline solutions|small volumes of hypertonic saline solutions (HSS) (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge Intervention: Hypertonic saline solutions (1.4-4.6%NaCl) Intervention other name: not specified
2511423|NCT02821377|Active Comparator|seriated paracentesis|no intervention Intervention: no drug only seriated paracentesis repeated paracentesis from the first day after admission until 3 days before discharge
2511492|NCT02820766||Journey II BCS Knee|Physical Therapy Observational
2511495|NCT02820766||All Other Posterior Stabilized Knees|Physical Therapy Observational
2511634|NCT02819635|Placebo Comparator|Placebo|Administered once daily.
2511638|NCT02819635|Experimental|Updacitinib (ABT-494) Dose A|Administered once daily.
2511640|NCT02819635|Experimental|Updacitinib (ABT-494) Dose B|Administered once daily.
2511643|NCT02819635|Experimental|Updacitinib (ABT-494) Dose C|Administered once daily.
2511646|NCT02819635|Experimental|Updacitinib (ABT-494) Dose D|Administered once daily.
2512047|NCT02816918|Experimental|Extraluminal use of Univent Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
2512054|NCT02816918|Experimental|Innerluminal use of Univent Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
2512069|NCT02816697|Active Comparator|Cease-Aim 1|"Cease Implementation~100 Patients after CEASE Implementation~Exit Interview and Tobacco Use Survey"
2512073|NCT02816697|Active Comparator|Pre Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month) patients in usual care (before CEASE implementation)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
2512074|NCT02816697|Experimental|After Cease Implementation Aim 2|"50 Current or former smokers (3 months +/-2 month)~Tobacco Use Survey (Baseline,1- 6 Months)~Biochemical verification"
2512075|NCT02816697|Active Comparator|Usual Care-Aim 1|"Usual Care Tobacco Treatment Services~100 patients in usual care~Exit Interview and Tobacco Use Survey"
2512076|NCT02816697|No Intervention|Clinician and Staff Survey|- Interview clinicians and support staff (40)
2512106|NCT02816515||Ectoin® mouth wash|The treatment will be started on the first day of radio- and/or chemotherapy, before development of mucositis
2511184|NCT02822755|Active Comparator|Conventional Printed Group|The active comparator group will receive individualized instruction from the participating physical therapist on how to perform their home exercise program as well as printed instructions of the exercises. No video recording of the control group participants will be performed. Intervention: Home Exercise Program and Adherence Logs
2511216|NCT02822456|Experimental|Individual 3D-printed guided tube|IOE tube feeding using individual 3D-printed guided tube and nelaton tube whenever they eat
2511219|NCT02822456|Active Comparator|traditional IOE tube|classic IOE tube feeding using nelaton tube only whenever they eat
2511222|NCT02822456|Active Comparator|nasogastric tube|nasogastric tube feeding using levin tube always
3197302|NCT00859768|Experimental|Intervention group 1|Pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
2511482|NCT02820753|No Intervention|Enhanced Usual Care|"Patients who have not received the initial 6 weeks of text message reminders telling them to take their medicines; or did not complete at least 1 portal survey that asks them if they filled their medications, if they had any side effects or concerns; or did not receive either intervention will be considered as enhanced usual care.~Patients will only receive EHR tools (patient-friendly med-sheets about their medicines, MedList putting their medicines into the Universal Medication Schedule, and UMS sigs on their Rx bottles)."
2511484|NCT02820753|Active Comparator|Text or Portal|Participants who received EHR strategies as well as, the initial 6 weeks of SMS messaging continuously that remind them to take their medicines; or logged on to the patient portal and completed at least one survey will be considered as receiving the intervention.
2511680|NCT02819427||epilepsy|children with absence epilepsy presenting either typical or atypical seizures
2511790|NCT02818582|Active Comparator|1|Active
2511793|NCT02818582|Placebo Comparator|2|Placebo
2511846|NCT02818283|Experimental|Soy Pretzel-Short Feasibility|6 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 28 days. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. This arm will precede the longer 28 week study
2511851|NCT02818283|Active Comparator|Soy Pretzel|28 week intervention involving daily consumption of soy pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
2511857|NCT02818283|Placebo Comparator|Wheat Pretzel|28 week intervention involving daily consumption of wheat pretzel (two packets, 5 oz./packet) for 12 weeks. Participants will follow a legume-free diet which restricts the consumption of legume foods (soy, beans, peas, peanuts, and lentils) during the study period. Participants will be randomized to start with soy pretzel or wheat pretzel arm and crossover to the other pretzel at week 14.
2512032|NCT02817152|Sham Comparator|Periodontal ultrasonic debridement|Periodontal pockets received ultrasonic periodontal debridement intervention.
2512034|NCT02817152|Active Comparator|Low-level laser therapy|Periodontal pockets received ultrasonic periodontal debridement plus low-level laser therapy intervention.
2512112|NCT02816775|Active Comparator|Group Laryngoscope|Group Laryngoscope; intubation will be made by Macintosh laryngoscope
2512122|NCT02816775|Active Comparator|Group Videolaryngoscope|Group Videolaryngoscope; intubation will be made by McGRATH Videolaryngoscope
2512166|NCT02816307|Experimental|Infective endocarditis|
2512260|NCT02815930||HCUs|Newly incident seniors with annual total healthcare expenditures in the top 5% of Ontarians
2512261|NCT02815930||Non-HCUs|Seniors with annual total healthcare expenditures below the top 5% of Ontarians
2512315|NCT02815449|Experimental|Low stabilizer level|Meals prepared with iron fortified cube with low stabilizer level
2512319|NCT02815449|Experimental|Medium stabilizer level|Meals prepared with iron fortified cube with medium stabilizer level
2512325|NCT02815449|Experimental|High stabilizer level|Meals prepared with iron fortified cube with high stabilizer level
2512391|NCT02814344||pregnant women not in labour|"from 24 weeks of gestation until term, provided that they are not in labour~Electrohysterography"
2512394|NCT02814344||women in labour|Electrohysterography
2512483|NCT02814253||Community Based Group|Patients who regularly present with exacerbations of COPD and have chronically-elevated CO2 levels. These patients are supported intensively in an out-patient setting (case-managed) and are potentially eligible for the community-based group.
2512486|NCT02814253||Acute Admissions Group|Patients who are admitted to hospital with an acute exacerbation of COPD. These patients are potentially eligible for the acute admission group.
2512525|NCT02813850|No Intervention|control|standard medical care
2512531|NCT02813850|Experimental|oxygen therapy|
2512605|NCT02813538||IGC and thromboelastometry|Patients that have hyper, normo o hypcoagulability measured by tromboelastometry and anticoagulant proteins levels early after major liver resection and clinical evolution and patients with liver funcion impairment or without it, measured by indocyanine green clearance early after surgery and clinical evolution
2512662|NCT02813057|Active Comparator|Stoppa repair|Stoppa inguinal hernia repair
2512664|NCT02813057|Experimental|TEP repair|Total extraperitoneal inguinal hernia repair
2512679|NCT02812667|Experimental|Nivolumab + Plinabulin|Nivolumab 240mg IV, day 1 and 15 until disease progression Plinabulin 3.5mg/m2, 20mg/m2, 30 mg/m2 or 40mg/m2 IV, day 1,8 and 15 until disease progression
2512779|NCT02812251|Experimental|Part 2|Participants will receive JNJ-61393215 (dose to be determined).
2511192|NCT02822937|Experimental|Triazolam, Methylphenidate, Placebo|The participants will receive 0.375mg Triazolam on the first day, 40mg Methylphenidate on the second day, and placebo on the third day. All drug administration and cognitive measurement will take place in the clinic under medical staff supervision. During each study day in the clinic, the participants will use Project: EVO Monitor and do a short digit symbol substitution task (DSST) 8 times over the day.
2511259|NCT02822326|Experimental|CD19-CAR-T2 T Cells|The subject's T cells will be modified to those which could identify and kill the tumor cells (CD19+ cells). These CD19-CAR-T2 T cells will be infused over 10-15 minutes on days Day 1, 2 and 3 tentatively according to the response to infusion.
2511270|NCT02821949||Patients|Patients with Non Small Cells Lung Cancer PCT dosage
2511310|NCT02821845||Control|Individuals with no spinal cord injury or other neurological deficits.
2511314|NCT02821845||Untrained and Trained SCI Hip and Knee|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Untrained individuals will complete 3 baseline measures and then complete eccentric training which will focus on rehabilitation of the hip joint or knee joint.
2511354|NCT02821585|Active Comparator|Mediterranean Diet|Participants will receive nutritional lessons on the principles of the Mediterranean diet. This type of diet is defined with a carbohydrate intake of 45-55% of total energy intake, 15-20% of proteins, 30-35% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
2511363|NCT02821585|Placebo Comparator|Low Fat Diet|Participants will receive nutritional lessons on the principles of the low fat diet. This type of diet is defined with a carbohydrate intake greater than 45% of total energy intake, 15-20% of proteins, less than 30% of lipids and less than 7% for saturated fat. Nine sessions with a nutritionist are planned to cover various topics of the diet.
2511499|NCT02820792|Active Comparator|LMA ProtectorTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2511501|NCT02820792|Active Comparator|Ambu AuraGainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2511543|NCT02820207||Vulnerable plague|The patients suffering from carotid artery stenosis were identified as the vulnerable plague group by Contrast Enhanced Ultrasound whose plagues were found intraplaque neovascularization
2511609|NCT02819921|Experimental|Desvenlafaxine succinate 100mg|Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
2511614|NCT02819921|Experimental|Desvenlafaxine succinate 50mg|50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
2511616|NCT02819921|Placebo Comparator|Placebo|50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.
2511698|NCT02819453||prior corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) by two clinicians on the first day of hospital admission (not receiving corticosteroids yet)
2511703|NCT02819453||after corticosteroid treatment|Patients diagnosed with acute respiratory distress syndrome(ARDS) after corticosteroids treatment
2511770|NCT02818725|Active Comparator|Chemotherapy|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin
2511774|NCT02818725|Experimental|Arm B: chemotherapy + panitumumab|Intensified- Methotrexate Vinblastin Doxorubicin Cisplatin +/- panitumumab
2511837|NCT02818205||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation
2511842|NCT02818205||Typically Developing Children|Typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2511904|NCT02817984|Experimental|Treatment Group|Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.
3164022|NCT00492011|Experimental|Ramelteon 4 mg QD|
3164023|NCT00492011|Experimental|Ramelteon 8 mg QD|
3164024|NCT00492011|Placebo Comparator|Placebo|
3164025|NCT00492050|Experimental|Bortezomib + Rituximab|Bortezomib 1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22. Rituximab 375 mg/m^2 IV on Day 8 and 22. Valacyclovir 500 mg orally daily (or acyclovir 200 mg orally twice daily).
3164026|NCT00492076|Active Comparator|1|Pangramin Plus Dermatophagoides pteronyssinus 100%
3164027|NCT00492076|Placebo Comparator|2|Pangramin Plus placebo
3164028|NCT00492102|Experimental|1|Nine VLBW pre-term infants older than 7 days will be enrolled in the study and receive one oral dose of Montelukast based on weight. Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
3164029|NCT00492128|Experimental|Losartan/hydrochlorothiazide|Combination drug with losartan 50mg and hydrochlorothiazide 12.5mg
3164030|NCT00492128|Active Comparator|Losartan/amlodipine|Combination therapy with losartan 50mg and amlodopine 5mg
2511193|NCT02822872||infertile couples|"couples addressing IVF treatment due to known infertility will fill questionnaire in order to assess their stress level (as mentioned above), after filling the questionnaire scalp hair sample will be taken to assess chronic cortisol secretion.~during the IVF treatment the stress level will be assessed every 3 month by using the same system (in order to find match between the stress level and cortisol secretion with the fertility treatment"
2511258|NCT02822404|Experimental|Urinary and blood sample|Urinary and blood samples for cystatin C dosage
2511276|NCT02821975|Experimental|Cognitive computer training|This is the intervention group receiving cognitive computer training three times a week for three months.
2511277|NCT02821975|No Intervention|cogntrol group|The control group do not receive cognitive computer training for three months
2511321|NCT02821793||Elderly patient (70 years and older)|
2511323|NCT02821793||Young patient (18 years - 69 years)|
2511344|NCT02821533|Other|TACE using a high dose of cisplatin|Two consecutive treatments at two months apart will be given. A delay in the second treatment is allowed if patients do not recover to an acceptable state for subsequent cycle of treatment. Two treatment sessions at one month apart may be required for each complete treatment to cover all lesions when the lesions are diffusely distributed and involving both lobes.
2511411|NCT02821325||MRI|Radiology
2511426|NCT02820974||Healthy control|Healthy women of child bearing age (25-39) with regular cycles.
2511428|NCT02820974||Perimenopause|Women at the age of 40-54 with irregular cycles filling in th criteria of perimenopause.
2511431|NCT02820974||Menopause|Women at the age of over 55 without normal cycles filling in th criteria of menopause.
2511517|NCT02820415||infertile couples undergoing ICSI for PGS/PGT|patients aged between 29.0 and 42.3 years, with basal FSH on day 3 between 2.9 and 12.0 IU/l. Undergoing 36 patients for RIF or RM. In each couple, the two partners had a normal karyotype. The patients underwent one to two cycles of ovarian stimulation to vitrify and accumulate oocytes and a last (second or third) cycle of ovarian stimulation. Ovarian stimulation was performed by the administration of recombinant FSH and LH (Gonal-F and Luveris: Merck-Serono, London, UK or Puregon, MSD, Franklin Lakes, USA) from cycle day 3 and luteal gonadotrophin-releasing hormone antagonist flexible schema (Cetrotide : Merck-Serono, London, UK).
2511605|NCT02819895|Experimental|Intervention|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive their usual care (an immunization card). In addition they will received automated text, calls and emails (if applicable) reminders through a customized windows® software application when their child's immunization visit is due.
2511606|NCT02819895|No Intervention|Control|Parents of healthy newborn infants delivered at Mother and Child Hospital Ondo (Akure or Ondo), who live in Akure or Ondo Town and plan to receive their immunizations at MCH Ondo will receive usual care (an immunization card)
3164031|NCT00492141|Experimental|L9-NC + Temozolomide|Liposomal 9-nitro-20(S)-camptothecin (L9-NC) alone, total 10 ml of 0.4 mg/ml in aerosol reservoir once a day for 5 days in row each 2 weeks, followed by 2 weeks off; then in combination with Temozolomide 100 mg/m^2 oral/day for Cycle 2 Days 1-5.
3164032|NCT00492167|Experimental|Beta-Glucan and Monoclonal Antibody 3F8|"This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer < 1,000 U/mL.~Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.~Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.~After completion of study treatment, patients are followed periodica"
3164033|NCT00492219|Active Comparator|1|Patients undergoing total knee replacement
3164034|NCT00492219|No Intervention|2|Healthy volunteers that are not undergoing knee replacement surgery
3164035|NCT00492219|Experimental|3|Patients undergoing partial knee replacement with the Oxford mobile bearing implant system
2511713|NCT02819232|Other|Patient with a prescription of a microbiologic diagnostic of|Patient with a prescription of a microbiologic diagnostic of keratitis
2511750|NCT02818933||Aim 1|This group follows a crossover design where adolescents 12-17 years old (n=10) complete a diet recall using one of the two methods (interviewer-administered vs web-based), and then does another diet recall using the other method about a week later. Participants are randomly assigned to the order in which they complete each method of diet recall.
2511754|NCT02818933||Aim 2, interviewer-administered recall|This group of adolescents 12-17 years old (n=10) completes an interviewer-administered diet recall once a week for 6 weeks.
2511757|NCT02818933||Aim 2, web-based recall|This group of adolescents 12-17 years old (n=10) completes a web-based self-administered diet recall once a week for 6 weeks.
2511771|NCT02818673|Experimental|Ascites in Patients With Cirrhosis|Patients will be further classified according to the refractory or sensitive ascitis
2512007|NCT02817308|Experimental|Patients|"Patients with a proven diagnosis of ductal adenocarcinoma of the pancreas with elevated levels of CA19-9 and possibly elevated CEA levels.~intervention: samples of blood, saliva and urine"
2512009|NCT02817308|Other|Control|"Patients or healthy volunteers with out a known evidence of malignancy with presumably normal levels of CA19-9 and CEA.~intervention: samples of blood, saliva and urine"
2512256|NCT02816151|Experimental|Group 2|
2511196|NCT02822911|Other|Alcohol Used Disorders Identification Test (AUDIT C)|Submission of Audit-C questionnaire to all the patients of the study. When the result to the AUDIT-C questionnaire reaches at least 1 point, the analysis of the Carbohydrate deficient transferrin (CDT) is performed within 3 days after the beginning of the study. Results of Gamma glutamyl transpeptidase (GGT) and Mean Corpuscular Volume (MCV) performed as routine practice collected at the same time as the CDT analysis.
2511256|NCT02822365||Diagnostic (PET/CT)|Patients undergo a PET/CT scan as part of their standard clinical care. While still positioned for the clinical scan, patients undergo additional research PET/CT scans in a smaller region over 10 minutes with the pocket phantom placed nearby and a low-dose single bed position CTAC.
2511316|NCT02821884|Experimental|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes.
2511320|NCT02821884|Active Comparator|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation.
2511322|NCT02821884|Sham Comparator|Combination of sham tDCS and sham NMES|"Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Shame tDCS is started in a ramp-like fashion but fade out slowly after 30 seconds.~Sham NMES electrodes are placed away from all motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation."
2511341|NCT02821507|Experimental|sirolimus and cyclophosphamide|combining sirolimus 4mg daily orally and cyclophosphamide 200mg day 1 to 7 and 15 to 21 orally in a 4 week schedule
3197303|NCT00859768|Experimental|Intervention group 2|No pre-test measures are assessed. The patient receives the SIPP twice during their RT period. The first time is before the first consultation with the radiotherapist and the second time is before the last consultation at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3197304|NCT00859768|No Intervention|Control group 1|Pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
2511465|NCT02820896|Placebo Comparator|Multiple Dose Placebo IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of matching placebo IV QW, a total of 4 doses.
2511466|NCT02820896|Experimental|Multiple Dose RO7105705 IV|Healthy participants or participants with Alzheimer's disease will receive multiple doses of RO7105705 IV QW, a total of 4 doses.
2511467|NCT02820896|Experimental|Single Dose RO7105705 SC|Healthy participants will receive a single dose of RO7105705 SC on Day 1.
2511468|NCT02820896|Placebo Comparator|Single dose Placebo IV|Healthy participants will receive a single dose of placebo IV on Day 1.
2511469|NCT02820896|Experimental|Single dose RO7105705 IV|Healthy participants will receive a single dose of RO7105705 IV on Day 1.
2511507|NCT02820506|Other|High risk endometrial cancer|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
2511510|NCT02820506|Other|Cervical cancer tumor size 2-4 cm|Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.
2511571|NCT02820116|Experimental|Icotinib|Patients receive Icotinib PO TID for 8 weeks and then undergo thoracotomy.
3197305|NCT00859768|No Intervention|Control group 2|No pre-test measures are assessed. Enhanced usual care. Follow-up measures are directly after first consultation (T2) and at three (T3) and twelve months (T4) after first measurement.
3197306|NCT00859781|Experimental|1. 177Lu-J591+Ketoconzole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 177Lu-J591 Infusion, continue ketoconazole and hydrocortisone
3197307|NCT00859781|Placebo Comparator|2. 111In-J591 + ketoconazole|Ketoconazole 400 mg 3 times a day plus hydrocortisone 20 mg AM, 10 mg PM x 4 weeks followed by 111In-J591 (placebo) Infusion, continue ketoconazole and hydrocortisone
3197308|NCT00859807|Experimental|Sequence 1 (19 subjects)|"Period 1: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment.~Period 2: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis); reference treatment)."
3197309|NCT00859807|Experimental|Sequence 2 (19 subjects)|Period 1: treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis Period 2: treatment A (15.3 mL (50 mg/5 mL) AQ suspension (Pfizer); test treatment
2511988|NCT02817334|Experimental|indocyanine green|"As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.~Intervention: Drug: indocyanine green"
3197310|NCT00859846|Experimental|Long Axis arterial line placement|Twenty four patients will undergo arterial line placements using long axis arterial line placement under ultrasound.
3197311|NCT00859846|Experimental|Short Axis arterial line placement|Twenty four patients will undergo arterial line placements using short axis arterial line placement under ultrasound.
2512102|NCT02816476|Experimental|Daratumumab|Patient will receive Daratumumab every week for the first 2 cycles then every 2 weeks from cycle 3 through cycle 6.
2512249|NCT02816242|Experimental|intervention|teaching anatomy by concept map
2512254|NCT02816242|Sham Comparator|placebo|teaching anatomy by traditional method
2512307|NCT02815475|Placebo Comparator|Placebo|Starch filled capsule
2512312|NCT02815475|Experimental|Curcumin|400mg of Curcumin via capsule to be consumed every other day
2512317|NCT02815475|Active Comparator|Turmeric powder|2 teaspoons of dried turmeric powder to be consumed every other day
2512346|NCT02814929||Demographic and Prenatal Characteristics|Gender, multiple pregnancy antenatal steroid therapy, invitro fertilisation, preeclampsia/eclampsia, infants of diabetic mother, chorioamnionitis will be compared among infants with and without ROP
2512356|NCT02814929||Neonatal Characteristics of infants|Neonatal characteristics: GA, BW, SGA, resuscitation in delivery room, RDS, duration of mechanical ventilation and oxygen therapy, intracranial hemorrhage, hemodynamically significant PDA, early/late sepsis, NEC, number of blood transfusions, BPD, breastfeeding and weight gain at postnatal 28th day will be compared among infants with and without ROP.
2512512|NCT02814006|No Intervention|CG|participants will respond to questionnaire with no knowledge of intervention
2511232|NCT02822378|Experimental|50g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).
2511240|NCT02822378|Experimental|100g Dried Plums|Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).
3197312|NCT00859846|Active Comparator|Palpation arterial line placement|Twenty four patients will undergo arterial line placements using Traditional palpation arterial line placement.
3197313|NCT00859872|Experimental|oral group|risperidone oral solution combination clonazepam oral
3197314|NCT00859872|Active Comparator|IM group|haloperidol IM injection
3197315|NCT00859885||1|Patients who receive antithrombotic treatment only
2511446|NCT02820935|Experimental|Part 1, Period 1: CC-220|Single dose of 0.6mg CC-220
2511447|NCT02820935|Experimental|Part 1, Period 2: itraconazole with CC-220|Multiple does of 200 mg itraconazole alone, with a single dose of 0.6 mg CC-220 plus itraconazole
2511448|NCT02820935|Experimental|Part 2, Period 1: CC-220|Single dose of 0.6mg CC-220
2511450|NCT02820935|Experimental|Part 2, Period 2: rifampin with CC-220|Multiple doses of 600 mg rifampin alone, with a single dose of 0.6 mg CC-220 plus rifampin
2511523|NCT02820558|Experimental|Substance P - 1nmol/kg|Substance P 1nmol/kg intra-celiac artery, single treatment
2511524|NCT02820558|Experimental|Substance P - 5nmol/kg|Substance P 5nmol/kg intra-celiac artery, single treatment
2511526|NCT02820558|Experimental|Substance P - 15nmol/kg|Substance P 15nmol/kg intra-celiac artery, single treatment
2511527|NCT02820558|Experimental|Substance P - 45nmol/kg|Substance P 45nmol/kg intra-celiac artery, single treatment
2511579|NCT02819960|Active Comparator|active probiotic formula|"Intervention: Probiotic formula PROBIO-FIX INUM® will be administered at a dose of 3x1 cps per day orally for 6 weeks. No premedication or patient monitoring after administration of probiotic formula is required. Probiotic formula may be taken after meals or snacks to reduce stomach upset. Swallow the capsule or in case of problems with swallowing, capsule can be opened, content mixed with small amount of food. Food must not be hot.~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
2511584|NCT02819960|Placebo Comparator|placebo|"Intervention: Maltodextrin will be used for placebo group and will be administered at a the same dose as active formula (3x1 cps per day orally for 6 weeks).~Patients should receive full supportive care during the study, including transfusion of blood and blood products, treatment with antibiotics, anti-emetics, anti-diarrheal agents, analgesics, erythropoetin, or bisphosphonates, when appropriate."
2511650|NCT02819622||Control group|control (no disease)
2511655|NCT02819622||central serous retinopathy group|Central serous retinopathy (with CSCR disease) by exam and OCT
2511694|NCT02819375|Active Comparator|Group Propofol|anesthesia will induced 1 mg/kg propofol
2511700|NCT02819375|Active Comparator|Group propofol/remifentanil|anesthesia will induced 0.5 mg/kg propofol and 1 µg/kg remifentanil
2511704|NCT02819375|Active Comparator|Group propofol/ketamine|anesthesia will induced propofol 0.5 mg/kg and ketamine 0.5 mg/kg
2511734|NCT02818985|Active Comparator|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
2511736|NCT02818985|Active Comparator|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
2511737|NCT02818985|Placebo Comparator|Control|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
2511761|NCT02818699|Placebo Comparator|Placebo Capsule|Participants assigned to this group will receive placebo capsules identical in appearance to EMIQ capsules.
2511762|NCT02818699|Experimental|EMIQ Capsule|Participants assigned to this group will receive EMIQ capsules identical in appearance to placebo capsules.
2511811|NCT02818517||Heart failure|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
2511885|NCT02817932|Experimental|Group 1 (Korean, 375 mg)|Group 1 (Korean, 375 mg): Ranolazine PR 375 mg
2511887|NCT02817932|Experimental|Group 2 (Korean, 500 mg):|Group 2 (Korean, 500 mg): Ranolazine PR 500 mg
2511888|NCT02817932|Experimental|Group 3 (Korean, 750 mg):|Group 3 (Korean, 750 mg): Ranolazine PR 750 mg
2511889|NCT02817932|Experimental|Group 4 (Caucasian, 375mg)|Group 4 (Caucasian, 375mg) : Ranolazine PR 375 mg
2511890|NCT02817932|Experimental|Group 5 (Caucasian, 750mg)|Group 5 (Caucasian, 750mg) : Ranolazine PR 750 mg
2511936|NCT02817672|Active Comparator|PRIME 1.0|8 weeks use of PRIME 1.0 (current version). Mobile application designed to improve psychosocial functioning and motivational deficits.
2511937|NCT02817672|Experimental|PRIME 2.0|8 weeks use of PRIME 2.0 (version with the NLP-powered dashboard). Mobile application designed to improve psychosocial functioning and motivational deficits.
2512000|NCT02817386||POD and Non-POD;|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The assessment of post deliriu (POD) was performed once per day between 8:00 AM to 10:00 AM. Patient notes were not reviewed for episodes of delirium which could occur outside the time of assessment. The clinical research assistants who performed the delirium assessments in this study had good training and went through quality control procedures. We used state-of-the-art delirium detection methods, which tend to report a higher incidence of delirium. The interview included the Confusion Assessment Method (CAM) and Memorial Delirium Assessment Scale (MDAS).
2512116|NCT02816593|Experimental|Group 2 - HP 15%|Group 2: Experimental: Office; hydrogen peroxide 15%,
2512125|NCT02816515||Supersaturated electrolyte mouth rinse|The treatment will be started after oral mucositis development in patients receiving radio and/or chemotherapy
3197316|NCT00859885||2|Patients who undergo percutaneous device closure
3197317|NCT00859911|Active Comparator|2|Thiamine Mononitrate 5mg, Riboflavin 2 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg
2511253|NCT02822313|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2511287|NCT02822014|Other|FDG-PET/CT arm|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients. We correlated evolution of FDG uptake with clinical evolution of patients.
2511378|NCT02821741|Experimental|Cymba Conchae|Mild electrical stimulation is applied to the cymba conchae of the left ear, and thermal stimulation is applied to the arms.
2511380|NCT02821741|Active Comparator|Ear Lobe|Mild electrical stimulation is applied to the earlobe of the left ear, and thermal stimulation is applied to the arms.
3197318|NCT00859911|Experimental|1|Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocobalamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
2511473|NCT02820519|Experimental|Loxapine|Loxapine Capsules 10 mg Day 1- 14: 10 mg b.i.d Day 15-28: 10 mg t.i.d Day 29-42: 20 mg b.i.d. Day 43-56: 20 mg t.i.d. Dosages will be escalated according to analgesic efficacy and tolerability.
2511522|NCT02820389||Optical colonoscopy|Patients with suspected colorectal cancer will undergo optical colonoscopy as the initial imaging modality.
2511525|NCT02820389||CT Colonography|Patients with suspected colorectal cancer will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan.
2511582|NCT02820025|Experimental|doxapram group|the doxapram group iv doxapram 1mg/kg,
2511586|NCT02820025|Placebo Comparator|Controlled group|the controlled group given equal volume of saline with the doxapram group.
2511632|NCT02819687|Experimental|RDX5791 10mg QD (SAD phase)|10mg of RDX5791 administered once daily PO fasting
2511637|NCT02819687|Experimental|RDX5791 50mg QD (SAD phase)|50mg of RDX5791 administered once daily PO fasting
2511639|NCT02819687|Experimental|RDX5791 150mg QD (SAD phase)|150mg of RDX5791 administered once daily PO fasting
2511641|NCT02819687|Experimental|RDX5791 450mg QD (SAD phase)|450mg of RDX5791 administered once daily PO fasting
2511644|NCT02819687|Experimental|RDX5791 900mg QD (SAD phase)|900mg of RDX5791 administered once daily PO fasting
2511647|NCT02819687|Experimental|RDX5791 3mg QD (MAD phase)|3mg of RDX5791 administered once daily PO fasting
2511651|NCT02819687|Experimental|RDX5791 10mg QD (MAD phase)|10mg of RDX5791 administered once daily PO fasting
2511656|NCT02819687|Experimental|RDX5791 30 mg QD (MAD phase)|30mg of RDX5791 administered once daily PO fasting
2511658|NCT02819687|Experimental|RDX5791 100 mg QD (MAD phase)|100mg of RDX5791 administered once daily PO fasting
2511686|NCT02819271|Experimental|CXL-1427 (BMS-986231)|Experimental
2511689|NCT02819271|Placebo Comparator|Placebo|Placebo
2511753|NCT02819089|Active Comparator|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
2511756|NCT02819089|Placebo Comparator|NSS|NSS loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
2511798|NCT02818595|Experimental|Normal children|Every child meet the age criteria and without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological
2511802|NCT02818595|Experimental|Abnormal children|Every child meet the criteria of age and having a detectable neurological disease after clinical, neurophysiological and radiological as intraventricular hemorrhage .
2511845|NCT02818296|Experimental|Active IU CBM-I|This paradigm was designed to train individuals to endorse benign interpretations of ambiguous information and reject negative/threatening interpretations of ambiguous information. Participant's baseline interpretation bias was measured at baseline. Participants then underwent two training phases in which their responses were either reinforced (i.e., they were told they were correct) or punished (i.e., they were told that they were incorrect). Interpretation bias was measured again at post-training.
2511850|NCT02818296|Sham Comparator|Control CBM-I|This paradigm was identical to the active condition except that the word/sentence pairings used were not relevant to IU and/or anxiety.
2512078|NCT02816957|Active Comparator|patients receiving Nigella|40 patients in the treatment group that will receive nigella sativa powder (2 gm/day) for 3 consecutive months.
2512080|NCT02816957|No Intervention|patients not received nigella as controls|40 patients in the control group will not receive nigella sativa and continued on the usual chelators
2512136|NCT02816489|Experimental|Group I|"will be treated using passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA).~Intervention: Device: passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner (3M Unitek - USA)."
2512137|NCT02816489|Experimental|Group II|"will be treated using conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA).~Intervention: Device: conventional stainless steel orthodontic brackets ligated with elastomeric ligature (3M Unitek - USA)."
2512169|NCT02816177|Experimental|Telemedicine|Usual care and telemedicine consultations during12 months.
2512171|NCT02816177|Active Comparator|Usual care alone|Usual care during12 months.
2512224|NCT02815865|Active Comparator|Foley catheter and pitocin|Intervention: Foley catheter and pitocin Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
2512228|NCT02815865|Active Comparator|Foley catheter and dinoprostone|Intervention: Foley catheter and dinoprostone Foley catheter will be inserted through the cervix and inflated with 80 ml saline dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
2512232|NCT02815865|Active Comparator|Dinoprostone|Intervention: Dinoprostone 3 mg will be inserted to the posterior fornix
2511295|NCT02822209|Active Comparator|Personalized care program as routine practice|"A personalized care program is decided for the newly diagnosed patient by the multidisciplinary team in charge of lung cancer.~The care provided will be organized by the medical team, and besides the oncologist, no principal coordinating contact will be in charge of the patient.~The quality of life questionnaire - EORTC QLQ-C30 and QLQ-LC13 - will be completed by the patient throughout the study.~2 Satisfaction questionnaires completed :~satisfaction questionnaire - patient,~satisfaction questionnaire - general practitioner or home nurse"
2511347|NCT02821546|Placebo Comparator|standard hydration|Patients underwent first-time ERCP to receive standard fluid hydration with Lactated Ringer's solution at a rate calculated by the Holliday-Segar method given peri-procedurally starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
2511349|NCT02821546|Active Comparator|aggressive hydration|Patients underwent first-time ERCP to receive aggressive fluid hydration with Lactated Ringer's solution at a rate of 150 ml/hr starting 2 hours prior to procedure, and continued during and after procedure to complete 24 hours.
2511520|NCT02820454|Experimental|AGuIX and radiotherapy|"Patients receive a single intravenous injection of AGuIX on day 1. Then patients undergo a whole brain radiation therapy, 5 days a week in weeks 1-2. The first radiotherapy session will be performed 4 hours after AGuIX injection.~Five dose escalation cohorts : 15 mg/kg, 30mg/kg, 50mg/kg, 75mg/kg and 100 mg/kg"
2511587|NCT02820051|Active Comparator|Midazolam|"In the group of midazolam, the initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
2511588|NCT02820051|Experimental|Propofol|"In the group of propofol, the starting dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of 3 to 4 in the Observer´s assessment of alertness/ sedation scale. All patients received nalbuphine in a starting dose of 2 mg with additional doses of 1 mg if it was necessary. Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.~Intervention: Transcutaneous CO2 monitor"
2511779|NCT02818803|Experimental|Propolis|Standardized-propolis extract (EPP-AF®) oral gel formulation, 3 times a day, for 14 days
2511787|NCT02818803|Active Comparator|Miconazole|Miconazole 20mg/g oral gel,3 times a day, for 14 days
2511834|NCT02818387|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
2511835|NCT02818387|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary.
2511836|NCT02818387|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.125 mcg/kg/min for 5 min followed by midazolam 0.015 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 0.5 mg/kg and will be adjusted as described in summary."
2511915|NCT02817789|Active Comparator|Standard group|154 patients
2511919|NCT02817789|Experimental|Ticagrelor group|154 patients
2511995|NCT02817412|Experimental|Go/No-Go Training|In the go/no go training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. They are told to press response keys as quickly as possible to indicate the side of presentation (go-trials). On half of the trials, the rectangular frame surrounding the image is not solid but hatched, which is a signal for them to withhold their response (no-go trials). This training is divided into 4 blocks of 50 trials.
2512002|NCT02817412|Experimental|Stop-Signal Training|In the stop signal training, participants are shown images in either a dark blue or light gray border. They are told to press the space bar as quickly as possible when the border is blue (go trials) and to withhold a response when the border is gray (no-go trials). This training is divided into 20 blocks of 32 trials.
2512005|NCT02817412|Experimental|Dot-Probe Training|In the dot-probe training, participants are shown images in which high-calorie foods are shown on one side of the screen and low-calorie foods on the other. Immediately after the images disappear, a small dot probe appears in the location of one of the images. Participants are told to press response keys as quickly as possible to indicate whether a visual probe appeared behind the left or right image during the trials. The probe appears in the location occupied by a high-calorie food image 10% of the time and in the location occupied by a low-calorie food image 90% of the time. This training is divided into 6 blocks of 40 trials.
2512006|NCT02817412|Placebo Comparator|Generic Training|In the generic training, participants complete a generic go/no-go training that uses images of flowers and office supplies instead of the images of high-calorie and low-calorie food images. This generic go/no go training is identical in duration and contact time to the go/no-go food training.
2512035|NCT02817009|No Intervention|Nutrition Group|This group will go through standard of care and visit the nutritionist on a monthly basis for the three months that they are a part of the study.
3164036|NCT00492219|Experimental|4|Patients undergoing partial knee replacement with the Vanguard M implant system
3164037|NCT00492271|Experimental|1|Experimental arm with increasing dosage
3164038|NCT00492310|Experimental|1|Cognitive-behavioral smoking cessation with yoga
3164039|NCT00492310|Active Comparator|2|smoking cessation with twice weekly wellness program
3164040|NCT00492323|Placebo Comparator|002|placebo twice daily for 4 weeks
3164041|NCT00492323|Experimental|001|carisbamate 200 mg tablet twice daily for 4 weeks
3164042|NCT00492362|Active Comparator|A|Ergometer during hemodialysis
3164043|NCT00492362|Active Comparator|B|Pedometer use outside of hemodialysis
3164044|NCT00492388|Experimental|A|PMI-150 (intranasal ketamine)
3164045|NCT00492388|Placebo Comparator|B|placebo
3164046|NCT00492427|Active Comparator|2|
3164047|NCT00492427|Experimental|1|
3164048|NCT00492440|Experimental|CYT107 (r-hIL-7)|
3164049|NCT00492453|Active Comparator|1|Laparoscopic cholecystectomy under spinal anesthesia
2511343|NCT02821520|Active Comparator|Delayed PDT combination with Conbercept|"Conbercept 0.5 mg(0.05ml): Administered at baseline, and then PRN based on retreatment criteria monthly from month 1 to 11.~PDT:PRN PDT combination with conbercept injection based on retreatment criteria from month 3 to 11.~PDT treatment must be administered within 7 days after the injection. If same day treatment of conbercept and PDT is performed, conbercept injection is to be administered at least 2 hours after the PDT.~PDT should cover the whole area of polyps and branch vascular net (BVN).The PRN PDT retreatment intervals should be no less than 3 months."
2511418|NCT02821299|Experimental|Laryngeal transplantation|Laryngeal transplantation
2511462|NCT02820883|Experimental|High dosage vaccine|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
2511463|NCT02820883|Experimental|Middle dosage vaccine|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)
2511464|NCT02820883|Experimental|Low dosage vaccine|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)
2511488|NCT02820532|Other|Tracking|The volunteers will be placed on the treatment couch. Their respiratory motion will be measured and the treatment couch will be moved accordingly. During the couch motion experiment the heartbeat, the skin humidity, the respiratory characteristics and the pupil motion will be additionally measured.
2511536|NCT02820376|Other|All patients|"Differential renal function assessment by 4D CT:~All patients will undergo both CT and SPECT assessment of differential renal function; each patient will be his own comparator"
3197319|NCT00860002||1|Ultramini laparotomy (UMLT) myomectomy (UMLT-M) versus laparoscopic myomectomy (LM)
3197320|NCT00860002||2|Laparoscopically aided myomectomy (LAM) versus LM
3197321|NCT00860002||3|LAM versus UMLT-M
3197322|NCT00860002||4|Mini laparotomy myomectomy (ML-M) versus UMLT-M
3197323|NCT00860002||5|Laparoscopic uterine artery occlusion with blockage of anastomosis between the uterine and ovarian vessels (LUVO) versus laparoscopic uterine artery occlusion without blockage of anastomosis between the uterine and ovarian vessels (LUAO)
3197324|NCT00860002||6|LUVO+LAM versus LUAO+LAM
2511864|NCT02818153|Experimental|questionnaire for allergic rhinitis control|Teenagers from 12 to 17 years old who complete a Self questionnaire regarding allergic rhinitis control during the consultation and after 15 days
3197325|NCT00860002||7|LUVO+LM versus LUAO+LM
2512023|NCT02817035|Experimental|noninvasive mechanical ventilation|To investigate the change of the neural inspiratory time and expiratory delay noninvasive mechanical ventilation ,in comparison to spontaneous breathing
2512088|NCT02816879|Experimental|Screening (anal cytology collection)|Patients undergo anal cytology collection using 2 NF swabs and 1 Dacron swab for analysis via Pap staining, HPV genotyping, and PCR.
2512264|NCT02816294|Experimental|Housing Prescription|Participants in the intervention group will be referred to the Care Coordinator at Project Hope, who will conduct case management with the family to stabilize their housing. The Care Coordinator will refer families all families to benefit maximization services and complete Problem Solving Education. The Care Coordinator will also refer families as necessary to Medical-Legal Partnership Boston for pro-bono legal services and/or the Boston Housing Authority for priority on a subsidized housing waitlist.
2512265|NCT02816294|No Intervention|Resource List|At present, for families facing housing insecurity, Children's HealthWatch offers paper resources with contact information for local social service agencies that may assist with housing stability.
2512322|NCT02815332|Placebo Comparator|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2512323|NCT02815332|Experimental|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2512326|NCT02815332|Experimental|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
2512361|NCT02814773||AD group|group suffering from Alzheimer-type dementia (mild to moderate dementia)
2512425|NCT02814539||congenital heart disease|children with severe congenital heart disease who undergo open heart surgery during infancy
2512426|NCT02814539||healthy controls|
2512474|NCT02814201||Parkinson best-On|two hours after taking two tablets of 125 mg dispersible Modopar®
2512475|NCT02814201||Parkinson worst-off|after a drug withdrawal period ( morning fasting all dopaminergic treatment since the day before midnight)
2512477|NCT02814201||Huntington|
2512479|NCT02814201||Control|Data collected from the existing database
2512689|NCT02812823|Other|High resolution anorectal manometry|All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
2512720|NCT02812381|Active Comparator|SCS (Jones tecnique)|18 patients were treatment with straincounterstrain
2512721|NCT02812381|Sham Comparator|KT Kinesiotaping|18 patients were treatment with neuromuscular bandage
2512745|NCT02812121|Experimental|Group MSC-1|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 8 weeks.
2512746|NCT02812121|Experimental|Group MSC-2|Patients in Group MSC-1 received standard medical treatment and infusions of umbilical cord blood mesenchymal stem cells via peripheral veins once a week for 4 weeks.
2512751|NCT02812173|Active Comparator|transurethral catheter ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a transurethral catheter, which was withdrawn on the 5th day after the surgery
3197326|NCT00860002||8|LUVO+UMLT-M versus LUAO+UMLT-M
3197327|NCT00860002||9|LUVO versus UMLT-UVO
3197328|NCT00860002||10|UMLT-UVO versus UMLT-UAO
3197329|NCT00860002||11|LUAO versus UMLT-UAO
3197330|NCT00860002||12|UMLT-UVO+UMLT-M versus UMLT-UAO+UMLT-M
3197331|NCT00860002||13|LUVO versus LM
3197332|NCT00860002||14|LUVO versus LAM
3197333|NCT00860002||15|LUVO versus LUAO+LM
3197334|NCT00860002||16|LUVO versus LUAO+UMLT-M
3197335|NCT00860002||17|LUVO versus LUAO+LAM
3197336|NCT00860041||Group I|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
2511417|NCT02821065|Experimental|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse receives and reviews the data electronically and will follow-up with the patient.
2511455|NCT02820922||Orthopedic emergency surgery|Patients of all ages who have undergone emergency orthopedic surgery The analysis of medical data with regard to age, sex, the American Society of Anesthesiologists (ASA) score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
3197337|NCT00860041||Group II|Patients complete pain questionnaires at baseline, 2-8 days after each weekly paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
2511590|NCT02819830|Experimental|Intervention group|"Participants, who have been randomly assigned to the intervention group, will take part in a six-week supervised exercise training programme. This programme takes place in a rehabilitation gymnasium. The exercise programme consists of two group sessions per week (scheduled for evenings, after typical working hours, approximately 12 patients per session). Each session lasts for approximately 70 minutes and includes a 5 minute warm up, 30 minutes of aerobic cycling exercise, 30 minutes of strength training, and a 5 minute cool down.~Participants will also perform a 30 minute walk each weekend as part of the intervention."
2511593|NCT02819830|No Intervention|Control group|Participants who have been randomly assigned to the control group will not undertake the exercise intervention. These participants are instructed to maintain their usual lifestyle.
2511648|NCT02819609||Myomectomy|Women with uterine fibroids who underwent myomectomy as their index procedure as part of their routine clinical care
2511653|NCT02819609||Endometrial ablation|Women with uterine fibroids who underwent endometrial ablation as their index procedure as part of their routine clinical care
2511654|NCT02819609||Uterine artery embolization|Women with uterine fibroids who underwent uterine artery embolization as their index procedure as part of their routine clinical care
2511657|NCT02819609||MRI-guided focused ultrasound ablation|Women with uterine fibroids who underwent MRI-guided focused ultrasound ablation as their index procedure as part of their routine clinical care
2511776|NCT02818790|No Intervention|Group 1. Control|
2511782|NCT02818790|Experimental|Group 2. Intervention 1|
2511785|NCT02818790|Experimental|Group 2. Intervention 2|
2511844|NCT02818413||U.S. Olympic Team and elite athletes|Biospecimens will be collected from and questionnaires will be administered to U.S. Olympic team members and other elite athletes
2511912|NCT02817945|Experimental|68Ga-NOTA-3P-TATE-RGD PET/CT|The patients were injected with 111-185 MBq of 68Ga-NOTA-3P-TATE-RGD in one dose intravenously and underwent PET/CT scan 45-60 min later.
2511956|NCT02817542||STEMI TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention with TA
2511961|NCT02817542||STEMI without TA hyperglycemic subjects|STEMI hyperglycemic patients, percutaneous coronary intervention without TA
2512038|NCT02817243|Other|SP2086 and Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
2512091|NCT02816762|Experimental|CPAP treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents plus continuous positive airway pressure (CPAP)
2512100|NCT02816762|Active Comparator|Control treatment|Diet and conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
2512170|NCT02816164|Active Comparator|Neupogen for 5 days|Neupogen injection for 5 days
2512173|NCT02816164|Active Comparator|Neupogen for 7 days|Neupogen injection for 7 days
2512174|NCT02816164|Active Comparator|Neupogen for 10 days|Neupogen injection for 10 days
2512227|NCT02815826||Barefoot training|16 weeks of progressive barefoot running training
2512305|NCT02815579|Experimental|Intervention|The Shamba Maisha Intervention includes: a) a microcredit loan (~$140) from a well-established Kenyan bank for purchasing agricultural implements and commodities; b) agricultural implements to be purchased with the microcredit loan including the KickStart treadle pump, seeds, fertilizers and pesticides; and c) education in financial management and sustainable farming practices occurring in the setting of patient support groups.
2512313|NCT02815579|No Intervention|Control|Participants in the control arm will receive the standard of care.
2512345|NCT02814825||ViviGen|Patients undergoing a two or three level ACDF using ViviGen Cellular Bone Matrix in conjunction with cervical allograft spacers and DePuy Synthes anterior cervical plate systems.
2512485|NCT02814058|Experimental|Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
2512488|NCT02814058|Experimental|Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
2512516|NCT02813772|Experimental|group 1|Patients with infantile colics who will receive the milk formula NAN Sensitive, Nestlè
2512520|NCT02813772|Active Comparator|group 2|Patients with infantile colics who will receive the milk formula NAN Optipro, Nestlè
2512583|NCT02813460|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliters (mL) of each 6 ALS-008176 formulations A B F C E D on day 1.
2511422|NCT02820987|Active Comparator|PIPERACILLIN-TAZOBACTAM|After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
2511424|NCT02820987|Active Comparator|CEFEPIME|After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.
2511982|NCT02817347|Experimental|YH1177 (4/0.5%+0.1%)|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%
2511986|NCT02817347|Experimental|YH1177 (8/1.0%+0.1%)|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%
2511992|NCT02817347|Experimental|YH1177-D (2/0.25%)|piperacillin 2% + tazobactam 0.25%
2511999|NCT02817347|Experimental|YH1177-D (4/0.5%)|piperacillin 4% + tazobactam 0.5%
2512004|NCT02817347|Experimental|YH1177-D (8/1.0%)|piperacillin 8% + tazobactam 1.0%
3164050|NCT00492453|Active Comparator|2|Laparoscopic cholecystectomy under general anesthesia
3164051|NCT00492466|Experimental|1|
3164052|NCT00492492|Other|trans-styloid and intrafocal pinning on the one side|trans-styloid and intrafocal pinning on the one side
3164053|NCT00492492|Other|volar fixed-angle plating on the other side|volar fixed-angle plating on the other side
2512452|NCT02814630|Other|Open-label Xolair|"The patients will receive one subcutaneous injection of omalizumab at a dose of 300 mg on Days 1, 30, and 60.~There is no control drug."
2512507|NCT02813993|Experimental|Intervention Group|A five-minute video concerning age-related fertility decline, fertility risk factors, success of infertility treatments and emotional consequences of childlessness
2512510|NCT02813993|No Intervention|Control|No intervention
2512528|NCT02813668|Experimental|Lifestyle Intervention Training Program|Participants at risk for developing diabetes or with unmedicated diabetes will participate in a lifestyle intervention training program. Individuals in the training program, as well as un-enrolled workers at the study sites, will be exposed to positive changes at the worksite to promote increased physical activity and healthier diets.
2512632|NCT02813486|Experimental|GC3111 Vaccine Group|Participants randomized to receive a single dose of GC3111 vaccine (Biological: GC3111 vaccine).
2512634|NCT02813486|Active Comparator|Boostrix® Vaccine Group|Participants randomized to receive a single dose of Boostrix® vaccine (Biological: Boostrix® vaccine).
2512674|NCT02812875|Experimental|CA-170|Taken orally in a once or twice daily schedule.
2512712|NCT02812537||patients with conduct disorders|Girls and boys having less than 16 years old and admitted to emergency room for aggressiveness, violence, fugue or theft.
2512740|NCT02812199|Experimental|pilot study group 1|Patients in pilot study group 1 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in pilot study group scheduled for 6 follow up visits at 1,2,3,4,6 and 12 weeks after implantation and for tampon removal at day 2 - 3 after FESS surgery. Stent will be removed between 14 and 28-day implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
2512741|NCT02812199|Experimental|study group 2|Patients in study group 2 will undergo post-FESS bilateral implantation of Composite Removable Sinus Stent into middle meatus. Nasal tampon will be placed to stop bleeding if necessary. Patients in 2nd study group scheduled for 4 follow up visits at 2, 4, 6 and 12 weeks after implantation. Before removal adrenaline - lidocaine administration will be used locally to minimize bleeding and cold saline wash applied to induce stent crimping.
2512742|NCT02812199|No Intervention|control group 3|control group patients will undergo post-FESS bilateral Standard of Care (tampon) placement into middle meatus as standard of care. Frontal tampon will be placed to stop bleeding. Patients in control group scheduled for 3 follow up visits at 2, 6 and 12 weeks after surgery and for tampon removal at day 2 - 3 after FESS surgery.
2512885|NCT02811484|Other|Group 1|Insulin titration and behavioral therapy.
2512888|NCT02811484|Placebo Comparator|Group 2|Exenatide-LAR plus Dapagliflozin placebo, basal insulin titration, and behavioral therapy.
2512890|NCT02811484|Experimental|Group 3|Exenatide-LAR plus Dapagliflozin, basal insulin titration, and behavioral therapy.
2512948|NCT02811029|Experimental|premature infants less than 32 weeks of age|measurement of phonology in premature infants less than 32 weeks of age who participated to LAMOPRESCO-1 study
2512994|NCT02810730|Other|Single arm|Pancreatic MRI in the 6 months following the first consultation
2513010|NCT02810262||First bone metastasis of adenocarcinoma lung cancer|Patients entering the group have a suspected first bone metastasis of adenocarcinoma lung cancer and should undergo bone biopsy to histologically prove the diagnosis.
3164054|NCT00492596|Experimental|device|insertion of balloon system
3164055|NCT00492596|Sham Comparator|sham|cystoscopy with sham system
3164056|NCT00492609||1|PATIENTS WITH COMPUTER-ASSISTED
3164057|NCT00492609||2|PATIENTS WITHOUT COMPUTER-ASSISTED
3164058|NCT00492635|Experimental|Arm 1|
3164059|NCT00492635|Experimental|Arm 2|
3164060|NCT00492635|Placebo Comparator|Arm 3|
3164061|NCT00492661|Experimental|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression (drug which suppresses the body's immune response, used in transplantation and diseases caused by disordered immunity) will be provided with intensive dietary advice and supervised progressive resistance training (PRT) for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
3164062|NCT00492713|Active Comparator|1|Dark chocolate
3164063|NCT00492713|Active Comparator|2|Milk chocolate 1
3164064|NCT00492713|Active Comparator|3|Milk chocolate 2
3164065|NCT00492739|Other|Varicella vaccine|2-3 doses of Varicella vaccine to seronegative patients two months apart
3164066|NCT00492765|Experimental|1|interferon beta-1a and Simvastatin
2511430|NCT02821026|Experimental|Omental islet transplant|At the time a suitable islet preparation becomes available, the patient will receive allogeneic islet cells placed in an omental pouch. Islet transplant will be performed under Anti-Thymocyte Globulin induction immunosuppression (5 doses, day -2 prior to transplant to day 2 post-transplant). Maintenance mycophenolate mofetil therapy (1-2 g/day as BID dosing) will be started on Day -1 pre-transplant. Tacrolimus will be administered orally twice daily on Day 1 post-transplant to maintain a trough level of 10-12 ng/mL for 3 months, then 6-10 ng/mL thereafter. Etanercept will be given IV before the islet transplant (50 mg), and then at 25 mg (subcutaneously) on POD +3, +7 and +10. Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
2511489|NCT02820662|Experimental|RETCAM|
2511535|NCT02820337||non comparative|Bariatric surgery patients infected with HIV, overweight with controlled viral load and HIV lipohypertrophy particularly truncal
2511604|NCT02820064|Other|only one arm|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
2511682|NCT02819544|Active Comparator|Ropivacaine|Ropivacaine 7.5 mg/mL administration
2511684|NCT02819544|Placebo Comparator|Sodium chloride|NaCl 0.9% administration
2511730|NCT02819102|Experimental|Metabolic Probes and BCX7353|"Day 1: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, and 30 mg dextromethorphan orally.~Day 2: a single oral dose of 2 mg midazolam. Days 3 to 9: 350 mg BCX7353 once a day. Day 10: 1 mg midazolam will be administered as an IV bolus simultaneously to administration of 500 mg tolbutamide, 40 mg omeprazole, 30 mg dextromethorphan and 350 mg BCX7353, orally.~Day 11: a single oral dose of 2 mg of midazolam along with 350 mg BCX7353."
2511766|NCT02818881|Experimental|High-speed then low-speed yoga|Subjects received a single session of High-speed yoga and within one week a single session of Low-speed yoga
2511767|NCT02818881|Experimental|Low-speed then high-speed yoga|Subjects received a single session of Low-speed yoga and within one week a single session of High-speed yoga
2511830|NCT02818465|Experimental|Patients|
2511922|NCT02818049|Experimental|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
3197338|NCT00860041||Group III|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3197339|NCT00860041||Group IV|Patients complete pain questionnaires at baseline, 2-8 days after each 2-4 week paclitaxel treatment not given in combination with a neurotoxic agent, and then monthly for 1 year. Information about the type, location, and duration of pain and neuropathy as well as types of interventions used to manage the pain symptoms and the patients' pain responses is collected.
3197340|NCT00860054|Experimental|Medium Phytosterols|Diets with daily 400 mg of phytosterols
3197341|NCT00860054|Experimental|High Phytosterols Diet|Diet with 2000 mg of daily phytosterols
3197342|NCT00860054|Placebo Comparator|Low Phyto Diet|Diet with less than 100 mg of daily phytosterols
3197343|NCT00860080|Experimental|PXL01|Four Subjects per cohort will receive 10, 20, or 40 mg PXL01 respectively.
3197344|NCT00860080|Placebo Comparator|Placebo|One subject per cohort will receive 10, 20, or 40 mg Placebo respectively.
3197345|NCT00860093|Experimental|1|MPC-5971
2512109|NCT02816814|Active Comparator|Love Diet|Overweight females (BMI > 25) in menopause
2512114|NCT02816814|Experimental|LωVE diet|Overweight females (BMI > 25) in menopause
2512214|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
3197346|NCT00860093|Placebo Comparator|2|placebo identical in appearance to study drug
3197347|NCT00860106|Other|Follow up|"ED score and DDimer level of patients who have stopped their VKA treatment (after the first or the second previous proximal VTE).~Phone follow up for 2 years."
3197348|NCT00860119|Experimental|Sublingual tablet|Test treatment
2512369|NCT02814760||Pre-intervention group (Control group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included before the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
2512373|NCT02814760||Post-intervention group (Training course group)|"AVC-II trial involves 18 ED and 10 stroke units in the Rhone-Alpes and Bourgogne area. All adult patients admitted to one of the participating ED for suspected ischemic stroke less than or equal to 4 hours from symptoms onset were included in the study.~Patients of this group are included after the intervention (training of emergency professionals to acute stroke management) in this ED or stroke units."
3197349|NCT00860119|Experimental|Oral tablet|Reference treatment
3197350|NCT00860132||2|a group of consecutive hip fracture patients admitted to a dedicated comprehensive orthogeriatric ward and a group of similar patients admitted to an orthopedic ward and later on transferred to geriatric rehab center
3197351|NCT00860145|Experimental|radiosurgery|Radiosurgical treatment of the medial temporal lobe
3197352|NCT00860145|Active Comparator|temporal lobectomy|Resection of medial temporal lobe
3197353|NCT00860184||50-79% stenosis|Subjects with 50-79% stenosis of the carotid artery Absence of prior ischemic neurological symptoms Age 18 or older
2512513|NCT02813863|Experimental|SP2086 and Metformin|In the first day,the subject takes metformin 1000mg once,and from Day 4 to Day 7 they need to take SP2086 100mg everyday. In Day 8,they will be given SP2086 100mg and metformin 1000mg.
2512591|NCT02813343|Experimental|Immediate Treatment Group|The Immediate Treatment group will receive access to the study intervention - BlueStar app, immediately after consenting for a total duration of 6 months.
2512594|NCT02813343|Other|Delayed Treatment Group|The Delayed Treatment group will receive access to the study intervention - BlueStar app, 3 months after consenting for a total duration of 3 months.
3197354|NCT00860197|No Intervention|Control|No coffee
3197355|NCT00860197|Experimental|Group 1|Fully torrefied coffee
2511441|NCT02821143|Other|Control group|Every patient identified as belonging to a palliative care after the inclusion criteria will receive Usual palliative care
2511486|NCT02820701|No Intervention|Control|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. After the ultrasound assessment, the control group will wait in another room for approximately 30 minutes.
2511493|NCT02820701|Experimental|Treatment|All participants will receive an initial palpatory assessment of the sacral base asymmetry and then an initial ultrasound evaluation of sacral base asymmetry. Participants in the Treatment group will receive OMT to address sacral base asymmetry after the initial ultrasound assessment.
2511530|NCT02820311|Experimental|TD-4208 175 mcg|double-blind
2511534|NCT02820311|Experimental|TD-4208 700 mcg|double-blind
2511537|NCT02820311|Placebo Comparator|Placebo for TD-4208|double-blind
2511539|NCT02820311|Active Comparator|Moxifloxacin 400 mg|open-label
3197356|NCT00860197|Experimental|Group 2|Partially torrefied coffee
3197357|NCT00860223|Experimental|1|Digoxin alone
2511799|NCT02818543|Experimental|Cohort 1|LYC-30937 25 mg single oral dose
2511804|NCT02818543|Experimental|Cohort 2|LYC-30937 100 mg single oral dose
2511825|NCT02818322|Experimental|telemedical monitoring ( T)|Home care by a nurse trained in the management of diabetic foot lesions with transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion every week
2511829|NCT02818322|Active Comparator|classic monitoring|Home care by a nurse trained in the management of diabetic foot lesions without transmission diabetologist doctor a photograph and a full description of the diabetic foot lesion
2511894|NCT02818062||Endophthalmitis|The diagnosis of endophthalmitis was made on the basis of clinical features including pain, decreased visual acuity (VA), diffuse bulbar conjunctival hyperaemia, chemosis, inflammation of the anterior segment and posterior segment inflammation (all patients had vitreous infiltration diagnosed by biomicroscopy or ophthalmic ultrasound).
2511896|NCT02818062||Cataract (Control)|Controls were patients who underwent cataract surgery.
2511964|NCT02817607|Experimental|Surgery|
2512036|NCT02817256|Active Comparator|Group A, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Ergocalciferol 300,000 IM - Every 3 months Oral Vitamin B12 tablets daily (500mcg) Calcium /D Tab 600-200mg Centrium -1 Tablet Daily~Mineral:~Iron preparation - Daily (47mg)"
2512046|NCT02817256|Active Comparator|Group B, 'vitamins and minerals'|"Ergocalciferol , Vitamin B12, Calcium /D , Iron or Centrium.~Centrium - 1 Tablet daily Ergocalciferol 50000 IU once every two weeks Vitamin B12 1000mcg IM every three months Calcium /D Tab 600-200mg~Minerals:~Iron preparation - Daily (47mg)"
3197358|NCT00860223|Experimental|2|Digoxin plus neratinib
3197359|NCT00860236|Active Comparator|Psycoeducation/counseling|
3197360|NCT00860236|Active Comparator|Cognitive behavioural therapy|
2512186|NCT02816034|Experimental|Experimental Explicit|Cannabis user performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
2512188|NCT02816034|Active Comparator|Control Explicit|Healthy subject performs visuo-motor rotation tasks informed of an explicit strategy to maximise performance
2512189|NCT02816034|Experimental|Experimental Implicit|Cannabis user performs visuo-motor rotation tasks without being informed of the explicit strategy
2512192|NCT02816034|Active Comparator|Control Implicit|Healthy subject performs visuo-motor rotation tasks without being informed of the explicit strategy
2512237|NCT02815657|Active Comparator|SP2086 and Valsartan|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from A stage to B stage.
2512238|NCT02815657|Active Comparator|Valsartan and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12.There were 6 days washout period between the two stages.The whole study needs 31 days.This group patient was given treatment from B stage to A stage.
2512296|NCT02815488|Experimental|CHF6297 Active|
2512297|NCT02815488|Placebo Comparator|Placebo|
2512360|NCT02814851|Experimental|Non valvular cardiac surgery|The study will be conducted at the CHU Brugmann Hospital, with collaboration between cardiac surgery and cardiology wards. Subjects referred for non valvular cardiac surgery will be prospectively included during the first 6 months following the onset of the protocol.
2512387|NCT02814500|Experimental|A group|Amlodipine and Rosuvastatin, DP-R212
2512393|NCT02814500|Experimental|B group|DP-R212, Amlodipine and Rosuvastatin
2512517|NCT02813954|Experimental|Study Group|Neonates with respiratory distress
2512521|NCT02813954|No Intervention|Control Group|Healthy Infants
3197361|NCT00860275|Active Comparator|BMS-708163 / Ketoconazole|
3197362|NCT00860275|Active Comparator|BMS-708163 / Fluconazole|
2512769|NCT02812095|Experimental|The refeeding group|Refeeding is initiated when 120mL/kg/day of enteral feed reaches or stoma loss exceeds more than 40ml/kg/day after operation.
3197363|NCT00860288|Experimental|Vildagliptin Dose 1|
3197364|NCT00860288|Experimental|Vildagliptin Dose 2|
3197365|NCT00860288|Placebo Comparator|Placebo|
2511516|NCT02820545||Sociological interview|Patients will take a sociological interview with a sociologist during their hospital stay
2511519|NCT02820545||Self-administrated questionnaire|Patients will take a self-administrated questionnaire at the end of their hospital stay and one week after they left hospital
2511564|NCT02820142||Bacteremia with Sepsis group|Patients aged 20 years or older with a diagnosis of bacteremia will be eligible for inclusion in the study.
2511597|NCT02819778|Other|Control group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
2511599|NCT02819778|Other|interventional group|"The study protocol corresponds to a diagnostic prospective, controlled, multicenter study using a randomized stepped wedge cluster design, in which pediatric patients (aged ≤ 16 years) presenting to the pediatric emergency room for mTBI with a GCS score of 15 will benefit from usual care (conventional management arm) in the control group, and from S100B management in the interventional group"
2511687|NCT02819492||Routine colonoscopy Cohort|Patients receiving routine colonoscopy at the study site
2511741|NCT02819167|Other|neurologic and neuropsychological evaluation|
2511763|NCT02818829||Cohort|Collection of biological samples
2511839|NCT02818257|Experimental|Strip A (wet)|Six strips of Strip A are applied on skin wetted with two different buffers (3 strips each)
2511841|NCT02818257|Experimental|Strip A (dry)|Six strips of Strip A are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
2511849|NCT02818257|Experimental|Strip B (wet)|Six strips of Strip B are applied on skin wetted with two different buffers (3 strips each)
2511854|NCT02818257|Experimental|Strip B (dry)|Six strips of Strip B are applied on skin that is dry (3 strips) and wetted with buffer (3 strips)
2511858|NCT02818257|Experimental|Strip C (wet)|Six strips of Strip C are applied on skin wetted with two different buffers (3 strips each)
2511860|NCT02818257|Experimental|Strip C (dry)|Six strips of Strip C are applied on skin that is either dry (3 strips) or wetted with buffer (3 strips)
2511910|NCT02817815|Active Comparator|Group 1|Volunteers
2511911|NCT02817815|Experimental|Group 2|Paroxysmal AF patients in sinus rhythm the day of inclusion
2511914|NCT02817815|Experimental|Group 3|Paroxysmal AF patients in atrial fibrillation the day of inclusion
2511916|NCT02817815|Experimental|Group 4|Persistent AF patients in sinus rhythm the day of inclusion
2511918|NCT02817815|Experimental|Group 5|Persistent AF patients in atrial fibrillation the day of inclusion
2511989|NCT02817321|Experimental|Single-injection TPVB +continuous TPVB|Single-injection of TPVB is given preoperatively followed with continuous infusion+ postoperative IPCA.
2511993|NCT02817321|Active Comparator|IPCA|postoperative IPCA is given alone
2512021|NCT02816970|Experimental|A Test|Test drug (Gliptus) 1 tablet contains 50 mg vildagliptin
2512022|NCT02816970|Active Comparator|B Reference|Reference drug (Galvus) 1 tablet contains 50 mg vildagliptin
2512081|NCT02816827|Experimental|E-AG-01|550 mg of 2 capsules having AG-01 and AG-07 will be administered orally twice daily for one day.
2512082|NCT02816827|Experimental|E-AG-02|550 mg of 2 capsules having AG-05 and AG-06 will be administered orally twice daily for one day.
2512083|NCT02816827|Experimental|E-AG-03|550 mg of 2 capsules having AG-01 and AG-05 will be administered orally twice daily for one day.
2512084|NCT02816827|Experimental|E-AG-04|550 mg of 2 capsules having AG-06 and AG-07 will be administered orally twice daily for one day.
2512120|NCT02816463|Experimental|Ambu AuraGain (Group A)|Laryngeal mask Ambu AuraGain will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
2512126|NCT02816463|Active Comparator|LMA Supreme (Group S)|Laryngeal mask Supreme will be used, and oropharyngeal leak pressure (OLP) after insertion will be recorded as the primary outcome measure
2512177|NCT02816320||Inpatient stays|All patients who were hospitalized in participating hospitals in France during the study period were eligible for inclusion.
2512235|NCT02815904|Experimental|Yakson touch and Kinesthetic stimulation|"Yakson touch (YT) The therapist will relax arms and shoulder muscles for 1 minute and will do deep breathing to accumulate Ki energy on the palms. The Therapist will apply Yakson on the neonate.~Kinesthetic stimulation (KS) For giving kinesthetic stimulation the neonate will be placed in supine position. There will be six passive flexion and extension movements. Each of the movement will each last for approximately 10 seconds. The movements will be performed in the following order -right arm, left arm, right leg, left leg, both legs simultaneously"
2512236|NCT02815904|Active Comparator|Conventional Handling and KMC|"Conventional Handling (CH) The neonates in control group will receive developmental positioning(positioning of preterm infants for optimal physiological development) for 20 minutes per hour for 5 days.~Kangaroo mother care (KMC) Holding the neonate skin to skin by mother for one hour a day"
2512276|NCT02815371|Experimental|Needle Acupuncture|Sterile, disposable needles were inserted into specific acupoints until Deqi sensation was elicited. The needles were retained for 25 minutes before and after embryo transfer.
2512278|NCT02815371|Experimental|Laser Acupuncture|Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
2512280|NCT02815371|Sham Comparator|Sham Laser Acupuncture|However, support staff uninvolved in the design of the trial or analysis of the data disarmed the machine, such that no laser irradiation was emitted. This system created an illusion for both the patient and the acupuncturist, and allowed for a truly double blinded control group.
2512281|NCT02815371|No Intervention|No Treatment|This control group was not exposed to any additional physical contact or acupuncture related protocol. They were only exposed to dim light and calming music before and after embryo transfer, mimicking the natural waiting room and procedure room setting for all patients undergoing embryo transfer.
2511494|NCT02820623|Experimental|Self-report|Therapists randomized to this condition will complete a brief self-report measure, the Therapy Process Observational Coding System for Child Psychotherapy Strategies Scale-Self Report version (TPOCS-SR) for each of the recorded clinical encounters with enrolled youth. The TPOCS-SR will be a self-report version of the Therapy Process Observational Coding System for Child Psychotherapy-Strategies Scale (TPOCS-S) and will be created in collaboration with the instrument developer (McLeod). In this condition, the investigators will (a) provide an operational definition for each item on the TPOCS-SR (e.g., cognitive education: teaches client the cognitive model (e.g., thoughts influence behavior)/identifies how the cognitive model applies to a specific aspects of the client's life), and (b) provide therapists with a 30-minute training session that includes sample vignettes of particular behaviors and information about how those vignettes should be rated.
2511498|NCT02820623|Experimental|Chart Stimulated Recall|"Therapists randomized to this condition will be asked to bring the charts of three enrolled youth to the chart-stimulated recall interview. A trained interviewer will ask the therapists how well they recall the encounter (rating of memory quality) followed by an open-ended question (Talk me through your last session with your client. Tell me what you did.). While the therapists are speaking, the interviewer will note any elements that represent a prescribed CBT strategy. The interviewer will go through a list of cognitive-behavioral strategies based upon the TPOCS-S and probe to determine if the therapists completed any of the strategies. Follow-up questions will be used to explore to what degree an element was used and how skillfully and responsively the strategies were used."
2511500|NCT02820623|Experimental|Behavioral Rehearsal|"Therapists randomized to this condition will be asked to engage in role-plays demonstrating the CBT strategies used with the three enrolled youth. The investigators will provide therapists with a list of the TPOCS-S CBT strategies and ask them to identify the CBT strategies used in their recorded encounter. The investigators will randomly select one of the strategies they report for each role-play. The investigators will then tell them, Please role-play how you used this strategy in session with your client, with the trained actor in front of you. Later, an independent rater will rate therapists' adherence and skill based on established scoring criteria."
2511603|NCT02819934|Experimental|Arm1|experimental group
2511666|NCT02819596|Experimental|Savolitinib|600 mg of Savolitinib monotherapy will administered once a day until study completion or withdrawal
2511667|NCT02819596|Experimental|MEDI4736|1500 mg MEDI4736 will be administered every 4 weeks until study completion or withdrawal
2511669|NCT02819596|Experimental|Savolitinib and MEDI4736|Savolitinib and MEDI4736 will be administered at the Recommended Phase 2 dose ascertained in the phase Ib.
2511671|NCT02819596|Experimental|Tremelimumab and MEDI4736|Subjects will receive 75 mg of Tremelimumab and 1500 mg medi4736 every 4 weeks for the first four cycles, then 750 mg MEDI4736 every 4 weeks until study completion or withdrawal.
2511726|NCT02819219|Placebo Comparator|Placebo|Participants will receive a flavored water placebo supplement. Part of the supplemental intervention. This, and all groups, simultaneously took part in the exercise intervention.
2511727|NCT02819219|Experimental|ElevATP|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts). Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
2511732|NCT02819219|Experimental|ElevATP w/Caffeine|Participants will receive the flavored water placebo with an additional 150mg of ElevATP (blend of ancient peat and apple extracts), a 180 mg blend of caffeine (caffeine anhydrous, pterostilbene-bound caffeine), and 38mg B vitamins. Part of the supplemental intervention.This, and all groups, simultaneously took part in the exercise intervention.
2511795|NCT02818738|Experimental|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
2511796|NCT02818738|Placebo Comparator|Placebo|matching verum
2511840|NCT02818335|Experimental|LY3023414 Reference Fasted|Single oral dose of LY3023414 (Reference) on day one fasting.
2511848|NCT02818335|Experimental|LY3023414 Test Fasted|Single oral dose of LY3023414 (Test) on day one fasting.
2511852|NCT02818335|Experimental|LY3023414 Test Fed|Single oral dose of LY3023414 (Test) on day one after a meal.
2511959|NCT02817503|Experimental|Standard BP control|"SBP within 140 - <150 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2511963|NCT02817503|Active Comparator|Moderate BP control|"SBP within 130 - <140 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2511968|NCT02817503|Active Comparator|Intensive BP control|"SBP <130 mmHg. For all participants, enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target. For those who can't tolerate enalapril-folic acid well, other types of antihypertensive agents may be used as alternative choices.~If the target BP level is not achieved during the Titration or Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol."
2512056|NCT02817113|Experimental|NC-6004, Cetuximab and 5-FU|Cetuximab will be administered before the start of chemotherapy at a loading dose of 400 mg/m2 given, followed by a subsequent weekly doses of 250 mg/m2; NC-6004 will be administered on Day 1 every 3 weeks, and 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
2512135|NCT02816580|Experimental|elderly subjects|
2512306|NCT02815462|Experimental|Intervention|FAM-FACE-SG risk score + decision making algorithm
2512314|NCT02815462|Active Comparator|Control|Usual Care
2512772|NCT02812095|No Intervention|The control group|
2511566|NCT02820129|Experimental|Wallet Card Group|"The intervention arm is comprised of:~Patients from the TAPER study who receive a medication wallet card with their medications and medical conditions listed."
2511568|NCT02820129|Placebo Comparator|Control Group|"Standard of care as well as wait list control. These participants will receive a reminder wallet card which states, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
2511610|NCT02819739|Experimental|normoxia|During cardiopulmonary bypass inspired fraction of oxygen is adapted to maintained a oxygen arterial pressure below 150 mmHg.
2511615|NCT02819739|Active Comparator|hyperoxia|During cardiopulmonary bypass inspired fraction of oxygen is set to 100 %.
2511681|NCT02819505|Experimental|Beta-alanine supplementation|Participants will be supplemented with 6.4g·d-1 β-alanine (CarnoSyn™, NAI, USA). The β-alanine dosing regimen will consist of two 800 mg tablets four times per day at 3-4 hour intervals or the same regimen for placebo tablets. The use of multiple small doses throughout the day has been used in numerous studies using β-alanine in solutions or gelatine capsules (Hoffman et al., 2008; Sale et al., 2011; Saunders et al., 2012; Sale et al., 2012; Tobias et al., 2013) in order to circumvent potential symptoms of paraesthesia (see box xii for possible risks and discomforts). Overall increases have been shown to be between 40% and 80% depending upon dose (between 3.2 and 6.4 g·d-1) and duration of administration (between 4 and 10 weeks) (Sale et al., 2012).
2511683|NCT02819505|Placebo Comparator|Placebo supplementation|Participants will be supplemented with 6.4g·d-1 placebo (maltodextrin; NAI, USA).
2511731|NCT02819141|No Intervention|Control|These patient will get usual care - sedation administered by ICU Nurses as deemed necessary by primary care team
2511735|NCT02819141|Experimental|Dexmedetomidine|These patients will receive a basal intravenous infusion of medication (Dexmedetomidine) and have access to self-administered sedation medication (Dexmedetomidine) for anxiety.
3197366|NCT00860288|Active Comparator|Sitagliptin|
2511866|NCT02818127|Active Comparator|normal coronary artery|coronary angiography will be performed by transfemoral or transradial route.
2511868|NCT02818127|Active Comparator|coronary slow flow|coronary angiography will be performed by transfemoral or transradial route.
2511869|NCT02818127|Active Comparator|coronary artery ectasia|coronary angiography will be performed by transfemoral or transradial route.
2511871|NCT02818127|Active Comparator|non-obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2511873|NCT02818127|Active Comparator|obstructive coronary artery disease|coronary angiography will be performed by transfemoral or transradial route.
2511906|NCT02817724|Active Comparator|m-Health group|BENECA System: The m-health group will use the BENECA app for 8 weeks.
2511908|NCT02817724|Experimental|Integral Group|BENECA System and Supervised-occupational therapy program: The integral groups will use the BENECA app and they will receive a face-to-face occupational therapy rehabilitation program for 8 weeks.
2511958|NCT02817568||Aggressive Periodontitis (case)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention.(Drawing Blood)
2511960|NCT02817568||Healthy (Control)|Single intervention has been performed for each subject. Peripheral blood sample was obtained in conjunction with clinical measurements in this intervention. (Drawing Blood)
2512042|NCT02817217|Other|SP2086 and Valsartan|
2512089|NCT02816749|Experimental|Maggot debridement therapy(MDT)|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
2512095|NCT02816749|Active Comparator|Conventional Dressing Therapy(CDT)|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
2512262|NCT02816203|Experimental|Primary Hemostatic Intra-Uterine suction cup|Patients who present primary postpartum hemorrhage requiring administration of Nalador and the suction cup placed in the uterine cavity
2512301|NCT02815358|Experimental|Segmental Stabilization Group|Patients receiving segmental stabilization exercises.
2512308|NCT02815358|Active Comparator|Control Group|Patients receiving home exercises.
2512347|NCT02815007|Experimental|Chidamide with EGFR-TKI|"Chidamide: Per Os, 30mg (5mg*6), twice a week, time interval between 2 medications should be ≥3 days, medicine taken 30 minutes after breakfast.~EGFR-TKI:~Taken according to the instruction book"
3197367|NCT00860301|Experimental|Acupuncture group|
3197368|NCT00860301|No Intervention|Control group|Infants come to the clinic six times, are left alone for five minutes with the acupuncture nurse who hold its hand and talks to it.
2512599|NCT02813590||Patients with liver cirrhosis and with SBP|
2512601|NCT02813590||Patients with liver cirrhosis and without SBP|
2512656|NCT02813044|Experimental|TIVA group|Anesthesia is maintained with propofol during surgery
2512658|NCT02813044|Active Comparator|inhalation anesthesia group|Anesthesia is maintained with sevoflurane during surgery
2512690|NCT02812719|Active Comparator|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
2512691|NCT02812719|Experimental|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
3197369|NCT00860327||Newborns|Newborns with hypoplastic left heart syndrome who are receiving a right ventricle to pulmonary artery shunt as first stage palliation.
2512823|NCT02811770||children with HSN|
3197370|NCT00860327||Infants|Infants who are undergoing complete repair for tetralogy of Fallot or similar pathology.
3197371|NCT00860340|Experimental|1|Study patient will take 100mg tablet of Spironolactone
3197372|NCT00860353|Experimental|1|
3197373|NCT00860353|Placebo Comparator|2|
3197374|NCT00860366|Experimental|Uric Acid|Single intravenous infusion of 1 gram of Uric Acid dissolved in vehicle (500 ml of 0'1% Lithium Carbonate and 5% Mannitol).
3197375|NCT00860366|Placebo Comparator|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
2511567|NCT02820103|Active Comparator|Information leaflet (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge. The information from two leaflets: 1. 'Using GTN', produced by the hospital and 'Angina' produced by the British Heart Foundation, published 08/04/2014 and available at https://www.bhf.org.uk/publications/heart-conditions/angina . The information explains the symptoms of angina and heart attack and advises what to do in the event of experiencing these symptoms. This information will be presented in written text format on screen.
2511570|NCT02820103|Experimental|Text+Visual BCT-based intervention (Intervention Group 1)|Participants in the visual intervention group will receive the control condition specified above PLUS a specifically developed Text+Visual BCT-based intervention, comprising the 12 BCTs identified earlier in a Systematic Review and expert consensus study. The BCTs are Problem solving; Action planning; Social support (practical); Social support (emotional); Instruction on how to perform the behaviour; Information about health consequences; Salience of health consequences; Prompts/cues; Credible source; Pro's & Con's; Comparative imagining of future outcomes; Mental rehearsal of successful performance
2511572|NCT02820103|Experimental|Text-only BCT-based intervention (Intervention Group 2)|Information leaflet (usual care) plus text-only BCT-based intervention (Intervention group 2) Participants in the text-only BCT-based intervention group will receive the control condition specified above plus a text-only BCT-based intervention. This was developed in the same way as the text+visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen instead.
2511633|NCT02819674||early-onset hypertension|early-onset hypertension patients recruited in Chinese multiple centers
2511714|NCT02819466||volunteers|Healthy volunteers over the age of 18 years employed by Amiens University Hospital 3D echography
2511768|NCT02818608|Active Comparator|Functional electrical stimulation (FES)|Chronic stroke patients submitted to functional electrical stimulation (FES).
2511769|NCT02818608|Experimental|Combination of transcranial direct current stimulation and FES|Chronic stroke patients submitted to transcranial direct current stimulation (tDCS) and functional and to functional electrical stimulation (FES).
2511862|NCT02818452|Experimental|Oatmeal containing beta-glucan|27 g oatmeal
2511865|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 1|27.72g oatmeal
2511867|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 2|28.43g oatmeal
2511870|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 3|29.86g oatmeal
2511872|NCT02818452|Experimental|Oatmeal containing beta-glucan + OatWell28XF Intervention 4|32.72g oatmeal
2511874|NCT02818452|Placebo Comparator|Hot Cereal - Cream of Rice|20g oatmeal
2511927|NCT02817750|Experimental|zolpidem hemitartarate (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
2511930|NCT02817750|Experimental|zolpidem hemitartarate (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
3164067|NCT00492765|Placebo Comparator|2|Interferon beta-1a and Placebo
3164068|NCT00492778|Experimental|Arm I (brachytherapy, radiation therapy)|Patients undergo EBRT to the pelvis daily on days 1-5 for 5 weeks. After completion of EBRT, patients undergo intracavitary low-dose rate or high-dose rate brachytherapy or low-dose rate interstitial brachytherapy.
3164069|NCT00492778|Experimental|Arm II (brachytherapy, radiation therapy, cisplatin)|Patients undergo EBRT as in Arm I and receive cisplatin IV over 1-2 hours on days 1, 8, 15, 22, and 29. Patients then undergo brachytherapy as in Arm I.
2512028|NCT02817191|Experimental|Hylo-Comod|The patients used Hylo-Comod eye drop after phaco+IOL in this group.
2512033|NCT02817191|Experimental|Tears Naturale Forte|The patients used Tears Naturale Forte eye drop after phaco+IOL in this group.
2512093|NCT02816788|Experimental|Equine Assisted Therapy (EAT)|Equine Assisted Therapy (EAT) treatment group
2512178|NCT02816385|Active Comparator|Antegrade Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
2512182|NCT02816385|Experimental|Retrograde Cardioplegia|Coronary artery bypass grafting (CABG) surgery in patients with a normal left ventricular ejection fraction (FEVG)
2512241|NCT02815839|Experimental|Cohort 1|2.5-mg SHR4640 or placebo
2512244|NCT02815839|Experimental|Cohort 2|5-mg SHR4640 or placebo
2512253|NCT02815839|Experimental|Cohort 3|7.5-mg SHR4640 or placebo
2512257|NCT02815839|Experimental|Cohort 4|10-mg SHR4640 or placebo
2512259|NCT02815839|Experimental|Cohort 5|20-mg SHR4640 or placebo
2512287|NCT02815319|Active Comparator|Standard of care|Physician's treatment recommendation for dexamethasone premedication
2512288|NCT02815319|Active Comparator|8mg PO dexamethasone|8mg PO dexamethasone premedication
3164070|NCT00492791||Endoscopic Capsule|Patient enrolled for performing an endoscopic capsule
3164071|NCT00492804|Other|Neurectomy|
2512573|NCT02813356||naloxegol|patients exposed to naloxegol
2512575|NCT02813356||non-PAMORA|patients exposed to non-peripherally acting mu-opioid antagonist
2512644|NCT02813213|Active Comparator|Standard skin graft|"This group is comprised of patients' wound halves that will receive meshed (1:3) split thickness skin graft (0.3-0.5mm thickness). This half will be covered with a standard tie over dressing. The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day."
2512648|NCT02813122||with x-ray|patients underwent bariatric surgery and underwent x-ray
2512650|NCT02813122||without x-ray|patients underwent bariatric surgery and did not underwent x-ray
2512667|NCT02812836|Other|Manometry|All patients will be investigated by anorectal manometry and after the procedure with balloon expulsion test as previously described.
2512776|NCT02812251|Experimental|Part 1: Cohort 6|Participants will receive 60 mg JNJ-61393215 or placebo.
2512777|NCT02812251|Experimental|Part 1: Cohort 7|Participants will receive 90 mg JNJ-61393215 or placebo.
3164072|NCT00492804|Other|Nerve preservation|
3164073|NCT00492817|Experimental|Single Session Stereotactic Body Radiotherapy (SBRT)|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
2511578|NCT02819999|Experimental|Rovalpituzumab Tesirine following Cisplatin, Etoposide|Cisplatin 80 mg/m2 and Etoposide 100 mg/m2 IV infusion followed by Rovalpituzumab Tesirine 0.3 mg/kg IV infusion
2511685|NCT02819531|Active Comparator|Rotational atherectomy|RA protocol: After IVUS protocol, patients who are randomized to RA will undergo coronary wiring of the target lesion and subsequent advancement of the RA burr. The RA system is performed using standard technique under intravenous infusion of heparin. The atherectomy burr size will be determined by the operator.
2511690|NCT02819531|Active Comparator|Orbital atherectomy|OAS protocol: After IVUS protocol, patients who are randomized to OAS will undergo coronary wiring of the target lesion and subsequent advancement of the OAS according to the manufacturer's guidelines.
2511692|NCT02819531|Active Comparator|Scoring balloon system|SBS protocol: After IVUS protocol, patients who are randomized to SBS will undergo coronary wiring of the target lesion and balloon inflation with SBS performed by standard technique under intravenous infusion of heparin. SBS will be used according to the manufacturer's guidelines.
2511723|NCT02819076||Painless Children|30 children
2511724|NCT02819076||Painful Children|70 children
2511817|NCT02818491|Placebo Comparator|Control group|Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls
2511819|NCT02818491|Active Comparator|Dex 1|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls
2511821|NCT02818491|Active Comparator|Dex 2|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls
2511826|NCT02818491|Active Comparator|Dex 3|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls
2511828|NCT02818491|Active Comparator|Dex 4|Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls
2511921|NCT02817880|Experimental|rTMS (repetitive transcranial magnetic stimulation)|rTMS (repetitive transcranial magnetic stimulation)
2511925|NCT02817880|Experimental|tDCS (transcranial direct-current stimulation)|tDCS (transcranial direct-current stimulation)
2511928|NCT02817880|Experimental|tsDCS (transcutaneous spinal Direct Current Stimulation)|tsDCS (transcutaneous spinal Direct Current Stimulation)
2511943|NCT02817425|Active Comparator|SOX Sequential S-1 Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 6 months and sequential S-1 for 6 months"
2511946|NCT02817425|Active Comparator|SOX Group|"Patients received chemotherapy with oxaliplatin+ S-1  for 12 months"
2511949|NCT02817425|Experimental|TEGAFOX Sequential S-1|"Patients received chemotherapy with TEGAFOX (oxaliplatin+ Tegafur +Leucovorin Calcium)  for 6 months and sequential S-1 for 6 months"
2512017|NCT02817230||Patients|Patients referred to the out-patient clinic with LDL levels >4.9 mmol/l
2512019|NCT02817230||Controls|Matched normocholesterolemic control subjects
2512067|NCT02816944|Experimental|EUS-guided laser ablation for refractory neoplasms|
2512103|NCT02816554|Experimental|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1.0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12days
2512115|NCT02816554|Experimental|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2512130|NCT02816554|Experimental|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2512134|NCT02816554|Active Comparator|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Composition: 1,0 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
2512162|NCT02816112|Active Comparator|Ciprofloxacin|Oral tablet taken twice a day at home starting 5 days after chemotherapy for 14 days for every cycle of TC
2512165|NCT02816112|Active Comparator|G-CSF|Daily injection at home for the number of days as chosen by the treating physician
2512207|NCT02815917|Experimental|Cohort 1a: Lorazepam; 1b: Perphenazine|"Up to 5 healthy volunteers will participate in a double-blind, placebo controlled serial imaging cohort 1a. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. On one scan day the patient will receive an IV injection of normal saline (placebo) prior to the FTP brain scan, on the other scan day the patient will receive an IV injection of lorazepam prior to the planned FTP injection scan. The type of injection (placebo versus lorazepam) will be double-blinded to the patient and the injecting nuclear medicine Authorized User. Up to 5 subjects will participate in Cohort 1b where subjects will undergo two FTP PET/CT with and without perphenazine.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2512209|NCT02815917|Experimental|Cohort 2: Healthy Volunteer Test/Retest|"Up to 10 healthy volunteers will participate in a serial imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2512210|NCT02815917|Experimental|Cohort 3: Arterial sampling|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo one dynamic [18F]FTP PET/CT brain scan. Patients will have an arterial line placed for blood draws during the scan. This group will be used to determine the arterial blood input and FTP parent to metabolite ratio curves for FTP for a cocaine-dependent patient population for comparison with previously collected data in healthy normal volunteers.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2512211|NCT02815917|Experimental|Cohort 4: Cocaine-dependent Test/Retest|"Up to 5 cocaine-dependent males who are voluntarily seeking treatment for cocaine dependence will participate in this imaging cohort. Each subject will undergo two dynamic [18F]FTP PET/CT brain scans on two separate days. This group will be used to test the variability of the [18F]FTP uptake measures in cocaine-dependent patients when scans are done following the consistent procedures with no other interventions.~Subjects in all cohorts are required to have a structural brain MRI performed within 1 year of study enrollment. If the subject has not had a brain MRI that is deemed acceptable for use for this study, they will be asked to undergo a research brain MRI after they have consented for this study."
2511581|NCT02820012|Other|Scoliosis|"Preoperative data: demographics, clinical diagnosis and etiology, relevant prior medical treatment, x-rays, and patient questionnaire will be completed in the database.~The self-questionnaire (SAQ parents, patients, SR22) provided will assess the state of health and disability of patients.~After surgery: the clinical questionnaire will be completed by the investigator to collect the parameters of the operation and the patient's clinical data Immediate Postoperative visit: J1 to S1: radiological and clinical examinations .~Visit Month 1 to M3, M 12, M 24 , M 36 , M 60 : During these visits, clinical and radiological examinations will be realized."
2511642|NCT02819648|Experimental|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France); administered 30 minutes before endodontic treatment
2511645|NCT02819648|Placebo Comparator|Control|Milk tablet administered 30 minutes before endodontic treatment
2511693|NCT02819336|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with middle frequency (30 Hz) of electrical stimulation~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
2511701|NCT02819336|Sham Comparator|Park sham (PS) group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions within 21 days)~CV2, CV3, CV4, CV6, and bilateral points of SP11, SP6 (8 acupoints in total)~20 minutes duration with undelivered electrostimulation of middle frequency (30 Hz)~Conventional treatments (drugs, traditional herbal medications, rehabilitation therapies, or acupuncture therapies without electrostimulation for stroke and urinary incontinence / electroacupuncture therapies other than the acupoints (CV2, CV3, CV4, CV6, SP1 and SP6) for stroke and urinary incontinence) are permitted."
3197376|NCT00860392|Experimental|1|Biomarker evaluation
3197377|NCT00860418|Active Comparator|1|Standard asthma education delivered during 2 home visits by a nurse.
3197378|NCT00860418|Experimental|2 PAAL|PAAL
2511875|NCT02818101|No Intervention|Control group|No hypnosis session before the coronary angiography
2511876|NCT02818101|Experimental|Hypnotised group|Hypnosis session before the coronary angiography
3197379|NCT00860431|No Intervention|1|Standard-of-care (conservative treatment)
2512039|NCT02817139|Active Comparator|active tDCS over primary motor cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left primary motor cortex.
2512048|NCT02817139|Experimental|active tDCS over prefrontal cortex|Duration: 20 minutes; Intensity: 2 mA; Placement: left prefrontal cortex.
2512052|NCT02817139|Placebo Comparator|sham tDCS over primary motor cortex|Duration: 20 minutes; The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham; Placement: left primary motor cortex.
2512097|NCT02816684|Active Comparator|SET-C|Social Effectiveness Therapy for Children (SET-C; Beidel et al., 2000) includes social skills training, peer generalization experiences, and in vivo exposure.
2512111|NCT02816684|Experimental|Pegasys-VR|SET-C SST and individual exposure sessions are the same as the active comparator. Peer generalization sessions are replaced by a virtual environment, known as Pegasys School. children engage with artificially intelligent avatars throughout the school.
2512179|NCT02816333||Type B aortic dissection|Patients with Type B aortic dissection requiring TEVAR
2512219|NCT02815956|Experimental|percutaneous tibial nerve stimulation (ST)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The protocol of stimulation is the same, that the one performed for fecal incontinence."
2512221|NCT02815956|Placebo Comparator|placebo (P)|"Stimulation the day before surgery (x1), 30 minutes Stimulation the day of surgery, before surgery (at least 2 hours before surgery) and after surgery.~Stimulation every day (x3) after surgery until gastrointestinal functions recovery.~The device delivers ineffective impulses."
2512275|NCT02815618||Infants delivered by elective caesarean|Infants to be measured immediately after birth and on their second day of life.
2512277|NCT02815618||Infants on mechanical ventilation|Infants to be measured while changing ventilator settings to normalize arterial pCO2.
2512279|NCT02815618||Infants on ventilatory support|Infants to be measured for 24 hours continuously to assess user-friendliness and loss of signal.
2512300|NCT02815228|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2512400|NCT02814617|Experimental|Cordyceps sinensis mycelium culture extract|Cordyceps sinensis mycelium culture extract 1.68 g
2512406|NCT02814617|Placebo Comparator|Placebo|Placebo
2512457|NCT02814214||ECG+IEGM|Surface ECG and intracardiac electrogram recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy settings
2512556|NCT02813967|Experimental|chemoradiotherapy|Radiotherapy 54 Gy was administered in 1.8 Gy fractions 5 times weekly. S-1 70mg/m2 was administered on days 1-14 and 29-42
2512560|NCT02813967|Active Comparator|Radiotherapy 60 Gy|Radiotherapy 60 Gy was administered in 2Gy fractions 5 times weekly.
2512580|NCT02813304|Experimental|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
2512585|NCT02813460|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations B C A D F E on day 1.
3197380|NCT00860431|Experimental|2|AST-120 6g/day (3 times a day)
3197381|NCT00860444|Active Comparator|1|Participants will take part in the basic educational and counseling program through their community health care center.
2511630|NCT02819661|Active Comparator|women BMI<30 POD4|Pregnant healthy women with BMI<30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
2511636|NCT02819661|Active Comparator|women BMI≥30 POD 4|Pregnant healthy women with BMI≥30 receiving spinal anesthesia with intrathecal morphine during elective caesarean section will be monitored by SOMNOTOUCH RESP post operative day 4 after elective cesarean section.
3197382|NCT00860444|Experimental|2|Participants will take part in the comprehensive educational and counseling program through their community health care center.
3197383|NCT00860483|No Intervention|observational|This is an observational study. no intervention occurs in subjects. their performance in a laparoscopic trainer is observed and correlated with brain activity
2511775|NCT02818764||Delirium|"Subjects undergoing elective total joint arthroplasty determined to have delirium by post operative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
2511778|NCT02818764||Non-delirium|"Subjects undergoing elective total joint arthroplasty determined not to have delirium by post oeprative 3D-CAM.~Data collected on intraoperative cerebral blood flow and oxygen extraction fraction.~CSF collected for biomarkers. Blood colelcted for biomarkers."
2511879|NCT02818010||exposed = patient practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire)~A patient is defined as practicing physical activity (exposed) when he meets one of the conditions following:~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
2511881|NCT02818010||unexposed = patient not practicing physical activity|"The practice of physical activity is measured by the GPAQ 2 questionnaire(Global Physical Activity Questionnaire)~A patient is defined as unexposed if he does not fulfill any of these conditions :~At least 20 minutes of vigorous-intensity physical activity for at least 3 days per week~At least 30 minutes of moderate-intensity physical activity or walking daily for at least 5 days per week~At least 5 days of walking and moderate- or vigorous-intensity physical activity achieving at least 600 MET-minutes per week.~The Metabolic equivalents (MET) is the ratio of metabolic rate during activity physical and metabolic rate at rest. One MET corresponds to the energy spent by a person sitting still and is equivalent to a consumption of 1 kcal / kg / hour. It is estimated that a moderately active person has an energetic cost four times higher, and a very active person eight times higher than the energy cost of a person sitting without move."
3197384|NCT00860496|Other|1|Treatment Arm 1 will receive one single dose of CP-690,550 on Day 1, Tacrolimus on Days 1-8, and one single dose of CP-690,550 on Day 8.
3197385|NCT00860496|Other|2|Treatment Arm 2 will receive one single dose of CP-690,550 on Day 1, Cyclosporine on Days 1-6, and one single dose of CP-690,550 on Day 6.
2512010|NCT02817295||elderly|patients underwent bariatric surgery and are above 65 years old
2512012|NCT02817295||non-elderly|patients underwent bariatric surgery and are below 65 years old
2512031|NCT02817022|Other|developmentally supportive care|enrolled neonates will be provided routine supportive care as per existing NICU protocols. This will be carried out in the initial 6 months (0-180 days) of study commencement. This group will serve as control group (group A). During subsequent 6 months (181-360 days) of the study period, enrolled neonates fulfilling the inclusion criteria will be provided routine supportive care and the components of developmentally supportive care(DSC). DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment. This group will be designated as group B
2512090|NCT02816801|Experimental|Intervention|Access to Butler-Program 2.0
2512101|NCT02816801|No Intervention|Waitlist|
2512176|NCT02816411|Experimental|Protein|Milk protein isolate supplementation: orally, 20g of protein immediately post-exercise and then 20g every 3h on 3 occasions (+3, +6, +9), on the exercise day. The remaining 8 days, 20g daily with breakfast.
2512183|NCT02816411|Active Comparator|Placebo|Placebo administration: orally 500 ml, immediately post-exercise as well as at +3, +6 and +9 hours, on the exercise day. The remaining 8 days, 500 ml daily with breakfast.
2512230|NCT02815813|Experimental|PeerFIT|PeerFIT is a group-based lifestyle intervention enhanced by mobile health technology and social media designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
2512234|NCT02815813|Active Comparator|BEAT|BEAT involves basic education in fitness and nutrition supported by a wearable activity tracking device designed to achieve clinically significant improvements in weight loss and cardiorespiratory fitness in young adults with serious mental illness.
2512303|NCT02815527||Fresubin Intensive|Adult critically ill non-septic ventilated patients admitted to the intensive care unit with an expected intensive care stay of four days or more.
2512349|NCT02814994|Experimental|tidal volume guided by respiratory system compliance|effects of tidal volume guided by respiratory system compliance on mortality in patients suffering from ARDS
2512359|NCT02814994|Experimental|low tidal volume|Ventilated patients with low tidal volume
2512429|NCT02814552|Other|High Blood Pressure Consented|Participants will have the following performed: medical history and blood pressure levels will be collected, and blood samples. Then using the HTN PRA App recommendation regarding standard of care medication dosing will be adjusted for optimal blood pressure control.
3197386|NCT00860509|Placebo Comparator|Low Phytosterol Diet|Diet with 100 mg of daily phytosterols
3197387|NCT00860509|Active Comparator|High Phytosterol Diet|Diet with 600 mg of daily phytosterols
3197388|NCT00860522|Experimental|Phase I|Three patients will be enrolled at dose Level 1. If the patient does not completed the three infusion of JVRS-100 during cycle 1 for reason other than toxicity, another patient will be accrued at the same dose level.
2511631|NCT02819869|Experimental|Taking both statin and metformin Group|The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.
2511635|NCT02819869|No Intervention|Non- taking both statin and metformin Group|Non- taking both statin and metformin.
2511812|NCT02818504|Experimental|Repeatability and reproducibility study|"Monitoring of system (Wize MIrror) measurements with changes in environmental conditions (fasting state, light, temperature)"
2511813|NCT02818504|Experimental|Validation study|"Longitudinal monitoring of cardiometabolic risk factors through an user---friendly, unobtrusive, personalized system for lifestyle self---management (the Wize Mirror)"
2511814|NCT02818166|Experimental|Endoaortic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and endoaortic balloon clamp
2511815|NCT02818166|Active Comparator|Transthoracic Clamp|Right mini-thoracotomy mitral valve surgery with retrograde perfusion and transthoracic clamp.
2511861|NCT02818140|Active Comparator|Ropivacaine TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml of ropivacaine 0.75%
2511863|NCT02818140|Placebo Comparator|Placebo TQL block|Unilateral single shot ultrasound-guided TQL block with 30 ml saline 0.9%
2511923|NCT02817737||CT|Measured with computed tomography
2511926|NCT02817737||plain Radiography|Measured with plain Radiography
2511952|NCT02817490||Patients with hypermobility type Ehlers-Danlos Syndrome|Patients with hypermobility type Ehlers-Danlos Syndrome participating to one out of the three patient education sessions included in the study.
2511954|NCT02817490||Caregivers|Caregivers participating to one out of the three patient education sessions included in the study.
2512027|NCT02817282|Other|Hand hygiene implementation strategy|The implementation strategy will be tested in a stepped wedge cluster randomized trial which is based on a random sequential roll-out of the CHANGE implementation strategy to all participating NHs (n=20) for comparison. All groups (hence all NHs) start with the control situation (no CHANGE implementation activities) at the beginning of the study. At each time point, a new group of five NHs crosses over from the control situation to the implementation situation. Each group will start the implementation phase of 4 months at a different time point, directly after one of the measurements periods (Point of Time (PT) 0, PT1, PT2, PT3, PT4, PT5). The time point a group crosses over is randomized (over the groups).
2512094|NCT02816866|Experimental|empowered primary care model|"patients receive an individualized prescription for survivorship care prepared by a cancer survivor specialist to be implemented by the primary care doctor"
2512099|NCT02816866|Experimental|specialty survivor clinic|patient attends a specialty survivor clinic at Yale for survivorship care
2512175|NCT02816372|Experimental|Tidal volume 4 ml/kg Predicted Body Weight (PBW)|
2512226|NCT02815878|Experimental|Group 1: Intervention with Disability|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
2512229|NCT02815878|Active Comparator|Group 2: Intervention without Disability|Participants without a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older receive Enhance Wellness for 6 months and complete pre and post outcome assessments.
2512231|NCT02815878|No Intervention|Group 3: No intervention|Participants with a diagnosis of multiple sclerosis, spinal cord injury, muscular dystrophy, or post-polio syndrome aged 45 or older complete pre and post outcome assessments.
2512282|NCT02815566|Experimental|Immediate switch|Open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for 96 weeks
2512283|NCT02815566|Active Comparator|delayed switch|Open-label tenofovir (300mg)-emtricitabine (200mg) tablet once daily by mouth for 48 weeks followed by open label tenofovir-alafenamide (25/10mg)-emtricitabine (200mg) tablet once daily by mouth for an additional 48 weeks
2512327|NCT02815150|Experimental|Treatment group|Preoperative oral carbohydrate drink: patients drink 5% glucose solution 250ml 2-3 hours before surgery.
2512329|NCT02815150|No Intervention|Control group|Patients undergo 6-8 hours of preoperative fasting.
2512352|NCT02814903||Planned cardiac surgery. POAF occurence or not|The ALDO-POAF study is an observational, 1-center and prospective pilot study that will enroll patients undergoing CABG ± aortic valve replacement. Patients who had emergency CABG, need for concomitant mitral surgery, left ventricular ejection fraction (LVEF) < 50%, a history of AF or other atrial arrhythmia, unstable angina or heart failure, cardiogenic shock, atrioventricular block, hypothyroidism/hyperthyroidism, previous heart surgery, and off-pump or on-pump beating CABG will be excluded.
2512446|NCT02814318||IV Vancomycin|GBS positive laboring women who are allergic to penicillin and clindamycin and are treated using IV vancomycin.
2512449|NCT02814318||IV Penicillin|GBS positive laboring women who are not allergic to penicillin and are treated using IV penicillin.
2512509|NCT02814006|Experimental|every other day|participants will visualize educational video with timed intercourse as recommended by NICE and ASRM
2512511|NCT02814006|Experimental|fertile window|participants will visualize educational video with timed intercourse as recommended by well-know evidence of better conception rates when using this strategy
2511786|NCT02818660|Experimental|Synacthen|The patient get Synacthen to stimulate the adrenals to produce cortisol
2511856|NCT02818426|Experimental|UCPVax|"UCPVax is a therapeutic cancer vaccine composed of two peptides called UCP2 and UCP4 derived from telomerase combined with Montanide ISA 51 VG as adjuvant.~The two peptides UCP2 and UCP4 will be emulsified in Montanide ISA 51 and injected subcutaneously in separate sites (one site per peptide), at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination every 8 weeks for 12 months."
2511897|NCT02817802||Magmaris|Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
2511966|NCT02817620|Experimental|Spirulysat®|Food supplement packaged in 10 ml vials called Spirulysat®. This product is a phycocyanin concentrated fresh spirulina water extract (Spirulina Platensis). 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
2511969|NCT02817620|Placebo Comparator|Placebo|Placebo with the same characteristics, appearance, packaging and composition as the active formula except for active ingredient (Spirulina) replaced by a classical blue food colorant used to colour desserts. 2 vials daily to consume in the morning, just before the breakfast, in a glass of water, during 12 weeks (from V1 to V3 visit).
2512043|NCT02817165|Experimental|Probiotic (BioK+)|Children will receive 10-40 billion CFUs/day of Bio-K+ (Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2), with dose based on their weight. The product will be administered as a strawberry flavored tub of milk.
2512051|NCT02817165|Placebo Comparator|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
2512110|NCT02816658|Active Comparator|Laparoscopic Surgery|Laparoscopic Inguinal Hernia Repair through a Transabdominal, Preperitoneal Approach
2512118|NCT02816658|Active Comparator|Robotic Surgery|Robotic Inguinal Hernia Repair
2512168|NCT02816229|Experimental|Insertion of endobronchial valve|Patients in this group will have one or more EBV inserted into the relevant lung regions to manage the haemoptysis via flexible bronchoscopy.
2512172|NCT02816229|No Intervention|Best care|Patients will receive best medical care.
2512353|NCT02814942||Heart Failure receiving CRT|Heart failure patients with QRS > 120ms receiving CRT
2512398|NCT02814591||Cohort 1: Controls|40 volunteers free from bone disease. No family histroy of osteogenesis imperfecta (OI). No history of non-accidental fracture. No history of osteoarthritis (OA) or clinical manifestations of disease. No clinical features of OI, OA or osteoporosis (OP). Normal haemoatology and biochemical blood screen. Controls will be gender and age matched (within five years) to the disease cohort patients. Children and adults both required.
2512403|NCT02814591||Cohort 2: Patients with ostegenesis imperfecta (OI).|40 patients with OI. Patients must have been clinically diagnosed with OI. Participants will be identified form the Royal National Orthopaedic Hospital, Metabolic Unit database. Bone mineral density (BMD) confirmed with DXA.
2512405|NCT02814591||Cohort 3: Patients with osteoarthritis (OA)|40 patients with OA. Patients must have been clinically diagnosed with OA. Participants will be identified from the Royal National Orthopaedic Hospital, Metabolic Unit database.
2512410|NCT02814591||Cohort 4: Patients with osteoporosis (OI)|40 patients with OI receiving treatment with bisphosphonates. Patients must have been clinically diagnosed with OI and bisphosphonates prescribed as a course of treatment. 20 Adults and 20 Children. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed.
2512413|NCT02814591||Cohort 5: Patients with osteoporosis (OP) (2 treatment groups)|Patients must have been clinically diagnosed with OP. The first group will have been prescribed with bisphosphonate anti-resorptive treatment; the second with anabolic agents. Where possible participants will be identified from the Royal National Orthopaedic Hospital (RNOH), Metabolic Unit Database; if not from the RNOH then diagnosis will be otherwise confirmed. Bone mineral density (BMD) will be confirmed with DXA. Where possible measurements will be acquired prior to the start of treatment and then up to 4 follow up visits at flexible time points to allow scheduling to coincide with hospital appointments. Minimum time between vistis should be 2 months.
2512416|NCT02814591||Cohort 6: Patients with rickets and osteomalacia|10-15 participants with rickets and 10-15 participants with osteomalacia. Patients must have been clinically diagnosed with rickets/osteomalacia. Blood tests for 25-hydroxyvitamin D should be less than or equal to 25 nmol/L. Once participants are on treatment further measurements will be made 6 months afterwards. Participants for rickets and osteomalacia groups will be recruited to give a total of 10 complete sets of data per group.
2512419|NCT02814591||Cohort 7: 5 patients with suspected bone infection.|Participants will have been diagnosed at RNOH with a suspected bone infection. Participants will be scanned around the localised area of suspected infection. Participants may have 1 or 2 vists; the latter to take place after all infection has cleared up. This is not subject to a fixed time frame.
2512461|NCT02814123|Active Comparator|Rapid Insulin-alone closed-loop delivery|Rapid Insulin will be delivered by subcutaneous infusion. Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine)
2512467|NCT02814123|Experimental|Rapid Insulin-plus-pramlintide closed-loop delivery|"Rapid insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Rapid acting Insulin (aspart, lispro, glulisine) Drug: Pramlintide"
2512472|NCT02814123|Experimental|Regular Insulin-plus-pramlintide closed-loop delivery|"Regular insulin and pramlintide will be delivered by subcutaneous infusion using a fixed ratio (6 µg pramlintide/unit insulin).~Interventions: 24-hour inpatient intervention Drug: Regular Insulin (humulin R) Drug: Pramlintide"
2512551|NCT02813824|Active Comparator|Aspirin300|Acetylsalicylic acid 300 mg tablet by mouth, daily dose during 4 years
2512552|NCT02813824|Placebo Comparator|Placebo300|Placebo (like Acetylsalicylic acid 300 mg) tablet by mouth, daily dose during 4 years
2512553|NCT02813824|Active Comparator|Aspirin100|Acetylsalicylic acid 100 mg tablet by mouth, daily dose during 4 years
2512554|NCT02813824|Placebo Comparator|Placebo100|Placebo (like Acetylsalicylic acid 100 mg) tablet by mouth, daily dose during 4 years
2511728|NCT02819206|Other|Uveitis|Patient with a prescription of a microbiologic diagnostic of uveitis
2511780|NCT02818842||Pregnant Women|"Medical and personal data will be collected for all the pregnant women who want to participate.~The source of data are :~Primary Health Insurance Fund data~Prenatal Diagnostic Center of Toulouse University Hospital data~Mother and child protection data collection~Medicalisation Program of Information Systems data"
2511853|NCT02818400|Experimental|Composite tissue allotransplantation|
2511899|NCT02817958|Experimental|A-Adjuvant Chemotherapy TIP|Lymphadenectomy (+/- sentinel node) + adjuvant chemotherapy TIP modified bilateral lymphadenectomy 4 cycles every 21 days
2511903|NCT02817958|Experimental|B-Neoadjuvant Chemotherapy TIP|fine needle biopsy or sentinel node + neoadjuvant chemotherapy TIP followed by a lymphadenectomy modified bilateral lymphadenectomy 4 cycles every 21 days
2511981|NCT02817399|Active Comparator|Neuro-muscular electrical stimulation|Active exercises & Neuro-muscular electrical stimulation in a stationary position (lying and/or sitting).
2511987|NCT02817399|Experimental|Functional electrical stimulation|Active exercises & Functional electrical stimulation while walking.
2512026|NCT02817061|Experimental|NIR brain stimulation|"An Omnilux device will be used to put NIR light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
2512029|NCT02817061|Sham Comparator|Sham|"An Omnilux Device will be used at a safe wavelength not associated with photobiomodulation, putting sham light on the head and forehead of the subject age 18-25 or 65-85. The device is a low risk device as determined by the IRB. Thirty (30) subjects will receive this light at 6 visits over 16 weeks.~An automated interactive software self-test will be used at baseline and at three subsequent visits to quantify subject cognitive functions."
2512139|NCT02816840|Experimental|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
2512142|NCT02816840|Experimental|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
2512143|NCT02816840|No Intervention|Computed Tomography|Patients in this arm take radiotherapy positioning with CT.
2512330|NCT02815215|Experimental|Intervention group|Minimally Invasive Carroll's Technique
2512332|NCT02815215|Active Comparator|Control group|Ponseti method
3164074|NCT00492843|Experimental|A|Intravenous infusion of either 6mg Bondronat on three consecutive days
3164075|NCT00492843|Active Comparator|B|Intravenous infusion of 6mg Bondronat on one day
2512600|NCT02813564|Experimental|Training group|This group of children will receive the software based intervention program (CAVINS) and will train at home during the training phase.
2512602|NCT02813564|No Intervention|Control group|This group of children will play video-games-as-usual and return in about 3 weeks for their next assessment appointment.
2512607|NCT02813564|Experimental|fMRI-training group|"This sub-group of children from the Training group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and train on CAVINS (the intervention) during the training phase."
2512610|NCT02813564|No Intervention|fMRI-Control group|"This sub-group of children from the Control group will carry out two of the tasks in the fMRI scanner during the baseline appointment. They will then go home and play video-games-as-usual until their next assessment appointment (after about 3 weeks)."
2512737|NCT02812303||Population Health Coordinator Support|"8 practices received the support of central population health coordinators (PHCs). PHCs utilized a population health management (PHM) information technology (IT) tool and performed administrative tasks including appointment scheduling, ordering overdue laboratory testing, chart reviews, and obtaining outside tests/labs. In addition, PHCs regularly met with physicians to review those patients who required clinical intervention to develop an action plan.~The network did not have sufficient resources to implement a PHC in all of the 18 network practices. So PHCs were allocated by responses from the practice leader, baseline quality scores, size of the practice, nature of the practice (health center vs not), and location of the practice. These decisions were made in a way that sought to equitably distribute available PHC resources within the practice network as a way to get network buy-in and maximize the impact of the program, both for practices with and without PHCs."
2512738|NCT02812303||No Population Health Coordinator Support|Ten practices without PHC support were provided training on how to use the PHM IT tool. The staff in these practices remained primarily responsible for managing administrative tasks.
2512780|NCT02811939|Experimental|Active THC and Placebo Pregnenolone|
2512782|NCT02811939|Experimental|Active THC and Active Pregnenolone|
2512784|NCT02811939|Experimental|Placebo THC and Active Pregnenolone|
2512786|NCT02811939|Placebo Comparator|Placebo THC and Placebo Pregnenolone|
3164076|NCT00492895|Other|A|one arm only. Crossover study
3164077|NCT00492908|Active Comparator|Titanium Nitride Oxide Coated Stent|Stent
3164078|NCT00492908|Active Comparator|Zotarohlimus Eluting Stent|Stent
3164079|NCT00492934|Active Comparator|1|Daily injections with a small dose of gonadotrophins from day 2 of the cycle
3164080|NCT00492934|No Intervention|2|No daily injections with hormones
3164081|NCT00492960|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3164082|NCT00492960|Experimental|Larazotide acetate 4 mg|larazotide acetate 4 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3164083|NCT00492960|Experimental|Larazotide acetate 8 mg|larazotide acetate 8 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3164084|NCT00492960|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
3164085|NCT00492986|Experimental|Arm 1|
3164086|NCT00492999|Experimental|Group 1|Patients receive hepatic arterial infusion (HAI) therapy comprising floxuridine and dexamethasone continuously on days 1-14. Patients also receive oxaliplatin IV over 2 hours and irinotecan hydrochloride IV over 30 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2511764|NCT02818634|Active Comparator|Muscle-sparing|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were passed with blunt dissection. Muscle fibers were dissected parallel to their positioning.
2511765|NCT02818634|Active Comparator|Muscle-cutting|Following skin incision with No.15 blade; all layers including the subcutaneous fat, muscle fascia and muscles covering the cartilage were cut with Monopolar electrocautery at (25 watts).
2511816|NCT02818478|Other|RA; at home first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
2511818|NCT02818478|Other|RA; outpatient clinic first|Patients in this arm (10 patients with rheumatoid arthirtis, RA) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
2511820|NCT02818478|Other|AxSpa; at home first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures from home via their own computer or tablet; subsequently these patients will fill in patient reported outcome measures at the outpatient clinic
2511824|NCT02818478|Other|AxSpa; outpatient clinic first|Patients in this arm (10 patients with axial spondyloarthritis, AxSpa) will be randomised to initially fill in patient reported outcome measures at the outpatient clinic; subsequently these patients will fill in patient reported outcome measures from home via their own computer or tablet
2511886|NCT02818088|Experimental|Cognitive Training|Cognitive Training - n Back.
2511929|NCT02817685||1|Chronic Hepatitis B patient
2511931|NCT02817685||2|Chronic Hepatitis B patient
2511932|NCT02817685||3|cirrhotic patient
2511933|NCT02817685||4|cirrhotic patient
2511934|NCT02817685||5|ultrasound-difficult patient
2511935|NCT02817685||6|ultrasound-difficult patient
2511997|NCT02817360|Experimental|Intensive therapy|RAS-antagonist and beta-blocker up-to maximal dosages as permitted and tolerated and following national guidelines.
2512003|NCT02817360|Other|Conventional therapy|No RAS-antagonist and beta-blocker or at stable dose as per study entrance. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase.
2512057|NCT02816892||Rupture group|Rupture was defined by direct visualisation of the discontinuity of the aortic wall by computed tomography, sonography, intraoperative findings or at autopsy with detection of blood in the pleural, pericardial or abdominal cavity.
2512059|NCT02816892||Covert rupture group|Covert rupture was defined as an intramural haematoma without detection of free blood in the body cavities.
2512062|NCT02816892||Acute dissection group|Acute dissection was defined when blood separating the layers of the aortic media was newly diagnosed.
2512064|NCT02816892||Chronic dissection group|Chronic dissection was defined as the absence of any visible propagation of a known dissection compared to preexisting examinations.
2512066|NCT02816892||Ectatic aneurysm group|Ectatic aneurysm was defined as a permanent localised dilatation of the aorta with a diameter of at least 50% greater than normal
2512123|NCT02816606||Standard Reconstruction Technique|ACL reconstruction using hamstring autograft Using 30-degree arthroscope Using rigid femoral tunnel reamer (Rigid Reamers)
2512131|NCT02816606||Alternative Reconstruction Group|ACL reconstruction using hamstring autograft Using 30-degree and 70-degree arthroscopes Using flexible femoral tunnel reamer (Flexible Reamers)
2512206|NCT02816268|Other|Conventional Pulmonary vein isolation|Conventional pulmonary vein isolation was gained by using an irrigated tip ablation catheter
2512208|NCT02816268|Other|Contact force pulmonary vein isolation|Contact force was meassured by using the SMART-Touch ablation catheter (Biosense-Webster®)
2512363|NCT02815176||Central serous chorioretinopathy|De novo eligible CSC patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2512367|NCT02815176||Polypoidal choroidal vasculopathy|De novo eligible PCV patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2512370|NCT02815176||Epiretinal membrane|Idiopathic ERM patients will be allocated in this group. Blood sampling, fluorescein angiography, indocyanine green angiography will be performed within a week after initial diagnosis.
2512415|NCT02814409|Active Comparator|Alteplase - standard care|Alteplase 0.9 mg/kg with 10% of the total dose administered as an initial intravenous bolus and remaining 90% of the total dose administered as an intravenous infusion over 1 hour (maximum dose 90mg).
2512421|NCT02814409|Experimental|Tenecteplase|Tenecteplase 0.25mg/kg administered as a single rapid intravenous bolus (maximum dose 25mg).
2512484|NCT02814136|Active Comparator|WACA|wide area circular ablation
2512487|NCT02814136|Active Comparator|EWACA|extra-wide area circular ablation
2512526|NCT02813759|Experimental|Sucralose|14 mg sucralose (Zero K sucralose powder, IANSA®) an 200 mL of water
2512533|NCT02813759|Placebo Comparator|Water|200 mL of water
2512597|NCT02813499||CARE Rule|Evaluation of the clinical suspicion of myocardial infarction and calculation of CARE rule.
2512703|NCT02812745||patients|"patients presenting an indication for general anaesthesia during elective cardiac surgery and being monitored for sedation depth~recording of cardiac output~other parameters"
2512757|NCT02812251|Experimental|Part 1: Cohort 1|Participants will receive 1 milligram (mg) JNJ-61393215 or placebo.
2512765|NCT02812251|Experimental|Part 1: Cohort 2|Participants will receive 5 mg JNJ-61393215 or placebo.
2512768|NCT02812251|Experimental|Part 1: Cohort 3|Participants will receive 15 mg JNJ-61393215 or placebo.
2512773|NCT02812251|Experimental|Part 1: Cohort 4|Participants will receive 30 mg JNJ-61393215 or placebo.
2512775|NCT02812251|Experimental|Part 1: Cohort 5|Participants will receive 45 mg JNJ-61393215 or placebo.
2511794|NCT02818751|No Intervention|Healthy Controls|Healthy adolescents will receive fMRI scans at the same time points, which will provide assessments of the stability of neurophysiologic measures and will be used to adjust and interpret comparisons within the patients (i.e., whether patient values are changing toward or away from those of healthy adolescents).
2511838|NCT02818348|Experimental|DRV cohort|Darunavir/Cobicistat 800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
2511843|NCT02818348|Experimental|ETR cohort|Etravirine 400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
2511892|NCT02817854||Patients with acute diverticulitis|Patients admitted in emergency setting for acute diverticulitis
2511945|NCT02817477|Experimental|IN Ketamine|A single administration of 1 mg/kg ketamine hydrochloride delivered in an intranasal route using an atomizer
2511948|NCT02817477|Active Comparator|IM Morphine|A single administration of 0.15 mg/kg intramuscular morphine
2511951|NCT02817477|Active Comparator|IV Morphine|A single administration of 0.1 mg/kg slow intravascular bolus of morphine.
2512070|NCT02817204|Experimental|Aerobic Exercise group|Cardio Pulmonary Exercise Test(CPET) Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
2512072|NCT02817204|Other|Health Education Group|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol Cardio Pulmonary Exercise Test(CPET) No Cycle ergometer exercise
2512092|NCT02816528||Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
2512098|NCT02816528||Nothing|Not Trained Physicians
2512157|NCT02816437|Experimental|OpenBiome FMT retention enema|OpenBiome Fecal Microbiota Transplantation retention enema, one rectal application.
2512187|NCT02815995|Experimental|Adipocytic Tumors Group|"Adipocytic Tumors Group consists of well-diff/de-differentiated, pleomorphic and myxoid LPS.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2512190|NCT02815995|Experimental|Vascular Tumors Group|"Vascular Tumors Group consists of leiomyosarcomas, angiosarcomas, epithelioid hemangioendotheliomas, and hemangiopericytomas.~Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2512191|NCT02815995|Experimental|Undifferentiated Pleomorphic Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by Durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2512195|NCT02815995|Experimental|Synovial Sarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2512198|NCT02815995|Experimental|Osteosarcoma Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
2512199|NCT02815995|Experimental|Other Sarcomas Group|"Age group ≥12 and <18: Dosages of study drugs to be determined (TBD).~Age group ≥ 18: Durvalumab 1500 mg and Tremelimumab 75 mg every 4 weeks for 4 cycles followed by durvalumab 1500 mg every 4 weeks for up to 8 additional cycles.~Combination of both agents administered every 4 weeks for a maximum of 4 doses, after which Durvalumab continues as a single agent every 4 weeks till progression or unacceptable toxicity for a maximum of 8 additional doses."
3197389|NCT00860522|Experimental|Phase II|3 patients will be enrolled at a given dose level. If one of these patients experiences a dose limiting toxicity, an additional 3 patients will be enrolled at the given dose level. If the 1st 2 subjects enrolled and treated at a given dose experience dose limiting toxicities, no additional subjects will be enrolled at that dose. Dose escalation may proceed if < 2/6 patients at a given dose level experience a LDT. If ≥ 2/6 patients experience a DLT at a given dose level, the next lower dose level will be considered the RP2D. If a patient does not complete the 3 infusions of JVRS-100 during Cycle 1 for reasons other than toxicity, another patient will be accrued at the same dose level. Once the RP2D is established, the cohort will be expanded to a total of 12 patients.
3197390|NCT00860561||1|Postmenopausal women with locally advanced or metastatic breast cancer who have failed 2 or more prior hormone therapies, or were intolerant to prior hormone therapy and have no endocrine therapeutic options.
3197391|NCT00860600|Experimental|1. PG2 Treatment: 5 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 5 days/week, 2 to 4 weeks
3197392|NCT00860600|Experimental|2. PG2 Treatment: 3 days/week|Powder for Injection, 500 mg PG2/500 ml normal saline, 3 days/week, 2 to 4 weeks
2512396|NCT02814383||ELBW Infants|This study seeks to collect data on premature ELBW infants (less than or equal to 2.2 lbs) at high risk of developing brain injury.
3197393|NCT00860613|Experimental|1|women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. They received a specific diet using carbohydrate counting (40-45% of carbohydrates)and a moderate energy restriction. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
2511822|NCT02818179|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every week during the brachytherapy treatment for 5 procedures
3197394|NCT00860613|Experimental|2|Women in this group received usual medical treatment and counseling from a nutritionist and diabetes educator. The diet they received was based on carbohydrate counting (40-45% of carbohydrates), but recommended only low-moderate glycemic index foods. Weight gain, adequacy of diet, results of the self glucose monitoring, and ketonuria were evaluated every two weeks. They also received education on diabetes, diet and glucose monitoring.
2511907|NCT02817698|Experimental|Drug of dependence|There is only one arm to the study. All subjects will receive their drug of dependence in this study. Nicotine dependent subjects will receive tobacco cigarettes, cannabis dependent subjects will receive cannabis cigarettes, and cocaine dependent subjects will receive IV cocaine.
3197395|NCT00860613|No Intervention|3|women in this group received the current hospital treatment. They did not receive any intervention except for the self glucose monitoring that they did every two weeks. Weight gain and the results of the self glucose monitoring, were evaluated every two weeks.
3197396|NCT00860626|Experimental|1|At the twelfth week of interferon α treatment, HBV DNA is detectable(>1000 copies/ml), or HBeAg is still positive. And nucleoside analogue is added for 12 weeks.
3197397|NCT00860626|Active Comparator|2|At the twelfth week of interferon α treatment, HBV DNA is detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
3197398|NCT00860626|Active Comparator|3|At the twelfth week of interferon α treatment, HBV DNA is undetectable (<1000 copies/ml), or HBeAg is negative. And interferon is continued for another 9 months.
2512153|NCT02816060|Experimental|neural tensionner exercise|This group will receive a specific tensionner nerve exercise to provide mechanical stress across the median nerve. This technique have two positions, start and end. It consists on going from one to the other position constantly, controlling the speed of the technique to be constant. In the start position, the subject will be supine lying on a couch with the following parameters: contralateral cervical side bending, shoulder depression, shoulder abduction and external rotation to 90°, elbow flexion to 90º, and forearm supination. In the final position, the therapist will perform full elbow extension while maintaining all the joints previously situated as described above until the patients feel tension, then return to the start position.
2512155|NCT02816060|Placebo Comparator|sham neural tensionner exercise|The control group will receive a sham technique (ST) with minimal mechanical stress across the median nerve. Patients will be placed in neutral cervical spine position with no shoulder depression, shoulder abduction and external rotation to 45°, 45° of elbow extension, and forearm pronation.. This technique will be passively repeated from elbow flexion to extension in the same way than the NTE group
2512193|NCT02816021|Experimental|Arm A: Metastatic Melanoma - PD-1 Naive|"Thirty-six participants with metastatic melanoma that are PD-1 naïve enrolled in treatment Arm A.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
2512197|NCT02816021|Experimental|Arm B: Metastatic Melanoma - Post PD-1 Progression|"Thirty-five participants with metastatic melanoma that have progressed on PD-1 directed therapy enrolled in treatment Arm B.~Treatment consists of 3-week cycles and continues until disease progression. Oral Azacitidine administered by mouth daily for 15 days (Days 1-15) of every cycle. Pembrolizumab administered by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days."
2512246|NCT02815722|Active Comparator|SP2086 and Simvastatin|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from A stage to B stage.
2512251|NCT02815722|Active Comparator|Simvastatin and SP2086|All subject were randomized into two groups,and the drugs will be administered according to the AB and BA sequences,all subjects must completed the two stages(A and B).The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.There were 5 days washout period between the two stages.The whole study needs 27 days.This group patient was given treatment from B stage to A stage.
2512291|NCT02815410|Other|Levetiracetam|Newly diagnosed histologically proven supratentorial glioblastoma patients received levetiracetam during and after their CCRT
2512343|NCT02815111||Control Group|Intensivists will proceed with analgesia utilizing conventional opioid based pain order sets.
2512354|NCT02815111||Study Group|The investigators plan to study an analgesic regimen of Ketamine and lidocaine as infusions with Neurontin and Acetaminophen delivered orally for postoperative analgesia and the subsequent effect on ventilator days and ICU stay.
2512478|NCT02814331||symptomatic partial epilepsy|whose brain MRI is abnormal multimodal high-resolution EEG-NIRS
2512480|NCT02814331||not symptomatic partial epilepsy|whose brain MRI is normal multimodal high-resolution EEG-NIRS
2512535|NCT02813837|Experimental|single arm|Experimental: CD19 CART cell.The target dose range administered in this study is 1x10e5-1x10e7 CART-19 cells/kg.
2512617|NCT02813408||Participants with Prostate Cancer (abiraterone acetate)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive abiraterone acetate at the discretion of his treating physician.
2512618|NCT02813408||Participants with Prostate Cancer (enzalutamide)|Participants with metastatic castration resistant prostate cancer (mCRPC) will receive enzalutamide at the discretion of his treating physician.
2512683|NCT02812927|Other|Standard infusion line|The standard insulin infusion system consisted in regular human insulin administration through a six-stopcock manifold connected to the distal line of a multilumen central venous catheter by 150 cm tubing. Insulin was systematically infused by syringe pump on the patient proximal port of the manifold. Carrier was infused via pump through the manifold. All others medicines were infused through the other five stopcocks.
2512778|NCT02812251|Experimental|Part 1: Cohort 8|Participants will receive 120 mg JNJ-61393215 or placebo.
2511900|NCT02817971|Experimental|Enhanced feedback|"Monthly written feedback incorporating goal setting, and action planning delivered by a senior clinical coordinator for selected pneumonia indicators~Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
2511905|NCT02817971|Active Comparator|Standard feedback|"Two-monthly written feedback on multiple quality of paediatric care indicators~Clinical network promoting clinical leadership linked to mentorship and peer to peer support~Improved use of health information on service delivery"
2511991|NCT02817451|Experimental|Study Group A|HIV exposed and infected infants
2511994|NCT02817451|Experimental|Study Group B|HIV exposed and uninfected infants
2512068|NCT02817048|Active Comparator|Tubeless|Interventions: VATS without chest tube placement
2512071|NCT02817048|Active Comparator|Chest tube|VATS with chest tube placement
2512085|NCT02816541|Experimental|Pelvis Retroverted|Pilates-based therapeutic exercises performed with a posterior pelvic tilt
2512086|NCT02816541|Experimental|Pelvis in Neutral Position|Pilates-based therapeutic exercises performed with a neutral position of the pelvis
2512087|NCT02816541|Active Comparator|Control Group|Aerobic exercise performed on a treadmill
2512138|NCT02816450|Experimental|HIGH|Increase water intake to 2.5 liters per day for 4 days
2512141|NCT02816450|Experimental|LOW|Decrease water intake to 0.5 liter per day for 4 days
2512250|NCT02816216|Other|End User Iterative Testing - CampAir|To ensure the software and website function as intended, investigators will systematically test each of the seven CampAir modules with target end users. Participants will review one module per week for seven weeks. As part of each module, participants will also complete a daily asthma checklist. Following the review of each module, participants will be prompted to complete measures assessing technology acceptability and usability and product quality. Results will be used to modify and finalize the user interface and navigation to maximize usability.
2512321|NCT02815501||women|"attending the emergency room and/or hospitalised or followed for: Spontaneous and/or repeated miscarriage Foetal death Pre-eclampsia Retroplacental haematoma Post-partum haemorrhage Premature delivery~Blood samples"
2512379|NCT02814968|Experimental|Single arm|Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
2512445|NCT02814357|Placebo Comparator|Control (market standard)|100 g wheat flour (atta)
2512448|NCT02814357|Active Comparator|High fibre 1|81% wheat flour (atta) + 15% chickpea + 4% guar gum
2512450|NCT02814357|Active Comparator|High fibre 2|80% wheat flour (atta) + 15% chickpea + 2% guar gum + 3% barley
2512451|NCT02814357|Active Comparator|High fibre 3|77% wheat flour (atta) + 15% chickpea + 3% guar gum + 5% barley
2512579|NCT02813434|Experimental|Florbetapir|
2512647|NCT02813174|Experimental|Automated online Compassionate Mind Training|
2512728|NCT02812849||Suspected cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
2512731|NCT02812849||Known cardiac sarcoidosis|Cu-64 DOTATATE PET/CT or PET/MRI
2512733|NCT02812849||Other inflammatory cardiac disease|Cu-64 DOTATATE PET/CT or PET/MRI
2512759|NCT02812043|Experimental|Amorolfine|This group of patients will receive only amorolfine nail lacquer to apply on the affected nail and the KOH examination and fungal culture will be performed every month
2512762|NCT02812043|Experimental|Long-pulsed Nd:YAG|This group of patients will receive only the long-pulsed Nd:YAG (Cynergy®, 5 Carlisle Road Westford, MA USA) fluence 35-45 J/Cm2, spot size 4mm for 2 passes each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
2512770|NCT02812043|Experimental|Amorolfine+Long-pulsed Nd:YAG|This group of patients will receive both amorolfine nail lacquer and the long-pulsed Nd:YAG laser treatment each visit with 4-week intervals and the KOH examination and fungal culture will be performed every month
2512807|NCT02811757|Experimental|tenodesis|
2512811|NCT02811757|Active Comparator|tenotomy|
2512878|NCT02811497|Experimental|Azacitidine and Durvalumab|"Azacitidine will be given by mouth at a fixed dose of 300 mg daily for 14 consecutive days of every 28 day cycle for 3 cycles.~Durvalumab will be given intravenously (by vein) at a fixed dose of 1500 mg (over 1 hour) on Day 1 of every 28 day cycle for 12 months or until disease progression."
2512936|NCT02811107||Patients in preoperative area|Patients in preoperative area before surgery or interventional procedure will complete questionnaires on tablet computers
2512963|NCT02810834|Experimental|Walking/Running Program|Walking/running/jogging program; school-based.
2512969|NCT02810834|Experimental|Classroom activity break program|Classroom physical activity break program; school-based.
2512973|NCT02810834|No Intervention|Control|Control/Delayed Intervention
2513007|NCT02810379|Placebo Comparator|written informed consent|participants read the written informed consent documents befor ERCP
2513008|NCT02810379|Experimental|video+written informed consent|participants watch a video about the ERCP and read the written informed consent documents before ERCP
2513043|NCT02810145||TBI with GCS <or= 8|Adult patients admitted to the surgical intensive care unit with traumatic brain injury and a Glasgow coma score less than or equal to 8.
2513100|NCT02809950|Experimental|oral carbohydrate beverage group|
2513104|NCT02809950|Placebo Comparator|control group|
2513180|NCT02809482|Other|Eucaloric Feeding|
2513185|NCT02809482|Other|Overfeeding|
2513212|NCT02808884|Experimental|Circulating tumor DNA assay- First test - Negative result|Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
2513298|NCT02808624|Experimental|Treatment group|this arm will receive L-CARNOSINE PO (each patient will receive 1 tablet daily and each tablet contains 500 mg thus a total of 500 mg per day) together with their chemotherapy wich is oxaliplatin.
2513346|NCT02808195|Experimental|constraint-induced therapy|training of the more affected arm and restraint the less affected arm
2511965|NCT02817529|Experimental|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
2511970|NCT02817529|Active Comparator|RC-Cornet|The RC-Cornet is a device that provides oscillatory positive expiratory pressure (OPEP) therapy for the detachment and removal of pulmonary secretions. Through variable pressure settings and optional aerosolized medication delivery, patients realize maximum efficacy specific to their unique clinical needs.The RC-Cornet uses the patient's full expired air volume to produce pressure and oscillatory vibrations. Participants who will be instructed to inhale and exhale through the PEP device at least ten times daily for up to six months.
2512041|NCT02817178|Other|Additional biological samples|"Additional blood samples will be realized specifically to the study at baseline, at 1 month, at 3 months, and 1 month after surgery (if applicable).~Peripheral Blood Mononuclear Cell (PBMC) and plasma will be collected. Tissue tumor is collected during surgery if applicable."
2512119|NCT02816619|Experimental|APA+|APA + : patients will beneficiate of Personalized Physical Activity coaching program during 3 months (1 hour, twice by week, during 3 months)
2512128|NCT02816619|Other|APA-|APA- : patients will do free practice of physical activity during 3 months.
2512180|NCT02816255|Placebo Comparator|Full Face Mask with same CPAP Pressure|After the two week period all will switch to a full face mask with half using the same CPAP pressure.
2512185|NCT02816255|Active Comparator|Full Face Mask with new Pressure|After the two week period all will switch to a full face mask with half using with a new cpap pressure derived from our formula.
2512225|NCT02815800|Experimental|ETHNODYNE VISIO|Administration 2 times a day of a dietary supplement, as add on therapy, in patients with Parkinson s disease
2512286|NCT02815306|Experimental|Brace goup|The infants who were brace group treated by braces which were designed and made by us.
2512333|NCT02815202|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2512392|NCT02814526|Experimental|Aerobic|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
2512399|NCT02814526|Active Comparator|Stretching/balance/range of motion|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
2512490|NCT02814110|Other|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor Muscle strength Muscular dystrophy
2512519|NCT02813733||Thyroid surgery|All patients who underwent a thyroid procedure in 5 high volume referral centers in France were eligible for inclusion.
3197399|NCT00860639|Active Comparator|gemtuzumab ozogamycin|Initial randomization will be completed upon receipt of karyotype results and will determine the administration of gemtuzumab ozogamycin (MYLOTARG ®) in combination with chemotherapy during the induction course and the first intensive consolidation course.
2512682|NCT02812979|Experimental|Airvo2 with Aerogen Solo|"AIRVOTM2 will be set to deliver air (21% oxygen concentration ) at a rate of 30 L / min at 100 % relative humidity at 37 ° C.~Nebulization of salbutamol will be effected by means of a nebulizer to the vibrating screen (Aerogen® Solo, Aerogen , Galway, Ireland ) which is a nebulizing device for single use, commonly used in invasive and non invasive mechanical ventilation.~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
2512684|NCT02812979|Active Comparator|Mask|"During nebulization in the usual way ( oral facial mask ) , it will be used a pneumatic nebulizer powered by a 6 L / min air flow rate ( usual method ).~Nebulizer will be responsible for a salbutamol solution available in the form of containers of 2.5 ml containing 2.5 mg of salbutamol"
2512686|NCT02812979|Placebo Comparator|arm control Airvo2 without nebulization of salbutamol|control procedure is to be placed under humidified high flow nasal alone
3197400|NCT00860639|No Intervention|without Mylotarg|
3197401|NCT00860652|Experimental|Adjuvant Radiotherapy (RT)|Adjuvant Radiotherapy (64Gy in 32 Fractions to the prostate bed)
3197402|NCT00860652|Experimental|Active Surveillance with Early SalvageRT|Active Surveillance with Early Salvage Radiotherapy
3197403|NCT00860665||1|Observational study on consecutive persons over the age of 55 years presenting for screening colonoscopy
3197404|NCT00860678|Active Comparator|A|Training group
3197405|NCT00860678|Other|B|Controls
3197406|NCT00860691|Active Comparator|ARM I - Open colorectal surgery|Open colorectal surgery
3197407|NCT00860691|Experimental|ARM II - Laparoscopic colorectal surgery|Laparoscopic colorectal surgery
2512978|NCT02810899|Experimental|Dexmedetomidine group|A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.
2512979|NCT02810899|Placebo Comparator|Control group|Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.
2513016|NCT02810275|Experimental|Folinic Acid|Folinic acid group received 5 mg daily during four weeks
2513020|NCT02810275|Placebo Comparator|Placebo|Placebo group received a tablet daily during four weeks
2513102|NCT02810054|Sham Comparator|Control Group (MIST without EMD)|Those participants who will receive the minimally invasive surgical techniques but without application Enamel Matrix Derivative (EMD) .
2513105|NCT02810054|Experimental|Test Group (MIST with EMD)|Those participant who will receive the minimally invasive surgical techniques with the application of Enamel Matrix Derivative (EMD) .
2513373|NCT02807974|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
2511998|NCT02817373|Other|transvaginal ultrasound study|Patients with a well established infertility requiring IVF treatment and who are <40. Cohort will consist of patients going through a fresh day 5 transfer with a planned transfer of a single good quality embryo. Patients will go thorough a Ultrasound scan performed through a vaginal probe on the morning of the embryo transfer.
2512044|NCT02817074|Active Comparator|MIND Diet +Weight loss|3-year intervention of dietary counseling to adhere to the MIND diet plus reduce calorie intake by 250 kcal /day for mild weight loss
2512050|NCT02817074|Placebo Comparator|Usual Diet + Weight Loss|3-year intervention of usual diet + counseling to reduce calorie intake by 250 kcal/day for mild weight loss
2512104|NCT02816645|Experimental|<5 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2512117|NCT02816645|Experimental|Between 5 and 10 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2512124|NCT02816645|Experimental|Between 10 and 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2512132|NCT02816645|Experimental|> 15 years|"160 PD patients divided into four subgroups of 40 patients according to disease duration:~< 5 years~Between 5 and 10 years~Between 10 and 15 years~> 15 years"
2512158|NCT02816086|No Intervention|Standard care|The study participants receives standard care in the ward, this does not include a pharmacist.
2512159|NCT02816086|Experimental|Intervention|Interdisciplinary collaboration structure
3197408|NCT00860691|Other|Control - reference value|Blood samples from healthy volunteers will be obtained at one time point.Peripheral blood samples will be obtained into tubes with no additive (BD Vacutainer System, Plymouth, UK).Samples will be processed to serum. Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA)using specific anti-Fas MoAbs, Human sFas Immunoassay. Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay. Serum concentration of IL - 17 will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using Human IL-17 Immunoassay. . Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube. burst neutrophil production will be determined quantitatively by flow cytometry as described by Rothe using a commercial kit Bursttest Kit.
3197409|NCT00860704|Active Comparator|Ringerlactate lean|fluidtherapy with crystalloids in lean patients
2512302|NCT02815436|Active Comparator|Telephone reminder|subjects in this arm will receive a telephone reminder
2512309|NCT02815436|Active Comparator|SMS reminder|Subjects in this arm will receive a SMS reminder
2512311|NCT02815436|No Intervention|No reminder|usual care, where no additional intervention will be offered
2512364|NCT02814955||referred for paroxysmal atrial fibrillation with fluindione|
2512368|NCT02814955||referred for paroxysmal atrial fibrillation with previscan|
2512372|NCT02814955||referred for paroxysmal atrial fibrillation with apixaban|
2512375|NCT02814955||referred for paroxysmal atrial fibrillation with rivaroxaban|
2512376|NCT02814955||referred for paroxysmal atrial fibrillation with dabigatran|
2512397|NCT02814461|Experimental|Axitinib|Combined axitinib and radiotherapy (fixed strength)
2512462|NCT02814188|Experimental|Carbohydrate Beverage|
2512469|NCT02814188|Placebo Comparator|Placebo Beverage|
2512546|NCT02813928|Experimental|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance.
2512606|NCT02813291|Experimental|Stimulation group (Young Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
2512609|NCT02813291|Experimental|Stimulation group (Elderly Stim)|Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex.
2512612|NCT02813291|Sham Comparator|Sham group (Young Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
2512614|NCT02813291|Sham Comparator|Sham group (Elderly Sham)|Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
2512661|NCT02813031|Experimental|Functional meat products with healthy lipids from olive oil|Healthy people consuming 300g/week of functional meat products with high diglyceride lipid from olive oil
2512665|NCT02813031|Placebo Comparator|Traditional meat products|Healthy people consuming the same amount of traditional meat products
2512676|NCT02812680||Esophageal Cancer Patients - Blood Draw|Look at blood samples to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy in patients with Esophageal Adenocarcinoma.
2512678|NCT02812680||Healthy volunteers - Blood Draw|Comparators for the esophageal cancer group
2512709|NCT02812511|Experimental|Skin biopsy|
3197410|NCT00860704|Active Comparator|Ringerlactate overweight|fluidtherapy with crystalloids in overweight patients
3197411|NCT00860704|Active Comparator|Ringerlactate obese|fluidtherapy with crystalloids in obese patients
2512841|NCT02811692||BAY86-5321|Anti-Vascular Endothelial Growth Factor (VEGF) - naive patients starting intravitreal Aflibercept injection treatment for Neovascular age-related macular degeneration (AMD), macular edema following Branch Retinal Vein Occlusion (BRVO), macular edema following central retinal vein occlusion (CRVO), and diabetic macular edema (DME)
2513013|NCT02810236|Active Comparator|No ultrasound|No ultrasound recommended. Discussion with radiologist.
2513019|NCT02810236|Active Comparator|Ultrasound|Ultrasound recommended.
2513084|NCT02810041|Experimental|yoghurts enriched with XXS|
3197412|NCT00860717|Active Comparator|1|Subjects from the arm number 1 received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
3197413|NCT00860717|Experimental|2|Subjects from the arm number 2 received low level laser therapy 3 times per week for 12 weeks, in addition to the same treatment as patients from the arm number 1.
2512058|NCT02816905|Active Comparator|Group A|20 eyes that received topical 0.1% Dexamethasone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2512061|NCT02816905|Active Comparator|Group B|20 eyes that received topical 0.1 % Fluorometholone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2512065|NCT02816905|Active Comparator|Group C|40 eyes that received topical 1% Rimexolone 4 times per day for 2 weeks after surgery. And topical Moxifloxacin 4 times per day for 2 weeks after surgery.
2512148|NCT02816567|Experimental|NMBA group|
2512149|NCT02816567|Placebo Comparator|placebo group|
2512161|NCT02816073|Active Comparator|1,700|Patients receive 1,700 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
2512163|NCT02816073|Active Comparator|2,500|Patients receive 2,500 (+/- 5%) laser shots in a single session of pan-retinal photocoagulation using pattern scanning laser
2512216|NCT02815969||Healthy volunteers|If no material of healthy volunteers of the SERT study can be used, then other matched volunteers are asked for a vena punction and urine collection
2512218|NCT02815969||Patients|Patients are asked for a vena punction and urine collection, if not already done because of medical care.
3197414|NCT00860730|Experimental|Perceval S|
2512338|NCT02815163|No Intervention|comparison group|The CG received no extra care; they could receive the usual routine care for THR in the unit as they had before participation in the study. The routine care included oral instruction by nurses follow by the handout. Also, a brochure was provided of the structure of hip, the risk factors of THR, care before and after THR, complications, care of discharge, and demonstration of rehabilitation with pictures) of THR designed by researchers in this study. Five orthopedics health care experts independently reviewed and rated each item in the brochure on a five-point Likert-type scale in terms of relevance, representativeness, specificity, and clarity.
2512339|NCT02815163|Experimental|Empowerment education group|"The 5 times total, 12-week EE intervention was aimed to empower older patients with THR to develop their own self-management program to meet their needs. This empowerment education intervention based on 6 empowerment components: Partnership, listening, dialogue, reflection, action, feedback and 5-step empowerment strategies: motivating patients self-awareness, assessing the causes of the problem, goal setting, individual self-care plan development, and checking whether goals or plans have been achieved who modified from Freire's 3-stage methodology. The difference between this program and the other health educations for patients with THR are that this program encourages them to explore their needs and worries, their own ability and power to meet their needs, and their capacity to seek and use their social support and resources etc."
2512350|NCT02814812|Experimental|pancreatic surgery|
2512389|NCT02814669|Experimental|Cohort 1: ATZ + R-223-D (Concurrent)|Participants will receive concurrent radium-223 dichloride and atezolizumab for a single-cycle, 28-day dose limiting toxicity (DLT) assessment. If the combination is initially found to be safe and tolerable, additional participants will be randomized to Arms A, B, and C.
2512395|NCT02814669|Experimental|RT Arm A: ATZ + R-223-D (Concurrent)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm (randomized treatment [RT]) to receive concurrent radium-223 dichloride and atezolizumab.
2512401|NCT02814669|Experimental|RT Arm B: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
2512404|NCT02814669|Experimental|RT Arm C: ATZ + R-223-D (Staggered, 28-Day ATZ Run-In)|If Cohort 1 regimen is found to be safe, additional participants will be randomized to this arm to receive atezolizumab in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward.
2512409|NCT02814669|Experimental|Cohort 2: ATZ + R-223-D (Staggered, 28-Day R-223-D Run-In)|If Cohort 1 regimen is not tolerable, Arms A, B, and C will not be introduced and additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab in Cycle 2. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycle 1 and radium-223 dichloride and atezolizumab from Cycle 2 onward). If, at Cycle 2, Cohort 2 regiment is not tolerable, additional participants will be enrolled in Cohort 3.
2512414|NCT02814669|Experimental|Cohort 3: ATZ + R-223-D (Staggered, 56-Day R-223-D Run-In)|If Cohort 2 regimen is not tolerable, additional participants will be enrolled in this cohort to receive radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab in Cycle 3. If the regimen is found to be safe, additional participants will be enrolled to receive this same treatment (radium-223 dichloride in Cycles 1, 2 and radium-223 dichloride and atezolizumab from Cycle 3 onward). If, at Cycle 3, Cohort 3 regiment is not tolerable, no additional participants will be enrolled in this study.
2512514|NCT02813980||High SUDEP-7 score|Patients with epilepsy who have a high SUDEP-7 score
2512515|NCT02813980||Low SUDEP-7 score|Patients with epilepsy who have a low SUDEP-7 score
2512566|NCT02813603||Study Product (19-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
2512568|NCT02813603||Control Intervention (22-gauge)|After randomization, the subject undergo EBUS-TBNA either with the 19-gauge needle or the 22-gauge needle
2512619|NCT02813278|Experimental|simo decoction and acupuncture with vitamin B1|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection for 5 days or until flatus.
2512621|NCT02813278|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection for 5 days or until flatus.
2512624|NCT02813278|No Intervention|empty control|Patients only receive best support care.
3197415|NCT00860756|Experimental|1|Intervention Group
3197416|NCT00860769|Experimental|ASHA Life|6-session educational group discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills.
3197417|NCT00860769|Active Comparator|Usual Care|3-session educational group focusing on HIV prevention, anti-retroviral therapy (ART) and parenting.
2512045|NCT02817009|Experimental|Healthy Families Group|Participants and their families will attend a weekly nutrition session, social support session and physical activity session for 12 weeks.
2512181|NCT02816424|Experimental|Brief Motivational Interviewing|Principles and skills of motivational interviewing will be used with participants assigned to brief intervention. These participants will receive feedback that they are at risk for unintended pregnancy. They will receive information on the likelihood of pregnancy given their self-reported frequency of unprotected sex. They will be given information regarding negative consequences associated with teen pregnancy. They will be provided with information on the chances of pregnancy with abstinence, condom use, oral contraceptives, and Long Acting Reversible Contraceptives (LARC). Following information exchange, participants who are high in readiness to change will engage in action planning, whereby a specific plan for reducing risk for unintended pregnancy will be collaboratively developed with the interventionist. Patients who are low in readiness to change will complete a motivational interviewing-based roadmap activity that is designed to strategically evoke motivational speech.
2512184|NCT02816424|No Intervention|Control|
2512294|NCT02815553|Experimental|Cardiac tumors|
2512386|NCT02815059|Experimental|Ibrutinib, Dasatinib and prednisone, all patients|
2512481|NCT02814266|Other|difficult intubation|Intubation difficulty score >5
2512482|NCT02814266|Other|Easy intubation|Intubation difficulty score >5
2512524|NCT02813798|Experimental|Mild Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2512530|NCT02813798|Experimental|Moderate Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2512537|NCT02813798|Experimental|Severe Renal Impairment|A single dose of IV Rivipansel over 20 minutes
2512540|NCT02813798|Experimental|Normal Renal Functions|A single dose of IV Rivipansel over 20 minutes
2512574|NCT02813330|Experimental|Sterile Water injection|Subcutenous injection at low back portion during labor pain
2512576|NCT02813330|Experimental|saline injection|Subcutenous injection at low back portion during labor pain
2512687|NCT02812940|Experimental|Everolimus as part of GvHD prophylaxis after allogeneic SCT|Everolimus from day +5 to day +100
2512714|NCT02812433|Active Comparator|Sildenafil|Sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
2512715|NCT02812433|Placebo Comparator|Ora-Blend|Ora-Blend 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
2512744|NCT02812134||anorexic|
2512812|NCT02811926||Ileostomy or colostomy|Patients with a ileostomy or colostomy in the Capital Region of Denmark
2512877|NCT02811523|Experimental|Doxorubicin 5 mcg/ml|Doxorubicin 5mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512880|NCT02811523|Experimental|Doxorubicin 7 mcg/ml|Doxorubicin 7mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512881|NCT02811523|Experimental|Doxorubicin 9 mcg/ml|Doxorubicin 9mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512884|NCT02811523|Experimental|Doxorubicin 11 mcg/ml|Doxorubicin 11mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512887|NCT02811523|Experimental|Doxorubicin 13 mcg/ml|Doxorubicin 13mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512889|NCT02811523|Experimental|Doxorubicin 15 mcg/ml|Doxorubicin 15mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512891|NCT02811523|Experimental|Doxorubicin 17 mcg/ml|Doxorubicin 17mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512892|NCT02811523|Experimental|Doxorubicin 20 mcg/ml|Doxorubicin 20mcg/ml by in vivo lung perfusion during surgical resection of pulmonary metastases
2512939|NCT02811055|Experimental|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
2512941|NCT02811055|Placebo Comparator|Administration of placebo|Administration of Placebo once per day during 14 days; Blood sampling, electrocardiogram, orthostatic test and Blood Pressure Measurement are done after 14 days
2512983|NCT02810665||Normal vision group|Individuals with VA 20/20 to 20/25
2512989|NCT02810665||Impaired vision group|Individuals with impaired vision: VA of 20/32 to 20/200 due to either cataract, diabetic macular edema, or age-related macular degeneration
3197418|NCT00860782|Experimental|Annual Parent Intervention (API) Group|Participants in this group will receive the parent educational support intervention once a year for 2 years.
3197419|NCT00860782|Experimental|Quarterly Parent Intervention (QPI) Group|Participants in this group will receive the parent educational support intervention quarterly (4 times a year) for 2 years.
2513128|NCT02809729|Placebo Comparator|placebo|The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction
2513133|NCT02809729|Active Comparator|cefazolin|The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction
2513174|NCT02809248|Active Comparator|coated stent|the patient get a coated coronary stent implantation (ZES - zotarolimus eluting stent)
2513177|NCT02809248|Active Comparator|uncoated stent|the patient get a uncoated coronary stent implantation (BMS - bare metal stent)
2513236|NCT02808949|Experimental|Age Groups|Dapivirine levels in breast milk will be measured in 16 participants. All participants will wear the Dapivirine Vaginal Ring for 14 consecutive days.
2513283|NCT02808585|Experimental|PB1046 Injection, 0.2 mg/kg|Four weekly doses of PB1046 Injection, 0.2 mg/kg
2513285|NCT02808585|Experimental|PB1046 Injection, 0.4 mg/kg|Four weekly doses of PB1046 Injection, 0.4 mg/kg
2513287|NCT02808585|Experimental|PB1046 Injection, 0.6 mg/kg|Four weekly doses of PB1046 Injection, 0.6 mg/kg
2513288|NCT02808585|Experimental|PB1046 Injection, 1.2 mg/kg|Four weekly doses of PB1046 Injection, 1.2 mg/kg
2513289|NCT02808585|Placebo Comparator|Placebo Comparator|Four weekly doses of Placebo (0.9% NaCl) Injection
2513324|NCT02808299||all the antigen and antibody of HBV are negative|Hepatitis B Virus surface antigen (HBsAg), Hepatitis B Virus surface antibody (HBsAb), Hepatitis B Virus e antigen (HBeAg), Hepatitis B Virus e antibody (HBeAb), Hepatitis B Virus core antibody (HBcAb) are all negative.
2512053|NCT02817100|Experimental|BAY1817080|Study Part 1: Dose 1 to 7 of BAY1817080 (increasing dose levels; redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]); Study part 2: Dose 1 to 4 of BAY1817080 together with an American breakfast (increasing dose levels; redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
2512055|NCT02817100|Placebo Comparator|Placebo|Study Part 1: Placebo Dose 1 to 7 of BAY1817080; Study Part 2: Placebo Dose 1 to 4 of BAY1817080
2512140|NCT02816632|Experimental|healthy volunteers|
2512351|NCT02815137|Other|XPO1 E571K mutation detection|Determination of mutation of XPO1571K in patient with classical hodgkin Lymphoma by digital PCR on blood samples and biopsy
2512388|NCT02814578|Experimental|Optical coherent tomography|Optical coherent tomography provides more detailed information about the morphology of scaffolds, microstructures and coronary vasculature based on tissue characteristics as compared to conventional IVUS. In spite of angiographic success in BVS placement, further scaffold optimization was required in over a quarter of cases based on OCT findings due to malapposition or scaffold under expansion.
2512390|NCT02814578|Active Comparator|IntraVascular UltraSound|Intravascular ultrasound guidance has been associated with improved event-free survival compared with angiographic guidance after DES placement.
3197420|NCT00860808|Experimental|1 AM-101|low dose
3197421|NCT00860808|Experimental|2 AM-101|high dose
3197422|NCT00860808|Placebo Comparator|3 Placebo|
3197423|NCT00860821|Experimental|1|AZD8309
2512675|NCT02812914|Experimental|Phase 1|In Phase I, 25 pregnant women will receive a low-cost gas stove and will be taught by peer educators in group classes how to safely use gas stoves and how to reduce exposure to air pollution.
2512677|NCT02812914|Experimental|Phase 2|In Phase 2, the investigators will assess a more resource-intensive behavioral intervention approach with a different group of 25 women who will follow the same study procedures described in Phase I.
2512702|NCT02812498|Experimental|Teleconsultation|Teleconsultation for patients affected by type 1 diabetes mellitus
2512704|NCT02812498|Other|Control|Standard visit in outpatient clinic for the same type of patients
2512793|NCT02812225|Experimental|BrainPulse|BrainPulse recordings will be obtained from patients when they come in to the ED after a trauma event. BrainPulse recordings will be also obtained from those subjects who also consent for follow-up.
2512850|NCT02811653|Experimental|Alzheimer disease|Alzheimer disease patients Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation
2512852|NCT02811653|Active Comparator|control|"Healthy age- and gender-matched volunteers will be recruited into the study from the general population.~Brain MRI (Magnetic Resonance Imaging) Blood neuropsychological evaluation"
2512938|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 8 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy
2512940|NCT02811250|Experimental|Stereotactic radiotherapy 5 x 8 Gy|Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy
2512942|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 10 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy
2512943|NCT02811250|Experimental|Stereotactic radiotherapy 4 x 12 Gy|Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy
2512958|NCT02810678|No Intervention|Control|No Intervention: Program runs as per usual. Minimal interference and visits from study staff. Main study outcomes evaluated in first and last 6 months of trial. Minimal visits to collect information on costing at control sites.
2512959|NCT02810678|Active Comparator|Intervention|Latent Tuberculosis Infection program evaluation & diagnosis: In intervention health facilities the current Latent Tuberculosis Infection program will be evaluated and gaps in the Latent Tuberculosis Infection cascade of care will be identified. Gaps in the current cascade will be quantified and solution proposed that are unique to the problems identified in each site. In phase 2 of the study low cost solutions will be implemented and the Latent Tuberculosis Infection program scaled up and improved. Study outcomes are evaluated in the first and last 6 months of trial. Costing evaluations are done throughout the trial.
2513014|NCT02810444|Experimental|BT595|Subjects will receive BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.
2513106|NCT02809872||Study Group|Study Group with Pleural effusion for any cause and receiving chest CT scan and thoracic Ultrasounds.
2513173|NCT02809495||Patients who will use the clinical application|
2513178|NCT02809495||Patients who do not make use of clinical application|
3197424|NCT00860821|Placebo Comparator|2|Placebo
3197425|NCT00860834|Experimental|1|Pediatricians and parents of children with asthma will participate in the asthma coaching program.
2513378|NCT02808039||DAPT patients|Patients planned for cessation of DAPT regimen containing Ticagrelor after 12 months of treatment following coronary stent implantation . the platelet reactivity will be assessed 1 week prior to cessation of DAPT and than at 1,3,and 12 weeks post DAPT cessation.
2513428|NCT02807675|Experimental|CVT-301, levodopa inhalation powder (LIP)|designed to deliver l-dopa to the lung using the CVT-301 inhaler.
2513432|NCT02807675|Placebo Comparator|Placebo|Administered in the same way as the investigational product, except that it does not contain l-dopa.
3197426|NCT00860834|Active Comparator|2|Children of parents enrolled in the study will receive usual asthma care from their pediatrician.
3197427|NCT00860873|Experimental|Test 1|Oral Powder EMS
3197428|NCT00860873|Experimental|Test 2|Hard Capsules EMS
3197429|NCT00860873|Active Comparator|Comparator 1|Oral Powder Zodiac
3197430|NCT00860873|Active Comparator|Comparator 2|Hard capsules - Zodiac
3197431|NCT00860886||1|Mongolian Women
3197432|NCT00860886||2|Women in other parts of the world other than Mongolia.
3197433|NCT00860899|Active Comparator|clonidine|Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
3197434|NCT00860899|Active Comparator|levobupivacaine|Levobupivacaine is long-acting local anesthetic, S-enantiomer of bupivacaine, with identical anesthetic potency.
2512077|NCT02817269|Experimental|Manual palpation group|For the manual palpation group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut band tried to elicit local twitch response and referred pain in the infraspinatus area. First, three attempts will be made to elicit an local twitch response (LTR) using snapping palpation if a response will be obtained. After LRT, referred pain could also be evoked by palpation.
2512079|NCT02817269|Experimental|Deep dry needling group|For the deep dry needling group, the reference position will be a lateral position, lying on the non affected shoulder while the affected side will be explored. The arm and elbow are flexed 90° resting on a pillow and legs placed with 90° hip and knee flexion to stabilize the body, with the head resting on a pillow to maintain body alignment. The physiotherapist will be in front of the participant and carried out the examination with flat palpation using the thumb to identify soreness taut before making the needle insertion. Sterile stainless steel needles (length 40mm/caliber 0.32 with a cylindrical plastic guide) will be used.
2512146|NCT02816502|Experimental|Stress Management Skill Building Program A|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
2512147|NCT02816502|Active Comparator|Stress Management Skill Building Program B|An eight week skill building group in which subjects meet with the teacher and other students in the group once a week, and complete homework and practice log during the week.
2512154|NCT02816125|Active Comparator|Habitual supplemented|habitual diet with 1.2 g EPA+DHA in capsule form/day.
2512156|NCT02816125|Experimental|Low-fat supplemented|Reduce dietary fat to less than 20% energy, add 1.2 g EPA+DHA in capsule form/day.
2512194|NCT02816008|Experimental|Cognitive rehabilitation group|Cognitive rehabilitation training with RGS in the clinic.
2512196|NCT02816008|Active Comparator|Passive control group|Passive/conventional cognitive training at home.
2512215|NCT02815774|Active Comparator|health volunteers|this group patients were given SP2086 50mg only one time.
2512217|NCT02815774|Active Comparator|mild renal insufficiency|this group patients were given SP2086 50mg only one time.
2512220|NCT02815774|Active Comparator|moderate renal insufficiency|this group patients were given SP2086 50mg only one time.
2512222|NCT02815774|Active Comparator|severe renal insufficiency|this group patients were given SP2086 50mg only one time.
2512223|NCT02815774|Active Comparator|end-stage renal insufficiency|this group patients were given SP2086 50mg only one time.
3164087|NCT00492999|Experimental|Group 2|Patients receive HAI therapy as in group 1. Patients also receive irinotecan hydrochloride IV over 30 minutes and leucovorin calcium IV over 30 minutes on days 1 and 15 and fluorouracil IV continuously over 48 hours on days 1, 2, 15, and 16. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2512489|NCT02814240|Experimental|Pituitary gland failure|
2512527|NCT02813720||Patients with peripheral PsA|
2512529|NCT02813720||Patients with psoriatic nail onycholysis|
2512538|NCT02813720||Patients with PsO only|
2512539|NCT02813720||Healthy match control subjects|
2512603|NCT02813382||B-group|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
2512608|NCT02813382||C-group|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
2512611|NCT02813382||P-group|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
2512646|NCT02813018|Experimental|preemptive group|Group who will be received ropivacaine bolus and continous infusion 5 minutes before skin incision.
2512649|NCT02813018|Placebo Comparator|saline group|Group who will be received saline bolus and continous infusion 5 minutes before skin incision
2512774|NCT02812407|Experimental|Mucosal Impedance|"Patient's having a clinically indicated endoscopy, a high resolution impedance manometry and a 24 hour pH impedance study.~During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. This device has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it."
2512808|NCT02811796||angio-based FFR estimation|The investigators will include all patients receiving successful coronary stent implantation. In these patients the investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
2512883|NCT02811458|Experimental|Transdiagnostic CBT|Group psychotherapy according to the Transdiagnostic Cognitive-Behavioral Therapy treatment protocol (Norton, 2012)
2512886|NCT02811458|No Intervention|Treatment-as-usual|Treatment-as-usual and a differed intervention (if desired by participants) after the 8-month follow up.
2512898|NCT02811094|Other|Adult patients with Systemic LupusErythematosus (SLE)|Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.
2512937|NCT02811003|Experimental|Treatment|Treatment with Rotation Medical Bioinductive Implant
2512967|NCT02810756|Experimental|Treated patients|
2513024|NCT02810535|Active Comparator|Allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and positive prick test for house dust mite
2513030|NCT02810535|Experimental|Non-allergic rhinitis|Clinical observation of 24 subjects with nasal symptoms and negative prick test for house dust mite
2513035|NCT02810535|Other|Healthy Control|Clinical observation of 20 subjects without nasal symptoms and with negative prick test
2512107|NCT02816853|Experimental|Sequence 1|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2512121|NCT02816853|Experimental|Sequence 2|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2512129|NCT02816853|Experimental|Sequence 3|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2512133|NCT02816853|Experimental|Sequence 4|Participants will be randomly assigned to 1 of 4 treatment sequence groups based on a computer generated randomization schedule and will receive the following 4 treatments in order specified by randomization: Treatment A (1 domperidone 10 mg tablet 3 times a day (tid) + 1 placebo tablet tid on Days 1 to 3 and a single dose of 1 domperidone 10 mg tablet +1 placebo tablet in the morning of Day 4), Treatment B (2 domperidone 10 mg tablets tid on Days 1 to 3 and a single dose of 2 domperidone 10 mg tablets in the morning of Day 4), Treatment C (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets in the morning of Day 4) and Treatment D (2 placebo tablets tid on Days 1 to 3 and a single dose of 2 placebo tablets + 1 moxifloxacin 400 mg tablet in the morning of Day 4).
2512160|NCT02816099|Experimental|Type-1 diabetes patients|
2512164|NCT02816099|Other|Controls|
2512239|NCT02815943|Other|Before DBP-DS surgery|
2512240|NCT02815943|Experimental|After DBP-DS surgery|It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.
2512242|NCT02815943|Other|Before SG surgery|
2512245|NCT02815943|Experimental|After SG surgery|It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
2512284|NCT02815254|Active Comparator|Low dose exercise intervention|
2512285|NCT02815254|Experimental|High dose exercise intervention|
2512335|NCT02815189|Experimental|Post operative Pain after a RCT|Ibuprofen for Post operative pain. Take 400 mg taken a week after. Incidence of flare ups after a single vs multiple visits root canal treatments.
2512337|NCT02815189|Experimental|Flare up|Acetaminophen 325 mg for Flare Up. Taken second day after. Incidence of Post operative pain after root canal treatment in one vs two visits.
2512377|NCT02814799||bone donors|
3197435|NCT00860912|Experimental|Intervention: Collagen matrix|Cystocele repair: Veritas reinforcing material implanted for reinforcement of cystocele repair with collagen matrix
3197436|NCT00860912|Other|Native tissue repair|Intervention: Cystocele repair performed: No reinforcing material used and routine performance of a cystocele repair using native tissues.
2512555|NCT02813642|Experimental|Cardiovascular risk evaluation|Measurement of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 2 year follow-up
2512640|NCT02813252||JCAR015-treated|Patients who received previous treatment with JCAR015
2512659|NCT02812888||Hyperthyroid Patients|Patients with hyperthyroidism
2512660|NCT02812888||NC group|Normal control subjects
2512688|NCT02812654|Experimental|Doxorubicin, Ifosfamide, radiotherapy|Doxorubicin 75mg/m2 (cycle 1,2 and 3), ifosfamide 9 g/m2 (cycle 1 and 3) and radiotherapy: 25 Gy / 5 x 500 cGy/day, beginning at Cycle2/Day1. The surgery will performed after 4-6 weeks from cycle 3. The remain viable cells in surgical specimen will be analyzed and if it accounts less than 30% the patient will receive more 3 cycles of cT. A boost of RT is indicated if margins are considered R1.
2512735|NCT02812394|Experimental|CVT-301|"CVT-301 (Dose Level 1): two (low dose) levodopa fine particle dose (FPD) capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~CVT-301 (Dose Level 2): two (high dose) levodopa FPD capsules administered to the lung via oral inhalation using the CVT 301 inhaler.~Sinemet® (carbidopa/levodopa)"
2512788|NCT02812355|Experimental|half heparinization|heparin I.V. 150 U/kg
3197437|NCT00860925|Experimental|active clonidine and active ASA|
3197438|NCT00860925|Experimental|active clonidine and ASA placebo|
3197439|NCT00860925|Experimental|Clonidine placebo and active ASA|
3197440|NCT00860925|Placebo Comparator|Clonidine placebo and ASA placebo|
3197441|NCT00860964|Placebo Comparator|Placebo|
3197442|NCT00860964|Experimental|estradiol valerate|
3197443|NCT00860977|Placebo Comparator|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
3197444|NCT00860977|Experimental|Valacyclovir|oral valacyclovir 500mg twice daily
3197445|NCT00860990||1|SCI or disabled
3197446|NCT00860990||2|Able-bodied
2512247|NCT02815787|Active Comparator|SP2086 and Glyburide|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days. In this group,the subjects was given the drugs from A sequence to the B sequence.
2512255|NCT02815787|Active Comparator|Glyburide and SP2086|The A sequence was that Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.The B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.The trial period were 25 days.In this group,the subjects was given the drugs from B sequence to the A sequence.
2512293|NCT02815423|Experimental|UCMSCs|Transplantation of umbilical cord mesenchymal stem cells (UCMSCs) in patients with fracture and bone nonunion.
2512295|NCT02815423|Placebo Comparator|Placebo|The patients with fracture and bone nonunion who underwent percutaneous injection of placebo.
2512378|NCT02815085|Experimental|RecoverLINK technology|RecoverLINK is a two-part mHealth technology designed to supplement traditional care transitional programs for heart failure (HF) patients.
2512459|NCT02814305|No Intervention|Control|Patient receives neither educational nor financial interventions
2512468|NCT02814305|Experimental|Financial intervention only|Patient receives financial (pharmacy offer) intervention only
2512471|NCT02814305|Experimental|Educational intervention only|Patient receives educational (narrative) intervention only
2512476|NCT02814305|Experimental|Both interventions|Patient receives both educational and financial interventions
2512522|NCT02813902|Active Comparator|Heliocare|240 mg administered orally daily
2512532|NCT02813902|Placebo Comparator|Sugar pill|a sugar pill matching the Heliocare tablet in look and weight will be administered orally daily
2512615|NCT02813447|Active Comparator|Pulmonary Rehab + Study Drug|Subjects randomized into this arm will be given active study drug (sertraline). Subjects will take 25mg tablets by mouth daily starting at visit 1 along with participating in the intensive pulmonary rehab program. Subjects will be assessed at one week intervals +/- 7 days for tolerability and side effects, and if tolerating study drug, the dose will be increased weekly by 25mg over the course of the first four weeks with maximum effective dose of 100mg daily by the end of week four. Subjects will continue this dose over the course of the remaining 8 weeks of the study, while participating in the graduate program of pulmonary rehab.
2512616|NCT02813447|Placebo Comparator|Pulmonary Rehab + Placebo|Subjects randomized to the placebo arm will have the same procedures as described above in the study drug arm with the exception that they will be receiving matched placebo drug.
2512653|NCT02813005|Experimental|Jet ventilation/ group A|Frequency : 120-200/min Pressure : 1-2 bars Inspiratory fraction of oxygen : 100% and 50% if Expiratory pressure : 5 -10 cmH2O
2512654|NCT02813005|Sham Comparator|Standard ventilation/ group B|Apnea made by the anesthesiologist to the request of the radiologist.
2512718|NCT02812732|Other|Intervention|Providers at each clinic will receive the intervention (DOSE HPV) on a rolling basis. Vaccination rates will be compared pre- and post-intervention at each clinic, and changes in rates will be compared across clinics.
3197447|NCT00861003||Schizophrenia, antipsychotics|Stable outpatient status of schizophrenia or schizoaffective disorder currently taking a single oral antipsychotic
3197448|NCT00861016|Experimental|1|The patients with mild to moderate essential hypertension
2512849|NCT02811575||Patients with diabetes|Patients with type 2 diabetes will have biopsy during coloscopy.
2512853|NCT02811575||Control|Patients without type 2 diabetes will have biopsy during coloscopy.
3197449|NCT00861029|Experimental|Pazopanib|Subjects will receive pazopanib during study
3197450|NCT00861029|Other|Placebo|Placebo as a comparator to pazopanib
3197451|NCT00861042|Experimental|1|
2513093|NCT02809768|Experimental|Avatrombopag plus fluconazole|Part A: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, fluconazole (400-mg) will be administered once daily on Days 1 to 16, and a single dose of avatrombopag (20-mg) on Day 7 in Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
2513095|NCT02809768|Experimental|Avatrombopag plus itraconazole|Part B: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, itraconazole (200-mg) will be administered twice daily on Day 1 and 200-mg once daily on Days 2 to 16. A single dose of avatrombopag (20-mg) will be administered on Day 7 of Treatment Period 2. Each dose of avatrombopag will be administered under fed conditions 30 minutes after the start of a meal.
2513096|NCT02809768|Experimental|Avatrombopag plus rifampin|Part C: Participants will be administered a single oral dose of avatrombopag (20-mg) on Day 1 of Treatment Period 1. In Treatment Period 2, rifampin (600-mg) will be administered once daily on Days 1 to 16. In order to avoid a food-effect on rifampin absorption, each dose will be administered 1 hour before participants consume a meal. On Day 7 of Treatment Period 2, rifampin (600-mg) and avatrombopag (20-mg) will be administered 1 hour before meal and 30 minutes after starting meal consumption.
2513170|NCT02809508|Experimental|Oily fish|
2513176|NCT02809508|Experimental|Poultry (control)|
2513213|NCT02808897|Active Comparator|Standard drainage|The control arm consist of consecutively enrolled cardiac surgery patients receiving < four (4) commercially available standard chest tubes.
2513221|NCT02808897|Experimental|Active Clearance Technology drainage|The test arm consists of consecutively enrolled cardiac surgery patients receiving < two (2) PleuraFlow® chest tubes with Active Clearance Technology® and < two (2) other commercially available standard chest tubes.
3197452|NCT00861055||Infants|Infants less than 7 days of age with clinical signs of sepsis
3197453|NCT00861055||Mothers|Mothers following antenatal care at SMRU antenatal clinic, Maela camp who are 28 - 30 weeks gestation
3197454|NCT00861068|Experimental|1|
3197455|NCT00861068|Placebo Comparator|2|
3197456|NCT00861081|Experimental|1: Care management|
3197457|NCT00861081|Active Comparator|2: Written Materials|
3197458|NCT00861094|Experimental|FOLFOX and radiotherapy|Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
3197459|NCT00861094|Experimental|5-FU / cisplatin and radiotherapy|5-FU (100mg/m2); Cisplatin (75mg/m2)
3197460|NCT00861159||1|
3197461|NCT00861172|Experimental|1|
3197462|NCT00861185|Experimental|Senicapoc|
3197463|NCT00861185|Placebo Comparator|Placebo|
2512267|NCT02815631|Experimental|Cardiogoniometry (CGM)|"Every patient involved in the study will undergo a series of CGM recordings whilst having their FFR procedure. These recordings will all be done whilst they are in the catheterisation laboratory and will be taking at the following points during the procedure.~First baseline recording - taken when the patient first enters the catheterisation laboratory and is prepped for their procedure.~Second baseline recording - taken when the FFR guide wire is in place in the coronary artery being assessed.~Maximal hyperaemia recording - this will be taken when the patient is at maximal hyperaemia during their adenosine infusion for their FFR procedure.~The patients involvement will then be finished in the study and will be cared for as per clinical practice.~If the CGM records a result of anything less than 0, it will be regarded as a positive result."
2512268|NCT02815631|Active Comparator|Fractional flow reserve (FFR)|"Every patient involved in the study will undergo an FFR assessment of their coronary arteries. These recordings will all be done whilst they are in the catheterisation laboratory. They will have the following recordings:~A baseline FFR will be recorded once the pressure wire has been advanced down the coronary artery being assessed.~Maximal hyperaemia FFR will be recorded during adenosine infusion.~An FFR ratio of <0.80 will be regarded as a positive result."
3197464|NCT00861211|Experimental|Active treatment arm|
3197465|NCT00861211|Placebo Comparator|Placebo|
2512362|NCT02814747|Experimental|quantitive study: 500 patients likely to be candidates for HTS|quantitive study: 500 patients likely to be candidates for HTS at CR in Dijon and Lyon, that is to say patients with development anomalies and/or intellectual deficiency with no etiological diagnosis.
2512366|NCT02814747|Experimental|qualitative study: 30 patients who have benefited from HTS and|qualitative study: 30 patients who have benefited from HTS and the medical geneticists who accompanied them in this approach.
2512382|NCT02814474|Placebo Comparator|SALINE|Infusion of saline (0.9 %)
2512384|NCT02814474|Experimental|KETONE|Infusion of Na-3-Hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
2512541|NCT02813915||Use of Cheetah medical NICOM|For those who consent to the study, the Cheetah NICOM will be used to obtain cardiac output, stroke volume, and fluid responsiveness.
2512620|NCT02813525||IUGR group|estimated fetal weight <10th percentile associated with an abnormal umbilical artery Doppler with IP>95th percentile or a confirmation of placental vascular disease by histological examination
2512623|NCT02813525||CONTROL group|non IUGR fetuses for gestational age (normal for weight, Doppler, and structural analyse)
2512672|NCT02812966|Active Comparator|Lutonix DCB|Lutonix 035 Drug coated Balloon PTA Catheter
2512673|NCT02812966|Active Comparator|IN.PACT DCB|IN.PACT Admiral Paclitaxel-Coated PTA Balloon Catheter
2512713|NCT02812550|Other|full-spectrum colonoscopy|Colonoscopy is performed with a full-spectrum colonoscopy (330º angle of view)
2512716|NCT02812550|Other|standar forward-viewing colonoscopy|Colonoscopy is performed with standar forward-viewing colonoscopy (170º angle of view)
2512749|NCT02812173|Active Comparator|suprapubic tube ex 2 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 2th day after the surgery
2512750|NCT02812173|Active Comparator|suprapubic tube ex 5 day|patients who underwent robot-assisted radical prostatectomy and got intraoperatively, a suprapubic tube, which was withdrawn on the 5th day after the surgery
2512842|NCT02811822|Experimental|Dose 1|
3197466|NCT00861224||Observed Subjects|Subjects that submitted bone marrow biopsy and aspirates.
3197467|NCT00861237|Placebo Comparator|Placebo globules group|Patients receive Placebo globules made out of sugar and looking similar to active drug sublingually before surgery.
3197468|NCT00861237|Active Comparator|Nux vomica group|Patients receive Nux vomica globules made out of sugar sublingually before surgery.
3197469|NCT00861250|Experimental|Vel/Dex|
3197470|NCT00861276|Experimental|1|Arm instructed to use spray at least once an hour when awake.
3197471|NCT00861276|Active Comparator|2|Ad libitum: patients were instructed to use NNS when craving appears.
3197472|NCT00861302|Experimental|Treatment group|This is the only group in the study. It consists of patients with chronic musculoskeletal pain who are receiving the treatment program
3197473|NCT00861315|Experimental|Nebulized amikacin|Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely
3197474|NCT00861315|Active Comparator|Intravenous amikacin|
3197475|NCT00861328|Experimental|A|Treatment of escalating doses of ON 01910.Na in combination with irinotecan
3197476|NCT00861328|Experimental|B|Treatment of escalating doses of ON 01910.Na in combination with oxaliplatin
3197477|NCT00861367|Active Comparator|1|aspirin 100mg
3197478|NCT00861367|Placebo Comparator|2|empty capsule
3197479|NCT00861393|Other|CBT|
3197480|NCT00861393|Other|Waitlist|
3197481|NCT00861406|Experimental|Group 1|Pegylated Interferon alfa-2b (Once week x 4 weeks) + GP-100 Peptide
3197482|NCT00861406|Experimental|Group 2|Pegylated Interferon alfa-2b (Once week x 8 weeks) + GP-100 Peptide
3197483|NCT00861406|Experimental|Group 3|Pegylated Interferon alfa-2b (Once week x 12 weeks) + GP-100 Peptide
3197484|NCT00861419|Experimental|D|3 mg/kg AMG 386 IV (QW) / 125 mg AMG 706 PO (QD)
3197485|NCT00861419|Experimental|A|3 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
3197486|NCT00861419|Experimental|B|3 mg/kg AMG 386 IV (QW) / 75 mg AMG 706 PO (QD)
3197487|NCT00861419|Experimental|E|3 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
3197488|NCT00861419|Experimental|H|10 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
3197489|NCT00861419|Experimental|G|3 mg/kg AMG 386 IV (QW) / 50 mg sunitinib PO (QD - 4 weeks on/2 weeks off)
3197490|NCT00861419|Experimental|C|10 mg/kg AMG 386 IV (QW) / 15 mg/kg bevacizumab IV (Q3W)
3197491|NCT00861419|Experimental|F|10 mg/kg AMG 386 IV (QW) / 400 mg sorafenib PO (BID)
3197492|NCT00861432|Active Comparator|additive homeopathic treatment|These patients receive additive homeopathic treatment during conventional cancer treatment.
2512205|NCT02816281||Reasons of case cancellation|"will be recorded and categorized into 6 groups including~patient issue such as surgery refusal, no show on the day of surgery, transport problems~facility such as equipment needs, improper estimate case time, case bumps~Surgeon unavailable, due to administrative schedules and other problems or changed line of management respectively~anesthesiologist fail to adequately prepare the patient, lead to some misunderstanding communication such as NPO violation, preoperative drug error~medical condition that may impact the patient's ability to endure anesthesia techniques or surgical procedure~miscellaneous."
2512263|NCT02815748|Other|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
2512292|NCT02815345|Experimental|Measure of the nasal cavity|"The nasal cavity of all the included neonates will be measured using rhinometry during their hospitalization every weeks. So one to 8 measurement will be performed for each neonates.~Some included neonates will also have rhinomanometry measurements."
3197493|NCT00861432|No Intervention|no additive homeopathic treatment|These patients do not receive additive homeopathic treatment during conventional cancer treatment.
3197494|NCT00861445|Experimental|1|
3197495|NCT00861445|Placebo Comparator|2|
2512563|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
2512564|NCT02813629|Active Comparator|SS-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
2512565|NCT02813629|Active Comparator|SS-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
2512567|NCT02813629|Sham Comparator|SS-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
2512569|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (active)|tDCS plus PES (n=15).
2512570|NCT02813629|Active Comparator|SC-tDCS (active) plus PES (simulated)|tDCS plus PES (n=15).
2512571|NCT02813629|Active Comparator|SC-tDCS (simulated) plus PES (active)|tDCS plus PES (n=15).
2512572|NCT02813629|Sham Comparator|SC-tDCS (simulated) plus PES (simulated)|tDCS plus PES (n=15).
2512638|NCT02813239||HCG triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG when at least 2 follicles had a mean diameter of 17 mm.
2512641|NCT02813239||HCG + GnRH agonist triggering|Patients were scheduled by prescribing oral contraceptive (OC) for 12-16 days and recombinant FSH and/or highly purified u-hMG according to the patient's age, BMI, antral follicular count, AMH and previous responses to ovarian controlled stimulation. GnRH antagonist was added when at least one follicle reached 13 mm. Ovulation was induced by hCG and GnRH agonist when at least 2 follicles had a mean diameter of 17 mm.
2512670|NCT02812862||treatment group|"50 male and female patients suffering from chronic heart failure and chronic obstructive pulmonary disease.~Ultibro/ Breezhaler combination therapy"
2512671|NCT02812862||control group|50 male and female patients suffering from chronic heart failure but not COPD and NOT receiving LAMA/ LABA
2512722|NCT02812589|Experimental|Diffusion tensor imaging (DTI) in breast MRI|
2512752|NCT02812108||HARET|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
2512809|NCT02811835||Renal Transplant Recipients|Renal Transplant Recipients that were more than 1 year post-transplantation
2512813|NCT02811835||Healthy Controls|Healthy subjects being evaluated as potential living kidney donors
2512859|NCT02811536||Diabetic retinopathy|Patients with various degrees of diabetic retinopathy
2512862|NCT02811536||Retinal detachment|Patients with a history of retinal detachment
2512863|NCT02811536||Retinal vein occlusion|Patients with a history of retinal vein occlusion
2512866|NCT02811536||Arterial hypertension|Patients with a history of arterial hypertension
2512868|NCT02811536||Carotid artery occlusion|Patients with a history of carotid artery occlusion
2512870|NCT02811536||Age related macular degeneration|Patients with a history of Age related macular degeneration
2512872|NCT02811536||Macroaneurysms|Patients with a history of retinal macroaneurysms
2512873|NCT02811536||Central serous chorioretinopathy|Patients with a history of central serous chorioretinopathy
2512935|NCT02811068||Venepuncture|Collection of single blood sample to assess antibody persistence over time
2512982|NCT02810769|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
2512988|NCT02810769|Experimental|Juiced berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
2512991|NCT02810769|Experimental|Powdered berry drink|Berry drink made up from a powdered concentrate. each drink will be standardised to contain 500mg of polyphenols
2513025|NCT02810314|Experimental|Clinical measures|MS patients recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works for each group and all MS patients will also complete a comprehensive neuropsychological battery including cognitive and behavioural tests of interest in MS
2513029|NCT02810314|Other|Control measures|Healthy participants recruited for this study will complete a resting state functional magnetic resonance image (rs-fMRI) session that will provide information on how DMN network works
3197496|NCT00861458|Experimental|PF-00868554|
2513166|NCT02809196|Active Comparator|1: Tailored, friend and mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend and mother are invited to participate."
2513167|NCT02809196|Active Comparator|2: Standardized, friend and mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend and mother are invited to participate."
2513301|NCT02808624|No Intervention|Control group|This arm wont receive L-CARNOSINE, they will receive their chemotherapy (oxaliplatin) only.
3197497|NCT00861484|Experimental|GSK958108 3 mg|Experimental
3197498|NCT00861484|Placebo Comparator|Placebo of GSK958108|Placebo
3197499|NCT00861497|Experimental|Bifeprunox|
3197500|NCT00861523|Active Comparator|1. thiamine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive thiamine IV
2512258|NCT02815696|Experimental|lumbar spine segmental instability|Patients with a segmental instability of the lumbar spine having undergone surgery. Lumbar spine instability diagnosis is based on imaging (Magnetic resonance imaging, standard radiography, and EOS imaging). Surgical treatment is indicated if the pain is relieved by wearing a brace during at least three months.
2512304|NCT02815514||Aortic valve procedures|"percutaneous transfemoral aortic valve implantation~percutaneous transapical aortic valve implantation~percutaneous transaortic aortic valve implantation~aortic valve valvuloplasty~surgical aortic valve replacement~conservative treatment"
2512357|NCT02815033|Other|Single arm|Experimental: Single arm Subjects will receive 1 dd 160 mg Enzalutamide orally continuously until progressive disease occurs. Serial PSA measurements, PET/CT scans, Whole Body MRI, bone scans will be performed to assess metastatic tumour load, progressive disease and response to treatment.
2512434|NCT02814513|Experimental|ANDAGO|ANDAGO
2512492|NCT02814032||PTC group 1|papillary thyroid carcinoma patients with cervical lymph node metastasis
2512494|NCT02814032||PTC group 2|papillary thyroid carcinoma patients without cervical lymph node metastasis
2512497|NCT02814032||Positive control group|benign disease
2512498|NCT02814032||Negative control group|histologically normal
2512604|NCT02813512|Experimental|GXNPC1|Three subjects will be to treatment (n=3) groups. The treatment group will receive brain transplants of autologous ADSCs. Treatment group will receive rehabilitation after the transplantation. Subjects will be assessed by magnetic resonance imaging (MRI) and four standardized stroke indices: National Institutes of Health Stroke Scale (NIHSS), European Stroke Scale (ESS), European Stroke Motor Subscale (EMS), Barthel Index, MMSE and Gait analyses at 1 month, 3 months, and 6 months after treatment.
2512655|NCT02813096|Experimental|folfox4 chemotherapy regimen|"details in the Intervention Description"
2512657|NCT02813096|Placebo Comparator|Placebo|"details in the Intervention Description"
2512696|NCT02812693|Experimental|Treatment (pembrolizumab, imatinib)|Patients receive pembrolizumab IV over 30 minutes on day 1 and imatinib mesylate orally PO QD on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3197501|NCT00861523|Active Comparator|2. promethazine|Pregnant women until 12 week of gestation who refer to the ER because of nausea and vomiting and didn't improve after hydration, will receive promethazine IV
3197502|NCT00861536|Experimental|ATG Fresenius|
2512860|NCT02811510|Active Comparator|THC|10 mg Dronabinol will be administered orally.
2512865|NCT02811510|Placebo Comparator|Placebo|Placebo pill (no active cannabinoids).
3197503|NCT00861536|Active Comparator|Thymoglobuline Genzyme|
3197504|NCT00861549|Experimental|cohort 1|1mg / 0.5 tablet
3197505|NCT00861549|Experimental|cohort 2|2mg / 1 tablet; crossover with Phencynonate hydrochloride (2mg/1 tablet) made in China
3197506|NCT00861549|Experimental|cohort 3|4mg / 2 tablets
3197507|NCT00861562|Active Comparator|Imescard pills/Placebo crossover|Patients received Imescard water smartweed composed pills during the first intervention period and placebo during the second, after a 10-day washout period.
3197508|NCT00861562|Active Comparator|Placebo/Imescard pills crossover|Patients received placebo during the first intervention period and Imescard water smartweed composed pills during the second, after a 10-day washout period.
3197509|NCT00861588|Experimental|isoflavones|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive isoflavones
3197510|NCT00861588|Placebo Comparator|starch|Subjects who met the inclusion and exclusion criteria would be randomly assigned (concealment of allocation) to receive placebo
2513261|NCT02808741|Experimental|F901318 SDD|Liquid formulation
2513265|NCT02808741|Experimental|F901318 IR|Solid formulation
2513267|NCT02808741|Experimental|F901318 IR Fasting|Fasting solid formulation
2513269|NCT02808741|Experimental|F901318 IR Fed|Fed solid formulation
2513350|NCT02808416|Experimental|Personalized cellular vaccine|Patients will undergo tumor resection or biopsy, and receive biweekly cellular vaccines consisting of mRNA-pulsed autologous DCs.
2513374|NCT02807909|Experimental|BMS-986177 and Itraconazole|Single dose BMS-986177 on day 1 followed by Itraconazole and BMS-986177 on specified days
2513375|NCT02807909|Experimental|BMS-986177 and Diltiazem|Single dose BMS-986177 on day 1 followed by Diltiazem ER and BMS-986177 on specified days
2513394|NCT02807701|Active Comparator|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy Under general anesthesia, the patient is placed in a supine position with the legs abducted. Carbon dioxide pneumoperitoneum is established using an open technique through a 10-mm trocar over the umbilicus. A 30 telescope is inserted to examine the peritoneal cavity, liver, stomach, and mesentric vessels.Then 4 to 6 more trocars are inserted under direct vision in the epigastrium and upper quadrants~dissection~reconstruction"
2513395|NCT02807701|Active Comparator|Open pancreaticoduodenectomy|"Open pancreaticoduodenectomy Abdomen is opened from the Bilateral Subcostal incision. (Chevron's Incision) 2. Abdominal cavity is explored for metastasis especially in liver, base of mesentary, mesocolon and pelvis.~Dissection Reconstruction Pancreaticogastrostomy Hepaticojejunostomy is next- Done in single layer and can be performed in interrupted or continuous fashion.~Gastrojejunostomy is the final step of reconstruction."
2513474|NCT02807454|Experimental|Pomalidomide+ Daratumumab+ Durvalumab+ Dexamethasone Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward~oral POM at 4mg/day on days 1 to 21~oral/IV dex at 40mg/day (>75 years old) or 20mg/day (>75 years old) on days 1, 8, 15 and 22"
3197511|NCT00861640|Experimental|Intravenous Omeprazole|100 cases of Intravenous Omeprazole
3197512|NCT00861640|Experimental|Oral Rabeprazole|100 cases of oral rabeprazole
3197513|NCT00861666|Other|Forgiveness-based Writing|
3197514|NCT00861679|Other|HSCT from matched family or unrelated donors(MD)|HSCT from matched family or unrelated donors(MD) to matched related donors.
3197515|NCT00861718|Experimental|AZD7268|
3197516|NCT00861718|Placebo Comparator|Placebo|
3197517|NCT00861731|Active Comparator|1|hypolipidemic treatment
3197518|NCT00861731|Sham Comparator|2|hypolipidemic treatment
3197519|NCT00861731|Sham Comparator|3|hypolipidemic treatment
2512318|NCT02815241|Experimental|BAY987517|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2512344|NCT02815020|Other|Boot Camp Translation|"Boot Camp Translation is rolled out in a stepped wedge design across participating PBRNs to assist practices with SMS implementation. The Boot Camp Translation intervention initiates practices to review and begin uptake and implementation of tools from the AHRQ Self-Management Support tool library."
3164088|NCT00493051|Other|1|Standardized Wound Care
3164089|NCT00493051|Placebo Comparator|2|Placebo 1 dose
3164090|NCT00493051|Placebo Comparator|3|Placebo 2 doses
3164091|NCT00493051|Active Comparator|4|Active 1 dose
2512496|NCT02814045||Alzheimer with OSA|Alzheimer with OSA after PSG
2512499|NCT02814045||Alzheimer without OSA|Alzheimer without OSA after PSG
2512734|NCT02812524|Experimental|Intratumoral Ipilimumab|Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure.
2512799|NCT02812004|Experimental|Study Eye|Ultra Q Reflex YAG laser (Ellex)
2512800|NCT02812004|Sham Comparator|Contralateral Eye|Short light impulse is simulated
2512929|NCT02811614|Experimental|Experimental 1: Endoscopic Evacuation|Endoscopic hematoma evacuation with the help of a self-developed working channel.
2512931|NCT02811614|Experimental|Experimental 2: Stereotactic Aspiration|Place a catheter into the main body of the hematoma and aspirate blood.
2512933|NCT02811614|Active Comparator|Active Comparator: Craniotomy|Craniotomy with a big bone flap to for hematoma evacuation.
2512981|NCT02810691|Active Comparator|Soluble fiber, dose #1|Soluble fiber supplementation with dose #1 (smaller dose) of psyllium fiber.
2512987|NCT02810691|Active Comparator|Soluble fiber, dose #2|Soluble fiber supplementation with dose #2 (bigger dose) of psyllium fiber.
2512990|NCT02810691|Placebo Comparator|Placebo|A 250 ml placebo solution of orange-flavored water will be drink at breakfast.
2513061|NCT02810301|Experimental|Treatment (Probiotic ES1)|Capsules containing 1 billion CFU of B. longum ES1 per capsule. One capsule taken before and after consuming 2 slices of bread for 7 days.
2513063|NCT02810301|Placebo Comparator|Placebo|Capsules not containing the active ingredient B. longum ES1. One capsule taken before and after consuming 2 slices of bread for 7 days.
2513090|NCT02809781|Experimental|Intravenous infusion of MSCs|Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
2513092|NCT02809781|Active Comparator|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
2513137|NCT02809547|Active Comparator|In Clinic monitoring|70 method comparison patients who represent a C-reactive protein (CRP) reference range and have retrievable study outcome measures will have a whole blood sample and DBSS taken at recruitment and at a routine six week review.
2513138|NCT02809547|Experimental|At Home monitoring|30 Prospective patients will provide (i) one whole blood sample and one set of dried blood spot samples (DBSS) at recruitment, (ii) a set of DBSS once a week for six weeks from recruitment, with a matched whole blood sample at six week appointment, (iii) two extra sets of DBSS to be taken during a flare and 24 hours after (iv) 6 prospective patients will have daily hand movement data collected for 5 minutes on each occasion using a provided data glove.
2513150|NCT02809287||study group|patients with left lateral position plus jackknife posture when perform laparoscopic hepatectomy
2513205|NCT02809105|Experimental|Part I ASP0456|ASP0456 will be administered orally for 4 weeks.
2513206|NCT02809105|Placebo Comparator|Part I Placebo|Placebo will be administered orally for 4 weeks.
2513207|NCT02809105|Experimental|Part II ASP0456|ASP0456 will be administered orally.
2513313|NCT02808364|Experimental|Personalized cellular vaccine|Subjects will undergo tumor resection. They will receive biweekly cellular vaccines consisting of mRNA tumor antigen pulsed autologous DCs.
2513358|NCT02808091|Experimental|Early stage (IB or bulky disease - II)|who will receive GIFOX-B chemotherapy followed by involved field radiotherapy.
2513360|NCT02808091|Experimental|Advanced stage (III - IV)|will receive only chemotherapy alone
2513421|NCT02807805|Experimental|Treatment (abiraterone acetate, niclosamide, prednisone)|Patients receive abiraterone acetate PO QD, niclosamide PO BID and prednisone PO BID. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
2513549|NCT02807168|No Intervention|Usual care|Control Group
2513553|NCT02807168|Experimental|Usual care plus NT-proBNP|Experimental Group
2513595|NCT02806765|Experimental|Dietary Supplement|This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol below the upper tolerable limit
2513596|NCT02806765|Experimental|Control|This experimental arm reflects administration of placebo in softgel capsule
2513631|NCT02806427||enterally fed adults|Adults subjects with a condition for which a calorically dense enteral formula is appropriate, with established enteral access, anticipated to require enteral tube feeding for at least 3 days.
2513653|NCT02806180|Experimental|Single-Operator|For the 'Single Operator Ultrasound Guided IV placement' arm the RN operator will use the ultrasound probe to identify the target vein, and continue to hold and adjust the probe while placing the IV.
2513662|NCT02806180|Experimental|Dual-Operator|For the 'Dual Operator Ultrasound Guided IV placement' arm the RN operator will use the US to identify the target vein, at which time the study coordinator will hold the ultrasound probe in position. The RN operator will then place the IV.
3164092|NCT00493051|Active Comparator|5|Active 2 doses
3164093|NCT00493077|Experimental|1|
3164094|NCT00493116|Experimental|1|
3164095|NCT00493129|Experimental|Ontak|Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
3164096|NCT00493142|Experimental|1|Usual care
3164097|NCT00493155|Experimental|1|
3164098|NCT00493233|Experimental|1|
3164099|NCT00493233|Placebo Comparator|2|
3164100|NCT00493272|Placebo Comparator|Placebo|Nacl
3164101|NCT00493272|Active Comparator|Fibrinogen|Fibrinogen
2512358|NCT02814929||Incidence of any ROP and severe ROP|Incidence of any ROP, severe ROP and its treatment in relation to BW and GA will be evaluated. The same parameters will also be evaluated in preterm babies of refugees.
2512427|NCT02814604|Experimental|Traffic Light|"Participants in this group will download an app which features the nutrition information of the selected product in a multiple coloured traffic light format (i.e. the traffic light system shows a coloured round indicator for each of saturated fat, sugar, and sodium; shaded red (high), amber (medium) or green (low), according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
2512430|NCT02814604|Experimental|Health Star Rating System|"Participants in this group will download an app which features the nutrition information of the selected product in a form of 0-5 stars to provide an overall healthy rating. The Health Star Rating provides a rating for all products and products not meeting the criteria still carry the symbol (with no colored stars). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
2512435|NCT02814604|No Intervention|Control|Participants in this group will only see the Nutrition Facts Table (as it appears on the product's package) when the product is scanned in the app.
2512437|NCT02814604|Experimental|High-in Warning Label|"Participants in this group will download an app which features the nutrition information of the selected product in a 'high-in' warning label format (i.e. stop signs for each of saturated fat, sugar, and sodium; according to thresholds set for each nutrient). In addition, a list of healthier similar products will appear on screen to facilitate comparisons.~Intervention: Device:Smartphone, Behavioural: Nutrition Rating Systems"
2512466|NCT02814084|Active Comparator|Bilateral Internal Mammary Artery grafts|Standard care wound dressings used as part of coronary artery bypass graft operation
2512473|NCT02814084|Experimental|Prevena|Prevena dressing used as part of coronary artery bypass graft operation.
2512544|NCT02813876|Experimental|Enhanced recovery|Enhanced recovery protocol for nursing, diet and analgesic regimen
2512547|NCT02813876|No Intervention|Standard care|Standard care arm
2512692|NCT02812992|Active Comparator|GO-GO arm|Nab-paclitaxel 125 mg/m^2 i.v. over 30 minutes followed by gemcitabine infusion 1000 mg/m^2 on days D1, D8, D15 of a 28-day cycle.
2512693|NCT02812992|Active Comparator|SLOW-GO arm|Gemcitabine 1000 mg/m^2 i.v. on days D1, D8, D15 of a 28-day cycle.
2512694|NCT02812992|Active Comparator|FRAIL arm|Best supportive care as determined by the investigator.
2512767|NCT02812329|Experimental|HIV prevention videogame|Participants will play PlayForward on a tablet computer for 1 hour, two times per week for 3 weeks.
2512831|NCT02811874|Experimental|diabetes education|Four community health workers receive a one-month diabetes education program (intervention group, patients n= 62)
2512833|NCT02811874|Active Comparator|education in other areas|Four community health workers receive an education course in other health issues (control group, patients n= 56).
2512914|NCT02811380|Experimental|BIP CVC|Bactiguard Infection Protection Central Venous Catheter
2512918|NCT02811380|Placebo Comparator|Uncoated standard CVC|Uncoated standard Central Venous Catheter
3164102|NCT00493298||natalizumab|According to the local prescribing information
3164103|NCT00493324|Experimental|1|
2513015|NCT02810249||African American YMSM|
2513081|NCT02810119|Experimental|LO2A|Sodium Hyaluronate
2513083|NCT02810119|Placebo Comparator|Placebo-Controlled Saline|Placebo
2513258|NCT02808767|Experimental|Patients treated with Prasugrel|Prasugrel Loading dose: 60 mg Maintenance dose: 10 mg once-daily; patients >75 years of age or < 60 kg of weight receive a maintenance dose of 5 mg o.d.
2513264|NCT02808767|Experimental|Patients treated with ticagrelor|Ticagrelor Loading dose: 180 mg Maintenance dose: 90mg twice-daily
2513443|NCT02807584|Experimental|ELECT|Adhesive Foam Dressing
3164104|NCT00493337|No Intervention|Control group|
3164105|NCT00493337|Experimental|Advanced counseling|
3164106|NCT00493337|Active Comparator|Compliance Card only|
3164107|NCT00493350||1|Patients with newly diagnosed stage IV breast cancer scheduled to start systemic therapy.
3164108|NCT00493363|Experimental|arm 1|
3164109|NCT00493363|Active Comparator|arm 2|
3164110|NCT00493402|Experimental|combined chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, with particle embolization.
3164111|NCT00493402|Experimental|combined chemotherapy without embolization|chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, without particle embolization.
3164112|NCT00493402|Experimental|single agent chemotherapy with embolization|chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
3164113|NCT00493415|Experimental|1|nitroglycerine iv
3164114|NCT00493415|Placebo Comparator|2|nacl 0.9% 4 ml/h iv in the first 30 minutes, 2 ml/h iv in the next 23 hours and 30 minutes
3164115|NCT00493441|Experimental|Treatment|
3164116|NCT00493480|Active Comparator|carvedilol|
3164117|NCT00493480|Active Comparator|propranolol|Cirrhotic patients treated with propranolol
3164118|NCT00493571|Experimental|Gimatecan|Gimatecan Starting dose: 0.6 mg capsules administered orally once daily.
3164119|NCT00493584|Experimental|1|Primary PCI in patients with acute Non-STEMI
3164120|NCT00493584|Active Comparator|2|Standard medical treatment and coronary angiography after 3 days in patients with Non-STEMI.
3164121|NCT00493610|Other|1|
3164122|NCT00493623|Experimental|1|
3164123|NCT00493623|Placebo Comparator|2|
3164124|NCT00493688||Cardiopulmonary Exercise Testing (CPET)|
3164125|NCT00493701|Other|Lifestyle|Measurement of body weight in a fown with light undercloting (30 minutes) and height.
3164126|NCT00493701|Other|DEXA Scanner|Low-dose X0rays to determine the amount of fat, bone and muscle in your body.
3164127|NCT00493714||Arm 1 (Patient)|Cancer patient who recently experienced confusion or restlessness.
3164128|NCT00493714||Arm 2 (Caregiver)|Caregivers of cancer patients who recently experienced confusion or restlessness.
3164129|NCT00493727|Other|1|
3164130|NCT00493766|Experimental|oral LBH589 alone|
3164131|NCT00493766|Experimental|oral LBH589 + IV docetaxel + oral prednisone|
2512365|NCT02814864|Experimental|Mesenchymal Stromal Cell (MSC)|Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)
2512433|NCT02814435||Patients|Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.
2512436|NCT02814435||Normal controls|Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.
2512458|NCT02814097|Experimental|40 mg elamipretide|40 mg elamipretide once daily for 28 consecutive days
2512464|NCT02814097|Placebo Comparator|Placebo|Placebo once daily for 28 consecutive days
2512534|NCT02813746||Obese non smoker vs Normoweight non smoker|Endometrial fluid (EF) will be obtained from non-smokers normo-weight and obese patients in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. They will be classified following the guidelines of the obesity classification system by the World Human Organization (WHO). Patients will be subjected to a fitness program during a year with the aim to achieve a weight reduction to normal values (19-24.9 kg/m2). The modifications in the miRNAs expression will be studied. After the weight loss, new EF will be collected from these patients.
2512536|NCT02813746||Normoweight smoker vs Normoweight non-smoker|EF will be obtained from non-smokers and smokers normo-weight in the receptive state. Samples will be collected 7 days after Luteinizing Hormone (LH) peak. Smokers patients will be urge to give up smoking during at least one year. After this time, new samples will be collected to determine if the non-exposition to this contaminant could exert any effect in the miRNAs signature. A regular control will be done in this group of patients to ensure that they have not been exposed to tobacco in 12 months. Professional support will be given in the same centre of the study to help the patient to accomplish its objective.
2512581|NCT02813369||naloxegol|patients exposed to naloxegol
2512584|NCT02813369||non-PAMORA laxative|patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
2512706|NCT02812810|Experimental|active rTMS|
2512708|NCT02812810|Placebo Comparator|placebo rTMS|
2512743|NCT02812212|Experimental|Open-label|"Device: ultrasonography and diuretic renography Bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.~Diuretic renography to measure the cortical transit time"
3164132|NCT00493792|Other|1|Stryker Orthopaedics N2Vac Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
3197520|NCT00861770|Other|1 - Control|All subjects will receive blood volume measurement immediately before and 30 minutes after ultrafiltration is completed. In the control group, the treating physician will not see the blood volume measurement results and treat according to standard of care.
2512851|NCT02811432|Experimental|Kangaroo mother care|Skin-to-skin care initiated as soon as possible following randomisation
2512854|NCT02811432|Active Comparator|Standard care|Incubator or radiant warmer
2512907|NCT02811276|No Intervention|Control Group|Those assigned to the Control Group will receive a eucaloric diet (a diet designed to meet the person's energy needs and maintain body weight) composed of 55% of carbohydrate, 15% of protein, and 30% of lipid.
2512908|NCT02811276|Experimental|High-Protein Diet Group|Those assigned to the High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®).
2512999|NCT02810925|Experimental|PENS T6 and 1200 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
2513000|NCT02810925|Active Comparator|PENST6 + Normocaloric 2000 Kcal/day diet|Patients undergo 12 sessions of percutaneous electrical stimulation of dermatome T6 (PENS T6), weekly, during 12 weeks. During this period they follow a normocaloric 2000 Kcal/day diet.
2513003|NCT02810925|Placebo Comparator|TENS T11/ T12 + 1200 Kcal/day diet|Patients undergo 12 sessions of transcutaneous electrical stimulation of dermatomes T11-T12 , weekly, during 12 weeks. During this period they follow a hypocaloric 1200 Kcal/day diet.
2513004|NCT02810925|Active Comparator|1200 Kcal/day diet|Patients follow only a hypocaloric 1200 Kcal/day diet.
2513034|NCT02810210||Cohort 1|Monitoring of children born without congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
2513037|NCT02810210||Cohort 2|Monitoring of children born with congenital anomalies to mothers with biologically confirmed ZIKV's infection during the pregnancy
2513039|NCT02810210||Cohort 3|Monitoring of children born without congenital anomalies to mothers with no biologically confirmed ZIKV's infection during the pregnancy
3197521|NCT00861770|Experimental|2 - BVM|Ultrafiltration will be guided by blood volume measurement results.
3197522|NCT00861783|Experimental|Group A - irinotecan|"Note: As of Amendment 2 (March 2009), treatment in the irinotecan arm of the study (Group A) is closed to enrollment.~Treatment with escalating doses of ON 01910.Na in combination with irinotecan."
2513156|NCT02809170|Active Comparator|Arginine|Endothelial function will be assessed before and after arginine supplementation
2513161|NCT02809170|Active Comparator|Citrulline|Endothelial function will be assessed before and after citrulline supplementation
2513430|NCT02807714||No CAD|Patients scheduled for elective cardiac catheterization for evaluation of suspected CAD that are found to not have CAD
2513434|NCT02807714||Obstructive CAD (non-ACS) Group|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have obstructive CAD requiring intervention.
2513438|NCT02807714||Stable CAD, no intervention required|Patients scheduled for elective cardiac catheterization for evaluation of known or suspected CAD that are found to have non-obstructive CAD not requiring intervention.
2513441|NCT02807714||Acute Coronary Syndrome (ACS)|Patients who undergo an emergent cardiac catheterization for evaluation of known or suspected STEMI, NSTEMI, Unstable Angina (UA).
2513470|NCT02807454|Experimental|Daratumumab Plus Durvalumab Treatment|"Intravenous (IV) durvalumab at 1500mg on Day 1 or 2 of a 28-day cycle~IV daratumumab at 16mg/kg on days 1, 8, 15 and 22 at cycles 1-2; on days 1 and 15 at cycles 3-6; and on day 1 from cycle 7 onward"
2513526|NCT02807064|Placebo Comparator|placebo|Placebo 0.5 ml per os all days for 2 months
2512428|NCT02814721|No Intervention|Standard cannulation|The standard cannulation protocol of the center was defined as using 17 gauge needles for the first 3 dialysis sessions, followed by 16 gauge for the next 3, and finally 15 gauge for subsequent sessions.
2512431|NCT02814721|Active Comparator|Ultrasound guided cannulation|The study protocol involved similar up titration of needle size over a 3-week period, except that a pre-cannulation evaluation of the fistula was performed using the Sonic Window ultrasound device. The device was used to evaluate and identify the optimal site of cannulation (image 1). Depending upon the cannulator's preference, real-time guidance could be employed during cannulation (image 2, 3). The cannulations were performed by 4 selected personnel trained in device use and successfully completed a competency evaluation on simulator models and a mature dialysis fistula.
2512463|NCT02814149|Active Comparator|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
2512470|NCT02814149|Active Comparator|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
3164133|NCT00493792|Other|2|X3 Polyethylene when used with a Triathlon Posterior Stabilized total knee system. This is a fixed- bearing knee intended for use in patients undergoing cemented total knee arthroplasty.
3164134|NCT00493844|Experimental|1|Discharge if clinical risk score <3 points + Nt-proBNP <110 ng/L
2512639|NCT02813200|Experimental|Group 1|
2512642|NCT02813200|Experimental|Group 2|
2512643|NCT02813200|Experimental|Group 3|
2512726|NCT02812368|Experimental|Clonidine|Taken once a day at bedtime; with the dose titrated from 0.05mg to 0.20mg over the course of 6 weeks
2512727|NCT02812368|Placebo Comparator|Placebo (for clonidine)|Taken once a day at bedtime
2512795|NCT02812056|Experimental|Alisertib + TAK-228|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase:~Alisertib and TAK-228 taken at the maximum tolerated dose from Dose Escalation Phase."
2512875|NCT02811666|Experimental|Patients operated for liver or pancreas cancer|
2512927|NCT02811133|Experimental|Inositol|Subjects will receive inositol
2512972|NCT02810782|Experimental|Phenobarbital|Phenobarbitone loading dose 10 mg/kg body weight maintenance dose 0.83 mg/kg body weight every 4 hours
2512974|NCT02810782|Active Comparator|Chlorpromazine|Chlorpromazine loading dose 0.5 mg/kg body weight maintenance dose 0.25 mg/kg every 4 hours
2512977|NCT02810782|Active Comparator|Morphine|Morphine (tinctura opii) 0.25 mg/kg body weight every 4 hours
2513009|NCT02810353|Experimental|Expander with differential opening group|The experimental group will comprise 25 patients who will be submitted to rapid maxillary expansion using the expander with differential opening. The expander will be composed by two 11-mm screws, one anteriorly and the other posteriorly positioned on the palate (Great lakes Orthodontics Ltd, NY, EUA).
2513011|NCT02810353|Active Comparator|Hyrax group|The control group will be comprised by 25 patients who will undergo rapid maxillary expansion using the conventional Hyrax expander. The expander will be composed by one 11-mm screw centrally positioned on the palate (Dentaurum, Ispringen, Germany).
2513085|NCT02810093||Breast cancer patients between 2000 and 2016|Patients treated for a breast cancer between 2000 and 2016 in the Hospital of Strasbourg (France).
2513132|NCT02809612|Experimental|Internet-based intervention|"Patients randomized to the internet-based intervention will be given access to the information in the internet-based platform directly after randomization. During the first 6 weeks, information will be offered in a structured way, with a theme changing weekly. After this time-point, the patients will have the possibility to navigate through all information. The platform encompasses internet-based training including information on the disorder, psycho-education and information of simple self-implemented intervention strategies cope with vulvodynia and ameliorate dyspareunia. The platform will also include videos where team members will describe their role in treating patients with the disorder, but also short videos from former patients willing to share their individual stories."
2513135|NCT02809612|No Intervention|Control group|Patients randomized to the control group through the platform will immediately be informed about the fact that there is available information and resources on the internet and that they will be called for a visit to the physiotherapist-midwife at due time, according to the present guidelines of care followed in the respective clinic (Uppsala, Falun, Gävle).
2513163|NCT02809326|Experimental|17 week Trauma Management Therapy (TMT)|TMTconsists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions (14 sessions) are followed by Social and Emotional Regulation (SER) sessions conducted in small groups. Individual exposure therapy includes virtual reality to assist in augmenting exposure therapy. Group therapy includes anger management, social skills training, problem solving and behavioral activation for depression. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
2513164|NCT02809326|Experimental|3 week Trauma Management Therapy (TMT)|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
2513165|NCT02809326|Active Comparator|17 week Exposure Therapy Control Arm|The Control Arm of the study contains 15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
3164135|NCT00493844|Active Comparator|2|Discharge if negative exercise testing
3164136|NCT00493857|Experimental|2|Nimotuzumab 400mg every week or every two weeks
2512432|NCT02814552|No Intervention|De-identified historical data|De-identified historical data will be collect based on age (no dates), blood pressure of treated (noted with medications), blood pressure of non-treated (noted without medications), and list of medications. The data will be compared to the High Blood Pressure Consented group to determine the effect of using the HTN PRA App.
2512460|NCT02814071|No Intervention|Fasting with intravenous fluids|The child will be kept fasted. Intravenous fluids will be at a rate and type as directed by the treating clinician. A low fat oral diet will be commenced once abdominal pain resolves and serum amylase/lipase levels decrease from the peak levels as per treating clinician. In the event that the patient is unable to tolerate oral feeding, tube feeding or parenteral nutrition may be commenced based on the clinical decision of the treating clinician(s). This will be recorded as an adverse event. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled as per treating clinician's discretion
2512465|NCT02814071|Experimental|Early enteral feeding|Patients will commence on an unrestricted oral diet within 24 hours of presentation, meeting 50% of EER with a regular diet and no fat restriction for the first 24 hours of enteral feeding. A 75-100% EER is targeted ≥ 24 hours of enteral feeding.If the targeted EER is not met orally, a nasogastric tube will be inserted to provide bolus feeds of a standard formula with standard fat content. If the patient fails to tolerate both oral and bolus nasogastric tube feeding, continuous nasogastric tube feeding will be provided. If all fails, enteral nutrition by nasojejunal tube feeding or parenteral nutrition may be commenced based on the clinical decision. Patients will be re-trialed on oral feeds once initial limiting symptoms or factors have improved or settled.
2512543|NCT02813941|Experimental|Alternative GRADE SoF table|Two SoF tables (alternative GRADE SoF table and EPC SoF table) will be used in this randomized controlled non-inferiority trial as an intervention. The alternative GRADE SoF table format will be developed from a user-testing survey.
2512545|NCT02813941|Experimental|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published.
2512548|NCT02813941|Active Comparator|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
2512663|NCT02813083||Rheumatoid Arthritis|Rheumatoid arthritis patients
3164137|NCT00493870|Experimental|TC|docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2
2512815|NCT02811991|Active Comparator|Experimental:Paracetamol Injection|325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment
2512818|NCT02811991|Placebo Comparator|Placebo:Normal Saline Injcetion|32.5mLor 50mL iv q6h according to assignment.
2513005|NCT02810574|Active Comparator|Active noninvasive brain stimulation and cognitive training|In active condition, subject will receive stimulation during all the 30-minute stimulation period combined with cognitive training.
2513006|NCT02810574|Sham Comparator|Sham noninvasive brain stimulation|In sham condition, subject will receive stimulation only during the first 30 seconds of the 30-minute stimulation period combined with cognitive training.
3164138|NCT00493870|Active Comparator|TAC|doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2 and docetaxel 75 mg/m2
3164139|NCT00493883|Other|TheraSphere|"Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver~--------------------------------------------------------------------------------"
2513139|NCT02809560|Experimental|Asthmatic children|Induced sputum method using hypertonic serum
2513140|NCT02809560|Sham Comparator|Control children|Induced sputum method using hypertonic serum
2513146|NCT02809261|Experimental|Perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% Dextrose (3cc) between proximal carpal tunnel and median nerve.
2513147|NCT02809261|Placebo Comparator|Perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and median nerve.
2513237|NCT02809040||Hypertensive Heart Disease|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2513241|NCT02809040||Volunteer subjects|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2513246|NCT02809040||Diagnosed Hypertension|Portable Digital Auscultation/ Electrocardiogram/Echocardiography/ Traditional Stethoscope
2513307|NCT02808533|Experimental|Topiramate|Topiramate will be dispensed on a biweekly basis, and pill counts conducted at each visit.
2513309|NCT02808533|Placebo Comparator|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
2513400|NCT02808104|Experimental|Mazindol Controlled Release|Mazindol controlled release taken once daily. Dosage starting at 1 mg increasing or decreasing in increments of 1 mg depending on efficacy and tolerability. Maximum dose during the study is 3 mg taken once daily.
2513401|NCT02808104|Placebo Comparator|Placebo|Matching placebo
2513561|NCT02807051|Experimental|Pacritinib and Clarithromycin|Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
2513608|NCT02806609|Other|Group 1|Cold water immersion, with 10 degrees, for 10 minutes
2513611|NCT02806609|Other|Group 2|immersion in water at room temperature
2513614|NCT02806609|Other|Group 3|active recovery - running
2513616|NCT02806609|Other|Group 4|rest in the chair
2513635|NCT02806258|Active Comparator|Arm A|6-8 cycles of Primary systemic therapy using anthracycline and/or taxane based regimens, according to their physician's preference and center policy
2513641|NCT02806258|Experimental|Arm B|The patients will receive 3D conformal or other modality (eg IMRT, VMAT) APBI during their PST sequence. APBI will be planned sequentially between the Primary systemic therapy cycles, 2 weeks after the 3rd/6 or the 4th/8 cycle of PST.
2513706|NCT02805959||Constipated, Elderly|Investigation with MTS for motility
2513707|NCT02805959||Constipation, Young|Investigation with MTS for motility
2513710|NCT02805959||Normal Bowel, Elderly|Investigation with MTS for motility
3164140|NCT00493896|Experimental|Fondaparinux|Fondaparinux treatment - one standard of care option
3164141|NCT00493896|Active Comparator|2|Enoxaparin
3164142|NCT00493909|Active Comparator|1|thoracic epidural analgesia
3164143|NCT00493909|Active Comparator|2|intrathecal opioids and thoracic paravertebral analgesia
2512631|NCT02813395|No Intervention|Control group|Volunteers remained at rest before and after the fatigue protocol.
2512633|NCT02813395|Placebo Comparator|Placebo group|Volunteers were subjected to laser application simulation for approximately four minutes with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
2512636|NCT02813395|Experimental|Laser before|Volunteers received effective application of laser before fatigue protocol.
2512637|NCT02813395|Experimental|Laser after|Volunteers received effective application of laser after fatigue protocol.
2512680|NCT02812901|Other|morning group|cardiac surgery scheduled in the morning
2512681|NCT02812901|Other|afternoon group|cardiac surgery scheduled in the afternoon
2512699|NCT02812459|Experimental|Kinesio taping plus exercise|Kinesio taping application for low back plus back exercises.This protocol will be administered three a week for 4 weeks.
2512700|NCT02812459|Active Comparator|Electrical stimulation plus exercise|Electrical stimulation for control pain applied in low back plus exercises.This protocol will be administered three a week for 4 weeks.
2512736|NCT02812277||Anastrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted anastrozole therapy with the completed follow-up data.
2512739|NCT02812277||letrozole treatment group|The study group was about HR positive postmenopausal breast cancer patients who were hospitalized between January, 2008 and October, 2010, and ever accepted letrozole therapy with the completed follow-up data.
2512796|NCT02811952||study group|Patients that need that need cystoscopy due to suspicion/known bladder malignancy.
2512798|NCT02811952||control group|Patients that need cystoscopy due to others reasons than malignancy.
2512861|NCT02811705||PFAPA group|Life quality for PFAPA patient report by themselves or parent
2512864|NCT02811705||FMF group|Life quality for FMF patient report by themselves or parent
2512895|NCT02811198||MDD with SI and No Attempt|Subjects will have MDD with current MDE, current suicidal ideation and no lifetime suicide attempts
2512896|NCT02811198||MDD with SI and Recent Attempt|Subjects with have MDD with current MDE, current suicidal ideation and a suicide attempt within the past 6 months
2512897|NCT02811198||MDD with no SI and Lifetime Attempt|Subjects with MDD and current MDE but no current suicidal ideation and a lifetime suicide attempt.
2512899|NCT02811198||Healthy Controls|Subjects will have no personal or family psychiatric history and no suicide attempts.
2512951|NCT02810990|Experimental|Bosutinib treatment|
2513027|NCT02810483|Experimental|Arm 1: Topiramate|Topiramate Arrow 50 mg hard capsules
2513032|NCT02810483|Placebo Comparator|Arm 2: Placebo Comparator|50 mg hard capsules with the same shape, color and taste than the active product
2513097|NCT02809937|Experimental|dexmedetomidine group|For patients who were not intubated, dexmedetomidine was infused at a rate of 0.1 microgram/kg per hour from study recruitment on the day of surgery until 8:00 am on the first day after surgery. For patients who were intubated and mechanically ventilated, dexmedetomidine infusion was started after the Richmond Agitation Sedation Scale was -2 or higher after intensive care unit admission until 8:00 am on the first day after surgery.
2513098|NCT02809937|Placebo Comparator|placebo group|Normal saline was infused in the same rate for the same duration as that in the placebo group.
2513183|NCT02809521|Other|Activity Liking|Subjects will look at images of people doing different types of activities (e.g., walking, skiing, watching television) and rate their liking of the activity.
2513211|NCT02808910|Experimental|Salt nudge|The following changes will be made in the cafeteria: Salt will be placed in a corner of the buffet, rather than on each dining table. Other spices, without sodium, will be provided on the table. A sign will be placed on the table that nudges participants to try the other spices. Food in the buffet that is high in salt will be labeled with a negative-appearing symbol, and food in the buffet that is low in salt will be labeled with a positive symbol.
2513220|NCT02808910|Experimental|Vegetable nudge|The following changes will be made in the cafeteria: Names of the vegetable dishes in the buffet will be made more attractive. Signs will be placed with reminders to eat more vegetables. Signs will be placed with a visual indication of the percentage of a meal that should consist of vegetables.
2513225|NCT02808910|Experimental|Portion size nudge|The following changes will be made in the cafeteria: Smaller plates will replace the regular plates. Verbal and visual nudges to reduce portion size will be given. Utensils for self-serving calorie-dense foods in the buffet will be smaller than normal.
2513230|NCT02808910|Experimental|Combined nudge|All three nudges are combined in this intervention.
2513232|NCT02808910|No Intervention|Control groups|No changes are made to the cafeteria, compared to the pre-study situation. One control group participates after each of the nudges to control for effects of time of the year.
2513300|NCT02808494||Affected Group|Women with a diagnosis of preeclampsia or fetal growth restriction.
2513304|NCT02808494||Control/Unaffected Group|Women who do not have a diagnosis of preeclampsia or fetal growth restriction.
2513359|NCT02808078|Experimental|Augmented reality training|Gait training with augmented reality
2513362|NCT02808078|Active Comparator|Standard training|Gait training without augmented reality
2513380|NCT02807818|Experimental|Nurse home visits|Nurse biweekly home visit.
2513383|NCT02807818|No Intervention|Usual care|Usual care.
2513437|NCT02807662|Experimental|Experimental|Intervention mothers receive adapted Seeking Safety intervention delivered by prenatal care advocate over 8 sessions
2513440|NCT02807662|No Intervention|No intervention|Treatment as usual mothers receive usual services of a prenatal care advocate
2513464|NCT02807428|Experimental|AYX1 Injection 660 mg/6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery.
2513465|NCT02807428|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
2513570|NCT02806882|Experimental|Ceftaroline fosamil|600mg 1 hour intravenous infusion ZINFORO
2515242|NCT02795429|Experimental|INC280+PDR001|PDR001 + INC280 treatment in Phase II
2512582|NCT02813304|Active Comparator|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap and a towel cloth. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
2512729|NCT02812628|Active Comparator|Conventional LAPR|Patients undergoing conventional laparoscopic abdominoperineal resection (LAPR).
2512732|NCT02812628|Experimental|LAPR-TILT|Patients undergoing LAPR with transabdominal individualized levator transection (TILT).
2512797|NCT02812030||aflibercept in real world|Patients receiving aflibercept for diabetic macular oedema at Bristol Eye Hospital or Gloucestershire Hospitals NHS Foundation Trust
2512848|NCT02811679|Experimental|Blinatumomab|Blinatumomab will be administered as a continuous IV infusion through a central venous catheter for a 42 day cycle. Blinatumomab will start with a 7 day infusion at 9mcg/d. If no dose limiting toxicity (table 6.1) after 7 days, the dose will be escalated to 28 mcg/d for 7 additional days. If no dose limiting toxicity (table 6.1) after 14 days, blinatumomab will be infused at a target dose of at 112mcg/d for 28 days. Subjects will be restaged after a 6 week treatment free period by PET CT. All subjects without disease progression will receive an additional 4 week cycle starting at the target dose of 112 mcg/d.
2512971|NCT02810886|Experimental|Single, arm exploratory|Patients will undergo a 68Ga-PSMA PET/CT within 1 month after routine imaging diagnostic work-up.
3197523|NCT00861783|Experimental|Group B - oxaliplatin|Treatment with escalating doses of ON 01910.Na in combination with oxaliplatin.
3197524|NCT00861796|Experimental|1|
2513094|NCT02809677|Other|Non-Interventional Longitudinal Study|This is a 52 week non-placebo controlled and non-randomized clinical research study to see whether treating Major Depressive Disorder (MDD) in caregivers of children with asthma will improve asthma outcomes in children. Caregivers may choose to receive an antidepressant medication that is considered standard medical care for MDD, or may opt out of antidepressant treatment. No treatment is withheld from participants and no placebos are used, thus there is no active intervention in this study.
2513154|NCT02809313|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct probiotic containing one sachet Lactobacillus rhamnosus per day during 3 month
2513158|NCT02809313|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral hygiene instruction) and adjunct placebo containing one sachet placebo (talc power) per day during 3 month
2513209|NCT02809027|Active Comparator|Ginger|Ginger capsule (500 mg), oral form, 2 capsules 3 time after meal for 3 days
2513217|NCT02809027|Sham Comparator|Placebo|Placebo capsule, oral form, 2 capsules 3 time after meal for 3 days
2513270|NCT02808702|Experimental|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
2513559|NCT02807155|No Intervention|Non-Intervention Control|No intervention will be delivered.
2513563|NCT02807155|Experimental|Continuity Group|"Continuity Group participants aged 20-21 (i.e. the last year of the LEAP Program) will be seen at one of the 2 study centers - 1) the newly established LAC+USC Diabetes Transition Clinic; or 2) Children's Hospital Los Angeles Pediatric Endocrinology Clinic, and will receive the full 1-year Transition Empowerment Program - Continuity Group"
2513564|NCT02807155|Experimental|Rescue Group|"Rescue Group participants aged 21-25 will be connected to a diabetes healthcare home (medical clinic or doctor's office) in Los Angeles County based on geography and personal preference. Those individuals connected to the LAC+USC Diabetes Transition Clinic will receive the full 1-year Transition Empowerment Program - Rescue Group (TEP-RG). Those assigned to other providers in LA County will have access to the web-based curriculum."
2513610|NCT02806622||Division II Collegiate Athletes|Student athletes (18-45) currently enrolled and participating on a sports team.
2513718|NCT02805920|Active Comparator|GROUP 1 : G20|Postoperative pain for ACLR : G20 : received ACB with 20 ml 0.25% Bupivacaine
2513719|NCT02805920|Active Comparator|GROUP 2 : G25|Postoperative pain for ACLR : G25: received ACB with 25 ml 0.25% Bupivacaine
2513720|NCT02805920|Active Comparator|GROUP 3 : G30|Postoperative pain for ACLR : G30 received ACB with 30 ml 0.25% Bupivacaine
2513807|NCT02805452|Experimental|Succinate of Solifenacin|1 tablet of 5 mg of succinate of Solifenacin will be administered each day for 3 months.
3197525|NCT00861796|Placebo Comparator|2|
3197526|NCT00861809|Experimental|Cohort 1 Period 1|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3197527|NCT00861809|Experimental|Cohort 1 Period 2|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3197528|NCT00861809|Experimental|Cohort 1 Period 3|All patients will receive placebo and 2 of the 3 possible doses of GSK962040 in a randomized, double blind, placebo controlled, incomplete block, three period crossover design.
3197529|NCT00861822|Active Comparator|RBC|Advance RBC transfusion' (ART) group
3197530|NCT00861822|Other|Standard Care|Standard-of-care RBC transfusion (SRT) group
2512586|NCT02813460|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations C D B E A F on day 1.
2512587|NCT02813460|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations D E C F B A on day 1.
2512588|NCT02813460|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations E F D A C B on day 1.
2512589|NCT02813460|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 mL of each 6 ALS-008176 formulations F A E B D C on day 1.
2512590|NCT02813460|Experimental|Session 2: Sequence 1|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G1 G2 H3 G3 H2 H1).
2512592|NCT02813460|Experimental|Session 2: Sequence 2|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G2 G3 G1 H1 H3 H2).
2512593|NCT02813460|Experimental|Session 2: Sequence 3|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (G3 H1 G2 H2 G1 H3).
2512595|NCT02813460|Experimental|Session 2: Sequence 4|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H1 H2 G3 H3 G2 G1).
2512596|NCT02813460|Experimental|Session 2: Sequence 5|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H2 H3 H1 G1 G3 G2).
2512598|NCT02813460|Experimental|Session 2: Sequence 6|Participants will receive 5 mL of two best scoring formulations from Session 1 with 3 varying concentrations of sucralose (H3 G1 H2 G2 H1 G3).
2512695|NCT02812615|Experimental|Malnourished participants|After screening the participants for any organic diseases and application of inclusion/exclusion criteria, stunted children, children who are at risk of stunting and malnourished adult cases will receive one egg, 150 ml of milk 6 days a week for 3, 2 and 2 months respectively. Along with that participants will also get Anti-helminthic treatment (Albendazole/Pyrantel Pamoate) and nutritional counselling. Children will get one sachet of multiple micro-nutrient sprinkles per day to be administered at home with the mid-day meal for two months.
2512761|NCT02812264|Experimental|API App|use of API weight loss mobile application for 12 months, plus fitness tracker and scale.
2512766|NCT02812264|Active Comparator|Attention Control|use of non-API app for weight loss over 12 months, plus fitness tracker and scale.
2512816|NCT02811744|Experimental|Amnestic MCI cohort|Patients with Mild Cognitive Impairment (MCI) (up to 14) will be recruited primarily from the Penn Memory Center (PMC). Clinical diagnostic criteria (described in further detail in Study Procedures section) will be used to identify subjects who are meet criteria for amnestic MCI. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
2512820|NCT02811744|Other|Control cohort|Normal control subjects in the same age range (up to 6) will be recruited from a current ongoing study investigating neuroinflammation in late life depression and healthy controls, from the control group in which all subjects receive MRI and LP and from the PMC research cohort. Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
2512947|NCT02811016|Experimental|budesonide 200|inhaled budesonide 200 µg bid
2512949|NCT02811016|Experimental|budesonide 800|inhaled budesonide 800 µg bid
2512950|NCT02811016|Placebo Comparator|placebo|inhaled placebo bid
2512964|NCT02810652|Experimental|Perioperative Geriatrics Intervention|Evaluation with a board-certified geriatric clinician, both pre- and post-operatively.
2512968|NCT02810652|Active Comparator|Standard Care|Usual care participants will not meet with a geriatric clinician perioperatively, but may receive a geriatric consult upon request or at the discretion of their treating clinician(s).
3164144|NCT00493922|Active Comparator|2|Microscopy for diagnosis of malaria
2513071|NCT02810015|Experimental|Botulinum Toxin A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
2513118|NCT02809690|Experimental|Diagnostic (18F-FMAU PET/CT)|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT on day 1. Patients then undergo standard of care multiparametic MRI and standard of care transrectal ultrasound-guided biopsy.
2513238|NCT02809001|Experimental|Experimental: Fat grafting|Autologous fat graft transplantation subdermally to expanded skin.
2513244|NCT02809001|No Intervention|Control|Expansion was discontinued until the early signs of complication disappeared.
2513321|NCT02808637|Experimental|Manual Pressure|
2513322|NCT02808637|Experimental|Rapid Injection without Aspiration|
2513323|NCT02808637|Experimental|Manual Pressure + Rapid Injection without Aspiration|
2513327|NCT02808637|Experimental|Control|
2513404|NCT02807961|Placebo Comparator|Placebo|Placebo comparator arm
2513406|NCT02807961|Active Comparator|Active treatment|ELX-02, active comparator
2513482|NCT02807506|Experimental|Clinicians, Caregivers and Elders|Observe Elders, Clinicians and Caregiver's survey, interview and observational responses to stage-wise experimental deployments of a mobile service robot - 1st concept, 2nd mobile base, and 3rd mobile base with arm in daily supportive tasks
2513531|NCT02807103|Experimental|Rituximab with FFS=0|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS=0 will receive 1 gram of rituximab at day 1 and day 15 as induction treatment"
3164145|NCT00493922|Active Comparator|3|Clinical diagnosis for malaria
3164146|NCT00493922|Experimental|1|Rapid Diagnostic Test for Malaria
3164147|NCT00493987|Active Comparator|Testosterone enanthate|
3164148|NCT00493987|Placebo Comparator|Duatesteride|Duatesteride
3164149|NCT00494052|Experimental|1|Heart to Heart intervention
2512622|NCT02813135|Experimental|ARM A. Ribociclib + Topotecan and Temozolomide|Topotecan iv QD and temozolomide capsules orally QD Days 1 to 5; Ribociclib capsules or oral solution orally QD from Day 6 to 20 of a 28 day cycle.
2512625|NCT02813135|Experimental|ARM C. AZD1775 + Carboplatin|AZD1775 capsules orally BID 3 days on / 4 days off in week 1; Carboplatin iv QD AUC 5 on Day 1 of a 21 day cycle.
2512626|NCT02813135|Experimental|ARM D. Olaparib + Irinotecan|Olaparib tablets orally BID on Day 1-10 of a 21 day cycle; Irinotecan iv QD Day 4-8 of a 21 day cycle.
2512627|NCT02813135|Experimental|Arm I. Enasidenib|Enasidenib orally on a continuous dosing once daily (QD) per 28 day cycle.
2512628|NCT02813135|Experimental|Arm J. Lirilumab + Nivolumab|Nivolumab iv QD every 2 weeks of a 28 day cycle (Days 1 and 15); Lirilumab iv QD every 4 weeks of a 28 day cycle (Day 1)
2512701|NCT02812758||patients|All sedated, intubated, mechanically ventilated adult patients admitted for elective cardiac surgery, monitored for sedation depth (with the BIS) and for preload dependence indices (SVV, PPV and PVI) transthoracic echocardiography
3164150|NCT00494052|No Intervention|2|Usual care
2512915|NCT02811224||Ovarian Cancer|
2512921|NCT02811224||Benign Neoplasm|
2512955|NCT02810912||Supraglottic airway device-based anesthesia|Investigators planned to enroll 200 cases who will receive scheduled surgery under supraglottic airway device-based general anesthesia.
2512996|NCT02810587||Topical antibiotics group|Those who receive topical antibiotics after intravitreous injection as home medication for 7 days.
2512997|NCT02810587||No topical antibiotics group|Those who does NOT receive topical antibiotics after intravitreous injection as home medication.
2513041|NCT02810288||Expert|Anaesthesiologist with large paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
2513042|NCT02810288||Non-experts|Anaesthesiologist with little paediatric daily practice. All participant voluntarily response all items in the questionnaire database.
2513067|NCT02809924|Experimental|Simulation-based just-in-time training|Viewing a short video showing the neonatal glottis of similar gestational age to the patient that is being intubated followed by practice on a mannequin (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada) with supervision and feedback from a senior provider (low fidelity simulation).
2513068|NCT02809924|Active Comparator|Video training|5 minutes video regarding endotracheal intubation
3164151|NCT00494065|Experimental|1|Chiropractic Spinal Manipulative Therapy + Home exercise
2513188|NCT02809534|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2513249|NCT02808871|Experimental|Pirfenidone|Pirfenidone 2403 mg/d for 52 weeks
2513253|NCT02808871|Placebo Comparator|Placebo|Placebo for 52 weeks
2513425|NCT02807883|Experimental|Blinatumomab|Blinatumomab as continuous intravenous infusion at dose of 28 µg/24 hours over 4 weeks followed by 2 week treatment-free period for 6-week treatment cycle; 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
3164152|NCT00494065|Active Comparator|2|Home exercise
3164153|NCT00494078|Active Comparator|1|Patients randomised to this arm are treated with intensive insulin therapy guided by the continuous glucose monitoring system.
2513601|NCT02806648|Experimental|Palbociclib|Palbociclib
2513649|NCT02806323|Experimental|Yoga Practice|12 week yoga intervention; 45 minutes/weekly practice Participants will be encouraged to practice their prescribed program of yoga at home, daily, for 20 minutes each day.
2513682|NCT02806050|Experimental|Palbociclib and FES PET|To evaluate whether low uptake on FES-PET at baseline is related to non-response to letrozole plus palbociclib treatment.
2513940|NCT02804074|Active Comparator|Group 1|Management strategy of blood pressure based on office BP as a guide to treatment
3164154|NCT00494078|Active Comparator|2|intensive insulin therapy guided by an algorithm
3164155|NCT00494104|Active Comparator|200 IU/day Vitamin D|200 IU/day Vitamin D
3164156|NCT00494104|Experimental|400 IU/day Vitamin D|400 IU/day Vitamin D
3164157|NCT00494104|Experimental|600 IU/day Vitamin D|600 IU/day Vitamin D
3164158|NCT00494104|Experimental|800 IU/day Vitamin D|800 IU/day Vitamin D
3164159|NCT00494182|Experimental|Treatment (carboplatin, paclitaxel, sorafenib)|Participants receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1, and sorafenib PO BID on days 2-19. Treatment repeats every 21 days for up to 6 courses. Starting with course 7, participants receive sorafenib PO daily in the absence of disease progression or unacceptable toxicity.
3164160|NCT00494195|Experimental|1|The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
3164161|NCT00494195|Experimental|2|The second cohort will receive the same dose of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
3164162|NCT00494208|Active Comparator|1|
3164163|NCT00494208|Active Comparator|2|
3164164|NCT00494208|Active Comparator|3|
3164165|NCT00494208|Active Comparator|4|
3164166|NCT00494208|Active Comparator|5|
3164167|NCT00494260|Experimental|Social learning and cognitive behavioral therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques.
3164168|NCT00494260|Active Comparator|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
2512645|NCT02813213|Experimental|Skin micro graft|"This group is comprised of the patients' wound halves that will receive skin micro grafts. To obtain this grafts the investigators will use Xpansion micro-autografting system. They will use 0.8 x 0.8 mm skin grafts with a graft to graft distance of 4mm (1:50 expansion).This half will be covered with a special hydrogel dressing with keratinocyte growth factor (Epilife medium with calcium) 1.5ml for each 14 square centimeters of the wound. This half will be covered with a wet adhesive foam dressing and then it will be covered up with a non-adherent interface dressing (tegaderm). The dressing will be removed at day 5, and then it will be removed every 3 days up to the 14th day. Each time of dressing change only the non-adherent interface dressing will be removed, and the area will be bathed with keratinocyte growth factor solution."
3164169|NCT00494286|Experimental|AF-CBT|Participants will receive abused-focused cognitive behavioral therapy
2512753|NCT02812147|Active Comparator|L-DOPS|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. L-dihydoxyphenylserine will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of L-DOPS three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over). After a 7-day washout, participants will cross over to the Placebo arm.
2512758|NCT02812147|Placebo Comparator|Placebo|All participants will be on levodopa/carbidopa, and may be on additional dopaminergic drugs including dopamine agonists and/or monoamine type B oxidase inhibitors or amantadine. Placebo will be added, administered as an oral capsule 3 times a day for 4 months. Dosing will begin at 100 mg of placebo three times per day and titrated upward, by 100 mg three times a day, as tolerated. Tolerability will be evaluated based upon questionnaires, patient interviews, vital signs and investigator examination. In order to participate in the study, all subjects must be able to tolerate a minimum tolerated dose of 400 mg three times per day (1200mg/day). Subject maximum dose will be 600 mg three times per day (1800mg/day). Patients will be maintained on this dose for 4 months (until the cross-over) After a 7-day washout, participants will cross over to the L-DOPS arm.
2512805|NCT02811809|Experimental|Apalutamide + IHT|Participants will be treated with 240 mg (4-60 mg tablets) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently.
2512806|NCT02811809|Active Comparator|IHT only|Participants will receive 22.5 mg 3-month depot intramuscular leuprolide until PSA progression, then they will crossover to Apalutamide + IHT
2512856|NCT02811406|Experimental|Receives IV albumin infusion|IV albumin 20% 50 mL for every 1L of ascitic fluid drained
2512857|NCT02811406|Placebo Comparator|Do not receive IV albumin infusion|No IV albumin infusion
2512913|NCT02811185|Other|PET/CT Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET/CT scanning according to departmental practice.
2512919|NCT02811185|Other|PET Scan|Subjects will receive a single dose of [F-18]-FDG Injection at Visit 1, followed by PET scanning according to departmental practice.
2512966|NCT02810821||male|
2512970|NCT02810821||female, premenopause|Women with regular menstrual cycles in normal range (22-35 days) for the previous three cycles.
2512975|NCT02810821||female, perimenopause|Women with variability in menstrual cycle length, defined as a persistent difference of 7 days or more in the length of consecutive cycles, or amenorrhea of at least 60 days but no longer than 12 months.
2512976|NCT02810821||female, postmenopause|Women with amenorrhea of at least 12 consecutive months.
3197531|NCT00861835|Experimental|ROSE for TBNA|
3197532|NCT00861835|No Intervention|NR|no on-site cytopathology assessment (NR)
2513243|NCT02808754|No Intervention|Usual Care|Patients in the usual care arm will undergo CEA without RIPC.
2513248|NCT02808754|Experimental|Remote Ischemic Preconditioning|Patients in the RIPC arm will undergo CEA with RIPC.
2513296|NCT02808559|Experimental|Bodystudio ATBM|The PASI of the patients will be evaluated by two dermatologists then by the bodystudio ATBMs.
2513392|NCT02808026|Experimental|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast for 8 weeks
2513431|NCT02807649|Placebo Comparator|Placebo|Placebo: Methyl cellulose and dextrose
2513436|NCT02807649|Active Comparator|Low dose|This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day
2513439|NCT02807649|Active Comparator|High dose|This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day
2513481|NCT02807337|Experimental|Caphosol rinse group|Caphosol consists of two solutions (A and B) which are mixed immediately before use. Caphosol mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
2513486|NCT02807337|Active Comparator|0,9% NaCl group.|0,9% NaCl consists of two solutions (A and B). Two vials of 0.9% NaCl will be mixed to maintain blinding. The study mouth rinse will begin concomitantly (the same day) with the beginning of chemotherapeutic drugs. It will be continued for seven consecutive days.
2513566|NCT02807038|Experimental|Lung function test|Pregnant women performed one spirometry at each trimester of pregnancy
3164170|NCT00494286|Active Comparator|TAU|Participants will receive treatment as usual
3164171|NCT00494312|Experimental|Pioglitazone QD|
2513683|NCT02806089|Experimental|Muscle strength|"single evaluation (the day of inclusion) of muscle strength (by handheld dynamometer), muscle mass (by creatinine index estimation), lean body mass (by electrical bioimpedance analysis), physical activity (by Voorrips score questionnaire), inflammatory and nutritional status."
3164172|NCT00494312|Active Comparator|Glyburide QD|
3164173|NCT00494416|No Intervention|ANC approach|Passive health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
3164174|NCT00494416|Other|advanced strategies SP|Joint with advanced strategies delivery approach (JAS). In addition to passive delivery of IPT/sulphadoxine pyrimethamine (SP) at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages, such as immunization, health promotion, and even ANC visits.
3197533|NCT00861848||12-50 with heart disease|12-50 with heart disease
3197534|NCT00861848||12-50 normal controls|12-50 normal controls
2512685|NCT02812927|Experimental|Optimised infusion line|The optimised insulin infusion system consisted in regular human insulin administration through a multilumen device (Edelvaiss Multiline-8, Doran International, Toussieu, France). This device had ports for eight infusions which run through separate channels within a 150 cm flexible plastic tube. Since fluids from the individual channels do not meet until they exit the distal tip. Carrier was infused through the high flow (HF) line and insulin was infused by syringe pump systematically next to the HF line port. All others medicines were administered via adjacent ports on the Multiline-8.
2512697|NCT02812446||IAI patients group|patients with Staphylococcus aureus of implant-associated infections
2512698|NCT02812446||control group|patients with Staphylococcus aureus nasal carriage
2512755|NCT02812316|Experimental|Scleral lenses|Subjects who meet all eligible requirements for entry into the study will be instructed to insert the Hi-Brite Large Diameter Rigid Gas Permeable contact lens in daily wear basis for clinical evaluation purposes.
3197535|NCT00861861|Active Comparator|1|pitavastatin group
3197536|NCT00861861|Active Comparator|2|atorvastatin group
3197537|NCT00861874|Experimental|Treatment|
2513116|NCT02809755|Experimental|4% lidocaine|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
2513117|NCT02809755|Placebo Comparator|Placebo Saline|10 mL vials filled with 4% lidocaine or normal saline (50 vials of each solution) and pharmacist will code the vials from 1 to 100 using a computer-generated randomization scheme.
2513155|NCT02809339||Epithelial ovarian cancer|
3197538|NCT00861887|Active Comparator|Vancomycin|Vancomycin 125 mg every 6 hours x 4 weeks
3197539|NCT00861887|Placebo Comparator|Placebo|Vancomycin 125 mg every 6 hours x 2 weeks, followed by placebo every 6 hours x 2 weeks
3197540|NCT00861926|Experimental|Beclometasone/formoterol (100/6 µg)|Foster : fixed combination of BDP extrafine 100 µg plus formoterol fumarate 6 µg administered via a pMDI standard actuator
2513376|NCT02808013|Experimental|NDS-446|NDS-446
2513377|NCT02808013|Placebo Comparator|Placebo|Placebo
2513427|NCT02807688|Experimental|Intervention|"Health Promotion Intervention package including elements of psychoeducation on healthy lifestyles and practical sessions of physical activity, with the use of motivational techniques."
2513433|NCT02807688|No Intervention|Control|Control subjects receive treatment as usual at the Community Mental Health Services of the Department of Mental Health.
2513467|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg QD|Leuprolide Oral Tablet QD: 4 mg for 28 consecutive days.
2513473|NCT02807363|Experimental|Leuprolide Oral Tablet, 4 mg BID|Leuprolide Oral Tablet BID: 4 mg, 12 hours apart for 28 consecutive days.
2513477|NCT02807363|Active Comparator|Leuprolide 1 month depot|Leuprolide Depot : intramuscular (IM) 3.75 mg depot injection administered for one month of therapy
2513478|NCT02807363|Experimental|Leuprolide Oral Tablet, 10 mg BID|Leuprolide Oral Tablet BID: 10 mg, 12 hours apart for 28 consecutive days
2513558|NCT02807090|Experimental|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
2513560|NCT02807090|Experimental|Circular Dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
2513670|NCT02806674|Experimental|Successful treatment|
2513671|NCT02806674|Experimental|Refractory infection of H.pylori|
2513709|NCT02805751|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have weight-bearing as tolerated from day 0. They are also instructed to perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
2513711|NCT02805751|Experimental|Early loading|The patients in the early loading group are also allowed to have weight-bearing as tolerated from day 0 and perform tendon strain exercises 3 times each day from 2 weeks after the rupture. The patients in this group will also remove the walker twice a day and use a special training pedal for 5 weeks (until walker removal).
2513790|NCT02805465|Experimental|HBP Group|CRT Device and His-bundle Pacing. Patients will get His-bundle pacing through a CRT device first for 9 months then switch to Bi-ventricular pacing by the same CRT device for another 9 months.
2513791|NCT02805465|Active Comparator|BiVP Group|CRT Device and Bi-ventricular Pacing. Patients will get BiV pacing for 9 months through a CRT device then switch to His-bundle pacing by the same CRT device for another 9 months.
2513838|NCT02804958||STEMI treated with primary PCI|Patients diagnosed with acute ST-segment elevation myocardial infarction and treated with primary percutaneous coronary intervention were consecutively registered.
2513913|NCT02804516|Experimental|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
2513915|NCT02804516|Experimental|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
2513921|NCT02804022|Experimental|VPIA analgesia system|Vital-signs-integrated patient-assisted intravenous opioid analgesia system (VPIA). The vital signs (oxygen saturation, respiratory rate, heart rate) will be close monitored when patients is using VPIA pump. The drug used is intravenous morphine (1mg per milligram) with bolus of 1 mg.
2514027|NCT02803723|Experimental|Holding-cuddling + Sucrose|The Holding-cuddling is started 5 minutes before and the sucrose administration is started 2 minutes before blood sampling.
2549565|NCT02568085|Experimental|3|Thyroidectomy with neck + Arista
3197541|NCT00861926|Active Comparator|salbutamol|Ventolin : salbutamol sulphate 100 µg per metered dose
3197542|NCT00861939|Experimental|1|Bupropion HCl 300mg Extended Release Tablet
2512707|NCT02812641|Experimental|BPF-CCRT (Run-in Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2512710|NCT02812641|Experimental|BPF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Bevacizumab, Cisplatin and 5-fluorouracil~Chemotherapy:~Bevacizumab(B): 10 mg/kg on day 1~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2512711|NCT02812641|Active Comparator|PF-CCRT (Randomized Phase)|"Neoadjuvant CCRT with Cisplatin and 5-fluorouracil~Chemotherapy:~Cisplatin(P): 75 mg/m2 on day 1~5-fluorouracil(F): 24 hours continuous infusion of 1,000 mg/m2 on days 1-4~Radiotherapy: 40 Gy/20 fractions: days 1-5, weeks 1-4"
2512760|NCT02812017|Experimental|1 - Intervention|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the Thirty Million Words-Well Baby intervention, which consists of educational, multimedia modules at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2512764|NCT02812017|Placebo Comparator|2 - Neutral|The Neutral Video group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will then view the neutral videos about car safety at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2512771|NCT02812017|No Intervention|3 - Usual care|The treatment group will complete a demographics questionnaire and the baseline measures before the intervention. Participants will receive care as usual at the one-, two-, four-, and six-month well baby pediatric visits. The participant will complete survey measures after the one-, two-, four- and six-month visits, as well as over email at seven-months old and in clinic again at the nine-, twelve-, eighteen-, and twenty-four month visits.
2512821|NCT02811718|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2512826|NCT02811718|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2512867|NCT02811393||Bariatric surgery|Women who have been submitted to a Roux-en-Y Gastric Bypass Surgery for at least 2 years
2512869|NCT02811393||Unoperated|Women with similar characteristics to control group (age, body mass index, physical activity level), but they have not been submitted to bariatric surgery
2512900|NCT02811146|Experimental|Cardiopulmonary exercise testing|Assess whether people who wore noninvasive ventilation during aerobic exercise have greater functional capacity than those who did not wear.
2512901|NCT02811146|Experimental|ADL Glitre test|Check that people who wore noninvasive ventilation during aerobic exercise have greater submaximal functional capacity than those who did not wear. Compare a ventilatory metabolic response of the ADL Glitre test with an six-minute walk test. .
2512902|NCT02811146|Experimental|Minnesota Living with Heart Failure|Check if people undergoing heart rehabilitation has improved quality of life.
2512903|NCT02811146|Experimental|Bioimpedance balance|Check if people undergoing heart rehabilitation has improved the body composition.
2512904|NCT02811146|No Intervention|Six-minute walk test|Compare a ventilatory metabolic response of the six-minute walk test with an ADL Glitre test.
2512905|NCT02811146|Experimental|Metabolic ventilatory response|"To verify if non-invasive ventilation during aerobic exercise modifies the ventilatory metabolic response in patients with heart failure.~Check the metabolic ventilatory response during the Glittre ADL test and six-minute walk test."
2512956|NCT02810847|Experimental|I-BiT Plus|6 weeks of I-Bit treatment plus (at least 30 mins/day, 6 days/week)
2512957|NCT02810847|No Intervention|Control|Refractive adaption or observation
2513028|NCT02810184|Other|CBCT arm|all participating patients receive an additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
2513069|NCT02810002|Experimental|DEFINITE-REGULATOR|Training with DEFINITE-REGULATOR experiment infantry boots manufactured by Brill Industries, Rishon LeZion, Israel
2513070|NCT02810002|Active Comparator|modified Belleville 390 TROP|Standard issue infantry boot
2513184|NCT02809443|Experimental|GLS-5700 at 1 mg|DNA/dose
2513187|NCT02809443|Experimental|GLS-5700 at 2 mg|DNA/dose
2513215|NCT02808845||microalbuminuria with eGFR≥60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
2513224|NCT02808845||normal-albuminuria group with eGFR≥60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) ≥60ml/min.
2513227|NCT02808845||microalbuminuria group with eGFR<60ml/min|microalbuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
2513231|NCT02808845||normal-albuminuria group with eGFR<60ml/min|normal-albuminuria group with estimated glomerular filtration rate (eGFR) <60ml/min.
2513276|NCT02808650|Experimental|Treatment (prexasertib)|Patients receive prexasertib IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
2513325|NCT02808286|Experimental|Hybrid|"The hybrid emotion-focused treatment consists of 10-15 individual 1/1,5 hour sessions. It includes the following stages (examples of methods in parathesis)~Stage I. Analysis of emotions and pain (Validation, Compassion, Chain analysis, Values & goals).~Stage II. Developing skills (Dialectics, Self-validation, Self-compassion, emotion regulation skills).~Stage III. Exposure training (Exposure for emotionally sensitive stimuli, exposure in vivo for avoided movements).~Stage IV. Maintenance (Identifying key elements, Planning for flare-ups)."
2513330|NCT02808286|Active Comparator|internet Cognitive Behavior Therapy (iCBT)|CBT pain treatment, delivered via the internet consists of 8, weekly, modules and includes topics such as pain education, pain coping strategies (e.g. pacing), relaxation, cognitive restructuring, problem solving, stress and sleep management, conflict resolution. Patients read materials included in each module and do homework tasks on which they report back to the therapist via the internet. The therapist gives written feedback and guidance after each module. See reference for details.
2512717|NCT02812602|Experimental|Lidocaine patch|The patients was randomly assigned to experimental group or placebo group. In this arm, lidocaine patches will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
2512719|NCT02812602|Placebo Comparator|Placebo|The patients was randomly assigned to experimental group or placebo group. In this arm, a placebo patch will be applied to the skin surrounding the surgical wound by one nurse practitioner. After more than 20 minutes the patch will be removed. Another nurse practitioner (double blinded) will remove the metal staples and record pain scale.
2512754|NCT02812082|Experimental|video web-based patient education application|This is a single-arm design. Development of the web-based application will occur over a 6 month period. Patient accrual will not occur until development of the program is complete. Controlled usability testing during the development/design process of the computer program will not be employed as we do not aim to assess the mechanics of patient use, but rather overall time spent interacting with the application in an uncontrolled environment. Following completion of the tool, patient accrual will occur over a six month time period in order to meet our target sample size of up to 50 participants. Participants will be directed to complete a pre-test questionnaire at the time of accrual and will have 3 months to use the program before being directed to complete the post-test questionnaire.
2512844|NCT02811848||Barbers|Barbers that service African American clientele mainly will be recruited for this study; there is no intervention.
2512906|NCT02811367|Experimental|HPV self-test|Women will perform the HPV self-test.
3164175|NCT00494416|Other|Community based|Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs). Each approach will be implemented in a zone constituted by the catchment area of a number of health centres to achieve the required sample size. The zones will be randomly assigned to a delivery approach. The main outcomes to be measured are: a) the coverage of IPT, b) compliance, c) infection prevalence, d) Hb level, e) difficulties and constraints of each approach, f) the acceptability to population and health staff and g) the performance of each approach to deliver IPT /SP. Coverage by 10%, each group should be composed of n = 3841 pregnant women.
2513033|NCT02810223|Experimental|Single dose of CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
2513099|NCT02810028|Experimental|ACT + Standard Medical Care (SMC)|This consists of 4 self-guided psycho-education modules supported by weekly telephone contact with a health professional trained in Acceptance and Commitment Therapy (ACT). Standard medical care will be provided as usual.
2513103|NCT02810028|No Intervention|Standard Medical Care (SMC)|All participants will receive SMC. As such, they will receive all the treatment and support they would otherwise receive outside of a research trial including a personalised assessment from the physiotherapist.
2513191|NCT02809469|Experimental|Dose reduction|Eligible patients with apixaban levels persistently above 170ng/mL on two occasions, 2 weeks apart, will undergo apixaban dose reduction.
2513259|NCT02808832|Experimental|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
2513262|NCT02808832|No Intervention|Usual care|Usual care
2513312|NCT02808351|Experimental|Berberine|Preoperative berberine 300 mg administration for at least 6 hours before interventional procedure, post-procedure berberine administration 100 mg at 24, 48 hours after procedure.
2513314|NCT02808351|No Intervention|Blank control|Blank control of berberine administration
2513364|NCT02808117||Targeted initially|Children who were in the Haiti villages and targeted by the MFI program with MNP delivery initially.
2513365|NCT02808117||Targeted later|Children who were in the Haiti villages and not targeted by the MFI program with MNP delivery until later.
3164176|NCT00494429|Experimental|1|Gestational Age< 29 weeks will be administered a loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/hr.
3164177|NCT00494429|Experimental|2|Gestational Age>= 29 weeks will be administered a loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
2513468|NCT02807519||Oncological patients|Children with confirmed haematological/oncological diagnosis who are admitted to the paediatric oncology ward at the Universitätsspital Beider Basel (UKBB), who will require radio- and/or chemotherapy . Collection of salivary cytokines will be performed in this group.
2513475|NCT02807519||Control group|Healthy children which are seen routinely at the Schulzahnklinik/Volkzahnklinik Basel. Collection of salivary cytokines will be performed in this group.
2513556|NCT02807116|Experimental|Pacritinib and Rifampin|On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Days 8 through 17, following a 7-day washout period, 600-mg oral doses of rifampin were administered QD. It was anticipated that steady-state concentrations of rifampin would be achieved by Day 17. On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
2513584|NCT02806635|No Intervention|Waitlist|Participants are assessed start, during, and end wait list; however, no active intervention is given.
2513588|NCT02806635|Experimental|OurRelationship|The OurRelationship program is based on Integrative Behavioral Couple Therapy and encourages couples to select, understand, and solve a relationship problem. Partners complete the majority of the web-based program on their own and come together for three key conversations with their partner. The first conversation between partners centers on discussing possible core relationship issues and jointly deciding on the problem(s) to focus on during the program. During the second conversation, both partners' previous written responses are displayed on the screen and conversation is encouraged. During the final conversation, couples share their strategies to decrease stress, improve patterns of communication, and engage in problem-solving exercises specific to their core issue(s).
2513612|NCT02806596|Other|sevoflurane|"induction of anesthesia using sevoflurane administered with facial mask at inspired concentration of 6% (in a mixture of oxygen and nitrous oxyde)~intervention : titration of inspired sevoflurane concentration until targeted bispectral index"
2513644|NCT02806310||Prospective|Group A: Patients with known BAV who are scheduled to have a cardiac MRI.
2513647|NCT02806310||Historic|Group B: Patients with known BAV who have already had an MRI within the past year
2512724|NCT02812472|Experimental|treadmill training with functional electrical stimulation|Subjects in the experimental group received additional treadmill training with functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
2512725|NCT02812472|Active Comparator|treadmill training without functional electrical stimulation|Subjects in the control group received additional treadmill training without functional electric stimulation for 25 minutes per session, followed by 5 minutes cool down for 12 sessions.
2512787|NCT02812069|Other|minor to moderate surgical procedure|The ThermaZone® Device will be used for 30 minutes to warm the cervical spine during
2512803|NCT02811731|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
2512804|NCT02811731|Experimental|CKD-330|CKD-330 16/5mg - B, PO, 1days or 22days
2512882|NCT02811549|Experimental|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid-Scala electrode will be implanted in adults who have severe to profound sensorineural hearing loss in one ear, and up to moderate sensorineural hearing loss in the other ear (asymmetric hearing loss).
2512909|NCT02811120||single arm|single venepuncture
2513062|NCT02810496|Experimental|patient|
2513107|NCT02809820|Active Comparator|Carvedilol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.
2513109|NCT02809820|Active Comparator|Metoprolol|Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.
2513182|NCT02809352||women tested positive for hrHPV|All women participating in START-HPV pilot program for cervical cancer screening and tested positive for hrHPV with the Hybrid Capture 2 test (Qiagen).
2513240|NCT02808962|Other|Cooled Radiofrequency Ablation|"This is a single arm, prospective observational study. All subjects enrolled are patients that meet the inclusion criteria, as deemed by a physician.~Typical standard of care for these patients is an initial visit followed by two diagnostic blocks ((0.5ml) of 1% Lidocaine per level). Subjects are asked to complete the pain diary and if they experience a 75% or more decrease in the NRS, they are scheduled for Cooled RFA of the lateral branches of S1, S2, and S3 dorsal rami nerves and of the dorsal ramus of L5 nerve."
2513293|NCT02808611|Active Comparator|Propranolol|Propranolol is a beta-blocker
2513295|NCT02808611|Placebo Comparator|Placebo|Placebo
2513337|NCT02808247|Experimental|Experimental arm (arm A): Nintedanib|Nintedanib 200 mg twice daily orally. Nintedanib will be given continuously until clinically relevant disease progression according to the investigator's assessment or until other criteria for treatment discontinuation are met as specified in the protocol. Dosing beyond RECIST 1.1 progression is allowed for the oral agent if the patient still derives benefit from the treatment.
2513342|NCT02808247|Active Comparator|Standard arm (arm B): Ifosfamide|Ifosfamide 3 g/m2 intravenously on days 1, 2 and 3 every 21 days for up to a maximum of 6 cycles.
2513410|NCT02807831|Experimental|Executive functions training|
2513411|NCT02807831|Experimental|Language skills training|
2513416|NCT02807831|Active Comparator|Regular school curriculum|
2513458|NCT02807467|Experimental|Dexmedetomidine|Dexmedetomidine is a potent selective α-2-adrenergic receptor agonist frequently used for sedation in the ICU, also among critically ill patients. It promotes sedation, anxiolysis, and moderate analgesia with minimal respiratory depression and has been shown to reduce severity and duration of ICU delirium.
2513459|NCT02807467|Active Comparator|Propofol|Standard therapy for ICU delirium.
2513512|NCT02807220|Experimental|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
3197543|NCT00861939|Active Comparator|2|WELLBUTRIN XL 300mg Tablets
3197544|NCT00861952|Experimental|Neuragen|Ad lib use of Neuragen (a natural health product) applied topically 2-3 times per day in 2-3 drops per application
3197545|NCT00861952|Sham Comparator|Mineral oil|Mineral oil, scent and color matched to intervention
3197546|NCT00861965|Experimental|Treatment|AlloStim-8
3197547|NCT00861978|Placebo Comparator|1|
2513669|NCT02806167|Experimental|Clinical algorithm|This is a single arm study. All eligible patients will be subject to our clinical algorithm.
2513731|NCT02805894|Experimental|NBTXR3 activated by IMRT only|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- EBRT delivered as 45 Gy in 25 fractions of 1.8 Gy each; to the prostate and seminal vesicles, followed by 34.2 Gy in 19 fractions to the prostate and proximal seminal vesicles , over 9-10 weeks, utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT A)"
2513739|NCT02805894|Experimental|NBTXR3 activated by Brachytherapy & IMRT|"Part I Dose Escalation~NBTXR3 will be administered by intra-prostate injection and then activated 10 days later by:~- Brachytherapy Boost and EBRT delivered as a single fraction of 15 Gy in one day to the prostate by High Dose Rate Brachytherapy followed by EBRT (initiated within 2-4 weeks after completion of Brachytherapy), delivered as 45 Gy in 25 fractions of 1.8 Gy to the prostate and seminal vesicles utilizing intensity modulated radiotherapy (IMRT) with daily image guidance aligned to implanted fiducial markers (COHORT B)"
2513776|NCT02805296|Active Comparator|Double light|"High-intensity phototherapy with blue LED light from above combined with a fiber optic, blue LED blanket from below.~Intervention: Light irradiance: 66 µW/cm2/nm + 39 µW/cm2/nm"
2513778|NCT02805296|Active Comparator|Single light|High-intensity phototherapy with blue LED light from above. Intervention: Light irradiance: 66 µW/cm2/nm
2513830|NCT02805101|Experimental|Biodentine|The perforation area of the root is going to be covered by Biodentine
2513831|NCT02805101|Active Comparator|MTA|The perforation area of the root is going to be covered by MTA.
2513870|NCT02804633|Active Comparator|IV acetaminophen group|In addition to PCA (morphine or hydromorphone) all patients receive 1 gram of IV acetaminophen (100 ml ) 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge.
2513941|NCT02804074|Experimental|Group 2|Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment
2549568|NCT02568085|No Intervention|4|Thyroidectomy with neck
3197548|NCT00861978|Experimental|2|
2512747|NCT02812121|No Intervention|Group Control|Patients in Group Control received standard medical treatment, including bed rest, nutritional supplementation, administration of human serum albumin (10g per day until serum albumin was 35g/L) and plasma (200 ml to 400 ml per day until the international normalized ratio was less than 1.5), anti-viral therapy, glycyrrhizin,S-adenosylmethionine and appropriate treatment for complications (such as infection, encephalopathy, hepatorenal syndrome and intestinal paralysis).
3197549|NCT00861991|Experimental|Perspective taking intervention|Students were given an instruction to take the perspectives of their standardized patients
3197550|NCT00861991|Active Comparator|Control|Students given standard instructions
3197551|NCT00862017|Experimental|MSG|Subjects receive a 6-d supplementation of MSG and are studied on the 7th day in the postprandial period following a standard meal ingestion with 2g MSG
2512932|NCT02811263|Active Comparator|Erythropoietin|Erythropoietin 1000 U/kg IV, at about 1, 2, 3, 4, and 7 days of age (i.e., 5 doses)
2512934|NCT02811263|Placebo Comparator|Placebo|Normal saline IV (equal volume), at about 1, 2, 3, 4, and 7 days of age
2512993|NCT02810626|No Intervention|Control|Control Group (surgical standard of care): Subjects 18 years and younger diagnosed with a pediatric brain tumor, and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
2512995|NCT02810626|Other|Interventional|Interventional Group (involvement of all BrightMatter™ products): Subjects 18 years and younger diagnosed with a pediatric brain tumor and who are eligible for surgical treatment will be recruited. All subjects will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol and will be sent to the interventional technology (BrightMatter Bridge) for quality control. The QC'ed images will then be sent to a pre-operating planning software (BrightMatter Plan) for planning the surgical approach. Surgery will be carried out with guidance from the exported plan and the intra-operative neuro-navigation software, BrightMatter Guide, with the use of post-processing DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative quality of life assessments, functional testing and clinical outcome tests will be conducted at this post-operative period (6-months).
3197552|NCT00862017|Placebo Comparator|Control|
3197553|NCT00862030||1|Study Cohort
2513082|NCT02809794|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
2513120|NCT02809638||DVT of the lower limbs|patients with first suspected episode of unprovoked DVT of the lower limbs and patients with episode of unprovoked DVT of the lower limbs at third month of follow-up
2513194|NCT02809144|Other|Nerve block|One novel nerve block combination
3197554|NCT00862043|Experimental|Sildenafil Citrate|Sildenafil Citrate 40 mg t.i.d. oral
3197555|NCT00862043|Placebo Comparator|Placebo|Sildenafil-matched oral placebo 40 mg t.i.d
3197556|NCT00862056||Cardiac CT|All participants will undergo a coronary artery CT angiogram
3197557|NCT00862095|Placebo Comparator|Placebo|Placebo group
2513727|NCT02805842|Active Comparator|Tacrolimus BID|20 patients receiving twice daily (BID) Tacrolimus
2513743|NCT02805842|Active Comparator|Advagraf QD|40 patients randomized to receive once daily (QD) Advagraf
2513773|NCT02805283||Dapagliflozin, dapagliflozin/met ER|Dapagliflozin cohort have at least one pharmacy claim for either dapagliflozin or dapagliflozin/metformin ER in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
2513777|NCT02805283||Sulfonylurea|Sulfonylurea cohort have at least one pharmacy claim for sulfonylurea in the most recent month of pharmacy data and no pharmacy claims for a medication in the same drug class during the 6 months prior to sample identification.
2513823|NCT02805114||Asthma and COPD patients|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken from the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
2513855|NCT02804711|Experimental|Four doses of low dose vaccine|four doses of 15µg/0.6ml per dose
2513856|NCT02804711|Experimental|Four doses of middle dose vaccine|four doses of 30µg/0.6ml per dose
2513857|NCT02804711|Experimental|Four doses of high dose vaccine|four doses of 60µg/0.6ml per dose
2513858|NCT02804711|Experimental|Three doses of low dose vaccine and one dose of placebo|three doses of 15µg/0.6ml per dose and one dose of placebo
2513859|NCT02804711|Experimental|Three doses of middle dose vaccine and one dose of placebo|three doses of 30µg/0.6ml per dose and one dose of placebo
2513860|NCT02804711|Experimental|Three doses of high dose vaccine and one dose of placebo|three doses of 60µg/0.6ml per dose and one dose of placebo
2513861|NCT02804711|Placebo Comparator|Four doses of placebo|four doses of placebo
2513962|NCT02803879|Experimental|Cardiogoniometry (CGM)|All patients attending clinic for follow up appointments following the implantation of a CRT device will be eligible for inclusion in the study. If they consent for enrolment in the study each patient will undergo a series of 4 CGM recordings whilst in their follow up appointment. They will undergo each of these during different pacemaker settings. These are: 1) No pacing, 2) Paced from the right ventricular lead; 3) Paced from the left ventricular lead and 4) Paced from both ventricular leads. After this has been done the participants involvement in the study will have finished.
2514007|NCT02803658|Experimental|infertile couples|smoking behavior
2514009|NCT02803658|Active Comparator|Fertile couples|smoking behavior
3197558|NCT00862095|Experimental|Propranolol|Propranolol (target dose 80 mg a day)
3197559|NCT00862095|Experimental|Topiramate|Topiramate (target dose 100 mg a day)
3197560|NCT00862095|Experimental|Amitriptyline|Amitriptyline (target dose 50 mg a day)
3197561|NCT00862108|Experimental|Methylphenidate|
3197562|NCT00862147|Experimental|ICDP|International Child Development Program
3197563|NCT00862147|Active Comparator|Treatment as usual|Treatment as usual
2512781|NCT02812251|Experimental|Part 3|Participants will receive JNJ-61393125 (dose to be determined) or placebo under fed conditions.
2512876|NCT02811562|Active Comparator|fiberoptic bronchoscope|Tracheal intubation in manikin using fiberoptic bronchoscope
2512879|NCT02811562|Experimental|fiberoptic bronchoscope with pentax-airwayscope|Tracheal intubation in manikin using fiberoptic bronchoscope with pentax-airwayscope
2512916|NCT02811081|Experimental|Control|Passive deflation of residual carbon dioxide
2512922|NCT02811081|Experimental|Normal Saline Instillation|Instillation of isotonic normal saline in the sub-diaphragmatic region
2512924|NCT02811081|Experimental|Combined Intervention|Normal Saline Instillation + Pulmonary Recruitment
2513136|NCT02809573|Experimental|study drugs|Lead-in period is 4 days. Patients take a single dose of Chidamide tablet, then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle. Cyclophosphamide, adriacin and vincristine are given in intravenous infusion on Day 1. On Day 1 to 5, prednisone is given orally. Treatment cycles are repeated every 3 weeks .The combination therapy lasts for at most 6 cycles. Patients enter the single agent therapy if attained complete response after 6-cycle combination therapy. In this stage, patients take chidamide orally on Day 1, 4, 8 and 11 of each cycle.
2513189|NCT02809222|Other|Patients with MDS at diagnosis|The intervention, specific to the study, is to take blood samples on patients with MDS at diagnosis. A quality of life questionnaire will also be used to monitor patients
2513190|NCT02809222|Other|Patients with MDS in treatment|The intervention, specific to the study, is to take blood samples on patients with MDS receiving treatment. A quality of life questionnaire will also be used to monitor patients
2513192|NCT02809222|Other|Healthy volunteers|The intervention, specific to the study, is to take blood samples on patients healthy volunteers.
2513202|NCT02808806|Active Comparator|real-time audio-visual feedback|real-time audio-visual feedback to caregivers (i.e. both in- and outside the hospital) bringing the patient to the location where IVT/IAT is administered . The real time audio-visual feedback consists in information on the actual TSD for a particular patient and whether or not this exceeds pre-set median time delay. The feedback is provided by handhelds in the ambulance and by pre-set monitors on different locations in the participating hospitals.
2513204|NCT02808806|No Intervention|regular care|no real-time audio-visual feedback
2513290|NCT02808520||Hodgkin-lymphoma|Children and adolescents aged 10-18 years
2513506|NCT02807246|Active Comparator|Probiotic|Experimental: Breast milk+ Probiotics(Maflor®, Mamsel Pharmaceuticals, Turkey) The study group will be fed with probiotics at a dose of 1x109 CFU/day (Lactobacillus rhamnosus GG 109colony ). Probiotic is in a liquid drop form at a dose of 5 drops a day and is used orally for 10 days.
2513509|NCT02807246|Active Comparator|Saline|Active Comparator: Breast milk+five drops of saline The control group will be given Breast milk without the addition of probiotics
2513551|NCT02807012|Experimental|Nursing educational intervention|The intervention will consist in three home visits (14, 21, 30 days after discharge) by nurses to family caregivers. The nurses will give verbal information and printed materials related to the care of older adults por stroke.
2513555|NCT02807012|No Intervention|Usual care|The family caregivers won't receive the home visits and could have or not the usual care guidelines provide by health services that have access.
2513654|NCT02806193||Cardiovascular Magnetic Resonance Imaging|Cardiovascular imaging techniques (other subsidiary techniques such as CT and ECG will also be followed)
2513680|NCT02806011||no Intervention|Long-term follow up of no intervention group
2513686|NCT02806011||1-time injection group|Long-term follow up of 1-time injection group
2513687|NCT02806011||2-time injection group|Long-term follow up of 2-time injection group
2513700|NCT02805712|Active Comparator|Control|Participant will receive usual care for Heart Failure patients, which include standard written material on Advanced Care planning and supportive cardiology/palliative care consult if ordered by attending.
2513701|NCT02805712|Experimental|Verbal Information and Discussion|Participants will participate in a guided goals of care conversation and the support of a Palliative Care Social Worker who is working closely with the patients' primary cardiology team. Social worker has ongoing clinical review of participants with a Palliative Care physician who will provide a full medical consult if appropriate.
3164178|NCT00494455|Active Comparator|1|Continuous subcutaneous glucose monitoring in patients without shock
3164179|NCT00494455|Active Comparator|2|continuous subcutaneous glucose monitoring in patients with shock
2513781|NCT02805322|Experimental|Temporal Temperature Measurement|Infrared Temporal Temperature Measurement using the ARC InstaTemp MD in three different age groups with a specified percentage reporting as febrile.
2513809|NCT02805452|Placebo Comparator|Placebo of Succinate of Solifenacin|1 tablet of placebo of succinate of solifenacin will be administered each day for 3 months.
3164180|NCT00494520|Experimental|Errorful training condition|A type of anomia rehabilitation paradigm which allows for errors. The intervention involves providing minimal auditory cues to allow for errors in picture naming.
3164181|NCT00494520|Experimental|Errorless training condition|A type of anomia rehabilitation paradigm in which the situation surrounding the performance of the desired task (i.e., picture naming) is controlled to prevent errors. The intervention involves providing maximal auditory cues to prevent errors in picture naming.
3164182|NCT00494559|Experimental|Actos|Actos group: pioglitazone 15mg or 30mg
3164183|NCT00494559|Placebo Comparator|Placebo|Placebo group: placebo without active medication
3164184|NCT00494572|Sham Comparator|Sterile Water|Sterile water
3164185|NCT00494572|Active Comparator|Montelukast|10mg rapid dissolving granules in sterile water orally once
3164186|NCT00494650|Experimental|1|Participants will receive cognitive behavioral therapy.
3164187|NCT00494650|Active Comparator|2|Participants will receive brief PTSD treatment.
3164188|NCT00494663|Experimental|1|150mg DIO-902 + 10mg atorvastatin
3164189|NCT00494663|Experimental|2|300mg DIO-902 + 10mg atorvastatin
3164190|NCT00494663|Experimental|3|450mg DIO-902 + 10mg atorvastatin
3164191|NCT00494663|Placebo Comparator|4|DIO-902 Placebo + 10mg atorvastatin
3164192|NCT00494663|Experimental|5|150mg DIO-902 + atorvastatin placebo
3164193|NCT00494663|Experimental|6|300mg DIO-902 + atorvastatin placebo
2512783|NCT02811978|Experimental|Group 1 : Intravenous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib intravenously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
2512785|NCT02811978|Experimental|Group 2 : Subcutaneous Bortezomib plus Dexamethasone|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2) bortezomib subcutaneously on Days 1, 4, 8, and 11 of a 3 week cycle. Participants will receive Dexamethasone at a dose of 20 mg oral (PO) on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
2512836|NCT02811588||Phase1:Screening phase: normocapnic group|Normocapnic COPD patients
2512838|NCT02811588||Phase1;Screening phase: hypercapnic group|Hypercapnic COPD patients
2512839|NCT02811588||Phase1:Treatment phase: control group|Hypercapnic COPD patients in whom NIV is not indicated or who have contraindication(s) for, or refuse, NIV treatment.
2512840|NCT02811588||Phase1:Treatment phase: non-invasive ventilation group|Hypercapnic COPD patients in whom NIV is indicated and who accept NIV treatment.
2512917|NCT02811341|Placebo Comparator|A group|Using normal saline before pcle examination
2512923|NCT02811341|Experimental|B group|Using Scopolamine Hydrobromide before pcle examination
2512952|NCT02810860|Other|Open Label|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
2513044|NCT02810366|Active Comparator|Physician Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the electronic Verbal Autopsy (eVA) instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a short checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness, followed by a free-text narrative.~Cause of death for these VAs will be assigned by trained physicians using the MDS physician coding system; this includes dual, independent coding of VA records, disagreements resolved by reconciliation, and remaining cases by adjudication by a third physician. The assignment of cause of deaths will be in line with the international classification of disease version 10 (ICD-10)."
2513047|NCT02810366|Experimental|Computer Coded Verbal Autopsy|"Of the approximately 12,500 VAs collected, 50% in each district will be randomly collected using the Extended Symptom List (ESL) VA instrument.~In addition to general information about the deceased (e.g. name, sex, age, etc.), this VA instrument contains a long checklist questionnaire to capture from the respondent the signs and symptoms noted during the final illness. This VA instrument does not contain a free-text narrative.~The cause of death for these VAs will be independently assigned by five leading computer-coding VA algorithms. The assignment of cause of deaths will be in line with 17 broad cause of death categories."
3197564|NCT00862160|Active Comparator|1|using minimized cardiopulmonary bypass circuit ROCsafeTM
2513172|NCT02809235|Experimental|coconut oil|Subjects will be instructed to supplement their diet with 3 tablespoons of coconut oil daily for three weeks.
2513266|NCT02808936|Experimental|RIPC group|remote ischemic conditioning group with three cycles of ischemia (5 min) / reperfusion (5 min) of upper or lower limb available with automated RIPC machine using blood pressure cuff
2513268|NCT02808936|Sham Comparator|Control group|No remote ischemic conditioning, but blood pressure cuff applied to the upper or lower limb available
2513297|NCT02808442|Experimental|UCART19|
2513356|NCT02808156|Experimental|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
2513357|NCT02808156|Experimental|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
3197565|NCT00862160|No Intervention|2|using standard cardiopulmonary bypass circuit
3197566|NCT00862173||Patients with NSCLC with CNS Metastasis|Patients who developed CNS metastasis of NSCLC during the treatment.
3197567|NCT00862173||Patients with NSCLC without CNS Metastasis|Patients with NSCLC that does not develop CNS metastasis during the treatment.
3197568|NCT00862212|Experimental|Brief Alcohol Intervention|Half of the subjects will be randomly assigned to receive a brief physician-delivered alcohol intervention designed by the NIAAA to be delivered by primary care and mental health providers.
3197569|NCT00862212|No Intervention|Control Group|
3197570|NCT00862225|Placebo Comparator|1|
3197571|NCT00862225|Active Comparator|2|
3197572|NCT00862225|Experimental|3|
3197573|NCT00862238|Experimental|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
3197574|NCT00862238|Other|Health Promotion|4-session education offering basic information about the prevention of hepatitis A, B & C
2513692|NCT02806063|Other|Intraoperative samples|During this study of health care procedure evaluating microbiological setting in PJI prior prosthesis implantation with one stage surgery, 3 additional perioperative samples will be performed prior prosthesis implantation for every patient.
2513732|NCT02805621||Subject|Patients with know or suspected coronary artery disease, who underwent both CT angiography and invasive coronary angiography including invasive FFR measurements.
2513801|NCT02805439|Experimental|S47445 15mg|
2513804|NCT02805439|Experimental|S47445 50mg|
2513805|NCT02805439|Placebo Comparator|Placebo|
2513892|NCT02804451|Experimental|Intubation without chest compression|normal airway, without chest compression during intubation.
2513897|NCT02804451|Experimental|Intubation with uninterrupted chest compression|normal airway, with continuous chest compressions
3164194|NCT00494663|Experimental|7|450mg DIO-902 + atorvastatin placebo
3197575|NCT00862264|Experimental|CHF 1535 pMDI|CHF 1535 HFA pMDI aerosol (100 µg/unit dose of beclomethasone dipropionate plus 6 µg of formoterol/unit dose
2514048|NCT02803684|Experimental|Single arm|Whole cohort
2514109|NCT02802956|Experimental|intervention group|Daily Life Promotion Program
2514118|NCT02802956|Experimental|control group|general rehabilitation treatment
2514177|NCT02802384||Cases|People with active Paget's Disease of Bone
3197576|NCT00862264|Active Comparator|BDP pMDI|Beclomethasone dipropionate-CFC pMDI, 250 µg/unit dose
3197577|NCT00862290||sepsis group|Patients who develop sepsis in the ICU
2512791|NCT02812355|Active Comparator|full heparinization (300 U/kg)|heparin I.V. 300 U/kg
2512847|NCT02811627|Experimental|Memantine and Magnetic Resonance Imaging|"Subjects will be started on memantine post the imaging session.~Memantine is available commercially as Namenda, Namenda XR and in the liquid form (for subjects who do not wish to take pills). Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks."
2512910|NCT02811289|Experimental|Mirabegron|Mirbetriq (Mirabegron) (50mg) will be administered orally at time 0 to activate brown adipose tissue.
2512911|NCT02811289|Active Comparator|Cold exposure|Cold exposure protocol using a water-conditioned cooling suit will be applied
2512998|NCT02810704|Experimental|Arm 1: Enteric Coated Aspirin|Enteric coated aspirin (162 mg po) will be administered on the day of operation, prior to surgery, with a sip of water. Thereafter, starting on postoperative day #1, all patients in the aspirin group will receive 81 mg po bid to complete the treatment period of 30 days. Patients on preoperative cardiac dose aspirin may continue their usual dosing regimen prior to the morning of surgery, and then commence the PEPPER trial aspirin dose of 81 mg po bid on the day after operation.
2513001|NCT02810704|Experimental|Arm 2: Warfarin Other Names: Coumadin|Warfarin will be administered starting on the day of operation, prior to surgery, with a sip of water. The initial dose will be empirically determined by body weight: less than 125 lbs (56.7 kg) - 2.5 mg; 125-250 lbs (56.7-113.4 kg) - 5 mg; greater than 250 lbs (113.4 kg) - 7.5mg. The initial dose will be repeated on the evening of surgery if the preoperative dose was administered prior to noon on the day of operation; no warfarin will be given on the evening of surgery if the preoperative dose was received after noon on the day of operation. Thereafter, starting on postoperative day #1, warfarin will be given each evening based on INR values to achieve a target of 2.0 (range 1.7-2.2).
2513002|NCT02810704|Experimental|Arm 3: Rivaroxaban Other Names: Xarelto|Rivaroxaban 10 mg will be first administered approximately 24 hours after completion of the index operation. Medication will then be administered in the evening on postoperative day #2 and thereafter each evening until completion.
2513089|NCT02809885|Experimental|Transplanted patients|All patients included are in the same arm.
2513122|NCT02809586|Active Comparator|SMI + Incentives|A Social Media + Incentives (SMI + I) condition
2513124|NCT02809586|Active Comparator|SMI|A Social Media Intervention (SMI) condition
2513127|NCT02809586|No Intervention|Control|An Attention-Control E-News (CONTROL) condition
2513151|NCT02809300|Experimental|ankylosing spondylarthritis|
2513195|NCT02809079|Experimental|Mycophenolate mofetil plus prednisone|Mycophenolate mofetil 500mg Bid and prednisone 10mg Qd
3164195|NCT00494663|Placebo Comparator|8|DIO-902 placebo + atorvastatin placebo
3164196|NCT00494702|Experimental|LOX|Low saturation group of premature infants that will be kept within preset limits of 85-89%
2513384|NCT02807922|Active Comparator|Zopiclone|Zopiclone six nights
2513388|NCT02807922|Placebo Comparator|Placebo|Placebo six nights
2513429|NCT02807610|Experimental|IV Propofol and IV Etomidate lipuro|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group P Patients received IV Propofol 2mg kg-1 slowly over 60 seconds till Entropy of 40 as a comparator agent in patients undergoing Medical termination of pregnancy(MTP) and Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP
2513435|NCT02807610|Active Comparator|IV Etomidate Lipuro and Placebo|After premedication with IV midazolam 0.2mg kg-1, IV Fentanyl 2ug kg-1, Group ' E' Patients received IV Etomidate Lipuro 0.3mg kg-1 slowly over 60 seconds till Entropy of 40 as intervention agent in patients undergoing MTP and placebo group received normal saline
2513491|NCT02807324||Controls|Controls are women (18 years or older) with an uncomplicated pregnancy (i.e no foetal or maternal placental complications, such as pregnancy induced hypertension, preeclampsia or HELLP-syndrome, or small for gestational birth infancies)
2513493|NCT02807324||Early PE with IUGR|These cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2513494|NCT02807324||Early PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2513499|NCT02807324||Late PE with IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2513523|NCT02807064|Active Comparator|Bifidobacteria mixture 0.5 ml|Bifidobacteria 0.5 ml per os all days for 2 months
3164197|NCT00494702|Active Comparator|HOX|HOX group of premature infants will be kept within preset saturation limits of 90-93%
3164198|NCT00494715|Experimental|Benazepril|
3164199|NCT00494715|Experimental|valsartan|
3164200|NCT00494715|Experimental|benazepril/valsartan|
3164201|NCT00494728|Other|CBASP + ST|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) + Smoking Cessation Treatment (ST)
3164202|NCT00494728|Other|ST|Smoking Cessation Treatment (ST)
3164203|NCT00494741|Experimental|mycophenolate mofetil|
3164204|NCT00494741|Experimental|azathioprine|
3164205|NCT00494767|Experimental|GW869682 1000 mg thrice daily (TID)|Subjects will be randomized to receive GW869682 1000 mg TID
2512912|NCT02811172||Healthy pregnant women|Healthy pregnant women
2512920|NCT02811172||Risk pregnant women|Hypertensive, obese and diabetic women
2513046|NCT02810158||Patients with suspected OSA|Persons with clinical suspicion of obstructive sleep apnoea syndrome (OSA)
3164206|NCT00494767|Experimental|GSK189075 250 mg TID|Subjects will be randomized to receive GSK189075 250 mg TID
2513332|NCT02808325|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
2513334|NCT02808325|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
2513372|NCT02807935|Other|OCT imaging of surgical/pharmacological/laser branch|"to evaluate the effect on the conventional outflow pathway, and specifically on the Schlemm's canal (SC) anatomy in the surgical branch:~Before and after trabeculotomy~Before and after cataract surgery~Before and after vitrectomy surgery~Before and after XEN™ Gel Stent implant~pharmacological branch-~Before and during the treatment with prostaglandins analogs~Before and during the treatment with alpha blockers~Before and during the treatment with beta blockers~Before and during the treatment with carbonic anhydrase inhibitor~laser branch-~Before and after trabeculoplasty~Before and after laser iridotomy~Before and after yag capsulotomy laser"
2513407|NCT02807753||Severe Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every 6 months.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
2513414|NCT02807753||Mild/Moderate Hemophilia A or B|"Medical history, physical exam, vital signs,physical therapist targeted exam and ultrasound joint assessment (ankles and knees) every year.~MRI joint assessment (knees and ankles) at End of Trial Visit (Month 60)."
2513463|NCT02807389|Experimental|MSC Fistula plug: Single Treatment Group|All patients received treatment of a stem cell coated fistula plug.
2513550|NCT02807194|Experimental|general anesthesia|'lumbar disc herniation'
2513554|NCT02807194|Experimental|spinal anesthesia|'lumbar disc herniation'
2513580|NCT02806661|Experimental|VPRDG for AGC|Vagus nerve-preserving Robot-assisted distal subtotal gastrectomy (VPRDG) with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
2513581|NCT02806661|Active Comparator|CRDG FOR AGC|Conventional Robot-assisted distal subtotal gastrectomy (CRDG) with D2 lymphadenectomy without preserving vagus nerve will be performed for the treatment of patients assigned to this group.
2513603|NCT02806531|Experimental|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in aged 6-35 months old, 28 days interval.
2513650|NCT02806375|Experimental|PTCy and ruxolitinib|
2513729|NCT02805803|Other|Quality of life questionary|"During this study of health and care procedure, we will assess the quality of life of patients treated with suppressive antibiotique therapy using three questionaries:~SF12~Beck~WOMAC"
2513786|NCT02805400|Other|Neurocognitive performance|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
2513808|NCT02805036||30 cmH20 for 30 seconds|"plateau pressure is hold on at 30 cmH20 pour 30 seconds. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
2513810|NCT02805036||10 cmH20 above|"plateau pressure is hold on at 10 cmH20 above. The cardiac output and the lung aeration is assessed by ultrasound measures at 3 times: before, at the end of the recruitment and 30 minutes later.~echocardiography - arterial oximetry"
2513841|NCT02804867||Depression|
2513844|NCT02804867||Bipolar disorder|
2513848|NCT02804867||Control|
2513898|NCT02804490|Placebo Comparator|White maize|Conventional maize flour
2513899|NCT02804490|Experimental|Biofortified maize|Provitamin A carotenoid biofortified maize flour
2513900|NCT02804490|Active Comparator|Fortified maize|Retinyl palmitate fortified maize flour
2513986|NCT02803697||Patients|All patients who underwent surgery for a NFPA in Reims university hospital between 01/01/1991 and 31/12/2004
3164207|NCT00494767|Placebo Comparator|GW869682-Placebo TID|Subjects will be randomized to receive Placebo matching GW869682 for TID
2514052|NCT02803099|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514080|NCT02802930|Experimental|SPF 50 Y65 110, SPF 50 Y51 002, and SPF 15 V27 104|All test products (SPF 50 Y65 110,SPF 50 Y51 002, and SPF 15 V27 l 04 compared to that of a negative control [0.9% NaCl]) were tested simultaneously on each subject.
2514101|NCT02802657|Experimental|Conbercept 0.5mg Treat-and-Extend regimen|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and Treat-and-Extend Regimen of the same dose guided by BCVA stabilization and optical coherence tomography (OCT) in the extension treatment period.~Intervention: Drug: Conbercept"
2549575|NCT02568163|Other|questionary|
3164208|NCT00494767|Placebo Comparator|GSK189075-Placebo TID|Subjects will be randomized to receive Placebo matching GSK189075 for TID
3164209|NCT00494793|Other|VAWC and mesh mediated fascial traction|This is a study aiming to evaluate one technique for temporary abdominal closure for open abdomen therapy in all patients applicable according to the inclusion criteria
3164210|NCT00494832|Active Comparator|Dexmedetomidine|Dexmedetomidine infusion
3164211|NCT00494832|Placebo Comparator|Placebo|Normal Saline infusion
3164212|NCT00494845|Experimental|Intervention|8-week Mindfulness Program for chronic low back pain
3164213|NCT00494845|Active Comparator|Comparison|8-week health education program
3164214|NCT00494858|Active Comparator|CBT-EF|Participants will receive cognitive behavioral therapy - focused
3164215|NCT00494858|Experimental|CBT-EB|Participants will receive cognitive behavioral therapy - broad
3164216|NCT00494910|Experimental|1|Meaning Centered Group Psychotherapy (MCGP)
3197578|NCT00862290||SIRS group|Patients who develop SIRS after cardiac surgery with cardiopulmonary bypass
2512925|NCT02811042|Active Comparator|Oropharyngeal leak pressure|Ambu AuraOnce
2512928|NCT02811042|Experimental|Fiberoptic position|Ambu AuraGain
2512953|NCT02810808|Experimental|Ranibizumab 0.5 mg 1+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization in the 11 month treatment period Intervention: Drug: Ranibizumab
2512954|NCT02810808|Active Comparator|Ranibizumab 0.5 mg 3+PRN|PRN intravitreal injections of ranibizumab 0.5 mg guided by BCVA stabilization after three Monthly intravitreal injections of the same dose.
2513012|NCT02810548|Placebo Comparator|OFD alone|Control group: including 15 defects that will receive open flap debridement (OFD).
2513017|NCT02810548|Active Comparator|PRF + OFD|Test group (1): including 15 defects that will receive platelet rich fibrin (PRF) with open flap debridement (OFD).
2513021|NCT02810548|Active Comparator|Bone + OFD|Test group (2): including 15 defects that will receive nanohydroxyapatite bone graft with open flap debridement OFD).
2513023|NCT02810548|Active Comparator|PRF + Bone + OFD|Test group (3): including 15 defects that will receive nanohydroxyapatite bone graft with platelet rich fibrin (PRF) after open flap debridement (OFD).
2513152|NCT02809391|Active Comparator|Orthotic|Recruited participants will be asked to wear the customizable foot orthotic, from baseline testing to a follow-up at 6 weeks post-baseline. Outcome measures at 6 weeks will be compared to those at baseline.
2513157|NCT02809391|Active Comparator|Orthotic+Textured Top Cover|At 6 weeks post-baseline, participants will received a different orthotic which has a textured material used as its top cover. Testing at 6 weeks post-baseline will determine if acute changes occur as a result of wearing the orthotic with textured top cover. Testing at 12 weeks post-baseline will determine if long-term changes occur as a result of the orthotic with textured top cover.
2513242|NCT02809014|Placebo Comparator|Placebo|Dentifrice without fluoride and tara gum.
2513247|NCT02809014|Active Comparator|Dentifrice standard|Dentifrice 1100 ppm sodium fluoride (NaF) without tara gum. Positive control
2513250|NCT02809014|Placebo Comparator|Dentifrice with tara gum|Dentifrice without fluoride but with hydrocolloid tara gum.
2513252|NCT02809014|Experimental|Dentifrice F-Complex + NaF|Dentifrice experimental with fluoride (1100 ppm) being half of fluoride incorporated in tara gum and other half freeform of NaF
2513254|NCT02809014|Experimental|Dentifrice F-Complex|Dentifrice experimental with fluoride (1100 ppm) all incorporated in tara gum.
2513310|NCT02808468|Active Comparator|Brief Cognitive Intervention|One in person session (90 minutes) of trauma focused cognitive therapy followed by 4 weekly coaching calls (20 minutes each) with the same study therapist
2513311|NCT02808468|No Intervention|Assessment Only|Assessment session followed by weekly completion of assessment measures
3197579|NCT00862290||control group|normal healthy volunteers
3197580|NCT00862303|Placebo Comparator|IL-2/IFN-α|
3197581|NCT00862303|Experimental|DC-CIK|
3197582|NCT00862316|Experimental|Computer Navigational Unit Assistance|Oxford Unicompartmental Knee arthroplasty will be performed with the assistance of a computer navigational unit.
3197583|NCT00862316|Active Comparator|Non- Computer Navigational Unit Assisted|Oxford Unicompartmental Knee arthroplasty will be performed traditionally (without the assistance of a computer navigational unit).
3197584|NCT00862329|Experimental|Casein|
2513450|NCT02807558|Experimental|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6mg/m2/day orally divided into twice a day dosing.
2513453|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with azacitidine|"SY-1425 days 8-28 of a 28-day cycle at 6mg/m2/day orally divided into twice a day dosing.~Azacitidine 75 mg/m2/day IV or SC days 1-7 of a 28-day cycle in combination with SY-1425."
2513713|NCT02805959||Normal Bowel, Young|Investigation with MTS for motility
3197585|NCT00862329|Experimental|MSP|
3197586|NCT00862329|Experimental|Casein/MSP|
3197587|NCT00862329|Experimental|Soy protein|
3197588|NCT00862342|Experimental|Bevacizumab|Bevacizumab continuation plus chemotherapy in patients who have failed previous bevacizumab plus other chemotherapy
3197589|NCT00862355|Experimental|1|SPARC147609
3197590|NCT00862355|Active Comparator|2|Reference147609
3197591|NCT00862368|Experimental|PAM -Enhanced/Asthma|The PAM-Enhanced/Asthma group: 2 in-home visits that included asthma education consistent with NIH recommendations (NIH, NAEPP, 1997) and smoking cessation counseling. Consistent with Motivational Interviewing (MI), smoking was broached in a non-judgmental manner and as another trigger for asthma. Feedback was given on expired air Carbon Monoxide (CO) levels of the smoker (to increase personal perception of risk) and the amount of smoke exposure to the child (to increase risk perception to the child). 6 phone calls were then provided over the next 4 months that focused on asthma education, a second round of feedback on the child's ETS exposure, and smoking cessation counseling. MI was used at all contacts. Free nicotine patch tx was given if they were ready to quit within 30 days.
3197592|NCT00862368|Active Comparator|PAM-Asthma|The PAM-Asthma arm received the same in-home counseling visits as PAM-Enhanced/Asthma. The 6 counseling phone calls were different from those received by PAM-Enhanced/Asthma, and included only an asthma follow-up and discussion of a child wellness topic. Smoking cessation was not discussed and additional feedback on ETS samplers was not provided. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
3197593|NCT00862368|Active Comparator|PAM-Healthy|The PAM-Healthy arm received the same in-home counseling visits as PAM and PAM Enhanced but asthma information was replaced with child wellness topics. The 6 counseling phone calls were the same timing and duration as the other two groups (six, 15 minutes calls, over four months) focused on a child wellness topic. Smoking cessation or sampler feedback was not discussed. Motivational Interviewing approaches were used in all in-home and phone counseling. Free nicotine patch tx was given if they were ready to quit within 30 days.
3197594|NCT00862381|Experimental|1|Hydrocortisone
3197595|NCT00862381|Placebo Comparator|2|Placebo
3197596|NCT00862394|Experimental|1|CHF 1535 Next DPI : BDP/Formoterol : 200/12 µg
3197597|NCT00862394|Active Comparator|2|CHF 1535 HFA pMDI : BDP/Formoterol : 200/12 µg
3197598|NCT00862394|Experimental|3|CHF 1535 Next DPI : BDP/Formoterol : 400/24 µg
3197599|NCT00862394|Active Comparator|4|CHF 1535 HFA pMDI : BDP/Formoterol : 400/24 µg
2512926|NCT02811354|Experimental|AZD9291|Patient will be treated with AZD9291 at a starting dose of 80mg once a day until the patient completes the study, withdraws from the study or closure of the study. A cycle of treatment is defined as 28 days of once daily AZD9291 treatment. Patients may continue to receive AZD9291 until objective disease progression (determined by RECIST 1.1) or if the subject is no longer receiving clinical benefit in the Investigator's opinion.
2512960|NCT02810717|Experimental|active TBS|40 patients with TRD will receive active theta-burst stimulation using a MagPro X1000 between the two PET measurements
2512961|NCT02810717|Sham Comparator|sham TBS|40 patients with TRD will receive sham stimulation using a MagPro X1000 between the two PET measurements. After the second PET scan they will receive active TBS
2513018|NCT02810470|Experimental|Cream appreciation tests|
2513022|NCT02810470|Experimental|Beverages appreciation tests|
2513079|NCT02810067|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
2513080|NCT02810067|Experimental|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
2513119|NCT02809651|Experimental|Ischemic stroke|patients suffering from ischemic stroke diagnosed by clinical examination and CT-scan
2513121|NCT02809651|Experimental|Brain tumor|patients diagnosed with a brain tumor diagnosed by clinical examination and CT-scan or MRI
2513123|NCT02809651|Experimental|Brain surgery|patients that have undergone brain surgery
2513126|NCT02809651|Active Comparator|Intracranial hemorrhage|patients with intracranial hemorrhage diagnosed by clinical examination and CT-scan
2513129|NCT02809651|Experimental|Headache|patients with headache complaints and a normal CT-scan of the brain
2513134|NCT02809651|Experimental|Headtrauma|patients with head trauma and a normal CT-scan of the brain
2513148|NCT02809274||Patients with PV, not newly diagnosed|"Patients with clinically overt PV treated with watchful waiting (with or without aspirin), Phlebotomy (PHL), Hydrea or any other treatment.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
2513149|NCT02809274||Newly diagnosed patients with PV|"Patients with clinically overt PV, newly diagnosed, before any treatment and before phlebotomy initiation.~Influence of iron parameters on Patient-reported symptoms will be evaluated by questionnaires Blood serum samples will be taken for iron parameters analysis"
2513291|NCT02808507|Experimental|Facility-based screening|This strategy will be implemented at all clinics (n=28) within this arm for 18 months. Study staff will encourage providers at each of the clinics to screen all consenting patients attending the clinic, regardless of the original reason for clinic presentation. Upon presenting for care (e.g., while waiting for their healthcare provider), patients will be informed about the study and screened for cough of any duration, fever, weight loss, or night sweats. Participants who are symptomatic and provide a sputum specimen (according to the clinic standard of care) will be given a study flyer informing them that they may be contacted by study staff, and a brief summary of the study. Per standard of care, all sputum samples will be sent to the local National Health Laboratory Service laboratory for Xpert testing.
2513292|NCT02808507|Experimental|Contact screening|"This arm is comprised of two sub-arms:~In the household contact screening sub-arm, a mobile field team visits the household of each consenting newly diagnosed pulmonary TB index case. Each visit consists of a household census, consent of all eligible household members for TB screening, administration of a brief questionnaire, sputum collection for testing with Xpert Mycobacterium tuberculosis (MTB)/rifampin (RIF) and the offer of HIV testing.~In the incentive-based contact screening sub-arm, all consenting newly diagnosed active TB cases are provided with 10 coupons for free TB screening to give to close contacts. When a contact presents at clinic with a coupon, they and the index case each receive a small amount of money. If the contact is diagnosed with active TB and starts treatment, the index case receives an additional larger amount of money. Each contact receives a brief questionnaire, TB symptom screen, optional HIV testing, and sputum sample collection for Xpert MTB/RIF."
2513363|NCT02808065||Tacrolimus + Mycophenolate mofetil|
2513424|NCT02807792|Experimental|Perianal access device|
2513479|NCT02807480|Experimental|Exposure-based therapy|Participants will complete 10, 90-minute sessions of Exposure-based therapy, conducted using a group format. Each group will include 8-12 participants. Exposure-based therapy seeks to increase abilities to manage anxiety through repeated practice in facing the situations or thoughts that are the focus of worry or fear. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
2513480|NCT02807480|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen negative mood. All participants will complete computer-based behavioral assessments, surveys and interviews, functional magnetic resonance imaging (fMRI), and electroencephalography (EEG).
3164217|NCT00494910|Active Comparator|2|standardized Supportive Group Psychotherapy
3164218|NCT00494936||HIV/HCV|HIV and HCV coinfected
2513673|NCT02806141|Experimental|Aerosolized plus intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
2513674|NCT02806141|Active Comparator|Intravenous colistin|Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
2513714|NCT02805738|Experimental|Experimental Group|once a time per a day, CKD-390 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
2513716|NCT02805738|Active Comparator|Active comparator Group|once a time per a day, Viread 1 Tablet for each other, PO, During 24 weeks, once a time per a day, 1 tab(CKD-390 1 Tablet) for each other, PO, From 24 weeks to 48 weeks
2513796|NCT02805192|Other|one Arm: size measurement by Smart phone App|
2513832|NCT02804919|Experimental|Investigational CPAP device|Fisher & Paykel Healthcare CPAP Device
3164219|NCT00494936||HIV infected|HIV monoinfected
3164220|NCT00494936||HIV/HCV nonviremnic|HIV and HCV coinfected with HCV RNA less than 600 copies
3164221|NCT00494936||HCV infected|HCV monoinfected with HCV viremia
3197600|NCT00862407||1|Non-pulsatile Group (conventional)
2513316|NCT02808273||Retrospective control|Patients who had received enoxaparine as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
2513318|NCT02808273||Prospective Cohort|Patients who will receive bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
3197601|NCT00862407||2|Pulsatile group (Alternate)
2513442|NCT02807597|Experimental|Phase I Dose Level 1: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.05 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
2513445|NCT02807597|Experimental|Phase I Dose Level 2: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.075 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
2513447|NCT02807597|Experimental|Phase I Dose Level 3: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (0.1 mg/kg)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
2513449|NCT02807597|Experimental|Phase I Dose Expansion: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I dose escalation portion)~9 patients will be enrolled (6 invasive ductal carcinoma and 3 DCIS)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
2513452|NCT02807597|Experimental|Phase II: LS301|"Patient will undergo surgery 4-24 hours after administration of LS301 (dose to be determined in Phase I portion)~Excised tissue will be examined for the presence of LS301 fluorescence using the Cancer Vision Goggles (CVG) to determine if LS301 accumulated in the breast cancer. The investigators will quantify fluorescence intensity in the cancer to establish the feasibility of observing LS301 fluorescence with the imaging system."
3197602|NCT00862420|Experimental|Clopidogrel|75 mg clopidogrel once daily from Day 1 to Week 12
3197603|NCT00862420|Active Comparator|Ticlopidine|200 mg ticlopidine once daily from Day 1 to Week 12
2513586|NCT02806843|Experimental|Stroke survivors and healthy subjects|Stroke survivors greater than 18 years of age with hemiplegia and varying levels of impairment as well as healthy subjects greater than 18 years old with no motor disabilities will be asked to interact with a therapist. The Patient-Therapist interactions will be recorded using the Rehab Intercap System and 3D Kinect Device.
2513630|NCT02806492|Experimental|Patient for cardiac surgery|All patient undergo the 5 different intervention in a randomised matter.
3197604|NCT00862433|Experimental|Arm 1|Determine optimal fat content of meal for optimal absorption of vitamin E
3197605|NCT00862433|Experimental|Arm 2|Determine optimal dose of vitamin E.
2513818|NCT02804984||ICUS|idiopathic cytopenia of undetermined significance (ICUS)
2513852|NCT02804698|Experimental|Meta Salud Diabetes-Intervention|"Attend the thirteen weekly educational classes and physical activity group (prior physician approval) that are part of the Meta Salud Diabetes program.~Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (at the start of the 13-week program, just after you finish the program, and nine months after you finish the program).~You may also be invited to participate in a follow-up interview, where you will be asked about your experience during and after the Meta Salud Diabetes program."
2513854|NCT02804698|No Intervention|Meta Salud Diabetes-Comparison Group|"Allow the research staff to collect your cholesterol, glucose, A1c, triglyceride levels, as well as your blood pressure, height, weight, and waist and hip circumference.~Respond to a survey about your nutrition and physical activity habits on three separate occasions (you will answer the first survey as soon as you finish reading and agree to participate by signing this form, the second survey will be three months from now, and the third survey will be 12 months from now)."
2513994|NCT02803840|Other|Experimental|DLBCL patients with indication for palliative radiotherapy
2514056|NCT02803359|Experimental|Planned Procedure|Endoscope will be connected to a camera and monitor. Needle electrodes will then be positioned into the false vocal fold mucosa bilaterally, under direct visualization of the needle tip on the monitor, but the needles will be passed trans-orally in the operating room. For those participating during an open-neck surgery, the surgery will commence as planned and once exposure of the superior laryngeal nerve is obtained, the surgeon will insert the electrodes directly into the nerve trunk for the purposes of recording. In Surgery or cervical lymphadenectomy, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold.
3197606|NCT00862433|Experimental|Arm 3|Investigate the relationship between vitamin C status and vitamin E turnover
3197607|NCT00862433|Experimental|NAFLD sub-study|Investigate the relationship between fatty liver disease and vitamin E turnover.
3197608|NCT00862472|Experimental|DuoTrav APS|DuoTrav APS QD AM
3197609|NCT00862472|Active Comparator|DuoTrav|DuoTrav QD AM
3197610|NCT00862485||StudyGroup|
3197611|NCT00862498|Experimental|Group 1 Treatment in Clinic|Participants will complete the written disclosure treatment in a clinic setting.
3197612|NCT00862498|Experimental|Group 2 Treatment via telephone|Participants will complete the written disclosure treatment in their homes via telephone.
2513056|NCT02810132|Active Comparator|Metformin|Drug: Metformin Target dose: 1000 mg x 2 (if eGFR 30-60 ml/min: 500 mg x 2) Other name: Glucophage XR 500
2513058|NCT02810132|Placebo Comparator|Placebo|Drug: Placebo
2513064|NCT02809807|Experimental|Baseline|Without a gas mask. We measure baseline respiratory index, parameters and the comfort.
2513065|NCT02809807|Experimental|Assessment with gas mask and canister A|With a gas mask, the measurement have been done with a high resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
2513066|NCT02809807|Experimental|Assessment with gas mask and canister B|With a gas mask, the measurement have been done with a low resistive canister. We measure baseline respiratory index, parameters and the comfort. These would serve for conduction comparison with the baseline.
2513115|NCT02809742||Epidural group|Epidural : automatic intermittent boluses ( 8-12 mL per hour) + patient controlled bolus (4 mL evrey 20 min) using ropivacaine
2513141|NCT02809378|Experimental|Sevoflurane|anesthesia induction with pentothal sodium (4-5 mg/kg), maintenance with sevoflurane(1.6-2.5 vol%)
2513142|NCT02809378|Experimental|sevoflurane, remifentanil, and propofol|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%)
2513143|NCT02809378|Experimental|Sevoflurane, remifentanil, propofol, and palonosetron|anesthesia induction and maintenance with remifentanil, propofol and sevoflurane(1.6-2.5 vol%), and palonosetron 75 ug administration prior to anesthesia induction.
2513239|NCT02809066|Experimental|Interventional group|8-week follow- up with dietary sufficient calcium intake
2513245|NCT02809066|No Intervention|Control group|8-week follow- up with no specific diet
2513299|NCT02808598|Experimental|Clinical Trials Education Program|Breast Cancer Clinical Trials Education program is offered to women in the experimental arm. This program was designed to promote increased clinical trials literacy among African American and Hispanic American women. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among these two groups of women who are traditionally underrepresented in breast cancer clinical trials.
2513303|NCT02808598|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of African American and Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
3164222|NCT00494949|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3164223|NCT00494949|Active Comparator|Control|Ringer's lactate
3164224|NCT00495053|Experimental|hMaxi-K 5000 µg/mL|5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
3164225|NCT00495053|Experimental|hMaxi-K 10000 µg/mL|10000 µg/90 mL intravesical instillation
2513402|NCT02807766|Experimental|Sensory Integration Training|Behavior modification and Sensory Integration Training
2513403|NCT02807766|Experimental|applied behavioral analysis|Behavior modification and applied behavioral analysis.
2513405|NCT02807766|Experimental|TEACCH|Behavior modification and TEACCH.
2513408|NCT02807766|Other|Behavior modification|Behavior modification.
2513415|NCT02807766|No Intervention|healthy control group|No intervention.
2513513|NCT02807207|Experimental|Sequence I|treatment sequence: A/B/C
2513514|NCT02807207|Experimental|Sequence II|treatment sequence: A/C/B
2513515|NCT02807207|Experimental|Sequence III|treatment sequence: B/A/C
2513516|NCT02807207|Experimental|Sequence IV|treatment sequence: B/C/A
2513517|NCT02807207|Experimental|Sequence V|treatment sequence: C/A/B
2513519|NCT02807207|Experimental|Sequence VI|treatment sequence: C/B/A
2513738|NCT02805816||Study group|Children with suspicion of CD based on positive serology (TG2 >2 times upper limit of normal) and classical clinical manifestations or belonging to high risk groups, who underwent gastroscopy with intestinal biopsies.
2513747|NCT02805816||Control group|Children without suspicion of CD who underwent gastroscopy and duodenal biopsies for other reasons (abdominal pain, failure to thrive, vomiting, eg)
2513794|NCT02805426|Experimental|Tranexamic acid|1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
2513797|NCT02805426|Placebo Comparator|Placebo|oral placebo + 800 mcg sublingual misoprostol
2513846|NCT02804880|Experimental|Group A|HAR + AWARD + Referral Card + A4 leaflet
2513850|NCT02804880|Experimental|Group B|LTM + AWARD + Referral Card + A4 leaflet
2513851|NCT02804880|Active Comparator|Group C|Brief advice + 12-page booklet
2513946|NCT02804308|No Intervention|Group Control with breast cancer and without breast cancer|Stretching exercises, lasting 40 minutes each session, 2 times a week for nine months
2513950|NCT02804308|Experimental|Combined Training with breast cancer and without breast cancer|Combined Training: 36 weeks duration, 3 times a week on nonconsecutive days. The combined training program lasts 70 minutes per session, with 40 minutes of resistance training and 30 minutes of aerobic training.
2514019|NCT02803736|Experimental|Real acupuncture group|Patients in the real acupuncture group will receive true acupuncture 3 times a week for 4 weeks (12 sessions). A standardized prescription of six acupuncture points is used unilaterally. Needles are inserted and manipulated manually until needling sensation (de qi) is obtained, and are retained for 20 minutes with manual manipulation at 10 minutes. Acupuncturists are trained to inquire about specific needle sensations when providing true acupuncture.
2514020|NCT02803736|Sham Comparator|Sham acupuncture group|Patients in the sham acupuncture group will receive sham acupuncture 3 times a week for 4 weeks (12 sessions).
2514087|NCT02802748|Active Comparator|Letrozole alone|Letrozole: 2.5mg daily, for 3 weeks
2514089|NCT02802748|Active Comparator|Metronomic Vinorelbine alone|Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks
3164226|NCT00495053|Placebo Comparator|Placebo|Matching placebo (PBS-20% sucrose)
3164227|NCT00495092|Experimental|1|This study arm will receive caffeine+placebo
3164228|NCT00495092|Experimental|2|this study arm will receive Caffeine+Biperiden
3164229|NCT00495092|Placebo Comparator|3|this study arm will receive placebo+placebo
2513111|NCT02809963|Active Comparator|Eplerenone|Eplerenone 50 mg tablets. 2-4 tablets once daily for 26 weeks
2513112|NCT02809963|Placebo Comparator|placebo|sugar pill manufactured to mimic Eplerenone 50 mg tablet. 2-4 tablets once daily for 26 weeks.
2513144|NCT02809365|Other|Libre|FreeStyle Libre users: FreeStyle Libre Flash Glucose Monitoring System is an interstitial glucose monitoring system intended to be replacement for the capillary blood glucose measurement. The system contains several features that distinguish it from exiting sensor technology including no user calibration during 14 days of wear. The sensor is applied to the upper arm of the patient and the hand-held reader is used to scan the sensor to receive glucose result along with historic results with a 15 min frequency for up to 8 hours.
2513145|NCT02809365|Other|SMBG|Self monitoring blood glucose: patients in this arm will measure blood glucose with personal glucometer
2513216|NCT02809131|Experimental|Saline irrigation|Saline irrigation
2513223|NCT02809131|Active Comparator|Antibiotic irrigation and PO antibiotics|Antibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
2513302|NCT02808546||Case Group|All the patients who were diagnosed as gallbladder stone disease with definite clinical symptoms and underwent cholecystectomy in Cheju Halla General Hospital, Jeju, Korea during 2009-2013
2513305|NCT02808546||Control Group|Control group was determined as 1:1 age-sex matched subjects selected from the participants without GBS among Health Promotion Center in the same institute and periods.
2513343|NCT02808208|Experimental|Single dose AMSC treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Subjects who receive a radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC)
2513347|NCT02808208|No Intervention|No Treatment in Radiocephalic (RCF)or brachiocepahlic (BCF) arteriovenous fistula|Patients receive standard of care.
2513351|NCT02808208|Experimental|Single dose AMSC treatment at first stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive a single dose of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at time of first stage of BBF
2513354|NCT02808208|Experimental|AMSC treatment at first and second stage of brachiobasilic arteriovenous fistula|Subjects who receive a brachiobasilic arteriovenous fistula (BBF) through standard of care procedure for dialysis, will receive Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) at first and second stage of BBF
2513355|NCT02808208|Placebo Comparator|Placebo treatment in brachiobasilic arteriovenous fistula|Subjects will receive placebo at first and second stage of BBF
3197613|NCT00862498|No Intervention|Group 3 Waitlist|Individuals will be placed on a waitlist for a period of 4 months, during which they will receive a phone call every other week to assess their suicidal ideation and post-traumatic stress disorder symptom severity.
2513733|NCT02805582|Active Comparator|Anterior musculus serratus block|"Proximal nerve block above the second intercostal space between Musculus serratus anterior and Musculus pectoralis minor.~Intervention: 10ml ropivacain 0.5%"
2513750|NCT02805582|Active Comparator|Subpectoral block|"Distal nerve block under the Musculus pectoralis major at the medial border of the axillary triangle.~Intervention: 10ml ropivacain 0.5%"
2513787|NCT02805348||Chronic kidney disease|Patients with pre-dialysis chronic kidney disease complicated by hyperphosphatemia who used bixalomer for the first time.
2513922|NCT02804373|Placebo Comparator|placebo daily|daily administration of placebo during 28 days : placebo continuous
2513923|NCT02804373|Active Comparator|24 IU of oxytocin daily|24 IU of daily oxytocin administration during 28 days : oxytocin continuous
2513924|NCT02804373|Active Comparator|24 IU of oxytocin every 3 days|24 IU of daily oxytocin every 3 days and placebo the following 2 days after each oxytocin administration during 28 days
2513948|NCT02803918|Experimental|Lixisenatide|Administration of 3 ascending repeated doses of lixisenatide once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
2513951|NCT02803918|Placebo Comparator|Placebo|Administration of 3 ascending repeated doses of matching placebo once daily and subcutaneously. Background therapy (metformin and basal insulin) will be administered daily about the same time as usually done.
2514022|NCT02803515|Experimental|Patient with HIPEC|
2514026|NCT02803515|Sham Comparator|Patient without HIPEC|
3197614|NCT00862511|Experimental|Coated Total Knee Arthroplasty|allergy coated TKA
3197615|NCT00862511|Active Comparator|Standard Total Knee Arthroplasty|normal TKA
3197616|NCT00862524|Experimental|ARRY-334543 + gemcitabine|
2514190|NCT02802202||Fibromyalgia|Individuals who met the criteria for a diagnosis of FM based upon the ACR diagnostic criteria.
2514195|NCT02802202||Myofascial Pain Syndrome|Individuals with a diagnosis of MPS that does not meet the American College of Rheumatology (ACR) diagnostic criteria for FM.
2514198|NCT02802202||Control|Individuals with no current or prior diagnosis consistent with MPS or FM.
2514335|NCT02801435|Experimental|Cohort 1-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2515250|NCT02795429|Experimental|PDR001 single agent|PDR001 single agent treatment in Phase II
3197617|NCT00862550|Experimental|Group 1|Acupuncture (Areas known to help dry mouth)
3197618|NCT00862550|Experimental|Group 2|Acupuncture (Areas not known to help dry mouth)
3197619|NCT00862576||1|Burning Mouth Syndrome Group
2513113|NCT02809599|No Intervention|Pre-intervention|Patients in hospitals that have not received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess BPPV processes at the ED Index visit. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
2513114|NCT02809599|Experimental|Post-intervention|Patients in hospitals that have received the intervention (DIZZTINCT) and that meet eligibility criteria will have their medical charts abstracted to assess the main study outcome, behavior change in medical providers. A random sample of these patients will be contacted by phone for a brief phone interview regarding their recent visit to the Emergency Department for dizziness.
2513159|NCT02809417||LICORNE platform|
2513162|NCT02809417||Control|
2513235|NCT02809092|Experimental|NK Cells + Chemotherapy Starting|"Starting on Day -7, G-CSF daily by vein until post nadir of absolute neutrophil counts (ANC) are equal or over 1000. Day -6 to Day -2 Fludarabine administrated by vein at 30 mg/m^2. Four hours later Cytarabine administrated by vein at 2 g/m^2. Natural killer (NK) cell infusion Days 0 to 14 for 6 doses total. The first group of participants receive lowest dose level. Each new group receives a higher dose than the group before it, if no intolerable side effects were seen. This will continue for up to 6 dose levels or until the highest tolerable dose of NK cells is found. One (1) to 10 participants will be treated in each dose level.~NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
2513275|NCT02808663|Experimental|Severe Alcoholic Hepatitis|
3197620|NCT00862576||2|Control Group
3197621|NCT00862602|Experimental|1|Stepping Up to Health
3197622|NCT00862602|No Intervention|2|Usual care group
2513466|NCT02807441|No Intervention|No aspirin|Patients will not be given any Acetylsalicylic acid in the perioperative period.
2513471|NCT02807441|Experimental|Low-dose aspirin|Patients will be given low-dose Acetylsalicylic acid (81 mg) in the perioperative period.
2513476|NCT02807441|Experimental|High-dose aspirin|Patients will be given high-dose Acetylsalicylic acid (325 mg) in the perioperative period.
2513552|NCT02807129|Experimental|patients|
3197623|NCT00862628|Experimental|Rebamipide|
3197624|NCT00862667|Experimental|Treatment A|PF-00241939 300ug using Inhaler A
2513655|NCT02806401|Experimental|landmark|landmark method_subclavian venous cannulation
2513663|NCT02806401|Active Comparator|US_Ax|ultrasound guided axillary venous cannulation
3197625|NCT00862667|Active Comparator|Treatment B|PF-00241939 300ug using Inhaler B
3197626|NCT00862667|Active Comparator|Treatment C|PF-00241939 300ug using Inhaler C
2513800|NCT02805335|No Intervention|Control group|Group with the sutureless device actually used
2513803|NCT02805335|Experimental|Innovative group|Group with the new device ( KTFIX PLUS)
2513837|NCT02804906|Experimental|Home-Based Physical Therapy|
2513839|NCT02804906|Active Comparator|Control-30-minute counseling session|Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge.
2513886|NCT02804529|Experimental|Meng's Point entry|Meng's entry involved a 0.2 cm horizontal or vertical incision using the Veress needle in the cross of lateral border of the left rectus abdominis and rib arch.
2513890|NCT02804529|Experimental|Palmer's Point entry|Palmer's entry involved a 0.2 cm horizontal or vertical incision with the Veress needle in the left midclavicular line approximately 3 cm caudal to the 10th rib
2513894|NCT02804529|Experimental|Periumbilllicus entry|Periumbilllicus entry involved a 0.2 cm horizontal or vertical midline incision using the Veress needle in the lower or uper border of the umbilicus.
2513942|NCT02804126|Experimental|TAP (transversus abdominis plane)|Ultrasound-guided transversus abdominis plane block at the end of cesarean section
2513943|NCT02804126|Experimental|QL (quadratus lumborum)|Ultrasound-guided quadratus lumborum block at the end of cesarean section
2514005|NCT02803463|Active Comparator|Peritoneal Closure|open appendectomy with peritoneal closure
2514006|NCT02803463|Active Comparator|Peritoneal Non Closure|open appendectomy without peritoneal closure
2514063|NCT02803268|Experimental|MT-8554 low dose|Patients who meet eligibility criteria will be administered once daily either low dose of MT-8554 or a matching Placebo from Day 1 to 14.
2514065|NCT02803268|Experimental|MT-8554 middle dose|Patients who meet eligibility criteria will be administered once daily either middle dose of MT-8554 or a matching Placebo from Day 1 to 14.
2514066|NCT02803268|Experimental|MT-8554 high dose|Patients who meet eligibility criteria will be administered once daily either high dose of MT-8554 or a matching Placebo from Day 1 to 14.
2514153|NCT02802488|Experimental|D-dimers|This arm encompasses patients between 18 and 80 years old and diagnosed with atrial fibrillation.
3197627|NCT00862680||Diagnostic (4D PET/CT)|Participants undergo 4D PET/CT scan over up to 12 minutes.
3197628|NCT00862693|Experimental|1 calcitriol|calcitriol 0.5ug/BIW for 12 months
2514315|NCT02801383|Active Comparator|Treatment group|received 1g recombinant human α-2b interferon gel every other day for consecutive 6-10 courses of treatment
2514320|NCT02801383|Placebo Comparator|controlled group|received 1g gel (without biological active ingredient) every other day for consecutive 6-10 courses of treatment
2514361|NCT02801058|No Intervention|Control|Simple observation
2514364|NCT02801058|Sham Comparator|Shame|Light touch manipulative simulation
2514366|NCT02801058|Experimental|Treatment|Osteopathic manipulative techniques on the abdominal diaphragm
2514387|NCT02800863||Dorsal Root Ganglion (DRG) Stimulation|
2514453|NCT02800395|Other|Nutritional evaluation|
2514682|NCT02798809||GeOrGS cohort|Clinical dental examination of all Children born in 2008 and 2009 in Chivari District (Italy)
3197629|NCT00862693|No Intervention|2|no intervention
3197630|NCT00862706|Experimental|A|
3197631|NCT00862732|Active Comparator|1 Cognitive Behavioural Therapy|Intervention group will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
2513153|NCT02809456|Experimental|Nicorandil|Beginning 4-6 weeks during radiation therapy, patients receive nicorandil is given during radiotherapy interval, 5mg each time, 3 times daily oral. Treatment repeats after completion of radiation therapy in the absence of disease progression or unacceptable toxicity.
2513160|NCT02809456|Active Comparator|observation|regular radiotherapy as our protocol
2513208|NCT02808988|Active Comparator|group A|periodontal phase 1 therapy consisted of scaling and root planning, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
2513210|NCT02808988|Active Comparator|group B|periodontal phase 1 therapy consisted of scaling and root planning, no bisphosphonate therapy,gingival crevicular fluid collection
2513218|NCT02808988|Active Comparator|group C|no periodontal phase 1 therapy, bisphosphonate therapy (zoledronic acid), gingival crevicular fluid collection
2513226|NCT02808988|Active Comparator|group D|no periodontal phase 1 therapy, no bisphosphonate therapy,gingival crevicular fluid collection
2513393|NCT02807987|Experimental|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally, once daily after breakfast for 12 weeks
3197632|NCT00862732|Active Comparator|2 Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
3197633|NCT00862797||endotracheal tube|Patients intubated with cuffed endotracheal tubes
3197634|NCT00862875|Experimental|1:Insulin detemir|Insulin detemir (Levemir® - Novolin® 4 pen)
2513602|NCT02806778||Hypoxic brain injury|Consecutive out-of-hospital, post-cardiac arrest patients who remain comatose after successful resuscitation, admitted on ICU of University Hospital Ostrava. The patients will undergo BIS monitor-guided sedation and jugular bulb catheterisation.
2513656|NCT02806362|Experimental|Ombitasvir/paritaprevir/ritonavir (12 weeks)|Ombitasvir/paritaprevir/ritonavir (25/50/100mg once daily) for 12 weeks
2513681|NCT02805998|Experimental|Web-based CBT-I|Sleepio delivers CBT-I through 6 weekly web-sessions (www.sleepio.com). Treatment content is based on CBT for insomnia manuals (Espie et al., 2007, 2008) and includes a behavioral component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, putting the day to rest) and an educational component (psycho-education, sleep hygiene).
2513684|NCT02805998|Other|Treatment as Usual|Our control condition was designed to reflect standard care for insomnia patients. No limits are placed on receiving non-study treatment, including medication or psychotherapy. Use of non-study treatment will be tracked.
2513728|NCT02805673|Experimental|OSTEO group|usual medical treatment + 6 osteopathic interventions
2513736|NCT02805673|No Intervention|witness group|usual medical treatment
2513788|NCT02805413|Other|DETERMINATION OF BLOOD PRESSURE|"determination and comparison of blood pressure by/with :~Pulse Curve Analysis~Inert gas re-breathing~Central blood pressure device~Vascular ultrasound device~Thoracic Impedance (ICG) - Electrocardiography (ECG) - Phonocardiography (Phono) - Carotid plethysmography (Pneumo)"
2513914|NCT02804347||Patient|Patients will be receiving either ECT or iTBS as a depression management. Olfactory functioning will be assessed at pre-treatment and 6 weeks later at post-treatment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
2513916|NCT02804347||Control|Controls will have their olfactory functioning assessed at baseline and 6 weeks after the baseline assessment using Sniffin Sticks. Cognition will also be tested using Cognitive Function Imaging and Battery in the fMRI as well as Cognitive Batteries outside of the scanner at pre-treatment, 6 weeks later at post-treatment, and 3 months after the final treatment session.
2513967|NCT02803996|Active Comparator|Part A- Single Dose- 400 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2513968|NCT02803996|Active Comparator|Part A- Single Dose- 600 mg Aramchol|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2513970|NCT02803996|Placebo Comparator|Part A-Single Dose-Placebo|Part A: Subjects will receive a single dose of 400 mg Aramchol, 600 mg Aramchol or placebo.
2513973|NCT02803996|Active Comparator|Part B-Multiple Dose-400 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2513975|NCT02803996|Active Comparator|Part B-Multiple Dose-600 mg Aramchol|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2513977|NCT02803996|Placebo Comparator|Part B-Multiple Dose-Placebo|Part B: Subjects will receive multiple doses of 400 mg Aramchol, 600 mg Aramchol or placebo tablets for 10 consecutive days.
2513999|NCT02803489|Experimental|medical device intervention|
2514059|NCT02803281||Lung Cancer - Frialty Assessment|Patients who will undergo surgery for lung cancer
2514061|NCT02803281||Esophageal Cancer - Frailty Assessment|Patients who will undergo esophagectomy for esophageal cancer
2514086|NCT02802800|Experimental|Water|Plyometric Training in water, twice per week for 6 weeks.
2514088|NCT02802800|Experimental|Land|Plyometric training on land, twice per week for 6 weeks.
2514160|NCT02802540|Experimental|Nabilone|Patients start receiving a dose of 0.5 mg daily oral nabilone the first 2 weeks and then 1 mg to complete 8 weeks.
2514169|NCT02802540|Placebo Comparator|placebo|Patients start receiving a dose of 0.5 mg daily oral placebo the first 2 weeks and then 1 mg to complete 8 weeks.
2514271|NCT02801734|Experimental|Intervention|"Participants in the EQUIP intervention group will individually receive four face-to-face sessions with a palliative care nurse.~For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate."
2514272|NCT02802046||FFR≦0.8|FFR is a score of 0 to 1, FFR < 0.75, has proved almost always accompanied by myocardial ischemia.
2514274|NCT02802046||FFR>0.8|FFR > 0.80 almost never associated with myocardial ischemia.
3197635|NCT00862875|Active Comparator|2:Insulin Glargin|Insulin glargine (Lantus® - Solostar®)
2513168|NCT02809196|Active Comparator|3:Tailored, friend and not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Friend is invited to participate but not mother."
2513169|NCT02809196|Active Comparator|4: Standardized, friend and not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Friend is invited to participate but not mother."
2513171|NCT02809196|Active Comparator|5:Tailored, mother and not friend|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Mother is invited to participate but not friend."
2513175|NCT02809196|Active Comparator|6: Standardized, mother and not friend|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend."
2513179|NCT02809196|Active Comparator|7:Tailored, not friend, not mother|"Depending on the responses to the online dietary questionnaire, the tailored SMS-based educational programs can be one out of three different programs, focusing on either sugar sweetened beverages (SSB), fruit and vegetables (F&V), or fish (FISH). About 40 messages will be distributed over 4 weeks.~Neither friend nor mother is invited to participate."
2513181|NCT02809196|Active Comparator|8: Standardized, not friend, not mother|"The standardized SMS-based educational program includes 121 messages there will be distributed over 12 weeks.~Mother is invited to participate but not friend. Neither friend nor mother is invited to participate."
2513186|NCT02809196|Other|9: No SMS program|Control Group; no SMS-based educational program
2513203|NCT02808793|Experimental|AK002|IV dose of AK002
2513260|NCT02808728|Active Comparator|Pain Cocktail with Ropivacaine|"patients given the standard intra-articular pain cocktail injection, consisting of ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.~given in one single dose"
2513263|NCT02808728|Experimental|Pain Cocktail with Exparel|"patients given a similar intra-articular injection consisting of bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel, 20cc of 1.3% Exparel, to total 100cc.~given in one single dose"
2513306|NCT02808455|Experimental|Sequence I: A/B|Treatment A: pacritinib 400 mg capsule
2513308|NCT02808455|Experimental|Sequence II: B/A|Treatment B: pacritinib 80 mg solution
2513361|NCT02808143|Experimental|Treatment (pembrolizumab, BCG solution)|"PRE-INDUCTION PHASE: Patients receive pembrolizumab intravesically once on day -14.~INDUCTION PHASE: Patients receive BCG solution intravesically once weekly for 6 weeks at weeks 0-5 and pembrolizumab intravesically every 2 weeks at weeks 0, 2, and 4.~MAINTENANCE PHASE: Beginning 2 weeks after the last dose of BCG solution, patients receive pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then receive pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses."
2513396|NCT02807740|Experimental|Virtual Reality|Patients will be treated with a virtual reality rehabilitation program
2513398|NCT02807740|Other|Conventional Rehabilitation Program|Patients will be treated with a conventional rehabilitation program.
2513469|NCT02807532||atrial fibrillation group|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
2513472|NCT02807532||non-atrial fibrillation group|Patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
2513533|NCT02807181|Active Comparator|Chemotherapy (Cisplatin-Gemcitabine)|Cisplatin 25mg/m2 in 1000ml 0.9% saline given over 1 hour followed by 500 ml 0.9% saline over 30 minutes, followed by Gemcitabine 1000 mg/m2 in 250-500 ml 0.9% saline over 30 minutes by intravenous infusions on days 1, and 8 of a 21-day cycle.
2513537|NCT02807181|Experimental|Radiation: SIRT + chemotherapy (Cisplatin-Gemcitabine)|A single treatment of hepatic arterial injection of SIR-Spheres Y-90 resin microspheres (SIRT) followed 14-16 days later by systemic chemotherapy (ABC-02 CIS-GEM protocol) with an intention to treat with 8 cycles of cisplatin + gemcitabine, or until progression, toxicity or patient choice. Treatment may be continued beyond 8 cycles in the absence of significant disease progression, at the treating clinicians' discretion.
2513597|NCT02806570|Experimental|AccuCinch® Ventricular Restoration System|
2513651|NCT02806349|Placebo Comparator|Control|3g/d Cornstarch and 14g/d wheat bran control
2513658|NCT02806349|Experimental|K-GB&AG|3g/d American Ginseng and 7g/d Konjac-glucomannan fiber blend
3197636|NCT00862888|Placebo Comparator|Cohort 1; Study Period 1, 2, 3 or 4|Cohort 1: Exploring two single doses of PF-00446687 200 mg as well as sildenafil 100mg and placebo (double dummy design)
2513793|NCT02805205|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
2513853|NCT02804724||Newly diagnosed individuals with HIV|Individuals newly diagnosed with HIV in Grampian between January 2009 and December 2014
2513944|NCT02804035|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
2514028|NCT02803775|Active Comparator|Paced|Paced arm in which the left heart lead electrode is selected utilizing the longest time to when patient right ventricle lead is pacing. The result of the pacing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
2514033|NCT02803775|Active Comparator|Sensed|Sensed arm is based on the longest time that patient own heart's conduction reaches the left heart lead electrode.The result of the sensing algorithm becomes the patient's pacing location for the study duration (self-assigned algorithm within this cohort).
2514081|NCT02803047|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514700|NCT02798549|Other|Viraemic|
2513214|NCT02808923|Experimental|Foam rolling|"Participants in the foam rolling group will perform unilateral rolling of the hamstring musculature from ischial tuberosity to posterior knee in supine for 2 repetitions of 1 minute with 15 second rest between repetitions at a consistent cadence of 1 second superiorly and 1 second inferiorly. Subjects will be asked to adjust pressure as needed to maintain a consistent moderate pressure on the treatment area. Participants will use new and individually issued high density foam rollers that are 6 diameter x 36 length."
2513222|NCT02808923|Experimental|Static stretching|Participants in the static stretching group will perform sustained static hamstring stretching for 2 repetitions of 1 minute bouts for the same leg before switching sides using moderate pressure in supine against the wall. Subjects will rest for 15 seconds between repetitions and adjust distance from the wall to perceive moderate intensity.
2513228|NCT02808923|No Intervention|Control|The control group will perform their regular baseline activities without the addition of a specific lower extremity flexibility program. If the subjects are currently performing stretching of any mode at baseline, they will be allowed to continue with that activity.
2513271|NCT02808689|Active Comparator|Asthma Center|"Use of Currently Accepted Asthma Care Guidelines:~Assessment and monitoring: the use of objective measures of lung function to assess severity of asthma and to monitor the course of therapy,~Control of factors contributing to symptom exacerbation: environmental control measures to avoid or eliminate factors that precipitate asthma symptoms or exacerbations,~Pharmacotherapy: comprehensive pharmacologic therapy for long-term management, and~Education for partnership in care: patient education that fosters a partnership among the patient, his/her family, and clinicians."
2513273|NCT02808689|Active Comparator|Asthma Center plus Functional Medicine|"All the factors in the Asthma Center Arm plus:~Address lifestyle factors such as nutrition and exercise that influence long-term health and chronic diseases. The intention is to reduce ongoing biologic imbalances from deficiencies in dietary oxidants/antioxidants via vitamin supplementation, hormonal imbalances through evaluation and management, and the need for medications with unwarranted side effects that compound the chronic medical conditions and adverse effects (e.g. excess use of antibiotics), and to systematically evaluate intolerances to certain foods and additives."
2513329|NCT02808377|Active Comparator|SPOP|This arm will have the soft silicone pessary inserted post operatively and it will remain in-situ for 3 weeks.
2513333|NCT02808377|No Intervention|Non Intervention|Routine post operative care
2513381|NCT02808000|Active Comparator|Group 1 (also called Group A )|Group 1/A will use standard catheter during the first ~6 months (observational period 1). Then the patients in this group will switch to the noble metal alloy urinary catheter (BIP Foley catheter of latex or silicone produced by Bactiguard AB) and be observed for another ~6 months (the second observational period).
2513385|NCT02808000|Experimental|Group 2 (also called Group B)|Group 2/B will use the BIP Foley (latex or silicone) during the first ~6 months (observational period 1). Then the patients in this group will switch to the standard catheter and be observed for another ~6 months (the second observational period).
3164230|NCT00495105|Experimental|Two Servings of Dairy Snacks|Intervention group received two servings of dairy food per day as a snack at school for 6 months as well as nutrition education.
3164231|NCT00495105|No Intervention|No Dairy Snacks|Control Group did not receive any snacks or education.
3164232|NCT00495183|Experimental|1|caffeine + placebo
2513726|NCT02805829|Experimental|Trastuzumab + NK cells|"On Cycle 1,day -2, patients will receive IV loading dose 8mg/Kg trastuzumab, followed by collection blood on day 0. After NK expansion and verification that the resulting NK cells meet release criteria, NK cells were washed and resuspended in isotonic sodium chloride for intravenous transfusion on day 14.~NK cellular therapy conduct 2 cycles per year. The maintenance dose of trastuzumab monotherapy is 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress."
2513784|NCT02805387|No Intervention|no treatment|Dystocic women where no bicarbonate was given
2513785|NCT02805387|Experimental|Treatment|Dystocic women where bicarbonate was ingested
2513827|NCT02805062||Pleural Effusion|Malignant pleural effusion patients requiring investigation with thoracoscopy.
2513959|NCT02804204||Anti-TNF|
2514057|NCT02803177|Experimental|BMC2012 + beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical standard, filled with a clinically established scaffold (beta-TCP Chronos® Synthes), and loaded with 1.3 x 10E6 BMC/ml TCP per 1 ml beta-TCP in situ.
2514060|NCT02803177|Placebo Comparator|beta-TCP Chronos® Synthes|The large bone defect will be bridged as per clinical Standard and filled with a clinically established scaffold (beta-TCP Chronos® Synthes).
2514113|NCT02802813|Active Comparator|Intervention arm|Dihydroartemisinin-piperaquine (DP) therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
2514121|NCT02802813|Placebo Comparator|Control arm|Dihydroartemisinin-piperaquine therapy plus 14 days identical placebo not containing primaquine.
2514558|NCT02800317|Experimental|RISAS|All patients will undergo RISAS procedure, followed by axillary lymph node dissection in a one-step surgical procedure.
2514701|NCT02798549|Other|Remission|
3164233|NCT00495183|Experimental|2|caffeine + biperiden
3164234|NCT00495183|Placebo Comparator|3|Placebo+placebo
3164235|NCT00495196|Experimental|1|
3164236|NCT00495196|Active Comparator|2|
3164237|NCT00495209||Qigong|"Pre-surgical Qigong therapy for women with breast cancer~External Qi Therapy = EQT"
3164238|NCT00495235||Endometrial Cancer Group|Participants who have had endometrial cancer (cases).
3164239|NCT00495235||Control Group|Participants who have not had endometrial cancer (controls).
3164240|NCT00495248|Experimental|1|
3164241|NCT00495248|Active Comparator|2|
3164242|NCT00495261|Experimental|1|
3164243|NCT00495261|Active Comparator|2|
3175142|NCT00630565|Experimental|Bone Marrow Transplant (less and 2 years old)|Patients under the age of two, and patients who cannot receive total body irradiation (TBI), will receive a cytoreductive regimen of Busulfan and cyclophosphamide (BU/CY) as per the Johns Hopkins University Hospital regimen as well as sargramostim, dexamethasone, etoposide, transplantation (bone marrow transplantation/hematopoietic stem cell transplantation/peripheral blood stem cell transplantation).
2513219|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Negative result|Participants whose sample provided a positive result after first test, will be contacted immediately by telephone by an oncologist co-investigator and concurrently sent a letter by mail informing them of the result and asking them to return for a second blood draw. We expect that this communication will happen with about a month of the original blood draw. The letter will include contact information for the study team and the oncologist co-investigators, in case the participant has any questions or concerns at this stage. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn at the blood collection visit, to allow repeat testing and confirmation that the mutation is present consistently. Once the data is analyzed, participants with a negative result will be sent an email thanking them for their participation and informing them of the negative result.
2513229|NCT02808884|Experimental|Circulating tumor DNA assay - Second test- Positive result|Participants with positive results after first test will be contacted by an oncologist and sent a letter informing them of the result. They will be ask to return for a second blood draw. The letter will include contact info of the study team and the oncologist co-investigators. A requisition form will be sent with the letter. Two 10mL tubes of blood will be drawn to allow repeat testing and confirmation that the mutation is consistently present. Participants whom additional blood sample yields a positive result for the same cancer mutations seen in the first blood draw, will be contacted by an oncologist to explain the results and next steps. This should happen within about a week of the second blood draw. Pending oncological evaluation of the participant and study results, a PET-CT scan with FDG agent, and possibly other tests will be requested. Unless exams suggest otherwise, the default follow-up will be a full body PET-CT.
2513280|NCT02808676|Experimental|Exercises+CognitiveTraining+Vitamin D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks."
2513281|NCT02808676|Experimental|Exercises+CognitiveTraining+Placebo D3|"Exercises will combine aerobic+resistance training. Cognitive training will be performed before exercise intervention and using using an ad-hoc software developed by us for tablets. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks."
2513282|NCT02808676|Experimental|Exercises+Control CogTraining+Vitamin D3|Exercises will combine aerobic+resistance training. Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc.). Vitamin D3 (10000IU) will be provided orally three time per week for 20 weeks
2513284|NCT02808676|Experimental|Exercises+Control CogTraining+Placebo D3|Exercises will combine aerobic+resistance training.Control cognitive training will be performed before exercise intervention and will consist in computer skills training courses. Each session will consist of introductory exercises for computers and different software (e.g., Word, Excel), as well as an initiation to the Internet (search engines, websites, games, etc. Matching placebo of vitamin D3 will be provided orally three time per week for 20 weeks.
2513286|NCT02808676|Placebo Comparator|Placebo exercise+Control Cog+Placebo D3|This will be the comparator arm with control/placebo activities.
2513345|NCT02808234|Other|Nucel treatment group|One or two level lumbar interbody fusion surgery with Nucel
2513409|NCT02807896||pancreatic cancer|pancreatic cancer 88
2513413|NCT02807896||bile duct cancer|bile duct cancer 101
2513418|NCT02807896||stomach cancer|stomach cancer 9
2513420|NCT02807896||colon cancer|colon cancer 5
2513423|NCT02807896||normal group|normal group 29
3197637|NCT00862888|Placebo Comparator|Cohort 2; study periods 1, 2, 3 or 4|Cohort 2: Exploring single doses of PF-00446687 20 mg - 175 mg. Subjects to receive two of 3 possible doses of PF-00446687 as well as a single dose of sildenafil 100mg and placebo (double dummy design).
2513609|NCT02806557||High risk group|"Defined as risk of severe neutropenia >20% or risk of neutropenic infective complications >10%, with severe neutropenia defined as absolute neutrophil count <1.0 x10^9/L.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2513613|NCT02806557||Frequently given regimens|"Defined as high number of cases of neutropenia, but risk of severe neutropenia <5%.~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2513615|NCT02806557||Prophylactic GCSF|"Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).~The intervention is home finger-prick capillary blood count monitoring (up to daily)."
2513642|NCT02806271|Experimental|Worry Postponement|Two weeks of daily worry postponement
2513645|NCT02806271|Active Comparator|Worry Monitoring|Two weeks of daily worry monitoring
2513648|NCT02806271|No Intervention|Assessment Only Control|No intervention, participants will complete three assessment time points
2513744|NCT02805764|Experimental|Homeoblock functional dental appliance|Removable functional dental appliance to be used at during sleep for one year.
2513812|NCT02805374|Experimental|ASP1517 fasting then fed|Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.
2513813|NCT02805374|Experimental|ASP1517 fed then fasting|Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.
2513840|NCT02804815|Active Comparator|Aspirin 100mg|Aspirin 100mg
2513842|NCT02804815|Placebo Comparator|Placebo 100mg|100mg Placebo
2513845|NCT02804815|Active Comparator|Aspirin 300mg|Aspirin 300mg
2513849|NCT02804815|Placebo Comparator|Placebo 300mg|300mg Placebo
3197638|NCT00862901|Experimental|1|100 J / cm2 over 24 hours
3197639|NCT00862901|Experimental|2|200 J / cm2 over 24 hours
2514085|NCT02802748|Experimental|Metronomic Vinorelbine + Letrozole|"Oral Vinorelbine: 50 mg (30 mg + 20 mg) three times a week, for 3 weeks~Letrozole: 2.5mg daily, for 3 weeks"
3197640|NCT00862901|Experimental|3|400 J / cm2 over 24 hours
3197641|NCT00862901|Experimental|4|800 J / cm2 over 24 hours
3197642|NCT00862914||1|benign melanocytic naevi
3197643|NCT00862914||2|dysplastic melanocytic naevi
3197644|NCT00862914||3|cutaneous malignant melanoma
2513328|NCT02808299||HBV infection history|One or more of HBsAb,HBeAb, HBcAb are positive, while HBsAg and HBeAg are negative. If only HBsAb is positive, the history of HBV vaccination need to be excluded.
2513331|NCT02808299||HBV carriers|One or two of HBsAg and HBeAg are positive, accompanied by any HBV antibody is positive or not.
2513524|NCT02806921|Active Comparator|ZenLens with Low limbal clearance|Scleral contact lens designed to provide approximately 25 microns of limbal clearance.
2513527|NCT02806921|Active Comparator|ZenLens with High limbal clearance|Scleral contact lens designed to provide approximately 80 microns of limbal clearance.
2513569|NCT02806856|Active Comparator|Active tDCS|
2513571|NCT02806856|Sham Comparator|Sham|
2513624|NCT02806583|Experimental|intervention|telephone based structured support groups
2513625|NCT02806583|No Intervention|control|Active Comparator: Usual care (intervention as experimental group after 3 month (after T1)
2513633|NCT02806219|Active Comparator|Certolizumab Pegol injection by prefilled syringe|
2513637|NCT02806219|Experimental|Certolizumab Pegol injection by e-Device|
2513678|NCT02806102||High-risk|"Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have at least one of the following risk factors:~Age ≥ 65 years~Diabetes mellitus requiring medication~Documented history of a second prior presumed spontaneous MI (>1 year ago)~Documented history of angiographic evidence of multivessel coronary artery disease~Chronic, non-end stage renal dysfunction"
2513679|NCT02806102||Low-risk|Acute myocardial infarction treated with percutaneous coronary intervention and/or long-term use of dual-antiplatelet therapy and have none of the pre-specified risk factors
2513730|NCT02805608|Experimental|uPAR PET/CT and FDG PET/MR|One injection of 68Ga-NOTA-AE105 followed by PET/CT and on a separate day one injection of 18F-FDG followed by PET/MRI. Both scans will be evaluated for possible regional lymph node metastases.
2513775|NCT02805270|Experimental|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
2513779|NCT02805270|No Intervention|usual care|Usual care provided by ward pharmacist, nurses and doctors in the ward
2513821|NCT02805088|Experimental|Bipolar Disorder patients|
2513826|NCT02805088|Experimental|Schizophrenia patients|
2513828|NCT02805088|Experimental|Healthy Volunteers|
2513883|NCT02804555|Active Comparator|Oxygen support|5 liter / minute oxygen has given to the mothers on face mask.
2513884|NCT02804555|No Intervention|Room air|Oxygen support has not given to the mothers.
3175143|NCT00630578|Active Comparator|1|Cognitive Processing Therapy
2513966|NCT02803944||Cystic fibrosis patients taking azithromycin|Cystic fibrosis patients taking azithromycin continuously for two years.
2513995|NCT02803632|Experimental|suicide attempt|questionnaires actigraphic recording
2514025|NCT02803346||septic shock patients|
2514094|NCT02802644|Experimental|DPP-4 Inhibitor|Any dose of Sitagliptin for 6 months with any other oral anti-diabetic medication
2514099|NCT02802644|Active Comparator|Non DPP-4 Inhibitor|Oral anti-diabetic medication except DPP-4 inhibitor
2514154|NCT02802332|Active Comparator|Footlength Card|Pregnant women will receive a card that enables them to measure the length of their baby's foot. The card contains a phone number to pre-recorded message that provides basic information/advice regarding care of preterm and/or low birth weight babies
2514163|NCT02802332|No Intervention|No Footlength Card|Women in this group do receive any footlength card.
2514254|NCT02802085||Knee Arthroplasty|Vega Knee Arthroplasty
2514632|NCT02799030|Placebo Comparator|BF-200 ALA 0%|Topical application of matched placebo gel without containing 5-ALA. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2514637|NCT02799030|Experimental|BF-200 ALA 1%|Topical application of BF-200 ALA gel containing 0.78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2514639|NCT02799030|Experimental|BF-200 ALA 3%|Topical application of BF-200 ALA gel containing 3.8 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2514642|NCT02799030|Experimental|BF-200 ALA 10%|Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid. Application of a 1 mm thick layer covering each lesion and approximately 1 cm of the surrounding margin.
2514692|NCT02798718|Active Comparator|lactose digesters|Participants in arm 1 are grouped as lactose digesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is less than 20 ppm.
2514693|NCT02798718|Active Comparator|lactose maldigesters|Participants in arm 2 are also grouped as lactose maldigesters based on breath hydrogen test after a 25-g lactose load. The breath hydrogen excretion is not less than 20 ppm.
2514783|NCT02798159|Experimental|Part A- Arm 1|Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
3175144|NCT00630578|No Intervention|2|Arm 2 participants will monitor their symptoms for a period of 10 weeks, prior to being crossed over into active treatment. This will allow investigators to account for the passage of time without intervention when tracking symptoms.
3175145|NCT00630591|Experimental|Standardized Materials Group|
3175146|NCT00630591|Experimental|Independent Tailored Intervention|
3175147|NCT00630591|Experimental|Partner-Assisted Tailored Intervention|
3175148|NCT00630630|Experimental|1|
3175149|NCT00630630|Placebo Comparator|2|
3175150|NCT00630643|Placebo Comparator|1|
3175151|NCT00630643|Experimental|2|
3175152|NCT00630656|Experimental|1|Talactoferrin alfa
3175153|NCT00630656|Placebo Comparator|2|Placebo
3175154|NCT00630669|Active Comparator|1|Rubber band ligation
3175155|NCT00630669|Active Comparator|2|Bipolar coagulation
3175156|NCT00630682|Active Comparator|Dextroamphetamine|Active drug
3175157|NCT00630682|Placebo Comparator|Placebo|Placebo of drug
3175158|NCT00630695|Experimental|1|Lanreotide LP 90
3175159|NCT00630695|Placebo Comparator|2|
3175160|NCT00630708|Active Comparator|1|Benazepril group
2513348|NCT02808195|Experimental|kinect-based constraint-induced therapy|training of the more affected arm and restraint the less affected arm by kinect-game
2513412|NCT02807870|Experimental|Methylphenidate-psychoeducational group|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments) and weekly psychoeducational groups for parents during 8 weeks.
2513417|NCT02807870|Experimental|Parental training-placebo pill|Weekly parental training conducted by behavioral psychologists and placebo pill during 8 weeks.
2513419|NCT02807870|Placebo Comparator|Psychoeducational group-placebo pill|Weekly psychoeducational groups for parents and placebo pill during 8 weeks.
2513496|NCT02807298|Active Comparator|2% Lignocaine (lidocaine)|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine (adrenaline)
2513500|NCT02807298|Experimental|4% Articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine (adrenaline)
2513521|NCT02806999|Experimental|Berberine; Insulin|"Follow the previous administration program，participants will continue to receive intensive insulin therapy; Besides injecting insulin, participants will receive 500mg berberine twice a day for 8 days.~Drug: Berberine; Insulin"
2513522|NCT02806999|Active Comparator|Insulin|"Besides receiving intensive insulin therapy, participants will take a placebo twice a day for 8 days.~Drug: Insulin"
2513598|NCT02806830|Experimental|Optive after the second anti-VEGF injection|Naive patients requiring intravitreal injection. Patients will be enrolled in this study within the 2 first intravitreal injections to assess quality of life and ocular discomfort without wetting agent (ie after the first injection) and with wetting agent (ie after the second injection)
2513715|NCT02805777|Experimental|Washing procedure 1|this group will apply washing technique 1
2513717|NCT02805777|Experimental|Washing procedure 2|this group will apply washing technique 2
3175161|NCT00630708|Active Comparator|2|Losartan group
2514224|NCT02801890|Experimental|AD-MSC|The patients with ultra filtration failure (UFF) underwent AD-MSC injection.
2514229|NCT02801890|Placebo Comparator|Placebo|The patients with ultra filtration failure (UFF) underwent Placebo injection.
2514296|NCT02801695|Experimental|L-Citrulline|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
2514299|NCT02801695|Placebo Comparator|Lactose|Bolus (9g) after patient stabilization, then 3g 3 times a day until delivery
2514405|NCT02801240|Experimental|Nutrition Support Product|Participants will be asked to take a nutrition support product twice per day for a period of 12 weeks.
2514460|NCT02800668||DJBL implant-group|"T2DM Patients implanted with a DJBL (Duodenal jejunal Bypass liner, EndoBarrier, GI Dynamics) due to medical reasons.~The subjects were regular in-patients of the Diabetes Center at the Heart and Diabetes Center NRW, Germany and gave informed consent for related procedures and data handling. The subjects had BMI ≥35 kg/m2, T2DM, and a history of frustrated weight loss attempts. Exclusion criteria: history of gastric surgery, gastric or duodenal ulcers, thyroid disorders, gastrointestinal disorders with intestinal resorption dysfunction, therapy with oral anticoagulants, use of acetyl salicylic acid or non-steroidal anti-inflammatory drugs, drug abuse (incl. alcohol), symptomatic cardiovascular disease, renal insufficiency (GFR <50 ml/min), pregnancy or breast feeding."
2514508|NCT02800252|Placebo Comparator|Control Group|Full-mouth periodontal debridement and placebo
2514509|NCT02800252|Active Comparator|Test 1|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
2514510|NCT02800252|Active Comparator|Test 2|omega-3 plus aspirin before periodontal therapy
2514540|NCT02799927|Experimental|Biodentine|"Biodentine (Septodont, Saint-Maur-des-Fosses, France) has been recently introduced and marketed as a bioactive dentin substitute. The Biodentine powder contains tricalcium silicate, dicalcium silicate and calcium oxide, while its liquid consists of calcium chloride and a carboxylate-based hydrosoluble polymer (water-reducing agent).~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the preparation of Biodentine liner (a mix of powder and liquid), following the manufacturers' instructions, and its placement over the remanent carious dentin layer."
2514543|NCT02799927|Active Comparator|Ultra-Blend plus (Calcium hydroxide)|"Ultra-Blend plus® (Ultradent Products Inc., South Jordan, UT, USA). This material is a light-activated calcium hydroxide based-liner. Calcium hydroxide has demonstrated to reduce and promote immediate deactivation of the residual microorganisms after IPT.~After local anesthesia and rubber dam isolation, carious peripheral dentin is eliminated with a high speed tungsten-carbide bur # 3, and air-water spray. Then, the cavity's floor soft dentin layer is carefully removed with a sharply-edged sterilized hand excavator, leaving only the hard dentin adjacent to the pulp ceiling. The cavity is thoroughly rinsed only with water and dried with sterilized cotton pellets. The next step consists in the placement of Ultra-Blend plus liner over the remanent carious dentin layer, using a dycal metallic applicator. Finally, the liner is cured through light exposure during 20 seconds ."
2514579|NCT02799550|Experimental|allogeneic CART-19|infusions of allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
2514651|NCT02799212|Experimental|Experimental group|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day
2514652|NCT02799212|Placebo Comparator|Control group|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days
2514869|NCT02797548|Experimental|Aspirin only|
2514871|NCT02797548|Active Comparator|No antiplatelet therapy|
3175162|NCT00630708|Active Comparator|3|Benazepril+Losartan group
3175163|NCT00630721|Other|IFNbeta-1b|no drug was given under study. patients already taking IFNbeta-1b were enrolled for blood draw only.
3175164|NCT00630760|Experimental|1|NRX 194204 capsules in escalating doses, starting at 3mg/m2.
3175165|NCT00630799|Experimental|1|leuprolide acetate administered by i.m. injection as two doses of 17 mg each during a period of 6 months (one dose every 3 months)
3175166|NCT00630851|Experimental|1|
3175167|NCT00630851|Placebo Comparator|2|
3175168|NCT00630890|Experimental|1|External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
3175169|NCT00630903|Active Comparator|A|8-MOP + UVA x 24 weeks
2513422|NCT02807727|Active Comparator|Intralipid 20%|Intravenous single bolus of 1.5 ml/kg of Intralipid 20% over 3 minutes.
2513426|NCT02807727|Placebo Comparator|Modified Ringers Lactate|Intravenous single bolus of 1.5 ml/kg of MRL over 3 minutes.
3197645|NCT00862927||Cue reactivity in virtual reality|Breath Scan + Saliva Sample + Questionnaires + View Virtual Reality Scenes
3197646|NCT00862953|Active Comparator|Normal protein normal carbohydrate|Normal protein normal carbohydrate calory restricted nutrition
3197647|NCT00862953|Experimental|Normal protein low carbohydrates|Normal protein low carbohydrate energy-restricted diet
3197648|NCT00862953|Experimental|High protein normal carbohydrates|High protein normal carbohydrates
3197649|NCT00862953|Experimental|High protein low carbohydrate|High protein low carbohydrate nutrition
2513735|NCT02805868|Experimental|Treatment (siltuximab)|Patients receive siltuximab IV over 60 minutes on day 1. Patients also undergo bone marrow biopsy and aspiration at baseline and at the end of treatment (within 30 days of last siltuximab dose) or as clinically indicated. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who are responding after 6 courses may receive additional siltuximab treatment for up to 1 year at the discretion of the study doctor.
2513819|NCT02805231||primary open-angle glaucoma patients|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
2513820|NCT02805231||randomly age-matched people|vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
2513879|NCT02804685|No Intervention|Control|It consists on only a regular training performance
2513881|NCT02804685|Experimental|Experimental|It consists on performing the protocol which includes 6 strength, agility and balance exercises together with the regular training. The exercise program has to be performed twice a week during 6 weeks
2513953|NCT02804269||Healthy Volunteer|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2513954|NCT02804269||Dilated Cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2513956|NCT02804269||Hypertrophic cardiomyopathy|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2513957|NCT02804269||Ischemic heart disease with reduced EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2513958|NCT02804269||Ischemic heart disease with normal EF|Subjects will undergo the following study procedure: Cardiovascular Magnetic Resonance Imaging and fatmass measurement
2513997|NCT02803502|Experimental|hemophilia|Patients with severe hemophilia (or moderate hemophilia if presence of hemorrhages) under prophylaxy and subjected to a pharmacokinetic profile of factor VIII
2514110|NCT02802969|Experimental|[18F]FAZA PET/CT|In residual chordoma tumors after surgery, Investigators propose a protontherapy guided by conventional imaging (CT/MRI) and a boost guided by FAZA PET/CT, in order to target the hypoxic zones and to increase the dose in an adequate manner, which could result in improving long-term local control and reducing complications.
2514199|NCT02802306|Experimental|Tack Implant|Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.
2514223|NCT02801812||Systemic Lupus Erythematosus|patients ≥18 years diagnosed SLE upon classification according to 2012 SLICC criteria and disease onset ≥16 years.
2514231|NCT02801812||Healthy controls|subjects ≥18 years fulfilling the definition proposed in the protocol.
2514398|NCT02801214||Recreational Cannabis Use|ages 18-40
2514414|NCT02801214||Healthy control subjects|socio-demographically matched
2514471|NCT02800733|Experimental|saffron|450 mg of saffron capsule once a day for 6 weeks
2514476|NCT02800733|Placebo Comparator|placebo|placebo capsule once a day for 6 weeks
2514634|NCT02799043|Active Comparator|Standard PVI|Standard catheter ablation including pulmonary vein isolation (PVI) procedure.
2514638|NCT02799043|Experimental|FIRM-guided Procedure and PVI|FIRM-guided procedure followed by PVI.
2514742|NCT02798497|Other|staphylococcus aureus PVL-|patients with staphylococcus aureus PVL-
2514748|NCT02798497|Other|staphylococcus aureus PVL+|patients with staphylococcus aureus PVL+
2514776|NCT02798120|Experimental|SB204 4%|SB204 4% once daily
2514876|NCT02797457|Other|Allograft|Bilateral allograft of the hands and forearms.
2514877|NCT02797457|Other|Prostheses|Prosthetic forehands
2514933|NCT02797067|Experimental|Indomethacin|Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
2514935|NCT02797067|Placebo Comparator|Glycerin|Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.
2514981|NCT02796742||Group MSSA|
2514986|NCT02796742||Group MRSA|
2514988|NCT02796742||Group PVL-negative strains|
2514989|NCT02796742||Group PVL-positive strains|
2515019|NCT02796469||Pentoxifylline + Corticosteroid|Association of treatment by pentoxifylline and corticosterone during 28 days
2515025|NCT02796469||Corticosteroid|treatment by corticosteroid during 28 days
2515030|NCT02796469||Pentoxifylline|treatment by pentoxifylline during 28 days
2515031|NCT02796469||Placebo|
2515066|NCT02796170|Active Comparator|Dapagliflozin|This arm will undergo 6 weeks of Dapagloflozin then 6 weeks of placebo
2515068|NCT02796170|Other|Sulfonylurea|This arm will be open label, participants will receive usual care for 6 weeks, then be provided a sulfonylurea medication for 6 weeks.
2515070|NCT02796170|Active Comparator|Placebo|This arm will undergo 6 weeks of placebo then 6 weeks of Dapagloflozin
2515440|NCT02794324|Active Comparator|Prone treatment|Stage 1B: Optimised supine DIBH vs prone position
3197650|NCT00862966|Experimental|citrate|
3197651|NCT00862966|Active Comparator|heparin|
3197652|NCT00863005|Experimental|1. K201|
2513454|NCT02807558|Experimental|SY-1425 (tamibarotene) in combination with daratumumab|"SY-1425 during a 7-day lead-in and days 1-28 of a 28 day cycle at 6mg/m2/day orally divided into twice a day dosing.~Daratumumab at 16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425."
2513557|NCT02807142|Experimental|NC 1 cell therapy|All patients will be treated with the same treatment: NC1 cell therapy
2513605|NCT02806739|Experimental|Soy Group (Soy Protein + Isoflavones)|"Intervention: Soy-based whole foods containing about 25 grams of soy protein and 60-75 mg isoflavones.~Intervention group will consume soy foods containing about 25 grams of soy protein and 60-75 mg isoflavones per day, from 16th gestational week to birth. Examples of soy foods that contain 25 grams of soy protein and 60-75mg isoflavones include: 2 cups of soy milk, or 12 ounces tofu, or a half cup of soy nuts. Women in the Soy Group will be instructed by a registered dietitian how to incorporate the soy foods into their daily diet."
2513607|NCT02806739|Placebo Comparator|Control Group (Minimize Soy Intake)|Control Group will avoid soy supplements and minimize intake of soy foods.
2513659|NCT02806297|Experimental|Early cholecystectomy with IOC|The experimental arm will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
2513665|NCT02806297|Active Comparator|Late cholecystectomy with IOC|The comparator will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
2513704|NCT02805946|Other|intravenous followed by oral|"Start with posaconazole IV 300mg BID on the first day. Posaconazole will be infused over a period of 90 minutes.~Days 2-7 patients will receive posaconazole IV 300mg QD.~Days 8-12 patients will receive posaconazole PO 300mg QD.~Days 13-16 patients will receive posaconazole PO 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
2513705|NCT02805946|Other|oral followed by intravenous|"Start with posaconazole PO 300mg BID on the first day.~Days 2-7: patients will receive posaconazole PO 300mg QD.~Days 8-12: patients will receive posaconazole IV 300mg QD. Posaconazole will be infused over a period of 90 minutes.~Days 13-16 patients will receive posaconazole IV 200mg QD.~3 PK curves will be determined on days 7, 12 and 16 (after the 7th, 12th and 16th dosage)."
2513761|NCT02805556|Experimental|Oral dose of BMS-663068 + intravenous dose of [13C]BMS 626529|Single oral dose of BMS-663068 followed by Single intravenous dose of [13C]BMS 626529
2513815|NCT02805153|Experimental|Experimental/PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
2513816|NCT02805153|Active Comparator|Active Comparator/rhG-CSF|patients received daily subcutaneous injections of rhG-CSF(filgrastim) 5 ug/ kg/day. Injections on day 3 after chemotherapy and continued daily until an ANC of at least 10.0 X 10^9/L was documented after the expected nadir, or for a maximum of 14 days
2513866|NCT02804737||Web Group|Patients given web site (aiddly) instructions for colonoscopy
2513868|NCT02804737||Paper Group|Patients given paper instructions for colonoscopy
2513905|NCT02804412|Active Comparator|Control group|Patients received a standard, house-typical aphasia therapy in single and group therapy sessions
2513907|NCT02804412|Experimental|CIAT-group|Patients received constraint-induced aphasia therapy.
2513909|NCT02804412|Active Comparator|communication treatment group (CTG)|Patients received aphasia group therapy without constraints
2513925|NCT02804061|Active Comparator|Full NELIP|This group will receive the full Nutrition and Exercise Lifestyle Intervention Program (two behavior changes) from enrollment until birth and serves as the comparator control (Group A).
2513926|NCT02804061|Experimental|Nutrition followed by Exercise (N+E)|Intervention - Nutrition component only (one behaviour) until 24 week assessment, then the addition of the second behavior change (Exercise component) at 25 weeks, with both behaviours followed until birth (Group B).
2513927|NCT02804061|Experimental|Exercise followed by Nutrition (E+N)|Intervention - Exercise component only (one behaviour) until 24 week assessment, after which there will be the addition of the second behaviour change (Nutrition component), with both behaviours followed until birth (Group C).
2513991|NCT02803892|Placebo Comparator|Group 1: Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received placebo x 2 placebo (Group 1) After 4 weeks of treatment, patients will discontinue relevant placebo treatment, but continue the second placebo for a further 8 weeks
2513992|NCT02803892|Experimental|Group 2: Rapamycin plus Placebo|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus placebo. After 4 weeks of treatment, patients will discontinue rapamycin, but continue the second placebo for a further 8 weeks
2513993|NCT02803892|Experimental|Group 3: Rapamycin plus Vildagliptin|Eligible participants will be randomized to one of three treatment arms. In this arm patients will received rapamycin plus vildagliptin. After 4 weeks of treatment, patients will discontinue rapamycin , but continue Vildagliptin o for a further 8 weeks
2514031|NCT02803307|Experimental|6 mg TLC599|6 mg DSP with 50 μmol PL
2514036|NCT02803307|Experimental|12 mg TLC599|12 mg DSP with 100 μmol PL
2514070|NCT02802995|Experimental|Treatment arm|Subjects receiving the study drug which is PRP/thrombin mixture
2514071|NCT02802995|No Intervention|Control arm|Subjects receiving the standard of care for chronic venous wounds
2514091|NCT02802722|Active Comparator|Immediate supplementation|Dietary supplement: Vitamin D3 supplementation - oral capsules 6400 International Units once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
2514096|NCT02802722|Placebo Comparator|Delayed supplementation|Placebo: oral placebo capsules once daily for 6 weeks Peripheral blood and induced sputum sampling Chest computerised tomography (CT) scans Symptom questionnaire
2514156|NCT02802293|Active Comparator|Standard rTMS Aiming|Active repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left DLPFC using the standard aiming strategy with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
3197653|NCT00863005|Active Comparator|2.|
2513456|NCT02807545|Experimental|Physical Therapy Exercise Group|"Each patient assigned to the SSE group will attend at least 8 hours of supervised exercise training led by a Schroth-based certified physical therapist over the course of 6 months. Ideally, patients will be seen for 7 sessions.~Patients will perform a home exercise program for 15 minutes a day, 5 days a week, when they can independently execute their prescribed exercises. An exercise log initialed by the guardian will help families keep track of their exercise adherence and serve as a way to monitor exercise adherence for patients who may not have a smartphone, tablet, or computer.~Patients will also be able to meet with the therapists at their return-to-clinic visits and every 2-3 months thereafter until their 1 year follow-up to assess performance quality, maintain motivation, and progress intensity. Patients will be withdrawn if they do not achieve 80% exercise adherence within 6 months."
2513457|NCT02807545|No Intervention|Control Group|Patients randomized to this group will continue receiving standard-of-care treatment from their orthopaedic physician which includes regularly scheduled clinic visits and observation. Observation consists of no treatment of the scoliosis, only routine clinical assessment by the orthopaedic surgeon to detect curve progression every 3 to 6 months.
2513485|NCT02807272|Experimental|Tipifarnib, Oral|Single arm
2513529|NCT02807025||Idiopathic Pulmonary Fibrosis(IPF)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2513530|NCT02807025||Sarcoidosis|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2513534|NCT02807025||Tuberculosis(TB)|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2513540|NCT02807025||Chronic Obstructive Pulmonary Disease|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2513542|NCT02807025||Asthma|Nasal, tracheal and bronchial sampling of MLF in patients with idiopathic pulmonary fibrosis(IPF), sarcoidosis, tuberculosis(TB), asthma and Chronic Obstructive Pulmonary Disease (COPD). Similar sampling from healthy controls for comparative data.
2513543|NCT02807025||Healthy|Nasal, tracheal and bronchial sampling of MLF in patients from healthy controls for comparative data.
2513587|NCT02806804|Experimental|one dose test vaccine|One dose of quadrivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
2513590|NCT02806804|Experimental|one dose commercially available trivalent influenza vaccine|One dose of trivalent influenza virus vaccine will be randomly given in aged 3-60 years old.
2513592|NCT02806804|Experimental|One dose quadrivalent influenza virus vaccine|One dose of quadrivalent influenza virus vaccine (trivalent influenza virus vaccine added to a new influenza B component) will be randomly given in aged 3-60 years old.
2513660|NCT02806453|Active Comparator|Group A|Group A: Mg alginate/thickened formula
2513666|NCT02806453|Active Comparator|Group B|Group B: thickened formula/Mg alginate
2513712|NCT02805881|Experimental|Neurolief System treatment|Treatment with the Neurolief system will be applied by the subject at his home and/or surrounding daily during a period of six weeks
3175170|NCT00630903|Active Comparator|B|IFN alone, 2 weeks, 8-MOP + UVA irradiation + IFN, 22 weeks
2513825|NCT02805140|Experimental|Virtual exercise and mobile apps|Participants randomized to the intervention arm will join a virtual group convenient for them. They will plan and participate in 8 weeks (every week day) of virtual exercise sessions. Sessions will all be under 30 minutes and include a brief check in amongst participants. The investigators will provide links to information on physical activity and links to online resources for being active.
2513829|NCT02805140|Active Comparator|Exercise resources and information|The investigators will provide links to information on physical activity and links to online resources for being active. Women will be invited to join the exercise groups at the end of the 8 weeks.
2513880|NCT02804607||skin lesion|severe skin traumatism occurring during childhood and which had required an initial graft.
2513917|NCT02804295|Other|Collaborative Care Intervention|All enrolled participants received the collaborative care intervention over 6 months.
2513990|NCT02803554|Experimental|Young donor plasma|An infusion of plasma derived from donors aged 25 years or younger
2514044|NCT02803372|Experimental|Intervention group|In addition to routine monitoring, invasive LiDCOrapid is used to monitor mean arterial pressure (MAP), stroke volume variation (SVV) and cardiac index (CI). Intraoperative goal-directed circulatory management is performed, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery.
2514046|NCT02803372|Active Comparator|Control group|Routine monitoring is performed, which includes invasive blood pressure and urine output. Intraoperative routine circulatory management is performed, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h.
2514103|NCT02802904|Experimental|Palm olein IV 64|Palm olein IV 64, n= 15, 4 weeks intervention
2514106|NCT02802904|Experimental|Cocoa butter|Cocoa butter, n= 15, 4 weeks intervention
2514108|NCT02802904|Experimental|Virgin olive oil|Virgin olive oil, n= 15, 4 weeks intervention
2514152|NCT02802423|Experimental|BLEX 404 Oral Liquid|During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Docetaxel monotherapy among 6 patients in the Phase I study.
2514220|NCT02802137|Active Comparator|Tafluprost drops|Treatment with preservative-free talfuprost drops administered once in the evening. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
2514221|NCT02802137|Active Comparator|Tafluprost and dorzolamide/timolol drops|Concomitant therapy with preservative-free talfuprost drops administered once in the evening and dorzolamide/timolol fixed combination drops given twice daily. Evaluation of 24-hour efficacy and ocular surface health after 3 months of therapy.
2515548|NCT02793349|Experimental|Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
3175171|NCT00630929|Active Comparator|A|
2513501|NCT02807324||Late PE without IUGR|Cases consist of women (18 years or older) with preeclampsia (PE) and/or HELLP syndrome in the current pregnancy (PE is defined as hypertension (systolic blood pressure ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg) developed after 20 weeks of pregnancy with de novo proteinuria (≥ 300 mg/ 24 hours)) Cases will be subdivides in early and late PE, with or without IUGR (Early PE is defined as the occurence of PE < 34 weeks of gestation, whereas late PE is defined as the occurence of PE ≥ 34 weeks of gestation. IUGR is defined as birthweight below the 10th percentile).
2513504|NCT02807324||HELLP syndrome|Cases consist of women (18 years or older) with HELLP syndrome in the current pregnancy (defined as (1) the presence of microangiopathic hemolytic anemia with abnormal blood smear, low serum haptoglobin and elevated lactate dehydrogenase (LDH) levels, (2) aspartate transaminase (ASAT) above 70 IU/L and lactate dehydrogenase (LD) above 600 IU/L or bilirubin more than 1.2 mg/dL, (3) platelet count below 100 x 10^9 L-1 )
2513672|NCT02806518||Women scheduled for DIEP|Women scheduled for DIEP breast reconstruction after mastectomy due to breast cancer are examined with DIRT, hand-held Doppler and CTA
2513737|NCT02805855|Experimental|S50|Subjects in the S50 cohort will receive one injection of 50 million AMSCs.
2513745|NCT02805855|Experimental|S100|Subjects in the S100 cohort will receive one injection of 100 million AMSCs.
2513751|NCT02805855|Experimental|M50|Subjects in the M50 cohort will receive three injections of 50 million AMSCs at one-month intervals.
2513752|NCT02805855|Experimental|M100|Subjects in the M100 cohort will receive three injections of 100 million AMSCs at one-month intervals.
2513814|NCT02805244|Experimental|JTZ-951, 14C-JTZ-951|Single oral administration on Day 1; 10 mg JTZ-951, 100 μCi of 14C-JTZ-951
2513862|NCT02804828|Active Comparator|Arm 1|
2513864|NCT02804828|Sham Comparator|Arm 2|
2513902|NCT02804425|Experimental|"actor-spectator group"|actor at least once during the immersive simulation session
2513904|NCT02804425|No Intervention|"spectator-only group"|observer during the whole one-day session but participation in the debriefing part of the four scenarios
2513938|NCT02804113|Experimental|Supera Peripheral Stent System|
2513980|NCT02803762|Experimental|Investigational: [14C] Pacritinib|All enrolled subjects are checked in the day before drug administration. Following at least a 10-hour fast (not including water), each subject will receive an oral dose of 400 mg [14C]pacritinib (containing 100 μCi radioactivity).
2514035|NCT02803476||Cases|Polycystic ovary syndrome (PCOS) female patients. 20-35 years of age.
2514037|NCT02803476||Controls|Non-PCOs female subjects. 20-35 years of age.
2514082|NCT02803021|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514093|NCT02802631|Experimental|Minocin for Injection (minocycline)|Minocin (minocycline for injection) for will be supplied as a sterile lyophilized powder in single-use 10-mL glass vials. Each vial contains 108 mg of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort receives one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg. Within each cohort, subjects will receive a single dose on Day 1, followed by 7 days of multiple-doses (Days 4-10, given every 12 hours), followed by a single dose on Day 11.
2514097|NCT02802631|Placebo Comparator|0.9% Sodium Chloride Injection USP|Placebo is in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection USP). Dosing is to the same schedule as subjects randomized to Minocin (minocycline) for Injection.
2514151|NCT02802462|Experimental|High intensity-interval (HIT)|
2514158|NCT02802462|Experimental|moderate intensity-continuous (MCT)|
2514165|NCT02802462|No Intervention|control (CTL)|
3164244|NCT00495274|Experimental|Healthy male subjects|In Part A each subject will participate in six sessions and will be administered, in randomized order, single doses of five new formulations (formulation B, C, D, E and F) of SB-649868 30 milligrams (mg), in fasted state and a single dose of the original formulation (formulation A), after a standard Food and Drug Administration (FDA) High-Fat breakfast. All dosing sessions will be separated by a washout session of at least 5 ± 2 days after each dose. In Part B a single dose of the selected SB-649868 30 mg formulation will be administered after a standard FDA High-Fat breakfast.
3164245|NCT00495287|Active Comparator|A|"Remission induction arm A is with conventional chemotherapy cycle (ICE: idarubicin, standard-dose cytarabine, etoposide)"
2514433|NCT02801175||RF|Patients with paroxysmal atrial fibrillation slated for radiofrequency pulmonary vein isolation
2514436|NCT02801175||Cryoballoon|Patients with paroxysmal atrial fibrillation slated for cryoballoon pulmonary vein isolation
2514454|NCT02800525|Experimental|Picosecond laser|"The pigmented lesions on this half-side of the face would be treated with picosecond laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
2514456|NCT02800525|Active Comparator|Q-switched Nd:YAG laser|"The pigmented lesions on this half-side of the face would be treated with q-switched Nd:YAG laser.~For epidermal lesions, 1 laser treatment would be performed. For dermal lesions, 5 laser treatments would be performed every 3 month-interval.~The wavelength of 532 or 1064 nm would be chosen for appropriate lesions"
2514636|NCT02799277|Experimental|Testosterone|14mg testosterone will be administered intranasally in a 1milliliter aqueous solution
2514641|NCT02799277|Placebo Comparator|Placebo|1ml blank (containing no drug) aqueous solution will be administered intranasally
2514691|NCT02798783||Diagnosed with EVA|Self-reported Enlarged Vestibular Aqueduct (EVA), or, when available, radiological diagnosis of EVA will be used to define the cohort.
2514941|NCT02797002||Chronic non specific neck pain|Experiencing neck pain for at least 3 months in the last year
3164246|NCT00495287|Experimental|B|Remission induction therapy with high-dose cytarabine sequential regimen (HD-Ara-C, idarubicin)
3164248|NCT00495313|Active Comparator|Cohort 1: doxycycline|Vibramycin plus metronidazole
3164249|NCT00495313|Active Comparator|Cohort 2|Oracea® delayed release plus metronidazole
3164250|NCT00495326|Experimental|1|Nevirapine-based ART
3164251|NCT00495326|Active Comparator|2|Efavirenz-based ART
2513525|NCT02807077|Experimental|Subjects with mild renal impairment|Group 1, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
2513528|NCT02807077|Experimental|Subjects with moderate renal impairment|Group 2, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
2513532|NCT02807077|Experimental|Subjects with severe renal impairment|Group 3, will consist of patients each with mild, moderate, or severe renal disease, respectively, based on their estimated glomerular filtration rate (eGFR, calculated by the Modification of Diet in Renal Disease [MDRD] study equation). Each of these patients will receive a single 400 mg dose of pacritinib.
2513536|NCT02807077|Experimental|Subjects with ESRD|Group 4, will consist of patients with ESRD requiring hemodialysis who have been on a stable dialysis regimen for at least 6 months. In this cohort only, patients will participate in 2 treatment periods, Dialysis and Inter-Dialysis, separated by a 14-day period between pacritinib administration. In the Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered 4 hours prior to each patient's normally scheduled hemodialysis. In the Inter-Dialysis Treatment Period, a single 400 mg dose of pacritinib will be administered immediately after the end of the patient's normally scheduled hemodialysis session.
2513538|NCT02807077|Experimental|Healthy subjects|Group 5, will consist of 8 healthy subjects enrolled to match the sex-, age-, and weight of the patients with mild, moderate, and severe renal impairment and patients with ESRD enrolled in the study. Healthy subjects will be administered a single 400 mg dose of pacritinib.
2513604|NCT02806752|Experimental|Ranibizumab + Triamcinolone Acetonide|intravitreal injection: Ranibizumab 0.5mg + Triamcinolone Acetonide 2mg
2513606|NCT02806752|Active Comparator|Ranibizumab|intravitreal injection: Ranibizumab 0.5mg
2513632|NCT02806245|Experimental|Biventricular pacing|Patients will be randomized pre-operatively to either the pacing group or to the control group. Patients randomized to receive pacing will 1st undergo an acute pacing phase where the order of the pacing mode will be randomized and then will continue to an extended pacing phase of biventricular pacing.
2513634|NCT02806245|No Intervention|Control|Controls will receive standard of care treatment consisting of placement of 2 pacing leads (right atrial and right ventricular), monitoring of the study outcomes, monitoring of oxygen consumption and echocardiography, but no pacing.
2513677|NCT02806115|Experimental|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
2513708|NCT02805686|Experimental|"En face OCT (C-scan)"|
2513765|NCT02805491||with hypospadias|parent-child triads as cases (male newborns with hypospadias)
2513766|NCT02805491||without hypospadias|parent-child triads as controls (male newborns without hypospadias)
2513824|NCT02805075|Experimental|Supportive care (Fructooligosaccharide)|Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
2513876|NCT02804646|Experimental|endostar and chemotherapy group|recombinant human endostatin(endostar) injection was continuous intravenous transfusion for 7 days,with the dose of 15mg/m2 per one day,every 21 days of a cycle,combined with pemetrexed plus cisplatin or carboplatin.
2513877|NCT02804646|Active Comparator|chemotherapy group|pemetrexed injection was intravenous with the dose of 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin,without recombinant human endostatin.
3164252|NCT00495339|Experimental|1|Levofloxacin
2513974|NCT02803905|Active Comparator|standard procedure: intrahepatic|Liver infusion: the islet mixture is delivered slowly via injection through a syringe attached to the catheter in the portal vein or portal vein tributary. Access to the portal vein is achieved by percutaneous transhepatic access under fluoroscopic, ultrasonographic, or real-time CT guidance. Alternatively access to a mesenteric or omental venous tributary of the portal vein can be obtained by mini-laparotomy under general anesthesia (transplant site preference or in the extremely rare circumstance that percutaneous access cannot be achieved). At a minimum, portal pressure will be monitored before and after infusion of the islet product. Portal pressure measurements will be documented in the medical record. Gel foam plugs and/or collagen/thrombin paste will be used to embolize the entire peripheral catheter tract immediately before the catheter is withdrawn, to reduce the chances of bleeding.
2513978|NCT02803905|Experimental|experimental procedure: omentum|Omentum infusion: briefly, islets are spread in the surface of the omentum, in a single omental pouch site. Transplanting in a single site will reduce risks. A single dose of at least 5000 IEQ/KG will be transplanted. The investigators should be able to achieve a meaningful metabolic improvement and prevention of severe hypoglycemia, as previously seen in experience with intraportal islet transplants. Recombinant human thrombin is added to the islets placed on the omentum to promote formation of a gel clot and facilitate adherence to the surface of the omentum. A pouch is then created by folding the omentum. The pouch is secured inn place with stitches.
2514003|NCT02803567|Experimental|Intervention|Those in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education on substance use. Content in the intervention will focus on health promotion and will deliver positive messages about health.
2514004|NCT02803567|No Intervention|Control|Those in the control arm will receive treatment as usual.
2514041|NCT02803294|Experimental|Aortic Stenosis/regurgitation|Transcatheter aortic valve replacement
2514076|NCT02802943|Experimental|Peptide Vaccine MRD +|MRD-positive (MRD+) patients (flow cytometry based, CLL cells in peripheral blood or bone marrow ≥ 10-4 6-10 weeks after the end of first line treatment)
2514077|NCT02802943|Experimental|Peptide Vaccine MRD-|MRD-negative (MRD-) patients (flow cytometry based, CLL cells in peripheral blood and bone marrow <10-4 6-10 weeks after the end of first line treatment)
2514111|NCT02802618|Experimental|Interactive 3D visualization technique|"The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with 3D technique.~Patients randomized into education by 3D technique."
2514187|NCT02802384||Controls|Age and sex matched people without history of Paget's Disease of Bone
2515592|NCT02792842|Experimental|ART-123 (3-day ART)|
2513535|NCT02807103|Placebo Comparator|Conventional therapy with FFS=0|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS=0 will receive placebo-rituximab at day 1 and day 15."
2513539|NCT02807103|Experimental|Rituximab with FFS≥1|"All patients in the rituximab group will receive corticosteroids with a predefined tapering schedule similar to the conventional therapy group.~Patients with FFS≥1 will receive a total of 9 pulses :~1 gram of rituximab at day 1 and day 15 as induction treatment~placebo-cyclophosphamide at days 1, 15, 29, 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
2513541|NCT02807103|Active Comparator|Conventional therapy with FFS≥1|"All patients will receive corticosteroids with a predefined tapering schedule similar to the experimental group.~Patients with FFS≥1 will receive intravenous pulses of cyclophosphamide for a total of 9 pulses: 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.~Maintenance therapy by azathioprine will be started at day 180 according to the standard of care of these patients, as recommended by the French Vasculitis Study Group."
2513593|NCT02806700|No Intervention|Twitter Diabetes Control|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys
2513594|NCT02806700|Experimental|Twitter Diabetes Intervention|This group will be identified as having diabetes from Twitter. This group will be contacted and asked to complete brief surveys. This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
2513626|NCT02806466|Active Comparator|Asthmatic children|
2513627|NCT02806466|Sham Comparator|Non-asthmatic children|
2513657|NCT02806206|Experimental|Drug: Prucalopride|A single 2 mg dose of prucalopride before ingesting the capsule endoscopy pill.
2513664|NCT02806206|Placebo Comparator|Drug: Placebo|A placebo pill just before ingesting the capsule endoscopy pill.
2513762|NCT02805543||diabetes group|34 T2DM patients without vascular complications as diabetes group
2513763|NCT02805543||control group|32 healthy people were recruited as control group
3197654|NCT00863018||Control|Eyes with glaucoma and on anti-glaucoma medication but without glaucoma surgery
3197655|NCT00863018||Implant surgery|Eyes underwent Ahmed glaucoma valve implantation
3197656|NCT00863018||Trabeculectomy|Eyes underwent conventional trabeculectomy with mitomycin-C
2513964|NCT02803983||Pediatric hip plate|The children were treated with pediatric hip plate.
2513965|NCT02803983||Cannulated screw|The children were treated with cannulated screw.
2514024|NCT02803645|Experimental|healthy|blood sample
2514055|NCT02803151|Experimental|Stereotactic ablative radiotherapy|Image-guided stereotactic ablative radiotherapy
2514122|NCT02802826|Experimental|Tailored Exercise Prescription|"Participants will have a discussion on the 'My Exercise Prescription' booklet on the benefits of increasing levels of physical activity. They will be encouraged to read this in more detail and guided through its completion. The participant will receive an exercise prescription using the Pre-Intervention Assessment Tool (PIAT) and following discussion with the participant on a realistic and achievable starting point.~The booklets provided will guide participants through the exercise programme which is a graduated walking-based activity intervention. Both booklets provide participants with a suggested starting point for walking distance per week based on their PIAT score as well as motivational and behaviour change strategies to encourage participation."
2514126|NCT02802826|No Intervention|Standard Care|No sham or placebo conditions will be used in the study. At visit 1 standard care participants will be given the Standard Care Information Sheet and asked to simply continue with standard care.
3197657|NCT00863031|Experimental|problem-solving therapy|Three sessions of brief problem-solving counselling at week 1, 3 and 5 by a family doctor.
3197658|NCT00863031|Placebo Comparator|viewing video|Three sessions of health education viewing video in groups of 3 to 5 people
3197659|NCT00863044|Active Comparator|High frequency ventilation|high frequency ventilation
3197660|NCT00863044|Placebo Comparator|Apnea|lung ventilation will be stopped during distal anastomosis as is commonly done
2514426|NCT02800889|Experimental|Treatment: Pixantrone|Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment. At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts. The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity. During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced. Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
2514484|NCT02800590|Experimental|ABP-700 30 μg/kg/min|Starting intravenous (IV) infusion rate of 50 micrograms per kilogram per minute (μg/kg/min) for 5 minutes, followed by 30 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
2514494|NCT02800590|Experimental|ABP-700 40 μg/kg/min|Starting IV infusion rate of 70 μg/kg/min for 3 minutes, followed by 40 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
2514498|NCT02800590|Experimental|ABP-700 45 μg/kg/min|Starting IV infusion rate of 80 μg/kg/min for 3 minutes, followed by 45 μg/kg/min until the procedure is complete. Up to 2 supplemental bolus injections of 50 μg/kg ABP-700 separated by a minimum of 5 minutes may be administered in order to achieve and/or maintain adequate procedure conditions.
3197661|NCT00863070||Bladder Exstrophy Patients|Patients who receive follow-up care at Connecticut CMC urology clinic for bladder exstrophy.
2514942|NCT02796989|Active Comparator|Healthy - Wheat Bran|Wheat bran 20 g each day
3197662|NCT00863083|Active Comparator|1|Multifamily group weight management intervention plus rewards for program attendance
3197663|NCT00863083|Active Comparator|2|Multifamily group weight management intervention plus rewards for attendance and goal attainment
3197664|NCT00863096||Gardasil|
3197665|NCT00863135|Experimental|Continuous Positive Airway Pressure|nocturnal continuous positive airways pressure
3197666|NCT00863135|Other|Control|Waiting list,3 months without any change in their treatment, come into the CPAP procedure after that time
2513619|NCT02806479||Case: Hypertrophic cardiomyopathy|HCM patients at high risk for ventricular arrhythmia
2513620|NCT02806479||Control I: Healthy|Healthy Controls
2513621|NCT02806479||Control II: Post-MI with arrhythmogenic substrate|Ischemic cardiomyopathy patients with documented history of ventricular tachyarrhythmia and left ventricular hypertrophy
2513623|NCT02806479||Control III: VT/VF-free ischemic cardiomyopathy|Ischemic cardiomyopathy patients without ventricular arrhythmia, as proven by non-inducibility and history of freedom from ventricular tachyarrhythmia during at least one ICD generator life
3197667|NCT00863161|Experimental|1|AZD3355 65 + 65 mg capsule
3197668|NCT00863174|Experimental|1|SPARC147709
3197669|NCT00863174|Active Comparator|2|Reference147709
3197670|NCT00863187|Experimental|rituximab|b cell depletion drug
3197671|NCT00863200||Telephone Intervention Group|
3197672|NCT00863200||Standard Care Group|
3197673|NCT00863213|Experimental|Atrial Fibrillation Ablation|
3197674|NCT00863213|Active Comparator|Drug therapy|
3197675|NCT00863239|Experimental|1|Locteron™ (controlled-release interferon alpha 2b) 320 µg as biweekly subcutaneous injection
2513754|NCT02805569|Active Comparator|Group A|articulating stylet
2513756|NCT02805569|Active Comparator|group C|conventional stylet
2513799|NCT02805218|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
2513822|NCT02804945|Experimental|Mesenchymal Stem Cells|"Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS).~Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1."
2514030|NCT02803593|No Intervention|Control|165 Asian American breast cancer survivors (55 per sub-ethnic group) who do not use the TICAA, but use the information on breast cancer by the American Cancer Society (ACS). Participants are asked to use the online ACS resources for 3 months.
2514034|NCT02803593|Experimental|Intervention (TICAA)|165 Asian American breast cancer survivors (55 per sub-ethnic group) who use the intervention (TICAA) and the information by the ACS. The intervention is a technology-based information and coaching/support program to enhance survivorship experience of Asian American breast cancer survivors. Participants are asked to use the TICAA program for 3 months.
2514069|NCT02803008|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514133|NCT02802774|Active Comparator|Plaster Splint|
2514134|NCT02802774|Active Comparator|Velcro Brace|
2514136|NCT02802774|Active Comparator|Soft Dressing|
2514178|NCT02802215|Active Comparator|Metformin group|40 women will receive metformin in dose of 1500 mg per day orally (500 mg every 8 hrs in the middle of meal) starting from 12th week of gestation till delivery.
2514185|NCT02802215|Placebo Comparator|control group|40 women will receive placebo which will be folic acid 500 micro gram which looks like metformin tablet.
3197676|NCT00863239|Experimental|2|Locteron™ (controlled-release interferon alpha 2b) 480 µg as biweekly subcutaneous injection
3197677|NCT00863239|Experimental|3|Locteron™ (controlled-release interferon alpha 2b) 640 µg as biweekly subcutaneous injection
3197678|NCT00863239|Active Comparator|4|PEG-Intron™ (12 kDalton pegylated interferon alpha 2b) 1.5 µg/kg body weight weekly subcutaneous injection
3197679|NCT00863252|Experimental|1|MMF
2514319|NCT02801318|Other|Polysomnography|
2514403|NCT02801188|Placebo Comparator|Bupivacaine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
2514412|NCT02801188|Active Comparator|Mixture of bupivacaine and dexmedetomidine group|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye and 1 ug/kg of dexmedetomidine
2514482|NCT02800629|Active Comparator|Intervention|Patients will be given Modified Citrus Pectin twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
2514492|NCT02800629|Placebo Comparator|Control|Patients will be given placebo twice daily for 12 weeks, and have their change in knee pain as measured by survey instruments assessed
2514943|NCT02797002||Without neck pain (asymptomatic)|No history of neck pain
3197680|NCT00863252|Active Comparator|2|Control
3197681|NCT00863278|Active Comparator|Arm A|"All patients will be treated by stabilized Kligman's trio with daily application during 4 months.~After one month, the left side of the face will be treated with pulsed dye laser at the rate of 3 sessions (one every weeks).~Applications of cream will be stopped on both side of the face for the 3 days following each laser session. Final visit will be scheduled 1 month after the end of applications of stabilized Kligman's trio.~All the patients will used a sunscreen indication 50 + for the duration of the entire study.~The patient is her own witness. They compare the hemiface treated without laser and the hemiface treated with the laser."
3197682|NCT00863278|Active Comparator|Arm B|"All patients will be treated by stabilized Kligman's trio at the rate of application in the evening during 4 months.~After one month, the side of the right face will be treated by pulsed dye laser at the rase of 3 sessions spaced out by 3 weeks each.~Applications will be stopped in the 3 days which will follow every session by laser with blown colouring agent. The patients will be seen again 1 month after the stopping of applications of stabilized Kligman's trio~All patients will be used a sunscreen indication 50 + for the duration of study.~The patient is her own witness. They compare the cheek treated without laser and the cheek treated with the laser."
3197683|NCT00863291|Active Comparator|1|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
3197684|NCT00863291|Placebo Comparator|2|Placebo given in a manner similar to he active comparator
3197685|NCT00863369|Experimental|Treatment (bortezomib, gemcitabine hydrochloride, rituximab)|Patients receive bortezomib IV, gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
3197686|NCT00863382|Active Comparator|1|Standard Event Monitor
2513585|NCT02806817|Experimental|Bevacizumab + ME-344|"Bevacizumab single dose (15 mg/kg infused IV) on day 1. ME-344 will be administered at 10 mg/kg infused IV over 30 minutes on days 8, 15 and 22 (arm 1).~ME-344 will be suspended in 250 mL sterile saline."
2513589|NCT02806817|Placebo Comparator|Bevacizumab + normal saline|Bevacizumab single dose (15 mg/kg infused IV) on day 1. Placebo: will be administered normal saline 250 mL infused IV over 30 minutes on days 8, 15 and 22 (arm 2).
2513639|NCT02806388||tumor tissue for molecular profiling|
2513675|NCT02806128|Experimental|Treatment group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) three times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
2513676|NCT02806128|Experimental|Control group|"Injection of Human Urinary Kallidinogenase for Injection (KLK) Once times a day, 14 days .~Patients need to complete laboratory tests within a specified time."
2513725|NCT02805725|Experimental|Phase 1: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
2513742|NCT02805725|Experimental|Phase 2: Trabectedin + Cyclophosphamide|Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule. Trabectedin will be administered intravenously, 3-hour infusion weekly for three consecutive weeks (days 1, 8 and 15) every 4 weeks.
2513780|NCT02805257|Experimental|Mitomycin-C|0.1 ml of Mitomycin-C 0.4mg/ml injection intraoperatively and twice postoperatively.
2513782|NCT02805257|Placebo Comparator|Balanced Salt Solution (BSS)|0.1ml Balanced Salt Solution injection intraoperatively and twice postoperatively.
2513834|NCT02805010|Experimental|Subcutaneous(SC) Abatacept|
2513836|NCT02805010|Placebo Comparator|Placebo|
2513871|NCT02804568|Experimental|Group 1|Olanzapine/samidorphan 10 mg/10 mg
2513875|NCT02804568|Experimental|Group 2|Olanzapine/samidorphan 20 mg/10 mg
2513937|NCT02804282|Experimental|sc2Wear Furosemide Combination Product|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump) for subcutaneous administration of 80 mg dose delivered over 5 hours.
2513983|NCT02803853|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in Native American Communities. Intervention components will occur at the policy level; food retail outlet level; neighborhood level- schools and worksites, and household level.
2513985|NCT02803853|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
2514008|NCT02803424|Experimental|Volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
2514010|NCT02803424|Active Comparator|Autoflow-volume controlled ventilation|During the steep trendelenburg position and pneumoperitoneum, Autoflow-volume controlled ventilation will be applied with 8ml/kg (ideal body weight) and inspiration:expiration ratio (I:E) = 1:2.
3197687|NCT00863382|Active Comparator|2|Sleuth recorder
3197688|NCT00863395|Experimental|Skin Biopsy|
3197689|NCT00863460|Active Comparator|A|MTX-based chemotherapy followed by WBRT
3197690|NCT00863460|Experimental|B|MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue
3197691|NCT00863473|No Intervention|Conservative /Physiotherapy|Active training protocol with instructed physiotherapy and self excercises
3197692|NCT00863473|Active Comparator|Surgery with LCP T plate|Surgical treatment with interlocking plate
3197693|NCT00863499|Active Comparator|A|Short Acting methylphenidate
2514257|NCT02802098|Experimental|Bevacizumab + Durvalumab|Treatment with DURVALUMAB 10 mg/kg Q2W IV infusion plus Bevacizumab 10 mg/ Kg Q2W, IV infusion for a maximum duration of treatment of 12 months. Study treatment should be discontinued prior to 12 months if there is confirmed PD (unless the investigator considers the subject to continue to receive benefit from treatment), initiation of alternative cancer therapy, unacceptable toxicity, withdrawal of consent, or if other reasons to discontinue study treatment occur.
2514317|NCT02801409|Active Comparator|General anesthesia alone|General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
2514325|NCT02801409|Experimental|Combined epidural-general anesthesia|Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
2514428|NCT02801019|Experimental|E-XLPE|E-poly
2514430|NCT02801019|Active Comparator|C-XLPE|ArComXL
2514450|NCT02800512|Active Comparator|Sacrocolpopexy|Robotic sacrocolpopexy
2514451|NCT02800512|Active Comparator|HUSLS|Vaginal high uterosacral ligament suspension
2514511|NCT02800226|Experimental|10Hz|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4-6 weeks
2514512|NCT02800226|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4-6 weeks
2514541|NCT02799953|Experimental|Technology-based self-management model|Participants randomized to the intervention group will be given a tablet-based, interactive touch-screen self-monitoring system free of charge to perform disease self-monitoring in their homes.
2514545|NCT02799953|No Intervention|Conventional self-management|Participants randomized to the usual care group will not be provided access to tablet computers but a 2-in-1 blood pressure and blood glucose monitor and a paper-based log book to perform conventional self-monitoring.
2514569|NCT02799576|Experimental|Curved needle|This will utilize the curved block needle of performance of regional block
2514570|NCT02799576|No Intervention|Traditional needle|This will utilize the traditional block needle of performance of regional block
2514595|NCT02799407|No Intervention|Traditional Long Form Consent|Participants will receive the traditional long-form consent form.
2514603|NCT02799407|Experimental|ResearchKit Consent|Participants will receive the Apple ResearchKit consent form.
2515595|NCT02792842|Experimental|ART-123 (1-day ART)|
2513591|NCT02806635|Experimental|PREP Online|The PREP Online program is based on the in-person Prevention and Relationship Enhancement Program. The PREP Online program consists of seven sections of material. In each section, new information and skills are presented, videos demonstrate real couples practicing the skills, participants are encouraged to discuss the information in the context of their own relationship, and a multiple choice quiz reiterates and summarizes the section. In addition to the core educational materials, couples are asked to complete six additional online and offline homework assignments (one per week), each lasting approximately one hour.
2513638|NCT02806440|Active Comparator|Low dose naltrexone|Low dose naltrexone 4.5 mg/tablet, 1 tablet a day for 21 days
2513643|NCT02806440|Placebo Comparator|Placebo|"Placebo tablet~1 tablet a day for 21 days"
3197694|NCT00863499|Active Comparator|B|Long Acting Methylphenidate
3197695|NCT00863499|No Intervention|C|Healthy Controls
2513792|NCT02805530|Experimental|single arm|"Patients with synchronous metastases at Central Nervous System (CNS), evaluated in less than one week by the Multidisciplinary Committee at National Cancer Institute of Mexico to define the initial treatment. Patients with metastases at other sites than CNS will receive first line systemic treatment, in those EGFR-mutated with tyrosine kinase inhibitors (TKI) and in patients without a driver mutation with first line duplet of chemotherapy based on platin. The type of TKI or chemotherapy will be at discretion of the treating physician.~After 4 cycles of treatment, patients with stable disease or partial response will be evaluated by de Multidisciplinary Committee to establish the type of radical treatment to the primary and to the metastases, radiation therapy and chemoradiotherapy."
2513869|NCT02804893|Active Comparator|VATS GROUP|VATS lobectomy or segmentectomy
2513873|NCT02804893|Active Comparator|RATS GROUP|Robotic lobectomy or segmentectomy
2513931|NCT02804243|Active Comparator|nasal high flow therapy|In this group, patients have undergone rehabilitation under the nasal high flow therapy (FiO2 100%, oxygen flow from 30 to 60 L/min) during four weeks.
2513932|NCT02804243|No Intervention|oxygen therapy|In this group, patients have undergone rehabilitation under the oxygen therapy via a nasal canula (6 L/min) during four weeks.
2513955|NCT02803866||Parents of preterm newborns (25-32 weeks of gestation)|Parents (mother or mother+father) of preterm newborns admitted at the Gregorio Marañón Hospital from birth, recruited during the first 10 days of preterm newborn hospitalization and receiving the training program CAP-PREM
2514011|NCT02803671|Experimental|patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2514012|NCT02803671|Experimental|without patent ductus arteriosus|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2514014|NCT02803671|Experimental|patent ductus arteriosus + cardiac or respiratory therapy|ultrasounds Transfontanellaires near-infrared spectroscopy (TFU-NIRS) near-infrared spectroscopy (NIRS) electroencephalogram (EEG)
2514128|NCT02802605|Experimental|Bemiparin|Bemiparin 3.500 U, once a day during hospitalization
2514130|NCT02802605|No Intervention|No drug|Clinical practice as usual
2514161|NCT02802371|No Intervention|control group|Patients and caregivers randomized in the control group will receive the current management in geriatric or memory consultation without multidisciplinary psychosocial intervention and pharmaceutical collaborative care.There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, but the recommendations will not be transmitted to the referring physicians of patients and caregivers.
2514166|NCT02802371|Active Comparator|Psychosocial intervention|Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
2514170|NCT02802371|Experimental|Pharmaceutical care and psychosocial support|Pharmaceutical collaborative care integrated in a psychosocial program. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of caregivers; 2) collective session on medication management; and 3) optimization of drug prescribing. These collective and individual sessions of pharmaceutical care will allow an extended 18 month follow-up. Psychosocial intervention including collective sessions and individual interview in face-to-face and by phone. These sessions will allow an extended psychosocial follow-up over one year.
2514259|NCT02802059|Experimental|EcN-Suspension|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with EcN-Suspension
2514263|NCT02802059|Placebo Comparator|Placebo|279 healthy functionally mature newborn infants up to 35 weeks gestational age, treated with Placebo
2514327|NCT02801422||Cannabis Dependence|ages 18-40
2514332|NCT02801422||Healthy control subjects|socio-demographically matched
2514362|NCT02801084|Experimental|Float|One arm only: restricted environmental stimulation
2514389|NCT02800850|Experimental|Bright Light Group|Bright Light Exposure
2514394|NCT02800850|Placebo Comparator|Control Group|Placebo Light Exposure
2514519|NCT02800174|Experimental|Smart nitinol stent implantation group|The Smart nitinol stent system was used (import product registration number YZB/USA 0115-2008; Nitinol stent system, trade name SMART Control). The stent system comprises a self-expanding stent and a delivery system. The self-expanding stent is composed of a nickel titanium alloy and the ends of the stent are equipped with tantalum radiopaque markers. The Smart nitinol stent system is sterilized with ethylene oxide gas and is intended for single use only.
2514520|NCT02800174|Active Comparator|Antiplatelet drug group|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
2514945|NCT02796989|Placebo Comparator|Healthy - Placebo|Placebo 20 g each day
2514946|NCT02796989|Active Comparator|Obese - Wheat bran|Wheat bran 20 g each day
3197696|NCT00863525|Experimental|1|Odanacatib
3197697|NCT00863525|Placebo Comparator|2|Placebo
3197698|NCT00863538|Experimental|1|
3197699|NCT00863564|Active Comparator|Whey Isolate|
3197700|NCT00863564|Active Comparator|Caseine|
3197701|NCT00863564|Active Comparator|Cod|
3197702|NCT00863564|Active Comparator|Gluten|
3197703|NCT00863590|Experimental|A|Panel A
3197704|NCT00863590|Experimental|B|Panel B
3197705|NCT00863590|Experimental|C|Panel C
2513636|NCT02806284|Active Comparator|Neurotrauma|Patients with basilar skull fracture with or without known cerebrospinal fluid leakage were enrolled in the neurotrauma (NT) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from trauma.
2513640|NCT02806284|Active Comparator|Neurosurgery|Patients scheduled for elective, transsphenoidal pituitary gland surgery were assigned to the neurosurgery (NS) group. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b.The vaccines were administered by subcutaneous injections within 10 days from surgery.
2513646|NCT02806284|Active Comparator|Control|All control patients had undergone neurotrauma with or without basilar skull fracture, or had neurosurgery, at least three weeks earlier. All patients were vaccinated with two vaccines at the same time, 0,5 ml PPSV23 and 0,5 ml Act-HIB which is a conjugate vaccine against H. influenzae type b. They were vaccinated at least three weeks after trauma or surgery. The vaccines were administered by subcutaneous injections.
2513688|NCT02806076|Experimental|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
2513689|NCT02806076|Active Comparator|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
2513734|NCT02805634|Experimental|Multiple sclerosis|Patients with multiple sclerosis, followed by Dr Dachy within the CHU Brugmann Hospital.
2513746|NCT02805634|Other|Control group|Control group without neurological pathology
3197706|NCT00863590|Experimental|D|Panel D
3197707|NCT00863603|No Intervention|1|No exposure to supplemental oxygen
3197708|NCT00863603|Other|Oxygen, treatment, supplement|6 weeks of supplemental oxygen delivered by nasal cannula post hemodialysis graft placement
2513885|NCT02804620|Experimental|PLEASED|The PLEASED intervention arm will receive peer leader who is patients with diabetes that has been gone through our trainings. Also, they will receive three free health screenings (baseline, 3 months, 12 months) and monetary compensation for their time and effort.
2513889|NCT02804620|No Intervention|Wait List|The wait list will receive three free health screening (at baseline, 3months, 12 months) and monetary compensation for their time and effort.
3197709|NCT00863616|Experimental|HFCWO|HFCWO twice a day delivered by SmartVest device at 13Hz FOR 20min x2. Duration 4 weeks in each phase with a 2week washout.
2514017|NCT02803528|Experimental|Biodentine|The exposed area of the pulp is going to be covered with Biodentine.
2514018|NCT02803528|Active Comparator|MTA|The exposed area of the pulp is going to be covered with MTA
2514090|NCT02802787|Experimental|Camp Discovery|One week activity based camp
2514188|NCT02802527|Other|Bronchoscopy Guided|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
2514194|NCT02802527|Other|Direct Laryngoscopy|Performing percutaneous tracheostomy by placing the tube higher up, near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
2514375|NCT02801227|Experimental|Oxytocin|
2514376|NCT02801227|Experimental|Prostaglandin E2|
2514383|NCT02800824|Experimental|Budesonide rectal foam|
2514386|NCT02800824|Active Comparator|Uceris rectal foam|
2514455|NCT02800759|Active Comparator|100% of JOINTRUS®|After randomization, 100% dose of JOINTRUS® is taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2514458|NCT02800759|Active Comparator|80% of JOINTRUS®|After randomization, 80% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2514459|NCT02800759|Active Comparator|62.4% of JOINTRUS®|After randomization, 62.4% dose of JOINTRUS® was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
2514462|NCT02800759|Placebo Comparator|Starch 100%|After randomization, starch 100% was taken per day for 3 months in 7 sub-healthy persons >18 years of age and knee joint pain with a 0-10 numerical rating scale (NRS) pain score ≤ 4. This study included a 7-day baseline screening period (Visit 1) and was followed by randomization (Visit 2), a 12-week ingestion period with clinic visits at week 4 (Visit 3), 8 (Visit 4), and 12 (Visit 5) after starting ingestion, and a 4-week post-ingestion safety follow-up. The pain intensity, functional disability state and change in the general status were assessed for a 12-week ingestion period.
3197710|NCT00863616|No Intervention|Placebo/Control|Self-administered breathing exercises
3197711|NCT00863629|No Intervention|1|25 normoglycemic patients as control group
2513685|NCT02805985|Experimental|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
2513721|NCT02805699|Experimental|Baofeikang Granule|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,cough,give BaoFeikang Granules(by Beijing KangRentang Pharmaceutical Co., Ltd.), 1 bag, twice each day.
2513722|NCT02805699|Placebo Comparator|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant,coughand give Chinese medicine placebo (by Beijing Kang Rentang Pharmaceutical Co., Ltd., requirements and Chinese medicine BaoFeikang Granules in appearance and taste similar),1bag，twice each day.
2513872|NCT02804854|Experimental|Patients in ICU|Delivery of Neutrophil Activation Probe (NAP) (80mcgs) to ventilated patients up to three times.
2513920|NCT02804360|Experimental|therapy|Dexamethasone injection
2513949|NCT02803957|Experimental|Treatment Group|Subjects with degenerative mitral valve insufficiency treated with artificial chordae implanted using the NeoChord DS1000
2513952|NCT02803957|Active Comparator|Control Group|Subjects with degenerative mitral valve insufficiency treated with standard surgical mitral valve repair
2514013|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Needle|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via epidural needle followed by catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2514015|NCT02803450|Experimental|High Volume, Low Concentration via Epidural Catheter|"Epidural loading: Participants will receive 20ml of 0.0625% bupivacaine with fentanyl 1mcg/ml epidural loading dose in 10ml increments five minutes apart via the epidural catheter administration following catheter placement.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.03125% bupivacaine with 1mcg/ml fentanyl. The infusion rate will be set at 20ml/hr basal rate and 8ml every 15 minutes on demand with lockout of 52ml/hr.~For inadequate analgesia: One additional 10ml boluses of the experimental 0.0625% bupivacaine with 1mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2514016|NCT02803450|Active Comparator|Low Volume, High Concentration via Epidural Catheter|"Standard of Care Epidural Administration Epidural loading: Participants will receive 10ml of 0.125% bupivacaine with fentanyl 2mcg/ml in 5 ml increments 5 minutes apart via the epidural catheter following epidural catheter placement, per standard of care.~For continuous infusions: The continuous patient controlled epidural anesthesia (PCEA) pump will contain 0.0625% bupivacaine with 2mcg/ml fentanyl. The infusion rate will be set at 10ml/hr basal rate and 4ml every 15 minutes on demand with lockout of 26ml/hr.~For inadequate analgesia: One additional 5ml boluses of the standard 0.125% bupivacaine with 2mcg/ml will be provided spaced 5 minutes apart via the epidural catheter."
2514083|NCT02803190|Experimental|ICG- integrated care group|Integraded Care Group
2514084|NCT02803190|Experimental|MTG- muscle training group|Muscle Traing Group
2514179|NCT02802176|Experimental|Intra-vaginal culture - INVOcell device|3 day intra-vaginal incubation using the INVOcell device
2514184|NCT02802176|Active Comparator|Traditional IVF culture|3 day traditional IVF incubation
2514256|NCT02801955||tumor marker|serum CEA and CA 19-9 levels in patients with curative gastrectomy preoperatively and peritoneal CEA and CA 19-9 levels in patients taken at the beginning of curative gastrectomy via sampling of peritoneal washing aspirate
2514411|NCT02800915|Experimental|Intervention, telemedicine and interdisciplinary cooperation|The intervention group will be offered regular interdisciplinary outpatient follow-up via telemedicine.
2514420|NCT02800915|Active Comparator|Control, interdisciplinary guidance on request.|The control group will receive guidance based on existing routines, and based on initiative taken by the local healthcare service/ patient/ next of kin.
2514479|NCT02800551|Experimental|SBRT (Arm A)|"dose-intensified image-guided SBRT using simultaneous integrated boost:~in the case of no epidural involvement: 40 Gy and 20 Gy in 5 fractions to the high-dose and conventional-dose target volume, respectively.~In the case epidural involvement: 48.5 Gy and 30 Gy in 10 fractions to the high-dose and conventional-dose target volume, respectively."
2514490|NCT02800551|Active Comparator|Conventional Radiation Therapy (Arm B)|"External 3-dimensional conformal radiotherapy (3D-CRT):~Homogeneous irradiation of the affected vertebra delivering either~20 Gy in 5 fractions or~30 Gy in 10 fractions."
2514497|NCT02800551|Experimental|SBRT (prospective observational)|Patients eligible for the prospective observational arm will be treated according to the investigational arm (arm A) of the randomised arm of the trial.
3164253|NCT00495352|Active Comparator|High-dose NRT, Low-dose NRT, bupropion|
3164254|NCT00495404|Other|Arm 1|
2514860|NCT02797626|Other|Primary RPNLD|
3164255|NCT00495404|Other|Arm 2|
3164256|NCT00495417|Active Comparator|1|
3164257|NCT00495417|Active Comparator|2|
3164258|NCT00495482||1|Patients receiving palliative care due to incurable illness
3164259|NCT00495573||1|HSV-2 seropositive subjects who will receive a 5-day course of acyclovir for treatment of a genital herpes recurrence.
3164260|NCT00495573||2|HSV-2 seropositive subjects who will be observed during a genital herpes recurrence but not receive acyclovir.
3164261|NCT00495651|Active Comparator|I|Standard of care
3164262|NCT00495651|Experimental|II|Standard of care+Isoniazid Prophylaxis:
3164263|NCT00495651|Experimental|III|Early Antiretroviral therapy
3164264|NCT00495651|Experimental|IV|Early Antiretroviral therapy + Isoniazid prophylaxis
3164265|NCT00495664|Experimental|TITANOX|Titanium-nitride-oxide coated stent
3164266|NCT00495664|Active Comparator|PES|Paclitaxel-eluting stent
3164267|NCT00495703|Experimental|1|Exercise
3175172|NCT00630929|Placebo Comparator|C|
3197712|NCT00863629|Active Comparator|2|20 hyperglycemic patients (glucose >140 mg/dl) randomized to conventional glycemic control by insulin (CGC group; glucose goal 180-200 mg/dl)
3197713|NCT00863629|Experimental|3|20 hyperglycemic patients (glucose >140 mg/dl) were randomized to intensive glycemic control by insunin (IGC group; glucose goal 80-140 mg/dl)
2513789|NCT02805166|Experimental|PEG-rhG-CSF|patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy.
2513833|NCT02805023|Placebo Comparator|Placebo|Intramuscular injection of control medium only
2513835|NCT02805023|Experimental|BGC101|Intramuscular injection of BGC101 (autologous EnEPC preparation)
2513891|NCT02804542||Fascia Iliaca Block Cohort|Prospective patients receiving fascia iliaca blocks A prospective Observational study of Hip fracture patients that are offered fascia iliaca blocks as standard of care in the ED.
2513895|NCT02804542||Retrospective Control Cohort|No fascia iliaca block performed A retrospective review will be done of hip fracture patients that did not receive fascia iliaca blocks (before fascia iliaca blocks being offered in the ED as standard of care).
2513933|NCT02804191|Experimental|LO2A|Sodium Hyaluronate
2513934|NCT02804191|Placebo Comparator|Placebo-Controlled|Saline.
2513981|NCT02803827|Experimental|Rapid diagnostics and probiotic|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
2513982|NCT02803827|Other|Rapid diagnostics and placebo|Participants randomized to this arm will have rapid enteric diagnostics performed on the day of enrolment. Those found to have a treatable pathogen will be prescribed antimicrobials that day. Participants will also be given placebo x 60 days.
2513984|NCT02803827|Other|No rapid diagnostics and probiotic|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given Lactobacillus reuteri DSM 17938 5 x 10e8 cfu/mL x 60 days.
2513987|NCT02803827|Placebo Comparator|No rapid diagnostics and placebo|Participants randomized to this arm will have stool specimens processed after the conclusion of the study. Participants will also be given placebo x 60 days.
2514001|NCT02803385|Active Comparator|Continous Epidural Analgesia|Continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The Patient Controlled Analgesia pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes
2514002|NCT02803385|Active Comparator|Patient Controlled Epidural Analgesia|Patient controlled epidural analgesia in form of PCA pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .
2514042|NCT02803255|Experimental|Assist-As-Needed Control|"Subjects in this group will interact with a robotic exoskeleton, the MAHI Exo-II, programmed with an adaptive mode. In this mode, the robot will continuously assist motion along pre-defined trajectories, but will employ an assist-as-needed protocol.~Here, the amount of assistance provided by the robot will not be always the 100% of that required to complete the task (as in the position control mode), but only a fraction of it. The robot will continuously estimate the residual movement capabilities of the subject, depending on the specific joint addressed in the movement, and will estimate the remaining contribution needed to complete the movement following a predefined trajectory, thus avoiding to over-support motion."
2514045|NCT02803255|Active Comparator|Subject-Triggered Control|Subjects in group B will interact with a robotic exoskeleton, the MAHI Exo-II, controlled via the subject-triggered mode, as in a previous clinical trial with the MAHI Exo II robotic system. In the subject triggered mode, the MAHIExo II is commanded to regulate joints motion following a position-control control scheme, and using as desired trajectories standardized single-joints profiles that require motion of one of the axes of the exoskeleton (i.e. elbow flexion and extension, forearm pronation and supination, wrist radial and ulnar deviation, wrist flexion and extension). The switch to position control of the exoskeleton is triggered by the application of sufficient force by the subject, in a previous phase where the robot implements a virtual wall.
2514114|NCT02802917|Experimental|SPF 50 Y49 091|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2514119|NCT02802917|Experimental|SPF 50 X15 158|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2514125|NCT02802917|Experimental|SPF 50 X15 160|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
2514127|NCT02802917|Experimental|SPF 50 X57 162|Subjects were given the control article (standard shampoo mixture, X46 046) in one eye and one of the test articles in the other eye according to the randomization schedule.
3197714|NCT00863642|Experimental|Early|In patients who present with mild to moderate gallstone pancreatitis, those randomized to the early arm will undergo laparoscopic cholecystectomy within 48 hours of admission, regardless of laboratory values normalization and resolution of abdominal pain.
2514247|NCT02801773|Experimental|Treatment Gingivitis with Probiotic|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and adjunct probiotic one lozenge containig Lactobacillus reuteri per day during 3 month
2514252|NCT02801773|Placebo Comparator|Treatment Gingivitis conventional|Gingivitis group of patient treated with conventional therapy (scaling, coronary polish and oral higiene instruction) and one lozenge containig placebo (mint lozenge) per day during 3 month
2514314|NCT02801591||GH AQ|
2514379|NCT02801162|Active Comparator|Conventional ABG analyser|
2514381|NCT02801162|Experimental|Proxima 3® arterial blood gas|
2514475|NCT02800681||Asperger syndrome|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
2515600|NCT02792842|Placebo Comparator|Placebo|
3164268|NCT00495703|Active Comparator|2|Usual Care
2513817|NCT02805127||Patients with COPD and Asthma .|"Patients with COPD and Asthma. Continuous capnography and spirometry measurements of the subjects will be taken form the subjects with at least two minutes recording before the first spirometry assessment.~All clinical diagnoses and treatments will be performed according to the department's protocols.~This is an observational study with no interventions"
2513867|NCT02804776|Experimental|Gefitinib|Gefitinib 250mg oral daily will be given for 4 weeks prior to surgery
2513988|NCT02803710||Case group|patients with decreased susceptibility to carbapenems Enterobacteriaceae isolate
2513989|NCT02803710||Control-group|patients with Enterobacteriaceae isolate without decreased susceptibility to carbapenems
2514058|NCT02803398|Experimental|Patient at risk of venous thrombosis|
2514209|NCT02802163|Experimental|Combination Therapy|Combination Therapy: Panobinostat, Carfilzomib, Lenalidomide, Dexamethasone (Ca-R-Pa-Diem) . Participants will receive up to 8 cycles of the combination as induction after which will proceed with consolidation therapy with transplant as per institutional standards. After transplant, participants receive maintenance with panobinostat/lenalidomide. The maintenance dose and schedule of panobinostat will be same given during induction for 1 year. The maintenance dose of lenalidomide will be 10 mg given for 21 days of 28 days cycle until disease progression.
2514226|NCT02801799|Active Comparator|Infusion group 1|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 12 mL/h. This infusion rate is normal clinical practice when administering a perineural infusion of ropivacaine."
2514232|NCT02801799|Experimental|Infusion group 2|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 60 mL/h. This infusion rate is experimental."
2514233|NCT02801799|Experimental|Infusion group 3|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 300 mL/h. This infusion rate is experimental."
2514240|NCT02801799|Experimental|Infusion group 4|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 600 mL/h. This infusion rate is experimental."
2514248|NCT02801799|Active Comparator|Infusion group 5|"Intervention:~One peri-neural infusion of a fixed volume of ropivacaine 0.2%, administered via a perineurial nerve catheter.~Infusion rate will be 1800 mL/h. This infusion rate is normal clinical practice when administering a perineural bolus of ropivacaine."
2514291|NCT02801461|Experimental|Three-sessions of ESWT|ESWT was given once a week for 3 weeks.
2514292|NCT02801461|Active Comparator|One-session of ESWT|Single ESWT was given.
2514329|NCT02801305|Placebo Comparator|Vaseline|About 60 patients will be considered to be in control group receiving vaseline ointment as the placebo applying 2 times daily on their ulcers for 8 weeks.
2514334|NCT02801305|Experimental|Diltiazem Gel 2%|About 30 patients will receive Diltiazem Gel 2% applying 2 times daily for 8 weeks on their digital ulcers.
2514337|NCT02801305|Experimental|Nitroglycerin Ointment 2%|About 30 patients will receive nitroglycerin 2% applying 2 times daily for 8 weeks on their digital ulcers.
2514432|NCT02800967|Active Comparator|Pure Aronia juice|Participants will consume 100 ml of pure Aronia juice per day for 28 days
2514435|NCT02800967|Active Comparator|Aronia juice-based beverage|Participants will consume 100 ml of Aronia juice-based beverage per day for 28 days.
2514437|NCT02800967|Placebo Comparator|Placebo beverage|Participants will consume 100 ml of Placebo beverage per day for 28 days
2514486|NCT02800460|Other|Deep brain stimulation with fMRI-3T|Patients will have a 3T-fMRI before their usual MRI-1,5T
3164269|NCT00495729|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.
3164270|NCT00495729|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.
3164271|NCT00495729|Experimental|Cohort 3|Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.
2514539|NCT02799823|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
2514584|NCT02799589|Experimental|Remifentanil-dexmedetomidine and caudal|Anesthesia will be induced with inhaled sevoflurane which will be discontinued once IV access is obtained and the airway is secured with an endotracheal tube. Patients will receive remifentanil loading dose of 1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min) and dexmedetomidine load at 1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr) A caudal block with 0.2% ropivacaine will be performed in all patients for intraoperative and postoperative pain control.
2514646|NCT02799147|Experimental|280 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 140 mg/m2/day iv.
2514648|NCT02799147|Experimental|200 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3 and +4: Bendamustine 100 mg/m2/day iv
2514650|NCT02799147|Experimental|140 mg/m2 bendamustine|10 patients Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -3: Busulfan 1 mg/kg po qid №14 Day 0: Infusion of unmanipulated graft Day +3, +4: Bendamustine 70 mg/m2/day iv.
2514779|NCT02798042||Patient population|Patients undergoing bariatric surgery
3164272|NCT00495807|No Intervention|1|No Words was delivered during the PCA management
3164273|NCT00495807|Active Comparator|2|Positive words was delivered as a positive control group during the therapy of the pain with PCA
3175173|NCT00630929|Experimental|B|
3197715|NCT00863642|Other|Control|In patients in the control arm, laparoscopic cholecystectomy is delayed until laboratory values normalize and abdominal pain resolves.
2513912|NCT02804386|Experimental|treatment|Sofosbuvir, 400 mg OD for 6 months
2513929|NCT02804048|Experimental|Pelvic Floor Muscle Training|"superficial heat pelvic floor muscle intra vaginal manual therapy. PERFECT scale is applied in 5 sessions and based on the result of each assessment is performed the treatment plan with exercises of the pelvic floor muscles.~It is performed manual therapy in iliopsoas, diaphragm and piriformis. From the fourth session, initiate treatment with electromyographic biofeedback based on the result of PERFECT scale."
2513930|NCT02804048|Placebo Comparator|Low back|superficial heat low back Manual therapy in piriform, lumbar, iliopsoas and diaphragm.
2513969|NCT02803801|Experimental|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
2514079|NCT02803060|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514092|NCT02802709|Experimental|SB-061|SB-061
2514098|NCT02802709|Placebo Comparator|Placebo|Placebo
2514180|NCT02802475||acquired chronic, focal, epilepsy|patients ≥18 years of age, with acquired chronic epilepsy of unknown origin
2514191|NCT02802475||new onset epilepsy|patients ≥18 years of age, with new onset status epilepticus or new onset seizures with suspicion of limbic encephalitis
2514237|NCT02801838|Experimental|Ventilator settings, morphine titration|First, ventilator settings optimization and when the clinician judges necessary (remains discomfortable), opioid titration with a maximum of 10mg of morphine
2514313|NCT02801656|Experimental|Fecal Microbiota Transplantation|Oral, encapsulated fecal microbiota transplantation
2514322|NCT02801656|Active Comparator|Vancomycin|125 mg po qid x 10 days
2514399|NCT02800941||Oral anticoagulant treatment|Patients with pulmonary hypertension are treated with oral anticoagulants according to the usual practice. Patients have follow-up at 3, 6 and 12 months.
2514489|NCT02800499||KOCOSS|The KOrea COpd Subgroup Study team (KOCOSS) cohort is an ongoing, longitudinal, prospective, non-interventional observational study within the Korean COPD patients
3197716|NCT00863668|Active Comparator|Efavirenz|
3197717|NCT00863668|Experimental|Raltegravir|
3197718|NCT00863759|Active Comparator|1|Patients will receive an aspheric intraocular lenses (IOL) Akreos AO in the right eye and an spheric IOL Akreos Fit in the left eye, during cataract surgery.
3197719|NCT00863759|Active Comparator|2|Patients will receive an spheric intraocular lens (IOL) Akreos Fit in the right eye and an aspheric IOL Akreos AO in the left eye, during cataract surgery.
2514676|NCT02798822|Active Comparator|RME on upper first permanent molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 35 ± 6 days for Gr6, and the average treatment time was 12 ± 1.3 months.
2514677|NCT02798822|Active Comparator|RME on upper second deciduous molars|Intervention/Procedure: Rapid maxillary expansion. When RME was in situ, patients started the screw activation (Snap-lock expander screw, Forestadent, Pforzheim, Germany) of one-quarter turn a day (0.22 mm) until overcorrection was achieved (ie, the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp), and the RME remained in place for 10 months. The screw was turned for 41 ± 8 days, and the average treatment time was 12 ± 1.3 months.
3197720|NCT00863785|Experimental|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
3197721|NCT00863811||2|POAG patients with IOP under control by prostaglandins eye drops treatment and assuming two tablets per day of the food supplement KRONEK
2514791|NCT02797951|Experimental|Galcanezumab|Galcanezumab given subcutaneously (SQ) up to once a month.
2514865|NCT02797496|Experimental|Asymmetric Motor Strengthening|
2514866|NCT02797496|Active Comparator|Conventional Therapy|
2514947|NCT02796989|Placebo Comparator|Obese - Placebo|Placebo 20 g each day
2515016|NCT02796599|Experimental|CWLT with facial mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
3197722|NCT00863811||1|POAG patients compensated by the treatment of betablockers eye drops and taking two tablets per day of KRONEK
3197723|NCT00863837|Active Comparator|Arm A|add pantoloc to reduce ulcer bleeding after banding ligation
3197724|NCT00863837|Placebo Comparator|Arm B: ligation + terlipressin 1mg q6h|Arm B, intervention: ligation + terlipressin 1mg q6h
3197725|NCT00863850|Experimental|1|
3197726|NCT00863863|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
3197727|NCT00863863|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
3197728|NCT00863876||1|non-operated healthy eyes
3197729|NCT00863876||2|eyes 1 months following LASIK
3197730|NCT00863876||3|eyes 3-6 months following LASIK
3197731|NCT00863876||4|eyes with spherical monofocal IOLs more than 3 months postop
3197732|NCT00863876||5|eyes with aspherical monofocal IOLs more than 3 months postop
3197733|NCT00863876||6|eyes with toric monofocal IOLs more than 3 months postop
3197734|NCT00863876||7|eyes with diffractive multifocal IOLs more than 3 months postop
3197735|NCT00863876||8|eyes with phakic IOLs more than 3 months postop
3197736|NCT00863876||9|eyes with keratoconus
3197737|NCT00863889|Experimental|1|1cc Depomedrol, 4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
3197738|NCT00863889|Placebo Comparator|2|4 cc 1% Lidocaine, 4 cc 0.25% Marcaine
3197739|NCT00863902|Experimental|Cetirizine Hydrochloride|Cetirizine Hydrochloride 10 mg tablets, single dose
3197740|NCT00863902|Active Comparator|Zyrtec|Zyrtec® 10 mg tablets, single dose
3197741|NCT00863915|Experimental|A|Ramipril10 mg Capsules, single dose
2513783|NCT02805322|Active Comparator|Tympanic and/or Sublingual Temperature|"Tympanic and/or Sublingual Temperature Measurement using one or both of two widely used reference clinical thermometers in three different age groups with a specified percentage reporting as febrile.~Choice between Tympanic and/or Sublingual is determined based on standard of care in study site~Reference Thermometer 1 - Covidien Genius 2 Tympanic Thermometer~Reference Thermometer 2 - Welch Allen SureTemp Plus Sublingual Thermometer"
2513811|NCT02805049|Experimental|The study population|The study population consisted of patients admitted to the ICU for septic shock associated with secondary peritonitis and requiring antifungal therapy via echinocandins (micafungin or caspofungin).
2513887|NCT02804581|Experimental|Gum Arabic|Oral intake of 30 gram of Gum Arabic daily for 12 weeks
2513939|NCT02804165|Other|Target high-risk subjects or subpopulations for T1D|Confirmation of the role of enteroviral infection in T1D and characterization of gene-enterovirus interactions should open up new avenues for understanding the pathogenesis of T1D and give clues on possible new therapeutic perspectives. Clinical applications might be further developed in order to extend the lag period might between positive autoantibodies detection and T1D age at onset in genetically predisposed subjects. This innovative project opens the door of the development of preventive therapy for T1D, as enterovirus vaccination.
2513996|NCT02803788|Active Comparator|Group O|this group will receive inj. ondansetron 4mg iv stat and inj. dexamethasone 8mg iv stat just before extubation.
2513998|NCT02803788|Experimental|Group R|this group will receive inj. ramosetron 0.3mg iv stat just before extubation.
3164274|NCT00495807|Active Comparator|3|Partially negative words was delivered during the PCA pain management
2514051|NCT02803125|Active Comparator|Developed psychosocial intervention|The active intervention in this study that will be compared to support group control
2514053|NCT02803125|Placebo Comparator|Support group control|This is the comparison group
2514115|NCT02802839|Experimental|Sperimental|The patient will be shown the headset for VR and a selection of age appropriate virtual realities to immerge in by the nurse not performing the procedure. There will be two lists of VRs to choose from, one for age 6 to 12 and one for age 12 to 18 with the following themes: amusement rides /carousel, space rides, zoo, safari, dinosaurs, city touring, landscapes, caverns. Once the patient is ready to wear the headset the application will start and 120 seconds later the procedure will take place. The nurse performing venipuncture will be a different one than the one handling distraction. Once the procedure ends the video will last for one more minute or up to the child' s desire. Only the first venipuncture attempt will be observed.
2514120|NCT02802839|No Intervention|Observational|Control intervention When arriving to the CF centre for routine visit that implies also the taking of blood samples, after having obtained the informed consent, a trained nurse of the CF Centre, will apply to each child recruited -in the presence of the parent, who may hold the child- the anesthetic cream. Only the first venipuncture attempt will be observed.
2514149|NCT02802358||Hip fracture|Patients with a hip fracture due to an accidental fall
2514150|NCT02802358||Wrist fracture|Patients with a wrist fracture due to an accidental fall
2514206|NCT02802150|Active Comparator|Zanthoxylum schinifolium seed Oil|Zanthoxylum schinifolium seed Oil 100% (4g/day)
2514208|NCT02802150|Placebo Comparator|soy bean oil|soy bean oil 99.9%, edible dyes 0.01% (4g/day)
2514262|NCT02801851|Experimental|Intervention SCREEN-ED|This is the arm that will receive the SCREEN-ED. SCREEN-ED is an innovative, yet practical intervention that combines screening with informing clinicians of the results and provides a checklist for delirium management that is tailored to the time-limited ED setting.
2514297|NCT02801526|Experimental|Candesartan and Amlodipine|Candesartan 16mg and Amlodipine 5mg, PO, 1days or 22days
2514300|NCT02801526|Experimental|CKD-330|CKD-330 16/5mg - A, PO, 1days or 22days
2514378|NCT02801266|Experimental|Intervention|The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.
2514382|NCT02801266|No Intervention|No intervention|The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.
2514469|NCT02800772|Experimental|acetic acid|spray 50ml acetic acid to duodenal bulb
2514472|NCT02800772|Placebo Comparator|saline|spray 50ml saline to duodenal bulb
2514550|NCT02800200|Experimental|Platelet rich plasma|The ultrasoud-guided injection with Platelet rich plasma (3cc) was perfomed in both groups.
2514551|NCT02800200|Experimental|Active shock wave|One-session active shock wave 2 weeks later after PRP injection was performed in intervention group.
2514554|NCT02800200|Placebo Comparator|Sham shock wave|One-session sham shock wave 2 weeks later after PRP injection was performed in control group.
2514601|NCT02799498|Active Comparator|A-etanercept (ENBREL®) by auto-injector|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
2514608|NCT02799498|Other|B-etanercept (ENBREL®) by Manual injection|Single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
2514755|NCT02798302|Active Comparator|Non rebreather|
2514756|NCT02798302|Active Comparator|Bag valve mask without leak|
2514757|NCT02798302|Active Comparator|Bag valve mask with simulated mask leak|
2514975|NCT02796872|Experimental|B-GOS 3%|Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
2514978|NCT02796872|Experimental|B-GOS 2%|Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
2515147|NCT02795702|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
3164275|NCT00495807|Active Comparator|4|Totally negative words was delivered during the PCA pain management
3164276|NCT00495833|No Intervention|1|
3164277|NCT00495833|Experimental|2|photo and blood pressure personalization
3164278|NCT00495833|Experimental|3|photo personalization only
3164279|NCT00495833|Experimental|4|blood pressure personalization only
3164280|NCT00495833|Experimental|5|no personalization
3164281|NCT00495833|Experimental|A|receives gift card in blood pressure (BP) kit
3164282|NCT00495833|Experimental|B|does not receive gift card in BP kit
3175174|NCT00630942|Experimental|Single Arm, active treatment|
2513843|NCT02804841|Experimental|Intervention|Healthy, Community Dwelling; Aged 60-80 years; Cholecalciferol -Vitamin D3, 4000 international units (IU) on alternating days.
2513847|NCT02804841|Placebo Comparator|Placebo|Healthy, Community Dwelling; Aged 60-80 years; Placebo -gel capsule containing no vitamin D on alternating days.
2513888|NCT02804503|Experimental|Calorie Labels|A menu with rank ordered calorie labels and a statement on the energy needs per meal.
2513893|NCT02804503|Experimental|Exercise Labels|A menu with rank ordered exercise labels showing minutes of brisk walking necessary to burn the food calories.
2513896|NCT02804503|Active Comparator|No Labels|A menu with no labels
2513935|NCT02804139|Active Comparator|Standard care|Standard Care after C-section with no additional physical therapy.
2513936|NCT02804139|Experimental|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization
2513971|NCT02803814|Experimental|Superior mesenteric artery approach|Initial approach of the superior mesenteric artery to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
2513972|NCT02803814|Active Comparator|Classic approach|Classic approach to perform a pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area
3197742|NCT00863915|Active Comparator|B|Atlace® 10 mg capsules, single dose
3197743|NCT00863941|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
3197744|NCT00863941|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
3197745|NCT00863954|Active Comparator|Output A|
3197746|NCT00863954|Active Comparator|Output B|
3197747|NCT00863954|Active Comparator|Output C|
3197748|NCT00863954|Active Comparator|Output D|
3197749|NCT00863954|Active Comparator|Output E|
3197750|NCT00863954|Active Comparator|Output F|
3197751|NCT00863967||1|no cardiovascular events
2514385|NCT02800798||High risk for OSA|High risk OSA defines as Stop-bang score ≥ 3
2514391|NCT02800798||Low risk for OSA|Low risk OSA defines as Stop-bang score < 3
2514504|NCT02800707|Active Comparator|Sucralose|Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
2514505|NCT02800707|Active Comparator|Stevia|Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
2514552|NCT02799901|Experimental|Patient|patient with Advanced melanoma
2514609|NCT02799420|Experimental|pCLE group|The intervention group
2514611|NCT02799420|Active Comparator|WLE group|The control group
3197752|NCT00863967||2|proven cardiovascular events
3197753|NCT00863967||3|possible cardiovascular events
2514749|NCT02798458|Experimental|SmartPill Test|All subjects will be asked to complete a SmartPill test. The SmartPill capsule is pill-shaped and about an inch long and ½ inch wide, or about the size of a vitamin pill. The receiver unit is about the size of a paperback book. The receiver gets signals from the capsule and stores the signals on a computer chip. The capsule detects the level of acidity, temperature, and pressures in your stomach and intestines and sends the information by radio wave signals to the receiver.
3197754|NCT00863980|Experimental|Telmisartan|Treatment with Telmisartan
3197755|NCT00863980|Active Comparator|Candesartan|Treatment with Candesartan
3197756|NCT00864006|Experimental|1|Divalproex Sodium 125 MG Delayed Release Tablets Sandoz
3197757|NCT00864006|Active Comparator|2|Depakote 125 MG DR Tablets Abbott Laboratories USA
3197758|NCT00864019|Experimental|A|Sertraline HCl 100 mg tablets, single dose
3197759|NCT00864019|Active Comparator|B|Zoloft® 100 mg tablets, single dose
3197760|NCT00864045|Experimental|Sertindole|
3197761|NCT00864045|Active Comparator|Olanzapine|
3197762|NCT00864058|Experimental|A|Gabapentin 400 mg capsules
3197763|NCT00864058|Active Comparator|B|Neurontin 400 mg capsules
3197764|NCT00864071|Experimental|A|Griseofulvin 125 mg/5 mL Suspension, single dose
3197765|NCT00864071|Active Comparator|B|Grifulvin V® 125 mg/5 mL Suspension, single dose
3197766|NCT00864110|Experimental|99mTc EC-DG|99mTc-EC-DG with SPECT/CT imaging
3197767|NCT00864110|Active Comparator|18F FDG|18F FDG with PET/CT imaging
3197768|NCT00864136||Group 1|
3197769|NCT00864136||Group 2|
3197770|NCT00864136||Group 3|
3197771|NCT00864149|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
3197772|NCT00864149|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
3197773|NCT00864162|Experimental|A|Ramipril10 mg Capsules, single dose
3197774|NCT00864162|Active Comparator|B|Atlace® 10 mg capsules, single dose
3197775|NCT00864175|Experimental|Treatment A - INCB007839 and Trastuzumab|"INCB007839 100 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3197776|NCT00864175|Experimental|Treatment B - INCB007839 and Trastuzumab|"INCB007839 200 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3197777|NCT00864175|Experimental|Treatment C - INCB007839 and Trastuzumab|"INCB007839 300 mg BID and trastuzumab~In Cycle 1, trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1."
3197778|NCT00864175|Experimental|Treatment D - INCB007839 and Docetaxel|INCB007839 300mg BID with docetaxel
3197779|NCT00864188|Placebo Comparator|1|Glucono-Delta-Lactone acidified milk containing no bacterial strains
3197780|NCT00864188|Experimental|2|Glucono-Delta-Lactone acidified milk containing one probiotic strain called Lactobacillus paracasei NCC2461.
2513874|NCT02804633|Placebo Comparator|Placebo Group|In addition to PCA (morphine or hydromorphone) all patients received placebo (100 ml normal saline) given 30 minutes prior to operation and every 6 hours thereafter for up to 5 days post-operatively or discharge
2513961|NCT02804334||Healthy Volunteers|Participants with no current or lifetime psychiatric disorders
2513963|NCT02804334||Untreated Bipolar Disorder|Participants who meet criteria for current bipolar disorder but who are not currently taking any psychotropic medications
2514029|NCT02803606||hypothermia|Preterm neonates less than 32 weeks of gestational age admitted at birth to the Neonatal Medicine unit
2514074|NCT02803073|Experimental|Testosterone Replacement|The experimental group will receive 0.5 ml (100 mg) testosterone cypionate Intramuscular injections each week for 11 weeks.
2514075|NCT02803073|Placebo Comparator|Control|Patients in the control group will receive intramuscular normal saline injections.
2514112|NCT02802696|Experimental|Furosemide|Diuretic
2514123|NCT02802696|Placebo Comparator|Placebo|Normal saline
2514172|NCT02802280|Other|Cardiovascular risk in HCV patients|"Intervention:~The only intervention to be carried out along the study will consist of a complete evaluation of cardiovascular risk of HCV patients both at baseline (pre-treatment) and after HCV treatment, through performing different tests (see below)~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied at different times before and after the end of the treatment.~The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
2514227|NCT02802007|Experimental|Elipse Intragastric Balloon|Patients seeking weight loss received the Elipse Intragastric Balloon.
2514310|NCT02801721|Active Comparator|Stimulation|Stimulation group received psycho social stimulation. In the stimulation there were anemic and non anemic children. All anemic children received iron(syrup) supplementation.
2514321|NCT02801721|No Intervention|No stimulation|No stimulation group did not receive any stimulation. In the no stimulation group there were anemic and non anemic children. All anemic children received iron (syrup) supplementation
2514384|NCT02801136|Experimental|ReACT for PNES|ReACT consists of 8 weekly sessions of therapy focused on teaching adolescents to regain control of their body through managing thoughts and behaviors that reinforce the PNES and return to previous activities. It teaches parents how to respond to PNES in a manner that encourages the adolescents to regain control of their body. The PNES is explained as behaviors learned through classical and operant conditioning .
2514390|NCT02801136|Active Comparator|Supportive Therapy|The supportive therapy treatment consists of 8 weekly sessions of therapy focused on discussing daily difficulties and/or stressors they experience and identifying stress triggers for PNES. The PNES is explained as physical manifestations of psychological stress.
2514395|NCT02801136|No Intervention|Healthy Control|Healthy controls are matched to patients with PNES based on age (+ or - 1 year), gender, race and family income. They come to one laboratory visit to complete initial visit questionnaires and computer tasks.
3197781|NCT00864188|Placebo Comparator|3|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii subsp.bulgaricus.
2514620|NCT02799303|Experimental|Multi-parametric MRI|Patients from the general population without history of previous prostate biopsy will be allocated to receive mpMRI in order to evaluate for risk of prostate cancer.
2514621|NCT02799303|Active Comparator|PSA Only|"Patients from the general population without history of previous prostate biopsy will be allocated to receive serum PSA testing in order to evaluate for risk of prostate cancer.~Patients with a serum PSA level less than 4.0 ng/mL will be managed expectantly with results provided to their primary care physician."
2514667|NCT02798874|Experimental|Ticagrelor Group|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
2514671|NCT02798874|Active Comparator|Clopidogrel Group|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
2514715|NCT02798640|Active Comparator|Active|Subject wearing Celliant garment
2514716|NCT02798640|Placebo Comparator|Control|Subject wearing non-celliant control garment
2514792|NCT02797925||Tendinopathy|Long slow strength training for 3 months that are performed at home or gym. Participants receive initial guidance to the exercises from a physiotherapist assigned to Bispebjerg H.
2514794|NCT02797925||Healthy|No intervention. No training
2514820|NCT02797717|Other|"A-COPDAC-28"|"standard COPDAC-28 (chemotherapy cycle:Cyclophosphamide,Doxorubicin,Prednisone,Dacarbazine), chemotherapy and standard involved node radiotherapy.~drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15. Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3. Vincristine 15mg/m2 , I.V. , day1+day 8. Cyclophosphamide 500mg/m2,infusion,day 1+day 8."
2514824|NCT02797717|Experimental|"B- DECOPDAC-21"|"DECOPDAC-21(chemotherapy cycle:Dacarbazine,Etoposide,Doxorubicin,Cyclophosphamide,Prednisone,Vincristine) intensified chemotherapy and no RT or restricted fields of radiotherapy.~Drugs: Prednisone 40mg/m2/day,P.O,day 1-day 15:~Dacarbazine 250mg/m2, I.V. , infusion,day 1- day 3 Vincristine 15mg/m2 , I.V. , day1+day 8 Cyclophosphamide 625mg/m2,infusion,day1+day2 Etoposide 100mg/m2/day,infusion,day 1- day 3 Doxorubicin 25mg/m2, infusion, day 1"
2514924|NCT02797379|Other|Immediate start|This group receive the intervention (psychoeducation guide) immediately following baseline assessment and are assessed 4 and 8 weeks later.
2514930|NCT02797379|Other|Delayed start|This group do not receive the intervention for 4 weeks. They are assessed after the wait period (4 weeks) and again after 4 weeks of having the intervention (psychoeducation guide) at week 8.
2514960|NCT02796794|Active Comparator|Genistein|Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
2514961|NCT02796794|Other|control|Control group are the patients receiving enteral nutrition
2515003|NCT02796612|Active Comparator|No intervention|Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.
2515022|NCT02796599|Experimental|CWLT with nasal mask|This study has a cross-over design. Patients will achieve CWLT with non-invasive ventilation using facial or nasal mask in a randomised order.
2513976|NCT02803931|Experimental|Cardiogoniometry|Every patient in the study will have a cardiogoniometry recording performed by the Cardiologic Explorer whilst an inpatient on the ward. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI. The researcher interpreting the cardiogoniometry recording will be blind to the results of the ECG and the coronary angiography,
2513979|NCT02803931|Active Comparator|12-lead ECG|For every patient in the study, copies of their 12-lead ECGs performed during their admission will be taken for interpretation by an independent cardiologist. This will then be taken for interpretation to see if it indicates what vessel is the culprit causing their NSTEMI.The researcher interpreting the ECG recordings will be blind to the results of the cardiogoniometry and the coronary angiography,
2514000|NCT02803541|Experimental|12 day mainstream summer camp experience|The 12 day mainstream camp experience involves increased exercise from baseline at home. Can this exercise and peer contact improve physical endurance as measured by the 6 minute walk test and self concept as measured by a modified Harter scale
2514038|NCT02803320|Experimental|SPF 50 Y65 110|All subjects received baseline skin evaluation and 1 day of sun exposure.
2514129|NCT02802579|Active Comparator|A: standard protocol|Standard dual-source computed tomography coronary angiography protocol
2514131|NCT02802579|Experimental|B: enhanced protocol|enhanced dual-source computed tomography coronary angiography protocol
2514132|NCT02802579|Experimental|C: enhanced obesity protocol|enhanced obesity-mode dual-source computed tomography coronary angiography protocol
2514173|NCT02802228|Experimental|Ifetroban|90 day course of oral ifetroban following intravenous loading dose
2514181|NCT02802228|Placebo Comparator|Placebo|90 day course of placebo following intravenous dose of D5W
2514236|NCT02801864|Experimental|Combined real tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. The stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. For the experimental group, the stimulation will be ramped up for 45 seconds and stay there for 20 min. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
2514243|NCT02801864|Sham Comparator|Combined sham tDCS + IST|Participants will receive tDCS via a Starstim device at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. For the sham group, the stimulation will be ramped up for 45 seconds and ramped down for 15 seconds. The stimulation will be ramped up for 45 seconds and then ramp down after the initial 45 seconds. The participants will receive three weeks of tDCS and continue receiving only intensive speech therapy for five weeks for three hours a day.
2514326|NCT02801513|Experimental|Brief Mindfulness Training|The brief mindfulness training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to engage in formal meditation practice for about 25 minutes twice per day on six out of seven days of each week using recorded guided meditations. Practices were shorter in duration than the practices in Mindfulness-Based Cognitive Therapy (MBCT, Segal et al., 2002) in order to allow for more flexibility in scheduling the practices, but followed the standard sequence of mindfulness-based interventions.
2514333|NCT02801513|Active Comparator|Resting Control Training|The resting control training comprised of three 1.5-hour weekly individual sessions and included intensive daily home practice. Participants were asked to schedule regular rest periods as a means of deliberately retreating from the activities of the day. Length and frequency of the rest periods mirrored the time demands of the meditation training. Participants received a plausible rationale for the control training that linked acute depression to stress and suggested rest, relaxation, and disengagement from negative thinking as an initial and preliminary step towards recovery.
3197782|NCT00864188|Experimental|4|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii and one probiotic strain called Lactobacillus paracasei NCC2461.
3197783|NCT00864188|Experimental|5|Fermented milk containing two standard bacterial strains for acidification - Streptococcus thermophilus and Lactobacillus delbrueckii, one probiotic strain called Lactobacillus paracasei NCC2461 and Vitamin B2,B3, C and E, Beta Carotene and an Oil.
2514466|NCT02800408|Experimental|Whole grain high-BCX maize|Whole grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2514468|NCT02800408|Experimental|Refined grain high-BCX maize|Refined (degermed) grain, high-beta-cryptoxanthin (BCX; orange) maize will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2514470|NCT02800408|Placebo Comparator|Whole grain white maize|Whole grain, white maize (low in beta-cryptoxanthin) will be incorporated into two muffins to be fed daily for 12 days. Complementary diet will be low in carotenoids.
2514524|NCT02800044|Experimental|Wearing glucose sensor|The study team will measure glucose readings from the non-invasive sensor and from a glucometer at the following time points: fasting, 1.5 to 2 hours after a meal, and before and after 15-30 minutes of pedaling on a stationary bicycle at 80% maximum heart rate..
2514561|NCT02799849|Other|Narcoleptic patients|
2514562|NCT02799849|Other|hypersomnic patients|
3197784|NCT00864201|Experimental|bosentan|
3197785|NCT00864214|Experimental|1|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
2515071|NCT02796339|Active Comparator|Mastiha|This arm of patients will receive natural Mastiha supplements at the dosage of 2.8g daily. Patients with active disease will be administered with supplements for 3 months, whereas patients in remission will be administered with supplements for 6 months.
2515072|NCT02796339|Placebo Comparator|Placebo|This arm of patients will receive placebo . Patients with active disease will be administered with placebo for 3 months, whereas patients in remission will be administered with placebo for 6 months.
2515138|NCT02795910|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions
2515149|NCT02795728|Experimental|Experimental arm|Fuji type VII is a GIC based sealant with an additional property of high fluoride release
2514032|NCT02803723|Active Comparator|Sucrose alone|The sucrose administration is started 2 minutes before blood sampling.
2514095|NCT02803034|Experimental|BAY987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3197786|NCT00864214|Experimental|2|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
3197787|NCT00864214|Experimental|3|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
3197788|NCT00864214|Experimental|4|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
2514302|NCT02801357|Experimental|lofexidine with tapering buprenorphine|Enrolled subjects must be on a daily dose of between 8 - 24 mg of buprenorphine for at least 30 days. Once enrolled, subjects will receive lofexidine as follows: Days 1 through 3, 0.6 mg 4 times daily (QID; 2.4 mg daily); Days 4 through 6, 0.8 mg QID (3.2 mg daily), and Day 7 0.8 mg at 8 AM. Subjects will take their scheduled lofexidine doses at approximately 8 AM, 1 PM, 6 PM and 11 PM. Subjects will also reduce their current buprenorphine dose by at least 4 mg on Day 1.
2514368|NCT02801149|No Intervention|No further imaging|Patients randomised to this group will receive standard care, i.e. will not undergo additional imaging scans at A&E/Urgent Care Centre.
2514370|NCT02801149|Experimental|Wrist Magnetic Resonance Imaging (MRI)|Patients randomised to this group will undergo an additional 3-sequence wrist MRI during the initial A&E/Urgent Care Centre episode.
2514463|NCT02800655|Experimental|DHFS with IS-ARV|Digital Health Feedback System (DHFS) with either IS- Odefsey®, IS- Genvoya®, IS-Biktarvy®, IS- Tivicay® and Truvada® or IS- Tivicay® and Descovy ® (IS-co-encapsulated with ingestion sensor) -1 or 2 capsules daily (QD), depending on the treatment regimen, administered orally for 16 weeks.
2514507|NCT02800239|Experimental|Active, adolescent females|Subjects will receive different levels of amino acid intakes, varying from 0.2-2.67 g/kg/d
2514559|NCT02799966|Other|Early Treatment Group|Initiate treatment with MyndMove device on or after 10 days to 6 months (182 days) post spinal cord injury
2514560|NCT02799966|Other|Late Treatment Group|Initiate treatment with MyndMove device on or after 6 months plus one day (183 days+) post spinal cord injury
2514592|NCT02799485|Experimental|Treatment (recombinant EphB4-HSA fusion protein)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1 and 15. Patients with disease progression after 2 or more courses who have not experienced toxicity may receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.
2514647|NCT02799004||Patients in acute pain|
2514706|NCT02798770||Stroke Center Basel|
3197789|NCT00864240|Experimental|A|Clobex TM 0.05% Lotion, single exposure
3197790|NCT00864266|Experimental|1|After obtaining the biopsy, patients will be treated by standard chemotherapy (the regimen has to be in agreement with the ELCWP guidelines, available on the website www.elcwp.org)
3197791|NCT00864279|Experimental|A|Cetirizine Hydrochloride 10 mg tablets, single dose
2514833|NCT02797756||Case|CC/GER+ presence of chronic cough and presence of GER evidenced by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
2514836|NCT02797756||Control|CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)
2514879|NCT02797392|Experimental|Lifestyle intervention|All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
2514912|NCT02797145|Active Comparator|Intensive Group|Dose adjusted digoxin by the recommended range for the serum digoxin: 0.5-0.9 nanogram/mL
2514913|NCT02797145|Placebo Comparator|Conventional|Use digoxin as recommended by the guidelines.
2514987|NCT02796807|Experimental|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
2515153|NCT02795728|Active Comparator|Resin based sealant|Helioseal F is a resin based sealant
3197792|NCT00864279|Active Comparator|B|Zyrtec® 10 mg tablets, single dose
3197793|NCT00864292||HIV-infected, no dementia|Patients with HIV-infection but no dementia
3197794|NCT00864292||HIV-infected, dementia|Patients with HIV-infection and dementia
3197795|NCT00864305|Experimental|A|Gabapentin 400 mg capsules
3197796|NCT00864305|Active Comparator|B|Neurontin 400 mg capsules
3197797|NCT00864331|Active Comparator|Radiotherapy|For patients in Group A (Stage IIIA or IIIB), EBRT 39 Gy in 13 daily fractions over, with no chemotherapy.
3197798|NCT00864331|Experimental|Chemotherapy and radiotherapy|For patients in Group A (either stage IIIA or IIIB) receive a course of up to 3 cycles of chemotherapy followed by EBRT of 10 Gy in a single fraction or 16 Gy in 2 fractions 1 week apart.
3197799|NCT00864331|Active Comparator|Chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive up to 3 cycles of chemotherapy, and no radiotherapy.
3197800|NCT00864331|Experimental|Palliative radiotherapy and chemotherapy|For patients in Group B (either stage IIIB (wet) or IV) receive EBRT of 10 Gy in a single fraction or 16 Gy in two fractions 1 week apart, followed by up to 3 cycles of chemotherapy.
3197801|NCT00864344|Experimental|A|Sertraline HCl 100 mg tablets, single dose
3197802|NCT00864344|Active Comparator|B|Zoloft® 100 mg tablets, single dose
3197803|NCT00864357|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
3197804|NCT00864357|Active Comparator|B|COMBONOX® tablets, single dose
3197805|NCT00864396|Experimental|Prevacid|
2514043|NCT02803216|Experimental|standard triple region|The patients in this group were given 10-day standard triple therapy.
2514047|NCT02803216|Active Comparator|standard triple region +2-week TCM|The patients in this group were given 10 days of standard triple therapy + 2-week Xiang-sha-liu-jun decoction.
2514049|NCT02803216|Active Comparator|standard triple region +4-week TCM|The patients in this group were given 10days of standard triple therapy + 4-week Xiang-sha-liu-jun decoction.
3197806|NCT00864409|Active Comparator|Hip 1|high volume local anesthetic infiltration
3197807|NCT00864409|Placebo Comparator|Hip 2|
2514196|NCT02802189|Experimental|exercise and INIT group|The first group (experimental) followed the exersice programme in combination with the integrated neuromuscular inhibition technique (INIT).
2514200|NCT02802189|Active Comparator|exercise group|"The protocol for this group was identical to the previous group with the sole difference that the application of INIT was not included.~At the end of the exercise programme, relaxing breathing exercise and gentle stretching was applied for 15 min"
2514270|NCT02801903|Experimental|SB204 4%|Topically Once Daily (AM)
2514293|NCT02801565|Experimental|GH AQ|Controlled ovarian stimulation in the middle of the corpus (D21 days) of the previous menstrual cycle to use recombinant Human Growth Hormone Injection（rhGH） Injection 15IU/5mg/3mL/cartridge, 5IU per day, Subcutaneous injection after 20:00 until the HCG trigger day.
2514328|NCT02801292|Other|administering of ketamine|adjuvant to standard of care
2514393|NCT02800876||asymptomatic not ruptured aneurysm|Patients with asymptomatic not ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
2514397|NCT02800876||symptomatic not ruptured aneurysm|Patients with symptomatic aortic aneurysms greater than 3 cm who received a clinical indicated CT
2514406|NCT02800876||symptomatic ruptured aneurysm|Patients with symptomatic ruptured aortic aneurysms greater than 3 cm who received a clinical indicated CT
2514416|NCT02800876||patients with small aneurysms|Patients with small aortic aneurysms approximately 5.5 cm, ruptured and not ruptured, who received a clinical indicated CT
2514481|NCT02800616|Experimental|Full intervention group|The full intervention ('The Healthy Primary School of the Future') is implemented in two schools involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years.
2514496|NCT02800616|Experimental|Partial intervention group|The partial intervention ('The Physical Activity School') is implemented in two other schools: involving extended school hours in which healthy nutrition, physical exercise, environmental, social, and educational activities are incorporated, during a period of four years. Hence, this intervention only differs from the full intervention on the absence of nutritional intervention. Instead, children bring their own food from home, as they normally do.
2514499|NCT02800616|No Intervention|Control group|Four primary schools will function as control schools. The control schools have a representative Dutch school environment in terms of lifestyle education, school hours and amount of Physical Education (PE) lessons.
2514532|NCT02800070|Experimental|Treatment Arm|Patients will receive Health Canada approved transduced autologous CD34+ cell product.
2514599|NCT02799446|Experimental|Reslizumab|Reslizumab will be administered intravenously every 4 weeks at a dose of 3mg/kg.
2514604|NCT02799446|Placebo Comparator|Placebo|Matching placebo.
2514654|NCT02799095|Experimental|ALKS 4230|
2514661|NCT02799095|Experimental|ALKS 4230 + pembrolizumab|
2514739|NCT02798432|Experimental|Hybrid NEXGEN LPS|Noncemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
2514746|NCT02798432|Sham Comparator|Cemented NEXGEN LPS|Cemented femoral component with cemented tibial component with the NexGen LPS Total Knee Arthroplasty
2514771|NCT02798094||Depressed Participants|No intervention
2514772|NCT02798094||Healthy Control Participants|No intervention
2514822|NCT02797899|Active Comparator|Palatal donor site received PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and received platelet rich fibrin and periodontal pack as assigned randomly by a flip of coin during the screening visits.
2514826|NCT02797899|Active Comparator|Palatal donor site NOT receiving PRF|Following profound anesthesia and harvesting free gingival graft from the palate, the graft was positioned to the recipient area. The donor area were cleaned with sterile saline and sutured followed by periodontal pack application.
2514858|NCT02797535|Other|GI fluids samples collection|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
2514902|NCT02797301|Experimental|synthetic test & computerised test|Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
2514906|NCT02797301|Experimental|computerised test & synthetic test|Sixteen preschool children (G2), with no motor impairments, from a private school. The children in G2 performed the computerised test before the synthetic test.
2514909|NCT02797301|Experimental|computerised test|Seven volunteers (G3), two males and five females, with moderate mobility impairment, patients from the Physical Therapy and Rehabilitation Clinic.
2514972|NCT02796872|Placebo Comparator|mother's breast milk.|mother's breast milk.
2514974|NCT02796872|Active Comparator|other GOS|Commercial infant formula containing 4% w/w FOS:GOS (1:3)
3197808|NCT00864422|Experimental|1|
3197809|NCT00864422|Active Comparator|2|
3197810|NCT00864435|Experimental|A|Carvedilol 12.5 mg Tablets, single dose
3197811|NCT00864435|Active Comparator|B|Coreg® 12.5 mg Tablets , single dose
3197812|NCT00864448|Experimental|A|Ramipril10 mg Capsules, single dose
3197813|NCT00864448|Active Comparator|B|Atlace® 10 mg capsules, single dose
3197814|NCT00864461||Case|Patients with clinical and cytogenetics diagnosis of Down syndrome, between 7 - 24 years old.
3197815|NCT00864461||Control|Siblings of the same gender of the case, between 7-24 years old.
3197816|NCT00864474||Maraviroc Tablets|Patients administered.
3197817|NCT00864487|Experimental|1|Neratinib alone
3197818|NCT00864487|Experimental|2|Neratinib plus rifampin
2514050|NCT02803086||1|To date, around 700 patients, who were treated with Radiotherapy for Prostate Cancer, have been enrolled. 34% of them underwent radiotherapy with radical intent, whereas the others were post-prostatectomy patients (29% adjuvant, 37% salvage). Various techniques of irradiation were used (1% 3DCRT, 6% SF-IMRT, 52% VMAT, 41% Tomotherapy) in conventional (42%, 1.7-2.0 Gy/fr.) and hypofractionated (58%, 2.1-2.7 Gy/fr.) settings. EQD2(alpha/beta=3) to prescribed PTV ranged between 64 and 93 Gy. Limph nodes were treated in the 98% of cases.
2514124|NCT02802891||Recruitment group|"Group of individuals (aged 6 to 18 years old) recruited for the JOIN project. Consent was obtained from legal guardians for individuals under 18.~Exclusion criteria:~Individuals who refused to partake in the clinical assessment, despite the legal guardians consent.~Individuals who provided an insufficient amount of sample (ex: low volume of EBC)"
3197819|NCT00864500|Experimental|A|Clobetasol Propionate 0.05% lotion, single exposure
3197820|NCT00864500|Active Comparator|B|Clobex TM 0.05% Lotion, single exposure
2514245|NCT02801747|Experimental|Condition 1|Receives a core intervention session and the navigation intervention component (long duration; that is, up to 6 months).
2514251|NCT02801747|Experimental|Condition 2|Receives a core intervention session, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2514255|NCT02801747|Experimental|Condition 3|Receives a core intervention session, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2514258|NCT02801747|Experimental|Condition 4|Receives a core intervention session, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2514260|NCT02801747|Experimental|Condition 5|Receives a core intervention session, the pre-adherence preparation component, and the navigation intervention component (short duration, that is, up to 3 months).
2514264|NCT02801747|Experimental|Condition 6|Receives a core intervention session, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2514269|NCT02801747|Experimental|Condition 7|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
2514276|NCT02801747|Experimental|Condition 8|Receives a core intervention session, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2514278|NCT02801747|Experimental|Condition 9|Receives a core intervention session, the Motivational Interviewing sessions component, and the navigation intervention component (short duration, that is, up to 3 months).
2514279|NCT02801747|Experimental|Condition 10|Receives a core intervention session, the Motivational Interviewing sessions component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2514281|NCT02801747|Experimental|Condition 11|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, and the navigation intervention component (long duration, that is, up to 6 months).
2514283|NCT02801747|Experimental|Condition 12|Receives a core intervention session, the Motivational Interviewing sessions component, the peer mentorship component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2514284|NCT02801747|Experimental|Condition 13|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, and the navigation intervention component (long duration, that is, up to 6 months).
2514285|NCT02801747|Experimental|Condition 14|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the focused support group component, and the navigation intervention component (short duration, that is, up to 3 months).
2514286|NCT02801747|Experimental|Condition 15|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, and the navigation intervention component (short duration, that is, up to 3 months).
2514287|NCT02801747|Experimental|Condition 16|Receives a core intervention session, the Motivational Interviewing sessions component, the pre-adherence preparation component, the peer mentorship component, the focused support group component, and the navigation intervention component (long duration, that is, up to 6 months).
2514316|NCT02801344|Experimental|Normal protein intake|participants will receive the controlled-diet containing 0.8 g protein /kg/day and the test drink containing 0.14 g protein/kg/d.
2514324|NCT02801344|Experimental|Moderate protein intake|participants will receive the controlled-diet containing 1.20 g protein /kg/day and the test drink containing 0.40 g protein/kg/d.
2514331|NCT02801344|Experimental|High protein intake|participants will receive the controlled-diet containing 1.83 g protein /kg/day and the test drink containing 1.03 g protein/kg/d.
2514404|NCT02800980||Drainage and sclerotherapy.|Patients with symptomatic lymphocele who are managed with percutaneous drainage and sclerotherapy.
2514413|NCT02800980||Drainage alone.|Patients with symptomatic lymphocele who are managed with percutaneous drainage alone.
2514464|NCT02800564|Experimental|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months plus interactive voice response systems (IVRS) and monthly open community meetings.
2514467|NCT02800564|Experimental|Passive mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months
3197821|NCT00864526|Experimental|A|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
3197822|NCT00864526|Active Comparator|B|COMBONOX® tablets, single dose
2514597|NCT02799433|Active Comparator|Usual Services|This group of child care centers receives standard services from the San Francisco Department of Public Health Child Care Health Program. CCHP offers services to child care centers annually. The standard services include nurse consultation, health education, monitoring of nutrition and physical activity resource need, vision, hearing, oral health, and height and weight screenings.
3197823|NCT00864552||Group 1|
3197824|NCT00864565|Experimental|A|Fentanyl 25 μg/h transdermal system, single application
3197825|NCT00864565|Active Comparator|B|Duragesic 25 μg/h transdermal system single application
2514062|NCT02803359|Experimental|Routine Laryngoscopy|Nasolaryngoscopy will be performed in the office in the standard fashion with the use of oxymetazoline for topical decongestion of the nasal mucosa, In both settings, the electrode will be placed at a superficial depth and needle placement will be performed with one on each side at a location approximately mid-fold
3197826|NCT00864591||SPECT and stress CMR patients|"patients undergoing SPECT stress imaging, for the evaluation of myocardial ischemia.~The study group will include patients with either normal undergoing SPECT stress imaging or with mild to severe ischemia, to include the entire spectrum of coronary artery disease.~Patients will be pre selected and evaluated by a non-dependent cardiologist in order to verify that patients in whom the repeat stress might pose a serious risk will be excluded from the study."
2514116|NCT02802670|Experimental|GDC-0810|GDC-0810 300-mg dose administered as oral solution, containing approximately 100 microcuries of [14C]-labeled GDC-0810.
2514155|NCT02802436|Experimental|Extraction with socket graft and GEM21|"Intervention - Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Test site (active arm) will be injected with Bioactive Agent (PDGF - Platelet derived growth factor). At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd.~Bioactive agent - GEM21S (Growth factor enhanced matrix) Dosage - one cup containing 0.5 cc of ß-TCP particles (0.25 to 1.0 mm); and one syringe containing a solution of 0.5 mL rhPDGF-BB (0.3 mg/mL)"
2514162|NCT02802436|Other|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used, site will be filled slightly below marginal bone level (1mm). Normal saline will be used and no growth factor to maintain the volume in control sites
2514213|NCT02802072|Experimental|Enterprise stent implantation group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive Enterprise stent implantation in combination with antiplatelet medication for carotid artery stenosis.
2514216|NCT02802072|Experimental|Only aspirin medication group|Patients with atherosclerotic ischemic stroke will be randomly allocated to receive only antiplatelet medication for carotid artery stenosis.
2514235|NCT02801786|Placebo Comparator|Placebo|Five capsules containing placebo
2514242|NCT02801786|Experimental|Tamoxifen|Five capsules containing 20mg of tamoxifen.
2514249|NCT02801786|Experimental|Lidocaine|One sachet containing lidocaine gel at 4%
2514312|NCT02801474|Experimental|direct reduction|Intervention: The posterior and lateral malleoli were accessed via a posterolateral approach with the patients in prone position. The fibular fracture was exposed and reduced anatomically in the first place. The posterior malleolus was then exposed between the fiexor halluces longus and peroneus longus interval. The posterior malleolar fragment was then reduced with reference to the typical metaphyseal-diaphyseal spike of the posterior malleolus. One-third tubular plate, reconstruction plate, or distal radius plate were applied spanning the fracture in a buttress mode. Cannulated screws could also be used.
2514323|NCT02801474|Experimental|indirect reduction|Intervention: After open reduction and internal fixation of lateral and medial malleolar fractures, the posterior malleolus was then reduced through ligamentotaxis with the ankle in dorsiflexion. One or two 4.0 mm cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
2514400|NCT02801097|Experimental|RRx-001 + Irinotecan|Cohorts of participants with an advanced, malignant, solid tumor(s) will receive weekly doses of RRx-001 for 3 weeks, switching at week 4 to every-other-week treatments of RRx-001 with irinotecan.
2514485|NCT02800603|Experimental|Family Check Up|FCU Intervention: All 280 participants will undergo screening and a baseline FCU assessment before randomization. Once randomized, the FCU group (n=140) will be provided with a feedback visit and up to 6 optional sessions of the EDP curriculum over 16 weeks.
2514493|NCT02800603|No Intervention|Community Control|The Community Control group (n=140) will receive general information that includes a list of all the relevant services available in Hamilton. As such, the community control group would be provided with all the information needed to obtain standard care.
2514578|NCT02799680|Experimental|allogeneic CART-33|infusions of allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
2514649|NCT02799225||Enterobacteria|
2514729|NCT02798328||Reference Range|Healthy Subjects
2514735|NCT02798328||DOAC Pivotal|DOAC Eligible Subjects
2514793|NCT02798146|Other|hormonal levels|Blood samples are collected for analysis of LH, E2, hCG and progesterone.
2514840|NCT02797730|Experimental|art-therapy sessions|Caregivers will receive 6 art-therapy sessions
2514841|NCT02797730|No Intervention|no art-therapy sessions|Caregivers will not receive 6 art-therapy sessions during the evaluation period
3197827|NCT00864604|Experimental|A|Nabumetone 750 mg tablets, single dose
2515106|NCT02796040|Experimental|patients with ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
2515111|NCT02796040|Other|patients without ICD (impulse control disorder)|More precisely, the main purpose is to demonstrate that fractional anisotropy (FA) (data obtained with DTI) in the ventral tegmental area (VTA) is different between patients with ICD and patients without ICD
2515143|NCT02795741|Experimental|Cooling Bolero|All participants will use the Cooling Bolero for one month
2515185|NCT02795494||Perthes Group|Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
2515186|NCT02795494||Fracture Control Group|Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
2515216|NCT02795156|Experimental|Arm 1|Patients with non-small cell lung cancer who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2515614|NCT02792764||Port|Subjects receiving chemotherapy through a port
3197828|NCT00864604|Active Comparator|B|Nabumetone 750 mg tablets, single dose
3197829|NCT00864617|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
3197830|NCT00864617|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
3197831|NCT00864630|No Intervention|Wait list|
2514100|NCT02802683|Experimental|"BUPI,P"|patients who received hyperbaric bupivacaine and continous infusion of phenylephrine
2514102|NCT02802683|Placebo Comparator|"BUPI,N"|patients who received hyperbaric bupivacaine and continous infusion of normal saline
2514105|NCT02802683|Experimental|"LEVO,P"|patients who received isobaric levobupivacaine and continous infusion of phenylephrine
2514107|NCT02802683|Active Comparator|"LEVO,N"|patients who received isobaric levobupivacaine and continous infusion of normal saline
2514182|NCT02802254|Experimental|Pedometer+physical-activity-feedback|At cardiac consultation patients receive a patient-targeted individual physical-activity-feedback.
2514189|NCT02802254|Active Comparator|Pedometer-only|Patients use a Pedometer in order to measure their daily step number
2514267|NCT02801929|Experimental|BAY987518|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2514318|NCT02801630|Sham Comparator|Sham Crossover|"After the enrollment and lead in period, subjects will be given a sham device to sleep with every night for a month. They will be asked to fill out their pain and analgesic use logs, and undergo the bi weekly assessments. After a month they will be crossed over to an active Painshield SAW patch device and will continue to complete their pain and analgesic use logs as well as undergo biweekly assessments for months two and 3."
2514330|NCT02801630|Active Comparator|Active Device|After the enrollent and lead in period, subjects will be given an active PainSHield SAW Patch device to sleep with every night. They will be asked to fill out their pain and analgesic use logs, and undergo bi weekly assessments. They will continue to use the device while completing their logs and undergoing assessments for 3 months.
2514408|NCT02801032|Active Comparator|Active Treatment|Tadalafil 20 mg Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
2514418|NCT02801032|Placebo Comparator|Control|Placebo Capsule. MRI of cerebrum pre dose. Transcranial Doppler, near-infrared spectroscopy (NIRS), endothelial response with EndoPAT2000, and endothelial biomarkers (pre and post dose).
2514446|NCT02800577|Other|All participants|Study has a single, non-interventional arm where the General Practitioner Emotional Test Battery (GP-ETB) will be administered.
2514461|NCT02800382|Other|Lung Malignancy|"Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.~The samples (fine-needle aspiration biopsy and fine-needle aspiration cytology) were diagnosed by pathological examination."
2514465|NCT02800382|Other|Lung bening Diseases|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
2514617|NCT02799251||Collection of plasma cell rate|Post operative infections and their association with lymphopenia are assessed in this study for patients over 18 years of age undergoing digestive or thoracic cancer surgery under general anesthesia.
2514625|NCT02798926||with the use of a polyethylene bag|
2514626|NCT02798926||without the use of a polyethylene bag|
2514670|NCT02798848|Experimental|Assistive technology: tablet computer|iPad tablet computers
2514673|NCT02798848|Active Comparator|Standard optical low vision devices|standard optical devices including magnifiers, telescopes, CCTV
2514702|NCT02798614|Active Comparator|10-day cast|Removal of plaster cast 10 Days after reduction
2514703|NCT02798614|No Intervention|1-month cast|Removal of plaster cast 1 month after reduction
3197832|NCT00864630|Experimental|Computer-based problem solving therapy|
2514795|NCT02798003||Cachectic cancer patients|Cachectic cancer patients, including non-small cell lung cancer (NSCLC) and gastro-intestinal cancer. The study participants will undergo fMRI scanning.
2514796|NCT02798003||Non-cachectic cancer patients|Non-cachectic cancer patients, including NSCLC and gastro-intestinal cancer. The study participants will undergo Functional magnetic resonance imaging (fMRI) scanning.
2514797|NCT02798003||Cachectic COPD patients|Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
2514798|NCT02798003||Non-cachectic COPD patients|Diagnosis of COPD consistent with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The study participants will undergo fMRI scanning.
3197833|NCT00864643|Experimental|Lapaquistat Acetate 100 mg QD + Atorvastatin QD|
3197834|NCT00864643|Active Comparator|Atorvastatin QD|
2514915|NCT02797106||health care professionals|health care professionals potentially involved in assessment and/or treatment of drooling in children with Cerebral Palsy.
3197835|NCT00864656||1|Patients submitted to application of 1 drop of 10% phenylephrine
2515038|NCT02796417|Experimental|Rehacop group|Cognitive rehabilitation
2515040|NCT02796417|Active Comparator|Control group|Occupational activities
2515067|NCT02796157|Active Comparator|absorb arm|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold
2515069|NCT02796157|Experimental|Xience arm|PCI with Xience everolimus-eluting metallic stent
2515122|NCT02795936|Active Comparator|Institutional based rehabilitation|Conduct cardiac rehabilitation exercise protocol within the hospital
2515127|NCT02795936|Active Comparator|Home based rehabilitation|Conduct cardiac rehabilitation exercise protocol at home
2515130|NCT02795936|Placebo Comparator|Observational arm|No prescribed exercises, followed up monthly
2515165|NCT02795624||Flight attendants|Flight attendants
3197836|NCT00864656||2|Patients submitted to application of 2 drops of 10% phenylephrine
3197837|NCT00864656||3|Patients submitted to application of 4 drops of 10% phenylephrine
3197838|NCT00864669|Experimental|A|Metformin HCl 500 mg tablets, single dose
3197839|NCT00864669|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3197840|NCT00864695||Surgical patients|Individuals who were hospitalized in the Botucatu Medical School Hospital to undergo surgery under anesthesia administered by the Anesthesiology Service of BMS Department of Anesthesiology.
3197841|NCT00864734|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
2514104|NCT02802657|Active Comparator|Conbercept 0.5mg Pro Re Nata|"Monthly intravitreal injections of Conbercept 0.5mg in the core treatment period and PRN intravitreal injections of the same dose guided by BCVA stabilization in the extension treatment period.~Intervention: Drug: Conbercept"
2514159|NCT02802267|Experimental|inecalcitol|Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.
2514167|NCT02802267|Placebo Comparator|placebo|Two tablets of placebo 2mg each (total 4mg) taken orally every other day
2514668|NCT02798913|Experimental|Short DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
2514672|NCT02798913|Experimental|Long DAPT|Patients who will be treated after PTA with acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
2514725|NCT02798601|Experimental|Hypernatremia|Serum sodium between 150 - 155 milliequivalent/L. 7,5% sodium chloride (2 ml/kg every 4 hours), with controls of serum sodium every 4 hours, to achieve a goal of serum sodium between 150 - 155 milliequivalent/L. If after 4 doses of 7.5% sodium chloride the serum sodium is below the target, a bolus of 1 ml/kg of 12% sodium chloride will be used every 4 hours. The goal of serum sodium will be maintained for 48 hours.
2514727|NCT02798601|No Intervention|Normonatremia|Serum sodium between 135 - 145 milliequivalent/L. Mannitol 100 ml every 4 hours for the first three days; 80 ml every 4 hours the fourth day; 60 ml every 4 hours the fifth day and 40 ml every 4 hours the sixth day and then stopping. The mannitol protocol will be interrupted at any moment if serum sodium is below 135, the systolic blood pressure is below 90 mmHg or the patient has signs of hypovolemia. In this case, 2 ml/kg of 3% sodium chloride every 4 hours will be used until the target of serum sodium is achieved and both, normovolemic state and blood pressure are restored. In addition, the mannitol protocol will be suspended when serum osmolality is above 320.
2515118|NCT02796001|Active Comparator|RV16|volunteers re-challenged with RV16
2515120|NCT02796001|Active Comparator|RV39|volunteers re-challenged with RV39
2515150|NCT02795676|Experimental|PRX-102 (pegunigalsidase alfa)|PRX-102 infusion every 2 weeks
2515154|NCT02795676|Active Comparator|agalsidase beta|agalsidase beta infusion every 2 weeks
2515227|NCT02795104|Experimental|ARM I (TIDVD)|Educational Intervention via DVD: In this arm of the intervention participants watch a tailored interactive DVD program and answer questions posed by the DVD program.
2515234|NCT02795104|Experimental|ARM II (TIDVD, PN)|Educational Intervention-DVD & Telephone based Navigation: In this arm of the intervention participants watch a TIDVD and are called by a patient navigator.
2515243|NCT02795104|Experimental|ARM III (UC)|Educational Intervention via brochure: In this arm of the intervention participants receive brochures that explain and provide information and encouragement for cancer screening.
2515405|NCT02794350||Cohort|
2515572|NCT02793050||Trabectedin|Trabectedin give according the market authorization for advanced soft tissue sarcoma
3164283|NCT00495846|Experimental|A|"Patients with cirrhosis without HCC in all liver function classes already receiving specific therapy for cirrhosis who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study~Patients with cirrhosis with multifocal HCC and clinical and/or radiological signs of persistence or recurrence of HCC in presence or absence of trombosis of the portal vein, with a single nodule of >6 cm in size or multiple nodules of >3 cm in size who accept be subjected to liver biopsy and to sign the written informed consent to participate to the study"
3164284|NCT00495846|Other|B|Historical controls
3164285|NCT00495859|Active Comparator|1|Study group will receive formula enriched with arginine, ω-3 fatty acids, and nucleotides once daily
3164286|NCT00495859|Active Comparator|2|controls receive an isocaloric isonitrogenous non-specific nutritional support
3164287|NCT00495872|Experimental|VN|Valproic Acid + Sorafenib
3164288|NCT00495872|Experimental|VS|Valproic Acid + Sunitinib
3164289|NCT00495872|Experimental|VD|Valproic Acid + Dasatinib
3164290|NCT00495872|Experimental|VT|Valproic Acid + Erlotinib
3164291|NCT00495872|Experimental|VL|Valproic Acid + Lapatinib
3164292|NCT00495872|Experimental|VR|Valproic Acid + Lenalidomide
3164293|NCT00495885|Experimental|Volinanserin|Volinanserin 2 mg for a maximum of 87 days
3164294|NCT00495885|Placebo Comparator|Placebo|Placebo for volinanserin for a maximum of 106 days
3164295|NCT00495898|Experimental|1|CYPHER sirolimus-eluting stent
3164296|NCT00495898|Active Comparator|2|uncoated Bx VELOCITY balloon-expandable stent
3164297|NCT00495924||PD|Patients undergoing pancreaticoduodenectomy for pancreatic or peri-ampullary tumours.
3164298|NCT00495950||Questionnaire|
3164299|NCT00496028|Experimental|1|AZD0530 + Paclitaxel
3164300|NCT00496028|Experimental|2|AZD0530 + Carboplatin
3164301|NCT00496028|Experimental|3|AZD0530 + Carboplatin + Paclitaxel
3164302|NCT00496041|Experimental|Smart Stent in the Superficial Femoral Artery .|
3164303|NCT00496067|Experimental|1|DUAO Device
3164304|NCT00496093|Experimental|Pneumococcal Vaccine, Polyvalent (23-valent)|Participants received one 0.5 mL dose of Pneumococcal Vaccine, Polyvalent (23-valent) by intramuscular (deltoid) injection on Day 1.
3164305|NCT00496106|Experimental|Control Arm|6 telephone counseling sessions
3164306|NCT00496106|Active Comparator|Usual Care Arm|6 telephone counseling sessions
3164307|NCT00496119|Experimental|70 Gray (Gy) Proton Beam Therapy|Participants treated to 70 cobalt Gray equivalent (CGE) only (the standard treatment).
3164308|NCT00496119|Experimental|Photon Beam Therapy|Proton beam therapy combined with photon radiation therapy where combination improves final dose distribution.
3164309|NCT00496132|Experimental|1|
3164310|NCT00496145|Experimental|treatment|Spanish Diabetes Self-Management Program
3164311|NCT00496145|No Intervention|control|usual-care control group
3164312|NCT00496223|Experimental|1|
3164313|NCT00496288|Experimental|prophylactic irradiation|prophylactic contralateral breast irradiation
3164314|NCT00496288|No Intervention|controls|Those that do not opt for prophylactic irradiation or mastectomy
3164315|NCT00496327|Experimental|1|Open label
3164316|NCT00496418|Experimental|Prophylactic stoma mesh|Mesh
3164317|NCT00496418|Active Comparator|No mesh prophylaxis|No mesh
2514117|NCT02802618|No Intervention|Conventional technique|The pulmonary rehabilitation consists of exercise training during 10 weeks and a theoretic part presented with conventional technique. Patients randomized into education by conventional technique.
2514175|NCT02802410|Experimental|IQ-Tape|IQ-application on leg muscles muscles
2514186|NCT02802410|Experimental|Kinesiotape|Kinesiotape application on leg muscles
2514192|NCT02802410|Experimental|No-Tape|No-Tape on leg muscles
2514261|NCT02801968|Experimental|Tap block|Tap block with ropivacaine 2 mg/kg at the end of cesarean delivery. Postoperative analgesia with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
2514265|NCT02801968|Active Comparator|control group|Postoperative analgesia after cesarean delivery with acetaminophen and tramadol plus NSAIDs (nonsteroidal anti-inflammatory drugs) as rescue dose.
2514305|NCT02801500|Experimental|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis.
2514307|NCT02801500|Active Comparator|Traditional Manual Anastomosis|A handsewn technique will be used during bilioenteric anastomosis.
2514410|NCT02801071|Experimental|L-citrulline|15 g L-citrulline p.o. per day (3x 5g) for 24 weeks
2514422|NCT02801071|Placebo Comparator|Placebo|L-citrulline Placebo 3 times daily p.o. for 24 weeks
2514487|NCT02800538|Experimental|Lauric acid|the nutrient that can be widely found in daily food.
2514495|NCT02800538|Experimental|Palmitic acid|the nutrient that can be widely found in daily food.
2514500|NCT02800538|Experimental|Capric acid|the nutrient that can be widely found in daily food.
2514501|NCT02800538|Placebo Comparator|Saline|physiological salt water
2514528|NCT02800083|Experimental|Pitolisant (BF2.649)|Histamine H3 receptor H3R antagonist/ inverse agonist
2514529|NCT02800083|Placebo Comparator|Placebo|placebo
2514563|NCT02799797|Active Comparator|short axis (SAX) placement of adductor canal catheters|Procedure: Ultrasound guided short axis (SAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a PAJUNK Contiplex S catheter along the short axis of the middle part of adductor canal
2514565|NCT02799797|Experimental|long axis (LAX) placement of adductor canal catheters|Procedure: Ultrasound guided long axis (LAX) placement of adductor canal catheters Philip CX50 ultrasound scanner guided insertion of a catheter along the long axis of the middle part of adductor canal
2514596|NCT02799394|Experimental|Activity modification, exercises and gradual return to sport|
2514645|NCT02799186|Experimental|SCAD (spontaneous coronary artery dissection)|Every patient included with a SCAD or hematoma, will systematic benefit a tomographic or MRI angiography of renal, cerebrovascular and iliac arteries, to look for the presence of a fibromuscular displasia. A blood sample will be collected for the genetic analysis which will be realized by the Team 3 of the INSERM UMR970, Paris Cardiovascular research Center, France.
2514711|NCT02798744|Experimental|Empagliflozin 25mg once daily|Empagliflozin (Jardiance™) 25mg once daily (orally)
2514712|NCT02798744|Experimental|Empagliflozin 25mg once daily + diet|Empagliflozin (Jardiance™) 25mg once daily (orally) + energy restriction diet
2514713|NCT02798744|Placebo Comparator|Placebo once daily|Placebo once daily (orally)
2514714|NCT02798744|Active Comparator|Placebo once daily + diet|Placebo once daily (orally) + energy restriction diet
2514769|NCT02798237|Experimental|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
2514770|NCT02798237|Sham Comparator|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program.
2514831|NCT02797912||CF children and young people|Observational study involving clinical procedures: lung function testing, respiratory muscle strength testing, body composition analysis & exercise tolerance.
2514878|NCT02797470|Experimental|Treatment (anti-HIV gene transduced CD34+ cells)|Patients receive BEAM regimen administered as standard of care comprising carmustine on day -6, cytarabine BID on days -5 to -2, etoposide BID on days -5 to -2, and melphalan on day -1. Patients undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells over 1 hour.
2515047|NCT02796443||Early laparoscopic cholecystectomy (ELC)|Operation within 72 hours after onset of symptoms
2515051|NCT02796443||Intermediate cholecystectomy (ILC)|Operation within 14 days after onset of symptoms
2515053|NCT02796443||Delayed LC (DLC)|Operation after 6-12 weeks
2515057|NCT02796443||Elective laparoscopic cholecystectomy|Biliary colic with no acute cholecystitis
2515244|NCT02795208|No Intervention|Control group|Patients received standard protective ventilation along the protocol.
2515252|NCT02795208|Experimental|Recruitment maneuver group|Patient received a lung recruitment maneuver after cardiopulmonary bypass. The recruitment maneuver consists in 10 breaths at 40/20 cmH2O of plateau pressure and PEEP, respectively. Then, the .ventilatory settings back to protective ventilation but adding 10 cmH2O of PEEP to keep the lungs open.
2515289|NCT02794948|Experimental|Chinese Medicine intervention|Chinese medicine HuYang Yang Kun Formula 1 capsule every time per day for 3 day per month, DHEA(dehydroepiandrosterone) placebo 1 sack every time, twice a day for three months
3164318|NCT00496431|Experimental|ITF2357|
3164319|NCT00496444|Experimental|Azacitidine + Valproic Acid|
3164320|NCT00496457|Experimental|1|TRO19622
3164321|NCT00496457|Placebo Comparator|2|
3164322|NCT00496509|Experimental|ZD6474 (vandetanib) 100mg|
2514164|NCT02802293|Active Comparator|Anterior DLPFC targeting|Active rTMS will be delivered to the left anterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
2514168|NCT02802293|Active Comparator|Posterior DLPFC targeting|Active rTMS will be delivered to the left posterior DLPFC using connectivity-based, image-guided aiming with the rTMS coil positioned using a robotic arm. In this arm, rTMS will be delivered at 10 Hz in 4 sec trains with 26 sec inter-train intervals, 37.5 minutes/session (i.e. 3,000 pulses/session), 5 sessions/week, for 4 weeks.
2514225|NCT02801981|Experimental|Sequence 1: GSK2230672 10mg, 30mg, 90mg, and Placebo|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and placebo in period 4.
2514230|NCT02801981|Experimental|Sequence 2:GSK2230672 10mg, 30mg, Placebo, and GSK2230672 90mg|Subjects will receive GSK2230672 10 mg in period 1, GSK2230672 30 mg in Period 2, placebo in period 3, and GSK2230672 90 mg in period 4.
2514234|NCT02801981|Experimental|Sequence 3:GSK2230672 10mg, Placebo, GSK2230672 90mg and 180mg|Subjects will receive GSK2230672 10 mg in period 1, placebo in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
2514241|NCT02801981|Experimental|Sequence 4: Placebo, GSK2230672 30mg, 90mg and 180mg|Subjects will receive placebo in period 1, GSK2230672 30 mg in Period 2, GSK2230672 90 mg in Period 3 and GSK2230672 180 mg in period 4.
2514336|NCT02801448|Placebo Comparator|Placebo|Placebo containing maltodextrine but no active sulforaphane
2514338|NCT02801448|Active Comparator|BSE|Broccoli sprout extract once daily for 12 weeks
2514401|NCT02801045|Experimental|art therapy|Individual 30-60 minutes art therapy sessions, twice a week, offering visual arts materials.
2514452|NCT02800746|Experimental|Experimental group|Ferric carboxymaltose
2514457|NCT02800746|Placebo Comparator|Control Group|Placebo
2514531|NCT02800330|Other|Arm A (e.g. sequence phase A-B-C)|In this arm patients will use regorafenib alone in the first cycle (treatment A), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib with esomeprazole 3 hours before (treatment C)
2514534|NCT02800330|Other|Arm B (e.q. sequence phase C-B-A)|In this arm patients will use regorafenib with esomeprazole 3 hours before (treatment C), then regorafenib with esomeprazole concomitantly in the second cycle (treatment B) and at last they will use regorafenib alone (treatment A),
2514675|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence AB (fasted followed by fed)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive a single tablet of cabotegravir 30 mg,(micronized 500 mg core weight) orally under fasted condition with at least 10 hours of prior fast. In Period 2, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
2514678|NCT02799264|Experimental|Cabotegravir 30 mg: Sequence BA (fed followed by fasted)|There will be two administration periods with 14 days of wash out. In Period 1, eligible subjects will receive single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally following a high fat meal. In Period 2, eligible subjects will receive a single tablet of cabotegravir 30 mg, micronized 500 mg core weight orally under fasted condition with at least 10 hours of prior fast. Blood samples will be withdrawn from subjects prior to dosing and upto 8 days after the last dose of cabotegravir.
2514719|NCT02798588|Experimental|Comatose patients in ICU|
2514758|NCT02798263|Experimental|Group I kinesiotherapy|Treated with standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes
2514761|NCT02798263|Experimental|: Group II Acupuncture|Treated with 30 minutes of classical acupuncture using predefined points
2514764|NCT02798263|Experimental|Group III Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper®
2514803|NCT02798016|Experimental|Platelet-Rich Plasma alone|The scars will be injected with Platelet-Rich Plasma alone.
2514806|NCT02798016|Active Comparator|Platelet-Rich Plasma with micro-needling|The scars will be dealt with using micro-needling as well as injecting Platelet-Rich Plasma
2514849|NCT02797652||Neoadjuvant chemotherapy|ctDNA of operable breast cancer patients with neoadjuvant chemotherapy before surgery in different periods: before neo-chemotherapy, during neo-chemotherapy, on surgery day, after surgery and follow-up time.
2514853|NCT02797652||Surgery|ctDNA of operable breast cancer patients with surgery followed by adjuvant chemotherapy in different periods: on surgery day, after surgery, before adjuvant chemotherapy, during adjuvant chemotherapy, and follow-up time.
2514880|NCT02797314|Other|Type 2 diabetic population|Bone biopsies
2514881|NCT02797314|Other|Non-diabetic control population|Bone biopsies
2514918|NCT02797119|Experimental|tranexamic acid 1 g (TA1)|"To measure the efficacy of a standard 1g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section.~To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration"
2514919|NCT02797119|Experimental|tranexamic acid 0.5 g (TA1/2)|To measure the efficacy of a low 0,5g dose TA to reduce blood loss in ongoing hemorrhagic cesarean section To correlate this clinical effect with the fibrinolysis inhibition and the TA venous and uterine blood concentration
2514923|NCT02797119|Placebo Comparator|Saline Solution (TA0)|To measure the evolution of blood loss without TA in ongoing hemorrhagic cesarean section To correlate this clinical evolution with fibrinolysis.
2514928|NCT02797119|No Intervention|NH|To measure the reference fibrinolytic activity in non-hemorrhagic cesarean section
2514967|NCT02796690||Group Methicillin susceptible Staphylococcus aureus (MSSA)|
2514971|NCT02796690||Group methicillin resistant Staphylococcus aureus (MRSA)|
2515018|NCT02796573|Experimental|B-CBT|6 face-to-face consultations plus 6 online modules.
2515023|NCT02796573|Active Comparator|Face-to-Face CBT|12 face-to-face consultations.
2515209|NCT02795468|Active Comparator|Palpation group|The operator will use the pulsation of the radial artery as a guide for the cannulation.
2515211|NCT02795468|Experimental|Ultrasound group|The ultrasound guided technique will be used to find a radial artery and insert a radial arterial catheter.
2515221|NCT02795091|Other|Manual clean|clean the rag and floor towel manually
2514176|NCT02802397|Other|Cases|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
2514183|NCT02802397|Other|Controls|"Cases and controls will benefit, as usual in France concerning infertility etiology examinations, of a follicle antral count by transvaginal ultrasound and AMH measurement.~At baseline, physicians will complete a short questionnaire to check the inclusion criterion, the results of the measurement of follicle count and hormone measurement (including AMH). Cases and controls will respond to self-administered questionnaire at inclusion with information about their medical history, their demographics, their tobacco and alcohol consumption, their occupation and products handled in the workplace. Blood samples (for measure of persistent organic pollutants and heavy metals) and urine (for measure of metabolites of glycol ethers) will be collect at baseline. Occupational exposures to solvents will be defined using job exposures matrices. The risk of decreased ovarian reserve will be analyzed using logistic regressions for each exposure of interest adjusting for potential confounders."
2514222|NCT02801916|Other|Study subjects|Each healthy subject will receive each of the interventions in randomized order.
2514303|NCT02801682||Healthy Controls|
2514304|NCT02801682||Invasive Candidiasis|
2514308|NCT02801682||Bacterial Sepsis (Bacteremia)|
2514311|NCT02801682||ICU patients without infectious disease|
2514377|NCT02801201|Active Comparator|sedation|Midazolam : 0,10 mg/kg
2514380|NCT02801201|Active Comparator|spinal anesthesia|Bupivacain 10 mg
2514473|NCT02800720|Experimental|Meditation Awareness Training|"Target Intervention Arm:~8-week meditation intervention"
2514477|NCT02800720|Active Comparator|Cognitive Behavioural Therapy for Groups|"Active Comparator Arm:~8-week CBT-based intervention"
2514514|NCT02800187|Experimental|three-sessions of ESWT|Active three-sessions of ESWT ( once a week for 3 weeks) was given.
2514515|NCT02800187|Active Comparator|one-session of ESWT|One-session of ESWTactive ESWT was given.
2514517|NCT02800187|Active Comparator|Night splint|The night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study. Another 3 sessions of sham ESWT was given.
2514544|NCT02799888|Experimental|Maraviroc + standard GVHD prophylaxis|Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.
2514590|NCT02799459||General anaesthesia|this group will allow us to compare the results like it is the treatment used in current practice ie general anesthesia.
2514594|NCT02799459||Hypnosis in conization|This group is the treatment being tested , where hypnosis is used in the conization
2514655|NCT02799134|Experimental|group1|take Dexamethasone at 22:00 on the first day, 0.5mg
2514659|NCT02799134|Placebo Comparator|group2|take Vitamin C at 22:00 on the first day, 0.5mg
2514662|NCT02799134|Other|group3|take Dexamethasone at 15:00 on the second day, 0.5mg
2514709|NCT02798666|Experimental|High intensity exercise training|The participants exercised for 40 minutes, twice a week, under supervision of two physiotherapists for in total 10 weeks. Each training session included a warming up, a sprint interval block [10 minutes], continuous aerobic exercise [10 minutes], another sprint interval block [10 minutes] and cooling down. For the first 5 weeks, each sprint interval block consisted of 10 sprint bouts [>100 r/min] of 15 seconds at a cycling resistance matching with the ventilatory threshold [VTR], alternated with 45 seconds relative rest [50 r/min at VTR]. Starting from week 6 until week 10, the intensity of sprinting and relative rest was increased up to 110% of VTR.
2514710|NCT02798666|Active Comparator|Continuous exercise training|The comparative group performed a continuous aerobic training [CAT] for 10 weeks, twice a week and 40 minutes per session [volume and frequency is equal to HIIT]. The protocol of the CAT group consisted of warming up [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes], continuous aerobic exercise training [3 times 10 minutes] and cooling down [stretching of the large muscle groups and cardiovascular exercises at 30% of peak cycling power output for five minutes]. During the continuous aerobic protocol [cycling or stepping] participants exercised for 10 minutes at a HR similar to the HR at VT [60 r/min], which was increased to 110% of VT from week 6 onwards.
2514816|NCT02797938|Experimental|Taper guard tube|Taper guard tube was intubated in 26 patients
2514818|NCT02797938|Active Comparator|Cylindrical tube|Cylindrical tube was intubated in 26 patients
3164323|NCT00496509|Experimental|ZD6474 (vandetanib) 300mg|
3164324|NCT00496522|Other|Proton Beam Therapy|Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
2514882|NCT02797236|Experimental|vaccine dose 1|SF2a-TT15 vaccine, 2 μg
2514883|NCT02797236|Experimental|vaccine dose 1+ adjuvant|SF2a-TT15 vaccine, 2 μg + alum
2514886|NCT02797236|Experimental|vaccine dose 2|SF2a-TT15 vaccine, 10 μg
2514889|NCT02797236|Experimental|vaccine dose 2 + adjuvant|SF2a-TT15 vaccine, 10 μg + alum
2514890|NCT02797236|Placebo Comparator|Placebo|Tris buffer
2514891|NCT02797236|Placebo Comparator|Placebo + adjuvant|Tris buffer + Alum
3164325|NCT00496548|Experimental|1|Fecal calprotectin and urinary PGE-M levels will be tested on all participants.
3164326|NCT00496561|Active Comparator|1|subcutaneous immunotherapy (House Dust Mites)
3164327|NCT00496561|Placebo Comparator|2|placebo of subcutaneous immunotherapy (House Dust Mites)
3164328|NCT00496574|Active Comparator|1|
3164329|NCT00496574|No Intervention|2|no intevention
2514219|NCT02801994|Experimental|Ventilator settings, PAV|"A first 30-minutes recording in PSV will be performed. Dyspnea-VAS, IC-RDOS will be measured at the beginning and at the end of this period. EMG and EEG will be recorded continuously. Patients will be subsequently switched to PAV.~The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min."
2514228|NCT02801760||Subjects Currently or Previously Enrolled in ATN 110/ATN 113|Younger and older YMSM and transgender women who have sex with men, ages 15 through 22 years, inclusive, at the time of consent into the ATN 110 or ATN 113 study.
2514238|NCT02801760||Sub-Sample of Subjects to Complete Qualitative Interview|A sub-sample of subjects who completed the web-based survey and indicated willingness to complete the qualitative interview.
2514290|NCT02801487|Experimental|CIRT with concurrent chemo arm|Treated with carcon ion radiotherapy along with concurrent chemotherapy (Cisplatin 40mg/m^2, weekly).
2514306|NCT02801331|Experimental|Stochastic Vibrotactile Stimulation (SVS)|Infants randomized to this arm will receive daily intervals of continuous SVS (ON) and no SVS (OFF) throughout hospitalization, starting within 48-hrs post birth. SVS will be complementary to standard of clinical care (e.g., clinically-determined pharmacological management; routine parental/volunteer holding; breast and/or bottle feed). Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
2514309|NCT02801331|No Intervention|Treatment as Usual (TAU)|Infants randomized to this arm will be enrolled within 48-hours post birth and receive treatment as usual (TAU)- standard of clinical care (e.g., clinically-determined pharmacological management, routine/volunteer holding; breast and/or bottle feed). Infants will not receive any SVS. Infants will be scored for severity of withdrawal using standardized, modified Finnegan scoring system by clinical care nurses per routine clinical care throughout hospitalization.
2514363|NCT02801123|Experimental|Preference: MBCR (im)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to immediate treatment
2514365|NCT02801123|Experimental|Preference: TCQ (im)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to immediate treatment
2514367|NCT02801123|Active Comparator|Preference: MBCR (wl)|Individuals with a preference for 'Mindfulness-Based Cancer Recovery (MBCR)' randomized to waitlist
2514369|NCT02801123|Active Comparator|Preference: TCQ (wl)|Individuals with a preference for 'Tai Chi/Qigong (TCQ) for Cancer Patients' randomized to waitlist
2514371|NCT02801123|Experimental|No Preference: MBCR (im)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - immediate
2514372|NCT02801123|Experimental|No Preference: TCQ (im)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - immediate
2514373|NCT02801123|Active Comparator|No Preference: MBCR (wl)|Individuals with no preference randomized to 'Mindfulness-Based Cancer Recovery (MBCR)' - waitlist
2514374|NCT02801123|Active Comparator|No Preference: TCQ (wl)|Individuals with no preference randomized to 'Tai Chi/Qigong (TCQ) for Cancer Patients' - waitlist
2514388|NCT02800811|Experimental|Part 1: Cohort A, Group 1, FR104|Dose: single 0.005 mg/kg.
2514392|NCT02800811|Experimental|Part 1: Cohort A, Group 2, FR104|Dose: single 0.05 mg/kg.
2514396|NCT02800811|Experimental|Part 1: Cohort A, Group 3, FR104|Dose: single 0.2 mg/kg.
2514402|NCT02800811|Experimental|Part 1: Cohort A, Group 4, FR104|Dose: single 0.5 mg/kg.
2514415|NCT02800811|Placebo Comparator|Part 1: Cohort A, placebo|Placebo, single administration, double blind (1/4 healthy subject in group 1, 1/4 in group 2, 2/5 in group 3 and 2/5 in group 4).
2514423|NCT02800811|Experimental|Part 1: Cohort B, Group 7, FR104|Dose: single 0.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2514429|NCT02800811|Experimental|Part 1: Cohort B, Group 8, FR104|Dose: single 0.2 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2514431|NCT02800811|Experimental|Part 1: Cohort B, Group 9, FR104|Dose: single 1.5 mg/kg. Healthy subject naïve to KLH and that will receive a KLH challenge.
2514434|NCT02800811|Experimental|Part 1: Cohort B, Group 9 bis, FR104|Dose: single 0.02 mg/kg group. Healthy subject naïve to KLH and that will receive a KLH challenge.
2514438|NCT02800811|Placebo Comparator|Part 1: Cohort B, placebo|placebo, single administration, double-blind: healthy subjects naïve to KLH and that will receive a KLH challenge (2/5 in each group of cohort B)
2514439|NCT02800811|Experimental|Part 2: Group 10, FR104|Dose: repeat, 0.2 mg/kg. Two administrations separated by an interval of 28 days.
2514440|NCT02800811|Experimental|Part 2: Group 11, FR104|Dose: repeat, 0.5 mg/kg. Two administrations separated by an interval of 28 days.
2514442|NCT02800811|Placebo Comparator|Part 2: placebo|placebo, repeat, double-blind: 2/5 subjects in each group of Part 2. Two administrations separated by an interval of 28 days.
2514448|NCT02800447|Experimental|Treatment|baseline BEACOPP regimen
2514449|NCT02800447|Active Comparator|controlled group|ABVD regimen
2514527|NCT02800343||Cardiovascular surgery|All adult patients undergoing elective or emergency cardiovascular surgery at the study site
2514537|NCT02799836|Experimental|Light deprived study subjects|Study subjects who are blindfolded for 48 hours
2514587|NCT02799706|Active Comparator|GnRH agonist + radiation therapy (RT)|"As the study investigates the effect of a drug given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) + A GnRH-agonist will be given for the duration selected for each patient.~A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.~Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm."
2514606|NCT02799433|Experimental|Usual services + HAP|This group of child care centers receives all the standard services plus invitation to participate in the voluntary Healthy Apple Program (HAP). The Healthy Apple program involves child care provider self-assessment, followed by an iterative process of goal setting, technical assistance/training, and re-assessment.
2549849|NCT02566226|Placebo Comparator|Bupivacaine with normal saline|
2514275|NCT02801734|No Intervention|Control|For all participants, whether in intervention or control, usual care is provided - the primary oncologist may make a referral for palliative care input if deemed appropriate.
2514298|NCT02801539|Experimental|Respiratory muscle training (RMT)|Subjects in the experimental arm will be given an inspiratory and expiratory RMT device to use during Duke-based and home-based RMT therapy.
2514301|NCT02801539|Sham Comparator|Sham-RMT|Subjects in control arm will be given an inspiratory and expiratory sham-device and will complete Duke-based and home-based sham-RMT therapy.
3197842|NCT00864734|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3197843|NCT00864747|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
2514474|NCT02800421||no organ damage|no evidence of HLI and CI-AKI
2514478|NCT02800421||CI-AKI only|CI-AKI, but no HLI
2514488|NCT02800421||HLI only|HLI, but no CI-AKI
2514491|NCT02800421||combined CI-AKI and HLI|Both CI-AKI and HLI
2514555|NCT02800265|Experimental|Avmacol during week 2 for 3 days|"Buccal cells line the inner cheek, and will be collected from the inner right cheek with a cytobrush (a q-tip like swab) by a trained investigator.~During the second week the participant will take 8 Avmacol tablets every evening for 3 evenings (Day 2, 3, 4), and record the time of each dose in the provided diary. Research blood collection: on days 1 and 5. Overnight urine collection."
2514583|NCT02799537|Experimental|Intervention|Participants in the intervention arm complete the Stanford letter advance directive
2514585|NCT02799537|Active Comparator|Control|Participants in the control arm complete the California state traditional advance directive
2514619|NCT02799173|Experimental|Systemic lupus erythematosus|RANKL/OPG ratio bone densitometry fan beam CT scan Doppler ultrasound
2514653|NCT02798939||cirrhotic patients|
2514965|NCT02796898|Experimental|Treated Group|"SM88 is a combination therapy consisting of 4 agents. One agent, the tyrosine isomer will be increased in each of 2 dose cohorts as follows:~Cohort 1:~Tyrosine isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd~Cohort 2:~Cohort 2 has increasing tyrosine isomer from q.d. to b.i.d.~Expansion Cohort:~The optimum dose will be expanded in 2nd stage of the study to 30 subjects."
2515024|NCT02796456||Normal weight women|BMI between 18.5 and 25 kg/m2 and without gestational diabetes
2515029|NCT02796456||Obese women without gestational diabetes|BMI more than 30 kg/m2 and without gestational diabetes
2515032|NCT02796456||Obese women with gestational diabetes|BMI more than 30 kg/m2 and with gestational diabetes
2515073|NCT02796196||Supportive care (monitoring device, medical chart review)|Data including demographics, type of HCT (e.g., allogeneic or autologous), preexisting physical conditions (e.g., chronic joint injury), CRF, steroid use data, ECOG and KPS scores are collected from patients' medical charts at time of enrollment. Patients are prescribed participation in a primarily self-directed physical activity program which encourages them to spend 6 hours out of bed daily and to perform 30 minutes of light-to-moderate daily aerobic activity. Patients who are able to maintain independent mobility undergo physical therapist assessment 2 times a week until hospital discharge. Patients wear a physical activity monitoring device and daily activity and sleep data are collected continuously during hospital LOS.
2515194|NCT02795481||Stroke patients|Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
2515197|NCT02795481||Control patients|50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
2515199|NCT02795481||Feeding control participants|15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
2515200|NCT02795481||Spasticity sub-group controls|10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
2515201|NCT02795481||Traumatic brain injury patients|10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.
2515225|NCT02795143|Experimental|Isotretinoin|"Isotretinoin will be given at the following dosage:~Dosing will be as listed on the table below.~Weight in Kg Total Daily Dose 40-49 Kg 40mg 50-89 Kg 80mg 90-150 Kg 120mg"
2515231|NCT02795143|Placebo Comparator|Placebo|Subjects will be given placebo capsules twice a day.
2515278|NCT02794896|Experimental|Deep Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a interscalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS 45 (group 1, deep anesthesia). Anesthesia depth was measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes below or equal to a BIS level of 45 were counted.
2515292|NCT02794896|Experimental|Shallow Anesthesia|Standard anesthesia with fentanyl, propofol for shoulder surgery together with a inter scalene plexus block was performed. The anesthesiologist only was informed about the group allocation by the study director and tried to control best for maintenance on target anesthesia level BIS ≥ 55 (group 2, shallow anesthesia). Anesthesia depth as measured by BIS monitors (BIS Vista, Aspect) for every minute and the minutes above a BIS level of 45 were counted.
2515352|NCT02794519|Experimental|Sirukumab 50 mg/mL administered subcutaneously every 4 weeks|Subjects will receive sirukumab 50 milligram/milliliter (mg/mL) subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Sirukumab will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
2515699|NCT02792075||gray scale IVUS|Patients with gray-scale IVUS(Intravascular ultrasound)
2514294|NCT02801552|Experimental|Regenerative Endodontic Procedure + PRF|Visit 1: root canal dressing with triple antibiotic paste. Visit 2: a 5 ml sample of whole blood was drawn intravenously from the patient's forearm. The blood sample is centrifuged at 400 g for 10 min. The prepared PRF membrane is cut into segments, the fragments are placed into the canal space. The coronal is sealed mineral trioxide aggregate and composite resin.
2514295|NCT02801552|No Intervention|Regenerative Endodontic Procedure|Regenerative Endodontic Procedure Visit 1: root canal dressing with triple antibiotic paste. Visit 2: Blood clot formation is induced in the root canal after disinfection. No PRF was used in this group. Then the canal access is sealed with mineral trioxide aggregate and composite resin.
2514346|NCT02801279|Experimental|Kinect-based bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
2514348|NCT02801279|Experimental|Conventional bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
2514409|NCT02800954|Experimental|multiple myeloma group|case group = patients with multiple myeloma
2514421|NCT02800954|Experimental|MGUS group|monoclonal gammopathy of undetermined significance
2514427|NCT02800954|Other|healthy control group|control group = healthy subjects
2514483|NCT02800473|Other|Experimental|"Patients with a suspicion of a bladder cancer or suspected recurrence of bladder cancer will have a cystoscopy under their care.~Patients will be randomized to know the order of carrying out cystoscopy with one or the other medical devices.~24 hours and 48 hours after the exam, a nurse will contact the patient to detect potential adverse effects"
2514547|NCT02800135|Experimental|Furosemide stress test|
2514591|NCT02799563|Experimental|Cohort A: Coach, Preselected number of cases|Cohort A completed the DKA simulator cases during two one-hour coached sessions. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
2514593|NCT02799563|Experimental|Cohort B: Coach, Self-selected number of cases|Cohort B completed the DKA simulator cases during two one-hour coached sessions. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
2514600|NCT02799563|Experimental|Cohort C: No coach, Preselected number of cases|Cohort C completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a pre-selected number of DKA simulator cases (2 cases with 2 reps each, for 4 reps in total).
2514605|NCT02799563|Experimental|Cohort D: No coach, Self-selected number of cases|Cohort D completed the DKA simulator cases in a non-coached setting, on their own time. They were assigned a self-selected number of DKA simulator cases and were instructed to complete as many cases until they felt comfortable with DKA management.
3197844|NCT00864747|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
3197845|NCT00864760|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
3197846|NCT00864760|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
2514834|NCT02797665|Active Comparator|Steroids group|The patients will be treated with oral corticosteroids (prednisone 0.6mg/kg/d) alone.
2514838|NCT02797665|Active Comparator|Stent group|The patients will be treated with oral corticosteroids and biliary stent.
2514894|NCT02797405|Other|Standard treatment|The patients will receive standard treatment according to international recommendations depending on their type of cancer.
2514977|NCT02796976|No Intervention|healthy older active|only cross-sectional
2514980|NCT02796976|No Intervention|healthy older sedentary|only cross-sectional
2514984|NCT02796976|Active Comparator|older sedentary at risk|cross-sectional and training or control condition
2515049|NCT02796521|Other|control group|The control group will receive usual dietary counseling for enrichment.
2515055|NCT02796521|Other|workshop group|The workshop group will have informations about interest of foods. They will enrich a meal with foods which can easily be added without cooking.
2515095|NCT02796105|Experimental|Progevera|Progevera 10 mg
2515099|NCT02796105|Active Comparator|Orgalutran|Orgalutran 0.25 mg
3197847|NCT00864786|Experimental|Cohort 1|200 mcg
3164330|NCT00496613||1|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with a combination of chemotherapy and hormonal therapy, matched on age and education
3197848|NCT00864786|Experimental|Cohort 2|600 mcg
3197849|NCT00864786|Experimental|Cohort 3|1000 mcg
2515347|NCT02794662|Experimental|Oxygen Environment|Blended oxygen delivered by servo-controlled incubator
2515356|NCT02794662|Active Comparator|Nasal cannula oxygen|Blended oxygen delivered by nasal cannula
2515408|NCT02794194|No Intervention|Control group|No intervention
2515415|NCT02794194|Experimental|Vibration group|Proprioceptive training on a whole body vibration platform. Participants in the Vibration group trained with a BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
2515418|NCT02794194|Experimental|Non-vibration group|Proprioceptive training with the BOSU® on the floor. Participants in the Non-Vibration group trained with a BOSU® on the floor.
2515494|NCT02793726||Symptomatic|Patients with pain and or other sign of prothesis failure
2515497|NCT02793726||Asymptomatic|Patients with regular clinical and radiographic evolution of the implant. No pain
2515511|NCT02793284|Experimental|Intervention 18F-DCFPyL PET/CT|18F-DCFPyL PET/CT scan obtained at the time of restaging for biochemical recurrence after primary radiotherapy
2515558|NCT02793167|No Intervention|Usual care|patients will receive standard clinical care by the doctor in charge.
2515559|NCT02793167|Experimental|AKI alert|an AKI alert will send to the the doctor in charge.Our team of nephrologists would give suggestions if the doctor in charge issue consultation application.
2515583|NCT02792816||Kawthaung Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Kawthaung is one of the sentinel site and located at the Southern Myanmar.
3197850|NCT00864786|Experimental|Cohort 4|Dose to be decided
3197851|NCT00864786|Experimental|Cohort 5|Dose to be decided
2514339|NCT02801435|Placebo Comparator|Cohort 1-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514340|NCT02801435|Experimental|Cohort 2-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514341|NCT02801435|Placebo Comparator|Cohort 2-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514342|NCT02801435|Experimental|Cohort 3-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514343|NCT02801435|Placebo Comparator|Cohort 3-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514344|NCT02801435|Experimental|Cohort 4-Experimental|8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514347|NCT02801435|Placebo Comparator|Cohort 4-Placebo|2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.
2514407|NCT02800902|Placebo Comparator|group 1|Scaling and root planing (SRP) followed by placebo gel local drug delivery
2514419|NCT02800902|Active Comparator|group 2|SRP followed by 1.2% rosuvastatin (RSV) gel
2514424|NCT02800902|Active Comparator|group 3|SRP followed by 1.2% Atorvastatin (ATV) gel
2514503|NCT02800486|Experimental|Intra-arterial Cetuximab with Re-Irradiation|Mannitol 20% 12.5ml over two minutes for blood brain barrier (BBB) disruption followed by Cetuximab administered intra-arterially for three doses at a dose of 250 mg/m2 combined with hypofractionated re-irradiation
2514542|NCT02800005|Other|BMI group (Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese. Investigators declare that there exists no conflicts of interest.
2514546|NCT02800005|Experimental|AFA group(Successive patients)|All successive patients meeting the including criteria and signed the informed consent will be measured BMI and the data will be recorded in the prospective database. The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit. No contrast agent is needed. Patients in the AFA group will be also measured by BMI. Investigators declare that there exists no conflicts of interest.
2514624|NCT02798991|Experimental|10 mg of GSK3179106 QD-Cohort 1|Eligible six subjects will receive 10 mg oral dose once daily for 14 days
2514627|NCT02798991|Experimental|50 mg of GSK3179106 QD-Cohort 2|Eligible six subjects will receive 50 mg oral dose once daily for 14 days
2514628|NCT02798991|Experimental|200 mg of GSK3179106 QD-Cohort 3|Eligible six subjects will receive 200 mg oral dose once daily for 14 days
2514630|NCT02798991|Experimental|400 mg of GSK3179106 QD-Cohort 4|Eligible six subjects will receive 400 mg oral dose once daily for 14 days
2514631|NCT02798991|Experimental|25 mg of GSK3179106 BID-Cohort 5|Eligible six subjects will receive 25 mg oral dose twice daily for 14 days
2514635|NCT02798991|Experimental|200 mg of GSK3179106 BID-Cohort 6|Eligible six subjects will receive 200 mg oral dose twice daily for 14 days
2514640|NCT02798991|Placebo Comparator|Matching placebo QD-Cohort 1, 2, 3, 4|Eligible two subjects, per cohort, will receive oral dose of matched placebo once daily for 14 days
2514643|NCT02798991|Placebo Comparator|Matching placebo BID-Cohort 5, 6|Eligible two subjects, per cohort, will receive oral dose of matched placebo twice daily for 14 days
2514704|NCT02798692|Active Comparator|Low dose HB-101 group|Intervention:Three administrations of a low dose of HB-101
2514705|NCT02798692|Active Comparator|Medium dose HB-101 group|Intervention:Three administrations of a middle dose of HB-101.
2514707|NCT02798692|Active Comparator|High dose HB101 group|Intervention:Three administrations of a high dose of HB-101.
2514708|NCT02798692|Placebo Comparator|Placebo group|Intervention:Three administrations of placebo (diluent)
2514828|NCT02797847|Active Comparator|ALN-TTRSC02|
2514830|NCT02797847|Placebo Comparator|Sterile normal saline 0.9% for SC administration|
2514932|NCT02797483|Experimental|Test Fat Blue|16 weeks interventions
2514934|NCT02797483|Experimental|Test Fat Green|16 weeks interventions
2514936|NCT02797483|Experimental|Test Fat Red|16 weeks interventions
2514963|NCT02796781|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected into lung via fiberoptic bronchoscopy.
2515012|NCT02796638|Experimental|Minute Ventilation Adaptive Servo-Ventilation plus SOC|Patients in this arm will be instructed to use the adaptive servo-ventilation (ASV) device for up to five days of inpatient stay while in the hospital. Patients are encouraged to use the device during any and all hours of sleep, and as needed during waking hours. Apart from this treatment, no other interventions will be administered, and the patient's standard of care will not otherwise be altered for the purposes of the study.Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
2515017|NCT02796638|No Intervention|Standard of Care (SOC)|Patients in this arm will not have their standard of care as dictated by their provider altered in any way. Two 6-mL tubes of blood will be drawn once daily for up to 5 days, and daily questionnaires will be administered regarding sleep and health quality.
2515746|NCT02791867|Active Comparator|Active|AphoelineBrake administration
2514417|NCT02800785|Active Comparator|Antibiotics Therapy Arm|Patients in the antibiotics (abx) arm will receive a total of 10 days of abx, with a minimum of 24 hours using an IV abx formulation (administered in q8, q12, or q24 hour regimens with or without concurrent oral abx) followed by oral abx for the remainder of the 10 days. Patients will be offered a treatment regimen of abx based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. Any of the IV abx options (Single antibiotic-Cefoxitin, Ertapenem, Moxifloxicin, Tigecycline, Ticarcillin-Clavulanic Acid or Dual antibiotics-Metronidazole plus one of the following-Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, Levofloxacin) will be considered acceptable. After IV abx, a regimen of oral abx will be continued for a total treatment length of 10 days.
2514425|NCT02800785|Active Comparator|Appendectomy Arm|Patients in the appendectomy arm will have an appendectomy performed by an open or laparoscopic approach, depending on patient and surgeon preference. Prior to their operation, patients in this arm will receive one dose of antibiotics per currently accepted standards when appendicitis diagnosis is confirmed. Patients may also receive preoperative antibiotics per hospital standards for surgical infection prevention bundle.
2514447|NCT02800434|Experimental|hand allograft|
2514506|NCT02800369|Experimental|ZFN-603 and ZFN-758|Subjects will receive suppository with ZFN-603 or ZFN-758
2514556|NCT02799979||Case|Echocardiographic data : 3D right ventricular imaging on 100 pulmonary hypertension patients at Baseline and after six months
2514557|NCT02799979||Control|Echocardiographic data : 3D right ventricular Imaging on 50 patients without pulmonary hypertension only at baseline
2514577|NCT02799511|Other|protein expression|
2514612|NCT02799316|Other|rheumatic disease with HBs-ag positive|• HBV core antibodies testing. • Real time PCR testing.
2514629|NCT02799017|Experimental|Intensive Phonology Treatment|"The participants in the experimental group will receive an hour of phonology treatment, an hour of group therapy, and an hour of reading. They will work on writing, generative naming during group time focusing on self-cueing with the sounds they learn during the individual session. They will be read to or read aloud depending on their level.~The participants in the experimental group will be taught all consonants and vowels over the course of 16 weeks."
2514633|NCT02799017|Active Comparator|Intensive SFA Treatment|The participants in the control group will receive an hour of individual therapy, an hour of reading and an hour of group therapy in a traditional setting. They will work on writing, generative naming during group time following the semantic feature analysis to retrieve the name.They will be read to or read aloud depending on their level.
2514684|NCT02798796|Experimental|MRI Group|MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI
2514686|NCT02798796|No Intervention|Control Group|Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.
3164331|NCT00496613||2|Breast cancer survivors (2-6 years post-treatment) who were post-menopausal at the time of diagnosis and treated with hormonal therapy only matched on age and education
3164332|NCT00496613||3|Healthy women matched on age and education
2514801|NCT02798185||Former NFL Players|120 former National Football League players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
2514802|NCT02798185||Former College Football Players|60 former college football players with and without reported cognitive, mood and behavior symptoms will be enrolled in this study.
2514805|NCT02798185||Control Group|60 asymptomatic same-age men without any history of participation in contact sports, military service, or traumatic brain injury will be enrolled in this study.
2514844|NCT02797691|Experimental|CaCBT plus Treatment As Usual|"Receiving CaCBT intervention in addition to the Treatment as usual"
2514845|NCT02797691|Active Comparator|Treatment As Usual (TAU)|Receiving Treatment as usual
2514898|NCT02797353|Experimental|Intervention Arm|Antenatal Care, Post natal care, Skilled birth attendance, recognition and referrals of complicated cases, immunization
2514900|NCT02797353|No Intervention|Control|This arm will receive the standard MNCH services as outlined in the MNCH policy of Government of Pakistan
2514937|NCT02797028|Placebo Comparator|Placebo capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. Control group taking placebo capsule
2514938|NCT02797028|Experimental|Anthocyanidins capsule|Simple hyperuricemia patients and with coronary heart disease in hospital. Double blind, randomized method. The experimental group taking anthocyanins capsule.
2514939|NCT02797028|Experimental|Allopurinol|The experimental group taking allopurinol.
2514996|NCT02796729|Experimental|dynamic glucose enhanced MRI after D-glucose injection|"IV catheter preparation: Catheter will be placed in one arm. Fasting glucose levels measured with a glucometer using a 1-2 mL sample of blood. Only participants with normal fasting blood glucose levels (70-125 mg/dL) will proceed with the study. First IV catheter will monitor blood glucose every 10 min after bolus injection until it returns to normal. Second IV catheter is placed on the opposite arm for glucose infusion and GBCA (gadobutrol) infusion.~Glucose infusion protocol: Occurs when the participant is in the MRI. Bolus injection of hospital grade 25g of 50% dextrose solution over 1 min is to increase blood glucose concentrations to about 3-4 times the normal level. Blood glucose levels should return to normal levels within 30 to 60 min.~GBCA infusion protocol: Occurs when the participant is in the MRI; approximately 20 min after glucose infusion. Standard intravenous bolus injection of 0.1mM/kg of gadobutrol (Gadovist) at an injection rate of 5 mL/sec."
2515048|NCT02796378|Active Comparator|Training+Simvastatin+Q10-placebo|Training+Simvastatin+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day and Q10-placebo.
2515140|NCT02795910|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will receive no outreach education training.
3164333|NCT00496652|Active Comparator|1|Radiotherapy (+cisplatin to stage 3+4)
3164334|NCT00496652|Experimental|2|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4) + Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
3164335|NCT00496665|Experimental|Vandetenib|Cyclophosphamide 50 mg daily, methotrexate 2.5 mg days 1-2 weekly, and daily vandetanib (zactima) in 3 dose-escalation cohorts (100mg=Cohort 1) (200mg=Cohort 2) (300mg=Cohort3)
2514480|NCT02800681||Schizotypal disorder|"Expert panel evaluation for identification of participants with typical symptoms~Semi-structured psychopathological interviews for general psychopathology, psychopathology within the schizophrenia spectrum, and psychopathology within the autism spectrum~Self-administered rating scales for assessment of autistic traits, schizotypal personality and subjective psychological well-being~Other general interviewer ratings for assessing functioning and severity of psychopathology"
2514549|NCT02799992|Active Comparator|Half Dose Photodynamic Therapy|Half Dose Photodynamic Therapy The safety enhanced PDT protocol for CSC was performed using half the normal dose of verteporfin (Visudyne, Novartis Pharma, Switzerland), which is 3 mg/m2 verteporfin
2514553|NCT02799992|Experimental|689 nm Laser Treatment|A 689 nm laser treatment delivering 95 J/cm2 by application of an intensity of 805 mW/cm2 over 118 seconds was performed. No verteporfin or other drugs were administered to the patients.
2514571|NCT02799628|Active Comparator|intervention|"Give the physical therapy of low back pain educational video + therapist introduction and recommendation video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
2514572|NCT02799628|Placebo Comparator|placebo|"Give the physical therapy of low back pain educational video, at the first time of clinic visit.~Physical therapy with hot packing + interference current therapy + pelvic traction + therapeutic exercise, 3 times per week for 4 weeks."
3197852|NCT00864799|Active Comparator|Vaginal misoprostol|"Women allocated to the vaginal misoprostol management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 4 hours by 400 mcg vaginal misoprostol, the latter repeated every 4 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
2514732|NCT02798484|Experimental|Breast cancer|Patients diagnosed with breast cancer and placed under neo-adjuvant treatment (hormonotherapy, chemotherapy) within the CHU Brugmann hospital.
2514782|NCT02798198||Diabetes group|37 T2DM adults (diabetes group) without DKD
2514785|NCT02798198||Control group|33 healthy adults (control group)
2514862|NCT02797795|Experimental|NEV801|"Part A - Dose escalation and de-escalation for the determination of the Maximum tolerated dose. All subjects will receive NEV801 intravenously on days 1, 8, 15 and 22 during each 28-day cycle.~Part B - Subjects will receive NEV801 at or below the highest tolerable dose from Part A."
2515110|NCT02795988|Experimental|Phase 1b|10, 30, 50μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine
2515113|NCT02795988|Experimental|Phase 2 - IMU 131 plus chemotherapy|50 μg IMU-131 plus Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
2515116|NCT02795988|Experimental|Phase 2 - Chemotherapy only|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and Capecitabine.
2515174|NCT02795533||Clinical follow-up|As part of the regular follow-up of aSAH patients at Oslo University Hospital patients with as aSAH in 2011-2012 will be invited to a clinical interview, medical examination and neuropsychological test. Patients will also be asked to answer Quality of Life Questionnaires.
2515248|NCT02795403|Experimental|Viraemic|
2515253|NCT02795403|Experimental|responder group|
2515280|NCT02794909|Experimental|CPUS group|The group of patients in the CPUS group will be those who receive a cardiopulmonary ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has received specific training in the CPUS protocol.
2515285|NCT02794909|No Intervention|Control group|The group of patients in the control group will be those who do not receive an ultrasound exam in accordance with a specified CPUS scanning protocol in addition to their routine care. Patients will be in this group if their treating physician has not received specific training in the CPUS protocol.
2515323|NCT02794571|Experimental|Phase Ia Dose-Escalation Stage: Tiragolumab|Cohorts of at least 3 participants each will be treated with escalating doses of tiragolumab.
2515326|NCT02794571|Experimental|Phase Ia Dose-Expansion Stage: Tiragolumab|Participants will be treated with tiragolumab at or below the maximum tolerated dose (MTD) or maximum administered dose (MAD) in the study.
2515330|NCT02794571|Experimental|Phase Ib Q3W Dose-Escalation Stage: Tiragolumab+Atezolizumab|A minimum of 3 participants will be treated for each dose level of tiragolumab in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
2515333|NCT02794571|Experimental|Phase Ib Q3W Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 3 weeks (Q3W) with tiragolumab at or below the MTD or MAD in combination with a fixed dose of atezolizumab with tiragolumab being administered prior to atezolizumab.
2515339|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort A|In Cohort A, carboplatin or cisplatin and pemetrexed chemotherapy will be administered after atezolizumab and tiragolumab intravenous (IV) infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin and pemetrexed on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab in combination with pemetrexed on Day 1 of each 21-day cycle.
2515345|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort B|In Cohort B, carboplatin and paclitaxel chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin and paclitaxel on Day 1 of each 21-day cycle for 4 to 6 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 21-day cycle (participants enrolled under protocol version 4) or Day 1 of each 28-day cycle (participants enrolled under protocol version 5).
2515478|NCT02793609|Other|Outpatient group|After insertion of double balloon induction catheter of labor, women are discharged overnight to home. Intervention is to let patient to go home.
2515480|NCT02793609|Other|Inpatient group|After insertion of double balloon induction catheter of labor, women are observed in the prenatal ward. Intervention is to observe women in the ward.
2514513|NCT02800031|Experimental|Participants|"Level-II Transvaginal ultrasonography will be done by the principle investigator (who is unaware about the recognition pattern method) to confirm the presence of the ovarian mass and measure its size and to apply the IOTA simple rules on it (complimentary transabdominal ultrasound might be done for huge pelvi-abdominal masses originating from the ovary).~Level-III ultrasound will be done by expert ultrasound operator (who is blinded to the results of IOTA simple rules assessment of the examined mass) to classify the mass (either benign or malignant) using the pattern recognition method.~Plan of management for each patient will be based solely on the findings of pattern recognition and the patient's wishes.~Exploratory laparotomy for excision of the ovarian mass either by ovarian Cystectomy or oophorectomy.~All specimens will be examined histopathologically."
2514548|NCT02799940||Computed tomography in acute respiratory distress syndrome|The lung on computed tomography (CT) in patients with acute respiratory distress syndrome (ARDS) has revealed a heterogeneous pattern of lung injury, with areas of normal lung interspersed with altered regions: ground-glass opacification and consolidation among the most frequent. It has been performed quantitative assessments of ARDS by means of CT, thus enabling a correlation of such pathologic details with physiologic, clinical parameters and with patient outcomes. Therefore, the primary objective of the study is to determine the correlation between the extent of oxygenation (PaO2/FiO2) and the degree of consolidation (total CO) in the CT. The secondary objectives are to determine: the correlation between the driving pressure, ventilator variables and the total CO; the independent variables associated with total CO; differences in the CT with respect to the total lung-disease score (total CO plus total value of ground-glass opacification) between survivors and nonsurvivors.
2514598|NCT02799368|Experimental|CJ Plasma Solution A Injection|Before contrast media administration : CJ Plasma Solution A Injection (3mL/kg for 1 hour) After contrast media administration : CJ Plasma Solution A Injection (1.5 mL/kg/h for 4 hours)
2514602|NCT02799368|Active Comparator|CJ 0.9% Normal Saline Injection|Before contrast media administration : CJ 0.9% Normal Saline Injection (3mL/kg for 1 hour) After contrast media administration : CJ 0.9% Normal Saline Injection (1.5mL/kg/h for 4 hours)
2514644|NCT02799108|Experimental|patients|children with drug-resistant partial epilepsy, in whom preoperative assessment is indicated
2514734|NCT02798757|Experimental|Dapagliflozin|All patients will take dapagliflozin, the intervention does not refer to a drug or device but to the specific 1HNMR test spectroscopy
2514781|NCT02798172|Experimental|Alogliptin+metformin|Alogliptin (alogliptin benzoate) is the most recent DPP-4 inhibitor; it entered the market in 2006. It is a potent and highly selective DPP-4 inhibitor with oral antidiabetic activity; Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
2514784|NCT02798172|Experimental|metformin|Metformin is the most commonly prescribed first-line drug worldwide for the treatment of T2DM, it acts by decreasing both hepatic glucose production and intestinal glucose absorption, while improving insulin sensitivity, metformin as a safe and valid oral antidiabetic drug was recommended to the obese patients with a body mass index (BMI) >30 kg/m2, it has some value in reducing or preventing weight gain and changes in metabolic parameters during treatment, and it can be combinated with other antidiabetic drug
2514835|NCT02797769||Non-TNFi Biologics|Real world patients with RA with a dispensing history for non-TNFi biologics (such as abatacept or tofacitinib) will be included.
2514837|NCT02797769||TNFi Biologics|Real world patients with RA with a dispensing history for TNFi biologics will be included.
2514839|NCT02797769||Tocilizumab|Real world patients with RA with a dispensing history for tocilizumab will be included.
2514892|NCT02797418|Experimental|Cognitus and Me|Cognitus & Me is a cognitiv remediation program focused on the functions of attention and visuospatial that is to say that can move in space, to perceive objects of our environment and organize them, to mentally imagine a physically absent operation object very involved in social behavior, in order to limit the presence of behavioral disorders among children with intellectual disabilities.
2514896|NCT02797418|Active Comparator|control group|the control management that involves fine motor skills and research computer information,management control is usually done
2514940|NCT02797015|Experimental|1 mg RPC1063|1 mg RPC1063 oral capsule daily
2514944|NCT02797015|Experimental|0.5 mg RPC1063|0.5 mg RPC1063 oral capsule daily
2514995|NCT02796703|Placebo Comparator|Control Group|Dietary Supplement: Placebo 2 cc/day of placebo diluted in mother's milk (when available) or premature formula.
2514998|NCT02796703|Active Comparator|Treatment Group|"Dietary Supplement: Heat Inactivated Probiotics~1 tsp heat inactivated Biotikid powder will be diluted in 2 cc of mother's milk (when available) or premature formula."
2515034|NCT02796404|Experimental|Homebased cardiac rehabilitation program|Homebased Cardiac rehabilitation program with monitoring vest and mixed surveillance.
2515036|NCT02796404|Other|Traditional cardiac rehabilitation|Multidisciplinary program in a cardiac rehabilitation gym. Routine clinical practice
2515081|NCT02796131|Experimental|30 mg bid|30 mg of RDX5791 administered twice daily PO (60 mg total dose/day).
2515082|NCT02796131|Experimental|30 mg tid|30 mg of RDX5791 administered three times daily PO (90 mg total dose/day).
2515084|NCT02796131|Experimental|60 mg bid|60 mg of RDX5791 administered two times daily (120 mg total dose/day).
2515087|NCT02796131|Experimental|15 mg bid|15 mg of RDX5791 administered two times daily (30 mg total dose/day).
2515089|NCT02796131|Experimental|30 mg QD|30 mg of RDX5791 administered once daily (30 mg total dose/day).
2515091|NCT02796131|Experimental|Escalating dose bid|15 mg or 30 mg or 45 mg of RDX5791 administered two times daily (30, 60, or 90 mg total dose/day respectively). The stopping criteria for the dose escalation is based on Bristol Stool Score and AEs.
2515093|NCT02796131|Experimental|30 mg bid with psyllium|30 mg of RDX5791 administered two times daily (60 mg total dose/day) with psyllium taken up to three times per day (maximum of 15 g psyllium/day).
2515144|NCT02795702|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2515226|NCT02795091|Other|machine clean|clean the rag and floor towel by machine
2514530|NCT02799875|Active Comparator|Higher permissive hypercapnia|Extubation criteria: partial pressure carbon dioxide (pCO2) ≥ 60mmHg with an upper limit ≤ 75mmHg; pH ≥ 7.20; oxygen saturation (SpO2) ≥ 88% with fraction of inspired oxygen (FiO2) ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 75mmHg; pH < 7.20; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
2514533|NCT02799875|Active Comparator|Lower permissive hypercapnia|Extubation criteria: pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg; pH ≥ 7.25; SpO2 ≥ 88% with FiO2 ≤ 0.50; mean airway pressure (MAP) < 8 cm H2O, ventilator rate ≤ 20 bpm, amplitude < 2X MAP if on high frequency ventilation (HFV); hemodynamically stable (clinically acceptable blood pressure and perfusion per clinical team opinion). In addition, reintubation may occur if any of the following are met: PCO2 > 55mmHg; pH < 7.25; FiO2 ≥0.80 required to maintain SpO2 ≥ 88% for one hour; hemodynamic instability; clinically defined shock; repetitive apnea (> 1 episode per hour) requiring bag and mask ventilation; sepsis; and/or need for surgery.
2514581|NCT02799758|Experimental|NK-104-CR|NK-104-CR 8 mg tablet and Placebo (for Livalo® IR 4 mg tablet) orally once daily for 52 weeks.
2514582|NCT02799758|Active Comparator|Livalo® IR|Livalo® IR 4 mg tablet and Placebo (for NK-104-CR 8 mg tablet) orally once daily for 52 weeks.
2514656|NCT02798887|Experimental|Ridge preservation membrane|Positive control Patients will receive ridge preservation intrasocket allograft and overlay xenograft resorbable with membrane
2514658|NCT02798887|Experimental|Ridge preservation no membrane|test patients will receive ridge preservation intrasocket allograft and overlay xenograft with no membrane
2514760|NCT02798276|Experimental|AGTP-treatment|Patients in which the non-revascularizable area will be covered by the adipose graft and the revascularizable area will be treated with the normal procedure.
2514763|NCT02798276|Other|Control|Patients in with the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
2514817|NCT02797886|Experimental|FES+VOL|Electrical stimulation (FES) in concert with volitional effort. The subject is visually cued to initiate the movement and when they begin the movement (as ascertained by EMG response), the stimulation is immediately applied until the completion of the trial.
2514819|NCT02797886|Active Comparator|FES|Electrical stimulation alone. The subject is asked to do nothing as electrical stimulation initiates and completes the movement for them.
2514823|NCT02797886|Active Comparator|VOL|Volitional effort alone. When cued, the subject initiates and completes the movement on their own until the completion of the trial. There is no electrical stimulation in this group.
2514851|NCT02797509|Experimental|Psychosocial Skills-Based Intervention|Based on information from Phase I (semi-structured interviews), the investigators will develop a detailed psychosocial intervention manual. The intervention will be tailored consistent with American Heart Association (AHA) recommendations for stroke skills based interventions and will include 2 general and 4 specific modules (selected from 7 available). Generally, in the intervention, stroke patients and stroke caregivers will learn skills to cope and manage stroke-related stressors. It is anticipated that the intervention will have 6 sessions with 2 general sessions delivered within the NICU face to face and 4 tailored specific sessions to be delivered via live video using Vidyo. Participants in the intervention group will also receive treatment as usual.
2514854|NCT02797509|No Intervention|Minimally Enhanced Usual Care (MEUC)|Those in the MEUC will continue with their current care. This may include meeting with nurses, physical therapist, medical doctors, and other members of the stroke patient's medical team. Treatment as usual may also involve administration of Selective Serotonin Reuptake Inhibitors (SSRIs) to those patients with motor problems. They will also received a pamphlet with educational information on stroke and recovery
2514893|NCT02797340|Experimental|Interventional|All participants
3197853|NCT00864799|Active Comparator|Oral misoprostol|"Women allocated to the standard management protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg misoprostol orally, the latter repeated every 3-hours to a maximum of 4 oral doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
2515080|NCT02796326|Experimental|Dilatation|Patients undergoing tracheal dilatation with the study device
2515156|NCT02795845|Experimental|Primary prevention- probiotic capsules|"patients with normal vaginal flora in the experimental arm will be treated with Probiotic capsules (containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus, Bifidobacterium bifidum and B. Lactis).~one capsule twice a day until delivery."
2515157|NCT02795845|Placebo Comparator|Primary prevention - Placebo|patients with normal vaginal flora in the placebo arm will be treated with a capsule without active ingredient, one capsule twice a day until delivery.
2515158|NCT02795845|Experimental|Secondary prevention - probiotic capsules|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given probiotic capsules.
2515161|NCT02795845|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora/bacterial vaginosis or vaginal candidiasis in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if necessary) or antimycotic treatment. Once the infection was eradicated, the patient will be given placebo without active ingredient.
2515240|NCT02795325|Experimental|PH Patients|
2515249|NCT02795325|Experimental|Healthy Volunteers|
2515350|NCT02794415|Other|Community-based exercise|
2515429|NCT02794259|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2515432|NCT02794259|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2515436|NCT02794259|Sham Comparator|Sham tDCS|Sham stimulation during resting state fMRI
2514535|NCT02800096|Active Comparator|Gambling Internet intervention|The gambling only Internet intervention (G-only) will consist of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
2514536|NCT02800096|Experimental|Gambling Internet intervention + MoodGYM|The G+MH intervention condition will consist of the G-only intervention and an online intervention for depression and anxiety. The mental health intervention chosen is MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
3164336|NCT00496678|Experimental|Navigation|Navigation through the cancer care system is the intervention
3164337|NCT00496678|Active Comparator|Standard of Care|Cancer patient receives standard of care.
2514814|NCT02797743||Whole blood from all ages and gender|- Ages from 0 to Adults (18 yrs of age or older)
2514846|NCT02797587|Active Comparator|Varenicline + Nicotine Replacement Therapy placebo|Study participants will receive active varenicline and be instructed to take the medication for 12 weeks; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
2514847|NCT02797587|Placebo Comparator|Varenicline placebo + Nicotine Replacement Therapy|Study participants will receive placebo varenicline and be instructed to take the placebo medication for 12 weeks; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
2514850|NCT02797587|Active Comparator|Cytisine + Nicotine Replacement Therapy placebo|Study participants will receive active cytisine and be instructed to take the medication for 25 days; participants will also receive a placebo Nicotine Replacement Therapy mouth spray for 8 weeks.
2514855|NCT02797587|Placebo Comparator|Cytisine placebo + Nicotine Replacement Therapy|Study participants will receive placebo cytisine and be instructed to take the medication for 25 days; participants will also receive an active Nicotine Replacement Therapy mouth spray for 8 weeks.
2515102|NCT02796079|Experimental|Autologous Bone Marrow Stem Cell|Mesenchymal stem cells derived from bone marrow infusion
2515103|NCT02796079|Placebo Comparator|saline|saline injections
2515178|NCT02795754|Experimental|GSK2838232 PIB (50 mg+100 mg+200 mg)+Placebo|During Part 1A, subjects will receive QD single dose of either GSK2838232 50 mg, 100 mg or 200 mg or placebo in each of the four visits (one treatment per visit).Subjects will also receive RTV along with all the doses and QD RTV for 48hours (2 doses) before all doses of GSK2838232 and placebo.
2515181|NCT02795754|Experimental|GSK2838232 PIB+IR1+IR2|During Part 1B, subjects will receive either GSK2838232 PIB, GSK2838232 IR1 or IR2 in each of the three visits (one treatment per visit) after at least 10 hours fasting and IR1 or IR2 after fat meal at visit 4.
2515182|NCT02795754|Experimental|GSK2838232 PIB (20mg/50 mg/100 mg/200 mg)/Placebo|During Part 2, subjects will receive repeated QD doses of either GSK2838232 (20 mg, 50 mg, 100 mg or 200 mg) or placebo for 11 days. Subjects will also receive RTV along with all the doses of GSK2838232 and placebo.
2515270|NCT02795182|Other|BGB-3111 and BGB-A317|Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tiselisumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
2515447|NCT02793973|Active Comparator|80% discrepancy lift height correction|Each participant will be given 80% discrepancy shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
2515451|NCT02793973|Experimental|optimal lift height correction|Each participant will be given the optimal shoe lift height correction through analyzing kinematic performance of center mass of body and will be required to wear the lifts in their shoes when they are walking or standing for 6 month.
2515505|NCT02793635|Experimental|SCI Patients|"10 subjects with complete or incomplete SCI (> 1 year post-injury) with preserved LE function will be recruited.~No control group"
2515547|NCT02793219|Experimental|Sipuleucel-T then Docetaxel|Sipuleucel-T IV over 1-hour every 14 days for 3 doses; 28 day rest; 75 mg/m2 docetaxel IV over 1-hour every 21 days for 6 cycles
2515582|NCT02792868||patient|patient with cardiovascular risk (moderate)
3164338|NCT00496691|Experimental|1|Parent-child
3164339|NCT00496691|Active Comparator|2|Adolescent only intervention focusing on condom use skills and assertiveness training around sexual discussions
3164340|NCT00496691|Placebo Comparator|3|Health promotion intervention including general health promotion topics such as smoking, diet, exercise, etc.
3164341|NCT00496717||1|There is only one arm and all patients will have their aortic calcium scoring by CT scan.
3164342|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin/docetaxel sequential, i.e. one arm study with Epirubicin 4 cycles 60 mg/m2 q2w, followed by docetaxel 4 cycles, 100 mg/m2 q2w. Each course with pegfilgrastim.
3164343|NCT00496847|Experimental|Drug Group|PERIOGEN
3164344|NCT00496847|Active Comparator|Control group|Beta TCP alone
3164345|NCT00496899||1|Women in active labor
3164346|NCT00496938|Other|1|Observational cohort using an all-comers design
3164347|NCT00496990|Active Comparator|control|Participants in this group receive the opportunity to attend a support group
3164348|NCT00496990|Experimental|Enhanced care|Participants in this arm receive the opportunity to have detoxification or methadone treatment as well as receive vouchers contingent upon drug free urine samples and individualized counseling
3164349|NCT00497068|Experimental|tobacco abstinent contingent voucher|Tobacco abstinent contingent voucher condition
3164350|NCT00497068|Experimental|non-contingent|Participants receive vouchers non-contingent upon tobacco use status
3164351|NCT00497068|Other|no voucher|This is the standard care intervention
3164352|NCT00497094|Active Comparator|1|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations. Additionally patients will undergo carotid artery stenting using a filter wire protection device.
2514538|NCT02800122||Patients with acute dyspnea|"Patients with acute dyspnea treated by a medical team of emergencies of CHRU of Nancy.~All patients admitted to the emergencies in the last 5 years matching the inclusion criteria will be evaluated. About 4,000 patients will be affected, including more than 800 patients with acute heart failure. (Figures based on export of ICD X codes (R06.0: Dyspnea) of patients cared in extra-hospital for acute dyspnea (diagnosis Dyspnea + Heart Failure) over the last 5 years)."
2514580|NCT02799693||Recurrent VT failing RF ablation|Patients undergoing intramural needle catheter ablation of recurrent monomorphic ventricular tachycardia who have failed prior attempted radiofrequency catheter ablation.
2514622|NCT02799238|Active Comparator|Radiotherapy in combination with Temozolomide (TMZ)|radiotherapy combined with TMZ treatment followed by adjuvant TMZ
2514623|NCT02799238|Experimental|ALECSAT + Radiotherapy in combination with TMZ|3 doses of ALECSAT /4 weeks followed by ALECSAT every 3 months
2514726|NCT02798510|Experimental|Arm 1|Patients in arm 1 will receive adjuvant chemotherapy followed by concurrent chemoradiotherapy. Patients will receive four cycles of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days followed by concurrent capecitabine (1,330mg/m2 per day) and radiotherapy (50.4Gy/28fx to regional lymphatics with or without tumor bed)
2514733|NCT02798510|Active Comparator|Arm 2|Patients in arm 2 will receive six cycles chemotherapy of gemcitabine (1,000mg/m2 intravenously on days 1 and 8) and capecitabine (1,500mg/m2 per day on days 1 to 14) every 21 days
2514799|NCT02798068|Active Comparator|Solu - Medrol|Solu - Medrol (methylprednisolone sodium succinate) 500mg IV once single administration
2514800|NCT02798068|Placebo Comparator|Placebo|NaCl 0,9% 100ml IV once single administration
2514848|NCT02797639|Experimental|Co-PID|Eight collaborative consultation meetings between occupational therapist to each teacher in purpose of enhancing participation of students in class
2514852|NCT02797639|Active Comparator|In-service|Three in- service meetings to all homeroom teachers together, in purpose of enhancing participation of students in class
2514969|NCT02796885||Possible hypophosphatasia|Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2514973|NCT02796885||Normal|Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2514976|NCT02796885||Known hypophosphatasia|Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
2515044|NCT02796482|Other|EnergieShake 1.5 kcal Complete Intervention|Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
2515076|NCT02796183|Other|Diabetic macular edema|Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
2515254|NCT02795377||male subjects with arterial hypertension|Measurements will be taken at baseline.
2515255|NCT02795377||male subjects without arterial hypertension and no CAD|Measurements will be taken at baseline.
2515257|NCT02795377||male subjects with hypertensive crises|Measurements will be taken before and after 4 hours and normalization of arterial blood pressure by urapidil.
2515259|NCT02795377||male subjects with stable CAD|Measurements will be taken before and after transfemoral coronary diagnostic angiography.
2515448|NCT02793908|Experimental|Pleyris|Subcutaneous progesterone will be administered 25 mg a day from the day following the ovulation for 14 days
2515453|NCT02793908|Active Comparator|Crinone8|Vaginal progesterone will be administered 90 mg a day from the day following the ovulation for 14 days
2515508|NCT02793531|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2515509|NCT02793531|Experimental|Cancer subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
3164353|NCT00497094|No Intervention|2|Patients receive medical treatment including medical therapy with statins (at least 40mg simvastatin daily irrespective of the baseline cholesterol level) and clopidogrel (75mg daily). Further conservative medical treatment includes modification of cardiovascular risk factors according to current recommendations
3164354|NCT00497107|Active Comparator|1|The Control Group (UFT + Calcium Folinate)
3164355|NCT00497107|Experimental|2|The PSK Group (UFT + Calcium Folinate + PSK)
3164356|NCT00497159|Placebo Comparator|1|Placebo
3164357|NCT00497159|Experimental|2|Dimebon
3164358|NCT00497172|Experimental|1|drug-eluting stent
3164359|NCT00497172|Active Comparator|2|bare-metal stent
3164360|NCT00497185|Other|A|Mindfulness-Based Cognitive Therapy
3164361|NCT00497185|No Intervention|B|Shared care: Treatment as usual augmented by psychiatric consultation intervention to optimise treatment in the present health care system.
3164362|NCT00497224|Experimental|Erlotinib|Eligible patients will receive erlotinib 150mg PO daily, with dose escalation occurring as tolerated.
3164363|NCT00497237|Experimental|1|Foster
3164364|NCT00497237|Active Comparator|2|Seretide
3173716|NCT00615186|Active Comparator|B|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
2514589|NCT02799706|Experimental|GnRH antagonist + radiation therapy (RT)|"As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT) +a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy.~Each institution has to adhere to the chosen duration of treatment for all patients throughout the study"
2514669|NCT02798900|Experimental|Functional task-training and Ultrasound|This group will receive 16 sessions of functional task-training program and therapeutic ultrasound will be applied prior to functional task-training.
2514674|NCT02798900|Active Comparator|Functional task-training|This group will receive 16 sessions of functional task-training program.
2514721|NCT02798562|Experimental|Native and dynamic contrast-enhanced CT|Patients will undergo a native high-resolution and a dynamic contrast-enhanced CT, both sides respectively.
3164365|NCT00497250|Other|1|Thoracic RT for patients will start from 54Gy, and then escalate dose at 2Gy increment to 60Gy. At each dose level, 8 patients are required to complete RT without dose limiting toxicity(DLT). Evaluation will be done after 8 patients have completed the treatment.If there are >=2 DLT in the first 8 patients, the maximum tolerated dose (MTD) is achieved. If there is a single DLT revealed, an additional 8 patients will be recruited to that dose level. Should there be severe complication occurred again be at least 1 more DLT, then MTD is thought to be achieved.Hence,MTD will be achieved if at least 2 out of the first 8 patients have a DLT,or if a further 8 patents are recruited, >=2 out of 16 patients have a DLT. Concurrent with RT, patients will be given gefitinib 250 mg/day PO as well as same dose PO for 60 days after the completion of RT.
3164366|NCT00497276|Experimental|I|Ultrasound guided placement of popliteal catheter
3164367|NCT00497276|Experimental|II|Nerve stimulation guided placement of popliteal catheter
2514925|NCT02797184|Experimental|Aim 1. KNO3 dose response|Intervention: Subjects with heart failure will receive a single oral dose of potassium nitrate (10 or 20 mmol KNO3) in 2 gelatin capsules during dose visit 1 and the other dose (10 or 20 mmol KNO3) during dose visit 2. The dose order will be randomized.
2514958|NCT02796820|Experimental|Huaier Granule|Huaier Granule will be administrated from 4 to 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
2514959|NCT02796820|No Intervention|Regular follow-up observation|Regular follow-up observation after surgery.
2515260|NCT02795416|Experimental|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
2515282|NCT02794818||Participating Patients|Participating patients will receive a prescription for weekly CSA produce boxes with nutritional education
2515290|NCT02794818||Participating Providers|Participating providers will be surveyed at the end of the pilot to evaluate their perceived program efficacy, the benefit of the program to their patients, and elicit program feedback.
2515354|NCT02794623|Experimental|Cochlear Implant Recipients|
2515392|NCT02794272|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2515393|NCT02794272|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2515394|NCT02794272|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
2515445|NCT02793843|Active Comparator|Ondansetron|
2515450|NCT02793843|Experimental|Ondansetron+ dexamethasone|
2515490|NCT02793544|Active Comparator|Regimen A (RIC: Flu/Cy/TBI)|"Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5~Total Body Irradiation (TBI) 200cGy on Day -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2515491|NCT02793544|Active Comparator|Regimen B 2a (FIC: Bu/Cy)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Cyclophosphamide 50mg/kg/day IV on Days -2,-1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2515492|NCT02793544|Active Comparator|Regimen B 2b (FIC: Bu/Flu)|"Busulfan ≥ 9mg/kg total dose on Days -6, -5, -4, -3 (IV or PO)~Fludarabine 30 mg/m2/day IV on Days -6, -5, -4, -3, -2~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
2515493|NCT02793544|Active Comparator|Regimen C (FIC: Cy/TBI)|"Cyclophosphamide 50mg/kg/day IV on Days -5,-4~Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1~Infusion of non-T-cell depleted bone marrow on Day 0~Although a schedule is proposed above, the regimen can be given according to institutional standards as long as the prescribed doses are the same as in the recommended regimen above."
3164368|NCT00497302|Experimental|1|receives housing based on drug abstinence
3164369|NCT00497302|Active Comparator|2|Usual care treatment at the Center for Addiction and Pregnancy
3164370|NCT00497315|Experimental|A|pemetrexed + cisplatin (3 cycles) followed by thoracic irradiation + pemetrexed
3164371|NCT00497315|Experimental|B|thoracic irradiation + pemetrexed followed by pemetrexed + cisplatin
3164372|NCT00497328|Other|N-acetylcysteine Group (NAC)|"N-acetylcysteine Group (NAC)~Intravenous infusion 154mEq/L of sodium chloride (0.9% normal saline) at a rate of 1mL/kg/hour from 12 hours before till 6 hours after cardiac catheterization Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses)"
3164373|NCT00497328|Other|Sodium Bicarbonate Group (SOB)|"Sodium Bicarbonate Group (SOB)~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 3 mL/kg/hour for 1 hour immediately before radiocontrast injection. For patients weighing more than 110 kg, the initial fluid bolus and drip will be limited to those doses administered to a patient weighing 110 kg.~Intravenous infusion154meq/L sodium bicarbonate in 5% dextrose in water at a rate of 1 mL/kg/hour during the contrast exposure and for 6 hours after the procedure"
3173717|NCT00615212|Active Comparator|Subjects receiving midazolam|Eligible subjects will receive midazolam oral syrup with a dose of 5 milligrams on Day 1.
2514731|NCT02798406|Experimental|DNX-2401 + pembrolizumab|Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.
2514804|NCT02797964|Experimental|Open label|
2514861|NCT02797600||ARM I|Woman residing in Appalachian counties who have prevalent invasive cervical cancer. Invasive cervical cancer cases participants will include women previously and currently treated for ICC during the past 10 years. Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. Biological samples will be collected during a scheduled visit with the research staff.
2514863|NCT02797600||ARM II|Woman residing in Appalachian counties who are newly diagnosed with invasive cervical cancer(ICC). Newly diagnosed with ICC, and currently being treated for ICC. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected during a scheduled clinic visit.
2514864|NCT02797600||ARM III|Healthy controls (women without a diagnosis of any type of cancer. Healthy controls will be women who are coming into one of the participating clinic or physician practice for a routine Pap test. Questionnaires will be used to obtain Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. All biological samples will be collected at the time of the clinical Pap smear.
2514922|NCT02797210|Experimental|Sham then Active Stimulation|Sham repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then active rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
2514927|NCT02797210|Experimental|Active then Sham Stimulation|Active repetitive transcranial magnetic stimulation (rTMS) to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks, then sham rTMS to right orbitofrontal cortex, twice daily, 5 days per week for 3 weeks
2514990|NCT02796859|Active Comparator|Treatment Group|Subjects in the siltuximab group will receive an 11 mg/kg infusion at baseline, and weeks 3 and 6, as per the recommended dosing for multicentric Castleman's disease
2514991|NCT02796859|Placebo Comparator|Control Group|Subjects in the placebo group will receive an infusion of normal saline (with the same packaging and volume as the siltuximab group) at baseline, and weeks 3 and 6.
2515050|NCT02796365|Experimental|Exercise|Patients will participate in a 10 week outpatient cardiac rehabilitation program. Exercise will consist of 3 days per week of interval training on a treadmill or bike at an intensity between 50-90% of heart rate reserve. Additionally patients will perform resistance exercises 1-2 days per week and attend 8 nutrition and lifestyle classes.
2515054|NCT02796365|No Intervention|Usual care|Control group will not be instructed on exercise, but encouraged to follow standard medical advice.
2515117|NCT02796118|Experimental|ASP2151 Low dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2515119|NCT02796118|Experimental|ASP2151 High dose in non-elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2515121|NCT02796118|Experimental|ASP2151 Low dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2515123|NCT02796118|Experimental|ASP2151 High dose in elderly subjects group|Subjects will receive ASP2151 daily on Days 1 to 7.
2515126|NCT02796118|Placebo Comparator|Placebo in non-elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
2515131|NCT02796118|Placebo Comparator|Placebo in elderly subjects group|Subjects will receive matching placebo daily on Days 1 to 7.
2515160|NCT02795611|Experimental|Treatment group|Patients who receive 'family-centered occupational therapy' in our hospital
2515169|NCT02795611|Active Comparator|Control group 1|Patients who receive regular occupational therapy in our hospital
2515170|NCT02795611|Other|Control group 2|Patients who don't receive intervention in our hospital
2515222|NCT02795299|Active Comparator|Gerilimzumab 5/2 mg/Methotrexate/folate|• 5 mg gerilimzumab loading dose followed by 2 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2515224|NCT02795299|Active Comparator|Gerilimzumab 10/5mg/Methotrexate/folate|• 10 mg gerilimzumab loading dose followed by 5 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2515230|NCT02795299|Active Comparator|Gerilimzumab 20/10mg/Methotrexate/folate|• 20 mg gerilimzumab loading dose followed by 10 mg gerilimzumab every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2515237|NCT02795299|Placebo Comparator|Placebo/Methotrexate/folate|• Placebo every 8 weeks + 15-25 mg Methotrexate every week + 1 mg folic acid once daily
2515307|NCT02794779|Experimental|Rule of three|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
2515311|NCT02794779|Active Comparator|Continuous infusion|Continuous infusion of variable rate if 0,4 UI of oxytocin until obstetrician determines that uterine tone is adequate.
2515322|NCT02794454|Active Comparator|HeezOn Ultra-1|HeezOn Ultra-1 includes ingredients like Shilajit, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
2515325|NCT02794454|Active Comparator|HeezOn Ultra-2|HeezOn Ultra-2 includes ingredients like Arjuna, Galangal, Fenugreek. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
2515329|NCT02794454|Placebo Comparator|Placebo|Placebo consists of Micro-crystalline Cellulose. Dose: 2 capsules daily half an hour before dinner to be taken orally for 21 days.
3173718|NCT00615212|Active Comparator|Subjects receiving rosiglitazone|Eligible subjects will receive rosiglitazone oral tablet with a dose of 4 milligrams on Day 2.
3173719|NCT00615212|Active Comparator|Subjects receiving flurbiprofen|Eligible subjects will receive flurbiprofen oral tablet with a dose of 50 milligrams on Day
3173720|NCT00615212|Experimental|Subjects receiving GSK376501|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams from Day 4 to Day 10.
2514618|NCT02799121|Experimental|ReGenerCell™|Debridement and/or a sterile saline rinse of ulcer, as clinically indicated, followed by ReGenerCell™ treatment and appropriate dressing and off-loading
2514665|NCT02798965|Other|Control|patients with goiter or nodule
2514666|NCT02798965|Experimental|Graves' disease|patients with Graves' disease
2514694|NCT02798653|Experimental|Choriomon®|subjects receive 1,500 IU of hCG (Choriomon®; IBSA) intramuscular (IM) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
2514695|NCT02798653|Experimental|Choriomon®+Endometrin ®|patients will receive 1,500 IU of hCG (Choriomon®; IBSA) (IM) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
2514696|NCT02798653|Experimental|Endometrin ®|patients will receive only Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
2514741|NCT02798419|Experimental|DFD05 Cream|DFD05 Cream
2514744|NCT02798419|Active Comparator|Active01 Cream|Active01 Cream
2514778|NCT02798029|Experimental|Treatment (FFSRT)|Patients undergo FFSRT daily over 30 minutes for 3-5 days.
2514832|NCT02797834||Patients Endometrial Fluid|"Endometrial fluid samples from healthy and fertile women in their natural cycles, with ages ranging from 18 to 35 years, normal karyotype, negative for HIV, HBV, HCV and RPR, BMI ranging from 18 to 30 Kg/m2 (both included) and regular menstrual cycle (3-4/28-30 days).~This unique assignment group will be divided into 5 subgroups attending to the moment of the menstrual cycle in which the patient could be classified: phase I (days 0-8), phase II (days 9-14), phase III (days 15-18), phase IV (days 19-24) and phase V (days 25-30)."
2514895|NCT02797431|Experimental|CYT107 high frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for 4 weeks
2514897|NCT02797431|Experimental|CYT107 low frequency|Patients will receive Interleukin-7 (CYT107 liquid solution) at 10µg/kg twice a week for the first week, followed by CYT107 and Placebo once a week for the three following weeks
2514899|NCT02797431|Placebo Comparator|Control|Patients will receive Placebo (NaCl 0.9%) twice a week for 4 weeks
2514979|NCT02796950|Experimental|Acipimox|Administration of acipimox 250 mg p.o.
2514985|NCT02796950|No Intervention|Control|No intervention.
2515042|NCT02796495|Experimental|Operation of hand prosthesis with direct nerve stimulation|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in one or two amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME-4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized Hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR/HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand~The EPIONE Psychophysical Testing Platform software for stimulator control"
2515159|NCT02795559|Other|Lean|Subjects within the range of desirable body weight (BMI<25)
2515166|NCT02795559|Other|OWO|Subjects who are overweight or obese (BMI between 25 and 40)
2515300|NCT02795000||Primary Ovarian insufficiency group|"amenorrhea one year or more than one year~amenorrhea more than 4 months and FSH≥40IU/L~≤42 years old and AMH≤0.071"
2515302|NCT02795000||The normal group|"normal regular menorrhea~≤42 years old~normal FSH and AMH level"
2515383|NCT02794493|Experimental|Arm I|Patients receive Traditional Chinese Medicine Formula LC09 by soaking their affected hand and feet 20 min twice daily.
2515386|NCT02794493|Placebo Comparator|Arm II|Patients receive placebo by soaking their affected hand and feet 20 min twice daily.
2515404|NCT02794064|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of breast and adjacent lymph nodes. Imaging time: Approximately 30 minutes
3164374|NCT00497328|Other|Combination Group (COM: NAC and SOB)|"Combination Group (COM: NAC and SOB)~Intravenous infusion of 154 meq/l sodium bicarbonate at a rate of 3ml/kg/hour for 1 hour before cardiac catheterization and 1 ml/kg/hour till 6 hours after procedure Oral NAC 1200mg dissolve in 250ml of water twice a day the day before to the day after the procedure (total 6 doses). All patients will be monitored regularly for pulmonary congestion and hemodynamics compromise hourly after PCI for 6 hours and every 4 hour thereafter for 24 hours."
3164375|NCT00497341|Experimental|1|antibiotic is given before tourniquet inflation and before tourniquet release
3164376|NCT00497341|Placebo Comparator|2|antibiotic is given before tourniquet inflation
3164377|NCT00497367|Experimental|TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent|This arm received the TAXUS® Petal™ Paclitaxel-Eluting Coronary Stent.
3164378|NCT00497380|Experimental|Arginine enriched nutrition|
3164379|NCT00497380|Placebo Comparator|Nutrition|
3164380|NCT00497393|No Intervention|Control|regular use of the 2-bed areas in the Emergency department
3164381|NCT00497445|Experimental|Angioplasty / surgery and exercise therapy|Angioplasty / surgery followed by supervised exercise therapy
3164382|NCT00497445|No Intervention|Angioplasty / surgery|Angioplasty / surgery alone
3164383|NCT00497458|Placebo Comparator|Arimidex|Arimidex 1 mg plus placebo
3164384|NCT00497458|Active Comparator|Arimidex test 40mg|Arimidex 1mg and testosterone 40mg
3164385|NCT00497458|Active Comparator|Arimidex plus test 80mg|Arimidex 1mg and testosterone 80mg
3164386|NCT00497497|Experimental|1|
3164387|NCT00497497|Experimental|2|
3164388|NCT00497523|Experimental|Beclomethasone dipropionate|
3164389|NCT00497523|Experimental|Beclomethasone dipropionate/Salbutamol combination|
3164390|NCT00497523|Active Comparator|Salbutamol|
3164391|NCT00497536|Active Comparator|1|≈ bolus protocol.
3164392|NCT00497536|Active Comparator|2|≈ CSII protocol
3164393|NCT00497536|Active Comparator|3|≈ CIII protocol.
3173721|NCT00615212|Experimental|Subjects receiving GSK376501+ midazolam|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with midazolam oral tablet of 5 milligrams on Day 11.
3173722|NCT00615212|Experimental|Subjects receiving GSK376501 + rosiglitazone|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with rosiglitazone oarl tablet of 4 milligrams on Day 12.
2514717|NCT02798393|Sham Comparator|HL-Sham|The placebo device (also referred to as the HL-SHAM device) will have an identical appearance to the HL-NIR device. Though the HL-NIR device will be applied, there will be no treatment administered.
2514718|NCT02798393|Experimental|HL-NIR|The device referred to as the HL-NIR device includes both a podiatric or foot and leg component, similar to a loose fitting boot, that is easily applied to all subjects (one size fits all). Application of the device is snug but comfortable without risk for constriction of soft tissue.
2514767|NCT02798250|Active Comparator|Dual-hormone CL with overestimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
2514768|NCT02798250|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A regular size standardized meal of 45g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 35g of carbohydrates.
2514821|NCT02797860||transabdominal cervicoisthmic cerclage|Second Stage of Labor pregnant women who are scheduled for transabdominal cervicoisthmic cerclage due to incompetent internal os of cervix
2514825|NCT02797860||control|women of childbearing age between 20 and 45
2515162|NCT02795637|Experimental|dasotraline|dasotraline 8mg capsule/day
2515266|NCT02795286|Experimental|ASIST A|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic
2515267|NCT02795286|Experimental|ASIST B|Artis Haemodialysis Machine w/ ASIST Software - Isotonic
2515268|NCT02795286|Active Comparator|Conventional HD|Artis Haemodialysis Machine w/o ASIST Software
2515401|NCT02793986|Experimental|dexmedetomidine sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h.
2515402|NCT02793986|Experimental|propofol sedation|Patients received local anesthesia, in this arm, the sedation of patients was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
2515449|NCT02793895|Experimental|Enhanced cardiac rhythm monitoring|Subjects in this group will receive up to 30 days of continuous cardiac rhythm monitoring with an adhesive monitor. Cardiac rhythm monitoring will begin on the day of randomization. The device that will be used is the Medtronic SEEQ™ mobile cardiac telemetry system or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
2515454|NCT02793895|Active Comparator|Usual care|Subjects randomized to the usual care arm will be discharged from hospital without protocol-mandated continuous cardiac rhythm monitoring. Within the first 30 days after randomization, no protocol-mandated cardiac rhythm assessment will be arranged. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device or the CardioSTAT (Icentia Inc.) cardiac rhythm monitoring device.
2515542|NCT02793479||BE|Patients presenting Barrett's Esophagus as a complication of a gastroesophageal reflux disease.
2515610|NCT02792972|Active Comparator|Acmella oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers 3 minutes before the venipuncture
2515611|NCT02792972|Placebo Comparator|alcohol 70%|70% alcohol were used in the volunteers 3 minutes before the venipuncture
3173723|NCT00615212|Experimental|Subjects receiving GSK376501 + flurbiprofen|Eligible subjects will receive GSK376501 oral tablet with a dose of 75 milligrams along with flurbiprofen oral tablet of 50 milligrams on Day 13.
3173724|NCT00615225||Brain dead patients|All patients meeting criteria for brain death
3173725|NCT00615225||Healthy control|Any healthy volunteers accepting to give some blood
3173726|NCT00615225||Volunteers having hip surgery|Patients undergoing hip surgery for degenerative non-inflammatory hip disease
3173727|NCT00615238|Experimental|Diet plus continuous bouts|diet-plus-continuous bouts of vigorous aerobic exercise
3173728|NCT00615238|Experimental|Diet plus short bouts|diet-plus-short bouts of vigorous aerobic exercise accumulated throughout the day
3173729|NCT00615238|Experimental|Diet plus moderate lifestyle activity|diet-plus-moderate intensity lifestyle activity accumulated throughout the day
3173730|NCT00615251|Experimental|1|
3173731|NCT00615251|Active Comparator|2|
3173732|NCT00615277|Active Comparator|1|1: omega-3 fatty acid supplement
3173733|NCT00615277|Placebo Comparator|2|2: olive oil
3173734|NCT00615303|Placebo Comparator|2|
3173735|NCT00615303|Active Comparator|1|
3173736|NCT00615316|Experimental|A|
3173737|NCT00615316|Placebo Comparator|B|
3173738|NCT00615329||Soft tissue tumor|Any patient with soft tissue tumor will be asked to give a sample for this study
3173739|NCT00615355|Other|Body location|Different body locations receive specific treatments
3173740|NCT00615355|Active Comparator|Control|Treatment with narrow-band UVB
3173741|NCT00615368|Placebo Comparator|Placebo|Isotonic NaCl, intravenously injection
3173742|NCT00615368|Experimental|Active|Epoetin alfa, injected
3173743|NCT00615381|Active Comparator|Normal insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using normal intensive insulin infusion rates (0-10 U/hr).
3173744|NCT00615381|Experimental|Supraphysiologic insulin|Maintenance of intraoperative euglycemia (blood glucose 80--110 mg/dL) using supraphysiologic insulin infusion doses (0.3 U/kg/hr) and exogenous dextrose to provide stable blood glucose levels .
3173745|NCT00615407||Alcohol Drinkers|Asthmatics who consume 3 or more alcoholic beverages per day (on average)
3173746|NCT00615407||Non Drinkers|Asthmatics who do not drink alcohol or consume less than or equal to 2 alcoholic beverages per month
3173747|NCT00615446|Experimental|A|
3173748|NCT00615498||Surgical cases|Subjects who are undergoing bariatric surgery
3173749|NCT00615498||Controls|Subjects who qualify for bariatric surgery but do not undergo the procedure
3173750|NCT00615511|Placebo Comparator|placebo|Approximately one third of subjects
3173751|NCT00615511|Experimental|Pregnenolone|
2514728|NCT02798445|Experimental|tapirs|this group will have surgery with endovascular laser treatment (EVLT) in the axial vein and foam sclerotherapy echo-guided in perforator veins and veins in relation with the ulcer, after the surgery the patients will have conventional wound care plus juxta cure system that give a continuous compression in the leg.
2514737|NCT02798445|Active Comparator|multilayer bandage|multilayer bandage and conventional wound care (grade 1A) recommendation in management of vein ulcers. gold standard
2514812|NCT02798133|Experimental|OLA|recruitment maneuver + individualized PEEP
2514813|NCT02798133|Active Comparator|RM-5|recruitment maneuver + fixed standard PEEP
2514982|NCT02797197|Experimental|patient undergoing to chemotherapy during 6 months|
2515004|NCT02796547|Experimental|Levobupivacaine|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with Levobupivacaine. This is the only intervention specific to the study, as compared to the standard of care.
2515007|NCT02796547|Placebo Comparator|Placebo|Primiparous patients in whom a instrumental delivery with episiotomy is conducted. The infiltration of the banks of the episiotomy will be done with physiological serum.This is the only intervention specific to the study, as compared to the standard of care.
2515077|NCT02796287|Experimental|Patients with Ictus amnesic|Patients admitted in the hospital as part of their medical care with amnesic Ictus episode
2515301|NCT02794987||Classification group|Group of endoscopists that will use the previous classification to select the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes
2515303|NCT02794987||No classification group|Group of endoscopists that will classified the bile duct tissular lesion images detected by SpyGlass® choledoscopy as benign or malignant with the different subtypes without using the classification.
2515460|NCT02793830|Experimental|Mobile App Group|Participants in the experimental group will receive daily reminders and educational materials from mobile applications.
2515464|NCT02793830|Active Comparator|Control Group|The control group will receive the same educational materials, but no daily reminder.
2515517|NCT02793505||Pregnant patient exposed to metformin|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to metformin (Anatomical Therapeutic Chemical A10BA02) any time during pregnancy (i. e. any time from conception to week 42 after last menstrual period (LMP)).
2515518|NCT02793505||Reference group|Pregnant women seeking counseling by themselves or through their healthcare provider for exposure to any drug not known as a major teratogen or fetotoxicant and different than metformin, insulin or any other hypoglycaemic agent.
2515560|NCT02793089||First quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
2515563|NCT02793089||Second quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7).
2515565|NCT02793089||Third quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
2515567|NCT02793089||Fourth quartile|No drugs are administered. It is an observational study. Collect retrospectively data.Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
3164394|NCT00497549|Active Comparator|1|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
3173752|NCT00615563||genotype test|
3173753|NCT00615563||combined phenotype/genotype test|
3173754|NCT00615576|Experimental|Subjects receiving SB-656933|Eligible subjects will be randomized to receive once daily doses of 100 milligrams of SB- 656933 for 14 days.
3173755|NCT00615576|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 14 days.
3173756|NCT00615602|Experimental|1|FEC -> TXT+H 12m
3173757|NCT00615602|Experimental|2|FEC -> TXT+H 6m
3173758|NCT00615615|Experimental|Levetiracetam (LEV)|LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.
3173759|NCT00615615|Placebo Comparator|Placebo|Subjects received Placebo matching to LEV treatment.
3173760|NCT00615628||family members|family members of the proband and father identified
3173761|NCT00615641||1|3 year old children
3173762|NCT00615641||2|4 year old children
3173763|NCT00615641||3|5 year old children
3173764|NCT00615654|Other|2|
3173765|NCT00615667|Experimental|tacrolimus(fk506) treatment|tacrolimus(fk506) treatment
3173766|NCT00615693|Experimental|1|
3173767|NCT00615706||1|Asthmatics
3173768|NCT00615706||2|Healthy volunteers (without asthma)
3173769|NCT00615732|Experimental|1|qigong
3173770|NCT00615732|Active Comparator|2|exercise therapy
3173771|NCT00615732|No Intervention|3|
3173772|NCT00615745|Experimental|Single Arm|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
3173773|NCT00615758|Experimental|1|Tarceva
3173774|NCT00615771|Experimental|Day 2 embryo transfer|Embryos are transferred 2 days after fertilization.
3173775|NCT00615771|Active Comparator|Day 3 embryo transfer|Standard of care for women undergoing IVF with a limited number of embryos is to transfer all embryos on Day 3 after fertilization
2514740|NCT02798367|Experimental|CBT-I plus Melatonin 3 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 3mg. Melatonin 3mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
2514743|NCT02798367|Experimental|CBT-I plus Melatonin 5 mg|"It's a tablet manufactured by Aché S.A., composed of melatonin 5mg. Melatonin 5mg tablet will be dispensed to 65 participants (first stage) of this group in a cartridge of 3 blisters with 10 tablets each, totalizing 30 tablets. If this arm is the best set for the second stage, more 56 participants will be randomly allocated in this group.The participant shall administer 01 tablet orally every 24 hours one hour before bedtime. The duration of treatment may be 21(±2) days.~CBT-I is a non-pharmacological effective treatment for insomnia disorder. Behavioral techniques of Sleep Hygiene and Stimuli control are the most used. The CBT-I guidelines are standardized in protocol."
2514747|NCT02798367|Other|CBT-I plus placebo|"It's a tablet manufactured by Aché S.A,. composed of placebo. The participants shall administer the placebo tablets to enable the double-blind study. Placebo will be dispensed to 65 (first stage) and 56 (second stage) participants of this group and shall administer 01 tablet orally every 24 hours one hour before bedtime for 21(±2) days.~Sleep hygiene is a psychoeducational intervention that teaches patients to prevent external or environmental factors generate adverse effects and harmful to sleep. The stimulus control technique is based on five instructions that encourages the patient to establish a proper sleep-wake rhythm and strengthens the links between the way for a quick and well consolidated sleep. The CBT-I guidelines are standardized in clinical protocol."
2514827|NCT02797977|Experimental|Standard-Dose Triplet Combination|SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
2514829|NCT02797977|Experimental|Low-Dose Gemcitabine Combination|SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.
2514901|NCT02797366|Other|Proton radiotherapy|Proton radiation therapy daily (Monday through Friday) for 4-8 weeks. This is a single arm study.
2514992|NCT02796937|Experimental|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
2515064|NCT02796313|Experimental|Intervention Group|Participants in the intervention group will receive tailored advice on adopting a low-sodium DASH diet, comprising nutritional education and ongoing guidance for purchasing heart-healthy foods, plus a weekly $35 credit for groceries.
2515065|NCT02796313|Active Comparator|Control Group|Participants in the control group will receive printed educational materials with general information about low-salt diets plus a weekly $35 credit for groceries.
2515152|NCT02795572|Experimental|Intervention Group|The intervention group will receive a daily dose of Vitamin D 2000 IU, Vitamin B6 100 mg, Vitamin B12 100 mcg and Omega-3 Fatty Acids 2700 mg [900 mg TID (600 mg EPA, 300 mg DHA)].
2515155|NCT02795572|No Intervention|Reference Group|Reference group will receive usual care.
2515236|NCT02795390|Experimental|Chinese herbal medicine|MaZiRenWan 10g plus HuangQi 20g are chosen as the core prescription. Furthermore, six herbal granules can be added according to the syndrome differentiated for individual participant. They are ShuDiHuang 15g and Danggui 10g for deficiency of blood, Maidong 15g and ShengDiHuang 10g for deficiency of Yin, and RouCongRong 15g and Niuxi 10g for deficiency of Yang.
2515245|NCT02795390|Placebo Comparator|Placebo|Placebo is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%), and caramel (0.34%) to achieve color, smell, taste, and texture comparable to the herbal granules.
2515313|NCT02794857|Experimental|NP001|NP001 2 mg/kg by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
2515314|NCT02794857|Placebo Comparator|Placebo|Normal saline by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6
2515380|NCT02794389|Experimental|N-acetyl cysteine|1200mg for 2 days 2400mg for 7 days
2515384|NCT02794389|Placebo Comparator|Placebo|Magnesium stearate capsules
2515406|NCT02794025|Experimental|esmolol group|patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava.
2515407|NCT02794025|Sham Comparator|control group|Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol.
2515473|NCT02793791|Experimental|Ablation|
2515476|NCT02793791|No Intervention|Observation|
2515527|NCT02793362||Normal subjects without stroke|"subjects who can walk independent without any difficult~subjects without history of CNS or PNS lesion~Modified ranking scale (MRS) <=2~Functional ambulation category (FAC) >=2"
2515529|NCT02793362||Post stroke patients with sarcopenia(by sarcopenia index)|Existence of sarcopenia will be determined by DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
2515531|NCT02793362||Post stroke patients without sarcopenia(by sarcopenia index)|patients who do not satisfy the value of DEXA scan where sarcopenia index of male less than 7.40 kg/m2, that of female less than 5. 14 kg/m2 are considered as sarcopenia.
2515538|NCT02793362||Post stroke patients with sarcopenia(by lean body mass)|Existence of sarcopenia will be determined by DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
2515540|NCT02793362||Post stroke patients without sarcopenia(by lean body mass)|patienst who do not satisfy the value of DEXA scan where appendicular lean mass less than <19.75 kg in men, and <15.02 kg in women are considered sarcopenia.
2515617|NCT02792764||Peripheral Intravenous (PIV) Lines|Subjects receiving chemotherapy through a peripheral IV
2514751|NCT02798458|Experimental|Endoscopic Mucosal Resection|An additional small group of subjects will also be asked to complete a Sigmoidoscopy (an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed. In the Endoscopy Mucosal Resection (EMR) procedure we will use an instrument called an endoscope (a lighted, flexible tube) to take a tissue sample from the rectum. This is the same type of instrument used in a routine colonoscopy
2514780|NCT02798081|Experimental|Single arm study|A minimum of 46 elderly, students of a informatics course, will participate in the study. Initially, the students will have 8 usual informatics classes in the institution where they were enrolled spontaneously. Then, during the next 8 classes (from class 9 to class 16) they will practice 10 minutes of virtual reality games, as part of the class.
2514885|NCT02797249|Experimental|aspirin|Low dose aspirin (100 mg) starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy, taking at night.
2514888|NCT02797249|Other|blank|Routine examination during pregnancy.
2515052|NCT02796430||Mechanically ventilated patients|Ease of use will be assessed by analysing the time needed to start indirect calorimetry measurement, and results of indirect calorimetry measurements by both the new indirect calorimeter and the currently used calorimeters at each study center.
2515096|NCT02796053|Placebo Comparator|Placebo|Placebo to TAB08
2515100|NCT02796053|Experimental|TAB08 Dose 1|Drug: TAB08 biologic
2515167|NCT02795793|Experimental|Non-operative management group (NOM)|Children in the NOM group will receive intravenous Piperacillin with Tazobactam (Tazocin) 100mg/kg/dose every 8 hours for at least 24 hours, and they will be observed and reassessed within 24 hours after randomisation. A further 24 hours of intravenous Piperacillin with Tazobactam therapy will be offered to children in invariable condition. A clinical decision will be made by the attending surgeon to offer OM if a patient's condition deteriorates at any time, or if a patient has failed to improve after 48 hours of intravenous antibiotic therapy. Once the patient is clinically improving and tolerating oral intake, the antibiotic regimen will be changed to oral Amoxicillin plus Clavulanic acid (Augmentin) 22.5mg/kg/dose twice per day to complete a total seven day course of antibiotics. Oral Ciprofloxacin 15mg/kg/dose twice daily and oral Metronidazole 10mg/kg/dose twice daily will be offered to children who are known to have an intolerance or allergy to Amoxicillin or Clavulanic acid.
2515171|NCT02795793|Active Comparator|Appendectomy group (Operative management, OM)|Children allocated to OM may receive preoperative antibiotic prophylaxis as clinically indicated. Appendicectomy will be performed laparoscopically, or via open surgery according to the surgeon's standard practice. Postoperative antibiotic treatment will be determined on the basis of intraoperative findings in accordance with the institutional practice. The appendix specimen will be examined by a paediatric pathologist, and the formal histopathology report will be recorded.
2515232|NCT02795273|Experimental|Grass-SPIRE|Eight intradermal injections of Grass-SPIRE
2515239|NCT02795273|Placebo Comparator|Placebo|Eight intradermal injections of Placebo
2515273|NCT02794922|Experimental|Interventional|Name: Neurovit Forte tab Dosage: Each tablet contains Vitamin B1 242.5mg, Vitamin B6 250mg, Vitamin B12 1mg Frequency: One tab, once per day Duration: 6 weeks
2515276|NCT02794922|Placebo Comparator|Placebo|Capsule containing 250mg corn starch
2515370|NCT02794545|Experimental|Recent infection patient|The patient who infected with HIV-1 and screened out by P24 ELISA, and they would receives early cART course.
2515435|NCT02794155|Experimental|Test Group|HDV Insulin Lispro subcutaneous, pre-prandial dosing, 26 week treatment period
2515439|NCT02794155|Active Comparator|Control Group|Insulin Lispro subcutaneous, Pre-prandial dosing, 26 week treatment period
2515544|NCT02793466|Experimental|Durvalumab; MEDI4736|Open label
3164395|NCT00497549|Active Comparator|2|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
3164396|NCT00497588|Active Comparator|radiotherapy|patients receive radiotherapy
3164397|NCT00497588|Experimental|surgery|Patients undergo surgery
3164398|NCT00497601|Experimental|A|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 and 3
3164399|NCT00497601|Experimental|B|Amphotericin B in fat emulsion (Amphomul) 10 mg/kg on day 1 and 5 mg/kg on day 3
3164400|NCT00497601|Experimental|C|Amphotericin B in fat emulsion (Amphomul) 12.5 mg/kg on day 1 and 2.5 mg/kg on day 3
3164401|NCT00497601|Experimental|D|Amphotericin B in fat emulsion (Amphomul) 15 mg/kg in a single dose administration on day 1
3164402|NCT00497614|Other|No arm|
3164403|NCT00497653|Experimental|DCI|
3164404|NCT00497653|Placebo Comparator|Placebo|
3164405|NCT00497757|Experimental|Cardiac Failure Patients|Recipients treated with an enriched hematopoetic stem cell infusion from the heart donor's bone marrow
3164406|NCT00497809|Experimental|1|AVI-014 2.5mcg/kg
3164407|NCT00497809|Experimental|2|AVI-014 5.0 mcg/kg
3164408|NCT00497809|Experimental|3|AVI014 10.0 mcg/kg
3164409|NCT00497809|Active Comparator|4|Filgrastim 5.0 mcg/kg
3164410|NCT00497848|Active Comparator|motivational interviewing|
3164411|NCT00497848|Experimental|The System Orientated Intervention|
3164412|NCT00497900|Experimental|1|Calcium and vitamin D
3164413|NCT00497900|Placebo Comparator|2|Calcium and placebo (cellulose)
3164414|NCT00497913|Active Comparator|A|
3164415|NCT00497913|Placebo Comparator|B|
3164417|NCT00497952|Experimental|Multiple Sclerosis Patients|Recipients treated with a hematopoetic stem cell infusion from a living donor
3164418|NCT00497978|Active Comparator|1|taurine will be given per capsule
2514786|NCT02798159|Experimental|Part A- Arm 2|Investigational dose = 0.5 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2514787|NCT02798159|Experimental|Part A- Arm 3|Investigational dose = 1 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2514788|NCT02798159|Experimental|Part A- Arm 4|Investigational dose = 1.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
2514789|NCT02798159|Experimental|Part B- Arm 1|"Investigational dose = optimal dose in Part A. The drug should not be taken more than one time a day or 3 times a week.~Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month"
2514790|NCT02798159|Active Comparator|Part B- Arm 2|Sildenafil Citrate 50 mg on demand The drug should not be taken more than one time a day or 3 times a week. Administered orally once a day, 1 hour before sexual activity, for 1 month
2514815|NCT02797704|Experimental|SC Aflibercept|The patients will be treated with a single subconjunctival injection of 0.08 ml aflibercept (25 mg/ml) in a single quarter of the conjunctiva, near the limbus in a proximity to the area of pathological neovascularization
2514867|NCT02797561||Tandem lesion evaluated by FFR|
2514926|NCT02797158|Experimental|Interventional Arm|
2514968|NCT02796846||CPAP prescription group|Patients with a CPAP prescription (both compliant and noncompliant)
2514970|NCT02796846||Without a CPAP prescription|Patients without a CPAP prescription to satisfy our primary goals/objectives.
2515033|NCT02796586|Placebo Comparator|Individual Contraceptive Counseling|Performed by a medical provider and planned to simulate a typical clinic visit addressing contraception.
2515035|NCT02796586|Experimental|Group Contraceptive Counseling|Performed by a bicultural study staff member who speaks the primary languages of participants and had been formally trained in contraception counseling.
2515083|NCT02796222||Hemophilia A patients on rFVIIIFc|Patients with hemophilia A who switch from on-demand or prophylactic treatment with rFVIII to rFVIIIFc
2515085|NCT02796222||Hemophilia A patients on rFVIII|Patients with hemophilia A who remain on on-demand or prophylactic treatment with rFVIII
2515086|NCT02796222||Hemophilia B patients on rFIXFc|Patients with hemophilia B who switch from on-demand or prophylactic treatment with rFIX to rFIXFc
2515088|NCT02796222||Hemophilia A patients on rFIX|Patients with hemophilia B who remain on on-demand or prophylactic treatment with rFIX
2515163|NCT02795858|Experimental|Ramucirumab In Combination With Somatostatin Analog|"Patients will receive treatment with Ramucirumab at a pre-determined dose intravenously every 14 days of a 28-day treatment cycle.~Patients will receive treatment with a Somatostatin Analog at a pre-determined dose.~Toxicity and adverse events will be examined in the first 10 patients who complete one cycle of therapy before expanding enrollment."
2515220|NCT02795247|Active Comparator|Hybrid Transtibial Technique|Reconstruction of the ACL using the hybrid transtibial technique
2515223|NCT02795247|Active Comparator|Accessory Anteromedial Portal Technique|Reconstruction of the ACL using the accessory anteromedial portal technique
2515229|NCT02795247|Active Comparator|Transtibial Technique|Reconstruction of the ACL using the transtibial technique.
2515272|NCT02794935|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
2515275|NCT02794935|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
2515371|NCT02794558|Experimental|Treatment Arm|Subjects in this arm are treated once with MRgFUS device
2515410|NCT02794168|Experimental|VAS203 (Ronopterin)|Intravenous infusion of 17 mg/kg VAS203 over 48 hours, daily dose 8.5 mg/kg
2515417|NCT02794168|Placebo Comparator|Saline|Intravenous infusion of physiological saline over 48 hours
2515514|NCT02793440|Active Comparator|cortivazol|anti-inflammatory therapy and epidural
2515516|NCT02793440|Experimental|Traction arm|Medical treatment associated with 5 lumbar traction sessions
2515556|NCT02793102|Experimental|Olfactory workshop + Somesthesia workshop|Olfactory workshop, Twenty odorants. Somesthesia workshop, time for moving the body, Talk Time
2515557|NCT02793102|Experimental|Auditory workshop + Somesthesia workshop|Auditory workshop, Twenty extracts of music tracks. Somesthesia workshop, time for moving the body, Talk Time
3164419|NCT00497978|Placebo Comparator|2|placebo capsules containing microcrystalline cellulose will be given
3164420|NCT00498043|Experimental|R-CHOP-14|R-CHOP14 induction regimen
3164421|NCT00498043|Experimental|R-ACVBP14|R-ACVBP14 induction regimen
3164422|NCT00498056|Experimental|1|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP. Injections will occur at study entry and Weeks 4, 8, and 24.
3164423|NCT00498056|Placebo Comparator|2|Participants will receive a total of three injections of the DNA vaccine VRC-HIVDNA016-00-VP placebo followed by one injection of the adenovirus vaccine VRC-HIVADV014-00-VP placebo. Injections will occur at study entry and Weeks 4, 8, and 24.
3164424|NCT00498069|Active Comparator|1|Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity
3164425|NCT00498069|Placebo Comparator|2|Injection of placebo into ischemic tissues of the lower extremity
2514810|NCT02797873|Experimental|EIP|"Patients from the DBT unit suffering from symptoms of Emotional Instability (n=30), with different levels of ADHD symptoms as assessed by questionnaires Brown-ADD, ASRS and SDQ.~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
2514811|NCT02797873|Experimental|Healthy controls|"Matched healthy controls (according to age, IQ and socio economic status) recruited from high schools in Stockholm area (n=30).~Interventions:~fMRI - Stroop task~fMRI - MID task~Stop Signal task~Structural T1 MRI scan~Structural T2 MRI scan~DTI MRI scan~Resting state MRI scan~FEFA 2~SCID-II~SDQ~ASRS~AQ~TAS-20~Raven's SPM~Reading ability~Ishihara's tests for colour deficiency~Additional questionnaire~Brown-ADD~MFQ~STAI-T~BIS~DAWBA~STAI-S~Sleepiness rating x 6~Motivation rating x 6"
2515283|NCT02795026|Active Comparator|Manual therapy|Intervention to be administered is manual therapy with myofascial release of trigger points for pelvic floor muscles, pelvis and abdominal musculature.
2515291|NCT02795026|Active Comparator|Dry needling & manual therapy|Intervention to be administered is Trans-perineal trigger point dry needling, done externally to target the trigger points in the pelvic floor muscles along with dry needling of the pelvis and abdominal musculature.Manual therapy will only be used in areas difficult to reach with the acupuncture needles.
2515332|NCT02794467|Experimental|Epelsiban 75 mg|Approximately 24 subjects will receive 75 mg of epelsiban three times a day (TID) via oral administration
2515338|NCT02794467|Experimental|Epelsiban 200 mg|Approximately 24 subjects will receive 200 mg of epelsiban TID via oral administration
2515341|NCT02794467|Placebo Comparator|Placebo|Approximately 24 subjects will receive a matching placebo TID via oral administration
2515397|NCT02794090|Active Comparator|Usual care, individual visits|Usual care according to regular treatment routines at the clinic during 18 months. The Child and parent(s) at regular visits to the nurse at the clinic.
2515399|NCT02794090|Active Comparator|Telephone coaching|Intervention: Telephone consultation each months except for summer holidays during 18 months. The treating nurse communicated with one of the parents.
2515446|NCT02793921|Experimental|Moderate-intensity aerobic exercise|Participants engage in a supervised 6-month moderate-intensity aerobic exercise intervention.
2515452|NCT02793921|No Intervention|Usual Care|Physical activity neither limited nor withheld. Participants engage in activity in the same manner as if they were not part of an active intervention.
3164426|NCT00498121||VAP patient|
3164427|NCT00498147||ADEC <6months|Patients new to the ADEC program who will be provided the ADEC interventions (prospective study)
3164428|NCT00498147||ADEC >6months|Patients who have been with the ADEC program as early as 2002 (coincides with ADEC's EMR initiation date) who continue to be provided the ADEC interventions (combined retrospective/prospective study)
3164429|NCT00498160|Experimental|Living or Deceased Donor Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same living donor. Recipients with the need for a deceased donor kidney allograft are treated with an enriched hematopoetic stem cell infusion from the same deceased donor
3164430|NCT00498212|Experimental|1018 ISS-HBsAg-Single|Single dose (3000 µg 1018 ISS + 20 µg rHBsAg)
3164431|NCT00498212|Experimental|1018 ISS-HBsAg-Double|Double dose (6000 µg 1018 ISS + 40 µg rHBsAg)
3164432|NCT00498225|Experimental|1|Gemcitabine plus TS-1
3164433|NCT00498225|Experimental|2|TS-1
3164434|NCT00498225|Active Comparator|3|Gemcitabine
3164435|NCT00498277||Spinal MRI|
3164436|NCT00498290|Experimental|A|received enhanced recovery after surgery (ERAS) protocol in colorectal surgery
3164437|NCT00498290|No Intervention|B|normal recovery protocol in colorectal surgery
3164438|NCT00498316|Other|Cord Blood Infusion|"Cord blood transplantation performed on day 0. Busulfan 32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4.~Fludarabine 10 mg/m2 by vein on Days -7 to -4, 40 mg/m2 by vein on Days -6 to -3 or on Days -5 to -2.~Rituximab 375 mg/m2 by vein on Day -9. ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3, 1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2.~Cyclophosphamide 50 mg/kg by vein on Day -6. Clofarabine 30 mg/m2 by vein on Days -7 to -4. Total body irradiation (TBI) 200 cGy at 25 cGy/minute delivered on Day -3. Melphalan 140 mg/m2 by vein on Day -2. Tacrolimus 0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present."
3164439|NCT00498459|Experimental|ICAPS|Promotion Physical Activity
3164440|NCT00498459|No Intervention|Control|No specific physical activity promotion Ususal school program
3164441|NCT00498472|Active Comparator|A|Pre-discharge NT-ProBNP based
3164442|NCT00498472|No Intervention|B|Discharge date and treatment not based on the knowledge of pre-discharge NT-proBNP levels
3164443|NCT00498524||1|Sib who has received an ICD
3164444|NCT00498524||2|Sib who has not received an ICD
3164445|NCT00498537|Other|1|
3164446|NCT00498537|Other|2|
3164447|NCT00498576||1|kidney transplant with hypertension
3164448|NCT00498576||2|hypertensive patients with native kidneys
3164449|NCT00498576||3|healthy controls
3164450|NCT00498589|Placebo Comparator|1|Methotrexate IM or SC 25 mg/week vs placebo IM or SC for 24 weeks
3164451|NCT00498589|Placebo Comparator|2|1 IM or SC of placebo per week during 24 weeks
3164452|NCT00498667||PET/CT|all patients with aggressive lymphoma who had a baseline and interim pet/ct study
3164453|NCT00498680|Active Comparator|Viagra 100mg|
3164454|NCT00498680|Active Comparator|Levitra 20mg|
3164455|NCT00498680|Active Comparator|Viagra 50mg+ Levitra 10mg|
3164456|NCT00498719||CTP Group|One-on-one cognitive training
3164457|NCT00498719||Control Group|Standard educational support.
3173776|NCT00615797|Experimental|1|Group randomized to receive intravenous immunoglobulins in addition to standard therapy for sydenham's chorea
3173777|NCT00615797|Placebo Comparator|2|Group randomized to receive standard intervention for sydenham's chorea alone
2514917|NCT02797093||HIV suppressed individuals|HIV suppressed individuals on chronic ART, suboptimal adherence and exposure, measured through TFV-DP in DBS.
2514993|NCT02796911|No Intervention|Corticotomy alone|Group I will be treated with a modified technique of corticotomy assisted orthodontic treatment (CAOT) alone
2514994|NCT02796911|Experimental|Corticotomy + xenograft|group II (included 6 females and 5 males) that treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
2514997|NCT02796911|Experimental|Corticotomy + bioactive glass|group III (included 7 females and 4 males) that treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
2515037|NCT02796391|Experimental|Study 1: Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mb nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction.~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
2515039|NCT02796391|Experimental|Study 1: Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 1: Participants will be randomly assigned to 1 of 2 groups (Immediate or gradual nicotine reduction). They will all receive a targeted intervention workbook (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) and will be provided with brief one-on-one counseling."
2515041|NCT02796391|Experimental|Study 2: Targeted/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2515043|NCT02796391|Experimental|Study 2: Targeted/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2515045|NCT02796391|Experimental|Study 2: Generic/Immediate Reduction|"This group will receive the lowest nicotine dose (.03 mg nicotine yield) very low nicotine content (VLNC) cigarettes, each of four pre-quit weeks (immediate reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2515046|NCT02796391|Experimental|Study 2: Generic/Gradual Reduction|"This group will receive VLNC cigarettes containing nicotine yields of .7 mg for week 1, .26 mg for week 2, .12 for week 3, and .03 for week 4 (gradual reduction).~Study 2: Participants will be randomly assigned to 1 of 4 groups (Immediate or gradual nicotine reduction/ Generic or targeted intervention). They will receive either targeted (Countdown: Preparing to Quit Smoking with Low-Nicotine Cigarettes) or generic (Clearing the Air) materials, and will receive one-on-one counseling."
2515141|NCT02795715|Experimental|Anodal tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with anodal stimulation
2515142|NCT02795715|Sham Comparator|Sham tDCS + training|Combination of intensive training of picture-word associations (Wernicko task) with sham stimulation
2515183|NCT02795507|Experimental|Device with feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in this specialized motion control apparatus which allows movement of the non involved hand while receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
2515184|NCT02795507|Active Comparator|Device without feedback & exercises|"Training using Rehabit-Tec System - patient's hand will be positioned in a specialized motion control apparatus which allows movement of the non involved hand but without receiving visual feedback of a virtual hand in the paretic side and a passive movement of the paretic hand + followed by 30 minutes of exercises (conventional sensorimotor active and passive exercises of the upper limb).~5 days per week for 3 weeks, 1 hour per day."
2515279|NCT02795195|Experimental|CIRT Arm (3GyE per fraction)|Patients included in this arm were treated with carbon ion radiotherapy with a fraction size of 3GyE.
2515327|NCT02794610|Experimental|Topical tacrolimus|Ten patients will be include. Topical tacrolimus 0.05% will be instilled into the eyes of patients 15 minutes before cataract surgery. Aqueous samples will be collected at the time of cataract surgery and will be subjected to detection of presence and level of tacrolimus.
2515433|NCT02794324|Experimental|Voluntary deep-inspiratory breath hold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
2515437|NCT02794324|Active Comparator|Active-breathing-controlled deep-inspiratory breathhold|Stage 1A: Voluntary deep-inspiratory breath hold (v_DIBH) vs Active-breathing-controlled deep-inspiratory breathhold (ABC_DIBH)
2515618|NCT02792647|Placebo Comparator|Placebo|Placebo
2514905|NCT02797275|Experimental|Albuterol & Placebo|Participants will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) after the completion of the baseline screening visit. They will use albuterol for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the placebo treatment for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
2514907|NCT02797275|Experimental|Placebo & Albuterol|Participants will be placed on the placebo treatment after the completion of the baseline screening visit. They will use placebo for 4 weeks prior to their scheduled second visit during which they will undergo testing. Subsequently, and after a minimum washout period of 2 weeks, they will be placed on the albuterol treatment (2 puffs twice a day, equivalent to 360 mcg per day) for 4 weeks prior to their scheduled third visit, after which they will come back to undergo testing.
2514962|NCT02796833|Other|SMOF/Intralipid|"Patients that are randomized to receive for the first 6 months SMOF as a lipid emulsion in their PN, and for the next 6 month (after 28 days of active washout on Intralipid) Intralipid, which is the standard lipid emulsion used in the hospital. SMOF is approved by Health Canada.~The parenteral nutrition bags are compounded individually for each patient based on their specific needs."
2514964|NCT02796833|Other|Intralipid/SMOF|Patients that are randomized to receive Intralipid, which is the standard lipid emulsion used in the hospital for the first 6 months, and for the next 6 month (after 28 days of active washout on Intralipid) SMOF as a lipid emulsion in their PN. SMOF is approved by Health Canada.The parenteral nutrition bags are compounded individually for each patient based on their specific needs.
2515074|NCT02796209|Experimental|Atomexetine|Following the dose optimization phase, investigators will stratify the treatment assignment by Atomexetine dose (10mg or 19mg twice a day)
2515078|NCT02796209|Placebo Comparator|Placebo|The placebo capsules will be of identical color, size, and approximate weight to provide an authentic blinded effect. The capsule contents will be a microcrystalline cellulose, NF (PH-105), which should not produce any adverse effects. It is a common pharmaceutical capsule filler used in the industry.
2515134|NCT02795871|Experimental|Group D+ 1|Girls and boys at risk of CAH treated in utero by Dexamethasone but unaffected.
2515135|NCT02795871|Experimental|Group D+ 2|Girls and boys affected by CAH and treated in utero by Dexamethasone.
2515136|NCT02795871|Active Comparator|: Group D - 1|Girls and boys not affected by CAH and not treated in utero by Dexamethasone.
2515137|NCT02795871|Active Comparator|Group D - 2|Girls and boys affected by CAH and not treated in utero by Dexamethasone.
2515139|NCT02795871|Other|Group D - 3|Girls and boys enrolled in school closed to Lyon
2515175|NCT02795585||QFR group|Patients with stable angina pectoris and indication for FFR.
2515256|NCT02795364|Active Comparator|Structural Image Guidance|In this arm, the patients will receive maximum resection of the tumor with the MRI T1W-enhanced image guidance, in addition to the standard therapy
2515258|NCT02795364|Experimental|Metabolic Image Guidance|In this arm, the patients will receive quantitative resection of the tumor with both the MRI T1W-enhanced and the MRS Cho-to-NAA index (CNI) image guidance, in addition to the standard therapy.
2515287|NCT02794805|Experimental|HCC positive|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
2515295|NCT02794805|Experimental|HCC negative|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
2515361|NCT02794506|Experimental|Propolis|400 mg oral proplois (capsule) was given to participants once daily for 6 months after performing scaling and root planing.
2515364|NCT02794506|Placebo Comparator|Placebo|Placebo capsule was given to participants once daily for 6 months after performing scaling and root planing.
2515421|NCT02794116|Active Comparator|Control group: Sound teeth|"20 first permanent molars sound, that not affected by MIH will be included.~The teeth were treated with conventional sealants to prevent caries lesion"
2515425|NCT02794116|Experimental|Test: Hypomineralized teeth|"20 first permanent molars affected by MIH will be included.~The MIH teeth were treated with a resin sealants."
2515543|NCT02793414||Malaria patients|
2515551|NCT02793414||Febrile controls|
2515574|NCT02793037|Experimental|A proof of concept of using zirconia bonded bridge|
3164458|NCT00498771|Active Comparator|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
3164459|NCT00498771|No Intervention|Control - No Exercise Arm|No exercise will be performed in Control arm. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL) at baseline, 6 week, 6 and 12 month.
3164460|NCT00498784|Experimental|Arm 1|
3164461|NCT00498875||Questionnaire + Depression Intervention|
3164462|NCT00498888|Active Comparator|1|Women were prescribed a 3 month supply of Tolterodine SR 4 mg (Detrusitol SR 4 mg, Pfizer Pharmaceuticals Israel LTD) . After the randomization she needs to get the first prescription from her doctor, and followed this protocol every three weeks. Her doctor how already knows this research were explained how to take the drug. After finished this protocol she get the money she pay after sending the receipts and the empty boxes.
3173778|NCT00615810|Active Comparator|2|Open label Kivexa (abacavir (as sulfate) 600 mg/lamivudine 300 mg) once daily for oral administration plus Sustiva (efavirenz 600 mg) once daily for oral administration
2514966|NCT02796768||Participants|"Study participants will be 0 to 4 months of age and undergoing DDH screening. They will have the following scans:~BASELINE - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2, 1 2D US scanning session of right and left hip by Specialist 1, 1 2D US scanning session of right and left hip by Specialist 2.~FOLLOW-UP (OPTIONAL) - 1 3D US scanning session of right and left hip by Specialist 1, 1 3D US scanning session of right and left hip by Specialist 2,~1 2D US scanning session of right and left hip by Specialist 1,~1 2D US scanning session of right and left hip by Specialist 2."
2515105|NCT02795949|Experimental|Antipseudomonal beta-lactam antibiotic|"Ampicillin 2g IV/6h~Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h~Cefuroxime 750-1000 mg IV/8h~Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h~Amoxicillin/clavulanate 1000/125 mg IV/8h~Ciprofloxacin 400 mg IV/12h~Ertapenem 1-2g/24h."
2515108|NCT02795949|Active Comparator|De-escalation(short-spectrum antibiotic)|"Piperacillin/tazobactam 4/0.5 g IV/8h~Meropenem 1-2 g IV/8h~Imipenem 0.5 g IV/6h - 1g IV/6h~Aztreonam 1-2 g IV/8h~Ceftazidime 1-2 g IV/8h~Cefepime 2 g IV/8-12h"
3164463|NCT00498888|Active Comparator|2|The Bladder training protocol aims o to increase the time interval between voids, either by a mandatory or self-adjustable schedule, so that incontinence is ultimately avoided and continence regained. It is generally comprised of three components: 1) patient education that includes information about bladder and how continence is usually maintained, 2) scheduled voiding- a 'timetable for voiding' which may fixed or flexible to suit the participant's rate of increase in interval between voids, commonly the aim is to achieve an interval of three to four hours between voids and 3) positive reinforcement- - psychological support and encouragement is generally considered important and usually provided by health care professional . Frequency volume chart (FVC) records the time and volumes of voided for 24 hours by the women between the appointments. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
3164464|NCT00498888|Active Comparator|3|The Pelvic floor muscle training (PFMT) protocol based on National Institute for health and clinical excellence (NICE clinical guideline 40, 2006), that the PFMT programs should comprise at least eight contractions performed three times per day, and the trial of supervised PFMT of at least 3 months' duration . Each appointment the women maid three sets of eight to 12 slow maximal contractions sustained for 6-8 second, and asked to made this protocol every day, and taught to contract these muscle to suppress urge filling. Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
3164465|NCT00498888|Active Comparator|4|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for pelvic floor muscle training and bladder training and lifestyle advice and information about good bladder and bowel habits.
2515296|NCT02794883|Active Comparator|Treatment (durvalumab)|Patients receive durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
2515297|NCT02794883|Active Comparator|Treatment (tremelimumab and durvalumab)|Patients receive tremelimumab IV over 1 hour on day 1 then durvalumab IV over 1 hour on days 1 and 15. Courses repeat every 4 weeks for up to 7 courses. Patients then receive both tremelimumab and durvalumab IV over 1 hour every 12 weeks in the absence of disease progression or unacceptable toxicity.
2515299|NCT02794883|Experimental|Treatment (tremelimumab)|Patients receive tremelimumab IV over 1 hour on day 1. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2515337|NCT02794402|Active Comparator|Bydureon|s.c. once Weekly
2515344|NCT02794402|Placebo Comparator|Placebo|s.c. once Weekly
2515420|NCT02794233|Experimental|PD patients with implanted DBS|Impedance measurements at different time points.
2515502|NCT02793739|Experimental|20 subjects|20 subjects will be enrolled to take part in this study and followed for a period of 12 months. Subjects will receive hyaluronic acid filler injection in the dorsal fingers (2-4 syringes) at the initial visit for volume restoration. If warranted, subjects will receive touch-up of hyaluronic acid at day 14 (1-2 syringes). The investigators expect volume restoration to last 9-12 months.
2515545|NCT02793258|Placebo Comparator|Placebo tDCS|"Subjects will receive 10 30-minutes sessions of sham tDCS, twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
2515549|NCT02793258|Experimental|Active tDCS|"receive 10 30-minutes sessions of two milliamps tDCS, twice a day for 5 consecutive day.~Stimulation will be performed using an tDCS stimulator with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system) The twice daily sessions will be separated by at least 2 hours."
2515589|NCT02792881|Experimental|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group
3164466|NCT00498914|Experimental|1|
3164467|NCT00498966|Experimental|Group A|Patients in group A will have previously failed a VEGF receptor inhibitor but not an mTOR inhibitor.Intervention: Perifosine.
3164468|NCT00498966|Experimental|Group B|Patients in group B will have failed both a VEGF receptor inhibitor and an mTOR inhibitor. Intervention: Perifosine.
3164469|NCT00498979|Experimental|recombinant interferon alfa-2b|recombinant interferon alfa-2b
3164470|NCT00499005|Active Comparator|Primi|
3164471|NCT00499005|Active Comparator|Multi|
3164472|NCT00499018|Experimental|1|R-MegaCHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
3164473|NCT00499018|Experimental|1 BIS|R-CHOP14 x 4 Restaging + R-MAD + MAD + BEAM + ASCT
3164474|NCT00499018|Experimental|2|R-MegaCHOP14 x 4 Restaging + R-MegaCHOP x 2
3164475|NCT00499018|Experimental|2 BIS|R-CHOP14 x 4 Restaging + R-CHOP14 x 4
3164476|NCT00499044|Experimental|1|MATRICS Consensus Cognitive Battery
3164477|NCT00499044|Experimental|2|Cognitive Drug Research Computerized Cognitive Assessment System
3164478|NCT00499057|Other|single arm study|single arm study
3164479|NCT00499135|Experimental|Schedule A|Patients receive sunitinib malate PO QD in weeks 1-4. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
2515006|NCT02796612|Experimental|Intervention group|"Patients receive the current standard of care and are asked to answer the questionnaires mentioned below.~Additionally, delivery of a take-home brochure to the patients during the first visit is planned. The biopsy is explained to the patient and performed by a psychological trained physician. Patient care by a psychologically trained physician is performed in the sense that patients are informed about their biopsy result by a specifically trained physician."
2515098|NCT02796235|Other|Spinal cord injury (SCI) patient|
2515288|NCT02795065|Active Comparator|Enoxaparin 40 mg subcutaneous once daily|
2515293|NCT02795065|Experimental|Bemiparin 3500 IU subcutaneous once daily|
2515369|NCT02794584|Active Comparator|Off-pump hybrid closure|Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.
2515372|NCT02794584|Placebo Comparator|Control|Control group: Conventional closure of ventricular septal defects was aided with cardiopulmonary bypass.
2515411|NCT02794038|Active Comparator|Soberlink Cellular Device|BAC reading with Soberlink Cellular Device
2515414|NCT02794038|Active Comparator|BACtrack S80 Pro|BAC reading with BACtrack S80 Pro
2515474|NCT02793765|Experimental|Docetaxel & Sipuleucel-T|75 mg/m2 docetaxel IV over 1-hour every 21 days x 6 cycles; 28 day rest then Sipuleucel-T IV over 1-hour every 14 days for 3 doses
2515506|NCT02793323|Experimental|Superficial cervical block|Patients will receive superficial cervical nerve block in which we inject 5 ml of local anaesthetic mixture. Each 17 ml of the mixture contain: 6 ml lidocaine 2%, 6 ml lidocaine 2% with adrenaline 5 µg/ml, and 5 ml bupivacaine 0.5. Patients will also receive 100 ml IV saline.
2515507|NCT02793323|Placebo Comparator|NSAID|Patients will receive 100 mg (100 ml) IV NSAIDs (Profenid) before induction of anesthesia. Superficial cervical nerve block containing 5 ml placebo will be performed.
3164480|NCT00499135|Experimental|Schedule B|Patients receive sunitinib malate PO QD in weeks 1, 2, 4, and 5. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3164481|NCT00499161|No Intervention|1|Control group received usual care
3164482|NCT00499161|Experimental|2|Received intervention New model of nursing care
3164483|NCT00499187||Fanconi Cases|This cohort enrolled participants with evidence of protocol-defined Fanconi syndrome (confirmed creatinine clearance decline and evidence of proximal tubulopathy).
3164484|NCT00499187||Control Cases|This cohort enrolled participants with no evidence of protocol-defined Fanconi syndrome.
3164485|NCT00499200|Experimental|SRA-444 + Placebo|Experimental; Placebo
3164486|NCT00499239|Experimental|GS-9219|Escalating doses of GS-9219 (5, 8, 11.5, 16, 22.5, 31.5, 44, and 61.5 mg/m^2) until determination of the maximum tolerated dose (MTD)
3164487|NCT00499265|Active Comparator|Gemcitabine|
3164488|NCT00499265|Experimental|Gemcitabine plus 200 mg WX-671|
3164489|NCT00499265|Experimental|Gemcitabine plus 400 mg WX-671|
3164490|NCT00499330|Other|Arm A|Patients undergo a standard operation for lung cancer called a lobectomy.
3164491|NCT00499330|Experimental|Arm B|Patents undergo a limited resection (segentectomy or wedge resection), which a smaller portion of the lung is removed.
3164492|NCT00499382||PET/CT scan + NM cardiac scan|
3164493|NCT00499421||CT Scan|CT Scan with Fiducial markers + external beam radiation therapy
3164494|NCT00499499|Experimental|1|
3164495|NCT00499512||Spirituality Questionnaire|Patients with newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer.
3164496|NCT00499525|Experimental|Arm I|Patients receive paclitaxel IV over 1 hour once weekly for 3 weeks. Patients also receive oral sorafenib tosylate twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3164497|NCT00499525|Active Comparator|Arm II|Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3164498|NCT00499577|Experimental|Group 1 (HLA-A2 positive)|Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
3164499|NCT00499577|Experimental|Group 2|Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
3164500|NCT00499577|Experimental|Second group 1|On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
3164501|NCT00499577|Experimental|Second group 2|On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
3164502|NCT00499629|Active Comparator|1|Arm 1: FXR 450
3164503|NCT00499629|Placebo Comparator|2|Placebo
3164504|NCT00499668|Experimental|ARM A|
3164505|NCT00499668|Experimental|ARM B|
3164506|NCT00499733|Experimental|Intervention|Participant will receive one time intravenous infusion of cyclophosphamide three days after scheduled cryoablation surgery.
3164507|NCT00499785||patients admitted with acute leukemia|
3164508|NCT00499798||patients on temozolimide for brain cancer|
3164509|NCT00499811|Experimental|Treatment (enzyme inhibitor therapy)|"Vorinostat (SAHA) will be administered as a single oral dose on day -6 for all patients. Blood samples are obtained periodically on day -6 for pharmacokinetic studies.~One week later (day 1), the first course of oral vorinostat will be initiated on a continuous daily oral regimen. Each treatment course will consist of 21 days of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity."
3164510|NCT00499824|Experimental|1|Medical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
3164511|NCT00499824|No Intervention|2|Medical practitioners who follow standard practice for management of their patients with type 2 diabetes
3164512|NCT00499837|Experimental|80 mg/kg AAT inhaled|80 mg/kg AAT inhaled
3164513|NCT00499837|Placebo Comparator|Placebo inhaled|Placebo inhaled
3164514|NCT00499876|Active Comparator|A|
3164515|NCT00499876|Placebo Comparator|B|
2515056|NCT02796378|Placebo Comparator|Training+Simvastatin-placebo+Q10-placebo|Training+Simvastatin-placebo+Q10-placebo. 8 Weeks of exercise training on a bicycle ergometer three times a week, Simvastatin-placebo and Q10-placebo.
2515058|NCT02796378|Active Comparator|Training+Simvastatin+Q10|Training+Simvastatin+Q10. 8 Weeks of exercise training on a bicycle ergometer three times a week and 40 mg of Simvastatin pr day in combination with 400 mg of oral supplementation with Q10.
2515090|NCT02796027|Experimental|Experimental: BRIDGE|Subjects assigned to this arm would receive an integrated HIV service model
2515092|NCT02796027|No Intervention|Pre-implementation|Subjects assigned to this arm would receive standard care (treatment as usual) and would not be exposed to the integrated HIV service model.
2515455|NCT02794012||At-Risk Rheumatoid Arthritis subjects|
2515456|NCT02794012||Early Rheumatoid Arthritis subjects|
2515457|NCT02794012||Healthy Controls|
2515458|NCT02794012||Non-Rheumatoid Arthritis Autoimmune Controls|
2515475|NCT02793596|Experimental|Obstetrical patients|Obstetrical patients requiring epidural analgesia for delivery
2515510|NCT02793375|Placebo Comparator|Control|Patients receiving placebo preoperatively (blinded)
2515512|NCT02793375|Experimental|Study group|Patients receiving montelukast preoperatively (blinded)
2515562|NCT02793115|Experimental|Arm 1|Disclosure Letter-RISKS
2515564|NCT02793115|Experimental|Arm 2|Disclosure Letter-BENEFITS
2515566|NCT02793115|Experimental|Arm 3|Disclosure Letter-RISKS AND BENEFITS
2515568|NCT02793115|Experimental|Arm 4|Disclosure Letter-NO RISKS OR BENEFITS
2515569|NCT02793115|Placebo Comparator|Arm 5|Letter-APPOINTMENT REMINDER
2515590|NCT02792712|Experimental|STEMI_MRI_Ticagrelor|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Ticagrelor Arm
2515591|NCT02792712|Active Comparator|STEMI_MRI_Clopidogrel|A Magnetic Resonance Imaging Study in myocardial salvage in patients with ST-Elevation myocardial infarction (STEMI) undergoing pRimary percutaneous coronary intervention - Clopidogrel Arm
3164516|NCT00499902|Other|2 stages|This is a two-stage study. The first stage is in a three-tier dose escalation format, followed by a second stage during which subjects will be randomized in an equal proportion to up to 3 qualifying dose arms.
3164517|NCT00499967|Experimental|Cohort 1|GS-9191 0.01% ointment
3164518|NCT00499967|Experimental|Cohort 2|GS-9191 0.03% ointment
3164519|NCT00499967|Experimental|Cohort 3|GS-9191 0.1% ointment
3164520|NCT00499967|Active Comparator|Cohort 4|GS-9191 0.3%
3164521|NCT00499967|Active Comparator|Cohort 5|GS-9191 1.0%
3164522|NCT00499967|Placebo Comparator|Cohorts 1, 2, 3, 4 & 5|Placebo in all cohorts
3164523|NCT00500006|Other|A|Arm A: Drug and comparator
3164524|NCT00500006|Other|B|Arm B: Drug and comparator
3164525|NCT00500019||1.|Elective Cesarean sections
3164526|NCT00500019||2.|Non-elective cesarean section
3164527|NCT00500032|Experimental|Arm 1|Active Comparator for all subjects enrolled in 6108A1-500
3164528|NCT00500058|Experimental|SB-485232+Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) will be administered to subjects with CD20+ B cell lymphoma by intravenous (IV) infusion once a week for four consecutive weeks on Day 1 of Weeks 1 to 4. SB-485232 will be administered by IV infusion over a 2 hour period, at doses ranging from 1 microgram (μg)/kilogram (kg) to 100 μg/kg. SB-485232 will be given once a week for 12 consecutive weeks on Day 2 of Weeks 1 to 4 and Day 2 (± 1 day) of Weeks 5 to 12. SB-485232 will be infused at least 24 hours after the Rituximab infusion was started.
3164529|NCT00500084|Experimental|Liprotamase|Liprotamase is a fixed combination of lipase (32,500 units), protease (25,000 units) and amylase (3,750 units) administered orally with each of three meals and two snacks daily for 12 months
3164530|NCT00500162|Active Comparator|1|
3164531|NCT00500162|Active Comparator|2|
3164532|NCT00500188|Experimental|7 Days|Imatinib Mesylate 300 mg orally twice daily starting 7 days before surgery.
3164533|NCT00500188|Experimental|5 Days|Imatinib Mesylate 300 mg orally twice daily starting 5 days before surgery.
3164534|NCT00500188|Experimental|3 Days|Imatinib Mesylate 300 mg orally twice daily starting 3 days before surgery.
3164535|NCT00500201|Experimental|Subjects in treatment sequence AB|In treatment sequence AB first subjects will be randomized to receive treatment A (two tablets of 60 milligram [mg] of SB-773812) and one placebo tablet. Then subjects will receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets . There will be a wash-out period of 20 days between.
3164536|NCT00500201|Experimental|Subjects in treatment sequence BA|In treatment sequence BA first subjects will be randomized to receive treatment B (one tablet of 120 mg of SB-773812) and two placebo tablets. Then subjects will receive treatment A (two tablets of 60 mg of SB-773812) and one placebo tablet. There will be a wash-out period of 20 days between.
3164537|NCT00500253|Active Comparator|1|children with asthma with FeNO monitored treatment (study group)
3164538|NCT00500253|Other|2|group of children with treatment monitored by GINA's grade of disease clinical control (control group)
3164539|NCT00500344|Other|1|
3164540|NCT00500409|Experimental|Drug Group|Osteoform
3164541|NCT00500409|Active Comparator|Control group|SHELCAL
3164542|NCT00500422|Experimental|Doxil + Gemcitabine + Velcade|Doxil Starting dose of 20 mg/m^2 intravenous (IV) over 2 hours on Day 1 and Gemcitabine 500 mg/m^2 IV over 30 minutes on Days 1 and 8; Velcade Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles.
3164543|NCT00500435||Laparoscopy Procedure|Laparoscopy procedure in abdomen to remove para aortic lymph nodes of patients diagnosed with cervical cancer.
3164544|NCT00500461|Experimental|Subjects receiving GSK233705|Each subject will receive one or more ascending doses given as a constant rate IV infusion over 30 minutes and a single oral dose of 250 microgram GSK233705 solution. IV doses will include 30, 70, 110 microgram of GSK233705 at specified time points.
3164545|NCT00500487|Experimental|1|
3164546|NCT00500487|Active Comparator|2|
3164547|NCT00500487|Active Comparator|3|
3164548|NCT00500500|Experimental|EGb 761® (Tanakan®)|EGb 761® (Tanakan®)
3164549|NCT00500500|Placebo Comparator|Placebo|Placebo
3164550|NCT00500513|Experimental|Implanted Markers + CT + RT|
2515059|NCT02796508|Experimental|Non-action video game training|Experimental: Non-action video game training 16 1-hour training sessions with 10 non-action video game training selected games from Lumosity.
2515060|NCT02796508|Active Comparator|Non-cognitive video game training|Active Control: Non-cognitive social video game training 16 1-hour training sessions with non-cognitive video game training with social games from The Sims.
2515125|NCT02796066|Placebo Comparator|Vehicle|Vehicle gel
2515129|NCT02796066|Experimental|Low Dose Active|Low Dose of TSN2898
2515132|NCT02796066|Experimental|Mid Dose Active|Mid Dose of TSN2898
2515133|NCT02796066|Experimental|High Dose Active|High Dose of TSN2898
2515176|NCT02795546|Experimental|Test group|400µg Alendronate sodium+ β-TCP + saline. 400µg alendronate sodium is combined with beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
2515179|NCT02795546|Active Comparator|Control group|β-TCP + saline Beta-tricalcium phosphate bone substitute and wetted with saline and used as bone grafting material in periodontal intra-osseous defects.
2515269|NCT02795234|Other|Participants with Vitamin D deficiency|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
2515271|NCT02795234|Other|Participants with sufficient Vitamin D Level|Blood sample, venous blood, about 10 ml will be drawn from participants and tested for the presence of Vitamin D antibodies
2515317|NCT02794688||Ductal lavage group|The patients will receive ductal lavage therapy every other day for two weeks, and will be followed up for one year.
2515334|NCT02794428|Active Comparator|Eflornithine|
2515340|NCT02794428|Placebo Comparator|Eflornithine Placebo|
2515481|NCT02793778|Experimental|CROWN|CROWN: A nutritionally based therapy with a high protein content, formulated as a powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2515483|NCT02793778|Placebo Comparator|CROWN Placebo|Placebo: An appearance and volume matched formulated powder. Twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2515534|NCT02793193|Experimental|Active (rifaximin/B.longum 1714)|
2515536|NCT02793193|Experimental|Placebo|
2515594|NCT02792946|Experimental|Sulfolase CR (200mg, QD)|for 7 days with or without meal
2515599|NCT02792946|Active Comparator|Sulfolase Capsule (100mg, BID)|for 7 days with or without meal
3164551|NCT00500526|Experimental|1 Singing Group|Patients who will receive singing classes
3164552|NCT00500526|Other|2 Control group|Patients who will attend hand craft classes
3164553|NCT00500565|Experimental|On-Q pump with Saline|On-Q Pump with Saline
3164554|NCT00500565|Experimental|On-Q Pump with Bupivicaine|On-Q Pump with bupivicaine
3164555|NCT00500591||Obese Women|
3164556|NCT00500604|Experimental|A|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 150/12.5mg tablet every morning for 8 weeks.~period 3: One 300/12.5mg tablet every morning for 8 weeks.~period 4: Two 150/12.5mg tablets every morning for 8 weeks."
3164557|NCT00500604|Active Comparator|B|"period 1: Hydrochlorothiazide 12.5 mg for 3-5 weeks~period 2: One 80/12.5mg tablet every morning for 8 weeks.~period 3: One 160/12.5mg tablet every morning for 8 weeks.~period 4: Two 80/12.5mg tablets every morning for 8 weeks."
3164558|NCT00500617||segment 1|Gene discovery blood draw
3164559|NCT00500617||sement 2|Assay development blood draw
3164560|NCT00500617||segment 3|Assay validation blood draw
3164561|NCT00500617||segment 4|Additional assay testing blood draw (Note: post discovery diabetic subjects assigned to this group)
3164562|NCT00500669|Experimental|Betadine|
3164563|NCT00500669|Active Comparator|Saline|
3164564|NCT00500695|Experimental|Motivational Interviewing|Motivational Interviewing
3164565|NCT00500695|Active Comparator|Psychoeducation|Psychoeducation
3164566|NCT00500734||Heart Disease Patients|
3164567|NCT00500747|Experimental|Group C: 100 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 100 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3164568|NCT00500747|Experimental|Group B: 20 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 20 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3164569|NCT00500747|Experimental|Group A: 4 mcg HCV E1E2/MF59 vaccine|Sixteen subjects receive four doses of 4 mcg HCV E1E2/MF59 vaccine (0.5 mL total volume) and 4 subjects receive placebo at 0, 4, 24, and 48 weeks.
3164570|NCT00500786|Experimental|100 mcg CYT006-AngQb Healthy Volunteers|
3164571|NCT00500786|Experimental|100 mcg CYT006-AngQb Hypertensives|
3164572|NCT00500786|Experimental|300 mcg CYT006-AngQb Hypertensives|
3164573|NCT00500786|Placebo Comparator|Placebo Healthy Volunteers|
3164574|NCT00500786|Placebo Comparator|Placebo Hypertensives|
3164575|NCT00500812|Experimental|0.3 mg|Subjects Receiving 0.3 mg Cethrin
3164576|NCT00500812|Experimental|1 mg|Subjects receiving 1 mg Cethrin
3164577|NCT00500812|Experimental|3 mg|Subjects receiving 3 mg Cethrin
3164578|NCT00500812|Experimental|6 mg|Subjects receiving 6 mg Cethrin
3164579|NCT00500812|Experimental|9 mg|Subjects receiving 9 mg Cethrin
3164580|NCT00500825||1|Patients successfully resuscitated after cardiac arrest undergoing therapeutic hypothermia
3164581|NCT00500838|Experimental|1|Transthoracic impedance device implanted.
3164582|NCT00500851|Active Comparator|1|In case of meeting clinical criteria for jejunal feeding, tubes are placed using CORTRAK (electromagnetic imaging).
3164583|NCT00500851|Active Comparator|2|Endoscopic placement of jejunal feeding tubes fulfilling clinical indication for jejunal feeding.
3164584|NCT00500877|Active Comparator|Mood Management Phone counseling|Mood management phone counseling for smoking cessation
3164585|NCT00500877|Placebo Comparator|Phone Counseling Standard|Phone counseling standard
3164586|NCT00500942||1|Patients having a standard procedure performed in Interventional Radiology.
3164587|NCT00500968|Active Comparator|Stent|
3164588|NCT00500968|Active Comparator|conventional distal pancreatectomy|
3164589|NCT00500981|Experimental|Intravenous fluid bolus|Administration of 500 ml of 10% pentastarch
2515109|NCT02795962|Active Comparator|Transfer to an Endovascular Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be directly transferred to the nearest Endovascular Center bypassing the Local Stroke Center.
2515114|NCT02795962|No Intervention|Transfer to the Local Stroke Center|Acute stroke patients with suspected acute large vessel occlusion identified by EMS at first assistance on the field will be transferred to the Local Stroke Center as done accordingly with the current stroke code protocol.
2515164|NCT02795650|Experimental|Experimental arm|Personalised treatment will be chosen for patients based on the results of tumor sequencing, bioinformatics and avatar model drug testing.
2515168|NCT02795650|Active Comparator|Control|Investigators are allowed to chose the best option of standard treatment for patients.
2515202|NCT02795312|Experimental|Smoking Cessation Training Program|Participants will take part in a 9-week Smoking Cessation Program class curriculum consisting of weekly 2.5 hour classes and complete pre and post questionnaires
2515233|NCT02795130|Experimental|8-0 polyglactin 910|
2515247|NCT02795130|Experimental|6-0 plain gut suture|
2515284|NCT02794961|Experimental|CD22 CAR-T|Enrolled patients will receive three escalating doses of autologous CAR-T.
2515348|NCT02794636||IFN Treatment|Adult (age ≥ 18 years) patients identified as having stage III melanoma and no other primary or secondary cancer who initiated treatment with IFN between 1/1/2007 and 12/31/2011. Patients are required to have continuous pharmaceutical benefit enrollment for 180 days before (pre-index) and after (post-index) IFN initiation and no evidence of treatment with systemic chemotherapy during the pre- or post-index period
2515398|NCT02794337|Active Comparator|DEB TACE Arm|Patients randomized to drug eluting beads(DEB) TACE arm will undergo 3 cycles of DEB-TACE (100 mg of doxorubicin drug eluting beads which will be repeated after 4-6 weeks. CT/MRI will be repeated prior to each cycle. Sorafenib will be omitted on the day of TACE and will be reinitiated after the TACE procedure. After completing all TACE cycles patients will continue to be on sorafenib till progression, or 12 months whichever is later, or in patients who fail to tolerate it after dose modifications. Hepatobiliary CTCAE will be completed at baseline, at each TACE cycle and subsequently at each follow up. QOL will be evaluated at the same time and also at two months after completing all sessions of TACE (matched time point with completion of SBRT in interventional arm)
2515400|NCT02794337|Experimental|DEB-TACE+SBRT arm|Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
2515459|NCT02793869||Total cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2515461|NCT02793869||Anterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2515463|NCT02793869||Interior cataracts group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2515465|NCT02793869||Posterior cataract group|All selected eyes were categorized into four groups: total cataracts, anterior cataracts, interior cataracts and posterior cataracts, based on the position of lens opacities shown by both a slit lamp (BX900, HAAG-STREIT AG, Bern, Switzerland) examination and a 3-dimensional anterior segment imaging and analysis system (Pentacam HR, Oculus Inc., Wetzlar, Germany) after mydriasis.
2515554|NCT02793518|Experimental|Bipolar Disorder patients|
2515555|NCT02793518|Experimental|Healthy Controls|
2515596|NCT02792855|Experimental|snifﬁng Position|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
2515601|NCT02792855|Experimental|Simple Head Extension|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
3164591|NCT00501072|Experimental|Open|Real-Time Continuous Glucose monitoring System (RT-CGMS) with alarm setting active and ability to view glucose trend profiles
3164592|NCT00501072|No Intervention|Blind|RT-CGMS is applied without alarm setting and without the ability to watch glucose trend profiles
3164593|NCT00501098|Experimental|I|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
3164594|NCT00501111|No Intervention|1|Placebo
3164595|NCT00501111|Active Comparator|2|donepezil
3164596|NCT00501111|Experimental|3|AZD3480
3164597|NCT00501137|Active Comparator|16-26 year olds 3 doses HPV Vaccine|Group 3 - 16-26 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0, 2, 6 mths
2515124|NCT02795884|Experimental|Intercalation arm|"Intercalation phase (Duration: 3wks x 4 cycles = 12 wks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Erlotinib 150mg D8-21 q3wks~Maintenance phase (Duration: 1 year) Erlotinib 150mg D1-28"
2515128|NCT02795884|Active Comparator|Chemotherapy alone arm|Duration: 3wks x 4 cycles = 12 wks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3wks
2515145|NCT02795663|Experimental|parkinson's patient stimulated at STN level|15 parkinson's disease patients stimulated at STN level NIRS EEG HR recording
2515148|NCT02795663|Experimental|non STN|5 Parkinson's Disease patients who received stimulation in another target that the STN NIRS EEG HR recording
2515151|NCT02795663|Experimental|control|20 control patients undergoing DBS for the treatment of OCD NIRS EEG HR recording
2515210|NCT02795442|Experimental|Even protein|Menu to provide 90 g of protein per day in an even distribution of 30 g at each meal.
2515212|NCT02795442|Experimental|Skewed protein|Menu to provide 90 g of protein per day in a skewed distribution of 10 g at breakfast, 15 g at lunch and 65 g at dinner.
2515335|NCT02794753|Experimental|True intervention|Working memory training on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
2515342|NCT02794753|Active Comparator|Active control|Similar time spent playing on computer 5 weeks 25 sessions (5 sessions per week) 50 minutes per session
2515495|NCT02793388|Active Comparator|Supervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure. Supervision of primaquine is done on alternate days at home (attended by a home visitor) or at the health centre.
2515498|NCT02793388|Active Comparator|Unsupervised primaquine arm|Following standard schizontocidal treatment according to national guidelines and if haemoglobin levels are above 8g/dL and G6PD testing is normal, the patient receives primaquine (0.5mg/kg/day) for 14 days for radical cure for self administration.
2515550|NCT02793297|Experimental|refined wheat crisp bread|refined wheat crisp bread was served as part of a complete standardized breakfast
2515552|NCT02793297|Experimental|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread was served as part of a complete standardized breakfast
2515553|NCT02793297|Experimental|unfermented rye crisp bread|Unfermented rye crisp bread was served as part of a complete standardized breakfast
2515593|NCT02792933|Active Comparator|air in epidural space|When the ALOR epidural localization technique will be used, an intermittent pressure with fast movements will be exerted on the plunger of the syringe while the Tuohy needle will be inserted until loss of resistance was felt.
2515597|NCT02792933|Experimental|saline in epidural space|When the SLOR technique is used, a continuous pressure will be exerted on the plunger of the Tuohy needle until loss of resistance was felt.
3164598|NCT00501137|Active Comparator|3 dose 9-13 HPV Vaccine|Group 2 - 9-13 year olds receiving 3 doses HPV (Human Papillomavirus) Vaccine at 0,2,6 mths
3164599|NCT00501137|Active Comparator|2 dose 9-13 yrs HPV Vaccine|Group 1 9-13 year olds 2 doses HPV (Human Papillomavirus) Vaccine at 0 and 6 mths
3164600|NCT00501176|Active Comparator|plastic stent|Stent insertion
3164601|NCT00501176|Active Comparator|metalic stent|Stent inserttion
3164602|NCT00501189||1|Those getting Gardasil vaccination for low grade Pap abnormality.
3164603|NCT00501189||2|Historical group that did not get Gardasil.
3164604|NCT00501202|Placebo Comparator|002|placebo twice daily for 4 weeks
3164605|NCT00501202|Experimental|001|RWJ-333369 (carisbamate) 200 mg tablet twice daily for 4 weeks
3164606|NCT00501215|Experimental|Parathyroidectomy + Observation|
3164607|NCT00501215|Other|Observation Alone|
3164608|NCT00501241|Placebo Comparator|1|placebo twice daily
3164609|NCT00501241|Experimental|2|20 mg ATI-7505, BID for 4 weeks
3164610|NCT00501241|Experimental|3|40 mg ATI, BID, 4 weeks
3164611|NCT00501241|Experimental|4|80 mg ATI-4505, BID for 4 weeks
3164612|NCT00501241|Experimental|5|120 mg ATI-7505, BID for 4 weeks
3164613|NCT00501280||MSF Women + their children|Blood and urine samples and interviews of Migrant or seasonal farmworker (MSF) woman + their children
3164614|NCT00501280||Non-MSF Women + their Children|Blood and urine samples and interviews of non-MSF women (women who have never worked in agriculture) and their children
3164615|NCT00501319||1|Patients with Non-Small Cell Lung Cancer.
3164616|NCT00501332|Active Comparator|2|
3164617|NCT00501371|Active Comparator|MCS|Group A: MCS 30 mg/day for 12 weeks
3164618|NCT00501371|Placebo Comparator|Placebo|Placebo, 2 capsules per day
3164619|NCT00501410|Experimental|FOLFOX + Dasatinib + Cetuximab|5-FU 2400 mg/m^2 by vein over 46 Hours On Days 1 & 2. Cetuximab initial dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8. Dasatinib 100 mg by mouth daily on days 1-14. Leucovorin 400 mg/m^2 by vein on day 1. Oxaliplatin 85 mg/m^2 by vein on day 1.
3164620|NCT00501449||Multiple Endocrine Neoplasia (MEN)|Patients with multiple endocrine neoplasia (MEN).
3164621|NCT00501462|Other|Mild renal impairmnent|
3164622|NCT00501462|Other|moderate renal impairment|
3164623|NCT00501462|Other|Normal renal function|
3164624|NCT00501527|Experimental|A: Biological vaccine|The first active arm will receive a dose that is 10x less than the dose of the other arm
3164625|NCT00501527|Experimental|B: biological vaccine|The first active arm will receive a dose that is 10x more than the dose of the other arm
3164626|NCT00501527|Placebo Comparator|C|
3164627|NCT00501618|Other|Fazaclo|open label switch from generic clozapine to Fazaclo
3164628|NCT00501657|Experimental|Sitagliptin (100mg)|Active drug (sitagliptin)
3164629|NCT00501657|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
3164630|NCT00501670||Group A|Collection of lesion samples and blood sampling from subjects aged >=50 years with clinically diagnosed herpes zoster
3164631|NCT00501696|Other|1|A randomized placebo-controlled, parallel-group study, crossover-design
3164632|NCT00501696|Other|2|A randomized placebo-controlled, parallel-group study, crossover-design
3164633|NCT00501709|Experimental|Treatment|Allogenic pancreatic islet transplant using belatacept and raptiva
3164634|NCT00501748|Experimental|Rituximab|
3164635|NCT00501761||1: Endometrial Cancer Survivors|
2515172|NCT02795598|Active Comparator|Single Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided single injection supraclavicular nerve block for surgical anesthesia.
2515177|NCT02795598|Active Comparator|Double Injection Supraclavicular Block|Patients scheduled for surgery distal to the elbow will have an ultrasound guided double injection supraclavicular nerve block for surgical anesthesia.
2515277|NCT02795013||Participants with Hodgkin Lymphoma|Those with a confirmed diagnosis of Hodgkin Lymphoma (HL) and family members who consent and enroll in this study.
2515286|NCT02795013||Family Members without Hodgkin Lymphoma|Those unaffected by HL will serve as a control group to compare with those with HL.
2515355|NCT02794649||healthy|Individuals without a history of kidney or bowel disease
2515360|NCT02794649||primary hyperoxaluria|Patients diagnosed with type I PH by genetic testing
2515363|NCT02794649||enteric hyperoxaluria|Patients with Roux-en-Y-gastric-bypass.
2515366|NCT02794649||calcium oxalate stone formers|History of passing or having surgically removed a calcium oxalate kidney stone within 5 years of recruitment.
2515409|NCT02794220|Experimental|CN Electronic cigarette 10 mg|"10 mg strength~- Administration once every hour for a total of 4 hours."
2515413|NCT02794220|Experimental|CN Electronic cigarette 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
2515419|NCT02794220|Active Comparator|Nicorette Inhalator 15 mg|"15 mg strength~- Administration once every hour for a total of 4 hours."
2515423|NCT02794220|Active Comparator|Cigarette|"Subjects will all smoke the same brand.~- Administration once every hour for a total of 4 hours."
2515469|NCT02793687|Experimental|Mexidol|"Sequential therapy with MEXIDOL® as follows: MEXIDOL® (i.v. solution) - 500 mg / day. for 10 days, followed by application MEXIDOL® 1 tablet of 125 mg three times a day (daily dose 375 mg) for 8 weeks.~The use of the study drug is held with basic therapy."
2515470|NCT02793687|Placebo Comparator|Placebo|"Sequential therapy as follows: Placebo (i.v. solution) for 10 days followed by placebo 1 tablet three times a day for 8 weeks.~The use of a placebo is held with basic therapy."
2515523|NCT02793401|Active Comparator|HILT group|71 of the patients were in the HILT group
2515524|NCT02793401|Active Comparator|US Group|70 of the patients were in the US group.
3164636|NCT00501761||2: Healthy Participants|Healthy participants that have no history of invasive cancer.
3164637|NCT00501787|Active Comparator|Group B|Non-tailoring
3164638|NCT00501787|Active Comparator|Group A|Tailoring
3164639|NCT00501800||Caucasian|
3164640|NCT00501800||African American|
3164641|NCT00501800||Chinese|
3164642|NCT00501800||Latina (Mexican or Central American)|
3164643|NCT00501800||Filipina|
3164644|NCT00501813|Active Comparator|surgery|initial palliative hepatectomy followed by TACE and/or local regional treatment
3164645|NCT00501813|Experimental|no surgery|TACE combined with local regional treatment without hepatectomy
3164647|NCT00501839|Active Comparator|Group A|Cyclic progestogens for nine months
3164648|NCT00501839|Active Comparator|Group B|CC treatment for further three cycles at the same ovulating doses followed by six months of cyclic progestogens
3164649|NCT00501839|Active Comparator|Group C|CC administration at the same ovulating doses for nine cycles
3164650|NCT00501865|Experimental|Sequence AB|Subjects will be randomized to sequence AB, where A represents fasted state and B represents fed state. Subjects will be administered a single oral dose of GW273225 50 milligrams (mg) in the fasted state in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 2. There will be at least 21 days between doses for the fasted and fed treatment phases of the study.
3164651|NCT00501865|Experimental|Sequence BA|Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
3164652|NCT00501904|Active Comparator|Group A|Short protocol
3164653|NCT00501904|Active Comparator|Group B|Long protocol
3164654|NCT00501956|Experimental|Intradialytic parenteral nutrition|Individually compounded intradialytic parenteral nutrition (IDPN) including glucose, amino acids, lipids, L-Carnitine, trace elements and water-soluable vitamins 3x / week over 16 weeks + 12 weeks postinterventional observation.
3164655|NCT00501956|No Intervention|Control Group|Observation over 28 weeks (16 + 12 weeks).
3164656|NCT00501982|No Intervention|1|N Cpap in delivery room and than rescue curosurf in case of need
3164657|NCT00501982|Experimental|2|Poractant alfa (Curosurf) + N Cpap in delivery room
3164658|NCT00502021|Experimental|1|Supplement of flaxseed powder (60 g/day)during 12 weeks
3164659|NCT00502021|Placebo Comparator|2|Placebo powder supplement 60 g/day during 12 weeks
3164660|NCT00502021|Experimental|3|Flaxseed oil 30 ml/day (10 g ALA)during 12 weeks
3164661|NCT00502021|Placebo Comparator|4|Safflower oil 30 ml/day (no ALA) during 12 weeks
3164662|NCT00502034|Experimental|A-immunotherapy|Immunotherapy with interferon-alpha and interleukin
3164663|NCT00502034|No Intervention|B-follow-up|Wait-and-see
3164664|NCT00502086|Experimental|I|Viusid, three sachets daily during 96 weeks
3164665|NCT00502086|Placebo Comparator|2|Placebo three sachets daily during 96 weeks
3164666|NCT00502099|Active Comparator|1|Pegylated interferon alpha 2a plus ribavirin
3164667|NCT00502099|Active Comparator|2|Pegylated interferon alpha 2b plus ribavirin
3164668|NCT00502112|Experimental|1|lintuzumab and lenalidomide
3164669|NCT00502125||Patients with oral lesions|
3164670|NCT00502138|Experimental|A|Interventional, continuous pramlintide infusion at 9 micrograms/hr plus 60 microgram meal bolus plus continuous insulin basal-bolus subcutaneous infusion
3164671|NCT00502177||Quality of Life Questionnaire|Patients undergoing continuous hyperthermic peritoneal perfusion with cisplatin and their parents/caregivers.
3164672|NCT00502190|Experimental|1|Silicon ring positioned in the vagina, around the cervix
2515213|NCT02795455|Experimental|Interoceptive Exposure (IE)|IE is an exposure-based intervention that involves consuming a food in session and tolerating uncomfortable feelings around eating.
2515214|NCT02795455|Active Comparator|Family Based Therapy-Weight Gain Control (FBT-WG)|Family-based therapy uses parent(s) to help modify disordered eating and develop contingencies to motivate eating.
2515215|NCT02795455|No Intervention|Healthy Controls (HC)|HC participants will only participate in the pre and post-intervention visits and not in the intervention sessions.
2515262|NCT02795039|Experimental|Fulvestrant 50mg/mL (Fresenius Kabi)|5 mL intramuscular injection
2515265|NCT02795039|Active Comparator|Fulvestrant 50 mg/mL (Faslodex®)|5 mL intramuscular injection
2515321|NCT02794740|Experimental|X0002 First Dose|Preliminary Experiment,4 Subjects,Single-Dose,Once,Non-Blind.
2515324|NCT02794740|Experimental|X0002 Second Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2515328|NCT02794740|Placebo Comparator|Placebo Second Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2515331|NCT02794740|Experimental|X0002 Third Dose|8 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2515336|NCT02794740|Placebo Comparator|Placebo Third Dose|2 Subjects,Single Dose once and Multiple Doses 7 Days,b.i.d,12 Hours Apart,Double-Blind.
2515343|NCT02794740|Experimental|X0002 Fourth Dose|8 Subjects,Single Dose,Once,Double-Blind.
2515349|NCT02794740|Placebo Comparator|Placebo Fourth Dose|2 Subjects,Single Dose,Once,Double-Blind.
2515428|NCT02794142|Experimental|HD patient|
2515431|NCT02794142|Other|Healthy volunteers|
2515496|NCT02793427|Experimental|Type 1 diabetes|
2515499|NCT02793427|Experimental|control|
2515535|NCT02793271|Active Comparator|PRIME|The behavioral intervention will be the PRIME/mhGAP training. This is standard mental health training for prescribers (primary care workers who can prescribe psychotropic medication, e.g., health assistants) and non-prescribers (primary care workers who cannot prescribe medications, e.g., auxilliary nurse midwives). For prescribers, training includes introduction to psychosocial techniques and mhGAP. For non-prescribers, training includes psychosocial techniques.
2515539|NCT02793271|Experimental|PRIME+RESHAPE|The behavioral intervention will be the PRIME/mhGAP training plus the RESHAPE training adjunct. This is the PRIME training plus social contact component in which mental health service users participate as training co-facilitators. The intended goal of the additional component is to reduce stigma against persons with mental illness.
3164673|NCT00502190|Experimental|2|Silicon ring positioned in the vagina, around the cervix
3164674|NCT00502229|Active Comparator|Group A|Continuing treatment
3164675|NCT00502229|Active Comparator|Group B|Gonadotrophins
3164676|NCT00502255|Experimental|telemonitoring|Health Buddy in patients home situation
3164677|NCT00502255|Experimental|usual care|patients receive care as usual
3164678|NCT00502268|Placebo Comparator|Group 1|Doxercalciferol administration by DOQI and 2nd Gen PTH assay
3164679|NCT00502268|Active Comparator|Group 2|Doxercalciferol administered by 1-84-7-84 ratio between 1.4-1.6
3164680|NCT00502281|Active Comparator|Group A|COS followed by TI
3164681|NCT00502281|Active Comparator|Group B|COS followed by IUI
3164682|NCT00502372|Experimental|Enriched product, dietary supplement|Subjects receiving enriched product compared to an unenriched product
3164683|NCT00502372|Active Comparator|1|Subjects not receiving enriched product
3164684|NCT00502411|Experimental|Doxorubicin + Radiation Therapy|Doxorubicin 17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4. Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
3164685|NCT00502502||Symptom-Related Cytokines Questionnaire|
3164686|NCT00502515|Experimental|25 mg SSR180575|orally once daily for 24 weeks
3164687|NCT00502515|Experimental|100 mg SSR180575|orally once daily for 24 weeks
3164688|NCT00502515|Placebo Comparator|Placebo|orally once daily for 24 weeks
3164689|NCT00502528|Placebo Comparator|1|Placebo
3164690|NCT00502528|Active Comparator|2|BQ-123
3164691|NCT00502541|Experimental|Fluocinolone acetonide|Fluocinolone acetonide intravitreal implant
3164692|NCT00502541|Active Comparator|Standard of Care|Standard of care
3164693|NCT00502554|No Intervention|1|Observation with standard care (macrolides, exercise, oxygen therapy etc.) alone.
3164694|NCT00502554|Active Comparator|2|2-day cycles of photopheresis every 3 weeks for 3 months
3164695|NCT00502580||1|Patients with lesions of the oral cavity mucosa.
3164696|NCT00502606||patients with provisional crowns|the same patient would serve as control and test
3164697|NCT00502619|Experimental|Acupuncture plus Treadmill Exercise|Acupuncture plus Treadmill Exercise
3164698|NCT00502632|Experimental|1|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
3164699|NCT00502632|Placebo Comparator|2|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
3164700|NCT00502684|Experimental|1|Peri-operative etodolac and propranolol as described in protocol
3164701|NCT00502684|Placebo Comparator|2|peri-operative placebo as described in protocol
3164702|NCT00502710|Experimental|RO4876904 1|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3164703|NCT00502710|Experimental|RO4876904 2|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3164704|NCT00502710|Experimental|RO4876904 3|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3164705|NCT00502710|Experimental|RO4876904 4|Escalating doses, at a starting dose of 12.5mg po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3164706|NCT00502710|Placebo Comparator|Placebo|Placebo po daily. Patients receiving metformin before the study will continue on the same dose of metformin.
3164707|NCT00502723|Active Comparator|2|Radical laparoscopy prostatectomy
2515217|NCT02795156|Experimental|Arm 2|Patients with urothelial carcinoma who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2515218|NCT02795156|Experimental|Arm 3|Patients with non-colon gastrointestinal cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2515219|NCT02795156|Experimental|Arm 4|Patients with upper aerodigestive tract cancers who have failed first line treatment may receive either regorafenib (Stivarga), afatinib (Gilotrif), or cabozantinib (Cabometyx) at the recommended dose level, depending on their specific genomic alterations.
2515353|NCT02794701||people with silicosis|
2515441|NCT02794298|Experimental|Anodal tDCS|Anodal stimulation during resting state fMRI
2515442|NCT02794298|Experimental|Cathodal tDCS|Cathodal stimulation during resting state fMRI
2515443|NCT02794298|Sham Comparator|sham tDCS|Sham stimulation during resting state fMRI
2515500|NCT02793648|Experimental|Treatment|Ascorbic acid 200mg twice a day for twelve weeks Alpha tocopherol 200mg twice a day for twelve weeks
2515501|NCT02793648|Placebo Comparator|Placebo|colloidal Silica 200mg twice a day for twelve weeks
3164708|NCT00502723|Experimental|1|Radical retropubic prostatectomy
3164709|NCT00502736|Experimental|1|
3164710|NCT00502749|Experimental|Exercise program|Daily (Monday-Friday) 45-minute group physical exercise program during each hospital admission for three months or individual 20 minute session bedside.
3164711|NCT00502814||1|Patients with Breast Cancer.
3164712|NCT00502827|Other|Recommended Standard of Care|Recommended Standard of Care (RSOC) = Physician Advice + Written Materials
3164713|NCT00502827|Other|RSOC + Cell Phone Intervention|Recommended Standard of Care (RSOC) + Cell Phone Intervention
3164714|NCT00502866||breastfed children|children, 6-15 months old, predominately breastfed for at least 6 months without supplemental vitamin D
3164715|NCT00502892|Experimental|Topotecan + Ifosfamide + Carboplatin|
3164716|NCT00502918||1|
3164717|NCT00502970|Experimental|1|16 weeks Interferon Tiw with Ribavirin
3164718|NCT00502970|Active Comparator|2|24 weeks Interferon Tiw with Ribavirin
3164719|NCT00502983||Interview|AML Patients & Healthy Controls
3164720|NCT00503035|Experimental|Celecoxib|Celecoxib 400 mg orally twice daily for 6 months. Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure.
3164721|NCT00503048||1|foster care children
3164722|NCT00503048||2|reference children (living with families)
3164723|NCT00503074|Experimental|1|Parents receive tailored health-behavior change messages designed to reduce their child's exposure to televised food commercials. Intervention is delivered by a case manager, by a website, and by periodic newsletters.
3164724|NCT00503074|Active Comparator|Control|Parents of children ages 2-5 receive behavioral-change counseling around toddler & preschooler safety and injury prevention.
3164725|NCT00503100||NICU full-term early pain group|
3164726|NCT00503100||NICU premature early pain group|
3164727|NCT00503100||NICU premature control group|
3164728|NCT00503100||Soroka- full-term control group|
3164729|NCT00503152|Experimental|benazepril|
3164730|NCT00503152|Experimental|valsartan|
3164731|NCT00503152|Experimental|benazepril/valsartan|
3164732|NCT00503178|Experimental|Patients undergoing imaging guided radiotherapy.|
3164733|NCT00503191|Experimental|Intention-based therapy treatment for autism|NeuroModulation Technique
3164734|NCT00503204|Experimental|1|Lomustine + Cediranib (AZD2171)
3164735|NCT00503230|Active Comparator|Standard Care Intervention (SCI)|
3164736|NCT00503230|Active Comparator|Culturally Tailored Intervention (CTI)|
3164737|NCT00503256||CLL - Linkage Families|Gene identification related to Chronic lymphocytic leukemia (CLL) development
3164738|NCT00503269|Active Comparator|1|30 ml of 1% Lignocaine with 1:10,000 Adrenaline
3164739|NCT00503269|Active Comparator|2|Standard General anaesthesia with Enflurane and Propofol.
3164740|NCT00503321|Experimental|Arm B|S-1 plus PSK group
3164741|NCT00503321|Active Comparator|Arm A|S-1 alone
3164742|NCT00503334|Experimental|preOP booster|
3164743|NCT00503334|Placebo Comparator|preOP booster placebo|
3164744|NCT00503347|Experimental|1|0.3 mg/kg
3164745|NCT00503347|Experimental|2|1 mg/kg
3164746|NCT00503347|Experimental|3|3 mg/kg
3164747|NCT00503347|Experimental|4|6 mg/kg
3164748|NCT00503438|Other|Salto Talaris Ankle|This is an Implant Registry of the approved Salto Talaris Ankle replacement device
3164749|NCT00503451|Experimental|LBH589|
3164750|NCT00503490|Experimental|1|Inhaled Levofloxacin
3164751|NCT00503490|Placebo Comparator|2|Placebo
3164752|NCT00503516|Experimental|1|Megestrol acetate 160 mg b.i.d. during 24 weeks
3164753|NCT00503516|Placebo Comparator|2|1 sachet of powder of placebo b.i.d. during 24 weeks
3164754|NCT00503542|Experimental|Intervention|Patients primarily with itching or irritation are treated for candidal vaginitis. Patients primarily with vaginal odor are treated for bacterial vaginosis. Patients who did not fit either of the previous groups are treated for both candidal vaginitis and bacterial vaginosis.
3164755|NCT00503542|Active Comparator|Control|Patient are examined and a wet mount is prepared. If a definitive diagnosis is made patient is treated for the condition diagnosed. If no diagnosis is made the clinician has the option of either foregoing treatment (watchful waiting) or following the protocol in the experimental group
3164756|NCT00503568|Experimental|DS-1: gp96-ig Dose Schedule 1|Dose Schedule 1 (DS-1): Ad100-gp96Ig-HLA A1 Vaccine 4x10^7 cells bi-weekly, maximum 9 vaccines/patient;
3164757|NCT00503568|Experimental|DS-2: gp96-ig Dose Schedule 3|Dose Schedule 2 (DS-2): Ad100-gp96Ig-HLA A1 Vaccine 2X10^7 cells weekly, maximum 18 vaccines/patient;
3164758|NCT00503568|Experimental|DS-3: gp96-ig Dose Schedule 3|Dose Schedule 3 (DS-3): Ad100-gp96Ig-HLA A1 Vaccine 1x10^7 cells twice weekly, maximum 36 vaccines/patient
2515235|NCT02795260|Experimental|ESAT6-CFP10 in the right arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of BCG immunization :ESAT6-CFP10 in the right arm and TB-PPD in the left arm concomitantly,according to a randomisation scheme.
2515246|NCT02795260|Experimental|ESAT6-CFP10 in the left arm|Each volunteer is intradermally injected two agents in different arms 12 weeks after Bacillus Calmette - Guerin (BCG) or placebo of Bacillus Calmette - Guerin immunization :ESAT6-CFP10 in the left arm and TB-PPD in the right arm concomitantly,according to a randomisation scheme.
2515274|NCT02794831||patient|Adult patient hospitalized in MCO in one of the study centers for severe community bacterial infection, infected with more than one site, and / or abscess collection, and / or a per-cutaneous drainage of the infection, and / or septic surgery.
2515281|NCT02794831||control|Patient hospitalized in the same center (different service or not), during the week or months of the inclusion of cases for infection without abscess or invasive procedure, only one infected site
2515373|NCT02794675|Experimental|Cesium 131 brachytherapy|Cesium 131 is the radioactive isotope in the protocol. The prescribed dose will range from 50-80 Gy at maximal delivery. It comes in 0.5 cm seeds that will be placed in the tumor resection bed at 1cm intervals. They are implantable seeds that do not require removal.
2515513|NCT02793453|Other|Diseased|Patients suffering of moderate to severe chronic periodontitis
2515515|NCT02793453|Other|Healthy|Healthy Patients not suffering of any periodontal disease a
3164759|NCT00503594|Experimental|1|Comparative evaluation of the efficiency of a new protocol of the primitive LYMPHOME of the central nervous system ( LPSNC) to the old subject, associating Methotrexate and Temozolomide with regard to a standard protocol associating Methotrexate, Procarbazine, Vincristine and Cytarabine.
3164760|NCT00503594|Active Comparator|bras conventional|bras conventional
3164761|NCT00503659|Active Comparator|A|Methacholine challenge, five-breath dosimeter protocol
3164762|NCT00503659|Active Comparator|B|Methacholine challenge five incremental dosages protocol
3164763|NCT00503711|Experimental|100 mg Vandetanib eod|100 mg Vandetanib every other day dosing
3164764|NCT00503711|Experimental|100 mg Vandetanib od|100 mg Vandetanib once daily dosing
3164765|NCT00503711|Experimental|300 mg Vandetanib od|300 mg Vandetanib once daily dosing
3164766|NCT00503737|Active Comparator|Colorectal Cancer Screening Toolkit|Toolbox includes tools and guides designed increase screening by primary care physicians
3164767|NCT00503737|No Intervention|Standard of Care Colorectal Cancer Screening|Primary Care physician will screen for colorectal cancer as per his/her standard practice
3164768|NCT00503789|Active Comparator|1|cow-milk based infant formula
3164769|NCT00503789|Experimental|2|cow milk based infant formula with prebiotics
3164770|NCT00503789|Other|3|human milk reference group
3164771|NCT00503802|Active Comparator|1|Active RF treatment
3164772|NCT00503802|Sham Comparator|2|Sham RF treatment
3164773|NCT00503828|Active Comparator|naproxen|Naproxen 500 mg/day for 4 weeks
3164774|NCT00503828|Experimental|Derris Scandens Benth|Derris Scandens Benth
3164775|NCT00503854||Observational (questionnaire)|Patients complete a questionnaire on days 1, 2, and 6 regarding fatigue, sleep disturbance, depression, and other symptoms.
3164776|NCT00503893||Wilm's Tumor PO1|Familial and Sporadic Wilm's tumor, genitourinary anomalies, Beckwith-Wiedemann hemihypertrophy and/or aniridia.
3164777|NCT00503919|Experimental|MDC|Multi-spectral Digital Colposcopy for Fluorescence Spectroscopy
3164778|NCT00503932|Experimental|Proton Therapy + Capecitabine|Capecitabine 825 mg/m^2 by mouth twice daily on Proton Therapy (radiation) days.
3164779|NCT00503971|Experimental|Vorinostat plus erlotinib|Vorinostat plus erlotinib
3164780|NCT00504010|Active Comparator|1|arnica containing cream
3164781|NCT00504010|Placebo Comparator|2|carrier cream without arnica
3164782|NCT00504036|Experimental|Intra-gastric balloon|Patients will receive either an air-filled or water-filled intra-gastric balloon.
3164783|NCT00504036|No Intervention|Usual care|Usual care will be given to the patients.
3164784|NCT00504114||1|Healthy volunteers without knee pain.
3164785|NCT00504114||2|Patients with mild arthritic symptoms and radiographic changes (Kellgren Lawrence score of 1, 2)
3164786|NCT00504114||3|Patients with severe pain and functional limitations associated with knee arthritis (Kellgren Lawrence score of 3, 4).
3164787|NCT00504114||4|Patients with acute anterior cruciate ligament (ACL) injuries with associated osseous contusion.
3164788|NCT00504114||5|Patients with posttraumatic knee injury or degenerative condition and will have cartilage resurfacing procedures.
3164789|NCT00504127|Experimental|naproxcinod 375 mg bid|
3164790|NCT00504127|Experimental|naproxcinod 750 mg bid|
3164791|NCT00504127|Active Comparator|naproxen 500 mg bid|
3164792|NCT00504127|Placebo Comparator|placebo|
3164793|NCT00504140|Experimental|Interferon Alpha + Etoposide|Interferon Alpha 5x10^6 mu/m^2 subcutaneously and Etoposide 100 mg/m^2 intravenously, both daily for 5 days
3164794|NCT00504270|Placebo Comparator|Placebo|po daily
3164795|NCT00504270|Experimental|RG3421 120mg|120mg po daily
3164796|NCT00504270|Experimental|RG3421 20mg|20mg po daily
3164797|NCT00504296|Experimental|SB939|
3164798|NCT00504322|Placebo Comparator|placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
3164799|NCT00504322|Active Comparator|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
3164800|NCT00504335|Experimental|500 BIO 300 capsule|The first cohort will receive one 500 BIO 300 capsule and pharmacokinetic blood sampling will be conducted over the first 4 days in an outpatient setting
2515241|NCT02795052|Active Comparator|Arm 1 - Intravenous BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously.
2515251|NCT02795052|Active Comparator|Arm 2- Intravenous and Intranasal BMSC|Intervention- Autologous bone marrow aspiration and separation of Bone Marrow Derived Stem Cell (BMSC) fraction then provided intravenously and intranasally (lower 1/3 of nasal passages).
2515308|NCT02794792|Active Comparator|Metformin and placebo|Participants will receive daily dosage of Metformin and Placebo as single tablets.
2515310|NCT02794792|Experimental|Metformin and Ipragliflozin|Participants will receive daily dosage of Metformin and Ipragliflozin (2 dose strengths) as single tablets.
2515312|NCT02794792|Other|Metformin, placebo and Ipragliflozin|Participants will receive daily dosage of Metformin, placebo and Ipragliflozin (1 dose strength) as single tablets.
2515376|NCT02794376|Experimental|Immediate Treatment Group|Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments.
2515379|NCT02794376|Other|Delayed Treatment Group|Waiting period plus Mindfulness course consisting of six weekly two hour mindfulness sessions plus meditation homework assignments after the waiting period has finished.
2515396|NCT02794077|Experimental|Cyclophosphamide|Patients receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progression or unacceptable toxicity.
2515434|NCT02793934||1st phase|"In the 1st phase of the study the staff of the medical organizations continue to work in the familiar old scheme, but using the set of scales."
2515438|NCT02793934||2nd phase|"In the 2nd phase, medical organizations will start to work on a new model with the implementation of problem-oriented multidisciplinary approach and the use of modern rehabilitation technologies. There is planning to use clearly defined criteria for transfer from stage to stage, developed by the professional community. When doctors will be trained program ICF-reader will have an opportunity to establish a rehabilitation diagnosis on the basis of the ICF, and the option for ICF assessment using rating scales."
2515526|NCT02793557|Placebo Comparator|Placebo|Intradermal injection of 50 μl solution. One application in SAD part for each dosing occasion. 2 or 3 times weekly for 3 month in MD part.
2515530|NCT02793557|Experimental|FOL-005: Solution 1|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2515532|NCT02793557|Experimental|FOL-005: Solution 2|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2515537|NCT02793557|Experimental|FOL-005: Solution 3|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
2515541|NCT02793557|Experimental|FOL-005: Solution 4|Intradermal injection of 50 μl solution. One application in SAD part. 2 or 3 times weekly for 3 month in MD part.
3164801|NCT00504335|Experimental|1000 BIO 300 capsule|the second cohort will be treated with 1000 mg BIO 300 using the same PK sampling program
3164802|NCT00504335|Experimental|1500 BIO 300 capsule|the third cohort will be treated with 1500 mg BIO 300using the same PK sampling program
3164803|NCT00504335|Experimental|2000 BIO 300 capsule|the forth cohort will be treated with 2000 mg BIO 300using the same PK sampling program
3164804|NCT00504361||1: Lung Disease|Individuals with at least one of the following: (1) symptoms consistent with pulmonary disease; (2) chest X-ray consistent with lung disease; (3) pulmonary function tests consistent with lung disease; (4) lung biopsy consistent with lung disease; (5) family history of lung disease; (6) patients with diseases of organs with known association with lung disease; and (7) individuals suspected of history of lung diseased based on history and/or physical examination
3164805|NCT00504361||2: Normal Control|Individuals without a history of lung disease.
3164806|NCT00504374||Symptoms Questionnaire|Patients with lung cancer.
3164807|NCT00504387||A: Patients|Patients with a primary burning mouth disorder Pain (VAS 0-10): 3<x<9 Patient understands and speaks german Age: >18 years
3164808|NCT00504387||B: Controls|Age and sex matched persons/patients who do not have any history of an oral burning sensation or a burning mouth disorder.
3164809|NCT00504400|Experimental|A|
3164810|NCT00504439|Experimental|Cohort 1|Subjects in Cohort 1 will receive 20 milligrams (mg) of SB-656933-AAA once daily or matching placebo once daily for 14 days.
3164811|NCT00504439|Experimental|Cohort 2|Subjects will be administered 40 mg simvastatin on day 1 followed by a washout period of two days. From day 3, the subjects will receive 50 mg of SB-656933-AAA once daily or matching placebo once daily for 14 days. On day 17, subjects will be administered 40 mg simvastatin along with SB-656933-AAA to assess statin interaction.
3164812|NCT00504439|Experimental|Cohort 3|Subjects will be administered 100 mg SB-656933-AAA/ day or matching placebo for 14 days. Dosing will initiate after cohort I and II have completed dosing.
3164813|NCT00504478|Experimental|1|8-weeks of high complex carbohydrate diet
3164814|NCT00504478|Experimental|2|omega-3 fatty acids supplements
3164815|NCT00504491|Experimental|1|"Four Rituximab - CHOP courses will be given The courses will be given every 21 days Drug Dose Day Rituximab (Mabthera) 500mg/m2 1(*) (**) Cyclophosphamide 750mg/m2 1 Adriamycin 50mg/m2 1 Vincristine 1,4 mg/m2 1 Prednisone 60mg/m2 1 to 5~(**) 1st course, 375 mg/m2 (*) If lymphocyte count is > 30 X 10 9/l, dose will be split up in two, which will be given in days 0 and 1"
3164816|NCT00504543|Active Comparator|Neoral|
3164817|NCT00504543|Active Comparator|AEB071 high dose with Cetican reduced dose|
3164818|NCT00504543|Active Comparator|AEB071 low dose with Cetican standard dose|
3164819|NCT00504621||sarcoidosis|Sarcoidosis known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
3164820|NCT00504621||pulmonary fibrosis|Idiopathic pulmonary fibrosis (IPF) patients known by the ild care team of the outpatient clinic of the department of Respiratory Medicine of the University Hospital Maastricht as well as new patients attending the out-patient clinic from August 2007 to January 2009
3164821|NCT00504634|Experimental|Bortezomib|1 mg/m^2 intravenous (IV) Days 1, 4, 8, and 11.
3164822|NCT00504686|Active Comparator|1|manual therapy - thoracic spine thrust manipulation
3164823|NCT00504686|Active Comparator|2|therapeutic exercise
3164824|NCT00504699|Experimental|letrozole|ovarian stimulation after breast cancer diagnosis and before breast cancer treatment
2515294|NCT02794948|Active Comparator|Western intervention|DHEA(dehydroepiandrosterone) 1 sack every time twice a day for three months. Chinese medicine formula granules placebo 1 capsule every time per day for 3 day per month.
2515351|NCT02794532|No Intervention|Pre oxygenation with 100% oxygen via tight fitting mask|Pre Oxygenation will be done using a tight mask
2515358|NCT02794532|Experimental|Pre oxygenation with 100% oxygen in high-flow nasal cannula|Pre Oxygenation will be done using high-flow nasal canula
2515503|NCT02793661|Experimental|RenalGuard Arm|In order to prevent patients from acute kidney injury, patients will receive the RenalGuard Therapy delivered by the RenalGuard system from one hour before the cardiovascular intervention to 4 hours after the intervention.
2515504|NCT02793661|Active Comparator|Control Arm|Patient will received standard treatment, as per ESC Guidelines 2014, to prevent from acute kidney injury.
2515561|NCT02793141||ICU Nosocomial Pneumonia|Nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ward patients (= or > 48 hours after hospital admission) that due to deterioration are subsequently admitted to ICU or nosocomial pneumonia (hospital-acquired pneumonia) with onset in non-intubated ICU patients (= or >48 hours after hospital admission) or ventilator-associated pneumonia with onset = or > 48 hours after intubation. No intervention will be administered.
3164825|NCT00504699|No Intervention|control|No ovarian stimulation before breast cancer treatment
3164826|NCT00504712|Experimental|Active|Testosterone 200 mg intramuscular every 2 weeks
3164827|NCT00504712|Placebo Comparator|Placebo|Saline
3164828|NCT00504790|Experimental|GSK923295|anti-mitotic compound under study
3164829|NCT00504803|Experimental|1|MSC co-infusion with either HLA-mismatched PBSC or cord blood
3164830|NCT00504816|Other|Brevicon|Oral contraceptive used to determine pharmacokinetics when given with GSK189075 to look for interaction.
3164831|NCT00504816|Experimental|GSK189075|Given in conjunction with Brevicon to see if GSK189075 interfered with Brevicon drug levels.
3164832|NCT00504855|Active Comparator|Gortex (Waterproof) Cast Padding|Randomized application of one of two cast padding materials
3164833|NCT00504855|Active Comparator|Cotton/Cotton-Poly Cast Padding|Randomized application of one of two cast padding materials
3164834|NCT00504907|Experimental|Cohort A|Placebo or BTA9881 -10mg
3164835|NCT00504907|Experimental|Cohort B|Placebo or BTA9881 - 10mg
3164836|NCT00504907|Experimental|Cohort C|Placebo or BTA9881 - 25mg
3164837|NCT00504907|Experimental|Cohort D|Placebo or BTA9881 - 50mg
3164838|NCT00504907|Experimental|Cohort E|Placebo or BTA9881 - 100mg
3164839|NCT00504907|Experimental|Cohort F|Placebo or BTA9881 - 200mg
3164840|NCT00504907|Experimental|Cohort G|Placebo or BTA9881 - 400mg
3164841|NCT00504920||Symptom Assessment|Drawing blood samples and matching the test results with questionnaire responses for symptoms patients experience from transplant treatment.
3164842|NCT00504933|Experimental|A|Bilastine
3164843|NCT00504933|Active Comparator|B|Cetirizine
3164844|NCT00504933|Placebo Comparator|C|Placebo
3164845|NCT00504946|Active Comparator|I|
3164846|NCT00504946|Active Comparator|II|
3164847|NCT00504946|Placebo Comparator|III|
3164848|NCT00504946|Active Comparator|A|
3164849|NCT00504946|Placebo Comparator|B|
3164850|NCT00504959|Experimental|1|ranibizumab
3164851|NCT00504972|Experimental|Study Treatment|This study is a single arm study
3164852|NCT00504998|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
3164853|NCT00504998|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
3164854|NCT00504998|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
3164855|NCT00504998|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
3164856|NCT00504998|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
3164857|NCT00505024|Experimental|IVRS Only|
3164858|NCT00505024|Experimental|IVRS + Symptoms Report|
3164859|NCT00505037|Experimental|ASP1585 dose #1|
3164860|NCT00505037|Experimental|ASP1585 dose #2|
3164861|NCT00505037|Experimental|ASP1585 dose #3|
3164862|NCT00505037|Placebo Comparator|Placebo|
3164863|NCT00505037|Active Comparator|Sevelamer hydrochloride|
3164864|NCT00505050|No Intervention|1|Standard follow-up medical visits and treatment for control group were performed during the study period by the same cardiologist team that was not informed of the randomization.
3164865|NCT00505063|Other|A|Immunization Schedule patients <7 years.
3164866|NCT00505063|Other|B|Immunization Schedule patients > or = to 7 years and <11 years of age
3164867|NCT00505063|Other|C|Immunization Schedule patients > or = to 11 years of age
3164868|NCT00505089|Experimental|1|ACZ885 10mg/kg subcutaneous
3164869|NCT00505089|Experimental|2|ACZ885 5mg/kg intravenous
3164870|NCT00505089|Experimental|3|ACZ885 2mg/kg subcutaneous
3164871|NCT00505089|Experimental|4|ACZ885 1mg/kg intravenous
3164872|NCT00505102|Active Comparator|A|
3164873|NCT00505128|Other|1|to test the interest of early bile duct decompression by endoscopic sphincterotomy after early non invasive diagnosis by endosonography or MR cholangiography
3164874|NCT00505154|Placebo Comparator|2|Placebo tablets
3164875|NCT00505154|Active Comparator|1|rosuvastatin
3164876|NCT00505167|Active Comparator|1|Patients randomized to receive memantine
3164877|NCT00505167|Active Comparator|2|Patients randomized to receive donepezil
3164878|NCT00505219|Experimental|Ixmyelocel-T|Core decompression & treatment with Tissue Repair Cells (TRCs), demineralized bone matrix bound in autologous plasma
3164879|NCT00505219|Active Comparator|Standard of Care Only|Core decompression, demineralized bone matrix bound in autologous plasma, without any TRCs.
3164880|NCT00505232|Experimental|Rituximab-HCVAD,Methotrexate/Cytarabine and Zevalin|Induction Treatment (Rituximab-HCVAD and Methotrexate/Cytarabine) followed by Consolidation Treatment (Rituximab and Y-90 Ibritumomab tiuxetan)
3164881|NCT00505245||Observational (questionnaire, QOL assessment, interview)|Participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.
2515381|NCT02794363|Other|Autologous platelet rich plasma|Autologous platelet rich plasma injection into vulvar skin. There are no placebo, sham, or active comparator arms
2515422|NCT02794129|Experimental|Bipolar Disorder patients|
2515426|NCT02794129|Experimental|Healthy Controls|
2515525|NCT02793752||Mitochondrial Activity of Cumulus Cells|One way that cumulus cells influence oocyte competence is via metabolism (Dumesic et al., 2015). Analysis of mitochondria respiration is an established methodology used for evaluation of cell metabolic homeostasis and for diagnosis of different pathologies.
2515528|NCT02793752||Competence to Blastocyst|The percentage of fertilized eggs that develop to the blastocyst stage.
2515573|NCT02793024|Experimental|Arm 1 - Intervention|Counties will be randomized to receive the intervention or act as a delayed control. Students in the intervention arm will receive the 12-week intervention to improve shopping choices.
2515575|NCT02793024|No Intervention|Arm 2 - Intervention|Control adolescents will not receive the intervention and will receive routine information normally distributed through schools.
2515613|NCT02792738|Experimental|hypnosis, visual distraction|"This is a crossover study in which each subject will be exposed to a 5 min phase of hypnotic suggestion and visual distraction.~For hypnotic suggestion, subject will be invited to experience a pleasant memory . Indirect and permissive suggestion will be used.~For visual distraction, subject will be watching the movie la marche des empereurs"
3164882|NCT00505271|Experimental|1|Escalating doses of Rexin-G will be given two or three times a week for four weeks, with a 2 week rest period
3164883|NCT00505297||A|Subjects with potentiall rapidl progressing OA
3164884|NCT00505297||B|Age-matched healthy subjects with no knee pain
3164885|NCT00505310|Experimental|Emotional Expression Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
3164886|NCT00505310|Experimental|Neutral Writing|20 minutes of writing on different topics at four different times. Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
3164887|NCT00505336|Experimental|1|Eplerenone
3164888|NCT00505336|Active Comparator|3|no additional treatment
3164889|NCT00505336|Experimental|2|Atorvastatin
3164890|NCT00505349|No Intervention|No Intervention Arm|Phase I in this study will involve the evaluation of blood-derived neurotrophic factors in healthy, younger adults (18-30.) Individuals in this group will not undergo computerized, cognitive training.
3164891|NCT00505349|Experimental|Cognitive Training|Phase II of this study will involve an evaluation of the pre- and post- cognitive training levels of blood-derived neurotrophic factors in healthy, mature adults. Participants randomized to this arm will receive SAAGE-based computerized cognitive training.
3164892|NCT00505401|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
3164893|NCT00505401|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 microgrammi), or with Saline, as placebo.
3164894|NCT00505440|Experimental|Computerized screening and referral|Computerized screening and referral: Intervention is a web-based screening and assessment tool completed by adolescents during primary care visits. Patient reported screening provided to primary care physicians in real time with recommendations for behavioral referrals.
3164895|NCT00505440|Active Comparator|Delayed feedback from screening|Active comparator is Usual pediatric care plus mailed screening results from computerized waiting room screens that arrive three days after screening.
3164896|NCT00505466||Pre-Test Genetic Counseling + Genetic Sample|
3164897|NCT00505492|Experimental|Radiation + Chemotherapy|Radiation with weekly Cisplatin 40 mg/m^2 intravenously (IV) Followed by Carboplatin (AUC 5 IV)/Paclitaxel (135 mg/m^2 IV) Chemotherapy every 28 days
3164898|NCT00505505|Experimental|A|Insulin infusion rate titrated to maintain glycemia between 80 and 100 mg/dl
3164899|NCT00505505|Active Comparator|B|Insulin infusion rate titrated to maintain glycemia between 80 and 220 mg/dl
3164900|NCT00505531||Tramadol ER- 200mg|Tramadol Extended Release capsules Weeks 1 & 6- 100 mg/day Weeks 2-5- 200 mg/day
3164901|NCT00505531||Tramadol ER- 300mg|Tramadol Extended Release capsules Weeks 1 & 7- 100 mg/day Weeks 2 & 6- 200 mg/day Weeks 3-5- 300 mg/day
3164902|NCT00505531||Placebo|Diphenhydramine capsules Weeks 1-6- 25 mg/day
3164903|NCT00505544||Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
3164904|NCT00505544||Questionnaire + Actigraphs|Questionnaires that ask about your sleep, symptoms, and mood. Wear actigraph to collect information on activity levels and sleep patterns for one week.
3164905|NCT00505570|No Intervention|Medical Management|
3164906|NCT00505570|Experimental|PFO Closure|
3164907|NCT00505596|Experimental|Computerized decision aid|Participants instructed to view the updated PT Tool and told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study (Informed free choice). They also participate in a baseline pre-randomization interview and one follow-up telephone interview.
3164908|NCT00505596|No Intervention|Usual care|Control group, in which participants receive no intervention beyond a baseline pre-randomization interview and one follow-up telephone interview.
3164909|NCT00505609|Experimental|A|The Institute for Reproductive Health trained health providers in teaching the Standard Days Method to study subjects and in study procedures. Providers counseled study participants in method use. Participants were followed for up to 13 cycles of method use.
3164910|NCT00505713|Experimental|1|Dose Level 1 of escalating doses of Rexin-G i.v.
3164911|NCT00505713|Experimental|3|Dose Level 3 of escalating doses of Rexin-G i.v.
3164912|NCT00505713|Experimental|4|Dose Level 4 of escalating doses of Rexin-G i.v.
3164913|NCT00505713|Experimental|5|Dose Level 5 of escalating doses of Rexin-G i.v.
3164914|NCT00505713|Experimental|2|Dose Level 2 of escalating doses of Rexin-G i.v.
3164915|NCT00505726||Confocal Microscopy|
3164916|NCT00505739|Experimental|Mifepristone|
3164917|NCT00505791|Placebo Comparator|Sugar pill|Lactose, NF (monohydrate)
2515315|NCT02794714|Experimental|deep neuromuscular blockade|Rocuronium will be administered to achieve PTC 1-2 throughout surgery.
2515316|NCT02794714|Active Comparator|moderate neuromuscular blockade|Rocuronium will be administered to achieve TOFC 2 throughout surgery
2515403|NCT02793960|Experimental|Topical BPM31510 3.0% Cream|Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
2515606|NCT02792894|No Intervention|Enhanced Usual Care (EUC)|Enhanced Usual Care comprises of normal routine visits conducted by the local community health workers / Lady Health Workers (LHWs). Care is enhanced in 2 ways: (a) LHWs in the EUC arm will receive training in identifying children with developmental disorders and delays, as well as making referrals to their primary care physicians for treatment using the WHO mhGAP training program for developmental disorders and (b) The primary care physicians will receive the training in WHO mental health GAP(mhGAP) program developmental disorders module, by WHO Collaborating Center in Rawalpindi, Pakistan.
2515607|NCT02792894|Experimental|Family Networks program|Intervention is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO Parent Skills Training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
3164918|NCT00505791|Active Comparator|Nesiritide|Natrecor (nesiritide) is a commercially available B-type natriuretic peptide which is indicated for intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
3164919|NCT00505804|Experimental|1|
3164920|NCT00505804|Active Comparator|2|
3164921|NCT00505830||1|50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
3164922|NCT00505830||2|50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
3164923|NCT00505830||3|50 adolescents with psychiatric disorders but no autism syndrom.
3164924|NCT00505830||4|Sample of 50 healthy adolescents selected randomly from 200.
3164925|NCT00505843|Other|1|7mg MK0657 capsules + >/=1.0 mg/kg/hr dose of levodopa.
3164926|NCT00505843|Other|2|7mg MK0657 Pbo capsules + >/=1.0 mg/kg/hr dose of levodopa.
3164927|NCT00505869||1|Health & Wellness Intervention + Questionnaire
3164928|NCT00505869||2|Mood Management Intervention + Questionnaire
3164929|NCT00505882|Active Comparator|Insulin|
3164930|NCT00505882|Experimental|Pramlintide|
3164931|NCT00505947|Active Comparator|A|"Infliximab 5 mg/Kg body weight by intravenous infusion on visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, arm A will receive placebo at visits 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
3164932|NCT00505947|Placebo Comparator|B|"Arm B will receive placebo at visit 1 (week 0), visit 2 (week 2), visit 3 (week 6)and visit 5 (week 14).~Afterwards, after a washout period of 2 weeks, group B will receive infliximab 5 mg/Kg body weight by intravenous infusion at visit 6 (week 16), visit 7 (week 18), visit 8 (week 22)and visit 30 (week 30)"
3164933|NCT00505960|Experimental|1|
3164934|NCT00505999||Questionnaire|Patients diagnosed with Multiple Myeloma and healthy controls.
3164935|NCT00506012|Experimental|1|T2000
3164936|NCT00506051|Experimental|ZD6474 (vandetanib) 100mg|
3164937|NCT00506051|Experimental|ZD6474 (vandetanib) 300mg|
3164938|NCT00506090|Experimental|A|pulsed dye laser and dynamic cooling device at 3 weeks intervals
3164939|NCT00506090|Active Comparator|B|pulsed dye laser and dynamic cooling device at 6 weeks intervals
3164940|NCT00506090|Sham Comparator|C|dynamic cooling device
3164941|NCT00506181|Active Comparator|X|receiving probiotics
3164942|NCT00506181|Placebo Comparator|Y|
3164943|NCT00506181|No Intervention|Z|
3164944|NCT00506194|Experimental|Insulin|Insulin therapy was initiated at a 75% total daily dose in the last day hospitalization with Insulatard. Two third of daily dose was administered before breakfast and the other was administered at bedtime. Insulin doses were titrated every 3 days to achieve target FPG and pre-supper blood glucose values between 90 and 130 mg/dl. Bedtime insulin doses were titrated based on FPG values and the pre-breakfast dose was titrated base on pre-supper blood glucose.
3164945|NCT00506194|Active Comparator|OAD|Subject in other OAD group was visited every two weeks in the two months and the every four weeks. The subjects will start with Gliclazide-MR 30mg before breakfast, The dosage was titrated based on the fasting blood glucose on the visiting day with the same target. Decreased by 30mg if blood glucose was <70mg /dl, decreased by 15 mg if blood glucose was 70-90mg/dl, no change if blood glucose was 90-130mg/dl, increased by 15 mg if blood glucose was 131-160 mg/dl, increased by 30 mg if blood glucose >160mg/dl. When the Gliclazide-MR dose each to the maximum dose of 60 mg twice daily, Metformin was added. The titration of Metformin was use 250mg for an adjust dosage with the same target.
3164946|NCT00506233||Chronic Graft-Versus Host Disease (GvHD)|Participants with chronic graft-versus host disease (GvHD)
3164947|NCT00506246|Experimental|1|Propofol MCT/LCT
3164948|NCT00506246|Active Comparator|2|Propofol LCT
3164949|NCT00506272|Experimental|Standard care|Patients admitted for elective surgery will receive standard diabetes care, including but not limited to finger stick blood glucose determinations, and insulin injections delivered by the nursing staff.
3164950|NCT00506272|Experimental|Patient administered care|Patients will self-monitor and record finger-stick blood glucose measurements, and self administer insulin at doses agreed upon with the consulting endocrinology in-patient service.
3164951|NCT00506298|Experimental|A|CRx-401 (bezafibrate + diflunisal)
3164952|NCT00506298|Active Comparator|B|bezafibrate + placebo
3164953|NCT00506311|Experimental|Fibrin Sealant|
3164954|NCT00506311|No Intervention|No Fibrin Sealant|
3164955|NCT00506363|Experimental|A|pulsed dye laser and dynamic cooling device on the day of suture removal
2515346|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort C|In Cohort C, carboplatin or cisplatin and etoposide chemotherapy will be administered after atezolizumab and tiragolumab IV infusion. During induction phase, participants will receive atezolizumab and tiragolumab in combination with carboplatin or cisplatin on Day 1 of each 21-day cycle and etoposide on Day 1 to 3 of each 21-day cycle for 4 cycles. During maintenance phase, participants will receive atezolizumab and tiragolumab on Day 1 of each 28-day cycle.
2515357|NCT02794571|Experimental|Phase Ib Chemotherapy Dose-Expansion Stage: Cohort D|In Cohort D, participants will receive atezolizumab and tiragolumab on Day 1 and capecitabine on Day 1-14 of each 21-day cycle.
2515362|NCT02794571|Experimental|Phase Ib Q4W Sequential Dose-Expansion Stage: Tiragolumab+Atezolizumab|Participants will be treated every 4 weeks (Q4W) with fixed doses of tiragolumab and atezolizumab with tiragolumab being administered prior to atezolizumab.
2515365|NCT02794571|Experimental|Phase Ib Q4W Coinfusion Expansion Cohort Tiragolumab+Atezolizumab|Participants will be treated Q4W with fixed doses of tiragolumab and atezolizumab mixed and administered in one IV bag.
2515367|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC1|In Cohort NC1, participants will receive atezolizumab and tiragolumab in combination with bevacizumab on Day 1 of each 21-day cycle.
2515368|NCT02794571|Experimental|Phase Ib Non-Chemotherapy Dose-Expansion Stage: Cohort NC2|In Cohort NC2, participants will receive tiragolumab in combination with pembrolizumab on Day 1 of each 21-day cycle.
2515467|NCT02793804|No Intervention|Control|All HIV testing and counselling services will be conducted as currently.
2515468|NCT02793804|Experimental|HIV Self-Testing|Community-based distribution agents (CBDA), including Voluntary Male Medical Circumcision (VMMC) mobilisers, will deliver OraQuick® HIV Self-Tests (Orasure Technologies, Thailand). The kits will also be available at the health facility.
3164956|NCT00506363|Active Comparator|B|pulsed dye laser and dynamic cooling device 2 months after suture removal
2515521|NCT02793310|Active Comparator|DMEK|The intervention group will receive cornea transplantation by DMEK
2515522|NCT02793310|Active Comparator|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
2515570|NCT02793076|Experimental|Bollywood Dance|Bollywood dance is a routine that doubles as both physical and mental exercise.
3164957|NCT00506363|Sham Comparator|C|dynamic cooling device
3164958|NCT00506376||Surgical Treatment Preferences|Assessment of patient's feelings toward risks associated with surgical treatment of cervical cancer.
3164959|NCT00506402|Experimental|1|
3164960|NCT00506467||VRI System|Vibration Response Imaging (VRI) System
3164961|NCT00506480|Experimental|OD|patients artificially prepared for OD will undergo a mock cycle consisting of estrogen and later by progesterone. a pipelle sample will be taken after 6 days of progesterone supplementation.
3164962|NCT00506480|Experimental|IVF|A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
3164963|NCT00506506|Experimental|1|N-acetylcysteine 1200 mg twice daily x 48 hours
3164964|NCT00506506|Placebo Comparator|2|
3164965|NCT00506545|Experimental|SCH 619734|
3164966|NCT00506545|Placebo Comparator|Placebo|
3164967|NCT00506558|Experimental|A|Ventral Decompression and Instrumented Fusion
3164968|NCT00506558|Active Comparator|B|Dorsal Decompression with or without fusion
3164969|NCT00506584|Experimental|Group 1, arm 1|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day, where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3164970|NCT00506584|Experimental|Group1, Arm 2|Human breast milk + Prolact20/Neo20 (as needed) + Prolact+4 (initiated when nutrition volume reaches 40 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3164971|NCT00506584|Active Comparator|Group 1, Arm 3|Human breast milk + bovine-based human milk fortifier (initiated when nutrition volume reaches 100 mL/kg/day) + pre-term formula (as needed)
3164972|NCT00506584|Experimental|Group 2, Arm 1|Prolact20/Neo20 + Prolact+4 (initiated when nutrition volume reaches 100 mL/kg/day), where Prolact20/Neo 20 are donor human milk formulations at 20 cal/oz, Prolact+4 is a human-milk derived human milk fortified designed to add 4 cal/oz to 20 cal/oz human breast milk.
3164973|NCT00506584|Active Comparator|Group 2, Arm 2|Pre-term/term formula (minimum 20 cal/oz)
3164974|NCT00506701|Experimental|Tadalafil treatment 40 mg|
3164975|NCT00506727|Experimental|Adderall XR|
3164976|NCT00506727|Active Comparator|Atomoxetine hydrochloride|
3164977|NCT00506740|Active Comparator|Electrocautery|Elesurgical instruments are used to cut and coagulate tissue using alternatig electric current focusing intense heat at the surgical site. In electrosurgery, the patient is included in the circuit and current enters the patient's body.
3164978|NCT00506792|Experimental|1|QAU145
3164979|NCT00506792|Placebo Comparator|2|Placebo
3164980|NCT00506805|Experimental|Single Arm|
3164981|NCT00506818|Active Comparator|2|Intensive risk factor intervention
3164982|NCT00506870|No Intervention|1|Conventional follow-up of anticoagulation
3164983|NCT00506870|Experimental|2|Self-monitoring of anticoagulation
3164984|NCT00506896|Active Comparator|1|
3164985|NCT00506935|Experimental|1|GVG
3164986|NCT00506935|Placebo Comparator|2|placebo
3164987|NCT00506961|Active Comparator|1|10 mg rosuvastatin for 4 weeks followed by 20 m rosuvastatin for another 8 weeks
3164988|NCT00506961|Active Comparator|2|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
3164989|NCT00506987|Experimental|SCH 486757|
3164990|NCT00506987|Placebo Comparator|Placebo|
3164991|NCT00507000|Active Comparator|A, Cholecalciferol|A Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
3164992|NCT00507000|Placebo Comparator|Vitamin D and Tuberculosis|B, Lactose
3164993|NCT00507013|Other|2|
2515359|NCT02794519|Placebo Comparator|Placebo administered subcutaneously every 4 weeks|Subjects will receive placebo subcutaneously every 4 weeks. They will receive the treatment for minimum of 20 weeks but up to 44 weeks of dosing. Placebo will be administered by the trained site staff at Baseline, Weeks 4 and Week 8. From the Week 12 visit onwards, subjects may start to self-administer study drug at the site under the supervision of the trained site staff if they are able and willing to do so. If not, study drug will continue to be administered by the trained site staff.
2515395|NCT02794051|Experimental|Unified Protocol for Children|Child participants with behavior problems between the ages of 8-12 and their caregivers will participate in a transdiagnostic group therapy protocol.
2515533|NCT02793336||infant cohort|"The study is designed as a continuation of a cohort of infants from 12 to 48 months of age. This follows on from two previous cohorts: STOP MIP, which is a cohort of pregnant women followed up until delivery and the Baby-Cohort study, which enrols babies from mothers in the STOP MIP trial and follows them until their first year of live. When participants of the Baby-cohort Study reach study end, they are offered to participate in this study."
2515571|NCT02793063||BBD Consortium Contact Registrants|Osteogenesis Imperfecta patients who have self-registered at the Brittle Bone Disorders Consortium (BBD) Consortium Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
2515608|NCT02792751|Active Comparator|Group R (Ramsey)=25 patients|Propofol infusion was administered to provide Ramsey Sedation Scale 3-4 in Group R
2515609|NCT02792751|Experimental|Group B (BIS)=25 patients|Propofol infusion was given to maintain the Bispectral index monitorisation (BIS) levels between 60 and 85 in Group B.
3164994|NCT00507039||grass allergy, bronchial challenge|subjects with known allergy against grass-pollen undergo bronchial challenges
3164995|NCT00507065|Experimental|Adderall XR (10 mg)|
3164996|NCT00507065|Experimental|Adderall XR (20 mg)|
3164997|NCT00507065|Experimental|Adderall XR (30 mg)|
3164998|NCT00507065|Experimental|Adderall XR (40 mg)|
3164999|NCT00507065|Placebo Comparator|placebo|
3165000|NCT00507091|Experimental|ZD6474 (vandetanib) 100mg|
3165001|NCT00507091|Experimental|ZD6474 (vandetanib) 300mg|
3165002|NCT00507117|Active Comparator|PSG|
3165003|NCT00507156|Experimental|Mek postcon|Re-opening of the infarcted coronary artery by several balloon inflations separated by reperfusion of the vessel.
3165004|NCT00507156|Active Comparator|Standard treatment|Standard treatment (primary PCI)
3165005|NCT00507182|Experimental|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
3165006|NCT00507221|Experimental|1|Arm 1 will receive an intensive regimen of anti-helminthic therapy consisting of albendazole every three months for two years and praziquantel at enrollment and at one year of follow up.
3165007|NCT00507221|Active Comparator|2|Arm 2 will receive symptomatic diagnosis and treatment of helminth infection as is current standard of care in Kenya.
3165008|NCT00507247|Experimental|Daptomycin|6mg/kg/day intravenous (IV) for 10 days
3165009|NCT00507260|Experimental|Control Group|Control Group (Food Record)
3165010|NCT00507260|Experimental|Treatment Group|Treatment Group (Food Record + Nutritional Consults)
3165011|NCT00507273||GIST|Patients diagnosed with a gastrointestinal stromal tumor (GIST)
3165012|NCT00507299|Experimental|Model Care (SEEK)|Residents in this group received special training on addressing pyschosocial problems. They then used a parent screening questionnaire, and addressed identified problems. A study social worker was also part of this intervention. Thus, this group provided enhanced pediatric primary care.
3165013|NCT00507299|Active Comparator|Standard pediatric primary care|This arm involved residents receiving the regular education through the program. They did not use the screening questionnaire to identify psychosocial problems, and did not have a dedicated social worker to assist them. Instead, residents in this group provided standard pediatric primary care
3165014|NCT00507312|Active Comparator|1|Healthy subjects (with no evidence of cardiovascular disease).
3165015|NCT00507312|Experimental|2|Patients with risk factors for heart failure
3165016|NCT00507312|Experimental|3|Patients with heart failure
3165017|NCT00507325||Blood Sample + Tumor Sample|Blood samples will be collected. Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
3165018|NCT00507338|Experimental|ARC1779 low dose|0.1 mg/kg
3165019|NCT00507338|Experimental|ARC1779 mid dose|0.3 mg/kg
3165020|NCT00507338|Experimental|ARC1779 high dose|1.0 mg/kg
3165021|NCT00507338|Active Comparator|abciximab|labeled regimen for primary PCI
3165022|NCT00507351||Cancer Pain Management|Patients receiving chemotherapy for breast, colon, lung, or prostate cancer.
3165023|NCT00507390|Active Comparator|A1|n-3 PUFAs
3165024|NCT00507390|Placebo Comparator|A2|olive oil capsules
3165025|NCT00507403|Active Comparator|Infliximab|Infliximab
3165026|NCT00507403|Experimental|Infliximab +methotrexate|Infliximab +methotrexate
3165027|NCT00507572||Observational (medical chart review)|Patients' medical records are reviewed prospectively and retrospectively.
3165028|NCT00507585|Experimental|Oxaliplatin + Fluorouracil + Leucovorin + Avastin|
3165029|NCT00507611|Other|Single-arm|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
3165030|NCT00507637|Experimental|NT 201 (IncobotulinumtoxinA/Xeomin®)|
3165031|NCT00507650|Active Comparator|Prescribed|Fluid volume and type prescribed by MD or provider.
3165032|NCT00507650|Experimental|Supplemental|Fluid volume and type prescribed by physician or provider plus 10 ml/kg X 5 days.
3165033|NCT00507663|Experimental|Atenolol|Atenolol given prior to and for up to 7 days after surgery
3165034|NCT00507663|No Intervention|routine care|routine clinical care
2515546|NCT02793245|Experimental|Studied population|Patients will be questioned about their main characteristics (age, gender, height, weight, smoking), they will also perform a simplified a pulmonary function test (if possible).
2515603|NCT02792985|Experimental|Multisensory stimulation protocol|The Experimental group will follow an intervention protocol.
2515604|NCT02792985|Active Comparator|Control protocol|The Control group will follow the current protocol for patients in PTA at the Institut Guttmann.
3165035|NCT00507676||Group 1|One hundred and sixty healthy infants between 1 and 24 months of age will be evaluated. Subjects will be recruited so that there are 40 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. The ethnic composition will be approximately 80% Caucasian and 20% African-American in each of the four groups, which represents the distribution within the cities where infants will be evaluated. Subjects will be excluded if they were born prematurely (<37 weeks gestation), have a history of congenital cardio-respiratory disease, or have history of lower respiratory illness.
3165036|NCT00507676||Group 2|Eighty infants between 1 and 24 months of age scheduled for CT scans of the abdomen or chest will be evaluated. Subjects will be excluded if they are born prematurely (<37 weeks gestation), have history of congenital cardio-respiratory disease, or have history of recurrent wheezing.
3165037|NCT00507676||Group 3|Eighty infants with recurrent wheezing between 1 and 24 months of age will be evaluated when they are not acutely symptomatic for at least 3 weeks. Subjects will be recruited so that there are 20 subjects within each of four subgroups: 1) Negative ETS exposure and Negative Fm Asthma, 2) Positive ETS exposure and Negative Fm Asthma, 3) Negative ETS exposure and Positive Fm Asthma and 4) Positive ETS exposure and Positive Fm Asthma. Equal numbers of males and females will be recruited. Subjects will be excluded if they were born prematurely (<37 weeks gestation) or have history of congenital cardio -respiratory disease.
3165038|NCT00507715|Experimental|1|Plantago ovata husk
3165039|NCT00507715|Placebo Comparator|2|hemicellulose crystalline
3165040|NCT00507741|Experimental|Ertafolide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
3165041|NCT00507754||Latent Tuberculosis Infection|Patients with cancer at risk for developing active tuberculosis (TB).
3165042|NCT00507832|Active Comparator|I|"Interindividual design:~active and comparator (one side each) applied twice daily"
3165043|NCT00507832|Active Comparator|II Hydrocortisone|Hydrocortisone, twice daily
3165044|NCT00507858|Experimental|Pemetrexed|Starting dose 500 mg/m^2 IV once every 3 weeks
3165045|NCT00507858|Experimental|Pemetrexed + IV Dexamethasone|Pemetrexed Starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 20 mg intravenous (IV) Day 1.
3165046|NCT00507858|Experimental|Pemetrexed + Oral Dexamethasone|Pemetrexed starting dose 500 mg/m^2 IV once every 3 weeks + Dexamethasone 4 mg orally twice daily for 3 Days.
3165047|NCT00507884||3 Tesla MRI|Patients with renal tumors scheduled to have a CT scan of the kidneys and abdomen.
3165048|NCT00507897||A|Cohort: Patients with normal blood pressure scheduled to have thyroid nodules surgically removed
3165049|NCT00507897||A1|Patients from group A not receiving any drugs and who lack other pathology, gender and age matched group B1
3165050|NCT00507897||B|Cohort: Patients with increased blood pressure scheduled to have thyroid nodules surgically removed
3165051|NCT00507897||B1|Patients from group B not receiving any drugs and who lack other pathology, gender and age matched group A1
3165052|NCT00507923|Experimental|Group I (Tibetan yoga)|Participants participate in Tibetan yoga sessions consisting of deep breathing or stretching exercises over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions.
3165053|NCT00507923|Active Comparator|Group II (stretching)|Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
3165054|NCT00507923|Active Comparator|Group III (usual care)|Participants receive usual care and wear actigraph activity monitor and complete a sleep diary for 7 days. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
3165055|NCT00507936|Experimental|A|ABT-894 1 mg BID
3165056|NCT00507936|Experimental|B|ABT-894 2 mg BID
3165057|NCT00507936|Experimental|C|ABT-894 4 mg BID
3165058|NCT00507936|Placebo Comparator|D|
3165059|NCT00507936|Active Comparator|E|Duloxetine 60 mg QD
3165060|NCT00507949|Experimental|1|Megestrol acetate: sachets of granulated 160 mg. Dose: 160 mg/b.i.d. Duration 8 weeks
3165061|NCT00507949|Placebo Comparator|2|The placebo is the excipient of the experimental drug.
3165062|NCT00507962|Experimental|Cisplatin + Liposomal Doxorubicin|Cisplatin 100 mg/m^2 Intraarterial and Liposomal Doxorubicin starting dose 20 mg/m^2 by vein on Day 1 every 4 weeks
3165063|NCT00507975|Placebo Comparator|A|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
3165064|NCT00507975|Experimental|B|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
3165065|NCT00507988|Experimental|A|Complex Problem Solving Training
2515577|NCT02793011|Experimental|Dexamethasone|Liquid or capsule dexamethasone - to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
2515578|NCT02793011|Placebo Comparator|Placebo|Placebo liquid or capsule to be taken orally the evening before scheduled tonsillectomy with or without adenoidectomy
3165066|NCT00507988|Active Comparator|B|Basic Cognitive Training
3165067|NCT00508014|Active Comparator|Control|usual care
3165068|NCT00508014|Experimental|Concurrent Peer Review Visit|See description of interventioin
3165069|NCT00508040|Experimental|A|To analyse the potential therapeutic effect of Interferon alpha2a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
3165070|NCT00508040|Active Comparator|B|
3165071|NCT00508053|Active Comparator|1|Mass closure
3165072|NCT00508053|Experimental|2|Small stitches
3165073|NCT00508066|Experimental|Arm 1|Subjects in arm 1 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse 0.25 - 0.5% (according to patient's weight) Bupivacaine at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
3165074|NCT00508066|Placebo Comparator|Arm 2|Subjects in arm 2 will intraoperatively have a continuous infusion catheter placed in the paraspinal musculature of the posterior spinal wound. Post-operatively, the catheter will infuse normal saline at a rate of 4ml/hr for 72 hours. This is in addition to the standardized PCA pain management.
3165075|NCT00508092|Active Comparator|A|lanz incision appendectomy
3165076|NCT00508092|Active Comparator|B|lanz incision appendectomy
3165077|NCT00508131|Active Comparator|A|Milk fortified with, iron, zinc and vitamin C
3165078|NCT00508131|Placebo Comparator|B|Milk not fortified
3165079|NCT00508170||Patients with Oropharyngeal Cancer|
3165080|NCT00508170||Patients with Non-Oropharyngeal Cancer|
3165081|NCT00508235||Quality of Friendships|Patients with Neurofibromatosis, type 1 (NF-1) between the ages of 8 and 18 years old.
3165082|NCT00508248|Active Comparator|A1|1 g omega 3 fatty acid supplements
3165083|NCT00508248|Placebo Comparator|A2|
3165084|NCT00508287|Experimental|A|
3165085|NCT00508287|Active Comparator|B|
3165086|NCT00508287|Placebo Comparator|C|
3165087|NCT00508313||With Lung Cancer|Patients with lung cancer.
3165088|NCT00508313||Healthy Participants|Healthy participants without cancer.
3165089|NCT00508326|Experimental|HAI Paclitaxel|Paclitaxel via Hepatic Artery Infusion (HAI)
3165090|NCT00508339||1|Patients with a diagnosis of soft tissue sarcoma.
3165091|NCT00508352|Experimental|Helical tomotherapy|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
3165092|NCT00508365|Experimental|Subjects receiving treatment sequence AB|Eligible subjects will receive treatment sequence AB; A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
3165093|NCT00508365|Experimental|Subjects receiving treatment sequence BA|Eligible subjects will receive treatment sequence BA; B=COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14). A= Placebo to match COREG CR 20 milligrams once daily plus lisinopril 10 milligrams once daily (Days 1-7). Placebo to match COREG CR 40 milligrams once daily plus lisinopril 10 milligrams once daily (Days 8-14).
3165094|NCT00508378||Interview & Questionnaires|
3165095|NCT00508430|Experimental|1|Low dose group
3165096|NCT00508430|Experimental|2|Middle dose group
3165097|NCT00508430|Experimental|3|High dose group
3165098|NCT00508430|Placebo Comparator|4|
3165099|NCT00508443|Experimental|Radiation Therapy|Radiation Therapy using CT-on-Rails or Trilogy procedure. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
3165100|NCT00508456|Experimental|Hominex®-2 + Temodar®|Dietary Methionine Restriction (Hominex®-2) Days 1-7 and 15-21 + Temodar® 150 mg/m^2 orally Days 8-15
3165101|NCT00508495|Experimental|Test drug|
3165102|NCT00508495|Active Comparator|Reference drug|
3165103|NCT00508495|Placebo Comparator|Placebo|
3165104|NCT00508508|Experimental|1|Behavioral: IVR
3165105|NCT00508508|Experimental|2|Behavioral: Nurse-Led Group Visits
3165106|NCT00508560|Experimental|Arm 1|Experimental
3165107|NCT00508560|Active Comparator|Arm 2|Active Comparator
3165108|NCT00508573||Lynch Syndrome Registry|Patient that has or is at risk for Lynch Syndrome.
3165109|NCT00508586|Experimental|1|PTC299 with an aromatase inhibitor
3165110|NCT00508599|No Intervention|1|Study 1 is the control arm in which participants continue with their normal activity.
3165111|NCT00508599|Experimental|2.|Study 2 consists of 48 hours of complete bed rest.
3165112|NCT00508612|Active Comparator|1|The 12-lesson Williams LifeSkills anger and stress management workshop (WLS) enhances awareness of thoughts and feelings in stressful situations, and provides training in evaluation, deflection, problem-solving, assertion, saying no, speaking, listening, empathy, and emphasizing positives.
3165113|NCT00508612|Placebo Comparator|2|Control group (will attend regular high school classes)
3165114|NCT00508625|Other|C|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3165115|NCT00508625|Experimental|E|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3165116|NCT00508625|Experimental|B|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.
2515584|NCT02792816||Myawaddy Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Myawaddy is one of the sentinel site and located at the northern part of the Southern Myanmar.
2515585|NCT02792816||Thanbyuzayat Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Thanbyuzayat is one of the sentinel site and located at the northern part of the Southern Myanmar.
2515586|NCT02792816||Shwegyin Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Shwegyin is one of the sentinel site and located at the southern part of the central Myanmar.
2515587|NCT02792816||Magway Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Magway is one of the sentinel site and located at the middle part of the central Myanmar.
2515588|NCT02792816||Rakhine Site|The efficacy and safety of the ACT in different sentinel sites will be assessed. The administrated anti-malarial were same and all will be administrated under direct observation. The dosage will be calculated by weight of the patients. Rakhine is one of the sentinel site and located at the western Myanmar.
2515615|NCT02792660|Experimental|Injeq IQ-Needle|Lumbar puncture is performed using Injeq IQ-Needle
2515657|NCT02792426|Active Comparator|Group 1 AB|Smoker subject's own brand of combustion cigarette
2515665|NCT02792426|Active Comparator|Group 1 BA|Smoker subject's own brand of combustion cigarette
2515668|NCT02792426|Active Comparator|Group 2|E-cigarette user's own brand of electronic nicotine delivery system (ENDS)
2515710|NCT02792088|Experimental|Besifovir|Besifovir 150 mg q.d.
2515721|NCT02792088|Active Comparator|Tenofovir|Tenofovir 300 mg q.d.
2515758|NCT02791737|Experimental|Supportive care (otago exercise programme)|Patients attend 8 physical therapy visits twice monthly for 4 months or until transplant. Patients also undergo an individualized exercise program at home for 6 months. The program comprises 3 main components: walking over 30 minutes twice a week, strengthening and balance retraining exercise over 30 minutes three times a week.
2515785|NCT02791542||Asthma|Participants with a history of asthma
2515786|NCT02791542||Healthy controls|Participants without a history of asthma
2515787|NCT02791542||Asthma Bronchoscopy sub-group|Participants with a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
2515788|NCT02791542||Healthy Bronchoscopy sub-group|Participants without a history of asthma who will undergo the same procedures as other healthy controls with the addition of bronchoscopy
2515814|NCT02791217||Diffused Large B cell Lymphoma|
2515816|NCT02791217||Follicular Lymphoma|
2515818|NCT02791217||Multiple Myeloma|
2515820|NCT02791217||Hodgkin Lymphoma|
2515822|NCT02791217||Healthy individuals|
2515826|NCT02791347|No Intervention|Control|"Upon discharge from the medical center, patients would be advised on a qualitative, neutropenic diet. Participants' quality of life, physical activity level, functional and nutritional status would be assessed at days +30, +60 and +100 post transplantation.~These participants will not receive nutritional counseling by the dietitian as outpatients except if referred by the medical team."
2515829|NCT02791347|Experimental|Nutrition Intervention Group|"Upon discharge from the medical center, NIG patients will receive tailored nutrition counseling with the provision of patient education material and oral nutritional supplements if needed. Patients will be advised on a diet high in energy and proteins and tailored to their medical condition in the hospital before discharge.~Patients will be followed up at days +30, +60 and +100 post transplantation. Compliance will be measured at each visit by comparing patients caloric and protein needs to their actual protein and energy intake. Compliance will be reinforced to meet patients' goals using nutritional tips, oral supplementation, and artificial nutrition use."
2515860|NCT02791087||Coronary Artery Disease for CABG|Patients undergoing or underwent Coronary Bypass Surgery with at least one saphenous vein graft. Intra-operative graft flow rate measurement will be done during CABG surgery.
2515862|NCT02791087||Stable/Unstable Angina|Patients with no known history of coronary artery disease undergoing Computed Tomography Angiography scan due to stable/Unstable Angina.
2515865|NCT02791061||Control|"Healthy Volunteers will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
2515866|NCT02791061||Congenital Disease|"Patients will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imagine (MRI) Cardiopulmonary exercise testing (CPET) Echocardiography"
2515892|NCT02790840|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (15mg and 30 mg) administered twice daily for 15 days + Omeprazole oral capsules (20 mg or 40 mg) administered once or twice daily for 10 days
2515899|NCT02790749|Experimental|PAO with adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) with adjunctive hip arthroscopy.
2515901|NCT02790749|Active Comparator|PAO WITHOUT adjunctive hip arthroscopy|Patients undergoing periacetabular osteotomy (PAO) WITHOUT adjunctive hip arthroscopy.
2515922|NCT02790450|Experimental|Benzbromarone|1x200mg Benzbromarone
2515958|NCT02790411|Experimental|healthy volunteers|Imaging devices New Non Invasive Devices
2515975|NCT02790268||Lens Subluxation|Pediatric eyes with lens subluxation undergoing Cionni Ring Bag fixation with in-the-bag IOL Implantation
2516005|NCT02789891|Experimental|D2 Lymphadenectomy including No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy including No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
2516289|NCT02787915|Experimental|dendritic cell vaccine|DC1-CTL cellular therapy
2515619|NCT02792647|Experimental|Experimental: IX-01|2 different dose groups 1,600 mg and 2,400 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
2515620|NCT02792998|Experimental|IW-1701|IW-1701 tablets administered orally in multiple ascending dose.
2515622|NCT02792998|Placebo Comparator|Placebo|Matching placebo tablets administered orally.
2515623|NCT02792907|Experimental|Compressive Stockings group|Patients with compressive stockings at the operated foot for 4 weeks
2515624|NCT02792907|No Intervention|No compressive stockings group|Patients with no compressive stockings at the operated foot
3197854|NCT00864799|Active Comparator|Sublingual misoprostol|"Women allocated to the sublingual misoprostol protocol will receive a loading dose of 800 mcg misoprostol vaginally followed in 3 hours by 400 mcg sublingual misoprostol, the latter repeated every 3 hours for a maximum of 4 doses.~If abortion does not occur within 24 hours of commencement of this regimen, the sequence will be repeated.~If delivery is not accomplished within 48 hours of prostaglandin commencement, a transcervical Foley catheter will be inserted and a solution of prostaglandin F2 alpha infused 2-hourly until delivery occurs."
3197855|NCT00864812|Experimental|1|tiotropium with fluticasone propionate/salmeterol (FSC)
3197856|NCT00864812|Active Comparator|2|tiotropium
3197857|NCT00864825|Experimental|Allopurinol|
3197858|NCT00864825|Placebo Comparator|Placebo|
3197859|NCT00864838|No Intervention|1|Patients submitted to 1,5 mg/0,06 ml intravitreal injection of bevacizumab and no treatment for intraocular pressure elevation
3197860|NCT00864838|Experimental|2|Acetazolamide: 250 mg of oral acetazolamide 1 hour before intravitreal bevacizumab injection
3197861|NCT00864838|Experimental|3|topic brimonidine tartarate: one drop of brimonidine tartarate 1 hour before intravitreal bevacizumab injection
2515633|NCT02792491|Experimental|Reduced dose R-CHOP|"Reduced dose R-CHOP is regimen including Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.~In this study, Rituximab 375 mg/m2, Cyclophosphamide 600 mg/m2, Doxorubicin 30 mg/m2 and Vincristine fixed dose of 1mg will be administrated through intravenous on day 1. and Prednisone 40mg will be administrated orally on day 1-5. This chemotherapy will be repeated every 21 days."
2515634|NCT02792556||patient having a drug abortion|Urine pregnancy test for adult women having a drug abortion until 8 weeks of amenorrhea, presenting to the control visit between the 14th and 21th day after drug intake.
2515635|NCT02792608|Experimental|Mindfulness-based Therapy|5 week, manual-based group MBI treatment for depression
2515636|NCT02792686|Experimental|ABX464|50, 100, 150 or 200 mg once a day / Single Administration
2515637|NCT02792803|Experimental|Xalatan --> Apo-/Co-Latanoprost|Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
2515638|NCT02792582|Active Comparator|Tumor-Surgery|"Participants who are eligible to undergo surgery to remove the tumor will proceed to surgery. If all tumor is removed, they will be followed over 5 years for outcome comparison to the other participant groups.~If the entire tumor is not removed by surgery, participants will receive 6 weeks of proton therapy. They will then be followed for 5 years to collect outcome data for comparison to the other participant groups."
2515639|NCT02792673|Active Comparator|"Embryo Glue®"|Hyaluronan-enriched medium
2515640|NCT02792803|Experimental|Apo-/Co-Latanoprost --> Xalatan|Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)
2515641|NCT02792582|Active Comparator|Tumor-No Surgery|Participants whose tumor cannot be resected through surgery will receive 6 weeks of proton therapy. They will then be followed over 5 years for outcome comparison to the other participant groups.
2515642|NCT02792673|Active Comparator|"Global Total®"|30% Protein-supplemented Culture Medium
2515643|NCT02792673|Experimental|Autologous Follicular Fluid|a novel technique
2515644|NCT02792413|Experimental|Denosumab|Denosumab 60 mg, subcutaneous injection every 6 months for 24 months
2515646|NCT02792413|Placebo Comparator|Placebo|NaCl 0.9% (1 mL), subcutaneous injection every 6 months for 24 months
2515653|NCT02792361|No Intervention|Control Group|Subjects who did not have a suction drain placed post-operatively following a Pterional Craniotomy.
2515662|NCT02792361|Experimental|Treatment Group|Subjects who did have a suction drain placed post-operatively following a Pterional Craniotomy at the location of surgical incision.
2515686|NCT02792322|Other|Trans Oral Robotic Surgery (TORS)|Patient's are having TORS surgery in a seated position
3197862|NCT00864838|Experimental|4|anterior chamber paracentesis: anterior chamber paracentesis immediately after intravitreal bevacizumab
3197863|NCT00864864|Experimental|Sunitinib|
3197864|NCT00864890|Experimental|A|Citalopram HBr 40 mg tablets, single dose
3197865|NCT00864890|Active Comparator|B|CelexaTM 40 mg tablets, single dose
3197866|NCT00864903||pediatric ER|any child undergoing a spinal tap due to suspected meningitis
3197867|NCT00864929||1|Appropriate antimicrobial treatment
3197868|NCT00864929||2|Inappropriate antimicrobial treatment
3197869|NCT00864942|Experimental|BL-NHL|Bendamustine and lenalidomide for NHL
3197870|NCT00864942|Experimental|BLR-CLL|Bendamustine, lenalidomide, rituximab for CLL
3197871|NCT00864942|Experimental|BLR-NHL|Bendamustine, lenalidomide, and rituximab for NHL
3197872|NCT00864942|Experimental|BL-CLL|bendamustine and lenalidomide in patients with CLL
3197873|NCT00864955|Experimental|phototype 2|Volunteers with cutaneous phototype 2
3197874|NCT00864955|Experimental|phototype 4|Volunteers with cutaneous phototype 4
3197875|NCT00864968|Experimental|A|Nabumetone 750 mg tablets, single dose
3197876|NCT00864968|Active Comparator|B|Nabumetone 750 mg tablets, single dose
3197877|NCT00864981|Experimental|1|Bupropion HCI ER Tablets, 150 mg
3197878|NCT00864981|Active Comparator|2|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg
3197879|NCT00864994||1|• 30 healthy subjects with 20 pack years smoking who have no signs of COPD (age 40-75 years)
3197880|NCT00864994||2|• 30 COPD patients with GOLD stage II (age 40-75 years)
2515645|NCT02792374||Dental patients group|Psychological measurement is done when they refer to a dental clinic.
2515647|NCT02792374||Control group|Psychological measurement is done when they refer to a dental clinic.
3197881|NCT00865007|Experimental|Monotherapy group|Lopinavir/ritonavir (LPV/r).
2515650|NCT02792478||RAS wild-type subjects|The blood samples will be collected according to the site's routine clinical practice usually prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation status will be carried out on blood samples taken at baseline, on those carried out at 20 +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment) and on the sample obtained upon progression, coinciding with routine clinical practices for collecting blood. Blood Samples will be collected to all subjects participating (119 subjects.)Objective to evaluate the RAS mutation status at baseline in liquid biopsies in subjects with RAS wild type metastatic colorectal cancer.
2515649|NCT02792595|Sham Comparator|Negative Control|Untreated area will be irradiated using a sun simulator with UV irradiation increment of 1.25 to detect MED of the unprotected skin.
2515651|NCT02792569|Experimental|Biopsy at Right side|Biopsy of ovarian cortical tissue (50% right side)
2515659|NCT02792569|Experimental|Biopsy at Left side|Biopsy of ovarian cortical tissue (50% left side)
2515660|NCT02792478||Patient RAS WT|As in cohort 1 blood samples will be collected for all subjects participating (119) 10 ml will be used for analysis of the RAS mutation status. The mutation status of BRAF and EGFR will be also analysed with the IdyllaTM (Biocartis) tests in this Cohort 2. In 20 patients included in Cohort 2, 10 ml additional taken at baseline will be used in order to determine the RAS mutation status by the BEAMing technique and 10 ml additional taken at disease progression will be used to determine the mutational profile in genes other than RAS by a NGS technique.
2515661|NCT02792595|Active Comparator|Positive Control|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, positive control will be applied. The dose of positive control will be measured in accordance to the application volume (2 milligram (mg)/centimeter (cm)^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Positive control will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 seconds (s). After waiting for 15 to 30 minutes (min), the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the SPF of positive control, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515666|NCT02792595|Experimental|Test Product A|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515670|NCT02792595|Experimental|Test Product B|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515674|NCT02792595|Experimental|Test Product C|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515676|NCT02792595|Experimental|Test Product D|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515689|NCT02792309|Experimental|MotherWise Programming|Three components: (1) 18 hours of core workshop sessions using the Within My Reach relationship education curriculum supplemented with content on mother-infant relationships; (2) case management services; and (3) optional relationship education workshops for couples.
2515690|NCT02792309|No Intervention|Control|No program services
2515691|NCT02792010|Experimental|T1rho MRI|Patients included had hip cartilage MRI with acquisition of T1rho MRI sequence.
2515703|NCT02792296|Experimental|Daily measurement|This arm will be asked to use the Project: EVO Monitor once a day for four weeks..
2515747|NCT02791867|Placebo Comparator|Placebo|Placebo Administration
3197882|NCT00865007|Active Comparator|Triple arm|Lopinavir/ritonavir (LPV/r)+ ABC/3TC
3197883|NCT00865033|Experimental|1|Metformin HCL Tablets, 1000 mg
2515652|NCT02792348||children with congenital urine flow impairment|this group contain children with an unilateral urinary tract dilatation diagnosed by prenatal ultrasonography
2515656|NCT02792348||control group|this group contains children, between 1 and 3 months of age, without nephrological or urological anomaly
2515654|NCT02792530|Other|arm 1|Unuric hemodialytic patients who accumulate above 2.5 (4%) in intradialytic intervals before the nutritional intervention.
2515655|NCT02792543|Active Comparator|parenteral nutrition|Parenteral nutrition consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
2515658|NCT02792621|Experimental|active oral supplement|The active supplement will contain the prescription drug Acipimox (250 mgs) , a nicotinic acid precursor traditionally used to lower blood lipid levels. The supplement will be administered 3 times per day, for a 14 day period.
2515667|NCT02792543|Experimental|chyme reinfusion|Chyme reinfusion consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
2515663|NCT02792400|Placebo Comparator|A1: GRA-placebo + MEAL + DPP4-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + linagliptin placebo
2515664|NCT02792465|Experimental|Cohort A|CFI-402257 capsules will be taken orally, once a day, every day.
2515669|NCT02792621|Placebo Comparator|placebo supplement|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
2515671|NCT02792400|Placebo Comparator|A2: GRA-active + MEAL + DPP4-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + linagliptin placebo
2515672|NCT02792465|Experimental|Cohort B|CFI-402257 capsules will be taken orally, once a day, every day.
2515673|NCT02792400|Active Comparator|A3: GRA-placebo + MEAL + DPP4-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
2515675|NCT02792465|Experimental|Cohort C|CFI-402257 capsules will be taken orally, once a day, every day + Fulvestrant injection on day 1 and day 15 of every 28 day cycle
2515677|NCT02792400|Active Comparator|A4: GRA-active + MEAL + DPP4-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 5 mg linagliptin (Trajenta)
2515679|NCT02792400|Placebo Comparator|B1: GRA-placebo + MEAL + SGLT2-placebo|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
2515680|NCT02792400|Placebo Comparator|B2: GRA-active + MEAL + SGLT2-placebo|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + empagliflozin placebo
2515682|NCT02792400|Active Comparator|B3: GRA-placebo + MEAL + SGLT2-active|LY2409021 placebo + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
2515684|NCT02792400|Active Comparator|B4: GRA-active + MEAL + SGLT2-active|300 mg LY2409021 + 4 hour standardised liquid mixed-meal test + 25 mg empagliflozin (Jardiance)
2515693|NCT02792127|Experimental|Experimental|These participants will be given access to a six-month online program for social anxiety.
2515695|NCT02792114|Experimental|T-cell infusion|A single blood volume leukapheresis for harvesting of PBMCs will be performed, As the transduced T cells will be frozen, the timing of leukapheresis is not defined & can vary from patient to patient. Subsequently, a single dose of mesothelin-targeted T cells will be infused via intravenous catheter or central line (i.e., mediport). Patients will be monitored in the hospital and discharged home after a minimum of 48 hours. Patients will be monitored closely as outpatients for the next 2 months. Patients will be followed weekly as outpatients for the first 8 weeks after treatment. All patients will be hydrated intravenously, premedicated with acetaminophen & diphenhydramine, & administered cyclophosphamide at 1.5 g/m2 2 to 7 days (Day -7 to Day -2) before administration of mesothelin-targeted T cells.
2515697|NCT02792127|No Intervention|Wait List Control|These participants will not be given an intervention until after they have completed the study.
3165117|NCT00508625|Other|A|40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only
3165118|NCT00508625|Experimental|D|40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.
3165119|NCT00508664|Experimental|A|TP + Radiation (TPF until Feb 2009)
3165120|NCT00508664|Experimental|B|TP + Cetuximab + Radiation (TPF until Feb 2009)
3197884|NCT00865033|Active Comparator|2|Glucophage 1000 mg Tablets
3165121|NCT00508690|Active Comparator|IV|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
3165122|NCT00508690|Active Comparator|Oral/IV|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
3165123|NCT00508703||CT Scan + IMRT Radiation Therapy|
3165124|NCT00508794|Experimental|Group 1 Yoga Program|3 sessions of yoga each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3165125|NCT00508794|Experimental|Group 2 Stretching Program|3 sessions of stretching each week for 6 weeks. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3165126|NCT00508794|Other|Group 3 Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended. Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
3165127|NCT00508807|Experimental|RTA 402|5 mg PO daily x 21 days
3165128|NCT00508846||HNPCC Patients|
3165129|NCT00508859|Experimental|Active, 1|sertraline
3165130|NCT00508859|Placebo Comparator|Placebo|placebo
3165131|NCT00508885|Experimental|1|Niacinamide starting at 250 mg twice daily titrated up to 750 mg twice daily
3165132|NCT00508885|Placebo Comparator|2|Placebo
3165133|NCT00508898|Experimental|treatment group|Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
3165134|NCT00508898|Active Comparator|control group|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
3173779|NCT00615810|Experimental|1|Open label Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir DF 300 mg) once daily for oral administration to be taken on an empty stomach
2515678|NCT02792595|Experimental|Test Product E|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515681|NCT02792595|Experimental|Test Product F|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515683|NCT02792595|Experimental|Test Product G|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515685|NCT02792595|Experimental|Test Product H|After irradiation of the test area with a sun simulator with an increment of UV radiation of 1.25, test product will be applied. The dose of test product will be measured in accordance to the application volume (2 mg/cm^2 (± 0.05 mg/cm^2) and it will be applied using a micro litre syringe in approximately 15-30 small droplets all over the test area. Test product will be then quickly spread by gently rubbing with a non-saturated finger cot, first with rotating followed by crosswise movements for a final uniform coating on the skin. Spreading time will be between 20 and 50 s. After waiting for 15 to 30 min, the test area will be again irradiated (increment of 1.12 or 1.25) with the sun simulator. The irradiation time will depend on the expected SPF of the test product, participants' skin prototype, determined MED after irradiation and actual power of sun simulator.
2515687|NCT02792335||patients naive to oral anticoagulant treatment|NVAF patients naïve to oral anticoagulant treatment (Naïve)
2515688|NCT02792335||patients with prior warfarin therapy|NVAF patients with prior warfarin therapy (Warfarin treated)
2515701|NCT02791971|Experimental|SpeakOut Intervention|"Primary participants will be randomized to this arm or the Alcohol Control Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the SpeakOut intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will not receive intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
2515708|NCT02791971|Active Comparator|Alcohol Control Intervention|"Primary participants will be randomized to this arm or the SpeakOut Intervention Arm at the time of enrollment. Secondary participants will be assigned to this arm if the primary participant whom initially told them about the study is in this arm. Primary participants in this arm will receive the Alcohol Control Intervention on the day of enrollment, and will complete surveys on their contraceptive knowledge, attitudes, behaviors, and social communication at baseline, three months, and nine months. Secondary participants in this arm will complete similar surveys at baseline, three months, and nine months.~Note: Secondary participants will receive an intervention, but will be assessed on outcomes that may have been affected as a result of social communication with primary participants."
2515727|NCT02791984|Experimental|Fluid challenge with 250 ml of Ringer Lactate|
2515773|NCT02791841|Experimental|RRT|Rhythmic Reading Training, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2515776|NCT02791750||Observational|Patients followed for a medical consultation in the Institut de Cancérologie de Lorraine at 5 years of the beginning of an adjuvant hormonal therapy.
2515780|NCT02791841|Experimental|VHSS+AVG|Visual Hemispheric-Specific Stimulation + Action Video Games, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2515783|NCT02791841|Experimental|AVG|Action Video Games only, administered for 13 hours over 9 days (two 45-minute training sessions per day).
2515835|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Patients with clinical suspicion for CTEPH, scheduled for SPECT
3197885|NCT00865059|Experimental|A|Gabapentin 800 mg Tablets, single dose
3197886|NCT00865059|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
2515925|NCT02790385|Experimental|NPWT|subjects will undergo negative pressure wound therapy
2516340|NCT02787733|Experimental|Citrus flavonoid|Citrus peel extract containing >90% flavonoids
3197887|NCT00865072|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
3197888|NCT00865072|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
3197889|NCT00865085|Experimental|A|Citalopram HBr 40 mg tablets, single dose
3197890|NCT00865085|Active Comparator|B|CelexaTM 40 mg tablets, single dose
3197891|NCT00865111|Experimental|A|Bupropion 150 mg Extended-Released Tablet, single dose
3197892|NCT00865111|Active Comparator|B|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose
3197893|NCT00865137|Experimental|1 FK506E|
2515700|NCT02792166|Active Comparator|BPD-DS|BPD-DS involves creating a sleeve gastrectomy and creation of a Roux-en-Y bypass involving a Roux limb (150cm) which is anastomosed to the transected first-stage of the duodenum and a short common channel (100cm).
2515704|NCT02792166|Experimental|SADI-S|SADI-S involves creating a sleeve gastrectomy but simplifies the bypass part of the BPD-DS by a single anastomosis of a loop of jejunum at 250cm from the ileocecal valve (longer common channel) to the transected first-stage of the duodenum instead of the Roux-en-Y construct.
2515767|NCT02791789|Other|Autism Spectrum Disorder|clinical exam, speech and language therapy and neuropsychological evaluations, Training to the SEMATIC serious game
2515840|NCT02791425|Experimental|Brain Computer Interface (BCI) device|The patient uses the Brain Computer Interface (BCI) device in the ICU for communication for 2 hours a day for 3 consecutive days. The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
2515891|NCT02790931|Experimental|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months.
2515896|NCT02790931|No Intervention|Control Group|Patients will not receive any exercise treatment, will not have acess to the software, but they will keep their recommended clinical treatment.
3197894|NCT00865176|Experimental|1|Eplerenone 50mg Tablets
3197895|NCT00865176|Active Comparator|2|INSPRA 50mg Tablets
2515998|NCT02789969|Experimental|Hydromorphone 15mcg/kg IV|Patient randomly assigned to hydromorphone
2515999|NCT02789969|Experimental|Fentanyl 1.5 mcg/kg IV|Patient randomly assigned to fentanyl
2516015|NCT02789670||MS patients|MS patient group is composed by 20 Individuals with inflammatory brain lesions seen in MRI (Radiologically Isolated syndrome) 20 patients with only one clinically isolated syndrome (CIS) 20 patients with relapsed remittent Multiple sclerosis (RRMS) 20 patients with primary progressive Multiple Sclerosis (PPMS)
2516016|NCT02789670||Control group patients|"Control patient cohort is composed by 20 patients suffering from inflammatory neurological disease other than MS Devic syndrome, Neurosarcoidosis, Neurobehcet... (autoimmune disease control group with neurological disease) 20 patients with systemic sclerosis (autoimmune disease control group) without neurological disease)~40 healthy subjects"
2516093|NCT02789475|Experimental|amplodipine group|Amlodipine for 8 days and Amlodipine+Rosuvastatin for 5 days
2516095|NCT02789475|Experimental|rosuvastatin group|Rosuvastatin for 5 days and Amlodipine+Rosuvastatin for 8 days
2516147|NCT02788955|Active Comparator|Normal Protein Diet|In the normal protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 1 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
2516150|NCT02788955|Experimental|High Protein Diet|In the high protein diet, participants will be instructed to follow a diet that will provide them with the amount of calories enough to meet their energy needs without changing their body weight and will contain 2 g of protein per kilogram of body weight. Participants will be instructed to consume protein primarily from animal food sources. A high quality whey protein supplement will be provided as needed.
3197896|NCT00865215|Experimental|A|Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose
3197897|NCT00865215|Active Comparator|B|INDERAL® LA 160 mg Capsules, single dose
2516275|NCT02787980|Other|Patients = premature newborns|"Patients will consist of all premature babies (<37 weeks of amenorrhea), managed in the first 24 hours of life at the Reims university hospital for whom parents accepted to participate in the research Additional taking blood"
2516279|NCT02787980|Other|"Controls = children born full term"|"For controls the participation to research would be proposed to parents of children born full term, just after each patient child included.~Additional taking blood"
2516351|NCT02787798|Experimental|Entresto|"Stop of all angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor during 2 days.~valsartan/sacubitril 100 mg tablets (51 and 49 mg) during 2 to 4 weeks twice a day.~valsartan/sacubitril 200 mg tablets (103 and 97 mg) during 2 to 4 weeks twice a day.~Microneurography recording of sympathetic activity in muscle destiny (MSNA)"
2516353|NCT02787798|Placebo Comparator|Control|"Hearth failure treatment as usual (angiotensin-converting-enzyme inhibitor or antagonist of angiotensin II receptor)~Microneurography recording of sympathetic activity in muscle destiny (MSNA) will be done"
2516415|NCT02787252|Experimental|HF DRG|HF DRG Implants
2516472|NCT02786875|Experimental|Group A (high intensity program):|"Diet: low glycemic index (GI) Mediterranean diet. All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Moderate physical activity: brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.~Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach blood levels of 60-80 ng/ml of 25(OH)D."
2516475|NCT02786875|Active Comparator|Group B (lower intensity program)|"Diet: general recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).~Basic physical activity: general recommendations to avoid sedentary behaviour. Vitamin D supplement (cholecalciferol) will be given only if vitamin D insufficiency is detected to reach blood levels of 30 ng/ml of 25(OH)D."
2516535|NCT02786368|Experimental|EHFP group|Households will receive training and inputs for an Enhanced Homestead Food Production (EHFP) package. Participants will also receive educational components through inter-personal behavioural change communication on nutrition (Essential Nutrition Actions), Water Sanitation and Hygiene (WASH), gender, and business/marketing.
3197898|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (morning)|
3197899|NCT00865228|Experimental|Lapaquistat Acetate 100 mg QD (evening)|
3197900|NCT00865228|Experimental|Lapaquistat Acetate 50 mg BID|
3197901|NCT00865228|Placebo Comparator|Placebo BID|
3197902|NCT00865241|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
3197903|NCT00865241|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3197904|NCT00865254|Experimental|Traditional Contingency Management|Standard treatment plus prize based contingency management.
2515706|NCT02792036|Experimental|Treatment|"Participants with retinoblastoma that is refractory or has relapsed inside the eye.~Interventions: Carboplatin, Maxitrol® , focal therapy, plaque radiotherapy."
2515795|NCT02791672||Same Day Discharge|Following a Latissimus Dorsi flap reconstruction patients will be offered discharge at 24 hours. Patients successfully discharged within 24 hours of their surgery will be included in the cohort group.
2515807|NCT02791295|Experimental|Diet and physical activity program|Diet and physical activity program with individual coaching
2515808|NCT02791295|No Intervention|control|standard care
2515856|NCT02791100|No Intervention|No promotion of chicken eggs|The community receives no chickens and therefore has no additional eggs or egg shell powder for children
2515857|NCT02791100|Experimental|Promotion of Chicken eggs for children|The community receives chickens so that each study child receives 2 eggs a day and also receives some egg shell daily (1/4 bottle cap which provides 500 mg Ca). The community receives information on using the egg and eggshell, and has help in caring for the chickens.
2515867|NCT02790853|Experimental|Diagnostic (multimodal imaging, biopsy)|Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.
2515955|NCT02790333|Experimental|Tri-Staple reloads|Tri-Staple reloads were used for pancreatic stump texture
2515957|NCT02790333|Active Comparator|traditional reloads|the traditional reloads were used for pancreatic stump texture
2516031|NCT02789696|Other|Acromegaly|Diagnosis of acromegaly
2516077|NCT02789436|Experimental|L. reuteri Prodentis® lozenges|"15 subjects~Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). Probiotic lozenges are used twice daily for 28 days."
2516078|NCT02789436|Placebo Comparator|Placebo lozenges|"15 subjects~Placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.Placebo lozenges are taken twice daily for 28 days."
2516185|NCT02788812|Active Comparator|Open modified Lichtenstein repair|
2516186|NCT02788812|Active Comparator|Laparoscopic TAPP inguinal hernia repair|
2516374|NCT02787434|Experimental|PCSPrep decision aid|All participants recruited to the trial will receive the decision aid. This a one-group study with a quasi-experiemental pre/post evaluation design.
2516461|NCT02787161|Active Comparator|Hemodialysis|Patients who are treated with high flux hemodialysis will continue the same treatment with high flux hemodialysis.
2516464|NCT02787161|Experimental|Hemodiafiltration|Patients who are treated with high flux hemodialysis will be switched to hemodiafiltration for 6 months.
2516605|NCT02785848||Asthma and/or Sickle Cell Anemia|The investigators will examine patients with sickle cell disease, asthma, or both who are aged 12-70 years who take daily medications.
2516678|NCT02785146|Experimental|mFOLFOX6 + Huaier Granule|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ). Huaier Granule will be administrated from the first cycle of chemotherapy until 48 weeks after surgery or until study termination. Huaier Granule is continuously taken three times per day, 20g per time.
2516682|NCT02785146|Active Comparator|mFOLFOX6|Twelve cycles of mFOLFOX6 (oxaliplatin, 85 mg/m²; calcium folinate, 400 mg/m²; 5-fluorouracil, 2800 mg/m²). Patients will be treated with chemotherapy every 2 weeks (+/- 2 days ).
2516809|NCT02784639|Other|determination of KRAS mutation|circulating cell free DNA (ccfDNA) plasma analysis
2516852|NCT02784171|Active Comparator|Arm A - Cisplatin/Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
2516854|NCT02784171|Active Comparator|Arm B - Cisplatin/Pemetrexed/Pembrolizumab|Pembrolizumab 200 mg* IV Day 1 over 30 min every 21 days for a total of 2 years Pemetrexed 500 mg/m2 IV Day 1 every 21 days for 6 cycles Cisplatin 75 mg/m2 IV Day 1 every 21 days for 6 cycles
2516856|NCT02784171|Active Comparator|Arm C - Pembrolizumab (Phase II only)|Pembrolizumab 200 mg* IV 30 min Day 1 every 21 days for a total of 2 years
2516945|NCT02783612|Experimental|glucose application|Regular high risk pregnancy clinic surveillance in addition to a Smart phone application for registering the Blood glucose levels and submitting via email every 3-5 days to the High risk Doctor involved in the trial.
2516950|NCT02783612|No Intervention|Regular monitoring|Regular high risk pregnancy clinic surveillance
2516993|NCT02783300|Experimental|Part 1: Dose Escalation, Food effect and Relative Bioavailability of Capsule formulation to Tablet|Participants will receive escalating doses of GSK3326595 until the maximum tolerated dose level is reached. The recommended phase 2 dose (RP2D) will be determined. Participants will be dosed in a fed (high-fat, high-calorie meal) and fasted state to determine the effect of food on bioavailability of GSK3326595, and will be dosed with tablet and capsule to compare two formulations of GSK3326595 (capsule versus tablet).
3173780|NCT00615823|Active Comparator|1|Atorvastatin group: receive atorvastatin 10 mg daily in addition to supportive care
3173781|NCT00615823|Placebo Comparator|2|Placebo group: receive matching placebo in addition to supportive care.
3173782|NCT00615862||AUD+ and AUD-|AUD stands for alcohol use disorders. Patients with alcohol use disorders are assigned the label AUD+. Patients without alcohol use disorders are assigned the label AUD-.
3173783|NCT00615875|Active Comparator|A|
3173784|NCT00615875|Placebo Comparator|P|
3173785|NCT00615888|Active Comparator|A|Traditional management including preoperative bowel washout, patient controlled analgesia (PCA), delayed start of enteral feeding
3173786|NCT00615888|Experimental|B|Fast track management including no bowel washout, patient controlled epidural anesthesia, early enteral feeding
3173787|NCT00615940|Experimental|1|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.
3173788|NCT00615940|Experimental|2|Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.
3173789|NCT00615966|Experimental|1|
3173790|NCT00615966|Experimental|2|
3173791|NCT00615966|Placebo Comparator|3|
2515709|NCT02792296|Experimental|Multiple times per day measurement|This arm will be asked to use the Project: EVO Monitor at least once per day and six times over the day every three days for four weeks.
2515718|NCT02792296|Experimental|Weekly measurement|This arm will be asked to use the Project: EVO Monitor once a week for eight weeks.
3197905|NCT00865254|Experimental|Early Enhanced Contingency Management|Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.
3197906|NCT00865254|Active Comparator|Standard Treatment|Counseling and monitoring of smoking cessation.
2515926|NCT02790632|Experimental|EG-1962 Group|"1 dose of intraventricular EG-1962 (nimodipine microparticles) 600 mg~Up to 21 days of placebo capsules/tablets"
2515929|NCT02790632|Active Comparator|Enteral Nimodipine Group|"1 dose of intraventricular normal saline~Up to 21 days of oral nimodipine capsules/tablets"
2516080|NCT02789150|Experimental|MAP 65-70|Goal MAP of 65-70
2516082|NCT02789150|Active Comparator|MAP greater than or equal to 85|MAP greater than or equal to 85
2516140|NCT02789059|Experimental|muscle oxygenation|assesment of muscle oxygenation and gas exchanges
2516169|NCT02788760|Other|6 weeks|This group of patients will be treated for 6 weeks with a cervical collar (Miami J collar - Össur)
2516171|NCT02788760|Other|12 weeks|This group of patients will be treated for 12 weeks with a cervical collar ( (Miami J collar - Össur)
3197907|NCT00865267|Experimental|A|Ultravate® 0.05% ointment, single exposure
3197908|NCT00865293||Obesity|Subjects with obesity, defined as BMI > 30, aged 25-60
2516410|NCT02787213||Women with preterm delivery|
2516413|NCT02787213||Women without preterm delivery|
2516476|NCT02786823|Experimental|Folic acid|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
2516478|NCT02786823|Experimental|Vitamin B12|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
2516479|NCT02786823|Experimental|"Folic acid and Vitamin B12"|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
2516480|NCT02786823|Active Comparator|Control|Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
2516496|NCT02786459|Experimental|Post Radical Prostatectomy|"Up to n=30 evaluable male patients, between ages 30-75, who were previously diagnosed with PCa, have undergone a RP at least 6 months before imaging and who experience rising PSA (biochemical failure). The RP group (n=30) will be stratified into PSA subgroups <0.005, 0.005-<0.2, >0.2.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI."
2516499|NCT02786459|Active Comparator|Active Surveillance|"Up to n=10 men, between ages 30-75, on active surveillance with known prostate adenocarcinoma diagnosis and multiple positive biopsies.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
2516504|NCT02786459|Experimental|Multiple Negative Biopsies|"Up to n=20 men, between ages 30-75, who have previously undergone one/or multiple negative biopsies, with elevated PSA (≥4 ng/mL) and/or an abnormal digital rectal exam suspicious for prostate cancer with a planned sextant prostate biopsy but who do not have a definitive PCa diagnosis.~Intervention: men will be imaged with ProxiScan, SPECT-CT and MRI, and also undergo a TRUS biopsy."
2516577|NCT02786082|Experimental|Group I|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group I, half are male and half are female, will take Azilsartan tablet 20mg orally on fasting.~For Pharmacokinetics Studies of Azilsartan with Multiple-dose oral administration, 12 subjects in group I will take 20mg Azilsartan orally once daily for 7 day (day 3~day 9) after completing the last time blood sample collection (in day 2, 48h) of the first time administration (day 1)"
2516584|NCT02786082|Experimental|Group II|"For Pharmacokinetics Studies of Azilsartan with Single-dose oral administration, 12 subjects in group II, half are male and half are female, will take Azilsartan tablet 40mg orally on fasting.~For The effects of diet for pharmacokinetic study: The 12 healthy subjects, in group II (in single-dose administration study), after 7-day washout period after the first administration (at day 1, 40mg) will receive Azilsartan tablet 40mg after high-fat diet at day 8"
2516627|NCT02785666|Experimental|Treatment and behavioural intervention:|"Treatment intervention: Patients with a replicating GT 1 and/or 4 HCV infection without or with cirrhosis will be treated with grazoprevir/elbasvir (100mg/50mg) for 12 weeks. GT 1a infected patients with baseline RAV's and GT 4 infected patients with a history of prior HCV treatment failure without or with cirrhosis will be treated with the same regimen for 16 weeks, in combination with weight-adjusted ribavirin.~Behavioural Intervention: Participants with inconsistent condom use with occasional partners will receive the behavioral Intervention and in addition standard of care written and oral information on prevention of HCV reinfection. Study participants with consistent condom use or those reporting inconsistent condom use with occasional partners but not willing to participate in the intervention will receive standard of care written and oral information on prevention of HCV reinfection only"
2516692|NCT02785315|Experimental|rehabilitation & remediation approach|The intervention group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention with various compensatory strategies. Investigators will use group discussion to discuss everyday situations with memory problem and specific strategies (internal and external) related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
2516703|NCT02785315|Active Comparator|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
3197909|NCT00865293||Control|Subjects with a BMI 18,5-25, aged 25-60
3197910|NCT00865319|Experimental|99 m Tc-EC-DG|99m Tc-Ec-DG injection followed by SPECT/CT imaging (range 20-30 mCi) 1mg EC-DG
3197911|NCT00865319|Active Comparator|18F-FDG|18 F FDG injection followed by PET/CT imaging
2515711|NCT02792153|Experimental|Estrogen|AN participants receive a course of transdermal estradiol treatment.
2515766|NCT02791815|Experimental|Sequence AB|Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
2515769|NCT02791815|Experimental|Sequence BA|Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
2515810|NCT02791334|Experimental|LY3300054|LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle.
2515811|NCT02791334|Experimental|LY3300054 + Ramucirumab|LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle.
2515812|NCT02791334|Experimental|Abemaciclib + LY3300054|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2515813|NCT02791334|Experimental|LY3300054 + Abemaciclib (Concurrent Dosing)|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2515815|NCT02791334|Experimental|LY3300054 + Abemaciclib|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required.
2515817|NCT02791334|Experimental|LY3300054 + Merestinib|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
2515819|NCT02791334|Experimental|LY3300054 Expansion (Metastatic Cutaneous Melanoma)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
2515821|NCT02791334|Experimental|LY3300054 Expansion (MSI-H Solid Tumors)|LY3300054 given IV on day 1 and day 15 of a 28 day cycle.
2515823|NCT02791334|Experimental|: LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle.
2515824|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H)|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
2515827|NCT02791334|Experimental|LY3300054 + LY3321367 Expansion|LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle.
2515828|NCT02791334|Experimental|LY3300054 + Merestinib (Pancreatic Cancer) Expansion|LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle.
2515893|NCT02790762|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
2515960|NCT02790476|Experimental|Letter intervention|The intervention arm will involve letters sent to prescribers in San Diego County.
2515961|NCT02790476|No Intervention|Control|The control group will involve prescribers not receiving letters
2516001|NCT02790047|Active Comparator|Home-base exercise|"Patients will receive intervention as following~A home-base exercise program~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
2516004|NCT02790047|Experimental|Home-base exercise with a PEP mask|"Patients will receive intervention as following~A home-base exercise program with using a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise~Health education~Breathing strategies for self secretion clearance~The medication following the COPD GOLD guidelines (2015)"
3165135|NCT00508911|Experimental|Healthy female subjects|Each subject will be administered a monophasic combined oral contraceptive (COC) containing ethinylestradiol 30 micrograms and levonorgestrel 150 micrograms for two complete cycles (Day 8 to Day 28) in Session 1. The subjects will be administered COC on Day 8 to Day 28 and GW876008 125 milligrams on Days 1 to 35 in Session 2.
3165136|NCT00508937|Active Comparator|1|
2516100|NCT02789332|Active Comparator|Paclitaxel with Carboplatin (PwCb)|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (37 patients) followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
2516104|NCT02789332|Experimental|Paclitaxel with Olaparib (PwO)|"paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (65 patients)~followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery."
2516180|NCT02788773|Experimental|Arm A - Durvalumab plus Tremelimumab|Durvalumab-IV for 60 minutes day 1 every 4 weeks Tremelimumab-IV every 60 minutes day 1, cycles 1-4
2516184|NCT02788773|Experimental|Arm B - Durvalumab alone|Durvalumab-IV for 60 minutes day 1 every 4 weeks
2516276|NCT02787824|Experimental|continuous iv administration of iron sucrose|Prior to the study, all our patients were receiving intravenous iron sucrose in an intermittent mode (every 1-4 weeks).Patients on this arm will receive the same previous dose of iron glucose but in a continuous mode (smaller doses of iron sucrose in every session).
2516281|NCT02787824|Active Comparator|intermittent iv administration of iron sucrose|Patients on this arm will continue to receive the same previous intermittent mode of iron sucrose.
2516350|NCT02787759|Active Comparator|Hands-Free Walking|Body-weight supported treadmill training
2516352|NCT02787759|Experimental|Challenge Based plus Hands-Free|9 different balance and locomotor challenges applied during walking while not holding onto anything
2516396|NCT02787317|Active Comparator|heparin|For the heparin group, a bolus dose of 100 U/kg was administered according to current guidelines.
2516400|NCT02787317|Experimental|not prolong infusion Bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure .
2516401|NCT02787317|Experimental|prolong infusion bivalirudin|Bivalirudin was given as a bolus of 0.75mg/kg followed by infusion of 1.75mg/kg/h during the PCI procedure and prolong for 4 hours after procedure.
3165137|NCT00508937|Experimental|2|
3165138|NCT00508937|Experimental|3|
3165139|NCT00508937|Experimental|4|
3165140|NCT00508937|Experimental|5|
3165141|NCT00508950|Other|All subjects|All subjects
3165142|NCT00508976|Experimental|3|
3165143|NCT00508976|Experimental|2|
3165144|NCT00508976|Experimental|4|
3165145|NCT00508976|Active Comparator|1|
2515712|NCT02792023|Other|Colonoscopy followed by upper endoscopy|In case of a positive immunochemical fecal occult blood test result, colonoscopy will be the first examination
2515720|NCT02792023|Other|Upper endoscopy followed by colonoscopy|In case of a negative immunochemical fecal occult blood test result, upper endoscopy will be the first examination
2515759|NCT02791685||Cardiac Rehabilitation - Movn Program|Participants with coronary artery disease (CAD) and chronic obstructive pulmonary disease (COPD) who are eligible for cardiac rehabilitation will undergo an in-home program.
2515763|NCT02791685||Pulmonary Rehabilitation - Movn Program|Participants with stable chronic obstructive pulmonary disease (COPD) or hospitalized with an acute exacerbation of COPD will undergo an in-home pulmonary rehabilitation program.
2515765|NCT02791685||Traditional Cardiac Rehabilitation|Participants enrolled in a facility's traditional cardiac rehabilitation program will be seen at baseline and during a 12 and 24 week follow-up visit.
2515895|NCT02790879||Transition|Patients who switched from pediatric cystic fibrosis care center to an adult cystic fibrosis care center during 2013 or 2014, regardless of their clinical status.
2515915|NCT02790515|Experimental|Treatment|"Participants receive a conditioning regimen of antithymocyte globulin (rabbit), cyclophosphamide, mesna, fludarabine, thiotepa, tacrolimus (first 5 participants enrolled), sirolimus (used beginning with 6th enrolled participant), melphalan, rituximab. This is followed by HPC,A infusion (transplant), then by G-CSF and blinatumomab.~Cells for infusion are prepared using the CliniMACS System."
2516007|NCT02789878|Experimental|ADT and Abiraterone|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months."
2516009|NCT02789878|Experimental|ADT, Abiraterone and Apalutamide|"Goserelin 10.8 mg, single dose, subcutaneously.~Abiraterone 1,000 mg, once daily, orally for 3 months.~Prednisone 5 mg, once daily, orally for 3 months.~Apalutamide 240 mg, once daily, orally for 3 months."
2516067|NCT02789501|Active Comparator|Control|Non-systemic intraluminal application of 4% citrate lock solution (CitraFlow™ 4%, MedXL, Montreal, Canada) 3 times per week after dialysis.
2516068|NCT02789501|Experimental|Test|"TauroLock™ based lock solution regimen:~Non-systemic intraluminal application of TauroLock™-Hep500, Tauropharm, Waldbüttelbrunn, Germany, 2x/week after dialysis (before short intervals) and TauroLock™-U25.000, Tauropharm, Waldbüttelbrunn, Germany, 1x/ week after dialysis (before long interval).~TauroLock™-Hep500 contains 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin.~TauroLock™-U25.000 contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase."
3197912|NCT00865358|Experimental|Yoga Group|A standardized hatha yoga protocol delivered in 12 weekly classes.
3197913|NCT00865358|No Intervention|Usual care|Participants continue to receive their usual medical care for their back pain
2516252|NCT02788617||Non treatment group|This is a non-interventional study in which embryo selection is performed according to standard of care. The Diafert output, the granulocyte colony-stimulating factor (G-CSF) concentration in follicular fluid (FF), will be recorded but will not be used in patient management, ie, values will not be used for embryo selection in the assisted reproduction procedure.
2516282|NCT02787876|Experimental|Chemotherapy induced neutropenia|Pegteograstim 100 ug/kg (maximum 6 mg) on day 7 of the chemotherapy cycle
2516349|NCT02787746|Other|donepezil|This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.
3197914|NCT00865371|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
3197915|NCT00865371|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
3197916|NCT00865384|Experimental|A|Mirtazapine 15 mg tablets, single dose
3197917|NCT00865384|Active Comparator|B|REMERON® 15 mg tablets, single dose
2516538|NCT02786342||Advanced HCC patients treated with sorafenib|
3197918|NCT00865397||A|
3197919|NCT00865410|Experimental|A|Abrika Bupropion 150 mg Extended-Released Tablet, single dose
3197920|NCT00865410|Active Comparator|B|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
3197921|NCT00865423|Experimental|A|Gabapentin 800 mg Tablets, single dose
3197922|NCT00865423|Active Comparator|B|NEURONTIN® 800 mg Tablets, single dose
2516787|NCT02784457|Active Comparator|GnRHant|women who received GnRH antagonist
2516788|NCT02784457|No Intervention|Control|women who did not receive GnRH antagonist
2516851|NCT02784366||Cancer immunotherapy patients - no GI side effect|Cancer immunotherapy patients who do not develop GI side effects.
2516853|NCT02784366||Cancer immunotherapy patients - develop GI side effects|Cancer immunotherapy patients who develop GI side effects
2516890|NCT02783859|Experimental|Active arm: Amoxicillin-clavulanic Acid|8 days of oral amoxicillin-clavulanic Acid 400/57 duo formulation (70-90mg/kg/day, twice daily dosing: max 980mg per day)
2516892|NCT02783859|Placebo Comparator|Placebo arm|8 days of oral placebo (equivalent volume as the active arm)
2517006|NCT02782962||Cohort|Patients with acute vertigo/unsteadiness
2517063|NCT02782858|Experimental|Dose 1 GNbAC1|Monthly IV repeated dose
3197923|NCT00865436|Experimental|A|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
3197924|NCT00865436|Active Comparator|B|CLUCOVANCE® 5 mg/500 mg Tablets, single dose
3197925|NCT00865449|Active Comparator|1|Peritoneal Dialysis patients on aldactone for 6 months
3197926|NCT00865449|Placebo Comparator|2|Peritoneal dialysis Patients on the placebo arm for 6 months
3197927|NCT00865462|Experimental|A|Abrika Bupropion 150 mg XL Tablet, single dose
3197928|NCT00865462|Active Comparator|B|Wellbutrin XL® 150 mg Tablet, single dose
3197929|NCT00865475|No Intervention|TZV (Trizivir)|Keeping on TZV in patients with viral suppression
3197930|NCT00865475|Experimental|2|Switching to LPV/r monotherapy
3197931|NCT00865488|No Intervention|1|patients who will be treated in accordance with standard of care
3197932|NCT00865488|Experimental|2|patients for which Adhexil will be applied to prevent/reduce adhesions
3197933|NCT00865501|Experimental|1|spironolactone
3197934|NCT00865501|Placebo Comparator|2|placebo
2515713|NCT02792257|Experimental|Dronabinol|Study medication will be administered twice daily. Capsules of dronabinol will contain 2.5 mg per dose (5mg daily) during Week 1, then increase to 5 mg per dose (10mg daily) for Weeks 2 and 3.
2515719|NCT02792257|Placebo Comparator|Placebo|Placebo medication will be administered twice daily.
2515777|NCT02791711|Other|High Flow Nasal Cannula|Use of High Flow Nasal Cannula
2515833|NCT02791373|Active Comparator|Mobilisation Chemotherapy: Vinorelbine|Vinorelbine is given at a standard dose of 35mg/m2 i.v. at day 1 as an infusion over 10 minutes, on an ambulatory basis.
2515838|NCT02791373|Experimental|Mobilisation Chemotherapy: Gemcitabine|Gemcitabine is given at the standard dose of 1250 mg/m2 i.v. in 500ml NaCl 0.9% (sodium chloride) as an infusion over 30 minutes, on an ambulatory basis.
2515872|NCT02790918||Diagnosed Pulmonary Hypertension|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
2515873|NCT02790918||Healthy Volunteer|Healthy Volunteer will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) and 6MWT.
2515920|NCT02790580|Active Comparator|Dose-dense doxorubicin/cyclophosphamide|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after doxorubicin/cyclophosphamide
2515921|NCT02790580|Experimental|Dose-dense doxorubicin/cyclophosphamide + sunitinib|Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles, Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles, Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide, Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0), Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
2515995|NCT02790229|Experimental|anti-gravity treadmill arm|Treatment with anti-gravity treadmill (alter G®)
2515996|NCT02790229|Other|control arm|Treatment with standardized physiotherapy
2516038|NCT02789722|Experimental|Yerba Mate Extract 750 mg|Yerba Mate Extract - Capsules: daily dose of 2.250 g, distributed in 3 doses of 750 mg, for 28 days.
2516042|NCT02789722|Placebo Comparator|Placebo|Starch - Capsules: 3 times daily for 28 days.
2516090|NCT02789358|Active Comparator|Control Arm|"Conventional protocol for cryoablation:~At least 2 applications of 180s each"
2516091|NCT02789358|Experimental|Study Arm|"Experimental protocol for cryoablation:~Time to effect + 1 minute and a bonus application of 120s"
2516157|NCT02788877|Experimental|treat-and-extend|Aflibercept 2mg is injected into the vitreous cavity. An injection is given every 4 weeks five times and then the Treat-and-Extend process begins. If 1mm central subfield macular thickness (CSMT) improved (10% or more reduction) compared to the previous visit, the next treatment will be performed at the same interval. If CSMT is maintained (less than 10% changes), the next interval will be extended by two weeks (up to 12 weeks). If CSMT is worsened (10% or more increase), the next interval will be shortened by two weeks (minimum 4 weeks). If CSMT is stable two times at 12 weeks-interval, the injection will be deferred, and the next visit will be 8 weeks later. These process will be continued for 2 years.
2516301|NCT02788266|Active Comparator|connective tissue graft+composite resin|connective tissue graft plus composite resin
2516305|NCT02788266|Active Comparator|connective tissue graft+ glass ionomer|connective tissue graft plus resin modified glass ionomer cement
2516307|NCT02788266|Active Comparator|connective tissue graft+giomer|connective tissue graft plus giomer
2516344|NCT02787616||Rosacea Group|
2516347|NCT02787616||Non-Rosacea Group|
2516379|NCT02787395|Experimental|Milch|modified Milch technique for self reduction
2516381|NCT02787395|Experimental|Boss Holtzach|Boss Holtzach technique for self reduction
2516384|NCT02787395|Experimental|Stimson|Stimson technique for self reduction
2516424|NCT02787135|Active Comparator|CBTd-E|Experimental: emotion-oriented Cognitive Behavior Therapy focused on delusions for patients with schizophrenia-spectrum disorders and delusions. The therapeutical intervention follows a treatment-manual consisting of two modules. Patients work on two modules every week for 25 weeks in a row. Module I comprises psychoeducation on emotions, training radical acceptance of emotions and mindfulness, cognitive and behavioral strategies in order to change negative emotions and in order to foster positive emotions and suggestions for life-style changes (positive activities, sports, stress reduction). In the second module, the focus is on self-acceptance. Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
2516425|NCT02787135|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait-list receive treatment as usual (regular visits to a physicist every third month and antipsychotic medication). After six month the waiting list patients receive the treatment specified above.
2516470|NCT02786797|Experimental|MBSR(BC) 6 Week Program|Participants who are randomized to MBSR(BC) program will receive of educational material; group practice of mindfulness meditation (MM) and homework assignments; and group processes related to the practice of MM and supportive group interaction. Participants who receive MBSR will receive training in (1) sitting meditation anchored to the breath; (2) body scan (observing body sensations from the toes to the head); (3) Gentle Yoga (postures and stretches that increase awareness and balance; and (4) walking meditation. Through this arm of the study the goal is to enhance executive cognition through training in self-regulation of attention and acceptance of experience.
2516473|NCT02786797|Active Comparator|BCES Education Support Program|Participants who are randomized to the BCES program will be scheduled for 6 weekly, 2-hour sessions. BCES compared to MBSR(BC) meets the following criteria: (1) professional contact and group support time matched equally to the MBSR(BC) program; and (2) the content or activities of the BCES program does not include meditation or attention, relaxation, yoga, body scan, or walking meditation. This program is as an active control condition that accounts for nonspecific effects related to attention from the leader and favorable outcome expectancy, the educational materials provided and supportive interaction between group members and is matched for homework activity time over the 6 months. This group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
3197935|NCT00865527|Active Comparator|Fecal Occult Blood Test|fecal occult blood test
3197936|NCT00865527|Active Comparator|Virtual Colonoscopy|virtual colonoscopy
3197937|NCT00865527|Active Comparator|Optical Colonoscopy|optical (conventional / endoscopic) colonoscopy
3197938|NCT00865540|Experimental|prednisolone acetate 1%|one drop every 8h two days before surgery
2515716|NCT02792270|Experimental|Caloric Restriction Diet|"Patients will meet with the Registered Dietitian to discuss calorie, protein and fluid needs.The dietitian will calculate calorie needs.~Calorie needs will then be reduced to 30%.~Protein needs will be estimated based on 0.8g/kg BW and then reduced by 70%.~Dietitian will educate participants on electrolytes and fluid intake based on the reduced food intake."
2515714|NCT02792179|Experimental|[18F]RO6958948|Each participant will receive a single intravenous (IV) dose of [18F]RO6958948 and a single PET scan approximately 9-24 months after the baseline scan (in Study BP29409).
2515725|NCT02792270|No Intervention|Normal Diet|Participant will follow a normal diet.
2515760|NCT02791802||Group A: Lipoprotein apheresis subjects|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~Additional lipoprotein apheresis is established following enrolment using the following established systems: Dextran-sulfate adsorption (DSA) from plasma and whole blood, Heparin-induced LDL precipitation apheresis (HELP®), Polyacrylate adsorption from whole blood and simple DFPP (DALI® and Monet®), ApoB100-immunoadsorption (TheraSorbLDL®, Temperature-optimized double filtration plasmapheresis (DFPP)."
2515764|NCT02791802||Group B: Control group|"Established cardiovascular disease with disease progression indicated by one major cardiovascular event. With or without subsequent cardiovascular events/interventions, despite adequately controlled cardiovascular risk factors occuring within the last 2 years prior to enrolment. Corrected Low-density lipoprotein cholesterol < 100 mg/dL (2.6 mmol/l) during 3 months prior to study enrolment.~The control group will not undergo a sham apheresis procedure. It is an open trial."
2515772|NCT02791854||Registry participant|This is a registry study, the same information is collected from all participants.
2515803|NCT02791243|Experimental|Finasteride 0.25%|approximately 0.2 ml of P-3074 (0.25% finasteride)
2515804|NCT02791243|Placebo Comparator|Placebo for Finasteride 0.25%|approximately 0.2 ml of the vehicle cutaneous solution
2515805|NCT02791243|Other|Negative Control|approximately 0.2 ml of 0.9% aqueous NaCl
2515852|NCT02791139||Control|Healthy Volunteers will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Hand-Grip Strength Measurement Body Fat Mass Analysis
2515855|NCT02791139||Ageing|"Ageing cohort will undergo the following studying procedures:~Cardiovascular Magnetic Resonance Imaging (CMRI) Echocardiography Tonometry Genetic Testing (Blood) Body Fat Mass Analysis"
2515869|NCT02790957|Experimental|Plerixafor|Single subcutaneous injection of Plerixafor (0.24 mg/kg)
2515870|NCT02790957|Placebo Comparator|Placebo|Single injection of an equal volume of NaCl solution
2515898|NCT02790801||1 group|observation of patients with chronic heart failure and atrial fibrillation
2515938|NCT02790489|Experimental|Valedia|Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses
2515939|NCT02790619|Active Comparator|Meditation and Active Stimulation 1|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 1 milliamp(mA) stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
2515942|NCT02790619|Active Comparator|Meditation and Active Stimulation 2|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.Participant will then receive 20 minutes of tDCS with Anode over F8 and cathode over left supraorbital area with 2 mA stimulation with intervention administration delivered by tDCS via Chattanooga Ionto Iontophoresis System-Phoresor.
2515950|NCT02790619|Sham Comparator|Meditation and Sham Stimulation|Electrodes will then be placed on the participant and participant will then listen to a meditative recording instructing to focus on participant's breath that will last approximately 5 minutes.The participants in the sham study will receive Sham tDCS (no stimulation) with Anode over F8 and cathode over left supraorbital area with intervention administration delivered by Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor
2515972|NCT02790125|Experimental|Dose Panel 1|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2515974|NCT02790125|Experimental|Dose Panel 2|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2515977|NCT02790125|Experimental|Dose Panel 3|"BMS-986166 or Placebo matching BMS-986166~Single oral dose of solution as specified"
2515978|NCT02790125|Experimental|Dose Panel 4|"BMS-986166 or Placebo matching BMS-986166~Multiple ascending solid dose formulation as specified"
2515980|NCT02790125|Experimental|Dose Panel 5a/b/c|"BMS-986166~Single oral solid dose formulation under fasting/fed/fasting with famotidine conditions"
2515992|NCT02790164|Experimental|Rocuronium|Patients will receive a bolus dose of 0.6 mg/kg, then a continuous I.V. infusion of 0.3-0.6 mg/kg/hr as per standard intensive care unit practice.
2515997|NCT02790164|Placebo Comparator|Usual Care|Patients will receive 100 mL of normal saline over 5-10 minutes at the beginning of the study in addition to usual care.
2516024|NCT02789761|Active Comparator|High-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days)
2516029|NCT02789761|Placebo Comparator|Low-flavanol milk chocolate|Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately <1 mg of (-)-epicatechin for 2-weeks (14 days)
2516052|NCT02789709||Non metastatic colon cancer patients|Consecutive patients undergoing elective surgery for non-metastatic colon or rectal cancer with curative intent.
3165146|NCT00508989|Experimental|1|
3165147|NCT00508989|Placebo Comparator|2|
2515728|NCT02791958|Experimental|CV Fixed Dose Combination Pill AAR|Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg).
2515731|NCT02791958|Active Comparator|Atorvastatin|Atorvastatin 40 mg (Lipitor®).
2515734|NCT02791958|Active Comparator|Ramipril|Ramipril 10 mg (Altace®).
2515781|NCT02791555||Pradaxa|20 men and 20 women on Pradaxa for non valvular atrial fibrillation
2515784|NCT02791555||Warfarin|20 men and 20 women on warfarin for non valvular atrial fibrillation, age matched to Pradaxa cohort
2515832|NCT02791412||unprotected left main|undergone percutaneous coronary intervention or coronary artery bypass graft
3165148|NCT00509015|Active Comparator|1|Sulphadoxine-pyrimethemine (day 1) artesunate (day 1-3) primaquine (day 3)
3165149|NCT00509015|Placebo Comparator|2|Placebo: lactose tablets (Albochin)
3165150|NCT00509275|Experimental|1|W0027
2515918|NCT02790671|Experimental|single study arm|DS-8500a and itraconazole
2515923|NCT02790424|Experimental|Patients|Imaging devices
2515982|NCT02790255|Experimental|Cold air|Subjects to be seated in an airtight chamber at an ambient temperature between 16 to 20 degrees Celsius for 1 hour.
2515984|NCT02790255|Experimental|Cold water|Subjects to be seated in an airtight chamber at an ambient temperature of 24 degrees Celsius, with their hands and feet fully immersed in cold water for 5 minutes.
2516033|NCT02789917|Experimental|Dual therapy (incl. NOAC)|Apixaban plus Clopidogrel
2516035|NCT02789917|Active Comparator|Triple therapy (incl. VKA)|Phrenprocoumon plus Clopidogrel plus ASA
2516065|NCT02789839|Experimental|Healthy volunteer|Blood test Medullar test
2516081|NCT02789280|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
2516084|NCT02789280|Active Comparator|Wait List|Participants will be asked to wait for a week until they receive the behavioral activation condition
2516115|NCT02789202|Experimental|Silver Diamine Fluoride|Control treatment
2516116|NCT02789202|Active Comparator|Fluoride Varnish|Test treatment
2516145|NCT02789072|Other|Microgravity|effect of microgravity on central aortic blood pressure.
2516165|NCT02788890|Active Comparator|Control Group (T0)|The supragingival scaling without LA
2516166|NCT02788890|Experimental|Test Group 1 (T1)|The simple restoration under LA
2516167|NCT02788890|Experimental|Test Group 2 (T2)|The simple exodontia under LA
2516202|NCT02788552|Active Comparator|Acute Symptomatic WKS- 300mg|Thiamine Hydrochloride 300mg daily (i.e. 100mg 3 times/day) for 5 days
2516204|NCT02788552|Active Comparator|Acute Symptomatic WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 5 days
2516205|NCT02788552|Active Comparator|Acute Symptomatic WKS - 1500mg|Thiamine Hydrochloride 1500mg daily (i.e. 500mg 3 times/day) for 5 days.
2516206|NCT02788552|Active Comparator|High-risk subclinical WKS- 100mg|Thiamine Hydrochloride 100mg once daily for 3 days.
2516207|NCT02788552|Active Comparator|High-risk subclinical WKS- 300mg|Thiamine Hydrochloride 300mg (i.e. 100mg 3 time/day) for 3 days
2516208|NCT02788552|Active Comparator|High-risk subclinical WKS - 900mg|Thiamine Hydrochloride 900mg daily (i.e. 300mg 3 times/day) for 3 days.
2516333|NCT02787603|Experimental|group A|Interruption of antibiotic treatment due to PCT measurement
2516335|NCT02787603|No Intervention|group B|Antibiotic therapy period will be determined by the physician without the knowledge of PCT levels.
2516394|NCT02787486||Aneuploidy Arm|Includes pregnant women at high risk for fetal chromosome aneuploidy for serum screening
2516397|NCT02787486||TORCH Arm|Infectious disease arm: Toxoplasmosis, other viruses, rubella, cytomegalovirus, and herpes simplex virus (TORCH). Includes pregnant women at low-risk for fetal aneuploidy that may be at increased risk for fetal infection for serum screening
2516433|NCT02787226|Active Comparator|TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after total shoulder arthroplasty (TSA).
2516571|NCT02786056|Experimental|Lung MRI examination|
3165151|NCT00509275|Experimental|2|W0027
3165152|NCT00509275|Experimental|3|W0027
3165153|NCT00509275|Placebo Comparator|4|Placebo
3165154|NCT00509301|Experimental|1|1.5 mCi/cc
3165155|NCT00509301|Experimental|2|2.0 mCi/cc
3165156|NCT00509301|Experimental|3|2.5 mCi/cc
3165157|NCT00509327|Active Comparator|1|bisacodyl 10mg twice daily from one day preoperative to day three postoperative
3165158|NCT00509327|Placebo Comparator|2|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
3165159|NCT00509340|No Intervention|1|Participants will receive usual clinical care, which may or may not include mental health treatment
3165160|NCT00509340|Experimental|2|Participants will receive cognitive behavioral intervention
3165161|NCT00509379|Experimental|1|All patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
3165162|NCT00509405|Placebo Comparator|Potassium citrate|
3165163|NCT00509418|Experimental|A|Viusid, a nutritional supplement, in combination with controlled diet and exercise
3165164|NCT00509418|Active Comparator|B|Controlled diet and exercise
3165165|NCT00509431|Experimental|Erlotinib + Sirolimus|This is an open-label,phase I single-arm dose-escalation and phase II study of continuous, once daily doses of erlotinib administered orally in combination with sirolimus in adult patients with malignant glioma at first, second or third recurrence
3165166|NCT00509444|Active Comparator|Educational materials|
3165167|NCT00509444|Experimental|Educational materials, plus patient navigation|
3165168|NCT00509470|Active Comparator|telmisartan plus low-dose hydrochlorothiazide|12 week combination therapy with telmisartan plus low-dose hydrochlorothiazide
3165169|NCT00509470|Active Comparator|Amlodipine|Amlodipine is continuously administered.
3165170|NCT00509548|Experimental|1|Dose 1
2515730|NCT02792140|Experimental|Naltrexone|daily administration of 50mg Naltrexone, reporting of dreams
2515732|NCT02792140|Placebo Comparator|Placebo|daily administration of Placebo, reporting of dreams
2515789|NCT02791724|Experimental|Desiconnect|Desiconnect is an Internet-administered intervention developed for persons with epilepsy and elevated depression symptoms.
2515790|NCT02791724|Active Comparator|Care-as-Usual (CAU) / wait list|In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Desiconnect three months post-baseline (i.e., wait list with respect to Desiconnect access).
2515878|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 1|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 1
2515882|NCT02790775|Active Comparator|Injection Anti-VEGF in quadrant 2|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 2
2515886|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 3|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 3
2515888|NCT02790775|Active Comparator|InjectionAnti-VEGF in quadrant 4|Each participant receive one injection Anti-vascular endothelial growth factor (Anti-VEGF) in one eye in the quadrant 4
2515913|NCT02790502|Other|Intervention|Intervention Group
2515945|NCT02790320||Patients with locally recurrent or metastatic breast cancer|Patients received 1.4 mg/m2 eribulin, administered intravenously on day 1 and 8 of each 21 day cycle until disease progression or unmanageable toxicity, per routine clinical practice.
2515994|NCT02790008||Aortic valve disease|Patients with aortic stenosis referred to surgery. Exclusion criteria are concomitant heart valve disease, congenital heart disease, hemodynamic instability, previous cardiac surgery, history of myocardial infarction and coronary artery disease.
2516017|NCT02789813|Experimental|Valproic Acid and fear reactivation|This group will receive once a combination of 500mg Valproic Acid (oral solution) and fear reactivation before exposure therapy.
2516018|NCT02789813|Active Comparator|Valproic Acid and no fear reactivation|This group will receive once 500mg Valproic Acid (oral solution) before exposure therapy.
2516019|NCT02789813|Placebo Comparator|Placebo and fear reactivation|This group will receive once a combination of Placebo (oral solution) and fear reactivation before exposure therapy.
2516020|NCT02789813|Placebo Comparator|Placebo and no fear reactivation|This group will receive once Placebo (oral solution) before exposure therapy.
2516136|NCT02789306||Peri-implantitis|"Peri-implantitis' - Loss radiographic bone beyond the biological bone remodeling at baseline (after prosthesis delivery) from the implant neck~Early:> 4 mm probing depth; <25% radiographic bone loss~Moderate:> 6mm probing depth; <50% radiographic bone loss~Severa:> 8 mm probing depth; > 50% radiographic bone loss"
2516138|NCT02789306||Healthy|No signs of inflammation and otherwise no bone loss beyond the biological bone remodeling
2516187|NCT02788799||Control|
2516190|NCT02788799||Intervention|
2516290|NCT02788123|Experimental|bismuth tripotassium dicitrate and pantoprazole|Participants will receive bismuth tripotassium dicitrate (twice daily) and pantoprazole (once daily) as single tablets
2516293|NCT02788123|Active Comparator|pantoprazole|Participants will receive pantoprazole (once daily) as single tablet
3165171|NCT00509548|Experimental|2|Dose 2
3165172|NCT00509561|Active Comparator|Chemo-radiotherapy|
2516466|NCT02786940|Experimental|Live Remote Cardiac Monitoring|Patients in this arm will receive the Cardiophone device, a live remote cardiac monitoring with transmission of cardiac rhythm (device-triggered: if rhythm abnormalities detected by device algorithm; or patient-triggered by pressing the transmit button because of symptoms) for 15 days.
2516468|NCT02786940|Active Comparator|Usual Care|Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
2516513|NCT02786576||Participants receiving adalimumab|Hidradenitis Suppurativa (HS) participants receiving adalimumab
2516583|NCT02785861|Experimental|supervised practice|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of supervised walking group will meet the student each session"
2516586|NCT02785861|Experimental|distance supervised physical activity|"brisk walking program twice a week over a period of 6 weeks, at an intensity of 60% of HR pic during 20 minutes.~Biweekly session from 60% of the heart rate pic during 20 minutes will be proposed.~Each patient of home-based walking group will be called by phone every week by the student to inform the patient of the progress of the training, collect the work and answer any questions"
2516625|NCT02785640|Experimental|Prompt group|Following feedback on their baseline sitting behaviour and an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered via Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing
2516631|NCT02785640|No Intervention|Control group|The control group will receive the same education session as the prompt group, as well as feedback on their baseline sitting behaviour. However, the will not receive prompts on their PC.
2516744|NCT02784964|Experimental|Elixcyte 8mL|ADSC 6.4*10^7 cells, allogeneic injection, one time injection on Day 1
3165173|NCT00509561|Experimental|Chemo-radiotherapy plus cetuximab|
3165174|NCT00509639|Experimental|Metronidazole 10% ointment|Metronidazole 10% ointment
3165175|NCT00509639|Placebo Comparator|Placebo ointment|Placebo ointment
3165176|NCT00509652|Experimental|Arm 1|Erythrocyte apheresis
3165177|NCT00509652|Active Comparator|Arm 2|Phlebotomy
3165178|NCT00509691|Experimental|Single arm study|
3165179|NCT00509717|Experimental|experimental|
3165180|NCT00509717|Active Comparator|control|
3165181|NCT00509743|Experimental|A|Low dose Diclofenac
3165182|NCT00509743|Experimental|B|High dose Diclofenac
3165183|NCT00509756|Active Comparator|1|Drug: FXR-450
3197939|NCT00865540|Experimental|ketorolac tromethamine 0.4%|one drop every 8h two days before surgery
3197940|NCT00865540|Experimental|nepafenac 0.1%|one drop every 8h two days before surgery
2515956|NCT02790307|Experimental|Daily stimulation (30mins/day)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
2515959|NCT02790307|Experimental|Weekly stimulation (30mins/week)|30 minutes daily for 12 weeks of Tibial nerve stimulation using the Geko device
2515973|NCT02790021|No Intervention|Complex decongestive therapy|Group A will continue complex decongestive therapy consisting of skin care, manual lymphatic drainage, and compression therapy using compression stockings.
2515976|NCT02790021|Experimental|Lymphaticovenous anastomosis (LVA)|Group B will undergo an LVA procedure under local anesthesia in surgical daycare setting. Patients are not allowed to wear compression stockings or have decongestive therapy for four weeks after the surgery.
2516012|NCT02789865|Active Comparator|Antibiotic therapy group|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
2516013|NCT02789865|Experimental|ERAT group|The patients will receive emergent endoscopic retrograde appendicitis therapy (ERAT).
2516014|NCT02789865|Active Comparator|Appendectomy group|The patients will receive laparoscopic appendectomy according to standard routines.
2516079|NCT02789488|Other|Furocyst|Furocyst one caps BID
2516155|NCT02789124|Experimental|Carotid Artery Flow Time|Patients with radial aline and flotrac vigileo will have carotid dopper measured for carotid flow time and a passive leg raise
2516288|NCT02788032|Other|EnergieShake Intervention|Single arm of intervention of Oral Nutritional Supplement in the open label study to be given to participants for 8 days Two 57g sachets of EnergieShake daily to be given to participants during the 8 day intervention period.
2516329|NCT02787720|Experimental|Family centered empowerment model|The Family-Centered Empowerment Model (FCEM)
2516334|NCT02787720|Experimental|Continuous care model|The Continuous Care Model
2516387|NCT02787499|No Intervention|Standard of Care|Follows the 2013 World Health Organization (WHO) HIV treatment guidelines. Study participants will receive adherence support and return for a repeat viral load test in 3 months (or in 1 month for pregnant participants). Treatment failure will be defined by two consecutive viral load measurements greater than 1,000 copies/mL. Participants who meet this criteria will be switched to second-line therapy. Those with a viral load <1,000 copies/mL at repeat testing will be retained on first-line therapy.
2516389|NCT02787499|Experimental|HIV-1 RNA Resistance Testing|Participants will receive HIV-1 RNA drug resistance testing at study enrollment. ART treatment regimen decisions will be determined based on the results of resistance testing.
2516428|NCT02787070|Active Comparator|Primaquine supervised|14 days of supervised primaquine treatment (0.5mg/kg/day).
2516431|NCT02787070|Active Comparator|Primaquine unsupervised|14 days of unsupervised primaquine treatment (0.5mg/kg/day).
2516487|NCT02786732|Experimental|210mg Brodalumab|Administered by subcutaneous injection until Week 12
2516489|NCT02786732|Experimental|140mg Brodalumab|Administered subcutaneous injection until Week 12
2516492|NCT02786732|Active Comparator|Ustekinumab|Administered subcutaneous injection until Week 52
2516494|NCT02786732|Placebo Comparator|Placebo|Administered subcutaneous injection until Week 12
2516502|NCT02786420||Observational|Pregnant women
2516590|NCT02786290|Experimental|Treatment Group|Receives intervention with the Zenflow Spring System.
2516618|NCT02785601|Experimental|I-1|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
2516623|NCT02785601|Experimental|I-2|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times)
2516629|NCT02785601|Experimental|I-3|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg;
2516637|NCT02785601|Experimental|I-4|This is a four different crossover treatments with 2 men and 2 women, give the following treatment sequence, with wash out period 7 days (D) postprandial single oral trazodone hydrochloride tablets 150mg (50mg for 3 times) (C) fasting single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg; (A) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 75 mg; (B) postprandial single oral dose of trazodone hydrochloride prolonged-release tablets 150 mg;
2516686|NCT02785302||Adolescents and Young Adults:|Behaviorally-infected, HIV-positive, adolescents and young adults enrolled in ATN 125, aged 18 through 24, inclusive who are transition eligible. All subjects with available endpoint data will be included in the analysis.
2516690|NCT02785302||AMTU and Adult Clinic Staff|Clinical staff at the Adolescent Medical Trials Units (AMTUs) and at adult clinics where the AMTUs refer their transitioning patients will be recruited to complete quantitative surveys and semi-structured interviews.
2516800|NCT02784743|Experimental|albendazole and ivermectin|Before and after design with all eligible volunteers receiving the study drugs. Administration of a yearly unique dose of albendazole 400mg and ivermectin 150ug/kg weight ( according to the height).
3197941|NCT00865540|Placebo Comparator|placebo|one drop every 8h two days before surgery
2515894|NCT02790892|Other|Art therapy - pre and post test measures|20 young adults aged 15-24 years with diabetes (10 with type 1 diabetes and 10 with type 2 diabetes) receiving 12 weeks of group art therapy. Participants serve as their own controls.
2515927|NCT02790528|Experimental|Atorvastatin|20mg QD
2515931|NCT02790528|Placebo Comparator|Placebo|
2515966|NCT02790203|Experimental|Celecoxib|"Celecoxib will be given orally to patients participating in the study and allocated to the treatment group, for an intervention period of 6 days, starting from the day of surgery.~Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses, a dose which is within the recommended and a widely used dosage and is expected to induce a significant inhibition of prostaglandin synthesis by the COX2 pathway. Celecoxib will be given throughout the intervention period of the study orally at a dose of 400 mg per day divided into two doses."
2515969|NCT02790203|Placebo Comparator|Placebo|"Placebo will be given orally to patients participating in the study and allocated to the control group that will receive placebo, for an intervention period of 6 days, starting from the day of surgery.~Placebo will be given throughout the intervention period of the study orally in capsules that resemble the drug, twice a day."
2516107|NCT02789527|Experimental|Healthy volunteers in Ethiopia|Phenotype and genotype of enzymes involved in drug metabolism in Ethiopia population
2516112|NCT02789527|Experimental|Healthy volunteers in Oman|Phenotype and genotype of enzymes involved in drug metabolism in Oman population
2516114|NCT02789527|Experimental|Healthy volunteers in the Czech Republic|Phenotype and genotype of enzymes involved in drug metabolism in Czech Republic population
2516117|NCT02789527|Experimental|Healthy volunteers in Greece|Phenotype and genotype of enzymes involved in drug metabolism in Greek population
2516146|NCT02788864|Active Comparator|Arterakine|Active drug: Arterakine (DHA/piperaquine) one tablet contains 40 mg of dihydroartemisinin and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinin; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
2516148|NCT02788864|Placebo Comparator|Placebo|Placebo (visually matched to Arterakine for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)
2516217|NCT02788682||Patients|WT+ Diplotype
2516218|NCT02788682||Controls|WT- Diplotype
3165184|NCT00509756|Placebo Comparator|2|Placebo
3165185|NCT00509782|Experimental|ZIO-101|
2516291|NCT02787967|Experimental|NEXThaler® 35/4µg|CHF 1535 35/4µg NEXThaler® Dry Powder Inhaler, 4 inhalations. Total Dose: BDP 200µg FF 16µg
2516296|NCT02787967|Active Comparator|Reference treatment|Drug: free comb. beclomethasone DPI and formoterol DPI 2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
2516495|NCT02786706||Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
2516746|NCT02784964|Active Comparator|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc., one time injection on Day 1
2516751|NCT02784964|Experimental|Elixcyte 4mL|ADSC 3.2*10^7 cells, allogeneic injection, one time injection on Day 1
3165186|NCT00509808|Sham Comparator|electrostimulation|Use of device for predetermined length
3165187|NCT00509834|Experimental|hLF1-11|hLF1-11 0.5mg
3165188|NCT00509834|Placebo Comparator|Placebo|Placebo formulation is Similar to hLF1-11 iv formulation except for the active component
3165189|NCT00509860|Experimental|Irinotecan|Irinotecan 16 mg/m2 by vein daily over 1 hour for 5 Days
3165190|NCT00509886|Experimental|1|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
3165191|NCT00509886|Experimental|2|ARMs were randomized. One side of the body received treatment with one antiperspirant and the contralateral side with a different antiperspirant.
3165192|NCT00509938|Experimental|1|5mg hLF1-11, single dose iv
3165193|NCT00509951|Active Comparator|1|One-session exposure treatment (OST)
3165194|NCT00509951|Experimental|2|Family-enhanced (augmented) OST
3165195|NCT00509964|Active Comparator|1|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
3165196|NCT00509964|Active Comparator|2|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and infusional 5-fluorouracil, on day 1 every 2 weeks.
3165197|NCT00509977|Experimental|1|Light therapy
3165198|NCT00509977|Experimental|2|Laser Treatment
3165199|NCT00510016|Experimental|Clonidine treatment|Infants intrauterine exposed to opioids (heroin or methadone) that demonstrate signs and symptoms of withdrawal with withdrawal scores (modified Finnegan score) greater than 9 on to consecutive scores taken 4 hours apart.
3165200|NCT00510029|Other|GAP-134, IV and Oral|Experimental; Active Comparator; Placebo
3165201|NCT00510081|Experimental|1|subjects will receive filler injections
3165202|NCT00510094|Experimental|1|Participants will receive the Friend to Friend program
3165203|NCT00510094|Active Comparator|2|Participants will receive the psychoeducational attention control intervention
3165204|NCT00510107|Active Comparator|1|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Cisplatin 60 mg/m2 will be administered on day 1 every 3 weeks.
3165205|NCT00510107|Experimental|2|Docetaxel 35 mg/m2 will be administered on days 1 and 8. Oxaliplatin 120 mg/m2 will be administered on day 1 every 3 weeks.
3165206|NCT00510120|Experimental|1|Participants will receive collaborative problem solving.
3165207|NCT00510120|Active Comparator|2|Participants will receive parent management training.
3165208|NCT00510120|Active Comparator|3|Participants assigned to waitlist control will receive one of the two treatments after a 10-weeks waitlist period.
3165209|NCT00510133|Experimental|GRNVAC1|Autologous dendritic cell vaccine
3165210|NCT00510172|Active Comparator|1|Active treatment
3165211|NCT00510172|Placebo Comparator|2|Placebo
3165212|NCT00510185|Experimental|1|Coronary angiography within 72h and revascularization as clinical indicated
3165213|NCT00510185|Sham Comparator|2|Initially conservative treatment with coronary angiography only for recurrent ischemia
3165214|NCT00510211||olanzapine coated tablet|
2515836|NCT02791256|Experimental|Peginterferon Alfa-2a + Ribavirin|Participants will receive 360 microgram (mcg) of Peginterferon Alfa-2a subcutaneous (SC) once a week plus ribavirin (1000 - 1200 milligram per day [mg/day] orally as a split dose in the morning and the evening based on the participant's body weight) for 32 weeks.
2515868|NCT02790827|Experimental|CETA|Participants in the experimental arm will receive the CETA intervention. The intervention period will last for approximately 4 months with weekly sessions. There will be separate groups for men, women, and children. Each group will have approximately six participants. Individuals who cannot attend group therapy (e.g., conflicting work schedules) may be offered the therapy individually.
2515871|NCT02790827|Active Comparator|Treatment as usual|There is no standard of care for domestic violence or alcohol use problems in Zambia. We will track any treatment or care that families receive during the course of the study. The active comparator arm will not receive any formal services provided by the study.
2515937|NCT02790658|Other|Grumixama Juice|"Juice of grumixama purple fruit (Eugenia brasiliensis Lam.), which is good source of anthocyanins and ellagitannins. It was made with filtered water and sanitized fruits, with a blender. It was administered in single dose of 0.97 mg of anthocyanins and of 4.71 mg of ellagitannins per mL of juice. Which volunteers ingested 10 mL of juice per each Kg body weight.~The metabolomic approach of plasma and urine samples following acute intake of grumixama juice was done by the collection of blood samples and urine, following the intake of grumixama juice."
2515968|NCT02790177|Experimental|HiB|This group will receive the compound for the reduction of adhesions
2515971|NCT02790177|Placebo Comparator|Normal saline|This group will just receive normal saline to ensure blinding.
2516008|NCT02789904||Chest pain patients in DEM|Recruitment done at SGH DEM. Blood taking will be done at 0, 1 and 2 hr.
2516058|NCT02789605|Experimental|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months
2516061|NCT02789605|Placebo Comparator|Placebo|Patient receiving placebo, orally taken, 4 times a day, during 3 months
2516137|NCT02789267|No Intervention|Control|"Group of patients with standard of care: the nutritional support is conducted by physicians.~No systematic dietary support"
2516139|NCT02789267|Experimental|Regular dietary support|Group of patients will benefit from a systematic and regular dietary support. Patients will be followed by a dietitian 1 month and 3 month after radiotherapy in hospital. Then, dietitian will realize a telephon interview 2 and 5 months after radiotherapy
3165215|NCT00510211||olanzapine orodispersable tablet|
3165216|NCT00510237|Experimental|1|5-7 females per group at each of the four sites.
2516236|NCT02788240|Experimental|Peg GCSF with standard medical therapy|
2516245|NCT02788240|Active Comparator|Placebo with standard medical therapy|
2516460|NCT02786784|Other|healthy control|patients with patellofemoral pain
2516522|NCT02786641|Active Comparator|Group A|low risk NPC treated with concurrent chemoradiotherapy
2516524|NCT02786641|Active Comparator|Group B|high risk NPC treated with concurrent chemoradiotherapy
2516525|NCT02786641|Experimental|Group C|high risk NPC treated with induction chemotherapy plus concurrent chemoradiotherapy
2516591|NCT02786017|Sham Comparator|Conventional therapy|
2516595|NCT02786017|Experimental|Injectable Collagen Scaffold + HUC-MSCs|
2516635|NCT02785627||Group A: ADT|Men with non-metastatic prostate cancer, about to start or within 2 weeks of starting ADT
2516640|NCT02785627||Group B: ADT + chemotherapy|Men with newly diagnosed hormone sensitive metastatic prostate cancer, starting ADT and who will have chemotherapy
2516646|NCT02785627||Group C: Controls|Healthy age matched men
2516695|NCT02785328|Experimental|obstructive sleep apnoea|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from obstructive sleep apnoea syndrome.
2516700|NCT02785328|Experimental|narcolepsy|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from narcolepsy.
2516706|NCT02785328|Experimental|BECTS (Benign epilepsy with centro-temporal spikes)|The objective of this task is to evaluate the sleep-dependent consolidation abilities before and after treatment in children suffering from BECTS.
2516708|NCT02785328|Experimental|high intellectual potential|The objective of this task is to evaluate the sleep-dependent consolidation abilities in children with high intellectual potential.
2516710|NCT02785328|Experimental|healthy children|The objective of this task is to evaluate the sleep-dependent consolidation abilities in healthy children.
2516777|NCT02784756|Other|Quantiferon-CMV assay|All patients will receive a CMV-immunity test at specific time points during the study. This is a single arm design
3165217|NCT00510237|Experimental|2|5-7 males per group at each of the four sites.
3165218|NCT00510250|Experimental|Cisplatin and Radiation in Combination with Sorafenib|
3165219|NCT00510263|Experimental|1|
3165220|NCT00510263|Experimental|2|
3165221|NCT00510263|Experimental|3|
3165222|NCT00510263|Placebo Comparator|4|
3165223|NCT00510302||Melanoma Risk-Reduction|Patients with melanoma, their spouses/partners, and first-degree relatives (FDRs).
3165224|NCT00510315||Women treated with SCT/TBI|
3165225|NCT00510315||1:1 Matched group of women|"Current age + or - 2 years~Race and ethnicity~Cancer diagnosis~Interval from completion of cancer therapy to study + or - 2 years"
3165226|NCT00510341|Active Comparator|1|CMP program
3165227|NCT00510341|No Intervention|2|Control group
3165228|NCT00510354|Experimental|RAD001 + Imatinib|
3165229|NCT00510367|Experimental|Multimodality Treatment|"Multimodality (chemotherapy, surgery and radiation therapy) treatment:~5-Fluorouracil + Doxorubicin + Cyclophosphamide (FAC)"
3165230|NCT00510380||growth-restricted Chinese pregnancies|
3165231|NCT00510380||appropriately-grown Chinese pregnancies|
3165232|NCT00510393|Experimental|1|drug eluting stent
2515748|NCT02791880||TAVR patients|The group of interest is the patient population with aortic stenosis who are undergoing transcatheter aortic valve replacement (TAVR)
2515825|NCT02791451|Experimental|Telemonitoring|Exacerbation of COPD with wireless telemonitoring of respiratory rate, heart rate and sleep.
2515863|NCT02791074||Control|"Healthy Volunteers will undergo the following studying procedures:~Echocardiography Arterial tonometry"
2515864|NCT02791074||Heart Failure Patients|"Patients will undergo the following studying procedures:~NTproBNP Echocardiography Arterial tonometry"
2515875|NCT02790814|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
2515876|NCT02790814|Active Comparator|Hand-held fetoscope|Intermittent fetal heart rate monitoring
2515917|NCT02790593|Experimental|Juxta-Cures™|Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
2515919|NCT02790593|Active Comparator|Standard compression|Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
2515991|NCT02790216||Brachytherapy|men eligible for monotherapy seed implant brachytherapy
2516048|NCT02789800|Active Comparator|Group A|Intervention group (n = 163) Intervention: Participates in DIMAC02 Program
2516051|NCT02789800|No Intervention|Group B|Control group (n = 163)
2516055|NCT02789800|No Intervention|Group C|Health Administrative Data Group (n = 1630) Number of matched data controls. Not taking part in intervention.
2516088|NCT02789319|Other|FreeStyle Lite|Blood Glucose Meter type
2516092|NCT02789319|Other|Contour Next|Blood Glucose Meter type
2516096|NCT02789319|Other|OneTouch Ultra2|Blood Glucose Meter type
2516098|NCT02789319|Other|ACCU-CHEK AVIVA Plus|Blood Glucose Meter type
2516102|NCT02789319|Other|Prodigy Auto Code|Blood Glucose Meter type
2516106|NCT02789319|Other|Walmart ReliOn Prime|Blood Glucose Meter type
2516110|NCT02789319|Other|Embrace|Blood Glucose Meter type
2516113|NCT02789319|Other|True Result|Blood Glucose Meter type
2516118|NCT02789319|Other|True Track|Blood Glucose Meter type
2516119|NCT02789319|Other|Walmart ReliOn Confirm|Blood Glucose Meter type
2516120|NCT02789319|Other|Advocate Redi-Code +|Blood Glucose Meter type
2516121|NCT02789319|Other|CVS Advanced|Blood Glucose Meter type
2516123|NCT02789319|Other|OneTouch Verio|Blood Glucose Meter type
2516124|NCT02789319|Other|Contour|Blood Glucose Meter type
2516130|NCT02789319|Other|Accu-Chek Nano|Blood Glucose Meter type
2516131|NCT02789319|Other|Walmart ReliOn Ultima|Blood Glucose Meter type
2516132|NCT02789319|Other|Gmate Smart|Blood Glucose Meter type
2516133|NCT02789319|Other|SolusV2|Blood Glucose Meter type
2516177|NCT02788734||INC Contact Registry|INC Contact Registry will complete the online questionnaires
2516243|NCT02788500||Swedish para-athletes|The total population of athletes in the Swedish Paralympic program, which covers candidates for the Paralympic Summer or Winter Games, will be invited by mail to participate in the study and report their incidence of sports-related injuries and illnesses
2516309|NCT02788058|Experimental|EGFR-TKI|Patients take EGFR-TKI alone till tumor progression
2516310|NCT02788058|Active Comparator|EGFR-TKI+hypofractionated radiotherapy|After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
2516345|NCT02787577|Experimental|Sleep Lengthening|The intervention group will receive a personalised sleep consultation session to lengthen sleep by 1-1.5 hours per night by targeting sleep hygiene using behaviour change techniques for 4 weeks.
2516348|NCT02787577|No Intervention|Control|The control group will be asked to resume their normal lifestyle.
2516399|NCT02787356|Experimental|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic with trained skin graders and images of skin
2516402|NCT02787356|Experimental|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD with trained skin graders and images of skin
2516481|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
2516509|NCT02786524|No Intervention|Standard of Care|Patients randomized to this arm receive standard symptom management care by their primary gynecologic oncologist and complete the NCCN distress thermometer and ESAS-r at each visit, every 3-4 weeks.
2516515|NCT02786524|Experimental|Symptom Management and Supportive Care|Patients randomized to this arm are referred to a specialized symptom management and supportive care clinic and seen within two weeks. Patients will be seen in follow-up as recommended by the symptom management providers, and at each visit they will complete the ESAS-r and NCCN distress thermometer and return their responses either in person or by mail to the study team in a pre-addressed postage paid envelope.
2516547|NCT02786238|Active Comparator|Standard Behavioral Treatment (SBT)|For the Standard Behavioral Treatment (SBT) condition, participants will participate in the standard behavioral weight loss programming, which utilizes strategies from existing obesity treatments (e.g., the Diabetes Prevention Program). These features include the following: 1) nutritional education, 2) diet and physical activity, 3) expectations for daily self-monitoring of calorie intake and activity, 4) stimulus control, behavior shaping, behavior analysis, and relapse prevention strategies, and 5) social support.
2516548|NCT02786238|Experimental|Acceptance-Based Treatment (ABT)|"The Acceptance-Based Treatment (ABT) group will receive most features listed in the SBT arm as well as unique ABT training designed to help individuals increase awareness of their cognitive and affective experiences, and the following exercises: 1) identifying weight-related goals from personal life values (e.g., health) and connecting these values to day-to-day eating, 2) increasing awareness of moment-by-moment behavior choices, 3) tolerating aversive internal states that include eating-related states as well as affective states such as stress, sadness, and anxiety (i.e., urge-surfing). These strategies that have been empirically tested and found to be effective in the NIH-funded Mind Your Health RCT (R21DK080430)."
2516633|NCT02785536|Active Comparator|Standard Treatment|The standard treatment was a well-established, manual-driven, multicomponent CBT for tobacco dependence that has been delivered in multiple modalities (i.e., group, individual, and telephone), used in numerous studies, and considered intensive, comprehensive, and consistent with the Public Health Service Clinical Practice Guideline.
2515749|NCT02791932|Experimental|Exercise|The intervention will last 8-10 months depending on when during pregnancy the participant is randomized. The intervention will consist of three components (i.e., telephone, print materials, and exercise log/goal setting) designed to increase exercise. Social Cognitive Theory (SCT) and Self-Determination Theory will guide the exercise intervention. The counseling sessions will be a collaboration between the counselor and participants on how to best integrate exercise into the participant's daily routine. Participants will receive 15 intervention phone calls lasting approximately 15-20 minutes each. There will be a one-month intensive phase (weekly contacts), followed by bi-weekly contacts for two months, and then monthly until delivery. Beginning at 6 weeks postpartum, bi-weekly contacts will resume through 3 months postpartum.
2515750|NCT02791932|No Intervention|Usual Care|Participants in the usual care condition will follow their usual standard of care as suggested by their healthcare provider. Participants will complete the same assessments and incentives as the active interventions but will not receive the exercise counseling sessions. Following completion of the nine-month follow-up, the usual care arm can choose to receive a six-month version of the exercise intervention.
2515771|NCT02791581|Experimental|Breast Cancer Patients|"Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment."
2515779|NCT02791581|Experimental|Non-Cancer Controls|"Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers.~Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities."
2515880|NCT02791035|Experimental|Ipragliflozin|Ipragliflozin 50 mg/tablet, orally, 1 tablet once daily for 12 weeks
3197942|NCT00865579|Experimental|1|All subjects to receive first 50mg/d Safinamide with an increase of target dose of 100mg/d after 14 days of taper period until end of treatment visit. In case of any intolerance the daily dose of 100mg might be decreased to 50mg/d. Patients permanently discontinuing treatment will enter a 7day taper phase before treatment discontinuation at a dose of 50mg/day. Subjects already taking 50mg/d may stop Safinamide immediately.
2516059|NCT02789787||Maxillary protraction|Early adolescents (11 - 14 yrs) with cleft lip and palate and Cl III malocclusion
2516063|NCT02789787||Orthognathic surgery|Late adolescents to young adults (16-21 years) with cleft lip and palate and Cl III malocclusion
2516126|NCT02789241|Experimental|Endotoxin (LPS)|The safety and tolerability will be assessed at different doses that will consist of 4 groups; each consisting of 4 subjects receiving endotoxin (LPS). Group 1 will test the low dose of LPS (0.6 ng/kg); Group 2 will test the 1.0 ng/kg dose; Group 3 will test the 2.0 ng/kg dose and Group 4 will test the 4.0 ng/kg dose.
2516129|NCT02789241|Placebo Comparator|Placebo|The trial will consist of 4 groups each group will have 2 subjects receiving Placebo (normal saline)].
2516260|NCT02788149|Experimental|STUDY GROUP|Model development group: This group will get Ultrasound of neck exam followed by polysomnography. We will use this group to identify the ultrasonographic parameters that have strong association of predicting obstructive sleep apnea. We will use these these predictors to estimate the patient's probability of severe OSA, which then will be used to test the receiver operating characteristic (ROC) curve of diagnosing severe OSA. The optimal cut-off value of the ROC curve will be defined as the one with the least (1 - sensitivity)2+ (1- specificity)2 in the model-development group. This formula will then tested in the validation group.
2516261|NCT02788149|Active Comparator|validation group|One third patients in the cohort will be randomly assigned to this group. This group will get ultrasound of neck exam followed by polysomnography. The predictors will be tested in his group.
3197943|NCT00865605|Experimental|A|Halobetasol Propionate 0.05% Ointment, single exposure
3197944|NCT00865605|Active Comparator|B|Ultravate® 0.05% ointment, single exposure
2516383|NCT02787525||A: patients on anticoagulation|Questionnaire to patients with non-valvular atrial fibrillation on OAC or NOAC
2516385|NCT02787525||B: patients treated by LAA-Closure|Questionnaire to patient with non-valvular atrial fibrillation who underwent LAAC between 2009 and 2014 at the University hospitals Bern or Zurich
2516416|NCT02787109|Experimental|CTH522-CAF01|"CTH522-CAF01: CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
2516420|NCT02787109|Experimental|CTH522-Al(OH)3|"CTH522-Al(OH)3: CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration (preferably the non-dominant arm)~CTH522 chlamydia antigen diluted with Tris buffer for IN administration"
2516423|NCT02787109|Placebo Comparator|Placebo|Saline for IM and In administrations
3197945|NCT00865618|Experimental|1|Eplerenone 50mg Tablets
2516534|NCT02786368|Other|Control group|For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
3197946|NCT00865618|Active Comparator|2|INSPRA 50mg Tablets
3197947|NCT00865631|Experimental|A|Gabapentin 800 mg tablets, single dose (1 tablet)
3197948|NCT00865631|Active Comparator|B|NEURONTIN® 400 mg capsules, single dose (2 capsules)
3197949|NCT00865644|Experimental|Imiquimod|
3197950|NCT00865657|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
3197951|NCT00865657|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
3197952|NCT00865670|Experimental|1|Azithromycin Monohydrate 600mg Tablets
3197953|NCT00865670|Active Comparator|2|Zithromax (azithromycin dihydrate)600mg Tablets
3197954|NCT00865683|Active Comparator|1|Participants will receive DHA supplements.
2515752|NCT02791919|Experimental|Treatment (AZD1775, FLAG chemotherapy)|Patients receive filgrastim IV or SC daily, fludarabine intravenously IV over 30 minutes, cytarabine IV over 1-3 hours and wee1 kinase inhibitor AZD1775 PO on days 1-5. Patients who meet criteria for CR, CRp or PR may receive a second course of therapy. Courses repeat every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
2515837|NCT02791204|Experimental|Participants with PAD|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
2515841|NCT02791204|Active Comparator|Controls|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
2515897|NCT02790970|Experimental|PReDicT Test|To determine whether use of the PReDicT Test to direct antidepressant treatment results in an increased proportion of depressed patients showing a response to treatment at week 8
2515900|NCT02790970|Placebo Comparator|Treatment as usual|Treat patients as usual without using the predict test to determine treatment.
2516000|NCT02789982|Experimental|Reconsolidation blockade|β-adrenergic blocker propranolol 1 mg / kg to each of the 6 treatment sessions
2516003|NCT02789982|Active Comparator|Treatment as usual|Treatment as usual like SSRIs, psychotherapy, ...
2516069|NCT02789644|Experimental|Ursodeoxycholic acid 400mg|Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
2516070|NCT02789644|Experimental|Ursodeoxycholic acid 800mg|Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
2516149|NCT02788968|Other|Adolescents|MRI 11-15 years
2516151|NCT02788968|Experimental|Young adults|MRI 19-25 years
2516222|NCT02788695||Group 1 - aged 20-90 years|25 participants from each decade from 20-90. Those from 50+ will be recruited from the NICOLA study and retinal/lens images assessed to confirm normality.
2516223|NCT02788695||Group 2: aged 60 years|Group 2: 250 participants NICOLA participants aged 60 will be invited to participate; only those whose ocular images confirm normality will be included.
2516255|NCT02788162|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2516286|NCT02787928|Experimental|Intrathecal Dilaudid|This will be a prospective up/down dosage study. After obtaining informed consent, eligible participants will be part of an up/down dose titration study. This first phase of our study will be conducted using intrathecal (spinal) hydromorphone to determine an appropriate dose range for our study population. Study drug dose will initially be 40 mcg. The only deviation from the current standard of care will be that patients will be given hydromorphone intrathecally instead of morphine. The rest of the care provided will be standard of care and per current practices at VCU labor and delivery floor.
2516321|NCT02787785|No Intervention|Conventional Medical Therapy|This arm of the trial continues with their current conventional medical therapy.
2516323|NCT02787785|Active Comparator|Subcutaneous Implantable Cardioverter Defibrillator|This arm of the trial receives a subcutaneous implantable defibrillator.
2516440|NCT02787018|Placebo Comparator|Block with Ropivacaine and Normal saline|Patients will receive brachial plexus block with 20 ml 0.5% ropivacaine with 1ml normal saline: Total volume 21 ml
2516445|NCT02787018|Active Comparator|Block with Ropivacaine and Dexamethasone|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 4mg (1ml) dexamethasone: Total volume 21 ml
2516451|NCT02787018|Experimental|Block with Ropivacaine and Dexmedetomidine|Patients will receive brachial plexus block with 20ml 0.5% ropivacaine with 50mcg (1ml) dexmedetomidine: Total volume 21 ml
2516559|NCT02786316|Experimental|intervention group|Hit program for the rehabilitation of persons with nonspecific chronic low backpain
2516560|NCT02786316|Active Comparator|Control group|a conventional rehabilitation program for persons with nonspecific chronic low backpain
2516578|NCT02785887|Experimental|Oncological and geriatrician review|Routine oncological care plus geriatric intervention
2516587|NCT02785887|No Intervention|Oncological care|Routine oncological care only
2516628|NCT02785614|Experimental|II-1|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days. Wash-out period is 14 days."
2516634|NCT02785614|Experimental|II-2|"This is 2-period, 2 cross (2x2) crossover design was used. each 3 males and 3 females, give the following two different crossover treatments in the following sequence:~T: trazodone hydrochloride prolonged-release tablets 150 mg per day for 7 days R: trazodone hydrochloride tablets 50mg for 3 times per day for 7 days. Wash-out period is 14 days."
2516681|NCT02785341|Other|Immediate adaptated physical activity (Group A)|"Group A began a physical activity program for 12 consecutive weeks from inclusion in the protocol, then underwent the usual care for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
2516683|NCT02785341|Other|Without immediate adaptated physical activity (Group B)|"Group B followed the usual care for 12 weeks then started the physical activity program for 12 additional weeks.~Then to complete five evaluations with several questionnaires, and 6-minute walk test every 6 weeks (T0, T1, T2, T3 and T4) and leptin level with a blood test every 12 weeks (T0, T2 and T4)."
2516740|NCT02785016||Stress Urinary Incontinence|Females with stress urinary incontinence, who undergo a tension free surgical sling procedure.
2516771|NCT02784717||Rivaroxaban (Xarelto, BAY 59-7939)|Female and male patients, who are at least 18 years of age with a diagnosis of non-valvular atrial fibrillation will be enrolled after the decision for a pharmacologic prophylaxis with rivaroxaban to prevent stroke or non-CNS systemic embolism has been made.
2516804|NCT02784496|Experimental|Treatment (ruxolitinib, follow-up)|Patients continue to receive ruxolitinib PO QD or BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo follow-up assessment for safety over 10 minutes every 3 cycles.
3197955|NCT00865683|Placebo Comparator|2|Participants will receive placebo capsules of corn oil.
3197956|NCT00865696|Experimental|A|Mirtazapine 15 mg tablets, single dose
3197957|NCT00865696|Active Comparator|B|REMERON® 15 mg tablets, single dose
2515908|NCT02790684|Experimental|DS-8500a|
3197958|NCT00865722|Active Comparator|RemotePostConditioning|Patients will receive pPCI and treatments according to guidelines for STEMI PLUS extrinsic cuff compression to the lower limb for 5 ' followed by 5' reperfusion for three cycles (30' in total) starting with myocardial reperfusion
2516022|NCT02789618|Active Comparator|A01|Toothpaste containing calcium silicate and Sodium Monofluorophosphate (1450ppm F) and a gel containing sodium fluoride (1450ppm F)
2516025|NCT02789618|Active Comparator|B99|Toothpaste containing Stannous Fluoride and a dentinal bonding agent
2516028|NCT02789618|Placebo Comparator|M89|Toothpaste containing sodium fluoride (1450ppm F)
2516172|NCT02789423|Active Comparator|Dycal|Intervention: drug: Dycal, Other names: Calcium Hydroxide. Intervention Description:DPC using Dycal for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria evaluated were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility. Radiographic criteria:Defective restoration/Recurrent caries,Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
2516173|NCT02789423|Active Comparator|Biodentine|Intervention: drug: Biodentine, Other names: Calcium Silicate. Intervention Description:DPC using Biodentine for direct pulp exposure was performed in 30 primary molar teeth after proper case selection.Clinical and radiographic evaluation was done.One month post operative criteria were-Clinical criteria:Spontaneous pain,Defective restoration/Recurrent caries,Sinus formation,TOP,Soft tissue swelling & Mobility.Radiographic criteria:Defective restoration/Recurrent caries, Periapical or furcal radiolucency,Pathological internal resorption,Replacement resorption,Intracanal calcification & Physiological resorption.The follow-up was at 3 and 6 months.
2516235|NCT02788539|No Intervention|Science Cafe|One time event, Group discussion for 30 participants who are chronic pain stakeholders on pain in their community.
2516241|NCT02788539|Experimental|Cohort 1- Pilot OWL Study|Participants will pilot test a website- Our Whole Lives website for nine weeks in order to determine if it will help with their chronic pain management.
2516270|NCT02788006|Experimental|Regorafenib 160 mg|
2516322|NCT02787707|Active Comparator|intervention|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour from 24 hour before to fifth day after chemotherapy.
2516324|NCT02787707|Placebo Comparator|control|2.7 grams Lactose every 8 hour from 24 hour before to fifth day after chemotherapy.
2516376|NCT02787473|Experimental|pemetrexed+carboplatin/cisplatin+radiation therapy->docetaxel|Patients received pemetrexed 500mg/m2 days 1,29+cisplatin 25 mg/m2 days 1-3,29-31 + Radiation 6000 cGy (200 cGy/day). Patients with complete response(CR), partial response(PR) or stable disease(SD) with manageable toxicity received docetaxel 60 mg/m2 days 57,78.
2516430|NCT02787096|Experimental|laxIRM|Patients will have dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
3197959|NCT00865722|Sham Comparator|Controls|pPCI and treatments according to guidelines for STEMI
2516536|NCT02786329|Active Comparator|TIVA + lidocaine|"TIVA-L. Patients allocated to receive TIVA (propofol-fentanyl) with lidocaine infusion.~Interventions: TIVA+lidocaine"
2516537|NCT02786329|Placebo Comparator|TIVA+placebo|TIVA-P. Patients allocated to receive TIVA without lidocaine (placebo). Intervention: TIVA+placebo (saline infusion)
2516539|NCT02786329|Placebo Comparator|Sevoflurane+placebo|"Sevo-P. Patients allocated to receive Sevoflurane anesthesia without lidocaine infusion (placebo).~Intervention: sevoflurane anesthesia +placebo (saline infusion)"
2516540|NCT02786329|Active Comparator|Sevoflurane+lidocaine|"Sevo-L. Patients allocated to receive sevoflurane anesthesia with lidocaine infusion for the first 48 h postoperatively.~Intervention: sevoflurane anesthesia+ lidocaine infusion"
2516562|NCT02785965|Experimental|acupuncture & lifestyle modification|Electro-acupuncture is given three times a week with diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks.
2516563|NCT02785965|Active Comparator|lifestyle modification|diet restriction to 1400 calories a day and moderate aerobic exercise 3h a week for 12 weeks
3197960|NCT00865748|Experimental|A|Metformin HCl 500 mg tablets, single dose
3197961|NCT00865748|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3197962|NCT00865761|Experimental|A|Alprazolam 3 mg Extended Release Tablets, single dose
3197963|NCT00865761|Active Comparator|B|XANAX XR® 3 mg tablets, single dose
2516802|NCT02784483|Experimental|Atezolizumab (1200mg via IV infusion)|
2516820|NCT02784236|Other|pre-post evaluation|All patients undergo the condition of telemedicine.
2516866|NCT02784054|Experimental|Intracranial NGGCT|"Six cycles of chemotherapy with carboplatin, etoposide, bleomycin (CEB) and cyclophosphamide, etoposide, bleomycin (CyEB) regimen.~Peripheral blood stem cell collection during the first cycle of chemotherapy.~Surgery, if there is residual tumor after chemotherapy.~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation (auto-SCT)~1st HDCT: Carboplatin, thiotepa, etoposide~2nd HDCT: Cyclophosphamide, melphalan~Reduced dose of radiotherapy"
2516906|NCT02783716|Active Comparator|Cardiac Resynchronization Therapy (CRT)|Participants will be undergoing Cardiac Resynchronization Therapy Implantation (CRT) implantation for heart failure
2516907|NCT02783716|Active Comparator|Control Group|Participants will undergo device pacemaker or implantable cardioverter-defibrillator (ICD) implantation or pack change for sinus node dysfunction or Atrioventricular (AV) block.
2516949|NCT02783508|Active Comparator|IV Meperidine|Intravenous injection of meperidine 50mg given in 100cc NaCl 0.9% over 10 minutes. Repeated doses (if needed) will be given in intervals of 2 hours minimum until a maximum of 4 doses.
2517064|NCT02782858|Experimental|Dose 2 GNbAC1|Monthly IV repeated dose
3197964|NCT00865774|Experimental|1|Arm number 1 focuses on the traditional quantity frequency model.
3197965|NCT00865774|Experimental|2|Arm number 2 targets subjective drunkenness.
3197966|NCT00865787||Olive Oil A|
3197967|NCT00865787||Olive Oil B|
3197968|NCT00865813|Experimental|Punch Biopsy|
2515830|NCT02791178||STEMI patients|"The patients presenting with a STEMI and undergoing PPCI will be screened and approached to participate in this study.~All patients to do Optical Coherence Tomography (OCT), Index of Microcirculatory Resistance (IMR) and Cardiac MRI."
2515907|NCT02790710|Experimental|Propanolol|Propranolol 40 mg capsule, given once after fear reactivation procedure
2515910|NCT02790710|Placebo Comparator|Placebo capsule|Placebo capsule, given once after fear reactivation procedure
2515948|NCT02790359|Active Comparator|Patient group 1|Air
2515951|NCT02790359|Active Comparator|Patient group 2|Carbon dioxide
2515987|NCT02790112|Other|GnRHas - Not GnRHas patients|Compared long term outcome of treated and untreated patients with idiopathic central precocious puberty : hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2515989|NCT02790112|Other|GnRHas - controls patients|Compared long term outcome of treated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2515990|NCT02790112|Other|Not GnRHas - Controls patients|Compared long term outcome of untreated patients with idiopathic central precocious puberty and control patients for: hormonal assessment; DNA for candidate single nucleotide polymorphisms (SNP) analyses; pelvic ultrasound; dual energy x-ray absorptiometry (DXA)
2516062|NCT02789735|Active Comparator|Device: LiteCure LCT-1000®|Treatment with 10 J/cm²
2516066|NCT02789735|Sham Comparator|Device: Sham LiteCure|Sham i.e. visible red light
2516083|NCT02789254|Experimental|Experimental: FLYSYN|IV infusion over a 3-hr duration
2516234|NCT02788435|No Intervention|Control|Patients in the control arm will undergo a graduated prescription of voice use immediately following surgery.
2516242|NCT02788435|Experimental|Absolute Voice Rest|Patients in the experimental arm will undergo 7 days of absolute voice rest following surgery.
2516278|NCT02787993|Active Comparator|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
2516284|NCT02787993|No Intervention|Treatment as usual|Treatment as usual
2516355|NCT02787772|Experimental|Elective Hernia Repair|Elective abdominal wall hernia surgery was performed in randomized cirrhotic patients.
2516358|NCT02787772|No Intervention|Clinical follow up|"Cirrhotic patients were kept in clinical follow up concerning their abdominal wall hernia.~If a complication occured at the hernia site (such as skin rupture, bowel strangulation,..) the patient underwent emergency hernia repair."
2516505|NCT02786550|Experimental|Botulinum Toxin|"Immediately after lower blepharoplasty surgery 3 injections of 2.5U of botulinum toxin over lateral part of orbicularis oculi muscle.~Intervention: Botulinum toxin injection"
2516508|NCT02786550|Placebo Comparator|Normal saline|"Immediately after lower blepharoplasty surgery 3 injections of same amount of normal saline over lateral part of orbicularis oculi muscle.~Intervention: Normal saline injection"
2516641|NCT02785523|Experimental|G. SPORE LIPIDS|"Form: Capsule Dosage and frequency: This group receives ganoderma spore lipids capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
2516645|NCT02785523|Placebo Comparator|Placebo|"Form: Capsule Dosage and frequency: This group receives placebo capsules 600mg TID in addition to the chemotherapy.~Duration: 6 chemotherapy cycles."
2516674|NCT02785263|Other|Standard radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
2516677|NCT02785263|Other|High dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 28 treatments
2516679|NCT02785263|Other|Low dose radiotherapy|Daily on weekdays: 2.15 gray for tumor and verified lymph node metastases and 1.8 gray for the elective volume. A total of 25 treatments
2516749|NCT02785029|Experimental|Normal healthy Volunteers|OCT imaging
3165233|NCT00510393|Placebo Comparator|2|Bare Metal Stent
2516826|NCT02784119|Experimental|temporary porto-caval shunt|patients in whom temporary porto-caval shunt is performed during orthotopic liver transplantation
2516828|NCT02784119|No Intervention|no temporary porto-caval shunt|patients in whom temporary porto-caval shunt is not performed during orthotopic liver transplantation
2516889|NCT02783963|Other|MI with nonobstructive CAD at coronary angiography|MI with nonobstructive CAD investigated by means of OCT and CMR
2516967|NCT02783638|Experimental|YHD1119 (Pregabalin 300mg)|YHD1119 (Pregabalin 300mg)
2516971|NCT02783638|Active Comparator|Lyrica (Pregabalin 150mg)|Lyrica (Pregabalin 150mg)
3165234|NCT00510406|Placebo Comparator|A|
3165235|NCT00510406|Active Comparator|B|
3165236|NCT00510406|Active Comparator|C|
3165237|NCT00510406|Active Comparator|D|
3165238|NCT00510406|Active Comparator|E|
3165239|NCT00510406|Active Comparator|F|
3165240|NCT00510406|Active Comparator|G|
3165241|NCT00510406|Active Comparator|H|
3165242|NCT00510432||s.c. anticoagulant therapy|All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)
3165243|NCT00510445|Experimental|Single Arm Trial|Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
3165244|NCT00510549|Active Comparator|1, PD|Peritoneal Dialysis
3165245|NCT00510549|Active Comparator|2, HD|Hemodialysis
3165246|NCT00510562|Experimental|1|Assessment for cranial strain patterns, followed by indirect osteopathic treatment of dysfunctions found on assessment, followed by reassessment.
3165247|NCT00510562|Sham Comparator|2|Assessment for cranial strain patterns, followed by laying on of hands, followed by reassessment.
3165248|NCT00510575|Active Comparator|1|Subjects in this arm will receive the 5.5mm stainless steel instrumentation rod.
3165249|NCT00510575|Active Comparator|2|Subjects in this arm will receive a 6.35mm stainless steel instrumentation rod.
3165250|NCT00510588|Other|1|regular physical exercise training
3165251|NCT00510588|Other|2|regular physical exercise training + metformin
2515757|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~collection of patient's radiographic and clinical parameters"
2515924|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
2515928|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
2515932|NCT02790645|Other|Group 1b. Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
2515933|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months).
2515983|NCT02790151|Active Comparator|Standard Therapy|Learning and practicing memory strategies
2515985|NCT02790151|Experimental|Experimental Intervention|Computerbased working memory training and Recollection training
2516032|NCT02789826|Experimental|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic Gastrectomy' group will undergo laparoscopic gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
2516036|NCT02789826|Active Comparator|Open gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive gastrectomy via laparotomy. This group is considered the control group
2516195|NCT02788721|Experimental|GLPG2451 single dose|Single dose of GLPG2451 oral suspension at up to 4 dose levels in ascending order
2516196|NCT02788721|Placebo Comparator|Placebo single dose|Single dose of Placebo oral suspension
2516297|NCT02788071|Experimental|FMT capsules|FMT capsules
2516302|NCT02788071|Placebo Comparator|FMT placebo|Placebo capsules
2516325|NCT02787629|Experimental|Simultaneous|Simultaneous Intubation with GlideScope and ETT inserted simultaneously
2516332|NCT02787629|Active Comparator|Control Standard|Standard Intubation with GlideScope inserted first and ETT inserted after the GlideScope view is obtained
2516373|NCT02787460|Experimental|Behavioral Text Messages|Couples assigned to a treatment group will receive weekly behavioral theory-based messages encouraging them to attend the sessions.
2516378|NCT02787460|No Intervention|Simple Reminder Text Messages|"Couples in the control group will receive simple reminder text messages that include the date, time, and location of their next group session"
2516406|NCT02787174|No Intervention|Control|Participants will receive routine clinical treatment care.
2516412|NCT02787174|Experimental|Intervention|Participants will receive interactive tailored asthma medication adherence education on an iPad.
2516498|NCT02786680|Experimental|stroop test in condition DBS off|Condition 1 : On Med /Off Stim
2516503|NCT02786680|Active Comparator|stroop test in condition DBS on|Condition 2 : On Med /On Stim
2516551|NCT02786251|Other|BAT+|Individuals with significant amounts of BAT (>20 ml)
2516554|NCT02786251|Other|BAT-|Individuals with no/minimal amounts of BAT (<20 ml)
2516594|NCT02785952|Experimental|Arm I (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on day 1 and ipilimumab IV over 60 minutes on day 1 of every third course (every 42 days). Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2516597|NCT02785952|Active Comparator|Arm II (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2517510|NCT02779946||CHD-positive|positive tested for coronary artery disease
2517513|NCT02779946||CHD-negative|negative tested for coronary artery disease
3165252|NCT00510588|Other|3|regular physical exercise training + glitazon
3165253|NCT00510588|No Intervention|4|Control
2517700|NCT02778373|Placebo Comparator|Placebo|Flavored Water
2517701|NCT02778373|Active Comparator|Low Molecular Weight Carbohydrate|low molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
2517705|NCT02778373|Experimental|High molecular weight carbohydrate|high molecular weight carbohydrate delivered post-endurance exercise in a 10% solution providing 1.2 grams/kg body weight carbohydrate
2517797|NCT02778191||Concomitant cisplatin|Patients treated with concomitant cisplatin
2517799|NCT02778191||Carboplatin plus 5-FU|Patients treated with carboplatin plus 5-FU
2518021|NCT02776527|Experimental|A group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox,and taking Apatinib 500mg/qd orally, 28 days as a cycle, till disease progresses.
2518026|NCT02776527|No Intervention|B group|D2 Radical Gastrectomy adding received postoprative adjuvant chemotherapy of eight cycles of Xelox
2518082|NCT02776228|Experimental|benzodiazepine|The patient which will be in the Experimental arm (after randomization) will receive 0.25 mg of Brotizolam (short acting benzodiazepine) for six weeks from the day of discharge.
2518084|NCT02776228|Placebo Comparator|placebo|The patient which will be in the placebo arm (after randomization) will receive placebo for six weeks from the day of discharge.
2518134|NCT02776072||dimethyl fumarate (DMF)|Participants who initiated DMF during the specified time period
3165254|NCT00510601|Experimental|1|
3165255|NCT00510614|Active Comparator|A|1 gram tinidazole twice weekly for 12 weeks
3165256|NCT00510614|Placebo Comparator|B|Placebo twice weekly for 12 weeks
3165257|NCT00510627|Experimental|A|Radiofrequency ablation in conjunction with chemotherapy
3165258|NCT00510627|Active Comparator|B|Standard of care chemotherapy regimen
3165259|NCT00510640|Experimental|Sunitinib|Sunitinib will be administered orally daily for 4 weeks followed by a 2-week rest; the daily starting dose will be 50 mg with a provision for dose reduction based on tolerability. All patients will receive repeated cycles until disease progression or occurrence of severe toxicity.
3165260|NCT00510666|Experimental|1|Butorphanol basal infusion adjunct to morphine PCA
3165261|NCT00510666|Experimental|2|Saline infusion adjunct to morphine PCA
3165262|NCT00510666|Experimental|3|Premedication of Tramadol
3165263|NCT00510666|Experimental|4|Preemptive saline for morphine PCA
3165264|NCT00510705|Other|1|Regular physical exercise training alone
2515770|NCT02791646|Experimental|PCST-Full|PCST-full will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
2515778|NCT02791646|Experimental|PCST-Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
2515831|NCT02791360|Other|MRI evaluation|Patient pretreated for brain tumor and witness
2515889|NCT02791048|Experimental|Experimental Group|Music therapy for up to 45 minutes twice a week for three weeks, in addition to usual care from the hospice multidisciplinary team.
2515890|NCT02791048|No Intervention|Control Group|Usual care only from the hospice multidisciplinary team. The dose and frequency of usual care will be as deemed appropriate by the hospice practitioner in charge of their treatment.
2515935|NCT02790541|Experimental|Treatment|Hyperbaric Oxygen Therapy: 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2515936|NCT02790541|Other|Control/Crossover|Hyperbaric Oxygen Therapy: 3 months control period (no treatment) followed by 3 months of treatment consisting of 60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week
2515963|NCT02790190|Experimental|Individualized Adaptive radiotherapy|GTV dose per fraction will be 2.2-2.4 y per fraction for 20 fractions and PTV dose per fraction will be 2.0 Gy per fraction.Perform PET/CT before radiotherapy and at 36 Gy for treatment response assessment and adaptive plan.Adaptive plan treated at 2.2-3.8 Gy per fraction for GTV and 2.0 Gy for PTV in the final 10 fractions.
2515964|NCT02790190|No Intervention|Conventional radiotherapy|2 Gy per fraction for all patient,perform PET/CT before radiotherapy and at 40 Gy for treatment response assessment .Continue treatment to a total dose of 60 Gy.
2516047|NCT02789592|Experimental|Group 1|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2516050|NCT02789592|Experimental|Group 2|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2516054|NCT02789592|Experimental|Group 3|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
2516057|NCT02789592|Experimental|Group 4|Phase 1: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks
2516060|NCT02789592|Experimental|Group 5|Phase 1: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2516064|NCT02789592|Experimental|Group 6|Phase 1: Melatonin PR placebo 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 2: Clonazepam 0.5 mg 1 tablet+Melatonin PR placebo 1 tablet, 1/day before sleeping for 4 weeks Phase 3: Melatonin PR 2 mg 1 tablet+Clonazepam placebo 1 tablet, 1/day before sleeping for 4 weeks
2516160|NCT02789085|No Intervention|Control|without tens stimulation
2516162|NCT02789085|Experimental|Test|with tens stimulation
2516197|NCT02788630|Experimental|Intervention group|Arm: Experimental: Intervention group Field workers trained in sleep hygiene counseling will advice the mothers randomly allocated to the intervention group. The intervention will be delivered at the child household and will include information on: Normal sleep behaviors during the first year of life; ideal conditions to promote sleep onset like environmental improvements that ensure restful sleep (no screen media, low noise and light); calming naptime routines and avoiding stimulating or stressing children just before naptime; practices that promote child self-regulation of sleep, including putting infants to sleep drowsy but awake; and how to handle nighttime awakenings. A booklet with the intervention content to aid the mother in implementing the intervention will be used.
2516198|NCT02788630|No Intervention|Control group|Mothers randomly allocated to the control group will be visited at home following the same schedule as the intervention group. The control group will receive a written material describing the advantages of breastfeeding over maternal and child health. No advice in relation to child sleep hygiene will be delivered to the mothers from the control group.
2516225|NCT02788331||Hospitals with increasing activity|Hospitals experiencing an increase in the volume of surgical procedures over the study period
2516227|NCT02788331||Hospitals with decreasing activity|Hospitals experiencing a decrease in the volume of surgical procedures over the study period
2516228|NCT02788331||Hospitals with stable activity|Hospitals experiencing no change in the volume of surgical procedures over the study period
2516277|NCT02788110|Other|NIV NAVA then NIPPV|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIV NAVA then NIPPV.
2516280|NCT02788110|Other|NIPPV then NIV NAVA|Infants will receive 15 minute trials of noninvasive neurally adjusted ventilatory assist (NIV NAVA) and nasal intermittent positive pressure ventilation (NIPPV) in random order with the first 10 minutes after changing to be considered a washout period and the last 5 minutes used for data collection. This group will receive NIPPV then NIV NAVA.
3197969|NCT00865826||1|HIV-infected males and females who are not currently receiving ART
2516395|NCT02787330|Active Comparator|Control Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2516863|NCT02784392|Experimental|Active|Ulimorelin
2515775|NCT02791529|Active Comparator|Scalpel|Skin incision performed by scalpel
2515782|NCT02791529|Experimental|Electrocautery|Skin incision performed by electrocautery
2515791|NCT02791503|Experimental|IRE group|FOLFIRINOX + IRE For patients diagnosed with LAPC, a combination of chemotherapy plus local tumor destruction using irreversible electroporation (IRE), a novel tumor ablation technique, has recently shown great promise. IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
2515793|NCT02791503|Active Comparator|SABR group|FOLFIRINOX + SABR Focal therapy using external beam radiation therapy (EBRT) may further improve survival, but outcome remains poor. Stereotactic ablative radiotherapy (SABR) is a form of EBRT that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
3165265|NCT00510705|Other|2|Regular physical exercise training + metformin
2515843|NCT02791386||Chinese Patients With CHB and Drug Resistance to NA Therapy|
2515881|NCT02790996|Experimental|Vancomycin - Optimised Regimen|"A single loading dose of 25 mg/kg followed by a maintenance dose of:~Postmenstrual age ≤ 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly"
2515885|NCT02790996|Active Comparator|Vancomycin - Standard Regimen|Postmenstrual age < 29 weeks - 15 mg/kg given 24 hourly; Postmenstrual age 29 - 35 weeks - 15 mg/kg 12 hourly; Postmenstrual age > 35 weeks - 15 mg/kg 8 hourly
2515914|NCT02790372|No Intervention|Control nursing homes|Nursing homes carries out usual care
2515916|NCT02790372|Active Comparator|Intervention nursing homes|Nursing homes that carries out regularly case conferencing
2515941|NCT02790554|Experimental|Moyo strap-on|Continous fetal heart rate monitoring
2515946|NCT02790554|Active Comparator|Hand-held Doppler|Intermittent fetal heart rate monitoring
2515962|NCT02790294|Experimental|Postoperative Magnetic Resonance Imaging|Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
2515965|NCT02790099|Experimental|Rectus sheath block only|Patient will be given surgical rectus sheath block postoperatively with 40ml of bupivacaine (2.5mg/mL) and 0.1ml of normal saline will be injected intrathecally at time of spinal anaesthesia.
2515967|NCT02790099|Active Comparator|Intrathecal morphine group|0.1mg preservative free morphine will be injected intrathecally at time of spinal anesthesia and 40ml of normal saline will be injected as rectus sheath block.
2515970|NCT02790099|Active Comparator|Both intervention|Patient will be given 0.1mg preservative free morphine intrathecally at time of spinal anaesthesia and surgical rectus sheath block with 40ml of bupivacaine (2.5mg/ml).
2515993|NCT02789995|Experimental|Patients with and without sepsis|"Patients with sepsis, Patients with inflammatory disease without sepsis, Patients without inflammatory disease without sepsis.~Human biological samples collected for research :~Blood sample~Muscle biopsy~Bone marrow sample (mesenchymal stem cells)"
2516023|NCT02789683|Experimental|Fine emulsion|Emulsion with small lipid droplet size served together with white bread
2516027|NCT02789683|Experimental|Coarse emulsion|Emulsion with large lipid droplet size served together with white bread
2516030|NCT02789683|Experimental|Control|Non-emulsified oil and water served together with white bread
2516053|NCT02789852|Experimental|Orthosis Group|Will use the night orthosis for interphalangeal in the treatment of OA hand.
2516056|NCT02789852|No Intervention|Control Group|wait for treatment
2516085|NCT02789371|Other|Arm A|the first pass is made with 5ml suction technique
2516086|NCT02789371|Other|Arm B|the first pass is made with modified wet suction technique
2516099|NCT02789397|Active Comparator|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12. Azathioprine: Starting dose of azathioprine will be 50 mg and increased in 25 mg increments to a maximum dose of 150 mg or 2 mg/k/day (whichever is lowest) as tolerated. Azathioprine will be administered by mouth daily for 18 months.
2516103|NCT02789397|Placebo Comparator|Placebo|IV placebo will be administered on the same schedule as Rituximab. Oral placebo will be administered by mouth daily for 18 months.
3197970|NCT00865839|Experimental|A|Metformin HCl 500 mg tablets, single dose
3197971|NCT00865839|Active Comparator|B|CLUCOPHAGE® XR 500 mg tablets, single dose
3197972|NCT00865852|Experimental|A|Metformin HCl 750 mg Extender Release tablets, single dose
2516193|NCT02788929|Active Comparator|Fitbit Charge HR|"Use of the Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.~All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback."
2516194|NCT02788929|No Intervention|No Device|No Fitbit used and no feedback on exercise goal adherence. All patients will wear the Actigraph wGT3X-BT, from which data is extracted. Actigraph does not provide patient any feedback.
2516214|NCT02788305||non obese|BMI<30. Misoprostol is given for induction of labour according to Bishop score
2516215|NCT02788305||obese|BMI>30. Misoprostol is given for induction of labour according to Bishop score
2516238|NCT02788214||Advanced intestinal metaplasia|"H. pylori strains from patients with:~Complete-type intestinal metaplasia with extension to corpus, or~Incomplete-type intestinal metaplasia of any extent"
2516247|NCT02788214||Non-atrophic gastritis|H. pylori strains from patients with non-atrophic gastritis
2516248|NCT02788214||Gastric cancer|H. pylori strains from patients with gastric cancer
2516249|NCT02788370|Sham Comparator|Sham-PEP breathing|Patients will perform a constant work load cycling test with sham-positive expiratory pressure breathing util symptom limit.
2516251|NCT02788370|Experimental|Conical-PEP breathing|Patients will perform a constant work load cycling test with positive expiratory pressure breathing using a conical positive expiratory pressure device until symptom limit.
3165266|NCT00510705|Other|3|Regular physical exercise training + glitazone
3197973|NCT00865852|Active Comparator|B|GLUCOPHAGE® XR 750 mg tablets, single dose
3197974|NCT00865865|Other|1|Conventional total knee arthroplasty
3197975|NCT00865865|Active Comparator|2|Computer aided total knee arthroplasty
3197976|NCT00865878|Active Comparator|1|Topical Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes and 40 seconds.
3197977|NCT00865878|Placebo Comparator|2|Kerastick containing vehicle ingredients only (VEH) will be applied to the entire scalp OR both forearms 90 +/- 30 minutes prior to blue light treatment for 16 minutes 40 seconds.
3197978|NCT00865891|Experimental|A|Nifedipine Extended Release tablets 60 mg, single dose
3197979|NCT00865891|Active Comparator|B|ADALAT® CC Extended Release Tablets 60 mg
3197980|NCT00865917|Active Comparator|1|beta-blocker
2516097|NCT02789566|Experimental|Regimen|Primaquine (PQ) 30 mg base single dose
2516179|NCT02788994|Experimental|Endovis BA2 Nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~stable fracture synthesis for fast rehabilitation and early mobilization~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)~This is a one off surgical fixation."
2516183|NCT02788994|Active Comparator|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
2516232|NCT02788461|Active Comparator|Chemoradiotherapy|Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.
2516237|NCT02788461|Experimental|Chemoradiotherapy with Integrated Boost Dose|Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
2516339|NCT02787902|Experimental|Communication|Behavioral weight loss program with communication skills training
2516341|NCT02787902|Active Comparator|Standard|Standard behavioral weight loss program
2516382|NCT02787408|Experimental|EW Tricuspid Transcatheter Repair System|Edwards (EW) Tricuspid Transcatheter Repair System
3197981|NCT00865917|Experimental|2|I(f)-blocker
3197982|NCT00865917|Placebo Comparator|3|Placebo
2516657|NCT02785497|Experimental|Treatment group|"Chronic ulcer patients will be treated with 50 minutes of the high-voltage current or 10 minutes of the diadynamic current. To burn patients 50 minutes high voltage current in the donor area. For both group the metal electrodes will be sterilized and the negative polarity in the active electrode.~50 min, 100Hz, intensity according to the sensitivity patient - High Voltage; 10 min, intensity according to the sensitivity patient - Diadynamic"
2516659|NCT02785497|Sham Comparator|Control group|"For the control group the unit is turned on, the time will pass but will not be given intensity~50min, 100Hz, Intensity according to the sensitivity patient"
2516680|NCT02785211|Experimental|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
2516684|NCT02785211|Placebo Comparator|control group|"For the control group, participants will receive regular physical examinations and education by village doctors weekly during the 8 week intervention.The weekly visits for every old people whose age above 65 by country doctors are not arranged by our study, it is the country doctors routine work by government health policy. This study was permitted by the local community health center, the director with specific responsibility will inform all country doctors to support our study."
3197983|NCT00865943|Experimental|A|Citalopram HBr eq. 10 mg tablets, single dose
3197984|NCT00865943|Active Comparator|B|CELEXATM 10 mg tablets, single dose
2516917|NCT02783703|Experimental|MCT|Medium chain triglyceride (MCT) oil ingested daily for 6 weeks
3197985|NCT00865956|Experimental|Care Management|Care Management plus voucher incentives for adherence to primary care appointments.
3197986|NCT00865956|No Intervention|Usual care|Usual care
2517023|NCT02782975|Experimental|aducanumab IV|Infusion of aducanumab over approximately 1 hour
2517030|NCT02782975|Experimental|aducanumab SC|Subcutaneously via injection
2517081|NCT02782728|Active Comparator|TIPS-Basic|Providers receive tailored scripts based on the patient's responses to the questions administered via tablet.
2517082|NCT02782728|Experimental|TIPS-Plus|Patients receive tailored messages in addition to the scripts given to providers.
2517124|NCT02782390|Experimental|Hall Technique|single placement of stainless dental crowns on atypical cavities
2517130|NCT02782390|Active Comparator|Composite Resin|single placement of composite resin on atypical cavities
3197987|NCT00865995||1|patients undergoing elective procedures with intubation and no known respiratory pathology
2517305|NCT02781142|Experimental|Motor imagery training|Persons with multiple sclerosis
2517306|NCT02781142|No Intervention|Control group|Persons with multiple sclerosis
2517307|NCT02781142|No Intervention|Healthy controls|Healthy participants
2517315|NCT02780817|Experimental|Error enhancement|Arm reaching rehabilitation training with error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
2517321|NCT02780817|Other|Control group|Arm reaching rehabilitation training without error-augmentation perturbation forces. One session of about 25 minutes of practicing arm reaching movements on 3D robotic device.
2517373|NCT02780544|Experimental|skin-to-skin contact + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in skin-to-skin position with a parent (intervention group) and one in the incubator (standard care). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination.
2517422|NCT02780271|Experimental|Arm A|Subjects will receive in-person education plus e-communication AND subjects will receive control intervention
3197988|NCT00865995||2|patients with tracheostomy
3197989|NCT00865995||3|patients with chronic lung disease or respiratory symptoms undergoing bronchoscopy
3197990|NCT00866008|Experimental|1|Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment.
3197991|NCT00866008|Experimental|2|Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
3197992|NCT00866021|Experimental|1|Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
2516010|NCT02789956|Experimental|Test: internal connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with implant level Co/cr Cad/Cam framework.
2516011|NCT02789956|Active Comparator|Test: external connection|Evaluate marginal bone level (MBL) changes at implants that are placed semi-edentulous patient when they are treated with abutment level Co/cr Cad/Cam framework.
2516072|NCT02789579|Experimental|levofloxacin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 3 days before Minimally invasive upper tract lithotomy.
2516073|NCT02789579|Experimental|nitrofurantoin 3 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 3 days before Minimally invasive upper tract lithotomy.
2516074|NCT02789579|Experimental|cefuroxime group|There are 150 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and does not receive oral antibiotics 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
2516075|NCT02789579|Experimental|levofloxacin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives levofloxacin 0.5g,qd,po 7 days before Minimally invasive upper tract lithotomy.
2516076|NCT02789579|Experimental|nitrofurantoin 7 days group|There are 30 patients in the group,each patient meets the eligibility criteria and does not meet the exclusion criteria,and receives nitrofurantoin 0.1g, tid, po 7 days before Minimally invasive upper tract lithotomy.
2516188|NCT02789098|Other|STEMI|All patients included in this study (1 arm)
2516203|NCT02788448|Experimental|VIVASURE CLOSURE DEVICE|Large hole closure device
2516258|NCT02788292|Experimental|Acetylcysteine (NAC)|NAC added to tumescent solution for liposuction and eventual fat grafting.
2516259|NCT02788292|No Intervention|Control|Just tumescent solution for liposuction and fat grafting.
2516304|NCT02787889|Experimental|Uneven Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks.Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
2516308|NCT02787889|Experimental|Even Protein Intake Pattern|Subjects consumed either dietary protein intake at 1.1g protein/kg/day over 8 weeks. Each participant will consume 33% of total protein consumed each meal
2516327|NCT02787668|Experimental|Carbohydrate-restricted diet|This diet is designed to minimize intake of carbohydrate sources such as added sugars, high glycemic grains, and fructose and will provide ≤10% energy from CHO, 25% energy from protein, and ≥65% energy from fat. During the first two weeks of the intervention,
2516331|NCT02787668|Active Comparator|Control, low-fat diet|The control, low-fat diet will contain 55:25:20 %energy from CHO:protein:fat based on the USDA MyPlate Daily Food Plan. For example, an 1800kcal/d plan will include 5 ounces lean meats, 3 cups low-fat dairy, 6 ounces of whole grains, 1 ½ cups fruit, 2 ½ cups vegetables (starchy and non-starchy) and limited fats.
2516375|NCT02787447|Experimental|1|After 3 mos TKI, patients showed stable disease take TKI, radiotherapy and thymosin alpha 1 till tumor progression.
2516446|NCT02787122|Active Comparator|CBT-E|"Emotion-focussed Cognitive behavior therapy:~Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy. Interventions are behavioral activation, training of emotion regulation strategies, improvement of self-esteem and relapse prevention."
2516449|NCT02787122|Placebo Comparator|Treatment as Usual|Patients who are randomized and assigned to the Wait list are required to wait for half a year, while they receive standardized care (antipsychotic medication). After half a year, they receive CBT-E, as well.
2516532|NCT02786615|Experimental|Peer Unity|Subjects assigned to this arm would receive a 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
2516533|NCT02786615|No Intervention|Pre-implementation|Subjects assigned to this arm would not receive the group-delivered intervention.
2516556|NCT02786043|Experimental|Single arm|
3197993|NCT00866021|Active Comparator|2|Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
3197994|NCT00866060|Active Comparator|1|"10mg donepezil plus 20mg memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards"
3197995|NCT00866060|Placebo Comparator|2|"Placebo donepezil plus 20mg memantine~Participants in this arm will immediately commence active memantine at a dose of 5mg per day, increasing in 5mg increments weekly until 20mg per day is achieved from week 4 onwards. Donepezil dose will be reduced to 5mg daily in weeks 1 to 4 and replaced with placebo donepezil in week 5."
3197996|NCT00866060|Placebo Comparator|3|"10mg donepezil plus placebo memantine~Participants in this arm will continue with their current donepezil 10mg/day regimen and immediately commence placebo memantine."
2517502|NCT02779751|Experimental|NSCLC KRAS mt, PD-L1+|Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3197997|NCT00866060|Placebo Comparator|4|"Placebo donepezil plus placebo memantine~Participants in this arm will immediately commence placebo memantine dose escalation and will switch to donepezil 5mg daily in weeks 1 to 4, and replaced with placebo donepezil in week 5."
3197998|NCT00866073|Experimental|A|Decitabine 15 mg/m2 i.v. - single arm
2515834|NCT02791464|No Intervention|wait list control|Waitlist control subjects interested in learning the TM program will be asked to wait for 4 months before learning if they were randomly assigned to this comparison group. Controls will receive usual medical care during 4 month intervention period.
2515839|NCT02791464|Experimental|Transcendental Meditation|The TM technique is a simple, effortless, mental technique to reducing stress which allows the mind to experience finer levels of the thinking process to achieve a state of restful alertness. The Transcendental Meditation program will be taught as a standard seven-step program over five consecutive days.
2515874|NCT02791009||Diagnosed Heart Failure [Prior]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2515877|NCT02791009||Control [Prior]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2515879|NCT02791009||Control [New]|Control will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection and Clinical Assessment.
2515883|NCT02791009||Diagnosed Heart Failure [New]|Patients will undergo the following studying procedures: Cardiovascular Magnetic Resonance Imaging (CMRI), Cardiovascular Ultrasound (CVUS), Electrocardiogram (ECG), Blood Sample Collection, Cognitive Test and Clinical Assessment.
2515944|NCT02790346|Experimental|arthrodesis talonavicular|arthrodesis talonavicular in addition to tendon gestures
2515949|NCT02790346|Active Comparator|tendon gestures|tendon gestures only
2516037|NCT02789774|Experimental|Surgical treatment|Stabilization of odontoid fracture with posterior fusion C1-C2
2516041|NCT02789774|Active Comparator|Conservative treatment|External stabilization of odontoid fracture with a rigid cervical collar for 3 months.
2516087|NCT02789293|Experimental|Focused Ultrasound treatment|Ultrasound ciliary pasty (UCP) using focused ultrasound
3165267|NCT00510705|No Intervention|4|Control
3165268|NCT00510757||Males|
2516244|NCT02788409||Medicare CRPC|Men in the US older than 65 years old having CRPC
2516337|NCT02788084||B cell Non-Hodgkin Lymphoma|18 years of age or older with new diagnosis of non-Hodgkin lymphoma with FFPE specimen demonstrating enough tissue for elucidation of lymphoma specific variant and immunoglobulin clonotype, willing to provide baseline and follow up bloodwork to look for presence of variant and clonotype.
2516386|NCT02787512|Active Comparator|Plastic stent|10 Fr plastic stent (Percuflex Amsterdam® or C-flex pigtail® or Advanix® Biliary stent)
2516390|NCT02787512|Experimental|Uncovered metal stent|Uncovered metal stent (WallFlex® Biliary RX stent)
2516444|NCT02787031||Neuraxial anesthesia|Participants in this group will be those who had a spinal or epidural anesthetic without concurrent general anesthesia
2516450|NCT02787031||General anesthesia|Participants in this group will be those who had general anesthesia, including those who had a general plus a concurrent spinal or epidural anesthetic.
2516527|NCT02786628||Solid tumor malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
2516529|NCT02786628||Hematologic malignancies|15 patients. Will participate in physical performance testing and patient-generated health data.
2516531|NCT02786628||Hematopoietic cell transplantation|15 patients. Will participate in physical performance testing and patient-generated health data.
2516575|NCT02786095||Code-AF registry|
2516662|NCT02785783|Active Comparator|Standard colonoscopy|A standard colonoscope will be used to complete the procedure
2516663|NCT02785783|Active Comparator|EndoRings™|An EndoRings™ device will be placed at the distal end of a standard colonoscope
2516694|NCT02785198|No Intervention|Control group|A control group receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
2516702|NCT02785198|Experimental|Passive training group|An Intervention group doing passive exercise for 8 weeks in knee extensor machine, and receiving standard wound treatment consisting of debridement, dressings, compression, offloading footwear and if necessary antibiotics.
2516761|NCT02785003|Experimental|Ketamine Infusion|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the ketamine solution at a calculated dose of 0.25 mg/kg. A continuous infusion of ketamine will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
2516763|NCT02785003|Placebo Comparator|Saline Placebo|All infusion rates will be calculated based on ideal body weight. Patients will receive a bolus of the saline solution at a calculated dose of 0.25 mg/kg. A continuous infusion of saline will immediately follow at a rate of 2 mcg/kg/min. The continuous infusion to run for a duration of 48-hours.
2516789|NCT02784470|Experimental|gastrojejunostomy arm|
2516791|NCT02784470|Active Comparator|gastroduodenal stent placement|
2516855|NCT02784314|Experimental|Robotic-Assisted Radical Prostatectomy|Robotic-Assisted Radical Prostatectomy using da Vinci Surgical System
2516857|NCT02784314|Active Comparator|Laparoscopic Radical Prostatectomy|Standard laparoscopic Radical Prostatectomy
2516896|NCT02783833|Experimental|MMV390048 40 mg|MMV390048 40 mg, tablets, single dose
2516899|NCT02783833|Experimental|MMV390048 dose to be determined mg|MMV390048 dose to be determined mg, tablets, single dose
3165269|NCT00510757||Females|
3165270|NCT00510796||High Risk Group|Colon and/or Endometrial Cancer
3165271|NCT00510822|Placebo Comparator|Placebo|Placebo + Sertraline
3165272|NCT00510822|Experimental|Cimicoxib|Sertraline + Cimicoxib
3165273|NCT00510848|Experimental|1|Reconstruction with an autograft tendon (hamstrings)
3165274|NCT00510848|Experimental|2|Reconstruction with an allograft tendon (tibialis posterior)
3165275|NCT00510965|Experimental|A|
3165276|NCT00510978|Active Comparator|1|Bifidobacterium infantis 35624
3165277|NCT00510978|Active Comparator|2|Lactobacillus salivarius UCC118
3165278|NCT00510978|Placebo Comparator|3|Placebo
3165279|NCT00510991|Experimental|A|NIPPV
3165280|NCT00511017|Experimental|Doxercalciferol|
3165281|NCT00511043|Experimental|All pts|PTK787
3173792|NCT00615979||Miniature echo machine|Diagnostic capabilities Wireless transfer
2515854|NCT02791126||Heart Failure|"Patients presented to hospital with a primary diagnosis of Heart Failure or are attending a hospital clinic for management of Heart Failure within 6 months of an episode of decompensated heart failure, which either resulted in a hospital admission (primary diagnosis) or was treated in out-patient clinic.~Cardiovascular Magnetic Resonance and Echocardiogram will be performed."
2515884|NCT02790866|Experimental|LuCaS Decision Aid|Access to LuCaS, a web-based lung cancer screening decision aid
2515887|NCT02790866|Active Comparator|NCI Website|Access to NCI website on lung cancer screening
2515943|NCT02790567||HIT study group|The HIT study group will include all patients admitted in our surgical intensive care unit (ICU) during the study period if the clinician in charge of the patient suspects the diagnosis of HIT. The HEP score, the 4Ts score, the immuno-diffusion particle gel immunoassay (ID-PaGIA) and the HIT-Ab(PF4-H) test will be done for each patient the day the diagnosis of HIT will be suspected.
3197999|NCT00866099|No Intervention|"Normal Care"|Primary care practices randomly allocated will be given a summary of the NICE/SCIE dementia guidelines (2006) and offered workshop training and software at the end of the study.
2516071|NCT02789514||children|Investigators give observation to the patients who need esophagogastroduodenoscopic procedures.
2516122|NCT02789215|Experimental|Intervention|Receive new CACFP menu pattern
2516125|NCT02789215|No Intervention|Control|Follow existing CACFP menu pattern
3198000|NCT00866099|Experimental|Training|Practices randomly allocated to the intervention arm will be asked to participate in tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
3198001|NCT00866112|Experimental|1|Intervention group to promote physical activity
2516230|NCT02788318||diagnostic of SUDEP|patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause (diagnosis of SUDEP). Brain samples and skin samples are collected.
2516233|NCT02788318||Control 1|Subjects with a known epilepsy, whose death is linked to a specific cause. Brain samples and skin samples are collected.
2516239|NCT02788318||Control 2|Subjects without known pathological history, remained victims of unexplained sudden unexpected death (SUDEP) after all investigations and for which a heart rhythm disorder is suspected in first intention. Brain samples and skin samples are collected.
2516271|NCT02787941|Experimental|Intervention group|The intervention group will receive the pharmacist-delivered multifaceted intervention with two counselling sessions in addition to usual care.
2516272|NCT02787941|No Intervention|Control group|The control group will receive usual care without the pharmacist-delivered multifaceted intervention.
2516343|NCT02787811|Active Comparator|Pregnant|women with positive serum beta HCG done 14 days after Intrauterine insemenation
2516346|NCT02787811|Active Comparator|Nonpregnant|women with negative serum beta HCG done 14 days after Intrauterine insemenation
2516388|NCT02787382|Experimental|Pregnant women with CMV infection|"An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography)."
2516391|NCT02787382|Experimental|Pregnant women with suspected CMV infection|"The healthy women from the group will serve as controls. An attempt to record the fetal myocardium will be done at the initial examination and at all the follow up examinations performed during pregnancy (every 3-4 weeks according to the clinical protocol currently in use at the OB-GYN US Unit).~The participants will undergo a detailed fetal echocardiography according to standard guidelines (see below, section echocardiography). As the control group-Newborns found to be negative for CMV will serve as control group."
3198002|NCT00866112|Other|2|Minimal contact control group
3198003|NCT00866138|Experimental|1|masitinib (AB1010)
2516526|NCT02786446|Active Comparator|Lidocaine gel|20 grams Lidocaine gel 2 % will be applied to corresponding lumber area of the patients 30 minutes before undergoing ESWL for renal stone.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2516528|NCT02786446|Active Comparator|Naproxen Sodium|Oral Naproxen sodium 550 mg will given to patients 45 minutes before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2516530|NCT02786446|Active Comparator|Lidocaine Gel and Naproxen Sodium|Oral Naproxen sodium 55o mg and locally applied 2 % lidocaine gel to patients before ESWL for renal stones.Max 4000 shockwaves will be administered. Rescue intravenous nalbuphine will be administered during procedure.Visual analogue pain score will be measured after completion of procedure or during procedure just before giving rescue iv analgesia if needed.
2516565|NCT02786030|Experimental|Intervention|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) and outreach education training. First trainers will be trained, then trainers will train groups of doctors and nurses at their workplaces, showing them how to use the guidelines, and using their own patients and clinical problems as examples. This outreach training is repeated several times in short sessions.
2516568|NCT02786030|Active Comparator|Control|Doctors and nurses in each clinic will receive printed copies of the patient management tool (PMT) but will not receive outreach education training.
2516617|NCT02785731||Women with a pelvic mass|Women diagnosed with a pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass) who are scheduled for a laparotomy or laparoscopy for removal of the pelvic mass. Must have a pelvic imaging study performed within 60 days prior to surgery and a research blood draw within 60 days prior to surgery.
2516687|NCT02785393|Placebo Comparator|Sugar Pill|
2516691|NCT02785393|Active Comparator|Doxazosin|
2516755|NCT02784990||Patient|
3198004|NCT00866151||1|"Previously enrolled subjects in the Benefits and Risks of Alternative Weight Loss Strategies - a Clinical Trial, which was run at Stanford 2003-2005. (A to Z Study)"
3198005|NCT00866190|Experimental|Cohort 1|SQ109 dose 75 mg or placebo once daily for 14 days.
3165282|NCT00511056||HIVNAT 006|HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
3165283|NCT00511082|Experimental|Treatment group|
2516127|NCT02789189|Experimental|nedaplatin combined with gemcitabine|
2516182|NCT02788916||Cohort 1|Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
2516299|NCT02788136|Experimental|Klinefelter syndrome|13 men with diagnosis of Klinefelter syndrome were stimulated with human chorionic gonadotropin (hCG)
2516306|NCT02788136|Active Comparator|Control|12 healthy age-related men were stimulated with human chorionic gonadotropin (hCG)
2516326|NCT02787642|Experimental|Olaparib in association with concomitant radiotherapy|Olaparib will be administered per os bi-daily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression. Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
2516392|NCT02787369|Experimental|Combination of ACY-1215 With Ibrutinib|ACY-1215 and Ibrutinib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
2516393|NCT02787369|Experimental|Combination of ACY-1215 With Idelalisib|ACY-1215 and Idelalisib will be administered orally continuously, with 28 consecutive days arbitrarily defined as a treatment cycle. The dose level will be predetermine.
2516517|NCT02786394|Experimental|REACH Participant Course|This study will run twice a week over 8 weeks with 6 REACH sessions 8 optional walking program sessions. The optional walking program will be run by SportMedBC and may consist of one or more educational sessions (e.g., nutrition). Each REACH session introduces new topics, strength and balance activities and home practices which progressively build on each other. We will ask participants to provide feedback after each session, and in two to three 30 minutes recorded interviews (in-person or over the telephone) at the end of the study.
2516549|NCT02786264||Propofol-dominant Sedation|Patients receiving propofol infusion for TAVR as the primary drug for sedation.
2516550|NCT02786264||Dexmedetomidine-dominant Sedation|Patients receiving dexmedetomidine infusion for TAVR as the primary drug for sedation.
2516552|NCT02786264||Fentanyl and/or Midazolam Sedation|Patients receiving fentanyl +/- midazolam as the primary drugs for sedation for TAVR
2516697|NCT02785445|Other|All participants (single arm)|All study participants once enrolled into the study were asked to collect their midstream urine in the designated device urine cups. The urine sample was then tested sequentially; first by the Dip.io Home Based Dipstick Analyzer (first intervention) and by the ACON U500 Mission® U500 Urine Analyzer (comparative device - second intervention). Part of the participants (100 out of 302) were asked to perform the Dip.io urine test by themselves for the user performance evaluation.
2516758|NCT02785055|Active Comparator|Ultrasound-Assisted|Ultrasound assisted marking of the thoracic spine on the skin for Thoracic Epidural Placement
2516764|NCT02785055|Active Comparator|Palpation|Palpation marking of the thoracic spine on the skin for Thoracic Epidural Placement
2516803|NCT02784535|Placebo Comparator|placebo|placebo capsules
2516805|NCT02784535|Active Comparator|atomoxetine|atomoxetine capsules 10 mg or 18 mg
2516823|NCT02784145|Other|RS|Resistant starch supplementation (5 g twice a day)
2516824|NCT02784145|Other|No RS|PD patients who do not receive resistant starch, but who receive recommendations concerning healthy Nutrition (based on the guidelines of the German Society for Nutrition)
2516867|NCT02784028|Experimental|SGM-101|6 dose levels of SGM-101 (5mg/patient, 7.5mg/patient, 10 mg/patient, 12.5mg/patient , 15 mg/patient - 24 h prior surgery and 15 mg/patient - 48h prior surgery
2516898|NCT02783794|Experimental|BP-C1|Patients randomized to BP-C1 arm will be treated for 32 consecutive days. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2516903|NCT02783794|Placebo Comparator|Placebo|Patients randomized to Placebo arm will be treated for 32 consecutive days. Thereafter the patients will cross over to 32-day treatment with BP-C1. Patients who respond to treatment and do not experience untolerated toxicity are invited to participate in the BMC2011-02 study, where they will be offered to continue treatment with BP-C1.
2517010|NCT02783183|Experimental|YHD1119|Pregabalin 300mg
2517019|NCT02783183|Active Comparator|Lyrica|Pregabalin 150mg
2517192|NCT02781831|Active Comparator|Standard Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation program
2517194|NCT02781831|Experimental|Robot-assisted Rehabilitation|Patient with stroke receiving standard hospital based rehabilitation as well as robot-assisted gait rehabilitation program
2549852|NCT02566226|Active Comparator|Bupivacaine with intrathecal morphine|
3165284|NCT00511160|Active Comparator|S|Study arm: Cardiac surgery group
3165285|NCT00511160|Active Comparator|C|Routine cardiology group
3165286|NCT00511186|Experimental|Bovine Intestinal AP|"Bovine Intestinal Alkaline Phosphatase (BIAP) Intravenous administration of 10 bolus (67,5U/kg) and 48h continuous infusion (132,5U/kg)"
3165287|NCT00511186|Placebo Comparator|2|"Placebo Intravenous administration of 10 bolus and 48h continuous infusion"
3165288|NCT00511225|Active Comparator|1|Will receive 10,000 IU of cholecalciferol weekly
3165289|NCT00511225|Placebo Comparator|2|Will receive a identical appearing placebo weekly
3165290|NCT00511316|Experimental|Drug|20 mg montelukast daily for 6 months
3165291|NCT00511316|Placebo Comparator|Placebo|20 mg daily placebo
3165292|NCT00511368|Placebo Comparator|1|placebo
3165293|NCT00511368|Experimental|2|Bevirimat
3165294|NCT00511394|Active Comparator|I|Infusion of 100 mL of 20% Albumin
3165295|NCT00511394|Placebo Comparator|II|100 mL Normal Saline
3165296|NCT00511407|Experimental|I|RAD Treatment
3165297|NCT00511407|No Intervention|II|Conventional CVVHD
2515911|NCT02790697||Mechanically ventilated ICU patient|Indirect calorimetry measurements will be conducted using the new calorimeter and the mass spectrometer system at the same time for all enrolled patients.
2515940|NCT02790398|Experimental|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol.
2515947|NCT02790398|Active Comparator|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol that includes a component aimed at the regulation of PA.
3198006|NCT00866190|Experimental|Cohort 3|SQ109 dose 150 mg or placebo once daily for 14 days.
3198007|NCT00866190|Experimental|Cohort 2|SQ109 dose 150 mg or placebo once daily on Days 1-5, 9, and 14.
2516108|NCT02789228|Experimental|Group A|"Group A includes patients who have undergone an allogeneic hematopoietic stem cell transplant (HSCT) as part of their prior therapy.~Group A patients (post allogeneic HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first."
2516111|NCT02789228|Experimental|Group B|"Group B includes patients who have undergone conventional (standard) therapy which does not include an allogeneic HSCT. Within group B, a cohort of patients with relapsed or refractory Wilms tumor will be enrolled and receive a lymphodepleting chemotherapy regimen followed by TAA-T.~Group B patients (no prior allogeneic HSCT): TAA-T will be infused any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. Patients receiving lymphodepletion will be >2 weeks from most recent course of conventional therapy and have nadired and recovered before beginning protocol therapy."
2516178|NCT02788942|No Intervention|Umbilical|The cholecystectomy material will be removed from umbilical port as usual. This will be control group. Port site infection rates will be measured.
2516181|NCT02788942|Experimental|Epigastric|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured.
2516211|NCT02788487|Active Comparator|CPAP1 use and TRD 2use|Wash-in period 1 week and Continuous positive airway pressure (CPAP) is used for 3 weeks then wash-out 1 week and Tongue retaining device (TRD) is used for another 3 weeks
2516212|NCT02788487|Experimental|TRD1 use and CPAP2 use|Wash-in period 1 week and Tongue retaining device (TRD) is used for 3 weeks then Wash-out period 1 week and Continuous positive airway pressure (CPAP) is used for another 3 weeks
3198008|NCT00866203|Experimental|HDS|modified high dose sequential therapy
2516294|NCT02787837||Abiraterone Acetate|Abiraterone Acetate 1000 mg/24h plus Prednisone 5mg/12h
2516359|NCT02787538|Experimental|US-ANSWER-2 decision aid|The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
2516361|NCT02787538|Active Comparator|Control group (Online medication guide)|The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
2516414|NCT02787278|Experimental|SP-8203 High dose group|SP-8203 160mg (80mg/dose twice a day for three days)
2516418|NCT02787278|Experimental|SP-8203 Low dose group|SP-8203 80mg (40mg/dose twice a day for three days)
2516421|NCT02787278|Placebo Comparator|Placebo group|Placebo group: twice a day for three days
3198009|NCT00866203|Active Comparator|ProMECE/CytaBOM|four additional courses of standard ProMECE/CytaBOM
2516501|NCT02786472|Active Comparator|Haven|"Online Bystander Training or Haven provides students with definitions and statistics associated with sexual assault and relationship violence, bystander skills and strategies, and campus policies and resources. The trainings are personalized and reflective and incorporate the student's unique perspectives and experiences. This 45-minute training is mandatory and students are asked to complete a follow-up survey 45-days after the training. Because this training is mandatory for all incoming students, all students are expected to have exposure to this training."
2516506|NCT02786472|Active Comparator|AlcoholEdu|Online Substance Abuse Training or AlcoholEdu provides confidential substance abuse education course which uses a science-based approach to educate students about alcohol and its effects. Whether the student drinks or not, the course will help them make informed decisions about alcohol and better deal with drinking behavior that may occur around them. AlcoholEdu is used by more than 500 colleges nationwide through EVERFi.
2516516|NCT02786472|Experimental|ConnectEd|In-person Combination Training provides Green Dot Intensive Bystander Training AND Substance Abuse Prevention cross-programming to develop ConnectED. The intentional coordination between substance abuse and violence prevention programming would include in-depth information related to interpersonal violence and substance use/abuse, activities to help participants explore their connection to these issues; information and activities related to the culture of violence, drinking and drug use and how everyone has a role in impacting that culture; information about bystander behaviors and barriers to taking action when they encounter problem situations; participant self-evaluation of their own attitudes, beliefs and biases around these issues; and, in-depth skill building activities to prepare participants to safely intervene in problem situations.
2516521|NCT02786472|Experimental|GreenDot|"In-person Bystander Training provides Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions. While a Popular Opinion Leader strategy has been used in prior training, for this trial all incoming students randomized to this condition will be offered intensive bystander training.~NOTE: Green Dot Speeches will be supplemental to Intensive Green Dot Bystander training. These speeches will continue to occur as usual. As the aim of this study is to compare bystander intensive training, we will not attempt to limit participation to Green Dot Speeches."
2516576|NCT02786069|Experimental|Single arm|
2516868|NCT02784392|Active Comparator|Comparator|Metoclopramide
3198010|NCT00866216|Experimental|1|Azithromycin Monohydrate 600mg Tablets
3198011|NCT00866216|Active Comparator|2|Zithromax (Azithromycin Dihydrate) 600mg Tablets
3198012|NCT00866242|Experimental|Challenge-recipients|
2515930|NCT02790385|Active Comparator|Standard Gauze|standard method of using gauze and dressing will be utilized
2516021|NCT02789748|Experimental|Treatment ON|Kinesthetic stimulation administered during one night
2516026|NCT02789748|No Intervention|Treatment OFF|NO kinesthetic stimulation administered during one night
2516105|NCT02789462||Patients undergoing laser-assisted PCI|Patients of VAMC centers who undergone laser-assisted percutaneous coronary interventions.
2516176|NCT02789007|Other|parabolic flight|To evaluate Structural and functional changes, Cognitive performance, and specifically spatial cognition, Key neurotrophins...
3198013|NCT00866268|Experimental|Low suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter.
2516454|NCT02786992|Active Comparator|Misoprostol + Oxytocin|400 ug sublingual misoprostol + 10 IU Oxytocin IVI
2516457|NCT02786992|Active Comparator|Carbetocin|100 ug Carbetocin IV
2516514|NCT02786563||Participants with RA receiving adalimumab|This group contains participants in China with RA receiving adalimumab
2516573|NCT02786212|Experimental|dexmedetomidine|Patients receiving intraoperative dexmedetomidine infusion. Infusion duration: from 10 minutes after anesthetic induction to the end of surgery.
2516582|NCT02786212|Placebo Comparator|control|control group, receiving same volume of normal saline infusion.
2516651|NCT02785679|No Intervention|Exclusive breast feeding|Exclusive breast feeding
2516653|NCT02785679|No Intervention|Exclusive CMF feeding|Exclusive CMF feeding
2516654|NCT02785679|Active Comparator|Breast feeding with small amount of CMF|Breast feeding with addition (as intervention) of 20 cc of cow's milk formula (CMF) per day
2516656|NCT02785679|Active Comparator|Breast feeding with one meal of CMF|Breast feeding with addition (as intervention) of one meal per day of cow's milk formula (CMF)
2516673|NCT02785250|Experimental|Arm 1|DPX-Survivac, Cyclophosphamide, Epacadostat (Phase 1 and initially Phase 2)
2516676|NCT02785250|Experimental|Arm 2|DPX-Survivac, Cyclophosphamide (in Phase 2 only)
2516739|NCT02784938|Experimental|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
2516741|NCT02784938|No Intervention|Wait-list Control|Services as usual
2516794|NCT02784678|Experimental|closed reduction group|Patients will be assigned to C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws (experimental group).
2516797|NCT02784678|Experimental|open reduction group|Patients will be assigned to open reduction (palmar and dorsal incisions) and internal fixation with titanium plate (control group).
2516974|NCT02783404|No Intervention|Control|Receiving no prophylaxis
2516976|NCT02783404|Active Comparator|Amoxicillin|"Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin"
2516978|NCT02783404|Experimental|Amoxicillin-Potassium Clavulanate|"Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
2517015|NCT02783040|Experimental|single dose cocktail (Midazolam, Warfarin, Omeprazole)|
2517021|NCT02783040|Experimental|single dose Midazolam|
2517029|NCT02783040|Experimental|single dose Digoxin|
2517034|NCT02783040|Experimental|multiple dose BI 425809|
2517062|NCT02782650||Survey and interviews|"* part one * (quantitative)~Survey on:~A) prenatal counseling at the limits of viability, both current and preferred, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling~B) treatment options at the limits of viability against the background of the Dutch guideline~* part two * (qualitative)~Focus groups interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
2517102|NCT02782494||Dialysis group|Patient receiving long term dialysis
2517144|NCT02782247||Short term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who are planning to start antiviral therapy will be enrolled. Patients will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2517145|NCT02782247||Medium term Hepatitis C patients|60 patients with chronic hepatitis C infection and cirrhosis who have been successfully treated in the past 3 or 5 years (+/- 3 months). Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2517146|NCT02782247||Hepatitis B Patients|60 patients with chronic hepatitis B and cirrhosis will be tested within 3 months prior to starting treatment. This will be repeated at 16 weeks (+/- 1 week) and again 1 calendar year after treatment initiation. Patients who have started treatment past 3 or 5 years (+/- 3 months) will also be tested. Patients will have transient elastography and Indocyanine green excretion tests at each appointment.
2517172|NCT02781922|Experimental|Autologous cardiac stem cells (JRM-001)|
2517177|NCT02781922|No Intervention|Usual care|
2517241|NCT02781662|No Intervention|Control|No Intervention; Control Arm: Receives Written Medication Information
2517246|NCT02781662|Experimental|Intervention|Behavioral: Pharmacist Home-Visit
2516006|NCT02789891|Active Comparator|D2 lymphadenectomy excluding No. 14v|Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v lymph node dissection will be performed for the treatment of patients assigned to this group
2516043|NCT02789631||chronic neck pain|experiencing neck pain for at least 3 months in the last year
2516046|NCT02789631||without neck pain (asymptomatic)|no history of neck pain
2516128|NCT02789384|Experimental|Procedure/Surgery|Newly obtained biopsy if applicable and blood samples collection according to the usual medical practices.
2516156|NCT02788786|Experimental|chlorhexidine|0.12% w/v chlorhexidine oral rinse; 15ml, twice-daily, for 12 weeks
2516158|NCT02788786|Experimental|cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride oral rinse; 15ml, twice-daily, for 12 weeks
2516161|NCT02788786|Active Comparator|Salt and Water|Salt and water based oral rinse; 15ml, twice-daily, for 12 weeks
2516164|NCT02788786|No Intervention|No oral rinse|No rinse provided in this group
2516240|NCT02788604|Experimental|Experimental Group|Participants in this arm will have a summary of their family's psychosocial risk factors provided to the treatment team. This will occur twice: once shortly after diagnosis (within 2-4 weeks) and once approximately 6 months following diagnosis.
2516246|NCT02788604|Active Comparator|Control Group|Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
2516287|NCT02787954||Transcatheter Chemoembolization or TACE|A technique called transcatheter chemoembolization (TACE) is used for some patients with liver cancer that cannot be treated surgically. The procedure is a way of delivering cancer treatment directly to a tumor through minimally-invasive means.
2516295|NCT02787954||Yittrium 90 or Y-90|Radioembolization is a minimally invasive procedure that combines embolization and radiation therapy to treat liver cancer. Tiny glass or resin beads filled with the radioactive isotope yttrium Y-90 are placed inside the blood vessels that feed a tumor. This blocks the supply of blood to the cancer cells and delivers a high dose of radiation to the tumor while sparing normal tissue.
2516298|NCT02787954||Microwave Ablation or MWA|Microwave ablation (MWA), destroys liver tumors using heat generated by microwave energy. A CT scan or ultrasonic guidance is used to pinpoint the exact location of the tumor. A thin antenna, which emits microwaves, is then inserted into the tumor. The probe produces intense heat that ablates (destroys) tumor tissue, often within 10 minutes.
2516303|NCT02787954||electroporation|Irreversible electroporation (IRE) is a nonthermal method of destroying the cell. A cell is subjected to a powerful electrical field using high-voltage direct current (up to 3 kV); this creates multiple holes in the cell membrane and irreversibly damages the cell's homeostasis mechanism, leading to instant cell death.
3198014|NCT00866268|Active Comparator|High suction drainage|The standard DRENOFAST® system was used in the control group, and the initial negative pressure was 700 mmHg.
3198015|NCT00866346|Experimental|PR1-CTL|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
2516448|NCT02787005|Experimental|Cohort 1: PD-L1 positive with measurable disease|Participants with programmed cell death ligand 1 (PD-L1)-positive, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2516452|NCT02787005|Experimental|Cohort 2: PD-L1 negative with measurable disease|Participants with PD-L1 negative, measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2516456|NCT02787005|Experimental|Cohort 3: Bone metastases with non-measurable disease|Participants with bone metastases and non-measurable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle for up to 2 years.
2516458|NCT02787005|Experimental|Cohort 4: RECIST 1.1-measureable disease|Participants with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)-measureable disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
2516459|NCT02787005|Experimental|Cohort 5: Bone metastases only or bone-predominant disease|Participants with bone metastases only or bone-predominant disease receive pembrolizumab 200 mg via intravenous infusion on Day 1 of every 3-week cycle and enzalutamide via oral capsules once daily for up to 2 years. The dose of enzalutamide will be the same dose each participant was receiving before the start of pembrolizumab treatment.
3198016|NCT00866398||1 DES|Patients receiving drug-eluting stent
3198017|NCT00866398||2 BMS|Patients receiving bare metal stent
3198018|NCT00866424|Experimental|A,2, II|
3198019|NCT00866437|Experimental|Healthy Control group|
3198020|NCT00866437|Experimental|PMS|
2516639|NCT02785718|Experimental|Patients with FXI or FXII deficiency|12 patients with FXI deficiency and 6 patients with FXII deficiency
3198021|NCT00866450|Active Comparator|Western style diet|high-fat, low-calcium diet
3198022|NCT00866450|Active Comparator|Prudent diet|low-fat, calcium-sufficient diet
3198023|NCT00866463|Active Comparator|Conventional Oral Tablet With Water|
3198024|NCT00866463|Experimental|Experimental Tablet With Water|
3198025|NCT00866463|Experimental|Experimental Tablet Without Water|
3198026|NCT00866476|Experimental|Vaccine-recipients|
3198027|NCT00866476|Placebo Comparator|Placebo|
3198028|NCT00866489|No Intervention|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
3198029|NCT00866489|Experimental|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
3198030|NCT00866502|Experimental|sNN0031|Continuous ICV infusion for two weeks at one of three dose levels
3198031|NCT00866502|Placebo Comparator|Placebo|Continuous ICV infusion
3198032|NCT00866515|Experimental|Active|Ketoconazole 400mg OD days 1-6
3198033|NCT00866515|Placebo Comparator|Placebo|Placebo OD for 1 to 6 days
3198034|NCT00866528|Experimental|Phase I|oral pazopanib once daily (Phase I starting dose 800 mg) and paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
3198035|NCT00866541|Experimental|volunteers|artificial increased respiratory resistance
2516034|NCT02789657|Experimental|Optimal- 18 weeks|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
2516039|NCT02789657|Experimental|Sub-optimal with AC|12 weeks (4 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post 12 weeks, initiation of doxorubicin and cyclophosphamide for 4 cycles (6 weeks), followed by surgery.
2516040|NCT02789657|Experimental|Optimal with AC|Less than 18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab, followed by initiation of doxorubicin and cyclophosphamide. Post treatment, patients will undergo surgery.
2516045|NCT02789657|Experimental|Sub-optimal no AC|18 weeks (6 cycles) of paclitaxel, carboplatin, trastuzumab and pertuzumab. Post treatment, patients will undergo surgery.
2516213|NCT02788708|Experimental|Treatment (lenvatinib, paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and lenvatinib mesylate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2516408|NCT02787239|Experimental|HLX01|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2516411|NCT02787239|Active Comparator|Rituximab|375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
2516462|NCT02786862|Experimental|Ventilation|Measurements were made for conventional and independent at 1:1 proportion ventilation in supine position; then independent ventilation was discontinued and patient was moved to right or left decubitus position due to left or right lung surgery. Then were made measurements for conventional anaesthetic practices and followed independent at 1:1, 2:1, 3:1, 5:1 proportions ventilation routines. Constantly were monitored expired volume, peak respiratory pressure, dynamic compliance separately for each lung. Measurements covered also hemodynamic (MAP, HR) and oxygenation (SpO2). These attributes were documented at each point of the study. Subsequently, the control system was disconnected and performed typical anaesthetic procedures for thoracic surgery with a one-lung ventilation procedure.
3165298|NCT00511420|Placebo Comparator|1|Cocoa and other ingredients (product type 1). This product is a control of type 2.
3165299|NCT00511420|Placebo Comparator|2|Cocoa plus hazelnuts and other ingredients (product type 2). This product is a control of type 3 and 4.
2516620|NCT02785692||Combined Radiation/ Surgery|All patients treated with combined radiotherapy and surgery at Balgrist University Hospital and University Hospital Zurich
2516675|NCT02785419|Experimental|Arm Training with Action Selection|Task-oriented, functional arm training with the addition of action selection cues to practice. All participants receive the same arm training intervention.
2516745|NCT02785094||A|Group of High Education level
2516748|NCT02785094||B|Group of Low/Non Education level
2516752|NCT02785094||C|Group has Accessibility to Social Media
2516754|NCT02785094||D|Group has not Accessibility to Social Media
2516989|NCT02783287|Experimental|Medication text message|Once daily text message reminder.
2516990|NCT02783287|Experimental|Exercise text message|4x daily text message reminder.
2516991|NCT02783287|No Intervention|Usual care, medication adherence|Usual care for medication adherence.
2516992|NCT02783287|No Intervention|Usual care, exercise regimen|Usual care for exercise regimen.
2517002|NCT02782949|Experimental|Arm I (curcumin)|Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.
2517003|NCT02782949|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.
2517131|NCT02782221|Active Comparator|Growth hormone|Subjects are receiving growth hormone
2517140|NCT02782221|Placebo Comparator|Placebo|Subjects are receiving pegvisomant to block the action of growth hormone
2517155|NCT02781987||CP group|Those patients with chronic pancreatitis underwent ERCP for pancreatic stone clearance, pancreatic stent placement, etc..
2517156|NCT02781987||BD group|Those patients with biliary ductal disease, such as choledocholithiasis, underwent ERCP to relieve outflow obstruction of the common bile duct.
2517188|NCT02781857||60 patients with lung cancer|"Group A: 30 patients with squamous cell carcinoma eligible for lung cancer surgery~Group B: 30 patients with any type of lung cancer not eligible to surgery (small-cell carcinoma, squamous cell carcinoma, adenocarcinoma, large-cell carcinoma)."
2517190|NCT02781857||60 controls|60 controls (group C) matched for age, gender, smoking history and lung function testing.
2517297|NCT02781181|Other|CAS with CPD|CAS performed under neuroprotection
2517299|NCT02781181|Active Comparator|CAS without CPD|CAS without neuroprotection
2517423|NCT02780271|Experimental|Arm B|Subjects will receive e-communication alone AND subjects will receive control intervention
3165300|NCT00511420|Active Comparator|3|Cocoa plus hazelnuts and other ingredients (cocoa product type 3).
3165301|NCT00511420|Active Comparator|4|Cocoa, hazelnuts and other ingredients called LMN (cocoa product type 4).
3165302|NCT00511446|Experimental|1|docetaxel, oxaliplatin, capecitabine
3165303|NCT00511459|Experimental|A|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 10 mg/kg IV QW
3165304|NCT00511459|Experimental|D|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + Open Label AMG 386 10 mg/kg IV QW
3165305|NCT00511459|Experimental|B|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 3 mg/kg IV QW
3165306|NCT00511459|Active Comparator|C|Paclitaxel 90 mg/m² IV QW (3 on/1 off) + bevacizumab 10 mg/kg IV Q2W + AMG 386 placebo IV QW
3165307|NCT00511485|Experimental|Etarfolatide + Vintafolide|Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg etarfolatide labeled with 20 to 25 mCi of technetium-99m. Induction phase of treatment: Two 4-week cycles; if stable disease or better at (week 8) computed tomography (CT), participant may proceed into maintenance phase. Maintenance phase of treatment: 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.
3165308|NCT00511498|Placebo Comparator|Placebo Arm|Placebo nightly
3165309|NCT00511498|Active Comparator|Drug|Sildenafil 50mg nightly
3165310|NCT00511524|Experimental|Subjects receiving GW842166|Subjects will receive single oral dose of 400 milligram (mg) un-labeled GW842166X. After 2-5 hours subjects will receive [carbonyl-^11C]GW842166.
2516152|NCT02788851|Active Comparator|Medication only|Stimulant or non-stimulant medication only - Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine. Investigators will be using a product approved for clinical use in Canada), with dose optimized for each participant based on report of efficacy and side effects. Once on an optimal dose of stimulant or non-stimulant medication they will attend 8 weekly education sessions about ADHD.
2516153|NCT02788851|Experimental|Aerobic Exercise only|Participants attend a structured aerobic exercise class, twice a week for 8 weeks.
2516154|NCT02788851|Active Comparator|Combination Group|Participants assigned to this group will be optimally medicated (either stimulant or non-stimulant medication - approved for clinical use in Canada) and will attend a structured aerobic exercise class, twice a week for 8 weeks.
2516216|NCT02788526|Experimental|Adjuvant TACE|Adjuvant TACE were performed 4-6 weeks after surgery
2516219|NCT02788526|Other|Follow-up|Routine follow-up were performed instead of adjuvant TACE
3198036|NCT00866554|Active Comparator|LHRH agonist|Administration of a 3-month treatment with an LHRH agonist (chosen by the treating radiation oncologist) and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
2516409|NCT02787265||spinal cord stimulation|Failed back surgery syndrome patients will receive high density spinal cord stimulation
2516429|NCT02786888||conventional needle|conventional needle used
2516432|NCT02786888||fenestrated needle|fenestrated needle used
2516500|NCT02786485|Experimental|Rivogenlecleucel & Rimiducid|"All subjects will receive 3 courses of rivogenlecleucel (BPX-501 T cells) infusions at 30 day intervals with 2 escalating dose levels (DL). DL1 on Day 0 and DL2 on Days 30 and 60.~Escalating doses of rimiducid (AP1903) (0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after rivogenlecleucel infusion."
2516574|NCT02786199||Hepatocellular carcinoma|patients HCC who are going to receive surgical resection
2516621|NCT02785705|Experimental|cIPV-bOPV-bOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two bivalent types 1 and 3 oral poliovirus vaccine sequentially.
2516626|NCT02785705|Experimental|cIPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with trivalent conventional inactivated poliovirus vaccine, and two trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
2516630|NCT02785705|Experimental|cIPV-cIPV-bOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one bivalent types 1 and 3 oral poliovirus vaccine sequentially.
2516636|NCT02785705|Experimental|cIPV-cIPV-tOPV poliovirus vaccine|Participants would be vaccine with two shots of trivalent conventional inactivated poliovirus vaccine, and one trivalent types 1, 2 and 3 oral poliovirus vaccine sequentially.
2516643|NCT02785705|Experimental|cIPV-cIPV-cIPV poliovirus vaccine|Participants would be vaccine with three shots of trivalent conventional inactivated poliovirus vaccine.
2516649|NCT02785705|Experimental|tOPV-tOPV-tOPV poliovirus vaccine|Participants would be vaccine with three times of trivalent types 1, 2 and 3 oral poliovirus vaccine .
2516693|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in first lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
2516701|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in first lesion|Patients with Ultimaster® Drug-eluting stent in first lesion
2516707|NCT02785237|Active Comparator|Coroflex® ISAR Drug-eluting stent in second lesion|Patients with with Ultimaster® Drug-eluting stent in first lesion
2516709|NCT02785237|Active Comparator|Ultimaster® Drug-eluting stent in second lesion|Patients with Coroflex® ISAR Drug-eluting stent in the first lesion
2516757|NCT02784873|No Intervention|Usual care|"Usual care cardiac rehabilitation with exercise training as per current guidelines~Warm up: 15 mins, < 40% heart rate reserve (HRR) Cardiovascular component: progress towards 20 - 40 mins continuous cardiovascular exercise at 40-70% HRR.~Muscular strength and endurance programme. Cool down: 10 mins, < 40% HRR. Initial duration based on participant's previous and current physical activity (PA) levels and cardiopulmonary exercise test (CPEX) performance.~Duration and workload of cardiovascular component adjusted, as tolerated, within the above parameters, in response to exercising heart rate (HR), participant reported rating of perceived exertion (RPE) and symptoms."
2516762|NCT02784873|Experimental|High intensity interval training|"High intensity interval training within a standard cardiac rehabilitation programme.~Warm up: 15 mins total, 10 mins <40-70% HRR, 5 mins <70% HRR. Cardiovascular component: exercise bike interval training: 10 x high @ 85-90% peak power output (PPO) from CPEX, 10 x low @ 20-25% PPO (exercise intensity will not to be prescribed from gas exchange data i.e. %VO2 peak). Change in intensity from low to high achieved by altering cadence (rpm).~Muscular strength and endurance programme. Cool down: 10 mins, <40% HRR. Duration of intervals and total programme duration increased in a standardised fashion.~Workload increased bi-weekly in response to participant reported RPE (only after the full 10 x 1 protocol has been achieved). If RPE < 17 then workload will be increased."
2516785|NCT02784652|Experimental|RT & Zoledronic acid|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions, Zoleronic acid: every 4 weeks, 6 times, 4.0 mg iv
2516821|NCT02784353|Active Comparator|Conventional|No intervention; conventional perioperative management without perioperative rehabilitation program
2516822|NCT02784353|Experimental|Intervention - PReHeBP|conventional perioperative management with preoperative and postoperative rehabilitation program
2516864|NCT02784041|Experimental|single adductor-canal-block|Patients in this group will receive ultrasound guided single adductor-canal- block with 0.35% ropivacaine 25ml.
2516870|NCT02784041|Experimental|periarticular infiltration|patients in this group will receive periarticular infiltration of local anesthetic.
3198037|NCT00866554|Experimental|Dutasteride, Bicalutamide, Tamoxifen|"Administration of Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
3198038|NCT00866567||1|Premature infants of less than 28 weeks of gestational age
2516983|NCT02783313|Experimental|PR-plasma-PCs|Pooled buffy coat-derived pathogen reduced plasma-stored platelet concentrates (PR-plasma-PCs)
2516985|NCT02783313|Active Comparator|Plasma-PCs|Pooled buffy coat-derived plasma-stored platelet concentrates (plasma-PCs)
2516159|NCT02788981|Experimental|Nab-Paclitaxel+Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
2516163|NCT02788981|Placebo Comparator|Nab-Paclitaxel+Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle)
2516229|NCT02788422|Experimental|Video|Video discharge instructions developed using Easy Sketch Pro3TM software (Easy Sketch Pro, United Kingdom). It was created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
2516231|NCT02788422|Active Comparator|Standard of care|This is a one-page paper handout created by the primary and co-investigator based results on a focus group consisting of two paediatric residents, two paediatric emergency medicine fellows, a paediatric emergency medicine nurse, and a paediatric emergency medicine staff physician.
3165311|NCT00511563|Experimental|GW876008 and GSK561679|GW876008 and GSK561679
3165312|NCT00511576|Active Comparator|Part 1|In Part 1, cohorts of three to six subjects will receive doses of MGCD0103 administered orally three times per week (TIW) in combination with 60 mg/m2 IV docetaxel administered as a 1-hour infusion on Day 1 of each 3-week (21-day) cycle. The starting dose of MGCD0103 in Part 1 will be 50 mg (approximately 25 mg/m2).
3165313|NCT00511576|Active Comparator|Part 2|Part 2 will begin once the MTD for MGCD0103 in combination with 60 mg/m2 IV docetaxel has been determined and further evaluated in the expansion phase. In Part 2, cohorts of three to six subjects will receive escalating doses of MGCD0103 administered orally TIW in combination with 75 mg/m2 docetaxel administered as a 1-hour IV infusion on Day 1 of each cycle. The starting dose of MGCD0103 administered in combination with 75 mg/m2 IV docetaxel will be the MTD from Part 1 minus 25 mg.
3165314|NCT00511602|Experimental|Technosphere Insulin Inhalation Powder|
2516729|NCT02785120|Experimental|High dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2516732|NCT02785120|Experimental|Middle dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2516733|NCT02785120|Experimental|Low dose|75 patients will be randomized to active or placebo treatment in a 2:1 ratio (TF0023 [50 patients] and placebo [25 patients]). Each patient enrolled in Group A will receive study treatment in a double-blind manner for 16 weeks starting between 3 and 60 days after the onset of stroke symptoms (Day 1 of the study).
2516796|NCT02784665|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
2516801|NCT02784665|Active Comparator|577-TL|"577nm Traditional laser(577-TL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area."
2516843|NCT02784223|Experimental|PET-CT with F18-choline|PET-CT with F18-choline examination will be performed before surgery
3165315|NCT00511602|Placebo Comparator|Technosphere Inhalation Powder|
3165316|NCT00511615||1|Patients with cervical cancer scheduled to be treated with the LEEP procedure.
2516941|NCT02783352|Experimental|treatment group|arthroscopic rotator cuff repair + injection of autologous micro-fragmented adipose tissue (10 mL)
2516943|NCT02783352|Other|control group|arthroscopic rotator cuff repair only
2517012|NCT02783235|Other|cervical cancer|cervical cancer screening and training for ANMs/ASHAs/PHWs To develop video-based tutorials to train ANMs/ASHAs/PHWs in conducting cervical cancer related health education, screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
2517058|NCT02782793||Patient's with complex colon polyps|
2517136|NCT02782533|Experimental|DBS V3|Deep Brain Stimulation V3
2517184|NCT02782130|Active Comparator|Intervention Group|Subjects randomized to the Epic Allies Intervention will download and install the intervention branch of the Epic Allies app and receive a tour of the app guided by site staff. During the 26-week intervention phase, intervention arm subjects will receive daily adherence reminders set up through Epic Allies with tailored feedback for encouragement and reinforcement. Intervention arm subjects will have 24-hour access to all features of Epic Allies and will receive supportive messages from other subjects on the intervention arm.
2517186|NCT02782130|Placebo Comparator|Control Group|Subjects randomized to the control arm will download and install the control branch of the Epic Allies app (phone-based notifications only) and be provided with instructions on using the app. During the 26-week intervention phase, the control arm subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
2517234|NCT02781493|Experimental|Prucalopride group|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
2517235|NCT02781493|Placebo Comparator|Placebo group|2 mg Placebo plus 2 L Polyethylene Glycol regimen
3165317|NCT00511628||001|Risperidone As prescribed
3165318|NCT00511641||Low Risk OVCA|Patient that is participating in an ovarian cancer (OVCA) screening program.
3165319|NCT00511654|Experimental|Subjects in Group 1 receiving GW823296|Subjects will receive single dose of GW823296 on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered GW823296 for 28 days in the repeat dosing period.
3165320|NCT00511654|Placebo Comparator|Subjects in Group 1 receiving placebo|Subjects will receive single dose of placebo on Day 1 followed by a wash-out period of 1 week. The subjects will then be administered placebo for 28 days in the repeat dosing period.
3165321|NCT00511654|Experimental|Subjects in Group 2 and 3 receiving GW823296|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered GW823296 on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of GW823296 for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
3173793|NCT00616005|Other|1|Pts taking EIAEDs
3173794|NCT00616005|Other|2|Pts not taking EIAEDs
3198039|NCT00866567||2|Premature infants of more than 28 weeks and less than 32 weeks of gestational age
3198040|NCT00866567||3|Term newborns
3198041|NCT00866567||4|Adults
3198042|NCT00866580|Experimental|Group A|
2516463|NCT02786849|Experimental|Group of high frequency and intensity|Group realized high frequency and intensity neuromuscular electrical stimulation
2516465|NCT02786849|Experimental|Group of low frequency and intensity|Group realized neuromuscular electrical stimulation of low frequency and intensity
2516523|NCT02786589|Experimental|Blood-stage infection of P. vivax|This is a single arm study that enrolls 30 patients to receive Plasmodium immunotherapy.
2516553|NCT02786186||Secikinumab|Patients treated with secukinumab
2516555|NCT02786186||Approved standard of care|Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy)
2516622|NCT02785575|Active Comparator|HeProCalc|This arm receives heparin and protamine doses according to the novel HeProCalc calculation model.
2516632|NCT02785575|No Intervention|Traditional calculations|This arm receives heparin and protamine doses according to the standard protocol (using calculations with body weight and ACT)
3198043|NCT00866580|Experimental|Group B|
3198044|NCT00866593|Experimental|1|Generic Escitalopram Oxalate Tablets
3198045|NCT00866593|Active Comparator|2|Innovator Escitalopram(Lexapro®)
3198046|NCT00866632|Experimental|Group Cognitive Behavioural Therapy|
3198047|NCT00866632|Experimental|Telephone Cognitive Behavioural Therapy|
3198048|NCT00866632|No Intervention|Group Education|
2516947|NCT02783378|Other|Gaviscon syrup|"Gaviscon will be given to threat patients with reflux after first 24 hours of oesophagal pH-monitoring.~This is a syrup and will be given after every meal. dosage depends from age between 1ml and 5ml after every meal"
2517027|NCT02783248||Mitral Stenosis|"No specific protocol intervention occurs. All the cares are made as done usually.~Patients who may be included are all consecutive patients who agreed to participate in the study and having a PMC in a French medical-surgical centers that perform more than 5 year PMC.~All patients undergoing echocardiography with the realization of the score Wilkins and Cormier.~Will then be included to validate the result of late score that patients who had a good immediate result of the PMC defined by: mitral valve area ≥ 1.5 cm² and IM ≤ 2/4. Patients with a poor immediate result of the PMC will not be monitored as part of the study but their data will be collected for the description of the population and analysis of immediate results.~Patients in the study will receive an annual monitoring as recommended, independently of the study."
2517117|NCT02782481|Experimental|ND0612 High dose (Levodopa/Carbidopa solution)|High dose ND0612 SC infusion over 24 h
2517123|NCT02782481|Experimental|ND0612 Low dose (Levodopa/Carbidopa solution)|Low dose ND0612 SC infusion over 24 h
2517133|NCT02782481|Placebo Comparator|Placebo|Placebo SC infusion over 24 h
2517157|NCT02782000|Experimental|Long-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 6 months.
2517158|NCT02782000|Active Comparator|Short-term supervision group|Firstly, this group will having lessons about dementia early recognition. Second, this group will receive face-to-face supervision and key messages by Wechat about dementia early recognition once a month in the following 3 months.
2517239|NCT02781779|Active Comparator|Silverlon®|Subjects randomized to this arm will receive Silverlon® dressing postoperative.
2517247|NCT02781779|Active Comparator|AQUACEL® AG|Subjects randomized to this arm will receive AQUACEL® AG dressing postoperative.
2517263|NCT02781233|Experimental|Training group|Each subject will participate in 2 sessions each week during 8 weeks, with 3 days of difference (rest) between the sessions.
2517264|NCT02781233|Placebo Comparator|Control group|Usual daily activities
2517313|NCT02780804|Experimental|Treatment (entinostat)|Patients receive entinostat PO on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
2517416|NCT02780401|Experimental|Treatment (WOKVAC with sargramostim)|"Patients receive WOKVAC with sargramostim ID on day 1. Courses repeat every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients with ALND will have vaccine administered to the contralateral arm. Patients with bilateral ALND will have vaccine administered in the thigh. As much as possible each vaccine dose will be given within the same draining lymph node site. Patients will be monitored for a minimum of 60 minutes post vaccine administration."
2517477|NCT02780050|No Intervention|chest compression before physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). Researchers record subject's chest compression depth and rate in 1st chest compression."
2517504|NCT02779751|Experimental|NSCLC Squamous|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
3198049|NCT00866632|No Intervention|Telephone Education|
3198050|NCT00866645|Experimental|1|Intramuscular Levosulpiride
3198051|NCT00866645|Active Comparator|2|Intramuscular Haloperidol
3198052|NCT00866671||Nelarabine|nelarabine 650mg/m2 IV daily for 5 days. repeat every 21 days.
3198053|NCT00866684|Experimental|1|Patients will receive Sirolimus in addition to their previous immunosuppressive therapy.
3198054|NCT00866684|Active Comparator|2|Patients will stay on their previous immunosuppressive regimen.
3198055|NCT00866736|Experimental|dasatinib|
3198056|NCT00866762|Experimental|1|Treatment with study drug approximately 6 months and follow-up for 3 months
3198057|NCT00866801||Healthy|Healthy subjects scheduled for general anesthesia
3198058|NCT00866801||Healthy with thoracic epidural anelgesia|Healthy subjects scheduled for general anesthesia and thoracic epidural analgesia
2516380|NCT02787421|Experimental|Functional Rhinoplasty|Participants undergoing functional rhinoplasty for nasal valve compromise and obstruction at the Emory Aesthetics Center.
2516437|NCT02787148|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy for Major Depression
2516439|NCT02787148|No Intervention|Waitlist group|Waitlist group to control for repeated physiological measures and fluctuations over time
2516497|NCT02786693||FUO and SII patients|Patients with fever > 38,3°C for more than a week, OR CRP> 5mg/L, without diagnosis after a first step clinical examination and paraclinical exams.
2516561|NCT02786303|Other|arm whole-body MRI|
2516564|NCT02785874|Experimental|Statin(Crestor) taken|Subjects take Statin(Crestor) 10mg per day for a- year
2516569|NCT02785874|No Intervention|non Statin(Crestor) taken|non Statin(Crestor) taken as a reference for experimental group.
2516698|NCT02785133|Experimental|Treatment group|Polychromatic light emitting diode system is a non-significant risk device that administers low-dose light generated by a light emitting diode. Small adapter attaches directly to a standard 20-gauge catheter that threads a small fiber optic through the distal end of the catheter. The optic terminates at the distal end of the catheter. Polychromatic light is emitted to illuminate the catheter and site of catheter entrance. Concurrently, normal saline flows through the optic adapter and through into the 20-gauge catheter.
2516747|NCT02784977||Obstructive Sleep Apnea (OSA)|Patients with apnea hypopnea index of at least 5 events per hour. Intervention with positive airway pressure, or intraoral device, or uvuloplasty, or conservative treatment.
2516750|NCT02784977||No-OSA|Patients with apnea hypopnea index less than 5 events per hour. No intervention.
3198059|NCT00866801||Diabetes|Subjects with diabetes scheduled for general anesthesia
3165322|NCT00511654|Placebo Comparator|Subjects in Group 2 and 3 receiving placebo|Subjects will receive single dose of midazolam on Day 1 followed by wash-out period of one day. Further the subjects will be administered placebo on Day 3 of single dose period followed by a wash-out period of 1 week. The subjects will then be administered a single dose of placebo for 28 days (Day 1 to Day 28 of repeat dosing period) and a single dose of midazolam on Day 29 of repeat dosing period.
2516900|NCT02783807|Experimental|Eyenez Retinal Camera v200|Retinal images from Eyenez Retinal Camera v200 of healthy and diseased subjects
2516905|NCT02783807|Active Comparator|Volk Pictor Ret 1|Retinal images from Volk Pictor Ret 1 of healthy and diseased subjects
2516961|NCT02783547|Experimental|SyB C-1101 and Azacytidine|
2517025|NCT02783196|Experimental|Liraglutide (LIR)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with Liraglutide ( IR) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with placebo (PLA)
2517033|NCT02783196|Placebo Comparator|Placebo (PLA)|Type 2 diabetic randomized to start with two 40 days treatment periods starting with placebo ( PLA) treatment, and then after 2 weeks of wash-out, will crossover to second treatment period of 40 days with Liraglutide ( LIR)
2517180|NCT02781909|Active Comparator|Control: Standard of Care TB treatment|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines; n=12
2517182|NCT02781909|Experimental|Ibuprofen-treated|Individuals with confirmed pulmonary XDR-TB and receiving Standard of Care TB treatment according to national and WHO guidelines plus ibuprofen (400mg/day/2 months); n=12
2517319|NCT02780791|Active Comparator|Transplantation into pelvic wall|Ovarian transplantation into the pelvic wall after cryopreservation of ovarian tissue before cytotoxic therapies
2517325|NCT02780791|Active Comparator|Transplantation into the ovary|Ovarian transplantation into ovary after cryopreservation of ovarian tissue before cytotoxic therapies
2517419|NCT02780336||Blepharospasm (BL)|Participants in this group should be diagnosed with blepharospasm, but may have dystonia in other body parts as well.
2517420|NCT02780336||Disease Control Group|Participants in this group should be diagnosed with a disorder affecting their eyes or face, such as hemifacial spasm, facial tics, or apraxia.
2517421|NCT02780336||Normal Control Group|Participants in this group should not have any neurologic problems or other disorders affecting patients eyes or face.
2517497|NCT02779998|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute in order to maintain peripheral oxygen saturation (SpO2) above 94% during electrophysiology procedure under light sedation.
2517515|NCT02779881||Children at diagnosis of cow's milk allergy|Children at diagnosis of cow's milk allergy
2517738|NCT02778477|Experimental|Part A_Cohort 1_Active|Multiple ascending dose of PF-06423264
3165323|NCT00511680|Experimental|Behavioral based In-home Intervention|This group will recieve up to 10 1-hour sessions over a 4 month period.
3165324|NCT00511693|Experimental|1|hospitals randomly allocated to receive physician and patient osteoporosis recommendations from the regional coordinator
3165325|NCT00511693|Active Comparator|2|hospitals randomly allocated to receive falls prevention advice
3165326|NCT00511719|Experimental|Technosphere Insulin|Technosphere Insulin Inhalation Powder
3165327|NCT00511719|Active Comparator|Actrapid|Subcutaneous regular human insulin
3165328|NCT00511732|Experimental|Technosphere Insulin|
3165329|NCT00511732|Placebo Comparator|Technosphere Inhalation Powder|
3165330|NCT00511745||001|
3165331|NCT00511758||Digital Imaging Device|Patients with a diagnosis of cervical dysplasia that are scheduled for a colposcopy.
3165332|NCT00511784||OrthoEvra(norelgestromin/ethinylestradiol contraceptive patch)|subjects in insurance claims database who used transdermal patch containing 6 milligrams norelgestromin and 0.75 milligram ethinyl estradiol worn for 1 week for 3 consecutive weeks; the fourth week was patch-free
2516398|NCT02787330|Experimental|Experimental Group|Behavioural: Participants in this arm will experience an 8-week manualized intervention program which focuses on education, therapeutic problem solving, and social support. Each intervention session is structured by theme relevant to the cancer experience and themes are addressed through fun activities, games, arts, and crafts.To maximize the therapeutic effect of the intervention fun work (homework) will be assigned after each session. Training for the EG facilitators requires reading and studying the manual to become fully familiarized with the intervention approaches, observing group sessions through a one-way mirror prior to participation as a group facilitator, and participating as a group facilitator assistant for the intervention program.
2516426|NCT02786979|Experimental|Beraprost sodium tablet and Aspirin combination group|Oral
2516427|NCT02786979|Experimental|Aspirin Group|Oral
3198060|NCT00866801||Diabetes with autonomic neuropathy|Subjects with diabetes and cardiovascular autonomic neuropathy scheduled for general anesthesia
3198061|NCT00866840|Experimental|Riluzole|100 mg orally twice daily
2516512|NCT02786407|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose,dextran and gelatin.
2516520|NCT02786407|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but include sucrose,dextran and gelatin.
2516566|NCT02786160|Active Comparator|HMO1|Daily bolus of HMO1
2516567|NCT02786160|Active Comparator|HMO2|Daily bolus of HMO2
2516570|NCT02786160|Placebo Comparator|Dextropur|Daily bolus of Dextropur
2516615|NCT02785744||Patients receiving DEXA Scan|Gaucher patients referred for dual energy X-ray absorptiometry (DEXA scan), who were found to have T-score <-1.0.
2516668|NCT02785484|Experimental|Label with constituent disclosure message|
2516670|NCT02785484|Other|Label with litter message|
3198062|NCT00866866|Experimental|N-Acetyl Cysteine|
3198063|NCT00866866|Placebo Comparator|Placebo|
3198064|NCT00866892|Active Comparator|irrigation|
3198065|NCT00866892|Experimental|no irrigation|
2516779|NCT02784808||Biologic DMARDs|Participants who received biologic DMARDs as per standard of care were included in this arm.
2516781|NCT02784808||Non-biological DMARDs|Participants who received non-biologic DMARDs as per standard of care were included in this arm.
2516881|NCT02784015|Experimental|Unresectable localized soft tissue sarcoma|"Six cycles of chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen.~Surgery, if possible~Concurrent chemoradiotherapy according to the treatment response (necrosis rate, tumor volume reduction, and residual FDG uptake in PET scan)~Tandem high dose chemotherapy (HDCT) and autologous stem cell transplantation, if there are still residual tumors after 9 cycle of chemotherapy, surgery, and radiotherapy.~1st HDCT: carboplatin, thiotepa, etoposide~2nd HDCT: cyclophosphamide, melphalan"
3198066|NCT00866944|Experimental|1|Adecatumumab alone
3198067|NCT00866944|Experimental|2|FOLFOX 4 followed by Adecatumumab
3198068|NCT00866944|Active Comparator|3|FOLFOX 4 alone
3198069|NCT00866957||Patients with liver cancer|Patients diagnosed with liver cancer
2517253|NCT02781467|Experimental|Cyclophosphamide + Fludarabine + PNK-007 + rhIL-2|Fludarabine Day -6 to -2 and Cyclophosphamide Day -5 and -4. On Day 0 PNK-007 at 4 varying dose levels followed by Human recombinant Interleukin-2 (rhIL-2) every other day, Day 0 to Day 10.
3198070|NCT00866970|Experimental|1|ALD518
2517359|NCT02780739|Experimental|Cognitive Training - 48 sessions|56 hours of video game training with Mind Frontiers adaptive cognitive training software (48 70-min sessions distributed over 16 weeks)
2517361|NCT02780739|Experimental|Fitness, Cognitive Training, sham tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers adaptive cognitive training software with simultaneous sham tDCS (20 70-min sessions distributed over weeks 5-16)
2517362|NCT02780739|Experimental|Fitness, Cognitive Training, active tDCS|32 hours and 40 min of high-intensity cardiorespiratory fitness training (28 70-min sessions distributed over 16 weeks); 23 hours and 20 min of video game training with Mind Frontiers 1.0 adaptive cognitive training software with simultaneous active tDCS for a total of 10 hrs (20 70-min sessions distributed over weeks 5-16)
2517363|NCT02780739|Active Comparator|Active Control|56 hours of video game training with visual search and change detection tasks using open sesame software (48 70-min sessions distributed over 16 weeks)
2517364|NCT02780739|No Intervention|No Contact Control|Completed no study activities for 16 weeks after pre-assessment, then returned for post-assessment
2517476|NCT02780258|Experimental|Restylane Silk Treated Hand|The dorsal aspect of one hand will be injected with Restylane Silk.
2517584|NCT02779296|No Intervention|No Glue|No cyanoacrylate glue will be applied.
3198071|NCT00866970|Experimental|2|ALD518
3198072|NCT00866970|Experimental|3|ALD518
3198073|NCT00866970|Placebo Comparator|4|No ALD518
3198074|NCT00867022||1|Women with gestational diabetes
3198075|NCT00867022||2|Pregnant women without gestational daibetes
3198076|NCT00867022||3|Women with gestational diabetes and hypertension
3198077|NCT00867022||4|Non pregnant women
3198078|NCT00867048|Experimental|Early ART|Initiate ART immediately following randomization
3198079|NCT00867048|Active Comparator|Deferred ART|Defer ART until the CD4+ count declines to <350 cells/cu mm or AIDS develops
3198080|NCT00867152|Experimental|Cohort 2|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/DRV/RTV 200/600/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
2516434|NCT02787226|Active Comparator|Reverse TSA - Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension for postoperative analgesia after reverse total shoulder arthroplasty (TSA).
2516435|NCT02787226|Active Comparator|TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after TSA.
2516436|NCT02787226|Active Comparator|Reverse TSA - Continuous Perineural Ropivacaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine for postoperative analgesia after reverse TSA.
2516510|NCT02786667|Experimental|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
2516519|NCT02786667|Placebo Comparator|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
2516589|NCT02786147||Patient Initiated|Patients randomized into this group will receive a standard handout explaining their result, which includes information on how to obtain cancer genetics services through Winship. However, neither the patient nor their ordering clinician will be directly contacted regarding the B-RST result.
2516593|NCT02786147||Physician Notification|Patients randomized into this group will also receive the standard handout explaining their result. In addition, their primary care physician or ordering physician will be notified via Emory Electronic Medical Record (EeMR) that the patient screened positive on the B-RST. The note will provide specific instructions on how to refer the patient for cancer genetic counseling services.
2516596|NCT02786147||Automatic Follow-Up By Genetic Counseling Staff|Patients randomized into this group will also receive the standard handout explaining their result. Within 1-2 weeks after their mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment. This call may take up to 10 - 15 minutes.
2516642|NCT02785562|Other|Assessment of PDL1 expression|Other : assess clinical and pathological characteristics of PDL1 expression in Non Small Cell Lung Cancer patients.
2516742|NCT02784951||Single group|Patients in haemorrhagic shock needing volume replacement and receiving prehospital transfusion of blood products, either red blood cells (RBC), freeze dried plasma (FDP) or whole blood (WB).
3198081|NCT00867152|Experimental|Cohort 1|All subjects will receive GSK1349572 50mg q24h (Treatment A) from Day 1 to Day 5 in Period 1. There will be no washout between treatment Periods 1 and 2. Subjects will receive GSK1349572 50mg q24h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14 in Period 2. Day 1 of Period 3 will be approximately 3 weeks after the last dose in Period 2. Subjects will receive GSK1349572 50mg q12h and ETV/LPV/RTV 200/400/100mg q12h from Day 1 to Day 14. Period 3 will not be performed if there is no significant interaction in Period 2.
3198082|NCT00867178|Experimental|Treatment (vorinostat, isotretinoin, chemotherapy)|See Detailed Description
2516918|NCT02783677||DM with PAD before angioplasty|Diabetic patients diagnosed with peripheral artery disease via vascular Duplex.
2516921|NCT02783677||DM without PAD|Diabetic patients diagnosed without peripheral artery disease via vascular Duplex.
2516922|NCT02783677||Healthy volunteers|Healthy volunteers
2516923|NCT02783677||DM with PAD after angioplasty|Diabetic patients diagnosed with PAD underwent balloon-angioplasty
2516962|NCT02783430|Experimental|Milnacipran + Ketamine|Ketamine 0,5mg/kg single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
2516969|NCT02783430|Active Comparator|Milnacipran + Placebo|Placebo single intravenous perfusion during 40 minutes. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
2516997|NCT02782988||CMV symptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
2516998|NCT02782988||CMV asymptomatic at birth|olfactory tests, otoacoustic emissions (OAE)
2516999|NCT02782988||Healthy controls|olfactory tests, otoacoustic emissions (OAE)
2517068|NCT02782897|Experimental|IVIg group|Participants will receive immunoglobulin therapy plus standard management. The first intravenous infusion of immunoglobulin must be given within 72 hours after the onset.
2517074|NCT02782897|Other|Control group|Participants will receive standard management according to Chinese guidelines for intracerebral Hemorrhage.
3198083|NCT00867191|Placebo Comparator|1|Placebo, 1 tablet daily, per os
3198084|NCT00867191|Active Comparator|2|Desloratadine, one 5 mg tablet daily, per os
2517167|NCT02781870|Other|No-fixation|These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible without fixation.
2517174|NCT02781870|Experimental|LiquiBand Fix glue fixation|"These patients will be randomized during the operation, at the time of mesh placement to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.~Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation."
2517238|NCT02781675|Experimental|Western Diet|Dietary Intervention: 3 wks of a typical Western Diet
2517243|NCT02781675|Experimental|Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet
2517249|NCT02781675|Experimental|Modified Mediterranean Diet|Dietary Intervention: 3 wks of a Mediterranean-style diet including full fat dairy products
2517282|NCT02781259|Experimental|Selective Lymph Node Dissection|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery. Routine axillary lymph node dissection is performed. Acquired lymph nodes are separated to fluorescent positive lymph nodes and fluorescent negative lymph nodes with imaging devices.
2517328|NCT02780921|Experimental|Prehab Group|In the experimental group (Prehab group) compared to the control group, the main objective will be to demonstrate an improvement of the percentage of patients reaching the complete oncological treatment fixed in a multidisciplinary tumour board
2517426|NCT02780271|Experimental|Arm C|Subjects will receive in-person education alone AND subjects will receive control intervention
2516477|NCT02786797|No Intervention|Usual Care|Participants who are randomized to the Usual Care (UC) or control group will continue to receive standard post-treatment medical and nursing clinic visits that will not be modified by study participation. The UC participants will participate in their standard care appointments and will not be required to alter their UC regimen; however, they will be asked not to initiate a mindfulness program during the study period. The UC group will be offered the MBSR(BC) program within 4 to 6 months after study completion.
2516507|NCT02786511||Subjects with multiple myeloma|Subjects treated with ex vivo gene therapy in a bluebird bio sponsored trial who agree to participate in this study.
2516579|NCT02786108|Experimental|left gastric artery embolization|Patients undergoing left gastric artery embolization
2516592|NCT02786108|Active Comparator|healthy diet and exercise|Patients undergoing healthy diet and exercise
2516644|NCT02785653|Experimental|sevoflurane and rocuronium|After induction of general anaesthesia, patients in the sevoflurane group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen with 2% inspired concentration of sevoflurane. After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
2516648|NCT02785653|Active Comparator|rocuronium|After induction of general anaesthesia, patients in the control group were ventilated with fresh gas flow of 5 lites per minute consisting of 66.6% nitrous oxide and 33.3% oxygen . After stabilization of end tidal carbondioxide to 30-35 mmHg ,intravenous rocuronium 0.6mg per Kg body weight was injected
2516689|NCT02785276|Experimental|Ropivacaine infusion|Following the insertion of the 2mm fenestrated catheter, the wound catheter will be connected to the 270mL AutoFuser Pain Pump. The intraperitoneal infusion with ropivacaine (0.2%) at 4 mL/hour will start immediately and continue for 68 hours post-operatively uninterrupted.
2516704|NCT02785276|Placebo Comparator|Placebo infusion|In the same manner as described for the ropivacaine infusion arm, 0.9% Normal Saline will be administered over 68 hours.
2516735|NCT02784899|Experimental|iloprost group|iloprost inhalation group
2516737|NCT02784899|Placebo Comparator|control group|normal saline inhalation group
2516795|NCT02784730|Experimental|Iterative PICC placement|New PICC placement at each chemotherapy cycle (removed after treatment administration)
2516799|NCT02784730|Active Comparator|Long term implantable device|Port-a-cath inserted prio first chemotherapy cycle and maintained throughout the study
3198085|NCT00867204||Short-wire device|The Fusion Short-wire ERCP device was used
3198086|NCT00867204||Long-wire device|The traditional Long-wire ERCP device was used
3198087|NCT00867230|Experimental|FTS (S-trans, trans-farnesylthiosalicylic acid)|
2516916|NCT02783742|Experimental|Intervention|Providers in this arm will receive a communication coaching intervention immediately post-randomization.
2516920|NCT02783742|Other|Waitlist Control|Providers assigned to this arm will be offered the option of receiving the communication coaching intervention after follow up data collection is complete.
2516956|NCT02783417|Experimental|Training with vascular occlusion|Strength Training: intensity of 30% of 1RM, with vascular occlusion pressure in members.
2516964|NCT02783417|Experimental|Traditional strength training|Strength Training: intensity of 80% of 1RM, without vascular occlusion pressure in members
2516968|NCT02783417|No Intervention|Control|Subject untrained.
3198088|NCT00867243||Group 1: HCV Positive|50 patients whom are HCV positive
3198089|NCT00867243||Group 2: HCV Negative|50 patients whom are HCV negative.
2517116|NCT02782403|Experimental|Treatment (alternating therapy)|Patients with chronic phase CML receive either bosutinib PO QD or axitinib PO BID alone for 3 months. Patients then switch to the other drug for 3 months and alternate between the two every 3 months in the absence of disease progression or unacceptable toxicity.
2517120|NCT02782403|Experimental|Treatment (combined therapy)|Patients with accelerated or blastic phase CML receive bosutinib PO QD and axitinib PO BID for 3 months. Courses repeat every 3 months in the absence of disease progression or unacceptable toxicity.
3198090|NCT00867256|Experimental|Large Diameter Metal on Metal|
3198091|NCT00867282|Experimental|Treatment A|
2517333|NCT02780934|Active Comparator|Pressure Dressing|Participants randomized to this group will receive the standard post-operative dressing following their Mohs procedure: a pressure dressing consisting of high absorbency gauze and retention tape.
2517342|NCT02780934|Experimental|Simple Adhesive Dressing|Participants randomized to this group will receive the experimental post-operative dressing following their Mohs procedure: a simple adhesive dressing consisting of a non-adherent pad and transparent dressing.
2517384|NCT02780596|Experimental|Items1;3|Caregiver is randomly assigned to receive screening items 1 and 3. Item 1: Does CHILD NAME often wake one or more times during the night? Item 3: Do you think CHILD NAME's sleep is a problem?
2517387|NCT02780596|Experimental|Items1;4|Caregiver is randomly assigned to receive screening items 1 and 4. Item 1: Does CHILD NAME often wake one or more times during the night? Item 4: Does you think CHILD NAME has a sleep problem?
2517388|NCT02780596|Experimental|Items1;5|Caregiver is randomly assigned to receive screening items 1 and 5. Item 1: Does CHILD NAME often wake one or more times during the night? Item 5: Do you have any concerns about CHILD NAME's sleep?
2517389|NCT02780596|Experimental|Items2;3|Caregiver is randomly assigned to receive screening items 2 and 3. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 3: Do you think CHILD NAME's sleep is a problem?
2517390|NCT02780596|Experimental|Items2;4|Caregiver is randomly assigned to receive screening items 2 and 4. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 4: Does you think CHILD NAME has a sleep problem?
2517391|NCT02780596|Experimental|Items2;5|Caregiver is randomly assigned to receive screening items 2 and 5. Item 2: Does CHILD NAME often wake one or more times per night and does an adult go to him/her? Item 5: Do you have any concerns about CHILD NAME's sleep?
2517392|NCT02780596|Experimental|Items3;5|Caregiver is randomly assigned to receive screening items 3 and 5. Item 3: Do you think CHILD NAME's sleep is a problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
2517430|NCT02780271|Active Comparator|Arm D|Subjects will receive control intervention
2517511|NCT02779881||Healthy controls|Healthy controls
3198092|NCT00867282|Active Comparator|Treatment B|
3198093|NCT00867295|Placebo Comparator|placebo|no antibiotic is used
3198094|NCT00867295|Active Comparator|drug|cefazolin Sodium 1g i.v. before the operation
3198095|NCT00867347|Active Comparator|Arm I|"Patients undergo a radical cystectomy, including pelvic lymphadenectomy,~between 4 and 6 weeks after initiating course 4 of chemotherapy."
3198096|NCT00867347|Experimental|Arm II|Patients with no visible residual tumor (cT0 or pT0) or residual but superficial tumor (pTa, pT1) undergo radiotherapy beginning within 4-6 weeks of day 1 of course 4 and continuing for 6.5 weeks.
2516619|NCT02785822|Active Comparator|Fostipur|
2516624|NCT02785822|Experimental|Meriofert|
3198097|NCT00867373|Experimental|Education Intervention|"The intervention used in the randomized controlled trial consists of 1) measuring the parents' height and weight and 2) providing the parents with feedback on their calculated BMI on an educational handout (included in Appendix V). The purpose of the handout is to convey the following 5 messages:~Definition of BMI~How BMI is calculated~What the parent's BMI is based on the measurements taken~What weight category the parent is in (underweight, normal weight, overweight, or obese)~Children with overweight or obese parents are at higher risk of becoming overweight themselves.~The Research Assistant will verbally review the educational handout with the parent. The handout will be available in both English and Spanish."
3198098|NCT00867373|No Intervention|Control Group|Parents assigned to the control group will proceed to their child's well child visit after their baseline data are collected.
2516782|NCT02784782|Experimental|Orthesis|Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol Intervention: After fitting the patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes.
2516783|NCT02784782|Active Comparator|No Orthesis|"Subjects will wear a TLSO for 6 weeks 24 hours a day or they will not. After 6 weeks the subjects in the TLSO group will decrease and stop the use of the orthesis. Depending on their pain complaints patients will be admitted to the hospital and will get adequate pain management following local protocol.~Control: The patient starts mobilising, under supervision of a physiotherapist, until pain is under control with oral analgesia. Sports and heavy lifting are prohibited for 3 months. No physiotherapy treatment is needed. During two year follow up patients will be seen at the outpatient clinic during standard care follow up moments. At or just before each scheduled appointment they will fill in questionnaires. These questionnaires will take 15-45 minutes."
2516829|NCT02784301|Experimental|Belly breathing with biofeedback app|
2516833|NCT02784301|No Intervention|Standard of Care|
2516839|NCT02784301|Active Comparator|Belly breathing without biofeedback app|
2516841|NCT02784301|Active Comparator|Belly breathing + visual distraction|
3198099|NCT00867399|Active Comparator|20mg of ABT-126 QD|20 mg of ABT-126 QD for 10 days
3198100|NCT00867399|Active Comparator|30mg and 45mg ABT-126 QD|30 mg and 45mg of ABT-126 QD for 21 days
2517024|NCT02783092|Experimental|Cannabidiol|Concentration unit: 200mg/ml; 5 - 25 mg/Kg/day ; Oral solution
2517031|NCT02783092|Placebo Comparator|Placebo|Oral solution
3198101|NCT00867412||Conventional staging|Staging with CT, mediastinoscopy and bronchoscopy
3198102|NCT00867412||Conventional staging and PET/CT|Staging with CT, mediastinoscopy and bronchoscopy, and PET/CT performed prior to mediastinoscopy
2517162|NCT02782182|Experimental|FOLFIRINOX+surgery|4 cycles of pre-operative FOLFIRINOX, followed by surgery, followed by 2 more cycles of FOLFIRINOX
2517240|NCT02781740|Active Comparator|CPAP therapy|Continuation of the already established CPAP therapy.
2517248|NCT02781740|Sham Comparator|Sham CPAP therapy|Sham-CPAP is achieved by setting the CPAP machine to the lowest pressure, insertion of a flow-restricting connector at the machine outlet, and insertion of six extra holes in the collar of the main tubing at the end of the mask to allow air escape and to prevent rebreathing of CO2.
2517265|NCT02781285||1group one|patients with standard TCM diagnosis and treatment of gastric cancer
2517266|NCT02781285||2 group two|patients take Chinese Medicine but not with standard TCM diagnosis and treatment of gastric cancer
2517268|NCT02781285||3group three|patients take no Chinese Medicine
2517304|NCT02781129|Experimental|RNS® Neurostimulator|Subjects with pharmaceutically intractable seizures who have been implanted with a RNS® Neurostimulator.
3198103|NCT00867425|Experimental|Intervention|
3198104|NCT00867438|Placebo Comparator|1|
3198105|NCT00867438|Experimental|2|
3198106|NCT00867464||Observational (long term follow-up)|Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
3198107|NCT00867477|Experimental|Cohort 1: Esophagus Cancer|Breathing Test + Respiratory Symptoms Questionnaire
3198108|NCT00867477|Experimental|Cohort 2: Lung Cancer|Breathing Test + Respiratory Symptoms Questionnaire
3198109|NCT00867516|Experimental|1|ALD518 80 mg
3198110|NCT00867516|Experimental|2|ALD518 160 mg
3198111|NCT00867516|Experimental|3|ALD518 320 mg
3198112|NCT00867516|Placebo Comparator|4|No ALD518
3198113|NCT00867542||past IUGR|3-4 y old children with past IUGR
3198114|NCT00867542||control|3-4 y old healthy children
3198115|NCT00867555|Experimental|EGCG|"Double blind randomized, placebo-controlled cross-over design with two arms:~the green tea extract TEAVIGO, high in EGCG and~placebo"
3198116|NCT00867555|Placebo Comparator|placebo|
3198117|NCT00867581||1|chronic-stage patients after infarction in the territory of unilateral middle cerebral artery
3198118|NCT00867581||2|age, sex and risk factor matched volunteers without ischemic stroke
3198119|NCT00867607|Experimental|MRX-6 (2%)|
3198120|NCT00867607|Experimental|MRX-6 (1%)|
3198121|NCT00867607|Experimental|MRX-6 (0.2%)|
3198122|NCT00867607|Active Comparator|Steroid|
3198123|NCT00867620||1|case group: patients with urothelial carcinoma
3198124|NCT00867620||2|control group: those without previous history of any malignancy
2516511|NCT02786433|Active Comparator|GROUP CONTROL|"Participants in the control group only underwent conventional physiotherapy. Conventional therapy includes stretching and strengthening exercises with cane aid, leggings , elastic band and overball for upper and lower limbs , in addition to gait and balance training.~The intervention for the control group was applied for five weeks with sessions of 60 minutes twice a week"
2516518|NCT02786433|Experimental|EXPERIMENTAL GROUP|The subjects in the experimental group underwent conventional physiotherapy (The same applied in the control group) associated with virtual reality , performed with the console X -Box Kinect® of Microsoft. Durante the achievement of the virtual reality practice, Kinect and Kinect games Adventures® Dance® demanded the anterior movements players -posterior and lateral , as well as jumps and squats to get rid of the game obstacles. They Kinect Dance® game were all required movements of the previous game more dance . The intervention lasted five weeks , with two weekly sessions lasting 30 minutes to conventional therapy and 30 minutes to virtual reality.
2516557|NCT02786225|Experimental|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a Vanderbilt University Medical Center (VUMC) perinatologist and a Vanderbilt University School of Nursing (VUSN) nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
2516558|NCT02786225|Active Comparator|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
3198125|NCT00867633||Urothelial carcinoma|The DNA samples extracted from the urothelial carcinoma tissue
3198126|NCT00867633||RCC|the DNA sample extracted from RCC
2517494|NCT02780024|Experimental|Registered one arm study|Two weeks of neo-adjuvant Metformin+Temozolomide followed by accelerated hypofractionation using an IMRT technique+TMZ & Metformin followed by TMZ, and Metformin as adjuvant component.
2517543|NCT02779647|Experimental|Study group|Consisting of 49 children who were recommended a programme of physical activity, play and nutritional advice, for both the children and their parents
2517544|NCT02779647|No Intervention|Control group|49 children, who received only nutritional advice
2517579|NCT02779283|Experimental|Arm I (AML)|Patients receive cytarabine IV continuously over 24 hours on days 1-7, and idarubicin IV over 30 minutes on days 1-3.Patients receive cyclophosphamide IV over 3 hours twice daily (BID) on days 1-3, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV on day 4, dexamethasone PO on days 1-4 and 11-14, and rituximab IV on day 1 and 11 (day 11 only of course 1). Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
2517580|NCT02779283|Experimental|Arm II (ALL)|Patients receive cytarabine IV over 2 hours BID on days 2-3, methotrexate IV over 2-22 hours on day 1, methylprednisolone sodium succinate IV BID on days 1-3, leucovorin calcium IV every 6 hours until methotrexate level is < 0.05 uM and rituximab IV on days 1 and 8. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Based on the results of the kinase inhibitor assay (In Vitro Kinase Inhibitor Assay), patients receive either sorafenib tosylate PO BID, sunitinib malate PO daily, dasatinib PO daily, ponatinib hydrochloride PO daily, ruxolitinib phosphate or idelalisib PO BID on days 8-28 in the absence of disease progression or unacceptable toxicity.
2517892|NCT02777359|Experimental|the closure group|In the closure group, the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA, in combination of clopidogrel(50mg/d, 3mon) and aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
2517896|NCT02777359|No Intervention|the medication group|In the medication group, in combination of clopidogrel (50mg/d, 3mon) and aspirin (0.1g/d, 6mon), current medication resumed, including conventional prescription for migraine as β-receptor blockers, calcium-ion antagonists, antiepileptics, antidepressants and non-steroid anti-inflammatory drugs (NSAID).
2517954|NCT02777229|Experimental|Dolutegravir|Dolutegravir 50 mg Quaque die (QD) + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg Fixed Dose Combination (FDC) QD
2517958|NCT02777229|Active Comparator|Efavirenz|Efavirenz 400 mg QD + tenofovir disoproxil fumarate/lamivudine 300 mg/ 300 mg FDC QD
2517992|NCT02776657|Active Comparator|Cohort 1 (Stable Angina)|20 patients with stable angina planned to undergo elective coronary angiography will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries.
2517997|NCT02776657|Active Comparator|Cohort 2 (Acute Coronary Syndrome)|20 patients diagnosed with acute coronary syndrome will be recruited and each participant will undergo magnetic resonance imaging (MRI) prior to invasive coronary angiography. During the angiogram, Optical Coherence Tomography (OCT) may be used to identify thrombus within the coronary arteries. If thrombus is identified, participants will be asked to undergo a repeat MRI scan at one and three months.
2518068|NCT02776319|Experimental|Active|Non-invasive brain stimulation (active)
2518072|NCT02776319|Placebo Comparator|Sham/Placebo|Non-invasive brain stimulation (sham)
2518248|NCT02774967|Active Comparator|extended flap technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
3198127|NCT00867633||Non-cancer|The DNA sample extracted from the non-cancerous kidney tissue
2518700|NCT02771782|Experimental|TDaP-IPV|Subjects are vaccinated with TDaP-IPV vaccine (Boostrix Polio) vaccine alone, 0,5ml intramuscular
3198128|NCT00867672|Experimental|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
2516572|NCT02785978|Experimental|Parkinson Disease Patients Group #1|PD patients with programmed levodopa challenge
2516581|NCT02785978|Experimental|Parkinson Disease Patients Group #2|PD patients without programmed levodopa challenge
2516588|NCT02785978|Experimental|Healthy volunteers|Healthy volunteers
2516658|NCT02785549|Experimental|Symptomatic treatment with NSAID|1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
2516660|NCT02785549|Active Comparator|Antibiotic+symptomatic treatment with NSAID|875/125mg /8h amoxicillin/clavulanic acid and symptomatic treatment with 1 g/8 h acetaminophen alternating with 600 mg/8 h ibuprofen
3198129|NCT00867672|Experimental|Decitabine+VPA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles
3198130|NCT00867672|Experimental|Decitabine+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
3198131|NCT00867672|Experimental|Decitabine+VPA+ATRA|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle
3198132|NCT00867685|Experimental|Treatment A|Single oral dose of 40 mg AZD2624 liquid suspension in a fasted state.
2516772|NCT02784795|Experimental|LY3039478 + Taladegib|LY3039478 given orally 3 times per week (TIW) in combination with taladegib given orally daily on a 28 day cycle. A single dose of taladegib will also be given on day 1 during a 3-day lead-in period.
2516773|NCT02784795|Experimental|LY3039478 + LY3023414|LY3039478 given orally TIW in combination with LY3023414 given orally every 12 hours on a 28-day cycle. A single dose of LY3023414 will also be given on day 1 during a 3-day lead-in period.
2516774|NCT02784795|Experimental|LY3039478 + Abemaciclib|LY3039478 given orally TIW in combination with abemaciclib given orally every 12 hours on a 28-day cycle. A single dose of abemaciclib will also be given on day 1 during a 3-day lead-in period.
2516775|NCT02784795|Experimental|LY3039478 + Cisplatin/Gemcitabine|LY3039478 given orally TIW in combination with cisplatin and gemcitabine given as intravenous (IV) infusions on days 1 and 8 of a 21 day cycle.
2516776|NCT02784795|Experimental|LY3039478 + Gemcitabine/Carboplatin|LY3039478 given orally TIW in combination with gemcitabine and carboplatin given as IV infusions on days 1 and 8 of a 21 day cycle.
2516831|NCT02784197|Other|Enrolled Subjects (PSR)|Patients who meet the study's inclusion and exclusion criteria, including signing the informed consent form, subjects will undergo signal acquisition prior to their scheduled cardiac catheterization on the day of the procedure.
2516901|NCT02784002|Experimental|Ridinilazole (SMT19969)|200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days
2516904|NCT02784002|Active Comparator|Fidaxomicin|200 mg tablet of Fidaxomicin twice a day for 10 days
2516966|NCT02783391|Experimental|BRAINSPEAK|Electrocorticographical (ECoG) and intracortical electrodes
3165333|NCT00511784||levonorgestrel-containing oral contraceptives|subjects in insurance claims database who were first time users of triphasic levonorgestrel-containing oral contraceptives with 30 micrograms ethinyl estradiol taken for 21 consecutive days followed by no pill or an inert pill for 7 days
2517065|NCT02782689|Experimental|Kit Biflex|The Kit Biflex® will be applied according to manufacturer recommendations for 16 weeks or until full healing.
2517066|NCT02782689|Active Comparator|Profore|The compression system Profore will be applied according to manufacturer recommendations for 16 weeks or until full healing.
2517132|NCT02782442|Experimental|Structured Cognitive Training & PRIME|Structured cognitive training consists of social cognition and auditory exercises.
2517138|NCT02782442|Active Comparator|Computer Games Control & PRIME|Computer games control condition comes in the official PositScience wrapper.
2517300|NCT02781194|Experimental|forced-air warming blanket|Forced-air warming blanket via 3M™ Bair Hugger™.
2517301|NCT02781194|Experimental|warmed, humidified insufflation|Warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
2517302|NCT02781194|Experimental|forced-air warming blanket & warmed, humidified insufflation|Combination of forced-air warming blanket via 3M™ Bair Hugger™ and warmed, humidified insufflation via the F&P HumiGard™ Surgical Humidification System.
2517327|NCT02780830|Experimental|AZD2014 plus Ibrutinib Combination|AZD2014 and ibrutinib will be dosed together in the morning under fasting conditions. When possible, the morning doses of AZD2014 and ibrutinib should be taken at approximately the same time each day. The morning doses must be taken in a fasted state (water to drink only) from at least 2 hours prior to the dose to at least 1 hour post dose. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
2517378|NCT02780557|Experimental|Contingent Reading Intervention|
2517381|NCT02780557|Other|Book Provision Control|
3165334|NCT00511823|Experimental|Subjects in Part A|Subjects will receive 100 milligrams (mg) of oral dolasetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 100 mg oral dolasetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant on day 1 and 50 mg oral casopitant on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
2517539|NCT02779699|Experimental|AL2846|AL2846 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2517568|NCT02779374|Experimental|Autologous bone marrow transplantation|autologous bone marrow will be given by intravenous infusion. the intervention will be preceded by a period of 6 months of follow up the a period of 12 months follow up
2517749|NCT02779088|Experimental|Early exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the AB arm receive exercise and nutrition intervention first, followed by the education course.
2518136|NCT02776072||glatiramer acetate (GA)|Participants who initiated GA during the specified time period
3198133|NCT00867685|Experimental|Treatment B|Single oral dose of 40 mg (2x20mg tablets)AZD2624 in a fasted state.
2516756|NCT02785107|Experimental|Intervention|Those who were randomized into the intervention group attended a workshop where the PI delivered a presentation that focused on establishing a preparatory exercise habit by using the M-PAC approach and proposed habit model. Participants were then provided with instructions on completing their exercise plan sheet.
2516760|NCT02785107|No Intervention|Control|Participants exercised on their own without receiving any instructions.
2516784|NCT02784626|Experimental|Dexmedetomidine|Patients who received dexmedetomidine during the operation
2516786|NCT02784626|Experimental|Propofol|Patients who received propofol during the operation
2516832|NCT02784340|Active Comparator|IV dexamethasone|40 women received 16 mg Dexamethasone IV drip.
2516835|NCT02784340|Active Comparator|Local dexamethasone|40 women received 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
2516838|NCT02784340|Placebo Comparator|placebo|Placebo in the form of IV fluids 500 cc saline infusion
3198134|NCT00867685|Experimental|Treatment C|Single oral dose of 40 mg (2x20mg tablets) in a fed state.
3198135|NCT00867698|Experimental|AST-120 (6g)|2 grams TID
3198136|NCT00867698|Placebo Comparator|Placebo A|2 grams TID
3198137|NCT00867698|Experimental|AST-120 (12g)|4 grams TID
3198138|NCT00867698|Placebo Comparator|Placebo B|4 grams TID
3198139|NCT00867724|Experimental|Aer-O-Scope Colonoscopy|Screening Colonoscopy
2516979|NCT02783326|Experimental|COPD Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
2516980|NCT02783326|Active Comparator|Control Group|Evaluation of oxidative stress, heart rate variability, quality of life with AQ20 questionary, function with TC6 before the application of rehabilitation protocol, after 10 weeks during protocol application and 2 months after protocol application
2517000|NCT02783053|Other|Metformin use|The investigators compare the use of metformin vs no metformin
2517001|NCT02783053|No Intervention|Lean or Obese|The investigators compare the effect of metformin on 18F-FDG uptake between lean and obese men.
2517052|NCT02782884||Outpatient general surgery operation|Patients undergoing outpatient general surgical operations They will be given a specified number of narcotic pills based on our retrospective analysis of patient post-operative opioid use
2517053|NCT02782884||Inpatient general surgical patients|Inpatients who are being discharged They will be given a specified number of narcotic pills based on the number of pills they took in the 24 hrs prior to discharge
2517095|NCT02782572|Experimental|Exercise with Non-invasive ventilation|Patients with acute haert failure who performed aerobic exercise with non-invasive ventilation. This group also received conventional medical treatment.
2517097|NCT02782572|Sham Comparator|Exercise|Patients with acute haert failure who performed aerobic exercise with placebo of non-invasive ventilation. This group also received conventional medical treatment.
2517098|NCT02782572|Other|Control|Patients who receiveid only conventional medical treatment and not performed exercise during protocol.
2517111|NCT02782273|Active Comparator|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
2517119|NCT02782273|Active Comparator|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
2517183|NCT02782117|Experimental|Treatment Regimen A|Treatment Regimen A will use the Luminopia device for an hour per day for 12 weeks.
2517286|NCT02781376|Experimental|CHICA-OSA|Two clinics will be randomized to receive the advanced CHICA-OSA computer decision support system designed to support PCPs in evidence-based identification and management of pediatric OSA. This module includes a snoring identification component (received by the control group).
2517288|NCT02781376|Other|Control|Two clinics will be randomized to receive a control computer decision support system module that automates screening for snoring and alerts the PCP, but does not provide any additional guidance on evidence-based diagnosis or management.
2517330|NCT02780973||Females|Female volunteers
2517339|NCT02780973||Males|Male volunteers
2517462|NCT02780232|Experimental|Internet-based program|"Adolescents in the intervention will receive a tailored online program during 3 months.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links."
2517466|NCT02780232|No Intervention|Treatment as usual|-Waiting list control group.
2517600|NCT02779361|Experimental|Green tea|Green tea consumption along 7 days.
2517627|NCT02778906|Active Comparator|Abatacept|Abatacept 125 mg s.c. weekly
2517629|NCT02778906|Placebo Comparator|Placebo|Placebo (NaCl 0,9%) s.c. weekly
2517686|NCT02778607||Progressive Supranuclear Palsy|Patients with a current clinical diagnosis of Progressive Supranuclear Palsy (PSP)
2517687|NCT02778607||Multiple System Atrophy|Patients with current clinical diagnosis of Multiple System Atrophy (MSA).
2517688|NCT02778607||Atypical Parkinsonian Syndrome|Atypical Parkinsonian Syndrome (APS) patients who do not fulfil existing criteria for PSP/CBD/MSA, but may represent variant clinical syndromes related to tau pathology including pure akinesia with gait freezing (PAGF), PSP-parkinsonism, overlap syndromes and atypical parkinsonian disorders not meeting clinical diagnostic criteria at entry
2517689|NCT02778607||Controls|Participants unaffected by neurological or psychiatric disease
2517690|NCT02778607||Corticobasal Degeneration|Patients with a current clinical diagnosis of Corticobasal Degeneration (CBD)
2549925|NCT02565459|No Intervention|No intervention|
3198140|NCT00867737|Experimental|Advair 115/21 MDI|Advair HFA 115/21 MDI Intervention = initiate intervention after screening
3198141|NCT00867737|Active Comparator|2 = Symbicort 160/4.5|Symbicort initiated after screening
3198142|NCT00867750|Experimental|RE|Device: Radioembolisation with yttrium-90 labelled SIR-Spheres microspheres
2516616|NCT02785757|Experimental|Patients with adenocarcinoma|60 Patients recently diagnosed with locally advanced or metastatic adenocarcinoma of any origin, who are scheduled for systemic chemotherapy
2516667|NCT02785471|Active Comparator|Screening for Mental Health only|Participants in the Screening for Mental Health only (control) group will complete the online depression and suicide screening and receive immediate feedback and referrals.
2516669|NCT02785471|Experimental|Screening for Mental Health & Man Therapy|Participants assigned to Screening for Mental Health & Man Therapy (intervention) group will be offered the Man Therapy program in conjunction with Screening for Mental Health.
3198143|NCT00867750|Active Comparator|TACE|Transarterial Chemoembolisation with embolising agent Embospheres and chemotherapeutic agent epirubicin
3198144|NCT00867763|Experimental|IVM|Early egg retrieval, in vitro maturation, then IVF
3198145|NCT00867763|Active Comparator|Mild IVF|Mild gonadotropin and conventional IVF
3198146|NCT00867776|Experimental|AAHC Excercise Program Support Group|Participants taking part in the AAHC Exercise Program Support Group (the intervention).
2516767|NCT02784821|Other|Antibiotics Control|"These neonates have a clinical indication to receive antibiotics, such as maternal chorioamnionitis with fetal tachycardia. The standard of care antibiotics include Ampicillin and Gentamicin or Cefotaxime and as part of standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
2516768|NCT02784821|Other|No Antibiotics Control|"These neonates show no signs of respiratory distress(RDS) or have no indications of maternal chorioamnionitis. Antibiotics is not indicated for this group as standard of care.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins."
2516769|NCT02784821|Other|Randomized to pre-emptive antibiotics|"This group will be randomized to receive standard of care antibiotics which include Ampicillin and Gentamicin or Cefotaxime. Standard of care blood tests such as complete blood cell counts, blood cultures, and C-reactive proteins will be performed.~Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome."
2516770|NCT02784821|Other|Randomized to no pre-emptive antibiotics|This group will be randomized not to receive standard of care antibiotics. Study interventions will include the collection of samples for the following: breast milk, gastric fluid and stool samples for analysis of the microbiome and metabolome, along with standard of care complete blood counts, blood cultures, and C-reactive proteins.
3198147|NCT00867802|Experimental|Mindfulness- Based Stress Reduction: Active Comparator|Mindfulness-Based Stress Reduction program
2516865|NCT02784080||HLA-alloantibodies exposure|Preformed, persistent, and de novo HLA-alloantibody exposure in the whole cohort.
3198148|NCT00867828|Experimental|1|Neptune Krill Oil(TM)softgels (1g QD). Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
3198149|NCT00867828|Active Comparator|2|Fish oil softgels (1g QD). Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
3198150|NCT00867828|Placebo Comparator|3|Placebo (soy oil) softgels (1g QD. The soy oil placebo will provide neither EPA nor DHA.
3198151|NCT00867841||Pneumonia|Children diagnosed with community-acquired pneumonia by the emergency department physician
3198152|NCT00867854||Experimental|25 evaluable subjects from the experimental arm of ATN 061 who undergo de-intensification to boosted atazanavir (ATV) with VL suppression of < 100 copies/ml and CD4+ T cells > 350 cells/mm3 at week 48 and maintain VL suppression to < 400 copies/ml with stable CD4+ T cell counts after week 48.
3198153|NCT00867854||Control|25 evaluable subjects from ATN 071 will also be enrolled. These subjects will have initiated HAART according to current DHHS guidelines (CD4+ T cells < 350 cells/mm3), had viral load suppression to < 100 copies/ml at 24 through 48 weeks on HAART and maintained suppression to < 400 copies/ml through week 80.
3198154|NCT00867867|Active Comparator|1|Ferrous Fumarate with Ferrous Sulphate
3198155|NCT00867867|Active Comparator|2|Ferric pyrophosphate with ferrous sulphate
2517303|NCT02781155|Other|Self administration of moxibustion|Participants will be taught to self administer moxibustion to the acupuncture point Zusanli St-36, and apply it daily throughout their chemotherapy treatments
2517347|NCT02780843|Experimental|Computerized Tomography|Patients will be examined with Computerized Tomography (CT) at admission
2517351|NCT02780843|Experimental|Magnetic Resonance Imaging|Patients will be examined with Magnetic Resonance Imaging (MRI) at admission
2517401|NCT02780427|Active Comparator|1-6 months (Group 1)|
2517411|NCT02780427|Active Comparator|7-12 months (Group 2)|
2517413|NCT02780427|Active Comparator|13-18 months (Group 3)|
2517414|NCT02780427|Active Comparator|19-24 months (Group 4)|
2517442|NCT02780076|Experimental|Functional training group|Participation in a functional training program in addition to usual care. The functional training program is initiated by the nurses and consists of walking, sit-to-stands, balance training, weight transfer training, knee squats. The program is performed 4 times a day for 3 weeks while at short-term stays.
2517449|NCT02780076|No Intervention|Control group|Usual care only. No participation in the functional training program while at short-term stays.
2517519|NCT02779972||60's decade|60's decade Echo stress test
2517524|NCT02779972||70's decade|70's decade Echo stress test
2517528|NCT02779972||80's decade|80's decade Echo stress test
2517560|NCT02779439|Experimental|3rd party CTL infusion|Virus specific CTLs
2517640|NCT02779179|Experimental|Immediate Periodontal treatment group|
2517651|NCT02779179|Active Comparator|Delayed Periodontal treatment Group|
2517740|NCT02778477|Placebo Comparator|Part A_Cohort 1_Placebo|Multiple dose of placebo
3198156|NCT00867867|Placebo Comparator|3|Ferrous sulphate
3198157|NCT00867880|Experimental|1|
3198158|NCT00867880|Active Comparator|2|
3198159|NCT00867893||DA group|RLS patients started treatment on dopamine agonists within the past year
3198160|NCT00867893||NonDA|RLS patients started treatment on medication other than dopamine agonists within the past year
2516638|NCT02785536|Experimental|RITCh Treatment|The RITCh treatment is an adaptation of the standard treatment which proactively addresses the needs and experiences of a diverse group of lower SES smokers as well as ensures that the treatment is culturally congruent and experientially resonant for African Americans while maintaining the same amount of treatment contact (i.e., six one-hour sessions).
2516696|NCT02785367|Experimental|Cord blood samples|8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml washed with Heparin.
2516765|NCT02785068|Experimental|Phase 1b/2a|"Phase 1b: Safety Evaluation - MM-151 (weekly dosing) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400mg/m2 every two weeks.~Phase 2a: Expansion - MM-151 (Maximum Tolerated Dose or Recommended Phase 2 Dose) in combination with fixed doses of nal-IRI 70mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2."
2516778|NCT02784522|Experimental|locking compression plate group|In the experimental group, patients will undergo closed reduction via a lateral approach to the shoulder followed by locking compression plate fixation using a minimally invasive technique.The locking compression plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
2516780|NCT02784522|Active Comparator|conventional locking plate group|Patients in the control group will be subjected to closed reduction via a lateral approach to the shoulder followed by conventional steel plate fixation using a minimally invasive technique. The conventional locking plate is purchased from Xiamen Dabo Yingjing Medical Devices Co., Ltd., Xiamen, China.
2516815|NCT02784418|Active Comparator|PCI of CTO|Intervention: PCI of CTO (Chronic Total Occlusion Percutaneous Coronary Intervention) Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. CTO PCI patients will receive blinded clopidogrel 75 mg daily for 6 months.
2516817|NCT02784418|Sham Comparator|Sham Procedure|"Intervention: Sham procedure Subjects will be blinded to randomization assignment using a combination of conscious sedation and sensory isolation (e.g., blindfold and noise isolation). Control subjects will only undergo a Sham procedure, wherein they will undergo bilateral arterial access, without angiography or PCI being performed. Hospitalized overnight after the procedure, with post procedure monitoring practices as per standard of care for PCI. Sham group will receive blinded placebo clopidogrel for 6 months."
2516848|NCT02784067|Experimental|Treatment|Subjects randomized to the active treatment arm will take Sucraid, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
2516850|NCT02784067|Placebo Comparator|Placebo|Subjects randomized to the placebo treatment arm will take Sucraid placebo, 2 mL (17,000 IU) with every meal or snack, administered orally following dilution with 2 to 4 ounces (60 to 120 mL) of water or milk (either cold or at room temperature). The study treatment period is one week.
2516946|NCT02783365|Experimental|Intervention|The intervention uses photo-elicitation and online group support (via Facebook) to improve patients' overall experience of chronic pain and patient-identified areas of function. This intervention was informed by the Photovoice methodology developed by Wang and Burris (1994). Photovoice participants will utilize cameras that enable them to record issues related to their experiences, and subsequently display them in office visits with their physician or mid-level clinician.
2516954|NCT02783365|No Intervention|Control|Patients in the control practices will receive usual care and will be eligible to participate in the intervention after their participation in the study is completed at 12 months.
2516996|NCT02783261||Post Y90 hypertrophy measurement|All prospective patients who undergo unilobar SIRT for HCC at SGH or NCC are potential candidates for this study. The study aims to recruit 25 subjects and it is anticipated that 50% will be from SGH and 50% will be from NCC
2517089|NCT02782585|Experimental|Experimental group 1|Cervical Manipulation
2517092|NCT02782585|Experimental|Experimental group 2|Cervical lateral glide
2517094|NCT02782585|Placebo Comparator|Control group|Cervical Mobilisation
2517126|NCT02782299|No Intervention|Control|This group will not be exposed to the decision aid. Patients will complete the same surveys, and will be followed for the same length of time.
2517139|NCT02782299|Experimental|Decision Aid|This group will be exposed to the decision aid before the patients appointment with the surgeon. Patients will also complete the same outcome surveys, and will be followed for the same length of time.
3165335|NCT00511823|Experimental|Subjects in Part B|Subjects will receive 2 mg of oral granisetron once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 2 mg oral granisetron once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
2517469|NCT02780219|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
3165336|NCT00511823|Experimental|Subjects in Part C|Subjects will receive 4 mg of oral rosiglitazone once daily for 3 days during treatment period 1. In treatment period 2, subjects will receive 4 mg oral rosiglitazone once daily on days 1, 2 and 3 along with 150 mg oral casopitant once daily on day 1 and 50 mg oral casopitant once daily on days 2 and 3. The treatment periods will be separated by will be separated by a 5 - 14 day wash-out period.
3165337|NCT00511849|Experimental|1|
3165338|NCT00511927||GHD|Patients with Growth Hormone Deficiency
3165339|NCT00511927||non-GHD|Patients with CHF, without coexisting growth hormone deficiency
3165340|NCT00511940|Experimental|1|acamprosate
3165341|NCT00511940|Placebo Comparator|2|sugar pill
3165342|NCT00511953|Active Comparator|Gabapentin ER|Active drug, Gabapentin extended release
3165343|NCT00511953|Placebo Comparator|Sugar Pill|Comparator arm is Placebo
3165344|NCT00511966||001|
3165345|NCT00511966||002|
3165346|NCT00511979|Experimental|Technosphere insulin inhalation system, 25 units|
3165347|NCT00511979|Experimental|Technosphere insulin inhalation system, 50 units|
3165348|NCT00511979|Experimental|Technosphere insulin inhalation system, 100 units|
3165349|NCT00511979|Active Comparator|Subcutaneous regular human insulin|
2516650|NCT02785796|Experimental|CV4|The practitioner will contact the participant's occiput (lateral to the external occipital protuberances, but medial to the occipital-mastoid suture) with his or her thenar eminences. When no cranial mobility will be found, operators will be free to use any kind of technique to enhance the cranial movement before CV4 procedure. Once the practitioner will detect the CRI, the practitioner will resist the flexion phase of the CRI and exaggerate the extension phase. This compressive pressure will be maintained until the CRI stopped, and the still-point is reached. The still-point will be held until the CRI return, at which point the compressive pressure will be slowly release
2516652|NCT02785796|Placebo Comparator|sham technique|"The operator will overlap the hands so that the thumbs formed a V. The operator's thenar eminences will contact the occiput very lightly well below the positioning used in the CV4 procedure but with no pressure on the occiput between the occipitomastoid sutures. Once placement will be achieved, the operator's hands will remain motionless for 10 min. Finally, the practitioner's hands will be gently removed and the participant's head will be placed on the table for both procedures"
2516655|NCT02785796|No Intervention|Control|The control group will not receive ant type of treatment: subject just stay quietly in supine position in ambulatory room for ten minutes
2516719|NCT02785289|Experimental|Flocked|Patients will perform vaginal cell collection beginning with the flocked swab, followed by the coton swab.
2516723|NCT02785289|Experimental|Coton|Patients will perform vaginal cell collection beginning with the coton swab, followed by the flocked swab.
2516734|NCT02784847|Other|treatment arm|pilot-study with single arm of 10 migraine patients treated for 3 months with triheptanoin 1mg/kg/day
2516808|NCT02784769|Experimental|aneurysm diameter of below 75 mm|
2516810|NCT02784769|Experimental|aneurysm diameter above 75 mm|
2516888|NCT02783846|Placebo Comparator|Group control|24 eligible patients are received equal volumes of saline intravenously for 10 minutes
2516891|NCT02783846|Active Comparator|Group dexmedetomidine 0.5 µg/kg|24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
2516893|NCT02783846|Active Comparator|Group dexmedetomidine 1.0 µg/kg|25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes
2516957|NCT02783586|Experimental|Quadratus Lumborum Block type II|Unilateral ultrasound guidance QLB on the operated side after induction of general anaesthesia - 20 ml of 0,25%bupivacaine with adrenaline injected with ultraplex needle
2516963|NCT02783586|Active Comparator|Transversus Abdominalis Plane Block|Unilateral ultrasound guidance TAPB on the operated side after induction of general anaesthesia - 20 ml of 0,25% bupivacaine with adrenaline injected with ultraplex needle
3198161|NCT00867906|Other|Cohort 1|Asthmatics using salbutamol only, subjects to receive either Cat-PAD or placebo comparator
2517088|NCT02782611|Experimental|Treatment|ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
2517091|NCT02782611|No Intervention|Waiting Group Control|The waiting group control will complete the same assessments as the experimental group but without receiving the intervention.
2517227|NCT02781792|Experimental|Arm 1: Temozolomide morning|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m^2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the morning (before 10:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
2517230|NCT02781792|Experimental|Arm 2: Temozolomide evening|"Temozolomide will be given as per standard of care. Typical dosing is 150 to 200 mg/m2 on Days 1 through 5 of a 28-day treatment cycle. Patients will be randomized to take their temozolomide doses in the evening (after 20:00).~FACT-Br quality of life at baseline, at the beginning of each cycle of chemotherapy, and 1 month after the final chemotherapy treatment"
2517270|NCT02781298|Experimental|New Infant Cereal|amount ingested according to pediatricians recommendations
2517272|NCT02781298|Active Comparator|Multicereals Infant Cereal|amount ingested according to pediatricians recommendations
2517318|NCT02780986|Active Comparator|Female entertainment worker intervention group|The intervention program for the female EE workers aims to increase STI/HIV prevention knowledge and develop their condom negotiation and application skills so as to increase condom use with both casual and paid partners. It consists of a total of 4 sessions: 2 on-site and 2 online sessions. For each on-site session, groups of 4 to 5 female EE workers will be gathered. The 2 on-site sessions would be delivered by peer educators. The 2 online sessions would be conducted via phone and other modes of network communication (e.g. SMS message or WhatsApp message) depending on the preference of each participant. In addition, all the intervention materials and video demonstrations will also be uploaded onto the web portal for the participant to access during their free time.
2517324|NCT02780986|No Intervention|Female entertainment worker control group|"The female EE workers in the control group will receive the same number of 2 onsite and 2 online sessions but covering healthy eating and physical activity.~The following gives a summarised breakdown and content of each session:~Session 1 (on-site immediately after baseline survey, 10 minutes):~The peer educator will share information on healthy eating and physical activity using the educational pamphlets from the Health Promotion Board (HPB) with the participants.~Session 2 (online 1-2 weeks after baseline survey, 5 minutes):~The peer educator will share an app on healthy eating with the participants.~Session 3 (online 3-4 weeks after baseline survey, 5 minutes):~The peer educator will share an app on physical activity with the participants.~Session 4 (onsite during follow-up survey, 10 minutes):~The peer educator will reinforce information on healthy eating and physical activity based on the educational pamphlets from HPB with the participants."
2517334|NCT02780986|Active Comparator|Heterosexual men intervention group|The intervention program for heterosexual men patronising EEs will be a holistic non disease-centric, non-stigmatising and non-judgemental program addressing sexual well-being, avoidance of casual and paid sex if possible and safe sex such as condom use.
3198162|NCT00867906|Other|Cohort 2|Asthmatics using inhaled corticosteroid, subjects to receive either Cat-PAD or placebo comparator
2517479|NCT02780258|No Intervention|Control Hand|The dorsal aspect of the hand that is not treated will be used for baseline comparison.
2516736|NCT02784860|Active Comparator|Lidocaine|Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.
2516738|NCT02784860|Placebo Comparator|Placebo|Placebo Administration of normal saline: same volume of saline as lidocaine.
2516792|NCT02784691|Experimental|Patients|
2516836|NCT02784327|Experimental|PRF110- oily solution|Post-operative application of new extended release PRF110- oily solution (Ropivacaine)
2516886|NCT02783937|Active Comparator|Filgrastim arm|Intervention: Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days
2516887|NCT02783937|Placebo Comparator|Placebo arm|Intervention: Injection of saline SC injection twice daily for five consecutive days.
2517041|NCT02782936|Experimental|Baseline|Randomised baseline without and with gas mask.
2517042|NCT02782936|Experimental|Induced Hypoxemia|Randomised hypoxemia: i. without gas mask; ii. with gas mask; and iii. correction with FreeO2 and gas mask.
2517044|NCT02782936|Experimental|Effort|Randomised effort without and with gas mask
2517070|NCT02782624|Experimental|Treatment A: Empagliflozin|5 mg bid
2517075|NCT02782624|Experimental|Treatment B: Empagliflozin|10 mg qd
2517125|NCT02782455|Experimental|CDobi|Calcium dobesylate is given in this group
2517129|NCT02782455|Active Comparator|Flavono|Flavonoids are given in this group
2517160|NCT02782026|Experimental|idiopathic PAH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2517163|NCT02782026|Experimental|heritable PAH with BMPR2 mutation|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2517168|NCT02782026|Experimental|chronic thromboembolic PH|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2517175|NCT02782026|Experimental|Controls|Exhaled Breath Olfactory Signature Detected by an Artificial Nose
2517237|NCT02781688|Experimental|Physical Activity Intervention|Participants will participate in a multi-component physical activity intervention for 12 weeks.
2517338|NCT02781012||Healthy|Healthy volunteers without any known pancreatic disease
2517343|NCT02781012||Healthy At-Risk|Healthy volunteers with no known benign or malignant pancreatic disease, AND with one first-degree relative with pancreatic cancer, OR two second-degree relatives with pancreatic cancer. These subjects also include those who have undergone surgery for suspected pancreatic cancer, and who are found to have a non-pancreatic cancer pathology upon final local site or central pathology review.
2517344|NCT02781012||Pancreatitis|Subjects diagnosed with acute or chronic pancreatitis
2517345|NCT02781012||Early Stage/Borderline/Locally Advanced|Subjects diagnosed with early stage pancreatic cancer who undergo surgery as standard of care therapy with or without preoperative (neoadjuvant) chemotherapy and/or radiation therapy; subjects diagnosed with borderline pancreatic cancer, or subjects diagnosed with locally advanced pancreatic cancer.
2517346|NCT02781012||Metastatic|Subjects diagnosed with metastatic pancreatic cancer and treated with any standard of care therapy/therapies.
2517394|NCT02780466||Patients with septic shock|
2517443|NCT02780245|Experimental|Group (X) Prophylactic Tranexamic Acid|Intravenously at 20 minutes preoperatively had an intervention of a single bolus TXA dose of 20•0 mg/kg, which was administered in Z solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g) (NCT02739815).
2517450|NCT02780245|Experimental|Group (Y) Intraoperative Uterine Cooling|Firstly intravenously at 20 minutes preoperatively had only the Z solution, and secondly [Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen].
3165350|NCT00512018|Active Comparator|Isokinetic Exercise only|Individuals were asked to perform a 8-session training, twice a week, in which they trained the knee extensors muscles in an isokinetic dynamometer, 3 sets of 10 repetitions.
2517589|NCT02779465|Experimental|Vitamin D|Drug: Vitamin D3 800 IU daily besides the anti-virus treatment with nucleos(t)ide medicine
2517591|NCT02779465|No Intervention|Control|chronic hepatitis B patients with long term anti-virus therapy
2517645|NCT02778958|Experimental|ibuprofen and morphine|iv ibuprofen 800 mg infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
3165351|NCT00512018|Experimental|Isokinetic exercise + NMES|In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES).
3165352|NCT00512044|Active Comparator|A: general|general anesthesia: spinal and general
3165353|NCT00512044|Experimental|B: pudendal|local anesthesia: pudendal block
3165354|NCT00512057|Experimental|1|
3165355|NCT00512057|Placebo Comparator|2|
3165356|NCT00512070|Experimental|IIA (0.3mg day melatonin)|0.3mg day melatonin
3165357|NCT00512070|Experimental|IIB (3.0 mg/day melatonin)|3.0 mg/day melatonin
3165358|NCT00512122|Experimental|EN only|Withholding PN during the first week of ICU stay
3165359|NCT00512122|Active Comparator|EN plus early PN|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E Parenteral nutrition targeted at covering calculated needs together with the enteral nutrition intake that is achieved
3165360|NCT00512187|Experimental|first group|patients who adhered to a low-calorie diet associated to sub-optimal cyclosporine dose (2.5 mg/Kg/day)for 24 weeks
3165361|NCT00512200||Case|Patients aged 65 or older
3165362|NCT00512200||Control|Patients aged 20 to 40
3165363|NCT00512200||Control 2|Healthy volunteers aged 65 or older
3165364|NCT00512213|Active Comparator|1|Immunonutrition containing RNA, omega-3-FAs, arginine
3165365|NCT00512213|Active Comparator|2|Standard enteral nutrition: isocaloric and isonitrogeneous but w/o active ingredients
3165366|NCT00512239||EUPA cohort|Consecutive adult patients presenting to receive rheumatological care at the Sherbrooke University Hospital Centre (CHUS) with an immune-mediated inflammatory arthritis affecting at least 3 joints for a duration of more than 4 and less than 52 weeks.
2516685|NCT02785380|Experimental|laparoscopic surgery(LS)|For LS,the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg.Intra-operative ultrasonography was performed routinely. Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. The Pringle maneuver was not used. Wedge resection, segmentectomy or subsegmentectomy was performed. The surgeon aimed to achieve a 1.0-cm safety margin during the liver resection.
2516688|NCT02785380|Active Comparator|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA).
2516759|NCT02785042|Experimental|Normal healthy volunteers|imaging with Heidelberg Spectralis OCT
3198163|NCT00867906|Other|Cohort 3|Asthmatics using inhaled corticosteroid and LABA, subjects to receive either Cat-PAD or placebo comparator
2516842|NCT02784184||1 year follow-up group|1 year follow-up group including 6 measurements
2516849|NCT02784184||40 days diaper study subgroup|"Subgroup of the 1 year follow-up group including 15 girls undergoing daily measurement of urinary hormone excretion"
2516882|NCT02783989|Active Comparator|White wine|Two glasses of a market white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14 g in women). It is estimated that wine will contain about 8-9 mg/l of tyrosol. Therefore the dose of tyrosol ingested in two glasses would be 2-2.5 mg (1-1.25 mg in women).
2516883|NCT02783989|Experimental|White wine plus tyrosol capsules|Two glasses of white wine (2x135 mL, 13º), each (135 mL) equivalent to 14 g of ethanol (in case of women only one glass, 135 mL), being the daily dose of 28 g (14g in women), in combination with capsules of 25 mg of TYR (each one to be ingested with a glass of wine), two capsules along the day for men (at lunch and at dinner) and one for woman (at lunch).
2516884|NCT02783989|No Intervention|Water|Drinking water along with meals
2516937|NCT02783651||No treatment 1|It is planned to have 20-30 sites participating on the trial for chart review of approximately 200-235 patients initiating treatment for Philadelphia chromosome-negative (Ph-) Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) between January 2013 and March 2019.
2516938|NCT02783651||No Treatment 2|Initial record abstraction will occur at study site with subsequent reviews occurring at the site every 3 months thereafter until study conclusion on March 2020.
2517013|NCT02783144|Experimental|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, 4 mg of Dexamethasone are added to 20 ml of 0,375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
2517018|NCT02783144|Placebo Comparator|TAP Block and Saline|After general anesthesia and before the beginning of surgery, 2 ml of saline are added to 20 ml of 0.375% Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block.
2517026|NCT02783144|Active Comparator|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, 20 ml of 0,375% Levobupivacaine are used in Ultrasound-guided Tranversus Abdominis Plain Block. In this group 4 mg of dexamethasone are injected intravenously.
3198164|NCT00867919|Experimental|1|Participants will receive a cognitive behavioral family therapy for adolescent depression to be developed in this study.
3198165|NCT00867919|Active Comparator|2|Participants will receive treatment as usual 1 year prior to the experimental treatment group.
2517149|NCT02782208|Active Comparator|Acipimox/GH substitution|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Continue GH substitution as usually.
2517150|NCT02782208|Active Comparator|Acipimox/GH pause|Drug: Acipimox Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day Other Name: Tablet Olbetam 250 mg Pause GH substitution to days prior to the study day.
2517152|NCT02782208|Placebo Comparator|Placebo/GH substitution|Drug: Placebo tablets Continue GH substitution as usually.
2517154|NCT02782208|Placebo Comparator|Placebo/GH pause|Drug: Placebo tablets Pause GH substitution to days prior to the study day.
2517226|NCT02781519|Active Comparator|THC|Active THC (0.015mg/kg) administered intravenously over 10 minutes.
2517231|NCT02781519|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 10 minutes.
2517267|NCT02781363|Other|Candidates patients chest X-ray with pneumonia|thoracic sonography CXR Clinical control 48h
2517269|NCT02781363|Other|Candidates patients chest X-ray without pneumonia|thoracic sonography CXR Clinical control 48h
2517308|NCT02781064|Active Comparator|Atorvastatin 20mg|Atorvastatin to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
2517309|NCT02781064|Placebo Comparator|Placebo - Microcrystalline Cellulose|Placebo to be taken daily in 2 month treatment periods, 3 treatment periods in 12 months
3198166|NCT00867945||1. Pregnant Women|
3198167|NCT00867945||2. Non-Pregnant Controls|
3198168|NCT00867945||3. IVF controls|
3198169|NCT00867971||RGH treated|
3198170|NCT00867971||Starting treatment with RGH|
3198171|NCT00867984|Experimental|1|Torsion-guided VV optimization plus AV optimization.
3198172|NCT00867984|Active Comparator|2|AV optimization only.
3198173|NCT00867997|Active Comparator|Dentifrice|Chemoactive (remineralizing, neuroactive) dentifrice treatment
3198174|NCT00867997|Active Comparator|Sealant|DBA/sealant application
3198175|NCT00867997|Active Comparator|Resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
3198176|NCT00868010|Experimental|1: donepezil|Participants will receive treatment for 12 weeks on donepezil 10 mg (or 5 mg if unable to tolerate 10 mg). Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
2516753|NCT02784964|Experimental|Elixcyte 2mL|ADSC 1.6*10^7 cells, allogeneic injection, one time injection on Day 1
2516845|NCT02784379||The breast with mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast with mastalgia.
2516847|NCT02784379||The breast without mastalgia|Electromyography will be performed to the pectoral muscle that is placed behind the breast without mastalgia.
2516885|NCT02783976||Sovaldi-based regimens|Adult patients with chronic HCV infection living in Mexico who take Sovaldi as part of routine clinical care at a participating clinical site.
2516953|NCT02783534|Experimental|Verum acupuncture|Participants will receive verum acupuncture plus usual care. Participants will receive acupuncture treatment start from the 5th or 7th day before the estimated first day of menstrual cycle, and for each cycle, participants will receive one session of treatment each day for 5 consecutive days, totally be treated with 15 sessions.Verum needles will be inserted into the skin and manipulated manually until deqi occurs. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and manipulates the needles to maintain the intensity of deqi. Participants will receive the same usual care as those in the usual care group.
2516960|NCT02783534|Sham Comparator|Sham acupuncture|Participants will receive sham acupuncture plus usual care. The Streitberger placebo needle will be placed at non-acupuncture points which are distant from the meridian parts and not located on the same neuromuscular segments as the prescribed points used in the VA group, so as to minimize any therapeutic and segmental effects. The same acupuncture schedule as that in the verum acupuncture group will be applied. The needles are retained for 30 min in each session. During the treatment, the acupuncturist inquires the patient about deqi sensations and pretends to manipulate the needles but deqi is not sought.Participants will receive the same usual care as those in the usual care group.
2516965|NCT02783534|Placebo Comparator|Usual care|Participants will not receive acupuncture treatment besides health education as a control group.
2517009|NCT02783079|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT)
2517017|NCT02783079|Active Comparator|Arm 2|Mindfulness Based Stress Reduction (MBSR)
2517069|NCT02782767|Active Comparator|Epidural catheter infusion|epidural catheter in the thoracic vertebra level to provide local anesthetic infusion
2517076|NCT02782767|Experimental|Wound catheter infusion|A multiorificed wound infusion catheter kept within the incision site to provide continuous local anesthetic infusion
2517141|NCT02782429|Experimental|Ketamine|This group received ketamine in a dose 0.5 mg / in anesthesia, in addition to other drugs used for induction, which will be standardized.
2517142|NCT02782429|Placebo Comparator|Placebo|This group received the equivalent volume of saline, in addition to other drugs used for induction, which will be standardized.
2517165|NCT02781974|Experimental|Intervention|Intervention consists of strength and balance exercise in group sessions, twice a week for 12 weeks
2517170|NCT02781974|No Intervention|Control|"Participants allocated in the control group are instructed to live as usual"
2517236|NCT02781753|Experimental|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C.
2517244|NCT02781753|Active Comparator|Pegasys|Peginterferon 180 μg single dose S.C.
2517350|NCT02780908|Experimental|Hypoxia at rest and exercise|The participants will perform a resting test, hypoxia sensitivity test and a graded exercise test to voluntary exhaustion in normoxic condition ((HYPO; FiO2=0.120 corresponding to terrestrial altitude of approx. 4000 m)
2517354|NCT02780908|Placebo Comparator|Normoxia at rest and exercise|The participants will perform a resting test and a graded exercise test to voluntary exhaustion in normoxic condition ((NORM; fraction of inspired oxygen (FiO2)=0.209, placebo)
2517399|NCT02780414||Study Cohort|A group of at least 1,541 pregnant women with NO Pre-E diagnosis
2517407|NCT02780414||Positive Pre-E Control|A group of at least 250 pregnant women diagnosed with Pre-E
2517481|NCT02780037|Experimental|Prevention|Regulatory frame: prevention
2517482|NCT02780037|Experimental|Promotion|Regulatory frame: promotion
2517483|NCT02780037|Sham Comparator|Neutral|Regulatory frame: not implied
2517529|NCT02779712|Active Comparator|Remote Ischaemic Conditioning|Remote ischaemic conditioning (RIC group): 4 cycles of intermittent limb ischaemia - alternating 5 minutes inflation (20mmHg above systolic BP) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
2517533|NCT02779712|Sham Comparator|Control|Control: 4 cycles of alternating 5 minutes inflation (up to 30 mmHg) followed by 5 minutes deflation of a standard upper arm blood pressure cuff
2517567|NCT02779387|Experimental|GnRH-a|"patients treated with GnRH-a after surgery and Outpatient guidance~."
2517574|NCT02779387|No Intervention|non GnRH-a|patients treated with outpatient guidance only.
2517612|NCT02779114|Other|Control group|After 1:1:1 randomization patients in the control group receive their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during 12 months of the study.
2517616|NCT02779114|Other|Reduction group 1|Patients in reduction group 1 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
2517620|NCT02779114|Other|Reduction group 2|Patients in reduction group 2 receive exactly 50% of their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study. If they are still in remission they will discontinue their previous disease modifying therapy of conventional DMARD, biologicals and glucocorticoids during the first six months of the study.
2517757|NCT02778737|Experimental|ACT-based intervention|The Acceptance and Commitment Therapy + MTAU consists of an unpublished manual developed for the purposes of the project (Karekla et al., 2013). The 8, 90-min weekly group sessions focus in fostering psychological flexibility or the capacity to engage or change behaviors based on what a situation affords and an individual's goals, needs, and desires (Hayes et al., 2004). The ACT protocol involves helping patients to engage in values-based behaviors while remain in contact with pain, especially, when efforts to control or reduce it fail or contribute to suffering.
2516806|NCT02784561|Experimental|Busulfan/FLAG conditioning regimen|"All recipients in this arm received the conditioning regimen consisting of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor).~The conditioning regimen for peripheral blood stem cell transplantation consisted of busulfan (3.2 mg/kg/ day intravenously [i.v.], days -10 to -8), fludarabine (30 mg/m2, day -7 to -3), cytarabine (1.6 g/m2/day, days~-7 to -3), granulocyte colony-stimulating factor (5 ug/ kg, day -8 to -3). ATG (Thymoglobuline, rabbit) for haploidentical and matched unrelated donors transplantation recipients was used on 2.5 mg/kg/d from days -5 to -2)."
2516862|NCT02784093|Experimental|Exposure Group|Participants were allocated to receive 100 mL of Gastrograﬁn orally once daily for 6 consecutive days.
2516869|NCT02784093|Placebo Comparator|Control Group|Participants were allocated to receive enemas twice daily for 6 consecutive days.
2516895|NCT02783781||Cardiac surgery|All patients (planned and urgent) needed cardiac surgery, and agreed to participate
2516952|NCT02783482|Experimental|GC5107|GC5107 Immune globulin intravenous (human) solution, 10% liquid
3198177|NCT00868010|Placebo Comparator|2. placebo|Participants will receive treatment for 12 weeks with placebo pill. Treatment will be then be terminated and participants followed for another 12 weeks naturalistically.
3198178|NCT00868023|Experimental|1|CHF 1535 DPI : BDP/Formo 400/24 µg
2517090|NCT02782598|Experimental|CRT+NAVH|Surface ECG and pressure-volume loop recordings will be taken during the adjustment of programmable Cardiac Resynchronization Therapy and Negative Atrioventricular Hysteresis settings at the device implant procedure
2517135|NCT02782351|Experimental|CAR-T|In interventional studies, patients enrolled will receive autologous 2nd generation CAR-T cells, which contain a humanized single chain antibody sequence against CD19.
2517164|NCT02782091|Experimental|Schizophrenia Patient|
2517169|NCT02782091|Experimental|Control Subject|
2517215|NCT02781714|Experimental|Two-way SMS|Pre-programmed SMS messages by partner track will be delivered twice weekly to participants in participants' preferred languages from enrollment to 6 months postpartum. They will include a question soliciting a response from the participant(s). Interactive SMS communication will be responded to and managed by the study nurse at each site. Content themes will include: general support/encouragement, postpartum visit reminders, postpartum pregnancy risk and benefits of birth spacing, postpartum contraceptive options and side effects, family planning misconceptions, and couple communication.
2517217|NCT02781714|No Intervention|Control|The control arm will receive standard education and counseling provided in antenatal care and in postnatal care.
2517274|NCT02781441|Active Comparator|Control group|Patients will receive only the education brochure of GFM
2517275|NCT02781441|Experimental|General QPL group|Patients will receive the brochure and the newly developed QPL (general version)
2517277|NCT02781441|Experimental|Targeted QPL group|Patients will receive the brochure and the newly developed QPL (general version)
2517320|NCT02780947|Active Comparator|Prophylactic substrate ablation group|Prophylactic substrate ablation group will undergo substrate mapping and ventricular tachycardia substrate ablation
2517326|NCT02780947|No Intervention|Control group|Control group will undergo substrate mapping
2517396|NCT02780648|Experimental|Stereotactic Body Radiation|Patients will receive 5 fractions of 5 Gy or 6.6 Gy (dose depending upon whether or not they have received prior radiation therapy to the pancreatic region) delivered over a five-day period.
2517507|NCT02780011|Experimental|Alsertib and Brentuximab Vedotin|Brentuximab vedotin at a fixed dose of 1.8 mg/kg will be administered by intravenous infusion on day 1 of every 21-day cycle. MLN8237 at a dose of 60 mg will be orally administered daily in 2 divided doses (30 mg qAM, 30 mg qPM) from days 1 to 7 of each 21-day cycle. MLN8237 dose will be escalated in 20-mg increments to the maximum dose of 100 mg (Level 2) or de-escalated in a 20-mg decrement to the minimum dose of 40 mg (Level -1).
3198179|NCT00868023|Active Comparator|2|CHF 1535 pMDI HFA : BDP/Formo 400/24 µg
3198180|NCT00868023|Experimental|3|CHF 1535 DPI : BDP/Formo 100/6 µg
3198181|NCT00868023|Active Comparator|4|CHF 1535 pMDI HFA : BDP/Formo 100/6 µg
3198182|NCT00868023|Placebo Comparator|5|Placebo
3198183|NCT00868036||Patch testing|Patch testing on patients with chronic idiopathic dermatitis.
3198184|NCT00868049||1|Obese subjects
3198185|NCT00868049||2|Normal-weight subjects
3198186|NCT00868062|Experimental|1|
2517750|NCT02778334|No Intervention|patients who return home|
2517753|NCT02778334|Experimental|patients who continued hospitalization in rehabilitation|
2517787|NCT02778035|Experimental|60 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 60 min).
2517788|NCT02778035|Experimental|30 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 30 min).
2517790|NCT02778035|Experimental|0 min inter-session interval|Repetitive transcranial magnetic stimulation (rTMS) to bilateral dorsomedial prefrontal cortex, twice daily, 5 days per week for 4 weeks (Inter-session interval, 0 min).
2517814|NCT02777814|Experimental|Prophylactic Entecavir|Entecavir is prophylactically used from the time of chemotherapy initiation at the dose of 0.5 mg p.o daily
3198187|NCT00868075|Experimental|Chest Physiotherapy|Twice daily chest physiotherapy
3198188|NCT00868075|Experimental|Chest Physiotherapy + Exercise Program|Chest Physiotherapy + Exercise Program
3198189|NCT00868088|Active Comparator|ALA + PDT|Topical ALA will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
3198190|NCT00868088|Placebo Comparator|placebo + PDT|Topical placebo will be applied to the entire lip surface and allowed to incubate for 60 minutes plus or minus 30 minutes. Blue light at a wavelength of 405-420 nm will be used for treatment at a dose of 1000 seconds.
3198191|NCT00868114|Experimental|1|3 weekly injections of intratumoral TNFerade plus radiation and 3 weekly intratumoral injections of dendritic cell vaccine
3198192|NCT00868114|Experimental|2|Radiation Only with 3 weekly intratumoral injections of dendritic cell vaccine
3198193|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD|
3198194|NCT00868127|Experimental|Lapaquistat Acetate 100 mg QD + Added Therapy|
2516825|NCT02784132|Other|Study Arm A|Right eye examined first with video diversion then left eye examined without video diversion
2516827|NCT02784132|Other|Study Arm B|Right eye examined first without video diversion then left eye examined with video diversion
2516830|NCT02784132|Other|Study Arm C|Left eye examined first with video diversion then right eye examined without video diversion
2516834|NCT02784132|Other|Study Arm D|Left eye examined first without video diversion then right eye examined with video diversion
2516879|NCT02783924|Active Comparator|Cholecalciferol|Vitamin d (as a 20.000 IU capsule) will be given i a dose of 40.000 IU per week for two months
2516880|NCT02783924|Placebo Comparator|Placebo|two capsules (identical looking to the vitamin D capsules) will be given per week for two months
3165367|NCT00512265|Active Comparator|1|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
3165368|NCT00512265|Placebo Comparator|2|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
2516948|NCT02783456|Active Comparator|Noise and silence|Exposition of 80dB flight noise for 30 minutes and 30 minutes silence.
2516955|NCT02783456|Active Comparator|silence and noise|Exposition of 30 minutes silence.and 80dB flight noise for 30 minutes
2517037|NCT02783157|Experimental|Transcutaneous low-level vagal nerve stimulation (LLVNS)|n=100 patients will be randomized to transcutaneous low-level vagal nerve stimulation (LLVNS), via a clip applied to the ear. Stimulation will be delivered throughout the procedure.
2517038|NCT02783157|Sham Comparator|Sham LLVNS|n=100 patients will be randomized to sham LLVNS, with the clip applied but no stimulation delivered.
2517112|NCT02782416|No Intervention|Waiting for renal transplant_no screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination but no LTBI check
2517118|NCT02782416|Placebo Comparator|Not waiting for renal transplant|Dialysis patients who are not waiting for renal transplant
2517122|NCT02782416|Other|Status post renal transplant|patients who have received renal transplant
2517134|NCT02782416|Experimental|Waiting for renal transplant_ screening of LTBI|patients with renal failure and are waiting for renal transplant We do routine examination in addition to LTBI check
2517173|NCT02782078|Other|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
2517398|NCT02780479|Experimental|Dexamethasone|Dexamethasone arm: will receive second dose of oral Dexamethasone 0.6 mg/kg/dose max of 16 mg, 24 hour from the first dose given in emergency department.
2517406|NCT02780479|Active Comparator|Prednisone|Prednisone arm: will receive oral Prednisone 1mg/kg with max of 30 mg twice daily starting 24 hours after the Dexamethasone dose given in emergency department for 8 additional doses.
2517437|NCT02780102|Experimental|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR): 20 sixty-minute sessions of cognitive-motor rehabilitation
2517444|NCT02780102|Experimental|Ritalin|2 to 3 doses of 10 mg Ritalin tablets per day during 8 week.
2517453|NCT02780102|Active Comparator|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
2517495|NCT02779868|Experimental|Omega-3|Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
2517496|NCT02779868|Placebo Comparator|Olive oil|Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
2517548|NCT02779621|Experimental|Self-sampling|(Self-collecting a vaginal sample with a swab for HPV testing) Women in the experimental arm will have the option of vaginal self-sampling for HPV testing, in addition to the routine screening test. They can choose one of them.
2517550|NCT02779621|Active Comparator|Routine smear|(Collection of cervical sample for routine cervical screening) Women in the control arm will only receive the routine cervical screening invitation letter.
2517596|NCT02779218|Experimental|Sequence 1|"The patients will receive in order :~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises"
2517598|NCT02779218|Experimental|Sequence 2|"The patients will receive in order :~Paired Associative Stimulation + Motor Imagery exercises~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation"
2517599|NCT02779218|Experimental|Sequence 3|"The patients will receive in order :~Placebo Paired Associative Stimulation + Motor Imagery exercises~Paired Associative Stimulation~Paired Associative Stimulation + Motor Imagery exercises"
2517770|NCT02778295||Observation|Patients with Fabry disease or high-grade suspicion for Fabry disease
2518008|NCT02776878|Experimental|Dasatinib|Dasatinib is given orally 50 mg 2 times a day for the first week, if subject is tolerate, then increased to 70 mg 2 times a day. Dasatinib will be continued until unacceptable toxicity and progression.
2518139|NCT02776072||teriflunomide|Participants who initiated teriflunomide during the specified time period
3165369|NCT00512291|Experimental|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses
3165370|NCT00512304|Experimental|Preoperative chemoradiotherapy|
3165371|NCT00512304|Experimental|Postoperative chemoradiotherapy|
3165372|NCT00512317|Experimental|ganaxolone|active experimental drug
3165373|NCT00512356|Experimental|Investigational product group|"Anti-Adhesion Product was applied to the rectal stump and the incision line.~Like in the control group, surgical measures to prevent adhesions were also taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves."
3165374|NCT00512356|No Intervention|Control group|Only surgical measures to prevent adhesions were taken, e.g. using minimum traumatizing surgical technique, using powder-free gloves. No specific additional treatment was applied.
3165375|NCT00512382||A|Babies and small children 1-24 months
3165376|NCT00512382||B|Children 2-18 years old
3165377|NCT00512395|Active Comparator|1|epidural analgesia
3165378|NCT00512395|No Intervention|2|traditional analgesia with opioids
3165379|NCT00512408||A|
2516844|NCT02784249|Experimental|Goniotomy|Procedure: Goniotomy and trabecular excision in combination with planned cataract extraction via Phaco and PCIOL implant.
2516846|NCT02784249|Active Comparator|Trabecular Micro-Bypass Stent|Procedure: Device implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
2516894|NCT02783872||Loss of control|30 overweight or obese (BMI≥85th %ile) youth endorsing loss of control eating within the past 3 months
2516897|NCT02783872||Overweight control|30 overweight or obese controls without any history of loss of control eating
2516902|NCT02783872||Normal-weight control|15 normal-weight controls without any history of loss of control eating
2516942|NCT02783625|Experimental|Romidepsin + duvelisib|Romidepsin/duvelisib: Cycle 1 and beyond Days 1, 8, 15* Romidepsin IVPB over 4 hours, days 1, 8, 15 duvelisib by mouth twice daily, days 1-28
2516944|NCT02783625|Experimental|Bortezomib + duvelisib|Bortezomib/duvelisib: Cycle 1 and beyond Days 1, 4, 8, and 11* Bortezomib subcutaneous injection, days 1, 4, 8, 11** duvelisib by mouth twice daily, days 1-28
2517059|NCT02782871|No Intervention|Control|Manual ventilation with Mapleson C-circuit
2517061|NCT02782871|Experimental|Intervention|Pneupac VR1 portable ventilator
2517252|NCT02781701|Experimental|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
2517276|NCT02781246|Active Comparator|saline (Group A)|perineural ropivacaine
2517278|NCT02781246|Active Comparator|0.5 mcg/kg dexmedetomidine (Group B)|(perineural ropivacaine plus 0.5 mcg/kg dexmedetomidine),
2517279|NCT02781246|Active Comparator|1 mcg/kg dexmedetomidine (Group C)|(perineural ropivacaine plus 1 mcg/kg dexmedetomidine)
2517284|NCT02781246|Active Comparator|1.5 mcg/kg dexmedetomidine (Group D)|(perineural ropivacaine plus 1.5mcg/kg dexmedetomidine)
2517289|NCT02781246|Active Comparator|2 mcg/kg dexmedetomidine (Group E)|(perineural ropivacaine plus 2 mcg/kg dexmedetomidine)
2517336|NCT02780960|Experimental|HPV self-testing|Patients will perform HPV self-testing at home, prior to their follow-up visit. At the colposcopy visit, the doctor or nurse will also perform HPV testing. This procedure will be repeated at 6 and 12 months following LEEP.
2517395|NCT02780674|Active Comparator|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
2517403|NCT02780674|Placebo Comparator|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
2517427|NCT02780089||Prospective Patients|There will be 1,600 prospective patients recruited over a period of two years and followed-up for a planned minimum of three years. For the prospective cohort, patients will be recruited after the course of treatment has been decided by the physician and prior to the start of treatment.Prior advanced melanoma treatment information will be collected from patient charts for pre-treated patients. Patients will be followed for a minimum of 3 years from their study index date until death, withdrawal of consent, lost to follow-up/record, or end of study, whichever comes first. Study index date will be the date when first study therapy is initiated.
2517431|NCT02780089||Treatment Group No. 1|Immune checkpoint inhibitor patients who remain on an immune checkpoint inhibitor therapy. Defined as immune checkpoint inhibitor therapy patients who either remained on their initial (index) immune checkpoint inhibitor therapy or switched to another immune checkpoint inhibitor therapy during the study period. Patients in this group remained on an immune checkpoint inhibitor therapy and did not switch to a non-immune checkpoint inhibitor therapy anytime during the study period.
2517432|NCT02780089||Treatment Group No. 2|Immune checkpoint inhibitor patients who switched to a non-immune checkpoint inhibitor therapy. Defined as patients who switched from their index immune checkpoint inhibitor therapy to a non-immune checkpoint inhibitor therapy anytime during the study period.
2517433|NCT02780089||Treatment Group No. 3|Targeted therapy patients who remain on a targeted therapy. Defined as targeted therapy patients who either remained on their initial (index) targeted therapy or switched to another targeted therapy during the study period. Patients in this group remained on a targeted therapy and did not switch to a non-targeted therapy anytime during the study period.
2517435|NCT02780089||Treatment Group No. 4|Targeted therapy patients who switched to a non-targeted therapy. Defined as patients who switched from their index targeted therapy to a non-targeted therapy anytime during the study period.
2517441|NCT02780089||Treatment Group No. 5|Chemotherapy/other therapy patients who remain on a chemotherapy/other therapy. Defined as chemotherapy/other therapy patients who either remained on their initial (index) chemotherapy/other therapy or switched to another chemotherapy/other therapy during the study period. Patients in this group remained on a chemotherapy/other therapy and did not switch to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
2517451|NCT02780089||Treatment Group No. 6|Chemotherapy/other patients who switched to an immune checkpoint inhibitor therapy or targeted therapy. Defined as patients who switched from their index chemotherapy/other therapy to an immune checkpoint inhibitor therapy or targeted therapy anytime during the study period.
2517459|NCT02780089||Retrospective Patients|Retrospective cohort of 600 patients with unresectable or metastatic melanoma, receiving therapies other than immune checkpoint inhibitor or targeted therapies during the four year period prior to the release of ipilimumab (March 25, 2007 -March 24, 2011), will be identified. The data for these 600 retrospective patients will be used as a benchmark for treatment patterns and outcomes prior to the marketed availability of immune checkpoint inhibitors or targeted therapies.
2517541|NCT02779660|Experimental|RIPC-Group|After randomization patients will undergo 3 sessions of RIPC (Remote ischemic preconditioning) intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
2517542|NCT02779660|Placebo Comparator|Control-Group|After randomization patients will undergo 3 sessions of sham-intervention: I) on preoperative day, II) 1 h before and III) directly before the blood sample collection and invasive measurement of electrophysiological parameters.
2517582|NCT02779296|Experimental|2-Octyl Cyanoacrylate Glue|At the surgical site, a thin layer of cyanoacrylate glue will be applied over the sutures at the time of closure.
2516909|NCT02783755|Experimental|Mobile Health Pain Coping Skills Training (mPCST)|Mobile Health Pain Coping Skills Training (mPCST) protocol for breast cancer survivors with persistent pain that will produce significant improvements in pain, pain disability, fatigue, physical disability, and adherence to post-treatment lifestyle recommendations that are impacted by pain (i.e., daily activity, self-monitoring of symptoms).
2516970|NCT02783495|Experimental|Device: iPad|Patients with brain tumors receive an iPad with the ReMind app. The patients will use the app to train neurocognitive and compensatory skills for 3 hours per week over the course of 12 weeks (36 hours in total)
2517032|NCT02783222|Active Comparator|Arm B|Nab-paclitaxel 125 mg/mq weekly for 3 out of every 4 weeks
2517035|NCT02783222|Experimental|Arm A|Nab-paclitaxel 100 mg/mq weekly for 3 out of every 4 weeks
2517079|NCT02782637||Survey and interviews|"*part one* (quantitative)~Survey on:~A. prenatal counseling at the limits of viability, within three domains of interest:~organization of prenatal counseling~content of prenatal counseling~decision-making in prenatal counseling Domains used to evaluate current counseling and counseling preferences~B. decision-making at the limits of viability: evaluation of the made decision (decisional conflict and regret)~*part two* (qualitative)~Individual interviews (qualitative) to in-depth explore preferences in prenatal counseling~insight in the specific preferred content of prenatal counseling.~study influencing factors on preferences in the domains of organization and decision-making."
3165380|NCT00512408||B|
3165381|NCT00512421||A|navigation technique
3165382|NCT00512421||B|conservative surgery
3165383|NCT00512421||C|Historical control
2517159|NCT02781948||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
2517161|NCT02781948||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus
2517228|NCT02781805|Experimental|Alendronate|Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
2517283|NCT02781402|Experimental|4 weeks of Aerobic Training for normal BMI group|4 weeks of aerobic training on treadmill 3 times per week.
2517287|NCT02781402|Experimental|4 weeks of Aerobic Training for overweight BMI group|4 weeks of aerobic training on treadmill 3 times per week.
3165384|NCT00512434|Active Comparator|Control in arm fields|Standard treatment Intervention no'Osteosynthesis'
2517452|NCT02780323|Experimental|CELBESTA® and CELEBREX® placebo|CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks
2517456|NCT02780323|Active Comparator|CELEBREX®|CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks
2517586|NCT02779400|Experimental|Evaluation of the device perfomance|
2517621|NCT02779023|Experimental|ICHP + CBT-I|Participants in this arm will receive the usual care (ICHP program) plus 6 Cognitive-Behavior Therapy for Insomnia (CBT-I) treatment sessions. Four of the treatment sessions will be in person and two will be over the phone.
2517622|NCT02779023|No Intervention|ICHP Only|Participants in this arm will receive the usual care (ICHP program).
2517633|NCT02778828|Experimental|Patients with Multi-Resistant Tb|
2517704|NCT02778659|Experimental|Zolpidem Normoxia|Acute zolpidem intake at sea level
2517712|NCT02778659|Sham Comparator|Placebo Normoxia|Acute placebo intake at sea level
2517715|NCT02778659|Experimental|Zolpidem Hypoxia|Acute zolpidem intake at high altitude
2517728|NCT02778659|Sham Comparator|Placebo Hypoxia|Acute placebo intake at high altitude
2517801|NCT02778087|Experimental|TAU plus 30 minutes of BT.|Intervention: Subjects randomized to the 30 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently two times per day in addition to their treatment as usual.
2517802|NCT02778087|Experimental|TAU plus 60 minute of BT.|Intervention: Subjects randomized to the 60 minute intervention will perform the above 15 minute Mirror Box Therapy intervention independently four times per day in addition to their treatment as usual.
2517803|NCT02778087|Sham Comparator|TAU plus 30 minutes of sham BT.|Intervention: Subjects randomized to the control (sham) group will perform the above Sham Mirror Box Therapy intervention independently two times per day. The control group will be using a mirror box with an opaque surface as opposed to a reflective mirror.
3165385|NCT00512434|Experimental|IMOCA|Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
3165386|NCT00512460|Experimental|RTA 744|
2517874|NCT02777476|Experimental|procedure with B-Lite® Light Weight Breast Implant|
2517919|NCT02777320|Experimental|paracetamol group|First Group: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes. (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
2517920|NCT02777320|Experimental|Ibuprofen group|Second Group: 400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
3198195|NCT00868153||Group 1|
2549953|NCT02565212|Experimental|GROUP 1|montelukast sodium and mometasone
3165387|NCT00512473|Placebo Comparator|A|I.v. saline for 8 hours
3165388|NCT00512473|Experimental|GH|Growth hormone (0.5 mg s.c. at t = 0 hours)
3165389|NCT00512473|Experimental|Pegvisomant|Pegvisomant injection 30 mg 36 hours prior to the study
3165390|NCT00512486|Active Comparator|1|MEDI-563
3165391|NCT00512499|Placebo Comparator|Group 1|CONTROL GROUP (first year only; maximum 300 patients): patients seen by CHUS orthopedists at the Hotel-Dieu site, where no nurse coordinator is available for inclusion. This is random but not randomized.
3173795|NCT00616044|Experimental|CSA|For CSA, an 22-G catheter (Spinocath, B.Braun Melsungen, Germany) over a 27-G Quincke needle was used. After identification of the epidural space with a Crawford needle, the catheter with the spinal needle inside was advanced through the epidural space until the dural puncture was felt and CSF was seen in the catheter. The catheter was then fed over the needle into the intrathecal space. The spinal needle and the modified Tuohy needle were removed and a luer connector and a filter previously filled with the anesthetic solution were attached to the catheter.
2516951|NCT02783521|Experimental|Intervention|Includes changing eating behaviors, increasing physical activity, and attending regular in-person weight loss meetings for 12 weeks. To support additional weight loss/weight maintenance, participants will receive bi-weekly phone calls across a 12 week follow-up.
2516959|NCT02783521|Other|Wait List Control|Wait-list control participants will not receive any intervention for the first 12 weeks. After 12 weeks, participants will receive the weight loss intervention plus mHealth technology support.
2517016|NCT02783209|Other|Cataract surgery|Patient acts as his own control
2517080|NCT02782845|Experimental|Pegfilgrastim|Participants will receive CT or ICT for 6 cycles on Days 1-6, as per standard of care. Protocol does not specify any choice of CT or ICT drugs. Participants will receive pegfilgrastim at a fixed dose of 6 mg subcutaneously, 24 hours after the last dose of CT or ICT in each treatment cycle. CT or ICT cycles of 21 days, as per standard of care.
2517108|NCT02782260|Experimental|Active|"Dipyridamole eye drops 8.48 mg in 100ml~1 drop three times a day for 1 year"
2517109|NCT02782260|Placebo Comparator|Placebo|"Fluorescein in Active Vehicle~1 drop three times a day for 1 year"
2517242|NCT02781636|Experimental|Chronic Tibial Implant Arm|StimGuard Protect System (Chronic Tibial Nerve Stimulation) Implant Procedure. Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
3198196|NCT00868179|Experimental|Pradax|This is the only arm in the study and all will follow the same protocol for the study which is taking the pradax after total knee replacement
3198197|NCT00868205|Experimental|low coffee dose|3 cups of coffee daily for 8 weeks
2517335|NCT02780778|Experimental|Treatment group|Apatinib：500 mg，po，qd； Docetaxel：60mg/m²，vein input 1hour，every 3w
2517371|NCT02780518|Experimental|Airvo|All patients scheduled for elective microlaryngeal surgery under general anaesthesia and subglottic high frequency jet ventilation
3198198|NCT00868205|Experimental|high coffee dose|5 cups of coffee daily for eight weeks
2517520|NCT02779725|Active Comparator|Group 1 SCC/SSR|This arm includes self-care coaching (SCC) message during daily self-reported symptom severity report (SSR) calls to the automated system.
2517522|NCT02779725|Active Comparator|Group 2 NP/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. These alerts are monitored and follow-up care is given by a nurse practitioner.
2517526|NCT02779725|Active Comparator|Group 3 NP/DSS/SSR|Alert reports are generated during the patient's daily symptom severity monitoring call if alert thresholds are reached. Nurse practitioner follow-up calls utilize the evidenced based SCH decision support system (DSS) when symptoms exceed alert thresholds
2517531|NCT02779725|Active Comparator|Group 4 Full Intervention SSR/SCC/NP/DSS|Complete intervention with all components used in prior efficacy study (Symptom Severity Report (SSR)+Self Care Coaching (SCC) +Nurse Practitioner (NP) +Decision Support System (DSS))
2517532|NCT02779725|Active Comparator|Group 5 SSR/SCC/AT|Symptom severity reporting (SSR), automated self-care coaching (SCC) based on daily symptom reporting plus activity tracker (AT)
2517590|NCT02779244|Experimental|Early Weight Bearing + Cam boot|
2517593|NCT02779244|Active Comparator|Standard Treatment Cam boot|
2517636|NCT02778945|Experimental|Group D (Deep NMB group)|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
2517648|NCT02778945|Active Comparator|Group I (Intermediate NMB group)|Use NMB as conventional clinical usage Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
2517714|NCT02778516|Active Comparator|Sodium Restriction 1500mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2517721|NCT02778516|Active Comparator|Sodium Restriction 2400mg Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2517729|NCT02778516|No Intervention|Control Group|During the intervention phase of the study, participants will consume iso-caloric diets provided by the CTRC Nutrition Services Metabolic Kitchen at the UPHS. Diets will differ only in sodium content. To ensure accurate calculation of calorie and dietary sodium content for each individual, sodium content from all uneaten foods will be deducted from total daily dietary sodium intake. Total sodium intake will be calculated by CTRC Nutrition Staff and recorded on the data collection sheet after each meal and used in final analyses.
2517784|NCT02778178|Experimental|TAP block with ropivacaine|Bilateral single shot TAP block under ultrasound guidance: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
2517785|NCT02778178|Placebo Comparator|TAP block with placebo|Placebo administration: bilateral single shot TAP block under ultrasound guidance: 20 mL saline 0.9%, per side
3198199|NCT00868205|No Intervention|Control|Consumption of water instead of coffee daily for eight weeks
3198200|NCT00868257||CHARTA study cohort|Primarily 5- to 10-year-old Ugandan children with HIV or AIDS who are taking ART, with some 1- to 4-year-olds included because of recent trends in treating younger children
3198201|NCT00868270||Children with UTIs|
3198202|NCT00868283|Experimental|Cerebrolysin|
3198203|NCT00868283|Placebo Comparator|0.9% Saline Solution|
3198204|NCT00868335|Active Comparator|1|Anterior cervical discectomy, no disc prosthesis
3198205|NCT00868335|Experimental|2|Anterior cervical discectomy, with disc prosthesis
3198206|NCT00868361|Experimental|Slow and rapid N-acetyl transferase genotypes|
3198207|NCT00868387|Experimental|energy-restricted, CHO-restricted diet|Interventions: carbohydrate restriction of diet: 40% Frequency: daily Duration: 12 months
2516958|NCT02783508|Active Comparator|Inhaled Nitrous Oxide|Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, the parturient will be advised not to breath through the mask.
2517014|NCT02783131|Experimental|MedNav|Team getting taught to use mednav, and using mednav in simulation managing Post partum Haemorrhage.
2517022|NCT02783131|No Intervention|non MedNav|Team undergoing routine simulation training in Post Partum Haemorrhage.
2517054|NCT02782819|Placebo Comparator|Crystalloid|Isotonic crystalloid solution resuscitation
2517056|NCT02782819|Active Comparator|Crystalloid plus Colloid|Colloid solution resuscitation
2517114|NCT02782546|Experimental|Recipient|"Standard of care reduced conditioning regimen on Day -1~Graft cell infusion on Day 0~Post-transplant cyclophosphamide on Days +3 and +4~GvHD prophylaxis with tacrolimus and mycophenolate mofetil (MMF) will start on Day +5. MMF will continue till Day +35 and tacrolimus till Day +180 in the absence of GvHD~G-CSF will start on Day +7 and will continue until neutrophil engraftment as per institutional guidelines~The cytokine-induced memory like natural killer (CIML NK) cells will be infused on Day +7 without a filter or pump, slowly by gravity over at least 15 minutes.~ALT-803 will start approximately 4 hours after the CIML NK cell infusion. ALT-803 will be administered subcutaneously at a dose of 10 mcg/kg subcutaneously beginning Day +7 (on the day of CIML NK cell infusion) and then every 21 days for a total of 4 doses"
2517128|NCT02782546|Experimental|Donor|"Donors will receive subcutaneous G-CSF from Day -4 till Day 0 and undergo 20L apheresis per institutional guidelines.~Two consecutive days for collection are allowed in case of the target CD34+ cell dose being less than the target 4 x106/kg-bw from the first day of collection.~On Day +6 (one day before the planned CIML NK cell infusion), peripheral blood mononuclear cells will be collected by a single standard 20-L apheresis over 4-5 hours from the same haploidentical related donor that provided the HCT graft."
2517166|NCT02781896|Active Comparator|Right ventricular pacing|Rapid pacing during TAVI is provided by a temporary pacing catheter placed in the right ventricle. An additional venous vascular access is required.
2517171|NCT02781896|Experimental|Left ventricular pacing|Rapid pacing during TAVI is provided by the valve delivery guidewire inserted into the left ventricle using two alligator clamps. One clamp is attached directly to the skin at the femoral entry site, the other is attached to the body of the valve delivery guidewire. No additional venous vascular access is required.
2517206|NCT02781584|Experimental|SEL (Cohort 1)|SEL (1 x 18 mg tablet) for 12 weeks
2517207|NCT02781584|Experimental|Firsocostat (Cohort 2)|"Firsocostat (2 x 10 mg capsules) for 12 weeks~Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1."
2517209|NCT02781584|Experimental|Cilofexor (Cohort 3)|"Cilofexor (3 x 10 mg tablets) for 12 weeks~Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2."
2517210|NCT02781584|Experimental|SEL+ Cilofexor(Cohort 4)|"SEL (1 x 18 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3."
2517212|NCT02781584|Experimental|SEL + Firsocostat(Cohort 5)|"SEL (1 x 18 mg tablet) + firsocostat (1 x 20 mg tablet) for 12 weeks~Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4."
2517214|NCT02781584|Experimental|Firsocostat + Cilofexor(Cohort 6)|"Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5."
2517216|NCT02781584|Experimental|Firsocostat Cirrhotic (Cohort 7)|"Firsocostat (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
2517218|NCT02781584|Experimental|Cilofexor Cirrhotic (Cohort 8)|"Cilofexor (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)~Enrollment into Cohorts 7 and 8 will be randomized in parallel."
2517220|NCT02781584|Experimental|SEL + Firsocostat + Cilofexor (Cohort 9)|"SEL (1 x 18 mg tablet) + Firsocostat (1 x 20 mg tablet) + Cilofexor (1 x 30 mg tablet) for 12 weeks~Enrollment into Cohort 9 will begin upon completion of enrollment for Cohort 6."
2517222|NCT02781584|Experimental|Firsocostat + Fenofibrate 48 mg (Cohort 10)|Pre-treatment with fenofibrate 48 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 48 mg tablet) for 24 weeks
2517225|NCT02781584|Experimental|Firsocostat + Fenofibrate 145 mg (Cohort 11)|Pre-treatment with fenofibrate 145 mg from Day -14 to Day -1 and will be treated with firsocostat (1 x 20 mg tablet) + fenofibrate (1 x 145 mg tablet) for 24 weeks
2517229|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + Vascepa® 4 g (Cohort 12)|Pre-treatment with Vascepa® (2 x 1 g tablet twice daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + Vascepa® (2 x 1 g tablet twice daily) for 6 weeks
2517232|NCT02781584|Experimental|Firsocostat + Cilofexor 30 mg + fenofibrate 145 mg (Cohort 13)|Pre-treatment with fenofibrate (1 x 145 mg tablet once daily) from Day -14 to Day -1. Then, treatment with Firsocostat (1 x 20 mg tablet once daily) + Cilofexor (1 x 30 mg tablet once daily) + fenofibrate (1 x 145 mg tablet once daily) for 6 weeks
2517296|NCT02781168|Experimental|Use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
2517298|NCT02781168|Active Comparator|No use of earmuffs|No use of earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels.
2517314|NCT02780895|Experimental|Single Arm Study|stereotactic brain surgery of human stem cells (OK99)
3198208|NCT00868387|Active Comparator|energy-restricted, CHO-rich diet|Comparator: carbohydrate content of diet: > 55% Frequency: daily Duration: 12 months
2517375|NCT02780544|Active Comparator|incubator + sucrose|the infants get 2 eye examinations within 1 week in randomized order, one in the incubator (standard care) and one in skin-to-skin position with a parent (intervention group). Sucrose (0.2 ml) lingual will be given for pain relief according to standard care two minutes before either eye examination
2517678|NCT02778750||Stable Group|
3198209|NCT00868400|Experimental|1|High-carbohydrate
3198210|NCT00868400|Placebo Comparator|2|Placebo
3198211|NCT00868400|No Intervention|3|Control
3198212|NCT00868413|Active Comparator|A|FCR+ABT-263
3198213|NCT00868413|Active Comparator|B|BR+ABT-263
2516972|NCT02783560|Experimental|Sleep First|Families in this condition will receive a behavioral sleep intervention program (The Sleep Train Program) first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive the mealtime intervention (The Family Mealtimes Program).
2516973|NCT02783560|Active Comparator|Mealtimes First|Families in this active comparison condition will receive a behavioral treatment to promote positive family mealtimes first, prior to a parent training intervention for disruptive behavior. After the completion of the parent training program and several assessment periods, families will receive a behavioral sleep intervention (The Sleep Train Program).
2517008|NCT02783118|Experimental|Healthy sample, active intervention|Healthy participants will be testing a depression prevention app employing a self administered online CBT intervention, for 4 weeks.
2517011|NCT02783118|No Intervention|Healthy sample, delayed intervention|Healthy participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
2517020|NCT02783118|Experimental|Mild depression, active intervention|Mildly depressed participants will be testing a depression prevention app, employing a self administered online CBT intervention, for 4 weeks.
2517028|NCT02783118|No Intervention|Mild depression, delayed intervention|Mildly depressed participants will be put on a wait list for 4 weeks, after which access to the depression prevention app will be given.
2517078|NCT02782754|Experimental|Intracranial germinoma|"Four cycles of chemotherapy with carboplatin, etoposide, (+ bleomycin) and cyclophosphamide, etoposide, (+ bleomycin) regimen~Reduced dose of radiotherapy~Without seeding: 18 Gy to ventricle + 12.6 Gy to primary site~With seeding: craniospinal irradiation 18 Gy + 12.6 Gy to primary site"
3198214|NCT00868426|Experimental|1|Budesonide/Formoterol Batch 1
3198215|NCT00868426|Experimental|2|Budesonide/Formoterol Batch 2
3198216|NCT00868426|Experimental|3|Budesonide/Formoterol Batch 1 and charcoal
3198217|NCT00868465|Active Comparator|1|Artemether-lumefantrine; currently the first line treatment in Tanzania
3198218|NCT00868465|Experimental|2|Dihydroartemisinin-piperaquine, alternative ACT
2517271|NCT02781415|Experimental|Acupuncture|Traditional Acupuncture Session:Patients in this group will benefit from a 30 minutes acupuncture session made by an experimented physician.
2517273|NCT02781415|Active Comparator|Titrated Morphine|Morphine Titration:Patients will receive an intravenous titration of morphine by a qualified nurse.
2517311|NCT02781103|Experimental|Guided imagery plus active tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
2517312|NCT02781103|Sham Comparator|Guided imagery plus Sham tDCS|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will be turned off. The device will remain in place, however, for 20 minutes while the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
3198219|NCT00868504||examined by endoscopy|Patients, examined by endoscopy, being screened for GI tract tumors
3198220|NCT00868543|Active Comparator|Long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with long (150 cm) alimentary Roux limb
2517439|NCT02780362|Experimental|A Test|Test drug (Prodactariv)1 tablet contains 60 mg Daclatasvir
2517446|NCT02780362|Active Comparator|B Reference|Reference drug (Clatazev) 1 tablet contains 60 mg Daclatasvir
2517501|NCT02779907||Study Population|Children aged 4-6 years resident in Chikwawa District.
2517565|NCT02779582|Experimental|Progesterone|Oral micronized progesterone, 300 mg po daily, taken as three capsules daily before sleep for three months
2517573|NCT02779582|Placebo Comparator|Placebo|Placebo, each taken as three capsules daily before sleep for three months
2517646|NCT02778971||Qualifying participants|All consented participants referred by a dementia expert physician to receive an amyloid PET scan with [18F]Flutametamol and meeting eligibility criteria will have visual and semi-quantitative software aided scan interpretation, complete care partner questionnaires and providers will document diagnosis, diagnostic confidence, and management plan before and after the scan.
3198221|NCT00868543|Active Comparator|Very long limb|Hospitalized male or female subjects 18-65 years of age,obese with body mass index (BMI= kg/m²)>50.Patients without mental or nervous disorders interfering with adequate evaluation of one's health condition, who read the informed consent form and gave a written consent to participate in the study. Gastric bypass was performed with very long (250 cm) alimentary Roux limb
3198222|NCT00868556||1 episodic migraine sufferers|
2517816|NCT02777814|Active Comparator|Preemptive Entecavir|Entecavir is preemptively used from the time that hepatitis B virus DNA copies are more than 100 IU/ml at the dose of 0.5 mg p.o daily
3198223|NCT00868556||2 chronic migraine sufferers|
3198224|NCT00868556||3 non migraine sufferers (controls)|
3198225|NCT00868569|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemoembolision (TACE) using oxaliplatin, fudr, mmc and iodine. Then begin folfox4 again.
3198226|NCT00868569|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy (TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
3198227|NCT00868582||FDG-PET|F-18 fluorodeoxyglucose (FDG-PET)
3198228|NCT00868582||NaF-18 PET|F-18 sodum-fluoride (NaF-18 PET)
3198229|NCT00868595|Experimental|Dose escalation|"Cohort 1: BPX-101, 4 x 10*6 cells administered every other week for 6 cycles Cohort 2: BPX-101, 12.5 x 10*6 cells administered every other week for 6 cycles Cohort 3: BPX-101, 25 x 10*6 cells administered every other week for 6 cycles Cohort 4: BPX-101, 25 x 10*6 cells administered every 4 weeks for 3 cycles~At 24 hours after each vaccination, a single dose of the activating agent, AP1903 for Injection, will be administered at a fixed dose of 0.4 mg/kg via intravenous (IV) infusion over 2 hours."
3198230|NCT00868621||1|Control
3198231|NCT00868621||2|Overactive Bladder Patients
2516994|NCT02783300|Experimental|Part 2: Disease-Specific Expansion cohort|Participants with triple-negative breast cancer (TNBC), metastatic transitional cell carcinoma of the urinary system (mTCC), Grade IV anaplastic astrocytoma (glioblastoma multiforme [GBM]), non-Hodgkin's lymphoma (NHL), adenoid cystic carcinoma (ACC), hormone receptor-positive adenocarcinoma of the breast (ER+BC), human papillomavirus (HPV)-positive solid tumors of any histology, and p53-wild type non-small cell lung cancer (NSCLC) will be administered GSK3326595 at the recommended phase 2 dose (RP2D) as determined in Part 1.
2516995|NCT02783300|Experimental|Part 3: GSK3326595 in combination with pembrolizumab|Participants with selected solid tumors will be administered GSK3326595 in combination with pembrolizumab as part of this dose determination study.
2517055|NCT02782910|Experimental|SBAA+|Upon exceeding pre defined SBAA-threshold limits during the randomisation phase the treating physician is alerted (+) to this signal and required to contact the patient so as to assess the current mental status and collaboratively discuss the potential need for medical/psychiatric treatment with the patient.
2517057|NCT02782910|No Intervention|SBAA|Continuous monitoring will occur analogous to SBAA+. Exceeding the pre defined SBAA-threshold will not result in any action taken.
2517093|NCT02782559|Experimental|Sildenafil|Sildenafil 40mg oral tablet three times a day from randomization until delivery
2517096|NCT02782559|Placebo Comparator|Placebo|Matched to oral capsule of active treatment three times a day from randomization until delivery
2517127|NCT02782286|Active Comparator|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
2517137|NCT02782286|Active Comparator|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
2517176|NCT02782052|Experimental|Nebulized ipratropium bromide|Administration in a random order nebulized ipratropium bromide at V3 or V4 or V5
2517178|NCT02782052|Experimental|Nebulized combination ipratropium bromide with salbutamol|Administration in a random order combination Ipratropium bromide and Salbutamol at V3 or V4 or V5
2517179|NCT02782052|Placebo Comparator|Placebo|Administration in a random order placebo at V3 or V4 or V5
3198232|NCT00868621||3|Urinary Tract Infection
3198233|NCT00868634|Active Comparator|A|Capecitabine / Bevacizumab
3198234|NCT00868634|Experimental|B|Capecitabine / Bevacizumab / Vinorelbine
3198235|NCT00868647|Other|Radiofrequency Ablation|
3198236|NCT00868660|Experimental|ZP1848|Healthy Subjects or Crohn's Disease patients
2517400|NCT02780453|Experimental|Negative pressure dressing|Negative pressure dressing
2517408|NCT02780453|Active Comparator|Standard dressing|Standard wound dressing
2517424|NCT02780180|Experimental|QGC001|QGC001 from 50mg to 500mg capsule twice daily, for 28 days, oral use
2517428|NCT02780180|Placebo Comparator|Placebo|Placebo, capsule twice daily, for 28 days, oral use
2517518|NCT02779738|Experimental|Merestinib Fasted|Single dose of merestinib administered in fasted state in one of three periods
2517521|NCT02779738|Experimental|Merestinib Standard Meal|Single dose of merestinib administered with a standard meal in one of three periods
2517527|NCT02779738|Experimental|Merestinib High-Fat Meal|Single dose of merestinib administered with a high-fat meal in one of three periods
2517570|NCT02779426|Experimental|Text Message Intervention + Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution as well as daily text messages with information about atopic dermatitis and treatment reminders. 1-2 times/week they will receive a message asking if they were able to complete their treatments in the last day. They will respond with 1=yes, 2=no, 3= I have questions about the treatment. Those who respond with 3 will be sent the contact information for the office. No other communications will be sent through text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
2517578|NCT02779426|No Intervention|Standard Care|Enrolled patients and their caregivers who are randomized to this group will receive the usual standard of care for atopic dermatitis patients treated at this institution. They will not receive text messages. Caregivers will take two in-office surveys: one upon enrollment, and one follow-up survey at the follow-up visit. Patient EASI Score will be assessed by the pediatric dermatologist and initial and follow up exam.
2517610|NCT02779049||MAC-LD|patients with MAC-LD Do Blood examination
2517611|NCT02779049||Control|controls without NTM or tuberculosis infection Do Blood examination
2517615|NCT02779049||Tuberculosis infection|patients with tuberculosis infection which diagnosis by culture or typical pathology Do Blood examination
2517619|NCT02779049||MAC colonization|patients with MAC pulmonary colonization by American Thoracic Society guideline Do Blood examination
2517644|NCT02778815|Experimental|Kindness for Mums|An online self-help course designed to promote self-kindness and self-compassion in new mothers
2517650|NCT02778815|No Intervention|Wait list control|A waiting list control group, who will receive access to the online self-help intervention once the RCT is complete.
2517694|NCT02778685|Experimental|Treatment (letrozole, palbociclib, pembrolizumab)|Patients receive letrozole PO QD on days 1-28 and palbociclib PO QD for 3 weeks. Cycles with letrozole and palbociclib repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles with pembrolizumab repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2517798|NCT02777957||mPAP ≥ 25 mmHg|mean pulmonary artery pressure (mPAP) ≥ 25 mmHg (37 patients)
2517800|NCT02777957||mPAP < 25 mmHg|mean pulmonary artery pressure (mPAP) < 25 mmHg (28 patients).
3198237|NCT00868660|Placebo Comparator|Placebo|Healthy subjects or Crohn's Disease patients
3198238|NCT00868673|Active Comparator|Low fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities, defined as: Diabetes (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~They will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and rest energy (without exercise).~This group will be assigned to a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of less than 20 grams/day fructose diet levels.~Total Time of intervention 6 weeks for each patient"
2517060|NCT02782806|Experimental|Test group|All subjects are enrolled into the test group and receive Masimo Rad-67 Pulse Oximeter for measurement of hemoglobin.
2517101|NCT02782520|Active Comparator|Ringer Lactate|Ringer Lactate group
2517103|NCT02782520|Experimental|Hypertonic saline|Hypertonic saline group
2517110|NCT02782234|No Intervention|not contract management|monthly follow-up phone or family visit completed as regulation, and instruct them proper healthy training.
2517113|NCT02782234|Experimental|Contract management|In accordance with the contract content, researchers and participants should manage and maintain the liquid balance of the participants. Signed doctors and nurses should undergo the follow-up phone or family visit on time, instruct them proper healthy training, and provided necessary information data. By telephone, SMS, wechat, remind and urge the participants to take the lifestyle and behavior regulate in the contract. Participants should supervise and manage the fluid unbalance (Edema, hypertension, heart failure, and fluid imbalance of intake and output etc.), and feedback the Management and supervision to researchers according to contract.
3198239|NCT00868673|Active Comparator|Normal fructose arm|"Overweighted or obese previously healthy adults (with no other comorbidities; defined as: Diabetes Mellitus (DM1 or DM2), hypertension, chronic kidney disease (CKD), hepatic damage, dyslipidemia medication, anemia, malignancy or pregnancy), with a Body Mass Index (BMI) of >25 kilograms(weight)/ squared meters (height).~Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet (of 15% proteins, 30% lipids and 55% carbohydrates); calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise).~This group will receive a controlled fructose diet between 50 and 70 grams/day of fructose intake.~Total time of intervention:6 weeks for each patient"
3198240|NCT00868686|Active Comparator|Volar aluminum splint|
2517251|NCT02781506|Experimental|Nivolumab and SABR|Nivolumab alone: IV, administered per standard of care according to institutional guidelines at the discretion of the treating medical oncologist, until disease progression or unacceptable toxicity. SABR, dose variable, in 1-3 fractions.
2517280|NCT02781220||Qualifying participants|All consented IDEAS trial participants will have additional data collected: visual and semi-quantitative software aided amyloid PET scan interpretation, care partner questionnaires and documented provider diagnosis, diagnostic confidence, and management plan following the IMPACT design
2517316|NCT02781038|Experimental|Interventional|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given a teaching intervention and receive another attitude survey.
2517322|NCT02781038|Other|Control|All subjects will receive a baseline attitude survey. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will receive another attitude survey.
3198241|NCT00868686|Active Comparator|Dorsal aluminum splint|
3198242|NCT00868686|Active Comparator|Custom thermoplastic|
2517534|NCT02779985|Experimental|Lycium Barbarum mixed meal|Subjects will receive a high-fat mixed meal containing Lycium Barbarum once.
2517535|NCT02779985|Active Comparator|Control mixed meal|Subjects will receive a high-fat mixed meal without Lycium Barbarum as a control.
2517569|NCT02779335|Other|Enteral formula tube feeding|Enteral fed children, ages 1-13, with establish enteral feeding access
2517657|NCT02779101|Experimental|Single arm|pembrolizumab
2517695|NCT02778581|Active Comparator|Lipidic Blend 1|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
2517697|NCT02778581|Active Comparator|Lipidic Blend 2|Glass bottle with 45 ml of vegetal mixture oil. 1 bottle per day
2517698|NCT02778581|Placebo Comparator|Placebo|Glass bottle with 45 ml of Olive oil. 1 bottle per day
2517782|NCT02778139||youth smokers|
2517783|NCT02778139||non-smokers|
3198243|NCT00868725||possible oral cancer|Patients reporting for oral cavity examination with the possibility or certainty of oral lesions
3198244|NCT00868738|Active Comparator|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU), given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
3198245|NCT00868738|Placebo Comparator|Placebo|Subjects will be provided a placebo, given once daily as a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
3198246|NCT00868764|Experimental|Sancuso® patch|Subjects receiving 1 Sancuso® patch worn for 7 days
3198247|NCT00868777|Experimental|Sinus grafting using allogenic bone|
3198248|NCT00868816|Experimental|1|12 cycles of oxaliplatine based adjuvant chemotherapy
2518019|NCT02776540|Active Comparator|900 mg Clopidogrel|67 patients will receive 12 tablets clopidogrel ( each 75 mg) as total 900 mg each patient
2518027|NCT02776540|Active Comparator|600 mg Clopidogrel|67 patient will receive 8 tablets clopidogrel (each 75 mg) as total 600 mg each patient and 4 tablets placebo to receive 12 tablets as total
2518029|NCT02776540|Placebo Comparator|400 mg Aspirin|67 patients will receive 4 tablets Aspirin ( each 75 mg) as total 300 mg for each patient and 8 tablets placebo to receive 12 tablets as total
3198249|NCT00868816|Active Comparator|2|8 cycles of oxaliplatine based adjuvant chemotherapy
3198250|NCT00868829|Experimental|Firebird2|
3198251|NCT00868855|Experimental|1|Bradykinin
3198252|NCT00868881||1|Blood Pressure poorly controlled in the previous year and poorly controlled at the inclusion in the study
3198253|NCT00868881||2|Blood Pressure poorly controlled in the previous year and well controlled at the inclusion in the study.
3198254|NCT00868881||3|Blood Pressure well controlled in the previous year and well controlled at the inclusion in the study
3198255|NCT00868881||4|Blood Pressure well controlled in the previous year and poorly controlled at the inclusion in the study
3198256|NCT00868881||5|Blood Pressure well controlled in the previous year independently of the level of control at the inclusion.
3198257|NCT00868881||6|Blood Pressure poorly controlled in the previous year independently of the level of control at the inclusion.
3198258|NCT00868894|Experimental|1|
3198259|NCT00868894|Experimental|2|
3198260|NCT00868894|Placebo Comparator|3|
3198261|NCT00868894|Active Comparator|4|
3198262|NCT00868907|Experimental|Treatment A|35 mg risedronate DR tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
2517115|NCT02782312|Experimental|ICS+LABA Group|Seretide 250，inhalation，twice daily，one year
2517121|NCT02782312|Active Comparator|Control Group|routine therapy for one year
2517203|NCT02781766|Other|One arm: patients with severe haemophilia A on prophylaxis|Patients with severe haemophilia A (FVIII < 1 IU/dl), currently on prophylactic therapy , having the same prophylaxis regimen in the last six months, aged between 2 (with a body weight ≥12.5 kg ) and 45 years , with adequate venous access, having patient's diary or equivalent regularly completed and able to give informed consent
3198263|NCT00868907|Experimental|Treatment B|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
3198264|NCT00868907|Active Comparator|Treatment C|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
3198265|NCT00868920|Experimental|1|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached, the button will be transferred to the patient for Patient C0ntrolled Sedation."
2517349|NCT02780726|Experimental|ASP1517 Low Dose Group (ESA Untreated)|This group includes subjects who have not received Erythropoieses Stimulating Agents (ESAs). Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517353|NCT02780726|Experimental|ASP1517 High Dose Group (ESA Untreated)|This group includes subjects who have not received ESAs. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517355|NCT02780726|Experimental|ASP1517 ESAs Treated Group|This group includes subjects who have received ESAs. The treatment was converted from ESAs to study drug. Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517415|NCT02780375||Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
2517438|NCT02780128|Other|Molecular Analysis|All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. There is no drug given in this arm of the trial.
2517447|NCT02780128|Experimental|Group 1: ALK|"Qualified participants whose tumors show certain mutations in the anaplastic lymphoma kinase (ALK) pathway (based on genetic sequencing results) will receive a combination therapy of ceritinib and ribociclib, to be administered orally in 28-day cycles.~Two different doses of ceritinib and three different doses of ribociclib will be evaluated. Once the investigators have identified the highest safe dose of both drugs that can be given at the same time, additional participants will be enrolled in the study at this dose level.~It is possible that if starting at a lower dose, participants may take a higher dose once that dose has been deemed safe."
2517545|NCT02779673|Experimental|Test group|Subjects randomized to the test group consumed yoghurt drink containing 3.4g plant stanol as ester for 1 per day for a period of 4 weeks.
2517546|NCT02779673|Placebo Comparator|Placebo group|Subjects randomized to the placebo group consumed yoghurt drink without plant stanol as ester for 1 per day for a period of 4 weeks.
2517583|NCT02779270|Experimental|BAY987518|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
2517588|NCT02779270|Active Comparator|Sunscreen control|Subject will apply the test product to all sun exposed areas of face and body, wait for 15 minutes, then sunbathe for 30 minutes, exercise for 20 minutes, and then sunbathe for additional 30 minutes. Immediately after the second sunbathing, enter the pool and remain in the water for 20 minutes. Then repeat the sun and water exposure activities again.
2517637|NCT02778984|Active Comparator|standard face masks|The standard mask is used in usual care
2517656|NCT02778984|Experimental|QuadraLite face masks|This study will compare tightness of 2 face masks during preoxygenation and after induction of anesthesia with propofol, sufentanil and rocuronium. During preoxygenation, a 10 l.min-1 fresh gas flow and 8 cm H2O PEEP will be applied. After induction of anesthesia, patients will receive pressure-controlled ventilation (fresh gaz flow 3 L.min-1, pressure set to obtain a 7 ml.kg-1 ideal body weight, 10 cpm, peep 5 cm H2O).
2517741|NCT02778620||Aortic Valve Replacement|Post Anaesthetic Care Unit (PACU) patients treated with aortic valve replacement (AVR) are highly eligible for this study.These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
2517885|NCT02777398|Experimental|Trans-Quadrant Channel Surgery|Patients in the experimental arm (experimental group, i.e. microsurgery through trans-Quadrant channel pathway) will be operated using Quadrant channel system. All the tumor resection will be operated through the Quadrant channel with assistance of microsurgical techniques.
2517888|NCT02777398|Active Comparator|Conventional Open Surgery|Patients in the active comparator arm (control group, i.e. conventional open surgery) will be operated using the conventional open surgery. All the tumor resection will be operated directly with conventional procedures. More posterior structures of spine will be removed.
2518013|NCT02776696|Experimental|Advanced HybridClosed Loop System (AHCL)|Advanced Hybrid Closed Loop System (AHCL) - all subjects wearing the study system during 36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3 or 5 days in a camp setting and 21 days at home during segment 4.
2518015|NCT02776696|Experimental|Hybrid Closed Loop System (HCL)|"Hybrid Closed Loop System (HCL) - all subjects wearing the study system during:~36 hours in the clinic during segment 1or 2 days in a camp setting during segment 2 or 12 days in a camp setting during segment 3"
2518101|NCT02775773|Experimental|arm A (TXA)|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
2517211|NCT02781597|Active Comparator|Tranexamic acid|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients in group T will receive Inj Tranexamic acid in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h.
2517213|NCT02781597|Placebo Comparator|Placebo|All patients will receive basic resuscitative measures and standard treatment like assessment and management of Airway, breathing, circulation, antitussives, and blood products. Patients will receive 0.9% normal saline instead of Tranexamic acid.
2517317|NCT02780882|Experimental|Pasireotide|Each patient will be treated with pasireotide at an initial dose of 600 μg twice daily for one month. The dose will be further increased to 900 μg twice daily for month 2 and 3. After month 3, patients who continue to meet the inclusion and exclusion criteria will be entered into an additional 3 months of treatment.
2517402|NCT02780635|Experimental|App + Couples Coach Intervention|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse. Those assigned to this arm will also receive mailed materials that are designed to help increase positive communication strategies.
2517410|NCT02780635|Active Comparator|App Alone|Both members of the couple will receive a mobile app for PTSD: PTSD Coach for the Veteran and PTSD Family Coach for the partner/spouse.
2517592|NCT02779530|Experimental|Diclofenac|
2517594|NCT02779530|Placebo Comparator|Placebo|
2517813|NCT02778217|No Intervention|Uninterrupted single embryo culture|The same single medium is used throughout the 5-6 days of culture with no replenishment on day 3.
2517817|NCT02778217|Experimental|Interrupted single medium culture|The single step medium is renewed on Day 3 of embryo culture.
2517869|NCT02777710|Experimental|Combination Pexidartinib-Durvalumab|"DURVALUMAB (MEDI4736): therapeutic Class anti-PD-L1 mAb, given IV every 4 weeks at a fixed dose of 1500mg, AstraZeneca~PEXIDARTINIB (PLX3397): therapeutic Class Kinase inhibitor targeting CSF1-R, Flt3 and Kit. Administered daily as split dose regimen, orally. Five dose-levels possible in dose escalation part: 400mg 5 days on 2 days off (intermittent schedule), 400 mg, 600 mg, 800 mg or 1000 mg.~In this combination trial, Pexidartinib should be taken first and the Durvalumab IV infusion should be scheduled 1 hour after the Pexidartinib morning dose."
2517893|NCT02777346|Experimental|Absorbable|Suture material: Polyglactin 910 thread (Vicryl Rapide®, Ethicon Inc).
2517895|NCT02777346|Active Comparator|Non Absorbable|Suture material: Polypropylene thread (Prolene®, Ethicon Inc).
2517955|NCT02777190|Experimental|Oral misoprostol|oral misoprostol given 25 mcg every 2 hours
2517960|NCT02777190|Active Comparator|Vaginal misoprostol|vaginal misoprostol given 25 mcg every 4 hours
2517993|NCT02776761|Experimental|Hantaan Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2517996|NCT02776761|Experimental|Puumala Vaccine:|1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2517999|NCT02776761|Experimental|Hantaan/Puumala Vaccine|The HTNV and PUUV vaccine will be combined (equal volumes) before use: 1 mg in 0.5 mL per administration, 2 administrations per vaccination, total injected volume 1 mL per vaccination (for 2.0 mg dose)
2518063|NCT02776371|Experimental|Modified non-clarithromycin triple therapy|H.pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
2518064|NCT02776371|Active Comparator|Sequential therapy|H.pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
3173796|NCT00616044|Experimental|CSE|"CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany). The block consists of performing a spinal block via a 27-G spinal needle (Spinocan 125mm) introduced through an 18-G Tuohy needle (Perican 88mm) which was placed cranially directed in the epidural space. We did rotate the Tuohy needle between the spinal block and the insertion of the epidural catheter."
3173797|NCT00616057|Placebo Comparator|B|Maltodextrin, non digestible carbohydrate
2518363|NCT02774070|Other|Symptomatic atlantoaxial joint affection|Undergo plain X-ray and magnetic resonance imaging
2518365|NCT02774070|Other|Asymptomatic atlantoaxial joint aff.|Undergo plain X-ray and magnetic resonance imaging
2549955|NCT02565212|Active Comparator|Group 2|montelukast
3173798|NCT00616057|Experimental|A|fructans, non digestible carbohydrates fermented in the caeco-colon
3173799|NCT00616070|Experimental|1|Difluprednate
3173800|NCT00616070|Placebo Comparator|2|Vehicle
3173801|NCT00616083||1|Healthy breast fed infants
3173802|NCT00616096|Experimental|1|
3173803|NCT00616148|Placebo Comparator|Placebo|
3173804|NCT00616148|Experimental|YKP3089|
3173805|NCT00616161|Experimental|1|Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
3173806|NCT00616161|Experimental|2|Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
3173807|NCT00616161|Experimental|3|Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
3173808|NCT00616161|Placebo Comparator|4|Placebo iv infusion for six ours
3173809|NCT00616174|Other|1|Active warming with Bair Hugger blanket
3173810|NCT00616187|Active Comparator|interferon|
3173811|NCT00616187|Sham Comparator|untreated|
3173812|NCT00616265|No Intervention|B|Group B. Only Usual Control
3173813|NCT00616265|Experimental|A|Group A: Cpap treatment plus Usual control
3173814|NCT00616291|Experimental|Group I|MHC Class I binding peptide at 1000 mcg
3173815|NCT00616291|Experimental|Group II|MHC Class II binding peptide at 1000 mcg
3173816|NCT00616291|Experimental|Group III|Combination MHC Class I and II binding peptide at 1000 mcg each
3173817|NCT00616304|Active Comparator|A|L-arginine infusion
3173818|NCT00616304|Placebo Comparator|S|Normal saline infusion
3173819|NCT00616330|Experimental|1|clindamycin phosphate/butoconazole nitrate
3173820|NCT00616330|Active Comparator|2|clindamycin phosphate
3173821|NCT00616330|Active Comparator|3|butoconazole nitrate
2517281|NCT02781350|Placebo Comparator|High fat high carbohydrate (HFHC) meal|Subjects will consume a HFHC meal. HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
2517285|NCT02781350|Experimental|HFHC meal plus Fiber|HFHC meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%). Subjects will also receive FiberOne Original cereal 14 grams (half cup) before and after the HFHC meal. 35 ml of blood will be obtained at 1h ,2h,3h and 4 h and 5 ml at 15 min,30 min,45 min,75 min and 90 min . A total of 165 ml (11 tablespoon) blood will be collected.
2517323|NCT02780999|Experimental|Experimental group|It is a thumb orthotic that does not include wrist joint but includes the metacarpophalangeal joint.
2517329|NCT02780999|Active Comparator|Control group|It is a thumb orthotic that does not include wrist joint neither metacarpophalangeal joint.
2517379|NCT02780570|Active Comparator|GBS patients|Small Volume Plasma Exchange
2517383|NCT02780570|No Intervention|non-GBS|non-GBS patients with central venous catheter
2517455|NCT02780284|Experimental|Physical activity intervention|Observation phase of usual activity and an intervention phase of regular physical activity
2517530|NCT02779920|Experimental|Per oral pylorotomy|Patients with gastroparesis (significant prolongation of gastric emptying) not improved prokinetic and antiemetic treatments undergoing per oral pylorotomy
2517576|NCT02779413||Insulin degludec|
2517639|NCT02778789||Tocilizumab|Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
2517649|NCT02778789||TNF-alpha Inhibitor|Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
2517699|NCT02778529|Other|Upper Limb Assessment on ADLs|Bilateral assessment robots (BiAS) Evaluate upper limb kinematics of Stroke, Amputees, SCI, Cerebral Palsy and Health Subjects will be assessed as they complete unilateral and bilateral activities of daily living. Subjects will complete exercises in 1 session
2517818|NCT02778230|Experimental|Pea Fiber|Two fiber snacks fortified with 5 g/each of pea fiber (Best Pea Fiber 200) will be consumed each day for a period of two weeks.
2517820|NCT02778230|Other|Control|Two control snacks will be consumed each day for a period of two weeks.
2517899|NCT02777671|Experimental|Group A|Period 1 - BIA 2-093 + Gliclazide Period 2 - Gliclazide
2517900|NCT02777671|Experimental|Group B|Period 1 - Gliclazide Period 2 - BIA 2-093 + Gliclazide
2517941|NCT02777112|Placebo Comparator|Control|This group will receive generic information about depression and serve as control
2517943|NCT02777112|Experimental|e-mental health program|This group will receive the developed e-mental health program
2517945|NCT02777112|Experimental|e-mental health program and job coaching|This group will receive the developed e-mental health program plus interactive job coaching through telephone.
2517987|NCT02776891|Experimental|Gallium citrate|The patients will be organized into two cohorts. Cohort 1 will receive 10 mCi and will be imaged 4 and 6 hours post injection. Cohort 2 will receive 15 millicurie (mCi) and will be imaged 4 and 6 hours post injection. Cohort 2 will be imaged if the optimal protocol identified image quality from cohort 1 does not allow for the resolution of cancer lesions.
2518050|NCT02776462||Potential Traumatic Brain Injury|This group will consist of people admitted to the ER, Trauma Bay, or Neurosurgery for potential traumatic brain injury.
2518177|NCT02775578|Experimental|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
2518180|NCT02775578|Experimental|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
2518184|NCT02775578|Experimental|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
2518227|NCT02775136|Experimental|HS-1000 recording|Non-invasive measurements duration with HS-1000 device will be for at least 30 minutes and up to 1 hour of aggregate recording either continuously in the event the patient's clinical condition allows it or in separate recording iterations in the event patient's condition will not allow continuous recording. For each patient, there may be several monitoring intervals from three times a day and up to as long as the patient undergoes brain monitoring, per the discretion of the investigator, patient and/or family members.
2518345|NCT02774369|Experimental|Physical exercise|A 6-week individualised, aerobic intervention program elaborated by a kinesiologist following a complete assessment of the individual's physical condition.
2518346|NCT02774369|Active Comparator|Cognitive-behavioral therapy|A 6-week self-administered cognitive-behavioral therapy for insomnia composed of a 60-min video (DVD format) and 6 booklets.
2518394|NCT02773940|Experimental|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during the patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
2518514|NCT02773108||Hospitalized|Hospitalized psychiatric patients
2518518|NCT02773108||Daily hospital|
2518521|NCT02773108||Outpatients|
2518596|NCT02772744||Group 1: Easy to treat group|"Treatment naïve~Total serum bilirubin ≤ 1.2 mg/dl~Serum albumin ≥ 3.5 g/dl~International normalized ratio ≤ 1.2~Platelet count ≥ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir for 12 weeks."
2518600|NCT02772744||Group 2: Difficult to treat group|"Peg interferon treatment experienced.~Total serum bilirubin ≥ 1.2 mg/dl~Serum albumin ≤ 3.5 g/dl~International normalized ratio ≥ 1.2~Platelet count ≤ 150000 mm3~This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 12 weeks."
2518606|NCT02772744||Group 3: Sofosbuvir resistant cases|This is the group of patients who failed in previous Sofosbuvir treatment regiment. This group will be receiving Sofosbuvir + daclatasvir + ribavirin for 24 weeks.
2518771|NCT02771704|Experimental|Saline|Sterile physiological saline will be applied in vivo on carious dentine lesions
3198266|NCT00868920|Experimental|2|"The Graseby 3300 PCA pump will be loaded with a mixture of propofol 10 mg/cc containing 10 µg/cc remifentanil. The loading and demand doses will be individualized based on patient weight, height, age, and gender.~The initial loading phase of sedation will be performed by the anesthesiologist to permit estimation of patient sensitivity. Following the initial loading dose, a series of button presses will be issued by the anesthesiologist to achieve a state of moderate sedation, as determined by a decrease in BIS to the range of 75-80. Once this state has been reached,the anesthesiologist will control the sedation."
3198267|NCT00868933|Active Comparator|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
3198268|NCT00868933|Placebo Comparator|Simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
2517348|NCT02780752|Active Comparator|Oral hymecromone 400mg po three times per day|Participants will be administered oral hymecromone 400mg po three times per day (1200 mg)
2517352|NCT02780752|Active Comparator|Oral hymecromone 800 mg po three times per day (2400 mg)|Participants will be be administered oral hymecromone 800 mg po three times per day (2400 mg)
2517356|NCT02780752|Active Comparator|Oral hymecromone 1200 mg three times per day (3600 mg)|Participants will be administered oral hymecromone 1200 mg three times per day (3600 mg)
2517397|NCT02780440||Control Group|Subjects will participate in standard occupational therapy rehabilitation protocol plus a traditional home based exercise program.
2517405|NCT02780440||Experimental Group 1|Subjects will participate in standard rehabilitation protocol plus unimanual home based mirror therapy program
2517412|NCT02780440||Experimental Group 2|Subjects will participate in standard rehabilitation protocol plus bimanual home based mirror therapy program.
2517425|NCT02780141|Experimental|ASP1517 Low dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517429|NCT02780141|Experimental|ASP1517 High dose Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517537|NCT02779686||ARMD Free|Patient free of ARMD on clinical examination
2517540|NCT02779686||ARMD Positive|Patients with evidence of ARMD on clinical examination
2517571|NCT02779322|Active Comparator|Minigastric bypass|Intervention(s): The patient will have done a Laparoscopic one anastomosis gastric bypass (minigastric bypass) at the time of the surgical procedure.
2517577|NCT02779322|Active Comparator|Gastric bypass|The patient will have a Laparoscopic Roux-en-Y gastric bypass at the time of the surgical procedure
2517742|NCT02778646||MINAP Audit|Individuals within this group are those that have been admitted into a United Kingdom (UK) based hospital following a major cardiac event. The FH status of individuals within this group is unknown.
2517747|NCT02778646||BCIS Audit|Individuals within this group are those who have undergone percutaneous coronary intervention in the United Kingdom (UK). The FH status of individuals within this group is unknown.
3198269|NCT00868946|Experimental|Treatment with IND Ribavirin|All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with IND Virazole (Ribavirin) for 7 days with multiple dosing regime based on weight and dosage day.
3198270|NCT00868972|Active Comparator|Embolic protection|Percutaneous renal stenting using a distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
3198271|NCT00868972|Sham Comparator|No embolic protection|Percutaneous renal stenting intervention without embolic protection
2517922|NCT02777645||Study group|Study group(n=50) included CP children with chewing disorder. Growth, feeding evaluation will be done.
2517923|NCT02777645||Control group|Control group(n=35)= healthy children without chewing disorder Growth, feeding evaluation will be done.
2518120|NCT02776397|Active Comparator|Hp 2-2 Vitamin E|The Haptoglobin 2-2 group randomised to Vitamin E
2518122|NCT02776397|Placebo Comparator|Hp 2-2 Placebo|The Haptoglobin 2-2 group randomised to placebo
2518125|NCT02776397|Active Comparator|Non Hp 2-2 Vitamin E|The Non Haptoglobin 2-2 group randomised to Vitamin E
2518132|NCT02776397|Placebo Comparator|Non Hp 2-2 Placebo|The Non Haptoglobin 2-2 group randomised to placebo
2518220|NCT02775383||Longitudinal|Participants with MDS, MDS/MPN overlap disorder, AML <30% blasts without core binding factor or acute promyelocytic leukemia, ICUS, or at risk based on select karyotypic or genetic abnormalities
2518222|NCT02775383||Cross-sectional|Participants who do not have MDS, MDS/MPN overlap disorder, or ICUS and have the baseline visit only
2518639|NCT02771964||All patients|All patients receive both types of quality of life assessment, thus serving as their own controls.
2518703|NCT02771834||Experimental|women with osteoporosis
2518707|NCT02771834||Control|women without osteoporosis
2518730|NCT02771496||Patients with OCD|Patients with diagnosis of OCD as confirmed by x-ray or MRI. Surveys collected from patients at 2 years, 5 years, 10 years, and 25 years.
2518790|NCT02771314|Experimental|AZD9291|AZD9291
2518802|NCT02770963|Experimental|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~Huatuo Brand needle (0.3*75 mm) will be used for BL25 and Huatuo Brand needle (0.3*40mm) will be used for BL23, BL40 and BL57."
2518803|NCT02770963|Sham Comparator|Sham acupuncture|The acupoints will be the same as the acupuncture group. Specially designed sham needles (0.3*25 mm) will be used . The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
2518872|NCT02770872||Obese, normal|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2. Observation of SAA on apoB containing lipoproteins
2518881|NCT02770872||Obese, MetS|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2, blood pressure above 135/80, HDL less than 40 mg/dl, triglycerides greater the 150 mg/dl and fasting blood glucose greater than 100 mg/dl but less than 126 mg/dl. Observation of SAA on apoB containing lipoproteins
2518883|NCT02770872||Obese, diabetic|Approximately 25 subjects aged 50-75 with BMI's between 27-45 kg/m2 and physician diagnosed diabetes mellitis. Observation of SAA on apoB containing lipoproteins
2519018|NCT02769650|Active Comparator|Stress-MRI + Optimal medicamentous treatment|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Optimal medicamentous treatment
2517337|NCT02780921|Other|control group|The control group will be treated according to conventional care; will not receive any specific intervention before surgery except nutritional support and physiotherapy at the surgeon's discretion
2517382|NCT02780492||Ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
2517385|NCT02780492||Non-ambulant patients|A set of assessment tools (blood analyses, functional, respiratory, quality of life questionnaires, Dexa scan, MRI) will be performed.
2517386|NCT02780492||Healthy volunteers and Disease controls|A set of assessment tools (upper limb function tests, MRI, blood analyses) will be performed
2517445|NCT02780206|Experimental|obese|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one approx 2 weeks of diet, one post-diet): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2517536|NCT02779959|Experimental|Buccal Prochlorperazine|Experimental arm of two buccally absorbable prochlorperazine tablets (6 mg) plus 2 cc IV saline
2517538|NCT02779959|Active Comparator|Intravenous Prochlorperazine|Accepted Standard of care receiving 10 mg (2 cc) of intravenous prochlorperazine plus two saccharin absorbable placebo tablets.
2517555|NCT02779348|Experimental|Nebicapone plus warfarin|BIA 3-202 200 mg tid + Warfarin 25 mg
2517557|NCT02779348|Experimental|Warfarin|Warfarin 25 mg
2517668|NCT02779153|Experimental|Acthar low dose (40 U)|
2517673|NCT02779153|Experimental|Acthar high dose (80 U)|
2517706|NCT02778464||Group A: Female IBD and RA (non-pregnant)|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2517719|NCT02778464||Group B: Female IBD|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All diaries and stool sample consumables for disease activity will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2517726|NCT02778464||Group C: Female - Healthy Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2517731|NCT02778464||Group D: Female - RA Pregnant|This group will be asked to provide three blood samples, one in each trimester. Stool samples are expected to average 8-10 per participant. All stool sample consumables will be issued at the initial visit. Bloods will be obtained at a hospital visit. Stool samples due between hospital visits will be obtained according to protocol to minimise pre-analytical variance.
2517789|NCT02778165|No Intervention|Usual Care|Patients receiving usual care are typically referred to CR at the time of discharge from the acute care center via paper or electronic systematic referral (completed by a physician or nurse practitioner). Additionally, a conversation with the patient regarding CR by a healthcare provider may occur, however this communication is not always a consistent occurrence. Once referred, patients will await contact from a CR program in their region/area and if actual program enrollment occurs, this usually happens between 8 to 10 weeks post discharge.
2517791|NCT02778165|Experimental|MyCaRe Android Application|The MyCaRe mobile application (education and symptom monitoring which includes pain, mood scales, wound monitoring) and Fitbit accelerometer (steps walked, distance) will be provided to patients receiving intervention group allocation for the initial 6 to 8 weeks recovery post cardiac surgery. The patients will be provided a temporary loan mobile device loaded with MyCaRe and Fitbit Flex before leaving hospital. They will be asked to input data (pain, mood, wounds, activity) daily if possible in first 2 weeks and once weekly thereafter until 6 to 8 weeks or until entry to a cardiac rehabilitation program.
2517827|NCT02777866|Experimental|1: Bupivacaine 0.5%|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
2517833|NCT02777866|Placebo Comparator|2: 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs, who will be infiltrated in the total thickness of the abdominal wall with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound.
2517925|NCT02777294|Experimental|Online intervention|Therapist-facilitated, cognitive behavioral therapy
2517928|NCT02777294|Active Comparator|Psycho-educational website|Self-help, psycho-educational website
2517956|NCT02777034|Experimental|Enhanced Recovery|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
2517961|NCT02777034|Other|Unenhanced Recovery|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
2517988|NCT02776709||Bile duct Stricture|Patients referred for the evaluation of indeterminate strictures.
2517990|NCT02776709||Common bile duct Stones|Patients referred for the removal of difficult stones.
2518107|NCT02775773|Active Comparator|arm B (OXY)|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
2517341|NCT02780986|No Intervention|Heterosexual men control group|There will be a simultaneous programme on healthy eating and physical activity at the control site at Tanjong Pagar. Health promoters will go around Tanjong Pagar and distribute pamphlets and brochures developed by the HPB on healthy eating and physical activity to the heterosexual men who step into or out of the EEs there. These health promoters have been trained to give simple health advice on healthy eating and physical activity if the heterosexual men wish to find out more information.
2517404|NCT02780505|Active Comparator|vitamin c|vitamin C supplement orally up to 250 mg per day for 6 weeks was prescribed. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study.
2517409|NCT02780505|Placebo Comparator|placebo|ُPlacebo prescribed to Group B. Plasma levels of vitamin C and other clinical parameters including hemoglobin, ferritin, TIBC, iron and CRP were measured at the beginning and end of the study
2517465|NCT02780154|Experimental|1600 7G8 PfSPZ|N= 7-9 participants will receive 1600 7G8 PfSPZ DVI in a volume of 500mcL
2517468|NCT02780154|Experimental|3200 7G8 PfSPZ|N= 9 participants will receive 3200 7G8 PfSPZ DVI in a volume of 500mcL
2517471|NCT02780154|Experimental|3200 NF54 PfSPZ|N= 5-6 participants will receive 3200 NF54 PfSPZ DVI in a volume of 500mcL
2517474|NCT02780154|Experimental|4800 7G8 PfSPZ|N= 2-3 participants will receive 4800 7G8 PfSPZ DVI in a volume of 500mcL
2517475|NCT02780154|Experimental|800 7G8 PfSPZ|N= 7-9 participants will receive 800 7G8 PfSPZ DVI in a volume of 500mcL
2517525|NCT02779777|Experimental|Tipifarnib, Oral|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
2517630|NCT02779452||GDM newborns|Newborns from gestational diabetes mellitus pregnancy
2517635|NCT02779452||No GDM newborns|Newborn from a normal pregnancy
2517780|NCT02778126|Experimental|[¹⁴C]Prexasertib|170 milligrams (mg) of prexasertib containing approximately 50 μCi [¹⁴C] prexasertib radiotracer administered intravenously (IV) as a 1 hour continuous IV infusion.
2517781|NCT02778126|Experimental|Prexasertib|"105 milligrams per square meter (mg/m²) of prexasertib administered IV as a 1 hour continuous IV infusion once every 14 days (14 day cycles). Treatment may continue until discontinuation criteria are met.~Treatment for this arm was administered after ¹⁴C administration (¹⁴C was administered during first phase of the study)"
2517811|NCT02777892||pulmonary valve replacement|SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
2517873|NCT02777723|Experimental|CKD-350|Xenobella
2517875|NCT02777723|Active Comparator|Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
2517927|NCT02777281|Other|Shoulder pain and SCI|Manual wheelchair users with SCI
2517929|NCT02777281|Other|Shoulder pain and able bodies|No SCI or wheelchair use but presence of shoulder pain
2517977|NCT02776982|Other|Research procedures|Participants enrolled in study will have confocal endomicroscopy, research biopsies, mucosal impedance, and Bravo ambulatory pH capsule performed at the time of clinically indicated endoscopy.
2517998|NCT02776592|Experimental|Experimental|A cow's milk-based formula with added nutrients
2518000|NCT02776592|Active Comparator|Control|A cow's milk-based formula
2518035|NCT02776410|Experimental|Intervention group|Group receiving tailored messages promoting sustainable and healthy eating through an mobile-application together with six principles of sustainable healthy eating that will be included in the mobile application,
2518037|NCT02776410|No Intervention|Control group|Group who will not download the mobile application
2518042|NCT02776215|Experimental|Pharmacokinetic Dosing|Single-dose pharmacokinetics of tasimelteon
2518110|NCT02776046|Experimental|High FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.8 FiO2 and individualized CPAP"
2518116|NCT02776046|Active Comparator|Conventional FiO2|"Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.3. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.~Postoperatively 3h with 0.3 FiO2 and individualized CPAP"
2518185|NCT02775513||Mutation|Patients with functional mutation in ion channels
2518188|NCT02775513||Control|Matched control
2518240|NCT02775201|Active Comparator|Plantaris release under ultrasound guidance|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris released under ultrasound guidance by a consultant radiologist
2518243|NCT02775201|Active Comparator|Plantaris excision surgically|Patients diagnosed with non-insertional Achilles tendinopathy will have plantaris excised in surgery by a consultant orthopaedic surgeon
3198272|NCT00868985|Experimental|PEG 3350 plus electrolytes|Patients were dosed with PEG 3350 with electrolytes
3198273|NCT00868985|Experimental|PEG 3350 without electrolytes|Patients were dosed with PEG 3350 without electrolytes
2518341|NCT02774200|Experimental|test group|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
2518382|NCT02773992||The IoT group|
2518386|NCT02773992||The routine management group|
2518440|NCT02773693|Active Comparator|CPT|Cognitive Processing Therapy-cognitive only version (typically labeled CPT-C, but labeled CPT in this grant for simplicity) is a type of Cognitive Therapy addressing daytime symptoms of PTSD. This arm will have 12 twice-weekly sessions, followed by 6 weekly sessions.
2518441|NCT02773693|Active Comparator|CBTin+CPT|Cognitive Behavioral Therapy of Insomnia and nightmares (CBTin) will be used to address nighttime symptoms of PTSD during 6 weekly sessions, followed by 12 twice-weekly sessions of CPT.
2518442|NCT02773693|Active Comparator|CPT+CBTin|12 twice-weekly sessions of CPT followed by 6 sessions of CBTin.
2518540|NCT02773030|Experimental|Cohort A: CC-220 Monotherapy - Part 1|Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle
2549957|NCT02565212|Active Comparator|Group 3|mometasone furoate
3198274|NCT00869011|Experimental|1|Exercise
3198275|NCT00869011|No Intervention|2|No structured exercise program
3198276|NCT00869037|Active Comparator|Periarticluar Multimodal Technique|
3198277|NCT00869037|Active Comparator|CFNB plus Posterior Capsular Injection|
2517626|NCT02778854||cohort 1|Participants are recruited for diagnostic test
2517628|NCT02778854||cohort 2|participants are recruited for follow-up
2517685|NCT02778711|Experimental|Cosentyx|secukinumab (anti-IL-17)
2517709|NCT02778386|Experimental|Cohort 1|6 subjects, male & female will receive one dose each of 200 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
2517716|NCT02778386|Experimental|Cohort 2|6 subjects, male & female will receive one dose each of 400 mg of N-Methanocarbathymidine orally in capsules. Each subject will be evaluated for any clinical signs of any toxicity.
2517727|NCT02778386|Experimental|Cohort 3|8 subjects, males and females, 6 subjects will receive one dose each 800 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
2517732|NCT02778386|Experimental|Cohort 4|8 subjects, males and females, 6 subjects will receive one dose each 1200 mg of N-Methanocarbathymidine orally in capsules and 2 will receive a placebo capsule. Each subject will be evaluated for any clinical signs of any toxicity.
2517890|NCT02777684||knee osteoarthritis|
3198278|NCT00869063|Experimental|Diclofenac Sodium Patch|
3198279|NCT00869063|Placebo Comparator|Placebo Patch|
2518130|NCT02775929|Other|PrEP as a bridge to ART|FTC-TDF PrEP for HIV uninfected partners and ART for HIV infected partners
3198280|NCT00869076|Experimental|Pharmacist Management|In this arm the Pharmacist managed the Diabetes in collaboration with the primary care physician
3198281|NCT00869076|Active Comparator|Usual Care|The patient was managed by the primary care physician
2518294|NCT02774564|Experimental|Nebicapone 50 mg|1 tablet of 50 mg plus 3 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2518297|NCT02774564|Experimental|Nebicapone 100 mg|2 tablets of 50 mg plus 2 tablets of placebo concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2518298|NCT02774564|Experimental|Nebicapone 200 mg|4 tablets of 50 mg concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
2518300|NCT02774564|Placebo Comparator|Placebo|4 tablets concomitantly with 1 tablet of Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg)
3198282|NCT00869102|Experimental|GLP-1|
3198283|NCT00869115|Experimental|1|TREATMENT 0.5 μg/kg/min
2518667|NCT02771951|Experimental|Special Intervention|Study participants randomized to receive Special Intervention receive a series of 7 group classes taught by trained clinic health educators; a series of phone calls; clinical visits with a mid-level provider; and a series of 6 booster group classes over 1 year.
2518669|NCT02771951|Placebo Comparator|Usual Care|Study participants randomized to receive Usual Care receive up to 2 visits with a usual care health educator over 1 year.
2518754|NCT02771704|Experimental|Silver diamine fluoride|Intervention: Silver diamine fluoride will be applied in vivo on carious dentine lesions
2518759|NCT02771704|Experimental|Potassium iodide|Potassium iodide will be applied in vivo on carious dentine lesions.
2518763|NCT02771704|Experimental|Chlorhexidine|Chlorhexidine will be applied in vivo on carious dentine lesions
2518767|NCT02771704|Experimental|Silver diamine fluoride+Potassium iodide|Silver diamine fluoride and potassium iodide mixture will be applied in vivo on carious dentine lesions
3198284|NCT00869115|Experimental|2|TREATMENT 1.0 μg/kg/min
3198285|NCT00869115|Experimental|3|TREATMENT 1.5 μg/kg/min
3198286|NCT00869115|Placebo Comparator|4|PLACEBO
3198287|NCT00869154|Active Comparator|Primary care follow up|Multidisciplinary examination and follow up by the family doctor.
3198288|NCT00869154|Experimental|Multidisciplinary follow up|Multidisciplinary examination and follow up by a multidisciplinary outpatient team.
3198289|NCT00869180|Experimental|Diclofenac Sodium Patch|
3198290|NCT00869180|Placebo Comparator|Topical Placebo Patch|
3198291|NCT00869193|Active Comparator|Grape seed|Grape seed extract
3198292|NCT00869193|Placebo Comparator|Placebo|Microcrystalline cellulose
3198293|NCT00869219|Active Comparator|Nevanac|
3198294|NCT00869219|Active Comparator|Acular LS|
3198295|NCT00869232|Experimental|MEL--VTD-PACE|Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide and Etoposide
3198296|NCT00869245|Experimental|1|Cardiac MRI Protocol. Patients will be transferred to the observation unit and undergo a stress cardiac MRI evaluation.
3198297|NCT00869245|Experimental|2|Conventional care cardiac testing. Patients will be transferred to the observation unit and undergo cardiac testing as determined by their treating physician.
3198298|NCT00869271|Experimental|1|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again.
3198299|NCT00869271|Active Comparator|2|folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle.
3198300|NCT00869297|Active Comparator|Control|
3198301|NCT00869297|Experimental|Intervention|These patients receive fluid boluses based on measurements from the FloTrac
3198302|NCT00869310|Experimental|1|Dexamethasone plus Aprepitant
3198303|NCT00869310|Active Comparator|2|dexamethasone plus metoclopramide
3198304|NCT00869336|Experimental|Luliconazole Cream 1% - 2 wks|Daily treatment with Luliconazole Cream 1% for 2 weeks
3198305|NCT00869336|Experimental|Luliconazole Cream 1% - 4 wks|Daily treatment with Luliconazole Cream 1% for 4 weeks
3198306|NCT00869336|Placebo Comparator|Placebo Comparator - 2 wks|Daily treatment with Vehicle Cream for 2 weeks
3198307|NCT00869336|Placebo Comparator|Placebo Comparator - 4 wks|Daily treatment with Vehicle Cream for 4 weeks
3198308|NCT00869388|Experimental|Arm 1|rBBX-01 1.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3198309|NCT00869388|Experimental|Arm 2|rBBX-01 2.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
2517393|NCT02780596|Experimental|Items4;5|Caregiver is randomly assigned to receive screening items 4 and 5. Item 4: Does you think CHILD NAME has a sleep problem? Item 5: Do you have any concerns about CHILD NAME's sleep?
2517478|NCT02780063|Experimental|Lenstar Biometry|Lenstar biometry will be performed on each eye prior to dilation. Subjects eyes will be dilated and subject will wait 20 minutes. Lenstar biometry will be performed after the 20 wait time.
2517516|NCT02779829|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2517696|NCT02778633||Sepsis|Patients diagnosed with septic shock, admitted to the intensive care unit, with a good left ventricular ejection fraction without significant co-morbidity are highly eligible for this study. Patients must be equipped with a pulse-contour cardiac output (PICCO)-system with a central venous catheter which will be applied by the intensivist on admission.Patients will be subsequently connected to the hemodynamic monitoring device Navigator™. In those patients with clinical signs of inadequate tissue perfusion, passive leg raising and standardized fluid challenge will be performed.
2517809|NCT02778269|Experimental|Study Treatment|The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System.
2517861|NCT02777697||cancer patients|
2517909|NCT02777437|No Intervention|Laparoscopic surgery|Patients with T4 colon cancer receive laparoscopic surgery only.
2517916|NCT02777437|Experimental|Neoadjuvantive chemotherapy + Laparoscopic surgery|Patients with T4 colon cancer receive neoadjuvantive chemotherapy and laparoscopic surgery.
3198310|NCT00869388|Experimental|Arm 3|rBBX-01 4.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
3198311|NCT00869388|Experimental|Arm 4 (optional)|rBBX-01 8.0 mg/m2 SC on 5 consecutive days on weeks 1, 3, 5, and 7
2518036|NCT02776501|Experimental|BAY987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2518047|NCT02776176|Experimental|ERAS group|Patients receive the Enhanced Recovery After Surgery program during the peri-operative period.
2518049|NCT02776176|Other|Traditional group|Patients receive the Traditional program during the peri-operative period.
2518103|NCT02775942|Experimental|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2518111|NCT02775942|Experimental|IPOVAC 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2518117|NCT02775942|Experimental|IPOVAC 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
2518119|NCT02775942|Active Comparator|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
2518267|NCT02774837|Experimental|combination|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks and Telbivudine 600mg oral tablets once daily for 96 weeks
2518271|NCT02774837|Active Comparator|mono therapy|Tenofovir disoproxil oral tablets 300mg once daily for 96 weeks
2518307|NCT02774408|Other|CPAP|"Infants on CPAP will receive backup breafs whenever the SpO2 <88 % along with~automated FiO2 controller. In the control period they will receive automated FiO2~alone"
2518308|NCT02774408|Other|NIMV/NIPPV|"Infants on NIMV NIPPV will receive an increase in the backup rate to 2 times the rate~of the backup triggered by apnoe (apnoe time 5s), whenever the SpO2 under 88%~( max rate 100/min) in the reference period as compared to baseline (automated FiO2~- control + unchanged SIPPV settings)"
2518357|NCT02774187|Experimental|Sorafenib combined with HAIC|Sorafenib combined with Hepatic arterial infusion chemotherapy with Folfox Protocol
2518361|NCT02774187|Active Comparator|Sorafenib alone|Sorafenib alone
2518419|NCT02773771|Placebo Comparator|Placebo + Vital HP|GROUP 1 will receive Placebo (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas.
2518421|NCT02773771|Experimental|B-hydroxy-B-methylbutyrate (HMB) + Vital HP|GROUP 2 will receive beta-hydroxy-beta-methylbutyrate (within 24 hours of ICU admission) and Vital HP ® (while on tube feeds). Vital HP® is on the Massachusetts General hospital formulary, but it is often restricted to patients with malabsorption due to its higher cost compared to other standard enteral nutrition formulas. The investigators will limit HMB dosing to 3g/day since this is the most widely studied dose.
2518472|NCT02773303|Active Comparator|Active|Children receiving Mente Autism™ neurofeedback therapy to use at home for 40 minutes a day for 12 weeks
2518477|NCT02773303|Sham Comparator|Control|Children not receiving neurofeedback based therapy, but receiving the Sham therapy
3198312|NCT00869427|Active Comparator|1 vitamin C|Vitamin C 1g bid
3198313|NCT00869427|No Intervention|2|Usual Care
3198314|NCT00869453||1|Healthy volunteers
3198315|NCT00869479||1|subjects with a histologically-proven diagnosis of NSF
3198316|NCT00869479||2|subjects with other fibrosing skin diseases
3198317|NCT00869479||3|subjects with non-fibrosing skin diseases
3198318|NCT00869479||4|subjects without skin diseases
3198319|NCT00869492|Other|A|instructed nadifloxacine 1% cream twice dailly, and placebo for benzoyl peroxide 5% solution once dailly
3198320|NCT00869492|Other|B|instructed nadifloxacine 1% cream twice dailly, and active benzoyl peroxide 5% solution once dailly
3198321|NCT00869505||Case Group|Intensive Residential Treatment with memantine augmentation
2517547|NCT02779634|Placebo Comparator|Placebo|Placebo three times daily
2517549|NCT02779634|Active Comparator|Active|Pills of 100 mg ubiquinol three times daily
2517595|NCT02779231|Experimental|Texting group|This group will be enrolled in bi-directional texting to send back blood pressure.
2517597|NCT02779231|No Intervention|Standard of care group|
2517662|NCT02778919|Experimental|KLH-2109, lowest dose|
2517663|NCT02778919|Experimental|KLH-2109, low dose|
2517666|NCT02778919|Experimental|KLH-2109, medium dose|
2517669|NCT02778919|Experimental|KLH-2109, high dose|
2517671|NCT02778919|Placebo Comparator|Placebo|First 12 week period; Placebo, Second 12 week period; randomize to one of the KLH-2109 dose levels
2517674|NCT02778919|Other|Leuprorelin acetate|Active reference
2517863|NCT02778256|Experimental|Vestibular stimulation|Patients of this group will receive a specific vestibular stimulation technique.
2517866|NCT02778256|Sham Comparator|Sham vestibular stimulation|This group of patients will receive sham vestibular stimulation, similar to experimental group vestibular stimulation in the range of under threshold frequencies undistinguished from real vestibular stimulation. The absence of vestibular nystagmic response confirms that the stimulus is sham.
2517908|NCT02777424|Experimental|Prothrombin Complex Concentrate|Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)
2517915|NCT02777424|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma of 15 mL/kg
2517947|NCT02777008|Experimental|CTP-543 Single Dose|Single oral dose
2517949|NCT02777008|Experimental|CTP-543 Multiple Dose|Multiple oral dose for 7 consecutive days
2518011|NCT02776865|Experimental|physical therapy and suprascapular nerve block|patient received ultrasound-guided suprascapular nerve block as well as physical therapy.
2518014|NCT02776865|Active Comparator|physical therapy only|patient received physical therapy only.
2518071|NCT02776254|Experimental|START|The START model aims to deliver a higher intensity of treatment services by offering same-day CD4 testing and results, streamlined adherence counseling, and quicker initiation of life-long ART to patients enrolling in HIV care and treatment services.
2518076|NCT02776254|Experimental|FAST Track|In the FAST-TRACK model a pharmacy technician will dispense drugs) and lay health care workers will provide brief symptom screening to identify patients in need of higher-level care. If there is no need of higher-level care, then the clinic visit is over.
2518079|NCT02776254|Experimental|CAG (intervention)|CAG intervention, consists of facilitated groups of six people based on geographic proximity of home address and patient preference. This group of six people, will meet monthly at a designated place in the community to provide support and receive medications. Each month one of the members will rotate visiting the clinic for their routine medical visit and will pick up medications for the entire CAG and bring them back to the community. This rotation schedule will recur every six months. Lay health care workers will provide brief symptom screening to identify patients in the group that need of higher-level care.
2518081|NCT02776254|Active Comparator|CAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
2518083|NCT02776254|Experimental|UAG (intervention)|Urban sites will be eligible for the UAG model in which patients will be joined into a UAG group consisting of 30 people. Each UAG group will meet every two to three months at a designated site (either at the clinic facility or another site in the community). Patients will receive (a) group adherence counseling led by a lay HCW (b) two to three month supply of ART medications via a pharmacy tech (c) attendance record and symptom assessment. As in the CAG model, patients may be referred up-referred for care based on acute illness or patient preference. Patients will continue to visit the facility for a routine medical visit with a professional HCW every six months.
2518085|NCT02776254|Active Comparator|UAG (comparison)|Eligible patients at control sites will be approached for willingness to participate in the study. Those who are willing will be enrolled in the study and consent will be obtained to use patient data within SmartCare to evaluate the primary outcome of retention.
2518140|NCT02775721|Other|Cohort A|"Head and Neck Cancer patients receiving Radiation Therapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts B and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2518142|NCT02775721|Other|Cohort B|"Head and Neck Cancer patients receiving Chemotherapy Only. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and C.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2518143|NCT02775721|Other|Cohort C|"Head and Neck Cancer patients receiving Chemotherapy and Radiation therapy. The purpose is to do a comparative analysis and identify if patient quality of life outcomes are the same, better or worse when compared to Cohorts A and B.~Interventions: The research nurse will provide gastrostomy tube care education and skin care education at each study visit utilizing the nursing process.~Speech therapy education and evaluation is assessed per standard of care by the attending speech therapist.~Nutritional therapy education and evaluation is assessed per the attending dietitian.~The European Organization for Research and Treatment of Cancer (EORTC) head and neck cancer module (QLQ-H&N35) and EORTC Core Questionnaire (QLQ-C30) version 3.0 will be completed by the subject."
2518205|NCT02775370|Experimental|Apatinib group|Apatinib Mesylate administered as a daily oral treatment
2517458|NCT02780310|Experimental|Lenvatinib|All eligible patients will receive a starting lenvatinib dose of 24 mg daily taken orally for each 4-week cycle. Patients may remain on study until progression of disease or unacceptable toxicity. Alternatively, Lenvatinib may be dissolved in fluid per the Food and Drug Administration (FDA) label and administered orally or via a feeding tube.
2517508|NCT02779842|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2517631|NCT02779569|Experimental|Ultra-low-dose group|decitabine was subcutaneously administered at 5 to 7 mg/m2 once daily for successive 3 days at the first week, and once daily at weeks 2 to 4, with a total dose of 60 mg in a 4-week cycle.
2517642|NCT02779569|Active Comparator|Low-dose group|decitabine was subcutaneously given at 20 mg/m2 once daily for successive 3 days, with a total dose of 60 mg/m2 in a 4-week cycle.
2517805|NCT02778243|Experimental|Bladder cancer|▪ Patients justifying prostatectomy together with the bladder (radical cystectomy for bladder cancer).
2517808|NCT02778243|Other|benign prostate hyperplasia|▪ Patients with benign prostate hyperplasia who justified a prostatectomy.
2517859|NCT02777736|Experimental|Arm A - Methotrexate i.v.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive 2 cycles of methotrexate 3g/m2 i.v. after the 3rd and 6th cycle of systemic chemotherapy (R CHOP or DA EPOCH R).
2517860|NCT02777736|Active Comparator|Arm B - Methotrexate i.t.|Patients with risk factors for CNS relapse ≥ 2 or with occult meningeal involvement will receive intrathecal methotrexate 12mg in each cycle of systemic chemotherapy (6x).
2517864|NCT02777736|No Intervention|Arm C - no Methotrexate|Patients with 0-1 risk factor for CNS relapse will not receive CNS prophylaxis.
2517957|NCT02777060|Experimental|Exergame|inertial sensor based system (wearable sensors, LEGSys, Biosensics LLC) will be used for balance training with computerized feedback. The balance training program is focused on lower extremities including ankle joint exercise and virtual obstacle crossing tasks.
2517962|NCT02777060|Active Comparator|Home based balance training|The control group will ask to perform a home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback. Exercises include postural balance tasks, such as backward and forward weight shifting, as well as dynamic balance exercises, such as marching in place (comparable to virtual obstacle crossing in experimental group).
2518018|NCT02776514|Active Comparator|Triamcort (1 ml, 40 mg/ml)|30 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
2518024|NCT02776514|Active Comparator|Platelet-rich-plasma (PRP 3 ml)|30 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
2518028|NCT02776514|Active Comparator|Suplasyn1-shot (60 mg/ ml)|30 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
2518032|NCT02776514|Placebo Comparator|Placebo (Iopamiro 200)|30 patients receive intraarticular injection with contrast media only
2518051|NCT02776150||MGIT liquid culture+drug sensitivity test|MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
2518053|NCT02776150||Xpert-MTB/RIF|xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
2518055|NCT02776150||probe melting curve detection|Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.
2518099|NCT02775981|Experimental|Active|RX0041-002
2518160|NCT02775656||Prospective cohort|For a pregnancy to be enrolled in the prospective cohort, the pregnancy outcome cannot be known (ie, no prenatal diagnosis of a fetus with a congenital defect and the pregnancy is still ongoing at the time of consent).
2518161|NCT02775656||Retrospective cohort|For a pregnancy to be enrolled in the retrospective cohort, the pregnancy outcome must already be known (ie, a congenital defect has already been identified at the time of consent into the pregnancy follow-up study, or the pregnancy has been completed at the time of consent).
2518212|NCT02775305|No Intervention|Not frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants do not meet criteria for frailty, baseline screening data will be used for comparative analysis as the no intervention arm.
2518213|NCT02775305|Experimental|Frail|Source of these participants will be the same as those who screen into the study; patients with chronic kidney disease receiving care at the San Francisco Veteran Affairs Medical Center. Based on initial screening if participants meet criteria for frailty participants will be enrolled in the intervention arm. Participants who are ambulatory regardless of co-morbidities will not be excluded from the study.
3198322|NCT00869505||Control Group|Intensive Residential Treatment without memantine augmentation
2549968|NCT02565316|Active Comparator|Sertraline capsule|
3198323|NCT00869531|Experimental|WW|wholegrain wheat
2517472|NCT02780219|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions with blood draws, acute exercise, cognition testing"
2517503|NCT02779764|Experimental|ASP1517 Group|Study drug will be dosed three times weekly and dose adjustments will be made during the study.
2517566|NCT02779309||Development Cohort|437,000 home care recipients who received services from January 1, 2007 to December 31, 2012.
2517572|NCT02779309||Validation Cohort|122,000 home care recipients who received services from January 1, 2013 to December 31, 2013.
3198324|NCT00869531|Active Comparator|RW|refined wheat
3198325|NCT00869544||HIV|Those positive for HIV and those negative but at high risk for HIV. Both positive and negative for HIV who smoke and those who do not smoke. Both HIV positive and negative with and without asthma and/or COPD
2517707|NCT02778399|Experimental|OBE2109 dose 1|
2517718|NCT02778399|Experimental|OBE2109 dose 2|
2517724|NCT02778399|Experimental|OBE2109 dose 3|
2517733|NCT02778399|Experimental|OBE2109 dose 4|
2517735|NCT02778399|Experimental|OBE2109 dose 5|
2517736|NCT02778399|Placebo Comparator|Placebo / OBE2109 dose 6|
3198326|NCT00869570|Experimental|Arm A: Sorafenib & Capecitabine & RT|"Sorafenib: day 1 to 33 (5 weeks, including Saturday and Sunday) every 24 hours, immediately or within two hours after RT according to the dose escalation table during phase I, and the recommended dose during phase IIa. The intake stops at the last day of RT. On nonradiotherapy days (e.g. Saturday, Sunday), the tablets have to be taken at the same time as during the week.~Capecitabine: day 1 to 33 (5 weeks, including Saturday and Sunday) according to dose escalation table during phase I, and at the recommended dose during phase IIa. The intake stops in the evening of the last day of RT.~External beam RT: Monday through Friday for 5 weeks starting on day 1 (daily fraction 1.8 Gy, final dose 45 Gy) each day at the same time (e.g. 11:00 a.m. daily).~Surgery: 6 weeks (± 1 week) after radiochemotherapy (RCT) has been completed"
3198327|NCT00869583|Experimental|1|Participants will immediately take part in the physical activity program.
3198328|NCT00869583|No Intervention|2|
3198329|NCT00869596|Placebo Comparator|1|Placebo
3198330|NCT00869596|Active Comparator|2|Fluticasone 440 mcg
2518022|NCT02776631|Experimental|Pinloc|Plate and 3 interlocked pins. A new device for fixation of femoral neck fractures.
2518025|NCT02776631|Active Comparator|LIH (Hansson pins)|2 pins. An established method for fixation of femoral neck fractures.
2518043|NCT02776163|Experimental|Cisplatin Group|Intensity-modulated radiotherapy+concurrent chemotherapy with cisplatin for squamous carcinoma of salivary gland
2518044|NCT02776163|Experimental|Docetaxel+Cisplatin|Intensity-modulated radiotherapy+concurrent chemotherapy with docetaxel and cisplatin for adenogenous types carcinoma of salivary gland
3198331|NCT00869596|Active Comparator|3|Fluticasone 1980 mcg
2518237|NCT02775097||Normal|Not having any history of refractive surgery, contact lens, dry eye or pathology
2518242|NCT02775097||Corneal condition|History of refractive surgery, contact lens, dry eye or keratoconus.
2518291|NCT02774811|Active Comparator|Selective laser trabeculoplasty|Selective laser trabeculoplasty
2518293|NCT02774811|Active Comparator|Prostaglandin analogue|Prostaglandin analogue topical medical therapy
2518368|NCT02774291|Experimental|Treatment (mTCR, aldesleukin)|Patients receive standard cyclophosphamide IV over 1 hour on days -7 to -6 and fludarabine phosphate via IVPB over 30 minutes on days -5 to -1 followed by anti-ESO (cancer/test antigen) mTCR-transduced autologous peripheral blood lymphocytes IV over 20-30 minutes on day 0 and aldesleukin IV over 15 minutes approximately every 8 hours on days 0-4. Patients also receive filgrastim SC on days 1-4.
2518457|NCT02773394||Group 1|Brazilian participants with Hepatitis C virus (HCV) chronic infection who are registered at the Brazilian reference centers and meet all the inclusion criteria and have sufficient information to identify the diagnosis of chronic HCV infection with identification of genotype.
2518530|NCT02773147|Experimental|Triobe|Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.
2518539|NCT02773147|No Intervention|Control|
2518663|NCT02772289|Experimental|Mesenchymal Stem Cells low-dose group|Target dose of 3 million Mesenchymal Stem Cells
2518666|NCT02772289|Experimental|Mesenchymal Stem Cells high-dose group|Target dose of 6 million Mesenchymal Stem Cells
2518668|NCT02772289|Placebo Comparator|Placebo|Placebo without Mesenchyme Stem Cells
2518743|NCT02771678||Asthma|All participants will have an asthma-related crisis event due to an asthma exacerbation that resulted in A&E attendance and/or hospital admission.
2518858|NCT02770560||Chronic hemodialysis patients with a tunneled cuffed catheter|In case of thrombotic dysfunction of the dialysis catheter : administration of Urokinase (100 000 units in total) as locking solution in the dead space of the catheter lumen, interdialytic (between two dialysis sessions) or intradialytic (during the dialysis in case of complete obstruction of the dialysis catheter)
2518920|NCT02770456|Experimental|High dose fish oil|Women will be offered 4 capsules per day containing fish oil
2518925|NCT02770456|Experimental|Low dose fish oil|Women will be offered 4 capsules per day containing mixed fish oil and olive oil
2518930|NCT02770456|Placebo Comparator|Control|Women will be offered 4 capsules per day containing olive oil
2519019|NCT02769598||ANI Index for Hospitalized children|"Each child will be registered upon arrival in the service and for a period of 24 hours. Registration will finish at the end of 24 hours or when the patient is discharged from the service. A FLACC scale (Face, Legs, Activity, Cry, Consolability scale) will be performed at the patient's input and then once every 4 hours corresponding to the patient's baseline. A FLACC scale will then be performed at each painful episode of the patient and 30 minutes after the end of production of analgesic treatment corresponding to the post-treatment painful condition of the patient.~A measurement of blood pressure will be performed at each pain rating by the patient assisted by the nurse."
2519138|NCT02768688|Experimental|Brain connectivity and physiology|Dexmedetomidine anesthesia on glymphatic flow in human subjects as visualized by diffusion tensor MRI.
2517480|NCT02780050|Experimental|after core muscle activation using physical fitness|"The subjects consist of 25 medical school students and interns had experienced in cardiopulmonary resuscitation (CPR) education.~After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 2nd chest compression."
2517512|NCT02779816|Experimental|Intervention (pen device)|Subjects will use the pen device when using their commercially available insulin pens
2517514|NCT02779816|No Intervention|Control|Subjects will use the commercially available insulin pens only (no adaptive pen device).
2517551|NCT02779517||Focus groups- Patients|Subjects with or without an upper extremity disability will be asked to observe and interact with the mobile service robot.
2517552|NCT02779517||Focus Groups-clinicians|Clinicians with neuro-rehab experience.
2517603|NCT02779205|Other|0-1 year old child|Adipose tissue sample in 0-1 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
2517605|NCT02779205|Other|>1-10 year old child|Adipose tissue sample in >1-10 year old child with an act of surgery settled by cure of inguinal hernia, or by vesico-ureteral ebb by abdominal way
2517670|NCT02778893|Experimental|Conmana and Thalidomide|"Conmana(Icotinib Hydrochloride Tablets) and Thalidomide:~Conmana(Icotinib Hydrochloride Tablets) will be administered at 125mg three times a day(TID）continuously; Thalidomide will be administered at 100mg one a day（QD)at night continuously,If can tolerance after 1 weeks to add to 200mg."
2517713|NCT02778425|Experimental|Secondary prevention-1|Endoscopic therapy+ beta blockers
2517722|NCT02778425|Experimental|Secondary prevention-2|Endoscopic therapy+ PSE+beta blockers
2517725|NCT02778425|Experimental|Primary prevention-1|Beta blockers
2517730|NCT02778425|Experimental|Primary prevention-2|Endoscopic therapy
2517734|NCT02778425|Experimental|Primary prevention-3|Endoscopic therapy+ PSE
2517737|NCT02778425|Experimental|Acute bleeding-1|Somatostatin+endoscopic therapy
2517739|NCT02778425|Experimental|Acute bleeding-2|Somatostatin+endoscopic therapy+PSE
2517829|NCT02777983|Experimental|Education Group|This will consist of a 6-minute educational video app created and delivered within an application (mobile app) that will be interactive in nature, asking multiple-choice questions at the end to help reinforce key points of the video message. It will include self-management guidance based on evidence related to activity, exercise, and other behavioral components known to influence the prognosis of low back pain. Subjects will also receive the 1-page general conditioning handout that the usual care group will receive.
2517836|NCT02777983|No Intervention|Usual Care Group|Subjects randomized to usual care will receive a 1-page generic informational handout on general conditioning recommended for low back pain, in addition to whatever education the subject's PCP decides to provide.
2517912|NCT02777606|Experimental|Si-Ni-Tang (a Chinese Herbal Formula)|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015. Besides, 150ml of Si-Ni-Tang will be given by p.o. or a nasogastric tube once per day for 3 days in the treatment group.
2517918|NCT02777606|No Intervention|Control|Treatment for severe sepsis adheres to the International guidelines for management of sepsis and septic shock 2012 and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015.
2517952|NCT02777047|Experimental|Intervention|Complex Intervention including focused discharge medication reconciliation; structured handovers to family physician, community pharmacy, patient and family, home care, telehealth providers; virtual visit follow-up focused on anticoagulation monitoring.
2517953|NCT02777047|No Intervention|Control|Usual care. Patients will be provided with the URL to Thrombosis Canada website.
2517991|NCT02776813|Experimental|ACTR087, in combination with rituximab|
2518073|NCT02776332|Active Comparator|3 day group|Manual expression for 3 days after delivery Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
2518075|NCT02776332|Active Comparator|7 day group|The 7 day group will manually express for 7 days after delivery. Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery follow up phone call at 5 days to encourage continued manual expression
2518263|NCT02774954|Experimental|Change the cycle|CTC uses the Information-Motivation-Behavioral skills (IMB) model to achieve changes among active PWID through seven short modules. Information and motivational domains are addressed in guided conversations about (1) their own first injection episode and consequences, (2) past experiences initiating injection-naive people and consequences, (3) health, legal, and social risks related to injection drugs, (4) health, legal, social risks of initiating people, and (5) identifying their own behaviors that might promote injection among others. The behavioral skills domain is addressed through a (6) skill-building discussion and rehearsal of responses to possible initiation scenarios, and (7) safer injection education.
2518265|NCT02774954|Active Comparator|Nutrition|The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
2518573|NCT02772861|Placebo Comparator|Placebo|Dextrose (glucose) was used in a dose of 20 g in this study.
2517498|NCT02779998|Experimental|non invasive ventilation|non invasive ventilation (NIV) which associated positive end expiratory pressure (PEEP: 5 to 10 cmH2O) and pressure support ventilation (PSV: 5 to 15 cmH2O, to achieve total Pressure bellow 20cmH2O) will be delivered during electrophysiology procedure under light sedation. The patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
2517556|NCT02779608|Experimental|intraperitoneal docetaxel and oral S-1|"Docetaxel is diluted in 1litre normal saline and administered intraperitoneal（IP）at a dose of 60 mg/m2 over 1 hour on day 1. S-1 was administered orally twice daily at a dose of 40mg/m2 per day for 14 consecutive days, followed by 7 days of rest.~Intervention: Drug: Intraperitoneal docetaxel Intervention：Drug：Oral S-1"
2517623|NCT02779140|Experimental|0.033 mg/kg NTM-1632|N=6 administered 0.033 mg/kg NTM-1632 IV, N=2 administered placebo IV
2517624|NCT02779140|Experimental|0.165 mg/kg NTM-1632|N=6 administered 0.165 mg/kg NTM-1632 IV, N=2 administered placebo IV
2517625|NCT02779140|Experimental|0.33 mg/kg NTM-1632|N=6 administered 0.33 mg/kg NTM-1632 IV, N=2 administered placebo IV
2517632|NCT02778763|Experimental|One injection of CBLB612 after Сhemo|One injection of placebo at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of 4 μg CBLB612 at Day 1 (24 hours after AC chemotherapy treatment)
2517643|NCT02778763|Experimental|One injection of CBLB612 prior Сhemo|One injection of 4 μg CBLB612 at Day -2 (48 hours prior AC chemotherapy treatment) and one injection of placebo at Day 1 (24 hours after AC chemotherapy treatment)
2517652|NCT02778763|Placebo Comparator|Placebo|Two injections of placebo at Day -2 and Day 1 (48 hours prior and 24 hours after AC chemotherapy treatment)
2517703|NCT02778503|Active Comparator|High Cost|Restoration using a high-cost glass ionomer cement.
2517711|NCT02778503|Experimental|Low Cost|Restoration using a low-cost glass ionomer cement.
3198332|NCT00869635|Experimental|1|"Treatment by combination of photodynamic therapy and S-1~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment"
3198333|NCT00869635|Active Comparator|2|"Treatment by photodynamic therapy only~PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation~Other managements except systemic chemotherapy were added freely."
3198334|NCT00869635|Other|3|Treatment by photodynamic therapy only or combined chemotherapy with photodynamic therapy: Open label
3198335|NCT00869648|Active Comparator|Neutralposition|Head placed in neutral position
2517924|NCT02777307|Experimental|Hemopatch Sealing Hemostat|
2517926|NCT02777307|No Intervention|No Hemopatch Sealing Hemostat|
2517970|NCT02776995|Other|Patients undergoing radiation|In this study, patients undergoing radiation treatment will undergo thermography imaging during radiation treatment course. Patients will be evaluated with thermography imaging every 5 fraction of radiation, starting prior to the first radiation treatment, periodically, until the end of radiation therapy (a period of several weeks).
2517986|NCT02776748|Other|FTC-TDF|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) PrEP: 200mg FTC /300 mg TDF
2518041|NCT02776475|Other|Sacral neuromodulation device turned off|Patients who are currently being successfully treated with sacral neuromodulation for the primary diagnosis of urinary urge incontinence or urgency and frequency (implantation for minimum 12 months) will be to have the sacral neuromodulation device turned off for four consecutive weeks.
2518100|NCT02776098||Cystic Fibrosis without Cystic Fibrosis-related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) without Cystic Fibrosis-related diabetes will be followed annually for 2 years for a total of four study visits over 2 years (screening, baseline, 12 and 24 month visits).
2518109|NCT02776098||Newly Diagnosed Cystic Fibrosis-Related Diabetes|Subjects with a confirmed diagnosis of Cystic Fibrosis (CF) and new diagnosis of Cystic Fibrosis-Related Diabetes (CFRD) will be followed for a total of 3 study visits over 6 months (screening, baseline and 6 months).
2518115|NCT02776098||Healthy Controls|Age, sex, ethnicity and body mass index matched (at time of enrollment to CF without CFRD subjects) healthy controls will be followed annually for 2 years for a total of four study visits (screening, baseline, 12 and 24 month visits).
2518176|NCT02775539|Active Comparator|Mirabegron|Oral mirabegron, starting with 50 mg once a day and titrated till a maximum of 200 mg once a day.
2518179|NCT02775539|Placebo Comparator|Placebo|Oral placebo, similarly titrated to ensure blindness.
2518223|NCT02775162|Experimental|Normothermic Machine Perfusion (NMP)|Following the routine retrieval procedure of the liver, it will be placed on the OrganOx metra for Normothermic Machine Perfusion (NMP) for transport per the Investigational Plan and the Instructions For Use.
2518226|NCT02775162|Other|Standard of Care (Ice)|Following the routine retrieval procedure of the liver, it will be placed in ice-cold perfusion solution within an ice box for transport as dictated by logistics and local policy.
2518334|NCT02774499|Experimental|Methadone|Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
2518336|NCT02774499|Placebo Comparator|Placebo|Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
2518358|NCT02774044|Experimental|Cadisurf (goat lung surfactant extract)|Neonates in the intervention group will be intratracheally administered 100 mg/kg of GLSE (CADISURF®).
2518362|NCT02774044|Active Comparator|Survanta (Beractant)|
2518398|NCT02773862|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an invasive monitoring device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 48 hours, continuously depending on the patient's clinical condition.
2518481|NCT02773381|Experimental|Semaglutide 3 mg, 7 mg, 14 mg|
2518490|NCT02773381|Placebo Comparator|Placebo|
2518561|NCT02772900|Active Comparator|Beetroot gel (dietary nitrate)|Beetroot-based nutritional gel containing approximately 10.0 mmol of nitrate per dose
2518565|NCT02772900|Active Comparator|Placebo gel (nitrate-depleted)|Nutritional gel nitrate-depleted
2518623|NCT02772328|Experimental|Peer Mentor|Individuals in this arm will be trained in communication skills to promote HIV and HCV testing to their social network members, linkage to care and risk reduction behaviors.
3198336|NCT00869648|Active Comparator|Extension|Head placed in extension
2517499|NCT02779894|No Intervention|Hospital group|Patients referred to the sleep unit and randomized to Hospital group. Participants will be diagnosed in the hospital either by Polysomnography , Respiratory Polygraphy or one night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the titration and adjustment of patient's will be accomplished at the hospital. This patient's will be monitored during 3 months of the study at the hospital.
2517500|NCT02779894|Other|ICT group|Patients referred to the sleep unit and randomized to intervention group. Participants will be diagnosed at home by 3 night Home Respiratory Polygraphy. In case of requiring CPAP treatment, the adjustment will be performed at the CPAP supplier center, titration will be performed at home and patient's compliance and treatment will be controlled via remote. During the 3 months of the study patient's will be controlled via phono/video conferences and with a platform designed for the study.
2517562|NCT02779595||Lung surgery|26 patients (up to 36) undergoing lung surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
2517564|NCT02779595||Flail chest|8 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
2517613|NCT02779127|Other|Intervention|"Subjects exposed to passive smoking at least 1 hour per day since 1 year, non active smokers, non exposed to passive smoking at home~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
2517618|NCT02779127|Other|Control|"Subjects non expose to passive smoking at home or at work, non active smokers~Subject will receive a complete medical follow-up including : medical examination, medical interrogatory, general bioassay, specific bioassay and endothelial function evaluation"
2517638|NCT02778776|Experimental|Agave inulin + Metfomin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
2517654|NCT02778776|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
2517658|NCT02778776|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
2517660|NCT02778776|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
2517708|NCT02778451|Other|Ultrasonography-experienced surgeons|Attending physicians and consultants in head and neck surgery using head and neck Ultrasonography on a daily basis.
2517720|NCT02778451|Other|Ultrasonography novices|Physicians participating in their one-year internship at other surgical or medical departments with no experience with head and neck US or head and neck surgery.
3165392|NCT00512499|Active Comparator|Group 2|"MINIMAL INTERVENTION GROUP: 1/2 of patients, randomly selected.~INTERVENTION: A nurse coordinator will identify patients with fragility fractures and inform the patient about osteoporosis as the cause of the fracture, the benefit of treatment, and the options of treatment adapted to the individual patient. Written information will be sent to his/her family physician containing a presumed osteoporosis diagnosis, investigation to be performed, correct interpretation of any osteodensitometry results in the context of a fragility fracture, the options of treatment, and alternatives if the first prescriptions are not tolerated or stopped. Intervention"
3198337|NCT00869648|Active Comparator|Anaesthesiologist's position|Head placed in position deemed optimal by an anaesthesiologist
3198338|NCT00869661|Experimental|Group 1|RO5024048 500 mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
2517965|NCT02776930||Return to Duty after Rehab from Injury|Patients deemed healthy enough to return to full duty without any restrictions after completing a course of rehabilitation for a lumbar/thoracic spine or lower extremity injury.
2517994|NCT02776787||Patients|Patients with diverticulitis
2517995|NCT02776787||Surgeons|Surgeons who perform elective colon resections
2518086|NCT02776358|Experimental|High Fidelity Simulation|Students will receive a 1 hour High fidelity simulation session
2518088|NCT02776358|Experimental|Video Case|Students will receive a 1 hour assisted Video Case learning session
2518137|NCT02775747|Experimental|platelet rich plasma gel|Injection of Platelet rich plasma (PRP) gel in 64 cases at time of wound closure in women undergoing cesarean section for improving wound healing after fullfit to all the inclusion and exclusion craiteria
2518138|NCT02775747|Placebo Comparator|Saline|64 Controlled Women with recurrent cesarean section and fullfit to all the inclusion and exclusion craiteria will reseve saline injection at time of wound closure
2518175|NCT02775422|Experimental|Pregnant women|Pregnant women
2518210|NCT02775214|No Intervention|Conventional Direct Laryngoscopy|Endotracheal intubation will be performed by conventional direct laryngoscopy.
2518215|NCT02775214|Active Comparator|Video Laryngoscopy|Endotracheal intubation will be performed by video laryngoscopy with the C-MAC.
2518299|NCT02774928||Chronic Obstructive Pulmonary Disease|Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality throughout the world.COPD, a common preventable and treatable disease, is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients.Spirometry is required to make a clinical diagnosis of COPD; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation and thus of COPD .
2518302|NCT02774928||Interstitial lung diseases|Interstitial lung disease is a general category that includes many different lung conditions. All interstitial lung diseases affect the interstitium, a part of the lungs' anatomic structure.
2518303|NCT02774928||Obstructive sleep apnea (OSA)|"Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep.~These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.~OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome-also referred to as obstructive sleep apnea-hypopnea syndrome."
2518343|NCT02774304|Active Comparator|arterial line|invasive haemodynamic monitoring
2518344|NCT02774304|Experimental|Cheetah®|non-invasive cardiac output
2517505|NCT02779751|Experimental|HR+, HER2- Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
2517506|NCT02779751|Experimental|HR+, HER2- Locally Advanced or Metastatic Breast Cancer|Abemaciclib given orally Q12H on days 1 to 21 of each 21 day cycle in combination with pembrolizumab given IV on day 1 of each 21 day cycle and anastrozole given orally Q24H on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
2517575|NCT02779257|Experimental|Pasireotide|Off label use of pasireotide to treat refractory hypoglycemia due to an insulin-producing pancreatic neuroendocrine tumor
2517614|NCT02779036|Experimental|Task-oriented Exercise|Structured, progressive, task-oriented, home exercise program
2517617|NCT02779036|Active Comparator|Usual Care|Usual Physiotherapy Care
2517745|NCT02778360|Experimental|Neurofeedback NFT|"Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.~Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home"
2517748|NCT02778360|Active Comparator|Methylphenidate MPH|"Methylphenidate long acting preparation.~Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).~Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day)."
2517840|NCT02777879||Chronic Obstructive Pulmonary Disease (COPD)|Case of early COPD (GOLD 1-2, FEV1/FVC<70 and FEV1>50%)
2517844|NCT02777879||Control|No obstruction (FEV1/FVC<70). Controls will be recruited after each case and will be matched by: age (±5 year), 2) gender, 3) smoking (±5 pack-year) and 4) BMI (±5).
2517906|NCT02777528|Other|Zone 0/1 Aortic aneurysm|Zone 0/1 Aortic aneurysm
2517907|NCT02777528|Other|Zone 0/1 Non-aneurysm aortic lesions|Includes dissection and other isolated lesion types
3198339|NCT00869661|Experimental|Group 2|RO5024048 1000mg bid + Pegasys + Copegus for 8 weeks, followed by SOC for 16 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
2518102|NCT02776020||Propofol sedated patients|Women undergoing a short trans vaginal ovum retrieval (TVOR) will be sedated with propofol , and monitored non-invasively for changes in blood propofol concentration levels. Propofol dosages will be adapted according to patients vital signs and their reaction to noxious stimuli exerted during the trans vaginal ovum retrieval (TVOR) procedure, irrespective to the proposed study in which these participants undergo.Those changes of administered propofol dosages will be observed by the anesthetic drug monitor (ADM). Propfol is administered by the anesthesiologist in a routine manner and according to anesthesiologist discretion .
2518162|NCT02775669||intracranial ICP monitoring|invasive intracranial ICP monitoring
2518163|NCT02775669||tranfontanel ICP monitoring|Noninvasive transfontanel ICP monitoring
2518203|NCT02775292|Experimental|Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)|"CONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.~NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28.~LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses."
2518295|NCT02774577|Experimental|healthy young and elderly|young adults (20 to 30 years) compare to elderly (60 to 74 years)
3198340|NCT00869661|Experimental|Group 3|RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
3198341|NCT00869661|Experimental|Group 4|Group 4 will receive RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 36 weeks
2518474|NCT02773407|Active Comparator|Group A|Azithromycin tablets 20mg/kg/day for 7 days (Maximum dose 1000mg/day)
2518476|NCT02773407|Active Comparator|Group B|Co-trimoxazole tablets (Trimethoprim 10 mg/kg+Sulphamethoxazole 50 mg/kg) in two divided doses everyday for 7 days (maximum 3000mg/day)
2518531|NCT02772952|Other|Control Group|a control group whose intervention will be to review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
2518541|NCT02772952|Experimental|Experimental Group|Experimental group whose intervention will be a Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program.
2518621|NCT02772601|Experimental|All patients|
2518690|NCT02771977|No Intervention|Usual Care|No alert will be fired.
2518693|NCT02771977|Experimental|Drug-specific alert|A drug-specific AKI alert, including information about the drug of interest as well as the presence of AKI will be fired.
2518779|NCT02771600|Experimental|Buzzy|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
2518782|NCT02771600|Active Comparator|Standard Care (Maxilene)|Maxilene topical anaesthetic cream will be applied 30 minutes before the needle-related procedure on the insertion site
2518811|NCT02771015|Active Comparator|Mepilex Border®|Mepilex Border® wound dressing at patients after hip-knee or primary spine surgery
2518817|NCT02771015|Active Comparator|Cosmopor steril®|Standard wound dressing at patients after hip-knee or primary spine surgery
2518874|NCT02770768|Active Comparator|Flibanserin|"Drug: Flibanserin~8 weeks~100mg once daily at bedtime"
2518882|NCT02770768|Placebo Comparator|Placebo|Drug: Matching Placebo Matching placebo capsules taken in same amount of pills as the active medication (for 8 weeks once daily at bedtime)
2519010|NCT02769897|Experimental|Intervention group|The exercise program, nutritional counseling and oral health will last for five to six months and will be held in the gym and rooms of the University of Santa Cruz do Sul (UNISC). The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
2517517|NCT02779881||Subjects outgrown cow's milk allergy with formula+probiotic|Tolerant with extensively hydrolyzed casein formula with Lactobacillus rhamnosus GG
2517523|NCT02779881||Subjects outgrown cow's milk allergy assuming other formulas|Subjects tolerant with other formulas
2517553|NCT02779504||Agluna treated METS|Patient implanted with Agluna treated METS
2517554|NCT02779504||Untreated METS|Patient implanted with untreated METS
2517607|NCT02779192|Active Comparator|SPI-1005 200 mg|200 mg SPI-1005, capsule, bid, po, x7d
2517608|NCT02779192|Active Comparator|SPI-1005 400 mg|400 mg SPI-1005, capsule, bid, po, x7d
2517609|NCT02779192|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, bid, po, x7d
2517641|NCT02778841|Experimental|XBox Kinact Exercise|Kinact game intervention group performed three times per week on non-consecutive days for eight weeks
2517655|NCT02778841|Experimental|conventional balance exercises|conventional balance exercises group performed three times per week on non-consecutive days for eight weeks
2517659|NCT02778841|Experimental|concurrent exercise group|Concurrent group performed mixed conventional balance and Xbox Kinact exercises three times per week on non-consecutive days for eight weeks
2517661|NCT02778841|No Intervention|control Group|There is no exercise for this group
2517691|NCT02778568|Experimental|Resistance Training|Patients performed resistance exercises
2517692|NCT02778568|Active Comparator|Control|Patients who performed flexibility exercise
2517777|NCT02778308|Active Comparator|chemotherapy group|6 cycles of Gemcitabine + Cisplatin as per the following schedule Injection Gemcitabine 1 gm/kgm2 intravenous over 30 min Day1 and Day8 Injection Cisplatin 70 mg/m2 intravenous on Day1
2517779|NCT02778308|No Intervention|control group|follow up
3198342|NCT00869661|Active Comparator|Group 5|Group 5 will receive SOC for 48 weeks
3198343|NCT00869661|Experimental|Group 6|Group 6 provides retreatment on an open-label basis for patients of Group 5 who failed treatment. Patients will receive RO5024048 1000mg bid + Pegasys + Copegus for 24 weeks, followed by SOC for 24 weeks.
2517876|NCT02777411|Experimental|Group A1|3 to 6 years
2517877|NCT02777411|Experimental|Group A2|3 to 6 years
2517878|NCT02777411|Experimental|Group A3|3 to 6 years
2517879|NCT02777411|Experimental|Group A4|3 to 6 years
2517880|NCT02777411|Experimental|Group B2|6 to 35 months
2517881|NCT02777411|Experimental|Group B3|6 to 35 months
2517882|NCT02777411|Experimental|Group B4|6 to 35 months
2517982|NCT02777216|Experimental|ConfidenHT system|ConfidenHT system
3198344|NCT00869674|No Intervention|Routine pathologic method|Half of each sentinal lymph node will have rountine pathologic examination as normal practice.
3198345|NCT00869674|Experimental|GeneSearch BLN Assay|Half of each sentinal lymph node will have GeneSearch BLN testing.
2518052|NCT02776085||Asymptomatic|Group of patients with CSF shunts who are evaluated for a reason other than concern for shunt failure. The optic nerve sheath diameter of these patients will be used as baseline measurements for children with CSF shunts.
2518054|NCT02776085||Symptomatic, Not Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, but either have shunt failure ruled out, or are felt to be safe for discharge to home. They are not admitted to the hospital. The optic nerve sheath diameter of these patients will be measured once in the emergency department.
2518056|NCT02776085||Symptomatic, Admitted|Group of patients with CSF shunts who are evaluated for concerns of shunt malfunction or failure, and then are admitted to the hospital secondary to these concerns. The optic nerve sheath diameter of these patients will be measured once in the emergency department or as close to admission as possible, and then measured again while they are still inpatient, but after they have an intervention performed (medical or surgical) to relieve their shunt malfunction or failure. These patients will have their initial optic nerve sheath diameters compared to the other two populations, but they will also have their initial and final optic nerve sheath diameters compared to each other.
2518106|NCT02775994|Experimental|Treatment Arm|Single dose of Canakinumab 4mg/kg
2518196|NCT02775630|Experimental|Examination under hypnosis in addition to local anesthesia|Patients will have hypnosis add-on local anesthesia
2518197|NCT02775630|No Intervention|Examination under local anesthesia|Patients will receive a local anesthesia only without hypnosis
2518239|NCT02775123|No Intervention|Control|Conventional cardio-pulmonary bypass
2518241|NCT02775123|Experimental|Cytosorb|Cytosorb added to cardio-pulmonary bypass
3198346|NCT00869687|Other|Poly-L-Lactic Acid Injection|
2518378|NCT02774174||METS Proximal Humeral system|Implanted with METS Proximal Humerus
3198347|NCT00869713|Other|primary vaccination with boost|Inactivated, Dried (TSI-GSD 200), RVF Vaccine
2518453|NCT02773459|Experimental|Phase 1 part|to assess the maximal tolerated dose (MTD) of MEK162+Capecitabine combination
2518454|NCT02773459|Experimental|Expansion part|to assess the efficacy (PFS) of MEK162+Capecitabine combination
2518462|NCT02773199||Cohort 1- Morning Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in morning hours (until 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for 8 hours
2518468|NCT02773199||Cohort 2- Afternoon Surgery|Patients' who are scheduled for surgery under spinal anesthesia with bupivacaine in afternoon hours (after 12pm) will be included in this cohort. Since all patients are ordered to stop oral ingestion by 12am at the day of the surgery, patients in this cohort will be exposed to a preoperative fasting for more than 12 hours
2518535|NCT02772939|Experimental|Renal Denervation|Renal denervation for therapy resistant arterial hypertension
2518582|NCT02772640|Active Comparator|Arm I: R+E morning->evening|Rosuvastatin and Ezetimibe morning or evening administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the morning (8:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the evening hours (20:00).
2518583|NCT02772640|Active Comparator|ARM II: R+E evening->morning|Rosuvastatin and Ezetimibe evening or morning administration: Rosuvastatin (R) plus Ezetimibe (E) administration in the evening (20:00) for 6 weeks. After 6 weeks - intervention - change of the timing of study drug administration to the morning hours (8:00).
3198348|NCT00869726|Experimental|Dirucotide|
3198349|NCT00869726|Placebo Comparator|Placebo|
2517634|NCT02779010|Experimental|Hand washing with soap|Hand washing with soap and health education every 2 weeks for 6 months
2517647|NCT02779010|No Intervention|Books and pens|Books and pens for every 2 months for 6 months
2517693|NCT02778672||Infants with potential pneumonia|
2517773|NCT02778282|No Intervention|Standard Care|Standard Care through office-based opioid treatment with buprenorphine/naloxone and weekly urine toxicology screening
2517774|NCT02778282|Experimental|Standard Care + MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing. This arm represents Standard Care plus MySafeRx™.
2517902|NCT02777632||HCV patients following living donor liver transplantation|single infection episode group
2517904|NCT02777632||patients following living donor liver transplantation|recurrent Infections episode group
2517964|NCT02777151|Experimental|Cohort 1|REGN3470-3471-3479 dosing level 1 or placebo
2517966|NCT02777151|Experimental|Cohort 2|REGN3470-3471-3479 dosing level 2 or placebo
2517967|NCT02777151|Experimental|Cohort 3|REGN3470-3471-3479 dosing level 3 or placebo
2517968|NCT02777151|Experimental|Cohort 4|REGN3470-3471-3479 dosing level 4 or placebo
2518012|NCT02776618|Experimental|Polyglactin 910|One half of excision site will be randomly assigned superficial closure with polyglactin 910 suture
2518016|NCT02776618|Experimental|poliglecaprone 25|One half of excision site will be randomly assigned superficial closure with poliglecaprone 25
2518062|NCT02776280|Placebo Comparator|Negative control|Meal prepared with non-fluoridated water and salt
2518065|NCT02776280|Experimental|Fluoridated water|Meal prepared with fluoridated water
2518066|NCT02776280|Experimental|Fluoridated salt|Meal prepared with fluoridated salt
2518207|NCT02775331|Experimental|Units using Titania1 software|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
2518208|NCT02775331|Experimental|Units using Titania2 software|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
2518209|NCT02775331|No Intervention|Units using Titania3 software|Employees working in shift planning units (clusters) where a standard shift planning software (Titania3) without interactive shift rostering or guidance for health-supporting shift ergonomics is used by shift planners.
2518253|NCT02775006|Active Comparator|Docetaxel|Docetaxel 75mg/m2 every 21 days until disease progression or toxicity related
2518255|NCT02775006|Active Comparator|Docetaxel plus erlotinib|Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days, until disease progression, or toxicity related.
3175175|NCT00630981||Intervention group|"Combined psychotherapy and pharmacological treatment~Open single arm 'pilot' clinical trial in patients with dissociative disorders, admitted to the psychiatric emergency unit of Geneva and in the Hogan Psychotherapeutic Center in Montreux.~Patients will be interviewed according to the Dissociative Experiences Scale (DES) and, if their score is 30 or higher, the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID) will be administered."
2518319|NCT02774330||Minneapolis, Minnesota Customers|"Minneapolis, Minnesota has a policy in place whereby minimum quantities and varieties of healthy food are required for all licensed food stores. The policy is our intervention condition."
2518323|NCT02774330||St. Paul, Minnesota Customers|No policy exists in St. Paul, Minnesota. This is the control condition.
2518371|NCT02774096|No Intervention|Control group（Ascending aorta）|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
2518373|NCT02774096|Experimental|Xenon Post-conditioning|undergo ascending aorta Dissection Repair and thoracoabdominal aortic Dissection Repair
2518410|NCT02773810|Experimental|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
2518465|NCT02773550|Experimental|Velcadito|Bortezomib 1.3 mg/m2 days 1,4,8 and 11 first cycle, the 1.0 mg/m2 days 1 and 4. Melphalan 9 mg/m2 days 1 to 4 Prednisone 60 mg/m2 days 1 to 4 Cycles of 28 days
2518544|NCT02772965|Experimental|Methotrexate|"Methotrexate (10, 12.5, or 15 mg), once weekly. Weight-based dosing. Ondansetron (4 mg), twice weekly, 1 hour prior to methotrexate dose and the morning after methotrexate dose.~Folic Acid (1 mg) daily"
2518548|NCT02772965|Placebo Comparator|Sugar pill (placebo)|"Placebo for methotrexate, once weekly. Placebo for ondansetron, twice weekly, 1 hour prior to methotrexate placebo dose and the morning after methotrexate placebo dose.~Folic Acid (1 mg) daily"
2518660|NCT02772250|Active Comparator|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by a investigator at 15:00-17:00 on the day before colonoscopy.
3175176|NCT00631033|Placebo Comparator|1|Placebo
3175177|NCT00631033|Experimental|2|Diazoxide
3175178|NCT00631033|Experimental|3|Metformin + Diazoxide
3175179|NCT00631046|Experimental|Fish Oil|containing n-3 LCPUFA
3175180|NCT00631046|Placebo Comparator|Sunflower oil|containing n-6 PUFA
3175181|NCT00631072|Other|GM-CSF +INKT|"INKT will be administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.~GM-CSF will be given subcutaneously once daily for 10 days beginning the second day of the second and third infusion"
3175182|NCT00631085|Other|1|
2517653|NCT02778958|Active Comparator|paracetamol and morphine|iv paracetamol 1 gram infusion at 30 min before skin incision closed and per 6 hours during postoperative period; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
2517761|NCT02778542|Active Comparator|Electronic Pill Bottle|Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication.
2517763|NCT02778542|Active Comparator|Bidirectional Text Messaging|Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day.
2517765|NCT02778542|No Intervention|Usual Care|Participants in this arm do not receive a medication reminder system.
2517828|NCT02777996|Active Comparator|Screening arm|Low Dose Computed Tomography offered at baseline and for 3 repeated rounds
2517834|NCT02777996|No Intervention|Passive Arm|Eligible subjects were randomized to follow up in usual care (in Europe lung cancer screening is not raccomended), according with the GP.
2517897|NCT02777593|Other|Zone 2 Aortic aneurysm - CLOSED TO ENROLLMENT|Zone 2 Aortic Aneurysm
2517898|NCT02777593|Other|Zone 2 Non-aneurysm aortic lesions|Includes dissection, traumatic transection and other isolated lesion types
2518007|NCT02776839|Other|Mobile Sensing|This phase of the study is designed to develop the app. due to algorithms the app should lern to detect depressive symptoms
2518057|NCT02776384||chronic heart failure|patients who are diagnosed with chronic heart failure with either preserved or reduced ejection fraction
2518123|NCT02775890||Eating lead-shot wild game|Hunters that have eaten lead-shot in the past week will have blood lead levels measured.
2518128|NCT02775890||Not eating lead-shot wild game|Hunters that have not eaten lead-shot in the past week will have blood lead levels measured.
2518156|NCT02775604|Other|Home-Based Video|GoPro Camera
2518157|NCT02775604|Other|Paper Checklist|Homeowner Print Checklist
2518191|NCT02775357|Experimental|Enhanced HIV counseling and testing|In addition to standard HIV testing and counseling,men randomized to this arm received Measurement and communication of HIV risk from the HIV counselors using an index developed and validated through the Rakai community cohort study. Their risk was communicated to them and subsequent HIV risk reduction counseling including male circumcision was given.
2518193|NCT02775357|Active Comparator|Standard HIV testing and counseling|Men randomized to this arm were given standard HIV testing and counseling following the current Uganda Ministry of Health guidelines. Following the counseling HIV risk reduction counseling including male circumcision was given.
2518236|NCT02775149||Reflux patients|Patients who are treated at the Clinic for Gastroenterology and Gastrointestinal Oncology and have a 24-hours pH monitoring or impedance measurement performed for medical reasons
2518304|NCT02774824||CABG patients from protocol 003-03|"Patients who will agree to be followed for an additional 9 months, which include:~2 phone calls at 6 and 9 months after coronary artery bypass graft surgery~1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography)"
2518315|NCT02774317|Active Comparator|FFP|Patients receive FFP as clinically indicated (INR 1.5 or more)
2518322|NCT02774317|Experimental|FP24|Patients receive FP24 as clinically indicated (INR 1.5 or more)
2518397|NCT02774135||direct occupational therapy intervention|group will be evaluated 4 times: on referral to waiting list for treatment, before and after 9-12 direct individual treatments of 45 minutes, and follow-up after 3 months.
2518428|NCT02773641|Active Comparator|Botulinum Toxin Type A|50 Allergan units (0.5 ml) injected in m bulbocavernosus twice with 3 months in between treatments
2518433|NCT02773641|Placebo Comparator|Sterile saline solution|0.5 ml of sterile saline injected in m bulbocavernosus twice with 3 months in between treatments
2518469|NCT02773277|Experimental|Single intervention arm|All patients will be assigned the intervention arm and will receive head-impulse testing before and in the days after skull base surgery.
2518559|NCT02773121|Experimental|Physical activity monitoring|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their physical activity level to at least 150 min of moderate-intensity physical activity per week. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
2518569|NCT02773121|Active Comparator|Flexibility and balance|"Participants will wear a physical activity sensor on the hip or waist with a belt. They will be instructed to increase their balance and flexibility over the 12 week period of the intervention. They will be asked to follow guidelines in the Go4Life brochure, website, and/or videos by the National Institute on Aging. Participants will receive weekly phone calls to monitor their progress, to provide feedback, and to suggest example exercises."
2518607|NCT02772471|Experimental|HS-1000 recording|ICP monitoring will be done in parallel for both HS-1000 and invasive ICP monitoring. HS-1000 ICP monitoring intervals will last at least 30 minutes, continuously depending on the patient's clinical condition.
2518665|NCT02772198|Experimental|Single Arm|All patients will be treated on this single arm
2518708|NCT02771730|Experimental|Vaccine A|Receive Ad4-mgag three times at 0,2,and 6 months with a boost at 8months
2518709|NCT02771730|Experimental|Vaccine B|Receive Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2518710|NCT02771730|Experimental|Vaccine A & B|Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2518711|NCT02771730|Placebo Comparator|Placebo|Receive placebo three times at 0,2,and 6 months with a boost at 8 months
2518712|NCT02771730|Experimental|Vaccine A & B (previously received study vaccine)|People who have previously had a study vaccine: Receive both Ad4-mgag and Ad4-EnvC150 three times at 0,2,and 6 months with a boost at 8 months
2518765|NCT02771431|No Intervention|Standard|Group 1 will consist of patients receiving in-person attending-patient encounters while inpatients.
2518770|NCT02771431|Experimental|Tele-rounding|Group 2 will consist of patients receiving video-conference attending-patient encounters. The intervention is being seen via ipad
2517702|NCT02778594|Placebo Comparator|Placebo|Placebo (4 tablets) Simultaneously with the placebo dose, subjects were administered 1 capsule of Madopar® HBS 125
2517710|NCT02778594|Experimental|Nebicapone 50 mg|Nebicapone 50 mg (1 tablet of 50 mg plus 3 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2517717|NCT02778594|Experimental|Nebicapone 100 mg|Nebicapone 100 mg (2 tablets of 50 mg plus 2 tablets of placebo). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2517723|NCT02778594|Experimental|Nebicapone 200 mg|Nebicapone 200 mg (4 tablets of 50 mg). Simultaneously with the nebicapone dose, subjects were administered 1 capsule of Madopar® HBS 125
2517841|NCT02778022|Experimental|Immediate PriCARE|Parent-child dyads assigned to the immediate PriCARE group will receive the PriCARE intervention as soon as possible plus usual treatment. The intervention will last approximately 6-8 weeks. Each group will have approximately 4-13 participants and 2 facilitators and will meet 6 times for 1-2 hours per session. Parents are expected to practice the skills they learn with their children between sessions.
2517842|NCT02778022|No Intervention|Delayed PriCARE|The delayed PriCARE group will not receive the PriCARE intervention until after their data collection for this study is complete (in 3-6 months). In addition, they will be immediately offered usual treatment. Under usual treatment, patients will be referred to a behavioral health specialist at the discretion of their pediatrician and the office social worker for additional diagnosis and treatment and/or provided with a 1-2 page informational handout on child behavior problems from the CHOP patient care manual.
3175183|NCT00631098|Experimental|1|Cannulation of external jugular vein and cannulation of cubital vein
3175184|NCT00631111|Experimental|1|
2518093|NCT02776111||Healthy Controls|Participants in this group will have a one time blood sample taken.
2518094|NCT02776111||Kidney Transplant Group|Participants in this group have had a kidney transplant and blood samples will be obtained as described in study plan
2518126|NCT02775695|Experimental|Doxycycline Administered to Patients|Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.
2518172|NCT02775461||Hereditary Pancreas Cancer Syndrome|Patients that have a diagnosis or any family history of a hereditary pancreas cancer syndrome, such as, but not limited to, Familial Pancreatic Cancer, hereditary pancreatitis, FAMMM syndrome, FAP and its variants, HNPCC (Lynch syndrome), Peutz-Jeghers syndrome, or BRCA1 and/or BRCA2 germline mutations.
2518173|NCT02775461||Personal or FHx of Pancreas Cancer or Pancreas Cysts|Patients that have personal or family history of pancreatic cancer or pancreatic cysts.
2518174|NCT02775461||Inflammatory Pancreatic Diseases|Patients that have a personal or family history of pancreatic dysplasia or inflammatory pancreatic diseases.
2518204|NCT02775227|Experimental|Hydrocortisone|
2518206|NCT02775227|Active Comparator|Pasireotide|
2518485|NCT02773511|Other|Bone healing|Bone healing in surgical or conservative treatment for children type 1 humeral condyle fracture
2518486|NCT02773511|Other|Fracture displacement|Fracture displacement in surgical or conservative treatment for children type 1 humeral condyle fracture
2518528|NCT02772926|Placebo Comparator|Placebo|450 g per pill, 2 pills per day to get 900 mg per day
2518537|NCT02772926|Active Comparator|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 450 mg per pill, 2 pills per day to get 900 mg per day
2518597|NCT02772614|Experimental|Nebicapone (200 mg)|"Each subject was to receive one single dose of 2.5 MBq [14C]-labelled BIA 3-202 (200 mg) together with a total of 250 mL non-carbonated water.~The study drug was given after an overnight fast of at least 10 hours after the in-house stay. During waking hours on Day 1, subjects had to have a fluid intake of at least 150 mL per hour starting 1 hour before study drug administration."
2518651|NCT02772224|Experimental|Drug eluting balloon angioplasty|Paclitaxel coated balloon angioplasty
2518654|NCT02772224|Active Comparator|Conventional balloon angioplasty|Conventional balloon angioplasty
2549980|NCT02565095|Other|Carotid Baroreflex measurements|
3175185|NCT00631111|Active Comparator|2|
3175186|NCT00631111|Active Comparator|3|
3175187|NCT00631111|Placebo Comparator|4|
3175188|NCT00631124|Experimental|Arm 1|
3175189|NCT00631124|Experimental|Arm 2|
3175190|NCT00631176|No Intervention|1|
3175191|NCT00631176|Experimental|2|
3175192|NCT00631202|Experimental|I|Treatment arm
3175193|NCT00631215|Experimental|1|Healthy Adults
3175194|NCT00631228||1|The group will be monitored to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
3175195|NCT00631241|Experimental|Intraoperative Lymphatic Mapping|Single Photon Emission Computed Tomography - First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients. Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
3175196|NCT00631254|Active Comparator|1|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
3175197|NCT00631254|Active Comparator|2|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
3175198|NCT00631267|Placebo Comparator|1|Manual Manipulation
3175199|NCT00631267|Active Comparator|2|Finger Trap Traction
3175200|NCT00631280|Experimental|Choice|
3175201|NCT00631280|Active Comparator|Recommendation|
3175202|NCT00631293|Experimental|1|administration of lactisole
3175203|NCT00631293|Placebo Comparator|2|administration of placebo
3175204|NCT00631306||Bottle number 615|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
2517743|NCT02778321|Other|Uses of SpiderFlash monitor|"The intervention corresponds to the use of Spiderflash as Holter monitor. Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist."
3198350|NCT00869752|Experimental|Arm 1|MK-0646, a monoclonial antibody in combination with etoposide and cisplatin.
3198351|NCT00869765|Experimental|tDCS and D-CYC|Major Depression tDCS and D-cyc
2517845|NCT02777788|Active Comparator|chemotherapy|"Eligible subjects will be treated with platinum-doublet 2 cycles chemotherapy:pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin. Each cycle was 21-days.~Dosage:pemetrexed i.v.500mg/m2 d1 ; docetaxel i.v.75mg/m2 d1 ; gemcitabine i.v.1250 mg/m2 d1,d8 ; paclitaxel i.v.175mg/m2 d1 ; vinorelbine i.v.25mg/m2 d1,d8; carboplatin i.v.area under curve (AUC) 5 d1 ；cis-platinum i.v.75mg/m2 d1（or divided into 3days）；nedaplatin i.v.80mg/m2 d1."
2517846|NCT02777788|Experimental|TCM combined chemotherapy|TCM：JinFuKang plus XingZaoRuanJian, chemotherapy will be the same. JinFuKang po.tid.30ml d6-d21 XingZaoRuanJian po.tid.30ml d6-d21
2517914|NCT02777450||Block group|Lumbar facet block. Levobupivacaine 0,25% and corticosteroids
2517948|NCT02777099|Experimental|RIPostC|Receiving RIPostC with pressure set at 200 mmHg. Intervention:Procedure:Remote Ischemic Postconditioning
2517950|NCT02777099|Sham Comparator|sham RIPostC|"Receiving sham RIPostC with pressure set at the patient's diastolic blood pressure.~Intervention:Procedure:Sham Remote Ischemic Postconditioning"
2518001|NCT02776800|Experimental|Allevyn Life|Foam Dressing
2518004|NCT02776800|Other|Foam Dressing|Standard Care - Foam Dressing
2518087|NCT02776345|Active Comparator|Ultrasound guided Needle Fragmentation|"Ultrasound guided Needle Fragmentation (Intervention):~Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed."
2518090|NCT02776345|Active Comparator|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
2518092|NCT02776345|Placebo Comparator|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
2518127|NCT02775708|Experimental|capsule endoscopy|open label arm ; up to 100 subjects indicated for capsule endoscopy (CE) procedure will undergo the CE procedure with the Pillcam endoscopy system
3198352|NCT00869804|Experimental|Exercise|combination aerobic (walking) and resistance (strength training) exercise
3198353|NCT00869804|Sham Comparator|attention control|attention control with daily journal and cancer-related education
3198354|NCT00869817||1|Mutation Positive
2518359|NCT02774356||Native Chinese speakers|
2518360|NCT02774356||Native English speakers without experience of a tonal language|
2518401|NCT02773914|Experimental|CGA intervention|The CGA intervention will include multidisciplinary teams consisting of physician, nurse (RN), physiotherapist (PT), occupational therapist (OT) and social worker (SW). The team will work according to CGA, and have the primary and continuing responsibility for planning of hospital care and discharge. CGA will include assessment of socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, as well as treatment and planning for discharge and follow-up.
2518403|NCT02773914|No Intervention|Control group|The control group receives usual hospital care, that is care given at an ordinary medical hospital ward, without the specialized multi-disciplinary team approach and CGA.
3198355|NCT00869817||2|Mutation Negative
3198356|NCT00869830|Experimental|biofeedback|
2518495|NCT02773173|Experimental|Individualized Pneumoperitoneum Pressure|In Individualized Pneumoperitoneum Pressure (IPP) group, measures to optimize and individualize intra-abdominal pressure (PIA) will be apply.
2518496|NCT02773173|Other|Standard Pneumoperitoneum Pressure|In Standard Pneumoperitoneum Pressure (SPP) group, a conventional operation without optimization measures and PIA preset to 12 mmHg will be conducted.
2518507|NCT02772874||Urge-predominant|All subjects who report fecal incontinence that is primarily urge-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
2518601|NCT02772458|Experimental|Crohn's Disease|Active Crohn's Disease
3198357|NCT00869843|Other|Single group|
3198358|NCT00869856|Experimental|1|HX575, EPO Hexal
3198359|NCT00869869|Experimental|melatonin|melatonin
3198360|NCT00869869|Placebo Comparator|placebo|placebo
3198361|NCT00869882|Experimental|1|Posterolateral fusion with instrumentation combined to transforaminal lumbar interbody fusion
3198362|NCT00869882|Active Comparator|2|Posterolateral fusion with instrumentation
3198363|NCT00869895|Experimental|1|
3198364|NCT00869908||A|
3198365|NCT00869934|Active Comparator|1. Cognitive-Behavior Therapy|
3198366|NCT00869934|Experimental|2. Behavior Therapy|
3198367|NCT00869934|Experimental|3. Cognitive Therapy|
3198368|NCT00869973|Experimental|1|Aprepitant
3198369|NCT00869973|Active Comparator|2|dexamethasone
2517744|NCT02778477|Experimental|Part A_Cohort 2_Active|Multiple ascending dose of PF-06423264
2517746|NCT02778477|Placebo Comparator|Part A_Cohort 2_Placebo|Multiple dose of placebo
2517751|NCT02778477|Experimental|Part A_Cohort 3_Active|Multiple ascending dose of PF-06423264
2517754|NCT02778477|Placebo Comparator|Part A_Cohort 3_Placebo|Multiple dose of placebo
2517755|NCT02778477|Experimental|Part A_Cohort 4_Active|Multiple ascending dose of PF-06423264
2517756|NCT02778477|Placebo Comparator|Part A_Cohort 4_Placebo|Multiple dose of placebo
2517758|NCT02778477|Experimental|Part A_Cohort 5_Active|Multiple ascending dose of PF-06423264
2517760|NCT02778477|Placebo Comparator|Part A_Cohort 5_Placebo|Multiple dose of placebo
2517762|NCT02778477|Experimental|Part A_Cohort 6_Active|Multiple ascending dose of PF-06423264
2517764|NCT02778477|Placebo Comparator|Part A_Cohort 6_Placebo|Multiple dose of placebo
2517766|NCT02778477|Experimental|Part A_Cohort 7_Active|Multiple ascending dose of PF-06423264
2517767|NCT02778477|Placebo Comparator|Part A_Cohort 7_Placebo|Multiple ascending dose of placebo
2517768|NCT02778477|Experimental|Part B_Cohort 1_Active|Multiple doses of PF-06423264
2517769|NCT02778477|Placebo Comparator|Part B_Cohort 1_Placebo|Multiple doses of placebo
2517771|NCT02778477|Experimental|Part B_Cohort 2_Active|Multiple doses of PF-06423264
2517772|NCT02778477|Placebo Comparator|Part B_Cohort 2_Placebo|Multiple doses of placebo
2517832|NCT02777853|Experimental|Active (green) tea|Tea to be ingested 3 times per day for 7 days.
2517837|NCT02777853|Placebo Comparator|Placebo tea|Tea to be ingested 3 times per day for 7 days.
2517903|NCT02777541|Other|Early enteral nutrition|3 hours after PEG implantation
2517905|NCT02777541|Other|Late enteral nutrition|8 hours after PEG implantation
2517972|NCT02777073|Active Comparator|liraglutide 1.8 mg|single dose of Victoza ( liraglutide) 1.8 mg
2517973|NCT02777073|Experimental|dapagliflozin 10|single dose of Farxiga ( dapagliflozin) 10 mg
2517974|NCT02777073|Placebo Comparator|Placebo|Single dose of placebo
2518020|NCT02776605|Experimental|Ponatinib|"Pre-phase (maximum 7 days, -7 to -1) with Prednisone and triple intrathecal therapy (TIT)~Induction (day 1 to day 28 or up to hematological recovery) Vincristine (VCR): 1.5 mg/m2 IV days 1, 8, 15 and 22. Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22. Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27. Ponatinib 30 mg, PO from day 1 to consolidation. TIT, days 1 and 22.~Consolidation Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63. MTX: 1,5 g/m2, IV days 1, 28 and 56. VP-16: 100 mg/m2/12 h, IV, days 14 and 42. ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43. TIT days 1, 28 and 56. Ponatinib 30 mg/d PO, from day 1 to day 7 before HSCT.~HSCT (performed ideally within 1 month from the end of consolidation).~Post HSCT therapy (MRD monitoring)"
2518108|NCT02776059|Experimental|prednisolone or pentoxifylline + pegfiltrastim|prednisolone or pentoxifylline for 28 days PO plus pegfilgrastim subcutaneous weekly shot
2518114|NCT02776059|Active Comparator|prednisolone or pentoxifylline|prednisolone or pentoxifylline for 28 days
2518190|NCT02775448|Experimental|Diet + exercise + Carduus marianus 6cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 6cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2518192|NCT02775448|Experimental|Diet + exercise + Carduus marianus 12cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 12cH, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2518194|NCT02775448|Experimental|Diet + exercise + Carduus marianus 30cH|Diet (1600 cal/day) + aerobic exercise (30 min daily) + Carduus marianus 30c, 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2518195|NCT02775448|Placebo Comparator|Diet + exercise + placebo|Diet (1600 cal/day) + aerobic exercise (30 min daily) + placebo (87°alcohol), 24 drops diluted in 20 ml of water, by mouth, every 8 hours for 8 weeks.
2518250|NCT02775019|Active Comparator|Lactobacillus reuteri lonzenges|2x daily repeated intake of lozenges containing 10E9 CFU Lactobacillus reuteri each for 42 days
2518251|NCT02775019|Placebo Comparator|Placebo lozenges|2x daily repeated intake of lozenges being void of Lactobacillus reuteri for 42 days.
2518277|NCT02774655|Experimental|PAI APP|personal activity index application
2518281|NCT02774655|Active Comparator|FitBit APP|
2518310|NCT02774382|Active Comparator|Vancomycin|"Oral vancomycin according to number of recurrences (Danish guidelines):~First recurrence: Capsule vancomycin 125 mg x 4 p.o. times daily for 14 days~≥2 recurrences:~capsule vancomycin 125 mg x 4 times daily p.o. for 14 days followed by~capsule vancomycin 125 mg x 2 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 times daily p.o. for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every second day for 7 days followed by~capsule vancomycin 125 mg x 1 p.o. every third day for 14 days"
2518312|NCT02774382|Experimental|Vancomycin + fecal microbiota transplantation|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
2518317|NCT02774382|Experimental|Vancomycin + rectal bacteriotherapy|Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Rectal bacteriotherapy with 200 ml suspension of a fixed mixture of bacterial strains administrated with a rectal catheter.
2518377|NCT02774057|Experimental|Initial therapy with Captafer®|This arm will consist of 10 patients who will begin Captafer® therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Iron Sulfate therapy twice daily for an additional 6 weeks.
2518379|NCT02774057|Experimental|Initial therapy with Iron Sulfate|This arm will consist of 10 patients who will begin Iron Sulfate therapy twice daily for 6 weeks, then undergo a 2 week washout period before crossing over to Captafer® therapy twice daily for an additional 6 weeks.
2518429|NCT02773706|Experimental|Usual Subspecialty Care|"Once a subject is screened positive for anxiety or depression, the subspecialty provider is informed of the positive screen, and left to manage or refer the condition as per usual care by that provider.~Intervention: Depression / anxiety screen + clinician informed."
2518432|NCT02773706|Active Comparator|Integrated Psychology Care|"Once a subject is screened positive for anxiety or depression, an automated psychology referral occurs, in addition to any intervention determined by the subspecialty provider.~Intervention: Depression / anxiety screen + clinician informed + automated psychologist visit."
2518610|NCT02772458|Experimental|Healthy|Healthy volunteers
2517752|NCT02779088|Active Comparator|Delayed exercise and nutrition|Enrolled participants with sarcopenia will be randomized to receive either strengthening exercise and nutrition or education courses (DVD and handbook) first and then will receive the opposite intervention subsequently. The study will consist of two periods of 12 weeks separated by a washout period of 2 weeks. It's the AB/BA study. Subjects in the BA arm receive the education course first, followed by exercise and nutrition.
2517786|NCT02778048||fecal incontinence patients (m/f)|patients suffering from fecal incontinence (m/f) are going to be assessed via MRI, US, FLIP, and HRAM
2517835|NCT02777840|Active Comparator|Face mask group|Patients will be given oxygen via face mask as per routine practice, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
2517838|NCT02777840|Active Comparator|THRIVE group|Patients will be given oxygen via high flow oxygen in Optiflo, blood gas sample taken after airway is secured, heart rate of anaesthetist monitored and time for desaturation noted.
2517886|NCT02777580|Experimental|Pharmaco-invasive strategy|Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.
2517889|NCT02777580|Active Comparator|Standard primary PCI|Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.
2518002|NCT02776852|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2518038|NCT02776449||Normal Tension Glaucoma|Patients with manifest normal tension glaucoma
2518070|NCT02776137|Experimental|Docetaxel Group|Concurrent Chemoradiotherapy With Docetaxel
2518121|NCT02775786|No Intervention|Healthy Volunteers|Normal volunteers with no pancreas mass or risk factors for pancreas cancer will be recruited for MRI protocol optimization and nothing more. No intravenous contrast will be given. They will be asked to lie in the scanner for up to 1 hour and non-contrast imaging will be performed.
2518124|NCT02775786|Experimental|Pancreatic Mass or Risk Factors Group|Participants with pancreatic adenocarcinoma who are planning to undergo surgical resection. Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis .
2518198|NCT02775552|Experimental|A&T intervention areas|
2518199|NCT02775552|Active Comparator|Comparison areas|(Receive standard government services)
2518238|NCT02775058||patients|The subjects enrolled in this CI just received dental grafting by the device under evaluation and in any case will be subject to the same procedures foreseen for this CI for the dental implant surgery.
2518340|NCT02774486|Experimental|IQP-AK-102|2 capsules to be taken 3 times daily orally, 30 min before each main meal (breakfast, lunch, dinner) with 250 mL of water
2518348|NCT02774031|Experimental|Aisys with Et control|the ventilation modus will be pressure control ventilation with volume guarantee (PCV-VG). Settings: tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR) 12 -14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP). Target for end expired desflurane concentration (F A des) is set to 4.2%, and target for end expired oxygen (F AO2) is set to 35%.
2518351|NCT02774031|Active Comparator|Aisys conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Aisys with PCV-VG'
2518354|NCT02774031|Experimental|Flow-i with ACG|the following parameters will be preset: FIO2= 40%; end expired gas concentration (FA des) to 4.2%; speed 6; and ventilation modus = pressure regulated volume control (PRVC) with tidal volume (TV) 7-9 ml/kg BW, respiratory rate (RR)12-14/min, and 8-10 cmH2O positive end expiratory pressure (PEEP).
2518356|NCT02774031|Active Comparator|Flow-I conventional ventilation|50% oxygen and 50% air in 1 liter FGF will be administered. To be started with a FGF of 5l/min and vaporizer setting at 6 Vol% for 5 min. Then the FGF will be reduced to 1 l/min. 25 min later the vaporizer setting will be reduced to 5.5 Vol % for the rest of the study period. Ventilation modus for this group will be the same as for 'Flow-i with ACG'
2518393|NCT02773888|Experimental|HS-1000 recording|ICP readings will be recorded in parallel from both the invasive ICP monitor, and HeadSense's non-invasive ICP monitor. Each recording session will be done until an aggregate of at least 30 minutes worth of quality data is collected, depending on the patient's clinical condition. For each patient, two recording sessions will be completed for 30-60 minutes each for 120 minutes total.
2518424|NCT02773628|Placebo Comparator|control group|stable asthmatics receiving an Acar'up placebo system
2518427|NCT02773628|Active Comparator|treatment group|stable asthmatics receiving Acar'up system
2518470|NCT02773342||Pathological findings in chest CT|
2518516|NCT02773095|Experimental|Intervention counties|In intervention counties, a Novartis Access portfolio of 15 medicines will be sold to local purchasers at a cost of 150 Kenyan Shillings (KES), around US$1.50, per monthly dose.
2518519|NCT02773095|No Intervention|Control counties|Control counties not exposed to the intervention.
3175205|NCT00631306||Bottle number 429|Patients are randomized to either Bottle number 615 or Bottle number 429 (actual product vs. placebo). This is a blinded study.
2518603|NCT02772406|Experimental|Experimental group|(With LCI endoscopy and 1 month later with white light endoscopy) The patients will be evaluated by Linked Color Imaging and 1 month later evaluated by White Light endoscopy
2518612|NCT02772406|Active Comparator|Control group|(With white light endoscopy and 1 month later with LCI endoscopy) The patients will be evaluated by White Light endoscopy and 1 month later evaluated by Linked Color Imaging
2518645|NCT02772146|Experimental|Device: CLS UF|The purpose of CLS UF is ultrafiltration and drain of excess fluid in patients with congestive heart failure. The function of the device is to extra corporeally recirculate profiled glucose based PD fluid in a system and maintain glucose levels by adding extra glucose, to an adjustable and constant level, in order to maintain a stable ultrafiltration.
2550744|NCT02560233|Experimental|Contingent|Contingent RT-fMRI-NF
2517759|NCT02778737|Active Comparator|CBT-based intervention|The Cognitive Behavioral group + MTAU consists of an unpublished manual developed by Kalantzi-Azizi & Karademas (2003). It includes 8, 90-min weekly group session and primarily focuses on teaching patients to manage their pain by utilizing various techniques, such as activity pacing, muscle relaxation(i.e., progressive muscle relaxation, diaphragmatic breathing, guided imagery), pain recording, thought challenging, problem solving skills, relapse prevention, etc. The CBT protocol involves helping patients to learn to control their pain and to modify dysfunctional thoughts that accompany it.
2517824|NCT02778009|Experimental|Fit Physician Group|"Subjects will receive activity monitor and will be required to attend monthly wellness lectures and weekly exercise intervention.~Every subject will undergo an iDEXA scan to measure body mass composition"
2517825|NCT02778009|Active Comparator|Activity Monitor Only Group|"Subjects will receive an activity monitor without any intervention Every subject will undergo an iDEXA scan to measure body mass composition~)"
2517830|NCT02778009|Other|Control Group|Subjects will not an activity monitor nor will they receive any intervention Every subject will undergo an iDEXA scan to measure body mass composition
2517883|NCT02777489|Experimental|Perindopril Bluepharma 8 mg|Each participant will have an at least 4-week run-in period, followed by a 6 weeks treatment period with Perindopril 8 mg.
2517932|NCT02777164|Experimental|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
2517979|NCT02776917|Experimental|Cirmtuzumab + Paclitaxel|"Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.~Paclitaxel 80 mg/m^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle."
2518005|NCT02776579|Experimental|Girls-only resistance training|8 weeks of 2-3x/week girls-only resistance training class with a female strength and conditioning specialist.
2518006|NCT02776579|No Intervention|No resistance training|8 weeks of usual activity.
2518045|NCT02776202|Experimental|Reduced-intensity conditioning regimen|"The HSCT preparative regimen will consist of~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~Fludarabine: 35 mg/m2/day IV on Days -8 through -4~Melphalan: 140 mg/m2 IV on Day -3~Rest on Day -2 and -1~Day 0 is the day of transplant~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
2518067|NCT02776007|Experimental|Libre Flash CGMS (Continuous Monitoring System)|Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
2518069|NCT02776007|Active Comparator|SMBG|Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
2518135|NCT02775838|Experimental|kidney transplantation|Intravenous injection of Indocyanine Green in patients receiving kidney transplantation
2518158|NCT02775474|Experimental|Methadone|Methadone used as anesthesia opioid: induction with 0,15 mg / kg intravenous methadone. Boluses of 0,05 mg / kg intravenous methadone as needed intraoperatively
2518159|NCT02775474|Active Comparator|Fentanyl|Fentanyl used as anesthesia opioid: induction with 6 mcg / kg intravenous fentanyl. Boluses of 2 mug / kg intravenous fentanyl as needed intraoperatively
3198370|NCT00869986|Experimental|Dirucotide|
3198371|NCT00869986|Placebo Comparator|Placebo|
3198372|NCT00870012|Active Comparator|Lepicol probiotic & prebiotic formula+simple lifestyle advice|
2518364|NCT02773966|Experimental|Arm A: Kypho-IORT|balloon kyphoplasty/vertebroplasty + intraoperative radiotherapy
2518366|NCT02773966|Active Comparator|Arm B: EBRT|external beam radiotherapy with 30 Gy during 10 days (3 Gy/day)
2518402|NCT02773823|Active Comparator|Intervention|"Lifestyle intervention includes diet instruction and exercise intervention:~Diet instruction: The children were asked to increase fruit/vegetables consumption, reduce high fat food, etc.~Exercise intervention: The children participated sports 60 min/day,5d/week for 8 months."
2518404|NCT02773823|No Intervention|Control|"No intervention in the group with control."
2518443|NCT02773524|Experimental|Regorafenib|Regorafenib 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
2518444|NCT02773524|Placebo Comparator|Placebo|Placebo 160mg (4 x 40 mg tablets) orally, once daily on days 1-21 of each 28 day cycle + best supportive care until progression
2518562|NCT02772822|Experimental|Experimental|SCT400 plus CHOP, six cycles SCT400: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
2518567|NCT02772822|Active Comparator|Active Comparator|Rituximab plus CHOP, six cycles Rituximab: 375 mg/m2, IV, day 1 of each cycle Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle Doxorubicin: 50 mg/m2, IV, day 2 of each cycle Vincristine: 1.4 mg/m2, up to a maximal dose of 2 mg, IV, day 2 of each cycle Prednisone: 100 mg, po, day 2 to day 6 of each cycle
2518608|NCT02772497|Experimental|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks
2518670|NCT02772172|Active Comparator|GuideMia surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in GuideMia program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
2518671|NCT02772172|Active Comparator|Control surgical template|A radiographic guide is prepared before CT/CBCT scan. The CT/CBCT scan DICOM ﬁles are loaded in control program and converted into 3D computer images. A surgical template is fabricated through this virtual planning.
2518742|NCT02771665||Breast cancer women with known recurrences|Breast cancer women with known recurrences (locoregional recurrence and distant metastasis)
2518747|NCT02771665||Breast cancer women without recurrences|Breast cancer women without recurrences
3198373|NCT00870012|Placebo Comparator|Simple lifestyle advice alone|
3198374|NCT00870025|Active Comparator|hCG|200 IU rec hCG s.c./5 days, 4 doses prior to onset of COH
3198375|NCT00870025|Placebo Comparator|placebo|similar injection at same time points with similar diluent but no hCG
3198376|NCT00870038|Experimental|1|Paclitaxel eluting balloon (Elutax) + Genous stent
3198377|NCT00870038|Experimental|2|Uncoated balloon + Genous stent
3198378|NCT00870038|Active Comparator|3|Drug eluting stent (Taxus stent)
2517826|NCT02777905|Experimental|MBCT intervention|"Mindfulness Based Cognitive therapy (MBCT) will consist of group meditative practices, lasting 2 hours per week (or whatever the patient can tolerate). The interventions will be conducted at the centre local de services communautaires (CLSC) Benny Farm, once a week. Patients will be invited to try various techniques during sessions. The patients will be encouraged to practice the Mindfulness techniques, that includes formal mindfulness meditation and informal mindfulness practices (e.g. being in the present moment while not meditating), at home, between sessions, and will be provided with meditation compact discs to help them do so. MBCT interventions also include a cognitive therapy perspective. Specifically, the interventionists will offer education regarding depression and anxiety and will work on automatic mental processes that are believed to be at the root of the recurrence of depressive and anxious symptoms."
2517831|NCT02777905|No Intervention|Control Group|Patients randomized to the control group will be offered literature on mental health promotion and will receive treatment as usual in the primary care health center setting. After the end of the study, the control group will be offered MBCT.
2517910|NCT02777619|Placebo Comparator|Propofol and 0.0ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.0ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2517913|NCT02777619|Experimental|Propofol and 0.4ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.4ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2517917|NCT02777619|Experimental|Propofol and 0.6ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.6ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2517921|NCT02777619|Experimental|Propofol and 0.8ng/ml Dexmedetomidine|Propofol infusion was started to provide an effect-site concentration of 1.0ug/ml after Dexmedetomidine which target plasma concentration is 0.8ng/ml administered for 15min, and increased by 0.2ug/ml until the patient's consciousness disappears.
2517975|NCT02776956|Experimental|atorvastatin group|atrial fibrillation in atorvastatin group will orally receive atorvastatin before and after operation.
2517976|NCT02776956|Other|non-atorvastatin group|atrial fibrillation in non-atorvastatin group will not receive atorvastatin before and after operation..
2518095|NCT02775955|Experimental|RX0041-002|Active
2518166|NCT02775682||patients with epilepsy|
2518169|NCT02775682||normal individuals without epilepsy|
2518230|NCT02775279||Acute coronary syndrome group|200 consecutive patients were recruited, who have diagnosed with acute coronary syndrom(ACS) by quantitative coronary angiography.
2518233|NCT02775279||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2518257|NCT02774889|Active Comparator|Stepping Online|"Stepping On graduates receive Stepping Online, a password-protected continuation website to maintain fall prevention behaviors.~Fall prevention tips~Fall prevention exercise videos noting technique and safety~Guest expert videos and communication with expert~Tools to set exercise goals, reminders and track progress~Fall prevention specialist for feedback and group activities~Discussion and messaging (1:1, small and large group)~Fall prevention resources."
2518258|NCT02774889|No Intervention|Stepping On Usual Care Control|Subjects control workshops in the condition will not have access to Stepping Online.
3198379|NCT00870051||AAA patients|Subjects diagnosed with an AAA who are considered candidates for endovascular repair with Endurant Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this registry
3198380|NCT00870064|Other|Formal Operative Treatment|Children randomized to the formal operative management arm will be taken to the Operating Room within 24 hours for irrigation and debridement and appropriate bone management.
3198381|NCT00870064|Other|Emergency Department Treatment|Children in the Emergency Department Treatment arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
2518395|NCT02773745|No Intervention|Standard of Care|Participant will receive standard of care and a brochure on healthy eating.
2518396|NCT02773745|Active Comparator|Aquatic Prehabilitation Group|The prehabilitation group will undergo 6-8 weeks of individualized aquatic exercise in a heated pool (60 min/session, 3 times per week). Aquatic equipment maybe used to challenge balance and trunk stabilization.
2518437|NCT02773680|Experimental|Study cohort 1|"electrical impedance tomography"
2518467|NCT02773290|Experimental|Romiplostim|Weekly Subcutaneous (SC) administration
2518525|NCT02773056|Active Comparator|Socket 1 (Ischial Ramus Containment)|This arm included unilateral transfemoral amputees who were assessed while using the Ischial Ramus Containment socket.
2518527|NCT02773056|Active Comparator|Socket 2 (Dynamic Socket IRC)|This arm included unilateral transfemoral amputees who were assessed while using the Dynamic Socket Ischial Ramus Containment socket.
2518536|NCT02773056|Active Comparator|Socket 3 (Sub-Ischial Interface)|This arm included unilateral transfemoral amputees who were assessed while using the Sub-Ischial Interface socket.
2518595|NCT02772588|Experimental|patients with prostate cancer|Eligible patients will receive a total of 6 months of leuprolide, abiraterone, and ARN-509 to begin three months prior to RT and continuing until approximately 3 months post-RT. Patients will be assessed every 4 weeks (±1 week) (a cycle = 28 days) throughout their treatment with the study drugs, and at least once during RT.
2518672|NCT02772003|Experimental|Treatment (INO-8000, INO-9012, EP)|Patients receive INO-8000 IM and DNA plasmid encoding interleukin-12 INO-9012 IM (dose levels 2-4) followed by EP at day 0 and at weeks 4, 12, and 24.
2518762|NCT02771548||Anterior Cruciate Ligament Reconstruction|Those who have undergone unilateral anterior cruciate ligament reconstructive surgery in the Sports Surgery Clinic.
2518766|NCT02771548||Control|Healthy volunteers with no previous knee injury, no current lower limb injuries and take part in regular multidirectional team sports.
2518820|NCT02771132|Experimental|Intervention|"12-hour intervention IMPower empowerment self defense course for girls and 12-hour Source of Strength for boys+ 2 refresher sessions (at 2 hrs. per session)"
3198382|NCT00870077|Experimental|1|
2517839|NCT02777801|Experimental|Prophylactic Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the initiation of chemotherapy till 6 months after the end of chemotherapy.
2517843|NCT02777801|Active Comparator|Preemptive Entecavir|use of entecavir in the dose of 0.5mg p.o. every day from the time that the DNA copies of hepatitis B virus are more than 100 IU/ml till 6 months after the end of chemotherapy.
2517901|NCT02777515|Other|Patients using electronic cigarette|The patients under the age of 35 followed at the consultation of rythmology for a cardiovascular assessment and already smoking the electronic cigarette and this since at least 1 month. The patient will receive a clinical examination, an electrocardiogram, a Holter-ECG and an echocardiogram before and after electronic cigarette consumption for 15 minutes.
2517959|NCT02777138||Young males aged 20-35 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
2517963|NCT02777138||Old males aged 65-85 years old|"Maintaining a normal daily living lifestyle~Healthy~Reasonably active- PAL: 1.4-1.9~Non-obese- Fat mass index based on DEXA of 4-8kg/m2~Weight stable for more than 3 months (±3% body mass)~Non-smoker~No chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, peripheral arterial disease, insulin- or non-insulin dependent diabetes or other metabolic disorders~No daily consumption of analgesic or anti-inflammatory drug(s) including NSAIDs and corticosteroids, prescription or non-prescription~No medications that may influence lipid or carbohydrate metabolism or immune system function~No known negative reaction to lidocaine~No participation in heavy resistance training"
2518089|NCT02776306|Experimental|Mirror box therapy|The participants in the mirror box therapy arm will receive mirror box therapy for 3 weeks for upper limb rehabilitation post stroke.
2518091|NCT02776306|No Intervention|Standard treatment group|The participants will receive the standard treatment arm for 3 weeks for upper limb rehabilitation post stroke.
2518113|NCT02775734|Active Comparator|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + LOD
2518118|NCT02775734|Active Comparator|NO N-acetyl-cysteine|Clomiphene citrate + LOD
2518183|NCT02775487||COPD and air quality|Persons enrolled in the study will have been diagnosed with Stage III or IV COPD and samples of air taken from their home environment.
2518229|NCT02775188|Experimental|Physical Therapy with InterACTION|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week supplemented by home exercise program with InterACTION device.
2518231|NCT02775188|Other|Physical Therapy|After ACL Reconstruction, subjects will undergo physical therapy 1 time per week
3198383|NCT00870116|Other|1 - SBRT using cyberknife|SBRT using cyberknife: treatment = 2x15 Gy during 2 weeks
3198384|NCT00870116|Other|2 - SBRT using linear accelerator|SBRT using linear accelerator: treatment = 2x15 Gy during 2 weeks
3198385|NCT00870116|Other|3 - Conformational radiotherapy|Conformational radiotherapy: treatment = 5x2 Gy during 7 weeks
3198386|NCT00870129|Experimental|MRI|The advanced MRI studies will be obtained at the time of the routinely scheduled preoperative planning MRI and/or the routinely scheduled pre-RT planning MRI at approximately 3±2 weeks after surgery. The routine sequences obtained for the planning MRI are standard of care. The advanced MRI sequences may or may not be additional as some have already been adopted into the standard of care imaging at MSKCC.
3198387|NCT00870142|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
3198388|NCT00870142|Active Comparator|B|Norvasc® 10 mg Tablets, single dose
2518482|NCT02773225|Experimental|Eltrombopag + Ciclosporin A|"Eltrombopag, 75 mg film tablets, starting dose: 2 tablets (150 mg per day), daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
2518487|NCT02773225|Placebo Comparator|Placebo + Ciclosporin A|"Placebo for Eltrombopag 75 mg film tablets, 2 tablets, daily, per os~+ According to European guidelines CSA is administered orally with an initial daily dose of 5 mg/kg/day divided into two doses. Then dosage should be adjusted with the aim of a trough CSA blood level of 200-400 ng/mL (using a polyclonal assay) or 150-250 ng/mL (using a monoclonal assay)."
2518563|NCT02772861|Experimental|Citrulline|Citrulline is a non-protein amino acid that is present in substantial amounts in watermelon (Citrullus vulgaris), with a mean content of 2.1 mg/g fresh weight, ranging from 0.5 to 3.6 mg/g according to variety. The oral dose can reach 20 g, which was administered orally in the present study in one single dose, followed by a washout period of one week Amino Acid Supplement - One dose
2518568|NCT02772861|Experimental|Glutamine|"L-glutamine is a protein amino acid found in proteins of all life forms. It is classified as a semi-essential or conditionally essential amino acid. This means that under normal circumstances the body can synthesize sufficient l-glutamine to meet physiological demands. However, there are conditions where the body cannot do so. Recently, l-glutamine has come to be regarded as one of the most important of the amino acids when the body is subjected to such metabolic stress situations as trauma (including surgical trauma), cancer, sepsis and burns. In the present study, glutamine was administered orally in one single dose of 20 g, followed by a washout period of one week.~Amino Acid Supplement - One dose"
2518570|NCT02772861|Experimental|Arginine|"Arginine was administered orally in 20 g for one single dose, followed by a washout period of 1 week.~Amino Acid Supplement - One dose"
2518571|NCT02772861|Experimental|3-Methyl-Histidine|"This amino acid is made by methylation of the actin and myosin peptide chains in the muscle. Metabolism after intravenous administration of L-3-methylhistidine involves excretion in the urine of 75% of the administered dose in 24 h and 95% in 48 h.~3-Methyl-Histidine was administered orally in 120 mg for one single dose, followed by a washout period of 1 week."
2550747|NCT02560233|Sham Comparator|Non-contingent|Sham RT-fMRI-NF
3198389|NCT00870155|Experimental|Dirucotide|
2517891|NCT02777658||Primary Study Cohort|Patients with prior confirmed EGFR mutation-positive locally advanced or advanced NSCLC (Non-Small Cell Lung Cancer) who have progressed on or after EGFR-TKI (Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor) therapy
2517894|NCT02777658||Secondary Study Cohort|Patients diagnosed with de-novo (wild-type) EGFR T790M mutation-positive (alone or in combination with other mutations) locally advanced or advanced NSCLC
3198390|NCT00870181|Experimental|ADV-TK/GCV|ADV-TK was administered via intraarterial cerebral infusion. Systemic GCV therapy was delivered at a dose of 5mg/kg intravenous, every 12 h at 36 hours after ADV-TK therapy.
2518058|NCT02776124|Experimental|ONS group|Individualized dietary counseling+ONS(Healing elements)during CRT Interventions: (Healing elements)
2518059|NCT02776124|No Intervention|control group|Individualized dietary counseling during CRT
3198391|NCT00870181|Active Comparator|Control group|Patients received surgery or systemic chemotherapy or palliative care.
3198392|NCT00870207|Other|Immediate Intervention Group|The immediate intervention group will receive the TSSC pilot worksite intervention in the initial 12 week period from the pre-test/enrollment visit.
2518313|NCT02774538|Other|Experimental arm|
2518347|NCT02774109|Experimental|Experimental group|Participants in the experimental group will take fish oil (five 1000mg fish oil soft capsules per day, each capsule containing 350mg EPA and 250mg DHA) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
2518349|NCT02774109|Placebo Comparator|Control group|Participants in the control group will take placebo (five 1000mg sunflower oil soft capsules per day) and receive physical modality treatment (hotpacking 15min and transcutaneous electrical nerve stimulation (TENS) 15min, three times a week) for 8 weeks
3198393|NCT00870207|Other|Delayed Intervention Group|The delayed intervention group will receive the TSSC pilot worksite intervention beginning in month 6 of the study (6 months from the enrollment/pre-test visit).
2518484|NCT02773420|Experimental|HET application arm|Patients with grade I-II internal hemorrhoids will undergo HET application
2518520|NCT02772913||acute mesenteric ischemia|patients with abdominal pain and acute mesenteric ischemia
2518523|NCT02772913||non-acute mesenteric ischemia|patients with abdominal pain without mesenteric ischemia
2518575|NCT02772692|Experimental|Squatting pan|Defecation using a squatting pan
2518578|NCT02772692|No Intervention|Toilet|defecation using a standard-sized toilet
2518605|NCT02772419|Experimental|benralizumab A|Subcutaneous (SC) administration
2518614|NCT02772419|Experimental|benralizumab B|SC administration
2518617|NCT02772419|Placebo Comparator|Placebo|Placebo SC administration
2518683|NCT02772120|Active Comparator|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
2518684|NCT02772120|Active Comparator|Intramuscular Progesterone|Progesterone-25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
3198394|NCT00870220|Experimental|GH alone, Low dose E2 patch, Very Low-dose E2 patch|"Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months."
3198395|NCT00870246||1|High mobility
3198396|NCT00870246||2|Lower mobility
3198397|NCT00870272|Active Comparator|1|400mcg sublingual misoprostol
3198398|NCT00870272|Active Comparator|2|400mcg buccal misoprostol
3198399|NCT00870298|Experimental|computerized alert|An automatic electronic stop of the tmp/sulfa or warfarin order whenever a resident or nurse practitioner places an order for tmp/sulfa with an already active warfarin order, or when ordering both simultaneously
3198400|NCT00870298|Other|2 Current practice|Current practice of the pharmacist recommending cessation of concurrent warfarin and tmp/sulfa orders
2518950|NCT02770118|Experimental|PSR-TSD|Partial sleep restriction (PSR) followed by total sleep deprivation (TSD). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
2518959|NCT02770118|Experimental|TSD-PSR|Total sleep deprivation (TSD) followed by partial sleep restriction (PSR). Experimental procedures will begin with a 3-day period of habitual sleep (HS).
2518996|NCT02769637||ON PPI|Subjects on proton pump inhibitor (PPI) treatment
2518997|NCT02769637||OFF PPI|Subjects off proton pump inhibitor (PPI) treatment
2519043|NCT02769455|No Intervention|Control|The control group will not be exposed to any FOP nutrition labels
2519047|NCT02769455|Experimental|Front-of-pack labelling (Reference Intakes)|The second group will be exposed to a FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are presented in the form of a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
2519057|NCT02769455|Experimental|Front-of-pack labelling (5-CNL)|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format of the 5-CNL system therefore includes five categories of nutritional quality of food products, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the letter/colour corresponding to the product being enlarged."
2519381|NCT02767297|Experimental|Part 2: Multiple dose (dose level 3)|FDL169 test formulation (Dose level 3) administered as repeat doses in healthy subjects
3198401|NCT00870311|Experimental|Blinded Lithium|Bipolar Disorder patients
3198402|NCT00870324||1. Control|Patients will receive the Tendril (wide-spaced) lead as part of their ICD implant
3198403|NCT00870324||2. Experimental|Patients will receive the OptiSense (narrow-spaced) lead as part of their ICD implant
3198404|NCT00870337|Experimental|Single arm|
3198405|NCT00870350|Active Comparator|Td5ap|Group 1 receiving Td5ap as a single intramuscular injection.
2517981|NCT02776943|Experimental|Mesenchymal stem cell treatment|Umbilical Cord Mesenchymal stem cells (UCMSC) expanded and treated for 1-2 weeks. Then administer 5x10^6 of UCMSC per cm^2 of the cartilage defect.
2517983|NCT02776943|Active Comparator|Hyaluronic acid treatment|Administer hyaluronic acid (30 mg) in a single injection
2518009|NCT02776566|Active Comparator|Anticoagulation Clinic|"Usual care through pharmacist managed anticoagulation clinic~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
2518010|NCT02776566|Experimental|Patient Self-Monitoring|"In home self-monitoring and pharmacist guided education~Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages."
2518078|NCT02776293|Active Comparator|Relaxation Group|The relaxation group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to sit undisturbed for 20 minutes.
2518080|NCT02776293|Experimental|Music Group|The music group was asked to listen to their assigned audio file for at least 20 minutes a day and to record each time they had engaged in this activity. The audio file consisted of a two minute introduction. Following this, participants were instructed to listen to pre-recorded songs specifically composed for pregnancy.
3198406|NCT00870350|Active Comparator|Td1aP|Group 2 receiving Td1aP as a single intramuscular injection
3198407|NCT00870376||urodynamic studies|
2518224|NCT02775175|No Intervention|Fasting as Usual|This group will continue to practice their usual fasting regimen during Ramadan
2518225|NCT02775175|Experimental|Modified Ramadan Fasting|This group will receive an educational intervention providing knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
2518259|NCT02774863||"Group Maternal and Child Protection"|Followed by the doctor and pediatric nurse of the Maternal and Child Protection . A child psychiatric consultation (usual care) can take place during the monitoring of this patient.
2518260|NCT02774863||"Group Home passages"|A child psychiatric consultation is scheduled in the month following the inclusion and three home passages between the 2nd and 3rd months of follow up.
2518276|NCT02774603|Active Comparator|Aquatic Locomotor Training|Aquatic Locomotor Training is a Locomotor Training technique utilizing an underwater treadmill to help increase a patient's independence and function. Aquatic Locomotor Training may require up to three people to obtain desirable gait kinematics: one at each of the patient's legs, and one at the patient's pelvis; however, typically with ambulatory patients, only one therapist is utilized. Therapists are highly trained, using their legs and feet to provide properly timed underwater cues throughout the gait cycle.
2518280|NCT02774603|Active Comparator|Land Locomotor Training|Locomotor Training encompasses a variety of interventions ranging from BWSTT to overground gait training to robotic-assisted walk training. Overground Locomotor Training, depending upon the technique used, can require up to four people to complete the intervention (one at each participant's leg, one at the participant's trunk and/or pelvis, and one monitoring the computer and/or treadmill).
2518352|NCT02774447||Rectal cancer patients with ileostoma|"In association with anterior resection of rectal cancer these patients obtain loop-ileostoma in order to avoid complications. These are closed within a few months and according to previous studies the admission time is 3-5 days after operation. This study is a single-arm study. The arm include patients having had rectal cancer operation and who have obtained a loop-ileostoma and that meet the inclusion criteria.~The operation procedure is standardized; shortly described by dissecting the ileostoma from the abdominal wall and everting the stoma ledges, which will be sutured or stapled. The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will be followed up."
2518417|NCT02773927|Experimental|Agave inulin + Metformin|5 g of Agave inulin powder every 12 hrs + 500 mg tablet of metformin every 24 hrs
2518418|NCT02773927|Active Comparator|Metformin + Placebo of agave inulin|500 mg tablet of metformin every 24 hrs + 5 g every 12 hrs of calcinated magnesia powder
2518420|NCT02773927|Active Comparator|Agave Inulin+Placebo of Metformin|5 g of agave inulin powder every 12 hrs + 500 mg tablet of calcinated magnesia as metformin placebo every 24 hrs
2518422|NCT02773927|Placebo Comparator|Placebo of Inulin + Placebo of Metformin|5 g of calcinated magnesia powder every 12 hrs + 500 mg tablet of calcinated magnesia every 24 hrs
2518494|NCT02773264||UltraSound Patients|All patients will undergo next to the clinical indicated conventional US-examination, US Elastography after informed consent. After completion of these three examinations, the participation in the study is completed.
2518511|NCT02772887|Experimental|Citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
2518513|NCT02772887|Placebo Comparator|Placebo|Placebo, 3 grams once per day for 3 weeks.
3198408|NCT00870402|Experimental|1|
2518619|NCT02772380|Experimental|VT/ VF induction and defibrillation|Ventricular Tachycardia and Ventricular Fibrillation (VT/VF) induction and termination through use of a defibrillator, will be carried out as the intervention in all subjects undergoing study procedures.
2518620|NCT02772445|Experimental|STROKE-CARE Intervention|In STROKE-CARE, caregivers will learn a problem-solving strategy. Participants will receive approximately 10 sessions by an occupational therapist in the home over a 5 week process.
3198409|NCT00870402|Placebo Comparator|2|
3198410|NCT00870415|Experimental|Surgerie|
3198411|NCT00870428||Preeclampsia Evaluation|Patients who are admitted for the evaluation of preeclampsia
3198412|NCT00870441|Experimental|1. ASP2151|
3198413|NCT00870441|Active Comparator|2. Valacyclovir|
3198414|NCT00870441|Placebo Comparator|3. Placebo|
3198415|NCT00870454|Experimental|001|Carisbamate 800 mg/d 200 mg/d twice daily titrated up to 400 mg twice daily as tolerated by Week 3
2518046|NCT02776189|Experimental|Midazolam & Dexmedetomidine|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
2518048|NCT02776189|Active Comparator|Midazolam & Propofol|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation. Intravenous propofol 2 mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
3198416|NCT00870454|Experimental|002|Carisbamate 1 200 mg/d 200 mg/d twice daily titrated up to 600 mg twice daily as tolerated by Week 3
3198417|NCT00870454|Active Comparator|003|Pregabalin 300 mg/d 75 mg/d twice daily for Week 1 followed by 150 mg twice daily for the remainder
2518202|NCT02775318|Other|Stellate Ganglion Block|After diagnosis of vasospasm patients were administered ultrasound guided Stellate Ganglion block using 10 cc of 0.5% Inj Bupivacaine on the same side of vasospasm or the side contralateral to the focal neurological deficit.Patients were then assessed using transcranial Doppler and digital subtraction angiography after 30 minutes
2518261|NCT02774694||observational cohort|patients undergoing interventional pain management procedures
2518305|NCT02774551|Experimental|Physical activity intervention group|The physical activity program includes 150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week are demonstrated by the research nurse. The resistance training is progressive by increasing resistance in the band based on patient's adaptability during the intervention.
2518306|NCT02774551|No Intervention|Standard care control group|Patients follow their routine daily physical activity.
3198418|NCT00870454|Placebo Comparator|004|Placebo Placebo capsules twice daily
3198419|NCT00870480|Experimental|A|Finasteride 5 mg single dose tablet, single dose
2518458|NCT02773316|Experimental|MR902 50/0.5 mg|MR902 50/0.5 mg PR tablets, single dose oral
2518459|NCT02773316|Experimental|MR902 200/2 mg|MR902 200/2 mg PR tablets, single dose oral
2518460|NCT02773316|Active Comparator|IR morphine sulphate 10 mg/5mL solution|IR morphine sulphate 10 mg/5mL solution, single dose oral
2518509|NCT02773134|Active Comparator|Brace Group|Patients in the brace group will be fitted by an orthotist postoperatively and will be instructed to wear a rigid molded Lumbosacral Orthosis (LSO) full time for 8 weeks except during hygiene and wound care followed by daytime wear for another 4 weeks. All patients will start wearing the brace 48 hours after the surgery following removal of the wound drain. All braces will be molded and fitted by the same experienced orthotist affiliated with the hospital. Self-compliance to brace wear will be noted every day for 3 months by each patient on a specific form.
2518510|NCT02773134|Experimental|Control Group|No brace prescription postoperatively. Patients in this group will be observed and results will be compared to the brace group.
2518533|NCT02772770||Non Operative: Rehabilitation, Bracing, Activity Restriction|
2518542|NCT02772770||Operative: Transphyseal|
2518547|NCT02772770||Operative: Partial Transphyseal|
2518550|NCT02772770||Operative: Physeal sparing by Anderson Technique|
2518553|NCT02772770||Operative: Physeal sparing by Micheli/Kocher Technique|
3198420|NCT00870480|Active Comparator|B|Proscar® 5 mg Tablet, single dose
3198421|NCT00870493|Experimental|I|each subject will receive oral aliskiren 300 mg/day for 16 weeks, followed by a washout period of 4 weeks, then crossed over to placebo for another 16 weeks
2518673|NCT02771938|Experimental|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
2518674|NCT02771938|Active Comparator|Radiotherapy after surgery|Mastectomy and DIEP flap reconstruction followed by radiotherapy (current standard treatment)
2518727|NCT02771652|Active Comparator|e-training intervention|Resistance and endurance training
2518728|NCT02771652|Other|Control|no exercise
2518740|NCT02771327|Experimental|CPAP plus gas|Treatment with Boussingnac valve CPAP during 6 hour, starting immediately after weaning
2518744|NCT02771327|Active Comparator|Usual treatment(ventimask plus gas)|ventimask
2518909|NCT02771171||Age groups|The cohort is divided into on the basis of age
2518954|NCT02770092|Experimental|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2518958|NCT02770092|Experimental|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2518964|NCT02770092|Experimental|Congestive Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day(s): may include combinations of stable isotope infusions and sip feeding with blood draws and cognition testing"
2519020|NCT02769728|Experimental|EndoBarrier|EndoBarrier will be implemented for 9 months.
2519076|NCT02769286|Experimental|Osimertinib in cohort 1|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA
2519077|NCT02769286|Experimental|Osimertinib in cohort 2|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring T790M which were detected from circulating tumor DNA
2519153|NCT02768675|Experimental|LOADPRO arm|Participants will temporarily receive a LOADPRO device affixed to kyphotic corrective rods. The device will not be implanted and will be removed prior to surgery closure.
2519204|NCT02768389|Experimental|Modified Atkins Diet and Bevacizumab|Patients and caregivers will be educated by a nutritionist skilled in the MAD. Patients will also be receiving Bevacizumab as standard of care.
3198422|NCT00870493|Active Comparator|II|each subject will receive placebo for 16 weeks, followed by a washout period of 4 weeks, then crossed over to oral aliskiren 300 mg/day for another 16 weeks
3198423|NCT00870506|No Intervention|2|No intervention (control)
3198424|NCT00870506|Experimental|1|5-minute video on donation and transplantation
3198425|NCT00870519|Experimental|I 123-MNI-168|
3198426|NCT00870519|Experimental|I123 MNI168|brain imaging using I123MNI168
2518060|NCT02776241|No Intervention|water restriction|20 patients will be subjected to 3 hours of water restriction following MR scan of the kidneys.
2518061|NCT02776241|Active Comparator|high water intake|20 patients will be subjected to 1 hour of high water intake (20 ml/kg) following MR scan of the kidneys.
2518129|NCT02775877|Experimental|letrozole and clomiphene|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and clomiphene100 mg tablet orally once a day from 11-15 day of menstrual cycle.
2518133|NCT02775877|Active Comparator|Letrozole and human menopausal gonadotropin (HMG)|Letrozole 5 mg tablet orally from 3-7 day of once a day menstrual cycle and HMG 75u once a day by intramuscular injection from 11-15day of menstrual cycle
2518171|NCT02775396|Experimental|Adult computer user|Wearing each of the two spectacle lens designs for one month in random sequence
2518218|NCT02775253|Experimental|Chronic cold acclimation group|All patients will be conducted a chronic cold acclimation intervention for 33 days.
2518335|NCT02774525|Active Comparator|Treatment as Usual (TAU)|Outpatient substance-abuse treatment plus drug and alcohol screening plus brief support for personal goal setting
2518337|NCT02774525|Experimental|Contingency Management|Contingency management for drug and alcohol abstinence plus TAU
2518338|NCT02774525|Experimental|Parenting Intervention|Parenting intervention plus TAU
2518339|NCT02774525|Experimental|Parenting Intervention + Contingency Management|Parenting intervention plus contingency management for drug and alcohol abstinence plus TAU
2518381|NCT02774018|Experimental|12 institutionalized elderly people|Mindfulness-Based Stress Reduction program.
2518415|NCT02773719|Experimental|True biofield therapist|Subject will have a 40 minutes therapy with a real biofield therapist to treat the wart
2518416|NCT02773719|Placebo Comparator|Fake biofield therapist|Subject will have a 40 minutes therapy with a fake biofield therapist to treat the wart
3198427|NCT00870532|Experimental|1|60 mg/week of vinorelbine + sorafenib
3198428|NCT00870532|Experimental|2|90 mg/week of vinorelbine + sorafenib
3198429|NCT00870532|Experimental|3|120 mg/week of vinorelbine + sorafenib
3198430|NCT00870558|Experimental|Arm I|Patients receive an intra-arterial infusion of iodine I 131 ethiodized oil.
3198431|NCT00870558|Placebo Comparator|Arm II|Patients receive an intra-arterial infusion of unlabeled ethiodized oil.
3198432|NCT00870571|Experimental|A|AMLODIPINE (as BESILATE) TABLETS 10 mg, single dose
3198433|NCT00870571|Active Comparator|B|NorvasC® 10 mg Tablets, single dose
3198434|NCT00870597|Experimental|1|Multifocal IOL implant associated with vitreous opacities that underwent 25-gauge vitrectomy were prospectively analyzed.
3198435|NCT00870597|Experimental|2|Multifocal IOL implantation without transconjunctival vitrectomy
2518632|NCT02772315||Hypertensive patients|Diagnostic procedures in patients with hypertension applying omics results
2518720|NCT02771886|Active Comparator|2-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 2nd week in the study. The duration of the study will be 6 weeks."
2518722|NCT02771886|Active Comparator|4-week intervention group|"The Surf the Urge intervention will be provided to the participant during his or her 4th week in the study. The duration of the study will be 6 weeks."
2518785|NCT02771405|Experimental|Sofosbuvir +Ribavirin|Sofosbuvir 400 mg/day +ribavirin for 24 weeks
2518786|NCT02771405|Experimental|Sofosbuvir+Simeprevir±Ribavirin|Sofosbuvir 400 mg/day +Simeprevir 150 mg/day ± ribavirin for 12 weeks
2518787|NCT02771405|Experimental|Sofosbuvir+Daclatasvir±Ribavirin|Sofosbuvir 400 mg/day +Daclatasvir 60 mg/day ± ribavirin for 12 weeks
2518788|NCT02771405|Experimental|Sofosbuvir+Ledipasvir±Ribavirin|Sofosbuvir 400 mg/day +Ledipasvir 90 mg/day ±ribavirin for 12 weeks
2518823|NCT02770911|Experimental|"without Dog Ear group"|Before anastomosis, the surgeon made a laparoscopic suturing on the two dog ears by using 3-0 monofilament sutures, and pull two dogears of staple line around the trocar by a tied suture through two dog ears. By this way, the staple line was kept within the circular knife when the circular stapler was closed. Then a true end-to-end anastomosis was performed after stapler firing.
2518826|NCT02770911|Active Comparator|"with Dog Ear group"|traditional double-stapled anastomosis was used for laparoscopic anterior resection
2518863|NCT02770651||Optical Coherence Tomography|To evaluate the incidence of late incomplete stent apposition (ISA) and un-coverage by optical coherence tomography (OCT) following everolimus-eluting stent (EES) with bioabsorbable polymerversus zotarolimus-eluting stent (ZES) with permanent polymer implantation in patients with AMI at 12 months.
3198436|NCT00870649|Experimental|Bilhvax vaccine (Sh28GST)|Arm 1 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of candidate vaccine at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
3198437|NCT00870649|Placebo Comparator|Placebo|Arm 2 : S. haematobium infected children pretreated by two doses of PZQ (at Week-9 and W-8)receiving 3 injections of placebo at D0, W4, W8 and a boost at W52, and then treated by a third dose of PZQ at W44.
3198438|NCT00870662|Experimental|Automatic Fluid Shunt|
3198439|NCT00870675||ventriculomegaly|Pregnant women carrying a fetus with the ultrasound finding of enlarged ventricles (ventriculomegaly).
2519168|NCT02768883|Experimental|Clinic + Home + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2519170|NCT02768883|Experimental|Clinic + Community|"Clinic Intervention = 4 clinical visits with provider over 12 months, 4 visits with clinic asthma educator~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2519171|NCT02768883|Experimental|Home + Community|"Home Intervention = 4 home visits with community health worker over 2 months, 4 mailers, and 4 phone calls~Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook."
2519172|NCT02768883|Active Comparator|Community only|Community Intervention = exposure to air quality flag program; 3 rotating messages distributed via TV, radio, posters, public presentations, website, Facebook.
2552687|NCT02547883|Experimental|Patients stopping statin|
2518074|NCT02776267|Experimental|Angiolite stent - 3-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 3-month post index PCI.
2518077|NCT02776267|Experimental|Angiolite stent - 6-month angiogram/OCT|Patients scheduled for PCI (and whot meet pre-specified inlcusion criteria) are enrolled to receive the Angiolite DES. They will undergo a scheduled repeat coronary angiogram and OCT evaluation at 6-month post index PCI.
2518105|NCT02775760|Experimental|Cardiovascular endurance|Participants will undergo cardiovascular endurance training. The trainer-supervised endurance training will involve walking on a treadmill at moderate intensity
2518112|NCT02775760|Active Comparator|Strength, balance, and flexibility|Participants will undergo Strength, balance, and flexibility training.
2518182|NCT02775591|Experimental|Motilitone arm|DA-9701 (Motilitone) 30mg 1T three times per day for 4+8 weeks
2518186|NCT02775591|Placebo Comparator|Placebo arm|DA-9701 placebo 30mg 1T three times per day for 4 weeks, DA-9701 (Motilitone) 30mg 1T three times per day for 8 weeks
2518219|NCT02775084|Experimental|Healthy Fish Oil|8 grams fish oil
2518221|NCT02775084|Placebo Comparator|Olive Oil|8 grams olive oil
2518269|NCT02774876|Active Comparator|Carbohydrate meal|
2518272|NCT02774876|Active Comparator|Carbohydrate + fat meal|
2518273|NCT02774876|Active Comparator|Carbohydrate + protein meal|
2518274|NCT02774876|Active Comparator|Carbohydrate + fat + protein meal|
2518355|NCT02774239|Experimental|SC Treatment Period|"Participants will receive 2gm/kg of Human normal immunoglobulin G (IgG) infused over 4 weeks in a dose escalating manner as follows:~1st week: 2-3 SCIG infusions of 10ml per site at four sites (total dose 16 to 24g)*~2nd week: 2-3 SCIG infusions of 15ml per site at four sites (total dose 24 to 36g)*~3rd week: 2-4 SCIG infusions of 20ml per site at four sites (total dose 32 to 64g)*~4th week: 2-4 SCIG infusions of 25ml per site at four sites (total dose 40 to 80g)*~Doses indicated are study recommended. Doses may be adjusted depending on tolerance and total dose required by the patient."
2518411|NCT02773901|Experimental|HS-1000 recording|ICP monitoring will be done with the HS-1000 to compare to CSF measurement from lumbar puncture (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals last 10 minutes.
2518489|NCT02773485|Active Comparator|Systemic Chemotherapy|Irrespective of arm allocation Baseline Positron Emission Tomography(PET) scan and hepatic function assessment will be done. Those randomized to this arm will receive systemic chemotherapy delivered on day 1 and 8 every 3 weekly, with gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2. After first 4 cycles patients will undergo repeat Contrast Enhanced Computed Tomography(CECT)/PET scan. If CECT/PET scan shows stable/ responding disease then patients will continue to receive the same chemotherapy. In case of locally progressive/ systemic disease on chemotherapy patients may be considered for second line palliative chemotherapy or best supportive care. The use of radical chemoradiation is not allowed on disease progression in this arm. However palliative radiation may be used.
2518492|NCT02773485|Experimental|Chemotherapy and radiation|In those randomized to radiation arm with receive high dose radiation with Intensity Modulated Radiation Therapy in addition to systemic and concurrent chemotherapy. The gross tumor will comprise the high dose volume. The adjacent areas of suspected microscopic disease will form the low dose volume. When only external radiation is used the aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
2518579|NCT02772705||Hyperthyroidism|Those with Grave's Disease(GD,Hyperthyroidism),with lower TSH, and higher FT3, FT4.
2518581|NCT02772705||Health Humans|Those humans who are healthy, without GD, without any treatment, with normal TSH, FT3, FT4.
2518609|NCT02772354|Experimental|Ablation|Standard radiosurgery ablation of premature ventricular complexes using navigation system.
2518613|NCT02772354|Active Comparator|Control|Antiarrhythmic therapy of premature ventricular complexes according to the guidlines
2518638|NCT02772042|Experimental|Intervention Group|Investigators will performed traction manipulation of those articulations of upper cervical spine with indication for this treatment. Before manipulation soft tissue techniques will be applied in order to prepare the joint. After manipulation the patient rest in supine position. The intervention will have a duration of 10 minutes.
2518643|NCT02772042|Other|Control Group|The patient of the control group maintain the supine position for 10 minutes.
2518702|NCT02771821|Experimental|Group Intervention|Individual routine consultation with the Family Health Unit team and participation in operative groups based on methodology of problematization
2518704|NCT02771821|No Intervention|Control Group|Individual routine consultation with the Family Health Unit team
2518732|NCT02771509|Active Comparator|ANG-3777|Study drug will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
2518734|NCT02771509|Placebo Comparator|Normal Saline|The placebo will be administered for a total of 4 daily intravenous (IV) infusions. The first post-operative dose MUST be started within 4 hours of completing CPB. The second dose will be administered 24 ± 2 hours after completing CPB, and the third and fourth doses will be administered 24 ± 2 hours after each previous dose. Duration of administration is 30 minutes.
2518804|NCT02770950|Active Comparator|High dose group|"High dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 24h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 24h per day."
2518805|NCT02770950|Active Comparator|Low dose group|"Low dose of Zushima plaster: a piece of Zushima plaster will be used topically for each knee for 12h per day.~Eligible subjects will use a piece of Zushima plaster topically for each knee for 12h per day."
2518806|NCT02770950|Active Comparator|Controlled group|Indometacin Cataplasms will be used topically on the knee for 24h per day
3198440|NCT00870701|Experimental|Absence of Radiotherapy|No Radiotherapy; Simple monitoring without active treatment
2519012|NCT02769897|No Intervention|Control group|The control group did not receive the intervention.
2519188|NCT02768454||inpatient under broad-spectrum antibiotics|medical review
3198441|NCT00870701|Active Comparator|Radiotherapy|Radiotherapy
2518096|NCT02776436|Experimental|Breast cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 12 mg dexamethasone per day (8-4mg/day) for 3 days starting 1 day before administration. (n=6)~STEP 2: 8mg dexamethasone per day (8mg once a day) for 3 days starting 1 day before administration. (n=6)~STEP 3: day -1: 4 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 4: day -1: 0 mg, day 0: 8 mg, day 1: 4 mg. (n=6)~STEP 5: day -1: 0 mg, day 0: 8 mg, day 1: 0 mg. (n=6)~STEP 6: day -1: 0 mg, day 0: 4 mg, day 1: 0 mg. (n=6)"
2518097|NCT02776436|Experimental|Prostate cancer|"Dose of prophylactic dexamethasone will be reduced as follows:~STEP 1: 2dd 8 mg at 12 and 1 hr before treatment (besides standard prednisone 5mg bid) (n=6)~STEP 2: 8mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 3: 4mg dexamethasone 1 hour before treatment (and standard prednisone 5mg bid). (n=6)~STEP 4: 0mg dexamethasone (only standard prednisone 5mg bid). (n=6)"
2518178|NCT02775500||Apremilast-Exposed Cohort|Women who have been exposed to apremilast in pregnancy for an approved indication in the first trimester of pregnancy for any length of time from the date of conception.
2518181|NCT02775500||Diseased Comparison Cohort|Women with an approved disease who have not been exposed to apremilast at any time in pregnancy.
2518187|NCT02775500||Healthy Comparison Cohort|Healthy women who have no diagnosis of an approved indication or other chronic illness, have not taken apremilast in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
2518189|NCT02775500||Apremilast-Exposed Registry Group|Women who have been exposed to apremilast in pregnancy, for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
2518211|NCT02775110|Active Comparator|Immediate Discontinuation Group|Patients will discontinue the natalizumab therapy at once and initiate another disease modifying therapy at 1 month following the last natalizumab infusion. The disease modifying therapy at 1 month following natalizumab discontinuation will be at the discretion of the neurologist and may differ among patients.
2518216|NCT02775110|Experimental|Taper-off Group|Patients will be administered two more natalizumab infusion, one at six weeks and the second at eight weeks (14 weeks from study entry), followed by six months natalizumab discontinuation. Another DMT will be initiated within two months after the last natalizumab infusion.
2518256|NCT02774902|Experimental|TAK-438 40 mg + Clarithromycin 500 mg|TAK-438 40 mg, tablets, orally once on Days 1 and 8 along with clarithromycin 500 mg, tablets, orally twice daily from Days 3 to 9.
2518320|NCT02774460|Active Comparator|Zestril® (Lisinopril)|Inhibition of angiotensin converting enzyme (ACE inhibitor). Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
2518324|NCT02774460|Active Comparator|Atacand® (Candesartan)|Angiotensin receptor blocker. Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
2518327|NCT02774460|Active Comparator|Norvasc® (Amlodipine)|Calcium channel blocker. Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
2518329|NCT02774460|Active Comparator|Hydrochlorothiazide® (Hydrochlorothiazide)|Diuretic agent. Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
2518331|NCT02774460|Active Comparator|Repeated treatment X|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
2518332|NCT02774460|Active Comparator|Repeated treatment Y|"Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y.~The repeated arms will be given with the same duration and dosing as the other arms."
2518333|NCT02774460|Placebo Comparator|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
2518383|NCT02773979|Active Comparator|Group 1: PfSPZ 51200 sporozoites/Placebo|Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1
2518387|NCT02773979|Active Comparator|Group 2: PfSPZ 102400 sporozoites/Placebo|CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1
2518388|NCT02773979|Active Comparator|Group 3: PfSPZ 102400 sporozoites|CQ/PfSPZ Challenge 102400 sporozoites N=9
2518445|NCT02773589|Experimental|Peroral endoscopic myotomy|
2518466|NCT02773251|Experimental|hyaluronic acid-carboxymethylcellulose treatment group|the HA/CMC treatment group after laparoscopic pelvic surgery
2518475|NCT02773251|No Intervention|control group|the HA/CMC non-treatment group after laparoscopic pelvic surgery
2518564|NCT02773082|Experimental|Reclaim™ DBS Therapy|Procedure: Reclaim™ DBS Therapy The DBS lead is stereotactically introduced into the target in the brain (AIC) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region. This is performed by a neurosurgeon skilled in this technique, as the same procedure is routinely performed in patients with other diseases (using other brain targets).
2518590|NCT02772523|Other|Intervention|
3198442|NCT00870714|Experimental|A|Eligible patients with high-risk prostate cancer who are scheduled to undergo radical prostatectomy will receive four cycles of therapy with ketoconazole and docetaxel prior to surgery resection
2518741|NCT02771691|Experimental|MBT therapy plus treatment as usual|Mentalization based group treatment for adolescents plus standard care
2518745|NCT02771691|No Intervention|Treatment as usual alone|Standard care provided by local Child and Adolescent Mental Health Services
2518851|NCT02770703|Experimental|Open inguinal hernia repair (Lichtenstein)|Open inguinal hernia repair using a DynaMesh visible mesh
2518853|NCT02770703|Experimental|Total extraperitoneal inguinal hernia repair (TEP)|Total extraperitoneal inguinal hernia repair using a DynaMesh visible mesh
2518855|NCT02770703|Experimental|Trans abdominal preperitoneal hernia repair (TAPP)|Trans abdominal preperitoneal hernia repair using a DynaMesh visible mesh
2518912|NCT02770508|Experimental|Darunavir/ritonavir plus lamivudine|Darunavir/ritonavir 800/100 mg, 1 coformulated tablet QD and lamivudine 300 mg, 1 tablet QD
2518914|NCT02770508|Active Comparator|Darunavir/ritonavir plus emtricitabine/tenofovir(FTC/TFD)|Darunavir/ritonavir 800/100 mg1 coformulated tablet QD (FDC) plus FTC/TDF 200/300 mg, 1 coformulated tablet QD
2518972|NCT02769988||Project SHARE|
2519017|NCT02769650|Experimental|Stress-MRI + Chronic total occlusion PCI|Pre- and postoperative stress-MRI with evaluation of myocardium perfusion defects + Coronary angioplasty with stenting of RCA CTO
2518141|NCT02776072||fingolimod|Participants who initiated fingolimod during the specified time period
2518252|NCT02774993|Experimental|Doxycycline|Doxycycline 100 mg twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently doxycycline will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
2518254|NCT02774993|Placebo Comparator|Placebo|Placebo twice daily with once daily anti-tuberculous treatment comprising of rifampicin 10 mg/kg, isoniazid 5 mg/kg, ethambutol 20 mg/kg, pyrazinamide 25 mg/kg and pyridoxine 10-50 mg per day according to managing physicians' discretion. These will be given daily for 14 days. Subsequently placebo will be ceased and patients are to continue with their standard anti-tuberculous treatment and duration according to their managing physician
3165393|NCT00512499|Experimental|Group 3|INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
3165394|NCT00512525|Placebo Comparator|2|
2518311|NCT02774395||endometrioid adenocarcinoma grade I|
2518318|NCT02774395||endometrioid adenocarcinoma grade II|
2518321|NCT02774395||endometrioid adenocarcinoma garde III|
2518326|NCT02774395||healthy endometrioid|obtain after hysterectomia provided for
2518342|NCT02774161|Experimental|Diagnostic (B-mode ultrasound imaging)|Patients undergo B-mode ultrasound imaging of the liver over 15 minutes.
2518384|NCT02774005|Experimental|Raxone|
2518479|NCT02773433|Experimental|PAV group|Using Proportional Assist Ventilation after failed Spontaneous Breathing Trial
2518480|NCT02773433|No Intervention|Control group|Using Volume Assist Control mode after failed SBT
2518512|NCT02772991|Experimental|Cases|All patients will be submmited to troponin measurements and CCTA. If CCTA shows coronary stenosis ≥ 50%, patient will initiate the ACS treatment and be hospitalized to have coronary cineangiography. If CCTA shows lesions < 50%, the patient will be discharged and monitored for 30 days. A second sampling of the troponin will be obtained from all patients three hours after the first collection in order to evaluate for an increase/decrease of troponin.
2518592|NCT02772731|Experimental|Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the shave margin group where additional tissue will be resected.
2518593|NCT02772731|Active Comparator|No Shave Margin|After partial mastectomy, patients will be subject to intraoperative randomization to the no shave margin group, where after initial surgery, no further tissue will be removed.
2518640|NCT02772133||STEMI patients|
2518642|NCT02772133||Healthy subjects|
2518650|NCT02772133||Unstable angina|
2518723|NCT02771808||diabetic patients|obtain biomarker samples from diabetic patients and examine for 1-1 & 1-2 & 2-2 haptoglobin genotype
2518733|NCT02771379||Patients who are treated with Raxone®|
2518808|NCT02771041|Experimental|Group with D-8 medical consultation|"A medical consultation 8 days before surgery would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
2518809|NCT02771041|No Intervention|Group without D-8 medical consultation|
3165395|NCT00512551||Cervical cancer tumor biopsy + radiation therapy|Cervical cancer tumor biopsy + radiation therapy.
3165396|NCT00512564||1|Patients suffering from Sickle cell disease
2519033|NCT02769572|Experimental|real moxibustion plus placebo gel|In subjects with osteoarthritis of the knee
2519040|NCT02769572|Active Comparator|diclofenac sodium gel plus sham moxibustion|In subjects with osteoarthritis of the knee
3165397|NCT00512577|Active Comparator|A|Patients will not receive a pre-operative transfusion.
3165398|NCT00512577|Active Comparator|B|Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
2519111|NCT02768714|Experimental|Eurofarma's pegfilgrastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Eurofarma's pegfilgrastim (subcutaneous injection)
2519113|NCT02768714|Active Comparator|Neulastim|A single 6 mg dose on Day 2 of each chemotherapy cycle of Neulastim (subcutaneous injection)
2519174|NCT02768623|Active Comparator|Control Group|Patients in the control group will receive standard, dispensing services they currently receive from pharmacists. Control group pharmacists will continue to provide these services in accordance with the standards of practice adopted by the Ontario College of Pharmacists. They will not provide either of the 3 intervention components outlined above. Should a control group patient request additional information and/or services, the pharmacist will comply and provide these as deemed necessary for the particular patient. This could include the full range of educational and drug therapy optimization services outlined for the intervention group. If this occurs then the pharmacists will document all services provided in order for the research team to account for this in the analysis.
2519296|NCT02767596|Experimental|Lixisenatide|S.C. Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks
2519579|NCT02766049|Active Comparator|(a) DC|Autologous dendritic cells (3x10e7)
3165399|NCT00512590|Experimental|Experimental|
3165400|NCT00512629|Experimental|Omegaven|Omegaven is a fish based intravenous fat emulsion
3165401|NCT00512629|Active Comparator|Intralipid|
3165402|NCT00512642||Patients at increased risk of lung cancer|Patients at increased risk of lung cancer
3165403|NCT00512655|Experimental|1|Intervention: 5 week training program, 2 sessions per week (total of 10 sessions). Training includes both the patient and the caregiver. The training consists of two components: a cognitive and a physical component.
2518167|NCT02775526|Active Comparator|Burch colposuspension|Burch colposuspension
2518234|NCT02775266|Active Comparator|ALA + Scaling and Root planing|Systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months(group B)
2518235|NCT02775266|Placebo Comparator|Scaling and root planing only|Patients will receive scaling and root planning at baseline and 3 months(group A)
2518262|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise and Resistance Training (NS-ART)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity and resistance training. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2518264|NCT02774759|Experimental|NEXT-Steps- Aerobic Exercise (NS-A)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor. Participants receive phone calls and text messages for support in reaching exercise and diet goals.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2518266|NCT02774759|Active Comparator|Standard Care Control Group (CG)|"Participant wears an accelerometer for 7 days before baseline visit. Six questionnaires completed regarding quality of life and diet. Fitness test given covering various physical activities at baseline and at 6 month visit.~Participants receive standard of care consisting of phone calls asking about their health and self-help materials.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
2518369|NCT02774252|Experimental|BAY987521|Each test site area is divided into test sub site areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2518413|NCT02773875|No Intervention|Sensor Augmented Pump (control)|Use sensor augmented pump (SAP) for 3 weeks.
2518414|NCT02773875|Experimental|Artificial Pancreas (intervention)|Artificial pancreas system (Algorithm + CGM + pump)--use the AP system for 3 weeks which consists of: (1) Fault detection and Zone MPC algorithm housed on the DiAs platform + (2) Roche insulin pump + (3) Dexcom CGM
2518473|NCT02773472|Experimental|Electroacupuncture Group|In addition to morphine, patients will receive 4 sessions of electroacupuncture after surgery over four days, with each session lasting 30 minutes.
2518478|NCT02773472|Other|Morphine Group|Neither electroacupuncture nor sham acupuncture will be given. Patient use morphine for analgesia.
2518529|NCT02773004|Other|EndoPredict (EP)clin testing|Once the patient is registered, the most representative block of the primary tumor from surgery (or 10 paraffin slides) are sent to the central analysis platform for EP clin testing. The EPclin method is based on analysis of tumour genes in combination with the classical prognostic factors of nodal status and tumour size.
2518598|NCT02772653||Severe trauma patients|"No interventions are done. It's a prospective and descriptive observational study where different markers are analyzed:~Blood Lactate levels~Blood Base Excess levels~Blood B-type Natriuretic Peptide levels~Blood Thromboelastometry (ROTEM) alterations~Near-infrared spectroscopy alterations~Sublingual videomicroscopy alterations~All these markers are analyzed at the 1rst, 8th and 24th hour from hospital admission."
2518635|NCT02772055|Experimental|moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
2518637|NCT02772055|Experimental|smoke-free moxibustion group|Conventional moxibustion treatment for knee osteoarthritis participants and have a purification device at the top of the moxibustion to remove the moxa smoke.12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
2518781|NCT02771873|No Intervention|Usual care|Screening for CVD risk factors plus one time education regarding management of risk factors will be provided to all family members.
2518784|NCT02771873|Experimental|Life style Intervention and care coordination|Integrated cardiovascular disease risk management.
2518812|NCT02771106||vision dysfunction|This group are subjects with mild TBI who have been diagnosed with profound oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist. These subjects will undergo neuro vision rehabilitation.
2518818|NCT02771106||control|This group are subjects with mild TBI who have no oculomotor (vision) dysfunction per objective measurements taken by the HCMC developmental optometrist
2518919|NCT02770469|Active Comparator|Standard Intervention|The standard intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship.
2518922|NCT02770469|Experimental|Enhanced Intervention|The enhanced intervention group received linguistically and culturally tailored information regarding breast cancer and survivorship as well as cognitive-behavioral stress management.
3198443|NCT00870753|Experimental|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
2519164|NCT02769078||Patients who received dabigatran|Patients who received dabigatran
2519166|NCT02769078||Patients who received rivaroxaban|Patients who received rivaroxaban
2519167|NCT02769078||Patients who received apixaban|Patients who received apixaban
2519169|NCT02769078||Patients who received warfarin|Patients who received warfarin
2519246|NCT02768155|Experimental|AF 4.0|Amniotic Fluid 4.0ml dose
2519251|NCT02768155|Experimental|AF 2.0|Amniotic Fluid 2.0ml dose
2519257|NCT02768155|Placebo Comparator|Placebo|Saline Placebo Control
3198444|NCT00870753|No Intervention|Controls|Control group are offered the yoga intervention after finishing the study
2519363|NCT02767336|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
3165404|NCT00512655|No Intervention|2|Usual care.
2552690|NCT02547883|No Intervention|Patients continuing statin|
2518246|NCT02775045||Eosinophil esophagitis|Adult patients (>18 yr) will be recruited from the Gastroenterology clinic following a diagnostic endoscopy for esophageal dysfunction with predominant symptom(s) of solid food dysphagia and/or esophageal food impaction. Patients with esophageal biopsy showing greater than 15 eosinophil/hpf (pathology results typically available within three business days) despite greater than two months use of high dose proton pump inhibitor will be invited to participate and enroll in the study within 1 week of the endoscopy.
2518275|NCT02774720|Experimental|Centre-based physical activity|People with Mild Cognitive Impairment (MCI) and early dementia will receive centre-based physical activity for one hour each week for three months, plus at-home prescribed exercise.
2518283|NCT02774720|Experimental|Home-based exercise|People with Mild Cognitive Impairment (MCI) and early dementia be prescribed at-home prescribed exercise and will received monthly support phone calls.
2518309|NCT02774434|Experimental|JM-105|Within 15 minutes of each ordered blood sample 2 TcB measurements will be performed using the JM-105 on the sternum and forehead. Subject's participation will end after a 10 day period.
2518399|NCT02774122|Active Comparator|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
2518400|NCT02774122|Experimental|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
2518448|NCT02773563||EUS with CO2 insufflation|Patients undergoing EUS with CO2 insufflation
2518450|NCT02773563||EUS with air insufflation|Patients undergoing EUS with air insufflation
2518483|NCT02773212|Experimental|d-Amphetamine and Contingency Management|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine with contingency management treatment for cocaine use disorder.
2518488|NCT02773212|Active Comparator|d-Amphetamine alone|Participants in this group will receive 4 weeks of treatment with 60mg of sustained release d-amphetamine but will not receive contingency management treatment for cocaine use disorder.
2518491|NCT02773212|Active Comparator|Placebo and Contingency Management|Participants in this group will receive 4 weeks of of placebo treatment, paired with contingency management treatment for cocaine use disorder.
2518534|NCT02772835|Active Comparator|nHFOV|Starting treatment mode: nHFOV with Medin-cno. Targeted oxygen saturation: 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the beginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A second capillary BGA will be performed at the end of second period.
2518543|NCT02772835|Active Comparator|nCPAP|Starting treatment mode: nCPAP with Medin-cno. Targeted oxygen saturation of 87-94%. Four 1 h study blocks, alternating from the initial mode to the alternate mode twice. All the data will be recorded at 1-min intervals. The following data will be recorded: tcPCO2, tcPO2, heart rate, respiratory rate, SaO2, Silverman score, cer-rSO2, ren-rSO2. Blood pressure will be taken 30 minutes after the beginning of each treatment block. At the be-ginning of the first period a BGA will be performed in order to test the reliability of the TcPCO2 data. A se-cond capillary BGA will be performed at the end of second period.
2518599|NCT02772484|Experimental|HS-1000 recording|The recording session should be performed in a quiet environment with no disturbance to the patient for a total of up to 60 minutes.
2518641|NCT02772237|Active Comparator|Treatment group|Riboflavin 400mg daily
2518644|NCT02772237|Placebo Comparator|Placebo group|Placebo
2518701|NCT02771795||Herceptin (trastuzumab)|Intravenous administration
2518705|NCT02771795||SB3 (proposed trastuzumab biosimilar)|Intravenous administration
3198445|NCT00870766|Active Comparator|CT|All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER.
3198446|NCT00870766|No Intervention|Current practice|The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only.
2518841|NCT02770924|Experimental|AT LISA TRI TORIC|All patients will be undergo to phacoemulsification with IOL implantation bilateral
2518846|NCT02770924|Experimental|AT LISA TRI|All patients will be undergo to phacoemulsification with IOL implantation bilateral
2518866|NCT02770573|Experimental|Patients with dentin hypersensitivity|"Patients with evident clinical signs of dentin hypersensitivity The following dental materials will be used following the manufacturers' instructions: Cavex Bite&White ExSense; Kuraray Teethmate™ Desensitizer; Ghimas Dentin Desensitizer.~In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~The application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
2518911|NCT02770378|Experimental|Temozolomide combined with 9 repurposed drugs|"After enrollment, the subject goes into the induction cycle, which lasts 35 days. The induction cycle consists of a drug-by-drug addition and up-dosing process.~Hereafter, the subject will enter the treatment cycles (up to 12). During the induction cycle and the first 2 treatment cycles, regimen adjustments (dropping of certain drugs, dose modification of certain drugs) may be executed to accommodate to the patients' individual toxicity reactions that may occur during this period."
2519011|NCT02769884|Experimental|MMPPC arm|Subjects in this arm will wear the experimental MMPPC algorithm artificial pancreas for 72 hours in a hotel/house setting. The study period will involve unannounced meals and exercise
3198447|NCT00870779|Experimental|5-aminolevulinic acid|
3198448|NCT00870792|Active Comparator|Received report|
3198449|NCT00870792|Placebo Comparator|Routine care|Patients receive usual, routine, care.
3198450|NCT00870805|Experimental|bilateral-ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 3-4 times seizure threshold.
3198451|NCT00870805|Active Comparator|bilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a bilateral placement at 1.5 times seizure threshold.
3198452|NCT00870805|Experimental|right-unilateral ultrabrief ECT|Patients will be treated with an ultrabrief (0.3ms) pulse with a right unilateral placement at 8 times seizure threshold.
2518249|NCT02774967|Experimental|tunnel technique|"root coverage comparing two techniques The aim of this study was to compare and show the benefits of the extended flap technique compared to Tunnel technique both techniques using the acellular dermal matrix for root coverage.~Other Names:~acellular dermal matrix extended flap technique"
2518278|NCT02774668|Active Comparator|"Grab-and-Go meal plan"|"The intervention of this arm is to use a Grab-and-Go meal plan. This meal plan provides Atkins shakes and bars for breakfast, lunch, and snacks for 2 weeks. For dinner the subject is given a freshly-prepared meal. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
2518282|NCT02774668|Active Comparator|"Jump-Start meal plan"|"The intervention of this arm is to use a Jump Start meal plan. This meal plan provides Atkins frozen meals at breakfast, lunch and dinner for 2 weeks and these meals are supplemented with fresh salads and vegetables. Upon finishing the 2-week provided food phase, the subject will consume a self-prepared meal of similar nutrient composition at home for another 2 weeks. For the next four weeks while he/she is still enrolled in the study, he/she will have his/her options for food choices which are not controlled for the study."
2518370|NCT02774083|Active Comparator|Feuerstein Program|The participants of the Intervention Group will participate in the Feuerstein mediated learning cognitive program.
2518372|NCT02774083|Placebo Comparator|Adler Program|The Control Group will participate in the program of the Adler Institute dealing with social and emotional development without specific cognitive skills training.
2518409|NCT02773784||invasive breast cancer|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
3198453|NCT00870805|Active Comparator|right-unilateral standard ECT|Patients will be treated with a standard (1.0ms) pulse with a right unilateral placement at 5 times seizure threshold.
3198454|NCT00870818|Experimental|1 Active|"Protege had 4 study arms, 3 were dosed with different doses of teplizumab, and 1 was a control group given placebo. This Extension study will continue to assess the subjects from these 4 arms.~In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses"
3198455|NCT00870818|Experimental|2 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
3198456|NCT00870818|Experimental|3 Active|In Protege: Experimental Drug: Teplizumab, IV dosing daily for 14 days times 2 courses
3198457|NCT00870818|Placebo Comparator|1 controlled|In Protege: Placebo Comparator: IV dosing daily for 14 days times 2 courses
3198458|NCT00870831||Islet Recipient|Subjects that have successfully received and maintained an Islet transplant at Washington University Center for Islet Transplantation
2518675|NCT02772276|Experimental|Normal-CKD Stage 2/QuantumLeap|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
2518676|NCT02772276|Experimental|CKD Stage 3-4/QuantumLeap|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-4), and fluorescence measured by the QuantumLeap ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. In order to determine the optimal dose of MB-102, participants may receive different doses.
2518678|NCT02772276|Experimental|Normal-CKD Stage 2/Radiance|MB-102 and iohexol administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518680|NCT02772276|Experimental|CKD Stage 3-5/Radiance|MB-102 and iohexol administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Radiance ORFM device. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518682|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance algorithm optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518685|NCT02772276|Experimental|CKD Stage 3-5/Brilliance algorithm optimization|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Algorithm optimization of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518686|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor optimization|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Sensor optimization of the Brilliance device will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518699|NCT02771782|Experimental|BCG|Subjects are vaccinated with BCG vaccine (SSI) alone, 0,1ml intradermal
3198459|NCT00870831||Control|subjects that were similar in height, weight and age that did NOT have diabetes to act as the comparative group
3198460|NCT00870844|Experimental|Lu AA24493 (CEPO): 0.5 mcg/kg|
3198461|NCT00870844|Experimental|Lu AA24493 (CEPO): 5.0 mcg/kg|
2518446|NCT02773602|Experimental|Dexamethasone|Dexamethasone has been used for adult epidurals and nerve blocks and in spine surgeries. It prolongs the duration of pain relief and causes less sedation. It is commonly administered to children during surgery to help decrease nausea and vomiting after surgery. It is also much cheaper than clonidine The patient will receive Ropivacaine plus 200 μgm/kg of dexamethasone in 1 ml saline
2518447|NCT02773602|Active Comparator|Clonidine|"Clonidine has been added to caudal analgesia for infants and children for many years. It increases the duration of pain relief of ropivicaine by itself, however, it may lead to prolonged sedation following the surgical procedure (an undesired effect) and it is expensive.~The patient will receive Ropivacaine plus 2 μg/kg of clonidine in 1 ml saline."
2518449|NCT02773602|Placebo Comparator|Normal Saline|The patient only will receive Ropivacaine
2518515|NCT02773160|Experimental|Sensor-based postural feedback|Subjects will receive visual feedback on a computer screen while practicing the motor control task. The feedback is based on information from from motion sensors that mointor the movements of the lumbar spine
2518517|NCT02773160|Experimental|Mirror Feedback|Subjects will receive feedback from a mirror while practicing the motor control task
2518522|NCT02773160|Active Comparator|control group|Subjects will receive no feedback while practicing the motor control task
2518622|NCT02772575||patients with primary liver or liver metastases|A biopsy will be performed as standard of care either at time of Hepatic trans-arterial embolization (TAE) or within 4 months prior to TAE. TAE is a standard of care procedure. Within 8 weeks of TAE, patient will have a clinic visit which will include medical history, physical examination, vital signs, EKG (if one is not available), and ECOG assessment. Additionally a dedicated liver CT or MR will be obtained as well as standard of care labs. IMPACT blood test will be performed at the time of any of the standard of care labs. As IMPACT platform at MSKCC continually evolves to include more genes, we will use the platform available at the time of initiation of the protocol, therefore all patients will be subjected to the same platform. RNA-seq has been demonstrated to be superior in detecting low abundance transcripts, demonstrating a broader dynamic range, and detecting different isoforms and genetic variants.
2518634|NCT02772016|Experimental|Intervention group|Patients in the treatment group received daily 15 g oral Colla corii asini(Shandong Dong-E E-Jiao Co., Ltd) in powder form for 4 consecutive weeks. The dosage was adjusted to 10 g per day for 6 consecutive weeks if patients encounter any of the following side effects: swollen gums, dry or sore throat, ulcers in oral cavity.
2518636|NCT02772016|No Intervention|Control group|Patients in control groups do not receive any intervention.
2518715|NCT02771912|Experimental|Propofol|"Infusion containing Propofol lipuro® 2% at a concentration of 2 mg/ml (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Propofol lipuro® 2 %).~Self administration of propofol via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution (0.25 mg/kg propofol) with a programmed lock-out period of 3 minutes.~Maximal dose of propofol : 1,25 mg/kg corresponding to 5mg/kg/h."
2518716|NCT02771912|Placebo Comparator|Intralipid|"Infusion containing Intralipid® (100 ml of 5% glucose at which is removed 20 ml replaced with 20 ml of Intralipid® 20%) to obtain an identical aspect to that of propofol infusion.~Self administration via patient-controlled sedation pump (ambIT pump) : bolus of 0.125 ml/kg of the solution with a programmed lock-out period of 3 minutes."
2518735|NCT02771444|Experimental|Tomo Assessment|Subjects will have a 4-view tomosynthesis examination with the study device.
2518801|NCT02771288|Other|Kawasaki disease|
2518837|NCT02770885|Experimental|Verum first|Dulaglutide (Trulicity®) 1.5 mg in 0.5 ml, via Pen s.c. once weekly for 3 weeks.
2518842|NCT02770885|Placebo Comparator|Placebo first|Placebo: 0.5 ml normal saline (0.9% sodium chloride [0.9% sodium chloride (NaCl)]), injection sc via syringe once weekly for 3 weeks.
2518864|NCT02770599||IBD multidisciplinary team model (MDT)|IBD multidisciplinary team model including IBD nurse
2518869|NCT02770599||IBD conventionally follow up model (CF)|IBD patient treated by doctors with specialist qualifications, assistant doctors, general practitioner or scarcity of follow-up-service.
2518924|NCT02770430|Active Comparator|conventional treatment|"After randomization, patients will be allocated to receive conventional treatment:~Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
2518932|NCT02770430|Experimental|mesenchymal stem cells|Patients in the study group will receive two infusions of MSC per week during two weeks and 1 more MSC infusion (2 + 2 + 1 scheme). Dosage: 2x10E6/Kg
2518998|NCT02769923|Active Comparator|Arm A|Westpharma ID Adapter
2518999|NCT02769923|Active Comparator|Arm B|Star ID syringe
2519000|NCT02769923|Active Comparator|Arm C|BCG NS
3198462|NCT00870844|Experimental|Lu AA24493 (CEPO): 50.0 mcg/kg|
3198463|NCT00870844|Placebo Comparator|Placebo|
2519124|NCT02769013||S. haematobium positives in Gabon|Asymptomatic volunteers infected with S. haematobium and living in Gabon
2519130|NCT02769013||S. haematobium negatives in Gabon|Volunteers not infected with S. haematobium and living in Gabon
2519131|NCT02769013||S. haematobium positives in Ghana|Asymptomatic volunteers infected with S. haematobium and living in Ghana
2519133|NCT02769013||S. haematobium negatives in Ghana|Volunteers not infected with S. haematobium and living in Ghana
2519223|NCT02768324||sepsis with diarrhea|
2519228|NCT02768324||sepsis without diarrhea|
2519298|NCT02767895|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health
2519304|NCT02767895|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
3198464|NCT00870857||1|Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling stratified by age and smoking history. Subjects will be recruited from the University of Pittsburgh and the University of Washington (UW) MACS sites. The University of California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort
2521907|NCT02751099||de novo renal transplanted patients|renal transplanted patients
2518374|NCT02774512|Experimental|Nilotinib|A specific colonoscopy is performed in order to take biopsy for biological studies to determine the ZAK-0 expression status. Then the patient receives nilotinib orally at the dose of 800 mg/day (400 mg twice a day) for 7 days. The patient is scheduled for surgery the morning after the last take of the nilotinib (12 hours). When the colectomy is performed, the surgeon collects different tumoral samples which are immediately delivered to the laboratory.
2518385|NCT02773797|Placebo Comparator|IN-DEX 1.0 mcg/kg, intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Intranasal-Dexmedetomidine (IN-DEX) intranasal 1.0 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2518390|NCT02773797|Placebo Comparator|IN-DEX, 1.5 mcg/kg intranasal saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label IN-DEX intranasal 1.5 mcg/kg will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2518392|NCT02773797|Active Comparator|Placebo - Saline|"Patients with clinically stable severe COPD will be randomized. Each group will participate in 3 drug study sessions separated by 7-14 days. Arm label Placebo - Saline will participate in 3 drug study sessions separated by 7-14 days. All drug study sessions will be conducted in a monitored acute care setting with medical staff in attendance. Sedation assessment and vital signs will be recorded at 15 minute and 5-15 minute intervals respectively, for a minimum of 3 hours."
2518423|NCT02773654||Healthy Volunteers|Asymptomatic subjects: subjects without complaints or history of shoulder pain or obvious movement abnormalities.
2518426|NCT02773654||Symptomatic Volunteers|Symptomatic subjects: subjects with shoulder pain who have active range of motion beyond 120° of elevation.
2518471|NCT02773355||Saxenda®|
2518526|NCT02773043|Other|non invasive imaging technique|
2518604|NCT02772627|Experimental|Nebicapone 100 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2518611|NCT02772627|Experimental|Nebicapone 200 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2518615|NCT02772627|Experimental|Nebicapone 300 mg / Placebo|Treatment consisted of nebicapone/placebo repeated administration: one dose at 4-h intervals, for 7 full days: first dose at approximately 08 h (±1 h) on Day 1 and final dose at approximately 08 h (±1 h) on Day 8. Within each group (n=8), 2 volunteers were be randomised to receive placebo and the remaining 6 volunteers to receive nebicapone.
2518689|NCT02772094|Experimental|Single arm, open-label|"Experimental:~ADCTA-G total 10 doses, each dose (30+/-5 millions autologous dendritic cells plus 6+/-0.5 millions 100Gy-irradiated short-term cultured autologous GBM tumor cells) divided in 2 halves for subcutaneous injection into both axillar areas, in a course of 6 months (sequential series of weekly injections 4 times, bi-weekly injections twice; then monthly injections 4 times.~Experimental: ADCTA-G total 10 doses, each dose (similar fore-mentioned numbers of 5:1 ratio of autologous dendritic cells and irradiated short-term cultured autologous GBM tumor cells) divided into 2 injections administered subcutaneously in both axillar areas, in a course of 8 months (sequential series of bi-weekly injections 4 times, then monthly injections 6 times)."
2518749|NCT02771587|Experimental|Alcohol and energy drink|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 energy drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
2518753|NCT02771587|Active Comparator|Alcohol|Alcohol 60 g, multiple dose (30 g+30 g), oral administration. 3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.
2518757|NCT02771587|Active Comparator|Energy drink|3 energy drinks (750 ml), multiple dose (375 ml+ 375 ml), oral administration. Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration.
2518761|NCT02771587|Placebo Comparator|Placebo|"3 non-caffeinated soft drinks (750 ml), multiple dose (375 ml+375 ml), oral administration.~Font Vella water (188ml), multiple dose (94 ml+ 94 ml), oral administration."
2518807|NCT02771067|Experimental|Pulse pressure variation|Pulse pressure variation will be recorded via an arterial catheter after anesthetic induction, before pneumoperitoneum, after pneumoperitoneum, before infusion of 6% hydroxyethyl starch, and after infusion of 6% hydroxyethyl starch. Stroke volume will be also measured to differentiate the fluid responders.
3198465|NCT00870883|Experimental|N-acetylcysteine plus deferoxamine|
3198466|NCT00870909|Active Comparator|active tDCS|"tDCS active; - Intensity = 2 milliamps (mA) during 20 minutes. ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC combined with cathodal tDCS applied over the left temporoparietal junction (TPJ).~10 sessions, 2 per day"
2519014|NCT02769715|Active Comparator|cast removable partial denture|patients received cast removable partial dentures fabricated using traditional lost-wax casting technique.
2519016|NCT02769715|Experimental|laser-sintered removable partial denture|patients received removable partial dentures fabricated using laser-sintering.
3198467|NCT00870909|Placebo Comparator|sham tDCS|tDCS placebo same electrode montage than in the active group. 30 sec of active tDCS in the beginning of the stimulation sessions; ramp up/ramp down 30 sec
3198468|NCT00870922|Experimental|TMD group|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
3198469|NCT00870935|Active Comparator|Balloon catheter|Hysterosalpingography using intrauterine Balloon catheter
3198470|NCT00870935|Active Comparator|Cervical vacuum cup|Hysterosalpingography using cervical vacuum cup
3198471|NCT00870935|Experimental|Operator choice|Hysterosalpingography is performed using either balloon catheter or cervical vacuum cup on the basis of the operator's choice
2518406|NCT02773953|Experimental|CPAP + T4PTelemonitoring device|T4P® (Telemonitoring device) is added to CPAP at home. Sleep lab technical staff are connecting to the web portal 2 X/ week. In case of air leaks, persistant significant apnea-hypopnea index, use < 3h on three consecutive days, they have to call the patient .
2518407|NCT02773953|Active Comparator|CPAP standard care|After CPAP titration night, patients are instructed to use the device each night for the whole night. They receive written instruction and can reach the sleep unit (phone call, visit) how often they need, during week days, to resolve CPAP-related problems. A group educational session is scheduled 1 month after and a visit to the pneumologist 1.5 months after.
2518455|NCT02773498|Active Comparator|conventional TESE|Conventional multiple TESE is performed under general or locoregional anesthesia. Through a small vertical incision in the median scrotal raphe, the skin, dartos muscle, and tunica vaginalis are opened to expose the tunica albuginea. The tunica albuginea is ordinarily incised for about 4 mm at the medium region of the testis. A similar biopsy will be systematically performed in the contralateral testis. The biopsy is analyzed by the biologist in the theatre in order to precise if sufficient spermatozoa is retrieved.
2518456|NCT02773498|Experimental|micro TESE|Microdissection TESE is also performed under general or locoregional anesthesia. After the tunica albuginea is opened widely along the antiepididymal border, direct examination of the testicular parenchyma is performed under the operating microscope. An attempt is made to identify individual seminiferous tubules that are larger, more opaque and whiter than other tubules in the testicular parenchyma, which are considered to contain spermatozoa. The extracted tubules are analyzed by the biologist in the theatre. The procedure is terminated when sperm are retrieved or further biopsy is thought likely to jeopardize the blood supply of the testis. If all tubules are seen to have an identical morphological appearance, at least three samples (upper, middle, and lower) are obtained. A similar microTESE will be systematically performed in the contralateral testis
2518524|NCT02773069|Experimental|Weight loss program|Participants will attend a 12 session weight loss program accompanied by maintenance support delivered by a church. Program will include peer education, telenutrition counseling and mobile health feedback.
2518624|NCT02772718|Experimental|Part 1 - single dose|Cohorts A, B, and C
2518626|NCT02772718|Experimental|Part 2 - multiple doses|Cohort 1
3198472|NCT00870948|Experimental|Regimen A|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
3198473|NCT00870948|Experimental|Regimen B|One 100 mg ABT-874 (pre-filled syringe liquid formulation from the 6000 L process) injected IV in an arm vein
2518736|NCT02771535|Experimental|D-MCT Group|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
2518738|NCT02771535|Active Comparator|Health Training Group|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
2518827|NCT02771223||Study group|patients scheduled for prolonged cardiac surgery (over 3 hours anticipated ECC time) with no known coagulation disorders
2518884|NCT02770807|Experimental|EDS-EP dose range of ~5-10 mg DSP/infusion|"Drug: EDS-EP dose range of ~5-10 mg DSP/infusion EDS-EP dose range of ~5-10 mg DSP/infusion: A DSP loading quantity of 50.0 mg will be added to the EDS process, by using 2.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of ~5-10 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 13.0 mL.~Other Names:~EryDex System end product"
2518887|NCT02770807|Experimental|EDS-EP dose range of ~14-22 mg DSP/infusion|"Drug: DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion DSP/infusion EDS-EP dose range of ~14-22 mg DSP/infusion: A DSP loading quantity of 125 mg will be added to the EDS process, by using 5.0 mL of the 25 mg/mL DSP solution to deliver an EDS dose range of 14-22 mg. DSP is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.~Other Names:~EryDex System end product"
2518888|NCT02770807|Placebo Comparator|Placebo EDS infusion|Patients will be treated with autologous erythrocytes prepared with the EDS process using a placebo solution (5 mL of 0.372% NaCl solution) instead of experimental drug (DSP). Placebo is diluted with 11 mL sterile water for injection in the same syringe, for a total of 16 mL.
2518944|NCT02770144|Experimental|Financial Coaching & Social Services Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2518945|NCT02770144|Active Comparator|Access to Referrals to Social Services|Enrollment provides access to referrals to social services to meet basic needs.
2518992|NCT02769871|Active Comparator|Standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at the participant's initial interview. Participants will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
2518993|NCT02769871|Experimental|Neuroimages of stroke|Participants in the intervention group will undergo standardized smoking cessation counseling (as offered to the active comparator group) and will also be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, participants will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Participants will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
3198474|NCT00870948|Experimental|Regimen C|One 100 mg ABT 874 (reconstituted lyophilized powder from the 3000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
3198475|NCT00870948|Experimental|Regimen D|One 100 mg ABT-874 (reconstituted lyophilized powder from the 1000 L process) injected subcutaneously in the abdominal region at a 45 degree angle
2518461|NCT02773329|Experimental|Intervention with game-based exercise|Subjects will be receiving sensor-based interactive exercise program (game-based exercise) intervention twice a week for 6 weeks.
2518464|NCT02773329|Active Comparator|Intervention without game-based exercise|Subjects will be receiving non-technology based foot and ankle exercise twice a week for 6 weeks
2518532|NCT02773017|Experimental|Youth female group|patients in the Youth female group, aged 20~35, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2518538|NCT02773017|Experimental|Middle-aged female group|patients in the Middle-aged female group, aged 40~60, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2518545|NCT02773017|Experimental|Elderly female group|Patient in the elderly female group, aged 65~79, were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
2518594|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study all participants are subject to a set of three visual stimulus conditions.~These are: Low ambient light; Self selected tinted light; White light"
2518664|NCT02772263|Experimental|CHAP-EMS Intervention|Participants guided through a 15-20 minute defined risk assessment by a trained paramedic. Risk factors assessed were those related to cardiovascular and diabetes risk (blood pressure, diabetes-risk status, lifestyle factors), and potential for falls. Based on these, the paramedic provided education and developed an individualized action plan directing participants to use available community resources to assist them in addressing their risk factors. They were advised to return to CHAP-EMS sessions regularly for BP monitoring and follow-up. Each participant's information was faxed to his/her family physician once a month.
2518751|NCT02771756|Experimental|test group|Zhen qishen capsule (2 capsules, Bid) and Oral Supplement of Yuyikang (50g, Bid), a total of 150 people, are used for 42 days continuously.
2518758|NCT02771756|Placebo Comparator|placebo group|Zhen qishen capsule placebo (2 capsules, Bid) and Oral Supplement of Yuyikang placebo (50g,Bid), a total of 150 people, are used for 42 days continuously.
2518873|NCT02770742||Patients for outpatient colonoscopy|The cohort consists of subsequent patients who present for routine colonoscopy. There is no active Intervention. However, groups who choose to perform colonoscopy with or without sedation will be compared.
2518948|NCT02770443|Experimental|Treatment|Withdrawal of beta blockers and ACE inhibitors
2518949|NCT02770443|Placebo Comparator|control|no withdrawal, standard of care
2519021|NCT02769494|Experimental|Mesalazine Group|Mesalazine Sustained-Release Tablets and 0.02L glycerol mixed, 2.5% mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. Daily treatment time of the drug is 8 am,12 pm and 4 pm.
2519025|NCT02769494|Active Comparator|Riboflavin Sodium Phosphate Group|wipe the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. Daily treatment time of the drug is am,12 pm and 4 pm.
2519074|NCT02769234||Alzheimer's disease|Subjects with a diagnosis of Alzheimer's disease that successfully performed an ERP/EEG test with the COGNISION(TM) System prior to enrollment for the current study are eligible to participate.
2519135|NCT02768922|Experimental|Aphasia telerehabilitation|Speech and language therapy is given by telemedicine to improve expressive language function. The therapy will include knowledge based tasks of aphasia rehabilitation including training of language forms and overall functional communication. A special emphasis will be put on naming training. The telerehabilitation will be given in a addition to standard face-to-face aphasia rehabilitation
2519137|NCT02768922|Active Comparator|Control|Control Group receives standard face-to-face aphasia rehabilitation
2519185|NCT02768415|Experimental|lapatinib+oral vinorelbine|"apatinib 425/500mg qd, 21days/cycle~oral vinorelbine 60mg/m2 d1, 8, 15 21days/cycle*3cycles, after 3 cycles: 80mg/m2 d1, 8, 15 21days/cycle"
3198476|NCT00870948|Experimental|Regimen E|700 mg ABT-874 (reconstituted lyophilized powder from the 3000 L process) in 100 mL 5% dextrose solution IV infusion in an arm vein
2519326|NCT02767687|Experimental|Noninvasive ventilation (NIV)|Noninvasive mechanical ventilation is a resource used to treat respiratory failure or to reestablish respiratory comfort and function. It is commonly used in the ICU with a regular mechanical ventilator and is offered using an interface that connects the machine to the patient. The interface used for adults and in this study, was a silicon facial mask that covers the nose and mouth of the patient, allowing him or her to open the eyes.
2519373|NCT02767375|Active Comparator|HAIC treatment group|HAIC treatment after resection Intervention: Drug: Oxaliplatin, 5-fluorouracil (5-FU) Procedure/Surgery: Hepatic arterial catheter implantation
2519377|NCT02767375|No Intervention|No HAIC treatment group|Best support care and follow up
2519500|NCT02766647|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
2519502|NCT02766647|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
2519536|NCT02766179|Active Comparator|CPAP Therapy|Continuous Positive Airway Pressure
2519544|NCT02766179|Experimental|Somnoguard|Somnoguard
2519639|NCT02765893|No Intervention|Foley|Patients will have Foley in place overnight after completion of surgery, which is currently standard of care at our institution.
2519641|NCT02765893|Active Comparator|No Foley|Patients will have Foley catheter removed 6 hours post-op.
2519684|NCT02765373||steroidal aromatase inhibitors(AIs)|Exemestane 25mg Qd for 5 years
2519692|NCT02765373||non-steroidal aromatase inhibitors(AIs)|Letrozole 2.5mg Qd or Anastrozole 1mg Qd for 5 years
2519728|NCT02764944|Experimental|Intervention|simple non-exposure EFTR group (single arm study)
2519779|NCT02764710|Experimental|Short treatment|Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
2519786|NCT02764710|Active Comparator|Long treatment|Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7.
2519827|NCT02764359|Experimental|IV Vancomycin loading dose- higher|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 4,000mg
2519835|NCT02764359|Experimental|IV Vancomycin loading dose- lower|IV Vancomycin loading dose: 20 mg/kg with a maximum dose of 2,000mg
2554328|NCT02537028|Placebo Comparator|Placebo|
2518463|NCT02773238|Experimental|Treatment|Patients undergo functional avoidance radiation therapy during weeks 1-3. Patients undergo fludeoxyglucose F-18 FDG PET/CT at baseline, 3 weeks, and 3 months post-radiation therapy and undergo technetium Tc-99m albumin aggregated (99mTc-MAA) and technetium Tc-99m sulfur colloid SPECT/CT radiation therapy at baseline and 3 months post-radiation therapy. Baseline PET/CT must be performed at University of Washington Medical Center/Seattle Cancer Care Alliance and be within one month of treatment start, therefore some patients may need to repeat a baseline PET/CT if their PET/CT is from an outside institution or > 1 month old. Patients not responding to treatment at 3 weeks, will receive an increased daily radiation therapy dosage.
2518572|NCT02772796|Experimental|SENS-218|2 x 10 mg administered once on Day 1.
2518616|NCT02772510|Experimental|Smart glove system with functional electrical stimulation|game-based virtual reality rehabilitation combined with functional electrical stimulation for upper extremity
2518618|NCT02772510|Active Comparator|Functional electrical stimulation|functional electrical stimulation on upper extremity
2518631|NCT02772107|Experimental|BSC group|Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. Radiotherapy was allowed. Follow-up until disease progression.
2518633|NCT02772107|Experimental|TMZ group|"Patients will receive platinum-based first-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cyclesfor the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study, radiotherapy was allowed."
2518774|NCT02771418|Sham Comparator|TIVA with propofol|Induction and maintenance of general anesthesia using TIVA with propofol
2518777|NCT02771418|Active Comparator|VIMA with sevoflurane|Induction and maintenance of general anesthesia using VIMA with sevoflurane
2518840|NCT02771028|Experimental|Intervention group|Patients assigned to intervention group receive an 8-week EFT-program
2518844|NCT02771028|No Intervention|Control group|Patients assigned to control group are placed on a waitlist for a period of 8 weeks
2518876|NCT02770586|Other|Breast PET|Breast PET
2518908|NCT02770404|Experimental|Nafithromycin|"Subjects in Cohorts 1 through 5 receive active treatments. Subjects in Cohort 6 will receive an IV dose of nafithromycin and a single oral dose of nafithromycin in each crossover period.~Subjects in each of Cohorts 1, 2, and 3 will receive a single dose of 100, 200, or 400 mg, respectively, of nafithromycin on Day 1"
2518910|NCT02770404|Placebo Comparator|Placebo|Subjects in Cohorts 1 through 5 will be randomly assigned in an 8:2 allocation to receive active or placebo treatments.
2518953|NCT02770079||Gestational diabetes|10 women with gestational diabetes
2518983|NCT02769832|Experimental|Nab-Paclitaxel with Gemcitabine|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days; Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
2519069|NCT02769585|Experimental|Self-hypnosis|Subjects underwent two group sessions one week apart with a certified hypnotherapist to teach them the process of self-hypnosis for the purpose of attaining weight loss. Subjects were asked to perform self-hypnosis once or twice a day for the duration of the one year trial.
2519071|NCT02769585|Active Comparator|CDE training|Subjects underwent two group sessions one week apart with a certified diabetes educator to teach them re: diet and nutrition specifically as regards to a diabetic striving to lose weight. Subjects were asked to remain compliant with dietary restrictions for the duration of the one year trial.
2519120|NCT02769039||Parkinson's Disease participants|People with early Parkinson's disease with mild-to-moderate severity of disease.
2519123|NCT02769039||Control participants|Volunteers who are age (+/- 3 years) and sex matched to the participants with Parkinson's disease
3198477|NCT00870961|Experimental|Arm I|Patients receive oral cholecalciferol (vitamin D3) supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
3198478|NCT00870961|Placebo Comparator|Arm II|Patients receive oral placebo supplementation daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
2519380|NCT02767284|Experimental|UCST-V1|The UCST-V1 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519384|NCT02767284|Experimental|UCST-V2|The UCST-V2 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519387|NCT02767284|Experimental|UCST-V3|The UCST-V3 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519390|NCT02767284|Experimental|Quick-CSF|The Quick-CSF test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519392|NCT02767284|Active Comparator|Pelli-Robson|The Pelli-Robson contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519393|NCT02767284|Active Comparator|Optec 6500|The Optec 6500 contrast sensitivity test, used to measure CSF thrice in each eye at two occasions in every treatment sequence (multi-period crossover)
2519432|NCT02766829|Experimental|CLSP Group|Those with cross leg sitting position: patients sit with both their knees flexed medially, hip flexed, resulting in pelvic leaning posteriorly and reducing lumbal lordosis.
2519433|NCT02766829|Active Comparator|TSP Group|Those with traditional sitting position: patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion.
2519505|NCT02766634|Experimental|Filgrastim Hospira (US) followed by U.S.-approved Neupogen®|
2519508|NCT02766634|Experimental|U.S.-approved Neupogen® followed by Filgrastim Hospira (US)|
2519556|NCT02766140|Experimental|SHR1020 plus Docetaxel|
2519560|NCT02766140|Placebo Comparator|Placebo plus Docetaxel|
2519617|NCT02765841|Experimental|Lomitapide|
2518508|NCT02772874||Passive-predominant|All subjects who report fecal incontinence that is primarily passive-predominant will undergo self-administered questionnaires, pelvic examination, endoanal ultrasound, and anorectal manometry.
3198479|NCT00870974|Experimental|Assess [18F]FPEB and PET imaging|To assess [18F] FPEB and PET imaging in subjects with neuropsychiatric conditions.
2518628|NCT02772341|Active Comparator|Salt room with halogenerator|Asthmatic patients sitting in a salt room with salt aerosol produced by a halogenerator.
2518630|NCT02772341|Placebo Comparator|Salt room without halogenerator|Asthmatic patients sitting in a salt room without salt aerosol
2518687|NCT02772029|Experimental|Apatinib Mesylate Tablets|Apatinib (Apatinib Mesylate Tablets) 750 mg is administered orally daily, until disease progression or intolerable toxicity.
2518748|NCT02771626|Experimental|CB-839 + Nivolumab Dose Escalation|Phase 1: CB-839 administered as oral capsules twice daily in combination with standard dose nivolumab in patients with advanced/metastatic ccRCC, MEL, and NSCLC to select the recommended Phase 2 dose (RP2D).
2518752|NCT02771626|Experimental|Clear Cell RCC Naïve to Checkpoint Inhibitors|Cohort 1: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who have previously received at least one tyrosine kinase inhibitors (TKI) but are treatment naive to checkpoint modulators programmed death-1/programmed death ligand-1 (PD-1/PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or any other agent that specifically targets a T-cell checkpoint or co-stimulation pathway.
2518756|NCT02771626|Experimental|Clear Cell RCC Recently Treated with Nivolumab|Cohort 2: CB-839/nivolumab combination in patients with advanced/metastatic ccRCC who received nivolumab in most recent treatment line that had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
2518760|NCT02771626|Experimental|Clear Cell RCC with Prior PD-1 Therapy|Phase 2 - Cohort 3: CB-839/ nivolumab combination in patients with advanced/metastatic ccRCC that had documented radiological disease progression while receiving an anti-PD-1/PD-L1 therapy in any prior line of therapy.
2518764|NCT02771626|Experimental|Melanoma with Prior PD-1 Therapy|Cohort 4: CB-839/ nivolumab combination in patients with unresectable or metastatic melanoma that had documented radiological disease progression while receiving an anti-PD-1 therapy in their most recent line of therapy.
2518769|NCT02771626|Experimental|NSCLC with Prior PD-1 Therapy|Cohort 5: CB-839/ nivolumab combination with NSCLC that does not harbor an activating mutation in the epidermal growth factor receptor (EGFR) oncogene and who received nivolumab in most recent treatment line and had documented radiological disease progression OR are currently receiving nivolumab with Stable Disease for at least 24 weeks.
2518810|NCT02770937|Active Comparator|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
2518816|NCT02770937|Active Comparator|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on box trainer.
2518821|NCT02770937|No Intervention|Control|The control group will not receive further training.
2518885|NCT02770677|No Intervention|Control group|Control group will be asked to continue their normal daily life without Yoga training
2518889|NCT02770677|Experimental|Yoga group|Yoga group will be exposed to Modified Dantien Salee Yoga Training Program for 12 weeks
2518906|NCT02770326|Experimental|Fecal Microbiota Transplantation (FMT)|Patients with recurrent or refractory CDI who meet study eligibility criteria, will consent to undergo either colonoscopy or upper endoscopy with infusion of stool admixture. Safety will be assessed by monitoring infections that occurred within 2 weeks of the FMT procedures. Additionally, 24-hours, 1 week, 2 weeks, 4 weeks, and 6 months post-FMT, a stool sample will be collected. The time window for each time point listed is +/- 48 hours, with the exception of the first, 24 hour, time point. The time window for the 24 hour time point is +48 hours post FMT.
2519065|NCT02769754|Placebo Comparator|Control|In the control group (group A) no additional treatment will be applied after performing the usual surgical hemostasis.
2519068|NCT02769754|Experimental|Hemopatch|Hemopatch will be apply in the treatment group (group B), once the standard surgical hemostasis is achieved
2519110|NCT02769052|Active Comparator|Follow-up/Treatment - Control Group|Composed of two phases of 8 weeks each (follow-up - treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
2519112|NCT02769052|Active Comparator|Treatment Group|Composed of one phase of 8 weeks (treatment). The treatment using the self-applied Transcutaneous Electrical Nerve Stimulation (TENS) will prescribe with daily application, twice a day for 20 minutes each application.
2519177|NCT02768610|Experimental|dexmedetomidine|0.5 mcg/kg dexmedetomidine is administered before endotracheal intubation for 10 minutes
2519181|NCT02768610|Placebo Comparator|Normal Saline|
2519221|NCT02768142|Experimental|Natural cesarean delivery|Placing the neonate on maternal chest immediately after the extraction from the uterus, and permitting breastfeeding during surgery.
2519226|NCT02768142|Active Comparator|Standard cesarean delivery|Presentation of the neonate to the mother during the operation.
2519302|NCT02767817|Sham Comparator|Stereotactic Hematoma Evacuation|
2519308|NCT02767817|Experimental|MSCs Transplantation|
2519312|NCT02767817|Experimental|Injectable Collagen Scaffold with MSCs Transplantation|
3198480|NCT00870987|Experimental|1|DNA vaccine prime Given at 0, 4, and 8 weeks
3198481|NCT00870987|Experimental|2|adenovirus type 5 vaccine boost Given at 24 weeks
2519483|NCT02766790|Placebo Comparator|Placebo|Placebo taken once daily in the morning and once daily in the evening
2554429|NCT02536235|No Intervention|Control: no intraoperative heat|
3198482|NCT00871026|Experimental|1|CAD/CAM group, customized archwires
3198483|NCT00871026|Active Comparator|2|prefabricated archwires (superelastic)
3198484|NCT00871039|Experimental|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
3198485|NCT00871039|Experimental|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
3198486|NCT00871065|Experimental|A|Trial Arm (single arm study)
3198487|NCT00871078||A|HIV-positive patients with CD4 cell counts below 100 cells/mm³ at some point of time in their medical history lasting for at least 6 months
2518546|NCT02773030|Experimental|Cohort B: CC-220 in combination with Dexamethasone - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment."
2518549|NCT02773030|Experimental|Cohort D: CC-220 in combination with Dexamethasone - Part 2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
2518552|NCT02773030|Experimental|Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.~Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA.~Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle."
2518555|NCT02773030|Experimental|Cohort F: CC-220 with DEX and bortezomib - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle.~Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle."
2518556|NCT02773030|Experimental|Cohort G1-CC-220 in combination with CFZ and DEX -Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle~Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle~Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg"
2518557|NCT02773030|Experimental|Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1|"Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle~Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle~Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg"
2518558|NCT02773030|Experimental|CohortI-CC-220 in combination with DEX in post BCMA RRMM-Part2|"Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle~Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle."
2518560|NCT02773030|Experimental|CohortJ1:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above).~Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle."
2518566|NCT02773030|Experimental|CohortJ2:CC-220 in combination with DEX and BTZ in NDMM-Part 2|"Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle.~Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle.~Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle."
2518717|NCT02771899|Experimental|EOS + spineEOS software in adults|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
2518718|NCT02771899|Active Comparator|EOS in adults|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
2518719|NCT02771899|Experimental|EOS + spineEOS software in children|Participants will receive standard of care (EOS) - 2D planning with 3D modeling.
2518721|NCT02771899|Active Comparator|EOS in children|Participants will receive standard of care (EOS) - 2D planning performed with current practice.
2518780|NCT02771353|Active Comparator|WT_vDIBH|Wide tangent radiotherapy in voluntary deep inspiratory breath hold
2518783|NCT02771353|Active Comparator|VMAT_FB|Volumetric modulated arc therapy in free breathing.
3198488|NCT00871078||B|HIV-positive patients with CD4 cell counts never below 100 cells/mm³ in their medical records
3198489|NCT00871078||C|HIV-negative patients (control group)
2518921|NCT02770261|Experimental|CR group|DP-R208+Candesartan 32mg pla+Rosuvastatin 20mg pla
2518928|NCT02770261|Active Comparator|CP group|DP-R208 pla+Candesartan 32mg+Rosuvastatin 20mg pla
2518936|NCT02770261|Active Comparator|PR group|DP-R208 pla+Candesartan 32mg pla+Rosuvastatin 20mg
2519008|NCT02769819|Experimental|Intubation with a flexible fiberscope|Following induction of general anesthesia and administration of a neuromuscular blocking agent, intubation will be performed using a flexible fiberscope.
2519039|NCT02769364||Participants treated with eribulin for at least 7 months|
2519141|NCT02768987|Experimental|Overweight|Sedentary adolescents with T1D and overweight
2519144|NCT02768987|Experimental|Normal Weight|Sedentary adolescents with T1D and normal weight
2519179|NCT02768428|Experimental|Video-Audio Media|watching the entire video in 15 mins
2519183|NCT02768428|No Intervention|Handbooks|study the hand book in 15 mins
2519208|NCT02768090|Experimental|Skin Patch|Sweat will be collected from inflammatory and neoplastic skin lesions with an FDA approved diagnostic skin patch for analysis with mass spectrometry
3198490|NCT00871091|Experimental|1|CAD/CAM group, customized archwires
3198491|NCT00871091|Active Comparator|2|prefabricated archwires (superelastic)
3198492|NCT00871091|Active Comparator|3|prefabricated archwires with manual adjustments
3198493|NCT00871104|Experimental|1|IV fosfomycin and imipenem adjusted to renal function
3198494|NCT00871104|Active Comparator|2|IV Vancomycin twice a day with valley leves higher than 15 mcg/kg
2518602|NCT02772367||Breast Cancer Patients|In study participants undergoing breast reconstruction surgery prior to breast radiation therapy, we will obtain skin tissue at the time of reconstruction surgery from the surgical specimen.
2518647|NCT02772185|Experimental|active tDCS plus real CT|Participants will receive active transcranial direct current stimulation and real cognitive training.
2518652|NCT02772185|Experimental|sham tDCS plus real CT|Participants will receive sham transcranial direct current stimulation and real cognitive training.
2518655|NCT02772185|Experimental|active tDCS plus placebo CT|Participants will receive active transcranial direct current stimulation and placebo cognitive training.
2518658|NCT02772185|Placebo Comparator|sham tDCS plus placebo CT|Participants will receive sham transcranial direct current stimulation and placebo cognitive training.
2518750|NCT02771639||Femoral neck fractures|Patients admitted to Sundsvall hospital for a displaced femoral neck fracture and treated with a hip arthroplasty
3198495|NCT00871156|Active Comparator|Part 1|Tafenoquine + Chloroquine vs. Chloroquine alone
3198496|NCT00871156|Placebo Comparator|Part 2|Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
2518957|NCT02770209|Experimental|the experimental group|Patients in the experimental group will be treated with the biomimetic cartilage matrix combined with autologous chondrocytes. The entire course of treatment includes two surgeries. The first surgery will be performed to observe articular cartilage damage by arthroscopy and assess treatment potential. If the patient's condition meets the surgical requirement, we will extract cartilage from the fossa intercondylar non-weight-bearing area during the first surgery. Chondrocytes will be in vitro-amplified and inoculated into the cartilage scaffold. The fully prepared seeded scaffold will be implanted into the site of injury during the second surgery.
2518963|NCT02770209|Experimental|the control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
2519027|NCT02769741|Other|Crossover 1: Control Diet followed by Active Diet|Treatment Period 1: Controlled diet without cashew nuts; Treatment Period 2: Controlled diet with cashew nuts
2519028|NCT02769741|Other|Crossover 2: Active Diet followed by Control Diet|Treatment Period 1: Controlled diet with cashew nuts; Treatment Period 2: Controlled diet without cashew nuts
2519088|NCT02769260|No Intervention|No toothbrushing during experiment and Pyrosequencing|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope) and 16S DNA pyrosequencing.
2519089|NCT02769260|No Intervention|No toothbrushing during experiment|Volunteers will not brush their teeth during 48 hours. Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
2519090|NCT02769260|Active Comparator|Toothbrushing during experiment|48hours-Dental plaque samples will be analyse by CLSM (confocal Laser scanning microscope).
2519114|NCT02768766|Experimental|Selumetinib|Subjects will receive selumetinib (hyd-sulfate AZD6244) orally twice a day for three days followed by four days off in four week cycles starting at a dose of 125mg. The doses to be studied on a 3 day on, 4 day off schedule are 100mg, 125mg, 150mg, 175mg, 200mg and 225mg as per the time to event continual reassessment (TITE-CRM) design.
2519184|NCT02768493|Experimental|low dose group|Patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block.
2519189|NCT02768493|Active Comparator|high dose group|Patients in the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block.
2519201|NCT02768077|Experimental|Melatonin(Circadin®)|Melatonin(Circadin®) is taken orally, once daily before going to sleep for a period of 4 weeks.
2519203|NCT02768077|Placebo Comparator|Placebo|Placebo tablet is taken orally, once daily before going to sleep for a period of 4 weeks.
2519249|NCT02767973|Experimental|Woodsmoke Exposure|
2519265|NCT02767648||cholestasis|infant suffering from cholestasis proteomic urine analysis
2519339|NCT02767557|Experimental|Tocilizumab & Gemcitabine and nab-Paclitaxel|"Tocilizumab:~8 mg/kg given I. V. on day 1 over 60 minutes every 28 day cycle.~Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
2519342|NCT02767557|Active Comparator|Gemcitabine and nab-Paclitaxel|"Gemcitabine:~1000 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle.~Nab-Paclitaxel:~125 mg/m² I. V. on day 1, day 8 and day 15 of every 28 day cycle."
2519412|NCT02767219|Other|Dexamethasone and 5-fluorouracil|The control arm consists of current standard therapy of subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of 5-fluorouracil as required for 4 consecutive weeks after entry into the trial.
2519415|NCT02767219|Active Comparator|Dexamethasone and Avastin|Subconjunctival injections of dexamethasone 3.3mg/ml and pre filled syringes of bevacizumab will be given for 4 consecutive weeks from time of entry into trial
2519459|NCT02766751|Placebo Comparator|Health Education|The seven sessions will cover: 1) nutrition (2 sessions), 2) sleep hygiene, 3) building immunity (e.g., how to avoid colds/flu), 4) injury/disease prevention (e.g., seat belts, sunscreen, when to get regular check-ups/screenings etc.), 5) benefits of exercise/cardiac health, 6) alternative medicine (massage, acupuncture). These sessions will be primarily didactic and consist of health education, followed by discussion as to how this information compares to that which the participants may have been exposed to in the past.
2519477|NCT02766738|No Intervention|Control|All participants assigned to the control group will be given the option to engage in other activities that were offered by the facility during the 24-week intervention period. However, no specific resistance exercises were offered in these activities.
2519485|NCT02766790|Active Comparator|TA-65MD 100 units Dose|TA-65MD 100 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
3198497|NCT00871182|Experimental|PT001 18 mcg|Inhaled PT001 18 mcg
3198498|NCT00871182|Experimental|PT001 36 mcg|Inhaled PT001 36 mcg
3198499|NCT00871182|Experimental|PT001 72 mcg|Inhaled PT001 72 mcg
3198500|NCT00871182|Experimental|PT001 144 mcg|Inhaled PT001 144 mcg
3198501|NCT00871182|Placebo Comparator|Inhaled Placebo|Inhaled Placebo
3198502|NCT00871182|Active Comparator|Tiotropium Handihaler|Tiotropium 18 mcg administered via Handihaler
2518625|NCT02772328|No Intervention|Neighborhood Matters|Participants in this arm will view a 15-20 minute video on issues in neighborhoods such as crime and violence, restoring communities and incarceration and discuss their reactions and thoughts.
2518653|NCT02772068|Active Comparator|Healthy Senior Control|Fifteen healthy senior subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
2518657|NCT02772068|Experimental|Heart failure patients|Fifteen HFpEF subjects will perform light exercise at a fixed heart rate of 100 beats per minute. Subjects will then be given either placebo infusion (normal saline) or Istaroxime infusion for one hour. Subjects will be blinded to which infusion they are receiving. Subjects will then repeat light exercise at a fixed heart rate of 100 beats per minute. Primary outcome is changes in cardiac filling pressures during exercise.
2518755|NCT02771743|Experimental|High risk neuroblastoma|"Nine cycles of induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide (CEDC) and ifosfamide, carboplatin, etoposide (ICE) regimen~Upfront surgery or surgery after 6 cycles of chemotherapy~Peripheral stem cell mobilization after 7 cycles of chemotherapy~Tandem high dose chemotherapy with autologous stem cell transplantation (Tandem HDCT/auto-SCT)~Dose of chemotherapeutic agents of 1st HDCT is tailored according to the residual positron emission tomography (PET)/Metaiodobenzylguanidine (MIBG) uptake before 1st HDCT~Dose of MIBG of 2nd HDCT is tailored according to the residual PET/MIBG uptake before 2nd HDCT~Radiotherapy after tandem HDCT~Immunotherapy and differentiation therapy with Interleukin-2/isotretinoin"
2518825|NCT02770989|Experimental|Vimecon Laser CAI Cardiac Ablation|Ablation of the cardiac tissue by the use of the Vimecon Laser CAI (Cardiac Ablation Instrument).
2518871|NCT02770716|Experimental|Terlipressin|"Participants will receive terlipressin intravenously as a bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (+/- 30 minutes), followed by a saline flush.~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
2518877|NCT02770716|Placebo Comparator|Placebo|"Participants will receive 1 vial of matching placebo intravenously as a bolus injection of 1 vial over 2 minutes every 6 hours (+/- 30 minutes), followed by a saline flush.~Dose, duration, retreatment and/or discontinuation may be modified by the investigator, per protocol."
2518984|NCT02769845|Experimental|Longitudinal Portion|All enrolled children will undergo yearly TCD examination. The goal of serial examination is to help define the natural history of cerebrovascular disease, specifically to determine the incidence of new conditional or abnormal velocities. The goal is to obtain a total of 3 TCD examinations per enrolled patient, regardless of treatment status.
2518985|NCT02769845|Experimental|Treatment Phase|Those children with TCD velocities between 170-199 cm/sec will be eligible for protocol-directed hydroxyurea therapy. Most participants will initiate hydroxyurea treatment but those who are already on hydroxyurea and have conditional velocities will receive dose optimization. Participants will be followed until a common study termination date, defined as 3 years from the first treatment. Participants with abnormal TCD velocities ≥200 cm/sec will commence with transfusion therapy per current practice guidelines at the clinical site. Patients already on transfusion therapy identified to have conditional velocities will also be eligible for hydroxyurea and those with abnormal velocities may require re-calculation of transfusion dosing.
2519034|NCT02769507|Experimental|real tDCS|DC Stimulator PLUS (NeuroConn) The real tDCS condition comprises two daily sessions of 20 min tDCS, separated by a minimum break of 3h, for five consecutive days. Anodal and cathodal tDCS will be applied with 2mA to the left dorsolateral prefrontal cortex (a point midway between F3 and FP1) and the left peri-Sylvian region (a point midway between T3 and P3), respectively. Electrode size is 7cm x 5cm.
2519041|NCT02769507|Sham Comparator|sham tDCS|"DC Stimulator PLUS (NeuroConn) The sham condition is identical to the real tDCS condition except that after 40s of tDCS stimulation is going to be reduced to a small pulse every 550msec (110 μA over 15 msec) through the remainder of the 20 minute period."
2519128|NCT02769182|Experimental|Monitoring and training using the system|
2519129|NCT02769182|Active Comparator|Standard of care|
2519162|NCT02768519|Experimental|OTS167IV|Cohort 1: 0.5 mg, Cohort 2: 1.0 mg, and Cohort 3: 2.0 mg without food on Period 1 Day 1 and with food on Day 1 Period 2.
2519165|NCT02768519|Placebo Comparator|Placebo|Cherry syrup
2519210|NCT02768220|Active Comparator|Linagliptin|Eligible patients were randomized to receive linagliptin 5mg daily for 30 days.
2519215|NCT02768220|Experimental|Empagliflozin|Eligible patients were randomized empagliflozin 25mg daily for 30 days.
3198503|NCT00871208|Experimental|1|Altabax (R) and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
3198504|NCT00871208|Active Comparator|2|Vehicle and Locoid Lipocream (R):Patients will apply both drugs sequentially to active lesions of atopic dermatitis. Physical examination, skin cultures, photos and quality of life scores will be performed at baseline, week 1, week 2 and week 4.
3198505|NCT00871247|Experimental|A|Finasteride 5 mg single dose tablet, single dose
3198506|NCT00871247|Active Comparator|B|Proscar® 5 mg Tablet, single dose
2519480|NCT02766686|Experimental|Radiotherapy with protons|Proton radiotherapy 74-80 Gray equivalent (GyE), 2Gy per fraction, 5 fractions peer week
2519482|NCT02766686|Active Comparator|Radiotherapy with photons|Photon-Intensity-Modulated Radiation Therapy (IMRT) without lymph drainage vessels, 74-80 Gy, 2Gray (Gy) per fraction, 5 fractions peer week
2519484|NCT02766686|Other|Radiotherapy with photons with lymph drainage vessels|Photon-IMRT with lymph drainage vessels, 74-80 Gy, 2Gy per fraction, 5 fractions peer week
2519543|NCT02766322||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
2519844|NCT02764372|Experimental|Serious games|The experimental group received Serious Games-based upper extremity therapy through Kinect
3165405|NCT00512668|Experimental|Treatment (hormone therapy, temsirolimus)|"Patients receive combined androgen ablation therapy comprising a luteinizing hormone-releasing hormone analogue (i.e., leuprolide acetate intramuscularly once monthly or goserelin subcutaneously every 3 months) and an oral anti-androgen drug (i.e., bicalutamide or nilutamide once daily or flutamide 3 times daily) on days 1-90.* Beginning on day 60 of hormonal therapy, patients receive temsirolimus IV over 30 minutes once weekly. Treatment with temsirolimus continues for up to 36 weeks in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive no more than 3 months of hormonal therapy, including therapy initiated within 2 months of study entry."
3165406|NCT00512746|Other|Surveillance|Screened arm
2518746|NCT02771561|Other|Patent Foramen Ovale Closure|All eligible participants undergo a patent foramen ovale closure procedure
2518899|NCT02771184|Other|Lung-Healthy|Subjects with no diagnosed lung disease. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2518900|NCT02771184|Other|Pneumothorax|Subjects with pneumothorax. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2518901|NCT02771184|Other|Pulmonary Fibrosis|Subjects with pulmonary fibrosis. The intervention is the recording of lung sounds with the Lung Sound Recording System.
2518966|NCT02770157|Experimental|DA-3002|1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
2518968|NCT02770157|Active Comparator|Genotropin®|1.44 IU (0.48mg)/kg/week of Genotropin is injected for 52 weeks by changing injecting areas(six or seven times per week).
2518969|NCT02770157|Other|Non-treatment control group|After no treatment for 26 weeks, 1.44 IU (0.48mg)/kg/week of DA-3002 is injected for 52 weeks by changing injecting areas(six or seven times per week).
2519030|NCT02769676|Experimental|3-week visit|Participants randomized to this arm will receive an additional visit at 3-weeks postpartum
2519032|NCT02769676|Active Comparator|usual care|Participants randomized to this arm will receive usual postpartum care, including the standard timing for a postpartum visit.
2519082|NCT02769221|Experimental|Optiscope|Endotracheal intubation by rigid video stylet, manufactural named Optiscope.
2519083|NCT02769221|Active Comparator|McGrath|Endotracheal intubation by video laryngoscope, manufactural named McGrath.
2519146|NCT02768805|Experimental|15 µg/strain of Quadrivalent VLP Vaccine|
2519147|NCT02768805|Experimental|30 µg/strain of Quadrivalent VLP Vaccine|
2519149|NCT02768805|Active Comparator|15 µg/strain of the licensed quadrivalent vaccine|
2519220|NCT02768272|Experimental|Epidural analgesia|Randomized allocation to receive patient controlled epidural analgesia or programed intermittent epidural boluses
2519225|NCT02768272|Experimental|Epidural technique|Randomized allocation to be punctioned a conventional epidural or a combined spinal-epidural technique
2519328|NCT02767778|Experimental|REAL Pulsed ELF-MF stimulation|Patients will receive REAL pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
2519335|NCT02767778|Sham Comparator|SHAM Pulsed ELF-MF stimulation|Patients will receive SHAM pulsed ELF-MF stimulation and the standard of care for acute ischemic stroke, according to current guidelines.
2519367|NCT02767349|Experimental|MNK-155|MNK-155, initial dose of two or three tablets followed by 2 tablets every 12 hours up to a maximum of five doses.
2519582|NCT02765685|Experimental|ODRA|
2519583|NCT02765685|Active Comparator|usual care|
2519642|NCT02765620||drug|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
2519645|NCT02765620||radiation|Early treatment response assessment: using baseline data and early follow-up data Evaluate treatment response: using baseline data, early follow-up data and final data Compare PERCIST to RECIST criteria: correlation analysis Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot
2519775|NCT02764814|Active Comparator|Treatment|subjects receiving cryopreserved amniotic membrane
2519784|NCT02764814|No Intervention|Control|no intervention
2519820|NCT02764346|Experimental|iCanCope app|iCanCope app
2519823|NCT02764346|Active Comparator|Attention control app|Control group: iCanCope attention control app
2519862|NCT02763930|Experimental|CONTROL (dairy-free)|6 weeks experimental diet with all meals and foods provided to participants. The diet contain 32% of fat, 11% of saturated fat (SFA), 13% of mono-unsaturated fat (MUFA), 8% of polyunsaturated fat (PUFA) and 15% of proteins.
2519866|NCT02763930|Experimental|MILK (low fat dairy)|6 weeks experimental diet with all meals and foods provided to participants including 3 servings/day of milk (1% fat) per 2500 kcal. The diet contain 32% of fat, 11% of SFA, 13% of MUFA, 8% of PUFA and 15% of proteins.
2519869|NCT02763930|Experimental|GABA-rich cheese (high-fat dairy )|6 weeks experimental diet with all meals and foods provided to participants including 50g/day of GABA-rich cheddar cheese (approximately 32% fat). The diet contain 32% of fat, 13% of SFA, 13% of MUFA, 6% of PUFA and 15% of proteins.
3165407|NCT00512746|Active Comparator|Control|Control arm
3165408|NCT00512759|No Intervention|Standard of care|Standard of care of acute decompensated heart failure will be according to the current guidelines of the European Society of Cardiology (ESC).
3165409|NCT00512759|Experimental|Intervention|Early goal-directed preload and afterload decrement using a fixed therapy schedule including sublingual or nitrospray and transdermal nitrates together with hydralazine, followed by rapid up-titration of ACE-inhibitors , AT-receptor blockers or neprilysin inhibitors/AT-receptor blockers to achieve maximal vasodilatation with a target systolic blood pressure of 90-110 mmHg. All other elements of treatment will be according to the current guidelines of the European Society of Cardiology (ESC)
3165410|NCT00512785|Experimental|E1|
3165411|NCT00512785|Experimental|E2|
3165412|NCT00512824|Placebo Comparator|1|
3165413|NCT00512824|Active Comparator|2|
3165414|NCT00512824|Active Comparator|3|
3165415|NCT00512824|Active Comparator|4|
3165416|NCT00512837|Active Comparator|2|
3165417|NCT00512850|Other|Folic acid|Folic acid supplement 1g/day
3165418|NCT00512850|Other|Placebo|Placebo pill once per day
2518649|NCT02772211|Experimental|D-cycloserine|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral D-cycloserine, titrated slowly up to 1000mg/d over the next 8 weeks.
2518656|NCT02772211|Placebo Comparator|Placebo|Participants in this group would receive 6 infusions of ketamine. Participants who demonstrate symptoms reduction following ketamine infusions would receive oral Placebo pills, titrated slowly up to 1000mg/d over the next 8 weeks.
2518713|NCT02771717|Experimental|Budesonide (Pulmicort)|Low dose inhaled corticosteroid.
2518714|NCT02771717|Placebo Comparator|Placebo - dummy inhaler|Placebo - dummy inhaler
2518724|NCT02771457|Experimental|Infliximab at weeks 0,2, and 6|In this arm subjects will receive re-induction treatment of infliximab at weeks 0,2, and 6.
2518725|NCT02771457|Experimental|Infliximab at weeks 0,4, and 8|In this arm subjects will receive re-induction treatment of infliximab at weeks 0, 4, and 8
2518726|NCT02771457|Active Comparator|Infliximab at weeks 0, and 8|In this arm subjects will not be randomized. They will receive re-induction therapy weeks 0 and 8.
3198507|NCT00871299|Experimental|1|Mindfulness Based Cognitive Therapy (MBCT) + medication management
3198508|NCT00871299|Active Comparator|2|The Health Enhancement Program (HEP) + medication management
3198509|NCT00871312|Active Comparator|Topical Wound Oxygen Therapy|Subjects will receive four 90 minute treatments of two2 therapy per week
2518839|NCT02770898|Experimental|Brief Intervention|The brief intervention is individual focus and consists of three main components, which include enhancing the individual personal attributes such as participant's knowledge, values, and behaviors related to physical exercise. Second, the intervention will promote changes in behavioral attributes by providing opportunities and experience in goal setting, skills development in physical exercise and self-monitoring. Finally, the brief intervention promotes family relations and well-being by encouraging individuals to share their knowledge and increase physical activities with other family members. The brief intervention will be delivered by the probation officer during regular monthly consultation.
2518843|NCT02770898|Experimental|Combined Intervention|Participants allocated to the combined intervention will receive the individual brief intervention and participate in a community group program. The components in the brief intervention will also be reinforced in the group program. The group nature is designed to create an environment that is supportive of physical exercise, through role models, peer support, and encourages families to exercise with probationers.
2518847|NCT02770898|No Intervention|Care-as-usual|Participants allocated to Care-as-usual arm will receive their usual services. Participants will be offered the combined interventions upon completion of 3-months follow up assessment.
3198510|NCT00871312|Placebo Comparator|Placebo Therapy|Subjects will receive four 90 minute treatments of Placebo two2 therapy per week
2518974|NCT02769975||Case Only|Children ages 0-18 with known or suspected endocrine or metabolism disorders.Family members ages 0-100. They may participate in the DNA part of the study
2519002|NCT02769663||OSA|Patients with newly diagnosed obstructive sleep apnea and no medical comorbidity affecting cognition.
2519004|NCT02769663||healthy controls|Participants with no sleep disorder or other medical comorbidity affecting cognition.
2519062|NCT02769403|Experimental|Treatment|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The treatment participants will use it daily for all 12 weeks, and will have the added component of weekly visits for the first 6 weeks of the study from the study team. The weekly visits is focused on reinforcing accountability and achievement of coherence. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
2519064|NCT02769403|Active Comparator|Control|Participants will use HeartMath EmWave Pro for at least one 5-minute session daily, Monday through Friday. The control participants will use it daily only for weeks 7-12. The participants will also complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance. Participants' blood pressure and heart rate will be collected at those three time points. Additionally, information about participants' use of HeartMath EmWave Pro, sick days, and patient satisfaction will be collected after week 12.
2519122|NCT02768974|Experimental|OPRX-106 2 mg|Open label, 1:1 randomization ration (up to 10 subjects)
2519125|NCT02768974|Experimental|OPRX-106 8 mg|Open label, 1:1 randomization ration (up to 10 subjects)
2519163|NCT02768441|Experimental|Study group|Participants receiving Dexamphetamine 60 mg SR
2519229|NCT02768246|Active Comparator|Begin with BVGA|The volunteers will be asked to breathe 5 minutes of room air through the BVGA, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the BVGA. Then the same volunteers will be asked to repeat the protocol with the face mask.
2519232|NCT02768246|Active Comparator|Begin with Face-mask|The volunteers will be asked to breathe 5 minutes of room air through the face mask, followed by, 5 minutes 100% oxygen, and 5 minutes room air again. This will be followed by 5 minutes room air breathing without the face mask. Then the same volunteers will be asked to repeat the protocol with the BVGA.
3198511|NCT00871325|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
3198512|NCT00871325|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
2519423|NCT02767167|Active Comparator|Milk treatment group|Semi-skimmed cow's milk + normal diet for 12 weeks
3198513|NCT00871325|Placebo Comparator|Placebo|Placebo TID
3198514|NCT00871364|Experimental|A|VENLAFAXINE TABLETS 50 mg, single dose
3198515|NCT00871364|Active Comparator|B|Effexor® (venlafaxine HCl) Tablets equivalent to 50 mg venlafaxine, single dose
3198516|NCT00871442|Active Comparator|No Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)"
3198517|NCT00871442|Active Comparator|Basal Infusion|"PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml~Group 2: Basal Infusion: 10 ml/hr; Bolus 5 ml q 30min prn (5ml demand dose with 30min lockout)"
3198518|NCT00871455|Experimental|1|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
2518662|NCT02772250|Experimental|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
2518789|NCT02771301|Other|dendritic cell|Patients will receive autolgous IDH1R132H dendritic cells and cytotoxic lymphocytes treatment.
2518813|NCT02771002||septic shock patients|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until normalisation of lactate sonographic assesment of perfusion of solid organs once within 24h after admission
2518819|NCT02771002||patients rewarming after cardiac surgery|measurements of peripheral perfusion including capillary refill time, mottling score, temperature gradient and peripheral perfusion index hourly until extubation
2518824|NCT02771002||healthy volunteers|measurements of peripheral perfusion including capillary refill time and peripheral perfusion index in ambient temperature and after cooling of extremity
2518870|NCT02770729|Active Comparator|Intracameral moxifloxacin|Intracameral injection of 0.5% moxifloxacin at conclusion of cataract surgery (150 micrograms)
2518878|NCT02770729|Sham Comparator|No injection of moxifloxacin|No injection of moxifloxacin at conclusion of cataract surgery
2518927|NCT02770274|Experimental|Group Cilostazol|Patients receiving dual antiplatelet therapy with cilostazol 100mg twice daily and aspirin 100mg once daily for 12 months.
2518934|NCT02770274|Active Comparator|Group Aspirin|Patients receiving monotherapy with aspirin 100mg once daily for 12 months.
2518994|NCT02769910|Other|Cowhage|Cowhage is used to induce non-histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hours and Qutenza Demo Patch.
2518995|NCT02769910|Other|Histamine|Histamine is used to induce histaminergic itch on the volar forearm at the locations treated with Capsaicin 24 Hours, Capsaicin 1 Hour and Qutenza Demo Patch.
2519044|NCT02769416||Spinal Cord and Traumatic Brain Injury Subjects|Patients with a history of spinal cord and/or traumatic brain injury will provide data and samples so that they may be queried for interventional studies.
2519050|NCT02769416||Family Members and Healthy Volunteers|Healthy volunteer controls or family members may be enrolled for identification of genetic mutations.
2519102|NCT02768844|Experimental|SVS vs Control|Prospective, within-subject design. Compare effects of mattress SVS (ON) and Control (SVS OFF) on physiology in opioid-exposed newborns. SVS is alternated in intervals between continuous stimulation (ON) and no stimulation (OFF/Control) throughout inter-feed intervals. The order of the ON-OFF cycles is randomized across subjects and counterbalanced between feeding periods within subjects.
3165419|NCT00512889|Experimental|Cohort 1|Different dose of CTL
2519199|NCT02768363|Active Comparator|ProstAtak®|Patients randomized to the ProstAtak arm will receive two courses of aglatimagene besadenovec (CAN-2409) + valacyclovir
2519200|NCT02768363|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive two corresponding courses of placebo + valacyclovir
2519399|NCT02767232|Active Comparator|Standard Anticoagulation Therapy|Anticoagulant therapy will be prescribed in accordance with 2012 ACCP Guidelines for children. Initial therapy generally will consist of low molecular weight heparin (LMWH) or unfractionated heparin (UFH), monitored to achieve and maintain a target anti-Xa activity of 0.5-1.0 IU/mL for LMWH and 0.35-0.7 IU/mL for UFH. Long-term therapy generally will consist of warfarin/coumadin, monitored to achieve and maintain a target INR of 2.0-3.0. The use of novel anticoagulants is permitted based on investigator preference.
2519401|NCT02767232|Experimental|Catheter-Directed Thrombolysis|Catheter-Directed Thrombolysis (CDT) with intrathrombus delivery of Recombinant tissue plasminogen activator (rt-PA) (maximum allowable total dose 35 mg/24 hours) into the DVT over a period of up to 24 hours. CDT will be initiated within 72 hours of diagnosis. Two methods of initial rt-PA delivery will be used: 1.) AngioJet Thrombectomy System- maximum first-session rt-PA dose 25 mg; or 2.) Catheter-directed rt-PA infusion for up to 24 hours at 0.01 mg/kg/hr (maximum 1.0 mg/hr) via a multisidehole catheter. Before and after CDT, patients will receive standard DVT therapy as in the standard anticoagulation group
2519443|NCT02766816|Experimental|Part 1 Study - BBio bOPV|
2519445|NCT02766816|Active Comparator|Part 1 Study - Licensed bOPV|
2519447|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 1|
2519449|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 2|
2519451|NCT02766816|Experimental|Part 2 Study - BBio bOPV Lot 3|
2519458|NCT02766816|Active Comparator|Part 2 Study - Licensed bOPV|
2519846|NCT02764372|Active Comparator|Exergames|The control played the same amount of time with commercial exergames of the Wii
3165420|NCT00512889|Experimental|Cohort 2|Different dose of CTL
3165421|NCT00512889|Experimental|Cohort 3|Combination of CTL with GMCSF +/- radiation
3165422|NCT00512915|Active Comparator|1699T (Optisense)|Implantation of the Optisense Lead 1699T, programming of the shortest possible postventricular atrial blanking period (PVAB)
3165423|NCT00512915|Active Comparator|Standard lead|Implantation of a standard bipolar atrial pacing lead. Optimization of the postventricular atrial blanking period (PVAB) after implantation.
3165424|NCT00512941||1|HBV: Carrier
3165425|NCT00512941||2|HBV: cure
3165426|NCT00512941||3|HBV: isolate anti-HBc
3165427|NCT00512941||4|HBV: vaccinated
3165428|NCT00512941||5|HCV: anti-HCV positive test
3165429|NCT00512941||6|HBV/HCV co-infection
3165430|NCT00512941||7|Susceptible individuals
3165431|NCT00512967||sarcoidosis|21 onset patients, non-treated
3165432|NCT00512967||IPF|15 IPF patients, partially treated
3165433|NCT00512967||COPD|15 COPD patients within 24 hours after their last exacerbation
3165434|NCT00512967||controls|25 healthy controls, matched for age and gender
3165435|NCT00512980|Active Comparator|1|
3165436|NCT00512980|Active Comparator|2|
3165437|NCT00512993|Active Comparator|Treatment|Patients receive zoledronic acid (4mg) for 5 years. Additionally patients receive standard endocrine, radiologic and trastuzumab treatment, respectively
3165438|NCT00512993|No Intervention|Observation|Patients will be under observation and receive standard endocrine, radiologic and trastuzumab treatment, respectively
3165439|NCT00513032||methylene blue|
3165440|NCT00513032||C|
2518679|NCT02772159|Experimental|Study Population|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
2518772|NCT02771613||Active experience feedback|Multi professional, in situ simulation , with scenarios based on the adverse events analyzed in MMR : After analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
2518773|NCT02771613||Passive experience feedback|Large diffusion of information about discussions and decisions of Morbidity Mortality Reviews : after the analysis of adverse effects in Morbidity Mortality reviews, a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out.
2518776|NCT02771613||No experience feedback|MMR will be performed as usual, without any feedback to the medical staff
2518961|NCT02770196|Experimental|Group One (Two-year Intervention, 2016 Enrollment)|Group one intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2016 and 2017. During the 2016 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2518965|NCT02770196|Experimental|Group Two (Delayed Two-year Intervention, 2016 Enrollment)|Group two intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year in 2017 and 2018. During the 2017 season they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2518967|NCT02770196|Experimental|Group Three (One-year Intervention, 2017 Enrollment)|Group three intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2017 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2518971|NCT02770196|Experimental|Group Four (Delayed One-year Intervention, 2017 Enrollment)|Group four delayed intervention participants in CO-CSA plus nutrition education will receive a subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks in 2018 and will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
2519009|NCT02769559||Patients with macromasty|Female adult patients with symptomatic macromasty selected for elective reduction surgery
3198519|NCT00871468|Active Comparator|superior plate|Clavicle plate on the superior surface of the bone
3198520|NCT00871468|Experimental|anterior inferior plate|plate placed on anterior inferior surface of bone
2519213|NCT02768311|Experimental|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system post-treatment pain after using neolix rotary system
2519217|NCT02768311|Experimental|waveone rotary system (reciprocating system)|Procedure: waveone rotary system post-treatment pain after using waveone rotary system
2519222|NCT02768311|Experimental|hand files k-files|Procedure: hand files post-treatment pain after using hand files
2519285|NCT02767791|Active Comparator|Acupuncture|Acupuncture wrist 6
2519288|NCT02767791|Active Comparator|Auriculotherapy|Auriculotherapy
2519291|NCT02767791|Experimental|Auriculotherapy and acupuncture|Auriculotherapy and acupuncture
2519295|NCT02767791|No Intervention|No treatment|No treatment
2519382|NCT02767453|Active Comparator|TSA with drain placement|Hemovac drains are placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
2519385|NCT02767453|Active Comparator|TSA without drain placement|Hemovac drains will not be placed in subjects during standard Total Shoulder Arthroplasty involving the replacement of damaged shoulder components with shoulder prosthesis.
2519434|NCT02766946|Experimental|Mechanical Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Mechanical Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
2519436|NCT02766946|Active Comparator|Non-invasive Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Non-invasive Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
2519438|NCT02766946|Active Comparator|Spontaneous Ventilation|"Evolution over time of Diaphragmatic and Pectoralis muscle atrophy under Spontaneous Ventilation~Interventions :~Ultrasound of the right diaphragm~Ultrasound of the pectoral muscle~Neuromyopathy score~Respiratory performances"
3198521|NCT00871481|Experimental|Treatment (laboratory-treated T cells and ipilimumab)|Patients receive cyclophosphamide IV on day -2, therapeutic cytotoxic T lymphocytes IV over 30-60 minutes on day 0, low-dose aldesleukin SC BID on days 0-13, and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
2519584|NCT02765750|Experimental|BIS 40-60|Patient with intraoperative Bispectral Index (BIS) 40-60.
2519587|NCT02765750|Experimental|BIS 20-40|Patient with intraoperative Bispectral Index (BIS) 20-40.
2519589|NCT02765750|Placebo Comparator|Placebo|Placebo group
2519686|NCT02765555|Experimental|RBP-7000|All subjects that meet initial study entry criteria will receive a test dose of 0.25mg of oral risperidone. Subjects who continue to be eligible will return to the clinical unit in one week and receive a single dose of 60mg RBP-7000 after a 2 hour fast. Subjects will remain in the clinical unit for 14 days, then return for 10 additional weeks after discharge.
2519723|NCT02765048|Experimental|GAIN Program|Subjects randomly assigned to receive the GAIN Program intervention
2519725|NCT02765048|No Intervention|Usual Care|Subjects randomly assigned to receive community-based services as part of their usual care
3198522|NCT00871507|Experimental|001|
2519818|NCT02764138|Experimental|BaSICS Intervention|"Intervention = Building a String Identity and Coping Skills (BaSICS). Children randomized to participate in 16 twice weekly BaSICS intervention sessions. Children learn coping skills, identity development, and collective action as ways to buffer against chronic stress.~These children also complete pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments."
3198523|NCT00871507|Experimental|002|
3198524|NCT00871507|Placebo Comparator|003|
3198525|NCT00871507|Active Comparator|004|
2518688|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance sensor verification|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518691|NCT02772276|Experimental|CKD Stage 3-5/Brilliance sensor verification|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. Verification of the Brilliance sensor will be conducted. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518694|NCT02772276|Experimental|Normal-CKD Stage 2/Brilliance final algorithm and sensor|MB-102 administered to participants with normal to chronic kidney disease (CKD) Stage 2 renal function, and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type. A subset of participants in this arm will receive two doses of MB-102, 12 hours apart.
2518696|NCT02772276|Experimental|CKD Stage 3-5/Brilliance final algorithm and sensor|MB-102 administered to participants with impaired renal function (chronic kidney disease (CKD) Stage 3-5), and fluorescence measured by the Brilliance ORFM device. The optimized algorithm and final device design of the Brilliance device will be tested. Approximately half of the participants will be enrolled with Fitzpatrick Scale Type I, II or III, and half with Type IV, V and VI skin color type.
2518729|NCT02771392|Experimental|Tetracaine Group|Patients with he primary diagnosis of corneal abrasion will be treated with ophthalmic tetracaine. Tetracaine will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of preservative-free, undiluted 1% tetracaine hydrochloride (a total of 1.5 mL or approximately 50 drops will be provide to avoid overuse). Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
2518731|NCT02771392|Placebo Comparator|Normal Saline Group|Patients with the primary diagnosis of corneal abrasion will be treated with normal saline eye drops. Normal saline will be supplied in three plastic prefilled, commercially available vials, each containing 0.5 mL of normal saline. Patients will be instructed to use 1-2 drops of up to every 30 min for pain control over a 48 hour period with subsequent followup with the ophthalmologist.
3198526|NCT00871520||Palliative Therapy|Patients referred to the oncology / radiation oncology departments for palliative therapy.
2518857|NCT02770534||Sickle patients in steady state|Well sickle cell patients attending the outpatient clinic
2518859|NCT02770534||Sickle cell patients admitted in crisis|Inpatients with acute vaso-occlusive crisis
2518861|NCT02770534||Sickle patients on transfusion program|Sickle patients managed on a regualar transfusion program
2518865|NCT02770534||Sickle patients on Hydroxycarbamide|Sickle cell patients managed on hydroxycarbamide and on a stable dose for at least 3 months
2518868|NCT02770534||Health controls|Well age and race matched individuals without a known diagnosis of sickle cell anaemia
3165441|NCT00513045|Experimental|IRT|Intervention based on Imagery Rehearsal Therapy
3165442|NCT00513045|Active Comparator|Exposure|Treatment based on exposure
3165443|NCT00513045|No Intervention|Nightmare diary|Recording nightmares in a diary
2518987|NCT02769806||GBM patients undergoing MRI|GBM patients undergoing standard-of-care post-operative combination chemoRT and clinically indicated MRI including standard DSC-PWI for follow-up.
2519007|NCT02769520|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
2519038|NCT02769377|No Intervention|Control|patients who decline or unable to do self-monitoring of blood glucose
2519046|NCT02769377|Active Comparator|Breeze2 glucometer|patients who do self-monitoring of blood glucose, but do not transfer data via mobile-phone
2519051|NCT02769377|Experimental|Breeze2 glucometer and H2|patients who do self-monitoring of blood glucose and transfer data via mobile-phone
2519139|NCT02768818|Experimental|Intervention|Probiotic VIVOMIXX™
2519145|NCT02768818|Placebo Comparator|Control|Placebo
2519192|NCT02768402|Experimental|Treatment Arm|All eligible patients will be in the treatment arm for the 'Caisson TMVR System' (transcatheter mitral valve replacement) procedure. No control or comparator in this study.
2519329|NCT02767713|Experimental|Dexamethasone|Dexamethasone dose of 0.1 mg/kg was administered intravenously 10h before surgery
2519334|NCT02767713|Placebo Comparator|Control|Equal volume of normal saline (placebo) was administered intravenously 10h before surgery
2519365|NCT02767297|Experimental|Part 1: Single dose (cross over)|FDL169 reference formulation and test formulation administered as a single dose in healthy subjects
2519374|NCT02767297|Experimental|Part 2: Multiple dose (dose level 1)|FDL169 test formulation (Dose level 1) administered as repeat doses in healthy subjects
2519378|NCT02767297|Experimental|Part 2: Multiple dose (dose level 2)|FDL169 test formulation (Dose level 2) administered as repeat doses in healthy subjects
2519386|NCT02767297|Experimental|Part 3: Single dose|FDL169 test formulation administered as a single dose in CF subjects
2518692|NCT02771925|Experimental|gabapentin|Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
2518695|NCT02771925|Placebo Comparator|Placebo|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2g/day divided in two doses for 24 weeks All patient will receive standard of care treatment
2518815|NCT02770976|Experimental|NAVA|Seven increasing and decreasing NAVA levels (0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 3.5, 3.0, 2.5, 2.0, 1.5, 1.0 and 0.5 cmH2O/uV) will applied to 20 preterm infants each for 10 minutes.
2518867|NCT02770781|Experimental|Personal Trainer|All subjects will meet a set amount of times with a personal trainer over the course of the study to participate in an exercise regimen.
2518913|NCT02770417|Active Comparator|COPD (beta-alanine)|
2518915|NCT02770417|Placebo Comparator|COPD (placebo)|
2518916|NCT02770417|Other|Healthy controls|
3165444|NCT00513045|No Intervention|Waiting list|Waiting list
3165445|NCT00513058|Experimental|lapatinib + vinorelbine|"starting with loading dose of lapatinib per os for 7 days~then, combining lapatinib (oral daily continuous) + vinorelbine (intravenous, day 1 and 8 every 3 weeks)"
3165446|NCT00513084|Experimental|SDT Intervention|This arm will follow main experimental intervention, as described elsewhere
2519023|NCT02769689|Experimental|Methylprednisolone|The primary purpose of this protocol is to investigate the impact of high dose of oral methylprednisolone, given once a month during the washout period between NTZ and Fingolimod (FTY).
2519024|NCT02769689|Placebo Comparator|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
2519107|NCT02769208|Active Comparator|Group A: Pre-Filter Only Intervention|Subjects in Group A start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which both the HEPA and ESP are removed, leaving only a pre-filter. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
2519108|NCT02769208|Active Comparator|Group B: Pre-filter + HEPA Intervention|Subjects in Group B start with baseline conditions of pre-filter + HEPA + ESP in their offices and dorms. After a baseline biological measurement, they then receive a 5-week intervention in which the ESP is removed, leaving a pre-filter + HEPA combination. This intervention period includes a biological measurement 2 weeks into the intervention and other 4-5 weeks into the intervention. The baseline air purification conditions are then restored, and another biological measurement is taken 2 weeks after that.
2519152|NCT02768649|Experimental|Cohort 1|Eligible subjects received a test dose of 0.25 risperidone prior to dosing with RBP-7000. Fifteen eligible subjects then received low dose RBP-7000
2519154|NCT02768649|Experimental|Cohort 2|After safety and tolerability review of the data from Day 1 to Day 15 of the low dose arm, 3 subjects were dosed in Cohort 2 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
2519155|NCT02768649|Experimental|Cohort 3|After safety and tolerability review of the data from Day 1 to Day 15 of the medium dose arm, 3 subjects were dosed in Cohort 3 with a higher dose of RBP-7000. A safety and tolerability review of the data from Day 1 to Day 15 was completed for the 3 subjects before the remaining 12 were dosed.
2519234|NCT02768350|Experimental|Control group|All of the participants in control group will be treated with conventional treatment for 3 days, The conventional treatments consist of: (1) Passive chest mobilization, (2) Positioning, (3) Side lying (good lung down), (4) Vibration. The conventional treatment consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
2519236|NCT02768350|Experimental|Experimental group|All of the participants of the experimental group will be treated with ventilator hyperinflation technique (VHI) for 3 days. Tidal volume will increase from baseline (100% VT) to the tidal volume target at 1.5 times (150% VT). At this level, patients will receive six breathes and in each breathe will be sustained for 5 second (6 hyperinflation breathe per set); expiratory VT will return to baseline after each breath. Four sets of hyperinflation breathing will be used. After this, VT will decrease to baseline and patients have a 60 second for rest between hyperinflation set. The ventilator hyperinflation technique (VHI) consists of three consecutive periods; (1) baseline period: 10 minutes, (2) intervention period, and (3) recovery period: 10 minutes.
2519307|NCT02767752|Experimental|T-ChOS + Gemcitabine + Capecitabine|"T-ChOS: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
2519314|NCT02767752|Placebo Comparator|Placebo + Gemcitabine + Capecitabine|"Placebo: 600 mg given p.o. (two capsules, each 300 mg) daily in the morning 30 minutes before food.~Gemcitabine: 1000 mg/m²i.v. on day 1, day 8 and day 15 of every 28 day cycle. Capecitabine: 1660 mg/m²/day p.o. twice daily 21/28 day i. e. 24 weeks."
2519359|NCT02767310|Experimental|Test Product|Rosuvastatin 20 mg film-coated tablets
2519362|NCT02767310|Active Comparator|Reference product|Crestor 20 mg film-coated tablets
2519446|NCT02767063|Experimental|Experimental Arm_ACTOS|"TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months~PIOGLITAZONE (Actos®):~30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE."
2519448|NCT02767063|No Intervention|controled Arm|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months
2519450|NCT02767063|Experimental|Experimental Arm_AVELUMAB|TKI : Daily dose and schedule identical to the daily dose and schedule administered during the last 3 months AVELUMAB: 10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period.(If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
2519538|NCT02766218||No Intervention: Standard Care|
2519566|NCT02766075|No Intervention|Standard of Care|Subjects in the no intervention arm will proceed with their TAVR after a minimum 4 weeks without an exercise intervention. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
2518697|NCT02771860|Active Comparator|Experimental: denosumab|50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks denosumab 60mg sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks. Calcium and vit D supplementation will be installed at baseline.
2518698|NCT02771860|Placebo Comparator|Comparator|"50 patients will be enrolled in this group for a total treatment duration of 24 months (96 weeks): 48 weeks placebo sc every 12 weeks followed by a 48-weeks open label phase denosumab 60mg sc every 12 weeks.~Calcium and vit D supplementation will be installed at baseline"
2518737|NCT02771470|Experimental|Probiotic|Microbial composition using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
2518739|NCT02771470|Placebo Comparator|Placebo|Microbiota modulation using probiotics,3 capsules/times,3 times/day for 3 to 4 weeks
2518832|NCT02771197|Experimental|Lymphodepletion plus Pembrolizumab|Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
2518860|NCT02770638|Experimental|Scoop Stretcher|Participant wearing light sports clothing will start with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
2518862|NCT02770638|Active Comparator|Long Back Spinal Board|Participant wearing light sports clothing will start with forty five minutes laid supine on the long back spinal board with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps). Followed by a forty five minute washout period (participant can mobilise freely). Participants will complete the observation with forty five minutes laid supine on the scoop stretcher with 'triple immobilisation ' (rigid cervical collar, two headblocks and fastening straps).
2518923|NCT02770313|Experimental|Intermittent Fasting|Water-only Intermittent Fasting
2518929|NCT02770313|No Intervention|Control|ad libitum Usual Diet
2518976|NCT02770027|Placebo Comparator|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2518978|NCT02770027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2519054|NCT02769611|Experimental|Ruboxistaurin 64 mg|ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration
2519059|NCT02769611|Experimental|Ruboxistaurin 128 mg|ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration
2519060|NCT02769611|Experimental|Ruboxistaurin 256 mg|ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration
3165447|NCT00513084|No Intervention|Comparison Group|Comparison Group receiving standard care health promotion intervention
3165448|NCT00513097|Experimental|Smoking Prevention & Cessation Program|
3165449|NCT00513110|Experimental|1|Endotoxin and AMPD1 polymorphism
3165450|NCT00513110|Experimental|2|Endotoxin and intervention with caffeine
3165451|NCT00513110|Placebo Comparator|3|Endotoxin combined with placebo
3165452|NCT00513123||Digital Colposcopy|Digital Colposcopy for Fluorescence (DCF)
3165453|NCT00513136|Active Comparator|I|10 week group-based mind body medicine intervention
3165454|NCT00513136|Experimental|II|Group-based mind body medicine intervention with a family focus
3165455|NCT00513149|Active Comparator|c6|Clopidogrel 600 mg loading
3165456|NCT00513162|Experimental|Valproate + Etoposide|Valproate Starting Dose of 10 mg/kg By Mouth Daily. Etoposide 25 - 50 mg/m^2 By Mouth Daily.
3165457|NCT00513214|Active Comparator|XOMA 052|
3165458|NCT00513214|Placebo Comparator|Placebo|
3165459|NCT00513279|Experimental|Cohort 1|Subjects in Cohort 1 will be randomized to one of the following sequences: ABDFH, BADFH, BDAFH, BDFAH and BDFHA in a 1:1:1:1:1 ratio where A = Placebo, B= GSK618334 dose 1 (2.5 mg), D = GSK618334 dose 3, F = GSK618334 dose 5, H = GSK618334 dose 7. On day 1, subjects will be administered a starting dose of 2.5 milligrams (mg) GSK618334. The planned doses of GSK618334 to be administered in Cohort 1 are 2.5, 25, 100 and 400mg. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
3165460|NCT00513279|Experimental|Cohort 2|Subjects in Cohort 2 will be randomized to one of the following sequences: ACEGI, CAEGI, CEAGI, CEGAI, CEGIA in a 1:1:1:1:1 ratio where A = Placebo, C= GSK618334 dose 2, E = GSK618334dose 4, G = GSK618334 dose 6, I= GSK618334 dose 8. In each dosing period 2 subjects will receive placebo and 8 subjects will receive GSK618334. Subjects within a cohort will have a washout period of at least two weeks from last dose before receiving another dose.
3165461|NCT00513331||Algorithm #1|Patients without visable lesions
3165462|NCT00513331||Algorithm #2|Patients with a visable lesion that is less than 1cm
3165463|NCT00513331||Algorithm #3|Patients with a visable lesion greater than 1cm
3165464|NCT00513383|Experimental|Part A|Determine the best dosing of panitumumab, chemotherapy and radiation.
3165465|NCT00513383|Experimental|Part B|Determine the best dosing of induction chemotherapy combined with panitumumab prior to receiving panitumumab and chemoradiotherapy.
3165466|NCT00513396|Experimental|1|
3165467|NCT00513396|Active Comparator|2|
3165468|NCT00513396|Placebo Comparator|3|
3165469|NCT00513422|Experimental|1|Glucosamine sulfate 1500mg and chondroitin sulfate 800mg (low molecular weight, bovine)
3165470|NCT00513422|Experimental|2|Glucosamine sulfate 1500mg
3165471|NCT00513422|Experimental|3|Chondroitin sulfate 800mg
3165472|NCT00513422|Placebo Comparator|4|Matching glucosamine/chondroitin placebo capsules
3165473|NCT00513539|Active Comparator|Arm A|Biliary Stenting alone
3165474|NCT00513539|Experimental|Arm B|Photodynamic Therapy plus biliary stenting
3165475|NCT00513552|Experimental|Antibiotics|Antibiotics
3165476|NCT00513565|Placebo Comparator|placebo arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
3165477|NCT00513565|Experimental|GSK561679 arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
2518706|NCT02771782|Experimental|BCG+TDaP-IPV|Subjects are vaccinated with BCG vaccine (SSI) (0.1ml intradermal) and TDaP-IPV vaccine Boostrix Polio (0.5ml intramuscular) simultaneously
2518775|NCT02771483||Suspected GCA (GCA final diagnosis)|
2518778|NCT02771483||Suspected GCA (alternative final diagnosis)|
3198527|NCT00871533|Experimental|1|"REGIONAL PEG IFN MAINTENANCE: Regional PEG IFN-a2b given subcutaneously at MAINTENANCE dose level. (This arm has completed enrollment; non-evaluable subjects as defined in section 9.5 may be replaced at any point during study."
2518897|NCT02770495|Experimental|Postoperative endoscopic recurrence|Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection
2518926|NCT02770235|Experimental|DE assessment and AGE measurements|To evaluate the association between erectile dysfunction (DE) and AGE levels by using non-invasive measurement AGE-ReaderTM, in diabetic patients
3198528|NCT00871533|Experimental|2|No intervention / no injection control.
2519031|NCT02769429||ultrasound-guided CISB|Group 1 will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
2519036|NCT02769429||nerve stimulator-guided CCPVB|Group 2 will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
2519091|NCT02769169|Experimental|double-dose|"double-dose~Lucentis® (Raibizumab), 1mg, 3+prn"
2519093|NCT02769169|Active Comparator|regular-dose|"regular-dose~Lucentis® (Raibizumab), 0.5mg, 3+prn"
2519115|NCT02768740|Active Comparator|200 mg group|Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
2519118|NCT02768740|Experimental|300 mg group|Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
2519158|NCT02768545|Experimental|Liver transplant candidates|Ezetimibe in a dose of 10 mg/d for 12 weeks.
2519214|NCT02768207|Experimental|Treatment Phase: Vemurafenib+Cobimetinib|Participants with BRAF V600 mutation will receive vemurafenib 960 milligrams (mg) tablets orally twice daily (BID) on Days 1 to 28 along with cobimetinib 60 mg tablets orally once daily (OD) for 21 consecutive days (Days 1 to 21) of each 28-day cycle until disease progression, consent withdrawal, or the development of unacceptable toxicity.
2519331|NCT02767674|Experimental|R-GemOx|Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)
2519336|NCT02767674|Active Comparator|R-miniCHOP|Rituximab, 375 mg/m2 IV d0 Cyclophosphamide 400 mg/m2 IV d1 Epirubicin 35 mg/m2 IV d1 vindesine 2 mg IVP d1 Prednisone 40mg/m2 PO d1-5(every 21 days a cycle)
2519366|NCT02767180||Critical care survivors|Former ICU-patients recruited six months to three years after discharge from the ICU
2519371|NCT02767180||Matched controls|Control patients who have not been critically ill, matched for age and sex.
2519440|NCT02766985||FSHD|Participants with FSHD-1 or FSHD-2. No intervention is given to participants. Participants will undergo series of tests and procedures in order to make a standardized and scalable Rasch-built clinical severity scale.
2519506|NCT02766621|Placebo Comparator|Placebo injection SC/IV|Placebo for injection SC/IV
2519509|NCT02766621|Active Comparator|PF-06823859|Study Drug being used in the study
2519557|NCT02766153||patients|
2519561|NCT02766153||healthy volunteers|intrafamily marrow donors
2519630|NCT02765906|No Intervention|No intervention|No additional education
2519635|NCT02765906|Experimental|Graphic card|Education with graphic card
2519637|NCT02765906|Experimental|Video|Education with video
2519653|NCT02765295|Active Comparator|hydrogen inhalation|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixture gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min). Usual care referred to mucolytics (see below for details) alone or plus chest physiotherapy.
2519655|NCT02765295|Sham Comparator|oxygen inhalation|Oxygen will be generated by an instrument provided by the sponsor, that would be capable of generating oxygen equivalent to that generated by the MUNHO (3L/min mixed gas containing 33.3% oxygen). Usual care referred to mucolytics [[ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily)/ serrapeptase (10mg thrice daily), or carbocisteine (500mg thrice daily)] alone or in combination with chest physiotherapy.
2519729|NCT02764983|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Driving safety professional, three x 1 hour sessions to discuss traffic safety, rules of the road, defensive driving, driving under influence, driver attitudes and safety. Additionally, the study will obtain real world driving data from the Department of Motor Vehicles (public records) which will include citations, violations, and recorded collisions/ crashes.
2519731|NCT02764983|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation (I-MAP's) clinical battery of tests and a simulated driving test, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors, and driving simulator with feedback. The study will also obtain real world driving data from the Department of Motor Vehicles (public records) which includes citations, violations, and recorded collisions/crashes.
2519732|NCT02764983|Active Comparator|Caregiver Control Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
3198529|NCT00871533|Experimental|3|"PEG IFN INDUCTION: System PEG IFN-a2b given subcutaneously at INDUCTION dose level"
2518814|NCT02771054|Experimental|TAF/emtricitabine (FTC)|All 20 patients will switch their nucleoside backbone, either ABC/3TC or TDF/FTC to TAF/FTC
2518879|NCT02770794|Experimental|All patients|Discontinue infliximab; Receive infliximab when relapse
2518907|NCT02770391|Experimental|Apalutamide + Leuprolide Acetate|All participating patients will receive a single dose of leuprolide 7.5 mg intramuscularly (IM) in addition to Apalutamide 240 mg orally daily for four weeks prior to radical prostatectomy (RP). Treatment will be started on day (-28) ± 3 from the scheduled RP date to minimize the variability of treatment duration. Apalutamide may be continued up to and including the day before
2518952|NCT02770053|Experimental|Intervention|Endodontic treatment will be performed in teeth with necrotic pulp and periapical periodontitis. Local anaesthesia will be provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation will be done.Using 2.5 % sodium hypochlorite, canal negotiation will be done. Foraminal enlargement will be achieved with #35 K-files in foraminal enlargement group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills will be done. The canals will be obturated with gutta-percha and epoxy resin sealer. The treatments will be carried out in single-visit.
2518955|NCT02770053|Active Comparator|Control|In the control group, no foraminal enlargement will be performed.
2519022|NCT02769793|Experimental|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
2519026|NCT02769793|Active Comparator|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
3198530|NCT00871533|Experimental|4|"REGIONAL HDI MAINTENANCE: Regional HDI given subcutaneously at MAINTENANCE dose level per standard HDI regimen"
3198531|NCT00871533|No Intervention|5|"HDI Induction: Systemic HDI given intravenously at INDUCTION dose level per the standard HDI regimen."
3198532|NCT00871546|Experimental|Participants with MCL randomized to SCH 727965|
3198533|NCT00871546|Active Comparator|Participants with MCL randomized to bortezomib|
2519159|NCT02768506||Gastric bypass|Subjects submitted to gastric bypass
2519161|NCT02768506||SADI-S|Subjects submitted to SADI-S
2519224|NCT02768285|Experimental|Intervention|Endodontic treatment was performed in posterior teeth with necrotic pulp and periapical periodontitis using a reciprocating single-file system (Reciproc). Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 2.5 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 K-files in patency group after determining working length. Coronal flaring with # 2 and #3 Gates-Glidden drills was done. The canals were obturated with gutta-percha and epoxy resin sealer. The treatments were carried out in one-visit.
2519230|NCT02768285|No Intervention|Control|In the control group, apical patency did not maintained.
2519327|NCT02767856|Experimental|Intense 12-hour IO-therapy Group|Participants wear 12-hour daily IO-therapy glasses for 4 weeks
2519333|NCT02767856|Active Comparator|Standard 4-hour IO-therapy Group|Participants wear 4-hour daily IO-therapy glasses for 12 weeks
2519372|NCT02767362|Experimental|Single Arm|Patients will undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgery. At the time of hysterectomy and surgical staging, women will undergo repeat endometrial biopsy in the operating room under general anesthesia.
2519441|NCT02766959||PAV/PAV Tasters|Individuals homozygous for the taster allele of the TAS2R38 gene, PAV/PAV.
2519442|NCT02766959||AVI/PAV.|Individuals heterozygous for the taster allele of the TAS2R38 gene, AVI/PAV.
2519444|NCT02766959||AVI/AVI|Individuals homozygous for the non-taster allele of the TAS2R38 gene, AVI/AVI.
2519542|NCT02766257|Other|children undergoing ambulatory surgery|
2519570|NCT02766010|Experimental|group A TensorTip|Male or female, age > 18
2519638|NCT02765737|Active Comparator|Group 1|Treatment 1 - dHACM plus Control Burn Area A Treatment 2 - Control Burn Area B
2519640|NCT02765737|Active Comparator|Group 2|Treatment 1 - dHACM plus Control Burn Area B Treatment 2 - Control Burn Area A
3198534|NCT00871546|Experimental|MCL treated w/SCH 727965 after progression on bortezomib|
3198535|NCT00871546|Experimental|Participants with B-CLL randomized to SCH 727965|
2519745|NCT02764905||intensive cognitive-physical rehabilitation group|will include a 2 phase multi-disciplinary intervention. The 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies
2519814|NCT02764593|Experimental|Arm 1 (Nivolumab + Cisplatin)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2519815|NCT02764593|Experimental|Arm 2 (Nivolumab + High-dose Cisplatin)|Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2519821|NCT02764138|No Intervention|Comparison|These children complete assessments only--timed to coincide with the intervention groups' assessments: pre- and post-intervention assessments, as well as 3-month and 12-month follow-up assessments. No intervention.
2520479|NCT02760316|Experimental|AZD9567 oral suspension of 20 mg|Participants will receive oral suspension of 20 mg dose strength
3198536|NCT00871546|Active Comparator|Participants with B-CLL randomized to alemtuzumab|
3198537|NCT00871546|Experimental|B-CLL treated w/ SCH 727965 after progression on alemtuzumab|
3198538|NCT00871559|Experimental|Q2W|REGN421 (SAR153192) taken once every two weeks (Q2W)
3198539|NCT00871598|Placebo Comparator|Placebo|
3198540|NCT00871598|Experimental|Single 0.3|
2518822|NCT02771132|Other|Standard of Care|1-2 hour course based on Ministry of Education life skills course (no refresher sessions)
2518850|NCT02770664|Experimental|LC28-0126 Dose A|
2518852|NCT02770664|Experimental|LC28-0126 Dose B|
2518854|NCT02770664|Experimental|LC28-0126 Dose C|
2518856|NCT02770664|Placebo Comparator|Placebo|
2518898|NCT02770482|Experimental|AD Patients|
2518935|NCT02770222|Experimental|Part 1, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. There is a washout period of 14 to 21 days between the two periods.
2518939|NCT02770222|Experimental|Part 1, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive multiple oral dose of gemfibrozil from Day 1 to Day 9. They also receive a single oral dose of selexipag on Day 4 concomitantly with gemfibrozil. During the second period (Treatment A) they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
2518942|NCT02770222|Experimental|Part 2, sequence AB|Subjects participate in two study periods: During the first period (Treatment A), they receive oral selexipag on Day 1. During the second period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin.There is a washout period of 14 to 21 days between the two periods.
2518943|NCT02770222|Experimental|Part 2, sequence BA|Subjects participate in two study periods: During the first period (Treatment B), they receive rifampicin once daily from Day 1 to Day 9. Subjects also receive a single oral dose of selexipag on Day 7 together with the dose of rifampicin. During the second period (Treatment A), they receive oral selexipag on Day 1. There is a washout period of 14 to 21 days between the two periods.
3198541|NCT00871598|Experimental|Repeat 1.0|
2519117|NCT02768935|Other|Diabetes|
2519127|NCT02768935|Other|normoglycaemic|
3198542|NCT00871598|Experimental|Repeat 2.0|
3198543|NCT00871598|Experimental|Repeat 4.0|
2519250|NCT02767960||STEMI group|The study population consists of 30 patients with ST-elevated acute myocardial infarction (STEMI,n = 30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2519255|NCT02767960||NSTEMI group|The study population consists of 30 patients with non-ST elevated acute myocardial infarction (NSTEMI,n=30) who are admitted within 24 hours after chest pain attack. They will all undergo coronary angiography. The diagnosis is made according to American Heart Association (AHA, 2014 and 2015) guidelines. Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2519259|NCT02767960||UAP group|The study population consists of 30 patients with unstable angina pectoris (UAP, n = 30). They will all undergo coronary angiography for the diagnosis of acute coronary syndrome. The diagnosis is made according to the criteria of the American Heart Association (AHA, 2014 and 2015). Patients who had autoimmune diseases, malignancies, chronic or acute infections, asthma, severe heart failure (NYHA class 3 and 4) and advanced liver or renal diseases are excluded.
2519261|NCT02767960||control group|15 age and body mass index matched healthy subjects with neither coronary artery disease nor any of the components of the metabolic syndrome are studied as Normal group.
2519268|NCT02767661|Experimental|Capecitabine+Aromatase inhibitor|Capecitabine, 625mg/m2, orally twice daily in combination with an aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
2519270|NCT02767661|Active Comparator|Aromatase inhibitor|Aromatase inhibitor (Anastrozole 1 mg, orally once daily or Letrozole 2.5mg, orally once daily or Exemestane 25mg, orally once daily)
2519345|NCT02767544|Experimental|ropivacaine group|Vaginal wound local analgesia by 10ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
2519346|NCT02767544|No Intervention|Control group|Vaginal wound no local analgesia by 10 ml ropivacaine 7.5mg/ml injection after laparoscopic hysterectomy
2519364|NCT02767206||portal hypertension|Patients with cirrhosis or non-cirrhotic portal hypertension.
2519460|NCT02767037|Active Comparator|Parkinson's disease (PD) patients|40 patients will be recruited. All will meet criteria for probable PD, according to the new MDS Clinical Diagnostic criteria. All participants will be 40 or older (young-onset PD includes many genetic causes, which often have normal autonomic function).
2519465|NCT02767037|Active Comparator|parkinsonsism (non-PD) patients|20 patients will also be recruited. These will include patients with progressive supranuclear palsy, multiple system atrophy, 'vascular parkinsonism' or corticobasal syndrome. All patients will have parkinsonism according to UK brain bank criteria, with a diagnosis of one of the above conditions made according to gold-standard expert evaluation. No patient will meet MDS Criteria for probable PD.
2519469|NCT02767037|Active Comparator|idiopathic REM sleep behavior disorder patient|40 patients will be recruited. All patients will have polysomnogram-confirmed RBD according to American Academy of Sleep Medicine Criteria. Patients will be free of parkinsonism and dementia according to neurological examination and will have no untreated sleep apnea, epilepsy, or other abnormalities that could cause dream enactment behavior.
2519472|NCT02767037|Placebo Comparator|Controls|40 controls will be age matched (within 5 years) and sex-matched (with >90% concordance). All controls will have an examination confirming the absence of parkinsonism, and will have no symptoms of REM sleep behavior disorder, as assessed with the RBD1Q and expert interview.
2519514|NCT02766439||Rhupus syndrome, SLE without RA|Rhupus syndrome, SLE without RA
2519565|NCT02766075|Experimental|Supervised TAVR Exercise Program (STEP)|Subjects in the experimental arm will participate in an individualized 4-week STEP prior to undergoing TAVR. All subjects will undergo serial frailty assessments by a blinded research assistant at baseline, pre-TAVR, and 30-days post-TAVR.
3198544|NCT00871598|Experimental|Repeat 8.0|
3198545|NCT00871637||Group One|Healthy non-smoking controls
3198546|NCT00871637||Group Two|Smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
2518828|NCT02771158|Experimental|midodrine|randomization to midodrine 20 mg every 8 hours to be increased to a maximum of 40 mg every 8 hours until intravenous vasopressor discontinuation
2518830|NCT02771158|Placebo Comparator|placebo|randomization to placebo control
2518886|NCT02770690|Experimental|spray|apply the ethyl chloride spray before propofol injection
2518890|NCT02770690|Active Comparator|lidocaine|apply the lidocaine 0.5 mg/kg under the touniquette state before propofol injection
2518892|NCT02770690|Placebo Comparator|placebo|apply the saline before propofol injection
2519078|NCT02769130|Experimental|Losartan|"Losartan will be given to children with stenosis in greater or equal to 2 pulmonary veins.~Maintenance daily dosing is 1mg/kg/day using suspension or tablet formulation of losartan. Losartan will be given for 1 year."
2519103|NCT02768896|No Intervention|Baseline|Patients will walk naturally with EEG measuring brain waves
2519104|NCT02768896|Experimental|Visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
2519105|NCT02768896|Experimental|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
2519106|NCT02768896|Experimental|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
2519156|NCT02768662|Experimental|OTO-104|12 mg dexamethasone
2519197|NCT02768376|Active Comparator|General anesthesia group|General anesthesia group: Standard anesthetic technique will be applied.Anesthesia will be induced by propofol 1% (1-2 mg/kg), Fentanyl 1-2 mic/kg, and Atracurium 0.5 mg/kg then according to train of four response. Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
2519198|NCT02768376|Experimental|Spinal anesthesia group|While in sitting position; intrathecal injection using 25 G spinal needle using 3 mls of Bupivacaine 0.5% with 20 mic Fentanyl, at L 2-3 level the patient head will be lowered till sensory blockade of T6 obtained at least.
2519245|NCT02767999|Experimental|Fluoxetine|One group will take a 20 mg of fluoxetine capsule per day from D0 to D90 and have fMRI
2519252|NCT02767999|Placebo Comparator|Placebo|The other group will take a cellulose placebo per day from D0 to D90 and have fMRI
2519343|NCT02767583|Experimental|Non diabetic obese|Non diabetic obese with BMI 35-55 kg / m2 consulting for the first time at the Centre of obesity of Paris Saint Joseph Hospital Group will got a themotest and Sudoscan exams de determine their neuropathology.
2519487|NCT02766725|Experimental|preparation F12 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F12 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
2519489|NCT02766725|Active Comparator|preparation F2 sildenafil in-situ gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + preparation F2 sildenafil gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator (25 mg) per dose
2519491|NCT02766725|Placebo Comparator|placebo gel group|women received clomiphene citrate 150 mg/d in three divided doses 50 mg each starting from day 2 of menstruation for 5 days + placebo gel vaginally from day 5 to day 12 of menstrual cycle twice daily by a specific applicator
2519537|NCT02766348|Experimental|DC-CTL|After accepting chemotherapy of gGemcitabine and Cisplatin according to National comprehensive Cancer Network(NCCN) guidelines, patients will receive 3 cycles of DC-CTL treatment
2519545|NCT02766348|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
2519601|NCT02765815|Active Comparator|Exparel plus multi-drug cocktail|Liposomal bupivacaine, 266mg plus Bupivacaine 0.25% with Epinephrine, Ketorolac 30mg, and Morphine 10mg.
2519610|NCT02765815|Active Comparator|Multi-drug cocktail alone|Bupivacaine 0.5% with Epinephrine, Ketorolac 30mg, Morphine 10mg.
2519689|NCT02765321|Experimental|Physical activity and healthy eating promotion|
3165478|NCT00513565|Active Comparator|lorazepam arm|There are single dose treatment arms of GSK561679, lorazepam as well as placebo.
3165479|NCT00513591||1|Women with lupus
2519774|NCT02764684|Experimental|HIV-infected patients|Probiotics (lactobacillus rhamnosus)
2519890|NCT02763709||Cases|Children admitted in Pediatric ICU for more than 24 hours with Pediatric Risk of Mortality (PRISM) score III > 20
2554862|NCT02533284|Experimental|B group|TAP bupevecaine
3165480|NCT00513591||2|Health women who are matched to women with lupus by age and race
3165481|NCT00513591||3|Women with other autoimmune diseases
3165482|NCT00513630|Active Comparator|metformin|
3165483|NCT00513630|Active Comparator|glipizide|
3165484|NCT00513643|Experimental|1|6 U insulin aspart
3165485|NCT00513643|Experimental|2|12 U insulin aspart
3165486|NCT00513643|Experimental|3|24 U insulin aspart
3165487|NCT00513643|Active Comparator|4|6 IU human regular insulin
3165488|NCT00513643|Active Comparator|5|12 IU human regular insulin
3165489|NCT00513643|Active Comparator|6|24 IU human regular insulin
3165490|NCT00513656|Active Comparator|Oxycodone Hydrochloride Tablets|
3165491|NCT00513656|Experimental|Oxycodone Naloxone Tablets|
3165492|NCT00513669|Experimental|1 PEV301&302|The vaccine includes two antigens (CSP and AMA1- derived)in combination and formulated with virosomes
3165493|NCT00513669|Active Comparator|2 Influenza vaccine|Inflexal V is the comparator that includes 3 antigens from flu formulated in virosomes
3165494|NCT00513721||III|Prostate specimens with positive surgical margins.
3165495|NCT00513734|Active Comparator|1|Geliperm Hydrogel Dressing
3165496|NCT00513734|Active Comparator|2|Lacrilube ointment
3165497|NCT00513760|Experimental|1|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
3165498|NCT00513760|Active Comparator|2|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
3165499|NCT00513760|Placebo Comparator|3|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
3165500|NCT00513786|Experimental|carboplatin/paclitaxel with bevacizumab|A regimen of Carboplatin and paclitaxel combined with bevacizumab given every 21 days in patients with advanced stage endometrial cancer for a maximum of 6 cycles.
2518875|NCT02770833|Experimental|Salmon vs. veal and CHO with low or high GI|"In the first clinical study (Study 1), subjects will eat salmon or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with salmon served with tomato sauce and other accompaniments with low GI~Meat balls with salmon served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
2518880|NCT02770833|Experimental|Cod vs. veal and CHO with low or high GI|"In the second clinical study (Study 2), subjects will eat codfish or veal combined with high or low GI carbohydrates. Each subject will be engaged in each of the following four 1-day test meals:~Meat balls with codfish served with tomato sauce and other accompaniments with low GI~Meat balls with codfish served with tomato sauce and other accompaniments with high GI~Meat balls with veal served with tomato sauce and other accompaniments with low GI~Meat balls with veal served with tomato sauce and other accompaniments with high GI"
2518970|NCT02770131||Group 1|To describe the clinical characteristics of subjects at initiation of Repatha® (up to 2000 subjects).
2519121|NCT02768831|Experimental|Cuffed ETT|
2519160|NCT02768532|Experimental|Crohn's disease patients|The patients will receive vedolizumab in compliance with the marketing authorization regimen (300 mg at weeks 0, 2, 6 and then every 8 weeks) in Crohn's Disease patients in clinical failure or intolerant to anti-TNF (Tumor Necrosis Factor) drugs. In case of lack of clinical response at week 10 or loss of response in the follow-up, all patients will be optimized with vedolizumab 300 mg at week 10 (additional infusion) and every following 4 weeks in contrast with responder patients at week 10 who will not have vedolizumab infusion at this time-point but will receive the next vedolizumab infusion at week 14 and then every 8 weeks, as recommended.
2519212|NCT02768168|Experimental|Group D|40 patients receive dezocine 0.1 mg/Kg
2519216|NCT02768168|Placebo Comparator|Group C|40 patients receive matching placebo （normal saline）
2519300|NCT02767804|Experimental|X-396 (ensartinib)|Eligible patients with ALK+ NSCLC will receive oral X-396 (ensartinib) at 225mg QD with or without food until progression or unacceptable toxicity develops
2519305|NCT02767804|Active Comparator|crizotinib|Eligible patients with ALK+ NSCLC will receive oral crizotinib at 250mg BID with or without food until progression or unacceptable toxicity develops
2519497|NCT02766660|Other|Thyroid ophthalmopathy|Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
2519501|NCT02766660|Other|Control|Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
2519568|NCT02766062|Active Comparator|propofol group|Patients with metabolic syndrome were randomly assigned to receive propofol anesthesia
2519569|NCT02766062|Active Comparator|sevoflurane group|Patients with metabolic syndrome were randomly assigned to receive sevoflurane anesthesia
2519595|NCT02765763|Sham Comparator|Group 1 Sham|Null Formula of the Test System
2519606|NCT02765763|Active Comparator|Group 2 Treated|Full Formulas of Test System
2519658|NCT02765399|Experimental|Liraglutide|"Liraglutide subcutaneous injection once daily with following dose escalation:~liraglutide 0.6 mg once daily for one week; liraglutide 1.2 mg once daily for one week and thereafter liraglutide 1.8 mg once daily for 3.5 months."
2519663|NCT02765399|Placebo Comparator|Placebo|"Placebo subcutaneous injection once daily with following dose escalation:~placebo 0.1 ml once daily for one week; placebo 0.2 ml once daily for one week and thereafter placebo 0.3 ml once daily for 3.5 months."
3165501|NCT00513825|Active Comparator|1|1075 cc of 77 mEq/L solution of NaCl 0.45% , prepared by adding 75 cc of 77 mEq/L NaCl 0.45 % to 1000 cc of 77 mEq/L NaCl 0.45%
3165502|NCT00513825|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate solution 8.4% to 1000 cc of NaCl 0.45%.
3165503|NCT00513851|Experimental|1|Once Daily Dosing
3165504|NCT00513851|Experimental|2|Twice Daily Dosing
3165505|NCT00513864|Active Comparator|CYP2D6-|This arm consists of subjects that are poor metabolizers (PM) and intermediate metabolizers (IM).
3165506|NCT00513864|Active Comparator|CYP2D6+|Extensive metabolizers (EM) of codeine
2520106|NCT02762604|Experimental|Imagined Gait Intervention|During the phone-based imagined gait intervention, participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
2520108|NCT02762604|Active Comparator|Visual Imagery Intervention|During the phone-based visual imagery intervention, participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
2520137|NCT02762305|Experimental|RSVP Bone Builder group exercise|A group of older adults who are participating in the RSVP Bone Builder group exercise.
2520182|NCT02762188|Experimental|wet ARMD patients|Patients with the wet form of ARMD who receive or have received in the past anti VEGF intra vitreal injections. Diagnosis of wet ARMD is made based on clinical data-visual acuity, fundus presence of subretinal fluid and/or haemorrhage and/or hard exudates, fundus photographs -color and red free, optical coherence tomography (SD-OCT), fluorescein angiography and indocyanine green angiography showing the presence and activity of subretinal neovascularisation.
2520394|NCT02760901|Active Comparator|Mannitol group|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
3165507|NCT00513877|Experimental|Bortezomib 1.6mg/m2|
3165508|NCT00513903|Active Comparator|Minimal intervention|Minimal intervention group patients will be seen by a clinical pharmacist in the hospital but will not receive followup after hospital discharge.
3165509|NCT00513903|Experimental|Enhanced intervention|Enhanced intervention patients will receive care from a clinical pharmacist during hospitalization and followup by phone after hospitalization.
3165510|NCT00513903|No Intervention|Control|Control arm patients will not be seen by the clinical pharmacist.
3165511|NCT00513916|Experimental|Arm I|"Participants partake in a high soy diet consisting of 2 daily soy servings (approximately 50mg isoflavones).~The choice of soy foods will include ½ cup of tofu, ¾ cup of soy milk, or ¼ cup of soy nuts. Replacement of currently consumed foods with soy foods will be encouraged."
2518933|NCT02770300|No Intervention|Conventional therapy|"The control group of patients will perform a conventional therapy without the use of the exoskeleton. The conventional therapy will consist in a traditional treatment of occupational therapy or physiotherapy without the use of the robotic device. The therapist will provide a specific conventional treatment comparable with the robotic treatment in terms of session time and therapeutic goals (i.e., 45 minutes per session, about 100, 150, 200 and 250 movements respectively for the first, second, third and fourth week). The level of difficulty of the exercises will be increased by the physiotherapist according to the degree of impairment of the patients.~The muscle and cerebral activity during the execution of the conventional therapy could be acquired."
2518937|NCT02770300|Experimental|Traditional robotic rehabilitation with ALEx RS|The rehabilitative task will be constituted of 3D reaching movements covering a sphere of fourteen centimeter of radius in front of the patient. The initial rehabilitative task will be the same for all the patients belonging to this group and the workspace will be extended accordingly to the therapist evaluation during the following training sessions. In order not to bias the comparisons of the effects of the different rehabilitative treatments, the therapist assisting this group during the rehabilitation will be the same for all the subjects belonging to this group and he/she will not take part in the rehabilitative treatment of the other groups. Initially, the patients will execute reaching movements in different directions in the horizontal plane. If the therapist will evaluate that the movements have been sufficiently recovered, reaching movements in the other planes will be proposed.
2518941|NCT02770300|Experimental|Automatic personalized robotic rehabilitation with ALEx RS|
2518988|NCT02769936|Placebo Comparator|Healthy Adult - Placebo|Single dose placebo pill in healthy adults
2518989|NCT02769936|Experimental|Healthy Adult - D-cycloserine|Single 100 mg dose D-cycloserine pill in healthy adults
2518990|NCT02769936|Placebo Comparator|Schizophrenia - Placebo|Single dose placebo pill in schizophrenia patients
2518991|NCT02769936|Experimental|Schizophrenia - D-cycloserine|Single 100 mg dose D-cycloserine pill in schizophrenia patients
2519035|NCT02769468|Active Comparator|The Back|The probe is placed lateral from the spine, 1 cm above the intergluteal cleft, and in side position to the flank between the hips and the ribs.
2519045|NCT02769468|Active Comparator|Chest|The probe is placed on the chest, 1 cm above the left nipple.
2519049|NCT02769468|Active Comparator|Left Axilla|The probe is placed deep in the left axilla
2519084|NCT02769104|Experimental|AI+Chemo|aromatase inhibitors (Letrozole 2.5mg po. QD for 5 years) starts at the beginning of neoadjuvant treatment combined with chemotherapy (AC*4-T*4) in patients with postmenopausal hormone receptor-positive breast cancer
2519086|NCT02769104|Active Comparator|Chemo|chemotherapy (AC*4-T*4) as neoadjuvant treatment without aromatase inhibitors in patients with postmenopausal hormone receptor-positive breast cancer
2519143|NCT02768779||HIV negative and positive individuals|HIV Negative or HIV positive individuals, aged 18 years or older, who have been taking their ARV medication for at least 3 months and are adherent based on blood plasma HIV RNA of <50 copies/mL or HIV negative status. Hair analysis.
2519207|NCT02768467|Experimental|Tissue Matrix Graft Placement|After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
2519209|NCT02768467|Active Comparator|Without stitches|After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
2519306|NCT02767882|Active Comparator|Group D1|Patients from group D will be given a bolus injection of 2 ml saline with 2 ml dexamethasone (4mg/ml) before skin incision.
2519315|NCT02767882|Experimental|Group D2|4ml bolus injection of dexamethasone (4mg/ml) will be given intravenously prior to incision.
2519319|NCT02767882|Placebo Comparator|Group C|4ml bolus injection of 0.9% saline will be given intravenously prior to incision
3198547|NCT00871637||Group Three|Non-smoking adults with chronic bronchitis/chronic obstructive pulmonary disease
3198548|NCT00871650||Combat Veterans with PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with Combat Exposure Scale score > 17, who are not on medication and do not have trauma history before age 18.
3198549|NCT00871650||Combat Veterans without PTSD|Male Veterans of Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom (OEF), ages 18-50, with combat experience, who are not suffering from PTSD, and who are not on medication.
2519411|NCT02767089|Other|Sequence A|Period 1: Placebo Period 2: Prednisone 2.5 mg Period 3: Prednisone 10 mg
2519413|NCT02767089|Other|Sequence B|Period 1: Prednisone 2.5 mg Period 2: Prednisone 5 mg Period 3: Prednisone 20 mg
2519414|NCT02767089|Other|Sequence C|Period 1: Prednisone 5 mg Period 2: Prednisone 10 mg Period 3: Prednisone 40 mg
2519416|NCT02767089|Other|Sequence D|Period 1: Prednisone 10 mg Period 2: Prednisone 20 mg Period 3: Prednisone 60 mg
2519417|NCT02767089|Other|Sequence E|Period 1: Prednisone 20 mg Period 2: Prednisone 40 mg Period 3: Placebo
2519419|NCT02767089|Other|Sequence F|Period 1: Prednisone 40 mg Period 2: Prednisone 60 mg Period 3: Prednisone 2.5 mg
2519421|NCT02767089|Other|Sequence G|Period 1: Prednisone 60 mg Period 2: Placebo Period 3: Prednisone 5 mg
3198550|NCT00871663|Experimental|Advanced solid tumors|Participants with advanced solid tumors treated with SCH 727965 in dose-escalation cohorts
3198551|NCT00871663|Experimental|Non-Hodgkin's lymphoma and multiple myeloma|Participants with non-Hodgkin's lymphoma or multiple myeloma treated with SCH 727965
2519576|NCT02766101|Experimental|Aerobic Exergaming PE|Progressive aerobic curriculum utilizing virtual reality exergaming stationary bicycles. Classes held 2 times per week for 30-40 minutes, aerobic exercise beginning at 10 minutes at moderate to vigorous intensity and building to 20 minutes plus.
2519578|NCT02766101|Active Comparator|Standard PE|Traditional PE focused on gross motor skill and sports skill acquisition, and team building. Typically non-aerobic.
2519603|NCT02765672|Active Comparator|Control Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving evaluation, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure (FTDS), and a Satisfaction with Life Questionnaire. Driving Safety Education by a traffic safety professional, three x 1 hour sessions to discuss traffic safety rules regarding person, vehicle, environmental factors.
2522075|NCT02749812|Experimental|automatic Continuous Positive Airway Pressure|
2518960|NCT02770183||Consecutive patients|"Consecutive patients waiting to have elective cardiac surgery will be eligible. Each week the principal investigator will track patients in the operating program. The day of the consultation or the day before the operation, one of the investigators will have a talk with the patient to provide information and clarify doubts, also allowing the patient to read and look good all the details before giving its approval. For the screening, the principal investigator will use the criteria of inclusion and exclusion to select patients for the study. The screening uses clinical, laboratory or without other biological information.~To minimize confounding factors, it will be taken consecutive patients, that will also be analyzed regarding all known variables that can affect the systolic function, as non-modifiable (age, cardiovascular risk factors, heart-rate variability and preoperative basal systolic function) and modifiable."
2519001|NCT02769767||Cases|Subjects with Relapsing-Remitting Multiple Sclerosis. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2519003|NCT02769767||Controls|Healthy subjects. Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2519005|NCT02769767||Responders|Subjects with MS treated for at least two years that have less than one relapse per year or who had an increase of <1.5 points on the Expanded Disability Status Scale (EDSS) (if baseline EDSS was 0) or no increase in EDSS (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2519006|NCT02769767||No responders|Subjects with MS that have more than one relapse per year treated for at least two years, and who had ≥1 relapse(s) or an increase of 1.5 points on the EDSS (if baseline EDSS was 0) or an increase of ≥0.5 points (baseline EDSS ≥1). Polymorphisms frequencies of Interleukins, Glypican, and Human Leukocyte Antigen Genes are determined.
2519055|NCT02769390|No Intervention|Bupivacaine 0,166%|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% for hypospadia surgery
2519061|NCT02769390|Active Comparator|Clonidine 1 mcg/Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 1 mcg/ Kg of clonidine for hypospadia surgery
2519063|NCT02769390|Active Comparator|Clonidine 2 mcg/ Kg|IGeneral Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 2 mcg/ Kg of clonidine for hypospadia surgery
2519066|NCT02769390|Active Comparator|Clonidine 3 mcg/Kg|General Anesthesia associated with caudal anesthesia with Bupivacaine 0,166% plus 3 mcg/ Kg of clonidine for hypospadia surgery
2519323|NCT02767908|No Intervention|Usual Care|Participants in the usual care group will be offered and, if accepted, provided with smoking cessation support that meets the recommendations of NICE PH48 guidance including pharmacotherapy and behavioural support before leaving hospital, referral to NHS SSS for continued care after discharge, and ascertainment of smoking status at 4 weeks; participants will also be asked to consent to smoking status ascertainment at three months. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation. All will be asked at four weeks and 3 months to list the cessation support, in terms of pharmacotherapy and behavioural support from local or other services, delivered since the last contact.
2519324|NCT02767908|Active Comparator|Intervention|A home visit will be carried out as soon as practicable after discharge and typically within 48 hours, to deliver a multi-component intervention. Intervention components all have an existing evidence base proving or suggesting potential efficacy for smoking cessation and/or relapse prevention, though their feasibility and importance when delivered as a combined package have not been tested.
2519355|NCT02767440|Experimental|Families on Track Intervention|This is a pre-post study. Enrolled parents will receive the Families on Track intervention plus usual care at the Healthy Lifestyles clinic at Duke University.
3165512|NCT00513916|Active Comparator|Arm II|Participants will be asked to keep their soy intake below 3 servings per week. The participants will also receive general nutrition counseling.
3165513|NCT00513929|Experimental|X: Zinc sulphate|
3165514|NCT00513942|No Intervention|A|These women will follow standard antenatal care according to the Norwegian Guidelines
3165515|NCT00513942|Active Comparator|B|Intervention group for Fetal Movement Counting
3165516|NCT00513955|Experimental|Bortezomib plus CHOP|"Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.~Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.~After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter."
3165517|NCT00513968|Experimental|I|HB-110 2mg, 4mg or 8mg combined with Adefovir
3165518|NCT00513968|Active Comparator|II|Adefovir
3165519|NCT00513994|Active Comparator|1|
3165520|NCT00514007|Experimental|OSI-906 QD|Once per day
3165521|NCT00514007|Experimental|OSI-906 BID|Twice per day
3165522|NCT00514033||Group A|PoliorixTM will be administered according to a 3-dose schedule at 2, 4, 6 months for primary vaccination followed by a booster dose between 4 to 6 years. For the primary vaccination course, 1 to 3 doses of the vaccine will be given depending on previous vaccination history with poliomyelitis vaccine.
3165523|NCT00514059|Other|1|
3165524|NCT00514072|Experimental|Arm I|Patients receive ONY-P1 vaccine with BCG intradermally on days 1 and 15. Patients then receive ONY-P1 vaccine alone on day 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3165525|NCT00514072|Placebo Comparator|Arm II|Patients receive placebo vaccine intradermally on days 1, 15, and 29 and then every 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3165526|NCT00514085|Experimental|Recombinant human interleukin-21|
3165527|NCT00514111||HVC Patients|HVC patients attended in SAE e HD.
3165528|NCT00514150|Active Comparator|1|1075 cc of 154 mEq/L solution of NaCl 0.9% , prepared by adding 75 cc of 154 mEq/L NaCl 0.9 % to 1000 cc of 154 mEq/L NaCl 0.9%
3165529|NCT00514150|Active Comparator|2|1075 cc fluid made by adding 75 cc of sodium bicarbonate 8.4% to 1000 cc of 154 mEq/ L NaCl 0.9%.
3165530|NCT00514163|Experimental|1|gemcitabine + S-1
3165531|NCT00514163|Active Comparator|2|S-1
2519048|NCT02769325|Experimental|Atropine|Patients under a standardised general surgery will receive 1mg atropine (10ml) at induction of anesthesia
2519056|NCT02769325|Placebo Comparator|placebo|Patients under a standardised general surgery will receive 10 ml of saline at induction of anesthesia
2519094|NCT02768948|Experimental|telmisartan|treatment with telmisartan at doses of 80 mg / day for 6 months
2519095|NCT02768948|Experimental|losartan|Losartan at a dose of 100 mg / d for 6 months.
2519109|NCT02768727|Experimental|Xenon|Xenon anesthesia to determine if neural inertia is present in humans as visualized by CT imaging.
2519157|NCT02768636|Experimental|Before and after omega-3 used|Before and after omega-3 used
2519191|NCT02768337|Other|Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)|No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.
2519193|NCT02768337|Experimental|Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.
2519194|NCT02768337|Experimental|Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy|Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.
2519205|NCT02768025|Experimental|Intervention group|NRT, counselling, traditional & complementary medicine treatment (Body acupuncture, Ear acupuncture and aromatic therapy).
2519206|NCT02768025|Active Comparator|Control group|NRT, counselling
3198552|NCT00871663|Experimental|B cell chronic lymphocytic leukemia|Participants with B-cell chronic lymphocytic leukemia treated with SCH 727965 in dose-escalation cohorts
3198553|NCT00871676|Active Comparator|1|Overweight/obese individuals being treated with lifestyle modification to facilitate weight loss.
2519457|NCT02767050||GROUP 1: CONTROL GROUPS|Patients with no habit history of tobacco are included in group 1.
2519463|NCT02767050||GROUP 2: SMOKING TOBACCO|Patients with a history of tobacco consumption in the form of smoking.
2519468|NCT02767050||GROUP 3: SMOKELESS TOBACCO|Patients with a history of tobacco consumption in the form of chewing.
2519534|NCT02766556|Active Comparator|arm 1|received ISB with 8mL of ropivacaine with 100 μg (1ml) of dexmedetomidine
2519540|NCT02766556|Placebo Comparator|arm 2|received ISB with 8mL of ropivacaine with 1ml of normal saline
2519586|NCT02765828||Late-Onset Pompe Disease|
2519588|NCT02765828||Acquired/Hereditary Myopathy|
2519590|NCT02765828||Neuropathy|
2519648|NCT02765594|Experimental|valsartan only:control group|valsartan (160mg/d)
2519649|NCT02765594|Experimental|hydroxychloroquine with valsartan:study group|valsartan (160mg/d) and Hydroxychloroquine Sulfate ( 400mg/d, twice daily)
2519696|NCT02765217|Experimental|Study group 1|"Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (5 drops per day, same time with the first dose of antibiotics).~Study Group 1a will received L. reuteri for 10-14 days. Study Group 1b will received L. reuteri for 21 days."
2519698|NCT02765217|Placebo Comparator|Study group 2|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 5 drops per day, same time with the antibiotics) Study Group 2a will received placebo for 10-14 days. Study Group 2b will received placebo for 21 days.
2519699|NCT02765217|Experimental|Study group 3|Amoxicilline-clavulanic acid (50-90 mg/kg/day, twice daily) and Lactobacillus reuteri DSM 17938 (2 x 5 drops per day) Study Group 3a will received L. reuteri for 10-14 days. Study Group 3b will received L. reuteri for 21 days.
2519701|NCT02765217|Placebo Comparator|Study group 4|Amoxicillin-clavulanic acid (50-90 mg / kg / day) and placebo ( 2 x 5 drops per day, same time with the antibiotics) Study Group 4a will received placebo for 10-14 days. Study Group 4b will received placebo for 21 days.
2519746|NCT02764892|Experimental|V81444|Single oral dose of V81444
2519764|NCT02764645|Experimental|CardioGard group|"Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.~2. The suction cannula of the 'Cardiogard cannula'."
2519765|NCT02764645|Active Comparator|Control group|Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
2519831|NCT02764424||Preterm or term newborns|Preterm or term newborns, hospitalized in neonatal intensive care units of our university hospital (Saint-Etienne - France), who have to acute painful stimuli related to their care will be included in the study. This painful stress is made in the patient's usual care and is not modified by the protocol. Their stress due to the painful stimuli will be measured with different scales (2 PIPP (Premature Infant Pain Profile) and DAN (Newborn Acute Pain)) and compared with the index obtained with the NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®).
3198554|NCT00871676|Experimental|2|Lifestyle modification plus use of chewing gum to facilitate weight loss in overweight/obese persons.
3198555|NCT00871702|Experimental|Donor lymphocyte infusion|CD34-TK75 transduced T lymphocytes from donors matched at a 5/6 or 6/6 antigen level at a dose of 1.0 x 105 cells/kg recipient weight.
2519968|NCT02763163||outdoor workers|Subjects with an excessive exposure to the sun on a daily basis
2519971|NCT02763163||office workers|Subjects who spend most of the day in a closed shaded room
2522644|NCT02746172|No Intervention|Normal Hearing Volunteers|Normal hearing volunteers
3198556|NCT00871767|Experimental|1|40 or 100mg AZD5672, Reference formulation
3198557|NCT00871767|Experimental|2|40 or 100mg AZD5672, Test formulation
3198558|NCT00871793|Active Comparator|1|Occupational therapy
3198559|NCT00871793|No Intervention|2|watchful waiting
3198560|NCT00871806|Active Comparator|Eletriptan commercial tablet with water|Eletriptan commercial tablet given with water
2519067|NCT02769338|Experimental|QI with External Facilitation|Receive external facilitation to support implementation of the quality improvement program
2519070|NCT02769338|No Intervention|Control|Non-Intervention VA Medical Centers
2519178|NCT02768597|Active Comparator|Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
2519180|NCT02768597|Active Comparator|Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
2519182|NCT02768597|Active Comparator|Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
2519186|NCT02768597|Active Comparator|Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
2519202|NCT02768051|Experimental|AF Ablation Intervention|Subjects who are scheduled to undergo ablation procedure due to atrial flutter.
3165532|NCT00514189|Experimental|Autologous Dendritic Cells|
2519356|NCT02767466||G|"All participants were randomly exposed to two different treatments:~Conventional physical therapy (no specific device used)~Robotic assisted gait training (Lokomat, Hocoma AG, Switzerland)~We consider the study as observational, since the both interventions of the study (physical therapy, robotic assisted gait training) did not change in the patients' usual therapy plan, as they received both interventions daily.~We only added diagnostic interventions to assess the affective responses."
2519398|NCT02767102|Experimental|Red wine with Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be enriched with 10 ng mL-1 MLT (MLT+) and used as experimental wine.
2519400|NCT02767102|Placebo Comparator|Red wine without Melatonin|Rosso di Marco is a wine without MLT (previous screening). This wine will be used as placebo treatment (PLC).
2519456|NCT02766842|Active Comparator|EUS-FNB with ProCore needle|General anesthesia or conscious sedation will be started and an upper endoscopic ultrasound will be inserted into the participants mouth and advanced to the site of the lesion. The lesion will be punctured by the ProCore needle, then the stylet is completely removed, and negative suction pressure is applied using a 10 ml syringe for 30 seconds while the needle is stationary with the target. Then, the needle is moved back and forth several times within the target, utilizing the fanning technique. Finally, suction is released by closing the lock of the syringe and the needle is removed.
2519462|NCT02766842|Active Comparator|EUS-FNB with SharkCore needle|The procedure will be done in the same manner with same endoscopic technique and method of tissue procurement. The only difference will be using the SharkCore needle to acquire tissue.
2519533|NCT02766478|Experimental|Genistein|Participants with and without diabetes will receive 60 mg/day oral genistein (30 mg taken twice daily) for 12 weeks.
2519541|NCT02766478|Placebo Comparator|Placebo|Participants with and without diabetes will receive placebo taken twice daily for 12 weeks.
2519597|NCT02765919|Experimental|Radiation HDR Brachytherapy 9 Gy|High dose rate (HDR) Brachytherapy of weekly 9 Gray in two fractions in two weeks after 50 Gray of EBRT in 2 Gray per fraction of 5 weeks with chemotherapy cisplatin 40 mg /m2 weekly for five weeks in locally advanced carcinoma cervix
2519605|NCT02765919|Active Comparator|Radiation HDR Brachytherapy 7 Gy|High dose rate (HDR) brachytherapy of weekly 7 Gray in three fractions in three weeks after 50 Gray EBRT of 2 Gray per fraction of 25 fractions concurrently with weekly chemotherapy cisplatin40 mg /m2 in five weeks in locally advanced carcinoma cervix
2519730|NCT02765087|Experimental|Pleural TB|"This group consist of patients with TB pleural effusion.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
2519734|NCT02765087|Active Comparator|Control|"Patients with pleural effusion with different aetiologies than Tuberculosis.~Intervention:~Inform Consent~Medical History~E-Nose Device~Chest CT~Cytomorphologic & Cytochemistry of pleural Fluid.~Adenosine Deaminase value of pleural Fluid."
2519813|NCT02764437||MRI-Bronch, PET-WLAC (Stress vs Control)|Subjects will have a functional MRI scan 24 hours before a bronchoscopy with segmental allergen challenge. 48 hours post segmental allergen challenge, the subject will have another MRI and bronchoscopy. 4-6 weeks later, subjects will have a PET scan and whole lung antigen challenge under a stress condition or control condition. 4-6 weeks later, subject will have another PET scan and whole lung antigen challenge under a stress condition or control condition (whatever they did not have the first time).
3165533|NCT00514202|Placebo Comparator|1|Placebo plus cognitive behavioral therapy
3165534|NCT00514202|Experimental|2|Dextroamphetamine SR (60 mg/kg) plus cognitive behavioral therapy
3165535|NCT00514228|Experimental|Continuous sunitinib treatment|
3165536|NCT00514241|Experimental|A|The arm utilizes the GPS™ II Platelet Concentrate Separation Kit.
2520177|NCT02761876|Experimental|Intervention (Participatory education)|Participatory education
2520188|NCT02761876|No Intervention|Control|Delayed participatory education
3165537|NCT00514241|No Intervention|B|This arm utilizes standard leg wound closure procedures.
3165538|NCT00514254||case|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
3165539|NCT00514254||control|Participants complete questionnaires about lifestyle factors and their usual diet and measure their waist and hips. Saliva or buccal specimens are collected for future research.
3165540|NCT00514267|Experimental|1. HRPC|
3165541|NCT00514267|Experimental|2. Solid Tumors|
3165542|NCT00514306|Experimental|Schedule 1|OSI-906 days 1-3 every 14 days
3165543|NCT00514306|Experimental|Schedule 2|OSI-906 days 1-5 every 14 days
3165544|NCT00514306|Experimental|Schedule 3|OSI-906 days 1-7 every 14 days
3165545|NCT00514332|Experimental|A|primary surgery group
3165546|NCT00514358||gestational age|
3165547|NCT00514371|Experimental|tanespimycin and bortezomib|A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin.
3165548|NCT00514371|Experimental|bortezomib and tanespimycin|A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin.
3165549|NCT00514371|Experimental|bortezomib tanespimycin|A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin.
3165550|NCT00514410|Experimental|Folic Acid|
2519079|NCT02769143|Experimental|Whole-Body Vibration Group (WBV)|Will be exposed to five minutes on a vibrating platform (Oscillating Platform Semi-Professional Horizontal - Arktus, Cascavel, Brazil), this type of platform vibrates through an anteroposterior axis, causing the right and left sides alternate horizontally denominated: alternating side vibration platforms, will be performed three times per week on alternate days (5 minutes). a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. The volunteers will be guided to stand on the platform with semi-flexed knees, barefoot and apart about hip width.
2519080|NCT02769143|Experimental|Pilates Group (PG)|Will be exposed to 60 minutes, held three times a week on alternate days. Pilates equipment used for the exercises are: Combo Chair, Cadillac Trapeze, Ladder Barrel, Reformer Universal, Step Barrel and Wall Unit. Will be selected for this study, 21 strengthening exercises and stretching to the main body segments. All exercises are performed in a series of ten repetitions with one minute interval between exercises. To determine the level of effort and consequently to changing loads, will be used verbal command according to the Borg CR10 scale. The level of effort will be maintained during the session heavy (Borg between 5 and 6).
2519081|NCT02769143|No Intervention|Control Group (CG)|The control group will be instructed to maintain their usual activities both in relation to their daily activities, dietary habits, failure to use drugs that can influence the increase in bone mass and participate in monthly meetings to address on issues osteoporosis and postmenopausal women. After the end of the interventions with WBV and GP groups, GC volunteers will be invited to also perform whole body vibration for six months. Exposure of vibration will be for five minutes on a vibrating platform, three times per week on alternate days. a frequency of 20 Hz (1 = 1 Hz oscillation / second) and a magnitude of 3.2 g (1 g = 9,81 m / s gravity) is used. Likewise which was offered for the WBV group.
2519119|NCT02768857|Experimental|Early sensorimotor reeducation intervention|The experimental group received 15 minutes of touch-observation and task-based mirror therapy program, followed by 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the mirror therapy program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
2519126|NCT02768857|Active Comparator|Traditional sensorimotor reeducation intervention|The control group received received 15 minutes traditional sensory reeducation program, 20 minutes of regular hand therapy and 20 minutes of physiotherapy in each treatment session before the returning of the touch of a Semmes-Weinstein monofilament marked 4.31. Once the patients had regained the protective sense (SWM < 4.31), the protective sensory reeducation program was replaced with a discriminative sensory reeducation program. Treatment duration was 12 weeks, at a frequency of three sessions per week.
2519195|NCT02768571|Experimental|Cerebrolysin|"Cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
2519196|NCT02768571|Placebo Comparator|Placebo|"Saline 100 ml/day * 21 days with rehabilitation~Study drug schedule - given from day 8 after stroke, but, if day 8 is weekend, the given day is the next Monday(day 9~10)~Rehabilitation~3 hours (physiotherapy: 2 hours, occupational therapy: 1 hour) / day~5 times/week for 3 weeks~Duration of Treatment:~Study drug will be given once daily by intravenous infusion for 21 consecutive days on study day 8 ~ 28.~The clinical observation period for each patient will be 90 days and will include four clinical evaluation visits at Screening(day ≤ 7), Baseline(day 8) and on study day 29, and 90."
2519211|NCT02768012|Active Comparator|mindfulness-based cognitive therapy|The practice of mindfulness will be followed plus the basics of cognitive therapy given in small group format.
2519218|NCT02768012|No Intervention|waitlist|Women diagnosed with AISD randomised to wait list will receive no active treatment during the trial period.
3165551|NCT00514410|Placebo Comparator|Placebo|
2519358|NCT02767245|Active Comparator|Thiamine|Thiamine intravenously 100 mg/day for 3 days
2519361|NCT02767245|No Intervention|No thiamine|No thiamine was given to the patient
2519429|NCT02767076|Active Comparator|Conventional|conventional paramedian spinal anesthesia
2519430|NCT02767076|Experimental|Ultrasound|ultrasound guided paramedian spinal anesthesia
2519493|NCT02766712|Experimental|CA 1st Half of lesion|During each of the 15 pre-specified lesions, pacing will be initiated at a 500ms cycle length from a catheter in the coronary sinus or right ventricle prior to the start of the lesion. Pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Weckebach behavior continues, the pacing catheter will be moved to the right ventricle, which and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
2519494|NCT02766712|Experimental|CA 2nd Half of Lesion|During each of the 15 pre-specified lesions, pacing will be stopped at the halfway point (e.g. after 10 seconds for a 20-second lesion and after 15 seconds for a 30-second lesion). In the event that Wenckebach behavior is noted, pacing will be adjusted to a 550ms cycle length. In the event that Wenckebach behavior persists, the cycle length will be adjusted to 600ms. In the event that Wenckebach behavior persists, the pacing catheter will be moved to the right ventricle and pacing will be performed at a 500ms cycle length. If Wenckebach behavior still persists, the patient will be withdrawn from the study.
2519531|NCT02766218||Behavioral: Lifestyle Intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
3165552|NCT00514423|Experimental|2|Psychoeducation by peer-moderators
3165553|NCT00514423|Experimental|1|Psychoeducation by professionals
3165554|NCT00514423|Experimental|3|Video-education
3165555|NCT00514423|Placebo Comparator|4|Control group
3165556|NCT00514436|No Intervention|Usual care|Usual care consisted of referral back to primary care provider after index hospitalization
2519116|NCT02768961|Experimental|Active treatment|"All HCV chronic infected patients will be treated with oral anti-HCV regimens containing sofosbuvir, ledipasvir (associated or not to ribavirin) according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver (EASL). EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
2519187|NCT02768480|Active Comparator|Primary Care|Patients will be followed by primary care team exclusively.
2519190|NCT02768480|Experimental|Phone Calls Support and Primary Care|Patients will be followed by primary care team and supported by periodic nurse phone calls.
2519256|NCT02768064|Experimental|Flexible screwed electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a flexible screwed electrode.
2519260|NCT02768064|Active Comparator|Stiff standard electrode|In the TAVI patients, during the intervention procedure, a temporary pacemaker will be implanted, using a stiff standard temporary electrode
2519286|NCT02767635|Experimental|Botox-Epic group|20 units of Botox injection into lateral epicondyle in Botox-Epic group
2519290|NCT02767635|Experimental|Botox-Tend group|20 units of Botox injected into tender point of muscles in Botox-Tend group
2519293|NCT02767635|Active Comparator|Steroid group|40mg of triamcinolone acetonide but not Botox injected into lateral epicondyle in Steroid group
2519389|NCT02767401|Active Comparator|PCI using stenting or balloon expansion|Opening single CTO lesions using drug-eluting stents (such as Xience V and Prime, Endeavor Resolute, Taxus express and Libete, Excel, Partner, BUMA, YINYI, TIVOLI,Firebird2,FireHawk, and Coroflex) or balloon expansion plus optimal medical therapy. Intravascular ultrasound (IVUS),optimal coherence tomgraphy (OCT) or fractional flow reserve (FFR) is used if they are needed. Optimal medical therapy includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-angina therapy should be used if the patients have symptoms.
2519391|NCT02767401|No Intervention|Optimal medical therapy|Optimal medical therapy. It includes dual antiplatelet therapy and statins. And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
2519478|NCT02766881||Patients with DCIS|Whether patients with DCIS receive radiotherapy based on Oncotype DX DCIS score, radiation oncologist treatment recommendation and patient's decision.
2519547|NCT02766361|Experimental|Cognitive Behavioral Rehabilitation|12 sessions of new intervention of cognitive behavior therapy and cognitive rehabilitation
2519549|NCT02766361|Active Comparator|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
2519598|NCT02765867|Experimental|RBP-6000|A single dose of RBP-6000 will be administered on Study Day 1
2519662|NCT02765516|Active Comparator|Plant sterols|
2519665|NCT02765516|Placebo Comparator|Placebo|
2519724|NCT02765113|Active Comparator|Facial nerve combing|Facial nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
2519727|NCT02765113|Active Comparator|Facial and Trigeminal nerve combing|Facial nerve combing、trigeminal nerve combing and Microvascular Decompression(MVD) was performed in all the patients in this group.
2519778|NCT02764723|Active Comparator|Hyperbaric bupivacaine|12.5 mg of 0.5% hyperbaric bupivacaine
2519788|NCT02764723|Experimental|Isobaric ropivacaine|15 mg of 0.5% isobaric ropivacaine
3165557|NCT00514436|Experimental|Behavioral|Asthma coaching, inperson contact followed by telephone contact
2519927|NCT02763800|Experimental|Group 1: BIA 3-202 50 mg/placebo|"Group 1: BIA 3-202 50 mg/placebo on Day 1; BIA 3-202 50 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 50 mg/placebo on Day 9.~50 mg BIA 3-202: 5 x 10 mg BIA 3-202 tablets"
2519931|NCT02763800|Experimental|Group 2: BIA 3-202 100 mg/placebo|"Group 2: BIA 3-202 100 mg/placebo on Day 1; BIA 3-202 100 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 100 mg/placebo on Day 9.~100 mg BIA 3-202: 1 x 100 mg BIA 3-202 tablet"
2519934|NCT02763800|Experimental|Group 3: BIA 3-202 200 mg/placebo|"Group 3: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo b.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
2519935|NCT02763800|Experimental|Group 4: BIA 3-202 200 mg/placebo|"Group 4: BIA 3-202 200 mg/placebo on Day 1; BIA 3-202 200 mg/placebo t.i.d. on Days 3-8 inclusively; final single dose of BIA 3-202 200 mg/placebo on Day 9.~200 mg BIA 3-202: 2 x 100 mg BIA 3-202 tablets"
2520053|NCT02762812|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
2520058|NCT02762812|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 5 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Wekk 38, Week 46, Week 54.
2520160|NCT02762448||Daclatasvir + Asunaprevir|Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks .
2520174|NCT02762006|Experimental|Durvalumab + Tremelimumab with Nephrectomy|"Following systemic therapy, patients will undergo nephrectomy. Adjuvant therapy will be administered within 4-6 weeks of surgery. Subsequent follow-up will then be completed to assess adverse event resolution and long-term outcomes.~Cohort 1: Durvalumab x 1 dose (n=6)~Cohort 2: Durvalumab + Tremelimumab x 1 dose (n=6)~Cohort 2a: Durvalumab + Tremelimumab x 1 dose (n=12)~Cohort 3: Durvalumab + Tremelimumab x 1 dose (n=9)~Cohorts 1 and 2: Adjuvant dosing of Durvalumab x 1 beginning 2-8 weeks after surgery.~Cohort 2a: Durvalumab monotherapy until 1 year after nephrectomy.~Cohort 3: Adjuvant dosing of durvalumab + tremelimumab x 1 beginning 2-8 weeks after surgery, then durvalumab monotherapy until 1 year after nephrectomy."
2554863|NCT02533284|Placebo Comparator|C group|control TAP saline
3165558|NCT00514462|Experimental|A|low level laser instrument (Painless Light PL-830, Advanced Chips & Products Crop., USA)
3165559|NCT00514527|Experimental|1|
3165560|NCT00514527|Experimental|2|
3165561|NCT00514527|Experimental|3|
3165562|NCT00514566|Active Comparator|1|Surgical Patient undergoing midline laparotomy closure
2519134|NCT02768909|Experimental|Pulmonary TB|"This arm will enroll 100 patients older than 15 years old, from Caracas, with pulmonary TB, culture proved.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J.~Follow Up 5 days after beginning of Tx~Follow Up 15 days after beginning of Tx~Follow Up 30 days after beginning of Tx~Follow Up 60 days after beginning of Tx"
2519136|NCT02768909|Active Comparator|Non - Pulmonary TB|"This arm will enroll 75 patients older than 15 years old, from Caracas, with non TB pulmonary infections, culture negative.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
2519142|NCT02768909|Active Comparator|Healthy Individuals|"This arm will enroll 75 patients older than 15 years old, from Caracas, without any symptom or sign of lower track infection.~Intervention:~They will be asked to perform a respiration for 5 minutes through the E-Nose Device, with a nose clamp.~Medical History: Symptom based Survey, Physical Exam, Anthropometric measurement.~Chest X-ray.~Sputum samples for Ziehl Neelsen smear and Culture in L-J."
2519237|NCT02768233|Experimental|Educational programme|Group 1: Educational programme + standard treatment
2519240|NCT02768233|No Intervention|Standard treatment|Standard treatment
2519301|NCT02767739|Experimental|Physical, social and cultural activities|"Physical Activity: The training program will be supervised by a physical activity specialist and will consiste of two aerobic exercise sessions per week, including walking and stretching exercises after walking. Each session will be 60 minutes and the size of groups will be from 15 to 30 participants. Additionally, participants will receive advice about the health benefits of PA and PHC nurses using different strategies to encourage the adherence of participants to the program.~Social and cultural support activities. Activities will include: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons. These activities will be performed once a month."
2519310|NCT02767739|No Intervention|Control Group|No intervention. We will measure the variables at the begining and after 9 months.
2519375|NCT02767505|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
2519379|NCT02767505|Active Comparator|Gastric bypass|Laparoscopic Roux-en-Y gastric bypass
3198561|NCT00871806|Experimental|Eletriptan oral disintegrating tablet (ODT) #1 without water|Oral disintegrating tablet formulation #1 without water
2519524|NCT02766296|Experimental|Active Emotional Working Memory Training|Each participant will receive 15 sessions (each lasting 20 minutes) over a 5 week. This will be Internet-based cognitive training based on the adaptive dual n-back paradigm.
2519525|NCT02766296|Placebo Comparator|Control Working Memory Training|Participants in this condition will receive 15 sessions (each lasting 20 minutes) over a 5-week period. This will also be home-based training over the Internet. This training will be based on a fixed 1-back training program.
2519594|NCT02765958||Healthy|subjects without heart disease or arrhythmia, no evidence of obstructive sleep apnea
2519600|NCT02765958||OSA|obstructive sleep apnea
2519669|NCT02765529|Experimental|20-30 years|Blood sampling
2519670|NCT02765529|Experimental|45-55 years|Blood sampling
2519671|NCT02765529|Experimental|70-80 years|Blood sampling
2519673|NCT02765529|Experimental|Control|Blood sampling for standardization of technical procedures
3198562|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 without water|Oral disintegrating tablet formulation #2 without water
3198563|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #1 with water|Oral disintegrating tablet formulation (ODT) #1 with water
2519828|NCT02764125|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
2519832|NCT02764125|Experimental|levodopa MR|Levodopa MR/carbidopa/ODM-104
2519910|NCT02763787|Experimental|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519919|NCT02763787|Experimental|10 mg|1 x 10 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519923|NCT02763787|Experimental|30 mg|3 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519929|NCT02763787|Experimental|50 mg|5 x 10 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519932|NCT02763787|Experimental|100 mg|1 x 100 mg BIA 3-202 tablet BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519936|NCT02763787|Experimental|200 mg|2 x 100 mg BIA 3-202 tablets
2519937|NCT02763787|Experimental|400 mg|4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519938|NCT02763787|Experimental|800 mg|8 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2519939|NCT02763787|Experimental|Food Effect (fed/fasted)|400 mg BIA 3-202: 4 x 100 mg BIA 3-202 tablets BIA 3-202 was administered in the form of oral tablets, given with 200 ml potable water (single oral doses)
2520076|NCT02762695|Experimental|Case Management|
2520081|NCT02762695|Active Comparator|Control|Usual Care at Primary Health Care
2520214|NCT02761811|Experimental|Renal Sympathetic Denervation|Percutaneous renal denervation using the SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator.
2519176|NCT02768623|Experimental|Intervention Group|"Pharmacists in the intervention group will provide patients with a comprehensive disease management program for asthma. The 3 major components of pharmacists' intervention are outlined below. The services delivered will be customized based on each patient's case.~Medication review and drug therapy optimization~Patient education~Improving patient adherence"
2519233|NCT02768181|Experimental|Arm 1: BCC+PNS+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with a lipid-based nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with a lipid-based nutrient supplement for children (CNS) aged 6m to 2 years.
2519235|NCT02768181|Experimental|Arm 2: BCC+PNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth, along with nutrient supplement to pregnant women (PNS) till delivery. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
2519238|NCT02768181|Experimental|Arm 3: BCC+CNS|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children, along with nutrient supplement to children (CNS) 6m to 2 years.
2519239|NCT02768181|Experimental|Arm 4: BCC only|Pregnant women receive nutrition-specific behaviour change communication (BCC) counselling on health, nutrition, hygiene etc during pregnancy and on exclusive breastfeeding (EBF) till 6 months of children's birth. After birth, counselling continues on EBF, on nutrition of lactating mothers, and on health and associated issues of mothers and children. From 6 months of children's age, counselling is covered on timely complementary feeding and continued breastfeeding till 2 years of age, nutrition of lactating mother, health other associated issues of mothers and children.
2519241|NCT02768181|No Intervention|Arm 5: comparison|No intervention will be provided by the study. The existing services delivered though government health systems will be continued. Government /NGO-led routine counseling and supplementary services available at Upazila and union levels, which include prenatal counseling, exclusive breastfeeding counseling, and maternal iron-folic acid supplementation and vitamin-A supplementation for children will continue. However, assessment of outcomes will be conducted in same frequency and schedule, alike in intervention arms, described in data collection section.
2519332|NCT02767622||Patient Group|Twenty right handed patients with biopsy-proven liver cirrhosis listed for liver transplantation.
2519338|NCT02767622||Control Group|Twenty age-matched healthy persons. They were similar to the patient group in respect to the number of education years, sex, and handedness.
2519349|NCT02767414|Experimental|Respirio Flu Test and eLab Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test; eLab Flu Test; and Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)"
2519452|NCT02766764|Active Comparator|Study group|Women will receive oral DHEA 25 mg t.d.s daily for 12 weeks before ICSI in addition to daily GH injections from day 6 of hMG administration until the day of hCG administration.
2519461|NCT02766764|Placebo Comparator|Placebo group|Women will receive an oral placebo similar to DHEA t.d.s daily for 12 weeks before ICSI in addition to daily placebo injections similar to GH from day 6 of hMG administration until the day of hCG administration.
2519496|NCT02766452|Experimental|Pre-operative educational DVD preparation|"After their pre-assessment clinic (PAC) appointment, parents in the intervention group took the hospital's 20 minute surgical virtual tour in the hospital's family library. Parents in the intervention group also watched the 12 minute DVD entitled, You and Your Child in the RR. This pre-operative educational tool was developed and tested in a previous study (Chartrand 2014). It was designed to enable parents to gain knowledge about the equipment and procedures related to the RR, and about nurses' and parents' roles in supporting their child in the RR. The DVD also focused on potential reactions of children waking up after a general anesthesia and strategies parents can use to support their child in the RR. The DVD included images of RR equipment and positive nurse-family and parent-child interactions."
2519499|NCT02766452|Placebo Comparator|Standard pre-operative preparation|After their PAC appointment, parents in the control groups took the hospital's 20 minute surgical virtual tour in the hospital's family library.
2519515|NCT02766192|Experimental|TIMBER-Ketamine arm|This arm received TIMBER psychotherapy and ketamine infusion.
2519516|NCT02766192|Placebo Comparator|TIMBER-placebo arm|This arm received TIMBER psychotherapy and placebo (normal saline) infusion.
3198564|NCT00871806|Experimental|Oral disintegrating tablet formulation (ODT) #2 with water|Oral disintegrating tablet formulation (ODT) #2 with water
3198565|NCT00871884|Active Comparator|Treatment As Usual|
2519714|NCT02764931|Experimental|Oat meal 1|A single gluten-free oat containing meal number 1 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
2519717|NCT02764931|Placebo Comparator|Placebo meal|A single meal which does not contain oats before ingesting the SmartPill capsule. Dietary intervention: gluten-free oats and gastrointestinal health.
2519721|NCT02764931|Experimental|Oat meal 2|A single gluten-free oat containing meal number 2 before ingesting the SmartPill capsule. Dietary intervention. Gluten free oats and gastrointestinal health
2519781|NCT02764736|Experimental|atorvastatin|Patients in this arm will receive 20mg atorvastatin PO daily for 12 weeks followed by 40mg atorvastatin PO daily for 12 weeks.
3198566|NCT00871884|Experimental|Experimental|
3198567|NCT00871897||Cardiac Rehabilitation|People with heart failure who elect to participate in cardiac rehabilitation.
2519219|NCT02768116|Experimental|ATP technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of non-left-main bifurcation lesion.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
2519227|NCT02768116|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects. Sirolimus-eluting Drug stent implantation via Provisional T stenting technique in the treatment of non-left-main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>75%, >type B dissection and TIMI flow<3.
3198568|NCT00871897||No Cardiac Rehabiliation|People with heart failure who elect NOT to participate in cardiac rehabilitation.
2519369|NCT02767193|Experimental|DCV3|Autologus differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus
2519376|NCT02767193|Experimental|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG-INF
2519383|NCT02767193|Placebo Comparator|CD placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded
2519388|NCT02767193|Placebo Comparator|CD placebo + PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG-INF
3198569|NCT00871910|Experimental|2 Hour SCH 727965 infusion|Participants treated with 2 hour SCH 727965 IV infusion
3198570|NCT00871910|Experimental|8 Hour SCH 727965 infusion|Participants treated with 8 hour SCH 727965 IV infusion.
2519521|NCT02766530|Experimental|PETMR study|All the study participants will receive PET MR examinations before neoadjuvant chemotherapy and during neoadjuvant chemotherapy (during early cycle as well as during mid-cycle of chemotherapy treatment). There will be two groups of patients after completion of neoadjuvant chemotherapy, that is, responders versus non-responders. We will compare the PET MR imaging parameters before, during neoadjuvant chemotherapy between the two groups of patients.
2519629|NCT02765997|Active Comparator|Unmanipulated UCB|Subjects will receive unmanipulated umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
2519636|NCT02765997|Experimental|StemRegenin-1 UCB|Subjects will receive StemRegenin-1 (SR-1) cultured umbilical cord blood transplantation after a myeloablative CY/FLU/TBI conditioning.
2519650|NCT02765347|Other|Metformin and Insulin|MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g bid or tid) for 24 weeks
2519651|NCT02765347|Other|Insulin|Accept insulin for 24 weeks
3198571|NCT00871910|Experimental|24 Hour SCH 727965 infusion|Participants treated with 24 hour SCH 727965 IV infusion.
2519752|NCT02764918||Children|
2519756|NCT02764918||Mothers|
2519812|NCT02764606||Patients with a non-small cell lung cancer|Serum and plasma samples (at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases).
2519836|NCT02764203|Experimental|Chocolate consumption|Subjects will consume 50g of dark chocolate for 2 weeks and have their blood pressure compared before chocolate and after chocolate
2519912|NCT02763683||Parkinsons Disease|Individuals with Parkinsons Disease
2519916|NCT02763683||Healthy Controls|Individuals without Parkinsons Disease
2519978|NCT02763345|Active Comparator|Paper-based CCM (Standard Care)|Children are assessed and treated according to the WHO and UNICEFs paper-based Community Case Management decision aid for Malawi for a minimum of 2 and a maximum of 7-weeks. Clinical assessment is guided by the paper-based 'Sick Child Form' presented in English, and clinical data is recorded by Health Surveillance Assistants manually in the Village Clinic Register.
2519989|NCT02763345|Experimental|SL eCCM App + paper CCM|Health Surveillance Assistants use the Supporting LIFE electronic Community Case Management App (SL eCCM App) deployed on a smartphone and replicating paper-based CCM guidelines to assess and treat children in conjunction with standard care, for a minimum of 2-weeks and maximum of 7-weeks. Clinical data is recorded in both the SL eCCM App and Village Clinic Register.
2520064|NCT02762942|Active Comparator|Vaginal misoprostol alone|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol according to local protocols
2520069|NCT02762942|Experimental|Vaginal misoprostol + Foley catheter|Women in this group will receive 25mcg of vaginal misoprostol every 4 hours up to a maximum of 5 doses. At the same time a 16French Foley catheter will be inserted through the internal os with visualization of the cervix by sterile speculum examination. The catheter balloon will be inflated with 30 ml of sterile normal saline solution and then the catheter will be taped with gentle traction to the inner thigh of the patient until spontaneous expulsion. If this does not occur, the catheter will be deflated and removed after 12 hours. Misoprostol will be stopped in case of a favorable cervix or if the patient is in active labor. In case of no progression after 5 doses of misoprostol, intravenous oxytocin will be perfused 4 hours after the last dose of misoprostol.
3198572|NCT00871910|Experimental|2 Hour SCH 727965 infusions plus aprepitant in Cycle 1|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 1 only.
2520186|NCT02761824|Experimental|Camp Discovery|One week activity based camp.
2520274|NCT02761720||MyPennMedicine (MPM)|Participants assigned to this arm downloaded only the MyPennMedicine mobile app.
2520276|NCT02761720||MPM and Ginger iO|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app.
2520481|NCT02760316|Experimental|AZD9567 oral suspension of 40 mg|Participants will receive oral suspension of 40 mg dose strength
3198573|NCT00871910|Experimental|2 Hour SCH 727965 infusion plus aprepitant in Cycle 2|Participants randomized to 2 Hour SCH 727965 infusion, plus concomitant ondansetron and dexamethasone in Cycles 1 and 2, and aprepitant in Cycle 2 only.
3198574|NCT00871936|Experimental|1|SLx-4090 in combination with Metformin
3198575|NCT00871936|Other|2|Placebo
2519340|NCT02767570|Experimental|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback. The goal of the training is to encourage participants to adopt an altered foot progression angle in an attempt to alter the distribution of forces crossing the knee joint. Training will occur once a week for six weeks. This will be followed by a 46-week home and community-based walking program to practice and internalize the new personalized, gait pattern and to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to enhance internalization of the new foot progression angle.
2519341|NCT02767570|Experimental|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback. The goal of the training is to encourage participants to maintain a consistent foot progression angle in an attempt to minimize the variability in the forces crossing the knee joint. Training will occur once a week, for 6 weeks. This will be followed by a 46-week home and community-based walking program to encourage daily walking. Refresher training with haptic feedback will be offered at weeks 11, 25 and 39 to maintain foot progression angle consistency.
2519357|NCT02767258|Active Comparator|Sham Comparator: Eye drop|Eye drop LACRIBELL® - two drops each eye, two times a day, after eye cleansing.
2519360|NCT02767258|Experimental|VIDISIC® GEL|Ocular gel VIDISIC® GEL applied two times a day at the lower palpebra from medium line to the lateral border.
2519464|NCT02767024|Experimental|Sodium Nitroprusside|Dose titration will start at 25 μg/min and increased by 25 μg every 5 minutes to maximal dose of 400 μg/min while maintaining SBP ≥ 90 mmHg. Every 5 minutes, the Pulmonary Capillary Wedge Pressure (PCWP), SBP will be measured. If PCWP > 16 mmHg while maintaining SBP ≥ 90 mmHg, the investigator will proceed to titrate dose with the goal to achieve the target of PCWP ≤ 16 mmHg and Cardiac Index (CI) > 2.2 L·min-1·m-2, or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
2519471|NCT02767024|Active Comparator|Dobutamine|Dose titration will start at 2.5 μg/kg/min and increased to doses of 5, 7.5 and 10 μg/kg/min (maximal dose). Every 30 minutes, the investigator will collect Pulmonary Artery (PA) blood samples for PA sat measurement to calculate Cardiac Output (CO) and CI by Fick. If CI ≤ 2.2 L·min-1·m-2, the investigator will proceed to titrate dose until CI > 2.2 L·min-1·m-2 or maximal infusion dose has been reached, whichever comes earliest. Continuous intravenous furosemide infusion dose will be maintained by protocol.
2519498|NCT02766426|Other|Lifestyle change intervention|Overweight/obese pregnant women enrolled in a healthy lifestyle change programm
2519517|NCT02766231||Physica CR|
2519518|NCT02766231||Physica PS|
2519676|NCT02765568|Experimental|Moderate Intensity Continuous Exercise|Moderate Intensity Continuous Exercise Training
2519683|NCT02765568|Experimental|Nordic Walking|Nordic Walking
2519691|NCT02765568|Experimental|High Intensity Interval Training|High Intensity Interval Training
2519720|NCT02764957|Active Comparator|intervention|400 mg green coffee extract capsules twice per day for 8 weeks The Green coffee extract is standardised with 45% total chlorogenic acid by HPLC
2519722|NCT02764957|Placebo Comparator|control|placebo capsules twice per day for 8 weeks have identical appearance to Green coffee extract capsules and contain starch
2519789|NCT02764749|Experimental|freeze dried powder whole cranberry dissolved in water|Dietary Supplement: freeze dried cranberry powder
2519790|NCT02764749|Placebo Comparator|freeze dried cranberry deprived powder dissolved in water|Placebo comparator: freeze dried cranberry deprived powder
2519825|NCT02764307|Experimental|Aerosolized drug depositions|Aerosol drug deposited on the inhaled and exhaled filters and the residual dose were evaluated delivered by four types of nebulizer: 1) a constant jet nebulizer, a breath enhanced nebulizer, a manual-actuated nebulizer, and a breath-actuated nebulizer.
2519875|NCT02763852|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Madopar 125. BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2519879|NCT02763852|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2519880|NCT02763852|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2519881|NCT02763852|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2520216|NCT02761811|Sham Comparator|Masked Procedure|Percutaneous renal artery angiography
3198576|NCT00871949|Experimental|Cohort 1, Sequence 1|Period 1- Placebo Period 2- 100 mg Period 3- 300 mg
3198577|NCT00871949|Experimental|Cohort 1, Sequence 2|Period 1- 35 mg Period 2- Placebo Period 3- 300 mg
3198578|NCT00871949|Experimental|Cohort 1, Sequence 3|Period 1- 35 mg Period 2- 100 mg Period 3- Placebo
3198579|NCT00871949|Experimental|Cohort 2, Sequence 1|Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
3198580|NCT00871949|Experimental|Cohort 2, Sequence 2|Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)
3198581|NCT00871949|Experimental|Cohort 2, Sequence 3|Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)
3198582|NCT00871962||1|COPD patients on necessity of long-term oxygen therapy
3198583|NCT00872014|Experimental|15mg/ kg cohort|AMG 386 15mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
3198584|NCT00872014|Experimental|10 mg/kg cohort|AMG 386 10mg/kg intravenously once weekly and Sorafenib 400mg orally twice daily in an every 4 weeks dosing schedule.
3198585|NCT00872040||Nuliparous women and their husbands|Women in their first pregnancy with their husbands
3198586|NCT00872053|Experimental|Arm 1|Focused Ankle Training
3198587|NCT00872053|Experimental|Arm 2|Combination Therapy
3198588|NCT00872066|Active Comparator|1) SmartSet® HV Bone Cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
3198589|NCT00872066|Active Comparator|2) SmartSet® GHV Bone Cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
3198590|NCT00872092||Breath test|Subjects with suspected SBBO
3198591|NCT00872105|Other|Non-operative treatment|The first treatment strategy will involve conservative (nonoperative) management of the clavicle fracture.
3198592|NCT00872105|Active Comparator|Operative treatment|The second treatment strategy will involve operative fixation (i.e. ORIF) of the fracture with a plate and screws.
3198593|NCT00872118|Experimental|1|Brief Intervention for Socially Anxious Drinkers
3198594|NCT00872118|Active Comparator|2|Enhanced Alcohol Skills and Education Program
3198595|NCT00872131||Generalized social anxiety disorder participants|Participants with generalized social anxiety disorder will undergo MRI scanning and sertraline treatment.
3198596|NCT00872131||Healthy control participants|Healthy control participants will undergo MRI scanning.
3198597|NCT00872144|Active Comparator|Sativex|
3198598|NCT00872157|Experimental|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
3198599|NCT00872196|Other|1 - Follow-up Study|This is a follow-up study with no treatment and only samples being collected.
3198600|NCT00872209|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
2519659|NCT02765308||Healthy volunteers|healthy age matched with cases volunteers as controls
2519664|NCT02765308||Uveitis with raised IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with raised intraocular pressure
2519667|NCT02765308||Uveitis with with normal IOP|Recurrent (> 5 attacks) idiopathic acute anterior uveitic with normal intraocular pressure
2519735|NCT02765139|Experimental|EMAP Treatment|Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
2519736|NCT02765139|Other|Control|In the 15 control sites, the male participants will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
2519770|NCT02764671|Experimental|10μg/0.5ml recombinant HBV vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
2519963|NCT02763514|Active Comparator|DHA-enriched oil|3 g PronovaPure 150:500 EE EU
2519965|NCT02763514|Active Comparator|EPA-enriched oil|3 g PronovaPure 500:200 EE EU
2519966|NCT02763514|Placebo Comparator|Placebo|3 g Olive oil
3198601|NCT00872209|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
3198602|NCT00872222|Other|Ceramic-on-Ceramic|Pinnacle™ Acetabular System with ceramic liner
3198603|NCT00872235|Experimental|1|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
2523695|NCT02739009|Experimental|MOR106|Single intravenous administration of MOR106
3198604|NCT00872235|Active Comparator|2|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
3198605|NCT00872235|Experimental|3|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)
3198606|NCT00872235|Active Comparator|4|Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)
3198607|NCT00872248|Experimental|1|Parturients received spinal anesthesia
3198608|NCT00872248|Active Comparator|2|Parturients received epidural anesthesia
3198609|NCT00872261||Proxy microbicide product|Use of vaginal lubricant as a proxy microbicide gel; use of multivitamin as proxy pre-exposure prophylaxis (PrEP) product
3198610|NCT00872274|Experimental|1|sumatriptan succinate tablets 100 mg (containing sumatriptan succinate equivalent to 100 mg of sumatriptan) manufactured by OHM Laboratories In
3198611|NCT00872274|Active Comparator|2|IMITREX® 100 mg tablets (containing sumatriptan succinate equivalent to 100 mg of sumatriptan)
3198612|NCT00872287|Active Comparator|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
3198613|NCT00872287|Active Comparator|SILS|Single transumbilical incision laparoscopic cholecystectomy
3198614|NCT00872300|Experimental|1|
3198615|NCT00872313||1|Psychoses within the first 3 months postpartum
3198616|NCT00872313||2|Psychoses > 3 months to 6 months postpartum
3198617|NCT00872326|Experimental|Autologous Bone Marrow Mononuclear Cells|Consecutive inclusion among diabetic patients with critical limb ischemia. Intraarterial infusion of autologous bone marrow mononuclear cells
3198618|NCT00872365|Other|1|Regular aerobic physical exercise + placebo
3198619|NCT00872365|Other|2|Activities of daily living + Micronutrients
3198620|NCT00872365|Other|3|Regular aerobic exercise + micronutrients
3198621|NCT00872365|Placebo Comparator|4|Activities of daily living + placebo
3198622|NCT00872378|Active Comparator|Exenatide|Laparoscopic adjustable gastric banding group: twice daily exenatide therapy plus a standard diet and exercise program
3198623|NCT00872378|Placebo Comparator|Placebo|Laparoscopic adjustable gastric banding group: twice daily placebo therapy plus a standard diet and exercise program
3198624|NCT00872391|Experimental|Hypofractionated LINAC radiotherapy|
3198625|NCT00872404|Experimental|1|CP-751,871 will be administered as an open-label intravenous solution. Patients will remain under clinical observation for one hour post-infusion
3198626|NCT00872417|Experimental|Treatment-naive|To explore the efficiency and safety of generic antiretroviral drugs for 520 treatment-naive HIV/AIDS patients
2519299|NCT02767830|Experimental|Excercise and Nutrition Program|Children and their care givers will receive 5 lectures on nutrition and exercise and will be given a weekly running program. At the end of the study children will be encouraged to participate in an annual 0.25-0.5 mile race.
2519350|NCT02767518|Experimental|Prehabilitation|Participants will be referred to the Michigan Surgical & Health Optimization Program in the month leading up to their surgery. Individuals are encouraged to increase their physical activity, practice stress reduction, and other behaviors associated with good health.
2519352|NCT02767518|No Intervention|Usual Care|Participants will follow the pre-operative instructions provided by their surgical team.
2519396|NCT02767115|Experimental|GSE mucoadhesive gel|2%GSE mucoadhesive gel administered in the periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
2519397|NCT02767115|Placebo Comparator|Control mucoadhesive gel|GSE free mucoadhesive gel administered in the periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
2519455|NCT02766855|Experimental|cysteamine eye drops|Patients used cysteamine eye drops every 2 hours while awake to both eyes.
2519495|NCT02766582|Experimental|Chemotherapy combined with pembrolizumab|"Single arm study:~Pembrolizumab IV every 21 days (200 mg) Carboplatin IV every 21 days Paclitaxel IV infusion (80 mg/m2) every 7 days for 6 cycles Followed by 12 months pembrolizumab IV every 21 days"
2519532|NCT02766166||Predictive Monitoring|
2519539|NCT02766166||No Predictive Monitoring|
2519608|NCT02765984||normal placental site|women with normal implantation site at early trimester with normal placental site
2519615|NCT02765984||Low placental site|women with low implantation site at early trimester with low placental site
2519675|NCT02765438|Experimental|BOBO|"Playing with the BOBO system."
2519726|NCT02765074|Experimental|Roactemra|subcutaneous tocilizumab
2519766|NCT02764658|Experimental|Pulmonary recovery on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
2519767|NCT02764658|Other|Routine care on the AECOPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in AECOPD Patients
2519768|NCT02764658|Other|Routine care on the stable COPD|Study in the pulmonary inflammation and the effectiveness of pulmonary recovery in stabel COPD Patients
2519830|NCT02764268|Experimental|Apatinib|
2519865|NCT02763969|Experimental|Part A: Single Ascending Dose|BMS-986202 or Placebo specified dose on specified days
2519867|NCT02763969|Experimental|Part B: Multiple Ascending Dose|BMS-986202 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
2519871|NCT02763969|Experimental|Part C: Multiple Ascending Dose-Japanese descent|BMS-986202 or Placebo specified dose on specified days in patients of Japanese descent
2519873|NCT02763969|Experimental|Part D: Relative Bioavailability|BMS-986202 (Liquid) or BMS-986202 (Capsule) + Famotidine specified dose on specified days
2519878|NCT02763969|Experimental|Part E: Proof of Mechanism|BMS-986202 or Placebo + Ustekinumab specified dose on specified days
2520155|NCT02762383|Experimental|Peginterferon Alfa-2a|Participants will receive a low dose of peginterferon alfa-2a for 18 months.
2520234|NCT02761785||Celiacs with oat-related symptoms|Celiac patients who have self-reported gastrointestinal symptoms after ingestion of gluten-free oats
2520237|NCT02761785||Celiacs without oat-related symptoms|Celiac patients who include gluten-free oats in their diet and have no symptoms related to oats
2520239|NCT02761785||Healthy controls|Healthy controls (without celiac disease) who include oats in their diet
2520241|NCT02761785||Non-celiac gluten sensitive subjects|Subjects with manifestations precipitated by ingestion of gluten in whom celiac disease and wheat allergy are excluded.
2520283|NCT02761486|Active Comparator|Aspirin|The subjects will receive 325 mg of aspirin once a day for 6 weeks followed by a 6-week washout.
2520292|NCT02761486|Placebo Comparator|Placebo|The subjects will receive placebo once a day for 6 weeks followed by a 6-week washout.
2520323|NCT02761148||Control|
2520334|NCT02761148||White matter hyperintensity|
2520467|NCT02760524|Experimental|Intervention|Subjects will receive NET intervention treatment immediately
2520472|NCT02760524|Active Comparator|Control|Subjects will receive NET intervention treatment and serve as a wait-list control
2520540|NCT02760017|Placebo Comparator|placebo|capsules containing placebo for B forticata
2520545|NCT02760017|Experimental|B. forficata|capsules of B. forficata containing 200 mg of plant extracts
2520576|NCT02759718|Experimental|pancreatic neuroendocrine tumor|chromogranin A
3165563|NCT00514579|Other|Myeloablative double unit UCBT|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
3165564|NCT00514618|Active Comparator|1|patients will be treated with misoprostol 50 mcg PO
2555070|NCT02531984|Other|ongoing Azithromycin treatment|
3165565|NCT00514618|Placebo Comparator|2|patients will receive placebo (Vitamin C)
3165566|NCT00514644|Experimental|Panorama to Ultrasound|100 asymptotic patients that have findings of calcifications in the area of the carotid arteries when examined with panorama. These persons are examined with carotid ultrasound.
3165567|NCT00514644|Experimental|Ultrasound to Panorama|100 patients with a known carotid stenosis seen on ultrasound will be examined with panorama before any intervention is made. These patients must undergo surgery to be finally included.
3165568|NCT00514657|Placebo Comparator|P|
3165569|NCT00514657|Experimental|L|low dose (0.03 %)
3165570|NCT00514657|Experimental|M|medium dose (0.1 %)
3165571|NCT00514657|Experimental|H|high dose (0.3 %)
3165572|NCT00514670|Experimental|1|Intervention classrooms received alcohol-based hand sanitizer and disinfecting wipes.
3165573|NCT00514670|No Intervention|2|No hand sanitizer or disinfecting wipes were used.
3165574|NCT00514696|Experimental|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
3165575|NCT00514748|Active Comparator|1|Patients who receive breast reconstruction with bilateral DIEP flap based on bilateral vessel pedicles
3165576|NCT00514748|Experimental|2|Patient who receive breast reconstruction with vessel interconnected DIEP flap based on one vessel pedicle
3165577|NCT00514761|Active Comparator|1|Xeloda
3165578|NCT00514761|Experimental|2|AZD6244
3165579|NCT00514774|Experimental|A|
2519394|NCT02767154|Active Comparator|PrimECC|1250 ml of a priming solution based on the colloid Dextran 40 to use for extracorporeal circulation.
2519395|NCT02767154|Active Comparator|Ringer-Acetate/Mannitol|1250 ml of a priming solution based on the crystalloid Ringer-Acetate (1000ml) and Mannitol (250ml).
2519454|NCT02766868|Experimental|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
3165580|NCT00514774|Experimental|B|
2519553|NCT02766127|Experimental|Xerostomic Patients|"Patients with evident clinical signs of xerostomia who experienced dentinal hypersensitivity after undergoing radiation therapy due to head and neck cancer.~The following dental materials will be used following the manufacturers' instructions: Veritise Flow; Universal Dentin Sealant; Clearfil Protect Bond, and Flor-Opal® Varnish. In view of the treatment with the desensitizing agents, teeth were randomly assigned into four groups.~the application of the materials will be made only once. The effectiveness will be evaluated: immediately after application and after 1, 4, 12 weeks."
2519679|NCT02765542|Experimental|Automated phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
2519716|NCT02765009|No Intervention|Control|Usual care provided according to the ward policy. Patients have to be weighed at least on admission (day 0), day 7 and day 14.
2519718|NCT02765009|Experimental|Strategy|Patients have to be weighed every day. Use of an algorithm based on weight changes from day 2 to day 14 in order to reduce weight gain (fluid overload) using diuretics, fluid restriction,albumin, and ultrafiltration (the latter when ongoing renal replacement)
2519808|NCT02764567|Experimental|Aromatherapy|"The participants randomized to aromatherapy will be offered one of three essential oils, 'applied' to their smell zone via cotton ball that are known to have anti-anxiety effect. These are:~ginger~calming~lavender The participant's choice will be documented in a database. The participant can chose an oil each time (i.e., they are not bound to use only the first choice oil). Pain and anxiety will be measured prior to receiving the essential oils and again after the phlebotomy procedure. Blood pressure and pulse will also be measured post-phlebotomy."
2519811|NCT02764567|No Intervention|Standard of Care|The participants randomized to standard of care will proceed to the outpatient phlebotomy room in the Heart Care Clinic as per usual care. Pain, anxiety, blood pressure and pulse will be assessed pre and post-procedure.
2519843|NCT02764216|Experimental|EMI group|Elective mucosal irradiation
2519911|NCT02763813|Experimental|Propulsion type appliance (Herbst)|
2519917|NCT02763813|Active Comparator|Retention type appliance (ORM)|Retention type appliance
2519981|NCT02763397|Experimental|NBM-DBS on|DBS is programmed to stimulate the NbM
2519986|NCT02763397|Placebo Comparator|DBS off|DBS is turned off, no stimulation will be exerted
2520014|NCT02762955|Experimental|BCD-057 group|"BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa."
2520015|NCT02762955|Active Comparator|Humira® group|"Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.~BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.~Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa."
2520039|NCT02762734|Experimental|MEDIA|"The patient will benefit of the usual care with additional text message (SMS or mail or other new media). The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt."
2520040|NCT02762734|No Intervention|CLASSIC|The patient will benefit of the usual care.
2520159|NCT02762539|No Intervention|Control group|Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion
2520164|NCT02762539|Experimental|SMOF group|SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.
2520368|NCT02761005|Experimental|23S rRNA wt|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains without mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and clarithromycin 200 mg bid for 1 week for the eradication of H. pylori.
2520370|NCT02761005|Experimental|23S rRNA mutation|As the 23S rRNA mutation guided selection of antimicrobial agent, patients infected with strains with mutation of 23S rRNA are assigned to this arm. In this arm, they are treated with vonoprazan 20 mg bid, amoxicillin 750 mg bid and metronidazole 250 mg bid for 1 week for the eradication of H. pylori,
2520421|NCT02760628|Experimental|The First Twenty (TF20)|Participants in TF20 will be provided an online wellness program focused on fitness and nutrition tailored to firefighters. TF20 is interactive and involves health coaching.
2520423|NCT02760628|Placebo Comparator|Life Simple Seven (LS7)|Participants assigned to the LS7 arm will be directed to a website that contains information about health and wellness from the American Heart Association that was developed for the general population. No health coaching is present and the site is not tailored for the fire service.
3165581|NCT00514774|Placebo Comparator|C|
3165582|NCT00514800|Experimental|Intervention|"Patients will be given a home blood pressure monitor and taught how to use it and how to respond to the readings using a standardised protocol and blood pressure targets. The study nurse will follow up patients at home after a month with additional telephone support according to a defined protocol. Patients will consult their own GP for medication changes when above target.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
2519406|NCT02767479|Active Comparator|rabeprazole group|rabeprazole-based regimen. This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
2519408|NCT02767479|Active Comparator|esomeprazole group|'esomeprazole^based regimen. This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
2519466|NCT02766803|Active Comparator|Simvastatin + resveratrol|simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily
2519470|NCT02766803|Placebo Comparator|simvastatin+ placebo|simvastatin 20 mg daily Placebo
3198627|NCT00872417|No Intervention|TREATMENT-EXPERIENCED|To explore the long term ARV of treatment-experienced patients who have no sign of drug resistance; to explore the long term efficiency and safety and drug sife effects of ARV in HIV/AIDS patients. These patients have taken ARV for approximately 3 years already.
2519562|NCT02766114|Experimental|Issa1|After local anesthesia, through transverse approach on the middle of dorsal wrist crease the incision is made for 1.5 cm length, then the subcutaneous fat is dissected, soon we see the the palmaris longus tendon or its connection with the carpal ligament , take the ulnar side of the palmaris longus tendon and cut the carpal ligament axillary by scalpel, not going deep with the scalpel to avoid medial nerve injury, soon we see the nerve, we use the scissors to cut the proximal part then the distal part of the carpal ligament by enclosing it between the blades of the scissors, now the full released carpal tunnel most be observed, and one stitch is enough, in this operation most be an assistant exist.
2519609|NCT02765854|Experimental|Arm B (ixazomib and dexamethasone)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A.
2519614|NCT02765854|Experimental|Arm C (ixazomib, dexamethasone, lenalidomide)|MUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone as in arm A and lenalidomide PO daily on days 1-21.
2519618|NCT02765854|Active Comparator|Arm A (ixazomib and dexamethasone)|UNMUTATED NFKB2 REARRANGEMENT: Patients receive ixazomib and dexamethasone.
2519711|NCT02764996|Experimental|Acupuncture for Migraine|Acupuncture treatments will be subject dependent, and points could include the N point (on scalp); various auricular points to include Shen Men, Point Zero, thalamus and Omega-2; body points to include Liver 2, Liver 3, Gall Bladder 20, bladder 10; and surface release over tense areas in the neck or shoulders
2519793|NCT02764801|Experimental|Contrast ultrasound arm|Patients receiving contrast-enhanced ultrasound for diagnosis of chemoembolization response.
3198628|NCT00872417|Experimental|drug resistance|To explore the second line drugs for those drug resistance patients
2519899|NCT02763735||Pulmonary Arterial Hypertension|Patients diagnosed with idiopathic or heritable pulmonary arterial hypertension according to consensus guidelines. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging.
2519906|NCT02763735||Subjects without cardiopulmonary disease|Subjects without known cardiopulmonary disease. RV oxidative metabolism and glycolysis will be measured using PET 11C acetate and [18F]fluoro-deoxy-Dglucose (FDG) imaging and measure myocardial lipid accumulation using MRS imaging
2519953|NCT02763475|Experimental|Natural Killer (NK) Cells + Chemotherapy|Starting on day -6, 60mg/Kg cyclophosphamide by vein will be administrated. Day -5 to -1 fludarabine administrated by vein at 25 mg/m2. 24-48 hours after chemotherapy completion, NK cell infusion will be injected (day 0). On day 7 a second NK cell infusion will be administrated. First infusion consist of 5x10^7/kg NK CD3-CD56+ NK cells. The second NK cell infusion will include up to 5x10^8 CD3-CD56+ cells if no treatment related toxicity occurred. Subcutaneous IL-2 (1x10^6 UI/m2) three times a week for two weeks will be administrated after first NK infusion.
3198629|NCT00872443||FOP|Patients who already have an occlusion of POF secondary to a cryptogenic CVA and younger than 55 years old and without characterized thromboembolic events.
2520049|NCT02762747|Experimental|Drain|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
2520050|NCT02762747|No Intervention|No-drain|No drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
3198630|NCT00872469|Active Comparator|Tranexamic acid|
3198631|NCT00872469|Placebo Comparator|placebo|
2520256|NCT02761473||Patients with Urticaria Pigmentosa|This group will undergo skin biopsy, blood and buccal swab analyses
2520257|NCT02761473||Family members of affected patients|This group will undergo blood and buccal swab analyses
2520349|NCT02761083|Experimental|Novosyn® Quick|Eye surgery using suture material
2520350|NCT02761083|Active Comparator|Vicryl® Rapid|Eye surgery using suture material
2520404|NCT02760771||with BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) with predilation of the aortic valve
2520405|NCT02760771||without BAV|patients undergoing transfemoral trans-catheter aortic valve implantations (TF-TAVI) without predilation of the aortic valve
3198632|NCT00872482|Experimental|1|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT. Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
2520615|NCT02759588|Experimental|GL-ONC1|
2520639|NCT02759172|Experimental|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
2520640|NCT02759172|No Intervention|Standard Care|Standard Care for pretrial jail detainees is assessment of risk and stabilization to the extent possible during their jail detention. No post-release community follow-up is typically provided. This study will augment standard care with regular assessment and emergency referral post-release, as well as provision of a list of community resources.
2520668|NCT02759107|Experimental|LY3298176 (Part B)|Escalating doses of LY3298176 administered SC once weekly for four weeks in healthy participants.
2519431|NCT02766933||hepatitis B cohort|CBCHB employees and/or spouses found to be hepatitis B surface antigen positive on screening
2519476|NCT02766699|Experimental|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox administered via 20 minute intravenous infusion once a week for seven weeks (1 Cycle). Subjects will receive one of two dose levels: 5 x 10^9 or 8 x 10^9. All subjects will undergo an adapted dose escalation regime in the first cycle of treatment. For subsequent cycles all doses will be administered at full strength (5x10^9 or 8x10^9 EGFR(V)-EDV-Dox). Subjects may receive further cycles of treatment if the tumor remains stable or is responding, and/or they are deriving clinical benefit from the therapy and are tolerating treatment.
3198633|NCT00872482|Placebo Comparator|2|"A placebo will be administered by the intravenous route weekly during WBRT and following WBRT.~Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day."
3198634|NCT00872495||1|"Bladder Cancer Group:~Patients scheduled to have a cystectomy or cystoscopy of their bladder with possible removal or biopsy of bladder tumor or tissue.~Two urine samples collected at the time of the scheduled procedure:~One sample collected through voiding. The other sample collected from atheterized urine in the operating room. Additional urine samples may be collected at each follow up visit over two years. These samples will be obtained via voiding, standard urine sample collection."
2519577|NCT02765789|Experimental|Immunoadsorption|Immunoadsoprtion (Immunosorba). All (anticipated) 8 participants will be treated with immunoadsorption
2519644|NCT02765581|Experimental|Verum acupuncture (VA)|Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
2519646|NCT02765581|Sham Comparator|Sham acupuncture (SA)|Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.
2519647|NCT02765581|Placebo Comparator|Usual care (UA)|Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.
2519654|NCT02765243|Experimental|effectiveness of Anti-GD2 CART|Anti-GD2 CART cells can recognize and kill neuroblastoma through the recognition of GD2. This study will evaluate the side effects and effective doses of Anti-GD2 CART cells in treating refractory and/or recurrent neuroblastoma
2519733|NCT02765152|Active Comparator|Conventional Physical Therapy|Usual therapy: joint mobility exercises, stimulating joint movement of the main active components of the upper limb; major muscle groups stretching, especially in the affected muscles by tone impairment; manual resistance training according to the degree of the patient's muscle strength, prioritizing the functional specificity of the upper limb, so the majority of the exercises will be held in open chain; motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks.
2519738|NCT02765152|Experimental|discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
2519740|NCT02765152|Experimental|rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
2519776|NCT02764619|Active Comparator|Aldo group|Fixed dose of spironolactone, Spirix (Takeda Pharma A/S), 25 mg once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
2519782|NCT02764619|Placebo Comparator|Control group|Matched placebo, 1 pill once daily, added to optimal medical treatment (usual care) for atrial fibrillation.
2519841|NCT02764294|Active Comparator|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
2519847|NCT02764294|Active Comparator|Stress Ball Group|"Stress ball group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
2519848|NCT02764294|Active Comparator|DVD Group|DVD group was watched a DVD of their choice (documentaries, interesting and amazing videos, comedies) on a ceiling-mounted monitor positioned at a comfortable distance to the participant.
2519849|NCT02764294|No Intervention|Control Group|Participants received usual care from health professionals. They didn't receive any intervention.
2519896|NCT02763761|Experimental|Infliximab + Prednisone|Infliximab intravenous solution (single dose) + low dose prednisone per oral for 18 days
2519905|NCT02763761|Experimental|Methylprednisolone + Prednisone|Methylprednisolone intravenous solution (single dose) + high dose prednisone per oral for 40 days
2519993|NCT02763267||Pregnant Women|Pregnant women with history of GDM or at risk for diabetes mellitus will enter study during first trimester (4-14 weeks) and receive an oral glucose tolerance test (OGTT) at baseline, mid-pregnancy, and at delivery.
2519995|NCT02763267||Nonpregnant Women|Nonpregnant women with a history of GDM will undergo an OGTT at baseline.
3198635|NCT00872495||2|Control Group: Patients with no known evidence of bladder cancer. One urine sample will be collected through voiding, as with standard urine sample collection at the time of clinic visit.
3198636|NCT00872547|Active Comparator|1|Resurfacing system
3198637|NCT00872547|Active Comparator|2|Large Metal-on-Metal Total Hip Replacement
3198638|NCT00872573|Other|C-Stem™ AMT Femoral Component|
3198639|NCT00872586|Experimental|1|Olmesartan medoxomil and hydrochlorothiazide
3198640|NCT00872586|Active Comparator|2|olmesartan medoxomil
3198641|NCT00872612|Experimental|A|Endosonography arm
2519467|NCT02766751|Experimental|HIVPASS|Over 7 sessions, the interventionist and the participant will explore the relationship between pain, depressive symptoms, and HIV. General information about pain, HIV and depression will be discussed, as will avoidance of physical activity. Psychoeducation about these areas will be tied to the participant's stated life goals, and exposure exercises and goal lists will be developed. Later sessions will integrate continued efforts towards reaching goals and reducing avoidance. A release of information will be obtained from the participant to allow study session chart notes to be placed in the medical record at the participant's PCP office and to allow the PCP and the study interventionist to discuss treatment coordination.
2519520|NCT02766491|Experimental|Strengthening and stretching|The intervention group will follow a strengthening-stretching program of the calf muscles.
2519523|NCT02766491|Active Comparator|conventional stretching|The control group will receive conventional stretching and strengthening exercises to the upper limb to assure that the same systemic physiological stimuli and a similar number of contact hours is received.
2519593|NCT02765971|Active Comparator|chewing gum group|180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval
2519602|NCT02765971|Active Comparator|laxatives group|180 women will receive laxatives after their operating room discharge by 3 hours
2519613|NCT02765971|Placebo Comparator|control|they will not receive neither gum nor oral fluids. They will be on intravenous fluid. starting oral fluids after hearing intestinal sounds
2519687|NCT02765412||standard implementation|Webinar, Promotion, Tool Access, academic detailing + Audit and Feedback
2519693|NCT02765412||intensive implementation|Webinar, Promotion, and Tool Access, academic detailing + Audit and Feedback + LEAP
2519749|NCT02764879|Experimental|omega 3 group|scaling and root planing omega3 received 2 times daily-for 6 months
2519753|NCT02764879|Placebo Comparator|control group|scaling and root planing placebo soft gelatin capsules 2 times daily-for 6 months
2519773|NCT02764515|Experimental|Kunxian capsule group|"Intervention:~Drug: Kunxian 2 capsules BID taken by mouth for 24 weeks. Kunxian capsule is composed of 4 ingredients: Tripterygium wilfordii Hook F 300mg, extracts from Gouqizi,Tusizi and yinyanghuo."
2519785|NCT02764515|Active Comparator|Methotrexate group|"Intervention:~Drug: Methotrexate tablet 10mg taken by mouth every week for 24 weeks."
2519868|NCT02763982||G1|High or normal left ventricular ejection fraction
2519870|NCT02763982||G2|Moderate left ventricular ejection fraction
2519874|NCT02763982||G3|Reduced left ventricular ejection fraction
2519909|NCT02763631|Experimental|Run In Phase|Eligible patients will have 6-Minute Walk Test (6-MWT) on self ventilation and on CPAP
2519920|NCT02763631|Experimental|Treatment|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Treatment arm - Patients will be setup onto portable CPAP during the day"
2519925|NCT02763631|Sham Comparator|Standard Care Arm|"Those patients who improve their 6-MWT by more than 30 meters will then be randomised to either:~Control Arm - Standard care arm."
2519990|NCT02763293|Experimental|Manual Therapy|Cranial therapy (CT). Neuro-lymphatic reflexes treatment (NL) Viscerosomatic reflexes (VR) Induction myofascial Visceral osteopathic therapy (VOT)
2519996|NCT02763293|No Intervention|Control Group|Patients only came to make assessments, without receiving any treatment.
2520068|NCT02762968|Placebo Comparator|Placebo|Placebo capsules similar to the experimental treatments.
2520072|NCT02762968|Experimental|HMB|HMB capsules providing 3 g of calcium HMB per day.
2520082|NCT02762968|Experimental|HMB + BC30|Capsules providing 3 g calcium HMB per day plus Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
3198642|NCT00872612|Active Comparator|B|Conventional bronchoscopy arm
3198643|NCT00872625|Experimental|Cyberknife|
2520270|NCT02761772||PEP-A|See detailed description
2520273|NCT02761772||PEP-S|See detailed description
2520326|NCT02761395|Experimental|Group 1: ALhijama|20 patients under went Al-hijamah procedure for iron chelation
2520335|NCT02761395|Experimental|Group 2: AL-hijama with deferasirox|20 patients receive deferasirox and Al-hijamah.
2520346|NCT02761395|Active Comparator|Group 3:deferasirox|20 patients already receiving deferasirox
2520387|NCT02760732|Experimental|drug eluting balloon group|patients with unstable angina were randomised to drug eluting balloon group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon(Flextome Cutting Balloon, Boston Scientific Corporation, US) pre-dilation first and then drug eluting balloon(Sequent please; B. Braun, Melsungen, Germany) .
2520393|NCT02760732|Experimental|drug eluting stent group|patients with unstable angina were randomised to this group for drug eluting stent (YINYI® Polymer-free Drug-coated (Paclitaxel) Coronary Stent System, Liaoning Biomedical Materials R&D Center Co., Ltd. China) implantation.
3198644|NCT00872638|Active Comparator|1|
3198645|NCT00872638|Active Comparator|2|
3198646|NCT00872651|Experimental|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
3198647|NCT00872651|Active Comparator|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
2520796|NCT02758457|Active Comparator|metal-based restorations|single crown with a metal framework and pressed ceramic
2520798|NCT02758457|Experimental|zirconia-based restorations|single crown with a zirconia framework and pressed ceramic
2523696|NCT02739009|Placebo Comparator|Placebo|Single intravenous administration of Placebo
3198648|NCT00872664|Active Comparator|formula with added carotenoids|Both arms are double-blinded. Infant will be assigned to receive preterm formula with added carotenoids. If infant is receiving human milk then the study formula will only be used as a supplement.
3198649|NCT00872664|Active Comparator|formula without added carotenoids|Both arms are double-blinded. This arm will use preterm formula as it is currently available, which is without any carotenoids. If the infant is receiving human milk, then the formula will be used as a supplement as needed.
3198650|NCT00872677||Dietitian-led counseling and Weight Watchers|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
3198651|NCT00872677||Dietitian & Weight Watchers + Spirituality Counseling|Dietitian wkly for the 1st-3 months, every other week for the next 3 months and monthly thereafter; Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
2519479|NCT02766738|Experimental|GrACE program|Participants in the exercise group will perform twice weekly training for 24 weeks. In brief, the program will include weight-bearing exercises and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. The following-weight bearing and resistance exercises: chair stands, chair dips, calf raises and hip flexor/abdominal lifts, trunk twists, and bicep curl and shoulder press. In total the sessions will be 45 minutes twice weekly.
2519481|NCT02766738|Experimental|GrACE + gait program|GrACE program as mentioned above plus focus on gait specific training will be one-hour training sessions for 24 weeks. Gait exercises will be a combination of exercises: heel and toe raises, stepping in different directions, single leg stand¬ing, step-ups, and task-specific balance work (e.g. reaching outward from the base of support while standing, sitting, and standing and turning). Gait exercises will be upgraded by: 1) reducing hand support and/or 2) narrowing the base of support, and/or 3) introducing a cognitive challenge (e.g. counting backwards while performing exercise) or perform¬ing exercise with the eyes closed.
2519526|NCT02766387|Experimental|2 minutes walk test|fast walk test during 2 minutes in first and the 10 meters walk test, the 6 minutes walk test and the 2 kilometers walk test
2519527|NCT02766387|Experimental|6 minutes walk test|comfortable walk test during 6 minutes in first and the 10 meters walk test, the 2 minutes walk test and the 2 kilometers walk test
2519592|NCT02766036|Active Comparator|Propolis|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
2519607|NCT02766036|Placebo Comparator|Placebo|Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.
2519677|NCT02765451|Active Comparator|A : 1 year of intervention|interventions of Cancéropôle Nord-Ouest during 1 year after an observational period of 2 years.
2519682|NCT02765451|Active Comparator|B : 2 years of intervention|interventions of Cancéropôle Nord-Ouest during 2 years after an observational period of 1 year.
2519796|NCT02764788|Experimental|Specific auriculotherapy|Auriculotherapy on specific points with needles
2519803|NCT02764788|Sham Comparator|Non-specific auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with needles
2519805|NCT02764788|Placebo Comparator|Seed auriculotherapy|Auriculotherapy on non-specific auriculotherapy points with seeds
3198652|NCT00872690||Group 1|OEF/OIF veterans with polytrauma who have been referred by the Tampa VA Polytrauma Rehabilitation Center (PRC) to the VA VR&E Regional Office in St. Petersburg, Florida for Chapter 31 (IL) services.
3198653|NCT00872690||Group 2|Caregivers of the veterans who enroll in the study
2519983|NCT02763410||control group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery, with no renal failure at the 48th hour after surgery, based on the RIFLE classification, and regardless of the transfusion received after the H6 assessment.
2519991|NCT02763410||Renal failure group|Patients who received between 1 and 5 PRBCs between incision and the 6th hour post-surgery and who developed renal failure before H48 with no new transfusion prior to diagnosis of kidney failure.
3198654|NCT00872703||1|
3198655|NCT00872703||2|
3198656|NCT00872716|Experimental|Quetiapine XR|100 mg single-dose Quetiapine XR
3198657|NCT00872716|Placebo Comparator|Placebo|
2520175|NCT02761928||Epidural|Positive response (>50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)
2520192|NCT02761928||Selective nerve root block|Positive response (>50% pain relief) to selective nerve root block
2520202|NCT02761928||Facet injection|Positive response (>50% pain relief) to intra-articular facet injection
2520206|NCT02761928||Medial branch block|Positive response (>50% pain relief) to median branch nerve block
2520208|NCT02761928||Medial branch RFA|Positive response (>50% pain relief) to median branch nerve radiofrequency ablation
2520209|NCT02761928||SIJ injection|Positive response (>50% pain relief) to sacroiliac joint injection
2520210|NCT02761928||Lateral branch block|Positive response (>50% pain relief) to lateral branch nerve block for SIJ
2520211|NCT02761928||Greater trochanter injection|Positive response (>50% pain relief) to greater trochanteric bursa injection
2520212|NCT02761928||Piriformis injection|Positive response (>50% pain relief) to piriformis injection
2520213|NCT02761928||Trigger point injection|Positive response (>50% pain relief) to trigger point injection
2520263|NCT02761512|Experimental|CJ-12420 50 mg QD|CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks
2520268|NCT02761512|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
2520272|NCT02761512|Active Comparator|Lansoprazole 30 mg QD|Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks
2520314|NCT02761174|Active Comparator|Brimonidine (Mirvaso cream)|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face (control) and 0.5 g of brimonidine (Mirvaso cream) to the randomized side of the face.
2520316|NCT02761174|Other|IPL+air-cooling|This is a split-face study, and patients are thereby their own control. Patients receive IPL-treatment and air-cooling to the whole face and IPL+air-cooling (control) are thereby compared to IPL+air-cooling+brimonidine (Mirvaso cream).
3198658|NCT00872742|Experimental|1|Participants will receive acceptance enhanced behavior therapy (AEBT) for trichotillomania (TTM).
3198659|NCT00872742|Active Comparator|2|Participants will receive psychoeducation and supportive therapy (PST) for TTM.
3198660|NCT00872755|Active Comparator|Nissen|Laparoscopic Nissen Fundoplication
3198661|NCT00872755|Active Comparator|Gastropexy|Procedure/Surgery Laparoscopic Nissen Fundoplication combined with posterior gastropexy
3198662|NCT00872781|Experimental|1|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc (a subsidiary of Ranbaxy pharmaceuticals Inc)
3198663|NCT00872781|Active Comparator|2|ACCURETICTM tablets (containing fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg)
3198664|NCT00872794|Other|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
2519486|NCT02766790|Active Comparator|TA-65MD 250 units Dose|TA-65MD 250 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2519488|NCT02766790|Active Comparator|TA-65MD 500 units Dose|TA-65MD 500 units capsule and placebo capsule; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2519490|NCT02766790|Active Comparator|TA-65MD 250 units a.m. and p.m. Dose|Two TA-65MD 250 units capsules; one of them will be taken in the a.m. and one of them will be taken in the p.m.
2520409|NCT02760693||bipolar patients|unselected admissions of bipolar patients
2520473|NCT02760381|Experimental|Routine colonoscopy Cohort|Patients receiving routine colonoscopy receive the intervention: NBI + Acetic Acid (AA)
2520549|NCT02760030|Experimental|Treatment (fulvestrant, palbociclib)|Patients receive fulvestrant IM on days 1 and 15. Patients also receive palbociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2520613|NCT02759510|Active Comparator|phenylephrine|phenylejphrine (one bolus for 40 ug/ml)
2520614|NCT02759510|Experimental|norepinephrine|norepinephrine (one bolus for 2 ug/ml)
2520676|NCT02759159|Experimental|AD-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on AD patients"
2520683|NCT02759159|Sham Comparator|AD-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on AD patients"
2520687|NCT02759159|Experimental|Mild Cognitive Impairment(MCI)-true acupuncture|"True acupuncture at the four-gateacupoints will be administered on MCI patients"
2520696|NCT02759159|Sham Comparator|MCI-sham acupuncture|"Sham acupuncture at the four-gateacupoints will be administered on MCI patients"
2520784|NCT02758691|Experimental|Intranasal Insulin|Healthy participants will self-administer 20 IU of Humulin® R U-100 with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
2520789|NCT02758691|Placebo Comparator|Saline Placebo|Healthy participants will self-administer a saline solution with the Precision Olfactory Delivery (POD) delivery device and complete a memory task in an fMRI (functional Magnetic Resonance Imaging) scanner.
2520842|NCT02758288||New Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a new treatment protocol, prospective data collection approach
2520847|NCT02758288||Standard Protocol to treat BK viremia or BKVAN|Adult kidney recipients who are determined to have BK viremia with a BK PCR viral load over 500 copy post-transplant treated with a traditional standard of care protocol, retrospective data collection approach
2520967|NCT02757469|Experimental|Yasmin|Pregnancies will occur while the women are taking oral contraceptives (Yasmin). The possible role of exogenous estrogens in sensitizing the granulosa cells to the effect of follicle-stimulating hormone and thereby inducing ovulation and conception in some women with premature ovarian failure is examined.
3198665|NCT00872807|Experimental|Group intervention|Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
2521093|NCT02756494||Ischemic Stroke in Young Adults|Patients between 18 and 45 years of age with a first ever ischaemic stroke are eligible for this study from the Department of Beijing Chaoyang Hospital between January 1, 2016 and December 31, 2016. All patients were defined as a sudden loss of global or focal cerebral function that persisted with a probable vascular cause for 24h and confirmed by brain CT or MRI.
2521094|NCT02756494||matched control subjects|The age-, sex-, and time of enrollment-matched control cohort was randomly identified after eliminating the study subjects and those who had been given a diagnosis of any stroke at any time.
2521139|NCT02756234||Qualifying CTP patients|A convenience sample of all qualifying patients for CTP procedure
2521202|NCT02755857|Experimental|Lozanoc|65 mg, capsules, at least 2 capsules twice a day
2521265|NCT02755194||Breastfeeding women on the study medications|The study population consists of lactating/breastfeeding women over the age of 18, who are able to communicate in English and are taking one or more of the study drugs (Infliximab, Adalimumab, Golimumab, Certolizumab, Etanercept, Methotrexate, Ezetimibe, Bupropion, Citalopram, Venlafaxine)
2521324|NCT02754830|Experimental|LY3303560|Single IV infusion or SC injection of LY3303560 on Day 1
2521326|NCT02754830|Placebo Comparator|Saline Solution|Single IV infusion of saline solution to match LY3303560 on Day 1
2521354|NCT02754479|Experimental|Laser treatments|Each subject will receive a combination of 532 nm KTP and/or 1064 nm Nd:YAG laser treatment
2521398|NCT02754336|Active Comparator|Cogmed Robomemo, working memory training|Robomemo working memory training, 25 sessions with 8 verbal and non-verbal tasks per session.
2521406|NCT02754336|Active Comparator|Othmer, neurofeedback|Othmer method neurofeedback, 25 sessions a 30 minutes.
2521464|NCT02753959|Experimental|Acute Intervention|Patients will need to be Clinically stable patients with established neuromuscular disease with clinical secretions or cough PEF <270 and history of chest infections. Patients are required to be stable for the preceding 4 weeks with no changes to medications or ventilator settings.
2521465|NCT02753959|Experimental|Stable Intervention|Patients with established neuromuscular disease admitted to either the Lane Fox Respiratory Unit or Critical Care at St Thomas' Hospital with acute respiratory deteriorations and with the need for respiratory physiotherapy for secretion management.
2519492|NCT02766595|Other|hyperventilation|Non-drug: performing hyperventilation while sitting up during routine EEG
2519591|NCT02765932|Active Comparator|Placebo Therapy|Dummy Movements
2519599|NCT02765932|Experimental|Psychosensory Therapy|Will involve touch technique, havening.
3198666|NCT00872807|Active Comparator|Individual intervention|Lifestyle counseling for each separate family practiced by single health professionals both in hospital and municipality. A more conventional model.
3198667|NCT00872820|Active Comparator|1|Participants will receive standard cognitive behavioral therapy.
2519797|NCT02764541|Experimental|Arm A Tamoxifen followed by Endocrine Therapy|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
2519802|NCT02764541|Experimental|Arm B Letrozole Followed By Endocrine Therapy|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy for 24 weeks.
2519806|NCT02764541|Experimental|Tamoxifen Followed By Endocrine Therapy and Palbociclib|Tamoxifen is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
2519809|NCT02764541|Experimental|Letrozole Followed By Endocrine Therapy and Palbociclib|Letrozole is given in the Window of Treatment phase for 2 weeks followed by Endocrine Therapy in combination with Palbociclib for 24 weeks.
2519913|NCT02763891|Experimental|Intervention group|Subjects submitted to a 30-minute session of suspension and tilting exercises on the Chordata equipment (PI: 0804871-1 and BR 10 2012 009901-2) twice a week for eight weeks.
2519918|NCT02763891|Sham Comparator|Control group|Subjects submitted to a 30-minute passive muscle stretching session twice a week for eight weeks.
2519955|NCT02763332|Experimental|Upper trunk group (UTG)|In the UTG, the bandage was applied over the superior fibbers of the trapezious and levator scapulae muscle using a strip in a 'Y' shape. The individuals were asked to remain in an upright sitting position and the base of the strip was attached to the skin beyond the acromion without any tension. Later, we placed the two straps of the bandage with a range of tension from 15 to 25%. The main goal of this shape is achieve muscular relaxation of the trapezius, scapula levator and supraspinatus.
2519958|NCT02763332|Active Comparator|Global trunk group (GTG)|In the GTG the bandage was applied parallel to the paravertebral muscles in a 'C' shape. The individuals were sit in the same position with the head in the neutral position. The strip was pasted with approximately 25% of tension all over the paravertebral musculature. The main goal was procuring a global mechanical correction of the superior part of the trunk.
2519975|NCT02763137|Active Comparator|Standard LD/CD|Standard LD/CD administered at patient's usual dose and frequency
2519985|NCT02763137|Experimental|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of LD/CD at a dose equivalent to the patient's regular dose of standard LD/CD
2520059|NCT02762890|Experimental|Deep neuromuscular blockade|Rocuronium will be administered continuously to achieve post-tetanic count 1-2 during surgery.
2520065|NCT02762890|Active Comparator|Moderate neuromuscular blockade|Rocuronium will be administered continuously to achieve Train-of-four 1-2 during surgery.
2520152|NCT02762474|Experimental|nab-paclitaxel group|Weekly Regimens of paclitaxel Plus Cispaltin Combined With Concurrent IMRT
2520183|NCT02762058|Experimental|Experimental Group|Patients receiving Virtual Reality Mirror Therapy
2520194|NCT02762058|Experimental|Control Group|Patients receiving Traditional Mirror Therapy
2520287|NCT02761590|Experimental|Circuit training protocol|"The CT protocol will be held in three sessions per week for 14 weeks. The volume of work is defined by the training section of time and intensity of effort by the heart rate response to exercise.~The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. that concludes in favor of the organization of training adapted to the reality of the public to be trained."
2520294|NCT02761590|Active Comparator|Strength training protocol|"The strength training protocol was performed in three sessions per week for 14 weeks and divided into three levels.~The initial load set for each exercise was based on the one repetition maximum test (1 RM). Strengthening exercises were performed in two sets of 15 repetitions, using 25% 1RM for hip adductors and abductors, and 50% 1RM for the quadriceps and hamstrings, using ankle weights. Exercises for the trunk were performed in 3 10-second series, increasing the duration when participants were able."
2520301|NCT02761590|No Intervention|Educational Protocol|In order to provide care, social interaction, and health education, an educational protocol was conducted. This protocol consisted in interactive presentations of 60 minutes, twice a month for 14 weeks, totaling 7 meetings. The topics addressed pathophysiology of osteoarthritis, and American College of Rheumatology (ACR) recommendations on nutrition, posture, and lifestyle.
2520311|NCT02761161|No Intervention|Treatment as usual|TAU: medicine according to algorithm, manual-based cognitive therapy, psychoeducation
2520315|NCT02761161|Active Comparator|Mianserin|10-30 mg of mianserin af sleep enhancing
2520318|NCT02761161|Active Comparator|Imagery Rehearsal Therapy|Therapy focusing on nightmares
2520321|NCT02761161|Active Comparator|mianserin and Imagery Rehearsal Therapy|Both mianserin and IRT
2520388|NCT02760784||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2520391|NCT02760784||Control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2520484|NCT02760498|Experimental|Group 1|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 2 weeks.
2520487|NCT02760498|Experimental|Group 2|Patients with unresectable locally advanced CSCC. Cemiplimab administered intravenously every 2 weeks.
2520491|NCT02760498|Experimental|Group 3|Patients with metastatic CSCC: to distant sites or lymph nodes. Cemiplimab administered intravenously every 3 weeks.
2519528|NCT02766270|Experimental|Chemoradiotherapy with Temozolomide|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy) and receive temozolomide PO QD (75 mg/m2/day, 7 days/week) for up to 7 weeks. Beginning 4 weeks after completion of chemotherapy and radiation therapy, patients receive temozolomide PO QD on days 1-5 (150-200 mg/m2). Treatment with temozolomide repeats every 28 days for up to 12 courses
2519530|NCT02766270|Active Comparator|Radiotherapy alone|Patients undergo intensity-modulated radiation therapy or 3-dimensional conformal radiation therapy 5 days a week for 6 weeks (for a total of 60 Gy)
2519596|NCT02765880|Experimental|Healthy volunteer|
2519604|NCT02765880|Experimental|Patients with schizophrenia|
2519612|NCT02765880|Experimental|Patient with bipolar disorder|
2519656|NCT02765425|Experimental|Training Group|Subjects will receive the same outcome measures at baseline, after 3 months training and 6 months later. Intervention will comprise of three sessions seated at the AMES device. Each training session will include 15 min of training of each ankle. Training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
2519660|NCT02765425|No Intervention|Control Group|Subjects will receive no intervention. Subjects will receive all outcome measures at baseline and at 3 months post enrollment. Subjects will also receive a fall-incidence reporting form 9 months post enrollment. No other intervention - i.e. no treatment - is given.
3198668|NCT00872820|Experimental|2|Participants will receive acceptance- and commitment-based behavioral therapy.
3198669|NCT00872820|No Intervention|3|Participants will be placed on a waitlist for 3 months before being offered treatment.
3198670|NCT00872859|Experimental|1|Dermamatrix with radiation
3198671|NCT00872859|Experimental|2|Dermamatrix without radiation
3198672|NCT00872859|Experimental|3|Alloderm with radiation
2519856|NCT02764060|Experimental|Tongue scraper|In this group the subjects are explained how to use a plastic loop-formed tongue cleaner (Halita® tongue cleaner (Dentaid, Spain)) to clean their tongues.
2519857|NCT02764060|Experimental|Toothbrush|In this group the subjects are explained how to use a toothbrush (Oral-B® Indicator® medium tooth brush) to clean their tongues.
2519885|NCT02763722|Experimental|Emollient spray product|"Study design~A 3 visits are planned:~0 week (first visit) 2nd week (second visit) 4th week (third visit)~B. During each visit will be made:~The clinical examination (including an assessment of any adverse effects)~Evaluation of transepidermal water loss (TEWL) and capacitance of outer areas of the stratum corneum as an indirect assessment of skin hydration,~fill out questionnaires CDLQI (The Children's Dermatology Life Quality Index)~will assess VAS (visual analogue scale)~C. All patients will be instructed to use emollients spray the entire surface of the skin at least twice daily for four weeks."
2519952|NCT02763449|Experimental|Sedentary|Individuals will reduce their physical activity level for 14-days
2519956|NCT02763449|Experimental|Active|Individuals will increase their physical activity level for 14-days
2519974|NCT02763202|No Intervention|Usual Care Group|Participants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
2519982|NCT02763202|Experimental|CHS-TS Group|Participants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
2520023|NCT02763007|Experimental|alogliptin+pioglitazone|A group who treat with alogliptin+pioglitazone: The Combination of Alogliptin 25 mg and pioglitazone 30 mg daily add on metformin for 28 week as extension and followed by 2 years of observation
2520026|NCT02763007|Active Comparator|alogliptin|A group who treat with alogliptin: Alogliptin 25 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
2520029|NCT02763007|Active Comparator|pioglitazone|A group who treat with pioglitazone: Pioglitazone 30 mg daily add on metformin for for 28 week as extension and followed by 2 years of observation
2520075|NCT02762656|Active Comparator|Lidocaine|Patients will receive Lidocaine drip during spine surgery
2520079|NCT02762656|Placebo Comparator|Placebo|Patients will receive placebo during spine surgery
2520190|NCT02762201|Experimental|PASI|PASI dental prosthesis delivery
2520200|NCT02762201|Active Comparator|PAC|PAC dental prosthesis delivery
2520286|NCT02761681|Experimental|ACT-CL Web-based guided self-help|Behavioral: Experimental Web-based guided self-help Program This intervention will involve counselor training and student use of the developed program. Counselors will complete training and invite students to participate, and will monitor and guide students in completing the series of 8 web-based sessions based on Acceptance and Commitment Therapy.
2520291|NCT02761681|Active Comparator|Control Web-based guided self-help|Behavioral: Control Web-based guided self-help program This intervention will be created for the current study. It will involve psycho-education on how students might get the most out of counseling. Counselors will go through the psycho-education session before inviting students to participate.
2520356|NCT02761187||Relapsed/refractory (R/R) MM|Patients who have received 1 to 3 prior lines of therapy
2520358|NCT02761187||Newly diagnosed (ND) MM|Patients within 3 months from initiation of treatment
2520529|NCT02760134|Other|SMP with F14 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F14 suction-evacuation sheath.
2520531|NCT02760134|Other|SMP with F12 sheath|Patients undergo Super-Mini Percutaneous Nephrolithotomy with F12 suction-evacuation sheath.
2520578|NCT02759770||ARDS|ARDS patients after cardiac surgery
2520579|NCT02759770||non-ARDS|non-ARDS patients after cardiac surgery
2520580|NCT02759770||propective group|patients of cardiac surgery including ARDS and non-ARDS patients
3198673|NCT00872859|Experimental|4|Alloderm without radiation
3198674|NCT00872872|Active Comparator|AZT/3TC 1 week after delivery|AZT/3TC 1week after delivery
3198675|NCT00872872|Experimental|AZT/3TC 2 weeks after delivery|AZT/3TC 2 weeks after delivery
3198676|NCT00872885|Experimental|A|Dose 1
2519546|NCT02766322||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight.
2519548|NCT02766322||Sleeve gastrectomy longitudinal|Morbidly obese subjects undergoing sleeve gastrectomy surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion before surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated. These four testing sessions will be repeated when subjects loose ~ 16% of their presurgery body weight..
2519550|NCT02766322||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2519551|NCT02766322||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2519555|NCT02766322||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy surgery 1-5 years ago. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2519559|NCT02766322||Non-surgical group|Subjects who are age and body mass index equivalent to gastric bypass (cross-sectional) and Sleeve gastrectomy (cross-sectional) but did not undergo any type of bariatric surgery. Subjects will be assessed in four testing sessions about 1 week apart in a randomized cross-over fashion after surgery. During the first two sessions, their response to alcohol or nonalcoholic (placebo) beverage will be evaluated. During testing sessions three and four, their response to alcohol administered intravenously will be evaluated.
2519623|NCT02765724|Experimental|Group 1|Patients with mild hepatic impairment
2519625|NCT02765724|Experimental|Group 2|Patients with moderate hepatic impairment
2519627|NCT02765724|Experimental|Group 3|Patients with severe hepatic impairment
2519628|NCT02765724|Experimental|Group 4|Healthy subjects
2519680|NCT02765334|Experimental|nBETTER and Conventional Therapy|Intervention: nBetter therapy
2519712|NCT02765022|Experimental|Clip|Clip closure of mucosal defects after endoscopic mucosal resection.
2519713|NCT02765022|Active Comparator|No clip|No clip closure of mucosal defects after endoscopic mucosal resection. Observation.
3165583|NCT00514800|Active Comparator|Control|
2519842|NCT02764086|Other|Trial Cohort Description|"Escalated dose of min 65Gy to the iGTV, with 60Gy to PTV delivered to successive cohorts of patients(pts) until the MTD oesophageal dose is determined. Toxicity will be analysed 2 months post 6pts treated in a cohort.~If: ≤2pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose (an additional +5Gy at each escalation upto max 75Gy)/3 of 6pts have ≥G3 toxicity, a further 6pts will be recruited into that dose level/≥4pts have ≥G3 toxicity, the MTD is fixed at dose level of previous cohort~Cohort is extended to 12pts:~If: ≤4pts have ≥G3 toxicity, next cohort will be enrolled & receive escalated dose/5 of 12pts have ≥G3 toxicity, the MTD is fixed at that dose level & recruitment continues up to 24pts/≥6pts have ≥G3 toxicity, the MTD is fixed at the dose level of previous cohort.~Once the max dose cohort is established, recruiting will continue at that dose until 24pts. Concurrent & neo-adjuvant/no chemotherapy arms will be escalated independently of each other"
2519900|NCT02763839|Experimental|BIA 3-202 50 mg|BIA 3-202 single-dose plus 1 tablet of Sinemet 25/100 BIA 3-202 50 mg: 5 tablets of 10 mg. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2519914|NCT02763839|Experimental|BIA 3-202 100 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 100 mg: 1 tablet of 100 mg + 4 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2519921|NCT02763839|Experimental|BIA 3-202 200 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 200 mg: 2 tablet of 100 mg + 3 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water.
2519926|NCT02763839|Experimental|BIA 3-202 300 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 300 mg: 3 tablet of 100 mg + 2 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2519930|NCT02763839|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Sinemet 25/100. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
3198677|NCT00872885|Experimental|B|Dose 2
3198678|NCT00872885|Experimental|C|Dose 3
2520043|NCT02762760|Experimental|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
3198679|NCT00872885|Active Comparator|D|Morphine
3165584|NCT00514839|No Intervention|C|Control group receiving a booklet on health behavior
3165585|NCT00514839|Experimental|MI|Counselling based on Motivational Interviewing plus individualized feedback
3165586|NCT00514865|Experimental|E1|1-2 mg of ONO-2333
3165587|NCT00514865|Experimental|E2|5-10 mg of ONO-2333
3165588|NCT00514865|Placebo Comparator|P|placebo comparator
3165589|NCT00514878||1|Adult same-day outpatients scheduled for general anesthesia
3165590|NCT00514891|Active Comparator|1|Vitamin A supplementation
3165591|NCT00514891|Placebo Comparator|2|Placebo
3198680|NCT00872885|Placebo Comparator|E|Placebo
2519585|NCT02765711||the use of ticagrelor in hospital|
2519643|NCT02765633|Experimental|Cangrelor|Cangrelor in up to four (4) dose cohorts consisting of a minimum of five participants in each cohort. One cohort of five participants will be enrolled at a time. Cohort 1 subjects will receive Cangrelor at 0.5 mcg/kg/min. Cohort 2 subjects will receive Cangrelor at 0.25 mcg/kg/min. Subsequent cohort dosing decisions are made at the completion of enrollment in each cohort.
2519707|NCT02765282|Experimental|DBS-Expert Programming First|These patients will be undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) first and then be programmed by a clinician within five days.
2519708|NCT02765282|Experimental|Traditional Programming First|These patients will be programmed by a clinician first and then undergo algorithm based programming using Kinesia-based assessment (DBS-Expert) within five days.
2519747|NCT02764853|Experimental|STEP-AD (10 sessions)|"Participants in this arm will receive the manualized 10 session behavioral medicine intervention titled Striving Towards EmPowerment and Medication Adherence."
2519748|NCT02764853|Active Comparator|Enhanced Treatment as Usual (E-TAU)|Participants in this arm will receive 1 session of Lifesteps and appropriate services and referrals as needed, followed by bi-weekly check-ins with a study research assistant.
2519769|NCT02764528|No Intervention|Control|Women will receive standard antenatal care but will not receive any additional handwashing promotion, soap, or handwashing device during their enrollment. At the end of data collection, handwashing with soap will be recommended to participants in the control arm and their families.
2519771|NCT02764528|Experimental|Clinic|Handwashing promotion from healthcare workers at antenatal care clinic.
2519772|NCT02764528|Experimental|Clinic + home|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits.
2519783|NCT02764528|Experimental|Clinic + home + handwashing device|Handwashing promotion from healthcare workers at antenatal care clinic and from community health volunteers at home visits with provision of one handwashing device.
3198681|NCT00872911|Experimental|Nutritional supplement|
3198682|NCT00872911|Experimental|Placebo + Exercise|
2519891|NCT02763696||normal women|Composition of Viginal flora of Child-Bearing women in normal woman
2519895|NCT02763696||vaginitis women|Women of childbearing age with vaginitis
2519954|NCT02763436|No Intervention|"Group immediate cord clamping (ICC)"|The cord will be clamped within the first minute after birth, afterwards the newborn will be placed on the mothers chest/abdomen. This corresponds to the present routine approach in Graz.
2519957|NCT02763436|Active Comparator|"Group physiological based cord clamping (PBCC)"|"The newborn will be placed on mother's chest/abdomen with intact cord. After the newborn has established stable breathing efforts (continuous regular breathing pattern and SpO2 values >25th percentile from Dawson et al reference range for oxygen saturation -minute 2>58%, minute 3>67%, minute 4>76%) the cord is clamped. This will need 2 - 4 minutes."
2520022|NCT02763059|Active Comparator|Group 1- Received Ibuprofen (N=44)|
2520025|NCT02763059|Active Comparator|Group 2- Received Dexamethasone (N=44)|
2520028|NCT02763059|Placebo Comparator|Group 3 - Received Placebo (N=44)|
2520070|NCT02762682||CASES OF ITS AND PRE ITS|"Either sex, age less than 3 years~Clinical diagnosis of Infantile Tremor Syndrome as evidenced by the following features:~[Developmental delay or regression WITH history of exclusive or predominant breast feeding WITH two or more of the following; skin pigmentation, hair depigmentation, tremors] ITS:1 and 2 plus tremors PreITS:1 and 2 without tremors"
2520073|NCT02762682||HEALTHY CONTROLS|Developmentally normal child not suffering from any acute or chronic neurological illness
2520140|NCT02762487|Experimental|LINX arm|Previous LSG patient will be treated with the LINX device and serve as their own control
2520191|NCT02762149|Active Comparator|0.1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
2520199|NCT02762149|Active Comparator|1ms pulse width|The nerve stimulator will be connected to the epidural catheter through an adapter, which will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle. All patients will have the trans-catheter electric stimulation test (TCEST) performed with both a 1 ms pulse width and 0.1 ms pulse width and the order of administration will be randomized.
3198683|NCT00872911|Experimental|Nutritional Supplement + Exercise|
3198684|NCT00872911|No Intervention|Placebo|
2520414|NCT02760680|Placebo Comparator|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
2520452|NCT02760303|Experimental|Cognitive Behavioral Therapy|Hains' adaptation of cognitive behavioral therapy for adolescents and young adults with type 1 diabetes
2520454|NCT02760303|Experimental|Mindfulness Based Stress Reduction|Sabinga's adaptation of Mindfulness Based Stress Reduction for adolescents and young adults with type 1 diabetes
2520455|NCT02760303|Active Comparator|Diabetes Support and Education|Investigator developed peer support group and diabetes education
3198685|NCT00872924|Experimental|1|sumatriptan succinate 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan) of OHM laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA).
3198686|NCT00872924|Active Comparator|2|IMITREX® 100 mg tablets (containing 140 mg of sumatriptan succinate equivalent to 100 mg sumatriptan)
3198687|NCT00872950|Other|Open label|Open label
3198688|NCT00872963||RABIES VACCINE|Those subjects who received the active comparator
3198689|NCT00872963||RTS,S/AS01E|The subjects who received investigational product
3198690|NCT00872976|Experimental|Cohort #1|
3198691|NCT00872976|Experimental|Cohort #2|
3198692|NCT00873002|Active Comparator|LBH589|This study utilizes a sequential dose-escalation design to define the MTD of LBH589 when combined with standard doses of sorafenib.
3198693|NCT00873028|Experimental|1|
3198694|NCT00873028|No Intervention|2|Those patients assigned to Control were followed by their own physicians, received routine nursing assistance, were visited daily by the one of the investigators (CPM), but were not exposed to any specific respiratory or motor physical intervention.
3198695|NCT00873054||1 ESWL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next the patient will be transferred to a separate room and sound waves will be aimed at the center of the stone until the stone is broken into pieces.
2519872|NCT02764047|Placebo Comparator|Placebo|Placebo capsule
2519877|NCT02764047|Active Comparator|Probiotic|Probiotic capsule
2519887|NCT02763592|Experimental|Lidocaine|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
2519892|NCT02763592|Placebo Comparator|placebo|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo
2519972|NCT02763423|Experimental|umbilical cord mesenchymal stem cell|single- or double-dose intravenous injection of umbilical cord mesenchymal stem cells for the treatment of severe type 1 diabetes patients
2520021|NCT02763020|Placebo Comparator|Food bar without fruit|snack bar without fruit
2520024|NCT02763020|Experimental|Food bar with cranberry extract (0.5%)|Snack bar with cranberry extract (0.5% total weight)
2520027|NCT02763020|Experimental|Food bar with cranberry extract (1.0%)|Snack bar with cranberry extract (1.0% total weight)
2520030|NCT02763020|Experimental|Food bar w/ dried black raspberry (10%)|Snack bar with freeze-dried black raspberry(10% total weight)
2520031|NCT02763020|Experimental|Food bar w/ dried black raspberry (20%)|Snack bar with freeze-dried black raspberry (20% total weight)
3165592|NCT00514982|Other|1/Drug #1|Oral mesalamine will be used as initial therapy in patients who are not taking any medication or have not received any prior treatment for their IBD. Dosing will begin at 2.4 g PO QD and will be increased to 4.8 g QD within 2 weeks. Topical mesalamine (enema 4 g PR HS/BID or suppository 1 g PR HS/BID) may be added for patients with inflammation that is limited to the rectum (proctitis) or who have prominent complaints of urgency, incomplete evacuation or rectal bleeding.
3165593|NCT00514982|Other|1/Drug#2|Add oral corticosteroids (prednisone) to mesalamine. The standard induction dose will be 40 mg/day. After 1 week of therapy, if the total SCCAI score has decreased by greater than or equal to 2 points the patient will continue on another week of therapy. If the SCCAI has not decreased by greater than or equal to 2 points (indicative of a reduction in symptoms) at one week, then the dose will be increased to 60 mg/day. Patients on either dosage will have another SCCAI assessment done a week later (2 weeks after beginning corticosteroids), and if they are found to be in remission (SCCAI less than or equal to 2), a steroid-tapering schedule will be initiated.
3165594|NCT00514982|Other|1/Drug#3|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
3165595|NCT00514982|Other|1/Drug#4|Infliximab and 6-MP will be added to patients with a SCCAI greater than 2 at week 8. The first infusion of infliximab (5 mg/kg) will be given during that week. In addition, 6-MP will be initiated at doses of 1.0-1.5 mg/kg PO QD to reduce the incidence of infliximab antibody formation and facilitate steroid tapering (the target dose of 6-MP will be decreased accordingly if patients are found to have low TMPT levels/activity by genotypic or phenotypic testing). Also, steroids will also be rapidly tapered off at this time.
2520176|NCT02762097|Experimental|intervention|All women would undergo saline sonography with normal saline. Women with endometrial polyps who consent to the removal of polyps will be offered polypectomy
2520189|NCT02762097|Placebo Comparator|control|All women would undergo saline sonography with normal saline. Women with endometrial polyps who do not consent to the removal would serve as controls
2520285|NCT02761655|No Intervention|Control Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement.
2520289|NCT02761655|Experimental|Intervention Group|Patients in both experimental and control groups will receive educations on cognitive impairment, dementia, community resources, and related medication as well as health promotion for PWCIs. The teaching material will be derived from the online resources such as Alzheimer Disease International and Taiwan Alzheimer's Disease Association (TADA) and reviewed by the expert panel as well. Written information will be given to both groups (patients and FCGs), which will be suitable to general public and address issues of cognitive impairment and FCG involvement. The intervention group will further receive memory strategies training on encoding and retention, retrieval, as well as execution and monitoring.
2520344|NCT02761239|Other|Cricopharyngeal muscle innervation|The recurrent laryngeal nerve (RLN), vagus nerve, external branch of the superior laryngeal nerve (EBSLN) and pharyngeal plexus were stimulated intraoperatively by the NIM 3.0 Nerve Monitoring System (Medtronic Xomed, Jacksonville, FL, USA). Responses were evaluated by visual observation of the cricopharyngeal muscle and electromyographies via needle electrodes inserted into the cricopharyngeal muscle.
2520470|NCT02760316|Experimental|AZD9567 oral suspension of 10 mg|Participants will receive oral supension of 10 mg dose strength
2519580|NCT02766049|Active Comparator|(b) DC 10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
2519581|NCT02766049|Active Comparator|(c) DC 10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
2519657|NCT02765477||Angiogram Cohort w Acute Coronary Occlusion|Inclusion Criteria: Angiogram Cohort. Patients who present 1) directly through the study site Emergency Department (ED) OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1.Underwent urgent or emergent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to chest pain [CP] and/or shortness of breath [SOB]) AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, a group of patients will be identified who had angiographic evidence of ACO, defined as an acute lesion with TIMI flow 0 or 1 when evaluated by an experienced study-site adjudicator.
2519661|NCT02765477||Non-ACO Angiogram Cohort|Inclusion Criteria: Angiogram Cohort. Each study site will first identify adult patients (age 18 years or older) who presented to the study site 1) directly through the study site ED OR 2) as a transfer or referral patient from the ED of another institution OR 3) as a direct admission to the study site's Catheterization Laboratory by an ambulance service, who also met the following criteria: 1. Underwent coronary angiography during the index presentation for suspected ischemic symptoms (including but not limited to CP and/or SOB AND 2. Had a VPR ECG recorded during the index presentation prior to the angiogram AND 3. Had sufficient troponins to rule in or rule out acute myocardial injury, per the study site's institutional protocol. From this Angiogram Cohort, those who had TIMI-2 or greater flow will be identified for several research questions.
2519666|NCT02765477||Random ED Sample w Paced Rhythm but No AMI|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly select 5 unique encounters for every one 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The primary control group selected from this search will be all patients in this group who do not meet criteria for acute myocardial injury, as defined by 1) all troponins below the 99th percentile or 2) Peak troponin < 3x the upper limit of normal AND no rise and/or fall of > 30%."
2519668|NCT02765477||ED Patients w Paced Rhythm Without AMI excluded|"Each site will select a random sample of all adult patients who present to the ED (or by ambulance directly to the Catheterization Lab) with suspected ischemic symptoms and a VPR ECG.~Each study site will randomly 5 unique encounters for every 1 ACO subject identified by the site. If a study site identifies no ACO subjects, they will randomly select 30 unique encounters.~Study subjects who are included as subjects in the Angiogram Cohort (data set #1, above) and who are also selected as part of the random sample (data set #2) will be identified in REDCap as subjects for analysis in both groups, but their data will be submitted only once.~The secondary control group will include patients in this group in whom Acute MI cannot be excluded because they either have at least 1 troponin > 3x the upper limit of normal or they have at least 1 troponin between 1x and 3x the ULN AND have a rise and/or fall of at least 30%."
2519751|NCT02765126|Active Comparator|Group 1|Diphtheria-tetanus-acellular pertussis vaccine administered day 0, followed by seasonal influenza vaccination four weeks later. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week, 4 weeks, 4 weeks + 24 hours, 5 weeks, 8 weeks and 30 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2519755|NCT02765126|Active Comparator|Group 2|Seasonal influenza vaccine administered on day 0, to be offered DTP vaccine at week 26. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2519757|NCT02765126|Active Comparator|Group 3|Seasonal influenza vaccine and DTP vaccine administered together on day 0. Blood testing to occur day 0 (prior to vaccine administration), 24 hours, 1 week 1, 4 weeks and 26 weeks. Stool samples to be taken at day 0 and 1 week post-vaccination.
2519804|NCT02764463|Other|FRCFPDs|Fiber reenforced Composite Fixed Partial Dentures
2519837|NCT02764281|Experimental|MEDA/Auto-HSCT|Patients will be initially treated with four cycles MEDA chemotherapy, followed by autologous hematopoietic stem cell transplantation (Auto-HSCT).
2519901|NCT02763748|Experimental|Laparoscopic surgery|Laparoscopic endoscopy combined surgery. This is a kind of traditional surgical method.
2519908|NCT02763748|Experimental|laparoscopic and endoscopic|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy .
2519922|NCT02763748|Experimental|Single-arch laparoscopic and endoscopic|Single-arch LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
3165596|NCT00514982|Other|1/Drug#5|Subjects with a SCCAI greater than 2 after 3 doses of infliximab will continue 6-MP, discontinue infliximab infusions and start adalimumab injections approximately 2 weeks after the 3rd dose of infliximab. Induction dosing will consist of a 160 Micro/g subcutaneous injection, followed by 80 Micro/g 2 weeks after.
3165597|NCT00514982|Other|1/Drug#6|Patients who have a SCCAI greater than 2 after 2 doses of adalimumab will continue 6-MP, discontinue adalimumab, and start therapy with tacrolimus 0.01 mg/kg PO BID approximately 2 weeks after the second dose of adalimumab.
3165598|NCT00514995|Experimental|1|
3165599|NCT00515047||Eczema Herpeticum (EH)|Participants with AD who currently have or have had EH
3165600|NCT00515047||Non-EH|Participants with AD who do not have and have never had EH
3165601|NCT00515047||Healthy Controls|Healthy participants without a history of AD
3165602|NCT00515060||Cancer Therapy-Induced Pain|Patients with advanced cancer entering chemotherapy or have reported pain as a result of cancer treatment.
3165603|NCT00515125|Other|Dietary Advice|Dietary Advice
3165604|NCT00515125|Other|Oral Nutritional Supplements|Oral Nutritional Supplements
3165605|NCT00515151|Active Comparator|Oct/Alc|
2519611|NCT02765672|Experimental|Experimental Group|Participants in this group will have the following performed: Institute of Mobility Activity and Participation's clinical battery tests and a simulated driving tests, a Brief Driving Behavior Interview, Propensity for Angry Driving Scale, Clinical Driving Assessment, Community Integration Questionnaire, Fitness-to-Drive Screening Measure(FTDS), and a Satisfaction with Life Questionnaire. Occupational Therapy Driving Intervention (OT-DI) consisting of three x 1 hour sessions to review explicit driving errors, strategies to mitigate errors and receiving feedback from the evaluator after driving the simulator.
2519616|NCT02765672|Active Comparator|Caregiver Control Group|Caregiver control group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
2519619|NCT02765672|Active Comparator|Caregiver Experimental Group|Caregivers of the experimental group will fill out a Fitness-to-Drive Screening Measure (FTDS) questionnaire at baseline and at the end of the study.
2519620|NCT02765672|Active Comparator|On-road driving Group|A subset of 30 Combat Veterans will be drawn from the control group (15 no.) and experimental group (15 no.). This group of Combat Veterans will will undergo an on-road driving test at baseline and month 5
2519621|NCT02765672|Active Comparator|Simulator-drives Evaluation Group|This group will comprise of 30 Combat Veterans who will be drawn outside of the randomized experimental and and control groups participants. This group will only perform simulator driving triggers evaluation
2519697|NCT02765204|Experimental|DS-D-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519700|NCT02765204|Experimental|DS-DG-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519702|NCT02765204|Experimental|D-DG-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519703|NCT02765204|Experimental|D-DS-DG|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519704|NCT02765204|Experimental|DG-D-DS|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519706|NCT02765204|Experimental|DG-DS-D|The arm label indicates the order of the given treatments in this crossover designed study (DS=Dapagliflozin and Saxagliptin, D=Dapagliflozin, DG=Dapagliflozin and Glucose).
2519780|NCT02764632|Active Comparator|Didgital group|After induction of anesthesia, and after ensuring muscle relaxation, NGT will be inserted through the selected nostril and advanced for 12 cm then the NGT was advanced according to study group advancing. In control group; NGT was inserted with patient head flexed. In D group, after feeling the NGT in pharynx, with the head in neutral position,the index finger was used to support the NGT with slight direction towards the left side. This will prevent tube kinking at this point in front of the resistance offered by the inflated tube cuff or arytenoids cartilage. Also, this digital support reinforces the tube at the area weakened by its openings
2519787|NCT02764632|No Intervention|Control group|
2519839|NCT02764411|Experimental|Onreltea ( Brimonidine)|All the patients enrolled in the study will apply Onreltea ( Brimonidine 0.33%) gel on the affected skin area for 12 weeks (from Day 0 to Week 12 visit).
3165606|NCT00515151|Active Comparator|Alc|
2519992|NCT02763371|Experimental|Dietary: high GI lunch|High GI-rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
2519994|NCT02763371|Experimental|Dietary: low GI lunch|Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
2520167|NCT02762227|Experimental|gallbladder polyps patients|"All patients with a gallbladder polypoid lesion visited our department, diagnosed by conventional transabdominal US, were enrolled in this study.~Of these patients, we excluded: (1) gallbladder polyp with a diameter less than 10 mm. (2) lesions highly suspected to be cancer due to visible metastasis. (3) allergy to contrast agents and cannot received CT or CEUS examination. (4) women in pregnancy or lactation.~All patients received transabdominal US, abdominal high resolution CT and contrast-enhanced ultrasonography (CEUS) before the cholecystectomy."
2520181|NCT02761889|Experimental|IGRT 45 Gy in 5 fractions of 9 Gy|Patients will be treated using volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. Patients will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
2520282|NCT02761603|Active Comparator|Healthy Aging Practice-centered Instruction (HAPI)|24 hours of group instruction in which experts present on a variety of health-related topics followed by class discussion, goal-setting, and goal review. Themes will include: sleep, nutrition, mental health, social support, bone-health, diabetes prevention, cognitive wellness, and resilience.
2520295|NCT02761603|Experimental|Tai Chi (CHI)|24 hours of group instruction in 8 meditative Tai Chi movements.
2520457|NCT02760394|Active Comparator|Treated group|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
2520459|NCT02760394|Other|Control group|Following 2 months of follow up the group will be crossed over to receive the same treatment as the treated group
2520670|NCT02759107|Placebo Comparator|Placebo (Part B)|Placebo administered SC once weekly for four weeks in healthy participants.
3165607|NCT00515164|Experimental|Group 1|Treatment will be administered in 2 treatment sessions.
3165608|NCT00515164|Experimental|Group 2|Treatment will be administered in a single treatment session.
3165609|NCT00515190|Active Comparator|A|(continuous):S-1 plus oxalipatin will be continued until disease progression, unacceptable toxicity or consent withdrawal.
3165610|NCT00515190|Active Comparator|B|(intermittent arm): Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles.
3165611|NCT00515229|Active Comparator|1|Verum 1: Each individual capsule has a filling volume of 25 mg amitriptyline, given once an day in the evening over 28 days
2519631|NCT02765802|Experimental|Lambda 180 μg|Lambda 180 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
2519633|NCT02765802|Experimental|Lambda 120 μg|Lambda 120 μg once weekly, administered by subcutaneous (SC) injection, for a total of 48 weeks.
2519652|NCT02765360|Experimental|Treatment|Each patient will be assigned to Continuous Positive Airway Pressure (CPAP), Pressure Support Ventilation (PSV) and Pressure Control Ventilation (PCV) modes in a random order with a 10 minute washout period modes.
2519709|NCT02765178||Patients with Tourette Syndrome|The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
2519710|NCT02765178||Patients with Diabetes type 1|The primary caregiver will be asked to fill the Children's motivation Scale. Demographic data will also be collected for each study patient.
2519750|NCT02764840|Experimental|experimental group isokinetic dynamometer (GEDI)|Isokinetic Biodex System Pro 4
2519754|NCT02764840|Experimental|experimental group elastic tube (GETE)|elastic tube brand LEMGRUBER 203
2519792|NCT02764554||Lenvatinib 4 milligram (mg) and 10 mg capsule|Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.
2519840|NCT02764099|Experimental|Life Skills Training|"All youth who consent to participate in the proposed study will 1) complete the youth peer court sanction delivered by the jury of peers (e.g., apologies or essays, restitution, curfew and travel restrictions, counseling, etc.), which will constitute treatment as usual; and 2) complete pre, post, and six-month follow-up surveys. Those randomized to the intervention condition (n=280) will participate in the LST program concurrently during the weeks when they serve as peer court jurors."
2519894|NCT02763878|Experimental|uncut Roux-en-Y anastomosis|After distal gastrectomy, duodenal stump closure, side to side anastomosis was underwent on the remnant stomach and jejunum,which was 25cm from Treitz ligament. Then underwent side to side anastomosis between jejunum about 35cm distance from gastrojejunostomy and jejunum about 5cm from Triez ligament . close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis by using uncut Closure devices
2519898|NCT02763878|Sham Comparator|Billroth II anastomosis|After distal gastrectomy, duodenal stump closure, the investigators first underwent remnant stomach and upper jejunum side anastomosis. Then choose the jejunum about 25cm from Treitz ligament, premenstrual colon using a disposable cutting closure (or tubular stapling) in the rear wall of the stomach and jejunum anastomosis, common opening was closed with the (barbed wire) hand-stitched. After that, steps were same with the group A.
2519961|NCT02763358|Other|Bites and Steps displayed|All subjects will be assigned to one arm-daily bites and steps displayed on Bite Counter device
2520032|NCT02763085|Experimental|Basic Filling Material|Fillings made with a new dental filling material.
2520083|NCT02762643|Experimental|RT group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2520086|NCT02762643|Experimental|TR group|combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
2520132|NCT02762357||Novosyn® Quick|episiotomy closure using suture material
2520168|NCT02762214|Active Comparator|With Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer using uterine manipulator.
2520169|NCT02762214|Experimental|Without Uterine Manipulator|77 Patients affected by early stage endometrial cancer submitted to elective laparoscopic/robotic hysterectomy for endometrial cancer without support of uterine manipulator.
2520187|NCT02761902||Preschool group|3-6 years old
2520203|NCT02761902||school age group|7-12 years old
2520207|NCT02761902||Adolescence group|13-15 years old
2520275|NCT02761668|Experimental|ParS+Ortho 4W|Orthodontic alignment starts 4 weeks post surgical
2520277|NCT02761668|Active Comparator|ParS+Ortho 6M|Orthodontic alignment starts 6 months post surgical
2520325|NCT02761226|Experimental|Group A (Platform Matched Design)|10 Patients with missing tooth in upper posterior area will receive dental implant (implants with the same abutment diameter)
2520337|NCT02761226|Active Comparator|Group B (intervention - Platform Switching Design)|10 patients with missing tooth in upper posterior area will receive dental implant (implants with smaller diameter abutment)
2520363|NCT02760849|Experimental|Arm I (ISDO)|Patients undergo ISDO.
2520364|NCT02760849|Active Comparator|Arm II (RRSO)|Patients undergo RRSO.
2520437|NCT02760563|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3198696|NCT00873054||2 PCNL|In this procedure,scope will be placed inside bladder and a plastic tube (stent) will be left to drain the kidney on the affected side in a routine manner. Next, a small (1cm) cut will be made in the back and a tube will be placed into the kidney. Through this tube a small camera will be placed inside the kidney and break the stone into many pieces and remove them through the same tube. All fragments that can be seen will be removed. A different plastic tube (drain) will be placed through the cut and into the kidney and left in place for 5-7 days.
3198697|NCT00873067|Active Comparator|ACVP plus roof line|Standard procedure for atrial fibrillation ablation, including pulmonary vein isolation plus roof line ablation. All ablation lines will be tested.
2520650|NCT02759068|Experimental|patients behavior|Behavior (motor reaction) to stimuli (sounds and odors)
2520651|NCT02759068|Active Comparator|healthy volunteers behavior|Behavior (motor reaction) to stimuli (sounds and odors)
2520677|NCT02758938|Experimental|Patient Subjects|Patients that are part of the UW LUTD Program (n=30) will undergo 3 weekly biofeedback sessions each lasting 1 hour. All interactive biofeedback sessions will be conducted by American Family Children's Hospital nurses that are experienced in standard biofeedback techniques. After the patient has completed all of the biofeedback sessions, he/she will complete a feedback form about their satisfaction with the device.
2520727|NCT02758886|No Intervention|Non-treatment|Participants randomized into the No-treatment group silently waited for 10 minutes without engaging in any physical or electronic social interactions.
2519678|NCT02765386|Experimental|Cochlear Implant Recipients|Newly implanted cochlear implant recipients with post-implantation acoustic hearing.
3198698|NCT00873067|Active Comparator|Additional CFAEs ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
2519819|NCT02764177|Experimental|Protein|In this arm the subjects were provided with a PROTEIN drink to consume after exercise. This protein drink contained whey protein isolate that provided 0.3 g/ kg body mass of protein.
2519822|NCT02764177|Experimental|Carbohydrate|In this arm the subjects were provided with a CARBOHYDRATE drink to consume after exercise. This carbohydrate drink was energy matched to the protein drink in the other arm of the experiment.
2519883|NCT02764021|Experimental|1.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
2519884|NCT02764021|Active Comparator|2.|Subjects will be randomly assigned to initially receive 6 weeks of standard antidiabetic dietary treatment or 6 weeks of experimental carbohydrate-restricted dietary treatment, crossing over to the opposite diet from week 6 to 12.
2519947|NCT02763540|Other|Lung cryobiopsy|
2519980|NCT02763241|Experimental|Cleanoze®|"Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
2519988|NCT02763241|Active Comparator|Syringe irrigation|"Nasal irrigation using sterile 0.9% NaCl 250 ml by 20 ml syringe~The patient will be instructed to use this isotonic solution for nasal irrigation daily."
2520052|NCT02762903|Active Comparator|Tenotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with tenotomy technique.
2520056|NCT02762903|Active Comparator|Osteotomy|Subjects will receive shoulder prosthesis for subscapularis repair during TSA with lesser tuberosity osteotomy technique.
2520128|NCT02762422|Experimental|Phlebotomy plus normal saline|Four serial phlebotomy procedures followed by infusion of normal saline
2520130|NCT02762422|Experimental|Phlebotomy plus intravenous iron|Four serial phlebotomy procedures followed by infusion of intravenous iron sucrose
2520131|NCT02762422|Placebo Comparator|Sham Phlebotomy|Four serial sham phlebotomy procedures followed by infusion of normal saline
2520149|NCT02762240|Active Comparator|DHQP 2016|This group consists of general practices allocated to undergo accreditation scheme in 2016.
2520151|NCT02762240|Placebo Comparator|DHQP 2018|This group consists of general practices allocated to undergo accreditation scheme in 2018.
2520179|NCT02762045|Experimental|Low dose Ad5-gag or Placebo|1ml low dose Ad5-gag(2x10^9VP) or Preservation solution at weeks 0 and weeks 4.
2520195|NCT02762045|Experimental|Medium dose Ad5-gag or Placebo|1ml medium dose Ad5-gag(2x10^10VP) or Preservation solution at weeks 0 and weeks 4.
2520204|NCT02762045|Experimental|High dose Ad5-gag or Placebo|1ml high dose Ad5-gag(2x10^11VP) or Preservation solution at weeks 0 and weeks 4.
2520281|NCT02761551|No Intervention|Usual Care|Patients in this group will not receive any reminders for influenza vaccine.
2520290|NCT02761551|Experimental|1 notice|Patients in this group will receive one reminder for influenza vaccine across the 2016 influenza season.
2520300|NCT02761551|Experimental|2 notices|Patients in this group will receive up to two reminders for influenza vaccine across the 2016 season.
2520304|NCT02761551|Experimental|3 notices|Patients in this group will receive up to three reminders for influenza vaccine across the 2016 season.
2520331|NCT02761135||Side-fire|Using side-fire technique during transrectal ultrasound.
2520338|NCT02761135||End-fire|Using end-fire technique during transrectal ultrasound.
2520407|NCT02760966|Experimental|Alcohol 70º|Umbilical cord care will be carried out using alcohol 70º at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
2520408|NCT02760966|Active Comparator|Soap|Umbilical cord care will be carried out using soap at least 3 times a day. Firstly, there must be a proper hand hygiene. Then, with sterile gauzes alcohol will be applied from the abdominal part to the end of the stump.
2520462|NCT02760355|Experimental|Active treatment|Ledipasvir 90 mg/Sofosbuvir 400 mg, one tablet once a day + b.w. dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks
3198699|NCT00873132||Data Collection|Collect data both retrospectively and prospectively on subjects seen at the Preston Robert Tisch Brain Tumor Center
3198700|NCT00873145||1|Patients with major bone defects around the elbow.
3198701|NCT00873158|No Intervention|Physical Therapy Group|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
2520637|NCT02759393|Experimental|DEX group|receiving 8-week dexlansoprazole 60 mg per day
2520638|NCT02759393|Active Comparator|Double-dose PPI group|receiving 8-week lansoprazole 30 mg twice daily
2520652|NCT02759029|Active Comparator|Susceptibility-guided group|Drugs according to antimicrobial susceptibility-guided treatment
2520653|NCT02759029|Sham Comparator|triple therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
2520654|NCT02759029|Sham Comparator|concomitant therapy group|Drugs - Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
3198702|NCT00873158|Experimental|Dynasplint Group|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
2520763|NCT02758561|No Intervention|Standard of care|Standard of care
2520767|NCT02758561|Experimental|Workshop|90 minute workshop on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (POP)
2521915|NCT02751177|Experimental|OncoBEAM|KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.
2519685|NCT02765503|Active Comparator|Control|'Standard' external beam radiotherapy to deliver 66Gy in 33 fractions treating with 6 fractions a week.
2519694|NCT02765503|Experimental|HYPNO|The experimental regimen in which patients receive external beam radiotherapy to deliver 55Gy in 20 fractions treating 5 times a week.
2519758|NCT02764866|Experimental|Sleep testing|Enrolled patients with lung cáncer will undergo home sleep testing during their initial oncologic evaluation, prior to treatment.
2519810|NCT02764502|Experimental|Pressure Gauge Manometer|Tuohy needle is introduced into intervertebral space at the level of L3-L4 up to the interspinous ligaments . The needle is advanced slowly using both hands while monitoring the manometer reading and is stopped when the pressure suddenly dropped ( the pressure usually drops by 5-10 mm Hg when the tip of the needle inters the epidural space ).
2519824|NCT02764242|Other|insect sting allergy|"Skin prick tests to local and imported insect sting allergen with different concentration are performed.~sIgE Measurement (to insect and the recombinant venom)"
2519858|NCT02763956|Experimental|Gelstix|The intradiscal insertion of the GelStix™ Nucleus Augmentation Device.
2519859|NCT02763956|Placebo Comparator|Placebo|Intradiscal saline solution (1 mL NaCl 0.9%) injection.
2519943|NCT02763618|Active Comparator|Group A: Theta/beta ratio Neurofeedback|"In this condition, participants will receive three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
2519945|NCT02763618|Active Comparator|Group B: Theta/beta ratio Neurofeedback|"In this condition, participants will receive nine baseline sessions and continue with eight theta/beta ratio Neurofeedback sessions.~Theta beta ratio Neurofeedback signal will be used to simultaneously down-train the EEG theta frequency band and up-train the beta frequency band. Three baseline sessions and continue with 14 theta/beta ratio Neurofeedback sessions."
2519946|NCT02763618|Placebo Comparator|Group C: Placebo Neurofeedback training|Three baseline sessions and continue with 14 placebo training sessions. The placebo training will be a previously recorded Neurofeedback session of a participant in group A (receiving 14 real Neurofeedback sessions). Before the participants in group C (placebo trainings) start, they will be matched to a participant in group A, and receive the exact same (prerecorded) feedback per session of their matched participant. In this way, participants in the placebo training are then made to think that the video and EEG feedback is their own, however they are actually not able to influence the continuation of the video.
2520001|NCT02763228|Experimental|Group 1: Exercise Program|"The exercise in this study will consist of two types of exercise training: resistance training and aerobic exercise. Resistance training is like weight lifting to improve strength and function. Participants will complete resistance training by using resistance machines and free weights. Aerobic exercise is exercise that intends to improve the cardiopulmonary or oxygen/lung and heart systems. It is often referred to as cardio exercise. Treadmill walking, stationary cycling sessions, and/or other exercises will be used for aerobic exercise.~Participants will be instructed in the exercise routine by physical fitness experts and trainers."
2520002|NCT02763228|Active Comparator|Group 2: Support Group|"First 20 Weeks: Participants will take part in a structured Health Education and Support Group sessions once a week.~Last 32 weeks: Participants will be encouraged to take part in any of the Support Group sessions offered regularly on their own schedule."
2520057|NCT02762786|Experimental|Experimental|Participants in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation. The Music Children Foundation is a non-governmental organization established by a group of professional musicians with the objective of transforming children's lives and instils positive values in the entire community through music. It aims to provide free musical training to low-income children and children with chronic diseases, including those with Down's syndrome, mucopolysaccharidoses, skeletal dysplasia and visual impairment.
2520063|NCT02762786|No Intervention|Wait-list control group|Participants in the waitlist control group will receive the same training after the experimental group had completed the intervention.
2520178|NCT02761863||CD74 - VEGF arm|
2520231|NCT02761707||Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Parkinson's Disease. Must be Hoehn and Yahr stage 2 or less with a history of motor symptoms less than two years.
2520235|NCT02761707||Alzheimer's Disease|Non-smokers, ages 18-80, diagnosed with Alzheimer's Disease. Must meet the 2011 National Institute on Aging-Alzheimer's Association and the 1984 National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer's disease and Related Disorders Association criteria for probable AD.
2520236|NCT02761707||Progressive Supranuclear Palsy|Non-smokers, ages 18-80, diagnosed with Progressive Supranuclear Palsy. Must meet the NINDS-SPSP criteria for probable PSP, which requires vertical supranuclear gaze palsy, prominent postural instability, and falls in the first year of onset, as well as a number of other clinical features.
2520238|NCT02761707||Essential Tremor|Non-smokers, ages 18-80, diagnosed with Essential Tremor.
2520240|NCT02761707||Drug-Induced Parkinson's Disease|Non-smokers, ages 18-80, diagnosed with Drug-Induced Parkinson's Disease.
2520242|NCT02761707||Myasthenia Gravis|Non-smokers, ages 18-80, diagnosed with Myasthenia Gravis.
2520245|NCT02761707||Multiple System Atrophy|Non-smokers, ages 18-80, who have been diagnosed with Multiple System Atrophy.
2520247|NCT02761707||Diffuse Lewy Body Disease|Non-smokers, ages 18-80, diagnosed with Diffuse Lewy Body Disease. Must meet the Consensus Criteria for the clinical diagnosis of DLBD.
2520248|NCT02761707||Healthy Controls|Non-smokers, ages 18-80, with no neurodegenerative disease, and no first-degree relatives with a neurodegenerative disease.
2520250|NCT02761707||Spinal Cord Injury|
2520252|NCT02761707||Asymptomatic Relatives|
2520327|NCT02761304|Experimental|ultrasound results given to obstetrical practionnair|
2520342|NCT02761304|Other|ultrasound results shaded to obstetrical practionnair|
2520420|NCT02760914||Coronary heart disease|Patients with coronary heart disease undergoing planned coronary artery bypass surgery
3165612|NCT00515229|Active Comparator|2|Verum 1: Each individual capsule has a filling volume of 50 mg amitriptyline, given once an day in the evening over 28 days
2519737|NCT02764983|Active Comparator|Caregiver Experimental Group|Participants in this group will perform the following: Fitness-to-Drive Screening Measure(FTDS) will be filled out at baseline and again at the end of the study.
2519739|NCT02764983|Other|Focus Group Discussion Interview Guide|This group will comprise of a subset of the control and experimental groups. A focus group with 8 participants (4 with Traumatic Brain Injury/Post Traumatic Stress Disorder and 4 with orthopedic conditions). The focus group will meet once for a discussion which will be guided with a semi-structured interview that will explore the driving behavior prior to war, during war and post-deployment. Responses will be outlined in an intervention matrix.
2519795|NCT02764450|Experimental|Astralis 10 HPM|Polymerization High-power mode: 1300 mW/cm2 for 10 s
2519798|NCT02764450|Experimental|Astralis 10 RM|Polymerisation regular mode: 650 mW/cm2 for 20
2519826|NCT02764255||embryoscope group|cases with embryos continuously monitored by the embryoscope followed by embryo selection based on a multivariable model
2519834|NCT02764255||control group|cases with embyos cultured in the standard incubator and evaluated only by morphology
2519924|NCT02764008|Active Comparator|Low thoracic paravertebral block|T8-T9 Ultrasound guided paravertebral block with 20 ml %0,25 bupivacaine
2519928|NCT02764008|Active Comparator|Peritubal infiltration|Peritubal infiltration with 20 ml %0,25 bupivacaine
2519933|NCT02764008|No Intervention|Control Group|No drug
2519967|NCT02763280|Experimental|Ginseng extract 1g|Ginseng extract 1g
2519970|NCT02763280|Experimental|Ginseng extract 3g|Ginseng extract 3g
2519979|NCT02763280|Placebo Comparator|Placebo|Placebo
2520044|NCT02762851|Experimental|Influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine prior to the influenza season.
2520046|NCT02762851|Placebo Comparator|Placebo vaccine|Participants at high risk for adverse vascular events will be vaccinated with a 0.5 ml dose of sterile saline prior to the influenza season.
2520150|NCT02762292|Experimental|Patients|
3198703|NCT00873171||1. OMT|This procedure consist of Sacral rocking is performed by placing the heel of the practitioner's hand over the sacrum and by using the palpatory skills of an osteopathic physician; rock the sacrum into a position with no restriction. Myofascial release will utilize various physical motions to place the patients lumbosacral region in a position of maximal comfort and tissue release.
2520324|NCT02761382|Experimental|Mindfulness-based treatment|"The mindfulness-based psychological treatment consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Mindfulness-based stress reduction (MBSR), Mindfulness-based cognitive therapy (MBCT) and Acceptance and commitment therapy (ACT). The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~mindfulness-training (including meditation and yoga),~therapy based on ACT, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
2520336|NCT02761382|Experimental|Non-specific treatment|"The non-specific general psychological treatment is matched the mindfulness-based psychological treatment and consists of 10 weekly group sessions of 3 hours duration. The treatment is based on Client-centered therapy. The intervention is partly manualized to accommodate demands of methodology, accuracy and repeatability. The group sessions will include:~relaxation and physical training,~therapy based on the non-specific factors of psychological treatment which emphasize a focus on the relation and alliance between the therapist and the client and the therapist being a warm empathic, non-directive and unconditionally accepting support, and~patient-education in themes specifically targeted living with endometriosis-related chronic pelvic pain."
2520345|NCT02761382|No Intervention|Waiting list control|Participants in this arm will be on the waiting list to participate in one of the two experimental treatments after a period of six months. Participants will receive medical treatment as usual in this period.
2520385|NCT02760797|Experimental|Part I (Dose-Finding Stage)|Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
2520386|NCT02760797|Experimental|Part II (Dose Expansion Stage)|Emactuzumab and RO7009789 will be administered IV at the maximum tolerated dose defined in Part I of the study. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
2520448|NCT02760420|Experimental|Placebo|250 mg of placebo (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
2520450|NCT02760420|Active Comparator|3 Days|250 mg amoxicillin (dispersible tablet) DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age)
2520505|NCT02760160|Other|Reconstituted grape powder|Open grape powder pouch and pour contents into volumetric measuring device. Add approximately 180 mL of water to container with grape powder. Stir for a minimum of 30 seconds and ingest.
2520548|NCT02759887|Other|DS adult group|Consists of 15 DS subjects aged 21 and older who do not qualify for the diagnosis of dementia at the beginning of the study. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2520550|NCT02759887|Other|DS/AD group|Consists of 15 DS subjects aged 40 and older who do qualify for the diagnosis of dementia by DSM-IV criteria. Diagnoses will be by standard consensus review of all cases. Interventions include biospecimen collection, cognitive assessments, caregiver questionnaire, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2520551|NCT02759887|Other|NC adult|Consists of 10 cognitively normal, non-DS individuals, age-matched to the DS adult group. Interventions include biospecimen collection, cognitive assessments, Florbetapir F18 imaging, MRI, Fludeoxyglucose F18 (FDG), Tau Pet, Actigraphy.
2520623|NCT02759406|Experimental|Mach-5 Grooved|grooved
2520624|NCT02759406|Experimental|Mach 5 Bare Metal|bare metal
2520661|NCT02759107|Experimental|LY3298176 (Part A)|Escalating doses of LY3298176 administered subcutaneously (SC) once in healthy participants.
2520666|NCT02759107|Placebo Comparator|Placebo (Part A)|Placebo administered SC once in healthy participants.
2519816|NCT02764593|Experimental|Arm 3 (Nivolumab + Cetuximab)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2519817|NCT02764593|Experimental|Arm 4 (Nivolumab + IMRT)|Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.
2519861|NCT02763904|Experimental|Intensive nutritional counseling|Dietary counseling + energy dense oral nutritional supplements
2519864|NCT02763904|Active Comparator|Dietary counseling|Dietary counseling
2519886|NCT02763670|Other|Interventional|PRETICARD patient care management
2519893|NCT02763670|Other|Control|"Heterogenous as usual patient care management."
2519977|NCT02763150|Experimental|Lifestyle Intervention|Intervention group will receive a comprehensive, multicomponent weight loss intervention targeting diet, physical activity, and behavioral strategies.
2519984|NCT02763150|Active Comparator|Health Promotion|Health promotion group will receive education on healthy eating and activity before pregnancy.
2520055|NCT02762929|Experimental|Part A Cohort A|200 mg of HTX-011A via closed wound infiltration
2520060|NCT02762929|Experimental|Part A Cohort B|200 mg of HTX 011A via open wound infiltration
2520066|NCT02762929|Experimental|Part A Cohort C|200 mg of HTX-011B via closed wound infiltration
2520071|NCT02762929|Experimental|Part A Cohort D|200 mg of HTX 011B via open wound infiltration
2520074|NCT02762929|Active Comparator|Part A Cohort E|50 mg 0.5% bupivacaine hydrochloride injection via a closed wound infiltration
2520078|NCT02762929|Placebo Comparator|Part A Cohort F|Saline Placebo via a closed wound infiltration
2520084|NCT02762929|Experimental|Part B Cohort A|200 mg HTX 002 via closed wound infiltration
2520087|NCT02762929|Experimental|Part B Cohort B|200 mg HTX 002 via open wound infiltration
2520089|NCT02762929|Placebo Comparator|Part B Cohort C|Saline placebo via a closed and open wound infiltration
2520092|NCT02762929|Experimental|Part C Cohort A|120 mg of HTX-011B via closed wound infiltration
2520093|NCT02762929|Experimental|Part C Cohort B|120 mg of HTX-011B via open wound infiltration
2520095|NCT02762929|Experimental|Part C Cohort C|120 mg of HTX-011B local administration via instillation
2520097|NCT02762929|Placebo Comparator|Part C Cohort D|Saline placebo via open wound infiltration
2520099|NCT02762929|Experimental|Part D Cohort A|60 mg of HTX-011B via closed wound infiltration
2520101|NCT02762929|Experimental|Part D Cohort B|60 mg of HTX-011B via open wound infiltration.
2520102|NCT02762929|Placebo Comparator|Part D Cohort C|Saline placebo via open wound infiltration
2520105|NCT02762929|Experimental|Part E Cohort A|120 mg HTX 002 via closed wound infiltration
2520107|NCT02762929|Experimental|Part E Cohort B|120mg HTX 002 via open wound infiltration
2520109|NCT02762929|Placebo Comparator|Part E Cohort C|Saline placebo via closed and open wound infiltration
2520110|NCT02762929|Experimental|Part F Cohort A|HTX 009 via closed wound infiltration
2520111|NCT02762929|Experimental|Part F Cohort B|HTX 009 via open wound infiltration
2520112|NCT02762929|Placebo Comparator|Part F Cohort C|Saline placebo via closed and open wound infiltration
2520113|NCT02762929|Experimental|Part G Cohort A|30 mg of HTX 011B via closed wound infiltration
2520114|NCT02762929|Placebo Comparator|Part G Cohort B|Saline placebo via closed wound infiltration
2520115|NCT02762929|Experimental|Part H Cohort A|120 mg of HTX-011-056
2520116|NCT02762929|Experimental|Part H Cohort B|60 mg of HTX-011-056
2520118|NCT02762929|Placebo Comparator|Part H Cohort C|4.1 mL of normal saline
3198704|NCT00873171||2. Attention control OMT|The procedure consist of light pressure applied to certain painful areas of the body and back to decrease pain and help patient relax. The physician will look for areas of the body that hurt, lay his/her hands on the those places, and apply light pressure.
3198705|NCT00873171||3. Standard of Care|This procedure consists of various conservative treatments that can help reduce stress. Those include dietary modifications, pharmaceuticals, bladder training, and neuromodulation. If these treatments are not successful, minimally invasive surgical procedures is performed.
2520306|NCT02761421||patients with IOPD|observation all patients with IOPD
2520333|NCT02761070|Active Comparator|Bevacizumab (BEV) alone|Bevacizumab 10 mg/kg, day 1 div, every 2 weeks
2520343|NCT02761070|Experimental|Dose Dense Temozolomide Followed by BEV|Temozolomide (120 mg/m2, po, 7 days on/7 days off, every 2 weeks per cycle) up to 48 cycles. The dose will be escalated to 150 mg/m2 at 3rd cycle if the defined conditions are met throughout the first 2 cycles. At recurrence or progression, bevacizumab alone(10 mg/kg, day 1 div, every 2 weeks)
2520443|NCT02760550||never smokers|who have never smoked at all
2520444|NCT02760550||ex-smokers|formerly smokers but currently do not smoke at all
2520445|NCT02760550||current smokers|current smokers who, at the time of the survey, smoke any tobacco product either daily or occasionally. Social smokers fall into this category and are defined as those who smoke less than one cigarette per week or smoke only in some occasions
2520477|NCT02760225|Experimental|89Zr-Pembrolizumab PET imaging|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
2520557|NCT02760095||Children with EED|Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
2519860|NCT02763917|Active Comparator|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. We have chosen to deploy two air purifiers because we have observed a 50% reduction in indoor PM concentrations with two air purifiers. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies. Participants will also receive educational materials about health benefits of maintaining a normal weight.
2519863|NCT02763917|Placebo Comparator|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will also be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
2520016|NCT02763098|Experimental|Remi 0.1|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [(0.1), 0.2, 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
2520017|NCT02763098|Experimental|Remi 0.2|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, (0.2), 0.3 µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-RoiFrance) for two minutes.
2520019|NCT02763098|Experimental|Remi 0.3|Following intravenous (IV) administration of 0.5 mg Atropine (Atropin, Biofarma, Istanbul, Turkey) prior to the induction, the patients randomly (by lot) received one of the three different doses [0.1, 0.2, (0.3) µg/kg/min] of remifentanil infusion (Ultiva, Glaxo Wellcome, Marly-le-Roi, France) for two minutes.
2520033|NCT02762708|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Subjects between the ages of 20-65 years of age seen for weight management in the Nutrition Clinic at Mayo Clinic, who have been approved for RYGB.
2520034|NCT02762708|Sham Comparator|Caloric restriction|Subjects between the ages of 20-65 years of age, with diagnosis of Type 2 diabetes mellitus or impaired fasting glucose. Subjects will undergo caloric restriction alone to mimic weight loss seen after gastric bypass surgery.
2520035|NCT02762708|Active Comparator|Exendin-9,39|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
2520036|NCT02762708|Placebo Comparator|Normal Saline|Four subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of Exendin-9,39 or normal saline.
2520156|NCT02762461||Exposed group|Women with peritoneal/ovarian endometriosis and DIE (rectovaginal and rectosigmoid endometriosis) undergoing ART (IVF or ICSI).
2520157|NCT02762461||Reference group 1|Women with infertility because of factors other than endometriosis, e.g. male factor, undergoing ART (IVF or ICSI).
2520162|NCT02762461||Reference group 2|Women with medically treated endometriosis not undergoing ART.
2520180|NCT02762019|Experimental|Laser therapy|Children are allocated to receive Laser therapy
2520196|NCT02762019|Sham Comparator|Sham therapy|Children are allocated to receive Sham therapy
2520266|NCT02761564|Experimental|ScVO2 group|Anemia (<9g/dL) requiring blood transfusion Measure of ScvO2 : ScVO2 is measured using the central venous catheter placed in the superior vena cava. Transfusion is performed if the ScVO2 is inferior or equal to 65%.
2520271|NCT02761564|Other|Control group|Anemia (<9g/dL) requiring blood transfusion : Transfusion is performed following national guidelines for red blood cell transfusion
2520475|NCT02760186|Experimental|Altitude Exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
2520537|NCT02760004|Experimental|Prism Intervention|PRogram In Support of Moms (PRISM)
2520543|NCT02760004|Experimental|Enhanced Usual Care|Enhanced Usual Care group (Access to MCPAP for Moms)
2520602|NCT02759640|Experimental|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
2520657|NCT02759302||Patients with LGMD2N|Five patients over 18 years old with genetically verified LGMD2N
2520732|NCT02758873|Experimental|Personalised Medicine|If an add-on controller is required, young people in this arm will be prescribed personalised medicine by results of the genotyping for the adrenergic beta2-receptor gene (ADRB2). Health professional's will be advised to prescribe inhaled salmeterol as 'add-on' controller if trial participants have the Gly/Gly variant on ADRB2, and montelukast if they have Arg/Arg or Arg/Gly variant on ADRB2.
2520736|NCT02758873|Active Comparator|Standard care|If an add-on controller is required, young people will be prescribed medication as per the choice of the primary or secondary care physician, without knowledge of genotypic status.
2520778|NCT02758548|Other|Capillary Blood Sampling|Capillary blood sampling, collected as two fingerprick samples with POCT device and two venous samples
3165613|NCT00515229|Active Comparator|3|Verum 3: Each individual capsule has a filling volume of 75 mg amitriptyline, given once an day in the evening over 28 days
3165614|NCT00515229|Placebo Comparator|0|Placebo: Each individual capsule has a filling volume of 25 mg placebo (corn starch), given once an day in the evening over 28 days
3165615|NCT00515242|Experimental|1|Therapeutic massage
3165616|NCT00515242|Active Comparator|2|Thermotherapy
3165617|NCT00515242|Placebo Comparator|3|Relaxation
3165618|NCT00515268|Experimental|Subjects receiving GSK256066|Eligible subjects will be randomized to receive GSK256066 with inhaled doses of 25 micrograms or 87.5 micrograms once daily for 7 days, administered via an ACCUHALER.
3165619|NCT00515268|Placebo Comparator|Subjects receiving placebo|Eligible subjects will be randomized to receive placebo for 7 days, administered via an ACCUHALER.
3165620|NCT00515281|Experimental|INO Treatment|The treatment group will receive iNO, combined with O2 or room air, until 33 weeks corrected age.
2519876|NCT02763995|Experimental|Pharmaceutical care|Dader method. Health education for lifestyle modification. Improve adherence. Resolution of negative outcome associated with medication.
2519889|NCT02763657|Experimental|Brain activity during reasoning|
2519962|NCT02763527|Experimental|Smoking reduction|"Subjects will receive a brief intervention on smoking reduction with a warning message plus a smoking reduction leaflet. They will be asked to think about a tailored smoking reduction schedule for themselves after the negotiation with the trained counsellor. The trained counsellor will negotiate a schedule with subjects to reduce their smoking over an acceptable level. For the subsequent telephone follow up in the intervention group, information on reduction and cessation will be collected, followed by a booster intervention, which will repeat the health warning to positively encourage them to reinforce their efforts and the next reduction target. Four consecutive (1, 3, 6 and 12 months) follow-ups will be conducted over the telephone by trained interviewers."
2519964|NCT02763527|Placebo Comparator|Smoking Cessation|"Subjects in the QI group will always be advised to quit immediately rather than to quit progressively. Subjects will receive a brief advice on quitting with a warning message similar to subjects in the QP group. In addition, subjects will receive a self-help quitting pamphlet published by the Hong Kong Council on Smoking and Health (COSH). Unlike the QP group, subjects in the QI group will not receive smoking reduction intervention and leaflet, and booster intervention during telephone follow-ups. However, they will undergo a similar schedule of telephone follow-up as those in the QP group."
2520018|NCT02763072|Experimental|Picosecond Q-switched Laser|12 subjects will receive one treatment with a dual wavelength 532 nm KTP and/or 1064 nm Nd: YAG picosecond pulse duration laser.
2520020|NCT02763072|Active Comparator|KTP Laser|12 subjects will receive up to four treatments with a dual wavelength 532nm KTP long pulsed laser and/or 1064 nm Nd: YAG.
2520103|NCT02762617|Experimental|TDF IVR group|"The Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core which contains the experimental drug, TDF, and sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
2520104|NCT02762617|Placebo Comparator|Placebo IVR group|"The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride. The intravaginal ring is worn continuously for 28 days and replaced with new rings twice (every 28 days) for total of 84 days (3 months).~Participants will be stratified by site and will be randomized in a 3:1 ratio (TDF:Placebo)."
2520148|NCT02762279|Experimental|Patients|"Patient baseline characteristics will be collected.~Specific nasogastric tube installation: a specific nasogastric tube equipped with pressure transducers (Gaeltec® probe) will be installed.~Connection of a pressure transducer to the existing chest-tube.~Simultaneous recordings of PES (Gaeltec®), PPL, PAW, respiratory volume and flow (5 minutes).~Removal of the Gaeltec® probe, and repositioning of the pre-existing nasogastric tube in the esophagus for PES measurement.~Simultaneous recordings of PES (feeding tube), PPL, PAW, respiratory volume and flow (5 minutes).~Repositioning of the nasogastric tube in the stomach, and disconnection of the different recording equipment."
2520172|NCT02761837|Active Comparator|IVR call/text|Identify gaps in care and contact patients by IVR phone call or text
2520173|NCT02761837|Active Comparator|Email|Identify gaps in care and contact patients by email
2520258|NCT02761798||Automated Mobile Interactive Audiometer, Test Retest|Each participant will act as his/her own control. The iPad audiogram will be compared to the audiogram in sound booth or to a second iPad audiogram.
2520260|NCT02761798||Automated Mobile Interactive Audiometer, Validation.|iPad testing will be compared to conventional audiometry in the sound booth.
2520264|NCT02761798||Automated Mobile Interactive Audiometer, Speech Recognition|Testing with NU-6 word lists will be conducted by the iPad and by an audiologist in the sound booth.
2520269|NCT02761798||Automated Mobile Interactive Audiometer, Cochlear Implant|Participants with cochlear implants will be tested using iPad against conventional audiometry (warble tone) in the sound booth.
2520330|NCT02761265|Experimental|Surgical Group|Gait and balance testing as well as self-reported outcome assessments to be administered before and after surgery
2520341|NCT02761265|Other|Control Group|Gait and balance testing to be administered once in healthy subjects
3198706|NCT00873184|Other|1|A prospective, single-arm intervention study, potential participants will be identified and screened for eligibility via medical record review of patient scheduled for their post surgical primary adjuvant treatment consultation at DUMC.
3198707|NCT00873197|Experimental|Sancuso® patch/IV granisetron|Subjects will receive 1 Sancuso® patch worn for 7 days (168 hours). Immediately after the patch has been applied on Day 1, IV granisetron will be administered over 30 seconds. Following patch removal at 168 hours, a new patch will be immediately applied to the opposite arm and will remain in place for a further 7 days (168 to 336 hours).
2520535|NCT02759978||Suspicion NVE|Patients with suspicion of native valve endocarditis, infective endocarditis and no intracardiac prosthetic material in situ
2520539|NCT02759978||Suspicion (PVE)|Patients with a suspicion of prosthetic valve endocarditis (PVE), infective endocarditis and one or more prosthetic valves in situ
2520541|NCT02759978||Suspicion pacemaker/ICD related endocarditis|Patients with a suspicion of infective endocarditis and a pacemaker or implantable cardiac defibrillator (ICD) in situ
2520575|NCT02759653||Symptomatic|Symptomatic carotid artery disease
2520577|NCT02759653||Asymptomatic|Asymptomatic carotid artery disease
2520679|NCT02758990|Experimental|Predictions: BMI vs. Broccoli|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520685|NCT02758990|Experimental|Predictions: BMI vs. Caffeine|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520694|NCT02758990|Experimental|Predictions: BMI vs. Coffee|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520698|NCT02758990|Experimental|Predictions: BMI vs. Spinach|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2519882|NCT02763852|Experimental|BIA 3-202 400 mg|BIA 3-202/Placebo single-dose plus 1 tablet of Madopar 125. BIA 3-202 400 mg: 4 tablet of 100 mg + 1 placebo tablets. The investigational products were administered orally, following an overnight fast of at least 7 hours, with approximately 200 mL of potable water
2519897|NCT02763553|Experimental|Ketogenic Feed|A low-carbohydrate, high-fat enteral feed (Nutrison KetoCal 4:1) containing 0.4g of carbohydrate and 10g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
2519904|NCT02763553|Active Comparator|Standard Feed|Standard enteral feed (Nutrison ProteinPlus MF 1.28) containing 11.1g of carbohydrate and 3.8g of fat per 100kcal. Given as a continuous feed via a naso-gastric tube as per standard feeding protocol.
2519973|NCT02763384|Experimental|Arm 1: BL-8040 and Nelarabine|"Cycle 1: BL-8040 subcutaneous daily from Day 1 to Day 6 and nelarabine intravenously over 2 hours on Days 2, 4, and 6~Cycles 2-4: BL-8040 subcutaneous daily from Day 1 to Day 5 and nelarabine intravenously over 2 hours on Days 1, 3, and 5~Treatment may be repeated every 21 days for up to 4 cycles"
2520037|NCT02762838|Experimental|BCD-055|Patients in this group will receive BCD-055 in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
2520038|NCT02762838|Active Comparator|Remicade®|Patients in this group will receive Remicade® in a dose of 3 mg/kg on Week 0, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, Week 54.
2520161|NCT02762253|Other|Riboflavin drops - epithelium on or off|Riboflavin is applied with Epithelium on or with it off. 6 months follow up to find out magnitude of Decrease in Kmax
3198708|NCT00873210||Patients treated with Sutent|125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
3198709|NCT00873223|Experimental|A|
3198710|NCT00873236|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.
3198711|NCT00873236|Experimental|Arm II|Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.
3198712|NCT00873236|Experimental|Arm III|Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.
3198713|NCT00873262|Active Comparator|Hormones|
2520389|NCT02760745||Febrile Shivering|
2520390|NCT02760745||Fever without Shivering|
2520469|NCT02760472|Active Comparator|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
2520478|NCT02760472|Experimental|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
2520629|NCT02759367|Experimental|High potassium diet group|Individuals in this arm were asked to increase dietary potassium intake over a 4 week period. This was achieved through an increase in consumption of fruits and vegetables.
2520632|NCT02759367|No Intervention|Usual diet group|Individuals in this group were asked to continue habitual dietary intake.
2520660|NCT02759081|Active Comparator|water exchange|The air was turned off at the beginning of colonoscopy. Water was infused and suctioned at the same time during insertion. The air was turned on when the colonoscope reached the cecum.
2520664|NCT02759081|Experimental|cap-assisted water exchange|Cap was mounted to the tip of the colonoscope when water exchange was performed.
2520780|NCT02758795|Placebo Comparator|CONTROL|A placebo nutrient drink with no anti-inflammatory bioactivity (measure by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
2520790|NCT02758795|Active Comparator|NUTRIENT|A nutrient drink with confirmed anti-inflammatory bioactivity (measured by cell bioassay in vitro) Dose provided per kg of body mass: 0.33g protein mixed in 500ml of water as a protein 'shake' Energy ~ 160 kcal
2520831|NCT02758262|Active Comparator|Noninvasive brain stimulation: active|In active condition, subject will receive stimulation during all the duration of the experimental session.
2520833|NCT02758262|Placebo Comparator|Noninvasive brain stimulation: sham|In sham condition, subject will receive stimulation only at the beginning and at the end of the experimental session.
3198714|NCT00873262|Placebo Comparator|Solvent|
3198715|NCT00873275|Experimental|Treatment (ursodiol, combination chemotherapy, bevacizumab)|Patients receive oral ursodiol twice daily on days 1-28 (days -6 to 28 of course 1), leucovorin calcium IV over 2 hours on days 1 and 15, fluorouracil IV over 46 hours on days 1-2 and 15-16, and oxaliplatin IV over 2 hours and bevacizumab IV over 30-90 minutes on days 1 and 15. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2521072|NCT02756741|Active Comparator|STANDARD DOSE|Albumin 1.5gm/kg on day 1 and 1gm/kg on day 3
2521076|NCT02756741|Placebo Comparator|LOW DOSE|Albumin 20g/d for 5 days
2521120|NCT02756429|Experimental|atrial fibrillation|Patients with atrial fibrillation
2521127|NCT02756429|Experimental|Control|Patients without atrial fibrillation
2521172|NCT02755961|No Intervention|Control group|No intervention was performed
2521179|NCT02755961|Experimental|Education group|Dietary education and education on phosphate binder use. Pharmacists instructed patients about how to take phosphate binders properly. Dietitians educated on dietary phosphate restriction.
2521213|NCT02755532|Active Comparator|Bupivacaine 0,25%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve) In the group bupicavaine 0.25%, 10 ml of 0.25% bupivacaine was injected into each nerve, for a total of 40 ml per patient.
2523699|NCT02739009|Experimental|MOR106 MAD|Multiple intravenous administration of MOR106
3198716|NCT00873301|Experimental|vulvodynia|
3198717|NCT00873314|Experimental|Bed rest|
3198718|NCT00873314|Placebo Comparator|Activity restriction|
3198719|NCT00873340||Group 1|
3198720|NCT00873353|Experimental|Unique arm|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
3198721|NCT00873379|Active Comparator|melatonin|.5 mg (one half of a 1 mg tablet of GNC rapid dissolving Melatonin, natural product number (NPN) 80001380)
2519888|NCT02763605||patients diagnosed with acanthamoeba keratitis|"Inclusion Criteria:~- All patients presenting to National Taiwan University Department from Jun. 1st, 2003 to dec. 30th , 2016 with the tissue proven corneal AK will be included.~Exclusion Criteria~- Patients with tissue proven corneal AK during from Jun. 1st, 2003 to dec. 30th , 2016, but without in vivo confocal data, or complete chart records."
2520003|NCT02763488|Active Comparator|Standard physical therapy|These individuals will conduct physical therapy for 12 sessions as per the institutional standard physical therapy protocol
2520007|NCT02763488|Experimental|Blood flow restriction|These individuals will conduct physical therapy for 12 sessions with the addition of blood flow restriction interventions to their standard physical therapy
2520041|NCT02762825|Experimental|Higher Intensity Interval Training (HIIT)|
2520042|NCT02762825|Active Comparator|Moderate Continuous Training (MCT)|
2520332|NCT02761369|Experimental|A PAS protocol, right-to-left, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the right DLPFC
2520339|NCT02761369|Experimental|A PAS protocol, left-to-right, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a PAS protocol, starting with the left DLPFC
2520348|NCT02761369|Sham Comparator|A sham PAS protocol, via deep TMS|Via a multi-channel deep TMS device with an H-coil (Brainsway Ltd), a sham PAS protocol, starting with the right DLPFC (@ 40% of individual MT)
2520399|NCT02760823|Active Comparator|Alpha Lipoic Acid|Subjects in this arm will receive ALA IV, as a dose of 600 mg/12 hours.
2520401|NCT02760823|Placebo Comparator|Non-Alpha Lipoic Acid|Subjects in this arm will to receive standard treatment only (without Alpha Lipoic Acid, instead they will receive placebo , which is determined by the attending physician who maintains clinical responsibility for all patients. It consists of patient resuscitation, gastric decontamination (with sodium bicarbonate, and activated charcoal [1 g/Kg, orally] in the first 6 hours after onset of poisoning), adequate hydration and supportive treatment.
2520690|NCT02758912|Experimental|arm 1, Cardionat®|oral intake of study drug capsules at a dose of 1 g per day for 3 weeks.
2520697|NCT02758912|Experimental|arm 2, Cardionat®|oral intake of study drug capsules at a dose of 2 g per day for 3 weeks.
2520776|NCT02758730|Experimental|AFFITOPE® PD01A + Adjuvant|3 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
2520783|NCT02758730|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks
2520841|NCT02758314||Cases / NSCLC patients|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 150 NSCLC, free treatment by flow cytometry.~Evaluate the expression of PD-1 / PD-L1 in tumor tissue obtained by biopsy of patients with NSCLC by immunohistochemistry.~The patients for the enrollment have to be diagnosed with advanced Non-Small Cell Lung Adenocarcinoma (clinical stages IIIA, IIIB and IV), treated at the Instituto Nacional de Cancerología (INCan) who had not received radiotherapy and / or chemotherapy prior to obtaining samples to analyze. ECOG performance status 0-2 and present evidence of measurable disease."
2520844|NCT02758314||Control / Healthy subjects|"Evaluation of PD-1/PDL-1 expression.~Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations (CD3 + (CD4 +, CD8 +), B cells (CD19 + CD20 +), natural killer (NK) cells (CD16 + CD56 +) NK T-cells (CD3 + CD16 + CD56 + ) peripheral blood samples in 50 samples, by flow cytometry.~Healthy subjects blood cells will be obtained from the blood bank at the Instituto Nacional de Cancerología (INCan)"
3165621|NCT00515281|Placebo Comparator|INO Control|INO will be given to infants in the control group for the first 7 days of the study gas, then O2 or room air, as clinically appropriate, on the 8th day, until 33 weeks corrected age
3165622|NCT00515307|Experimental|A|
3165623|NCT00515320|Experimental|Fluoxetine|
2520925|NCT02757560|Experimental|SFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour saturated fatty acids enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the SFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (SFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2520987|NCT02757248|Experimental|Cohort 1|Volasertib 75mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
2520990|NCT02757248|Experimental|Cohort 2|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 12mg/m2 on days 1, 8 and 15
2520993|NCT02757248|Experimental|Cohort 3|Volasertib 100mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
3165624|NCT00515320|Placebo Comparator|Placebo|
3165625|NCT00515333|Placebo Comparator|1|Placebo: 0 milligrams; t.i.d.
3165626|NCT00515333|Active Comparator|2|Treatment group: 30 milligrams; t.i.d.
3165627|NCT00515333|Active Comparator|3|Treatment group: 60 milligrams; t.i.d.
3165628|NCT00515333|Active Comparator|4|Treatment group: 100 milligrams; t.i.d.
3165629|NCT00515359|Active Comparator|Dose Comparison|continuous versus intermittent bolus dosing
3165630|NCT00515372|Active Comparator|Intervention Group|Weekly phone calls lasting about 30 minutes. Lists of professional resources and referral recommendations will be provided.
3165631|NCT00515372|Other|Usual Care Group|Lists of professional resources and referral recommendations will be provided.
3165632|NCT00515385|Experimental|1a|Cohort 1 completed
3165633|NCT00515385|Placebo Comparator|1b|Cohort 1 placebo completed
3165634|NCT00515385|Experimental|2a|Cohort 2 completed completed
3165635|NCT00515385|Placebo Comparator|2b|Cohort 2 placebo completed
3165636|NCT00515385|Experimental|3a|Cohort 3 active
3165637|NCT00515385|Placebo Comparator|3b|Cohort 3 placebo
3165638|NCT00515385|Experimental|4a|Cohort 4 active
3165639|NCT00515385|Placebo Comparator|4b|Cohort 4 placebo
3165640|NCT00515385|Experimental|5a|Cohort 5 active
3165641|NCT00515385|Placebo Comparator|5b|Cohort 5 placebo
3165642|NCT00515398||1|Group 1 (all subjects)
3165643|NCT00515450|Experimental|1|
2519903|NCT02763774|Experimental|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
2519907|NCT02763774|Experimental|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
2519915|NCT02763774|Experimental|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
2519987|NCT02763306|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
2520048|NCT02762981|Experimental|CORT125134 with nab-paclitaxel|"Part I - Dose Escalation:~Patients will be treated with CORT125134 in combination with nab-paclitaxel at escalating dose levels in either a Continuous-Dosing Regimen or an Intermittent-Dosing Regimen.~Part 2 - Dose Expansion:~Expansion cohorts in the Continuous-Dosing and Intermittent-Dosing Regimens will be enrolled to better characterize the antitumor activity in patients with specific tumor types and to better define the safety profile."
2520141|NCT02762435|Placebo Comparator|control|No pressure applied to the 3 points
2520144|NCT02762435|Sham Comparator|sham|Light touch applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
2520146|NCT02762435|Experimental|acupressure|Moderate pressure applied to the 3 points (2 minutes each at PC6, LI4, and HT7, three times per day for 2 days)
3198722|NCT00873379|Placebo Comparator|placebo|half a white placebo tablet
3198723|NCT00873392|Experimental|1|Experimental drug
2520299|NCT02761447|Experimental|Treatment Traditional and Motor Imaginary Program|"Amputees patients also conservative protocol will undergo physiotherapy techniques work Motor Imaginary Program, based on a system of two videos that allow the patient to recreate the normal way. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases. This protocol will be applied 3 days a week (25-30minutos) for one month."
2520303|NCT02761447|Active Comparator|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physical therapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
2520309|NCT02761096|Experimental|Study group|The acupuncture intervention will start no more than 48 hours after craniotomy and will be given once a day for 6 days (a total of 6 sessions within 8 days). It will be given in addition to conventional treatments. All interventions will be performed by one Korean Medicine doctor with over 5 years of working experience with a college education of 6 years. This doctor will be trained in the study protocol before the start of the trial.
2520310|NCT02761096|Other|Control group|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery.
2520376|NCT02760979|Active Comparator|Denosumab|Patients treated with Denosumab
2520379|NCT02760979|Placebo Comparator|Placebo|Patients treated with placebo
2520439|NCT02760589||ACL tear - conservative|conservative treatment
2520440|NCT02760589||ACL tear - ACL reconstruction|reconstruction of the ACL with autologous tendons
2520441|NCT02760589||ACL tear - Internal brace|augmentation of the ruptured ACL with Internal brace
2520442|NCT02760589||healthy subjects|control group of healthy subjects with no previous injury
2520471|NCT02760238||Patients with a diagnosis of MPN|"Patients with a myeloproliferative neoplasm (MPN) diagnosis:~Atypical chronic myeloid leukemia (aCML), chronic eosinophilic leukemia-not otherwise specified (CEL NOS), chronic myelomonocytic leukemia (CMML), chronic neutrophilic leukemia (CNL), polycythemia vera (PV), essential thrombocythemia (ET), JMML, mastocytosis, MPN unclassifiable, myeloproliferative neoplasm/myelodysplastic syndrome unclassifiable (MPN/MDS unclassifiable), primary myelofibrosis (PMF), post-ET MF, post-PV MF, or (refractory anemia with ringed sideroblasts associated with marked thrombocytosis) RARS-T"
2520546|NCT02759991|Active Comparator|HEV vaccine|Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
2520547|NCT02759991|Placebo Comparator|HBV vaccine|Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
2520609|NCT02759614|Experimental|Bevacizumab and Erlotinib|Bevacizumab 15 mg/kg shall be intravenous infusion on day 1 once every 3 weeks, Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
2520611|NCT02759614|Active Comparator|Erlotinib|Erlotinib 150 mg tablets shall be administered orally every day at least one hour before or two hours after the ingestion of food.
2520680|NCT02759198|Experimental|YH23537|YH23537 750/1500/3000mg
2520686|NCT02759198|Active Comparator|Celebrex|Celecoxib 200mg
2520692|NCT02759198|Placebo Comparator|Placebo|YH23537 Placebo
2520773|NCT02758704|Experimental|High-Stress (HS)|In the HS environment, the resident will be exposed to various stressors. There will be the presence of audio alarms as well as the presence of a senior physician who will be supervising the performance of the resident. In addition, the mannequin will be slightly unstable which will be reflected in its oxygen saturation dropping throughout the first 30 seconds the procedure.
2520996|NCT02757248|Experimental|Cohort 4|Volasertib 150mg/m2 on days 1 and 8 Romidepsin 14mg/m2 on days 1, 8 and 15
3198724|NCT00873392|Active Comparator|2|Usual treatment
3198725|NCT00873405|Active Comparator|SRSG|Silastic® ring sleeve gastrectomy (SRSG).
3198726|NCT00873405|Other|SRGB|Silastic® ring gastric bypass.
2519969|NCT02763501|Active Comparator|RCT|"patients operated with laparoscopic gastric bypass surgery within a register based RCT from May 1st 2010 until Nov 14th 2011.~1:1 randomization to closure of mesenteric defects by running, non-absorbable sutures"
2519976|NCT02763501|Active Comparator|non-RCT|"patients operated with laparoscopic gastric bypass surgery outside of the RCT from May 1st 2010 until Nov 14th 2011.~Intervention of mesenteric defects according to local tradition or choice of surgeon (non-randomized)"
2520061|NCT02762916|Experimental|1- Telemedicine arm|"The intervention arm (IA), telehealth control, were followed up by himself helped by CONTECI program. They have to use every three months and if somethings was wrong the patient have to send mail to the doctor.~The intervention consisted to use the CONTECI program (included test) for the following of the patients."
2520067|NCT02762916|No Intervention|2- Control arm|The Control Arm (CA) were followed up as usual every 6 months in outpatient vascular visits in the clinical hospital. If some patient have a complications or and emergency they have to do usual protocol, go to primary care or emergency.
2520280|NCT02761525|Experimental|gel silver nanoparticles|topic gel silver nanoparticles 12 ppm
2520293|NCT02761525|Placebo Comparator|placebo|topic innocuous gel
2520313|NCT02761200||volunteer who completion of a recent ATI|
2520374|NCT02760992|Active Comparator|Oral Baclofen|Subject will start baclofen at a 5 mg oral dose every 8 hours. Oral baclofen will be increased incrementally and self-administered over 13 days to a maximum dose of 20 mg every 8 hours. Following IV administration, subjects will be changed back to oral baclofen at a 15 mg dose self-administered every 8 hours and tapered off of baclofen over 15 days.
2520377|NCT02760992|Experimental|IV Baclofen|Subjects will be crossed over to 16 mg intravenous baclofen infused over 120 or 150 minutes every 8 hours for 11 doses.
2520458|NCT02760615|Other|Part 1: UC and CD Participants|Participants with UC or CD and not concurrently treated with vedolizumab or other biologics will receive caffeine 200 milligram (mg), tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan, 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2520460|NCT02760615|Other|Part 1: Healthy Participants|Healthy participants will receive caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2520464|NCT02760615|Experimental|Part 2: Vedolizumab|Participants who are on established vedolizumab intravenous (IV) maintenance treatment of 300 mg for treatment of UC or CD and in clinical remission will receive vedolizumab 300 mg IV infusion, once, caffeine 200 mg, tablets, orally, once, losartan 50 mg, tablets, orally, once, omeprazole 40 mg, capsules, orally, once, dextromethorphan 30 mg (2*15 mg), capsules, orally, once, and midazolam 10 mg, syrup, orally, once, on Day 1.
2520519|NCT02759874|Experimental|Experimental|Intervention is pregnant women enrolled and using specialized breathalyzer device w face recognition technology linked to a cellphone
2520520|NCT02759874|No Intervention|Control Group|No intervention. No breathalyzer given. Access granted by participant to IHE to collect data from Alberta Health Services (medical records)
2520558|NCT02759822||Group A: Acute Lymphoblastic Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy)~Preferred conditioning:~Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120)~Alternative conditionings:~Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200)~Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)"
2520563|NCT02759822||Group B: Acute Myeloid Leukemia|"Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200~Alternative conditionings:~Bu9,6 + Flu150 + TBI200~Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF"
2520604|NCT02759601|Other|Tefinostat|"This is an open label, dose escalating, phase I/II study of Tefinostat administered orally, once or twice daily in 28 day cycles of treatment in patients with advanced hepatocellular carcinoma.~Up to 5 cohorts of 3-6 patients (number is dependent on DLT occurrence) will be treated for 28 days once or twice daily (360, 480mg once daily, then 240, 360, 480mg twice daily) to determine safety and tolerability of Tefinostat and to identify the recommended dose for Phase II."
2520634|NCT02759250|Experimental|adjuvant monotherapy|ARGX-110 5mg/kg once every three weeks for a maximum of 18 cycles
2520635|NCT02759250|Experimental|metastatic/recurrent monotherapy|ARGX-110 5mg/kg once every three weeks until disease progression
2520636|NCT02759250|Experimental|metastatic/recurrent combination therapy|ARGX-110 5mg/kg once every three weeks plus chemotherapy until disease progression. The choice of the chemotherapy agents is limited to: cisplatin, carboplatin, 5-fluorouracil, gemcitabine and paclitaxel.
2520863|NCT02758145|Active Comparator|Influenza vaccine information (G1)|During the recruitment visit at the occupational medicine unit between the 04/29/16 and the 10/31/16, the workers in this group (G1) in addition to their recruitment visit, will benefit from a short intervention given by the nurse concerning the flu, the advantages of the flu vaccination, and how they can be vaccinated in the institution. The nurse also transmits an information sheet concerning the benefits of the vaccination. 2 weeks after the beginning of the next flu vaccination campaign, they will receive a reminder letter to encourage vaccination.
2520864|NCT02758145|No Intervention|No information (G2)|Workers in the control group (G2) receive no intervention, only recruitment visit.
2520918|NCT02757781|No Intervention|Control Group|Group of healthcare professionals that NOT receive the intervention (community of practice)
2520920|NCT02757781|Experimental|Intervention group|Group of healthcare professionals that receive the intervention (community of practice)
2520964|NCT02757365|Experimental|the NSAIDs group|Patients in the this Group will received the aspirin 100mg qd until the experiment finished
2520969|NCT02757365|Experimental|the antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks
2520971|NCT02757365|Experimental|the NSAIDs+antibiotics group|Patients in the this Group will received the Levofloxacin 0.5g qd for 4~8 weeks and aspirin 100mg qd until the experiment finished
2520973|NCT02757365|No Intervention|the control group|No treatment
3165644|NCT00515450|Active Comparator|2|
3165645|NCT00515489||001|Risperidone as prescribed
2520047|NCT02762760|Experimental|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
2520147|NCT02762552|Experimental|Transcranial-holter monitoring|Transcranial doppler in patient with ischemic stroke
2520184|NCT02762136|Placebo Comparator|placebo|Participants will orally take the placebo granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
2520197|NCT02762136|Active Comparator|Xiang-sha-liu-jun granules|Participants will orally take the herbal formula granules 12g twice a day for 4 weeks. No other interventions during the study period will be allowed.
2520278|NCT02761616||eBC treated participants|Participants with metastatic disease after previously being treated for eBC were observed for 24 months.
2520320|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression Before Polypectomy|A biopsy will taken in infertility patients with endometrial polyp before polypectomy
2520322|NCT02761278|Active Comparator|HOXA10 and HOXA11 Expression After Polypectomy|A biopsy will taken in infertility patients with endometrial polyp 1-3 months after polypectomy
2520375|NCT02760940|Experimental|Oral liposomal iron treatment|Oral liposomal iron - 28 mg per day over 8 weeks
2520436|NCT02760576|Experimental|BAY 987521|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2520678|NCT02759276||Resistant Hypertension (RH)|uncontrolled hypertension, with values ≥140/90 mmHg, using three or more antihypertensive drugs of different classes, including a diuretic, or controlled hypertension with four or more drugs.
2520682|NCT02759276||Stages 1 and 2 Hypertension (MMH)|According to the VI Brazilian Guidelines of hypertension, with blood pressure levels ranging from 140/90 mmHg to 179/109 mmHg, with up to two antihypertensive drugs of different classes and blood pressure levels controlled in the last two months.
2520688|NCT02759276||Normotensive (CG)|Blood Pressure <140/90 mmHg and without comorbidities.
2520754|NCT02758782|Active Comparator|Golimumab monotherapy|Treatment with 50 mg Golimumab subcutaneous once monthly
2520755|NCT02758782|Active Comparator|Golimumab combined with Celecoxib|Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day
3165646|NCT00515554|Active Comparator|A|8 cycles BEACOPPesc
3165647|NCT00515554|Experimental|B|8 cycles BEACOPPesc plus rituximab
3165648|NCT00515554|Active Comparator|C|8 cycles BEACOPPesc
2520935|NCT02757924|Experimental|Infant formula supplemented with prebiotics|infant formula powder, feed ad libitum
2520957|NCT02757209|Active Comparator|Spiromax Inhaler|"Evaluation of correct use of Spiromax inhaler - DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
2520960|NCT02757209|Active Comparator|Turbohaler inhaler|"Turbohaler® - Symbicort® 160/4.5 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate). Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
2520961|NCT02757209|Active Comparator|Diskus Inhaler|"Diskus® inhaler - Seretide Diskus 50/250 mcg ® or 50/500 mcg (50 mcg salmeterol & 250/500 mcg fluticasone propionate). Dose of one inhalation twice a day for 1 week.~Additional 8 weeks in one subgroup"
2521024|NCT02757040|Experimental|Ibrutinib combined with As2O3|Ibrutinib combined with As2O3
2521025|NCT02757040|Active Comparator|Ibrutinib|Ibrutinib only
2521057|NCT02756806|Experimental|Picosecond Q-switched Laser|Treatment with investigational wavelengths of the Cutera enlighten laser for tattoo removal.
2521079|NCT02756559||sepsis, severe sepsis and septic shock|Septic patients were divided into sepsis, severe sepsis and septic shock
2521141|NCT02756403|Active Comparator|Azithromycin|500 mg of Azithromycin
2521144|NCT02756403|Active Comparator|Doxycycline|200 mg of Doxycycline
2521147|NCT02756403|Active Comparator|Metronidazole|500 mg of Metronidazole
2521149|NCT02756403|Placebo Comparator|Placebo|Inactive Ingredient
2521204|NCT02755792|Experimental|Calligraphy Training|This group receives a Chinese calligraphy training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
2521205|NCT02755792|Active Comparator|iPad Training|This group receives an iPad training program of 16 sessions over 8 weeks in a class of 8-12 participants. Each session is 1.5 hours.
3165649|NCT00515554|Experimental|D|4 cycles BEACOPPesc
3165650|NCT00515580|Experimental|A|Pilot study of 5 patients, with an additional 20 patients with conditional approval by the IRB once the initial 5 patient's data is reviewed.
2521325|NCT02754791|Experimental|Steripath|The Steripath device (Magnolia) will be used to take blood cultures in this arm instead of standard methods. This will be in addition to a departmental monthly report (described above).
3165651|NCT00515632|Experimental|Balaglitazone 10 mg per day|
3165652|NCT00515632|Experimental|Balaglitazone 20 mg per day|
3165653|NCT00515632|Active Comparator|Pioglitazone 45 mg per day|
3165654|NCT00515632|Placebo Comparator|Placebo|
3165655|NCT00515645|Experimental|1|
3165656|NCT00515710||1|Prior gene therapy study subjects receiving AAV2-hFIX16.
3165657|NCT00515736|Experimental|AOX group|Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
3165658|NCT00515736|Placebo Comparator|0|Group receiving vehicle solution for 5 days (double dose for 48 hours)
3165659|NCT00515762|Experimental|1: scalp cooling|scalp cooling
3165660|NCT00515788|Experimental|DepoCyt + Temozolomide|DepoCyt Starting 50 mg Intrathecal Day 1 every 14 days for 12 weeks (6 treatments), then every 28 days for 40 weeks (10 treatments). Temozolomide 100 mg/m^2 by mouth daily for 7 days every 14 days.
3165661|NCT00515801|Experimental|A|Glibenclamide 5 mg tablets
3165662|NCT00515801|Placebo Comparator|B|placebo capsules
3165663|NCT00515814|Experimental|1, 2|During measurement/test periods, investigator sets implant into ON or OFF condition without subjects knowledge of when device is active.
3165664|NCT00515840|Sham Comparator|1|equal time with health care professional (asthma nurse)
2520138|NCT02762266|Active Comparator|Arm I (TACE)|Patients undergo TACE.
2520145|NCT02762266|Experimental|Arm II (SBRT)|Beginning within 2 weeks of the radiation set-up scan and within 4 weeks of fiducial seed implantation (if applicable), patients undergo image guided SBRT 3 fractions within 1 week or 5 fractions within 2 weeks.
2520185|NCT02762032|Active Comparator|Arm 1|15 subjects will be randomized to receive PrimaVie Herbal Supplement 125 mg to take twice daily for 14 weeks.
2520198|NCT02762032|Active Comparator|Arm 2|15 subjects will be randomized to receive PrimaVie Herbal Supplement 250 mg to take twice daily for 14 weeks.
2520205|NCT02762032|Placebo Comparator|Arm 3|15 subjects will be randomized to receive placebo (control supplement) to take twice daily for 14 weeks.
2520261|NCT02761538|Experimental|AVIITAM Group|Utilization of the web platform Aviitam
2520265|NCT02761538|No Intervention|Control group|No utilization of web-platform Aviitam
2520352|NCT02761356||Tc99-MAA and SPECT-CT|26 of the patients were examined with Tc99-MAA and SPECT-C
2520354|NCT02761356||Tc99-MAA , SPECT-CT and PET-CT|24 patients were examined with Tc99-MAA , SPECT-CT and PET-CT.
2520438|NCT02760667|Experimental|Induction Therapy with 3 cycles|Cisplatin 75mg/m2 IV and Taxotere 75mg/m2 every 3 weeks for 3 cycles (Induction Chemotherapy) followed by surgical treatment
2520482|NCT02760199|Experimental|89Zr-AMG211 and 89Zr-AMG211 PET|
3165665|NCT00515866|Experimental|1|Gemcitabine + KU-0059436
3165666|NCT00515918||1|Iron deficient
3165667|NCT00515918||2|Iron sufficient
2520887|NCT02758002|Experimental|Firm ablation for transitional AF rotors|All subjects will undergo this ablation, in addition to their standard PVI and Firm ablation for sustained AF rotors.
2520924|NCT02757573|Experimental|Hypercarbia|Hypercarbia: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
2520975|NCT02757417|Active Comparator|Sodium Fluorescein|Patients will receive an intravenous dose of 0.25 mL of 10% (500 mg, 5 mL) sodium fluorescein at the time of cystoscope insertion, for a total dose of 25 mg. Cystoscopy will be performed in the standard fashion during the course of the operation.
2520977|NCT02757417|Active Comparator|oral phenazopyridine|Patients randomized to the phenazopyridine arm will be given a 200 mg pill with a sip of water in the pre-operative area 1 hour before their scheduled procedure. Cystoscopy will be performed in the standard fashion during the course of the operation.
2521049|NCT02756988|Experimental|Coppertone (BAY987704)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3165668|NCT00515931|Experimental|Radiotherapy|GIST patients who have progressing metastases will be treated with radiotherapy.
2521227|NCT02755623|Active Comparator|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|low-frequency (1 Hertz) rTMS
2521233|NCT02755623|Sham Comparator|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|sham TMS
2521290|NCT02754986|Experimental|measuring Holter electrocardiogram|Hotter ECG will be recorded continuously during hemodialysis
2521420|NCT02754076|Experimental|AX 250|In Part 1, patients will receive up to 3 escalating doses of AX 250 (30, 100 and 300 mg) via ICV infusion every week until the maximum tolerated tested dose (MTTD) is established. In Part 2, patients will receive weekly doses of AX 250 via ICV infusion that will continue for 48 weeks at the MTTD established in Part 1.
2521514|NCT02753452|Active Comparator|Residential Immersive Life Skills group|Youth will take part in a residential life skills program of between one and three weeks, consisting of formal workshops, peer learning, outings in the community, one-on-one coaching and daily living tasks carried out with peers (e.g. cooking, laundry, grocery shopping).
3165669|NCT00515957|Experimental|Patients|Patients with Nasopharyngeal Carcinoma in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV-genome or antigens have been demonstrated in tissue biopsies
3165670|NCT00515970|Experimental|1|Clinical or histologic diagnosis of nodular BCC
3165671|NCT00515970|Active Comparator|2|Clinical or histologic diagnosis of nodular BCC
3165672|NCT00515970|Experimental|3|Clinical or histologic diagnosis of superficial BCC
3165673|NCT00515970|Active Comparator|4|Clinical or histologic diagnosis of superficial BCC
3165674|NCT00515996||2|paroxetine treatment group vs. normal control group
3165675|NCT00516009|Experimental|1 TREATMENT GROUP|20 PATIENTS WILL RECEIVE DEXAMETHASONE 30 MG IV 3 DAYS AND 20 AND 10 MG FOR THE OTHER TWO DAYS
3165676|NCT00516009|Placebo Comparator|2|20 PATIENTS WILL RECEIVE PLACEBO FOR 5 DAYS
3165677|NCT00516022|Experimental|Investigator product|The patients randomized to this arm will receive the IP injections at home 3 times a week (the patients will inject the IP themselves).
3165678|NCT00516022|Other|Control|The patients randomized to this arm will continue to receive chemotherapy as usual without further treatment (unless prescribed by the Doctor).
3165679|NCT00516035|Experimental|1|0.50 ml (0.25 ml in each nostril) of Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca) administered by nasal spray at two timepoints (at study entry and between Weeks 4 and 8)
3165680|NCT00516087|Experimental|Patients|Patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies.
3165681|NCT00516113|Active Comparator|1|Paroxetine 20mg during the luteal phase of the menstrual cycle
3165682|NCT00516113|Placebo Comparator|2|Placebo during the luteal phase of the menstrual cycle
3165683|NCT00516126||Point-of-Care managed|This arm includes all patients in which the hemostatic therapy is guided by POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
3165684|NCT00516126||Conventional hemostasis lab managed|This arm includes all patients in which the hemostatic therapy is guided by conventional hemostasis laboratory data e.g. INR, aPTT, fibrinogen concentration, platelet count but no POC devices e.g. MULTIPLATE (a platelet function analyzer) or ROTEM (thromboelastometry)
3165685|NCT00516178|Placebo Comparator|Placebo|Saline (No lipid emulsion)
2520054|NCT02762864|Experimental|PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period. For patients in the PRU-target group with PRU ≥234 seconds, rescue medicine (ticagrelor) will be added to keep PRU<234 seconds.
2520062|NCT02762864|Active Comparator|non PRU-guided|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patients with PRU <234 seconds and followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period, regardless the levels of PRU.
2520135|NCT02762344||ACT < 150 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec
2520136|NCT02762344||ACT between 150 and 249 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec
2520142|NCT02762344||ACT >= 250 sec|patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec
2520193|NCT02762123|Experimental|Cohort 1 (BMS-986142: 200 mg)|200mg BMS-986142 administered orally once daily on specified days.
2520201|NCT02762123|Experimental|Cohort 2 (BMS-986142: 350 mg)|350mg BMS-986142 administered orally once daily on specified days.
2520284|NCT02761577|No Intervention|control|perorally 1500 ml water on the day of the procedure
2520298|NCT02761577|Experimental|Sodium bicarbonate|3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
2520302|NCT02761577|Experimental|N-acetylcysteine plus Sodium bicarbonate|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.
2520351|NCT02761018|Experimental|Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
2520353|NCT02761018|Experimental|Fitness Tracker with Group Participation|will use a fitness tracker and will be able to see other member's daily and weekly results
2520395|NCT02760719|Experimental|hypertonic saline|4 ml of nebulized 3 % hypertonic saline + salbutamol 0,03 ml/kg every 8 hours for the time of hospitalisation and standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
2520397|NCT02760719|No Intervention|supportive care|Standard supportive care (oxygen to correct hypoxia, minimal handling to minimise the risk of exhaustion, provision of fluids, gentle nasal aspiration)
3198727|NCT00873418|Experimental|Coping Skills Training|16 week telephone intervention using coping skills training to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
2520525|NCT02759900|Experimental|Non-thermal atmospheric plasma treatment|Device treatment
2520527|NCT02759900|Experimental|Indirect non-thermal atmospheric plasma treatment|A compound of non-thermal atmospheric plasma and medium is used to treat the target by direct application or by on-site generation of the compound
2520568|NCT02759796|Placebo Comparator|Clinical assessment of flap perfusion|Tailoring the flap according to clinical assessment of flap perfusion
2520569|NCT02759796|Experimental|Angiography assessment of flap perfusion|Tailoring the flap according to ICG Angiography assessment of flap perfusion
2520605|NCT02759549|Experimental|eSMART-MH|Participants undergoing radiation treatment for breast cancer will receive the Electronic Self-Management Resource Training for Mental Health (eSMART-MH) intervention.
2520606|NCT02759549|Other|Theater Testing|Participants undergoing radiation treatment for breast cancer will participate in a theater testing workshop.
2520674|NCT02759237||Patient Group|Patients identified for treatment of symptomatic aortic sten
2520749|NCT02758769||ORENCIA with Exposure|ORENCIA with Exposure
2520765|NCT02758574|Active Comparator|CDT without ultrasound acceleration|Standard Catheter-Directed Thrombolysis: Utilization of a standard infusion catheter, placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications to treat/dissolve pulmonary embolus
2520768|NCT02758574|Experimental|CDT ultrasound accelerated|Ultrasound Accelerated Catheter-Directed Thrombolysis: Utilization of an infusion catheter that incorporates an ultrasound emitting wire both placed at the site of pulmonary thrombus. The catheter will be used for the delivery of thrombolytic medications with the ultrasound emitting wire activated to treat/dissolve pulmonary embolus
2520809|NCT02758340|Experimental|M=misoprostol|Patients who would receive Only oral misoprostol{(50 micrograms) tab cytotec ¼ tablets (Searle)}. All patients in this group will be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes). If labor is not established within 4 hours of the administration of the fourth dose, induction will be considered to be failed
2520813|NCT02758340|Experimental|M+F=MISOPROSTOL+FOLEY'S BALLOON CATHETER|All patients in this group will be explained the technique of foley's catheter ballooning and informed consent will be taken. The cervix will be visualized with the help of Cusco's speculum. The balloon will be inflated with about 30 cc of sterile water. The catheter will be pulled down to bring the balloon into the cervical canal and will be tapped around the thigh. Patients will also be given oral misoprostol 50 μg per dose. The dose will be repeated at 4 hours interval up to a maximum of 4 doses till labor is induced (3 contractions per 10 minutes).
2520888|NCT02758067|Experimental|brexpiprazole|
2520889|NCT02758067|Experimental|risperidone|
2521014|NCT02757131|Experimental|Intervention|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the Physical Therapy (PT) staff 3 times daily under the supervision of the dedicated ambulator PCNA.~The ambulator will be trained by the physical therapy team on how to implement the protocol prior to initiation of the study."
2521018|NCT02757131|No Intervention|Control|"The cohort of patients randomized to usual care will not be seen by the dedicated ambulator, but will not otherwise be restricted in nursing's baseline ability to execute nursing specific recommendations placed by the PT team."
2520139|NCT02762409||patients exposed|Patients exposed will be estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015, and in 17 centers of the group control some study IPREA3 during October 2015
2520143|NCT02762409||patients non exposed|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015 and in 17 centers of the interventional group during October 2014"
3165686|NCT00516178|Experimental|Fish oil emulsion|3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)
2520328|NCT02761317|Active Comparator|GroupA：standard preparation|Subjects who are randomized into group A receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
2520340|NCT02761317|Experimental|Group B:low-volume preparation|Subjects who are randomized into group B receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure. ( 2L PEG-ELS and 10mg bisacodyl )
2520347|NCT02761317|Experimental|Group C：high-volume preparation|Subjects who are randomized into group C will receive 2L PEG-ELS at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure. (4 L PEG-ELS)
2520410|NCT02760758|Experimental|Cohort 1A HV|CDI-31244 20 mg active or placebo single dose (SD)
2520411|NCT02760758|Experimental|Cohort 2A HV|CDI-31244 50 mg active or placebo SD
2520412|NCT02760758|Experimental|Cohort 3A HV|CDI-31244 100 mg active or placebo SD
2520413|NCT02760758|Experimental|Cohort 4A HV|CDI-31244 200 mg active or placebo SD; food effect
2520415|NCT02760758|Experimental|Cohort 5A HV|CDI-31244 400 mg active or placebo SD
2520417|NCT02760758|Experimental|Cohort 6A HV|CDI-31244 200 mg active or placebo multiple dose (MD)
2520418|NCT02760758|Experimental|Cohort 7A HV|CDI-31244 200 mg active or placebo MD
2520419|NCT02760758|Experimental|Cohort 8A HV|CDI-31244 400 mg active or placebo MD
2520422|NCT02760758|Experimental|Cohort 1B HCV genotype (GT) 1|CDI-31244 400 mg active or placebo MD
2520424|NCT02760758|Experimental|Cohort 2B HCV GT 1|CDI-31244 600 mg active or placebo MD
2520425|NCT02760758|Experimental|Cohort 3B HCV GT 1|CDI-31244 800 mg active or placebo MD
2520474|NCT02760212|Experimental|Group 1 - Radial Shockwave Therapy Group|Participants in Group 1 will receive RSWT to the most painful spot within each of the 3 most painful regions as described by the participant. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with treatment to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot.
2520480|NCT02760212|Placebo Comparator|Group 2 - Placebo Group|Participants in Group 2 will receive a placebo treatment with a soft rubber cap applied to the applicator, leaving air between the transmitter and the cap and the participant's skin so that no shockwave will be generated nor applied to the participant's skin. Treatments will be spaced one week apart over a 5 week period of time. 5 weekly sessions with placebo treatment to the painful areas will be undertaken with 2000 placebo shocks (15 Hz) producing an audible sound but no therapeutic dosage to the most painful spot. Upon completion of the placebo treatment, participant's will be offered the experimental treatment but this data will not be used for comparison and analysis.
2520647|NCT02759341|Other|Cardiac X Syndrome (CSX)|patients with Cardiac X Syndrome (CSX), according to the diagnostic criteria previously proposed by Lanza (Lanza, Heart. 2007)
2520648|NCT02759341|Other|Takotsubo Cardiomyopathy (TTC)|Tako-Tsubo Cardiomyopathy (TTC), according to Mayo diagnostic criteria at least six months after the event. (Prasad A, et al. Am Heart J. 2008)
2520649|NCT02759341|Other|Acute myocardial infarction (AMI)|Type 1, 4a, 4b myocardial infarction (ST-segment elevation acute myocardial infarction [STEMI] and Non ST-segment elevation acute myocardial infarction [NSTEMI] acute coronary syndrome [ACS] with significant ≥70% coronary stenosis) at least six months after the event. (Thygesen K, et al. Eur Heart J. 2012)
2520719|NCT02758886|Experimental|Stress reduction method|Participants randomized into the PYSA group engaged in a 10 minute direct interaction with the animals (dogs and cats) of the Pet Your Stress Away program
2520723|NCT02758886|Placebo Comparator|Control|Participants randomized into the Control group watched a 10 minute slide show of dog and cat photos
3165687|NCT00516204||Patients at very high risk|
3165688|NCT00516204||Patients at high risk|
3165689|NCT00516204||Patients at medium risk|
3165690|NCT00516204||Patients at low risk|
3165691|NCT00516243|Experimental|Arm I (defined green tea catechin extract)|Patients receive defined green tea catechin extract PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3165692|NCT00516243|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 6 months in the absence of disease progression or unacceptable toxicity.
3165693|NCT00516256|Experimental|CHESS System|CHESS System - Internet-based computer program for 6 months.
3165694|NCT00516256|Experimental|Cancer Information Mentor|Cancer Information Mentor - Phone calls to the patient for 6 months.
3165695|NCT00516256|Experimental|CHESS System + Cancer Information Mentor|CHESS System + Cancer Information Mentor
3165696|NCT00516360|Experimental|1|Chlorhexidien as the antibacterial agent used to cleanse the hub of neonatal central lines
3165697|NCT00516360|Active Comparator|2|Isopropyl alcohol as the antibacterial agent used to cleanse the hub of neonatal central lines
3165698|NCT00516399|Experimental|I:|povidone-iodine 1.25% ophthalmic solution. The associated intervention descriptions contain sufficient information to describe the arm.
3165699|NCT00516399|Active Comparator|II|natamycin ophthalmic suspension, USP 5%. The associated intervention descriptions contain sufficient information to describe the arm.
3165700|NCT00516412|Experimental|Everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3165701|NCT00516438|Experimental|1|Topotecan + KU-0059436
2520262|NCT02761434|Active Comparator|Dehydration|Infusion of 3% sodium chloride for osmotic stimulation of vasopressin
2520267|NCT02761434|Placebo Comparator|Euhydration|Infusion of 0.9% sodium chloride that will induce similar expansion of plasma volume without any significant change in osmolality and vasopressin
2520329|NCT02761343|Other|MRI scan|Post ablation MRI scan will be performed for all subjects who are clinically stable.
2520365|NCT02760888|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
2520366|NCT02760888|Active Comparator|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
2520367|NCT02760888|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure
2520392|NCT02760641|Experimental|Egg-based diet (EBD)|This arm will provide ≤25% energy from CHO, 25% energy from protein, and ≥50% energy from fat. EBD participants will be asked to consume ≥2 eggs per day along with other protein sources including meat, fish, pork, and poultry. Carbohydrate (CHO) sources will be primarily derived from leafy greens and non-starchy vegetables and CHO intake will be equally distributed across meals throughout the day.
2520396|NCT02760641|Placebo Comparator|Carbohydrate-based diet (CBD)|The CBD group will be asked to avoid whole egg consumption when possible during the 8 week intervention period. They will be counseled to consume a low fat diet with 55:25:20 %energy from CHO:protein:fat. This diet will place an emphasis on consuming lean meats, low fat dairy, whole grains, legumes, fruits and vegetables.
2520463|NCT02760446|Other|CAM-ICU.fr|CAM-ICU and ICDSC evaluation proceed by two investigators and a Neuropsychologist (Speech & language therapist specialized in neuropsychology)
2520533|NCT02760121|Experimental|Acetazolamide|Participants will be dosed 250mg Acetazolamide (p.o.) three times per day for two days prior to and a single dose on the day of study.
2520534|NCT02760121|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) twice daily separated by a placebo for two days prior to and a single dose on the day of study. The placebo dose is provided to match the dosing schedule between conditions.
2520536|NCT02760121|Placebo Comparator|Placebo|Participants will take (p.o.) placebo pills three times per day for two days prior to and a single dose on the day of study.
2520603|NCT02759666|Experimental|SHR3162|"3 to 6 participants (traditional 3+3 design) will be enrolled in 6 dose levels. SHR3162 was administered once daily in dose levels 1 and 2 and will be administered twice daily in dose levels 3 to 6."
2520658|NCT02759263|Experimental|Working Memory Intervention|The group randomized to the Working Memory intervention will receive Cogmed computerized training of executive function and attention skills. The standard Cogmed RM will be used for this trial arm. This is a child-friendly web-based software program. The investigators will use a version of the program that contains 12 different neurocognitive tasks. Tasks become more difficult as a function of performance on a session-by-session basis. Each training session lasts 35-40 minutes, with one session to be completed per day 5 days each week for 5 weeks, for a total of 25 sessions. The program yields individual session-by-session and task-by- task training results, including the adolescents' responses, time spent on each task, and evolution curves.
2520659|NCT02759263|No Intervention|Control group - Standard of Care|Adolescents randomly assigned to the control group will receive the standard of care recommended for patients with critical CHD. This includes cardiac surveillance and neurodevelopmental counseling and screening at our Cardiac Neurodevelopmental Program if needed. Once enrolled in our study, an adolescent in the control group will not receive Cogmed intervention or any other cognitive intervention that targets executive functions or ADHD symptoms until after the 3-month follow-up neurodevelopmental evaluation is performed, i.e., 5-6 months after initial enrollment. Like adolescents assigned to the intervention group, controls can continue on treatments that are already in place for other neurodevelopmental disabilities (e.g., speech therapy, occupational services).
2520830|NCT02758470|Experimental|Acetazolamide|Participants will be dosed 250mg acetazolamide (p.o.) three times per day for two days prior to and a single dose on the morning of the experimental day.
2520834|NCT02758470|Experimental|Methazolamide|Participants will be dosed 100mg Methazolamide (p.o.) two times per day separated by a placebo dose for two days prior to and a single dose on the morning of the experimental day. The placebo dose is used to match the timing and number of pills taken between all arms of the study.
2520837|NCT02758470|Placebo Comparator|Placebo|Participants will take three placebo pills per day for two days prior to and a single dose on the morning of the experimental day.
2520911|NCT02757898|Experimental|Biotin-Labeled Red Blood Cell (RBC) Infusion|Blood will be drawn from participants and labeled with biotin before being re-infused back to the participant. Blood samples will be obtained weekly over 10 weeks.
2520992|NCT02757443|Experimental|Phosphocreatine|"Participants randomly assigned to the phosphocreatine arm receive:~after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV);~together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV;~immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV"
2520997|NCT02757248|Experimental|Cohort -1|Volasertib 50mg/m2 on days 1 and 8 Romidepsin 10mg/m2 on days 1, 8 and 15
3165702|NCT00516451|Experimental|1|
3165703|NCT00516477|Experimental|dose cohort 1|1.5E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
3165704|NCT00516477|Experimental|dose cohort 2|4.8E10 vector genomes voretigene neparvovec-rzyl in 150 microliters administered subretinally
3165705|NCT00516477|Experimental|dose cohort 3|1.5E11 vector genomes voretigene neparvovec-rzyl in 300 microliters administered subretinally
3165706|NCT00516490|Experimental|1|GnRH agonist administration
3165707|NCT00516490|Placebo Comparator|2|Sterile saline injection
3165708|NCT00516516|Experimental|I|Oral L-Carnitine, 1g PO twice daily
2520279|NCT02761720||Lottery|Participants assigned to this arm downloaded both the MyPennMedicine mobile app and Ginger iO mood tracking app. They were also given a lottery incentive if they completed 70% of the daily mood ratings.
2520369|NCT02761291|Experimental|gemcitabine dose escalation|In three combined drugs used in nasopharyngeal carcinoma, the valproic acid and valganciclovir administration will be followed by indication to find the maximum tolerance dose of gemcitabine.
3198728|NCT00873418|Active Comparator|Educational Control|16 weekly telephone calls for extended (standardized) care on heart failure education.
3198729|NCT00873431|Experimental|IC47 30 mcg|30 mcg with Alum
2520691|NCT02759211|Active Comparator|Forwards Walking Group (FWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
2520699|NCT02759211|Experimental|Backwards Walking Group (BWG)|The intervention will consist of three (3), treadmill exercise sessions per week, for eight (8) weeks, for a total of 24 exercise sessions.
2520771|NCT02758743|Experimental|Acetium Lozenge|Acetium lozenge (L-cysteine 3mg) is used in context of each cigarette smoked.
2520775|NCT02758743|Placebo Comparator|Placebo|Identical in appearance with Acetium lozenge, placebo lozenges will be used in the same manner as in experimental arm.
2520812|NCT02758353|Experimental|Community distribution of SP|All the eligible pregnant women were reached with SP either at health clinic and/or at community/household level with sulphadoxine-pyrimethamine (SP). Alerts and reminders were sent to them by community-based health volunteers ahead of subsequent SP doses.
2520840|NCT02758093|Experimental|Speed of Processing Training (10 hours)|Participants randomized to this arm will receive 10 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2520845|NCT02758093|Experimental|Speed of Processing Training (20 hours)|Participants randomized to this arm will receive 20 hours of speed of processing training; this training is designed to improve the speed/accuracy in which they identify and locate visual information using five games/exercises from the POSIT Science Speed of Processing Training. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2520849|NCT02758093|Sham Comparator|Internet Navigational (10 hours)|In this group, participants will receive 10 hours of Internet Navigation Training. Specifically, participants will be given instructional materials and exercises on how to navigate the Internet. For more computer savvy participants, they will be directed to the Thinks.com website. Those who receive 20 hours of speed of processing training will be compared to those participants who are randomized only to receive 10 hours speed of processing training; both of these groups will be compared to those randomized to receive only 10 hours of a computer training (Contact Control Group).
2520939|NCT02757833|Other|Late Life Depressed Arm|Participants in the Late Life Depressed arm will have a confirmed diagnosis of late-life depression.
2520940|NCT02757833|Other|Healthy Control Arm|Participants in the Healthy Control Arm will have no history of mental illness.
2520999|NCT02757261|Experimental|Application of Low-level laser therapy.|The intervention will be twelve sessions (two per week). Laser parameters: wavelength - 786.94 nm; conventional tip; energy density - 25 J/cm²; intensity - 1.675 mW/cm²; output power - 70 mW (0.070 W); and exposure time - 20 seconds per point. The point application method will be used with direct contact with the skin (spot beam of 0.04 cm²), following the protocol suggested by Carvalho et al.50 and Venezian et al.44 A potentiometer will be used to determine the mean power of the laser equipment to ensure the safety of the operator.
2521001|NCT02757261|Experimental|Treatment with Occlusal splint.|The intervention will be a maxillary occlusal splint will be used on the maxilla with palatal and occlusal coverage. Following the protocol established by Hachmann et al., the children will only use the splint at night for two months, with weekly adjustments of a quarter turn.46
2521003|NCT02757261|Active Comparator|Placebo laser|Placebo laser will be performed using the same equipment.
2521006|NCT02757261|No Intervention|Children without bruxism|Control group
2521038|NCT02756871|Experimental|Online guided self-help intervention|CBT based online guided self-help intervention. Intervention can be found at www.overcomingperfectionism.co.uk
2521041|NCT02756871|No Intervention|Control|No intervention.
3198730|NCT00873431|Experimental|IC47 30 mcg w/o|30 mcg without Alum
3198731|NCT00873431|Experimental|IC47 150 mcg|150 mcg with Alum
2521216|NCT02755363|Active Comparator|osteopathic manual therapy (OMT group)|patients who will undergo manual osteopathic therapy.
2521218|NCT02755363|Placebo Comparator|control group (C group)|patients who will undergo manual therapy not aimed to decrease hyperinflation.
2521305|NCT02755077|Experimental|Mask ventilation in rotated head position|Patient's head will be axially rotated 45 degrees to the right
2521308|NCT02755077|No Intervention|Mask ventilation in neutral head position|
2521342|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-10|A total of 40 participants week 0 and week 8 will have low dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 10 L3 in 200 microliter (uL) of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
2521992|NCT02750293|Active Comparator|cholecalciferol|vitamin D (as a 20 000 IU capsule) will be given once a week for 4 months
3198732|NCT00873431|Experimental|IC47 150 mcg w/o|150 mcg without Alum
3198733|NCT00873444|Active Comparator|1) Ceramic-on-Metal Bearing|A cementless acetabular cup with ceramic liner for use in total hip replacement
3198734|NCT00873444|Active Comparator|2) Metal-on-Metal Bearing|A cementless acetabular cup with metal liner for use in total hip replacement
3198735|NCT00873470|Experimental|Stimulation|All patients included have the stimulation
2520296|NCT02761460|Experimental|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy,
2520317|NCT02761213|Experimental|Oral sulfate solution (OSS)|oral sulfate solution (OSS)
2520319|NCT02761213|Active Comparator|2-L PEG/Asc|low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc)
3198736|NCT00873483|Experimental|Arm 1|
3198737|NCT00873496||Sjögren|Pre and post treatment establishment of salivary flow rate, objective and subjective clinical oral complications' severity of the patients using hydroxychloroquine
2520449|NCT02760537|Experimental|Lay Health Worker Intervention|LHWs conducted phone interventions by reminding participants of a series of vaccinations at months 1, 2, and 5 among those assigned to the intervention group. Those who had health insurance were encouraged to complete vaccinations through their providers. If participants did not have health insurance, LHWs provided resources to help those in the intervention access vaccinations by referring them to free vaccine events in the community.
2520451|NCT02760537|Placebo Comparator|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
2520506|NCT02760147|Other|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
2520507|NCT02760147|Other|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
2520509|NCT02760147|Other|PEEP Over Level|PEEP Level upward by 50%, 2 hours
2520511|NCT02760147|Other|PEEP Under Level|PEEP Level downward by 50%, 2 hours
2520522|NCT02759861|Experimental|Harvoni x 8 or 12 weeks|patient will receive 8 or 12 weeks depending on clinical data
2520567|NCT02759809||Children previously assigned to donor milk in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive donor milk when mother's own breastmilk was unavailable. Donor milk was from a milk bank part of the Human Milk Banking Association of North America (HMBANA).
2520570|NCT02759809||Children previously assigned to formula in the DoMINO trial|This study is an observational study of children who were enrolled in a previous trial (DoMINO trial) between 2010 and 2012 during which they were randomized to receive preterm formula when mother's own breastmilk was unavailable. Preterm formula was either Similac Special Care or Enfamil Premature depending on hospital contract with formula companies.
2520600|NCT02759536|Experimental|Boronophenylalanine and IHNI-based BNCT|
3198738|NCT00873509|Experimental|1|Buspirone 2.5 mg
3198739|NCT00873509|Experimental|2|Buspirone 5.0 mg
3198740|NCT00873509|Placebo Comparator|3|Placebo match
3198741|NCT00873522||Community acquired pneumonia|
3198742|NCT00873522||Health-Care-Associated pneumonia|
3198743|NCT00873535|Active Comparator|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
2520795|NCT02758496||ASD Subjects|Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.
2520797|NCT02758496||Healthy Controls|Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group
2520843|NCT02758184|Experimental|ROTEM Group|Patients who are randomized to receive ROTEM
2520848|NCT02758184|No Intervention|Control Group|Patients who are randomized not to receive ROTEM
3165709|NCT00516516|Placebo Comparator|II|Placebo, similar in appearance to experimental drug, given orally twice daily.
3165710|NCT00516555||A, 07, 001|Pregnant women at term with a baby in breech presentation who will have an external cephalic version.
3165711|NCT00516581||no HAART|Patients that no received HAART
3165712|NCT00516581||with HAART|Patients that received HAART
3165713|NCT00516620|Active Comparator|1|Participants receive Health Canada's Food Guide and Physical Activity guide.
3165714|NCT00516620|Active Comparator|2|Participants receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
3198744|NCT00873535|Placebo Comparator|Placebo|This group (N=40) will receive placebo in the same dosing regimen as for Varenicline. The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
3198745|NCT00873548||PFNA_Asia treated|
3198746|NCT00873561|Active Comparator|1 Experimental|NBI-6024 0.1 mg
3198747|NCT00873561|Active Comparator|2 Experimental|NBI-6024 0.5 mg
3198748|NCT00873561|Active Comparator|3 Experimental|NBI-6024 1 mg
3198749|NCT00873561|No Intervention|4 placebo|Placebo injection
3198750|NCT00873574||1|2 patients with MPD for each family. One case for each family will be randomised ; the cohort will be of 120 patients.
3198751|NCT00873574||2|1 control for each family
3198752|NCT00873587|Other|Inspiration|
3198753|NCT00873587|Other|Expiration|
3198754|NCT00873613|No Intervention|Direct ophthalmoscopy|
3198755|NCT00873613|Experimental|Non-dilated retinal photography|
3198756|NCT00873626|Active Comparator|1|fluoroquinolones 5 days
3198757|NCT00873626|Active Comparator|2|fluoroquinolones 10 days
3198758|NCT00873639||A|
3198759|NCT00873665|Experimental|Aerobic exercise|"To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.~The test of the arm effect of incidence of ED will be made with the Wald chi-square test from the logistic regression model. A dichotomous variable indicating whether the patient received PDE-5 inhibitor therapy will be used as a covariate in the model. The arm effect will be summarized by giving arm-specific covariate-adjusted proportions and their 80% confidence intervals, and the p-value."
2520312|NCT02761122|Experimental|Patients with lichen|"Patients with non-erosive lichen planus, erosive lichen planus or lichen sclerosus.~Human biological samples :~Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
2520383|NCT02760953|Experimental|TUR with Cryoablation|Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
2520384|NCT02760953|Active Comparator|TUR with instant instillation|Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
2520426|NCT02760511|Placebo Comparator|Control|Intake of placebo capsules
2520427|NCT02760511|Active Comparator|20 mg|Daily intake of 20 mg anthocyanin
2520428|NCT02760511|Active Comparator|40 mg|Daily intake of 40 mg anthocyanin
2520429|NCT02760511|Active Comparator|80 mg|Daily intake of 80 mg anthocyanin
2520430|NCT02760511|Active Comparator|160 mg|Daily intake of 160 mg anthocyanin
2520432|NCT02760511|Active Comparator|320 mg|Daily intake of 320 mg anthocyanin
2520476|NCT02760251|Experimental|Romiplostim|Romiplostim (a thrombopoietin-receptor agonist, TPO-RA) will be administered subcutaneously once weekly over 22 weeks with a starting dose of 1mcg/kg body weight. The dose will be adjusted based on platelet counts as described in the summary of Product Characteristics (SmPC). Followup examination at week 52.
2520588|NCT02759926|Active Comparator|Denatonium benzoate intragastric|1 µmol/kg bodyweight (10mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
2520589|NCT02759926|Active Comparator|Quinine hydrochloride intragastric|10 µmol/kg bodyweight (100mM) was administered as a bolus into the stomach through a nasogastric feeding tube.
2520591|NCT02759926|Placebo Comparator|Tap water intragastric|An equal amount of tap water was administered as a bolus into the stomach through a nasogastric feeding tube.
2520592|NCT02759926|Active Comparator|Denatonium benzoate intraduodenal|1 µmol/kg bodyweight (10mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
2520593|NCT02759926|Active Comparator|Quinine hydrochloride intraduodenal|10 µmol/kg bodyweight (100mM) was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
2520594|NCT02759926|Placebo Comparator|Tap water intraduodenal|An equal amount of tap water was administered as a bolus into the proximal part of the duodenum through a nasogastric feeding tube.
3198760|NCT00873665|Other|Wait-list control|"To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.~For the analyses of arm differences in erectile dysfunction (IIEF) score, sexual functioning, urinary incontinence, and QOL, the primary endpoints will be the change across time in these continuous variables. Specifically, change across time for LTF patients will be imputed to be zero for all these analyses."
3198761|NCT00873678||1|Children or adult patients affected with JS/CORS
3198762|NCT00873691||1|ICD shocks programmed to Tuned Waveform
3198763|NCT00873691||2|ICD shocks programmed to 50% Tilt waveform
2520779|NCT02758522|Active Comparator|Once-daily insulin|60% of total dose of insulin as NPH insulin in the once-daily regimen was administered subcutaneously before breakfast. Also, 40% in rapid insulin before meals (every 8 hours).
2520782|NCT02758522|Active Comparator|Twice-daily insulin|60% of total dose of insulin as NPH insulin in the twice-daily regimen it was given before breakfast and before dinner. Also, 40% in rapid insulin before meals (every 8 hours).
2520788|NCT02758522|Active Comparator|Triple-daily insulin|60% of total dose of insulin as NPH insulin in the triple daily regimen it was administered before each meal. Also, 40% in rapid insulin before meals (every 8 hours).
2520819|NCT02758249|Active Comparator|sevoflurane|patients under sevoflurane anesthesia
2520820|NCT02758249|Active Comparator|propofol|patients under propofol anesthesia
2520872|NCT02758054|No Intervention|Usual Care|Participants will experience standard practice for lung cancer early detection.
2520874|NCT02758054|Experimental|Usual Care + Patient Navigation|Participants will experience standard practice for lung cancer early detection plus the intervention.
2520906|NCT02757703|Active Comparator|somatostatin group|Somatostatin (Somatosan, BAG Health Care GmbH, Lich, Germany) was given by intravenous bolus (250 μg) followed by 250 μg/hour and continued for 3 days in group S.
2520910|NCT02757703|Placebo Comparator|terlipressin group|Terlipressin (Glypressin, Ferring GmbH, Kiel, Germany) was started at 2mg bolus injection and followed by 1 mg infusion every 6 hours for 3 days in group T.
2520979|NCT02757235|Active Comparator|Irrigation fluid of body temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of body temperature (approximately 37 degrees Celsius)
2520982|NCT02757235|Active Comparator|Irrigation fluid of room temperature|During burr hole evacuation of the chronic subdural hematoma the irrigation fluid used will be of room temperature (approximately 22 degrees Celsius)
3198764|NCT00873704|Active Comparator|1|recieves supplemental oxygen postoperatively
3198765|NCT00873704|No Intervention|2|treated as usual without supplemental oxygen
2521174|NCT02755727|Experimental|Platelet Rich Plasma injection|"In the outpatient setting a sample of venous whole blood will be taken from the patient (40mls), from the antecubital fossa using standard phlebotomy techniques. The Angel™ system will be in the available also in the outpatient clinic and will be used to separate the blood to yield a PRP sample (approximately 15 minutes preparation time). The PRP sample is then injected into the common extensor origin.~2 injections will be used per patient over 2 weeks."
3198766|NCT00873717|Experimental|Dentary|Intervention: trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
3198767|NCT00873717|Experimental|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
3198768|NCT00873717|Experimental|Dentary + nutrition|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed) associated with control of the administration of dietary prescriptions, incitement to eat.
2520378|NCT02761057|Experimental|Arm I (sunitinib malate)|Patients receive sunitinib malate PO on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2520380|NCT02761057|Experimental|Arm II (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2520381|NCT02761057|Experimental|Arm III (crizotinib closed to accrual 12/5/18)|Patients receive crizotinib PO BID on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2520382|NCT02761057|Experimental|Arm IV (savolitinib closed to accrual 12/5/18)|Patients receive savolitinib PO on days 1-42. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
2520943|NCT02757508|Active Comparator|Control|Vitamins/minerals-200 mg premix
2520944|NCT02757508|Experimental|Group 1|Vitamins/minerals + Milk Protein (8.75 g)-the milk protein is a skim milk powder with the sugar lactose.
2520946|NCT02757508|Experimental|Group 2|Vitamins/minerals + Milk/plant Protein (8.75g)-the milk protein is a skim milk protein powder and the plant protein is a rice protein concentrate and the sugar lactose.
2520947|NCT02757508|Experimental|Group 3|Vitamins/minerals + Milk Protein (4.38g)-the milk protein is a skim milk protein powder with the sugar lactose.
3198769|NCT00873717|No Intervention|Control|usual care
3198770|NCT00873743||1|60 women after elective cesarian section
2521112|NCT02756325|Experimental|MRI|
3198771|NCT00873743||2|60 women after elective cesarian section
3198772|NCT00873756|Experimental|A|
2521193|NCT02755688|Experimental|Thoracoscopic surgical ablation|Pulmonary vein isolation, ganglionic plexi ablation, left atrial appendage exclusion
2521195|NCT02755688|Active Comparator|Catheter ablation|Pulmonary vein isolation, linear lines
2521206|NCT02755402|Experimental|Rapid evaluation|Transient elastography, Xpert HCV Viral load, medical and nurse visits
2521257|NCT02755246|Experimental|Polyamine supplementation|750 mg polyamine-rich plant extract per day
2521258|NCT02755246|Placebo Comparator|Placebo|750 mg potato starch per day
2521286|NCT02754843|Active Comparator|Naida Q90-SP|Phonak's commercial power Behind-The-Ear (BTE) device, type 1.
2521288|NCT02754843|Active Comparator|Naida Q90-UP|Phonak's commercial power Behind-The-Ear (BTE) device, type 2.
2521350|NCT02754700|Experimental|Biofeedback Hip|Hip focused biofeedback with neuromuscular training
2521352|NCT02754700|Experimental|Biofeedback Knee|Knee focused biofeedback with neuromuscular training
2521355|NCT02754700|Active Comparator|Neuromuscular Training|Neuromuscular Training component
3198773|NCT00873769|Experimental|Healthy smokers|Healthy smokers, male and female
3198774|NCT00873769|Experimental|Healthy nonsmokers|Healthy nonsmokers, Healthy smokers, male and female
2521439|NCT02753803|Experimental|A group|Evogliptin Pioglitazone Evogliptin+Pioglitazone
2521440|NCT02753803|Experimental|B group|Pioglitazone Evogliptin Evogliptin+Pioglitazone
2521441|NCT02753803|Experimental|C group|Evogliptin Evogliptin+Pioglitazone Pioglitazone
2521442|NCT02753803|Experimental|D group|Pioglitazone Evogliptin+Pioglitazone Evogliptin
2521443|NCT02753803|Experimental|E group|Evogliptin+Pioglitazone Evogliptin Pioglitazone
2521444|NCT02753803|Experimental|F group|Evogliptin+Pioglitazone Pioglitazone Evogliptin
3198775|NCT00873795|Experimental|aripiprazole and sertraline|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and aripiprazole 2.5mg/day.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
3198776|NCT00873795|Placebo Comparator|sertraline and placebo|The patients of this arm receive ten weeks of treatment with a combination of sertraline 50mg/day and placebo.The effect of this arm is assessed for HAM-D17, CGI, SF-36 and BSRS-50.
2521632|NCT02752685||triple negative breast cancer (TNBC)|
2521635|NCT02752685||hormone receptor (HR)-positive cohort|(currently not recruiting for this group)
2521683|NCT02752425|Experimental|With visual feedback|Session of speech therapy conducted with the additional use of articulatory visual feedback based on ultrasound echography, which allows to visualize the patient's tongue in real time on a computer screen
2521685|NCT02752425|No Intervention|Without visual feedback|Session of speech therapy without use of ultrasound echography
3198777|NCT00873834|Experimental|Fluoxetine arm|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
3198778|NCT00873834|Placebo Comparator|placebo arm|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
2521920|NCT02750774|Experimental|Low-Glycemic Index Group|Women in the low- glycaemic index group received a dietary intervention based on 3 main meals and 3 snacks, with a precise macronutrient composition, and a physical activity counseling according to the ACOG and ACSM recommendations.
2521923|NCT02750774|Other|Standard Care Group|Women in the Standard Care Group received a simple nutritional booklet regarding lifestyle, which was in agreement with the Italian Guidelines for a healthy diet during pregnancy that included general advice regarding food consumption and physical activity.
2521984|NCT02750462|Experimental|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
2521988|NCT02750462|Active Comparator|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
2522020|NCT02750150|Experimental|Freezed-dried plasma|transfusion of 4 units of freezed dried plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
3198779|NCT00873886|Experimental|Oseltamivir (Tamiflu)|
3198780|NCT00873886|Other|Esterase|
3198781|NCT00873899||Remote Arm|The patients in Remote arm will receive a Medtronic CareLink Monitor to perform remote interrogation and transmission of ICD data. The remote arm ICD will be programmed to transmit over the CareLink Network.
3198782|NCT00873899||Implantable defibrillator patients|Heart failure patients implanted with a wireless-transmission-enabled ICD.
2520398|NCT02760901|Active Comparator|ACTZ group|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.
2520400|NCT02760901|Active Comparator|NAC group|patients received acetylcysteine NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.
2520456|NCT02760342|Experimental|ASP015K and Metformin|Subjects will receive a single oral dose of metformin on Days 1 and 10, a single dose of ASP015K on Day 3 and multiple doses of ASP015K once daily Day 5 to Day 11. Subjects will receive a single dose of metformin and ASP015K concurrently on Day 10.
2520538|NCT02760082||Semi-structured interviews|20 participants (anticipated)
2520542|NCT02760082||Questionnaire survey|400 respondents (anticipated)
2520544|NCT02760082||Focus group interviews|3-5 focus group interviews (anticipated)
2520573|NCT02759679|Other|Lung cancer|Patients with lung cancer
2520574|NCT02759679|Other|Controls|Controls being either healthy or having other lung disease
2520643|NCT02759484|Experimental|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
2520644|NCT02759484|Active Comparator|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
2520675|NCT02758925|Experimental|DLBCL patients|they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles
2520764|NCT02758665|Experimental|Obinutuzumab, Ibrutinib, Venetoclax|Obinutuzumab i.v.: Cycle 1 (3000 mg), Cycle 2-6 (1000 mg) Ibrutinib (tablet): Cycle 1-15 (420 mg daily) Venetoclax (tablet): Cycle 1 (last 7 days 20 mg daily), Cycle 2 (ramp up 50 mg to 400 mg) Cycle 3-12 (400 mg daily)
2520882|NCT02757820|Active Comparator|LMA classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
2520883|NCT02757820|Active Comparator|I-gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
2520886|NCT02757820|Active Comparator|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
2520966|NCT02757378|Experimental|Neuroplasticity Education Group|Patients who receive manual physical therapy treatment with a neuroplasticity explanation of the basis for the technique
2520970|NCT02757378|Active Comparator|Biomechanical Education Group|Patients who receive manual physical therapy treatment with a traditional, biomechanical explanation of the basis for the technique
2521077|NCT02757014|Experimental|Coppertone (BAY987517)|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2521115|NCT02756416|Experimental|ASL MRI and MRA|All participants will undergo ASL-MRI and MRA at three points; baseline, month 1, and month 3.
3198783|NCT00873925|Experimental|Autologous UCB Plus Vit D Omega 3 FA|A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
3198784|NCT00873925|No Intervention|Control|Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
3198785|NCT00873938||1-supervised|
2521477|NCT02753764|No Intervention|Normal control|Health volunteers will be recruited as an additional control group.
2521479|NCT02753764|Other|Corticosteroid sensitive (CS) asthmatics|After the initial visit, asthmatics will be given oral prednisone for 1 week and patients will return for the spirometer assessment. Patients will be defined as CR if <10% improvement in FEV1 % predicted is observed and as CS in >12% improvement in FEV1% predicted is observed.
2521481|NCT02753764|Active Comparator|Corticosteroid resistant (CR) asthmatics active|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
2521484|NCT02753764|Placebo Comparator|Corticosteroid resistant (CR) asthmatics placebo|The study will have a 1 week oral corticosteroid (OSC) run-in period. Subjects unresponsive to OCS will be defined as corticosteroid resistant (CR) and randomized to two crossover treatment sequences consisting of 4 weeks of inhaled AZD7624 or placebo, followed by 4 weeks of a washout period, and another 4 weeks of placebo or ASD7624
2521539|NCT02753387|Experimental|CHLORHEXIDINE|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of chlorhexidine
2521540|NCT02753387|Placebo Comparator|NaCl 0.9 %|Patients will receive 1 preoperative oral preparation and 1 peroperative oral preparation of NaCl 0.9%
3198786|NCT00873938||2 -unsupervised|
3198787|NCT00873951|Experimental|Intact casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled intact casein
3198788|NCT00873951|Experimental|Hydrolyzed casein|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
3198789|NCT00873951|Experimental|AA|Subjects undergo an intestinal and metabolic exploration following the ingestion of a standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
3198790|NCT00873977|Active Comparator|C-flex|
3198791|NCT00873977|Active Comparator|A-flex|
3198792|NCT00873977|No Intervention|Auto-CPAP|
3198793|NCT00873990|Active Comparator|1|application of total etch bonding agent ( 5th generation) for placement of resing based pit and fissure sealants.
3198794|NCT00873990|Experimental|2|Self etch bonding agent (7th generation) application for placement of resin based pit and fissure sealant
3198795|NCT00874003|Experimental|mirtazapine, tablet, 30 mg|n=29
3198796|NCT00874003|Placebo Comparator|sugar pill|n=30
2520402|NCT02760875||Early Weight Bearing|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from day 1. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2520403|NCT02760875||control|"Ankle immobilized with orthosis (DJO Nextep Contour 2 Walker) with 3 1.5 cm wedges in the heel, fixing the angle between 20-30 degrees. The orthosis was used for 8 weeks, gradually removing the wedges. Full weight bearing was allowed from week 6. The orthosis was worn 24 hours / day the first 2 weeks.~From week 2 controlled motion exercises and removal of the orthosis 5 times a day."
2520465|NCT02760459|Active Comparator|Dexamethasone|The steroid group will receive Dexamethasone 10 mg IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of Dexamethasone 10 mg IV postoperatively at 24 and 48 hrs.
2520466|NCT02760459|Placebo Comparator|Placebo|The control group will receive sterile normal saline solution, serving as placebo, IV immediately prior to induction of spinal anesthesia and will receive a second and third dose of placebo IV postoperatively 24 and 48 hrs. Both Dexamethasone and normal saline solution will be administered as an IV push.
2520521|NCT02760043|Experimental|Dexamethasone|LIA mixture with the addition of 8mg Dexamethasone.
2520523|NCT02760043|Sham Comparator|Saline|LIA mixture with the addition of 2mL of 0.9% NaCl Saline.
2520590|NCT02759744|Experimental|1|ultrasound image-guided focal laser ablation device
2520625|NCT02759432|Experimental|Intervention|Participants in the intervention group will complete a 4-week school-based high-intensity interval exercise training programme. The intervention will take place twice per week, and comprise of 6-8 repetitions of 45 s maximal effort exercise (boxing, running, soccer and basketball drills), each interspersed with 90-s rest. Participants will be encouraged to work maximally during the 45-s repetitions.
2520626|NCT02759432|No Intervention|Control|Participants in the control group will be instructed not to change their lifestyle, dietary or physical activity habits during the intervention period, and maintain their normal school physical education routine
2520663|NCT02759094|Experimental|Treatment with RefluxStop device|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ at all time
2520865|NCT02758106|Active Comparator|HFCW oscillation|"HFCWO was performed using a Vest Airway Clearance System Model 105 (Hill-Rom, St. Paul, Minnesota). HFCWO was applied to each subject at a frequency of 10-12 Hz and a pulse pressure setting of 1-2 selected for 15 minutes. The patients receiving HFCWO were placed in a semi-upright sitting position. Following HFCWO, suction was performed immediately via an endotracheal tube.~Changes to the initial ventilator settings during HFCWO were recorded before and at 5, 10 and 15 minutes. The variables included peak airway pressure, positive-end expiratory pressure, respiratory rate, fraction of inspired oxygen, inspiratory time, and sensitivity settings. Following HFCWO, suction was performed immediately via an endotracheal tube."
2520866|NCT02758106|Placebo Comparator|placebo intervention|the patients undergoing CCPT received cup-hand percussion with the hands positioned 3 inches from the chest, striking the chest with a waving movement while they were placed in right and left decubitus positions for 5-10 minutes each. Following CCPT, suction was performed immediately via an endotracheal tube.
2520900|NCT02757729|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 8 weeks
2520901|NCT02757729|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 8 weeks
2520904|NCT02757729|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 8 weeks
2520907|NCT02757729|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 8 weeks
2520968|NCT02757404|Experimental|Ultrasonography guidance|Ultrasonography guidance injection of Meditoxin®.
2520972|NCT02757404|Experimental|Electrical stimulation guidance|Electrical stimulation guidance injection of Meditoxin®.
2520974|NCT02757404|Experimental|Manual needle placement|Manual needle placement injection of Meditoxin®.
2521067|NCT02756663|Experimental|Arm A: PAN (10mg) + CFZ + Dex|Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2521069|NCT02756663|Experimental|Arm B: PAN (20mg) + CFZ + Dex|Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2521070|NCT02756663|Active Comparator|Arm C: CFZ + Dex|Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
2521108|NCT02756273|Experimental|no bridge device|After the ileostomy creation, no bridge device was placed.
2521110|NCT02756273|Active Comparator|bridge device|A bridge device was placed after the stoma creation.
2521171|NCT02755909|Other|Subjects|Pra-anesthetic education given to the subjects includes the anatomy of a normal heart, normal blood circulation, anatomy and pathophysiology of the disease in the respected subject, surgery procedures needed, anesthetic procedures needed for the surgery, and cardiopulmonary bypass procedures. Education and discussion were given repeatedly until subjects could repeat the materials given correctly.
3198797|NCT00874016|Active Comparator|Airtraq|Intubation with the use of the Airtraq
2521223|NCT02755376|Active Comparator|ACL reconstruction only|only ACL reconstruction without any injection
2521232|NCT02755376|Experimental|ACL reconstruction + Cartistem(TM)|ACL reconstruction and concomitant Cartistem(TM) injection which is human cord blood derived mesenchymal stem cell under arthroscopy.
2521239|NCT02755376|Experimental|ACL reconstruction + Hyaluronic acid|ACL reconstruction and concomitant hyaluronic acid injection under arthroscopy
2521377|NCT02754544|Experimental|Diagnostic (electrocorticography)|Patients undergo tumor resection. During surgery, patients also undergo electrocorticography with either the CorTec high resolution hybrid grid, the PMT high-resolution grid, or the Ad-Tech grid followed by direct electrocortical stimulation.
2521421|NCT02754128|Active Comparator|BeFAST|Motor learning-based program involving athletic lower extremity training of gait-related skills.
2521422|NCT02754128|Active Comparator|BeSTRONG|Lower limb strength training program involving progressive muscle resistance exercises.
2521521|NCT02753686||Cohort 1: Endocrine Therapy (ET)|HR+ HER2- male, female pre/postmenopausal advanced breast cancer patients being treated with endocrine therapy
2520416|NCT02760680|Active Comparator|Diagnostic Device (WatchPAT 200 (TM))|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
2520446|NCT02760290|Experimental|Extraperitoneal group|Extraperitoneal cesarean section will perform after rectus sheat incision and carefully bladder dissecting.
2520447|NCT02760290|Active Comparator|Intraperitoneal group|Conventional transperitoneal cesarean will perform
2520468|NCT02760173|Experimental|Single intervention arm|This is the only arm in this study, measuring verticality perception after prolonged roll-tilt over 5min.
3198798|NCT00874016|Active Comparator|Direct Laryngoscopy|Intubation using direct laryngoscopy
3198799|NCT00874042|Experimental|ARQ 197 in combination with gemcitabine|
3198800|NCT00874068|Active Comparator|Standard vegetable oil formula|
3198801|NCT00874068|Active Comparator|InFat|
3198802|NCT00874068|No Intervention|Breast-fed|
3198803|NCT00874107|Experimental|1|Imprime PGG + bevacizumab + paclitaxel/carboplatin
3198804|NCT00874107|Other|2|bevacizumab + paclitaxel/carboplatin
3198805|NCT00874133|Active Comparator|Motillium|20 mg motilium thrice daily for 12 weeks.
3198806|NCT00874133|Active Comparator|Acupuncture|Acupuncture treatment.
3198807|NCT00874146||1|HER2-positive advanced breast cancer
3198808|NCT00874159||A|
3198809|NCT00874172|Active Comparator|2|Combination of acetaminophen, morphine
2520799|NCT02758509||PEG/RBV|Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2011)
2520800|NCT02758509||PEG/RBV+BOC or TVR|Boceprevir 800 mg/8h or Telaprevir 750 mg/8h plus Pegylated interferon alfa-2a 180 microg/week plus ribavirin 800-1200 mg during 48 weeks according to routine practice and European Guidelines (EASL recommendations 2014)
2520802|NCT02758509||IF-DAAs|"Interferon-free direct-acting antiviral combinations according to routine practice and European Guidelines (EASL recommendations 2015)~Fixed-dose combination of sofosbuvir (400 mg) and ledipasvir (90 mg) daily +/- ribavirin 12-24 weeks~Fixed-dose combination of ombitasvir (75 mg), paritaprevir (12.5 mg) and ritonavir (50 mg) in one single tablet (two tablets once daily) and dasabuvir (250 mg) (one tablet twice daily) with ribavirin 800-1200 mg 12 weeks (Genotype 1b) or 24 weeks (genotype 1a)~Daily sofosbuvir (400 mg) and daily simeprevir (150 mg) +/- ribavirin 12-24 weeks~Daily sofosbuvir (400 mg) and daily daclatasvir (60 mg) +/- ribavirin 12-24 weeks"
2520870|NCT02758158|Experimental|Tri-modal imaging|Ultrasound and photoacoustic imaging of thyroid and adjacent lymph nodes. Imaging time: Approximately 30 minutes
2520936|NCT02757742||Non-ischemic cardiomyopathy|Non-ischemic cardiomyopathy patients with baseline cardiac magnetic resonance LVEF≤35%
2520956|NCT02757313|Experimental|Regular Users|People who use marijuana regularly will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
2520959|NCT02757313|Experimental|Occasional Users|People who use marijuana occasionally will be given a low dose THC marijuana, high dose THC marijuana and placebo marijuana, in a randomized order, at the study visits.
3198810|NCT00874172|Experimental|1|Combination of acetaminophen, nitrous oxide, nefopam, morphine
3198811|NCT00874185||Questionnaire|filling in questionnaires
2521192|NCT02755701|Experimental|BCAA group|Branched-chain amino acid, 4.15g, Tid
2521194|NCT02755701|Placebo Comparator|Placebo group|Placebo, 4.15g, Tid
2521248|NCT02755350|Experimental|Truvada|Daily oral PrEP (Truvada) is provided to a cohort of 2100 participants who will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period. In between some visits, they will return to the pharmacy for a refill of PrEP, counselling on adherence and medication of side effects.
2521306|NCT02754960|Active Comparator|Thalidomide group|Patients were randomly assigned to the thalidomide group and received 100 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
2521312|NCT02754960|Placebo Comparator|Placebo group|Patients were randomly assigned to the placebo group and received 100 mg of thalidomide placebo (Pharmaceutical Co., Ltd. of Chang Zhou, China) orally four times daily at 10 p.m. for four months.
3198812|NCT00874211||Observation|Patients will be observed and will undergo assessment of therapy complications.
3198813|NCT00874224|Active Comparator|1|patients undergoing open left lateral hepatic sectionectomy
3198814|NCT00874224|Active Comparator|2|patients undergoing a laparoscopic left lateral hepatic sectionectomy
3198815|NCT00874224|Active Comparator|3|Prospective registry of patients that cannot be randomized (both open and laparoscopic left lateral hepatic sectionectomy)
3198816|NCT00874289||Acute heart failure patients|
3198817|NCT00874289||Chronic heart failure patients|
3198818|NCT00874302|Experimental|25 mg|25 mg Proellex
3198819|NCT00874302|Experimental|50 mg|50 mg Proellex
3198820|NCT00874328|Experimental|study arm|Irinotecan /IV D1 Cisplatin 60mg/m2 iv D1 S-1 bid, P.o. D1 ~ 14 q 3 weeks until maximum 6 cycles
3198821|NCT00874341|No Intervention|1|
3198822|NCT00874341|Active Comparator|2|4 portions fruit and vegetables daily for 12 weeks
3198823|NCT00874341|Active Comparator|3|7 portions of fruit and vegetables daily for 12 weeks
3198824|NCT00874354|Experimental|Autologous bone marrow stem cells|Patients within 3 to 14 days from percutaneous coronary intervention (PCI) and stent implantation for Acute Myocardial Infarction (AMI) will receive either 50 cc's or 100 cc's of autologous bone marrow mononuclear cells through an intracoronary tranplantation of stem cells into the infarct-related coronary artery.
3198825|NCT00874380||1|First describe the diet of a cohort of dialysis patients with focus on fiber content.
3198826|NCT00874393|Active Comparator|Dopamine and hydrocortisone|Dopamine AND hydrocortisone
2520483|NCT02760316|Experimental|AZD9567 oral suspension of 80 mg|Participants will receive oral suspension of 80mg dose strength
2520485|NCT02760316|Active Comparator|Prednisolone oral capsules of 20 mg|Participants will receive oral capsules of 5 mg dose strength
2520489|NCT02760316|Experimental|AZD9567 oral suspension of 125 mg|Participants will receive oral suspension of 125 mg dose strength
2520496|NCT02760316|Experimental|AZD9567 oral suspension of 155 mg|Participants will receive oral suspension of 155 mg dose strength
2520498|NCT02760316|Active Comparator|Prednisolone oral capsules of 5 mg|Participants will receive oral capsules of 5 mg dose strength
2520502|NCT02760316|Active Comparator|Prednisolone oral capsules of 40 mg|Participants will receive oral capsules of 5 mg dose strength
2520555|NCT02759848||with history of TB|
2520559|NCT02759848||without history of TB|
2520607|NCT02759627|No Intervention|Conventional Training|Conventional physical therapy consisted of neurophysiological concepts such as Bobath and Brunnstrom.Training sessions focused on static and dynamic postural tasks, improving lower and upper extremity range of motion, strengthening and overground walking. During walking training, emphasis was on distance walked than on gait quality. Symmetrical weight distribution was encouraged through verbal and tactile cues and was made more difficult by the addition of arm activities or actions requiring trunk rotation. In an effort to improve rhythmic weight-shifting ability, subjects practiced shifting their weight in forward and backward directions and side to side while performing reaching tasks. A session lasted 45 minutes, for 5 days per week for 6 weeks.
2520608|NCT02759627|Experimental|Robotic-Assisted Gait Training|Lokomat (Hocoma) was used in Robotic-Assisted Gait Training group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait. Robotic-Assisted Gait Training sessions lasted 45-minute sessions, 2 days a week during 6 weeks.
2520610|NCT02759627|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-Robotic-Assisted Gait Training, 2 days a week during 6 weeks.
2520628|NCT02759224|Other|Arm A (Lafutidine and Irsogladine maleate --> BRI-1501)|Subjects of Arm A take Lafutidine and Irsogladine maleate Individual tablets at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm A take a BRI-1501 tablet at 36th day
2520631|NCT02759224|Other|Arm B (BRI-1501 --> Lafutidine and Irsogladine maleate)|Subjects of Arm B take a BRI-1501 tablet at 1st day as period I. And then, after wash out for 35 days, as period II, subjects of Arm B take Lafutidine and Irsogladine maleate Individual tablets at 36th day
3198827|NCT00874393|Active Comparator|Dopamine and placebo|Dopamine AND normal saline placebo
3198828|NCT00874393|Active Comparator|Placebo and hydrocortisone|Dextrose (D5W) placebo AND hydrocortisone
2520786|NCT02758587|Experimental|Dose - escalation|"Does-escalation in an all-comers phase I population, with treatment-refractory advanced solid malignancies, unselected by tumour type. Two cohorts of up to evaluable 6 patients in each:~Cohort 1: 200mg (IV) pembrolizumab every 3 weeks; plus 200mg (oral) defactinib twice daily~Cohort 2: 200mg (IV) pembrolizumab every 3 weeks; plus 400mg (oral) defactinib twice daily~Interventions:~Drug: Defactinib~Drug: Pembrolizumab"
2520791|NCT02758587|Experimental|Pancreatic|Pancreatic expansion for response assessment (single arm). Optional paired biopsies prior to treatment and after 14 days of treatment. All would have concurrent therapy with pembrolizumab + defactinib (VS-6063) from the start (c.f. NSCLC & mesothelioma expansions below). 15 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 6
2520792|NCT02758587|Experimental|NSCLC|NSCLC paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and after around 14 days of treatment. 1:1 randomised split of patients having their mandatory on-treatment biopsy after concurrent therapy, or after a defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
2520793|NCT02758587|Experimental|Mesothelioma|Mesothelioma paired-biopsy expansion for tissue biomarkers. Mandatory biopsies prior to treatment and around 14 days of treatment. 1:1 randomised split of patients having thier on-treatment biopsy after concurrent therapy, or after defactinib (VS-6063) monotherapy run-in. 16 evaluable patients with an interim futility assessment for clinical response and tolerability when data available from 11.
3198829|NCT00874393|Placebo Comparator|Placebo and Placebo|Dextrose (D5W) placebo AND normal saline placebo
3198830|NCT00874406|Experimental|1|transhepatic arterial chemotherapy (TAC) were given 7 days before liver metastasis resection. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
2520937|NCT02757664|Active Comparator|Shock wave plus eccentric exercises|Shock wave therapy associated with eccentric exercises rehabilitation program.
2520938|NCT02757664|Placebo Comparator|Placebo plus eccentric exercises|Placebo associated with eccentric exercises rehabilitation program.
2520980|NCT02757196|Experimental|Rituximab plus methylprednisolone|Combination therapy with rituximab （1000mg IV day1, week 3, week 17 , and week 19）plus short-term methylprednisolone (1mg/kg, oral or IV; reduce to 50% of base dose at week 4, then reduce 8mg every 1 week until stopped).
2520985|NCT02757196|Active Comparator|Methylprednisolone|standard dose methylprednisolone alone (1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks).
2521044|NCT02756936|Experimental|A Test|Test drug (Daclatasvir zeta)1 tablet contains 60 mg Daclatasvir
2521045|NCT02756936|Active Comparator|B Reference|Reference drug (Clatazev)) 1 tablet contains 60 mg Daclatasvir
2521062|NCT02756598|Active Comparator|Sufentanil I|"Randomized arm moderate sufentanil I: bolus 1 microgram/kg propofol I: infusion 0.03 mg/kg/min"
2521065|NCT02756598|Active Comparator|Sufentanil II|"Randomized arm low sufentanil II bolus 0.5 microgram/kg propofol II: infusion 0.06 mg/kg/min"
2522785|NCT02745405|Experimental|Fat Suit Condition|Participants are randomly assigned to wear a fat suit and then walk across campus.
3198831|NCT00874406|Active Comparator|2|Liver metastasis resection was done without TAC. Adjuvant folfox4 chemotherapy was done within 28 days after surgery.
3198832|NCT00874419|Experimental|erlotinib|Arm 1 receive erlotinib 150 mg oral, once a day until progression or unacceptable toxicity
2520495|NCT02760498|Experimental|Group 4|Patients with advanced CSCC [metastatic (nodal or distal) or unresectable locally advanced] Cemplimab administered intravenously every 4 weeks.
2520499|NCT02760498|Experimental|Group 6|Patients with advanced CSCC (metastatic [nodal or distant] or locally advanced). Cemiplimab administered IV every 3weeks.
2520618|NCT02759497||Serum amyloid A level in SBP|serum amyloid A level
2520619|NCT02759497||Serum amyloid A level in cirrhosis|Serum amyloid A level
3198833|NCT00874419|Active Comparator|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
3198834|NCT00874445||ICD shocks programmed to Tuned Waveform|ICD shocks programmed to Tuned Waveform
2520922|NCT02758080|Experimental|Matched|A molecular profile is identified using next generation sequencing. A participant in this arm is assigned to early clinical trial studying targeted agent, which is anticipated to have the best response rate.
2520926|NCT02758080|Other|Not matched|A participants in this arm is assigned to a clinical trial at physician's choice.
2520962|NCT02757300|Experimental|Hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
2520965|NCT02757300|Active Comparator|Without hypopharyngeal packing|"Patients with indication for surgery of the sinuses were randomly assigned to one of the two study groups.~After standardized anaesthetic management and PONV prophylaxis routinely applied the patients were screened for mucosal injury on second postoperative day. Furthermore, the amount of analgetic and anti-emetic drugs and the severity of pain and PONV were recorded throughout the hospital stay."
2521034|NCT02757066|Experimental|NPC-15 Granules Lower Dose|NPC-15 Granules Lower Dose group which is administered 1mg melatonin
2521036|NCT02757066|Experimental|NPC-15 Granules Higher Dose|NPC-15 Granules Higher Dose group which is administered 4 mg melatonin
2521040|NCT02757066|Placebo Comparator|NPC-15 Placebo Granule|NPC-15 Placebo Granules group which is administered placebo melatonin
3198835|NCT00874445||ICD shocks programmed to Fixed Tilt Waveform|ICD shocks programmed to Fixed Tilt Waveform
3198836|NCT00874458|Experimental|MRI|
2521246|NCT02755298|Experimental|Acetazolamide|Twice a day 250 mg acetazolamide for 5 weeks
2521247|NCT02755298|Placebo Comparator|Placebo|Placebo capsule 250 mg (Mannitol) twice a day 5 weeks
2521292|NCT02754921|Experimental|Ultra-perc|
2521297|NCT02754921|Experimental|Ciaglia Blue Dolphin|
2521374|NCT02754687|Placebo Comparator|Placebo|Placebo
2521376|NCT02754687|Experimental|11βmethyl nortestosterone dodecylcarbonate|11β-MNTDC in doses of 100 mg, 200 mg, 400 mg, and 800 mg
2521430|NCT02754193|Experimental|Moderate hypothermia|Moderate hypothermia :Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of moderate hypothermia during 24 hours (Temperature at 33°C≤ T°C ≤34°C) associated with usual care
2521431|NCT02754193|No Intervention|Normothermia|Normothermia: Patients with cardiogenic shock treated with arteriovenous ECMO to a strategy of normothermia (36°C≤ T°C ≤37°C) associated with usual care
3198837|NCT00874471||sarcoidosis|
3198838|NCT00874471||ankylosing spondylitis|
3198839|NCT00874471||Behcet's disease|
2521669|NCT02752347|Experimental|unilateral crossbite|unilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
2521671|NCT02752347|No Intervention|control|the surface Electromyography (surface EMG device) device will be used to examine the muscle activities on normal patients
2521672|NCT02752347|Experimental|Bilateral crossbite|Bilateral crossbite patients with constricted maxilla, going to be treated by rapid maxillary expanders the surface Electromyography (surface EMG device) device will be used to examine the muscle activities before and after expansion
2521693|NCT02752178||DEP+MA+|Incompletely responsive patients (approximately N ~100) who are currently depressed after greater than 6 weeks of treatment with one or more monoaminergic antidepressants
2521696|NCT02752178||DEP-MA+|Responsive patients (approximately N~50) who are not currently depressed after greater than 6 weeks of treatment with a monoaminergic antidepressant
2521697|NCT02752178||DEP+MA-|Untreated patients (approximately N~50) who are currently depressed but have not been treated with monoaminergic antidepressants in the previous 6 weeks
2521698|NCT02752178||DEP-MA-|Healthy volunteers (approximately N~50) who have no personal history of depression requiring treatment with either monoaminergic antidepressants or other clinical interventions including psychotherapy
2521757|NCT02751957|Experimental|Intervention|Receives caregiver coaching version of the Early Start Denver Model (ESDM) intervention, delivered by non-specialist workers. ESDM is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
2521824|NCT02751749|Experimental|Unified Protocol|"CBT based Internet delivered treatment targeting transdiagnostic vulnerability and maintaining factors for chronic pain and emotional problems.~Since this is a new target Group, a replicated single case design was used and participants are their own Control Group (no other treatment arms)."
2521856|NCT02751268|Placebo Comparator|Control|placebo for the realization of infraorbital and infratrochlear block
2521857|NCT02751268|Active Comparator|Ropivacaine|ropivacaine for the realization of infraorbital and infratrochlear block
2521913|NCT02750982|Experimental|Laughter therapy|effects of Laughter therapy (LT) on mood, self-efficacy and other wellness measures in people with neurological conditions.
3198840|NCT00874471||toxoplasmosis|
3198841|NCT00874471||herpetic acute retinal necrosis|
3198842|NCT00874471||idiopathic uveitis|
3198843|NCT00874471||ankylosing spondylitis (no uveitis)|
3198844|NCT00874471||sarcoidosis (no uveitis)|
3198845|NCT00874471||Behcet's disease (no uveitis)|
3198846|NCT00874471||normal control|
3198847|NCT00874484|Experimental|1|
3198848|NCT00874484|Placebo Comparator|2|
3198849|NCT00874523|Active Comparator|Arm A|
2520524|NCT02760108||Index case|Patients with a family history of Parkinson's/parkinsonism, and/or early onset Parkinson's/parkinsonism. The first individual member from a family who is recruited to the study.
2520526|NCT02760108||Affected relatives|Patients with Parkinson's/parkinsonism who are first or second degree relatives of an Index Case.
2520528|NCT02760108||Unaffected relatives|Participants who do not have Parkinson's/parkinsonism and are first or second degree relatives of an Index Case.
2520571|NCT02759783|Active Comparator|Standard of Care|Standard of care (SOC) is at the discretion of the local oncologist.
2520572|NCT02759783|Experimental|Standard of Care + SBRT|Patients randomised to SBRT will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC.
2520641|NCT02759328|Experimental|Xbox Kinect™ training group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program plus 60 minutes/day, 5 days/week, 4 weeks (20 sessions) Xbox Kinect™ upper extremity training. Two games both of which require using upper extremities, were chosen and each game was played for 30 minutes per session.
2520642|NCT02759328|Active Comparator|Conventional rehabilitation group|60 minutes/day, 5 days/week, 4 weeks (20 sessions) conventional rehabilitation program only. The treatment protocol was individualized according to the goals which were determined depending on each patient's needs and functional level.
2520693|NCT02758977|Experimental|ALPPS|"ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS)~Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) is performed according to local practice in the respective centers. Preconditions to participation are experience with major liver resections and documentation of having performed at least 5 ALPPS cases prior to participation due to the learning curve with this quite complex procedure.~The amount of transsection (in-situ split/liver partition) in Step 1 is left to the participating center, no minimal % of transsection is specified."
2520700|NCT02758977|Active Comparator|TWO STAGE HEPATECTOMY|"TWO STAGE HEPATECTOMY (TSH)~Two-Stage Hepatectomy is defined as:~Partial resection + portal vein ligation (RES PVL)~Partial resection + secondary portal vein embolization (RES PVE). Followed by (extended) hemihepatectomy after an interval to induce hypertrophy of the liver.~Conventional Two- Stage Hepatectomies will be standard procedures of the centers participating in the study."
2520769|NCT02758678||1-patients with operating tumor|"1- 23 patients with operating tumor; In 1 group the specimens of blood will be collected day before surgery and 1-2 month after surgery. Will be collected: histopathology outcomes - type carcinoma, tumore volume and before surgery: morphology and coagulation system. Will be assessed correlation between mentioned above factors and concentration of P-selectin.~Will be compared concentration of P-selectin in 3 groups of patients.~Serum separation and Raman spectroscopy analysis. A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
2520770|NCT02758678||2-patients with advanced desease.|"2- ten patients with advanced and metastatic disease who received palliative RT (RT - radiotherapy);~In 2 group - the specimens of blood we collected before palliative treatment-radiotherapy. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens.The Raman spectra (RS) assessed as above"
2520772|NCT02758678||3-patients with inoperable disease|"In group 3 - the specimens of blood we collected before radical treatment and one month after completion treatment. Will be collected: histopathology outcomes - type carcinoma, morphology. Will be assessed correlation between mentioned above factors and concentration of P-selectin. Will be compared concentration of P-selectin in 3 groups of patients. Serum separation and Raman spectroscopy analysis:~A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. The Raman spectra (RS) of the solid residues from serum samples were measurement by placing 10µl of serum from the aliquots onto an aluminium substrate and allowed to dry for at least 30 min."
2520839|NCT02758327|Experimental|TheraTears Lubrication Drop|TheraTears Lubricating Eye Drops to be instilled 1 drop in both eyes 4 times per day over a period of 8 weeks.
2520930|NCT02757885|Other|Bone Marrow Donor|Participants who are related marrow donors and are 2-4 (out of 8) human leukocyte antigen (HLA) antigen mismatched and towards whom the recipient does not have donor specific antibodies.
2520932|NCT02757885|Experimental|Bone Marrow Recipient|Participants with sickle cell disease (SCD) will receive bone marrow from a human leukocyte antigen (HLA) matched donor.
2521015|NCT02757170|Experimental|I|Thromboelastography Acute on chronic liver failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
2521017|NCT02757170|Active Comparator|Group II|Thromboelastography Healthy Controls: Healthy persons' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation.
2521020|NCT02757170|Experimental|Group III|Thromboelastography Chronic Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
2521022|NCT02757170|Experimental|Group IV|Thromboelastography Acute Liver Failure: Patients' whole blood will be taken and subjected to undergo coagulation with thromboelastometry and various graphic tracings will be recorded which will highlight the process of coagulation in these patients
3198850|NCT00874523|Active Comparator|Arm B|
2521145|NCT02756065||Control|Individuals between 18-30 years old No diagnosis of Bipolar Disorder or Schizophrenia No intervention used
2521151|NCT02756065||Bipolar Disorder|Individuals between 18-30 years old Diagnosis of Bipolar Disorder No intervention used
2521153|NCT02756065||Schizophrenia|Individuals between 18-30 years old Diagnosis of Schizophrenia or Schizoaffective Disorder No intervention used
2521593|NCT02753010||Elective hip replacement|Women on waiting list for elective hip replacement with gastric emptying of carbohydrate-rich beverage
3198851|NCT00874536|Experimental|ALA|This group will receive the ALA supplement
3198852|NCT00874536|Placebo Comparator|Placebo|This group will receive the placebo supplement
2520530|NCT02759913||Amyotrophic lateral sclerosis|Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.
2520532|NCT02759913||ALS mimics|Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection
2520581|NCT02759757|Experimental|Kinesio Taping|"Patients from this group will receive the kinesio Taping® Tex Gold tape according to the manufacturer's instructions. Kinesio Taping will be applied for the purpose of inhibiting the erector spinal muscle from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae with 10 to 15% tension (paper-OFF) in a I position bilaterally."
2520582|NCT02759757|Placebo Comparator|Placebo|Patient from this group will receive a 5cm-wide Micropore® tape from the twelfth thoracic vertebrae (longissimus portion) up to the first sacral vertebrae bilaterally.
2520585|NCT02759757|No Intervention|Control|Patients allocated will not receive any intervention.
2520616|NCT02759380|Experimental|Phytoestrogen-rich foods|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks).~The patients in the experimental group will be given a package containing food with a high amount of phytoestrogens."
2520617|NCT02759380|No Intervention|Control group|"Introduced to the study by a dietitian.~Receive general information about healthy food choices (according to the Swedish National Food Agency's recommendations for the general public).~Be told not not to eat any dietary supplements, though no other dietary restrictions will be given.~Called one time during the study and perform a 24-hour recall.~The intervention continues until the day before the surgery (at least 6 weeks)."
3198853|NCT00874562|Active Comparator|Steroid Only|Corticosteroid Alone
3198854|NCT00874562|Active Comparator|Steroid plus Rapamycin|Corticosteroid plus Rapamycin
3198855|NCT00874575|Placebo Comparator|1|Control
2520869|NCT02758028|Other|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
2520894|NCT02757716|Other|Sleeve Gastrectomy|Obese patients who undergo sleeve gastrectomy fill in questionnaire
2520895|NCT02757716|Other|Roux-en-Y-Gastric Bypass|Obese patients who undergo roux-en-y-gastric bypass fill in questionnaire
2520896|NCT02757716|Other|One anastomosis-Gastric Bypass|Obese patients who undergo one anastomosis gastric bypass fill in questionnaire
2520955|NCT02757495|No Intervention|Traditional|This will utilize the traditional method of performance of single dose caudal epidural block
2520958|NCT02757495|Experimental|Caudal dexmedetomidine|In this arm, single dose caudal epidural injection will be done patients in this arm will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%
2521010|NCT02757118|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2521013|NCT02757118|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2521075|NCT02756897|Experimental|Treatment (ibrutinib, venetoclax)|Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
2521102|NCT02756221|Experimental|Probiotics|Probiotics capsules, one capsule daily for 90 days.
2521103|NCT02756221|Placebo Comparator|Placebo|Starch capsules, one capsule daily for 90 days
2521122|NCT02756143|No Intervention|Control Group|Non- supervised physical exercise program during pregnancy
2521131|NCT02756143|Experimental|Exercise Group|Supervised physical exercise program during pregnancy
2521178|NCT02755948|Experimental|RSV A Memphis 37|Half the participants will be inoculated with RSV Memphis 37 10(4) plaque forming units (PFU) in 1 milliliter (mL) 25% sucrose/Dulbecco's Modification of Eagle's Medium (DMEM) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2521187|NCT02755948|Experimental|Influenza A/California/04/2009|Half the participants will be inoculated with Influenza A/California/04/09 3.5x10(4) tissue culture infective dose 50% (TCID50) in 1 mL in Dulbecco's phosphate buffered saline (DPBS) delivered by intranasal drops. They will then be monitored as in-patients for 10 days with daily clinical assessment and blood and respiratory tract sampling. Following discharge, they will be followed up for up to 6 months post-inoculation.
2521229|NCT02755467|Experimental|Laser treatment|Each subject will receive a 532 nm KTP laser treatment for their spider angioma(s).
2521323|NCT02754791|No Intervention|Monthly report|A monthly report will be submitted to department heads describing their departments rate of blood culture contamination and comparing it to blood culture contamination rate in previous months and to blood culture contamination rate of the hospital as a whole
3198856|NCT00874575|Experimental|2|Beta-hydroxy-Beta-methylbutyrate, 3 g/d
3198857|NCT00874575|Experimental|3|Vitamin D, 2000 IU/d
3198858|NCT00874575|Experimental|4|Beta-hydroxy-Beta-methylbutyrate (3 g/d) + Vitamin D (2000 IU/d)
3198859|NCT00874588|Experimental|Phase I study|
2520562|NCT02760095||Children without EED|Children are placed in this arm if they screen negative for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
2520620|NCT02759289||Group A|Prediabetes glycohemoglobin test A1c 5.7-6.4%
2520621|NCT02759289||Group B|"T2D glycohemoglobin test= A1c 6.5-7.9% without T2D medications~T2D glycohemoglobin test=A1c ≥ 8.0% with/without T2D medications"
2520622|NCT02759289||Group C|Control
2520655|NCT02759133|Active Comparator|A - A standard Localization technique|A standard Localization technique : Metal wire as localization technique for breast cancer surgery
2520656|NCT02759133|Experimental|B - Experimental Localization technique|Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery
3165715|NCT00516620|Active Comparator|3|Participants receive intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products.
2520846|NCT02758392|Experimental|Dose 1: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.
2520851|NCT02758392|Experimental|Dose 2: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.
2520853|NCT02758392|Experimental|Dose 3: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.
2520855|NCT02758392|Experimental|Dose 4: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.
2520856|NCT02758392|Experimental|Dose 5: JNJ-61178104 OR Placebo IV|Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.
2520858|NCT02758392|Experimental|Dose 6: JNJ-61178104 OR Placebo SC|Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.
2520902|NCT02757755|Experimental|Cohort 10^8|AB-SA01 (10^8) and Placebo
2520903|NCT02757755|Experimental|Cohort 10^9|AB-SA01 (10^9) and Placebo
2521066|NCT02756676|Experimental|Rehabilitative treatment (MIRT)|Rehabilitative treatment MIRT consist in daily sessions of: motor treatment, occupational therapy and language speech therapy
2521106|NCT02756442|Experimental|pregnant women with gestational diabetes|
2521107|NCT02756442|Active Comparator|pregnant women without gestational diabetes|
2521140|NCT02756117|Experimental|Healthy|"10 Healthy subjects will be enrolled and each will undergo study procedures at one study visit. After screening and consent have been conducted over the phone, subjects will participate in the study procedures. Subjects will arrive in a fasting state (no eat or drink for 8 hours, excluding water). Following collection of blood pressure, height, weight, and a urine and blood sample, subjects will be given an oral bolus of L-lysine (10 g) in 100 ml water. This amount of lysine is equivalent to that which is found in a 10oz. serving of beef. Subjects will provide additional urine and blood samples serially post-ingestion. Because blood draws will be collected through an IV, Normal (0.9%) Saline (NS) will be infused at a rate of 10 ml/hr to flush the canula prior to each blood draw.~All subjects will undergo the same procedures and interventions."
2521230|NCT02755506|Experimental|patients with thoracic lesions|Patients with thoracic lesions is going to undergo endobronchial ultrasound elastography followed by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).
2521307|NCT02755051|Experimental|CBT-CI-A Therapy|Participants in this group receive Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder (CBT-CI-A)
2521488|NCT02754089|Experimental|Rhus|500 mg twice daily after meal for 6 weeks
2521489|NCT02754089|Placebo Comparator|Placebo|500 mg twice daily after meal for 6 weeks
2521579|NCT02752867|Experimental|Jianpi Yishen Huatan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
2521580|NCT02752867|Placebo Comparator|The control group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
2521642|NCT02752750||AD_GROUP|Patients with Alzheimer's disease
2521645|NCT02752750||HC_GROUP|Healthy controls
2521665|NCT02752386|Experimental|Biofeedback Training 1|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide pain relief when relaxation is achieved.
2521666|NCT02752386|Active Comparator|Biofeedback Training 2|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback. Electric stimulations will be delivered throughout the biofeedback to provide a painful context in which to practice relaxing.
2521667|NCT02752386|Active Comparator|Biofeedback Training 3|Participants will receive brief training in relaxation and biofeedback to develop basic skills in relaxation/arousal reduction. Then they will receive instructions to relax and reduce arousal as they view graphical arousal feedback.
3165716|NCT00516620|Active Comparator|4|Participants receive intensive dietary counseling for 6 months to decrease intake of sweetened soft drink.
3165717|NCT00516633|No Intervention|CG|The control group had regular individual information and support in connection with ordinary clinical follow-ups
3165718|NCT00516633|Experimental|IG|The intervention group had extra support and information in the form of four group discussions with parents
3165719|NCT00516646|Active Comparator|1|ALT-711 200 mg bid
3165720|NCT00516646|Placebo Comparator|2|
3165721|NCT00516659|Active Comparator|Group 1|Group 1 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 37.5µg LT
3165722|NCT00516659|Placebo Comparator|Group 2|Group 2 subjects will receive two vaccinations via transcutaneous immunization (TCI), 14 to 21 days apart, with a patch containing 0µg LT (placebo patch containing no LT)
3165723|NCT00516672|Experimental|Arm 1|Pazopanib monotherapy or in combination with lapatinib
3165724|NCT00516685|Experimental|Vaccine Group|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
2520662|NCT02759003|Active Comparator|inpatients group|"In-hospital nightime NIV initiation. For the inpatients Group, NIV was initiated in the respiratory wards of the two hospitals and continued during night for a minimum of 4 hours/night.~Inpatients had a 24-h availability of health staff care. During the night, they had nurses and physicians available on-hand."
2520665|NCT02759003|Experimental|outpatients group|"Home nightime NIV initiation. For the outpatients group, diurnal NIV was initiated during a scheduled visit in a hospital dedicated room(at least 4 hours/day of care), the trial proceeded at home during the night with a personal caregiver.~A minimum of 4 hours/night was required. No support during the night was provided to these patients."
2520758|NCT02758821|Other|CRP-Control|The health care provider will manage the patient using standard guidelines. No CRP will be measured onsite
2520759|NCT02758821|Other|CRP-A|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
2520760|NCT02758821|Other|CRP-B|CRP will be measured by a study nurse onsite and the result will be communicated to the health care provider.
2520822|NCT02758405|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2520823|NCT02758405|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2520825|NCT02758405|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2520827|NCT02758405|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.125% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2520885|NCT02757807|Experimental|Utilization of Serenita for Relaxation|Intervention is that Users continue to take their PDE-5 Inhibitor prior to sexual interaction and IN ADDITION Utilize the Serenita App daily and before any sexual encounters.
2520933|NCT02757599|Other|Top-down (TD)|The group having the transvaginal ultrasound image top-down. During training and transfer test.
2520934|NCT02757599|Other|Bottom-up (BU)|The group having the transvaginal ultrasound image bottom-up. During training and transfer test.
2520951|NCT02757339||Women with History of Childhood Abuse|The study will enroll up to 140 female patients with either DID or PTSD ages 18-89
2520952|NCT02757339||Healthy Control Group|We will recruit up to 60 control subjects matched for demographics (age, race, gender).
2521009|NCT02757157|Experimental|COPD (normal weight)|People with COPD (BMI 21 kg/m2 to 29 kg/m2)
2521011|NCT02757157|Experimental|COPD (obese)|People with COPD (BMI >/= 30 kg/m2)
2521037|NCT02756858|Experimental|ANAVEX2-73 Oral as assigned in ANAVEX2-73-002|
2521081|NCT02756702||All-Poly|All-polyethylene tibia VEGA System® PS - A posterior stabilized total knee arthroplasty (TKA) system using solely all-polyethylene tibia components
3198860|NCT00874601|Experimental|valsartan group|The valsartan group will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
2521156|NCT02756052|Sham Comparator|Medical Student - Sham tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2521157|NCT02756052|Sham Comparator|General Surgery Resident - Sham tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Sham tDCS. 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2521158|NCT02756052|Experimental|Medical Student - Anodal tDCS|"Participants: 1st to 3rd year medical students from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2521159|NCT02756052|Experimental|General Surgery Resident - Anodal tDCS|"Participants: 1st to 5th year general surgery residents from the Cumming School of Medicine (University of Calgary).~Device: Anodal tDCS. 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area."
2521176|NCT02755766||Clubfeet|Babies, ages 0-1, with a diagnosis with clubfoot or clubfeet who are beginning treatment with foot abduction bracing following casting treatment.
2521180|NCT02755766||Adolescent Idiopathic Scoliosis|Patients, ages 10-14, with a diagnosis of AIS who are beginning treatment with TLSO (initial bracing).
2521185|NCT02755766||Guardians (CF babies)|Clubfoot patients' guardians.
2521241|NCT02755597|Placebo Comparator|Placebo + Bortezomib and Dexamethasone|Cycles 1-8: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Placebo (to match venetoclax 100mg tablet) 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
2521245|NCT02755597|Experimental|Venetoclax + Bortezomib and Dexamethasone|Cycles 1-8: Venetoclax 800mg orally every day (QD) on days 1 - 21 plus bortezomib 1.3mg/m2 on days 1,4,8 & 11 and dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 Cycles 9 and beyond: Venetoclax 800mg orally every day (QD) on days 1 - 35 plus bortezomib 1.3mg/m2 on days 1, 8, 15 and 22 and dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
2521381|NCT02754453|Other|Behavioral|
2520667|NCT02758951|Experimental|Perioperative systemic therapy and CRS-HIPEC|"At the discretion of the treating physician, perioperative systemic therapy consists of either four 3-weekly neoadjuvant and adjuvant cycles of capecitabine with oxaliplatin (CAPOX), six 2-weekly neoadjuvant and adjuvant cycles of 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), or six 2-weekly neoadjuvant cycles of 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) followed by either four 3-weekly (capecitabine) or six 2-weekly (5-fluorouracil/leucovorin) adjuvant cycles of fluoropyrimidine monotherapy. Bevacizumab is added to the first three (CAPOX) or four (FOLFOX/FOLFIRI) neoadjuvant cycles.~CRS-HIPEC is performed according to the Dutch protocol in all study centres."
2520669|NCT02758951|Active Comparator|Upfront CRS-HIPEC alone|CRS-HIPEC is performed according to the Dutch protocol in all study centres.
2520781|NCT02758600|Experimental|LVEF < 45%|Patients with left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
2520787|NCT02758600|Experimental|LVEF > 45%|Patients without left ventricular dysfunction will be evaluated before and 6 days after after coronary arterial bypass graft surgery. Postoperatively, subjects will be submitted to a portable cycle ergometer exercise protocol from the first day until hospital discharge.
3198861|NCT00874601|No Intervention|control group|Patients on control group will not receive any other antihypertensive medication for first 7 days after stroke onset. However, rescue therapy with antihypertensive agents can be permitted for episodes with severely elevated blood pressures during acute periods.
2520914|NCT02757690|Active Comparator|2-dimenasional distal pancreatectomy|device: 2 dimensional laparoscopy of Olympus
2520916|NCT02757690|Experimental|3-dimenasional distal pancreatectomy|device : 3 dimensional laparoscopy of Olympus
2520976|NCT02757391|Experimental|Treatment (CD8 +T cell therapy, pembrolizumab)|Beginning 2 days prior to CD8+ T cell infusion, patients receive cyclophosphamide IV over 30 minutes. Patients undergo CD8+ T cell infusion IV over 2 hours on day 0 and receive aldesleukin SC BID on days 1-14. Beginning on day 1 about 24 hours after CD8+ T cell infusion, patients receive pembrolizumab IV over 30-60 minutes on weeks 3, 6, 12, and 15.
2521080|NCT02756585|Other|ct perfusion|All participants will undergo the imaging protocol with CTP of head at the time of initial diagnostic imaging upon hospital arrival.
2521119|NCT02756390|Experimental|Arm A (Sleep Hygiene & CBTI-CS)|Participants receive a single educational session describing principles of Sleep Hygiene for Cancer Survivors. Those who continue to have significant symptoms of insomnia then receive 3 groups CBTI-CS sessions
2521126|NCT02756390|Other|Arm B (Telehealth Pilot of CBTI-CS)|Descriptive data collected on 10 participants (non-randomized) receiving CBTI-CS via Telehealth.
2521211|NCT02755545|Active Comparator|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
2521215|NCT02755545|Active Comparator|Product B (salicylic acid)|Product B applied topically to the affected area of the skin 1 to 3 times daily.
3198862|NCT00874627|Experimental|Experimental|Administration of Milk
3198863|NCT00874627|Placebo Comparator|Placebo|meals without milk
3198864|NCT00874640||Group 1|
3198865|NCT00874653||Group 1|
3198866|NCT00874666|Active Comparator|1|Positive control with 100% allicin bioavailability
3198867|NCT00874666|Experimental|2|garlic powder tablet
3198868|NCT00874679||Group 1|
2521583|NCT02752932|Other|HNSCC -PDX development|Participants with HNSCC who will undergo curative surgery will be included in this group. This involves PDX development only, no drug testing will be done on the PDX.
2521600|NCT02753010||Healthy volunteers|Healthy female volunteers with gastric emptying of carbohydrate-rich beverage
2521638|NCT02753062|Experimental|bendamustine, rituximab|Bendamustine plus subcutaneous Rituximab treatment of 6 cycles. Rituximab 1400mg subcutaneous over 5mins on day 1 and bendamustine 120mg/m2 + NS 500mL iv over 1hour on day 1 and 2.
3198869|NCT00874692|Experimental|BMS and sterilisation|BMS and sterilisation programme will be delivered
3198870|NCT00874692|No Intervention|BMS standard water heating|
3198871|NCT00874718|Active Comparator|Action group|
3198872|NCT00874718|Other|Control group|Non-specific educational program for general health.
3198873|NCT00874744|Experimental|bevacizumab|
3198874|NCT00874744|Experimental|Triamcinolone|
3198875|NCT00874796|Experimental|GS-9450 10 mg/day|GS-9450 taken as one 10 mg capsule by mouth once daily
3198876|NCT00874796|Experimental|GS-9450 40 mg/day|GS-9450 taken as one 40 mg capsule by mouth once daily
3198877|NCT00874796|Placebo Comparator|Placebo|Placebo taken as one placebo capsule by mouth once daily
3198878|NCT00874809|Other|Insulin Treatment|There is only one arm for this study using lispro insulin administered by insulin pump.
3198879|NCT00874861|Experimental|Vaccine + Poly-ICLC|Peptide Vaccine + Poly-ICLC
3198880|NCT00874900|Experimental|Game|
3198881|NCT00874900|Experimental|Game + Activation|
3198882|NCT00874900|No Intervention|Booklet|
3198883|NCT00874900|Experimental|Booklet + Activation|
3198884|NCT00874913|Experimental|Laser Doppler Flowmetry|
3198885|NCT00874926||Group 1|
3198886|NCT00874965|Active Comparator|ES|Electrostimulation
3198887|NCT00874965|Placebo Comparator|Sham ES|Sham stimulation
3198888|NCT00874978|Experimental|lenalidomide|
3198889|NCT00875030|Experimental|1.0|
3198890|NCT00875030|Active Comparator|2.0|
3198891|NCT00875043||1. flat Jackson table|All measurements previously described will be done with the patient in the prone postion and Jackson table flat.
3198892|NCT00875043||2. Elevated Jackson tablet|All measurements previously described will be performed with subjects placed prone on the elevated Jackson table.
3198893|NCT00875069|Experimental|ethanol|
3198894|NCT00875069|Placebo Comparator|placebo|
2520671|NCT02759107|Active Comparator|Dulaglutide (Part B)|Dulaglutide administered SC once weekly for four weeks in healthy participants
2520672|NCT02759107|Experimental|LY3298176 (Part C)|Two dose levels of LY3298176 administered SC once weekly for four weeks in participants with T2DM.
2520673|NCT02759107|Placebo Comparator|Placebo (Part C)|Placebo administered SC once weekly for four weeks in participants with T2DM.
2520828|NCT02758418|Experimental|Online Computerized Program group.|"Intervention group that uses TAO program."
2520836|NCT02758418|No Intervention|Waiting list control group.|Participants of this group are able to access the treatment program after 7 weeks of waiting period. After this waiting period of 7 weeks, those participants still interested in receiving assistance are randomly assigned to one of two intervention conditions (Online Computerized Program group or Bibliotherapy group).
2520875|NCT02757911|Experimental|open label|X vivo gene therapy
2520917|NCT02757638|Experimental|Healthy matched controls|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~study day: muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
2520919|NCT02757638|Experimental|Obese subjects|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical and psychological information about them that will help determine study eligibility or can be used for later coding.~3 study days (one baseline, one pre-surgery, one post-surgery): muscle mass and function tests, resting energy expenditure, stable isotope infusions with blood draws, and questionnaires regarding quality of life, mood and depression, diet."
3198895|NCT00875082|Active Comparator|Montelukast|Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
3198896|NCT00875082|Placebo Comparator|placebo|placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed
3198897|NCT00875095||IUI patients|Patients undergoing routine semen analysis as part of their infertility treatment pertaining to success or failure with intrauterine insemination, based upon their sperm DNA integrity
2521254|NCT02755220|Experimental|Cingularbio® Heart valve|the patients will replaced by artificial heart valve
2521327|NCT02754752|Experimental|Group I (electroacupuncture therapy)|Patients undergo electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions.
2521330|NCT02754752|Placebo Comparator|Group II (sham electroacupuncture therapy)|Patients undergo modified electroacupuncture therapy over 45 minutes 2-3 times per week over 4 weeks for a total of 10 sessions. Acupuncture needles are placed in different locations using a different technique than those used for Group I.
2521332|NCT02754752|Active Comparator|Group III (waitlist control)|Patients receive standard of care without any kind of acupuncture therapy.
2521502|NCT02753517|Other|Extended hepatectomy|Hepatic Scintigraphy
2521563|NCT02753231|Experimental|Low physical activity program|Three Physical Education sessions / week
2521564|NCT02753231|Experimental|High physical activity program|Three Physical Education sessions / week (increased volume)
2521565|NCT02753231|Experimental|Low and High physical activity program|Three Physical Education sessions / week (increased volume and intensity)
2521566|NCT02753231|Active Comparator|Conventional physical activity program|One Physical Education sessions / week
3198898|NCT00875095||IVF patients|Couples undergoing routine screening prior to IVF retrievals to assess their reproductive treatment outcomes as compared to the sperm DNA integrity
3198899|NCT00875108|Experimental|VIAject™|Single injection
2521699|NCT02752204|Other|Stage 1|AZD 2014 oral tablets will be given to patients
2521700|NCT02752204|Other|Stage 2|AZD 2014 oral tablets and rituximab infusion will be given to patients
3198900|NCT00875134|Experimental|Verbal prompt, cutaneous stimulation|Patient receives either or both a verbal stimulus or cutaneous stimulus
3198901|NCT00875147||with bevacizumab|Neoadjuvant chemotherapy with bevacizumab
2522079|NCT02749890|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2522083|NCT02749890|Active Comparator|lixisenatide|"Lixisenatide (AVE0010) is injected subcutaneously (under the skin) once daily. It will be initiated with Dose 1 for 1 week and then continue with Dose 2 for 1 week followed by the maintenance dose of Dose 3 up to the end of treatment period.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2522134|NCT02749266|Experimental|Chiropractic Activator Adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
2522138|NCT02749266|Sham Comparator|Chiropractic sham adjustment|Participant will receive a sham (simulated) chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
2555424|NCT02529917|Active Comparator|Soy powder|Soy powder supplement
3198902|NCT00875147||without Bevacizumab|Neoadjuvant chemotherapy without Bevacizumab
3198903|NCT00875160|Experimental|AT2101|
3198904|NCT00875173|Experimental|Selenium|Sodium selenite 100 micrograms in capsugel by mouth diary for 365 consecutive days
3198905|NCT00875173|Active Comparator|Placebo|Capsugel for placebo (selenium 100 micrograms capsugel) by mouth diary for 365 consecutive days
3198906|NCT00875186||multiple-exercise group (ME)|participants exercised 2 times weekly for 1 hour (aerobic endurance training)
3198907|NCT00875186||Low-exercise group (LE)|participants exercises 1 time weekly for 1 hour (aerobic endurance training)
3198908|NCT00875199|Active Comparator|A|Participants assigned to Group A will receive the DPP manual (Wing & Gillis, 1996), a behavioral weight-loss program with demonstrated efficacy in facilitating weight loss. Participants in Group A will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
2520684|NCT02758938|Experimental|Biofeedback Nurse Subjects|"The nurses (n=3) involved in the biofeedback portion of the UW LUTD Program will undergo a Nurse Training Session where they will be asked to think aloud while completing an outlined scenario. Their feedback will be used to update the software to make it more user friendly. After the session, they will be asked to complete the System Usability Scale (SUS). Additionally, after guiding patients through biofeedback sessions using the new software, they will be asked to complete the Nurse Feedback Form."
2520689|NCT02758938|Experimental|Biofeedback Physician Subject|The physician (n=1) that oversees the UW LUTD Program will assess data from each patients session. Based on the information he gathers from the session, he will complete a feedback form. Each patient's EMG activity will be stored by the video game which will allow the physician to review the patient's performance. Specifically, the physician will look for the minimum relaxation and the maximum contraction levels of the patient throughout play as well as muscular isolation.
2520695|NCT02758938|Experimental|Focus Group Subjects|A Focus Group session will involve the physician involved in this study, an advisor on the project and staff involved in the project as well as three random individuals outside of the project (n=7). These individuals will provide feedback on the software that will be used to improve the software.
3198909|NCT00875199|Experimental|B|Participants assigned to Group B will receive the DPP manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
3165725|NCT00516685|No Intervention|Control Group|Patients in this arm will only receive Best Supportive Care.
3173822|NCT00616369||1|"I:~For those patients who have had blood samples drawn as a result of participating in current protocol, Identification of Genetic Markers for Primary Pulmonary Hypertension study (X980515002), we would like to use their previously obtained blood and continue to draw samples (12mL; less than 3 tablespoons) ONLY if they change disease therapies.~For those patients who participated in Pulmonary Arterial Hypertension (PAH) Database study (X030403017), these participants will also sign a consent form to participant in this new trial. We would like to use the previously obtained data from the X030403017 in part with this study.~As for the X980515002 expired patients, we would like to use the previously obtained data ONLY in part for this study that was collected as a result of the X980515002 study."
3198910|NCT00875225|Active Comparator|Control DVD|Control DVD with usual care information
2521054|NCT02756780|Experimental|Tenovus Cancer Choir|Participants will be asked to attend 12 weeks of weekly choir rehearsals lasting approximately 1 hour. Following the first 12 weeks, participants will no longer be asked to attend rehearsals, but are welcome to do so. Whether or not they do and how many they attend will be measured as an outcome variable to assess whether initial 3-month involvement leads to long-term engagement.
2521058|NCT02756780|No Intervention|Control (no choir) Group|If eligible participants are unable to make the dates and times or live too far away but fulfil all the same criteria (including expressing an interest in singing) they will become part of the control group. This will involve the same data collection as the Cancer Choir Group but participants will not sing in a weekly choir.
2521078|NCT02756546|No Intervention|Control|Healthy volunteers
2521084|NCT02756546|Active Comparator|Patients|SLE patients further divided into mild and severe patients
2521109|NCT02756312|Other|Intravenous anesthesia|Patients will receive total intravenous anesthesia undergoing brain tumor resection.
2521111|NCT02756312|Other|Inhalation anesthesia|Patients will receive volatile inhalational anesthesia undergoing brain tumor resection.
2521138|NCT02756104|Other|Volunteers|Healthy People on each collecting blood for phenotyping Tcells
2521142|NCT02756104|Other|Patients with ALS|"Patients with ALS deficient or not in Vitamin D on each collecting blood for phenotyping Tcells.~The patients who are deficient in Vitamin D will have supplementation in vitamin D"
3198911|NCT00875225|Active Comparator|Intervention DVD|Intervention group will receive DVD with patient stories and information from health care professionals
3198912|NCT00875251||term infants body composition|Term infants from 2 days of life to 7 days of life without IUGR
3198913|NCT00875251||preterm infants body composition|very low birth weight infants before discharge
2521259|NCT02755207||Suspected ACS group|Patients admitted to the hospital with the diagnosis of ACS
2521260|NCT02755207||Blank control group|Patients admitted to the hospital without the diagnosis of ACS
2521281|NCT02754856|Experimental|Treatment (tremelimumab, durvalumab)|Patients receive tremelimumab IV over 1 hour and durvalumab IV over 4 hours during week 11. Between weeks 15 and 17, patients undergo liver surgery. Patients then receive durvalumab IV over 1 hour during weeks 21, 25, 29, and 33.
2521380|NCT02754622||Observational Group|"2hours before planned physical rehabilitation patients will have their regular ventilator changed to the study ventilator by an ICU Consultant and patients will be clinical stable for 30mins prior to the start of the planned physical rehabilitation.~Intended physical rehabilitation as planned will continue without change. This session will be observed by a member of the research team to ensure accurate documentation of the exact timing of performance of the physical rehabilitation activity.~Patients will also undergo an assessment by the Medical Research Council Sum-score and maximal inspiratory pressure (all part of routine physiotherapy assessment).~Following the physical rehabilitation session, the patient to rate their perceived exertion then patients will also undergo ultrasound assessment of peripheral skeletal muscle architecture.~Patients return to their original ventilator after 30mins by an ICU Consultant."
2521445|NCT02754154||Patients using Warfarin|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Warfarin
2521446|NCT02754154||Patients using Apixaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Apixaban
2521450|NCT02754154||Patients using Dabigatran|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Dabigatran
2521454|NCT02754154||Patients using Rivaroxaban|Patients 18 years of age and older with Non-Valvular Atrial Fibrillation (NVAF) using Rivaroxaban
2521544|NCT02753608|Sham Comparator|No ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients without clinical signs of VAP
2521547|NCT02753608|Experimental|Ventilator-associated pneumonia (VAP)|Collection of exhaled breath condensate (EBC) in patients displaying clinical signs of VAP
2521587|NCT02753010||Acute hip fracture|Women preoperatively with acute hip fracture with gastric emptying of carbohydrate-rich beverage
2520701|NCT02758990|Experimental|Predictions: BMI vs. Vitamin A|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520702|NCT02758990|Experimental|Predictions: BMI vs. Vitamin C|BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520703|NCT02758990|Experimental|Predictions: Headache vs. Vitamin B6|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520704|NCT02758990|Experimental|Predictions: Headache vs. Vitamin C|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520705|NCT02758990|Experimental|Predictions: Headache vs. Nicotinamide|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520706|NCT02758990|Experimental|Predictions: Headache vs. Axon Eyewear|Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520707|NCT02758990|Experimental|Predictions: Rhinitis vs Broccoli|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520709|NCT02758990|Experimental|Predictions: Rhinitis vs Caffeine|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520711|NCT02758990|Experimental|Predictions: Rhinitis vs Chocolate|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520715|NCT02758990|Experimental|Predictions: Rhinitis vs Coffee|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520717|NCT02758990|Experimental|Predictions: Rhinitis vs Vitamin A|Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520720|NCT02758990|Experimental|Predictions: Insomnia vs Axon Eyewear|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520725|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin A|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520729|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin E|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520734|NCT02758990|Experimental|Predictions: Insomnia vs Nicotinamide|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520735|NCT02758990|Experimental|Predictions: Insomnia vs Vitamin D3|Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520738|NCT02758990|Experimental|Predictions: Joint pain vs Broccoli|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520741|NCT02758990|Experimental|Predictions: Joint pain vs Caffeine|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520744|NCT02758990|Experimental|Predictions: Joint pain vs Coffee|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520747|NCT02758756|Active Comparator|Massage|Subjects assigned to Arm 1 will receive two massage treatments approximately two weeks apart.
2555903|NCT02526459|Experimental|birth plan|Use of birth plan
2520731|NCT02758886|Placebo Comparator|Observation|Participants randomized into the observation group observed 10 minutes of others in the general PYSA program petting cats and dogs, while they 'waited in line' for there turn.
2520777|NCT02758626|Active Comparator|Ataluren Followed By Placebo|Cross Over Design: Treatment Period 1 with Ataluren (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Placebo Treatment Period 2 (Week 16 to Week 28), and Follow-up (Week 28 to Week 32).
2520785|NCT02758626|Active Comparator|Placebo Followed by Ataluren|Treatment Period 1 with Placebo (Week 0/Day 1 to Week 12), Washout Period (Week 12 to Week 16), crossover to Treatment Period 2 with Ataluren(Week 16 to Week 28).
2520835|NCT02758223|Experimental|Treatment|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
2520927|NCT02757976|Active Comparator|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging
2520929|NCT02757976|Experimental|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
2521071|NCT02756715|Active Comparator|propofol group|The patient who anesthetized by using propofol.
2521073|NCT02756715|Active Comparator|Desflurane group|The patient who anesthetized by using sevoflurane.
2521117|NCT02756377|Active Comparator|cetylpyridinium chloride|mouthwash (cetylpyridinium chloride)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2521118|NCT02756377|Active Comparator|Chlorhexidine mouthwash|mouthwash ( Alcohol-free chlorhexidine)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2521162|NCT02755896|Other|Arm 1 - 600 cGY x 5 fractions|Patients will receive 600 cGY x 5 fractions of radiation therapy over 5 consecutive days.
2521163|NCT02755896|Other|Arm 2 - 800 cGY x 3 fractions|Patients will receive 800 cGY x 3 fractions of radiation therapy every other day for 3 days.
2521207|NCT02755480|Experimental|ultralow dose research|"An Ultralow Dose Thoracic Computed Tomography scan will be added to the standard of care Low dose CT scan.~The image quality of the ultralow dose CT will be compared to the Low dose thoracic Computed Tomography."
2521250|NCT02755233||Pulmonary function|Patients in whom treatment with ipilimumab due to metastatic melanoma is indicated
2521284|NCT02754973|Experimental|Experimental group|During hospitalization for cancer treatment, besides receiving usual care, participants in the experimental group will first receive a health education talk Participants will then be taught and encouraged to practice with some stretching and relaxing exercises during their hospitalization. After hospitalization, participants will receive an integrated experiential training program with coaching by nursing students through home visits.
2521287|NCT02754973|Placebo Comparator|Placebo Control group|Since participants in both groups are hospitalized in the same unit, to avoid contamination, participants in the placebo control group will receive the same intervention as those participants in the experimental group during their hospitalization. When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures.
2521341|NCT02754713||Patients with acute pericarditis|300 patients with a first episode of acute pericarditis
2521384|NCT02754401|Other|group 1|non-periodontitis persons (PSI 0-2)
2521387|NCT02754401|Other|group 2|periodontitis persons (PSI 3-4)
2521436|NCT02754011|Experimental|combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
2521520|NCT02753712|Active Comparator|fluticasone/vilanterol DPI (Relvar Ellipta DPI)|Inhalation powder. 92/22µg, I inhalation od
2521523|NCT02753712|Experimental|Fluticasone/formoterol BAI|Pressurised suspension for inhalation 125/5µg, 2 inhalations bid
2521601|NCT02753023||acute coronary syndromes|No intervention related
2521603|NCT02753023||acute decompensated heart failure|No intervention related
2521604|NCT02753023||warfarin intoxication|No intervention related
2521605|NCT02753023||acute pulmonary edema|No intervention related
2521606|NCT02753023||acute aortic dissection|No intervention related
2521607|NCT02753023||chest pain|No intervention related
2521609|NCT02753023||pulmonary embolism|No intervention related
2521611|NCT02753023||syncope|No intervention related
2521744|NCT02752516|Experimental|Anlotinib|
2521838|NCT02751398|Experimental|Dapagliflozin|Dapagliflozin 10mg/day
2521840|NCT02751398|Placebo Comparator|Placebo|
2521935|NCT02750735||Prospective NCWS control patients|As for the retrospective study, to compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 patients with functional gastroenterological symptoms, was selected, with the same criteria adopted for the retrospective study.
2520746|NCT02758990|Experimental|Predictions: Joint pain vs Spinach|Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.
2520808|NCT02758444|Active Comparator|Micronutrient Powder (MNP) + 15 mg Zn|1 sachet of Micronutrient Powder (MNP) + 15 mg Zn will be added to a single meal on study day 8
2520810|NCT02758444|Active Comparator|MNP + 10 mg Zn|1 sachet of MNP + 10 mg Zn will be added to a single meal on study day 8
2520815|NCT02758444|Active Comparator|MNP + 5 mg Zn|1 sachet of MNP + 5 mg Zn will be added to a single meal on study day 8
2520817|NCT02758444|Placebo Comparator|MNP without Zn|1 sachet of MNP without Zn will be added to a single meal on study day 8
2520867|NCT02758015|Active Comparator|Standardized Meal|Standardized meal given to patients.
2520868|NCT02758015|Experimental|Beatine PO (by mouth) 1500mg|Betaine (natural supplement)
2520871|NCT02758015|Experimental|Betaine PO (by mouth) 3000mg|Betaine (natural supplement)
2520873|NCT02758015|Experimental|Betaine PO (by mouth) 4500mg|Betaine (natural supplement)
2520892|NCT02757612|Active Comparator|Interventional|"Device Laser diode parameters: spot size of 0.04 mm2, average power (output) of 40 mW and 0.4 J per irradiation point, energy density of 10 J cm2, irradiation time of 10 seconds per point~1 session per week during 4 session"
2520893|NCT02757612|Sham Comparator|Comparator|"laser probe inactive for similar duration as for the laser diode group; only a beep sound was produced by the laser machine~1 session per week during 4 session"
3198914|NCT00875264|Experimental|1|At least one 6-week (42-day) cycle in which patients will be treated daily with CEP-11981 for 28 days, followed by a treatment-free period of 14 days.
3198915|NCT00875290|No Intervention|Control|Observational arm
2521026|NCT02757027|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2521027|NCT02757027|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
3198916|NCT00875290|Experimental|Real-time glucose sensor|Subjects wear real-time glucose sensor
2521169|NCT02755753|Experimental|Study Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta® (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
2521170|NCT02755753|Placebo Comparator|Control Group|"Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast~Mucosta®-placebo (rebamipide-placebo), 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner"
2521255|NCT02755259|Experimental|Acetazolamide|Diamox 500mg i.v. (1x)
2521256|NCT02755259|Placebo Comparator|Placebo|Placebo Saline injection (1x)
2521309|NCT02754869||Control Subject-Drug Study|The first part of this investigation is an interventional blinded cross over study with two dosing dates spread at least one week apart. Each volunteer will receive baseline scans before drug/placebo which will be used to assess intra---patient variation over the two study dates after which the drug or saline placebo will be administered with each volunteer acting as their own control to assess software ability to quantify changes in bowel motility.
2521313|NCT02754869||Dysmotility Subjects-Drug Study|The second component of this study will be exactly the same for the participants with dysmotility except the time to repeat scan will be reduced with a follow up time aimed at around 1---3 days reducing patient time off medication
2521316|NCT02754869||Reference Range Study|The third component of this study will assess basal small bowel motility in larger numbers of healthy controls, dysmotility subjects and irritable bowel syndrome to establish reference ranges to inform future clinical investigations and guide clinical decision making using global motility scoring. Each scan will last around 20 minutes and will not involve follow up or use of pharmaceutical agents.
2521317|NCT02754869||Desmotility Reversibility Study|The fourth component of the study will assess small bowel motility in a cohort of Crohns disease patients will small bowel disease before and 11---16 weeks after starting anti TNF alpha therapy, or undergoing endoscopic dilatation of a small bowel stricture. Each scan will last around 45 minutes
2521360|NCT02754583|Experimental|WASH arm (WUHA)|"WUHA I, Behavioral: Water, sanitation, and hygiene (WASH) intervention: Communities will receive the water, sanitation, and hygiene (WASH) intervention including community water point construction, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.~WUHA II, Behavioral and Treatment: WASH intervention communities will continue to receive the water, sanitation, and hygiene (WASH) intervention.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline."
2521363|NCT02754583|Other|Standard of care WASH arm (WUHA)|"WUHA I: Standard of care WASH intervention: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~WUHA II: Standard of care WASH intervention and treatment: Communities will continue to receive the standard of care WASH programming offered by the Ethiopian government.~A single mass azithromycin distribution will be given in all 40 WUHA I communities (both intervention and control) after the final study visit (i.e., month 36). Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.~These communities will receive a WASH package at the conclusion of the SWIFT II study, including water point construction, hygiene and sanitation promotion, and educational materials."
2521365|NCT02754583|Experimental|Targeted antibiotics arm (TAITU)|Targeted antibiotic treatment: Communities will receive targeted antibiotic treatments for children testing positive for ocular chlamydia at 3, 6, 9, and 12 months after baseline testing. After testing for ocular chlamydia at 12 months, any children testing positive at this time point will receive antibiotic treatments at 15, 18, 21, and 24 months. Children 6 months and up will be offered azithromycin 20mg/kg; those under 6 months will be offered tetracycline.
2521679|NCT02752451|Other|CO|8 subjects who did not undergo arthroscopy simulation training prior to assessment on cadaveric specimens. These served as controls.
3198917|NCT00875303|Placebo Comparator|Control|Routine primary care.
3198918|NCT00875303|Experimental|Multimedia intervention|
3198919|NCT00875316|Experimental|Cohort A|
2520751|NCT02758756|Experimental|Two Reiki Tx|Subjects assigned to Arm 2 will receive two Reiki treatments approximately two weeks apart.
2520752|NCT02758756|Experimental|Four Reiki Tx|Subjects assigned to Arm 3 will receive four Reiki treatments approximately 1 week apart.
2520756|NCT02758535|Experimental|Core needle biopsy with coaxial method|The patients undergo renal biopsy with a coaxial Tru-Cut needle
2520757|NCT02758535|Experimental|Core needle biopsy with noncoaxial method|The patients undergo renal biopsy with a noncoaxial Tru-Cut needle
2520801|NCT02758483|Other|Test diet|"Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
2520803|NCT02758483|Other|Control diet|"Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).~Note: Both diets had the same calories, carbohydrates, proteins, fat, and fiber, and were prescribed according to the American Diabetes Association recommendations."
3198920|NCT00875316|Experimental|Cohort B|
3198921|NCT00875316|Experimental|Cohort C|
2520905|NCT02757651|Experimental|Radiotherapy + radiation sensitizer|Patients in phase I and patients randomised to the test group in phase II will receive standard radiotherapy for breast cancer + a radiation sensitizer
2520909|NCT02757651|No Intervention|Radiotherapy alone|Patients randomised to the control group in phase II will receive standard radiotherapy for breast cancer alone.
2520978|NCT02757456|Other|Aerobic Exercise program|Intervention of aerobic exercise
2520983|NCT02757456|Other|Control|no aerobic exercise program
3198922|NCT00875316|Experimental|Cohort D (Optional)|
3198923|NCT00875355|Experimental|Arm I|Patients undergo isocentric radiotherapy to the brain 5 times a week for 2 weeks.
2521098|NCT02756481||NVAF Treatment patterns|"Treatment patterns will be collected during the follow-up period. Data will be directly extracted from medical charts of the arrhythmia unit.~Anticoagulation use will be reported as drug class: Vitamin K antagonist, antiplatelet, nonsteroidal anti-inflammatory drugs. The following data on anticoagulation use will be collected:~Type of treatment, start & stop dates, dosage, administration schedule, method of administration, reason for discontinuation if applicable~Type of therapy utilized (monotherapy/combination therapy)~Total number of therapy changes or switches through the course of treatment~Monitoring visit (visits per month) for International normalized ratio (INR) control by Time in Therapeutic Range(cTTR)~Routine care (visits per month) by anticoagulation regimen"
3198924|NCT00875355|Experimental|Arm II|Patients undergo radiotherapy as in arm I and receive oral temozolomide once daily for 2 weeks.
2521214|NCT02755389|Placebo Comparator|0 L/min|These participants will receive 0 L/min oxygen via conventional nasal cannulae during the apneic period.
2521220|NCT02755389|Experimental|15 L/min|These participants will receive 15 L/min oxygen via conventional nasal cannulae during the apneic period.
2521221|NCT02755389|Experimental|60 L/min|These participants will receive 60 L/min oxygen via high-flow nasal cannulae during the apneic period.
2521293|NCT02755012||Longitudinal|155 women enrolled in 2nd or 3rd trimester of pregnancy, and seen again, with their infant, at 0-6 wk postpartum, and 4-6 mo postpartum
2521296|NCT02755012||Early Postpartum|60 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
2521298|NCT02755012||Later Postpartum|56 women enrolled at 0-6 wk postpartum and seen once with their infant (cross-sectional)
2521345|NCT02754726|Other|single arm|open label using combination therapy
2521392|NCT02754284|Experimental|Autologous fat transplantation|
2521393|NCT02754284|Experimental|Functional collagen scaffold transplantation|
2521531|NCT02753660|Active Comparator|Traditional sitting position|Patient is positioned with her knees flexed 90o, both feet hanging of the bed and propped up by a chair, both arms hugging a pillow, adducted pelvic, maximum pelvic flexion were done to create maximal sagittal lumbal flexion before spinal anesthesia begun.
2521532|NCT02753660|Experimental|Pendant position|Patients sit with both their underarms propped up on a metal prop, thus both arms hanging from the prop before spinal anesthesia begun.
2521613|NCT02753101|Experimental|Single Arm|[18F]-FTC-146
2521663|NCT02752581|Other|Drain Group|Suction drain was applied to these patients after arthroscopic knee surgery.
2521664|NCT02752581|Other|Control Group|No suction drain was applied to this group, therefore used as a control group.
3198925|NCT00875368|Active Comparator|Maraviroc|
3198926|NCT00875368|Placebo Comparator|Placebo|Placebo drug
2521753|NCT02751892|Experimental|Active Lifestyle Programme|Supervised exercises for 3 months and motivational interviewing to facilitate physical activity behaviour change. Supervised exercise sessions took place twice per week for the first four weeks. This was tapered off to once per week for the second four weeks. During the last month of the intervention participants continued with the exercise at home and were encouraged to achieve 150min of moderate to vigorous PA per week.
2521760|NCT02751892|No Intervention|Standard Care|Received usual care. Was offered the intervention after the completion of the study.
2521795|NCT02751723||lung cancer|validated questionnaires
2521797|NCT02751723||malignant melanoma|validated questionnaires
2521799|NCT02751723||cancer of the hepatobiliary system|validated questionnaires
2521800|NCT02751723||head and neck cancer|validated questionnaires
2521801|NCT02751723||breast cancer|validated questionnaires
2521802|NCT02751723||ovarian carcinoma|validated questionnaires
3198927|NCT00875446|Experimental|Subjects receiving GSK1223249|"Eligible subjects will receive sequential dose of intravenous infusion of GSK1223249 with a starting dose of 0.01 milligram per kilogram followed by 0.1, 0.5,~1, 2.5, 5, 7.5, and 15 milligrams per kilograms."
3198928|NCT00875446|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive intravenous infusion of placebo.
3198929|NCT00875459|Experimental|VIAject™|Single injection
2520762|NCT02758639|Experimental|W & W Intervention|Wonders & Worries Psychosocial intervention is a 6 week group or individual sessions for children who have a parent with cancer focusing on psycho-educational information about cancer, treatment and its side effects, feelings expression, positive coping strategies, and family communication about the illness.
2520766|NCT02758639|Other|Wait list control|Wait list group will complete baseline, 6 week and 8 week follow up measures and then will be enrolled to receive W & W intervention.
2520821|NCT02758366|Experimental|Doxorubicin|"Patients are treated with Weller-Stupp protocol: initial radiotherapy (1.8 Gy/die, days 1-5; total dose 54-60 Gy) with concomitant oral temozolomide (75mg/m2/die, days 1-7) per 6 weeks.~At week 10 (4 weeks after the chemo-radiotherapy treatment completion): 1 cycle of oral temozolomide (150-180 mg/m2, days 1-5)~At week 14 (8 weeks after the chemo-radiotherapy treatment completion) 1 cycle of prolonged infusion of Doxorubicin (25mg/m2/die in 24 hours, days 1-4; total cumulative dose 100 mg/m2).~At week 18 (4 weeks after the end of doxorubicin administration): 16 cycles of oral temozolomide (initial dose of 150 mg/m2 increasing to 180 mg/m2 days 1-5, 28-day cycle).~Oral valproic acid (20-30 mg/Kg/die bid) is administered from week 1 until the last treatment day."
2520860|NCT02758041|Experimental|Sebacia Microparticles|
2520921|NCT02757794|Active Comparator|Cognitive remediation parents|
2520923|NCT02757794|Placebo Comparator|Remediation standard|
2520988|NCT02757144|Experimental|Cohort 1: DWP14012 Amg|DWP14012 Amg, tablets, orally, single dose administration
2520991|NCT02757144|Experimental|Cohort 2: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, single dose administration
2520995|NCT02757144|Experimental|Cohort 3: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, single dose administration
2520998|NCT02757144|Experimental|Cohort 4: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, single dose administration
2521000|NCT02757144|Experimental|Cohort 5: DWP14012 Emg|DWP14012 Emg, tablets, orally, single dose administration
2521002|NCT02757144|Experimental|Cohort 6: DWP14012 Fmg|DWP14012 Emg, tablets, orally, single dose administration
2521004|NCT02757144|Placebo Comparator|Cohort 1-6: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, single dose administration
2521007|NCT02757144|Active Comparator|Cohort 1-6: Esomeprazole|Nexium® tablets, orally, single dose administration
2521008|NCT02757144|Experimental|Cohort 7: DWP14012 Amg|DWP14012 Amg, tablets, orally, repeated dose administration(for 7days)
2521012|NCT02757144|Experimental|Cohort 8: DWP14012 Bmg|DWP14012 Bmg, tablets, orally, repeated dose administration(for 7days)
2521016|NCT02757144|Experimental|Cohort 9: DWP14012 Cmg|DWP14012 Cmg, tablets, orally, repeated dose administration(for 7days)
2521019|NCT02757144|Placebo Comparator|Cohort 7-10: Placebo|DWP14012 placebo-matching tablets, Active-control placebo-matching tablets, orally, repeated dose administration(for 7days)
2521021|NCT02757144|Active Comparator|Cohort 7-10: Esomeprazole|Nexium®, orally, repeated dose administration(for 7days)
2521023|NCT02757144|Experimental|Cohort 9: DWP14012 Dmg|DWP14012 Dmg, tablets, orally, repeated dose administration(for 7days)
3198930|NCT00875498|Active Comparator|active iTBS|iTBS active intensity = 80%MT during 6 minutes. 20 sessions, 2 per day
2521146|NCT02756130|Experimental|Treatment (birinapant, carboplatin)|Patients receive birinapant IV over 30 minutes on days 1 and 8, and carboplatin IV over 30 minutes to 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2521173|NCT02755714|No Intervention|No Atrovent ®|NO INTERVENTION: The patient will not receive Ipratropium bromide spray (MDI) 20 μg ,(Atrovent ®) prior to CLE testing
2521181|NCT02755714|Experimental|Atrovent ®|INTERVENTION: Ipratropium bromide spray (MDI) 20 μg (Atrovent ®) prior to CLE testing
2521226|NCT02755519||Primary Aldosteronism|"Those with hypertension, and with or without hypoglycemia;~Those with PAC/PRC≥42.95 pg·mL-1/µIU·mL-1"
2521237|NCT02755519||Non-Primary Aldosteronism|"Those with Primary Hypertension;~Those with adrenal diseases except for Primary Aldosteronism"
3198931|NCT00875498|Placebo Comparator|sham iTBS|iTBS placebo (placebo coil)with same parameters than active
3198932|NCT00875537|Active Comparator|Capsaicin oral gel 0.01%|
2521348|NCT02754505|Other|Early rehabilitation group|Directly after transfer to a general ward the early rehabilitation group started with an early rehabilitation program, as ordered by an experienced physiatrist. The applied intervention (early rehabilitation) is a combination out of different therapeutic modalities (for further information please see interventions).
2521349|NCT02754505|Other|Usual care group|The usual care group received single physical therapy sessions as ordered by the primary care team after transfer from the ICU to the general ward. The applied intervention (usual care) is a combination out of different therapeutic modalities (for further information please see interventions).
2521388|NCT02754362|Experimental|Block 1|
2521390|NCT02754362|Experimental|Block 2|
2521391|NCT02754362|Experimental|Block 3|
2521463|NCT02753907|Experimental|Low LA (linoleic acid)|Individuals who replaced 10 mL soy oil with one apple
2521466|NCT02753907|No Intervention|Medium LA|Individuals who maintained their usual food intake
2521467|NCT02753907|Experimental|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9 g of soy oil as a supplement
2521512|NCT02753582|Active Comparator|Intervention|SOD+Gliadin capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
2521515|NCT02753582|Placebo Comparator|Placebo|Placebo capsule is given in a dosage of 250 mg twice a day, for 24 weeks.
2521581|NCT02753205|Experimental|Control|Infusion of normal saline
2521582|NCT02753205|Active Comparator|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
2521837|NCT02751528|Experimental|ETBX-021|Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection
3198933|NCT00875537|Active Comparator|Capsaicin oral gel 0.025%|
3198934|NCT00875602|No Intervention|control|before-after (retrospective) and concurrent controls as comparators with a prospective intervention group
3198935|NCT00875602|Active Comparator|Study unit|Hospitalized patients in the study group will be continously monitored / supervised by the contact-free device
3198936|NCT00875628|Other|Cohort 1|PF-00868554 100 mg or placebo
3198937|NCT00875628|Other|Cohort 2|PF-00868554 300 mg or placebo
2520774|NCT02758704|Active Comparator|Low-Stress (LS)|In the LS environment, there will be absence of audio (alarms), physical (third-party supervisor, nurse and respiratory therapist) and situational (unstable infant) stressors.
2520824|NCT02758275|Experimental|Teaching: Individual (5606)|People will receive an education session per month for a period of six months with an average duration of 30 minutes. These will be performed by nurses outside the collection of phase base line and follow-up measurements, previously trained for the purpose.
2520826|NCT02758275|No Intervention|Usual care|People will continue to receive usual care in the health center where they usually assist to medical controls.
3198938|NCT00875628|Other|Cohort 3|PF-00868554 600 mg or placebo
2521056|NCT02756767||Completed subjects|Subjects will complete patient-reported outcomes assessments during and after radiation therapy.
3198939|NCT00875654|No Intervention|1|Control group without intervention nor placebo
2521209|NCT02755454|Other|open label|Perfusion CT Imaging
2521268|NCT02755168|Other|External Pop-Out Cesarean Section|
2521270|NCT02755168|Other|Classic technique|
2521291|NCT02754765|Experimental|endTB regimen 1 (BeLiMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
2521295|NCT02754765|Experimental|endTB regimen 2 (BeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
2521299|NCT02754765|Experimental|endTB regimen 3 (BeDeLiLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
2521300|NCT02754765|Experimental|endTB regimen 4 (DeLiCLeZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based. Subjects will undergo a linezoilid dose reduction randomization to either 300mg daily or 600mg three times a week after 16 weeks of treatment or after a linezolid-related AE requiring dose reduction, whichever is earlier.
2521301|NCT02754765|Experimental|endTB regimen 5 (DeCMoZ)|Subjects who are randomized to this arm will receive treatment for 39 weeks and post-treatment followup for 65 weeks. Participants may take as long as 47 weeks to complete all doses of a 39-week treatment regimen. Dosing of experimental regimens will be oral and weight based.
2521303|NCT02754765|Active Comparator|endTB regimen 6 (Control)|endTB regimen 6 is the control regimen.
2521404|NCT02754245||JPS|study sample at JPS included for analysis
2521409|NCT02754245||BUMC Dallas|study sample at Baylor University Medical Center Dallas included for analysis
2521410|NCT02754245||BUMC at Gardin|study sample at Baylor University Medical Center Gardin included for analysis
2521411|NCT02754245||BUMC Waxahachie|study sample at Baylor University Medical Center Waxahachie included for analysis
2521412|NCT02754245||BUMC Carrolton|study sample at Baylor University Medical Center Carrolton included for analysis
2521413|NCT02754245||BUMC McKinney|study sample at Baylor University Medical Center McKinney included for analysis
3198940|NCT00875654|Experimental|2|First dose of stem cells
3198941|NCT00875654|Experimental|3|Second dose of stem cells
2521619|NCT02752789||Pediatric Heart Transplant Recipients|CTOTC-04 (ClinicalTrials.gov ID NCT01005316) participants who consent to long-term follow-up as part of this study as well as candidates less than 21 years of age who are listed for isolated orthotopic heart transplantation at one of the participating sites
2521668|NCT02752542|Experimental|Psychotherapy|Cognitive Behavioral Therapy
2521670|NCT02752542|Experimental|Pharmacotherapy|Antidepressant medication
2521687|NCT02752191|Active Comparator|Ferumoxytol|Ferumoxytol, 4mg/kg of body weight, one time infusion of several minutes
2521688|NCT02752191|Active Comparator|gadofosveset|gadofosveset, 0.03mmol/kg, one time bolus injection
3198942|NCT00875680|Experimental|autoPPC|
3198943|NCT00875693|Experimental|Arm A dose of CPX - 351|Dose level 1A: 60 units/m2 days -28, -26 and -24 Dose level 2A: 80 units/m2 days -28, -26 and -24 Dose level 3A: 100 units/m2 days -28, -26 and -24 Dose level 4A: 120 units/m2 days -28, -26 and -24 Dose level 5A: 140 units/m2 days -28, -26 and -24 Dose level 6A: 160 units/m2 days -28, -26 and -24
3198944|NCT00875693|Experimental|Arm B dose of CPX-351|Dose level 1B: 60 units/m2 days -21, -19 and -17 Dose level 2B: 80 units/m2 days -21, -19 and -17 Dose level 3B: 100 units/m2 days -21, -19 and -17 Dose level 4B: 120 units/m2 days -21, -19 and -17 Dose level 5B: 140 units/m2 days -21, -19 and -17
3198945|NCT00875719|Active Comparator|continuous v intermittent Oxygen therapy|intermittent oxygen compared to constant flow oxygen as regards walking distance
3198946|NCT00875732|Experimental|1|Biventricular Pacing
3198947|NCT00875732|Active Comparator|2|Right Ventricular Pacing
3198948|NCT00875745|Experimental|Sorafenib-Vorinostat|This is a single-arm, non-randomized feasibility and safety Phase I trial of a combination of Sorafenib and Vorinostat, both administered orally.
3198949|NCT00875758|Active Comparator|Standard threshold|
3198950|NCT00875758|Experimental|Low-threshold|
3198951|NCT00875771|Experimental|1|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks"
3198952|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (4mg)|TREXIMA™ (sumatriptan succinate / naproxen sodium) Tablet followed by IMITREX® (sumatriptan succinate) Injection 4mg administered using the IMITREX STATdose System®
2520811|NCT02758379|Experimental|Shockwave Coronary Lithoplasty System|Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
2520897|NCT02757677||Longitudinal arm|Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
2520898|NCT02757677||24-h Intraocular pressure (IOP) arm|Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
2520899|NCT02757677||Surgery arm|Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients
2520981|NCT02757482|Experimental|intervention|Patient training
2520984|NCT02757482|No Intervention|control|no patient training
2521043|NCT02756962|Experimental|Cohort A: HiDAC|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~Patients who have clearance of their leukemia-associated mutations, defined as a LAM VAF <2.5% will be assigned to the high-dose cytarabine consolidation (HiDAC) arm.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
2521046|NCT02756962|Experimental|Cohort B: Investigator's choice (HiDAC, AlloSCT)|"At the time of diagnostic bone marrow biopsy, samples will be clinically sequenced via ClinSeq~Patients who have persistent leukemia-associated mutations, defined as a LAM VAF ≥2.5% will be assigned to the investigator's choice arm.~Patients assigned to this arm may received either HiDAC or AlloSCT.~HiDAC = Standard regimen of cytarabine 1.5 g/m^2 or 3 g/m^2 over 2-3 hours twice a day on Days 1, 3, & 5 of each 28 day cycle for 3-4 cycles. Can be replaced by Onureg with permission from PI.~The source of stem cell product, donor selection, conditioning regimen, graft-versus-host-prophylaxis, and supportive care will be at the discretion of the treatment physician~For patients with the FLT3-ITD or a FLT3-TKD mutation, therapy with the FDA-approved FLT3 inhibitor midostaurin is permitted at the discretion of the treating physician."
2521097|NCT02756455||gastric cancer pts undergoing surgery|all pts receiving gastric resection for cancer, with anastomosis
3165726|NCT00516698||Group 1|"Patients undergo blood sample collection at baseline and at 1 year after initiation of aromatase inhibitor therapy (anastrozole or exemestane). Samples are analyzed for estrogen and testosterone levels and additional hormone levels and growth factors that have been previously linked with breast density and that could be altered by aromatase inhibitor use (i.e., sex hormone-binding globulin [SHBG], DHEA, DHEA sulfate, progesterone, prolactin, insulin-like growth factor-1 [IGF-1], and insulin-like growth factor binding protein 3 [IGF BP3]). Samples are also analyzed for anastrozole and exemestane levels by HPLC. Pharmacogenetic studies are also performed. Haplotype-tagged single nucleotide polymorphisms in genes in the aromatase pathway are examined.~Patients also undergo mammogram at baseline (≤ 6 months prior to study registration) and at 1 year after initiation of aromatase inhibitor therapy."
3165727|NCT00516802|Experimental|1|DTIC + KU-0059436
3165728|NCT00516828|Experimental|Sorafenib and Cytarabine|Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
3165729|NCT00516841|Experimental|volociximab|15 mg/kg volociximab once weekly
3165730|NCT00516867|Active Comparator|UVB 0.5%|
3165731|NCT00516867|No Intervention|Controls|
2521231|NCT02755675|Experimental|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
2521340|NCT02755025||Prospective cohort|This group will include ICU patients for the two month period after the automated SOFA score has been activated within the electronic patient care dashboard.
2521385|NCT02754414|Experimental|Healthy Volunteers|Autologous, cold stored, PAS/plasma suspended platelets stored for various periods (3 to 20 days).
2521432|NCT02754024||Total shoulder arthroplasty (TSA)|Replacement of humeral head and glenoid
2521433|NCT02754024||Hemi shoulder arthroplasty (HSA)|Replacement of humeral head only
2521483|NCT02753738|Experimental|SSRI treatment|Subjects will receive 21 days of 10mg escitalopram treatment while performing learning paradigms.
2521487|NCT02753738|Placebo Comparator|Placebo treatment|Subjects will receive 21 days of placebo treatment while performing learning paradigms.
2521529|NCT02753361|No Intervention|Traditional|This will utilize the traditional method of performance of regional block
2521530|NCT02753361|Experimental|US-guided|In this arm, regional block will be performed under the ultrasound guidance
2521570|NCT02753153|Experimental|Mucograft®, Geistlich Biomaterials|A Mucograft membrane will be used in state of a connective tissue graft. The dimension of the Mucograft® will be previously calculated according to the site dimensions and inserted into buccal pouch and sutured to be stabilized on the buccal aspect. The membrane is then positioned to cover the socket and inserted and sutured in the palatal pouch by the means of vertical interrupted sutures
2521572|NCT02753153|Active Comparator|Soft tissue graft|
2521644|NCT02752841|Experimental|Intervention|Nutritional vitamin D repletion and maintenance
2521768|NCT02752412|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide fixed ratio combination) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Metformin will be continued."
2521776|NCT02752412|Active Comparator|insulin glargine|"Insulin glargine U100 (Lantus) will be injected subcutaneously (under skin) once daily. Dose will be individually adjusted.~Metformin will be continued."
2521905|NCT02750839||proximal humerus fracture|Patients with proximal humerus fracture treated with mini-invasive plate.
3165732|NCT00516867|Active Comparator|UVB 1.4%|
3165733|NCT00516958|Experimental|1|Topical Dermacyn
3165734|NCT00516958|Active Comparator|2|Topical Dermacyn and levofloxacin
3165735|NCT00516958|Active Comparator|3|Topical saline and levofloxacin
3165736|NCT00516984|Placebo Comparator|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
3165737|NCT00516984|Sham Comparator|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
2520829|NCT02758197|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
2520832|NCT02758197|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
2520877|NCT02757937|Experimental|Health & Wellness Website|Subjects will receive access to an interactive health & wellness website for 6 months. The site aims to provide patients with information, tools, and resources to manage their chronic condition (e.g., Type 2 diabetes). The website will send subjects emails with tips to help them take better care of their diabetes, such as how to track diet and exercise habits and how to cook healthy meals. The study researchers will keep track of how many times subjects access the website and which parts of the site are most commonly viewed. Intervention subjects will receive questionnaires assessing engagement and satisfaction with the website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline.
2520879|NCT02757937|Other|Control Arm|Subjects in the control arm will continue with standard diabetes care without getting access to the intervention website. Subjects will also complete questionnaires at baseline and 2, 4, and 6 months post-baseline. Control subjects will be granted access to the health & wellness website after the study is completed.
3198953|NCT00875784|Experimental|TREXIMA tablet followed by IMITREX injection (6mg)|TREXIMA tablet followed by IMITREX® (sumatriptan succinate) Injection 6mg administered using the IMITREX STATdose System®
2521061|NCT02756754|Experimental|Radiofrequency ablation|"Radiofrequency ablation (RFA) is a minimally invasive technique for eliminating both primary tumors and metastases.~The needles that will be used are monopolar RFA, the LeVeen™ Needle Electrode Family with a generator RF 3000 by Boston Scientific. The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored."
2521099|NCT02756468||pts operated for pancreatic cancer|all pts operated of pancreatic resection for cancer in the involved units
2521132|NCT02756169|Experimental|Intervention|One workshop during pregnancy Support for breastfeeding at immediate postpartum Telephonic support after delivery
2521133|NCT02756169|No Intervention|Control|Standar procedures of neonatal and pregnancy health care at the clinics or hospitals.
2521165|NCT02755870|Experimental|CNM-Au8|"CNM-Au8 is an orally administered, clean-surface gold nanocrystal suspension drug. It is atomically clean-surface elemental nanocrystals, free of any residual surface chemicals or surface-capping agents.~CNM-Au8 15, 30, 60, 90mg as an oral suspension"
2521168|NCT02755870|Placebo Comparator|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
2521225|NCT02755610|Experimental|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
2521235|NCT02755610|No Intervention|Control|Standard care
2521310|NCT02755038||premenopausal and postmenopausal women|One group will include 20 premenopausal women under the age 40 years old, with regular menstruation cycles and without any illness or medication including birth control pills or steroidal ointments, and without known diagnosis of polycystic ovaries or fertility disorder. The second group will include 20 postmenopausal women over the age of 60, with no menstruation at least for the last five years, and without hormone therapy or treatment of any Steroidal therapy for the last year.
2521369|NCT02754596|Experimental|Travoprost Intraocular Implant, high elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
2521371|NCT02754596|Experimental|Travoprost Intraocular Implant, low elution|This implant will be surgically implanted and elute travoprost, a prostaglandin.
2521372|NCT02754596|Active Comparator|Timolol Maleate Ophthalmic Solution, 0.5%|Timolol, a beta blocker, will be dosed twice daily
2521396|NCT02754232|Active Comparator|Telemedical training|Patients in the intervention group will receive telemedical training 21 times, three times weekly for seven weeks. During the first three weeks the regional physiotherapists will be responsible for the training. Municipal occupational -and physiotherapists will manage the last four weeks' training.
2521402|NCT02754232|No Intervention|The usual training or no training|Patients in the control-group will receive no telemedical training. They will be discharged to the municipal sphere with a rehabilitation plan, where they have the possibility to receive training.
2521647|NCT02752672||Psoriasis|Psoriasis patients treated with dithranol
2521648|NCT02752672||Non-Psoriasis|Non-Psoriasis patients undergoing surgery for skin lesions. Tumor-adjacent skin is collected for control purposes.
2521691|NCT02752113|Active Comparator|Empagliflozin and Linagliptin|After the 4 weeks run-in phase (stable metformin medication), patients will be consecutively randomized (1:1) to empagliflozin 10 mg and linagliptin 5 mg orally once daily. After 14 days empagliflozin will be up-titrated to 25 mg (once daily), if fasting blood glucose is ≥ 100 mg /dl and no hypoglycemic symptoms are recognized.
2521692|NCT02752113|Active Comparator|Metformin and Insulin sc|Metformin p.o. and insulin sc After the 4 weeks run-in phase (stable metformin medication), patients will maintain on their metformin dosage (850 or 1000 mg orally twice daily) and insulin glargine (Lantus™) once daily subcutaneous will be added. Initially 2 - 4 U Lantus™ daily (depending on body weight) will be given, and adjusted every third day (telephone counseling) by adding 2 U if fasting blood glucose is not ≤ 125 mg/dl (16). After a stable dosage (i.e. no change of dosage for 1 week) has been reached, adjustments regarding an increment of Lantus™ will be based on confirmed fasting blood glucose of ≥ 126 mg/dl (on at least two consecutive day).
2521729|NCT02751996|Active Comparator|Part A Cohort 1: 25mg SB 9200|Part A Cohort 1: 25mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521730|NCT02751996|Placebo Comparator|Part A Cohort 1: 25mg Placebo|Part A Cohort 1: 25mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
3198954|NCT00875784|Active Comparator|IMITREX tablet (100mg)|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
3198955|NCT00875823||PH Patients|"Patients with:~Primary Hyperoxaluria Type I Primary Hyperoxaluria Type II Primary Hyperoxaluria NonI-NonII"
3198956|NCT00875849|Experimental|Cetuximab|
2521166|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
2521224|NCT02755662|Active Comparator|Narval O.R.M CC™|First mandibular retention device : Narval O.R.M CC™
2521234|NCT02755662|Active Comparator|Narval O.R.M™ trad|Second mandibular retention device : Narval O.R.M TRAD™
2521339|NCT02754999|Experimental|SANGUINATE™|As Needed Dosing of SANGUINATE
2521418|NCT02754219|Experimental|Evogliptin|Hepatic dysfunction, Healthy control
2521456|NCT02753868|Experimental|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
2521461|NCT02753868|Experimental|Hemodialysis with Exercise (1-st hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 1-st hour into treatment
2521462|NCT02753868|Experimental|Hemodialysis with Exercise (3-rd hr)|Participants will be monitored during a normal dialysis treatment in which they cycle at mild to moderate intensity for 30 minutes during 3-rd hour into treatment
2521506|NCT02753543|Experimental|Chidamide plus previous chemotherapy|Chidamide 20mg/d Biw p.o. on d1,4,8,11 for of each cycle for 3 cycles
2521555|NCT02753283|Experimental|Denosumab, then Zoledronic Acid|Semi-annual dose: denosumab 60 mg semi-annual injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of Denosumab.
2521559|NCT02753283|Placebo Comparator|Placebo Group, then Zoledronic Acid|Semi-annual: placebo saline injection; Vitamin D 800-1000 IU/daily and Calcium approximately1200 mg/daily (dietary + supplements); Zoledronic acid will be offered to all study participants upon completing the course of placebo.
2521636|NCT02752763|Experimental|preservative free artificial tear drop|preservative free artificial tears drop is a drop group declaring different kind of active agent like hydroxypropyl methylcellulose, carboxymethyl cellulose etc commonly used in dry eye treatment. Preservative free artificial tear( carboxymethyl cellulose, hydroxypropyl methylcellulose) was used as four times one drop daily. In our study, we prescribed to patients preservative free artificial tears drop(hydroxypropyl methylcellulose or carboxymethyl cellulose) four times one drop daily.
2521637|NCT02752763|Experimental|%40 Autologous serum(AS)|peripheral venous blood (14-20 ml) that drawn from antecubital vein of patients to prepare Autologous Serum. Blood sample was left at room temperature over 2 hours for clotting. Serum was obtained after centrifugation at 4000 revolutions per minute (rpm) for 10 minutes at 4 °C using a Nuve NF1200R. Next, in a laminar flow cabinet under sterile conditions, approximately 10 mL of supernatant was collected and diluted to 40 % with isotonic saline solution. It is recommended for dry eye diseases, too. %40 diluted Autologous Serum used as four times one drop daily.
2521754|NCT02752438||Survived|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation and survived.
2521764|NCT02752438||Death|Patients who are treated with HFOV at least for 4 h in case of unresponse to conventional ventilation but died.
2521818|NCT02751645|No Intervention|Standard of Care Control|This group will consist of all the participants that receive the standard of care treatment for elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
2521820|NCT02751645|Experimental|Acute Normovolemic Hemodilution|This group will consist of all the participants that receive the acute normovolemic hemodilution prior to their elective surgical repair or palliation of their cardiac defect with the use of the cardiopulmonary bypass machine.
2521841|NCT02751281|Active Comparator|pneumatic percutaneous nephrolithotomy|pneumatic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
2521842|NCT02751281|Active Comparator|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery in treatment of kidney stone
2521916|NCT02751086||Robotic Gastrectomy|Patients who will be treated for gastric cancer with the assistance of the robotic surgical system
2521917|NCT02751086||Laparoscopic Gastrectomy|Patients who will be treated for gastric cancer through laparoscopic devices.
2521918|NCT02751086||Open Gastrectomy|Patients who will be treated for gastric cancer with traditional open surgery.
2521979|NCT02750475|Experimental|Arm 1|All subjects are patched.
2522043|NCT02750189||Mild Group|FEV₁/FVC <70% and FEV₁≥80% direct/indirect cost
2522044|NCT02750189||Moderate Group|FEV₁/FVC <70% and 50%≤FEV₁≤80% direct/indirect cost
2522046|NCT02750189||Severe Group|FEV₁/FVC <70% and 30%≤FEV₁≤50% direct/indirect cost
2522050|NCT02750189||Very Severe Group|FEV₁/FVC <70% and FEV₁<30% direct/indirect cost
2522125|NCT02749500|Active Comparator|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
2522177|NCT02749032|Active Comparator|Vildagliptin - stratum metformin|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
2523597|NCT02739568|Experimental|Pitolisant (BF2.6449|Histamine H3 receptor H3R antagonist/ inverse agonist
2520928|NCT02757560|Experimental|MUFA versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour monounsaturated fatty acids (MUFA) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the MUFA diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (MUFA or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2520931|NCT02757560|Experimental|CARB versus control diet|Participants will be randomized in a cross-over design to either a weight-maintaining, nutritionally-balanced American Heart Association based eucaloric control diet or a high calorie 24-hour carbohydrate (CARB) enriched diet. For the control diet participants will follow a dietary plan for 72 hours prior to testing. For the CARB diet, participants will be provided with high caloric liquid shakes for breakfast, lunch, dinner and a bedtime snack. On the morning of each test day, participants will be admitted in the fasting state and will provided with a breakfast meal corresponding to the assigned diet (CARB or control). Three hours after completion of the meal, insulin sensitivity will be measured by insulin-suppression test (IST).
2520963|NCT02757287|Experimental|FSH-CTP + DESOGESTREL|Single injection of FSH-CTP and oral desogestrel since the first menstruation day, until bolus of GnRH agonist to follicular maturation
2521033|NCT02757079|Experimental|NPC-15 Granule|NPC-15 granule 1 mg, 2 mg or 4 mg once a day, administered orally before going to bed.
2521064|NCT02756728|Active Comparator|HDM+ASCT|Standard of care; High dose Melphalan + Autologous Stem Cell Transplantation
2521068|NCT02756728|Experimental|BI-505|Biweekly infusions of BI-505 in addition to High dose Melphalan + Autologous Stem Cell Transplantation
3198957|NCT00875862|Active Comparator|1. 0.2% Ropivicaine perinueral infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to 0.2% Ropivicaine attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
3198958|NCT00875862|Placebo Comparator|2. Normal Saline perineural infusion|Patients will receive normal standard of care post-manipulation (single-injection brachial plexus nerve block, oral analgesics, and cold therapy). They will then be randomized to normal saline attached to the perineural catheter and an infusion will be initiated. The outcome measures will be assessed by study staff on the phone and at regular visits to the surgeon's office.
3198959|NCT00875875|Active Comparator|1|This is the approved treatment regimen for travelers' diarrhea (600 mg)
3198960|NCT00875875|Active Comparator|2|This is the same dose as the standard dose, given once daily (200 mg)
2521346|NCT02754908|Experimental|Experimental group|In addition to medical follow-up, the subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation. Qualified orchestral performers will provide the musical training. Training will start at the lowest level (hitting simple notes) and end at the highest level (able to play an entire song). The subjects will continue on to the next level if they successfully pass the relevant test; those who do not will be encouraged to repeat test.
2521347|NCT02754908|Placebo Comparator|Placebo Control group|"The subjects will receive medical follow-up according to the schedule of the oncology units.~They will receive the same amount of time and attention as those in the experimental group but not in a way designed to have any specific effect on the outcome measures. They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks)."
2521383|NCT02754375|Experimental|Patient|Patient with resistant depression treated with rTMS
2521416|NCT02754102|Experimental|Sunscreen Spray-Liquid|All subjects are patched with the same product
3198961|NCT00875888|Experimental|HCO|High cut-off filters HCO1100
3198962|NCT00875888|Active Comparator|control|conventional high-flux filters
2521574|NCT02753179|Experimental|Bilateral vestibular hypofunction|Patients suffering from chronic bilateral vestibular hypofunction.
3198963|NCT00875901|Experimental|Peripherally located lung tumor|12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent
3198964|NCT00875901|Experimental|Centrally located lung tumor|6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent
3198965|NCT00875914|Experimental|Manually guided|Treatment with manually guided RF-catheter
3198966|NCT00875914|Experimental|Magnetically navigated|Treatment with magnetically navigated RF-catheter.
3198967|NCT00875927|Active Comparator|1 - control|candy not including scraping microcapsules
3198968|NCT00875927|Active Comparator|2 - Scraping|candy including scraping TCP microcapsules
2521830|NCT02751476|Active Comparator|standard SAM treatment (control group)|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure.
2523602|NCT02739568|Placebo Comparator|Placebo|Placebo
3198969|NCT00875927|Active Comparator|3 - Scraping plus Propolis|candy including scraping Propolis microcapsules
3198970|NCT00875927|Active Comparator|4 - Scraping plus Zinc|candy including scraping Zinc microcapsules
3198971|NCT00875927|Active Comparator|5 - Scraping plus Propolis and Zinc|candy including scraping Propolis and Zinc microcapsules
3198972|NCT00875940||Group 1|Patients having both Tc-99m perfusion scan and echocardiogram.
3198973|NCT00875953|Active Comparator|Standard dissection|standard neck dissection technique: scalpel and cautery.
3198974|NCT00875953|Experimental|Harmonic Scalpel|Harmonic scalpel used in neck dissection.
3198975|NCT00875966|Experimental|1|Azithromycin for oral suspension 200mg/5mL
3198976|NCT00875966|Active Comparator|2|Zithromax (azithromycin for oral suspension) 200mg/5mL
3198977|NCT00875992|Experimental|ETN with ASLS|Angle stable locking of the Expert Tibial Nail using ASLS
3198978|NCT00875992|Active Comparator|ETN with conventional locking|Conventional locking of the Expert Tibial Nail using conventional locking bolts
3198979|NCT00876005|Active Comparator|1|80% oxygen during cesarean section
3198980|NCT00876005|Active Comparator|2|30% oxygen during cesarean section
3198981|NCT00876044|Experimental|1|4 mg/kg every 2 weeks
2520994|NCT02757443|Placebo Comparator|Control|"Participants randomly assigned to the placebo arm receive:~after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany);~immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes;~immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes"
2521055|NCT02756793|Active Comparator|Standard of Care Treatment|"Patient treatment may include the following 3 options, at the discretion of the treating physicians:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment"
2521059|NCT02756793|Experimental|Stereotactic Ablative Radiotherapy (SABR)|SABR is delivered to all sites of progressive disease with continuation of current systemic agents. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in Arm 1.
2521095|NCT02756507|Experimental|video-based transdiagnostic REBT|Children and adolescents in the experimental group attend 6 modules of video-based transdiagnostic rational emotive behavioral therapy (REBT). Each of the six modules aimes a different component: Psychoeducation, Relaxation, Relationship between cognitive distortions/irrational beliefs and emotions, Cognitive restructuring, Exposure/ behavior activation and problem solving, Maintenance of gaining.
2521096|NCT02756507|Sham Comparator|wait list|The wait-list is a delayed treatment condition.
2521121|NCT02756195||Neonates receiving first-time non-cardiac surgery|No intervention will be administered. This is a prospective observational patient safety study focusing on the safety of care delivered to neonates in perioperative care settings. Neonates who receive NICU care both pre- and post-operatively will be eligible for this study.
2521177|NCT02756000|Experimental|complete PCI at initial hospitalization|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session during initial hospitalization for ST elevation myocardial infarction
2521183|NCT02756000|Experimental|complete PCI after 30 days|Staged, complete revascularization of all non-culprit significant lesions in a single PCI session after 30 days from initial hospitalization for ST elevation myocardial infarction
2521186|NCT02756000|Active Comparator|Dobutamine stress testing|Revascularization by PCI or deferral of revascularization of non-culprit coronary artery lesions based on ischemia testing using Dobutamin stress echocardiography
2521208|NCT02755428|Experimental|retinal pigment epithelium transplantation|Subretinal transplantation of human embryonic stem cell derived retinal pigment epitheliums.
2521283|NCT02755155|Experimental|Continuous low dosage (CLD)|The subjects will received human serum albumin infusion 4%.CLD patients are infused with15ml/kg/day of 4% human serum albumin from inclusion to the day norepinephrine infusion is weaned by 30% (provided their plasma albumin stays in the range 30+3g/L)
2521285|NCT02755155|Active Comparator|Intermittent high dosage (IHD)|The subjects will received human serum albumin infusion 20%.IHD patients are infused with 20% human serum albumin (up to 600 ml/day) until the plasma albumin concentration is in the range 30+3g/L from inclusion to the day norepinephrine infusion is weaned by 30%
3198982|NCT00876044|Placebo Comparator|2|matching placebo
3198983|NCT00876057|Active Comparator|TH|Total hysterectomy
2521423|NCT02754206||Control|Subjects who are collegiate level athletes who do not have a concussion and are currently playing a contact-collision sport.
2521424|NCT02754206||Concussed|Subjects who have recently suffered a sports-related concussion and are currently a collegiate athlete playing a contact-collision sport.
2521448|NCT02753855|Experimental|Telavancin Administration|Single dose of telavancin administered as a 1-hour intravenous infusion
2521527|NCT02753673||Breast Cancer|The assessments are all qualitative. The assessments include an in-person, open-ended qualitative interview, during which the interviewer will use an interview guide to ensure that all relevant topics are discussed. Participants will also complete the Patient Expectations with Breast Reconstruction questionnaire using the think-aloud technique in order to identify which questions reflect the expectations of BCT patients, which questions need modification to reflect the expectations of BCT patients and which questions are not appropriate for BCT patients. The responses to the expectations questionnaire for this portion of the interview will not be recorded or analyzed; only the participants' thoughts and opinions about the questions will be recorded.
2521567|NCT02753140|Experimental|RT concurrent with cetuximab|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy.To observe the curative effect of the treatment of the cetuximab
2521680|NCT02752451|Experimental|CBAT|8 Subjects who received 4 hours of simulation training on the Cigar Box Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
3198984|NCT00876057|Active Comparator|SH|Subtotal hysterectomy
3198985|NCT00876083||Group 1|
3198986|NCT00876096|Other|1|precocious diagnosis and taken care therapeutics of the systematic athlete's feet
3198987|NCT00876109|Experimental|Group A: GDC-0941 QD Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally QD at a starting dose of 15 milligrams (mg).
3198988|NCT00876109|Experimental|Group B: GDC-0941 BID Dose Escalation|Participants will receive GDC-0941 for up to 1 year, administered orally BID at a starting dose determined from Group A assessments.
3198989|NCT00876109|Experimental|Group C: GDC-0941 QD or BID Expansion|Participants will receive GDC-0941 for up to 1 year, administered orally QD or BID. The dose/regimen will be determined on the basis of data from Groups A and B.
3198990|NCT00876122|Experimental|1|
3198991|NCT00876135|Placebo Comparator|Inhaled Bronchodilator|
3198992|NCT00876161|Experimental|DAS181|
3198993|NCT00876161|Placebo Comparator|Lactose|
3198994|NCT00876174||Patients|20 patients with genotype 1, chronic hepatitis C who are to undergo standard antiviral therapy
3198995|NCT00876174||control|Group 2, (control): 10 healthy family members or significant others of patients who are to undergo standard antiviral therapy
3198996|NCT00876252|Active Comparator|IC43 100 mcg|IC43 100 mcg with Aluminum hydroxide
3198997|NCT00876252|Active Comparator|IC43 200 mcg|IC43 200 mcg with Aluminum hydroxide
2521089|NCT02756520||Chronic kidney disease (pre-dialysis)|Observational study: supplemented protein-restricted diet
2521125|NCT02756299|Active Comparator|Device and Standard Care|Positive Airway Pressure Device and Standard Support
2521128|NCT02756299|Active Comparator|Device and Educational Care|Positive Airway Pressure Device and Educational Support
2521212|NCT02755415|Active Comparator|Static Standing Table Training|Patients in this group will receive standard hospital based rehabilitation as well as static standing table training
2521217|NCT02755415|Experimental|Robotic Gait Training|Patients in this group will receive standard hospital based rehabilitation as well as robot-assisted gait rehabilitation training
3165738|NCT00516984|Active Comparator|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
3165739|NCT00517023|Active Comparator|ILR + Syncope Clinic|Patients will have ILR implanted and follow-up in Syncope Clinic
2521425|NCT02754258|Placebo Comparator|Placebo|60 day oral administration of sugar placebo twice per day before lunch and supper.
2521427|NCT02754258|Experimental|Methylphenidate (MPH)|60 day oral administration of active study drug (methylphenidate) twice per day before lunch and supper.
2521480|NCT02753751|No Intervention|Usual Care|No alert will be fired.
2521482|NCT02753751|Experimental|Electronic AKI Alert|A pop-up alert will fire when a provider opens the electronic health record of a patient with AKI until such time as AKI is documented in the problem list, or AKI resolves.
2521533|NCT02753439|Experimental|3rd molar|Drug: Geistlich Bio Oss
2521569|NCT02753114|Experimental|Intranasal Ketamine|Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
2521571|NCT02753114|Placebo Comparator|Placebo|"Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered."
2521622|NCT02752828|Experimental|LixiLan|"LixiLan (insulin glargine/lixisenatide) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
2521625|NCT02752828|Active Comparator|insulin glargine|"Insulin glargine (HOE901) is injected subcutaneously (under the skin) once daily. Dose is individually adjusted.~Background therapy with OADs (except dipeptidyl-peptidase-4 inhibitor) should be continued during the treatment period."
3165740|NCT00517023|Active Comparator|ILR Only|Patients will have ILR implanted and routine follow up.
3165741|NCT00517023|Active Comparator|Routine Mx + Syncope Clinic|Patients will receive routine care and management plus follow up in Syncope Clinic
3165742|NCT00517023|Active Comparator|Routine Mx|Patients will receive routine care and management
3165743|NCT00517036|Experimental|A|Participants will take EPA
2521909|NCT02750878|No Intervention|Control group|Participants will receive only the standard verbal TOT surgical consent counseling.
2521912|NCT02750878|Other|Intervention group|Participants will receive the standard verbal TOT surgical consent counseling plus a handout describing their surgical intervention
2521976|NCT02750579|Active Comparator|Control group|control group: Percutaneous coronary intervention for revascularization delayed intervention (12 to 72 hours)
2521978|NCT02750579|Experimental|experimental group|experimental group: early Percutaneous coronary intervention for revascularization intervention (<2 hours)
2522018|NCT02750215|Experimental|Capmatinib (INC280)|"Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib.~After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles"
2522070|NCT02749968|Active Comparator|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
2522077|NCT02749968|Placebo Comparator|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
2522117|NCT02749591|Experimental|Robot-assisted therapy (RT)|After injection with Botulinum Toxin Type A, a schedule of robot-assisted therapy appointments will be established. Each intervention includes 45 minutes of robotic training and 30 minutes of training in functional activities.
3165744|NCT00517036|Experimental|B|Participants will take DHA
3165745|NCT00517036|Placebo Comparator|C|Participants will take placebo
3165746|NCT00517049|Experimental|1|
3165747|NCT00517062|Active Comparator|A|Growth hormone
3165748|NCT00517062|Placebo Comparator|B|Placebo
2521039|NCT02756884|Experimental|LoFU and aADSC|Low Frequency Ultrasound LFUS will be delivered in a non-sterile manner using a custom modified LFUS combined imaging/therapy probe. Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area after the administration of the low frequency ultrasound
2521042|NCT02756884|Active Comparator|Adipose Derived Stem Cells|Adipose derived stem cells from the patient will be harvested through lipoaspiration. This solution will be injected intra-venous, intra-adventitia and intramuscular in the affected vessel and area without the administration of the low frequency ultrasound
3198998|NCT00876252|Active Comparator|IC43 100 mcg w/o|IC43 100 mcg without Aluminum hydroxide
3198999|NCT00876252|Placebo Comparator|Placebo|phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant
2521116|NCT02756247|Experimental|Buparlisib and Ibrutinib|"This is a two stage protocol comprised of a single institution phase Ib dose escalation trial. The first stage is a standard 3+3 phase I dose escalation trial to assess the safety of buparlisib and ibrutinib. The second stage is a single center expansion cohort in MCL, FL and DLBCL respectively evaluating the efficacy of buparlisib and ibrutinib combination.~Treatment will be with ibrutinib orally daily and buparlisib orally daily. A cycle is defined as 4 weeks of therapy. Therapy will continue until disease progression, intolerable toxicities or death with a maximum duration for 36 cycles, not exceeding 36 months on therapy."
2521175|NCT02755922|Experimental|Fractures with Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, with application of autologous mesenchymal stem cells on the fracture site.
2521182|NCT02755922|No Intervention|Fractures without Mesenchymal Stem Cells|10 patients with mandibular fractures were managed by open reduction and internal fixation, without application of autologous mesenchymal stem cells on the fracture site.
2521228|NCT02755558|Experimental|Low energy density, small portion|Low milk energy density and small portion size
2521236|NCT02755558|Experimental|Low energy density, large portion|Low milk energy density and large portion size
2521240|NCT02755558|Experimental|High energy density, small portion|High milk energy density and small portion size
2521243|NCT02755558|Experimental|High energy density, large portion|High milk energy density and large portion size
2521280|NCT02754882|Active Comparator|Bevacizumab (Avastin)|Avastin® + Carboplatin/Paclitaxel
2521282|NCT02754882|Experimental|SB8 (A proposed bevacizumab biosimilar)|SB8 + Carboplatin/Paclitaxel
2521449|NCT02753894|Experimental|4.5 g/day group|Three times a day
2521455|NCT02753894|Experimental|6.0 g/day group|Three times a day
2521459|NCT02753894|Experimental|7.5 g/day group|Three times a day
2521538|NCT02753504|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
2521542|NCT02753504|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
2521543|NCT02753504|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
2521590|NCT02752984||PICC insertion|Peripherally Inserted Central Catheter insertion
2521673|NCT02752724|Experimental|Ketamine Interventional Arm|1.0 mg/kg IV ketamine (experimental arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
2521674|NCT02752724|Active Comparator|Methohexital Control Arm|1mg/kg of methohexital (standard arm) intravenously (IV) for the duration of their ECT index course over 2-3 weeks
2521714|NCT02752152|Experimental|Computer-assisted counseling|Computer-assisted informational/educational interactive session followed by an interactive face-to-face session to discuss personal issues with a counselor as needed
2521715|NCT02752152|Experimental|On-demand counseling|The counselor asks whether the participant has any questions
2521716|NCT02752152|Active Comparator|Standard counseling|Interactive face-to-face counseling session
2521719|NCT02752152|Experimental|Appointment + reminder|Make appointment and send SMS reminder
2521722|NCT02752152|Experimental|Reminder only|Send SMS reminder only
2521723|NCT02752152|Active Comparator|No appointment and no reminder|No appointment and no SMS reminder sent
2521809|NCT02751606|Experimental|Breast and rectal cancer|Subjects will receive intravenous dose of ferumoxtran-10. 24-36 hours later a 7 Tesla MRI scan will be performed, to detect lymph node metastases. In rectal cancer patients the mesorectum will be imaged and for breast cancer patients this will be performed in the ipsilateral axilla. Subjects will also undergo a 3 Tesla MRI scan as a comparison to the 7 Tesla MRI scan.
3199000|NCT00876278|Other|*AT.Smart 46LC|The *AT.Smart 46LC is indicated for primary implantation for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
3199001|NCT00876291|Placebo Comparator|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
3199002|NCT00876291|Active Comparator|Probiotic|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
3199003|NCT00876304|Experimental|PF-04802540|
3199004|NCT00876304|Placebo Comparator|Placebo|
3199005|NCT00876317|Active Comparator|1|Etoricoxib 60 mg per oz for 14 days
2521995|NCT02750293|Placebo Comparator|placebo|placebo capsules (identical looking to the vitamin D capsules) will be given once a week for 4 months
3199006|NCT00876317|Active Comparator|2|Etoricoxib 90 mg per oz for 14 days
3199007|NCT00876330|Experimental|1|Receives Hypertension and Hyperlipidemia Intervention using Clinical Decision Support.
3199008|NCT00876330|Experimental|2|Receives Hypertension and Hyperlipidemia Intervention with automated telephone outreach.
3199009|NCT00876356|Active Comparator|1|Conjugated Linoleic Acid 4.5g/day in three divided doses p.o. for 12 weeks
3199010|NCT00876356|Placebo Comparator|2|Olive oil 4.5g/day x 12 weeks.
3199011|NCT00876369||Urticaria/Angioedema|Subjects with chronic urticaria and/or angioedema
3199012|NCT00876369||allergy control|Subjects with physician diagnosed allergic rhinitis
3199013|NCT00876421|Placebo Comparator|P|
3199014|NCT00876421|Active Comparator|A|
3199015|NCT00876421|Experimental|E1|
3199016|NCT00876421|Experimental|E2|
3199017|NCT00876421|Experimental|E3|
2521052|NCT02756975|Experimental|transperineal prostate biopsy with coaxial method|The patients undergo transperineal biopsy with a coaxial Tru-Cut needle (18-gauge Core Biopsy Instrument with a 17-gauge Disposable Coaxial Needle).
2521053|NCT02756975|Experimental|transperineal prostate biopsy with noncoaxial method|The patients undergo transperineal biopsy with a noncoaxial 18-gauge needle.
2521082|NCT02756533|Experimental|Telemonitoring|Telemonitoring of daily parameters recorded by NIV, transmitted to a remote monitoring platform. When an alert is received the patient is contacted by phone by a nurse to evaluate the worsening of symptoms. Information are transferred to a referent physician for further medical care if needed.
2521085|NCT02756533|Placebo Comparator|control|"Telemonitoring of daily parameters by NIV, transmitted to a remote monitoring platform with no generation of alerts.~Phone calls to patient during the follow-up like false alerts for the blind procedure."
2521123|NCT02756286||ADHD: Adults with ADHD|NAT electroencephalography (EEG) test
2521129|NCT02756286||Controls: Healthy adults without ADHD|NAT electroencephalography (EEG) test
2521201|NCT02755883|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
2521203|NCT02755883|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
2521210|NCT02755324|Experimental|Intervention|Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae
2521269|NCT02755181||BPD|Borderline Personality Disorder as diagnosed by DSM-5
2521271|NCT02755181||normal volunteers|normal volunteers
2521328|NCT02754778|No Intervention|control group|no intervention, regular family life
2521331|NCT02754778|Active Comparator|intervention group|6 month of regular conditional workout 1-3 times a week
3199018|NCT00876473||1|Acute Respiratory Failure patients
3199019|NCT00876486|Experimental|Genexol®-PM|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
3199020|NCT00876486|Active Comparator|Genexol®|This is a open-labeled, randomized, parallel, phase III Trial. Up to 106 elgible patients will be enrolled in each treatment arm(Total 212 subjects will recruited) according to the trial design. Patients will be randomly allocated to arm A (Genexol-PM) or arm B (Paclitaxel).
2521468|NCT02753933||MRI scan|Direct referral from Primary Care (GPs) to an MRI scan as the initial Secondary Care point of contact.
2521470|NCT02753933||Neurology Appointment|Referral from Primary Care (GPs) to Neurology Services in Secondary Care as the initial Secondary Care point of contact.
2521500|NCT02753530|Experimental|Arimoclomol|Participants will be asked to take 400mg arimoclomol three times a day.
2521501|NCT02753530|Placebo Comparator|Placebo|Participants will be asked to take 400mg placebo three times a day.
2521620|NCT02752815|Active Comparator|6R-CHOP+2R|"6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
2521623|NCT02752815|Experimental|4R-CHOP+4R|"4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Frequency 21days~2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days"
2521766|NCT02752477|Experimental|Opioid-free anesthetic (OFA) group|
2521777|NCT02752477|Active Comparator|Traditional Anesthesia (TA) group|
2521807|NCT02751632|Experimental|Step 1-Regular SPS Therapy|Support and Problem Solving Therapy delivered to all study participants over a six-week period with a minimum of three sessions.
2521811|NCT02751632|Experimental|Responders- Monthly SPS Therapy|Participants are randomised to receive monthly Support and Problem Solving Therapy for up to 12 months.
2521812|NCT02751632|Experimental|Responders- 3-monthly monitoring|Participants are randomised to be monitored for risk every 3 months for up to 12 months.
2521813|NCT02751632|Experimental|Step 2- Regular SPS Therapy|Participants are randomised to receive regular sessions of Support and Problem Solving Therapy, with a minimum of six sessions delivered over an 18-week period.
2521814|NCT02751632|Experimental|Step 2- Regular CBCM|Participants are randomised to receive regular sessions of Cognitive Behavioural Case Management, with a minimum of six sessions delivered over an 18-week period.
2521815|NCT02751632|Experimental|Step 3- Regular CBCM + Fluoxetine|Participants are randomised to receive either Cognitive Behavioural Case Management plus an antidepressant medication for six months .
2521816|NCT02751632|Placebo Comparator|Step 3- Regular CBCM+ placebo|Participants are randomised to receive Cognitive Behavioural Case Management plus placebo medication for six months.
2521885|NCT02751164||Weekday daytime|Admitted to the critical care unit Monday-Friday 08:00-17:59
2521887|NCT02751164||Weekend daytime|Admitted to the critical care unit Saturday-Sunday 08:00-17:59
2521889|NCT02751164||Weekday night|Admitted to the critical care unit Monday-Friday 18:00-07:59 the next day
2521890|NCT02751164||Weekend night|Admitted to the critical care unit Saturday-Sunday 18:00-07:59 the next day
2521926|NCT02750722|Experimental|Cycling in combination with Flutter® therapy|Participants perform 30 minutes of moderately intense cycling exercise in 4-min intervals at 75% of their maximal heart rate and interspersed with 2-min resting periods during which 6-8 breathing maneuvers are performed with the Flutter®.
2521931|NCT02750722|Active Comparator|Cycling without Flutter® therapy|Participants perform 30 minutes of continuous moderately intense cycling exercise at 75% of their maximal heart rate without additional Flutter® breathing maneuvers.
2522000|NCT02750371|Experimental|Patients with brain tumors treated by radiotherapy|"Patients with:~- meningioma of the cavernous sinus for which radiotherapy is planned~Or~- a pituitary adenoma for which radiotherapy is planned"
2522058|NCT02750072|Active Comparator|Infrapatellar approach|Infrapatellar approach using the surgeon's incision of choice (i.e., patellar tendon split, tendon retraction medial, tendon retraction lateral).
3199021|NCT00876499||Questionnaire|
3199022|NCT00876525|Experimental|Freedom SOLO stentless valve|
3199023|NCT00876538|Experimental|TRO19622|2 capsules of TRO19622 (330mg) once day with the noon meal
2521164|NCT02756026|Experimental|Micronutrient supplementation|"On day 3, all mothers are given a commercial multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).~On day 4, all mothers are given two commercial multiple micronutrient supplements (Nutri-Fem) manufactured by Thorne, containing twice the Recommended Dietary Intake (RDA)."
2521238|NCT02755636|Experimental|PCPHC intervention|PCPHC intervention during 6-month intervention period plus study assessments at baseline, 6, and 12 months
2521242|NCT02755636|Active Comparator|Usual care|Usual primary care plus study assessments at baseline, 6, and 12 months
2521272|NCT02754895|Experimental|PP-weekly|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week.
2521273|NCT02754895|Experimental|PP-daily|Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day.
2521274|NCT02754895|Experimental|Shortened PP-weekly plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week.
2521275|NCT02754895|Experimental|Shortened PP-daily plus MI|Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day.
2521276|NCT02754895|Experimental|PP-weekly with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per week. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
2521277|NCT02754895|Experimental|PP-daily with boosters|"Participants will receive the positive psychology intervention and will be asked to complete a PP exercise once per day. Participants will also receive three booster phone calls following the completion of the 8 week intervention."
2521278|NCT02754895|Experimental|Shortened PP-weekly plus MI + boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per week. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
2521279|NCT02754895|Experimental|Shortened PP-daily plus MI with boosters|"Participants will receive a shortened version of the positive psychology intervention in addition to motivational interviewing and will be asked to complete a PP exercise once per day. Participants will also receive three additional booster phone calls following the completion of the 8 week intervention."
2521351|NCT02754648|Active Comparator|Group A; laparoscopic ovarian endometrial aspiration|Laparoscopic ovarian endometrial aspiration will be done for thirty patients with ovarian endometriotic cyst. .
2521353|NCT02754648|Active Comparator|group B; laparoscopic ovarian endometrial stripping|Laparoscopic ovarian endometrial stripping will be done for thirty patients with ovarian endometriotic cyst.
2521357|NCT02754648|Active Comparator|Group c laparoscopic ovarian endometrial de-roofing|Laparoscopic ovarian endometrial de-roofing and bed cauterization will be done for thirty patients with ovarian endometriotic cyst.
2521382|NCT02754349|Experimental|Validation|SphygmoCor version 7, AtCor Medical, Sydney, Australia
2521417|NCT02754167|Experimental|PRS-080#022-DP|Hepcidin antagonist, single administration, ascending doses
2521419|NCT02754167|Placebo Comparator|PRS-080-Placebo#001|Comparator treatment, single administration
2521447|NCT02753829|Experimental|Experimental group 1|Cardiovascular rehabilitation program using Kinect of Xbox, in home care context,virtual format
2521452|NCT02753829|Experimental|Experimental group 2|Cardiovascular rehabilitation program using paper manual, in home care context, conventional format
2521458|NCT02753829|Other|Control Group|Educational component
2521507|NCT02753621|Experimental|Singing Intervention|Twelve weekly group singing classes lasting 60-90 minutes under the direction of a professional choir director and a social worker with a music background.
2521508|NCT02753621|Active Comparator|Discussion/Support Group Intervention|Twelve weekly 60-90 minute discussion groups led by a facilitator trained in discussion group facilitation; occurring at the same time and in the same location (next door) as experimental intervention (group singing).
2521545|NCT02753270|Active Comparator|Short catheter|Twenty-five patients will receive the sclerosant foam by a short catheter 18 G. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
2521549|NCT02753270|Experimental|Long catheter preceded by tumescence|Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
2521594|NCT02752997|Experimental|Intervention|"Discharge medication services included:~Discharge medication reconciliation~Identification of medication discrepancies and resolution~Medication counseling using health coaching techniques with short term goal setting and follow up phone call"
2521599|NCT02752997|No Intervention|Comparator|Current standard of care provided by nursing staff.
2521628|NCT02752698|Experimental|Micro Hand S robotic group|Micro Hand S robotic surgery group
2521630|NCT02752698|Other|laparoscopic surgery|laparoscopic surgery group
2521633|NCT02752698|Other|da Vinci robotic group|da Vinci robotic robotic group
2521706|NCT02752464|Experimental|Feedback report plus peer counseling|Feedback report plus peer counseling Participants receive 12 sessions of behavioral counseling and a brief printed feedback report
2521708|NCT02752464|Active Comparator|Feedback report|Feedback report Participants receive a brief printed feedback report
2521758|NCT02751944|Experimental|NEM Treatment|NEM, 500 mg, once daily, orally for 2 weeks
2521770|NCT02751944|Placebo Comparator|Placebo|Placebo, 500 mg, once daily, orally for 2 weeks
2521821|NCT02751658|Other|patients in the Otorhinolaryngology|patients in the Otorhinolaryngology department realization of a levy into the mouth swab on the day of admission to hospital and the day of release
2521849|NCT02751307|Active Comparator|metformin 500 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2522026|NCT02750085||2-point and 6-point PK sampling|
2521184|NCT02755727|Active Comparator|Open Surgical Release|Standardised surgical technique based on the Nirschl technique will be used. The patient will then have a small scar centred over the lateral epicondyle and the plane opened between ECRL (Extensor Carpi Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the damaged ECRB (Extensor Carpi Radialis Brevis) tendon. The amount of abnormal tendon will be documented and excised. EDC will also be inspected and any abnormal tissue documented then excised. The footprint of the excised ECRB +/- EDC is cleared of soft tissue and the bone scored with an osteotome to promote bleeding. The interval is closed with suture material and the skin wound closed.
2521222|NCT02755493|Experimental|Sleep Deprivation|Sleep deprivation
2521401|NCT02754297|Experimental|Personalized PRRT (P-PRRT)|"177Lu-Octreotate (LuTate) P-PRRT will be administered as follows:~Renal absorbed radiation dose will be prescribed for the 4-cycle induction course (23 Gy) and for each subsequent cycle (6 Gy), with a reduction in cases of impaired renal or bone marrow function, or significant toxicity from prior cycles.~The personalized activity to be administered at each cycle will be derived from renal dose per unit of injected activity that is predicted by patient characteristics or renal dose delivered during prior cycle(s).~Participants responding to the induction course of P-PRRT will be eligible to receive additional consolidation and/or maintenance cycles.~Participants with prior PRRT exposure outside the trial may receive less induction cycles, or only consolidation/maintenance cycle(s)."
2521534|NCT02753348||Newborns|Newborns (within 14 days from birth)
2521639|NCT02753088|Experimental|BCD-063 (glatiramer acetate)|Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day
2521640|NCT02753088|Active Comparator|Copaxone-Teva (glatiramer acetate)|Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day
2521641|NCT02753088|Placebo Comparator|Placebo|Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day
2521762|NCT02752022||Heavy smokers|Heavy smokers (continuous smoking of >10 cigarettes per day) for at least 6 months who will give up smoking and switch to nicotine containing e-cigarettes for 28 days to help them quit smoking.
2521806|NCT02751762||Prospective Longitudinal Cohort|Patients who have recently initiated long-term opioid therapy or initiated ER/LA opioid therapy
2521808|NCT02751762||Cross-sectional Cohort|Patients who have been treated with opioids (including at least one ER/LA opioid) for greater than one year
2521847|NCT02751346||Patients with Pain|Patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
2521852|NCT02751346||Patients without Pain|Patients without pain age and gender matched to patients with pain identified through the survey will be invited to undergo sensory assessment by quantitative sensory testing (QST) around the surgical scar and a control area: Thermal (cold and heat) detection and pain thresholds; mechanical detection and pain threshold; dynamic mechanical allodynia; temporal summation (wind-up).
2521925|NCT02750735||Retrospective NCWS patients|The clinical charts of NCWS patients attending the outpatient centers of the Department of Internal Medicine at the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca were retrospectively reviewed. Patients had all been diagnosed with NCWS between January 2001 and June 2011, by a DBPCC method, and included in a previously published study. These charts included specific sections for the presence of associated atopic diseases, including nickel allergy. In this way, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy. Incomplete clinical charts were excluded.
2521928|NCT02750735||Prospective NCWS patients|The investigators also prospectively surveyed adult patients with functional gastroenterological symptoms according to the Rome III criteria, and a definitive diagnosis of NCWS. The patients were recruited between December 2014 and March 2016 at 3 centers: the two already mentioned and the Gastroenterology Unit of the ARNAS Civico Hospital of Palermo, Italy. Most of the patients had been referred due to gastrointestinal symptoms, the onset of which, they reported, could be related to wheat ingestion. Again, the characteristics of the NCWS patients suffering from nickel allergy were compared with those of the NCWS patients who did not suffer from nickel allergy.
2521933|NCT02750735||Retrospective NCWS control patients|To compare the frequency of nickel allergy in NCWS and non-NCWS patients, a control group composed of 70 irritable bowel syndrome (IBS) patients, was selected. These controls were randomly chosen by a computer-generated method from subjects diagnosed during the same period and age- (+/-2 years) and sex-matched (+/-5%) with the NCWS patients. The IBS controls had been receiving the same elimination diet as the NCWS patients and had not shown any clinical improvement; they belonged to the cohort of subjects the investigators had studied previously.
3165749|NCT00517088|Other|Other|Group Description
2522072|NCT02749812|Experimental|Constant Continuous Positive Airway Pressure|
3165750|NCT00517127|Active Comparator|1|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
3165751|NCT00517127|Active Comparator|2|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
3165752|NCT00517153|Experimental|1|OGT-918 - Zavesca (miglustat)
3165753|NCT00517153|No Intervention|2|Standard treatment
3165754|NCT00517166||A|Individuals on whom tourniquet was used.
3165755|NCT00517244||A|Primary anxiety disorder
3165756|NCT00517244||B|Primary obsessive compulsive disorder
3165757|NCT00517244||C|Healthy children with no previous history of an anxiety disorder
3165758|NCT00517257|Experimental|A|Atorvastatin 80 mg orally once daily for 24 weeks
3165759|NCT00517257|Placebo Comparator|P|Placebo tablet orally once daily for 24 weeks
3165760|NCT00517283|Experimental|Sequence 1|Exenatide 5 mcg - Exentatide 10 mcg - Placebo
3165761|NCT00517283|Experimental|Sequence 2|Exenatide 10 mcg - Placebo - Exenatide 5 mcg
3165762|NCT00517283|Experimental|Sequence 3|Placebo - Exenatide 5 mcg - Exenatide 10 mcg
3165763|NCT00517322|Experimental|1|treatment with ramipril
3165764|NCT00517322|Experimental|2|treatment with irbesartan
3165765|NCT00517335||1|Women who are healthy controls
3165766|NCT00517335||2|Women who have recovered from bulimia
3199024|NCT00876538|Placebo Comparator|Control|2 capsules of placebo once day with the noon meal
2521249|NCT02755311|Experimental|liver resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
2521252|NCT02755311|Active Comparator|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
2521289|NCT02754804||PAD patients|Patients with grade 1 claudication Measurement of biomechanic parameters while walking on treadmill
2521358|NCT02754739|Experimental|Pravastatin|Pravastatin 40mg tablet by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
2521359|NCT02754739|Placebo Comparator|Placebo|Placebo drug indistiguishable from pravastatin 40mg tablet, by mouth, once daily for 24 weeks. Also, nutritional education was provided to participants in all arms by a nutritionist, and participants were instructed to follow the educated guideline.
2521361|NCT02754739|Other|Open-label control|No medication. Only nutritional education was provided to participants by a nutritionist, and participants were instructed to follow the educated guideline.
2521395|NCT02754271|Experimental|Intervention|A research-based film (Fit for Dialysis) and a 16-week exercise program involving activities during dialysis, at home, and in the community.
2521400|NCT02754271|No Intervention|Control|The 16-week exercise program involving activities during dialysis, at home, and in the community.
2521451|NCT02753972|Experimental|Mindful Eating and Living|The goal of the Mindful Eating and Living (MEAL) intervention was to apply mindfulness to apply mindfulness to eating behavior. The content for the MEAL sessions included group discussion, mindfulness meditation, and group eating exercises. The course, based on the work of Kristeller, Baer, & Quillian-Wolever (31), emphasized brief daily meditation and pairing meditation with eating, but was more streamlined in terms of didactic content and course length. Participants examined hunger and satiety cues, the qualities of foods they crave, and emotional and cognitive states associated with eating. Each session included an eating exercise with a variety of foods. The monthly refresher sessions included a brief meditation, a brief eating exercise, and group discussion. (The MEAL curriculum is available from the authors.)
2521457|NCT02753972|Active Comparator|Active Control|The Active Control (CONT) group matched the MEAL group regarding schedule. The agenda for the CONT sessions involved giving each participant the opportunity to discuss issues such as food choices, activity levels, and caloric goals. The sessions began by having the participants check-in about their experiences with eating. Next, the clinical psychology graduate student led the participants in goal setting and finally there was a question and answer period when the registered dietician answered questions about food selection. The monthly refresher sessions had the same agenda as the initial weekly sessions.
2521528|NCT02753647|Experimental|Chidamide plus R-CHOP|Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Doxorubicin 50mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2-6 Chidamide 20mg/d PO d1, 4, 8, 11 Frequency every 21 days for 6 cycles
2521591|NCT02753036||Chemotherapy|patients with ovarian cancer and paclitaxel + carboplatin combination chemotherapy as well as patients with breast cancer and paclitaxel +/- carboplatin combination chemotherapy
2521598|NCT02753036||Healthy control|patients with benign gynecological tumors after laparoscopic surgical resection
2521602|NCT02753036||Tumor control|patients with breast cancer with anti-hormonal and/or localized radiation treatment but no chemotherapy
2521656|NCT02752659|Experimental|Women with breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
2521659|NCT02752659|Experimental|Women at risk of breast cancer-related lymphedema|Participants will measure their own arm circumference and be measured by a specialized physiotherapist and by a perometer.
2521769|NCT02752282|Sham Comparator|Control Video|Participants in this study arm will be assigned to watch a short educational video about new pap screening guidelines for women. Intervention: Cancer Screening Guidelines.
2521778|NCT02752282|Active Comparator|Intervention Video|Participants in this group will be assigned to watch a short educational video providing anticipatory counseling on their LNG-IUS' side effects and expected changes in bleeding. Intervention: Anticipatory Counseling
2521822|NCT02751619|Experimental|Lidocaine Group|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, PA, USA) measuring 10 x 14 cm and containing 700 mg of Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
2521823|NCT02751619|Active Comparator|Placebo Patch|A patch, that was identical in appearance to the active patch but did not contain Lidocaine, was applied to cover the planned skin incision, marked with a pen by surgeon. Patch was applied for 12 hours during the night, removed for the subsequent 12 hours during the day, and then a new patch was applied at the same level the night after. This process was continued for 3 days before thoracotomy
2521982|NCT02750436|Experimental|Ultrasound guided|Ultrasound guided sacral lateral branch block
3199025|NCT00876551|Experimental|E-V.A.C.|Patients that are treated with E-V.A.C.
3199026|NCT00876564|Other|Trauma patients|Included in trauma registry
3199027|NCT00876577||Group 1|
3199028|NCT00876603||1|
3199029|NCT00876603||2|
2521219|NCT02755532|Active Comparator|Bupivacaine 0,5%|Routine surgical procedure monitoring with an electrocardiogram, sphygmomanometer, and pulse oximeter was performed. One experienced anesthesiologist performed an ultrasound guided axillary brachial plexus block (S Series, FUJIFILM Sonosite, Seattle, USA) with the patient in the supine position. Local anesthetic injection was performed on each nerve identified in this pathway (i.e., the radial nerve, the ulnar nerve, the median nerve, and the musculocutaneous nerve). In the group bupivacaine 0.5% , 5 ml of 0.5% bupivacaine was injected into each nerve, for a total of 20 ml per patient.
2521264|NCT02755142|Active Comparator|Dose level 1|0,2 mg/Kg
2521266|NCT02755142|Active Comparator|Dose level 2|2,0 mg/Kg
2521267|NCT02755142|Active Comparator|Dose level 3|20 mg/Kg
2521294|NCT02754817||Insulin degludec/liraglutide|
2521333|NCT02754635|Active Comparator|Induction of labour|Induction of labour at 38-39 weeks
2521334|NCT02754635|Active Comparator|Expectant management|Expectant management until 41 weeks.
2521386|NCT02754466|Experimental|Deep dentin lesions|Subjective vs objective criteria in selective excavation of carious lesions Group 1: selective carious dentin excavation using subjective criteria (standard protocol in Dentistry) Group 2: selective carious dentin excavation using objective criteria (polymer burs) All restorations performed using high-viscosity glass-ionomer.
2521389|NCT02754466|Experimental|Shallow and medium depth dentin lesion|Glass-ionomer vs Bulk fill composites in the ART approach All cavities excavated using hand-instruments only (ART approach) Group 1: restorations using high-viscosity glass-ionomer Group 2: restorations using self-etch adhesive and bulk fill composite
2521434|NCT02754063|Active Comparator|ICP Management|
2521435|NCT02754063|Experimental|PbtO2 + ICP Management|
2521503|NCT02753478|Experimental|intracoronary hypothermia group|Patients who will receive intracoronary hypothermia before and during percutaneous coronary intervention
2521546|NCT02753322|Experimental|Dual-task training group|"Subjects in this group will have 30 minutes of dual-task training with simultaneously performing balance and walking exercise and attention demanding tasks, and 30 minutes of stretching exercises.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2521548|NCT02753322|Active Comparator|Single-task training group|"Subjects in this group will have single-task training with 30 minutes of balance and walking exercise and 30 minutes of attention demanding task performed separately.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2521551|NCT02753322|Active Comparator|Limbs exercise group|"Subjects in this group will have stretching and strengthening exercise for 60 minutes.~The training program will last for 8 weeks with frequency of 2 sessions a week."
2521585|NCT02752971|Experimental|Bupivacaine|A dilution of Bupivacaine 0,25% , 15 ml was infiltrated in surgical wound after close the aponeurosis
2521595|NCT02752971|Experimental|Bupivacaine, sodium diclofenac|A dilution of Bupivacaine 0,25% and sodium diclofenac 75 mgr, was infiltrated in surgical wound after close the aponeurosis
2521597|NCT02752971|Experimental|Sodium diclofenac|A dilution of sodium diclofenac 75 mgrs (3ml) and 12 ml of solution 0,9% was infiltrated in surgical wound after close the aponeurosis
3199030|NCT00876603||CSM - ACDF|Cervical spondylotic myelopathy treated with anterior cervical decompression and fusion
2521701|NCT02752217|Experimental|Inspiratory Muscle Training (IMT)|"Subjects in the inspiratory muscle training (IMT) group will perform loaded deep breathing exercise at 6 breaths/min using BreatheMaxยฎ device. The IMT protocol at 6 breathing rate (inspiratory time = 4 seconds and expiratory time = 6 seconds) with load at 25 percent of MIP for eighth weeks.~The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks"
2521702|NCT02752217|Placebo Comparator|Control|Subjects in the control (CON) group will perform breathing exercise with inspiratory load at 2 cmH2O at 6 breathing rate using one BreatheMAXยฎ device. The pressure will be control by pressure manometer and duty cycle are control by subjects count duration for inspiration and expiration during training. The program will perform at home for 10 breaths/min/set, 6 sets/day with at least 1 minutes rest between sessions, 7 days/week for 8 weeks
2521755|NCT02751970|Active Comparator|3 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of a primer and subsequently an adhesive resin.
2521765|NCT02751970|Experimental|2 step ER & Dental restoration|Dental restoration with etching the dental substrates 35% phosphoric acid, followed by the application of an adhesive/primer step.
2521773|NCT02751970|Active Comparator|2 step SE & Dental restoration|Dental restoration with etching the dental substrates with acidic primer, followed by the application of adhesive resin.
2521780|NCT02751970|Experimental|1 step SE & Dental restoration|Dental restoration with etching and infiltrate the dental substrates with acidic primer/adhesive system.
2521827|NCT02751541|Experimental|BAY987519|All subjects are patched
2521867|NCT02751216|Experimental|spinal cord stimulation|
2521901|NCT02750917|Experimental|GROUP LORNOXICAM|Immediately in postoperative care unit patients received lornoxicam 8 mg PO/12 hours for 48 hours
2521902|NCT02750917|Active Comparator|GROUP ETORICOXIB|Immediately in postoperative care unit patients received etoricoxib 120 mg PO and another pill at 24 hours.
2521981|NCT02750566|Experimental|Osteopathic Manipulative Treatment|A board certified NMM/OMM or FP/OMM physician will perform an osteopathic structural exam and osteopathic treatment for a 30 minute session. The investigators will follow a generalized protocol for diagnosis and treatment of the head, neck, spine, rib cage, and pelvis. The following techniques will be included in the treatment protocol, OA (Occipitoatlantal) decompression, V-Spread, venous sinus drainage, balanced membranous tension (BMT), cranial lifts, CV4, and a mix of balanced ligamentous tension (BLT), muscle energy techniques, facilitated positional release, articulatory techniques (ART), high-velocity low-amplitude, and counterstrain to address any somatic dysfunctions.
2521991|NCT02750436|Active Comparator|Fluoroscopy guided|Fluoroscopically guided sacral lateral branch block
3199031|NCT00876603||CSM - Cervical laminoplasty|Cervical spondylotic myelopathy treated with cervical laminoplasty
3199032|NCT00876616|Experimental|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d+MMF 1.0g/d
3199033|NCT00876616|Active Comparator|Cyclophosphamide|CTX iv 0.75 g/m2 body surface area (BSA)
3199034|NCT00876642|Experimental|1|
2521315|NCT02755064|Experimental|Erythromycin lactobionate IV 2 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
2521319|NCT02755064|Active Comparator|Erythromycin lactobionate IV 3 mg/kg|During the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.Thereafter, an infusion of 1.5 mg/kg was given over the next 50 min with the same infusion pump.
2521320|NCT02755064|Placebo Comparator|Placebo IV|Saline was given as an initial bolus over 10 min immediately before the meal. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
2521321|NCT02755064|Experimental|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
2521322|NCT02755064|Placebo Comparator|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days. The GEBT was performed approximately on day 7. The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
3199035|NCT00876642|No Intervention|2|
3199036|NCT00876655|Experimental|free acid|TR-701 free acid phosphate powder in capsule formulation (equivalent to 150 mg TR-700)
2521474|NCT02753790|Experimental|Intensity Modulated Radiotherapy (IMRT)|Radiation therapy to a dose of 60 Gray (Gy)/45 Gy to gross disease and 30 Gy to subclinical sites, delivered over 15 fractions
2521509|NCT02753465|Experimental|left colic artery group|Laparoscopic D3 Lymph Node Dissection with preservation of the left colic artery
2521510|NCT02753465|Active Comparator|High ligation group|Laparoscopic D3 Lymph Node Dissection with high ligation
2521556|NCT02753244|Experimental|Intendu FBT inpatient|Other: Motion Based Cognitive Video Games Software
2521561|NCT02753244|Active Comparator|iPad games|Other: iPad apps
2521562|NCT02753244|Experimental|Intendu FBT community|Other: Motion Based Cognitive Video Games Software
2521575|NCT02752919|Experimental|Part A Galunisertib - 1 tablet|Single oral dose of galunisertib in Japanese participants
2521576|NCT02752919|Experimental|Part A Galunisertib - 2 tablets|Single oral dose of galunisertib in Japanese participants
2521577|NCT02752919|Experimental|Part B Galunisertib - 1 tablet|Single oral dose of galunisertib in non-Japanese participants
2521578|NCT02752919|Experimental|Part B Galunisertib - 2 tablets|Single oral dose of galunisertib in non-Japanese participants
3199037|NCT00876655|Experimental|di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
2521921|NCT02750787|Experimental|Nutritional Study Product|A ready-to-drink peptide-based liquid formula for patients with impaired gastro-intestinal function.
3199038|NCT00876681|Active Comparator|1. Ultrasound|Ultrasound method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement and then again the first day after surgery. Time of placement is also measured and begins when the ultrasound probe first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
3199039|NCT00876681|Active Comparator|2. Electrical Stimulation|Electrical stimulation (nerve stimulation) method of placement is selected randomly, using a computer program. The patient is asked their pain and discomfort using a 0-10 scale where 0=no pain/discomfort and 10=worst pain/discomfort imaginable. The patient is asked this question prior to surgery, but after catheter placement, and then again the first day after surgery. Time of placement is also measured and begins when the nerve stimulation needle first touches the skin. Patients are also asked the numbness of their foot and toes based on a 0-10 scale where 0=no numbness and 10=completely numb.
3199040|NCT00876707|Active Comparator|Tecnis|
3199041|NCT00876707|Active Comparator|ReSTOR|
3199042|NCT00876707|Active Comparator|ReZoom|
2522199|NCT02749149||Cardiac Surgery|Patients undergoing cardiac surgery: coronary artery bypass graft (CABG); valve replacement/repair; or transcatheter aortic valve implantation (TAVI) surgery
2522211|NCT02748707|Experimental|Arm 1|Celecoxib 200mg twice daily for 21 days
2522212|NCT02748707|Experimental|Arm 2|Erlotinib 150 mg once daily for 21 days
2522213|NCT02748707|Experimental|Arm 3|Celecoxib 200 mg twice daily for 21 days and Erlotinib 150 mg once daily for 21 days
2522217|NCT02748707|Sham Comparator|Arm 4|Control group with no drug
2522312|NCT02748395|Placebo Comparator|Placebo|Injection of 3.5mL of normal saline into the point of maximal tenderness in the abdomen
2522319|NCT02748395|Experimental|Treatment|Injection of 20mg triamcinolone and 1% lidocaine into the point of maximal tenderness in the abdomen
2522379|NCT02748005|Experimental|Fenugreek seeds extract 500 mg|Fenugreek seeds extract(Furosap) 500 mg
3199043|NCT00876720|Experimental|1|Combined frontal and temporal transcranial magnetic stimulation
3199044|NCT00876720|Experimental|2|Temporal transcranial magnetic stimulation
2522498|NCT02747147|No Intervention|A- Control|Group A will have their PIVs assessed daily and record kept of PIV dislodgement or replacement
2523702|NCT02739009|Placebo Comparator|Placebo MAD|Multiple intravenous adminstration of Placebo
2521329|NCT02754791|Experimental|Soluprep wipes|In this arm, skin sterilization will be achieved using Soluprep wipes (3M) instead of standard methods (alcohol wipes).This will be in addition to a departmental monthly report (described above).
3199045|NCT00876746|Active Comparator|1. Supraclavicular|Patients will be randomized to placement of a nerve block in the supraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
2521592|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons.
2521643|NCT02752646|Active Comparator|nepafenac 0.3%|Patients in this arm will receive nepafenac 0.3% eye drops once daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
2521646|NCT02752646|Active Comparator|ketorolac 0.5%|Patients in this arm will receive ketorolac 0.5% eye drops four times daily following cataract surgery, combined with a topical antibiotic and steroid. This regimen is FDA approved and withing the standard of care.
2521694|NCT02752360|Experimental|BSA Group|Patients accept the management of Biodegradable Stenting Anastomoses for reconstruction in the surgery of Intestinal Anastomosis
2521695|NCT02752360|Experimental|DHS Group|Patients accept the management of Double-layer Hand Sutures for reconstruction in the surgery of Intestinal Anastomosis
2521727|NCT02752009|Experimental|Axillary Lymph Node Sampling Clip|"Axillary Lymph Node Biopsy~-- Axillary lymph node sampling with clip placement into the sampled lymph node. After the tissue sampling of any suspicious nodes, a marker clip will be placed to allow for intra-operative identification of the biopsied nodes.~Neoadjuvant therapy at the discretion of the treating Medical Oncologist. Once Neoadjuvant therapy is completed, surgery in the form of either Lumpectomy or Mastectomy is performed.~Wire-localization of the clipped node on the day of surgery.~Lymphatic mapping performed with either radiocolloid and/or blue dye.~Sentinel lymph node biopsy will be performed on the day of surgery.~--- If the clipped node which contains the wire is not part of this sentinel lymph node specimen, then it will be removed separately and be sent to Pathology as a separate specimen.~Axillary lymph node dissection as is the standard of care."
3199046|NCT00876746|Active Comparator|2. Infraclavicular|Patients will be randomized to placement of a nerve block in the infraclavicular position. After the catheter has been placed, sensory and motor deficit will be assessed and following surgery, for the next three days, the patient will be contacted by research staff to assess pain scores and other outcome measures.
2521858|NCT02751242||Usual Care|All patients will receive a dose of intravenous furosemide.
2521942|NCT02750670|Experimental|GD2P|Obinutuzumab 1000mg by IV for 1.5-6.5 hours with Gemcitabine 1000mg/m^2 by IV for 30 minutes with dexamethasone 40mg by mouth daily and Cisplatin 75mg/m^2 by IV for 1 hour all for a duration of 3 cycles
3199047|NCT00876759|Active Comparator|WBRT|standard WBRT to a total dose of 30 Gy in 10 fractions
3199048|NCT00876759|Experimental|WBRT with simulatneous boost|The experimental group will be treated with helical tomotherapy giving 3 Gy per fraction to the whole brain up to a total dose of 30 Gy in 10 fractions and raising the prescribed dose to the brain metastases to 5 Gy per fraction. The dose fall off to the normal brain should be as steep as possible around each brain metastasis. The optic chiasm and the optic nerves should not receive more than 3.5 Gy per fraction.
2522064|NCT02749929|Experimental|Low-Level Laser therapy|"After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the laser to make skin contact. The laser is a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. The light from the laser is not visible to the eye, and will not give any perceptible stimulus.~Low-Level Laser therapy (LLLT) will be given according to the recommended dosage from World Association of Laser Therapy (WALT). A LLLT dose of 3.6 Joules will be administered at two points over the fracture site."
2522068|NCT02749929|Placebo Comparator|Placebo Low-Level Laser therapy|After inclusion in the study, a small window of approximately 1 cm2 opening will be made in the cast in order for the placebo laser to make skin contact. The placebo laser is identical in apperance to a super pulsed infrared laser with a wavelength of 904 nm, belonging to laser class 3B. Since the light from the laser is invisible, neither the participant nor the therapist will know whether the laser is a placebo. The treatment time and number of treated points will be identical to group 1.
2522110|NCT02749578|Other|Treatment|Atorvastatin followed by MGL-3196 daily followed by separate co-administration of atorvastatin
2522238|NCT02748850|Active Comparator|leukemia patients|Patients with acute leukemia and / or refractory anemia with excess blasts and comprising a number of blasts in the blood greater than 5% device.
2522243|NCT02748850|Placebo Comparator|apheresis patients|patients with non-myeloid hematological malignancy
2522287|NCT02748499|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
2522288|NCT02748499|Active Comparator|Control|The control group maintains daily activities.
2522347|NCT02748200|Experimental|external beam radiotherapy: Dose level 1|57.6 Gray (Gy) (20 x 2.88 Gy, 5 fractions/week, 4 weeks)
2522350|NCT02748200|Experimental|external beam radiotherapy: dose level 2|60 Gy (20 x 3.00 Gy, 5 fractions/week, 4 weeks)
2522351|NCT02748200|Experimental|external beam radiotherapy: dose level 3|62.4 Gy (20 x 3.12Gy, 5 fractions/week, 4 weeks)
2522373|NCT02747901|Experimental|Kinesiotaping Group|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
2522376|NCT02747901|Active Comparator|Cold Therapy Group|Cold Therapy group received cold pack immediately after operation and following postoperative days.
2522378|NCT02747901|No Intervention|Control Group|Control group have no intervention.
2522423|NCT02747589|Experimental|Treatment Group|Subjects will be implanted to assess the feasibility of stimulating visual cortex to restore vision in blind volunteers.
2521343|NCT02754609|Placebo Comparator|Tabasco® Sauce|A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing. Tabasco® Sauce is an ideal placebo as the sensation to the skin is similar to a hookworm. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge.
2521344|NCT02754609|Experimental|Necator americanus-hookworm larvae L3-20|A total of 10 participants at week 0 and week 8 will have medium dose hookworms present in 2-3 drops of water applied to their skin and then covered in a light dressing. The hookworms are Necator americanus-hookworm larvae L3; 20 L3 in 200 uL of deionized water presented in an Eppendorf tube. All participants will undergo interventions of Gluten free diet, Gluten micro-challenge, Inadvertent gluten challenge and Moderate gluten challenge. At week 42, participants will have the option of going on the liberal diet.
2521471|NCT02754180|Active Comparator|chemotherapy|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles.
2521472|NCT02754180|Experimental|chemotherapy with chemoradiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
2521504|NCT02753491|Active Comparator|Intervention|In intervention group, three or four motivational short interview made with every participants.
2521505|NCT02753491|No Intervention|Control|non intervention group,
2521553|NCT02753309|Active Comparator|Rapamycin 0.5mg|Subject will take Rapamycin (Sirolimus) 0.5mg once daily for approximately 28 days
2521557|NCT02753309|Active Comparator|Rapamycin 2.0mg|Subject will take Rapamycin (Sirolimus) 2.0mg once daily for approximately 28 days
2521560|NCT02753309|No Intervention|Control|Subject will be apart of the control group and won't take the study drug being tested
2521584|NCT02752945|Experimental|One-day CBT workshop (+Usual Care)|"One-day CBT-based workshop (DISCOVER), followed by up to three brief telephone contacts to review goals set in workshop."
2521588|NCT02752945|Active Comparator|Usual care|Usual care afforded by local CAMHS services
2521655|NCT02752620|Experimental|Osteopathic Manipulative Treatment|"We selected two types of osteopathic techniques for this study:~Technical articulation: rhythmic technique with low speed in which the goal is the full gain range of motion.~Myofascial techniques (Neuromuscular): techniques involving lateral stretching, linear, deep pressures and pulls of the origins and insertions aiming at a myofascial relaxation.~Sacroiliac articulatory technique; Dorsal articulatory technique; Lumbar paraspinal muscles stretching technique; Lumbar myofascial technique (inhibitory)."
2521657|NCT02752620|Active Comparator|Exercise Therapy|"2 types of therapeutic exercises techniques were used:~Stabilization exercises~Stretches~Stabilization exercises:~Bridge on the ball 10 - 15 sec Side plank 10 - 15 sec Front board 10 - 15 sec active mobilization lumbopelvic 3 x 6 rep Squats with the ball on the wall 3 x 8 rep~Static-passive stretch (2 x 30 sec):~Paraspinal; Abdominals; Quadratus lumborum; Hip extenders; Hip flexors; Hip abductors; Hip adductors."
2521726|NCT02752100|Experimental|Interventional Therapy|Percutaneous transluminal angioplasty.
2521728|NCT02752100|No Intervention|Non-Interventional Therapy|
2521785|NCT02751801||Adults and children with hypophosphatasia|Healthcare use interview
2521855|NCT02751567|Experimental|Arm 1|All subjects are patched with the same product
2521906|NCT02751034|Experimental|Neuramis® Deep Lidocaine|Neuramis® Deep Lidocaine Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2521910|NCT02751034|Active Comparator|Restylane® PERLANE-L|Restylane® PERLANE-L Hyaluronic Acid Gel and Lidocaine Hydrochlorid, total dose 1ml, single injection
2521970|NCT02750553|Experimental|Pre-test|Three healthy male subjects were randomized in 2:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
2521971|NCT02750553|Experimental|Cohort 1|Eight healthy subjects were randomized in 3:1 ratio to receive single and then multiple (14 days) oral dose of 5 mg SHR0534 or matching placebo.
2521972|NCT02750553|Experimental|Cohort 2|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 10 mg SHR0534 or matching placebo.
2521973|NCT02750553|Experimental|Cohort 3|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 25 mg SHR0534 or matching placebo.
2521975|NCT02750553|Experimental|Cohort 4|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 50 mg SHR0534 or matching placebo.
2521977|NCT02750553|Experimental|Cohort 5|Ten healthy subjects were randomized in 4:1 ratio to receive single and then multiple (14 days) oral dose of 100 mg SHR0534 or matching placebo.
2522037|NCT02750098|Experimental|Diabetic patients|Diabetic patients planned to undergo elective cataract surgery
2522102|NCT02749760|Other|Minor league pitchers|Minor league pitchers from a single professional baseball organization. Strength tests of the elbows will be administered at spring training and end of season for 5 years. If strength correlates to injury, strengthening and exercise programs may be established to target the stabilizers of the elbows.
2522141|NCT02749305|Other|Preop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures preoperatively and annually postoperatively will occur with all metabolic and bariatric surgery patients scheduled for surgery at a participating center.
2522144|NCT02749305|Other|Postop Metabolic & Bariatric Patients|Attempted collection of patient-reported outcome measures annually postoperatively will occur with all metabolic and bariatric surgery patients who had surgery at a participating center within the preceding 12 months.
2522207|NCT02749019|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
2522276|NCT02748590|Experimental|Neuromodulation|
2522374|NCT02748122|Experimental|Adolescents with T2DM|
2522421|NCT02747641|Other|treatment|only one arm
2522454|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 20|
2522455|NCT02747316|Experimental|Isotopically labeled test meal week of pregnancy 30|
2522466|NCT02747030|Experimental|Ocriplasmin intravenously|All subjects included in this phase I study are in the experimental treatment arm and will undergo a vitrectomy augmented with retinal vein cannulation and intravenous Ocriplasmin infusion.
2522523|NCT02746887||Preterm cohort|Preterm infants with a gestational age less than 32 weeks or birth weight less than 1,500 g
2521356|NCT02754531|Experimental|Subjects|USG was used to measure the internal transversal subglottic diameter on the crichoid cartilago level while the head was in sniffing position. After USG measurement was recorded, Cole formula was used to measure internal diameter of uncuffed endotracheal tube.
2521394|NCT02754323|Other|apparatus CODESNA|correlation between job stress measurement by the Maslach Burnout INVENTORY and KARASEK questionnaires and measurement of chronic stress by CODESNA tool
2521469|NCT02754050|Experimental|Polypectomy|When a 6-25mm polyp is identified the Tandem snare will be inserted through the colonoscope, remove and retrieve the polyp.
2521498|NCT02753634|Experimental|Square-stepping exercise Intervention|Participant attend sessions 2 times per week for 24-weeks at a community location. An instructor demonstrated increasingly difficulty walking or stepping patterns across a gridded mat and participants are asked to try and remember and repeat the patterns. Social engagement is encouraged.
2521499|NCT02753634|No Intervention|Usual care wait-list control group|This group will be invited to participate in square-stepping exercise after final assessments are completed.
2521614|NCT02753166|Experimental|Dexamethasone|
2521618|NCT02753166|No Intervention|Control|
2521660|NCT02752568|Active Comparator|Endometrial scratch group|endometrial scratch controlled ovarian hyperstimulation
2521661|NCT02752568|Active Comparator|Assisted hatching group|assisted hatching controlled ovarian hyperstimulation
2521662|NCT02752568|Sham Comparator|ovarian stimulation only group|controlled ovarian hyperstimulation
2521713|NCT02752243|Experimental|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
3199049|NCT00876785|Active Comparator|1|Reference wheat bread breakfast
3199050|NCT00876785|Experimental|2|Rye bread breakfast
3199051|NCT00876798|Experimental|1|Lixivaptan
2521924|NCT02750891|Experimental|DSP-7888|
2521989|NCT02750449|Experimental|Arm 1|All subjects are patched.
2522057|NCT02750176|Experimental|CERCT|Closed chain exercises
2522111|NCT02749656|Experimental|0.25% Desoximetasone cream (Topoxy®)|"0.25% Desoximetasone cream (Topoxy®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
2522113|NCT02749656|Active Comparator|0.25% Desoximetasone cream (Topicorte®)|"0.25% Desoximetasone cream (Topicorte®): apply on scalp psoriasis lesion twice a day for 8 weeks.~(Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)"
2522114|NCT02749656|Placebo Comparator|Placebo|Placebo: apply on scalp psoriasis lesion twice a day for 8 weeks. (Tar shampoo will be given to all participants. The Shampoo should be applied on wet scalp every other day, then massage and allow shampoo to remain on the scalp for 5 minutes, after that rinse off by water.)
2522194|NCT02749110|Experimental|Self-sampling for HPV test|Invitation to participate to the screening process by means of the usual care (pap-test) or the provision of a vaginal self-sampling brush (Evalyn Brush°). Self-collected samples are mailed to a central lab for HPV testing.
2522196|NCT02749110|No Intervention|Usual care (Pap test)|Intervention: invitation to participate to the screening process by means of the usual care (pap-test).
3199052|NCT00876798|Placebo Comparator|2|Placebo
3199053|NCT00876811|Experimental|one-cup|
3199054|NCT00876811|Experimental|two-cups|
3199055|NCT00876811|Experimental|four-cups|
3199056|NCT00876824|Experimental|Amphotericin B lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
3199057|NCT00876824|Active Comparator|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
3199058|NCT00876837||Adults with pediatric-onset SCI|
3199059|NCT00876850|Experimental|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
3199060|NCT00876850|Active Comparator|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
3199061|NCT00876863|Experimental|CERE-110|CERE-110: Adeno-Associated Virus Delivery of NGF
3199062|NCT00876863|Sham Comparator|Placebo|Placebo Surgery
3199063|NCT00876876|Placebo Comparator|Placebo QD or BID|Placebo QD or BID
3199064|NCT00876876|Experimental|Lixivaptan QD or BID|Lixivaptan QD or BID
2524302|NCT02734966|Active Comparator|Tiopronin Injection|Tiopronin Injection 200mg OD for 4 weeks
3199065|NCT00876902|Experimental|1|Active Group: (18 subjects) YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One extra IV dose of 1 mg/kg will be given at the end of the procedure only to patients that have experienced an intraoperative blood loss of greater than 10 units.
3199066|NCT00876902|Placebo Comparator|2|Placebo Control: (18 subjects) Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient PRIOR to arterial reperfusion of the liver. One additional infusion of 0.1 mL/kg placebo control (saline) will be given at the end of the procedure to patients that have experienced an intraoperative blood loss of greater than 10 units.
3199067|NCT00876941|Experimental|Standard Brief Intervention|
3199068|NCT00876941|Experimental|Enhanced Brief Intervention|
3199069|NCT00876941|Active Comparator|Control|
3199070|NCT00876954|Placebo Comparator|Placebo|Warming without increase in core temperature
3199071|NCT00876954|Active Comparator|Hyperthermia|Hyperthermia for 2,5 hours (39 °C core temperature)
3199072|NCT00876967|Experimental|1|metallic single use blade
3199073|NCT00876967|Experimental|2|plastic single use blade
3199074|NCT00876967|Active Comparator|3|metallic reusable blade
3199075|NCT00876980|Active Comparator|1|nasal Continuous Positive Airway Pressure treatment for 3 months
3199076|NCT00876980|No Intervention|2|controls have no treatment, being observed for 3 months
2521366|NCT02754583|Other|Delayed mass antibiotics arm (TAITU)|Delayed mass antibiotic treatment: Communities will receive no mass azithromycin treatment during the study period. Communities in this treatment group have previously received at least 8 rounds of mass azithromycin treatment. These clusters will be enrolled in an antibiotics treatment program (azithromycin or tetracycline) after the completion of the study.
2521367|NCT02754583|Active Comparator|Mass antibiotics arm (TAITU)|Mass antibiotic treatment: Communities will receive mass azithromycin treatment of all individuals aged 6 months and up (20mg/kg for children; 1 g for adults); those younger than 6 months, pregnant, or allergic to macrolide antibiotics will be offered a 2-week course of tetracycline.
2521475|NCT02753725|Active Comparator|Fentanyl group|Fentanyl given at a dose of one micro gram per kilogram body weight
2521478|NCT02753725|Placebo Comparator|normal saline group|placebo arm will be given normal saline at a volume equivalent to Fentanyl dose as per body weight.
2521535|NCT02753426|Other|Doxycycline-Placebo|Doxycycline 20mg capsule for 30 days, 30-day washout, and then placebo capsule for 30 days.
2521536|NCT02753426|Other|Placebo-Doxycycline|Placebo capsule for 30 days, 30-day washout, and then Doxycycline 20mg capsule for 30 days.
2521747|NCT02752165|Experimental|TEAM-ED Intervention Group|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
2521752|NCT02752165|Active Comparator|Enhanced Usual Care|Report of symptoms to primary care physician
3165767|NCT00517335||3|Women who have recovered from anorexia
3165768|NCT00517387|Active Comparator|1|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
3165769|NCT00517400|Active Comparator|Exposure-Stimulation|
3165770|NCT00517400|Active Comparator|Sham exposure - Real stimulation|
2522073|NCT02750007|Experimental|Experimental|Weekly-dose titration from 0.04mg/day HS-20004 to the maximum tolerable dose or of the ultimate 0.18mg/day
2522105|NCT02749604|Active Comparator|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
2522106|NCT02749604|Experimental|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
2522148|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program (Youth Empowerment Seminar, YES!) will be offered to at risk youth participating in programs or resources offered by Youth Opportunities Unlimited. The YES! program will be taught in two phases: (1) an active learning phase which consists of four consecutive days (3 hrs/day) of SEL skills taught in a multi-modality interactive format as well as SKY training, and (2) a reinforcement phase which involves weekly follow up sessions (75-90 mins each) for the 7 weeks following the active phase. Two certified instructors from the Art of Living Foundation (Spencer Delisle and Mark Frye) will deliver this training under supervision of Ronnie Newman (RN). After the initial 4 day training, participants will be asked to practice SKY daily for 20-25 minutes in addition to attending the weekly follow up sessions.
2522204|NCT02748954|Experimental|Thoughts.|"Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week"
2522205|NCT02748954|Experimental|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated."
2522206|NCT02748954|Experimental|Assertiveness|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict
2522208|NCT02748954|Experimental|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
2522209|NCT02748954|Active Comparator|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
3165771|NCT00517400|Active Comparator|Exposure - Sham Stimulation|
3165772|NCT00517426|Experimental|Active Acetazolamide|
3165773|NCT00517439|Experimental|Group 1|Group 1 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3165774|NCT00517439|Experimental|Group 2|Group 2 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (180 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3165775|NCT00517439|Experimental|Group 3|Group 3 will receive HCV polymerase inhibitor pro-drug 500mg po bid plus PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd for 24 weeks; after 24 weeks, those achieving a rapid virological response (RVR) will stop all medication, and non-RVR patients will remain on triple combination for an additional 24 weeks.
3165776|NCT00517439|Experimental|Group 4|Group 4 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3165777|NCT00517439|Experimental|Group 5|Group 5 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (1000 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3199077|NCT00877084|Experimental|1|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
3199078|NCT00877084|Placebo Comparator|2|Usual care according to clinical pathway for COPD exacerbations + NO training
3199079|NCT00877097|Experimental|1|Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
3199080|NCT00877097|Placebo Comparator|2|Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
3199081|NCT00877097|Active Comparator|3|Clodronate 800 mg / day for five years.
3199082|NCT00877110|Experimental|chemotherapy, allogeneic NK cells, 3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with 3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups of 3 patients/dose of NK cells. Four dose levels of NK cells, starting at dose level I, will be evaluated in this treatment protocol. In the unlikely case toxicity is encountered at dose level I, patients will then be treated at the lower dose level 0. Patients can receive up to 3 cycles of treatment on protocol. For subsequent cycles, patients will be treated at either less than or at the same dose level of NK cells as their first cycle.
2521589|NCT02753127|Experimental|Napabucasin plus FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will start at least 2 hours following the first daily dose of napabucasin and will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion or at least 2 hours following the first daily dose of napabucasin if bevacizumab is not administered. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
2521596|NCT02753127|Active Comparator|FOLFIRI|Addition of bevacizumab to the FOLFIRI regimen will be permissible. FOLFIRI chemotherapy infusion will be administered every 2 weeks. Irinotecan/leucovorin infusion will follow bevacizumab infusion in selected patients to receive standard dose of bevacizumab (5 mg/kg). Irinotecan 180 mg/m^2 together with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively, starting on Day 1 of Cycle 1, following bevacizumab infusion. 5-FU 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by 5-FU 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion. This regimen will be repeated on Day 1 of every 14 day cycle.
2521845|NCT02751463|Experimental|BAY987519|All subjects are patched .
2521898|NCT02751047|Placebo Comparator|Manual ventilation|During anesthetic induction, facemask ventilation is performed by manual bagging, after setting adjustable pressure limiting (APL) valve at 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
2521900|NCT02751047|Active Comparator|Pressure controlled mechanical ventilation|During anesthetic induction, facemask ventilation is performed with mechanical ventilator by pressure controlled mode, with inspiratory pressure of 13 cmH2O. During mask ventilation, gastric ultrasonography is continuously performed to detect gastric insufflation.
3199083|NCT00877123|Experimental|Vitamin D|Intervention arm: Oral vitamin D 100,000 IU once a month for three consecutive months.
3199084|NCT00877123|Placebo Comparator|Placebo|
3199085|NCT00877149|Experimental|A|
2522045|NCT02749942|Active Comparator|AutoRIC: Remote Ischemic Conditioning|Daily cuff treatment of arm with 4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG of pressure) on top of standard care.
2522048|NCT02749942|Sham Comparator|AutoRIC: Sham device treatment|Daily sham device treatment of arm, 4 cycles of 5 minute (0 mmHG of pressure) on top of standard care. No ischemia induced.
2522099|NCT02749643|Experimental|Vibrotactile feedback|Vibrotactile system - comprises of force sensors, attached to the fingertips of the prosthetic hand, and a set of 8 vibration actuators attached to a fabric arm cuff. When the subject applies force on the sensors with his prosthetic hand, he receives a vibration on the skin of his arm. The sensors and actuators are connected to an electronic control board, which transforms the resistance from the sensors to an electric signal that activates the vibration actuators.
2522150|NCT02749344|Experimental|FET after endometrial preparation|Natural cycle/progesterone fortified endometrial preparation before embryo transfer
2522183|NCT02748915|Experimental|Patients using cochlear implants|All patients using cochlear implants included in the study will take electrophysiological and psychoacoustic tests to measure auditive parameters regarding the study objectives : ECAP, EABR, speech recognition and MCL.
2522187|NCT02748915|Experimental|Patients using EAS device|Patients using EAS device for more than 11 months will take electrophysiological and psychoacoustic tests with the implant functioning only with electrical pulses or in bimodal mode to measure ECAP, EABR, speech recognition and MCL ; this will allow to perform bimodal comparison.
2522190|NCT02748915|Experimental|Patients with bilateral cochlear implant|Patients with bilateral cochlear implant for more than 11 months will take electrophysiological and psychoacoustic tests to measure ECAP, EABR, speech recognition, and MCL. The binaural interaction component will also be measured ; this will allow to perform binaural comparison.
3199086|NCT00877162|Experimental|1|Providing parents with a group teaching intervention (2 hours long). The teaching session is followed by 2 weeks of phone calls twice a week to offer parents support for their use of the strategies described in the teaching session and to clarify any questions about the teaching session content. The arm will have baseline data collected one week prior to the teaching session. Follow-up data will be collected at 6 and 24 weeks post intervention. A pamphlet on infant safety will be distributed to the intervention arm following the 6 week data collection point. A pamphlet on managing behavioural sleep problems will distributed to the control group following the 6 week data collection point.
3199087|NCT00877175|Experimental|1|Lower conjunctival fornix packing arm. For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix.
2521517|NCT02753452|Active Comparator|Non-residential life skills program|Youth will take part in programs focusing on increasing specific life skills, but taking place only during the day (i.e. non- residential).
2521519|NCT02753452|No Intervention|Deferred RILS applicants|Youth who applied to a Residential Immersive Life Skills program but are deferred to a subsequent year. These youth are included as a comparator group to match the motivation level required to apply to a RILS program.
2521524|NCT02753452|No Intervention|No life skills program|Youth who did not apply or take part in any group life skills program. These youth provide a diagnosis and age matched comparator group.
2521573|NCT02753218|Experimental|Midazolam and LEO 32731|
2521612|NCT02752854||Group A|Pain threshold measurement in high altitude
2521615|NCT02752854||Group B|Pain threshold measurement in low altitude
2521650|NCT02752594|Experimental|probiotic|2 mg of probiotic powder mixed in 10 ml of distilled water
2521651|NCT02752594|Placebo Comparator|placebo|10 ml of distilled water
2521676|NCT02752321|Experimental|eDischarge + Standard Discharge (SDeD)|"Patients in this arm will be enrolled in the eDischarge technology prior to hospital discharge. Upon hospital discharge, these patients will receive a personalized eDischarge, containing text and multimedia information, in addition to receiving the standard discharge process.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
2521678|NCT02752321|No Intervention|Standard Discharge (SD)|"Patients in this arm will receive the standard discharge process upon hospital discharge.~Follow-up interviews and surveys will be conducted at 7-14 days post discharge, and at 30-45 days post discharge."
2521709|NCT02752126|Active Comparator|Standard Palliative Radiation|Patients in the standard arm will receive a conventional radiotherapy dose will be either 30 gray (Gy) in 10 fraction or 20Gy in 5 fractions. Patients will be stratified by intended dose prior to randomization. Radiation for patients in the standard arm should adhere to the principles of palliative radiation, with goals of alleviating symptoms or preventing potential complications.
2521710|NCT02752126|Experimental|Esophageal Sparing IMRT|Patients on the experimental arm will receive esophageal-sparing intensity-modulated radiotherapy, with the same dose(s) as in the standard arm.
2521745|NCT02751905|Experimental|BIIB074|Single oral dose on Day 1
2521817|NCT02751736|Experimental|Intervention|"2 g sachet (CJLP 243) once a day for 3 weeks~10 billion lactic acid bacteria(lactobacillus plantarum CJLP243), maltodextrin, glucose(anhydrous)"
2521819|NCT02751736|Placebo Comparator|Control|"2g sachet (near identically appearing placebo) once day for 3 weeks~maltodextrin, glucose(anhydrous)"
2521844|NCT02751294|Experimental|TQ Control+ TQ SIL|Subjects received TQ Control product (2 tablets) and 30 mg TQ SIL solution orally with water after a meal.
2521848|NCT02751294|Experimental|TQ X + TQ SIL|Subjects received 2 tablets of Tafenoquine dissolution profile X and 30 mg TQ SIL solution orally with water after a meal.
2521911|NCT02750995|Experimental|Vaccination|Azacitidine + NPMW-peptide vaccine
2521958|NCT02750540|Active Comparator|Product A dose|Product A will contain tenofovir (TFV) 220 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2521961|NCT02750540|Active Comparator|Product B dose|Product B will contain tenofovir (TFV) *660 mg in 125 mL iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2521963|NCT02750540|Active Comparator|Product C dose|Product C will contain tenofovir (TFV) *660 mg in 125 mL hypo-osmolar solution at half the osmolarity of iso-osmolar solution: Participants will have a single dose administered in clinic or a research unit, followed by various specimen collections over 8 days, according to individual sampling schedule assigned to each participant; specimens will be collected on Day 1, 2, 4, and 8.
2521965|NCT02750540|Placebo Comparator|Take-home normal saline (NS) enema|The normal saline (NS) solution will be provided following administration of Product A which is iso-osmolar. The volume of NS enema (120 mL) was selected to approximately match that of Product A (125 mL)
2521966|NCT02750540|Placebo Comparator|Take-home half normal saline (½ NS) enema|The ½ normal saline (½ NS) solution will be provided following administration of Product C which is hypo-osmolar. The volume of the ½ NS enema (120 mL) was selected to approximately match that of Product C (125 mL)
2522010|NCT02750241|Experimental|Active video game-based intervention|This arm will receive the active video game-based intervention, which will include attending 12 weekly group sessions at the UTMB Breast Health Clinic, participate in self-paced home session, and monitor daily, weekly, and monthly steps using Wii Fit Meter. All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
2522011|NCT02750241|Active Comparator|Pedometer|This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
2522047|NCT02749994|Active Comparator|R5|Rosuvastatin 5mg
2522053|NCT02749994|Active Comparator|R10|Rosuvastatin 10mg
2522055|NCT02749994|Active Comparator|R20|Rosuvastatin 20mg
2522059|NCT02749994|Experimental|R5/E10|Rosuvastatin 5mg/Ezetimibe 10mg
2522061|NCT02749994|Experimental|R10/E10|Rosuvastatin 10mg/Ezetimibe 10mg
2522063|NCT02749994|Experimental|R20/E10|Rosuvastatin 20mg/Ezetimibe 10mg
2522104|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
2522702|NCT02745847|Experimental|Re-irradiation with SBRT|Patients with relapsed pancreatic cancer meeting all inclusion criteria will receive re-irradiation with SBRT.
2521525|NCT02753686||Cohort 2: Endocrine Therapy (ET) plus Targeted Therapy (TT)|HR+ HER2- male, female pre/ postmenopausal advanced breast cancer patients being treated with endocrine therapy in combination with targeted therapy including CDK4/6 inhibitor therapy
3199088|NCT00877175|Active Comparator|2|Conventional instillation arm. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
2521839|NCT02751372|Experimental|BAY 987517|All subjects are patched .
2521869|NCT02751151|Experimental|1|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
2521892|NCT02750904|Experimental|Experimental therapy|
2521895|NCT02750904|Active Comparator|Control Therapy|
2521944|NCT02750631|Experimental|Triple Therapy|Combined Wake Therapy (one night of missed sleep), early morning bright light and sleep phase advance
3199089|NCT00877188|Experimental|exercise|supervised combined aerobic and resistance training for 12 weeks
3199090|NCT00877188|No Intervention|control|waist list control with usual care
3199091|NCT00877214|Experimental|Rituximab|Follicular Lymphomas: Rituximab 375 mg/m² for additional 2 years after 2 years of standard maintainance All other lymphomas: Rituximab 375 mg/m² for 2 years as maintainance. From 2014 only Morbus Waldenstroem: Rituximab 1.400 mg absolute s. c. injection
3199092|NCT00877214|Active Comparator|Standard|Rituximab / Observation
3199093|NCT00877227|Experimental|folinic acid|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns
3199094|NCT00877227|No Intervention|2|control subjects admitted at the Neonatal Intensive Care Unit (NICU)
3199095|NCT00877240|Other|Lifestyle counseling|
2522153|NCT02749396||IFN-β / Cohort 1|Exposure to IFN-β only
2522155|NCT02749396||IFN-β + other MSDMDs / Cohort 2|Women with MS exposed to IFN-β regardless of exposure to other MSDMDs
2522156|NCT02749396||No MSDMDs / Cohort 3|Women with MS exposed with no exposure to any MSDMDs
2522157|NCT02749396||No IFN-β + other MSDMDs / Cohort 4|Women with MS exposed to IFN-β exposure regardless of exposure to other MSDMDs
2522158|NCT02749396||Other MSDMDs / Cohort 5|Women with MS exposed to other MSDMD only excluding IFN-β or glatiramer acetate (Copaxone) or dimethyl fumarate (Tecfidera)
2522160|NCT02749396||Control / Cohort 6|Women from the general population without MS
2522231|NCT02748772|Active Comparator|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Two Anti-angiogenesis Drugs（Endostar and Thalidomide） Combined With Chemotherapy for the patients of Advanced Colorectal Cancer
2522239|NCT02748772|Placebo Comparator|Pure chemotherapy（Xelox）|chemotherapy alone for the patients of Advanced Colorectal Cancer
2522313|NCT02748382|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline) higher chloride albumin (5% Octalbin)
2522318|NCT02748382|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate) lower chloride albumin (5% Plasbumin)
2522377|NCT02747953|Experimental|afatinib|
2522432|NCT02747654|No Intervention|standard dosing|a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight
2522433|NCT02747654|Experimental|Genotype-guided dosing|INH dose determined based on developed model
2522481|NCT02747082|Active Comparator|1% sodium hypochlorite (NaOCl)|"Retreatment of root-filled teeth with infection with 1% NaOCl as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
2522487|NCT02747082|Active Comparator|2% chlorhexidine gluconate (CHX)|"Retreatment of root-filled teeth with infection with 2% CHX as irrigation solution.~Total bacterial counts, Streptococcal species and Enterococcus faecalis species were quantified using qPCR against 16SrRNA before irrigation (S1), after irrigation (S2), and after intracanal medication (S3)."
2522554|NCT02746770|Experimental|Cawthorne and Cooksey exercises group|Intervention: Participants allocated in both control and experimental groups were receiving treatment for their specific vestibular disorders. Patients assigned to the experimental group also performed the Cawthorne and Cooksey exercises for vestibular rehabilitation during a six week of treatment period.
2522556|NCT02746770|No Intervention|control group|intervention: The control group will not perform the active exercise that will be applied to intervention group.
3199096|NCT00877253|Experimental|Dose Level One|
2522642|NCT02746172|Experimental|Cochlear Implant Recipients|cochlear implant recipients
3199097|NCT00877253|Experimental|Dose Level Two|
3199098|NCT00877253|Experimental|Dose Level Three|
3199099|NCT00877266|Active Comparator|1. Ultrasound|Ultrasound is randomly chosen by use of a computer program. The time for catheter placement will begin with the ultrasound probe touches the patient. Patients will be asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and will be called the next day by the research staff.
3199100|NCT00877266|Active Comparator|2. Electrical Stimulation|Nerve Stimulation (electrical stimulation) is randomly chosen using a computer program. Time of placement begins when the catheter-placement first touches the patient. After catheter placement patient is asked their discomfort on a 0-10 scale (0=no discomfort and 10=worst discomfort imaginable) and called the day after surgery by the research staff.
3199101|NCT00877279|Experimental|Belotero® Soft|Comparator will be given into the opposite side of the face that Belotero® Soft was administered for facial wrinkles, such as nasolabial folds.
3199102|NCT00877279|Active Comparator|CosmoDerm1|
3199103|NCT00877292||Down syndrome|Women having CVS or amniocentesis who, as a group, have a high prevalence of Down syndrome.
3199104|NCT00877305|Active Comparator|RIPC|Remote Ischemic Preconditioning
3199105|NCT00877305|Placebo Comparator|CONTROL|Control
3199106|NCT00877318|No Intervention|Control|Program of cardiac rehabilitation introduced in complete hospitalization pursued in day hospital during 3 months
3165778|NCT00517439|Experimental|Group 6|Group 6 will receive triple combination treatment with HCV polymerase inhibitor pro-drug (500 mg po bid) plus PEGASYS (90 micrograms sc weekly) plus Copegus (1000 or 1200mg po qd) for 24 weeks, followed by 24 weeks of open label Standard of Care (PEGASYS 180 micrograms sc weekly plus Copegus 1000/1200mg po qd).
3199107|NCT00877318|Experimental|telemedicine|Program of cardiac rehabilitation introduced in complete hospitalization pursued at home via a terminal during 3 months
2521617|NCT02753049|Experimental|Peer led mHealth adherence intervention|Eligible participants enrolled will receive five, weekly-60 minute, 'ACCESS' sessions, delivered by a peer adherence coach via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
2521653|NCT02752555|No Intervention|Antioxidant group|In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).
2521654|NCT02752555|Experimental|Antioxidant+modifiable lifestyle factors|In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
2521682|NCT02752295|No Intervention|Waiting list, intervention after EOS|control group / waiting list one week stress-coping intervention planned after end of study (EOS) without one week stress-coping intervention AND without an additional two days follow-up care
2521684|NCT02752295|Active Comparator|Stress-coping week without follow-up|active comparator with one week stress-coping intervention BUT without an additional two days follow-up weekend
2521686|NCT02752295|Active Comparator|Stress-coping week with follow-up|active comparator with one week stress-coping intervention AND with an additional two days follow-up weekend
2521724|NCT02752061|Experimental|Kweneng East District|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in Kweneng East District during study period.
2521725|NCT02752061|No Intervention|All other districts|Patient presenting with possible cancer symptoms/sign to a clinic or hospital in all other districts of Botswana (or Kweneng East prior to implementation of intervention).
3199108|NCT00877331|Experimental|1|Brief intervention using motivational interviewing. One in-person session (30-45 minutes) with a brief phone follow-up one week later.
3199109|NCT00877331|No Intervention|2|Enhanced care as usual.
3199110|NCT00877344|Experimental|1|Immediate insertion of either a LNG-IUC or a Copper T380 IUD after 12-24 week abortion
2521846|NCT02751333|Active Comparator|FCSEMS with Endostitching (ES)|General anesthesia or conscious sedation will be started and an upper endoscope will be inserted into the participants mouth and advanced into the stomach. Endoscopic stenting with a fully covered self-expanding metal stents (FCSEMS) will then be performed. Once the stent is in place, the endoscope will be withdrawn from the participant to set-up the endostitch device unto the endoscope. Bites are taken separately with the first on the esophageal mucosa followed by a second on the stent itself and finishing with a last bite on esophageal mucosa. A cinch is then used to secure the deployed suture. An attempt at placing 2 sutures will be performed. Stent removal will then be performed at 8-weeks post-stent insertion.
2521850|NCT02751333|Active Comparator|FCSEMS with No Suturing (NS)|The procedure will be done in the same manner with same endoscopic technique, stent deployment, and timing of stent removal. The only difference would be the lack of suturing and naturally the need for suture cutting at stent removal.
2521897|NCT02750969|Experimental|1. lidoderm patches first|"29 tinnitus patients treated first with 3 patches of lidoderm for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 neutral patches (containing no drug) attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
2521899|NCT02750969|Experimental|2. tegaderm patches first|"29 tinnitus patients treated first with 3 patches of tegaderm (neutral patch containing no drug) for 1 day, for 12 consecutive hours. 60 hours after removal of the patches the patients will have 3 lidoderm patches attach to their back for 12 hours.~after the removal of each kind of patch the patient will fill 4 types of questionnaires that assess his amount of tinnitus we will compare the questionnaires results before and after the application of those patches."
3199111|NCT00877344|Experimental|2|Interval insertion (two to four weeks post abortion) of either a LNG-IUC or a Copper T380 IUD after 12-24 abortion
3199112|NCT00877357|Experimental|Shan 5 Lot No 1|
3199113|NCT00877357|Experimental|Shan 5 Lot No 2|
3199114|NCT00877357|Experimental|Shan 5 Lot No 3|
3199115|NCT00877396|Experimental|Influenza|Inactivated Influenza vaccination
3199116|NCT00877396|Placebo Comparator|Control|Hepatitis A vaccine
3199117|NCT00877409|Active Comparator|Acnase|
3199118|NCT00877409|Placebo Comparator|Vehicle|
3199119|NCT00877422|No Intervention|Group A|Group A is identified as serum vitamin D level more than 16 ng/dl.
3199120|NCT00877422|Active Comparator|Group B|Group B is identified as serum vitamin D level less than 16 ng/dl and is supplemented with vitamin D3.
3199121|NCT00877422|No Intervention|Group C|Group C is identified as serum vitamin D less than 16 ng/dl and is not supplemented with vitamin D3.
3199122|NCT00877435|Experimental|1|Cognitive behavioral therapy (CBT) + prize-based contingency management (prizeCM)
3199123|NCT00877435|Active Comparator|2|Cognitive behavioral therapy (CBT)
3199124|NCT00877474|Experimental|Arm 1|PM01183 administered i.v. over one hour, on Day 1, every three weeks, at a starting dose of 20 µg/m2.
3199125|NCT00877500|Experimental|Group I (ixabepilone)|Participants receive ixabepilone IV over 3 hours on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3199126|NCT00877500|Active Comparator|Group II (standard of care)|Participants receive standard of care for 18 weeks.
3199127|NCT00877513|Experimental|Smokers|Cigarette smokers wishing to quit
3199128|NCT00877526||A|
3199129|NCT00877539|Experimental|PF-03526299|
3199130|NCT00877539|Placebo Comparator|Placebo|
2521568|NCT02753140|Experimental|RT concurrent with TP|Selected 60 patients with locally advanced squamous cell carcinoma of the head and neck. They will be randomized to concurrent chemoradiotherapy versus concomitant cetuximab with radiotherapy after neoadjuvant chemotherapy. To observe the curative effect of concurrent radiotherapy and chemotherapy
2521675|NCT02752529|Experimental|Tacrolimus/dose1|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
2521677|NCT02752529|Active Comparator|Tacrolimus/dose2|Tacrolimus 5mg tablet and dosage based on Co once/twice a day for 7 days
2521717|NCT02752139||patients with sleep disorders|
2521720|NCT02752139||normal individuals without sleep disorders|
2521756|NCT02751853|Experimental|HFPEF|Patient with heart failure with preserved ejection fraction (HFPEF)
2521763|NCT02751853|Experimental|HFREF|Patient with heart failure with reduced ejection fraction (HFREF)
2521772|NCT02751853|Active Comparator|No HFPEF/HFREF|Patient without heart failure with preserved ejection fraction (HFPEF) or heart failure with reduced ejection fraction (HFREF)
2521794|NCT02751671|Experimental|POCUS before clean catch sampling|The intervention of interest will be the use of emergency point-of-care ultrasound performed by a research assistant to evaluate bladder fullness before clean-catch stimulation manoeuvre. More specifically, following randomisation, children in the experimental group will have ePOCUS to measure the transversal bladder diameter. If the transversal bladder diameter is > 2 cm, the CCU procedure will be started without a prior feeding period. If the diameter is < 2 cm, the CCU will be postponed for a 20 minute feeding period and a new ePOCUS will be done. After the second ePOCUS, the CCU will be done if the transversal bladder diameter reaches > 2cm. If not, the child will have another 20 minute feeding period and a third ePOCUS prior to proceeding to the CCU regardless the bladder diameter.
2521796|NCT02751671|Experimental|Standard clean catch sampling|Patients allocated to this arm will have a 20 minute feeding period either being breastfed or provided with formula intake appropriate to the infant's age and weight. If possible, the genital areas of the infant will be cleaned with warm water and soap and dried with sterile gauze prior to the feeding. The parents will let the diaper opened and will be will be ready to collect urine if the child voids during the feeding period. After the feeding, the stimulated clean-catch procedure will be performed without prior ultrasound
2521831|NCT02751411|Experimental|micro-enema with Promelaxin|2,5 g, 5 g or 2X5 g (calculated considering patient age) have to be administered daily (in the evening) for one week, once every other day for the second week and as needed for the following 6 weeks
2521833|NCT02751411|Active Comparator|Macrogol 4000|One/Two sachets of the study treatment has to be solubilized in 50mL of water and then administered daily. The administration should take place in the morning (the first sachet or in the event that only one sachet/day should be administered) and in the evening (second sachet).
2521903|NCT02751125|Experimental|Augmentation of new alveolar bone|Augmentation of atrophied alveolar ridge with mesenchymal stem cells( MSC) and bis calcium phosphate(BCP)
2521941|NCT02750644||High-risk|Patients with atherosclerotic carotid disease with (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
2521943|NCT02750644||Standard-risk|Patients with atherosclerotic carotid disease without (1) severe comorbidity (class III/IV congestive heart failure, class III/IV angina, coronary disease involving ≥ 2 major vessels, left ventricular ejection fraction ≤ 30%, myocardial infarction, severe pulmonary disease, severe renal failure) and (2) Technical/challenging anatomical criteria (previous neck surgery, cervical irradiation, contralateral carotid occlusion, post-endarterectomy restenosis, inaccessible lesions or tracheotomy).
2522008|NCT02750397||HIV D+/R+|HIV+ recipients who receive an organ transplant from an HIV+ donor
2522009|NCT02750397||HIV D-/R+|HIV+ recipients who receive an organ transplant from an HIV- donor
2522065|NCT02750059|Experimental|TDF/3TC/EFV + Telmisartan|The subjects will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART
2522069|NCT02750059|Active Comparator|TDF/3TC/EFV only|Subjects will receive ART only
3165779|NCT00517439|Active Comparator|Group 7|Standard of care (SOC)
2522133|NCT02749357|Active Comparator|Control|"Intervention: Control group, with 30 training sessions in robotic orthosis with duration of 30 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
2522136|NCT02749357|Experimental|Experimental|"Intervention: Experimental group, with 30 training sessions in robotic orthosis with duration of 60 minutes during 6 weeks.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen.The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
2522174|NCT02749032|Active Comparator|Vildagliptin - stratum diet/exercise|"Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.~Mixed meal test were performed in the morning after an overnight fast."
2555906|NCT02526459|No Intervention|no birth plan|No use of birth plan
3165780|NCT00517452||Platelet Rich Plasma|Group received platelet rich plasma and observed over a period of 30 days or until wound closure
3165781|NCT00517452||Standard Wound Care|Group was treated as per standard care
3165782|NCT00517465|Experimental|1|
3165783|NCT00517465|Experimental|2|
3165784|NCT00517465|Experimental|3|
3165785|NCT00517465|Placebo Comparator|4|
3165786|NCT00517491|Experimental|1|
3165787|NCT00517517|Experimental|1|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 7.5 µg of H5N1 HA antigen per 0.5 mL in a non-adjuvanted formulation
3165788|NCT00517517|Experimental|2|Intramuscular injection of whole virion, Vero cell-derived influenza vaccine containing 3.75 µg of H5N1 HA antigen per 0.25 mL in a non-adjuvanted formulation
3165789|NCT00517569|Experimental|1|GX-12 combined with HAART
2521586|NCT02752932|Other|RMHNSCC -PDX drug testing|Participants with RMHNSCC who are under palliative treatment will be included in this group. Drug testing on PDX per Investigator's choice (upto 4): PDX will be developed and upto four Chemotherapeutics (that are funded in Ontario) will be tested on the PDX. Chemotherapeutics will be selected at the discretion of the treating Medical Oncologists. Result of the drug testing will be provided to the responsible physician and can be utilized in patient care.
2521652|NCT02752503|Experimental|Nalmafene|
2521718|NCT02752334|No Intervention|group Bupivacaine|patients will receive 23 mL of Bupivacaine HCL 0.5% (Marcaine, 5 mg per mL; Hospira, USA) in addition to 2 mL normal saline using Ultrasound-guided Supraclavicular Brachial Plexus Block
2521721|NCT02752334|Active Comparator|group Bupivacaine Magnesium|patients will receive 23 mL of Bupivacaine HCL 0.5% in addition to 2 mL (100 mg) Magnesium Sulphate (Magnesium Sulphate 50 %, 500 mg per mL; Hospira, USA) diluted with normal saline. using Ultrasound-guided Supraclavicular Brachial Plexus Block
2521759|NCT02751840|Experimental|Caffeine|Caffeine capsule (200 mg) is taken prior to RMR measurement
2521767|NCT02751840|Placebo Comparator|Placebo|Placebo (starch) capsule is taken prior to RMR measurement
2521775|NCT02751840|Experimental|Coffee|Black coffee (9 grams) is consumed prior to RMR measurement
2521781|NCT02751840|Placebo Comparator|Decaffeinated|Decaffeinated Black coffee (9 grams) is consumed prior to RMR measurement
2521825|NCT02751502|Experimental|Bimanual-to-unimanual device home training program|
2521826|NCT02751502|No Intervention|Conventional non-device home training program|Subjects receive 6 weeks of ongoing usual and customary care schedule of home physical and occupational therapy as usual and customary care independent of the study.
2521860|NCT02751229|Experimental|Honest Open Proud|"The group program is about disclosure ('coming out') versus secrecy of one's mental illness. The groups are facilitated by peers (young adults with mental illness) and mental health professionals. Each group runs for three weeks, one meeting per week, and two hours per meeting.~Fidelity to manual: rated by PhD student in each session as proportion of key topics covered"
2521862|NCT02751229|No Intervention|Control Group|treatment as usual (TAU)
3199131|NCT00877539|Active Comparator|Fluticasone propionate|
2521980|NCT02750488|Experimental|BAY987517|All subjects are patched with the same product
2522038|NCT02750202|Active Comparator|Quadrivalent HPV vaccine|Three doses of 4 HPV vaccine is given at registered intervals.
2522042|NCT02750202|Sham Comparator|Hepatitis B vaccine|Three doses of Hepatitis B vaccine is given at the same intervals as the quadrivalent HPV vaccine.
2522097|NCT02749565||asthmatic patients with OSA|
2522100|NCT02749565||asthmatic patients without OSA|
2522137|NCT02749318|Experimental|Experimental Group|Consented patients who complete the initial Experimental Group Questionnaire, receive a prophylaxis, have the IL-1 genetic test for risk of severe periodontitis performed, their dental records monitored for 18 months post-enrollment, and answer a Study Completion Questionnaire 18 months post-enrollment.
2522139|NCT02749318|No Intervention|Usual Care Group|Consented patients who complete the initial Usual Care Group Questionnaire, receive a prophylaxis and have their dental records monitored for 18 months post-enrollment.
2522166|NCT02749058|Other|Capsulectomy|Procedure: Capsulectomy in Direct Anterior Total Hip Arthroplasty
2522169|NCT02749058|Other|Capsulotomy|Procedure: Capsulotomy in Direct Anterior Total Hip Arthroplasty
2522225|NCT02748798|Experimental|Healthy Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
2522234|NCT02748798|Experimental|Lung Disorder Participants|Participants will inhale investigational gases (HP 3He, HP 129Xe, PFP and SF6) according to the procedure for that intervention. All participants can potentially inhale all the gases. Magnetic resonance imaging will be performed during breath-holds or continuous breathing (gas-dependent) with the appropriate investigational human lung coil (3He Human Lung Coil, 129Xe Small and Large Human Lung Coil, or PFP and SF6 Human Lung Coil), using the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre.
2522301|NCT02748252||HIV patients|HIV patients admitted in Stroke units for the first occurence of acute stroke
2522304|NCT02748252||non HIV patients|non HIV patients admitted in Stroke units for the first occurence of acute stroke
2522365|NCT02748135|Experimental|TB-403 20mg/kg|
2522366|NCT02748135|Experimental|TB-403 50mg/kg|
2522367|NCT02748135|Experimental|TB-403 100mg/kg|
2522368|NCT02748135|Experimental|TB-403 175mg/kg|
2522396|NCT02747732|Experimental|one arm|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
2522441|NCT02747381|Experimental|intervention|receive Alfacalcidol 1 mcg daily for 4 months beside the conventional asthma medications
2522442|NCT02747381|No Intervention|control|Asthmatic patients receiving conventional asthma medications
2522462|NCT02747160|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a six-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
2522491|NCT02746952|Experimental|UCART19|
2522550|NCT02746653|Experimental|Use of TroClose1200(TM) for access port and closure device|TroClose in 1 port
2522581|NCT02746432|No Intervention|Control group|Routine intra operative saline infusion to be administered.pre-operation and timed assessment lab set to be obtained.
2522720|NCT02745678|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation.
2522767|NCT02745275|Experimental|Peer-led Health Education|A single 60 minute interactive workshop led by the trained health coach followed by a series of three one hour discussion groups
3199132|NCT00877552||Control|Typically developing
2521681|NCT02752451|Experimental|AKAT|8 Subjects who received 4 hours of simulation training on the Anatomic Knee Arthroscopy Trainer. They then underwent assessment on cadaveric specimens.
3199133|NCT00877552||Mild ventriculomegaly (MVM)|Fetal isolated mild ventriculomegaly
3199134|NCT00877552||Schizophrenia High Risk|Offspring of mothers with schizophrenia
2521853|NCT02751515|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
2521904|NCT02751021|Other|Sleep apnea diagnosis|The intervention is the use of the pacemaker diagnostic algorithm named Sleep Apnea Monitoring to detect sleep apnea and the attended cardiorespiratory sleep study to confirm the diagnostic.
3199135|NCT00877552||Bipolar High Risk|Offspring of mothers with schizophrenia
2522066|NCT02749916||Patients with acute or recent (within 3months) stroke|
2522121|NCT02749630|Experimental|Healthy Volunteer|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2522127|NCT02749630|Experimental|Ulcerative Colitis|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2522131|NCT02749630|Experimental|Crohn's Disease|Participants will be given escalating doses of UTTR1147A or Placebo intravenously
2522203|NCT02748941|Experimental|symptomatic and asymptomatic patients|
2522272|NCT02748603||Patient with non ST Elevation - Acute Coronary Syndrome|
2522274|NCT02748603||Patient with stable Coronary Artery Disease (CAD)|
2522332|NCT02748343|Active Comparator|allograft bone|traditional allograft bone
2522334|NCT02748343|Experimental|tissue-engineered bone|tissue-engineered bone
2522420|NCT02747667||Eye with late IOL complication|Alle patients with IOL complication (subgroup: in-the-bag dislocation; out-of-the-bag dislocation; haptic dislocation)
2522422|NCT02747667||Eyes with no late IOl complication|
2522458|NCT02747342|Experimental|SHR3680; SHR3680+SHR3162|In dose esclation and expansion phase, SHR3680 will be administered orally In combination phase, SHR3680 will be administered together with SHR3162
3199136|NCT00877578|Experimental|1|Nutri-Energie ®, a cake of high caloric density and palatability, twice a day for 4 weeks, in addition to an enriched diet.
3199137|NCT00877578|Active Comparator|2|Clinutren 1.5 ® standard isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet.
2522568|NCT02746497|Active Comparator|Group E (early intervention)|One weekly treatment with acupuncture in five consecutive weeks. In trial week 1-5 Group E will receive treatment and Group L will act as control group.
2522571|NCT02746497|Active Comparator|Group L (late intervention)|After trial week five the Groups must cross-over. Group L will then receive treatment for five weeks (trial week 6-11) and Group E will act as follow up group.
2522670|NCT02745899|Active Comparator|Soy milk substitute Healthy|Healthy children aged 6-18 will drink 240 ml of soy milk substitute.
2522672|NCT02745899|Active Comparator|Soy milk substitute Asthma|Asthmatic children aged 6-18 will drink 240 ml of soy milk substitute.
2522674|NCT02745899|Experimental|Cow milk Healthy|Healthy children aged 6-18 will drink 240 ml of cow milk.
2522676|NCT02745899|Experimental|Cow milk Asthma|Asthmatic children aged 6-18 will drink 240 ml of cow milk.
3199138|NCT00877591|Experimental|1|Buprenorphine + Fosamprenavir/Ritonavir
3199139|NCT00877591|Active Comparator|2|Control Fosamprenavir/Ritonavir
3199140|NCT00877591|Experimental|3|Buprenorphine + Darunavir/Ritonavir
3199141|NCT00877591|Active Comparator|4|Control Darunavir/Ritonavir
3199142|NCT00877591|Experimental|5|Buprenorphine + Rifampin
3199143|NCT00877591|Experimental|6|Buprenorphine + Rifabutin
3199144|NCT00877617||QOL Questionnaire|
2523101|NCT02742714|Experimental|PillCam SBC|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
2523161|NCT02742610|Experimental|Mindfulness with Contingency Management|The intervention (MSI-CM) will involve two individual pre-quit in-person sessions and two post-quit phone counseling sessions, a series of brief mindfulness trainings that will be delivered via smartphone, that prompts participants to practice a mindfulness exercise five times a day while abstinent during the 2-week incentivized abstinence period (using CM) plus an additional 2 weeks (without CM) following the participant's target quit date. The MSI-CM participants will be asked to provide CO video via smartphone twice daily with monetary incentives provided (CM). Participants will receive monetary incentives contingent on each confirmed CO level (less than 7 ppm) for the CM period. We will use CM as an adjunct strategy to enhance the efficacy of mindfulness training.
2523162|NCT02742610|Active Comparator|Active Control|Participants assigned to the control group will receive two individual pre-quit in-person sessions and two post-quit phone counseling sessions, similar to the MSI-CM except for mindfulness introduction/discussion. Participants in the control group will receive the same monetary incentives on average as the participants in the MSI-CM for submitting CO videos, regardless of CO levels (non-abstinent contingent), during the 2-week post-TQD period. Each participant in the group (the non-contingent CO group) will be yoked to a single participant (selected randomly with stratification) in the MSI-CM. The yoked participant receives the same amount of monetary incentives as his or her matched participant in the contingent CO (MSI-CM) group.
2523196|NCT02742272||ED Headache or Migraine Patients|The investigators will perform a prospective cohort study of patients ages 6-18 years presenting to the ED with a complaint of headache or migraine over a 12 month period.
2523251|NCT02742025|Other|Standard Care|"Patients randomized to this arm will have standard care with no extra interventions.~Intervention: Inclusion visit~Intervention: Coronarography on day 0"
3199145|NCT00877630||1:endoscopic group|patients underwent endoscopic thyroidectomy
2523502|NCT02740452|Other|Ligamys technique|Ligamys technique (device) or standard technique
3199146|NCT00877630||2:conventional group|patients underwent open thyroidectomy
3199147|NCT00877643|Experimental|Upstream rhythm control|
3199148|NCT00877643|Active Comparator|Conventional rhythm control|
3199149|NCT00877656|Experimental|CD4|Open label treatment arm
3199150|NCT00877669|Active Comparator|Transurethral resection of the prostate|TURP group
3199151|NCT00877669|Experimental|Holmium Laser Enucleation of Prostate|HoLEP group
2521704|NCT02752308|Active Comparator|General anesthesia + caudal block|Patients who receive general anesthesia plus caudal epidural block and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
2521707|NCT02752308|Active Comparator|General anesthesia only|Patients who receive only general anesthesia and dilute epinephrine injection before hypospadias repair, intraoperative fentanyl, intraoperative intravenous fluid and reversing the muscle relaxants' effect at the end of operation
2521746|NCT02751866|Active Comparator|Active supplement, low carbohydrate|Whole fruit berry powder, low carbohydrate diet
2521749|NCT02751866|Placebo Comparator|Placebo, Control|placebo powder, higher carbohydrate diet
3199152|NCT00877682|Experimental|Cryotherapy|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
3199153|NCT00877695|Experimental|Motive8 2 Change FtF|This arm of the motivational enhancement intervention (MEI) will be delivered face to face (FtF) using a real-time, dynamic implementation approach. The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
2521886|NCT02750852||Analysis group|Create an algorithm to predict blood loss using patients data
2521888|NCT02750852||Control group|The algorithm was applied to analyze sensitivity and specificity
2521929|NCT02750748|Experimental|4mg Intranasal Naltrexone|Administer one 0.1 mL spray of a 40 mg/mL solution in one nostril
2521932|NCT02750748|Experimental|4mg Intranasal Naltrexone with Intravail|Administer 0.1 mL spray of a 40 mg/mL solution with 0.25% Intravail in one nostril
2521934|NCT02750748|Experimental|2mg Intramuscular Naltrexone|Administer 2 mg formulation intramuscularly
2521937|NCT02750748|Experimental|50mg Naltrexone|Administer 50mg formulation orally
2521985|NCT02750358|Experimental|Enzalutamide|160mg orally as daily continuous dosing for 52 weeks. Patients will be seen for protocol visits every 4 weeks (+/- 2 week window) for the first 12 weeks followed by every 12 weeks (+/- 2 week window) to complete 52 weeks. An assessment will also be performed at 52 weeks (+ 4 week window).
2522051|NCT02750046|Experimental|osteoporotic fractures|patients with osteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2522054|NCT02750046|Sham Comparator|nonosteoporotic fractures|patients with nonosteoporotic fractures, including femoral neck fracture and pertrochanteric fracture. Total hip arthroplasty or proximal femoral nails was needed.
2522143|NCT02749669|Other|Qualitative research|Semi-structured interviews
2522146|NCT02749669|No Intervention|Economic evaluation|Questionnaire
2522215|NCT02749006|Active Comparator|Active iTBS rTMS|The active arm involves magnetic stimulation of the brain to the left dorsolateral prefrontal cortex (DLPFC) daily for four weeks. The active arm will be receiving intermittent Theta-Burst (iTBS) repetitive Transcranial Magnetic Stimulation (rTMS) to deliver magnetic pulses.
2522220|NCT02749006|Sham Comparator|Sham rTMS|sham rTMS treatment involves scalp stimulation with no magnetic pulse daily for four weeks (20 sessions). Sham rTMS involves only the click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
2522283|NCT02748473|Other|pelvic floor muscle strength|evaluated pelvic floor muscle strength before and after Pilates exercises program on sedentary nulliparous women
2522285|NCT02748473|Other|Device: 3D perineal ultrasound|evaluated the pubovisceral muscle thickness and the levator hiatus area before and after Pilates exercises program on sedentary nulliparous women
3199154|NCT00877695|Experimental|Motive8 2Change -Internet|This arm of the motivational enhancement intervention (MEI) will be delivered via the Internet face to face (FtF) using a real-time, dynamic implementation approach.The intervention consisted of 2 sessions lasting approximately 60 to 90 minutes. The sessions focused on increasing participants' awareness of the multiple influences on behaviors from self, family, culture and community and how these influences impact the way we think and behave including sexually. Through a series of exercises the participant develops strategies for understanding and managing his own triggers that helps them to make healthy life choices. Both Motiv8 2Change arms used the exact same intervention, with the exception that one was delivered face to face and the other through the internet.
2522429|NCT02747537|Experimental|Arm 1: Sorafenib and Irinotecan|"Sorafenib is an oral drug which will be administered on an outpatient basis twice a day continuously (every day of a 21-day cycle) at approximately the same times each day. For patients unable to swallow whole pills, an oral suspension may be prepared with tablets.~Irinotecan will be administered orally (mixed with cranberry type juice) on an outpatient basis once a day on Days 1-5 of a 21-day cycle. Irinotecan should be given at least 1 hour after sorafenib."
2522594|NCT02746458|No Intervention|Standard of Care Physical Therapy|This group will receive the standard of care physical therapy program for 6 weeks.
2522597|NCT02746458|Experimental|Blood Flow Restriction Plus Standard of Care Physical Therapy|This group will receive the same standard of care physical therapy program for 6 weeks plus blood flow restriction.
2522641|NCT02746094|Experimental|The study population|"The study population is comprised of adult men less than 80 years of age who are consulting for ED lasting for over 6 months following a prostatectomy that took place 18 to 60 months ago. The patients are currently in a stable relationship that has been going on for at least 3 months, have an IIEF-EF score between 6 and 25, and have at least a natural tumescence during sexual stimulation (EHS score ≥ 1).~Intervention: 8 bi-weekly LIESWT sessions"
2522692|NCT02745717|Experimental|cord blood and IST group|Administration of antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days, Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml, plus one unit of at least 4/6 HLA loci matched cord blood transfusion 24 hours after last dose of ATG.
2522699|NCT02745717|Active Comparator|IST group|Antithymocyte ( Thymoglobulin ) 3.5mg/kg/d for 5 days , Cyclosporine Oral Product 5mg/kg/d with trough serum concentration of 200-300ng/ml.
2523069|NCT02743208|Active Comparator|Furlong H-A.C. femoral stem|Total hip arthroplasty (THA) using a Furlong H-A.C. femoral stem, and a Furlong H-A.C. CSF plus acetabular cup system.
2521711|NCT02752230|Active Comparator|Exparel (Bupivicaine Liposome)|Patient will have Exparel (Bupivicaine Liposome) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
2521712|NCT02752230|Active Comparator|Marcaine (Bupivicaine)|Patient will have Marcaine (Bupivicaine) injected at Laparoscopic Port sites during the Laparoscopic Roux en Y or Laparoscopic Sleeve Gastrectomy.
2521750|NCT02751918|Experimental|Anetumab ravtansine|Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.
2521791|NCT02751593|Experimental|dexamethasone|dexamethasone 40mg/d for 4 days
2521828|NCT02751437|No Intervention|Low Arginine unsupplemented|These infants identified as having low blood arginine levels will receive standard care.
2521829|NCT02751437|Experimental|Low Arginine supplemented|These infants identified as having low arginine levels will receive an additional arginine infusion between days 3 and 10 of life.
2521832|NCT02751437|No Intervention|Normal Arginine|These infants identified as having normal arginine levels will receive standard care.
2521880|NCT02751203|Experimental|Make Safe Happen App Intervention|Pre- and post-test delivered to online survey panel participants. Instruction to download and use the intervention (Make Safe Happen Mobile App) for 1 week.
2521881|NCT02751203|No Intervention|Make Safe Happen App Control|A subset of online survey panel participants (n=200) will complete a pre- and post-test survey but will receive a non-safety app (e.g. a free recipe app). After the study, participants will be asked to download the intervention app.
3199155|NCT00877695|No Intervention|delayed|
3199156|NCT00877695|Active Comparator|Motiv8 2Change Careers|Comparable in number of sessions and duration to the experimental arms, but focused on resume development and interviewing skills. This arm consisted of 2 sessions. In the first session participants reviewed different career choices and created a winning resume. The second session focused on job interviewing skills. It included role plays with feedback. It also contains ethically mandated information regarding HIV prevention. It was delivered on line by a trained facilitator.
2521990|NCT02750280|Experimental|Urinary Bladder matrix (UBM)|UBM covered with silicone foam dressing plus total contact cast
2521993|NCT02750280|Active Comparator|Standard Care|Silicone foam dressing plus total contact cast
2522062|NCT02750124|Active Comparator|HPV self sampling test sent|A Cobas PCR (polymerase chain reaction) Female swab sample Packet will be sent directly to women with a study invitation letter and instructions. Response rate will be measured.
2522067|NCT02750124|Active Comparator|HPV self sampling test ordered|An invitation to order a Cobas PCR Female swab sample Packet through an online application will be sent. Response rates will be measured.
2522078|NCT02750124|Active Comparator|Nurse navigator contact|An invitation to call the coordinating midwife with questions and concerns regarding screening will be sent. The coordinating midwife can help the participant order a Cobas PCR Female swab sample Packet or book a standard screening visit, if desired. Response rates will be measured
2522082|NCT02750124|Placebo Comparator|Control|The standard, annual renewed invitation to cervical screening will be sent (control, routine practice). Response rate will be measured as a baseline.
2522119|NCT02749474||Pregnant women diagnosed with cancer|Any pregnant woman diagnosed with any cancer within 6 weeks prior to their last menstrual period, or up to 6 months after the end of their pregnancy can be enrolled.
2522193|NCT02749162|Placebo Comparator|Group A|After the spinal anesthesia regressed, the investigators performed a single shot femoral block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2522195|NCT02749162|Active Comparator|Group B|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg + lidocaine 1% 200 mg and 4 mg dexamethasone phosphate. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2522198|NCT02749162|Active Comparator|Group C|After the spinal anesthesia regressed, the investigators performed a single shot femural block with ropivacaine 0,5% 200 mg+ lidocaine 1% 200 mg and 8 mg dexamethasone phosphate.After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.1 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2522256|NCT02748629|Active Comparator|ProGrip Mesh Repair|80 patients are randomized to inguinal hernia repair using selfgripping ProGrip Mesh (Covidien Parietex ProGrip Self-Fixating Mesh) - sutureless fixation.
2522263|NCT02748629|Active Comparator|Lichtenstein Operation|80 patients are randomized to inguinal hernia repair using lightweight polypropylene mesh (<40 g/m2) with standard Lichtenstein technique.
3199157|NCT00877721|Experimental|balance treatment|
2522391|NCT02747862||Attenuated Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Attenuated Familial Adenomatous Polyposis (AFAP) who have not undergone surgical resection of the colon.
2522393|NCT02747862||Deleterious Familial Adenomatous Polyposis|Chart review study to evaluate the outcomes of subjects with Deleterious Familial Adenomatous Polyposis (FAP) who have not undergone surgical resection of the colon.
2522465|NCT02747485|Experimental|organic left-sided regurgitant valve|
2522513|NCT02746913|Experimental|Urodynamics, followed by Pessary|
2522518|NCT02746913|Experimental|Pessary, followed by Urodynamics|
3199158|NCT00877734|Experimental|1|Baclofen
2522622|NCT02746302|Experimental|HS-20004|One dose of HS-20004(0.02,0.04,0.05,0.06,0.08,0.1mg) Injected s.c. (under the skin) once for one subject.
3199159|NCT00877734|Placebo Comparator|2|Placebo
2521731|NCT02751996|Active Comparator|Part A Cohort 2: 50mg SB 9200|Part A Cohort 2: 50mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521732|NCT02751996|Placebo Comparator|Part A Cohort 2: 50mg Placebo|Part A Cohort 2: 50mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521733|NCT02751996|Active Comparator|Part A Cohort 3: 100mg SB 9200|Part A Cohort 3: 100mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521734|NCT02751996|Placebo Comparator|Part A Cohort 3: 100mg Placebo|Part A Cohort 3: 100mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521735|NCT02751996|Active Comparator|Part A Cohort 4: 200mg SB 9200|Part A Cohort 4: 200mg SB 9200. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521736|NCT02751996|Placebo Comparator|Part A Cohort 4: 200mg Placebo|Part A Cohort 4: 200mg Placebo. After 12 weeks of Placebo this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521737|NCT02751996|Active Comparator|Part B: SB 9200 with tenofovir|Part B: SB 9200 selected dose from Part A administered in combination with tenofovir 300 mg qd. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521738|NCT02751996|Active Comparator|Part B: Tenofovir 300 mg|Part B: Tenofovir 300 mg qd monotherapy. After 12 weeks of SB 9200 this medication will be stopped. From weeks 12 - 24 patients will be given 12 weeks of Tenofovir (current standard of care)
2521843|NCT02751489|Experimental|Bain De Soliel - Solid|All subjects are patched with the same product
2521883|NCT02751138||Isocitrate dehydrogenase - 1 mutated|Immunophenotype of Glioblastoma and correlation with outcome
2521884|NCT02751138||Isocitrate dehydrogenase - 1 wild type|Immunophenotype of Glioblastoma and correlation with outcome
2522071|NCT02749864||A: Age 20-34 yr|No intervention Cohort of subjects aged 20-34 years old.
2522076|NCT02749864||B: Age 35-49 yr|No intervention Cohort of subjects aged 35-49 years old.
2522081|NCT02749864||C: Age 50-79 yr|No intervention Cohort of subjects aged 50-79 years old.
2522094|NCT02749552|Experimental|Acceptance and Commitment Therapy|ACT intervention
2522142|NCT02749383|Experimental|PAC-14028 cream 0.3%|Twice daily for 4 weeks
2522145|NCT02749383|Experimental|PAC-14028 cream 1.0%|Twice daily for 4 weeks
2522147|NCT02749383|Placebo Comparator|PAC-14028 cream vehicle|Twice daily for 4 weeks
2522250|NCT02748967|Experimental|Group 1|Participants with age (greater than or equal to [>=] 20 to less than [<] 50 years) will receive single dose of 0.5 milliliter (mL) of ExPEC4V (4:4:4:4) or placebo on Day 1.
2522255|NCT02748967|Experimental|Group 2|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
2522261|NCT02748967|Experimental|Group 3|Participants with age >= 20 to < 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
2522265|NCT02748967|Experimental|Group 4|Participants with age greater than or equal to [>=] 50 will receive single dose of 0.5 mL of ExPEC4V (4:4:4:4) or placebo on Day 1.
2522266|NCT02748967|Experimental|Group 5|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (8:8:8:8) or placebo on Day 1.
2522267|NCT02748967|Experimental|Group 6|Participants with age >= 50 will receive single dose of 0.5 mL of ExPEC4V (16:16:16:16) or placebo on Day 1.
2522296|NCT02748239|Active Comparator|MEDIAS 2 CT|The MEDIAS CT is a newly developed education program for the initiation of a conventional insulin therapy in type 2 diabetic patients.
2522300|NCT02748239|Placebo Comparator|Current CT program|This program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients.
3165790|NCT00517582|Experimental|HOE-140|Administration of HOE-140 (icatibant) 30 mg at time 0 and at 6 hours
3165791|NCT00517582|Placebo Comparator|Placebo|Administration of placebo at time 0 and 6 hours
2522398|NCT02747823|Experimental|CBT124|CBT124, single dose of 1 mg/kg, IV infusion
2522404|NCT02747823|Active Comparator|EU Sourced Avastin®|EU Sourced Avastin®, single dose of 1 mg/kg, IV infusion
2522408|NCT02747823|Active Comparator|US Sourced Avastin®|US Sourced Avastin®, single dose of 1 mg/kg, IV infusion
2522627|NCT02746302|Placebo Comparator|Placebo|Placebo Injected s.c. (under the skin) once for one subject.
3165792|NCT00517673|Experimental|GSK945237|Active Study Drug
3165793|NCT00517673|Placebo Comparator|Sugar Pill|Placebo
3165794|NCT00517686|Experimental|1|The study will use automated databases and PHASE information systems to identify patients and incorporate feedback on a monthly basis into the ongoing reports used by program staff at facilities randomized to this intervention arm (n=4).
3165795|NCT00517686|No Intervention|2|Usual care facilities (n=4) will continue to use current PHASE reports that include information on recent risk factor levels and current use of selected medications but no treatment intensification information, and no information on medication adherence.
3165796|NCT00517712|Active Comparator|A|Duration of maintenance therapy with single agent ATO of 12 months
3165797|NCT00517712|Active Comparator|B|Duration of maintenance therapy with single agent ATO for 6 months
3165798|NCT00517725|Active Comparator|Carvedilol|
3165799|NCT00517725|Active Comparator|Bisoprolol|
3165800|NCT00517725|Active Comparator|Nebivolol|
3165801|NCT00517738|Experimental|Physical training - No encephalopathy|Patients randomized to the physical training program and diet intervention
3165802|NCT00517738|Active Comparator|Control - No encephalopathy|Patients not allocated to exercise program, but undergoing diet intervention
3165803|NCT00517738|Experimental|Physical training - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grade 1-2) randomized to the physical training program
3165804|NCT00517738|Active Comparator|Control - Early encephalopathy|Patients with early hepatic encephalopathy (minimal or clinical grades 1-2) not allocated to the physical training program, but undergoing diet intervention
2521834|NCT02751476|Experimental|SAM treatment + flocculent-disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a flocculent-disinfectant for household level application.
2521835|NCT02751476|Experimental|SAM treatment + chlorine disinfectant|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a chlorine disinfectant for household level application.
2521836|NCT02751476|Experimental|SAM treatment + ceramic water filter|Standard Severe acute malnutrition treatment provided according to national nutrition protocol, in link with MoH health centers and structure. In addition, caregivers receive a ceramic water filter for household level application.
2521879|NCT02751060||patients with coronary heart disease symptoms|
3165805|NCT00517764|No Intervention|Healthy control|Healthy matched control, no intervention
3165806|NCT00517764|Active Comparator|Escitalopram|Depressed subjects receiving escitalopram
2523147|NCT02742805|Experimental|High Dose Vitamin D|Participants receive high dose of Vitamin D (4,000 IU/day) in addition to standard of care dose of Omalizumab.
2523149|NCT02742805|Active Comparator|Low Dose Vitamin D|Participants receive low dose of Vitamin D (400 IU/day) in addition to standard of care dose of Omalizumab.
2523198|NCT02742324|Experimental|Ruxolotinib and peg-IFN alpha -2a|"Phase I~LeveL 1 Ruxolotinib 10 mg BID and peg-IFN alpha -2a 45 mcg weekly increasing doses to level 9 : Ruxolotinib 20 mg BID and peg-IFN alpha -2a 135 mcg weekly~Phase II~Ruxolotinib and peg-IFN alpha -2a randomized between selected doses from phase I"
2523266|NCT02741986||Physicians|"All surgeons and anesthesiologists at large single-center tertiary academic center will be recruited to participate in this study.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS."
2523269|NCT02741986||Intelligent Perioperative System (IPS)|"Intelligent perioperative system (IPS) is designed as the set of computer softwares and algorithms that in real-time predict risk for postoperative complications using routine clinical data in electronic health records. The system is designed as the self-learning system with the ability to interact with physicians and solicit their feedback.~Intervention: Risk estimation prior to surgery and immediately after the surgery.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
2523343|NCT02741414|Experimental|H pylori culture negative group|The patients who have the negative result of H pylori culture were classified into H pylori culture negative group.
2523349|NCT02741414|Experimental|The first successful eradication group|The patients with first eradication therapy of H. pylori infection have the first successful treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and proton pump inhibitors （PPIs) dose selection from CYP2C19 gene sequencing.
2523351|NCT02741414|Experimental|The refractory infection of H. pylori group|The patients with first eradication therapy of H. pylori infection have the two failure treatment based on the standardized treatment including antibiotics selection from antibiotic susceptibility testing and PPIs dose selection from CYP2C19 gene sequencing.
2523566|NCT02740062|Active Comparator|Active treatment|Active tDCS treatment
2523572|NCT02740062|Sham Comparator|Sham treatment|Sham tDCS treatment
2523616|NCT02739607|Experimental|Transdiagnostic program|This arm represents the Transdiagnostic intervention program for emotional disorders. The intervention, based on the Cognitive Behavioral Therapy (CBT) principles, is designed to encourage participants to confront and experience uncomfortable emotions, and use adaptive coping mechanisms.
2523618|NCT02739607|No Intervention|Wait list control group|This arm represents the wait-list comparison group.
2523643|NCT02739191|Experimental|Intervention|Prophylactic negative pressure wound therapy
2523690|NCT02738970|Active Comparator|Part 1-Cohort 1: Pertuzumab 420 Milligrams (mg) IV|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 420 mg IV.
2523693|NCT02738970|Experimental|Part 1-Cohort 2: Pertuzumab 400 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 400 mg SC.
2523694|NCT02738970|Experimental|Part 1-Cohort 3: Pertuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 600 mg SC.
2523697|NCT02738970|Experimental|Part 1-Cohort 4: Pertuzumab 1200 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of pertuzumab 1200 mg SC.
2523700|NCT02738970|Active Comparator|Part 1-Cohort 5: Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of trastuzumab 600 mg SC.
2523703|NCT02738970|Experimental|Part 1-Cohort 6: Pertuzumab 400 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 400 mg and trastuzumab 600 mg SC.
3165807|NCT00517764|No Intervention|subjects with major depression|Depressed subjects not receiving study treatment, but taking part in study measures.
3165808|NCT00517777|Experimental|1|continuous positive airway pressure ventilation + dietary and life style recommendations
3165809|NCT00517777|Active Comparator|2|dietary and life style recommendations
3165810|NCT00517790|Experimental|ABT-869 0.25 mg/kg|Approximately half of the subjects were randomized to receive the high dose
3165811|NCT00517790|Experimental|ABT-869 0.10 mg/kg|Approximately half of the subjects were randomized to receive the Low Dose
3165812|NCT00517803|Experimental|1|
3165813|NCT00517803|Placebo Comparator|2|
3165814|NCT00517816|Experimental|1|
3165815|NCT00517816|Experimental|2|
3165816|NCT00517816|Experimental|3|
3165817|NCT00517816|Experimental|4|
3165818|NCT00517816|Experimental|5|
3165819|NCT00517816|Experimental|6|
3165820|NCT00517816|Experimental|7|
3165821|NCT00517816|Experimental|8|
3165822|NCT00517868|Other|Crossover|Placebo Treatment on Visit 1 followed by URG101 Treatment on Visit 2
2521851|NCT02751307|Active Comparator|metformin 1000 mg/d; clozapine 100 mg|In the first week, 500 mg of metformin was administered in the morning. In the second week, 500 mg of metformin twice a day was administered. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2521854|NCT02751307|Placebo Comparator|placebo; clozapine 100 mg|In the first week, one pill of placebo was given and in the second week, placebo BID was given. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
2521998|NCT02750384|Experimental|50% SDD granules, fasting|50% spray dried dispersion granules, fasting
2522003|NCT02750384|Active Comparator|25% SDD powder for suspension, fasting|25% spray dried dispersion powder for suspension, fasting
2522004|NCT02750384|Experimental|50% SDD granules, fed|50% spray dried dispersion granules, fed
2522027|NCT02750020||never smokers|Around 1667 never smokers will be required to answer a questionnaire via telephone.
2522028|NCT02750020||ex-smokers|Around 1667 ex-smokers will be required to answer a questionnaire via telephone.
2522029|NCT02750020||current smokers|Around 1667 current smokers will be required to answer a questionnaire via telephone.
2522074|NCT02749825|Experimental|Trelstar|Per prescribing information
2522080|NCT02749825|Active Comparator|Lupron|Per prescribing information
2522084|NCT02749825|Active Comparator|Zoladex|Per prescribing information
2522126|NCT02749435||Standard of Care + digital disease management cohort|Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
2522128|NCT02749435||Standard of Care cohort|Participants will have standard care with no access to the digital disease management tool.
2522228|NCT02748902|Experimental|ingenol mebutate 0.05% gel|Single group, open label. All subjects will receive active product.
2522280|NCT02748486|Experimental|Jumping To Conculsions|Metacognitive Training Jumping to conclusions module
2522282|NCT02748486|Experimental|Theory of Mind|Metacognitive Training To empathize... module
2522284|NCT02748486|Sham Comparator|Control|group discussion of current events
2522310|NCT02748226||Retrospective cohort|This cohort retrospectively enrolls patients with lower extremity artery disease who underwent endovascular treatment from January 2006 to the date of approval by IRB in the participating hospitals.
2522316|NCT02748226||Prospective cohort|This cohort prospectively enrolls patients with lower extremity artery disease who undergo endovascular treatment from the date of approval by IRB to July, 2018 in the participating hospitals.
2522369|NCT02748044|Experimental|Eligible patients for CC-Cruiser test|
2522444|NCT02747680|Other|type 1 diabetes|type 1 diabetes >5 years duration Well controlled (a1c <7.5%)
2522446|NCT02747680|Other|healthy controls|healthy controls
2522489|NCT02747134|Experimental|Emotion Regulation and Mindfulness skills|A 10 week intervention including emotion regulation and mindfulness skills from dialectical behavioral therapy (DBT) was delivered.
2522494|NCT02747134|Active Comparator|Psychoeducation|Psychoeducation consisted of 5 session in which basic information about depressive symptoms and how to prevent depression relapse was given.
3165823|NCT00517868|Other|Crossover 2|URG101 Treatment on Visit 1 followed by Placebo Treatment on Visit 2
2522655|NCT02746068|Experimental|AXS-02|Administered orally in the morning for 6 weeks
2522656|NCT02746068|Placebo Comparator|Placebo|Administered orally in the morning for 6 weeks
2522733|NCT02745483|Experimental|Separable clustered electrodes|Enrolled patients in the prospective study (RFA using separable clustered electrodes (Octopus®)) for treatment-naive HCC (n=79)
2522734|NCT02745483|No Intervention|Historical control group|Patients who received RFA according to routine protocol in our center (multiple internally-cooled electrodes) for treatment-naive HCC from Jan 2011 to July 2013 in our institution (n=74) .
2522933|NCT02744040|Other|Early ART initiation|Immediate ART initiation at the time of HIV diagnosis; daily dose of combination ART (one pill/day)
2522939|NCT02744040|Other|Deferred ART initiation|ART initiation at 24 weeks after HIV diagnosis; daily dose of combination ART (one pill/day)
2522961|NCT02743728||All Infants|Each infant will receive an Magnetic Resonance Imaging, then Transcranial Magnetic Stimulation Cortical Excitability testing, and General Movement Assessment. These 3 different components of the one arm in which all infants are involved will be collectively assessed.
2523082|NCT02743143|Experimental|Exercise therapy|High aerobic intensity training and maximal strength training 2 times per week in 1 year at the Hospital's Exercise Training Clinic. Patients receive comprehensive support from Trondheim municipal administration to facilitate adherence.
2523083|NCT02743143|Active Comparator|Follow-up care as usual|The usual care (UC) group will receive the usual physical activity offered by the primary health care system. UC includes the traditional physical activity advice from the Health Directorate. The UC group are invited to supervised exercise at the exercise training Clinic after 1 year.
2523132|NCT02742740|Experimental|Chemo Buddy|Subject receives instructions on how to use the personalized touch screen tablet and takes it home for 2 months.
3165824|NCT00517907|Experimental|1|6 steroid-resistant acute GVHD patients, post-matched BMT (serial)
3165825|NCT00517920|Experimental|ABT-869|
3165826|NCT00517959|Experimental|1|Stereotactic conformal radiotherapy (SCRT)
3165827|NCT00517959|Other|2|Conventional radiotherapy Patients in this arm will be treated with conventional radiotherapy techniques being used at the moment in the department. This involves patient being immobilised with a customised thermoplastic mask after which they will have a contrast enhanced planning CT scan. The radiation oncologist will draw the tumour on the appropriate CT slices and a margin of 1-2 cms grown for the planning target volume. Beam arrangement will be relatively simple and typically consist of 2-3 coplanar fields using 6 MV photons. Conventional planning optimisation will be carried out by the use of wedges, beam weightage and corner shields as appropriate. Radiotherapy doses, prescription and fractionation schedules will be identical to the SCRT arm
3165828|NCT00517998|Experimental|Group1|Treatment will be administered in two sessions.
3165829|NCT00517998|Experimental|Group2|Treatment will be administered in a single session.
3165830|NCT00518024|Experimental|1|Bilateral theta burst stimulation to the secondary auditory cortex
2521859|NCT02751255|Experimental|daratumumab--> daratumumab + ATRA|In part A of the study patients will be treated with daratumumab as a single agent. In case patients have progressive disease after cycle 1, or in case patients achieve less than minimal response after cycle 2, or patients achieve less than PR after cycle 3, or in case patients experience progression during daratumumab therapy after having obtained a response, then ATRA will be added to daratumumab (part B).
2521891|NCT02750956||Group 1|Periodontal healthy individuals
2521894|NCT02750956||Group 2|Patients with chronic periodontitis
2521896|NCT02750956||Group 3|the same patients in group 2 after they had been treated with scaling and root planing (SRP) were considered as Group 3.
3199160|NCT00877747||PET2 negative|Patients with negative early interim PET after 2 courses of ABVD who continued therapy with ABVD
3199161|NCT00877747||PET2 positive|Patients with positive early interim PET after 2 courses of ABVD who changed their therapy to BEACOPP
3199162|NCT00877760|Experimental|ETV + pegIFN|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. From week 24 to week 48, they also receive pegylated-interferon a-2a in a dose of 180 μg per week s.c. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
3199163|NCT00877760|Active Comparator|ETV|Patients receive Entecavir in a dosage of 0.5 mg once daily per os from day 0, up to week 48. At week 48, response will be assessed. Responders will continue to take Entecavir until week 72, and quit subsequently. Non-responders at week 48 will continue on Entecavir up to week 96.
3199164|NCT00877786|Active Comparator|Face-to-face group therapy|
3199165|NCT00877786|Active Comparator|Online chat group therapy|
2522202|NCT02749136|Experimental|Perioperative chemotherapy|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~Postoperative gemcitabine, every 4 weeks, 3-6 cycles"
2522229|NCT02748642|Experimental|Part A Cohort A: BITS7201A Dose Level 1 Subcutaneous (SC)|Healthy participants will receive a single SC dose of BITS7201A dose Level 1 on Day 1.
2522235|NCT02748642|Experimental|Part A Cohort B: BITS7201A Dose Level 2 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 2 on Day 1.
2522240|NCT02748642|Experimental|Part A Cohort C: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 on Day 1.
2522244|NCT02748642|Experimental|Part A Cohort D: BITS7201A Dose Level 4 Intravenous (IV)|Healthy participants will receive a single IV dose of BITS7201A dose Level 4 on Day 1.
2522245|NCT02748642|Experimental|Part A Cohort E: BITS7201A Dose Level 6 IV|Healthy participants will receive a single IV dose of BITS7201A dose Level 6 on Day 1.
2522246|NCT02748642|Placebo Comparator|Part A: Placebo|Healthy participants will receive a single SC or IV dose of placebo matched to BITS7201A on Day 1.
2522247|NCT02748642|Experimental|Part B Cohort F: BITS7201A Dose Level 3 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 3 every 4 weeks (Q4W) on Days 1, 29, and 57.
2522248|NCT02748642|Experimental|Part B Cohort G: BITS7201A Dose Level 4 SC|Healthy participants will receive a single SC dose of BITS7201A dose Level 4 Q4W on Days 1, 29, and 57.
2522249|NCT02748642|Experimental|Part B Cohort H: BITS7201A Dose Level 5 SC|Healthy participants will receive SC dose of BITS7201A dose Level 5 Q4W on Days 1, 29, and 57.
2522253|NCT02748642|Experimental|Part B Cohort I:BITS7201A Dose Level 5 SC (Mild Atopic Asthma)|Mild atopic asthma participants will receive SC dose of BITS7201 dose Level 5 Q4W on Days 1, 29, and 57.
2522259|NCT02748642|Placebo Comparator|Part B: Placebo|Healthy participants or mild atopic asthma participants will receive SC doses of placebo matched to BITS7201A Q4W on Days 1, 29, and 57.
2522314|NCT02748304|Placebo Comparator|control|just follow up after liver resection in HCC patients
2522320|NCT02748304|Active Comparator|sorafenib|use sorafenib after liver resection in HCC patients
2522322|NCT02748304|Active Comparator|sorafenib and aspirin|use sorafenib and aspirin after liver resection in HCC patients
3199166|NCT00877812|Experimental|Arm 1 glycine and leucine infusion|Determine in healthy, adequately pyridoxine nourished humans using a protocol based on amino acid glycine tracer methods: (a) the postprandial rates of in vivo glycine turnover, glycine-based generation of one-carbon units, thymidylate and purine synthesis, and the impact of vitamin B6 deficiency on the rates of these processes and (b) the effect of vitamin B6 deficiency on the postprandial rate of glutathione synthesis. 14 subjects will be chosen after screening is complete and will begin a B6 deficient diet for 30 days. At the beginning and end of the 30 days they will receive an infusion of leucine and glycine then they will begin the four week diet. At the end of four weeks the infusion will be repeated.
3199167|NCT00877812|Experimental|Arm 2 Intervention of Serine and methionine infusion|This arm will allow investigation of total Hcy remethylation and remethylation from serine-derived 1C units, kinetics of serine and the methionine cycle and kinetics of transsulfuration reactions. 14 healthy subjects will be selected and screened. Prior to starting a B6 deficient diet for four weeks an infusion of serine and methionine will commence. Following the first infusion the diet will begin and after four weeks another infusion will be done.
3199168|NCT00877851|Experimental|1 CD-ROM|Use of CD-ROM for 12 weeks
2522473|NCT02747290|Experimental|68Ga-NOTA-BBN-RGD PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-BBN-RGD in one dose intravenously and underwent PET/CT scan 15-30 min later.
2522535|NCT02746848|Experimental|Patients with cornea injury|Patients with cornea injury who received healing Amniotic Membrane Extract Eye Drop.
3199169|NCT00877851|No Intervention|2 Control|Usual care and list of useful websites
3199170|NCT00877864|Active Comparator|High volume combined aerobic/resistance exercise|
3199171|NCT00877864|Active Comparator|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
3199172|NCT00877864|Active Comparator|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
3199173|NCT00877864|Active Comparator|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
3199174|NCT00877864|Active Comparator|Printed PA information, pedometers and step log group|Printed physical activity information, pedometers and step log group
3199175|NCT00877864|Placebo Comparator|Control|
3199178|NCT00877942||1|Typically developing children drawn from the general population
3199179|NCT00877942||2|Children with Turner Syndrome
3199180|NCT00877955|Active Comparator|alprazolam sublingual tablet reference|
2521994|NCT02750254|Experimental|Arm 1: Azacitidine|"Treating physician must choose from one of these conditioning regimens (will be given per standard of care)~fludarabine and fractionated total body irradiation (Flu/FrTBI)~fludarabine and busulfan (Flu/Bu4)~fludarabine, cyclophosphamide, and single dose total body irradiation (Flu/Cy/sdTBI)~fludarabine and melphalan (Flu/Mel)~reduced-intensity fludarabine and busulfan (Flu/Bu2)~G-CSF from Day -5 through Day -1 per standard of care~On Day 0, the allograft will be infused per standard of care.~Azacitidine will be administered on Day +1 and +2 post-stem cell transfusion days~Cyclophosphamide on Days +3 and +4 post-transplant"
2522032|NCT02749851||Non-smokers|Pregnant women that identify as non-smokers with low risk for placental insufficiency will receive the MRI Imaging intervention.
2522035|NCT02749851||Smokers|Pregnant women that identify as smokers will receive the MRI Imaging intervention.
2522039|NCT02749851||High risk/Non-Smokers|Pregnant women that identify as non-smokers who are at a high risk for adverse outcomes based on prior clinical history will receive the MRI Imaging intervention.
2522041|NCT02749851||Confirmed IUGR|Pregnant women identified by their clinical care provided to have confirmed IUGR during their current pregnancy
3199181|NCT00877955|Experimental|alprazolam sublingual tablet test|
2522179|NCT02749071|Sham Comparator|Control Group|This group will undergo laparoscopic implantation surgery. The device will not be activated: Sham EndoStim stimulation for first six months of study. It will be activated at the Month 6 visit and provide lower esophageal stimulation from Month 6 thru end of study.
2522184|NCT02749071|Experimental|Treatment Group|The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
2522257|NCT02748655|Placebo Comparator|Tap water|Oral consumption of tap water
2522262|NCT02748655|Active Comparator|Alkaline ionized water|Oral consumption of alkaline ionized water
2522293|NCT02748434|Other|Lipohypertrophy|Participants inject their insulin into the abdomen into areas of lipohypertrophy that were identified by ultrasound in Phase 1 of the study.
2522295|NCT02748434|Other|Normal Subcutaneous Tissue|Participants inject their insulin into the abdomen into areas with normal subcutaneous tissue.
2522355|NCT02748109|Experimental|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback
2522359|NCT02748109|Active Comparator|Vestibular Rehabilitation|Vestibular rehabilitation
2522389|NCT02747797|Experimental|Advanced cancer with lucitanib-targeting biomarker(s)|Lucitanib 10 mg orally daily
2522424|NCT02747511|Active Comparator|Haloperidol|
2522427|NCT02747511|Placebo Comparator|Placebo|
2522451|NCT02747251|Experimental|Strengthen your Shoulder & Usual Care|"Instructions in a home-based intervention consisting of progressive high volume resistance training with an elastic band. Instructions provided 0, 2, 5, and 10 weeks after baseline. Usual care includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
2522452|NCT02747251|Active Comparator|Usual Care|"Includes all treatment received by a patient during the time between baseline and follow-up, except that included in Strengthen your Shoulder."
3199182|NCT00877968|Placebo Comparator|Whole wheat banana bread|Banana bread made with whole wheat flour
3199183|NCT00877968|Active Comparator|Whole pea flour banana bread|Banana bread made with whole pea flour
2522766|NCT02745262||Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
2522769|NCT02745262||Non Controlled ovarian stimulation|No drugs are administered. It is an observational study. Collect retrospectively the follow-up data
2522834|NCT02744833|Experimental|GMI-1271|
2522845|NCT02744833|Active Comparator|Enoxaparin Sodium (Lovenox®)|
3199184|NCT00877968|Placebo Comparator|Whole wheat biscotti|Biscotti made with whole wheat flour
3199185|NCT00877968|Active Comparator|Whole pea biscotti|Biscotti made with whole pea flour
3199186|NCT00877968|Placebo Comparator|Whole wheat pasta|Pasta made with whole wheat durum
2523066|NCT02743208|Experimental|Furlong Evolution femoral stem|Short stem hip arthroplasty (SHA) using a Furlong Evolution femoral stem, and a Furlong H-A.C. Cortical Scree Fit (CSF) plus acetabular cup system.
3199187|NCT00877968|Active Comparator|Whole pea flour|Pasta made with 30% whole pea flour and 70% white wheat durum
3199188|NCT00877968|Placebo Comparator|White bread|
3199189|NCT00877968|Placebo Comparator|Boiled yellow peas|
3199190|NCT00877981|Active Comparator|Videoassited surgery|"In patients randomized to a video-assisted approach, the surgeon has the option to choose either the lateral- (VAPLA) or medial (MIVAP) techniques, both initiated with a 15 mm transverse skin incision. The lateral approach is performed as described by Henry.~The medial approach is performed using the gasless procedure developed by Miccoli."
3199191|NCT00877981|Active Comparator|Open surgery|Open surgery, a 15 mm transverse skin incision is made close to the site of the parathyroid adenoma indicated by sestamibi scintigraphy.
3199192|NCT00877994|Active Comparator|Immediate|This group will receive the nurture group therapy immediately after enrolling in the study.
3199193|NCT00877994|Active Comparator|Delayed|This group will receive the nurture group therapy 16 weeks after enrolling in the study.
3199194|NCT00878007|Experimental|1|"Intermittent screening and treatment (IST) for malaria.~This intervention is a change from a previous intervention based on intermittent preventive treatment for malaria owning to the withdrawal of amodiaquine (one of the previous IPT drugs) in Kenya in 2009."
3199195|NCT00878007|Experimental|2|Enhanced teacher training on literacy instruction.
3199196|NCT00878007|Experimental|3|Intermittent screening and treatment (IST) for malaria and enhanced teacher training on literacy instruction
3199197|NCT00878007|No Intervention|4|
3199198|NCT00878020|Active Comparator|Arm 1|BMS-830216 (10 mg)
3199199|NCT00878020|Active Comparator|Arm 2|BMS-830216 (30 mg)
3199200|NCT00878020|Active Comparator|Arm 3|BMS-830216 (100 mg)
2521893|NCT02751112|Experimental|Couple donor / recipient|"Each couple will be treated the same way :~An additional blood sample of the donor will be taken prior GCSF mobilization. This blood sample will then be analyzed via Predictor's kit, by the immunology laboratory of the hospital where the graft will be done.~Whatever the result given by the Predictor' kit, the graft will be done for the recipient patient. No change will be done on the usual graft process."
2521939|NCT02750696|Active Comparator|Co/ Ac|Codeine/acetaminophen (30 mg/500 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of codeine/acetaminophen (30 mg/500 mg) every 4 hours for 3 days.
2521940|NCT02750696|Experimental|Tr/ Ac|Tramadol/acetaminophen (37.5 mg/325 mg) analgesic association tablets. Patients in this group received one fixed-dose oral tablet of tramadol/acetaminophen (37.5 mg/325 mg) every 4 hours for 3 days.
2521983|NCT02750319|Placebo Comparator|Amiodarone + Placebo|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading matching placebo; 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 NAC matched placebo continuously for 48 hours.
2521986|NCT02750319|Experimental|Amiodarone + N-Acetylcysteine|Amiodarone loading: 150 mg IV in PACU over one hour, then 1.0 gm/24h x 2 + NAC loading: 50 mg/kg IV in PACU over one hour, then 50 mg/kg/24h x 2 and then continuously for 48 hours.
2522049|NCT02750033||Basal Cell Carcinoma (BCC)|Adult patients undergoing Mohs surgery to remove basal cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
2522052|NCT02750033||Squamous Cell Carcinoma (SCC)|Adult patients undergoing Mohs surgery to remove squamous cell carcinoma (BCC) will have surgical margins assessed with multimodal optical spectroscopy (MMS) device, as well as standard histopathology evaluation.
3199201|NCT00878020|Active Comparator|Arm 4|BMS-830216 (300 mg)
2522512|NCT02746965|Experimental|magnetic seizure therapy|10 treatment sessions of MST, three times per week in the first two weeks, two times per in the following two weeks.
2522517|NCT02746965|Active Comparator|electroconvulsive therapy|10 treatment sessions of modified-ECT, three times per week in the first two weeks, two times per in the following two weeks.
2522578|NCT02746549|Experimental|1.5 Tesla MRI|Measurement of renal perfusion by 1.5 Tesla MRI with arterial spin labelling
2522579|NCT02746549|Experimental|3.0 Tesla MRI|Measurement of renal perfusion by 3.0 Tesla MRI with arterial spin labelling
2522603|NCT02746237|Experimental|KAR5585|KAR5585 Capsules
2522605|NCT02746237|Placebo Comparator|Placebo|Placebo capsules
2522621|NCT02745938||Mitochondrial disease|Patients with mitochondrial disease, investigated by blood samples and exercise test.
2522631|NCT02745938||Metabolic myopathy|Patients with metabolic myopathy, investigated by blood samples and exercise test.
2522635|NCT02745938||Muscular dystrophy|Patients with muscular dystrophy, investigated by blood samples and exercise test.
2522639|NCT02745938||Healthy controls|Healthy controls, investigated by blood samples and exercise test.
2522696|NCT02745808|Experimental|HUC-MSCs|Intracavernous injection of 15 million HUC-MSCs.
2522706|NCT02745808|Experimental|Injectable Collagen Scaffold + HUC-MSCs|Intracavernous injection of injectable collagen scaffold combined with 15 million HUC-MSCs.
3199202|NCT00878020|Active Comparator|Arm 5|BMS-830216 (600 mg)
3199203|NCT00878020|Active Comparator|Arm 6|BMS-830216 (1200 mg)
2522749|NCT02745041|Experimental|Fibrinogen Concentrate|Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
2522756|NCT02745041|Active Comparator|Cryoprecipitate|Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
2522825|NCT02744885|Experimental|Crave Crush|Crave Crush is a plant-based tablet that alters taste perception by affecting sweet taste receptors on the tongue.
2522832|NCT02744885|Placebo Comparator|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
2522888|NCT02744456|Other|N-of-1 trial|Patients with hypertension who are taking none or one BP medication will be will be provided with prescriptions for up to 3 BP medications representative of different BP medication classes (i.e., losartan, an angiotensin system blocking agent; amlodipine, a calcium channel blocker; and hydrochlorothiazide, a thiazide diuretic). Patients will be asked to take each medication for 2 weeks at a low dose, 2 weeks at a medium dose, and then 2 weeks at a high dose; provide health information and identify which medication they prefer to remain on following the N-of-1 trial (i.e., for long-term use).
2522922|NCT02743988|Experimental|Low target range|Low oxygen saturation target range: SpO2 85-89%
2522925|NCT02743988|Active Comparator|High target range|High oxygen saturation target range: SpO2 91-95%
2522983|NCT02743819|Experimental|Treatment|Treatment with the combination of pembrolizumab and ipilimumab.
3199204|NCT00878033||1|Diabetic Dialysis Patients
3199205|NCT00878033||2|Non-Diabetic Dialysis Patients
2523142|NCT02742675|Experimental|androgen deprivation therapy|Patients will receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide acetate, goserelin acetate, buserelin, or triptorelin) subcutaneously or as an injection AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily).
2523143|NCT02742675|Experimental|androgen deprivation therapy plus definitive treatment|Patients will receive androgen-deprivation therapy as in arm I in addition to definitive treatment including surgery to remove prostate or radiation therapy to the prostate.
2524247|NCT02735330|Placebo Comparator|GROUP 2|68 Patients undergo Frey's procedure with Placebo celiac plexus injection using saline
3199206|NCT00878033||3|Healthy Controls
3199207|NCT00878046|Experimental|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
3199208|NCT00878059||Proxies|A family member-caregiver (the medical decision-maker) for someone with Alzheimer's Disease. Must be the person who would be able to make decisions for someone with Alzheimer's disease about being in medical research.
3199209|NCT00878085|Experimental|1|Robot Therapy with activities of daily living (ADLs)
3199210|NCT00878085|Active Comparator|2|Standard Occupational Therapy
3199211|NCT00878111|Experimental|A: escalating dose levels of NGR-hTNF|NGR-hTNF administered at high doses
3199212|NCT00878124|Experimental|CoQ10|Coenzyme Q10 co-treatment
3199213|NCT00878124|Placebo Comparator|Placebo control|Placebo Co-treatment
3199214|NCT00878137||APLA|Patients with antiphospholipid antibody syndrome.
2522056|NCT02749981||Cefazolin|patients receiving cefazolin as part of routine clinical care
2522088|NCT02749695|Experimental|Group 1 (Melsmon)|20 women used placental extract Melsmon® (Japan), 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
2522089|NCT02749695|Placebo Comparator|Group 2 (placebo)|20 patients used placebo (normal saline solution): 2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
2522135|NCT02749409|Active Comparator|Control group|The control group will be given Morphine prn after admission
2522140|NCT02749409|Experimental|Experimental group|the experimental group will be given parecoxib after admission by intravenous method every 12 hours for 4 days. Then Morphine agent will be given prn usage
2522168|NCT02749045|Other|Image acquisition arm|Subjects who have undergone a clinically indicated fractional flow reserve measurement in the cardiac catheterization laboratory will receive standard dose Tc-99m sestamibi and undergo resting SPECT image acquisition within three hours from end of cardiac catheterization procedure.
2522223|NCT02748837|Experimental|Dose escalation cohort of ERY974|Dose escalation (DE) will proceed with the dose level increment and the dose cohort size being guided by a safety evaluations during and at the end of each cohort. DE initially utilizes an accelerated titration design (ATD) and once the first dose limiting toxicity (DLT) is observed, DE will continue using a modified continual reassessment method (mCRM) until MTD.
2522230|NCT02748837|Experimental|Cohort expansion in gastric cancer|Patients with GPC3 positive advanced gastric cancer or gastroesophageal junction cancer will receive ERY974 at recommended dose until disease progression.
2522237|NCT02748837|Experimental|Cohort expansion in esophageal carcinoma|Patients with GPC3 positive advanced squamous cell esophageal carcinoma will receive ERY974 at recommended dose until disease progression.
2522242|NCT02748837|Experimental|Cohort expansion in other solid tumors|Patients with other GPC3 positive advanced solid tumors will receive ERY974 at recommended dose until disease progression
2522326|NCT02748369|No Intervention|Control Group|No somatostatin and glucagon infusions
2522331|NCT02748369|Active Comparator|Intervention Group|Somatostatin and glucagon infusions
2522381|NCT02747940|Experimental|patients with chronic migraine|flunarizine for patients with chronic migraine
2522383|NCT02747940|Experimental|patients with fibromyalgia|pregabalin for patients with fibromyalgia
2522384|NCT02747940|Experimental|patients with chronic migraine and fibromyalgia|flunarizine and pregabalin for patients with chronic migraine and myalgia
2522425|NCT02747563|Experimental|Active Surveillance|Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement
2522428|NCT02747563|Active Comparator|Controls|Patients without known diagnosis of prostate cancer Intervention - PSA measurement
2522482|NCT02747264|Experimental|eRAPID intervention|Participants in the intervention arm will receive training in using the eRAPID system to report their symptoms and side effects (at least on a weekly basis) from home via the internet whilst they are receiving treatment online and weekly for 6 weeks post treatment (a total of 12 weeks) and then at 18 & 24 weeks. Hospital staff will be able to review eRAPID reports and use the information during the consultation in clinic, when attending radiotherapy or answering phone calls. Alerts will also be sent to the relevant clinical team when severe symptoms are reported by patients.
2522486|NCT02747264|No Intervention|Usual care|The Usual care patients act as a comparison to the patients using eRAPID. They complete a paper-based quality of life questionnaire at baseline and then 6, 12 and 24 weeks after. The researchers will also collect clinical process measures for this group including number of hospital contacts and admissions.
2522573|NCT02746783|Active Comparator|Group 1|Single dose of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
2522574|NCT02746783|Experimental|Group 2|Double dose of MUTAGRIP® (one dose into the right deltoid area and the other one into the left deltoid area) containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012.
2522610|NCT02746276|Other|Ceftriaxone and metronidazole|Pharmacokinetic study of ceftriaxone and metronidazole in malnourished children
2522646|NCT02745925|Experimental|normal-weight|normal-weight women
2522649|NCT02745925|Experimental|obesity|obese women
2522687|NCT02745652|Experimental|pulsed electromagnetic field (PEMF)|patients in this group received the pulse electromagnetic field with frequency 50 Hz and intensity 80 gauss for 30 min.The patient was in sitting position, while the forearm was rested on the bed inside the solenoid in supination position
2522701|NCT02745652|Experimental|Therapeutic ultrasound (US)|Pulsed mode US was applied over the volar surface of the forearm (the carpal tunnel area) 15 min per session with a frequency of 1 MHz and intensity of 1.0 W/cm2
2522747|NCT02745366|Experimental|BFPSC+|The combination of BFPSC+FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure.
2522755|NCT02745366|Active Comparator|BFPSC-|The combination of FDBA+PRF is utilized in cortical tenting technique with block graft obtained from lateral ramus for posterior mandible augmentation procedure
2522830|NCT02744924|Experimental|Physical activity intervention|Participants undergo the community-based physical activity promotion (see Intervention)
2522901|NCT02744482|Experimental|Risedronate|Patients take an oral tablet of Risedronate 75 mg, 2 consecutive days per month during 18 months.
2522903|NCT02744482|Placebo Comparator|Placebo|Patients take an oral tablet of Placebo, 2 consecutive days per month during 18 months.
2522918|NCT02744001|Experimental|Low Added Sugar Diet|Menu containing <10% of total daily energy intake from added sugars.
3199215|NCT00878137||Control|Patients on warfarin therapy but without antiphosphilipid antibody syndrome.
3199216|NCT00878150|Experimental|Telephone-based CBT|- 12 counseling sessions over 16 weeks over the telephone
2523300|NCT02741765|Active Comparator|Group 1: Sham Group|Sham group will receive Sham rTMS+Aerobic Exercise
2523305|NCT02741765|Experimental|Group 2: Real Group|rTMS+Aerobic Exercise
3199217|NCT00878150|Experimental|In-person CBT|- 12 counseling sessions over 16 weeks at either Harborview Medical Center or the University of Washington Medical Center in Seattle, WA
2524303|NCT02734927|Active Comparator|schizophrenia group|Schizophrenia patients suffering
2521968|NCT02750423|Active Comparator|DHCA+RCP|Participants undergoing ascending aortic and hemiarch replacement will receive deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP).
2521969|NCT02750423|Active Comparator|MHCA+uSACP|Participants undergoing ascending aortic and hemiarch replacement will receive moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA+uSACP).
2522030|NCT02749955|Experimental|PS-PrEP Intervention Group|
2522031|NCT02749955|Active Comparator|PrEPLine Control Group|
2522034|NCT02749955|No Intervention|CDPH Prevention Projects|
2522101|NCT02749747|Active Comparator|Sulpiride use|50mg sulpiride once a day use for 60 days
2522103|NCT02749747|Placebo Comparator|Placebo|50mg placebo once a day use for 60 days
3199218|NCT00878150|No Intervention|3: Usual care|- No counseling sessions as part of this study, however you are free to pursue regular medical care and counseling outside of this study
2522290|NCT02748564|Experimental|Treatment (pembrolizumab, aldesleukin)|Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks and aldesleukin IV every 8 hours for up to 14 doses at weeks 4, 7, 16, 19, 28, and 31 in the absence of disease progression or unacceptable toxicity.
2522370|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA330)|Combination of hemodialysis and hemoperfusion (HA330) therapy All subjects in the study phase will receive hemodialysis plus hemoperfusion(HA330) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
2522371|NCT02747979|Experimental|hemodialysis+hemoperfusion (HA130)|Combination of hemodialysis and hemoperfusion (HA130) treatment All subjects in the study phase will receive hemodialysis and hemoperfusion(HA130) treatment once per week, and regular hemodialysis treatment in the remaining two sessions.
2522375|NCT02747979|Active Comparator|hemodialysis only|hemodialysis only All subjects in the study phase will receive regular hemodialysis treatment three times per week.
2522418|NCT02747550|Experimental|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
2522419|NCT02747550|Active Comparator|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy.
3165831|NCT00518024|Experimental|2|Bilateral theta burst stimulation to the tertiary auditory cortex
3165832|NCT00518024|Sham Comparator|3|Bilateral theta burst stimulation to a non-cortical region
3165834|NCT00518050||Specific Aim 1- Focus Group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
2522590|NCT02746484|Experimental|Ability platform program|Multi-domain at home rehabilitation program delivered through the Ability platform.
2522591|NCT02746484|Active Comparator|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
2522685|NCT02745613|Experimental|Family history of T2D|The participants will undergo 8 weeks of combined exercise
2522693|NCT02745613|Experimental|No Family history of T2D|The participants will undergo 8 weeks of combined exercise
2522740|NCT02745431|Experimental|Oxytocin nasal spray|Oxytocin nasal spray
2522741|NCT02745431|Placebo Comparator|Placebo nasal spray|Placebo nasal spray
2522748|NCT02745028|Other|With monosodium glutamate|Results of one time gastric emptying study with a single dose of monosodium glutamate; 1 g for weight greater than 45 kg, 700mg between 35 and 44,900 kg, 600mg between 25 and 34,900, 500mg between 15 and 25 kg and 250mg in less than 15 kg
2522810|NCT02744976|Experimental|Prediabetes, metformin|Patients with HbA1c 5.7-6.4 receiving metformin and lifestyle recommendations
2522811|NCT02744976|Active Comparator|Prediabetes, lifestyle|Patients with HbA1c 5.7-6.4 receiving lifestyle recommendations
2522828|NCT02744547|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2522839|NCT02744547|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
2522880|NCT02744430|Active Comparator|Arm 1 - Active|Mirabegron 50 mg orally once every 24 hours starting immediately
2522884|NCT02744430|Placebo Comparator|Arm 2 - Placebo|Placebo orally once every 24 hours starting immediately
3199219|NCT00878163|Experimental|Treatment (vismodegib, erlotinib hydrochloride, gemcitabine)|Patients receive Hedgehog antagonist GDC-0449 PO QD and erlotinib hydrochloride PO QD on days 1-28. Some patients also receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2522980|NCT02743663||Wheezing subjects|Two study visits will be completed with wheezing subjects. The baseline visit will be completed within a 5 day window from the child's discharge from the emergency department. The follow-up visit will be completed 3 months after the baseline visit. At both visits, participants will provide a nasal swab and urine sample, complete three breathing tests: multiple-breath washout, forced oscillation technique, and Spirometry. In addition, at the follow-up visit, children will have an allergy skin test done, a nasal brush to collect epithelial cells and provide a blood sample. Whole blood will be used for basophil activation test (BAT). Children age 4+ will also complete post-bronchodilator testing using Salbutamol to capture information about bronchodilator response.
2522987|NCT02743663||Healthy cohort|One study visit will be completed with healthy participants. At this visit, three breathing tests will be performed: multiple-breath washout, forced oscillation technique, and spirometry. As well, an allergy skin test will be performed at the visit.
2523086|NCT02743130|Active Comparator|Reference|Sugar control, contains 17.5 g glucose and 17.5 g fructose in water
2523158|NCT02742597|Active Comparator|Group B|Before/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting
3199220|NCT00878176|Experimental|1|(Crossover study)
3199221|NCT00878202|No Intervention|Control|Optimal medical treatment of Heart failure and therapeutic education
2522095|NCT02749773|Active Comparator|Oocyte aspiration with 17G needle|Oocyte Aspiration with 17G needle.
2522096|NCT02749773|Active Comparator|Oocyte aspiration with (20-17G) needle|Oocyte Aspiration (20-17G) needle.
3199222|NCT00878202|Experimental|Telemedicine|Optimal medical treatment of heart failure disease and therapeutic education
2522197|NCT02749175|Experimental|Cricoid force sensor monitor system|Nurse applied cricoid pressure with a sensor guided by monitoring Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons.
2522200|NCT02749175|Sham Comparator|Sham cricoid force sensor monitor system|Nurse applied pressure on a sham sensor with no monitor input. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
2522201|NCT02749175|No Intervention|Current standard|Nurse applied cricoid force according to memory. Nurses instructed to apply cricoid pressure at target force of 20-30 Newtons
2522251|NCT02748681|Active Comparator|Telemedicine Group|Patient group with a telemedicine monitoring system
2522254|NCT02748681|Active Comparator|Standard Group|Patient Group without a telemedicine monitoring
2522354|NCT02748083|Active Comparator|tDCS group|The active tDCS group will be stimulated with transcranial Direct Current Stimulation (tDCS).
2522358|NCT02748083|Sham Comparator|Sham tDCS group|The sham tDCS group will have stimulation with sham transcranial Direct Current Stimulation (tDCS).
2522400|NCT02747810|Experimental|New TENS design|To determine the function and safety of the strap design by evaluating the electrical connection to electrode, 2) the security in the insole and the electronic unit, and 3) facilitating observation and hand access to the top panel for adjusting the stimulation strength. 4) to elicit toe twitching with stimulation of tribal nerve
2522474|NCT02747498|Active Comparator|circumferential pulmonary vein isolation|Procedure with circumferential pulmonary vein isolation for atrial fibrillation
2522477|NCT02747498|Experimental|Posterior box isolation in addiction to pulmonary vein isolation|Posterior box isolation in addiction to circumferential pulmonary vein isolation
2522534|NCT02746835|Experimental|Exercise Protocol|Set of exercises for balance, endurance, muscle strength and flexibility
2522572|NCT02746523||Case / Retired NHL Players|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
2522575|NCT02746523||Age Matched Controls|"All interventions for this group are described below:~Sensory Organization Test (SOT): Balance and proprioception test~Connor's Adult ADHD Rating Scale (CAARS): A computer based questionnaire used to measure the presence of adult attention deficit hyperactivity disorder.~Beck's Depression Inventory: A 21 question multiple choice self report measuring the severity of depression~Patient Health Questionnaire 9 (PHQ-9): Self administered screening questionnaire for mental health disorders~Montreal Cognitive Assessment (MoCA): A validated screening tool to assess cognitive mild impairment~Blood/Urine/Saliva Biomarker analysis: These samples will be analyzed for relevant biomarkers"
2522616|NCT02746146|Experimental|Chronic dialysis patients|"The study population consists of patients over 70 (≥) and under 85 years (<) of age with stage 5 chronic renal disease and initiating a first session of chronic dialysis in the Languedoc-Roussillon and Midi-Pyrénées regions. Eligible patients must have a 3 year prognostic mortality score less than (<) 7 points (Dusseux et al. 2015).~Intervention: Systematic use of a prognostic score"
2522694|NCT02745587|Experimental|Prostate(bed) only|external beam radiotherapy limited to the prostate(bed)
2522705|NCT02745587|Active Comparator|Prostate(bed) and pelvis|external beam radiotherapy to the prostate(bed) and pelvic lymph node regions
3199223|NCT00878254|Experimental|R-MACLO/IVAM|"Four 21-day cycles, followed by Maintenance Therapy as follows:~Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol.~Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol.~Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol."
3199224|NCT00878267||Interview|
3199225|NCT00878280||1|1:control(healthy subjects)
3199226|NCT00878280||2|2:case(dementia patients)
2522858|NCT02744586|Experimental|Strengthening our Vows (SOV) Group|"Participants in the SOV arm will participate in the Together HIV Free and Protecting My Spouse plans."
2522860|NCT02744586|Placebo Comparator|Good Health Package Plus (GHPP) Group|Participants in the GHPP arm will receive education on the prevention of helminths, schistosomiasis, hypertension, diabetes, and diarrheal diseases through participatory and interactive group sessions.
2522915|NCT02744235|Other|Patients undergoing Polysomnography|
2522963|NCT02743871|Experimental|Cohort 1|10 mg of PF-06817024 or placebo
2522966|NCT02743871|Experimental|Cohort 2|30 mg of PF-06817024 or placebo
2522967|NCT02743871|Experimental|Cohort 3|100 mg of PF-06817024 or placebo
2522970|NCT02743871|Experimental|Cohort 4|300 mg of PF-06817024 or placebo
2522971|NCT02743871|Experimental|Cohort 5|1000 mg of PF-06817024 or placebo
2522972|NCT02743871|Experimental|Cohort 6|2000 mg of PF-06817024 or placebo
2522973|NCT02743871|Experimental|Cohort 7|30 mg subcutaneous dose of PF-06817024 or placebo
2522974|NCT02743871|Experimental|Cohort 8|300 mg of PF-06817024 or placebo
2522975|NCT02743871|Experimental|Cohort 9|IV dose to be determined of PF-06817024 or placebo
2522978|NCT02743871|Experimental|Cohort 10|PF-06817024 or placebo
2522986|NCT02743871|Experimental|Cohort 11|PF-06817024 or placebo
3199227|NCT00878293|Experimental|A|Dose 1, 40 µg
3199228|NCT00878293|Experimental|B|Dose 2, 120 µg
3199229|NCT00878293|Experimental|C|Dose 3
3199230|NCT00878293|Experimental|D|Dose 4
3199231|NCT00878293|Experimental|E|Dose 5
3199232|NCT00878293|Experimental|F|Dose 6
3199233|NCT00878293|Experimental|G|Dose 7
2521987|NCT02750566|Active Comparator|Counseling|"For the control group, an investigator will complete a 30-minute counseling session with the subject. The focus of discussion will be from the CDC's What to expect after a concussion article. Other resources that will also be used come from the American Academy of Family Physicians (AAFP), FamilyDoctor.org, and the Brain Care Center. Each counseling session will follow the same protocol. The counseling session will provide subject with similar face-to-face time with the OMT arm."
2522108|NCT02749734|Experimental|hESC-RPE|Subretinal transplantation of Human embryo stem cell derived retinal pigment epitheliums
2522149|NCT02749253|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
2522338|NCT02748330|Experimental|Ticagrelor|Oral ticagrelor 90 mg tablet, twice daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
2522340|NCT02748330|Active Comparator|Clopidogrel|Oral clopidogrel 75 mg tablet, once daily for 15±2 days. Oral aspirin 100 mg tablet, once daily for 15±2 days
2522463|NCT02747303|Active Comparator|Stereotactic Radiosurgery to 2 mm GTV to PTV margins|
2522464|NCT02747303|Experimental|Stereotactic Radiosurgery to 0 mm GTV to PTV margins|
2522493|NCT02746926|Experimental|4x20 mg tafamidis meglumine soft gel capsule|
2522499|NCT02746926|Experimental|48.8 mgA tafamidis free acid capsule|
2522503|NCT02746926|Experimental|61 mgA tafamidis free acid capsule|
3165835|NCT00518050||Specific Aim 2- Survey Study|A separate random sample of melanoma survivors will complete the pilot questionnaire. To enhance completion rates, survey instruments will be developed to be both self-administered and interviewer-administered. The survey will include questions from existing surveys, regarding demographics, sun sensitivity, eye and hair color, color of untanned skin, sun exposure, skin selfexamination, sun protection practices and frequency of sunburns, psychosocial/cognitive factors: skin cancer knowledge, skin awareness, cancer worry, perceived risk of recurrence, cancer risk and screening behaviors, and access to health care and insurance.
2522779|NCT02745288|Experimental|Nerve block|This arm will receive inferior alveolar nerve block
2522782|NCT02745288|No Intervention|control|Control arm will not receive inferior alveolar block
2522822|NCT02744781|Experimental|Lumbar disc degeneration; LDD|The LDD group included subjects with at least 1 abnormal disc from L1-2 to L5-S1 of grade III, IV, or V. The non-LDD group included subjects with 5 normal discs of grade I or II. For further assessment, the most damaged disc of the 5 constituted the highest grade of LDD.
2522882|NCT02744508|Active Comparator|P group|Palonosetron group
2522886|NCT02744508|Experimental|PD group|Palonosetron and dexamethasone group
2523140|NCT02742688|Experimental|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|
2523141|NCT02742688|Placebo Comparator|Placebo|
2523209|NCT02742415|Experimental|Cancer patients receiving hand massage|Caring Hand massage will be provided to the outpatients undergoing chemotherapy
2523247|NCT02741947|Active Comparator|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
2523250|NCT02741947|Experimental|Levodopa Benserazide Teva Italia|Levodopa Benserazide Teva Italia100+25mg and 200+50mg, tablet, tid e qid, for four weeks
2523327|NCT02741232|Active Comparator|Pectoral nerve block|After induction of general anesthesia and under ultrasound visual guidance, pectoral block is performed with 30 mL total of local anesthetic (1% lidocaine + 1/400000 epinephrine). 10 mL of local anesthetic between pectoralis major muscle and pectoralis minor muscle and 20 mL between pectoralis minor muscle and serratus anterior muscle at the third rib.
2523330|NCT02741232|Sham Comparator|Sham block|No needle or injection will be used
3165836|NCT00518102||001|REGRANEX (becaplermin) A cohort of REGRANEX (becaplermin) users (ie patients treated with REGRANEX (becaplermin) a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
3165837|NCT00518102||002|REGRANEX (becaplermin) comparators A cohort of REGRANEX (becaplermin) nonusers (ie patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
3165838|NCT00518128|Active Comparator|1|Surgical OSA Treatment Group: Moderate to Severe OSA patients who are unable to tolerate PAP (Positive Airway Pressure) and elect to proceed with surgical treatment (surgical cohort).
3165839|NCT00518128|Active Comparator|2|Positive Airway Pressure Therapy Comparison Group: Moderate to Severe OSA patients who tolerate PAP (Positive Airway Pressure).
3165840|NCT00518141|Experimental|1|FER
3165841|NCT00518141|No Intervention|2|FER
3165842|NCT00518141|Experimental|3|SET
3165843|NCT00518141|No Intervention|4|SET
3165844|NCT00518141|Experimental|5|DET
3165845|NCT00518141|No Intervention|6|DET
3165846|NCT00518167|Experimental|1|Intensive lifestyle intervention
3165847|NCT00518167|No Intervention|2|Standard counselling at baseline
3165848|NCT00518219|Experimental|immunosuppressor|TW 120mg/d，Valsartan,160mg/d
3165849|NCT00518245|Experimental|1|
3165850|NCT00518245|No Intervention|2|
2522087|NCT02749786|Other|Control Group|Participants who do not have rosacea (control group)
2522151|NCT02749487||cured (c)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
2522154|NCT02749487||Died ( M)|Neutrophil Lymphocyte and platelet lymphocyte ratios as Predictors of Outcome in Traumatic Critically ill Patients
2522303|NCT02748291|Experimental|Walking|Randomised participants will be instructed to walk 6,000 steps per day and throughout the day for 12 weeks. Step counts will be monitored by an issued pedometer. A 12 week paper diary will be provided for daily recording of step counts.
2522308|NCT02748291|Active Comparator|Control|Department of Health (United Kingdom) Physical Activity Guidelines flyer (current standard of care).
2522372|NCT02748031|Experimental|eligible patients group|
2522611|NCT02746315|Experimental|Experimental 1|Once daily subcutaneous dose for 7 Days of HS-20004 0.02 mg or Matched Placebo.
2522612|NCT02746315|Experimental|Experimental 2|Once daily subcutaneous dose for 7 Days of HS-20004 0.04 mg or Matched Placebo.
2522613|NCT02746315|Experimental|Experimental 3|Once daily subcutaneous dose for 7 Days of HS-20004 0.06 mg or Matched Placebo.
2522614|NCT02746315|Experimental|Experimental 4|Once daily subcutaneous dose for 7 Days of HS-20004 0.08 mg or Matched Placebo.
2522648|NCT02745912|Experimental|Metformin + Naltrexone/Bupropion|Metformin (850 mg, immediate release tablet, orally, once on Day 1 and Day 14) naltrexone/bupropion (8/90 mg/mg, extended-release tablets, orally, twice daily from Day 3 through Day 5 and 16/180 mg/mg, twice daily from Day 6 through Day 15.
2522695|NCT02745665||1-Elite Cyclist|"10 symptomatic cyclists with unilateral diagnosis of iliac EF,~FLOW MEDIATED DILATION Ankle brachial pressure index (ABPI) PULSE WAVE VELOCITY AND AUGMENTATION INDEX Blood pressure RAMP Test"
2522703|NCT02745665||2-Amateur Cyclist|"10 asymptomatic cyclists with no evidence of EF~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
2522707|NCT02745665||3-Control|"10 age-matched healthy male group~FLOW MEDIATED DILATION ABPI PULSE WAVE VELOCITY AND AUGMENTATION Blood pressure RAMP Test"
2522764|NCT02745093|Experimental|64-84 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-84 days will receive 200 µg mifepristone followed by misoprostol 24-48 hours later.
2522768|NCT02745093|No Intervention|57-63 days gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range: 200 µg mifepristone administered orally in the clinic on Day 1 then 800 μg misoprostol administered sublingually 24-48 hours later at home with a subsequent dose of 400 μg misoprostol sublingually 6 hours later if she has not expelled the pregnancy).
2522821|NCT02744716|Experimental|non-balloon group|with aspirin
2522824|NCT02744716|Experimental|balloon group|with aspirin and intrauterine balloon
2522831|NCT02744716|No Intervention|control group|without aspirin and intrauterine balloon
3165851|NCT00518258||1|Patient Group
2523001|NCT02743624|Other|Pressure Support Titration|The analysis of the diagnostic accuracy of the breathing pattern variables, P 0.1 and the rate of tracheal muscle relaxation.
2523077|NCT02743390|Active Comparator|TNF-alpha inhibitor drug|Infliximab infusion (TNF-α inhibitor, 3 mg/kg, 250mL)
2523079|NCT02743390|Placebo Comparator|Placebo drug|Saline infusion (250mL)
2523116|NCT02742870||Patients with MRI pelvic imaging|Women over 18 years old, having undergone a magnetic resonance imaging of the pelvis within the CHU Brugmann Hospital
2523309|NCT02741700|Experimental|Gout storytelling video|Patients view a culturally relevant patient storytelling in African-American Veterans' own voices about gout and its treatment.
3165852|NCT00518258||2|Control Group
3165853|NCT00518297|Active Comparator|1|
3165854|NCT00518297|Active Comparator|2|
3165855|NCT00518297|Active Comparator|3|
3165856|NCT00518310|Placebo Comparator|0|Placebo
3165857|NCT00518310|Active Comparator|1|Azathiprine Prednisone
3165858|NCT00518362|Experimental|immunosuppressor|Valsartan,160mg/d,TW 120mg/d
3165859|NCT00518388||Focus Group + Questionnaire|Participants that are self identified as Korean, Filipino, or Vietnamese.
3165860|NCT00518414|Active Comparator|Marketed infant formula with DHA and ARA|Marketed milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
3165861|NCT00518414|Experimental|Milk-based infant formula with DHA and ARA|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA)
3165862|NCT00518414|Experimental|Milk-based formula with DHA, ARA, prebiotics|Experimental milk-based infant formula containing docosahexaenoic acid (DHA) and arachidonic acid (ARA) and prebiotic blend
3165863|NCT00518427|Experimental|1|insulin glargine
3165864|NCT00518453|Experimental|Arm 1: Fluvirin|
3165865|NCT00518466|Experimental|treatment 1|"One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsule and two 25 mg topiramate MR capsules at Hour 0 on Days 4 - 21 of Period 2."
3165866|NCT00518466|Experimental|treatment 2|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~One 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsules at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules (Cardinal) and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
3165867|NCT00518466|Experimental|treatment 3|"Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate MR capsule at Hour 0 on Days 1, 2, and 3 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and two 25 mg topiramate MR capsule at Hour 0 on Days 4, 5, and 6 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and three 25 mg topiramate MR capsules at Hour 0 on Days 7, 8, and 9 of Period 2.~Two 7.5 mg phentermine hydrochloride IR capsules and four 25 mg topiramate MR capsules at Hour 0 on Days 10 - 21 of Period 2."
2522022|NCT02750150|Active Comparator|Fresh-frozen plasma|transfusion of 4 units of fresh frozen plasma when available in patients at risk pf massive bleeding (transfusion of 4 red blood cells units in the first 6 hours after trauma)
2522033|NCT02749877|Experimental|Cognitive Training|"This group will undergo a working memory training program (Training A). The children will receive individual memory training based on the computer program Cogmed RM and will be supervised by trained neuropsychologists. Its efficacy in the use with children with cancer has been recently published. The children will undergo 25 training sessions online; each session takes about 45 minutes and consists of a selection of various tasks that target the different aspects of working memory."
2522036|NCT02749877|Experimental|Physical Training|This group will receive a physical training that can be executed at home (Training B). The training will be based on xbox Kinect games and comprise games and activities such as jump'n'run games, physical training, and dance activities. One training session will last approximately 45 minutes and will be performed 3 days a week over a period of 8 weeks (in total 25 sessions).
2522040|NCT02749877|Active Comparator|Waiting Control Group|This group will serve as a waiting control group and will receive either the physical or the working memory training program after completion of the Neuropsychological Assessment II
2522092|NCT02749708|Experimental|Dose level 1|IRX5183 50 mg daily
2522093|NCT02749708|Experimental|Dose level 2|IRX5183 75 mg daily
3199234|NCT00878293|Active Comparator|H|Morphin
3199235|NCT00878293|Placebo Comparator|I|Placebo
3199236|NCT00878306|Active Comparator|Disulfiram|Disulfiram
2522380|NCT02747888|No Intervention|Lower Suspected Familial Predisposition|"Lower Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Sample stored in Biorepository"
2522382|NCT02747888|Experimental|Higher Suspected Familial Predisposition|"Higher Suspected Familial Predisposition~Screening and Enrollment:~Consent, Family HX, Medical HX, Blood/Saliva which will categorize by suspected hereditary predisposition: Based on family and medical history.~- Specimen Testing and Analysis~•Referral to Genetic Counselor, if indicated"
2522426|NCT02747602|Experimental|Group ABC|AC-1204, caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast
2522430|NCT02747602|Experimental|Group BCA|caprylic triglyceride oil standard breakfast, caprylic triglyceride high fat breakfast, AC-1204
2522431|NCT02747602|Experimental|Group CAB|caprylic triglyceride high fat breakfast, AC-1204, caprylic triglyceride oil standard breakfast
2522492|NCT02747199|Active Comparator|Coronary artery implanted with SYNERGY stent|One of the blocked coronary artery of a patient will received SYNERGY stent
2522496|NCT02747199|Active Comparator|Coronary artery implanted with ABSORB scaffold|Another blocked coronary artery of the same patient will received ABSORB scaffold
2522541|NCT02746731|Experimental|Prehabilitation|'Cardiorespiratory and resistance training.
2522542|NCT02746731|Active Comparator|Reference|Usual care.
2522628|NCT02745990|Experimental|EPO group|In EPO group, The recombinant human erythropoietin (rhEPO) will be given by 500 U/kg/dose intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
2522634|NCT02745990|Placebo Comparator|Normal saline|Normal saline is administered the same volume with EPO, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
2522718|NCT02745769|Experimental|Ramucirumab + Merestinib|Ramucirumab intravenously (IV) on day 1 and day 15 in combination with merestinib orally once a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.
2522723|NCT02745769|Experimental|Ramucirumab + Abemaciclib|"Ramucirumab IV on day 1 and day 15 in combination with abemaciclib orally twice a day over a 28 day cycle. Participants receiving benefit may continue until disease progression.~On June 21st 2017 the Ramucirumab + Abemaciclib arm was cancelled with no participants enrolled."
2522784|NCT02745132|Other|Cognitive evaluation in HCV patients|"Neuropsychological evaluation and Brain MRI~Intervention: The only intervention to be carried out along the study will consist of complete neuro-psychological tests and MRI studies performed at different times.~Chronic HCV patients who are going to be treated with new DAAs according to current guidelines will be studied: A neuro-psychological battery of tests and brain MRI studies will be performed at different times before and after the end of the treatment. The participation in the study will not influence neither the indication to treat nor the treatment used.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines"
2522827|NCT02744664|Experimental|Experimental|The subject receive Cryotherapy and than receive Icotinib 125mg, 3 times a day, orally administered until disease progression or intolerable toxicity reaction.
2522871|NCT02744404||POC EID|Point of Care Early Infant Diagnosis qualitative technologies (Alere q) will be implemented. Sample collection and testing will happen in the same location within the health care facility.
2522873|NCT02744404||Laboratory-based testing|Conventional laboratory-based testing using the Abbott m2000 technology will continue to be used per standard of care in Malawi. Dried blood spot samples will be collected at health care facilities and transported within the national network to centralized laboratories for testing.
2522929|NCT02744170|Experimental|COPD patients with delivery order 1, 2, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2522938|NCT02744170|Experimental|COPD patients with delivery order 2,3, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2522942|NCT02744170|Experimental|COPD patients with delivery order 3, 2, 1|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2522944|NCT02744170|Experimental|COPD patients with delivery order 1, 3, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2523099|NCT02743000||Women ages 18-35|Women ages 18-35 who do and do not engage in binge eating will be included in the study
3199237|NCT00878306|Experimental|Disulfiram + Efavirenz|Efavirenz alone, then in addition with Disulfiram
3199238|NCT00878306|Experimental|Disulfiram + Atazanavir|Atazanavir alone, then in addition with Disulfiram
2522060|NCT02750072|Experimental|Semi-extended suprapatellar approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed suprapatellar percutaneous instrumentation (patellofemoral protection sleeve).
2522107|NCT02749526|Experimental|Endostar combined with MPFC|"Chemotherapy regimens (er degree + mPFC) :~Endostar:~degrees 30 mg civ24h d0-6;~Liposo:~135 mg/m2 D1; cisplatin: D1-3, 25 mg/m2~Gimeracil and Oteracil Potassium (Tegafur):~(40 mg bid Tegafur), D1-14. A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy."
2522159|NCT02749214||Parkinson's Disease (PD)|Participant's with Parkinson's Disease will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
2522161|NCT02749214||Healthy Control|Age and gender-matched healthy controls will provide peripheral blood and breath samples. Participants will also be asked to complete a neurologic exam and questionnaires.
2522214|NCT02748876|Experimental|His-Ventricular (HV)-optimised|His-Ventricular (HV) optimised atrioventricular delay
2522218|NCT02748876|No Intervention|Non-optimised|Standard atrioventricular delay
2522289|NCT02748577|Experimental|Migraine|Participants with migraines will complete one study visit where they will complete several questionnaires and will also complete Quantitative Sensory Testing (QST) Pain Measurements. They must be migraine-free during the visit and no migraine within 48 hrs of study visit
2522292|NCT02748577|Active Comparator|Healthy Controls|Healthy Controls will complete one study visit where they will complete several questionnaires and will complete Quantitative Sensory Testing (QST) Pain Measurements.
3199239|NCT00878306|Experimental|Disulfiram + Ritonavir|Ritonavir alone, then in addition with Disulfiram
3199240|NCT00878319|Active Comparator|Surgical|Surgical intervention: open reduction and internal fixation (ORIF)
2522390|NCT02747719|Experimental|Light and exercise|Exposure to light with exercise
2522467|NCT02747524|Experimental|Vita Mamba|Nutrient fortified peanut butter paste for 26 weeks.
2522468|NCT02747524|No Intervention|Control|
2522521|NCT02746900|Experimental|Cervical cerclage|After the woman is placed in the dorsal lithotomy position and the bladder is emptied with a urinary catheter to reduce the chance of bladder injury, surgical preparation with Betadine will be performed. Breisky retractors and Sims retractors will be used to exposure the entire cervix. Sponge ring forceps will be used to optimized visualization of the cervix and provide the necessary countertraction at the suture entry and exit sites. McDonald technique will be performed placing 4-6 bites circumferentially around the cervix. Only one stitch will be used. The suture will be places as high as feasible
2522526|NCT02746900|No Intervention|No intervention|Bed rest will be not recommended.
2522596|NCT02746367||MDD|Patients diagnosed with Major Depressive Disorder
2522598|NCT02746367||BPI|Patients diagnosed with bipolar I
2522599|NCT02746367||BPII|Patients diagnosed with bipolar II
2522623|NCT02746042|Experimental|Sinupret extract coated tablets|"Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.~There will be no dose change during the trial."
2522637|NCT02746042|Placebo Comparator|Placebo coated tablets|Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.
2522719|NCT02745496|Other|TRUS Biopsy|Standard of Care Treatment
2522724|NCT02745496|Other|TRUS/FUSION Biopsy|Interventional Treatment
2522773|NCT02745171|No Intervention|Control group|This group will be evaluated after three months there will be a reassessment, in this case the participating subjects do not perform any kind of therapy.
2522777|NCT02745171|Experimental|Experimental group|There will be an initial evaluation, after a month of physical therapy at the end of the protocol, and twice more after the protocol, both interval a month.
2522818|NCT02744807||non-Chronic endometritis|patients with intrauterine adhesion only
2522820|NCT02744807||Chronic endometritis|patients with intrauterine adhesion as well as Chronic endometritis
2522911|NCT02744495|Experimental|postoperative nausea and vomiting risk factors|Preoperative collection of postoperative nausea and vomiting risk factors available for practicians.
2522912|NCT02744495|No Intervention|control|No prophylaxis whatever risk score is. Postoperative nausea and vomiting risk factors not available for practicians.
2522957|NCT02743910||Stage II-III breast cancer|Up to 229 newly diagnosed stage II-III invasive HER2-positive or triple-negative breast cancer patients planning neoadjuvant therapy (NAT) will be enrolled. ptDNA blood samples as well as a representative tumor tissue sample from both the diagnostic and surgical procedure (if available) will be collected.
2523004|NCT02743598|Experimental|Liraglutide|
2523037|NCT02743325|Active Comparator|ALARA protocol|SVT ablation by ALARA protocol
2523041|NCT02743325|Active Comparator|current treatment|SVT ablation by conventional protocol
2523087|NCT02743104|Active Comparator|Ketamine for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to ketamine as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
2523088|NCT02743104|Active Comparator|Propofol for procedural sedation|"All patients will be sedated according to a written protocol which includes intravenous administration of midazolam and atropine. In addition, local anesthesia will be performed using lidocaine 1% sprayed once just above the vocal cords, and again at the level of the carina. Lidocaine doses are limited to a maximum total dose of 5mg/kg.~This study group will be exposed to propofol as the main drug for sedation, as an initial bolus of 1-2 mg/kg initially and then titrated by additional doses of 1mg/kg per dose."
2523145|NCT02742727|Experimental|CAR-pNK Cell immunotherapy|Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
2523255|NCT02741960|Experimental|metformin|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
3199241|NCT00878319|Active Comparator|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
3199242|NCT00878332||partially edentulous patients|"Adult (post growth period) patients who are interested in fixed dental rehabilitation (non- removable denture) by dental implants.~Partially edentulous patients with insufficient bone height for dental implant insertion."
2522353|NCT02748161|Active Comparator|DEB-TACE: Standard Endhole Catheter|Subjects will undergo DEB-TACE using a standard endhole catheter.
2522357|NCT02748161|Active Comparator|DEB-TACE: Surefire Infusion System|Subjects will undergo DEB-TACE using the Surefire Infusion System.
2522399|NCT02747706|Experimental|Parent Mentoring|1-on-1, phone, SMS/text, and smartphone-based parent-to-parent mentoring.
2522403|NCT02747706|No Intervention|Usual Care|No intervention through study.
2522509|NCT02747459|Experimental|SSS Intervention|Sensory Supported Swimming-eight, 30 minute lessons
3199243|NCT00878345|Active Comparator|1|Dexmedetomidine sedation protocol
3199244|NCT00878345|Active Comparator|2|Pentobarbital sedation protocol
2522643|NCT02746003|Other|Managed Aquifer Recharge water|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control at different times.
2522645|NCT02746003|Other|Control|All the study population will receive the intervention by a random allocation over the study period. The study participants will be in both intervention and control arms at different times.
3199245|NCT00878358|Active Comparator|Physiotherapy|
3199246|NCT00878358|Experimental|Hydrotherapy|
3199247|NCT00878371|Other|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
2522751|NCT02745067|Other|Enhanced cognitive behavioral therapy|Enhanced cognitive behavioral therapy (CBT-E) for eating disorders
2522814|NCT02744989|Experimental|Active tDCS|Stimulation will be performed using an tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl). The anode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex, assumed to correspond to a region including Brodmann's Areas (BA) 8, 9, 10, and 46, depending on the patient). The cathode will be located over a point midway between T3 and P3 (left temporo-parietal junction, assumed to correspond to a region including BA 22, 39, 40, 41, and 42, depending on the patient). The stimulation level will be set at 2 mA for 20 minutes during stimulation sessions twice a day for 5 consecutive weekdays. The twice daily sessions will be separated by at least 2 hours.
2522815|NCT02744989|Sham Comparator|Sham tDCS|
2522895|NCT02744469||New patients|''New tuberculosis patients'' are patients just diagnosed for tuberculosis, and who were never treated for tuberculosis or who are treated for less than 1 month. In total, 1192 new patients will be recruited.
2522897|NCT02744469||Retreatment patients|''Retreatment tuberculosis patients'' are patients just diagnosed for tuberculosis and who were previously treated for tuberculosis (for a duration of 1 month at least). This group includes: patients with treatment relapse, failure and patients who return after default. In total, 298 retreatment patients will be recruited.
2522979|NCT02743832|Experimental|High-level tumor budding group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
2522988|NCT02743832|Active Comparator|High-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a high level.
2522990|NCT02743832|Experimental|Low-level group with CLND|Resection for primary lesion and cervical lymph node dissection(CLND) are performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
2522991|NCT02743832|Active Comparator|Low-level group without CLND|Only resection for primary lesion is performed in the early-stage oral squamous cell carcinoma which tumor budding is a low level.
2523131|NCT02742948|Active Comparator|preoperative antibiotic group|200 women will receive IV ceftriaxone (2g) 60 minutes before skin incision
2523135|NCT02742948|Active Comparator|early intraoperative antibiotic group|200 women will receive IV ceftriaxone (2g) immediately with skin incision
2523138|NCT02742948|Active Comparator|post cord clamping antibiotic group|200 women will receive IV ceftriaxone (2g) immediately after umbilical cord clamping
2523208|NCT02742402|Experimental|Observation|Clinical follow-up for at least 6-8 hours, after follow-up repeated laboratory tests and repeated clinical examination is done. Adult Appendicitis Score is calculated after observation to determine further actions. Observation is continued in patients with decreasing score. Patients with the same or higher score undergo diagnostic imaging (score 11-15) or laparoscopy (score 16 or higher). Diagnostic imaging is abdominal ultrasound first and if the result is inconclusive or negative for appendicitis abdominal computed tomography is done. Laparoscopic appendectomy is done for those patients with appendicitis in diagnostic imaging.
2523213|NCT02742402|Active Comparator|Diagnostic imaging|Patients undergo abdominal ultrasound and if the result is inconclusive or negative for appendicitis patients will have abdominal computed tomography. Laparoscopic appendectomy is done for patients with appendicitis in diagnostic imaging.
2523279|NCT02741869|Experimental|single arm|This is a single arm, open label study. Subjects who meet eligibility criteria will be treated with photodisinfection therapy (MRSAid™).
2523340|NCT02741492|Active Comparator|Block Group|Continuous Transversus Abdominis Plane Catheter
3199248|NCT00878384|Active Comparator|Rate control|Strategy of 'rate-control': acceptance of atrial fibrillation, and dose-adjusted drug therapy as needed to control ventricular rate.
3199249|NCT00878384|Active Comparator|Catheter Ablation|Strategy of 'rhythm control' by catheter ablation: patients will undergo catheter ablation with the intention of restoring sinus rhythm.
3199250|NCT00878397|Experimental|1|Free distribution of long lasting insecticide nets to school children and their younger siblings
3199251|NCT00878397|Experimental|2|No school-based delivery of long lasting insecticide nets in the first year, followed by free delivery in the second year
3199252|NCT00878449|Experimental|ABT-263 + etoposide/cisplatin|
2522090|NCT02749682||constipation & hernia group|The effect of constipation on study group whether there is a correlation between subgroups of operated patients on the view of direct and indirect hernias(Nyhuss classification).
2522091|NCT02749682||constipation & normal population|The level of constipation on normal population using constipation severity scale.
2522129|NCT02749422|Active Comparator|Healthy Subjects|
2522132|NCT02749422|Experimental|Temporal Lobe Epilepsy Patients|
2522165|NCT02749123|Active Comparator|Lidocaine5% v Lidocaine3.6%,Menthol1.25%|Daily patch Q12 followed by Q12 of no patch
2522167|NCT02749123|Placebo Comparator|Lidocaine 3.6%, menthol 1.25% v placebo|Daily patch Q12 followed by Q12 of no patch
3199253|NCT00878462|Experimental|Sequence 1|Subjects randomly assigned to this sequence receive in order: Treatment A, C, B, A, C, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3199254|NCT00878462|Experimental|Sequence 2|Subjects randomly assigned to this sequence receive in order: Treatment A, B, C, A, B, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3199255|NCT00878462|Experimental|Sequence 3|Subjects randomly assigned to this sequence receive in order: Treatment B, C, A, B, C, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3199256|NCT00878462|Experimental|Sequence 4|Subjects randomly assigned to this sequence receive in order: Treatment B, A, C, B, A, C. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
2522341|NCT02748174|Experimental|Episodic Migraine group|100 patients with chronic or episodic migraine
2522343|NCT02748174|Experimental|Chronic Migraine Group|100 patients with chronic or episodic migraine
2522346|NCT02748174|Experimental|Post concussive Headache Group|75 patients
3199257|NCT00878462|Experimental|Sequence 5|Subjects randomly assigned to this sequence receive in order: Treatment C, B, A, C, B, A. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
3199258|NCT00878462|Experimental|Sequence 6|Subjects randomly assigned to this sequence receive in order: Treatment C, A, B, C, A, B. Each treatment was one dose, and each patient received a dose in the morning and evening for 3 consecutive days.
2522459|NCT02747446|Experimental|Honey|added sugar: diet with 25% acacia honey
2522460|NCT02747446|Experimental|Fructose:glucose mixture|added sugar: Diet with 25% energy as a fructose:glucose mixture
2522461|NCT02747446|No Intervention|control|no intervention: Diet with 45% starch and no honey or added sugars
2522678|NCT02745873|Experimental|Arm A|Ascorbic Acid 250 mg in tablet form was used.
2522679|NCT02745873|Experimental|Arm B|Ascorbic Acid 500 mg in tablet form was used.
2522713|NCT02745561|Experimental|Chemoradiotherapy Arm|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy. Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
2522742|NCT02745236|Experimental|Nurse Practitioner Led-Care|"Nurse Practitioner (NP) Intervention Initial Visit and Interventions: An experienced nurse practitioner with extra atrial fibrillation (AF) management training will complete the initial assessment to determine a treatment plan based on current AF Guidelines. The NP will provide patient education on AF management.~Follow-up: Follow-up will occur at 3 and 6 months from baseline to evaluate the patient's response to treatment and will be modified as required based on AF symptoms, testing results and physical assessment.~A physician will be consulted for advanced specialty AF management or if a patient requires admission to hospital."
2522743|NCT02745236|Active Comparator|Cardiologist Led-Care|"Standard Care Initial Visit and Intervention: A general cardiologist will manage patients as per their usual practice.~Follow-up: As per the cardiologist's usual practice. The patient's care will remain with the family physician if no follow-up is required.~Follow-up: Follow-up will be determined as per the cardiologist's usual practice. If a follow-up appointment is required it will done in the cardiologist's own independent clinic. The patient's care will be referred back to the family physician if no follow-up is required."
2522802|NCT02744690|Experimental|MMC Injection|Intervention: At the intended surgical site and about 6mm from the limbus, 0.2ml of 0.2mg/ml of mitomycin-C (MMC) will be injected subconjunctivally before peritomy
2522803|NCT02744690|Active Comparator|MMC Sponge Application|Intervention: After peritomy, three half-sponges soaked in 0.2mg/ml mitomycin-C (MMC) will be placed posterior to the area of intended filtration. After 2 minutes, the sponges will be removed
2522856|NCT02744625|Active Comparator|Shock lower Mean Arterial Pressure (MAP)|Vasopressor-dependent treated to lower MAP (65 mmHg)
2522861|NCT02744625|Experimental|Shock higher MAP|Vasopressor-dependent treated to higher MAP (75 mmHg)
2522865|NCT02744625|No Intervention|Healthy participant awake|Healthy participant awake
2522866|NCT02744625|Experimental|Healthy participant sedated|Healthy participant Under light sedation
2522920|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Contrast Imaging|Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
2522998|NCT02743806|Experimental|Vedolizumab 300 mg|Vedolizumab 300 mg, intravenous (IV) infusion, once every 8 weeks until vedolizumab is commercially available. (Per MM approval, dosing regimen may be modified per physician's decision).
2523103|NCT02742792|Experimental|Resistance training|Resistance training, twice a week during 12 weeks.
2523104|NCT02742792|Other|Advice on lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
2523156|NCT02742597|Active Comparator|Group A|Intervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting
2523159|NCT02742597|No Intervention|Group C|Control group (n = 77)
2522109|NCT02749539|Experimental|Kinesio tape|The first 3 kinesio tape application was inhibition technique for supraspinatus, deltoid and teres minor muscles. the fourth Kinesio tape was mechanical correction for the shoulder joint. in addition to active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
2522112|NCT02749539|Active Comparator|Physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
2522164|NCT02749188|Other|bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes.
3199259|NCT00878475||Group with obstructive causes of dyspnea|Criteria for clinical assessment of severe asthma (diffuse polyphonic bilateral and particular expiratory wheezes, chest tightness, shortness of breath, using accessory muscles of breathing, signs of hyperinflation, atopic condition, personal or family history of asthma, tachypnea, previous asthma and asthma medications, and the value of modified Boston criteria for HF ≤ 5) and criteria for chronic obstructive pulmonary disease (COPD) exacerbation (history of COPD, COPD medications, cough, worsening dyspnea, increased sputum production and volume, increased sputum purulence, rhonchi and rales, modified Boston criteria for HF ≤ 5)
3199260|NCT00878475||Heart failure group|The investigators protocol for clinical assessment of HF-related acute dyspnea (the prehospital clinical assessment for HF) was designed based on Boston (13) and Framingham criteria for HF (14) (Table 1). The investigators did not use certain criteria from the original protocols, which were not available in the prehospital setting (e.g., chest radiography).
3199261|NCT00878514|Experimental|Alprazolam|Alprazolam 1 mg tablet
2522395|NCT02747836||Healthy Volunteers|Ultrasound of the wrist
2522401|NCT02747836||Participants with Carpal Tunnel Syndrome|Ultrasound of the wrist
2522478|NCT02747472|Placebo Comparator|Placebo|Infusion of saline
2522483|NCT02747472|Active Comparator|GIP(1-42)|Infusion of agonist, GIP(1-42)
2522488|NCT02747472|Experimental|GIP-A|Infusion of GIP-A alone
2522490|NCT02747472|Experimental|GIP-A + GIP(1-42)|Infusion of GIP-A and GIP(1-42)
2522557|NCT02746692|Experimental|Intervention|
2522558|NCT02746692|Active Comparator|Comparison|
2522600|NCT02746354|Experimental|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
2522601|NCT02746354|No Intervention|Usual care|
2522625|NCT02746133||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
2522686|NCT02745821|Experimental|Coronary physiology|Non-target and target vessels of patients with diabetes mellitus referred for PCI will be assessed for FFR, CFR and IMR. Intravenous adenosine at 140 micrograms/kg/min will be used to induce maximal hyperemia.
2522835|NCT02744651|Active Comparator|EUS-FNA|All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
2522841|NCT02744651|Active Comparator|EUS-Endodrill biopsy|All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.
2522883|NCT02744378|Active Comparator|Clobetasol Group|clobetasol propionate (0.05%) cream
2522885|NCT02744378|Active Comparator|Tacrolimus Group|tacrolimus (0.1%) cream
2522940|NCT02744131|Active Comparator|OCP|Arm 1: oral contraceptive pill, combination pill of ethyl estradiol 20 micro gram with Cyproterone acetate.
2522943|NCT02744131|Active Comparator|Metformin|Arm 2: Metformin . Oral insulin sensitising drug in the dose of 1500gms daily.
2522976|NCT02743715|Active Comparator|Active tDCS|Electric current of 2mA delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
2522985|NCT02743715|Sham Comparator|Sham tDCS|In this group, the cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
3199262|NCT00878514|Active Comparator|Xanax|Xanax 1 mg tablet
2523182|NCT02742311|Active Comparator|transforaminal endoscopic discectomy|
2523183|NCT02742311|Active Comparator|interlaminar endoscopic discectomy|
2523278|NCT02741739|Experimental|Reference Drug|REGN1033 Reference Formulation
2523285|NCT02741739|Experimental|Test Drug|REGN1033 Test Formulation
2523319|NCT02741479|Experimental|K Tape Group|
2523320|NCT02741479|Active Comparator|Sham Group|
2523321|NCT02741479|Experimental|No Tape|
2523371|NCT02741167||CRS and HIPEC|Patients subjected to cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) due to primary or secondary peritoneal malignancy
2523390|NCT02740829|Placebo Comparator|Intranasal placebo|placebo comparator
2523395|NCT02740829|Experimental|Intranasal glucagon|active intervention
2523555|NCT02740023|Active Comparator|Phonak Audéo V90-13|The Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
2523560|NCT02740023|Experimental|Successor of Phonak Audéo V90-13|The successor of Phonak Audéo V90-13 will be fitted to the participants individual hearing loss.
2523596|NCT02739737|Experimental|Blinded Reviewers|Subjects receiving randomized sham manuscript for review
2523604|NCT02739737|Experimental|Unblinded Reviewers|Subjects receiving randomized sham manuscript for review
2523660|NCT02739347|Experimental|Active Stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
2523664|NCT02739347|Sham Comparator|Sham Stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
2523940|NCT02737280|Experimental|High flow oxygen therapy|High flow nasal cannula oxygen therapy with Airvo (TM, Fisher & Paykel Healthcare) device
2522118|NCT02749591|Experimental|Mirror therapy (MT)|After injection with Botulinum Toxin Type A, a schedule of mirror therapy appointments will be established.The MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
2522124|NCT02749591|Active Comparator|Control Intervention (CI)|After injection with Botulinum Toxin Type A, a schedule of control intervention appointments will be established.The CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
2522173|NCT02748993|Experimental|PAC-14028 Cream 0.1%|PAC-14028 Cream 0.1%, Twice daily for 4 weeks
2522176|NCT02748993|Experimental|PAC-14028 Cream 0.3%|PAC-14028 Cream 0.3%, Twice daily for 4 weeks
2522180|NCT02748993|Experimental|PAC-14028 Cream 1.0%|PAC-14028 Cream 1.0%, Twice daily for 4 weeks
2522185|NCT02748993|Placebo Comparator|PAC-14028 Cream Vehicle|PAC-14028 Cream Vehicle, twice daily for 4 weeks
2522236|NCT02748733|Active Comparator|Adapted double mini PET|"PET = Peritoneal Equilibration Test, a test routinely performed to measure peritoneal transport rates of solutes and water in peritoneal dialysis patients. To this end the routinely administered dialysis fluid is infused into the peritoneal cavity. The test will be modified (adapted):~A short, small cycle (0.6 mL/m² BSA, 30 min) followed by a long, large cycle (1.4 mL/m², 120 min) will be performed in each patient and compared to a standard double mini PET."
2522241|NCT02748733|Placebo Comparator|Standard double mini PET|The Standard double mini PET consists of two identical cycles (fill volume 1 L/m², 75 min of dwell time)
2522325|NCT02748460||Patients treated with Esmya|Any patient who was confirmed as receiving one dose of Esmya
3199263|NCT00878527|Experimental|Treatment with the pump|Treatment with the CircuLite Synergy Pocket Circulatory Assist Device
3199264|NCT00878540|Experimental|mirtazapine|
2522479|NCT02747069||NICU electronic stethoscope|Neonatal patients of any gestation admitted to the neonatal intensive care unit (NICU) and undergoing routine monitoring with ECG and pulse oximetry Heart rate will be evaluated using an electronic stethoscope
2522484|NCT02747069||Newborns <32 weeks and ECG|Neonatal patients <32 weeks gestation Heart rate will be assessed at the time of delivery with both an electronic stethoscope and ECG using a pre placed lead system
2522559|NCT02746718|Other|Restrictive Respiratory Failure|A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology
3199265|NCT00878566|Active Comparator|Usual Care|
3199266|NCT00878566|Experimental|Enhanced pharmacist care|
3199267|NCT00878579|Experimental|PDS System|
3199268|NCT00878579|Active Comparator|Fusion|
3199269|NCT00878592|No Intervention|Control group|The first group (Group 1) will include the control subjects. They will receive one session of dietary and behavioral education.
3199270|NCT00878592|Experimental|Dietary and Lifestyle counseling|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
3199271|NCT00878618|Experimental|HAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with heavy breakfast
2522735|NCT02745470|Experimental|Lixisenatide injection|intervention : Lyxumia® pen injection 10 microgram (Lixisenatide) subcutaneous injection 30 minutes before functional MRI
2522736|NCT02745470|Placebo Comparator|Normal saline|control : normal saline 0.3 cc subcutaneous injection before functional MRI
2522753|NCT02745106|Experimental|PADN treatment|"Procedure/Surgery: Right heart catheterization, Radiofrequency pulmonary artery denervation using following devices:~Ablation catheter~Carto 3, Carto RMT, Stereotaxis~Swan-Ganz catheter"
2522760|NCT02745106|Sham Comparator|Control (Sham)|"Procedure: Right heart catheterization~Using following device:~- Swan-Ganz catheter"
2522836|NCT02744872|Active Comparator|Felodipine|Tablet Felodipin 10 mg x 1 daily
2522846|NCT02744872|Placebo Comparator|Placebo|Identical placebo once daily
2522870|NCT02744365||Prediction Group|The women recruited in the biobank through the Prediction Study (NCT02189148) are low-risk pregnant women between 11 and 13 6/7 weeks of gestation (N=7600 maximum).
2522874|NCT02744365||PEARL Group|"The women recruited in the biobank through the PEARL Study (NCT02379832) are :~low-risk pregnant women between 11 and 13 6/7 weeks of gestation (controls, N=45)~pregnant women with diagnosis of preeclampsia between 20 and 41 6/7 weeks of gestation (cases, N=45)"
2522876|NCT02744365||GAP Group|The women recruited in the biobank through the GAP Trial (NCT02280031) are women pregnant with twins between 11 3/7 and 13 6/7 weeks of gestation(N=50 maximum) randomized for placebo or aspirin.
2522878|NCT02744365||PREDICTION 2 Group|The women recruited in the biobank through the Prediction-2 Study (NCT03067298) are nulliparous pregnant women between 14 and 15 6/7 weeks of gestation (N=1000 maximum).
2522879|NCT02744365||HAUPE Study|Women that are at risk of pre-eclampsia and great obstetrical syndroms (elevated maternal age, invitro fertilization, chronic disease) (N=60) and a control group not at risk (N=60)
2522931|NCT02744144||Non-infection|Patients without clinical infection or positive wound culture
2522937|NCT02744144||Infection|Patients with clinical infection and positive wound culture
2522960|NCT02743767|No Intervention|Before interventions|Only observational activity for this arm, to record the frequency and triggering factors of airway complications during general anaesthesia.
2522965|NCT02743767|Experimental|After interventions|After introducing five different treating adaptations in airway management we want to record the frequency of airway complications during general anaesthesia.
2523036|NCT02743299|Experimental|CPR simulation|CPR simulation with and without ventilator
2523084|NCT02743130|Experimental|Blackcurrant nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
2523085|NCT02743130|Experimental|Lingonberry nectar|Contains 17.5 g glucose and 17.5 g fructose representing 35 g completely inverted sucrose
2522120|NCT02749292|Active Comparator|B cell reconstitution|Subjects will no longer receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months for B cell return. Once peripheral B cells rise to ≥ 10cells/mm3 they will receive rituximab 1000 mg IV x 2 (doses spaced approx. 2-3 weeks apart). Subsequent dosing will be again based on B cell return (≥ 10 B cells/mm3), with patients seen in clinic and B cells monitored every 3 months.
2522122|NCT02749292|Active Comparator|Serologic ANCA flare|Subjects will not receive regularly-scheduled every six-month doses of rituximab (1000mg IV) and will instead be monitored every three months in clinic. Re-dosing will occur once the subject's ANCA titer has risen above the predetermined treatment value (MPO treatment value defined as a 5-fold rise from baseline and a level greater than 4 times the cutoff value for the assay; PR3 treatment value defined as a 4-fold rise from baseline and a level greater than 2-fold above the cutoff for the assay). Subjects who meet this criteria will then be re-dosed with rituximab 1000 mg IV x2 (spaced 2-3 weeks apart). If the ANCA titer remains 2-fold above baseline and above a specified threshold (the cutoff value of the assay for PR3 and 4 times the cutoff value for MPO), subjects will then receive rituximab 1000mg IV every 6 months x 2 doses and a new ANCA titer baseline will be established. The cycle will then re-start.
2522171|NCT02749097|Experimental|Cohort 1|Single oral dose of 10 mg SHR0534 or matching placebo
2522172|NCT02749097|Experimental|Cohort 2|Single oral dose of 25 mg SHR0534 or matching placebo
2522175|NCT02749097|Experimental|Cohort 3|Single oral dose of 50 mg SHR0534 or matching placebo
2522178|NCT02749097|Experimental|Cohort 4|Single oral dose of 100 mg SHR0534 or matching placebo
2522181|NCT02749097|Experimental|Cohort 5|Single oral dose of 200 mg SHR0534 or matching placebo
2522221|NCT02748720|Experimental|RFM Visible|Patients will be randomize in other Group 1, where these parameters (from the device Respiratory Function Monitor) of lung mechanics would be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). We adapt or change PIP using visible TVe.
2522226|NCT02748720|No Intervention|RFM No Visible|Patients will be randomize in a Group 2, where the parameters of TVe and respiratory flow would not be visible by the rescuer (the usual parameters of PIP and PEEP will be visible). Always, in both groups, current recommendations ventilation measures included in cardiopulmonary resuscitation of newborns of the Spanish Society of Neonatology, based on international recommendations (1-3.5) apply. In turn, the results analyzed in two subgroups between 24 and 27 + 6 weeks gestational age and 28 to 32 + 6 weeks
2522344|NCT02748551|Experimental|Laparoscopic surgery|Traditional open procedure for patient with locally advanced gastric cancer
2522348|NCT02748551|Active Comparator|Open surgery|Minimum invasive procedure (laparoscopic) for patient with locally advanced gastric cancer
2522411|NCT02747849|Placebo Comparator|Hand neuromodulation|The stimulation characteristics for this arm include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for finger twitching - or the intensity that the subject feels comfortable with. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
2522416|NCT02747849|Active Comparator|Foot Neuromodulation|The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will be asked to wear socks on their foot to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a minimum of 60 minutes prior to bedtime for two weeks, or longer if they can tolerate it, have the time, and accurately record the total duration. Stimulation will be performed during the first, second, and third weeks of the study.
2522439|NCT02747394|Experimental|Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of adaptive Cogmed
2522440|NCT02747394|Other|Non-Adaptive Cogmed|5 days per week for 5-6 weeks of parent aided visual working memory training, consisting of non-adaptive Cogmed
2522453|NCT02747173||RCC patients with bone metastases|Patients will receive the standard TKI treatment for first line treatment naive metastatic RCC. Sunitinib or pazopanib as decided by the investigator.
2522502|NCT02747017||CDI patients|Adults with a first episode of CDI within 2 years after solid-organ or stem-cell transplant.
2522563|NCT02746666|Experimental|Intervention|Under pharmacist's behavioral intervention
2522566|NCT02746666|No Intervention|Control|No pharmacist's behavioral intervention
2522607|NCT02746328|Experimental|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
2522647|NCT02745951|Experimental|Heliox|Cardioplegia enriched with a 70:30 (Helium:Oxygen) Heliox mixture while the patient is on cardiopulmonary bypass
2522651|NCT02745951|Active Comparator|Standard of care|Cardioplegia enriched with a Nitrogen and Oxygen mixture while the patient is on cardiopulmonary bypass
2522683|NCT02745639|Experimental|VMAT-SIB + XELOX|"A VMAT-SIB technique was used. Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and Organs at risks.~The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment."
2522765|NCT02745444|Other|low-calorie formula diet|Donor taking low-calorie formula diet, 50% of basal energy rate, individually calculated with Mifflin-St. Jeor formula.
2522771|NCT02745444|No Intervention|no diet|Donor ingesting food as usual.
2522775|NCT02745444|Other|protein-restricted diet|Donor taking protein-restricted diet according to diet plans of clinical dietetics of University Hospital of Cologne, with unchanged calorie supply, individually calculated with Mifflin-St. Jeor formula.
2522780|NCT02745444|No Intervention|Normal protein supply|Donor taking same dishes as protein-restricted diet group but with customary protein levels, with unchanged calorie supply.
3199272|NCT00878618|Experimental|HBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with heavy breakfast
3199273|NCT00878618|Experimental|LAB|AZD0837 test- (in session 1) and reference- (in session 2) formulation with light breakfast
2522130|NCT02749500|Experimental|OT + Device-assisted therapy|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy. The m2 BAT will enable repeated movement of the affected body part without the help of a therapist, providing the opportunity to maintain range-of motion in the affected limb to limit spasticity, contracture and the ensuing deformity, a major goal of rehabilitation therapy and produces movement in the affected limb from activating the patient's own brain, rather than from being acted on by an external powered source such as a robot.
2522170|NCT02749084|Experimental|T reg DLI|"This is a INTERVENTIONAL TRANSPLANTATION STUDY WITHOUT DRUGS.~The INTERVENTION is represented by the INFUSION of DONOR T REGULATORY CELL-ENRICHED LYMPHOCYTES to PATIENTS suffering from REFRACTORY CHRONIC GVHD after ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION.~The study is single center single arm open label and includes a DOSE ESCALATION phase followed by an EXTENDED PHASE with the MAXIMUM TOLERATED DOSE (MTD).~During the dose escalation phase each patient will receive three doses of purified donor T reg cells each administered intravenously 1 month apart. Dose levels of purified Tregs will be 5x10e5/kg, 1x10e6/kg and 2x10e6/kg, resulting in three doses of 1.7x10e5/kg, 3.3x10e5/kg and 6.6x10e5/kg, respectively.~In the dose escalation study at least 9 patients will be required depending on the occurrence of adverse events during the study).~Patients in the MTD study should be about 10, according to Fleming."
2522224|NCT02748811|No Intervention|Control group|The control group receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change in treatment or progression. If the patient has other health problems, those issues will be assessed either by the oncologist or by the general practitioner. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
2522232|NCT02748811|Active Comparator|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. They will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
2522279|NCT02748538||Face Down|To posture in the face down position for the first 24 hours following surgery.
2522281|NCT02748538||Position to Support the Break|The head is positioned so that the retinal breaks (which caused the retinal detachment) are positioned at the highest point of the eye and well supported by the intra-ocular gas bubble left within the eye at the completion of surgery.
2522307|NCT02748265|Other|Inhaled Epoprostenol, phenylephrine, sevoflurane|Inhaled Epoprostenol (Flolan), phenylephrine, volatile anesthesia maintenance (Sevoflurane)
2522315|NCT02748265|Other|Inhaled Epoprostenol phenylephrine & Propofol|Inhaled Epoprostenol (Flolan), phenylephrine and intravenous anesthesia maintenance (Propofol)
2522387|NCT02747992||PECS 0|receiving paravertebral block
2522388|NCT02747992||PECS 1|receiving paravertebral block and blocks targeting pectoral musculature
3199274|NCT00878618|Experimental|LBA|AZD0837 reference- (in session 1) and test- (in session 2) formulation with light breakfast
3199275|NCT00878631|Active Comparator|1 Normal Saline|infusion of 250 ccs of Normal Saline within 4 hours of the accident
2522469|NCT02747121|Other|Control before intervention|External inspection of health services. The intervention is external inspection of sepsis detection and treatment. The intervention is delivered on the organizational Level. Patient are not assigned to the intervention. The intervention is rolled out sequentially to 24 hospitals. We collect data at base line, before the inspections and 8 and 14 month after the inspections. The first arm is the Control period before the inspections.
2522470|NCT02747121|Experimental|Intervention|External inspection of health services. We compare the effect measures before and after the inspection. The intervention arm is data after the hospitals have received the inspection.
2522530|NCT02746861|Experimental|Diabetes Self-Management Support (DSMS)|Patient receives 6-months of DSMS while receiving support from a trained peer mentor (Peer-supported DSMS).
2522533|NCT02746861|No Intervention|Usual Care|Patient continues to receive usual care.
2522553|NCT02746562|Experimental|Freeze all|Transfer of a frozen, thawed blastocyst in a subsequent natural menstrual cycle
2522555|NCT02746562|No Intervention|Fresh embryo transfer|Standard procedure
2522632|NCT02746016|Experimental|Infant Formula supplemented with Oligosaccharides|Ready to feed infant formula ; Feed ad libitum.
2522680|NCT02745704|Experimental|PEG-IFN group|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 48 weeks.
2522682|NCT02745704|No Intervention|NAs group|Patients do not need to change their NAs treatment.
2522796|NCT02744859|Experimental|Calorie Label|"Labels will read [lower calorie bound] - [upper calorie bound] calories per container. 2,000 calories a day is used for general nutrition advice but calorie needs vary."
2522797|NCT02744859|Experimental|Warning Label|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay."
2522798|NCT02744859|Experimental|Warning Label with Graphics|"Labels will read WARNING: Drinking beverages with added sugar(s) contributes to obesity, diabetes, and tooth decay. These labels will also have graphic depictions of each health condition above the corresponding text."
2522799|NCT02744859|No Intervention|No label|We will also have a condition where no labels are presented-- business as usual.
2522849|NCT02744638|Experimental|probiotic yoghurt & Arilin|probiotic yoghurt, 2 units (125 g), containing living strains of L.crispatus, L.gasseri, L.rhamnosus, L.jensenii, each in a concentration of 1 x 107 CFU/ml product for 4 weeks Two yoghurts are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
2522850|NCT02744638|Placebo Comparator|chemically acidified milk & Arilin|chemically (H3PO4) acidified milk (125g) without bacterial strains. Two products are consumed every day for 28 days. 2 tablets Metronidazol 500mg daily for 7 days
2522945|NCT02744170|Experimental|COPD patients with delivery order 2, 1, 3|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2523977|NCT02736942|Experimental|Transanal|TaTME
2522182|NCT02749032|Active Comparator|Sitagliptin - stratum diet/exercise|"The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2522186|NCT02749032|Active Comparator|Sitagliptin - stratum metformin|"In patients treated with metformin, sitagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening.~Mixed meal test were performed in the morning after an overnight fast."
2522188|NCT02749032|Placebo Comparator|Placebo - stratum diet/exercise|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2522189|NCT02749032|Placebo Comparator|Placebo - stratum metformin|"Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).~Mixed meal test were performed in the morning after an overnight fast."
2522258|NCT02748668||ECMO|No intervention. Blood specimen collection.
2522264|NCT02748668||Control|No intervention. Blood specimen collection.
2522323|NCT02748447|Experimental|A-FiO2|24 hours in automated FiO2 adjustment to maintain SpO2 within a target range
2522327|NCT02748447|No Intervention|M-FiO2|24 hours in manual adjustment of FiO2 to maintain SpO2 within a target range
3173823|NCT00616369||2|"II:~Group 2: After signing a consent form, these participants will have a 12mL (less than 3 teaspoons) blood sample drawn at baseline, at 3-4 month, at 6-8 month, at 12 month, and at 24 month visits. With each disease therapy change, the blood draws (12mL samples) will begin again at baseline and continue through the 3-4, 6-8, 12, and 24 month visits."
3173824|NCT00616382|Experimental|Stepwise Indo|Stepwise escalating doses of indomethacin, until ductal closure or maximum of 1 mg/kg/dose.
2522485|NCT02747095|Experimental|Spectral CT image|Interventions: IQon Spectral CT
2522562|NCT02746796|Experimental|ONO-4538 + SOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (BSA) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 14 days, followed by 7 days off Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2522564|NCT02746796|Experimental|ONO-4538 + CapeOX Therapy Cohort (Part 1)|"ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Capecitabine 1200 - 2100 mg bid orally in 14 days, followed by 7 days off. Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2522567|NCT02746796|Experimental|ONO-4538 + chemotherapy group (Part 2)|"With regard to the ONO-4538 + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~ONO-4538 360 mg solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2522570|NCT02746796|Placebo Comparator|Placebo + Chemotherapy group (Part 2)|"With regard to the placebo + chemotherapy group, either SOX therapy or CapeOX therapy will be selected as the chemotherapy by the investigator or the subinvestigator, taking into account the condition of each subject.~Placebo solution intravenously for 30 min in every 3 weeks. Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.~Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid or Capecitabine 1000 mg/ m2 (body surface area) bid orally in 14 days, followed by 7 days off.~Each drug will be continued until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends."
2522728|NCT02745509|Experimental|Extensive Intraoperative Peritoneal Lavage|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles), followed by complete aspiration of the fluid . The abdomen will be closed as per standard.
2522731|NCT02745509|No Intervention|Standard Treatment|Gastrectomy with D2 lymphadenectomy is performed. The peritoneal lavage will be done < 3 cycles with 3 liters or less of warmed normal saline. The abdomen will be closed as per standard.
3199276|NCT00878631|Experimental|2 - hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
3199277|NCT00878657|Experimental|Radiotherapy plus gemcitabine|"Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy"
2523005|NCT02743546|Experimental|Dose Optimization:Participant with Certain B-Cell Malignancies|Participants with certain B-cell malignancies (diffuse large B-cell lymphoma [DLBCL], mantle cell lymphoma [MCL], or follicular lymphoma [FL]) will receive rising doses of intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met. Dose escalation will continue until the recommended phase 2 dose or maximum tolerated dose is reached.
2523008|NCT02743546|Experimental|Dose Expansion: Participants with DLBCL|Participants with DLBCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2523126|NCT02742740|No Intervention|Control|Standard of care for chemotherapy treatment.
3199278|NCT00878683|Experimental|1|Device and standard catheter
3199279|NCT00878683|No Intervention|2|Standard catheter
3199280|NCT00878696||Tinnitus|Tinnitus patients
3199281|NCT00878735|Experimental|1|Zen meditation
2522191|NCT02748980||Non- obstructive coronary artery disease, non- diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed without diabetes.
2522192|NCT02748980||Non- obstructive coronary artery disease, diabetic|Clinical evidences such as Holter, Treadmill exercise test and cardiac ECT support myocardial ischemia. CAG showed 20%-70% arterial stenosis. Patients are diagnosed with type 2 diabetes.
2522216|NCT02748759|Active Comparator|EXP 1: Manual mobilization / CPM|Patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist. After a pause of 5 minutes, the patient was collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension.
2522219|NCT02748759|Active Comparator|EXP 2: CPM / Manual mobilization|Patients were collocated in a commercially available CPM device (Kinetec Advanced Prima) and received 15 repetitions of flexo-extension. After a pause of 5 minutes, patients were subjected to a manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist.
3199282|NCT00878735|No Intervention|2|No meditation (no intervention; keep regular activities) or a resting group (this group stays at the same place of the retreat group, but only to rest)
2522298|NCT02748187|Experimental|Intervention|Cognitive Behavioural Analysis System of Psychotherapy
2522364|NCT02748148|Experimental|Medication therapy management|Medication therapy management service that is enhanced by the incorporation of pharmacogenomics and medication risk mitigation factor technology
2522397|NCT02747758|Sham Comparator|Control|sham transcranial direct current stimulation (tDCS)
2522402|NCT02747758|Experimental|cathodal stimulation|cathodal transcranial direct current stimulation (tDCS)
2522410|NCT02747758|Experimental|anodal stimulation|anodal transcranial direct current stimulation (tDCS)
2522480|NCT02747368|Other|Wet age related macular degeneration|Ocusweep system is compared to results of conventional devices.
2522629|NCT02746380|Experimental|LBAL|Adalimumab
2522636|NCT02746380|Active Comparator|Humira®|Adalimumab
2522690|NCT02745756|Experimental|Combined Cell Therapy|Hematopoietic progenitor cell (HPC) transplant (HPCT) with autologous tumor cell lysate and keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine.
2522750|NCT02745340|Active Comparator|Acetate|
2522758|NCT02745340|Experimental|Citrate|
2522838|NCT02744911|Experimental|Telemedicine group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device via the internet using the telemedicine application. Also includes speech-language pathologists providing treatment via the telemedicine application.
2522843|NCT02744911|Active Comparator|In person group|People with Parkinson's disease and their caregivers obtaining treatment using the SpeechVive device in person. Also includes speech-language pathologists providing treatment in person.
2522875|NCT02744339|Experimental|Riociguat|Riociguat up-titrated to a maximum of 1.5mg TID
2522877|NCT02744339|Placebo Comparator|Placebo|Placebo sham-titrated TID
2522930|NCT02744183|Active Comparator|Control Group|Maintain habitual habits
2522936|NCT02744183|Active Comparator|Fed Exercise|6 weeks of moderate intensity exercise with breakfast consumption
2522941|NCT02744183|Experimental|Fasted Exercise|6 weeks of moderate intensity exercise with breakfast omission
2522982|NCT02743676||Avian influenza A|Natural history of Avian influenza A, particularly H5N1 strain which has a high potential of causing a global human pandemic, and real-world treatment practices will be observed in this study. This registry program will not require, recommend, or provide any specific treatment or medications.
3199283|NCT00878748|Experimental|A|Effexor XR
3199284|NCT00878748|Other|B|Effexor XR discontinue
3199285|NCT00878761|Experimental|STX-100 (0.03mg/kg)|8 patients (6 active and 2 placebo)
3199286|NCT00878761|Experimental|STX-100 (0.1mg/kg)|8 patients (6 active and 2 placebo)
2523419|NCT02740803|Experimental|NaF - R|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523422|NCT02740803|Experimental|NaF - NR|Participants will use sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2523426|NCT02740803|Experimental|NaMFP- R|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523429|NCT02740803|Experimental|NaMFP- NR|Participants will use sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2523435|NCT02740803|Experimental|SnF + NaF - R|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523439|NCT02740803|Experimental|SnF + NaF - NR|Participants will use stannous fluoride combined with sodium fluoride toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2523442|NCT02740803|Experimental|NaF + NaMFP - R|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523444|NCT02740803|Experimental|NaF + NaMFP - NR|Participants will use sodium fluoride combined sodium monofluorophosphate toothpaste (1,450 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2523447|NCT02740803|Experimental|AmF - R|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523450|NCT02740803|Experimental|AmF - NR|Participants will use amine fluoride toothpaste (1,400 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2556118|NCT02525276|Experimental|training + HT|training + HT
3199287|NCT00878761|Experimental|STX-100 (0.3mg/kg)|16 patients (12 active and 4 placebo)
3199288|NCT00878761|Experimental|STX-100 (1mg/kg)|16 patients (12 active and 4 placebo)
3199289|NCT00878774|Experimental|Cohort 1|ToleroMune Ragweed, subjects to receive either active or placebo comparator
3199290|NCT00878774|Experimental|Cohort 2|ToleroMune Ragweed or placebo comparator
3199291|NCT00878774|Experimental|Cohort 3|ToleroMune Ragweed or placebo comparator
3199292|NCT00878774|Experimental|Cohort 4|ToleroMune Ragweed or placebo comparator
2522222|NCT02748746|Experimental|Surgery no Lymphedema|The inclusion criteria for involving the first group is surgery time. No one will be involved into the first group if surgery was applied 18 months ago before enrollment to this study. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum. Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2522227|NCT02748746|Experimental|Surgery having Lymphedema|The second group will contain patients who had breast cancer surgery and having upper extremity lymphedema.Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2522233|NCT02748746|Active Comparator|Healthy Women|The third group will contain healthy women. Measurements will be done at baseline, 6th month and 12th month. Tissue dielectric constant measurement will be applied to upper extremity both affected and unaffected. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. Bio Impedance Analysis measurement will be done at both side. Self-adhesive electrodes will be applied related side's foot dorsum and hand dorsum.Impedance ratios will be calculated for each side then dividing process is conducted for determining L-dex ratio.
2522306|NCT02748421|Other|Lumera Microscope with OCT RESCAN|in the group microscope coupled to OCT, patients will undergo retinal surgery using the Lumera microscope with Rescan OCT Zeiss
2522311|NCT02748421|Other|Conventional Microscope|control group without OCT RESCAN
3199293|NCT00878774|Experimental|Cohort 5|ToleroMune Ragweed or placebo comparator
3199294|NCT00878787|Experimental|Theta-burst Trancranial Magnetic Stim|
2522407|NCT02747745|No Intervention|Control Group|Group receive no intervention
2522409|NCT02747745|Experimental|Interventional Group|Four risk areas reflecting the great needs of FCGs of PWDs: depressive symptoms, burden, distress to problematic behaviors of PWDs and healthy behaviors.
3199295|NCT00878813||1|All consecutive stroke patients undergoing acute intra-arterial revascularisation therapy
3199296|NCT00878813||2|All consecutive stroke patients undergoing acute intra-venous revascularisation therapy
2522516|NCT02746978|Active Comparator|Peer directed education|A revised education approach that focuses on problem solving discussions delivered by peers and grounded clinical information is compared to traditional approach of didactic clinician-driven education lectures
2522520|NCT02746978|Other|Patient Engagement Portal|A patient-owned portal to manage injury information is maintained in real-time by patients and families and shared with other care providers after inpatient rehabilitation discharge.
2522551|NCT02746601|Experimental|Risk Assessment, Counselling & Resources|Patients complete an electronic preconception health risk assessment tool. Results from the tool are directly uploaded or scanned into the patients' electronic medical record. A healthcare provider provides behavioural counselling, based on results of the risk assessment. Patients are given a customized handout that includes health recommendations and resources based on the patient's identified risk factors.
2522586|NCT02746393|Experimental|Intervention|Health Advocates Program
2522588|NCT02746393|Active Comparator|211 Arm|211 Information Sheet
2522608|NCT02746185|Active Comparator|Low-molecular-weight heparin|dalteparin, 200 IU/kg subcutaneously once daily for one month followed by 150 IU/kg subcutaneously once daily for 2 months
2522609|NCT02746185|Experimental|Rivaroxaban|rivaroxaban, orally, 15 mg twice daily for 3 weeks followed by 20 mg once daily for 9 weeks
2522665|NCT02745886|Experimental|Metformin group|Metformin 0.85 twice daily for 6 months
2522666|NCT02745886|No Intervention|Standard diet group|
2522669|NCT02745886|Other|CR group|Calorie restriction diet will be given to this group.
2522709|NCT02745574|Experimental|Combined maneuver|Combined maneuver: the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm dihydrogen monoxide (H2O). The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
2522711|NCT02745574|Experimental|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
2522712|NCT02745574|No Intervention|Control group|CO2 was removed by passive exsufflation through the port site.
2522739|NCT02745184|Experimental|lung stem cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade lung stem cells (LSCs)injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2522819|NCT02744729|Experimental|Esophagus Cancer, 99mTc-3PRGD2, SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis of Esophagus cancer patients.
2522889|NCT02744443|Experimental|Leucine|Leucine supplementation (10 g/d)
2522890|NCT02744443|Placebo Comparator|Placebo|Placebo supplementation (alanine, 10 g/d)
2522916|NCT02744079|Active Comparator|Low carbohydrate diet|45 subjects will receive a very low carbohydrate diet between a positive breast biopsy and surgical tumor removal
2522917|NCT02744079|Active Comparator|Low fat diet|20 subjects will receive a lo fat diet between a positive breast biopsy and surgical tumor removal
3199297|NCT00878813||3|All consecutive stroke patients treated conservatively
3199298|NCT00878813||4|All consecutive TIA patients
3199299|NCT00878839|Other|Toric|AcrySof Toric IOL to assess corneal aberration
3199300|NCT00878852|Active Comparator|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
2522497|NCT02747056|Experimental|Autism spectrum disorder studyA part1|The subjects will perform clinical, psychological and neuropsychological assessment. the subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2522500|NCT02747056|Experimental|Autism spectrum disorder studyA part2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
2522507|NCT02747056|Other|Control adults Study A, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2522508|NCT02747056|Other|Control adults Study A, part 2|The subjects will perform Autobiographical memories Assessment. The subjects will tell autobiographical memories freely first and secondly by answering focused questions to specify the characteristics of subjects' memories
2522510|NCT02747056|Experimental|Autism spectrum disorder Study B, part 1|The subjects will perform clinical, psychological and neuropsychological assessment. The subjects will do 3 tests about executive functions. The participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2522511|NCT02747056|Experimental|Autism spectrum disorder Study B, part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements.
2522514|NCT02747056|Other|Control adults, Study B part 1|The subjects will perform clinical, psychological and neuropsychological assessment.The subjects will do 3 tests about executive functions. Finally, the participants will complete 3 questionnaires about autism and 3 questionnaires about the self concept.
2522515|NCT02747056|Other|Control adults, Study B part 2|The subjects will perform Autobiographical memories assessment characteristics. The subjects will say the self statements which define them. Then, the participants will have to tell and specify the characteristics of the autobiographical memories linked to the self statements
2522576|NCT02746536|Experimental|Slow chest compression|Patients will receive the slow chest compression for one minute, immediately after 6MST.
2522577|NCT02746536|Placebo Comparator|No slow chest compression|Immediately after 6MST, the patient will not receive the SCC and will remain seated at rest for one minute, without any intervention.
3199301|NCT00878852|Experimental|Experimental|Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
3199302|NCT00878865|Experimental|Alprazolam 1 mg tablet|Alprazolam 1 mg tablet
2522715|NCT02745522|Experimental|Oxytocin|Oxytocin nasal spray
2522716|NCT02745522|Placebo Comparator|Placebo|Placebo nasal spray
2522781|NCT02745249|Experimental|A&T- intensive|A&T-intensive arm receive standard MNCH services and intensified maternal nutrition behavior change intervention which focus on improving dietary practices, specifically improved diversity of foods and energy intakes of pregnant women, and improved intake of calcium and iron/folic acid (IFA) supplements.
2522783|NCT02745249|No Intervention|A&T-non intensive|A&T-non intensive aim only receive MNCH services
2522829|NCT02744742|Experimental|G-CSF + Decitabine + BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，Granulocyte Colony-Stimulating Factor(G-CSF)+Decitabine+BUCY conditioning regimen was G-CSF 5-10ug/kg/day on days -17 and -10 (when white blood cell is more than 20G/L, stop using G-CSF)；Decitabine 20mg/m2/day on days -14 and -10； Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2522840|NCT02744742|Active Comparator|BUCY|For patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT ，BUCY conditioning regimen was Busulfan (BU) 3.2 mg/kg/day on days -7 and -4；Cyclophosphamide (CY) 60 mg/kg/day on days -3 and -2.
2522906|NCT02744300|Experimental|BABI-2 Lifestyle Intervention|Participants in this group will take part in the web-based lifestyle intervention which includes access to the lifestyle intervention website and personalized coaching from a Lifestyle Coach.
2522910|NCT02744300|No Intervention|Post-GDM Follow-up Group|Participants in this group will have access to a separate website containing links to information about diabetes prevention.
3199303|NCT00878865|Active Comparator|Xanax 1 mg tablet|Xanax 1 mg tablet
3199304|NCT00878891|Active Comparator|1. Conventional glucose monitoring|Discontinuous glucose monitoring - GlucoDay Device with Continue record blinded
2523057|NCT02743429|Experimental|Long term infusion of ch14.18/CHO|10 day continuous Infusion of ch14.18/CHO.
2523093|NCT02743026|Experimental|Intervention|participants will complete the FOXY intervention
3199305|NCT00878891|Experimental|2. Conventional glucose monitoring + Glucoday|Continuous glucose monitoring - GlucoDay device with Continue record displayed
2523253|NCT02742025|Experimental|HEARTLINK|"Patients randomized to this arm will participate in the HEARTLINK program, which includes a specific nurse consultation and telephone contact.~Intervention: Inclusion visit~Intervention: Nurse consultation~Intervention: Telephone contact~Intervention: Coronarography on day 0"
2556452|NCT02522871|Other|Control|Standard of care (ice)
3199306|NCT00878904|Experimental|treatment with Panobinostat and Epirubicin|
3199307|NCT00878917|Experimental|Dorzolamide|
3199308|NCT00878956|Active Comparator|1|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
2522405|NCT02747784|Experimental|Study group experimental|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Divided Attention 2 (GEA2)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
2522413|NCT02747784|Active Comparator|Study group active comparator|24 female patients aged 18 years or older undergoing urogynecological or breast cancer surgery; the patients are recommended to perform the RehaCom® training modules 'Topological Memory (MEMO)' and 'Working memory (WOME)' daily during inpatient hospital stay, and at least three times a week for 30 to 60 minutes until month 3.
2522415|NCT02747784|No Intervention|Control group|48 female control subjects aged 18 years or older (24 without surgery, 24 with urogynecological or breast cancer surgery) with a similar health status and age as the study group patients (similar distribution in the American Society of Anaesthesiologists physical status classification and relevant co-morbidities, e.g. diabetes, coronary artery disease, hypertension and hyperlipidemia). The patients are analyzed to correct for learning effects of the cognitive assessment testings in the study groups.
3165868|NCT00518466|Experimental|treatment 4|"Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Day 1 of Period 1.~One 7.5 mg phentermine hydrochloride IR capsule and one 25 mg topiramate IR tablet at Hour 0 on Days 1, 2, and 3 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and two 25 mg topiramate IR tablets at Hour 0 on Days 4, 5, and 6 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and three 25 mg topiramate IR tablets at Hour 0 on Days 7, 8, and 9 of Period 2.~Half of a 37.5 mg phentermine hydrochloride IR tablet and one 100 mg topiramate IR tablet at Hour 0 on Days 10 - 21 of Period 2."
3165869|NCT00518479|Experimental|1|Neurohormonal stimulatory arm
2522519|NCT02746939|No Intervention|Pre-curriculum assessment|Assessments will be administered to 3rd and 4th grade students prior to receiving curriculum training in fitness and nutrition.
2522524|NCT02746939|Experimental|Post-curriculum assessment|Assessments will be administered to 3rd and 4th grade students (matched from pre-curriculum assessment) after receiving 4-6 week InSciEd Out Fitness and Nutrition Curriculum.
2522688|NCT02745743|Experimental|Arm 1|Biomarker-enriched advanced hematological neoplasms
2522700|NCT02745743|Experimental|Arm 2|Other selected advanced hematological neoplasms
2522854|NCT02744612|Experimental|Treatment (Ibrutinib and Brentuximab Vedotin)|Patients receive ibrutinib PO QD on days 1-21 and brentuximab vedotin IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2522923|NCT02744196|Experimental|Acellbia + methotrexate|"106 patients of this group will receive methotrexate in combination with a drug Acellbia to be used at a dose of 600 mg as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the therapy with Acellbia is repeated by the same scheme - 2 infusion at a dose of 600 mg at intervals of 14 days."
2522926|NCT02744196|Placebo Comparator|Placebo + methotrexate|"53 patients of this group will receive methotrexate in combination with a placebo to be used as a slow intravenous infusion carried out on day 1 and day 15.~If a follow-up examination at 24 weeks or later (up to 48 weeks) reveals that the patient still has active arthritis (evaluation index DAS28-4 (ESR)> 2,6 points), the patient receives open therapy with Acellbia is initiated: 2 infusion at a dose of 600 mg at intervals of 14 days."
2522962|NCT02743741|Experimental|Lutetium-177 Octreotate|Lutetium-177 Octreotate 200 mCi (7.4 GBq) by IV for 18-30 weeks
3165870|NCT00518479|Experimental|2|Neurohormonal inhibitory arm
2523074|NCT02743169||Standard Practice|This group will consist of ambulance calls under the standard practice of Aman Foundation for ambulance placement.
2523076|NCT02743169||Post-Intervention|This group will consist of ambulance calls after the spatially-optimized placement of ambulances.
2523112|NCT02742935|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes.
2523179|NCT02742207||Observational|All comers with Atrial fibrillation
3165871|NCT00518492|Experimental|Arm 1|Includes subjects from a trial involving experimental vaccine and an active comparator vaccine. Comparator is Twinrix (not a MnB vaccine) and thus is comparator for safety but not immunogencity
3165872|NCT00518505|Other|I|This is a single arm study. All patients will be asked to complete questionnaires and have their medical charts reviewed.
2523432|NCT02740790|Experimental|HPV vaccine 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2523436|NCT02740790|Placebo Comparator|Placebo 1|300 women between 9-17 yeas of age, receiving 0,2,6 month-schedule Placebo.
2523438|NCT02740790|Experimental|HPV vaccine 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2524519|NCT02733497|Active Comparator|Sympathectomy Group|Excision of ganglia at T3 level
3165873|NCT00518518|Active Comparator|1|
3165874|NCT00518518|Placebo Comparator|2|
3165875|NCT00518557|Experimental|1|All patients of this arm are treated by TACE together with Andostatin.
3165876|NCT00518557|Active Comparator|2|All patients of this arm are treated by TACE alone: only mixture of Epirubicin and Lipiodol is injected into the feeding arteries of the tumor, without injection of Andostatin.
3165877|NCT00518570|Experimental|Open-Label treatment|Patients prospectively diagnosed with premenstrual dysphoric disorder.
3165878|NCT00518596|Experimental|Probiotic Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, given L. plantarum preparations orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
3165879|NCT00518596|Placebo Comparator|Control Arm|Newborn infants' ≥ 35 weeks of gestation and ≥1800g, receiving placebo preparations (a control solution of sterile 2.0 cc 5% dextrose-saline)orally once a day starting on day 1, 2, or 3 of life and continuing for seven days thereafter.
3165880|NCT00518609||Indian Neonates|All hospitalized neonates (all live born infants <60 days of age, independent of birth weight and gestational age) brought to hospital, with the diagnosis of suspected sepsis.
3165881|NCT00518635|Experimental|A|Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
3165882|NCT00518648|Experimental|I|Multifactorial fall prevention program
3165883|NCT00518648|Other|II|Usual care
3165884|NCT00518726|Experimental|Arm 1|
2522545|NCT02746744|Experimental|Rituximab|Infusion of Mabthera/Rituximab every 6 months
2522547|NCT02746744|Active Comparator|Dimethyl Fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
2522548|NCT02746744|Sham Comparator|Sodium Chloride solution|Sham infusion with sodium chloride solution for the Tecfidera/Dimethyl Fumarate arm every 6 months (so that the examining physician will be blinded)
2522604|NCT02746250|Active Comparator|Tension type headache|The investigator measures the muscle soreness and muscle stiffness before the patients starts their prescribed treatment with amitriptyline - and again after they have reached their optimal dosage of amitriptyline.
2522606|NCT02746250|No Intervention|Healthy controls|The investigator measures the muscle soreness and muscle stiffness once.
2522615|NCT02745964|Experimental|LMA supreme|Anesthesia is maintained using LMA supreme during surgery.
2522618|NCT02745964|Active Comparator|I-gel|Anesthesia is maintained using I-gel during surgery.
2522681|NCT02745860|Experimental|Sequence AB|Subjects receive 200 µg of selexipag (adult formulation) as a single oral dose during Period 1 and 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 2
2522684|NCT02745860|Experimental|Sequence BA|Subjects receive 200 µg of selexipag (pediatric formulation) as a single oral dose during Period 1 and 200 µg of selexipag (adult formulation) as a single oral dose during Period 2
2522833|NCT02744703|Active Comparator|self-etch adhesive|application of self-etch adhesive on cavities.
2522844|NCT02744703|Experimental|CAPE-S|CAPE before self-etch adhesive
2522847|NCT02744703|Active Comparator|total-etch adhesive|total-etch adhesive on cavities.
2522848|NCT02744703|Experimental|CAPE-T|CAPE before total-etch adhesive application
2522907|NCT02744248|Active Comparator|IOP Injection|Participants will receive 1 injection of the IOP at Days 1,once time.
2522909|NCT02744248|Placebo Comparator|0.9% normal saline|Participants will receive 1 injection of 0.9% normal saline at Days 1,once time.
2523055|NCT02743403|Active Comparator|Neurodyn Portable TENS|"Subjects in this study arm will receive active treatment. The active TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The subject receives both devices at the same time. The parameters of the active TENS are: frequency (f) of 100 Hertz (Hz) oscillator every 0.5 seconds pulse duration (T) 200 microseconds (microsiemens) and the amplitude (I) will be adjusted at the time of application the carboxiterapia.~The application of Carboxytherapy is realized by a carboxy Derm S20-1C equipment Derm® mark, which uses carbon dioxide (CO2) medical and non-toxic.~Each prick with a needle carboxiterapia will 100ml / min and will last 1 minute long.~Before each puncture will be adjusted to the intensity of TENS as sensitivity of the subject."
2523058|NCT02743403|Placebo Comparator|Placebo TENS- Neurodyn Portable TENS|"Subjects in this study arm will receive placebo treatment. The placebo TENS device will be Neurodyn Portable TENS the IBRAMED® and application of carboxytherapy device will be Carboxyderm S20-1C equipment, Tone Derm® brand.~The application of placebo TENS will be made by the same unit of active TENS; however, it is used a device specially developed for this study. The device remains active only during the first 30 seconds of application. After this time, the current amplitude will gradually decrease over the next 15 seconds until it reaches zero, thereby interrupting the emission of electrical power to the remainder of the application time. The display of placebo TENS device shows a light on all the time of application, indicating the patient that the device is active."
2523062|NCT02743403|No Intervention|Control|"Subjects in this study arm only receive the application carboxiterapia through Carboxyderm S20-1C equipment, Tone Derm® brand.~The group (active - control Carboxytherapy) will be submitted to the application of Carboxytherapy and off TENS."
2523118|NCT02742922|Experimental|Culturally adapted therapy (C-MAP)|Culturally adapted manual assisted (C-MAP) brief problem solving therapy
2523122|NCT02742922|No Intervention|Treatment as usual|This arm will receive no intervention only TAٓU.
2523202|NCT02742376|Other|Soft surface|A soft sponge used for physiotherapy is placed on the floor along a path,
2523203|NCT02742376|Other|Floor|The subject will walk on the floor.
2523205|NCT02742376|Other|Shoes|Special shoes (Kyboot) with air cushions that are meant to relieve pressure will be used.
2523294|NCT02741856|Experimental|Arm 1 (carboplatin/paclitaxel+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (50Gy/25 fractions)"
2523297|NCT02741856|Experimental|Arm 2 (cisplatin/capecitabine+standard RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14~Cycles 3 and 4 are given concomitantly with radiotherapy (50Gy/25 fractions). Capecitabine stops on last day of RT."
2523304|NCT02741856|Experimental|Arm 3 (carboplatin/paclitaxel+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: carboplatin AUC 5 on D1 and paclitaxel 175mg/m2 on D1~Week 7-11: Weekly carboplatin AUC 2 and paclitaxel 50mg/m2 concomitant with radiotherapy (60Gy/25 fractions)"
2523310|NCT02741700|Active Comparator|Video about management of another chronic condition|Patient narrated slide show of roughly the same duration as the experimental arm, summarizing management of a non-gout condition.
3165885|NCT00518752|Active Comparator|A|Standard Oral Care
3165886|NCT00518752|Experimental|B|Comprehensive Oral Care
3165887|NCT00518765|Experimental|1|Various sequences of different doses of Aliskiren
3165888|NCT00518765|Experimental|2|Various sequences of different doses of Aliskiren plus placebo
3165889|NCT00518765|Experimental|3|Various sequences of different doses of Aliskiren
2522504|NCT02747147|Experimental|B - Device Intervention|patients will have their PIVs assessed daily and record kept of PIV displodgement or replacement. patients will additionally have a single blood collection attempted using the study device
2522543|NCT02746757|No Intervention|Ischemia-reperfusion no intervention|Ischemia-reperfusion without intervention
2522544|NCT02746757|Experimental|Ischemia-reperfusion with RIPC|Ischemia-reperfusion with intervention by RIPC
2522546|NCT02746757|Experimental|Ischemia-reperfusion with RIPC and Ex 9-39|Ischemia-reperfusion with RIPC and Ex 9-39
2522582|NCT02746419|Experimental|Experimental|Subjects will receive renal denervation.
2522584|NCT02746419|Sham Comparator|Control|Subjects will receive all procedures as experimental group but renal denervation system will not be turned on.
2522650|NCT02746211|Experimental|High Titre Influenza virus|High Titre Influenza virus
2522652|NCT02746211|Experimental|Medium - High Influenza virus|Medium - High Influenza virus
2522653|NCT02746211|Experimental|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
2522654|NCT02746211|Experimental|Low titre Influenza Vaccine|Low titre Influenza Vaccine
2522691|NCT02745600|Other|Software assisted RFA treatment|Non-controlled, prospective, multicenter study arm, to evaluate RFA therapy simulation software.
2522770|NCT02745314||>74 years|Older than 74 year-old patients
2522823|NCT02744794|Experimental|Treatment with cryotherapy|Treatment with dermal cooling system.
2522872|NCT02744417|Experimental|Smoking cessation therapy|Non-surgical periodontal therapy and concurrent smoking cessation therapy, with Smoking cessation counseling, Nicotine replacement therapy, use of bupropion hydrochloride and varenicline
2522934|NCT02744105|Experimental|thalassemic children with hepatitis C|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2522935|NCT02744105|No Intervention|thalassemic children without hepatitis C|30 multitransfused beta thalassemic children without hepatitis C virus infection
2522997|NCT02743754|Placebo Comparator|Standard Therapy|Standard supportive therapies for Acute Kidney Injury (AKI), which entail optimization of hemodynamics and hemoglobin levels.
2523002|NCT02743754|Active Comparator|Standard Therapy and hyperbaric oxygen|Standard therapies and treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 atmospheres absolute (ATA).
2523026|NCT02743351|Experimental|ProTmune|
2523028|NCT02743351|Active Comparator|Control Arm|
2523109|NCT02743065||Device: HepaSphere Microspheres|HepaSphere Microsphere
2523194|NCT02742480||Dabigatran|300 patients treated with dabigatran under the habitual clinical practice.
2523197|NCT02742480||Acenocoumarol|200 patients treated with acenocoumarol under the habitual clinical practice.
2523301|NCT02741583|Experimental|altitude rehabilitation program|3 weeks rehabilitation program at high altitude (3200m)
2523307|NCT02741583|Active Comparator|rehabilitation program|3 weeks rehabilitation program at low altitude (760m)
3199309|NCT00878956|Placebo Comparator|2|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
3199310|NCT00879008||Group 1|
2523510|NCT02740283|Experimental|Pregnant women|As a diagnostic study, the cohort will recruit 300 pregnant women who meet inclusion and exclusion criteria outlined below. OGTTs will be performed between 18 and 20 gestational weeks (early-OGTT) and 24 to 28 gestational weeks (regular-OGTT). Clinical and laboratory information of the mother and their offspring will be collected for analysis.
2523591|NCT02739815|Placebo Comparator|Placebo|Will receive a placebo (10 ml of distilled water) in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2523592|NCT02739815|Active Comparator|T1|Will receive Tranexamic acid 15 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2523593|NCT02739815|Active Comparator|T2|Will receive Tranexamic acid 20 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2523598|NCT02739815|Active Comparator|T3|Will receive Tranexamic acid 25 mg/kg in Z solution [500 ml of normal saline containing a prophylactic Antibiotic 1 g] (At 20 minutes preoperatively).
2523662|NCT02739256|Experimental|voiding trial 4 hours post-op|
2523663|NCT02739256|Active Comparator|voiding trial post-op day 1|
2523746|NCT02738619|Active Comparator|vitamin d3|1600 UI
2523748|NCT02738619|Placebo Comparator|placebo|placebo
3199311|NCT00879021|Placebo Comparator|Pregabalin, (other name) Lyrica|Study subjects wil be randomized to either the Pregabalin or Placebo group. There is a 5o ,50 chance of being in either group.
3199312|NCT00879021|Placebo Comparator|pregabalin, drug|study subjects that are randomized to the placebo group will receive matching placebo
2523898|NCT02737566|Experimental|Standard Care + Financial Incentives|Participants randomized to Standard Care + Financial Incentives for Abstinence will be offered smoking cessation counseling and pharmacotherapy (standard care) and they will have the opportunity to earn small gift cards for biochemically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level. Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
2523900|NCT02737566|Active Comparator|Standard Care|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
2523978|NCT02736877|Experimental|Lumera Microscope with OCT RESCAN|In the group microscope coupled to OCT, patients will undergo corneal surgery using the Lumera Microscope WITH RESCAN OCT - ZEISS. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
3199313|NCT00879047|Experimental|HIV+, Ritonavir-regimen|10 subjects will be HIV+ and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
2522630|NCT02745977|Other|Dairy Free Diet- guaiac + on dairy free diet|Dairy Free Diet x 3 weeks then stool guaiac positive
2522633|NCT02745977|Other|Guaiac negative on dairy free diet|on dairy free diet x 3 weeks, then stool guaiac negative
2522714|NCT02745795|Experimental|MIG: Motivational Interview Group|Group submitted to three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
2522717|NCT02745795|Sham Comparator|CIG: Conventional Intervention Group|Group submitted to three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
2522744|NCT02745223|Experimental|PresbiDrops (CSF-1)|Participants self-administered PresbiDrops (CSF-1), 1 drop in each eye each morning for 2 weeks.
2522745|NCT02745223|Placebo Comparator|Placebo|Participants self-administered placebo, 1 drop in each eye each morning for 2 weeks.
2522752|NCT02745015|Experimental|treatment|immediate non-surgical periodontal treatment
2522759|NCT02745015|Other|control|non-surgical periodontal treatment scheduled for the following 3-monthly visit
2522806|NCT02744950|Active Comparator|Intermediate/complex repair|This arm will have closures of scalp defects with deep and superficial suture placement.
2522808|NCT02744950|Experimental|Pulley stitches|This arm of the study will have only pulley stitches to close the entire defect.
2522816|NCT02744599|Experimental|Device prompting|
2522817|NCT02744599|No Intervention|Control|Patients receive standard of care
2522898|NCT02744521|Experimental|Symptom based screening intervention|
2522900|NCT02744521|No Intervention|control|
2522948|NCT02744014|Experimental|Early intervention group|The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
2522950|NCT02744014|Other|Late intervention group|This group will receive the same training with a delay of 60-90 days, serving initially as control.
2522984|NCT02743650|Experimental|Sodium Bicarbonate|"All participants will receive oral sodium bicarbonate for 6 weeks (On-treatment period). After the 6 week visit, participants will stop taking sodium bicarbonate and return for a final visit 4 weeks later (Off-treatment period).~The initial dose of sodium bicarbonate prescribed is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d. Half the dose will be taken by mouth in the morning and the other half in the evening."
2523040|NCT02743455|Active Comparator|Group 1|Subjects will receive 1.0x10^8 TCID50 of MVA-BN as two doses subcutaneously on Day 1 and Day 29. N=15
2523044|NCT02743455|Experimental|Group 2|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
2523045|NCT02743455|Experimental|Group 3|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as two doses intramuscularly on Day 1 and Day 29. N=15
2523047|NCT02743455|Experimental|Group 4|Subjects will receive 1.0x10^8 TCID50 of MVA-BN-YF + ISA 720 as a single dose intramuscularly on Day 1 and matching placebo on Day 29. N=15
2523048|NCT02743455|Active Comparator|Group 5|Subjects will receive = / > 4.74 log10 PFU of YF-Vax as a single dose subcutaneously on Day 1 and matching placebo on Day 29. N=15
2523049|NCT02743455|Experimental|Group 6|Subjects with prior receipt of MVA-BN will receive 1.0x10^8 TCID50 of MVA-BN-YF as two doses intramuscularly on Day 1 and Day 29. N=15
2523102|NCT02742883|Experimental|Antineoplaston therapy|Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for up to 104 days. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dosage is reached, but not exceeding 12.0 g/kg/d Atengenal or 0.4 mg/kg/d Astugenal.
2523152|NCT02742636|Experimental|Group A (treatment group)|The patients in this group will have their catheter directly removed in the OR after LH.
2523155|NCT02742636|Active Comparator|Group B (control group)|The patients in the control group will have their catheter removed according to the regular protocol of the hospital (at least 6 hours in place).
2523190|NCT02742285|Other|Artemether + lumefantrine|One single adult dose of artemether + lumefantrine 80 + 480 mg
2523243|NCT02742038|Experimental|Fluoride varnish plus education|Biannual fluoride varnish every 6 month/ 24 months plus educational component
2523244|NCT02742038|Placebo Comparator|Placebo varnish plus education|Biannual placebo varnish every 6 month/ 24 months plus educational component
3199314|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Ritonavir-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Ritonavir-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3199315|NCT00879047|Experimental|HIV+, Efavirenz-regimen|10 subjects will be HIV+ and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
2523376|NCT02740933|Experimental|Demeclocycline|"All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives.~The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first."
2523456|NCT02740764|Experimental|Optimization of drug prescribing|The group with optimization program will have: (i) a medical history of the drug prescribing; (ii) analysis and pharmaceutical recommendations and (iii) preparation of a management plan. Notices will be sent only to referring physicians in this experimental group.
3199316|NCT00879047|Experimental|HIV+/HCV+ Co-infected, Efavirenz-regimen|10 subjects will be HIV+/HCV+ co-infected and will begin receiving Efavirenz-containing regimen, and their PK interactions with alcohol/placebo will be evaluated.
3199317|NCT00879047|Experimental|Maraviroc in Healthy Subjects|10 healthy subjects will begin receiving maraviroc, and their PK interactions with alcohol/placebo will be evaluated.
2522549|NCT02746614|Active Comparator|Psychomotor Therapy & Adaptive Behavior|After the initial assessment of adaptive behavior, i.e.., set of skills that each individual with intellectual disability should train to cope with environmental demands, a Psychomotor Intervention Program was designed specifically. The program integrated individual and group sessions during 3 months, and the main goals of the program were related to independent functioning, motor development, economic and professional activities, academic and verbal skills.
2522552|NCT02746614|Active Comparator|Psychomotor Therapy & Motor Proficiency|Motor Proficiency After the initial assessment, a Psychomotor Intervention Program was designed specifically for participants with IDD. This program integrated individual and group sessions during 3 months, and the main goals of the program were related to motor coordination (balance, manual dexterity and coordination, global and fine praxis).
2522602|NCT02746445||ASD Subjects|No interventions. This is an observation of subjects who received MeRT utilizing assessment documentation.
2522626|NCT02746029||Children with cardiac murmur|
2522689|NCT02745834|Experimental|Chronic Ankle Instability|Soldiers who suffer from chronic ankle instability who had a first major ankle sprain one year or more ago, and did not sustained any major ankle sprain in the last two months, will go through Gait analysis intervention.
2522698|NCT02745834|Experimental|Healthy controls|Healthy soldiers who are not suffering from chronic ankle instability, will go through Gait analysis intervention.
2522746|NCT02745379|Experimental|BFPSC+|The group receives a combination (DFDBA)+buccal fat pad derived stem cells BFPSC and PRF for sinus augmentation
2522757|NCT02745379|Active Comparator|BFPSC-|The group receives a combination of demineralized freeze-dried bone allografts DFDBA (lacking any cells) and PRF for sinus augmentation
2522896|NCT02744222|Experimental|BCD-054, 180 mcg, biweekly|Patients of Groups 1 will receive blinded BCD-054 180 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 1 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
2522899|NCT02744222|Experimental|BCD-054, 240 mcg, biweekly|Patients of Groups 2 will receive blinded BCD-054 240 mcg intramuscularly once every two weeks for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive). Between every two injections of the active drug, once every 2 weeks, patients will receive intramuscular injections of placebo.From Week 53 until Week 100, patients of Groups 2 will receive open-label BCD-054 180 mcg or 240 mcg intramuscularly once every 2 weeks
2522902|NCT02744222|Active Comparator|Avonex®, 30 mcg, weekly|Patients of Group 3 (reference group) will receive blinded Avonex® 30 mcgintramuscularly once a week for the first 52 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive).
2522904|NCT02744222|Placebo Comparator|Placebo, 0,5 ml, weekly|Patients of Group 4 (placebo) will receive blinded placebo once a week for the first 20 weeks (including a 4-week titration phase from Week 0 to Week 3 inclusive)
2523187|NCT02742246|No Intervention|Standard treatment as usual (TAU)|This is the regular treatment a participant would normally receive at the clinic and generally includes individual and/or group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks and include issues such as teaching about the treatment program, teaching important ideas about recovery, increasing knowledge about specific problems participants may have with addiction and/or demonstrating new ways of coping with skills designed to fit their lifestyle. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
2523188|NCT02742246|Active Comparator|Individual clinician-provided CBT|This is individual treatment provided by a trained Cognitive Behavioral Therapy (CBT) clinician who will focus on teaching skills to understand and change participants behaviors to help them avoid alcohol use. Sessions with the clinician will generally last for 1 hour one time per week for 8 weeks. Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
2523189|NCT02742246|Experimental|CBT4CBT|In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on. The CBT4CBT program will cover the same skills as the individual clinician-provided CBT, only here it will be done by a computer. Participants will be taught how to use the computer program by a staff member and will be asked to spend about 8 hours using the program (approximately one hour per week) at the clinic.Participants will also be asked to complete a brief questionnaire and to provide urine and breath specimens for alcohol and drug testing once each week.
3165890|NCT00518765|Experimental|4|Various sequences of different doses of Aliskiren plus placebo
3165891|NCT00518791|Experimental|I|Multidisciplinary Care
2524300|NCT02734966|Experimental|arm 1|lower dose： Magnesium Isoglycyrrhizinate injection 100mg OD for 4 weeks
3165892|NCT00518791|Other|II|Usual Care
3165893|NCT00518830|Experimental|PND-MCI|The multi-component intervention involved a psychoeducational group, treatment adherence support, and pharmacotherapy if needed
3165894|NCT00518830|Active Comparator|usual care|'Usual care' included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
3165895|NCT00518843|Experimental|FBT-BN|Family-based treatment
3165896|NCT00518843|Active Comparator|SPT|Individual Supportive Psychotherapy
3165897|NCT00518856|Experimental|intervention|TBAs who receive training and supplies for the intervention
3165898|NCT00518856|Active Comparator|control|TBAs continuing with current standard of practice
3165899|NCT00518869|Experimental|Treatment group|PG2 plus standard chemotherapies
3165900|NCT00518869|Placebo Comparator|Placeo group|Placebo plus standard chemotherapies
3165901|NCT00518895|Experimental|A|Dacarbazine with Genasense
3165902|NCT00518895|Active Comparator|B|Dacarbazine with placebo
3165903|NCT00518908|Experimental|Sevoflurane|Sevoflurane for pharmacological postconditioning
3165904|NCT00518908|Experimental|Propofol|Anesthesia maintenance with propofol instead of Sevoflurane postconditioning
3165905|NCT00518921|Experimental|Arm 1|
3165906|NCT00518921|Experimental|Arm 2|
2522580|NCT02746510|Experimental|Array comparative genomic hybridization|The investigators plan to include 150 patients with defined (DSM V) schizophrenia and aged 15 years and more. The clinical grid will be prospectively fulfilled for every patients on the basis of his/her medical history and clinical examination. Array comparative genomic hybridization (CGH-a) will be performed on jugal mucosae sample to detect precisely syndromic forms of schizophrenia linked to the presence of a pathogenic Copy Number Variation (CNV) or a pathogenic sequence variation (exome trio sequencing).
2522617|NCT02746224|Other|group 1A|the surgical technique initially dissects the inferior mesenteric vein (IMV).
2522619|NCT02746224|Other|group 1B|the surgical technique initially dissects the inferior mesenteric artery (IMA).
2522620|NCT02746224|Other|group 2A|the patients will have a latero-terminal colorectal anastomosis
2522624|NCT02746224|Other|group 2B|the patients will have a termino-terminal colorectal anastomosis.
2522697|NCT02745691||A. Surgery|A.1 Surgery alone and/or before any adjuvant therapy A.2 Surgery (late effects)
2522704|NCT02745691||B. Radiochemotherapy|B.1 Chemotherapy alone B.2 Radiotherapy alone B.3 Sequential radiochemotherapy B.4 Concurrent radiochemotherapy
2522708|NCT02745691||C. Targeted therapy|C.1 Targeted therapy alone C.2 Targeted therapy in combination with any other therapy
2522710|NCT02745691||D. Immunotherapy|Any new immunotherapy for lung cancer
2522761|NCT02745197|Experimental|Nutritional Supplement|2 nutritional supplement capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
2522762|NCT02745197|Placebo Comparator|Placebo|2 placebo capsules, taken by mouth 3 times per day, for approximately 10 to 15 weeks.
2522852|NCT02744937|Experimental|A|continuing LDA
2522855|NCT02744937|No Intervention|B|discontinuing LDA
2522894|NCT02744313||AP Naive|Group followed over 12 weeks to measure fat deposition, insulin resistance, and glucose tolerance.
2522932|NCT02744053|Experimental|Diagnostic (DCE-MRI, MBI)|Patients undergo DCE-MRI over 45-60 minutes. Patients receive technetium Tc-99m sestamibi via injection, and after 5 minutes patients undergo MBI scan over 1 hour. Both DCE-MRI and MBI are performed at the time of enrollment, at the end of anthracycline therapy, and at the conclusion of NAC before surgery. All patients also undergo standard of care imaging with DM and US (at the same time points if the treating doctor chooses to do so).
2522993|NCT02743572|No Intervention|control group|preterm infants of this group with iron-free PN for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2522994|NCT02743572|Experimental|iron sucrose-1|preterm infants of this group with iron supplementation of 100μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2522995|NCT02743572|Experimental|iron sucrose-2|preterm infants of this group with iron supplementation of 200μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2522996|NCT02743572|Experimental|iron sucrose-3|preterm infants of this group with iron supplementation of 300μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2522999|NCT02743572|Experimental|iron sucrose-4|preterm infants of this group with iron supplementation of 400μg/kg/d for more than seven days, compare erythrocyte parameters, serum iron, iron protein and MDA on baseline and after intervention
2523031|NCT02743260|Experimental|pitavastatin (OATP1B1)|2 mg pitavastatin single dose
2523033|NCT02743260|Experimental|metformin (MATE1, MATE2K, OCT1, OCT2)|500 mg metformin single dose
2523035|NCT02743260|Experimental|digoxin (intestinal & renal P-glycoprotein)|0.5 mg digoxin single dose
2523038|NCT02743260|Experimental|adefovir dipivoxil (OAT1)|10 mg adefovir dipivoxil single dose
2523042|NCT02743260|Experimental|sitagliptin (OAT3)|100 mg sitagliptin single dose
2523046|NCT02743260|Experimental|cocktail (all substances)|combination of all individual drugs at respective single doses
2523120|NCT02742909|Active Comparator|rhBNP|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received rhBNP.
2523129|NCT02742909|Placebo Comparator|Placebo|the study is a self controlled study. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.The date of this arm is from the occasion the subject received placebo.
2523204|NCT02742454|Active Comparator|Standard 30-60 Seconds Cord Clamping|Standard treatment for extremely preterm infants which is delayed cord clamping 30-60 seconds after birth, and assisted ventilation after cord clamping.
2523206|NCT02742454|Experimental|VentFirst 120 Seconds Cord Clamping|Assisted ventilation (face mask Continuous Positive Airway Pressure, CPAP, or Positive Pressure Ventilation, PPV) will be provided prior to cord clamping at 120 seconds.
2523259|NCT02741726|Experimental|dual acupoint stimulation|The acupoints of dual point group are bilateral Neiguan points(PC6) combined with Danzhong point(RN17), electric stimulation was given through electrode attached to the acupoints.
2523261|NCT02741726|Experimental|single acupoint stimulation|The acupoints of single point group is bilateral Neiguan points(PC6), Electric stimulation was given through electrode attached to the acupoints.
2523263|NCT02741726|Placebo Comparator|no stimulation|false stimulation group only attach electrodes without electric current.
2523317|NCT02741466|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
2523359|NCT02741193|Experimental|nTMS|Patients will receive a single-pulse TMS mapping of the motor area for the following reasons to determine the motor threshold, measure concurrent EMG, and mapping of the upper extremity.
2523382|NCT02740946|Experimental|Exercise therapy|Exercise therapy 5 months
2523480|NCT02740712|Other|single arm probe drugs and rucaparib|Caffeine Warfarin Vitamin K Omeprazole Midazolam Digoxin rucaparib
2522583|NCT02746432|Experimental|Intervention group.Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin (Human regular insulin) ) infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
2522638|NCT02746198|Experimental|Verum|2 bottles (á 65ml) of a probiotic dairy drink consumed daily for 6 weeks
2522640|NCT02746198|Placebo Comparator|Placebo|2 bottles (á 65ml) of a dairy drink containing chemically acidified milk without bacterial strains consumed daily for 6 weeks
2522721|NCT02745730|Active Comparator|Glucose|Shake sweetened with glucose
2522725|NCT02745730|Active Comparator|Fructose|Shake sweetened with fructose
2522727|NCT02745730|Experimental|Sucralose|Shake sweetened with sucralose
2522730|NCT02745730|Experimental|Allulose|Shake sweetened with allulose
2522754|NCT02745158||FOP Patients|
2522812|NCT02744963|Experimental|Free and convenient medicine access|Free access to a list of essential medicines. Medicines are either mailed to the patient or dispensed at the point of care.
2522813|NCT02744963|No Intervention|Usual medicine access|Usual access to medicines.
2522853|NCT02744560|Experimental|patients|30 multitransfused beta thalassemic children infected with hepatitis C virus diagnosed by serological detection of HCV-antibodies and HCV RNA by polymerase chain reaction will be given Spirulina in a dose of 250 mg/kg/day orally for 3 months.
2522881|NCT02744326|Experimental|Text message reminder group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive text message reminders to attend or schedule a follow-up outpatient referral.
2522887|NCT02744326|No Intervention|Usual Care group|A subset of patients discharged from the ED with an outpatient referral will be randomized to receive the usual standard of care.
2522946|NCT02744118|Experimental|Marijuana Screening and Brief Counseling|The marijuana screening and brief counseling intervention will be developed based on a tested adolescent tobacco cessation intervention and the Public Health Service 5As model. The proposed intervention will be adapted using current literature, input from content experts, and qualitative data gathered using focus groups.
2522949|NCT02744118|Active Comparator|Healthy Internet Use Model|The media screening and brief counseling intervention is based on a media use screening and brief counseling intervention tested as the active comparator for a 5As tobacco cessation randomized control trial (NCT01312480) and the 2010 American Academy of Pediatrics policy statement on children and media.
2523009|NCT02743559|Active Comparator|Vitamin D group|Children born to mothers who received vitamin D during pregnancy will undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform(LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
2523013|NCT02743559|Placebo Comparator|Placebo group|Children born to mothers who received placebo during pregnancy will also undergo mechanical stimulation using whole body vibration(WBV) by standing on the vibration platform (LivMd) for 10 minutes on 5 consecutive mornings, at 7.30-8 am.
2523065|NCT02743286|No Intervention|Control condition (Protocol A)|Following a one-hour sitting run-in period, participants will sit for a 5-hour period including a mid-point bathroom break.
2523068|NCT02743286|Experimental|Frequent sit-to-stands (Protocol B)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 15 2-minute standing interruptions, 3 per hour, and a mid-point bathroom break.
2523070|NCT02743286|Experimental|Walking breaks (Protocol C)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 2-minute walking interruptions, 3 per hour, and a mid-point bathroom break.
2523071|NCT02743286|Experimental|Stand More (Protocol D)|Following a 1-hour sitting run-in period, participants will sit for a 5-hour period including 5 10-minute standing breaks, 1 per hour, and a mid-point bathroom break.
2523115|NCT02742896||Restoration of Erectile dysfunction|The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
2523246|NCT02741973|Experimental|Yoga|Students have 10 weeks yoga instead of school sport.
2523249|NCT02741973|Active Comparator|School sport|Students have 10 weeks regular school sport.
2523311|NCT02741661||Normal coronary arteries|Patients in whom coronary arteriography has demonstrated no significant tortuosity.
2523313|NCT02741661||Tortuous coronary arteries|Patients in whom coronary arteriography has demonstrated tortuous coronary arteries defined as >1 major bend of >45 degrees in a major coronary artery
3165907|NCT00518921|Experimental|Arm 3|
3165908|NCT00518921|Placebo Comparator|Arm 4|
2523384|NCT02740894||targeted therapy|according to national healthy policy, targeted therapy is the optional therapy
2523387|NCT02740894||traditional chemotherapy|according to national healthy policy, chemotherapy is the first line treatment.
3165909|NCT00518947|Active Comparator|1|Continued-Lithium
2523641|NCT02739295|Experimental|G-CSF|An intravenous dose of 5 microg/kg of G-CSF (Neupogen) will be administered daily, from admission (day 0) to day 4.
3165910|NCT00518947|Experimental|2.|Verapamil
3165911|NCT00518947|Experimental|3.|Verapamil plus Lithium
3165912|NCT00518999||1|Schizophrenia patients who performed earlier cognitive assessment as part of routine assessment for patients in the Shalvata Mental Health Center.
3165913|NCT00519012|Active Comparator|Arm-1|Sertraline to Paroxetine
3165914|NCT00519012|Active Comparator|2|Paroxetine to Sertraline
3165915|NCT00519038|Experimental|1|Patients treated according to clinical pathways
3165916|NCT00519038|Other|2|Patients treated according to usual care
3165917|NCT00519051|Active Comparator|control group|patients can receive pharmacotherapy and psychotherapy and specialized treatment
3165918|NCT00519064|Active Comparator|Arm 1|
2522786|NCT02745405|Other|Control Condition|Participants are randomly assigned to wear the same clothing that is on the fat suit but in their own size and then walk across campus.
2522837|NCT02744677|Experimental|TPVR - Main Cohort|Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).
2522842|NCT02744677|Experimental|TPVR - THV Registry|Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.
2522905|NCT02744274|Experimental|Verum acupuncture|16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
2522908|NCT02744274|Placebo Comparator|Sham acupuncture|16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
2522956|NCT02743975|Experimental|Treatment group|Bevacizumab-800CW
2523007|NCT02743611|Experimental|Arm 1 Does Escalation|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
2523011|NCT02743611|Experimental|Arm 2 Dose Escalation|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701. Dose escalation of BPX-701 will continue until the recommended cell dose level is reached.~Rimiducid may be administered in response to treatment-related toxicity."
2523016|NCT02743611|Experimental|Arm 1 Part 2 Dose Expansion|"Participants with relapsed AML or previously treated MDS will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
2523018|NCT02743611|Experimental|Arm 2 Part 2 Dose Expansion|"Participants with metastatic uveal melanoma will receive an intravenous infusion of BPX-701 at the recommended cell dose level.~Rimiducid may be administered in response to treatment-related toxicity."
2523050|NCT02743182|Active Comparator|Pegylated interferon alfa-2a|adding Pegylated interferon alfa-2a (180 microgs /week during 48 weeks) in HBeAg-negative patients receiving nucleos(t)ide analogues
2523053|NCT02743182|No Intervention|Control|HBeAg-negative patients receiving nucleos(t)ide analogues
2523172|NCT02742545|Experimental|MayoExpertAdvisor|Clinicians in care teams assigned to the intervention arm will have access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
2523173|NCT02742545|No Intervention|Usual Care|Clinicians in care teams assigned to the standard of care arm will continue to provide up-to-date, patient-specific guideline-based treatment recommendations as is the standard of care at Mayo Clinic.
2523228|NCT02742155|Experimental|Play2Sleep|For the experimental intervention, Play2Sleep consists of video-recording the mother and father separately while engaged in a structured play session. Immediately following the play session, the home visitor will review the video recording with each parent separately to provide positive feedback on parental behaviors that promotes contingent interaction and identification of infant cues. At the end of the visit, standard public health handouts on infant sleep will be provided to both parents.
2523233|NCT02742155|Active Comparator|Comparison|In the comparison group, only standard public health handouts on infant sleep will be reviewed with parents.
2523274|NCT02741752|Experimental|test group|decortication group
2523280|NCT02741752|No Intervention|control|without decortication
2523336|NCT02741505|Experimental|Sleep Deprivation followed by Normal Sleep|Subjects will be sleep deprived at the sleep laboratory.
2523380|NCT02741089||Indication for a flexible bronchoscopy|Patients representing to the hospital with the indication for a flexible bronchoscopy
2523466|NCT02740686||Frequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the frequent exacerbators group based on whether they have had 2 or more hospitalisations for exacerbations or have taken 2 or more courses on steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
2523472|NCT02740686||Infrequent exacerbators|"Exacerbations will be defined as a respiratory event which led to a hospitalisation or the prescription of antibiotics and/or oral corticosteroids. Clinicians will ask patients to retrospectively recall how many exacerbations they have had in the past 12 months. Patients will be allocated to the infrequent exacerbators group based on whether they have had no more than 1 hospitalisation for exacerbations or have not taken more than 1 course of steroids/antibiotics within the past 12 months. Blood sample collection at the following pulmonary rehabilitation sessions: 1st (pre-exercise), 2nd (pre and post-exercise), 8th (pre-exercise), last session (pre and post exercise). Sputum samples collected pre-exercise at the following pulmonary rehabilitation sessions: 1st, 8th, and last session."
2523476|NCT02740686||Healthy smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and currently smoke.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. A resting blood sample will be taken from these patients and used to compare baseline measurements with the COPD groups.
2523478|NCT02740686||Healthy never smokers|Recruited in accordance with inclusion/exclusion criteria with no medical history of COPD diagnosis and have never smoked.This group will be recruited by a nurse using medical records to assess smoking status and age-matching to the COPD groups. Resting blood samples will be taken from these patients and used to compare baseline measurements with the COPD groups.
3165919|NCT00519064|Active Comparator|Arm 2|
2523642|NCT02739295|Placebo Comparator|Placebo|An intravenous dose of 5 ml of NaCl 0.9% will be administered daily, from admission (day 0) to day 4.
3165920|NCT00519103|Experimental|1|Active resistive excercise for 7 weeks
3165921|NCT00519142|Placebo Comparator|1|metformin + placebo for mitiglinide
3165922|NCT00519142|Experimental|2|metformin + mitiglinide three times a day with meals
2522804|NCT02744820|Placebo Comparator|Cohort 1 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2522805|NCT02744820|Placebo Comparator|Cohort 2 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2522807|NCT02744820|Placebo Comparator|Cohort 3 (Part 1)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2522809|NCT02744820|Placebo Comparator|Cohort 4 (Part 2)|"Multiple ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Salt Other: Placebo"
2522857|NCT02744573||General Anaesthesia|ANI and SPI values under general anaesthesia
2522862|NCT02744573||Spinal Anaesthesia|ANI and SPI values under spinal anaesthesia
2522864|NCT02744573||Spinal Anaesthesia + Sedation|ANI and SPI values under spinal anesthesia in combination with sedation
2522867|NCT02744573||Control|ANI and SPI values under no anaesthesia
2522913|NCT02744287|Experimental|Arm 1: Phase 1 Dose Escalation|Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
2522914|NCT02744287|Experimental|Arm 2: Phase 2 Dose Expansion|Participants with advanced pancreatic or prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
3199318|NCT00879073|Experimental|A - Cohort 1 Treatment|Cohort 1: Bendamustine 60 mg/m² x 4 weeks
2523059|NCT02743234|Experimental|FMT|Fecal microbiota transplantation (FMT) following 4-10 days of vancomycin 125 mg x 4, using cryopreserved feces from a healthy anonymous donor
2523063|NCT02743234|Active Comparator|Fidaxomicin|10 days fidaxomicin 200 mg x 2 daily
2523067|NCT02743234|Active Comparator|Vancomycin|10 days vancomycin 125 x 4 daily
2523121|NCT02742961||Peripheral nerve block|Intervention arm. Participants who receive a peripheral nerve block identified through submission of an appropriate physician billing code
2523130|NCT02742961||No peripheral nerve block|Control arm. Participants who do not receive a peripheral nerve block identified through lack of a submission of an appropriate physician billing code
2523184|NCT02742493|Experimental|0.028 bonded to canines|lower fixed canine and canine retainer and upper removable Hawley (Intervention A)
2523185|NCT02742493|Experimental|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer and upper removable Hawley (Intervention B)
2523186|NCT02742493|Active Comparator|removable Hawley-type|lower hawley-type and upper hawley removable retainer (Control)
2523229|NCT02742064||MDD-Single Episode|1. Subjects who have experienced 1 episode of major depressive disorder (MDD) in their lifetime.
2523232|NCT02742064||MDD-Recurrent|1. Subjects who have experienced 2 or more episodes of depressive disorder (MDD) in their lifetime.
2523234|NCT02742064||Bipolar Disorder|1. Subjects who have been diagnosed with bipolar disorder in their lifetime.
2523267|NCT02741804|Active Comparator|BBH-1001 Brain Health Supplement|Patients will be given supplement containing ingredients all approved by the FDA: Turmeric (125mg), fisetin (16.65mg), green tea leaf extract (17.5mg), EPA (75mg), DHA (150mg) and Vitamin D3 (250IU). Patients will take 4 softgels once per day for entire study duration (18 months).
2523271|NCT02741804|Placebo Comparator|Brain Health Placebo|Patients will be given a pill resembling the study supplement, but instead consisting of Soybean oil (608mg). Patients will take 4 softgels once per day for the entire study duration (18 months).
3199319|NCT00879073|Experimental|B - Cohort 2 Treatment|Cohort 2: Bendamustine 80 mg/m² x 4 weeks
3199320|NCT00879073|Experimental|C - Cohort 3 Treatment|Cohort 3: Bendamustine 100 mg/m² x 4 weeks
3199321|NCT00879099|Active Comparator|Paroxetine|
3199322|NCT00879099|Placebo Comparator|Gelatine capsule|
2523594|NCT02739711|Active Comparator|Glycoprotein IIb/IIIa inhibitor|Glycoprotein IIb/IIIa inhibitor administration
2523600|NCT02739711|No Intervention|Standard therapy|No glycoprotein IIb/IIIa inhibitors
3199323|NCT00879099|Experimental|Timolol 0.5 % eye drops|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
2523755|NCT02738658|Experimental|Bioresorbable vascular scaffold (BVS)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
2523756|NCT02738658|Active Comparator|Everolimus-eluting stent (EES)|Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
2523787|NCT02738242|Experimental|Novus system users|Sixteen (16) subjects suffering from foot drop and thigh muscles weakness due to upper motor neuron injury or disease will be recruit for this study and will receive the Novus system for daily use.
2523806|NCT02738021|Experimental|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
2523839|NCT02737878|Experimental|Aerobic Training and Resistance Training (A&RT)|The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
3199324|NCT00879099|Experimental|Timosan 0.1% eye gel|The plasm levels of timolol will be measured after one drop of timolol has been administered into both eyes.
3199325|NCT00879112|Experimental|1|MB07811 Cohort 1
3199326|NCT00879112|Experimental|2|MB07811 Cohort 2
3199327|NCT00879112|Experimental|3|MB07811 Cohort 3
3199328|NCT00879112|Placebo Comparator|4|Cohort 4
3199329|NCT00879138|Placebo Comparator|Sugar pill|
3199330|NCT00879138|Experimental|VA106483 2 mg|
2522826|NCT02744768|Experimental|Treatment|"Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84. Prednisone (PDN) will be administered from day -6 to day +0 (during which the presence of the BCR/ABL1 alteration will be established), at escalating doses up to 60 mg/m2; PDN will be continued up to day +24 and progressively tapered up to day +31.~HLA typing will be performed immediately after the diagnosis for eligible patients.~MRD will be evaluated by RT-PCR at fixed time points (days +22, +45, +57) during the induction and at day +85, the latter for molecular response evaluation."
2522953|NCT02743884|Experimental|Esophageal Cooling Device|Esophageal cooling
2522954|NCT02743884|Experimental|Esophageal Warming|Esophageal warming
2522964|NCT02743637|Experimental|SDX-7320|Increasing dose cohorts, until the maximum tolerated dose (MTD) is determined.
3199331|NCT00879138|Experimental|VA106483 4 mg|
2523075|NCT02743156|Active Comparator|angiography-guided PCI|angiography-guided percutaneous coronary intervention
2523078|NCT02743156|Experimental|IVUS-guided PCI|intravascular ultrasound guided percutaneous coronary intervention
2523110|NCT02742844|Experimental|APZ2 application|Topical, single application of APZ2; 500000 cells per square cm;
2523168|NCT02742558|Experimental|cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
2523169|NCT02742558|Active Comparator|shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
2523223|NCT02742181|Experimental|Alvimopan group|In addition to standard postoperative care, patients randomized to the study group will be given 12mg of alvimopan orally twice a day, from the time of diagnosis of postoperative ileus to the time of return of bowel function or for 5 days.
2523224|NCT02742181|Other|Control Group|Patients randomized to the control group receive standard postoperative care which includes but is not limited to NPO status, IV fluid rehydration, and nasogastric decompression.
2523273|NCT02741817|Experimental|Aspirin 20mg|Supplied with sachets of 100mg soluble aspirin and training, instructions and equipment will be provided to prepare 20 mg dose twice daily x14 then aspirin 75mg once daily x14
2523282|NCT02741817|Experimental|Aspirin 75mg|This is the standard dose of aspirin the participant will already be taking. The study will require the participants to switch to soluble aspirin for two weeks to enable accurate comparison with the other dose and to take their aspirin dose in the morning. Participants will be provided with a supply of soluble aspirin, along with training, instructions and equipment to help prepare it. They should not take their usual aspirin tablets whilst receiving the study medication, but should continue all other usual medications.
2523325|NCT02741375||Brain Death Group (BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely brain-dead on the basis of this evaluation were classified as the BD group.
2523326|NCT02741375||Non-Brain Death Group (Non BD group)|Patients assessed as brain-dead at the first clinical evaluation by the OTBD committee were definitively diagnosed with BD through repeat clinical evaluation after 24 h or through CT angiography as a corroboratory test. Patients regarded as definitely not brain-dead on the basis of this evaluation were classified as the non-BD group.
2523410|NCT02741154|Experimental|aromataze group|patients will receive induction with HMG plus aromataze inhibitor plus GnRh antagonist plus HCG injection
2523412|NCT02741154|Active Comparator|classic group|same protocol for induction without aromataze inhibitor
2523499|NCT02740530|Experimental|rTMS Active|High frequency pulsed repetitive magnetic stimulation at 100 % resting motor threshold will be delivered using a figure of 8 air film cooled coil attached to the Magstim® Rapid 2 machine. Resting motor threshold will be determined minimum energy needed to elicit the a reliable visible contraction in the contra-lateral first interosseous muscle using single pulse rTMS applied to the area between C1-C3 using the 10-20 international EEG electrode system. For stimulation, the coil will be positioned on the scalp corresponding to F4 then F3 electrode position using the 10-20 international EEG system. Real stimulation will consist of delivering 1200 pulses at 20 hz frequency to F4 location followed by the same stimulation to F3. The total time needed to deliver pulses is 20 minutes.
2523501|NCT02740530|Placebo Comparator|rTMS Sham|Sham stimulation will also involve delivering the same stimulus but with angulation of the coil at 45 degrees, which will give similar scalp sensation but unlikely to deliver magnetic stimulation to the cortex
3199332|NCT00879138|Experimental|VA106483 8 mg|
3199333|NCT00879151|Experimental|Psychotherapy|Patients are randomized to one of three different types of psychotherapy: Cognitive-Behavioral Therapy for adolescents, Family-Based Therapy for Bulimia Nervosa, and Supportive Psychotherapy. All treatments consist of 18 sessions over a period of approximately 6 months.
2523610|NCT02739542|Active Comparator|Tecfidera|Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
2523612|NCT02739542|Placebo Comparator|Placebo|Placebo by mouth twice daily.
2523665|NCT02739165|Experimental|ART-123|
2523666|NCT02739165|Placebo Comparator|Placebo|
3199334|NCT00879177|Active Comparator|Group A|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, and ambulatory blood pressure monitoring at Weeks 6 and 24.
3199335|NCT00879177|Experimental|Group B|Study drug (varenicline) for 12 weeks, brief smoking cessation counseling for 5 weeks, ambulatory blood pressure monitoring at Weeks 6 and 24, and behavioral therapy for Weeks 2-5.
2524068|NCT02736292|Experimental|participant|
2524099|NCT02736084|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events Using personal strengths Gratitude letter Enjoyable and meaningful activities Recalling past success Performing acts of kindness Repeating one of the previous exercises."
2524301|NCT02734966|Experimental|arm 2|higher dose：Magnesium Isoglycyrrhizinate injection 200mg OD for 4 weeks.
3199336|NCT00879203||Type 1 Diabetes (T1DM)|Youth and young adults with T1DM
3199337|NCT00879203||Non diabetic siblings|Non diabetic, young siblings of T1DM participants
2523061|NCT02743247|Experimental|Tacrolimus and Mycophenolate mofetil|Tacrolimus 5mg single dose, Mycophenolate 1,000mg single dose, Tacrolimus 5mg and Mycophenolate 1,000mg single dose.
2523117|NCT02742974|No Intervention|FloTrac™ and EV1000™ pre and post-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the pre and post-operative period in the control arm.
2523123|NCT02742974|Experimental|FloTrac™ and EV1000™ peri-operatively|Cardiovascular management guided by minimally invasive hemodynamic monitoring via FloTrac™ and EV1000™ will be utilized in the perioperative period for the intervention arm
2523212|NCT02742467|Experimental|1|Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
2523216|NCT02742467|Active Comparator|2|Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
2523217|NCT02742467|Active Comparator|3|Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.
2523276|NCT02741830||Uterosacral ligament suspension (USLS)|This group of patients underwent the procedure of native tissue vaginal reconstructive surgery using uterosacral ligament suspension for pelvic organ prolapse.
2523283|NCT02741830||Robotic sacrocolpopexy (RSC)|This group of patients underwent the reconstructive pelvic surgery of robotic sacrocolpopexy using synthetic mesh.
3199338|NCT00879216|Placebo Comparator|Sugar pill|
3199339|NCT00879216|Experimental|VA106483|
2523465|NCT02740751|Active Comparator|Still-Tee|Generic name: galactogoe herbal tee, still-tee Dosage: Three cups (each 200 ml) of tea of Still-Tee galactogogue tea will be used Frequency: Three times in a day Duration: for 4 weeks after birth
2523468|NCT02740751|Placebo Comparator|Placebo|The mothers of the babies will receive placebo tea which does not contain galactogogue herbs
2523471|NCT02740751|No Intervention|Water|The mothers of the babies will receive water
2523520|NCT02740335|Experimental|Octaplex|Participants to receive1 Octaplex infusion intravenously
2523522|NCT02740335|Active Comparator|Beriplex P/N (Kcentra)|Participants to receive1 Kcentra infusions intravenously
2523630|NCT02739516|Active Comparator|Control|In letrozole stimulated cycle: On the day of ovulation trigger the patient received standard dose of Human chorionic gonadotropin (10,000 IU).
2523632|NCT02739516|Experimental|Study|In letrozole stimulated cycle: On the day of ovulation trigger the patient received hCG 10000 IU plus FSH co-trigger (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once .
2523675|NCT02739139|Placebo Comparator|Placebo|Placebo
2523680|NCT02739139|Experimental|AlphaBrain|AlphaBrain(TM)
2523727|NCT02738723|Experimental|GROUP 1|SBRT plus EP
2523732|NCT02738723|Active Comparator|GROUP 2|IMRT plus EP
3199340|NCT00879242|Experimental|Deferasirox|30 mg/kg/day. The daily dose can be increased to 40 mg/kg in case of unsatisfactory response after 12 weeks of treatment.
2523812|NCT02738060|Experimental|Case group|The patients in case group will be received baked milk daily in the form of muffin for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
2523856|NCT02737748|Experimental|Treatment Group|TWB-103 add-on Tegaderm
2523859|NCT02737748|Placebo Comparator|Control Group|Placebo+Tegaderm
2523899|NCT02737462|Experimental|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
2524006|NCT02736838|Experimental|Phase I|Interventions: Different positions will be applied to subjects to measure preipheral tissue oxygenation, pressure, and changes in microvascular flow. Subjects will be placed up to 4 hours in each of the standard positions for the experiment: supine decubitus (SD) right lateral decubitus (RLD), left lateral decubitus (LLD). SD measurements will be made at 0, 30 and 45 degrees of inclination to bed. RLD and LLD positions will be evaluated with a body inclination of 30 and 90ª. The subjects will lie down on a memory foam mattress for an articulated bed, as are commonly used at home, residential or hospital care. Between the subject and the mattress will be inserted the pressure measuring surface. Measurements in each position will be made during intervals of 0-4 hours in the same position (SD-RLD-LLD) in each of the inclinations of the bed (0º, 30°, 45 °) or body (30º, 90º), respectively.
2524049|NCT02736591|Active Comparator|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI
2524054|NCT02736591|Active Comparator|Growth hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
2524130|NCT02736006|Experimental|20 meters air dive|
3199341|NCT00879281|No Intervention|1 Care as usual|Regular care
3199342|NCT00879281|Experimental|2 Intervention|"Regular Care + individualized written action plan to enhance self-mananagement and early detection/treatment of an exacerbation."
3199343|NCT00879294|Sham Comparator|1 Wristband|Some patients will be randomized to wear a motion sickness wristband which does not have any drug effect.
2524356|NCT02734680|Experimental|Concurrent chemoradiotherapy(CCRT) Group|Concurrent chemoradiotherapy(CCRT) (Total dose: 46 Gy; Single dose: 2 Gy; Frequency: 23; Gemcitabine(GEM), 300 mg/m2 weekly); Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
2524359|NCT02734680|Experimental|Stereotactic Radiotherapy(SBRT) Group|Stereotactic Radiotherapy(SBRT) (Total dose: 45 Gy; Single dose: 3 Gy; Frequency: 15) Followed by taking S-1 orally (40 mg/m2, bid on Day 1-28, Q42d)
3199344|NCT00879294|Experimental|Chewing Gum|Patients will be randomized to use chewing gum after surgery.
3199345|NCT00879294|No Intervention|Control|Usual post-operative care.
3199346|NCT00879307|Experimental|1|Use of quetiapine
3199347|NCT00879320||1|Adults with ADHD
3199348|NCT00879320||2|Healthy adults without ADHD
3199349|NCT00879346|Experimental|1|160mg oral dose of AZD8931
3199350|NCT00879372|Placebo Comparator|1|Placebo
3199351|NCT00879372|Active Comparator|2|Tianeptine
3199352|NCT00879385|Experimental|All patients|All participants enrolled.
3199353|NCT00879424|Experimental|1|
2522928|NCT02744157|Other|structured lifestyle program|The program consisted of an individual visit to a nurse for a health check-up and lifestyle counseling at baseline, six month and one year. The program also consisted of five group educations which included lectures on nicotine, alcohol, physical inactivity, eating habits, stress, sleeping habits and behavior changes
3199354|NCT00879424|Placebo Comparator|2|
3199355|NCT00879450|Experimental|1 Booklet|
2523106|NCT02742857|Experimental|Treatment Group|
2523150|NCT02742584|Experimental|Group A|Cough Stress Test with a comfortably full bladder.
2523153|NCT02742584|Experimental|Group B|Cough Stress Test with an empty bladder after straight catheterization.
2523154|NCT02742584|Experimental|Group C|Cough Stress Test with a bladder infused with 200 cc of saline.
2523157|NCT02742584|Experimental|Group D|Cough Stress Test with the bladder filled to half functional capacity as determined from the largest voided volume recorded in the patient's voiding diary.
2523180|NCT02742298|Other|QMUS|All patients will undergo serial quantitative muscle ultrasound.
2523181|NCT02742298|Other|EIM|All patients will undergo serial electrical impedance myography measures.
2523277|NCT02741934||Preterm cohort|Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled.
2523286|NCT02741934||Term control cohort|The infants who were born from 2008 to 2009 with term gestational age will be enrolled.
2523338|NCT02741531|Experimental|Intervention|Patients in this group will have their bladder filled with 150 cubic centimeters (cc) of saline solution prior to being moved to the PACU.
2523345|NCT02741531|No Intervention|Control|patients in this group will have their bladders drained completely prior to being moved to the PACU as is the current standard of care.
2523425|NCT02741024|Active Comparator|Amodiaquine-Artesunate (ASAQ)|Treatment regimen consisted of Amodiaquine-Artesunate (ASAQ) fixed dose (FD) (Winthrop Sanofi Aventis), given as 1 tablet/day 3 days (5-8 kg 1 tab of 25mg artesunate/67.5 mg amodiaquine base, 9-17 kg 50 mg artesunate/135 mg amodiaquine base)
2523430|NCT02741024|Active Comparator|Artemether-Lumefantrine (AL)|Treatment consisted of Artemether-Lumefantrine (AL) (Coartem, Novartis) given as six twice/daily doses over three days (5-14 kg 1tab of 20mg artemether/120mg lumefantrine BD, 15-24 kg 2tabs of 20mg artemether/120mg lumefantrine BD with fatty food).
2523473|NCT02740556|Placebo Comparator|AdhereTech Passive Monitoring|Patients not using the HepCure patient app while AdhereTech passively monitors adherence (no chimes or reminders).
2523474|NCT02740556|Experimental|HepCure Toolkit|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard with AdhereTech passively monitoring adherence (no chimes or reminders).
2523479|NCT02740556|Experimental|HepCure Toolkit and AdhereTech Active Features|Patients using the HepCure patient app linked to a provider using the HepCure Provider Dashboard and with AdhereTech actively monitoring adherence (chimes and reminders enabled).
2523539|NCT02740296||Healthy controls|Healthy controls
2523540|NCT02740296||RRMS|Relapsing-Remitting Multiple Sclerosis
2523542|NCT02740296||RRMS+MDD|Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder
2523545|NCT02740296||MDD|Major Depressive Disorder
3199356|NCT00879450|Active Comparator|2 standard|
3199357|NCT00879463|Active Comparator|GROUP A|Brain tissue oxygen saturation monitoring
2523646|NCT02739308|Experimental|Intervention: Proprioceptive Training|"The intervention will be the implementation of a proprioceptive training program for the fencing athletes in the intervention group.~In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes, three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes, and preferably one of each category. The categories have exercises with different levels of difficulty and can change the exercises occur by different proposed levels or the complexity of the exercise by changing category. The training program will be implemented by the same evaluator over the 12 weeks."
2523648|NCT02739308|Placebo Comparator|Control|The control group will not make the intervention and will continue with the usual training fencing.
2523708|NCT02738918|Experimental|Nulojix|
2523788|NCT02738632|Experimental|Telmisartan/Amlodipine+Hydrochlorothiazide|Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
2523793|NCT02738632|Active Comparator|Telmisartan/Amlodipine|Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
2523831|NCT02737982||IHD Men|Men with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
2523833|NCT02737982||IHD Women|Women with acute or chronic ischemic heart disease undergoing percutaneous coronary interventions
2523843|NCT02737670|Active Comparator|Sulodexide|Sulodexide 25 mg twice per day for 40 days
2523847|NCT02737670|Placebo Comparator|Placebo|1 tablet twice per day for 40 days
3199358|NCT00879463|Active Comparator|GROUP B|CONTROL GROUP
3199359|NCT00879476|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
3199360|NCT00879476|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
2524155|NCT02735499|Experimental|Treatment with Botox|Onabotulinum toxin A. 200 units of Botox installed into the bladder by catheter.
2524240|NCT02735330|Active Comparator|GROUP 1|68 Patients undergo Frey's procedure with celiac plexus neurolysis using absolute alcohol
3199361|NCT00879502||1|Men with the fragile X premutation
3199362|NCT00879502||2|Healthy men
3199363|NCT00879502||3|Brothers of men with the fragile X premutation
3199364|NCT00879515||1|Males and females with fragile X syndrome, ages 5 to 25 years old
3199365|NCT00879515||2|Males and females with the FMR1 premutation, ages 5 to 25 year old
3199366|NCT00879515||3|Males and females with Down syndrome, ages 5 to 25 years old
3199367|NCT00879515||4|Males and females with normal development, ages 5 to 25 years old
3199368|NCT00879541|Other|PK Biostate® [SP]|"Part 1: PK subjects are randomized to receive Biostate® [SP] either on Day 1 or Day 8.~Part 3: All PK subjects receive Biostate® [SP] on Day 180."
3199369|NCT00879541|Other|PK Biostate® [RP]|Part 1: PK subjects are randomized to receive Biostate® [RP] either on Day 1 or Day 8.
2522947|NCT02744170|Experimental|COPD patients with delivery order 3, 1, 2|Patients on long-term oxygen therapy will perform 3 Endurance Shuttle Walk Tests on three consecutive days with one of three different Oxygen delivery devices.
2523000|NCT02743585|Experimental|Rapid diagnostic arm|"Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) AND FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen will be performed.~The Interventions to be administered are the rapid diagnostic tests: FilmArray Blood Culture ID (BCID) Panel test AND Rosco Diagnostica ESBL and carbapenemase screen.~Subjects will be recruited 8am-3pm daily, weekdays only. Results of the BCID and Rosco test will be communicated to the managing physicians by phone in real-time."
2523003|NCT02743585|No Intervention|Standard of care (control)|Standard Tan Tock Seng Hospital (TTSH) practices (bacterial culture and susceptibility testing) will be used. FilmArray BCID and Rosco Diagnostica ESBL and carbapenemase screen will NOT be performed. Subjects will be recruited 8am-3pm daily, weekdays only.
2523024|NCT02743338|Experimental|Sleep Restriction followed by additional CBT-i components|Sleep Restriction treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
2523025|NCT02743338|Active Comparator|Sleep Compression followed by additional CBT-i components|Sleep Compression treatment during 5+5 weeks. Followed by being offered an additional intervention consisting of other ICBT-i components during 10 weeks.
2523027|NCT02743338|Active Comparator|Sleep Restriction followed by no intervention|Sleep Restriction treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
2523029|NCT02743338|Active Comparator|Sleep Compression followed by no intervention|Sleep Compression treatment during 5+5 weeks. Followed by NOT being offered or informed of an additional intervention consisting of other ICBT-i components during 10 weeks.
2523144|NCT02742662|Experimental|Smart Technology Group|The Smart Technology Group will receive a technology-based lifestyle intervention program which uses wearable technology, smartscales and smartphone applications to track and deliver feedback on caloric expenditure, physical activity, caloric intake and body weight. Participants will receive information through smartphone applications on strategies to make changes to their diet, physical activity, and weight-related behaviors along with standard 3 monthly in-person weight management visits.
2523148|NCT02742662|Other|Standard Weight Management Group|The Standard Weight Management Group will receive 3 monthly in-person weight management visits during which they will receive standard of care lifestyle recommendations in accordance with the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guideline.
2523214|NCT02742337||Test|Newly diagnosed female patients with rheumatoid arthritis who have not previously used a disease modifying anti-rheumatic drug.
2523218|NCT02742337||Control|Female patients not having a diagnosis of rheumatoid arthritis and who have not previously used a disease modifying anti-rheumatic drug.
2523275|NCT02741921|Experimental|Normal airway|intubation with normal airway Cormack-Lehane classivication I
2523281|NCT02741921|Experimental|difficult airway|intubation with difficult airway Cormack-Lehane classivication III
2523391|NCT02740959|Experimental|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
2523399|NCT02740959|Experimental|Astragalus Polysaccharides 250 mg|PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
2523462|NCT02740621||Patients with coronary heart disease|coronary angiography with finding coronary heart disease currently no cancer 40 years or older
2523463|NCT02740621||control patients|coronary angiography with exclusion coronary heart disease or other patients with non-cardiac diseases currently no cancer 40 years or older
2523528|NCT02740387|Experimental|OTO-104|12 mg dexamethasone
2523567|NCT02739893|Experimental|Scope Guide Assisted|Scope Guide Assist to be utilized during colonoscopy
2523569|NCT02739893|Placebo Comparator|Standard|Colonoscopy completed using current SOC without scopeguide assist.
2523613|NCT02739633|Experimental|Genexol-PM + Gemcitabine|Genexol-PM125 mg/m2 will be administered in combination with gemcitabine 1,000 mg/m2 weekly for 3 weeks followed by one week of rest. Each cycle is 28 days.
2523656|NCT02739230|Active Comparator|Exparel Injection|
2523658|NCT02739230|Active Comparator|On-Q intraarthicual catheter placement|
3165923|NCT00519142|Experimental|3|metformin + mitiglinide two times a day with morning and evening meal, placebo for mitiglinide with midday meal
2523881|NCT02738294|Experimental|Suspected EGC group|Participants with suspected EGC from white light endoscopy were enrolled.The endoscopist first used white light endoscopy to identify suspected gastric lesions and assessed lesions carefully with magnifying view, non-magnifying NBI view and ME-NBI view in sequence. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
2523933|NCT02737228|Experimental|CG200745 PPA|CG200745 PPA plus Gemcitabine and Erlotinib
2523983|NCT02736929|Active Comparator|Cognitive Processing Therapy - Cognitive|Cognitive Processing Therapy - Cognitive (CPT-C), is a brief cognitive behavioral treatment for PTSD. CPT-C consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
2556726|NCT02521337||pregnant women in term labor|
3165924|NCT00519155|Experimental|1|Open flap debridement + MD05
3165925|NCT00519155|Active Comparator|2|Open flap debridement
3165926|NCT00519207|Active Comparator|1|This group will receive lidocaine and sucrose placebo (water).
3165927|NCT00519207|Active Comparator|2|This group will receive lidocaine placebo and sucrose.
3165928|NCT00519207|Active Comparator|3|This group will receive lidocaine and sucrose.
3165929|NCT00519220||I|Patients will answer symptom questionnaires and have their charts reviewed for relevant medical information.
3165930|NCT00519233|Experimental|1.AGS-1C4D4|
2523056|NCT02743416||ECG screening|Will be screened for AF using only one-stop protocol
2523060|NCT02743416||Control group|as per regular standard as of today
2523095|NCT02743039|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
2523097|NCT02743039|No Intervention|Control Standard of CAP|No assignment to participate in the CareerAdvance® program, but given community referrals and resources
2523146|NCT02742753||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
2523166|NCT02742389|No Intervention|Standard counseling|This group will receive the standard counseling that all our patients would receive if they are scheduled to have urodynamic testing. This counseling will include a description of the procedure and a handout about urodynamic testing
2523167|NCT02742389|Other|Standard + Preprocedure Telephone Call|The participants will receive the standard counseling that all our patients who are scheduled for urodynamic testing receive (just like those who are assigned to group 1). In addition, the participants will receive intervention: a pre-procedural telephone call from the investigators 1 week before their testing to talk about the procedure.
2523207|NCT02742194|Placebo Comparator|Placebo|Conventional treatment (restrictive diet) plus capsules of 200 mg of cellulose (placebo) to be taken three times a day for six months.
2523210|NCT02742194|Experimental|Ginger group|Conventional treatment (restrictive diet) plus capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
2523252|NCT02741882||Cases|Mothers who delivered a baby with microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
2523254|NCT02741882||Controls|Mothers who delivered a baby without microcephaly at Nossa Senhora de Lourdes maternity hospital located in Aracaju, state of Sergipe, Brazil from September 1, 2015 through January 5, 2016. The intervention will be a questionary.
2523288|NCT02741622|Experimental|Exercise|Acute High aerobic intensity training (HIT) and long slow distance training (LSD)
2523335|NCT02741362|Experimental|ADSC arm|Single intravenous administration of Stromal Vacsular Fraction (SVF) cells soinating Adipose Derived Stem Cells (ADSC) 6 week baseline data prior to the injection of ADSC will be collected. 6 week, 3 months and 6 months follow up data will be compared against baseline.
2523394|NCT02741050|Experimental|Tailored Physical Activity Intervention|Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
2523401|NCT02741050|Active Comparator|Standard of Care Control Group|Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.
2523495|NCT02740634|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive two Tau PET scans during this study.
2523498|NCT02740634|Experimental|PiB PET Scan, C-11 PiB|All subjects will receive two PiB PET scans during this study.
3165931|NCT00519246|Placebo Comparator|I|No drug was delivered.
3165932|NCT00519246|Active Comparator|II|Butorphanol tartrate 1mg was given intravenously.
2523686|NCT02739061|Active Comparator|cognitive behavioral group therapy|cognitive behavioral group therapy
2523688|NCT02739061|Active Comparator|drug therapy|drug therapy
2523691|NCT02739061|Active Comparator|The combination therapy|cognitive behavioral group therapy and drug therapy
2523742|NCT02738671||Type 1 Diabetes Mellitus|These T1DM patients have late diabetes onset.(latent autoimmune diabetes in adult, LADA)
2523743|NCT02738671||Type 2 Diabetes Mellitus|A subgroup of these T2DM patients are obesity patients who will have the bariatric surgery. These obese T2DM subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain MRI at baseline and 6 months after their surgery.
2523744|NCT02738671||Control|A subgroup of these non-diabetic people are obesity patients who will have the bariatric surgery. These obese subjects will undergo a physical exam, cognitive and olfactory test as well as structural and functional brain fMRI at baseline and 6 months after their surgery.
2523876|NCT02738320|Experimental|Intervention|Intervention patients will receive access to NHCPlus when discharge to a nursing home from the hospital is expected.
2523878|NCT02738320|No Intervention|Usual Care|Control patients will receive the usual care when discharge to a nursing home from the hospital is expected.
2523932|NCT02737280|Active Comparator|Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
2524039|NCT02736695|Experimental|Tau PET Scan, F-18 AV 1451|All subjects will receive a Tau PET scan.
3165933|NCT00519246|Active Comparator|III|Butorphanol tartrate 2 mg was given intravenously.
3165934|NCT00519246|Active Comparator|IV|Flurbiprofen Axetil 50 mg was given intravenously.
3165935|NCT00519246|Active Comparator|V|Flurbiprofen Axetil 100 mg was given intravenously.
3165936|NCT00519246|Active Comparator|VI|Tramadol Hydrochloride 10 mg was given intravenously.
3165937|NCT00519246|Active Comparator|VII|Tramadol Hydrochloride 20 mg was given intravenously.
3165938|NCT00519272||Cervical Cancer Care Questionnaires|New cervical cancer patients through stage IVB presenting to the LBJ Gyn-Onc Clinic.
3165939|NCT00519298|Experimental|1|
3165940|NCT00519298|Placebo Comparator|2|
3165941|NCT00519298|Active Comparator|3|
3165942|NCT00519311|Experimental|School based health intervention|Educational intervention based on health diary + health check
3165943|NCT00519311|No Intervention|Usual care|Normal school curriculum and usual medical care
3165944|NCT00519324|Experimental|RAD001|
3165945|NCT00519337|Active Comparator|1|Ascorbic acid
3165946|NCT00519337|Placebo Comparator|2|Identical placebo
3165947|NCT00519350||I|Liver surgery
3165948|NCT00519350||II|Colon surgery
3165949|NCT00519350||III|Femur Fracture
3165950|NCT00519389|Experimental|Low dose H5N1 VLP Vaccine|
3165951|NCT00519389|Experimental|Mid dose H5N1 VLP Vaccine|
3165952|NCT00519389|Experimental|High dose H5N1 VLP Vaccine|
3165953|NCT00519389|Placebo Comparator|Placebo|
2523012|NCT02743546|Experimental|Dose Expansion: Participants with FL|Participants with FL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2523014|NCT02743546|Experimental|Dose Expansion: Participants with MCL|Participants with MCL will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
2523019|NCT02743546|Experimental|Dose Expansion: Participants with CLL|Participants with chronic lymphocytic leukemia (CLL) will receive intravenous infusions of duvortuxizumab either with or without a priming dose in combination with oral ibrutinib at the recommended phase 2 dose until disease progression, unacceptable toxicity, or other protocol-specified withdrawal criteria are met.
3199370|NCT00879541|Experimental|Efficacy|Part 2: This arm includes all subjects during the efficacy component of the study.
3199371|NCT00879554|Experimental|1|
3199372|NCT00879580||Non-ruptured aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have one or more non-ruptured or late ruptured (>30days), intracranial aneurysm.
3199373|NCT00879580||Acute ruptured Aneurysms|Patients with intracranial aneurysm(s) requiring an endovascular treatment with a Codman ENTERPRISE stent who have a on or more acute ruptured (<30Days) aneurysms
3199374|NCT00879593|Experimental|PtcCO2|
2523372|NCT02740998||Depo Provera|Ten women ages 18-40 who elect to start a using Depo Provera for contraception.
2523373|NCT02740998||Mirena IUD|Ten women ages 18-40 who elect to start a using a Mirena IUD for contraception.
2523374|NCT02740998||Nexplanon|Ten women ages 18-40 who elect to start a using Nexplanon for contraception.
2523375|NCT02740998||Control: Tubal Sterilization|Five women ages 18-40 who elect to have a tubal sterilization.
2523467|NCT02740595|Experimental|Nicotine|Use an e-cig filled with liquid with nicotine
2523470|NCT02740595|Experimental|no nicotine|Use an e-cig filled with liquid without nicotine
2523475|NCT02740595|Sham Comparator|sham comparator|Use an empty e-cigarette (sham control)
2523535|NCT02740309|Experimental|Integrated Brief Behavior Therapy (IBBT) Intervention|4-sessions of IBBT for youth anxiety and depression.
2523537|NCT02740309|Active Comparator|Treatment as usual|Treatment as usual
3199375|NCT00879606|Experimental|1|Participants will be randomized to receive ALT-836.
2523706|NCT02738866|Experimental|Palbociclib and Fulvestrant|Participants will receive fulvestrant with palbociclib until disease progression or unacceptable toxicity.
2523875|NCT02738515|Active Comparator|Group 1|Scaling and Root Planing (SRP) with 0.75% BORIC ACID GEL for treating furcation defect
2523877|NCT02738515|Placebo Comparator|Group 2|Scaling and Root Planing (SRP) with PLACEBO GEL for treating furcation defect.
2523942|NCT02737267|Experimental|Moderately high protein diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 40% of the energy derived from carbohydrates, 30% of the energy derived from protein and 30% of the energy derived from fat
2523949|NCT02737267|Placebo Comparator|Low fat diet|Caloric restriction (-30% total energy intake) Macronutrient distribution: 60% of the energy derived from carbohydrates, 18% of the energy derived from protein and 22% of the energy derived from fat
2523992|NCT02736981|Active Comparator|Behavioral Weight Loss (BWL)|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment.
2523995|NCT02736981|Active Comparator|BWL + Autonomous Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
2524206|NCT02735395|Active Comparator|MTZ 250 (14 days)|SRP +MTZ (250mg/TID) + AMX for 14 days
3199376|NCT00879606|Placebo Comparator|2|Patients will be randomized to receive placebo.
3199377|NCT00879632||1|TREATMENT AS USUAL
3199378|NCT00879632||2|CONTROLS
3199379|NCT00879671|Active Comparator|1|Lutamax
3199380|NCT00879671|Placebo Comparator|2|Placebo
3199381|NCT00879723|Experimental|Vitamin and mineral supplementation|Intravenous micronutrient solution or an oral micronutrient supplementation twice per day for 14 days. Treatment is determined by percent total body surface area burned.
3199382|NCT00879723|No Intervention|Control|current vitamin regimen as listed on the Memorial medical Center Order Set for burn unit admission.
3199383|NCT00879736|Active Comparator|THT PACE eLearning module|The PACE (prepare, ask, check, express) training methodology will be available to patients before their 2nd doctor visit
3199384|NCT00879736|Active Comparator|THT PACE eLearning module & nurse-led workshop training|THT PACE eLearning and then nurse-led workshop for training on PACE methodology
3199385|NCT00879736|Placebo Comparator|Usual care|Patients just go to their doctor as they normally would but get some disease specific information in the form of brochures as do intervention arms
3199386|NCT00879749|Placebo Comparator|Saline|
3199387|NCT00879749|Experimental|Nexvax2|
3199388|NCT00879762|Experimental|Group A: High Dose|Single high dose of IMVAMUNE® (5x10^8 TCID50, consisting of two 0.5 mL injections) vaccine on Day 0 and a single saline placebo dose (single 0.5 mL injection) on Day 28 to match the two dose regimen of Group B.
3199389|NCT00879762|Active Comparator|Group B: Standard Dose|Standard two dose regimen of IMVAMUNE® (1x10^8 TCID50) vaccine on Day 0 (consisting of 0.5 mL injection of vaccine and 0.5 mL injection of saline placebo) and Day 28 (single 0.5 mL injection of vaccine).
2523064|NCT02743195|Other|Polyphenol/prebiotic blend|Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
2523089|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI|with/without Charcoal Block
2523090|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI (replicate)|with/without Charcoal Block
2523092|NCT02743013|Active Comparator|CHF 5993 100/6/12,5 pMDI VHC|with/without Charcoal Block with Valved Holding Chamber
2523096|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 1|with/without Charcoal Block
2523098|NCT02743013|Experimental|CHF 5993 100/6/12,5 DPI test 2|with/without Charcoal Block
2523221|NCT02742428|Experimental|Ascites drainage before surgery.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. An indwelling catheter insertion into abdominal cavity and slow, systematic ascites evacuation for 7 or more days before surgery (if it cannot be scheduled immediately) will be performed. Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
2523222|NCT02742428|Other|Observation.|A group of patients with (or suspected for) advanced ovarian cancer and significant ascites. A standard of care: observation or acute paracentesis (>5000ml) will be performed while waiting for the surgery (if it cannot be scheduled immediately). Patients will undergo an interview, will be asked to fill in questionnaires concerning a quality of life and nutritional status. If available noninvasive bioimpedance analysis will be performed and 2ml of blood will be taken for serum prealbumin concentration evaluation. If possible 20ml of ascitic fluid will be taken for cytology examination.
2523291|NCT02741778|Other|Minimally invasive group|"In this group, all manipulations are finished by laparoscopy and thoracoscopy.~Horizontal position, undergoing laparoscopy through 5-port method. The sequence: gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes ), gastric tube making, and jejunostomy.~Left lateral position, undergoing thoracoscopy through 3-port method. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection, gastro-esophageal anastomosis by using CEEA."
2523295|NCT02741778|Other|Open group|"Right lateral position, Traditional thoracotomy through the 7th intercostal incision. The sequence: mobilization of lower esophagus, lower paraesophagesl nodes and diaphragmatic nodes dissection.~Then,oped the diaphragm,undergoing gastric mobilization, lymph nodes dissection(including paracardial nodes, left gastric nodes, and detecting splenic nodes and common hepatic nodes), gastric tube making, gastro-esophageal anastomosis by using CEEA. Nasointestinal tube is placed for feeding."
2523337|NCT02741336|Experimental|CBT-I Intervention|For those randomized to the CBT-I group, the therapist will initiate telephone-delivered cognitive-behavioral therapy within 2 weeks of baseline assessment. Participants will complete 4 telephone sessions over a period of 8 weeks. Sessions last approximately 45 minutes. CBT-I is a short-term, focused psychotherapy that is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training.
2523344|NCT02741336|Active Comparator|Self-Monitoring Control Group|Individuals randomized to the self-monitoring control group will be asked to complete a weeklong sleep diary every other week for 8 weeks. The sleep diary will inquire about (1) the time of getting into bed; (2) the time at which the individual attempted to fall asleep; (3) sleep onset latency; (4) number of awakenings; (5) duration of awakenings; (6) time of final awakening; (7) final rise time; (8) perceived sleep quality (rated via Likert scale); and (9) an additional space for open-ended comments from the respondent. The control condition is designed to increase self-monitoring, which has been demonstrated to be an effective means of inducing change for various health behaviors such as diet and exercise.
2523388|NCT02741102|Experimental|Women with AUFI|Women with AUFI must meet criteria for uterine transplant. In vitro fertilization to obtain 6 (screened) healthy embryos for cryo-preservation precedes uterine transplant from an appropriate donor The recipient will be required to take potent anti rejection medications including Thymoglobulin, Prednisone, Tacrolimus, Mycophenolate Mofetil (MMF) , later substituted with Azathioprine to avoid birth defects. One year later, up to 6 attempts using 1 screened embryo at a time will be tried to achieve pregnancy. During pregnancy, the high risk pregnancy and transplant teams will follow the recipient. The goal is a full term baby and delivery will be by Caesarian section. A second pregnancy may be attempted. Afterward, the uterus will be explanted.
2523490|NCT02740673|Other|Driving simulator|Using the driving simulator for 30 min.
2523523|NCT02740270|Experimental|Arm A|
2523524|NCT02740270|Experimental|Arm B|
2523606|NCT02739685|Experimental|Bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
2523608|NCT02739685|Active Comparator|Stent|Implantation everolimus-eluting stent in chronic total occlusion
2523651|NCT02739282|Active Comparator|Systematic therapeutic drug monitoring|"Systematic therapeutic drug monitoring performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring (rescue therapeutic drug monitoring, transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events."
2523653|NCT02739282|No Intervention|"Rescue therapeutic drug monitoring"|"In the rescue therapeutic drug monitoring arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached."
2523712|NCT02738931|Experimental|Treatment Sequence ABC|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2524212|NCT02735395|Active Comparator|MTZ 400 (14 days)|SRP +MTZ (400mg/TID) + AMX for 14 days
2523105|NCT02742831|Experimental|Intervention|"The intervention group will receive a one-on-one in-person intervention of 6 sessions, each lasting approximately 60 minutes. The intervention is intended to be delivered over a period of 12 weeks, with sessions occurring every 1-2 weeks. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episodes where parent felt stressed and episode where things went well. Identification of sources of interpersonal support.~Stress relief. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation exercises.~Positive parenting, review of parenting challenges.~Reflection, repeat behavioral chain analysis. Update crisis plan."
2523107|NCT02742831|Active Comparator|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
2523151|NCT02742623||Rivaroxaban|Female and male patients with active cancer and treated with rivaroxaban after a diagnosis of DVT/ and/or PE
2523191|NCT02742259||Beta Cutoff|Assay
2523192|NCT02742259||Pivotal|Assay
2523240|NCT02742051|Experimental|Everolimus+Letrozole|everolimus 10mg/d,po + letrozole 2.5mg/d,po * 18 weeks
2523242|NCT02742051|Active Comparator|Fluorouracil+epirubicin+cyclophosphamide|Fluorouracil 600mg/m2,iv,d1 + epirubicin 90mg/m2,iv,d1 + cyclophosphamide 600mg/m2,iv,d1 * 6 cycles (every 21 days per cycle)
2523258|NCT02741648||ELBW Infants with Prolonged Irradiation Storage Time|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion had prolonged Irradiation Storage Time (IST) being tested with metabolomics profile.
2523260|NCT02741648||ELBW Infants without Irradiation Storage|Extremely Low Birth Weight Infants whose Red Blood Cell (RBC) transfusion did not have Irradiation Storage being tested with metabolomics profile.
2523262|NCT02741648||ELBW Infants with NEC|"Extremely Low Birth Weight Infants with Necrotizing Enterocolitis (NEC defined as Bell's Stage II or greater) and receiving Red Blood Cell (RBC) Transfusions being tested with Near Infrared Spectroscopy."
2523264|NCT02741648||ELBW Infants without NEC|Extremely Low Birth Weight Infants without Necrotizing Enterocolitis being tested with Near Infrared Spectroscopy.
2523323|NCT02741401|Active Comparator|Therapy standard|Patients receive usual postoperative care
2523324|NCT02741401|Experimental|Therapy standard + hand-foot massage|Patients receive usual postoperative care and hand-foot massage
3165954|NCT00519402||Partial Tonsillectomy|Patients who received a partial tonsillectomy
3165955|NCT00519402||Complete Tonsillectomy|Patients who received a complete tonsillectomy
2523469|NCT02740608|Other|Liver transplantation|All Participants will receive liver transplantation using the OrganOx metra device
2523517|NCT02740361|Experimental|Deprexis|This group will receive access to the web-based Deprexis program, an online tool based on principles of cognitive behavioral therapy. Contents include (1) psychoeducation, (2) behavioral activation, (3) cognitive modification, (4) mindfulness and acceptance, (5) interpersonal skills, (6) relaxation, physical exercise and lifestyle modification, (7) problem solving, (8) expressive writing and forgiveness, (9) positive psychology, and (10) emotion-focused interventions.
2523519|NCT02740361|Experimental|DeprexisPlus|This group will receive the web-based Deprexis program (see above) plus scheduled e-mail contact (1x/week)
2523521|NCT02740361|No Intervention|Waitlist Control|Participants randomized to the control group will wait for access to the Deprexis program (waitlist control) for 6 months. After the 6-month waiting period, participants in this group will have full access to Deprexis.
2523574|NCT02739945|Other|Open cubital tunnel release|In situ decompression (MacKinnon and Novak 2005) is made through a 6-10 cm longitudinal incision along the course of the ulnar nerve midway between the medial epicondyle and the olecranon.
2523575|NCT02739945|Other|Endoscopic cubital tunnel release|Endoscopic release follows Hoffmann's technique (Hoffmann 2006) that demonstrated the safety and efficacy of this technique in a cadaveric model and in a clinical study.
2523620|NCT02739581|Experimental|Endoscopic variceal ligation with Non-selective B-blockers|
2523622|NCT02739581|Active Comparator|Endoscopic variceal ligation with Placebo|
2523650|NCT02739178|Experimental|GSF Sanitation intervention|This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
2523655|NCT02739178|No Intervention|Comparator|This arm will receive the GSF intervention in 2017 or later.
2523757|NCT02738645||pneumonia in RICU|The patients admit in RICU because of pneumonia.
2523781|NCT02738216|Experimental|Prenatal Yoga|A 9-week prenatal yoga program
2523783|NCT02738216|Active Comparator|Mother Baby Wellness Workshop|A 9-week workshop on mother and baby wellness in the first postpartum year
2523813|NCT02737995|Experimental|Iron Replacement|
2523852|NCT02737774|Experimental|Icotinib and Pemetrexed/Carboplatin|"Icotinib: Icotinib for 18 weeks, 125mg Tid，PO. Chemotherapy: pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.~Then continue with Icotinib, 125mg Tid，PO. until disease progression."
2523901|NCT02737488|Experimental|TST|
2523904|NCT02737488|Active Comparator|TAU Group|
2523956|NCT02737124|Experimental|1000 Mg Acetaminophen|Acetaminophen will be given 24 hours before surgery
2523960|NCT02737124|Active Comparator|Placebo|A sugar pill will be given 24 hours before the scheduled surgery.
2524027|NCT02736656|Experimental|Open-Label Treatment|"Subjects 6-11 yrs of age will be treated with 100 to 400 mg SPN-812 ER (100 mg capsule).~Subjects 12-17 yrs of age will be treated with 100 to 600 mg SPN-812 ER (100, 200 mg capsule).~Subjects are given a choice to extend their participation in the study every 6 months for up to 72 months."
2524124|NCT02735954||Marijuana Users|Individuals who use marijuana
2524127|NCT02735954||Combined Marijuana and Tobacco Users|Individuals who use marijuana and also smoke cigarettes
2524135|NCT02735954||Non-Marijuana Users|Individuals who do not use marijuana
3165956|NCT00519415|Experimental|A|
3165957|NCT00519415|Experimental|B|
3165958|NCT00519441|Other|I|All patients in the study will have pH studies done in order to determine the degree of reflux after laparoscopic Heller myotomies.
3165959|NCT00519454||Female Lupus patients|Females who are still childbearing age, not on hormones, with Systemic Lupus Erythematosus, still cycling.
2523108|NCT02742779|Experimental|High-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2523111|NCT02742779|Experimental|High-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a high-fat meal after a 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 3.
2523113|NCT02742779|Experimental|Low-Fat Meal SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using PIC on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2523114|NCT02742779|Experimental|Low-Fat Meal SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose given orally using PIC based on PK results from earlier SD cohorts up to an established dose yielding at least a 2-fold exposure margin to the MTD administered orally following a low-fat meal after an 8-hour/overnight fast using solution on Day 1 of the treatment period (5 days) in an additional cohort of Part 1.
2523119|NCT02742779|Experimental|MD Cohort: PIC (Part 2)|Participants will receive multiple ascending dose administered orally using PIC from Day 1 to Day 13 twice daily (BID) or may even be thrice daily (TID) or four times a day (QD) depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
2523125|NCT02742779|Experimental|MD Cohort: Solution Formulation (Part 4)|Participants will receive multiple ascending dose in fed or fast condition, administered orally using solution from Day 1 to Day 13 BID or may even be TID or QD depending on clinical PK, followed by morning dose on Day 14 in 7 cohorts of Part 2.
2523127|NCT02742779|Placebo Comparator|Placebo PIC|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
2523133|NCT02742779|Placebo Comparator|Placebo Solution|Participants will receive placebo matched to GDC-0310 single or multiple ascending dose administered orally in the fasted (SD cohorts) or fed state using PIC on Day 1 of the treatment period (5 days) to the SD cohorts and from Day 1 to 14 BID or may even be TID or QD depending on clinical PK, to the MD cohorts.
2523134|NCT02742779|Experimental|SD Cohort: PIC (Part 1)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using PIC on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 1.
2523136|NCT02742779|Experimental|SD Cohort: Solution Formulation (Part 3)|Participants will receive GDC-0310 single ascending dose administered orally in the fasted state using solution formulation on Day 1 of the treatment period (5 days) in the 9 cohorts of Part 3.
2523219|NCT02742350|Experimental|IMT+Exercise|The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
2523220|NCT02742350|No Intervention|Exercise Control|Aerobic Exercise and Stretching
2523256|NCT02741895||Postoperative patients|The target populations for the study are patients undergoing robotic cystectomy, open colectomy, abdominal hysterectomy, esophagectomy, lung lobectomy, gastric bypass, and hip replacement at Cedars-Sinai Medical Center.
2523298|NCT02741557|Experimental|DTG/RPV FDC-DTG plus RPV|Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 2 under fed state.
2523306|NCT02741557|Experimental|DTG plus RPV-DTG/RPV FDC|Subjects will receive a single oral dose of separate tablet formulations of DTG 50 mg and RPV 25 mg together in Period 1 under fed state. After a washout period of at least 21 days, subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet in Period 2 under fed state.
2523339|NCT02741219|Placebo Comparator|Control Group|Parturients in this group receive 20ml intravenous normal saline immediately after delivery. Their patient controlled analgesia (PCA) protocol after surgery consists of 100 mcg sufentanil diluted into 100ml and administer at a background infusion of 1ml/h,and a bolus of 2ml, with a lock-out of 8min.
2523347|NCT02741219|Experimental|Dex Group|Parturients in this group receive 0.5mcg/kg intravenous dexmedetomidine diluted to 20ml with normal saline. Their PCA protocol after surgery is 100mcg sufentanil and 300mcg dexmedetomidine diluted to 100ml in saline, with the continuous infusion of 1ml/h, and a bolus of 2 ml, with a lock-out of 8min.
3165960|NCT00519480|Placebo Comparator|Subjects receiving treatment P|Eligible subjects will receive placebo twice daily along with metformin twice daily for 13 days.
3165961|NCT00519480|Experimental|Subjects receiving treatment A|Eligible subjects will receive GSK189075 500 milligrams twice daily along with metformin twice daily for 13 days.
3165962|NCT00519480|Experimental|Subjects receiving treatment B|Eligible subjects will receive GSK189075 750 milligrams twice daily along with metformin twice daily for 13 days.
3165963|NCT00519493|Active Comparator|Suture|A keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
3165964|NCT00519493|Active Comparator|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
3165965|NCT00519519|Active Comparator|2|regular dose versus high dose
2523505|NCT02740452|Other|standard technique|Ligamys technique (device) or standard technique
2523160|NCT02742597|No Intervention|Group D|Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention.
2523200|NCT02742233|Experimental|saxagliptin|"saxagliptin & Regular treatment:~saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd"
2523201|NCT02742233|Placebo Comparator|placebo|"placebo & Regular treatment:~placebo, dose: 5mg, po, qd"
2523245|NCT02741908|Experimental|Fixed diet plan|Patients received a fixed diet plan to assist in the choice of foods aimed at changing eating behavior. Dietary intake was evaluated by using 3 nonconsecutive 24-hour dietary recalls collected at each visit. Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
2523248|NCT02741908|Experimental|Calorie counting diet|Patients underwent a calorie counting diet, in which each patient has received a table list with equivalent points for food and drinks, and was instructed to record all daily food or drink intake and calculate the total score of points consumed (1 point = 3.6 calories). They were allowed to eat any food but were limited to the recommended amount of points (or calories equivalents). Received a reduction of 500 calories in the total energy expenditure calculated by the equation predicted by Dietary Reference Intake (DRI) from the Institute of Medicine (2005). Also received qualitative information regarding healthy food behaviours, by a same dietitian, based on the DRI for Acceptable Macronutrient Ranges, appropriated for age and gender.
2523292|NCT02741674||Roux-en-y gastric bypass (RYGB)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) Roux-en-y gastric bypass from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
2523296|NCT02741674||Adjustable gastric banding (AGB)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) adjustable gastric banding procedure from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
2523302|NCT02741674||Sleeve gastrectomy (SG)|"Adults and children age ≤79 years at time of surgery~Had a primary (not revision) sleeve gastrectomy from years 2005-2015 (based on ICD-9-CM, CPT-4, and HCPCS codes)~Have a Body Mass Index (BMI) measurement in the year prior to surgery that is ≥35 kg/m2 for adults and adolescents"
3165966|NCT00519545|Experimental|1|scripted prayer group (intervention group)
3165967|NCT00519545|No Intervention|2|no prayer intervention group (non-intervention group)
2523714|NCT02738827|Other|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.
3165968|NCT00519571|Experimental|1|
3165969|NCT00519597|Experimental|I|Asymptomatic OSA (CPAP)
2523836|NCT02737709|Experimental|Paclitaxel and Carboplatin regimen|Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection. 21 days per cycle; 6 cycles in total.
2523871|NCT02737579|Other|XFM guidance|X-ray fused cardiac MRI images used for guidance tool to perform cardiac catheterization procedure
2523930|NCT02737306|Experimental|PRO 140|up to 60 subjects will be enrolled. PRO 140 will be administered as a 525 mg subcutaneous injection on Day -3 or Day -2 prior to stem cell infusion, on the day of stem cell infusion (Day 0), and then weekly for up to 100±7 days. Subjects will return to the clinic for three Follow-up visits at 2 weeks after the last treatment visit, 30 days after the last treatment visit and one year after the first treatment visit.
2523976|NCT02736942|Active Comparator|Laparoscopic|Laparoscopic TME
3165970|NCT00519597|No Intervention|II|Asymptomatic OSA (no CPAP)
3165971|NCT00519597|Active Comparator|III|Symptomatic OSA (OSAS)
3165972|NCT00519597|No Intervention|IV|Non-OSA
3165973|NCT00519610||I|Patients will have charts reviewed for relevant medical information before and after surgery to assess patient outcome after placement of H-graft shunt for the treatment of portal hypertension.
3165974|NCT00519662|Experimental|Dose escalating cohorts of SNS-314|Sequential groups, starting at a dose of 30 mg/m2, will be escalated according to identification of dose limiting toxicities against various criteria. Doses escalated by doubling the dose until the first observation of clinically significant Grade 2 or greater toxicity related to SNS-314 injection. Results in dosing increments of 67%, 50%, 40%, 33%, and subsequently 25% based on modified Fibonacci schema.
3165975|NCT00519688|Experimental|Thalidomide plus Tegafur/Uracil1|Thalidomide plus Tegafur/Uracil
3165976|NCT00519701|Experimental|1|hydroxyurea
3165977|NCT00519714|Placebo Comparator|1|three placebo capsules PO three times daily.
3165978|NCT00519714|Active Comparator|2|1-MNA 90 mg daily: one active treatment capsule and two placebo capsules PO three times daily
3165979|NCT00519714|Active Comparator|3|1-MNA 270 mg daily: three active treatment capsules PO three times daily.
3165980|NCT00519727|Experimental|A|50 mg ISIS 325568 vs Placebo, s.c. injection
3165981|NCT00519727|Experimental|B|100 mg ISIS 325568 vs Placebo , s.c. injection
3165982|NCT00519727|Experimental|C|200 mg ISIS 325568 vs Placebo , s.c. injection
3165983|NCT00519727|Experimental|D|400 mg ISIS 325568 vs Placebo, s.c. injection
3165984|NCT00519727|Experimental|AA|50 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3165985|NCT00519727|Experimental|BB|100 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3165986|NCT00519727|Experimental|CC|200 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3165987|NCT00519727|Experimental|DD|400 mg ISIS 325568, 3x over 1 week i.v. infusion, weekly s.c. injection for 5 weeks vs Placebo
3165988|NCT00519753|Experimental|DuoTrav|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
3165989|NCT00519792|Experimental|1|Omega DUROS: Dose 25
3165990|NCT00519792|Experimental|2|Omega DUROS: Dose 50
3165991|NCT00519857|Active Comparator|1|Tibolone
3165992|NCT00519857|Placebo Comparator|2|Placebo
3165993|NCT00519870|Active Comparator|I, II|I: nifedipine II: losartan
3165994|NCT00519883|Active Comparator|A|Arm A: Standard Supportive Care (no supervised exercise)
3199390|NCT00879788|Experimental|1|Ramipril capsules 10 mg (containing Ramipril 10 mg)of of OHM Laboratories Inc., USA (a subsidiary of Ranbaxy Pharmaceuticals Inc), USA
3199391|NCT00879788|Active Comparator|2|ALTACE® capsule 10 mg (containing Ramipril 10 mg)of King Pharmaceuticals Inc., Bristol, TN 37620, USA
3199392|NCT00879801||Subjects with IGR|Subjects at high risk of diabetes, such as those with impaired glucose regulation (IFG and or IGT)
3199393|NCT00879827|Experimental|Single Group|
3199394|NCT00879840||Females|With endometrial cancer, ovarian cancer, and women undergoing hysterectomy for benign reasons.
2523329|NCT02741427|Placebo Comparator|G1 (group 1) - Conventional toothpaste|G1 used a conventional toothpaste in daily oral regimen
2523331|NCT02741427|Experimental|G2 (group 2) - Whitening toothpaste|G2 used a whitening toothpaste containing blue pigment in daily oral regimen
2523334|NCT02741427|Active Comparator|G3 (group 3) - 10 % Carbamide peroxide|G3 made an at-home tooth bleaching with 10 % Carbamide peroxide
2523421|NCT02741011|Other|Radiological imaging|Mentally handicapped patients underwent sedation anesthesia with IV Propofol and then tomographic images were obtained with NewTom 5G. Orthopantomographies (OPGs) were obtained by processing the raw images and radiological examination of the patients were performed on OPGs.
3199395|NCT00879853|Experimental|Interpersonal Therapy|
3199396|NCT00879853|No Intervention|Wait List Control|
2523568|NCT02739958|Active Comparator|Propofol group|Patients receive only intravenous anesthetics
2523571|NCT02739958|Placebo Comparator|Isoflurane group|Patients receive isoflurane /fentanyl anesthesia
2523595|NCT02739620|Experimental|NMES|Neuromuscular electrical stimulation (NMES) group
2523603|NCT02739620|No Intervention|Control|Control group
2523647|NCT02739373|Experimental|BMS-986189|Specified Dose on Specified Day
2523649|NCT02739373|Placebo Comparator|Placebo|Specified Dose on Specified Day
2523711|NCT02738905|Experimental|Rifaximin|Participants will receive study drug for a period of 7 days.
2523880|NCT02738567||local anesthesia with adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia with adrenaline
2523885|NCT02738567||local anesthesia without adrenaline|patients undergoing surgery or medical procedure with the use of local anesthesia without adrenaline
2523944|NCT02737241|Active Comparator|LP-HoLEP|Low power Holmium laser enucleation of the prostate
2523947|NCT02737241|Active Comparator|HP-HoLEP|High power Holmium laser enucleation of the prostate
2523994|NCT02737033|Experimental|Rhodiola|Rhodiola rosea 800mg single dose
2524000|NCT02737033|Placebo Comparator|Placebo|placebo 800mg single dose
3199397|NCT00879866|Experimental|1|
3199398|NCT00879892|Active Comparator|Hypothermia and xenon|
2524156|NCT02735681|Active Comparator|Probing Treatment Right Eye|Meibomian gland will be performed on the right upper eye lid of each participant.
2524159|NCT02735681|Placebo Comparator|Fellow Eye (Left) Untreated|The fellow eye (left) will be used at the untreated control
2524255|NCT02735317|Experimental|FORRAD group|"This group of patients will receive Oral Ulcer Gargle (FORRAD®) during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the experimental group."
2524261|NCT02735317|Active Comparator|Quadruple mixture group|"This group of patients will receive quadruple mixture, which is composed of dexamethasone, gentamicin, vitamin B12, and procaine, during study for prevention and treatment of acute radiation-induced oral mucositis (OM).~This is the active comparator group."
3199399|NCT00879892|Active Comparator|Hypothermia|
3199400|NCT00879905|Experimental|once weekly dosing schedule|
3199401|NCT00879905|Experimental|twice weekly dosing schedule|
3199402|NCT00879918|Experimental|Nicotine pharmacokinetics|circadian smoking protocol and IV pharmacokinetic protocol
3199403|NCT00879931|Experimental|1|methylprednisolone
3199404|NCT00879931|Placebo Comparator|2|Placebo (NaCl 0.9%)
3199405|NCT00879944||Psoriasis|Children ages 5-17 years old with moderate or severe plaque type psoriasis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
3199406|NCT00879944||Atopic Dermatitis Controls|Children ages 5 to 17 years old with moderate to severe atopic dermatitis. Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
3199407|NCT00879944||Healthy Controls|"Children 5-17 years of age who are healthy and seen in dermatology clinic for a non-systemic skin condition.~Blood pressure will be measured once while patient is seated Height will be measured in centimeters at the time of enrollment Weight will be measured in kilograms at enrollment Body Mass Index (BMI) will be calculated from a subject's height and weight Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm"
3199408|NCT00879957|Active Comparator|Heparin group|The heparin group is the arm of the study in which all of the subjects will be treated according to current standard medical therapy. All fluids to be infused through their PICCs will have 0.5 units heparin per milliliter of intravenous fluid.
3199409|NCT00879957|Experimental|No heparin group|This group will only receive the prescribed fluids to infuse through their PICCs. No heparin will be added to the intravenous infusions.
3199410|NCT00879983|Other|Group 1|Will accept azithromycin ER first, after at least 14 days washout, then accept azithromycin tablet.
3199411|NCT00879983|Other|Group 2|Will accept azithromycin tablet first, after at least 14 days washout, then accept azithromycin ER .
3199412|NCT00880035|Experimental|Group A|Group A: day 1 = music, day 2 = washout, day 3 = headphone without music
3199413|NCT00880035|Experimental|Group B|Group B: day 1 = headphone without music, day 2 = washout, day 3 = music
2523170|NCT02742506|Experimental|Brain-damaged patients|Electroencephalography (EEG) will be performed in patients in coma, in a vegetative state or in a minimally conscious state to assess the P300 response after different auditive stimulations
2523171|NCT02742506|Active Comparator|Healthy volunteers|Electroencephalography (EEG) will be performed in healthy participants to assess the P300 response and medial prefrontal cortex activity after different auditive stimulations
2523227|NCT02742168|Experimental|Breast Cancer,99mTc-3PRGD2,SPECT/CT|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of breast cancer
2523289|NCT02741843|Experimental|Patient Education|
2523293|NCT02741843|No Intervention|Control|
3165995|NCT00519883|Experimental|B|Arm B: Exercise Intervention
2523360|NCT02741180|Other|Patients with Arrhythmias|
2523362|NCT02741180|Other|Healthy Control|
2523377|NCT02740881|Experimental|Training Support System|Participants receive training in Contingency Management and immediately receive the full training support system and quality assurance feedback for 15 months while they provide the treatment.
2523378|NCT02740881|Active Comparator|CM-CAT then TSS|Participants are trained in Contingency Management and use the treatment without training support and quality assurance feedback for 9 months. After 9 months they continue using Contingency Management but now receive the full training support system and quality assurance feedback for 6 months.
2523491|NCT02740725|Active Comparator|Recommendation of Patching|Patients will receive two hours of patching in the case of one line difference of best corrected visual acuity(BCVA) between two eyes during one month.
2523492|NCT02740725|Active Comparator|Recommendation of Patching and interactive binocular treatment|Patients will receive interactive binocular treatment addition to patch therapy in the least of 4 to 5 days of a week within 20-30 minutes in each day during one month.
2523550|NCT02740205|No Intervention|Control group|Hospital's standard EN support at the discretion of the Clinical Nutrition Service that is composed by physicians, dietitians, and students, provides nutritional assessments, recommendations and consultations for the in-patients that required nutrition support during their hospitalization stay. There is no protocols or algorithms for the nutritional support in our institution, the currently clinical practice of the EN is prescribed by the physician, dietitians and students during the morning rounds each 24h, the kind of EN formulas prescribed depends of the clinical status of the patient, when the patients required protein supplements modular protein supplements are added.
2523557|NCT02740205|Experimental|Algorithm for enteral nutrition support|Initial infusion of 20 to 40 ml/h, evaluated the tolerability in the next 8-12h, then the infusion can be increased 25 ml/ 8-12h for gastric infusion and 10-20 ml/h for the post-pyloric feeding, for bolus infusion an initial infusion of 125 ml each 4-5hrs and evaluated the tolerability in the next 8-12h. If the subject present intolerability to the EN, the action in the algorithm indicate hold the infusion 4h then restarted at 10 ml/h with prokinetics agents rather than the suspension. As a part of the intervention, several educational sessions for the medical, nutritionist and nurse staff were performed during the period of the study.
2523601|NCT02739763|Experimental|Plasmodium falciparum sprozoite (PfSPZ) challenge|Challenge agent
2523780|NCT02738307|Experimental|altitude exposure|Altitude Exposure Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
2523860|NCT02737839|Experimental|Arm 1: STEPPING ON|"Adaptation Waves is to adapt Stepping On to the oncology setting/Pilot Waves is to determine the feasibility & acceptability of the program for older adults receiving cancer care/Gait & Balance Waves is to determine whether the participants experience changes in their gait & balance~Complete baseline questionnaires about Instrumental Activities of Daily Living, Medical Outcome Study Activities, Karnofsky Performance Status, falls in past 3 months, medications, comorbidities, vision & hearing, The Falls Behavioral Scale, The Falls Efficacy Scale-International, Patient Reported Outcome pain, PRO neuropathy~7 week STEPPING ON program is multi-component learning environment which has shown to help reduce falls~A home visit to gather any feedback on the experience of the program~Follow-up questionnaires up to 3 months after completion of the program~Participants may elect to participate in a booster session to reinforce concepts 3-6 months after completion of the program"
2523887|NCT02737371|Experimental|F901318 Dose level A oral|F901318 adverse events days 1-10
2523889|NCT02737371|Placebo Comparator|Placebo Dose level A oral|Placebo adverse events days 1-10
2523891|NCT02737371|Experimental|F901318 Dose level B oral|F901318 adverse events days 1-10
2523893|NCT02737371|Placebo Comparator|Placebo Dose level B oral|Placebo adverse events days 1-10
2523894|NCT02737371|Experimental|F901318 Dose level C oral|F901318 adverse events days 1-10
2523895|NCT02737371|Placebo Comparator|Placebo Dose level C oral|Placebo adverse events days 1-10
2523969|NCT02737098|Active Comparator|Standard Implementation|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
2523982|NCT02737007|Experimental|[14C]-GSK3191607 IV Microdose|Subjects will receive a single microdose of 100 micrograms (mcg) of [14C]-GSK3191607 by intravenous infusion over 15 minutes on Day 1 of the study.
3165996|NCT00519909|Other|1|Diet with high content of calcium and high content of fat
3165997|NCT00519909|Other|2|Diet with low content of calcium and high content of fat
3165998|NCT00519909|Other|3|Diet with high content of calcium and normal content of fat
3165999|NCT00519909|Other|4|Diet with low content of calcium and normal content of fat
3166000|NCT00519909|Other|5|Diet with high content of calcium fra supplement and high content of fat
3166001|NCT00519922|Experimental|1|KBA = Kinesthesia, Balance, Agility Exercise Training
3166002|NCT00519922|Active Comparator|2|Standard Lower Extremity Strength Training
3166003|NCT00519935|Experimental|Multisystemic Therapy|In-home, intensive family therapy
3166004|NCT00519935|No Intervention|Standard Medical Care (TAU)|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
3166005|NCT00519961|Experimental|A|
3166006|NCT00519961|Experimental|B|
3166007|NCT00519987|Experimental|Treatment A|intranasal ketamine
2523177|NCT02742220|Experimental|Isometric Handgrip Training Group|Experimental group will perform home-based unilateral handgrip exercise and will be recommended to increase daily physical activity levels.
2523178|NCT02742220|Sham Comparator|Control Group|Control group will be recommended to increase daily physical activity levels.
2523225|NCT02742142|Placebo Comparator|control|Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
2523230|NCT02742142|Experimental|silver diammine fluoride|the subjects received the same intervention as those provided to subjects in the control group except that a 38% SDF solution (Saforide, Toyo Seiyaku Kasei Co. Ltd, Osaka, Japan) instead of the placebo solution was painted onto the exposed tooth root surfaces. This treatment was repeated after 12 and 24 months.
2523268|NCT02741791|Experimental|AXS-05|
2523272|NCT02741791|Active Comparator|Bupropion|
2523383|NCT02740842|Active Comparator|Non-intensive group|Essential Health Care (EHC) only This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
2523386|NCT02740842|Experimental|Intensive group|"Interpersonal behavioral change communication This arm will have a behavior change communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.~In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm."
2523477|NCT02740647|Experimental|Intervention group|Intervention group will be getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery.
2523481|NCT02740647|Placebo Comparator|Control group|the Control group will be getting intra-venous Placebo (0.9% 50 ml of sodium chloride) for 5 days.
2523512|NCT02740322|Other|Hum Test|To examine and compare the Hum Test, Weber Test, and audiogram in their ability to detect and identify hearing loss, hearing loss will be simulated with the use of ear plugs (mimicking conductive hearing loss). Subjects will serve as their own control as these tests will be conducted with and without ear plugs.
2523536|NCT02739971|Active Comparator|Low AGEs diet|Participants randomized to this arm will receive active instruction on reducing dietary AGEs intake, in addition to standard of care dietary guidance for type 2 diabetes.
2523538|NCT02739971|Placebo Comparator|Standard of care dietary guidance|Participants randomized to this arm will only recieve standard of care dietary guidance for type 2 diabetes.
2523635|NCT02739490|No Intervention|Group control|It does not perform any kind of guided exercise.
2523639|NCT02739490|Experimental|Core Training Group|The training was distributed in four positions defined ventral plank, side plank left, right side board and bridge semiflexion knees, respectively. With time isometric contraction of 30 seconds repeated four times with rest 30 seconds between repetitions. During 10 sessions distributed twice weekly.
2523676|NCT02739087|Experimental|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures.
2523741|NCT02738684||lung cancer|A small sample exploratory study to predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free nucleic acids EGFR gene mutation test
2523764|NCT02738385|Experimental|High Intensity Interval Training|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal until the end of training.
2523770|NCT02738385|Active Comparator|Moderate Intensity Interval Training|Walking on a treadmill at 60-80% peak heart rate until expenditure of 300 kcal until the end of training.
2523810|NCT02738099||Arrest from presume Cardiac etiology|Comatose patients following arrest of presumed cardiac etiology arriving to receiving facility within 12 hours of event.
2523837|NCT02737813|Experimental|Isobaric Marcaine|Isobaric Marcaine 2.2 mL for spinal block
2523838|NCT02737813|Active Comparator|Hyperbaric Marcaine|Hyperbaric Marcaine 2.2 mL for spinal block
2523912|NCT02737527|Experimental|Ultrasound with Fluoroscope|"This group undergoes lumbar sympathetic block using ultrasound and fluoroscope.~Preparation: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Ultrasound for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
2523914|NCT02737527|Active Comparator|Fluoroscope only|"This group undergoes lumbar sympathetic block using fluoroscope only.~Device: Inserts 24G intravenous route for Lumbar Sympathetic Block (LSB) Device: Uses 15-cm Chiba needle for Lumbar Sympathetic Block (LSB) Device: Uses Fluoroscope for Lumbar Sympathetic Block (LSB) Drug: 10 ml of 0.25% levobupivacaine injection for LSB Intervention: Temperature measurement for Lumbar Sympathetic Block (LSB) Intervention: Postprocedure care for LSB"
2523974|NCT02736916|Experimental|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
2523975|NCT02736916|Active Comparator|Conventional PCI|LD-SCLC patients with Conventional PCI
2524035|NCT02736708||PSC|Male or female > 18 years of age Clinically Indicated for ERCP and/or cholangioscopy for dominant PSC stricture Inclusion of patients either previously stented or not
2524076|NCT02736266|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered at the dose of 200mg, as a 30-minute intravenous infusion, every 3 weeks, for a total of 3 cycles prior to radical cystectomy.
2524120|NCT02735863|Experimental|ABX464|Fixed dose of ABX464 50mg once daily given during 28 days in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
2524121|NCT02735863|Placebo Comparator|ABX464 Matching placebo|Matching placebo of ABX464 given at 50mg once daily in association with darunavir + ritonavir (DRV/RTV) or darunavir + cobicistat (DRV/COBI)
2524238|NCT02735356|Experimental|Treatment (itraconazole and placebo)|Patients apply itraconazole topically BID and placebo topically BID for 12 weeks.
2523354|NCT02741206|Active Comparator|High Risk PTSD Group 1|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
2523355|NCT02741206|Active Comparator|High Risk PTSD Group 2|Forty women who are eligible for the study will be randomized into either the Bellevue ROSE intervention (treatment group) or a psycho-education session and usual, standard of care (control group 1)
2523357|NCT02741206|Experimental|Low Risk PTSD Control|Twenty additional women, who are at lower risk and thus not eligible for randomization, will also receive one psycho-education session and usual care (control group 2).
2523443|NCT02740777|Experimental|2-dose adolescent|300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.
2523445|NCT02740777|Experimental|3-dose adolescent|300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
2523448|NCT02740777|Experimental|3-dose adult|300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.
2523494|NCT02740491||The study population|The study population consists of adult patients diagnosed with localized breast cancer who have completed adjuvant treatment (chemotherapy, radiotherapy) and who are cared for in the Medical Oncology department of the Nîmes University Hospital.
2523553|NCT02740166|No Intervention|Banding ligation group|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
2523559|NCT02740166|Experimental|Propranolol group|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
2523614|NCT02739477|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
2523640|NCT02739217|Experimental|PBI-4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2523661|NCT02739022|Experimental|Early Psychological Support for the Critically Ill (EPSCI)|patients will receive EPSCI in parallel with medical treatment
2524022|NCT02736734|Other|CRH condition|All HV first underwent a baseline manometry measurement. After 30 minutes, an intravenous CRH injection was done. The same measurement was repeated but now with CRH administered.
3166008|NCT00520000|Active Comparator|Weekly Arm|Carboplatin day 1, abraxane days 1, 8, 15 every 28 day cycle
3166009|NCT00520000|Experimental|Every 3 week Arm|Carboplatin day 1, abraxane day 1, every 21 day cycle
2524091|NCT02736045|No Intervention|Control|Sham control. Subjects will be asked to write a journal (per week).
2524094|NCT02736045|Experimental|emWave|Our approach will be to test the impact of a behavioral intervention through a smartphone application, emWave software, which will be provided to all our subjects. The intervention (emWave) is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention.
2524145|NCT02735772|Other|cystocele|"Arm: Patients with paravaginal defect cystocele~Intervention: transobturator approach for paravaginal repair"
2524307|NCT02735057|Experimental|Phase I|"for chemotherapy 3 levels: 50%, 75% and 100% of the standard Dutch dose (carboplatin AUC 2 and paclitaxel 50 mg/m2)~for radiotherapy 3 levels: 41.4 Gy/1.8 Gy/f; 45 Gy/1.8 Gy/f; 50.4 Gy/1.8 Gy/f basel level being : 41.4 Gy and 50% of standard CT doses The phase I is conducted with increasing doses of each component with 9 levels."
2524372|NCT02734732|Active Comparator|Ciprofloxacin|T. Ciprofloxacin 750mg, single dose immediately prior to prostate biopsy
2524377|NCT02734732|Active Comparator|Trimethoprim/Sulfamethoxazole|Trimethoprim/Sulfamethoxazole 160mg/800mg immediately prior to prostate biopsy
2524414|NCT02734277||Group 1: Detectable C-peptide by MMTT|"Participants with detectable C-peptide at their:~Last Immune Tolerance Network (ITN) T1DM week 104 study visit,~Last AbATE (NCT00129259) follow-up visit, or~Last ITN066AI T1DES visit~Detectable C-peptide is defined as a value above the lower limit of detection."
2524418|NCT02734277||Group 2:Undetectable C-peptide by MMTT|"Participants without detectable C-peptide at their:~Last ITN T1DM week 104 study visit,~Last AbATE follow-up visit, or last~ITN066AI T1DES visit~Undetectable C-peptide is defined as a value below the lower limit of detection."
3166010|NCT00520000|Experimental|Arm C|Carboplatin day 1, abraxane day 1, 8 every 21 day cycle
3166011|NCT00520026|Active Comparator|1|Lithium treatment
3166012|NCT00520026|Placebo Comparator|2|Placebo treatment
3166013|NCT00520052|Active Comparator|LHRH Group|Patients on LHRH agonists and zoledronic acid
3166014|NCT00520052|Active Comparator|Bicalutamide Group|Patients on Bicalutamide and zoledronic acid
3166015|NCT00520065|Experimental|#1|Diabetes specific enteral product
3166016|NCT00520065|Active Comparator|#2|Standard enteral feeding
3166017|NCT00520091|Active Comparator|Cohort 1|Induction chemotherapy and chemoradiation without celecoxib
3166018|NCT00520091|Experimental|Cohort 2|Induction chemotherapy and chemoradiation with celecoxib
3166019|NCT00520104|Experimental|A|intranasal ketamine
3166020|NCT00520104|Experimental|B|oxymetazoline plus intranasal ketamine
3166021|NCT00520104|Experimental|C|intranasal steroid plus intranasal ketamine
3166022|NCT00520117||negative pap-smear|
3166023|NCT00520117||positive pap-smear|
3166024|NCT00520169|Active Comparator|A|oral ketamine
3166025|NCT00520169|Experimental|B|intranasal ketamine
3166026|NCT00520169|Active Comparator|C|intravenous ketamine
3166027|NCT00520182|Active Comparator|1|ADA 2003 diet
3166028|NCT00520182|Active Comparator|2|Low Glycemic index (LGI) diet
3166029|NCT00520182|Active Comparator|3|MUFA diet
3166030|NCT00520221||2|"Minocycline group: 300 mg of minocycline hydrochloride was instilled into the pleural space through the catheter.~Control group consisted of 33 patients who had successful simple aspiration alone between January 2004 and December 2005."
3166031|NCT00520260|Active Comparator|1|Active treatment arm bromfenac 0.09% BID for 6 weeks
3166032|NCT00520260|Active Comparator|2|ketorolac 0.4% BID for 6 weeks
3166033|NCT00520273|Experimental|A|
3166034|NCT00520325|Other|0.5 mg/kg|
3166035|NCT00520325|Other|1.0 mg/kg|
3166036|NCT00520338|Placebo Comparator|2|"placebo~celecoxib"
2523257|NCT02741960|Placebo Comparator|placebo|Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.
2523290|NCT02741544||Patients with newly-diagnosed multiple myeloma (NDMM)|Patients with newly-diagnosed multiple myeloma (NDMM) who are treated with Revlimid Capsules (Revlimid)
2523341|NCT02741453|Active Comparator|Standard Practice|Placement of a CVC by standard practice
2523346|NCT02741453|Experimental|Bilateral IJ Ultrasound Scanning|Placement of a CVC after mandatory ultrasound scanning of both right and left internal jugular veins
2523393|NCT02741063|Experimental|high autistic and oxytocin group|subject with high ASQ scores will receive oxytocin treatment
2523400|NCT02741063|Experimental|low autistic and oxytocin group|subject with low ASQ scores will receive oxytocin treatment
2523406|NCT02741063|Placebo Comparator|high autistic and placebo group|subject with high ASQ scores will receive placebo treatment
2523409|NCT02741063|Placebo Comparator|low autistic and placebo group|subject with low ASQ scores will receive placebo treatment
2523543|NCT02740179|Experimental|Eplerenone|Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
2523547|NCT02740179|Placebo Comparator|Placebo|Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
2523590|NCT02739776||A|Pt receiving standard Epidural block care for vaginal delivery
2523633|NCT02739399|Other|Patient receiving phenylephrine 2ug/kg|phenylephrine 2ug/kg in case of hypotension
2523644|NCT02739126|Active Comparator|Thick USS (1.7mm) with use of additional aspiration needle|
2523645|NCT02739126|Active Comparator|Thin USS (1.4mm)|
2523678|NCT02738957|Other|Prenatal Counseling Group|"Patients in the PCG will receive specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one two midwives involved in the study. The information will include: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models. During the counseling sessions patients will have the opportunity to discuss questions on breastfeeding."
2523681|NCT02738957|No Intervention|Control Group|No breastfeeding counseling during the antenatal period will be provided. The Control Group will receive non-specific counseling with standard orientation regarding breastfeeding after delivery and during their postpartum hospitalization period. This standard orientation will be provided by one of the midwives of the hospital during a single counseling session with brief guidance covering the following topics: starting breastfeeding, hygiene, infants' conditions, colostrum/breast milk, infants' positions, duration of breastfeeding, frequency of feeds, mammary milking, and stopping breastfeeding.
2523725|NCT02738697|Experimental|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
2523730|NCT02738697|Other|Follow-up|Routine follow-up were performed instead of adjuvant chemotherapy
2523767|NCT02738411||The study population|The study population corresponds to infants born at less than 33 weeks of gestation.
2523928|NCT02737319|Experimental|Rosuvastatin|40 mg of Rosuvastatin up to 6 hours before elective percutaneous coronary intervention.
2523939|NCT02737319|No Intervention|Control|Use of standard therapy in elective angioplasty.
2523993|NCT02737059|Placebo Comparator|Codeine/naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and placebo tablet matching naloxegol q.d."
2523997|NCT02737059|Placebo Comparator|Naloxegol/ codeine placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Naloxegol tablet 25 mg q.d and placebo tablet matching codeine q.i.d."
2524001|NCT02737059|Active Comparator|Codeine/ naloxegol|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Codeine tablet 30 mg q.i.d., and naloxegol tablet 25 mg q.d."
2524003|NCT02737059|Active Comparator|codeine placebo/ naloxegol placebo|"Each subject will receive two medications to which they are randomized for 1 day before and for the 2 days during transit measurement.~Placebo tablet matching codeine q.i.d., and placebo tablet matching naloxegol q.d."
2524033|NCT02736461||Group 1- With strabismus|Study group with strabismus happening after floor fracture repair
2524034|NCT02736461||Group 2- Without strabismus|No strabismus happening after floor fracture repair
2524071|NCT02736305|Experimental|Regorafenib|Patients will receive Regorafenib 120mg once daily, with consideration for dose escalation to 160mg if there are no toxicities
3166037|NCT00520338|No Intervention|1|1 placebo
3166038|NCT00520364||History of chemotherapy|IVF after chemotherapy
3166039|NCT00520364||IVF without history of chemotherapy|IVF without history of prior chemotherapy
3166040|NCT00520377|Experimental|1|MD05
3166041|NCT00520377|Active Comparator|2|Beta-TCP and autologous bone
3166042|NCT00520416||1|There is no control or experimental group. The same patients undergoing endovascular AAA repair with serve as their own control
3166043|NCT00520429|Other|1|This study is an open pilot; therefore all participants were given the opportunity to receive treatment.
3166044|NCT00520442|Experimental|Ibuprofen|
3166045|NCT00520442|Active Comparator|acetamin w codeine|
3166046|NCT00520455|No Intervention|Control|Control participants were advised where they could obtain hormonal contraception on a sliding scale basis. Participants were also advised where they could obtain hormonal contraception on a sliding scale basis.
3166047|NCT00520455|Experimental|Intervention|Study subjects were prescribed levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and a package of 30 condoms provided via a commerical pharmacy at no cost to the study subject. The subject could refill this prescription as many times as they wanted for 12 months
3166048|NCT00520507|Experimental|1|
3166049|NCT00520507|Placebo Comparator|2|
2523284|NCT02741609|Experimental|Early/Late Stage Lyme disease|Have early Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with early stage Lyme disease. Subjects must have a physician-diagnosed erythema migrans (EM) rash and should have systemic symptoms indicative of disseminated infection. Symptoms may include fever, headache, fatigue, myalgias, arthralgias, and stiff neck. Paired acute and convalescent titers will be drawn (first draw at time of initial visit and second draw 4 weeks later). Have late Lyme disease based on the following criteria: Signs, symptoms and clinical history consistent with late stage Lyme disease, including but not limited to disseminated rash, arthritis, meningitis, facial palsy, or carditis. Qualified subjects will be administered the Borrelia Diagnostic Test.
2523506|NCT02740400|Experimental|CT-TTNB|patients receive CT-TTNB to diagnose PPLs.
2523507|NCT02740400|Experimental|EBUS-GS|patients receive EBUS-GS to diagnose PPLs.
2523599|NCT02739672|Experimental|TAH tablet|Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet
2523605|NCT02739672|Active Comparator|Telmisartan+Amlodipine besylate+Hydrochlorothiazide|coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide
2523652|NCT02739334|Experimental|ENRICH|The intervention will integrate the Play and Learning Strategies (PALS) program, a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler with Coordinated Approach To Child Health (CATCH), a behaviorally-based school health promotion program based on Social Cognitive Theory (SCT) to increase opportunities for healthy eating and activity.
2523654|NCT02739334|Active Comparator|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
2523879|NCT02738229|Experimental|Valacyclovir|"Valacyclovir will be given twice a day with following doses according to weight:~10 to 13,9 kg : Valacyclovir 250 mg PO twice per day 14 to 19,9 kg : Valacyclovir 375 mg PO twice per day 20 to 28 kg : Valacyclovir 500 mg PO twice per day"
2523882|NCT02738229|Placebo Comparator|control|placebo pill
2523934|NCT02737202|Experimental|Saracatinib|Saracatinib will be given orally at a dose of 125 milligrams once daily for 9 months. Saracatinib is provided as a pink tablet.
3166050|NCT00520598|Active Comparator|1|Arm 1: 0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen.
3166051|NCT00520598|Experimental|2|Arm 2: 0.5 ml injection of V505 formulation 1 as 3 dose regimen.
3166052|NCT00520598|Experimental|3|Arm 3: 0.5 ml injection of V505 formulation 2 as 3 dose regimen
3166053|NCT00520598|Experimental|4|Arm 4: 0.5 ml injection of V505 formulation 2 as 2 dose regimen and 1 Pbo injection
2524040|NCT02736617|Experimental|Treatment (obinutuzumab and ibrutinib)|Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
2524102|NCT02736123|Experimental|Arm A consists of 3 phases or steps|"Induction Phase Nivolumab 3 mg/kg IV infusion every 2 weeks for 3 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 3 mg/kg IV infusion every 3 weeks"
2524104|NCT02736123|Experimental|Arm B consists of 3 phases or steps|"Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses~Definitive Surgery Complete lymph node dissection/ lymphatic, cutaneous, subcutaneous disease resection (week 6-8+)~Maintenance Phase (after recovery from surgery) Nivolumab 1 mg/kg IV infusion every 3 weeks for 2 doses given concurrently with Ipilimumab 3 mg/kg IV infusion every 3 weeks for 2 doses; then, Nivolumab 3 mg/kg IV infusion every 3 weeks"
2524142|NCT02735720||TEVAR group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with TEVAR.~Standard work-up examinations for TEVAR will be collected, consisting of computed tomography (CT), echocardiography, blood pressure, heart rate, ECG and blood tests. Prior to the TEVAR procedure, a non-invasive MRI scan and blood samples will be acquired. Intraoperative pressure measurements will be collected during the TEVAR. One year following TEVAR, the subject will undergo a second non-invasive MRI study in addition to the standard clinical imaging follow-up CT-scan. Measurements of blood pressure, heart rate, ECG, and blood testing will also be repeated at follow-up."
2524144|NCT02735720||Non-TEVAR medical treatment group|"Adult patients whose clinician's are managing their thoracic aortic aneurysms or with penetrating aortic ulcers with pharmacological treatment alone.~Patients with stable thoracic aortic aneurysms or with penetrating aortic ulcers not requiring aortic repair are monitored in the outpatient clinic as standard of care. The investigators will collect blood pressures and heart rates in these patients, which are acquired as standard of care. In addition, in this study, these subjects will undergo an ECG, blood testing and one non-invasive MRI scan at baseline. One year after baseline, this group will undergo a second non-invasive MRI study, with subsequent blood pressure and heart rate measurements, ECG and blood testing."
2524195|NCT02735395|Placebo Comparator|Control|Scaling and root planing (SRP) + two placebo pills thrice a day (TID) for 14 days (control group)
2524198|NCT02735395|Active Comparator|MTZ 250 (7 days)|SRP + MTZ (250mg/TID) + AMX, for 7 days and placebos for another 7 days
2524201|NCT02735395|Active Comparator|MTZ 400 (7 days)|SRP + MTZ (400mg/TID) + AMX, for 7 days and placebos for another 7 days
3166054|NCT00520598|Experimental|5|Arm 5: 0.5 ml injection of V505 formulation 3 as 2 dose regimen and 1 Pbo injection
3166055|NCT00520611|Active Comparator|Lottery|Participants are entered into daily lotteries to win $10 or $100 every day their weight is at or below daily targets.
3166056|NCT00520611|Active Comparator|Deposit|Participants receive $3/day if they are at or below their daily weight goals, plus have opportunity to deposit up to $3/day of their own money, which is then matched 1:1 every day they are at or below their daily weight goals.
3166057|NCT00520611|No Intervention|Control|Participants would receive usual care from their providers and have monthly weigh ins.
3166058|NCT00520624|Experimental|1|Treatment 1, for those with high degree of EIL
3166059|NCT00520624|Experimental|2|Treatment 2, for those with high degree of EIL
3166060|NCT00520624|No Intervention|3|Control group of those with high degree of EIL
2523308|NCT02741856|Experimental|Arm 4 (Cisplatin+Capecitabine+high RT dose)|"Cycle 1: Week 1-3: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 2: Week 4-6: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 3: Week 7-9: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-21~Cycle 4: Week 10-11: cisplatin 60mg/m2 on D1 and capecitabine 625mg/m2 bd D1-14 Cycles 3 and 4 are given concomitantly with radiotherapy (60Gy/25 fractions). Capecitabine stops on last day of RT."
2523397|NCT02740868|Active Comparator|Healthy|Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
2523403|NCT02740868|Active Comparator|Cystic Fibrisos|Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
2523407|NCT02740868|Active Comparator|Asthma|Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.
3199414|NCT00880074|Experimental|FLT-PET Scan|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. 3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
2523525|NCT02740348|Experimental|ZocDoc Assistance|Research assistant sets up follow-up appointment for subject using ZocDoc.
2523526|NCT02740348|Active Comparator|ZocDoc Information|Research assistance provides subject with written information about ZocDoc.
2523527|NCT02740348|No Intervention|Usual Care|ED staff gives written and verbal discharge instructions to subject.
2523588|NCT02739646|Experimental|Females|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2523589|NCT02739646|Experimental|Males|Functional MRI scan of the somatosensory cortex while the breast skin is stimulated by piezo-stimulators.
2523659|NCT02739412|Experimental|Interleukin-2|IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.
3199415|NCT00880113||Acute stroke|Patients over 18 years of age with acute stroke symptoms of less then 9 hours duration and no hemorrhage on non-contrast CT.
3199416|NCT00880126|Experimental|CDT|Community Development Teams bring together counties who are implementing a new practice
2523791|NCT02738281||Rett Syndrome|This is a prospective natural history study examining the phenotypic variations of individuals with mutations in MECP2 or meeting the diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome. The overwhelming majority will be female, but males meeting diagnostic criteria will be included. No interventions are planned.
2523797|NCT02738281||MECP2 Duplication|This is a prospective natural history study examining the phenotypic variations of individuals with MECP2 duplications. The majority are expected to be males, but females expressing a duplication will be included. No interventions are planned.
2523798|NCT02738281||RTT related disorders|This is a prospective natural history study examining individuals, both females and males who do not meet criteria for Rett syndrome, but have a mutation in MECP2, CDKL5, or FOXG1. No interventions are planned.
2523823|NCT02737943|Experimental|Arm1 Mebo|20 : receiving Moist Exposed Burn Ointment (MEBO) at sites of donor graft and recipient at time of operation and in dressing
2523825|NCT02737943|Placebo Comparator|Arm2 Placebo|20 : receiving Standard cream Zagazig University Hospital (Antibiotics & analgesics)
2523854|NCT02737657||Cohort 1|Participants who are already receiving Canagliflozin and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as the part of study.
2523858|NCT02737657||Cohort 2|Participants who are already receiving any sulphonylurea and Metformin with or without a DPP-4 inhibitor daily during Ramadan period will be observed as a part of study.
2523915|NCT02737436|Experimental|Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
2523917|NCT02737436|Experimental|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
2523970|NCT02737085|Experimental|Diffuse Large B Cell Lymphoma(DLBCL)|The trial will be conducted in a manner of simon two-stage design with Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with Diffuse Large B Cell Lymphoma(DLBCL). Only when the expected reaction rate is achieved the 30 patients left can be recruited.
3199417|NCT00880152|Experimental|MBSR|An 8-week course in mindfulness-based stress reduction (MBSR)
3199418|NCT00880152|No Intervention|2|Treatment as usual
2524105|NCT02736019|Active Comparator|Celecoxib|Women will receive oral celecoxib 200mg 2 hours before the procedure
2524106|NCT02736019|Active Comparator|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
2524107|NCT02736019|Placebo Comparator|Placebo|Women will receive a placebo similar to celecoxib and a placebo similar to Tramadol
2524179|NCT02735668|Active Comparator|Shoulder Conventional Exercises|"The protocol consists in:~Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment.~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
2524182|NCT02735668|Experimental|Multimodal Physiotherapy|"The protocol consists in:~Dry Needling in active myofascial trigger points.~Neurodynamic techniques.~Scapular exercises.~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
2524191|NCT02735668|Experimental|Scapular exercises|"The protocol consists in:~Scapular exercises~Therapeutic Education about chronic shoulder pain.~The treatment duration is 1 day per week during 6 weeks."
2524312|NCT02735135|Experimental|Airsoft Duo First|"Patients randomized to this arm will be placed on an AIRSOFT DUO mattress for day 0. They will then be switched to a SENTRY 1200 mattress until the end of month 1.~Intervention: AIRSOFT DUO for 1 day Intervention: SENTRY 1200 for 1 month"
3199419|NCT00880178||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
3199420|NCT00880178||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
2523328|NCT02741258|Experimental|Mepitel Film|Mepitel film will be placed on the patients' skin just before the start of the radiotherapy and will be replaced once a week until the end of the radiotherapy. In case of skin toxicities mepitel film will be placed until resolution of the toxicities. In case of new skin toxicities appearance the patient will be retreated with Mepitel.
2523332|NCT02741258|Active Comparator|Excipial U hydrolotion, Flammazin skin cream|Patients will be treated with aqueous (Excipial U hydrolotion) or antiseptic (Flammazine or Ialugen Plus) cream in case of skin erythema due to radiotherapy. In case of new skin toxicities appearance the patient will be retreated with standard of care treatment.
2523398|NCT02741115|Experimental|Drug|Udenafil. One tablet twice daily for 26 weeks
2523405|NCT02741115|Experimental|Placebo|Placebo. One tablet twice daily for 26 weeks
2523493|NCT02740426|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy.
2523496|NCT02740426|Experimental|Single intravesical instillation|intravesical instillation within 24 hours postoperatively
3166061|NCT00520624|Experimental|4|Treatment 1, for those with low degree of EIL
2523615|NCT02739425|Other|Standard Procedure plus use of sentimag|Detection of the nodes carried out using the gamma probe and also the sentimag - all patients receive both diagnostic interventions
2523670|NCT02739243|Experimental|Tailored group intervention|"Participants take part in the tailored group intervention which consists of five 90-minute group sessions over eight weeks. The sessions are in the form of structured group talk/discussions following specific themes:~Session 1 - Coping and acceptance: identification of common themes from participants' feedback, provision of information about support services, mindfulness practices~Session 2 - Distress: introduction of the distress model, identification of resources, breathing practices~Session 3 - Handling of stressful situations: individual identification in tandems, discussion of common pitfalls in the group~Session 4 - Self-care: inspection of individual daily routines, group collects positive experiences with windows for self-care~Session 5 - Feedback and outlook: stabilisation, retrospective reflection on the group experience and its benefits and, if applicable, potential adverse events"
2523672|NCT02739243|Active Comparator|Treatment as usual|Participants are provided with brief information in a leaflet, about the possibilities for individual counselling including referral to the local outpatient cancer counselling centre providing client-centred counselling and financial social work.
2523737|NCT02738749|Other|ICD group|Adult patients with newly implanted ICD devices for primary prevention will be enrolled. At baseline, 3-, 6-, 9-, and 12-month followup visit, the medial information and blood samples will be collected.
3166062|NCT00520624|No Intervention|5|Control group of those with low degree of EIL
3166063|NCT00520663|Experimental|Healthy male subjects|Each subject will receive a single oral dose of 14C-SB649868 (containing approximately 70 microcuries of radiocarbon and 30 milligrams of SB649868).
3166064|NCT00520689|Active Comparator|1|
2523840|NCT02737787|Experimental|WT1 Vaccine and Nivolumab|Patients will initially receive 6 vaccinations over 12 weeks and 7 infusions of nivolumab every two weeks over 14 weeks. Toxicity assessments will be performed with each dose of vaccine, and 3 weeks after the completion of therapy at week 15. Patients who do not have disease progression at the week 15 evaluation are permitted to receive 4 additional vaccines administered approximately every 8 weeks. This maintenance vaccine course would begin at week 19.This cohort has completed recruitment.
2523841|NCT02737787|Experimental|ESO-1 Vaccine and Nivolumab|Patients will be vaccinated with the NY-ESO-1 OLP4 vaccine. Patients will receive a 1.0 mL emulsion of NY-ESO-1 OLPs with Poly-ICLC and Montanide.Nivolumab will be administered intravenously as a 30-minute infusion per institutional guidelines on weeks 0, 2, 4, 6, 8, 10 and 12.
2523935|NCT02737293|Experimental|Control Diet|Menu based on the average American diet.
2523943|NCT02737293|Experimental|Med Diet|Menu based on the typical Mediterranean diet (Med Diet) pattern.
2523948|NCT02737293|Experimental|Med Diet + Whole Egg|Menu based on the typical Mediterranean diet (Med Diet) pattern with the addition of 1 whole egg per 1000 kilocalories.
2523991|NCT02736994|Other|Immersion in water|water
2523996|NCT02736994|Active Comparator|Immersion in water + cleansing tablet|Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
2523998|NCT02736994|Experimental|Immersion in water with PIP|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium)
3166065|NCT00520689|Active Comparator|2|
2524077|NCT02736201|Experimental|IMT+ T-CaRe®on; n = 10|The instrumental manual therapy with the switched on capacitive diathermy electrode
2524079|NCT02736201|Sham Comparator|IMT+ T-CaRe® off; n = 10|The instrumental manual therapy with the switched off capacitive diathermy electrode
2524116|NCT02735837|Active Comparator|doxycycline gel|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
2524118|NCT02735837|Placebo Comparator|placebo gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
2524343|NCT02734758||Atrial fibrillation stroke|
2524344|NCT02734758||Non-atrial fibrillation Stroke|
3166066|NCT00520689|Active Comparator|3|
3166067|NCT00520689|Active Comparator|4|
3166068|NCT00520702|Active Comparator|3D CRT|3-Dimensional Conformal Radiation Therapy (3D CRT)
3166069|NCT00520702|Active Comparator|IMRT|Intensity-Modulated Radiation Therapy (IMRT)
3166070|NCT00520715||Patients at hospital admission|Patients at hospital admission in medical wards on our tertiray care hospital (Hôpital Beaujon, Clichy, France).
3166071|NCT00520728|Experimental|A|Experimental arm receives 12 week intervention along with standard care.
3166072|NCT00520780|Experimental|1|
3166073|NCT00520780|Placebo Comparator|2|
3166074|NCT00520806|Placebo Comparator|Placebo|48 hour iv infusion of placebo
3166075|NCT00520806|Experimental|Relaxin|48 hour iv infusion of relaxin at 30 ug/kg/day
3166076|NCT00520832|Experimental|MC-E|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
3166077|NCT00520832|Placebo Comparator|MC-P|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
3166078|NCT00520858|No Intervention|C|
3166079|NCT00520858|Active Comparator|RE|Resistance Exercise
3166080|NCT00520858|Active Comparator|AE|Aerobic Exercise
3166081|NCT00520858|Active Comparator|RAE|Resistance and Aerobic
3166082|NCT00520897|Experimental|MK0518 + cART|Raltegravir + standard of care combined antiretroviral therapy
3166083|NCT00520897|Placebo Comparator|Placebo + cART|Placebo + standard of care combined antiretroviral therapy
3166084|NCT00520923|Experimental|1|160mg of LY2140023, taken orally as 80mg twice daily, for up to 4 weeks.
3166085|NCT00520923|Experimental|2|80mg of LY2140023, taken orally as 40mg twice daily, for up to 4 weeks.
3166086|NCT00520923|Experimental|3|40mg of LY2140023, taken orally as 20mg twice daily, for up to 4 weeks.
3166087|NCT00520923|Experimental|4|10mg of LY2140023, taken orally as 5mg twice daily, for up to 4 weeks.
3166088|NCT00520923|Placebo Comparator|5|Placebo of LY2140023, taken orally twice daily, for up to 4 weeks.
3166089|NCT00520923|Active Comparator|6|Placebo, taken orally every morning, followed by Olanzapine 15mg taken orally every evening for up to 4 weeks.
3166090|NCT00520949|Experimental|Quadruple Therapy|
2523673|NCT02738996|Experimental|60-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 30 min
2523679|NCT02738996|Experimental|30-15 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 15 min
2523682|NCT02738996|Experimental|15-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 60 min
2523685|NCT02738996|Experimental|60-15|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min and 15 min
2523687|NCT02738996|Experimental|30-60 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min and 60 min
2523689|NCT02738996|Experimental|15-30 min|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min and 30 min
2523766|NCT02738541|Active Comparator|Group 1|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
2523771|NCT02738541|Placebo Comparator|Group 2|PLACEBO DENTRIFICE WITHOUT PYROPHOSPATE WAS PRESCRIBED AND SUBJECTS WERE EVALUATED AT 3MONTH AND 6 MONTHS
2523927|NCT02737254|Experimental|Oxytocin and Secure CBM training|
2523937|NCT02737254|Active Comparator|Placebo and Secure CBM training|
2523945|NCT02737254|Active Comparator|Oxytocin and Neutral CBM training|
2523946|NCT02737254|Placebo Comparator|Placebo and Neutral CBM training|
2524061|NCT02736318|Experimental|processed osteochondral allograft|Implantation of 1 to 3 osteochondral products in osteochondral lesion of talus.
2524136|NCT02735798|Experimental|Single Arm Study - Arm 1|10 patients will receive standard imaging at baseline, incl. FDG-PET/CT plus MR brain imaging. Patients will subsequently start protocol therapy with MM-302 and trastuzumab given on day 1 of an every 21-day dosing cycle, at recommended phase 2 dose of 30 mg/m2. Patients will receive 64Cu-labeled MM-302 (3-5 mg/m2 doxorubicin) 3 hours after unlabeled dose of MM-302. Integrated MR/PET imaging of brain and whole body will be performed at 2 time points following 64Cu-labeled MM-302 administration: (1) within 3 hours (+/- 1 hour) of labeled drug injection, and (2) 24 hours (+/- 6 hours) post-injection. Patients will continue to receive doses of unlabeled MM-302 plus trastuzumab every 3 weeks until clinical or radiographic disease progression (in brain or systemically) or unacceptable toxicity, whichever occurs soonest. MRI and FDG-PET/CT scans will be performed every 9 weeks to monitor for treatment response and disease progression.
2524215|NCT02735486|Experimental|Ginger drink|Experimental: Ginger drink (300 ml) to be consumed during the study visit
2524218|NCT02735486|Placebo Comparator|Placebo: Super pure water|Super Pure water low in nitrate content
2524313|NCT02735109|Other|description|photographies and biopsy on normal area
3166091|NCT00520962||1,2,3|"First degree relatives of patients with type 2 diabetes~Patients with cardiovascular disease and stroke~patients with heart valve disease"
3166092|NCT00520962||4|Healthy controls
3166093|NCT00520988|Experimental|1|Usual care plus use of Interactive Voice Recognition system
3166094|NCT00520988|No Intervention|2|Usual care
3166095|NCT00521027|Other|Treatment|Debridement with Versajet Hydrosurgery system
3166096|NCT00521027|Other|Control|Conventional surgical debridement techniques
3166097|NCT00521066||1|Prosima Pelvic Floor Repair System
3166098|NCT00521092|Experimental|Arm I|Patients receive oral sunitinib malate 50 mg once daily for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3166099|NCT00521105|No Intervention|1|Participants will be seen every 3-4 months with a physician-only visit alternating with a multidisciplinary visit (MD, RN and RD). This is the current standard of practice.
3166100|NCT00521105|Experimental|2|Participants will be seen every 3-4 months with a phone contact, with the diabetes nurse educator, alternating with a multidisciplinary visit (MD, RN and RD).
3166101|NCT00521118|Experimental|Treatment (second curettage)|Patients undergo a second curettage rather than standard treatment (immediate chemotherapy) within 14 days of registration.
3166102|NCT00521157|Experimental|intervention|Experimental group randomised after abstinence oriented treatment
3166103|NCT00521157|No Intervention|2|waiting list control
3166104|NCT00521183|Experimental|CldC + H4U|
3166105|NCT00521196|No Intervention|Baseline- 1 month|Subjects will be asked to maintain a migraine diary in which they will record the onset of each migraine, migraine-associated symptoms, migraine-associated pain, daily average pain, and daily average anxiety.
3166106|NCT00521196|Experimental|tDCS- 1 month|"There will be 10- twenty minute sessions of the tDCS intervention over a four week period. During each tDCS session, two electrodes are placed over selected areas of the brain. 2 mA of direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The subject may feel a slight itching on the scalp. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.~During this phase, participants will continue to maintain their migraine diary. In addition, the pain threshold of patients will be measured at the first, fifth, and tenth sessions via Thermal Sensory Analysis and Von Frey Hair tests."
3166107|NCT00521196|No Intervention|Follow Up- 4 months|During the follow up phase, subjects will meet with the study investigators a total of 5 times for follow up monitoring. Participants will continue to maintain their migraine diary during this time.
3166108|NCT00521196|Other|Active tDCS- 1 month|Participants randomized to sham tDCS (placebo) will be given the opportunity to receive the active intervention if the intervention is found to be safe and efficacious.
2523531|NCT02740192|Experimental|Adductor Canal Block|Patients in this group received local infiltration of bupivacaine in the adductor canal after surgery, in addition to the periarticular injection intra-op.
2523532|NCT02740192|Sham Comparator|Periarticular Injection|Patients in this group received a bandaid at the presumed adductor canal injection site, in addition to the periarticular injection intra-op.
2523583|NCT02739841|Experimental|Ventilator hyperinflation|For the ventilator hyperinflation techniques (VHI), the study consists of three consecutive periods 1) baseline period: 10 minutes rest in side lying by effected lung uppermost with head-up 30 degree 2) Intervention period: Patients were positioned as same as baseline period and 4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial 3) recovery period: 10 minutes rest in the same position but reduce VT to initial.
2523585|NCT02739841|Experimental|Chest physical therapy|For the conventional chest physical therapy (CPT), the study will be performed in the similar procedure except the intervention period, the patient will be received vibration and passive of the both upper extremity.
2523626|NCT02739438||E Cigarette users|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months. Total pack years of smoking should be less than 20 for their smoking history, with normal lung function (FEV1 and FEV1/FVC) and no clinical symptoms of airway obstruction/inflammation (cough, dyspnea, sputum and wheeze).
2523629|NCT02739438||Cigarette smokers|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
2523631|NCT02739438||Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
2523784|NCT02738554|Other|Treatment cessation arm|Cessation of treatment as according to European Association for the Study of the Liver Guidelines for chronic hepatitis B
3166109|NCT00521209|Experimental|Clinic 1 - intervention|Clinic 1 will feature the Self-Care Stimulating Disease Prevention Program (SCSDPP) intervention
3166110|NCT00521209|Other|Clinic 2 - no intervention|Clinic 2 will continue with standard procedures no intervention
2523844|NCT02737800|Active Comparator|1A endometrioma more than 5cm|Endometrioma aspiration GnRh agonist :Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
2523845|NCT02737800|Sham Comparator|1B endometrioma more than 5cm control|Endometrioma aspiration Standard long stimulation protocol & ICSI
2523850|NCT02737800|Active Comparator|2A endometrioma less than 5cm|Decapeptyl 3.75mg intramuscular Standard long stimulation protocol & ICSI
2523851|NCT02737800|Sham Comparator|2B endometrioma less than 5cm control|Standard long stimulation protocol & ICSI
2523897|NCT02737423|Experimental|vitamin D|single IM dose 600,000 IU of cholecalciferol
2523963|NCT02737176|Experimental|Tobacco cessation intervention|Tobacco cessation intervention is implemented for 12 weeks. The nicotine dependence status is evaluated by the FTND (Fagerstrom Test for Nicotine Dependence) test. The point 3 or more is regarded as a moderate or high tobacco dependence and determining a cessation intervention. During the tobacco cessation intervention for the subjects, attending doctors implement standard treatments for their oral diseases. Even if participants fail to abstain from smoking, the oral treatment is continued. In case of the use of the NRTs (nicotine patch and/or gum), the investigators supply it for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
2523966|NCT02737176|No Intervention|Non-tobacco cessation intervention|Those who do not intention to abstinence from smoking strongly and/or having less than 3 points in FTND test are allocated to non-tobacco cessation intervention group. The same treatment as the tobacco cessation intervention group is carried out for their oral diseases.
2524012|NCT02736851|No Intervention|Control group|Usual care
2524013|NCT02736851|Active Comparator|Home-based telemedicine group|Nurse-tutor support at home for 6 months
2524043|NCT02736539|Experimental|Active|galacto-oligosaccharides
2524044|NCT02736539|Placebo Comparator|Placebo|Placebo
2524358|NCT02734641||intravenous (IV) iron therapy|"Patients register to intravenous (IV) iron therapy due to iron deficiency anemia that wasn't responded to oral treatment or wasn't tolerable due to side effects.~20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines the appetite of the patient before and after treatment. At the end of Iron administration Ghrelin will be retested."
3166111|NCT00521222|Active Comparator|Arg/Arg genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Arg/Arg genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
3166112|NCT00521222|Active Comparator|Gly/Gly genotype on Advair (Fluticasone with Salmeterol) HFA|Asthma patients with the Gly/Gly genotype who are randomized to continue the combination therapy of a specific long-acting beta 2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) in the form of Advair HFA.
3166113|NCT00521222|Experimental|Arg/Arg genotype on Fluticasone HFA|Asthma patients with the Arg/Arg genotype who are randomized to fluticasone (Flovent HFA) alone.
3166114|NCT00521222|Experimental|Gly/Gly genotype on Fluticasone HFA|Asthma patients with the Gly/Gly genotype who are randomized to fluticasone (Flovent HFA) alone.
3166115|NCT00521248|Active Comparator|Oral morphine solution|Oral morphine solution
3166116|NCT00521248|Experimental|Buprenorphine|Sublingual buprenorphine
3166117|NCT00521274|Experimental|1|"Patients randomized to Arm 1 will receive treatment cycles of Docetaxel and vaccine.~PI relocated, data not available."
3166118|NCT00521274|Active Comparator|2|"Patients randomized to Arm 2 will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over).~PI relocated, data not available."
3166119|NCT00521287|Other|Early (E)|Early stage cancer
3166120|NCT00521287|Other|Advanced (A)|Advanced stage cancer (Stage IV without treatment)
3166121|NCT00521287|Other|Terminal (T)|Terminal stage cancer (Stage IV with chemotherapy)
3166122|NCT00521300|Experimental|octreotide|6 months preoperative treatment with octreotide before transsphenoidal surgery for acromegaly
2523433|NCT02741037|Experimental|Dyadic lifestyle intervention|Mothers and daughters participate in the Unidas partner intervention together.
2523437|NCT02741037|Experimental|Individual lifestyle intervention|Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers.
2523440|NCT02741037|Other|Usual Care|Mothers and daughters receive usual care.
3199421|NCT00880204|Experimental|Trained doctors|ESS-EMCH Training will be provided to doctors working in general emergency, pediatrics and obstetrics department in district hospitals.
3199422|NCT00880204|No Intervention|No Training|No training will be given to doctors (act as controls)
3199423|NCT00880217|Experimental|001|JNJ-31001074 1 mg/d 1-mg capsule once daily for 42 days
2523511|NCT02740244|Active Comparator|active iTBS|Participants will receive 10 to 30 sessions of active intermittent theta burst stimulation (iTBS) consisting in delivering 2 s train of bursts containing three pulses at 50 Hz repeated each 200 ms every 10 s (iTBS). Each iTBS session contained 990 pulses and lasted 6 min. Stimulation intensity will be set at 80% of the patient's resting motor threshold. iTBS will be applied twice per day, with at least three hours between each session. Ten to 30 sessions will be delivered until patient achieved remission (i.e., 13-item Beck Depression Inventory (BDI13) score < 10). iTBS will be applied over the left dorsolateral prefrontal cortex (DLPFC) according to the individual's 3D-T1 MRI.
2523513|NCT02740244|Sham Comparator|sham iTBS|The same protocol (location, intensity, parameters of stimulation) will be applied using a commercial sham coil.
3199424|NCT00880217|Experimental|002|JNJ-31001074 3 mg/d 3-mg capsule once daily for 42 days
3199425|NCT00880217|Experimental|003|JNJ-31001074 10 mg/d 10-mg capsule once daily for 42 days
2523733|NCT02738736|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
2523736|NCT02738736|No Intervention|Usual Care|Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
3199426|NCT00880217|Active Comparator|004|Atomoxetine 80 mg/d 40-mg capsule for 3 days followed by 80-mg capsule once daily for 39 days
3199427|NCT00880217|Active Comparator|005|OROS methylphenidate HCl 54 mg/d 36-mg capsule for 3 days followed by 54-mg capsule once daily for 39 days
3199428|NCT00880217|Placebo Comparator|006|Placebo capsule once daily for 42 days
2523896|NCT02737384|Experimental|Treatment|
2523962|NCT02737189|Experimental|Endovascular Arm|"Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration~Best Medical Treatment and maximum supportive care"
2523964|NCT02737189|Other|Control Arm|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
2524075|NCT02736344|Experimental|BioNIR Ridaforolimus (drug eluting stent (DES)|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0~The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
2524128|NCT02735902|Experimental|vitamin K antagonist or Direct oral anticoagulant treatment|"In this group, patients will receive monotherapy via anticoagulant (AVK or DOAC) excepted rivaroxaban; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant"
2524134|NCT02735902|Active Comparator|vitamin K antagonist or Direct oral anticoagulant + Aspirin|"In this group, patients will receive combination therapy via anticoagulant (AVK or DOAC) and aspirin, whose daily dose is between 75 mg and 100 mg; the anticoagulant treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.~Intervention: anticoagulant Intervention: Aspirin"
3199429|NCT00880243|Experimental|EMA+GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10.~GM-CSF (LeucomaxR): 5 µg/kg/jour IV over 6 hours from day 1 to day 10."
3199430|NCT00880243|Active Comparator|EMA without GM-CSF|"Daunorubicine (CérubidineR) : 80 mg/m2/jour IV over 30 min from day 1 to day 3,~AraC (AracytineR) : 500 mg/m2/jour IV from day 1 to day 3,~Mitoxantrone (NovantroneR) : 12 mg/m2/jour IV over 30 min from day 8 to 9~AraC (AracytineR) : 500 mg/m2/12h IV over 3 hours from day 8 to day10."
3199431|NCT00880243|Experimental|HD AraC+ GM-CSF|"AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5~GM-CSF :5 µg/kg/d IV (6 hours) from day1 to day 5"
3199432|NCT00880243|Active Comparator|HD-AraC without GM-CSF|- AraC (Aracytine) : 3 g/m2/12h IV (3 hours) on days 1, 3 , 5
3199433|NCT00880282|Experimental|Treatment (cixutumumab, temsirolimus)|Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 25 courses in the absence of disease progression or unacceptable toxicity.
3199434|NCT00880295|Active Comparator|endoscopic surgery|
3199435|NCT00880295|Active Comparator|open surgery|
3199436|NCT00880308|Experimental|LDE225|
3199437|NCT00880321|Experimental|Part 1|Part 1 will identify the recommended Part 2 dose using a dose-escalation procedure. Escalation may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached. Subjects may dose up to three times a day.
3199438|NCT00880321|Experimental|Part 2|Part 2 will explore further the safety, tolerability, and clinical activity of GSK2118436 in subjects with BRAF mutation-positive tumors using the recommended part 2 dose identified during Part 1. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
3199439|NCT00880347|Other|Alzheimer's Disease|Group of patients clinically diagnosed with probable AD
2523441|NCT02740790|Experimental|HPV vaccine 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule experimental HPV vaccines
2523446|NCT02740790|Placebo Comparator|Placebo 2|120 women between 18-26 yeas of age, receiving 0,2,6 month-schedule Placebo.
2523449|NCT02740790|Placebo Comparator|Placebo 3|180 women between 27-45 yeas of age, receiving 0,2,6 month-schedule Placebo.
2523503|NCT02740465|Experimental|COPD Patients|
2523529|NCT02740101|Experimental|oxytocin nasal spray|subjects administrating oxytocin were divided into experimental group
2523530|NCT02740101|Placebo Comparator|placebo nasal spray|subjects administrating placebo were divided into controlled group
2523580|NCT02739880|Experimental|The study population|"The study population consists of postmenopausal patients (more than 2 years and less than 10 years) with a body mass index <35 with sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness.~Intervention: Intra-mucosal Injections of Cross-linked Hyaluronic Acid"
2523634|NCT02739451|Active Comparator|standard oxygen group|Oxygen therapy will be delivered using any device or combination of devices that are part of usual care: nasal oxygen, and mask with or without a reservoir bag and with or without the Venturi system
2523636|NCT02739451|Experimental|High-flow nasal oxygen (HFNO) group|"Device that delivers humidified and warmed high-flow oxygen at flows greater than 15 L/min.~HFNO will be initiated at a flow rate of 50 L/min and 100% FiO2. If the target SpO2 is not reached, the flow rate will be increased to 60 L/min. Then, FiO2 will be tapered to target an SpO2≥95. The minimal flow rate will be 45 L/min"
2523657|NCT02738983|Experimental|Bioradiotherapy|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day) with concurrent radiotherapy to a total radiation dose of 60-66 Gray (Gy).
2523716|NCT02738814|Experimental|PAED > 13|When severe emergence agitation(PAED is 14 or more) is occured, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
2523719|NCT02738814|No Intervention|PAED < 14|Caregivers must first try to reassure patients.
2523769|NCT02738489|Experimental|Injection SHR-1210|SHR-1210 injection, 60,200,400mg/dose, intravenous infusion over 30 minutes. Only one arm in this study
2523821|NCT02738125||Subjects starting/ receiving adalimumab|Subjects starting/ receiving Adalimumab for UC
2523926|NCT02737345||Waiting list|Patients on the liver transplant waiting list
3199440|NCT00880347|Other|Non-AD dementia|Group of patients clinically diagnosed with one of the 5 most frequent non-AD dementia : vascular dementia, mixed dementia, frontotemporal dementia, Lewy bodies dementia, Parkinson's disease dementia.
3199441|NCT00880347|Other|control subjects|Group of control subjects without any clinical cognitive impairment.
3199442|NCT00880373|Active Comparator|1|Diamorphine or Morphine by PCA and oral ibuprofen
2524062|NCT02736396||Healthy Controls|Medical History, Neuropsychological tests, clinical assessments, fMRI
2524067|NCT02736396||Cognitive impairment|Medical History, Neuropsychological tests, clinical assessments, fMRI
2524115|NCT02735967|Experimental|Group manual therapy + diadynamic|"Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.~Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient."
2524117|NCT02735967|Active Comparator|Group manual therapy|Initially, the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
2524119|NCT02735967|Active Comparator|Group diadynamic|An electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF),4 minutes long periods (LP) and 4 minutes short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
2524152|NCT02735590|Experimental|Open-label 3HP|Participants in the Treatment Arm will receive high dose INH (15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg) with Pyridoxine supplementation (25mg), and Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months. Dispensing of IP and Directly Observed Treatment (DOT) field visits in Treatment Arm participants will be performed by staff members not involved in TB symptom screening or investigation. Participants receiving 3HP who develop symptoms of hepatotoxicity will be evaluated by an Investigator.
2524153|NCT02735590|No Intervention|Baseline Screening; Active Surveillance|Adult volunteers living in TB hyperendemic communities of South Africa will be consented and screened. Individuals with HIV infection and conditions likely to affect the performance of the COR assay, or the safety and/or efficacy of the 3HP investigational regimen, will not be enrolled. Active surveillance for TB disease (Observation Arm), including regular symptom screening and symptom-targeted TB investigation (all participants) will be conducted on this Arm.
2524250|NCT02735291|Experimental|Single arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:The first day,the second day,29 days,injection once a day in this three days Duration:Only injection three times
2524324|NCT02735005|Experimental|SMAF assessment|"Face to face interview for the Functional Autonomy Measurement System (SMAF) tool questionnaire For disabled patients living at home, the Social SMAF questionnaire is used in addition.~Data related to care consumption of each enrolled patients are collected too."
2524416|NCT02734329|Experimental|Zero Ischemia group|Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
2524419|NCT02734329|Active Comparator|Conventional group|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
3199443|NCT00880373|Placebo Comparator|2|Diamorphine or Morphine by PCA and oral placebo
3199444|NCT00880386|Experimental|Losartan Group|50 mg Losartan tablet taken daily for 24 weeks
2523451|NCT02740803|Experimental|0 Fluoride - R|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes followed by rinsing with distilled water.
2523452|NCT02740803|Experimental|0 Fluoride - NR|Participants will use non-fluoridated toothpaste (0 ppmF) to brush for two minutes not followed by rinsing with distilled water.
2523621|NCT02739724|Active Comparator|Classic laparoscopy|Patients will undergo laparoscopy surgery with classic laparoscopy technic.
2523623|NCT02739724|Experimental|Laparoscopy single port access|Patients will undergo laparoscopy surgery by single port access technic.
2523669|NCT02739204|Experimental|Celecoxib|Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
2523734|NCT02738710|Experimental|transumbilical wound|transumbilical incision
2523735|NCT02738710|Active Comparator|infra umbilical wound|infra umbilical incision
2523753|NCT02738437|No Intervention|control|Control Group receiving standard treatment
2523754|NCT02738437|Active Comparator|intervention group|Intervention Group receiving the standard treatment and the kryptonite-bone cement
2523758|NCT02738268|Sham Comparator|Control group|Control group: receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
2523759|NCT02738268|Experimental|Treatment Group|Treatment Group: receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy
2523802|NCT02738190|Active Comparator|Albumin|5% Albumin to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and albumin to reach the standard volume administered to these patients (400 ml)
2523804|NCT02738190|Active Comparator|Fresh Frozen Plasma|Fresh Frozen Plasma to be added to the priming solution composed of concentrated red cells to reach a target of 28-30% hematocrit and plasma to reach the standard volume administered to these patients (400 ml)
3166123|NCT00521300|Active Comparator|standard surgery|Standard transphenoidal surgery soon after the diagnosis of acromegaly
3166124|NCT00521326||A|Patients with an acute coronary syndrome that are candidates for coronary angiography. Doppler results will be compared to angiographic findings.
2524045|NCT02736448|Experimental|Arm Lu-PRRT-Cap|Arm Lu-PRRT-Cap: oral low dose of capecitabine in association with Lu-PRRT (at 3.7 Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
2524047|NCT02736448|Experimental|Arm Lu-PRRT|Arm Lu-PRRT: Lu-PRRT (at 3.7Gbq per cycle x 7 cycles) followed by long acting octreotide or lanreotide (SS-LAR)
2524204|NCT02735473|Experimental|Choline bitartrate|Powdered drink mix containing choline bitartrate 19 mg. per kg.
2524209|NCT02735473|Placebo Comparator|Placebo|Powdered drink mix containing matching placebo
2524437|NCT02734121|Experimental|Educational group intervention|The pre-consultation educational group intervention will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.
2524441|NCT02734121|No Intervention|Standard Care|Routine pre-consultation education
2524491|NCT02733822|Experimental|IMP: buccal naloxone (single dose)|0.8 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
2524498|NCT02733822|Experimental|IMP: buccal naloxone (double dose)|1.6 mg buccal (solution) of 1 mg/ml Naloxone Hydrochloride Injection
2524503|NCT02733822|Active Comparator|Intramuscular (IM) reference|0.8 mg IM injection of 1 mg/ml Naloxone Hydrochloride Injection
2524507|NCT02733822|Active Comparator|Intravenous (IV) reference|0.8 mg IV injection of 1 mg/ml Naloxone Hydrochloride Injection
2524569|NCT02733237|Experimental|male oxytocin group|male subjects with oxytocin treatment
2524575|NCT02733237|Experimental|female oxytocin group|female subjects with oxytocin treatment
2524580|NCT02733237|Placebo Comparator|male placebo group|male subjects with placebo treatment
2524584|NCT02733237|Placebo Comparator|female placebo group|female subjects with placebo treatment
2524624|NCT02732808|Experimental|poor ovarian responder|The women with diagnose of poor ovarian responder after IVF/ICSI treatments underwent ovulation stimulation and egg collection in the same IVF/ ICSI cycle ( Shanghai protocol)
2524652|NCT02732522|Experimental|Misoprostol sublingual|
2524653|NCT02732522|Active Comparator|Misoprostol vaginal|
2524712|NCT02732288|Experimental|Melatonin, brain injured patients|Melatonin 3mg, orally, at 8pm, daily for 3 months
2524714|NCT02732288|Experimental|Healthy volunteers|Melatonin 3mg, orally, at 8pm
3166125|NCT00521391|Experimental|A|a tailored physical activity intervention involving moderate-intensity exercise
3166126|NCT00521391|No Intervention|B|
3166127|NCT00521417|Experimental|short-term dynamic therapy|Group therapy 20 sessions, give insight
3166128|NCT00521417|Active Comparator|long-term dynamic therapy|Group therapy 80 sessions, give insight
3166129|NCT00521443||Normal|Embryos derived from morphologically normal MII oocytes
3166130|NCT00521443||Irregular Shapes|Embryos derived from irregularly shaped oocytes.
3166131|NCT00521443||Large PVS|Embryos derived from oocytes with large perivitelline space.
3166132|NCT00521443||Dark Zona|Embryos derived from oocytes with dark zona pellucida
3166133|NCT00521443||Dark cytoplasm|Embryos derived from oocytes with dark cytoplasm
3166134|NCT00521443||Vacuolar cytoplasm|Embryos derived from oocytes with vacuolated cytoplasm
3166135|NCT00521443||Central granulation|Embryos derived from oocytes with centrally granulated cytoplasm
3166136|NCT00521443||Double extra|Embryos derived from oocytes with double extracytoplasmic abnormalities
3166137|NCT00521443||Double combined|Embryos derived from oocytes with any combination of one extracytoplasmic and one cytoplasmic anomaly
3166138|NCT00521443||Double cytoplasmic|Embryos derived from oocytes with any two cytoplasmic anomalies
3166139|NCT00521443||Triple extra|Embryos derived from oocytes with triple extracytoplasmic anomaly
3166140|NCT00521443||Triple combined|Embryos derived from oocytes with triple combined anomalies
3166141|NCT00521482|Active Comparator|A|Temozolomide 75 mg/m2 daily for 21 days during each 28-day cycle until tumor progression.
3166142|NCT00521482|Experimental|B|Temozolomide 200 mg/m2 for 5 days during each 28-day cycle plus Thalidomide 100 mg for 2 weeks, thereafter 200 mg daily continuously until tumor progression.
2523457|NCT02740764|No Intervention|No intervention|This group will receive the current management of patients in geriatric or memory consultation, during which the intervention of a clinician pharmacist is not provided. There will be a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital, but the recommendations will not be transmitted to the referring physicians of patients.
2523497|NCT02740439|Experimental|Intervention Meal|Intervention meals will contain 1 large avocado and be consumed daily for 12 weeks.
2523500|NCT02740439|Placebo Comparator|Control Meal|Control meals will be isocaloric to the intervention meals but without avocado. They will also be consumed daily for 12 weeks.
2523582|NCT02739906|Experimental|HinsBet®|
2523584|NCT02739906|Active Comparator|Humalog®|
2523586|NCT02739906|Active Comparator|Huminsulin® Normal|
2523722|NCT02739386||Cohort Population|Individuals included in a large US-based administrative medical claims database with underlying autoimmune disorder exposed to ipilimumab for the treatment of melanoma.
2523765|NCT02738528|Experimental|Experimental Group|Mental practice and brushing guidance in patients with Parkinson Disease
2523772|NCT02738528|No Intervention|Control group|Brushing guidance in patients without Parkinson Disease
2523864|NCT02737644||CHD birth cohort|Cases are identified as those whose newborns screened and confirmed with CHD during the follow-up and four age- and delivery-hospital matched controls are selected for each case from the rest of the cohort.
3199445|NCT00880412|Experimental|EHT 0202 40 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
3199446|NCT00880412|Experimental|EHT 0202 80 mg bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
3199447|NCT00880412|Placebo Comparator|placebo bid|study treatment is given in addition to one acetylcholinesterase inhibitor (galantamine, rivastigmine or donepezil)
2524007|NCT02736903|Active Comparator|Individual intervention|Behavioral: PennFit mobile individual intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their own daily steps and the minutes for vigorous, moderate, and muscle-strengthening exercises that they completed for each day. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening.
2524011|NCT02736903|Experimental|Online network intervention|Behavioral: PennFit mobile online network intervention. Participants were given a Fitbit (zip) to track their daily exercises. Participants used the PennFit app to track their exercises. Participants also received system-generated notifications that reminded them to wear their Fitbit in the morning and to log their activity minutes in the evening. Participants were randomly assigned to 4-person online networks in the PennFit app. Participants in the online networks could see both their own information and the profiles and activity logs of the three other people assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
2524031|NCT02736604|Experimental|Air anesthesia|air will be used as carrier agent for maintenance of anesthesia
2524032|NCT02736604|Active Comparator|Nitrous Oxide anesthesia|nitrous oxide will be used as carrier agent for maintenance of anesthesia
2524111|NCT02735824||patients with suspected PID|From included patients with suspected primary immunodeficiency (PID), i.e. patients with recurrent/unusual infection, immune dysregulation and/or susceptibility to malignancies from whom consent to participate was obtained, nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
2524112|NCT02735824||healthy relatives of patients with PID|From healthy relatives of patients with suspected PID from whom consent to participate was obtained, nucleated cells will be used for genetic testing in order to compare their genetic information with the one form their relatives with suspected PID.
2524114|NCT02735824||Healthy volunteers|From healthy volunteers from whom consent to participate was obtained, nucleated blood cells will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement. The data obtained will be compared to age matched patients with suspected PID.
2524169|NCT02735525|Experimental|Smartphone monitoring|Intervention arm
2524235|NCT02735265|Experimental|Virtual reality group|45 min standard treatment plus 45 min virtual reality balance training used by Kinect for Xbox game. Game choosed based on motor learning principle. Training task such as reach or stepping in various direction, squat, stand up, upper trunk forward or lateral bench.
2524241|NCT02735265|Active Comparator|Standard treatment only group|90 min standard treatment. Depended on patient's ability, principle used by motor learning, sensory process, motor control, task oriented training, symmetry w't bearing.
2524338|NCT02734992|Other|Acceptance and Commitment therapy + MTAU|"The Acceptance and Commitment therapy + MTAU (active treatment) consists of an unpublished manual developed for the purposes of the Algea project (Vasiliou & Karekla, 2015). The protocol specifies the following goals: (a) increase individuals' willingness to face uncomfortable internal experiences; b) promoting meaningful activities even in the present of head pain; (c) emphasizing acceptance as an alternative to avoidance in coping with headache; (d) clarifying individuals' values in important life domains; e) enhancing present moment-to-moment awareness.~Participants will be asked to remain stable on their pharmacotherapy during this study. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions.~Participants will complete questionnaires at pre-, post-treatment, and at 3-month follow-up. The WL group will enter treatment at the 3-month follow-up of the ACT-group."
2524341|NCT02734992|Other|MTAU/ Wait-list Control Gr|"The MTAU/ Wait-list Control Gr will follow their usual treatments, including any new treatments their GPs or Neurologists might prescribe (mostly prophylactic and abortive medication), during the study at the time. Following the completion of the active group follow up 3months, participants allocated to the control group will receive the active treatment. Participants will complete the same questionnaires at three different time points: pre-, post-treatment, and at 3-month follow-up.~Participants will be asked to remain stable on their pharmacotherapy during this study and inform the researchers of any changes. All eligible participants will be monitored (medication taken and amount) prior to the beginning of the intervention for three weeks to ensure stability of their conditions. Excluded participants will be referred to appropriate services."
2523514|NCT02740374|Experimental|ROTEM|"ROTEM will be performed in patients with signs of clinically relevant bleeding and in whom blood transfusion is considered (Temp above 35 Celsius degrees; pH below 7.2; Cai above 4.6 mg/dL; Hb below 9g/dL, or below 10g/dL with anticipated greater blood loss) or at a fixed range every 2 hours or at Anesthesiologist criteria based on patient's clinical situation.~There will be also be performed standard of care test for this set of patients, as described for the CONTROL arm. ROTEM results will guide transfusion strategy."
2523515|NCT02740374|Active Comparator|CONTROL/STANDARD OF CARE|"If patients are randomized to standard coagulation tests (SCT), these will be performed according to Ohio State Wexner University Medical Center standard practices and attending's criteria, or at 2 hour intervals per protocol.~Standard of care tests include but are not limited to: hemoglobin, platelet count, fibrinogen concentration, INR, aPTT, and PT. These will be performed at fixed time points (preoperatively, every 2 hours intraoperatively, procedure completion, and 24 hours after procedure completion). Arterial blood gases will be performed repetitively intraoperatively at a fixed range every 1-hour or at attending's criteria, as well as any postoperative laboratory tests. SCT will guide transfusion management."
3199448|NCT00880477|Experimental|Group A|
2523607|NCT02739529|Experimental|Cohort 1|Genexol-PM 100mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
2523609|NCT02739529|Experimental|Cohort 2|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 5 AUC IV infusion D1
2523611|NCT02739529|Experimental|Cohort 3|Genexol-PM 120mg/m2 IV infusion D1,D8,D15 Carboplatin 6 AUC IV infusion D1
3199449|NCT00880477|Experimental|Group B|
3199450|NCT00880490|Experimental|1|Inhaled PT005 2.4 mcg
2523760|NCT02738463||Group 1 case|This group will include 32 pregnant females whose fetuses show intrauterine growth restriction at full term ( the 32 neonates with birth weight less than 10th percentile for corresponding gestational age will be included as small for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
2523761|NCT02738463||Group 2 control|This group will include at least 32 pregnant females whose fetuses are appropriate for gestational age at full term ( the 32 neonates with birth more than or equal to the 10th percentile for corresponding gestational age will be included as average for gestational age and the investigator will thaw their maternal frozen samples for detection of serum ferritin level)
2523811|NCT02738177|Active Comparator|misoprostol group|30 candidates were receive 2 tablets of misoprostol (PGE1) 200ug (i.e. 400 ug) 4 hrs prior to surgical evacuation
2523814|NCT02738177|Active Comparator|Effox group|30 candidates were received 2 tablets of Effox (Isosorbide mononitrate) 20 mg (i.e 40 mg) 4 hrs prior to surgical evacuation
2523815|NCT02738177|Active Comparator|combination therapy group|30 candidates were received 1 tablets of misoprostol 200ug & 1 tablets of Effox 20 mg 4 hrs prior to surgical evacuation.
3199451|NCT00880490|Experimental|2|Inhaled PT005 4.8 mcg
3199452|NCT00880490|Experimental|3|Inhaled PT005 9.6 mcg
2524021|NCT02736773|Experimental|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
2524036|NCT02736487|Active Comparator|Group A: True-Washout-Sham|Subjects in group A receives true air filtration intervention, then at least two weeks of washout period, followed by sham air filtration intervention.
2524037|NCT02736487|Active Comparator|Group B: Sham-Washout-True|Subjects in group B receives sham air filtration intervention, then at least two weeks of washout period, followed by true air filtration intervention.
2524082|NCT02736227|Experimental|Tacrolimus Withdrawal and Everolimus Monotherapy|Tacrolimus will be tapered while continual use of everolimus.
2524108|NCT02735850|Experimental|Ablative SBRT to all (max 3) sites followed by L19-IL2|Ablative cohort
2524109|NCT02735850|Active Comparator|Ablative SBRT to all (max 3) sites|Ablative cohort
2524110|NCT02735850|Experimental|SBRT 1 site, L19-IL2 and then standard of care|Non-ablative cohort
2524113|NCT02735850|Active Comparator|Standard of care|Non-ablative cohort
2524176|NCT02735616||study|"15 CVA patients, 1-3 weeks after their first stroke. The patients will be hospitalized in the neurology department at the geriatric Beit-Rivka hospital at Petah-Tiva, Israel.~patients with pacemaker or those who use Beta-Blocker drugs, as well as patients with cerebellar injury, will be excluded from the research"
2524178|NCT02735616||control|15 patients from the orthopedic department at the same hospital, matching by age and gender to the study group.
2524246|NCT02735252|Experimental|Group A: Androgen Signaling Inhibition|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving treatments that inhibit androgen signaling to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524254|NCT02735252|Experimental|Group B: Immunotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving immunotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524256|NCT02735252|Experimental|Group C: Radiotherapy|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving radiotherapy to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
3199453|NCT00880490|Placebo Comparator|4|Inhaled Placebo
3199454|NCT00880490|Active Comparator|5|Formoterol Fumarate 12 mcg (Foradil Aerolizer)
3199455|NCT00880516||control|Adults with normal sinuses
3199456|NCT00880516||case|Adults with chronic sinusitis and positive findings on imaging.
3199457|NCT00880529|Experimental|ON-Q|Subcutaneous bupivicaine administration and IV opioid medication if necessary
3199458|NCT00880529|Active Comparator|IV opioids alone|Standard therapy with IV opioid administration
3199459|NCT00880594|Experimental|Open label desipramine|
3199460|NCT00880646|Experimental|1|
3199461|NCT00880646|Placebo Comparator|2|
3199462|NCT00880659|Experimental|1|Promotion of handwashing with soap and maintenance of a fully stocked handwashing station.
3199463|NCT00880659|No Intervention|2|Practice of routine handwashing among the household members
3166143|NCT00521495|Experimental|A|Surface magnetic field strength at target 450 Gauss permanent magnet
2523577|NCT02739867||Unprovoked VTE|Patients aged 40 years or older with a first episode of objectively confirmed, symptomatic, unprovoked deep vein thrombosis of the leg (distal or proximal) or pulmonary embolism
2523637|NCT02739464|Experimental|Exercise + SOC PT/OT|SOC treatment plus a personalized, structured, and quantifiable exercise program (MP10) carried out soon after admission until hospital discharge (including during the BICU stay and time on ventilation.
2523638|NCT02739464|Active Comparator|SOC PT/OT|Only SOC for treating in-patient burn subjects
2523677|NCT02739035|No Intervention|MUA alone|Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
2523684|NCT02739035|Experimental|MUA with dexamethasone and celecoxib|For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.
2523762|NCT02738424||3T patients : Calculate the ADC scores|In this group all the patients perform a 3 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS (picture archiving and communication system) Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
2523763|NCT02738424||1.5T patients : Calculate the ADC scores|In this group all the patients perform a 1,5 Tesla RMI. With these data, three methods will be used to calculate the ADC score : Siemens, PACS Carestream, Osirix. The ADC scores obtained with these three post-processing softwares will be compared.
2523848|NCT02737761|Experimental|Optimal Adherence|"Participants will all undergo a qualitative interview and adherence measurements at baseline and 12 weeks after hospital discharge.~In person the participants will receive a MEMSCaps device and an Actigraph accelerometer. They will be asked to begin wearing the accelerometer after their initial interview and to begin using the MEMSCaps device once they arrive at home. Participants will use the MEMSCap throughout the entire study and will wear the Actigraph for 2 weeks at baseline and again at 12 weeks."
2523907|NCT02737540||Major depressive episode|This study population consists of patients over 60 years of age with or without a personal history of suicide attempts, hospitalized in the Nîmes University Hospital psychiatry department or the Sophoras clinic for a major depressive episode.
2523908|NCT02737540||Healthy subjects|Healthy subjects over 60 years, not depressed and without personal history of severe mental illness or suicide attempts will be recruited.
2523972|NCT02737137|Other|Manual measurement by the anesthetist|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic : Group 1
2523973|NCT02737137|Experimental|Measurement by a pressure gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the injection pressure of the local anesthetic : Group 2
2524002|NCT02736799|Sham Comparator|Sham vibrating capsule|Sham vibrating capsule
2524004|NCT02736799|Active Comparator|Vibrant Capsule (1 vibration)|1 vibration/min
2524008|NCT02736799|Active Comparator|Vibrant Capsule (3 vibration)|3 vibrations/min
2524010|NCT02736799|Active Comparator|Vibrant Capsule (5 vibration)|5 vibrations/min
3166144|NCT00521495|Experimental|B|Surface field strength at target 150 Gauss permanent magnet
3166145|NCT00521495|Active Comparator|C|
3166146|NCT00521508|Other|1|Patient affected by Berger's disease confirmed by renal biopsy with increased rate of Ig A
3166147|NCT00521508|Other|2|Patient affected by Berger's disease with normal rate of Ig A
3166148|NCT00521508|Other|3|Healthy volunteers
3166149|NCT00521521|Active Comparator|docetaxel and cisplatin|
3166150|NCT00521521|Experimental|docetaxel|
3166151|NCT00521534||A|CRT programmed to VDD pacing mode
3166152|NCT00521534||B|CRT programmed to DDD with overdrive pacing based on first night average sinus rate.
3166153|NCT00521560|Experimental|1|
2523551|NCT02740075||Hand-ventilated|This group will be transported from the operating room to the intensive care unit with the anesthesia provider ventilating the patient by hand via Mapleson circuit and supplemental oxygen. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators. The anesthesia provider will be blinded to the end-tidal carbon dioxide levels and respiratory rate.
2523556|NCT02740075||Mechanically ventilated|This group will be transported from the operating room to the intensive care unit with the patient being ventilated by a transport ventilator with controlled tidal volume, respiratory rate, and positive end-expiratory pressure. Vital signs and end-tidal carbon dioxide will be monitored and recorded by one of the investigators.
2523576|NCT02739802|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
3199464|NCT00880672|Active Comparator|dutasteride|oral, 5mg, once per day, 2 weeks
3199465|NCT00880672|Placebo Comparator|placebo|oral, 5mg, once per day, 2 weeks
3199466|NCT00880711||1|Patient with advanced BC, already receiving Faslodex therapy
3199467|NCT00880724|No Intervention|Medical management|
3199468|NCT00880737||Stable PE patients|Hemodynamically stable patients with acute symptomatic pulmonary embolism
3199469|NCT00880789|Experimental|Dose Level One: 5x10^6/m2|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
3199470|NCT00880815|Experimental|Treatment (chemotherapy, stem cell transplant, rituximab)|Participants receive rituximab IV over 5-7 hours on days -13 and -6, fludarabine IV over 1 hour and bendamustine IV over 1 hour on days -5 to -3, and tacrolimus IV starting on day -2 and PO after hospital discharge for 6 to 8 months. Participants with MUD receive thymoglobulin on days -2 and -1. Participants undergo allogenic stem cell transplant over 30-45 minutes on day 0. Participants receive rituximab IV over 5-7 hours on days 1 and 8 and methotrexate IV over 30 minutes on days 1, 3, and 6. Participants with MUD also receive methotrexate IV on day 11. Participants receive G-CSF SC once daily starting on day 7 until white blood cell counts recover.
3199471|NCT00880828|Experimental|A|FIR cervical collar plus Acetaminophen
2523857|NCT02737865|Experimental|SMI and sonazoid (single arm)|Patients with focal nodular hyperplasia will undergo ultrasonography with Superb-Microvascular imaging and additional sonazoid-enhanced ultrasonography. SMI is a software function in a Toshiba Aplio 500 system. Sonazoid is contrast-material for US and it is a intervention for patient with FNH. Sonazoid will be administered at a dose of 0.015 mL/kg by manual bolus injection, followed by a 10 mL normal saline flush via a peripheral venous line
2523909|NCT02737475|Experimental|Part 1: Dose Escalation|"BMS-986178 at specified doses at specified intervals~Enrollment is closed for this arm"
2523910|NCT02737475|Experimental|Part 2: Dose Escalation and Expansion|"BMS-986178 in combination with Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523911|NCT02737475|Experimental|Part 3: Dose Escalation and Expansion|"BMS-986178 in combination with Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523913|NCT02737475|Experimental|Part 4: Dose Schedule and Exploration|"BMS-986178/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523916|NCT02737475|Experimental|Part 5: Dose Schedule and Exploration|"BMS-986178/Ipilimumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523918|NCT02737475|Experimental|Part 6: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523919|NCT02737475|Experimental|Part 7: Dose Safety and Expansion|"BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals~Enrollment is closed for this arm"
2523920|NCT02737475|Experimental|Part 8: Dose Exploration|"BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval~Enrollment is closed for this arm"
2523922|NCT02737475|Experimental|Part 9: Dose Exploration|"BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals~Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]"
2524057|NCT02736383||Tranexamic Acid|Patients that receive 2 gm TXA during surgery
2524060|NCT02736383||No Tranexamic Acid|Patients that receive no TXA during surgery
2524097|NCT02736162||Perampanel|Participants with a diagnosis of epilepsy who received perampanel as primary or secondary (conversion) monotherapy at any time between 1 Jan 2013 and 15 Oct 2015.
2524129|NCT02735785|Experimental|intervention|behavioral intervention
2524133|NCT02735785|No Intervention|control|control
2524154|NCT02735564|Experimental|RYGB|Bariatric Surgery:Roux-en-y
2524158|NCT02735564|Experimental|SG|Bariatric Surgery: Sleeve Gastrectomy
2524161|NCT02735564|Placebo Comparator|Control|BMI matched control
2524239|NCT02735304|Other|Innovation treatment 3M ESPE materials|"The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment during the Impression intervention.~Materials to be used all 3M ESPE - Astringent Retraction Paste, Imprint™ 4 Preliminary, Imprint™4 VPS, Imprint™ 4 Bite, Intra-oral syringes, Impression Tray,"
2524245|NCT02735304|Other|standard clinical practice treatment|"The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment during the Impression intervention~Materials as per the operating dentist's choice to be recorded on CRF"
3199472|NCT00880828|Active Comparator|B|Conservative cervical collar plus Acetaminophen
3199473|NCT00880828|Placebo Comparator|C|Acetaminophen only
3199474|NCT00880841||no treatment|phase 1a study for healthy normals
3199475|NCT00880854|Experimental|1|BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 in combination with CP-675,206 I.V. week 3, week 1
2523724|NCT02738944|Active Comparator|Integrated Care|Telepsychiatry Collaborative Care
2523728|NCT02738944|Active Comparator|Referral Care|Telepsychiatry Enhanced Referral
2523776|NCT02738359||1rst arm: optical colonoscopy (OC)|t0: optical colonoscopy; Follow-up: yearly by phone call for three years
2523777|NCT02738359||2nd arm: colon capsule endoscopy (CC)|t0: colon capsule endoscopy -> if positive: OC; At three years: OC for those patients with negative initial CC; Follow-up: yearly by phone call for 3 years
2523778|NCT02738359||3rd arm: fecal immunological test (FIT)|"FIT yearly for two years:~t0: FIT -> if positive : OC; t = 1 year: FIT -> if positive : OC; t = 2 years: FIT -> if positive : OC; At three years: OC for those patients with negative FIT during the study Follow-up: yearly by phone call for 3 years"
2524014|NCT02737020|Experimental|Rhodiola|Rhodiola rosea 200mg up to four times a day for 28 days
2524016|NCT02737020|Placebo Comparator|Placebo|Placebo pill manufactured to mimic Rhodiola rosea 200mg, up to four times a day for 28 days
2524098|NCT02736136|Experimental|Intervention|Joint observation and video feedback plus usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
2524101|NCT02736136|No Intervention|Control|Usual care in the neonatology (plus completion of self-report questionnaires and 15 min filmed mother-infant interaction)
3166154|NCT00521612|Experimental|A|Sevoflurane group, experimental group
2524234|NCT02735369|Placebo Comparator|Placebo|Placebo Comparator
2524243|NCT02735369|Experimental|2% OC-10X|2% OC-10X
2524487|NCT02733783|Experimental|septorhinoplasty patients|Elective septorhinoplasty patients that will undergo bilateral osteotomies. All the patients will undergo cold dry air provocation and 3 hours later capsaicin provocation, during a preoperative visit, one week before the intervention and during three post-operative visits two weeks, three months and six months.
2524583|NCT02733432|Experimental|Cohort 1|CD101 Vaginal Gel (3%) topically self-administered intravaginally as a single dose on days 1 and 2 and for symptomatic relief CD101 External Gel (1%)topically self-applied to external vulva up to twice per day over 72 hours.
2524585|NCT02733432|Experimental|Cohort 2|CD101 Vaginal Ointment (6%) topically self-administered intravaginally as a single dose on day 1 and for symptomatic relief CD101 External Ointment (1%) topically self-applied to external vulva up to twice per day over 72 hours.
2524586|NCT02733432|Active Comparator|Cohort 3|Oral fluconazole (150mg) administered on day 1.
2524658|NCT02732496|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
2524660|NCT02732496|Placebo Comparator|Youth Appropriate Online Games|Engaging games not designed to improve cognition
2524766|NCT02731651|Active Comparator|Open Hysterectomy|Open hysterectomy was performed with taking one of the ovaries at the beginning and the other ovary was removed at the end of the surgery.
2524773|NCT02731651|Active Comparator|LaparoscopicAssistedVaginalHysterectomy|Surgery in Group 2 (LAVH): Laparoscopic Assisted Vaginal Hysterectomy was performed with taking one of the ovary at the beginning of the procedure and the other ovary was removed at the end of the surgery.
2524796|NCT02731495|Experimental|EGCG|Participants were randomly divided based on age, sex and severity of TBI in two groups. Randomization lists was computer-generated by a statistician and participants, project managers and employees at the clinic are completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients received EGCG supplement was in the form of 400 mg oral capsules with a purity of 80% catechin. EGCG powder of each capsule was dissolved in 10 ml deionized water and given to patients via gavage (1 capsule per day) for a week.
2524797|NCT02731495|Placebo Comparator|Placebo|Placebo group only received 10 ml of deionized water via gavage for a week.
2524815|NCT02731326|Experimental|iHEART|Participants will transmit daily ECGs using AliveCor for 6 months following cardioversion or ablation procedure to treat AF/AFL. Participants will also receive read-only behavioral altering messaging three times per week focusing on AF, cardiovascular risk factors, and healthy living.
2524828|NCT02731326|No Intervention|Usual Care|Participants will continue with usual care with their physician.
2524872|NCT02731079|Active Comparator|Covidien|Group that will have sleeve gastrectomy performed using the Covidien iDrive powered stapler with absorbable polymer membrane staple line reinforcement.
2525203|NCT02728778|Other|Acupuncture|Patients will receive four facial acupuncture treatments every two weeks.
3166155|NCT00521612|Active Comparator|B|Isoflurane group, control group
3166156|NCT00521638|Experimental|1|
3166157|NCT00521651||Community Cohort|Men and Women from two Shanghai cohort studies.
3166158|NCT00521664|Active Comparator|1|Therapeutic platelet transfusion (TP) strategy versus prophylactic platelet transfusion (PP) strategy. In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
3166159|NCT00521664|Active Comparator|2|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
3166160|NCT00521677|Experimental|1|Procedure: Use of protocol that use special suction connected toothbrush to clean the teeth and the oral cavity, use of non alcoholic antiseptic solution and lubrication of the lips and the oral cavity.
3166161|NCT00521677|Active Comparator|2|The traditional method of oral care with cleaning of the oral cavity with a sponge soaked with antiseptic non alcoholic solution
3166162|NCT00521703|Experimental|1|group treated
3166163|NCT00521703|Placebo Comparator|2|control group
3166164|NCT00521716|Experimental|A|
3166165|NCT00521742|Experimental|Pioglitazone 15 mg to 45 mg QD|
3166166|NCT00521742|Active Comparator|Glyburide 2.5 mg to 15 mg, QD|
3166167|NCT00521742|Experimental|Pioglitazone 15 mg or 30 mg QD|
3166168|NCT00521742|Active Comparator|Glyburide 5 mg or 10 mg, QD|
3166169|NCT00521755|Experimental|A|
3166170|NCT00521781|Experimental|1|Treatment will be Abraxane/hormonal therapy (LHRH Agonist) for four nine-week cycles, followed by Total androgen blockade therapy (LHRH Agonist+ Anti-androgen) for 2 years from the time the hormonal therapy was started.
2523704|NCT02738970|Experimental|Part 1-Cohort 7: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC.
2523705|NCT02738970|Experimental|Part 1-Cohort 8: Pertuzumab 1200 mg SC + Trastuzumab 600 mg SC|Part 1 includes healthy male participants. Participants will receive a single injection of co-mixed pertuzumab 1200 mg and trastuzumab 600 mg SC without recombinant human hyaluronidase (rHuPH20) excipient.
2523707|NCT02738970|Experimental|Part 2-Cohort A: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohort A will be enrolled only if FDC of pertuzumab and trastuzumab is not feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC administered separately. The dose of pertuzumab will be identified during Part 1.
2523709|NCT02738970|Experimental|Part 2-Cohort B: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
2523710|NCT02738970|Experimental|Part 2-Cohort C: Pertuzumab SC + Trastuzumab SC|Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents formulated together and administered in one injection (FDC). The dose of pertuzumab will be identified during Part 1.
2523774|NCT02738372||Chronic Shoulder Pain|"Men / women aged between 18 and 70 years.~Patients suffering from shoulder pain, defined as pain presented or exacerbated by movements in the shoulder, pain intensity ≥ 2 measured by a numerical scale with values from 0 to 10, meaning 0= no pain and 10= the worst pain, will be included in this study, among all these following shoulder pain conditions: (i) Rotator Cuff tendinopathy; (ii) Adhesive Capsulitis; (iii) glenohumeral instability; (iv) SLAP lesion; (v) and/or acromioclavicular pathology. Subjects will not be required to undergo diagnostic imaging (i.e. Magnetic Resonance Imaging) to diagnosis the pathology because of the recruitment will be carried out by clinical findings.~Duration of symptoms: greater than 3 months."
2523816|NCT02738073|Placebo Comparator|Control|
2523817|NCT02738073|Active Comparator|Interventional|
2523853|NCT02737735|Experimental|Chemotherapy combined with compound herbal medicine|Standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks combined with compound Chinese herbal medicine for 2 years，which include 15 kinds of Chinese herbs:Thunberg fritillary bulb,antimutangenic ,cimicifuga foetida,astragalus,pinellia ,Radix Ophiopogonis ,Solanum nigrum,Hedyotis diffusa,Prunella vulgaris ,cordate houttuynia,Herba Patriniae,dried orange peel ,Codonopsis,Wolfiporia extensa,Coix seed,Rhizoma Alismatis.
2523855|NCT02737735|Active Comparator|Chemotherapy|The therapy of standard chemotherapy protocols on phase IIIB/IV non-small-cell lung cancer for 24 weeks
2523929|NCT02737514|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
2523936|NCT02737514|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy
2523951|NCT02737514|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
2524080|NCT02736240|Active Comparator|Control Arm|7-valent pneumococcal conjugate vaccine
2524081|NCT02736240|Experimental|Test Arm|13-valent pneumococcal conjugate vaccine
2524125|NCT02735876|Experimental|acalabrutinib plus rituximab|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity. Rituximab IV infusions will be administered weekly for 4 weeks and on Day 1 of Cycle 3 through 8, and thereafter every other cycle for less than or equal to two years (approximately 200 subjects).
2524132|NCT02735876|Active Comparator|ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 200 subjects).
2524139|NCT02735876|Experimental|acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity (approximately 50 subjects).
2524197|NCT02735460|Experimental|Treatment arm|In this arm the Andago V2.0 is used.
2524287|NCT02735213|Experimental|577-MPL|"577nm subthreshold micropulse laser(577-MPL) will be performed on the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein. Multiple laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
2524288|NCT02735213|Active Comparator|TLT|"Traditional laser will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Traditional laser spots will be applied, covering the leakage area. Retreatment will be given in 12 weeks If SRF is not completely absorbed and CRT>= 250um."
2524336|NCT02734888|Other|Healthy control|"Will undergo PET scan as a negative control"
2524340|NCT02734888|Other|Tobacco cigarette smoker|"Will undergo PET scan as a positive control"
2524342|NCT02734888|Other|E-cigarette user|Will undergo PET scan
2524387|NCT02734511|Experimental|Drug: sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
2524426|NCT02734303||Potentially Exposed NM Residents|residents of the state of New Mexico (NM) potentially exposed to radioactive fallout fromthe Trinity nuclear test conducted in 1945
2524469|NCT02733926|No Intervention|City kindergarten|Children living in a normal city kindergarten that hardly has vegetation in backyards
2524474|NCT02733926|Experimental|adding of vegetation into the backyards.|"Children living in a normal city kindergarten that has plenty of vegetation in backyards.~Intervention: adding of vegetation into the backyards."
2524475|NCT02733926|No Intervention|Nature kindergarten|Children living in a city kindergarten where children go regularly into a natural forest
2524593|NCT02733055|Experimental|subjects|participant undergoing posturographic evaluation
2524645|NCT02732743|Other|Food Supplement Physiomanna® Baby|Dosage: 1g/kg body
2524678|NCT02732392|Experimental|lymphadenectomy|
3166171|NCT00521807|No Intervention|A 1|
3166172|NCT00521807|Experimental|A 2|Treatment group
3166173|NCT00521820|Experimental|Pioglitazone QD|
3166174|NCT00521820|Active Comparator|Glyburide QD|
3166175|NCT00521833|Experimental|1|Temporal (right eye)
3166176|NCT00521833|Experimental|2|Nasal (Left eye)
2523713|NCT02738931|Experimental|Treatment Sequence BCA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AA, treatment B) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablet (Product Code AB, treatment C) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2523715|NCT02738931|Experimental|Treatment Sequence CAB|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2523717|NCT02738931|Experimental|Treatment Sequence ACB|Subject will receive reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 1, experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2523718|NCT02738931|Experimental|Treatment Sequence BAC|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 1 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 2 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2523721|NCT02738931|Experimental|Treatment Sequence CBA|Subject will receive experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AB, treatment C) in period 1 and experimental Dolutegravir/Lamivudine 50 mg/300 mg FDC tablets (Product Code AA, treatment B) in period 2 and reference treatment DTG 50mg and 3TC 300mg administered as single entity tablets (treatment A) in period 3 in a fasted state. There will be at least 7 days washout between dosing periods.
2523773|NCT02738346|Experimental|Arm A : Carboplatin-Etoposide|Intravenous administration of Carboplatin Auc 5 at Day 1 and Intravenous administration of 100 mg / m² / of Etoposide J Day 1 to Day 3 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
2523775|NCT02738346|Active Comparator|Arm B : Topotecan|Per os administration of 2.3 mg / m² of Topotecan Day 1 to Day 5 The CT scans evaluations will be conducted during chemotherapy every 6 weeks
3199476|NCT00880867|Experimental|Poly-ICLC|Poly-ICLC plus low dose local radiation.
2523883|NCT02737605|Experimental|Sequence 1|Participants will receive Treatment A (intravenous placebo, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 1, Treatment B (intravenous placebo, 84 milligram (mg) of intranasal esketamine and Oral placebo tablet matched to the moxifloxacin tablet) on Day 1 of period 2, Treatment C (intravenous placebo, Intranasal placebo and 400 mg oral moxifloxacin tablet) on Day 1 of period 3, Treatment D (0.8 milligram per kilogram of intravenous esketamine, Intranasal placebo and Oral placebo tablet matched to the moxifloxacin tablet ) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2523884|NCT02737605|Experimental|Sequence 2|Participants will receive Treatment A on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2523886|NCT02737605|Experimental|Sequence 3|Participants will receive Treatment B on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2523888|NCT02737605|Experimental|Sequence 4|Participants will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2523890|NCT02737605|Experimental|Sequence 5|Participants will receive Treatment C on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment B on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2523892|NCT02737605|Experimental|Sequence 6|Participants will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 5 to 7 days.
2524018|NCT02736812|Experimental|French Lyophilized Plasma|receives French Lyophilized Plasma with the usual treatment for post traumatic hemorrhagic shock as given in the recommendations for best practice
2524023|NCT02736812|Active Comparator|Normal Saline Solution|receives Normale Saline Solution with the usual treatment of post traumatic hemorrhagic shock as given in the recommendations for best practice
2524065|NCT02736331|Experimental|Treatment 1 Beverage|Treatment 1
2524070|NCT02736331|Placebo Comparator|Treatment 2 Beverage|Treatment 2
3199477|NCT00880880|Experimental|pre-visit e-PAQ-PF|Participants assigned to fill out the e-PAQ-PF prior to their clinic visit. Participants will arrive early to clinic appointment and fill out e-PAQ-PF. Results will be given to clinician and participant. After their visit they will complete the post visit questionnaire.
3199478|NCT00880880|No Intervention|post-visit e-PAQ-PF|Participants assigned to complete the e-PAQ-PF after their clinic visit. Pre-visit participants will sign consent form - but otherwise will receive no study interventions. Post-visit they will fill out e-PAQ-PF and post visit questionnaire.
3199479|NCT00880932|Experimental|customized electronic alert|"This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a reason for override whenever the combination drugs of warfarin and NSAID were ordered together."
3199480|NCT00880932|No Intervention|Standard practice|The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.
3199481|NCT00880945||36-40 patients|patients with small peripheral lesions who need bronchoscopy for diagnostic purposes
3199482|NCT00880958|Experimental|1|
3199483|NCT00880958|Placebo Comparator|2|
3199484|NCT00880971|Experimental|PORT|Patients undergo thoracic radiotherapy using 3D-CRT or IMRT (50 Gy, 2 Gy once daily over 5 weeks) after postoperative chemotherapy.
3199485|NCT00880971|No Intervention|Non-PORT|Patients undergo postoperative chemotherapy.
3199486|NCT00881010||Telephone Intervention|
2523726|NCT02738762|Active Comparator|intervention group|enteral glutamine supplementation guided by glutamine level Enteral glutamine supplementation is started (day 1) at a dose of 3 sachets per day given at 6.00, 14.00 and 22.00 hr. A sachet contains 9 grams of L-glutamine ( Glutaperos®, GLNP Life Sciences). Enteral glutamine supplementation will be given for a maximum of 10 days or until the patient is discharged from the ICU
2523731|NCT02738762|No Intervention|control group|patients receive normal treatment, no glutamine supplementation
2523768|NCT02738502|Experimental|Single Group|Intervention: Darunavir monotherapy darunavir/ritonavir 600 mg/100mg twice day in monotherapy.
2523807|NCT02737969||TEE/Angio fusion software|Patients planned to undergo a transcatheter-based structural heart disease procedure that utilizes TEE and fluoroscopic guidance
2523990|NCT02737046|Experimental|Belinostat + Zidovudine|Belinostat + Zidovudine (AZT) in combination as consolidation therapy, followed by standard zidovudine (AZT)-based maintenance therapy with optional Interferon-Alfa-2b (IFNalfa-2b) or Pegylated Interferon-Alfa-2b (PEG-IFN-alfa-2b)
2524050|NCT02736500|Experimental|28 GBq 177Lu-DOTATATE|5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) 177Lu-DOTATATE
2524055|NCT02736500|Experimental|22 GBq 177Lu-DOTATATE|6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi) 177Lu-DOTATATE
2524095|NCT02736071|Active Comparator|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
2524100|NCT02736071|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
2524103|NCT02736071|Placebo Comparator|Placebo|Women will receive an oral placebo similar to Tramadol and an oral placebo similar to Celecoxib 2 hours before the procedure
2524162|NCT02735694|Active Comparator|Cycloserine|Cycloserine, 250 mg capsules by mouth, one hour prior to initiation of sleep study, single dose
2524164|NCT02735694|Placebo Comparator|Placebo|Placebo, sugar capsule by mouth, one hour prior to initiation of sleep study, single dose
3166178|NCT00521859|Experimental|Cloretazine + Fludarabine|
3166179|NCT00521898|Experimental|DMEK|DMEK as intervention
3166180|NCT00521911|Active Comparator|1|Cognitive Behavioural Therapy
3166181|NCT00521911|No Intervention|2|Treatment as Usual
3166182|NCT00521937|Experimental|A|Dermagen®
2524330|NCT02734784|Experimental|Photodynamic Therapy and SRP|
2524334|NCT02734784|Sham Comparator|SRP and Sham Photodynamic Therapy|
2524388|NCT02734563||Multiple hernia group|Males undergoing at least three repairs of abdominal wall hernias at three different anatomic locations. Collagen turnover is analysed.
2524389|NCT02734563||Control group|Males without any history or presence of hernias
2524412|NCT02734251|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2524417|NCT02734251|Experimental|Relora|Dietary Supplement: Relora, 750 mg/day
2524455|NCT02734030||Control Group|"Knee pain-free females with no history of lower limb injuries serving as a control group.~."
2524457|NCT02734030||Anterior Knee Pain Group|Females with anterior knee pain syndrome were enrolled in this group.
2524506|NCT02733718|Other|Group 1: no enteral feeding|intervention: NIRS (near-infrared spectroscopy)
2524508|NCT02733718|Other|Group 2: Feeding is reduced by %50|intervention: NIRS (near-infrared spectroscopy)
2524513|NCT02733718|Other|Group 3: Feeding will be continued|intervention: NIRS (near-infrared spectroscopy)
2524697|NCT02732379|Experimental|Rose Aromatherapy|Aromatherapy with rose essential oil
2559111|NCT02505126|Experimental|Active tDCS group|Active tDCS
3166183|NCT00521937|Active Comparator|B|Conventional treatment
3166184|NCT00521950|Experimental|Intervention, TPMT genotyping|Pre-treatment TPMT genotyping to optimize initial thiopurine treatment dose. Intervention is based on the genotype.
3166185|NCT00521950|Active Comparator|control|Standard thiopurine treatment
3166186|NCT00521963|Experimental|E|
3166187|NCT00522015|Active Comparator|1|patients take 6 mg rivastigmine daily, if well tolerable increase to 12 mg rivastigmine maximum daily
3166188|NCT00522054|Other|A|Single group study
3166189|NCT00522067|Experimental|Arm 1|FLUAD
3166190|NCT00522106|Experimental|A|Behavioral graded activity
3166191|NCT00522106|Active Comparator|B|Exercise therapy
3166192|NCT00522132|Active Comparator|cohort 1|2.4 mg/kg iv artesunate at 0, 12, 24, 48and 72 hours
3166193|NCT00522132|Experimental|cohort 2|4.0 mg/kg iv Artesunate at 0, 24 and 48 h
3166194|NCT00522145|Experimental|Group 1|
3166195|NCT00522184|Experimental|1|patient receiving etanercept intra-articular injection
3166196|NCT00522184|Active Comparator|2|patient receiving steroid intra-articular injection
3166197|NCT00522197|Active Comparator|ACAPHA|
3166198|NCT00522197|Placebo Comparator|Sugar Pill|
3166199|NCT00522210|Experimental|BID insulin with LA analogue|Treatment Group: BID Insulin Regimen with Long Acting Insulin Analogue (Detemir)
3166200|NCT00522210|Active Comparator|Standard TID insulin|Active Control Group: Usual TID Insulin Regimen (intermediate insulin- Humulin N or Novolin NPH)
3166201|NCT00522223||Questionnaire|Questionnaire
3166202|NCT00522236|Experimental|Arm 1|
3166203|NCT00522249|Experimental|1|One cycle of the combination therapy will be 42 days (6 weeks). All patients will receive PEG-Intron given subcutaneously on Day 1 each week. Patients will receive Sunitinib orally on Days 1-28 of each cycle. Patients will receive Tarceva orally on Days 1-42.
3166204|NCT00522262|Experimental|Exercise|Women randomized to the exercise intervention arm completed a one year aerobic exercise intervention of 225 minutes/week.
3166205|NCT00522262|No Intervention|Control|Women randomized to the control arm were asked to maintain their regular lifestyle which meant no changes to their exercise or dietary intake. Women eligible for this trial were inactive and hence were expected not to increase their levels of physical activity in the control arm.
2523789|NCT02738606|Experimental|Group I (surgery, chemotherapy)|Patients undergo hepatectomy and receive chemotherapy at the discretion of treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
2523794|NCT02738606|Active Comparator|Group II (chemotherapy)|Patients receive chemotherapy at the discretion of the treating oncologist. Patients whose lung tumors become able to be removed by surgery with chemotherapy may undergo lung metastasectomy.
2523820|NCT02737904|Active Comparator|Control group|Usual care - conventional, personalised in-patient rehabilitation 4 weeks duration
2523822|NCT02737904|Experimental|Intervention group|Usual care - conventional, personalised in-patient rehabilitation - plus APT cycling programme 4 weeks duration
2523866|NCT02737696|Active Comparator|Control|Participants in this group will have access to Drug Enforcement Administration's website (JustThinkTwice.gov). The JustThinkTwice website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz. Youth in this group will be informed that they will be prompted (by email and phone; described below) when the next online survey is available to complete. Youth will be asked to use this website for 30 minutes, twice per week (for a total of 60 minutes per week) for about 3-4 weeks.
2523868|NCT02737696|Experimental|Experimental|"Participants assigned to the Web-based prescription opioid prevention for adolescents will immediately (post-group assignment) be asked to start completing modules. All youth can choose to access modules in any order. Youth will be encouraged to complete 1-2 modules per login, 2x/week (about 30 mins. minimum per login to parallel the manner in which other evidence-based prevention programs have been provided to youth. We do not plan to place an artificial constraint on module access but will encourage youth to use the flexible, web- based tool in a manner that is most useful to them. In our experience providing online interventions, we expect that most youth will complete all 9 modules within 3-4 weeks."
3199487|NCT00881010||Usual Care|
3199488|NCT00881023|Active Comparator|1|Randomized to Microfracture
2524019|NCT02736747|Active Comparator|Cryotherapy (ice pack)|A pack with 1000g of crushed ice without air will be placed for 20 consecutive minutes on a pre-delimited rectangular area with dimensions of 25 x 35 cm and will be fixed with a non-compressive elastic band. One strip of plastic paper will encompass the paretic leg of the subjects, avoiding direct contact from the skin with the ice pack.
2524024|NCT02736747|Placebo Comparator|Placebo (sand pack)|"For placebo application, the pack will be filled with 1000g of thin sand, in environmental temperature, so that the pressure exerted will be the same as the ice pack. All other experimental procedures will follow the same protocol as cryotherapy application."
2524063|NCT02736435|Experimental|Fibroid dimension < 8 cm|"Women with a maximum fibroid dimension less than 8 cm and a total uterine volume less than 900 cc.~Intervention: Treatment of fibroids with Magnetic Resonance Guided High Intensity Focused Ultrasound."
2524064|NCT02736435|Experimental|Fibroid dimension > 8 cm|"Women with a maximum fibroid dimension greater than 8 cm or a total uterine volume greater than 900 cc.~Intervention A: Pre-treated with 11.25mg leuprolide acetate for depot suspension for 3 months to reduce size of fibroids.~Intervention B: Treatment with Magnetic Resonance Guided High Intensity Focused Ultrasound if fibroids decrease to treatable size of less than 8cm and uterine volume less than 900cc."
2524123|NCT02735941||UC group|Patients with ulcerative colitis (active or remission)
2524126|NCT02735941||CD group|Patients with Crohn's disease (active or remission)
2524131|NCT02735941||Colon cancer group|Patients with colon cancer or metastasis
2524137|NCT02735941||control group|healthy individuals
2524236|NCT02735603|Experimental|Nalterxone/Bupropion + Placebo + Moxifloxacin|Naltrexone hydrochloride (HCl) 8 milligram (mg)/bupropion HCl 90 mg (NB) placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
2524244|NCT02735603|Experimental|Placebo + Moxifloxacin + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
2524248|NCT02735603|Experimental|Moxifloxacin + Naltrexone/Bupropion + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Day 4 to 10, and once in the morning on Day 11 in treatment period 2, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in the treatment period 3.
2524260|NCT02735252|Experimental|Group D: Targeted Therapy Not Otherwise Specified|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving targeted therapy and investigational therapeutics to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
3199489|NCT00881023|Experimental|2|Randomized to Device
3199490|NCT00881023|Experimental|3|Non-randomized with lesion greater than 6cmˆ2
2523842|NCT02737878|Experimental|Aerobic Training (AT)|The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2523846|NCT02737878|Experimental|Resistance Training (RT)|The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2523849|NCT02737878|Active Comparator|Balance and Tone Program (CON)|The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
2523902|NCT02737410|Active Comparator|Treatment|Treatment group obtaining Gut-directed Hypnotherapy
2523906|NCT02737410|No Intervention|Control|Control group
2523961|NCT02737150|Active Comparator|Self-expandable valve under local anesthesia|CoreValve Evolut R valve under local anesthesia with conscious sedation
2523965|NCT02737150|Active Comparator|Self-expandable valve under general anesthesia|CoreValve Evolut R valve under general anesthesia
2523967|NCT02737150|Active Comparator|Balloon-expandable valve under local anesthesia|Edwards Sapien 3 valve under local anesthesia with conscious sedation
2523968|NCT02737150|Active Comparator|Balloon-expandable valve under general anesthesia|Edwards Sapien 3 valve under under general anesthesia
3199491|NCT00881062|Experimental|25 mg Proellex|25 mg (100 µCi) [14C]-Proellex
3199492|NCT00881075|Experimental|SeeMore(TM)|intravenous imaging agent for enhanced magnetic resonance imaging.
3199493|NCT00881088|No Intervention|1|Patients randomized to the no intervention group
3199494|NCT00881088|Experimental|Nadroparin|Subjects randomized to group receiving nadroparin 0,3 cc daily during immobilization
2524337|NCT02734771|Experimental|BV+mini-R-CHP|Brentuximab vedotin 1.8 mg/kg IV day 1 for six cycles Rituximab 375 mg/m2 IV day 1 for six cycles Cyclophosphamide 400 mg/m2 IV day 1for six cycles Doxorubicin 25 mg/m2 IV day 1 for six cycles Prednisone 40 mg/m1 PO days 1-5 for six cycles
2524409|NCT02734342|Experimental|Exercise, Kinesiophobia and Knee Osteoarthritis|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. During the hour, participants will complete a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improve aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted.
3199495|NCT00881088|Experimental|Fondaparinux|Subjects randomized to fondaparinux 2,5 mg daily group during immobilization
3199496|NCT00881101|Experimental|1|Liposomal paclitaxel
2524489|NCT02733562||Binge eaters|Classificated preoperatively
2524495|NCT02733562||Volume eaters|Classificated preoperatively
2524497|NCT02733562||sweet eaters|Classificated preoperatively
2524501|NCT02733562||snack eaters|Classificated preoperatively
2524573|NCT02733393|Experimental|SPG Block|
3199497|NCT00881114|Experimental|Cetuximab|patients with 2 or fewer genetic variants will receive cetuximab
3199498|NCT00881114|Experimental|Cisplatin|Subjects with 3 to 8 genetic variants will receive cisplatin
2524671|NCT02732483|Experimental|Endo-Clot(TM)|
2524690|NCT02732171|Other|Screening Bone Marrow Aspirate|All patients will undergo screening bone marrow aspirate to test for disseminated tumor cells (DTCs) by immunohistochemistry. The bone marrow sample is also used for other research tests.
2524727|NCT02732002|Experimental|OCBRA group.|This group of patients will follow the proposed methodological approach for work related injuries rehabilitation.
3199499|NCT00881127|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
3199500|NCT00881127|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
3199501|NCT00881140|Experimental|antiprogestin|Daily use of 10 mg administrated per vagina
3199502|NCT00881153|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)
2524901|NCT02730897||VATS|Patients operated by means of minimal invasive technique (VATS or roboticVATS)
2524906|NCT02730897||Open|Patients operated by means of open thoracotomy
3199503|NCT00881153|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)
3199504|NCT00881166|Experimental|1|oral MP-470 + paclitaxel/carboplatin
2525009|NCT02730000|Active Comparator|ART with Equia|Occlusal-proximal restoration in primary molars using Equia (Easy/Quick/Unique/Intelligent/Aesthetic) from GC Corp, encapsulated, pre-dosed and mechanized handling.
2525011|NCT02730000|Experimental|ART with Riva Self Cure|Occlusal-proximal restoration in primary molars using Riva Self Cure from SDI, encapsulated, pre-dosed and mechanized handling.
2525074|NCT02729597||Controls|"Healthy control subjects who meet all inclusion and exclusion criteria for healthy controls.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
3199505|NCT00881166|Experimental|2|oral MP-470 + carboplatin/etoposide
3199506|NCT00881166|Experimental|3|oral MP-470 + topotecan
3199507|NCT00881166|Experimental|4|oral MP-470 + docetaxel
3199508|NCT00881166|Experimental|5|oral MP-470 + Erlotinib
3199509|NCT00881179|Experimental|1|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
3199510|NCT00881179|Active Comparator|2|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
2523971|NCT02737098|Active Comparator|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
2524005|NCT02736760|Experimental|Daylight photodynamic therapy (PDT)|"One intervention in the daylight photodynamic therapy arm:~Daylight photodynamic therapy using Methylaminolevulinate (MAL) will be performed five times within 18 months (visits 1-5). In the PDT group the patients will apply a chemical sunscreen (SPF 50+) to the whole face and other light-exposed, unprotected areas of the skin. After at least 15 minutes a lesion preparation of AKs (removal of crusts) will be performed and methylaminolevulinate (MAL) will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours."
2524009|NCT02736760|Active Comparator|Cryosurgery|In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. In the control group, cryosurgery will be performed using liquid nitrogen spray in each AK lesion; this will be done at visit 1 and, if necessary, also at visits 2-5. At visits 2-6, the efficacy of the treatment will be evaluated by the observer by documenting all existing and newly appearing AKs in the face.
2524052|NCT02736513|Experimental|AZD9291 80 mg - naive patients|naive patients with tumors harbouring either exon 19 deletion, L858R, T790M, or uncommon sensitizing EGFR mutations, will be treated with AZD9291 80 mg/day
2524056|NCT02736513|Experimental|AZD9291 80 mg - previously treated T790M was diagnosed|Patients previously treated with first and second generation EFGR TKIs (either Gefitinib, Erlotinib or Afatinib) in whom T790Mwas diagnosed either in the tumor specimen or in the ctDNA after testing it following the most recent disease progression, will be treated with AZD9291 80 mg/day
2524059|NCT02736513|Experimental|AZD9291 80 mg - previously treated unrelated to T790M|patients advanced NSCLC previously treated with 1st/2nd generation EGFR TKIs (either gefitinib. erlotinib or afatinib) who progressed unrelated to T790M (T790M-). No restriction regarding the number of prior EGFR TKIs or cytotoxic chemotherapy lines of treatment is applied.
2524096|NCT02736058|Experimental|Participants|the included pregnant females will undergo trans-abdominal sonography as well as trans-vaginal sonography , to diagnose the abnormal placentation and the results will be compared to the intra- operative as well as the pathological examination of the specimen.
2524167|NCT02735733|Active Comparator|Room temperature arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at room temperature.
2524168|NCT02735733|Experimental|Cold arm|Intervention: The balloon catheter will be placed through the vagina into the uterus and inflated using normal saline at approximately 32 degrees F for the study group.
3199511|NCT00881192|No Intervention|Control|No preoperative IABP; if needed, postoperative IABP placement
2524391|NCT02734485|Active Comparator|active Deep Tms|Each DTMS session consisted in two consecutive stimulations: a first low-frequency (1 Hz) stimulation in the motor cortex (110% of the motor threshold, for 15 minutes)and a second high-frequency (10Hz) one in the prefrontal cortex (100% motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).The coil contains two symmetric devices, perfectly designed to rouse both hemispheres at the same time.
2524392|NCT02734485|Sham Comparator|sham deep tms|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an inactive DTMS coil.
2524443|NCT02734199||Enrollment Period 1 Cohort|Cohort 1 includes approximately 650 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Contraceptive access will be the same as it was prior to the study beginning, meaning participants either have to use insurance or self-pay for their method of choice.
2524447|NCT02734199||Enrollment Period 2 Cohort|Cohort 2 includes approximately 1000 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 2 participants and they can initiate which ever contraceptive method they want at no cost to them for three years.
2524450|NCT02734199||Enrollment Period 3 Cohort|Cohort 3 includes approximately 1350 participants who receive a standardized client centered contraceptive counseling session with a clinical assistant. Financial barriers are removed for Period 3 participants and they can initiate which ever contraceptive method they want at no cost to them for three years. During enrollment period 3, a community-wide, media driven intervention will be implemented and population level changes in HER-C initiation will be examined.
2524485|NCT02733835|Experimental|Remifentanil|Remifentanil Patient Controlled Analgesia
2524589|NCT02733380|Experimental|Chidamide combined with VDDT regimen|Chidamide 30mg，Oral twice a week with an interval of no less than 3 days combined with regimen：VDDT（Vinorelbine，Liposomal doxorubicin or mitoxantrone ，Dexamethasone and Thalidomide）：repeated every 14 days ，up to 12 cycles
2524654|NCT02732613|Experimental|Actual weight Group|Patients in Actual weight Group: The selection of Laryngeal Mask Airway classic will be based on actual body weight, followed the recommendations of manufacturer (size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
2524656|NCT02732613|Experimental|Ideal weight Group|Patients in Ideal weight Group: The selection of Laryngeal Mask Airway classic will be based on ideal body weight, followed the recommendations of manufacturer ( size 3 for weight < 50 kg, size 4 for weight 50-70 kg, and size 5 for weight > 70 kg ).
2524765|NCT02731885|Experimental|Fasted Conditions|50mg of ABX464 (two 25mg capsules) /Fasted
2524772|NCT02731885|Experimental|Fed Conditions|50mg of ABX464 (two 25mg capsules) /Fed
2524819|NCT02731456|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude.
2524875|NCT02731170|Experimental|rehabilitation treatment (MIRT)|MIRT consists of a 4-week physical therapy. daily sessions are subdivided in: motor treatment (2 hour), occupational therapy (1 hour) and speech Therapy (1 hour)
3199512|NCT00881192|Active Comparator|IABP|Preoperative IABP placement
2523979|NCT02736877|Active Comparator|Conventional Microscope|The control group will undergo corneal transplant with conventional microscope without coupled OCT. The team of surgeons will answer the questionnaire on the surgical difficulty regarding corneal transplantation
2524066|NCT02736682|Experimental|Single dose antibiotic|2g of intra venous Ceftriaxone and 500 mgs Intra venous metronidazole is administered to the mothers as a Single dose pre-operative30-60 minutes before surgery.
2524069|NCT02736682|Active Comparator|multiple dose antibiotic.|Multiple doses of IV Ceftriaxone 1g and metronidazole 500mgs given to the mother during surgery there after Ceftriaxone 1g every day for 3 days and IV metronidazole 500 mgs every 8 hours for 3 days.
2524122|NCT02735928|Experimental|PIPAC|PIPAC stands for Pressurized IntraPeritoneal Aerosol Chemotherapies. Enrolled patients will undergo to explorative laparoscopy as usual and PC index will be determined according to Fagotti score (PIV). Pathological response will be determined by serial peritoneal biopsies. Then a pressurized aerosol containing cisplatin followed by doxorubicin will be applied via a nebulizer. The PIPAC procedure can be repeated after 4-6 weeks until progression or limiting toxicity
2524157|NCT02735538||osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
2524160|NCT02735538||osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement. Femoral head specimens will be collected and ex vivo specimens numbered. Using RT-PCR, Runx2, BMP-2, BMP-7 and osteoprotegerin, mRNA expression levels will be quantitatively analyzed. Osteocalcin immunoreactivity will be detected using immunohistochemical staining.
2524228|NCT02735343|Active Comparator|Standard treatment arm|compazine 10 mg Intravenously along with diphenhydramine 25 mg Intravenously
2524231|NCT02735343|Experimental|Research arm|Ketamine 0.3 mg/kg Intravenously along with ondansetron 4 mg Intravenously
2524319|NCT02735018|Experimental|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
2524320|NCT02735018|Experimental|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
2524357|NCT02734654|No Intervention|Control group|patients do not receive remote preconditioning prior to lung lobectomy
2524360|NCT02734654|Experimental|RIPC group|patients receive remote preconditioning prior to lung lobectomy
2524445|NCT02734095|Experimental|Intravascular Ultrasound data|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
2524494|NCT02733887|Experimental|lymphoma|The lymph nodes or masses, fludeoxyglucose F18 positron emission tomography/computed tomography(PET/CT) standard uptake value(SUV) results, whole body magnetic resonance imaging(MRI) intravoxel incoherent motion(IVIM) sequence D, D*,f values and MRI volumes of lymphoma were compared before and after the chemotherapy in this project prospectively to provide data for evaluating the dependency and differences of PET/CT and whole body MRI in lymphoma staging and therapeutic evaluation.
2524549|NCT02733198|Experimental|Prognosis-guided|Duration of bed rest and duration of length of stay will be guided according to a predefined prognostic algorithm.
2524551|NCT02733198|No Intervention|Standard medical therapy|Duration of bed rest and duration of length of stay will be decided by the attending physician.
2524601|NCT02733003|Experimental|Women's Health CoOp (WHC)|This is an adapted behavioral intervention for women in South Africa, who use alcohol and other drugs and are living with HIV or at risk of acquiring HIV.
2524664|NCT02732678|Experimental|Cohort of a dose of Propranolol 80 mg/day|
2524665|NCT02732678|Experimental|Cohort of a dose of Propranolol 120 mg/day|
2524666|NCT02732678|Experimental|Cohort of a dose of Propranolol 160 mg/day|
2524692|NCT02732197||Sedation (S)|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
2524694|NCT02732197||No sedation (NS)|Parturients who did not receive any sedative agent after the spinal anesthesia performance.
2524807|NCT02731482|Experimental|Training Group|Patients with bronchiectasis in home-based pulmonary rehabilitation
2524817|NCT02731482|Active Comparator|Control Group|Patients with bronchiectasis in usual care and recommendations for performing exercises
2524909|NCT02731053|Experimental|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
2524913|NCT02731053|No Intervention|Control|Participants will receive a brochure describing the nature, causes, and consequences of depression, as well as available prevention/treatment options
2524944|NCT02730559|Experimental|Intervention Group|Group A (Parent-adolescent dyads)
2524952|NCT02730559|Active Comparator|Control Group - Active Comparator|Group B (Adolescents only)
2525032|NCT02729662|Other|Patients with ADPKD|This analysis set consists of patients whose at least 2 TKV data are available both before and after taking tolvaptan.
2525083|NCT02729519|Other|Group A|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation)
2525086|NCT02729519|Experimental|Groupe B|standard procedure TAVI performed without pre dilatation (Without prior balloon dilatation)
2525103|NCT02729246|No Intervention|Control Group|
2525104|NCT02729246|Other|Surgery Group|The patients in this group will undergo Laparoscopic Gastric Bypass surgery
2525148|NCT02729129|Experimental|Commercially available highly-efficient facemask|
2525150|NCT02729129|Sham Comparator|Sham facemask|
2525202|NCT02728778|Active Comparator|Botulinum toxin A|Single administration of incobotulinumtoxin A into the forehead (glabellar region); 34 U in five injection sites.
2562266|NCT02484313|Experimental|Cookies|25 g available carbohydrates
2523986|NCT02736929|No Intervention|Waiting Period Control (WP-CON)|WP-CON group will receive minimal attention in the form of weekly telephone calls to assess current emotional state and to provide supportive, nondirective, brief counseling if participants report experiencing a crisis. Any participant assigned to the WP-CON group will be given the opportunity to receive CPT-C after the post-waiting period assessment.
2524029|NCT02736669|Active Comparator|Fixed Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to reduce their food intake by a moderate amount and stay at this level of moderate reduction until their weight loss goal is achieved.
2524030|NCT02736669|Experimental|Variable Energy (or Calorie) Reduction|Participants randomly assigned to this arm will be instructed to alternate between two levels of calorie reduction. One level will be a small amount of calorie reduction, while the other will be a more significant amount of calorie reduction. At the instruction of the research team, participants will periodically alternate back and forth between these two goals until their weight loss goal is achieved.
2524085|NCT02736149|Experimental|ubenimex|"ubenimex capsules 150 mg three times a day (TID), administered orally, minimum of 24 weeks for all patients.~The maximum anticipated time an individual patient will participate will vary because treatment will continue until the last patient enrolled has received at least 24 weeks of open-label treatment."
2524180|NCT02735629|Experimental|CX1739 - 300 mg|Study Drug - low dose
2524183|NCT02735629|Placebo Comparator|Placebo|Placebo
2524188|NCT02735629|Experimental|CX1739 - 600 mg|Study drug - mid Dose
2524194|NCT02735629|Experimental|CX1739 - 900 mg|Study drug - high dose
2524306|NCT02735148|No Intervention|Conventional Training|Conventional training sessions generally consisted of exercises which aimed to improve range of motion, strength, and movement quality in upper and lower extremity as an in-patient rehabilitation protocol. Also developing static and dynamic postural control and increasing walking distance were the other aims of training. Duration of the Conventional Training is 45 minute per session, 3 days a week for 6 weeks.
2524309|NCT02735148|Experimental|Body Weight Supported Treadmill Training|"Body weight supported treadmill training (BWSTT) was composed of outpatients who were undertaken only BWST training with 45-minute sessions, 2 days a week during 6 weeks.~BWST Training~Locomat (Hocoma) was used in BWSTT group with 20 % body weight reduced. The participants walked on device at 1.8 km/h (0.5 m/sec) velocity. For each participant body weight portion was ensured by a security belt while walking. Each session took 45 minutes including setup, commands and rest time. Verbal instructions were used for encouragement but no manual assistance was given to improve gait pattern."
2524311|NCT02735148|No Intervention|Combined Training|Combined Training consisted of inpatient participants who were treated with 45 minute-conventional training, 5 days a week during 6 weeks. Additionally this group had 45 minute-BWST training, 2 days a week during 6 weeks.
2524354|NCT02734706|Experimental|LRC™ capsule|
2524355|NCT02734706|Placebo Comparator|Placebo capsule|
2524405|NCT02734394|Experimental|Cardiovascular and strength training exercise|24 sessions (~12 weeks) exercise
2524439|NCT02734082||Elevated Troponin and pathological EC|Patients with acute ischemic stroke with elevated Troponin
2524444|NCT02734082||No elevated Troponin or pathological EC|Patients with acute ischemic stroke without elevated Troponin
2524448|NCT02734082||Elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke with elevated Troponin T and pathological ECG and coronary angiography
2524452|NCT02734082||No elevated Troponin, pathological ECG & coronary angiography|Patients with acute ischemic stroke without elevated Troponin T and pathological ECG and coronary angiography
2524514|NCT02733874|Experimental|test group|Compound Clobetasol Propionate Ointment
2524515|NCT02733874|Active Comparator|control group|Calcipotriol Betamethasone Ointment
2524564|NCT02733276|Experimental|Electroacupuncture|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: 6 needles in each lower limb, 8 abdominal, 3 in upper extremity and 3 on the front
2524566|NCT02733276|Sham Comparator|Electroacupuncture sham|Using electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes. Acupoints are: needles on each forearm on nonselective points
2524574|NCT02733276|No Intervention|Control|Initially no intervention. In a second period in this group we will perform EAP
2524612|NCT02732860||Triple Negative Breast Cancer|"Triple negative breast cancer patients with residual invasive disease following neoadjuvant chemotherapy (n= up to 15) or with newly diagnosed metastatic disease (n=up to 30).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2524617|NCT02732860||Colorectal Cancer|"Colorectal cancer patients with metastatic disease undergoing resection of liver metastases, or with lesions amenable to biopsy (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2524620|NCT02732860||High Grade Serous Ovarian Cancer|"High grade serous ovarian cancer patients with recurrent disease with a life expectancy of at least 12 months (n=up to 15), or Stage III or IV with residual disease following neoadjuvant chemotherapy, or at risk of high recurrence (n=up to 15).~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2524623|NCT02732860||Other tumor types|"Other selected tumor types at the discretion of the PI (n= up to 30)~After the screening procedures confirms patient eligibility:~Molecular Profiling will be performed on clinical sample~pPDX generation for in vivo drug testing~In vitro organoid culture generation (if sufficient fresh tissue available)~Identifying an actionable genomic alteration and drug making a matched treatment therapy recommendation."
2524648|NCT02732509||Lean|Body mass index less than 25 kg/m2
2524649|NCT02732509||Overweight/obese|Body mass index 25-45 kg/m2
2524695|NCT02732379|Experimental|Lavender Aromatherapy|Aromatherapy with lavender essential oil.
2523999|NCT02736981|Active Comparator|BWL + Extrinsic Motivation|24 week treatment program consisting of a single, 90-minute, in-person group session in week 1, and a single 45 minute individual in-person session in week two, followed by a 6 month technology mediated program. The program includes evidenced-based behavioral weight loss content, individualized diet and physical activity goals, weekly lessons as well as reporting of key behaviors and personalized feedback to aid in goal attainment. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
2524046|NCT02736552|Experimental|S-1 for 6 months|S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection
2524048|NCT02736552|Active Comparator|S-1 for 1 year|S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection
2524089|NCT02736032|Active Comparator|With GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using GnRHa followed by external estradiol and progesterone. The GnRHa depot from will be given on day 21 of the preceding cycle, on day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol followed up on day 12 of the cycle, if the endometrium is less than 8 mm, till day 15 of the cycle estradiol will be increased to 8 mg/day until 8 mm or more. Then, serum estradiol and progesterone levels are collected, and progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
2524093|NCT02736032|Active Comparator|Without GnRHa|Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
2524315|NCT02735083|Experimental|UCART19 follow-up|
3166206|NCT00522288|Experimental|Contact Lens|Soft contact lenses
3166207|NCT00522288|Active Comparator|Spectacle|Spectacles
2525231|NCT02728635|Active Comparator|Group A- Women- Healthy 'pears'|This group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.78 or less.
2525236|NCT02728635|Active Comparator|Group B- Women- Healthy 'apples'|The group will consist of healthy women with a BMI between 23 and 35 kg/m2 as a waist-to-hip ratio of 0.85 or more.
2525239|NCT02728635|Active Comparator|Group C- Men- Healthy 'apples'|The group will consist of men with a BMI between 23 and 35 kg/m2.
2525607|NCT02726035|Experimental|Group 1 A-ABAB|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 1 will receive oral naltrexone 50 mg daily during weeks 5-7 (3 weeks). They will switch to placebo for weeks 8-10, then return to naltrexone for weeks 11-13, then placebo for weeks 14-16 (i.e., A-ABAB double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
2525608|NCT02726035|Experimental|Group 2 A-BABA|After 4 week open label oral naltrexone run-in, participants are randomized to 2 groups (50% each). Group 2 will receive oral placebo once daily during weeks 5-7. They will then be switched to oral naltrexone 50 mg daily for weeks 8-10, then return to placebo for weeks 11-13, then naltrexone for weeks 14-16 (i.e., A-BABA double crossover design, participants act as own controls). Study drug and placebo will be encapsulated so as to appear identical.
2525669|NCT02725697||TCM treatment|TCM treatment (e.g. acupuncture, Tuina massage, Chinese herbal medicine, moxibustion, electroacupuncture, ear acupuncture)
2525689|NCT02725255|Experimental|Papaya seed porridge|Arm receiving porridge fortified with dried papaya seeds (Ujiplus)
2525691|NCT02725255|Active Comparator|Albendazole and Plain porridge|Arm receiving the approved albendazole treatment of 400mg once with plain porridge daily (without papaya seeds)
2525694|NCT02725255|Placebo Comparator|Plain porridge|arm receiving 300ml plain porridge daily (without papaya seeds)
2525764|NCT02725086|Experimental|Part 1; Filgrastim 5 ㎍/kg|Neupogen®(Filgrastim) 5 ㎍/kg or Leucostim®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 5 ㎍/kg or Neupogen®(Filgrastim) 5 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
2525771|NCT02725086|Experimental|Part 2; Filgrastim 10 ㎍/kg|Neupogen®(Filgrastim) 10 ㎍/kg or Leucostim®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 1, Day 1. And wash out for 28 days or more. Leucostim®(Filgrastim) 10 ㎍/kg or Neupogen®(Filgrastim) 10 ㎍/kg will be administered subcutaneously on Period 2, Day 1.
2525813|NCT02724670|Other|Radiation|IGRT 5x 2Gy/week, total dose: 78 Gy
2525850|NCT02724345||CK18 positive|HCC patients with CK18 high expression levels in tumor tissue.
2525852|NCT02724345||CK18 negative|HCC patients with CK18 high expression levels in tumor tissue.
2525921|NCT02724007||All participants|
2525990|NCT02723461|Active Comparator|continuous oxytocin|Continuous group will be administrated oxytocin (Syntocinon, stock solution: 10 iU/mL) at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
3166208|NCT00522314|Active Comparator|1|NIV & ACBT
3166209|NCT00522314|Placebo Comparator|2|Active cycle of breathing techniques
3166210|NCT00522327|Experimental|1|remote simult med interpret
3166211|NCT00522327|Active Comparator|2|Usual & Customary
3166212|NCT00522327|Other|3|comparison group
3166213|NCT00522340|Experimental|Aerobic Exercise Program|
3166214|NCT00522340|No Intervention|Usual Care|
3166215|NCT00522353|Active Comparator|1|Oligofructose
3166216|NCT00522353|Placebo Comparator|2|Placebo
3166217|NCT00522405|Active Comparator|1|Transarterial Chemoembolisation
3166218|NCT00522405|Active Comparator|2|TACE Plus oral chemotherapy
3166219|NCT00522444|Experimental|nebulized magnesium sulfate|6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
3166220|NCT00522444|Placebo Comparator|normal saline nebulization|standard of care
3166221|NCT00522535|Active Comparator|Open Surgical Repair|Open surgical repair of abdominal aortic aneurysm. All patient enrollment and 2-year follow-ups completed.
3173825|NCT00616382|Experimental|PTX|Combined administration of indomethacin and pentoxifylline, an inhibitor of TNF alpha
2524074|NCT02736214|Experimental|Lifestyle counseling|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
2524078|NCT02736214|No Intervention|Control group|The control group answered a baseline questionnaire in the waiting room and received standard care.
2524138|NCT02735889|Other|No carbonation (control)|No carbonation (NC, control): Potable water + sugar
2524140|NCT02735889|Active Comparator|Low carbonation|Low carbonation (LC): Potable water + sugar + little CO2
2524141|NCT02735889|Active Comparator|High carbonation|High carbonation (HC): Potable water + sugar+ high CO2
2524203|NCT02735434|Experimental|Internet-based ACT|Brief clinical psychiatric assessment to determine eligibility (video-based).
2524208|NCT02735434|Active Comparator|Internet-based discussion forum|Brief clinical psychiatric assessment to determine eligibility (video-based).
2524283|NCT02735161|Experimental|Exercise training|"Four exercise training sessions. Two endurance training sessions, one with high intensity interval training and one session of moderate intensity of longer duration. Two strength training session; one with high load and few repetitions and one with low load and many repetitions.~Fatigue and lactate will be measured before, after and 24 hours post-exercise. Trainings sessions will be randomized."
2524326|NCT02734901|Active Comparator|400 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
2524328|NCT02734901|Active Comparator|200 g frozen raspberries|Red raspberry beverage Acute intake of 600 mL (1x daily)
2524331|NCT02734901|Placebo Comparator|Placebo control|Raspberry deprived supplement Acute intake of 600 mL (1x daily)
2524375|NCT02734550|Active Comparator|Control|Diagnosis of invasive candida infection according to standard of care.
2524379|NCT02734550|Experimental|(1,3)-β-D-glucan guidance|Treatment according to BDG-result
3199513|NCT00881218|Experimental|Regadenoson CMR|Images in the cardiac short axis will be obtained using a gradient recalled echo sequence, TR 2.3 msec/TE 1.1 msec, 80*256 matrix, slice thickness 10 mm. Images will be obtained during power injection of 0.075 mmol/Kg of a conventional gadolinium based MR contrast agent at a rate of 5 mL/sec followed by a 15 mL saline flush into an antecubital vein. Perfusion imaging will be performed at stress and rest. Stress: Regadenoson 400 mcg will be administered IV bolus via an antecubital cannula. Immediately after injection, MR scanning will begin and contrast will be given. Rest: After 10 minutes, rest imaging will be performed identically, but without regadenoson injection. To identify late enhancement of myocardial tissue inversion recovery prepared images will be obtained.
2524493|NCT02733536|Experimental|Scenario A|manikin with normal standard airway
2524499|NCT02733536|Experimental|Scenario B|Cervical immobilization using a standard Patriot cervical extraction collar (Oessur Americas, Foothill Ranch, CA, USA), applied to the manikin's neck by an instructor.
2524502|NCT02733536|Experimental|Scenario C|Cervical immobilization using a vacuum mattress (Ferno-Washington, Inc. Wilmington, OH, USA), applied to the manikin's neck by an instructor
2524568|NCT02733250|Other|Pembrolizumab + Nab-Paclitaxel|"Phase I will determine the recommended Phase II dose (RP2D) of nab-paclitaxel when given in combination with pembrolizumab. Escalation for nab-paclitaxel will be conducted following a 3+3 design. First cohort of 3 patients will receive nab-paclitaxel on Days 1 and 8 at a dose of 100 mg/m2 intravenous (IV) in combination with pembrolizumab at 200 mg IV every 3 weeks. If no dose limiting toxicities (DLT) occur, the dose of nab-paclitaxel will be escalated to 100 mg/m2 on Days 1, 8 and 15 every 3 weeks. The dose of pembrolizumab will remain the same. If no DLTs occur, dose level 2 will be defined as the RP2D. In the Phase II, pembrolizumab will be administered at 200 mg IV every 3 weeks and nab-paclitaxel will be administered at the RP2D."
2524611|NCT02732821||Gastric Per Oral Endoscopic Myotomy|All patients presenting with Gastroparesis will undergo Per oral endoscopic gastric myotomy
2524799|NCT02731573|Experimental|Treatment arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care with treatment by D-PLEX.
2524800|NCT02731573|Other|Control arm|Subjects who meet the eligibility criteria and provide signed informed consent, will undergo open heart surgery according to standard of care.
2524838|NCT02731235|Other|Control|Prophylactic stroke medication and recommendations for lifestyle changes
2524841|NCT02731235|Active Comparator|Exercise|Prophylactic stroke medication and recommendations for lifestyle changes AND high-intensity training at home, 5 days a week in 12 weeks
2524874|NCT02730936|Experimental|Antimicrobial Hernia Repair Device|Antimicrobial hernia repair device for repair of ventral or incisional hernias in Class II and III surgical fields.
2524940|NCT02730494|Active Comparator|Lcr Regenerans® vaginal capsule|Name: Lcr Regenerans® containing at least 10e7 CFU per intravaginal capsule. 1 vaginal capsule per day
2524948|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 3 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 3 days
2524953|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 4 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 4 days
2524958|NCT02730494|Experimental|Lcr Regenerans® vaginal tablet every 5 days|Lcr Regenerans® containing at least 10e7 CFU per intravaginal table. One vaginal tablet every 5 days
2524981|NCT02730065|Active Comparator|Structured Aerobic Dance Training Group|Active intervention will last for 24 weeks and consists of 60-minute/session, which includes 10 minutes warm-up, 40 minutes of dancing and 10 minutes of cool down. In groups of 5, participants will practice the dance led by a physiotherapist once per week for the first 2 months and twice per week for 3rd to 6th month.
2524983|NCT02730065|Placebo Comparator|Stretching plus education|Participants in the control group will receive a weekly 3-hour group-based (group of 5 participants) programme containing stretching exercise, stress reduction and health education on dementia and stroke prevention for 6 months. The programme consists of low-intensity seated stretching, psychoeducation on stress management, various relaxation methods with practice as well as education on the causes, identification, treatment and prevention of stroke and dementia. Benefits of physical exercise will also be discussed but will its weight will be evenly balanced with other forms of evidence-based preventive strategies.
2525128|NCT02729259|Other|Virtual Reality Snowworld|The subjects will receive Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
2563681|NCT02474524|Experimental|Health intervention|+ treatment as usual
3199514|NCT00881231|Experimental|1|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
2524396|NCT02734446|Active Comparator|Reuterin D3 drops|Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)
2524398|NCT02734446|Placebo Comparator|Placebo|The patients will receive 5 drops/day of placebo for 3 months
2524433|NCT02734173|Active Comparator|Genotype 1a Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1a-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
2524436|NCT02734173|Active Comparator|Genotype 1b Non-Cirrhotic Arm|• 8 non-cirrhotic genotype 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy without ribavirin
2524440|NCT02734173|Active Comparator|Genotype 1a/1b Compensated Cirrhotic Arm|• 8 compensated cirrhotic genotype 1a or 1b-infected recipients will receive a 12 week course of ABT450r-ABT267-ABT333 therapy plus ribavirin
2524534|NCT02733471|Experimental|Lidocaine|Five lidocaine solution puffs (10mg lidocaine/puff) on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy.
2524535|NCT02733471|Placebo Comparator|Control|Five placebo solution puffs on the four posterior quadrants of the pharynx and on the base of the tongue, 3 minutes before the oesophago-gastro-duodenoscopy
3173826|NCT00616395||no grouping|IDE used for outcome measurement not for an intervention.
3173827|NCT00616408||A|Newly diagnosed active acromegaly out of the 297 patients coming to our Department for acromegaly who received first-line treatment with LAR
2524639|NCT02732730|Experimental|PrEP Acceptor|"For those women who choose to accept PrEP (Truvada), the following adherence support package will be provided:~Cognitive Behavioral Theory adherence support sessions~Two-way SMS communications~Optional monthly adherence support clubs Drug level counseling for those randomized to that extra intervention (1:1)"
2524640|NCT02732730|No Intervention|PrEP Decliner|Standard of care
2524679|NCT02732418|Experimental|Depo-Provera CI 45 mg|a single subcutaneous (SC) injection of 45 mg/0.3 mL
2524680|NCT02732418|Experimental|Depo-Provera CI 75 mg|a single subcutaneous (SC) injection of 75 mg/0.5 mL
2524681|NCT02732418|Experimental|Depo-Provera CI 105 mg|a single subcutaneous (SC) injection of 105 mg/0.7 mL
2524682|NCT02732418|Active Comparator|Depo-subQ 104|a single subcutaneous (SC) injection of 104 mg/0.65 mL
2524951|NCT02730364|Experimental|Theraflu night powder|Participants will receive a single dose (1 sachet) of Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
2524956|NCT02730364|No Intervention|No Treatment|Participants in this arm will not receive any medication
2525159|NCT02729077||Increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry. Patients in this arm will be especially evaluated for hypoxemia and other complications.
2525163|NCT02729077||Not increased risk for OSA|Vital signs including oxygen saturation, respiratory rate, ECG, arterial pressure, BIS, blood pressure, heart rate will be monitored and hypoxemia will be measured during anesthetic care, and oxygen saturation and respiratory rate will be measured for 48 hours after surgery with pulse oximetry.
2525273|NCT02728427|Experimental|Suprapubic Catheterization|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients in this group.
2525276|NCT02728427|Active Comparator|Transurethral Catheterization|Transurethral catheterization using Foley catheter will be performed for patients in this group.
2525314|NCT02728063|Experimental|Single arm|Supplementation with Lactibiane Tolerance
2525434|NCT02727127||Healthy Volunteers|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
3173828|NCT00616447|Experimental|1|
3173829|NCT00616447|Sham Comparator|2|
3173830|NCT00616460|Experimental|Bivalirudin|
3173831|NCT00616473||1 Nursing Home Staff|Direct care staff
3173832|NCT00616473||2 Family Members|Family members/Significant other of nursing home resident.
3173833|NCT00616486|Experimental|1|
3173834|NCT00616486|Placebo Comparator|2|
3173835|NCT00616512|Experimental|1|GF Strong Water Protocol/ water allowed between meals after oral care for selected clients/ Fraser Water Protocol
3173836|NCT00616538|Active Comparator|Cutivate(r)|Topical mid-strength steroid
3173837|NCT00616538|Experimental|EpiCeram(r)|EpiCeram(r) topical barrier repair cream.
3173838|NCT00616551|Experimental|A|
3173839|NCT00616551|Active Comparator|B|
3173840|NCT00616616|Experimental|1|all subjects
3173841|NCT00616733|Experimental|1|
3173842|NCT00616733|Experimental|2|
3173843|NCT00616733|Experimental|3|
3173844|NCT00616746|Experimental|1|Three test days, within-subject design.
3173845|NCT00616798|Experimental|3|
3173846|NCT00616798|Placebo Comparator|4|
3173847|NCT00616798|Experimental|1|
3173848|NCT00616798|Experimental|2|
3173849|NCT00616811|Experimental|Vildagliptin|
3173850|NCT00616811|Active Comparator|Sitagliptin|
3173851|NCT00616824|Active Comparator|Traditional Method|Arm which uses the Serratus Anterior muscle mobilization for lateral coverage of the tissue expander
3173852|NCT00616824|Experimental|Dermamatrix Arm|Arm which uses Dermamatrix as the lateral expander coverage
3173853|NCT00616837|Active Comparator|Standard consultation|Standard care in orthopaedic outpatient clinic
3173854|NCT00616837|Experimental|Telemedicine consultation|Orthopaedic care in outpatient clinic by use of telemedicine.
3173855|NCT00616850|Active Comparator|Group A|Group A subjects will receive a continuous femoral block catheter and a Patient Controlled Analgesia (PCA).
3173856|NCT00616850|Experimental|Group B|Group B subjects will receive a low dose lidocaine (1.33 mg/kg/hr) infusion and a Patient Controlled Analgesia.
2524146|NCT02735759|Other|Healthy Volunteers|This cohort will consist of ten healthy volunteers. The photoacoustic flow cytometry device will be used to establish device settings. The intervention with the subject will include the PAFC device to establish appropriate device settings.
2524147|NCT02735759|Other|Venous Thromboembolism|This cohort will consist of ten patients with newly diagnosed, non-life threatening acute venous thromboembolism. The intervention with the subjects is to perform the photoacoustic flow cytometry device to detect circulating emboli in vivo in patients with venous thromboembolism at diagnosis, during and after anticoagulation therapy.
2524200|NCT02735408|Experimental|100% KT Tension|100% KT Tension
2524207|NCT02735408|Experimental|50% KT Tension|50% KT Tension
2524211|NCT02735408|Experimental|0% KT Tension|0% KT Tension
2524214|NCT02735408|No Intervention|Control (Without KT)|Control (Without KT)
2524289|NCT02735122|Experimental|Test acetaminophen|acetaminophen tablet and placebo caplet and placebo liquid-filled capsule
2524290|NCT02735122|Active Comparator|Commercial acetaminophen|acetaminophen caplet and placebo tablet and placebo liquid-filled capsule
2524291|NCT02735122|Active Comparator|Commercial ibuprofen|ibuprofen liquid-filled capsule and placebo tablet and placebo caplet
2524292|NCT02735122|Placebo Comparator|Placebo|Placebo tablet and placebo caplet and placebo liquid-filled capsule
2524325|NCT02734797||Pediatric patients|This is an observational study. Validated measures of nutritional status, dietary intake, body composition, functional status and psychosocial factors will be used to measure outcomes in study patients at 4 time-points: (1) pre-HCT (Baseline), (2) 30-days post-HCT, (3) 100-days post-HCT and (4) one year post-HCT.
2524363|NCT02734615|Experimental|Arm A|Patients will get LSZ102 single agent during dose escalation.
2524366|NCT02734615|Experimental|Arm B|Patients will get LSZ102 in combination with LEE011 during dose escalation.
2524368|NCT02734615|Experimental|Arm C|Patients will get LSZ102 in combination with BYL719 during dose escalation.
2524370|NCT02734615|Experimental|Arm 1|Patients will get LSZ102 single agent during dose expansion
2524371|NCT02734615|Experimental|Arm 2|Patients will get LSZ102 + LEE011 (LEE011 intermittent regimen) during dose expansion
2524373|NCT02734615|Experimental|Arm 3|Patients will get LSZ102 + LEE011 (LEE011 continuous regimen) during dose expansion
2524376|NCT02734615|Experimental|Arm 4|Patient will get LSZ102 in combination with BYL719 during dose expansion
3173857|NCT00616850|Placebo Comparator|Group C|Group C subjects will receive placebo (preservative free normal saline) infusion and a Patient Controlled Analgesia.
2524547|NCT02733445||dasatinib cohort|Patients with CML receiving dasatinib
2524548|NCT02733445||nilotinib cohort|Patients with CML receiving nilotinib
2524643|NCT02732756|Experimental|Sleep Restriction|The Sleep Restriction condition will allow 6.5 hours in bed, which in previous research results in an average of 6.1-6.3 hours of nightly sleep. This condition reflects a realistic dose of sleep restriction (similar to the school-night sleep of 15-20% of healthy adolescents) that has been shown to be feasible and to induce daytime sleepiness, inattention, and irritability/moodiness in typically developing adolescents.
2524644|NCT02732756|Experimental|Sleep Extension|The Sleep Extension condition will allow adolescents to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep), which (a) is how long adolescents sleep during controlled trials of sleep satiation and naturally on non-school nights, (b) has been shown to result in a well-rested state, and (c) matches clinical recommendations for adolescents.
2524718|NCT02731976|Experimental|GFD|After instruction of a dietician, participants adhered to a gluten-free diet for 4 weeks.
2524758|NCT02731846|Experimental|FF/UMEC/VI (100/62.5/25 mcg) + placebo|Subjects will receive FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg delivered via single ELLIPTA inhaler ('closed' triple) and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2524760|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + UMEC 62.5 mcg|Subjects will receive FF/VI (100 mcg/25 mcg) and UMEC 62.5 mcg delivered via two ELLIPTA inhaler ('open' triple) once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2524762|NCT02731846|Experimental|FF/VI 100 mcg/25 mcg + placebo|Subjects will receive FF/ VI (100 mcg/25 mcg) delivered via single ELLIPTA inhaler and matching placebo via ELLIPTA inhaler once daily in the morning for 4 weeks as per the randomization. Albuterol/salbutamol will be used as rescue medication throughout the study as needed.
2524808|NCT02731365|Experimental|DBS LFP Activa PC+S|The study aims at testing a slightly modified device (battery) that is similar to the approved system that has the potential of offering future patients a closed loop system with automatic adjustments of stimulation. The purpose of this clinical study is to allow the investigation of local field potential (LFP) signals in patients treated with DBS of the STN. This study will identify common LFP biomarkers observed as a function of disease symptoms, medication effect, fluctuations in disease, and changes resulting from adjustments from current standard practices of DBS programming.
2524954|NCT02730572||Concerta to equivalent generic (EG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to EG formulation will be observed.
3173858|NCT00616876|Experimental|1|Study group will receive 1% lactulose in all their feeds (human milk or preterm formula)
3173859|NCT00616876|Placebo Comparator|2|Control group will receive 1% dextrose placebo in all their feeds (human milk or preterm formula).
3173860|NCT00616889||1|Seroquel added to medication regime and sleep quality measured
3173861|NCT00616915|Other|1|Wellbutrin SR switched to Wellbutrin XL
3173862|NCT00616954|Experimental|1|with ATG-F
3173863|NCT00616954|No Intervention|2|control
3173864|NCT00616980|Active Comparator|Low Dose|
3173865|NCT00616980|Active Comparator|High Dose|
3173866|NCT00616980|Placebo Comparator|Saline|
3173867|NCT00616993|Placebo Comparator|2|Vehicle
3173868|NCT00616993|Experimental|1|Difluprednate
3173869|NCT00617006||Before (Control)|Study group representative of standard practice
3173870|NCT00617006||After(Treatment)|After treatment group with the personal hand hygiene device ie. Device Group.
3166222|NCT00522535|Experimental|Endovascular Repair|"Endovascular treatment arm of 160 patients having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. Use of stent grafts in aortic angles greater than 60° has not been approved for other devices available in the US. As a result, a minimum of 120 patients in this arm will have an aortic angle between 60° and 90°.~Patient recruitment completed; 5-year follow-up evaluations continue."
3166223|NCT00522535|Experimental|Continued Access|"Endovascular treatment arm of 50 patients maximum having suitable anatomy for the Aorfix™ AAA Flexible Stent Graft System. This Arm will provide active sites with ongoing device access while FDA reviews the PMA.~Patient recruitment completed; 5-year patient follow-ups continue."
3166224|NCT00522561|Other|1|healthy volunteers
2524285|NCT02735226||Acute Stroke patient|Patients who are presented to hospital within 7days from onset. The key measurement of clinical quality controlled in patients with acute stroke managment and inhouse stroke care were record automatically
2524318|NCT02734836|Experimental|Zilver PTX Stent|Diagnostic assessment of the lesion after implantation of drug eluting stent with Balloon Angioplasty and placement of the Zilver PTX Stent with Optical Coherence Tomography (OCT)
2524361|NCT02734628|Experimental|Dexpanthenol|A squeeze of ointment, approximately 0.5 cm in length corresponding to an amount of about 0.3 g of ointment, which is equal to 15 mg dexpanthenol , twice daily (once in the morning and once in the evening) over a period of 14 days was applied topically under occluded conditions
2524364|NCT02734628|Placebo Comparator|Placebo|Subjects received applications of placebo corresponding to verum
2524408|NCT02734368||Healthy non-smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2524410|NCT02734368||Asymptomatic smokers|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2524411|NCT02734368||COPD subjects|Hyperpolarized Helium-3. Amounts adjusted based on subject's total lung capacity
2524496|NCT02733679|Experimental|Ataxia Telangiectasia|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
2524500|NCT02733679|Active Comparator|Healthy controls|Participants will receive two treatments - metformin and pioglitazone for eight weeks each, separated by a one week washout period.
2524556|NCT02733263|Experimental|Group 1|Participants will first consume in the the order of 0 g RMD, 15 g RMD, 25 g RMD for 3 weeks each
2524557|NCT02733263|Experimental|Group 2|Participants will first consume RMD in the the order of 0 g RMD, 25 g RMD, 15 g RMD for 3 weeks each
2524558|NCT02733263|Experimental|Group 3|Participants will first consume RMD in the the order of 15 g RMD, 0 g RMD, 25 g RMD for 3 weeks each
2524559|NCT02733263|Experimental|Group 4|Participants will first consume RMD in the the order of 15 g RMD, 25 g RMD, 0 g RMD for 3 weeks each
2524562|NCT02733263|Experimental|Group 5|Participants will first consume RMD in the the order of 25 g RMD, 15 g RMD, 0 g RMD for 3 weeks each
2524563|NCT02733263|Experimental|Group 6|Participants will first consume RMD in the the order of 25 g RMD, 0 g RMD, 15 g RMD for 3 weeks each
2524715|NCT02732314|Experimental|Investigational OTC Cream|Investigational OTC Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2524717|NCT02732314|Placebo Comparator|Placebo Cream|Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2524721|NCT02732314|Active Comparator|Cosmetic Eczema Cream|Cosmetic Eczema Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and anywhere else the patient would apply their ordinary body moisturizer.
2524723|NCT02732314|Active Comparator|0.05% Desonide Cream|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 4 weeks to atopic dermatitis lesions and then on any new lesions that appear for 4 weeks and as directed by the study doctor.~Placebo Cream applied topically, twice daily, for 12 weeks, once in the morning and once in the evening, anywhere the patient would apply their ordinary body moisturizer except atopic dermatitis lesions."
2524767|NCT02731677|Experimental|Experimental|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
2524774|NCT02731677|No Intervention|Control|The control group no suffered intervention.
2524813|NCT02731521||3 Tesla Scanning and 7 Tesla Scanning|Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.
2524890|NCT02731040||Controls|Women who are/have been on bisphosphonate therapy for osteoporosis who have not suffered an atypical femoral fracture
2524892|NCT02731040||Fracture Group|Women who are/have been on bisphosphonate therapy for osteoporosis who have suffered an atypical femoral fracture
3199515|NCT00881231|Active Comparator|2|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
2524988|NCT02730013|Experimental|Square Stepping Exercise|Square-Stepping Exercise (SSE) Intervention Participants in this group will attend a square-stepping exercise intervention 60 minutes: 5 minute for attendance, 5-10 minute warm-up 40-45 minute SSE and 5-10 minute cool-down, on two days a week for a duration of 12 weeks.
2524996|NCT02730013|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
2525168|NCT02728986|Active Comparator|Compression1|Multilayer compression bandage (Profore)
2525175|NCT02728986|Experimental|Compression2|Coban2 compression system
3166225|NCT00522587|Experimental|1|Fixed sevoflurane dose 1
3166226|NCT00522587|Experimental|2|Fixed sevoflurane dose 2
3166227|NCT00522587|Experimental|3|Fixed sevoflurane dose 3
3166228|NCT00522587|Experimental|4|Fixed sevoflurane dose 4
3166229|NCT00522587|Experimental|5|Fixed sevoflurane dose 5
3166230|NCT00522587|Experimental|6|Fixed sevoflurane dose 6
3166231|NCT00522587|Experimental|7|Fixed remifentanil dose 1
3166232|NCT00522587|Experimental|8|Fixed remifentanil dose 2
3166233|NCT00522587|Experimental|9|Fixed remifentanil dose 3
3166234|NCT00522587|Experimental|10|Fixed remifentanil dose 4
3166235|NCT00522587|Experimental|11|Fixed remifentanil dose 5
3166236|NCT00522587|Experimental|12|Fixed remifentanil dose 6
3166237|NCT00522652|Experimental|Investigational Drug|Dose Escalation
2524293|NCT02735031|Active Comparator|EXENATIDE|"Exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
2524294|NCT02735031|Placebo Comparator|PLACEBO|"Placebo matched to exenatide~week 1-2: 5 µg twice daily~week 3-6: 10 µg twice daily (if tolerated)"
3199516|NCT00881244|Experimental|1|AS1411
2524468|NCT02733900|Experimental|Osteonecrosis group|Patients with an aseptic osteonecrosis of the femoral head
2524473|NCT02733900|Other|Control group|Patients with coxarthrosis
2524545|NCT02733120|Experimental|Healthy matched controls|Study Day: The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
2524546|NCT02733120|Experimental|Adults with Autism Spectrum Disorder|The subject will arrive fasted. A catheter will be inserted in the arm for stable isotope infusion and blood sampling. The hand of the arm used for blood sampling will be placed in a thermostatically controlled warmed box that heats the air. Immediately after a baseline blood sample is taken, an infusion with stable isotopes will be administered by the research nurse. Stable isotopes are given to measure amino acid metabolism. Blood samples will be collected before and/or after infusion. Subjects will be asked to complete a list of questions regarding quality of life, mood and depression, diet.
2524591|NCT02733029|Experimental|Sonazoid contrast|The contrast agent Sonazoid will be used during contrast enhanced ultrasonography. This will be a one-time administration of the contrast agent. The contrast agent, Sonazoid (GE Healthcare), is a lipid-stabilized suspension of perfluorobutane microbubbles with a median diameter of 2.4-3.5 μm and will be administered per package insert (intravenously as a continuous infusion). Sonazoid contrast agent will be given at a dose 0.0075 mL/Kg as a bolus intravenous injection while visualizing the kidney transplant.
2524597|NCT02733029|No Intervention|Medical Review|Ultrasound imaging will be taken from a group of subjects recruited for stage 2. These will be obtained through medical record review from subjects with successful renal transplant at BWH and no transplant rejection.
2524651|NCT02732691|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.
2524686|NCT02732184|Experimental|AEB1102 (Co-ArgI-PEG) administered via IV weekly.|Co-ArgI-PEG modified human arginase I
2524729|NCT02731989||study group|The surgeon will estimate the size difference between the undescended and the normally located testis. Independently the ultrasonographer will measure the true size of both testes in the study group.
2524731|NCT02731989||Control group|The same measurments will be done by the surgeon and the ultrasonographer on boys without cryptorchism.
2524876|NCT02730949|Experimental|1 g D-chiro-Inositol + 400 mcg Folic Acid|1 g D-chiro-Inositol + 400 mcg folic acid once daily
2524877|NCT02730949|Active Comparator|400 mcg folic|400 mcg folic acid only once daily
2524942|NCT02730481|Experimental|ORAXOL|"Oraxol (paclitaxel + HM30181AK-US) Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
2524985|NCT02730156|Experimental|Altitude exposure|Acute high altitude exposure followed by 7 day acclimatization and reexposure after 7 days at low altitude
2525028|NCT02729961|Experimental|Treatment (brentuximab vedotin, ceritinib)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive ceritinib PO QD on days 8-21 of course 1 and on days 1-21 for all subsequent courses. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
2525100|NCT02729389|Experimental|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
2525102|NCT02729389|Experimental|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
2525136|NCT02729155|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
2525140|NCT02729155|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
2525143|NCT02729155|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
2525145|NCT02729155|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
3166238|NCT00522665|Active Comparator|Arm A: Irinotecan + Cetuximab +/- RAD001|
3166239|NCT00522665|Active Comparator|Arm B: Ironotecan + Cetuximab|
3166240|NCT00522678|Experimental|Cohort A|In Cohort A, subjects will be randomized (3:1) to receive once daily doses of GW685698X 400 microgram (mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3166241|NCT00522678|Experimental|Cohort B|In Cohort B, subjects will be randomized (3:1) to receive once daily doses of GW685698X (600 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3166242|NCT00522678|Experimental|Cohort C|InIn Cohort C, subjects will be randomized (3:1) to receive once daily doses of GW685698X (800 mcg) containing magnesium stearate or placebo via DISKUS, for 14 days.
3166243|NCT00522691|Experimental|A: sacral first|Phase 1: sacral nerve stimulation crossover Phase 2 : sham stimulation
3166244|NCT00522691|Experimental|B: sham first|Phase 1: sham stimulation crossover Phase 2: sacral nerve stimulation
3166245|NCT00522717|Experimental|1|
3166246|NCT00522717|Active Comparator|2|
3166247|NCT00522730|Experimental|1|Parenteral nutrition
3166248|NCT00522730|Active Comparator|2|Enteral nutrition
3166249|NCT00522743|Experimental|1|GH & GNRHa treatment
3166250|NCT00522743|Active Comparator|2|GH treatment
3166251|NCT00522756|Experimental|Intervention|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
3166252|NCT00522756|Active Comparator|Control|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
2524504|NCT02733692|Experimental|GURHL Code Smartphone application|Experimental arm will receive the 'Understanding Reproductive Health for Ladeez (GURHL) Code 'app' (application) for their smartphone with sexual health information. The intervention is embedded in the smart phone application. This includes sexual and reproductive health knowledge, plus access to a National Planned Parenthood health educator, and directions to other nearby clinics. Participants will be assessed using A-CASI at 3 months after enrollment.
2524510|NCT02733692|No Intervention|Control|"The control arm will receive usual care. That is, they will receive a web-based flyer. This flyer will include a list of clinics and other trusted available resources, but without hyperlinks.~Participants will be assessed using A-CASI at 3 months after enrollment."
2524572|NCT02733302|Experimental|Hope theory|
2524605|NCT02732925|Sham Comparator|Arm 1 - Sham Procedure|"Sham Procedure & Conservative Treatment~Subjects will be blinded and randomised to Arm 1 and will undergo a general anaesthetic and undergo a sham procedure. They will also be treated under conservative management alone.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a non interventional as conservative treatment (standard of care for multiple myeloma patients) is used."
2524606|NCT02732925|Active Comparator|Arm 2 - Balloon Kyphoplasty|"Balloon Kyphoplasty & Conservative Treatment - Interventional Arm~Subjects will be blinded and randomised to Arm 2 (balloon kyphoplasty) and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy~This is a interventional arm (balloon kyphoplasty procedure) and the patient will receive conservative treatment (standard of multiple myeloma patients) is used."
3199517|NCT00881257|Experimental|1|GRST Peripheral Catheter System
3199518|NCT00881270|Experimental|Dermacyd infantile (Lactic Acid)|treatment duration 21 consecutive days
2524707|NCT02732132|Active Comparator|Ketamine and Midazolam|ketamine 1 mg/kg midazolam 0.1 mg/kg
2524709|NCT02732132|Experimental|Propofol and Fentanyl|propofol 1 mg/kg fentanyl 1 mcg/kg
2524743|NCT02731794|Experimental|LVA group|LVA group: left ventricular assist group.
2524744|NCT02731794|Active Comparator|BiVA group|BiVA group: Biventricular assist group.
2524252|NCT02735603|Experimental|Naltrexone/Bupropion + Moxifloxacin + Placebo|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 3.
2524258|NCT02735603|Experimental|Placebo + Naltrexone/Bupropion + Moxifloxacin|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 1, followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 3.
2524262|NCT02735603|Experimental|Moxifloxacin + Placebo + Naltrexone/Bupropion|NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10, moxifloxacin 400 mg, tablet, orally, once in the morning on Day 11 in treatment period 1 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, twice daily from Days 1 to 10 and once in the morning on Day 11 in treatment period 2 followed by 14 days washout period, followed by NB placebo-matching 2 tablets, orally, once in the morning on Day -1, NB, 1 extended-release tablet, orally, twice daily and NB placebo-matching 1 tablet, orally, twice daily from Days 1 to 3, NB, 2 extended-release tablets, orally, twice daily from Days 4 to 10 and once in the morning on Day 11 in treatment period 3.
2524314|NCT02734875|Experimental|Intervention|Primary care providers in the intervention arm will receive lists of their patients with AF who are identified as being at high risk of stroke but not currently on anticoagulation therapy. Along with this list, which includes information on risks and benefits of anticoagulation, primary care providers will receive an offer of assistance from a respected Anticoagulation Management Service within the hospital network to help manage anticoagulation for referred patients.
2524317|NCT02734875|No Intervention|Usual Care|Primary care providers will provide usual care.
3199519|NCT00881283||cured Cushing's disease|
3199520|NCT00881296|Experimental|1|"Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks"
2524463|NCT02734017|Other|standard course|group not receiving medication review
2524464|NCT02734017|Other|pharmacist-led standardized medication review|"pharmacist-led standardized medication review including :~Medical and pharmaceutical admission medication reconciliation and treatment review~Medical and pharmaceutical medication reconciliation at discharge and treatment review~Medication Liaison Service"
2524484|NCT02733640|Active Comparator|Pantoprazole|Drug: Pantoprazole 40 mg once-daily
2524486|NCT02733640|Experimental|Ranitidine|Drug: Ranitidine 150 mg twice-daily
2524571|NCT02733419|Experimental|Enfuvirtide + OB (Not Randomized)|Participants will receive enfuvirtide 90 milligram (mg) twice daily (b.i.d.) and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants not meeting the randomization criteria will receive enfuvirtide 90 mg b.i.d and OB for next 24 weeks (up to Week 52).
2524576|NCT02733419|Experimental|Enfuvirtide + OB (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive enfuvirtide 90 mg b.i.d. and OB for next 24 weeks (up to Week 52).
2524581|NCT02733419|Experimental|OB alone (Randomized)|Participants will receive enfuvirtide 90 mg b.i.d. and OB as per investigator's discretion for 28 weeks during induction period. After induction period participants meeting the randomization criteria will be randomized to receive OB alone for next 24 weeks (up to Week 52).
2524710|NCT02732249|Active Comparator|Triple regimen group|Esomeprazole 20mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
2524713|NCT02732249|Experimental|Low metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg bid for 14 days
2524716|NCT02732249|Experimental|High metronidazole group|Esomeprazole 20mg bid, bismuth potassium citrate 600mg bid, clarithromycin 500mg bid and metronidazole 400mg qid for 14 days
2524753|NCT02731664|Experimental|GLP-1|Intravenous infusion of GLP-1 at 0.7 and 1.2 mol/kg per minute
2524756|NCT02731664|Placebo Comparator|Control|Intravenous saline
2524824|NCT02731534|Experimental|Z-213|
2524829|NCT02731534|Active Comparator|Saccharated Ferric Oxide|
2524860|NCT02731105|Active Comparator|Arm 1|Acnatac® Gel on left face and Epiduo® Gel on right face once daily for three weeks
2524864|NCT02731105|Active Comparator|Arm 2|Epiduo® Gel on left face and Acnatac® Gel on right face once daily for three weeks
2524905|NCT02730767|Experimental|Intervention Group|Partially supervised exercise intervention: Survivors in the intervention group will be asked to add at least 2.5 hours of intense physical activities per week. These should include at least 30 min of strength building exercises and 2 hours of aerobic exercises per week. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
2524907|NCT02730767|No Intervention|Control Group|The control group will keep their physical activity level constant over the 1 year of the study. Thereafter, they will have the opportunity to receive the same intervention than the intervention group had received (off-trial) to benefit in the same way from an active lifestyle.
2524946|NCT02730572||Concerta to authorized generic (AG) formulation|Participants in the Truven Commercial Claims and Encounters (CCAE) database who enroll in the study will have a confirmed diagnosis of ADHD and continuously using Concerta for at least 60 days. Participants who will switch from Concerta to AG formulation will be observed.
2524957|NCT02730546|Experimental|Treatment (pembrolizumab, chemotherapy, radiation, surgery)|See Detailed Description
2525057|NCT02729584||Normal weight|
3199521|NCT00881296|Active Comparator|2|Gemcitabine 1000mg/m2 Day 1, 8, 15
2524265|NCT02735252|Experimental|Group E: DNA Damage Response|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524267|NCT02735252|Experimental|Group F: Aggressive Variant Disease|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients with variants of disease that display aggressive behavior to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524270|NCT02735252|Experimental|Group G1: Castration Sensitive, ADT naïve and ADT < 3 months|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524272|NCT02735252|Experimental|Group G2:Castration Sensitive,Pre-treated w/ sub-optimal PSA|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524275|NCT02735252|Experimental|Group R: Advanced Renal Cell Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
2524278|NCT02735252|Experimental|Cohort U: Advanced Urothelial Carcinoma|"Tumor biopsies: required prior to treatment and optional at time of disease progression.~Blood draws: required prior to treatment, every 3 months during treatment, and at time of disease progression.~Molecular markers will be studied in patients receiving therapies that target DNA damage response pathways to identify predictors of benefit and/or response. Treatments are assigned per investigator discretion."
3166253|NCT00522769|Active Comparator|Delayed Intervention|1/2 of participants are randomized to immediate intervention that starts within a week of randomization. The other 1/2 of the participants are randomized to delayed intervention which starts 6 months after randomization.
2524400|NCT02734472||Hanzhong cohort|A total of 4623 adolescents aged 6-15 years old in Hanzhong rural areas were recruited in 1987.During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
2524401|NCT02734472||Mei county cohort|A total of 675 individuals from 126 families were recruited in this family-based dietary intervention study. A community-based BP screening was conducted among adults aged 18-60 years in the study villages. The probands who had a mean systolic BP (SBP) between 130-160 mmHg and/or a diastolic BP (DBP) between 85-100 mmHg and no use of antihypertensive medications and their parents, siblings, spouses, and offspring were recruited in this study. During the follow-up period, the information about the incidence and risk factors of hypertension will be collected.
2524454|NCT02734160|Experimental|Galunisertib + Durvalumab|(Dose Escalation and Cohort Expansion) Galunisertib administered orally in combination with durvalumab administered intravenously (IV).
2524490|NCT02733666|Experimental|Absorbable screw group|One absorbable screw was used for fixation in the experimental group
2524492|NCT02733666|No Intervention|K-wires group|two 1.8-mm K-wires were used for the fixation in the control group. The K-wires were the most common used by the orthopaedic surgeon.
2524700|NCT02732340|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
2524754|NCT02731911||Ozurdex® (dexamethasone intravitreal implant)|Patients who received Ozurdex® in the treatment of Diabetic Macular Oedema per local standard of care in clinical practice.
2524812|NCT02731417|Experimental|Urinary retention-group 1|For women with post partum urinary retention designated for experimental treatment.
2524818|NCT02731417|Active Comparator|Urinary retention-group 2|For women with post partum urinary retention designated for current departmental protocol treatment.
2525012|NCT02729987|Experimental|Minimum Support Group (MSG)|Intervention group with 8 week access to the online stress management programme with minimal support from a coach (WorkGuru).
2525014|NCT02729987|Experimental|Discussion Group|Intervention group with 8 week access to the online stress management programme with minimal support from a coach, plus access to an online facilitated messaging board (WorkGuru).
2525015|NCT02729987|No Intervention|Waiting List Control (WLC)|Control group with access to the intervention after 16 weeks
2525185|NCT02728921|Active Comparator|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 30 min.
2525188|NCT02728921|Experimental|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10ml/kg during 3 hours. Dose is based on ideal body weight
2525248|NCT02728557|Experimental|Supportive psychotherapy|Participants will receive supportive therapy.
3166254|NCT00522769|Experimental|Immediate intervention|Immediate intervention starts within two weeks of randomization. Delayed interventions starts 6 months after randomization.
3166255|NCT00522782|Active Comparator|A|Nebulized budesonide
3166256|NCT00522821|Other|Antibiotics|"A: co-trimoxazole prophylactically for 12 months followed by intravenous immunoglobulin treatment for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
2524305|NCT02734927|Sham Comparator|control group|subjects showing no psychological or neurological disorder
2524345|NCT02734745|Experimental|flash glucose monitoring|Patients will use a device: Freestyle Libre for 14 days
2524395|NCT02734459|Experimental|tobramycin and dexamethasone ophthalmic test ointment|The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
2524399|NCT02734459|Active Comparator|TobraDex® ointment|The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
2524430|NCT02734225|Experimental|EXPERIMENTAL|Functional recovery Balance training
2524432|NCT02734225|Active Comparator|CONTROL|Functional recovery Balance training Dynamometric Platform training
2524483|NCT02733809|Experimental|Sorafenib|Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.
2524578|NCT02733406|Other|Target Controlled Infusion|This group of patients will have their anaesthesia induced with Target Controlled Infusion (TCI)
2524582|NCT02733406|Other|Velocity Controlled Infusion|This group of patients will have their anaesthesia induced with Velocity Controlled Infusion (VCI)
2524615|NCT02732873|Experimental|FibroFix|
3199522|NCT00881309|Experimental|immunosuppressor|
2524732|NCT02731950|Active Comparator|A magnesium|"Consists of 20 patients:~Each receive bupivacaine 0.125% with 5% magnesium sulfate by infusion through a small diameter multi-hole soft catheter generally used for epidural analgesia positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 hours postoperative. A bolus of 5 ml of the study solution will be injected in the catheter after aspiration test before connection to infusion pump that delivers continuous infusion pump that delivers continuous infusion at a fixed rate of 5 ml/h.~postoperative : 25 µg fentanyl for breakthrough pain. placebo will be given in same intravenous instead of paracetamol and ketorolac of group B , to keep the investigator blinded"
2524733|NCT02731950|No Intervention|B control|"Consists of 20 patients:~saline as placebo infusion through a small diameter multi-hole soft catheter positioned anterior to the sternum above the fascia in the subcutaneous tissue during wound closure for 48 Postoperative pain control will be managed with 1gm paracetamol /6 hr, Ketorolac 30 mg every 8-12 hour .25 µg fentanyl for breakthrough pain."
3199523|NCT00881322|Experimental|BC-130|Active Arm
2524904|NCT02730923|Experimental|Arm A: AZD2014 plus anastrozole|
2524908|NCT02730923|Active Comparator|Arm B: anastrozole alone|
2524934|NCT02730429|Placebo Comparator|Letrozole + placebo|"letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity. Letrozole is administered as standard of care in both study arms.~Placebo for palbociclib once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity."
2524935|NCT02730429|Experimental|Letrozole + palbociclib|"Palbociclib 125mg once daily days 1-21 every 28 days shall be administered until progression of disease or unacceptable toxicity.~letrozole 2.5mg once daily days 1-28 every 28 days shall be administered until progression of disease or unacceptable toxicity.~Letrozole is administered as standard of care in both study arms."
2525002|NCT02730104||Cohort A: Patients with small bowel NET|Patients with small bowel NET (including appendiceal NETs)
2525004|NCT02730104||Cohort B: Patients with gastric NET|Patients with gastric NET (gastroduodenal)
2525005|NCT02730104||Cohort C: Patients with pancreatic NET|
2525006|NCT02730104||Cohort D: Patients with colorectal NET|Patients with colorectal NET (this includes mid-gut)
2525007|NCT02730104||Cohort E: Unknown primary tumor|
3199524|NCT00881322|Placebo Comparator|Sugar Pill|Placebo
3199525|NCT00881348|Experimental|Dermacyd infantile (Lactic Acid)|5 weeks treatment
2525108|NCT02729233|Other|patients receiving biopsies|UC patients who will be started on golimumab for treatment of UC (moderate to severe flare, steroid dependence, or failure of other therapies), epithelial barrier function will be characterized using probe-based confocal laser endomicroscopy (pCLE).
2525152|NCT02729116|Experimental|Sitafloxacin group|Sitafloxacin 100 mg oral twice daily
2525155|NCT02729116|Active Comparator|Ertapenem group|Ertapenem 1 gm IV every 24 h
2525230|NCT02728713|Experimental|Cranial manipulation|"Assessment for cranial strain patterns, followed by indirect cranial manipulation to treat dysfunctions found on assessment, followed by reassessment.~Repeated for a total of eight visits no less than one week apart."
2525232|NCT02728713|Sham Comparator|Sham/placebo|Assessment for cranial strain patterns, followed a laying on of hands, followed by reassessment. Repeated for a total of eight visits no less than one week apart.
2525280|NCT02728336|Active Comparator|Heart Failure Patients|patients who are scheduled to undergo clinically ordered CRT for heart failure complicated by dyssynchrony
2525282|NCT02728336|Active Comparator|Control|20 matched control subjects
2525318|NCT02728037|Experimental|Magnesium-Based Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
2525340|NCT02727803|Experimental|Myeloablative regimen 1|"Patients receive anti-thymocyte globulin IV over 4 hours on days -9 and -8, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -7 to -4. Patients undergo TBI on day -3.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
2525438|NCT02727127||Bipolar Patients|MRI on 3 Tesla (3T) or 7 Tesla (7T) scanner, without contrast
3199526|NCT00881374|Experimental|Dermacyd Infantile (Lactic Acid)|six weeks treatment
2524308|NCT02735070|Experimental|Corisitina D|The patient will use the medication 4 times a day - orally The tablets of Coristina® d contain 400 mg acetylsalicylic acid, dexchlorpheniramine 1 mg, 10 mg phenylephrine, and 30 mg of caffeine. Coristina® d is indicated as an analgesic, antipyretic, antiallergic, and nasal congestion for the treatment of the symptoms of influenza and common cold.
2524310|NCT02735070|Active Comparator|Resfenol|The patient will use the medication 4x / day - orally Resfenol® drug acts against the symptoms of colds and flu, such as nasal congestion, runny nose, fever, headache, muscle pain and other symptoms. The capsules containing 400mg of paracetamol, 4 mg chlorpheniramine and 4mg phenylephrine.
2524422|NCT02734290|Experimental|Arm A|pembrolizumab + weekly paclitaxel
2524423|NCT02734290|Experimental|Arm B|pembrolizumab + capecitabine
2524470|NCT02733952|Active Comparator|tranexamic acid|"bolus intravenous injection of tranexamic acid 10mg/kg (maximum1g) 15 min before incision followed by continuous infusion of 1mg/kg/h dissolved in 1L of saline for 10 h (maximum~1 g/10 h)"
2524472|NCT02733952|Active Comparator|Pericervical Tourniquet|The tourniquet method will be used where the urinary bladder will be dissected downwards from the lower uterine segment, and then a perforation will be made in the posterior leaflet of the broad ligament bilaterally at the level of uterine isthmus. A tourniquet (using 16- inch Foley catheter) will be passed through the perforation encircling the uterine arteries bilaterally. The Fallopian tubes and the ovaries will be carefully excluded from the line of the tourniquet to avoid direct compression and necrosis. The tourniquet will be released intermittently (at about 30 minutes interval) during the surgery and ﬁnally removed after the repair of the uterus
2524517|NCT02733549||patient|Patients with sudden onset dizziness (SOD) analysed LFTs
2524522|NCT02733549||control|The control group with 98 healthy volunteer analysed LFTs
2524550|NCT02733185|Active Comparator|Active/Active|Active disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
2524552|NCT02733185|Active Comparator|Active/Placebo|Active disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
2524553|NCT02733185|Active Comparator|Placebo/ Active|Placebo disodium EDTA (chelation) + Active Oral Multi Vitamins/Minerals (OMVM)
2524554|NCT02733185|Placebo Comparator|Placebo/Placebo|Placebo disodium EDTA (chelation) + Placebo Oral Multi Vitamins/Minerals (OMVM)
2524614|NCT02732886|Experimental|Betafoam®|Brand name: Betafoam® Generic term: Wound dressing with 3% povidone iodine
2524616|NCT02732886|Active Comparator|Medifoam®|Brand name: Medifoam® Generic term: Wound dressing
2524668|NCT02732574|Experimental|OPEP Device Treatment|Patients randomized to OPEP will receive the device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The OPEP device group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The OPEP device will be set to the highest pressure setting unless deemed inappropriate by the PT, at which time the most appropriate pressure setting will be selected and then increased daily until the OPEP device is set to the highest pressure setting by POD #3 if able. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
2524670|NCT02732574|Sham Comparator|SHAM Device|Patients randomized to the sham treatment will receive the sham device on postoperative day (POD) 1 or day of extubation, whichever comes first. Patients will be seen on POD #1 by a blinded physiotherapist (PT) for mobility and education on supported coughing. The sham group will also be instructed to complete 15 breaths twice per waking hour in a seated position and receive education on proper use of the device. The sham device is identical in exterior appearance to the OPEP device but does not contain the internal mechanism providing expiratory pressure. As such, the device will be set to the highest setting and will not need to be adjusted at all for patient tolerance. The PT will reassess the patients on POD 2 and 3 to assess for proper technique and continued use of the device, as well as usual care. Patients will use the OPEP device up to POD#5 pressure settings and compliance will be recorded and measure by use of a daily log.
2524691|NCT02732158|Experimental|Nutrition Products|Two servings per day of the sachet study product mixed with water; 1 carotenoid capsule per day
2524719|NCT02731963|Experimental|Mechanical bowel preparation|80 Patients who received mechanical bowel preparation with 4 packets of polyethylene glycol in 4 liters of water, 4 hours before intervention.
2524724|NCT02731963|No Intervention|No mechanical bowel preparation|81 Patients who received clear liquid diet 1 day before intervention.
2524752|NCT02731807|Experimental|Dose A, B, C, D, E|All participants will receive all doses throughout the course of the study.
2524757|NCT02731807|Experimental|Dose D, E, C, B, A|All participants will receive all doses throughout the course of the study.
2524759|NCT02731807|Experimental|Dose C, D, E, A, B|All participants will receive all doses throughout the course of the study.
2524761|NCT02731807|Experimental|Dose E, D, C, B, A|All participants will receive all doses throughout the course of the study.
2524809|NCT02731378|Experimental|EPO plus sustained iron dextran|Group 1, EPO treatment at the original dose plus IV iron dextran 200 mg every three weeks (Q3W) for 15 weeks
2524816|NCT02731378|Experimental|EPO plus aggressive iron dextran|Group 2, EPO treatment at the original dose plus IV iron dextran 100 mg, twice a week (BIW) for five weeks
2524827|NCT02731378|Active Comparator|Double EPO|Group 3, the control group, doubling the EPO dose without preplanned iron supplementation
2524857|NCT02731001|Experimental|Proton therapy|Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.
2524859|NCT02731001|Active Comparator|Photon therapy|Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.
2524899|NCT02730858|Experimental|Palliative and oncology care model|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care with palliative care."
2524903|NCT02730858|Active Comparator|Standard oncology care|"After the screening procedure confirm eligibility to participate in the research study. Participants will be randomized into one of two study groups;~-- Standard oncology care"
2525061|NCT02729584||Obese|
2524316|NCT02735135|Experimental|SENTRY 1200 First|"Patients randomized to this arm will be placed on a SENTRY 1200 mattress for day 0. They will then be switched to an AIRSOFT DUO mattress until the end of month 1.~Intervention: SENTRY 1200 for 1 day Intervention: AIRSOFT DUO for 1 month"
2524365|NCT02734589|Active Comparator|Fecal microbiota transplantation (FMT) without Diet|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 from the same donor without dietary conditioning.
2524367|NCT02734589|Experimental|FMT with Diet for the donor and for the recipient|undergo standard fecal transplantation by colonoscopy on day 1 and 60 ml rectal enemas on days 2 and 14 with dietary pre-conditioning of the donor for 14 days and dietary treatment of the recipient immediately after transplantation and for the following 12 weeks.
2524369|NCT02734589|Active Comparator|Dietary therapy only|The patient will receive detailed instructions regarding the UC diet to be used over 12 weeks without FMT.
2524458|NCT02734134|Active Comparator|One-stage exchange|One surgery where the infected implants are removed and the hip or knee joint are 'washed out' before new joint replacement implants are re-implanted during the same surgical procedure.
2524460|NCT02734134|Active Comparator|Two-stage exchange|Two surgeries; during the first surgery the infected implants are removed and a spacer is placed in the hip or knee joint in place of the implants. A second surgery to re-implant the hip or knee joint replacement implants is performed if and when the infection has cleared.
3166257|NCT00522821|Other|intravenous immunoglobulins|"B: intravenous immunoglobulin treatment for 12 months followed by co-trimoxazole prophylactically for 12 months.~Treatments will be separated by a washout period of 3 months during which co-trimoxazole will be given."
3166258|NCT00522834|Active Comparator|1|Elesclomol (STA-4783) in Combination With Paclitaxel
2524595|NCT02733341|Active Comparator|Oral Ticagrelor|Patients in the oral Ticagrelor arm will receive Ticagrelor at a loading dose of 180mg followed by maintenance dose of 90mg twice daily for 12 months.
2524598|NCT02733341|Active Comparator|Intravenous Cangrelor|Patients in the intravenous Cangrelor arm will receive Cangrelor as an initial bolus dose given as per body weight followed by an intravenous infusion for no longer than three hours, they will then switch to oral Ticagrelor given at maintenance dose of 90mg twice daily for 12 months
2524669|NCT02732704|Experimental|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with JenaValve Pericardial Valve and Delivery System
2524763|NCT02731924||Ultrasound for Appendicitis|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected appendicitis
3166259|NCT00522834|Other|2|Paclitaxel alone
3166260|NCT00522860|Experimental|Vicryl Suture|Vicryl sutures, 5/0, 3/8 curved cutting needle
2524836|NCT02731261|Experimental|Experimental|
2524839|NCT02731261|No Intervention|Control|
2524891|NCT02730975|Experimental|AA Reduced dose-normal diet (A)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a standard breakfast
2524893|NCT02730975|Experimental|AA reduced dose-fat diet (B)|Abiraterone acetate at reduced dose of 250 mg po daily in cycles of 28 days administered with a fat breakfast
2524894|NCT02730975|Active Comparator|AA normal dose-fasting conditions (C)|Abiraterone acetate at approved dose of 1000 mg po daily in cycles of 28 days administered in fasting conditions
2524950|NCT02730585||Acute appendicitis|all patients admitted to our hospital with a clinically suspected acute appendicitis.
2524982|NCT02730143|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure after 6 days at low altitude
2525027|NCT02729948|Experimental|Screening (TCE)|Patients swallow the TCE and undergo endoscopic examination while they are seated on a standard endoscopy gurney. Patients undergo standard of care EGD on the same day.
2525081|NCT02729571|Experimental|MTBVAC Group 1|Intervention: MTBVAC live vaccine (low dose)
2525085|NCT02729571|Experimental|MTBVAC Group 2|Intervention: MTBVAC live vaccine (middle dose)
2525088|NCT02729571|Experimental|MTBVAC Group 3|Intervention: MTBVAC live vaccine (high dose)
2525089|NCT02729571|Active Comparator|BCG Control Group|Intervention: commercially available BCG live vaccine
3166261|NCT00522860|Active Comparator|Silk Suture|Silk suture, 4/0, 3/8 curved cutting needle
3173871|NCT00617019||Parkinson's patients|Observational study to compare rates of impulse control disorders in patients taking different medications for Parkinson's Disease
2525167|NCT02728856|Experimental|Sun Protection Factor (SPF) 50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2525171|NCT02728856|Experimental|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2525242|NCT02728622|Experimental|Tamoxifen|Tamoxifen 40 mg is given orally once daily until progression
2525243|NCT02728622|Active Comparator|Chemotherapy|Paclitaxel 80 mg/m2 is given as an 1 hour infusion every 7 days or Caelyx 40 mg/m2 is given iv, first dose over 2 hours, later doses are infused over 1 hour, administered every 4 weeks or up to a maximum dose of 550 mg/m2. Until progression
2525334|NCT02728245|Placebo Comparator|Control group|"Placebo drug 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
2525337|NCT02728245|Experimental|Case group|"Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 3months before surgery in ovarian endometrioma patients.~Dienogest(DNG) 2mg 1 tablet per day will be prescribed for 2 months from 1month after surgery."
2525343|NCT02727673||healthy volunteers|matched group
2525345|NCT02727673||hepatitis cirrhosis|negative group
2525348|NCT02727673||hepatocellular carcinoma|patients with primary HCC
2525406|NCT02727569||Feasibility Study|10 subjects. Subjects will performed two different versions of the new visual field algorithm with DLS (differential light sensitivity) strategies. Two repeats of each strategy will be performed.
2525408|NCT02727569||Clinical evaluation study|100 subjects. Subjects will performed a visual field assessment with the new visual field algorithm with MMDT (Moorfields Motion Displacement Test) and DLS -like stimuli and a commercial available SITA algorithm (DLS-like strategy). Two repeats of each strategy will be performed.
2567166|NCT02451891|Active Comparator|Group 1b|MVA-EBO Z (1.5 x 10^8 pfu)
2524322|NCT02734914|Experimental|SF-URS with automatic control of RPP|Participants in SF-URS with automatic control of renal pelvic pressure (RPP) group undergo ureteroscopy using the intelligent pressure control device (Medical irrigation and suctioning platform with pressure feedback function, and suctioning ureteral access sheath with function of pressure measuring).
2524323|NCT02734914|Active Comparator|conventional F-URS|Participants in conventional F-URS group undergo ureteroscopy using the classic flexible ureteroscope.
2524374|NCT02734602|Other|Cognitive Testing|Subjects will take part in verbal assessments as well as computer testing.
2524378|NCT02734602|Active Comparator|Magnetic Resonance Imaging|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. We will acquire the following: structural MRI, resting state MRI, diffusion tensor imaging data (DTI), and arterial spin labeling (ASL). We may also ask subjects to complete an emotional capture task.
2524381|NCT02734602|Active Comparator|Positron Emission Tomography|Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.
2524451|NCT02734186|Experimental|Sh|Mono infected with Schistosoma haematobium
2524453|NCT02734186|Experimental|ShMp|Coinfected with Schistosoma haematobium andMansonella perstans
2524488|NCT02733744|Experimental|Fecal Microbiota Transplant|"Each participant will undergo allogeneic hematopoietic stem cell transplantation, according to institutional standards.~Participants will receive a single standard dose of oral Fecal Microbiota Transplantation (FMT), which is 15 capsules per day for two consecutive days, for a total of 30 capsules. Participants will be asked to fast for 4 hours prior to and 1 hour following capsule intake. Capsules will be individually handed to participants by a research nurse or physician. Each capsule will be taken with a sip of water."
2524570|NCT02733354||Control Group|Control Group:perform routine oral education.Both groups were asked to complete kidney disease knowledge questionnaire before education.
2524577|NCT02733354||Intervention Group|Intervention Group ：On the basis of Control Group, watching video demonstration of each type of dialysis. The videos were based on real cases, showing patients with peritoneal and hemodialysis life modes, lasting for 20 minutes respectively for each type of dialysis. Both groups were asked to complete kidney disease knowledge questionnaire before education.
3199527|NCT00881387|Experimental|Group 1 (eligible for SCT)|Patients receive rituximab IV, vinorelbine ditartrate IV over 6-10 minutes, and gemcitabine hydrochloride IV over 30 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients with complete response (CR) or partial response (PR) undergo SCT.
3199528|NCT00881387|Experimental|Group 2 (ineligible for SCT)|Patients receive rituximab, vinorelbine ditartrate, gemcitabine hydrochloride, and pegfilgrastim as in group 1. Patients with CR, PR, or stable disease after 3 courses continue to receive therapy in the absence of disease progression or unacceptable toxicity.
2524722|NCT02732093|Active Comparator|stellate block|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml of lidocaine 2% after routine induction of general anesthesia and before endotracheal intubation
2524728|NCT02732093|Placebo Comparator|control|patients in this arm will receive ultrasonographic guided left stellate block with 6 ml normal saline (Na.Cl 0.9%) (control group) after routine induction of general anesthesia and before endotracheal intubation
2524770|NCT02731703||Overdenture Treatment|Guided maxillary implant placement with palateless overdenture
3199529|NCT00881400|Experimental|1|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
3199530|NCT00881400|Active Comparator|2|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
3199531|NCT00881413|Experimental|Esomeprazole|High-dose esomeprazole
3199532|NCT00881413|Active Comparator|Pantoprazole|High-dose pantoprazole
3199533|NCT00881426|Experimental|1|Cefprozil 500 mg Tablets (Sandoz GmbH)
3199534|NCT00881426|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)
3199535|NCT00881439|Placebo Comparator|Placebo|
3199536|NCT00881439|Active Comparator|Aliskiren|
3199537|NCT00881452|Active Comparator|CM-AT|CM-AT (Luminenz-AT)- 900mg CM-AT, pancreatic enzyme concentrate (720mg)
3199538|NCT00881452|Placebo Comparator|Placebo|Placebo 900mg (Sucanate (98% w/w), Citric Acid (2% w/w)
3199539|NCT00881478|Active Comparator|Nutrition counselling alone|Nutrition counseling session with registered dietician
2524949|NCT02730442|Experimental|Single dose F901318 with fluconazole|AUC0-t for F901318 will be assessed before and after 5 days of treatment with fluconazole oral
2524989|NCT02730091|Active Comparator|Letrozole or anastrozole|Letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
2524994|NCT02730091|Experimental|Vinorelbine + Anastrozole or letrozole|Oral vinorelbine 50 mg (1 soft capsule of 30 mg and 1 soft capsule of 20 mg) three times a week every ( Monday, Wednesday and Friday) before lunch and letrozole 2,5 mg once a day or anastrozole 1 mg once a day until disease progression, unacceptable toxicity, patient's refusal, consent withdrawal, death, or discontinuation from the study treatment for any other reason.
2525051|NCT02729792|Experimental|Single site rTMS|"Each treatment session will consist of:~1200 pulses of iTBS over a posterior target location followed by a 60 minute interval, then 1200 pulses of iTBS over an anterior target location."
2525052|NCT02729792|Active Comparator|Dual site rTMS|"Each treatment session will consist of:~600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location followed by a 60 minute interval, then 600 pulses of iTBS over the posterior target, followed immediately by 600 pulses of iTBS over the anterior target location."
2525118|NCT02729363|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline visit to determine the immediate effects of guided relaxation intervention on stress and pain in outpatients with sickle cell disease.
2524520|NCT02733731|Experimental|Chinese Herbal Compound Ointment|This kind of CHCO composed of several chinese herbs,dong quai,angelica,resina draconis and lithospermum.The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks.
2524524|NCT02733731|Active Comparator|Estriol|The dosage of medicine for single treatment once a day in two group is 0.5g,The total time for therapy is 3 weeks in two groups.
2524781|NCT02731625|Experimental|Kettlebell Training|Army Physical Readiness Training (PRT) with kettlebell training in place of strength training circuits
2524783|NCT02731625|Active Comparator|Army Physical Readiness Training|Army Physical Readiness Training (PRT) per Army Field Manual 7-22
2524806|NCT02731430|Active Comparator|group I: morphine group|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
2524820|NCT02731430|Placebo Comparator|group II: control group|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
2524914|NCT02731183|Experimental|FMT|Patients included will receive standard FMT, and then will be followed up for 8 weeks.
2524955|NCT02730507|Experimental|PSR|Bras A : 167 patients in the experimental PSR group. Surgery with patient-specific rod, which are designed according to the preoperative surgical planning of the surgeon in collaboration with the manufacturer.
2524960|NCT02730507|Active Comparator|Conventional rod|Bras B: 167 patients in the experimental conventional rod group
2525042|NCT02729727|Other|Single Arm|To evaluate safety and treatment effect of the CryoBalloon Ablation System for the Ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy
2525192|NCT02728817|Active Comparator|arteriovenous fistula (AVF)|Patient receiving a traditional arteriovenous fistula at the wrist (end-cephalic vein to side-radial artery)
2525193|NCT02728817|Experimental|RADAR|Patient receiving an arteriovenous fistula at the wrist using the Radial Artery Deviation And Reimplantation technique (end-radial artery to side-cephalic vein)
2525252|NCT02728531|Experimental|Bendamustine, Rituximab, Cytarabine|"Bendamustine on Days 1 and 2 of Cycles 1, 3, and 5.~In Cycle 1, rituximab on Day 1 or 2 at the investigator's discretion. Given on Day 1 of Cycles 2 through 6.~On Days 1 and 2 of Cycles 2, 4, and 6, cytarabine will be administered every 12 hours for a total of 4 doses.~Growth factor will be administered subcutaneously within 72 hours of completion of each even-numbered cycles of chemotherapy.~Leukapheresis will begin when the total WBC ≥ 5000/ μL and continue daily until collection of ≥ 2x106 CD34+ cells/kg (with a maximum of 5 courses of apheresis).~Standard of care peripheral blood autologous stem cell harvest will proceed per institutional guidelines and begin during Cycle 6 following rituximab and cytarabine therapy, when the total WBC ≥ 5000/ μL. Collection will continue on a daily basis until collection of ≥ 2x106 CD34+ cells/kg."
3173872|NCT00617032|Active Comparator|1|1x10^10 DRP/mL tgAAC94
2525425|NCT02727361|Experimental|Cholinergic striatal imaging|Cholinergic striatal imaging (IRM and TEP) to compare the intensity of the binding of cholinergic tracer
2525489|NCT02726984|Experimental|case|Patients with carotid plaque ≥ 50% symptomatic (ischemic stroke on CT or MR) during the last 15 days
2525492|NCT02726984|Experimental|control|Patients with asymptomatic carotid plaque ≥ 50%
2525537|NCT02726425|Experimental|Second Life Participants|Half of participants will receive the Diabetes Self Management Medical Group Visits intervention while meeting in the virtual world (Second Life platform)
2525544|NCT02726425|Active Comparator|Face-to-Face Participants|The other half of the participants will receive the Diabetes Self Management Medical Group Visitsintervention while meeting face-to-face in person at Boston Medical Center.
2525574|NCT02726269|Active Comparator|CLA (Clarithro+Lanso+Amoxi)|Clarithromycin 500 mg bid, Lansoprazole 30 mg bid and Amoxicillin 500 bid, tablets of oral administration, during 10 days.
2525579|NCT02726269|Experimental|PLA (Panto+Levoflox+Azithro)|Pantoprazole 80 mg od, Levofloxacin 500 mg od and Azithromycin 500 mg od, tablets of oral administration, during 10 days.
2525640|NCT02725918|Experimental|Pem mono|Patients in arm B will receive pemetrexed (500 mg/m2, d1) every 3 weeks until PD or intolerable toxicities.
2525682|NCT02725398|Active Comparator|Scopolamine group|First to use standard white light to observe, to record spasm score, to observe the lesion.Scopolamine is administered by endoscopic nurse, recorded blindly.
2567225|NCT02451475|Active Comparator|Paroxetine|Paroxetine 25 mg/day
3173873|NCT00617032|Active Comparator|2|1x10^11 DRP/mL tgAAC94
3173874|NCT00617032|Placebo Comparator|3|Single dose tgAAC94 placebo
3173875|NCT00617045|Experimental|Duloxetine|type of experimental agent
3173876|NCT00617110|Sham Comparator|allergic clean air|subjects with allergic rhinitis will be exposed to clean air followed by LAIV
3173877|NCT00617110|Active Comparator|Allergic diesel|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
3173878|NCT00617110|Sham Comparator|control clean air|Healthy control subjects will be exposed to clean air followed by LAIV
3173879|NCT00617110|Sham Comparator|Control diesel|Healthy control will be exposed to diesel followed by LAIV
3173880|NCT00617136|Experimental|III|Prewarming by HotDog
3173881|NCT00617136|Active Comparator|I|Intraoperative warming by Bair Hugger
3173882|NCT00617136|Active Comparator|II|Intraoperative warming by HotDog
3173883|NCT00617214||All|Schizophrenic outpatients who are treated with Seroquel IR and who are additionally intended to start with an integrated care program
3173884|NCT00617253|Experimental|A|
3173885|NCT00617253|Experimental|B|
3173886|NCT00617253|Experimental|C|
3173887|NCT00617253|Experimental|D|
3173888|NCT00617266|Active Comparator|Arm 1 Control Group|Distribution of pamphlets containing information on the hazards of tobacco
3173889|NCT00617266|Experimental|Arm 2|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
3173890|NCT00617266|Experimental|Arm 3|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
3173891|NCT00617266|Experimental|Arm 4|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
3173892|NCT00617292||Category 1, Group 1|Children who have 21OHD and received prenatal dexamethasone treatment
3199540|NCT00881478|Experimental|Nutrition counselling + portion control|Nutrition counseling with registered dietician in addition to teaching about use of a portion control tool
3199541|NCT00881491|Experimental|Group A|Group A - Double antibiotic paste: intracanal medicament consisting of ciprofloxacin and metronidazole
2524521|NCT02733523|Experimental|"Program Sentirnos bien"|"The intervention Program Sentirnos bien is based around a group dynamic, held once a week during 3 months, aimed at:~Promoting the uptake of self-care healthy habits~Promoting social capital at individual level:~Promoting health literacy"
2524526|NCT02733523|No Intervention|Control arm|The control arm will receive no intervention. Once the trial is finished, i.e. after the last follow-up evaluation, this arm will receive the intervention (waiting-list approach).
2524613|NCT02732964|No Intervention|Control|baseline hemodynamics and anxiety screen; no music
2524619|NCT02732964|Experimental|Pandora Music|A study investigator will create a station in the Pandora® music application based on the patient's preferred music genre or artist.
2524622|NCT02732964|Experimental|Mozart Music|A study investigator will turn on a playlist of pre-selected Mozart music.
3199542|NCT00881491|Experimental|Group B|Group B - Triple Antibiotic Paste: intracanal medicament consisting of ciprofloxacin, metronidazole, minocycline
2524701|NCT02732262|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
2524702|NCT02732262|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
2524704|NCT02732262|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patientcontrolled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
2524768|NCT02731768|Active Comparator|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively. They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
2524769|NCT02731768|Experimental|Social support-enhanced|Participants will receive the same intervention components as the Standard group, as well as two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
2524814|NCT02731443||ESx|Epilepsy patients undergoing elective surgical resection of brain tissue; study group: epilepsy surgery=ESx.
2524822|NCT02731443||DE|Epilepsy patients undergoing elective depth electrodes insertion in general anesthesia; control group: depth electrodes=DE.
2524862|NCT02731066|Experimental|High pro, carbo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
2524865|NCT02731066|Experimental|Standard pro, carbo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
2524866|NCT02731066|Experimental|High pro, placebo bev|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
2524867|NCT02731066|Experimental|Standard pro, placebo bev|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d within a 40% energy deficit diet. During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
2524910|NCT02730741|Experimental|Lcr restituo® sachet and placebo|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening) and the placebo at a rate of 2 sachets of 1.5 grams per day (one sachet in the morning and one in the evening).
2524912|NCT02730741|Experimental|Lcr restituo® sachet|The active treatment (Total freeze-dried culture of Lcr restituo® sachet) at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
2524915|NCT02730741|Placebo Comparator|Placebo|The placebo at a rate of 4 sachets of 1.5 grams per day (two sachets in the morning and two in the evening).
3199543|NCT00881491|Active Comparator|Group C|Group C - Mineral trioxide aggregate: used as an apical barrier
3199544|NCT00881517|Experimental|Cytotect|
3199545|NCT00881517|Placebo Comparator|placebo|
2525065|NCT02729597||Myotonic dystrophy type 1 patients|"Patients with myotonic dystrophy type 1 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
2525070|NCT02729597||Myotonic dystrophy type 2 patients|"Patients with myotonic dystrophy type 2 (diagnosis confirmed by genetic testing) who meet all inclusion and exclusion criteria for patients.~To be assessed at baseline and follow-up:~medical history, neurological clinical examination, neuropsychological testing, brain MRI"
2525131|NCT02729259|Other|Virtual Reality slides of nature|The subjects will see several slides of the nature through virtual reality goggles during their wound care. The nurse will be doing the wound care.
3199546|NCT00881543|Placebo Comparator|1|This arm will begin taking the placebo by a month, after a month will be tested the diets (the same caloric amount with different composition on fat, protein and carbohydrates)making curves of insulin, glucagon, C peptide and glp 1 and lipid when diets are tested (three acute tests with diets). After that, the patient will begin the drug by month (Januvia, 100 mg a day)and repeat all the three curves using the prepared diets to compare with the first month.
3199547|NCT00881543|Active Comparator|2|Since the beginning they will use the drug. Then will make the three tests and after will stop the drug by 1 month and come back to do the tests. We objective to demonstrate the washout of the drug clinically.
3199548|NCT00881556|Experimental|RIC Group|"Reduced Intensity Transplant Conditioning (RIC):~Palifermin (Kepivance®) 60 mcg/kg/day for 6 days Fludarabine 30 mg/m2 IV x 1 for 6 days Busulfan 4 mg/kg/day IV divided BID for 4 days Lorazepam 0.02-0.05 mg/kg for 5 days Alemtuzumab 20 mg/m2 IV for 5 days Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
2524362|NCT02734641||healthy volunteer|healthy volunteer, will be asked 20 mL of blood will be draw for complete blood count, renal function, electrolytes and ghrelin. In addition, the patient will fill a structured questionnaire that examines his appetite. Ghrelin will be retested after 6 weeks.
2524415|NCT02734407|Experimental|Open-Label Arm|"2mg Aflibercept, as needed, intravitreal administration.~All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
3166262|NCT00522899|Experimental|Aerobic exercise|Study-specific group exercise classes include 10' warm-up, 30' cardio, 5' cool down, 15' stretching/toning. Target heart rate is 60-75% of maximum. Study participants attend classes 60 min/day, 3 days/week for 12 weeks.
3166263|NCT00522899|Active Comparator|Stretching/toning|Study-specific stretching/toning exercise classes include 10' warm-up, 40' stretching/toning, 10' relaxation. Participants attend classes 60 minutes/day, 3 days/week for 12 weeks.
3166264|NCT00522899|Experimental|Computer-based mental activity training|Computer-based visual and auditory stimulation training programs developed by Posit Science corporation. Participants perform assigned mental activity on computers in their homes for 60 minutes/day, 3 days/week for 12 weeks.
2524523|NCT02733510||subclinical rejection group|patients whose protocol biopsy outcome is subclinical rejection and treat with steroid pulse therapy (methylprednisolone)
2524528|NCT02733510||No rejection group|patients whose protocol biopsy outcome is normal
2524561|NCT02733159|Experimental|Pembrolizumab|Pembrolizumab: 200 mg Q3W, intravenous administration for a maximum of 2 years, or until progression or unacceptable toxicity.
2524625|NCT02732795|Experimental|Morphine dosing|Evaluating morphine pharmacokinetics (PK) in 3 groups: normal controls, children with severe OSAS, and obese children with OSAS. Morphine is dosed on ideal body weight in obese children, as recommended by manufacturer. Biomarkers were taken from patients to evaluate their relation to changes in morphine PK.
2524693|NCT02732223|Experimental|Functional treatment|Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.
2524696|NCT02732223|Placebo Comparator|Control treatment|Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets
2524755|NCT02731937|Other|GE Healthcare CT Revolution (CT scanner)|Each subject will be scanned twice: the first time will be the subjects' clinically indicated CT exam and the second scan will be performed on the GE Healthcare CT Revolution (CT scanner) both scans will will be obtained.
2524798|NCT02731586|Experimental|osseointegration using Allogenic MSC's|Evaluation of Osseointegration of Dental Implants to be done using Allogenic Mesenchymal Stem Cells.Primary and Secondary stability are measured using RFA.
3199549|NCT00881582|Experimental|Pegylated interferon alfa-2a plus ribavarin|Pegylated interferon alfa-2a plus ribavarin for 48 weeks
2524895|NCT02730910|Experimental|Purple Wheat Crackers|Bran-enriched purple wheat wholegrain crackers served in 120 g portion.
2524896|NCT02730910|Experimental|Purple Wheat Granola Bars|Bran-enriched purple wheat wholegrain granola bars served in 160 g portion.
2524943|NCT02730624|Experimental|piperacillin/tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h
2524986|NCT02730221||Patients admitted during measurement 1|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period before the implementation of a new electronic patient data management system
2524991|NCT02730221||Patients admitted during measurement 2|All patients admitted to the Intensive Care and Medium Care Unit during a two-week study period after the implementation of a new electronic patient data management system
2525049|NCT02729701|Experimental|Duavee|Participants will be asked to take Duavee for 6 months while on the study.
2525120|NCT02729467|Experimental|Panel 1|Participants will receive a single 250 milligram (mg) dose of JNJ-53718678 on Day 1 and 200 mg itraconazole once a day on Days 4 to 11 along with a single 250-mg dose of JNJ-53718678 on Day 9.
2525121|NCT02729467|Experimental|Panel 2|Participants will receive a single 500-mg dose of JNJ-53718678 on Day 1; a single 600-mg dose of rifampicin along with a single 500-mg dose of JNJ-53718678 on Day 4 and 600 mg rifampicin once daily on Days 5 to 11 along with a single 500-mg dose of JNJ-53718678 on Day 9.
2525166|NCT02728947|Active Comparator|2mg|1 week on 2mg/24 hr patch
2525172|NCT02728947|Active Comparator|4mg|1 week on 4mg/24hr patch
2525176|NCT02728947|Active Comparator|6mg|1 week on 6mg/24hr patch
2525182|NCT02728947|Active Comparator|8mg|1 week on 8mg/24hr patch
2525221|NCT02728518|Experimental|Nebulized Amikacin|patients in this arm will take amikacin nebulizer 400 mg twice daily in addition to standard beta lactam
2525222|NCT02728518|Active Comparator|Amikacin Intravenous|patients in this arm will take intravenous (IV) amikacin 20 mg/kg once daily in addition to standard beta lactam
2525270|NCT02728401||INSI|Infection-negative systemic inflammation (INSI). The INSI group consists of children who have undergone congenital cardiac defect corrective surgery requiring cardiopulmonary bypass, known to induce an INSI response for ~24 hours thereafter; all children in this cohort are culture negative. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2525274|NCT02728401||CSSS|Clinical severe sepsis syndrome (CSSS). Children assigned to the CSSS group had confirmed or highly suspected infection (microbial culture orders, antimicrobial prescription), exhibited 2 or more systemic inflammatory response syndrome criteria (including temperature and leukocyte criteria), and demonstrated at least cardiovascular ± pulmonary organ dysfunction. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2525278|NCT02728401||Viral|The Viral Infection group consists of children who displayed signs and symptoms of severe viral infection, and who tested positive for respiratory viral infection(s) by a molecular virus panel test. These children were clinically evaluated to not have bacterial sepsis. This group is demarcated further by inclusion & exclusion criteria (see Eligibility section below).
2525422|NCT02727439|Experimental|Athletes|Active athletes.
2524380|NCT02734524|Experimental|NK infusion+chemotherapy|Treatment includes four cycles. For each cycle: Taxol and carboplatin will be given at the first week. Lymphodepletion will be conducted at the second week. Autologous NK cells will be infused at the third week. Each cycle includes four weeks.
2524382|NCT02734524|Active Comparator|chemotherapy|Receive the same taxol and carboplatin in experimental arm without NK cell infusion.
3199550|NCT00881595|Other|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Temozolomide five days per week during radiotherapy for 5 weeks. Proton radiation five days per week for 5 weeks Standard surgery will take place 4-6 weeks after completion of chemoradiation.
3199551|NCT00881595|Active Comparator|Chemoradiotherapy Temozolomide|Chemoradiotherapy Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
2524478|NCT02733848|Experimental|DIET|A registered dietician (RD) will meet with and thoroughly review the patients diet. The patient will be counseled on a diet lower in refined carbohydrates and higher in protein.
2524479|NCT02733848|Active Comparator|Creon|Subjects will be provided Creon at a dose of 500 units/kg of lipase to be taken with meals and snacks to see if this decreases frequency and severity of hypoglycemia.
2524480|NCT02733848|Placebo Comparator|Placebo|Subjects will be provided placebo and advised to take it with meals and snacks to provide.
2524540|NCT02733484|Experimental|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
2524541|NCT02733484|Placebo Comparator|Placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
2524590|NCT02733081|No Intervention|Arm 1: Traditional IUD Insertion|Standard IUD insertion according to package insert. Bimanual pelvic exam to assess uterine size and position will be performed. Uterine sound will be used to measure depth of uterus prior to insertion.
2524596|NCT02733081|Experimental|Arm 2: Simplified IUD Insertion|Simplified, investigational IUD insertion performed. No bimanual pelvic exam or uterine sounding.
2524635|NCT02732769|Active Comparator|Group treated by radiosurgery with stereotaxic frame|Subjects will receive a radiosurgery during a brief hospitalization by LeksellGammaKnifePerfexion® (LGKP)
2524637|NCT02732769|Experimental|Group treated by radiosurgery with the thermoformed mask|Subjects will receive a radiosurgery with thermoformed mask during a brief hospitalization by GammaKnifeICON® (GKI) with Efficast®
2524676|NCT02732405|Experimental|MK5172 /MK8742|
2524741|NCT02731872|Experimental|High Flow humidification system|In addition to their usual oxygen apparatuses, the treatment group will have an Airvo humidifier system installed in the home. The supplied oxygen flow will be entrained along with room air through the Airvo humidification system. this combined respiratory gas will then be warmed and humidified and delivered to the patient via a nasal cannula. The total respiratory gas flow rate will be between 20-25 l/min, depending on participant´s preference. Then the oxygen fraction is adjusted until the subjects target oxygen saturation levels are achieved.
2524742|NCT02731872|No Intervention|Standard oxygen therapy|The control group will continue receiving the standard oxygen therapy prescribed by the department
3199552|NCT00881595|Active Comparator|Proton Therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
3199553|NCT00881634|Experimental|1|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
2524837|NCT02731209|Experimental|catheter insertion for 2 weeks|50 randomized patients that will do urodynamic urinary examination and will be inserted urinary catheter for 2 weeks
2524840|NCT02731209|No Intervention|follow up|50 randomized patients that will do urodynamic urinary examination and will be regularly followed by nephrologist
3199554|NCT00881634|Active Comparator|2|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)
3199555|NCT00881660|Experimental|Fetal Endotracheal Occlusion|Placement and retrieval of the GoldBAL4 or GoldBal2 Detachable balloon using the plug/unplug method, using BALTACCIDBPE100 Delivery Catheter.
2525033|NCT02729766|Active Comparator|Empagliflozin 25mg Tbl|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
2525039|NCT02729766|Placebo Comparator|Placebo P-Tablet|Induced hypotonic hyponatremia - SIAD model: Hypotonic hyponatremia will be induced in healthy volunteers through oral overhydration and parenteral administration of desmopressin (Minirin)® 4ug. After administration of the study drug, the artificial SIAD will be sustained with infusion of hypotonic sodium-solution (NaCl 0.45%) over two hours.
2525109|NCT02729441|Active Comparator|Ramipril|"Maximal recommended dose of ramipril Altace® (10 mg/d) given as an active comparator for 12 week."
2525111|NCT02729441|Experimental|Perindopril|"Perindopril Coversyl® at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks."
2525151|NCT02729064|Experimental|Intranasal 40|Patients will receive 40 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
2525154|NCT02729064|Experimental|Intranasal 80|Patients will receive 80 IU of intranasal insulin (Humulin R) via a metered nasal dispenser
2525157|NCT02729064|Placebo Comparator|Placebo|Patients will receive intranasal normal saline via a metered nasal dispenser
2525211|NCT02728739|Experimental|Acute Heart Failure Patients|Acute Heart Failure patients with elevated levels of BNP ( >30pg/ml) will undergo Transthoracic Echocardiogram (TTE) for grading of MR severity within 7 days.
2525284|NCT02728310|Active Comparator|Levobupivacaine infusion|1500 mg of Levobupivacaine by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
2525286|NCT02728310|Placebo Comparator|Saline infusion|300 ml of Saline (for Levobupivacaine as placebo) by an infusion rate of 10 ml/h for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected.
2525315|NCT02728232|Experimental|Internal Iliac artery ligation group|in this group the patients will undergo bilateral internal iliac artery ligation prior to the hysterectomy procedure
3199556|NCT00881673|Experimental|1|
3199557|NCT00881673|Active Comparator|2|
2524402|NCT02734420|Experimental|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs; Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up: Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
2524403|NCT02734420|Experimental|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette; Follow up; Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
2524438|NCT02734069||Sarcopenic|Patients with sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
2524442|NCT02734069||Non Sarcopenic|Patients without sarcopenia (evaluated according to CT scans) will be followed up through treatment with carboplatin for identification of any toxicity grade 3 or 4 (Common Terminology Criteria of Adverse Events)
2524481|NCT02733770|Active Comparator|Sleeve gastrectomy|US DOopler for Patient with BMI of 40 or more than 35 with co-morbidities underwent Sleeve gastrectomy
2524482|NCT02733770|Active Comparator|Mini Gastric Bypass|US DOopler for Patient with BMI of 40 or more than 35 wtih co-morbidities underwent mini gastric bypass
2524542|NCT02733458|Experimental|GELAD/Radiation|Patients will be initially treated with two cycles GELAD chemotherapy, followed by 50-56Gy radiotherapy, and completed with another two cycles GELAD chemotherapy. GELAD chemotherapy will be repeated every 21 days. Radiotherapy will be delivered in 25-32 fractions.
2524594|NCT02733068|Experimental|HPV-16/18 vaccine|Including 6000 participants who received the HPV-16/18 vaccine 0.5ml.
2524599|NCT02733068|Placebo Comparator|HPV-16/18 placebo|Including 6000 participants who received the HPV-16/18 placebo 0.5ml.
2524634|NCT02732717||abnormal ultrasound index|twin pregnancy with abnormal ultrasound index
2524636|NCT02732717||normal ultrasound index|twin pregnancy with normal ultrasound index
2524672|NCT02732470|Experimental|Qi Gong|The effect of Qi Gong training on quality of life in patients with systemic lupus erythematosus
3199558|NCT00881673|Placebo Comparator|3|
3199559|NCT00881686|Experimental|adenosine|Adenosine will be administered intravenously before surgery
3199560|NCT00881699|Experimental|1|Participants will complete HIV risk reduction group meetings.
3199561|NCT00881699|Active Comparator|2|Participants will complete health promotion group meetings.
2525626|NCT02725957|Experimental|Trehalose 9%|Single dose administration of Trehalose 9% for IV infusion.
2525628|NCT02725957|Placebo Comparator|Saline 0.9%|Single dose administration of 0.9% saline in the same volume and duration as Treatment Arm 1 (9% trehalose)
3199562|NCT00881725|Experimental|Metformin|500mg t.i.d. for 4-12 weeks prior to Radical Prostatectomy
3199563|NCT00881738|Experimental|1|Clarithromycin 250 mg Tablets (Geneva, USA)
2525835|NCT02724605|Other|Group A|Red blood cells unit age 14 days or less
2525838|NCT02724605|Other|Group B|Red blood cells unit age more than 14 days
2525875|NCT02724176|Experimental|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
2525944|NCT02723877|Experimental|Eribulin and PQR309|PQR309 in combination with standard approved dose of eribulin mesylate 1.4 mg/m2 intravenous (iv) on days 1 and 8 in a period of 21 days per cycle will be investigated. . PQR309 will be administered maximum 15 minutes after eribulin iv dosing.
2525967|NCT02723578|Experimental|Pemetrexed and Erlotinib|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and Erlotinib 150 mg PO once daily on days 1-21 every 21 days
2526011|NCT02723305||Testosterone Naive|Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5. No exogenous testosterone exposure in the past 5 years
2526018|NCT02723305||Testosterone exposed|"Boys with Klinefelter syndrome age 12-17 who are Tanner 3, 4, or 5.~+topical testosterone treatment for >1 year"
2526075|NCT02723045|Active Comparator|Open modified Lichtenstein repair|Patients will undergo open repair of their inguinal hernias
2526076|NCT02723045|Active Comparator|Laparoscopic TEP inguinal hernia repair|Patients will undergo laparoscopic repair of their inguinal hernias
2526142|NCT02722694|Experimental|Subcutaneous(SC) Abatacept|
2526146|NCT02722694|Placebo Comparator|Placebo|
2526246|NCT02721732|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or toxicity. Patients with clinical response or disease stabilization may continue treatment for up to an additional 12 months.
2526308|NCT02721433|Active Comparator|4 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
3199564|NCT00881738|Active Comparator|2|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)
3199565|NCT00881764||Exposed Cohort|Children who had inguinal hernia surgery and general anesthesia before 36 months of age (n=500). These children should be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
3199566|NCT00881764||Unexposed Cohort|Children who are siblings of the exposed children (inguinal hernia surgery and general anesthesia) and differ in age from the exposed children by less than 36 months and have no history of surgery or exposure to volatile and intravenous anesthetics or sedatives including barbiturates, benzodiazepines and chloral hydrate less than 36 months of age. These children should also be ages 8 yr, 0 mo to 15 yr, 0 mo at the time of the study period.
3199567|NCT00881777|Experimental|RF Heating + CABG|Radiofrequency heating of the myocardial infarct scar plus Coronary Artery Bypass Grafting (CABG) surgery
3199568|NCT00881777|Active Comparator|CABG Alone|Coronary Artery Bypass Grafting (CABG) surgery only, without radiofrequency heating of the myocardial infarct scar
2524456|NCT02733978|Experimental|ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
2524459|NCT02733978|No Intervention|non-ozone treated group|Therapeutic effects will be graded into 4 levels from grade 0 (no change) to grade 3 (wound healing). The wound sizes will be measured at baseline and day 20, respectively. Tissue biopsies will be performed at baseline and day 20, expressions of VEGF, ETAR and AT1R autoantibodies proteins will be determined by immune-histochemical examinations
2524518|NCT02733705|Placebo Comparator|Control|normal saline IV plus propofol infusion
2524527|NCT02733705|Active Comparator|Fentanyl|0.5 mcg/kg ideal body weight IV plus propofol infusion
2524555|NCT02733146||cardiac arrest patients|Patients who has suffered a cardiac arrest
2524602|NCT02732990|Experimental|Exercise training - Whole body exercise|Control subjects will train 2-legged cycling (whole body exercise) for 6 weeks
2524603|NCT02732990|Experimental|Exercise training - One-legged exercise|Control subjects will train high intense one-legged exercise for 6 weeks
2524607|NCT02732990|Experimental|Exercise training - 2-legged cycling CHF|CHF patients will train 2-legged cycling (whole body exercise) for 6 weeks
2524609|NCT02732990|Experimental|Exercise training - CHF|CHF Patients will train high intense one-legged exercise for 6 weeks
2524646|NCT02732548|Active Comparator|NPWT Only|Study subjects who are randomized to the control arm will be treated with Negative Pressure Wound Therapy (NPWT) and additional standard care treatments. No cellular or acellular biological tissue scaffold will be allowed for subjects in this study arm for the first 6 weeks of the study. Subjects who are randomized to this arm and who do not experience at least a 50% surface area reduction of the study wound by the 6 week study visit will have the option to cross over into the NPWT + MIRODERM treatment arm.
2524647|NCT02732548|Experimental|NPWT + MIRODERM|Subjects in this arm will receive NPWT and standard care, plus application(s) of the MIRODERM product.
2524706|NCT02732353|Active Comparator|Minced beef|Minced beef
2524711|NCT02732353|Experimental|Hydrolyzed beef|Hydrolyzed beef
3199569|NCT00881790||Fluoride application|
3199570|NCT00881803||Group 1|Ascorbic Acid Supplementation Only
2524810|NCT02731352|Experimental|iodine-131 Refractory/Resistant Differentiated Thyroid Cancer|iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer
2524856|NCT02731092|Experimental|Lactoferrin 100 mg/kg|100 mg/kg enteral administration daily for 30 days
2524861|NCT02731092|Experimental|Lactoferrin 200 mg/kg|200 mg/kg enteral administration daily for 30 days
2524863|NCT02731092|Experimental|Lactoferrin 300 mg/kg|300 mg/kg enteral administration daily for 30 days
3199571|NCT00881803||Group 2|Iron Supplementation Only
3199572|NCT00881803||Group 3|Concurrent Ascorbic Acid & Iron Supplementation
3199573|NCT00881816|Experimental|Liposomal paclitaxel plus capecitabine|
2525268|NCT02728440||Hypogonadotropic hypogonadism patients|30 patients with idiopathic hypogonadotrophic hypogonadism
2525303|NCT02728167|Experimental|Pre-coagulation by HIFU-AR|Pre-coagulation of the liver parenchyma with HIFU and standard liver resection
2525305|NCT02728167|No Intervention|Standard liver resection|Standard liver resection
2525352|NCT02727881|Experimental|Squalamine solution, 0.2% BID|Squalamine lactate ophthalmic solution, 0.2% bis in die (BID) + ranibizumab every 4 weeks
2525357|NCT02727881|Placebo Comparator|Placebo solution BID|Placebo ophthalmic solution BID + ranibizumab every 4 weeks
2525483|NCT02726958||group M|patients who died or suffered from stroke, acute coronary syndrome, heart failure, complete atrioventricular block or life-threatening ventricular arrhythmias within 30 days after the procedure
2525487|NCT02726958||group T|other patients
2525535|NCT02726685|Experimental|RT (respiratory training) group|Besides traditional rehabilitation therapy, subjects also receive 12-week respiratory training.
2525547|NCT02726685|Sham Comparator|Control group|Besides traditional rehabilitation therapy, subjects receive 12-week sham training unrelated to respiratory function.
3199574|NCT00881829||Healthy volunteer|Smoker or non-smoker
3199575|NCT00881842|Experimental|1|
2525638|NCT02725736|Experimental|Atosiban|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Atosiban group.
2525639|NCT02725736|Experimental|Nifedipine|Women with twin pregnancy with preterm labor between 24 weeks 0 days and 32 weeks 6 days of gestation will be included and randomly assigned to the Nifedipine group.
2525778|NCT02725112|Experimental|Pregabalin ER - Aberrant Fast 330mg|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
2525804|NCT02724683||Symptomatic ascites drainage with CVC.|Patients with malignant, symptomatic, refractory ascites. Ascites drainage with vascular catheter (CVC) inserted into abdominal cavity will be performed. Patients will be asked to complete interview, quality of life questionnaire, nutritional status assessment and quality of procedure survey.
3199576|NCT00881855|Experimental|1|Cefprozil 500 mg Tablets (Sandoz, GmbH)
3199577|NCT00881855|Active Comparator|2|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)
3199578|NCT00881881||1|Patients with early RA
3199579|NCT00881907|Experimental|Group A|Group A subjects will be asked to attend a recall visit 2 months following completion of the treatment visits.
3199580|NCT00881907|Experimental|Group B|Group B subjects will be asked to attend a recall visit at 4 months following completion of the treatment visits.
3199581|NCT00881907|Experimental|Group C|Group C subjects will be asked to attend a recall visit at 6 months following completion of the treatment visits.
3199582|NCT00881920|Experimental|Kappa CD28 T cells for B-CLL|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
2524465|NCT02733965|Other|standard course|"The patients in the control group will have a classic course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs.~Group workshops entitled Disease and drugs, Dietary and sports activity, Psychology Workshop during which the patient will be able to participate in order to get all the information he needs.~Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment.~Moreover, in the control arm, a systematic short pharmaceutical interview with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):"
2524467|NCT02733965|Other|Long Pharmaceutical Consultations|The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
2524516|NCT02733575|Other|Compassion Focused Therapy|Intervention
2524565|NCT02733328||AKI Patients|Patients with AKI
2524567|NCT02733328||Non-AKI Patients|Patients without AKI
3199583|NCT00881920|Experimental|Kappa CD28 T cells for B-cell lymphoma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
3199584|NCT00881920|Experimental|Kappa CD28 T cells for myeloma|T cells will be infused at least 24 hours after chemotherapy. Three dose levels will be evaluated. Cohorts of size 2 will be enrolled at each dose level. Each patient will receive one injection 2-30 mL of each dose over 1 to 20 minutes.
3199585|NCT00881933|Experimental|Fludarabine|
3199586|NCT00881946|Experimental|GSK2119183|
2524782|NCT02731612|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
2524784|NCT02731612|Placebo Comparator|Placebo|Placebo added to current treatment for 6 weeks
2524811|NCT02731339|Experimental|Women with Urinary incontinence|
2524823|NCT02731339|Experimental|Women without Urinary incontinence|
2524853|NCT02731027||Healthy Controls|
2524854|NCT02731027||Participants with Spinal Cord Injury|
3199587|NCT00881972|Experimental|exercise|
3199588|NCT00881985|Active Comparator|continuous positive airway pressure|
3199589|NCT00881985|No Intervention|observation|
2525064|NCT02729610|Active Comparator|DLT group|In this arm, patient will be intubated with a double lumen endotracheal tube
2525069|NCT02729610|Experimental|BB group|In this arm, patient will be intubated with an endobronchial blocker
2525123|NCT02729324|Experimental|FORRAD group|This group of patients will receive Medical Radiation Protectants (FORRAD®) during study for prevention and treatment of acute radiation-induced dermatitis. This is the experimental group.
2525125|NCT02729324|Active Comparator|Biafine group|This group of patients will receive Trolamine (Biafine) during study for prevention and treatment of acute radiation-induced dermatitis. This is the active comparator group.
2525174|NCT02728934||Golimumab Intravenous (IV)|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Golimumab IV.
2525177|NCT02728934||Infliximab|Patients in the US who enroll in the study will have a rheumatologist confirmed diagnosis of Rheumatoid arthritis (RA) and will be medically eligible for, and will have been prescribed but not yet initiated treatment with Infliximab.
2525328|NCT02727985|Experimental|Pharmacist weaning schedule|The Neuromodulation clinic pharmacist will develop a weaning schedule for these patients. Schedules will be individualized taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
2525330|NCT02727985|No Intervention|Self/Family Physician weaning schedule|Patients will wean off their opioids by themselves or with their family physician without the assistance of a prepared schedule.
3199590|NCT00881998|Active Comparator|1|Minimally invasive total hip arthroplasty
2525421|NCT02727439|Experimental|Sedentary Subjects|Healthy lean sedentary subjects.
3199591|NCT00881998|Active Comparator|2|
3199592|NCT00882011||Arm 1|Adult patients with T-lymphoblastic lymphoma treated with intensive chemo/radiotherapy or intensive chemotherapy followed by transplant.
3199593|NCT00882024|Experimental|1 Tranilast|Tranilast, 300 mg/day
3199594|NCT00882024|Experimental|2 Tranilast|Tranilast, 150 mg/day
3199595|NCT00882024|Placebo Comparator|3|Placebo
3199596|NCT00882037||Meth Dependence|Methamphetamine Dependence in residential Substance Abuse Treatment Program
3199597|NCT00882050|Active Comparator|1|Exenatide to be infused by intravenous method at 0.27 ng/kg/min (0.066 pmol/kg/min)
3199598|NCT00882050|Active Comparator|2|IV Exenatide to be infused by intravenous method at0.41 ng/kg/min (0.099 pmol/kg/min)
3199599|NCT00882050|Placebo Comparator|3|Placebo of normal saline solution
3199600|NCT00882063|Experimental|P276-00|Starting dose level of P276-00 is 50 mg/m2/day. The drug will be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min. Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.
3199601|NCT00882076|Experimental|Treatment Cohort 1|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6) 20 mg/m2
3199602|NCT00882076|Experimental|Treatment Cohort 2|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 25 mg/m2
3199603|NCT00882076|Experimental|Treatment Cohort 3|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
2524466|NCT02733939|Experimental|Technology intervention|Patients randomized in the intervention group will receive a technical home monitoring kit for 12 months. The kits will be composed of a control unit and a set of sensors that immediately notify caregivers, through their phones, of any potential risks for the person with dementia. The kit will have home leaving sensors, bed occupancy sensors, smoke and water leak sensors, automatic lights, and other interactive functions. These devices will be connected to a single-board microcontroller that will transmit alarm messages to the caregivers in case of need.
2524471|NCT02733939|No Intervention|Usual care|"Patients receiving usual care, as provided to people with dementia in Southern Sweden can vary. In the target area, people with dementia usually receive comparable pharmaceutical treatment depending on the dementia type, as prescribed by a general practitioner or a specialist at a memory clinic. The social worker from the Municipality (Biståndshandläggaren) where the person resides, together with the district nurse, have a meaningful role in tailoring the care plan by mediating access to other care services such as respite care homes, home help and (dementia) nurse home visits. Use of such services depends on the specific needs of the person with dementia, which can also be unrelated to dementia, but rather dependent upon concomitant health and social issues."
2524579|NCT02733315|Experimental|DCMP|
3199604|NCT00882076|Experimental|Treatment Cohort 4|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-5) 8 mg/m2; Clofarabine (Days 2-6) 30 mg/m2
3199605|NCT00882076|Experimental|Treatment Cohort 0|Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2; Clofarabine (Days 2-6) 10 mg/m2 (In the event of a DLT in Treatment Cohort 1)
2524674|NCT02732444||COPD and APD patients in LTOT|• COPD and APD patients in LTOT
2524675|NCT02732444||Healthy Control|• Patients without significant cardiorespiratory disease, matched for age and body mass index with the other group.
3199606|NCT00882089|Experimental|1|A Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial irradiation begins.
3199607|NCT00882128||1|
3199608|NCT00882141|Experimental|1|Weight loss
3199609|NCT00882141|Experimental|2|Exercise plus weight loss
3199610|NCT00882154|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
2524897|NCT02730806|Experimental|NLP PTSD intervention protocol|Behavioral intervention (NLP) - intervention method will be 5 weekly personal therapy and counseling sessions with a certified therapist specializing in NLP, implementing the NLP PTSD protocol, such as Visual Kinesthetic Dissociation (VKD) behavioral technique for PPPTSD cases
2524939|NCT02730637|No Intervention|Standard care|Patients with elevated biomarkers receive a standard treatment.
2524947|NCT02730637|Active Comparator|Interventional care|Patients in the interventional population receive an early nephrologist consultation which deliberates with attending doctor on preventing measures according to AKI-KDIGO recommendations.
3199611|NCT00882154|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
2525037|NCT02729714|Active Comparator|Suvorexant or Placebo|10 Suvorexant or Placebo mg orally at bedtime with an optional up-titration to 15 mg Suvorexant or Placebo orally at bedtime after 2 weeks. The first treatment period will be 4 weeks. Subjects will be randomized 1;1 to receive Suvorexant or matching placebo. Followed by a 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant
2525043|NCT02729714|Placebo Comparator|Placebo or Suvorexant|First treatment period will be 4 week which subjects will be randomized 1;1 with either Suvorexant or placebo. Followed by 2 week washout period with placebo. Subjects will then be crossed over into the alternate treatment group. Subjects on active treatment for period 1 will be switched to placebo, those on placebo in period 1 will switch to Suvorexant.
2525117|NCT02729376|Experimental|Single dose of [14C]-galeterone|[14C]-galeterone will be supplied as 325 mg capsules (powder in capsule [PIC]). The treatment to be administered will be 2600 mg (~500 µCi) (8 x 325 mg capsules).
2525173|NCT02729012|Active Comparator|Case|Allergic Rhinitis Children treated with hypertonic saline solution (NACL 3%+NAHCO3)
2525180|NCT02729012|Placebo Comparator|Control|Allergic Rhinitis Children treated with saline solution (NACL 0,9%)
2525244|NCT02728687|Experimental|Mannitol and menthol cream|Mannitol and menthol cream (Water, Mannitol, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the menthol cream will be applied to the participant's feet. Whether the mannitol and menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
2525253|NCT02728557|Experimental|Supportive-expressive psychotherapy|Participants will receive supportive-expressive therapy.
2525257|NCT02728492|Experimental|Quisinostat 8 mg & Paclitaxel & Carboplatin|Quisinostat 8 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
2525260|NCT02728492|Experimental|Quisinostat 10 mg & Paclitaxel & Carboplatin|Quisinostat 10 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
3199612|NCT00882167||1|Patients with laparotomy in history
3199613|NCT00882219|Experimental|Xience V®|
3199614|NCT00882232|Experimental|1|Cross-linked hyaluronan gel and radiotherapy. Cross-linked hyaluronan gel is injected under anesthesia between the prostate and rectum prior to the start of radiotherapy. The gel pushes the prostate away from the rectum over several months, thereby reducing the dose of radiation delivered to the rectum. Hyaluronic acid is a naturally-occurring substance that is gradually absorbed by the body.
3199615|NCT00882245|Placebo Comparator|Vehicle ointment|
3199616|NCT00882245|Experimental|SRD441 Ointment|
3199617|NCT00882258|Experimental|12.5 mg Proellex|Proellex 12.5 mg daily
3199618|NCT00882258|Experimental|25 mg Proellex daily|Proellex 25 mg
2524560|NCT02733107|Other|Apatinib+Etoposide|Apatinib combined with Etoposide
2524608|NCT02732834||Part 1: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. We will include an introductory email with the survey link. Will audio-record actual patient-physician clinical consultations with lung cancer patients at Memorial Sloan Kettering (MSK). Completing the survey will take about 15 minutes. Answer a few open-ended questions about the consultation with the doctor. We will audio record your answers to these questions. This will take about 15 minutes.
2524610|NCT02732834||Part 1: Thoracic physicians and clinicians|Will have 5 visits/consultations with their patients audio recorded.
2524618|NCT02732834||Part 2: Lung patients|Following informed consent, the patient will complete the patient questionnaire, either electronically, by phone, or on paper. Patients who prefer to complete the survey electronically will be emailed a link to access to a secure electronic (web-based) version of the study assessment which they will have access to from any computer. Completing the survey will take about 15 minutes.
2524621|NCT02732834||Part 2: Thoracic and pulmonary clinicians|Following informed consent, clinicians will be scheduled to participate in a 2 hour training on empathic communication with lung cancer patients. Surveys will be collected from 6 patients (3 pre-training, 3 post-training). Clinicians will complete one standardized patient assessment before training (pre-SPA) and one assessment after training (post-SPA). These are 12-minute video-recorded clinic consultations with standardized patients (trained actors).
2524886|NCT02731014|Experimental|Dry Needling Group|Dry Needling, Manual Therapy, and Exercise.
2524889|NCT02731014|Sham Comparator|Sham Dry Needling Group|Sham Dry Needling, Manual Therapy, and Exercise.
2524937|NCT02730650|Experimental|Platelet Rich Therapy|Each subject will receive six injections of Platelet Rich Plasma (PRP) at designated points on each side of their face (twelve total). Injection points are spaced evenly across the inferior border of the cheek and mid-cheek, and are consistent on each patient. Patients will receive a post-injection phone call within 48 hours of the procedure. Photographs will be taken at two time points as part of the research to serve as a point of comparison before and after platelet rich plasma. Patients will receive the Global Aesthetic Improvement Scale amd tje Face-Q Questionnaire 1 month post-op
3199619|NCT00882258|Placebo Comparator|Placebo|Placebo daily
3199620|NCT00882271|Experimental|1|Traditional Chinese Acupuncture
2525031|NCT02729675|Experimental|Access Intervention|Worksites in this condition received weekly Fruit and Vegetable markets
2525036|NCT02729675|Experimental|Enhanced Intervention|Worksites in this condition received weekly Fruit and Vegetable markets and Educational Interventions including Campaigns, Newsletters, DVDs, A Website, and Chef Demonstrations
2525038|NCT02729675|Active Comparator|Comparison Intervention|Worksites in this condition received Stress and Physical Activity Interventions
2525106|NCT02729415|Experimental|Stromal Vascular Fraction Cells (SVF Cells)|The participants will undergo a standard tumescent liposuction to harvest adipose tissue. The adipose tissue will then be processed for obtain the Stromal Vascular Fraction Cells (SVF Cells) for a single injection for the treatment of androgenetic alopecia. Before the procedure, hair measurements will be performed in the 2cm x 2cm site for density (number of hairs per square centimeter) and thickness (mm) of the hair to compare to the measurements after the procedure at pre-procedure, 6 weeks, 3 months and 6 months.
3199621|NCT00882271|Placebo Comparator|2|Placebo Acupuncture
3199622|NCT00882297|Active Comparator|1|Transversal approach guided placement
2525277|NCT02728375|Experimental|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 45 minutes,three times per week for sixteen weeks
2525279|NCT02728375|Active Comparator|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength. The exercises will be performed 45 minutes, three times per week for sixteen weeks
2525295|NCT02728076|Experimental|Radiation Therapy followed by Lumpectom|Phase II-Preoperative MRI-BasedRadiation followed by Lumpectomy
2525389|NCT02727595|Experimental|CyclaPlex Implant|Implant device for reduction of the inter metatarsal angle (IMA) without osteotomy.
2525423|NCT02727296|Active Comparator|propofol|Group 1 PROP (control): propofol: a propofol-remifentanil based general anesthesia.
2525424|NCT02727296|Active Comparator|sevoflurane|Group 2 SEVO (intervention): Sevoflurane: a sevoflurane-remifentanil based general anesthesia.
2525461|NCT02726997|Experimental|Treatment (durvalumab, carboplatin, paclitaxel, questionnaire)|"NEOADJUVANT CHEMOTHERAPY: Before debulking surgery, patients receive durvalumab and carboplatin IV over 1 hour on day 1, and paclitaxel IV over 3 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo debulking surgery.~SURGERY: After 3 courses of chemotherapy, patients undergo debulking laparoscopic surgery.~ADJUVANT THERAPY: Beginning after debulking surgery, patients receive carboplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on days 1, 8, and 15, and durvalumab IV over 1 hour on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive durvalumab IV over 1 hour on day 1 and 15. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity."
2525621|NCT02726295|Active Comparator|E. coli Nissle 1917 (Mutaflor®)|Mutaflor® group will receive E. coli Nissle 1917 (Mutaflor®) 28mg 2T tid for initial 2 days, then E. coli Nissle 1917, Mutaflor® 4T qd for the next 26 days.
2525622|NCT02726295|Placebo Comparator|Matched placebo|Matched placebo group will receive placebo drug 28mg 2T tid for initial 2 days, then placebo 4T qd for the next 26 days. Placebo drug has same shape and size with E. coli Nissle 1917 (Mutaflor®).
3199623|NCT00882297|Active Comparator|2|Longitudinal approach guided placement
3199624|NCT00882323|Experimental|Fludarabine|
3199625|NCT00882336||1|Patients 50+ years old, with at least one additional CV risk factor (with no previous CV event or hospitalization for a CV event)
3199626|NCT00882375|Experimental|Nicotine|Nicotine
3199627|NCT00882375|Placebo Comparator|Placebo|Placebo
2524525|NCT02733497|Active Comparator|Sympathicotomy Group|Resection of sympathetic chain at T3 level
2524543|NCT02733211|Experimental|Closed Loop System|MD-Logic automated insulin delivery system - all subjects wearing the study system during nights over 4 weeks
2524544|NCT02733211|Active Comparator|Sensor augmented pump therapy|Sensor augmented pump therapy - all subjects are using sensor augmented pump therapy over 4 weeks
2524993|NCT02730299|Experimental|NiCord® (omidubicel)|"NiCord® is a cryopreserved stem/progenitor cell based product comprised of:~ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF))~the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells.~Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation."
2524997|NCT02730299|Active Comparator|Unmanipulated CBU(s)|
3166265|NCT00522899|Active Comparator|Educational DVD training|Watching and listening to in-depth, college-level lectures on art, history and science on the computer. Participants perform assigned mental activities 60 minutes/day, 3 days/week for 12 weeks.
3166266|NCT00522912|Experimental|A|Immediate posterior lamella tarsal rotation surgery for minor trichiasis
2525153|NCT02729311|Experimental|Group 1|Paired PLIÉ Program, immediate start
2525156|NCT02729311|Other|Group 2|Paired PLIÉ Program, delayed start
2525205|NCT02728765|Active Comparator|auto CPAP|Each patient will be interviewed by the physician on duty and invited to participate in the overnight hospital based auto continuous positive airway pressure (CPAP) titration study for 1 night and then commencement of auto CPAP treatment for 6 months.
2525207|NCT02728765|Placebo Comparator|Subtherapeutic CPAP|Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
2525247|NCT02728466|Active Comparator|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
2525251|NCT02728466|Active Comparator|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
2525254|NCT02728466|Placebo Comparator|Flavanols and procyanidins deprived supplement|Control supplement deprived of flavanols and procyanidins Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
2525291|NCT02728193|Experimental|RFA|Radiofrequency ablation
2525292|NCT02728193|Experimental|MWV|Microwave ablation
2525293|NCT02728193|Experimental|PEI|Percutaneous ethanol injection
2525372|NCT02727907|Experimental|BCD-033|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
2525375|NCT02727907|Active Comparator|Rebif|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks, followed by 48 weeks of open-label BCD-033 usage
2525377|NCT02727907|Placebo Comparator|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for 48 weeks, followed by 72 weeks of open-label BCD-033 usage
3166267|NCT00522912|Active Comparator|B|Regular epilation by another person
2525515|NCT02726477|Experimental|Wuling San|"This is a double-blinded, randomized placebo-controlled, multi-center clinic trial, using before and after treatment measurements.~A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the intervention group administers Wuling San, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry."
3166268|NCT00522964|Experimental|Intervention|
3166269|NCT00522990|Experimental|1|Refractory Hematological Malignancies
3166270|NCT00523003|Experimental|1,|2.2 g protein/kg LBM/day high protein diet
3166271|NCT00523003|Placebo Comparator|2, standard protein|1.1 g protein/kg LBM/day standard protein diet
3166272|NCT00523016|Experimental|Electroacupuncture|Subjects will receive Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP) electroacupuncture protocol for 20 minutes per treatment session; a total of 13 treatments will be administered over 3-4 weeks.
3166273|NCT00523016|Sham Comparator|Sham acupuncture|Subjects will receive simulated acupuncture that includes insertion of acupuncture needles on the head. During each treatment session, needles will be stimulated with electricity for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
3166274|NCT00523029|Experimental|1|Participants will receive a chronic disease self-management program
3166275|NCT00523042|Experimental|A|
3166276|NCT00523042|Active Comparator|B|
3166277|NCT00523068|Active Comparator|1|Tension Free Vaginal Tape
3166278|NCT00523068|Active Comparator|2|Tolterodine tartrate 4mg
3166279|NCT00523081|Experimental|Experimental|Teens in the experimental group will meet with a research counselor for five to nine individual, 50-minute weekly sessions. They will learn ways to deal with stress and feel better. The study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
3166280|NCT00523081|Active Comparator|Active Control|
3166281|NCT00523107|Experimental|PG2|PG2 500 mg / 500 ml normal saline will be given t.i.w for 8 weeks.
3166282|NCT00523107|Placebo Comparator|Placebo|500 ml normal saline will be given t.i.w 1-4 weeks, then PG2 500 mg / 500 ml normal saline will be given 5-8 weeks.
3166283|NCT00523120|Active Comparator|1|voltaren ophta
3166284|NCT00523120|Active Comparator|2|dexotic
3166285|NCT00523159|Other|1|Pre-treatment with a single low dose of Cyclophosphamide followed by IMA901 vaccination plus GM-CSF as adjuvant
3166286|NCT00523159|Other|2|No pre-treatment with Cyclophosphamide before vaccination with IMA901 and GM-CSF as adjuvant
3173893|NCT00617292||Category 1, Group 2|Children who have 21OHD and did not receive prenatal dexamethasone treatment (control)
3173894|NCT00617292||Category 2|Mothers of children who received prenatal dexamethasone treatment
2524588|NCT02733094|Experimental|Open-label|300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 2 weeks until week 32.
2524638|NCT02732782|Experimental|Isometric exercise|Isometric exercise (90% maximum voluntary contraction (MVC), 12 weeks, 4 times a week, 5 sets of 4 repetitions a 3 seconds)
2524641|NCT02732782|Active Comparator|Eccentric exercise|"Eccentric training (Alfredson approach, 12 weeks, 2 sets per day with extended and two sets per day with bended knee, 15 repetitions per set)"
2524642|NCT02732782|No Intervention|Control|Control, no intervention
2524677|NCT02732431|Other|trisomy 21|Parents will complete two sleep symptom questionnaires (PSQ-SRBD and CSHQ) and children will be evaluated by a paediatric pulmonologist and allergist with skin allergy test. An Ear, Nose and Throat specialist will complete two questionnaires (CAS-15 and SCR) carrying a nasopharyngoscopy. Then, children will perform an overnight polysomnography in the Department of Paediatric Functional Investigations of University Hospital in Nice.
2524726|NCT02732080|Experimental|Deferred coronary stenting|In this arm, after establishing TIMI -3 flow in infarct related artery with balloon angioplasty, patients will undergo stent implantation when coronary autoregulatory function was recovered (initial hyperemic flow was subsided and baseline resistance was increased). Recovery of the auto regulatory function will be determined by measuring microvascular flow and resistance. After stenting microvascular flow / resistance will continue to be monitored using pressure/flow sensor tipped guide wire until the completion of 1 hour follow up period.
2524730|NCT02732080|Active Comparator|Immediate stenting|In this arm, patients will undergo stenting immediately after balloon angioplasty. After stent implantation, microvascular flow / resistance values will be continuously monitored using pressure/flow sensor tipped guide wire until the end of 1 hour follow up period.
2524745|NCT02731716|Experimental|New Payment Model|Providers in the first arm will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level.
2524746|NCT02731716|Experimental|Social Comparisons|Providers will no longer be paid based upon FFS, but on the new payment model. Providers will receive a PMPM payment for attributed members, a quality incentive payment based upon attainment of sixteen quality metrics, and a possible bonus payment for savings in total cost of care at the provider organization level. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care.
2524748|NCT02731716|Experimental|A1c Member/Provider Incentive|Providers will no longer be paid based upon FFS, but on the new payment model, which includes a PMPM payment for attributed members, a quality incentive payment based upon attainment of quality metrics, and a possible bonus payment for savings in total cost of care. Providers will also receive weekly emails that will show comparisons of their own performance against their peers within the same provider organization on specific quality measures and total cost of care. There is also a shared incentive between the member and the provider. The member incentive will be a payment made to diabetic patients with an A1C of greater than or equal to 9% who experience a reduction of at least 0.5%. Each participating member and PCP can receive up to $75 per quarter for A1C reduction.
2524803|NCT02731560|Other|Single Arm|Treatment with Rituximab in RA patients showing inadequate response to standard DMARDs
2524832|NCT02731287|Experimental|Timolol|Timolol maleate 0.5% topical solution; 50% of the patients treated (randomized)
2524833|NCT02731287|Placebo Comparator|Placebo|Saline topical solution; 50% of the patients treated (randomized)
2524936|NCT02730676||Electronic Cigarette #1|VUSE® Original Digital Vapor Cigarettes (29 mg nicotine)
2524941|NCT02730676||Electronic Cigarette #2|VUSE® Menthol Digital Vapor Cigarettes (29 mg nicotine)
2524987|NCT02730078|Active Comparator|Attention-meetings (AG)|Attention-control
2524992|NCT02730078|Experimental|VEMOFIT (VG)|Personal value exploration, disease education, emotional skills and goal setting.
2525050|NCT02729883|Experimental|Supportive care (Take the Fight)|Patients receive patient navigation via strategists from the Take the Fight for 8 weeks. Patients also complete interviews regarding perceived physical, logistical, psychosocial, and informational challenges experienced prior to meeting with strategists/navigators and how challenges were addressed by navigator or others, perceived benefits or limitations of navigator assistance. Strategists also complete interviews regarding their perceptions on how patients benefited from participation, challenges patients experienced that were directly or indirectly related to their cancer diagnosis and treatment, how these concerns were addressed, barriers to addressing these concerns, and patient health literacy.
3173895|NCT00617318|Experimental|A|
3173896|NCT00617318|Placebo Comparator|B|
3173897|NCT00617331|Experimental|Dose 7.5 mcg|7.5 micrograms of vaccine administered on Day 0 and Day 28.
3173898|NCT00617331|Experimental|Dose 30 mcg|30 micrograms of vaccine administered on Day 0 and Day 28.
3173899|NCT00617370|Experimental|1|The regimen consists of EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 with pegfilgrastim subcutaneously (SQ) on day # 2, followed by paclitaxel (175 mg/m2) q 14 days x 6 with pegfilgrastim SQ on day # 2.
3173900|NCT00617435|Experimental|V|
3173901|NCT00617435|Experimental|N|
3173902|NCT00617435|Experimental|J|
3173903|NCT00617448|Active Comparator|I|conventional diathermy haemorrhoidectomy under spinal anaesthesia
3173904|NCT00617448|Active Comparator|II|conventional diathermy haemorrhoidectomy with local anaesthesia combined with intravenous sedation (group II)
3173905|NCT00617448|Active Comparator|III|Ligasure haemorrhoidectomy under spinal anesthesia
3173906|NCT00617448|Active Comparator|IV|Ligasure haemorrhoidectomy under local anesthesia
3173907|NCT00617474|Experimental|1|Group of patient with anemia, that treated by erythropoietin
3173908|NCT00617474|Placebo Comparator|2|Patients group with anemia that treated by placebo
3173909|NCT00617500|Active Comparator|Hormone|
3173910|NCT00617500|Experimental|flower therapy|
3173911|NCT00617500|Experimental|therapeutic touch|
3173912|NCT00617500|Experimental|auriculotherapy|
3173913|NCT00617513|Active Comparator|1|
3173914|NCT00617513|Active Comparator|2|
3173915|NCT00617513|Active Comparator|3|
3173916|NCT00617513|Placebo Comparator|4|
2524604|NCT02732977|Other|expert system|System for predicting patients heart failure, that can predict response to a personalized treatment from the analysis of a set of data (images, physiological data , treatment outcomes ) .
2524659|NCT02732626|Active Comparator|pulmonary vein isolation alone|patients randomized to this group receive stand alone pulmonary vein isolation regardless to their left atrial voltage map
2524663|NCT02732626|Experimental|pulmonary vein isolation + low voltage area guided ablation|patients randomized to this group receive pulmonary vein isolation + low voltage area guided linear substrate modification in the case if there are any
2524804|NCT02731547|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
2524805|NCT02731547|No Intervention|Control group|
2524869|NCT02731196|Experimental|Early exercise intervention group|Education, stabilization and neurodynamic level one exercises will be provided to the intervention group within one to two weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will be provided with education, stabilization and neurodynamic level two exercises and a pedometer to monitor step count between week 4 and week 10 following the surgery.
2524871|NCT02731196|Active Comparator|Late exercise intervention group|Education, stabilization and neurodynamic level one and two exercises will be provided to the active comparator group within 4-6 weeks following a unilateral lumbar microdiscectomy L3-4, L4-5, L5-S1. Within 4-6 weeks, this group will also be given instructions and a pedometer to monitor step count between week 4 and week 10 following the surgery.
2524975|NCT02730312|Experimental|XmAb14045|Biological/Vaccine: XmAb14045 Administered IV weekly up to 8 weeks
2524990|NCT02730026|Experimental|Surgery with Ketoprofen|Fifty healthy volunteers underwent removal one of lower third molar, will be treated to control pain, swelling and trismus with ketoprofen 100 mg
2524995|NCT02730026|Experimental|Surgery with Ketoprofen and Omeprazole|Fifty healthy volunteers underwent removal the other lower third molars, will be treated to control pain, swelling and trismus with ketoprofen 200 mg associated with Omeprazole 20 mg
3166287|NCT00523172|Active Comparator|Group A|"1) Group A will receive 9 manipulative therapy treatments (adjustments) to one area: the hip with pre-manipulative static and post active-assisted stretch of tight hip muscles. After the last (or 9th) treatment these patients will receive general advice and recommendations on managing HOA and how to gently and safely increase general exercise.~• Based on a previous trial, Group A treatment appears superior than placebo. There will be a 3, 6 and 9 month follow up."
2525058|NCT02729623|Experimental|Single CannaHALER dose 10 ± 0.1 mg|Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2525063|NCT02729623|Experimental|Single CannaHALER dose 15 ± 0.1 mg|Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2525067|NCT02729623|Experimental|Single CannaHALER dose 20 ± 0.1 mg|Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2525071|NCT02729623|Experimental|Single CannaHALER dose 25 ± 0.1 mg|Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.
2525098|NCT02729337|Experimental|ITG (In This Together)|This will be a multi-week behavioral intervention delivered daily via text messaging. Content will be based upon the IMB model of HIV preventive behavior and informed by our formative work.
2525101|NCT02729337|No Intervention|Control Group|Given the preliminary nature of the intervention development, the control group will be inactive but blinded. They will receive two messages per week encouraging them to make healthy sexual decisions to reduce their HIV risk. Messages will be didactic and not driven by the IMB model.
2525135|NCT02729168|Experimental|Human rabies vaccines|Five doses 0.5 mL vaccine INDIRAB® on D0, D3, D7, D14, D28 using administered intramuscularly.
2525310|NCT02728297|Experimental|Staged ETS|Video-assisted endoscopic sympathicotomy from level of T3 to level of T12 on one side
3166288|NCT00523172|Active Comparator|Group B|2) Group B will receive 9 treatments with manipulative therapy treatments (adjustments) to the entire kinetic chain (five areas): the lumbosacral, sacroiliac, hip, knee, ankle and foot joints with pre-manipulative static and post active-assisted stretch of tight hip muscles. There will be a 3, 6 and 9 month follow up.
3173917|NCT00617526|Experimental|RDEA806 400 mg|Placebo or RDEA806 400 mg twice daily (BID) for 7 days and a single morning dose on Day 8.
3173918|NCT00617526|Experimental|RDEA806 600 mg|Placebo or RDEA806 600 mg once daily (QD) for 7 days with an additional dose on the morning of Day 8.
3173919|NCT00617526|Experimental|RDEA806 800 mg|Placebo or RDEA806 800 mg QD using enteric coated tablets for 7 days with an additional morning dose on Day 8.
3173920|NCT00617526|Experimental|RDEA806 1000 mg|Placebo or RDEA806 1000 mg QD using enteric coated tablets for 7 days with an additional dose on the morning of Day 8.
3173921|NCT00617552|Placebo Comparator|1|
2525505|NCT02726828|Active Comparator|group I: morphine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine in 1 ml volume intrathecally.
2525507|NCT02726828|Active Comparator|group II: ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume intrathecally.
2525509|NCT02726828|Active Comparator|group III: morphine + ketamine group|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg morphine plus 0.1 mg/kg of Ketamine in 1 ml volume intrathecally.
2525516|NCT02726529|Experimental|Brighter Bites|Children of families in the intervention group will also receive the Coordinated Approach to Child Health (CATCH) school-based curriculum in addition to families receiving fresh fruits and vegetables to take home from school once a week along with nutrition education for 8 weeks in Fall and 8 weeks in Spring semesters of the school year.
2525521|NCT02726529|Active Comparator|Comparison|
2525685|NCT02725398|Placebo Comparator|physiological saline group|First to use standard white light to observe, to record spasm score, to observe the lesion. Physiological saline is administered by endoscopic nurse, recorded blindly.
2525753|NCT02725099|Active Comparator|Oral Ticagrelor|
3173922|NCT00617552|Experimental|2|
3173923|NCT00617552|Experimental|3|
3173924|NCT00617552|Experimental|4|
3173925|NCT00617552|Experimental|5|
3173926|NCT00617552|Experimental|6|
3173927|NCT00617552|Experimental|7|
3173928|NCT00617552|Experimental|8|
2524698|NCT02732379|Experimental|Ginger Aromatherapy|Aromatherapy with ginger essential oil
2524699|NCT02732379|Placebo Comparator|Placebo Aromatherapy|Aromatherapy with pure water
2524764|NCT02731859||EndoBarrier|All patients with EndoBarrier treatment
2524821|NCT02731404|Other|IPPV ventilation|standard intermittent positive pressure ventilation in patients undergoing laparoscopic cholecystectomy
2524826|NCT02731404|Other|HFJV ventilation|high frequency jet ventilation in patients undergoing laparoscopic cholecystectomy
2524883|NCT02731144|Experimental|Study group|Individualization of caloric administration with indirect calorimetry and 2.0 to 2.2 g/kg/day of protein. Early initiation of nutritional support (24 hours of admission)
2524885|NCT02731144|Active Comparator|Control group|Nutritional support initiated in the first 24 hours of admission. Protein and caloric goals calculated as 25 Kcal/kg/day and 1.4 to 1.5 g/kg/day of protein.
2524928|NCT02730689|Experimental|A group|DP-R207 >> rosuvastatin+ezetimibe
2524929|NCT02730689|Active Comparator|B group|rosuvastatin+ezetimibe >> DP-R207
3199628|NCT00882388|Active Comparator|ASA|aspirin only
3199629|NCT00882388|Active Comparator|Cele|
2525024|NCT02729974|Experimental|ROTEM|Participants randomized to this arm will have rapid testing of hematocrit and clotting function every 30 minutes during the hysterectomy portion of their surgery for placenta accreta, with transfusion of blood products based on defined abnormalities in these tests.
2525025|NCT02729974|Active Comparator|Standard treatment|Participants randomized to this arm will have standard visual assessment of blood loss and standard laboratory studies to assess blood count and clotting function when indicated during the hysterectomy portion of their surgery for placenta accreta. Transfusion of blood products will be based on abnormalities of these test results.
2525040|NCT02729649|Experimental|ArmAssist therapy|The group will be treated with ArmAssist robot therapy.
2525045|NCT02729649|Active Comparator|Conventional therapy|The group will be treated with conventional therapy.
2525048|NCT02729649|Active Comparator|Extended Conventional therapy|The group will be treated with extended conventional therapy.
2525105|NCT02729428||Exercise trained young adults|Exercise trained young adults between the age of 18-35 years.
2525107|NCT02729428||Sedentary young adults|Sedentary young adults between the age of 18-35 years.
2525110|NCT02729428||Exercise trained older adults|Exercise trained older adults between the age of 55-75 years.
2525113|NCT02729428||Sedentary older adults|Sedentary older adults between the age of 55-75 years.
3199630|NCT00882388|Experimental|ASA + Cele|
3199631|NCT00882388|Active Comparator|ASA + Clo|
2525384|NCT02727621|Active Comparator|Dexmedetomidine group|
2525387|NCT02727621|Active Comparator|Propofol group|
2525442|NCT02727335||patients ALK + who received crizotinib|patients with ALK rearrangement who started treatment with crizotinib (250 mg twice a day) between the 18/11/2010 and the 31/12/2013 (will include patients from the ATU programs and patients treated after the marketing of crizotinib)
3199632|NCT00882388|Experimental|ASA + Clo + Cele|
3199633|NCT00882401|Active Comparator|Ergocalciferol (oral)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
2525584|NCT02726048|Experimental|Full face/Nasal masks|Simplus/Eson
2525697|NCT02725554|Active Comparator|Delayed Continuation Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the delayed continuation group will have their systems deactivated until their 3 months follow-up visit. After this visit the stimulation will be reactivated.
2525700|NCT02725554|Experimental|Continued Stim Group|All Subjects will be implanted with the StimRelieve HALO System. Subjects randomized to the continued stim group will continue with active stimulation and monitored at defined intervals for data collection and device reprogramming, if needed.
2525765|NCT02725112|Experimental|Pregabalin ER- Target Release 330mg|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
2525772|NCT02725112|Experimental|Pregabalin ER - Slow Release 330mg|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
2525775|NCT02725112|Experimental|Pregabalin ER - Fast Release 330mg|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
2525776|NCT02725112|Experimental|Pregabalin IR - 300mg|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
2525777|NCT02725112|Experimental|Pregabalin ER - Target Release 82.5mg|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
3199634|NCT00882401|Placebo Comparator|Placebo|Matching placebo at same dose schedule as ergocalciferol
3199635|NCT00882414|Placebo Comparator|ThromboVIT Placebo|Patients will receive 1 placebo infusion of 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions.
3199636|NCT00882414|Experimental|ThromboVIT 1000|ThromboVIT 1000: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 2 infusions (1000 mg) followed by 1 placebo infusion of 100ml 0.9% sodium chloride.
3199637|NCT00882414|Experimental|ThromboVIT 1500|Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride every 7 days for a total of 3 infusions (1500 mg).
3199638|NCT00882414|Experimental|ThromboVIT 500|ThromboVIT 500: Patients will receive 1 infusion of 500mg Ferinject® diluted in 100ml 0.9% sodium chloride (500 mg) followed by 2 placebo infusions of 100ml 0.9% sodium chloride every 7 days.
3199639|NCT00882427|Experimental|eMPC|improved model predictive control algorithm (eMPC) for glycaemic control in ICU patients
3199640|NCT00882453||Group 1|
3199641|NCT00882466|No Intervention|PCI only|primary PCI only
3199642|NCT00882466|Experimental|EPO|
2524720|NCT02732054|Active Comparator|HIV-Group 1|Receiving three intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, and 6
2524725|NCT02732054|Experimental|HIV-Group 2|Receiving four intramuscular injections of 20 µg of recombinant hepatitis B vaccine [(CIGB) La Habana, Cuba] at months 0, 1, 2, and 6
3199643|NCT00882492|Active Comparator|1|This active arm is a continuous infusion of GLP-1 during cardiac surgery
3199644|NCT00882492|Placebo Comparator|2|This is a continuous infusion of normal saline solution infusion as placebo at (1.5 pmol/kg/min)
3199645|NCT00882531|Experimental|Isotretinoin|
3199646|NCT00882531|Placebo Comparator|placebo|
3199647|NCT00882544||Diagnosed Pediatric Hydronephrosis|Children diagnosed with hydronephrosis who are to receive robotic pyeloplasty surgery
3199648|NCT00882570|Experimental|1|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)
2524868|NCT02731274|Experimental|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental one. Before the intervention of physical exercise program, subjects performed a Tapping Pedal Test to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
2524870|NCT02731274|No Intervention|Control|
2524898|NCT02730832|Experimental|Patients with schizophrenia|
2524959|NCT02730611||Patients|Patients with morbid obesity and vertical sleeve gastrectomy
2524984|NCT02730182|Experimental|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and reexposure for 8 days after 6 days at low altitude
2525062|NCT02729935|Experimental|Parecoxib|40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
2525068|NCT02729935|Placebo Comparator|Placebo|An equal volume of saline
2525094|NCT02729285|Experimental|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 minutes before scleral buckle surgery.
2525096|NCT02729285|Placebo Comparator|placebo|On operation day, the patients were randomly assigned to receive placebo before scleral buckle surgery.
2525134|NCT02729142|Experimental|Tibial cortical density evaluation|
2525187|NCT02728882|Experimental|single arm|"Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days，the first day,the fourth day,the seventh day,28 days,31 days,34 days.~Duration:Total seven times."
2525463|NCT02727166|Experimental|Inulin 8 g/d|Mixture of oligo- and polysaccharides composed of fructose units connected by β (2→1) links with a total number of fructose and glucose units ranging between 2 and 70.
2525468|NCT02727166|Placebo Comparator|maltodextrine 8 g/d|
2525562|NCT02726308|Active Comparator|Dexamethasone Group|I.V. Dexamethasone 5 mg just before induction plus intra-operative 10 ml/kg Ringer's lactate solution.
2525566|NCT02726308|Active Comparator|Dexamethasone and super-hydration Group|I.V. Dexamethasone 5 mg just before induction of anesthesia plus intraoperative 30 ml/kg Ringer's lactate solution
3199649|NCT00882570|Active Comparator|2|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)
2525738|NCT02725190|Other|Group 1|Normal sleep night.
2525739|NCT02725190|Other|Group 2|Sleepless night.
3199650|NCT00882596|Experimental|1|Contura accelerated partial breast irradiation. Following a lumpectomy, a Contura balloon catheter is placed in the lumpectomy cavity. Later that morning, accelerated partial breast irradiation begins.
3199651|NCT00882609|Active Comparator|TC-MDP Bone Scan|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
3199652|NCT00882609|Experimental|F18-Fluoride PET/CT|Patients without known bone metastases who are newly diagnosed with ≥ stage 3 breast cancer, ≥ stage 3 lung cancer, or ≥ stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancer; Patient is scheduled to undergo a conventional bone scan
2525972|NCT02723552|No Intervention|Control|Control participants undergo no intervention.
3199653|NCT00882622|Active Comparator|RIPC|
2526006|NCT02723422|Active Comparator|Control|Standard of care physical therapy post-TAVR
3199654|NCT00882622|Sham Comparator|CONTROL|
3199655|NCT00882635|Experimental|Enoxaparin|
3199656|NCT00882635|Active Comparator|Unfractionated heparin|
3199657|NCT00882648||Drug dependent women|All drug dependent women enrolled in comprehensive substance abuse treatment at the Center for Addiction and Pregnancy of Johns Hopkins University between 2004 and 2009; retrospective chart review.
3199658|NCT00882674|Experimental|1|
3199659|NCT00882700|Experimental|1|Cefdinir 300 mg Capsule (Sandoz, Austria)
3199660|NCT00882700|Active Comparator|2|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
3199661|NCT00882726|Experimental|CNTO 3649 IV (Healthy participants)|
3199662|NCT00882726|Experimental|CNTO 3649 SC (Healthy participants)|
3199663|NCT00882726|Experimental|CNTO 3649 SC (Diabetic patients)|
3199664|NCT00882739|Other|no pre-treatment|No pre-treatment at first medical contact - Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
3199665|NCT00882739|Experimental|600 mg loading dose|600 mg clopidogrel loading dose at first medical contact
2524793|NCT02731599|Experimental|treadmill training|20-minutes treadmill training per day, 6 times a week, for 4 weeks
2524825|NCT02731391|Experimental|Mesh repairment|patients undergoing pelvic floor Reconstruction using mesh
2524830|NCT02731391|Active Comparator|Tradition Neoplasty|patients undergoing traditional surgical approaches
2524855|NCT02731118|Experimental|Placebo and Salovum|6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14
2524858|NCT02731118|Experimental|Salovum and placebo|6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14
2524900|NCT02730845|Active Comparator|Intra-articular dexmedetomidine|Patients will be subjected for elective knee arthroscopy under local anesthesia (Intra-articular dexmedetomidine + Intra-articular bupivacaine).
2524902|NCT02730845|Placebo Comparator|Intravenous dexmedetomidine|patients will be subjected for elective knee arthroscopy under local anesthesia (i.v. dexmedetomidine + Intra-articular bupivacaine).
2524931|NCT02730533|Active Comparator|Control group|No PPI treatment should given after the initial allocation. Patient will be admitted, and ESD will be performed. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
2524932|NCT02730533|Experimental|Esomeprazole group|Esomeprazole should start as soon as possible after the initial allocation. During the 7 days of p.o. treatment, patient will be admitted, and ESD will be performed as soon as completing the p.o. treatment. Then a 3-day i.v. treatment of esomeprazole will be initiated after ESD procedure and followed by a 26 days oral treatment with esomeprazole tablets 40 mg.
2525030|NCT02729688|Active Comparator|ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
2525034|NCT02729688|Active Comparator|customized pressure guide bandage|Bandaging was applied by spiral methods. Three customized pressure guide elastic bandage were applied by stretching until the elliptical shape marker in the bandage turned into circular shape with 50% overlapping from foot to just below knee level.
2525084|NCT02729506|Active Comparator|Arm A|"Intervention:~Yttrium-90 Transarterial Radioembolization~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
2525087|NCT02729506|Active Comparator|Arm B|"Intervention:~Trans-arterial chemo-embolization using Drug-eluting beads~Patients with measurable, locally advanced HCC those are not suitable to have or have failed potentially curable intervention (Radio frequency ablation for small tumor, resection or transplantation).~The diagnosis of HCC should be established either by cyto/histology; or, by characteristic imaging studies in patients with cirrhosis of the liver and/or chronic viral hepatitis B or C infection.~Patients must not be less than 18 and not more than 80 and can be either gender.~Patients must have a performance status of ECOG score equal to or less than 2.~Child-Pugh's A or Early B, score 8 and above"
2525138|NCT02729220|Other|Healthy controls|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2525141|NCT02729220|Other|Smokers|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2525142|NCT02729220|Other|COPD rapid decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2525144|NCT02729220|Other|COPD slow decline|Bronchoscopy with collection of bronchial biopsies and lavages Arterial stiffness
2525204|NCT02728804||Health Services Research (questionnaire administration)|Patients complete questionnaires (including the Baseline, Financial/Employment Impact, Insurance Impact, Quality of Life, and Treatment Perceptions questionnaires) over 30-60 minutes at baseline and at 3, 6, 9, and 12 months. Caregivers complete questionnaires over 30-60 minutes at baseline and at 6 and 12 months.
2525648|NCT02725905|Experimental|Multi-Modal Education (MME)|1) The MME is a three year multi-modal educational intervention including a series of interactive learning components and interventions focused on integrated weight management counseling. Prior to its launch, each component of the curriculum will be refined using a school participatory approach to help ensure feasibility and acceptability.
2525650|NCT02725905|Active Comparator|Traditional Education (TE)|2) The TE arm of the study includes the school's current curriculum which may include topics related to the treatment of weight management and obesity.
2525710|NCT02725333|Other|Shoulder Stabilization|Anteroposterior and superoinferior translations were assessed in patients, before and after shoulder stabilization, through a dedicated patient-specific measurement technique based on optical motion capture and computed tomography.
2525760|NCT02725047|Experimental|TREATMENT - CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
2525767|NCT02725047|Placebo Comparator|PLACEBO - SAND|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
3166289|NCT00523172|Other|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
3166290|NCT00523185|Active Comparator|2|
2526028|NCT02723409|Active Comparator|"Scarless round procedure"|umbilicoplasty technique
3166291|NCT00523185|Active Comparator|1|
3166292|NCT00523211|Experimental|Test Arm|Vicriviroc 30 mg QD
3166293|NCT00523211|Placebo Comparator|Placebo Control Arm|Placebo
3166294|NCT00523224|Experimental|single arm|open lable,single arm , intervention is Angiogenic Cell Precusors(ACPs)
3166295|NCT00523250|Experimental|AR-102 0.003% Ophthalmic Solution|q.d. ocular
3166296|NCT00523250|Experimental|AR-102 0.005% Ophthalmic Solution|q.d. ocular
3166297|NCT00523250|Experimental|AR-102 0.01% Ophthalmic Solution|q.d. ocular
3166298|NCT00523250|Experimental|AR-102 0.03% Ophthalmic Solution|q.d. ocular
2524873|NCT02731079|Active Comparator|Ethicon|Group that will have sleeve gastrectomy performed using the Ethicon Echilon powered stapler with absorbable polymer membrane staple line reinforcement.
2524920|NCT02730780|Other|African-American|40 healthy African-American subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
2524923|NCT02730780|Other|Whites|40 healthy white subjects will be enrolled and each will undergo study procedures at 4 separate visits, with each visit occurring 7-days apart. After a baseline visit, the subject will begin either a low-salt or high-salt diet, based upon randomization assignment to one of the two following dietary protocols: A) low-salt diet, washout, then high-salt diet; or B) high-salt diet, washout, then low-salt diet. Each dietary or washout period lasts for 7 days.
2524938|NCT02730416|Experimental|A: Nintedanib|Nintedanib 200mg twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatin-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
2524945|NCT02730416|Placebo Comparator|B: Placebo|Placebo twice daily days 2-21 every 21 days for 6 courses during simultaneous treatment with carboplatib-paclitaxel; afterwards in maintenance 200mg twice daily days 1-21 every 21 days. Treatment continues until progression or unacceptable toxicity.
2524977|NCT02730117|Experimental|Early renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, starting within 12 hours after randomization~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
2524978|NCT02730117|Placebo Comparator|Conventional renal replacement therapy|"Dialysis with continuous renal replacement therapy machine e.g. Aquarius, Prismaflex, Infomed, after the patients reached at least one of the following criteria;~pH < 7.15 or serum HCO3 < 15 mEq/L~serum K >= 6 mEq/L~Signs of volume overload or P/F ratio < 200~BUN > 60 mg/dL~Patients will receive standard treatments such as anti-bacterial agents, mechanical ventilator, vasopressors as appropriate"
2525090|NCT02729558|No Intervention|observation|Watchful waiting
2525091|NCT02729558|Active Comparator|local stereotactic radiotherapy (SRT)|local SRT in three fractions of 8 Gy to the surgical cavity
2525186|NCT02728960|Experimental|Traumatic Brain Injury|Documented history of Traumatic Brain Injury
2525191|NCT02728960|Active Comparator|Normal Controls|No prior history of concussion, TBI, blast exposure, stroke, or other major neurological disorder
2525194|NCT02728960|Active Comparator|Sequence Development Volunteers|
2525245|NCT02728570|Experimental|Low Flavonoids then High Flavonoids|Participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks.
2525249|NCT02728570|Experimental|High Flavonoids then Low Flavonoids|Participants receive a prepared diet with High Dietary Flavonoids (340 mg of flavonoids/1000 Kcals) for six weeks. After a minimum washout period of 2 weeks, participants receive a prepared diet with Low Dietary Flavonoids (10 mg of flavonoids/1000 Kcals) for six weeks.
2525296|NCT02728219|Experimental|hepatectomy|Comparison of Treatment of recurrent hepatocellular carcinoma with repeat hepatectomy,and transcatheter arterial chemoembolization (TACE) with AFP conversion
2525300|NCT02728219|Active Comparator|TACE|
2525407|NCT02727556|Experimental|Functional dyspepsia patient|Visual stimuli of food and non-food images will be presented to patients. Non-food images include positive, neutral, negative emotional pictures.
2525409|NCT02727556|Experimental|Healthy|Visual stimuli of food and non-food images will be presented to participants. Non-food images include positive, neutral, negative emotional pictures.
2525465|NCT02727140|Experimental|Yoga with Asana (yoga postures)|
2525471|NCT02727140|Experimental|Yoga without Asana (yoga postures)|
2525472|NCT02727140|No Intervention|Wait-list control group|
2525552|NCT02726776|Experimental|Suspension without prior climbing|Free Suspension in a harness after baseline measurements and without prior climbing
2525554|NCT02726776|Experimental|Suspension with prior climbing|Free Suspension in a harness after baseline measurements and after climbing in moderate intensity for 10 minutes
2525590|NCT02726087|Experimental|ministernotomy|"Minimally invasive aortic valve replacement with Partial J upper hemisternotomy through right 4th intercostal space, performed according to current standard of care practice."
2525594|NCT02726087|Active Comparator|full sternotomy|Full sternotomy AVR through a standard median sternotomy, performed according to current standard of care practice.
3199666|NCT00882739|Experimental|900 mg loading dose|900 mg clopidogrel loading dose at first medical contact
3199667|NCT00882752||Ulcerative colitius|The method used to identify the microbes in the sample was chosen because it had the potential to provide more exhaustive identification of the bacteria present in the sample as compared to culturing methodology.
2525724|NCT02725242|Experimental|Once-daily budesonide/formoterol (160/4.5 μg/d)|once-daily budesonide/formoterol (160/4.5 μg/d)
2525728|NCT02725242|Active Comparator|Twice-daily Budesonide (200μg)|twice-daily Budesonide (400μg/d)
2525864|NCT02724410|Active Comparator|home intravenous ertapenem and PICC|Placement of peripheral inserted central catheter (PICC) and completion of ten day antibiotic treatment with home (IV) ertapenem (Drug Class:carbapenem antibiotic) (15 mg/kg IV every twelve hours not to exceed 1 gm/day for ages <13; age 13 or greater, then 1 gm daily)
2525865|NCT02724410|Experimental|home oral amoxicillin-clavulanate|Completion of ten day antibiotic treatment with home oral amoxicillin-clavulanate(Drug Class:beta lactam antibiotic)(15mg/kg every eight hours or 22.5mg/kg extended release tablets every twelve hours).
2525968|NCT02723500|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
3199668|NCT00882765|Experimental|Arm I|Patients receive neoadjuvant oral genistein once daily for 2 weeks in the absence of disease progression or unacceptable toxicity.
3199669|NCT00882765|No Intervention|No intervention|Patients receive no specific neoadjuvant therapy.
2524970|NCT02730338|Active Comparator|Arm A: Supervised exercise group|Supervised high intensity aerobic and resistance exercise tapering to self management with psychosocial support
2524972|NCT02730338|Other|Arm B: Self directed exercise group|Self directed exercise and psychosocial support group
3199670|NCT00882804|Experimental|Hemin|
3199671|NCT00882804|Placebo Comparator|placebo|
2525082|NCT02729493|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
2525126|NCT02729272|Experimental|Ultrasonic ESD|Laparoscopic colpotomy by ultrasonic ESD (Harmonic Synergy Hook Blade; Ethicon Endo-Surgery) during total laparoscopic hysterectomy.
2525129|NCT02729272|Active Comparator|Monopolar ESD|Laparoscopic colpotomy by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany) during total laparoscopic hysterectomy.
3199672|NCT00882817|Active Comparator|1|Pulmonary Rehabilitation
2525240|NCT02728453|Experimental|Empagliflozin|25 mg/d empagliflozin + matching glimepiride placebo for 24 weeks.
2525241|NCT02728453|Active Comparator|Glimepiride|2 or 4 mg/d glimepiride+ matching empagliflozin placebo for 24 weeks.
3199673|NCT00882817|No Intervention|2|
2525396|NCT02727530|Experimental|GROUP RECEIVING VISCERAL MANUAL THERAPY-ADVICES|Subjects will receive 2 manual therapy sessions and advices.
2525403|NCT02727530|Experimental|GROUP RECEIVING ADVICES|Subjects will receive advices.
2525459|NCT02727179|Experimental|Laparoscopic group|Liver resection performed by laparoscopic approach
2525460|NCT02727179|Active Comparator|Open group|Liver resection performed by open approach
2525504|NCT02726841|Experimental|Hybrid TAAD repair|The group includes patients who underwent open thoracoabdominal aortic repair + abdominal stenting.
2525506|NCT02726841|Active Comparator|Conventional TAAD repair|The group includes patients who underwent classic thoracoabdominal aortic repair with dacron prosthesis.
2525536|NCT02726490|Active Comparator|Glyburide|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glyburide may be 2.5milligrams (mg) to 5mg every day(QD) or twice daily (BID) depending on the degree of hyperglycemia.~The dose of glyburide will be increased as needed to a maximum of 20mg /day.~Antenatal testing will be initiated at 28 weeks~Patients will receive monthly growth scans"
2525545|NCT02726490|Active Comparator|Glucovance|"Patients will check and record blood glucose fasting and 1 hour after each meal each day. Patients will also keep a diary of all meals.~The starting dose of glucovance may be 1.25/250milligrams (mg) either once daily (QD) or twice a day (BID) increased to a maximum of 20mg/2000mg as needed.~Patients will receive monthly growth scans~Antenatal testing will be initiated at 28 weeks."
3199674|NCT00882830|Experimental|EMS group|
3199675|NCT00882830|No Intervention|control group|
2525653|NCT02725606|Active Comparator|Pegylated Recombinant Human G-CSF|100ug/kg 6 subjects (2 subjects per GW003 cohort)
2525658|NCT02725606|Experimental|GW003 300ug/kg|6-8 subjects
2525660|NCT02725606|Experimental|GW003 650ug/kg|6-8 subjects
2525662|NCT02725606|Experimental|GW003 850ug/kg|6-8 subjects
2525740|NCT02725164|Placebo Comparator|Uncuffed tracheal tubes|After tracheal intubation with an uncuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
2525741|NCT02725164|Active Comparator|Cuffed tracheal tubes|After tracheal intubation with a cuffed tube, the interventions will be the oxygen concentration, nitrous oxide concentration, carbon dioxide concentration and sevoflurane concentration measured in the tracheal tube compared with those in the oropharynx during spontaneous and controlled ventilation.
3199676|NCT00882843||Group 1|Healthy Able bodied Control
2525846|NCT02724397|Experimental|Experimental group|(White endoscopy and then LCI/BLI) The patients will be evaluated by Standard White Light and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI).
2525847|NCT02724397|Active Comparator|Control group|(LCI/BLI then white endoscopy) The patients will be evaluated by Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy.
3199677|NCT00882843||Group 2|Spinal Cord Injury
3199678|NCT00882856|Active Comparator|Bisoprolol-washout -placebo|Bisoprolol - wash out - placebo
3199679|NCT00882856|Active Comparator|Placebo - wash out - bisoprolol|Placebo - wash out - bisoprolol
2525974|NCT02723526||Single arm|
2526031|NCT02723409|Active Comparator|"Inverted U procedure"|umbilicoplasty technique
2526035|NCT02723409|Active Comparator|"Inverted V procedure"|umbilicoplasty technique
3199680|NCT00882882|Experimental|1|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
3199681|NCT00882882|Experimental|2|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
3199682|NCT00882882|Active Comparator|3|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
3199683|NCT00882882|Active Comparator|4|GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
3199684|NCT00882895|Experimental|Allogeneic Transplant|"TLI - 80 cGy on days -14, -11, -10, -9, -8, -7, -4, -3, -2, -1~Anti-thymocyte globulin (ATG) 1.5 mg/kg on days -11, -10, -8, -7~Solumedrol - 1 mg/kg on days -11, -10, -9, -8, -7~Tacrolimus - beginning on day -3 with starting dose of 0.3 mg/kg PO BID. Will be continued per institutional guidelines.~Stem cell infusion - day 0~Mycophenolate mofetil (MMF) - beginning on day 0 with dose of 15 mg/kg PO (5-10 hours after transplant)"
3199685|NCT00882934|Experimental|A1|Arm 1 received an informative letter explaining that they were allocated to receive a substance for Erectile Dysfunction treatment.
3199686|NCT00882934|Placebo Comparator|A2|Arm 2 (A2) was written informed that they could or could not receive an active drug for ED treatment.
3199687|NCT00882934|Experimental|A3|Arm 3 (A3) was properly written informed to be using no effective drug for ED treatment.
3199688|NCT00882947||Group 1|
2524930|NCT02730390||Probucol Tablets|Target is 3,000 patients in the Philippines diagnosed with hyperlipidemia (including familial hypercholesterolemia and xanthoma).
3166299|NCT00523250|Experimental|AR-102 Vehicle Ophthalmic Solution|q.d. ocular
3166300|NCT00523263|Active Comparator|Dacron|Patients receiving polyester above-knee femoro-popliteal bypass
3166301|NCT00523263|Active Comparator|HUV|patients receiving HUV femoro-popliteal bypass
2525184|NCT02729103||Treatment patterns, healthcare resource utilization and costs|Part 1 - Assessment of treatment patterns, healthcare resource utilization and costs. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no skeletal-related events (SREs) in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before and at least 6 months after the index date.
2525189|NCT02729103||Mortality|Part 2 - Assessment of mortality. The study cohort will include all patients with prostate cancer with incident bone metastases during the index period (1 June 2013 to 1 July 2014) based on a large database encompassing a broad sample of the commercially insured U.S. population. The first date of bone metastases diagnosis or first date of treatment indicative of bone metastases (whichever occurs first) will be designated as the index date. All patients must have no diagnosis of other cancers, no diagnosis of bone metastases or a claim for a treatment indicative of bone metastases, and no SREs in the 12-month pre-index period. Additionally, all subjects must be continuously enrolled for at least 12 months before the index date. Unlike in Part 1, there will be no required minimum follow-up time after the index date (in order to assess mortality).
2525217|NCT02728583|Active Comparator|Margarine enriched with plant sterols and fish oil|Low-fat margarine (25 g per day) with added plant sterols and Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) from fish oil
2525219|NCT02728583|Placebo Comparator|Placebo margarine|Low-fat margarine (25 g per day) without added plant sterols and EPA + DHA
2525271|NCT02728414|Experimental|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
2525275|NCT02728414|Other|placebo|the patients in this arm will receive placebo with similar appearance of probiotics.
2525388|NCT02727608|Experimental|Eculizumab|Intravenous infusion
2525586|NCT02726061|Experimental|Internet Based psychological support|The internet-based psychological support intervention (PATH) is an internet based Problem Solving Therapy, stress management training and conflict management training program.
2525665|NCT02725827|Active Comparator|HA group|One the day of frozen-thawed embryo transfer, frozen embryos will be thawed and incubated for at least 10 minutes in embryo transfer medium. For women allocated to the HA group, EmbryoGlue (Vitrolife), a hyaluronan-enriched embryo transfer medium, will be used as embryo transfer medium. EmbryoGlue contains a higher concentration of hyaluronan than the control medium.
2525667|NCT02725827|Active Comparator|Control group|For women allocated to the control group, the usual transfer medium used in the study centers will be used and will serve as control. The main difference between the two media is that EmbryoGlue contains a higher concentration of HA.
2525717|NCT02725320||Female Rotator Cuff Surgical Group|Females, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
2525721|NCT02725320||Male Rotator Cuff Surgical Group|Males, 35-75 receiving surgery for predominantly unilateral rotator cuff syndrome
2525769|NCT02725073|Experimental|photodynamic therapy|Photodynamic therapy with a novel photosensitizer and flexible laser catheter
2525818|NCT02724891||Arm 2 web/smartphone form first|web/smart phone questionnaires first then paper questionnaires after a 2-week washout period
3166302|NCT00523276||HCWs|Who may/may not have contact with SARS patients
3166303|NCT00523276||Family/close contacts|No illness but household/close contact
3166304|NCT00523276||SARS subjects|Diagnosed with active disease
3166305|NCT00523289|Active Comparator|B|Arm number B corresponds to the Bupivacaine group.
3166306|NCT00523289|Active Comparator|R|Arm number R corresponds to the Ropivacaine group.
3166307|NCT00523328|Experimental|BG9924|dosage administered as per Biogen-idec protocol
3166308|NCT00523354|Experimental|1 (open-label)|prospective, open label, uncontrolled trial
3166309|NCT00523380|Experimental|A|
3166310|NCT00523393|No Intervention|1|
3166311|NCT00523393|Experimental|2|
3166312|NCT00523393|Active Comparator|3|
3166313|NCT00523406|Active Comparator|A|standard fluence photodynamic therapy and intravitreal triamcinolone combination
3166314|NCT00523406|Active Comparator|B|reduced fluence photodynamic therapy and intravitreal triamcinolone combination
3166315|NCT00523432|Experimental|A|Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
3166316|NCT00523432|Experimental|B|Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.
3166317|NCT00523445|Experimental|Varenicline|The effect of varenicline on cognitive function of Varenicline(Chantix) is being compared to that of placebo
3166318|NCT00523445|Placebo Comparator|Placebo|The effect of placebo comparator is being compared to that of varenicline
3166319|NCT00523458|Active Comparator|1|Standard dose nevirapine (200 mg 2x daily) in combination with 2 nucleoside analogs
3166320|NCT00523458|Experimental|2|High dose nevirapine (400 mg in the morning, 200 mg in the evening) in combination with 2 nucleoside analogs
3166321|NCT00523458|Active Comparator|3|Standard dose efavirenz (600 mg at bedtime) in combination with 2 nucleoside analogs
3166322|NCT00523458|Experimental|4|High dose efavirenz (800 mg at bedtime) in combination with 2 nucleoside analogs
3173929|NCT00617578|Experimental|1|programming of VF therapy: ATP (antitachycardia pacing) One Shot ON
3173930|NCT00617578|Active Comparator|2|programming of VF therapy: ATP (antitachycardia pacing) One Shot OFF
2524933|NCT02730520||Immuno-allergology patients|Patients followed within the Immuno-Allergology Service of the CHU Brugmann Hospital, who received an allergy assessment between 01/01/2015 and 31/12/2015. At least 1400 dermis will be analyzed. The allergens tested include: dermatophagoides pteronyssinus (DEPT), dermatophagoides farinae (DPF), blomia, cat, dog, cockroach, orchardgrass, timothy grass, alder, hazel,birch, olive tree, cypress, ash, latex, aspergillus, alternaria, cladosporium, peanut, hazel.
2525003|NCT02730273|Experimental|Trial Nasal Mask|Participants to use nasal mask in-home for a week and one night in lab overnight polysomnography.
2525044|NCT02729857|Experimental|Familial hypercholesterolemia|Subjects diagnosed with familial hypercholesterolemia receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
2525047|NCT02729857|Active Comparator|Healthy|Subjects with no chronic diseases receive in randomized order muffin with saturated fat (SFA muffin) and polyunsaturated fat (PUFA muffin) at baseline
2525122|NCT02729480|Experimental|Continued Stimulation Group|Subjects randomized to this group will have the Halo Craniofacial Nerve Stimulator System activated immediately.
2525124|NCT02729480|Active Comparator|Delayed Continuation Group|Subjects randomized to this group with have the Halo Craniofacial Nerve Stimulator System activated after 90 days.
2525235|NCT02728609||Blue towel: vacuum pack device|Trauma subjects undergoing temporary abdominal closure with vacuum pack technique
2525238|NCT02728609||ABThera abdominal closure|Trauma subjects undergoing temporary abdominal closure with the commercially available ABThera vacuum device
2525285|NCT02728349|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
2525297|NCT02728011|Experimental|Intervention|Scientific Brain Training (SBT)
2525299|NCT02728011|Placebo Comparator|Controle|Tetris
2525354|NCT02727868|Other|exclusive breast irradiation group|to assess the impact of irradiation areas
2525359|NCT02727868|Other|breast and sternal irradiation group|to assess the impact of irradiation areas
2525398|NCT02727517|Active Comparator|Early (≤ 60 seconds) cord clamping|Early (≤ 60 seconds) cord clamping
2525404|NCT02727517|Active Comparator|Delayed cord clamping|Delayed (≥ 180 seconds) cord clamping
2525474|NCT02727153|Experimental|"Ultra E.R.A.S."|Discharge patients on Post Operative Day 2
2525475|NCT02727153|Active Comparator|Classic E.R.A.S.|Discharge patients on Post Operative Day 4
2525559|NCT02726152|Experimental|Polymer clips|Patients will be randomised to polymer clips for closure of the appendiceal stump
2525560|NCT02726152|Active Comparator|Endoloops|Patients will be randomised to endoloops for closure of the appendiceal stump
2525609|NCT02725970||Children's Nutrition Research Center|Survey, no intervention.
2525611|NCT02725970||Western Human Nutrition Research Center|Survey, no intervention.
2525614|NCT02725970||Human Nutrition Research Center On Aging|Survey, no intervention.
2525615|NCT02725970||Delta Obesity Prevention Research Center|Survey, no intervention.
2525616|NCT02725970||Beltsville Human Nutr Research Center|Survey, no intervention.
2525618|NCT02725970||Grand Forks Human Nutr Research Center|Survey, no intervention.
3199689|NCT00882960|Active Comparator|1|patients who are randomized to receive intravenous fentanyl for control of their pain
2525714|NCT02725489|Experimental|Part 1 Cohort 1: 1x10^6 cells Vigil|The first part will be a safety run-in comprised of 2 cohorts that will use a 3 + 3 design to determine the Vigil dose in Part 2. Cohort 1 will receive a low dose of Vigil (1x10^6 cells/intradermal (ID) injection) in combination with durvalumab (1500 mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2525719|NCT02725489|Experimental|Part 1 Cohort 2: 1x10^7 cells Vigil|Cohort 2 will receive Vigil at 1x10^7 cells/ID injection and durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2525723|NCT02725489|Experimental|Part 1 Cohort -1: 1x10^5 cells Vigil|If needed, Cohort -1 will be used which will receive Vigil at 1x10^5 cells/ID injection and Durvalumab (1500mg (if > 30 kg) IV over 60 minutes) every 4 weeks.
2525790|NCT02724943|Experimental|TX CORD Intervention|TX CORD Intervention. The intervention entailed: (1) BMI screening, (2) Next Steps brief counseling materials for the healthcare provider, (3) a 3-month intensive Mind Exercise Nutrition Do It! and Coordinated Approach To Child Health (MEND/CATCH) phase, which included the Mind Exercise Nutrition Do it! ( MEND) programs for preschool (ages 2-5) and school-aged (ages 6-12) children coupled with adapted CATCH activities, and (5) a 9-month transition MEND/CATCH Transition phase, which offered monthly reinforcement sessions for parents and children, and twice weekly Young Men's Christian Association (YMCA) sports for children. Community Health Workers (CHWs) serve as program liaisons and assist in delivering all intervention group sessions as well as tracking families. Electronic Health Record (EHR) changes supported the screening and Next Steps delivery.
2525791|NCT02724943|Active Comparator|Brief Clinic Comparison|Next Steps brief clinical intervention. The comparison program was a 12-month clinic-based program conducted at twelve partner healthcare clinics and entailed (1) EHR changes to support childhood obesity clinical visits; (2) BMI screening, (3) Next Steps brief counseling materials for the healthcare provider, and (4) Next Steps self-paced booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity.
2525840|NCT02724436|Experimental|TACE|transcatheter arterial chemoembolization
2525841|NCT02724436|Experimental|TACE+radioembolization|TACE plus radioembolization with Y-90: 100
2525922|NCT02724163|Active Comparator|Mitoxantrone|"Course 1~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2, 3 and 4 (total 4 doses).~Cytarabine:100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Mitoxantrone: 12 mg/m2 daily by IV infusion over 1 hour on days 1, 2 and 3 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
2525926|NCT02724163|Experimental|Liposomal daunorubicin|"Randomisation 1 (R1)) closed early to recruitment on 8th September 2017, due to liposomal daunorubicin manufacturing issues resulting in unavailability of the drug.~Course 1~Liposomal daunorubicin: 80 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-10 inclusive (total 20 doses).~Course 2~Liposomal daunorubicin: 60 mg/m2 daily by 1 hour IV infusion on days 1, 3 and 5 (total 3 doses).~Cytarabine: 100 mg/m2 12 hourly by IV bolus on days 1-8 inclusive (total 16 doses)."
2524979|NCT02730052|Active Comparator|Omron 9200T without Telemonitoring|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
2524980|NCT02730052|Experimental|Omron 9200T plus Telemonitoring|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
2525054|NCT02729805|Placebo Comparator|Saline|A syringe of 50 ml 0.9% normal saline will be prepared as placebo for infusion and a syringe of 10ml 0.9% normal saline for bolus injection.
2525055|NCT02729805|Active Comparator|Ketamine 0.5mg/kg|A bolus injection of intravenous ketamine at a dose of 0.5mg/kg during anaesthetic induction before skin incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation.
2525056|NCT02729805|Experimental|Ketamine 0.75mg/kg|A bolus injection of intravenous ketamine at a dose of 0.75mg/kg during anaesthetic induction before skin incision followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation.
3166323|NCT00523510|Experimental|Feasibility Study|HIV positive women [and a smaller number of HIV negative/unknown status (1 for every 3 infected women)] to avoid stigmatizing home-based counseling will be recruited at 1-2 postpartum and provided enhanced home-based infant feeding counseling by community health workers to exclusively breastfeed for 6 months. Mothers will also be told about the option to Flash-heat breastmilk during and after the transition from exclusive breastfeeding. Mothers who choose to Flash-heat will be provided continued home-based counseling and support. Feasibility data will be collected during the time mothers Flash-heat.
3166324|NCT00523510|Experimental|Pilot efficacy|We will collect infant health data to monitor and compare health outcomes among 3 groups of infants who had exclusive breast feeding (EBF) for the first months and then either: 1) fed Flash-heated breast milk and complementary foods (n=30), or 2) weaned to replacement foods and NO breast milk (n=15; per standard WHO recommendation for rapid cessation), or 3) continued feeding at the breast and providing other foods and/or fluids, i.e. mixed feeds (n=15; per WHO consensus that breastfeeding continue if replacement feeding is not AFASS94). We will collect infant growth and morbidity data. Infant health outcomes will be compared for the 3 groups noted above. These data will be collected primarily to pilot an efficacy trial.
3166325|NCT00523523|Experimental|A|This group will complete a 2 week program of functional task practice with auditory rhythm cuing.
3166326|NCT00523523|Active Comparator|F|This group will complete a 2 week program of functional task practice without auditory rhythm cuing.
3166327|NCT00523536|Experimental|1|Patient navigator-nurse disease management intervention
2525160|NCT02729090|Experimental|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks
2525165|NCT02729090|Active Comparator|Device: treadmill Train_Comb_aerobic|strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series.
2525233|NCT02728661|Experimental|PACE|PACE participants will begin up to 6 weeks prior to their scheduled TKR and continue until 12 weeks after their TKR. Participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks (from up to 6 weeks pre-op to 12 weeks post-op). Further, participants may opt to receive regular text messages or emails from coaches if they prefer. At 12 weeks, PACE participants will enter a maintenance period and not have any contact with coaches.
2525237|NCT02728661|Experimental|Delayed PACE|After being notified of their randomized condition at baseline (up to 6 weeks prior to surgery), Delayed PACE participants will not have contact with coaches until 12 weeks after surgery. At 12 weeks after surgery, Delayed PACE participants will be given personalized weight, dietary, and physical activity goals. Participants will be encouraged to monitor their dietary intake and physical activity using their preferred method of self-monitoring. Participants will have regular contact with their coaches either in-person or over the telephone on a weekly or bi-weekly basis, based on preference during the first 14 weeks. Further, participants may opt to receive regular text messages or emails from coaches if they prefer.
2525281|NCT02728323|Active Comparator|Levobupivacaine 100 mg, USG TAP Block|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
2525283|NCT02728323|Placebo Comparator|Placebo|20 ml of Saline (for 100 mg Levobupivacaine) intramuscularly, at the end of surgery
2525302|NCT02728024||A|Complete the questionnaires with personal aid
2525304|NCT02728024||B|questionnaires are completed by patients alone
2525420|NCT02727309|Experimental|apatinib|Patients with advanced hepatocellular carcinoma after been treated with TACE receive apatinib (750mg) daily, until disease progression or unacceptable toxicity.
2525482|NCT02727036|Experimental|Pumpkin seed oil|Pumpkin seed oil (1g) capsules - 2 capsules per day for 12 weeks
2525488|NCT02727036|Active Comparator|Pumpkin seeds|Packet of pumpkin seeds (4.1 grams /~0.15ounces) - 1 pack per day for 12 weeks
2525531|NCT02726607|Experimental|HITSystem 2.0|Pregnant women who are eligible for PMTCT services will be enrolled in the HIV Infant Tracking System 2.0 (HITSystem 2.0) intervention during their first PMTCT appointment and followed until 12 weeks postpartum.
2525533|NCT02726607|Active Comparator|Standard of PMTCT Care|Pregnant women who are eligible for PMTCT services will receive standard of care PMTCT services at the control hospital. The records of women enrolled during their first PMTCT appointment will be used to assess outcomes during the same follow-up period.
2525568|NCT02726204|Active Comparator|Healthy Subjects|Seven healthy patients will serve as controls based on preliminary data in healthy volunteers using CAREX with gravity elimination alone versus gravity elimination plus path assistance.
2525575|NCT02726204|Active Comparator|Chronic Post Stroke Right Side Hemiparesis|Radiologically verified unilateral stroke patients with at least 4 months previously.
2525649|NCT02725892||lungcancer patients|Men or women diagnosed with lung cancer all types and stages confirmed over 12 months of recruitment period by a pathologist
2525680|NCT02725398|Experimental|Buscopan group|First to use standard white light to observe, to record spasm score, to observe the lesion.Buscopan (BSP, 20mg) is administered by endoscopic nurse, recorded blindly.
2525755|NCT02725099|Experimental|Chewing Ticagrelor|
3166328|NCT00523536|No Intervention|2|Usual clinical care
3173931|NCT00617617|Experimental|A|Dietary Supplement: Prevastein HC®
2525029|NCT02729779|Experimental|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
2525035|NCT02729779|Active Comparator|Aerobic Group|The Aerobic Group will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
2525130|NCT02729532||Xpert cohort|HIV-positive presumptive TB patients tested for TB using Xpert MTB/RIF assay (fluorescence microscopy and TB culture also done to serve as reference standard)
2525133|NCT02729532||Standard of Care cohort|HIV-positive presumptive TB patients tested for TB using standard of care testing (sputum smear microscopy plus clinical evaluation)
2525158|NCT02728869|Experimental|Heat Stable Rotavirus (HSRV) Vaccine|25 healthy adults who will be administered a single dose of test HSRV vaccine
2525162|NCT02728869|Placebo Comparator|Placebo for Heatstable Rotavirus vaccine|25 healthy adults who will be administered a single dose of placebo
2525169|NCT02728869|Experimental|Heat Stable Rotavirus Vaccine|25 healthy infants who will be administered 3-doses of test HSRV vaccine spaced at 4-week intervals
2525179|NCT02728869|Active Comparator|RotaTeq|25 healthy infants who will be administered 3-doses of comparator Rotateq® vaccine spaced at 4-week intervals
2525250|NCT02728544|Experimental|Prader Willi syndrome|16 (8 males) PWS adolescents and young adults
2525256|NCT02728544|Active Comparator|Obese controls|16 - sex, age, and BMI-matched controls
2525313|NCT02728284|Active Comparator|Normal Cardiovascular System|70 with a history of heart or lung disease
2525316|NCT02728284|Active Comparator|Abnormal Cardiovascular System|30 without any history of heart or lung disease
3199690|NCT00882960|Active Comparator|2|patients who are randomized to receive intra-nasal fentanyl for control of their pain
3199691|NCT00882973|Experimental|Cohort 1|Genexol-PM 220 mg/m2 + Gemcitabine 1,250 mg/m2
3199692|NCT00882973|Experimental|Cohort 2|Genexol-PM 260 mg/m2 + Gemcitabine 1,250 mg/m2
2525430|NCT02727231|Experimental|day and night closed loop control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
2525432|NCT02727231|Active Comparator|usual insulin pump therapy management|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (FreeStyle Navigator CGM)
2525462|NCT02726906|Experimental|Moderate-aerobic walking|Participants will complete a 6-month home-based moderate-aerobic walking program of 150 minutes per week with the assistance of an interventionist.
2525469|NCT02726906|Placebo Comparator|Healthy Living Education|Participants will receive monthly topics on healthy living lifestyles for self-paced reading over 6 months with the assistance of an interventionist.
2525550|NCT02726646|Placebo Comparator|Debridement|mechanical debridement in one session and application of 1 mg placebo microspheres in two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
2525553|NCT02726646|Experimental|Debridement plus Doxycycline|mechanical debridement in one session associated with the application of 1 mg of microspheres loaded with doxycycline per periodontal pockts, two periodontal pockts between 5 and 6 mm, and two periodontal pockts greater than or equal to 7 mm
3199693|NCT00882973|Experimental|Cohort 3|Genexol-PM 300 mg/m2 + Gemcitabine 1,250 mg/m2
2525674|NCT02725502|Active Comparator|Linagliptin treatment group|Group will receive linagliptin ( 5 mg / day ) for 3 months in addition to their insulin
2525675|NCT02725502|Placebo Comparator|Placebo group|Group will receive placebo for 3 months in addition to their insulin
2525729|NCT02725203|Experimental|Intervention: Activate intervention|Participants in the intervention arm will visit their primary care nurse four times in a three-month period for structured and comprehensive support in achieving an improved level of physical activity.
2525731|NCT02725203|No Intervention|Control|Patients in the control arm will receive care as usual.
3199694|NCT00882986||1|Men with high fitness (above VO2max of 60)
3199695|NCT00882986||2|Men with average fitness (below VO2max of 50)
2526037|NCT02723409|Active Comparator|"Y deepithelialized procedure"|umbilicoplasty technique
3199696|NCT00883012|Experimental|Influenza vaccine|Two doses of trivalent sub-unit influenza vaccine (2009) to be administered one month apart
3199697|NCT00883012|Placebo Comparator|Placebo|Two doses of saline administered one month apart
3199698|NCT00883025||1|OSAS patients
3199699|NCT00883025||2|no OSAS Patient
3199700|NCT00883038|Active Comparator|Active Comparator|Diabetic diet following the DNSG guidelines
3199701|NCT00883038|Experimental|Experimental|Low-fat vegetarian diet
3199702|NCT00883064|Experimental|1|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)
3199703|NCT00883064|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)
3199704|NCT00883077||Inflammation|Patients with long standing history or short onset of ulcerative colitis.
3199705|NCT00883077||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3199706|NCT00883077||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting ROME III criteria of irritable bowel syndrome.
3199707|NCT00883142||Group 1|
3199708|NCT00883155|Experimental|1|Bupropion HCl 100 mg Tablets (Invamed Inc.)
3199709|NCT00883155|Active Comparator|2|Wellbutrin 100 mg Tablets (Glaxo Wellcome)
3199710|NCT00883194|Experimental|1|PRF-108 Gel, 4% ropivacaine
2525041|NCT02729870||Oral Glucose Gel|This group will consist of participants ages 1 - 7. The subject who are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
2525046|NCT02729870||Oral Placebo Gel|The group will consist of participants ages 1 - 7. The subjects who are less than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3- 7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
2525127|NCT02729402|Experimental|Older Cochlear Implant Subjects|We will assign the study participants to a diagnostic intervention (cognitive testing) before and after their cochlear implant.
2525170|NCT02728973||ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
2525178|NCT02728973||conventional treatment program|conventional treatment
2525228|NCT02728700|Experimental|Treatment (sirolimus, HSCT, MMF)|Patients receive sirolimus PO starting on day -3, 3 times a week during hospitalization and then once a week for up to 6 months. Patients undergo HSCT on day 0. Patients also receive mycophenolate mofetil IV or PO TID on days 1-180. Treatment continues in the absence of disease progression or unacceptable toxicity.
2525298|NCT02728180|Experimental|Xingnaojing and standard care|Subjects will receive intravenously administered Xingnaojing injection, combined with guidelines-based standard care.
2525301|NCT02728180|Active Comparator|Standard care only|Subjects will receive guidelines-based standard care only.
3199711|NCT00883194|Placebo Comparator|2|PRF-108 Gel, Vehicle
2525416|NCT02727374|Experimental|EXPERIMENTAL|Physiotherapy intervention, plus cognitive-behavioural intervention
2525418|NCT02727374|Active Comparator|CONTROL|Physiotherapy intervention
2525494|NCT02727049|Experimental|injured athlete for OMM|Participating athletes who sustain an injury will receive standard of care with the Intervention osteopathic manipulative medicine (OMM)
2525495|NCT02727049|No Intervention|injured athlete no OMM|Participating athletes who sustain an injury will receive standard of care withOUT osteopathic manipulative medicine (OMM)
2525518|NCT02726581|Experimental|Investigational Arm|"Nivolumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
2525524|NCT02726581|Active Comparator|Control Arm|"Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
2525526|NCT02726581|Experimental|Exploratory Arm|"Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone~Enrollment is closed for this arm"
2525652|NCT02725632|No Intervention|Control|"An age-matched control group will be enrolled and consented. A Data Collection Sheet will be used to document data from the subject's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. Another blood drawn will be collected after one month. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
2525656|NCT02725632|Active Comparator|OSA|"Newly diagnosed OSA patients will be enrolled and consented. A Data Collection Sheet will be used to document data from the patient's medical records including history, physical exam, active medications, laboratory data, polysomnogram, electrocardiogram, echocardiography and cardiac catheterization.~At the time of enrollment, one blood drawn through peripheral venipuncture will be collected. The patients on CPAP treatment will be followed-up for 1 month. Another blood drawn will be collected after one month of CPAP treatment. The blood samples will be processed and analyzed to assess for levels of SCN5A mRNA splicing variants."
3199712|NCT00883194|Active Comparator|3|Ropivacaine Solution 0.5%
3199713|NCT00883194|Experimental|PRF-110, 4%|PRF-110, 4% ropivacaine
3199714|NCT00883220|Experimental|Self-management of urinary catheter|Intervention: Self-management group--teaching behavioral approaches(awareness, self-monitoring, and self-management) to prevent or minimize urinary catheter complications.
2526096|NCT02722824|Placebo Comparator|Placebo|Wearable stimulators will be placed on the patients and controls without stimulation for 20 minutes
2526099|NCT02722824|Experimental|Active Stimulation|Instrinsic auricular muscles will be stimulated for 20 minutes
2526100|NCT02722824|Sham Comparator|Sham|An area out of the instrinsic auricular muscles region will be stimulated with the same parameters of the active group for 20 minutes
2526101|NCT02722824|No Intervention|Passive Control|Only the electrodes of the wearable stimulators will be inserted but there will not be electrostimulation for 20 minutes
2526141|NCT02722590||All Participants|Participants who are prescribed Fycompa (Perampanel) film-coated tablets and oral suspension per approved prescribing information in a normal clinical practice setting will be enrolled and observed prospectively for up to 24 Weeks.
2526170|NCT02722187|Experimental|microsurgery|40 patients will undergo subinguinal microscopic varicocelectomy
2526171|NCT02722187|Active Comparator|laparoscopy|20 patients will undergo laparoscopic varicocelectomy
2526237|NCT02721953|Experimental|Hypocaloric diet plus butyrate|Hypocaloric diet plus butyrate
2526241|NCT02721953|Placebo Comparator|Hypocaloric diet plus placebo|Hypocaloric diet plus placebo
2526294|NCT02721602|Experimental|Intervention Group|Families in the Families Preventing Diabetes Together intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
2526295|NCT02721602|No Intervention|Measurement Only|No intervention only measurements
2526352|NCT02721173|Experimental|Tazarotene group|This group will receive tazarotene 0.1% gel plus clindamycin 1% gel for 4 weeks.
2568170|NCT02445313||AMD|Age-related Macular Degeneration participants
3199715|NCT00883220|No Intervention|Usual care 2|Usual care for urinary catheter. Home care and/or clinic care is the usual care for people with long-term urinary catheters.
2525115|NCT02729350|Experimental|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.
2525116|NCT02729350|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
3199716|NCT00883259|Experimental|Experimental|Metformin treatment
3199717|NCT00883259|Placebo Comparator|Placebo|Placebo tablets
3199718|NCT00883272||Normal Controls|25 women with CADP-CT > 66 seconds were treated with Femarelle
3199719|NCT00883272||Thrombophilic|Seven women in cohort of a previous study were found to have shortened closure times (CADP-CT < 61s) at time of enrollment. They all underwent genetic testing for a hypercoagulable state.
3199720|NCT00883285||1|conventional aortic valve replacement
3199721|NCT00883285||2|transfemoral aortic valve replacement
2525366|NCT02727634|Other|Postoperative elective CABG patients|Patients included for coronary artery bypass graft (CABG) surgery, secondary to ischaemic heart disease.
2525390|NCT02727465||meningitis cases|any individual with culture-confirmed IMD in England from 01 September 2015 to 31 August 2019 with written informed consent from the individual, the parent (for children aged <16 years) or next-of-kin (for non-survivors)
2525437|NCT02727283|Experimental|Cohort 1|Subjects will receive 1 placebo and 3 escalating doses in one of the four treatment periods. The planned dose range is 10 mg to 200 mg. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
2525441|NCT02727283|Experimental|Cohort 2|Cohort 2 will proceed after completion of the treatment periods in Cohort 1. Subjects assigned to Cohort 2 will participate in up to 4 dosing periods which include up to 2 escalating doses and placebo in Periods 1 and 2, and a pilot food effect in Periods 3 and 4. A review of safety and tolerability will occur prior to administration of the next dose level and the same procedure will be followed for each escalating dosing period. The actual doses to be administered may be adjusted based on safety, tolerability, and pharmacokinetic data at previous dose levels; these dose adjustments may involve either an increase or a decrease in the planned dose for both Cohorts 1 and 2
2525479|NCT02726893||patients undergoing colonoscopy|patients undergoing colonoscopy were observed in terms of the bowel preparation quality which is measured by Boston Bowel Preparation Scale (BBPS).
2525534|NCT02726711|Experimental|Trimethaphan|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the trimethaphan infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
2525546|NCT02726711|Placebo Comparator|Placebo|"The investigator will measure cardiac output by studying the air the participant breathes in and out. The participant will also wear a facemask to apply a low air pressure to the airway.~After this, the placebo (saline) infusion will begin with a small dose and the investigators increase at 1-2 minute intervals for up to five doses. The measurements will be collected again.~Next, a standard blood pressure cuffs will be wrapped around the participant's abdomen. the cuff will inflate to apply pressure for 5 - 15 minutes."
2525597|NCT02726100|Experimental|Intervention arm|Participants in intervention communities will receive the SMARTHealth Diabetes intervention that connects community health service centers and family health providers for diabetes management. Medical staff and FHPs in the intervention communities will be provided with an initial training session on the installation and use of the platform.
2525601|NCT02726100|No Intervention|Control arm|"Control group doesn't use SMARTHealth Diabetes.The usual-care in our study will be conducted in a standard way which is defined in the Guidance of National Essential Public Health Service. All the relevant doctors in control group will be trained and required to record the activities defined in the guidance."
2525645|NCT02725775|Active Comparator|100% OJ|240ml 100% Florida Orange Juice consumed on a daily basis for 10 weeks.
2525646|NCT02725775|Placebo Comparator|Equicaloric Orange Drink|An equicaloric placebo orange drink (containing equivalent dose of sucrose, glucose, fructose, vitamin C and citric acid for flavour) consumed daily for 10 weeks.
2525683|NCT02725450|Experimental|Motor Imagery + Psychomotor Battery of fine motor skills|Application of Motor Imagery together with normal practice improves fine motor skills in disabled individuals.
2525736|NCT02725177|Experimental|H.P. Achtar Gel 80 U|H.P. Acthar Gel (repository corticotropin) Injection, 80 U daily for 10 days, then 80 U twice weekly for up to a total of 24 weeks on therapy.
2525815|NCT02724891||Arm 1 paper form first|paper questionnaires first then web/smart phone questionnaires after a 2-week washout period
2525915|NCT02724072|Experimental|Thoraflex™ Hybrid Device.|Plexus™ 4 and Ante-Flo™ configurations will be included in this study.
3199722|NCT00883285||3|transapical aortic valve replacement
3199723|NCT00883298|Experimental|Open Label|temozolomide plus bevacizumab administered as open label single arm treatment
3199724|NCT00883324||1|fetal fibronectin specimens collected with a speculum
3199725|NCT00883324||2|fetal fibronectin specimens collected without a speculum
3199726|NCT00883350|Experimental|RIDE|Participants randomized to utilize the RIDE e-health application for the duration of the 12 week intervention.
2525119|NCT02729363|Other|Sickle cell experience discussion|Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients talk about their sickle cell disease experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.
2525161|NCT02728999|Other|Group A|Steep Trendelenburg
2525164|NCT02728999|Experimental|Group B|Decreased Trendelenburg
2525224|NCT02728674|Other|Man+Breathlessness|Person in the case is a male. Symptom in the case is breathlessness.
2525226|NCT02728674|Other|Man+Pain|Person in the case is a male. Symptom in the case is pain.
2525227|NCT02728674|Other|Woman+Breathlessness|Person in the case is a female. Symptom in the case is breathlessness.
2525229|NCT02728674|Other|Woman+Pain|Person in the case is a female.Symptom in the case is pain.
2525294|NCT02728271|Experimental|HPC cell infusion|Autologous HPC will be infused within 24 hours of completing the chemotherapy. A total of 5 x 106/kg CD34+ HPC will be infused. The remaining HPC will be stored as back-up, to be used in case of graft failure.
2525339|NCT02727946|Other|optimal resuscitation|This group of multiple trauma patients will be resuscitated with crystalloids, analgesics, blood products as needed. Then follow up of the difference between arterial and venous CO2 to difference between arterial and venous oxygen tension, serum lactate, renal function, other organ affection along over the short hospital stay period
2525369|NCT02727686|Experimental|Water Load (WL) Post-Operative Day 1|All enrolled subjects passing conditions outlined in Intervention are eligible to be included. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Patient will have 30 minutes to consume WL, or will be excluded.
2525393|NCT02727452|Experimental|immediate mother-skin-to-skin contact(SSC)|The immediate mother-SSC begins directly after birth (still during the C-section)
2525394|NCT02727452|Active Comparator|immediate father-SSC|The immediate father-SSC begins directly after birth (still during C-section)
2525400|NCT02727452|Other|Routine care;mother-SSC after 30 minutes|After birth (still during C-section) the newborn gets routine care of a midwife close to the mother. SSC with mother after 30 minutes
2525413|NCT02727257|Experimental|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. All the exercises are aerobic. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
2525414|NCT02727257|No Intervention|healthy controls|we assessed the attentive Reaction Times in healthy controls, that don't receive rehabilitative treatment
2525464|NCT02727088|Active Comparator|Pulpectomy : root canal treatment|Pulpectomy : ablation of the whole dental pulp, preparation and filling of the whole root canal system
2525467|NCT02727088|Experimental|Pulpotomy : Conservative pulp management|Pulpotomy : ablation of the coronal part of the pulp
2525512|NCT02726763|Experimental|tDCS with cognitive training|We will collect: 1) self-reported demographic information (~5 min) 2) cognitive functioning data (PAOFI) at session 1 and session 4 (~10min) [60]; 3) behavioral data and EEG data from the tDCS stimulation task for each session (downloaded by investigators); 4) patient feedback on their experience with tDCS (tDCS Patient Experience Questionnaire (tPEQ)) for each session (~5 min); 5) tDCS accrual and session completion rates at the completion of treatment and 6) Brunoni Adverse Events Questionnaire (~5 min)
3199727|NCT00883350|No Intervention|Control|Participants assigned to the Health-Ed (control) group will receive health information via the cell phone throughout the 84-day study. We have generated numerous health information tips for other studies on a variety of topics, including stress management, the benefits of eating fruits and vegetables, etc. [6-9]. These lessons will be modified for delivery via cell phone. We have found that participants assigned to these health information control groups report being satisfied with the information and their assignment. Importantly, our data also indicate that such health information results in very little behavior change or weight loss, e.g., [6].
2525673|NCT02725684||Glioblastoma|Observational study, no intervention
2525722|NCT02725229|Active Comparator|parasternal block group|Patients in this group will be randomized to receive an parasternal block and PCA.
2525727|NCT02725229|Active Comparator|TENS group|Patients in this group will be randomized to receive an TENS and PCA.
2525732|NCT02725229|Active Comparator|control group|Patients in this group will be randomized to receive an PCA.
2525797|NCT02724969|Experimental|MILK intervention group|Semi-automated text messages sent to participants' cellular phones 3-5 times per week beginning Week 25 of pregnancy, through 8 weeks postpartum, specific to breastfeeding support and prevention of perceived insufficient milk supply.
2525799|NCT02724969|Active Comparator|Text4Baby control intervention group|Text4Baby automated texts sent to participants' cellular phones 3-5 times per week from Week 25 of pregnancy through the postpartum period from the national Text4Baby system. Messages provide general prenatal and postpartum support, including breastfeeding.
3199728|NCT00883363|Experimental|Precondition|Induction of precondition at start of operation on a arm
3199729|NCT00883363|No Intervention|Control|No precondition
2525897|NCT02724124|Experimental|static stretching|group of 11 volunteers (gSS)
2525902|NCT02724124|Experimental|warm up -|group of 11 volunteers (gWU)
2525909|NCT02724124|Experimental|static stretching + warm up|(group of 11 volunteers - SS+WU)
2525911|NCT02724124|Experimental|warm up+static stretching|(group of 11 volunteers - WU+SS)
2525914|NCT02724124|Other|Control Group|No intervention - athletes rested
2525955|NCT02723656|Active Comparator|Proactive mailed care coordination|
2525961|NCT02723656|Active Comparator|Proactive telephone care coordination.|
2526023|NCT02723409|Active Comparator|Round Procedure|umbilicoplasty technique
3199730|NCT00883376||1|OSAS patients
3199731|NCT00883376||2|no OSAS patients
3199732|NCT00883402|Active Comparator|CEA|Carotid endarterectomy
2525132|NCT02729259|Other|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
2525190|NCT02728843|Experimental|Deferiprone 300 mg|One-half of a 600 mg tablet of deferiprone twice a day, for a total daily dosage of 600 mg
2525195|NCT02728843|Experimental|Deferiprone 600 mg|One 600 mg tablet of deferiprone twice a day, for a total daily dosage of 1200 mg
2525196|NCT02728843|Experimental|Deferiprone 900 mg|One and a half 600 mg tablets of deferiprone twice a day, for a total daily dosage of 1800 mg
2525198|NCT02728843|Experimental|Deferiprone 1200 mg|Two 600 mg tablets of deferiprone twice a day, for a total daily dosage of 2400 mg
2525199|NCT02728843|Placebo Comparator|Placebo|Depending on dosage cohort, either one half-tablet, one tablet, one and a half tablets, or two tablets of placebo, twice a day
3166329|NCT00523562|Experimental|normal weight male high fructose diet|"Effects of diet intervention  high fructose in normal weight subjects"
3166330|NCT00523562|Experimental|offsprings of T2DM high fructose diet|"Effect of diet intervention high fructose in healthy non-obese offsprings of patients with type 2 diabetes"
3166331|NCT00523562|Experimental|normal weight subjects high fat diet|"effects of diet intervention high fat in healthy male subjects"
3166332|NCT00523562|Experimental|Normal weight high fat+protein diet|"effect of diet intervention high fat + protein subjects in healthy male subjects"
2525449|NCT02727348|Experimental|Sciatic block with or without femoral block|Sciatic block with or without femoral block performed on the patient with 3mg/kg of ropivacaine
2525451|NCT02727348|Active Comparator|Spinal anaesthesia|Spinal anaesthesia will be performed on the patient with heavy marcaine 0.5% up to 3mls
2525466|NCT02726880|Active Comparator|Referral for care|
2525470|NCT02726880|Experimental|Behavioral therapy|
2525539|NCT02726802|Experimental|Physical Therapy route of entry|The subject will see a physical therapist as their initial encounter into the healthcare system
2525542|NCT02726802|Active Comparator|Primary Care Provider rout of entry|The subject will see a primary care provider as their initial encounter into the healthcare system
2525688|NCT02725931|Experimental|Activity group|Pulmonary rehabilitation plus physical activity intervention
2525766|NCT02724930|No Intervention|Standard Implementation|Standard COPES implementation consists of provider education including brief in-person presentations and written material.
2525773|NCT02724930|Experimental|Implementation Facilitation|"Enhanced facilitation of COPES implementation.~All clusters start in the standard implementation group and cross-over from the control group to the intervention group in a randomized stepped-wedge fashion at 7 time points over the course of the 33 week implementation."
2525807|NCT02724657|Experimental|Buteyko Method|Children will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
2525809|NCT02724657|No Intervention|Control|Asthma education.
2525891|NCT02724046|No Intervention|Standard care|No chemoprevention for contacts of cases of meningitis (current standard of care) with a health promotion visit by a study nurse after the first notification of cases during the epidemic
2525895|NCT02724046|Active Comparator|Household prophylaxis|Chemoprophylaxis with a single dose of oral ciprofloxacin for household members of reported cases of meningitis. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
2525901|NCT02724046|Active Comparator|Village prophylaxis|Chemoprophylaxis with ciprofloxacin in the setting of a village-wide distribution after the notification of the first case of meningitis in a village. For participants age >12 years: 500 mg tablet; age 5-12 years: 250 mg tablet; age 1-4 years: 125 mg tablet; age 3-11 months: 100 mg (2 ml oral suspension); age <3 months: 75 mg (1.5 ml oral suspension).
2525951|NCT02723721|Experimental|Picato gel|application on1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
2526020|NCT02723435|Experimental|Midostaurin|Beginning 30 days post-HCT, participants receive oral midostaurin twice-a-day in 28-day treatment cycles, continuing up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2526063|NCT02722980|Placebo Comparator|Placebo|Capsules
2526064|NCT02722980|Active Comparator|Active|Capsules.
2526118|NCT02722759|Other|hemoglobin measurement arm|"In this arm hemoglobin measurement is done by four different devices~device Radical-7 for non-invasive measurement of SpHb~device HemoCue for taking capillary and venous blood for measurement of HcHb~device ABL 800 for measurement of BGAHb~device Siemens ADVIA for measurement of labHb~For measurement of haemoglobin by the devices the following interventions have to be done:~venous or arterial puncture (routine)~capillary puncture~placing of the Radical 7 sensor"
2526160|NCT02722382|No Intervention|Usual Nephrology Care|Nephrology care at Geisinger Health System.
2526162|NCT02722382|Active Comparator|Patient-Centered Kidney Transitions Care|Health system intervention which will implement informatics tools (including a disease registry, predictive modeling, and advance directives) and a disease specific care manager who will provide services and navigate patients through kidney disease transitions.
2526213|NCT02722070||Healthy Controls|Age matched control for the various clinical groups
2526214|NCT02722070||Neurodegenerative patients|
2526215|NCT02722070||Stroke patients|
2526216|NCT02722070||Neuropsychiatric patients|
2526306|NCT02721680|Experimental|Healthy Subjects- Awareness Training Group 1|Subjects in this arm will undergo an internal awareness training program.
3166333|NCT00523575|No Intervention|C|Usual nurse and dietetic care
3166334|NCT00523575|Experimental|I|Intensive nutritional support composed of oral dietary supplement combined with dietetic counselling.
3166336|NCT00523666|Active Comparator|1|
3166337|NCT00523666|Placebo Comparator|2|
3166338|NCT00523692|Experimental|1|Intensive therapy
3166339|NCT00523692|Active Comparator|2|Standard therapy
3166340|NCT00523757|Experimental|1|Spironolactone
3166341|NCT00523757|Placebo Comparator|2|
3166342|NCT00523770||Group A|Non-pneumococcal infected healthy elderly volunteers
3166343|NCT00523835||KS|Patients with Klinefelter syndrome verified by chromosome analysis
2525147|NCT02729454|Active Comparator|Exclusively physical therapy|The patients will be submitted to 15 therapeutical sessions two times per week with length of 40 minutes for motor physiotherapy . Each session of the motor physiotherapy will be constituted of exercises that include stretching (emphasizing the front of the torso), reinforcement (with emphasis in inferior members extensores); active exercises as transference (for example, to put into motion it bed or uprising of a chair), to reach and to grasp and training of balance and march.
2525149|NCT02729454|Experimental|Mental Practice And Physical Therapy|In the group submitted to the mental Practice the sessions will be individualized and occur in tranquil room after physical therapy (Same performed with the control group). During the mental practice the patient will be guided to stand, where he will be requested initially to identify and to sequencer the necessary joints for the accomplishment of an only step, being they:flexion of the thigh and leg rights, extension of the right leg more dorsiflexed of the right foot; touch of the heel and discharge of weight of the right foot and inclined body to the front. The sessions occur two times per week during 15 minutes.
2525264|NCT02728505|Active Comparator|SinuSurf irrigation twice daily|This arm is going to get low-concentration SinuSurf sinus irrigation solution, then a washout period, then standard NeilMed Sinus rinse.
2525267|NCT02728505|Placebo Comparator|NeilMed Sinus rinse irrigation twice daily|This arm is going to get standard NeilMed Sinus rinse, then a washout period, then low-concentration SinuSurf sinus irrigation solution.
2525319|NCT02728128||Low cardiac output syndrome|Patients who experience low cardiac output syndrome
2525323|NCT02728128||No low cardiac output syndrome|Group that does not experience low cardiac output syndrome.
2525344|NCT02727790|Experimental|PES Treatment|Eligible patients will receive daily 5 min PES treatment for two weeks. Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) continuous glucose monitor (CGM) System
2525347|NCT02727790|No Intervention|Control|Interstitial glucose will be monitored throughout the study using a FreeStyle Navigator (Abbott Diabetes Care, Alameda, CA) CGM System
2525395|NCT02727543|No Intervention|Control|Participants randomized to this arm will not receive the intervention.
2525401|NCT02727543|Experimental|Intervention|Participants randomized to this arm will receive the intervention, Medisafe, a smartphone application.
3199733|NCT00883402|Active Comparator|CAS|Carotid Artery Stenting
2525513|NCT02726438|Experimental|Debio 1450|"Participants will receive 3 oral administrations of Debio 1450 at a dose of 240 mg approximately 12 hours apart. The last dose should be given approximately 2, 4, 6 or 12 hours prior to surgery with 3 patients each to be dosed at each of these time points.~If the surgery is delayed by more than 12 hours postdose, the patients could receive up to 2 additional administrations (approximately 12 hours apart) to ensure that the last dose is administered between 2 and 12 hours before the surgery."
2525520|NCT02726438|No Intervention|Calibration|A single participant will not receive the study drug, providing data to be used as calibration.
2525580|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 1|Regimen 1 of ND0612 continuous SC infusion over 24 hrs
2525581|NCT02726386|Experimental|ND0612 (Levodopa/Carbidopa solution) - Regimen 3|Regimen 3 of ND0612 continuous SC for over 16 hrs
2525686|NCT02725372|Experimental|Inhaled Nitric Oxide 75mcg/KgIBW/Hr|"Part 1:~15Mcg/kg IBW/hr during Run-in Period dose titrated to Inhaled Nitric Oxide / 75mcg/KgIBW/Hr upon randomization to treatment arm.~Part 2: iNO 75 mcg/kg IBW/hr Open Label Treatment (Open Label Treatment - All Subjects)"
2525687|NCT02725372|Placebo Comparator|Placebo|"Part 1:~Placebo dose setting 15mcg/kg IBW/hr Run In Period / Placebo dose setting 75 mcg/kg IBW/hr treatment period"
3199734|NCT00883428||Pergnant women|Pregnant women, of 28 weeks or more of gestation, who are seen in the Health Centers participating in the study.
2525898|NCT02724137|Experimental|Physical Therapy Rehab and Fitbit®|Standard outpatient physical therapy rehabilitation after total knee replacement with the addition of a Fitbit® to promote physical activity.
2525904|NCT02724137|Active Comparator|Physical Therapy Rehab|Standard outpatient physical therapy rehabilitation after total knee replacement.
2525953|NCT02723760|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and efficacy evaluation of rheumatoid arthritis
2525989|NCT02723461|Active Comparator|pulsatile oxytocin|Using a programmable syringe pump, the pulsatile regime, oxytocin (Syntocinon, stock solution: 10 iU/mL) will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes). This regime stems from the observation that physiologic oxytocin may be released in a pulsatile fashion every 4-6 minutes (Dawood et al.,1979)
3199735|NCT00883441|Experimental|VM|implementation of new vector control tools (insecticide treated curtains and jar covers) through the existing routine vector control programme
3199736|NCT00883441|Experimental|PM|implementation of new vector control tools (insecticide treated covers and curtains) through partnerships
2525355|NCT02727920|Experimental|Experimental|drink containing pyridoxine, folate; B12); taurine, choline, glucuronic acid; tyrosine, phenylalanine*, malic acid, and caffeine administered one time.
2525358|NCT02727920|Placebo Comparator|Placebo drink|Placebo drink administered one time.
2525391|NCT02727491|Experimental|dextromethorphan|1 mg/kg of dextromethorphan syrup orally 30 min preoperatively and then again 8 hours post-tonsillectomy
2525392|NCT02727491|Placebo Comparator|Placebo|30 min preoperatively and then again 8 hours postoperatively, received inactive placebo syrup identical in volume, appearance and taste as the experimental group
3199737|NCT00883467|Other|1|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes
3199738|NCT00883467|Other|2|baseline MR signal prior to, during and 30 minutes after an ischemic period of 20 minutes with additional 5 minutes of cuff stenosis directly after cuff release
2525565|NCT02726191|Experimental|Posit Science|
2525571|NCT02726191|Experimental|Lumosity|
2525642|NCT02725749|Experimental|Laser|
2525643|NCT02725749|Experimental|Exercise|
2525644|NCT02725749|Experimental|Laser and Exercise|
2525726|NCT02725463|Experimental|vestibular implant|Up to 30 participants will undergo implantation, activation and deactivation of a Labyrinth Devices MVI™ Multichannel Vestibular Implant System
2525779|NCT02725021|Experimental|Intervention group|The intervention group receives a school-based module taking about two hours delivered by medical students in the schools.
2525780|NCT02725021|No Intervention|Control group|
2525817|NCT02724618|Experimental|Curcumin plus RT|120mg/day nanocurcumin during RT course
2525819|NCT02724618|Placebo Comparator|Placebo plus RT|120mg/day placebo of nanocurcumin during RT course
2525877|NCT02724280|Active Comparator|Group A|Patients with indications for gastroduodenoscopy will be evaluated with WLE and then LCI.
2525881|NCT02724280|Placebo Comparator|Group B|Patients with indications for gastroduodenoscopy will be evaluated with LCI and then WLE.
2525957|NCT02723825|Placebo Comparator|Less or equal to 2mm|the residual displacement is less than or equal to 2mm
2525960|NCT02723825|Placebo Comparator|Between 2-4mm|the residual shift is between 2-4mm, manual reset once again, as still between 2-4mm
2525962|NCT02723825|Active Comparator|Greater than 4mm|the residual displacement is greater than 4mm
2526048|NCT02723396||Parkinson|Prospective observation of a cohort of consecutive patients with idiopathic PD in an ecological setting.
2526050|NCT02723396||Healthy|The same assessments will be performed in a subgroup of age- and sex-matched healthy volunteers.
2526080|NCT02722876|Experimental|Contralateral rehabilitation|8-weeks of resistance training of the non-operative limb following ACL reconstruction
2526082|NCT02722876|Placebo Comparator|Placebo flexibility exercise|8-weeks of 'placebo' flexibility training of the upper limb
2526139|NCT02722642|Experimental|Bronchial basal cells|Patients will receive 10^6 (1 million)/Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
2526176|NCT02722252||Embryoscope group|
2526180|NCT02722252||Embryo culture without incorporated camera group|
2526226|NCT02721862|Experimental|Experimental|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking an oral drug (Ursodeoxycholic Acid 250mg) twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
2526231|NCT02721862|Placebo Comparator|Control|This arm will include 50 patients who, at baseline ultrasound, have no gallbladder pathology and have no previous cholecystectomy. Those patients will be taking a placebo, that is dispensed from the pharmacy and having the same color as the ursodeoxycholic acid 250mg, twice daily for a period of six months and undergoing a total of three gallbladder ultrasounds (at 6 months, at 12 months, and at 18 months) to check for gallstones.
3199739|NCT00883467|Other|3|short time preconditioning, other details according arm 2
3199740|NCT00883467|Other|4|long time preconditioning, other details according arm 2
2526470|NCT02720367|Experimental|7-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the TURBT.
2526472|NCT02720367|Experimental|21-Day Regimen|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 21. TAR-200 releases gemcitabine gradually during the 21 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 42.
2526515|NCT02720055|Experimental|Psychological Workbook|Psychological work book containing information and activities aimed at improving outcomes.
2526519|NCT02720055|Active Comparator|Basic information workbook|Basic information which represents current practice
2526593|NCT02719561|Experimental|Fatigue intervention|Fatigue Intervention is to be co-designed by participants, and likely to include education, energy conservation and activity promotion. Participants will also decide the name of the Fatigue Intervention
2568244|NCT02445079||HIV infected|HIV infected sub-group
3199741|NCT00883480|Experimental|2|The rest of the patients who do not carry the Factor Receptor mutation of Epidermal Growth will receive chemotherapy treatment individualized based on BRCA 1 m RNA levels. Function of these levels, three different subgroups of treatment: Subgroup A with low BRCA1 mRNA levels will receive treatment with gemcitabine / cisplatin Subgroup B with intermediate levels of BRCA1 mRNA: will receive treatment with docetaxel / cisplatin Subgroup C with high levels of BRCA1 mRNA: will receive treatment with docetaxel
3199742|NCT00883480|Experimental|1|The group of patients carrying EGFR mutation will receive treatment with Erlotinib, a selective oral Receptor tyrosine kinase inhibitor Epidermal Growth Factor
3199743|NCT00883506|Experimental|1|Lisinopril 40 mg Tablet under fed conditions.
2525234|NCT02728648|Other|Active|Open label IV Oxycodone 0.1 mg/kg Bolus Pharmacokinetic-Pharmacodynamic Study
2525329|NCT02728115|Experimental|Cellavita HD Lower Dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 1x10^6 cells/weight range per administration of Cellavita HD (n= 3) .
2525331|NCT02728115|Experimental|Cellavita HD Higher dose|Participants assigned to this arm will receive 3 administrations, one every 30 days, of 2x10^6 cells/weight range per administration of Cellavita HD (n= 3).
2525346|NCT02727712|Experimental|TPVB T2/3+T5/6+GA|the group A of patients has been received bilateral thoracic paravertebral block (TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4), before general anesthesia management
2525349|NCT02727712|Experimental|TPVB T3/4+GA|the group Bof patients has been received bilateral thoracic paravertebral block (TPVB 3/4) by ropivacaine(0.3%,10ml*4), before general anesthesia management Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
2525353|NCT02727712|Placebo Comparator|GA|group C under control (without TPVB)program Device: The use of Transesophageal Echocardiography（TEE）、STAT PROFILE® and Haemonetics® during the surgery
2525411|NCT02727400||advanced maternal age|Infertile women due to advanced maternal age
2525412|NCT02727400||Young patients|women under 35 undergoing infertility treatments
2525426|NCT02727114||participants aged 8 weeks to 3 years|"Echographic measurement of skin thickness at the proximal forearm, the deltoid region and medial thigh (till age of 2 years) in participants aged 8 weeks to 3 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2525427|NCT02727114||participants aged 3 to 6 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 3 to 6 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2525428|NCT02727114||participants aged 6 to 12 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 6 to 12 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2525429|NCT02727114||participants aged 12 to 18 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 12 to 18 years.~aimed number: 32 boys & 32 girls / maximum number: 50 boys & 50 girls"
2525473|NCT02726919|Other|Clobazam treatment|This will be an open label study comparing seizure frequency during 12 weeks of baseline observation period with seizure frequency during 16 weeks of clobazam adjunctive treatment
2525527|NCT02726672|Experimental|Respiratory rehabilitation|Respiratory rehabilitation: Powerbreathe training of the inspiratory muscles at home twice a day (2 sessions of 30 inspirations / day) during 10 weeks
2525528|NCT02726672|No Intervention|control group|No respiratory rehabilitation
2525570|NCT02726334|Experimental|Group/Stream 1 - Monotherapy|"Patient group: Patients who have failed at least two lines of chemotherapy for metastatic disease.~Treatment: BNC101 administered via intravenous infusion over 60 minutes weekly.~Patients with stable disease or a response at or after day 56 (2 cycles) will be allowed to continue to receive weekly doses of BNC101 until disease progression."
2525578|NCT02726334|Experimental|Group/Stream 2 - Combination Chemo|"Patient Group: Patients who have failed at least one line of chemotherapy for metastatic disease.~Treatment: BNC101 administered in combination with FOLFIRI~Participants will be treated until disease progression, intolerable toxicity, withdrawal of consent, or study termination by the Sponsor, whichever occurs first."
2525631|NCT02725879||HASIMOTO's PATIENTS (HT)|Children and Adolescents diagnosed with Hashimoto's clinical hypothyroidism.
2525633|NCT02725879||CONTROL GROUP (C)|Healthy individuals matched for gender and age
2525647|NCT02725580|Experimental|Open Label|Subjects with diagnosis of vLINCL6 Batten disease will receive a single intrathecal injection into the lumbar spinal cord region of AT-GTX-501.
2525676|NCT02725437|Experimental|Low-dose C. difficile Vaccine (accelerated schedule)|
2525677|NCT02725437|Experimental|High-dose C. difficile Vaccine (accelerated schedule)|
2525678|NCT02725437|Placebo Comparator|Placebo (accelerated schedule)|
2525679|NCT02725437|Experimental|Low-dose C. difficile Vaccine (non-accelerated schedule)|
2525681|NCT02725437|Experimental|High-dose C. difficile Vaccine (non-accelerated schedule)|
2525684|NCT02725437|Placebo Comparator|Placebo (non-accelerated schedule)|
2525754|NCT02725125|Experimental|Single-arm|Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0days,the first day,the second day,28 days,29 days Duration:total five times
2525784|NCT02724722|Experimental|Intervention|a simple flyer in one empty bag with face-to-face health education
2525787|NCT02724722|Placebo Comparator|No Intervention|a simple flyer in one empty bag with no face-to-face health education
2525820|NCT02724553|Other|Vertical orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the vertical position during routine cataract surgery
2525821|NCT02724553|Other|Horizontal orientation of Haptic orientation|The orientation of the IOL haptic will be implanted in the horizontal position during routine cataract surgery
2525899|NCT02724293|Placebo Comparator|Group I (placebo)|patients received placebo.
2525903|NCT02724293|Active Comparator|Group II (pregabaline 300 once)|patients received pregabalin 300 mg 2 hours preoperatively.
2525908|NCT02724293|Active Comparator|Group III (pregabaline 300 twice)|patients received pregabalin 300 mg 2 hours preoperatively and 12 hours after the preoperative dose.
2525910|NCT02724293|Active Comparator|Group IV (pregabaline 600)|patients received pregabalin 600 mg 2 hours preoperatively
2525980|NCT02723695|Experimental|Patients|Surgery (cochlear implantation)
2525984|NCT02723695|Active Comparator|Controls|Asymptomatic subjects
2526005|NCT02723240|Other|Part 1|"NUC-3373 IV Infusion on Day 1, Day 8, Day 15, Day 22, (28 day cycle)~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
2526008|NCT02723240|Other|Part 2|"NUC-3373 IV Infusion on Day 1, Day 15 (28 day cycle)~Participants can remain on study and receive treatment until disease progression or unacceptable toxicity occurs."
2526066|NCT02723019|Experimental|Intervention Group|Volunteer Peer Mentor + Behavioral Health Nurse
2526072|NCT02723019|No Intervention|Control|Care as Usual
2526310|NCT02721433|Active Comparator|12 weekly bone-targeted agent x 1 year|Bone targeting agents as standard of care
2525246|NCT02728687|Active Comparator|Menthol cream|Cream containing menthol (Water, Propylene glycol, Isopropyl palmitate. Caprylic capric triglyceride, Ceteareth 20, Cetearyl alcohol, Glyceryl stearate, Polyethylene glycol 100 Stearate, Dimethicone, Octyldodecanol, Menthol, Lecithin, Ethylhexyl glycerin, Phenoxyethanol) applied as needed, up to 4 times daily for one month, to the feet of a person suffering from painful diabetic peripheral neuropathy. During the other month, the mannitol and menthol cream will applied to the participant's feet. Whether the menthol cream will be given in the first or the second month will be chosen at random. At the end of the 2 months, if the participant chooses this cream, they will be given 3 months' supply of the cream to apply as needed to both feet.
2525332|NCT02728141|Placebo Comparator|Water|Newborn infants with ID numbers ending in odd numbers offered 2ml distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
2525335|NCT02728141|Active Comparator|Sucrose|Newborn infants with ID numbers ending in even numbers offered 2 ml 25% sucrose in distilled water by syringe once in the side of the infant's mouth 2 minutes before heel stick.
2525363|NCT02727738|Experimental|Methimazole plus selenium|Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days
2525365|NCT02727738|Active Comparator|Methimazole|Methimazole 5-30 mg daily for 90 days
2525417|NCT02727413||Infective endocarditis|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with infective endocarditis in accordance with Duke criteria and scheduled for valve surgery
2525419|NCT02727413||Valvular heart disease|Blood sample collection and assessment of signs of organ dysfunction in patients diagnosed with valvular heart disease, with no signs of infection, scheduled for valve replacement surgery
2525496|NCT02727023|Experimental|Osteopathic Manipulative Medicine|The thoracic inlet release, The Miller Thoracic Pump, Pedal Pump will be performed. These techniques are gentle and would be rhythmic in motion.
3199744|NCT00883506|Active Comparator|2|Lisinopril 40 mg Tablet (Zestril)
3199745|NCT00883506|Experimental|3|Lisinopril 40 mg Tablet under fasting conditions.
2525788|NCT02724826|Experimental|Qigong therapy|The qigong treatment was done according to medical qigong, and is a way of affecting and directing qi (energy) for medical benefit. Each qigong practice included body posture adjustment, gentle movement, meditation, relaxation, breathing regulation practices and massage. The qigong was practiced in groups of ten to 15 participants. Each qigong session started with information about the philosophy and a general warm-up with soft movements and 14 selected qigong exercises according to the Biyun method.
2525789|NCT02724826|Active Comparator|Exercise therapy|Exercise therapy was carried out individually, adjusted for each participant. A physiotherapist instructed the participant with focused on the cervical and shoulder/thoracic regions. Each training session included stationary bicycle for ten minutes, 40 minutes of dynamic exercises. These exercises consisted of active movements in all neck directions and muscle exercises aimed to maintain/increase circulation, endurance and strength. The load at the muscle exercises was to achieve between 30 and 70% of maximum muscle capacity and was gradually increased as endurance and strength were gained.
2525824|NCT02724527|Placebo Comparator|Placebo|Matching capsule (BID administration Q12H)
2525826|NCT02724527|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) at 400 mg dose (100 mg x 4 capsules) (BID administration Q12H)
2525866|NCT02724150|Active Comparator|Omeprazole High dose|Omeprazole 80 mg loading dose,then 8mg/h IV continuous infusion for 3 days
2525868|NCT02724150|Experimental|Omeprazole Low Dose|Omeprazole 80 mg loading dose IV then 40 mg two times per day IV for 3 days
2525924|NCT02723903|Other|with CAD and somatic symptom|Patients with the coronary artery disease and with the somatization symptom, the investigators treat the patients according to the guideline for coronary artery disease and anti-somatic agents (Deanxit, Prozac according to the somatization type)
2525928|NCT02723903|Other|without CAD, with somatic symptom|Only somatic symptom is presented, anti-somatic agents is prescribed (Deanxit, Prozac according to the somatization type)
2525932|NCT02723903|No Intervention|without CAD, without somatic symptom|Have neither coronary artery disease nor somatic symptom, continue follow-up.
2525933|NCT02723903|Other|with CAD, without somatic symptom|Patient with the coronary artery disease, without the somatization symptom, the investigators treat the patients according to coronary artery disease treatment guideline including coronary artery stent implantation,medication according to the severity of stenosis of the coronary arteries.
2525973|NCT02723617|Other|MED 0.5|
2525981|NCT02723617|Other|MED 2.5|
2525983|NCT02723617|Other|MED 5.5|
2525986|NCT02723617|Other|AAD 2.5|
3199746|NCT00883519|Active Comparator|IPT-A|
3199747|NCT00883519|Active Comparator|IPT-AP|
3199748|NCT00883532|Experimental|budesonide|The treatment group will receive surfactant and budesonide.
3199749|NCT00883532|Placebo Comparator|surfactant and air|The placebo group will receive surfactant and air as control.
2526079|NCT02723097|Experimental|Relaxation Response Resiliency Program (3RP)|
3199750|NCT00883545|Experimental|Woman endoscopist|
3199751|NCT00883545|Active Comparator|Usual care|
3199752|NCT00883571|Active Comparator|house advancement flap|house advancement flap
3199753|NCT00883571|Active Comparator|Rhomboid flap|rhomboid flapa was incised in the ischiorectal fossa. Without undermining of its fatty base, the flap was then mobilized into the anal canal so that the tip could be sutured to the top of the strictured area using Vicryl 3/0 sutures
3199754|NCT00883571|Active Comparator|Y-V anoplasty|Y-V anoplasty
3199755|NCT00883584|Active Comparator|1|IMD-1041
3199756|NCT00883584|Placebo Comparator|2|
3199757|NCT00883597||Controls|Patients with ileostomy.
3199758|NCT00883597||Standard Sepsis Treatment|Patients with ileostomy and sepsis
3199759|NCT00883623|Experimental|Treatment Arm|Treatment Arm
3199760|NCT00883636||Focal Segmental Glomerulosclerosis|
3199761|NCT00883636||Non-Focal Segmental Glomerulosclerosis|
3199762|NCT00883649|Placebo Comparator|1|
3199763|NCT00883649|Active Comparator|2|
3199764|NCT00883662||Group 1|
3199765|NCT00883701||COPD patients|COPD patients who undergo exacerbation
3199766|NCT00883701||Non COPD patients (controls)|Subjects who undergo respiratory infection (acute bronchitis) without COPD or other respiratory illness
3199767|NCT00883714|Experimental|Supervised exercise|
2525262|NCT02728492|Experimental|Quisinostat 12 mg & Paclitaxel & Carboplatin|Quisinostat 12 mg capsule every other day and Paclitaxel 175 mg/m2 on Day 7 of every 3-weeks course and Carboplatin (mg/ml х min) х [GFR (ml/min) + 25] on Day 7 of every 3-weeks course up to 6 cycles
2525263|NCT02728492|Experimental|Quisinostat 8 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 8 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2525265|NCT02728492|Experimental|Quisinostat 10 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 10 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2525266|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1000 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1000 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
2525269|NCT02728492|Experimental|Quisinostat 12 mg & Gemcitabine 1250 mg/m2 & Cisplatin|Quisinostat 12 mg capsule every other day and Gemcitabine 1250 mg/m2 on Day 7 and on Day 14 of every 3-weeks course and Cisplatin 75 mg/m2 on Day 7 of every 3-weeks course up to 6 cycles
3166344|NCT00523835||Normal|Normal men Age matched to KS patients
3166345|NCT00523900|Experimental|Experimental|Malnourished adults who will be given a dietary supplement.
3166346|NCT00523952|Experimental|1|
2525350|NCT02727647|Experimental|Arm 1|FVIII concentration at 35-40 U/kg/dose 1 time/week for 5 months
2525351|NCT02727647|Experimental|Arm 2|FVIII concentration at 15-20 U/kg/dose 2 time/week for 5 months
2525410|NCT02727504||Patient with aortic valve stenosis|"115 patients will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~2D and 3D echocardiography~Dobutamine stress echocardiography~Blood tests : blood electrolytes, creatinine, hemoglobin, N-terminal pro-brain natriuretic peptide (NT-ProBNP), C reactive protein (CRP), soluble suppression of tumorigenicity-2 (ST-2)~A cardiac MRI~A cardiac scanner~A 6-minutes walking test~An evolution of the Duke Activity Score"
2525431|NCT02727101|Active Comparator|phenobarbital|"After 12 weeks of baseline observation on phenobarbital medication, the treatment with perampanel will introduced as add on medication."
2525433|NCT02727101|Active Comparator|valproate|"After 12 weeks of baseline observation on valproate medication, the treatment with perampanel will introduced as add on medication."
2525435|NCT02727101|Active Comparator|lamotrigine|"After 12 weeks of baseline observation on lamotrigine medication, the treatment with perampanel will introduced as add on medication."
2525439|NCT02727101|Active Comparator|levetiracetam|"After 12 weeks of baseline observation on levetiracetam medication, the treatment with perampanel will introduced as add on medication."
2525443|NCT02727101|Active Comparator|zonisamide|"After 12 weeks of baseline observation on zonisamide medication, the treatment with perampanel will introduced as add on medication."
2525444|NCT02727101|Active Comparator|pregabalin|"After 12 weeks of baseline observation on pregabaline medication, the treatment with perampanel will introduced as add on medication."
2525445|NCT02727101|Active Comparator|lacosamide|"After 12 weeks of baseline observation on lacosasmide medication, the treatment with perampanel will introduced as add on medication."
2525446|NCT02727101|Active Comparator|clobazam|"After 12 weeks of baseline observation on clobazam medication, the treatment with perampanel will introduced as add on medication."
2525447|NCT02727101|Active Comparator|ezogabine|"After 12 weeks of baseline observation on ezogabine medication, the treatment with perampanel will introduced as add on medication."
2525448|NCT02727101|Active Comparator|eslicarbazepine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2525450|NCT02727101|Active Comparator|topiramate|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2525452|NCT02727101|Active Comparator|tiagabine|"After 12 weeks of baseline observation on eslicarbamazepine medication, the treatment with perampanel will introduced as add on medication."
2525499|NCT02726854|Experimental|Apatinib|Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.
2525523|NCT02726555|Experimental|Red yeast rice and atorvastatin|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 300mg of red yeast rice and 2 10mg of atorvastatin.
2525525|NCT02726555|Active Comparator|Atorvastatin alone|Participants will receive 4 identically appearing capsules twice daily for 24 weeks: 2 placebo and 2 10mg of atorvastatin.
2525655|NCT02725658|Other|DOSI|
2525706|NCT02725385||Ancillary-Correlative (stress and coping)|"PART I:~Participants complete a questionnaire that measures several psychological constructs including stress, anxiety, depression, coping mechanisms, uncertainty, positive and negative emotions, and life satisfaction over 15-30 minutes.~PART II:~Participants undergo a Trier Social Stress Test during a laboratory session over 1.5 hours."
2525751|NCT02725034|Active Comparator|Group 1|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
2525752|NCT02725034|Experimental|Group 2|High definition endoscopy with Optic Enhancement targeted biopsies for gastric intestinal metaplasia.
2525805|NCT02724735||Longitudinal Observational Cohort|Following completion of the NS2014-1 final study visit procedures, Subjects will be offered the opportunity to enroll in this longitudinal observational cohort protocol to monitor their depression and to assess durability of effect and long-term safety of NSI-189.
3166347|NCT00523965|Experimental|A|AmBisome 5 mg/kg iv infusion over 2 h x 1 day (single dose) + oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 7 days on day 2-8
2525954|NCT02723747||Healthy volunteers|Healthy subjects with normal 12-lead electrocardiogram at rest.
2526004|NCT02723422|Experimental|Prehabilitation Visit/Increased Physical Therapy post-TAVR|
3166348|NCT00523965|Experimental|B|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
3166349|NCT00523965|Experimental|C|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
3166350|NCT00523965|Active Comparator|D|amphotericin B deoxycholate at 1 mg/kg every other day for 15 infusions
2525320|NCT02727959||Patients newly diagnosed with IBD|
2525326|NCT02727959||Symptomatic non IBD-controls|Patients referred with symptoms suspicious of IBD, but who, after examination, are found not to have the diagnosis.
2525485|NCT02727062||OM Pain Smartphone Application|This study examines whether the smartphone OM Pain App is a feasible and valid tool to assess pain from radiation-induced oral mucositis.
2525549|NCT02726594||Patients|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district of the University Zurich / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
2525551|NCT02726594||Subjects|For the present study, patients who are assigned to the clinically indicated MRI scan, as well as healthy subjects will be included. Healthy volunteers will be recruited through public notices (flyer) (mainly in the district ETH / USZ). For all patients, the duration of clinical MRI routine examination is 30-90 minutes, depending on the requirements to answer the clinical question. The subjects are interviewed after the MRI scan by a visual analog scale oral and written on various aspects of their perception during the examination. This means an additional expenditure of time of about 10 minutes. The patients arises except for this additional time not a disadvantage by taking part in the study.
2525567|NCT02726217|Experimental|CareSmarts Intervention|Participants in the program receive text messages about diabetes self-care
2525576|NCT02726217|Active Comparator|Control|Standard of Care reminders and assessments for individuals with Diabetes
2525657|NCT02725944||Patients with cryptogenic stroke and TIA|Implantation of ICRM in all participants.
2525698|NCT02725424|Active Comparator|Her2 Positive with SOX|Her-2 Positive patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin 130 mg/m2, iv, d1 S-1 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks
2525703|NCT02725424|Experimental|Her2 Positive with SOXT|Her-2 positive patients treated with Oxaliplatin plus S-1 and Trastuzumab Oxaliplatin : As Above S-1: As Above Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks
2525705|NCT02725424|Active Comparator|Her2 Negative with SOX|Her2 Negative patients treated with Oxaliplatin plus S-1（SOX） Oxaliplatin As Above S-1 As Above Every 3 weeks
2525708|NCT02725424|Experimental|Her2 Negative with DOS|Her-2 Negative patients treated with Docetaxel plus Oxaliplatin and S-1（DOS） Docetaxel 60 mg/m2, iv, d1 Oxaliplatin 100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
2525759|NCT02724865|Active Comparator|Oral appliance therapy; Somnodent®|Somnodent is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
2525762|NCT02724865|Active Comparator|Oral appliance therapy; Herbst®|Herbst is a duobloc appliance, which is frequently used in OSA treatment and is titratable.
2525854|NCT02724358|Experimental|TACE|iodized oil (5ml) + Pirarubicin (20mg)
2525860|NCT02724358|Experimental|Rg3|20mg, BID, maintained though Month 12
2525862|NCT02724358|Experimental|TACE + Rg3|the combination of the treatments for the above two groups. Rg3 will be stopped on the day performing TACE.
2525863|NCT02724358|Experimental|Control|standard liver protective therapy
2525876|NCT02723955|Experimental|Part 1A: Dose escalation feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level dependent on to which dose level the participant is accrued.
2525878|NCT02723955|Experimental|Part 1B: Expansion feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously at a dose level chosen for further exploration in dose expansion cohorts.
2525882|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+pembrolizumab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
2525885|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+GSK3174998)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with GSK3174998.
2525886|NCT02723955|Experimental|Part 2A: Safety run-in (feladilimab (GSK3359609)+chemotherapy)|Participants participating in Part 2A chemotherapy combination cohorts will receive feladilimab (GSK3359609) in combination with chemotherapy at doses and schedules based on standard of care practice.
2525888|NCT02723955|Experimental|Part 2B: Expansion-feladilimab (GSK3359609)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with pembrolizumab.
2525890|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+ dostarlimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab.
2525893|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+dostarlimab+cobolimab)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with dostarlimab followed by cobolimab.
2525900|NCT02723955|Experimental|Part 2A: Dose escalation (feladilimab (GSK3359609)+bintrafusp alfa)|Participants will receive feladilimab (GSK3359609) administered continuously in combination with bintrafusp alfa.
3166351|NCT00524004|Experimental|Anti-CsbD Bovine IgG|Anti CsbD Bovine Milk Immunoglobulin
3166352|NCT00524004|Experimental|Placebo|Lacto-free milk supplement
3166353|NCT00524004|Experimental|Anti-CS17 Bovin IgG|Anti-CS17 Bovin Milk Immunoglobulin
3166354|NCT00524056|Experimental|001|Carisbamate two 100 mg tablets twice per day
3166355|NCT00524056|Placebo Comparator|002|Placebo two placebo tablets twice per day
3166356|NCT00524095|No Intervention|1|standard of care
3166357|NCT00524095|Experimental|2|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
3166358|NCT00524095|Experimental|3|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
2525312|NCT02727998|Experimental|Single infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
2525317|NCT02727998|Experimental|Two infusion of Ketamine with prolonged exposure|After the reactivation of the scripted memories during PE on day 4, the ketamine infusion procedure will begin inside the MRI. A physician will oversee and administer the ketamine infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following ketamine infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady state ketamine infusion of 0.50 mg/kg/hour. The infusion will continue for 40 minutes.
2525324|NCT02727998|Active Comparator|Midazolam with prolonged exposure|After the reactivation of the scripted memories during PE on day 2, the midazolam infusion procedure will begin inside the MRI. A physician will oversee and administer the Midazolam infusions. A nurse will accompany the subject throughout the study sessions, from the insertion of bilateral cannula for drug infusion and blood sampling, to the recovery following midazolam infusion. Whilst subjects undergo the infusion, their heart rate and blood pressure will be constantly monitored. The participant will receive a steady midazolam infusions at a rate 0.045 mg/kg for 40 minutes.
2525360|NCT02727725|Experimental|Traminer MRI Sequence|The TRAMINER MRI sequence implementation to be tested allows the acquisition of high resolution MR images in the free-breathing patient, by combining multiple averages and motion correction with the TRAMINER preparation.
2525399|NCT02727478|Experimental|Balance training group|1 hour group balance training twice weekly for 10 weeks, as well as perform a home exercise program.
2525405|NCT02727478|No Intervention|Control group|Subjects in this group will receive no intervention and will be advised to continue their normal level of exercise throughout the intervention period.
2525436|NCT02727218|Experimental|chest tube removal after 3 hours|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal after 3 hours.
2525440|NCT02727218|Active Comparator|delayed chest tube removal|30 patients, post thoracoscopic lobectomy, segmentectomy, thoracoscopic mediastinal biopsy, will undergo chest tube removal according to the department's protocol, most probably post operative day 1 (POD1)
2525541|NCT02726750||Observational (biospecimen collection)|Patients undergo collection of blood samples every 6 months for 3 years. Patients may also undergo a biopsy, x-rays, PET/CT scans, and/or MRI scans to check the status of disease at the discretion of the treating physician.
2525619|NCT02726230|Experimental|Ananya Intervention|"Strengthen enumeration and mapping of areas to ensure reach of front line workers (FLWs: auxiliary nurse midwives- ANMs; community health workers- ASHAs; anganwadi workers- AWWs).~Convene monthly FLW meetings to build skills and get trained in job kits to increase the quantity and quality of household visits.~Train FLWs on communication skills and use of mobile kunji, a job-aid tool, to improve FLWs' communication with households.~A mass media campaign inclusive of street theatre, tv and radio, and a mobile van.~Community mobilization linking mass media efforts with self-help groups.~Quality improvement activities at public health facilities.~Facility-based skills training to staff delivering infants to improve quality of care"
2525620|NCT02726230|No Intervention|Control Condition|standard of care public health services in India
3199768|NCT00883714|Active Comparator|Control group|
3199769|NCT00883727|Experimental|stem cells|
2525798|NCT02724748|Experimental|Educational intervention|Beside usual care the intervention will encourage collaborative practices between staff, patients and family members to adopt more human patient-centred approach on the unit. The intervention is designed to impact on treatment culture and thereby treatment practices on the study wards.
2525802|NCT02724748|No Intervention|Treatment as usual|Wards allocated to comparison wards continue with their usual care. No restrictions on how nursing staff works in these wards, although participation in corresponding projects is not supported.
2525834|NCT02724475|Experimental|LA group|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated.
2525837|NCT02724475|Experimental|3D-CRT group|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times.
2525917|NCT02724189||Patients attending the preoperative assessment clinic|Patients in preoperative assessment clinic
2525956|NCT02723773|Experimental|LTFU Group|Long-Term Follow-Up of the subjects who received at least one dose of the HZ/su vaccine in the primary studies ZOSTER-006/022
2525959|NCT02723773|Experimental|Additional Dose Group (1AdD Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 1 additional dose of the HZ/su vaccine in the current study.
2525963|NCT02723773|Experimental|Revaccination Group (Rev Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive 2 additional doses of the HZ/su vaccine in the current study on a 0, 2 Month schedule (N=60).
2525965|NCT02723773|Sham Comparator|Control Group (Ctrl Group)|Subjects who received 2 doses of the HZ/su vaccine in the primary studies ZOSTER-006/022 and will receive no additional doses of the HZ/su vaccine in the current study and will control for the 1-Additional and Revaccination groups
2526154|NCT02722434|Experimental|Arm I (MC5-A scrambler therapy)|Patients undergo MC5-A scrambler therapy over 30 minutes for 10 consecutive weekdays.
2526157|NCT02722434|Active Comparator|Arm II (TENS therapy)|Patients undergo TENS therapy over 30 minutes daily for 14 days.
2526249|NCT02721810|No Intervention|Control|Prompts standard to rounds or electronic medical records.
2526256|NCT02721810|Experimental|Prompting Intervention|Prompting consideration of 3-month functional outcome.
2526307|NCT02721680|Experimental|Healthy Subjects - Awareness Training Group 2|Subjects in this arm will undergo an external awareness training program.
3199770|NCT00883727|Placebo Comparator|Placebo|
3199771|NCT00883766|Active Comparator|Long agonist protocol|
3199772|NCT00883766|Experimental|Antagonist protocol|
2525322|NCT02728232|Active Comparator|Hysterectomy only|in this group patients will undergo cesarean hysterectomy only
2525361|NCT02727764|Experimental|Cohort I|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e12 vg/ MCP joint, 0.6x10e12 vg/ PIP joint or 0.3x10e12 vg/ DIP joint single intra-articular injection
2525362|NCT02727764|Experimental|Cohort II|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint single intra-articular injection
2525364|NCT02727764|Experimental|Cohort III|ART-I02 1.2x10e12 vg/ CMC joint, 1.2x10e13 vg/ MCP joint, 0.6x10e13 vg/ PIP joint or 0.3x10e13 vg/ DIP joint ART-I02 or maximum Tolerated Dose (MTD) as assessed in cohorts I and II: single intra-articular injection
2525397|NCT02727426|Experimental|low salt diet|All subjects will be instructed to maintain a low-sodium (LS) diet, with an intake of less than 2.3 g of salt per day (DASH eating plan; US Department of Health and Human Services, 2006) for 7 days (washout period).
2525402|NCT02727426|Experimental|high salt diet|After washout period, all subjects will be instructed to maintain a high-sodium (HS) diet, with an intake of 11.2 g of salt per day for 7 days.
2525476|NCT02727205|Experimental|Single Arm|One-half (½) of the test patch and one-half (½) of the reference patch (Rotigotine Transdermal System) was applied daily to the same site for each product over a 21 day period followed by a 14 day rest phase and a 48 hour challenge phase.
2525508|NCT02726724|Experimental|Condition B|An audience of 5 people with at least 2 neonatologists will be present with the operator during the intubation of the mannequin.
2525510|NCT02726724|Experimental|Condition A|Only the staff will be present with the operator during the intubation of the mannequin.
2525514|NCT02726503|Experimental|Treatment Arm|
2525583|NCT02726126||C group, (n=25)|C group, (n=25) each patient received transdermal placebo patch
2525587|NCT02726126||TDF group, (n=25)|TDF group, (n=25) each patient received transdermal therapeutic system-fentanyl 50μg/h
2525591|NCT02726126||TDM group, (n=25)|TDM group, (n=25) each patient received transdermal therapeutic system containing 7 mg of melatonin
3173932|NCT00617617|Placebo Comparator|B|Placebo
2525711|NCT02725359|Placebo Comparator|Placebo|Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
2525715|NCT02725359|Experimental|Tizanidine|Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
2525720|NCT02725359|Active Comparator|Bupivacaine|Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
2525758|NCT02724917|Experimental|APN1125, Low Dose|APN1125, Low Dose
2525761|NCT02724917|Experimental|APN1125, Mid Dose|APN1125, Mid Dose
2525770|NCT02724917|Experimental|APN1125, High Dose|APN1125, High Dose
2525774|NCT02724917|Placebo Comparator|Placebo|Placebo to match
2525816|NCT02724631|Experimental|TubeClear® (Phase I)|To determine feasibility and tolerability, 15 subjects will receive the TubeClear® intervention. If the TubeClear® intervention is unable to restore Enteral Access Device patency, further steps to restore patency of the occluded EAD will be determined by the clinical team per usual practice.
2525851|NCT02724332|No Intervention|control group|Patients will be treated with radical hepatectomy only.
2525853|NCT02724332|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE
2525930|NCT02723994|Experimental|Ruxolitinib in combination with chemotherapy|
2526379|NCT02720939||ASD group|ASD patients who met the diagnostic criteria of either autistic disorder or Asperger's disorder defined by the DSM-IV criteria
2526383|NCT02720939||TD group|Typically development controls without lifetime diagnosis with ASD or any psychiatric disorders
2526420|NCT02720549|Experimental|post-ischemic conditioning group|
2526424|NCT02720549|Placebo Comparator|valvular surgery with bypass group|
2526506|NCT02720315|Experimental|Intensive cryotherapy|Application of ice in a plastic bag wrapped to the patient's site of pain, and kept in place for 20min.
2526513|NCT02720315|No Intervention|Control|Existing pain control practice of physicians and nurses, which includes application of a chemical cold pack.
2526574|NCT02719873||control group|the group with normal BMI
2526578|NCT02719873||study group|The group with the BMI more than 24.9 kg per meter square to study the impact of maternal obesity in pregnancy outcome
2526631|NCT02719418||Tinzaparin|Hospitalized patients with chronic renal insufficiency (eGFR ≤ 30 mL/min/1.73 m2) at risk of VTE secondary to non-surgical reasons and receiving thromboprophylactic doses of tinzaparin 3500 or 4500 unit sub-cutaneous once daily.
2526691|NCT02719041||Tissue samples|Tissue samples taken from women treated for ovarian cancer will be stained.
2526705|NCT02718755|Experimental|Fludarabine + Cytarabine + Erwinase|"Induction Phase: Participants receive 1-2 cycles during the Induction phase.~Participants receive 1-2 cycles during the Induction phase.~Participants receive Fludarabine by vein on Days 1-5 and Cytarabine by vein.~Participants receive Erwinase by vein or as an injection into the muscle on Days 1-7.~Consolidation Phase: Participants receive up to 3 cycles during the Consolidation phase.~Participants receive Fludarabine by vein on Days 1-4 and Cytarabine by vein.~On Day 1 and then every other day for 15 days (3, 5, 7 and so on), participant receives Erwinase by vein or as an injection into the muscle."
2526784|NCT02718456|No Intervention|Standard of care|Standard HIV counseling and referral to care
2526853|NCT02717988|Experimental|SKI-O-703 400 mg|SKI-O-703 capsule (2x200 mg)
3173933|NCT00617643|Active Comparator|2|Triomune® 30 one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
3173934|NCT00617643|Experimental|1|Triomune® 30 one tablet twice daily for two weeks
3173935|NCT00617656|Active Comparator|A|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
3173936|NCT00617656|Experimental|B1|Low RAP expression and any levels of BRCA1 expression: Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
3173937|NCT00617656|Experimental|B2|Intermediate or high RAP expression and low or intermediate BRCA1 expression: Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
2525325|NCT02728037|Active Comparator|Lidocaine-Only Injection Formulation|Examination will involve systematic palpation of the 3 distinct levels of pelvic musculature. Injections into level 1 and level 2 muscles will be done under ultrasound guidance. Level 3 injections will be facilitated with a trumpet guide when needed. As the pelvic muscle trigger points are identified they will be injected with 2-3ml of the prepared injection formulation. The investigator will continue until no further trigger points can be identified, a maximum dose of lidocaine has been used, or the participant indicates they wish to stop. The maximum dose of lidocaine is 5mg per kg of body weight (280 mg of lidocaine in a 55kg woman or approximately 40cc of the final mixture).
2525327|NCT02728037|No Intervention|Wait-Listed Patients|This arm is a non-randomized, no-treatment arm consisting of women who are on the waiting list for the chronic pain clinic.
3199773|NCT00883792|Experimental|Colonoscopy screening|One-time colonoscopy is the screening tool used in this trial. All individuals in the screening group will be offered a full colonoscopy. At colonoscopy, all detected CRC precursor lesions will be removed, whenever possible.
3199774|NCT00883792|No Intervention|Control|"The control group will not be offered any screening or intervention within the trial, but follow usual care in the participating countries. Individuals assigned to the control group will not be informed about their status as controls in the trial. This approach facilitates a truly population-based study, which will be used to estimate the effect of the screening intervention in the general population, mimicking national CRC screening programs.~All ethics committees at the participating centres have approved the study protocol before recruiting individuals to the trial. In Sweden, the national ethics committee particularly reviewed the non-information of the control group and found it ethically acceptable."
2525538|NCT02726659|Experimental|Celecoxib|Adjunct celecoxib in 6 week treatment
2525543|NCT02726659|Placebo Comparator|Placebo|Adjunct placebo in 6 week treatment
2525582|NCT02726243||IBD without CRC|
2525585|NCT02726243||IBD with CRC|
2525588|NCT02726243||IBD with dysplasia|
2525592|NCT02726243||non IBD without CRC|
2525595|NCT02726243||non IBD with CRC|
2525598|NCT02726243||IBD-PSC without CRC|
2525602|NCT02726243||IBD-PSC with CRC|
2525604|NCT02726243||IBD-PSC with dysplasia or healthy subjects|IBD-PSC with dysplasia or healthy subjects for whom a colonoscopy is scheduled
3199775|NCT00883805||Metal-on-Metal Articulations|Subjects will be people who have had metal-on-metal total hip arthroplasties
3199776|NCT00883805||Ceramic-on-Metal Articulations|Subjects will be people who have had ceramic-on-metal total hip arthroplasties
3199777|NCT00883818|Experimental|Antibiotics therapy|
3199778|NCT00883831|Experimental|Individualized manual acupuncture|
2525879|NCT02724267|Active Comparator|transcatheter arterial chemoembolization|Patients will be treated with TACE only.
2525883|NCT02724267|Experimental|internal radiation group|Patients will be treated with TACE combined with internal radiation.
2526032|NCT02723357|Experimental|Financial Coaching & Access to Services|Participants in this arm will receive monthly financial coaching and access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
2526036|NCT02723357|Active Comparator|Access to Services|Participants in this arm will receive access to basic social service referrals until either one year, closure of all financial needs, or loss to follow up.
3199779|NCT00883844|Experimental|1|Continuation of any Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
3199780|NCT00883844|Active Comparator|2|Continuation of Nucleos(t)ide analogue mono-therapy
3199781|NCT00883870|Experimental|mesenchymal stem cells|Intramuscular injection
2526676|NCT02719119|Experimental|monthly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation monthly.
2526677|NCT02719119|Experimental|bi-weekly EVL|Elective band ligation was applied after premedication with hyoscine-N-butylbromide (20 mg intramuscularly). A multiband ligator and video endoscopes were utilized. Ligation was initiated at or slightly below the bleeding point. During each treatment session, each varix was ligated with one or two elastic bands. Variceal obliteration success was when all varices disappeared or residual varices were too small to be ligated further. Once esophageal varices were obliterated, surveillance endoscopy was performed every 3 months for 1 year and then every 6 months to check for recurrent varices. Patients in this group will underwent endoscopic variceal ligation bi-weekly.
2526736|NCT02718794|Experimental|Simulation training first|A highly customized interactive medium or program that allows individuals to learn and practice real world activities in an accurate, realistic, safe and secure environment.
2526739|NCT02718794|Experimental|Problem-based learning first|Instructional use of examples or cases to teach using problem-solving skills and critical thinking.
2526789|NCT02718274|No Intervention|Control|Standard of care.
2526792|NCT02718274|Active Comparator|Self-testing|Community-Based Distribution Agents (CBDAs) in the HIV Self-Testing (HIVST) Arm villages will be trained to provide HIVST services as well as reproductive health services.
2526798|NCT02718274|Active Comparator|Self-testing + home HIV care home initiation|CBDAs will be trained to provide HIV Self-Testing plus offer home assessment and HIV care initiation (first assessment and first 14 days of HIV care medications), with this additional intervention aimed at facilitating linkage into care.
2526844|NCT02717988|Experimental|SKI-O-703 50 mg|SKI-O-703 capsule (2x25 mg)
3199782|NCT00883870|Experimental|Placebo|Intramuscular injection
3199783|NCT00883883|Experimental|1|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)
3199784|NCT00883883|Active Comparator|2|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)
3199785|NCT00883896|Placebo Comparator|Arm 1|Part 1: Placebo
3199786|NCT00883896|Experimental|Arm 2|Part 1: 100 mg ILV-094 SC Q4W
3199787|NCT00883896|Experimental|Arm 3|Part 1: 100 mg ILV-094 SC Q2W
3199788|NCT00883896|Placebo Comparator|Arm 4|
2525341|NCT02727803|Experimental|Non-myeloablative regimen 2|"Patients with CD20 positive malignancies receive rituximab IV over 6 hours on day -9. Patients receive anti-thymocyte globulin IV over 4 hours on days -8 and -7, fludarabine phosphate IV over 1 hour on days -6 to -3, and cyclophosphamide IV over 3 hours on day -6 and undergo TBI on day -1 at the discretion of the investigator(s).~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
2525342|NCT02727803|Experimental|Reduced intensity regimen 3|"Patients receive anti-thymocyte globulin IV over 4 hours on days -7 and -6, fludarabine phosphate IV over 1 hour on days -5 to -2, and melphalan IV over 30 minutes on day -2.~UMBILICAL CORD BLOOD TRANSPLANT: Patients undergo umbilical cord blood transplantation on day 0.~NK CELLS INFUSION: Patients receive NK cells IV over 30 minutes between days 30-180."
2525478|NCT02726867|Active Comparator|levetiracetam|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 4000 mg levetiracetam.
2525481|NCT02726867|Active Comparator|lacosamide|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 600 mg lacosamide.
2525486|NCT02726867|Active Comparator|ketamine|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after phenytoin loading will receive intravenously (i.v.) 2.5 mg/kg ketamine.
2525491|NCT02726867|Active Comparator|phenobarbital|Patients with status epilepticus who have been treated with standard dose lorazepam (or midazolam) and ≥ 1000 mg phenytoin (PHT) with documented levels of ≥20 mg/ml and continue to have clinical SE for ≥1-24 hours after PHT loading will receive intravenously (i.v.) phenobarbital 15 mg/kg.
2525530|NCT02726568|Experimental|Icotinib 375mg Tid|The human subject gets icotinib 375mg, Tid until intracranial PD or intolerable toxicity reaction.
2525561|NCT02726256||Diabetes and Impaired glucose Tolerance (G-CREDIT)|Patients with either type 2 diabetes or impaired glucose tolerance who are older than 20 years old and have attended Gangnam Severance hospital for regular follow up.
3199789|NCT00883896|Experimental|Arm 5|Part 2: 200 mg ILV-094 SC Q2W
3199790|NCT00883909||observational|A follow-up study in adult male subjects who have received investigational
2525792|NCT02724761|Experimental|Experimental: Racemic Epinephrine|Over the Counter (OTC) - 0.5 mL Nebulized Racemic Epinephrine
2525795|NCT02724761|Placebo Comparator|Placebo: 0.9% Normal Saline|0.5 mL 0.9% Normal Saline
2525836|NCT02724488||Part 1|Patients with a histological or cytological diagnosis of advanced solid tumors who are currently on immune checkpoint inhibitors will have archival tumor specimens requested and used for whole exome sequencing (WES) of tumor DNA. 3 tubes of blood at a single time point will be collected for ctDNA analysis and germ line DNA analysis (to study normal variants) using next generation sequencing.
2525839|NCT02724488||Part 2|Patients with a histological or cytological diagnosis of advanced solid tumors who are candidates for a phase I, II, or III clinical trial testing immune checkpoint inhibitors (ICIs) or planning to have treatment with ICIs or other immunological therapy as standard of care will have image-guided fresh tumor core needle biopsy at a maximum of 3 time points: 1) prior to commencement of immune checkpoint inhibitors, 2) when disease response to therapy is confirmed using radiology RECIST 1.1 criteria and/or immune related response criteria, and 3) when radiological disease progression is confirmed by using RECIST 1.1. Blood samples for ctDNA analysis will be collected at the commencement of immunotherapy and every 6-12 weeks thereafter until radiological disease progression is confirmed.
2525855|NCT02724202|Experimental|Open Label|All subjects will receive induction oral curcumin 500 mg twice per day for 2 weeks. Patients will continue on curcumin at same dose for an additional 6 weeks while being treated with 3 cycles of 5FU.
2525918|NCT02723968|Other|Continuous glucose monitoring system|OGTT followed by continuous glucose monitoring system and finally IGTT and HbA1C dosage
2525969|NCT02723669|Experimental|AR10|AR10 acetylcysteine effervescent tablets for oral solution (two 0.5 g and four 2.5 g)
2525979|NCT02723669|Active Comparator|acetylcysteine|acetylcysteine solution; oral 20% (200 mg/mL)
2526007|NCT02723227|Experimental|Financial Coaching & Social Service Referral|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2526010|NCT02723227|Active Comparator|Social Services Referral|Enrollment provides for access to referrals to social services.
2526077|NCT02723032|Other|Healthy Subjects and patients|Validation of SpO2 sensor in healthy subjects as a first step. Validation of SpO2 sensor in patients as a second step.
2526130|NCT02722733|Active Comparator|G-CSF (filgrastim)|1.G-CSF at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days.
2526137|NCT02722733|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|"Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2).~G-CSF 5-10 μg/kg per day (divided into two doses every 12 hours) will be started on day 5 subcutaneously and continued until last leukapheresis."
2526175|NCT02722174||BED|Binge Eating Disorder
2526179|NCT02722174||ADHD|Attention Deficit Hyperactivity Disorder
2526184|NCT02722174||SUD, cocaine subtype|Stimulant Use Disorder, cocaine subtype
2526185|NCT02722174||BPD|Borderline Personality Disorder
2526186|NCT02722174||BPD, Cohort 2|Borderline Personality Disorder, Cohort 2
2526188|NCT02722174||HC|Healthy Controls
2526238|NCT02721901|Experimental|iEAT Manual Intervention|Caretakers of 10 children will be randomized to participate in the integrated Eating Aversion Treatment (iEAT) intervention. iEAT is a technology-based manual which aims to increase the child's food consumption.
2525477|NCT02727010||mothers with motor impairment due to a rare disease|20 Women with motor impairment due to a rare disease
2525480|NCT02727010||mothers with motor impairment not related to a rare disease|controls, 20 women with motor impairment not related to a rare disease
2525540|NCT02726737|Experimental|sodium bicarbonate|0.7 mL of 8.4% sodium bicarbonate & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
2525548|NCT02726737|Active Comparator|Non-sodium bicarbonate|Sterile distilled water & 0.3 mL of 2% lidocaine with 1:100,000 epinephrine
2525569|NCT02726139||Emory University|Samples obtained at and shipped from Emory University
2525577|NCT02726139||University of Michigan|Samples obtained at and shipped from University of Michigan
2525627|NCT02725996|Experimental|curative therapy+NK infusion|Adjuvant adoptive immune therapy using NK cell 4 times after curative therapy
2525629|NCT02725996|Other|curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation[RFA]) for HCC of pretreatment clinical stage I or II according to the American Joint Committee on Cancer staging system(6th edition) based on radiologic imaging studies were eligible for this study with no adjuvant treatment
2525763|NCT02724904|Experimental|Allogeneic Stem Cell Transplantation|Patients will undergo reduced intensity conditioning (fludarabine and thiotepa) followed by fully matched related or unrelated allogeneic stem cell transplantation. Afterwards, patients will receive standard post-transplant care (Methotrexate).
3199791|NCT00883935|Experimental|Sequence 2|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV 400mg q24h (treatment C) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3199792|NCT00883935|Experimental|Sequence 1|In the first treatment period, all subjects will receive GSK1349572 30mg q24h for 5 days (treatment A). In period two, subjects will receive GSK1349572 30mg q24h in combination with ATV/RTV 300/100mg q24h (treatment B) for 14 days. There will be no washout between treatment periods. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3199793|NCT00883948|Experimental|1|Participants will receive initial minimal (trophic) enteral feeding.
3199794|NCT00883948|Experimental|2|Participants will receive initial full-calorie enteral feeding.
3199795|NCT00883961|Experimental|Supervised exercise|
3199796|NCT00883961|No Intervention|Control group|The patients will not carry out a structured exercise program.
2526235|NCT02721888|Experimental|Main study|
2526301|NCT02721524|Active Comparator|Group R (ring)|Patients in Group R will undergo tricuspid ring annuloplasty
2526302|NCT02721524|Active Comparator|Group S (suture)|Patients in Group S will undergo De Vega's suture annuloplasty
2526344|NCT02721121|Active Comparator|circumferential pulmonary vein isolation|circumferential pulmonary vein isolation
2526345|NCT02721121|Experimental|Linear ablation in addiction to pulmonary vein isolation|Linear ablation in addiction to pulmonary vein isolation
2526390|NCT02720783|Experimental|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg|One vaginal pessary (2.7 g) of Econazole nitrate 150 mg plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
2526392|NCT02720783|Active Comparator|Placebo plus Econazole nitrate 150 mg|One vaginal pessary (2,7 g) of Placebo plus Econazole nitrate 150 mg, once daily, for 3 consecutive days
2526398|NCT02720783|Active Comparator|Placebo plus Benzydamine HCl 6 mg|One vaginal pessary (2,7 g) of Placebo plus Benzydamine HCl 6 mg, once daily, for 3 consecutive days
2526399|NCT02720783|Placebo Comparator|Placebo|One vaginal pessary (2.7 g) of Placebo, once daily, for 3 consecutive days
2526493|NCT02720146||Artificital tear|The epitheliotrophic ability in cell and animal model
2526495|NCT02720146||Human peripheral serum|The epitheliotrophic ability in cell and animal model
3199797|NCT00883974|Experimental|1|
3199798|NCT00883974|No Intervention|2|Standard Neonatal Intensive Care Unit (NICU) procedures for the care of pre-term infants
3199799|NCT00883987||Back Pain|"Patients with chronic mechanical low back pain (Chronic low back pain is defined as having pain between the lower ribs and gluteal folds, with minimal radiation to the thigh and never below the knee, present for a minimum of seven weeks)"
3199800|NCT00884000|Active Comparator|1|
3199801|NCT00884000|Experimental|2|
3199802|NCT00884013||1|Quality Payment and all clinical reminders turned on
3199803|NCT00884013||2|Quality Payment and ABCS measures reminders turned on
3199804|NCT00884013||3|Quality Payment and non-ABCS measures reminders turned on
2525517|NCT02726516|Experimental|Treated|Treated volunteers will be administered one dose of PRJ-205 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of PRJ-205 for 4 days for the chronic testing.
2525522|NCT02726516|Placebo Comparator|Placebo|Placebo volunteers will be administered one dose of placebo 1,5 hours before the exercise task for the acute testing and will be taking one dose per day of placebo for 4 days for the chronic testing.
2525563|NCT02726373|Experimental|Intermittent walking training|
2525573|NCT02726373|Active Comparator|Continuous Walking Training|
2525610|NCT02725983|Experimental|Intra Oral Camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015). Special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation). In this group, the device SOPROCARE® by Acteon was used in the examination and diagnosis and also for the establishment of therapeutic goals, strategies and skills.
2525612|NCT02725983|Active Comparator|No Intra Oral camera|Dental appointment, one hour and included activities that are normally part of a SPT consultation (Bardet et al. 1999), as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback as described by Newton and Asimakopoulou (2015) and considered crucial to the accomplishment of long term behavior change. Moreover, special attention was given to patient communication and words such as 'cleaning' and 'hygiene' were replaced by therapeutic synonyms (e.g. inflamed areas and controlling the inflammation) in order to focus patients´ attention on the varied facets of oral health care and increase their perception of the treatment needs. In this group, the device SOPROCARE® by Acteon was not used.
2525671|NCT02725723|Experimental|Subject after epidural injection|Subjects are patients from the clinic who have been diagnosed with Lumbar spinal stenosis and determined eligible for receiving steroidal epidural injection for pain management
2525725|NCT02725281|No Intervention|Control group|"The patients in Group-I were not interfered by researchers before and during lithotripsy."
2525730|NCT02725281|Active Comparator|Stress ball|"The patients in Group II were given stress ball into their both palms as a before the lithotripsy and told to squeeze the ball whenever they would like."
2525733|NCT02725281|Active Comparator|Music|"The patients in Group-III were listened to the music chosen by them with a headset as a nonpharmacological method during lithotripsy."
2525822|NCT02724566|Other|Apelin then Placebo|First clamp during which an apelin infusion will be administered followed by a wash-out period and then, a second clamp in which a placebo infusion will be administered
2525823|NCT02724566|Other|Placebo then Apelin|First clamp during which a placebo infusion will be administered followed by a wash-out period and then, a second clamp in which an apelin infusion will be administered
2525870|NCT02724228|Experimental|BMN 111 - Subcutaneous Injection|111-205 is an open-label, extension study. Subjects receive the same stable dose of BMN 111 received upon completion of the 111-202 study, initially up to 30 μg/kg. BMN 111 will be administered in the daily dosing regimen: 15 μg/kg per day.
2525945|NCT02723864|Experimental|1|VX-970 will be administered IV on Days 2 and 9 of each 21-day cycle; Veliparib will be administered orally twice a day (BID) Days 1-3 and 8-10 of each cycle; Cisplatin will be administered at 40 mg/m2 IV Day 1 (and Day 8 from DL3 onwards) of each cycle
2525966|NCT02723604|Experimental|Experimental: Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
2526014|NCT02723318|Experimental|Financia Coaching & Social Services Referrals|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2526019|NCT02723318|Active Comparator|Social Services|Enrollment in the control arm offers access to social services referrals.
2526062|NCT02722954|Experimental|Demcizumab and Pembrolizumab|Demcizumab will be administered prior to pembrolizumab
3166359|NCT00524186|Experimental|Oral Sunitinib|Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses
3166360|NCT00524199|Placebo Comparator|Placebo|Saline IV infusion over five minutes at the beginning of dialysis.
2526425|NCT02720601|Experimental|Irinotecan & Capecitabine|"Irinotecan at 120 mg/m2 intravenously every three weeks + Capecitabine at 1500 mg/m2/day orally twice per day for a total of 14 days.~The treatment cycle is once every 21 days."
2526856|NCT02717988|Experimental|SKI-O-703 600 mg|SKI-O-703 capsule (3x200 mg)
2526859|NCT02717988|Experimental|SKI-O-703 800 mg|SKI-O-703 capsule (4x200 mg)
3166361|NCT00524199|Active Comparator|Mesna|12 mg/kg mesna IV infusion over five minutes at the beginning of dialysis.
3166362|NCT00524212||IE confirmed IE rejected|Prospective, controlled, blinded study of clinical/TEE criteria of IE compare to clinical/blood test criteria of IE.
3166363|NCT00524212||IE confirmed IE rejected|
3166364|NCT00524238|Other|1|11 hypothyroid patients, newly diagnosed, examined before and after treatment
3166365|NCT00524238|No Intervention|2|10 healthy controls
3166366|NCT00524277|Experimental|Arm I|HLA-A2-positive patients receive GP2 peptide + GM-CSF vaccine intradermally (ID) every 3-4 weeks for a total of up to 6 inoculations.
3166367|NCT00524277|Active Comparator|Arm II|HLA-A2-positive patients receive GM-CSF ID every 3-4 weeks for a total of up to 6 inoculations.
3166368|NCT00524277|Experimental|Arm III|HLA-A2-negative patients receive AE37 peptide/GM-CSF vaccine ID every 3-4 weeks for a total of up to 6 inoculations.
3166369|NCT00524277|Active Comparator|Arm IV|HLA-A2-negative patients receive GM-CSF ID ID every 3-4 weeks for a total of up to 6 inoculations
3166370|NCT00524433|Experimental|1|tezosentan
3166371|NCT00524433|Placebo Comparator|2|
3166372|NCT00524446|No Intervention|ST-DI|Standard treatment - delayed intervention. Counselling on complementary feeding + Vitamin A (200,000 IU) every 6 months until 36 months + 1 kg maize / soy flour 2-weekly (71 g / day) between 18 and 30 months of age.
2525519|NCT02726477|Placebo Comparator|placebo|A total of 200 clinical diagnosed BCRL participants with affected arm circumference 10-40% larger than unaffected arm, are randomly allocated to two groups: the Wuling San group or the placebo group, where the placebo group administers a placebo powder, at a dosage of 1g/kg, twice a day for six weeks. The primary outcome measurement will be the percentage of limb volume changes measured by perometry.
2525596|NCT02726347|Active Comparator|Smokers between the ages of 19-80|current smokers between the ages of 19 and 80
2525599|NCT02726347|Active Comparator|elderly individuals (over age 50)|elderly individuals, defined as subjects age 50 years or older, without a history of frequent infections, COPD, or asthma
2525603|NCT02726347|Active Comparator|COPD subjects|COPD subjects between the age of 19 and 80, without history of recurrent bacterial infections.
2525605|NCT02726347|Active Comparator|Asthmatics subjects|Asthmatics between the ages of 19 and 80
2525606|NCT02726347|Active Comparator|Subjects with recurrent bacterial infections|Individuals between the age of 19 and 80 who have a history of frequent bacterial infections and are being evaluated for humoral immunodeficiency
2525635|NCT02725762|Experimental|Photobiomodulation Treatment|Treatment with Photobiomodulation to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
2525637|NCT02725762|Sham Comparator|Sham Treatment|Sham treatment to the retina at specific wavelengths to the eye three times a week for three weeks, repeated at six months.
2525668|NCT02725541|Experimental|Experimental|Trastuzumab emtansine at a dose of 3.6 mg/kg will be administered via intravenous infusion for 6 weeks (two 21-day cycles).
2525701|NCT02725346|Experimental|Computer-assisted planning|Acromioplasty with planification
2525704|NCT02725346|Active Comparator|No planning|Acromioplasty without planification
2525768|NCT02725060|Experimental|Autonomic and Antibody Assessments|"On up to 3 study days, POTS patients and control subjects will have several tests to assess autonomic function and to detect the presence of autoantibodies to adrenergic receptors. The following tests will de done but in some participants it may not be necessary to do all of them. The investigator will discuss with each participant which particular tests will be done in each particular case:~Posture study with blood samples for autoantibody testing~24-hour heart rhythm and blood pressure monitoring~autonomic function tests~Quantitative Axonal Sudomotor Reflex Testing~Total blood volume assessment~Pharmacologic testing with phenylephrine~Pharmacologic testing with isoproterenol~Cardiac output with rebreathing~Assessment of splanchnic capacitance~Microneurography"
2525857|NCT02724215||Patients with Sleep Apnea|Patients with increased apnea-hypopnea-index (>5/h)
2525859|NCT02724215||Patients without Sleep Apnea|Patients with normal apnea-hypopnea-index (5/h and below)
2525920|NCT02723981|Experimental|COMBO-Stent|Implantation of COMBO-Stent and medication with (N)OAC and clopidogrel for 3 months followed by (N)OAC alone
2525925|NCT02723981|Active Comparator|Any Drug eluting or bare metal stent|Implantation of any drug eluting oder bare metal stent combined with anticoagulant medication according to ESC guidelines
2525995|NCT02723474|Other|MRI at baseline and over time|Patients with chronic lung disease will undergo pulmonary function tests, hyperpolarized Helium and or Xenon MRI at each visit.
2526024|NCT02723162|Experimental|VRN+ NAC|Titrated VRN up to 1mg BID with NAC at 1200mg BID for 28 days
2526029|NCT02723162|Active Comparator|NAC+ PBO|1200mg BID for 28 days plus VRN placebo for 28 days
2526030|NCT02723162|Active Comparator|VRN+ PBO|Titrated VRN up to 1mg BID with NAC placebo for 28 days
2526034|NCT02723162|Placebo Comparator|PBO+PBO|Double placebo taken for 28 days
2526069|NCT02722889||Healthy controls|Healthy control patients
2526070|NCT02722889||Type A dissection|Patients with proven type A dissection,
2526129|NCT02722772|Experimental|Etanercept treatment group|Intra-articular injection of etanercept of 25 mg/w/joint and Health education, exercise and diet guidance; treatment: 5 weeks (If both knees are involved, the more significant symptomatic side is chosen for injection by etanercept)
2526134|NCT02722772|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 5 weeks
3199805|NCT00884013||4|Quality Reporting and Recognition with all clinical reminders turned on
2526252|NCT02721758|Experimental|Brief Motivational Intervention|Single, 60-minute, manualized behavioural intervention designed to support cardiac rehabilitation enrollment, informed by principles of motivational interviewing
2526259|NCT02721758|No Intervention|Usual Care|Standard encouragement to enroll in cardiac rehabilitation, and meeting with a researcher to complete study questionnaires
3199806|NCT00884013||5|Quality Reporting and Recognition with ABCS measures reminders turned on
2526334|NCT02721225|Active Comparator|Fructooligosaccharide|"One kind of prebiotics agent defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
2526339|NCT02721225|Placebo Comparator|Pocari-Sweat|Commercially produced isotonic solution by Otsuka Pharmaceutical Co., Ltd., Tokyo,Japan
2526369|NCT02720822|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
2526370|NCT02720822|Experimental|Morphine Sulfate (0, 0, 8 mg)|Placebo on weeks one and two. Morphine 8 mg/day on week three.
2526372|NCT02720822|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo on week one. Morphine 8 mg/day on weeks two and three.
2526373|NCT02720822|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo on week one. Morphine 8 mg/day on week two. Morphine 16 mg/day on week three.
2526374|NCT02720822|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg/day on weeks one, two and three.
2526375|NCT02720822|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
2526377|NCT02720822|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on weeks two and three.
2526378|NCT02720822|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg/day on week one. Morphine 16 mg/day on week two. Morphine 24 mg/day on week three.
2526385|NCT02720822|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg/day on weeks one, two and three.
2526389|NCT02720822|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg/day on weeks one and two. Morphine 24 mg/day on week three.
3199807|NCT00884013||6|Quality Reporting and Recognition with non-ABCS measures reminders turned on
2525564|NCT02726360||Oncology physician|Physicians (MD or DO) in the oncology departments of participating hospitals will complete a survey. Non-English language proficiency will be assessed by self-assessment using Interagency Language Roundtable (ILR) scale, which the PI has previously used. The physician survey is collected among treating physicians of patients enrolled to MSK IRB approved protocols 12-099 and 12-223 at some of the participating hospitals. For physicians who already completed this survey as part of participation in protocol 12-099 or 12-223, data will be extracted from the respective study's REDCap database.
2525572|NCT02726360||patients|Audio record the initial visits between patients and their treating physician. Analyze 48 patient-physician dyad recordings using the Roter Interaction Analysis System (RIAS).
2525651|NCT02725840||Proton beam radiation therapy|The participants in this group will be receiving proton therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
2525654|NCT02725840||X-ray based radiation therapy|The participants in this group will be receiving X-ray radiation therapy of the affected breast and chest wall as part of their standard of care. In addition, a Computed Tomography (CT) Scan of the chest wall will be performed, and pulmonary function test (PFT).
3166373|NCT00524446|Experimental|FSm|Fortified Spread (milk). Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
3166374|NCT00524446|Experimental|FSs|Counselling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
3166375|NCT00524446|Experimental|LP|Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
3166376|NCT00524498|Experimental|A|FAIT
2525927|NCT02723890|Experimental|Tyto Device|examination with Tyto device carried out by a nurse and sent online to the principle and co-investigators for remote analysis.
3166377|NCT00524498|Active Comparator|B|BST
2525991|NCT02723487|No Intervention|Group A|Control
2525992|NCT02723487|Active Comparator|Group B|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.125%), 0.5 ml/kg on each side.
2525993|NCT02723487|Active Comparator|Group C|patients will receive bilateral ultrasound guided TAP block using bupivacaine (0.25%), 0.5 ml/kg on each side.
2526039|NCT02723149|Experimental|Approach Avoidance Training Condition|The AAT group will push away the joystick from marijuana pictures 90% of the trials and pull towards the marijuana pictures 10% of the trials.
2526040|NCT02723149|Sham Comparator|Sham Condition|The sham group will undergo the same procedures, except the ratio for marijuana pictures will be 50% push and 50% pull.
2526065|NCT02722915|Experimental|fMRI Neurofeedback up-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
2526073|NCT02722915|Experimental|fMRI Neurofeedback down-regulation|Study related procedures included: PANAS, AVHRS, SF 36 (questionnaires or evaluations)
2526178|NCT02722200|Experimental|Intravenous glucocorticoids|Subjects in the glucocorticoids arm will receive an infusion of hydrocortisone overnight in the research unit prior to fMRI testing on either the first or second visit.
2526182|NCT02722200|Placebo Comparator|Intravenous saline|Subjects in the saline arm will receive an infusion of saline overnight in the research unit prior to fMRI testing on either the first or second visit.
2526230|NCT02721836|Experimental|Yoga|12 week yoga course, two times a week 75 minutes each time
2526234|NCT02721836|Active Comparator|Nutrition|3 counselling sessions within 12 weeks
2526309|NCT02721615|Active Comparator|Laminectomy|Comparison of bone decompression versus no decompression for reducing intra spinal pressure
2526312|NCT02721615|Active Comparator|Duraplasty|Expansion duraplasty versus no duraplasty for reducing intraspinal pressure
2526316|NCT02721615|Active Comparator|Hypothermia|Localised hypothermia for reducing intra spinal pressure and improving spinal cord metabolism
2526386|NCT02720965|Experimental|Electronic pump|Continuous nerve blocks Remote-controlled perineural local anesthetics delivery
2526391|NCT02720965|No Intervention|single injection|single injection
2526431|NCT02720497|Experimental|60-minute Prolonged Exposure|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
2526437|NCT02720497|Active Comparator|90-minute Prolonged Exposure|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
2526643|NCT02719470|Experimental|normal cognition|Group 1: patients with normal cognitive profile, assessed with MMSE (27 ≤ correct score ≤ 30) undergoing MIRT
2526655|NCT02719470|Experimental|mildly impaired cognition|Group 3: patients with middle cognitive decline, assessed with MMSE (20 ≤ correct score < 27) undergoing MIRT
2526661|NCT02719470|Experimental|moderately-severely impaired cognition|Group 2: patients cognitive decline, assessed with MMSE (correct score < 20) undergoing MIRT
2526669|NCT02719470|Experimental|patients with normal executive functions|Group 4: patients with pathological executive functions, assessed with FAB (FAB ≥ 13.8) undergoing MIRT
2526860|NCT02717988|Placebo Comparator|Placebo|Placebo capsule
3166378|NCT00524615|Active Comparator|1|25 mg of Spironolactone oraly once daily
3166379|NCT00524615|Placebo Comparator|2|placebo oraly once daily
3166380|NCT00524667|Experimental|1|
3166381|NCT00524693|Active Comparator|1|4mg Singulair© sachets
3166382|NCT00524693|Placebo Comparator|2|
3166383|NCT00524719|Active Comparator|Open, internal fixation volar plate|Open reduction and internal fixation (ORIF) with volar locked plate
3166384|NCT00524719|Active Comparator|Closed reduction with external fixator|Surgical procedure - Closed reduction and non-spanning external fixation (Ex-FIX)
3166385|NCT00524719|Active Comparator|Closed reduction percutaneous pinning|Surgical procedure - Closed reduction with percutaneous pinning (CRPP) and the application of a cast
3166386|NCT00524732||1|18 to 30 months since last prior dose of TD/Td vaccine.
3166387|NCT00524732||2|30 to 42 months since last prior dose of TD/Td vaccine.
3166388|NCT00524732||3|42 to 54 months since last prior dose of TD/Td vaccine.
3166389|NCT00524732||4|54 to 66 months since last prior dose of TD/Td vaccine.
2525641|NCT02725918|Active Comparator|Pem+Cis|Patients in arm A will receive 4 cycles of cisplatin (75 mg/m2, d1) and pemetrexed (500 mg/m2, d1) every 3 weeks, those without disease progression (PD) and being tolerable judged by investigator will continue single-agent pemetrexed (500 mg/m2, d1) every 3 weeks as maintenance until progression or intolerable toxicities.
2525783|NCT02724852|Active Comparator|HIV-infected adults|"Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
2525786|NCT02724852|Experimental|HIV-uninfected adults|"Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains."
3166390|NCT00524732||5|66 to 78 months since last prior dose of TD/Td vaccine.
3166391|NCT00524732||6|78 to 90 months since last prior dose of TD/Td vaccine.
3166392|NCT00524732||7|90 to 102 months since last prior dose of TD/Td vaccine.
2525971|NCT02723539|Experimental|MBN-101|MBN-101: a suspension of 150, 375, or 600 microgram (µg)/milliliter (mL) (w:v) BisEDT drug particles in suspension in 3% methylcellulose / 0.5% polysorbate 80 / 10 millimole (mM) sodium chloride / 10 mM sodium phosphate.
2525976|NCT02723539|Placebo Comparator|Vehicle|MBN-101 diluent (placebo): 3% methylcellulose / 0.5% polysorbate 80 / 10 mM sodium chloride / 10 mM sodium phosphate
2526002|NCT02723214|Active Comparator|Frame-based stereotactic brain biopsy|Brain biopsy
2526003|NCT02723214|Active Comparator|Frameless fiducial-less brain biopsy|Brain biopsy
2526068|NCT02723110||rs78408340 heterozygous carriers|
2526074|NCT02723110||homozygous non-risk allele carriers|
2526132|NCT02722629|Experimental|Aspiration in COPD patients|All COPD patient will be evaluated systematically by FEESST (Flexible Endoscopic Evaluation of Swallowing with Sensory Testing) with direct evaluation of aspiration by direct observation.
2526173|NCT02722291|Experimental|presbyopia|All participants perform all exams under 3 conditions, that is baseline, with out pinhole glasses, and with multiple pinhole glasses
2526224|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|Subjects will receive 4 massotherapy sessions and 4 of HYPOPRESSIVE ABDOMINAL GYMNASTIC (HAG).
2526225|NCT02721914|Experimental|GROUP RECEIVING MASSOTHERAPY|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
2526227|NCT02721914|Experimental|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive a total of 8 sessions of 30 minutes each.
2526269|NCT02721563|Active Comparator|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
2526271|NCT02721563|Placebo Comparator|Control Group|"Placebo：dissolved in 100mlphysiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 6 weeks course.Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T60Gy/30f,week 1-6"
2526332|NCT02721303|Active Comparator|obese older aged, aged 65-85, BMI 30-40|Older aged patients who are obese and between the ages of 65-85 with a BMI between 30-40.
2526333|NCT02721303|Active Comparator|normal weight older aged, aged 65-85, BMI 18-25|Older aged patients who are of normal weight and between the ages of 65-85 with a BMI between 18-25.
2526357|NCT02721173|Active Comparator|Adapalene group|This group will receive adapalene 0.1% gel plus clindamycin 1% gel for 4 weeks.
3166393|NCT00524732||8|102 to 114 months since last prior dose of TD/Td vaccine.
3166394|NCT00524732||9|Control - over 114 months since last prior dose of TD/Td vaccine.
3166395|NCT00524758|Experimental|Ologen in Trabeculectomy|Ologen in Trabeculectomy
3166396|NCT00524758|Active Comparator|MMC in Trabeculectomy|MMC in Trabeculectomy
2525690|NCT02725294||COPD patients|Veterans with COPD who are cared for at VA Puget Sound Health Care System (Seattle, WA) or VA Eastern Colorado (Denver, CO) who are at high risk for a COPD exacerbation based on an exacerbation treated with prednisone or antibiotics in the year preceding enrollment.
2525692|NCT02725294||Informal Caregiver for COPD patients|Informal caregiver (ie. family member, friend, etc.) for the patient with COPD who is participating in the COPD patients cohort.
2525743|NCT02725138|Experimental|Probiotic|subjects will be treated with probiotic containing Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
2525747|NCT02725138|Placebo Comparator|Placebo|subjects will be treated with placebo without Lactobacillus acidophilus，Lactobacillus rhamnosus, 1pack, twice daily, for 4 weeks
3199808|NCT00884026|Active Comparator|1|Subjects that experience hypotension after spinal anesthesia.
3199809|NCT00884026|Active Comparator|2|Subjects that do not experience hypotension after spinal anesthesia.
3199810|NCT00884078|Experimental|1|C-MAPS (Culturally adapted manualized problem solving training) will be a brief problem focused therapy comprising of 8 sessions within three months after a self-harm episode. We will have two engagement sessions before the actual therapy. The adapted therapy/training will be delivered by therapists/trained counselors in the patient's home/GP practice depending upon patient's choice. Sessions will be offered weekly in the first month and than fortnightly and will last 50 minutes.
2525856|NCT02724384|Experimental|Group 1|Plasma treatment using Plasma delivery system A 3 treatments/week for 2 weeks, then monthly
2525858|NCT02724384|Experimental|Group 2|Plasma treatment using Plasma delivery system A 2 treatments/week for 2 weeks, then monthly
2525861|NCT02724384|Experimental|Group 3|Plasma treatment using Plasma delivery system B 3 treatments/week for 2 weeks, then monthly
2525919|NCT02723942|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen by infusion.
2525923|NCT02723942|No Intervention|no intervention|no intervention
2526022|NCT02723383|Experimental|BACLOFEN|patient will receive baclofen caps
2526026|NCT02723383|Placebo Comparator|PLACEBO|patient will receive placebo caps (lactose)
2526156|NCT02722395||Single arm cohort study|
2526172|NCT02722161|Experimental|[14C]BI 1482694|
2526228|NCT02721940|Experimental|Treatment group|In the treatment group, patients will be given local injection of enriched autologous mononuclear cells and zoledronic acid into the necrotic area following core decompression by drilling.
2526233|NCT02721940|Experimental|Control group|In the control group, core decompression will be performed, but no treatment will be given.
2526270|NCT02721511|Experimental|Furosemide injection solution 8mg/mL|8mg/mL (total dose=80mg) of furosemide injection solution administered subcutaneously as 30mg over the first hour and then as 12.5 mg per hours over the subsequent 4 hours.
2526315|NCT02721316|Experimental|Supported with intensive nursing follow|Supported with intensive nursing follow post hospitalization the team of hospital output of the unit to 12 weeks after discharge. These interviews will be conducted at the hospital, at home or by phone and their pace will be adjusted according to the patient's condition. The expected duration of close outpatient follow-up is of maximum 3 months.
2526319|NCT02721316|No Intervention|usual care|For control patients, monitoring will be identical to their usual care as part of their pathology.
2526343|NCT02721082|Experimental|Opt Out|"Participants in this arm will be first enrolled to receive cessation treatment and will only not receive it by opting out. Participant will receive a Opt Out treatment program. Participants will receive counseling and nicotine replacement therapy."
2526346|NCT02721082|Active Comparator|Opt In|"Traditional approach to tobacco treatment program. Participants must first indicate they are ready to quit smoking by opting in to receive Opt In treatment program."
2526404|NCT02720692|Experimental|N1539 30mg|N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
2526406|NCT02720692|Placebo Comparator|IV Placebo|IV Placebo every 24 hours for up to 7 doses.
2526469|NCT02720211|Active Comparator|Gray tinted spectacle lenses|Subjects in this arm will be asked to wear a neutral gray tint that blocks all wavelengths equally
2526473|NCT02720211|Experimental|Thin-Film spectacle lenses|Subjects in this arm well be asked to wear a thin-film coating that specifically blocks 480-nm wavelength
2526529|NCT02720029|Experimental|pH/impedance monitor|
2526572|NCT02719795|Experimental|Ropivacaine|Ropivacaine hydrochloride injection； Generic name：Naropin； Dosage form：Liquid、Injectable formulation； Dosage：105mg；30ml； Frequency：Once.
2526577|NCT02719795|Placebo Comparator|Normal saline|Medical Normal saline Generic name：Normal saline； Dosage form：Liquid、Injectable formulation； Dosage：30ml； Frequency：Once.
2526647|NCT02719314||Rh-GIOP(A)|Glucocorticoid-induced osteoporosis (GIOP) in the context of chronic inflammatory rheumatic diseases
2526656|NCT02719314||Rh-GIOP(B)|Glucocorticoid-induced osteoporosis (GIOP) in the context of psoriasis
2526663|NCT02719314||Rh-GIOP(C)|Patients with or without chronic/inflammatory rheumatic diseases or psoriasis and/or without glucocorticoid treatment
2526701|NCT02718885|Sham Comparator|Maltodextrin|Maltodextrin
2526702|NCT02718885|Active Comparator|Inulin|Inulin-type fructans
2526752|NCT02718573||Non-liver transplants with HCV|
2526753|NCT02718573||Liver transplants with HCV|
2526861|NCT02717845|Experimental|CT scan Ellipse|New medical device for high tibial osteotomy
2526862|NCT02717845|Active Comparator|CT scan Tomofix|Established medical device for high tibial osteotomy
2526910|NCT02717429|No Intervention|Wait-List Control Group|This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
2527015|NCT02716623|Experimental|CR Diet and Exercise|Participants will be asked to follow specific diet intervention and exercise regimen.
2525793|NCT02724813|Experimental|Intervention arm|Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
2525794|NCT02724813|Active Comparator|Wait-list arm|Participant in this arm will receive therapy 8 weeks after initial assessment. Participants will receive 16 one-hour tele-CO-OP sessions delivered over a 10-week period by a licensed health care professional. We will deliver tele-CO-OP via Skype™ and record all sessions using Pamela software for Skype™.
2525872|NCT02724254|Experimental|AP611074 5% gel|100 mg twice daily doses of AP611074 5% gel
2525874|NCT02724254|Placebo Comparator|Placebo|AP611074 matching placebo gel
2525949|NCT02723851||Acute MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
2525950|NCT02723851||Non-MI patients|Corsens Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT).
2525982|NCT02723513|Experimental|Preterm Adults|All enrolled preterm adults will undergo non-contrast enhanced MRI (using ultra-short echo time methods), hyperpolarized noble gas MRI (using hyperpolarized xenon-129), x-ray computed tomography (CT), pulmonary function tests, and questionnaires in a single visit.
2526013|NCT02723253|Experimental|Radiotherapy plus Tom-Ox|Patients received concomitant boost RT (55 Gy/5 weeks) with concurrent Tom-Ox chemotherapy. The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
2526084|NCT02723071|Experimental|Cohort A: Ocrelizumab 200 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2526087|NCT02723071|Experimental|Cohort B: Ocrelizumab 375 mg/m^2|Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2526088|NCT02723071|Experimental|Cohort C: Ocrelizumab 375/750 mg/m^2|Participants will receive first infusion of ocrelizumab 375 mg/m^2 followed by 7 infusions of 750 mg/m^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
2526123|NCT02722512|Experimental|Newly Diagnosed High Grade Glioma (HGG)|Heat Shock Protein Peptide Complex-96 (HSPPC-96) therapy will be given between 0-28 days after the completion of radiation therapy (XRT) AND no more than 60 days from completion of XRT. Vaccine will be given once weekly for 4 weeks. The 4 weeks (28 days) of vaccine administration will be followed by an observation visit. In patients with sufficient vaccine (on both Arms A and B), a maintenance therapy will be instituted. It will be administered at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be administered 7 days after completion of the observation visit.
2526124|NCT02722512|Experimental|Recurrent HGG and Ependymoma|On Arm B, Heat Shock Protein Peptide Complex-96 (HSPPC-96) will be given as soon as possible after tumor resection post-operative recovery and sufficient time for vaccine preparation (typically 0-28 days post-operatively) AND no more than 60 days post-operatively. Vaccine will be given once weekly for 4 weeks. These 4 weeks (28 days) of vaccines will be followed by an observation visit. In patients with sufficient vaccine, a maintenance therapy will be given. It will be given at the same dose the patient was enrolled at and given every 2 weeks until vaccine is exhausted or there is evidence of tumor progression. The first dose of maintenance vaccine should be given 7 days after completion of the observation visit.
2526304|NCT02721329|Active Comparator|APAP without SensAwake|Auto CPAP delivered from the ICON+ CPAP device.
2526305|NCT02721329|Experimental|APAP with SensAwake|Auto CPAP with SensAwake turned on and set at a pressure of 4cmH2O. SensAwake is a pressure relief function that reduces the CPAP pressure on the transition from sleep to wake.
2526331|NCT02721043|Experimental|Personalized Genome Vaccine 001|"PGV-001 (peptides + Poly-ICLC)~Peptides: 100mcg per peptide per dose.~Poly-ICLC (Hiltonol®, Oncovir): 1.4mg (0.7mL, 2mg/mL)"
2526388|NCT02720874|Experimental|Intervention Arm|In the multifaceted intervention, participants will first receive an educational session with monthly follow-up phone calls from a trained rheumatology nurse. A rheumatoid arthritis educational booklet will also be provided. During regularly scheduled clinic appointments (at baseline, 3 months, 6 months, 9 months, and 12 months), participants will receive multidisciplinary rheumatologic care, including evaluation by a rheumatologist, physical therapist and psychologist. In addition, participants will be scheduled for ad hoc rheumatology appointments if technology-based symptom monitoring and reporting indicates a marked increase in RA disease activity.
2526428|NCT02720653||Appropriate Medical Therapy|Patients will self-select continued, non-standardized, appropriate medical management of symptoms associated with chronic sinusitis.
3166397|NCT00524784|Experimental|A|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses
2526274|NCT02721628|Experimental|Epi-keratoplasty Group|Epi-keratoplasty Group: Reversible keratoplasty performed with only the removal of corneal epithelium of the host cornea. A donor graft is transplanted on the recipients' eye locating on the Bowman's layer.
2526277|NCT02721628|Active Comparator|Collagen Cross-Linking Group|Collagen Cross-Linking: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
2526409|NCT02720744|Experimental|Sodium Oxybate|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g sodium oxybate, 6.0 g sodium oxybate, 7.5 g sodium oxybate, and 9.0 g sodium oxybate.
2526411|NCT02720744|Placebo Comparator|Placebo|Patients will undergo a screening period and will then be titrated to the following once-nightly doses: 4.5 g placebo, 6.0 g placebo, 7.5 g placebo, and 9.0 g placebo.
3166398|NCT00524797|Active Comparator|Main|50 patients will receive Profonycia 5 gr/day PO for 7 days
3166399|NCT00524810|Experimental|Caelyx - Taxotere|
3166400|NCT00524823||1|10 diagnosed men in age 60 - 90 with Prostate Cancer
3166401|NCT00524823||2|10 patients with benign growth
3166402|NCT00524823||3|10 health volunteers
3166403|NCT00524823||4|10 patients diagnosed with other cancer
3166404|NCT00524849|Active Comparator|conventional Zometa|Zometa 4mg IV q4w, in combination with other antitumor agents one month after the initial dosing.
3166405|NCT00524849|Experimental|weekly Zometa|Weekly Zometa in combination with other antitumor agents one month after the initial dosing.
3166406|NCT00524862|Other|1|
3166407|NCT00524862|Other|2|
3166408|NCT00524875|Experimental|1|Intravitreal bevacizumab injection 1-2 weeks before surgery
3166409|NCT00524875|Sham Comparator|2|Sham injection (needleless syringe pressed against conjunctiva)
3166410|NCT00524888|Active Comparator|1|suturing lacerations of the hand
3166411|NCT00524888|Active Comparator|2|using bioadhesive on lacerations of hand
3166412|NCT00524901|Experimental|1|25 patients undergoing CABG for three vessel disease, receiving a single dose of erythropoietin periprocedural.
3166413|NCT00524901|Placebo Comparator|2|25 patients undergoing CABG for three vessel disease, receiving placebo (NaCl 0.9%) periprocedural.
3166414|NCT00524914|Experimental|1|Apomorphine
3166415|NCT00524914|Placebo Comparator|2|Placebo
2526627|NCT02719483|Active Comparator|rESWT + traditional conservative therapy|Radial extracorporeal shock wave therapy (rESWT) performed with the Swiss DolorClast device (EMS Electro Medical Systems, Nyon, Switzerland) plus traditional conservative therapy.
2526628|NCT02719483|Other|Traditional conservative therapy|Traditional conservative therapy alone.
2526703|NCT02718820|Experimental|Docetaxel plus pembrolizumab|Docetaxel 75mg/m2 plus pembrolizumab 200mg will be administered every 3 weeks intravenously for 6 cycles. Thereafter pembrolizumab 200mg every 3 weeks will be given as maintenance therapy until progression.
2526888|NCT02717676|No Intervention|Group B|no episiotomy
3166416|NCT00524927|Active Comparator|A|
3166417|NCT00524927|Placebo Comparator|B|
3166418|NCT00524953|Experimental|I|10 patients after allogeneic BMT (non T-depleted).
3166419|NCT00524979||Schizophrenia|People who are diagnosed as schizophrenic by DSM-IV
3166420|NCT00524979||Mental diseases|Patients who are deagnosed as having mental disease other then schizophrenia
3166421|NCT00524979||Mentally healthy|People who have no mental disease
3166422|NCT00525005|Experimental|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
3166423|NCT00525096|Placebo Comparator|Placebo|Aromasin + placebo in place of Celebrex
3166424|NCT00525096|Experimental|Celebrex|Aromasin + Celebrex
3166425|NCT00525109||1|Single family cohort
3166426|NCT00525122||1|Patients with hyperthyroidism who are will be treated with radioactive iodine.
3166427|NCT00525200|Active Comparator|A|
3166428|NCT00525200|Experimental|B|
3166429|NCT00525213|Active Comparator|A|
3166430|NCT00525213|Active Comparator|B|
3166431|NCT00525213|Active Comparator|C|
3166432|NCT00525213|Placebo Comparator|D|
3166433|NCT00525226||1|Women who have experienced symptoms of depression or anxiety during pregnancy.
3166434|NCT00525239|Experimental|1: Ritonaivr|Pre and post ritonavir, lopinavir/ritonavir or atazanavir/ritonavir
3166435|NCT00525252|Placebo Comparator|2|A total of 42 alcoholic patients with liver cirrhosis treated with placebo
3166436|NCT00525252|Active Comparator|1|a total of 42 alcoholic patients with liver cirrhosis treated by baclofen
3166437|NCT00525291|Experimental|EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
3166438|NCT00525291|Active Comparator|EMG-biofeedback alone|
3166439|NCT00525304|Experimental|1|Participants will receive a self-management program for chronic illness
3166440|NCT00525304|No Intervention|Usaual Care|Usual Care; no additional intervention
3166441|NCT00525317|Active Comparator|Magnesium tablet suplementation (1)|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"
3166442|NCT00525317|Placebo Comparator|Placebo tablet suplementation (2)|Placebo (3 times daily for 2 weeks)
3166443|NCT00525330|Experimental|KRP-104 120 mg QD|
3166444|NCT00525330|Experimental|KRP-104 60 mg BID|
3166445|NCT00525330|Placebo Comparator|Placebo|
3166446|NCT00525356|Active Comparator|1|Anti-hypertensive medical treatment
3166447|NCT00525395|Experimental|A|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
3166448|NCT00525395|Active Comparator|B|Group B: 6 months non-stop treatment.
3166449|NCT00525408|Experimental|2|Docetaxel+Mw
3166450|NCT00525408|Active Comparator|1|Docetaxel
3166451|NCT00525434|Experimental|A|
3166452|NCT00525447|Experimental|1|
3166453|NCT00525486|Experimental|A|The treated group of pregnant women, after having successful treatment for PTL
2525845|NCT02724319||Left heart catheterization patients|Patients presenting to the UF Health Jacksonville cardiac catheterization laboratory for left heart catheterization for suspected coronary artery disease and intent to undergo percutaneous coronary intervention will be targeted for enrollment and will be genotyped by SpartanRX
2525889|NCT02724098|Active Comparator|intravenous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.
2525896|NCT02724098|Active Comparator|subcutaneous|1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.
2525970|NCT02723799|Experimental|Hope Promotion Program (HPP)|Plus to the standard treatment protocol, all the participants in this group attend the HPP, consisting of a three individual session's carried out by the nurse in patients' homes. It includes viewing the film Hopeful Living, enrolling in a hope activity from the Hope activity book, a relaxation activity and a negotiated plan to exercise hope in a regular basis.
2525977|NCT02723799|Other|Standard Treatment Protocol|Participants in this group has not access to a hope intervention. Data collection for outcome variables is the same as the participants in the other arms.
2526009|NCT02723279|Experimental|EPNS group|
2526015|NCT02723279|Active Comparator|TT group|
3166454|NCT00525486|No Intervention|B|The no treatment arm of women treated with tocolysis for PTL.
3166455|NCT00525551|Active Comparator|1|
3166456|NCT00525551|Placebo Comparator|2|
2526212|NCT02722122|Experimental|AIR DNase™ 2.5 mg|2.5 mg of AIR DNase™ administered once daily via inhalation for 28 days
3166457|NCT00525564|Placebo Comparator|A|Placebo diskus
3166458|NCT00525564|Active Comparator|B|Salmeterol diskus powder
2526381|NCT02720926|Experimental|TKI258 combined with Xeloda/Oxaliplatin|TKI258 200 mg once a day (OD) 5 days on/2 days off Capecitabine (Xeloda) 2000 mg/m2 bid d1-14 Oxaliplatin 130mg/m2 d1 q21days
2526541|NCT02719951|Experimental|autistic patients|[18F]FPEB PET imaging MRI (Magnetic Resonance Imaging) Biological samples
2526543|NCT02719951|Experimental|FXS patients|[18F]FPEB PET imaging MRI Biological samples
2526545|NCT02719951|Experimental|Healthy subjects|[18F]FPEB PET imaging MRI Biological samples
2526564|NCT02719678|Experimental|Intervention group|Invitation to up to three general health checks over a 10-year period
2526566|NCT02719678|No Intervention|Control group|Control group
2526601|NCT02719496|Experimental|IBEROGAST|Dose of 20 drops three times a day for 28 days, on constipation parkinsonian patients with disorders intestinal transit.
2526674|NCT02719210|Experimental|High Volume Plasma Exchange with Standard Treatment|
2526675|NCT02719210|Active Comparator|Standard Treatment|"Standard Treatment is defined as anti raised Intra-cranial pressure~Elective positive pressure ventilation in hepatic encephalopathy grade 3 or 4 and in those with features of raised ICP (Intra-cranial pressure).~Mannitol~Hypertonic 3% Saline"
2526730|NCT02718781|Experimental|Talk and leaders|This group will comprise of health talk and regular contact with community leaders.
2526735|NCT02718781|Experimental|Talk, leaders and equipment|This group will comprise of health talk and regular contact with community leaders. Moreover, a home-based equipment (handgrip) will be delivered to them
2526738|NCT02718781|Active Comparator|Talk|This group will comprise of a health talk only.
2526794|NCT02718261|Experimental|Verum (pantoprazole)|
2526796|NCT02718261|Placebo Comparator|Placebo|0.9% saline
2526839|NCT02717923|Experimental|Maintenance Treatment|A single arm of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil based standard chemotherapy plus cetuximab.
2526865|NCT02717728|Active Comparator|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter placement Drug: Local anesthetic bolus :Ropivacaine 0.2% 0.5 ml/kg total in divided doses~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug:Infusion: Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
2526866|NCT02717728|Sham Comparator|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement (20 g catheter tip laid at appropriate insertion site)~Device: Dressing: Catheter labeled: Fascia Iliaca Catheter~Drug: Infusion: Ropivacaine 0.1% to plastic bag. rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
2526901|NCT02717429|Experimental|Mindfulness Meditation Training (MMT)|Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration. The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness. In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
2526904|NCT02717429|Active Comparator|Computerized Cognitive Training|The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group. Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
3166459|NCT00525577|Experimental|1:A|Placebo
3166460|NCT00525577|Experimental|2:B|AGI-1067 75 mg
3166461|NCT00525577|Experimental|3:C|AGI-1067 150 mg
3166462|NCT00525616|Experimental|Rituximab|Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .
3166463|NCT00525642|Experimental|A|six cycles of adjuvant TAC
3166464|NCT00525642|Experimental|B|four cycles of T followed by 4 cycles of AC
3166465|NCT00525655|Experimental|Multimedia Intervention|
3166466|NCT00525668|Active Comparator|verum|Sunphenon plus glatiramer acetate
3166467|NCT00525668|Active Comparator|placebo|placebo plus glatiramer acetate
3166468|NCT00525681|Other|CsA|Investigation of systemic exposure of cyclosporine before and after 2 moths of co-adminiastration of rimonabant.
3166469|NCT00525681|Other|Tac|Investigation of systemic exposure of tacrolimus before and after 2 moths of co-adminiastration of rimonabant.
3166470|NCT00525694|Other|1|glucose tolerance test solution
3166471|NCT00525694|Other|2|Diet Coke
3166472|NCT00525694|Other|3.|Coke Zero
2525848|NCT02724306|Experimental|Active Lifestyle Programme|ALP will receive supervised exercise sessions twice per week for three months and once per week for the following three months. Participants will also take part in biweekly physical activity workshops for the period of the intervention. Each session consists of a warm-up (5-10min), aerobic (20-30min) and resistance exercises (15-20), and cool-down (5-10)stretches lasting in total 60min. The intensity of exercises will be at 65-85% of maximum heart rate as determined by maximal fitness test. Exercise will take place in small groups of two to five people. Behaviour change workshops to aid the uptake and maintenance of physical activity will be delivered every fortnight throughout the whole intervention period totalling 12 workshops. Workshops will also take place in small groups.
2525849|NCT02724306|No Intervention|Standard Care|The standard care group will not be offered the intervention until the end of the study at 12 months. Participants in this group will be encouraged to continue with their usual lifestyle.
2525906|NCT02724059|Experimental|Patients with mediastinal lesions|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA
2525975|NCT02723812|Experimental|GCFLU® Influenza vaccine (Split virion, Inactivated)|One dose 0.5 mL vaccine GCFLU® administered intramuscularly.
3199811|NCT00884078|No Intervention|2 Control group|"Patients who will be randomized to the treatment as usual arm will receive routine care. In most cases this consists of an assessment by a casualty doctor or a junior psychiatrist in the emergency department, on the basis of which about one third patients are referred for follow up as a psychiatry outpatient, a small number are referred to addiction services, and the remainder are advised to consult their own general practitioner (Kapur 1998) this is particularly so in case of Asian females (Cooper et al, 2006). No patients are routinely referred to psychotherapy or psychology services. Participants will receive an initial assessment along with treatment as usual (TAU) as ascertained by the general practitioner or mental health professional any type of treatment apart from C-MAPS will be permitted. We will record the degree of patient adherence to standard care."
3199812|NCT00884091||Healthy Adults|"Chinese in origin~Healthy~No medication at least two weeks before the study"
2526128|NCT02722655||Type 1 diabetes mellitus|Sudden onset of symptoms and non-overweight/obese
2526136|NCT02722655||Type 2 diabetes mellitus|Insidious onset of symptoms and overweight/obese
2526145|NCT02722655||Type 1.5 diabetes mellitus|Overlap of type 1 and type2 diabetes mellitus clinical characteristics
2526149|NCT02722655||Other types of diabetes mellitus|According American Diabetes Association criteria
3199813|NCT00884104|Experimental|1.tamsulosin + solifenacin|
3199814|NCT00884130||Laparoscopic|Patients having a laparoscopic colorectal resection
2526285|NCT02721589|Experimental|Injection SHR-1210|200mg/vial
3199815|NCT00884130||Open|Patients having an open colorectal resection
2526474|NCT02720289|Experimental|Video-based social learning|Video-based social learning class
2526475|NCT02720289|Active Comparator|Traditional didactic|Traditional didactic class
2526511|NCT02720003|Experimental|LTX DCB|Patients treated with Bard Lutonix DCB
2526571|NCT02719704|Experimental|"MEXA-SE"|Intervention on physical fitness, eating habits and body image
2526575|NCT02719704|No Intervention|Control|School of the control group carried out one semester with the regular and traditional activities. The control school had three physical educations lessons per week, similar of experimental schools.
2526580|NCT02719704|Experimental|"Espelho, espelho meu"|School-based intervention on body image
2526648|NCT02719379|Experimental|Asthmatics|19-20 year old asthmatics who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. They will also be follow up after 1 year to assess for asthma control and outcomes. This arm will additionally allow for comparison of asthma outcomes and vaccine response
2526657|NCT02719379|Active Comparator|Non-asthmatics|19-20 year old non-asthmatic smokers who agree to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. Those who agree to receive the vaccine will have a second draw for serum 4-6 weeks post vaccination for immunization response. This arm will allow for comparison of vaccine response between asthmatics and non-asthmatics (smokers)
2526662|NCT02719379|Other|Asthmatics - Serum Stored|Once the accrual for the experimental arm is met, 19-20 year old asthmatics who wish to participate in study will have serum collected for analysis. PPSV23 vaccine [Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)] will be offered per the ACIP/CDC guidelines. This arm will allow for study of baseline vaccine titers to pneumococcus in asthmatics at same time increase the vaccine uptake in the community.
3199816|NCT00884182|Experimental|Group 1|Participants on vaccination schedule 1 (Day 0 and Day 21)
3199817|NCT00884182|Experimental|Group 2|Participants on vaccination schedule 2 (Day 0 and Day 14)
2526915|NCT02717403|Experimental|Facebook + Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website and the Facebook page on the internet about rheumatoid arthritis. Patients assessed at three and six months after baseline via email self response electronic questionnaires.
2526995|NCT02716857|Experimental|Oxycodone extended-release|Egalet ADER oxycodone tablet
2526996|NCT02716857|Placebo Comparator|Placebo of Oxycodone extended-release|Egalet ADER oxycodone placebo tablet
3199818|NCT00884182|Experimental|Group 3|Participants on vaccination schedule 3 (Day 0 and Day 42)
3199819|NCT00884195|Experimental|1|Gratitude Journaling
3199820|NCT00884195|Placebo Comparator|2|Neutral Journaling
3199821|NCT00884208||Group 1|Recommend assistive device
3199822|NCT00884208||Group 2|Consultation for PT assessment
3199823|NCT00884234|Experimental|1|RT001 (Botulinum Toxin Type A Topical Gel)
3199824|NCT00884234|Placebo Comparator|2|Vehicle Control
3199825|NCT00884260|Experimental|Arm 1|
3199826|NCT00884299|No Intervention|1|Free diet
3166473|NCT00525707|Experimental|1|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
2526016|NCT02723370|Experimental|Initial Intervention|Staff will receive the intervention during the initial intervention period.
2526021|NCT02723370|Experimental|Delayed Intervention|Staff will receive the intervention during the replication study.
2526155|NCT02722447|Active Comparator|Rivaroxaban|Rivaroxaban 20 mg od for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks and 20 mg od for 3 weeks)
2526158|NCT02722447|Experimental|Placebo|Placebo for 6 weeks after an initial course of rivaroxaban for 6 weeks (15 mg bid for 3 weeks followed by 20 mg od for 3 weeks)
2526335|NCT02721290|Active Comparator|Femoral nerve block using Ultrasound and neurostimulator|Femoral block using the standard technique of ultrasound for femoral nerve identification and neurostimulator set at between 0.3-0.5 mA with quads muscle response for needle placement confirmation before injecting 20cc of Ropivacaine 0.5%.
2526340|NCT02721290|Experimental|Femoral nerve block using femoral artery target|Femoral block using the alternate technique of aiming for the inferolateral aspect of the femoral artery and injecting 20cc of Ropivacaine 0.5%.
2526538|NCT02720354|Experimental|A single Intravenous bolus injection|A single Intravenous bolus injection of 11C[DMDPA]
2526581|NCT02719821|Experimental|Intervention|Individuals treated with HSCT will learn behavioral techniques to improve sleep and increase daytime activity with the goal of alleviating insomnia, fatigue, and depression. Study investigators will conduct semi-structured interviews after each session to determine participant satisfaction with and acceptability of the behavioral strategies, timing, delivery mode, assessment strategy, and time commitment. Participants will be asked to complete a daily checklist indicating which intervention strategies they used daily. Participants will be asked to complete self-report assessments, to wear a wrist-worn actigraphy device, and to complete a sleep log at three time points: prior to HSCT and approximately 9 and 18 weeks post-HSCT.
2526614|NCT02719405|Placebo Comparator|Amino Acid Formula|
2526616|NCT02719405|Active Comparator|EHCF|Extensively Hydrolyzed Casein Formula
2526619|NCT02719405|Active Comparator|EHCF + LGG|Extensively Hydrolyzed Casein Formula + Lactobacillus GG
2526679|NCT02719132|Experimental|Arm 1|Arm 1 - therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for 24 weeks (Treatment Regimen 1) followed by metformin monotherapy with dose titrated up to 2,500 mg/day for further 24 weeks (Treatment Regimen 2)
2526681|NCT02719132|Active Comparator|Arm 2|Arm 2 - metformin monotherapy with dose titrated up to 2,500 mg/day for 24 weeks (Treatment Regimen 2) followed by therapy with dapagliflozin 10 mg once daily in combination with metformin ≤ 1,500 mg (daily dose) for further 24 weeks (Treatment Regimen 1)
2526779|NCT02718495|Placebo Comparator|Part A|Part A consists of two treatment groups, SAD and MAD. Both treatment groups will consist of 3 cohorts. In SAD, subjects will receive a single dose of PTI-428 or placebo. In MAD, subjects will receive once daily dosing of PTI-428 or placebo for 7 days.
2526781|NCT02718495|Placebo Comparator|Part B|Part B will consist of 2 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
2526785|NCT02718495|Placebo Comparator|Part C|Part C will consist of 3 cohorts. Subjects will receive once daily dosing of PTI-428 or placebo for 28 days.
2526854|NCT02717858|Experimental|Liraglutide|
2526857|NCT02717858|Placebo Comparator|Placebo|
2526879|NCT02717611|Experimental|ACP-196 (acalabrutinib)|ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
2526932|NCT02717065|Experimental|Characterization, Audiovisual|"Characterization: Tinnitus characterization tools (Minimal Masking Level, Tinnitus Functional Index, Tinnitus Handicap Inventory, and Subjective rating scale) are assessed in an individual over time to determine baseline variability.~Audiovisual: The individual will watch a series of silent videos of a person speaking, both with and without a tone matched to their tinnitus as well as videos of a still face with and without the matched tone."
2526988|NCT02716961|No Intervention|Monotherapy|Barely epirubicin was instilled after TURBT. Epirubicin was immediately instilled in 24h after TURBT. Instillation was conducted regularly for a year: once in a week for 8 times, once in two weeks for 8 times, once in a month for 6 times.
2526990|NCT02716961|Experimental|Combination|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. Intervention: GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
2527014|NCT02716662|Experimental|Open Label|Axona
2527088|NCT02716493|Experimental|Telerehabilitation group|Patients with unresectable thoracic neoplasia receiving chemotherapy treatment
2527143|NCT02715973|Experimental|Nutritional Supplement|"Diet Counseling (Energy=200 kcal/kg/day, (present weight) protein =3-4 gm/kg/day)~Nutritional supplement (Providing extra 40 kcal/kg/day)"
2527144|NCT02715973|Active Comparator|Standard nutritional treatment|"Diet counselling only (Energy=200 kcal/kg/day (present weight) protein =3-4 gm/kg/day).~Standard nutritional treatment"
3166474|NCT00525707|Placebo Comparator|2|
3166475|NCT00525720|Experimental|Brachytherapy - Participants with < 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
3166476|NCT00525720|Experimental|Brachytherapy - Participants with > 35% biopsy core|Brachytherapy implant procedure lasting 1-2 hours. Questionnaires taking 30 total minutes.
3166477|NCT00525746||Cases|Patients with a confirmed diagnosis of AML or MDS (cases).
3166478|NCT00525746||Controls|Patients treated for a primary malignancy (controls).
3166479|NCT00525759|Active Comparator|A|Neoadjuvant chemotherapy alone
3166480|NCT00525759|Experimental|B|Neoadjuvant chemotherapy + zoledronic acid
3166481|NCT00525772|Active Comparator|1|ciclesonide 50 and 200ug
3166482|NCT00525772|Active Comparator|2|ciclesonide 100ug and 400ug
2525929|NCT02724163|Experimental|Gemtuzumab Ozogamicin Dose Finding Study|"Cohort 1: 1x3mg/m2 IV infusion over 2hours on day 4.~Cohort 2: 2x3mg/m2 IV infusion over 2hours on day 4 and day 7.~Cohort 3: 3x3mg/m2 IV infusion over 2hours on days 4, 7 and 10."
2525931|NCT02724163|Active Comparator|High dose cytarabine|Two courses of Cytarabine: 3 g/m2 12 hourly by IV infusion over 4 hours on days 1, 3 and 5 (total 6 doses).
2525934|NCT02724163|Experimental|Fludarabine & cytarabine|"Two courses of:~Fludarabine: 30 mg/m2 daily by IV infusion over 30 minutes on days 1-5 inclusive (total 5 doses).~Cytarabine: 2 g/m2 daily by IV infusion over 4 hours on days 1-5 inclusive (total 5 doses).The cytarabine infusion should be started 4 hours after the start of the fludarabine infusion"
2525936|NCT02724163|Active Comparator|Myeloablative conditioning|"Busulfan Area Under the Curve (AUC) 70-100mg/L x hr by IV infusion over 3 hours, given 12 hourly on days -10 to -7 (8 doses).~Cyclophosphamide 50mg/kg/day by IV infusion over 1 hour, on days -5 to -2 (4 doses)."
2525939|NCT02724163|Experimental|Reduced intensity conditioning|"Busulfan AUC60-65mg/L X hr by IV infusion over 3 hours, given 12 hourly on days -5 to -2 (8 doses).~Fludarabine 30mg/m2/day by IV infusion over 30 minutes on days -8 to -3 (6 doses)."
2526044|NCT02723136|Experimental|Smartphone application|Participants allocated to this arm will receive a smartphone application developed to assist and guide the study of internal medicine and its subspecialties. The application will provide feedback to participants regarding their overall performance in terms of correct answers and the overall time required to solve a clinical vignette.
2526046|NCT02723136|No Intervention|Usual care|Students allocated to this arm will not receive any further assistance in studying for this trial's tests.
2526090|NCT02722902|Experimental|LIPID + Carnitor|"intravenous Lipid infusion (IntraLipid) combined with carnitor (L-carnitine) infusion~L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
2526091|NCT02722902|Placebo Comparator|LIPID + PLAC|"Intravenous Lipid infusion (IntraLipid) combined with placebo infusion (saline)~Intralipid will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 mL/h."
2526092|NCT02722902|Placebo Comparator|PLAC|"Infusion of saline (no IntraLipid and no carnitor)~Saline will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The maximum dosage will not exceed 90 ml/h."
2526122|NCT02722551|Experimental|Treatment|Treatment with the CardiAQ-Edwards™ Transcatheter Mitral Valve (transapical or transseptal delivery)
2526177|NCT02722213|Experimental|Mindfulness-Based Stress Reduction|"The intervention is an 8-week Mindfulness-Based Stress Reduction (MBSR) course, with 8 weekly 2.5-hour group sessions, and 1 all-day (6.5 hours) retreat, taught per standard protocol in a group setting. The course includes instruction and practice of meditation, breathing techniques, gentle yoga and Tai Chi poses, with shared discussion, brief readings and home practice between sessions. Participants will continue with usual care and receive standard educational materials on healthy lifestyles and stress management.~Note: This study will recruit patients eligible for exercise-based cardiac rehabilitation (CR). Randomization to either MBSR or control (no MBSR) condition will occur within two strata (CR; no CR) will occur based on current enrollment in CR at time of study enrollment."
2526183|NCT02722213|No Intervention|Control (No MBSR)|"Those randomized to the control condition will continue with usual care and receive standard educational materials on healthy lifestyles and stress management. At the end of the study control participants will receive a compact disc and workbook on MBSR.~Note: This study will recruit patients who are eligible for traditional exercise-based cardiac rehabilitation (CR). Randomization will be stratified based on whether or not patients are actively enrolled in CR at the time of the study. Within each stratum, participants will be randomized to either the intervention (MBSR) or control (no MBSR) condition."
2526351|NCT02720913|Experimental|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
2526355|NCT02720913|Active Comparator|Standard Suture Tying|Standard Suture Tying
2526427|NCT02720718|Experimental|Stratafix|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using unidirectional barbed (knotless) sutures: Stratafix Unidirectional 2/0."
2526432|NCT02720718|Active Comparator|Vicryl|"Patients undergoing laparoscopic RYGB (antecolic, antegastric, linear anastomosis-technique) using classic sutures: Vicryl 2/0."
3166483|NCT00525811|Experimental|A|Interactive decision aid
2526485|NCT02720016|Experimental|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
2526487|NCT02720016|Active Comparator|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
2526489|NCT02720016|Active Comparator|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
2526671|NCT02719470|Experimental|pathological executive functions|Group 5: patients with pathological executive functions, assessed with FAB (FAB < 13.8) undergoing MIRT
3166484|NCT00525811|Active Comparator|B|Regular patient information
2526052|NCT02723123|Experimental|CPAP|CPAP will be provided for a approximately 45 minutes.
2526053|NCT02723123|Experimental|NIPPV|NIPPV will be provided for a approximately 45 minutes.
2526054|NCT02723123|Experimental|NIV-NAVA|NIV-NAVA will be provided for a approximately 45 minutes.
2526109|NCT02722811|Experimental|Etanercept treatment group|Subcutaneous injection etanercept of 50 mg/w and Health education, exercise and diet guidance; treatment: 8 weeks
2526110|NCT02722811|Placebo Comparator|Routine care group|Health education, exercise and diet guidance; treatment: 8 weeks
2526115|NCT02722486|Active Comparator|Standard Vestibular Rehabilitation|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions of an hour each). During these sessions, standard balance training exercises will be done at the discretion of the physical therapists.
2526117|NCT02722486|Experimental|Vestibular Rehabilitation/Balance Belt|Subjects will undergo weekly vestibular rehabilitation sessions for 3 months (a total of 12 sessions). They will undergo standard balance training exercises with the physical therapists like the control group, but will also undergo an additional 15 minutes of Balance Belt exercises during each session.
2526161|NCT02722369|Active Comparator|Control Arm|"IV carboplatin AUC5 (area under curve) on Day1~IV etoposide 120mg/m2 Day 1, followed by oral etoposide 100mg BD (twice daily) on Day 2 and Day 3"
2526163|NCT02722369|Experimental|Investigational Arm|"IV gemcitabine 1200mg/m2 on Day 1 and Day 8~IV carboplatin AUC5 on Day 1~Oral HCQ will be taken at a dose of 400mg BD from day 1 of cycle 1 (maximum of 30 months)"
2526250|NCT02721706|Experimental|CIPA screening tool|Patients are evaluated by CIPA nutritional screening tool
2526254|NCT02721706|No Intervention|usual hospital clinical care|Patients are not subject of CIPA screening tool, and continue the usual hospital clinical care
2526298|NCT02721472|Other|sickle cell disease patients|Sickle cell disease patients included in the study and Plasma DNA levels will be analyzed and compared in patients with a reactive hyperaemia index (RHI) < 1.67 (endothelial dysfunction) assessed by Endo-PAT 2000 versus those recorded in patients with a RHI ≥ 1.67 (no endothelial dysfunction).
2526508|NCT02720276|Experimental|Training after acute stroke|Intervention: Outdoor walking and strength training.
2526573|NCT02719860|Experimental|Green tea|
2526576|NCT02719860|Experimental|Black tea|
2526582|NCT02719860|Placebo Comparator|Placebo tea|
2526629|NCT02719392|Active Comparator|Minocycline|Patients in the minocycline group will take 1 minocycline (100mg) and 2 NAC placebo capsules in the morning and 1 minocycline (100mg) and 2 NAC placebo capsules in the evening for a total of 6 capsules per day over the course of the study.
2526630|NCT02719392|Active Comparator|N-acetylcysteine|Patients in the NAC group will take 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the morning and 2 NAC (500mg) capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
2526632|NCT02719392|Active Comparator|Minocycline + N-acetylcysteine|Patients in the minocycline NAC combination group will take 2 NAC (500mg) and 1 minocycline (100mg) capsule in the morning and 2 NAC (500mg) and 1 minocycline (100mg) capsule in the evening for a total of 6 capsules per day over the course of the study.
2526633|NCT02719392|Placebo Comparator|Placebo Control|Patients in the placebo control group will take 2 NAC placebo capsules and 1 minocycline placebo capsule in the morning and 2 NAC placebo capsules and 1 minocycline placebo capsule in the evening for a total of 6 capsules per day over the course of the study.
2526707|NCT02719015|Experimental|rAd.CD40L + Pembrolizumab|"The dose escalation phase will include rAd.CD40L dose escalation and increase in the number of injected sites/lesions. Once patients tolerate dose level 1 (1 injection site and 1x1011vp-MTD) in Dose Escalation cohort, Expansion cohort will open with same maximum number of injection sites at maximum tolerated dose from Dose Escalation cohort.~All participants receive same dosage of Pembrolizumab in both phases."
2526766|NCT02718521|Experimental|Hydration Therapy Combined With Isosorbide Dinitrate|Intravenous Infusion of Isosorbide Dinitrate 2mg/h combined with normal saline 1 ml/kg·h 6 hours before angiography and 12 hours after angiography
2526769|NCT02718521|Active Comparator|Conventional hydration group|normal saline 0.5 ml/kg·h 6 hours before angiography and 12 hours after angiography
2526818|NCT02717975|Active Comparator|Without valve|"Trial removal of catheter without catheter valve in patients with urinary retention. These are those patients who have catheter on free drainage, attend the clinic for catheter removal and bladder to be filled naturally ( which may take upto 4-5 hours). After removal of catheter they will be asked to drink plenty of fluids while waiting for the bladder to fill up.~This is the traditional method of catheter removal."
2526820|NCT02717975|Experimental|With valve|"Trial removal of catheter in patients with urinary retention with closed catheter valve. These patients will be asked to close the valve 3-4 hours before attending the clinic prior to catheter removal. Here the intervention is catheter valve that allows bladder to be comfortably full by the time patient arrives in the clinic. By this intervention the investigators hypothesise that the investigators can save the clinic time as the patient will not need to wait for natural bladder filling which generally takes 4-5 hours.~Intervention: Urinary catheter valve"
2527010|NCT02716935|No Intervention|non intervention group|This group will not be supplemented
2527035|NCT02716545|Experimental|Endoscopic Intervention Group|Endoscopic therapy
3166485|NCT00525850|Other|1|high saturated fat diet
3166486|NCT00525850|Other|2|low calorie low saturated fat low trans fat high fiber diet
3166487|NCT00525889|Experimental|Rapamycin/IL-2 combination therapy|IL-2 (Proleukin) was administered at 4.5 3 106 IU s.c., three times per week for 4 weeks for a total of 12 doses. Rapamycin (Rapamune or Sirolimus) was administered without a loading dose at 2 mg/day, with adjustments to maintain trough blood levels of 5-10 ng/mL for 3 months.
3166488|NCT00525967|Active Comparator|1|Methadone plus Placebo
3166489|NCT00525967|Experimental|2|Methadone plus Acetaminophen
3166490|NCT00525980|Experimental|Group 1: Written Materials|One group asked to read educational materials.
3166491|NCT00525980|Experimental|Group 2: Computer Program Only|Group 2 use an educational computer program to learn about breast cancer risk and genetic testing without guidance.
3166492|NCT00525980|Experimental|Group 3: Computer Program + Promotora|Group 3 use the computer program with the guidance of a promotora.
3166493|NCT00525993|Experimental|A|
3166494|NCT00525993|Active Comparator|B|
2525978|NCT02723552|Experimental|Exercise|Exercise group participants will undergo 16 weeks of 3x/week supervised aerobic exercise of at least 40 minutes per session. After the supervised exercise phase, they will be monitored and supported to maintain an increased physical activity level for eight months.
2526012|NCT02723266|Experimental|Intervention|Treatment receives the STOPPING-GDM intervention. Control does not receive the intervention.
2526017|NCT02723266|No Intervention|Control|Control does not receive the intervention.
2526078|NCT02723058|Experimental|ICMHM|ICMHM mothers receive services of a primary care clinician (PCP) and a care manager both trained in depression care management in a shelter-based primary care clinic.
2526081|NCT02723058|No Intervention|Treatment as Usual|Treatment as Usual mothers receive usual services of a PCP and case manager from a shelter-based primary care clinic. .
2526138|NCT02722720|Experimental|Carotid stenting, Transradial approach|Internal carotid artery stenting using transradial arterial approach
2526143|NCT02722720|Active Comparator|Carotid stenting, Transfemoral approach|Internal carotid artery stenting using transfemoral arterial approach
3199827|NCT00884299|Experimental|Diet rich in antioxidants|Diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients in this arm will be seen regularly in the outpatient clinic where there will be informed for the potential beneficial effects of fruits and vegetables in health status by two members of the study team (attending physician and specialist nurse). At baseline and at each visit it is clearly explained to them that the dietary goal is to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the 3-year study period.
3199828|NCT00884338|Experimental|Exercise|
3199829|NCT00884338|Active Comparator|Control group|
2526366|NCT02720887||pregnant woman|Patient to receive an amniocentesis for medical reasons other than study and who will have a measure of nanoparticles load
2526436|NCT02720614|Experimental|Hypofractionated radiation/chemotherapy|"Hypofractionated radiation：Patients receive accelerated hypofractionated radiation: three-dimensional conformal radiation therapy (3-DCRT) with a total dose of 69 Gy, delivered at 3 Gy per fraction, once daily, five fractions per week, completed within 4.6 weeks.~Chemotherapy: Regimen 1 is as follows: vinorelbine (NVB) was administered by intravenous infusion at a dose of 25 mg/m2 on day 1 (d1) and day 8 (d8), and carboplatin (CBP) is administered at a concentration-time curve (AUC) of 5 mg/ml on d8. This treatment was repeated every 28 days. One cycle of chemotherapy is performed concurrently with the radiotherapy.~Chemotherapy: Regimen 2 is as follows: paclitaxel at 30 mg/m2 and cisplatin at 20 mg/m2 (TP) are administrated every week for 5 weeks continuously."
3199830|NCT00884364|Active Comparator|Control|
2526694|NCT02719093|Experimental|recombinant FSH|recombinant FSH 150UI daily
2526745|NCT02718703|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
2526828|NCT02718079|Experimental|Standard medical therapy with Plasma Exchange|Plasma Exchange will be performed for consecutive days. Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
2526835|NCT02718079|Active Comparator|Standard medical therapy alone|Standard medical therapy included as per requirement,management of cerebral edema/intracranial hypertension: transfer to ICU,prophylactic antibiotics, intubation of trachea (as required),administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure,volume replacement and pressor support (norepinephrine, vasopressin) as needed, NAC, correction of metabolic parameters and nutrition.
2527018|NCT02716883|No Intervention|Non AMT|"Freshly prepared fortified eye drops (cefazolin 50 mg/mL and amikacin 14 mg/mL) were applied as starting treatment. In the first 3 days, eye drops are applied round the clock followed by drops every 2 h during waking hours until results of laboratory investigation were available.~After preparation of the culture results, the antimicrobial treatment was narrowed according to bacterial sensitivity. Also topical betamethasone 0.1% four times a day on a tapering weekly dosage until 3-4 weeks is used for all patients. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented"
2527020|NCT02716883|Active Comparator|AMT|"This group (case group) received above mentioned routine antibiotic therapy followed by double-layer amniotic membrane transplantation 2-5 days after the start of medications and the second group (control group) only received routine antibacterial therapy.~The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. If the patient underwent any tectonic procedure during the treatment such as keratoplasty, cyanoacrylate glue are documented."
2527053|NCT02716467|Experimental|intercessory prayer group|Patients in the experimental group receive prayer of intercession during radiotherapy treatment.
2527056|NCT02716467|Active Comparator|Radiotherapy Treatment|Patients in the radiotherapy group not receive prayer of intercession during radiotherapy treatment.
2527095|NCT02716246|Experimental|Cohort 1 Low Dose|Dose of 0.5 X 10^13 vg/kg
2527102|NCT02716246|Experimental|Cohort 2 Mid Dose|Dose of 1 X 10^13 vg/kg
2527112|NCT02716246|Experimental|Cohort 3 High Dose|Dose of 3 X 10^13 vg/kg
3199831|NCT00884364|Experimental|Exercise|
3199832|NCT00884416|Experimental|Sorafenib dose titration|
3199833|NCT00884429|Active Comparator|1- Conventional Chest Physiotherapy|Percussion , thorax compression and Postural Drainage/suction if necessary
3199834|NCT00884429|Active Comparator|2- Chest physiotherapy- Actual techniques|slow prolonged expiration and clearance rhinopharynx and suction if necessary
3199835|NCT00884429|Active Comparator|3- Airway Suction|Suction superior airways. Only in admission.
3199836|NCT00884442|Active Comparator|1|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fasted state
2526111|NCT02722473|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5°C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5°C for 24 hours.
2526112|NCT02722473|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5°C for 48 hours
2526165|NCT02722343|Experimental|Tenofovir intravaginal ring|The tenofovir intravaginal ring (TFV IVR) is 55.0 mm in diameter, consisting of a single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. The IVR delivers 8-10mg/day of TFV.
2526167|NCT02722343|Active Comparator|Truvada oral tablets|"The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg). The tablets are commercially available as Truvada. The tablets are blue, capsule-shaped, film-coated, debossed with GILEAD on one side and with 701 on the other side"
2526220|NCT02721992||Graves' Disease|Patients with Graves' disease, without Graves' Orbitopathy
2526223|NCT02721992||Graves' Orbitopathy|Patients with Graves' disease, with Graves' Orbitopathy
2526291|NCT02721667|No Intervention|Enhanced Usual Care|"Participants receive a home BP monitor, are taught how to measure home BP and are encouraged to take BP readings to appointments with their providers. In addition, they will be reminded to perform a home BP series each quarter for study outcome purposes, which will encourage self-monitoring.~Home BP readings will be teletransmitted for data collection purposes but neither participants nor providers will have access to the these readings. High BP levels that trigger safety alerts to research personnel are the only exception - participants and their primary care providers will be made aware of these."
2526292|NCT02721667|Active Comparator|Telemonitoring and Case Management|"Home BP series mean, trends and individual readings will be generated for use by the case manager. Participants in this arm will each be assigned a pharmacist case manager who holds full prescribing privileges and who will:~Administer health behaviour modification counselling, teach BP self-monitoring, and monitor medication adherence;~Review telemonitored health portal BP summaries and make medication regimen adjustments according to guideline-concordant study protocol;~Fax a summary of these adjustments to the participant's primary care provider (to make them aware of treatment changes); and~Facilitate communication between participants and providers."
2526324|NCT02721199||Prospective Cohort|Neural Respiratory Drive Automated EMGpara assessment
2526363|NCT02720991|Experimental|Mifepristone and sublingual misoprostol|200 mg mifepristone and 400 ug sublingual misoprostol
2526447|NCT02720588||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV criteria
2526449|NCT02720588||Sibling group|Sex-matched unaffected siblings of ASD probands
2526450|NCT02720588||TD group|Typically developing controls without lifetime ASD or a family history of ASD
2526537|NCT02720172|Experimental|Early Home Exercise Program|The early home exercise program is an exercise-based self-management program for patients immediately after cervical spine surgery.
2526540|NCT02720172|Other|Usual Care|Usual postoperative care.
2526568|NCT02719730|Experimental|Reimbursement arm|Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
2526569|NCT02719730|No Intervention|Control arm|Participating caregivers will mail in receipts from grocery store purchases. Participants in the control arm will also be given the same guidance about preferred whole grain foods and whole grain products but will have no specific financial incentive related to purchases of whole grain foods during the 12-week study period.
2526692|NCT02719054|Experimental|stimulation|Cognitive behavioral therapy for mother and play stimulation for children aged 6 to 12 months
2526693|NCT02719054|No Intervention|Mother child dyad|
2526733|NCT02718716|Experimental|UCB7665 dose 1|Subjects in this Arm will receive 5 subcutaneous (sc) doses of UCB7665 at 1-week intervals
2526737|NCT02718716|Experimental|UCB7665 dose 2|Subjects in this Arm will receive 3 subcutaneous (sc) doses of UCB7665 dose 2 at 1-week intervals
2526741|NCT02718716|Experimental|UCB7665 dose 3|Subjects in this Arm will receive 2 subcutaneous (sc) doses of UCB7665 dose 3 at 1-week intervals
2526742|NCT02718716|Experimental|UCB7665 dose 4|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 4
2526744|NCT02718716|Experimental|UCB7665 dose 5|Subjects in this Arm will receive 1 subcutaneous (sc) dose of UCB7665 dose 5
3199837|NCT00884442|Active Comparator|2|One tablet of Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL, fed state
3199838|NCT00884442|Active Comparator|3|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fasted state
2526877|NCT02717442|Experimental|OTO-104|12 mg dexamethasone
2526883|NCT02717442|Placebo Comparator|Placebo|
2526942|NCT02717351|Experimental|BAY 987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2527007|NCT02716935|Experimental|Fortified lipid based nutrient supplement|lipid based nutrient supplement (Nutributter) fortified with fructo-oligosaccharides and inulin
2527008|NCT02716935|Active Comparator|lipid based nutrient supplement|lipid based nutrient supplement (Nutributter)
2527083|NCT02716311|Other|Afatinib|Afatinib 40 mg/d until progression
3199839|NCT00884442|Active Comparator|4|One tablet of Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS, fed state
3199840|NCT00884468||1|Patients with PsA that fulfill the eligibility criteria of the study
3199841|NCT00884481||Natalizumab|Participants with MS treated with Tysabri over 12 months
3199842|NCT00884494|Experimental|Roux-en-Y gastric bypass|
3199843|NCT00884494|Experimental|Lean|
3199844|NCT00884507|Placebo Comparator|Placebo|
3199845|NCT00884507|Experimental|RO5313534 15mg|
2525994|NCT02723448|Other|Single Arm Study|Aclarubicin (6 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days (Days 2-5) of each 28 day cycle to each participant [Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL) patients]. There is no maximum number of cycles.
3199846|NCT00884507|Experimental|RO5313534 1mg|
3199847|NCT00884507|Experimental|RO5313534 5mg|
3199848|NCT00884520|Experimental|VM4-037|Approximately sixteen (16) adult subjects including four (4) healthy volunteers and twelve (12) cancer subjects who have confirmed or highly suspected diagnosis of head & neck, lung, large solitary hepatic and renal cell cancer, as defined by protocol criteria
2526204|NCT02722018|Experimental|Part 1: GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of three Phase III prototype tablets (Prototype 1, 2 or 3) in a crossover fashion.
2526208|NCT02722018|Experimental|Part 2 (Optional): GDC-0810 dose level A - Low Fat Meal|Participants will receive a single dose of GDC-0810 dose level A on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal in the form of Phase II tablet or one of two Phase III prototype tablets (Prototype 4 or 5) in a crossover fashion.
2526209|NCT02722018|Experimental|Part 3: GDC-0810 dose level B - Low Fat Meal/Fasted|Participants will receive a single dose of GDC-0810 dose level B on Day 1 of each treatment period. GDC-0810 will be administered with low fat meal or under fasted condition either as Phase II tablet (with low fat meal) or as the Phase III prototype tablet selected from Parts 1 or 2 (with low fat meal or under fasted conditions), in a crossover fashion.
2526268|NCT02721693|Experimental|Treadmill exercise test|Patients are subjected to an incremental Cardiopulmonary Exercise Test to exhaustion
2526314|NCT02721394|Experimental|Researcher Implemented FCT|Children receive functional communication training. Assessment and initial intervention sessions are completed by the researcher and family carers are trained to continue the intervention at home.
2526318|NCT02721394|Experimental|Family Carer Implemented FCT 1|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher in person.
2526321|NCT02721394|Experimental|Family Carer Implemented FCT 2|Children receive functional communication training. Family carers are trained to implement all sessions (including assessment and initial intervention sessions) with coaching from the researcher via videoconferencing and support from a family carer assistant in person.
2526415|NCT02720861||non embolic ischemic stroke|acute ischemic stroke from atherosclerosis or lacunar stroke
2526457|NCT02720380|Experimental|Buteyko|Children in the intervention group will perform 6 sessions (twice a week) of treatment with the Buteyko Method.
2526459|NCT02720380|Active Comparator|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
2526492|NCT02720120|Experimental|Part 1: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
2526496|NCT02720120|Experimental|Part 1: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
2526500|NCT02720120|Experimental|Part 1: Ocrelizumab 2000 mg|Participants will receive single IV infusion of ocrelizumab 2000 mg.
2526509|NCT02720120|Experimental|Part 1: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)
2526518|NCT02720120|Placebo Comparator|Part 1: Placebo|Participants will receive single IV infusion of placebo matched to ocrelizumab.
2526521|NCT02720120|Experimental|Part 2: Ocrelizumab 1000 mg|Participants will receive single IV infusion of ocrelizumab 1000 mg.
2526524|NCT02720120|Experimental|Part 2: Ocrelizumab 1500 mg|Participants will receive single IV infusion of ocrelizumab 1500 mg.
2526528|NCT02720120|Experimental|Part 2: Ocrelizumab 400 mg|Participants will receive single IV infusion of ocrelizumab 400 mg.
2526599|NCT02719574|Experimental|PH1 Dose Escalation & Expansion FT-2102 (olutasidenib)|
2526600|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Azacitidine|
2526602|NCT02719574|Experimental|PH1 Esc. and Exp. FT-2102 (olutasidenib)+Cytarabine|
2526604|NCT02719574|Experimental|PH2 Cohort 1 FT-2102 (olutasidenib) Single Agent|Relapsed or Refractory (R/R) AML
2526608|NCT02719574|Experimental|PH2 Cohort 2 FT-2102 (olutasidenib) Single Agent|AML in morphologic complete remission or complete remission with incomplete blood count recovery (CR/CRi) after prior therapy with residual IDH1-R132 mutation
2526610|NCT02719574|Experimental|PH2 Cohort 3 FT-2102 (olutasidenib) Single Agent|R/R AML/MDS, previously treated with FT-2102
2526611|NCT02719574|Experimental|PH2 Cohort 4 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that are naïve to prior hypomethylating therapy and IDH1 inhibitor therapy
2526612|NCT02719574|Experimental|PH2 Cohort 5 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have inadequately responded to or have progressed on prior hypomethylating therapy
2526613|NCT02719574|Experimental|PH2 Cohort 6 FT-2102 (olutasidenib)+Azacitidine|R/R AML/MDS that have been previously treated with single-agent FT-2102 as their last therapy prior to study enrollment
2526615|NCT02719574|Experimental|PH2 Cohort 7 FT-2102 (olutasidenib) Single Agent|Treatment naïve AML for whom standard treatments are contraindicated
2526617|NCT02719574|Experimental|PH2 Cohort 8 FT-2102 (olutasidenib)+Azacitidine|Treatment naïve AML who are candidates for azacitidine first line treatment
3199849|NCT00884533|Experimental|Group 1|Group 1 - placebo on Day -1, rosi XR 8mg from Days 1-20, rosi XR 20mg on Day 21
3199850|NCT00884533|Placebo Comparator|Group 3|Placebo on Day -1, Days 1-20 and Day 21
3199851|NCT00884533|Active Comparator|Group 2|Placebo for Day -1, placebo on Days 1-20 and moxifloxacin active comparator 400 mg on Day 21
2526939|NCT02717091|Experimental|FOLFIRINOX|4 course of FILFIRINOX before surgery
2526946|NCT02717091|Experimental|GEM + nab-PTX|2 course of GEM + nab-PTX before surgery
3199852|NCT00884546|Experimental|Arm 1|BMS-833923 (Starting dose is a loading dose of 60 mg for 7 days with a 30 mg daily dose thereafter)
3199853|NCT00884546|Active Comparator|Arm 2|"BMS-833923 (MTD or below)~Lenalidomide (at or below the recommended prescribing dose)~Dexamethasone (40 mg)"
3199854|NCT00884546|Active Comparator|Arm 3|"BMS-833923 (MTD or below)~Bortezomib (at or below the recommended prescribing dose)"
3199855|NCT00884559|Active Comparator|Technical|Technical Instructions
3199856|NCT00884559|Experimental|Leadership|Leadership-Instructions
3199857|NCT00884624||A|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3199858|NCT00884637||CNV subjects|
2526102|NCT02722798|Experimental|KRN23|Subjects will receive subcutaneous injections of KRN23 every 4 weeks from Week 0 through Week 44
2526148|NCT02722603|Experimental|gabapentin / placebo tramadol|gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
2526152|NCT02722603|Active Comparator|tramadol / placebo gabapentin|tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.
2526189|NCT02722083|Experimental|BAY X002134|Subjects will be given BAY X002134
2526190|NCT02722083|Placebo Comparator|Placebo|Subjects will be given a placebo
2526236|NCT02721823|Experimental|lifestyle-modification|Once a week for 10 weeks with a circumference of 60 hours with mindfulness-based stress reduction and further process of the Mind / body medicine.
2526242|NCT02721823|Active Comparator|control group|A unique education unit within the scope of 3 hours on the influence of lifestyle factors on the disease and self-help materials for the independent training.
2526320|NCT02721550|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-4 Cisplatin:20 mg/m²,d1,week 1-4 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T40Gy/20f,week 1-4"
2526361|NCT02720978|Experimental|Intravenous oxytocin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group Intravenous oxytocin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
2526362|NCT02720978|Experimental|vaginal prostaglandin|"Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.~Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:~Verification rupture of membranes and gestational age.~Choosing the treatment group vaginal prostaglandin from red envelope, randomly.~Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way.~Data collecting after the delivery."
3199859|NCT00884663|Experimental|1 Candesartan|
2526497|NCT02720094|Experimental|Arm A|In Step 1, participants will receive daily oral CAB and daily oral TDF/FTC placebo for 5 weeks. In Step 2, participants will receive CAB LA and daily oral TDF/FTC placebo to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
2526502|NCT02720094|Experimental|Arm B|In Step 1, participants will receive daily oral TDF/FTC and daily oral CAB placebo for 5 weeks. In Step 2, participants will receive daily oral TDF/FTC and placebo for CAB LA to Week 153. In Step 3, participants will receive daily oral TDF/FTC starting at Week 153 and for 48 weeks.
2526804|NCT02718222|Experimental|3-9 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 3 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 9 months. Post-partum IUD intervention begins after 9 months and continues for 9 months."
2526806|NCT02718222|Experimental|9-15 months PPIUD intervention|"Tanzania: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 9 months.~Nepal and Sri Lanka: Baseline (no intervention) period is 3 months. Post-partum IUD intervention begins after 3 months and continues for 15 months."
2526847|NCT02717871|Experimental|Treatment (PACK-CXL)|Photoactivated chromophore for infectious keratitis-corneal cross-linking (PACK-CXL)
2526852|NCT02717871|Active Comparator|Antimicrobial therapy|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml).~OR~1b. a Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)~2. Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.~3. Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium"
2526930|NCT02717364||Population With Yervoy Exposure|Population With Yervoy Exposure
2526987|NCT02716974|Experimental|chemohormonal and definitive therapy|(1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation (Leuprolide Acetate) and up to 6 cycles of chemotherapy (Docetaxel), (2nd) definitive local tumor control with prostatectomy +/- adjuvant radiation therapy, and (3rd) consolidative stereotactic radiation to oligometastatic lesions. The men will receive a total of 1 year of androgen deprivation. Androgen blockade (Bicalutamide) will be the same throughout the course of treatment.
3199860|NCT00884663|Active Comparator|2 propranolol|
3199861|NCT00884663|Placebo Comparator|3 Placebo|
3199862|NCT00884676|Experimental|Schedule A|Schedule A: Ixabepilone - Weekly for 3 weeks each cycle (Days 1, 8 and 15) For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1
2526025|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for R-PDAC|Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
2526027|NCT02723331|Experimental|Nab-paclitaxel/Gemcitabine for BR-PDAC|Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
2526083|NCT02722850|Experimental|ALIVE - Physical Activity|PA CONDITION: The goal of the PA condition is to encourage participants to gradually increase moderate to vigorous PA to 150 minutes per week and to increase resistance training to a total of 15 minutes per day twice per week.
2526086|NCT02722850|Experimental|ALIVE - Dietary Modification|DIET CONDITION: The goal of the dietary condition includes increasing intake of fruit and vegetable to 5-servings per day. The program also encourages participants to increase the consumption of colorful fruits and vegetables. The fat goals consist of reducing saturated fats to <10% of total kilocalories per day, trans fats to <3 grams per day, and added sugar to <50 grams per day.
2526125|NCT02722616|Active Comparator|Pancreatic Cancer|"A 4D ultrasound scan of the pancreas will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor pancreas motion. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
2526127|NCT02722616|Active Comparator|Liver Cancer|"A 4D ultrasound scan of the liver will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery.~On each treatment day, 4D ultrasound images will be acquired continuously during beam on time to monitor liver motion. The system will record all relevant images, but will not be used in clinical decision making. Intra-fraction CBCT images acquired during treatment will be registered with reference CT images. Organ motion registered by ultrasound will be compared to motion recorded by CBCT and the accuracy of the ultrasound system will be evaluated."
2526131|NCT02722616|Other|Healthy Volunteer|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images. Additional registration of ultrasound images will be performed with Velocity software to evaluate accuracy of automated registration software in the ultrasound system.
2526199|NCT02722135|Experimental|Volasertib|
2526293|NCT02721342||Ramipril, Irbesartan and Atorvastin treatment|A multidrug approach, including Angiotensin II Converting Enzyme (ACE) inhibitor, Ramipril, and Angiotensin II Receptor Blocker (ARB), Irbesartan, and Atorvastin will be done. Treatment doses of drugs will be up-titrated gradually considering the tolerability.
2526350|NCT02721108|Experimental|Mindfulness: Group A|Using a 60-day mindfulness instruction meditation app: 60 days of 10 and 20 minute long app modules with a spoken guide to mindfulness meditation, to be used once a day, including modules on the basics of mindfulness and a module targeted to pain, which can re-revisited until the end of the study
2526353|NCT02721108|Active Comparator|Relaxation: Group B|Using comparison relaxation app with a series of non-meditative progressive muscle relaxation instructions: 60 days of 10 and 20 minute long app modules to be used once per day with spoken words and relaxing sounds, which can re-revisited until the end of the study
2526356|NCT02721108|No Intervention|Treatment as usual: Group C|No app: treatment as usual (watch and wait, medication and/or surgery) to investigate if any app intervention makes a difference to wellbeing and to ascertain dropout rates for the full-scale trial in patients who perceive that they are getting no intervention.
2526400|NCT02720679||Study Participants|Participants will be (1) individuals with a non-malignant hematologic disorder confirmed or suspected to have a genetic basis, and (2) affected and unaffected family members of those individuals who are willing to provide clinical data and undergo genetic testing.
2526418|NCT02720471|Active Comparator|Locoregional anesthesia|Classical locoregional analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh will be performed in patients of this arm
2526422|NCT02720471|Experimental|Peroperative infiltration|Peroperative infiltration of local anesthetics (IAL) will be performed in patients of this arm
2526477|NCT02720328|Other|DOAC-treated patients|Concerning patients taking DOACs, blood samples are drawn to evaluate DOAC plasma concentration. One EDTA tube is also drawn to extract DNA and determine the genetic profile of genes involved in the metabolism of DOACs. The aim will be to assess if genetic determinants can explain the observed interindividual variability in plasma concentrations.
3199863|NCT00884676|Experimental|Schedule B|Ixabepilone - Day 1 of each 3-week cycle For both Schedules A and B, Sunitinib daily, orally, starting on Day 8 of Cycle 1.
3199864|NCT00884689||1|Asthma patient with specific treatment
3199865|NCT00884689||2|Asthma patient on different specific treatment compared to the other group
2526698|NCT02718859|Active Comparator|irreversible electroporation (IRE)|Advanced pancreatic cancer patients received only irreversible electroporation (IRE) without immunotherapy
2527032|NCT02716610|Experimental|INH 69 U (low)|single 69 U dose administration of Dance inhaled human insulin using a low-concentration formulation (300 U/mL)
3199866|NCT00884715|Experimental|1 implant|117 mg Octreotide implant
3199867|NCT00884715|Experimental|2 implants|234 mg Octreotide implant
2526033|NCT02723292|Experimental|Experimental group services|This study will replicate the evidence-based TOP™ in after-school sessions held during RC hours. The primary components of TOP™ include: Comprehensive age-appropriate sexuality education; 90-minute sessions, once a week after-school, during the school year for nine months, using the Changing Scenes© curriculum, and at least twenty hours of youth-led service learning, which involves youth in planning, implementing and reflecting on, community service and leadership.
2526038|NCT02723292|Active Comparator|Control group services|Youth in the control arm will receive a work readiness training curriculum focused on competencies to secure employment. This will include such topics as building customer service skills, clear and direct communication, and creating a work portfolio.
2526067|NCT02722993|Active Comparator|Probiotics|
2526071|NCT02722993|Placebo Comparator|Placebo|
2526119|NCT02722746|Placebo Comparator|Ropivacaine only Control group|The participants in this group will receive standard anesthesia, epidural analgesia with 0.2% ropivacaine with no epinephrine added during the procedure.
2526120|NCT02722746|Active Comparator|Ropivacaine + 2 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 2mcg/mL of epinephrine during the procedure.
2526121|NCT02722746|Active Comparator|Ropivacaine + 5 mcg/mL epinephrine|The participants in this group will receive standard anesthesia (Ropivacaine 0.2%) with the addition of 5mcg/mL of epinephrine during the procedure.
3173938|NCT00617656|Experimental|B3|Intermediate or high RAP expression and high BRCA1 expression: Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
2526273|NCT02721446|Other|VHA Cohort|Investigators will use Veteran Health Administration (VHA) electronic health record (EHR) data to construct patient-level Framingham stroke risk scores using previously validated methodology. Investigators will establish a cohort of live patients with at least one primary care visit 12 months prior to study initiation (Oct 1, 2015). Investigators will obtain EHR data for Framingham measurements of age, sex, systolic blood pressure (SBP), blood pressure treatment (yes/no), total cholesterol, high-density lipoprotein cholesterol, and smoking status in the prior 12 month period. SBP will be obtained from outpatient primary care visits only; if > 1 SBP is available the investigators will use the average of the last 2 outpatient SBPs prior to study initiation.
2526275|NCT02721446|Other|Eskenazi Health System Cohort|Investigators will use EHR data from Indiana Network for Patient Care (INPC) to identify a cohort of live patients with at least one primary care visit in the prior 12 months. Investigators will use identical methods to construct Framingham risk score variables from the EHR data.
2526341|NCT02721212|Experimental|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
2526342|NCT02721212|Active Comparator|Control Group|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
2526384|NCT02720770|Experimental|norditropine simplex|
2526665|NCT02719236|Active Comparator|Direct anterior approach|Primary total hip arthroplasty using a direct anterior approach
2526666|NCT02719236|Active Comparator|Direct lateral approach|Primary total hip arthroplasty using a direct lateral approach
2526695|NCT02718846|Experimental|Meniace and Isobide|co-administration Isobide solution and Meniace tablets
2526697|NCT02718846|Active Comparator|Meniace|single administration Meniace tablets
2526728|NCT02718677||1. Refacto AF (NIS)|Non-Interventional Study
2526778|NCT02718391|Experimental|Arm A: Autologous Dendritic Cell vaccine|Daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days starting from the second day after each vaccine dose. Vaccine doses will be given intradermally in two sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis.The first dose (WK1) will consist of freshly prepared vaccine, whereas for all the further doses cryopreserved aliquots will be utilized. The remaining 5 doses will be administered every 4 weeks to complete six months of therapy (six vaccines).
2526782|NCT02718391|No Intervention|Arm B: follow up|Arm B: Patients will undergo laboratory and clinical assessment, tumor re-staging, blood collection for immunological biomarkers every 12 weeks until relapse.
2526827|NCT02718053||spasticity|patients affected by spasticity of the lower limbs
2526829|NCT02718053||controls|healthy subjects
2526886|NCT02717676|Experimental|Group A|Episiotomy
3173939|NCT00617682|Active Comparator|Group 1|Group 1 (experimental)
3173940|NCT00617682|Placebo Comparator|Group 2|Group 2 (placebo comparator)
3173941|NCT00617695|Experimental|1|
3173942|NCT00617695|Placebo Comparator|2|
3173943|NCT00617721||1|patients with unexplained bleeding disorder
3173944|NCT00617721||2|healthy volunteers
3173945|NCT00617747|Experimental|1|
3173946|NCT00617747|Placebo Comparator|2|
3173947|NCT00617760|Experimental|1|Concomitant administration of MenC-TT vaccine and PCV7, 170 subjects
3173948|NCT00617760|Active Comparator|2|PCV7 administration only, 85 subjects
3173949|NCT00617760|Active Comparator|3|MenC-TT vaccine only, 85 subjects
3173950|NCT00617812|Experimental|Shan5|
3173951|NCT00617838|Active Comparator|1|Optimization of gluten introduction by nutritional councelling
3173952|NCT00617838|No Intervention|2|No specific nutritional councelling. Follow-up of gluten introduction
3173953|NCT00617864|Experimental|1|Group will receive infusion of human albumin
3173954|NCT00617864|Placebo Comparator|2|Group will receive infusion of saline
3173955|NCT00617877|Experimental|1|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day in case of BP more than 140/90 mm Hg. HCTZ 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
3199868|NCT00884728||Indigenous children aged <15 years|Indigenous children aged <15 years within participating communities of the Northern Territory
2526107|NCT02722785|No Intervention|Usual Care Observation Group|Patients allocated to usual care control will receive the standard patient care program as provided by the department of surgical gastroenterology, Rigshospitalet
2526108|NCT02722785|Experimental|Aerobic and Resistance Exercise Training|Patients allocated to this group will receive usual care plus a supervised aerobic and resistance exercise program at CFAS' facilities consisting of 2 weekly sessions of approximately 60 minutes.
2526114|NCT02722538|Experimental|Residual Tumor following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
2526116|NCT02722538|Experimental|No Residual Tumor Following TURBT|TAR-200 is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 7. TAR-200 releases gemcitabine gradually during the 7 day indwelling time. A second TAR-200 is placed in the bladder on Study Day 21 and is removed on Study Day 28, which is the day of the Radical Cystectomy (RC).
2526164|NCT02722356|Experimental|Oxytocin|Oxytocin administered according to proposed protocol
2526166|NCT02722356|Active Comparator|Standard Practice|Oxytocin administered according to standard practice at facility
2526200|NCT02722005|Experimental|Financial Coaching & Access to Services|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
2526203|NCT02722005|Active Comparator|Access to Services|Participants will have access to a host of referrals to social services (this is the intervention for this group)
2526253|NCT02721719||Healthy Adults|[Not receiving Vedolizumab] Healthy adults who have not donated blood within the past two months and who have no history of blood-borne diseases.
2526258|NCT02721719||Adults with no Inflammatory Bowl Disease|[Not receiving Vedolizumab] Adult patients undergoing endoscopy for indications other than Inflammatory Bowel Disease or other inflammatory conditions of the bowel (such as colon cancer screening or polypectomy)
2526262|NCT02721719||Donors with Ulcerative Colitis|[Set to receive Vedolizumab] Adults with an established diagnosis of UC (≥ 6 months preceding involvement in study) who are both scheduled for an endoscopy and are about to receive Vedolizumab treatment (standard of care).
2526276|NCT02721420|Other|Drug + short message(SMS) reminder|dihydroartemesinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with SMS reminders prior to each treatment course
2526280|NCT02721420|Other|Drug + no short message(SMS) reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) without SMS reminders prior to each treatment course.
2526283|NCT02721420|Other|Drug+ Health worker reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) with Health surveillance assistants reminders prior to each treatment course.
2526286|NCT02721420|Other|Drug at hospital + SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department without an SMS reminders prior to each treatment course.
2526288|NCT02721420|Other|Drug at Hospital+no SMS reminder|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrolment) collected at the outpatient department with a short message reminder prior to each treatment course
2526359|NCT02721160|Experimental|Nutrition PBF|45 health centres are assigned to this group. The intervention consists in a performance based financing scheme applied to nutrition services.
2526360|NCT02721160|No Intervention|Control|45 health centres are in the control group. Health centres in this group are not incentivized, but they receive an equivalent funding to the one received by the intervention group. The main difference is that this payment is not based on their own performance.
2526410|NCT02720666|Experimental|Group A:K-001 2700mg/d (1350mg BID)|K-001 1350mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2526412|NCT02720666|Experimental|Group B: K-001 3240mg/d (1620mg BID)|K-001 1620mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2526413|NCT02720666|Experimental|Group C: K-001 3780mg/d (1890mg BID)|K-001 1890mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2526414|NCT02720666|Experimental|Group D: K-001 4320mg/d (2160mg BID)|K-001 2160mg twice a day, to be taken with warm water on an empty stomach; 4 weeks' administration for each group.
2526455|NCT02720393|Placebo Comparator|Regular diet|Meals and snacks will contain carrageenan in the amount consumed in the typical daily diet and will be selected by the study dietician and distributed to study subjects randomized to the regular diet study arm.
2526458|NCT02720393|Experimental|No-carrageenan diet|No-carrageenan diet will be composed of meals and snacks selected by the study dietician and distributed to study participants who are randomized to the no-carrageenan diet study arm.
3199869|NCT00884780||Pediatric Pain|Children between the ages of 8 and 17 experiencing pain.
2526603|NCT02719548|Experimental|Breastshield treatment group A|"Participants will be treated with the following three breast shields:~Soft edge oval - Hard oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2526605|NCT02719548|Experimental|Breastshield treatment group B|"Participants will be treated with the following three breast shields:~Modified PF breast shield - Soft edge oval - Hard oval Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2526606|NCT02719548|Experimental|Breastshield treatment group C|"Participants will be treated with the following three breast shields:~Hard oval - Soft edge oval - Modified PF breast shield Treatment order is described in the corresponding Intervention. Participant will use each breastshield for 2 min after milk ejection."
2526641|NCT02719145||Control group (group 1)|10 healthy volunteer subjects.
2526654|NCT02719145||Asthma group (group 2)|10 asthmatic patients.
2526660|NCT02719145||COPD group (group 3)|10 COPD patients.
2526846|NCT02717988|Experimental|SKI-O-703 100 mg|SKI-O-703 capsule (4x25 mg)
3199870|NCT00884819|Experimental|1|fenofibrate 200mg/daily for 6 months
2526159|NCT02722421|Experimental|Efavirenz group|HIV-infected women receiving efavirenz-based antiretroviral therapy plus increased dose levonorgestrel subdermal implants.
2526202|NCT02722057||Cohort 1 - Interventional|The Interventional cohort will not be utilized.
2526206|NCT02722057||Cohort 2 - Non Interventional|A Non-Interventional Cohort comprising pediatric (<18 years of age) and adult R117H-CFTR patients treated with commercially-available Kalydeco.
2526207|NCT02722057||Cohort 3 - Historical|A Historical Cohort comprising data from an earlier time period for pediatric (<18 years of age) and adult patients with the R117H-CFTR mutation who have never been exposed to Kalydeco and matched on age, gender, and lung function to patients in the Non-Interventional Cohort.
2526267|NCT02721784|Other|Pre- and Post- Radiotherapy MRI|"mpMRI/VERDICT sequences to be preformed pre- and post- EBRT (external beam radiotherapy) according to the following schedule:~Pre-Androgen Deprivation Therapy 3 weeks before radiotherapy 6 week after starting radiotherapy 6 Months after starting radiotherapy~External Beam Radiotherapy to be given after 3 months of androgen deprivation"
2526296|NCT02721368|Experimental|Investigational medical device|Neuramis® Volume Lidocaine
2526299|NCT02721368|Active Comparator|Comparator medical device|Juvederm® Voluma® with Lidocaine
2526347|NCT02721134|Other|additional blood tubes|
2526421|NCT02720562||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
2526423|NCT02720562||TD group|Typically development controls without lifetime diagnosis with ADHD
2526510|NCT02720341|Experimental|ARMin|Therapy on ARMin robotic device
2526774|NCT02718508|No Intervention|Standard Care|All enrolled adolescents will continue to receive standard trauma center care, a brief intervention during their hospitalization by a trauma center social worker which is required by institutional policy.
2526775|NCT02718508|Experimental|Standard Care plus e-Parenting Group|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
3166495|NCT00526019||Complete remission of their asthma|Subjects in complete remission of their asthma Subjects in complete remission of their asthma: absence of respiratory symptoms, no rescue asthma medication need and an optimal pulmonary function and normal PC20 methacholine (>16 mg/ml) for more than two years (with no current treatment).
3166496|NCT00526019||Symptomatic remission ofasthma|Subjects in symptomatic remission of their asthma (No asthma symptoms in the last 2 years, no asthma medication, PC20 methacholine <16 mg/ml)
2526931|NCT02717052|Experimental|(S)-ketamine|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)~all patients and 10 HC (randomized, double blind)~Interventions:~Drug: (S)-ketamine (Main study) Other: Main study: PET1 Other: Main study: PET2"
2526933|NCT02717052|Placebo Comparator|Placebo|"0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)~10 HC (randomized, double blind)~Interventions:~Drug: Placebo Other: Main study: PET1 Other: Main study: PET2"
2526934|NCT02717052|Experimental|(S)-ketamine (Pilot Study II, 5 subj.)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
2526935|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study II, 5 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied over the course of 130 minutes.~Pilot-study II is cross-over design!~Interventions:~Drug: (R,S)-ketamine (Pilot II) Other: PILOT Study II: PET1 Other: PILOT Study II: PET2"
2527037|NCT02716610|Experimental|INH 69 U (high)|single 69 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
3166497|NCT00526019||Current asthma (mild asthma)|Subjects with current asthma (Mild asthma)
3166498|NCT00526019||Healthy controls|Healthy controls
3166499|NCT00526032||Spectroscopic Oblique-Incidence Reflectometry (OIR)|
3166500|NCT00526045|Experimental|Escalation|
3166501|NCT00526045|Experimental|HER2 Positive|
3166502|NCT00526045|Experimental|ER+ breast cancer|
3166503|NCT00526136|Placebo Comparator|1|Placebo (b.i.d.)
3166504|NCT00526136|Experimental|2|Vernakalant (oral), 150 mg (b.i.d.)
3166505|NCT00526136|Experimental|3|Vernakalant (oral), 300 mg (b.i.d.)
3166506|NCT00526136|Experimental|4|Vernakalant (oral), 500 mg (b.i.d.)
3166507|NCT00526201|Experimental|Exercise|Subjects will be randomized to exercise (12 week EnhanceFitness class) or a wait-list control group.
3166508|NCT00526201|Other|Control|Wait-list control group will receive intervention after 12-weeks.
3166509|NCT00526214|No Intervention|1|In the control group, patients will not take the drug. We do not use placebo drugs.
3166510|NCT00526214|Experimental|2|In the intervention group, patients will take celecoxib.
3166511|NCT00526253|Active Comparator|Low Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
3166512|NCT00526253|Active Comparator|High Dose|Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
3166513|NCT00526253|Placebo Comparator|Control|Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
3166514|NCT00526266|Experimental|1|
3166515|NCT00526266|Placebo Comparator|2|
3166516|NCT00526266|No Intervention|3|No Treatment
3166517|NCT00526344||1|Subjects with complete remission of asthma
3166518|NCT00526344||2|Subjects with symptomatic remission of asthma
3166519|NCT00526344||3|Subjects with asthma
3166520|NCT00526344||4|Healthy controls
3166521|NCT00526357|Other|A|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists alone to treat their asthma
3166522|NCT00526357|Other|B|Of the 24 asthmatic subjects, 12 will be enrolled who are taking beta2 agonists and inhaled steroids to treat their asthma
3166523|NCT00526370||A|Women with at least moderate dysplasia in biopsies from cervix uteri
2526198|NCT02722265|Experimental|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
2526247|NCT02721797||Skin|Patients with EDS diagnosis having surgery, have debrided skin retained for this research
2526251|NCT02721797||Tendon|Patients with EDS diagnosis having surgery, have debrided tendon retained for this research
2526257|NCT02721797||Uterine tissue|Patients with EDS diagnosis having surgery, have debrided uterine tissue retained for this research
2526261|NCT02721797||Vaginal tissue|Patients with EDS diagnosis having surgery, have debrided vaginal tissues retained for this research
2526264|NCT02721797||Ligaments|Patients with EDS diagnosis having surgery, have debrided ligaments retained for this research
2526317|NCT02721407|Experimental|Anti-CD22 CAR-T|Administrated with CD22.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2526338|NCT02721069|Experimental|NRL-1|Intranasal dose of NRL-1 will be administered at either 5 mg, 10 mg, 15 mg, or 20 mg based on the subject's body weight.
2526387|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
2526476|NCT02719990|Experimental|Somavaratan in adults with GHD|Cohort 1: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult subjects with GHD irrespective of age and gender
2526478|NCT02719990|Experimental|Somavaratan in women on estrogen|Cohort 2: Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly in adult female subjects with GHD on oral estrogen (regardless of age)
2526549|NCT02719925|Experimental|Mineral water rich in magnesium|- 1,5 L per day of mineral water containing 160 mg/L of magnesium
2526550|NCT02719925|Active Comparator|Water low in magnesium|- 1,5 L per day of mineral water containing 50 mg/L of magnesium
2526558|NCT02719652||symptomatic ICAD|symptomatic intracranial atherosclerosis diseases
2526559|NCT02719652||asymptomatic ICAD|asymptomatic intracranial atherosclerosis diseases
2526684|NCT02719067||ASD group|Subjects have a clinical diagnosis of autistic disorder or Asperger disorder defined by the DSM-IV and ICD-10 criteria
2526686|NCT02719067||TD group|Typically developing controls without lifetime ASD or a family history of ASD
2526726|NCT02718807||Post-partum Women|Post-partum women following an atraumatic pregnancy.
2526732|NCT02718807||Co-Parents|Co-parents to post-partum women following an atraumatic pregnancy.
2526759|NCT02718365|Experimental|Group A|Wedge resection
2526762|NCT02718365|Active Comparator|Group B|Segmentectomy
2526833|NCT02718092|Active Comparator|Plastic Stent|Three 7 Fr OR two 10 Fr Plastic Stents will be used
2526841|NCT02718092|Active Comparator|Axios FCSEMS|15 mm Axios Fully Covered Self Expanding Metal Stent
2526867|NCT02717702||ACS Patients|Subjects will be patients presenting to the Emergency Department for evaluation of ACS.
2526894|NCT02717481||Patients with known aortic aneurysm|"Patients with known abdominal aortic aneurysm diagnosed in clinical follow-up or after an invasive procedure to repair it.~US-CT Fusion examination"
2526951|NCT02717260|Sham Comparator|Sham transcranial noise stimulation|subjects are stimulated 3 times with sham transcranial random noise stimulation (tRNS) (Starstim) with a 30 seconds offset
2526962|NCT02717260|Active Comparator|1 Active transcranial random noise stimulation|subjects are stimulated 1 time with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes and 2 times with sham tRNS
2526964|NCT02717260|Active Comparator|3 Active transcranial random noise stimulation|subjects are stimulated 3 times with active transcranial random noise stimulation (tRNS) (Starstim) at 2mA with a oscillatory frequency between 100 and 500 Hz during 20 minutes
2527133|NCT02716038|Experimental|MPDL3280A, Carboplatin, Nab-paclitaxel|"Subjects with advanced or recurrent cancers receiving:~MPDL3280A every 21 days for up to 84 days~Carboplatin every 21 days for up to 84 days~Nab-paclitaxel every 7 days for up to 84 days"
2527369|NCT02714543|Experimental|aloevera group|aloevera juice twice daily for 3 months. aloevera gel one scoop to be applied 3-4 times daily for 3 months
2527371|NCT02714543|Active Comparator|steroid group|intralesional injection of hydrocortisone 100mg and injection hyaluronic acid 1500IU once a week for 6 weeks with Capsules SM Fibro once daily for 3 months.
3166524|NCT00526370||B|Women with only normal PAP-smears
3166525|NCT00526383|Experimental|A|antidepressant versus medical dispositive
3166526|NCT00526383|Placebo Comparator|B|
3166527|NCT00526396|Active Comparator|A|standard fixed doses
3166528|NCT00526396|Experimental|B|toxicity adjusted dosing
3166529|NCT00526435|Experimental|Group WWE|Subjects will participate in a group-assisted 6 week WWE program.
3166530|NCT00526435|Experimental|Self-directed|Subjects will follow the self-directed WWE program.
3166531|NCT00526448|Experimental|1|Peginterferon alfa-2a 180 mcg/week + ribavirin 2000 mg/day + epoetin beta 450 UI/week
3166532|NCT00526448|Active Comparator|2|Peginterferon alfa-2a 180 mcg/week + ribavirin 1000-1200 mg/day
3166533|NCT00526461|Experimental|PDT using HPPH|Patients receive HPPH IV over 1 hour on day 1. Patients then receive photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
3166534|NCT00526487|Other|1|Endovascular Repair
3166535|NCT00526500|Experimental|P-T|
3166536|NCT00526500|Experimental|P- SAH|
3166537|NCT00526500|Experimental|P- A|
3166538|NCT00526500|Experimental|Control|
3166539|NCT00526565|Experimental|1|TAT (Tapas Acupressure Technique)
3166540|NCT00526565|Active Comparator|2|SS (Professionally facilitated social support groups)
3166541|NCT00526578||Questionnaire|Pancreatic cancer patients or family member.
3166542|NCT00526604|Active Comparator|2|The control group will have an clinical examination and exercise and then return to general practitioner, which will take decision about sick leave or return to work.
3166543|NCT00526617|Experimental|Open Label|Within each dose level, subjects are treated with the same regimen/doses of ABT-888 and TMZ.
3166544|NCT00526643|Experimental|Arm B|combination chemotherapy
2526135|NCT02722681||Symptomatic spinal lipoma patients|Spinal lipoma patients undergoing surgery due to symptomatic lipoma. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intraoperatively and usually discarded, some will be kept for research.
2526144|NCT02722681||Asymptomatic spinal lipoma patients|Spinal lipoma patients who remain asymptomatic. Routine blood and urine samples will be taken as part of routine clinical care, some will be kept for research.
2526150|NCT02722681||Non-lipoma spinal conditions|Patients undergoing spinal surgery for a non-lipoma related condition. Routine blood and urine samples will be taken pre-operatively, some will be kept aside for research. Cerebrospinal fluid is drained intra-operatively and usually discarded, some will be kept for research.
2526201|NCT02722096|Experimental|Axillary block anesthesia|Axillary brachial plexus block anesthesia (with Ropivacaine and Lidocaine) will be performed by anesthetist 30 to 45 minutes before surgery
2526205|NCT02722096|Active Comparator|Local anesthesia|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
2526248|NCT02721745|Experimental|Natural Fatigue|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526255|NCT02721745|Experimental|tDCS anodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526260|NCT02721745|Experimental|tDCS cathodal|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526263|NCT02721745|Experimental|tDCS sham|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526265|NCT02721745|Experimental|inhibitory TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526266|NCT02721745|Experimental|Sham TMS|Brain activity will be record through EEG (physiological measure),O2 consumption will be record through a metabolic monitor (physiological measure), or eye tracker according to the group.
2526282|NCT02721381|Experimental|Self-Directed Group|Participants assigned to the self-directed group will receive access to the secure, password-protected, ImPACT Online web-based program for four months. The web application contains 12, self-directed lessons, each of which takes approximately 75 minutes to complete. Participants will be encouraged to complete one lesson per week and to practice the intervention techniques with their child between each lesson. Each lesson consists of a Narrated Slideshow with embedded video clips, a Written Manual, a self-check quiz, short interactive exercises, a Homework Plan, and reflection questions. Participants in the self-directed group may contact project staff via phone or email for assistance with technology-related problems (e.g., difficulty with logins, problems playing video). However, they will receive no assistance or support in learning the intervention from project staff outside of the self-directed web-based program.
2526284|NCT02721381|Experimental|Therapist-Assisted Group|"Participants assigned to the therapist-assisted group will be given access to the ImPACT Online web-based program for four months and will be encouraged to work through the program at the same pace as the self-directed group. Participants will also receive 2, 30-minute remote coaching sessions per week (24 total sessions) via video conferencing software by a trained therapist to assist them in learning the intervention. The first coaching session of the week will involve the coach and participant and will be used to help clarify the content of the relevant lesson and help the participant apply the lesson content to their own child. The second coaching session of the week will involve the coach, participant, and child and will be used to provide the participant with live feedback on their use of the intervention techniques as they practice with their child."
2526289|NCT02721381|No Intervention|Web-Based Information Control Group|Participants assigned to the web-based information control group will be given access the Resources page with links to the same ASD information websites, but will not receive access to other aspect of the ImPACT Online program. This condition will be used to control for participant maturation as well as the potentially confounding effect of having access to autism-related information via the internet.
2526322|NCT02721238|Active Comparator|Resuscitation with 30ml/kg plasmalyte|
2526323|NCT02721238|Experimental|Resuscitation with 20% Albumin|
2526337|NCT02721004||Rheumatoid arthritis participants|Rheumatoid arthritis participants receiving tocilizumab intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
2526364|NCT02720848|Experimental|Stiffening wire|A stiffening wire inserted into the instrument channel of the double/single balloon enteroscope will be used.
2526367|NCT02720848|Active Comparator|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
2526438|NCT02720575|Active Comparator|A|50,000 IU of crystalline D2 in 5 capsules.. Vitamin D2 in its natural state consumed orally via capsule
2526441|NCT02720575|Active Comparator|B|50,000 IU of crystalline D3 in 5 capsules.. Vitamin D3 in its natural state consumed orally via capsule
2526444|NCT02720575|Active Comparator|C|50,000 IU of vitamin D2 from vitamin D2 yeast in 5 capsules. Vitamin D generated in yeast. Acts as a comparator to the yeast in bread.
2526446|NCT02720575|Active Comparator|D|50,000 IU of vitamin D2 from yeast cell walls in 5 capsules. Yeast cell walls rich in Vitamin D. Acts as a comparator to the yeast in bread.
2526448|NCT02720575|Experimental|E|50,000 IU of vitamin D2 from 2 slices of bread made from bread. Bread raised with yeast rich in vitamin D. Main experimental arm.
2526451|NCT02720575|Experimental|F|50,000 IU of vitamin D2 from 2 slices of bread. Bread raised with yeast and yeast cell walls rich in vitamin D.
2526504|NCT02720133||Patients with cardiovascular risk factors who fast Ramadan|Stable clinical and biochemical parameters before Ramadan fasting
2526579|NCT02719834||Acetaminophen, then placebo|Participants in this group will receive acetaminophen for the first four weeks, then placebo for the next four weeks.
2526585|NCT02719834||Placebo, then acetaminophen|Participants in this group will receive placebo for the first four weeks, then acetaminophen for the next four weeks.
2526851|NCT02717988|Experimental|SKI-O-703 200 mg|SKI-O-703 capsule (1x200 mg)
2526174|NCT02722226|Experimental|Simulation based sedation learning (Intervention Group)|The program includes online learning. It is followed by development of interactive presentations, based on simulated cases or simulated patients (actors), low fidelity simulation for specific technical skills as well as high fidelity scenarios of complications related to sedation.
2526181|NCT02722226|No Intervention|Control Group|
2526229|NCT02721849|Experimental|adolescent yoga / parent control|The adolescent will receive an 12 week yoga course, while one parent will only answer the questionnaires.
2526232|NCT02721849|Experimental|adolescent waitlist / parent yoga|One parent will participate in an 12 week yoga course, while the adolescent will receive the intervention after the follow-up period.
2526239|NCT02721849|Experimental|adolescent yoga / parent yoga|Both adolescent and parent will participate in an 12 week yoga course at the same time.
2526243|NCT02721849|No Intervention|adolescent waitlist / parent control|The adolescent will receive the intervention after the follow-up period, while one parent will only answer the questionnaires.
2526287|NCT02721537|Active Comparator|Arm A: Healthy Collegiate Athletes|Healthy collegiate athletes will take active Nicotinamide Riboside
2526290|NCT02721537|Placebo Comparator|Arm B: Healthy Collegiate Athletes|Healthy collegiate athletes will take a matching placebo
2526354|NCT02721186|Experimental|MDA with DHAp and SLD Primaquine|MDA will be conducted at two time points with an approximate four-week interval. All consenting and eligible community members will be administered age-appropriate treatment dose of dihydroartemisinin-piperaquine (D-ARTEPP, Guilin Pharmaceutical (Shanghai) Co., Ltd., China) and single low dose (0.25mg/kg) primaquine (Primaquine, Remedica Ltd., Cyprus) in house-to-house campaigns.
2526358|NCT02721186|No Intervention|Control|The control arm (no MDA) will have the standard care offered by the Ministry of Health and Social welfare which applies to both arms. This includes passive case detection of individuals seeking treatment at local health facilities, and universal coverage of long lasting insecticide treated bed nets and indoor residual spraying in the study areas.
2526419|NCT02720640|Experimental|Implant 'on' vs implant 'off'|Intra-individual comparison of implant 'on' vs implant 'off'
2526503|NCT02720250|Experimental|Omega-3|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
2526512|NCT02720250|Experimental|Regular|Intake of 3 regular chicken eggs per day for three weeks.
2526560|NCT02719756|Experimental|Metformin & Dapagliflozin|Metformin stable dose tablets and Dapagliflozin 10 mg tablets by mouths, once daily in morning for 3 months
2526562|NCT02719756|Active Comparator|Metformin up-titration|Metformin tablets up-titration by mouths, for 3 months
3199871|NCT00884819|Placebo Comparator|2|Placebo match for 6 months
3199872|NCT00884845|Experimental|Arm 1|Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib
2526751|NCT02718742|Experimental|Treatment (nab-paclitaxel)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2526832|NCT02718196|Experimental|Application Users|English-speaking parents of children ages 6-24 months who are interested in starting sleep training within the next month.
2526913|NCT02717793|Experimental|isometric muscle strength|"isometric muscle strength was measured with a digital hand-held dynamometer. The digital hand-held dynamometer was held by the therapist against the flexor aspect of the distal forearm of the subject, on the wrist joint. Subject was asked to maintain the position and a break test was done with progressive loading of 5 seconds given by the tester. The peak isometric strength was recorded by a second tester at the end of 5 seconds. A standardised instructions and verbal encouragement was given to the subject for motivation. Subject as well as the tester was blinded to the values recorded on the digital hand-held dynamometer. An average of three measurements (with a rest period of 4 minutes in between each trial session) was recorded for the analysis. After each trial session, the rate of perceived exertion (RPE) was asked to the subject using the 1-10 Borg rating of perceived exertion scale"
2526914|NCT02717793|Experimental|1RM measurement of muscle strength|1RM measurement was done using the Brzycki 1RM prediction equation. In first testing session, subject was instructed to perform a general warm up for 5 minutes. Thereafter, the subject was asked to perform 10 repetitions of the movement using the amount of resistance that the subject felt she will be able to lift for only less than 10 times. The selection of the weight is made based on a list of weights provided (1kg to 10kg). When the subject performed the movement for 10 times or more, then the resistance was increased 1kg at a time, until the subject can perform only 9 or fewer repetitions of the movement correctly throughout the range of motion. A 3 minutes rest period was given to the subject before the new attempt was done with the increased weight. A standardized verbal encouragement was provided for motivation
2526944|NCT02717169|Other|Biometrical Tracker|The participants are equipped with an wrist watch. The activity tracker measures biometrical information like, steps, sleep duration and heart rate.
2527057|NCT02716831|Experimental|Counseling & Acceptance-based Therapy|Nutritional Counseling & Acceptance-based Therapy (N-CAAT) incorporates acceptance-based behavioral strategies and nutritional counseling designed to encourage willingness to tolerate distress and the ability to pursue chosen values in an adaptive manner despite distressing internal experiences. In addition to these skills, a principal focus of the treatment will be on identifying, practicing, and achieving behavioral goals, such as normalization of eating, reduction of maladaptive dietary restraint and restriction, and elimination of compensatory behaviors.
2527058|NCT02716831|Active Comparator|Cognitive Therapy for Eating Disorders|Participants in the Cognitive Behavioral Therapy for Eating Disorders (CBT) condition will receive 20-sessions of standard CBT for eating disorders based on the treatment approach developed by Dr. Christopher Fairburn and published in his book Cognitive Behavioral Therapy and Eating Disorders.
3199873|NCT00884858|Experimental|Maraviroc|Subjects in this group will add Maraviroc to their current HAART.
2527178|NCT02715947|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial.Methotrexate:2.5mg per piece, oral.
3199874|NCT00884858|No Intervention|2|Subjects in this group will continue their current HAART without adding Maraviroc.
3199875|NCT00884871||Laparoscopic adjustable gastric banding|100 obese women undergoing laparoscopic adjustable gastric banding
3199876|NCT00884884|Placebo Comparator|Double Placebo|Placebo, Placebo
3199877|NCT00884884|Experimental|Aripiprazole 15, Placebo|15 mg Aripiprazole, Placebo
2526240|NCT02721901|Active Comparator|Control group|Caretakers of 10 children will be randomized to participate in the control group. Participants assigned to the control group will be able to receive the iEAT treatment after the study ends.
2526272|NCT02721576|Experimental|Sodium Glycididazole|"Sodium Glycididazole：800mg/m2，finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy. Chemotherapy Paclitaxel:45 mg/m²,d1,week 1-6 Cisplatin:20 mg/m²,d1,week 1-6 OR Docetaxel: 75 mg / m², 1 day or divided into D1, D8 days, 21 days / cycle. Cisplatin: 75 mg / m², divided into D1-D3 days or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle.~OR 5-FU: 500 mg / m² / day, divided into D1 ~ D5 for use, 21 days / cycle. Cisplatin: 75 mg / m² / day, divided into D1-D3 day or D1-D5 days, 21 days / cycle. Or nedaplatin: 80 mg / m², 21 days / cycle 3DCRT/IMRT:2.0Gy/f/day,T>40Gy/20f,week 1->5"
2526380|NCT02721264|Experimental|Fecal Microbiota Transplantation (FMT)|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 5 month.
2526382|NCT02721264|Active Comparator|Standard Treatment Care|
2526533|NCT02719964|Experimental|A: UCR Games→SP-Directed Therapy|Participants in Arm A will first participate in Visual Attention Program (UCR Games) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
2526536|NCT02719964|Experimental|B: Lumosity→SP-Directed Therapy|Participants in Arm B will first participate in General Cognitive Rehabilitation Games (Lumosity) followed by Speech Pathologist-Directed Therapy with assessment sessions prior to and following each treatment intervention.
2526539|NCT02719964|Experimental|C: SP-Directed Therapy→UCR Games|Participants in Arm C will first participate in Speech Pathologist-Directed Therapy followed by Visual Attention Program (UCR Games) with assessment sessions prior to and following each treatment intervention.
2526542|NCT02719964|Experimental|D: SP-Directed Therapy→Lumosity|Participants in Arm D will first participate in Speech Pathologist-Directed Therapy followed by General Cognitive Rehabilitation Games (Lumosity) with assessment sessions prior to and following each treatment intervention.
2526584|NCT02719665|Experimental|Phase 1a (OMEGA-SPM-DOSE)|PAD patients and healthy volunteers in study for SPM Emulsion, dose-modality.
2526586|NCT02719665|Active Comparator|SPM - Phase 1b (OMEGA-SPM-DOSE)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
2526590|NCT02719665|Placebo Comparator|Placebo - Phase 1b (OMEGA-SPM-PLACEBO)|PAD and Osteoarthritis (OA) patients using softgel, dose-modality.
2526639|NCT02719288|Experimental|CLARIX® CORD 1K|Applied in addition to standard of care tendon repair surgery.
2526650|NCT02719288|No Intervention|Standard of care tendon repair surgery only|
2526706|NCT02718911|Experimental|LY3022855 + Durvalumab (Dose Escalation)|LY3022855 given intravenously (IV) in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
2526709|NCT02718911|Experimental|LY3022855 + Tremelimumab (Dose Escalation)|LY3022855 given IV in combination with tremelimumab given IV. Treatment may continue until disease progression or discontinuation.
2526712|NCT02718911|Experimental|LY3022855 + Durvalumab (Expansion)|LY3022855 given IV in combination with durvalumab given IV. Treatment may continue until disease progression or discontinuation.
2526763|NCT02718378|Placebo Comparator|No added active|placebo without estetrol
2526767|NCT02718378|Active Comparator|estetrol dose level 1|estetrol given in dose level 1
2526772|NCT02718378|Active Comparator|estetrol dose level 2|estetrol given in dose level 2
2526773|NCT02718378|Active Comparator|estetrol dose level 3|estetrol given in dose level 3
3166545|NCT00526643|Active Comparator|Arm A|monochemotherapy
2526911|NCT02717598|Experimental|CSP|Cold snare polypectomy is an easy-to-apply technique and has been the most popular technique esprcially for small and diminutive polyps. Briefly, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp, until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
2526912|NCT02717598|Experimental|HSP|Hot snare polypectomy, the endoscopist advances the snare sheath, opens the snare and encircles the polyp. The snare is then slowly and progressively closed, with the aim of capturing 1-2 mm of normal tissue around the polyp,then use Electrocoagulation until complete closure is achieved and the polyp is guillotined. The polyp can then be suctioned and retrieved for histologic assessment.
2526929|NCT02717117|Experimental|Feeding|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
2526979|NCT02717000||NASH|
2526983|NCT02717000||No NASH|
2527023|NCT02716740|Experimental|Leucine-enriched amino acid : 2.16g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (2.16g/day)
2527025|NCT02716740|Experimental|Leucine-enriched amino acid : 4g/day|Dietary Supplement: Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week (4g/day).
2527064|NCT02716415|Active Comparator|Calmoseptine Ointment|Calmoseptine Ointment as part of a structured skin care regimen.
2527065|NCT02716415|Active Comparator|Destin Maximum Strength 40% Zinc|Destin Maximum Strength 40% Zinc as part of a structured skin care regimen.
2527135|NCT02716025||Case Group|
2527136|NCT02716025||Control Group|
2527223|NCT02715622||Open Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia open repair surgical procedure
2527231|NCT02715622||Laparoscopic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia laparoscopic repair surgical procedure
2527239|NCT02715622||Robotic Hernia Repair|A minimum of 300 patients will be enrolled in the Incisional and Inguinal Hernia robotic-assisted laparoscopic repair surgical procedure
3166546|NCT00526682|Active Comparator|1|Comparison of actives for synergy
3166547|NCT00526747||Epo-resistant|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are receiving greater than or equal to 100IU/kg/week of epoetin alpha and/or 1mcg/kg/week darbepoetin to obtain target hemoglobin or hematocrit.
3173956|NCT00617955||Surgical|Cardiac surgery patients that received Aprotinin or Amicar
2526300|NCT02721485|Other|Normal Saline|Half of the hospitals will be allocated to start the 90-day test period using Normal Saline administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Ringer's Lactate following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
2526303|NCT02721485|Other|Ringer's Lactate|Half of the hospitals will be allocated to start the 90-day test period using Ringer's Lactate administered as 500 or 1000 ml boluses or infusions as specified by the treating physicians. After a 1 week run out, half of participating hospitals will have up to 2 weeks to switch out stock then will be crossed over to using Normal Saline following a 1 week run in as 500 or 1000 ml boluses or infusions as specified by the treating physicians in for the final 90-day test period.
2526348|NCT02721095|Experimental|0.9%NaCl|KCl plus 0.9%NaCl
2526349|NCT02721095|Active Comparator|0.45%NaCl|KCl plus 0.45%NaCl
2526405|NCT02720705|Active Comparator|DEX I|active comparator receive 0.5µg/kg dexmedetomidine orally half an hour before operation
2526407|NCT02720705|Placebo Comparator|Saline Control|2ml oral 0.9%saline half an hour before operation
2526408|NCT02720705|Active Comparator|DEX II|active comparator receive,1µg/kg dexmedetomidine orally half an hour before operation
2526452|NCT02720406|Active Comparator|Intravenous ketamine0.5mg/kg|intravenous ketamine 0.5 mg/kg given after induction of anesthesia and before surgery.
2526453|NCT02720406|Active Comparator|Nebulized ketamine 1mg/kg|nebulized ketamine group received 1mg/kg ketamine by nebulzation before induction of anesthesia.
2526454|NCT02720406|Active Comparator|Nebulized ketamine 2mg/kg|nebulized ketamine group received 2mg/kg ketamine by nebulzation before induction of anesthesia.
2526456|NCT02720406|Placebo Comparator|control group|control group received placebo nebulization
3199878|NCT00884884|Experimental|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
3199879|NCT00884884|Experimental|Topiramate 100mg, Placebo|Topiramate 100 mg daily plus Placebo daily
2526636|NCT02719249||Men with ESRD on dialysis or transplant|
2526708|NCT02718989|Experimental|10 Kilohertz (KHz)|"Transcutaneous application of 10 Kilohertz (KHz) current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2526710|NCT02718989|Experimental|Transcutaneous Electrical Stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are frequency 100 Hz and pulse width 100 microseconds"
2526716|NCT02718989|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
2526764|NCT02718482|Experimental|Gemcitabine and Docetaxel|Gemcitabine i.v. 900 mg/m2 in 30 min on day 1 and day 8 every 3 weeks Docetaxel i.v. 75 mg/m2 in 60 min on day 8 every 3 weeks
2526770|NCT02718482|Experimental|Ifosfamide|Ifosfamide i.v. 14 g/m2 continous dose for 14 days every 3 weeks
2526842|NCT02717910|Experimental|Health game group|Participants in this arm will receive the health game intervention including both 20 minutes guided training session at school and 2 weeks free usage of the health game during free time.
2526845|NCT02717910|Sham Comparator|Web page group|Participants in this arm will receive the web page intervention including both 20 minutes guided training session at school and 2 weeks free usage of the web page during free time.
2526849|NCT02717910|No Intervention|Group with no intervention|The participants in this arm will receive no intervention.
2526918|NCT02717390|Experimental|Bright By Three (BB3) Intervention|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years
2526921|NCT02717390|Active Comparator|Texts for Child Safety (TCS) Intervention|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
2526981|NCT02717039||Blood Draw|A one time blood draw of 50mL or 15mL will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
3199880|NCT00884884|Experimental|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
3199881|NCT00884884|Experimental|Topiramate 100, Aripiprazole 5|Topiramate 100 daily plus, Aripiprazole 5mg daily
2527107|NCT02716064|Experimental|TAP-CM Intervention|Patients in this arm will be encouraged to complete the Healthy Lifestyle App modules and use McMaster PHR to self manage their chronic disease. Participants will also be completing the health and life goals using the App. The TAPESTRY-CM reports generated will then be reviewed by the clinic huddle teams
2527534|NCT02713399||Rigid Contact Lenses|healthy subjects wearing rigid contact lenses
3199882|NCT00884884|Experimental|Topiramate 200, Aripiprazole 15|Topiramate 200 mg daily plus Aripiprazole 15mg daily
3199883|NCT00884884|Experimental|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily, Aripiprazole 7.5 mg daily
3199884|NCT00884884|Experimental|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
3199885|NCT00884936||Group 1|Young age: 20 to 30 years old
3199886|NCT00884936||Group 2|Middle Age: 38 to 48 years old (pre-menopausal only)
3199887|NCT00884936||Group 3|Elderly Age: 60 to 75 years old (Post-menopausal only)
3199888|NCT00884962|Experimental|PLVR|
3199889|NCT00884988|Active Comparator|Lymphomyosot|homeopathic remedy
2526330|NCT02721056|Experimental|NBTXR3, IL or IA injection +SBRT|"Patients will receive a single intralesional (IL) injection of NBTXR3 at four increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 42% of the baseline tumor volume, activated by SBRT.~Patients with primary and secondary nodular intra hepatic cancers only will receive a single superselective transcatheter arterial (IA) injection of NBTXR3 at five increasing dose levels (Volume levels) equivalent to: 10%, 15%, 22%, 33% and 45% of the baseline tumor volume, activated by SBRT."
2526402|NCT02720900|Placebo Comparator|Maltodextrin|powder, 1.8g/day
2526403|NCT02720900|Active Comparator|B-GOS|powder, 1.8g/day
3166548|NCT00526747||Epo-responsive|Patients with CKD (estimated GFR < 60cc/min) not on hemodialysis who are requiring <100IU/kg/week of epoetin alpha and/or 1mcg/kg/week of darbepoetin to obtain target hemoglobin/hematocrit.
3166549|NCT00526760|Experimental|Dexmedetomidine|
2526570|NCT02719912|Experimental|Valve Replacement|Mitral valve replacement
2526670|NCT02719327|Experimental|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
2526673|NCT02719327|Placebo Comparator|placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
3166550|NCT00526773|Other|1|Telephone management plus a motivational intervention
2526805|NCT02718209|Experimental|Frozen section|Frozen sections taken from women operated on for possible gynecologic malignancies.
2526890|NCT02717819|Experimental|Resistance training and protein|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x 125 ml protein-enriched, milk-based supplements (whey protein), in the same period (additional ~25 g protein and 1953 kJ per day). Daily vitamin D supplements.
2526898|NCT02717819|Placebo Comparator|Resistance training and placebo|Daily supervised resistance training offered while hospitalized, and encouragement of self-training 4 times per week for duration of 12 weeks after discharge (standardized training program, which will be monitered). Daily intake of 2 x125 ml iso-energetic placebo-supplements, in the same period. Daily vitamin D supplements.
2526945|NCT02717078|Experimental|LoBAG Diet|Assignment to consume the LoBAG diet (30% carbohydrate, 30% protein, 40% fat; carbohydrates that are low in starch emphasized) for 12 weeks.
2526958|NCT02717078|Active Comparator|Control Diet|Assignment to consume the control diet (50% carbohydrate, 15% protein, 35% fat) for 12 weeks.
2527026|NCT02716792|Experimental|Ibandronate 15-Minute Infusion|Participants will receive ibandronate IV infusions over a 15-minute interval.
2527028|NCT02716792|Active Comparator|Ibandronate 60-Minute Infusion|Participants will receive ibandronate IV infusions over a 60-minute interval.
2527090|NCT02716233|Active Comparator|Arm 1|pegaspargase 2500 IU/m2 x 1: infusion of a conventional dose of pegaspargase during induction therapy: 2500 IU/m2x1
2527101|NCT02716233|Experimental|Arm 2|pegaspargase 1250 IU/m2 x 2: fractionation of the 2500 IU/m2 pegaspargase dose in two infusions of 1250 IU/m2 each
2527191|NCT02715648|No Intervention|No Phenazopyridine before cystoscopy|This group will not receive phenazopyridine prior to cystoscopy
2527193|NCT02715648|Experimental|Phenazopyridine before cystoscopy|This group will receive 200mg of phenazopyridine prior to cystoscopy
2527236|NCT02715375|Experimental|Device: CREON2000A|Children with mild to moderate asthma maintains allergy medicines have an experimental ultra violet device installed in their homes.
2527242|NCT02715375|Sham Comparator|Device: Sham Comparator|Children with mild to moderate asthma maintains allergy medicines have a sham device using a shielded blue light sham lamp that otherwise resembles the experimental device installed in their homes.
2527287|NCT02715011|Experimental|Part 1: Dose Escalation|Participants will receive JNJ-63709178 in Part 1 (in different cohorts). Each subsequent cohort will receive JNJ-63709178 at an increased dose level. Ascending doses may be given initially to minimize or prevent cytokine release syndrome. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered.
2527295|NCT02715011|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-63709178 at the recommended Phase 2 dose(s) (RP2D) determined in dose expansion phase.
2527336|NCT02714673||ADELC|Cohort of patients on long term anticoagulation and undergoing a primary hip or knee replacement.
2527344|NCT02714673||CONTROL|Cohort of patients not on long term anticoagulation and undergoing a primary hip or knee replacement.
2527422|NCT02714465|Experimental|Hyperbaric oxygen therapy|All patients underwent radiosurgery with clinical and instrumental signs of cerebral radionecrosis
2527453|NCT02713932||Transcatheter aortic valve implantation|
2527561|NCT02713269|Experimental|Treatment (thermal ablation, SSRS)|Patients undergo thermal ablation and CT-guided SSRS via intensity-modulated radiation therapy on different dates within a 1-14 day window. The order of treatment is at the doctor's discretion.
2527623|NCT02712866||Patients treated with vedolizumab|
2527648|NCT02712658|Active Comparator|terbutaline|terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
2527659|NCT02712658|Placebo Comparator|Placebo|placebo is administered as isotonic saline (10 ml)
2527687|NCT02712346|Experimental|Treatment|Ambrisentan 5 mg PO daily
2527690|NCT02712346|Placebo Comparator|Placebo|One inactive pill PO daily
2527732|NCT02712086|No Intervention|usual dietary management|Control group: usual dietary management Following the intervention, the stomach of patients underwent many changes
3166551|NCT00526773|Other|2|Telephone management with standard patient education
3166552|NCT00526812|Experimental|Group A (RTA 744)|Receive study drug for three consecutive days, Cycle repeated every 21 days.
3166553|NCT00526812|Experimental|Group C (RTA 744 Injection)|Receive study drug once a week for four consecutive weeks. Repeat cycle every 5 weeks.
3166554|NCT00526838|Experimental|1|once-weekly dosing
3166555|NCT00526838|Experimental|2|twice-weekly dosing
3166556|NCT00526864||Elderly patients|
3166557|NCT00526864||HIV infected patients|
3166558|NCT00526864||Immunosuppressed patients|
3166559|NCT00526877|Experimental|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
2526336|NCT02721303|Active Comparator|obese younger aged, aged 21-45, BMI 30-40|Younger aged patients who are obese and between the ages of 21-45 with a BMI between 30-40 .
2526416|NCT02720731||children|aged from 1 to 18 years with motor disorder
2526417|NCT02720731||adults|aged from 18 to 80 years with motor disorder
2526507|NCT02720302|Experimental|SOFT|"All Children have their first and their last consultation at The Child Obesity Unit.~The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3). The intervention use psychological techniques developed in systemic family therapy applied on advice regarding exercise and diet as well as behavioural Life style Changes.~At each consultation with the overweight child and his/her biological parents there are two therapists present."
2526516|NCT02720302|Experimental|TeleSOFT|"The same method Lifestyle intervention SOFT is used. The only difference is that the communication in the second, third (and fourth) visit is made by use of video on distance. The investigators use Standardized Obesity Family Therapy SOFT as described by Nowicka & Flodmark (1-3)."
2526555|NCT02719782|Experimental|HBV/TCR T cell Infusion|"This is a single-arm study.~Patients will receive a total of 2 cycles, in which first 28-day treatment cycle consists of escalating doses of TCR-T on Day 1, Day 8, Day 15 and Day 22, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of second (final) cycle. A one month treatment break will be given between the cycles."
2526678|NCT02719106||Ultimaster stent|
2526749|NCT02718729|Other|Rectal cancer patients|All patients who will fulfill the inclusions criteria. Patients will undergo formal curative radical Laparoscopic resection for rectal cancer
2526892|NCT02717832|Experimental|Insulin Sensitivity|
2526947|NCT02717286|Sham Comparator|Control|"20 first permanent molars from children aged between 6 to 12 years old presenting MIH will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the European Academy of Pediatric Dentistry (EADP) criteria.~Intervention of Control: The restorative treatment using a total-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
2526959|NCT02717286|Experimental|Test|"20 first permanent molars from children aged between 6 to 12 years old presenting Molar Incisor Hypomineralization will be included. A calibrated pediatric dentist examined the selected teeth to classify MIH according to the EAPD criteria.~Intervention of test: the restorative treatment using a self-etching adhesive system, which was performed according to the following operative sequence: prophylaxis, infiltrative anesthesia, rubber dam, application of 37.5% phosphoric acid to enamel (30 s) and dentine (15 s), extensive washing, drying with cotton and air jet (5 s), priming (5 s), air jet (5 s), adhesive application (5 s), light curing (20 s), restoration with composite resin (Filtek XT350), examination of occlusal contact, and final polishing."
2527005|NCT02716844|Experimental|Exercise Group,|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
2527006|NCT02716844|No Intervention|Control Group|Nothing given to control group, told to continue their normal life for 6 weeks.
2527033|NCT02716558|Experimental|Moisture tolerant resin sealant|Moisture resistant sealant (wet bond sealant)
2527039|NCT02716558|Active Comparator|ART sealant|Glass inomer based sealant
2527082|NCT02716376|Experimental|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
2527086|NCT02716376|No Intervention|No treatment|Observation: No treatment.
2527156|NCT02715986|Experimental|Severly depressed patients|Recruitment of twenty depressive subjects will be conducted within the hospital service adult psychiatry.These patients are referred for indication of ECT sessions for severe resistant depression. Four MRI evaluations (3T MRI examination) are programmed in such patients to analyze structural changes in the hippocampus.
2527210|NCT02715531|Experimental|Arm A (Hepatocellular Carcinoma [HCC], All subtypes)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior treatment are non-randomized and will receive atezolizumab and bevacizumab, every 3 weeks (q3w), each cycle of 21 days, as long as participants are experiencing clinical benefit in the opinion of the investigator.
2527216|NCT02715531|Experimental|Arm B (Gastric Cancer)|Participants with previously untreated human epidermal growth factor receptor 2 (HER2)-negative adenocarcinoma of the stomach or gastroesophageal junction (GEJ) are non-randomized and will receive atezolizumab, bevacizumab, and FOLFOX (oxaliplatin, leucovorin, and 5-fluorouracil [FU]), every 2 weeks (q2w), each cycle of 28 days, as long as participants are experiencing clinical benefit in the opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. After 6 months, at discretion of investigator, capecitabine may be administered as maintenance therapy without oxaliplatin instead of infusional 5-FU and leucovorin, and biologic therapy may be given every 3 weeks (q3w). In the event that a patient experiences unacceptable toxicity after replacement of infusional 5-FU and leucovorin with capecitabine, the patient may be allowed to switch back to 5-FU and leucovorin following investigator discussion with the Medical Monitor.
2527218|NCT02715531|Experimental|Arm C (Metastatic Pancreatic Cancer)|Participants with previously untreated metastatic pancreatic cancer are non-randomized and will receive atezolizumab q2w starting on Day 1, Cycle 1 (each cycle of 28 days). Administration of nab-paclitaxel followed by gemcitabine will occur on Days 1, 8, and 15 of each cycle (3-weeks-on/1-week-off schedule). Treatment consisting of atezolizumab with gemcitabine and nab-paclitaxel may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator.
2527225|NCT02715453|Experimental|Intervention on frailty|Intervention on frailty in addition to the usual care by the cardiologist. A multidisciplinary team (physicians, nurses and physiotherapists and nutritionists) will carry out the intervention on frailty
3199890|NCT00884988|Placebo Comparator|Placebo remedy|identical in color, constituency and taste to true remedy
2526429|NCT02720458|Experimental|Standardized hypnotic taper and self-help program|
2526435|NCT02720458|Active Comparator|Standardized hypnotic taper only|
2526501|NCT02720159|Experimental|TREATMENT|
2526563|NCT02719886|Experimental|Fetal growth ultrasound every 2 weeks|Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
2526565|NCT02719886|Active Comparator|Fetal growth ultrasound every 4 weeks|Ultrasound to measure fetal growth every 4 weeks (i.e. 28, 32 and 36 weeks gestation). Usual Care.
2526638|NCT02719431|Other|Warfarin/Warfarin + K-877|
2526714|NCT02719002|Experimental|OCT C-scan|
2526776|NCT02718430|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
3199891|NCT00885001|Experimental|Short Arc Banding Group|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
3199892|NCT00885014|Experimental|CBT|Telephone cognitive-behavioral therapy
2526875|NCT02717650|Experimental|A-STEP|Study A) A-STEP Study Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).
2526882|NCT02717650|Experimental|A-STEP (New Protocol)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
2526885|NCT02717650|Active Comparator|CPET cycle ergometer (Gold Standard)|Study B) A-STEPmax Study Validity Study (random allocation of test order).
2526938|NCT02717221|Experimental|18F-MPG:EGFR+|Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.
2526943|NCT02717221|Experimental|18F-MPG:post-TKI EGFR+|Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.
2526954|NCT02717221|Experimental|18F-MPG:post-chemo EGFR+|Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.
2526965|NCT02717221|Experimental|18F-MPG:EGFR wild type|Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.
2526970|NCT02717221|Experimental|18F-MPG:post-chemo EGFR wild type|Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.
2526973|NCT02717221|Experimental|18F-MPG:unknown EGFR mutational status|Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group
3199893|NCT00885014|Active Comparator|TAU|Treatment as usual through the Employees Assistance Program
3199894|NCT00885053|Experimental|Fish oil|
2527134|NCT02716103||Initial Cohort: feasibility|Bone marrow collection and peripheral blood collection from ten patients with untreated AL amyloidosis will be evaluated to determine feasibility of isolating a plasma cell clone. An additional three teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving any treatment. There will be no extra procedures or visits specifically for this research.
2527137|NCT02716103||2nd Cohort - pre-treatment|If feasibility is determined with initial cohort, bone marrow collection and peripheral blood collection from 20 patients with untreated AL amyloidosis who are scheduled to undergo antineoplastic therapy will be evaluated to isolate a plasma cell clone. An additional 3 teaspoons of bone marrow and 4 teaspoons of blood will be collected at the time of standard blood draw and bone marrow biopsy before receiving therapy. For those who complete therapy and achieve complete response or very good partial response, subsequent samples of bone marrow and peripheral blood will be sent for minimal residual disease detection (based on the previously identified cancer clone) at 6 to 12 months post treatment.
2527157|NCT02715739||All participants|
2527227|NCT02715596|Experimental|Intervention A|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
2527234|NCT02715596|Placebo Comparator|Intervention B|Placebo supplementation in a 15 cc emulsion stick-pack
2527282|NCT02715089||Precise treatment|All patients should accept next-generation sequencing (NGS) test before treatment.
3199895|NCT00885053|Placebo Comparator|Olive oil|
3199896|NCT00885066|Experimental|gemcitabine, capecitabine, erlotinib|
2527438|NCT02714101|Experimental|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
2527464|NCT02713841|Experimental|Inhaled insulin (LOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a low output mesh (aerosol particles sized 3.5-4.0 μm)
2527466|NCT02713841|Experimental|Inhaled insulin (MOM1)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
2527469|NCT02713841|Experimental|Inhaled insulin (MOM2)|repeat of single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a medium output mesh (aerosol particles sized 4.3-4.8 μm)
2527470|NCT02713841|Experimental|Inhaled insulin (HOM)|single 50 unit dose of Dance inhaled insulin administered using the Adagio-01 inhaler device with a high output mesh (aerosol particles sized 5.0-5.5 μm)
3199897|NCT00885157|Experimental|Group A|Will receive fractional doses of IPV Intradermally
3199898|NCT00885157|Active Comparator|Group B|Will receive full doses of IPV Intramuscularly
3199899|NCT00885183|Experimental|acupuncture therapy|Breast cancer patients are randomised to additional 12 acupuncture treatment sessions while undergoing standard chemotherapy
3199900|NCT00885183|Other|Usual care|Control group (usual care) receives standard chemotherapy alone
3199901|NCT00885196|Experimental|AEB071 200 mg BID|
3199902|NCT00885196|Experimental|AEB071 400 mg OD|
3199903|NCT00885196|Experimental|AEB071 300 mg BID|
3199904|NCT00885196|Placebo Comparator|Placebo BID|
3199905|NCT00885209||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
3199906|NCT00885222|Active Comparator|1|PD patient that were treated with STN DBS and developed depression after the surgery (n=5).
3199907|NCT00885222|Active Comparator|2|PD patients with depression that are candidates for STN DBS (n=5).
3199908|NCT00885222|Active Comparator|3|PD patients without depression that are candidates for STN DBS (n=10).
3199909|NCT00885235||A|Subjects that are indicated for colonoscopy who are suspected or known to suffer from large bowel diseases.
2526393|NCT02720822|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on weeks two and three.
2526397|NCT02720822|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg/day on week one. Morphine 24 mg/day on week two. Morphine 32 mg/day on week three.
2526607|NCT02719600|Experimental|Down Syndrome Group|Group with Down Syndrome
2526609|NCT02719600|Active Comparator|Typical Development Group|Control group with typical development
2526808|NCT02718235||Overall survival HCCIS low risk|HCCIS 2 points
2526810|NCT02718235||Overall survival HCCIS medium risk|HCCIS 1 point
2526811|NCT02718235||Overall survival HCCIS high risk|HCCIS 0 point
2526823|NCT02717884|Experimental|TCP, ATRA, Cytarabine|"Phase I part:~The rolling-six phase I design will be used to determine the MTD of TCP in combination with fixed-dose of ATRA and with fixed-dose AraC in patients with AML/MDS.~Intervention: Four dose levels of TCP (20 mg, 40 mg**, 60 mg**, 80 mg** on days 1-28) will be examined in combination with ATRA (45 mg/m2 on days 10-28) and with fixed-dose AraC (40 mg on days 1-10) in the first cycle. In case of dose-limiting toxicity (DLT) on the starting level 1 of 20 mg a de-escalation to dose level of 10 mg (level -1) will be investigated.~**TCP dose will be slowly increased to achieve the necessary dose level and slowly tapered off at the end of treatment"
2526891|NCT02717520|Experimental|All study participants|One permanent molar with an approximal and occlusal carious lesion restored with EQUIA Forte, and one permanent molar with an approximal and occlusal carious lesion restored with Tetric EvoCeram
2526950|NCT02717234|Active Comparator|Impact Advanced Recovery|Oral nutrition supplement intended for consumption at 3 servings per day
2526961|NCT02717234|Experimental|Impact Advanced Recovery-R|Oral nutrition supplement intended for consumption at 3 servings per day
2527016|NCT02716922|Experimental|Cervical cerclage|Women randomized to receive cerclage should receive cervical cerclage Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
2527017|NCT02716922|No Intervention|No intervention|No cerclage Women randomized to not receive cerclage represent the control arm
2527149|NCT02715778||Adult Participants|
2527160|NCT02715778||Child Participants|
3166560|NCT00526903|Experimental|Fiber|Fiber added to diet for a total of 6 weeks.
3166561|NCT00526903|Placebo Comparator|Placebo|Placebo powder taken for a total of 6 weeks.
2527268|NCT02714998|Active Comparator|Methotrexate only|Single dose of systemic Methotrexate administered to 55 patients.
2527269|NCT02714998|Active Comparator|Salpingectomy only group|Laparoscopic unilateral salpingectomy performed to 61 patients.
2527271|NCT02714998|Active Comparator|Salpingectomy following Methotrexate|15 patients underwent laparoscopic unilateral salpingectomy following unsuccessful single dose of methotrexate administration.
2527351|NCT02714803|Experimental|Connective tissue massage group|Connective tissue massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2527356|NCT02714803|Active Comparator|Classic massage group|Classic massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2527360|NCT02714803|Sham Comparator|Sham massage group|Sham massage plus conservative applications including superficial thermal, electrotherapy and home exercise program were applied
2527392|NCT02714270|Active Comparator|modified partograph|routine modified partograph
2527397|NCT02714270|Active Comparator|paperless partograph|paperless partograph with no graph paper
2527442|NCT02714036|Experimental|MN-166 (ibudilast)|MN-166 (ibudilast) 10 mg capsules administered orally. Fifty (50) mg b.i.d. (5 capsules) in the morning and 50 mg b.i.d. (5 capsules) evening will be administered for a total daily dose of 100 mg/d. Study drug dosing may vary based on individual tolerability.
2527485|NCT02713724|Active Comparator|DAPS-group|Physical exercise
2527489|NCT02713724|Active Comparator|Standard-group|Limited physical exercise
2527528|NCT02713399||Soft Contact Lenses|healthy subjects wearing soft contact lenses
3166562|NCT00526929|Experimental|darbepoetin alfa|darbepoetin alfa (NESP)
3166563|NCT00526942|No Intervention|I|No contact control (NCC)
3166564|NCT00526942|Experimental|II|Computerized, SAAGE-designed, visual memory-based cognitive training
3166565|NCT00526968|Experimental|1|EVT 101 8 mg capsule
3166566|NCT00526968|Experimental|2|EVT 101 15 mg capsule
3166567|NCT00526968|Placebo Comparator|3|Matching placebo capsule
3166568|NCT00526981|Experimental|Treatment|Prone position + all conventional treatment.
3166569|NCT00526981|No Intervention|Control|Conventional treatment
3166570|NCT00527007|Experimental|A|
3166571|NCT00527007|No Intervention|B|
3166572|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort A|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3166573|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort B|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3166574|NCT00527020|Experimental|Part A: Subjects receiving treatment in cohort C|Eligible subjects will be randomized to receive GSK101892 and placebo. Subjects will receive escalated doses of GSK101892 with a starting dose of 0.5 milligrams. Each subject will receive no more than 4 doses of GSK1018921 in a maximum of 5 dosing sessions. Within each cohort, each session will be separated by a washout period of at least 7 days.
3166575|NCT00527020|Experimental|Part B: Subjects in 5 period crossover period|Eligible subjects (first 14 subjects) will be randomized to one of the following 14 sequences as a 5 period crossover with sequences; LMNOQ, MNOLQ, NOLMQ, OLMNQ, ONMLQ, NMLOQ, MLONQ, LONMQ, LNMOQ, NMOLQM MOLNQ, OLNMQ, OMNLQ and MNLOQ) (L= 80 milligrams GSK1018921 given in fasted state, M= 200 milligrams GSK1018921 given in fasted state, N= nicotine lozenge, O= placebo and Q= 80 milligrams GSK1018921 in fed state).
2526395|NCT02720874|Active Comparator|Control Arm|Participants will receive standard of care treatment from their assigned rheumatologists during routine clinic appointments scheduled quarterly for the 12-month trial duration. Referrals to ancillary services will occur in a standard of care fashion. Participants will additionally receive monthly healthcare coordinator calls and be given the rheumatoid arthritis educational booklet.
2526442|NCT02720419||Synergy stent|
2526514|NCT02719977|Experimental|CX-5461|CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
2526583|NCT02719808||Tenofovir1|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one week after delivery.
2526588|NCT02719808||Tenofovir2|100 patients receive tenofovir （300mg/d）from (28±2） weeks of pregnancy to one month after delivery.
2526589|NCT02719808||Tenofovir3|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one week after delivery.
2526591|NCT02719808||Tenofovir4|100 patients receive tenofovir （300mg/d）from （24±2）weeks of pregnancy to one month after delivery.
2526592|NCT02719808||Group without any treatment|100 patients don't receive any blockade therapies
2526644|NCT02719262|Experimental|Intervention|installing ventilation in the workplace
3199910|NCT00885274|Experimental|Split Dose|Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
3199911|NCT00885274|Active Comparator|Traditional Dose|Both doses of Pico-Salax taken the evening prior to colonoscopy.
3199912|NCT00885287|Active Comparator|HIV-positives on ARVs receiving AL for malaria|HIV-positive patients on first-line ARVs receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
3199913|NCT00885287|Active Comparator|HIV-positives receiving AL for malaria|HIV-positive patients not receiving antiretrovirals but receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
3199914|NCT00885287|Active Comparator|HIV-negatives receiving AL for malaria|HIV-negative patients receiving artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria
2527198|NCT02715635|Active Comparator|Nitrate-rich beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml containing ~8 mmol of inorganic nitrate"
2527200|NCT02715635|Placebo Comparator|Nitrate-deplete beetroot juice|"Biological: Typhoid vaccine The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution Other Name: Typhim Vi®~Dietary Supplement: Concentrate beetroot Juice 140 ml which is nitrate-depleted"
2527240|NCT02715349|Experimental|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
2527244|NCT02715349|No Intervention|Control|Family and patient do not receive psychoeducation, but still receive standard hospital services for schizophrenia.
3199915|NCT00885300|Experimental|1|cloxacillin 100 mg/ml + heparin 1000iu/ml as catheter lock at the end of hemodialysis
3199916|NCT00885300|Active Comparator|2|heparin 1000iu/ml as catheter lock at the end of hemodialysis
3199917|NCT00885313|Experimental|DHA250|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3199918|NCT00885313|Experimental|DHA500|DHA 250 mg/kg/d plus lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3199919|NCT00885313|Placebo Comparator|PLA|placebo and lifestyle intervention [hypocaloric Diet (25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3199920|NCT00885326|Other|Treatment|"Bevacizumab: Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.~Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).~Zoledronic acid will be administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first."
2527367|NCT02714530|Experimental|Radiotherapy combined with erlotinib|Standard treatment 3 Gy x 10 to lung tumor and mediastinal lymph nodes and erlotinib given concomitantly, 150 mg p.o. daily from the day before radiation, until the last day of radiation.
2527370|NCT02714530|Active Comparator|Radiotherapy alone|Radiotherapy 3 Gy x 10 alone
2527395|NCT02714231|Experimental|diclofenac|oral diclofuhenac sodium
2527402|NCT02714231|Active Comparator|hyoscine|oral hyoscine butyl bromide
2527482|NCT02714010|Experimental|Arm 1|Patients take EGFR-TKI alone till tumor progression
2527483|NCT02714010|Active Comparator|Arm 2|Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI
2527529|NCT02713412|Experimental|Glucose|75g glucose and 150mg C13-acetate in 300ml water
2527533|NCT02713412|Placebo Comparator|Control|300ml water
2527580|NCT02713191|Experimental|Dexmedetomidine|Dexmedetomidine + fentanyl before, and dexmedetomidine infusion during, procedure
2527581|NCT02713191|Active Comparator|Midazolam|Midazolam + fentanyl before, and matching saline infusion during, procedure
2527639|NCT02712853||Autism Spectrum Disorder (ASD)|"Age at enrollment: 18 months to 6 years with established DSM-5 diagnosis of autism spectrum disorder. Exclusion criteria include:~wards of the state syndromic autism (attributed to a known genetic mutation) active periodontal infection active upper respiratory infection"
2528362|NCT02708160|Placebo Comparator|Fluoride Free toothpaste|Fluoride free (0%), silica based toothpaste
3199921|NCT00885339||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases.
3199922|NCT00885404|Other|Intravenous fluids|
3199923|NCT00885417|Experimental|Cravit-based sequential therapy|Cravit-based sequential therapy Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
2526434|NCT02720653||Endoscopic Sinus Surgery|Patients will self-select endoscopic sinus surgery for symptoms associated with chronic sinusitis.
2526523|NCT02720263|Experimental|Double-Blind ASP4345 Multiple Dose Levels|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered under fasting conditions. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions.
2526526|NCT02720263|Placebo Comparator|Double-Blind Placebo Multiple Dose|Matching placebo capsules will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, matching placebo capsules will be administered with food. On days 2-6 and 8-13, matching placebo will be administered under fed conditions.
2526531|NCT02720263|Experimental|Open-Label ASP4345|ASP4345 will be administered orally as a single daily dose on days 1 through 14 with water. On days 1, 7, and 14, ASP4345 will be administered with food. On days 2-6 and 8-13, ASP4345 will be administered under fed conditions. This is an optional cohort where subjects will be enrolled to further characterize pharmacodynamics in the event a higher sample size is necessary to determine changes in electrophysiological biomarkers.
2526567|NCT02719717|Experimental|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
2526642|NCT02719457|Other|6 minute walk test (6 MWT)|patients will be perform the six minute walk test (6 mwt) to evaluate their exercise capacity.
2526653|NCT02719457|Other|spot marching test (SMT)|patients will be perform the spot marching test (SMT) to evaluate their exercise capacity.
2526700|NCT02718872|Experimental|Tobacco cessation online training|Six hour smoking cessation online training addressed to health professionals from hospitals in 3 Latin American Countries. Participants are monitored by local coordinators that act as champions. They offer their assistance to log into the online platform, fill out the questionnaires, complete the evaluation, including other technical support. Participants' progress is monitored in real time onto the web platform. The project coordinator at ICO sends a report of the participants progress every other week to coordinators, and if necessary personal emails to motivate students to finish the course and complete the evaluations.
3199924|NCT00885430|Experimental|Pico-Salax|
3199925|NCT00885443|Active Comparator|1|
2526843|NCT02717936|Other|Immunohistochemistry|Patients are investigated using immunohistochemistry with Pancytokeratin
2526899|NCT02717689|Experimental|Biomarker arm|Biomarker based adjustment of corticosteroid dose.
2526903|NCT02717689|No Intervention|Standard care|The subject's corticosteroid dose will be adjusted based upon asthma symptom control and lung function
2526940|NCT02717143||Acute myocarditis|"Patients with a clinical picture suggestive of acute myocarditis: increase of troponin above the threshold defined by the pathological laboratory, associated with at least one of the three following criteria:~prolonged chest pain > 10 minutes,~recent infectious context <7 days~young subject and / or absence of cardiovascular risk factors and / or absence of significant coronary lesion~Patients will be included after completion of MRI confirm the diagnosis. They will be followed for 3 years, every year, by the doctor who included them in the study.~This is an observational study that does not affect the management of patients."
3199926|NCT00885443|Active Comparator|2|
3199927|NCT00885456|Experimental|PREVENT program|12-week program of exercise and education to induce physiological and behavioral changes needed to reduce vascular risk factors.
2527098|NCT02716220|Experimental|'Percutaneous Coronary Intervention' /Scaffold Implantation|PCI for enrolled subjects: implantation of the DREAMS 2G Drug-Eluting Coronary Scaffold System
2527203|NCT02715882|Experimental|1 injection of CBLB502 0.35 μg/kg|One subcutaneous injection of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 before tumor removal
2527205|NCT02715882|Experimental|1 injection of CBLB502 0.45 μg/kg|One subcutaneous injection of CBLB502 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 before tumor removal
2527208|NCT02715882|Experimental|2 injections of CBLB502 0.35 μg/kg|Two subcutaneous injections of CBLB502 0.35 μg/kg (not more 30 μg/injection) or Placebo at Day 1 and Day 4 before tumor removal
2527213|NCT02715882|Experimental|2 injections of CBLB502 0.45 μg/kg|Two subcutaneous injections of CBLB502 at 0.45 μg/kg (not more 40 μg /injection) or Placebo at Day 1 and Day 4 before tumor removal
2527334|NCT02714894||Clozapine Responders (Non-URS)|"Definition of non-URS~(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment."
2527337|NCT02714894||Clozapine Non-Responders (URS)|"Definition of URS~Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.~CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items."
2527347|NCT02714894||Healthy Controls|Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.
2527396|NCT02714309|Experimental|Control Trial|A mixed macronutrient breakfast meal is consumed without additional protein, following a period of rest. An ad libitum lunch meal is subsequently consumed.
2527403|NCT02714309|Experimental|Exercise No Preload Trial|Following an exercise bout a mixed macronutrient breakfast meal is consumed without additional protein. An ad libitum lunch meal is subsequently consumed.
2527415|NCT02714179|Active Comparator|Group Preemptive (Group PE),|Group I: i.V. paracetamol 1 g (100 ml) was given 30 min before induction of anesthesia.
3199928|NCT00885456|Active Comparator|Usual Care|Average of three visits to the Neurovascular Clinic for a neurological and health assessment, counseling regarding stroke/TIA and diagnostic test results, and assessment, modification and education of secondary prevention factors
3199929|NCT00885469||1|Patients with known Barrett's Esophagus or chronic GERD
3199930|NCT00885495|Active Comparator|B|Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
3199931|NCT00885495|Active Comparator|A|Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
3199932|NCT00885508|Experimental|Aracytidine, Daunaurubicine, Lenalidomide|
3199933|NCT00885521|Experimental|Exercise|8 week, twice weekly exercise program with both endurance and upper and lower limb strength training
3199934|NCT00885521|No Intervention|2|No exercise, twice weekly phone calls
3199935|NCT00885547|Experimental|immunosuppressor|
2526498|NCT02720146||Human platelet lysate|The epitheliotrophic ability in cell and animal model
2526598|NCT02719509||Observational Cohort|All emergency department patients who had a cardiac ultrasound performed as part of their diagnostic workup
2526640|NCT02719223|Experimental|High Flux Hemodialysis|
2526652|NCT02719223|Experimental|OL-HDF|
2526718|NCT02718937|Experimental|BTA-C585|BTA-C585 100 mg oral capsule
2526719|NCT02718937|Placebo Comparator|Placebo|Matching placebo capsule
2526757|NCT02718469|Experimental|Ebola Vaccine - low dose|Low Dose Zaire Ebola Vaccine
2526760|NCT02718469|Experimental|Ebola Vaccine - mid dose|Mid Dose Zaire Ebola Vaccine
2526765|NCT02718469|Experimental|Ebola Vaccine - high dose|High Dose Zaire Ebola Vaccine
2526768|NCT02718469|Placebo Comparator|Placebo|Placebo
2526830|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 1)|Patients with recurrent/progressive GBM
2526836|NCT02717962|Experimental|VAL-083, Dianhydrogalactitol (Group 2)|Newly diagnosed GBM patients who have completed chemoradiation treatment with temozolomide and received no subsequent maintenance temozolomide
3166576|NCT00527020|Experimental|Part B: Subjects in 4 period crossover period|Eligible subjects (last 7 subjects) will be randomized to one of the following 7 sequences as a 4 period crossover with sequences; NLOM, LOMN, OLNM, LNMO, NMOL, MOLN, and MNLO.
3166577|NCT00527033|Experimental|1|Oral
3166578|NCT00527033|Experimental|2|Oral
3166579|NCT00527033|Experimental|3|Oral
2527021|NCT02716688|Experimental|Radiotherapy and S-1 arm|Radiotherapy will be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy. Preplanned concurrent S-1 (70mg/m²/day) will be administered on Day 1 for 14 days, every 3 weeks. After dCRT, maintenance S-1 will be given up to two cycles.
2527063|NCT02716402|Other|Cyanotic congenital heart disease|Patients who previously have been examined with cerebral MRI and V/Q SPECT/CT will be re-examined with cerebral MRI and V/Q SPECT/CT
2527092|NCT02716207|Experimental|Maximal tolerated dose with CyberKnife|SBRT will be delivered in 5 fractions within 1 to 2 weeks by the following schedule: Doses of 7 Gy, 7.5 Gy, 8 Gy, 8.5 Gy, 9 Gy, 9.5 Gy x 5 with BED10 in correspondence to 59.5 Gy, 65.6 Gy, 72 Gy, 78.6 Gy, 85.5 Gy, 92.6 Gy respectively while meeting with normal tissue constraints. A minimum of three patients will be included for each dosage level. And an interval is four weeks between each dose level. In case patient presents III/IV GI toxicity, three additional patients will be included at the same dose level. The Maximal Tolerated Dose will be defined as the dose for which at least 2 patients in 3, or at least 3 patients in 9, will present with a limiting toxicity.
2527163|NCT02715934|Experimental|Glucose to Goal|Three diabetes educators will be assigned to the Glucose to Goal/experimental arm. The educators will each identify two primary care practices of mid to large size to participate in the Glucose to Goal intervention. Patients will not be formally recruited or enrolled. Rather, information documented in the electronic medical record system will be extracted to evaluate patient-level outcomes. Based on a random sampling of mid to large size primary care practices in study communities, an estimated 2,200 patients with diabetes per study group will meet eligibility criteria for DSME referral.
2527173|NCT02715934|Other|Control Group|Two usual care diabetes educators will each identify three primary care practices of mid to large size to include in the control arm and participate in the usual care intervention. Uneven group assignment accounts for the amount of time (one day equivalent/per week) that the intervention diabetes educators will devote to each primary care practice versus the full-time availability of the usual care diabetes educators to see patients at the outpatient, hospital-based program. Like the experimental arm, an estimated 2,200 patients with diabetes will meet eligibility criteria for DSME referral. Patients will not be formally recruited or enrolled into the control arm; data will be extracted from the electronic medical record system to evaluate patient-level outcomes.
2527212|NCT02715492|Active Comparator|Transarterial Chemoembolization|1st group: included 20 patients with HCC treated by TACE only.
2527217|NCT02715492|Experimental|TACE and LMWH|2nd group: included 20 patients with HCC treated by TACE and adjuvant dose of Low Molecular Weight Heparins (LMWH).
2527305|NCT02715206|Experimental|Control|middle schools not receiving keepin' it REAL; continue their own programs if any.
2527308|NCT02715206|Experimental|keepin' it REAL classic|middle schools will implement keepin' it REAL classic drug prevention curriculum
2527312|NCT02715206|Experimental|keepin' it REAL rural|middle schools will implement the keepin' it REAL rural curriculum
2527339|NCT02714634|Experimental|methotrexate + biologic group|"Methotrexate +~biologic chosen by investigator"
2527345|NCT02714634|Active Comparator|Triple therapy|Triple therapy using 3 conventional disease modifying drugs (DMARDs)
2527758|NCT02712229|Experimental|CONNECT Intervention|At clinics randomized to the CONNECT intervention, oncology nurses will be selected by a nurse advisory panel to receive standardized primary palliative care training. A multi-step deployment strategy will be employed to orient oncologists and implement CONNECT processes. CONNECT nurses will administer CONNECT to enrolled patients and caregivers. An intervention fidelity monitoring and maintenance plan will be implemented to ensure high quality and consistent delivery of the intervention.
2527759|NCT02712229|No Intervention|Usual Care Control|At clinics randomized to Usual Care, enrolled patients and caregivers will continue to receive supportive oncology care according to usual practice.
3166580|NCT00527033|Placebo Comparator|4|Oral
3166581|NCT00527059|Experimental|1|patients with acute heart failure
3166582|NCT00527059|Active Comparator|2|standard therapy for heart failure
3166583|NCT00527085|Experimental|AMG 073|
3166584|NCT00527085|Placebo Comparator|Placebo|
3166585|NCT00527137|Active Comparator|rHuEPO|
3166586|NCT00527137|Experimental|darbepoetin alfa|
3166587|NCT00527150|Other|Cohort 1|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3166588|NCT00527150|Other|Cohort 2|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3166589|NCT00527150|Other|Cohort 3|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
3166590|NCT00527150|Other|Optional Cohort 4|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
2526525|NCT02720237|Experimental|Brief Intervention|Brief Intervention (2 in-person sessions and 2 phone sessions), study assessment visits, and standard of care from providers at the ART clinic
2526530|NCT02720237|Experimental|MET+CBT Intervention|MET+CBT Intervention (6 in-person sessions and 3 optional group sessions), study assessment visits, and standard of care from providers at the ART clinic
2526534|NCT02720237|No Intervention|Assessment-Only Control|Study assessment visits and standard of care from providers at the ART clinic
2526556|NCT02719691|Experimental|Dose-Escalation of Alisertib and MLN0128|This group will receive a Dose-Escalation: Combination of MLN0128 and Alisertib using a standard 3 + 3 design. The starting dose of Alisertib is 30 mg given PO twice daily (BID) Days 1-7 repeat every 21 days. The starting dose for MLN0128 is 1 mg given by mouth (PO) once daily with continuous dosing.
2526557|NCT02719691|Experimental|Dose-Expansion of Alisertib and MLN0128|"Group 1:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, single agent Alisertib will be administered at the MTD on days 1-7 and MLN0128 will be administered on days 8-21. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Group 2:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. In cycle 1, MLN0128 will be administered at the MTD days 1-28 and Alisertib will be administered at the MTD on days 8-15. In cycle 2 and beyond, dosing with both agents will begin on day 1, with Alisertib administered days 1-7 and MLN0128 administered days 1-21.~Pancreatic Cancer Cohort:~This group will receive a Dose-Expansion of Alisertib and Dose-Expansion of MLN0128. On each cycle, Alisertib will be administered on days 1-7, while MLN0128 will be administered continuously on days 1-21."
2526595|NCT02719587|Placebo Comparator|control group|Control group (8 males, 7 females; 42.54±5.82 years) (SRP): SRP followed by administration of a placebo. The placebo was identical except for the fish oil.
2526596|NCT02719587|Active Comparator|test group|Test group (8 males, 7 females; 40.87±9.7 years) (SRP+omega-3 PUFAs): SRP followed by omega-3 PUFAs supplementation. The test drug contained omega-3 PUFAs including 6.25 mg EPA and 19.19 mg DHA obtained from the Atlantic salmon Salmo salar.Both test and placebo drugs were taken twice a day by the patients for six months. Subjects came to the clinic every 4 weeks during the 6 month course of the experiment to replenish their medication. Remaining medications were checked for compliance. At each evaluation visit (1, 3 and 6 months), oral soft and hard tissue examinations and adverse-event evaluations were performed.
2526645|NCT02719275||Suicidal Behaviour|
2526651|NCT02719275||Suicidal Ideation|
2526659|NCT02719275||Other Mental Health|
2526667|NCT02719275||Other Health|
2526713|NCT02718924||morbidly obese pregnant|Term pregnant women with BMI more than 40
2526717|NCT02718924||non obese pregnant|Term pregnant women with BMI less than 30
2526743|NCT02718560|Experimental|Group 1 - Writing with 1 cm cue|This group uses to write space of 1 cm size
2526746|NCT02718560|Experimental|Group 2 - Writing with 1.5 cm cue|This group uses to write space of 1.5 cm size
2526748|NCT02718560|Experimental|Group 3 - Writing without cue|This group writes without using cues
2526750|NCT02718560|No Intervention|Group 4 - no writing|This group do not write. Only wrist mobilization is performed.
2526788|NCT02718287|Experimental|Treatment:|Home visiting with PCCSF
2526790|NCT02718287|Experimental|Control|Home visiting no PCCSF
3166591|NCT00527150|Other|Optional Cohort 5|Subjects will be randomized to receive either experimental drug (N=9) or matching placebo (N=3).
2526870|NCT02717533||blood volume|dry weight adjusted according to ideal blood volume obtained from absolute blood volume measurement (Daxor)
2526876|NCT02717416|Experimental|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|The intervention group
2526881|NCT02717416|Active Comparator|Hemoclip (HX-610-135, Olympus, Japan) or electrical coagulation group|Patients in the control group will undergo endoscopic hemostasis with combination therapy, epinephrine injection therapy and hemoclip or electrical coagulation therapy.
2526955|NCT02717299|Experimental|Sensor Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The surgeon will use this data to intraoperatively align the knee according to the indications of the data.
2526966|NCT02717299|Placebo Comparator|Surgeon Guided Tissue Balancing|Patients in this group will have the Verasense trial sensor device inserted, and the data collected electronically. The computer displaying the data will be turned away from the surgeon, so that he is not able to use the sensor data, and must balance the knee with feel and visual estimation of balance.
2527462|NCT02713971|Experimental|Gamepad|Biofeedback rehabilitation with Gamepad system.
2527463|NCT02713971|Active Comparator|Control|Conventional physiotherapy.
2527520|NCT02713568|Active Comparator|Ultrasound|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~An Ultrasound scan to estimate the fetal weigth will be carried out during the 36th week of gestation."
2527585|NCT02713165|Experimental|Raisins Enhanced Diet|Participants will be provide with a Raisin Enhanced Diet over a short term period of time.
3166592|NCT00527202|Experimental|botulinum toxin A|active treatment arm using botulinum toxin A max 200 U injected into the painful area using SC injections 2 cm apart
3166593|NCT00527202|Placebo Comparator|placebo|saline injection with the same dosages injected using the same procedure as botulinum toxin A
3166594|NCT00527215|Experimental|darbepoetin alfa|
3166595|NCT00527228|Active Comparator|A|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm B
3166596|NCT00527228|Placebo Comparator|B|After 6 months of treatment, and a 3-months wash-out, there is cross-over to Arm A
3166597|NCT00527241|Experimental|1: A|
3166598|NCT00527241|No Intervention|2 B|wait-listed for intervention to begin in 6 months
3166599|NCT00527254|No Intervention|Control group|
3166600|NCT00527254|Active Comparator|Telemedicine group|
3166601|NCT00527267|Experimental|AMG 073|AMG 073
2526587|NCT02719847|Experimental|EBUS-TBNA|"Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.~A conventional flexible bronchoscopy performed to examine the tracheobronchial tree, followed by a systematic examination of the accessible intra-thoracic lymph nodes using a linear array ultrasound bronchoscope."
3199936|NCT00885573|Other|Sleep apnea subjects|"Patients with suspected sleep apnea syndrome will have nocturnal polysomnography. According to the number of respiratory events per hour of sleep, patients will be classified as sleep apnea or controls. All the patients will be blindly assessed for pharyngeal sensitivity the morning following the nocturnal recording."
2526722|NCT02718690|Experimental|Transcutaneous nerve stimulation|"Transcutaneous application of TENS current over the back for a 40 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold."
2526723|NCT02718690|Sham Comparator|Sham stimulation|Electrodes are placed over the back for a 40 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel
2526771|NCT02718443|Experimental|VXM01|VXM01 10E6 or 10E7 CFU
2526821|NCT02718170|Experimental|Buried Intramedullary K-wire Fixation|Patients randomized to buried intramedullary k-wire fixation will undergo a standardized antegrade open reduction and fixation procedure with an intramedullary k-wire.
2526824|NCT02718170|Active Comparator|Plate and Screw Fixation|Patients randomized to Plate and Screw Fixation will undergo a standardized open reduction and internal fixation with plate and screws. Brand of plate will be left to the operating surgeon's discretion.
2526896|NCT02717780|Active Comparator|SEVO-FENTA|Patients scheduled for lower limb surgery will receive a balanced anesthesia with fentanyl and sevoflurane.
2526908|NCT02717780|Experimental|DES-REMI|Patients scheduled for lower limb surgery will receive a balanced anesthesia with remifentanil and desflurane.
2526956|NCT02717208|Active Comparator|HL036 0.5mg/ml|Administration : 2 times per day for one day
2526967|NCT02717208|Active Comparator|HL036 5mg/ml|Administration : 2 times per day for one day
2527059|NCT02716753|Experimental|Seminal plasma|Half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
2527061|NCT02716753|Placebo Comparator|Physiological NaCL solution|An amount of physiological NaCL solution equal to half of the amount of seminal plasma received after preparation of the spermatozoa used for IVF will be deposited around the external cervical opening
2527094|NCT02716181|Active Comparator|"Атопик phase 1"|"For the first phase of the study, subjects will be randomized to receive treatment with Атопик Soothing Cream."
2527106|NCT02716181|Placebo Comparator|Placebo - phase 1|For the first phase of the study, subjects will be randomized to receive treatment with Placebo Cream.
2527114|NCT02716181|Active Comparator|"Атопик phase 2"|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
2527117|NCT02716181|Placebo Comparator|Placebo - phase 2|"The second phase of the study is an open-label extension with all subjects receiving Атопик Soothing Cream."
2527153|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of study will receive access to the Healthy Lifestyle App and the McMaster PHR
2527159|NCT02715791|Other|TAP-HC-DM|Patients randomized to the intervention group will get TAP-HC-DM intervention from time zero
2527222|NCT02715479|Experimental|Treatment A|Single DTG tablet under fed conditions for a specified period
2527229|NCT02715479|Experimental|Treatment B|Two BMS955176 tablets under fed conditions for a specified period
2527235|NCT02715479|Experimental|Treatment C|Single DTG tablet and Two BMS955176 tablets under fed conditions for a specified period
2527281|NCT02715037||Acute tonsillitis|Patients referred to the tertiary care center with severe acute tonsillitis but without peritonsillar cellulitis, infectious mononucleosis, or abscess formation.
2527285|NCT02715037||Peritonsillar cellulitis|Patients referred to the tertiary care center with severe acute tonsillitis and peritonsillar cellulitis but without abscess formation.
2527291|NCT02715037||Infectious mononucleosis|Patients referred to the tertiary care center with acute tonsillitis and biochemical or serological signs of infectious mononucleosis but without abscess formation.
2527299|NCT02715037||Controls|Patients treated for conditions not related to the throat and without signs or symptoms of recent throat disease.
2527359|NCT02714712||HCV group (Peginterferon alfa-2a)|A total of 156 chronic HCV genotype 1 or 2 patients who received Peginterferon alfa-2a (Peg-IFN alfa-2a) plus ribavirin therapy were consecutively enrolled from the gastroenterological clinics.
2527364|NCT02714712||Control Group|There were 153 healthy controls negative for anti-HCV enrolled simultaneously from the database of Health Management Center.
2527393|NCT02714296|Active Comparator|Group Nutridrink 200ml|50 patients: two days before the investigation is assigned to a diet with the use of specialized clinical nutrition Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
2527398|NCT02714296|Active Comparator|Group Nutridrink compact protein|two days before the study is assigned diet with the addition of specialized clinical nutrition Nutridrinc compact protein 125 ml 2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
2527405|NCT02714296|No Intervention|Group control|only diet without receiving specialized nutrition
2527444|NCT02713945|Experimental|Simvastatin|Simvastatin administrated orally at 10 mg once a day in the morning during the first month Simvastatin administrated orally at 20 mg once a day in the morning during the second month During months 3 to 12, the dose will be fixed at 20 mg per day for children aged 12 years and younger and 40 mg for adolescent older than 12 years.
2527449|NCT02713945|Placebo Comparator|Control|Placebo administrated orally once daily in the morning
2527515|NCT02713620|Placebo Comparator|Healthy|"the Healthy group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
2527517|NCT02713620|Active Comparator|HIV-Group1|"the Standard doses group receiving three intramuscular injections of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, and 6"
2526623|NCT02719301||Men/Women between 18 & 85|Accepting both healthy and non-healthy subjects. A portion of the subjects will have a fluid management issue or heart failure.
2526729|NCT02718664|No Intervention|A (fasting)|Fasting condition
2526734|NCT02718664|Experimental|B (fed)|Fed condition (test meal)
2526756|NCT02718404|Experimental|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI.~During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.~Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI."
2526837|NCT02718105||Receiver patients in donor oocyte -ART|Maternal and fetal compatibility KIR HLA-C determinations in ART -oocyte donor
2526893|NCT02717741|Experimental|tafetinib|tafetinib administered daily for 2 weeks, followed by a 1-week off period
3166602|NCT00527267|Placebo Comparator|Placebo|Placebo
2527128|NCT02716077|Experimental|Single arm|FDG PET/CT scan pre-therapy
2527187|NCT02715856|Active Comparator|Group I (standard follow up, physical activity measurement)|Patients undergo standard face-to-face follow up visits at 2, 6, 12, and 24 weeks after surgery. Patients also undergo a physical activity assessment over 15 minutes.
2527188|NCT02715856|Experimental|Group II (mobile surveillance)|Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
2527255|NCT02715297|Experimental|Arm A: SRT to the resection cavity|Postoperative stereotactic fractionated radiotherapy (SRT) to the resection cavity to a Total Dose of 46 Gy, 2 Gy single dose, or 36 Gy in 3 Gy single dose 5 fractions/week, depending on the volume and location of the treatment region.
2527258|NCT02715297|No Intervention|Arm B: Observation|Observation without adjuvant radiotherapy.
2527296|NCT02714972|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
2527297|NCT02714972|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
2527448|NCT02713906|Experimental|X-Ray Knee Guide group|Total knee arthroplasy using Materialise X-Ray Knee Guides
2527484|NCT02713750||HIV female adolescents|sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status
2527541|NCT02713451|Active Comparator|Liberal Oxygenation (LO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg that will be checked on arterial blood gases (ABG). Between these measurements, SpO2 will be kept more or equal to 96 percent. Alarms will be set at 95 percent for SpO2.
2527548|NCT02713451|Experimental|Conservative Oxygenation (CO) group|A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg that will be checked on arterial blood gases. Between these measurements, SpO2 will be kept between 88 and 92 percent. Alarms will be set between 87 and 93 percent for SpO2.
2527599|NCT02713087|Active Comparator|Ephedrine|
2527601|NCT02713087|Active Comparator|Phenylephrine|
2527644|NCT02712697|Experimental|WM Group|Shentong Granules, two packs, bid, P.O., 48weeks; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
2527656|NCT02712697|Placebo Comparator|Hormone Group|Placebo ; Prednisone, 0.5-1mg/kg.d, P.O., eight to twelve weeks; then reduced to 30mg by reduce 5mg every two weeks; followed by the monthly reduction of 5mg, about 9-12 months
2527755|NCT02712268|Other|After introduction of the checklist|Review of medications of all consecutive admitted patients during the study period using a checklist
2527767|NCT02711904|Active Comparator|Extubation U|Remifentanil concentration between 2 - 3 ng/ml.
2527770|NCT02711904|Experimental|Extubation T|Remifentanil concentration between 3 - 4 ng/ml
2527866|NCT02711579|Experimental|Celecoxib for electroencephalography|Electroencephalography will be performed before and after celecoxib administration
2527867|NCT02711579|Placebo Comparator|Placebo for electroencephalography|Electroencephalography will be performed before and after placebo administration
2527868|NCT02711579|Experimental|Celecoxib for motor evoked potential|Motor evoked potential will be measured before and after celecoxib administration
2527869|NCT02711579|Placebo Comparator|Placebo for motor evoked potential|Motor evoked potential will be measured before and after placebo administration
3166603|NCT00527280|Experimental|1|
3166604|NCT00527293|Experimental|MammoSite Brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
3166605|NCT00527293|Experimental|3-dimensional conformal radiotherapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
3166606|NCT00527306|Experimental|I - Multivitamin|The multivitamin will contain 100% of the US reference daily intakes (recommended daily amounts) of vitamins A, B1, B2, B3, B5, B6, B9, B12, C, D, and E. It also contains several inactive ingredients including sodium bisulfite and gelatin.
3166607|NCT00527306|Placebo Comparator|II - Inactive Medication|The placebo will be a gelatin capsule filled with lactose.
3166608|NCT00527345||1|children riding retrofitted school buses or private cars
3166609|NCT00527345||2|children riding old buses who will change to retrofitted buses during the first or second year of the study
3166610|NCT00527345||3|children who ride old diesel buses through the study
3173957|NCT00617994|Experimental|Group A|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a small percent BSA.
3173958|NCT00617994|Experimental|Group B|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 1.
2526637|NCT02719197|Experimental|AC-083, Single Ascending Dose|AC-083 administered at different single dose levels in a sequential manner, and in a maximum of 9 dose levels starting from 1 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each dose level will be investigated in a new group of 8 healthy male subjects (6 on active drug and 2 on placebo)
2526649|NCT02719197|Placebo Comparator|Placebo, Single Ascending Dose|Matched placebo administered as single ascending doses in parallel to AC-083
2526704|NCT02718950|Experimental|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks.
2526777|NCT02718599|Active Comparator|Terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
2526780|NCT02718599|Placebo Comparator|CONTROL|Patients receive the same volume of 0.9% saline in place of terlipressin for the same duration(50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours).
2526822|NCT02718014|Other|pre menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
2526825|NCT02718014|Other|post menopause with periodontitis|non surgical periodontal therapy (SCALING & ROOT PLANING) (SRP)
2526897|NCT02717806|Experimental|PATHway|"Patients allocated to the PATHway intervention will be given a 4 week run-in period as an outpatient to get acquainted with the system. During this run-in period, the PATHway system will also be installed in each participant's home. They will be provided with a training manual and a quick set up guide for getting started with PATHway in the home.~After this 4 week run-in period, the PATHway system will be set up for each individual patient including a patient specific exercise prescription. The patient will then exercise with the PATHway platform for 6 months."
2526906|NCT02717806|No Intervention|Usual care|Patients randomized to the control group will receive usual care.
2526952|NCT02717247|Experimental|Active tRNS treatment|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsalateral prefrontal cortex (F4).~100 (Hertz)Hz-650Hz, 2milliampere(mA), 30min, twice daily, 5 days"
2526960|NCT02717247|Sham Comparator|Placebo tRNS treatment|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
2527022|NCT02716766|Experimental|SECOX|Sorafenib 400 mg twice daily from Day 1 to 14, Capecitabine 850 mg/m2 twice daily from Day 1 to 7, Oxaliplatin 85 mg/m2 on Day 1
2527024|NCT02716766|Active Comparator|Sorafenib|Sorafenib 400 mg twice daily from Day 1 to 14
3199937|NCT00885586|Sham Comparator|Sham-laser acupuncture|Sham laser acupuncture (c) is applied at equivalent points as needle acupuncture. Laser irradiation is faked.
3199938|NCT00885586|Active Comparator|gabapentine|standard analgesic treatment
2527246|NCT02715505|Experimental|HSC835|HSC835 is an expanded umbilical cord blood product used during single umbilical cord blood transplantation
2527270|NCT02715063|Experimental|High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
2527272|NCT02715063|Active Comparator|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
2527273|NCT02715063|Active Comparator|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
2527276|NCT02715063|Placebo Comparator|Usual clinical care|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
2527352|NCT02714777||Pediatric population from 4 to 8 years-old|Description of the Autonomic nervous system activity (parasympathetic activity)
2527414|NCT02714413|Placebo Comparator|Sucrose 50g + placebo|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2527421|NCT02714413|Experimental|Sucrose 50g + D-allulose 2.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2527426|NCT02714413|Experimental|Sucrose 50g + D-allulose 5.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2527429|NCT02714413|Experimental|Sucrose 50g + D-allulose 7.5 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2527430|NCT02714413|Experimental|Sucrose 50g + D-allulose10.0 g|All the test sugars will be dissolved in 300 ml water to be consumed within 10 minutes
2527493|NCT02713776|Experimental|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
2527498|NCT02713776|Placebo Comparator|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
3199939|NCT00885586|Active Comparator|Acupuncture|Acupuncture treatment is semi-standardized, i.e. beside a scheme of basic points, individual points can be chosen according to the TCM diagnostic pattern.
3199940|NCT00885599|Experimental|PERIORINSE|naturopathic remedy
3199941|NCT00885599|Active Comparator|CPC|Cepacol, standard anti-bacterial mouthwash
3199942|NCT00885599|Active Comparator|Listerine|standard anti-bacterial mouthwash
3199943|NCT00885599|Placebo Comparator|placebo|colored water
3199944|NCT00885651|Experimental|1|Metoprolol for 10 days followed by placebo for 7 days.
3199945|NCT00885651|Placebo Comparator|2|Placebo for 7 days followed by Metoprolol for 10 days
3199946|NCT00885664|Active Comparator|Truvada|
3199947|NCT00885664|Active Comparator|Kaletra|
3199948|NCT00885690|Active Comparator|Sertindole|Sertindole 16-24 mg
2526699|NCT02718859|Experimental|IRE & NK cells|Advanced pancreatic cancer patients received both irreversible electroporation (IRE ) and immunotherapy of nature killer(NK) cells
2526747|NCT02718638|Other|physical exercises group|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months (36 sessions). The patients remained seated while performing the exercises that were performed in both lower limbs. Ankle-cuffs and elastic bands (Theraband®, Akron-OH, USA) were used for performed the exercises. The physical exercises consisted of four different exercises and they were administered by a physical therapist following the adapted protocol.
2526783|NCT02718313||Intraventricular conduction delay|Transthoracic echocardiography will be performed to investigate whether the patients have the cardiac disease or not. The transthoracic echocardiography will be performed after the induction of general anesthesia and before the start of surgery.
2526834|NCT02718183|Experimental|PH|Hydrogen peroxide 35% to intracoronal bleaching in discoloration teeth eith endodontic treatment
2526840|NCT02718183|Experimental|PC|Carbamide peroxide 37% to intracoronal bleaching in discoloration teeth eith endodontic treatment
2526873|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in TN patients|Part 1: Acalabrutinib in combination with drugs bendamustine and rituximab (BR) in treatment naive patients
2526874|NCT02717624|Experimental|Part 1: Acalabrutinib+BR in RR patients|Part 1: Acalabrutinib in combination with bendamustine and rituximab (BR) in relapse refractory patients
2526880|NCT02717624|Experimental|Part 2: Acalabrutinib+VR in TN patients|Part 2: Acalabrutinib in combination with venetoclax and rituximab (VR) in treatment naive patients
3173959|NCT00617994|Experimental|Group C|Patients with active stable plaque psoriasis treated with topical cream application on lesions involving a larger percent BSA than Cohort 2.
2527030|NCT02716636|No Intervention|Fast placement|Placement of the tenaculum quickly and without avoiding ratchet
2527031|NCT02716636|Experimental|Slow placement of the tenaculum|Placement of the tenaculum over a 7-10 second time frame and not allowing the tenaculum to ratchet audibly.
2527072|NCT02716428|Experimental|Cohort 1|12 weeks of Faldaprevir plus TD-6450 plus Ribavirin
2527075|NCT02716428|Experimental|Cohort 2|12 weeks of Faldaprevir plus TD-6450
2527138|NCT02716090|Experimental|Dalap Duo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel cream. Apply the product on the areas affected by acne once a day in the evening for 84 days.
2527139|NCT02716090|Active Comparator|Epiduo®|0.1% of adapalene and 2.5% and benzoyl peroxide gel. Apply the product on the areas affected by acne once a day in the evening for 84 days.
3199949|NCT00885690|Active Comparator|Olanzapine|Olanzapine 10-20 mg
3199950|NCT00885716|Experimental|communication skills training|group training in shared decision making.
2527278|NCT02715115|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
2527279|NCT02715115|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
2527328|NCT02714608|Experimental|Ginsenoside H dripping pills|Drug: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
2527330|NCT02714608|Experimental|Ginsenoside H dripping pills+Placebo|Drug: Ginsenoside H dripping pills ,Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
2527331|NCT02714608|Placebo Comparator|Placebo|Drug: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
2527410|NCT02714257|No Intervention|Enhanced Usual Care - control group|Participants will receive enhanced usual care by reviewing three printed pamphlets on fall risks and recommendation to exercise. In addition, to maximize patient safety, the investigators will communicate the baseline bone density results (measured by Dual-energy X-ray absorptiometry, DXA) to the patient's primary care provider, and any critical values of a baseline measure.
2527412|NCT02714257|Experimental|Enhanced Usual Care plus Exercise Coaching Intervention|Participants will receive the three printed pamphlets on fall risks and exercising in groups (same as the controls) plus: (1) an exercise program that includes strength, balance, and aerobic exercises; (2) an exercise coach that provides in-person and telephone support/feedbacks to enhance participation in the exercise program; and (3) regular progress reports sent by coaches by fax/Electronic Health Records every 4 months, to communicate the patient's progress.
2527468|NCT02713984|Experimental|HER2 positive cancers|Patients with relapsed and refractory cancer of HER2 expression will be treated with anti-HER2 CAR-T cells
2527568|NCT02713217||Pre-Implementation Cohort|Eligible patients will be recruited and enrolled prior to implementation of the blended integrated care model in each study site. They will be exposed to care as usual in the CBOCs.
2527569|NCT02713217||Post-Implementation Cohort|"Eligible patients will be recruited and enrolled following implementation of the blended integrated care model in each study site. These participants are thus exposed to the intervention model."
2527611|NCT02712970||stage-I|Single pit in the midline, no lateral extension. Pit-picking technique will be performed.
2527612|NCT02712970||Stage-II|>1 pits in the midline, no lateral extension. Pit-picking and Bascom cleft lift techniques will be performed.
2527614|NCT02712970||Stage-III|Midline pit/pits plus lateral extension in one direction. Bascom cleft lift technique will be performed.
2527616|NCT02712970||Stage-IV|Midline pit/pits plus lateral extension in both directions. Rhomboid excision with the Limberg Flap will be performed.
3173960|NCT00618007|Experimental|30 mg QD|
3173961|NCT00618007|Experimental|20 mg QD|
3173962|NCT00618007|Placebo Comparator|Placebo|
3173963|NCT00618033|Active Comparator|1|
3173964|NCT00618033|Active Comparator|2|
3173965|NCT00618085|Experimental|1|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the experimental group will receive 2 instruction DVD's introducing them to motor imagery practice, taking 35 minutes in total. The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to help incorporate motor imagery within the therapy. Thereafter the therapist will help the patient use motor imagery as part of their normal treatment. The total amount spent on motor imagery during therapy sessions will be 6.5 hours in 6 weeks."
2526711|NCT02718976|Experimental|Shamrock guided by US/MR image fusion|Use of US/MR image fusion guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
2526715|NCT02718976|Other|Shamrock guided by US|Use of US guided Shamrock technique to place lumbar plexus block (20 ml 2% lidocaine with epinephrine added gadoterate meglumine).
2526758|NCT02718534|Experimental|ERTAS-1|first limb rehabilitation therapy took place within 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
2526761|NCT02718534|Active Comparator|ERTAS-2|first limb rehabilitation therapy took place after 48h for patients with acute stroke (modified Rankin Scale Score 3-4)
2526831|NCT02718144|Experimental|estetrol|3 + 3 design with inter-patient dose escalation
3199951|NCT00885716|Active Comparator|cognitive training|standard group training of cognitive skills (Konzentrationstraining)
3199952|NCT00885729|Experimental|Stem cells|Cartilage defect are treated surgical either with chondrocytes or stem cells
3199953|NCT00885729|Active Comparator|Rehabilitation|Active rehabilitation program
3199954|NCT00885781|Experimental|SMOFlipid|
3199955|NCT00885781|Active Comparator|Lipovenoes MCT|
3199956|NCT00885794|Experimental|0.5 mg Ranibizumab|3 intravitreal injections of 0.5 mg Ranibizumab every 5 weeks
3199957|NCT00885794|Experimental|1.0 mg of Ranibizumab|3 intravitreal injections of 1.0mg Ranibizumab every 5 weeks
3199958|NCT00885820|Experimental|1|Protocol biopsies at 1, 2 and 3 months
2527070|NCT02716350|Experimental|B-GOS|powder, 3.5g/day
2527074|NCT02716350|Placebo Comparator|Maltodextrin|powder, 3.5g/day
2527089|NCT02716129|Active Comparator|Group 1|Morphine group
2527099|NCT02716129|Active Comparator|Group 2|Morphine plus Nalbuphine group
2527181|NCT02715895|Experimental|Friso|Friso formula feeding
2527185|NCT02715895|Experimental|Wyeth|Wyeth formula feeding
2527186|NCT02715895|Active Comparator|Breast milk|Breast milk feeding
2527248|NCT02715362|Experimental|TAI-GPC3-CART cells|A single dose of GPC3-CART cells will be administered by transcatheter arterial infusion(TAI) mediated as one dose infusion. The dose is 1-10x106/kg GPC3-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide. Patients will undergo cannula--DSA radiography--CAR-T cells perfused into hepatic artery. The cells perfusion process would last 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
2527280|NCT02715024|Experimental|Tamsulosin alone|
2527283|NCT02715024|Experimental|Tamsulosin + solifenacin|
2527338|NCT02714738|Experimental|Infraclavicular Block|The patient will be positioned supine. The operating limb may be positioned abducted or adducted by side depending on operator preference and patient factors. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. Local anaesthetic (lidocaine 2% with epinephrine 1:200.000) will be injected posterior to the artery with the intention achieving the U shape, cranio-postero-caudal spread. Local anaesthetic will be deposited to the lateral and medial cords as well, if required. The total dose of the local anaesthetic will be 20-30 ml, as clinically indicated.
2527346|NCT02714738|Experimental|Axillary Brachial Plexus Block|The patient will be positioned supine with the operative upper limb extended, flexed at the elbow, rested on a pillow to expose the axilla. After standard preparation, the needle will be directed towards the target area using an in-plane, short-axis technique. All four nerves in the axillary region are being blocked. The local anesthetic (lidocaine 2% with epinephrine 1:200.000, 15-25 ml) will be divided among the four nerves as clinically indicated by the spread, but at least 3 ml applied to each nerve.
3199959|NCT00885820|Active Comparator|2|No protocol biopsies
3199960|NCT00885833|Experimental|Fludarabine|
3199961|NCT00885859||1|responders: patients who have a pain reduction of 30% or more after two weeks TENS-treatment
3199962|NCT00885859||2|non-responders: patient who have a pain reduction smaller than 15% after two weeks TENS-treatment
3199963|NCT00885872|Experimental|Treat|At visit 2 each eligible subject will be allocated to rosuvastatin. Subjects who reach the criteria at visit 3, dosage of rosuvastatin will be titrated. The subjects will be encouraged to take the study drug at the same time each day for 104 weeks.
3199964|NCT00885885|Experimental|1|Panitumumab+FOLFOX 4
2527649|NCT02712593|Experimental|Niagen™ 100|
2527660|NCT02712593|Experimental|Niagen™ 300|
2527665|NCT02712593|Experimental|Niagen™ 1000|
2527667|NCT02712593|Experimental|Placebo|
2527747|NCT02712255|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2527750|NCT02712255|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the patient. The partner is actively participating in forming plans by the patient.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning"
3199965|NCT00885885|Experimental|2|Panitumumab+FOLFIRI
3199966|NCT00885898|Active Comparator|1|"Non-invasive ventilation"
3199967|NCT00885898|Active Comparator|2|"Conventional"
3199968|NCT00885911||Extraglottic device|The laryngeal mask airway (LMA) used during pediatric anesthesia for routine and difficult airway management.
3199969|NCT00885924|Active Comparator|Active treatment|Desmopressin 0.3 microgram/kg
3199970|NCT00885924|Placebo Comparator|Placebo|NaCl 0.9%
3199971|NCT00885937|Experimental|Arm 1|
3199972|NCT00885937|Active Comparator|Arm 2|
3199973|NCT00885937|Placebo Comparator|Arm 3|
3199974|NCT00885950||Colorectal liver metastases|Patients with colorectal liver metastases undergoing partial hepatic resection who were preoperatively treated with either neoadjuvant chemotherapy or not and/or anticoagulants or not
3199976|NCT00885989|Experimental|1|
3199977|NCT00885989|Placebo Comparator|2|
2526902|NCT02717507|Experimental|Arm I (carvedilol)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
2526907|NCT02717507|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
2527019|NCT02716649||All participants|No intervention
2527069|NCT02716480|Experimental|Mobility Coaching|"45 patients undergoing bariatric surgery received a monthly mobility coaching session of 20 to 30 min by phone during 6 months."
2527073|NCT02716480|Experimental|Diet Coaching|"45 patients undergoing bariatric surgery received a monthly diet coaching session of 20 to 30 min by phone during 6 months."
2527093|NCT02716116|Experimental|Part 1: Dose Escalation Component|TAK-788 treatment for participants with advanced NSCLC.
2527103|NCT02716116|Experimental|Part 2: Expansion Cohort 1|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have either not received or not shown an objective response to an EGFR tyrosine kinase inhibitors (TKI), and who have no active, measurable central nervous system (CNS) metastases.
2527110|NCT02716116|Experimental|Part 2: Expansion Cohort 2|TAK-788 treatment for NSCLC participants with HER2 exon 20 activating insertions or point mutations and no active, measurable CNS metastases.
2527118|NCT02716116|Experimental|Part 2: Expansion Cohort 3|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions or HER2 exon 20 activating insertions or point mutations and active, measurable CNS metastases.
2527119|NCT02716116|Experimental|Part 2: Expansion Cohort 4|TAK-788 treatment for NSCLC participants with other targets against which TAK-788 is active (examples include EGFR exon 19 deletions or exon 21 substitutions [with or without T790M mutations] and other uncommon EGFR activating mutations), without active CNS metastases.
2527121|NCT02716116|Experimental|Part 2: Expansion Cohort 5|TAK-788 treatment for NSCLC participants with EGFR exon 20 activating insertions, who have previously shown an objective response to an EGFR TKI and subsequently progressed without active CNS metastases.
2527123|NCT02716116|Experimental|Part 2: Expansion Cohort 6|TAK-788 treatment NSCLC participants with EGFR exon 20 activating insertions, who have not received prior systemic anticancer treatment for locally advanced or metastatic disease without active CNS metastases
2527124|NCT02716116|Experimental|Part 2: Expansion Cohort 7|TAK-788 treatment for participants with solid tumors other than NSCLC with EGFR/HER2 mutations against which TAK-788 is active without active CNS metastases.
2527126|NCT02716116|Experimental|Part 3: Extension Cohort|TAK-788 treatment for participants with previously treated locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 20 insertion mutations.
2527129|NCT02716116|Experimental|Part 1A: Dose Escalation Combination Component|TAK-788 treatment in combination with pemetrexed/carboplatin for participants with NSCLC harboring EGFR exon 20 insertion mutation in approximately 3 dose levels. This cohort is only for participants at selected sites in the United States.
2527131|NCT02716116|Experimental|Part 1B, Cohort 1: TAK 788 Antidiarrhea Prophylaxis, Monotherapy|TAK-788 monotherapy with primary antidiarrhea prophylaxis for participants with NSCLC with EGFR exon 20 activating insertions and who have no active, measurable CNS metastases. This cohort is only for participants at selected sites in the United States.
2527132|NCT02716116|Experimental|Part 1B, Cohort 2: TAK 788 Antidiarrhea Prophylaxis, Combination Therapy|TAK-788 in combination with pemetrexed/carboplatin treatment with primary antidiarrhea prophylaxis for participants with NSCLC with EGFR exon 20 activating insertions and who have no active, measurable CNS metastases. This cohort is only for participants at selected sites in the United States.
3166611|NCT00527358|Experimental|SAFER|"The intervention community will receive 4 services:~community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, and provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center: will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
3166612|NCT00527358|No Intervention|2|Business as usual.
3166613|NCT00527371|Experimental|PVP|Photoselective vaporization of the prostate.
2527321|NCT02714933|Experimental|MRI sequence Advanced ZTE|
2527420|NCT02714179|Active Comparator|Group Preventive (Group PV),|Group II: i.V. paracetamol 1 g (100 ml) was given before the end of surgery.
3166614|NCT00527371|Active Comparator|TURP|Transurethral resection of the prostate.
3166615|NCT00527410|Experimental|RTA 744|RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
3166616|NCT00527436|Other|Dietary Supplement|Fish oil pill
3166617|NCT00527436|Placebo Comparator|Placebo|Placebo matched corn oil pill
3166618|NCT00527527|Active Comparator|1|8 flexion distraction visits
3166619|NCT00527527|Active Comparator|2|12 flexion distraction visits
3166620|NCT00527527|Active Comparator|3|18 flexion distraction visits
3166621|NCT00527527|Placebo Comparator|4|8 placebo control visits
3166622|NCT00527553|Experimental|A|daily consumption of a regular egg
3166623|NCT00527553|Experimental|B|daily consumption of a lutein-enriched egg, eggs laid by chickens on a lutein-enriched feed.
3166624|NCT00527553|Experimental|C|daily consumtion of a zeaxanthin-enriched egg, eggs laid by chickens on a zeaxantin-enriched feed.
3166625|NCT00527553|Experimental|D|daily egg product from enriched eggs
3166626|NCT00527553|No Intervention|E|control subjects were not blinded as they did not receive any aditional supplementation. Only markers measured during the trial period as a control.
3166627|NCT00527657|Experimental|Lomustine + Temozolomide + Thalidomide|Lomustine starting dose 30 mg/m^2 by mouth daily on Day 1 and 29. Temozolomide 75 mg/m^2 by mouth daily on Days 1 to 42. Thalidomide 200 mg/m^2 by mouth daily.
3166628|NCT00527670||Normal Controls|Healthy patients undergoing laparoscopic surgery for cholelithiasis, appendicitis, and adrenalectomy.
3166629|NCT00527670||Recurrent Hernia|Patients presenting for laparoscopic repair of ventral or incisional hernias.
2526740|NCT02718547|Experimental|Participants receiving Combigan drops in order to reduce IOP|All of the Participants in this study will be instructed to instill combigan eye drops twice daily in one eye (randomly chosen)
2526791|NCT02718339|Experimental|Intensive counseling by a pulmonologist|Counselor visit during hospitalization, telephone follow up for 4 weeks and a follow up visits.
2526795|NCT02718339|No Intervention|Usual care|
3199978|NCT00886028|Experimental|Liposomal doxorubicin|Thirty patients with MPM who received liposomal doxorubicin 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
3199979|NCT00886041|Other|laparoscopy group|laparoscopy
3199980|NCT00886041|Active Comparator|ovarian stimulation group|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
3199981|NCT00886054||Neurocritical patients|Neurocritical patients including those sustaining head injury, cerebrovascular events (such as intracerebral hemorrhage, subarachnoid hemorrhage, etc.), brain tumor, or hydrocephalus.
3199982|NCT00886067|Experimental|2-[18F]-F-A85380|Single microdose
3199983|NCT00886067|Experimental|AZD1446|Single oral administration
2527054|NCT02716519|Experimental|Santyl|Collagenase ointment applied topically once per day for up to six weeks
2527055|NCT02716519|Active Comparator|Standard Card|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
2527097|NCT02716259|Experimental|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and oral antiseptics (clorhexidine 0.12% rinse),
2527108|NCT02716259|Placebo Comparator|Supragingival prophylaxis|Two sessions of supragingival prophylaxis under local anesthesia and an oral rinse with no antiseptic properties.
2527154|NCT02715869|Active Comparator|A pharmacologic cardiac preconditioning|Sevoflurane as a pharmacologic preconditioner for the heart
2527172|NCT02715869|Active Comparator|B ischeamic preconditioning|ischemic preconditioning by inflation the cuff of blood pressure
2527256|NCT02715466|Experimental|Gelatine|Balanced gelatine solution
2527260|NCT02715466|Active Comparator|Electrolyte|Balanced electrolyte solution
2527318|NCT02714907|Experimental|AF assessed from Cortrium C3 data|Atrial fibrillation assessed from Cortrium C3 device data
2527319|NCT02714907|Experimental|AF assessed from Holter data|Atrial fibrillation assessed from Holter data
2527375|NCT02714517|Experimental|hydrotherapy|patients receive daily conventional physiotherapy and three 30- minutes sessions of in- water exercises per week, for four weeks
2527376|NCT02714517|Active Comparator|controls|patients receive daily conventional physiotherapy and three 30- minutes sessions of on- land exercises per week, for four weeks
2527390|NCT02714166|Experimental|Sunscreen lotion Sun Protection Factor 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2527391|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
2527486|NCT02714075|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
2527535|NCT02713360|Experimental|Cognitive therapy|The intervention consists of 3 steps. 1: Consultation with a nurse that aims of identifying what the anxiety consist of and how the patient experiences his or her life situation with an ICD. A plan is made to structure the treatment. 2: Participation in an individualized intervention based on anxiety type specific protocols. 3. The intervention is considered finalized if the patient has a HADS-A score under 8 two times in a row. The intervention group will receive usual care as well.
2527539|NCT02713360|No Intervention|Usual care|The control group will receive usual care which consists of control of ICD, disease control and treatment, and at one of the sites an offer of a group information meeting where experiences and events with ICD are discussed. The meeting takes place at Rigshospitalet every other month.
2527570|NCT02713113|Active Comparator|group 1|patients were given 1.5 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2527571|NCT02713113|Active Comparator|group II|patients were given 2 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2527574|NCT02713113|Active Comparator|group III|patients were given 4 mg / kg. of sugammadex administrated (according to the IBW after T2 of TOF)
2527613|NCT02712957|Experimental|NEO6860|NEO6860 is provided as a powder in individual containers to be reconstituted as a suspension. In this arm patients will receive both NEO6860 and a placebo of naproxen.
2527615|NCT02712957|Placebo Comparator|Placebo|In this arm, patients will receive both placebo: oral liquid suspension (NEO6860 placebo) and capsule (naproxen placebo).
2527618|NCT02712957|Active Comparator|Naproxen|Naproxen is provided as over-encapsulated tablets using a commercially approved medication. In this arm patients will receive both naproxen and a placebo of NEO6860.
2527642|NCT02712580|Active Comparator|First investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light."
2527650|NCT02712580|Active Comparator|Second investigational device|"official name of product: Wireless microcurrent Stimulation Wetling W 200 n=47 patients The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light."
2527662|NCT02712580|Placebo Comparator|ES Wetling W200 with white light|Placebo device - 'ES Wetling W200 Placebo with white light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
2527666|NCT02712580|Placebo Comparator|ES Wetling W200 with red light|Placebo device - 'ES Wetling W200 Placebo with red light' n=47 patients The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
2526786|NCT02718456|Experimental|CD4 testing|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week.
2526787|NCT02718456|Experimental|CD4 testing plus peer counseling|Standard HIV counseling and testing plus blood drawn for CD4 testing at time of HIV diagnosis. CD4 results are reported to participants via telephone within 1 week. Additionally, a trained peer counselor provides supplemental counseling at the time of diagnosis and at the 1 week telephone follow-up.
2526826|NCT02718027||Participants with Alport Syndrome|Participants diagnosed with Alport syndrome aged between 2 months and 50 years
2526868|NCT02717715|Experimental|Intervention group|Stroke patients from the intervention group will be, on top of usual care, offered a holistic home based and semi-supervised stroke rehabilitation program followed by a period of tele-supervision.
2526869|NCT02717715|No Intervention|Control group|The participants in the control group will only receive usual care.
2526941|NCT02717338|Experimental|Competence|Participants will be assigned to review our donor coping website.
2526953|NCT02717338|Experimental|Autonomy|Participants will be assigned to receive a brief telephone interview.
2526963|NCT02717338|Experimental|Relatedness|Participants will be asked to join a closed Facebook group for one month.
2526969|NCT02717338|Experimental|Competence + Autonomy|Participants will be assigned to the web site review, followed by the brief telephone interview.
2526972|NCT02717338|Experimental|Competence + Relatedness|Participants will be assigned to the web site review, followed by the one-month Facebook group membership.
2526974|NCT02717338|Experimental|Autonomy + Relatedness|Participants will be assigned to the brief telephone interview, followed by the one-month Facebook group membership.
2526976|NCT02717338|Experimental|Competence + Autonomy + Relatedness|Participants will be assigned to the web site review, brief telephone interview, and one-month Facebook group membership.
2526977|NCT02717338|No Intervention|Treatment-as-Usual Control|Participants will receive the standard communications that New York Blood Center has with all first-time donors.
2527002|NCT02716675|Experimental|Group 1: Low-Dose VRC01|Participants will receive an intravenous (IV) infusion of 10 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2527003|NCT02716675|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2527004|NCT02716675|Placebo Comparator|Group 3: VRC01 Placebo|Participants will receive an IV infusion of placebo for VRC01 over about 15 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2527045|NCT02716532|Other|Peptamen AF|over 7 days
2527078|NCT02716363|Experimental|Device : Rotablator|We compare in-hospital and long-term efficacy or safety of elective Rotational Atherectomy versus bailout Rotational Atherectomy and low-volume operator versus high-volume operator in patients with severe calcified lesions treated.
2527127|NCT02716051|Experimental|MRI|Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.
2527130|NCT02716051|Active Comparator|PET|At day 1 , in the morning, patient will undergo an PET analysis
2527147|NCT02715830|Experimental|One Artery|In this arm after obtain the good result after the angioplasty of one artery the procedure stops
2527152|NCT02715830|Experimental|More than one artery|In this arm, after obtain a good result of the angioplasty of one artery, we continue trying one or two more arteries
2527209|NCT02715544|Experimental|Intervention group|The group will receive healthy lifestyle intervention
2527215|NCT02715544|Active Comparator|control group|Other: physical activity and dietary guidelines
2527300|NCT02715232|Experimental|Female-to-Males|Female-to-Male Transsexuals receiving Testosterone treatment
2527304|NCT02715232|Experimental|Male-to-Females|Male-to-Female Transsexuals receiving Estradiol and Anti-androgen treatment
2527310|NCT02715232|No Intervention|Female Controls|Female Controls receiving no intervention
2527311|NCT02715232|No Intervention|Male Controls|Male controls receiving no intervention
3199984|NCT00886080|Experimental|Add-on arrhythmia surgery|"Adjuvant anti-arrhythmic surgery consists of a beating heart epicardial box isolation of all pulmonary veins using microwave energy (Flex 4 or Flex 10 ablation probes and Microwave generator by Guidant/Afix, Fremont, CA, USA). The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. In addition excision or exclusion of the left atrial appendage is performed in both the treated as the control group."
3199985|NCT00886093|Experimental|Sequence 1|
3199986|NCT00886093|Experimental|Sequence 2|
3199987|NCT00886106|Experimental|1|Remifentanil
2527547|NCT02713321||Health Home patients|The cohort is made up of patients with type 2 diabetes, insured by Medicaid, and eligible for participation in a Medicaid Health Home (either due to HIV infection, serious mental illness, substance abuse, or multiple chronic conditions). One group will include patients who participate in the Health Home program.
2527550|NCT02713321||non-Health Home patients|The second group will include patients who do not participate in the Health Home program, but have type 2 diabetes, are insured by Medicaid, and meet eligibility requirements for the Health Homes.
2527572|NCT02713126|Placebo Comparator|Placebo|Subjects will undergo cardiac exercise training and receive oral placebo capsules three times per day for 12 weeks while wearing an accelerometer
2527573|NCT02713126|Active Comparator|Sodium Nitrite|Subjects will undergo cardiac exercise training and receive oral sodium nitrite capsules three times per day for 12 weeks while wearing an accelerometer
2527617|NCT02712905|Experimental|INCB059872|
2527640|NCT02712671||Enrolled subjects|Subjects attending the Ian Charleson Centre and agreeing to be tested for latent, subclinical and active tuberculosis using Chest radiograph, Blood interferon gamma release assay, Tuberculin skin testing, Sputum induction for mycobacterial microscopy and culture with spirometry, and Mycobacterium tuberculosis polymerase chain reaction testing.
2527734|NCT02712242|Experimental|Platelet Rich Fibrin|PRF was laid directly on the palatal wound immediately after harvesting the tissue graft and stabilized
3199988|NCT00886106|Active Comparator|2|Midazolam
3199989|NCT00886132|Experimental|Sunitinib|Patients with progressive, recurrent and/or metastatic ACC treated with sunitinib 37.5 mg daily in this single-arm, two-stage phase II trial.
2526871|NCT02717572|Experimental|FDG-PET/CT and FDG-PET/MR|"10 mCI fludeoxyglucose IV bolus approximately 60 minutes before first PET/CT~Immediately following PET/CT scan, the participant will be moved to PET/MR scanner~The scans will take place at baseline and also one more time point between Day 1 and Day 7. There needs to be at least 24 hours between the baseline and repeat imaging"
2526957|NCT02717377|No Intervention|Uninterrupted sitting|Subjects remained seated all day except to rise from the chair to void.
2526968|NCT02717377|Active Comparator|Sitting + one bout of activity|Subjects remained seated all day, except to rise from the chair to void, and to perform one bout of 30-minutes moderate-intensity walking. Physical activity was performed at 0800, after measures of vitals and basal questionnaire assessments, but before breakfast.
2526971|NCT02717377|Experimental|Sitting + microbursts of activity|Subjects rose from the seated position every hour for 6-hours from 0910 to 1430 to complete 5-minute bouts of moderate-intensity walking, yielding a total activity time of 30-minutes.
2527081|NCT02716285|Experimental|Ileocolonic release peppermint oil|Colon-targeted-delivery capsule containing 182mg of Peppermint Oil, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2527084|NCT02716285|Experimental|Small intestinal release peppermint oil (Tempocol®)|Enteric-coated capsule containing 182mg of Peppermint Oil that release the oil in the small intestine, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2527087|NCT02716285|Placebo Comparator|Placebo|Capsule containing microcrystalline cellulose, to be taken orally, 3 times daily for 8 weeks (first week, dosing will be titred).
2527162|NCT02715908|Experimental|LBEC0101|Etanercept 50mg
2527204|NCT02715570|Experimental|Single dose - healthy volunteers|
2527206|NCT02715570|Experimental|Repeat dose - healthy volunteers|
2527211|NCT02715570|Experimental|Single dose - asthmatic patients|
2527289|NCT02715180|Other|Chest computed tomography|Low dose chest computed tomography during expiration and inspiration
2527411|NCT02714322|Experimental|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
2527416|NCT02714322|Active Comparator|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
2527492|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
2527497|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
3166630|NCT00527683|Active Comparator|A|Subjects will receive vigabatrin in escalating doses to 3 grams per day over three weeks, continued for 4 weeks and then tapered to zero over the next 2 weeks.
3166631|NCT00527683|Placebo Comparator|B|Orange juice and administration identical to Arm A.
2527729|NCT02712151|Active Comparator|Abdominal Wall Block with Ropivacaine 0.2%|Patients will receive bilateral transversus abdominis plane and rectus sheath blocks via ultrasound guidance. A total of 1.0ml/kg distributed between the four blocks (0.4+0.4+0.1+0.1) of 0.2% Ropivacaine (max 50ml) will be injected, as a one time single shot injection, into the fours sites. Surgical infiltration of the four port sites will receive 0.4ml/kg of sterile saline.
2527740|NCT02712151|Active Comparator|Surgical Infiltration with Ropivacaine 0.5%|Patients will receive surgical infiltration of local anesthetic into the 4 laparoscopic port sites. A total of 0.4 ml/kg (0.1+0.1+0.1+0.1) of 0.5% Ropivacaine, divided between the four port sites (max 20 ml), will be used. A total of 1ml/kg, divided between the TAP (0.4ml/kg on each side) and RS (0.1ml/kg on each side), of sterile saline will be used for the nerve blocks.
2527791|NCT02711722|Active Comparator|PScli1|Patients are ventilated in Pressure support (PS) according to the Clinical settings for 30min.
2527800|NCT02711722|Active Comparator|NAVAcli|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to match to respiratory muscle unloading reached with PScli1. Patients are ventilated in NAVAcli for 30min.
3166632|NCT00527696|Active Comparator|TVT SECURE|sling
3166633|NCT00527696|Active Comparator|TVT O|sling
3166634|NCT00527761|Experimental|Temozolomide, Docetaxel + Cisplatin|
3166635|NCT00527774||A|HCV(+) maintenance hemodialysis patients
3166636|NCT00527774||B|HCV(-) maintenance hemodialysis patients
3166637|NCT00527800|Experimental|1|Treatment for episodes of uncomplicated malaria
3166638|NCT00527800|Active Comparator|2|Treatment for uncomplicated malaria
3166639|NCT00527800|Experimental|A|Prevention of malaria in HIV uninfected, exposed children
3166640|NCT00527800|No Intervention|B|Prevention of malaria in HIV uninfected, exposed children
3166641|NCT00527813|Experimental|A|prone position for at least 16 hours per day
3166642|NCT00527813|No Intervention|B|semi-recumbent position
3166643|NCT00527865|Experimental|1|6 subjects DAS181 dosage 0.5 mg; 3 subjects placebo
3166644|NCT00527865|Experimental|2|6 subjects DAS181 dosage 1.0 mg; 3 subjects placebo
3166645|NCT00527865|Experimental|3|6 subjects DAS181 dosage 2.25 mg; 3 subjects placebo
3166646|NCT00527865|Experimental|4|6 subjects DAS181 dosage 4.5 mg; 3 subjects placebo
3166647|NCT00527891||Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI Scan
3166648|NCT00527917|Experimental|Uracyst|Sodium chondroitin sulfate
3166649|NCT00527917|Placebo Comparator|Placebo|placebo
3166650|NCT00528008|Active Comparator|A|povidone-iodine
3166651|NCT00528008|Active Comparator|B|chlorhexidine gluconate
3166652|NCT00528034|Experimental|Lymphoscintigraphy|
3166653|NCT00528047|Experimental|PRLX 93936|
2526900|NCT02717585|No Intervention|Control Group|For the no intervention group (Control), patients will only receive standardized treatment for FM at the Pain Clinic. All patients will receive a multifaceted tailored regimen that incorporates one or more lines of pharmacological and/or non-pharmacological therapy. All assessment and management will be performed according to evidence-based therapeutic recommendations put forward by the Canadian Rheumatology Association and Canadian Pain Society.
2526909|NCT02717585|Active Comparator|Treatment Group (CPAP)|In addition to standard FM treatment at the Pain Clinic, patients who are randomized to the treatment will meet with a sleep physician for possible therapy with a Continuous Positive Airway Pressure (CPAP) machine. A CPAP titration study will be arranged for in a laboratory setting, where in addition to the regular parameters of a diagnostic sleep study, CPAP will be titrated upwards starting from 5cm H2O to an optimal setting where the obstructive respiratory events are abolished. Patients will undergo regular follow-up as determined by their sleep physician. Adherence to CPAP treatment will be recorded at follow-up visits.
3199990|NCT00886158||Solid Organ Transplant Recipients|Solid organ transplant recipients receiving their care at Seattle Children's Hospital
3199991|NCT00886171|Experimental|Social Skills Training|
3199992|NCT00886171|Experimental|Physical Activity Training|
3199993|NCT00886184|Experimental|1|Induction of pre hospital early hypothermia in patients having a cardiac .
3199994|NCT00886184|Active Comparator|2|Induction of hypothermia only at hospital arrival.
3199995|NCT00886197||GERD|"Symptomatic reflux subjects who receive esophagogastroscopy, aged from 20 to 70 years old.~Patients with typical reflux symptoms (heartburn and/or acid regurgitation) at least 3 times per week in recent 4 months."
2527433|NCT02714114||Cases: HPV vaccinated group|"Women (18-26 years old) whom are previously vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
2527435|NCT02714114||Controls: HPV unvaccinated group|"Women (18-26 years old) whom are not vaccinated with the bivalent (Cervarix) or quadrivalent (Gardasil) prophylactic HPV vaccine.~No clinical evaluations will be performed."
2527488|NCT02713802|Experimental|Test product|Propofol solution (1% [10 mg/mL]), via intravenous injection
2527495|NCT02713802|Active Comparator|Reference product|Propofol emulsion (1% [10 mg/mL]), via intravenous injection
2527545|NCT02713464|Active Comparator|maternal education|Phase IIa: Pregnant women attending antenatal clinics or postpartum in clinics or hospital who receive programmed maternal education about risks and care of newborn jaundice.
2527549|NCT02713464|No Intervention|Historic control|Phase I: (before-after design) Baseline prevalence of acute bilirubin encephalopathy before maternal education instituted.
2527552|NCT02713464|No Intervention|No intervention|Phase IIb: Opportunistic controls - infants of mothers who failed to receive education about risks and care of newborn jaundice.
2527624|NCT02712918|Experimental|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression. The study utilized the revised version of the Brief Behavioral Activation Treatment for Depression (BATD) protocol from 2011. The treatment was added to treatment as usual. Up to 10 sessions were administered.
2527625|NCT02712918|Placebo Comparator|Standard care|Standard CARE (SC) at the inpatient unit. Mandatory: Therapeutic conversations with psychiatrist, psychologist or M.D, milieu therapy. Optional: Psychosomatic physiotherapy, therapeutic groups, psychopharmacological treatment.
2527635|NCT02712619|Experimental|metformin 250mg|metformin 375/250 mg
2527636|NCT02712619|Experimental|metformin 1000mg|metformin 1000/1000 mg
2527703|NCT02712463||Participants with Schizophrenia|This is an observational study. Data will be collected from the medical records of participants diagnosed with schizophrenia and who had been on oral antipsychotics for at least one year and thereafter have been switched to Long Acting Injectable atypical antipsychotics for at least one year.
2527773|NCT02712034|Placebo Comparator|Medication-assisted treatment (MAT)|Patients will receive standard medication-assisted treatment (MAT) as prescribed by their health care provider.
2527777|NCT02712034|Experimental|MAT + A-CHESS|Patients in the MAT + A-CHESS arm will receive MAT as described plus the A-CHESS recovery support system via a smartphone.
2527857|NCT02711605|Experimental|Unilateral UltraShape treatment|One side of the chest (left or right breast) will be treated with the UltraShape focused ultrasound device, while the opposite will serve as an untreated control.
2527860|NCT02711605|Experimental|Bilateral UltraShape treatment|Both sides of the chest (right and left breasts) will be treated with the UltraShape focused ultrasound device.
2527884|NCT02711150|Experimental|EPD Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed on the Epidural Positioning Device."
2527885|NCT02711150|Active Comparator|Flexed Position Measurements|"Intervention:~PLL Length Measured through US will be done with the subject placed in a flexed lumbar spine position."
3199996|NCT00886210|Active Comparator|1LC with drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
3199997|NCT00886210|Active Comparator|2LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. no drain at the end of operation.
3199998|NCT00886223|Experimental|1|
3199999|NCT00886275|Experimental|Dexmedetomidine|
3200000|NCT00886275|Active Comparator|Midazolam|
3200001|NCT00886275|Experimental|Dexmedetomidine, Midazolam|Combination
3200002|NCT00886301|Other|1|obese or overweight patients with fatty liver or ectopic fat
3200003|NCT00886314|Active Comparator|midazolam|
3200004|NCT00886314|Active Comparator|clown doctor|
3200005|NCT00886327||Postoperative patients|Patients with CD who recently underwent bowel resection
3200006|NCT00886353|Active Comparator|APN01|Healthy volunteers will receive APN01
3200007|NCT00886353|Placebo Comparator|Placebo|Physiological saline administrated i.v.
3200008|NCT00886366|Experimental|1|AZD6714 in 8 increasing oral single doses a-h given to 8 groups (3 on active and 1 on placebo in each group)
3200009|NCT00886366|Experimental|2|2 oral single doses d and g suspensions of AZD6714 given to 2 groups (3+1) together with food
2526916|NCT02717403|Experimental|Educational Website Group|Participants complete a self response electronic questionnaire at baseline. Participant shown how to access the Educational Website on the internet about rheumatoid arthritis. Content includes the following: (i) a learning center; (ii) relevant links to other evidence-based web pages; (iii) news released by major rheumatology and dermatology organizations/societies; and (iv) chronic disease management strategies. Participants assessed at three and six months after baseline via email self response electronic questionnaires.
2526917|NCT02717403|Experimental|Pilot Testing Group|Participants access the Educational Website and Facebook page about rheumatoid arthritis for a period of one week. After 1 week, research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
2526982|NCT02717013|Placebo Comparator|Placebo Diet Restriction|
2526984|NCT02717013|Placebo Comparator|Placebo No Diet Restriction|
2526985|NCT02717013|Active Comparator|HMB Diet Restriction|
2526986|NCT02717013|Active Comparator|HMB No Diet Restriction|
2527060|NCT02716701|Experimental|Exercise Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will be asked to increase their activity level, with a goal of at least doubling their average daily activity (steps)
2527062|NCT02716701|Active Comparator|Control Group|Subjects will wear a wristband activity tracker to monitor their physical activity and will not be encouraged to increase their activity level
2527091|NCT02716168|Experimental|Video consultation|Video consultation between cancer patient, general practitioner and oncologist at the start of chemotherapy treatment
2527104|NCT02716168|No Intervention|usual care|Usual care. The patients General Practitioner will receive standard discharge summary and ambulant notes from the oncologist specialist
2527179|NCT02715960|Experimental|single-arm|intervention: open registry, non-randomized, single-arm trial. Acitretin Capsules: 2.5 per piece.
2527226|NCT02715440|Experimental|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs : 25% reduction of the benzodiazepines dose or related drugs every 2 weeks during nine weeks in order to stop the treatment .
2527233|NCT02715440|No Intervention|Delayed intervention|usual care without intervention
2527354|NCT02714621|No Intervention|Feasibility of MR-HIFU for painful gynaecological metastases|Investigating whether it would be possible to use the MRgHIFU system to treat recurrent gynaecological cancers.
2527362|NCT02714621|Experimental|Treatment using MR-HIFU of painful gynaecological metastases|Testing whether MRgHIFU could be an effective treatment for the symptoms of recurrent gynaecological cancers (pain and bleeding)
2527413|NCT02714361|Active Comparator|Vitamin D3 supplement|Participants will be asked to take 1 capsule of vitamin D3 supplement (1500 IU) (37.5ug) daily for a total duration of 8 weeks.
2527419|NCT02714361|Placebo Comparator|Placebo|Participants will be asked to take 1 capsule of placebo (65% olive oil) daily for a total duration of 8 weeks.
3200010|NCT00886366|Experimental|3|Two increasing oral doses of AZD6714 and one placebo given to 2 groups with 3 type 2 diabetic patients.
3200011|NCT00886392||diabetic macular edema|Type 2 diabetes patients who had clinically significant macular edema by the criterion of the ETDRS
2527696|NCT02712489||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-003"
2527827|NCT02711449|Experimental|Methylprednisolone|125 mg Methylprednisolone intravenously approximately 30 minutes prior to skin incision
2527829|NCT02711449|Placebo Comparator|Placebo|0.9% Saline intravenously approximately 30 minutes prior to skin incision
2527888|NCT02711202|Active Comparator|Sirolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at post-operative day (POD) 14, they were randomized to sirolimus monotherapy.
2527890|NCT02711202|Active Comparator|Tacrolimus|Patients received two applications of anti-CD52 MabCampath (Alemtuzumab), a single dose of anti-TNF-α Remicade (Infliximab) monoclonal antibodies in the early posttransplant period. First 14 days patients received tacrolimus monotherapy, at POD 14, they were randomized to tacrolimus monotherapy.
2527965|NCT02710812||Rectum sparing group|"Patients who have all of the following requirements:~Major or complete clinical response at restaging after 7-8 weeks from the end of neoadjuvant therapy, confirmed at second restaging (after 11-12 weeks from the end of neoadjuvant therapy);~Written informed consent (after 2nd restaging).~Note: They will be subject to wait-and-see approach only patients with cCR."
2528017|NCT02710409|Experimental|Quadrivalent influenza vaccine|
2528018|NCT02710409|Active Comparator|Trivalent influenza vaccine A|Active Comparator A
2528020|NCT02710409|Active Comparator|Trivalent influenza vaccine B|Active Comparator B
2528078|NCT02710058||Arab American Women with Breast Cancer|We conducted a study using an evaluation assessment survey to assess the impact of the AMBER support groups on quality of life parameters, compliance with treatment appointments, and patient/family support. After reviewing preliminary results, we identified several recurrent themes, such as the need for health information, discrepancies around the extent of family support and disease disclosure, and an overall satisfaction with the support groups. To further examine these themes, we are initiating a qualitative research study using an in-depth interview guide. A trained interviewer bilingual in Arabic and English will conduct 10-15 in-depth interviews, to saturation, with AMBER's support group participants over a 6 month period.
2528134|NCT02709811|Experimental|electrochemotherapy|
3200012|NCT00886405|Experimental|Nytroglicerin|
2528908|NCT02704910|Placebo Comparator|Voluntary subject|Patient without parkinson disease, without deep brain stimulation
2528917|NCT02704910|Active Comparator|Patients|Subthalamic stimulation
2528982|NCT02704299|Experimental|Autologous T cells-Based Immunotherapy|Surgery Chemotherapy Autologous T cells-Based Immunotherapy
2529038|NCT02703961|Experimental|experimental|"concurrent and adjuvant chemotherapy with cisplatin and docetaxel combined radical radiotherapy.~During external beam radiotherapy: cisplatin 60mg/m2, d1,d22; docetaxel 60mg/m2, d1,d22.~After external beam radiotherapy: cisplatin 75mg/m2, d43,d64;~The patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.~docetaxel 75mg/m2, d43,d64."
2526936|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study I, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 5 minutes before PET measurement)~Interventions:~Drug: (R,S)-ketamine (Pilot I) Other: PILOT Study I: PET1 Other: PILOT Study I: PET2"
2526937|NCT02717052|Experimental|(R,S)-ketamine (Pilot Study III, 12 subj.)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50 Minutes~Interventions:~Drug: (R,S)-ketamine (Pilot III) Other: PILOT Study III: PET1 Other: PILOT Study III: PET2"
2527034|NCT02716597|Experimental|25% Albumin|25% albumin 75 grams IV over 1 hour once.
2527038|NCT02716597|Placebo Comparator|Placebo|0.9% normal saline 200mL IV over 1 hour once.
2527080|NCT02716337|Other|Intervention group|In the intervention group VLBW infants were fed target fortified human milk Growth and safety were compared to a historical group of VLBW infants fed with standard fortified human milk
2527168|NCT02716012|Experimental|MTL-CEBPA Monotherapy|MTL-CEBPA administered weekly, twice weekly or thrice weekly over 3 weeks followed by 1 week of rest defining a 28-day cycle.
2527175|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (combination)|MTL-CEBPA is administered weekly or twice weekly in combination with sorafenib over 3 weeks followed by 1 week of rest defining a 28-day cycle.
2527180|NCT02716012|Experimental|MTL-CEBPA & Sorafenib (sequential)|MTL-CEBPA is administered weekly or twice weekly for 2 cycles (28-day cycle) followed by 2 cycles of sorafenib
2527286|NCT02715193|Experimental|REMD-477 Treatment A|Administered as a single SC dose in subjects with Type 1 Diabetes
2527293|NCT02715193|Placebo Comparator|Matching placebo|Administered as a single SC dose in subjects with Type 1 Diabetes
2527340|NCT02714725|Placebo Comparator|Control group (Group C)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus normal saline infusion
2527350|NCT02714725|Active Comparator|Group Dexmedetomidine (Group DEX)|During bypass, patients in this group will receive propofol infusion 50 - 70 mcg/kg/min plus dexmedetomidine infusion 0.5 mcg/kg/hr
3200013|NCT00886418|Active Comparator|1|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. A muscle relaxant is used to facilitate tracheal intubation; its administration is continued throughout anesthesia.
3200014|NCT00886418|Experimental|2|Total intravenous anesthesia (propofol and remifentanil) is provided using the close-loop system. No muscle relaxant is used and a placebo is infused throughout anesthesia.
3200015|NCT00886431|Experimental|Vitrification|The embryos of patients allocated to this arm will be cryopreserved by vitrification.
3200016|NCT00886431|No Intervention|Slow cooling|The embryos of patients allocated to this arm will be cryopreserved by the slow cooling method, which is the standard method (=no intervention)
2527620|NCT02712944|Active Comparator|Testosterone|Testosterone intramuscular every 2 weeks
2527622|NCT02712944|Placebo Comparator|Saline|Saline intramuscular every 2 weeks
2527737|NCT02712450||Control group|"Patients included from January 2016 to August 2016~Before regulating doctors training course"
2527742|NCT02712450||Experimental group|"Patients included from January 2017 to August 2017~After regulating doctors training course"
3200017|NCT00886444|Experimental|Ferucarbotran|
3200018|NCT00886457|Experimental|Decitabine plus PEG Interferon-alfa 2B|3.7 mg/m**2 decitabine plus 0, 0.5, 1.5, 3, or 6 mcg/kg PET-Intron
2527894|NCT02711358|Experimental|indomethacin|indomethacin suppositories
2527897|NCT02711358|Placebo Comparator|placebo|placebo suppositories
2527977|NCT02710955|Experimental|Thickened infant formula|
2528011|NCT02710357|Active Comparator|Mandibular complete denture|Participants allocated to this group will not receive any additional treatment. When needed, retreatment or any adjustment/repair in the dentures will be performed accordingly. Participants will receive regular maintenance for their dentures, including adjustments for the elimination of sore areas, denture relining and repair of fractures, when needed, until the end of the follow-up period.
2528012|NCT02710357|Experimental|Single-implant mandibular overdenture|Participants allocated to this group will have an implant placed in the mandibular midline and after 4 weeks (healing period - early loading) an attachment system will be tightened and a retention matrix will be incorporated to the mandibular denture.
2528066|NCT02710149|Experimental|B Cell Malignancies|The trial will be conducted in a manner of simon two-stage design with Anti-CD20-CAR-transduced T cells, beginning in the first stage with the aim of over 30% reaction rate among 15 patients with B cell malignancies. Only when the expected reaction rate is achieved the 30 patients left can be recruited.
2528108|NCT02709863|Active Comparator|Sevoflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
2528111|NCT02709863|Active Comparator|Desflurane|1-1.5 minimum alveolar concentration (MAC), inhalation route, during operation
2528114|NCT02709863|Active Comparator|Propofol|6-10 mg/kg/h, iv infusion, during operation
3200019|NCT00886470|Experimental|ST266 1|Topical treatment every other day
3200020|NCT00886470|Experimental|ST266 2|Topical treatment every 4th day
3200021|NCT00886470|Experimental|ST266 3|Topical treatment every 7th day
2528325|NCT02708602||β2AR Arg16Arg (AA group)|People with β2AR Arg16Arg genotype.
2528329|NCT02708602||β2AR Arg16Gly (AG group)|People with β2AR Arg16Gly genotype.
2528332|NCT02708602||β2AR Gly16Gly (GG group)|People with β2AR Gly16Gly genotype.
2528334|NCT02708602||β2AR Gln27Gln (CC group)|People with β2AR Gln16Gln genotype.
2528335|NCT02708602||β2AR Gln27Glu (CG group)|People with β2AR Gln27Glu genotype.
2528336|NCT02708602||β2AR Glu27Glu (GG group)|People with β2AR Glu27Glu genotype.
2528453|NCT02707692|Other|Placebo, Flu, Pneumovax|"Each subject will take Influenza (Fluarix®, GSK), Pneumococcal (Pneumovax®23, Merck), and placebo. Randomization will determine the order in which the subjects receive the injections. There are six potential study arms, one for each order in which someone could receive the injections:~Arm 1: Placebo, Flu, Pneumovax"
2528456|NCT02707692|Other|Arm 2: Placebo, Pneumovax, Flu|Arm 2: Placebo, Pneumovax, Flu
3200022|NCT00886509|Experimental|Collateral promotion; PCI after 6 months|First pegGCSF or placebo; PCI after 6 months
3200023|NCT00886509|Experimental|Collateral promotion after PCI at baseline|Collateral promotion with pegGCSF after PCI at baseline
2526949|NCT02717325|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application fo test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application
2527027|NCT02716909|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
2527029|NCT02716909|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
2527079|NCT02716441||Radio-opaque Tissue Markers|Patients undergoing rotator cuff repair with implantation of radio-opaque tissue markers
2527166|NCT02715999|Active Comparator|Quadratus Lumborum Block|Quadratus Lumborum block group (QL) patients will receive unilaterally Quadratus Lumborum block using Bupivacaine 0.2 %
2527174|NCT02715999|Active Comparator|Transversus abdominis plane block|Transversus abdominis plane block (TAP) patients will receive unilaterally TAP block using Bupivacaine 0.2 %
2527254|NCT02715401|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
2527259|NCT02715401|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
2527275|NCT02714946|Active Comparator|LA Arm|Percutaneous Laser Ablation
2527277|NCT02714946|Active Comparator|RFA Arm|Percutaneous Radiofrequency Ablation
2527357|NCT02714842|Experimental|Radiolabelled Diclofenac tablet A|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2527361|NCT02714842|Experimental|Radiolabelled diclofenac tablet B|Single dose of delayed release diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2527363|NCT02714842|Active Comparator|Voltaren|Single dose of enteric coated diclofenac sodium (50 mg) tablet radiolabelled with 4 MBq 99mTc
2527365|NCT02714842|Experimental|Radiolabelled diclofenac tablet C|Single dose of delayed release diclofenac sodium (25 mg) tablet radiolabelled with 4 MBq 99mTc
2527423|NCT02714192|Experimental|BCTT|Participants received an standardized exercise stress test within 7 days of concussive injury. Stress test is stopped when participant experiences any exacerbation of symptoms. Heart rate at time of symptom exacerbation is referred to as the threshold heart rate (THR). Stress test is known as the Buffalo Concussion Treadmill Test.
2527424|NCT02714192|No Intervention|No BCTT|All participants in the no intervention arm did not get assessed using the BCTT until they had fully recovered or when they had their second clinic visit fourteen days after their first visit.
2527472|NCT02713893|Experimental|Econazole nitrate 1% plus Benzydamine HCl 0.12%|5 grams of Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days
2527474|NCT02713893|Active Comparator|Placebo plus Econazole nitrate 1%|5 grams of Placebo plus Econazole nitrate 1% intravaginal cream, once daily for 15 consecutive days
2527476|NCT02713893|Active Comparator|Placebo plus Benzydamine HCl 0.12%|5 grams of Placebo plus Benzydamine HCl 0.12% intravaginal cream, once daily for 15 consecutive days.
2527477|NCT02713893|Placebo Comparator|Placebo|5 grams of Placebo intravaginal cream, once daily for 15 consecutive days.
2527542|NCT02713503||Healthy Drivers|Driving Observation and VisionCoach
2527595|NCT02713152||Patients with OAG|Patients with a diagnosis of Open Angle Glaucoma
2527598|NCT02713152||Controls|Controls without a diagnosis of Open Angle Glaucoma
2527645|NCT02712827|Experimental|Progrip|The Progrip group is the intervention group. Patients will undergo laparoscopic total extraperitoneal repair of inguinal hernia. The surgeon will use a self-gripping mesh to repair the hernia. No fixation is required for the mesh.
2527654|NCT02712827|Active Comparator|Non-Progrip|"The Non-Progrip group is the control group.~Operation is performed under general anesthesia. A standard three-trocar technique is used: one infra-umbilical camera trocar (1cm) and two 5mm trocars placed at midline between the umbilicus and pubic bone (or one at the side of inguinal hernia). A laparoscope is inserted to the preperitoneal space through the incision. The space is insufflated with carbon dioxide. Dissection is performed, hernia content (if any) is reduced.~A non self-gripping synthetic mesh is placed. Fibrin glue is used for fixation."
2527727|NCT02712307|Experimental|5 days|Phenoxymethylpenicillin 800 mg x 4 for 5 days
2527731|NCT02712307|Active Comparator|10 days|Phenoxymethylpenicillin 1000 mg x 3 for 10 days
3200024|NCT00886522|Experimental|Intrabone cord blood infusion|All adults patients with hematological malignancies, lacking a HLA matched donor but with a HLA compatible CB unit, fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
2527918|NCT02711059|Active Comparator|parathyroidectomy|change in insulin resistance
2527920|NCT02711059|No Intervention|control|the study participant will be examined parallel with the active comparator
2527935|NCT02710773|Experimental|Backward Walking Treadmill Training|The subjects will perform a backward walking training on treadmill device
2527937|NCT02710773|Active Comparator|Treadmill training|The subjects will perform a walking training on treadmill device
2527991|NCT02710500|Experimental|Cohort 1 (Low Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 2 x 10^12 in one muscle.~Intervention Drug: rAAVrh.MHCK7.DYSF.DV"
2527993|NCT02710500|Experimental|Cohort 2 (High Dose)|"Three (n=3) dysferlin deficiency subjects will receive bilateral injections with one extensor digitorum brevis muscle (EDB) receiving the rAAVrh74.MHCK7.DYSF.DV and the other side receiving saline alone.Subjects will receive a total dose of 6 x 10^12 vg in one muscle.~Intervention Drug: rAAVrh74.MHCK7.DYSF.DV"
2528038|NCT02710305|Active Comparator|Group A|oral hyoscine butyl bromide tablets plus lidocaine cream
2528044|NCT02710305|Placebo Comparator|Group B|oral placebo tablets plus placebo cream
2528082|NCT02710032|Experimental|Intervention|Social Network-Based Adherence Intervention
2528085|NCT02710032|No Intervention|Control|Control
3200025|NCT00886561|Experimental|HIV risk reduction intervention|Behavioral intervention designed to reduce HIV risk behaviors and enhance enhance HIV-preventive behaviors among female sex workers (FSWs) in Armenia
3200026|NCT00886561|Active Comparator|Wait list control|Will receive behavioral intervention after completion of study upon request.
3200027|NCT00886574|Active Comparator|Aspirin|Aspirin 100 mg once a day
3200028|NCT00886574|Active Comparator|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
3200029|NCT00886652|Experimental|Exercise|"The patients of the Exercise group were submitted to a four-month physiotherapy protocol, with three weekly sessions of 60 minutes each, accompanied by a physiotherapist, and consisting of warm-up, aerobic exercise on an electric treadmill, and then winding down and relaxation.~Each patient in this group was therefore submitted to an average of 48 sessions of exercises, always carried out at the same physiotherapy center."
2527036|NCT02716571|Other|Healthy Donors|Healthy Donors will given white blood cell and plasma
2527068|NCT02716389|Other|Mask on|
2527071|NCT02716389|Other|Mask off|
2527100|NCT02716142|Experimental|Group A|rectal misoprostol 400 microgram
2527111|NCT02716142|Active Comparator|Group B|sublingual misoprostol 400 microgram
2527158|NCT02715921|Experimental|Cystic fibrosis patients|Receive tele-exercise training and undergo pulmonary function testing and exercise testing
2527207|NCT02715557|Experimental|Full Access to the relapse prevention program|The participants will receive access to the relapse prevention program throughout the entire 6-week trial period.
2527214|NCT02715557|Experimental|TAU|The participants will receive treatment as usual (TAU) for 6-weeks, and will receive access to the relapse prevention program after the completion of the 6 month follow-up.
2527266|NCT02715271||Retrospective cohort|Tuberculosis patients submitted to therapeutical surgery during the last 2-5 years.
2527267|NCT02715271||Prospective cohort|Tuberculosis patients prospectively submitted to therapeutical surgery.
2527341|NCT02714647|Experimental|Experimental|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on accuracy over speed prior to practicing the motor task. Participants will also have extended deadlines (750 ms) throughout the task to ensure an accuracy preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
2527349|NCT02714647|Sham Comparator|Control|"This group will perform the attention demanding activity (a variant of the Simon Task) with a focus on speed over accuracy prior to practicing the motor task. Participants will also have short deadlines (250 ms) throughout the task to ensure a speed preference. Participants will then perform 50 trials of the simulated feeding task where they will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90°, and 135° around the start cup as fast as possible using the non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition where each trial will consist of 15 repetitions."
2527407|NCT02714374|Experimental|GL-ONC1|Cohort 3, 5, 7, 8, 9
2527441|NCT02713997|No Intervention|Standard Care|Patients in the standard care arm will undergo the usual procedure of TPIAT with no ancillary therapies provided.
2527443|NCT02713997|Experimental|etanercept|Patients in the etanercept arm will undergo the usual procedure of TPIAT with additional therapy of etanercept.
2527447|NCT02713997|Experimental|alpha-1 antitrypsin|Patients in the alpha-1 antitrypsin arm will undergo the usual procedure of TPIAT with additional therapy of alpha-1 antitrypsin (Aralast NP)
2527479|NCT02713672|Experimental|Intervention group|Psychiatric patients with a CYP2D6 or CYP2C19 PM or IM genotype, using antidepressants or antipsychotics metabolized by CYP2D6 or CYP2C19
2527481|NCT02713672|No Intervention|Control group|Psychiatric patients with a CYP2D6 or CYP2C19 EM genotype using antidepressants or antipsychotics
2527556|NCT02713516|Experimental|Single Arm|The children in this study will have a single visit. During this visit the child and their parent will be introduced to the virtual reality (VR) system. The child will interact with the VR system and after they have finished, they will be asked questions about their experience with the VR system.
2527594|NCT02713061|Experimental|TAK-850 0.5 mL|TAK-850 0.5 mL (15 µg of hemagglutinin [HA] antigen per strain), subcutaneous injection, once on Day 1.
2527669|NCT02712814||Hormonally mediated PVD|"The entire vestibule is tender~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)"
2527671|NCT02712814||Congenital Neuroproliferative PVD|"The entire vestibule is tender~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule"
2527672|NCT02712814||Acquired neuroproliferative PVD|"The entire vestibule is tender~Secondary PVD, The pain had begun after a severe allergic reaction or vaginitis.~Normal appearing vestibule"
2527673|NCT02712814||Hypertonic pelvic muscle dysfunction|"The pain is at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule~Pelvic floor muscles are tight and tender~Primary or Secondary PVD"
2527674|NCT02712814||Neuroproliferative +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~Primary PVD~There may be sensitivity to palpation of the umbilicus~Normal appearing vestibule~Pelvic floor muscles are tight and tender"
2527675|NCT02712814||Hormonally +Hypertonic|"The entire vestibule is tender, but worse at 4-8 o'clock position of the vestibule~The pain began while taking hormonal contraceptive~Secondary PVD~On exam, atrophic vestibular tissue (dry and thin)~Pelvic floor muscles are tight and tender"
2527736|NCT02712164|Experimental|Experimental: Modified NPWT dressing|In the experimental group, a microporous silver-impregnated foam with a thin silicone contact layer (Mepilex Ag) will be applied. A macroporous foam layer (V.A.C. GranuFoam) and an occlusive dressing (V.A.C. Drape) will then be applied to cover the foam, plus 3-5cm border of intact skin. The occlusive dressing will then be pinched and a 2cm hole will be cut to apply the SensaT.R.A.C. Pad that supplies pressure from the NPWT unit. NPWT will be applied at 125mmHg throughout treatment using KCI's InfoV.A.C. Therapy Unit. The donor site dressing will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
2527879|NCT02711371||Healthy|Healthy controls, socio-demographically matched
3200030|NCT00886652|No Intervention|2|The patients of the control group were not submitted to any type of physical exercises. Like the patients submitted to the protocol, they were evaluated at the beginning, and again after four months.
3200031|NCT00886665|Placebo Comparator|Placebo|
2527040|NCT02716610|Experimental|INH 139 U|single 139 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL) This arm was repeated in order to evaluate intra-subject variability.
2527041|NCT02716610|Experimental|INH 208 U|single 208 U dose administration of Dance inhaled human insulin using a high-concentration formulation (900 U/mL)
2527043|NCT02716610|Active Comparator|LIS 18 U|single 18 U dose administration of subcutaneous insulin lispro using a 100 U/mL formulation This arm was repeated in order to evaluate intra-subject variability.
2527109|NCT02716272|Experimental|MONOTHERAPY ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
2527115|NCT02716272|Experimental|COMBINATION ARM|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
2527151|NCT02715713||testosterone deficiency group|Men between the ages of 40 to 80-years-old with testosterone deficiency
2527165|NCT02715713||prostate cancer group|Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.
2527314|NCT02715219|Experimental|intervention group|Subjects in intervention group will be given an appointment date to attend the an Asthma Education Programme.
2527315|NCT02715219|No Intervention|control group|Subjects in control group will routinely go for the normal follow up in Respiratory Clinic without receive any intervention.
2527333|NCT02714660||Participants with Type 2 Diabetes|Adults with type 2 diabetes will be enrolled in this mixed methods observational study.
2527399|NCT02714491|Active Comparator|Music|Erigo + Music: During each stepping verticalization session the patient receives auditory stimulation (earphones) with previously preferred music
2527404|NCT02714491|Active Comparator|Metronome|Erigo + Metronome: During each stepping verticalization session the patient receives auditory stimulation (earphones) with a metronome (rhythmic with the stepping movement)
2527408|NCT02714491|Active Comparator|Silence|Erigo + Silence: During each stepping verticalization session the patient does note receive any auditory stimulation.
2527446|NCT02713919|Experimental|Intervention Group|Adapted German PRO-SELF© Plus Pain Control Program
2527451|NCT02713919|No Intervention|Control Group|No intervention
3200032|NCT00886665|Experimental|JWHGWT|
3200033|NCT00886678|Experimental|1|patients receiving pemetrexed, carboplatin and radiation therapy.
3200034|NCT00886730|Experimental|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
3200035|NCT00886730|Experimental|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
3200036|NCT00886730|Experimental|Physicians endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
3200037|NCT00886756|Experimental|1|
3200038|NCT00886756|Placebo Comparator|2|
2527668|NCT02712528|Active Comparator|remifentanil-based|remifentanil-based regimen consisting of remifentanil 0.75 mcg/kg/min and supplemental propofol for maintaining BIS 40-60
2527670|NCT02712528|Placebo Comparator|sevoflurane-sufentanil balanced|balanced sevoflurane (end-tidal 1.2-2.8 vol%) and sufentanil (0.015 mcg/kg/min) regimen
2527756|NCT02712281|Experimental|Autism MEAL Plan|Parents of eligible children who are randomized to the Autism Managing Eating Aversions and Limited variety (MEAL) Plan will participate in group-based parent training sessions (4 parents per group).
2527757|NCT02712281|Active Comparator|Parent Education|Parents of eligible children who are randomized to the Parent Education Arm will receive group-based parent education (PE). Each group includes 4 parents.
3200039|NCT00886782|Experimental|Cdc7-inhibitor|
2527841|NCT02711397||Celiac patients|Celiac patients following a GFD for at least one year prior to the inclusion in the study.
2527848|NCT02711397||Positive controls|Healthy children and adults on an unrestricted gluten containing diet.
2527849|NCT02711397||Negative controls|Healthy infants who were exclusively fed with infant formula specifically labelled as gluten-free.
2527908|NCT02711280|Experimental|Sevoflurane General anesthesia|Anesthesia was induced with 8% sevoflurane with 8L/min oxygen. Anesthesia was maintained with 1-3% sevoflurane in oxygen/air mixture.
2527913|NCT02711280|Experimental|Propofol General anesthesia|Anesthesia was induced with propofol 4mg/kg. Anesthesia was maintained with propofol 7-12mg/kg/h.
2528207|NCT02709265|Experimental|Cohort 5|amikacin/fosfomycin (Dose and Nebulizer to be chosen based on results from Cohorts 1 - 4)
2527085|NCT02716311|Experimental|Afatinib + cetuximab|Afatinib 40 mg/d until progression + cetuximab 500 mg/m² every 2 weeks during 6 months (beginning at D15 at 250 mg/m²)
2527155|NCT02715687|Placebo Comparator|Placebo|Will receive 30 days treatment with oral placebo of 200mg
2527170|NCT02715687|Active Comparator|Interventional|Will receive 30 days treatment with oral Amiodarone of 200mg
2527228|NCT02715518|Active Comparator|FFR-guided strategy arm|FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180ug/kg/min) or intracoronary nicorandil (2mg bolus) injection. The FFR ≤ 0.80 will be targeted for PCI using 2nd generation drug-eluting stent. In case of non-IRA stenosis > 90%, we will judge FFR value of ≤ 0.80.
2527238|NCT02715518|Active Comparator|Angiography-guided strategy arm|"Non-IRA stenosis with > 50% stenosis will be the target of PCI using 2nd generation drug-eluting stent.~As for the angiography-guided strategy arm, PCI for non-IRA stenosis will be recommended during same procedure. However, exceptions can be made for complex lesions where the operator estimates that the revascularization procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a staged procedure during the same hospitalization."
2527290|NCT02715050|Experimental|Group A - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
2527298|NCT02715050|Experimental|Group B - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
2527302|NCT02715050|Experimental|Group C - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
2527309|NCT02715050|Experimental|Group D - Active or Placebo Phototherapy|"Participants enrolled in this group performed a training protocol for 12 weeks with light application before and after the exercise protocol. The phototherapy device was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group D, received program 2 before strength training, and program 2 after training."
2527335|NCT02714686|Experimental|Radio Mass Media Family Planning Campaign|Clusters receive a three-year mass media campaign on family planning in an attempt to reduce cognitive barriers to contraception
2527343|NCT02714686|No Intervention|Control group|
2527378|NCT02714439|Experimental|High-Resolution Microendoscopy (HRME)|After standard colposcopy examination performed, participants undergo a high-resolution microendoscopy imaging procedure. Proflavine 0.01% is applied to the cervix, then high-resolution microendoscopy imaging procedure performed. Standard colposcopy procedure will then continue.
2527425|NCT02714140|Experimental|Group A: More preferred Existing + Common|Group A participants will be offered the common option and 3 currently available testing options that are targeted at the distribution of preferences among participants.
2527427|NCT02714140|Experimental|Group B: More preferred Enhanced + Common|"Group B participants will be offered the common option and 3 preference-informed enhanced testing options, which include combinations of features that may not yet be available in the study area."
2527428|NCT02714140|Active Comparator|Group C: Less preferred + Common|Group C participants will be offered the common option and 3 predicted less-preferred options. With the common option being the best option in Group C, this group is effectively a non-PB-HCT comparison group.
3200040|NCT00886808|Experimental|1|110 microgram dose of iCo-007 Intravitreal Injection
3200041|NCT00886808|Experimental|2|350microgram dose of iCo-007 Intravitreal Injection
2527698|NCT02712437|Experimental|PROSPECT|Participants who have received treatment for early stage breast cancer and who experience chronic insomnia as assessed by difficulty sleeping for >30 days with an insomnia severity index score of >14. Participants will complete baseline symptom questionnaires and actigraphy, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 6 weeks. Participants will then repeat questionnaires and actigraphy at 6 weeks and questionnaires at 12 weeks.
2527761|NCT02712073||patients undergoing colonoscopy|
2527788|NCT02711787|Experimental|Experimental group|Robotic device Gloreha (Gloreha, Idrogenet, Italy) and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
2527794|NCT02711787|Active Comparator|Control group|Physiotherapy, occupational therapy and traditional rehabilitation, 60-minute session for 3 consecutive weeks (3 days/week).
2527929|NCT02710994|Experimental|CDFR0209, Then Losec|Subjects first received CDFR0209 each morning in a fasting state for 7 days. After a washout period of 14 days, they then received Losec 40 mg in a fasting state each morning for 7 days.
2527930|NCT02710994|Experimental|Losec, Then CDFR0209|Subjects first received Losec 40 mg each morning in a fasting state for 7 days. After a washout period of 14 days, they then received CDFR0209 in a fasting state each morning for 7 days.
2527978|NCT02710682|Active Comparator|Mini-open surgery|Surgery
2527980|NCT02710682|Experimental|Ultrasound-guided Tendon fenestration|Tendon fenestration
2528056|NCT02710344|No Intervention|Usual Care|Usual care at community mental health care provider
2528059|NCT02710344|Experimental|Telehealth|Usual care at community mental health care provider PLUS psychiatric telehealth program with remote monitoring.
2528091|NCT02709941|Active Comparator|IMST Training Group|Subjects in inspiratory muscle strength training group will complete 30 breaths against a resistance set at 75% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
3200042|NCT00886808|Experimental|3|700microgram dose of iCo-007 Intravitreal Injection
3200043|NCT00886808|Experimental|4|1,000microgram dose of iCo-007 Intravitreal Injection
3200044|NCT00886847|Experimental|EBUS FNA vs FNC|
2527096|NCT02716454|Experimental|Early Surgery - ES|Early laparoscopic ileocaecal resection
2527105|NCT02716454|No Intervention|Step-up therapy - STUP|Treatment with step-up conservative approach according to good clinical practice.
2527161|NCT02715752||Herpes Simplex Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2527171|NCT02715752||Human Papillomavirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2527176|NCT02715752||Epstein-Barr Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2527182|NCT02715752||Cytomegalovirus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2527184|NCT02715752||Varicella Zoster Virus Infection|Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
2527221|NCT02715388|Experimental|Silicon oil removal 3D visualization|
2527303|NCT02715167|Active Comparator|Group Budesonide|Inhaled corticoids
2527307|NCT02715167|Placebo Comparator|Group Placebo|Placebo by inhalation
2527377|NCT02714452|Other|Intervention|Person-centred care
2527379|NCT02714452|No Intervention|Control|Conventional care
3200045|NCT00886860|Active Comparator|conventional oral misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 centimeters
2527473|NCT02713737|Experimental|HFNC group|HFNC: Heated humidified high-flow nasal cannula.
2527475|NCT02713737|Active Comparator|NIV group|NIV: Noninvasive ventilation.
3200046|NCT00886860|Experimental|titrated oral misoprostol|misoprostol 20 micrograms oral every hour until cervical dilatation 3 centimeters
3200047|NCT00886873|Experimental|Group 1|Oral administration of mifepristone 5 mg daily for six months.
3200048|NCT00886873|Experimental|Group 2|Oral administration of mifepristone 10 mg daily for six months.
3200049|NCT00886886|Other|Reboxetine, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
2527774|NCT02711878|Experimental|Let's Move Program|Participants in this group will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes in their home while wearing a heart rate monitor and a pedometer. Participants will then enter a maintenance exercise period for 65 weeks.
2527779|NCT02711878|Active Comparator|Let's Flex Program|Participants in this group will be asked to stretch five times per week for twelve weeks for a minimum of thirty minutes in their home. Participants will then enter a maintenance exercise period for 65 weeks.
2527836|NCT02711527|Active Comparator|Acupunture group A|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total) Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation , all needles will be retained for 30 minutes."
2527847|NCT02711527|Active Comparator|Acupunture group B|"The subjects will receive acupuncture treatment twice weekly for 3 weeks (6 treatments in total). Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes."
2527944|NCT02710851|Experimental|low dosage HPV Vaccine(1:1)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
2527948|NCT02710851|Experimental|low dosage HPV Vaccine(1:2)|Participants in this arm would receive low dosage HPV vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
2527950|NCT02710851|Experimental|high dosage HPV Vaccine(1:1)|Participants in this arm would receive high dosage HPV vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
2527953|NCT02710851|Placebo Comparator|Hepatitis E vaccine,Hecolin®|Participants in this arm would receive Hepatitis E vaccine,Hecolin®
2528013|NCT02710448|Experimental|Metformin|Metformin in patients with renal failure
2528071|NCT02710097|Experimental|Active THC and Placebo Ethanol|
2528074|NCT02710097|Experimental|Active THC and Active Ethanol|
2528076|NCT02710097|Experimental|Placebo THC and Active Ethanol|
2528077|NCT02710097|Placebo Comparator|Placebo THC and Placebo Ethanol|
2528142|NCT02709772|Active Comparator|Provider Alert|This arm is the intervention arm. This arm will receive the Electronic Record Alert.
2528145|NCT02709772|No Intervention|No Provider Alert|This arm is the control arm.
2528200|NCT02709460|Experimental|Lateral occlusion|Women included in this arm is randomized to lateral occlusion of the uterine artery
2528208|NCT02709460|Active Comparator|cervical occlusion|Women included in this arm is randomized to occlusion of the uterine artery at cervical entry
2528270|NCT02709057|Active Comparator|Life-style intervention 1|Life-style intervention in participants with low genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
2528272|NCT02709057|Active Comparator|Life-style intervention 2|Life-style intervention in participants with high genetic risk score: The 3-year lifestyle intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
2528276|NCT02709057|No Intervention|Control 1|No intervention in participants with low genetic risk score
2528279|NCT02709057|No Intervention|Control 2|No intervention in participants with high genetic risk score
2528324|NCT02708615|Other|Vertical rotation|Vertical insertion and 90 degree rotation of speculum in vagina
2528330|NCT02708615|Other|Straight horizontal insertion|Straight horizontal insertion of speculum with no rotation in vagina
3200050|NCT00886912|Active Comparator|Hypoxia|training in simulated altitude
3200051|NCT00886912|Placebo Comparator|Normoxia|training under normoxic conditions
3200052|NCT00886925|Active Comparator|Albumin|
3200053|NCT00886925|Placebo Comparator|Saline|
2527145|NCT02715674|Placebo Comparator|control group|take 4lt/min oxygen with Plasti-med oxygen therapy mask
2527146|NCT02715674|Active Comparator|IS group|in postoperatively, patients will carry out Plasti-med TRIFLO 5 min per hour for 6 hours.
2527148|NCT02715674|Active Comparator|CPAP group|in postoperatively, patients will carry out 10 cmH2O noninvasive continuous positive airway pressure with BIPAP VISION 5 min per hour for 6 hours.
2527224|NCT02715427|Active Comparator|Conventional care|"Preoperative consultation Information support conventional perioperative No bowel preparation~Day before surgery Normal diet until midnight No carbohydrate loading Premedication with anxiolytic~Operative day Conventional general anaesthesia Classic management perfused volumes Conventional use of drains at the operative site Standard nasogastric drainage Conventional analgesia protocol~Postoperative time Mobilization from J1 Progressive refeeding Progressive removal of venous, arterial and urinary catheters. Gradual recovery of the usual treatment from J1 Breathe physiotherapy depending on the clinical course No stimulation of intestinal transit"
2527230|NCT02715427|Experimental|Enhanced recovery|"Preoperative consultation Specific information about the enhanced rehabilitation No bowel preparation Immunonutrition for the 7 preoperative days~Day before surgery Minimal preoperative fasting No premedication Carbohydrate loading~Operative day Optimized general anesthesia Reduced volumes perfused Limiting use of drains at the operative site Reduced doses of morphine Local anesthetic usage No standard use of nasogastric drainage~Postoperative time Stimulation mobilization from D0 Refeeding on demand  from D0 Early removal of venous, arterial and urinary catheters. J1 recovery from the majority of the usual treatment Breathe physiotherapy from D0 to D5 Ileus prevention by chewing gum"
2527288|NCT02715128|Active Comparator|real tDCS|anode over electrode position F3, cathode over F4, 20 min, 2mA intensity
2527294|NCT02715128|Sham Comparator|sham tDCS|frequency and duration correspondent active tDCS, ramp in and ramp out periods only without intermittent stimulation
2527348|NCT02714751|No Intervention|Observational group|
2527355|NCT02714751|Other|Group after information intervention|Control group after daily information to healthcare team
2527436|NCT02714478|Experimental|treatment|"3 Equistasi devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
2527437|NCT02714478|Placebo Comparator|controls|"3 placebo devices will be placed during physiotherapy, 5 times per week, for 4 weeks"
2527487|NCT02713815|Sham Comparator|control group|sham repetitive transcranial magnetic stimulation (rTMS) of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
2527491|NCT02713815|Active Comparator|rTMS group|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
3200054|NCT00886951|Experimental|Access I123MNI388/I123MNI390 and brain imaging|
3200055|NCT00886964|Active Comparator|1|HBV ID
3200056|NCT00886964|Active Comparator|2|HBV IM
2527677|NCT02712515||Essential tremor|Participants in this group will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
2527679|NCT02712515||Parkinson's disease and dystonia|Participants in this group with Parkinson's disease and/or dystonia will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
2527723|NCT02712177||Coadministration B_RV246|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar).
2527726|NCT02712177||Coadministration B_RV234|Subjects in this group received 4CMenB vaccine at 2, 3 and 4 months of age, administered concomitantly with routine infant vaccinations (Infanrix Hexa+Prevenar)..
2527730|NCT02712177||Coadministration B_MMRV12|Subjects in this group previously received three doses of 4CMenB and routine vaccine at 2, 4 and 6 months of age,respectively. They also received a booster (fourth) dose at 12 months of age concomitantly with one dose of MMRV vaccine.
2527738|NCT02712177||Separate administration B246_RV357|Subjects in this group received 4CMenB vaccine at 2, 4, and 6 months of age; routine infant vaccinations (Infanrix Hexa+Prevenar) were administered at 3, 5 and 7 months of age.
2527748|NCT02712177||Separate administration B12_MMRV13|Subjects in this group previously received three doses of 4CMenB and routine vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age. They also received a booster (fourth) dose of 4CMenB at 12 months of age and one dose of MMRV vaccine at 13 months of age.
2527749|NCT02712177||Routine vaccines only at 2, 3 and 4 months of age (RV234)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 3 and 4 months of age.
2527751|NCT02712177||Routine vaccines only at 2, 4 and 6 months of age.(RV246)|Subjects in this group received routine infant vaccines (Infanrix Hexa+Prevenar) at 2, 4 and 6 months of age.
2527853|NCT02711670|Experimental|thiazide|Stone formers History of calcium containing kidney stones, hypercalciuria on previous urine tests, no kidney disease, not pregnant/lactating
2527898|NCT02711137|Experimental|INCB057643|
2527902|NCT02711137|Experimental|INCB057643 + Standard of Care (SOC) agents|
3200057|NCT00886990||1|Receiving a single PI boosted by low dose ritonavir
3200058|NCT00886990||2|Receiving two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
3200059|NCT00887003|Experimental|LV/LD 1|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
3200060|NCT00887003|Experimental|LV/HD 2|Low Volume, High Dose (5cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
3200061|NCT00887003|Experimental|HV/LD 3|High Volume, Low Dose (10cc, 5mg plain Bupivacaine) + 80mg Depo-Medrol
3200062|NCT00887003|Experimental|HV/HD 4|High Volume, High Dose (10cc, 10mg plain Bupivacaine) + 80mg Depo-Medrol
3200063|NCT00887029|Active Comparator|DuoTrav|
3200064|NCT00887029|Active Comparator|Xalacom|
3200065|NCT00887042|Experimental|Fludarabine|
2527284|NCT02715245|Experimental|Experimental Group|Patients with multiple chronic disease referred to Mobile Rehabilitation and Physical therapy team (MRPTT) and Nurse-led case Management in the province of Almeria that comply the inclusion criteria; as well as their caregivers.
2527292|NCT02715245|No Intervention|Control Group|Patients with multiple chronic disease and their caregivers belonging to health centers or areas where there is no figure MRPTT or Nurse-led case Management to reach this population
2527353|NCT02714829|Experimental|Inject BMP|ExcelOS-inject containing rhBMP-2
2527358|NCT02714829|Active Comparator|ExcelOS-inject|ExcelOS-inject without rhBMP-2
2527454|NCT02714049|Experimental|flibanserin|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug
2527455|NCT02714049|Experimental|flibanserin and sex therapy|Subjects meeting inclusion/exclusion criteria who respond to flibanserin will have a total of 20 weeks of open label drug as well as 9 sex therapy visits
3200066|NCT00887081|Experimental|Interferon and Ribavirin|Patients with hemoglobinopathy will receive Interferon and Ribavirin
3200067|NCT00887094|Experimental|Aerobic exercise|One bout of aerobic physical training will be performed on a cycle ergometer for 50 min
2527695|NCT02712476|Active Comparator|Mannitol,furosemide|Mannitol 0.5mg/kg and furosemide 0.5mg/kg IV is compared with mannitol 1mg/kg and furosemide 0.5mg/kg
2527697|NCT02712476|Placebo Comparator|Mannitol, placebo|Mannitol 0.5mg/kg and placebo is compared with mannitol+forosemide
2527763|NCT02712060||EDS patients|Patients with the diagnosis of Ehlers-Danlos syndrome
2527764|NCT02712060||controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
2527784|NCT02711735|Active Comparator|RUTI® vaccine|Intervention: Patients randomized to receive RUTI® vaccine will receive one injection of RUTI® vaccine in their right or left deltoid muscle.
2527792|NCT02711735|Placebo Comparator|Matching RUTI® Placebo|Intervention: Patients randomized to receive Placebo will receive one injection of Placebo in their right or left deltoid muscle.
2527830|NCT02711462|Other|Cohort 1|Subjects will receive 2mg of PF 06687234 or placebo via the SC route
2527834|NCT02711462|Other|Cohort 2|Subjects will receive 20mg PF 06687234 or placebo via the SC route
2527846|NCT02711462|Other|Cohort 3|This is an optional cohort that may be added anytime during the study. In this cohort, subjects will receive PF 06687234 or placebo via the SC route
2527850|NCT02711462|Other|Cohort 4|Subjects will receive 40mg of PF 06687234 or placebo via the SC route
2527852|NCT02711462|Other|Cohort 5|Subjects will receive 80mg of PF 06687234 or placebo via the SC route
2527854|NCT02711462|Other|Cohort 6|Subjects receive a single dose of PF 06687234 or placebo via the IV route
2527856|NCT02711462|Other|Cohort 7|This is an optional cohort where Japanese subjects will receive PF 06687234 or placebo via the SC route
2527859|NCT02711462|Other|Cohort 8|Subjects in this cohort may receive 20 mg of PF 06687234 or placebo via the SC route every week with a total of 5 doses
2527861|NCT02711462|Other|Cohort 9|Subjects in this cohort may receive 40 mg of PF 06687234 or placebo via the SC route every two weeks with a total of 3 doses
2527862|NCT02711462|Other|Cohort 10|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
2527864|NCT02711462|Other|Cohort 11|This is an optional cohort. The maximum dose tested in the multiple dose cohort will not exceed the highest dose tested in the single dose cohorts
2527880|NCT02711046|Experimental|single stage nasolabial flap|single staged nasolabial flap as an interpositional material after surgical resection of fibrous band in oral submucous fibrosis
2527923|NCT02711020|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy delivered in individual format.
2527927|NCT02711020|Experimental|Personal Construct Therapy|Personal Constructs Therapy delivered in individual format.
2527954|NCT02710695|Active Comparator|Control|This group will receive a 10 minute discussion
2527957|NCT02710695|Active Comparator|Intervention|This group will receive a 10 minute standardized discussion
2528000|NCT02710552|Active Comparator|Three antihypertensive Drugs|Patients will be treated with Tripliam, that is a commercially available fixed low-dose combination of three antihypertensive drugs, that is 5 mg/daily perindopril, 1,25 mg/daily indapamide and 5 mg/day amlodipine
2528004|NCT02710552|Active Comparator|Two antihypertensive drugs|Patients will be treated with Reaptan, that is a commercially available fixed high-dose combination of two antihypertensive drugs, that is 10 mg/daily perindopril and 5 mg/day amlodipine
3200068|NCT00887094|Experimental|Aerobic-resistance exercise|One bout of aerobic-resistance physical training will be performed on a cycle ergometer added by a strenght training for 50 min (total)
3200069|NCT00887107|Experimental|sorafenib|30 patients with non-radioiodine avid differentiated thyroid carcinoma
2528169|NCT02709551|Experimental|HRV-Bfb|HRV biofeedback, training about 30 minutes/day
2528173|NCT02709551|Experimental|MBI|Mindfulness based intervention, training about 30 minutes/day
2528174|NCT02709551|Other|MBI_HRV-Bfb|Mindfulness based HRV biofeedback. Wait list control group for the interventions HRV-Bfb and MBI, after the main phase intervention with combined method.
2528186|NCT02709265|Experimental|Cohort 1|amikacin/fosfomycin (30/12 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2528192|NCT02709265|Experimental|Cohort 2|amikacin/fosfomycin (60/24 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2528195|NCT02709265|Experimental|Cohort 3|amikacin/fosfomycin (90/36 mg) delivered via the PARI Investigational eFlow Nebulizer (single dose)
2528199|NCT02709265|Experimental|Cohort 4|amikacin/fosfomycin (90/36 mg) delivered via the PARI LC Sprint Nebulizer (single dose)
3200070|NCT00887120|Active Comparator|1|Lopinavir/ritonavir standard dose + zidovudine and lamivudine
3200071|NCT00887120|Active Comparator|2|Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine
3200072|NCT00887133||1|Patients consulting Western Medicine outpatient clinics for a new episode of illness
3200073|NCT00887172|Experimental|1|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took treatment of Jing Fang Bai Du san.
2527150|NCT02715817|Active Comparator|Virtual Rehabilitation - VR|"A virtual rehabilitation program (G0) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The G0 treatment program consists of the following protocols: a) protocol 1 games (Balance Bubble Plus and Tennis); b) protocol 2 games (Rhythm Parade and Boxing)."
2527164|NCT02715817|Active Comparator|Conventional Therapeutic Exercises - CTE|A program of conventional therapeutic exercises (G1) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The G1 treatment program consists of the following protocols: a) protocol 1: 30 minutes of upper limb PNF diagonal exercise (flexion-abduction-external rotation and extension-abduction-internal rotation), and 10 minutes of scapula PNF diagonal exercise (anterior and posterior elevation); b) protocol 2: 20 minutes of lower limb PNF diagonal exercise (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes of pelvis PNF diagonal exercise (anterior and posterior depression), and 10 minutes gait cycle training;
2527169|NCT02715817|Experimental|VR and CTE|In G2 program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
2527237|NCT02715336|Experimental|Study group: High Responders|1000 units hCG
2527241|NCT02715336|No Intervention|Control group: High Responders|1000 units hCG
2527243|NCT02715336|Experimental|Study group: Normal Responders|5000 units hCG
2527245|NCT02715336|No Intervention|Control group: Normal Responders|5000 units hCG
2527247|NCT02715336|Experimental|Study group: Low Responders|10000 units hCG
2527249|NCT02715336|No Intervention|Control group: Low Responders|10000 units hCG
2527320|NCT02714959|Experimental|Proleukin|Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9
3200074|NCT00887172|Placebo Comparator|2|Wind-cold syndrome group were patients classified by Chinese Medicine practitioner of Wind-cold syndrome and took placebo of Jing Fang Bai Du san.
3200075|NCT00887172|Experimental|3|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took treatment of Ying Qiao san.
3200076|NCT00887172|Placebo Comparator|4|Wind-heat syndrome group were patients classified by Chinese Medicine practitioner of Wind-heat syndrome and took placebo of Ying Qiao san.
3200077|NCT00887185|Active Comparator|1 - Traditional training|Temporal bone dissection training in cadaveric laboratory. Subjects are provided 2 cadaveric temporal bones and asked to spend 2 weeks practicing the surgical technique of complete mastoidectomy with facial recess approach.
3200078|NCT00887185|Experimental|2 Simulator training|Subjects perform temporal bone surgical dissection training on a simulator.
3200079|NCT00887211|Active Comparator|ProStent|implant ProStent drug-eluting stents
3200080|NCT00887211|Active Comparator|Firebird|implant Firebird drug-eluting stents
3200081|NCT00887237|Experimental|TRIV|Cardiac resynchronization with triple site ventricular stimulation (2 RV leads and 1 LV lead)
3200082|NCT00887237|Active Comparator|BIV|Conventional cardiac resynchronization
3200083|NCT00887263|Experimental|A|
3200084|NCT00887263|Placebo Comparator|B|
2528003|NCT02710513|Experimental|Beta-glucans|2 months run-in period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of normal pasta) + 2 months intervention period (Mediterranean Diet-based dietary scheme including a daily supply of 100 g of functional pasta providing 3 g of beta-glucans/day)
3200085|NCT00887276|Active Comparator|Moxifloxacin|
3200086|NCT00887276|Active Comparator|Ampicillin; Amoxicillin|
2528132|NCT02709798|Experimental|Shenfu Injection|80ml Shenfu Injection + 70ml 5% glucose injection), ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
2528133|NCT02709798|Placebo Comparator|5% Glucose Injection|150 ml 5% glucose injection, ivdrip, 30 minutes before PCI and 1-5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
2528197|NCT02709434|Active Comparator|Intervention group|Patients with quiescent IBD who are randomized to receive the active intervention of the psychoeducational programme
2528204|NCT02709434|Placebo Comparator|Control group|Randomized to standard care
2528249|NCT02709070|Active Comparator|resection|Resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. The investigators performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
2528255|NCT02709070|Experimental|highly-purified CTL|Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective participants who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Participants in the immunotherapy group received a number up to 5×10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. Participants were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving resection, followed by 6-9 treatments during 6 months to 2 years after receiving resection.
2528363|NCT02708160|Experimental|1.1% Fluoride toothpaste|Prevident 5000 Plus, silica based toothpaste
3200087|NCT00887302||1|Gastric Band
3200088|NCT00887302||2|Gastric Sleeve
3200089|NCT00887302||3|Gastric Bypass with PEG tube
3200090|NCT00887328|Experimental|IV tPA|intravenous tissue plasminogen activator
3200091|NCT00887328|Placebo Comparator|Placebo|
3200092|NCT00887367|Placebo Comparator|Placebo to match GSK598809|Placebo to match GSK598809.
3200093|NCT00887367|Placebo Comparator|Placebo to match ethanol infusion|Glucose solution to be given in the same way as ethanol.
2527167|NCT02715661|Active Comparator|Coronary artery disease|those with a diagnosis of coronary artery disease having been hospitalized for a cardiac event. The intervention is six-month interval of exercise .
2527177|NCT02715661|Active Comparator|Metabolic Syndrome|Metabolic Syndrome patients are defined by having Systolic Blood Pressure (SBP)>130 and/or Diastolic Blood Pressure (DBP)>85 mmHg and any two of the following criteria: Abdominal obesity (waist circumference >102cm in males;>88cm in females), Fasting triglycerides > 1.695 mmol/L, Low HDL cholesterol: Males < 1.04 mmol/L; Females < 1.29 mmol/L, Fasting glucose >5.60 mmol/L. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
2527183|NCT02715661|Active Comparator|Health Control|Control individuals will have no diagnosis of cardiac, vascular, metabolic, inflammatory or neurological disease, and have not been on any medication for such conditions in the past 12 months. Participants will be assigned randomly into an exercise and a delayed exercise intervention, 6 months.
2527250|NCT02715414|Active Comparator|Multiple Family Group (MFG)|A multiple family group (MFG) is a 12-week, family-centered, group delivered intervention consists of six to eight families (caregiver/child dyads). Groups meet for approximately two hours per week, and sessions focus on targeting family-level factors that are associated with child problem behaviors. Specifically, eight of the 12 sessions are devoted to establishing rules (family organization, consistent discipline), responsibilities (inter-connectedness, expectancies), relationships (family warmth, within family support), respectful communication (family communication and conflict). An additional four sessions are focused on factors that impact the ability of families to incorporate new behaviors (family stress and social support).
2527251|NCT02715414|Experimental|MFG + Clinic Implementation Team|This condition consists of service providers, directors, and clinic staff who will create site-specific plans to enhance uptake and implementation of MFG. CITs address potential barriers to implementation and adjust the format and structure of MFG as needed in order to be implemented as part of clinic care.
2527252|NCT02715414|No Intervention|Standard Care|Standard Care consists of services including outpatient individual and family therapy, which are offered as part of clinic care.
2527274|NCT02714985||confirmed chikungunya cases|cases with confirmed chikungunya fever and included for follow-up as per protocol
2527342|NCT02714881|Other|Tumor necrosis factor inhibitor|Subjects who are about to start on a tumor necrosis factor inhibitor (TNFi) as part of usual care will be recruited. They will have measurements including routine lipids, advanced lipoproteins, and coronary flow reserve (CFR) before and after their TNFi.
2527445|NCT02714023|Active Comparator|Normal Saline|Patients were randomized to receive normal saline as an irrigation solution during appendectomy.
2527450|NCT02714023|Active Comparator|Sterile Water|Patients were randomized to receive sterile water as an irrigation solution during appendectomy.
2527452|NCT02714023|No Intervention|No irrigation used|Patients who do not receive any irrigation at time of operation.
2527478|NCT02713685|Experimental|Subarachnoid block|Subarachnoid block will be given in lateral position
2527480|NCT02713685|Active Comparator|Peripheral nerve block|Combined Femoral and Sciatic nerve block will be given using nerve stimulation technique
2527546|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 1 Test 1|Test 1 will be administered thru subcutaneous (SC) injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2527551|NCT02713477|Experimental|Insulin glargine/ lixisenatide dose 2 Test 2|Test 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2527553|NCT02713477|Placebo Comparator|Placebo - Reference 1|Reference 1 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour prior to breakfast under fasted condition
2527554|NCT02713477|Other|Insulin glargine (Lantus) - Reference 2|Reference 2 will be administered thru SC injection into one peri-umbilical site of the abdomen 1 hour pior to breakfast under fasted condition
2527586|NCT02713022||Breast Cancer|DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
2527588|NCT02713022||Prostate Cancer|DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.
2527641|NCT02712749|Experimental|Group A : Sound with Binaural Beats|"Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz through generated by the software Gnaural in stereo option"
2527646|NCT02712749|Active Comparator|Group B : Sound without Binaural Beats|"Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the software Gnaural in mono option"
3200094|NCT00887380|Active Comparator|Arm A: Concurrent|Investigational treatment: Anastrozole commenced before (Pre-radiotherapy commencement of anastrozole) and continued during radiotherapy.
2527870|NCT02711683||DL-3-n-butylphthalide group|using DL-3-n-butylphthalide treatment in patients with mild to moderate AD already receiving donepezil
2527873|NCT02711683||donepezil group|only using donepezil treatment in patients with mild to moderate AD
2527914|NCT02711072|Placebo Comparator|control group|
2527917|NCT02711072|Active Comparator|infiltration group|
2527941|NCT02710838|Experimental|Cancer group|All patients receive the infrared endoscopy after injecting indocyanine green（ICG） intravenously.
2527945|NCT02710838|Other|Non-cancer group|All patients receive the infrared endoscopy after injecting ICG intravenously.
2527999|NCT02710565|Other|Cohort|"Participants who are scheduled to have an endo bronchial ultrasound (EBUS) trans bronchial needle aspiration (TBNA) will provide additional samples. These samples will then be sent to Imperial College London to see whether a cell line can be grown.~If growth is successful then the samples will be returned to our pathology department to see if grading is possible and then to compare these results with the previous diagnostic samples.~The cell line samples will not be used for patient diagnosis."
2528049|NCT02710279|Other|Depressive patients|Depressive patients with or without story of suicidal behavior will pass the TSST and will have a psychological assessment to complete with a questionnaire on their smartphone
2528092|NCT02709980|Placebo Comparator|Sleep Education|6 sessions of sleep education.
2527219|NCT02715531|Experimental|Arm E (Randomized Metastatic Esophageal Cancer)|Participants with squamous metastatic esophageal cancer (mEC) will be randomized (1:1) into Group E1 and Group E2. All participants with metastatic adenocarcinoma of esophageal carcinoma or GEJ Siewert Classification Type I will be enrolled into Group E3. In Groups E1 and E3, participants will receive atezolizumab and FOLFOX, q2w, each cycle of 28 days, as long as participants are experiencing clinical benefit in opinion of the investigator. Oxaliplatin will be administered for up to 8 cycles. In Group E2, participants will receive atezolizumab followed by cisplatin and 5-FU q3w. Cisplatin will be administered for up to 6 cycles. Treatment with atezolizumab in combination with 5-FU may be continued as long as participants experience clinical benefit in opinion of the investigator.
2527220|NCT02715531|Experimental|Arm F (Randomized HCC)|Participants with advanced or metastatic and/or unresectable HCC who have received no prior systemic treatment will be randomized (1:1) into Group F1 and Group F2. Participants will receive atezolizumab alone (Group F2) or combined with bevacizumab (Group F1) on a q3w schedule, with dosing on Day 1 of each 21 day Cycle. Treatment with atezolizumab with or without bevacizumab may be continued as long as participants are experiencing clinical benefit in the opinion of the investigator. Participants who are randomly assigned to Group F2 (atezolizumab monotherapy) and experience investigator-assessed unequivocal radiographic progression as per RECIST v1.1 will also be given the option to cross over to atezolizumab and bevacizumab combination therapy, provided they meet the criteria for crossover and Medical Monitor approval is obtained.
3200095|NCT00887380|Active Comparator|Arm B: Sequential|Standard Treatment: Anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy (Post radiotherapy commencement of anastrozole)
3200096|NCT00887393|Other|Low carbohydrate|Low carbohydrate pre-bariatric surgery diet
2527388|NCT02714127||Cases|"Women (25-64 years old) with abnormal cytology results and/or (high risk) HPV infection refered for colposcopy, and hence possibly diagnosed with an (high risk) HPV infection and/or cervical (pre)cancerous lesions.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
2527389|NCT02714127||Controls|"Healthy women (25-64 years old), falsely diagnosed with abnormal cytology and/or (high risk) HPV infection, but referred for colposcopy, are included as negative controls. Based on a specificity of 76.14% of the HPV type-specific PCR (polymerase chain reaction) used, an estimated 24 out of these 100 participants will be incorrectly scheduled for colposcopy and serve as the control group.~No clinical evaluations/interventions will be performed by our research group. Participants have an already scheduled colposcopy exam. However, this visit is not an extra investigation that the participants should undergo when participating in the study."
2527439|NCT02714088|Experimental|Intervention|Participants will undertake a high-intensity interval training intervention, completing two exercise sessions per week for 12 weeks. The exercise sessions will consist of 4 sets of 4-6 repetitions of 60s (45s high-intensity exercise, followed by 15s rest), interspersed with 3 minutes rest. During each exercise repetition participants will be encouraged to reach >90% of their maximal heart rate.
2527440|NCT02714088|No Intervention|Control|Participants will not undertake any formal intervention and will be asked to maintain their usual physical activity habits and diet.
2527494|NCT02713763|Experimental|Sunitinib|Sunitinib 37.5 mg/day
2527587|NCT02713009|Experimental|Treatment 1|Pregnancy multivitamin + vitamin D daily from ~Week 12 gestation until delivery
2527589|NCT02713009|Placebo Comparator|Treatment 2|Pregnancy multivitamin + placebo daily from ~Week 12 gestation until delivery
2527637|NCT02712840|Experimental|Freeze-All Protocol|Participants freezing all good quality embryos, with subsequent frozen embryo transfer of best quality blastocyst.
2527638|NCT02712840|Active Comparator|Fresh Protocol|Participants receiving fresh embryo transfer of best quality blastocyst and freezing of all good quality supernumerary embryos.
3200097|NCT00887393|Other|Low fat|Low fat pre-bariatric surgery diet
2527787|NCT02711813|Placebo Comparator|Placebo|Placebo to TAB08
2527797|NCT02711813|Experimental|TAB08 Dose 1|
2527802|NCT02711813|Experimental|TAB08 Dose 2|
2527837|NCT02711488|Experimental|Intervention group|Combine primary prevention activities at the school level with secondary prevention at the household level
2527844|NCT02711488|No Intervention|Control group|No intervention
3200098|NCT00887406|Experimental|Cohort 1, Period 2|GSK961081 3mcg, Placebo, GSK961081 15mcg, GSK961081 50mcg
3200099|NCT00887406|Experimental|Cohort 1, period 1|Placebo, GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg
3200100|NCT00887406|Experimental|Cohort 1, period 3|GSK961081 3mcg, GSK961081 15mcg, Placebo, GSK961081 50mcg
3200101|NCT00887406|Experimental|Cohort 1, period 4|GSK961081 3mcg, GSK961081 15mcg, GSK961081 50mcg, Placebo
3200102|NCT00887406|Experimental|Cohort 2, period 1|Placebo, GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg,
2528093|NCT02709941|Placebo Comparator|Placebo Training Group|Subjects in placebo training group will complete 30 breaths against a resistance set at 15% of Maximal Inspiratory Pressure (PI Max) everyday for period of 6 weeks.
3200103|NCT00887406|Experimental|Cohort 2, period 2|GSK961081 100mcg, Placebo, GSK961081 200mcg, GSK961081 300mcg
3200104|NCT00887406|Experimental|Cohort 2, period 3|GSK961081 100mcg, GSK961081 200mcg, Placebo, GSK961081 300mcg
3200105|NCT00887406|Experimental|Cohort 2, period 4|GSK961081 100mcg, GSK961081 200mcg, GSK961081 300mcg, Placebo
3200106|NCT00887406|Experimental|Cohort 3|GSK961081 100mcg or Placebo
3200107|NCT00887406|Experimental|Cohort 4|GSK961081 300mcg or Placebo
3200108|NCT00887419|Experimental|Coping Skills Training|Coping Skills Training in pain management
3200109|NCT00887419|Active Comparator|Education|Chronic Pain Education
3200110|NCT00887419|No Intervention|Usual Care|Patients receive no study intervention, continue with usual medical care.
3200111|NCT00887445|Experimental|A|
3200112|NCT00887445|Placebo Comparator|B|
2527232|NCT02715453|No Intervention|Control|Conventional strategy consisting only of the usual care by the cardiologist
2527301|NCT02715154|Active Comparator|Dexmedetomidine 0.5 µg/kg/h|Solution containing 5 µg/mL of dexmedetomidine was continuously infused by 0.5 μg/kg in 10 min, followed with 0.1 ml/kg/hr continuous infusion until the closure of the abdominal.
2527306|NCT02715154|Placebo Comparator|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal.
2527366|NCT02714699|Experimental|diclofenac potassium|oral diclofenac potassium
2527368|NCT02714699|Active Comparator|hyoscine butyl bromide|oral hyoscine butyl bromide
2527372|NCT02714699|Placebo Comparator|placebo|oral placebo
3200113|NCT00887497|Experimental|Catheterization|Patients receive angioembolization prior to surgery
3200114|NCT00887523|Experimental|1|prone intensity-modulated radiotherapy
3200115|NCT00887523|Active Comparator|2|supine intensity-modulated radiotherapy
2527647|NCT02712775|Experimental|Minocycline|Experimental group will receive an infusion of minocycline, the investigational drug, through a needle in a vein in the arm at the dose of 200 mg at 1 h prior to transplantation and 100 mg 12 h and 24 h after transplantation. In addition, the donated liver will be flushed with 200 mg minocycline 1 h prior to transplantation.
2527655|NCT02712775|Placebo Comparator|Saline|Placebo group will receive an infusion of saline, a placebo, through a needle in a vein in the arm according to the same schedule. In addition, the donated liver will be flushed with saline 1 h prior to transplantation.
3200116|NCT00887536|Active Comparator|Group 1: TAC then pegfilgrastim|docetaxel, doxorubicin, cyclophosphamide, and pegfilgrastim/filgrastim
3200117|NCT00887536|Active Comparator|Group 2: TC|docetaxel and cyclophosphamide
2527786|NCT02711748|Experimental|Bradycardia|Treatment In case of bradycardia. The patient unconscious, breathing preserved in ECG - bradycardia 40 / min with pulse.
2527793|NCT02711748|Experimental|PEA|In case of bradycardia. The patient unconscious, not breathing, the ECG - bradycardia 30 / min - no pulse. Pulseless electrical activity
2527835|NCT02711501|Experimental|Laser irradiation|laser-assisted surgery with the following parameters: Wavelength:810 nanometer, power: 3 W, pulse mode,pulse length 100 µs, pulse interval 200 µs
2527845|NCT02711501|Experimental|blade|conventional surgery by blade
2527882|NCT02711176|Experimental|Tavanex & Nexium & Tinafas|"Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days"
2527883|NCT02711176|Active Comparator|Lanzol & Klacid &Iramox|Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days
2527967|NCT02710760|No Intervention|Control|Households in the control group receive no special treatment.
2527971|NCT02710760|Experimental|Adoption Encouragement Treatment|"Households in the Adoption Encouragement Treatment group were visited between March and April 2015 and offered child nutrition focused adoption encouragement. Both the male household head and the primary female caregiver were invited to attend these meetings (though the household head is the primary target), where the nutritional benefits of Quality Protein Maize (QPM) adoption for children were emphasized along with the agronomic properties. In addition, the fact that only small amounts of QPM are necessary to nourish children was highlighted and small seed bag sizes were offered. During the adoption encouragement visit, we offered the option to order up to three 2 kg bags of QPM for free."
2527973|NCT02710760|Experimental|Consumption Encouragement Treatment|In addition to receiving the Adoption Encouragement Treatment, households in the Consumption Encouragement Treatment group received additional information, targeted to the caregiver, and tools for separating Quality Protein Maize and targeting it to young children in the household in August 2015. They will additionally receive further guidance in February 2016.
2528016|NCT02710383||Participants genetically diagnosed with Cystic fibrosis|Participants diagnosed with Cystic fibrosis aged between 2 months and 50 years
2528065|NCT02710110|Experimental|Active Respiratory Trainer|Participants enrolled in this arm will be given the PowerLung trainer. The adjustable spring allows for discrete and calibrated changes to the valve, which in turn blocks air until sufficient inspiratory or expiratory pressure is applied by an individual. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
2528068|NCT02710110|Sham Comparator|Sham Trainer|Participants enrolled in this arm will be given the PowerLung trainer; however, the adjustable spring allows for discrete and calibrated changes to the valve and these will not have any resistance. In addition, the Micro Mouth Pressure Meter, Pulmonary Function testing, videofluoroscopic swallowing study (VFSS), Swallowing Quality of Life Questionnaire (SWAL-QOL), Iowa Oral Pressure Instrument (IOPI), and capsaicin for use in the reflexive cough test.
2528259|NCT02708875|Experimental|Mixed Meal Challenge|Participants will consume a liquid mixed meal (~300 calories - fat, carbohydrate, and protein) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
2528264|NCT02708875|Active Comparator|Glucose Challenge|Participants will consume a glucose challenge (50g glucose) for monitoring changes in glucose metabolism, plasma insulin and microvascular responses in skeletal muscle over 2 hours.
2528307|NCT02708628|Active Comparator|Patients using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin two times in a day.
2528311|NCT02708628|Active Comparator|Patients not using contractubex|Scar excision will be performed in second c-section for 60 patients and these patients will not use prophylactic topical scar gel containing extract of allium cepae, allantoin and heparin.
3200118|NCT00887536|Experimental|Group 3: TC + bevacizumab|docetaxel, cyclophosphamide, and bevacizumab
3200119|NCT00887601|Experimental|Part I|Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences.
3166654|NCT00528073|Experimental|A|Rifaximin-EIR tablet 1x400 mg + Placebo 2 tablets bid
3166655|NCT00528073|Experimental|B|Rifaximin-EIR tablet 2x400 mg + Placebo 1 tablet bid
3166656|NCT00528073|Experimental|C|Rifaximin-EIR tablet 3x400 mg bid
3166657|NCT00528073|Placebo Comparator|D|Placebo 3 tablets bid
2527465|NCT02713880||Patients with Transthyretin-Related Familial|Patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy or high-grade suspicion for Transthyretin-Related Familial Amyloidotic Polyneuropathy
2527512|NCT02713607|Experimental|doxycycline|Given doxycycline and assessment of gut, blood and skin
2527513|NCT02713607|No Intervention|Control|Control subjects to assess if there is baseline difference in these micro-evironments.
2527531|NCT02713347|Experimental|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist.~The nurse and social worker visits are in-person or by phone."
2527538|NCT02713347|No Intervention|Enhanced usual care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referrals to and ongoing care from cardiology, pulmonary, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of baseline depression surveys if they screen positive for depression, and patients will be given an information sheet that outlines self-care for CHF or COPD.
2527575|NCT02713139|Experimental|Colpistatin 5DT|
2527576|NCT02713139|Active Comparator|Gynecological Flagyl|
2527578|NCT02713139|Active Comparator|Gino-Canesten 3|
2527657|NCT02712710|Experimental|wear a functional knee brace|20 subjects with symptomatic medial compartment knee OA, with grade 2 to 4 on Kellgren and Lawrence scale, and showing willing to wear a functional knee brace. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
2527663|NCT02712710|No Intervention|no wear a functional knee brace|Another 20 subjects with comparable body height, weight, and sex. All of the subjects received 4 weeks' rehabilitation treatment (3 times a week)
2527765|NCT02711865||MK-0646|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
2527766|NCT02711865||Control|Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice who receive no other treatment.
2527863|NCT02711644|Experimental|Supportive Lifestyle Counselling|Two supportive lifestyle counselling sessions with Registered Dietitian from study entry to 34 weeks.gestation.
2527865|NCT02711644|Active Comparator|Standard Lifestyle Counselling|Two standard counselling sessions with Registered Dietitian from study entry to 34 weeks gestation
2527924|NCT02711111|Experimental|orthodontic bone anchor|new bone anchor device, which creates anterior traction on the upper jaw. Placed on the chin-region intra-orally.
2527926|NCT02711111|Active Comparator|face mask protraction|control group, conventional treatment method. Face mask creates anterior traction on the upper jaw
3166658|NCT00528086||1|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in group visit format.
3166659|NCT00528086||2|Parkinson disease patients and their family members or caregivers randomly assigned to receive their PD care in standard of care format (one-on-one physician-patient visits).
3166660|NCT00528125|Active Comparator|A|Active laser acupuncture
3166661|NCT00528125|Placebo Comparator|B|placebo laser acupuncture
3166662|NCT00528138||1|Simple appendicitis
3166663|NCT00528138||2|Perforated appendicitis
3166664|NCT00528151|Placebo Comparator|2|"curcumin~placebo"
3166665|NCT00528164|Experimental|Team PLAY Group|6-month family-centered intervention to increase physical activity and healthy eating patterns, primarily directed at parents. Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
3166666|NCT00528164|No Intervention|Standard Care Group|Participants receive standard care by primary care physician.
3166667|NCT00528177|Active Comparator|O|This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.
3166668|NCT00528177|Active Comparator|M|This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.
3166669|NCT00528242|Experimental|1|SLx-2101
3166670|NCT00528242|Placebo Comparator|2|Matching Placebo Dose
3166671|NCT00528255|Experimental|1|
3166672|NCT00528281|Experimental|Lapatinib + pemetrexed|This is a single-arm, two-stage, multicenter Phase II study to determine the clinical activity of pemetrexed with lapatinib.
3166673|NCT00528294|Experimental|1|GRID-radiotherapy followed by biological imaging guided IMRT
3166674|NCT00528307|Active Comparator|1|First 3 months of biventricular pacing, second 3 months right ventricular apical pacing
3166675|NCT00528307|Active Comparator|2|First 3 months of right ventricular apical pacing, second 3 months biventricular pacing
3166676|NCT00528333|Experimental|1|Lintuzumab plus low dose cytarabine
3166677|NCT00528333|Active Comparator|2|Placebo plus low dose cytarabine
3166678|NCT00528346|Active Comparator|1|Participants will see their own brain activation.
3166679|NCT00528346|Placebo Comparator|2|Participants will see simulated data that does not come from their own brains.
3166680|NCT00528359||A|36 lean schizophrenic subjects free of metabolic syndrome(M:F 24:12; Caucasian n=23; North-African n=12; South-Asian n=1)aged 35±9 years
3166681|NCT00528463|Experimental|sciatic block|One arm, all patient studied received a block
2527329|NCT02714582|Experimental|Bedside shift report|"The experimental group (nurses and patients) will:~develop a tailored BSR-intervention by use of co-design, diagnostic interviews, and pilot testing~use the tailored BSR-intervention, with participation of the patient, instead of the regular nurse shift report"
2527332|NCT02714582|No Intervention|No bedside shift report|The control group will not use bedside shift report, but will use the regular nurse shift report without participation of the patient
2527417|NCT02714387||ICU patients|Patients with Non Traumatic Neuro-Vascular Diseases. Medical data concerning ICU stay will be collected.
2527683|NCT02712411|Experimental|Sequence 1|"T → R~T : HCP1303 R : HGP1201 + HIP1402"
2527684|NCT02712411|Experimental|Sequence 2|"R → T~T : HCP1303 R : HGP1201 + HIP1402"
3166682|NCT00528476||1|Patients, who were treated because of recurrent (2 or more urinary tract infections per year) pyelonephritis or cystitis.
3166683|NCT00528476||2|Patients with nonrecurrent urinary tract infections (patients who had no history of more than one urinary tract infections in last year).
2527785|NCT02711761|Experimental|15 cm|The depth of guide wire will be 15 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2527795|NCT02711761|Experimental|17.5 cm|The depth of guide wire will be 17.5 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2527801|NCT02711761|Active Comparator|20 cm|The depth of guide wire will be 20 cm from puncture site of skin prior to tissue dilation during central venous catheterization
2527889|NCT02711319|Active Comparator|active (real) rTMS (ACTIVE GROUP)|"The patients were randomly distributed in two study groups: real or sham rTMS group.~For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes."
2527892|NCT02711319|Sham Comparator|sham rTMS (SHAM GROUP)|For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).
2527938|NCT02710903|Experimental|Healthy with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with probing depths (PD) ≤4mm, no evidence of inter proximal clinical attachment loss (CAL), and <20% of sites with bleeding on probing (BOP).
2527946|NCT02710903|Experimental|Periodontal Disease with Dominant IL28B and IL29|Stent-induced biofilm overgrowth model will be used in dominant IL28B and IL29 allelic with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
2527951|NCT02710903|Experimental|Healthy with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with PD ≤4mm, no evidence of interproximal CAL, and <20% of sites with BOP.
2527955|NCT02710903|Experimental|Periodontal Disease with IL28B and/or IL29 SNP variants|Stent-induced biofilm overgrowth model will be used in IL28B or IL29 SNP variants with the presence of at least four periodontal sites with PD ≥ 5mm, evidence of interproximal CAL, and ≥20% of sites with BOP.
2528001|NCT02710487|Experimental|REM Sleep Awakening (REMSA)|The investigators will actively awaken each subject from nocturnal REM sleep in a sleep laboratory setting, in the hour preceding her/his habitual wake time.
2528005|NCT02710487|Experimental|NREM Sleep Awakening (NREMSA)|Awakening from the NREM sleep stage N2 will be the control intervention.
3166684|NCT00528489|Experimental|1|PENNVAX-B with 0.8 mg IL-15 administered in both deltoids at Months 0, 1, 3, and 6
3166685|NCT00528489|Experimental|2|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
3166686|NCT00528489|Experimental|3|PENNVAX-B administered alone in both deltoids at Months 0, 1, 3, and 6
3166687|NCT00528489|Experimental|4|PENNVAX-B with 2 mg IL-15 injected into both deltoids at Months 0, 1, 3, and 6
3166688|NCT00528502|Experimental|Saline|Saline misted into the air breathe during the surgery.
3166689|NCT00528502|Experimental|Lidocaine|Lidocaine misted into the air during the surgery.
3166690|NCT00528515|Active Comparator|1|propofol
3166691|NCT00528515|Experimental|2|desflurane
3166692|NCT00528554|Active Comparator|A|Active laser acupuncture
3166693|NCT00528554|Placebo Comparator|B|Placebo laser acupuncture
3166694|NCT00528593|Active Comparator|1|
3166695|NCT00528619|Experimental|A|
3166696|NCT00528632||Cholesterolosis|I. Patients with gallbladder cholesterolosis and symptomatic cholelithiasis
3166697|NCT00528632||Cholelithiasis|II. Patients without gallbladder cholesterolosis and with symptomatic cholelithiasis
3166698|NCT00528658|Experimental|1|
3166699|NCT00528658|Experimental|2|
3166700|NCT00528658|Experimental|3|
3166701|NCT00528671|Active Comparator|A|Low dose oral anticoagulation, INR self-management once a week
3166702|NCT00528671|Active Comparator|B|very low dose oral anticoagulation, INR self-management once a week
3166703|NCT00528671|Experimental|C|very low dose oral anticoagulation, INR self-management twice a week
3166704|NCT00528697|Experimental|1|Lowest ABT-089 dose
3166705|NCT00528697|Experimental|2|Low-medium ABT-089 dose
3166706|NCT00528697|Experimental|3|Medium-high ABT-089 dose
3166707|NCT00528697|Experimental|4|Highest ABT-089 dose
3166708|NCT00528697|Active Comparator|5|atomoxetine
3166709|NCT00528697|Placebo Comparator|6|placebo
3166710|NCT00528710|Placebo Comparator|P|Placebo Control Group
3166711|NCT00528723|Experimental|A|BDP/salbutamol HFA pMDI
3166712|NCT00528723|Active Comparator|B|BDP/salbutamol CFC pMDI
3166713|NCT00528762||Focus Group|Mexican American or African American females (aged 6-12 years old) and their parents
3166714|NCT00528814|Experimental|Two Step Hand-Hygiene|Hand washing plus hand sanitizer
3166715|NCT00528814|No Intervention|Usual Care Hand Hygiene|
3166716|NCT00528827|Placebo Comparator|1|
3166717|NCT00528827|Experimental|2|5 mcg
3166718|NCT00528827|Experimental|3|2.5
3166719|NCT00528827|Experimental|4|0.5
3166720|NCT00528892|Experimental|1|Switch current boosted-PI to raltegravir 400 mg BID.
3166721|NCT00528892|Active Comparator|2|Continue current regimen (ritonavir-boosted PI plus at least 2 other drugs)
2527409|NCT02714309|Experimental|Exercise With Preload Trial|Following low/moderate intensity exercise bout, whey protein (20g) administered prior to consumption of mixed macronutrient breakfast meal. An ad libitum lunch meal is subsequently consumed.
2527467|NCT02713854|Experimental|Endometrial biopsy group|Women who have an endometrial biopsy 2-3 months prior to IVF
2527518|NCT02713581||Women with proximal VTE|"Patients will correspond to cases of proximal venous thromboembolism. They will be recruited during consultations conducted for the chronic management of a history of proximal venous thromboembolism or thrombophilia following a recent history of proximal venous thromboembolism. Venous thromboembolism, outside of acute phase episodes, has good symptom stability over time; no difference is to be expected between patients with a chronic history of proximal venous thromboembolism and new patients coming in for a checkup. Note that these patients may or may not have a history of placental vascular disease.~Intervention: Blood sampling"
2527521|NCT02713581||Women with >1 healthy pregnancy|"This populations is composed of healthy, female, adult volunteers (<50 years in age) that have had at least 1 healthy pregnancy.~Intervention: Blood sampling"
2527557|NCT02713308||Group1-CRT|Patients with RV-to-LV delay≥80ms, CRT standard programming (single-point)
2527560|NCT02713308||Group2-MPP|Patients with RV-to-LV delay<80ms, CRT programming with MPP (multi-point)
2527590|NCT02713048||Acute coronary syndrome culprit coronary lesion|
2527591|NCT02713048||Stable obstructive coronary artery disease|
2527592|NCT02713048||Non-obstructive coronary artery disease|
2527651|NCT02712801|Experimental|Intervention group|Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
2527658|NCT02712801|Active Comparator|Control group|Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.
2527725|NCT02712203||12 months|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age
2527735|NCT02712203||13 months|MMR vaccine / MMRV vaccine : administration of the first dose at 13 months of age
2527741|NCT02712203||14 months|MMR vaccine / MMRV vaccine : administration of the first dose at 14 months of age
2527746|NCT02712203||15 months or more|MMR vaccine / MMRV vaccine : administration of the first dose at 12 months of age or older
2527772|NCT02711891|Experimental|5% Loperamide gel|Participants received 5% loperamide gel (0.2gm equivalent to 10 mg) applied following a single surgilance to the 5th digit. The loperamide gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the loperamide gel which was left in place for 30 minutes. The placebo gel contained the same ingredients without the loperamide. The loperamide gel formulation includes: Loperamide 5%, Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
2527778|NCT02711891|Placebo Comparator|Placebo gel|Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
2527851|NCT02711592|Other|Genetic Panel for Analgesics|Genetic testing for analgesics prior to surgery will be conducted. The subject will receive postoperative analgesia based on test results.
2527886|NCT02711189|Active Comparator|Oxytocin|Intranasal oxytocin will be delivered on twice daily basis in this crossover trial.
2527887|NCT02711189|Placebo Comparator|Placebo|Within Subject Design
2527949|NCT02710942|Experimental|SPHERE intervention|It is a comprehensive self-guided Internet-based cognitive-behavioral therapy (CBT) that includes three components: (1) the myWHI diary. (2) 30 multi-media learning topics that the user is encouraged to go through in a sequential way. The topics contain education information and teach strategies to cope better with their headaches.
2527952|NCT02710942|Experimental|PRISM intervention|It is a targeted self-guided Internet-based CBT intervention. PRISM was built upon the myWHI diary, an electronic headache diary. PRISM helps users discover their headache triggers by analyzing the inputted diary data using association rule mining. Once one or multiple headache triggers are identified the application uses an algorithm to provide the user with a few personalized recommendations to help them to cope with these triggers. The algorithm is based on the opinion of clinical experts (e.g., medical health professionals, psychologists). The user chooses recommendations to follow and sets goals in the application to follow them. To support the process, the application checks in with users about their goals and tracks goal completion.
2527956|NCT02710942|No Intervention|Usual care|Participants can continue doing what they usually do to deal with their migraines.
3166722|NCT00528905|Placebo Comparator|1|Placebo
3166723|NCT00528905|Experimental|2|AZD3480 oral
3166724|NCT00528905|Experimental|3|AZD3480 oral dose
3166725|NCT00528918|Active Comparator|Apidra|Direct 1:1 comparison of Apidra and Regular insulin.
2528081|NCT02709928|Experimental|TD-0714|Capsule formulation
2528087|NCT02709928|Placebo Comparator|Placebo|Capsule formulation
3166726|NCT00528918|Active Comparator|Regular|Direct 1:1 comparison of Apidra and Regular insulin.
3166727|NCT00528944||Cohort A|Patients with obstructive defects and radiological evidence of emphysema
3166728|NCT00528944||Cohort B|Patients with obstructive ventilatory defects and no radiological evidence of emphysema
3166729|NCT00528944||Cohort C|Non-smokers without obstructive ventilatory defects or history of cardiopulmonary disease
2527471|NCT02713841|Active Comparator|subcutaneous insulin lispro (LIS)|single 6 unit dose of insulin lispro administered subcutaneously
2527530|NCT02713555|Experimental|Roux-en-Y Gastric Bypass group|Morbidly obese patients with type 2 diabetes mellitus will be examined before and after the Roux-en-Y Gastric Bypass procedure
2527537|NCT02713555|Experimental|Gastric sleeve group|Morbidly obese patient with type 2 diabetes Mellitus will be examined before and after the Gastric Sleeve procedure
2527543|NCT02713555|No Intervention|Method /control group|Healthy normal weight participants matched by age and gender to the intervention study will be examined with the same methods as the intervention groups and serve as participants in a method study and as a metabolic normal reference group.
2527593|NCT02713074|Active Comparator|Group A|povidone-iodine group
2527597|NCT02713074|Active Comparator|Group B|Normal saline group
2527688|NCT02712385|No Intervention|Control - usual care|Usual post-TIA/minor stroke care as per current healthcare system protocol will be given to patients in control group and details will be recorded.
2527691|NCT02712385|Active Comparator|Manual|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual'.
2527693|NCT02712385|Active Comparator|Manual + pedometer, 1|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a General Practitioner.
2527694|NCT02712385|Active Comparator|Manual + pedometer, 2|Receiving usual post-TIA/minor stroke care plus 'The Healthy Brain Rehabilitation Manual' and a pedometer with telephone follow-up from a Stroke nurse.
3200120|NCT00887601|Experimental|Part II|Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
3200121|NCT00887614|Experimental|MBSR|Participation will involve online completion of a questionnaire survey before and after the Mindfulness-Based Stress Reduction (MBSR) intervention. Specifically, research study participants will complete validated self-report measures to assess mindfulness, cognitive-emotional processes, sleep quality, symptoms of stress, sense of spirituality, and quality of life before and after the MBSR intervention.
2528014|NCT02710370||Controls|Patients who meet criteria for gastric bypass surgery, and do not have a documented history of Type 1 or Type 2 Diabetes.
2528015|NCT02710370||Participants with Type 2 Diabetes|Patients who meet criteria for gastric bypass surgery, and have a documented history of Type 2 Diabetes.
3200122|NCT00887627|Experimental|1. Mild Renal Function Impaired Subjects|
2528161|NCT02709590|Experimental|Group A|oral diclofenac potassium plus lidocaine anesthetic cream placed into their cervix immediately before HSG
2528162|NCT02709590|Placebo Comparator|Group B|oral placebo tablets plus placebo cream placed into their cervix immediately before HSG
2528179|NCT02709317|Active Comparator|Standard Care|In this arm, veterans receive the care that they would receive had they not enrolled in the research. No one will receive less than standard care.
2528182|NCT02709317|Experimental|Prevention Intervention|An adaptive monitoring intervention, delivered through text messages and brief telephone calls, that can provide extended prevention services for veterans engaging in risky alcohol use. After a veteran receives a BI for risky drinking, we will monitor alcohol use for 4 weeks. Veterans who reduce alcohol use to safe levels will be placed in a monitoring track, which consists of tailored text messages and brief monthly telephone contacts. Conversely, veterans who continue to use alcohol at hazardous levels will be placed in a track that provides tailored text messages and more frequent telephone calls. These calls provide further prevention/intervention services to help the veteran reduce alcohol use. These services address motivational issues and identify more effective ways to cope with stress and other factors that trigger unsafe alcohol use. Information on the veteran's progress is used to guide the content of subsequent text messages and prevention interventions.
2528246|NCT02709135||Pre-hospital HEART Score|All subjects included in this quality surveillance study will have had a HEART score, including POC troponin calculated by paramedics prior to arrival at the emergency department.
2528366|NCT02708420|Other|Glidescope intubation|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
2528368|NCT02708420|Other|Macintosh Laryngoscope|This standard technique involves laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
2528437|NCT02707913|Experimental|BF-Amlodipine Tablet 10mg|During the study session, healthy subjects will be administered a single dose of BF-Amlodipine Tablet 10mg after an overnight fast of approximately 10 hours
2528440|NCT02707913|Active Comparator|Norvasc Tablet 10mg|During the study session, healthy subjects will be administered a single dose of Norvasc Tablet 10mg after an overnight fast of approximately 10 hours
3200123|NCT00887627|Experimental|2. Moderate Renal Function Impaired Subjects|
3200124|NCT00887627|Experimental|3. Subjects with Normal Renal Function|
2528524|NCT02707068|Experimental|QOLITI|"Intervention group receives the QOLITI (Quality Of LIfe Tool for IBD) manual immediately to work with over the course of several weeks along with 3 x 30 minutes of telephone support by a trained healthcare professional. Telephone calls will occur at two, four and six weeks post-randomisation.~Participants will be invited to discuss their experiences after the end of the actual study. These interviews are no obligatory part of the QOLITI study."
2528527|NCT02707068|No Intervention|Waitlist Control group (WLC)|Waitlist control group waits until after the study finishes to receive the same manual, but without telephone support sessions.
3200125|NCT00887705|No Intervention|1: Standard rehabilitation programme|
2528680|NCT02706405|Experimental|Group II (durvalumab, JCAR014)|Patients receive durvalumab IV over 60 minutes on day -1, JCAR014 IV over 20-30 minutes on day 0, then up to 10 additional doses of durvalumab every 4 weeks in the absence of disease progression or unacceptable toxicity.
3200126|NCT00887705|Experimental|2. Additional ADL training|
3200127|NCT00887718|Experimental|PET scan for lymphoma assessment|
3200128|NCT00887731||Part 1 group|Observational study with a convenience sample of ten (10) patients. PART 1 will end when at least 3 of 4 consecutive patients achieve the goal of less than six (6) operator required interruptions per hour for oxygen saturation deviations from study guidelines, or at ten (10) patients.
2527490|NCT02713958|Experimental|Tele rehabilitation|Telerehabilitation:The subjects in the study group will receive two treatments in Telerehabilitation and one treatment in the clinic weekly . At home they will be asked practice daily active exercises with the Meditouch Ltd. system.
2527496|NCT02713958|Active Comparator|rehabilitation|Traditional Occupational Therapy:The subjects in this group will receive three treatments in the clinic every week. At home they will be asked to practice daily active exercises in the same level of difficulty and duration as the study group but without the Meditouch Ltd. system
2527527|NCT02713438|Experimental|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2527532|NCT02713438|Experimental|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad, the child. The parent is actively participating in forming plans by the child.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2527536|NCT02713438|Experimental|Collaborative Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (child and parent). Physical activity may be performed jointly by both persons in the dyad.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
2527544|NCT02713438|Active Comparator|Education|The education group received extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
2527603|NCT02713035|No Intervention|Usual|Receive standard medical therapy for eczema
2527606|NCT02713035|Experimental|Treatment|Receive standard medical therapy for eczema plus behavioral self help intervention
2527652|NCT02712723|Active Comparator|Placebo + Letrozole|Placebo randomized to 3 capsules/day 3 weeks on/1week off or 2 capsules/day continuous dosing + Letrozole 2.5 mg PO daily
2527661|NCT02712723|Experimental|Ribociclib 600 mg + Letrozole|Ribociclib 600 mg PO daily 21 days on/7 days off + Letrozole 2.5 mg PO daily
2527664|NCT02712723|Experimental|Ribociclib 400 mg + Letrozole|Ribociclib 400 mg continuous daily dosing + Letrozole 2.5 mg PO daily
2527716|NCT02712125|Active Comparator|isosorbide mononitrate|Received 20 mg isosorbid mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily until delivery
2527719|NCT02712125|Placebo Comparator|Control|Received placebo vaginal tablets once daily until delivery
2527769|NCT02712021|Experimental|Cerebral Palsy-Study group|The intervention consisted of wearing a lycra suit, with shoulder, trunk and pelvis coverage, for more than 4 hours per day for 6 months. The motor function assessments will be performed without the Lycra suit, whereas the static balance assessments were performed with and without the suit.
2527775|NCT02712021|Active Comparator|Cerebral Palsy-Control Group|Children with clinical characteristics similar to the study group; they will be assessed using the same protocol but with no use of lycra garments
2527840|NCT02711618|Experimental|UltraShape Contour I V3 treatment|Up to 60 healthy adult volunteers seeking noninvasive fat reduction, male and females at up to four sites, age of 18 to 60, with BMI above 28
2527910|NCT02711241|Active Comparator|Dipyrone|
2527916|NCT02711241|Active Comparator|Papaverine|
2527933|NCT02710799|Active Comparator|Control|Referrals will be evaluated through the state's protocols
2527934|NCT02710799|Experimental|Intervention|Referrals will be evaluated through the state's protocols associated with telephone-based teleconsultations.
2527997|NCT02710604|Active Comparator|CMX157 5mg versus TDF|CMX157, 5mg tablet, 28 days versus TDF(tenofovir disoproxil fumerate) 300mg tablet, 28 days
2528002|NCT02710604|Active Comparator|CMX157 10mg versus TDF|CMX157, 10mg tablet, 28 days versus TDF 300mg tablet, 28 days
2528007|NCT02710604|Active Comparator|CMX157 25mg versus TDF|CMX157, 25mg tablet, 28 days versus TDF 300mg tablet, 28 days
2528008|NCT02710604|Active Comparator|CMX157 50mg versus TDF|CMX157, 50mg tablet, 28 days versus TDF 300mg tablet, 28 days
2528010|NCT02710604|Active Comparator|CMX157 100mg versus TDF|CMX157, 100mg tablet, 28 days versus TDF 300mg tablet, 28 days
2528061|NCT02710123|Experimental|Aerobic Exercise|Participants will receive an exercise prescription based on their heart rate threshold (HRT) for symptom exacerbation during the Buffalo Concussion Treadmill Test (BCTT). The script will ask the participant to exercise one a day for 20 minutes at 80% of HRT. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Sub-Threshold exercise prescription
2528062|NCT02710123|Placebo Comparator|Stretching Exercise|Participants will receive a prescription for stretching exercises that they will be asked to do daily. Participants will wear a smart watch to monitor their frequency, actual time and HR during exercise. Treatment will continue until participant is fully recovered from their concussion. Intervention: Structured stretching exercise prescription.
3200129|NCT00887731||Part 2 group|(After successful completion of PART 1) Within patient cross-over study with a randomized cross-over sequence. Sequential data analysis methods will be used to help minimize the patient sample size which will be no more than twenty (20) patients plus up to a maximum of seven (7) who might be eligible from PART 1.
2528348|NCT02708511|Experimental|Diagnostic (Cu 64 DOTA-B-Fab)|Patients receive copper Cu 64-DOTA-B-Fab IV followed by PET/CT 60 minutes post-injection and 24 hours post-injection
3200130|NCT00887731||Part 3 Group|(After successful completion of PART 2) Within patient cross-over study with a randomized cross-over sequence. Studies will last 4 to 12 hours divided in two (2) equal time blocks with one cross-over to either automatic or manual control modes.
3200131|NCT00887757|Experimental|gemcitabine +ABT-263|
2528576|NCT02706704|Active Comparator|Intravitreal|Intravitreal injection of 1.5mg/0.03ml adalimumab given at zero, 2 weeks, and then every 4 weeks.
2527519|NCT02713620|Active Comparator|HIV-Group 2|"the Four doses group receiving four intramuscular doses of 20 μg of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
2527522|NCT02713620|Active Comparator|HIV-Group 3|"the Four double doses group receiving four intramuscular double doses (40 μg) of recombinant HBV vaccine (Hepavax-Gene® Berna, Korea) at months 0, 1, 2, and 6"
2527559|NCT02713295||Subjects with Moderate to Severe Plaque Psoriasis|Subjects with Moderate to Severe Plaque Psoriasis in Greece
2527653|NCT02712736|Other|Survey respondents|The patients who consent to participate will be sent home from the clinic with a survey to complete and return via mail in a provided addressed, stamped envelope. The survey consists of the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ), questions from the PROMIS SexFs v2.0, questions regarding perceived risk for liver transplant, cholangiocarcinoma, and colorectal carcinoma, as well as perceived overall life expectancy, and questions regarding complementary and alternative medicine use.
2527705|NCT02712372|Experimental|Part 1, Dose Level 1|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527707|NCT02712372|Experimental|Part 1, Dose Level 2|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527709|NCT02712372|Experimental|Part 1, Dose Level 3|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527710|NCT02712372|Experimental|Part 1, Dose Level 4|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527711|NCT02712372|Experimental|Part 1, Dose Level 5|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527712|NCT02712372|Experimental|Part 1, Dose Level 6|Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.
2527713|NCT02712372|Experimental|Part 2, Dose Level 1|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2527714|NCT02712372|Experimental|Part 2, Dose Level 2|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2527715|NCT02712372|Experimental|Part 2, Dose Level 3|Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12
2527717|NCT02712372|Placebo Comparator|AZD4831 Placebo|"Part 1: Part 1A: Single dose administered in the morning on Day 1 under fasted conditions. Part 1B: Single dose administered in the morning of Day 1 under fed conditions.~Part 2: Single dose administered in the morning on Day 1 and multiple doses administered once daily, in the morning, Days 3 to 12"
2527790|NCT02711917|Experimental|SP1- sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
2527799|NCT02711917|Experimental|SP2- Sevoflurane MAC 0.75|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen.Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
2527804|NCT02711917|Experimental|SP3 -Sevoflurane MAC 1.0|In this group, patient of age 40-60 years, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 1.0. Propofol infusion is started to keep BIS between 40-60.
2527805|NCT02711917|Experimental|SP4- Sevoflurane MAC 0.5|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Propofol infusion is started to keep BIS between 40-60.
2527807|NCT02711917|Experimental|SP5- Sevoflurane MAC 0.75|In this group, patient above 60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.75. Propofol infusion is started to keep BIS between 40-60.
2527809|NCT02711917|Experimental|SE1- Sevoflurane MAC 0.5|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2527811|NCT02711917|Experimental|SE2- Sevoflurane 0.75|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2527812|NCT02711917|Experimental|SE3- Sevoflurane MAC 1.0|In this group, patient of age 40-60 years of age, ASA I/II, undergoing elective abdominal or gynecological surgery are chosen. Neuromuscular function prior to induction is assessed by acceleromyography by stimulation of ulnar nerve and noting the response of adductor pollicis. After induction and intubation, Sevoflurane is started to achieve the desired MAC of 0.5. Etomidate infusion is started to keep BIS between 40-60.
2527878|NCT02711371||Cannabis Dependence|Cannabis dependent individuals according to DSM 4 criteria, aged 18-40 years
2527523|NCT02713568|Experimental|Magnetic Resonance|"During routine third trimester ultrasound scan between 30 weeks and 35 weeks +6 days of gestational age, all women with an apparently normal, live singleton pregnancy, planning to deliver at the investigator's hospital maternity, will be invited to participate in the study.~A Magnetic Resonance examination to estimate the fetal weigth will be carried out during the 36th week of gestation."
2527540|NCT02713282|Experimental|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq.) up to 525 mg eq. based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
3200132|NCT00887770|Experimental|A|600mg AZD5672 + Moxifloxacin placebo
3200133|NCT00887770|Experimental|B|100mg AZD5672 + Moxifloxacin placebo
2527783|NCT02711826|Active Comparator|Maintenance CNI based immunosuppression therapy group|"Standard of care~(N=15 participants in this group)"
2527796|NCT02711826|Experimental|Polyclonal Regulatory T Cells group|"Subjects to receive polyTregs (550 ± 450 x 10^6). After receiving at least 300X10^6 polyTregs infusion, eligible subjects will start mammalian Target of Rapamycin (mTOR) inhibitor.~Target tacrolimus trough levels prior to conversion to everolimus are 4-11 μg/dl, which falls within standard of care. For eligible participants in polyTregs and darTregs groups, the tacrolimus dose will be reduced by 50% when everolimus is initiated. Tacrolimus will be discontinued 4 weeks after initiation of everolimus therapy.~Everolimus, a mTOR inhibitor immunosuppressant, will be initiated at a dose of 1.5 mg orally twice daily and titrated, as needed. Participants will begin everolimus with target trough levels of 3-8μg/L for 4 weeks while still taking tacrolimus. Everolimus target trough levels will be 6-10 μg/L when tacrolimus is discontinued.~(N=15 participants in this group)"
2527900|NCT02711124||Group with hemoglobin A1c < 7|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
2527905|NCT02711124||Group with hemoglobin A1c ≥ 7%|There will be no intervention administered to the group. The group will be observed for platelet function pre- and postoperatively.
2527968|NCT02710916|Sham Comparator|perimetric glaucoma patients|
2527972|NCT02710916|Active Comparator|preperimetric glaucoma patients|
2527974|NCT02710916|Sham Comparator|perimetric glaucoma control patients|
2528023|NCT02710396|Experimental|Cohort 1|Subjects will receive single agent pembrolizumab 200 mg IV will be administered every 3 weeks for up to 2 years.
2528024|NCT02710396|Experimental|Cohort 2|Subjects will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of nab-paclitaxel and carboplatin administered with cycles 1 and 2.
2528025|NCT02710396|Experimental|Cohort 3|Subject will receive pembrolizumab 200 mg IV every 3 weeks for up to 2 years with 2 cycles of pemetrexed and carboplatin administered with cycles 1 and 2.
2528089|NCT02709915|Experimental|Breakfast Diet (Bdiet)|The Bdiet will consist in 3 meals with distribution of calories: breakfast 50%, lunch 33% and dinner 17%.
2528090|NCT02709915|Active Comparator|6 small meals diet (6Mdiet)|The 6Mdiet will consist on 6 meals (breakfast, lunch and dinner and 3 snacks) with distribution of calories: breakfast 15%, lunch 25%, dinner 30% and 10% each of the three snacks.
2528185|NCT02709421||Indomethacin Group|"All the patients with high risks of PEP received administration of one single dose of 100mg rectal indomethacin after ERCP.~Patients were considered high risk of PEP if they met one of the following criteria: clinical suspicion of sphincter of Oddi dysfunction, a history of PEP, pancreatic sphincterotomy, precut sphincterotomy, ≥8 cannulation attempts, cannulation time≥10 minutes; pneumatic dilatation of an intact biliary sphincter, ≥3 inadvertent pancreatic duct cannulation, opacification of pancreatic acini, or the acquisition of a cytologic specimen from the pancreatic duct with the use of a brush or forceps."
2528269|NCT02709148|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
2528295|NCT02708784||Pompe disease|Patients will perform muscle strength measurement with dynamometer and MR-imaging. After 8 months the investigations will be repeated.
2528296|NCT02708784||Myotonic Dystrophy|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
2528297|NCT02708784||Healthy controls|Patients will perform muscle strength measurement with dynamometer and MR-imaging. The investigations will not be repeated after 8 months.
3200134|NCT00887770|Active Comparator|C|AZD5672 placebo + Moxifloxacin 400mg
3200135|NCT00887770|Placebo Comparator|D|AZD5672 placebo + Moxifloxacin placebo
2528374|NCT02708134||Pediatric Cardiac Arrests|Pediatric cardiac arrests requiring chest compressions for at least 1 minute managed at clinical centers identified as part of standard clinical operations.
2528423|NCT02707835|Active Comparator|control group|self massage, skin care education, manual lymph drainage exercise, compression garment
2528428|NCT02707835|Active Comparator|manual lymph drainage group|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
2528430|NCT02707835|Experimental|experimental group|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
2528578|NCT02706704|Active Comparator|Systemic|Subcutaneous injection of 40 mg adalimumab (Humira) given every 2 weeks.
3200136|NCT00887835|Experimental|PERPOS™ PLS|Minimally invasive transfacet fixation with PERPOS™ PLS as an aid to fusion
3200137|NCT00887848|Experimental|Lokomat training|Lokomat training
3200138|NCT00887848|Other|Waiting list|Lokomat training after waiting phase of 5 weeks
3200139|NCT00887861|Experimental|BGG492|
3200140|NCT00887861|Placebo Comparator|Placebo|
3200141|NCT00887874||A|
3200142|NCT00887887||liver surgery|patients with benign or malignant hepatobiliary disease requiring partial hepatic resection
2527815|NCT02711709|Other|Intra-abdominal sepsis|Frailty measurements. Modified Minnesota Leisure Time Activities. Computed tomography morphometrics. Mobility Monitors.
2527904|NCT02711332||Degree of Haemolysis|Each subject will have four capillary blood sampling on different fingers. A reference venous blood sampling will be conducted.
3200143|NCT00887900|Experimental|1|Submitted to deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
2528120|NCT02709954|Experimental|Active THC and Placebo Ethanol|
2528123|NCT02709954|Experimental|Active THC and Active Ethanol|
2528124|NCT02709954|Experimental|Placebo THC and Active Ethanol|
2528125|NCT02709954|Placebo Comparator|Placebo THC and Placebo Ethanol|
2528201|NCT02709356|Experimental|Alzheimer's disease|"Patients with mild Alzheimer's disease.~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
2528209|NCT02709356|Experimental|Controls|"Healthy elderly people~1-month of 60-40 MCT oil and 1-month of C8 MCT oil (order of the two intervention are randomized)"
3200144|NCT00887900|Active Comparator|2|Submitted to regular penetrating keratoplasty
3200145|NCT00887952|Experimental|1|Partial removal of carious dentine. Carious dentine partial removal plus restoration in one session. The group is divided according to the filling material: amalgam or resin.
3200146|NCT00887952|Active Comparator|2|Stepwise excavation: Carious dentine removal performed in 2 steps: partial removal of carious dentine, indirect pulp capping (calcium hydroxide cement); temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling (amalgam or resin).
3200147|NCT00887991||Electric Pump 1 (ISIS Duo iQ Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
3200148|NCT00887991||Electric Pump 2 (Medela Symphony Electric Breast Pump)|This is a parallel trial where subjects (mother of preterm infants) will be allocated to use one of two electric breast pumps to express milk. The use of electric breast pumps is routine practice on neonatal units in the UK.
3200149|NCT00888004|Experimental|Active|
2528429|NCT02707874|Active Comparator|CI 0.2% ropivacaine|"Patients in Group Continuous Infusion (CI) will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
2528432|NCT02707874|Active Comparator|PIB 0.2% ropivacaine|"Patients in Group programmed intermittent boluses (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine.~• All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required.~2) Oral patient controlled analgesia (PCA) using oxycodone or hydromorphone. Patients under 70 years of age will receive either 10 mg of oxycodone or 2 mg of hydromorphone 2 hourly as needed, and patients 70 years of age or older will receive 5 mg of oxycodone or 1 mg of hydromorphone 2 hourly as needed.~3) Oral acetaminophen 1,000 mg 6 hourly."
2528492|NCT02707471|Experimental|SM-AET|a self-management intervention for enhancing skills to improve adherence and reduce symptom interference (SM-AET) (active intervention group)
2528500|NCT02707471|Other|general health education Intervention|general health education Intervention (control group)
3200150|NCT00888004|Placebo Comparator|Placebo|
3200151|NCT00888017||PPI group|This group of infants have received treatment with a PPI as ordered by their neonatologist during their hospital stay.
2528579|NCT02706587|Experimental|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
2528583|NCT02706587|Sham Comparator|Sham Control|No electrostimulation
2528674|NCT02706431|No Intervention|Normoventilation|The patients will be normoventilated before anesthesia
2528681|NCT02706431|Experimental|Hyperventilation|Prior to anesthesia, the patients will hyperventilate during 2 mins or until symptoms from the central nervous system (e.g. dizziness).
2528739|NCT02706080||Antithrombotic agents|We propose to realize a single-center prospective registry of patient under Antithrombotic agent who came to the emergency unit for any reason.
2528797|NCT02705664|Experimental|Loceryl NL|Amorolfine hydrochloride NL 5% to be applied once weekly for 7 weeks on all affected toenails of one foot
2528800|NCT02705664|Active Comparator|Urea Ointment + Bifonazole Cream|"On the opposite foot:~Urea 40% ointment to be applied once a day under occlusion for 2-3 weeks depending on the achievement of optimal diseased toenail plates removal)~Bifonazole 1% cream to be applied for 4 weeks on affected toenails (after the maximum 3-week treatment period with Urea ointment)"
2528859|NCT02705118|Experimental|Automatic registration arm|"Automatic registration for fusion imaging of US and MRI will be performed.~Automatic Imaging fusion of ultrasonography and MRI"
2528860|NCT02705118|Active Comparator|Manual registration arm|"Manual registration for fusion imaging of US and MRI will be performed.~Manual Imaging fusion of ultrasonography and MRI"
3200152|NCT00888017||non-PPI group|These infants did not receive PPIs during their hospital stay.
3200153|NCT00888030||2|CKD patients with normal p-cresol
3200154|NCT00888030||3|CKD patient with normal indoxyl sulfate
3200155|NCT00888030||4|CKD patients with high indoxyl sulfate
3200156|NCT00888030||1|CKD patients with high p cresol
3200157|NCT00888043|Other|I|CNTO 95 and avastin
3200158|NCT00888056|Experimental|ARM A|Bilateral chronic electrical stimulation of the hypothalamus/fornix
2527619|NCT02712970||Stage-R|Recurrent PSD following any type of treatment. Other flap techniques such as V-Y advancement flap, Z-Plasty will be performed.
2527680|NCT02712502||Study group (OG).|"50 patients c and acute exacerbation of chronic bacterial rhinosinusitis in the study group (OG).~The treatment regimen in the study group.~Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
2527681|NCT02712502||Control group (CG).|"50 patients c and acute exacerbation of chronic rhinosinusitis in the control group (CG).~The treatment regimen of the control group. Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
2527733|NCT02712216|Other|Trocar Insertion Sites|Insertion of a 21-gauge 3.5inch spinal needle perpendicular to the abdominal wall at each possible trocar site. The needle will be placed after the abdomen is insufflated under direct visualization with the laparoscopic camera. The needle will be inserted to the level of the peritoneum and a hemostat will be place on the needle at the level of the epidermis.
2527872|NCT02711657|Experimental|Fibrocyte measurement and lung function test|All participants has a peripheral blood sample taken, where fibrocytes are measured using flowcytometry. Further peripheral blood mononuclear cells (PBMC) are isolated and cultured. All, except healthy controls, have their lung function measured.
2527881|NCT02711085||Acute trauma|Those within the first 3 weeks of a non-catastrophic injury affecting the musculoskeletal system, including but not limited to whiplash or other road-traffic collisions, sports injuries, work-related injuries, sprains, strains, slips and falls and non-displaced fractures that don't require surgical correction.
2527928|NCT02711007|Experimental|apatinib|apatinib 750mg tablet or 500mg tablet by mouth, Qd half an hour after dinner
2527960|NCT02710708|Experimental|Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)|Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
2528064|NCT02710188|Experimental|HTL0009936 modified release (MR) Formulation|Intervention: 5 different modified release formulations of HTL0009936, as a single dose
2528069|NCT02710188|Active Comparator|HTL00009936 immediate release (IR) fasted|Intervention: 1 immediate release formulation of HTL0009936, as a single dose in the fasted state
2528103|NCT02709837|Active Comparator|Poorly cooked meat-Good chewing|Meat cooked 10min at 75°C, chewing without appliance
2528105|NCT02709837|Active Comparator|Highly cooked meat-Good chewing|Meat cooked 45min at 90°C, chewing without appliance
2528107|NCT02709837|Active Comparator|Poorly cooked meat-Bad chewing|Meat cooked 10min at 75°C, chewing with appliance
2528110|NCT02709837|Active Comparator|Highly cooked meat-Bad chewing|Meat cooked 45min at 90°C, chewing with appliance
2528160|NCT02709603|Experimental|Group A|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
2528163|NCT02709603|Placebo Comparator|Group B|oral 2 tablets (PLACEBO) 30 minutes before the procedure
2528189|NCT02709304|Placebo Comparator|Standard Gel|Standard gel not containing local anesthetic used to insert urinary catheters.
2528193|NCT02709304|Experimental|Lidocaine Gel|lidocaine containing gel uses to insert urinary catheters
2528256|NCT02709122|Experimental|With Tension pneumothorax|evaluation of the patient with the existing tension pneumothorax during a simulated CPR - breathing
2528260|NCT02709122|Experimental|Without Tension pneumothorax|evaluation of the patient without the existing tension pneumothorax during a simulated CPR - breathing
2528319|NCT02708810|Other|80 Gy Radiation & Unframed Virtual Cone|80 Gy Virtual Cone Radiosurgery unframed (face mask)
3200159|NCT00888069|Experimental|Low Dose CTAP101 Capsules|CTAP101 Capsules, 450 mcg dose
3200160|NCT00888069|Experimental|High Dose CTAP101 Capsules|CTAP101 Capsules, 900 mcg dose
2528425|NCT02707822||kidney or liver transplantation|Renal or liver transplant recipients with tacrolimus as immunosuppressive drugs.
2528488|NCT02707614||Robotic vs open prostastectomy|One group is operated by open prostatectomy the other by robotic assistance
2528538|NCT02707224|Experimental|Group A|combination dose of Candesartan cilexetil and Rosuvastatin and DP-R208 in order
2528545|NCT02707224|Experimental|Group B|DP-R208 and combination dose of Candesartan cilexetil and Rosuvastatin in order
3200161|NCT00888069|Experimental|CTAP101 Injection|IV injection, 448 mcg dose
3200162|NCT00888082|No Intervention|A|Patients receiving only adjuvant chemotherapy
2528729|NCT02705911|Experimental|Isometric Handgrip training|Participants are asked to perform daily 4 x 2 minute contractions with alternating hands , separated with 1 minute rest period using a ZonaHealth device;
2528734|NCT02705911|Active Comparator|Aerobic endurance training|Participants are asked to perform at least 150 minutes extra of moderate aerobic exercise per week
2528742|NCT02705911|No Intervention|Control|Participants are asked to continue with their daily routine and not to perform extra exercise.
3200163|NCT00888082|Experimental|B|Patient receiving goserelin acetate along with adjuvant chemotherapy
3200164|NCT00888095|Experimental|1|caudal Zona incerta (cZI)
3200165|NCT00888095|Experimental|2|Nucleus subthalamicus (STN)
2528936|NCT02704533|Experimental|Optimization Phase - Group A|"n=6; three times 9x10^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 (Group B1).~If <75% efficacious, the treatment will be increased to three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)"
2528938|NCT02704533|Experimental|Optimization Phase - Group B1|"n=6; two times 1.35x10^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to one injection 2.7x10^6 PfSPZ Vaccine (Group C1).~If <75% efficacious, the treatment will be increased to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2)."
2528964|NCT02704468||CAVI and FGF-21|renal transplant patients for more than 1 month measured FGF-21 and CAVI
3200166|NCT00888108|Experimental|docetaxel +ABT-263|
2527621|NCT02712905|Experimental|INCB059872 in combination with other therapies|"Initial cohort dose of INCB059872 to evaluate different doses of INCB0599872 in combination with other therapies in the following treatment groups:~Combination with all-trans retinoic acid (ATRA) in subjects with relapsed/refractory AML.~Combination with azacitidine in subjects with newly diagnosed, treatment-naive AML~Combination with nivolumab in subjects with advanced SCLC previously progressed on platinum-based treatment.~Upon identification of the recommended dose(s) for each treatment combination, expansion cohorts of approximately 30 subjects in each treatment group may begin enrollment to further determine safety, tolerability, efficacy, PK, and PD of the selected dose(s)."
3200167|NCT00888147||Fiber formula|This group will receive tube feeding formula that contains fiber.
3200168|NCT00888186|Active Comparator|1. Duodopa optimal dose|
3200169|NCT00888186|Experimental|2. Duodopa 20% too high dose|
3200170|NCT00888186|Experimental|3. Duodopa 10% too low dose|
3200171|NCT00888186|Experimental|4. Duodopa 20% too low dose|
2527942|NCT02710786||Gastric bypass|Patients undergoing gastric bypass
2528052|NCT02710318|Experimental|Immunization Alert on|Children with visits seen when the immunization alert is on
2528054|NCT02710318|No Intervention|Immunization Alert off|Children with visits seen when the alert is off
2528083|NCT02709993|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
3200172|NCT00888186|Experimental|5. Duodopa 10% too high dose|
3200173|NCT00888199|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
3200174|NCT00888199|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
2528224|NCT02709200||Dexmedetomidine|Patients that received dexmedetomidine during open heart surgery.
2528225|NCT02709200||No dexmedetomidine|Patients that didn't receive dexmedetomidine during open heart surgery.
2528244|NCT02708979|Active Comparator|University Exam Period|This visit takes place the week before an exam at the university assuming that this will induce a stress response. Measurements (see description elsewhere) are being taken within 1-2 weeks prior to an university exam.
2528247|NCT02708979|Placebo Comparator|University Non-exam Period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period. Measurements (see description elsewhere) are being taken in a control-period without exams (at least 4 weeks after and 4 weeks prior to an exam)
2528310|NCT02708797|Other|Migraine with aura Patients|Patients with migraine with aura will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
2528317|NCT02708797|Other|Controls|Control group with healthy volunteers will be studied 30 days after the pre inclusion visit with both magnetic resonance imaging and Transcranial Doppler.
3200175|NCT00888212|Experimental|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
3200176|NCT00888225|Experimental|Eccentric exercise|Group exposed to eccentric exercise treatment
3200177|NCT00888225|Active Comparator|Concentric exercise|Group exposed to concentric exercise treatment
3200178|NCT00888251||Comprehensive weight management program|
3200179|NCT00888290|Experimental|Single arm|Crossover design. Participants will be getting either placebo or different doses of sodium bicarbonate during the study.
3200180|NCT00888303|Active Comparator|A (dexamethasone)|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
2528700|NCT02706158|Experimental|supplement and balanced diet|"Woman at high risk of pre-eclampsia:~supplements. 1500 mg Calcium and 1200 IU Vitamin D for 2 months. balanced diet."
2528701|NCT02706158|No Intervention|women without nutrition or supplement intervention|usual follow-up in the gynecology out patient clinic, without nutrition or supplement intervention.
2528711|NCT02705833||Population with R/M SCCHN|Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) patients diagnosed between 01July2013 and 30June2014, alive or deceased, at the time of data collection
3200181|NCT00888303|Placebo Comparator|B (Control)|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
2528855|NCT02705027|Active Comparator|Standard|"After randomization one half of the patients receive a Freka®-Trilumina probe, which is inserted in nasogastric route an then pushed  using a small forceps which is inserted through the endoscope into the small intestine."
2528857|NCT02705027|Experimental|Freka®-EasyIn|The other half of the patients will receive a Freka®-EasyIn probe which is directly placed in the small intestine inserted over the endoscope, after endoscopy was initially pushed - as far as possible - into the small intestine.
3200182|NCT00888316||Without Iron Overload|Patients entering study without pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
3200183|NCT00888316||With Iron-Overload|Patients entering study with pre-HSCT iron-overload. Iron overload will be defined as liver ion concentration (LIC above normal (>1.8 mg/g) on R2 magnetic resonance imaging (MRI) of the liver.
3200184|NCT00888342|Active Comparator|1 supplementary oxygen|participant receives supplementary oxygen one night, polysomnography with capnography will be compared to no treatment another night
3200185|NCT00888342|Active Comparator|2 Zopiclone|participant receives 5 mg zopiclone one night, polysomnography with capnography will be compared to no treatment another night
3200186|NCT00888342|Active Comparator|3 Alcohol|participant receives 0,5 mg alcohol /kg body weight before sleep one night, polysomnography with capnography will be compared to no intervention another night
3200187|NCT00888368|Experimental|Transpatellar Approach|
3200188|NCT00888368|Active Comparator|Suprapatellar Approach|
3200189|NCT00888394|Experimental|1|
3200190|NCT00888394|Experimental|2|
3200191|NCT00888394|Experimental|3|
2527643|NCT02712853||Control|"Age 18 months to 6 years without autism spectrum disorder (may have typical development or developmental delay without autism - as defined by negative MCHAT-R or negative ADOS-II evaluation)~Exclusion criteria include:~wards of the state active periodontal infection active upper respiratory infection"
2527721|NCT02712294|No Intervention|Control Group (GC)|The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
2527722|NCT02712294|Experimental|NMES Group (GE)|Receiving the usual care and guidance on their illness, underwent 30 minute NMES sessions twice a week for two months using an electrostimulator. Specifically, 5 cm adhesive surface electrodes in four alternate channels on the Rectus Femoris (two channels the right and two on the left) were used to deliver two-phase symmetrical currents, with a rectangular pulse wave at a frequency of 35 Hz and pulse duration of 250 μ. The time of ascent and descent was one second, contraction time was four seconds and relaxation was eight seconds.
3200192|NCT00888394|Experimental|4|
3200193|NCT00888407|Experimental|HBV Screening|Small group educational session with HBV screening resources provided.
3200194|NCT00888407|Sham Comparator|Nutrition|Small group educational discussion, diet & nutrition resources provided.
3200195|NCT00888420||Medical Management|Patient satisfaction under current operational conditions
3200196|NCT00888420||Interventional Management|Patient satisfaction under the PSDA (Plan, do, study, act) performance improvement measures
3200197|NCT00888446|Experimental|Group A|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0 + 6"
3200198|NCT00888446|Experimental|Group B|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^10 DRP~Month 0+12"
3200199|NCT00888446|Experimental|Group C|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+6"
2527975|NCT02710656|Experimental|Drug Coated Balloon (DCB) - Legflow®|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting Legflow® balloon.
2527976|NCT02710656|Active Comparator|Standard PTA - POBA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug eluting balloon (POBA, plain old balloon angioplasty).
2528112|NCT02709902|Experimental|Adapalene/BP gel, 0.3%/2.5%|Topical, once daily, for 84 days.
2528116|NCT02709902|Active Comparator|EPIDUO® FORTE|Topical, once daily, for 84 days.
2528118|NCT02709902|Placebo Comparator|Placebo|Topical, once daily, for 84 days.
2528217|NCT02709499|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
2528220|NCT02709499|Experimental|6J LLLT|The Laser radiation will be made with 4J by spot
3200200|NCT00888446|Experimental|Group D|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^11 DRP~Month 0+12"
3200201|NCT00888446|Experimental|Group E|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+6"
2528339|NCT02708472|Experimental|Open-label|"Subjects who qualify will receive daily active synchronized Transcranial Magnetic Stimulation (sTMS) treatments. Treatment will be initiated on Day 1 of the study. Subjects will come to the clinic for 5 daily treatment sessions for a total of 4 treatment weeks (20 treatment sessions). Treatment will be discontinued at the end of Week 4. Subjects will be clinically evaluated for safety and efficacy at the end of each of the four weekly treatment courses.~At the end of Week 4, subjects who have not met the endpoint of 50% reduction in Hamilton Anxiety Rating Scale (HAM-A) score will be eligible to be considered for 2 additional weeks of daily treatment in an extended phase (for a total of 30 treatment sessions)."
2528439|NCT02708004|Experimental|ACT-132577|3 different dose levels
2528441|NCT02708004|Placebo Comparator|Placebo|Matching active drug
2528473|NCT02707445|Experimental|GENIUS|All comer patients who had undergone percutaneous coronary intervention with administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months
2528548|NCT02707250|Placebo Comparator|Placebo|Oblique subcostal tap block with normal sterile saline ,20 ml, bilateral, single shot,24h
2528551|NCT02707250|Active Comparator|Bupivacaine|Oblique subcostal tap block with bupivacaine 0,25% ,20 ml, bilateral, single shot,24h
2528557|NCT02707250|Active Comparator|Pethidine|Oblique subcostal tap block with pethidine 1% ,10 ml,bilateral,single shot,24h
2528561|NCT02707250|Active Comparator|Pethidine Local Infiltration (L.I.)|Local infiltration of pethidine 1% at trocar insertion sites, 5ml /site, 24h compared with Tap Block with pethidine 1%
2528590|NCT02706600|Other|Written Self Management|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
2528759|NCT02705755|Experimental|TD-9855 Part B|Subjects will receive a single dose of TD-9855 or placebo.
3200202|NCT00888446|Experimental|Group F|"Number of Vaccine Recipients: 10~Dosage level 3 x 10^12 DRP~Month 0+12"
3200203|NCT00888446|Experimental|Group G|"Number of Vaccine Recipients: 10~Preselected for baseline AAV neutralization titers of <1/8~Dosage level 3 x 10^12 DRP~Month 0+6"
3200204|NCT00888446|Placebo Comparator|Placebo|3 volunteers will receive placebo matched to each experimental group.
3200205|NCT00888472|Experimental|1|
3200206|NCT00888485|Experimental|Behavioral intervention|Group exposed to behavioral intervention program
3200207|NCT00888485|Active Comparator|Standard treatment|
3200208|NCT00888498|Placebo Comparator|Hands-On Control|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the experimental groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
2527724|NCT02712190|Experimental|Low - High frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 250/min and respiratory rate 500/min
2527728|NCT02712190|Experimental|High - Low frequence sequence|High-Frequency non-invasive ventilation (HF-NIV) with 2 different settings, sequence of respiratory rate 500/min and respiratory rate 250/min
2527768|NCT02711969|Experimental|Apatinib mesylate|
2527855|NCT02711631|No Intervention|Control: Standard therapy|Participants in this arm of the study will receive standard therapy.
2527858|NCT02711631|Experimental|MedBIKE|Participants in this arm will be using the new MedBIKE system as their method of rehabilitation.
2527909|NCT02711163|Experimental|Extensively hydrolyzed formula|Feeding extensively hydrolyzed formula
2527912|NCT02711163|Placebo Comparator|Amino acid formula|Feeding amino acid formula
2527931|NCT02710877|Experimental|Programmed Intermittent bolus (PIEB)|Intervention: epidural analgesia through administration of a mixture of levobupivacaine 0,0625% and sufentanil 4 mcg. Intermittent bolus of 10 ml mixture every 75 minutes. Patient controlled bolus of 5 ml same mixture, lock-out 15 minutes.
2527932|NCT02710877|Active Comparator|Manuale epidural bolus (TOP-UP)|Intervention: manual epidural bolus of 15 ml levobupivacaine 0,0625% and sufentanil 5 mcg on maternal request.
3200209|NCT00888498|Experimental|Fast Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
3200210|NCT00888498|Experimental|Slow Stretching|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
2528135|NCT02709720|Experimental|1|2 cycles of metronomic Vinorelbine 50 mg + cisplatin, followed by 2 cycles of Vinorelbine 30 mg + cisplatin concomitant with radiotherapy
2528183|NCT02709213||Patients with CT-diagnosed acute colitis|Patients with symptomatic colitis (fever and/or pain and/or diarrhea) proven by computed tomography
3200211|NCT00888524|Experimental|General Practice (GP) in Physio plus Deep water running|A supplementation of Deep Water running exercises of 20 minutes in high intensity around aerobic thresholds estimated in individual land and water test
3200212|NCT00888524|Experimental|General Practice in Physio|A procedure of evidence-based physiotherapy is usual care in pragmatic trial
3200213|NCT00888537|Experimental|Decision Aid|Patients in this arm will discuss medications to help the heart heal after a heart attack with the clinician and the help of the acute myocardial infarction (AMI) Choice Decision Aid.
3200214|NCT00888537|Active Comparator|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
3200215|NCT00888550|Experimental|1. Splinting|
3200216|NCT00888550|Active Comparator|2. No Splinting|
2528449|NCT02707705|Experimental|: Auricular Acupuncture (needle patch) group A|Needle patch: Patients receiving the auricular acupuncture protocol with needles inserted on adhesive tape.
2528454|NCT02707705|Placebo Comparator|Needle-free patch: group P.|Patients who received the auricular acupuncture protocol with adhesive tape without needles.
2528457|NCT02707705|No Intervention|No intervention: group C|Patients without any device or intervention.
2528496|NCT02707354|Experimental|Probe based confocal laser endomicroscopy (Cellvizio)|intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console.
2528540|NCT02707159|Experimental|Nab paclitaxel / gemcitabine|Patients will receive 125 mg per m2 nab-paclitaxel and 1000 mg per m2 on days 1, 8 and 15 followed by one week of rest before new treatment cycle.
2528581|NCT02706782|Experimental|TAI-meso-CART|A single dose of meso-CART cells will be administered by vascular interventional mediated as one dose infusions. The dose is 1-10x106/kg meso-CAR positive T cells. The infusion will be scheduled to occur 2 days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures. Patients will undergo cannula--DSA radiography--CAR-T cells perfusion. The cells perfusion process would lasts 15min to 2 h, and the specific time depends on patent's tumor-burdened state.
3200217|NCT00888576||1|Non-intervention
2528876|NCT02704676||control patients|normal pregnant women, 3rd trimester
2528883|NCT02704676||mild pre-eclampsia|patients with albuminuria +1 and blood pressure >140/90 and <160/110
2528894|NCT02704676||sever pre-eclampsia|patients diagnosed as sever pre-eclampsia according to criteria done by ACOG
3200218|NCT00888602|Experimental|MM1 - Meal|3.4g psyllium served with a meal
3200219|NCT00888602|Experimental|MM2 - Meal|6.8 g psyllium served with a meal
3200220|NCT00888602|Experimental|MM2 (no Meal)|6.8 g psyllium consumed with no meal
3200221|NCT00888602|Sham Comparator|Meal Only|meal only
3200222|NCT00888641|No Intervention|Normothermia|After arterial clamping, no ice slush will be used
3200223|NCT00888641|Experimental|Hypothermia|After arterial clamping, the kidney will be surrounded in ice slush for 10 minutes
3200224|NCT00888667||ICD patient with frequent PVCs|
3200225|NCT00888680|Experimental|BGC20-1531 200 mg|
3200226|NCT00888680|Experimental|BGC20-1531 400mg|
3200227|NCT00888680|Placebo Comparator|Lactose|
3200228|NCT00888693|Experimental|1|ABT-288 vs placebo capsules administered orally once daily for 14 days
3200229|NCT00888693|Experimental|2|ABT-288 vs placebo capsules administered orally once daily for 14 days
3200230|NCT00888693|Experimental|3|ABT-288 vs placebo capsules administered orally once daily for 14 days
3200231|NCT00888693|Experimental|4|ABT288 vs placebo administered orally once daily for 14 days
3200232|NCT00888693|Experimental|5|ABT-288 vs placebo administered orally once daily for 14 days
3200233|NCT00888693|Experimental|6|ABT-288 vs placebo administered orally once daily for 14 days
3200234|NCT00888693|Experimental|7|ABT-288 vs placebo administered orally once daily for 14 days
2527739|NCT02712086|Experimental|care of with usual dietary protein supplementation|Intervention group: Usual dietary management with protein supplementation (30g) in addition to the usual inputs
2527771|NCT02711982|Active Comparator|Optic nerve decompression|Optic canal and optic nerve sheath decompression within 5 days from trauma occur.
2527776|NCT02711982|Active Comparator|methylprednisolone|a maximum daily dose of 1 g of methylprednisolone
2527826|NCT02711540||Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
2527828|NCT02711540||No Pre-TAVI Balloon Aortic Valvuloplasty|This is the cohort of patients in the study who did not receive Balloon Aortic Valvuloplasty (BAV) prior to TAVI implantation
3200235|NCT00888693|Experimental|8|ABT-288 vs placebo administered orally once daily for 14 days
3200236|NCT00888693|Experimental|9|ABT-288 vs placebo administered orally once daily for 14 days
3200237|NCT00888706|Active Comparator|1|
3200238|NCT00888706|Active Comparator|2|
3200239|NCT00888706|Active Comparator|3|
3200240|NCT00888706|Experimental|4|
3200241|NCT00888719|Experimental|CWP-0403 50mg|
2528229|NCT02709174||pregnant with pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
2528230|NCT02709174||pregnant without pulmonary embolism|Pregnant women who underwent diagnostic imaging to evaluate for suspected PE at our institution
2528248|NCT02708940|Active Comparator|Usual care|Control arm - these patients will get usual care as part of the PHP and IOP programs at UCLA. They will not receive mobile support messages.
2528252|NCT02708940|Active Comparator|Participatory technology development|Intervention - Patients will have access to a website that allows them to co-create mobile support messages with their therapist to support their care as part of the PHP and IOP programs at UCLA.
2528320|NCT02708719|Other|Pulmonary rehabilitation|multimodal pulmonary Rehabilitation program (3 weeks Duration)
2528369|NCT02708407|Experimental|Peritoneal Dialysis Group|These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
2528371|NCT02708407|No Intervention|Control Group|These participants will continue to receive standard HF care.
2528436|NCT02707978|Experimental|Experimental F 18 T807|
2528469|NCT02707484|Experimental|Thalidomide Group（100mg）|
2528470|NCT02707484|Experimental|Thalidomide Group（50mg）|
2528472|NCT02707484|Placebo Comparator|placebo -controlled Group|
2528563|NCT02707016|Other|High dose sevoflurane|"Inhaled sevoflurane 8% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
2528566|NCT02707016|Other|Low dose sevoflurane|"Inhaled sevoflurane 5% during induction of general anesthesia (from the start of gas administration to the insertion of a laryngeal mask).~After laryngeal mask insertion, sevoflurane will be reduced to 4%. Caudal block with L-bupivacaine 0.25% will be performed in all children.~After caudal block, sevoflurane will be reduced to 0.75 MAC according to age of the child and maintained until the end of surgery After surgery, PAED and pain scales will be administered every 15 minutes up to 2 hours after surgery."
2528666|NCT02706379|Experimental|Local cerebral oxygen saturation|use NIRS technical to detect local cerebral oxygen saturation of both sides of brain
2528719|NCT02706106|Experimental|Knee brace with a hole|Patients will be prepared to receive the device of knee brace with a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
2528720|NCT02706106|Placebo Comparator|Knee brace without a hole|Patients will be prepared to receive the device of knee brace without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
3200242|NCT00888719|Experimental|CWP-0403 100mg|
3200243|NCT00888719|Placebo Comparator|placebo|
2528851|NCT02705261|Experimental|Cognitive-behavior therapy|Cognitive-behavior therapy to teach parents the skills to help their children. Participants will have access to the program as often as they wish and have the post assessment at week 12.
2528874|NCT02704741|Experimental|all subjects|"Eligible subjects will undergo 3 treatments in 4±1 weeks interval on the Vagina (External/Vulva and Internal/Vagina) with the CO2RE device according to study protocol.~Subject will return for to 5 follow-up (FU) visits: 1 week ± 2 days post first treatment visit and 1, 3, 6 and 12 months after last (third) treatment (± 2 weeks).~Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit at the clinic."
3200244|NCT00888732|Experimental|Insulin therapy|Insulin Aspart, Biphasic Insulin Aspart 70 and 50 & Fast-acting Human Insulin
3200245|NCT00888745|Experimental|1|
3200246|NCT00888745|Placebo Comparator|2|
3200247|NCT00888758|Experimental|1|
3200248|NCT00888758|Active Comparator|2|
3200249|NCT00888771||1|
3200250|NCT00888771||2|
3200251|NCT00888771||3|
3200252|NCT00888771||4|
3200253|NCT00888784|Active Comparator|1. Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in the gastric varix
2527743|NCT02712242|Active Comparator|Butyl cyanoacrylate|Butyl cyanoacrylate was directly applied on the palatal wound after harvesting the tissue graft
2527745|NCT02712242|Placebo Comparator|Wet Gauze|Wet Gauze was placed for 1 minute on the palatal wound after harvesting the tissue graft
2527816|NCT02711696|Active Comparator|A, GCED cohort|GCED, Gluten Contamination Elimination Diet
2527818|NCT02711696|No Intervention|B, time cohort|Cohort B consisted of patients on long term follow-up that accepted a repeated biopsies 60 or more months later the first control biopsy.
2527832|NCT02711436|Active Comparator|Computed Tomography Scan|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with Computed Tomography scan.
2527838|NCT02711436|Active Comparator|Fast Magnetic Resonance Imaging|To determine the presence of periosteal or orbital abscess, intracranial abscess and dural venous sinus thrombosis that are imaged properly with T1/T2-weighted MRI.
2527901|NCT02711267|Experimental|Phase 1: Optimization Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes (OFM Probe) will be implanted per site resulting in 12 dOFM probes per subject (operated by OFM pump). On each the arm and the leg the proximal and distal site of the 3 adjacent sites will be treated by 5% Zovirax® cream. The central site on arm and leg will be left untreated in order to test a potential lateral carry-over of acyclovir from one application site to the other. Blood samples will be taken to test for uptake into the blood stream and redistribution to other application sites.
2527906|NCT02711267|Experimental|Phase 2: Formulation Study|6 subjects will be included in this study, each with 3 application sites on the arm and 3 on the leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. Different topical 5% acyclovir formulations currently available on the market will be tested. One application site on the arm and one on the leg will be used for U.S. Zovirax® cream 5% application. The remaining two application sites on the arm and the remaining 2 on the leg will be used to randomly administer two of the remaining formulations (5% Aciclostad cream, 5% Aciclovir cream 1A Pharma, 5% Zovirax® cream (Austria), 5% Zovirax Cold Sore Cream) according to an application pattern.
2527911|NCT02711267|Experimental|Phase 3: Pilot BE study|4 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug product (R) and one test drug product (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied, and to test for non-BE between application sites with R and T applied.
2527915|NCT02711267|Experimental|Phase 4: Main BE Study|20 subjects will be included in the pilot BE study with 3 application sites on each leg. 2 dOFM probes will be implanted per site resulting in 12 dOFM probes per subject. One reference drug (R) and one test drug (T) will be applied on the application sites in order to test for BE between duplicate sites with R applied and to test for non-BE between application sites with R and T applied.
2527998|NCT02710461|Experimental|Subjects with abdominal obesity|Intervention with grape pomace and pomegranate pomace
2528029|NCT02710266|Placebo Comparator|Placebo group|hepatectomy without Gabexate Mesilate
2528032|NCT02710266|Experimental|Preoperative Gabexate Mesilate group|Gabexate Mesilate administered from the preoperative day
2528035|NCT02710266|Experimental|Intraoperative Gabexate Mesilate group|Gabexate Mesilate administered from the operative day
2528096|NCT02710019|Experimental|Psychoeducational video games|Participants in this group will play the Back to Reality Series video games: (1) Harry's Journey which delivers experiential knowledge about psychosis and marijuana use; (2) Harry's Journal which challenges their understanding of 12 psychiatric symptoms associated with psychosis and (3) the PathwaysToCare Map which uses colourful 3D images and voice-overs to depict actual mental health and addictions services for youth available in Hamilton. These in
2528099|NCT02710019|Other|Control video game|The control video game is a spelling/memory quiz involving with themes from pop culture. The control game will not provide any education about mental health and addictions issues It should be noted that all participants will play both sets of games during their initial and only visit. Participants are randomized to determine which game they will play first during this visit. This is not an RCT or a crossover design. There is no follow up or clinical assessments.
2528147|NCT02709642|No Intervention|Control|Control Participants will complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight.
2528151|NCT02709642|Experimental|Deposit Contract|The deposit contract group will also complete weekly weigh-ins and receive emails about how their current weight compares to their baseline weight. In addition, the deposit contract group will be asked to make a deposit of at least $100 each 10-week period over the course of one year (50 weeks). Each week, they will recoup 1/10 of their 10-week deposit if they are within two pounds of their baseline weight or lower. If they are more than two pounds above their baseline weight, they will forfeit 1/10 of their 10-week deposit. The money they forfeited for that week will go into a collective pool to be divided up at the end of each 10-week period by all deposit contract participants who successfully maintained their weight loss at the end of the 10-week period.
2528203|NCT02709395|Experimental|Navina Smart|Navina Smart will be used, during 4 weeks, for transanal irrigation (TAI).
3200254|NCT00888784|Placebo Comparator|2. Beta-blocker|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
3200255|NCT00888797|Active Comparator|1|Perioperative Propranolol and Etodolac
2528302|NCT02708550|Experimental|Participatory Organizational Intervention|Participatory intervention (workshops) with workers, consultants and leaders. The workshops will find solutions for increased use of assistive devices
2528314|NCT02708550|No Intervention|Control|This group will go through the same baseline and follow-up tests as the intervention group, but will not receive any intervention.
3200256|NCT00888797|Placebo Comparator|2|Placebo
2527744|NCT02712164|Active Comparator|Control: Tegaderm|In the control group, the donor sites will be dressed with an occlusive dressing only (Tegaderm). The donor site dressings will be replaced on postoperative day 5-7 and a new occlusive dressing (Tegaderm) will be applied.
3166730|NCT00528983|Experimental|Subcutaneous (SC) Azacitidine and Oral Azacitidine|Cycle 1 subjects receive SC Azacitidine for first 7 days of 28 day cycle. For Cycle 2 and beyond subjects receive Oral Azacitidine (experimental) for first 7 days of 28 day cycle.
2528030|NCT02710253|Experimental|Treatment (SBRT or EBRT)|Patients undergo either 4, 5, or 10 fractions of SBRT, or 5-15 fractions of EBRT to any site of metastatic disease daily for any time between 4 days and 3 weeks as determined by the treating radiation oncologist. Patients with at least SD after the second imaging evaluation may undergo additional SBRT in 4 fractions or EBRT in 3 fractions.
2528101|NCT02709850|Placebo Comparator|Cohorts A, D: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
2528102|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 20 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 20 milligrams (mg) subcutaneously on Day 1.
2528104|NCT02709850|Experimental|Cohorts A, D: IONIS ANGPTL3-LRx 120 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 120 mg subcutaneously on Day 1.
2528106|NCT02709850|Placebo Comparator|Cohorts B, C: Placebo|Participants received a single-dose of IONIS ANGPTL3-LRx-matching placebo subcutaneously on Day 1.
2528109|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 40 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 40 mg subcutaneously on Day 1.
2528113|NCT02709850|Experimental|Cohorts B, C: IONIS ANGPTL3-LRx 80 mg|Participants received a single-dose of IONIS ANGPTL3-LRx 80 mg subcutaneously on Day 1.
2528115|NCT02709850|Placebo Comparator|Cohorts AA-DD: Placebo|Participants received IONIS ANGPTL3-LRx-matching placebo subcutaneously once per week for 6 weeks.
2528117|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 10 mg|Participants received IONIS ANGPTL3-LRx 10 mg subcutaneously once per week for 6 weeks.
2528119|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 20 mg|Participants received IONIS ANGPTL3-LRx 20 mg subcutaneously once per week for 6 weeks.
2528121|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 40 mg|Participants received IONIS ANGPTL3-LRx 40 mg subcutaneously once per week for 6 weeks.
2528122|NCT02709850|Experimental|Cohorts AA-DD: IONIS ANGPTL3-LRx 60 mg|Participants received IONIS ANGPTL3-LRx 60 mg subcutaneously once per week for 6 weeks.
2528379|NCT02708173|Experimental|One dose Vaccine in aged 18-60 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 18-60 years old.
2528386|NCT02708173|Experimental|One dose Vaccine in aged 3-17 years old|One dose of Quadrivalent Influenza Virus Vaccine will be given in aged 3-17 years old.
2528419|NCT02707900|Experimental|Vorinostat + AGS-004|"Vorinostat (VOR) 400 mg PO - two paired doses at Step 2 (Enrollment) - Only participants demonstrating an in vivo response to the 2nd of the paired VOR doses will proceed to the AGS-004 manufacturing and treatment in Steps 3 through 7.~Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal (ID) injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses."
2528486|NCT02707536|No Intervention|No socket grafting|Extraction with normal socket healing
2528489|NCT02707536|Active Comparator|Socket grafting with platelet rich fibrin (PRF) alone|Extraction with socket grafting with platelet rich fibrin (PRF) alone.
2528494|NCT02707536|Active Comparator|Socket grafting with bone grafting alone|Extraction with socket grafting using bone graft (xenograft).
2528501|NCT02707536|Active Comparator|Socket grafting with PRF and bone grafting|Extraction with socket grafting using PRF combined with bone graft (xenograft).
2528526|NCT02707120|Experimental|PRGF-Endoret eye-drops|
2528530|NCT02707120|Active Comparator|Artificial tears eye-drops|
2528580|NCT02706795|Experimental|daxibotulinumtoxinA (DAXI) for injection|DAXI for injection
2528677|NCT02706275|Experimental|Warming Group|External warming via forced air warming
2528682|NCT02706275|No Intervention|Control Group|Standard of care body temperature management
3166731|NCT00528983|Experimental|Oral Azacitidine|Subjects receive Oral Azacitidine (experimental) QD or BID for the first 14 or 21 days of 28 day cycle.
3166732|NCT00529022|Experimental|Azacitidine + Valproic Acid + Carboplatin|Azacitidine 75 mg/m^2 subcutaneous injection or by vein daily for 5 Days. Valproic Acid 40 mg/kg by mouth daily for 7 days. Carboplatin area under the curve (AUC) 2 by vein on Days 3 and 10 over 60 Minutes.
2528773|NCT02705573|Experimental|Mannitol 20%|Mannitol 1g/ kg BW
2528775|NCT02705573|Placebo Comparator|Nacl 0.9%|NaCl 0.9% 5ml/ kg BW
2528900|NCT02704663|Experimental|Transumbilical route|Transumbilical removal of benign adnexal masses via laparoscopy.
3166733|NCT00529048||T2DM|T2DM patients (WHO-criteria)
3166734|NCT00529048||CTRL|Healthy control subjects matched individually to the cases.
3166735|NCT00529113|Experimental|Phase 1 Cohort 1|Bardoxolone methyl 150 mg/day x 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166736|NCT00529113|Experimental|Phase 1 Cohort 2|Bardoxolone methyl 300 mg /day for 21 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166737|NCT00529113|Experimental|Phase 1 Cohort 3|Bardoxolone methyl 150 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166738|NCT00529113|Experimental|Phase 1 Cohort 4|Bardoxolone methyl 200 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166739|NCT00529113|Experimental|Phase 1 Cohort 5|Bardoxolone methyl 250 mg/day for 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166740|NCT00529113|Experimental|Phase 1 Cohort 6|Bardoxolone methyl 300 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166741|NCT00529113|Experimental|Phase 1 Cohort 7|Bardoxolone methyl 350 mg/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166742|NCT00529113|Experimental|Phase 2 Cohort 1|Bardoxolone methyl maximum tolerated dose(as determined in the Phase 1 portion of the study)/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
3166743|NCT00529113|Placebo Comparator|Phase 2 Cohort 2|Placebo capsules/day x 28 days and gemcitabine (1000 mg/m2 by intravenous infusion on Days 1, 9, and 15)
2527752|NCT02712255|Experimental|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad (the patient and the partner). Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
2527753|NCT02712255|Active Comparator|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participant, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
2527833|NCT02711566|Active Comparator|Sensorimotor training|"Patients in this arm were assigned to the 'Physioassistant: Haptic training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation.~All participating centers used the exact same apparatus and experimental set-up."
2527842|NCT02711566|Experimental|Haptic training|Patients in this arm were assigned to the 'Physioassistant: Sensorimotor training' intervention. The treatments were delivered through a planar robotic manipulandum, specifically designed for motor learning studies and robot-assisted rehabilitation. All participating centers used the exact same apparatus and experimental set-up.
2527895|NCT02711293|Experimental|ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard plus enhanced nutrition counseling.
2527899|NCT02711293|Experimental|ART home delivery + no enhanced nutrition counseling|Community health workers visit participants at home (maintaining patients' prior clinic visit frequency) to deliver antiretroviral therapy (ART) and to provide standard counseling.
2527903|NCT02711293|Experimental|No ART home delivery + enhanced nutrition counseling|Community health workers visit participants at home to provide enhanced nutrition counseling. Participants will not receive ART home delivery.
2527907|NCT02711293|No Intervention|Standard of care|Participants in this arm receive facility-based ART care and no enhanced nutrition counseling. They receive community health worker visits as per the standard of care in Dar es Salaam.
2527936|NCT02710825|Experimental|Osteopathic treatment|
2527939|NCT02710825|Placebo Comparator|Simulated osteopathic treatment|
2528006|NCT02710578|Active Comparator|Alcohol|Alcohol
2528009|NCT02710578|Placebo Comparator|Placebo|Tonic water
2528050|NCT02710201|No Intervention|Control|No feedback on progress of other participants.
2528055|NCT02710201|Experimental|Descriptive Social Norm|Average physical activity of other participants in study conveyed to this group.
2528057|NCT02710201|Experimental|Descriptive-plus-Injunctive Social Norm|Average physical activity of other participants in study and message of approval or disapproval (depending on how one is faring compared to others) conveyed to this group.
2528095|NCT02710006|Experimental|SonoHysteroAVC|Three-dimensional sonohysterography is the first point for uterine cavity volume estimation, and it is going to be performed in all participants. The investigators are going to fill the uterine cavity twice by saline solution during single sonohysterography procedure, and acquise the volumetric datasets of uterus for offline analysis. The 3D dataset containing the entire uterine cavity will by analyzed using a personal computer and/or the ultrasound machine with specific softwere.
2528140|NCT02709681||SCD patients|Patients followed in 32 Italian Centers.
3166744|NCT00529139|Active Comparator|A|
3166745|NCT00529139|Active Comparator|B|
2528245|NCT02708992|Experimental|Cefixime/Azithromycin|Eight participants will receive three oral doses of 800 mg cefixime (q 8 hours) on Day 1, followed by three oral doses of 800 mg cefixime (q 8 hours)+ one oral dose of 1000 mg azithromycin (with first dose of cefixime) on day 10
2528321|NCT02708771|Experimental|Intervention|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
2528323|NCT02708771|Placebo Comparator|Control|Capsules of similar appearance and flavor without active drug
2528442|NCT02707666|Experimental|Pembrolizumab+Surgery+Chemotherapy|Neoadjuvant pembrolizumab, followed by surgery, followed by adjuvant pemetrexed and cisplatin
2528474|NCT02707406|Experimental|NEOX®CORD 1K|Intervention Other: hct/p human cell or tissue product: NEOX®CORD 1K Intervention other: human tissue application of of NEOX®CORD 1K on subject wound
2528476|NCT02707406|Active Comparator|Standard of Care|Intervention Other: standard of care alone Other intervention of Standard dressing with a non-adherent wound contact layer, a classic foam pad or gauze for moderately draining wounds, a secondary bandage, and institution of an investigator-approved off-loading device
3166746|NCT00529165|Experimental|A|with injection-meal-interval,cross over after 3 month, than without injection-meal-interval for 3 month
3166747|NCT00529165|Experimental|B|without injection-meal-interval,cross over after 3 month, than with injection-meal-interval for 3 month
3166748|NCT00529230||Chronic opioid therapy + Gonadal function|Males on chronic opioid therapy for cancer-related pain syndromes
2528592|NCT02706808|Experimental|resistance starch for CKD|- Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
2528600|NCT02706808|Experimental|cross-over period|intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
2528675|NCT02706405|Experimental|Group I (JCAR014, durvalumab)|Patients receive JCAR014 IV over 20-30 minutes on day 0 and durvalumab IV over 60 minutes on day 21 (may occur as early as day 7) and then every 4 weeks for up to 10 doses in the absence of disease progression or unacceptable toxicity.
3166749|NCT00529256|No Intervention|2|No intervention
3166750|NCT00529295|Experimental|1|Titrated oral misoprostol
3166751|NCT00529295|Active Comparator|2|Vaginal misoprostol
3166752|NCT00529334|Experimental|1|CyberKnife Partial Breast Irradiation (PBI)
3166753|NCT00529360|Experimental|Part A|Part A will be the dose escalation phase to determine the MTD and/or safe/tolerated dose of clofarabine.
2527780|NCT02711852|Experimental|Drug: Duvelisib (IPI-145)|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg.
3200257|NCT00888836|Active Comparator|GBP|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo gastric bypass
3200258|NCT00888836|Active Comparator|BPD 2|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 years undergo bilio-pancreatic diversion
3200259|NCT00888836|Active Comparator|Med Ter3|Type 2 diabetic subjects with BMI ≥ 35, poor glycemic control (HbA1c ≥ 7.0%) and diabetes duration ≥ 5 yearsundergo medical therapy
3200260|NCT00888862|Experimental|A|Use of desvenlafaxine succinate, flexible dose (50-100mg/day)
2528168|NCT02709564|Placebo Comparator|Group A|400 mg placebo
2528171|NCT02709564|Active Comparator|Group B|400 microgram misoprostol
2528181|NCT02709278|Other|Group 1A: low dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^3 cfu by the aerosol inhaled route, followed by bronchoscopy.
2528184|NCT02709278|Other|Group 1B: medium dose aerosol BCG SSI|3 volunteers receiving BCG SSI at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
2528191|NCT02709278|Experimental|Group 1C: standard dose aerosol BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
2528196|NCT02709278|Experimental|Group 1D: standard dose intradermal BCG SSI|12 volunteers receiving BCG SSI at a dose of 1 x 10^5 cfu by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
2528198|NCT02709278|Other|Group 2A: lower than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^4 cfu by the aerosol inhaled route, followed by bronchoscopy.
2528206|NCT02709278|Other|Group 2B: close to the standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^5 cfu by the aerosol route, followed by bronchoscopy.
2528211|NCT02709278|Other|Group 2C: higher than standard dose aerosol BCG Bulgaria|3 volunteers receiving BCG Bulgaria (InterVax) at a dose of 1 x 10^6 cfu by the aerosol inhaled route, followed by bronchoscopy.
2528214|NCT02709278|Experimental|Group 2D: close to or higher than standard aerosol BCG|9 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the aerosol inhaled route and intradermal saline placebo, followed by bronchoscopy.
2528216|NCT02709278|Experimental|Group 2E: close to or higher than standard intradermal BCG|12 volunteers receiving BCG Bulgaria (InterVax) at the optimal dose identified from preliminary results obtained from Groups 2B and 2C by the intradermal route and aerosol inhaled saline placebo, followed by bronchoscopy and punch biopsy at the intradermal injection site.
2528257|NCT02708927|Experimental|patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
2528262|NCT02708927|Experimental|Control|healthy subject
2528327|NCT02708680|Active Comparator|Entinostat plus Atezolizumab|Patients in this arm will receive entinostat at the RP2D in combination with atezolizumab
2528331|NCT02708680|Placebo Comparator|Placebo plus Atezolizumab|Patients in this arm will receive placebo in combination with atezolizumab
2528372|NCT02708147|Sham Comparator|Conventional treatment|"Conventional treatment means that there will be only contact with physician/paediatrician and maybe drugs prescription.~Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after."
2528383|NCT02708147|Experimental|Physiotheraphy + Conventional treatment|Apart Conventional treatment a Physiotherapy protocol (techniques and education) will be performed on 5 sessions and evaluations will be made after each session as well as on baseline and on the 3th, 5th and 21st days and an interview 30 days after.
2528414|NCT02707887|Placebo Comparator|Treatment as Usual|Patients are offered substance use group therapy including relapse prevention. They are also provided medical consultation on an ongoing basis as needed.
2528415|NCT02707887|Active Comparator|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT) involves the discussion of the treatment rationale, identification of values and goals in various life areas and activities in line with chosen life areas, and training for patients to identify their cycle of negative mood and behavior using forms to track their daily goals.
2528416|NCT02707887|Active Comparator|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
2528467|NCT02707419|Experimental|Experimental group|Video of the exercises and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
2528468|NCT02707419|Active Comparator|Control group|Video of nature scenes and conventional physiotherapy. 45 minutes twice a day, 5 days a week for 2 weeks.
2528543|NCT02707276|Experimental|Active LFMS|Active Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
2528549|NCT02707276|Sham Comparator|Sham LFMS|Sham Low Field Magnetic Stimulation three 20 minute treatments, once per day for five consecutive days
2528901|NCT02704663|Active Comparator|Lateral abdominal route|Lateral transabdominal removal of benign adnexal masses via laparoscopy.
3200261|NCT00888875|Experimental|1|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
3200262|NCT00888875|Active Comparator|2|Computer randomized insertion of the i-gel. Intubation fiberoptically of a tracheal tube
3200263|NCT00888888||Cohort: Patients with colonic resections|Colonic resections in patients submitted to appendicectomy for suspected acute appendicitis
3200264|NCT00888901|Experimental|1|Patients on eltrombopag
3200265|NCT00888901|Active Comparator|2|Patients on corticosteroids
3200266|NCT00888901|No Intervention|3|Untreated patients
3200267|NCT00888914|Active Comparator|Dose A|RT001 Dose A; Active Comparator
3200268|NCT00888914|Active Comparator|Dose B|RT001 Dose B; Active Comparator
3200269|NCT00888914|Active Comparator|Dose C|RT001 Dose C; Active Comparator
3200270|NCT00888914|Active Comparator|Dose D|RT001 Dose D; Active Comparator
2527803|NCT02711722|Active Comparator|NAVA40%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 40% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA40% for 30min.
2527806|NCT02711722|Active Comparator|NAVA60%|Patients are ventilated in Neurally Adjusted Ventilatory Assist (NAVA) and the assist is set in order to target 60% muscle unloading based on the Neuro-Ventilatory Efficiency (NVE) measurement. Patients are ventilated in NAVA60% for 30min.
2527808|NCT02711722|Active Comparator|PScli2|Patients return to PS ventilation, according to the Clinical settings as in PScli1 for 30min.
2527831|NCT02711423|Experimental|Part I (Dose Escalation): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1.
2527839|NCT02711423|Placebo Comparator|Part I (Dose Escalation): Placebo|Participants will receive a single SC dose of matching placebo on Day 1.
2527843|NCT02711423|Experimental|Part II (PK Extension): Gantenerumab|Participants will receive a single SC dose of gantenerumab on Day 1. The dose range will be determined by safety and tolerability data collected from Part I.
2527893|NCT02711228|Experimental|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
2527958|NCT02710929||ADHD group|Subjects with clinical diagnosis of ADHD according to the DSM-IV criteria
2527959|NCT02710929||TD group|Typically development controls without lifetime diagnosis with ADHD
2527995|NCT02710539|Active Comparator|Free combination|Perindopril 10 mg/daily, indapamide 2,5 mg/daily, and amlodipine 10 mg/daily will be given according to a free combination strategy
2527996|NCT02710539|Active Comparator|Tripliam|fixed combination of perindopril 10 mg/daily, indapamide 2,5 mg/daily, amlodipine 10 mg/daily
2528051|NCT02710227||liver cirrhosis|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
2528053|NCT02710227||control|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
2528097|NCT02709967|Active Comparator|Material support|Writing materials
2528098|NCT02709967|Experimental|Economic support|Writing materials and economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9).
2528100|NCT02709967|Experimental|Combined intervention|Writing materials, economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9) and community dialogue (youth club meetings, community and parent meetings)
2528156|NCT02709616|Experimental|Personalized cellular vaccine|DC based cellular vaccine
3200271|NCT00888914|Placebo Comparator|Dose E|RT001 Dose E; Vehicle Comparator
3200272|NCT00888953|Experimental|Intervention|Residents living in nursing homes allocated to intervention group. Assessment of risk factors. Implementation of a multifactorial tailored program to prevent falls.
2528258|NCT02708888|Experimental|Trunk training|Exercises: Core stability training
2528266|NCT02708888|Sham Comparator|Cognitive exercises|Exercises: The RevArte Visual Search Test (RVST) of Lafosse et al (2013) and the Visuospatial Neglect Test Battery (VNTB) of Vaes et al. (2015)
2528309|NCT02708693|Experimental|experimental: steroid injection and splinting|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine) and a customized volar thermoplastic wrist splint
2528316|NCT02708693|Active Comparator|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort) mixed with 1 ml of 2% lidocaine hydrochloride (Xylocaine)
2528360|NCT02708225|Experimental|interventional - with a medical clown|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test with a medical clown present
2528361|NCT02708225|No Intervention|non interventional|will perform pulmonary function test without the presence of a clown and an hour later will re-do the test without a medical clown present
2528422|NCT02708030|Active Comparator|Ketogenic Diet|Ketogenic diet (KD) will be administered by the non-fasting protocol. The child will be admitted to the hospital, and KD will be started in 1:1 ratio. The ratio will increased every 48hours to a maximum of 4:1 or ketosis (urinary ketones 40-80mg/dL) is attained. The child will thereafter be discharged and followed up on Out patient basis.
2528426|NCT02708030|Experimental|Modified Atkins Diet|Modified Atkins Diet (MAD) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
2528427|NCT02708030|Experimental|Low Glycemic Index Therapy|Low Glycemic Index Therapy (LGIT) will be administered on out patient basis. Parents of children will be advised to monitor for seizure frequency and ketosis at home.
2528493|NCT02707549|Active Comparator|Normal Saline Group|the patients included in this group will receive normal saline solution (0.9% sodium chloride) during surgery and in the first 24 hours after ICU admission.
2528499|NCT02707549|Experimental|Balanced Crystalloid Solution Group|the patients included in this group will receive balanced crystalloid solution during surgery and in the first 24 hours after ICU admission.
3200273|NCT00888953|Other|Control|Residents living in nursing homes allocated to control group. Assessment of risk factors. Receive the usual attention.
3200274|NCT00888966||Out of hospital cardiac arrest|Out of hospital cardiac patients successfully resuscitated and admitted to ICU
2528760|NCT02705755|Experimental|TD-9855 Part C|Subjects will receive once daily doses of TD-9855 for up to 5 months as part of an optional outpatient open-label extension arm.
3200275|NCT00888992|No Intervention|Group A|Receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls.
3200276|NCT00888992|Experimental|Group B|
3200277|NCT00888992|Experimental|Group C|
3200278|NCT00889018|Active Comparator|group 1|chemotherapy using carboplatin 560mg/m2
3200279|NCT00889018|Experimental|group 2|chemotherapy using 750mg/m2 carboplatin
3200280|NCT00889031||No Treatment|
3200281|NCT00889044|Experimental|clopidogrel by chewing|
3200282|NCT00889044|Placebo Comparator|Placebo|
3200283|NCT00889057|Experimental|sorafenib|
2527891|NCT02711098|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
2527896|NCT02711098|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
2527943|NCT02710721|Experimental|Fasting|60h-modified fasting (36h before and 24h after chemotherapy)
2527947|NCT02710721|Active Comparator|Control|mediterranean diet
2528129|NCT02709876|Experimental|Stem Cells|Intravitreal Injection of bone marrow derived CD34+, CD133+, CD271+ stem cells.
2528241|NCT02709525|Experimental|hyaluronic acid|Immediately after the extractions, one socket was randomly filled with 1% hyaluronic acid gel.
2528243|NCT02709525|Placebo Comparator|Blood clot|Immediately after the extractions, the other side socket was naturally filled with blood clot.
2528308|NCT02708563|Experimental|Immediate intubation|These infants will have immediate endotracheal suctioning after delivery. They will then have resuscitation per Neonatal Resuscitation Program guidelines.
2528315|NCT02708563|Experimental|Immediate resuscitation|These infants will have immediate resuscitation per the Neonatal Resuscitation Program guidelines without endotracheal suctioning.
2528378|NCT02708381||Senior Adult Cancer Patients|Cancer patient population 70 years and older, eligible for screening.
2528595|NCT02706561|Experimental|Standard care plus the ACT intervention (ACT-ED)|SC + ACT-ED-Group A uses Acceptance and Commitment Therapy (ACT). In this group, men focus on: long-term goals of rehabilitation; acceptance of the frustration related to ED; identifying and overcoming barriers; and committing to an erectile rehabilitation program. All participants will be asked to complete a set of questionnaires (baseline). The participants can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. You will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes)
2528604|NCT02706561|Experimental|SC plus nurse Enhanced Monitoring and Education (EME)|SC + EME-Group B uses enhanced monitoring and education. This group focuses on answering questions about the rehabilitation program, manage technical issues related to injections, and the dose titration of injection medication. Participants in this group will also receive education on the side effects and impact of prostate cancer surgery, and strategies for restarting sexual activity. All participants will be asked to complete a set of questionnaires (baseline). You can complete it using your personal computer, one of MSKCC computers, in-person or over the phone. The questionnaires will take about 45-60 minutes to complete. The participant will also complete the same set of questionnaires at 6, 12, 18, and 24 months following study entry. In both groups, the participant will receive three in-person sessions or phone (30-45 minutes), six brief telephone sessions (5-10 minutes), and six monthly phone calls (5-10 minutes).
3166754|NCT00529360|Experimental|Part B|Part B will accrue patients to further define the event free, disease free and overall survival at the MTD or safe/tolerated dose of clofarabine.
3166755|NCT00529412|No Intervention|control|no Seprafilm
3166756|NCT00529412|Active Comparator|Seprafilm|
3166757|NCT00529425|Active Comparator|Ropivacaine|
3166758|NCT00529425|Placebo Comparator|Saline|
3166759|NCT00529438|Experimental|Bardoxolone methyl capsules|"Bardoxolone methyl to be taken orally for 21 consecutive days, once a day, in the morning prior to food intake.~Patients to continue to receive treatment for the first 21 days of each 28-day cycle until they experience intolerable toxicity, show evidence of disease progression, or receive a maximum of 18 cycles (18 months)."
3166760|NCT00529477|Active Comparator|1|The Wright Nebulizer will be used to perform the methacholine challenge in arm 1.
3166761|NCT00529477|Active Comparator|2|The Pari LC nebulizer will be used to perform the methacholine challenge in arm 2.
3166762|NCT00529477|Active Comparator|3|The Pari Sinustar nebulizer will be used to perform the methacholine challenge in arm 3.
3166763|NCT00529490|Experimental|HL|Hypertonic lactate group
3166764|NCT00529490|Active Comparator|RL|Ringer's lactate
3166765|NCT00529503|Experimental|1|SGN-40, rituximab, etoposide, carboplatin, ifosfamide
3166766|NCT00529503|Placebo Comparator|2|placebo, rituximab, etoposide, carboplatin, ifosfamide
3166767|NCT00529594|Placebo Comparator|Control Group|Patients who received placebo
3166768|NCT00529594|Active Comparator|Treatment Group|Patients who received etoricoxib 120 mg
3166769|NCT00529607||1|- patients with acute ST elevation myocardial infarction and consecutive percutaneous coronary intervention of the infarct-related artery
3166770|NCT00529607||2|- 30 patients with stable CAD (control group 1)
3166771|NCT00529607||3|- 30 healthy volunteers regarding cardiovascular diseases (control group 2)
3166772|NCT00529620|Active Comparator|1|sulfalene pyrimethamine plus amodiaquine
3166773|NCT00529620|Active Comparator|2|dihydroartemisinin piperaquine
3166774|NCT00529620|Active Comparator|3|sulfadoxine-pyrimethamine plus piperaquine
3166775|NCT00529672|Active Comparator|1|Surgery: crossectomy plus short stripping
3166776|NCT00529672|Active Comparator|2|ultrasound guided sclerotherapy with foam (3% polidocanol)
3166777|NCT00529672|Active Comparator|3|Endovenous laser therapy (940 nm, about 70 J/cm)
3166778|NCT00529698|Other|A|Subjects were immunized subcutaneously with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), in association with Alum as adjuvant, or with Saline + Alum, as placebo.
3166779|NCT00529698|Other|B|Subjects were immunized intradermally with Tat, 3 dosage groups (7.5, 15 or 30 micrograms), or with Saline, as placebo.
3166780|NCT00529711|Experimental|Group 1|Hypertonic lactate
3166781|NCT00529711|Active Comparator|Group 2|Ringer's lactate
3166782|NCT00529737|Experimental|Group 1|Post Procedure Mammogram Projection View A -- (view same projection as used in the biopsy procedure), then View B (view orthogonal projection to the first view).
3166783|NCT00529737|Experimental|Group 2|Post Procedure Mammogram Projection View B than View A
3166784|NCT00529750|Experimental|Irbesartan Group|150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
2527922|NCT02711033|Experimental|Laparoscopic-assisted total gastrectomy|Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.
2527925|NCT02711033|Active Comparator|Open total gastrectomy|Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.
2527966|NCT02710747|Experimental|Genetic Group|Dose (mg/week) = [5.6044 - 0.02614 × Age [in years] + 0.0087 × Height [cm] + 0.0128 × Weight [kg] - 0.8677 × VKORC1 A/G -1.6974 × VKORC1 A/A - 0.5211 × CYP2C9 *1/*2 - 0.9357 × CYP2C9 *1/*3 - 1.0616 × CYP2C9 *2/*2 - 1.9206 × CYP2C9*2/*3 - 2.3312 × CYP2C9 *3/*3 - 0.1092 × Asian race - 0.5503 × amiodarone ]2
2527969|NCT02710747|No Intervention|Control Group|Dose for the first three days after operation will be 4.5mg/d.
3166785|NCT00529750|Active Comparator|Atenolol Group|50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
3166786|NCT00529776|Active Comparator|1|Continuous lateral rotation therapy
3166787|NCT00529776|No Intervention|2|Standard manual positioning (Supine position)
2528137|NCT02709759|Active Comparator|MI|Motivational interviewing focused on reducing alcohol use, delivered by videoconferencing.
2528141|NCT02709759|Active Comparator|BA|Brief Advice to reduce drinking delivered by videoconferencing
2528144|NCT02709759|Active Comparator|MI + ITM|Motivational intervention to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
2528146|NCT02709759|Active Comparator|BA + ITM|Brief Advice to reduce drinking, delivered by videoconferencing, plus Interactive text messaging around alcohol use
2528150|NCT02709759|Active Comparator|MI + ITM + EI|Participants in this arm receive MI delivered by videoconferencing and ITM over 9 months rather than 1
2528154|NCT02709759|Active Comparator|BA + ITM + EI|Participants in this arm receive BA delivered by videoconferencing and ITM over 9 months rather than 1
2528157|NCT02709759|Active Comparator|BA + EI|Participants in this arm receive BA delivered by videoconferencing over 9 months rather than 1
2528159|NCT02709759|Active Comparator|MI + EI|Participants in this arm receive MI delivered by videoconferencing over 9 months rather than 1
2528188|NCT02709252|Experimental|Cohort|Only one cohort is included with comparisons of two different hemodynamic parameters
2528251|NCT02709161|Experimental|real-time fMRI neurofeedback: Amygdala|Amygdala neurofeedback - attempt to upregulate the left amygdala during positive autobiographical memory recall via real time fMRI neurofeedback from the amygdala. Two sessions will be performed one week apart.
2528253|NCT02709161|Active Comparator|real-time fMRI neurofeedback: HIPS|HIPS neurofeedback - attempt to upregulate the left horizontal segment of the intraparietal sulcus (HIPS), a region not involved in emotional processing, during positive autobiographical memory recall via real time fMRI neurofeedback from the HIPS. Two sessions will be performed one week apart.
2528391|NCT02708069|Other|e-Unstuck condition|Parents in the e-Unstuck condition will be asked to complete each of the e-Unstuck modules (one per week) over the course of the nine-week intervention, in addition to reading the UOT manual.
2528393|NCT02708069|Other|In-Person condition|Parents participating in the in-person condition will be asked to attend two in-person trainings (approximately 125 and 100 minutes respectively) on the Unstuck and On Target (UOT) curriculum, in addition to reading the UOT manual.
2528438|NCT02707783||Bioresorbable vascular scaffold (BVS) implantation|Patients with un/stable angina that require coronary revascularization undergoing the BVS implantation
2528484|NCT02707393|Experimental|single arm|Fludarabine intravenous - daily dose: 40mg/sqm on day -7, -6, -5, -4; Thiotepa intravenous - daily dose: 2 x 5mg/kg on day -3; Melphalan intravenous - daily dose: 140/mg/sqm on day - 2; ATG intravenous - dose according to local standards on day -3, -2, -1; bone marrow or peripheral blood stem cells of an HLA identical sibling or matched unrelated donor on day 0; GvHD propyhlaxis with Mycophenolate Mofetil and Cyclosporine A
2528556|NCT02706990|Other|Physica KR|Patients who have received a Physica KR total knee implant.
2528562|NCT02706990|Other|Physica PS|Patients who have received a Physica PS total knee implant.
2528585|NCT02706769|Active Comparator|Paracetamol|Participants will take blinded Paracetamol (as they were taking before entering the study)
2528586|NCT02706769|Placebo Comparator|Placebo|Participants will take blinded Paracetamol
2528625|NCT02706470|Experimental|Cyclosporin A|Patients allocated to Cyclosporin A group will receive oral Cyclosporin A in a dose of 50 mg three times a day for 20-30 days in early pregnancy.
2528629|NCT02706470|Active Comparator|Dydrogesterone|Patients allocated to dydrogesterone group will receive oral dydrogesterone in a dose of 10 mg three times a day for 30 days in early pregnancy.
2528702|NCT02706197|Experimental|IA No treatment except standard-of-care (SOC) surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IA, patients will not have any cancer therapy prior to removal of the OxyChip and duration of implantation is typically less than 4 weeks but may be up to 52 weeks.
2528705|NCT02706197|Experimental|IB SOC adjuvant therapy and SOC surgery|Placement of OxyChip will be through a minimally invasive procedure (needle injection) and removal will be at the time of surgical resection. In Phase IB, patients will have standard of care neoadjuvant chemotherapy or pre-operative radiation therapy during the time that the OxyChip is within the tumor, which is typically 6 weeks but may be up to 52 weeks.
2528761|NCT02705781|Experimental|General|One arm study: smARTrack Feeding Tube System.
2528777|NCT02705469|Experimental|Dose Escalation and Dose Confirmation - ZEN003694 Single Agent|ZEN003694 will be administered orally as a single agent once daily in 28-day cycles, enrolling mCRPC patients.
3166788|NCT00529815|Experimental|1CGM and SBGM|Intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
3166789|NCT00529815|Active Comparator|2 SBGM|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
3166790|NCT00529841|Experimental|1 (Hydrocortisone sodium acetate)|Subcutaneous administration of Hydrocortisone sodium acetate via insulin pump
3166791|NCT00529854||1|Observational evaluation of current billing and documentation practices
3166792|NCT00529854||2|Use of SIC-IR Billing Module
3166793|NCT00529867|Active Comparator|A|
3166794|NCT00529867|Active Comparator|B|
2527940|NCT02710968|Experimental|11540KE and Balt Goldbal 2 balloon|"Patients meeting inclusion criteria will receive fetoscopic tracheal occlusion using the fetoscopy sheath 11540 KE and the Balt Goldbal2 detachable balloon.~Participants with an O/E LHR 25% (severe group) will have FETO completed at 27 weeks + 0 days to 29 weeks + 6 days gestation. Balloon removal is 4-5 weeks after that.~Participants with an O/E LHR 25 - <30% (less severe group) will have FETO completed at 30 weeks + 0 days to 31 weeks + 6 days gestation. Balloon removal is 3 - 4 weeks after that."
3200284|NCT00889070||1|Stage 1 (Pilot Study) All infants enrolled in the pilot stage and completing baseline screening will be evaluated as the analyzable set.
3200285|NCT00889083||Control|Non septic patients needing hepatic surgery
3200286|NCT00889083||Sepsis|Septic patients needing surgery for peritonitis
2528222|NCT02709187|Experimental|RT group|combination dose of Candesartan and Rosuvastatin and DP-R208 in order
2528223|NCT02709187|Experimental|TR group|DP-R208 and combination dose of Candesartan and Rosuvastatin in order
3200287|NCT00889096|Active Comparator|study day 1 propanolol|Oral administration of 80 mg propranolol (1 capsule containing two Obsidan® tablets: 2 x 40 mg propranolol) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
3200288|NCT00889096|Placebo Comparator|study day 1 placebo|Oral administration of placebo (1 capsule containing two placebo tablets) according to randomization list with 240 ml. Determination of blood pressure, heart rate over 4 hours and until return to the initial baseline values.
2528354|NCT02708329|Active Comparator|CTO coronary angioplasty +T-provisional stenting|Coronary angioplasty using T-provisional stenting in patients with bifurcational lesion in Chronic total occlusion segment.
2528355|NCT02708329|Experimental|CTO coronary angioplasty + Mini-crush stenting|Coronary angioplasty using Mini-crush stenting in patients with bifurcational lesion in Chronic total occlusion segment.
2528406|NCT02708056|Other|Sugammadex, Bridion|Drug were given intravenously by a anesthesiologist at the end of surgery
3200289|NCT00889109||1|Open Capsular Shift
3200290|NCT00889109||2|Arthroscopic Bankart Repair
3200291|NCT00889109||3|Healthy controls
3200292|NCT00889122|Experimental|Lifestyle Counseling|
3200293|NCT00889148|Experimental|Gabapentin|600mg of gabapentin will be given orally two hours preoperatively and 200mg for 3 times a day after surgery for three days.
2528690|NCT02706184|Experimental|Intervention|Patients receive E. coli Nissle suspension
2528694|NCT02706184|Placebo Comparator|Control|Patients receive placebo
2528727|NCT02705885|Experimental|Gingipain IgY|Participants consume lozenges containing IgY against gingipains of Porphyromonas gingivalis
2528733|NCT02705885|Placebo Comparator|Placebo IgY|Participants consume lozenges containing placebo IgY
2528791|NCT02705703|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
2528819|NCT02705287||Vitamin D dynamics-pregnant|Pregnant women recruited to measure Vitamin D dynamics during pregnancy.
2528821|NCT02705287||Vitamin D dynamics-nonpregnant|Non-pregnant women recruited to measure Vitamin D dynamics.
2528822|NCT02705287||Delivery-placental transfer|Pregnant women planning to deliver by scheduled c-section who will be dosed with vitamin D3 in late gestation (week 36-38).
2528824|NCT02705287||Delivery-Vitamin D|Pregnant women will be dosed with vitamin D3 at term when they come in for their pre-surgical appointments prior to their scheduled c-section
2528826|NCT02705287||Delivery-25(OH) Vitamin D|Pregnant women will be dosed with 25(OH)D3 when they come in for their pre-surgical appointments
2528891|NCT02704845||Ankylosing Spondylitis|
2528895|NCT02704845||Chronic non-specific low back pain|
2528950|NCT02704429|Experimental|PRN1008|Part A: Open-label PRN1008, 12 weeks; 12 week follow up; Part B: Open-label PRN1008, 24 weeks;4 weeks follow up
2528993|NCT02703870|Active Comparator|Verum tDCS|Verum group receiving complete treatment of tDCS
2529003|NCT02703870|Sham Comparator|sham tDCS|Sham group receiving sham tDCS
2529011|NCT02703870|Active Comparator|real VRT|Real Vision Restoration Training
2529044|NCT02703558|No Intervention|No dye|Participants will not receive a preoperative or intraoperative dye prior to their intraoperative concomitant cystoscopy.
2529045|NCT02703558|Active Comparator|Phenazopyridine|Participants will receive a single 200mg oral dose of phenazopyridine with a sip of water 30 minutes prior to their surgery which involves an intraoperative concomitant cystoscopy.
2529046|NCT02703558|Active Comparator|Fluorescein|Participants will receive 0.25cc of 10% intravenous sodium fluorescein administered by anesthesia during their surgery, immediately prior to their intraoperative concomitant cystoscopy.
2529181|NCT02702973||Observe the fundus characteristics|Observe the fundus characteristics after high doses of interferonα-2b therapy in patients with melanomas of the skin.
2529273|NCT02702427|Experimental|ARM 1|Patients with Adenovirus or CMV infection after HSCT and no reduction of viral disease or stable disease with 10E6 viral copies within 2 weeks of antiviral treatment will receive a single infusion of virus-specific T-Cells
2529336|NCT02701855||Hypertension and progressive MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2529339|NCT02701855||Hypertension and stable MCI|50 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2529340|NCT02701855||Hypertension, without MCI|60 subjects will perform brain and aorta RMI, blood test, cognitive tests and adaptative optics.
2529381|NCT02701322|Experimental|Medical Clown|the study group will be accompanied by a medical clown from the arrival to the premise, through the actual examination and after exiting the exam room. The medical clown will explain about the upcoming examination and will induce a less stressed atmosphere. After the examination the clown will close the session for the patient.
2529384|NCT02701322|No Intervention|Control|The control group will do the same videofluoroscopic procedure but without a medical clown.
2529440|NCT02701231|Sham Comparator|Sham control|Subjects will receive one cycle of treatment of sham low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
2528128|NCT02709824|Active Comparator|Chlorhexidine gluconate with ADS|Chlorhexidine 0.12% plus Anti-Discoloration System Mouthwash
2528131|NCT02709824|Active Comparator|Chlorhexidine gluconate without ADS|Chlorhexidine 0.12% Mouthwash
2528202|NCT02709447|Experimental|Date SMART|Group based prevention
2528210|NCT02709447|Active Comparator|Health Promotion|Group based prevention
3200294|NCT00889148|Placebo Comparator|Placebo|
3200295|NCT00889213|Experimental|Patch and glue arm|Randomized patients to the patch and glue arm will undergo placement of a falciform ligament tissue patch and fibrin glue to the resection margin of the remnant pancreas following distal pancreatectomy
3200296|NCT00889213|Active Comparator|stapled /sutured pancreatic closure|
3200297|NCT00889239|Experimental|A|ceramic crown
3200298|NCT00889304||A|HTO cohort
2528408|NCT02708043|Other|F-LMA group|LMA were placed to 814 patients for adenoidectomy surgery. Researchers evaluated flexible laryngeal mask airway use during pediatric adenoidectomies in terms of patient safety, comfort, complications and surgeon satisfaction levels.
2528431|NCT02707744||sinus rhythm|patients with heart failure and sinus rhythm
2528433|NCT02707744||atrial fibrillation|patients with heart failure and atrial fibrillation
2528477|NCT02707510|Experimental|Intervention Arm|Patients in the intervention group will be provided with all programmatic materials (including copies of power point presentations, copies of reading texts, and audio CDs) and classes will be held in group format, with a maximum of 9 participants per group. Classes will meet weekly, in a group, and at a set time. All classes will be facilitated jointly by the two Co-PIs. All participants will complete surveys before class, during class, at the end of class, 1 month after the end of class, 6 months after the end of class and 1 year after the end of the class. Additionally, those randomized to the intervention group will be asked to attend a 1 time focus group 1 week after the end of the class.
2528480|NCT02707510|No Intervention|Control Arm|Patients in the control group will be asked to complete surveys at: baseline, 6 weeks after baseline (T1), and 1 month after T1. After T1, the control group will off study and will be permitted to attend the next available GRACE course.
2528546|NCT02707211|Experimental|Anti-oxLDL IgM antibodies|administration Anti-oxLDL IgM antibodies
3200299|NCT00889317||healthy adults|
3200300|NCT00889343|Experimental|1|
3200301|NCT00889343|Placebo Comparator|2|
3200302|NCT00889356|Experimental|Clindamycin 100mg and Ketoconazole 400mg|
2528861|NCT02704988|Active Comparator|Colon Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2528862|NCT02704988|Active Comparator|Colon Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2528864|NCT02704988|Active Comparator|Rectal Cancer - Carnoy|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
2528865|NCT02704988|Active Comparator|Rectal Cancer - GEWF|(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy.
3200303|NCT00889356|Active Comparator|Tetracycline 100mg and Amphotericin B 50mg|
3200304|NCT00889369|Experimental|A|Use of duloxetine, flexible dose (60-120mg/day) for 8 weeks, following a 2-week placebo lead-in phase
3200305|NCT00889382|Experimental|Phase 1 Arm A|Intermittent OSI-906 Once Daily (QD) on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15 (except Treatment Period 1 (TP 1); in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22)
3200306|NCT00889382|Experimental|Phase 1 Arm B1|Continuous OSI-906 Twice Daily (BID) (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15;(except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 15 - 17, and 22 - 24 with paclitaxel on Days 8, 15 and 22)
3200307|NCT00889382|Experimental|Phase 1 Arm B2|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 (except TP 1; in TP 1 OSI-906 on Days 1 - 3, 8 - 10, 5 - 17, and 22 - 24 with paclitaxel on Days 8, 15, and 22); (additional PK sampling on Days 9 or 13 0r 14 for TP 1)
3200308|NCT00889382|Experimental|Phase 1 Arm B3|Continuous OSI-906 BID (Days 1 - 21) with paclitaxel dosing on Days 1, 8, and 15 with no separation in OSI-906 and paclitaxel dosing (except TP 1; in TP 1 continuous OSI-906 dosing 2 hours prior to the initiation of paclitaxel infusion on Day 8 only, with paclitaxel on Days 8, 15, and 22, and additional PK sampling on Day 9 or 13 or 14)
2528072|NCT02710162|Experimental|Screening|Participants enrolled will have the following test: Micro Mouth Pressure Meter, reflexive cough testing (with capsaicin used in blocks), lingual strength and endurance trials using the Iowa Oral Performance Instrument, Electrical Impedance Myography of the tongue, Pulmonary Function Testing, and a Videofluoroscopic Swallowing Study. In addition, the patient will complete the following surveys: Swallowing Related Quality of Life Questionnaire (SWAL-QOL), Eating Assessment Tool-10 (EAT-10), Functional Oral Intake Scale (FOIS), Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS), and the Communicative Effectiveness Survey (CES).
2528187|NCT02709512|Experimental|Drug: ADI-PEG 20 plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
2528190|NCT02709512|Placebo Comparator|Drug: Placebo plus Pem Cis|"Dose: 36 mg/m2 given weekly Route of Administration: Intramuscular (IM) Duration : Course of Study~In Combination With:~Pemetrexed Dose: 500 mg/m2 every 3 weeks Route of Administration: Intravenous Cisplatin Dose: 75 mg/m2 every 3 weeks Route of Administration: Intravenous"
2528303|NCT02708836|Active Comparator|ETT only|Endotracheal tube intubation after induction of anesthesia. Ventilation with ETT until emergence.
2528312|NCT02708836|Experimental|Combined ETT/LMA technique|Placement of LMA after induction of anesthesia. Intubation of trachea with ETT via LMA with fiberoptic bronchoscope. Ventilation with ETT throughout case. Removal of ETT while deeply anesthetized. Ventilation with LMA until emergence.
2528452|NCT02707653|Other|Miso|Misoprostol 400 s/l
2528471|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 1|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include two pre-tests and two post-tests, building in an observation period that is not present in Wave 2.
2528475|NCT02707367|Experimental|Recovery Roadmap (RR) Wave 2|All participants, in both Wave 1 and Wave 2, will act as their own comparator in a randomized stepped wedge design. Data collection in Wave 1 will include one pre-test and three post-tests.
2528537|NCT02707237|Other|Verbal counseling|Parents with threatened delivery will receive verbal counseling only
2528541|NCT02707237|Other|Verbal, pictorial, written counseling|Parents with threatened delivery will receive verbal counseling supplemented with pictorial and written information
2528673|NCT02706496||young adults (20-35yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2528679|NCT02706496||middle age(45-60yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2528684|NCT02706496||elderly(65-74yr)|The participants were first screened by the telephone interview, the inclusion criterion contained: able to walk and climb the stairs without assistive devices, could follow the instructions, and without well-known balance related diseases or impairments. With the disease of cardiac and pulmonary system, neuromusculoskeletal system, vision, vestibular apparatus, dizziness experience or cognitive deficit would be excluded the study.
2528755|NCT02706067|Experimental|Orlistat|Participants will receive intermittent orlistat for up to 4 years, with the dose determined according to body weight changes.
2528771|NCT02705534|Experimental|Treatment|Subjects will receive sofosbuvir, ledipasvir and ribavirin
2528875|NCT02704572|Experimental|6months to 2years after shingles|Patients will be vaccinated with Zostavax from 6 months to 2 years after zoster illness.
2528884|NCT02704572|Active Comparator|2years to 5years after shingles|Patients will be vaccinated with Zostavax from 2 years to 5 years after zoster illness.
2528957|NCT02704494|Experimental|Resveratrol|Resveratrol + Losartan
2528965|NCT02704494|Placebo Comparator|Placebo|Placebo + Losartan
2529104|NCT02703389|Experimental|Video|An innovative video will be developed to explain the nature of non-severe acute otitis media and the rationale for watchful waiting and antimicrobial stewardship. This video will be viewed at recruitment and will be available online for further viewing later.
2529109|NCT02703389|Active Comparator|Pamphlet|Informative pamphlet containing the same information as the video.
2529111|NCT02703389|No Intervention|No intervention|This is the reference standard currently.
2529163|NCT02703064|Experimental|Furocyst|Furocyst 500mg capsule, BD
3166795|NCT00529919|Active Comparator|1|MCT oil consumption
3166796|NCT00529919|Placebo Comparator|2|Olive oil consumption
3166797|NCT00529932|Active Comparator|1|Enriched CD133+, bone marrow-derived, autologous progenitor cells for this trial will be infused in the coronary arteries
3166798|NCT00529932|Placebo Comparator|2|Control group patients will receive 3 injections of 0.3 mL each of buffered normal saline (the vehicle used for cell suspension) into comparable vessels. Subjects will have an identical intra-coronary injection procedure to those randomized to autologous CD133+ progenitor cell injections.
3166799|NCT00529971|Experimental|1|Participants in the first arm participate in an 8-week MBSR group
3166800|NCT00529971|Active Comparator|2|Participants assigned to the control arm do not receive the MBSR program but may or may not be receiving current psychotherapy or counselling
3166801|NCT00529984|Experimental|Cohort 1|
3166802|NCT00529984|Experimental|Cohort 2|
3166803|NCT00529984|Experimental|Cohort 3|
3166804|NCT00529984|Experimental|Cohort 4|
3166805|NCT00529984|Experimental|Cohort 5|
3166806|NCT00529997|Experimental|1|Posterior Dynamic Stabilization with the Stabilimax NZ
3166807|NCT00529997|Active Comparator|2|Posteriolateral instrumented fusion
3166808|NCT00530036||Continent|"54% of 699 patients followed as outpatient by the Fondation des Services d'Aide et de Soins à Domicile in Geneva without urinary incontinence"
2528094|NCT02709980|Active Comparator|Cognitive Behavior Therapy for Insomnia|6 sessions of cognitive behavioral therapy for insomnia (CBT-I).
2528138|NCT02709707||Patients with diabetes|
2528205|NCT02709473|Active Comparator|propofol|Propofol arm includes patients that induction of general anesthesia started with propofol and followed by remifentanil and rocuronium administration
2528212|NCT02709473|Active Comparator|remifentanil|Remifentanil arm include patients that induction of general anesthesia started with remifentanil and followed by propofol and rocuronium administration
2528250|NCT02708953|Experimental|Treatment (thoracic manipulation)|Patients in the initial manipulation group will attend physical therapy two sessions per week for 3 weeks for a total of 6 sessions. Each treatment session will last for a total of 15 minutes. After the initial manipulation group receives 3 weeks of treatment they will wait for 1-week, be retested, and then crossover into the other group.
2528254|NCT02708953|Active Comparator|Wait-list (thoracic manipulation)|When individuals are assigned to the wait-list control group they will serve as the control for 3 weeks while the initial manipulation group receives treatment. After serving as the wait-list control condition for 3 weeks, this group will then return for testing and will receive the manipulation package as described below at 4 weeks.
2528353|NCT02708303||Foregut Surgery|Foregut surgery includes conditions of the esophagus, stomach and proximal small intestine. More specifically foregut surgery includes surgery for gastroesophageal reflux disease, hiatal hernias, and paraesophageal hernias.
2528370|NCT02708082||Glaucoma|Early, moderate or advanced glaucoma, glaucoma suspects or pre-perimetric glaucoma will perform OCT scanning and HFA perimetry
3200309|NCT00889382|Experimental|Phase 2 Arm A|Intermittent OSI-906 QD on Days 1 - 3, 8 - 10, and 15 - 17 with paclitaxel on Days 1, 8, and 15
3200310|NCT00889382|Experimental|Phase 2 Arm B|Continuous OSI-906 BID from Day 1 onwards with paclitaxel on Days 1, 8, and 15
3200311|NCT00889382|Experimental|Phase 2 Arm C|Paclitaxel on Days 1, 8, and 15
3200312|NCT00889382|Experimental|Phase 2 Arm C Roll-over|Continuous OSI-906 BID from Day 1 onwards
2528531|NCT02707081|Placebo Comparator|Placebo control group|Saline was given both intraperitoneally and intravenously during caesarean section
2528534|NCT02707081|Active Comparator|Intraperitoneal instillation group|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure with intravenous normal saline in a volume equivalent to that used in intravenous lidocaine group as placebo to ensure blinding.
2528535|NCT02707081|Active Comparator|Intravenous injection group|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding
2528589|NCT02706678|Experimental|Tacrolimus sustained-release capsule group|Oral
2528685|NCT02706301|Experimental|Telephone-Based Coping Skills Training (CST)|The CST condition will receive 5 sessions of a cognitive behavior theory-based protocol that teaches coping skills (e.g., relaxation, activity pacing/planning, cognitive restructuring) relevant to managing pain as well as psychological distress.
2528691|NCT02706301|No Intervention|Standard care control|The standard care control condition will receive resources and referrals related to survivorship health. This information will be provided to the participant during their initial survivorship care consult.
2528728|NCT02706015|Experimental|Cefaliv® & Placebo|Dihydroergotamine mesylate+ dipyrone sodium + caffeine
2528736|NCT02706015|Active Comparator|Neosaldina® & Placebo|Isometheptene mucate + dipyrone sodium + anhydrous caffeine
2528772|NCT02705547|Experimental|Rosuvastatin (Crestor)|This is an open-label study of Rosuvastatin (Crestor) in patients with FRDA. Study subjects will receive 10 mg of Rosuvastatin daily for 3 months.
3200313|NCT00889395|No Intervention|Home visit|Patients will have monthly home visits during which health educational talks will be given
3200314|NCT00889408|Experimental|Treatment|DT2219ARL at assigned dose IV over 4 hours in the outpatient setting on day 1, 3, 5, and 8
3200315|NCT00889434|Active Comparator|EGCG|Two cycles comprising 28 days of continuous daily treatment with EGCGgiven 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
2528978|NCT02704182|Active Comparator|Real tDCS|Direct current stimulation using anodal electrode, 25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
2528984|NCT02704182|Sham Comparator|Sham tDCS|Sham direct current stimulation, 25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
2528990|NCT02703935|Experimental|health talk and adventure-based training|Participate will join a four-day adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 12 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
3200316|NCT00889434|Active Comparator|Tocotrienol|
3200317|NCT00889434|Other|EGCG + Tocotrienol|Combination of both arms
3200318|NCT00889460|Placebo Comparator|1|Placebo group
3200319|NCT00889460|Experimental|2|rBet v 1 tablets
3200320|NCT00889473|Experimental|Larazotide acetate 1 mg|larazotide acetate 1 mg capsules TID + 900 mg gluten capsules TID for 6 weeks
3200321|NCT00889473|Placebo Comparator|Placebo|placebo capsules TID + 900 mg gluten capsules TID for 6 weeks
3200322|NCT00889486|Placebo Comparator|Placebo|Four placebo capsules taken orally once per day for 28 days
3200323|NCT00889486|Experimental|10 mg TZP-102|One 10 mg TZP-102 Capsule and three placebo capsules taken orally once per day for 28 days
3200324|NCT00889486|Experimental|20 mg TZP-102|Two 10 mg TZP-102 Capsules and two placebo capsules taken orally once per day for 28 days
3200325|NCT00889486|Experimental|40 mg TZP-102|Four 10 mg TZP-102 Capsules taken orally once per day for 28 days
3200326|NCT00889499|Placebo Comparator|Crossover study|Crossover study
3200327|NCT00889499|Placebo Comparator|2|Crossover Study
3200328|NCT00889499|Placebo Comparator|3|Crossover Study
3200329|NCT00889525|Experimental|Cabergoline|
2528139|NCT02709733|Experimental|VR Motivation Training|Weekly training sessions with a VR motivation treatment 1 hour per week for 8 weeks.
2528233|NCT02709408||Carbapenem-resistant Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-resistant Enterobacteriaceae
2528235|NCT02709408||Carbapenem-resistant A. baumannii|Patients with bloodstream infections due to carbapenem-resistant Acinetobacter baumannii
2528236|NCT02709408||Susceptible Enterobacteriaceae|Patients with complicated intrabdominal infections, pneumonia, complicated urinary tract infection and bloodstream infection due to carbapenem-susceptible Enterobacteriaceae matched to carbapenem-resistant ones by centre, type of ward, infection type, acquisition and previous duration of hospitalisation.
2528237|NCT02709408||Admitted control patients|Patients without infection due to Enterobacteriaceae matched to carbapenem-resistant Enterobacteriaceae cases according to centre, ward and previous length of hospitalisation.
2528305|NCT02708589|Active Comparator|probiotic|the probiotics capsules contain 7 strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic (fructooligosaccharide).
2528313|NCT02708589|Placebo Comparator|Placebo|Placebo capsules have identical appearance to probiotic capsules and contain Maltodextrin.
2528417|NCT02708017|Active Comparator|S-TAP block|ultrasound guided bilateral subcostal TAP block
2528421|NCT02708017|Active Comparator|P-TAP block|ultrasound guided bilateral Posterior TAP block
2528491|NCT02707575||Ranibizumab|Intravitreal Ranibizumab
2528570|NCT02706912|Experimental|VOTA Group|All enrolled subjects are in this arm. After pre-assessment subjects have an 8-week waiting period, after which a mid-assessment takes place. Subject then participate in VOTA therapy for 8 weeks, followed by a post-assessment . The pre-/mid-assessment difference is used to control for spontaneous recovery. The mid-/post-assessment difference is used to ascertain efficacy.
2528584|NCT02706626|Experimental|Brigatinib|Experimental: Brigatinib until progressive disease, unacceptable toxicity, withdrawal of consent
2528688|NCT02706314||Critically ill patients with CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 with CIP
2528692|NCT02706314||Critically ill patients without CIP|Critically ill patients with a Sequential Organ Failure Assessment (SOFA)-Score >7 without CIP
2528696|NCT02706314||Healthy volunteers|Healthy volunteers with neither critical illness nor CIP
2528740|NCT02705989|Placebo Comparator|Single Ascending Dose (SAD)|Single ascending dose of BMS-986195 or Placebo matching BMS-986195
2528745|NCT02705989|Placebo Comparator|Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195
2528750|NCT02705989|Placebo Comparator|Japanese-Multiple Ascending Dose(MAD)|Multiple ascending dose of BMS-986195 or Placebo matching BMS-986195 in subjects with Japanese heritage
2528754|NCT02705989|Experimental|Relative Bioavailability with Food Effects (Open Label)|
2528809|NCT02705443||Tissue w/ Thermographic Anomaly|"Visibly undamaged tissue with anomaly identified by the thermographic image~No intervention~Standard of care"
2528810|NCT02705443||Tissue w/o Thermographic Anomaly|"Visibly undamaged tissue with no anomaly identified by the thermographic image~No intervention~Standard of care"
2528812|NCT02705443||Tissue w/ Visible Anomaly|"Visibly damaged tissue~No intervention~Standard of care"
2528909|NCT02704949|Experimental|Low-dose|The intervention is to use 1/4 fluoroscopy dose while the ureteroscopy is being performed
2528916|NCT02704949|Active Comparator|Full-dose|The intervention is to use full fluoroscopy dose while the ureteroscopy is being performed
2529010|NCT02704013|Other|Intervention|Patients with overactive bladder will receive anticholinergic therapy: oral oxybutynin in daily dose 0.2-0.5 mg/kg divided in two daily doses for 3 to 6 months depending on treatment outcome assessed 3 months after start of intervention.
2529042|NCT02703662|Active Comparator|Strattice biologic mesh|Strattice mesh is made of noncross-linked porcine dermis, which is used to support abdominal wall reconstruction.
2529043|NCT02703662|Experimental|Permacol biologic mesh|Permacol mesh is made of cross-linked porcine dermis, which is used to support abdominal wall reconstruction.
2529110|NCT02703441|Experimental|Intervention: Tablet computer|Patients from the local municipality, planned to be discharged to a rehabilitation stay at the municipality training centre receive a tablet computer. The patient will be introduced to the tablet and informed about the nutritional and mobilisation intervention based on his/her individual needs and preferences. The patient and the research assistant will jointly prepare an individual plan for nutrition and physical activity The patient uses the tablet for ordering meals, registering dietary intake, viewing his/her instruction videos for the activity programme and registering physical activity during hospital admission and at the training centre up to 6 weeks after discharge from hospital.
2529114|NCT02703441|No Intervention|Control group|Patients in the control group receive usual care during their hospital stay and after discharge at the municipality training centre. Data are recorded at baseline and 6 and 12 weeks after discharge.
2529166|NCT02703077|Active Comparator|1: ERCP + Spyglass + EHL|This group after the diagnosis of difficult bile duct stones, will be submitted to spyglass cholangioscopy + EHL (electrohydraulic lithotripsy)
2529168|NCT02703077|Active Comparator|2: ERCP + Balloon Dilation|This group after the diagnosis of difficult bile duct stones, will be submitted to Balloon dilation of the papilla
3200330|NCT00889538|Placebo Comparator|Placebo|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
3200331|NCT00889538|Active Comparator|Glutathione|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
2529304|NCT02702063|Other|TTE vs. EC + calibration group|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial."
2529344|NCT02701920||NICU infants and hat|Newborn infants of any gestation on the neonatal intensive care unit (NICU).
2528148|NCT02709629|Experimental|Individualized and adaptive computerised cognitive training|Training in this group is individualized using a computer algorithm which assigns tasks (from a pool of 33 training tasks) on the basis of cognitive strengths and weaknesses as determined by the training program. In addition, task difficulty is adaptive and responsive to performance level. Participants are able to see feedback on their progress each training session in the form of a session-score. A range of behavior change techniques are used throughout the training period (delivered via scheduled monitoring phone calls, and email contact with participants) to support the compliance and adherence of participants. These include a range of motivation and confidence building strategies, based on a theoretical framework. Participants are required to train for approx. 30 min., 3 times per week, for 8 weeks.
2528152|NCT02709629|Active Comparator|Active control|"Training in this group is generic, and tasks (from the same pool of 33 training tasks) are randomly selected by the training program. In addition, task difficulty is fixed, such that irrespective of performance, each time a participant is presented with a given task, the level of difficulty returns to the basic level. Participants in this arm do not receive feedback on their progress at the end of each training session. The same protocol of behavior change techniques is used in this intervention arm.~Participants are also required to train for approx. 30 min., 3 times per week, for 8 weeks."
2528178|NCT02709343|Experimental|Bone-marrow derived MSCs|4 doses of Allogeneic bone-marrow derived MSCs (2x106 cells/kg) given intravenously twice weekly for 2 weeks
2528180|NCT02709343|Placebo Comparator|Placebo|Placebo product manufactured to look like MSCs
2528265|NCT02709031|Active Comparator|Cicletanine|Patients will take escalating doses of cicletanine
2528271|NCT02709031|Experimental|Cicletanine + magnesium|Patients will take escalating doses of cicletanine; patients will in addition take magnesium
2528318|NCT02708706|Experimental|physical therapy and hyaluronic acid|patient received ultrasound-guided steroid injection via rotator interval
2528322|NCT02708706|Active Comparator|physical therapy only|patient received ultrasound-guided steroid injection via posterior recess
3200332|NCT00889538|Active Comparator|Glutathione, Vit C and NAC|Randomized to placebo or treatment (glutathione or glutathione/vit C/NAC)
3200333|NCT00889590|Experimental|Zoledronic acid|Adjuvant zoledronic acid
3200334|NCT00889590|No Intervention|Control|Standard care
2528495|NCT02707627||Laser Therapy|Participants will receive laser therapy for the treatment of their hypertrophic burn scars. Laser treatment decisions will be tailored to meet the needs of the patient.
2528547|NCT02707198|No Intervention|Group A|Will receive prescribed antibiotics and will not receive kefir. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2528550|NCT02707198|Active Comparator|Group B|Will receive prescribed antibiotics and will receive kefir only during hospital stay. Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2528552|NCT02707198|Active Comparator|Group C|Will receive prescribed antibiotics and will receive kefir during hospital stay and for the duration of the prescribed antibiotic regimen for up to a total of 30 days . Patients in this arm will be asked to record daily symptoms of diarrhea for up to 30 days post-discharge.
2528597|NCT02706730|Experimental|OTO-104|12 mg dexamethasone
2528657|NCT02706509|Active Comparator|oral tramadol|Patients will receive oral Tramadol 50 mg capsules (n=50)' . After an hour, Jaydess intrauterine device will be inserted.
2528658|NCT02706509|Sham Comparator|verbal anesthesia|'verbal anesthesia' (n=50) After an hour, Jaydess intrauterine device will be inserted
2528708|NCT02706132|Experimental|The MSCs group|The group of patients receive allogeneic MSCs therapies.
2528726|NCT02705872|Experimental|Programmed intermittent boluses|Epidural analgesia performed with programmed intermittent boluses.
2528732|NCT02705872|Active Comparator|Continuous perfusion|Epidural analgesia performed with a continuous perfusion.
2528781|NCT02705612|Other|control group|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy.
2528784|NCT02705612|Experimental|experimental group|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as the patients in control group. Patients also receive nimotuzumab during the external radiotherapy.
2528856|NCT02705196|Experimental|Arm 1 Intratumoral LOAd703|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment.~The following LOAd703 doses will be evaluated:~Dose level 1: 5 X 10^10 viral particles per treatment Dose level 2: 1 X 10^11 viral particles per treatment Dose level 3: 5 X 10^11 viral particles per treatment"
2528858|NCT02705196|Experimental|Arm 2: Intratumoral LOAd703 + atezolizumab|"Patients will receive gemcitabine intravenously at a dose of 1000mg/m2 + nab-paclitaxel 125 mg/m2 as per hospital standards. One cycle will be one dose of gemcitabine +nab-paclitaxel given on days 1, 8, and 15 of a 28 day cycle. LOAd703 will be given every other week for 6 doses starting on day 15 of the first cycle of chemotherapy. There is an option for an additional 6 doses if patients benefit from treatment. A fixed dose of atezolizumab 1680 mg will be given every 4 weeks on day 1 of each chemotherapy cycle.~Patients will be assigned to the following LOAd703 doses:~Dose level 1: 1 X 10^11 viral particles per treatment Dose level 2: 5 X 10^11 viral particles per treatment"
2528880|NCT02704585|Other|Nellcor|Connection to Nellcor pulse oximeter for measuring oxygen saturation after birth
2528887|NCT02704585|Other|Masimo|Connection to Masimo pulse oximeter for measuring oxygen saturation after birth
2528952|NCT02704403|Experimental|120 mg Elafibranor|Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water
2529176|NCT02702843|Active Comparator|Xenon Light|Laparoscopic cholecystectomy with Xenon Light
2528231|NCT02709382|Experimental|FEP-TAZ|Cefepime and Tazobactam combination; IV infusion over a period of 90 minutes Healthy subjects, Mild and Moderate RI: 4 g (2 g FEP and 2 g TAZ) Severe RI and patients on HD: 2 g (1 g FEP and 1 g TAZ)
2528261|NCT02708914|Other|UB-851|
2528267|NCT02708914|Other|Eprex then UB-851|
2528375|NCT02708446|Active Comparator|Sublingual misoprostol|200mg mifepristone + 400mcg sublingual misoprostol q3h
2528380|NCT02708446|Active Comparator|Buccal misoprostol|200mg mifepristone + 400mcg buccal misoprostol q3h
2528451|NCT02707731|Experimental|Hydrokinesiotherapy in preterm|Salivary cortisol samples, pain applying the Neonatal Infant Pain Scale Scale, heart rate, respiratory rate and oxygen saturation were collected before and after hydrokinesiotherapy
2528485|NCT02707380|Active Comparator|Group 1 Resistance Training Group|Participants will perform 3 exercises, one of which will be a series of 7 muscle-strengthening exercises using body weight resistance and elastic resistance bands + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
2528487|NCT02707380|Active Comparator|Group 2 Standard of Care|Participants will perform 3 exercises that do not include the 7 muscle-strengthening exercises + 36 sessions of a standard cardiac rehabilitation program consisting of monitored exercise, nutritional guidance, and heart-healthy lifestyle education three times weekly.
2528525|NCT02707185|Other|Physicians|"Physician in training:~All internal medicine (IM), emergency medicine (EM), anesthesia (A), surgery (S) residents and all hospital ICU nurses."
2528528|NCT02707185|Other|Nurses|Nurses in Training
3200335|NCT00889629|Experimental|Doxercalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Active group receives doxercalciferol (Hectorol) 1mcgwith active titration based on intact PTH plus 25-OH Vitamin D3 (cholecalciferol) 400 IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol if target PTH value is not achieved by the predetermined midpoint.
3200336|NCT00889629|Placebo Comparator|Cholecalciferol|Patients are randomized using an A B C D randomization scheme in which the patient and the primary investigator are blinded but the study staff is not. Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol) plus 25-OH Vitamin D3 (cholecalciferol) 400IU. Safety labs and end point labs are monitored as per protocol, with the opportunity to increase the dose of doxercalciferol placebo if target PTH value is not achieved by the predetermined midpoint.
3200337|NCT00889642|Active Comparator|Active|Contains Lidocaine and Epinephrine
3200338|NCT00889642|Placebo Comparator|Placebo|Contains Epinephrine
3200339|NCT00889655|Active Comparator|Golytely|216 patients at random will provided a prescription for the standard 4 L golytely preparation as the bowel cleanser for their colonoscopy
3200340|NCT00889655|Experimental|MiraLax|216 patients will be randomized to take 238 gm of miralax mixed with 64 oz of gatorade for their bowel cleanser
3200341|NCT00889668|Experimental|Experimental|subjects with a diagnosis of type 1 or 2 diabetes; GlucoTrack results will be compared with the readings from approved invasive glucose meter device.
3200342|NCT00889785|Active Comparator|1 (Usual Care)|Patients will continue to review usual care in the diabetes clinic. Patients will receive monthly phone calls as an active control condition.
3200343|NCT00889785|Experimental|Intervention|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
2528768|NCT02705742|Other|stem cells group|mesenchymal stem cells only
2528889|NCT02704923|Active Comparator|Atropine|
2528897|NCT02704923|Placebo Comparator|Placebo|
3200344|NCT00889837|Experimental|Inhaled Loxapine|Staccato Loxapine, 10 mg doses x 2, 10 hours apart
3200345|NCT00889837|Placebo Comparator|Inhaled Placebo|Staccato Placebo,inhalations x 2, 10 hours apart
2529120|NCT02703181|Experimental|Cohort 1(600 mg Epelsiban or placebo[every 8 hours])|Each subject will receive 200 mg of epelsiban administered TID (every 8 hours) (total daily dose of 600 mg) or a matching placebo administered every 8 hours.
2529173|NCT02702986|Experimental|imILT of pancreatic cancer|10 patients suffering from LAPC will be submitted to immunostimulating interstitial laser thermotherapy (imILT) in a single-arm setting
2529241|NCT02702557|Other|Elastic Band Exercises|Unsupervised Elastic band exercises performed once a day until the patient is discharged from the hospital. One exercise for the upper extremity (row exercise level 1-3) and one exercise for the lower extremity (knee extension level 1-3). The two exercises are both performed as 3 sets of 10 repetitions.
2529249|NCT02702232||Parkinson's disease|Patients with PD will be recruited consecutively from a neurology clinic. A group of sex- and age-matched normal subjects with be recruited from the public. These patients will be evaluated by ultrasonography for shoulder.
2529250|NCT02702232||Normal|Normal controls who will be evaluated by ultrasonography for shoulder
2529265|NCT02702050|Active Comparator|Conventional treatment group|Conventional treatment group will receive an educational session before commencement of the program. Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises will be provided within a 6-week period (i.e., two sessions per week) to all subjects. No mechanical stimulation will be given.
2529267|NCT02702050|Experimental|Mechanical stimulation group|A 10 minute mechanical stimulation program - 'Mechanical stimulation (LPG system; Cellu M6 Integral I), will be provided after each of the twelve sessions of conventional treatment.
3200346|NCT00889850|Active Comparator|1|Oral fasted administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
2528232|NCT02709291|Other|Community Health Workers|Community health workers will complete a 5-day interventionist training to deliver a behavioral parent training intervention.
2528234|NCT02709291|Other|Parent-Child Dyads|Parents and children will receive a behavioral parent training intervention delivered by community health workers.
2528273|NCT02708901|Active Comparator|GI Vivomixx®|25 children with GI symptoms
2528275|NCT02708901|Placebo Comparator|GI Placebo|25 children with GI symptoms
2528278|NCT02708901|Active Comparator|NGI Vivomixx®|25 children without GI symptoms
2528280|NCT02708901|Placebo Comparator|NGI placebo|25 children without GI symptoms
2528326|NCT02708576|Experimental|NGM313|Administration of active NGM313
2528328|NCT02708576|Placebo Comparator|Placebo|Administration of placebo comparator
2528388|NCT02708316||schizophrenia group|schizophrenia patients in the group
2528389|NCT02708316||control group|healthy population
3200347|NCT00889850|Active Comparator|2|Oral fasted administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
3200348|NCT00889850|Active Comparator|3|Oral fed administration of one capsule of 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
2528516|NCT02706977|Experimental|Diabetes Group - Low Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive low dose Sinemet CR twice daily for two weeks.
2528517|NCT02706977|Experimental|Diabetes Group - High Dose Sinemet CR|Participants with diabetes mellitus type-2 and electroretinogram (ERG) delays will receive high dose Sinemet CR twice daily for two weeks.
2528518|NCT02706977|Other|Diabetes Group - No Electroretinogram (ERG) Delays|Participants with diabetes mellitus type-2 who do not have electroretinogram (ERG) delays. Participants in this group will have one baseline visit only.
2528519|NCT02706977|Other|Age-Matched Controls|Participants will serve as age-matched controls for participants with diabetes. This group will participate in the baseline, week 2, and week 4 visits only.
3200349|NCT00889850|Active Comparator|4|Oral fed administration of one tablet of INexium 40 mg MUPS tablets (AstraZeneca, France)
3200350|NCT00889876|Experimental|Metformin|
3200351|NCT00889876|Experimental|Exercise|
2528741|NCT02705820|Experimental|single arm study|experimental treatment with maintenance pembrolizumab
2528818|NCT02705339|Experimental|Arm 1: Rociletinib|"Rociletinib is an oral drug which will be administered on an outpatient basis at a dose of 500 mg twice per day during each 28-day cycle.~After completion of cycle 1, patients who tolerate the 500 mg twice per day dose without significant adverse effect may increase dosing to 625 mg twice per day at the discretion of the investigator"
2528905|NCT02704767|Placebo Comparator|TarceP|Tarceva with Placebo
2528911|NCT02704767|Experimental|TarceA|Tarceva with Apatinib
2528948|NCT02704260|Experimental|GENETIC ANALISYS|GENETIC ANALYSIS AND RESEARCH OF GENETIC BLOOD SAMPLE
2528988|NCT02704065||Recurrent AA amyloidosis|Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft
2528994|NCT02704065||Control group 1|Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft
2529005|NCT02704065||Control group 2|Renal transplant recipients whose primary diseases are other than amyloidosis
2529061|NCT02703623|Experimental|Arm 2A (abiraterone acetate, prednisone, apalutamide)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily in the absence of disease progression or unexpected toxicity.
2529067|NCT02703623|Experimental|Arm 2B (abiraterone acetate, prednisone, ARN-509, ipilimumab)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive ipilimumab IV over 90 minutes on day 1 of courses 4-7. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
2529073|NCT02703623|Active Comparator|Arm 3(abiraterone, prednisone, ARN509,cabazitaxel,carboplatin)|Patients receive abiraterone acetate PO daily, prednisone PO BID, and apalutamide PO daily. Patients also receive cabazitaxel IV over 60 minutes and carboplatin IV, over 60 minutes on day 1 of courses 4-13. Courses repeat every 3 weeks in the absence of disease progression or unexpected toxicity.
2529199|NCT02702674|Active Comparator|propranolol plus oxytocin|121 patients who will receive a capsule containing 20 mg propranolol (propranolol plus oxytocin) administrated orally before beginning induction and repeated after 8 hours if no sufficient uterine contractions reached.
2529201|NCT02702674|Placebo Comparator|placebo plus oxytocin|121 control patients who will receive a similar capsule as a placebo (oxytocin plus placebo) before beginning induction.
2529258|NCT02702297||Single arm|daily multimodal monitoring during pregnancy after PPROM, Analysis of neonatal routine parameters and histologic examination of placenta
2529279|NCT02701959|Placebo Comparator|Low nitrate lettuce|50g of low nitrate lettuce (placebo) on single occasions
2529282|NCT02701959|Active Comparator|High nitrate lettuce|50g of high nitrate lettuce (intervention) on single occasions
3200352|NCT00889889|Experimental|1|
3200353|NCT00889889|Placebo Comparator|2|
3200354|NCT00889941|Active Comparator|small|
3200355|NCT00889941|Active Comparator|medium|
3200356|NCT00889941|Active Comparator|large|
3200357|NCT00889954|Experimental|TGFBeta resistant HER2/EBV-CTLs|"The following dose levels will be evaluated:~Dose Level 1: 1 x 10^4 cells/m^2~Dose Level 2: 3 x 10^4 cells/m^2~Dose Level 5: 1 x 10^6 cells/m^2~Dose Level 6: 3 x 10^6 cells/m^2~Dose Level 7: 1 x 10^7 cells/m^2~Dose Level 8: 3 x 10^7 cells/m^2~Dose Level 9:1 x 10^8 cells/m^2"
3200358|NCT00889967|Experimental|1|Ciprofloxacin for Inhalation 100 mg/day by inhalation
3200359|NCT00889967|Experimental|2|Ciprofloxacin for inhalation 150 mg/day by inhalation
3200360|NCT00889967|Placebo Comparator|Placebo|Placebo by inhalation
3200361|NCT00889980||Melanoma|Patients with primary melanoma
3200362|NCT00890006|Experimental|MRI + CBCT in prostate cancer|
2528263|NCT02709044|Experimental|Ringer lactate 20 mL/kg|This group of subjects will receive a bolus of 20 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
2528268|NCT02709044|Experimental|Ringer lactate 40 ml/kg|This group of subjects will receive a bolus of 40 ml / kg of Ringer's solution for infusion within first hour of the diagnosis
2528298|NCT02708654|Experimental|Intervention|Participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.(5) Research coordinators to remotely monitor weight gain thresholds and add alert into the participant's electronic health record for verified weight gain
2528299|NCT02708654|No Intervention|Control|Participants will receive usual care.
2528364|NCT02708368||Patients on dialysis|16 patients on dialysis with a sex ratio 1:1; 8 patients on hemodialysis and 8 patients on hemodiafiltration
2528367|NCT02708368||Healthy Subjects|16 healthy subjects with a sex ratio 1:1
2528434|NCT02707939||Autism Spectrum Disorder|Patients with a diagnosis of autism spectrum disorder
2528435|NCT02707939||Controls|Patients with no developmental diagnoses
2528466|NCT02707458|Experimental|Single arm|All subjects will receive probucol, starting with a fixed dose of 600 mg daily following the evening meal. The variable plasma concentrations achieved and the resulting modification in concentration of CSF apoE will suggest an ideal range of plasma concentrations for use of the drug as an inducer of increased availability of apoE in the CSF. The known dose-proportionality of the drug in plasma will then be used to estimate an ideal individualized dose for each participant. The effects of such individualized dosage will be tested over 1 year of follow-up observations, searching for treatment effects on CSF apoE and for evidence of other treatment effects, particularly including adverse effects.
2528512|NCT02707315|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 weekly x 3 on 28 day cycle~Radiation:~25 Gy over 5 fractions~Surgery:~surgical resection of pancreas~treatment plan:~1 cycle of chemotherapy, followed by stereotactic radiosurgery, followed by an additional 6 cycles of chemotherapy or surgical resection"
2528565|NCT02706964|Experimental|Proactive imaging|All enrolled subjects will under go a single whole-body Positron emission tomography/x-ray computed tomography (PET/CT) scan and a diagnostic-quality x-ray computed tomography (CT) scan with contrast acquired in the same imaging session; and a single brain magnetic resonance imaging (MRI) scan with contrast to be completed in separate imaging session but within 2 weeks of the PET/CT scan. Imaging will take place within 7 months after enrollment.
3200363|NCT00890019|Experimental|1A, 2A, 3A, 4A, 5A, 6A, 7A|AdCh63 ME-TRAP
2528648|NCT02706535|Experimental|Part 1 Cohort 1|Subjects will receive a single dose of GSK525762 10 mg on Day 1 followed by 200 mg Itraconazole two times a day (BID) on Day 3. On Day 4 to Day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On Day 7 subjects will receive a single dose of GSK525762 5 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
2528650|NCT02706535|Experimental|Part 1 Cohort 2|Subjects will receive a single dose of GSK525762 10 mg on day 1 followed by 200 mg Itraconazole BID on day 3. On day 4 to day 6 inclusive subjects will receive a single dose of itraconazole 200 mg in the morning. On day 7 subjects will receive a single dose of GSK525762 5 mg or GSK525762 10 mg one hour after receiving 200 mg dose of itraconazole. On day 8 and 9 subjects will receive a single dose of 200 mg itraconazole in the morning.
2528652|NCT02706535|Experimental|Part 2|Subjects will receive a single dose of GSK525762 10 mg on day 1. From day 3 to 17 inclusive, subjects will receive a single dose of 600 mg rifampicin in fasting conditions. On day 18 subjects will receive single dose of GSK525762 either 20 or 30 mg along with 600 mg dose of rifampicin. On day 19 subjects will receive a single dose of rifampicin 600 mg.
2528695|NCT02706171|Experimental|A: pre-operative|"Radiation- CyberKnife:~35-40 Gy over 5 fractions~Surgery:~Surgical resection of sarcoma"
2528697|NCT02706171|Experimental|B: Post-operative|"Radiation- CyberKnife:~40 Gy over 5 fractions"
2528698|NCT02706171|Experimental|C: Non-resectable|"Radiation- CyberKnife:~50 Gy over 5 fractions"
2528751|NCT02705898|Experimental|LPA+Fitbit|A 12-week LPA+Fitbit intervention for depressed women in intensive alcohol treatment. This will include: 1) a single in-person physical activity (PA) counseling orientation session; 2) 6 brief, phone-based PA counseling sessions focused on increasing PA and strategically using bouts of PA to cope with affect and alcohol cravings; 3) use of the Fitbit fitness tracker for physical activity goal-setting and daily self-monitoring; and 4) weekly supportive messages delivered by email.
2528757|NCT02705898|Active Comparator|Health Education Contact Control (HEC)|The HEC condition will include: 1) an in-person orientation session, 2) 6 telephone-delivered health education sessions, and 3) weekly health-related e-mails. A variety of health and lifestyle topics will be addressed including the following: Session 1 (week 1) - Nutrition-What to Eat and What Not to Eat; Session 2 (week 2) - Sleep Problems and Sleep Hygiene; Session 3 (week 4) - Alcohol Use among Women; Session 4 (week 6) - Relaxation training; Session 5 (week 8) - Time Management and Assertiveness; and Session 6 (week 10) - Being a Smart Patient when Coordinating your Healthcare.
2528782|NCT02705482|Experimental|Arm A: MEDI0562 and durvalumab|MEDI0562 and durvalumab
2528785|NCT02705482|Experimental|Arm B: MEDI0562 and tremelimumab|MEDI0562 and tremelimumab
2528820|NCT02705144||biopsies from lung tissue affected by emphysema|analysis of the number of stem cell niches
2528823|NCT02705144||biopsies from lung tissue affected by interstitial fibrosis|analysis of the number of stem cell niches
2528825|NCT02705144||biopsies from normal appearance lung tissue|analysis of the number of stem cell niches
2528868|NCT02704962|Experimental|trifluoperazine plus olanzapine|trifluoperazine 5mg/day + olanzapine 5mg/day
2528869|NCT02704962|Active Comparator|full-dose olanzapine|olanzapine 10mg/day
2528902|NCT02704598|Active Comparator|Rivaroxaban|Patients with deep venous thrombosis using Rivaroxaban for 6 months, and then will be evaluated with DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
3200364|NCT00890019|Experimental|1B, 2B, 3B, 4B, 6B, 7B, 7C|AdCh63 ME-TRAP; MVA ME-TRAP
2528304|NCT02708537||PRGF in candidates for sperm donors|Prospective study of 58 candidates for sperm donors clinic IVI Bilbao.
2528351|NCT02708394|Experimental|olanzapine|Atypical antipsychotic
2528352|NCT02708394|Placebo Comparator|placebo|Placebo comparator
2528394|NCT02708108|Experimental|Obesity Intervention|Personalized 28-day Dietary Intervention and Activity and Exercise Intervention with the goal to reduce fat gain and lean muscle loss while inducing an overall negative energy balance.
2528424|NCT02707796|Experimental|Hemicolectomy|Oxygen reserve index and partial oxygen pressure will be noted for patients undergoing hemicolectomy
2528490|NCT02707588|Experimental|Pembrolizumab and radiotherapy|200 mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy
2528498|NCT02707588|Active Comparator|Cetuximab and radiotherapy|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
2528554|NCT02707094|Other|Usual Care (Medication + Exercise)|Usual Care: Participants will receive guidance on over-the-counter and prescribed pain medications to use to treat their chronic low back pain symptoms. The Research Coordinator (RC) will provide instructions for low back pain stretching and strengthening exercises. The Licensed Provider (LP) will determine if any exercises should be excluded based on their physical limitations. Participants enrolled in the usual care treatment arm will track the frequency of their back stretching and strengthening exercise sessions on the Pain Medication & Exercise Diary. For the purpose of this study, treatment compliance will be met if participants complete the exercises a minimum of three times per week.
2528558|NCT02707094|Experimental|Biomodulator + Usual Care|Biomodulator + Usual Care treatment group: Usual care, as described above, will be provided to all participants randomly allocated to this treatment group, in addition to treatment with the Biomodulator three times per week x 4 weeks. The licensed provider will review medication and treatment logs, prescribe pain medications as indicated, and assess for treatment side effects. In addition to treatment with the Biomodulator, the participant will perform back stretching and core strengthening exercises for a minimum of three times per week as instructed and will be told to use their prescribed pain medications as needed to self-treat their low back pain symptoms (as previously described above).
2528659|NCT02706522|Experimental|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
2528660|NCT02706522|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
2528709|NCT02706119|Experimental|Glargine insulin|Single dose glargine insulin (basal component) + regular insulin within total parenteral nutrition (TPN) reservoir (prandial component). 50% of the total calculated dose of insulin is administered subcutaneously as single dose subcutaneous glargine insulin; remaining 50% of the total calculated dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Intravenous glargine insulin, and regular insulin added to TPN bag
2528710|NCT02706119|Active Comparator|Regular insulin|Regular insulin added to TPN bag (basal + prandial component). The calculated total dose of insulin is administered as regular insulin in the TPN reservoir. Interventions used: Regular insulin added to TPN bag
2528798|NCT02705521|No Intervention|Treatment as usual group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). They will be assessed for progression and be provided with a home exercise program. Range of motion in their shoulder will be collected on a weekly basis using the MIRA technology. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
2528801|NCT02705521|Experimental|Treatment as usual plus Exergames group|Patients will attend physiotherapy on a weekly basis for assessment (standard physiotherapy). Rather than use a home exercise program patients will be provided with a laptop computer and kinect sensor. they will use the new technology to play 'Exergames' each program will be tailored to the patients progress and patients can play the system as often as they wish. Patients will be required to complete an exercise diary documenting the exercises performed as well as duration and frequency.
2528834|NCT02705131|Experimental|Balance Chiropractic Therapy(BCT)|patients are in the sitting position and receive the Balance Chiropractic Therapy(BCT) .1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.The patients will received BCT 1 time every other day, 20min each time. a total of 10 times in 20 days.
2528837|NCT02705131|Active Comparator|Traction Therapy(TT)|patients will receive the Traction Therapy(TT):The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
2528944|NCT02704481|Experimental|Mifepristone-misoprostol|Women randomized to receive 200 mg mifepristone to take on Day 1, 800 mcg buccal misoprostol to take 24-48 hours after later, and four placebo misoprostol pills to take a further 3-12 hours later.
2528947|NCT02704481|Experimental|Misoprostol-misoprostol|Women randomized to receive a placebo mifepristone pill to take on Day 1 and two doses of 800 mcg buccal misoprostol, the first of which should be taken 24-48 hours after the placebo and the second of which should be taken 3-12 hours after the first misoprostol dose.
2528987|NCT02703831|Active Comparator|Dual attending|Two attending spine surgeons during the critical portions of the surgery
2528995|NCT02703831|Placebo Comparator|Single attending|One spine attending and an assistant during the critical portions of the surgery, The assistant can be a spine fellow, a resident or a physician's assistant.
2529063|NCT02703688|Experimental|Healthy Homes|Behavioral Intervention
2529070|NCT02703688|Active Comparator|Usual Care|Counseling session delivered by pediatrician
3200365|NCT00890032|Experimental|BTSC mRNA-loaded DCs|BTSC mRNA-loaded DCs administered intradermally weekly for first 3 vaccines, then monthly until progression or withdrawal.
3200366|NCT00890058||Cases|Postmenopausal breast cancer patients with hand pain receiving aromatase inhibitors
3200367|NCT00890058||Controls|Postmenopausal breast cancer patients with hand pain not receiving aromatase inhibitors
2528306|NCT02708732||DLBCL Participants|A cohort of approximately 100 patients in first remission with DLBCL will complete questionnaires through a 15-minute postal or online survey.
2528376|NCT02708459|Active Comparator|Control|Control group where postoperative analgesia will be maintained by Morphine intravenous boluses (2 mg) if Visual analogue scale (VAS) scale more than 4.
2528381|NCT02708459|Active Comparator|Bupevecaine group|Postoperative analgesia will be maintained by 20 ml Bupevecaine (0.25%) boluses in surgically inserted TAP catheter each 8 hours for 48 hours with rescue analgesia intravenous morphine (2mg) if VAS more than 4
2528385|NCT02708459|Active Comparator|Dex group|catheter will surgically inserted in Transversus abdominus plane (TAP) plane before wound closure Postoperative analgesia will be maintained by Dexmedetomedine 0.4 mg/kg plus Bupevecaine 0.25 20 ml boluses each 8 hours for 48 hours in surgically inserted TAP catheter with rescue analgesia intravenous morphine (2mg) if VAS more 4
3200368|NCT00890071||Acute circulatory failure|Patients for whom the decision to give fluids was taken because the presence of one or more clinical signs of acute circulatory failure.
3200369|NCT00890110|Experimental|Autologus vaccination with suntinib|Combination of autologous dnp irradiated modified cells with sunitinib treatments
2528511|NCT02707302|Experimental|Iodophor-impregnated adhesive drapes|"In the iodophor-impregnated adhesive drapes group, routine disinfection will be carried out and bacteria samples will be harvested 1 cm from the wound site using sterilized swabs prior to use of the surgical adhesive drapes, and again at the end of surgery before skin suturing, for preoperative bacterial culture. The packaging of the 3M™ iodophor-impregnated adhesive drapes will be opened and the aseptic adhesive drapes unfolded until the stop instruction. The adhesive drapes will then be pasted to the surgical wound and smoothed using an aseptic cloth, taking care to avoid air bubbles."
2528513|NCT02707302|Experimental|Iodophor-free adhesive drapes|Patients in the iodophor-free adhesive drapes group will undergo the same procedures, but with iodophor-free drapes.
2528523|NCT02707055|Experimental|Active Drug|Ghrelin Receptor Inverse Agonist
2528529|NCT02707055|Other|Counseling Support|Counseling support
2528532|NCT02707055|Other|MI-VF|Motivational Interviewing with Video Feedback
2528533|NCT02707055|Placebo Comparator|Placebo|Placebo
2528577|NCT02706613|Other|Face to Face Pulmonary Rehabilitaton|6 week incremental pulmonary rehabilitation (PR) programme. Participants will attend 12 sessions over the 6 week period. The components of the PR programme will include an exercise programme. Education sessions will also be provided and include anatomy of the lungs and what is COPD, anxiety and depression, self management, managing breathlessness, medications and treatments, managing exacerbations of COPD and chest infections, clearing sputum and the Active Cycle of Breathing Technique, nutrition, pacing, smoking cessation. Participants on the face to face arm will also be instructed to carry out the pulmonary rehabilitation exercises an additional three times a week at home.
2528582|NCT02706613|Active Comparator|Online Pulmonary Rehabilitation|Those randomised to receive the online programme will be given log-in details and a password, and instructions to begin the 6 week programme at home. The online programme mirrors the conventional face-to-face PR programme and the exercise and educational components are given by means of instructional videos. Participants will be instructed to exercise five times a week. Participants in the online arm will receive during the PR course telephone contact to record any adverse or serious adverse events.
2528630|NCT02706418|Other|Clinical Massage Therapy|
2528663|NCT02706223|Experimental|Pharmacist Led|This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
2528667|NCT02706223|Experimental|Nurse Led|This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
2528746|NCT02706028|Active Comparator|ultrasound group|Patients in the ultrasound group received underwater US therapy to both hands and wrists for 7 minutes with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
2528753|NCT02706028|Sham Comparator|control group|The control group received sham treatment (the ULTRON home OE-302® device was not turned on) during 10 sessions for 7 minutes per session.
2528783|NCT02705560|Experimental|Cow´s milk (3.9% fat, pasteurized)|Cow´s milk (3.9% fat, pasteurized) Single dose, 600 ml milk
2528786|NCT02705560|Experimental|Hard, yellow cheese|"Hard, yellow cheese Single dose, 100 g cheese~+ 500 ml water"
2528788|NCT02705560|Active Comparator|Soy based drink|Soy based drink Single dose, 600 ml soy drink (soy drink + plant based cream)
2528842|NCT02705248||Group A|(Group A) case group: 40 pregnant females at 6- 13wks presenting with a history of recurrent pregnancy loss (two or more failed clinical pregnancies as documented by ultrasonography or histopathology examination according to the American Society of Reproductive Medicine) (ASRM, 2008).
2528845|NCT02705248||Group B|control group: 40 pregnant females at 6- 13wks with no history of abortion.
2528882|NCT02704897|Experimental|Intervention Arm|"Wound assessment tool - delivered via a smartphone. A link will be sent to participants on discharge, which can be accessed at any point should they have concerns about their wound.~They will also be sent the tool at 3 additional time-points."
2528886|NCT02704897|No Intervention|Control Arm|Normal Post-operative Care
2528959|NCT02704416|No Intervention|Control arm|Control arm - continued implanted cardioverter defibrillator therapy
2528971|NCT02704416|Active Comparator|Intervention Arm|ablation of areas of fragmented signal in the right ventricular outflow tract plus continued implanted cardioverter defibrillator therapy
2528981|NCT02704416|Other|Single Cross Over Arm|these patients were initially assigned to the control arm of the study. When these patients met the primary outcome of the study it is allowed for these patients to be included in the intervention arm and/or to start quinidine
2529062|NCT02703766|Active Comparator|Lean|"Lean individuals are defined as having body fat content less or equal to 25% in men and less than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
2529066|NCT02703766|Experimental|Obese|"obese individuals are defined as having body fat content more than 25% in men and more than 35% for women.~Overfeeding induced weight gain and subsequent weight loss"
2529092|NCT02703376|Other|Patients after esophageal surgery|Oral Prednisone for 12 weeks
2529153|NCT02703155|Other|Home Oral Glucose tolerance test kit|Providing children with Cystic Fibrosis between 10 and 17 years of age with Home Oral glucose tolerance test kit to screen Cystic fibrosis related Diabetes.
2528365|NCT02708160|Active Comparator|0.243% Fluoride Toothpaste|silica based fluoride toothpaste
2528418|NCT02707809|No Intervention|Control|Routine anesthesia care for kidney transplant
2528420|NCT02707809|Experimental|Dexmedetomidine|Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine
2528497|NCT02707562|Experimental|GLPG1837 dose 1, GLPG1837 dose 2, GLPG1837 dose 3|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
2528555|NCT02707003||AZ PACU|Observation of standard of care with capnography blinded
2528559|NCT02707003||TWH PACU|Observation of standard of care with capnography blinded
2528599|NCT02706756|Experimental|Education, exercise and manual therapy|"One group will receive education and advice, manual therapy that is applied toward the impairments of the subject, a prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Subjects will be seen twice weekly for 4 to 6 weeks, depending on the progression.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2528605|NCT02706756|Active Comparator|Education and exercise|"Group will receive a prescriptive intervention designed to strengthen the hip and surrounding regions as well as improve flexibility of the lower extremity. This group will not receive additional physiotherapy management but will be schedule bi-weekly to review the home exercises and to receive appropriate educational support.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2528608|NCT02706756|Placebo Comparator|Supervised neglect|"Group will receive supervised neglect. We will monitor this group for changes or emergent situations but no formal care will be provided.~All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care). All interventions will be provided by licensed physical therapists that are named as investigators in this study."
2528735|NCT02706002|Active Comparator|hip prosthesis under fluoroscopy|implantation of femoral stem of hip prosthesis in this group of patients are under fluoroscopic guidance for stem size and stem alignment and last rap before original stem implantation will be checked for alignment , lateral and vertical offsets parameters.
2528744|NCT02706002|Sham Comparator|hip prosthesis without fluoroscopy|in this group of patients rasping of femoral canal during hip prosthesis is made via anatomic landmarks which confirmed by to senior surgeons and than original stem implanted.
2528794|NCT02705677||Rett syndrome|This is a biobanking project for individuals with mutations in MECP2 or meeting diagnostic criteria for classic (typical) or variant (atypical) Rett syndrome in order to identify other genetic factors such as X-chromosome inactivation or genetic background that may explain the variations noted in these individuals, including those with the same MECP2 mutation. No interventions are anticipated.
2528795|NCT02705677||MECP2 Duplication disorder|This is a biobanking project for individuals with MECP2 duplications to understand the difference in the size of the duplication and the potential impact of other genes in the duplicated segment. No interventions are anticipated.
2528796|NCT02705677||Rett-related disorders: CDKL5, FOXG1|This is a biobanking project for individuals with mutations in MECP2, CDKL5, and FOXG1 to understand the interplay of mutations in these individuals and the resultant phenotypic expression; for example, individuals with mutations in MECP2 but not meeting diagnostic criteria for Rett syndrome or individuals with mutations in CDKL5 or FOXG1 who may or may not meet diagnostic criteria for atypical Rett syndrome. No interventions are anticipated.
3200370|NCT00890123|Active Comparator|Omegaven|Patients in this arm will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively.
3200371|NCT00890123|No Intervention|Without Omegaven|Patients will not receive IV Omega 3 fatty acids
2528923|NCT02704559|Experimental|Study effect of DWC20156 on DWC20155 PK|To study effect of DWC20156 on DWC20155 PK
2528924|NCT02704559|Experimental|Study effect of DWC20155 on DWC20156 PK|To study effect of DWC20155 on DWC20156 PK
2528949|NCT02704195|Active Comparator|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
2528956|NCT02704195|Experimental|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
2528986|NCT02704000|No Intervention|Control|No interventions - only baseline and endline assessments to be conducted at children's home.
2528996|NCT02704000|Experimental|Home visits by CDAs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained child development agents (CDAs). CDAs will implement the Jamaica curriculum intervention during the home visits..
2529002|NCT02704000|Experimental|Home visits by CHWs|Intervention: Behavioral: Home visiting program (Jamaica curriculum) Children in this intervention arm will be visited twice a months by trained community health workers (CHWs) trained on delivering the intervention. CHWs will implement the Jamaica curriculum intervention during the home visits..
2529083|NCT02703740|Experimental|HA 20 mg/mL|
2529084|NCT02703740|Experimental|HA 24 mg/mL|
2529122|NCT02703233|Active Comparator|Nitrous Oxide|Patients receive nitrous oxide via mask.
2529130|NCT02703233|Placebo Comparator|Placebo (Oxygen)|Patients receive oxygen via mask.
3200372|NCT00890149|Experimental|Ondansetron|Ondansetron + BASICS Plus
3200373|NCT00890149|Placebo Comparator|Placebo|Placebo + BASICS Plus
3200374|NCT00890175|Experimental|Inhaled loxapine @ 0 & 10 h|Inhalation of 10 mg of loxapine at 0 and 10 hours
3200375|NCT00890175|Placebo Comparator|Inhaled placebo @ 2 & 10 hours|Inhalation of 0 mg of loxapine (placebo) at 0 and 10 hours
3200376|NCT00890188|Experimental|THALIDOMIDE and UFUR|
2528373|NCT02708264|Experimental|Cervical Pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 36th week of pregnancy (or earlier if indicated)
2528382|NCT02708264|No Intervention|No intervention|No pessary No pessary will be used. Subjects will receive standard obstetrical management
3200377|NCT00890214|Active Comparator|1 prostacyclin group|prostacyclin analogue (PGIA) used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
3200378|NCT00890214|Active Comparator|2 heparin group|unfractionated heparin used as circuit anticoagulant during continuous venovenous hemodiafiltration (CVVHDF) in acute kidney failure patients
2528502|NCT02707328|Experimental|A|"Chemotherapy:~Gemcitabine 1000 mg/m2 and Abraxane 125 mg/m2 weekly x3 of 28 day cycle~Radiation:~20-55 GY over 5 fractions~Dosing schedule: 3 cycles of chemotherapy, followed by CyberKnife, followed by 3 additional cycles of chemotherapy."
3200379|NCT00890227|Active Comparator|Traditional technique|All level open instrumented posterior spinal fusions
3200380|NCT00890227|Active Comparator|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
3200381|NCT00890253|Experimental|CNI-free Immunosuppression|Immunosuppression after OLT including basiliximab, enteric-coated mycophenolate sodium (EC-MPS), and everolimus.
3200382|NCT00890279|Experimental|Cilnidipine|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group A, blood pressure is controlled by Candesartan plus Cilnidipine.
3200383|NCT00890279|Active Comparator|Imidapril|The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
3200384|NCT00890305|Experimental|CT-011 in combination with FOLFOX|"CT-011 (3 mg/kg) administered intravenously every 4 weeks for 4 weeks and every 12 weeks thereafter until disease progression or maximum tolerance.~FOLFOX (FOLFOX4 or mFOLFOX6) administered 7 days after the first administration of CT-011 and repeated every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation."
3200385|NCT00890305|Active Comparator|FOLFOX|FOLFOX (FOLFOX-4 or mFOLFOX6) administered every 14 days for up to 24 cycles. At the end of FOLFOX therapy, patients who have not progressed will be eligible for maintenance chemotherapy with 5-FU/leucovorin at the same dose and schedule until disease progression or study drug discontinuation.
3200386|NCT00890318|Other|1|Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole
3200387|NCT00890318|Other|2|Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.
3200388|NCT00890318|Other|3|Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.
3200389|NCT00890331|Active Comparator|Diabetes Education|
3200390|NCT00890331|Experimental|TeamWork CS Sessions|
2528758|NCT02705755|Experimental|TD-9855 Part A|Subjects will receive placebo and escalating single doses of TD-9855
2529177|NCT02702856||Men screened for prostate cancer|
3200391|NCT00890357||Triptan User|
3200392|NCT00890357||Triptan Discontinued|
3200393|NCT00890370|Other|1|Active cycle of breathing techniques
3200394|NCT00890370|Other|2|Autogenic drainage
3200395|NCT00890370|Other|3|R-C Cornet
3200396|NCT00890370|Other|4|Flutter
3200397|NCT00890370|Other|5|PEP
3200398|NCT00890383|No Intervention|Crystalloid only|patients will receive crystalloid fluids only for volume therapy of severe trauma
3200399|NCT00890383|Active Comparator|Colloid + Crystalloid arm|Goal directed volume therapy for severe trauma resuscitation
3200400|NCT00890422|Experimental|1FSME vaccination|2 vaccination on day 0
3200401|NCT00890422|Experimental|2 FSME vaccination|1 vaccination on day 0 and one vaccination on day 4
3200402|NCT00890422|Experimental|3 FSME vaccination|2 vaccinations on day 0 and 1 vaccination on day 4
3200403|NCT00890448||Lapaquistat acetate participants|
3200404|NCT00890461||Defibrillator|The subject population will be obtained by approaching the Principal and Co- Investigators' patients who have been referred for ICD implantation or who already have an ICD. This population ranges in age from 18 years on, and includes both males and females. A maximum of 50 subjects will be enrolled in this study.
3200405|NCT00890474|Experimental|Moxibustion|
3200406|NCT00890474|No Intervention|Control|
3200407|NCT00890487|Other|hyaluroni acid pill|
3200408|NCT00890500|Active Comparator|Group 1|2 umbilical cord units: Second cord blood unit modulated with ProHema
3200409|NCT00890500|Active Comparator|Group 2|2 umbilical cord units: First cord blood unit modulated with ProHema
3200410|NCT00890526|Experimental|1|Full treatment = Counseling + sound therapy.
3200411|NCT00890526|Experimental|2|Counseling + placebo sound therapy.
3200412|NCT00890526|Experimental|3|No Counseling + Sound Therapy
3200413|NCT00890526|Placebo Comparator|4|No counseling + Placebo sound therapy.
3200414|NCT00890539|Experimental|Quadrupling|methacholine challenge using quadrupling concentrations
3200415|NCT00890539|Active Comparator|doubling|doubling concentrations of methacholine
3200416|NCT00890565|Experimental|Treatment A: Sancuso® patch|Treatment A: Sancuso® patch (Day 1) and placebo IV (Day 3)
3200417|NCT00890565|Experimental|Treatment B: IV Granisetron 10 mcg/kg|Treatment B: placebo patch (Day 1) and granisetron IV (Day 3)
3200418|NCT00890565|Placebo Comparator|Treatment C: Matching placebo patch|Treatment C: placebo patch (Day 1) and placebo IV (Day 3)
3200419|NCT00890565|Active Comparator|Treatment D: Oral Moxifloxacin 400 mg|Treatment D: placebo patch (Day 1) and oral moxifloxacin (Day 3).
3200420|NCT00890578||1-abdominal|half abdominal surgeries (20 patients out of 40)
3200421|NCT00890578||2-breast|half breast surgeries (20 out of 40)
3200422|NCT00890604|Other|1|Usual Care
3200423|NCT00890604|Experimental|2|Normothermia Protocol
3200424|NCT00890630|Active Comparator|Oxytocin|Induction of Labour with Oxytocin Alone
2528377|NCT02708251|Experimental|glyceryl trinitrate cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL glyceryl trinitrate cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
2528384|NCT02708251|Experimental|lidocaine cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine. 1 mL lidocaine creamwill be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
2528387|NCT02708251|Placebo Comparator|placebo cream|The clinician will perform a bimanual examination, place the speculum, and cleanse the cervix with Betadine.1 mL placebo cream will be placed on the cervix at the anterior lip and 1 mL in the cervix up to the level of the internal os using cotton swab.
3200425|NCT00890630|Experimental|Intracervical Catheter|Insertion of an Intracervical Balloon Catheter plus administration of oxytocin for labour induction.
3200426|NCT00890643|Experimental|Arm 1|Persons with PTSD
3200427|NCT00890643|Placebo Comparator|Arm 2|Persons with PTSD
2528622|NCT02706548|Experimental|Occupational Therapy Intervention Group|Thirty-minute intervention in which the participant and interventionist discuss past medication taking performance, medication-related goals, and strategies to meet goals. Intervention is enhanced with motivational interviewing and therapeutic use of self.
2528627|NCT02706548|Active Comparator|Standard Care Intervention Group|Thirty-minute educational intervention in which the participant and interventionist review a pamphlet on adherence to medication.
2528661|NCT02706210||vascular cognitive disorders pre-dementia (VCD-P)|
2528665|NCT02706210||amnestic mild cognitive impairment (aMCI)|
2528723|NCT02706093|Other|High Intensity Interval Training #1|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2528724|NCT02706093|Other|Moderate intensity continuous training|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2528730|NCT02706093|Other|High Intensity Interval Training #2|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2528737|NCT02706093|Other|High Intensity Interval Training #3|Obese adults with impaired glucose tolerance will be randomized into one of four different exercise training groups for a 3 month exercise intervention.
2528774|NCT02705456|Experimental|HA-Tooth Paste|"Tooth Brushing HA~Cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
2528776|NCT02705456|Active Comparator|FL-Tooth Paste|"Tooth Brushing FL~Cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste twice daily over the duration of the study (24 weeks).~Professional caries prevention by professional supragingival tooth cleaning and the subsequent application of a 1% chlorhexidine gel once every 4 weeks over the duration of the study (24 weeks)."
2528846|NCT02705326|Experimental|Opti-Speech|Speech treatment will be guided by Opti-Speech's visual feedback of tongue movement during speech
2528912|NCT02704793|Experimental|Bilateral 1 Hz Cerebellar rTMS|Patients will be treated with 900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere for 5 consecutive days.
2528918|NCT02704793|Sham Comparator|Sham (electrical stimulation)|Sham treatment will be performed with the same protocol using a small device placed on the TMS coil (not visible to the patients) producing electrical stimulation (less than 3 mili amperes), to simulate the sensation of real TMS.
2528945|NCT02704312|Experimental|Radiotherapy techniques|Quantitative Physics: dosimetric comparison of doses in target volumes and organs at risk. The technique used is that of which the dose on the organs at risk is as low as possible, and whose dose to the target volume is the closest possible to the prescribed dose (100% of the prescribed dose)
3200428|NCT00890669|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
3200429|NCT00890708|No Intervention|non-TDM of voriconazole|conventional dose
2529134|NCT02703194|Experimental|Prednisone|Prednisone mono-therapy
2529135|NCT02703194|Experimental|Prednisone and Leflunomide|Prednisone and Leflunomide combination therapy
2529178|NCT02702908||mPC|Prostate cancer patients with bone metastases (mPC)
2529184|NCT02702908||mCRPC|Patients with castration-resistant prostate cancer with bone metastases (mCRPC)
2529200|NCT02702570|Other|CASA intervention|Each participant serves as his/her own control. Measures administered before and after an intervention.
2529266|NCT02702414|Experimental|Prior Systemic Therapy|Participants with previously systemically treated HCC receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
2529268|NCT02702414|Experimental|Systemic Therapy Naive|Participants with HCC who had not received treatment for systemic disease receive a pembrolizumab 200 mg intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations. Participants who stop pembrolizumab as a result of obtaining a confirmed complete response (CR) or those who stop after receiving 35 trial treatments may be eligible for an additional 17 trial treatments (approximately an additional 1 year of treatment) after progressive disease if they meet the criteria for re-treatment.
3200430|NCT00890708|Experimental|TDM of voriconazole|
2529894|NCT02698020|No Intervention|Control|High level of supplemental inspired oxygen
3200431|NCT00890734|Experimental|1|
3200432|NCT00890734|Placebo Comparator|2|
3200433|NCT00890747|Experimental|Treatment (sunitinib malate)|Patients receive sunitinib malate PO daily on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3200434|NCT00890760|Experimental|Group 1|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
2528450|NCT02707679|Other|Effects of Mulligan's Mobilization|The patients in this arm (n=18) received two techniques pertaining to Mulligan's Mobilization with movement approach (Mulligan's Straight Leg-Raise with Traction and Tibial Gliding) along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed before the treatment, 45 minutes after the initial treatment, at the end of the 4-session-treatment during 2-week period and 6 weeks later.
2528455|NCT02707679|Other|Effects of Kinesiotaping|Patients in this arm were applied kinesiotaping on quadriceps and hamstring muscle along with an exercise therapy. Patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. The same assessment parameters was conducted on this arm too.
2528478|NCT02707341||Psoriasis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
2528539|NCT02707263|Active Comparator|Intravenous continuous infusion of heparin (IV UFH)|Heparin will be administered intravenously.
2528544|NCT02707263|Active Comparator|Subcutaneous heparin|Heparin will be subcutaneously administered.
2528587|NCT02706821|Active Comparator|Treatment sequence 1|PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.
2528593|NCT02706821|Active Comparator|Treatment sequence 2|Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.
3166809|NCT00530036||Incontinent|"46% of 699 patients followed by the Fondation des Services d'Aide et de Soins à Domicile in Geneva and with an urinary incontinence"
2528747|NCT02705963|Experimental|Oral Contraceptive / Trametinib|In treatment period 1 of the PK Phase patients will take the Oral Contraceptive once daily from Days 1-5. Period 2 of the PK Phase starts on Day 6 when patients take both the Oral Contraceptive and trametinib once daily from Days 6 to 21. Patients may continue dosing with trametinib only once daily from Day 22 onwards (post PK Phase).
2528787|NCT02705430|No Intervention|A|Group A will continue their actual therapy (control).
2528789|NCT02705430|Experimental|B|Group B will continue their standard therapy with additional stress management application only using a mobile phone (Eco Fusion Mentally) for 3 months of the study
2528790|NCT02705430|Experimental|C|Group C will continue their standard therapy with additional life style program using a mobile phone (Eco Mentally and NewMe) for 3 months of the study
2528793|NCT02705430|Experimental|D|Group D will continue their standard therapy plus additional life style program using a mobile phone with additional supplemental EPA and DHA capsules of 2 g/day to be taken daily for the 3 months of the study
2528827|NCT02705170||left ventricle dilatation|The subjects of the investigation will be patients with recent diagnosis of unknown left ventricle dilatation. These subjects received coronary artery angiography as exam suggested by guidelines to discriminate the cause of left ventricle dilatation. In subjects without documentation of coronary artery lesions, the Authors will assess the index of microvascular resistance.
2528906|NCT02704936||Male donor|42 samples of semen from male donor attached to a donation program Normal sperm count as WHO 2010.
2528910|NCT02704936||IUI positive pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and have obtained positive pregnancy in any of the first 4 treatments IUI
2528915|NCT02704936||IUI unsuccessful pregnancy|42 samples of semen from a program attached to patients for insemination Male indication Normal / slightly abnormal sperm count or infertility source unknown and after undergoing maximum 4 cycles have unsuccessfully IUI indication of IVF / ICSI.
2528934|NCT02704364|Experimental|NGM282 Dose 1|NGM282 Dose 1
2528935|NCT02704364|Experimental|NGM282 Dose 2|NGM282 Dose 2
2528937|NCT02704364|Active Comparator|Placebo|Placebo
2529013|NCT02703818|Experimental|Senza|Spinal Cord Stimulation for UEP
2529098|NCT02703727||OAC|Patients on oral anticoagulation therapy (OAC) will receive a pharmacists led medication review with a focus on anticoagulation therapy (extended polymedication check)
2529149|NCT02703142||Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
2529347|NCT02701920||NICU infants and sensor|Newborn infants of any gestation requiring heart rate monitoring on the neonatal intensive care unit.
3200435|NCT00890760|Experimental|Group 2|AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
3200436|NCT00890760|Experimental|Group 3|Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
3200437|NCT00890760|Experimental|Group 4|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
3200438|NCT00890760|Experimental|Group 5|AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
3200439|NCT00890760|Experimental|Group 6|Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
3200440|NCT00890760|Experimental|Group 7|Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
3200441|NCT00890760|Experimental|Group 8|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
3200442|NCT00890760|Experimental|Group 9|2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
3200443|NCT00890760|Experimental|Group 10|3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
3200444|NCT00890786|Experimental|HGG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the intervention section.
3200445|NCT00890786|Experimental|DIPG|Temozolomide, Bevacizumab, and Irinotecan according to the treatment schedule in the interventions section.
2528458|NCT02707692|Other|Arm 3: Flu, Placebo, Pneumovax|Arm 3: Flu, Placebo, Pneumovax
2528459|NCT02707692|Other|Arm 4: Pneumovax, Placebo, Flu|Arm 4: Pneumovax, Placebo, Flu
2528460|NCT02707692|Other|Arm 5: Pneumovax, Flu, Placebo|Arm 5: Pneumovax, Flu, Placebo
2528461|NCT02707692|Other|Arm 6: Flu, Pneumovax, Placebo|Arm 6: Flu, Pneumovax, Placebo
3200446|NCT00890799|Experimental|occluders|Shanghai pmVSD occluder (LEPU Medical Tech-nology Co, Ltd, Beijing, China) was used in this study.
3200447|NCT00890812||Factors VIII, IX and XI levels measured|Case group
2528662|NCT02706353|Experimental|APX005M + Pembrolizumab|"Dose Escalation Phase:~Starting dose level of APX005M is 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses. Tumor site chosen based on volume to be injected.~All participants receive Pembrolizumab at 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.~Dose Expansion Phase:~Starting dose level of APX005M is maximum tolerated dose from Dose Escalation Phase.~Participants receive same dosage of Pembrolizumab as in Dose Escalation Phase."
2528752|NCT02705937|Experimental|Dairy product|The product will be taken for 14 days
2528756|NCT02705937|Active Comparator|Aequasyal mouth spray medical device|The spray will be taken for 14 days
2528779|NCT02705508|Experimental|PEG group|Treatment PEG dosages were as follows: days 1 and 8,30min intravenous infusion of 1000mg/m2 gemcitabine;day1,4h intravenous infusion of 100mg/m2 etoposide,day1-3,deep intramuscular injection of 2500U/m2 Pegaspargase at three different sites.The regimen was repeated every 3 weeks.Stage IE/IIE patients underwent four cycles induction chemotherapy, followed by involved-field radiotherapy after got CR, PR or SD. Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved-field radiation (IFRT) dose was 50-56 Gy.Stage IIIE/IVE patients were given for a maximum of six cycles.
2528848|NCT02705209|Active Comparator|Treatment|
2528853|NCT02705209|Placebo Comparator|Control|
2528907|NCT02704728|Experimental|Thetanix|In Part A, 8 subjects will receive a single dose and in Part B, 8 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules
2528914|NCT02704728|Placebo Comparator|Placebo|In Part A, 2 subjects will receive a single dose and in Part B, 2 subjects will receive twice daily doses for 7.5 days (a total of 15 doses). Each dose consists of three capsules.
2528962|NCT02704221|Active Comparator|Behavioral Parent Training (BPT)|The control group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks and 2) attend 12 weekly BPT training sessions.
2528974|NCT02704221|Experimental|BPT + Contingency Management (BPT+CM)|The experimental group will include 10 participants who will 1) wear Fitbit activity trackers daily for 12 weeks, 2) attend 12 weekly BPT training sessions, and 3) receive monetary rewards for achieving weekly step-count goals.
2529007|NCT02703883|Experimental|Body Weight Support|Treatment protocol consisted of 18 training sessions on the BWST, three times a week, every session included three sets of six minutes of locomotion with rest intervals of 2 min of rest.
2529058|NCT02703714|Experimental|Treatment|Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive sargramostim subcutaneous injection (SC) on days 1-14 of courses 1-2 or 2-3. Treatment repeats every 21 days for up to 2 courses for sargramostim and for up to 35 courses (24 months) for pembrolizumab in the absence of disease or unaccepted toxicity.
3200448|NCT00890812||Non Stroke patients|This is the control group. This group represents patients who were initially evaluated for stroke.
3200449|NCT00890838|Active Comparator|Omegaven|will receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperatively
3200450|NCT00890838|No Intervention|Without Omegaven|will not receive IV Omega 3 fatty acids (Omegaven®) for 3 days preoperativel
3200451|NCT00890851|Other|Procedure TUNA|
2529195|NCT02702648|Experimental|AC-082, Single Ascending Dose|Subjects receive AC-082 at different single dose levels in a sequential manner, starting from 10 mg (number of cohorts and dose levels will depend on the safety and pharmacokinetic results of the previous cohort). Each subject can participate in only one dose level
2529196|NCT02702648|Placebo Comparator|Placebo, Single Ascending Dose|Subjects receive a single dose of the matched placebo
2529197|NCT02702648|Experimental|AC-082, Multiple Ascending Dose|Subjects receive AC-082 at different dose levels for 4 consecutive days in a sequential manner (dose levels and duration to be adapted according to the results of the single ascending dose cohorts). Each subject can participate in only one dose level
2529198|NCT02702648|Placebo Comparator|Placebo, Multiple Ascending Dose|Subjects receive the matched placebo for 4 days
3200452|NCT00890864|Active Comparator|1|Women aged 47-49 invited for breast screening
3200453|NCT00890864|Active Comparator|2|Women aged 71-73 invited for breast screening
3200454|NCT00890877|Experimental|1|
3200455|NCT00890877|Experimental|2|
2529388|NCT02701491|Experimental|Ginger|Ginger
2529393|NCT02701491|Placebo Comparator|Placebo|Placebo-no intervention
2529434|NCT02701140|Active Comparator|Ticagrelor|Ticagrelor will be given in a loading dose of 180 mg followed by a dose of 90 mg twice daily.
2529442|NCT02701140|Active Comparator|Clopidogrel|Clopidogrel will be given in a loading dose of 600 mg followed by a dose of 75 mg once a day.
2529500|NCT02700620|Experimental|Treatment group|Internet-delivered CBT
2529506|NCT02700620|No Intervention|Control group|Waitlist control
2529747|NCT02698943||Study Group|Participants who underwent phacoemulsification surgery and implantation of the Envista MX-60 IOL
3200456|NCT00890877|Experimental|3|
3200457|NCT00890877|Experimental|4|
3200458|NCT00890890|Experimental|Avagacestat (50 mg)|
3200459|NCT00890890|Placebo Comparator|Placebo|
3200460|NCT00890903||NSCLC|Patients with advanced non-small cell lung cancer
3200461|NCT00890903||MBC|Female patients with metastatic, Anthracycline-resistent breast cancer
3200462|NCT00890942|Experimental|naloxone|
3200463|NCT00890942|Placebo Comparator|normal saline|
2528481|NCT02707497|Experimental|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
2528483|NCT02707497|Placebo Comparator|placebo|The control group will not use any platelet-increased drugs.
2528536|NCT02707107|Active Comparator|3 g of zidebactam (1 g q8h) and 6 g of cefepime (2 g q8h) or 6|administered as IV infusions every q8h, over a period of 60 minutes.
2528542|NCT02707107|Placebo Comparator|Placebo|administered as IV infusions every q8h, over a period of 60 minutes.
2528596|NCT02706860|Experimental|"80 mg atorvastatin for 2 days regimen"|80 mg atorvastatin/ day for 2 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2528603|NCT02706860|Experimental|"40 mg atorvastatin for 5-9 days preoperative regime"|40 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2528607|NCT02706860|Experimental|"80 mg atorvastatin for 5-9 days preoperative regime"|80 mg atorvastatin/ day for 5-9 days before coronary artery bypass grafting. This dose was restarted postoperative and continued for 1 month.
2528670|NCT02706340||Vaginal delivery|Women who have had a copper IUD placed within 10 minutes of a vaginal delivery of at least 34 weeks 0 days gestation.
2528672|NCT02706340||Cesarean delivery|Women who have had a copper IUD placed within 10 minutes of a cesarean delivery of at least 34 weeks 0 days gestation.
2528725|NCT02706054|Placebo Comparator|C-group|patients receiving an IM saline injection near the nerve root (periradicular)
2528731|NCT02706054|Experimental|M-group|patients receiving an IM Meloxicam injection near the nerve root (periradicular)
3200464|NCT00890955|Experimental|1|"Amrubicin + Cyclophosphamide 3+3 design with the following dose levels:~Dose Level -1: Amrubicin 20mg/m2, Cyclophosphamide 500mg/m2~Dose Level 1: Amrubicin 25mg/m2, Cyclophosphamide 500mg/m2~Dose Level 2: Amrubicin 30mg/m2, Cyclophosphamide 500mg/m2~Dose Level 3: Amrubicin 35mg/m2, Cyclophosphamide 500mg/m2~Dose Level 4: Amrubicin 40mg/m2, Cyclophosphamide 500mg/m2"
2528828|NCT02705183|Active Comparator|A: Surgery & Post-operative radiotherapy|Surgery & Post-operative radiotherapy
2528830|NCT02705183|No Intervention|B: Surgery only|Surgery only
2528873|NCT02704884|Experimental|probiotic soy milk|consume a diet containing 200 ml/day probiotic soy milk in intervention group
2528881|NCT02704884|Active Comparator|soy milk|200 ml/day soy milk in the control condition
2528931|NCT02704546|Experimental|Methylphenidate|In experimental days taking MPH, subjects will take 20mg Ritalin® (Novartis AG) in two tablets of 10mg, by swallow 1 hour prior to performing the physical test.
2528933|NCT02704546|Placebo Comparator|Placebo|In experimental days with placebo subjects will be asked to ingest 2 capsules identical to Ritalin® capsules, by swallow 1 hour prior to performing the physical test.
2529018|NCT02704117|Experimental|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation applied over the pre-supplementary motor area (pSMA), for ten sessions, Monday through Friday, over the course of two weeks.
2529050|NCT02703584|Experimental|Double trigger|Triggering of ovulation with GnRH agonist ( Suprefact 0.5mg) + hCG ( Pregnyl 10,000IU)
2529054|NCT02703584|Placebo Comparator|control|Triggering of ovulation with hCH ( Pregnyl 10,000IU) + Placebo
2529127|NCT02703285|Experimental|questionnaire|task of the participants in the study to determine the chest sound based on specific sounds
2529154|NCT02703012|Experimental|Adjustment of ventilator settings by EIT|Individual Adjustment of Ventilator settings using an algorithm based on electrical impedance tomography.
2529208|NCT02702752|Other|DYNASDY|The study considers changes in SDF-1α levels in response to treatment of cardiac disease (myocardial infarction, heart failure or atrial fibrillation). SDF-1α levels will be measured at the acute stages of the disease, after stabilization and at longer term as detailed below. Levels of SDF-1α will be correlated to the outcome of disease.
2529210|NCT02702752|Active Comparator|Control group|A control group of 20 subjects without cardiac disease (including hypertension), diabetes, hypercholesterolemia, and malignant disease.
2529271|NCT02702362|Active Comparator|anodal stimulation|"Patients received anodal tDCS (on the precuneus ) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS.~A final CRS-R is performed 5 days after the end of the session to assess the potential long term effects of the tDCS."
2529275|NCT02702362|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed 5 days after the end of the session.
2529352|NCT02701881|Experimental|Long stenting group|
2529354|NCT02701881|Active Comparator|Short stenting group|
3200465|NCT00890968|Experimental|Triamcinolone Acetonide (TAC) DuraPeel|
3200466|NCT00890968|Placebo Comparator|Placebo|
3200467|NCT00890994||Suspected breast cancer|
2529433|NCT02700867|Experimental|Proximal tibia|Assumption of intraosseous access into the proximal tibia. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
2529438|NCT02700867|Experimental|Proximal humerus|Assumption of intraosseous access into the proximal humerus. Simulation of continous resuscitation was carried out using a system of chest compression LifeLine ARM.
2529558|NCT02700802|Experimental|Feed1st: Face-to-face provider delivered referral|In this arm of the study, caregivers will receive usual care and a brief face-to-face referral to the Feed1st program delivered by the provider.
2529560|NCT02700802|Experimental|Feed1st: Text message delivered referral|In this arm of the study, caregivers will receive usual care and an automated brief text message referral to the Feed1st program from the health care provider. The text message referral will align as closely as possible with the face-to-face referral.
2529563|NCT02700802|No Intervention|Standard of Care|Usual care includes passive delivery of information from nursing staff about all available food options in the hospital including the self-serve food pantries in the standard Caregiver FYI Admissions Packet.
2529795|NCT02698631|Experimental|LGE-MRI guided AF ablation.|Fibrosis information obtained from post-processed LGE-MRI will be used to guide AF ablation procedures.
3200468|NCT00891007|Experimental|Group 1|
3200469|NCT00891007|Experimental|Group 2|
3200470|NCT00891007|Active Comparator|Group 3|
3200471|NCT00891033|Experimental|Cohort 1|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 5 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3200472|NCT00891033|Experimental|Cohort 2|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 10 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3200473|NCT00891033|Experimental|Cohort 3|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 15 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
3200474|NCT00891033|Experimental|Cohort 4|1 mg/m2 IV Bortezomib on days 1, 4, 8, and 11 of Cycles 1 and 2 and 20 mg/m2 IV Panobinostat on days 1 and 8 of Cycle 2.
2528778|NCT02705495|Active Comparator|acupuncture|12 acupuncture treatments according to a standardized protocol, plus recommendation for use of cranberry products
2528780|NCT02705495|Other|Control|Recommendation for use of cranberry products only
2528850|NCT02705274|Active Comparator|Prompt Panretinal Photocoagulation|PRP= Panretinal Photocoagulation. PRP alone.
2528854|NCT02705274|Experimental|Bevacizumab with deferred PRP|Bevacizumab = Anti vascular endothelial growth factor. PRP= Panretinal photocoagulation. Intravitreal anti-VEGF with PRP only if indicated.
2528878|NCT02704715|Other|general anesthesia,orbital operation|"diagnosed as orbital disease and ocular tumor~over 16 years old~orbital operation under general anesthesia"
2528989|NCT02704052|Active Comparator|Standard enoxaparin dose|We will identify a convenience sample of surgical patients placed on enoxaparin prophylaxis at their attending surgeon's discretion-the proposed research will not dictate the initial enoxaparin dose magnitude or frequency. However, we will identify patients already on enoxaparin, evaluate peak and trough steady state aFXa levels, and adjust patient's dose if necessary based on steady state aFXa levels. Eligible patients will have enoxaparin prophylaxis started within 36 after surgery at their surgeon's discretion. Steady state peak and trough aFXa levels will be drawn at 4 and 12 hours, respectively, after the third enoxaparin dose. Goal peak aFXa levels will be 0.2-0.4 IU/mL for twice daily dosing and 0.3-0.5 IU/mL for once daily dosing.
2528998|NCT02704052|Experimental|Real time enoxaparin dose adjustment|Patients with identified out of range levels will receive pharmacist-driven real time enoxaparin dose adjustment and will receive followup steady state peak and trough aFXa levels. aFXa monitoring will be discontinued when in range peak levels are obtained, when enoxaparin prophylaxis is discontinued at surgeon discretion, or when the patient is discharged. Patients may be continued on enoxaparin prophylaxis after discharge per attending surgeon discretion but aFXa levels will not be followed in the outpatient environment.
3200475|NCT00891059||Placebo Diskus Inhaler|
2529152|NCT02702934|Experimental|High-amylose rusks|Test meal with 100g of carbohydrates coming from high-amylose rusks
2529155|NCT02702934|Active Comparator|Control rusks|Test meal with 100g of carbohydrates coming from regular rusks used as control
2529204|NCT02702726|No Intervention|Congee and juice only|Control breakfast providing 50g carbohydrate
2529214|NCT02702726|Active Comparator|Congee and juice with coconut gel|Control breakfast, plus 25g coconut oleogel (solid)
2529218|NCT02702726|Active Comparator|Congee and juice with coconut oil|Control breakfast, plus 25g coconut oil (liquid)
2529220|NCT02702726|Active Comparator|Congee and juice with sunflower gel|Control breakfast, plus 25g sunflower oleogel (solid)
2529223|NCT02702726|Active Comparator|Congee and juice with sunflower oil|Control breakfast, plus 25g sunflower oil (liquid)
2529280|NCT02702271|Experimental|WATCHMAN FLX|WATCHMAN FLX implant: This is a single arm study
2529358|NCT02701608|Experimental|Oral switch treatment|Oral switch to the combination of levofloxacin and rifampicin
2529361|NCT02701608|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of staphylococci IE (European guidelines 2015)
2529431|NCT02700880||Heart failure patients with LifeVest|Subjects with ischemic cardiomyopathy and heart failure (including NYHA II, III, IV and an ejection fraction ≤ 35%) who wear a medically prescribed ZOLL LifeVest Wearable Defibrillator
3200476|NCT00891072|Experimental|Treatment|Patients receive oral R-(-)-gossypol acetic acid twice daily on days 1-3. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3200477|NCT00891085||Open Lung Ventilation|within 24 hours of arrival trauma patients with ISS >25 will be randomized to BiVent (APRV)
3200478|NCT00891085||SIMV|within 24 hours of arrival trauma patients with ISS >25 will be randomized to either SIMV or BiVent
3200479|NCT00891098|Active Comparator|Imaginal exposure|
2529646|NCT02699710|Experimental|Part 1: GDC-0853, Rabeprazole (Fasting State)|Participants will receive single dose of GDC-0853 (200 milligrams [mg]) in a crossover design as either the capsule or tablet formulation in the fasted state with the final fixed treatment consisting of the tablet formulation administered in the fasted state after prior administration of rabeprazole (20 mg twice daily [BID]) for 3 days.
2529651|NCT02699710|Experimental|Part 2: GDC-0853, Rabeprazole (Fasting or Fed State)|Participants will receive single dose of GDC-0853 (200 mg) tablet formulation in the fasted or fed state in a crossover design with the final fixed treatment consisting of the tablet formulation administered in the fed state after prior administration of rabeprazole (20 mg BID) for 3 days.
2529654|NCT02699710|Experimental|Part 3: GDC-0853, Methotrexate|Participants will receive single dose of methotrexate (7.5 mg) under fasting conditions on Day 1 (5 mg folic acid will be administered the following day [Day 2]) and then GDC-0853 (200 mg) tablet formulation twice daily (BID) under fasting conditions (an overnight fast for the morning dose and a 2 hour fast for the evening dose) from Days 15 to 20 after washout period from Days 2 to 14. On Day 21, participants will receive single dose of methotrexate (7.5 mg) with single dose of GDC-0853 (200 mg) tablet formulation under fasting conditions, and folic acid (5 mg) will be administered on Day 22.
2529678|NCT02699320||"Asymptomatic"|"Asymptomatic meaning patients showed well tolerance to parenteral nutrient (PN) administration and there were no complications occurred within two months (n=7);"
2529832|NCT02698267|Experimental|BIIB074|Administered orally on Day 1 and Day 11
3200480|NCT00891098|Experimental|Imagery rescripting|
3200481|NCT00891111|Experimental|Direct Payment|Direct Payment: Employees receive a $25 gift card upon completion of a Health Risk Assessment
2528594|NCT02706574||Isolated Traumatic Brain Injury|This group will present to our Level 1 Trauma Center with a Traumatic Brain Injury and no other associated injuries. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2528602|NCT02706574||Isolated Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient with no injury to their head. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2528606|NCT02706574||Combined Traumatic Brain Injury and Body Trauma|This group will present to our Level 1 Trauma Center as a trauma patient that had injuries to both their head and body. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2528609|NCT02706574||Healthy, Uninjured Controls|This group will consist of subjects that have not been exposed to any major trauma in the previous 12 months. They will be older than age 4, have no major neurologic or psychiatric disorder, be developmentally normal, and will not be prisoners.
2528623|NCT02706457||cohort 2012 - 2014|all patients admitted for > 48 hours on the Intensive Care Unit in 2012, 2013 and 2014
2528669|NCT02706236|Active Comparator|Intervention Arm|Pancreatic enzyme replacement (Pancrelipase) with meals and snacks daily, for 4 weeks.
2528676|NCT02706236|Placebo Comparator|Placebo Arm|Lactose placebo tablets with meals and snacks, for 4 weeks.
2528743|NCT02705976|Active Comparator|self-managing warfarin|self-managing warfarin patients who are educated in dosing warfarin to achieve target INR value
2528749|NCT02705976|Experimental|algorithm-suggested warfarin dosing|algorithm-suggested warfarin dosing, where the participants are provided with a dosage suggestion of their warfarin dosage (calculated dose) to achieve target INR
2528808|NCT02705638|Experimental|Rituximab and Lenalidomide|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15, as well as Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
2528831|NCT02705066|Placebo Comparator|Placebo (Cellulose)|
2528835|NCT02705066|Experimental|Cognizin 250 mg/day|
2528839|NCT02705066|Experimental|Cognizin 500 mg/day|
2528877|NCT02704819|Experimental|Non-specialist doctor +DSS|"Patients allocated to +DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor with the support of the DSS~V2: appointment with an overseeing expert~V3: DSS Customised Vestibular Physiotherapy~V4: follow-up visit with the overseeing expert"
2528888|NCT02704819|Active Comparator|Non-specialist doctor -DSS|"Patients allocated to -DSS group will receive the following intervention:~V1: appointment with a non-specialist doctor without the support of the DSS~V2: appointment with an overseeing expert~V3: Standard Physiotherapy Practice~V4: follow-up visit with the overseeing expert"
2528975|NCT02704208|Experimental|Behavioral: Thrive With Me Intervention|Participants randomized to the TWM Intervention will gain access to a website for 150 days. The TWM website includes: peer-to-peer support through a private social network and optimized gaming features; daily SMS communication for medication reminders and mood tracking; medication adherence monitoring; and tailored HIV informational content.
2528980|NCT02704208|Placebo Comparator|Behavioral: Thrive With Me Control|Participants randomized to the TWM Control group will receive HIV related content through a weekly web link. The web links will be static pages (not interactive) with information aimed at improving overall wellbeing while living with HIV, but not focused on improving ART medication adherence.
2529019|NCT02703922|Other|GCA suspicion|A first screening is performed using color Doppler ultrasound. In case of negative results, patients undergo TAB.
2529057|NCT02703571|Experimental|Advanced or metastatic solid tumors|Patients in the Phase I portion of the study who have advanced or metastatic solid tumors
2529121|NCT02703207|Active Comparator|Positive airway pressure therapy|Control group patients will receive standard care with PAP- positive airway pressure.
2529125|NCT02703207|No Intervention|COPD|The COPD control group will be patients with moderate-to-severe COPD alone per the GOLD criteria.
2529133|NCT02703207|No Intervention|OSA and comorbid COPD|Eligible elderly (age >/=60yrs) Veterans with moderate to severe Overlap Syndrome.
2529150|NCT02702960|Experimental|part. liver transplant and BMT|"Patients receive living related donor partial liver transplantation performed according to standard practices. Patients will be maintained on tacrolimus, MMF, and prednisone after liver transplantation.~Upon recovery, patient must undergo eligibility screening for bone marrow transplantation (BMT).~If eligible, patients will begin:~Antithymocyte globulin (ATG): Day -16 to Day -14; fludarabine: Days -6 to Day -2 low-dose cyclophosphamide: Day -6 and -5. Tacrolimus, mycophenolate mofetil (MMF), and prednisone: day -7 and day -6. Total body irradiation on Day -1 Bone marrow infusion on Day 0. High dose cyclophosphamide plus MESNA: Day 3 and 4th Filgrastim, tacrolimus,MMF, and prednisone: Day 5 until neutrophil counts recover.~Patients followed up through post transplant day 60, then weekly following discharge."
2529243|NCT02702492|Experimental|KPT-9274|"Part A: [CLOSED TO ENROLLMENT]~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
2529244|NCT02702492|Experimental|KPT-9274 & Niacin Extended Release (ER)|"Part B:[CLOSED TO ENROLLMENT]~500 mg niacin ER co-administered with each dose of oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle."
2529245|NCT02702492|Experimental|KPT-9274 + Nivolumab|"Part C:~Oral KPT-9274 three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28 day cycle.~Nivolumab 480 mg IV administered Day 1 during each 28 day cycle."
2529302|NCT02702089||IAPE|Intersphincteric AP excision
2529309|NCT02702089||HP|Hartmann's procedure
2529326|NCT02701712|Experimental|Magnetic resonance - guided radiation therapy (MRgRT)|Magnetic resonance (MR) - guided radiation therapy
2529389|NCT02701504||Sleep apnea group|The patients who are found to have sleep apnea based on the results of the portable sleep study
2529392|NCT02701504||Non sleep apnea group|The patients who are found to have no sleep apnea based on the results of the portable sleep study
2529680|NCT02699320||CLABSI|with central catheter-related blood stream infections (CLABSI) meaning patients had fever, increased neutrophils, documented positive catheter blood culture but exclude other source of infection (n=5)
2529919|NCT02697526|Other|Terumo|Patients in this arm will receive Terumo after catheterization
2528598|NCT02706600|Active Comparator|Online Self Management|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary, pulmonary rehabilitation videos to promote and support exercises that can be done in the home.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
3200482|NCT00891111|Experimental|Regret Lottery|Regret Lottery: Employees are divided into work units of about 5 employees. Employees in the lottery-linked incentive condition will be eligible for a weekly lottery drawing only if they have already completed their health risk assessment. The lotteries will work as follows. Participants will be assigned to work units of about 10 people. Each week, one work group is drawn at random. If a participants group was drawn and that participant already completed the health risk assessment, then that person will win a $100 cash prize. If all of the members of his or her work group also filled out the health risk assessment, then the prize will be boosted.
3200483|NCT00891124||1|Type II DM and Hypertension and/or Hyperlipidemia
3200484|NCT00891137|Experimental|Group A|Low dose, single donor CLT-008 (human myeloid progenitor cells)
2528712|NCT02705846||BRCA1 mutation carriers|Men with a known pathogenic germline BRCA1 mutation
2528713|NCT02705846||BRCA2 mutation carriers|Men with a known pathogenic germline BRCA2 mutation
2528714|NCT02705846||BRCA1 controls|Men known not to carry a pathogenic germline BRCA1 mutation
2528715|NCT02705846||BRCA2 controls|Men known not to carry a pathogenic germline BRCA2 mutation
2528762|NCT02705768|No Intervention|Healthy control|Twenty five (25) healthy individuals of same age group will serve as the control group. Control subjects will be evaluated at baseline only.
2528763|NCT02705768|Experimental|Carbamazepine group|Twenty five (25) patients recruited in this group will receive Tab. Carbamazepine. Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
2528764|NCT02705768|Experimental|Oxcarbazepine group|Twenty five (25) patients recruited in this group will receive Tab. Oxcarbazepine. Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
2528802|NCT02705417||Group A|Patients in whom selection of vascular access relied upon physical examination and medical history, during pre-operative surgical assessment
2528804|NCT02705417||Group B|Patients who underwent vascular mapping using color Doppler Ultrasonography in addition to physical examination and history during pre-operative evaluation.
2528847|NCT02705040||Normal|bone mineral density T>=-1.0
2528849|NCT02705040||Osteopenia|bone mineral density -1.0>T>=-2.5
2528852|NCT02705040||Osteoporosis|bone mineral density T<-2.5
2528872|NCT02704637|Experimental|HS-1000 recording|Each non-invasive recording session with the HS-1000 device will be done for 10 consecutive uninterrupted minutes. Patients will be recorded once daily for the duration of their time in ICU or for up to 14 days total. In the case the PI or a member of the study team positively confirms vasospasm based on clinical assessment or follow-up care during the monitoring period, the patient will be recorded twice daily for up to 14 consecutive days or for their duration in the ICU.
2528970|NCT02704507|Experimental|Topical steroid|Topical retinoid plus topical steroid applied daily to half of the face for 4 weeks, followed by 4 weeks of topical tretinoin. Patients will be randomized to which side receives the topical steroid.
2528977|NCT02704507|Placebo Comparator|Topical emollient|Topical retinoid plus topical emollient applied daily to the opposite half of the face for 4 weeks, followed by 4 weeks of topical tretinoin.
2528991|NCT02703896|Placebo Comparator|Group C (placebo)|"Drug intervention Two doses of Placebo at 8.00 pm and then at 6.00 am~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)~Group C (placebo)"
2529000|NCT02703896|Active Comparator|Either PPIs or H2RAs|"Drug Intervention Two doses at 8.00 pm and then at 6.00 am~Group L (lansoprazole 15 mg)~Group E(esomeprazole 20 mg)~Group P (pantoprazole 20 mg)~Group R (rabeprazole 10 mg)~Group O (omeprazole 20 mg)~Group T (cimetidine 200 mg)~Group F (famotidine 20 mg)~Group N (nizatidine 150 mg)~Group Z (ranitidine 150 mg)~Group S (lafutidine 10 mg)"
2529009|NCT02703896|Active Comparator|Either PPIs or H2RAs+prokinetics|"Drug intervention Two doses at 8.00 pm and then at 6.00 am~Group L D (lansoprazole 15 mg+ domperidone 10 mg)~Group EM (esomeprazole 20 mg+metoclopramide 10 mg)~Group PD (pantoprazole 20 mg+domperidone 10)~Group RM (rabeprazole 10 mg+metoclopramide 10 mg)~Group OD (omeprazole 20 mg+domperidone 10)~Group TD (cimetidine 200 mg+domperidone 10)~Group FM (famotidine 20 mg+metoclopramide 10 mg)~Group NM (nizatidine 150 mg+metoclopramide 10 mg)~Group ZD (ranitidine 150 mg+ domperidone 10 mg)~Group SD (lafutidine 10 mg+domperidone 10 mg)"
2529014|NCT02703896|Active Comparator|Either PPIs or H2RAs+Prokinetic|Drug intervention Two doses at 8.00 pm and then at 6.00 am Group OM (omeprazole 20 mg +metoclopramide 10 mg) Group SM (lafutidine 10 mg + metoclopramide 10 mg )
2529015|NCT02703896|Other|Intervention Orogastric intubation|After general anesthesia, an oro-gastric tube was inserted through another endotracheal tube placed in upper esophagus into the stomach for aspiration of gastric contents.
2529076|NCT02703506|Experimental|Experimental. Pain Education Program|Ten group sessions of treatment with a patient education pain for chronic neck pain (biopsychosocial approach). The group sessions of 60-120 minutes twice a week with a maximum of 10 participants.
2529079|NCT02703506|Active Comparator|Control|"The control group: individualized session of physical therapy (TENS and exercise).~Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises ."
2529123|NCT02703298|Experimental|TRX-818|
2529161|NCT02703025|Experimental|GCB 70 administered group|Green coffee bean extract capsule 500mg, BD
2529209|NCT02702713|Active Comparator|Dairy BEF + egg placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Dairy BEF + 1 portion of Egg placebo + 1 portion of Bakery placebo
3200485|NCT00891137|Experimental|Group B|Low dose, multiple donor CLT-008 (human myeloid progenitor cells)
3200486|NCT00891137|Experimental|Group C|Intermediate dose, multiple donor CLT-008 (human myeloid progenitor cells)
3200487|NCT00891137|Experimental|Group D|High dose, multiple donor CLT-008 (human myeloid progenitor cells)
2529020|NCT02703805|Experimental|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors.
2529021|NCT02703805|Active Comparator|Standard YMCA membership|A 12 week standard YMCA membership.
2529078|NCT02703519|No Intervention|1 cesarean section|control group
2529081|NCT02703519|No Intervention|2 cesarean sections|control group
2529082|NCT02703519|Experimental|resection of uterine scar tissue|2 cesarean sections with resection of uterine scar tissue from first cesarean section
2529095|NCT02703246|Active Comparator|abdominal morcellation|Women randomized to this group will undergo abdominal morcellation.
2529097|NCT02703246|Active Comparator|vaginal morcellation|Women randomized to this group will undergo vaginal morcellation.
2529151|NCT02703129|Experimental|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
2529234|NCT02702765|Experimental|Wilsons disease|All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
2529259|NCT02702154|Experimental|High-frequency rTMS|20 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2529260|NCT02702154|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2529261|NCT02702154|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, twice daily, 5 days per week for 3 weeks
2529327|NCT02701933|Other|Ketamine-Saline|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, ketamine is administered on the first assessment and placebo (saline) is administered on the second assessment.
2529332|NCT02701933|Other|Saline-Ketamine|Each participant receives both ketamine and placebo (saline) in randomised order in a repeated-measures design. In this arm, placebo (saline) is administered on the first assessment and ketamine is administered on the second assessment.
3200488|NCT00891150|Active Comparator|oxytocin|group 1 will receive oxytocin solutions with 20U/500ml during cesarean section
3200489|NCT00891150|Active Comparator|oxytocin2|group 2 will receive oxytocin solutions with 30U/500ml during cesarean section
2529456|NCT02700893|Experimental|Atropine + propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
2529459|NCT02700893|Active Comparator|Atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
2529486|NCT02700659||UC monitoring patients|"Patients undergoing investigative cystoscopy for the detection of urothelial carcinoma as part of a standard-of-care schedule of investigations.~All patients will have urine samples taken and analyzed for NMP22 ELISA, NMP22 BladderChek, urine cytology and Cxbladder.~No results for any tests under evaluation in this study are provided to the clinician for diagnostic purposes."
2529550|NCT02700256||Patients undergoing a procedure|Patients will be asked to complete a baseline survey after enrollment. After surgery, enrollees who opt for the email/online access will receive an email upon discharge with a link to the WebCore site. Email will be sent at 9 am on postoperative day (POD) 2 to the email address the patient provided at consent. On post-operative days 2 through 6 the patient will be asked to complete a symptom inventory, they will receive an email with a link to the WebCore website, where they will be able to complete that day's survey. Enrollees who opt for the automated phone calls will complete their surveys via Interactive Voice Response (IVR), which will be automatically set-up to call the patient at 9 am on POD 2. Patients will complete phone surveys daily for 5 days. If the first phone call does not connect to the patient, a second phone call will be made at 10:00am. If the second call is unsuccessful a third & final call for that day will be placed at 11:00am.
2529612|NCT02700009|Experimental|Computer-assisted CBT (CCBT)|12 weeks of CCBT for depression
2529613|NCT02700009|Active Comparator|Treatment as Usual (TAU)|Treatment as usual by primary care physicians
3200490|NCT00891150|Active Comparator|oxytocin3|group 3 will receive oxytocin solutions with 40U/500ml during cesarean section
2529682|NCT02699320||PNALD|with parenteral nutrient associated liver disease (PNALD), meaning SBS patients showed elevated liver enzymes and bilirubin (n=14).
2529689|NCT02699320||healthy controls|Seven healthy infants who had added complementary were served as controls (n=7).
3200491|NCT00891163|Experimental|Synera|
3200492|NCT00891163|Placebo Comparator|Placebo|
3200493|NCT00891189||1 Control|Healthy participants without asthma
3200494|NCT00891189||2 Non-nocturnal asthma|Participants with non-nocturnal asthma
3200495|NCT00891189||3 Nocturnal asthma|Participants with nocturnal asthma
3200496|NCT00891241|Experimental|Cohort 1|Healthy Population
3200497|NCT00891241|Experimental|Cohort 2|Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement
3200498|NCT00891254|Active Comparator|1. Intraperitoneal repair|Patients with incisional hernia, 5 cm in diameter or with an area of 25 cm2, submitted to elective surgery
3200499|NCT00891254|Active Comparator|2. On-Lay repair|Patients with incisional hernia, with a diameter of 5 cm or an area of 25 cm2, submitted to elective surgery
3200500|NCT00891267|Experimental|Olmesartan medoxomil low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
3200501|NCT00891267|Experimental|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
3200502|NCT00891267|Active Comparator|Amlodipine|Amlodipine taken once daily for 6 weeks
3200503|NCT00891306|Experimental|Treatment arm|Gene Therapy
3200504|NCT00891332|Experimental|1|S-1 plus LV
2528689|NCT02706444|Active Comparator|Conventional Balloon Angioplasty|Conventional balloon angioplasty. After fistulogram, full expansion of conventional balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
2528693|NCT02706444|Active Comparator|Drug-Coated Balloon Angioplasty|Drug-coated balloon angioplasty. After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram
2528721|NCT02705950|Active Comparator|intrathecal baclofen bolus|In ITB bolus group: An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level. A 50 µg.
2528722|NCT02705950|Placebo Comparator|placebo|In the placebo group: 1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
2528836|NCT02705222|Active Comparator|D&C group|Women will undergo D&C
2528840|NCT02705222|Active Comparator|Hysteroscopy group|Women will undergo hysteroscopy
2528920|NCT02704832|No Intervention|Arm A|"Arm A Standard oncological care: patients will be treated according to daily oncological practices as defined for each type of cancer, in the Management protocol of Oncology written and validated by a group of expert oncologists. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months."
2528921|NCT02704832|Experimental|Arm B|"Arm B Geriatrician Intervention: patients will be treated according to the same Management protocol of Oncology than patients in the arm Standard oncological care.~Before the beginning of the medical treatment, a comprehensive geriatric assessment will be performed by the geriatrician and the nurse that will define a plan of geriatric management care, according to the Management protocol of Geriatrics.~The nurse, under the supervision of a geriatrician, will monitor implemented geriatric interventions. Phone follow-up will be performed every month for 6 months and at 9 months or during any change of situation according to a pre-established phone call plan. A full geriatric assessment by the geriatrician and the nurse will be performed at 6 and 12 months."
2529008|NCT02704169|Experimental|Spatially registered endoscopy for H&N cancer|
2529075|NCT02703701||Usual Care|Group enrolled during normal emergency department operating procedures (without a physician present at triage).
2529077|NCT02703701||Physician at Triage|Group enrolled while a physician is present at triage.
3200505|NCT00891358|Experimental|Focus Group|Participants in focus groups will meet and discuss their intervention needs.
3200506|NCT00891384|Experimental|1|25 mg lenalidomide
2529192|NCT02702817|Active Comparator|naproxen|naproxen sodium tablets 220 mg twice daily for two years
2529193|NCT02702817|Placebo Comparator|placebo|tablets identical in appearance to naproxen tablets twice daily for two years
2529240|NCT02702466|Experimental|Immediate SPA Therapy|6 day immediate SPA treatment (soon after randomization) and written information with physical exercises adapted to their pathology and also a program of healthcare at the USB key
2529242|NCT02702466|Active Comparator|Late SPA Therapy|Written information with physical exercises adapted to their pathology and a program of healthcare at the USB key and late 6 day SPA treatment
2529291|NCT02702141|Experimental|SGN-CD19B|
2529346|NCT02701621|Active Comparator|MIRT Group|Individuals underwent Multidisciplinary Intensive Rehabilitation Treatment. It consists of 4 weeks of physical therapy in a hospital setting with four daily sessions for five days and one hour of physical exercise on the sixth day.The duration of each session is about one hour. The first session comprises cardiovascular warm-up activities, relaxation and muscle-stretching. The second session includes aerobic exercises and the use of different devices: a stabilometric platform, treadmill plus, crossover, cycloergometer. The third is a session of occupational therapy. The last session includes one hour of speech therapy. The rehabilitation program can also include: robotic-assisted walking training, virtual reality training and meetings with a Psychologist.
2529349|NCT02701621|Experimental|MIRT-AT|"Patients underwent land-based therapy in association with aquatic therapy, three times per week for four weeks.~The land-based activities included the second and the third session of MIRT.~The water sessions were divided in 3 phases:~i) Warm Up Exercises. This phase lasted 10 minutes and comprised walking performances.~ii) Central session Training. This phase lasted 30-45 minutes and comprised trunk mobility exercises in standing position and sitting on a floating device, static and dynamic exercises. The successive balance training exercises comprised: maintaining balance with closed eyes; balance control with one leg resting on a step; postural control changing the support base.~iii) Cool-down. This phase lasted 5 minutes and comprised general stretching exercises and gentle walking."
2529451|NCT02701166|Experimental|Bezafibrate|Bezalip retard 400mg tablet
2529454|NCT02701166|Placebo Comparator|Placebo|Placebo 400mg tablet
2529483|NCT02700594|Active Comparator|Hip mobilization|Prone posterior-to-anterior Grade IV hip joint mobilization: The subject will be placed in prone on a treatment table. The intervening physical therapist will place the heel of his hand on the greater trochanter of the femur on the involved side provide rhythmic anterior-directed force. The subject will receive 3 bouts of 30 seconds of continuous mobilizations with 10 seconds rest in between bouts. For the prone posterior-to-anterior Grade IV hip joint mobilization, the intervening therapist will perform all 3 bouts in the same position.
2529511|NCT02700503|Experimental|Intervention|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
3200507|NCT00891384|Experimental|2|5 mg lenalidomide
3200508|NCT00891397|Experimental|1|Pregabalin group is made up of 20 patients. Patients will receive 150mg/day in two divided does. The patients will be assessed weekly and the dose can be increased to 300mg/day, if the patient does not report any decrease in pain. The following week the dose may be increased to 600mg/day if once again the patient reports no decrease in pain. This is also the maximum permissible does that will be given to the patient. If patient reports any side effects then the dose can be decreased once. The time period of 2 to 5 weeks will be the dose adjustment period. After which the drug maintenance period extends from week 5 to 12. All doses will be given in two divided doses/day.
2528766|NCT02705729|Active Comparator|Ketac Universal|Simplified glass ionomer tooth filling
2528767|NCT02705729|Active Comparator|Ketac Molar Quick|Glass ionomer tooth filling
2528799|NCT02705378|Active Comparator|Polyethylene glycol|17g power qday; reconstituted in water for naso/orogastric tube administration
2528803|NCT02705378|Experimental|naloxegol|25mg qday; crushed pill reconstituted in water for naso/orogastric tube administration
2528841|NCT02705092|Experimental|Subliminal priming with subliminal reward stimuli|"This intervention consisted of five presentations [three cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal priming (displayed for 17 ms), and positive words as subliminal reward (displayed for 17 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
2528843|NCT02705092|Experimental|Subliminal priming with supraliminal reward stimuli|"This intervention consisted of four presentations [two cycles of mosaic (displayed for 117 ms each), physical exertion words as subliminal prime (displayed for 17 ms), and positive words as supraliminal reward (displayed for 150 ms)].~These were set to 1 package. 1 package is 24 times per 5 seconds presented in the animation (Animation of Skateboarding) for approximately 2 min."
3166811|NCT00530114|Placebo Comparator|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
2528966|NCT02704234|Experimental|Active Acupuncture|Active Acupuncture 2 times per week for 5 weeks
2528976|NCT02704234|Placebo Comparator|Placebo|Placebo Acupuncture 2 times per week for 5 weeks
2529034|NCT02703974|Experimental|Early handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and nudges built after Phase II data collection.
2529036|NCT02703974|Experimental|Late handwashing station + nudge|This arm will include 5 randomly selected schools that will have had handwashing stations and nudges built at the same time, after Phase II data collection.
2529039|NCT02703974|Active Comparator|Early handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after the baseline observation (Phase I), and will receive a Hand hygiene education-based program, after Phase II data collection is complete.
2529041|NCT02703974|Active Comparator|Late handwashing station + education|This arm will include 5 randomly selected schools that will have had handwashing stations built after Phase II data collection is complete, when the Hand hygiene education-based program will commence.
2529246|NCT02702453|Experimental|Development and Testing|Develop an online interactive, tailored intervention to address the needs of men and partners interested in sexual recovery after treatment for localized prostate cancer during the first 6 months after treatment. The intervention will undergo content testing through 4 focus groups with prostate cancer survivors and partners and usability testing with 5 survivors and partners
2529274|NCT02702180|Experimental|molgramostim continuously|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg once daily for 24 weeks
2529278|NCT02702180|Experimental|molgramostim intermittently|Inhalation of molgramostim nebuliser solution (rhGM-CSF) 300 mcg for seven days and placebo nebuliser solution for seven days for 24 weeks (12 cycles)
2529281|NCT02702180|Placebo Comparator|placebo|Inhalation of placebo nebuliser solution once daily for 24 weeks
2529350|NCT02701595|Experimental|Oral switch treatment|Oral switch to amoxicillin
2529356|NCT02701595|Active Comparator|Conventional IV treatment according to european guidelines|Conventional IV treatment of streptococci/enterococci IE (European guidelines 2015)
2529458|NCT02700906|Active Comparator|Corticosteroid injection|For corticosteroid injection, triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
2529461|NCT02700906|Active Comparator|Lidocaine injection|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
2529489|NCT02700685|Experimental|Pycnogenol|"Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.~Subjects < 30 kg body weight: 20 mg Pycnogenol/day Subjects >= 30 kg body weight: 40 mg Pycnogenol/day"
2529495|NCT02700685|Placebo Comparator|Placebo|Placebo treatment (identical capsules containing excipients only)
2529504|NCT02700685|Active Comparator|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release. Subjects < 30 kg body weight: 20 mg methylphenidate once per day Subjects >= 30 kg body weight: 30 mg methylphenidate once per day
3166812|NCT00530114|Experimental|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
2529615|NCT02699723|Experimental|Treatment (arsenic trioxide, itraconazole)|Patients receive arsenic trioxide PO and itraconazole PO daily for 50 days, followed by maintenance therapy consisting of 2 weeks off treatment and then 2 weeks on treatment for up to 6 months in the absence of disease progression or unacceptable toxicity.
2529699|NCT02699385|Experimental|Oral Rehydration Therapy (ORT) + Domperidone|Each participants will initiate ORT in the physician's office and domperidone 0.25 milligram per kilogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
2529709|NCT02699385|Experimental|Oral Rehydration Therapy + Placebo|Each participants will initiate ORT in the physician's office and placebo oral suspension thrice daily for up to 7 days.
2529792|NCT02698631|Active Comparator|Conventional AF ablation.|A standard radiofrequency AF ablation procedure will be carried out without LGE information.
3166813|NCT00530127|Placebo Comparator|A|Placebo solution
3166814|NCT00530127|Experimental|B|Deferiprone oral solution 20 mg/kg/day
3166815|NCT00530127|Experimental|C|Deferiprone oral solution 40 mg/kg/day
3166816|NCT00530127|Placebo Comparator|D|Placebo solution
3166817|NCT00530127|Experimental|E|deferiprone oral solution 60 mg/kg/day
2528718|NCT02705859|Other|Single Arm|"This study is a Phase Ib/II open label, single arm, adaptive multi-centre trial.~Patients with HER2-positive, metastatic or incurable recurrent breast cancer, following disease progression during, or after, treatment with at least one systemic treatment regimen in the metastatic or recurrent setting, will be treated with copanlisib (at 30, 45 or 60 mg flat dosing IV weekly - depending on the maximum tolerated dose (MTD) determined in the Phase Ib part of the study) plus trastuzumab (4 mg/kg IV Cycle 1 Day 1 and then 2 mg/kg IV weekly starting from day 8)."
2528814|NCT02705651|Experimental|Somatostatin-Analog|A long acting somatostatin analog will be applied.
2528815|NCT02705651|No Intervention|No treatment|This arm will be be the observational control according to the endpoints of the study. No intervention will be made.
2528833|NCT02705053|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 2)|The subjects' Sensor-Augmented Pump Open-Loop Care for the second week of the study before any adjustments to pump settings, using a CGM and Insulin Pump.
2528838|NCT02705053|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on CGM glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device. Algorithmic adjustment of carbohydrate ratios prior to closed-loop initiation, and continued basal rate and carbohydrate ratio algorithmic optimization during closed-loop use will occur.
2528913|NCT02704780|Active Comparator|400 Microgram Misoprostol|Misoprostol 400 micro-gram dissolved in 20 mL normal saline will be injected in the umbilical vein in the first group
2528919|NCT02704780|Active Comparator|800 Microgram Misoprostol|Misoprostol 800 micro-gram dissolved in 20 mL normal saline will be injected in umbilical cord of the second group
2528953|NCT02704247|Experimental|Testing CARDIOSPACE System|Healthy volunteers have to test CARDIOSPACE System
2529004|NCT02704078|Active Comparator|EBUS-TBNA|Mediastinal lymph node aspiration shall be performed transtracheally.
2529012|NCT02704078|Experimental|EUS-B-FNA|Mediastinal lymph node aspiration shall be performed transesophageally
2529100|NCT02703610|Active Comparator|Oxycodone/acetaminophen|Oxycodone/acetaminophen (5 mg/325 mg)
2529101|NCT02703610|Active Comparator|Ibuprofen/acetaminophen|Ibuprofen/acetaminophen (400 mg/500 mg)
2529172|NCT02703090|Placebo Comparator|Placebo|Normal saline infusion
2529179|NCT02703090|Active Comparator|Drug lower dose|Remifentanil infusion
2529185|NCT02703090|Active Comparator|Drug higher dose|Remifentanil infusion
2529226|NCT02702531|Experimental|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
2529227|NCT02702531|Experimental|Water + Povidone-iodine Solution|Clearify Visualization with Water + Povidone-iodine Solutionused during laparoscopic surgery
2529288|NCT02702284|Other|Adequate health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
2529293|NCT02702284|Experimental|Adequate health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
2529299|NCT02702284|Other|Limited health literacy, control|This group of subjects will be referred to clinic staff for assistance with the advance directives (AD) and will not receive assistance from a research assistant. In addition, the research assistance will ask questions regarding the information received for the AD.
2529310|NCT02702284|Experimental|Limited health literacy, intervention|The subjects in this group will hear a research assistant review the advance directive and be offered an opportunity to watch a video about advance directives.
3200509|NCT00891397|Placebo Comparator|2|Ten patients will be be in the placebo group.
3200510|NCT00891423|Active Comparator|Meropenem short infusion|"Meropenem 1g infused over 30 minutes~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
3166818|NCT00530140|Experimental|A|All patients will receive the same vaccination schedule/formulation
3166819|NCT00530166|Experimental|002|sham comparator 3(100 mg) tablets once daily for 12 weeks
2529531|NCT02700451|Placebo Comparator|Intravenous (IV) Placebo|IV Placebo arm
2529536|NCT02700451|Experimental|IV Ketorolac|IV Ketorolac arm
2529539|NCT02700451|Experimental|IV Acetaminophen|IV Acetaminophen arm
2529588|NCT02700035|Experimental|BZDDD Prevention Program Intervention|We employed an experimental randomized block (RB) design; blocked on reservation where 157 were assigned to the intervention condition (Bii-Zin-Da-De-Dah (Listening to One Another) 14 week family based prevention program). The first 4 weeks of the program are oriented towards the Anishinabe cultural traditions and the traditional Anishinabe family. Weeks 5 through 8 focus on identifying feelings and how to manage negative feelings such as anger and sadness in positive ways. The last 6 weeks of the program focus on outside influences and how to build positive support systems. Prior to the intervention, we completed a pre-test with families in the experimental group. Following the program, we completed a post-test and a 6-month youth follow-up.
2529592|NCT02700035|No Intervention|BZDDD Prevention Program Control|We employed a randomized block (RB) design; blocked on reservation, 147 families were randomly assigned to the control condition. We completed a post-test and a 6-month youth follow-up.
2529643|NCT02699775||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
2529679|NCT02699424|Other|Radiotherapy|
2529798|NCT02698709||Healthy corneas (C)|Corneas of normal candidates to refractive surgery who did not develop any sign of corneal ectasia after laser in situ keratomileusis during a two year follow-up period were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2529885|NCT02697955|Experimental|Bupivacaine-epinephrine|10 mL of 5 mg/mL bupivacaine with 5 μg/mL epinephrine = 50 mg bupivacaine and 50 μg epinephrine
2529888|NCT02697955|Placebo Comparator|Placebo|10 ml normal saline water (sodium chloride solution, 0,9%)
3166820|NCT00530166|Experimental|001|JNJ-18054478 3(100 mg) tablets once daily for 12 weeks
2528867|NCT02705014|Experimental|treatment group|patients were administered with pulsatile gonadotropin-releasing hormone (GnRH )therapy for 12 months at an interval of 90 minutes.The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L.
2528890|NCT02704624|Active Comparator|Vitamin D|Tablets with 50000UI cholecalciferol (vitamin D3) will be administered, weekly, for six months.
2528896|NCT02704624|Placebo Comparator|Placebo|The patients selected to the placebo group will receive inert content tablets without therapeutic effect, weekly, for six months.
2528968|NCT02704377|Experimental|Supportive care (quality of life, supportive care preferences)|Participants complete questionnaires about quality of life and preferences for supportive care treatment, wear accelerometerundergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week, and undergo a single Dual X-ray Absorptiometry (iDXA) scan over 10 minutes. Other interventions include: Laboratory Biomarker Analysis, Quality-of-Life Assessments, and othe Questionnaire Administration.
2529035|NCT02703844|Active Comparator|Active|Participants will be receiving an active Caloric Vestibular Stimulation treatment for a duration of 12 weeks, 7 days a week, twice daily for 20 minutes.
2529037|NCT02703844|Sham Comparator|Placebo|"Participants will be receiving a Sham Caloric Vestibular Stimulation treatment for a duration of 12 weeks in the same manner as the active arm: 7 days a week, twice daily for 20 minutes.~Individuals allocated to this arm will be later crossed over, in unblinded fashion. to the active arm if the treatment shows evidence of efficacy and safety."
2529085|NCT02703480|Experimental|All Study Participants - d-PTFE|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane.
2529086|NCT02703480|Experimental|All Study Participants - Ti-mesh|The proposed study design is a randomized controlled trial, split mouth design, to compare the two different vertical augmentation procedures: Titanium mesh (Ti-mesh) technique and Guided Bone Regeneration (GBR) technique with a high-density polytetrafluoroethylene (d-PTFE) membrane
2529148|NCT02702947|Experimental|Prunus Domestica|Prunus domestica extract capsules, 100mg, BD
2529236|NCT02702791|Experimental|Intervention|Telecoaching - feasible goal setting and feedback to enhance patient's motivation and commitment - in addition to pulmonary rehabilitation.
2529239|NCT02702791|Other|Usual care|includes only general advices regarding physical activity.
3200511|NCT00891423|Experimental|Meropenem extended infusion|"Meropenem 500mg infused over 3 hours~every 8 hours if calculated CrCL greater than or equal to 50 mL/min OR~every 12 hours if calculated CrCL less than 50 mL/min or hemofiltration"
3200512|NCT00891475|Experimental|Arm 1|38 patients
2529382|NCT02701465|Experimental|Intervention group|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
2529385|NCT02701465|Active Comparator|Control group|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
2529448|NCT02701127|Active Comparator|Niacinamide 1 gram|Oral niacinamide, 1 gram daily
2529453|NCT02701127|Active Comparator|Niacinamide 3 grams|Oral niacinamide, 3 grams daily
2529457|NCT02701127|Placebo Comparator|Placebo|Oral placebo pill
2529476|NCT02700672||Institutionalized older adults|Observational study
2529479|NCT02700672||Non-institutionalized older adults|Observational study
2529532|NCT02700477|Active Comparator|Fenugreek seed extract|Fenugreek seeds extract 500 mg capsule twice a day for 12 weeks
2529535|NCT02700477|Placebo Comparator|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
2529579|NCT02700100|Experimental|Pulmonary Valved Conduit (PV-001)|Bioabsorbable Pulmonary Valved Conduit (PV-001) implantation through open surgery.
2529605|NCT02699853|Experimental|Arm I (RRC)|Patients undergo RRC at day 0.
2529606|NCT02699853|Experimental|Arm II (ORC)|Patients undergo ORC at day 0.
3200513|NCT00891475|Experimental|Arm 2|38 patients
2529672|NCT02699333||Microscopic colitis cases|Patients found to have microscopic colitis based on colonic biopsies.
2529674|NCT02699333||Controls|Patients who meet eligibility requirements but do not have microscopic colitis on biopsy.
2529855|NCT02698111|Experimental|Donafeinib|donafenib 200mg,bid
2529902|NCT02697838|Experimental|Experimental: Apatinib plus chemotherapy|
3200514|NCT00891475|Experimental|Arm 3|38 patients
3200515|NCT00891488||Fit|
3200516|NCT00891488||Unfit|
3200517|NCT00891501|Experimental|Single|Clinical case series
3200518|NCT00891514|Experimental|Aerobic Exercise|Treadmill training
3200519|NCT00891514|Active Comparator|Stretch Control|Stretching exercises
3200520|NCT00891540|Active Comparator|1|Local infiltration with Ropivacaine
2528844|NCT02705157||Bone metastasis of the long bone|Patients with bone metastases of the long bone(s) receiving surgical stabilisation of a pathologic or impending fracture or receiving radiotherapy for a painful metastasis.
2528892|NCT02704754|Experimental|suvorexant|10 to 20 mg to be administered before bedtime
2528898|NCT02704754|Placebo Comparator|Placebo pill|A pill without active ingredients
2528932|NCT02704351||Sugammadex group|sugammadex to reverse neuromuscular blockade following cardiac surgery
3200521|NCT00891540|Active Comparator|2|Local infiltration with Ropivacaine
3200522|NCT00891540|Placebo Comparator|3|Local infiltration with NaCl
3200523|NCT00891553||Ronacaleret|Subjects receiving ronacaleret (200mg,300mg or 400mg) in study CR9108963 will be enrolled into this study.
3200524|NCT00891553||Placebo|Subjects receiving placebo in study CR9108963 will be enrolled into this study.
2529187|NCT02702882|Other|Fenugreek seeds extract 500 mg|Fenugreek seeds extract ( Furosap) one caps once a day
2529213|NCT02702544|Experimental|neutral position|the patient is in the neutral position, located on his back on a flat surface
2529217|NCT02702544|Experimental|legs raised for 20 degrees|patient is placed on a flat surface, legs raised for 20 degrees, supported around ankles
2529221|NCT02702544|Experimental|legs raised for 30 degrees|patient is placed on a flat surface, legs raised for 30 degrees, supported around ankles
2529224|NCT02702544|Experimental|legs raised for 45 degrees|patient is placed on a flat surface, legs raised for 45 degrees, supported around ankles
2529225|NCT02702544|Experimental|legs raised for 60 degrees|patient is placed on a flat surface, legs raised for 60 degrees, supported around ankles
2529294|NCT02702219|Experimental|Dynamic streching|Mobility training of the hamstrings muscles to be performed every day
2529305|NCT02702219|Active Comparator|Static stretching|Static stretching of the hamstrings muscles to be performed every day
3200525|NCT00891579|Active Comparator|Alimta|Treatment of Alimta
3200526|NCT00891579|Active Comparator|IRESSA|Treatment of IRESSA
3200527|NCT00891592|Experimental|Dose Escalation Arm|Subjects with cord blood stored in more than one fraction will be enrolled into Dose Escalation Arm. Subjects will receive Cord Blood Stem Cell Transplant followed by expanded Cord Blood T cells on Day 0.
3200528|NCT00891592|Active Comparator|Observation Arm|Subjects with cord blood stored in one fraction will be enrolled into the Observation Arm. Subjects will receive Cord Blood Stem Cell Transplant on Day 0.
3200529|NCT00891605|Experimental|Paclitaxel and ABT-263|
3200530|NCT00891631|Experimental|iSBIRT|Participants will complete the iSBIRT system.
3200531|NCT00891631|Experimental|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system and technological extenders
2529429|NCT02700932|Experimental|PicoWay laser treatment|3 wavelength tattoo treatment with picosecond laser (PicoWay)
2529460|NCT02700854|Experimental|5% carbon-dioxide inhalation|5% carbon-dioxide will be administered through patient circuits to asphyxiated, cooled, mechanically ventilated newborns at risk for hypocapnia
2529491|NCT02700750|Other|OCT exam|OCT exam No Arm No Intervention
3200532|NCT00891631|No Intervention|TAU|Participants will receive Treatment as Usual from their primary care provider.
2529647|NCT02699905||Sepsis|Patients with the diagnosis of sepsis or septic shock
2529650|NCT02699905||Control|Healthy control with no evidence of active infection, or recent infection in the past 4 weeks.
2529685|NCT02699372|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RO6889450 as oral capsules.
2529695|NCT02699372|Experimental|RO6889450: Part 1 Single Ascending Dose (SAD)|Participants will undergo a series of screening visits prior to treatment and 4 weeks follow-up. Healthy volunteers will be enrolled in up to 7 dose groups (5 milligram [mg] to 450 mg) and will receive single oral dose of RO6889450 in the morning of the Day 1.
2529702|NCT02699372|Experimental|RO6889450: Part 2 Multiple Ascending Dose (MAD)|The starting dose for Part 2 MAD will be determined by analysis of safety and pharmacokinetic data of Part 1 SAD. All participants will receive RO6889450 orally for 14 days.
2529732|NCT02698917|Active Comparator|Group 1|Low normal PaCO2, low normal PaO2, low normal MAP
2529735|NCT02698917|Active Comparator|Group 2|High normal PaCO2, low normal PaO2, low normal MAP
2529739|NCT02698917|Active Comparator|Group 3|Low normal PaCO2, high normal PaO2, low normal MAP
2529741|NCT02698917|Active Comparator|Group 4|High normal PaCO2, high normal PaO2, low normal MAP
2529742|NCT02698917|Active Comparator|Group 5|Low normal PaCO2, low normal PaO2, high normal MAP
2529744|NCT02698917|Active Comparator|Group 6|High normal PaCO2, low normal PaO2, high normal MAP
2529750|NCT02698917|Active Comparator|Group 7|Low normal PaCO2, high normal PaO2, high normal MAP
2529754|NCT02698917|Active Comparator|Group 8|High normal PaCO2, high normal PaO2, high normal MAP
3200533|NCT00891644||1|HIV positive adolescents who never initiated care within 6 months of receipt of HIV positive results.
3200534|NCT00891644||2|HIV positive adolescents who initiated care, but did not follow up with care within 12 months of the initial care visit. Also included in this group are those who initiated and followed-up with care, but have dropped out of care for 12 or more months.
3200535|NCT00891644||3|HIV positive adolescents who initiated care and maintained care. These youth are currently in care.
3200536|NCT00891670|Active Comparator|triple group|received cilostazol 100 mg twice daily in addition to aspirin 100mg and clopidogrel 75mg once daily
3200537|NCT00891670|Active Comparator|high maintenance dose group|received clopidogrel 150 mg/day with aspirin 100mg once daily
3200538|NCT00891683|Placebo Comparator|Placebo|4 Capsules of Placebo
3200539|NCT00891683|Active Comparator|100 mg|One 100 mg capsule and 3 placebo capsules of AEG33773
3200540|NCT00891683|Active Comparator|200 mg|Two 100 mg capsules and two placebo capsules
3200541|NCT00891683|Active Comparator|400 mg|Four 100 mg AEG33773 capsules
3200542|NCT00891696|Active Comparator|Exp 1: AA + Rap|Participants will receive amino acid supplementation and rapamycin.
3200543|NCT00891696|Placebo Comparator|Exp 1: AA|Participants will receive amino acid supplementation and placebo rapamycin.
2528863|NCT02704975|Experimental|Rehabilitation and Dry Needling|Standard Rehabilitation Protocol following shoulder stabilization surgery and Dry Needling to the Shoulder girdle 1 time a week for 4 weeks between weeks 4 and 8 post operatively
2528866|NCT02704975|Active Comparator|Rehabilitation|Standard Rehabilitation Protocol following shoulder stabilization surgery alone
2528879|NCT02704650|Experimental|Vaginal fluid of healthy patient|vaginal fluid sample from healthy patients
2528885|NCT02704650|Experimental|Vaginal fluid of ovary cancer patients|vaginal fluid sample from patients with ovary cancer
2528967|NCT02704520|Other|Control arm|Patients in the control arm will undergo surgery and then receive a course of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil) and follow-up assessments as standard i.e. standard clinical practice
2528972|NCT02704520|Experimental|Intervention arm|Patients in the intervention arm will be split into one of two groups according to their response to chemoradiotherapy. Patients who show a good response (mrTRG I&II) will be offered deferral of surgery and receive the standard course of chemotherapy. Patients who show a poor response (mrTRG III-V) will receive 12 weeks of chemotherapy (CAPOX [capecitabine and oxaliplatin] or FOLFOX [5-fluorouracil, oxaliplatin, folinic acid], or single agent capecitabine or 5-fluorouracil), undergo repeat restaging, and then continue to surgery or defer surgery. Depending on chemotherapy regimen received patients may then receive a further 12 weeks of chemotherapy.
3200544|NCT00891696|Active Comparator|Exp 1: HEx + Rap|Participants will receive rapamycin and placebo amino acid supplementation, and they will undergo high-intensity resistance exercise.
3200545|NCT00891696|Placebo Comparator|Exp 1: HEx|Participants will receive placebo amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
2529142|NCT02703168||Immediate loading|Patients were allocated to treatment group in the core study. Immediate loading was defined as follows: Implant(s) will be restored with a temporary restoration on the day of surgery
2529143|NCT02703168||Early loading|Patients were allocated to treatment group in the core study. Early loading was defined as follows: Healing caps will be placed on the implant(s) immediately after surgery. A provisional restoration will be placed between day 28 to day 34 post surgery
2529156|NCT02702895||Phase 1|Former ASPIRE participants
2529157|NCT02702895||Phase 2 HOPE participants|Former HOPE participants
2529160|NCT02702895||Phase 2 Male Partners|Male partners of HOPE participants
2529233|NCT02702635|Experimental|All Subjects|All recruited subjects
2529301|NCT02702258|Experimental|MB-BP|This is the primary intervention tested in this single arm trial.
3200546|NCT00891696|Active Comparator|Exp 1: HEx + AA + Rap|Participants will receive amino acid supplementation and rapamycin, and they will undergo high-intensity resistance exercise.
3200547|NCT00891696|Placebo Comparator|Exp 1: HEx + AA|Participants will receive amino acid supplementation and placebo rapamycin, and they will undergo high-intensity resistance exercise.
3200548|NCT00891696|Active Comparator|Exp 2: LExFR + Rap|Participants will receive rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
3200549|NCT00891696|Placebo Comparator|Exp 2 and 3: LExFR|Participants will receive placebo rapamycin and will undergo low-intensity resistance exercise with blood flow restriction.
2529705|NCT02699242|Experimental|Simulator arm|In the Simulation arm group the subjects will be trained on the virtual reality bronchoscopic simulator (ORSIM simulator) for up to 60 minutes as active intervention, before they undertake the 2nd Fiber optic intubations.
2529712|NCT02699242|No Intervention|Control arms|The control arm will be exposed only to the didactic teaching. The subjects will not undergo simulator training before undergoing 2nd fiber optic intubations.
2529861|NCT02698228|Sham Comparator|Standard of Care|Intravenous injection of 0.1mg/kg of morphine. Injection of 5cc of 0.9% normal saline into the subcutaneous tissue of the thigh.
2529864|NCT02698228|Active Comparator|Femoral nerve block|Intravenous injection of 0.1mg/kg of morphine. Injection of 20cc of 0.5% bupivacaine into the fascia iliaca space using standard anatomic landmarks.
2529866|NCT02698228|Active Comparator|Ultra-sound guided femoral nerve block|Intravenous injection of 0.1mg/kg of morphine.Injection of 20cc of 0.5% bupivacaine around their femoral nerve under direct ultrasound guidance
2529928|NCT02697747||Ultrasound education|Training in the use of ultrasound to identify the L3-L4 interspace
2529991|NCT02697331|Active Comparator|progesterone|74 patients will receive progesterone pessary 200mg twice daily
2529995|NCT02697331|Placebo Comparator|Placebo|74 patients will receive placebo
2530045|NCT02696941|Experimental|Metformin|Participants with insulin resistance who have not yet started any diabetic medication will be recruited and will be prescribed metformin at standard clinical doses.
2530052|NCT02696941|Experimental|SGLT2|Participants with poorly controlled type 2 Diabetes (T2DM) who have been recommended to start an SGLT2 inhibitor will be recruited.
2530093|NCT02696512|Experimental|IBRF ACP/MCP Group 1|The Treatment group will be receiving a combination of pharmaceuticals (polypharmacy using FDA-approved products) and nutraceuticals (Nutraceutical supplementation) and median nerve stimulation (MNS)
2530094|NCT02696512|Other|Standard of Care Group 2|Standard of Care only
2530150|NCT02696252||CGM Users|
2530264|NCT02695836|Active Comparator|Standard feedback|Facilities in this arm will receive an initial face-to-face dissemination workshop that includes feedback of research data on modifiable aspects of their microsystem context but no goal setting.
2530266|NCT02695836|Experimental|Basic assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive a face-to-face goal setting workshop focused on modifiable areas of their microsystem context and two virtual support workshops at six month intervals.
2530268|NCT02695836|Experimental|Enhanced assisted feedback|In addition to the face-to-face dissemination workshop, facilities in this arm will receive an additional face-to-face goal setting workshop focused on modifiable areas of their microsystem context, two additional face-to-face support workshops at six month intervals plus on-demand email and telephone support.
3200550|NCT00891696|Active Comparator|Exp 2: SNP|Participants will receive sodium nitroprusside in a resting state.
3200551|NCT00891696|Active Comparator|Exp 2: FR|Participants will undergo blood flow restriction in a resting state.
2528893|NCT02704611|Active Comparator|Group I|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week).
2528899|NCT02704611|Sham Comparator|Group II|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec.
2528939|NCT02704338|Experimental|Regulatory T cells|CD4(cluster of differentiation)+CD25+CD127- T cells isolated from peripheral blood mononuclear cells were be expanded with GMP(Good Manufacturing Practice) anti-CD3/CD28 coated beads in the presence of IL-2 and all-trans retinoid acid.
2528992|NCT02704130|Experimental|TAE + MWA combination therapy|In patients randomized to receive the experimental therapy, transarterial embolization (TAE) treatments will be initiated within one week of randomization. Blunt embolization will be performed with LC beads with a maximum size of 700 µm. Microwave ablation (MWA) will be performed up to one month following randomization. The LC beads will be admixed with 8-15 mL of contrast and injected into the arterial branch at a rate of 1-2 mL/min. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request.
2529001|NCT02704130|Active Comparator|MWA monotherapy|Microwave ablation (MWA) will be performed up to one month following randomization. Treatment may be discontinued if any exclusion criteria develop in the patient or at the patient's request. All operative MWAs will be performed in a laparoscopic or robot-assisted laparoscopic setting. All ablations will be guided by intraoperative ultrasound. Ablations will be performed with a 2.45-GHz generator with a 1.8-mm-diameter transcutaneous antenna.
2529048|NCT02703597|Experimental|ASPIRE Group|"ASPIRE Group contains participants with and without intent to use tobacco. Participants engage in five 70-minute sessions of ASPIRE spread over a period of 4 weeks (2 sessions in the last week). During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco. During each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute breaks.~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys. Also, baseline survey again completed."
2529052|NCT02703597|Experimental|GSA-ASPIRE-Network Group|"GSA-ASPIRE-Network Group contains participants with and without intent to use tobacco. In groups, participants engage in five 70-minute sessions of ASPIRE conducted over a period of 4 weeks (2 sessions in the last week). However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. During each session, participants will alternate between 10 minutes of ASPIRE use and 5-minute GSAs. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.~At baseline, after 2 sessions, following the last session of the intervention, and one month after the intervention has ended, participants complete psychosocial surveys and social network surveys."
3200552|NCT00891696|Active Comparator|Exp 2: LEx + SNP|Participants will receive sodium nitroprusside and undergo low-intensity resistance exercise.
2529175|NCT02702830||Diagnostic (MRI and CPET)|Patients undergo CPET using a one-way breathing mask in 2 separate days 1-2 weeks apart. Patients also undergo MRI before and within 60 seconds after exercising.
2529247|NCT02702505|Experimental|NeoMTA|The new formulation of MTA (does not contain bismuth oxide) will be used in one tooth receiving a pulpotomy to determine if the color of the tooth changes over time. The new formulation has received the Food and Drug Administrations 510(k) substantial equivalence clearance for Class II dental materials and is equivalent to its MTA predicate (ProRoot, Dentsply Tulsa Dental, Tulsa, OK, USA).19
2529248|NCT02702505|Other|ProRoot MTA|Control group. This group will receive the old formulation of MTA in the pulpotomy and the tooth will receive a full coverage stainless steel crown restoration.
2529298|NCT02702128|Active Comparator|Tranexamic acid|1g of Tranexamic acid on 1hour and 1g of tranexamic acid on 8 hours
2529311|NCT02702128|Placebo Comparator|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
2529325|NCT02701686|Experimental|quit immediately (QI)|Subjects in the QI group will receive a smoking cessation booklet plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit now, as quitting can greatly reduce risks, (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention during each telephone follow-up. The whole intervention will be limited to less than 1 min or slightly longer if necessary. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the counsellor will congratulate to the subjects who successfully quit smoking, while deliver the same brief intervention as a booster for those who continue to smoke.
2529333|NCT02701686|Experimental|cut down to quit (CDTQ)|Subjects in the CDTQ group will also receive the smoking cessation booklet plus a brief intervention using the AWARD model. Instead of asking them to quit immediately, they will be advised gradually cutting down on their cigarette consumption. Also, the subjects will be provided with an education card that contains reduction strategies and a suggested plan to reduce smoking. For the subsequent telephone follow-ups at 1, 3, 6 and 12 months, the nurse counsellor will repeat the warning message that one out of two smokers will be killed by smoking, and remind the subjects of their next reduction target. The counsellor will congratulate subjects who quit or reduce smoking on their success. When subjects fail to quit or reduce their cigarette consumption, the counsellor will reinforce the health hazards of continued smoking and the benefits of quitting, and encourage them to try again immediately or in the near future.
2529390|NCT02701478|Other|N2O exposure|"There is only one arm in this study. All patients under General Anesthesia are exposed to 4 different doses or concentrations of inhaled N2O that is combined with the anesthetic desflurane. Each patient will be submitted to the standard nociceptive stimulus when inhaled N2O is at 0, 50, 25, and finally back to 0%. ANI and NoL Indices variations between before stimulus and after stimulus at each N2O concentration will be assessed and compared. This will allow to demonstrate an analgesic effect (less variations of ANI and NoL) when inhaled N2O is high (50%) testifying for the analgesic effect of this gas N2O."
3200553|NCT00891696|Placebo Comparator|Exp 3: LEx|Participants will undergo low-intensity resistance exercise.
2528903|NCT02704598|Active Comparator|Warfarin|Patients with deep venous thrombosis using Warfarin for 6 months, and then will be evaluated wiht DUPLEX SCAN to assess the recanalization rate, and also the clinical signs and symptoms.
2528955|NCT02704286|Sham Comparator|Generic Osteoarthritis Risk Information|Participants in this arm received generic osteoarthritis information that was not personalized.
2528963|NCT02704286|Experimental|Personalized Osteoarthritis Risk|Participants in this arm obtained their personalized osteoarthritis risk from the internet-based Osteoarthritis Risk Calculator.
2529059|NCT02703753|Experimental|Intervention group|The intervention is an integral and multidisciplinary lifestyle intervention consisting of a healthy diet, appropriate physical activity and, if applicable, smoking cessation, customised to the needs of the women.
2529064|NCT02703753|No Intervention|Control group|The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
2529103|NCT02703402|Experimental|Exercise protocol|Will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA
2529106|NCT02703402|Experimental|Manual of exercises|Treatment Group: will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises.
2529162|NCT02703103|Experimental|Standard cardiopulmonary resuscitation|standard CPR (30:2) according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
2529165|NCT02703103|Experimental|asynchronous cardiopulmonary resuscitation|asynchronuos CPR according to European Resuscitation Council 2015 guidelines for cardiopulmonary resuscitation.
2529205|NCT02702661|Experimental|Procedure - FICB|Fascia Iliaca Block following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
2529215|NCT02702661|Active Comparator|Procedure - LAI|Local Anaesthetic Infiltration following Hip Arthroscopy - Drug - Levobupivacaine 0.125% - 40ml
3200554|NCT00891696|Active Comparator|Exp 3: HEx|Participants will undergo high-intensity resistance exercise.
3200555|NCT00891696|Active Comparator|Exp 3: HEx + AA|Participants will receive amino acid supplementation and will undergo high-intensity resistance exercise.
2529436|NCT02700958|Experimental|Remote ischemic preconditioning|Remote Ischemic Preconditioning (RIPC) is performed by inflating blood pressure cuff for 5-minutes at 200 mmHg, or if patients systolic blood pressure is higher than 200 mmHg 20 mmHg above systolic pressure, alternated with 5-minute deflation for 4 times.
2529441|NCT02700958|Sham Comparator|SHAM remote ischemic preconditioning|SHAM Remote Ischemic Preconditioning (RIPC-SHAM) is accomplished by alternating 4 cycles of 5-minute inflation with 5-minute deflation. Blood pressure cuff will be inflated to 10-20 mmHg. RIPC-SHAM is performed with standard blood pressure cuff on upper-arm.
2529508|NCT02700776||COHORT I-BIRADS 1 or 2,|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0 and 6-12.
2529509|NCT02700776||COHORT II -BIRADS 3|Phlebotomy - Blood sampling for GP88 and MM. Occurs at months 0, 3-6, and 6-12.
2529514|NCT02700776||COHORT III-BIRADS 4-6|SOC Tissue Biopsy. Occurs at months 0, 3-6, and 6-12.
2529549|NCT02700191|No Intervention|Control|For subjects in the Control arm, the parameters measured by the (µ-Cor) µ-Cor system will not be analysed or made available to the investigator.
2529553|NCT02700191|Experimental|uCor|For subjects in the Interventional arm, all of the parameters measured by the (µ-Cor) µ-Cor system will be available to the investigator and will remain blinded to the subjects. The investigator will use µ-Cor information to aid in therapy adjustment decisions during the study period.
2529600|NCT02700048|Placebo Comparator|Placebo|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
2529601|NCT02700048|Experimental|Treatment with intra-nasal Naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
2529631|NCT02699658|Experimental|levofloxacin in healthy|
2529676|NCT02699554||Orthopaedic surgery|
3200556|NCT00891709|Experimental|1|LEO 29102 2.5 mg/g cream
3200557|NCT00891709|Placebo Comparator|2|LEO 29102 cream vehicle
3200558|NCT00891748|Experimental|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter.
3200559|NCT00891761|Active Comparator|Active Comparator|Patients receive IV casopitant (active), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
3200560|NCT00891761|Placebo Comparator|Placebo Comparator|Patients receive IV casopitant (placebo), IV ondansetron and oral dexamethasone on Day 1 as well as oral dexamethasone on Days 2-4 of each cycle of cisplatin-based highly emetogenic chemotherapy for the prevention of chemotherapy induced nausea and vomiting.
3200561|NCT00891800|Experimental|1|All patients will be treated with SIR-Sphere therapy.
3200562|NCT00891826|Placebo Comparator|Corn oil|
3200563|NCT00891826|Experimental|Omega-3 fatty acids|
3200564|NCT00891865||Pediatric lung transplantation|
2529080|NCT02703493|Experimental|Cohort 1|Patients will receive 6 weeks of Intensity-Modulated Radiation Therapy (IMRT) (standard of care) followed by the dose escalated stereotactic radiosurgery (SRS Boost). Cohort 1 will receive 8 Gy in a single fraction, cohort 2 will receive 10 Gy in a single fraction and cohort 3 will receive 10 Gy split into two fractions.
2529128|NCT02703272|Experimental|Part 1: Ibrutinib|The first 2 participants enrolled in each age group (1-5 years, 6-11 years and 12-17 years) will receive starting dose of Ibrutinib 240 milligram per square meter (mg/m^2) for the first cycle, followed by dose escalation at the start of Cycle 2 as long as all pharmacokinetic assessments are within the expected range and there are no safety concerns. For participants being treated at 240 mg/m^2 dose level during the first cycle, the maximum dose should not exceed a total of 420 mg/day. All participants will receive rituximab, ifosfamide, carboplatin, etoposide and dexamethasone (RICE) or ituximab, vincristine, ifosfamide, carboplatin, idarubicin and dexamethasone (RVICI) background therapy (investigator's choice), during treatment phase. Participants with PR or better only will receive Ibrutinib for 3 cycles or until PD, unacceptable toxicity or until initiating antilymphoma therapy or a conditioning regimen for stem cell transplantation during post-treatment phase.
2529132|NCT02703272|Experimental|Part 2: Ibrutinib|Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
2529251|NCT02702206|Experimental|corticosteroids SASD injection|under US guidance 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
2529252|NCT02702206|Experimental|hyaluronic acid (ARTZ) SASD injection|under US guidance 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
2529253|NCT02702206|Placebo Comparator|normal saline SASD injection|under US guidance 2.5ml normal saline and 0.5ml distilled water and 1ml 1% lidocaine
3200565|NCT00891891||Spina Bifida|140 children with spina bifida (ages 8-15)
3200566|NCT00891917|Placebo Comparator|Syrup|identical placebo formulation to be administered twice a day.
3166821|NCT00530179|Active Comparator|Arm A|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined negative for disease intensity patient receives 4 more cycles R-CHOP (total 6 cycles R-CHOP)~Assigned interventions: Drug: R-CHOP (Rituximab, Cyclophosphamide, Etoposide, Cisplatin, Mesna, G-CSF 6 - 21 DAY Cycles of R-CHOP"
3200567|NCT00891917|Active Comparator|Ubiquinol-10 Syrup|CoQ (LiQ-NOL®) 10.0 mg/kg/d to be administered twice a day
2529485|NCT02700581|Active Comparator|low PEEP conventional ventilation|PEEP 2 mmHg tidal volume 10ml/kg
2529498|NCT02700581|Experimental|moderate PEEP conventional ventilation|PEEP 7 mmHg tidal volume 10ml/kg
2529505|NCT02700581|Experimental|low PEEP protective ventilation|PEEP 2 mmHg with tidal volume 6 ml/kg
2529507|NCT02700581|Experimental|moderate PEEP protective ventilation|PEEP 7 mmHg tidal volume 6ml/kg
2529521|NCT02700295||Orthokeratology contact lens group|
2529570|NCT02700178|Experimental|Biofeedback|Participants will be asked to participate in all or a subset of daily activities for wheelchair users. The intervention will consist of visual and/or auditory cues to guide their movement while performing the tasks during one to two sessions.
2529599|NCT02699957||Atrial Fibrillation|Those patients with the condition of atrial fibrillation.
3200568|NCT00891943|Other|Structured lifestyle support|Intervention group-structured lifestyle support.
3200569|NCT00891943|No Intervention|Usual care for weight management|"This is the control group, and they will receive usual care for weight management at their GP practice."
2529706|NCT02699203|Experimental|High-carbohydrate meal|High carbohydrate breakfast meal consisting of oatmeal and berries.
2529713|NCT02699203|Experimental|Low-carbohydrate meal|Low carbohydrate breakfast meal consisting of eggs and avocado.
2529757|NCT02698930|Experimental|dexmedetomidine group|
2529760|NCT02698930|Placebo Comparator|Control group|
2529780|NCT02698553|Experimental|Bupropion XL once daily|Healthy subjects will receive Bupropion XL 150milligram (mg) once daily for 5 days (Day 1 to Day 5) and then Bupropion XL 300 mg once daily from Day 6 to Day 14.
3200570|NCT00892021|Experimental|NSA-789|Active study drug
3200571|NCT00892021|Placebo Comparator|Placebo|Inactive study drug
3200572|NCT00892073|Experimental|Diazoxide and Metformin Therapy|
3200573|NCT00892112|Active Comparator|intravenous immunoglobulins|IV, 40 ml/kg over 4 days
3200574|NCT00892112|Placebo Comparator|plasma volume expander Albuman|IV, 40 ml/kg over 4 days
3200575|NCT00892138|Experimental|Mindfulness training|Mindfulness training
3200576|NCT00892138|No Intervention|Control|Study program as usual
3200577|NCT00892164|Active Comparator|FOCUS (Group A)|Patients submitted to total thyroidectomy with the use of the FOCUS harmonic scalpel device
3200578|NCT00892164|Active Comparator|LIGASURE (Group Β)|Patients submitted to total thyroidectomy with the use of the electrothermal bipolar vessel sealing device
3200579|NCT00892190|Experimental|dasatinib (SPRYCEL) and all trans retinoic acid (VESANOID)|"Dasatinib DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours~ATRA 22.5mg/m2 every 12 hours"
3200580|NCT00892203|Experimental|Active|
3200581|NCT00892203|Active Comparator|Comparator|
3200582|NCT00892203|Placebo Comparator|Placebo|
3208763|NCT00977847|Experimental|Wireless Tablet PC Practice|Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
2528940|NCT02704533|Experimental|Optimization Phase - Group B2|"n=6; three times 1.35x10^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine.~If >75% efficacious, the treatment will be simplified to two times 2.7x10^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).~If <75% efficacious, the treatment will be increased to three times 2.7x10^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3)."
2528942|NCT02704533|Experimental|Optimization Phase - Group C1|"n=6; one time 2.7x10^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C1 gets vaccinated, study will proceed to verification phase after completion."
2528943|NCT02704533|Experimental|Optimization Phase - Group C2|"n=6; two times 2.7x10^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~If Group C2 gets vaccinated, study will proceed to verification phase after completion."
2528946|NCT02704533|Experimental|Optimization Phase - Group C3|"n=6; three times 2.7x10^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination.~In case C3 shows <75% efficacy, verification phase will not be done."
2528951|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D1|"n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2528954|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D2|"n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2528961|NCT02704533|Experimental|PfSPZ Challenge (7G8) dose finding - Group D3|"n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI.~This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment."
2528973|NCT02704533|Experimental|Verification Phase - Group V1|"n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides >75% protection (5/6) against homologous CHMI (V1).~Optimal & maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2).~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8."
2528979|NCT02704533|Experimental|Verification Phase - Group V2|"n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2).~Optimal & maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides >75% protection (5/6) against homologous CHMI (V1).~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2528983|NCT02704533|Placebo Comparator|Verification Phase - Group P1|"n=6; normal saline as placebo. This group will follow the regimen selected for Group V1.~Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2528985|NCT02704533|Placebo Comparator|Verification Phase - Group P2|"n=6; NS as placebo. This group will follow the regimen selected for Group V2.~In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10^6 PfSPZ). Group V2/P2 will not be immunized.~Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart.~CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1."
2529026|NCT02703792||Care home staff|Care home staff working in the homes in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2529027|NCT02703792||NHS staff|GPs supporting residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2529028|NCT02703792||Service user representatives|Service or carers of an older person with dementia attending and Age UK carers group
2529029|NCT02703792||Relatives of residents|Relatives of residents living in the top 10% of service use of the 102 participating homes referring to the Care Home Support Service
2528958|NCT02704325|Experimental|GALGT2 Viral Vector|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
2528969|NCT02704325|Experimental|Saline|Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
3200583|NCT00892216|Experimental|Acupressure Band|A band with bead attachment will be used to produce Acupressure and applied to the P6 (three fingers breath from the wrist crease on th ventral surface of the upper limb). The application will be done 20 minutes prior to anesthesia and explanation as to usage after surgery will be given. The patient of caregiver will apply pressure on the bead for three minutes and repeat this four times a day for the next five days. None of the protocol for prevention of PONV in this group of patients will be changed. The postoperative therapy for nausea and vomiting will be on a PRN (as required) basis. Nausea and vomiting scores and VAS scores for pain estimation will be carried out according to hospital protocol in the PACU amd twice a day thereafter for their period of stay in the hospital. The amount of analgesics and antiemetics used and the number of days spent in the hospital will be registered.
2529051|NCT02703545||Peutz-Jeghers syndrome|
2529055|NCT02703545||Familial pancreas cancer|"at least 2 close relatives affected with pancreas cancer on same side of family~first degree relative and 1 second degree relative(1st degree link) or~first degree relatives or~1 first degree relative and 2 or more second degree relatives"
2529060|NCT02703545||Germline mutation Carrier 10 % risk|BRCA2 mutation carrier with family history of pancreas cancer or, PALB2 mutation carrier or, FAMMM (p16/CDKN2A) mutation carrier
2529068|NCT02703545||Germline mutation carrier 5 % risk|BRCA1 mutation carrier with family history of pancreas cancer or, HNPCC (Lynch Syndrome) with family history of pancreas cancer or, ATM gene mutation
2529072|NCT02703545||Hereditary pancreatitis|PRSS1, PRSS2, CTRC gene mutations
2529107|NCT02703415|Active Comparator|Bupivacaine|caudal Bupivacaine
2529112|NCT02703415|Active Comparator|Tramadol|caudal Tramadol
2529158|NCT02703038||Cardiogenic shock|Patient with cardiogenic shock table defined by the combination of a low cardiac output even as the filling pressures are normal or high, originally of hypoperfusion and organ suffering.
2529203|NCT02702739|Active Comparator|Group I (<65 years)|Group I treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
2529211|NCT02702739|Active Comparator|Group II (>65 years)|Group II treated with Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
2529256|NCT02702323|Experimental|Apatinib & TACE|Apatinib 500mg tablet by mouth per day, until disease progression, combined with TACE therapy one times every 4-6 weeks.
2529257|NCT02702323|Active Comparator|TACE|TACE therapy one times every 4-6 weeks.
2529303|NCT02701972|Experimental|Control and Test|Pre-implantation and Post-implantation of BACE device
2529324|NCT02701751|Other|Exercise session|Subjects will exercise at a moderate intensity for 60 minutes. There are no different arms in this study.
2529387|NCT02701530|Experimental|Targeted smoking cessation|"Smoking cessation program tailored in cooperation with the target group; smokers with low education.~Peer-based anti-relapse strategy. Recruitment strategy: peer-driven, written invitations and posters."
2529394|NCT02701530|No Intervention|Control|No smoking cessation program.
2529578|NCT02701205|Experimental|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 50mg twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
2529580|NCT02701205|Experimental|etanercept (half dose)|One vial of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®） 25mg and one vial of placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week from Week 12 to Week 24
2529581|NCT02701205|Placebo Comparator|Placebo|Two vials of Placebo twice a week for 12 weeks, then Two vials of Recombinant Human TNF Receptor-Ig Fusion Protein for Injection（Qiangke®) 25mg twice a week from Week 12 to Week 24
3200584|NCT00892216|Sham Comparator|Sham Acupressure|The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
2529791|NCT02698696|Experimental|ECo program|Objective: to inform the patient about cognitive impairments and their repercussions; to train the patient in problem-solving skills through exercises; to implement strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises, tools (tokens, cards, maps, chessboard) Modules: Psychoeducation, Attention, Memory, Executive Functions, Functional Impairments
2529793|NCT02698696|Experimental|CRT program|Objective: problem-solving skills training through exercises, in order to use strategies in daily life Duration: three months Frequency: two one-hour individual sessions and one hour of at-home training per week Modalities: pen and paper exercises Modules: Cognitive Flexibility, Working Memory, Planning
2529794|NCT02698696|Active Comparator|Supportive psychotherapy|Individual psychotherapy sessions focussing on autonomy in daily life, management of mood disorders' cognitive and functional impact, social skills, and the regulation of sleep and daily activities.
2529840|NCT02698280|Experimental|Treatment|Patients are treated with bevacizumab and nimustine. Every 6 weeks is defined as one therapeutic cycle. Adverse effect is evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.03). Hematologic toxicity is evaluated every 2 weeks. Liver function, renal function, and electrolytes are assessed every 4-6 weeks. Platelet should be no less than 100*10^9/L and neutrophil count should be no less than 1.5*10^9/L.
3200585|NCT00892229|Active Comparator|Buccal Misoprostol|Group one: 50 patients with first trimester missed abortion received buccal misoprostol
2530272|NCT02695381|Experimental|Etodolac-lidocaine Topical Patch|Therapy with experimental drug
2530275|NCT02695381|Placebo Comparator|Placebo|Therapy with placebo
2530304|NCT02695134|Other|Intervention Group|This group will receive 6 Healing Touch treatments over 3 weeks
2528960|NCT02704403|Placebo Comparator|Placebo|Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water
2529335|NCT02701946|Experimental|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US).
2529338|NCT02701946|Placebo Comparator|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
2529395|NCT02701426|Experimental|participant|agree to participate to the program combining physical activity and nutritional counseling
2529398|NCT02701426|No Intervention|no participant|disagree to participate to the program
3200586|NCT00892229|Active Comparator|Vaginal Misoprostol|Group two: 5 patients received vaginal misoprostol
2529490|NCT02700607|Placebo Comparator|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2529499|NCT02700607|Active Comparator|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
2529538|NCT02700373|Experimental|PDC-APB|"PDC-APB Intra-Muscular (IM)~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
2529540|NCT02700373|Placebo Comparator|Placebo|"Placebo~One single dose will be administered with an inpatient direct observational period of 24 hours following the dose, followed by outpatient follow-up for a total of 28 days. After Day 28, the subject will continue to be followed up for study related AE assessments thru Week 24."
2529586|NCT02700087|Placebo Comparator|H2 blocker versus placebo|"The patient will then be randomly placed in the control group (placebo) or the intervention group (ranitidine 2mg/kg every 12 hours or famotidine 0.5 mg/kg daily).~Patients will stay on medication for a minimum of 6 months, or until symptoms resolve. Patients will be seen in follow up at 1, 2, 3, 4, 5, 6, 8 and 10 months. At which time I-GERQ, ASQ and weights will be taken. The primary outcome measure will be the time for the ASQ score to drop to normal on ranitidine or famotidine versus placebo."
2529589|NCT02700087|Active Comparator|Treatment arm|Patients who develop severe airway symptoms while they are in the H2 blocker versus placebo arm will then cross over to the treatment arm of the study. These patients will exit randomization and be unblinded. These patients will all be given H2 blockers, and the effects of the H2 blockers will be monitored and studied. Alternatively, patients' families may also elect to undergo surgery to treat laryngomalacia.
2529636|NCT02699762|Experimental|experimental group|self rehabilitation of upper limb in experimental group + BTI + usual physiotherapy
2529639|NCT02699762|No Intervention|control group|BTI + usual physiotherapy
3200587|NCT00892229|Active Comparator|Buccal and Vaginal Misoprostol|"50 primiparous and 50 multiparous women: one hundred patients have been administered the medication buccally (25 primigravida and 25 multigravida), and vaginally (25 primigravida and 25 multigravida), three hours before dilation and curettage. They were admitted to the hospital one day before the surgical evacuation, and preparation of cross matched blood done for all recruited subjects.~Each group was randomly allocated (1,3,5,... for the buccal group & 2,4,6,... for the vaginal group) to receive 400 microgram misoprostol."
3200588|NCT00892242|Experimental|Neoadjuvant Zoledronic Acid|"Zoledronic acid 4 mg IV prior to pancreatic resection (approximately 2 weeks prior to resection)~Pancreatic resection~Zoledronic acid 4 mg IV monthly for two additional doses"
3200589|NCT00892268|Experimental|Arm I|Patients undergo acupuncture for 20-30 minutes, on the appropriate pain points on the anterior portion of the body alternating with posterior portion of the body, thrice weekly for 2 weeks and then twice weekly for 3 weeks.
2530012|NCT02697097||Control Arm Group|Participants aged 18-30, Male and Female (10 participants each). Control group must have normal range of movement and no evidence of femoro-acetabular impingement (FAI) on clinical examination (negative impingement test, no symptoms). Other exclusions for Control Group include previous surgery to hip joint/s, history of arthritis, family history of FAI, patients who have had symptoms of hip pain in the preceding 1 year or may have other conditions which may affect the hip joint or hip muscle strength including neurological conditions or muscular dystrophy.
2530016|NCT02697097||FAI Arm Comparison Group|Participants aged 18-30, Male and Female (10 participants each). Participants with femoro-acetabular impingement as diagnosed clinically and on radiological imaging for the comparison group (MRI).
3200590|NCT00892268|Active Comparator|Arm II|Patients receive standard-of-care analgesics (i.e., NSAIDs, narcotics, acetaminophen, or other) for 5 weeks. Patients not responding to analgesia may cross over to arm I.
3200591|NCT00892346|Experimental|Single ASCT with Thalidomide maintenance|"Single ASCT followed by Thalidomide maintenance:~patients recieved 4-6 cycles of standard VAD chemotherapy or Thalidomide/dexamethasone as induction therapy~CTX+G-SCF mobilization to collecetd PBSC~Patiens recieved Mel 200 as conditioning followed by Thalidomide 100mg maintenance"
2530359|NCT02694679|Experimental|Friendship 75|The CBNH intervention will be delivered to 75% of households identified through friendship nomination.
3200592|NCT00892359|Experimental|Anidulafungin|
3200593|NCT00892372||1 (type 2 diabetes, body weight, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 70 type 2 diabetic patients treated with the diet therapy. Recorded values at 0, 2 and 4 months for body weight (BW) and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
3200594|NCT00892372||2 (type 2 diabetes, pioglitazone, HbA1c)|The investigators analyzed the recorded data (body weight and glycohemoglobin) of 23 type 2 diabetic patients treated with pioglitazone. Recorded values at 0, 2 and 4 months for body weight (BW)and glycohemoglobin (HbA1c) were used. And changes from baseline (0 month) in BW (ΔBW) were plotted against those of HbA1c (ΔHbA1c).
2528997|NCT02704026||Inflammatory Bowel Disease|Patients 6-18 of age at the time of enrolment who have IBD at any stage of disease activity, on any or no treatment
2529006|NCT02704026||Control|Age- and sex-matched healthy controls
2529102|NCT02703675|Experimental|adult healthy volunteer|Adult healthy volunteers will be recruited from staff in Dept. Neurology, medical students. They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.
2529105|NCT02703675|Experimental|adult normothermic patient|"Adult normothermic patients will be recruited from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~They will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours."
2529108|NCT02703675|Experimental|adult sick febrile patient|"Adult sick febrile patients will be enrolled from Neurocritical Care ICU in The Ohio State University Wexner Medical Center.~Five of the patients will receive a cooling procedure by using the Excel Cryo Cooling Collar around their neck and fitted with activated cooling element for 2 hours.~Other five patients will received 2 rounds of cooling process each 2 hours long"
3166822|NCT00530179|Active Comparator|Arm B|"Standard R-CHOP chemotherapy every 21 days X 2 Cycles followed by PET/CT scan. If scan is determined positive for disease intensity the patient receives one cycle or R-DICEP/R-BEAM the autologous blood stem cell transplantation.~Assigned Interventions: Procedure/Surgery: Autologous Blood Stem Transplantation 2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION"
3166823|NCT00530244|Experimental|1|Infants will be fed formula supplemented with docosahexaenoic acid
2529290|NCT02702076|Experimental|Apomorphine|This arm will be treated with continuous subcutaneous infusion of apomorphine. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator, aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
2529295|NCT02702076|Placebo Comparator|Placebo|This arm will be treated with continuous subcutaneous infusion of placebo. The infusion will start with 1 mg/hr during the waking day (approximately 16 hours). The flow rate will be adjusted on a weekly basis, and may be increased with 0.5 to 1.0 mg/hr per discretion of the investigator aiming at the disappearance of visual hallucinations. The duration of treatment is 4 weeks.
2529323|NCT02701673|Experimental|Belinostat/Gem/Bu/Mel + AutoSCT|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1.~Caphosol oral rinses 30 mL four times a day used from Day -8. Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.~Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1. Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2. Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2. Participants with cluster of differentiation antigen 20 (CD20+) tumors receive Rituximab 375 mg/m2 by vein on Day -9.~Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.~Melphalan 60 mg/m2/d by vein on Day -2. Stem cell transplant by vein given on Day 0."
2529408|NCT02701309||Non-invasive Iron detection|Children between 9months and 5years will be recruited for a non-invasive iron measurement on the lower lip. This study is focusing on the feasability of a non-invasive detection method. There is no intervention planed. The device is tested once for 3-5 Minutes.
2529582|NCT02701036||sporadic adult onset ataxia|SAOA denotes the non-hereditary degenerative adult-onset ataxia disorders that are distinct from multiple system atrophy (MSA). SAOA is a group of ataxia of unknown etiology characterized by a slowly progressive cerebellar syndrome starting around the age of 50 years. Possibly is accompanied by signs of mild autonomic dysfunction that do not meet the criteria of severe autonomic failure required for a diagnosis of MSA.
2529584|NCT02701036||cerebellar multiple system atrophy|Multiple system atrophy of cerebellar type is a cerebellar syndrome with sporadic onset developing in midlife, with autonomic features of otherwise unexplained bladder dysfunction with or without erectile dysfunction in males, orthostatic hypotension and atrophy of the cerebellum, brainstem, and middle cerebellar peduncles.
2529701|NCT02699307|Experimental|Intervention|OT-led counseling based on home activity pattern
3166824|NCT00530244|Placebo Comparator|2|Infants will be fed standard formula (Enfamil)
3166825|NCT00530283||A|Patients with Squamous cell cancer of neck nodes, unknown primary
2529808|NCT02698722|No Intervention|Control|This group will receive verbal education about dialytic and non-dialytic therapies via a standardized script.
2529809|NCT02698722|Experimental|Intervention|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
3166826|NCT00530309|Experimental|Subjects receiving GSK716155 + placebo|Eligible subjects will receive GSK716155 with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks. Subjects will also receive placebo.
3166827|NCT00530322||A|"Patients who have had previous open colorectal surgery and are referred for a further operative procedure, at which time a second-look laparoscopy can be performed."
2529947|NCT02697461|Experimental|Intrinsic Foot Arm|In arm 1, a randomized control trial will be used in the investigation of validity and reliability comparing multisegmented foot motion, clinical joint physiological and accessory motion, and morphologic foot measurements, and the effect of intrinsic foot strengthening on multisegmented foot function.
2529948|NCT02697461|Experimental|Joint Mobilization Arm|In arm 2, the investigation of group differences in clinical and laboratory measures of multisegmented foot motion and kinetics will use a case control design. A randomized controlled trial will be conducted in the study investigating joint mobilization, with the researcher performing the assessments and the provider performing the treatments blinded to group allocation
3166828|NCT00530322||B|"Patients who have had a previous laparoscopic colorectal procedure and are having a second-look procedure"
3166829|NCT00530374|Active Comparator|1|Each child in this group will receive daily supplementation of Iron Sprinkles with a single sachet for 60 days
2528999|NCT02703935|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
2529049|NCT02703649|Experimental|Single dose|Single 20 mg dose of Letrozole on day 3 of the menstrual cycle.
2529056|NCT02703649|Active Comparator|Daily dose|Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
2529093|NCT02703363|Experimental|Minocycline with TAU|
2529094|NCT02703363|Experimental|Celecoxib with TAU|
2529096|NCT02703363|Experimental|Minocycline and celecoxib with TAU|
2529099|NCT02703363|Active Comparator|Placebo with TAU|
2529159|NCT02703051|Experimental|GMI-1271|GMI-1271
2529164|NCT02703051|Active Comparator|Filgrastim|Filgrastim
2529167|NCT02703051|Experimental|GMI-1271 with Filgrastim|GMI-1271 with Filgrastim
2529202|NCT02702596|Experimental|MBIC + DEF|Measurement-Based Integrated Care with Depression Education Fotonovela
2529207|NCT02702596|Experimental|MBIC + SE|Measurement-Based Integrated Care + Standard Education
2529254|NCT02702336|Experimental|EYTO-Kids Intervention Group|Adolescents will receive 16h of training (2h healthy lifestyle training, social marketing and communication, 6h to design activities, 2h session together with all intervention high-schools, 6h to practice and standardize activities) and 4h (1h/activity) to implement 4 activities in schools. The scholars will receive 4 activities designed by adolescents, focusing on: 1) increasing fruit consumption, 2) increasing vegetable consumption, 3) increasing physical activity practice and to reduce sedentary lifestyles and, 4) decreasing sugary drinks and fast-food consumption.
2529255|NCT02702336|No Intervention|Control Group|The control group will not receive any kind of intervention (only the assessment).
2529321|NCT02701816||K-INNOVA|Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).
3200595|NCT00892385|Experimental|Non-CNS Disease|A traditional 3 + 3 dose escalation design will be implemented. Successive cohorts of participants (3 participants/cohort) will be entered sequentially to each dose level. If 0/3 participants at a dose level experience dose limiting toxicity (DLT) new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 2 or more experience DLT in the first cycle, no further participants are started at that dose and the MTD is the highest dose level in which <2 (of 6) participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if a DLT has not been observed.
3200596|NCT00892385|Experimental|CNS Disease|A traditional 3 + 3 dose escalation design with successive cohorts of 3 participants will be entered sequentially to each dose level. If 0/3 participants experience DLT, new participants may be entered at the next higher dose level. If 1 participant has a DLT, 3 more will be enrolled at the same dose level. If the 1st participant in the expanded cohort (4th at the given DL), experiences no DLT, the remaining 2 participants can start treatment. If 1/3 participants experience a non-CNS DLT in Cohort B dose level 6, dose escalation will continue to dose level 7, as 3 subjects have already been treated in Cohort A dose level 6 and 7 subjects in Cohort A dose level 7, none of whom experienced non-CNS toxicities. If 2 or more experience DLT in cycle 1, no more participants are started at that dose and the MTD is the highest dose where <2/6 participants develop DLT. If the final dose level is deemed the MTD, 6 participants will be treated at this dose level even if no DLT has been observed.
2529437|NCT02700971|Experimental|Cutaneous Biopsy for microarray analysis|To determine whether outcomes improve as a function of anti-tumor immunity which may enable the use of this technique as a predictive biomarker of treatment response.
2529501|NCT02700789||Pregnant women|Women with a positive urinary pregnancy test following in vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI) treatment will be invited to attend for an additional transvaginal ultrasound scan at 33-34 days gestation. This will be conducted by a single investigator with experience in early pregnancy ultrasound using a Voluson E8 machine with a high frequency (5-9MHz and 9-12MHz) transvaginal probe and following standard operating procedures.
3200597|NCT00892398|Experimental|ranibizumab|Trabeculectomy with mitomycin C associated with 2 subconjunctival injections of ranibizumab: 1 intraoperatively and 1 at 2 weeks post-operatively
3200598|NCT00892398|Active Comparator|standard care|Trabeculectomy with mitomycin C and standard post-operative care
2529656|NCT02699580|Experimental|Biodegradable collagen implant|Both eyes are needed to correct strabismus. One eye is randomly selected for the placement of biodegradable collagen implant.
2529657|NCT02699580|Active Comparator|Without biodegradable collagen implant|Strabismus surgery is done without placing of biodegradable collagen implant in the other eye.
2529688|NCT02699346|Experimental|HS-1000 recording|Eligible patients and healthy subjects will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears. HS-1000 monitoring intervals will last from 20 minutes continuously. Following completion of data collection, HS-1000 will be removed.
2529839|NCT02698358||K-EPIC|Patients with femoropopliteal artery disease undergoing endovascular therapy using Epic stent (Boston Scientific).
2529876|NCT02698007|No Intervention|without lma|standard fiberoptic bronchoscopy without lma
2529881|NCT02698007|Experimental|with lma|fiberoptic bronchoscopy with the use of lma
2530003|NCT02697357||Caregivers|This study is a pilot, single-arm intervention of Emotion Regulation Therapy for Cancer Caregivers (ERT-C). We plan to recruit a pilot sample 32 consented (24 evaluable) caregivers of patients diagnosed with cancer and measure their distress, anxiety, and other psychological outcomes at baseline. Caregivers will be consented into an 8-session ERT-C therapy (approximately 12 - 16 weeks).
2530036|NCT02696863||filling a questionnaire and interview|"The questionnaire is tracking occupational carcinogens. It consists of 30 questions , fills an average of 3 minutes and includes three response categories: yes, no and do not know. A questionnaire will be added social and professional issues.~Interviews will be conducted with the patient to identify obstacles and facilitating elements"
2530371|NCT02694510|Active Comparator|Light-exposure|TPN bags and infusion sets will be exposed to light throughout the study period.
2529040|NCT02703961|Other|control|"standard chemoradiotherapy with weekly cisplatin.~Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29.~Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate intracavitary brachytherapy."
3200599|NCT00892411||All study participants|Patients With Acute Low Back Pain
3200600|NCT00892424|Experimental|Sorafenib + RT|
3200601|NCT00892450|Experimental|Arm 1|crossover design
3200602|NCT00892476|Experimental|1|Infants receive supplemental calcium in their 24 cal/oz formula or fortified breast milk.
2529235|NCT02702804|Experimental|High Intensity Interval Training|Participants will attend two sessions per week for the 6 week intervention. Each session will consist of 6-10 sets of 60 second high intensity intervals interspersed with 60 seconds recovery. The workload during each interval will be set at 80-90% of peak power achieved during the VO2peak test. This is predicted to elicit 85-95% heart rate reserve in the participants. After each interval the participant's heart rate and rate of perceived exertion (RPE) will be collected. After each session a researcher will complete an Adverse Event form to record if an event occurred or not. Additionally the participant will complete a physical activity enjoyment (Perceived activity enjoyment scale) after one session per week.
2529283|NCT02702245|Placebo Comparator|Placebo comparator: Control|OGTT without thylakoids.
2529284|NCT02702245|Experimental|Experimental: Thylakoids 5 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 5 g. Intervention: OGTT at one occasion.
2529285|NCT02702245|Experimental|Experimental: Thylakoids 10 g|Intervention type: Dietary supplement. Supplement: thylakoid powder, dose 10 g. Intervention: OGTT at one occasion.
3200603|NCT00892476|Active Comparator|2|Infants will receive fortified breast milk or 24 cal/oz formula
3200604|NCT00892502|Active Comparator|1|Bismuth tablets
3200605|NCT00892502|Placebo Comparator|2|Placebo tablets, containing no active substance
3200606|NCT00892515|Experimental|exercise|
3200607|NCT00892554|Experimental|DHA supplementation|
3200608|NCT00892554|Placebo Comparator|corn/soy capsule, no DHA|
3200609|NCT00892567|Experimental|9 Peptide Vaccine|
2529482|NCT02700529|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
2529497|NCT02700529|Placebo Comparator|placebo|matched placebo capsules TID, administered orally for a total of 24 weeks
3200610|NCT00892593|Experimental|1 Fecal Immunochemical Testing-Surveillance|Fecal Immunochemical Testing performed at yearly intervals.
3200611|NCT00892593|No Intervention|2 Usual Care - Surveillance|
2529683|NCT02699216|Experimental|Phase 1 Active Treatment|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
2529687|NCT02699216|Placebo Comparator|Phase 1 Sham Treatment|Subjects will undergo 8 sham treatments, approximately 11 minutes, with a non-functional device to the enrolled eyes daily for three consecutive days during week 1, with no treatments on day 4 and 5. Followed by 8 active treatments, for approximately 11 minutes, for three consecutive days, with an active device during week 2, with no treatments on day 4 and 5.
2529693|NCT02699216|Experimental|Phase 2 Open Label|Subjects will undergo 8 treatments, approximately 11 minutes, to the enrolled eyes daily for three consecutive days, with an active device. They will receive no treatments on day 4 and 5.
2529731|NCT02699073|Experimental|Regorafenib|dose of regorafenib : 160mg once daily
2529796|NCT02698644|Experimental|isoamyl2cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
2529844|NCT02698319|No Intervention|Conventional Triage|Conventional triage using Danish Emergency Process Triage (DEPT).
2529846|NCT02698319|Experimental|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is used as triage form in the ED. The Copenhagen Triage Algorithm consists of a few vital parameters and a clinical assessment from the ED nurse.
3200612|NCT00892593|No Intervention|3 Usual Care - Screening|
3200613|NCT00892593|Experimental|4 Fecal Immunochemical Testing-Screening|Fecal Immunochemical Testing yearly, beginning at year 6.
3200614|NCT00892619|Experimental|ILM forceps|Using ILM forceps to initiate and complete peel
3200615|NCT00892619|Active Comparator|Other|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
3200616|NCT00892632|Experimental|1|1. To compare confocal image characteristics of benign vs. malignant biliary strictures
3200617|NCT00892658|Experimental|Sorafenib + RT|
3200618|NCT00892671||medical students|
3200619|NCT00892736|Experimental|Treatment (veliparib)|"Patients receive veliparib PO BID* on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients receive veliparib once on day 1 of course 1 for pharmacokinetic and pharmacodynamic studies."
3200620|NCT00892749|Experimental|1. ASP1585|
3200621|NCT00892762|Experimental|Travoprost APS|Travoprost APS 40 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
3200622|NCT00892762|Active Comparator|XALATAN|Latanoprost 50 micrograms/ml eye drop solution, 1 drop in the study eye(s), once daily each evening, for 90 days
3200623|NCT00892788|Active Comparator|A|Participants assigned to Group A will receive the LEARN (Lifestyle, Exercise, Attitudes, Relationships, Nutrition) Program weight loss manual and will be instructed to read a section of the manual each week and complete suggested activities. They will also meet with the research staff once a week for weigh-in and supportive counseling.
3200624|NCT00892788|Experimental|B|Participants assigned to Group B will receive the LEARN manual and will meet with research staff each week for weigh-in and supportive counseling. They will also receive contingency management or the opportunity to earn draws with the chance of winning prizes for losing weight and completing healthy activities.
3200625|NCT00892801|Experimental|Treatment|RAD001 + radiation therapy
3200626|NCT00892814|Experimental|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
2529297|NCT02702037|Experimental|Intervention|"The participants will be supported to perform the sit-to-stand exercise at least four times per day during 12 weeks (7 days/week).~The participants will also be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week)."
2529308|NCT02702037|No Intervention|Control|Standard care
2529345|NCT02701699|Experimental|18-F-FAZA Scan|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
2529378|NCT02701374|Experimental|1:TRK-700|high dose
2529379|NCT02701374|Experimental|2:TRK-700|low dose
2529380|NCT02701374|Placebo Comparator|3:Placebo|Placebo
2529417|NCT02701244||Permanent Breast Seed Implant (PBSI)|Women with eligible early stage breast cancer who received a permanent breast seed implant status post lumpectomy
3200627|NCT00892814|Active Comparator|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
2529492|NCT02700633||Those with pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
2529502|NCT02700633||Those without pacemaker at discharge|Landmark analysis of early mortality dependant on pacemaker status at discharge
2529562|NCT02700399|Other|Erigo® First|"Erigo® 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Traditional Tilt table 0 - 60 degrees~Step frequency on Erigo® = 48"
2529564|NCT02700399|Other|Traditional first|"Traditional Tilt table 0 - 60 degrees - Wash out period (min 30 minutes, max 120 minutes) - Erigo® 0 - 60 degrees~Step frequency on Erigo® = 48"
2529629|NCT02699944|Experimental|CRT sub-optimal responder|Subjects who have had CRT for at least 6 months and who have not responded as well as they could, in their cardiologists opinion. Subjects' ejection fraction are still <50% despite CRT. A ECG Vest Optimization protocol will be utilized as one aspect to determine the best CRT programming for each individual subject.
2529691|NCT02699541|Experimental|Intervention group|Intervention group participants will receive the educational intervention based on the Information, Motivational, Behavioral change model.
2529697|NCT02699541|No Intervention|Control group|Control group participants will receive usual care treatment and referral to diabetes educational consultation if required.
2529820|NCT02698761|No Intervention|Standard of Care|Patient will receive standard of care. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be aware of study presence but will not receive any specific instruction for the patient.
2529821|NCT02698761|Experimental|Comprehensive Care Plan|Patient will abide by the comprehensive care plan and sign an agreement stating compliance. Subject will have an actiwatch to compare activity and sleep habits. Nursing staff will be notified of study and support patient's compliance with study procedures.
2529854|NCT02698098||Compulsory Drug Detention Center|Conventional drug treatment in Malaysia and Southeast Asia including detention for an average of 2 years, including educational and job skills programs and physical education. Medical therapies for treating substance use disorders, such as opioid-agonist treatment (OAT), are unavailable.
2529856|NCT02698098||Voluntary Treatment Center|Voluntary drug treatment facilities, called 'Cure and Care' centers in Malaysia, that provide methadone maintenance therapy in addition to psychosocial interventions, recreational programming, and vocational training, among other activities.
2529892|NCT02697851|Experimental|Group 1|Microgynon 30® for 21 days, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Evotaz® for 14 days
2529897|NCT02697851|Experimental|Group 2|Evotaz® for 14 days followed by 7 days wash-out, Followed by Microgynon 30® for 21 days plus Evotaz® for 14 days, Followed by Microgynon 30® for 14 days (participants may chose to complete a 21 day pack). The total duration of the study is 57 days (+screening and follow up visits) and patients will have 3 intensive pharmacokinetic days on days 14, 35 and 56
2529998|NCT02697370|Other|Pharmacokinetic based factor VIII dosage|Patient's routine prophylactic factor VIII concentrate infusion will be given in the morning and the exact time (hours and minutes) and dose recorded. There is no wash out so the date, time and dose of the previous 2 prophylactic doses must be accurately known. Samples will be collected that afternoon, the following morning and the following afternoon. Samples can be taken at any convenient time but the exact time must be recorded. Factor VIII levels will be measured and this pharmacokinetic data will be used to calculate the dose of factor VIII (to be infused on alternate days) required to maintain a predicted factor VIII ≥1.5 IU/dL at all times(this will be rounded up to the nearest full 250 IU vial)
2530027|NCT02696876|Active Comparator|Control group|Patients in this group will received conventional microfracture treatment as indicated for isolated cartilage defects and defined by the inclusion criteria.
2530033|NCT02696876|Experimental|Intervention group|Patients in this group will also receive microfracture for the treatment of isolated cartilage defects in combination with arthroscopic synovial brushing to access and release synovial MSCs into the joint space.
2530120|NCT02696551|Experimental|Interventional hospital|Interventional hospital, which will receive 3-month medical education
2530123|NCT02696551|No Intervention|Non-interventional hospital|Non-interventional hospital, which will not receive 3-month medical education.
3200628|NCT00892827|Experimental|Single Arm Study|Rituximab
3200629|NCT00892840|Experimental|Panels 1 to 7 (BMS-820836 or Placebo)|
2529183|NCT02702843|Experimental|Near infrared light|Laparoscopic cholecystectomy with Near infrared light
2529262|NCT02702167|Experimental|High-frequency rTMS|10 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2529263|NCT02702167|Experimental|Low-frequency rTMS|1 Hz repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2529264|NCT02702167|Sham Comparator|Sham rTMS|Sham repetitive transcranial magnetic stimulation to dorsomedial prefrontal cortex, once daily, 5 days per week for 6 weeks
2529572|NCT02701010|Active Comparator|Group 1|Structured training and leaflet
2529573|NCT02701010|Active Comparator|Group 2|Structured training
2529574|NCT02701010|Active Comparator|Group 3|Leaflet
2529575|NCT02701010|Sham Comparator|Group 4|Control group
2529658|NCT02699840||Menactra Study Group 1|Participant aged 2 through 11 years at vaccination
2529659|NCT02699840||Menactra Study Group 2|Participant aged 12 through 17 years at vaccination
2529660|NCT02699840||Menactra Study Group 3|Participant aged 18 through 55 years at vaccination
2529711|NCT02699294|Experimental|Contract-relax PNF stretch|A contract-relax PNF stretching techniques of the pectoralis minor muscle including latent trigger points will be applied by Group 1 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
2529714|NCT02699294|Experimental|Z-stretch|The Z- stretch of the pectoralis minor muscle including latent trigger points will be applied by Group 2 after a single intervention of manual pressure release will be performed according to the techniques describe by Simons et al. (1999).
2529716|NCT02699294|Experimental|Manual pressure release|The single intervention of manual pressure release will be only applied to Group 3 according to the techniques describe by Simons et al. (1999).
2529718|NCT02699294|No Intervention|Control|This is a control group.
2529767|NCT02698852|Experimental|BuMA Supreme group|Totally 1000 subjects combined the 220 subjects from randomized controlled trial(RCT) group
2529853|NCT02698345||K-POP|Patients with isolated popliteal artery disease undergoing endovascular therapy using drug-eluting balloon (In.PACT Admiral, Medtronic)
2529903|NCT02697903|Experimental|9 elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Natural Pomegranate Juice supplementation during and 48h following the first weightlifting training session."
2529905|NCT02697903|Placebo Comparator|9elite weightlifters|"age: 21 ± 0.5 years, body mass: 80 ± 20 kg, height 175 ± 8.1 cm (mean ± SD). They received Placebo Juice supplementation during and 48h following the second weightlifting training session."
2529999|NCT02697396||with text messaging reminder system|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
2530004|NCT02697396||without text messaging reminder system|Participants in this arm will receive no additional vaccination reminders. However, the study staff will ask and record if the participant's pediatrician provides appointment reminder cards, emails and/or calls prior to each scheduled vaccination as captured in the Outcomes Survey.
2530048|NCT02696811|Placebo Comparator|Oat biscuits|Participants will eat 3 oat biscuits per day for 6 weeks
2530058|NCT02696811|Experimental|White Carrots|Participants will eat 100g (cooked weight) of white carrots per day for 6 weeks
2530086|NCT02696473|Experimental|High Carrot Dose|The volunteer will eat 250g carrot for breakfast with 2 slices of bread and 10g butter
2530090|NCT02696473|Experimental|Low Carrot Dose|The volunteer will eat 100g of carrot for breakfast with 2 slices of bread and 10g butter
2530112|NCT02696278|Experimental|Hummus and vegetables|Children will receive a lesson about vegetables and hummus and vegetables as part of their daily snack.
2530117|NCT02696278|Experimental|Vegetables only|Children will receive a lesson about vegetables and vegetables as part of their daily snack.
3166830|NCT00530374|Placebo Comparator|2|Each child in this group will receive daily supplementation of placebo Sprinkles with a single sachet for 60 days
3166831|NCT00530400|Experimental|1|intravenous 1.5g cefuroxime
3166832|NCT00530400|Placebo Comparator|2|intravenous placebo
2530392|NCT02694471|Experimental|Old group|16 old participants (55-65 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
2530394|NCT02694471|Active Comparator|Young group|7 young participants (18-30 years) were included in physical inactivity or bed rest with supervised recovery intervent and underwent 14-day of bed rest. Bed rest was followed by 28-day recovery. During the bed rest participants will remain 24-hour horizontal with all daily activities performed lying in a bed. No social isolation will be forced. During the recovery participants will 3-times weekly per 75 minutes perform guided exercises to achieve baseline level.
2530478|NCT02694224|Experimental|vismodegib plus chemotherapy|Vismodegib 150 mg orally during paclitaxel and then dose dense epirubicin + cyclophosphamide (EC) therapy (see active comparator arm)
2530484|NCT02694224|Active Comparator|chemotherapy|Paclitaxel 80 mg/m2 weekly on days 1, 8 and 15 each 21 days x 12 doses and then dose dense E (90 mg/m2) plus cyclophosphamide (CPA) 600 mg/m2 each 2 weeks x 4 doses
2530577|NCT02693392|Active Comparator|Control|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up without add-on fenugreek extract.
2530586|NCT02693392|Experimental|Fenugreek|One hundred type-2 diabetes patients with standard oral hypoglycemic drugs (metformin +/- sulfonylurea) will be recruited and followed up with add-on fenugreek extract.
2530696|NCT02692781|Experimental|Dose Cohort 1|20mg MOD-6031 / Placebo
2530697|NCT02692781|Experimental|Dose Cohort 2|50mg MOD-6031 / Placebo
2530698|NCT02692781|Experimental|Dose Cohort 3|100mg MOD-6031 / Placebo
3166833|NCT00530413|Experimental|1|Phenobarbital - dose based by weight range
3166834|NCT00530413|Placebo Comparator|2|Placebo group
3166835|NCT00530452|Experimental|A|2.0 mg (loading dose, Day 0) followed by 0.3 mg/day (Days 1-20)
3200630|NCT00892853|Other|Bone Density Scanning|To acquire high resolution images of the bones and aid in determining bone density.
3166836|NCT00530452|Experimental|B|4.0 mg (loading dose, Day 0) followed by 0.6 mg/day (Days 1-20)
3166837|NCT00530452|Experimental|C|8.0 mg (loading dose, Day 0) followed by 1.2 mg/day (Days 1-20)
2529396|NCT02701439||HIV-infected|"Enrollment of 740 HIV-infected adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
2529397|NCT02701439||HIV negative|"Enrollment of 350 HIV negative adults with suspicion of pulmonary TB.~Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention"
2529576|NCT02701114|Active Comparator|Proximal|Proximal Adductor Canal Block
2529577|NCT02701114|Active Comparator|Distal|Distal Adductor Canal Block
2529608|NCT02699879||Pirfenidone|Participants will receive pirfenidone orally according to the physician discretion.
2529715|NCT02699190||Prospective Study Cohort|This cohort comprises recently identified individuals for whom a clinical decision has been made to pursue whole genome sequencing (WGS) as a first-line diagnostic test. The cohort also includes each subject's biological parents.
2529717|NCT02699190||Historical Study Cohort|This cohort comprises approximately 50 historical controls who received either whole genome sequencing (WGS) or standard diagnostic testing as part of their participation in a previous version of this protocol, which used a randomized controlled design to assess diagnostic efficacy of WGS. This cohort is closed to new enrollment, and exists for statistical analysis purposes only.
2529743|NCT02698891|Experimental|Neulasta|"After the screening procedures confirm participation in the research study:~Completion of 4 cycles of dose dense Adjuvant Doxorubicin Cyclophosphamide (AC)~Paclitaxel via IV, once every 2 week x 4 cycles~Neulasta™ (Pegfilgrastim) will be administered in Paclitaxel cycles, if:~The patient experiences a prior episode of fever and neutropenia.~If the patient has an active infection this decision will be at provider discretion.~If Neulasta™(Pegfilgrastim) is administered in any Paclitaxel cycle for a given patient, it will be then administered for all future cycles."
2529810|NCT02698488|Active Comparator|Embryo Selection by Morphology|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study
2529812|NCT02698488|Active Comparator|Embryo Selection by Morphology and Mass Spectroscopy|Embryos will be morphologically evaluated according to the number and regularity of blastomeres and fragmentation degree. Only embryo culture media of good quality embryos (embryos with ≥6 cells with no fragmentation) will be included in the study. After dilution, embryo culture media will be analyzed by electrospray ionization quadrupole time-of-flight (ESI-QTOF) MS. The spectra will be collected in the negative ion mode. Abundance of ions in each spectrum will be further analyzed.
2529841|NCT02698124||Decitabine|"Decitabine 20mg/m2 will be given IV daily on Days 1-5 in 28-day cycles. Treatment should be given for at least 4 cycles in the absence of unacceptable toxicity or disease progression requiring alternative therapy.~Beyond 4 cycles, treatment should continue as long as the subject continues to benefit based on investigator's judgment of no definitive progression."
2529906|NCT02697968|Experimental|Electroacupuncture|
2529931|NCT02697552|Experimental|HBI-8000|HBI-8000 at the assigned dose twice weekly.
2530047|NCT02696694||P25-P75|serum progesterone between 25 and 75 percentile
2530056|NCT02696694||<P25 ó >P75|serum progesterone <25 or >75 percentile
2530238|NCT02695576|Experimental|Surgery|Lumbar fusion surgery Physiotherapy Cognitive behavioral therapy
2530247|NCT02695576|Active Comparator|Non-surgery|Physiotherapy Cognitive behavioral therapy
2530313|NCT02695225|Other|Lay-led tobacco abstinence|Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
2530314|NCT02695225|Other|Lay-led promotion of Ohio Quit Line|Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
3166838|NCT00530452|Placebo Comparator|D|Placebo (identical number of capsules to active drug groups) (Days 0-20)
3166839|NCT00530491|Active Comparator|1|conventional perioperative management for lung surgery
3166840|NCT00530491|Experimental|2|fast track management for lung surgery
3166841|NCT00530517|Experimental|1|
3166842|NCT00530530|Experimental|1|Dose 1
3166843|NCT00530530|Experimental|2|Dose 2
3166844|NCT00530530|Experimental|3|Dose 3
3166845|NCT00530530|Placebo Comparator|4|
3166846|NCT00530725|Active Comparator|chest drainage|This represents the best current standard of care although this is quite controversial
3166847|NCT00530725|Experimental|close observation|This is the novel approach that has some justification in the literature
3166848|NCT00530738|Experimental|1|treatment with Lipoplus & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
3166849|NCT00530738|Active Comparator|2|treatment with Lipofundin MCT & Nutriflex plus (commercially available and marketed 2 Chamber Bag)
3166850|NCT00530829|Experimental|1|Mothers recieve a blister pack of zinc tablets in home every two months for use when child in home under 5 years has diarrhea. ORS satchets also given. Instructions on when and how to use zinc and ORS and when to take child in clinic are given by community health worker. Zinc will also be given in clinic if child visits clinic with diarrhea and has not yet started zinc at home.
2529194|NCT02702700|Experimental|Lipoplatin/Visudyne-mediated photodynamic therapy|200 mg/m2 Lipoplatin™ will be delivered as iv perfusion. Then, intrapleural photo-induction will be realized through a classical video-assisted thoracoscopic (VATS) approach using 3 mg/m2 Visudyne® activated at 689 nm. At the end of the procedure, the patients will receive chemical pleurodesis by VATS as per standard-of-care treatment for malignant pleural effusion.
3166851|NCT00530829|Active Comparator|2|Mothers recieve ORS satchets at home every two months for use when child in home under 5 years has diarrhea. Instructions on when and how to use ORS and when to take child in clinic are given by community health worker. Zinc will be given in clinic if child visits clinic with diarrhea.
3166852|NCT00530868|Experimental|Letrozole + Avastin|
3166853|NCT00530868|Experimental|Letrozole alone|
3166854|NCT00530881|Placebo Comparator|4|
2529512|NCT02700516||Recurrent GN|Renal transplant recipients with biopsy-confirmed recurrent primary glomerulonephritis.
2529515|NCT02700516||Non-recurrent GN|Renal transplant recipients with non-recurrent primary glomerulonephritis.
2529516|NCT02700516||Non-GN|Renal transplant recipients with etiologies other than primary glomerulonephritis.
2529567|NCT02700217|Experimental|Spinal Anaesthesia|2.5ml of heavy 0.5% Bupivacaine, 400mg of Diamorphine (Spinal Anaesthesia) & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
2529568|NCT02700217|Active Comparator|Rectus Sheath Injection|50ml of 0.25% I-Bupivacaine max 2mg/kg (IV block Anaesthesia) injected into rectus sheath bilaterally & IV infusion of Remifentanil 0.2-0.3ug/kg/min, Propofol 2-3mg/kg and 0.2 mg/kg of Cistracurium (General Anaesthesia)
2529628|NCT02699918|Experimental|screening oxymetry|nocturnal oxymetry to screen for sleep apnea
2529704|NCT02699515|Experimental|MSB0011359C (M7824)|
2529762|NCT02698813|Experimental|UCMSCs-HA|Multipoint of Transdermal injection into the wrinkles. Injectable filler agent composed of umbilical cord mesenchymal stem cells (UCMSCs) and hyaluronic acid (HA).
2529764|NCT02698813|Active Comparator|Control|Procedure: Transdermal injection of hyaluronic acid only.
2529805|NCT02698592|Active Comparator|CelsiusTMDS® 8 mm catheter|50 patients underwent ablation with CelsiusTMDS® 8 mm catheter.
2529806|NCT02698592|Active Comparator|Thermocool® 3.5 mm irrigated catheter|50 patients underwent ablation with Thermocool® 3.5 mm catheter of irrigated tip.
2529807|NCT02698592|Experimental|Thermocool® SF catheter|50 patients underwent ablation with Thermocool® SF catheter.
2529827|NCT02698202|Experimental|Digital Breast Tomosynthesis|to the experimental arm will be offered twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
2529829|NCT02698202|No Intervention|standard mammography|to the control arm the usual 2D standard mammography exam will be offered
2529909|NCT02697513|No Intervention|Before Period|Collection of patient-related data without interventions being made
2529910|NCT02697513|Active Comparator|After Period|Implementation of a simple infection management protocol as well as a 'Sepsis First Aid' kit to assist in the management of patients with acute infection
2529929|NCT02697474|Experimental|Hexaxim® Group|Subjects that received Hexaxim® in Study A3L12
2529933|NCT02697474|Experimental|Infanrix® hexa Group|Subjects that received Infanrix® hexa in Study A3L12
2529996|NCT02697175|Experimental|Live Video-Colposcopy|Women are able to observe their colposcopic examination in real-time watching a flat screen in front of them
2529997|NCT02697175|Active Comparator|No Live Video-Colposcopy|Women are not able to observe their colposcopic examination in real-time
2530025|NCT02696837|Active Comparator|ETT & Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and Muscle Relaxant
2530031|NCT02696837|Active Comparator|ETT & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Endotracheal Intubation and No Muscle Relaxant
2530040|NCT02696837|Active Comparator|Proseal LMA & No Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and NO Muscle Relaxant
2530042|NCT02696837|Active Comparator|Proseal LMA & Subparalytic Muscle Relaxant|Children undergoing laparoscopic inguinal hernia repair using PIRS method with Proseal Laryngeal Mask Airway and subparalytic dose Muscle Relaxant
2530108|NCT02696447||Cancer treated by radiotherapy|Patient with a solid cancer (all locations) treated with radiation therapy and/or brachytherapy as curative intent
2530170|NCT02696187|Experimental|KOLwebben|Patients in the experimental group will be introduced to KOL-webben during their ordinary visits to the primary care center. All patients will receive a pedometer
2530175|NCT02696187|No Intervention|Control group|Other than receiving a pedometer the patients in the control group will not receive any intervention.
2530210|NCT02695784|Experimental|Probiotic continuation|This Group will Continue probiotics Beyond 34 weeks corrected Gestational agent standard practice
2530213|NCT02695784|No Intervention|Standard treatment Group|This group will continue current standard practice of stopping probiotics at 34 weeks corrected gestational age
2530240|NCT02695511|Experimental|25% CR|25% caloric restriction
2530248|NCT02695511|No Intervention|CO (control)|healthy lifestyle recommendation
2530305|NCT02695134|No Intervention|Control Group[|This group will continue with their usual medical treatments but receive NO Healing Touch
2530427|NCT02694419||obese/PCO|Women with PCOS who are overweight\obese with BMI ≥ 25 kg/m2.
3166855|NCT00530881|Placebo Comparator|3 active, 1 placebo|
3166856|NCT00530907|Experimental|Valproic Acid + Bevacizumab|"Valproic acid administered at a dose of 5.3 mg/Kg/day on days 1 - 28. Depending on the calculated dose, patients will take capsules once or twice a day per mouth.~Bevacizumab administered at a dose of 2.5 mg/kg by vein every 2 weeks."
3166857|NCT00530933|Sham Comparator|1|Sham tibial nerve stimulation
3166858|NCT00530933|Experimental|2|Percutaneous tibial nerve stimulation
3166859|NCT00530933|Experimental|3|Transcutaneous tibial nerve stimulation
3166860|NCT00530972|Experimental|Peginterferon alfa-2a plus ribavirin|
3166861|NCT00530985|Experimental|1|Benefits Counseling
3166862|NCT00530985|Active Comparator|2|VA Orientation
3166863|NCT00530998||1|Group #1 NOTES Appendectomy - Transvaginal approach
3166864|NCT00530998||2|Group #2 NOTES Cholecystectomy - Transvaginal approach
2529216|NCT02702713|Active Comparator|Egg BEF + dairy placebo + bakery placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg BEF + 1 portion of Dairy placebo + 1 portion of Bakery placebo
2529219|NCT02702713|Active Comparator|Bakery BEF + dairy placebo + egg placebo|200 subjects consuming every day for 12 weeks: 1 portion of Bakery BEF + 1 portion of Dairy placebo + 1 portion of Egg placebo
2529222|NCT02702713|Placebo Comparator|All placebo|200 subjects consuming every day for 12 weeks: 1 portion of Egg placebo + 1 portion of Dairy placebo + 1 portion of Bakery placebo
2529292|NCT02702102|Experimental|11C-PBR28 PET scans|Participants will receive one IV injection of up to 20 millicuries of 11C-PBR28.
2529322|NCT02701738|Experimental|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
2529369|NCT02701569|Experimental|Rebound exercise|Repeated jumping on a mini trampoline was performed with feet slightly apart
2529370|NCT02701569|No Intervention|Control|No exercise was administered but participants continued with routine medical care
2529383|NCT02701335|Experimental|Experimental group|Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
2529386|NCT02701335|Active Comparator|Control group|Gloreha device and standardized exercise. 12 sessions over 4 weeks (3 sessions per week).
3166865|NCT00531024|Experimental|1|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
2529478|NCT02700737|Active Comparator|Group A|"Interventional cardiologists presented with limited dataset including only information that is available from imaging parameters currently recommended by clinical practice guidelines."
2529480|NCT02700737|Experimental|Group B|Interventional cardiologists presented with the full dataset, including imaging parameters currently recommended by clinical practice guidelines and image-based simulation modelling.
2529649|NCT02699671||acute myocardial infarction|
2529686|NCT02699411|Active Comparator|dry needling|Dry needling on the vastus is performed in patients undergoing ACL fortnight after the intervention and then evaluated. REL dry needling while supplies last twenty insertions before treatment, at midnight, a week and five weeks.
2529694|NCT02699411|Active Comparator|Stability and propioception|Proprioception and stability exercises in patients undergoing ACL fortnight after the intervention and then evaluates performed before treatment, at midnight, a week and five weeks.
2529755|NCT02698904|Experimental|Guided Relaxation Technique|Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes, one-session, guided relaxation technique Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes relaxation technique (listening via headphone to audio recording. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes.
2529759|NCT02698904|Sham Comparator|Documentary movie|"Forced Vital Capacity (FVC), Forced Expiratory Volume in the First Second (FEV1), FEV1/FVC, Heart Rate Variability (HRV), airway resistance (kPa/l/s), before and after an 11 minutes documentary movie.~Following 30-40 minutes questionnaire, 5 minutes heart rate (HR) and oxygen saturation (SpO2) recording, 11 minutes documentary movie (listening via headphone. In the meanwhile, heart rate and saturation are recording) to be completed by second heart rate (HR) and oxygen saturation (SpO2) recording. Entire procedure 60-80 minutes."
2529936|NCT02697799|Experimental|High-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
2529943|NCT02697799|Experimental|Mid-level recruitment strategy|Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
2529946|NCT02697799|No Intervention|No modified recruitment strategy|Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
2529966|NCT02697136|Experimental|CER-001|CER-001 infusion; 9 weekly infusions followed by 20 biweekly infusions
2529969|NCT02697136|Placebo Comparator|Placebo|Saline infusion; 9 weekly infusions followed by 20 biweekly infusions
2530050|NCT02696915|Placebo Comparator|Placebo|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of saline 0.9%. Then intrathecal medications will be administered.
2530059|NCT02696915|Active Comparator|Bupivacaine|Patients received ultrasound guided fascia iliaca compartment block using 40 ml of 0.25% bupivacaine. Then intrathecal medications will be administered.
3166866|NCT00531024|Placebo Comparator|2|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
3166867|NCT00531089|Experimental|Study group|"All patients in the study will be in the study group and will receive rituximab. There is no control arm."
3166868|NCT00531102|Experimental|1|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. All infants will have a pulse oximetry probe placed on the right hand (pre-ductal position) immediately after birth. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 1 - infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes."
3166869|NCT00531102|Active Comparator|2|"Resuscitation will proceed as per standard of care and infants are only to receive respiratory support if they remain cyanotic despite 60 seconds of spontaneous regular respirations. Infants that meet the entry criteria will be randomized to resuscitation with one of two neonatal T-piece resuscitator circuits:~GROUP 2 - infants will receive 50% oxygen at a rate of 6 liters per minute continuously for at least 5 minutes using a modified neonatal T-piece resuscitator circuit that does not generate pressure. Fifty percent oxygen was chosen because it reflects the actual inspired oxygen concentration when 100% oxygen is blown towards the infant's face."
3166870|NCT00531115|Experimental|1|
2529230|NCT02702778|Active Comparator|4mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 4mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
2529231|NCT02702778|Active Comparator|7mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 7mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
2529238|NCT02702778|Active Comparator|10mg DR-Prednisone|Subjects in this arm will receive a night-time dose of 10mg delayed-release prednisone for two weeks followed by treatment with 15mg IR-prednisone in the morning for two weeks.
3166871|NCT00531141||A|examination twice by examiner 1
3166872|NCT00531141||B|examination first by examiner 1 thereafter by examiner 2
3166873|NCT00531141||C|examination first by examiner 2 thereafter by examiner 1
2529329|NCT02701842|Experimental|Validity|ImPACT Online a computerized test will be administered to subjects. They will also receive a battery of paper and pencil neuropsychological tests.
2529334|NCT02701842|Active Comparator|Test/Re-Test|ImPACT Online will be administered at 2 time points.
2529391|NCT02701452|Experimental|COAGO|All patients undergoing antagonist protocol and at high risk of OHSS (estradiol level ≥ 3000 pg/mL and/or more than 20 follicles ≥ 11mm on the day of triggering) were triggered by GnRH agonist.
2529435|NCT02701179|Active Comparator|1 % Lignocaine|1 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
2529443|NCT02701179|Active Comparator|2 % Lignocaine|2 % Lignocaine administered for topical anaesthesia during bronchoscopy procedure
2529488|NCT02700763|Experimental|[18F]dabrafenib molecular imaging|A [18F]dabrafenib PET scan will be performed at baseline (7 days or less before the start of treatment with oral dabrafenib).
2529552|NCT02700360|Experimental|Part 1(1,000mg dose): group 1|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; cross-over period: 7 days
2529556|NCT02700360|Experimental|Part 1(1,000mg dose): group 2|period 1: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, on an empty stomach; period 2: EC-18 1,000 mg(500 mg/cap, 2 capsules) once daily, after high-fat diet intake; cross-over period: 7 days
2529559|NCT02700360|Experimental|Part 2(500mg dose): group 3|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; cross-over period: 7 days
2529561|NCT02700360|Experimental|Part 2(500mg dose): group 4|period 1: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, on an empty stomach; period 2: EC-18 500 mg(500 mg/cap, 1 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
2529565|NCT02700360|Experimental|Part 2(2,000mg dose): group 5|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, after high-fat diet intake; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; cross-over period: 7 days
2529566|NCT02700360|Experimental|Part 2(2,000mg dose): group 6|period 1: EC-18 2,000 mg(500 mg/cap, 4 capsules) once daily, on an empty stomach; period 2: EC-18 2,000 mg(500 mg/cap, 4 capsule) once daily, after high-fat diet intake; cross-over period: 7 days
2529602|NCT02699814|Experimental|H3 Parent/Child Dyads|A child is eligible for the H3 partnered evaluation if he or she is: 1) between the ages of 0.0-16.99 years; 2) speaks Spanish or English; 3) screens positive for a developmental delay or mental health problem. For children in the intervention groups, the additional eligibility criteria are: 1) referral to the H3 care program by a pediatrician based on clinical judgment; and 2) no prior history of receiving any H3 services in the past year.
2529624|NCT02699645|Experimental|Triple Pill (active treatment)|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
2529632|NCT02699645|Placebo Comparator|Placebo|received via blinded study capsules
2529719|NCT02699177||Suspected PCD but negative|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
2529720|NCT02699177||Suspected PCD but positive|"CBF measurements:~Patients with suspected PCD will have their nasal cavity photographed using a Sony-video camera that will record the reflected light of a green LED bulb.Ciliary beat frequency (CBF) will be calculated by interferometry using a program developed by the PI.~Patients will undergo a nasal brush biopsies. The fresh biopsies will be analyzed by high-speed video microscopy to calculate CBF.~The two methods will be compared."
2529768|NCT02698826|Experimental|Adult patients resuscitated from cardiac arrest|Rapid FiO2 optimization protocol
2529782|NCT02698501|Experimental|MEDI9929|MEDI9929 is a human monoclonal antibody immunoglobulin IgG2λ directed against TSLP. MEDI9929 binds with human TSLP and prevents its interaction with thymic stromal lymphopoietin receptor (TSLPR).
2529784|NCT02698501|Placebo Comparator|Placebo|Apart from the active substance, the placebo is otherwise identical to IMP.
2529874|NCT02698072|Experimental|Exercise and dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using Hong's fast-in and fast-out technique with multiple rapid needle insertion."
2529879|NCT02698072|Active Comparator|Exercise and sham dry needling|"24 therapeutic exercise sessions (twice a week) of a land-based therapeutic exercise program consisting of aerobic exercise (20-25 min warm-up), lower limbs muscle strengthening (20-25 min) and lower limbs muscles stretching (10-15 min).~6 sham dry needling sessions (once a week) at all the pain points of the involved symptomatic lower limb/s using a park sham device consists of a base with a hole in the centre and sticky tape on the bottom. From the top of the base extends a double tube, continuing the central hole in the base."
3166874|NCT00531141||D|examination performed twice by examiner 2
3166875|NCT00531167|Experimental|A|combination therapy
3166876|NCT00531167|Active Comparator|B|entecavir
3166877|NCT00531180|Experimental|4-DCT Ventilation Validation|
3166878|NCT00531193|Other|1|Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
3166879|NCT00531219||1|Group #1 NOTES Appendectomy - Transgastric approach
2529300|NCT02701998|Experimental|mHealth-Enhance Physical Activity Intervention|Tech-PAI participants will be given 3 goals: 1) to increase their average baseline daily walking exercise by 30 minutes at week 12; 2) to increase their average baseline daily steps by 4,000 at week 12; and 3) to get up and walk for at least 2 minutes after every 60 minutes of sitting. Participants will receive instruction on how to gradually and safely increase their bout-related walking exercise and steps over the 12 week period. In addition to goal setting, Tech-PAI participants will receive a commercially available activity tracker and accompanying that provides real-time monitoring of steps, activity minutes, and issues a text-based prompt after 60 minutes of sitting to get up and move. Also, participants will receive a weekly e-mail feedback message from research staff on goal progress and will be asked to view weekly Internet-based video lessons that will provide behavioral strategies to increase MPA and steps and decrease SB during the first 6 weeks of the intervention period.
2529307|NCT02701998|Active Comparator|Physical Activity Intervention|PAI participants will be given the same goals as Tech-PAI intervention participants and receive a pedometer and related print materials to assist them in recording and increasing daily steps and bout-related MPA (but no activity tracker, access to video-based skills training lessons, or weekly feedback).
2529330|NCT02701660|Experimental|electronic medication dispenser|An Automatic Tablet Dispensing and Packaging System is used to repack all solid oral prescription medications for each participant into unit-of-dose pouches. Every participant receives a roll with pouches for 14-28 days loaded into a dispenser installed at their homes. The electronic medication dispenser is a remote controlled, electronic medication management aid reminding the patients with acoustic alerts to take their medication.
2529399|NCT02701517|Active Comparator|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by folinic acid rescue. All patients will receive CSA from day -7.
2529400|NCT02701517|Experimental|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
2529470|NCT02700828|Active Comparator|Hydrocortisone|Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland
2529471|NCT02700828|Placebo Comparator|Placebo|Isotonic sodium chloride is an aqueous solution of 0.9 percent sodium chloride which is isotonic with the blood and tissue fluid
2529481|NCT02700568|Experimental|axitinib|Patients will receive axitinib.
2529523|NCT02700243|Experimental|Fitbit|Participants receive a Fitbit and are followed over the course of one year, completing surveys and exercise tests.
2529527|NCT02700243|No Intervention|Usual Care|Participants receive usual care over the course of one year and are offered a Fitbit in the second year. Followed to assess use of Fitbit and health outcomes.
2529585|NCT02700152|Experimental|all subjects|"Eligible subjects will receive 3 treatments, 2 weeks interval, with the UltraShape device according to the study protocol and user manual.~The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment, for total expected study duration of 16 weeks"
2529641|NCT02699801|Active Comparator|Propofol|Patients received propofol for post-operative sedation
2529644|NCT02699801|Active Comparator|Dexmedetomidine|Patients received dexmedetomidine for post-operative sedation
2529690|NCT02699359|Experimental|HS-1000 recording|Study participants will receive HS-1000 ICP readings for a continuous 16 minute interval in a 30 degree supine position. Recordings will be obtained in one session. When possible, these recordings will be obtained at their initial examination and all follow-up visits. Sports Medicine staff will coordinate the HS-1000 device earplug insertion and recordings so as not to interfere with, nor marginally delay the patient's normal, routine clinical evaluation.
2529756|NCT02699034|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device ( Vision-MR ablation catheter )
2529803|NCT02698605|Experimental|Usability test study of the MirrorPath|This study was a one-arm study and all subjects used the device and received usability test.
2529838|NCT02698254|Experimental|Arm I (conventional fractionation)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
2529842|NCT02698254|Active Comparator|Arm II (conventional fractionation, bevacizumab)|Patients undergo radiation therapy with conventional fractionation and dose constraints. Patients also receive bevacizumab concurrently at the discretion of the treating neuro-oncologist. Treatment continues for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
2529952|NCT02697630|Experimental|Pembrolizumab and Entinostat|
2530049|NCT02696954|Experimental|Group A|
2530057|NCT02696954|Experimental|Group B|
2530130|NCT02696343|Experimental|EPI experimental|Preterm infants randomized to receive the PULSED orocutaneous somatosensory stimulation from the NTrainer during tube feedings.
2530133|NCT02696343|Sham Comparator|EPI control|Preterm infants randomized to receive the Sham (blind pacifier) during tube feedings.
2530183|NCT02695992|Active Comparator|Metoprolol|Metoprolol, extended release tablets. 100 mg daily
2530186|NCT02695992|Active Comparator|Diltiazem|Diltiazem, extended release tablets. 360 mg daily
2530223|NCT02695693|Experimental|TeachTown|Students in kindergarten-through-second-grade autism support classrooms in this arm receive access to TeachTown, an online academic and pre-academic intervention designed for students with autism. Their teachers also receive coaching in the use of TeachTown, as well as coaching in other evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
2530224|NCT02695693|Active Comparator|Control|Teachers in kindergarten-through-second-grade autism support classrooms in this arm receive coaching in evidence-based practices for students with autism, including discrete trial training, pivotal response training, and teaching in functional routines
2530261|NCT02695407|Experimental|3 days cannulation|radial artery cannula removed after 3 days
2530263|NCT02695407|Experimental|5 days cannulation|radial artery cannula removed after 5 days
2530369|NCT02694510|Active Comparator|Light-protection|Light-protection of TPN solutions. TPN bags and infusion sets will be protected from light by aluminum foils throughout the study period.
2529306|NCT02702063|Other|Right heart catheterisation|Twenty five patients undergoing routine right heart catheterization (RHC) at the department of cardiology for the evaluation of suspected pulmonary hypertension or heart failure will be included in this trial. EC measurements will be obtained during RHC, and a TTE (for measuring LVOT-area) will be performed immediately before undergoing RHC. Inclusion and exclusion criteria are similar as described above.
2529312|NCT02702063|Other|Passive leg raising test|"50 Patients undergoing routine transthoracic echocardiography at laboratory for transthoracic echocardiography at the department of cardiology of Medical University Vienna will be enrolled following informed consent. Non-inclusion criteria are inability to understand study procedure and age under 18 years old.~Patients with any grade of aortic regurgitation, congenital heart disease with intracardiac shunt (left-right shunt or right-left shunt) or arrhythmia (atrial fibrillation) or withdrawing consent during study procedure will be excluded. In addition, patients with intraabdominal (IAH), intracranial (ICH) hypertension or any disease of the hip joint, will not be included into the trial.~SV and CO will be measured using TTE and EC. Patient's legs will then be raised by 45degree, and SV and CO measurements will be repeated after 1 minute. Changes in SV and CO observed with both methods will be compared."
3200631|NCT00892866||Ancillary-Correlative (biomarkers in cervical cancer)|Patients undergo liquid-based cytology specimen sample collection for analysis of CA-IX, p16, Ki-67, and MCM2 expression via IHC and for the presence of high risk HPV DNA and HPV genotyping.
3200632|NCT00892879|Experimental|1|Single port laparoscopic device
3200633|NCT00892879|Active Comparator|2|Four-port laparoscopic device
2529450|NCT02701075|Experimental|MC5-A Scrambler Therapy|MC5-A Scrambler Therapy is an electroanalgesia device that interferes with pain signal transmission by using nerve fibers as a passive means to convey a no pain message to the central nervous system. Electrodes are placed on dermatomes that correspond to the area of pain. Patient is treated for 30 minutes and given up to 10 treatment sessions.
2529455|NCT02701075|Sham Comparator|MC5-A Scrambler Therapy Sham Device|The MC5-A Scrambler Therapy Device will be used as an active sham device in this randomized double blind study. Participants assigned to this arm will not receive active therapy.
2529475|NCT02700724|Other|Observation|Patients will not undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Surgery will commence after 12 months of observation or sooner if cystoscopic evidence of disease progression or patient desire.
2529477|NCT02700724|Other|Immediate Surgery|Patients will undergo immediate surgery. These patients will undergo surveillance cystoscopy and urinary cytology every 3 months for 12 months. Repeated surgery will be offered for additional recurrences.
2529551|NCT02700438|Active Comparator|Glyceryl trinitrate ointment|Commercially available aluminium tubes containing 0.4 glyceryl trinitrate ointment (Rectogesic, proStrakan Group, Galashiels, UK) were purchased from pharmacies. The dosage for all the patients was 375 mg of ointment (containing 1.5 mg of glyceryl trinitrate), applied with a gloved finger to the distal anal canal, every 12 hours for an 8-week period.
2529555|NCT02700438|Experimental|Urgent PC Neuromodulation System®|The Urgent PC Neuromodulation System® (Uroplasty, Minnetonka, MN, USA) was used for percutaneous posterior tibial nerve stimulation. Subjects underwent one 30-min session 2 days per week for 8 consecutive weeks in an outpatient clinic. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion. PPTNS was undertaken at the highest amplification (0-20 mA) at a frequency of 20 Hz, causing neither a motor response nor pain.
3200634|NCT00892892|Experimental|Arm 1|Rilmenidine as a sympatholytic agent for three months
2529736|NCT02699138|Experimental|Trazodone|To determine effect of trazodone on quality of sleep as measured by apnea hypopnea index in subjects with obstructive sleep apnea and PTSD on routine overnight polysomnogram.
2529740|NCT02699138|Placebo Comparator|Placebo|To compare placebo outcomes against administration of trazodone
2529797|NCT02698657|Experimental|ASP5094 Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
2529799|NCT02698657|Placebo Comparator|Placebo Dose Escalation|Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.
2529826|NCT02698150||Remote monitoring|Active group of patients undergoing daily remote monitoring using sensors and wearables
2529828|NCT02698150||Control|Control group of patients undergoing standard follow up wth no remote monitoring
2529880|NCT02698059|Experimental|Treated|iNAP® Sleep Therapy System Treatment
2529886|NCT02698059|No Intervention|Baseline/Control|Self-controlled, pre-treatment baseline
3200635|NCT00892892|Active Comparator|Arm 2|Nitrendipine as a non-sympatholytic agent for three months
3200636|NCT00892905||POC INR and APTT Hemochron|Adult patients undergoing elective on pump coronary artery bypass grafting surgery who have not received anticoagulants or clopidogrel within 5 days preoperatively.
3200637|NCT00892918|Active Comparator|Moxifloxacin|About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
3200638|NCT00892918|Active Comparator|Gatifloxacin|About 20 patients treated by Gatifloxacin ophthalmic solution 0.3% (Zymar) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.
3200639|NCT00892944|Experimental|1|AZD2516
3200640|NCT00892970|Experimental|1|
3200641|NCT00892970|Placebo Comparator|2|
3200642|NCT00892983|No Intervention|Standard well child care|Standard Well Child Care (SWCC) - 8 Core visits at 2-4 weeks, 6 weeks, 3, 5, 8-10 and 15 months, 2 and 3 years.
2529353|NCT02701920||Newborns and surgical delivery|Well term newborn infants following birth by cesarean section.
2529357|NCT02701920||Newborns needing stabilisation|Newborn infants requiring resuscitation or stabilisation following birth.
2529360|NCT02701920||Parental feedback|Parental feedback of babies recruited into HeartLight will be sought.
2529363|NCT02701920||Healthcare provider feedback|Healthcare professionals caring for babies recruited into HeartLight will have their feedback on the device sought.
2529590|NCT02700126||undergoing propofol based TIVA for clip|This study is an observational study performed in adult patients undergoing propofol based TIVA for clipping of unruptured cerebral aneurysm. We will collect data regarding recovery after stopping propofol infusion (time for eye opening and extubation), propofol requirement during anesthesia maintenance, and propofol effect site concentration to achieve bispectral index 40 during anesthesia induction, without doing any interventions. Data collection will be established with just observing and recording values displayed in screens of monitoring devices, and reviewing patient charts.
2529614|NCT02699827|Active Comparator|Magnesium sulphate group|Patients will receive epidural levobupivacaine hydrochloride + magnesium sulphate
2529616|NCT02699827|Placebo Comparator|Placebo group|Patients will receive epidural levobupivacaine hydrochloride + saline 0.9%
2529692|NCT02699476|Active Comparator|Individual + Computer A|Daily activities involve playing one hour of computer games (e.g., hangman, boggle, word scramble, chess; computer cognitive training A (CCA)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
2529698|NCT02699476|Experimental|Individual + Computer B|Daily activities involve playing an alternative set of computer games (computer cognitive training B (CCB)), and two (2) 90 minute individual training sessions interacting one-on-one with a trainer in a variety of cognitive tasks including attention, memory, and comprehension of information.
2529703|NCT02699476|Active Comparator|Group + Computer B|Daily activities involve group and individual cognitive therapy discussions on health, nutrition, and other topics and computer cognitive training B (CCB).
3166880|NCT00531219||2|Group #2 NOTES Cholecystectomy - Transgastric approach
3166881|NCT00531258|Active Comparator|1|
2529843|NCT02698332|Active Comparator|Algorithm for UTI|Practices in this groups receives a diagnostic algorithm for UTI by post
2529845|NCT02698332|No Intervention|Control|Practices in this group does not receive anything in addition to instructions in the observational registration.
2529870|NCT02697942|No Intervention|Standard of care|Participants randomized to the standard of care arm will not receive any intervention.
2529875|NCT02697942|Experimental|Cognitive training (CT)|"Participants randomized to the CT arm will be given a tablet with connection to Lumosity®, which is a web-based brain game. Participants will use the tablets to play brain games at each dialysis session."
2529882|NCT02697942|Active Comparator|Exercise training (ET)|Participants randomized to ET arm will be given a stationary foot peddler. This foot peddler will be situated at a comfortable distance from the dialysis chair so that the patient can comfortably reach the peddler. Participants will use the foot peddlers at each dialysis session.
2529927|NCT02697721|Experimental|Powerful Tools for Caregivers|A 6-week psycho-educational program
2529935|NCT02697721|Other|Control group, delayed intervention|Control group with delayed intervention
3166882|NCT00531258|Placebo Comparator|2|
3166883|NCT00531297|Experimental|Treatment arm|endoscopic posterior mesorectal resection
2530231|NCT02695823|Experimental|Patients undergoing liver transplantation|
2530288|NCT02695355|Experimental|ADHD medication effects|Single dose methylphenidate (Ritalin tablets); 10 mg for ages 8-13; 15 mg for ages 13-17
2530302|NCT02695069|Experimental|All Participants|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
2530422|NCT02694354|Experimental|BI 685509|
2530426|NCT02694354|Placebo Comparator|Placebo|matching placebo
2530471|NCT02693990|Experimental|Grade II (Atypical) Meningiomas, STR|Patient will be treated at the starting dose of Intensity Modulated Proton Therapy (IMPT) which is pre-determined.
2530474|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, GTR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
2530476|NCT02693990|Experimental|Grade III (Malignant) Meningiomas, STR|Patient will be treated at a pre determined dose of Intensity Modulated Proton Therapy (IMPT) for the specific cohort.
2530550|NCT02693561|Active Comparator|Deep Breathing Exercises|Technical Deep Breathing.
2530553|NCT02693561|Active Comparator|Self-Help Book|Reading the self-help book.
3166884|NCT00531310|Experimental|Matched Family Donor|Matched Family Donor
3166885|NCT00531310|Experimental|Unrelated Donor|Unrelated Donor Transplant/ Cord Blood Transplant
3166886|NCT00531323|Other|1|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
3166887|NCT00531323|Other|2|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
3166888|NCT00531336|Experimental|1|Avastin first followed by retreatment of Macugen
3166889|NCT00531336|Active Comparator|2|Avastin intravitreally every 6 weeks
3166890|NCT00531336|Active Comparator|3|Macugen intravitreally every 6 weeks
3166891|NCT00531349|Active Comparator|A|General anesthesia and opioid analgesia for the treatment of pain after surgery.
3166892|NCT00531349|Active Comparator|B|Regional anesthesia and analgesia (epidural) combined with deep sedation or general anesthesia.
3166893|NCT00531362||Patients|All patients (acute or stable) presenting to a cardiovascular clinic and on aspirin.
3166894|NCT00531466|Active Comparator|1|
3166895|NCT00531466|Placebo Comparator|2|
3166896|NCT00531492|Experimental|A|
3166897|NCT00531492|Active Comparator|B|
2529449|NCT02701218|Experimental|Single cycle|single cycle of canalith repositioning procedure
2529452|NCT02701218|Experimental|multiple cycles of CRP|multiple cycles of canalith repositioning procedure CRP will be stopped if 1) no nystagmus and vertigo in all positions 2) complications exited 3) stable nystagmus in the 2 last cycles
2529484|NCT02700711|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and methylphenidate during placebo maintenance.
2529493|NCT02700711|Experimental|Duloxetine|Subjects will be maintained on oral duloxetine. Subjects will be maintained on placebo and methylphenidate during duloxetine maintenance.
2529526|NCT02700282|Experimental|Cystic Fibrosis children|"Children with Cystic Fibrosis will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
2529529|NCT02700282|Active Comparator|Healthy Children|"Healthy Children will experience lung function measurement while backpack carrying.~Aerobic Capacities will also be assessed during treadmill gait."
2529587|NCT02700139|Experimental|Aspheric lens|An aspheric lens which is supposed to slow myopic progression in children by unique asphericity (proprietary information)
2529591|NCT02700139|No Intervention|Single vision spheric/toric lenses|Control: single vision spheric/toric lenses
2529637|NCT02699788|Experimental|Multifunction Cardiogram|non-invasive computerized, multiphase, resting electrocardiogram analysis device
3200643|NCT00892983|Experimental|Food Activity Breast feeding support|FAB (Food Activity Breast feeding support) 8 extra parent contacts for augmented education and support around breast feeding, food and activity
3200644|NCT00892983|Experimental|Sleep|Prevention of sleep problems in first 6 months and then active early intervention for sleep problems from 6 months to 24 months
2529800|NCT02698618|Experimental|Ticagrelor|A loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours)
2529801|NCT02698618|Active Comparator|Clopidogrel|A loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg
3200645|NCT00892983|Experimental|FAB + Sleep|combination of interventions used in arms 2 and 3
3200646|NCT00892996|No Intervention|1|Metoclopramide 10 mg intravenous
3200647|NCT00892996|No Intervention|2|Ondansetron 8 mg intravenous
3200648|NCT00892996|Active Comparator|3|dexamethasone 5 mg and metoclopramide 10 mg
3200649|NCT00892996|Active Comparator|4|dexamethasone 5 mg and ondansetron 8 mg IV
3200650|NCT00893009|Placebo Comparator|Placebo|
3200651|NCT00893009|Active Comparator|Theophylline|100 twice a day
3200652|NCT00893035||Intermediate prognosis prostate cancer|Intermediate prognosis prostate cancer
2530126|NCT02696330|Active Comparator|clopidogrel|50 patients undergoing ICSI
2530131|NCT02696330|Active Comparator|enoxaparin|50 patients undergoing ICSI
2530134|NCT02696330|Placebo Comparator|placebo|50 patients undergoing ICSI
2530166|NCT02696005||Group I|15 patients who will continue participation in Exercise- Based Cardiac Rehabilitation Programme after completion initial 3-months period.
2530169|NCT02696005||Group II|15 patients who will stop participation in Exercise- Based Cardiac Rehabilitation Programme after the initial 3-months period.
2530211|NCT02695810|Experimental|Dapagliflozin|Dapagliflozin, 10 mg per day
2530214|NCT02695810|Active Comparator|Metformin|Metformin, 2 x 850 mg per day
2530216|NCT02695810|Active Comparator|Exercise|Exercise, interval training
2530218|NCT02695810|No Intervention|Control|No intervention
3200653|NCT00893035||Breast cancer|conservative treatment and age<60 Boost irradiation and age>60
3200654|NCT00893048|Experimental|Prednisone|Use of prednisone to decrease LOS and overall treatment time of cellulitis
3200655|NCT00893048|Experimental|Placebo|
3200656|NCT00893061|Experimental|Arm I|Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.
3200657|NCT00893061|Experimental|Arm II|Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.
3200658|NCT00893087|Active Comparator|1|Flow triggering
3200659|NCT00893087|Active Comparator|2|Pressure triggering
3200660|NCT00893087|Active Comparator|3|NAVA triggering
3200661|NCT00893100|Experimental|Diltiazem|
3200662|NCT00893126||Subjects with severe psoriasis|Subjects 18 to 55 with severe psoriasis. Subject will undergo a CCTA (Coronary CT Angiogram) scan.
3166898|NCT00531505||2a|Morbid Obese individuals undergoing bariatric surgery (i.e. Laparoscopic Banding, Gastric Bypass). These individuals are a subset population of the greater Longitudinal Assessment of Bariatric Surgery (LABS-1) study population. This subpopulation engaged in memory tests as well as tissue extraction.
3166899|NCT00531557|Other|1|Darunavir 600mg BID with ritonavir 100mg BID administered orally.
2529554|NCT02700464|Experimental|Bladder EpiCheck Urine Test|Bladder EpiCheck Urine Test
2529557|NCT02700464|Active Comparator|Gold Standard|Cystoscopy and pathology
2529665|NCT02699567||Lean AA|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
2529666|NCT02699567||Obese AA|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with low CD36 expression levels
2529667|NCT02699567||Lean GG|Subjects with a BMI<=25 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
2529668|NCT02699567||Obese GG|Subjects with a BMI>29.9 kg/m2 and carriers of a CD36 gene variation associated with high CD36 expression levels
2529684|NCT02699281|Experimental|Ultra-micronized Palmitoylethanolamide|Ultra-micronized Palmitoylethanolamide 600 mg twice a day
2529696|NCT02699281|Placebo Comparator|Placebo|Placebo tab twice a day
2529746|NCT02698878|Active Comparator|Control Group|Control Group consisting of six healthy male subjects wearing only the HEPHAISTOS ORTHOSIS for lower leg unloading (60 days).
2529752|NCT02698878|Experimental|Intervention Group|Intervention group consisting of seven healthy mal subjects, wearing the HEPHAISTOS orthosis for lower leg unloading (60 days), plus receiving lupin protein every day and performing a neuromuscular electrical stimulation training twice a day.
2529785|NCT02698527|Active Comparator|Non-Buffered Lidocaine|Vulvar biopsy conducted using non-buffered lidocaine as anesthesia
2529786|NCT02698527|Experimental|Buffered Lidocaine|Vulvar biopsy conducted using buffered lidocaine as anesthesia
2530122|NCT02696538|Experimental|Experimental|All participants included in this group and will complete all three outcomes assessment
2530174|NCT02696096|Other|All Participants|FMRI Suboxone
2530233|NCT02695758|Active Comparator|interscalene brachial plexus block|Direct interscalene nerve block injection via brachial plexus
2530236|NCT02695758|Active Comparator|Bupivacaine extended-release liposome injection|Infiltration of local anesthetic/analgesic, Bupivacaine extended-release liposome injection (Exparel) + Diluted in 40cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues.
2530279|NCT02695316|Other|Migrant Women|Focus Group Discussion in native Language with n=20
2530281|NCT02695316|Other|Health Care Professionals|Focus Group Discussion with n=20 Health Care Professionals
2530285|NCT02695316|Other|Interpreters|One-to-one Interviews with n=4 intercultural Interpreters
2530286|NCT02695316|Other|Telephone Interpreting Protocols|Retrospective quantitative analysis of n=50 Telephone Interpreting Protocols (questionnairs)
2530315|NCT02694991|Experimental|OMT Group|Osteopathic Manipulative Treatment 15 minutes once a day for 8 days
2530316|NCT02694991|No Intervention|Control Group|No intervention, only usual care
2530367|NCT02694692||Follow-up|No further interventions are planned for this trial and the three pain management interventions from the original study (NCT01561457) will remain our comparison groups (Kangaroo Mother Care alone, Sucrose alone, and Kangaroo Mother Care & Sucrose). All participants will be invited to back to the IWK Health Centre to receive their Vaccinations at 2, 6, 12 and 18 month time points as well as for their Neurodevelopment assessment at 18 corrected age (BSID-III).
2530518|NCT02693587||Misodel group in Holbæk|Misodel for induction of labour in Holbæk
2530521|NCT02693587||Angusta group in Roskilde and Næstved|Angusta for induction of labour in Roskilde and Næstved
3166900|NCT00531596|Active Comparator|A|EMSAM 6mg/24hr
3166901|NCT00531596|Active Comparator|B|EMSAM 9mg/24Hr
3166902|NCT00531596|Active Comparator|C|EMSAM 12mg/24Hr
3166903|NCT00531622|Experimental|Saredudant/Escitalopram|Saredutant 100 mg and Escitalopram 10 mg once daily for a maximum of 8 weeks
3166904|NCT00531622|Active Comparator|Placebo and Escitalopram|Placebo for saredutant and Escitalopram 10 mg once daily for a maximum of 8 weeks
3166905|NCT00531622|Placebo Comparator|Placebo|Placebo for saredutant and Placebo for Escitalopram once daily for one week during the screening phase and for a maximum of 8 weeks during the active phase
3166906|NCT00531648||1|Families with toddlers that having feeding disorders and SPD
3166907|NCT00531674|Experimental|1|Nutritional supplementation for pregnant and lactating women
3166908|NCT00531674|Experimental|2|Nutritional supplementation for children
3166909|NCT00531687|Other|GCT|cisplatin Paclitaxel gemcitabine
3166910|NCT00531700|Experimental|I|Exposure to both tailored/targeted health messages about influenza and also to reports about contextualized influenza risk
3166911|NCT00531700|Experimental|II|Exposure to tailored/targeted health messages
3166912|NCT00531700|Experimental|III|Exposure to reports about influenza related contextualized risk
3166913|NCT00531700|Active Comparator|IV|Comparison group exposed to community level health promotion messages not generated by the study
3166914|NCT00531713|No Intervention|1|Usual T4 dose is given
3166915|NCT00531713|Active Comparator|2|20 microgram of T3 is given and 50 microgram of T4 is withdrawn
3166916|NCT00531726|Sham Comparator|B|
3166917|NCT00531726|Experimental|A|
3166918|NCT00531739|No Intervention|A|Colorectal Surgery without use of SurgiWrapTM
3166919|NCT00531739|Active Comparator|B|Colorectal Surgery with use of SurgiWrapTM film secured in two study areas: the posterior pelvic rim and directly below the abdominal incision
3166920|NCT00531765|Active Comparator|1|hydration with normal saline
3166921|NCT00531765|Experimental|2|hydration with sodium bicarbonate
3166922|NCT00531778||NYU OCEDP Population|
3166923|NCT00531791|Active Comparator|1|
3166924|NCT00531791|Experimental|2|
3166925|NCT00531804|Experimental|1|
3166926|NCT00531830||1|Preschool children with PDD
3166927|NCT00531830||2|Preschool children without PDD
3166928|NCT00531856|Experimental|1|5.97 mg/L of carbon monoxide in 30% oxygen
3166929|NCT00531856|Placebo Comparator|2|Oxygen 30% in Nitrogen
2529445|NCT02701231|Experimental|Low-frequency Rotating Magnetic Therapy|Subjects will receive one cycle of treatment of low-frequency rotating magnetic therapy system plus systemic anti-tumor therapy after randomization
2529487|NCT02700646|No Intervention|standard care|Standard care comparison
2529494|NCT02700646|Experimental|inpatient|Inpatient recommendations to parents regarding infant motor activities
2529503|NCT02700646|Experimental|inpatient/outpatient|Inpatient and outpatient recommendations to parents regarding infant motor activities
2529541|NCT02700321|Experimental|High Flow nasal cannula oxygen (HFNC)|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/Airvo® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
2529544|NCT02700321|Active Comparator|STANDARD high flow Face Mask (HFFM)|"Patients randomized in Standard face mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
3200663|NCT00893126||Subjects without psoriasis|Subjects 18 to 55 who do not have psoriasis or rheumatologic conditions, including rheumatoid arthritis and systemic lupus erythematosus. This group of subjects will complete a CCTA (Coronary CT Angiogram)scan.
2529707|NCT02699268||Infants (term borns and preterm borns)|Intervention: simultaneous lung function measurement using VoluSense Pediatrics and a mask-based method with an ultrasonic flowmeter (EcoMedics Exhalyzer)
2529748|NCT02698969|Experimental|Sugammadex|patients enrolled who will receive sugammadex 2 mg*kg-1 at the end of surgery
2529751|NCT02698969|Active Comparator|Nestigmine, Atropine|patients enrolled who will receive neostigmine 50 mcg*kg-1 and atropine 15 mcg*kg-1 at the end of surgery
2529816|NCT02698449|Experimental|cognitive rehabilitation + transcranial stimulation|specific cognitive rehabilitation combined to transcranial direct current stimulation
2529817|NCT02698449|Experimental|cognitive rehabilitation + stimulation sham|specific cognitive rehabilitation combined to transcranial direct current stimulation sham
2529818|NCT02698449|Experimental|placebo rehab + transcranial stimulation|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation
2529819|NCT02698449|Experimental|placebo rehab + stimulation sham|nonspecific cognitive rehabilitation (placebo rehab) combined to transcranial direct current stimulation sham
2529857|NCT02698085|Experimental|Intervention Goup|Actual Diacutaneous Fibrolysis
2529858|NCT02698085|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis
2529904|NCT02697825|Other|changes in eye|Changes in both intraocular pressure and optic nerve sheath diameter will be correlated in robotic surgeries to find out any statistical relation existing between two.
2529922|NCT02697539|Placebo Comparator|AmF/SnF2 group|Patients in this arm were adviced to use a standart dentifrice over the course of the study (AmF/SnF2, Meridol®, GABA, Lörrach, Germany).
2529925|NCT02697539|Active Comparator|mHA group|Patients in this arm were adviced to use the new dentifrice over the course of the study (mHA, BioRepair®, Wolff, Bielefeld, Germany).
2529981|NCT02697266||Post-call anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
2529983|NCT02697266||Regular-shift anesthesiologists|Attending anesthesiologists, and Anesthesiology residents
2530043|NCT02696993|Experimental|Group A (nivolumab, SRS)|Patients receive nivolumab IV over 90 minutes every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
2530053|NCT02696993|Experimental|Group B (nivolumab, WBRT)|Patients then receive nivolumab as in Group A. Patients undergo WBRT once daily for 10 days.
2530063|NCT02696993|Experimental|Group C (nivolumab, ipilimumab, SRS)|Patients receive nivolumab as in Group A and ipilimumab IV over 90 minutes every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo SRS once the day after nivolumab administration.
2530064|NCT02696993|Experimental|Group D (nivolumab, ipilimumab, WBRT)|GROUP D: Patients receive nivolumab as in Group A and ipilimumab as in Group C. Patients undergo WBRT once daily for 10 days.
2530155|NCT02696265|Active Comparator|CFAE guided ablation|CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
2530156|NCT02696265|Active Comparator|PVI guided ablation|PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.
2530206|NCT02695875|Experimental|Aquatic therapy|Aquatic therapy is the experimental group. This therapy will take place in a warm pool which is located in Rialta's Sports Complex. Aquatic therapy session will be conducted by the main researcher with the help of an assistant. Because the number of patients (n=17), they will be subdivided into two subgroups of 8 and 9 people respectively in order to ensure the safety and care of patients. The intervention will last for one hour: Warming (15 minutes); exercises to train the static and dynamic balance (25 minutes); stretching (10 minutes); relaxation (10 minutes). Over 12 weeks of treatment, difficulty in performing exercises to train balance will increase progressively.
2530207|NCT02695875|Other|Land-based therapy|"The description is the same as aquatic therapy. The difference is land-based therapy sessions will be made at Faculty of Physiotherapy at University of A Coruña."
3200664|NCT00893139|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution 0.05%, 1 drop per eye, 3 times a day, for 35 days
2530377|NCT02694952|Active Comparator|FAV-Africa|FAV-Africa infusion at enrollment, and then at two and six hours after enrollment, if necessary. To be given as unblinded rescue dose at twelve hours if fourth dose of antivenom necessary.
2530378|NCT02694952|Experimental|EchiTabPlus-ICP|EchiTabPlus-ICP infusion at enrollment, and then at two and six hours after enrollment, if necessary.
2530457|NCT02694380||Head and Neck|Subjects with head and neck cancer receiving radiation therapy.
2530458|NCT02694380||Prostate|Subjects with prostate cancer receiving radiation therapy.
2530459|NCT02694380||Breast|Subjects with breast cancer receiving radiation therapy.
3200665|NCT00893139|Experimental|AL-38583 0.10%|AL-38583 ophthalmic solution 0.10%, 1 drop per eye, 3 times a day, for 35 days
3200666|NCT00893139|Placebo Comparator|AL-38583 vehicle|Inactive ingredients used as a placebo comparator, 1 drop per eye, 3 times a day, for 35 days
3200667|NCT00893165||hemodialysis patients|chronic hemodialysis patients with elevated inflammation markers
3200668|NCT00893191||Sildenafil|Treated with 50 mg of Sildenafil at night
2529446|NCT02701153|Experimental|Treatment (hypofractionated radiation therapy)|Patients undergo hypofractionated radiation therapy on Monday-Friday for 5 days. Beginning 2-12 weeks after completion of radiation therapy, patients undergo surgery.
3166930|NCT00531908|Experimental|A|To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly
3166931|NCT00531921||Kidney transplants|patients from 5 specific sites
2529510|NCT02700490|Active Comparator|Specialist|Assessment and treatment of common mental disorders by a clinical psychologist in primary care facilities.
2529513|NCT02700490|Experimental|Enhanced Usual Care|Assessment and treatment of common mental disorders by a general practitioner and nurse practitioner, who have been trained in the WHO mhGap manual, in primary care facilities.
2529530|NCT02700204|Experimental|PicoWay 532nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 532nm hand-piece
2529537|NCT02700204|Experimental|PicoWay 1064nm fractional treatment|subjects will receive one treatment for peri auricular and/or Buttocks by 1064nm hand-piece
2529593|NCT02700074||Minimally Verbal|Minimally verbal adolescents with Autism Spectrum Disorder
2529594|NCT02700074||Verbal Impaired|Language impaired adolescents with ASD
2529595|NCT02700074||Verbal Normal|Language normal adolescents with ASD
2529596|NCT02700074||Typically Developing|Typically developing adolescent controls
2529630|NCT02699736||Cohort I|Enrolled from August 1994. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529633|NCT02699736||Cohort II|Enrolled from January 1996. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529634|NCT02699736||Cohort III|Enrolled from February 1997. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). For patients included in the study from 1994-1997, it was requested that the patients had a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529635|NCT02699736||Cohort IV|Enrolled from March 1999. Patients to be included were those attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit). The eligibility criteria of a cluster of differentiation 4 (CD4) count < 500 cells/µL within the last 5 months before inclusion has been removed for patients joining the study in 1999 and beyond, since the intention of the study is to include most patients eligible for antiretroviral therapy. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529638|NCT02699736||Cohort V|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529640|NCT02699736||Cohort VI|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529642|NCT02699736||Cohort VII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529645|NCT02699736||Cohort VIII|Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529648|NCT02699736||Cohort IX|Enrolled from December 2011. Patients to be included were those aged 16 years or older attending the out-patient clinic for a scheduled visit (i.e. appointment made more than 2 weeks before time of visit), regardless of cluster of differentiation 4 (CD4) cell count. For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529670|NCT02699229||Malignant|Tissue sample
3166932|NCT00531921||Liver transplants|patients from 5 specific sites
3166933|NCT00531921||Heart transplants|patients from 5 specific sites
3166934|NCT00531921||Lung transplants|patients from 5 specific sites
2529496|NCT02700594|Active Comparator|Spine mobilization|Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization: The subject will be placed in prone on the treatment table. The intervening physical therapist will place his thumbs on the transverse process, on the affected side, of the L3, L4 or L5 vertebrae and provide a rhythmic anterior-directed force. Prone unilateral posterior-to-anterior Grade IV lumbar spinal joint mobilization, the intervening therapist will perform 1 bout on each of L3, L4 and L5 for a total of 3 bouts
2529525|NCT02700386|Experimental|Adjuvant Hypofractionated Radiation|"Adjuvant Hypofractionated Radiation (4005 cGy) will last 3-4 weeks with 15 treatments, +/- 4 additional fractions as a boost. Radiation should commence within 180 days of the date of primary surgery. Four additional fractions (a boost or conedown) to areas deemed to be at particularly high risk of recurrence may be added at the end of the radiation course. Fraction size for the boost treatment will continue at 267 cGy for an additional 1068 cGy in four fractions."
2529627|NCT02700113||ASD|There is only one group; minimally verbal individuals with Autism Spectrum Disorder aged 4 to 17 years.
2529700|NCT02699489|Experimental|Laparoscopic donor nephrectomy arm|This group will undergo laparoscopic donor nephrectomy
2529708|NCT02699489|Active Comparator|Open donor nephrectomy arm|This group will undergo open donor nephrectomy
2529745|NCT02698982|Experimental|Monitoring|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring accessible to the anesthesia provider.
2529749|NCT02698982|Sham Comparator|Sham|Elderly scheduled for moderate risk surgery Depth of anesthesia monitoring and Continuous non invasive blood pressure monitoring blinded to the anesthesia provider
2529753|NCT02698982|No Intervention|Control|elderly non scheduled for surgery
2529787|NCT02698579||Participants treated with Lenti-D|Partcipants who have received Lenti-D Drug Product in a parent clinical study (bluebird bio-sponsored clinical trial) and who meet the eligibility criteria for the study LTF-304.
3166935|NCT00531973|Experimental|A|Liposomal doxorubicin
3166936|NCT00531973|Active Comparator|B|epirubicin
3166937|NCT00531986|Experimental|Monotherapy|Ritonavir-boosted lopinavir (Kaletra®) will be used as monotherapy
2529889|NCT02697864|Experimental|48.8 mgA tafamidis free acid tablet|
2529890|NCT02697864|Experimental|58 mgA tafamidis free acid tablet|
2529891|NCT02697864|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
2530055|NCT02696707|Active Comparator|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
2530062|NCT02696707|Active Comparator|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
2530092|NCT02696486|Experimental|Exercise Training|
2530172|NCT02695888|Experimental|Risky driving prevention|Web-based behavioral intervention to promote teen driver attention to the roadway, addressing mobile technology and passengers.
2530178|NCT02695888|Experimental|Control group|Web-based behavioral intervention for healthy lifestyles.
2530273|NCT02695732|Experimental|Carvedilol|Carvedilol，6.25mg-12.5mg/d,oral,6-36 months
2530276|NCT02695732|Active Comparator|endoscopy|endoscopy，every 4 weeks until eradication of varices
2530311|NCT02695108|Experimental|classical approach for neck pain|patients in this arm received classical approaches for neck pain. Cervical manual therapy was performed on patients in this arm and they were also instructed to to perform cervical endurance, strength and stretching exercises. Rehabilitation period was lasted for 6 weeks. Pain, quality of life and scapular kinematics were assessed before and after rehabilitation program.
2530321|NCT02695433|Experimental|Active treatment (AT) diet plan|1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period
2530358|NCT02694679|Experimental|Friendship 50|The CBNH intervention will be delivered to 50% of households identified through friendship nomination.
3166938|NCT00531986|Active Comparator|Continued ART|Continuation Therapy, conventional triple HAART
3166939|NCT00531999|Active Comparator|1|Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study
3166940|NCT00531999|Active Comparator|2|"Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.~Raltegravir 400 mg twice daily for the last 14 days of the study."
3166941|NCT00532025|Experimental|1|Sorafenib treatment
3166942|NCT00532064||Ancillary-correlative (biospecimen collection)|Patients receive sunitinib malate or sorafenib chemotherapy then undergo blood collection 2 weeks later, and then every 4-6 weeks for up to 6 months to test for troponin I and BNP.
3166943|NCT00532090|Experimental|1|
3166944|NCT00532090|Experimental|2|
3166945|NCT00532090|Experimental|3|
3166946|NCT00532116|Active Comparator|A|EMSAM 6mg
3166947|NCT00532116|Active Comparator|B|EMSAM (Selegiline Transdermal System) 12mg
3166948|NCT00532168|Experimental|1|tenofovir plus emtricitabine plus efavirenz
3166949|NCT00532168|Experimental|2|tenofovir plus emtricitabine plus lopinavir-ritonavir
3166950|NCT00532168|Experimental|3|tenofovir plus emtricitabine plus atazanavir-ritonavir
3166951|NCT00532194|Placebo Comparator|A (reference)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral placebo tablet for the duration of chemotherapy and then until protocol defined disease progression occurs.
3166952|NCT00532194|Active Comparator|B (concurrent cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy only and then an oral daily placebo tablet until protocol defined disease progression occurs.
3166953|NCT00532194|Active Comparator|C (concurrent and maintenance cediranib)|Patients in this arm will receive standard platinum based chemotherapy plus a daily oral cediranib tablet during chemotherapy until protocol defined disease progression occurs.
3166954|NCT00532207|Experimental|A|
3166955|NCT00532220|Active Comparator|A|
3166956|NCT00532220|Placebo Comparator|B|
3166957|NCT00532233|Experimental|1|QAX576
3166958|NCT00532246|Experimental|A|raloxifene
3166959|NCT00532246|Placebo Comparator|B|placebo
3166960|NCT00532272|Experimental|letrozole|letrozole(2.5mg orally daily)
3166961|NCT00532272|Active Comparator|goserelin plus letrozole|goserelin (3.6mg subcutaneously every 28 days) plus letrozole(2.5mg orally daily)
2529524|NCT02700347|Experimental|Low dose pyrazinamide|Day 0: Pyrazinamide 10mg/kg, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 10mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2529528|NCT02700347|Experimental|Standard dose pyrazinamide|Day 0: Pyrazinamide 25mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 25mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2529534|NCT02700347|Experimental|High dose pyrazinamide|Day 0: Pyrazinamide 35mg/kg single dose, Day 5: Allopurinol 100mg single dose, Day 6: Allopurinol 100mg single dose, Day 7: Pyrazinamide 35mg/kg plus allopurinol 100mg single dose, Day 8: Allopurinol 100mg single dose.
2529617|NCT02700061|Experimental|Induced Constraint Therapy - ICT|Physical rehabilitation with Induced Constraint Therapy as part of the occupational therapy. Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
2529619|NCT02700061|Experimental|Robotic occupational therapy|Physical rehabilitation with Robotic occupational therapy. Robotic Occupational Therapy three times a week for twelve weeks.
2529710|NCT02699502|Experimental|patients with osteoporotic hip fractures|The intervention includes matching an appropriate drug to patients with hip fractures. All the relevant parameters regarding the patients with osteoporotic hip fractures will be reviewed (age, kidney function, previous treatment) and an appropriate anti osteoporosis medication will be determined. A recommendation regarding treatment will be sent to the local regulatory authorities, which will send the approved recommendation the the family physician.
2529758|NCT02698995|Placebo Comparator|Group A|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+1 ml saline=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2529761|NCT02698995|Active Comparator|Group B|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+2 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
2529763|NCT02698995|Active Comparator|Group C|VIB block with ropivacaine 0,5%100 mg+lidocaine1%100 mg+4 mg dexamethasone=21 ml. After the block regression, at the first analgetic request the patients received the analgesia protocol was started for 24 h with paracetamol 1 g IV every 8 h and lornoxicam 8 mg PO every 12 h; if VAS was still over 3 after 30 min, morphine was given as a loading bolus of 0.05 mg/kg IV supplemented with 2 mg IV every 5 minutes until VAS <3. After 2 h morphine was administered SC ½ of the total loading dose at request.
3166962|NCT00532285|Experimental|Paclitaxel/Gemcitabine|paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8) every 3 weeks, 4 cycles
2529916|NCT02697708|Placebo Comparator|Control Diet|Control (no additional potassium added to diet): Arm will consist of a 16 day balance period with a basal diet set at ~2340mg K/day; based on average American intake.
2529917|NCT02697708|Active Comparator|Potassium Supplement Diet|Potassium gluconate: Arm will consist of a 16 day balance period with the basal (control) diet plus the addition of 1000mg of K/day from potassium gluconate (12 tablets).
2529918|NCT02697708|Experimental|Potato Diet|Potato diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg of K/day from white potatoes.
2529921|NCT02697708|Experimental|French fries Diet|French fry diet: Arm will consist of a 16 day balance period with a basal (control) diet with an addition of 1000mg K/day from French fries.
2530069|NCT02696681|Experimental|Cognitive Behavioral Therapy|Integrating CBT for any substance use or mental health problems with CBT for adherence/self-care
2530165|NCT02696057|Active Comparator|Manual technics|Manual technics was consisted of soft tissue technics, muscle energy technics, joint mobilization.
2530167|NCT02696057|Active Comparator|Exercise|Spinal stabilization exercises were applied all the patients in this group accompanied by physiotherapist.
2530215|NCT02695797|Experimental|Immunotherapy|Intravenous immunoglobulin (IVIG) and oral prednisolone. IVIG and oral prednisolone are administered simultaneously: IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day).
2530217|NCT02695797|No Intervention|Control|No immunotherapy.
2530308|NCT02695160|Experimental|Cohort 1|SB-FIX: Low Dose
2530309|NCT02695160|Experimental|Cohort 2|SB-FIX: Medium Dose
2530310|NCT02695160|Experimental|Cohort 3|SB-FIX: High Dose
3166963|NCT00532311|Experimental|Lapaquistat Acetate 50 mg QD|(and stable statin therapy)
3166964|NCT00532311|Active Comparator|Stable statin therapy|
3166965|NCT00532324|No Intervention|A|Pregnant women not receiving CA-MRSA decolonization therapy.
3166966|NCT00532324|Other|B|Pregnant women receiving CA-MRSA decolonization therapy.
3166967|NCT00532337|Placebo Comparator|P|
3166968|NCT00532337|Experimental|E1|
3166969|NCT00532337|Experimental|E2|
3166970|NCT00532337|Experimental|E3|
3166971|NCT00532337|Active Comparator|A|
3166972|NCT00532350|Experimental|1|QAT370
3166973|NCT00532350|Placebo Comparator|2|Placebo
3166974|NCT00532350|Active Comparator|3|Tiotropium
3166975|NCT00532363||Obese asthmatics|Obese subjects with asthma (on inhaled corticosteroids)
3166976|NCT00532363||Non obese asthmatics|Non obese subjects with asthma (on inhaled corticosteroids)
3166977|NCT00532389|Experimental|Panobinostat (LBH589)|
3166978|NCT00532415|Experimental|Triamcinolone|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
3166979|NCT00532428|Active Comparator|1|
3166980|NCT00532428|Active Comparator|2|
3166981|NCT00532428|Placebo Comparator|3|
3166982|NCT00532454|Other|tamoxifen|observation for clinical efficacy on tamoxifen according to CYP2D6 genotype
3166983|NCT00532532|Experimental|1|AV650 low dose
3166984|NCT00532532|Experimental|2|AV650 high dose
2529533|NCT02700230|Experimental|Treatment (MV-NIS)|Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
3200669|NCT00893191||Placebo|Treated with placebo at night
2529623|NCT02699619|Active Comparator|2 Hansson pins without plate|Patients with undisplaced femoral neck fractures operated with 2 isolated Hansson pins.
2529626|NCT02699619|Active Comparator|3 Hansson pins interlocked in a plate|Patients with undisplaced femoral neck fractures operated with 3 Hansson pins interlocked in plate (Pinloc).
2529681|NCT02699437||Pregnant women with preeclampsia|Testing for antiphospholipid antibodies (anticardiolipin antibodies and lupus anticoagulant) will be performed in pregnant women with preeclampsia.
2529734|NCT02699047|Experimental|Fish oil|3.6 g/day of the encapsulated fish oil (2 capsules/day) providing 1.55 g/d of the n-3 polyunsaturated fatty acids (EPA and DHA) during 9 weeks
2529738|NCT02699047|Placebo Comparator|Control group|3.2 g/day of the olive oil (2 capsules/day) without n-3 polyunsaturated fatty acids
2529813|NCT02698683||malnourished|low zinc, low albumin, anthropometric measures lower than percentile 5 lymphocyte count
2529814|NCT02698683||well nourished|normal zinc, normal albumin, anthropometric measures higher than percentile 5 lymphocyte count
2529871|NCT02698046|Experimental|Ferrous sulfate|
2529878|NCT02698046|Placebo Comparator|Placebo|
2529926|NCT02697695||laparoscopic sleeve gastrectomy|patients who underwent laparoscopic sleeve gastrectomy (LSG) due to obesity and/or metabolic syndrome
2529930|NCT02697695||laparoscopic Roux-en-Y- gastric bypass|patients who underwent laparoscopic Roux-en-Y- gastric bypass (LRYGB) due to obesity and/or metabolic syndrome
2529938|NCT02697695||laparoscopic omega-loop gastric bypass|patients who underwent laparoscopic omega-loop gastric bypass (LOLGB) due to obesity and/or metabolic syndrome
2529964|NCT02697253|Experimental|Successful drug|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
2529967|NCT02697253|Experimental|Unsuccessful drug|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered Sitagliptin and receive infusion of Exendin 9-39 prior to an intake test.~Drug: Exendin 9-39 Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Sitagliptin 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
2529970|NCT02697253|Placebo Comparator|Success placebo|"Participants who have a % weight loss ≥35 at 2 years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
2529972|NCT02697253|Placebo Comparator|Unsuccess placebo|"Participants who have a % weight loss of ≤25 at two years post RYGB/SG surgery will be administered a placebo and receive a placebo infusion prior to an intake test.~Drug: Placebo Infusion of 0.9% saline solution (placebo infusion) for 80 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~Drug: Placebo 100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
2530020|NCT02697032|Experimental|Patients|At day 0 before start with bicalutamide, a FDHT-PET/CT will be performed, and one after 6 weeks (i.e. 2 weeks after steady-state). The second FDHT-PET will be performed to determine if this scan can be used as a biomarker for early response. Patients will be treated with bicalutamide until progression or unacceptable toxicity is encountered.
3200670|NCT00893217|Active Comparator|Arm 1|
2530141|NCT02696369|Experimental|2% Lidocaine HCL:Epinephrine inj.|2% Lidocaine HCL with epinephrine 1:200,000
2530148|NCT02696369|Active Comparator|2% Lidocaine HCL:Epinephrine inj. (3M)|2% Lidocaine HCl with epinephrine 1:80,000
2530229|NCT02695862|Experimental|Bolus Terlipressin|Injection terlipressin after 2 mg bolus it will be given 2 mg QID
2530232|NCT02695862|Active Comparator|Terlipressin continuous(4mg/24hours)|Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)
2530328|NCT02695342|Experimental|Home balance exercise program|The home-based exercise program will be tailored to address the underlying balance deficits in COPD and individualized according to each participant's ability. Physiotherapists will teach the program in four home visits over the first 6 weeks of the study; in the event of an exacerbation, a fifth visit will be provided to modify the program. Participants will be given an exercise DVD (with portable player), and will be instructed to perform the program 3 times/week for 6 months. Therapists will provide bi-monthly telephone support.
2530390|NCT02694627|Experimental|Intervention|See intervention description
2530391|NCT02694627|No Intervention|Control|Participants randomized into the control arm are surveyed at the same time points as intervention participants, but do not receive any intervention.
2530418|NCT02694263|Experimental|Canagliflozin + Metformin|Canagliflozin + metformin (using the participant's current dose, or dose recommended by the study clinician). An initial dose of 100mg once daily of Canagliflozin will be prescribed, and this will be titrated up to a maximum of 300mg once daily.
2530429|NCT02694419||normal weight/PCO|Women with PCOS who are normal weight with BMI < 25 kg/m2.
2530436|NCT02694393|Experimental|sodium nitrite|Inhalation of 46 or 80 mg of sodium nitrite twice daily for four weeks
3200671|NCT00893217|Experimental|Arm 2|
3200672|NCT00893230|Experimental|Lactobacillus sakei KCTC 10755BP|
3200673|NCT00893230|Placebo Comparator|microcrystalline cellulose|
3200674|NCT00893243||1Tears Again/Control|
3200675|NCT00893243||2Opticol/Control|
3200676|NCT00893243||3Optive/Control|
2529569|NCT02700542|Active Comparator|Intervention|"Participants randomly assigned to the intervention group will receive the Integrated Pest Management (IPM) treatment 2-4 weeks of completion of the baseline assessment.The IPM protocol for this research will focus on pest control in the bathrooms and kitchen and will include an assessment of the pest problem, thorough cleaning, patching of small holes, identification and referral of any necessary large repairs, and targeted application of safe pesticides as needed. In cases of severe infestation, a second treatment visit might be required in the home.~In addition to the intervention, the family will be provided with basic information about good pest-control practices, such as appropriate food storage, and be given a set of food storage containers."
2529571|NCT02700542|Placebo Comparator|Control|Participants randomly assigned to the control group will be offered the equivalent intervention, information, and food storage containers after completion of their 12-month assessment.
2529618|NCT02699931|Experimental|Electric3D|3D electric toothbrush (Oral-B) with orthodontic head.
2529620|NCT02699931|Active Comparator|Manual|Manual orthodontic toothbrush (Oral-B).
2529725|NCT02699008|Active Comparator|HPR-Ticagrelor row|ACS patients aftergoing PCI treated with clopidogrel and aspirin were included. in the 3-5th day after prescription of clopidogrel, platelet function were tested simultaneously by three methods: Light transmittance aggregometry（LTA）, Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
2529728|NCT02699008|Active Comparator|HPR-Clopidogrel row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
2529729|NCT02699008|Active Comparator|unHPR row|Thrombelastography (TEG) ,Innovance PFA-200 . According to three method results（Two of three or all three results higher than cutoff value was identified as HPR, MPALTA>50%;MAADP>47mm;CTP2Y<106s）.Patients was defined as HPR and unHPR, HPR patients were randomized divided into HPR-Ticagrelor(HPR-T) and HPR-Clopidogrel(HPR-C)
3200677|NCT00893243||4Tears Again/Opticol|
3200678|NCT00893243||5Tears Again/Optive|
2529893|NCT02697994|Experimental|Sterile Water Injection|Participants randomised to the intervention group received 4 intracutaneous injections of 0.1 ml sterile water into the skin surrounding the Michaelis rhomboid over the sacral area.
2529895|NCT02697994|Placebo Comparator|Dry Injection|Participants in the control group received 4 dry injections in the same region using an insulin needle .
2529934|NCT02697656|Active Comparator|Treatment as usual + self-help|Interdisciplinary treatment as usual at the outpatient pain clinic + an additional self-help binder with resources about pain management and employment advice.
2529942|NCT02697656|Experimental|Treatment as usual + IPS|Individual job support (IPS) as an integrated part of the interdisciplinary treatment at the outpatient pain clinic.
2529982|NCT02697149||intervention|patients undergoing nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
2529984|NCT02697149||control|patients undergoing standard endoscopic retrograde cholangiopancreatography
2530044|NCT02696980|Experimental|Rescue|Intervention: Positive expiratory pressure (PEEP) 10 will be applied after the administration of methacholine
2530054|NCT02696980|Experimental|Prophylaxis|Intervention: Positive expiratory pressure (PEEP) 10 will be applied during the administration of methacholine
2530061|NCT02696980|Placebo Comparator|No PEEP|Intervention: Positive expiratory pressure (PEEP) 0 will be applied during the administration of methacholine
2530109|NCT02696460|Active Comparator|N2O/O2 analgesia|Wound debridement under analgesia with N2O/O2 premix.
2530116|NCT02696460|Active Comparator|Lidocaine/Prilocaine analgesia|Wound debridement under analgesia with eutectic mixture of 5% lidocaine/prilocaine.
2530164|NCT02696044|Experimental|Participants aged 0 months to 3 years|Participants will receive 4 grams of triheptanoin per kilogram of body weight daily.
2530168|NCT02696044|Experimental|Participants aged 4 to 6 years|Participants will receive 3 grams of triheptanoin per kilogram of body weight daily.
2530173|NCT02696044|Experimental|Participants aged 7 to 9 years|Participants will receive 2.5 grams of triheptanoin per kilogram of body weight daily.
2530176|NCT02696044|Experimental|Participants aged 10 to 14 years|Participants will receive 2 grams of triheptanoin per kilogram of body weight daily.
2530180|NCT02696044|Experimental|Participants aged 15 to 20 years|Participants will receive 1.5 grams of triheptanoin per kilogram of body weight daily.
2530184|NCT02696044|Experimental|Participants aged 21 years and older|Participants will receive 1.2 grams of triheptanoin per kilogram of body weight daily.
2530221|NCT02695680||Lung SBRT|Respiratory motion causes significant geometric and dosimetric errors in the administration of lung stereotactic radiotherapy (SBRT). The purpose of this study is to create and validate patient-specific motion models of the thoracic anatomy with high spatial and temporal resolution. These models will be used to develop novel four-dimensional (4D=3D+time) techniques for radiotherapy treatment planning and real-time motion-adaptive dose delivery.
2530244|NCT02695459|Experimental|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
2530301|NCT02695238|Experimental|prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, prophylactic manual rotation will be performed.
2530303|NCT02695238|No Intervention|No prophylactic manual rotation group|During persistent occipital posterior presentation during the second stage of labor, expectant management for delevery will be performed
2530368|NCT02694848|Other|Salvianolate injection group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;other routine treatment according to the condition of the disease
2530370|NCT02694848|Active Comparator|Aspirin group|Aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
2530373|NCT02694848|Experimental|Salvianolate injection and aspirin group|Salvianolate injection,intravenously infusion,0.2g/time,once a day;aspirin,oral administration method,0.1g/time,once a day;other routine treatment according to the condition of the disease
2530699|NCT02692781|Experimental|Dose Cohort 4|150mg MOD-6031 / Placebo
3200679|NCT00893243||6Opticol/Optive|
2529625|NCT02700022|Experimental|Alisertib combined with R-EPOCH|Dose escalation will take place within cohorts. Subjects will receive alisertib tablets twice daily in combination with R-EPOCH chemotherapy on days 1 through 5 of each 21-day cycle. The treatment will be given in 6 cycles. The first 3 patients to be enrolled will receive a 20 milligram (mg) dose of alisertib. The dose of alisertib will be increased or decreased as more subjects enter the study. Each dose level will be evaluated for safety and tolerability before the next higher dose is given. The dose levels will be modified until the maximum tolerated dose (MTD) is reached. Once the MTD has been established, enrollment into that cohort will continue with up to a maximum of 24 patients total enrolled into the study.
2529675|NCT02699398|Experimental|VR-based therapy|3 weeks of home-based treatment for motor training using a virtual reality rehabilitation setup.
2529677|NCT02699398|Active Comparator|Control|3 weeks of home-based occupational therapy for motor training.
3200680|NCT00893256|Experimental|Risperidone and citalopram|24 patients were randomized to receive add-on citalopram (20 mg/day) in a double-blind fashion to open-label risperidone (4-8 mg/day)
3200681|NCT00893256|Placebo Comparator|Risperidone and placebo|24 patients were randomized to receive add-on placebo in a double-blind fashion to open-label treatment with risperidone (4-8 mg/day)
3200682|NCT00893269|Experimental|Active Medication|Participants receive active hypnotic medication prior to sleep
2529914|NCT02697786|Active Comparator|AVR preformed with full sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
2529915|NCT02697786|Experimental|AVR preformed with minimal invasive sternotomy|"30 patients, 7 days before and after surgery mini mental test and measurement of visual evoked cerebral blood flow response (VEFR) will be done.~Transcranial doppler measurements 1. beginning of the surgery, 2.after sternotomy, 3.during aortic cannulation,4.during CPB,5. during de-airing, 6. opening of the clamp on the aorta, 7. after CPB removal before chest closure. Prolonged de airing if needed"
2529986|NCT02697409|Experimental|Intervention group|The intervention group receives two school-based modules taking less than two hours each delivered by medical students in the schools.
2529990|NCT02697409|No Intervention|Control group|
2530079|NCT02696590|Experimental|MS patients injectable Vitamin D3|MS patients who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
2530083|NCT02696590|Experimental|MS patients orally Vitamin D3|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
2530085|NCT02696590|Active Comparator|Healthy groups Injectable Vitamin D3|who received injectable form of Vitamin D3, received 600.000 IU Intramuscular vitamin D3 injection, in two weeks; 300.000 IU at the study entry and 300.000 IU in second week
2530088|NCT02696590|Active Comparator|Healthy groups Vitamin D3 orally|received the same total dose of 600 000 IU D3 in two weeks, in the form of twelve pearls, each containing 50 000 IU D3 as follows: the first pearl was delivered at study entry, followed by one pearl each day for another 11 Days.
2530138|NCT02696304|Other|TBI for childhood leukemia|Patients with a metabolic syndrom who received TBI.
2530143|NCT02696304|Other|No TBI for childhood leukemia|Patients with a metabolic syndrom without previousTBI
2530195|NCT02695901|Experimental|Chlorhexidine gluconate (0,12%)|Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).
2530196|NCT02695901|Experimental|M. alternifolia oil (Nanoparticle solution)|Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).
3200683|NCT00893269|Placebo Comparator|Placebo|Participants receive placebo prior to sleep
3200684|NCT00893282|Experimental|BackStop|Intracorporeal lithotripsy with the use of an anti-retropulsion device.
3200685|NCT00893282|Active Comparator|Control|No anti-retropulsion device will be used during lithotripsy.
2530448|NCT02694211|Experimental|Intervention group ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
2530449|NCT02694211|No Intervention|Control group|No intervention, business as usual
2530465|NCT02693821|Experimental|Gabapentin|300mg of Gabapentin per day (two doses), orally during 30 days
2530466|NCT02693821|Placebo Comparator|Placebo|300mg of Placebo per day (two doses), orally during 30 days
2530503|NCT02693678|Experimental|Massage|10 min massage therapy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2530509|NCT02693678|Experimental|Diathermy|10 min diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2530516|NCT02693678|Sham Comparator|Sham diathermy|10 min sham diathermy with neutral cream on lower limbs following the patients indications, the points need to be related to the presence of DOMS
2530567|NCT02693353||Study Group|Patients with diagnosed epiretinal membrane undergoing cataract surgery.
2530571|NCT02693353||Control Group|Patients without epiretinal membrane undergoing cataract surgery.
2530632|NCT02692963|Experimental|BCG vaccination|
2530634|NCT02692963|No Intervention|Control|
2530679|NCT02692690|Experimental|before-after|TENS stimulation neck and thigh
3200686|NCT00893321|Other|Inferior Oblique Muscle Recession and Myectomy|
3200687|NCT00893334||BMD:|Patients diagnosed with Becker Muscular Dystrophy
3200688|NCT00893334||LGMD2A|patient diagnosed with Limb-Girdle Muscular Dystrophy, type 2A Calpain-3 deficiency
3200689|NCT00893334||LGMD2B|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2B Miyoshi myopathy Dysferlin deficiency
3200690|NCT00893334||LGMD2I|Patients diagnosed with Limb-Girdle Muscular Dystrophy, type 2I FKRP-deficiency
3200691|NCT00893334||Control|Healthy Controls
3200692|NCT00893347|Active Comparator|I|Treatment as usual
2529653|NCT02699736||Cohort X|All patients should be consecutive patients (except those already enrolled in EuroSIDA), or patients who had a scheduled visit (i.e. those who made an appointment >2 weeks prior to their visit) in the outpatient clinic regardless of cluster of differentiation 4 (CD4) cell count and ART status). Enroll patients of 16 years or older and positive for antibodies against hepatitis C virus (regardless of HCV-RNA status, fibrosis stage and prior treatment against hepatitis C). For all HIV patients enrolled and under follow up, laboratory, therapeutic and clinical data are collected twice annually. Demographic data, date on pregnancy and serological evidence for infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually.
2529655|NCT02699736||Cohort XI|"HIV-1 positive persons ≥18 years of age, not already enrolled in EuroSIDA, are eligible for inclusion. Participants should be enrolled consecutively in one of the following two groups:~Participants who have started integrase inhibitor (INSTI) based antiretroviral therapy (ART) after 1/1/2012 and have a CD4 cell count and HIV-RNA available in the 12 months prior to starting INSTI or within 3 months after starting INSTI~If participants have not started INSTI, they should be included providing they have a CD4/HIV-RNA in the 12 months prior to baseline or within 3 months after baseline.~For all patients enrolled and under follow up, laboratory, therapeutic, clinical and demographic data, date on pregnancy and data on hepatitis B virus (HBV) and hepatitis C virus (HCV) are collected once annually."
2529765|NCT02698839|Experimental|BuMA Supreme group|This group contains 319 subjects. Among them, 220 subjects will be implanted with regular specifications and 99 subjects with narrower, wider or longer ones.
2529766|NCT02698839|Active Comparator|BuMA™ group|This group contains 220 subjects.
2529781|NCT02698514|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2529783|NCT02698514|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2529900|NCT02697929|Active Comparator|sugammadex|at the end of surgery administration of 2 mg/kg of sugammadex after the third T2 twitch at Train of Four (TOF) stimulation
2529901|NCT02697929|Active Comparator|neostigmine|at the end of surgery administration of 50 mcg/kg of neostigmine after the third T2 twitch at Train of Four (TOF) stimulation
2529939|NCT02697565|Experimental|Train-the-Trainers Arm|Intervention Arm receives the Healthy Caregivers- Healthy Children Toolkit (healthy lifestyle role modeling intervention) via a nutritional gate keeper. The toolkit reinforces center health and activity policy standards.
2529944|NCT02697565|Other|Attention Control Arm|Control Arm that receives an attention control safety curriculum.
3200693|NCT00893347|Experimental|II|Treatment as usual + cognitive-behavioural therapy
2530051|NCT02696733|Experimental|UG - ONB|Patients with the bladder tumor located on the lateral wall, with the high risk of adductor muscles contraction during TURBT under spinal anesthesia.
2530124|NCT02696421||Non diabetic, non obese|
2530127|NCT02696421||Non diabetic obese|
2530132|NCT02696421||Diabetic|
2530193|NCT02696148|Experimental|Liraglutide|
2530194|NCT02696148|Placebo Comparator|Placebo|
2530241|NCT02695550|Experimental|CT-707|ALK-positive non-small cell lung cancer resistant to Crizotinib treatment
2530663|NCT02692625|Experimental|Group A|"Group A (test group): This group consist of 80 children receiving the probiotic lozenges.~The Probiotic lozenges used in the trial is a non-commercial product provided by BioGaia AB, Lund, Sweden. The Probiotic lozenges consist of a minimum of 200 million live L. reuteri (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289 (L. reuteri Prodentis®). The probiotic lozenge is used twice daily for two months."
2530665|NCT02692625|Placebo Comparator|Group B|"Group B (control group): This group consist of 80 children receiving the placebo lozenges.~The placebo lozenges used in the trial is non-commercial product provided by BioGaia AB, Lund, Sweden.The placebo lozenges is used twice daily for two months."
2530730|NCT02692365|Experimental|Calcium channels|Magnetic Resonance assessment Hemodynamics + + infusion of manganese chloride
2530736|NCT02692365|Experimental|Tumor perfusion|Magnetic Resonance + hemodynamic + infusion of gadolinium
2530770|NCT02691988|Experimental|ICS withdrawal|Guided ICS withdrawal combined with optimization of bronchodilator treatment
2530771|NCT02691988|Active Comparator|Usual care|Optimization of bronchodilator treatment
2531039|NCT02690246||patients with HHT|patients with Hereditary Haemorrhagic Telangiectasia
2531040|NCT02690246||control cohort|indirectly only as a control cohort in questionnaire of affected persons
2531156|NCT02689544|Experimental|static stretching|Group of 15 volunteers (gSS)
3166985|NCT00532532|Experimental|3|Placebo
3166986|NCT00532545|Experimental|A|Teriparatide
3166987|NCT00532558|Experimental|Lapaquistat Acetate 50 mg QD|
3166988|NCT00532558|Placebo Comparator|Placebo QD|
3166989|NCT00532584|Experimental|treatment with inhaled beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
3166990|NCT00532584|No Intervention|Control - healthy smokers|Group B will act as control and include healthy smokers who receive no treatment.
3166991|NCT00532584|No Intervention|control - healthy non-smokers|Group C will act as control and include healthy non-smokers who receive no treatment.
3166992|NCT00532597|Experimental|O|
3166993|NCT00532597|Active Comparator|L|
3166994|NCT00532623|Active Comparator|Combination|
3166995|NCT00532623|Active Comparator|Seqeuntial|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
3166996|NCT00532636|Active Comparator|1|Children 1-5 years of age
3166997|NCT00532636|Active Comparator|2|Children 6-10 years of age
3166998|NCT00532662|Experimental|1|epidural s(+)-ketamine for supplementation of caudal anesthesia
3166999|NCT00532662|Active Comparator|2|intravenous ketamine for supplementation of caudal anesthesia
3167000|NCT00532675|Experimental|PAN 5 mg|Panobinostat 5 mg
3167001|NCT00532675|Experimental|PAN 10 mg|Panobinostat 10 mg
3167002|NCT00532675|Experimental|PAN 20 mg|Panobinostat 20 mg
3167003|NCT00532675|Experimental|PAN 25 mg|Panobinostat 25 mg
2529723|NCT02699164|Experimental|combine group|"Conventional physiotherapy applied 15 sessions of treatment. In addition to conventional physiotherapy non-surgical spinal decompression therapy applied.~First 10 sessions of treatment non-surgical decompression therapy applied and last 5 sessions spinal stabilization exercise applied."
2529724|NCT02699164|Experimental|conventional physiotherapy|conventional physiotherapy applied 15 sessions of treatment. Conventional physiotherapy consisted hotpack, Transcutaneal Electric Nerve Stimulation(TENS) and Ultrasound Currents. Spinal stabilization exercises applied last five sessions of therapy.
3167004|NCT00532688|Experimental|1|5 patients: 28 days of n-acetylcysteine (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period.
2530008|NCT02697318|Other|Professional Administration|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) administered by a professional, using the standard clinical method.
2530013|NCT02697318|Other|Self-Administration (new method)|Instillation of Timolol maleate 0.5% ophthalmic solution (or participant's own glaucoma medication) self-administered by the participant, using the new proposed method.
2530026|NCT02696824|Experimental|CBT-AD|Those assigned to the CBT-AD [cognitive behavioral therapy for adherence and depression) condition, will have up to 8 additional sessions delivered by the study clinic nurse. Additionally, those assigned to CBT-AD will have the procedures available to those assigned to ETAU.
2530032|NCT02696824|No Intervention|ETAU|"Participants in both conditions receive usual care plus the following procedures below.~All participant will have the benefit of the psychosocial assessment, and the clinic nurse will provide feedback to the participant and to their clinic doctor about their depression. Additionally, all participants will undergo standard of care second line treatment adherence counseling in the clinic . The clinic doctor will not be restricted in terms of referral or treatment of depression for their patient with respect to antidepressant medications or other interventions available."
2530099|NCT02696603|Experimental|Participants with Parkinson disease|People who report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
2530100|NCT02696603|Experimental|Participants without Parkinson disease|People who do not report a diagnosis of Parkinson disease. Participants are invited via the Parkinson mPower mobile application to complete the following behavioral interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, and Participant open-response writing.
2530171|NCT02696161|Experimental|platelet rich plasma injection|The platelet rich plasma (PRP) is a new and potential treatment for peripheral neuropathy in many animal studies.
2530177|NCT02696161|Placebo Comparator|5% dextrose|5% dextrose for hydrodissection
2530226|NCT02695771|Experimental|Mitomycin C|Mitomycin C 40 mg in 40 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
2530227|NCT02695771|Active Comparator|Gemcitabine|Gemcitabine 2 grams in 100 mL of 0.9% sodium chloride intravesicular immediately following TURBT one time.
2530228|NCT02695771|No Intervention|No intervention|Patients randomized to this arm will receive no intervention intravesicular immediately following TURBT one time.
2530262|NCT02695394||MS / CIS|
2530265|NCT02695394||Healthy controls|
2530293|NCT02695199|Experimental|laparoscopic varicocelectomy|laparoscopic Doppler ultrasound assisted laparoscopic varicocelectomy group
2530294|NCT02695199|Sham Comparator|microscopic varicocelectomy|conventional Microscopic Subinguinal varicocelectomy group
2530331|NCT02694861||Registry Group|Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
2530332|NCT02694861||Prospective Group|A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
2530384|NCT02694614|Experimental|smartphone-assisted dietary coaching|
2530415|NCT02694302|Experimental|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
2530419|NCT02694302|Active Comparator|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
2530481|NCT02693964||Postmenopausal women with T1D|Postmenopausal between 45-70 years of age and having T1D for at least 10 years
2530489|NCT02693964||Postmenopausal women without diabetes|Postmenopausal between 45-70 years of age without diabetes
2530710|NCT02692469|Active Comparator|Duodenal Switch Surgical Intervention|a DS procedure involves creating a sleeve gastrectomy with preservation of the pylorus, and creation of a Roux limb with a short common channel
2530711|NCT02692469|Experimental|Single Anastomosis Duodenal-Ileal Bypass|The SADI defers from the DS in that after the duodenum is separated from the stomach, preserving the pylorus, a loop of bowel 200 cm from the ileo-cecal valve is anastomosed with the pylorus, thus requiring only one anastomosis
2530776|NCT02692079|Experimental|T-PRF+Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Test group sites were treated with T-PRF+allograft
2530778|NCT02692079|Experimental|Allograft|The defects were debrided and root planed with ultrasonic instrumentation and area-specific curets. All sites were washed with sterile salin solution and bleeding control was performed. Control group sites were treated with only allograft
3167005|NCT00532688|Placebo Comparator|2|28 days of oral distilled water (5ml) (in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to intervention (N-acetylcysteine 500mg oral bd) for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
3167006|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-16 in patients with RVR
3167007|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 16 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-6, and then low dose ribavirin (800 mg/day) from weeks 6-16 in patients with RVR
3167008|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 24 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-24 in patients without RVR
2529789|NCT02698748|Experimental|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
2529790|NCT02698748|Placebo Comparator|Placebo|Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain.
2529848|NCT02698306|Experimental|Dexamethasone|Dexamethasone: Dexametasone 4mg tablet every 8/8hs for 3 days
2529850|NCT02698306|Active Comparator|Diclofenac Sodium|Diclofenac Sodium: Diclofenac Sodium 50 mg tablet every 8/8 hs for 3 days
2529899|NCT02697877||Patients with known or suspected coronary artery disease.|Patients with known or suspected coronary artery disease undergoing clinically ordered stress cardiac magnetic resonance imaging.
3200694|NCT00893360|Experimental|Cardiac Stem Cell Treatment - Group 1|Autologous stem cell infusion of 12.5 MIL CDCs via intracoronary infusion.
3200695|NCT00893360|Experimental|Cardiac Stem Cell Treatment -Group 2|Autologous stem cell infusion of 25 MIL CDCs via intracoronary infusion.
3200696|NCT00893360|No Intervention|Observation (Control Group)|Observation of myocardial recovery after usual medical management.
3200697|NCT00893373|Experimental|Sorafenib|Induction, Consolidation and Maintenance plus Sorafenib 2x 400 mg/d
3200698|NCT00893373|Placebo Comparator|Placebo|Induction, Consolidation and Maintenance plus Placebo
3200699|NCT00893386||Non-4195 Lead, 181 days|Patients with a Medtronic LV Lead, other than Model 4195, implanted at least 181 days
3200700|NCT00893386||4195 Lead, 181 days|Patients with a Medtronic Model 4195 LV Lead implanted at least 181 days
3200701|NCT00893386||4195 Lead, 90-180 days|Patients with Medtronic Model 4195 LV Lead implanted for 90-180 days
3200702|NCT00893399|Experimental|1|chemotherapy in combination with ATRA with gemtuzumab ozogamicin
3200703|NCT00893399|Active Comparator|2|chemotherapy in combination with ATRA without gemtuzumab ozogamicin
2530070|NCT02696668|Active Comparator|modified FaME|Participants in the modified FaME group will receive a 16 weeks falls rehabilitation programme which will be tailored and progressed according to their abilities and their needs by the physiotherapist / instructor providing the rehabilitation at the hospital.
2530071|NCT02696668|Experimental|Multisensory|Participants in the multisensory group will receive balance exercises training which will be tailored and progressed to their abilities and needs.
2530139|NCT02696395|Active Comparator|DePuy Tri-Lock®|Total hip replacement with DePuy Tri-Lock® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
2530146|NCT02696395|Active Comparator|DePuy Corail®|Total hip replacement with DePuy Corail® femoral stem and Deltamotion® acetabular component. The surgery will be conducted using a postero-lateral approach followed by post operative rehabilitation as per standard care.
2530208|NCT02695979||Patients undergoing OLT|Patients aged 18-70 with end-stage liver disease undergoing orthotopic liver transplantation (OLT).
3200704|NCT00893412|Active Comparator|Tramadol + Metal cannula|Fast-release Orodispersible Tramadol Tablet + Metal cannula
3200705|NCT00893412|Placebo Comparator|Placebo + Metal cannula|Placebo + Metal cannula
2530317|NCT02695017|Experimental|Iso inertial|Subjects should do 12 exercise repetition with Iso inertial machine
2530318|NCT02695017|Experimental|Conventional machine|Subjects should do 12 exercise repetition with conventional machine
2530341|NCT02694679|No Intervention|Random 0|The CBNH intervention will be delivered to 0% of population targeted households in the village.
2530342|NCT02694679|Active Comparator|Random 5|The CBNH intervention will be delivered to a random 5% of targeted households in the village.
2530343|NCT02694679|Active Comparator|Random 10|The CBNH intervention will be delivered to a random 10% of targeted households in the village.
2530344|NCT02694679|Active Comparator|Random 20|The CBNH intervention will be delivered to a random 20% of targeted households in the village.
2530345|NCT02694679|Active Comparator|Random 30|The CBNH intervention will be delivered to a random 30% of targeted households in the village.
2530347|NCT02694679|Active Comparator|Random 50|The CBNH intervention will be delivered to a random 50% of targeted households in the village.
2530349|NCT02694679|Active Comparator|Random 75|The CBNH intervention will be delivered to a random 75% of targeted households in the village.
2530350|NCT02694679|Active Comparator|Random 100|The CBNH intervention will be delivered to a random 100% of targeted households in the village.
2530351|NCT02694679|No Intervention|Friendship 0|CBNH 0% of population targeted
2530352|NCT02694679|Experimental|Friendship 5|The CBNH intervention will be delivered to 5% of households identified through friendship nomination.
2530353|NCT02694679|Experimental|Friendship 10|The CBNH intervention will be delivered to 10% of households identified through friendship nomination.
2530355|NCT02694679|Experimental|Friendship 20|The CBNH intervention will be delivered to 20% of households identified through friendship nomination.
2530357|NCT02694679|Experimental|Friendship 30|The CBNH intervention will be delivered to 30% of households identified through friendship nomination.
3200706|NCT00893412|Active Comparator|Tramadol + Balloon|Fast-release Orodispersible Tramadol Tablet + balloon catheter
3200707|NCT00893412|Placebo Comparator|Placebo + Balloon|Placebo + balloon catheter
3200708|NCT00893438|Experimental|FitNet treatment|FitNet treatment: web-based cognitive behaviour therapy
3200709|NCT00893438|Active Comparator|Usual care|waiting list for FitNet intervention (usual care allowed)
3200710|NCT00893451|Active Comparator|A|Vitamin D3 1600 IU orally twice daily
3200711|NCT00893451|Placebo Comparator|B|Placebo orally twice daily
3200712|NCT00893490|Experimental|Ahmed Glaucoma Valve (AGV) alone|
3200713|NCT00893490|Experimental|AGV plus MMC|
3200714|NCT00893490|Experimental|AGV plus amniotic membrane coverage|
3200715|NCT00893529|Experimental|dietary intervention 1|
3200716|NCT00893529|Experimental|dietary intervention 2|
2529802|NCT02698709||Overt keratoconus (Kc)|Whether both eyes manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers. Such eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2529804|NCT02698709||Forme fruste keratoconus (FFKc)|Whether only one eye manifested classic Kc-suggestive topographic features, such as corneal steepness higher than 47.20 diopters (D), superior-inferior asymmetry higher than 1.40 D and thinnest pachymetric reading lower than 500 micrometers, and the fellow eye seemed unaffected. Such unaffected eyes were analyzed by an Scheimpflug-based tomographer. Vector astigmatism analysis of anterior and posterior corneal surfaces were studied in accordance to method proposed by Thibos.
2530525|NCT02693574|Active Comparator|Clarithromycin|Clarithromycin 500 mg Tablets and Esomeprazole 20 mg Capsule And Amoxicillin 1000 mg,Tablets by mouth every 12 hours for 14 days
2530527|NCT02693574|Experimental|Levofloxacin|Levofloxacin 500 mg coated tablets and Esomeprazole 20 mg Capsule and Amoxicillin 1000 mg Tablets by mouth every 12 hours for 14 days
2530561|NCT02693236|Experimental|adenovirus-transfected autologous DC vaccine plus CIK cells|
2531079|NCT02689882|Experimental|pharmacokinetic study|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
2531302|NCT02688400|Experimental|Diacerein|One placebo capsule once daily in the morning (breakfast) and one diacerein 50 mg capsule once daily in the evening (dinner) for the first month, then diacerein capsules twice daily with meals in the morning (breakfast) and the evening (dinner).
2531303|NCT02688400|Active Comparator|Celecoxib|One celecoxib 200 mg capsule once daily in the morning (breakfast) and one placebo capsule once daily in the evening (dinner).
2531372|NCT02687789|Experimental|Medical Device: WO3191|The vaginal suppository is used for the reduction and/or inhibition of vaginal biofilms that were shown to be related to recurrent bacterial vaginosis.
2531378|NCT02687789|Active Comparator|Medical Device: Vagisan® Lactic Acid|It is used for the maintenance and restoration of a natural pH level in the vagina. The acidification of the vaginal milieu with lactic acid promotes the growth of typical vaginal flora (lactic acid bacteria) and is unfavourable for the growth of pathogens in the vagina. Vagisan® Lactic Acid is used in the post-treatment of bacterial vaginosis.
3167009|NCT00532701|Active Comparator|Peg-IFN + WB RBV for 48 weeks|Weight-based ribavirin (1000-1200 mg/day) from weeks 1-48 in patients without RVR
3167010|NCT00532701|Active Comparator|Peg-IFN + LD RBV for 24 weeks|Low dose ribavirin (800 mg/day) from weeks 1-24 in patients with or without RVR
2531598|NCT02686827|Experimental|Paricalcitol (Vitamin D3)|paricalcitol, (Zemplar® 5 μg/ml Abbvie), will be administered via the subcutaneous route 4 times at 0.5 ml (registered dose of 5 μg/ml, thus 2.5 μg per sub-cutaneous injection). The minimum time interval between two injections is 4 days, which is a significantly lower frequency than the prescribed maximum of 3 times a week or every other day.
2531600|NCT02686827|Active Comparator|Placebo|Placebo, the same constituents as Zemplar (propylene glycol 30% (v/v) alcohol 20% (v/v)) but no paricalcitol, same dosage as verum-arm.
2531712|NCT02685865|Active Comparator|FCSEM Stent|WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
2531717|NCT02685865|Active Comparator|Plastic Stents|WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
2531956|NCT02684305|Experimental|Administration of Propess|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~1.Administration of Propess for additional 24 hours."
2532095|NCT02683031|No Intervention|Without Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
3167011|NCT00532714|No Intervention|Irinotecan plus capecitabine|Irinotecan 80 mg/m2 (intravenously once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period) Capecitabine (orally at a dose of 1,000 mg/m2 twice daily 3-week cycles (2 weeks of treatment followed by a 1-week rest period))
3167012|NCT00532727|Experimental|Arm A|Carboplatin
3167013|NCT00532727|Active Comparator|Arm B|Docetaxel
3167014|NCT00532740||All Patients|Patients with metastatic cancer of the liver who are not surgical resection candidates and who will be treated with TheraSphere per institutional standard of care.
3167015|NCT00532766|Experimental|2|Jusline Humulin
3167016|NCT00532792|Experimental|Group 1|
3167017|NCT00532792|Experimental|Group 2|
3167018|NCT00532792|Experimental|Group 3|
3167019|NCT00532792|Experimental|Group 4|
3167020|NCT00532792|Experimental|Group 5|
3167021|NCT00532792|Experimental|Group 6|
3167022|NCT00532792|Experimental|Group 7|
3167023|NCT00532792|Experimental|Group 8|
3167024|NCT00532792|Experimental|Group 9|
3167025|NCT00532792|Placebo Comparator|Group 10|
2529811|NCT02698462|Other|FIT and Questionnaire|Six thousand persons eligible for the national CRC screening program will be selected. They will be selected from four areas that are considered representative of the Netherlands. All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
2529831|NCT02698163|Active Comparator|Gutta Percha|For all the patients in the control arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The root canals will be filled with standard root canal filler material: gutta percha at the apical third up to and including the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
2529834|NCT02698163|Experimental|Nanodiamond reinforced Gutta Percha|For all the patients in the treatment arm of the study, standard treatment of care procedures will be given. Root canal therapy will be given according to the vertical obturation technique. The difference between the two arms will be the root canal filler material used. The root canals for the treatment arm of the study will be filled with gutta percha at the apical third, Nanodiamond gutta percha (NDGP) in the middle third, and again with gutta percha at the coronal third. The tooth will be restored with a crown for posterior teeth, or a composite filling for anterior teeth.
2529873|NCT02697981|Experimental|intervention group|Pregnant post bariatric surgery women will receive nutritional counseling from a specialist dietitian, to ensure a healthy balanced diet including adequate daily servings from all food groups, intake of essential nutrient during pregnancy such as iron and folic acid and limitation of high-sugar and fatty foods. Patients will also be advised concerning eating at scheduled times (e.g., 4-6 times daily), supplements, preference of water. Advice concerning healthy cooking methods will also be given, as well as advised to avoid soft drinks, drinking during meals, grazing and emotional eating, and fast foods. Subject of lifestyle in general - encouraged to incorporate suitable physical activity on most days, refraining from alcohol, and smoking. intervention: nutrition counseling
2529884|NCT02697981|No Intervention|control group|The control group is comprised of healthy pregnant women, of similar age, smoking behavior and background. No treatment will be given, just follow-up data collection.
3167026|NCT00532818|Placebo Comparator|1|
3167027|NCT00532818|Experimental|2|
2530001|NCT02697058|Experimental|Part 1: Safety and PK|BAX2398 in combination with 5-FU/calcium levofolinate
2530006|NCT02697058|Experimental|Part 2: Safety, PK, Efficacy|BAX2398 in combination with 5-FU/calcium levofolinate
2530014|NCT02697058|Active Comparator|Part 2: 5-FU/calcium levofolinate alone|5-FU/calcium levofolinate
2530037|NCT02696720|Experimental|Lidocaine|During a period of six weeks, a lidocaine patch will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
2530039|NCT02696720|Sham Comparator|Sham|During a period of six weeks, a visually identical patch (sham) will be applied around the wound (cut in two parts, 1cm above and below the wound, without direct contact with the scar) for a total of twelve hours per day, during night time.
2530101|NCT02696577|Active Comparator|Low dose aspirin|Received aspirin 81mg once daily for 6 weeks
2530102|NCT02696577|Active Comparator|Low dose aspirin plus omega 3 group|Received aspirin 81mg and omega 3 once daily for 6 weeks.
2530219|NCT02695667||OSAS subjects|CPAP Referral OSAS
2530222|NCT02695667||Risk-Free subjects|paired normal control subjects
2530269|NCT02695485|Other|sensate flap|the donor nerve harvested with the flap
2530297|NCT02695186||A/IM alone|Patients with intestinal metaplasia who undergo gastroscopy and blood sample analysis
2530298|NCT02695186||B/IM and MS|Patients with intestinal metaplasia and metabolic syndrome who undergo gastroscopy and blood sample analysis
2530300|NCT02695186||C/Healthy controls|Healthy controls without intestinal metaplasia or metabolic syndrome who undergo gastroscopy and blood sample analysis
2530412|NCT02694276|Experimental|Internet-based cognitive behavior therapy|10 sessions of ICBT during 10 weeks.
2530485|NCT02694055|Experimental|Proactive Community Case Management (ProCCM)|Villages assigned to the experimental arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing proactive case detection in addition to integrated Community Case Management (ProCCM).
2530490|NCT02694055|Active Comparator|integrated Community Case Management (iCCM)|Villages assigned to the active comparator arm will receive the following health system strengthening interventions: training of primary health centre staff, infrastructure improvements at primary health centre, removal of point-of-care user fees, and the presence of Community Health Workers providing passive integrated Community Case Management (iCCM) exclusively at a fixed health post to patients who initiate their own care-seeking.
2530636|NCT02692976|Experimental|Myeloid dendritic cells (mDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A). DC will be loaded with major histocompatibility complex (MHC) class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with keyhole limpet hemocyanin (KLH) as an immune control.
2530700|NCT02692781|Experimental|Dose Cohort 5|200mg MOD-6031 / Placebo
3167028|NCT00532831||Obese asthmatics|Obese subjects with asthma (on inhaled bd only)
3167029|NCT00532831||Non-obese asthmatics|Non-obese subjects with asthma(on inhaled bd only)
3167030|NCT00532857|Experimental|Paclitaxel/Gemcitabine/Trastuzumab|
3167031|NCT00532870|Active Comparator|1|laparoscopy
3167032|NCT00532896||bariatric surgery|patients with morbid obesity undergoing a bariatric surgery
3167033|NCT00532896||No bariatric surgery|patients with morbid obesity on a waiting list for a bariatric surgery but who will have their surgery in more than one year.
3167034|NCT00532922||1|Chinese asthma patient prescribed Symbicort® Turbuhaler®
2529896|NCT02698020|Experimental|Room-air|Supplemental oxygen only provided if oxygen saturation below target
2529911|NCT02697682|Experimental|Intervention|All patients are recieving the treatment.
2529949|NCT02697448|Active Comparator|propofol|Participants receiving propofol as anesthetic for cardiac ablation.
2529950|NCT02697448|Active Comparator|sevoflurane|Participants receiving sevoflurane as anesthetic for cardiac ablation.
2529985|NCT02697162|Experimental|Antiseptic-coated catheter|Hydrophilic intermittent urinary catheter coated with octenidine chloride
2529989|NCT02697162|Placebo Comparator|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
2530030|NCT02696928|Other|Artemeter-Lumefantrine (combination therapy)|"33 patients~(standard of care)"
2530038|NCT02696928|Active Comparator|Artemeter-Lumefantrine and Primaquine (combination therapy)|33 patients
2530041|NCT02696928|Experimental|Artemeter-Lumefantrine and MB (combination therapy)|33 patients
2530095|NCT02696499|Experimental|PA101B|
2530096|NCT02696499|Placebo Comparator|Placebo|
2530149|NCT02696239|Active Comparator|V-lock suture|V-lock absorbable Wound Closure Device, by Covidien
2530151|NCT02696239|Active Comparator|Vicryl suture|Vicryl suture by Ethicon
2530153|NCT02696239|Active Comparator|Lapra-Ty II|Lapra-Ty II, Absorbable Suture Clip, by Ethicon
2530182|NCT02695914||Control group|Conventional treatment methods will be given to cases in control group.
2530185|NCT02695914||Experiment group|On the base of control group, Compound Qingre Granule will be added to in experiment group.
2530253|NCT02695745|Experimental|V116517|V116517 aqueous suspension; 300 mg
2530257|NCT02695745|Active Comparator|Celecoxib|Celecoxib capsules; 400 mg (2 capsules of 200 mg each)
2530258|NCT02695745|Placebo Comparator|Placebo|Placebo
2530296|NCT02695147||TAVI via Subclavian approach|Any TAVI procedure using any valve type performed via the subclavian approach
2530299|NCT02695147||TAVI via Direct Aortic approach|Any TAVI procedure using any valve type performed via the direct aortic approach
3200717|NCT00893555|Active Comparator|control|Voriconazole dosing based on SPC
2530441|NCT02694042|Experimental|Mission is Remission® Group|Participants in this group will be given access to the Mission is Remission® web-based teaching and support site. They will also be emailed a link to complete online questionnaires at set time points throughout the study.
2530442|NCT02694042|No Intervention|Control Group|Participants in this group will continue to receive standard care without access to the Mission is Remission® website. They will also be emailed a link to complete online questionnaires. At the end of the 6 month study period, participants in this group will be given access to the study website.
2530475|NCT02693873|Other|Single Arm Study:|All participants will receive GLA:D Canada, an education and neuromuscular exercise program
2530535|NCT02693600|Active Comparator|Partial Trapeziectomy (PT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with with ligamentoplasty and partial trapeziectomy.
2530540|NCT02693600|Active Comparator|Total Trapeziectomy (TT)|Patients with Osteoarthritis of the trapeziometacarpal joint determined by the classification of Eaton-Littler (stages II-III) treated with ligamentoplasty and total trapeziectomy.
3200718|NCT00893555|Experimental|TDM|Voriconazole serum concentration based dosing
2530653|NCT02692729|Experimental|supraumbilical transverse|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis. Above the panniculus, the fatty tissues are not particularly thick. A transverse opening of the aponeurosis and of the parietal peritoneum was done. Then the approach to the lower uterine segment was easy. A Ricard retractor was put in place.
2530654|NCT02692729|Active Comparator|pfannenstiel|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
3200719|NCT00893568|Active Comparator|Healthy volunteers|Healthy volunteers without treatment
3200720|NCT00893568|Experimental|CBT|Psychotraumatized patients treated by Cognitive and Behavioral Therapies (CBT)
2530777|NCT02692066||Healthy Controls|Healthy Children ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) markers of humoral immunity at baseline and 4 weeks post vaccination and 2) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
2530779|NCT02692066||Children with Chronic Liver Disease|Children with chronic liver disease ages 6 months-21 years who have not received varicella vaccine and who do not have prior varicella or zoster will receive Varivax. We will then measure 1) varicella DNA in the blood and saliva at enrollment, 1 week, 2 weeks, 3 weeks, 4 weeks post vaccination 2)markers of humoral immunity at baseline and 4 weeks post vaccination and 3) markers of cell mediated immunity at baseline, 1 week, and 4 weeks post vaccination
2530818|NCT02691663|Active Comparator|Oral bicarbonate supplementation group|0.3 meq/kg/day NaHCO3 capsules
2530820|NCT02691663|Placebo Comparator|Placebo group|Methylcellulose capsules
3200721|NCT00893568|Experimental|EMDR|Psychotraumatized patients treated by Eye Movement Desensitization and Reprocessing (EMDR)
3200722|NCT00893581|Active Comparator|1--Quetiapine & Placebo|Quetiapine & Placebo in the place of Lithium
3200723|NCT00893581|Active Comparator|2-- Lithium & Placebo|Lithium & Placebo in the place of Quetiapine
3200724|NCT00893581|Placebo Comparator|Placebo|Sugar Pill (Placebo) given to mimic drug
3200725|NCT00893594|Placebo Comparator|1|Placebo taken at onset of aura associated with migraine.
3200726|NCT00893594|Active Comparator|2|Sumatriptan with naprosyn taken at onset of aura associated with migraine.
3200727|NCT00893607|Experimental|Intra-anal|The first 12 subjects were administered 10mg NRL001 as a slow release suppository into the anal canal.
3200728|NCT00893607|Experimental|Rectal|The second 12 subjects were administered 10mg NRL001 as a slow release rectal suppository.
3200729|NCT00893620|Other|1|Treatment
3200730|NCT00893646|Experimental|weight loss counseling|individual monthly counseling on diet, physical activity and sleep
3200731|NCT00893646|No Intervention|control|no lifestyle advice, yearly assessments
2529920|NCT02697812|Experimental|slow sternal retraction|sternal retraction (which is required for exposure of the heart during coronary artery bypass graft surgery) will be performed gradually over 15 minutes
2529924|NCT02697812|No Intervention|standard sternal retraction|sternal retraction will be performed as per standard practice (sternum opened rapidly over 30 sec.)
2530011|NCT02697344|Experimental|Treatment (AT-101, lenalidomide, and dexamethasone)|Patients receive R-(-)-gossypol acetic acid PO QD on days 1-21. Beginning in course 2, patients also receive lenalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, and 15 of courses 2-12. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3167035|NCT00532961|Experimental|Zylet|Zylet (loteprednol etabonate and tobramycin)
3167036|NCT00532961|Active Comparator|Tobradex|TobraDex (dexamethasone and tobramycin)
2530187|NCT02696122|Experimental|Local Group|Local infiltration under general anesthesia via laryngeal mask
2530189|NCT02696122|Experimental|Spinal Group|Spinal anesthesia with 15 mg of 0.5% hyperbaric bupivacaine
2530225|NCT02695654||Chronic pain in knee osteoarthritis|Ultrasound guided single shot Adductor canal block with 0,25% Levobupivacaine 14 ml and 100 mcg Clonidine
3200732|NCT00893659|Experimental|wheat bread with beta-glucan supplementation|
2530383|NCT02694640|Experimental|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
2530385|NCT02694640|Experimental|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
2530387|NCT02694640|Experimental|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
2530453|NCT02694250|Other|DTRAX Cervical Cervical Cage with DTRAX Bone Screw|
2530494|NCT02693756|No Intervention|Control|Participants will be allowed to perform all usual activities but should refrain from performing the motor imagery exercises.
2530496|NCT02693756|Experimental|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
2530608|NCT02693093|Placebo Comparator|placebo|TID Day for 28 Days
2530609|NCT02693093|Experimental|100 mg NI-03|TID Day for 28 Days
2530615|NCT02693093|Experimental|200 mg NI-03|TID Day for 28 Days
2530619|NCT02693093|Experimental|300 mg NI-03|TID Day for 28 Days
2530738|NCT02692300|No Intervention|Control Group|Patients will undergo standard anesthesia and will be blinded to EEG-based data, as per standard of care in this patient population.
2530741|NCT02692300|Experimental|EEG-Guided Group|Practitioners will follow the EEG-Guided protocol to limit the incidence of EEG burst suppression by decreasing administration of anesthesia. The EEG-guided protocol is suggestive rather than prescriptive, and practitioners will exercise judgment depending on the clinical situation.
2530853|NCT02691312||Type 1 diabetes (T1D)|Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
2530902|NCT02691026|Experimental|Pembrolizumab|200 mg pembrolizumab, i.v. infusion every 3 weeks for up to 10 cycles
2530966|NCT02690818|Experimental|Behavioral intervention arm|"Regularly scheduled medication reminder text messages~Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication.~Standard of care: Monthly reminder call and clinic visit"
2530969|NCT02690818|No Intervention|Control group receiving standard care|Standard of care: Monthly reminder call and clinic visit
2531020|NCT02690519|Experimental|GLPG1837 dose 1 and GLPG1837 dose 2|GLPG1837 twice daily oral dosing - morning and evening, for 4 weeks
3167037|NCT00533000|Experimental|A|Smoking cessation
3167038|NCT00533000|No Intervention|B|
3167039|NCT00533013|Active Comparator|Usual care|Management of heart failure is provided by primary practitioners and consultant cardiologists
3167040|NCT00533013|Experimental|Disease Management|Disease management led by nurse specialists in regional Heart Failure Clinics and a national Call Center. Tele-Monitoring of body weight, pulse rate and blood pressure is performed at participants' homes.
3167041|NCT00533026|Active Comparator|A|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60mg QD, PO for the 14 days. Duloxetine doses were tapered, subjects received 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
3167042|NCT00533026|Active Comparator|B|Subjects received warfarin QD, PO for approximately 12 days. Subjects with stabilized INR after approximately 12 days continued to receive warfarin QD, PO for an additional 14 days and also received duloxetine 60 mg QD, PO for 4 days followed by duloxetine 120 mg QD, PO for 10 days. Duloxetine doses were tapered, subjects received 60mg QD, PO for 4 days followed by 30mg QD, PO for 4 days. No warfarin was received during the taper phase.
2529923|NCT02697526|Other|Tensoplast|Patients in this arm will receive Tensoplast after catheterization
2530005|NCT02697305|Experimental|IV BCAA test|IV application of BCAA solution
2530010|NCT02697305|Experimental|ORAL BCAA test|At once oral ingestion of BCAA capsules
2530015|NCT02697305|Placebo Comparator|ORAL PLACEBO test|At once oral ingestion of placebo capsules
2530379|NCT02694939|Experimental|STAND|Receives STAND intervention delivered in community mental health setting.
2530380|NCT02694939|Active Comparator|Usual Care|Receives usual care from community therapists.
2530421|NCT02694367||Recurrent miscarriage group|Women with previous history of RM, defined as two or more consecutive miscarriages
2530424|NCT02694367||Control group|Women with no history of RM
2530480|NCT02694016|Experimental|Remote ischemic preconditioning|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis and a preoperative lower leg remote ischemic preconditioning(RIPC) phase.
2530488|NCT02694016|No Intervention|Control group|Patient will undergo normal isolated aortic valve replacement surgery with a biological prosthesis
3167043|NCT00533039|Placebo Comparator|Control|Subjects take 2 tablets BID. Placebo tablets are identical to active medication.
3167044|NCT00533039|Experimental|Varespladib (A-002)|Subjects take 250mg tablets BID beginning 3-5 days pre-angioplasty and for 5 days post-angioplasty.
3167045|NCT00533052|Experimental|Affective and Cognitive Skills Training|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training
3167046|NCT00533078|Other|1|
3167047|NCT00533091|Active Comparator|1|MEDI-545
3167048|NCT00533091|Other|2|Placebo
3167049|NCT00533104|Experimental|BM-MNC|Patients are implanted with bone marrow - mononuclear cells
3167050|NCT00533104|Experimental|PB-MNC|Patients are implanted with peripheral blood - mononuclear cells
3167051|NCT00533130||1|Pediatric patients under 16 years old with long bones fractures
3167052|NCT00533143|Experimental|2|Non-invasive ventilation
3167053|NCT00533169|Experimental|ZD6474 + Retinoic Acid|Part A = ZD6474 Alone, Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = ZD6474 + Retinoic Acid 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
3167057|NCT00533195|Active Comparator|0|5-MOP photochemotherapy. Intake of Geralen capsules (1.2 mg/kg) 2 hours before irradiation. Determination of the minimal phototoxic dose (MPD) and Geralen serum level prior to treatment. Start with 70 % of the MPD, no dose increments in the first treatment week. From the second week increments of the UVA dose by 20 % in the absence of an erythemal reaction, respectively by 10 % in cases of a barely perceptible erythemal response. Increments of the UVA dose at the earliest 96 hours after the last increments. Treatment frequency 3 x week for 5 weeks (=15 exposures). No maintenance therapy except emollients.
3167058|NCT00533195|Experimental|1|UVA1 phototherapy. Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability. No maintenance therapy except emollients.
3167059|NCT00533221|Active Comparator|Somatotropin|subcutaneous application of somatotropin over 12 weeks followed by 8 weeks wash out period followed by 12 weeks subcutaneous placebo application
3167060|NCT00533221|Placebo Comparator|Placebo|12 weeks placebo subcutaneous application followed by 8 weeks wash out and 12 weeks subcutaneous application of somatotropin
2530832|NCT02691559|Active Comparator|maternal inflammation group|Amniotic fluid analysis by blood gas device: evaluate the possible association between maternal inflammation and amniotic fluid pH two groups will be designed. One group will consist of infants born to mothers with infection/inflammation whereas the control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
3167061|NCT00533286|Placebo Comparator|A|placebo (2 tablets daily)
3167062|NCT00533286|Experimental|B|diazepam (2 x 5 mg)
3167063|NCT00533299|Experimental|1|Topotecan hydralazine valproate
3167064|NCT00533299|Placebo Comparator|2|Placebo, hydralazine, valproate
3167065|NCT00533338|Experimental|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling. Packet of questionnaires will be completed.
3167066|NCT00533338|Active Comparator|Standard Care Group|Packet of questionnaires will be completed.
3167067|NCT00533377|Experimental|CP-533,536 Dose Level 2|
3167068|NCT00533377|Placebo Comparator|Placebo|
3167069|NCT00533377|Other|Standard of Care|
3167070|NCT00533377|Experimental|CP-533,536 Dose Level 1|
3167071|NCT00533377|Experimental|CP-533,536 Dose Level 3|
3167072|NCT00533377|Experimental|CP-533.536 Dose Level 4|
3167073|NCT00533390|Experimental|EFAVIRENZ 800mg|Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
3167074|NCT00533390|Active Comparator|EFAVIRENZ 600mg|Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
3167075|NCT00533494|Active Comparator|B|Feedback to physicians + reminder letters to patients
3167076|NCT00533494|Active Comparator|A|Feedback information to physicians
3167077|NCT00533520|Active Comparator|0.5mg ranibizumab|Subjects will be treated with 0.5mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3167078|NCT00533520|Active Comparator|1.0mg ranibizumab|Subjects will be treated with 1.0mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3167079|NCT00533520|Active Comparator|2.0mg ranibizumab|Subjects will be treated with 2.0 mg ranibizumab at the Day 0 visit and the as needed based on defined retreatment criteria no sooner than every 28 days since last treatment.
3167080|NCT00533559|Experimental|buphenyl|
3167081|NCT00533559|Placebo Comparator|Placebo|
2529932|NCT02697643|Experimental|BHCDS-based recommendations|The Experimental condition will use the BH-CDS tool and receive tailored recommendations in addition to treatment as usual.
2529940|NCT02697643|Placebo Comparator|Non-tailored recommendations|The Control condition will use the BH-CDS tool and receive non-tailored recommendations in addition to treatment as usual.
2529988|NCT02697227|Active Comparator|Group I (NRT, SC)|Patients receive NRT patch daily for 8 weeks. Patients receive individual behavioral treatment sessions consisting of behavioral treatment strategies for smoking cessation and health education information over 45 minutes for 8 sessions.
2529993|NCT02697227|Active Comparator|Group II (NRT, BATS)|Patients receive NRT patch daily for 8 weeks. Patients complete individual treatment sessions consisting of SC strategies and BA strategies over 45 minutes for 8 sessions.
2530034|NCT02696746||Pain related conditions|Subjects with painful or painless conditions (observational study, no interventions)
2530128|NCT02696616|Experimental|BI 655088|
2530135|NCT02696616|Placebo Comparator|Placebo|
3200733|NCT00893659|Placebo Comparator|wheat bread without beta-glucan|
3200734|NCT00893672||1|Routine strategy of chest radiograph prescription
2530242|NCT02695602|Experimental|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|Turbinoplasty using microdebrider turbinate blade (2.9mm inferior turbinate blade, Medtronic, 5000 Hz)
2530249|NCT02695602|Experimental|Submucous Resection (SMR)|Turbinoplasty using non-powered instruments
2530306|NCT02695251|Experimental|Low AGE meal|Renal functional parameters are measured at baseline and after a low AGE (eggs) meal
2530307|NCT02695251|Experimental|High AGE meal|Renal functional parameters are measured at baseline and after a high (mixed nuggets) AGE (eggs) meal
2530361|NCT02694796|Experimental|Intervention|The 'Physical activity program after a balneotherapy' intervention involves providing a workshop during a balneotherapy about physical activity and use of automated physical activity program including website, mobile app and connected devices, and after the balneotherapy, the access to the automated program during 12 months.
2530362|NCT02694796|No Intervention|Control|Patients included in the control arm will receive a booklet including informations about physical activity recommendations and practice.
2530455|NCT02694107|Experimental|Proprioceptive exercises|Proprioceptive exercises performed 3 sessions per week for 4weeks
2530456|NCT02694107|No Intervention|Control|Without any exercises
2530505|NCT02693782|Placebo Comparator|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
2530510|NCT02693782|Active Comparator|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
2530538|NCT02693379|Experimental|D-VIA|HPV high risk-positive (16, 18, 45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68) women had a cervical examination using acetic acid (VIA) application and visual inspection.
2530604|NCT02693028|Active Comparator|probiotic lozenge|Two probiotic lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2530606|NCT02693028|Active Comparator|Probiotic capsule|Two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2530610|NCT02693028|Active Comparator|Probiotic chewing gum|The probiotic chewing gum should be chewed on for about 10 minutes. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2530617|NCT02693028|Placebo Comparator|Placebo lozenge|Two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2530618|NCT02693028|Placebo Comparator|Placebo capsule|Two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
2530667|NCT02692677|Experimental|JNJ-42756493|Each participant will receive a single oral dose of 12 milligram (mg) of unlabeled JNJ-42756493 admixed with 14C JNJ-42756493 at Pre-dose,0.5,1,2,3,4,8,12 hour post-dose(pd) on Day 1;24,36 h pd on Day 2;48 h pd on Day 3,72 h pd on Day 4; 96 h pd on Day 5;192 h pd on Day 9,216 h pd on Day 10,240 h pd on Day 11,264 h pd on Day 12,288 h pd on Day 13 and 312 h pd on Day 14
2530712|NCT02692378|Active Comparator|Treatment|"Standard haemodialysis treatment thrice weekly (using a standard dialysate containing bicarbonate at a concentration of 35mmols/L) with the addition of oral sodium bicarbonate 500mg capsules for 12 weeks (weeks 5-16 of the study).~The dosage will be titrated to individual blood levels. Starting dose will be 1g twice daily and if predialysis bicarbonate levels remain <22mmols/L the dose will be increased by 0.5g twice daily each week. The maximum dose would be 3g twice daily.~The oral sodium bicarbonate may be withheld on dialysis days, when bicarbonate will be supplemented through the dialysate. This will be assessed on a case by case basis."
2530713|NCT02692378|No Intervention|Control|Standard haemodialysis treatment thrice weekly using a standard dialysate containing bicarbonate at a concentration of 35mmols/L.
2530757|NCT02692053|Experimental|Patients with septic shock|
2530759|NCT02692053|Other|Blood samples from a historical cohort of healthy volunteers|
2530813|NCT02691806|Experimental|research arm|Each of the 14 participants will undergo the same 2 days experimental protocol, separated by at least 2 days rest.
2530859|NCT02691299|Active Comparator|Treatment Arm|All subjects will receive study treatment in 4-week cycles: Fruquintinib, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease progression.
2530861|NCT02691299|Placebo Comparator|Control Arm|All subjects will receive study treatment in 4-week cycles: Placebo, QD, 5mg with best supportive care for 3 consecutive weeks, and then one week off. Tumor assessment will be performed every 4 weeks in the first 2 cycles, and every 8 weeks since the 3rd cycle, until disease progression or death. Subsequent anti-neoplastic treatment and survival status will be followed up after disease
3200735|NCT00893672||2|On-demand strategy of chest radiograph prescription
3200736|NCT00893685|Experimental|Home telemonitoring|
3200737|NCT00893685|No Intervention|Usual care (control group)|
2529956|NCT02697422|Experimental|Peer health coach intervention group|Eligible participants will be randomly assigned to receive a home-visit peer health coach intervention to promote health outcomes and behavior change among Veterans with multiple cardiovascular disease (CVD) risk factors.
2529957|NCT02697422|No Intervention|Control group|Participants who meet the same eligibility criteria as participants in the intervention group will be randomly assigned to receive no intervention. Participants will continue to receive their regular, usual primary care.
2529977|NCT02697110|Experimental|A: Edutainment based intervention|This group receives the usual routine immunization at 6, 10, 14 weeks and 9 months and an Edutainment intervention package of limited group (i.e., 3-5 women) drama based video session (Edutainment) followed by a Question and Answer session with mothers on early brain development, parenting skills, communication and negotiating skills at 6 weeks. Mothers will be encouraged to train fathers and other caregivers at home with reinforcement of key messages at subsequent clinic visits. Key messages will be delivered through the use of flip charts at 14 weeks and given to mothers as take home for use in engaging the fathers partners and other caregivers for their child. Reinforcement of key messages at subsequent visits will be through the use of videos and flip chart.
2529979|NCT02697110|No Intervention|B|This group receives routine immunization care (usually includes group health talk) at 6, 10, 14 weeks and 9 months.
2530046|NCT02697019|Experimental|Internet-delivered ERITA|
2530080|NCT02696564|Active Comparator|Losartan|At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.
2530081|NCT02696564|Placebo Comparator|placebo|At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is >90 mm Hg and diastolic BP is > 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.
2530152|NCT02696213|Experimental|SCOOT Immediate|This group will receive SCOOT immediately
2530154|NCT02696213|Other|SCOOT Delayed|This group will receive SCOOT after 6 weeks
2530198|NCT02695927|Experimental|Chronic|Crossover study on the benefits of computer rehabilitation glasses on chronic sufferers of hemispatial neglect
2530201|NCT02695927|Experimental|Acute|Randomized, controlled study on the benefits of computer rehabilitation glasses on acute sufferers of hemispatial neglect
2530203|NCT02695927|Experimental|Optimization|Study to identify optimal operating parameters of computer rehabilitation glasses
2530205|NCT02695927|Active Comparator|Duration|Study to determine duration of effect of computer rehabilitation glasses
2530239|NCT02695563|No Intervention|controls|The patients will be not treated with vaginal lactoferrin
2530246|NCT02695563|Active Comparator|Lactoferrin|The patients will be administered with a single dose of 300 mg vaginal lactoferrin 4 hours prior to mid-trimester genetic amniocentesis.
2530283|NCT02695277|Experimental|Hybrid Procedure|Endoscopic epicardial surgical ablation (first stage) combined with endocardial catheter ablation (second stage) performed between 91 and 180 days post index procedure.
2530287|NCT02695277|Active Comparator|Catheter Procedure|Standard catheter ablation with pulmonary vein (PV) isolation (minimum lesion set) and optional additional lesions (index procedure). When required due to AF recurrence, ablation may be repeated within 6 months after the index-procedure according to clinical indications and consistent with the Heart Rhythm Society (HRS)/European Heart Rhythm Association (EHRA)/European Cardiac Arrhythmia Society (ECAS) Consensus Statement
2530329|NCT02694965||Stage IV/Unresectable Stage III Melanoma|Observational - Eligible patients with stage IV/unresectable stage III melanoma selected to undergo treatment with an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or a combination of an anti-CTLA-4 antibody/anti-PD-1 antibody will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.
2530330|NCT02694965||Stage III/IV Adjuvant Melanoma|Observational - 1) Patients either undergoing resection of stage III or stage IV melanoma or have previously undergone resection and who are considered candidates for adjuvant anti-PD-1 antibody immunotherapy. 2) Patients who previously underwent resection of stage III or stage IV melanoma and received prior adjuvant anti-PD-1 antibody immunotherapy and have subsequently developed recurrent melanoma.
3200738|NCT00893711|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops of a commercially available oil suspension, 30 min before feeding, once a day for 30 days.
2530472|NCT02694094||Adults on Chronic ketogenic diets|Adults who have been on Modified Atkins or ketogenic diets for over 1 year
2530473|NCT02694094||Adults naive to ketogenic diets|Adults who have never been on Modified Atkins or ketogenic diets
2530519|NCT02693613|Experimental|Group 1|Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
2530522|NCT02693613|Experimental|Group 2|Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
2530562|NCT02693288|No Intervention|Ultrasound-guided nerve block|
2530563|NCT02693288|Experimental|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaine 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
2530647|NCT02692937|Experimental|Surgery and exercise|Neurolysis of peripheral nerves in the back of the head and/or neck. Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
2530649|NCT02692937|Active Comparator|Exercise, Active Comparator|Traditional neck-specific exercise program including five individual treatments sessions within 3 months plus home program over 9 months.
2530708|NCT02692547|Other|Hybrid-logic closed loop system|All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.
3200739|NCT00893711|Placebo Comparator|Placebo|Placebo is administered in V drops once a day for 30 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
2529987|NCT02697201|Experimental|Intralipid Infusion, then Saline|Participants in this arm will first receive a lipid infusion. Then 4 weeks later the saline infusion.
2529992|NCT02697201|Sham Comparator|Saline Infusion, then Intralipid|Participants in this arm will first receive a saline infusion. Then 4 weeks later the lipid infusion.
2530029|NCT02696889|Experimental|ROSE-1 Protocol|Patients with POF, POI or Low Ovarian Reserve choosing to enroll will be provided informed consent for Rejuvenation of Premature Ovarian Failure With Stem Cells (ROSE-1). They will undergo diagnosis and screening confirming diagnosis including History and Physical Exams, Labs and Diagnostic Procedures. Following final approval and under anesthesia, bone marrow aspiration with separation of the bone marrow derived stem cell fraction will be performed. Diagnostic laparoscopy will allow for assessment of pelvic anatomy and subsequent injection of the bone marrow derived stem cells into the right ovary.
2530105|NCT02696642|Experimental|Control group|Anetumab ravtansine was given at 6.5 mg/kg body weight (BW) as a 1 hour intravenous (IV) infusion once every 3 weeks (Q3W) for subjects with adequate hepatic and renal function.
2530111|NCT02696642|Experimental|mild HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with mild hepatic impairment (HI).
2530115|NCT02696642|Experimental|moderate HI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate hepatic impairment (HI).
2530119|NCT02696642|Experimental|moderate RI group|Anetumab ravtansine was given at 6.5 mg/kg BW as a 1 hour IV infusion Q3W for subjects with moderate renal impairment (RI).
2530163|NCT02696018||Critically ill patients|Ultrasonography in critically ill patients in weaning from mechanical ventilation
2530230|NCT02695849||NSCLC Participants|Participants with non-squamous NSCLC will be enrolled in this study.
2530280|NCT02695368|Experimental|Exposed patients: Plasma-filter on|"Those operated with Novaerus NV800 on for at least 2 Days prior to index surgery. This Group will also in the analysis be sub-grouped according to measurements prior to study start into:~regular operating theater~ultra-Clean operating theaters"
2530282|NCT02695368|Experimental|Unexposed patients: Plasma-filter off|Those with Novaerus NV800 off for at least 2 Days prior to index surgery
2530284|NCT02695368|Experimental|Mixed patients: Plasma-filter on or off|Those receiving multiple surgeries in different theaters with Novaerus NV800 on or off status will belong to a mixed Group.
2530319|NCT02695043|Experimental|MMPET Group|This group of subjects will be comprised of a subset of culturally diverse patients admitted to the Bellevue the Traumatic Brain Injury Unit at Bellevue. Treatment will focus on improving awareness and comprehension of TBI and its long-term consequences, fostering increased trust in the TBI rehabilitation team, and conveying the importance of continued TBI follow up to maximize recovery.
2530322|NCT02695043|Active Comparator|Control Group|The Control Group will be comprised of equally diverse subset of patients who will receive Standard of Care Treatment.
2530381|NCT02694666|Experimental|Vibration training group|The vibration group will receive 8-week controlled whole-body vibration training as the intervention on the Galileo Med L device
2530386|NCT02694666|Placebo Comparator|Placebo training group|The placebo group will receive 8-week placebo training on the Galileo Med L device
2530414|NCT02694289|Other|Metformin|Continue Metformin while admitted to hospital
2530417|NCT02694289|Other|Subcutaneous (sliding scale) Insulin|Discontinue Metformin upon admission and be placed on sliding scale subcutaneous insulin treatment while admitted to hospital
2530548|NCT02693522|Experimental|somatropin|Subcutaneous injection
2530551|NCT02693522|Active Comparator|Eutropin|Subcutaneous injection
2530602|NCT02693067|Experimental|PV-10|Intralesional rose bengal disodium (PV-10) to one or more neuroendocrine tumor metastases to the liver
2530648|NCT02692820|Experimental|Probiotic|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of probiotics (containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 (each at 2.5 x 109 colony forming units (CFUs)). The product contains freeze-dried bacteria and excipients in a gelatin capsule.
2530652|NCT02692820|Placebo Comparator|Placebo|Those who provide consent will be randomised to receive once daily for the remainder of their pregnancy capsules of the placebo containing excipients alone in a gelatin capsule
2530694|NCT02692534||Cocaine negative|Patients with preoperative urine cocaine negative results
2530695|NCT02692534||Cocaine positive|Patients with preoperative urine cocaine positive results
2530714|NCT02692248|Experimental|Ibrutinib -R-GEMOX-Dexa|"Subjects will receive Ibrutinib with R-GEMOX-Dexa followed by Ibrutinib maintenance according to:~Induction phase:~Rituximab 375 mg/m2 IV day 1~Gemcitabine 1000 mg/msq IV on day 1 or 2 (at investigator discretion).~Oxaliplatine 100 mg/msq on day 1 or 2 (after Gemcitabine administration);~Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3.~Ibrutinib 560 mg daily for 14 days.~Responding patients will receive 2 (if CR) or 4 (if PR) additional cycles every 14 days.Patients with SD and ABC profile will receive 4 additional cycles.~Maintenance phase: Responding patients will receive Ibrutinib 560 mg daily - Continuous cycles until a maximum of 2 years, disease progression or unacceptable toxicity."
2530800|NCT02691832|Experimental|research arm|"the trial contains one group which will undergo the described protocol three times:~connected to rectal thermistor and to the double sensor~connected to rectal thermistor, double sensor and cooling system of Icetron Technologies Ltd.~connected to rectal thermistor and to the double sensor integrated into a helmet."
3200740|NCT00893711|Active Comparator|L.reuteri + vit D|L. reuteri DSM 17938 (10^8 CFU) plus vitamin D3 (400 UI) five drops/day for 3 months
3200741|NCT00893711|Placebo Comparator|Vit D Placebo|vitamin D3 (400 UI) five drops/day for 3 months
2531123|NCT02689388|Active Comparator|General Anesthesia with nerve block|Femoral Nerve Block
2531124|NCT02689388|No Intervention|General Anesthesia no nerve block|No femoral Nerve Block
2531185|NCT02689336|Experimental|Erlotinib and Temozolomide|"Erlotinib is an oral drug that will be administered on an outpatient basis at a dose of 85 mg/m^2/dose once a day continuously (every day of a 28-day cycle)~Temozolomide is an oral drug that will be administered on an outpatient basis at a dose of 180mg/m2/dose once a day on Days 1-5 of a 28-day cycle."
2531240|NCT02688790|Experimental|Cohort 1|One dose of intravenous dalbavancin infusion 22.5 mg/kg in young infants aged greater than 28 days to 3 months
3200742|NCT00893724|Placebo Comparator|P (Placebo)|
3200743|NCT00893724|Active Comparator|S (Supplement)|
2530000|NCT02697045|Other|ARIPIPRAZOLE|ABILIFY MAINTENA 400 MG LAI Aripiprazole 400mg, IM, Once a month
2530028|NCT02696772|Experimental|Energy balance|Intervention day diet containing 100% of estimated energy requirements
2530035|NCT02696772|Experimental|Energy restriction|Intervention day diet containing 25% of estimated energy requirements
2530106|NCT02696655|Experimental|liver transplant patients|Patients will use a behavioural intervention to assess its usability
2530209|NCT02696174|Experimental|Health Microinsurance Scheme|Households owning the HMI package, entitling them to visit and receive treatment from the selected primary care clinic
2530212|NCT02696174|No Intervention|Out-Of-Pocket|Households who visit the selected primary care clinic, but pay by Out-Of-Pocket
2530235|NCT02695498|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a standardized course in mindfulness mediation and yoga.
2530243|NCT02695498|Experimental|Migraine/stress Education|This course will educate participants about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
2530295|NCT02695264|Experimental|HS-1000 recording|ICP readings will be recorded from both the invasive and HeadSense non-invasive ICP monitor for an aggregate of 30 minutes. During the recording sessions, a webcam will take periodic snapshots of the ICP monitor and/or bedside monitor picturing the ICP values and other clinical parameters that are displayed on screen, with a focus on blood pressure and heart rate (HR). Recording sessions will be done until an aggregate of at least 30 minutes of data are collected, depending on the patient's clinical condition. Recording sessions may be repeated over several days until the 30 minute target is reached.
2530346|NCT02694900|Experimental|Resuscitation on the flor|2 min asynchronous cardiopulmonary resuscitation. The patient lies on the floor
2530348|NCT02694900|Experimental|Resuscitation on the stretcher|2 min asynchronous cardiopulmonary resuscitation. The patient lies on a stretcher
2530382|NCT02694484|Other|Healthy volunteers|For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit
3200744|NCT00893724|Active Comparator|SM (Supplement with Minocycline)|
2530495|NCT02693938|Experimental|luteal phase clamp|Luteal euglycemic clamp administered during luteal phase of menstrual cycle.
2530497|NCT02693938|Active Comparator|follicular phase clamp|Follicular euglycemic clamp administered during follicular phase of menstrual cycle.
2530544|NCT02693444|Active Comparator|Subacromial Lidocaine Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of lidocaine, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
2530545|NCT02693444|Placebo Comparator|Subacromial Saline Injection|Both of your shoulders will be examined and evaluated (shoulder survey). Following the exam, you will be randomized (assigned by chance, similar to a coin toss) to receive a 10cc (2 teaspoon) subacromial injection of saline, will be given under ultrasound (using sound waves) guidance to your affected shoulder. A repeat shoulder exam will be performed and recorded
3200745|NCT00893750|Experimental|NET Truth Education|
3200746|NCT00893750|Experimental|Conflict Resolution Trainings|
2530756|NCT02692196|Experimental|Neurofeedback Training|Neurofeedback training - neurofeedback of fronto-limbic functional connectivity.
2530758|NCT02692196|Sham Comparator|Sham Control|Sham training - feedback that is not related with fronts-limbic connectivity (motor connectivity)
2530828|NCT02691611||Alpha-1 Antitrypsin|All AATD patients who will start treatment with alpha-1 antitrypsin augmentation therapy
2530829|NCT02691611||Healthy Control|Healthy controls with no lung diseases
3200747|NCT00893750|Experimental|Traditional Methods|
3200748|NCT00893776|Active Comparator|1 Unilateral Group|This group will wear the SaeboFlex orthosis on their affected extremity and do exercises with that extremity only. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
3200749|NCT00893776|Experimental|2 Bilateral training|Members of this group will wear the SaeboFlex orthosis on the affected extremity and do exercises with the affected extremity and the non-affected extremity at the same time. SaeboFlex exercises include moving the ball in high repetition of grasp and release while wearing the SaeboFlex orthosis to various positions individualized to each participant based on movement deficits, as well as Task Training (using the affected arm during specific functional activities to use newly acquired movement patterns)
2530955|NCT02690740|Experimental|open label|"test/retest of a titrated quantitative CPT (TqCPT) with outcomes: CPT-scoring system and correlation with digital photo analysis.~in all patients: 1 Arm = CPT test/re-test, no comparator~No intervention of a new drug (CPT-solution registered (ALK- Abelló, Hørsholm, Denmark));"
2531003|NCT02690571|Sham Comparator|Filtered air exposure|One hour exposure to filtered air during intermittent exercise in controlled chamber, 6 hours after exposure bronchoscopy is performed.
2531009|NCT02690571|Experimental|Biodiesel exhaust exposure|One hour exposure to biodiesel exhaust (generated at same running conditions as earlier studies with diesel exhaust at approximate particle matter concentration 300 mcg/m3) during intermittent exercise in controlled chamber. Six hours after exposure bronchoscopy is performed.
3200750|NCT00893802|Experimental|Periodontal treatment|Scaling and root planning
3200751|NCT00893802|No Intervention|Control|
2531159|NCT02689544|Experimental|dynamic stretching|Group of 15 volunteers (gDS)
2531160|NCT02689544|Other|control|Group of 15 volunteers (gC)
3200752|NCT00893815||1|HIV-Positive and Early HIV infection
3200753|NCT00893815||2|HIV-Positive and Late HIV-infection
3200754|NCT00893815||3|HIV-negative
3200755|NCT00893841|Placebo Comparator|1|Quetiapine XR 300mg + Placebo
3200756|NCT00893841|Experimental|2|Quetiapine XR 300mg + Pramipexole 0.25mg
3200757|NCT00893841|Experimental|3|Quetiapine XR 300mg + Pramipexole 0.50mg
3200758|NCT00893854|Experimental|Diclophenac|
3200759|NCT00893854|Experimental|Triamcinolone|
3200760|NCT00893867|Experimental|DP-b99|
2530103|NCT02696356|Experimental|Cohort 1|0.1mg GRN-1201
2530104|NCT02696356|Active Comparator|Cohort 2|1.0mg GRN-1201
2530107|NCT02696356|Experimental|Cohort 3|3.0mg GRN-1201
2530179|NCT02696109|Experimental|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
2530181|NCT02696109|Active Comparator|Treatment as Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
3200761|NCT00893867|Placebo Comparator|Mannitol|
3200762|NCT00893880|Experimental|1|(1) 30min treatment
2530320|NCT02695004|Experimental|Donepezil 35 mg|Donepezil 35 mg or placebo
2530323|NCT02695004|Experimental|Donepezil 70 mg|Donepezil 70 mg or placebo
2530325|NCT02695004|Experimental|Donepezil140 mg|Donepezil 140 mg or placebo
2530326|NCT02695004|Experimental|Donepezil 210 mg|Donepezil 210 mg or placebo
2530327|NCT02695004|Experimental|Donepezil 280 mg|Donepezil 280 mg or placebo
2530403|NCT02694575||Other|Other - currently on other treatment (i.e., non-incretin based therapies)
2530405|NCT02694575||GLP-1|Currently on GLP-1 analogue therapy
2530407|NCT02694575||DPP-4|Currently on DPP-4 inhibitor therapy
3200763|NCT00893880|Experimental|2|(1) 60min treatment
3200764|NCT00893880|Experimental|3|(2) 30min treatments over two consecutive days.
3200765|NCT00893880|Experimental|4|(2) 60min treatments over two consecutive days.
3200766|NCT00893893||1|Lean premenopausal women
2530560|NCT02693184||Fragility Fracture Case|Men and women, age >65 years with a fragility fracture (defined as a fracture sustained after a fall from a standing height or less).
2530655|NCT02692807|Active Comparator|Hip arthroscopy surgical procedures (HIPARTI Study)|Surgery is performed under general anaesthesia. Traction and joint access is controlled by fluoroscopy. A diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented. Any labral, chondral and bony pathology (cam or pincer) is treated. Labrum may be debrided, sutured, detached and refixed if needed to treat a pincer lesion. Labrum is secured with suture anchors. Pincer and cam resection is performed using an arthroscopic burr. Cartilage lesions maybe left untreated or treated with debridement or microfracture.
2530656|NCT02692807|Placebo Comparator|Sham surgery (HIPARTI Study)|The same arthroscopic procedures as stated above are preformed, but no surgical interventions related to Cam, Pincer, or labral tear are performed, only diagnostic round in the central and peripheral compartment is performed. Labrum, cartilage, and other possible conditions are looked for and findings are documented.
2530657|NCT02692807|Active Comparator|Prospective Cohort (HARP Study)|Those that are not willing to be included in the RCT (HIPARTI Study), will be asked if they are willing to be included in the prospective cohort, or ongoing in countries were ONLY the surgery is performed (Australia). They will sign an informed concent and will undergo surgical interventions as part of usual care. Outcomes collected and follow-ups will be the same as for the RCT (HIPARTI).
2530718|NCT02692456|Active Comparator|Double needle celiac neurolysis (DNCN)|Patients were subjected to CT guided celiac neurolysis using 2 needle antero-crural technique on each side with patient in prone position and both needles will be lateral to the aorta
2530724|NCT02692456|Placebo Comparator|Single needle celiac neurolysis (SNCN)|Patients were subjected to CT guided celiac neurolysis using a single needle antero-crural approach from left side to be just in the front of the aorta near the origin of celiac trunk with patient in lateral position with his left side up then after the injection the patient were kept to his right side up for more homogenous spread of the dye.
3200767|NCT00893893||2|Visceral obese premenopausal women
3200768|NCT00893906|Experimental|TIV|Children living in villages randomized to influenza vaccine
3200769|NCT00893906|Experimental|IPV|Children living in villages randomized to polio vaccine
3200770|NCT00893932||SIRS|
3200771|NCT00893945|Experimental|DC/AAT vaccine|Intradermal injection of 3 Autologous dendritic cell vaccines (DC/AAT, DC/AAT-flu, DC/KLH) that have been co-cultured with autologous apoptotic tumor specimens.
3200772|NCT00894023|Experimental|Abciximab|IC bolus of abciximab
3200773|NCT00894023|Active Comparator|IV Abciximab|IV abciximab + infusion
3200774|NCT00894049|Experimental|Flu-Bu-ATG|Fludarabine (30mg/m²/5 days) Oral Busulfan (8 mg/kg over 2 days) Thymoglobuline (2.5 mg/m²/1day).
3200775|NCT00894049|Experimental|Fluda-TBI|Fludarabine (25mg/m²/ 3 days) 2 Gy TBI
3200776|NCT00894062|Active Comparator|1|ZES resolute (Endeavor® resolute)
3200777|NCT00894062|Active Comparator|2|EES (Xience®)
3200778|NCT00894101|Experimental|[F-18] FLT and FDG|
3200779|NCT00894114|Other|Stratum 1|Placebo recipients in the parent protocol (Merck V520 Protocols 007 or 012) will receive ALVAC-HIV Vaccine
3200780|NCT00894114|Experimental|Stratum 2|Nonresponders who received active vaccine in parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3200781|NCT00894114|Experimental|Stratum 3|Low responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3200782|NCT00894114|Experimental|Stratum 4|High responders who received active vaccine in the parent protocol will be randomized to receive ALVAC-HIV vaccine or MRKAd5 HIV-1 gag vaccine
3200783|NCT00894140|Other|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
3200784|NCT00894153|Experimental|chemo plus p53|chemotherapy plus p53
3200785|NCT00894153|Active Comparator|chemo only|chemotherapy group
3200786|NCT00894153|Active Comparator|radio|radiotherapy
3200787|NCT00894192|Active Comparator|Wavefront guided lenses|
3200788|NCT00894192|Placebo Comparator|Conventional lenses|
3200789|NCT00894205|Experimental|strengthening exercise|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises."
2530113|NCT02696629||Education and follow up|Participants who refuse or fail to have PAP treatment or Oral appliance or other treatments for sleep apnea. They also refuse or have counter-indication for surgical treatment. The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
2530118|NCT02696629||Upper airway surgery|Participants who undergo uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery.
2530121|NCT02696629||Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
3200790|NCT00894218|Active Comparator|Conventional arthroplasty|Total hip or knee conventional arthroplasty
2530250|NCT02695641|Experimental|Stage 1 - Low dose administration|Ten hemodialysis patients will receive IV infusion treatment with 1.25mg bevacizumab and undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and pharmacokinetic/dynamic (PK/PD) data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcomes are met in stage 1, the study will be terminated, otherwise the study will progress to stage 2.
2530252|NCT02695641|Experimental|Stage 2 - Dose escalation|If outcomes are not met in stage 1, Ten additional hemodialysis patients will receive IV infusion treatment with 2.50mg bevacizumab treatment. They will undergo serial blood draws on Days 0, 1, 3, 6, 10, 15, 22, and 29 during dialysis sessions. ELISA will be performed to evaluate drug serum concentration and corresponding plasma free VEGF-A levels (pg/ml). The safety and PK/PD data will be analysed and ≥50% VEGF-A suppression retained from baseline by Day 15 will be considered successful. If target outcome is not met, the study will be terminated.
2530292|NCT02695212|Experimental|Apremilast ( open label)|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
2530337|NCT02694926|Other|adrenal insufficiency|
2530416|NCT02694341|Active Comparator|Bakri Balloon with abdominal traction stitch|bakri balloon will be inserted with abdominal traction stitch
2530420|NCT02694341|Experimental|Bakri Balloon without abdominal traction stitch|bakri balloon will be inserted with no performance of abdominal traction stitch
2530443|NCT02694003|Experimental|Intervention|The intervention arm will receive access to the BNBD-NDD Intervention.
2530444|NCT02694003|No Intervention|Usual Care|The usual care arm does not receive the BNBD-NDD intervention. This arm is free to access other resources while enrolled in the study. After the 8-month follow up time point, the usual care arm will be able to access the intervention.
2530565|NCT02693054|Experimental|Hybrid Fractional Laser Treatment|Halo (1470nm and 2940 nm) laser
2530640|NCT02692950|Other|Dialysis Patients|Honor My Decisions Advance Care Planning Videos, self-recorded by a patient using a computer application, followed immediately by a post-video questionnaire and a follow-up questionnaire 2-4 weeks later.
2530793|NCT02691754|Experimental|free paracetamol|the General Practitioners can prescribe paracetamol for free (covered by NHS). Patients can receive monthly dose at the local hospital
2530803|NCT02691754|No Intervention|standard drug prescription|"Paracetamol is not included in the list of drugs than can be prescribed in charge of National Health System by General Practitioners.~The General Practitioners can prescribe other drugs or recommend paracetamol payed by the patient (out of pocket) at the chemistry."
3167082|NCT00533585|Experimental|BAY 43-9006 + Bevacizumab|BAY 43-9006 (Sorafenib) + Bevacizumab + Paclitaxel + Carboplatin
3167083|NCT00533624|Active Comparator|1: Myfortic|Myfortic Group: Myfortic® 1,440 mg/day in two divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
2530936|NCT02690883|Active Comparator|Lispro|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
2530939|NCT02690883|Experimental|Exenatide|Patients are treated with Glargine (Lantus, Sanofi-Aventis), the dosage is initiated according to the previous treatment plan and weight of the patients, injection before bed time, titration following FPG <7.2mmol/L and >4.4mmol/L.
2530995|NCT02690597|Other|Patient|"State-trait anxiety inventory Y-A form (STAI Y-A form)~Anxiety visual analog scale evaluation(A-AVS)."
2531033|NCT02690285|Other|Part 1: glutathione transferase zeta 1 (GSTZ1) haplotyping|The participants will have blood collection and cheek cell collection after signing the informed consent, to determine GSTZ1 haplotype.
2531035|NCT02690285|Experimental|Part 2: Dichloroacetate (DCA) Kinetics|Eight study participants will be administered oral Dichloroacetate (DCA) 25 mg/kg daily for 5 days. On the fifth day frequent blood samples will be obtain over the following 24 hours. Study participants will complete a DCA kinetic study on day 5, at the Clinical Research Clinic (CRC).
2531076|NCT02689934|Experimental|Lactoflorene colesterolo|Red Yeast Rice titrated in 10 mg monacolin K per daily dose plus Bifidobacterium longum 50 mg, powder form, 1 packet per day
2531080|NCT02689934|Placebo Comparator|Placebo Lactoflorene colesterolo|placebo, powder form, 1 packet per day
3167084|NCT00533624|Active Comparator|2. Cellcept|Cellcept® 2,000 mg/day, in divided doses (induced with either the IL-2 receptor inhibitors or thymoglobulin). Tacrolimus will be dosed to 12-hour trough levels of 8-10 ng/ml. Methylprednisolone is to be given as per our center protocols, weaning to dose levels of <0.1 mg/kg by 3-6 months post-operatively.
3167085|NCT00533637|Experimental|1|NLA Nasal Spray
3167086|NCT00533637|Active Comparator|2|
3167087|NCT00533637|Placebo Comparator|3|
3167088|NCT00533663|Experimental|Healing Touch (HT)|A a gentle, non-invasive form of energy-balancing work that promotes relaxation and can help manage the side effects of chemotherapy. It occurs every other week (during their infusion).
3167089|NCT00533663|Active Comparator|Guided relaxation|Guided relaxation every other week (during their infusion).
3167090|NCT00533663|Active Comparator|standard care|Standard care
2530140|NCT02696408|Experimental|Laser treatment|preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)
2530144|NCT02696408|Placebo Comparator|laser-off|daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)
2530197|NCT02695940|Active Comparator|LEO 124249 ointment 30 mg/g|Drug LEO 124249 ointment 30 mg/g twice daily application for 6 weeks, maximum of 1.44 g ointment per day
2530200|NCT02695940|Placebo Comparator|LEO 124249 ointment vehicle|LEO 124249 ointment vehicle twice daily application for 6 weeks, maximum of 1.44 g ointment per day
2530338|NCT02694874|Experimental|Rosiglitazone|Participants will receive rosiglitazone 0.045mg/kg/dose twice daily dosing, for 4 days
2530339|NCT02694874|Placebo Comparator|Placebo|Participants will receive placebo (grounded placebo powder) at a dose of 0.045mg/kg/dose twice daily for 4 days
3167091|NCT00533715||>100|"The study included healthy children (2.5-6.5 years old) from a number of public kindergartens. An initial screening questionnaire based on the ATA-DLD-78-A for adults, adapted for children and translated into Hebrew, concerning the child's birth, past and present health status, was completed by the parents.~Exclusion criteria: Previous symptoms or treatment for asthma, current respiratory symptoms or other present respiratory diseases."
2530814|NCT02691637||H. pylori eradication group|Patients who have had H. pylori infection. After diagnosis of H. pylori infection, the patients who subsequently received successful H. pylori eradication treatment according to appropriate indication.
2530816|NCT02691637||Control Group|Patients who still have H. pylori infection. The patients of control group do not have successful H. pylori eradication result or do not received eradication treatment for any reason.
2530988|NCT02690636|Active Comparator|Conventional|The patients will receive adjuvant radiotherapy conventionally fractionated 5000 cgy fractionated by 200cgy daily fractions, five fractions per week over 5 weeks with an additional 200cgy daily for five days as boost for patients with breast conservative surgery.
2530989|NCT02690636|Experimental|Hypofractionated|The patients will receive adjuvant radiotherapy hypofractionated 266cgy daily fractions, five fractions per week for total 16 fractions and an additional five daily fractions will be added as boost for patients with breast conservative surgery.
2530998|NCT02690350|Experimental|Cohort 1 U3-1784 2.5 mg/kg|U3-1784 (2.5 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2531000|NCT02690350|Experimental|Cohort 2 U3-1784 3.75 mg/kg|U3-1784 (3.75 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2531001|NCT02690350|Experimental|Cohort 3 U3-1784 5.6 mg/kg|U3-1784 (5.6 mg/kg) by intravenous infusion, along with colestyramine or equivalent if clinically indicated
2531056|NCT02690155||Rivaroxaban|NVAF patients who were initiated on rivaroxaban for stroke prevention
2531060|NCT02690155||VKA (Vitamin K antagonist)|NVAF patients who were initiated on VKA for stroke prevention
2531103|NCT02689752|Experimental|fruquintinib|fruquintinib suspension, 5 mg （100 mCi）oral taken once
3167092|NCT00533741|Experimental|1c (10 mcg)|4 subjects randomized in a 1:3 fashion to receive a two dose regimen of placebo or vaccine with 10 mcg of antigen and no adjuvant.
3167093|NCT00533741|Experimental|2 (dose comparison stage)|54 subjects (9 per vaccine group) randomized 1:1:1:1:1:1 to receive vaccines containing, 2.5, 5.0, or 10.0 mcg of antigen without adjuvant, or 2.5 or 5.0 mcg of antigen with Alum, or placebo.
2531197|NCT02689089|Other|3HP|The interrupted time series design aims to collect data at multiple time points before (standard regimen) and after the introduction of the new 3HP regimen (interruption) to detect if a significant increase in the number of completions has occurred with the new regimen
2531335|NCT02688322|Experimental|2 g q12 of sulbactam, 1 h infusion|2 g of sulbactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 1 h every 12 h.
2531397|NCT02687932|Experimental|LCZ696|LCZ696 for 12 months
2531400|NCT02687932|Active Comparator|Valsartan|Valsartan for 12 months
3167094|NCT00533741|Experimental|1a (2.5 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 2.5 mcg of antigen and no adjuvant, or 2.5 mcg of antigen and Alum adjuvant.
3167095|NCT00533741|Experimental|1b (5.0 mcg)|7 subjects randomized in a 1:3:3 fashion to receive a 2 dose regimen of placebo, vaccine containing 5.0 mcg of antigen and no adjuvant, or 5.0 mcg of antigen and Alum adjuvant.
3167096|NCT00533793|Active Comparator|SoC|Standard of Care
3167097|NCT00533793|Active Comparator|SoC plus 0.133 mg/mL|
3167098|NCT00533793|Active Comparator|SoC plus 0.4 mg/mL|
3167099|NCT00533793|Active Comparator|SoC plus 1.0 mg/mL|
3167100|NCT00533806|Experimental|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy.
3167101|NCT00533806|Active Comparator|Relaxation therapy.|Participants will receive relaxation therapy.
3167102|NCT00533819|Experimental|1|
3167103|NCT00533819|No Intervention|2|would have routine physical activity
3167104|NCT00533832|Active Comparator|1|Patients implanted with the vagus nerve stimulation (VNS) device and receiving VNS Intervention: vagus nerve stimulation (VNS)
3167105|NCT00533832|Placebo Comparator|2|Implanted with vagus nerve stimulation (VNS) device, but not receiving VNS
3167106|NCT00533871||Normotensive|Pregnant women in the third trimester with normal blood pressure this pregnancy and no history of HTN or pre-eclampsia in a previous pregnancy
3167107|NCT00533871||Chronic Hypertensive|Pregnant women in their third trimester with known hypertension prior to the current pregnancy
2530191|NCT02696135||Hypertrophic cardiomyopathy|Individuals with an unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and/or cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM, in the absence of other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.
2530220|NCT02695706|Experimental|Laboratoires Mercurochrome Reparador|A group of patients will be treated with a new restorative skin cream consists of hyperoxygenation essential fatty acids (60% linoleic acid) which does not contain preservatives (parabens) or known allergens.
2530237|NCT02695472|Placebo Comparator|Placebo Arm|One Placebo tablet, twice daily
2530245|NCT02695472|Experimental|40 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet and 1 placebo tablet per day
2530251|NCT02695472|Experimental|80 Milligrams NSI-189, total dose daily|One 40 Milligrams NSI-189 tablet twice per day
2530363|NCT02694783|Experimental|Treatment Arm|ex vivo generated polyomavirus-specific T cells from HLAmatched donor
2530404|NCT02694458|Experimental|Modeling arm|Early vancomycin monitoring and bayesian dosage adjustment
2530406|NCT02694458|Sham Comparator|Control arm|Usual vancomycin dose and monitoring strategy
2530450|NCT02694133|Experimental|Aphasia group|Aphasia
2530499|NCT02693808|Active Comparator|Autologous fat injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
2530502|NCT02693808|Active Comparator|Hyaluronic acid injection|Patients have undergone lateral orbital wall decompression on both sides. Temporal hollowing after surgery will be treated with injection on one side with autologous fat and the other side with long-lasting hyaluronic acid.
2530578|NCT02693366|Experimental|Autologous Cell Therapy|We are conducting a prospective, non-randomized, single-center longitudinal study in five patients with progressive chronic kidney disease and estimated clearance between 40 and 20 ml / min. Patients will be followed by clinical and laboratory examination for 3 months prior to the procedure. These previous results serve as a control for comparison with a second time when the same patients receive treatment with stem cells being subsequently followed up for 9 months a total of one year of clinical follow-up.
2530646|NCT02692911||Women with gallstones|Women aged 50-74 with gallstones
2530672|NCT02692612||Young|
2530676|NCT02692612||Middle-Aged|
2530681|NCT02692612||Old|
2530737|NCT02692404||Hospital Birth|Healthy nulliparous participants, planning spontaneous vaginal or induced vaginal delivery, and planning delivery at a hospital woman-care birth center (Magee-Womens Hospital of UPMC) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to utilize labor epidural analgesia for pain control during labor.
2530740|NCT02692404||Midwife Center Birth|Healthy nulliparous participants, planning vaginal delivery under the primary care of a nurse midwife (The Midwife Center for Birth and Womens Health, or UPMC-Mercy) will be consented to participate in the study at their 3rd trimester clinic visit. Participants and their newborns will be followed for a period of 3 months postpartum. They will be planning to avoid labor epidural analgesia for pain control during labor.
2530772|NCT02691975|Experimental|SHR3680|Tablet
2530849|NCT02691273|Experimental|breathing technique|this arm includes learning breathing technique using the patient's smartphone.
3200791|NCT00894218|Experimental|Mini-invasive arthroplasty|Total hip or knee mini-invasive arthroplasty
3200792|NCT00894218|Experimental|Mini-invasive and computer-assisted arthroplasty|Mini-invasive and computer-assisted total hip or knee arthroplasty
2530976|NCT02690675|Experimental|Intervention high-iron fortified milk|This group received a high dose of iron by formula milk (1.2mg/100mL) between 6 and 12 months of age.
2530978|NCT02690675|Experimental|Intervention low-iron fortified milk|This group received a low dose of iron by formula milk (0.4mg/100mL) between 6 and 12 months of age.
2531021|NCT02690493|Active Comparator|Acupuncture Only|Patients will be treated with acupuncture only.
2531024|NCT02690493|Active Comparator|Functional Taping Only|Patients will be treated with taping only.
2531026|NCT02690493|Experimental|Acupuncture and Functional Taping|Patients will be treated with both acupuncture and taping at the same session.
2531071|NCT02689960|Other|vaginal administration first|Intervention first visit: vaginal administration of 100mg prednisone suppository, Intervention second visit: rectal administration of 100mg prednisone suppository
2531073|NCT02689960|Other|rectal administration first|Intervention first visit: rectal administration of 100mg prednisone suppository, Intervention second visit: vaginal administration 100mg prednisone suppository
2531126|NCT02689635|Active Comparator|Sodium Restricted Diet|Low Salt (cardiac) diet
2531129|NCT02689635|Active Comparator|Regular Diet|Non-Cardiac diet
2531179|NCT02689310|Other|Standard Care - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
2531193|NCT02689310|Experimental|Honey Treatment - Stage III Pressure Ulcers|Patients with a stage III pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
2531199|NCT02689310|Other|Standard Care - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this arm will be given standard treatment (hydrogel, collegense, and silver alginate dressings).
2531204|NCT02689310|Experimental|Honey Treatment - Stage IV Pressure Ulcers|Patients with a stage IV pressure ulcer who are randomized into this treatment arm will be given leptospermum scoparium honey dressings for treatment of their wound.
3200793|NCT00894231|Placebo Comparator|placebo|Sugar tablet
3200794|NCT00894231|Active Comparator|Xyzal|
3200795|NCT00894257||HCV/HIV infected pregnant women|
2530278|NCT02695303|Experimental|BAY 987516|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
2530395|NCT02694588|Active Comparator|Infliximab|5 mg/kg body weight, week 0/2/6, then every 8 weeks
2530401|NCT02694588|Active Comparator|Vedolizumab|300 mg, week 0/2/6, then every 8 weeks
2530498|NCT02693860|Experimental|huJ591 followed by 89Zr-J591|Subjects will receive two infusions of unlabeled huJ591 on days 1 and 15 (+/- 1 day). 89Zr-J591 will be administered on day 22 (+/- 1 day) and 5-8 days later. PET/CT will be performed followed by repeat imaging of the prostate. Radical prostatectomy with or without lymph node dissection is performed 2 to 4 weeks after the second dose of J591.
2530564|NCT02693197|Experimental|Cohort 1:T-817MA|Mild hepatic impairment subjects
2530570|NCT02693197|Experimental|Cohort 2:T-817MA|Healthy subjects matched to subjects in Cohort 1
2530574|NCT02693197|Experimental|Cohort 3:T-817MA|Moderate hepatic impairment subjects
2530582|NCT02693197|Experimental|Cohort 4:T-817MA|Healthy subjects matched to subjects in Cohort 3
2530588|NCT02693197|Experimental|Cohort 5 :T-817MA|Severe hepatic impairment subjects
2530593|NCT02693197|Experimental|Cohort 6:T-817MA|Healthy subjects matched to subjects in Cohort 5
2530669|NCT02692742|Experimental|Myelo001|Myelo001 100 mg QD
2530674|NCT02692742|Placebo Comparator|Placebo|Matching Placebo QD
3200796|NCT00894283|Active Comparator|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
3200797|NCT00894283|Active Comparator|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
2530804|NCT02691767|Experimental|pazopanib|pazopanib 800 mg will be administered orally daily every 3weeks
3200798|NCT00894296||1|schizophrenia patients
3200799|NCT00894296||2|healthy control
3200800|NCT00894335||1|Pheochromocytoma
2531087|NCT02689869|Experimental|Ibrutinib and GA 101|"Initial therapy 6 cycles of Ibrutinib:~Ibrutinib 560 mg once daily every day until start of maintenance for a total of 24 weeks.~1000 mg of GA101 I.V. on days d 1, 8, 15 of cycle 1 and on day 1 of cycles 2-6 (21 day cycles).~Maintenance with another 24 months of ibrutinib plus GA101 in patients with clinical remission after the last induction cycle:~Ibrutinib 560 mg once daily every day. GA101 at a dose of 1000 mg I.V. every 2 months for a total of 24 months. The total duration of ibrutinib plus obinutuzumab therapy will therefore be 30 months.~In patients remaining MRD positive at 30 months without clinical progression, single agent ibrutinib therapy is continued for another 12 months."
2531116|NCT02689531||High-Risk (Adult =>18 years old)|"Treated with one or more of the following respiratory modalities for at least 12 continuous hours, either currently or within the prior 7 days:~Invasive mechanical ventilation~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy via nasal cannula. Only include systems that using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask). Only include systems using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM.~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
2531117|NCT02689531||Other-ICU/Standard Risk|Patients do not fulfill high-risk criteria, but, are receiving an antibiotic for treatment of lower respiratory tract infection or undifferentiated sepsis.
2531118|NCT02689531||High-Risk (Pediatric ≥120 days old and <18 years old)|"Currently treated with one or more of the following respiratory modalities for at least 24 hours:~Invasive mechanical ventilation via endotracheal intubation~New initiation of mechanical ventilation, BiPAP or CPAP via tracheostomy~Noninvasive ventilation (BiPAP or CPAP for any indication other than obstructive sleep apnea)~High-flow, supplemental oxygen therapy delivering at least 1.5LMP with 100% FiO2 via nasal cannula when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~High flow supplemental oxygen therapy delivering at least 50% FiO2 via aerosol facemask or tracheostomy collar (mask) when delivered using an air/oxygen blender capable of delivering a precise FiO2 level, not just a flow in LPM~Supplemental oxygen therapy delivered via either partial or non-rebreather face mask"
2531119|NCT02689531||High-Risk (Pediatric <120 days old)|Currently treated with mechanical ventilation via endotracheal intubation for at least 5 days
2531175|NCT02689349|Experimental|Esteem Implant|Implantation of Esteem
3200801|NCT00894335||2|Conn-Syndrome
3200802|NCT00894335||3|Cushing disease
3200803|NCT00894335||4|Metastasis
3200804|NCT00894335||5|Non-functional tumor
3200805|NCT00894374|Experimental|Artesunate (Pfizer)|
3200806|NCT00894374|Active Comparator|Artesunate (Arsuamoon® Tablets Guilin-China)|
3200807|NCT00894400|Experimental|Targeting of most fractionated electrograms first|During catheter ablation of AF patients will have fractionated electrograms targeted. In the experimental group the fractionated electrograms believed to be most critical will be targeted first.
2531685|NCT02685657|Experimental|AC followed by Docetaxel with Selumetinib|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle, 75 mg of SELUMETINIB twice a day PO on days 1-21 of every 3 week cycle
2531695|NCT02685657|Active Comparator|AC followed by Docetaxel|Doxorubicin 60 mg/m2 and Cyclophosphamide 600 mg/m2 as a single IV infusion on day 1 of every 3 week cycle then 75 mg/m2 of Docetaxel given as a single IV infusion on day 1 of every 3 week cycle
2531741|NCT02685306|Active Comparator|Taxane|Taxane (Paclitaxel) weekly on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
2531745|NCT02685306|Experimental|Bavituximab plus Taxane|Bavituximab 3 mg/kg weekly PLUS Taxane (Paclitaxel) on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
3200808|NCT00894400|Active Comparator|Targeting least fractionated electrograms first|During catheter ablation of AF fractionated electrograms are targeted. In this arm the least fractionated electrograms will be targeted first.
3200809|NCT00894426||1|Morning Symptoms (+)
2530312|NCT02695108|Experimental|scapular exercise on neck pain|patients in this arm received cervical manual therapy and cervical exercises too. Apart from cervical manual therapy and cervical exercises,patients also performed scapular stabilization exercise targeting trapezius, serratus anterior and rhomboid muscles. Rehabilitation period was lasted for 6 weeks. The same assessment parameters was conducted on this arm too.
3200810|NCT00894426||2|Morning Symptoms (-)
2530445|NCT02694146|Experimental|PRP (platelet rich plasma)|"37 patients with coxarthrosis are treated with 6ml of PRP (platelet rich plasma), obtained from blood extracted from patients in the 20 minutes prior to infiltration thereof.~For PRP administration:~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The PRP is injected into the synovial space."
2530447|NCT02694146|Active Comparator|Hylan G-F 20 (Synvisc-One ®)|"37 patients with coxarthrosis are treated with a pre-filled syringe of hyaluronic acid 60mg / 6ml (Synvisc-One ®).~It is necessary to remove synovial fluid before injecting Hylan G-F 20.~The injection should be performed at room temperature.~The administration should be carried out under aseptic conditions.~The patient will be placed in the supine position and the administration will be performed by an anterolateral approach.~The Hylan G-F 20 is injected into the synovial space.~After injecting Hylan G-F 20 the patient should stand 5 minutes."
2530486|NCT02693795|Experimental|Baduanjin exercise group|"The participants randomized to Baduanjin exercise will collectively practice at cardiac rehabilitation centre in Guangdong Provincial Hospital of Chinese Medicine. A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
2530493|NCT02693795|Active Comparator|usual exercise control group|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
2530583|NCT02693483|Active Comparator|povidone iodine|153 cases undergoing cesarean sections will have preoperative vaginal cleansing with 10% povidone iodine
2530587|NCT02693483|No Intervention|no vaginal cleansing|153 cases undergoing cesarean sections
3200811|NCT00894439|Experimental|1|
3200812|NCT00894478||1|12 children with MRI-negative partial epilepsy who are being worked-up for epilepsy surgery
3200813|NCT00894478||2|12 children with MRI-visible FCD who are being worked-up for epilepsy surgery
3200814|NCT00894478||3|Control Group- Healthy Volunteers
3200815|NCT00894530|Experimental|1|
3200816|NCT00894530|Placebo Comparator|2|
3200817|NCT00894569|Active Comparator|A|6 cycles of carboplatin/paclitaxel
3200818|NCT00894569|Experimental|B|carboplatin/paclitaxel plus cetuximab until disease progression
3200819|NCT00894595|Experimental|Intervention group|The clubs in the intervention group are instructed to perform a warm-up program at two training sessions per week throughout the entire 2009 competitive season.
3200820|NCT00894595|Active Comparator|Control group|The clubs in the control group are instructed to train and play as usual throughout the 2009 season
3200821|NCT00894608|Experimental|letrozole protocol|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
3200822|NCT00894608|Experimental|long GnRHa protocol|patients in long GnRHa protocol for ovarian stimulation with Gnrha and gonadotropins
3200823|NCT00894621|Experimental|Norepinephrine|
3200824|NCT00894621|Placebo Comparator|Placebo|
3200825|NCT00894634|Experimental|Brompheniramine maleate|Brompheniramine maleate oral solution 1 mg/5 mL, single dose
3200826|NCT00894660|Experimental|Amodiaquine (Pfizer)|
3200827|NCT00894660|Active Comparator|Amodiaquine tablets (Arsuamoon-Guilin China)|
3200828|NCT00894673|Experimental|1|Heparin sodium Hipolabor
3200829|NCT00894673|Active Comparator|2|Heparim Sodium APP 5.000 USP
3200830|NCT00894725|Experimental|LPS|laparoscopic left colonic resection
2531319|NCT02688374|Other|Treatment A:Treatment B:Treatment C|Participants will be administered with Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531330|NCT02688374|Other|Treatment B:Treatment C:Treatment A|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531517|NCT02687061||Chronic hepatitis B|Patients diagnosed with chronic hepatitis B
3200831|NCT00894725|Active Comparator|Open|open left colonic resection
3200832|NCT00894751|Active Comparator|dexmedetomidine|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
3200833|NCT00894751|Active Comparator|propofol|Determine if there is a significant difference in the quality of care between our two standard anesthesia techniques for children undergoing a MRI of the body and/or extremity MRI.
3200834|NCT00894764||Routine Follow Up|Monthly nasopharyngeal swab for infant. Seen during acute illness.
3200835|NCT00894764||Immunology|Monthly nasopharyngeal swab for mother and infant. Serum sample taken from Infant. Seen during acute illness.
3200836|NCT00894777||1|Patients with moderate and severe psoriasis under treatment with topical and/or systemic drugs
3200837|NCT00894816|Active Comparator|1|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19) 10E8 CFU per serving
3200838|NCT00894816|Placebo Comparator|2|Placebo (infant cereals without any additions)
3200839|NCT00894829|Experimental|1|Heparin sodium - Eurofarma
3200840|NCT00894829|Active Comparator|2|Heparin APP
2530324|NCT02695433|Placebo Comparator|Control (CT) diet plan|at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period
2530397|NCT02694653|Active Comparator|Drug Arm|Acetaminophen 1000 mg in 100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
2530400|NCT02694653|Placebo Comparator|Placebo Arm|100 mL normal saline IV administered 30 minutes prior to c/section incision to infuse within 15 minutes
2530451|NCT02694172|No Intervention|Lean non diabetic|Lean and healthy subjects receiving no intervention
2530452|NCT02694172|Experimental|Overweight non diabetic|fiber rich cereal bars, two bars a day for 4 weeks
2530454|NCT02694172|Experimental|Overweight diabetic|fiber rich cereal bars, two bars a day for 4 weeks
2530469|NCT02693769|Experimental|fluticasone/formoterol BAI|To compare the efficacy of fluticasone/formoterol BAI 125/5 μg (2 puffs b.i.d.)
2530470|NCT02693769|Active Comparator|Ultibro Breezhaler|Ultibro Breezhaler 85/43 µg (1 puff o.d.)
2530536|NCT02693626|Experimental|intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per day for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
2530539|NCT02693626|No Intervention|No cessation message intervention|Control group participants only will receive one text message every week, thanking them for being in the study, providing study center contact details, and reminding them of the time until their free month at the end of follow up. Another one to two messages will be sent per week until the end of the 24 week. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points.
2530542|NCT02693626|Experimental|Not intensive cessation message|"Participants who allocate to this intervention group will receive regular, personalized text messages providing smoking cessation advice, support, and distraction. A quit day will be negotiated with each participant, and one to five messages will be sent per week for the time leading up to the quit day and the following 12 weeks.~One to three messages will be sent per week until the end of the 24 week follow up. In order to measure the main two outcomes (self-reported continuous smoking abstinence and point prevalence of abstinence), continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last 4 weeks and past 1 week if they are still smoking, they will also be checked by phone call at 4, 8, 12, 16, 20, 24 week points."
3200841|NCT00894842|Active Comparator|Pregnenolone|
3200842|NCT00894842|Placebo Comparator|Sugar pill|
3200843|NCT00894855|Active Comparator|education only|This comprehensive education program included a health educator visit, on the education van, who gave education about sun safety.
2530719|NCT02692443||SVR Survivors|Through the SVR and SVR II studies vital status has been followed annually for the entire SVR cohort. As of June 2014 352 subjects are alive, 18 of whom have undergone cardiac transplantation, and 18 have undergone biventricular conversion leaving 334 transplant-free survivors with single ventricle physiology. Each patient enrolled to this ancillary study from the parent SVR study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to the already scheduled parent study follow-up procedures.
2530725|NCT02692443||Healthy Controls|In addition to the SVR survivors, investigators plan to enroll 100 age- and gender-matched healthy controls. Healthy controls enrolled for participation in this ancillary study will be asked to undergo Magnetic Resonance Imaging (Brain MRI without Contrast) in addition to completing the Neurodevelopmental Testing Battery that is already part of the parent SVR study and completed by SVR Survivors as part of their SVR follow-up appointments.
2530773|NCT02691949|Experimental|Mycophenolate mofetil standard|mycophenolate mofetil 250mg 2# twice per day (BID)
2530774|NCT02691949|Experimental|Mycophenolate sodium low|mycophenolate mofetil 250mg 1# twice per day (BID)
2530797|NCT02691676|Experimental|Plasmalyte|Arm 1: Plasmalyte in 5% glucose infusion solution (PL), manufactured by Baxter Healthcare as slightly alkalizing (Na+ 140; K+ 5.0; Mg2+ 1.5; Cl- 98; acetate 27; gluconate 23)
2530801|NCT02691676|Active Comparator|Ringerfundin|Arm 2: Ringerfundin infusion solution (RF), manufactured by B. Braun as acid-base neutral (Na+ 145; K+ 4.0; Mg2+ 1.0; Ca2+ 2.5; Cl- 127; acetate 24; malate 5.0).
2530830|NCT02691377|Experimental|Acupuncture group|Participants will receive acupuncture for 8 weeks. In particular, acupuncture will be performed three times a week in earlier 4 weeks and twice a week in later 4 weeks.
2530831|NCT02691377|Sham Comparator|Sham Acupuncture group|Participants will receive sham acupuncture for 8 weeks. The procedure is the same as the acupuncture arm.
2530900|NCT02691208|Experimental|Group I Kinesiotherapy|women with pain treated with a predefinided exercises protocol of 30 minutes.
2530903|NCT02691208|Experimental|Group II Acupuncture|women with pain treated with a predefinided exercises protocol of 30 minutes followed by 30 minutes of acupuncture, used in predefined points
2530931|NCT02690805||Breast cancer patients receiving neoadjuvant chemotherapy|One arm: Combined MRI-SMM Imaging
2530981|NCT02690662|Experimental|Obese with kidney stones|Hypocaloric diet for 3 months
2531012|NCT02690415||Antibiotics Given|Patients who's treating physician prescribed antibiotics following incision and drainage of their abscess.
2531016|NCT02690415||Antibiotics Not Given|Patients who's treating physician did not prescribed antibiotics following incision and drainage of their abscess.
2530333|NCT02694770|Experimental|Neihulizumab|Patients will receive a total of 4 doses of Neihulizumab (AbGn-168H) on Day 1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), and Day 22 (Week 3) by 1-hour i.v. infusion.
2530334|NCT02694770|Active Comparator|"Conventional Treatment"|Patients will receive a 2nd line therapy for aGvHD at the discretion of attending physician according to the standard practice at the study center. Currently there is no treatment for sr-aGvHD is approved in USA or Europe. There is no Standard treatment of this disease is recommended by American Society for Blood and Marrow Transplantation (ASBMT). Therefore, the study is designed to allow any established institutional practice for off-label use of a commercially available product for patients in the Conventional Treatment arm. Patients in this arm may receive treatments provided in ASBMT guidance such as ATG, TNF-alpha inhibitors (such as Etanercept and infliximab), pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis, methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept, Dacliz + etanercept, Dacliz+ infliximab, and Dacliz/inflix/horse ATG.
3200844|NCT00894855|Experimental|education plus dermatologist skin exam|"In addition to the education program, participants received free skin exams by board certified dermatologists from Brigham and Women's Hospital. The van was equipped with a private clinical setting conducive to carry out such examinations. Based on the recommendations of the American Academy of Dermatology (AAD), a visual full body exam was provided to participants. At the end of each skin exam the dermatologist provided a presumptive diagnosis to the participant, and made appropriate recommendations and referrals for follow up with the participants' physician/dermatologist (if and when necessary). All participants undergoing the skin exam were required to complete an AAD Skin Cancer Screening Registration and Report form."
2530467|NCT02694081|Experimental|Uncut Roux-en-Y Reconstruction|Uncut Roux-en-Y Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
2530468|NCT02694081|Active Comparator|Billroth II Reconstruction|Billroth II Reconstruction will be used after laparoscopy-assisted distal gastrectomy for early gastric cancer.
2530534|NCT02693639||liver transplantation grafts|
2530613|NCT02693210|Active Comparator|Group A: Methotrexate|Participants will receive methotrexate at dosage >=10 milligrams per week (mg/week) orally as determined by the investigator. They also receive placebo infusion on days 1 and 15 in place of rituximab and on Days 3 and 17 in place of cyclophosphamide.
2530616|NCT02693210|Experimental|Group B: Rituximab Monotherapy|Participants will receive 1 g intravenous infusions of rituximab on Days 1 and 15. They also receive Weekly placebo orally instead of methotrexate and placebo infusion in place of cyclophosphamide on Days 3 and 17.
2530620|NCT02693210|Experimental|Group C: Rituximab and Cyclophosphamide|Participants will receive 1g IV infusion of rituximab on Days 1 and 15 and 750 mg infusion of Cyclophosphamide on Days 3 and 17. They also receive weekly oral placebo in place of methotrexate.
2530622|NCT02693210|Experimental|Group D: Methotrexate and Rituximab|Participants will receive >=10 mg/week methotrexate orally along with 2 times 1 gram (g) rituximab IV infusions on Days 1 and 15. Participants will also receive placebo infusions on Days 3 and 17 in place of cyclophosphamide.
2530706|NCT02692339||Lenalidomide/Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma
2530760|NCT02692105|Active Comparator|Low dose rate brachytherapy|Device: Radiation Low dose rate prostate brachytherapy is delivered under anaesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.
2530762|NCT02692105|Experimental|High dose rate brachytherapy|"Device: Radiation High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anaesthesia, but no follow-up imaging visit is required.~HDR brachytherapy is also accomplished as an out-patient."
2531004|NCT02690376|Other|Magnetic Assisted Capsule Endoscopy|There is only one arm and its does not reach criteria for other options
2531064|NCT02690129|Active Comparator|Group I (Progesterone Group)|"Complete bed rest as an in/or out- patient, according to patient's preference for first 48-72 hours.~Vaginal progesterone treatment as single daily dose of natural micronized progesterone (Prontogest ® 200 mg) at bedtime for 15 days.~If needed, a pain killer as Indomethacin 50 mg/ rectally twice daily up to control of uterine colic .~Complete abstaining from sexual activity or strenuous effort. Additionally, Rh-ve women with established viable fetuses and continue bleeding will be given a shot of anti-D immunoglobulin 300 ugm/IM ; after 12 weeks' gestation or if undergo surgical evacuation."
2531067|NCT02690129|Placebo Comparator|Group II ( Control group)|Will follow the same plan of management without progesterone support.
2531120|NCT02689726|Experimental|GTL001 + Aldara, 5% imiquimod cream|2 doses, 6 weeks apart, GTL001 will be adjuvanted with Aldara, 5% imiquimod cream, applied to the injection site 15 minutes and 24 hours after each vaccination
2531183|NCT02689297|Other|group A|Mouthwash (chlorine dioxide 12ml two times per day, for three weeks)
2531194|NCT02689297|Other|group B|Small toothbrush for tongue cleaning two times per day for three weeks
2531294|NCT02688426|Sham Comparator|0J LLLT|The sham treatment is performed in the same way as treatment with LBP, however, with the apparatus switched off
2531295|NCT02688426|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
2531338|NCT02688075||Canagliflozin Plus or Minus(+/-) Other Antihyperglycemic Agent|Participants who are receiving Canagliflozin +/- other antihyperglycemic agent (AHA) as per usual clinical practice will be observed for effectiveness, safety and PRO.
2531355|NCT02687763|Experimental|Open Label|Open Label. Two 0.5-mL doses of ProQuad® will be given by intramuscular injection at least 30 days but no more than 365 days apart..
2531602|NCT02686515|Active Comparator|Single-task balance training group|Participants in the single-task training group will participate in 12-session programs administered for 60 minutes each session, 3 times per week for 4 weeks. They will start walking on a treadmill with a self-selected comfortable speed for 5 minutes of warm-up and then receive an individually-progressed program of balance training aimed at improving standing balance and walking abilities.
2531644|NCT02686190|No Intervention|Not luxtherapy|Not luxtherapy exposition
2531686|NCT02685813||Pregnant women in Denmark|Pregnant women in Denmark participating in prenatal screening. This counts for approximately 50000 pregnancies/year and covers >95% of all pregnancies nationally.
2531827|NCT02685059|Experimental|MEDI4736|part 1: MEDI4736 (with half dose as monotherapy for the first two weeks) part 2: MEDI4736 1.5 g total for 20 weeks
2530360|NCT02694679|Experimental|Friendship 100|The CBNH intervention will be delivered to 100% of households identified through friendship nomination.
2530410|NCT02694432|Active Comparator|GOALS|Participants will use for approximately four months an online platform, GOALS, consisting of weekly lessons designed to enhance blood pressure control. Recommended lifestyle changes for hypertension, including a low-sodium diet, physical activity, weight loss (if appropriate) and behavioral self-management skills will be offered. Attention to medication adherence and pharmacist support as well as that of a dedicated online health coach and ongoing collaboration with the primary care physician are also provided.
2530411|NCT02694432|Experimental|Minding GOALS|Participants in this arm will also use the GOALS standard tools for blood pressure control. To further maximize success, they will receive additional online behavioral training throughout the 4-month intervention that focuses on mind-body approaches. Weekly topics, for example, will include meditation lessons, mindfulness-based stress reduction and mindfulness-based eating awareness.
2530566|NCT02693301|No Intervention|Control|Children who follow the recommendations of their pneumologist
2530568|NCT02693301|Experimental|Experimental|A two month intervention program 3 days/week will be carried out. The session will last ~60 minutes, and will consist of a combined training (aerobic training ~30 min, and strength ~30 min of 7 whole body exercises (3 sets x 10 repetitions).The load was gradually increased as the strength of each child improved, i.e., from 40% of five-repetition maximum (5RM) lifting ability at the start of the program to 60% of 5RM at the end of the program. All sessions were individually supervised by trained professionals.
2530659|NCT02692898||1|Archived CNS neoplasm specimens, in which primary diagnostic studies are complete, and for which there is excess tissue for analysis in the form of unstained slides or paraffin blocks
2530720|NCT02692157|Placebo Comparator|Placebo|Placebo Comparator: Placebo - During this arm, Placebo medication will be administered orally each evening at 8pm.
2530726|NCT02692157|Active Comparator|NT-814 50 mg|Active Comparator: NT-814 50 mg - During this arm, 50 mg NT-814 will be administered orally each evening at 8pm.
2530729|NCT02692157|Active Comparator|NT-814 100 mg|Active Comparator: NT-814 100 mg - During this arm, 100 mg NT-814 will be administered orally each evening at 8pm.
2530734|NCT02692157|Active Comparator|NT-814 200 mg|Active Comparator: NT-814 200 mg - During this arm, 200 mg NT-814 will be administered orally each evening at 8pm.
2530795|NCT02691871|Experimental|Apatinib + Docetaxel|Low, medium or high dose of Apatinib (days 3-19, q3w) and Docetaxel (60 mg/m2, day 1, q3w)
2530958|NCT02690753|Experimental|Tailored repositioning + Standardised incontinence care + TAP|A protocol tailored to individual risk factors will be applied to patients at risk.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
2530960|NCT02690753|Experimental|Standard repositioning + Standardised incontinence care + TAP|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care.Comfort Shield® barrier cream cloths will be used for incontinence care every morning and after each episode of incontinence. The Prevalon® Turn and Position System 2.0, SAGE will be used for turning and positioning patients at risk when laying in bed.
2530963|NCT02690753|No Intervention|Usual care|Instead of developing and using a tailored pressure ulcer prevention protocol, patients will receive standard care. Instead of using comfort Shield® barrier cream cloths, incontinence care will be given to patients using the standard procedure on the ward. Instead of using the turn and position system, patients will be turned according to the standard procedure on the ward.
2531006|NCT02690337|Experimental|DS-1123|This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.
3167108|NCT00533871||Pre-eclampsia|Pregnant women in their third trimester who meet ACOG diagnostic criteria for pre-eclampsia
3167109|NCT00533884||Treatment|Patients undergoing treatment for head and neck, lung, and esophagus cancers
3167110|NCT00533988|No Intervention|5592|Standard triple lumen catheter
3167111|NCT00533988|Active Comparator|5593|Antimicrobial impregnated catheter (chlorhexidine silver-sulfadiazine)
2531332|NCT02688166||Breast Cancer|Breast cancer patients who are undergoing internal mammary lymph node radiation
2531334|NCT02688166||Lung Cancer, thymic cancer or mesothelioma|"Non-surgical Stage III non-small cell lung cancer patients undergoing mediastinal nodal irradiation with curative intent using concurrent chemotherapy~Any lung cancer, thymic cancer or mesothelioma patient getting either chemoradiation or radiation alone wherein heart gets radiation exposure"
2531393|NCT02687906|Experimental|Single dose IV meropenem-vaborbactam|"Vabomere (meropenem-vaborbactam) for IV injection will be administered as a single dose diluted in normal saline infused IV over 3 hours~The starting dose for Cohort 1 (ages 12 to <18 years) was 40 mg/kg meropenem and 40 mg/kg vaborbactam, or 2 g meropenem 2 g vaborbactam for subjects ≥50kg in weight. Following completion of Cohorts 1 and 2 an independent DSMB assessed the PK, safety and tolerability data and determined that the new starting dose for Cohort 3 (ages 2 to < 6 years) would be 60 mg/kg or 2 g meropenem 2 g vaborbactam for subjects >33 kg in weight."
2531424|NCT02687295|Placebo Comparator|Control group|Control group subjects received the same diet restriction intervention as treatment group. However, their food products did not contain any active component.
2531524|NCT02687061||Chronic hepatitis C|Patients diagnosed with chronic hepatitis C
3167112|NCT00534014|Placebo Comparator|A|0 mg of Vitamin C
3167113|NCT00534014|Active Comparator|B|250 mg Vitamin C
3167114|NCT00534014|Active Comparator|C|500 mg Vitamin C
3167115|NCT00534014|Active Comparator|D|1000 mg Vitamin C
3167116|NCT00534027|Experimental|Arm 2|Low Dose AMG 655 with paclitaxel/carboplatin
3167117|NCT00534027|Placebo Comparator|Arm 3|Placebo with paclitaxel/carboplatin
3167118|NCT00534027|Experimental|Arm 1|AMG 655 High doseplus paclitaxel/carboplatin
2530364|NCT02694809|Experimental|Arm I (conjugated estrogens/bazedoxifene)|Patients receive conjugated estrogens/bazedoxifene orally (PO) once daily (QD) for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
2530365|NCT02694809|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 28 +/- 7 days in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.
2530446|NCT02694120||colonoscopy population|
2530541|NCT02693457|Active Comparator|Drain|Intra-articular drain will be placed at closure of randomized knee for 24 hours
2530543|NCT02693457|Experimental|No Drain|No intra-articular will be placed in the contralateral knee of the same patient. A placebo drain will be placed so patient is unaware of which knee contains working drain.
3167119|NCT00534053|Experimental|1|400 patients will be given a mailed educational reminder 10 days after picking up their FOBT cards from the VA laboratory.
3167120|NCT00534053|No Intervention|2|400 patients will not receive a mailed educational reminder to return their FOBT cards after they have picked up the FOBT cards from the VA laboratory
3167121|NCT00534066||Admitted|Patients presenting to the ED with acute exacerbation of CHF who require admission to the hospital directly from the ED
3167122|NCT00534066||Observational|Patients who present to the ED for acute exacerbation of CHF who are transferred to the Observation Unit from the ED for up to 24 hours.
2530887|NCT02691221|Other|Participants with previous suicide attempt or ideation|Participants will complete daily tasks assigned for completion through a downloaded application on their mobile device and completing six 2-hour long outcome assessment sessions including rater-lead scales over the course of six months.
2531005|NCT02690324|Experimental|Major depressive disorder|DSM-5 major depressive disorder HAMD-17 > 16
2531011|NCT02690324|Active Comparator|panic disorder|DSM-5 panic disorder PDSS>7
2531015|NCT02690324|Active Comparator|normal control|age >20, healthy adults HAMD-17<17 PDSS<7
2531048|NCT02690116|Experimental|Qigong/Tai Chi Easy|The Qigong/Tai Chi Easy (QG/TCE) intervention has been standardized, manualized, and has a formal training program for instructors from the Institute of Integral Qigong and Tai Chi (IIQTC).
2531051|NCT02690116|Sham Comparator|Sham Qigong|This active control group uses a gentle movement intervention, with similar types of movements with the same energy expenditure, but without the meditative states and breath focus as QG/TCE (validated in the pilot study using the Meditative Movement Inventory).
2531057|NCT02690116|Active Comparator|Educational Support|The Recovery Support Group will consist of a classroom-style intervention, designed to educate, engage interaction, and maintain participation and attention over 8 weeks. This group will include readings/discussions specific to breast cancer, and social interaction facilitation.
2531127|NCT02689713|Experimental|Topical Voriconazole Study Drug Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Voriconazole study drug placed on graft site.
2531133|NCT02689713|Placebo Comparator|Topical Sterile Water Placebo Group|Subjects between 18 and 60 years old who have sustained a burn wound of less than 30% total body surface area, or traumatic wounds requiring skin graft will have the Topical Sterile Water Placebo placed on graft site.
2531176|NCT02689232|Experimental|Thromboelastography (TEG) level|
2531188|NCT02689232|Active Comparator|Coagulation Profile|
2531263|NCT02688699|Experimental|EndoClot|spraying of Endoclot powder after EMR or ESD
2531264|NCT02688699|No Intervention|control|
2531306|NCT02688348|Other|Ancillary-Correlative (late toxicity and QOL)|Patients complete the EORTC QLQ-BLM-C30 at baseline, every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter after completion of chemo-radiotherapy.
2531366|NCT02687945|Active Comparator|Outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of outpatient physiotherapy with 2-3 weekly sessions
2531368|NCT02687945|Active Comparator|No outpatient physiotherapy|two weeks of in-home physiotherapy following total hip replacement followed by two months of self-guided physiotherapy exercises
2531414|NCT02687607||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured intracranial aneurysms.
2531563|NCT02686866|Experimental|Body composition measurement|All patients will undergo body composition measurement with dual-energy X-ray absorptiometry and bioelectrical impedance analysis methods. Hand grip strength will also be performed.
2531622|NCT02686333|Experimental|Meditation Intervention Arm|10-15 minute meditation practices (brief silent meditations, guided meditations, body scans, gentle arm movement exercises). Before each session, the interventionist will perform a brief check in, and may discuss the patient's experience with them for 1-2 minutes after the intervention. Patients will be encouraged to practice the techniques at home between sessions. Patients will also be offered literature on mental health promotion.
2531627|NCT02686333|No Intervention|Control Group (No Meditation Exposure)|Patients randomized to the control group will be offered literature on mental health promotion and Treatment as Usual in the dialysis setting.
2531726|NCT02685384||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2531727|NCT02685397|Active Comparator|LHRH agonist + Enzalutamide|Subjects will receive LHRH agonist in combination with the new generation of hormonal therapy (enzalutamide, 40mg)
3167123|NCT00534079|Experimental|Dornase alfa|28 days of sinonasal inhalation (Pari Sinus)
3167124|NCT00534079|Placebo Comparator|isotonic saline|28 days of sinonasal inhalation (Pari Sinus)
3167125|NCT00534131|Active Comparator|Arm 1|Patients for whom a standard abdominal approach is adequate to excise the distal third of the rectum (without jeopardising oncological clearance if appropriate).
3167126|NCT00534131|Experimental|Arm 2|Combined abdominal and trans-perineal approach to excise the distal third of the rectum, while preserving the anal canal
3167127|NCT00534131|Active Comparator|Arm 3|Standard proctectomy to excise the distal third of the rectum and the anal canal
3167128|NCT00534144|Active Comparator|Iron Sucrose|
3167129|NCT00534144|Active Comparator|Ferric Gluconate|
3167130|NCT00534170|Experimental|A,F,T,K|Two arms are for intervention and two are for control or placebo
3167131|NCT00534183|Experimental|1|Olanzapine
2530393|NCT02694705|Experimental|CPAP|3 minutes of preoxygenation with a portable ventilator providing Continuous Positive Airway Pressure (CPAP) at 5 cmH20 and an FiO2 of 100%.
2530396|NCT02694705|Experimental|BVM|3 minutes of preoxygenation with a bag-valve-mask (BVM) device and oxygen flow rate of 15 litres / minute.
2530398|NCT02694705|Experimental|NRM|3 minutes of preoxygenation with a non-rebreather mask (NRM) device and oxygen flow rate of 15 litres / minute.
3167132|NCT00534183|Active Comparator|2|Risperidone
3167133|NCT00534183|Active Comparator|3|haloperidol
2530500|NCT02693886||A group|Experience of endoscopist: >2000 cases
2530504|NCT02693886||B group|Experience of endoscopist:between 1000 and 2000 cases
2530507|NCT02693886||C group|Experience of endoscopist:between 500 and 1000 cases
2530513|NCT02693886||D group|Experience of endoscopist:<500 cases
2530754|NCT02692092||Total Arthroplasty Patients|Any patient who has received a total hip or total knee arthroplasty at a healtheast acute care hospital.
2530782|NCT02691858|Experimental|Hydrocortisone|Hydrocortisone IV 10 mg/kg with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
2530787|NCT02691858|Placebo Comparator|Saline|Saline IV 100 ml with Resuscitation before attempting reduction, single dose with Resuscitation before attempting reduction
2531044|NCT02690051|Experimental|BeSmooth Peripheral Stent system|Patients treated with the BeSmooth Peripheral Stent System
2531215|NCT02688985|Experimental|RMS Cohort Arm 1: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 12. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
2531217|NCT02688985|Experimental|RMS Cohort Arm 2: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 24. Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
2531219|NCT02688985|Experimental|RMS Cohort Arm 3: Ocrelizumab + LP|Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP before the start of dosing (Week 1, treatment baseline) with ocrelizumab and a second LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
2531220|NCT02688985|Experimental|RMS Cohort Arm 4: Ocrelizumab + LP|Ocrelizumab treatment will be delayed for 12 weeks from pre-treatment baseline. Participants with RMS will receive ocrelizumab as two 300-mg IV infusion on Days 1 and 15 then as single infusion of 600 mg on Weeks 24 and 48. Participants will receive a LP at Week -12 (pre-treatment baseline) and a second LP before the start of dosing (Week 1, treatment baseline). Participants will be asked to have an additional optional LP at Week 52. Participants that complete the study and continue to receive ocrelizumab will receive single infusions every 24 weeks starting from Week 72.
2531221|NCT02688985|Experimental|PPMS Cohort: Ocrelizumab + LP|For the PPMS cohort, ocrelizumab will be administered as two 300-mg IV infusions separated by 14 days at a scheduled interval of every 24 weeks during the treatment period and then as a single 600-mg dose every 24 weeks starting week 72 during the Long-Term Extension period.
2531426|NCT02687295|Active Comparator|Thylakoid group|Thylakoid group subjects received the same diet restriction intervention as the control group. However, their food products did contain an active component in the form of thylakoid powder.
3167134|NCT00534196||Group under operation of brachytherapy|Patients with histologically confirmed adenocarcinoma of the prostate and who are planning to undergo brachytherapy with PI (permanent iodine) or combination of PI with other tratement.
3167135|NCT00534222||Quetiapine|
3167136|NCT00534222||Olanzapine|
3167137|NCT00534222||Risperidone|
3167138|NCT00534261|Experimental|1|patients received Avonex IM injections and be evaluated for quality of life criteria
3167139|NCT00534274|Experimental|TEP FLT|
3167140|NCT00534287|Active Comparator|MeroMono|Monotherapy with meropenem
3167141|NCT00534287|Active Comparator|MeroMoxi|Combination therapy with meropenem + moxifloxacin
3167142|NCT00534300|Experimental|A|
3167143|NCT00534300|Placebo Comparator|B|
3167144|NCT00534326|Active Comparator|1|Standard Reaming of femoral shaft fracture prior to intramedullary nailing
3167145|NCT00534326|Active Comparator|2|Reamer/Irrigator/Aspirating of femoral shaft fracture prior to intramedullary nailing
3167146|NCT00534378|No Intervention|1|
3167147|NCT00534391|Placebo Comparator|B|Artificial tear containing antibiotic solution base
3167148|NCT00534391|Experimental|A|combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
3167149|NCT00534430|Experimental|Busulfan, FTBI and VP16|IV Busulfan + 12 cGy FTBI + VP16 prior to allogeneic Bone Marrow Transplant
3167150|NCT00534443|Experimental|1|A total of 130 patients with peptic ulcer disease and /or chronic gastritis will be enrolled in the study after written informed consent. Patients will be prescribed oral treatment with rabeprazole or esomeprazole according to standard guidelines. Rabeprazole is administered 20mg twice daily and esomeprazole 10 mg once daily. Selection of rabeprazole or esomeprazole is at the discretion of the attending physicians. The drug is administered for four weeks in patients with duodenal ulcers, for eight weeks in patients with gastric ulcers and for four weeks in patients with chronic gastritis.
3167151|NCT00534456|Experimental|Active|
3167152|NCT00534456|Placebo Comparator|Placebo|
3167153|NCT00534469|Active Comparator|HD ARA-C with Idarubicin|HD ARA-C with Idarubicin Consolidation, Busulfan/FTBI/VP16/PSC/BMT
3167154|NCT00534469|Active Comparator|HD ARA-C without Idarubicin|HD ARA-C Consolidation, Busulfan/FTBI/VP16/PSC/BMT
3167155|NCT00534482|Experimental|A, 1, I|Practice-level treatment group
3167156|NCT00534482|Active Comparator|A, 1, II|Practice-level comparison group
2530402|NCT02694731|Experimental|Mobile application intervention|Participants receive a mobile app with a 5-week mindful eating program and ongoing tools for coping with cravings
2530438|NCT02694237|Active Comparator|Verbal|This group will only receive a verbal discussion based on the same script used for all three groups. This is the control group.
2530439|NCT02694237|Active Comparator|Verbal + Model|This group will receive a verbal discussion aided with an anatomic model intervention that group participants will be able to touch throughout the discussion.
2530440|NCT02694237|Active Comparator|Verbal + Video|This group will receive a verbal discussion aided with a knee anatomy video intervention that will be played on silent an orated by an interviewer.
2530524|NCT02693652|Experimental|CVI-HBV-002 (20ug, 3 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2 month"
2530526|NCT02693652|Experimental|CVI-HBV-002 (20ug, 6 shots)|"HBV surface antigen 20ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
2530528|NCT02693652|Experimental|CVI-HBV-002 (40ug, 3 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2 month"
2530529|NCT02693652|Experimental|CVI-HBV-002 (40ug, 6 shots)|"HBV surface antigen 40ug/dose~Intramuscular injection at 0, 1, 2, 3, 4, 5 month"
3167157|NCT00534482|Experimental|B, 1, I|Patient-level treatment group
2530790|NCT02691845|Other|BA|Brief advice to exercise. This serves as a control condition.
2530791|NCT02691845|Active Comparator|BA + SHE + HE|Brief advice to exercise + supervised & home-based exercise + health education
2530792|NCT02691845|Experimental|BA + SHE + CBEX|Brief advice to exercise + supervised & home-based exercise + cognitive-behavioral sessions focused on increasing and maintaining exercise
2530919|NCT02690909|Experimental|Redy™ Renal Denervation System|Renal Denervation System
2530996|NCT02690610|Experimental|Patients with mediastinal lesions|EBUS TBNA of mediastinal lesions or lymph nodes
2531032|NCT02690272|Experimental|Psychic processes|Quantitative and qualitative approche of the psychic process for patients awaiting kidney transplant
2531043|NCT02690090||enoxaparin|enoxaparin prophylaxis as directed by treating Intensivist
2531107|NCT02689830|Experimental|Bead Block microspheres|Prostate embolization
2531150|NCT02689440|Experimental|Treatment (dasatinib, venetoclax)|Patients receive dasatinib PO QD for 15 years in the absence of disease progression or unacceptable toxicity. After 3 months of dasatinib treatment, patients also receive venetoclax PO QD on days 1-14 of each month for 3 years in the absence of disease progression or unacceptable toxicity (patients enrolled prior to 4/1/2018 receive only dasatinib).
2531181|NCT02689011|Experimental|Group F|Femoral nerve Block Group
2531191|NCT02689011|Active Comparator|Group E|Epidural Group
2531279|NCT02688491|Experimental|A (Intervention group,sunitinib)|Beginning 4-12 weeks following radical nephrectomy, patients receive sunitinib malate PO QD for 4 weeks
2531284|NCT02688491|No Intervention|B(observation group)|Patients with radical nephrectomy are observed without intervention
2531357|NCT02687737|Experimental|Exercise|The participants will have the following tests performed: Maximum Expiratory Pressure (MEP), insertion of a fine-wire electromyography (EMG) electrode into the mid-line base of the tongue, will complete swallowing tasks and breathing tasks under Videofluoroscopy (fluoroscopy on only during the actual task)
2531404|NCT02687633|Experimental|Treatment Group|The Treatment Group begins the JASPER intervention immediately upon enrollment in the study.
2531406|NCT02687633|Active Comparator|Delayed Treatment Group|The Delayed treatment group receives the same JASPER intervention as the Treatment Group, but after 6 months of receiving services in the community as usual.
2531428|NCT02687321||Advanced ovarian cancer patients|Patient with histologically confirmed advanced (FIGO III and IV) epithelial ovarian, fallopian tube or primary peritoneal carcinoma with complete remission after first line treatment are included into the study. The patient is regularly followed up every 3-4 months, blood sample collection is performed to determinate tumor marker found in blood, elevated by the presence of cancer recurrence. In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
2531538|NCT02686892||Group|Spanish territory population of 46,439,864 inhabitants
3167158|NCT00534482|Active Comparator|B, 1, II|Patient-level comparison group
3167159|NCT00534521|Active Comparator|Active Treatment Arm|Subjects will have their leg and foot draped to remain blinded to the test. They will be in a supine position with the knees abducted and flexed. The medial aspect of the lower extremity is palpated and a needle insertion site is identified. Between the posterior margin of the tibia and the soleus muscle, an acupuncture-like needle is inserted. An adhesive grounding pad is placed on the bottom of the foot just below the smallest toe. The needle and grounding pad are connected to the stimulator and the stimulation is increased as tolerated.
3167160|NCT00534521|Sham Comparator|Sham Arm|"Since subjects with the PTNS will feel foot stimulation, the sham was devised to mimic this feeling without the tibial nerve being stimulated. Again the leg and foot will be draped and out of view from the subject. The medial aspect of the lower extremity is palpated (Figure 4) and the tibial nerve site is identified approximately 5 cm cephalad from the medial malleolus. A Streitberger needle is used at the tibial nerve insertion site to simulate needle placement without puncturing the skin. The needle will be taped in place as in the PTNS procedure. The grounding pad will be a gel electrode pad from a TENS unit device that is placed on the bottom of the foot just below the smallest toe."
3167161|NCT00534534|Active Comparator|1|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. In addition, they also will undergo repeated similar interventions at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
3167162|NCT00534534|No Intervention|Standard|All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion. No drugs will be used. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period.
3167163|NCT00534560|Experimental|1|
3167164|NCT00534560|Experimental|2|
3167165|NCT00534560|Placebo Comparator|3|
2530423|NCT02694263|Active Comparator|Repaglinide + Metformin|Repaglinide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). An initial dose of 0.5mg once daily where no prior treatment has been given will be prescribed. However, where prior treatment has been in place, an initial dose of 1-2mg once daily will be started and this will be titrated up to a maximum dose of 4mg daily.
2530425|NCT02694263|Active Comparator|Pioglitazone + Metformin|Piogliazone + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Pioglitazone dose will initially be 15mg or 30mg once daily. If the response is inadequate, the maximum daily dosage will be increased to 45mg once daily.
2530428|NCT02694263|Active Comparator|Gliclazide + Metformin|Gliclazide + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). For example, Gliclazide dose will initially be 40-80 mg once daily, up to maximum dose of 160mg twice daily..
2530430|NCT02694263|Active Comparator|Glimepiride + Metformin|Glimepiride + Metformin (using the participant's current dose(s), or dose recommended by the study clinician). Glimepiride will initially be administered as 1mg once daily, up to a maximum dose of 4mg once daily.
2530506|NCT02693912||acute lung injury|Patients with a diagnosis of acute lung injury (ALI) under mechanical ventilation.Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
2530511|NCT02693912||control|Patient under mechanical ventilation without any lung diseases. Patients will underwent bronchoscopy for bronchoalveolar lavage fluid.
2530581|NCT02693405|Experimental|child and adult survivors of brain tumor|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
2530585|NCT02693405|Experimental|healthy controls|"Executive functions and social cognition will be assessed using cognitive (Stroop task, Modified Card Sorting Task, Digit spans) and behavioral (BRIEF for childrens and BRIEF-A for adults) tests.~Quality of life will be assessed by questionaires (SF-36, QLQC30-BN20 for adults and Peds-Ql for childrens)"
2530761|NCT02692222||PPV|This study will track changes in PPV and CO before and after of volume expansion, which goal is to change the cardiac output.
2530811|NCT02691793|Experimental|sunitinib|sunitinib 50 mg will be administered orally daily
2530854|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 10%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
2530864|NCT02691429|Active Comparator|acai dye (Euterpe oleracea) 25%|"Twenty-four different retina surgeons will operate one of the 24 selected patients, using the standard vitrectomy technique that employs 4 sclerotomies and a 23-gauge system with accessory illumination. All surgeries will be performed using the acai dye (Euterpe oleracea) in the following concentrations: 10% (n=12) or 25% (n=12).~Immediately after the procedure, each surgeon will be given an evaluation questionnaire to fill-in"
2530924|NCT02690922|Experimental|ph+ ALL with dasatinib|patients in the arm are newly diagnosed ph+ ALL,the patient first receive dexamethasone as pretreatment,then dasatinib and prednisone are used as inductive treatment,and methotrexate to consolidate the therapy.
2530993|NCT02690623|Experimental|Pediatric hospitalist program|As currently planned, hospitalist services will involve an in-house hospitalist at all hours. The attending hospitalist on each hospitalist service will make morning rounds on weekdays and be present supervising the residents or providing care throughout the day. A different hospitalist will cover at night. On weekends, one hospitalist will cover up to 2 services each day. None will work for more than 25 hours at a stretch.
2530994|NCT02690623|Active Comparator|General Pediatric Inpatient Services|The attending pediatrician on each service conducts daily morning rounds on weekdays, supervises the students and house staff and is available to the residents by phone or in person during the day. On some afternoons the attending physician may be responsible for supervising care in a pediatric clinic. On weeknights, an on-call pediatrician is available to the residents by phone. On weekends two on-call pediatricians make rounds, supervise the residents, and take call from home for the 4 services. Each service usually maintains 10-20 patients at a time and generally accepts 8-12 new admissions per admitting day. This approach on the General Pediatric Services will not be changed materially as hospitalists assume responsibility for one or more of the 4 services.
2531047|NCT02690077|Active Comparator|Method 1 by Preference 1|Delivery through the Family-Centered Cesarean for patients with known Family-Centered preference.
2531052|NCT02690077|Active Comparator|Method 1 by Preference 2|Delivery through the Family-Centered Cesarean for patients with known Traditional Cesarean preference.
2531059|NCT02690077|Active Comparator|Method 2 by Preference 1|Delivery through the Traditional Cesarean for patients with known Family-Centered preference.
2531062|NCT02690077|Active Comparator|Method 2 by Preference 2|Delivery through the Traditional Cesarean for patients with known Traditional Cesarean preference.
2531131|NCT02689687|Experimental|Intervention|All participants will be (1) given an electronic pill bottle for their diuretic and a Bluetooth scale; (2) asked to provide the coordinator with name and contact information of a family member or friend to serve as a support partner; (3) will be assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence and registering a weight measurement; and, (4) will determine their preferences for Way to Health platform communication methods during the study.
2531184|NCT02689245|Experimental|Tenofovir + Fecal Microbiota Transplantation (FMT)|
2531195|NCT02689245|Active Comparator|Tenofovir|
2531257|NCT02688816||Women undergoing cervical cancer screening|"HIV-infected women will undergo a cervical cancer screening examination using the VIA method. A digital photograph of the cervix will also be taken to aide visual screening. This is known as digital cervicography, and it is currently standard of care within cervical cancer screening clinics in Zambia.~Cervical samples will be collected for molecular testing using Xpert HPV, and OncoE6. Cervical biopsy samples will also be obtained for confirmatory histopathologic diagnosis."
2531312|NCT02688296||Pilon Fractures|Patients who are implanted with Fibulock and have a Pilon fracture
2530431|NCT02694419||Obese/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are overweight\obese with BMI ≥ 25 kg/m2.
2530432|NCT02694419||normal weight/fertile|Fertile regularly menstruating women with at least one previous spontaneous pregnancy who are normal weight with BMI < 25 kg/m2.
2530487|NCT02693951|Experimental|the prophylactic use of antibiotics group|Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
2530492|NCT02693951|No Intervention|Control|Routine endoscopic examination and treatment. Antibiotics are not used before endoscopic treatment
2530537|NCT02693470|Other|single-arm study|"50 patients with severe psoriasis who received Stelara(ustekinumab) at 0 and 1 month. The investigators check microparticles level at baseline and 4 months later.~50 patients without psoriasis: the microparticles are checked at baseline."
2530589|NCT02693145|No Intervention|standard of care (SOC) arm|Individuals found to be out of HIV medical care will receive standard of care to re-engage. This will not include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
2530597|NCT02693145|Experimental|Intervention arm|Individuals randomized to the intervention arm will receive field services to locate, contact, and provide assistance to access HIV medical care. Intervention may include use of disease intervention specialist to locate and recruit back to HIV medical care or use of the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention.
2530645|NCT02692833||AKI Patients|Patients who develop acute kidney injury within the first 5 days following their cardiac surgical operation.
2530650|NCT02692833||Non-AKI patients|Patients who do not develop acute kidney injury within the first 5 days following their cardiac surgical operation.
2530684|NCT02692573|Experimental|prone|Prone positioned after delivery
2530689|NCT02692573|Active Comparator|supine|Supine positioned after delivery
2530709|NCT02692287|Other|Use of the PPH Butterfly|The PPH Butterfly will be inserted into the vagina of a healthy postnatal woman
2530752|NCT02692118||sepsis|Patients with septic shock admitted to ICU
2530783|NCT02691910|Active Comparator|CONCURRENT CHLOROQUINE+PRIMAQUINE|"The infected individuals were treated with the standard chloroquine (CQ)+primaquine(PQ) regimen to malaria caused by Plasmodium vivax.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 0 of CQ treatment. Total dose, 3.5mg/kg The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
2530786|NCT02691910|Experimental|CHLOROQUINE|"The infected individuals were initially treated with chloroquine (CQ) alone and the primaquine(PQ) was introduced on day 28.~Chloroquine (tablet containing 150mg of base) - it was given on days 0 (10mg/kg), 1 (7.5mg/kg) and 2 (7.5mg/kg). Total dose, 25 mg base/kg.~Primaquine - it was given once a day (0.5 mg/kg) for seven days, starting on day 28 of CQ treatment. Total dose, 3.5mg/kg.~The medications were administered under direct observation and the patient was monitored for vomiting for 60 minutes."
2530850|NCT02691546||Subjects aged 75 years or older|
2530896|NCT02691052||Pts receiving nab-paclitaxel/gemcitabine|Patients with metastatic pancreatic cancer undergoing a firstline therapy with nab-paclitaxel and gemcitabine will be asked to fill in an EORTC QLQ-C30 questionnaire and an additional questionnaire on worries about quality of life impairments every 4 weeks. No further intervention.
2530964|NCT02690870|Experimental|tamoxifen|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from D3 for 5 days.All patients will check serum E2 and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle. The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG administration. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
2530967|NCT02690870|Active Comparator|clomiphene|All patients will have serum hormone examination and be monitored by transvaginal ultrasound for ovaries on the day 3 of the menses（D3）.Patients in clomiphene group will take 100 mg of CC oral tablets daily from D3 for 5 days.All patients will have sexual hormone determination and be monitored by transvaginal ultrasound for the mean follicular diameter and endometrial thickness on the day 8 of the cycle.The investigators will add HMG and GnRH-ant according to follicular diameter,E2 and LH. Human chorionic gonadotropin(hCG) (5000-10000 IU IM) will be given when one follicle measured at least 18 mm is found. IVF or ICSI will be performed 34-36 h after hCG injection. All patients will receive luteal phase support with progesterone 60 mg im qd for 2 weeks.
2531029|NCT02690467|Experimental|Insupen G34x3,5mm|Needle for insulin pen 3,5 mm long and with a diameter of 34 gauge
2531030|NCT02690467|Active Comparator|Insupen G32x4mm|Needle for insulin pen 4 mm long and with a diameter of 32 gauge
2531074|NCT02689908|Other|The patients underwent thorax CT|The patients refered to radiology service underwent thorax computed tomography without contrast material for the evaluation of various complaints such as dyspnea, hemoptysis and pulmonary infections.
2531142|NCT02689661||Obese participants|Obese participants recruited from the University of Michigan Investigational Weight Management Clinic. Subjects in this group complete the five surveys, undergo extensive metabolic phenotyping, and a comprehensive neuropathy assessment at study entry and again at 2 years.
2531146|NCT02689661||Lean participants|Healthy lean age and gender matched controls recruited via the umclinicaltrials.org complete the five surveys, complete an oral glucose tolerance test and cholesterol panel, as well as the complete comprehensive neuropathy assessment.
3200845|NCT00894855|Experimental|educ, biometric fb, and derm skin exam|Participants received the active components of the other three conditions.
2530512|NCT02693665|Experimental|FACE-TC Intervention|Adolescent/family dyads randomized to the experimental condition receive Family Centered Advance Care Planning for Teens with Cancer (FACE-TC) intervention - 3 sessions scheduled one week apart of approximately 60 minutes duration each. Session 1 - Lyon Advance Care Planning Survey-Adolescent & Surrogate versions. Session 2 - Respecting Choices Interview facilitated by trained/certified facilitator with adolescent and family. Focuses on patient's understanding of their illness, possible complications, goals of care and treatment preferences in 3 bad outcome situations; and the Session 3 - Five Wishes an advance directive.
2530517|NCT02693665|No Intervention|Treatment As Usual (TAU)|Adolescent/family dyads randomized to the treatment as usual (TAU) condition receive written information on advance care planning, but no active intervention.
2530572|NCT02693327||Mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
2530575|NCT02693327||Non-mental illness group|Participants in this group will provide biological samples to include both stool and blood samples.
2530671|NCT02692651|Active Comparator|Fidaxomicin|Fidaxomicin 200 mg PO BID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
2530675|NCT02692651|Active Comparator|Vancomycin|Vancomycin 125 mg PO QID for 10 days or until the end of the duration of concomitant antibiotic exposure, whichever is longer.
2530702|NCT02692274||Primary Health care clinics|A survey of 100 primary Health care clinics was carried out
2530704|NCT02692274||Pregnant and breast feeding women|208 patients were recruited from nine clinics that participated in the survey for evaluation of the accuracy of results produced by the HIV rapid test.
2530751|NCT02692183||Parkinson Disease (PD) tremor patients|Patients with PD before and after MRI guided Focused ultrasound thalamotomy
2530755|NCT02692183||Essential tremor (ET) patients|Patients with ET before and after MRIFocused ultrasound guided thalamotomy
2530807|NCT02691923|Active Comparator|Fluorescein|Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.
2530808|NCT02691923|Experimental|Fluorescein + ALA|"Fluorescein administered IV at 5mg/kg approximately 30 minutes prior to the beginning of the tumor resection. A second injection may occur if the fluorescein fluorescence is dissipated substantially during the course of the procedure.~ALA administered orally at 20mg/kg approximately 3 hours before surgery."
2530834|NCT02691325|Experimental|Part A (Sequence 1) - Placebo, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 matching placebo (one inhalation) in treatment period 1, and single dose of GSK2269557 200 microgram (mcg) (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2530835|NCT02691325|Experimental|Part A (Sequence 2) - GSK2269557 100 mcg, Placebo|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 matching placebo (two inhalations) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2530838|NCT02691325|Experimental|Part A (Sequence 3) - GSK2269557 100 mcg, GSK2269557 200 mcg|Subjects will receive a single dose of GSK2269557 100 mcg (one inhalation) in treatment period 1, and single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) in treatment period 2 via the ELLIPTA DPI. The washout period between each dosing day will be at least 14 days. Doses of GSK2269557 may be modified based on emerging data.
2530844|NCT02691325|Experimental|Part B- GSK2269557 200 mcg|Subjects will receive repeated doses of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) once daily via the ELLIPTA DPI for 10 days. Doses of GSK2269557 may be modified based on emerging data from Part A.
2530847|NCT02691325|Experimental|Part B- GSK2269557 matching Placebo|Subjects will receive repeated doses of GSK2269557 matching Placebo (2 inhalations) once daily via the ELLIPTA DPI for 10 days.
2530848|NCT02691325|Experimental|Part C- GSK2269557 200 mcg with and without activated charcoal|Subjects will receive a single dose of GSK2269557 200 mcg (2 inhalations of GSK2269557 100 mcg) via the ELLIPTA DPI with activated charcoal in one treatment period and without ingestion of activated charcoal in another treatment period. The washout period between each dosing day will be at least 14 days. Dose of GSK2269557 may be modified based on emerging data from Part A.
2530943|NCT02690961|Experimental|Kukoamine B Mesilate 0.06mg/kg|Dose Escalation: Kukoamine B Mesilate 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530944|NCT02690961|Experimental|Kukoamine B Mesilate 0.12mg/kg|Dose Escalation: Kukoamine B Mesilate 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530947|NCT02690961|Experimental|Kukoamine B Mesilate 0.24mg/kg|Dose Escalation: Kukoamine B Mesilate 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530949|NCT02690961|Experimental|Placebo 0.06mg/kg|Dose Escalation: placebo 0.06mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530951|NCT02690961|Experimental|Placebo 0.12mg/kg|Dose Escalation: placebo 0.12mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530953|NCT02690961|Experimental|Placebo 0.24mg/kg|Dose Escalation: placebo 0.24mg/kg multiple-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
2530460|NCT02694380||Lung|Subjects with lung cancer receiving radiation therapy.
2530477|NCT02693730||Healthy Control|Does not have diagnosis of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD) and is otherwise healthy and able to participate as defined by the exclusionary criteria.
2530479|NCT02693730||Irritable Bowel Syndrome (IBS)|Diagnosed with IBS and meets the Rome III criteria, in the absence of red flag signs (i.e., unexplained weight loss, bloody stool, fever, anemia)
2530482|NCT02693730||Ulcerative Colitis (UC)|Clinically and histologically confirmed diagnosis of ulcerative colitis
3167166|NCT00534573|Active Comparator|Moclobemide,|treatment during 2 weeks
3167167|NCT00534573|Active Comparator|Amisulpride|Comparison
2530573|NCT02693080|Experimental|Diagnostic (CT perfusion imaging)|Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first SABR, and at 2-4 months after completion of SABR. Isovue-200 is used as contrast agent
3167168|NCT00534586|Active Comparator|1|remifentanil
3167169|NCT00534586|Active Comparator|2|propofol
3167170|NCT00534586|Active Comparator|3|sevoflurane
2530678|NCT02692599|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0;~Intervention: investigational live attenuated mumps vaccine;"
2530683|NCT02692599|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0;~Intervention: control live attenuated mumps vaccine;"
2530717|NCT02692313|Placebo Comparator|Saline infusion|Hyperinsulinemic euglycemic glucose clamp with saline infusion
2530721|NCT02692313|Experimental|Epinephrine infusion-0.015ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.015 ug/kg/min
2530728|NCT02692313|Experimental|Epinephrine infusion-0.03 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.03 ug/kg/min
2530733|NCT02692313|Experimental|Epinephrine infusion-0.06 ug/kg/min|Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion of 0.06 ug/kg/min
2530794|NCT02691897|Experimental|Melatonin|Melatonin 3mg once daily at bedtime
2530799|NCT02691897|Placebo Comparator|Placebo|Placebo 1 tablet once daily at bedtime
2530836|NCT02691364||Healthy|Healthy women
2530842|NCT02691364||Preeclamptic|Pregnant women with preeclampsia
2530908|NCT02691182|Experimental|Open-label treatment with SPN-810|Subjects aged 6-12 years will be treated with SPN-810 starting day 1 of Visit 1 of the study. The subjects will be given a choice of extending their participation in the study every 6-month period for up to 36 months. The clinician will be able to adjust the dose of SPN-810 throughout the study based on subject's response and tolerability.
2530971|NCT02690779|Experimental|Patients watching educational video|The educational intervention will consist of a 2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration. This video will be posted on YouTube. Group 1 will consist of 30 subjects who will be instructed to view this video prior to beginning their colonoscopy preparation. Information to access the YouTube video will be provided to the patients by endoscopy nurse assessment staff when contacting the patients as per standard practice to review appointment scheduling and procedure-day logistics.
2530975|NCT02690779|Sham Comparator|Patients not watching educational video|Group 2 will consist of 30 subjects who will not receive instructions to view the video. They will be given routine care instructions for bowel prep.
2530997|NCT02690506|Placebo Comparator|Group C|Oral placebo pill was administered 2 hours before anesthesia
2530999|NCT02690506|Active Comparator|Group P|Oral pregabalin 150 mg was administered 2 hours before anesthesia
2531041|NCT02690220|Other|surgical mesh implantation|Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.
2531088|NCT02689856|Placebo Comparator|Vehicle cream|Placebo control base cream
2531089|NCT02689856|Experimental|3% hydrocortisone|3% Hydrocortisone acetate cream
2531090|NCT02689856|Experimental|0.5% hydrocortisone|0.5% Hydrocortisone acetate cream
2531092|NCT02689856|Experimental|5% lidocaine|5% Lidocaine hydrochloride cream
2531095|NCT02689856|Experimental|1% lidocaine|1% Lidocaine hydrochloride cream
2531096|NCT02689856|Experimental|3% Hydro 5% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 3% and 5% cream
2531097|NCT02689856|Experimental|0.5% Hydro 1% Lido|Hydrocortisone acetate and lidocaine hydrochloride at 0.5% and 1% cream
2531267|NCT02688907|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
3167171|NCT00534586|Active Comparator|4|s-ketamine
3167172|NCT00534612|Experimental|1|fine needle aspiration biopsy of the parotid gland mass
2531358|NCT02687828||Subjects receiving adalimumab|The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.
2531402|NCT02687646|Experimental|Allogeneic Mesenchymal Cells|All patients will receive Adult Allogeneic Mesenchymal Cell from adipose tissue. It is not considered ethical the inclusion of a control group.
2531431|NCT02687347|Experimental|study arm|low dose methadone (1-10mg daily)
2531435|NCT02687347|Active Comparator|control arm|low dose morphine (1-10 mg/day)
3167173|NCT00534625|Placebo Comparator|1|
3167174|NCT00534625|Experimental|2|150 mg zileuton by intravenous injection
3167175|NCT00534625|Experimental|3|300 mg zileuton by intravenous injection
3167176|NCT00534677|Active Comparator|A|
3167177|NCT00534677|Active Comparator|B|
3167178|NCT00534690|Other|1|
3167179|NCT00534690|Other|2|
3167180|NCT00534755|Other|Breast database|Database
3167181|NCT00534768|Active Comparator|1|debridement on 1st, 3-5th and 7th postoperative days
3167182|NCT00534768|Active Comparator|2|
3167183|NCT00534781|Experimental|A|plasma microtenotomy
3167184|NCT00534781|Active Comparator|B|Standard Surgical Debridement
3167185|NCT00534846|Placebo Comparator|A placebo|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
2530600|NCT02693275|Other|Quotient® System iPad Test|The Quotient® System iPad Test is a test specifically designed to provide clinicians with objective measures in ability to maintain seated stillness, sustained attention to a monotonous task and inhibiting incorrect impulsive responses. The attention task with motion analyses provides a number of objective measures for detailed assessment of the subject's movements and attentiveness.
2530670|NCT02692768|Active Comparator|Live Music Therapy|Live sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will experience this music intervention live, including patient-centered interaction with the music therapist and education for repeated use of the routine on recording.
2530677|NCT02692768|Active Comparator|Recorded Music Therapy|Recorded sedative guitar playing within a limited chord progression will be utilized. Added to this music will be vocal and verbal therapeutic suggestion for active listening, focused breathing, muscle relaxation, and guided imagery. Patients will choose from one of three nature scene options for the guided imagery in order to include patient preference of content. This treatment group will be given a recording of their chosen music relaxation routine for use throughout the study process.
2530682|NCT02692768|Active Comparator|Control|This group will receive standard of care with no music therapy intervention
2530727|NCT02692261|Active Comparator|Hyalossᵀᴹ matrix|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution used for maxillary sinus augmentation
2530735|NCT02692261|Active Comparator|Apatos alone xenograft|Each sinus was filled with 1 gr xenograft (with or without Hyaluronic Acide) for maxillary sinus augmentation
3167186|NCT00534846|Active Comparator|B toremifene|The participants were randomly allocated to receive toremifene (20 mg) or placebo during the luteal phase for three consecutive menstrual cycles.
2530825|NCT02691533|Experimental|ω3 PUFA(10% Omegavan 100 ml)|
2530826|NCT02691533|Experimental|ω6 PUFA (20% Intralipid 50 ml)|
2530827|NCT02691533|Placebo Comparator|Placebo Arm|No Lipid Emulsion will be given in this arm
2530857|NCT02691234|Experimental|Extracorporeal Shockwave Therapy and debridement|The treatment will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing before each treatment. The transducer device will be positioned against the lesion area and shockwaves will be delivered at a gradually increasing energy, with a maximum energy level of 0.09mJ/mm2
2530865|NCT02691234|Active Comparator|debridement and cleansing.|The standard treatment to the control group and the treatment group will be performed as an outpatient care procedure with no anesthesia. Patients will undergo wound debridement and cleansing. The physician will treat the patient in regard to his medical state: antibiotic medication if needed, dressing and off loading with Orthotic devices
2530905|NCT02691078|Experimental|Adult patients with neuroendocrine tumors|
2530957|NCT02690844|Active Comparator|Clonazepam|Clonazepam (Klonopin®) treatment arm - 1 mg clonazepam (Klonopin® tablet) TID, dissolved in mouth for 3 minutes then expectorated
2530959|NCT02690844|Placebo Comparator|Mucolox® alone|Mucolox® only - 5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated
2530962|NCT02690844|Experimental|Mucolox® and clonazepam|Mucolox® and clonazepam - 1mg Clonazepam/5mL Mucolox® TID, swished around mouth for 3 minutes then expectorated.
2531028|NCT02690532||High risk group|Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease).
2531031|NCT02690532||Non-celiac group|Children who are self-diagnosed with non-celiac gluten sensitivity.
2531034|NCT02690532||Control Group|Healthy control group (matched for age and gender).
2531077|NCT02690025|Experimental|ZP1848 High dose|s.c. administration of high dose
2531084|NCT02690025|Experimental|ZP1848 Medium dose|s.c. administration of medium dose
2531086|NCT02690025|Experimental|ZP1848 Low dose|s.c. administration of low dose
2531143|NCT02689596|Active Comparator|OT|Oxytocin
2531151|NCT02689596|Placebo Comparator|Placebo|Placebo
3167187|NCT00534872|Experimental|SB649868|10 mg
3167188|NCT00534885|Experimental|1: Healive® Lot 1|
2531231|NCT02688803|Active Comparator|Dose dense AC-P|Dose dense AC-P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
2531232|NCT02688803|Active Comparator|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
2531233|NCT02688803|Active Comparator|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
2531262|NCT02688517|Other|Ancillary-Correlative (genomic analysis)|Previously collected tissue samples are analyzed for the presence of mutations via next generation sequencing. Patients may also undergo collection of blood samples for analysis of circulating cell-free DNA and circulating tumor cells.
2531304|NCT02688114|Experimental|Barrett's Esophagus Treatment|All participants are in the treatment arm. Patients with Barrett's esophagus will undergo baseline surveillance endoscopy, be treated with radiofrequency ablation, and undergo follow up endoscopy 1, follow up endoscopy 2, and follow up endoscopy 3.
2531374|NCT02687880||All Subjects|"All subjects will undergo a surgical procedure (Testicular biopsy) to harvest their testicular tissue. In most cases, this will be done as part of their routine care but it is possible the subject may elect to have the procedure as part of a research only biopsy."
2531425|NCT02687581|Experimental|12-hour IO-therapy Glasses|wear IO-therapy glasses for 12-hour
2531427|NCT02687581|Active Comparator|6-hour patching|wear the eye patch for 6-hour
3167189|NCT00534885|Experimental|2: Healive® Lot 2|
3167190|NCT00534885|Experimental|3: Healive® Lot 3|
3167191|NCT00534885|Active Comparator|4: control vaccine (Havrix)|
3167192|NCT00534911|Experimental|Cognitive Behavioral Therapy|Primary & Secondary Control Enhancement Training (PASCET)
3167193|NCT00534911|Active Comparator|Supportive Non-Directive Therapy (SNDT)|Supportive Non-Directive Therapy
3167194|NCT00534924|Placebo Comparator|1|No intervention after IR injury
3167195|NCT00534924|Experimental|2|Postconditioning
2530555|NCT02693561|Active Comparator|Deep Breathing Exercises and Book|"Technical Deep Breathing and Reading the self-help book.~Reading the self-help book and will be trained by the physical therapist to perform deep breathing."
2530557|NCT02693561|No Intervention|Control|Not suffer any intervention
2530569|NCT02693041|Active Comparator|PROBIOTIC in low-risk women|In low-risk women, probiotic group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2530576|NCT02693041|Placebo Comparator|PLACEBO in low-risk women|In low-risk women, placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2530579|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PTB|In women with a prior preterm birth (PTB), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2530584|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PTB|In women with a prior preterm birth (PTB), placebo group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2530591|NCT02693041|Active Comparator|PROBIOTIC in women with a prior PE|In women with a prior preeclampsia (PE), probiotic Group will be treated with the Active ingredient containing Lactobacillus rhamnosus (LGG) (> 10x8 CFU) during all pregnancy until delivery. Capsules contain maltodextrin, LGG and vegetal magnesium stearate.
2530594|NCT02693041|Placebo Comparator|PLACEBO in women with a prior PE|In women with a prior preeclampsia (PE), placebo Group will be treated with the placebo ingredient during all pregnancy until delivery. The capsules of the placebo Group have similar content but lack the probiotic lactic acid bacteria which has been replaced by maltodextrin to make the mg amount equal.
2530798|NCT02691780|Experimental|Sorafenib|Sorafenib 200mg bid will be administered orally daily every 3weeks
2530851|NCT02691520||Taiwan Participants with Treatment Resistant Depression|Taiwan participants with Depression will be followed up to 8 years for incidence and duration of treatment resistant depression.
2530907|NCT02691130|Experimental|A: M-001 0.5mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 0.5mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
2530909|NCT02691130|Experimental|B: M-001 1.0mg & H5N1 influenza vaccine|"Biological/Vaccine: Two Multimeric-001 administrations followed by H5N1 influenza vaccine~Two administrations of non adjuvanted M-001, 1.0mg followed by 3mcg Alum/H5N1 influenza vaccine at intervals of 19-23 days"
2530911|NCT02691130|Placebo Comparator|C: Saline & H5N1 influenza vaccine|"Biological/Vaccine: Two saline administrations followed by H5N1 influenza vaccine~Two administrations of saline followed by 3mcg Alum/H5N1 influenza vaccinated intervals of 19-23 days"
2530982|NCT02690688||Pneumoperitoneum|Patients scheduled for laparoscopic (minimal invasive) abdominal surgery supported by pneumoperitoneum. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
2530983|NCT02690688||Open Surgery|Patients scheduled for conventional (open) abdominal surgery. Hemodynamic monitoring will be performed using Vigileo® monitor, Edwards Lifescience
2531008|NCT02690389|No Intervention|Control|standard procedure is used
2531014|NCT02690389|Sham Comparator|Flumazenil only group|flumazenil is given
2531017|NCT02690389|Active Comparator|control with acupuncture|control with acupuncture
2531019|NCT02690389|Active Comparator|control with acupuncture and flumazenil|control with acupuncture and flumazenil
2531046|NCT02690038|Experimental|Intervention Arm 1: Treatment|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
2531053|NCT02690038|Active Comparator|Intervention Arm 2: Control|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks).~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization during hospital admission and then every 4 weeks for 44 weeks (total 48 weeks)."
2531130|NCT02689700||HCMV antibody-transfer|Materno-fetal HCMV antibody-Transfer form 24-41 weeks of gestation
2531135|NCT02689700||VZV antibody-transfer|Materno-fetal VZV antibody-Transfer form 24-41 weeks of gestation
2531189|NCT02689284|Experimental|Margetuximab plus pembrolizumab|margetuximab administered in combination with pembrolizumab
2531255|NCT02688660||ADAPT Study Population|This cohort will be subjects from the ADAPT study who had an acute MRI scan which has been uploaded into the ADAPT database from all participating sites.
2531256|NCT02688660||Follow-Up MRI|This cohort will include patients from ADAPT sites who choose to participate in this option and obtain a follow-up MRI approximately 1 year after the TBI.
2531259|NCT02688660||Healthy Controls|This cohort will have one MRI to be used in comparison of the above cohorts.
2531343|NCT02688101|Experimental|DpC|DpC capsules, administered orally
2531395|NCT02687854||Apixaban|Non-valvular atrial fibrillation patients who were initiated on apixaban for stroke prevention
2531399|NCT02687854||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on Vitamin K antagonist for stroke prevention
3167196|NCT00534924|Experimental|3|Vit. C
2531504|NCT02686983|Experimental|Active|Betamethasone and local anesthetic.
2531505|NCT02686983|Placebo Comparator|Placebo|Saline with local anesthetic.
3167197|NCT00535028|Experimental|A|AER 001 s.c. once daily for 28 days
3167198|NCT00535028|Placebo Comparator|P|placebo s.c. once daily for 28 days
3167199|NCT00535054|Experimental|Tears Again|All subjects shall be treated with Tears Again.
3167200|NCT00535067||Breast Cancer Survivors|
2530580|NCT02693314|Experimental|Jarro-Dophilus EPS® Group|Jarro-Dophilus EPS® (5 billion CFU/capsule) probiotic formulation capsule for 28 days
2530590|NCT02693314|Experimental|Jarro-Dophilus EPS® High Potency Group|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule) probiotic formulation capsule for 28 days
2530595|NCT02693314|Placebo Comparator|Placebo Group|Placebo capsule for 28 days
2530701|NCT02692326|Experimental|Intervention: Cyclic parenteral nutrition Cohort|All newborn who were included in the study to receive cyclic parenteral nutrition (within 24 hours). The parenteral nutrition was stopped for one hour the first day until 4 hours in preterm infants and 6 hours in term neonates.
2530703|NCT02692326|No Intervention|Control: Continuous parenteral nutrition|All newborn who were included in the study to receive continuous parenteral nutrition (24 hours). The parenteral nutrition was given by a central line in 24 hours with a basal flow
2530763|NCT02692170|Experimental|CVI-HBV-001 (5 μg)|"HBV surface antigen 5 μg/dose~Intramuscular injection at 0, 1, 6th month"
2530764|NCT02692170|Experimental|CVI-HBV-001 (10 μg)|"HBV surface antigen 10 μg/dose~Intramuscular injection at 0, 1, 6th month"
2530766|NCT02692170|Experimental|CVI-HBV-001 (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
2530768|NCT02692170|Experimental|CVI-HBV-001 (40 μg)|"HBV surface antigen 40 μg/dose~Intramuscular injection at 0, 1, 6th month"
2530769|NCT02692170|Active Comparator|Conventional Hepatitis B vaccine (20 μg)|"HBV surface antigen 20 μg/dose~Intramuscular injection at 0, 1, 6th month"
2530806|NCT02691689|Other|Patients with ASD or VSD and PAH|
2530856|NCT02691442|Active Comparator|Ropivacaine 0.75%|The investigators administer 5 milliliters of Ropivacaine 0.75% in the inter scalene space
2530860|NCT02691442|Active Comparator|Levobupivacaine 0.5%|The investigators administer 5ml of Levobupivacaine 0.5% in the inter scalene space
2530869|NCT02691442|Active Comparator|Levobupivacaine 0.5% + epinephrin|The investigators administer 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in the inter scalene space
2530918|NCT02690987|Experimental|Overweight/obese subjects|Overweight/obese volunteers with BMI 28.0-50.0 kg/m2, otherwise healthy. This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design.
2530920|NCT02690987|Experimental|Ex-smokers|"Abstinent tobacco dependent individuals who score at least moderately on tobacco dependence as measured retrospectively using the Fagerström Test for Nicotine Dependence (FTND), and who have been in stable tobacco abstinence for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
2530923|NCT02690987|Experimental|Ex-alcohol dependent subjects|"Abstinent alcohol dependent individuals who score at least moderately alcohol dependent as measured retrospectively using the Severity of Alcohol Dependence Questionnaire (SADQ), and who have been abstinent for at least 6 weeks.~This group will receive interventions with saline as placebo, Exenatide and desacyl ghrelin infusions at separate visits in a within subject randomised crossover design."
3167201|NCT00535093|No Intervention|1|All patients fulfilling inclusion criteria will be evaluated for GAS infection using both a rapid streptococcus test and also a standard throat culture
2531072|NCT02689947|Experimental|Restylane Silk|open label no placebo control
2531132|NCT02689765|Experimental|Anthocyanins|Volunteers will be randomised double blinded into 'Anthocyanins' groups(n=60 per group)and given twice daily two capsules of either 80 grams of Anthocyanins, which corresponds a mixture of fresh blue berries and blackcurrants.The total duration of this trial was 24wk.
2531137|NCT02689765|Placebo Comparator|Control|A daily intake of 320mg Placebo to instead of treatment of Anthocyanins.
2531244|NCT02688920||With T2DM|Subjects with type 2 diabetes.
2531245|NCT02688920||Without T2DM|Subjects without type 2 diabetes
3167202|NCT00535106|Active Comparator|Standard resusc|Patients in this arm will be treated with standard resuscitation efforts, including the delivery of an immediate defibrillatory shock for all patients presenting in VF.
3167203|NCT00535106|Experimental|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
2531354|NCT02688036|Experimental|hypofractionated CRT|hypofractionated concurrent chemoradiotherapy
2531356|NCT02688036|Active Comparator|conventionally fractionated CRT|conventionally fractionated concurrent chemoradiotherapy
2531407|NCT02687672|Experimental|Stem Cell Transplantation|Injection of leukapheresis-derived, purified, autologous CD34+and CD133+ stem cells
2531408|NCT02687672|Experimental|Stem Cells|Injection of bone marrow-derived, purified, autologous CD34+and CD133+ stem cells.
2531521|NCT02687152|Experimental|Arginase inhibition|N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min
2531573|NCT02686736|Other|Internet-based educational intervention|The Internet-based educational intervention will include four educational sessions that will be provided during a four-week period. The follow up will last three-months.
2531578|NCT02686736|No Intervention|Control group|In the control group, teens will continue the usual school provided sexual education and will be invited to answer the internet-based self-applied questionnaire at the same time as the intervention group.
2531614|NCT02686489|Experimental|Heated humidification (HH)|Addition of water vapor (molecular water) to the inspired gas of spontaneously breathing tracheostomy patients.
2531615|NCT02686489|Active Comparator|Cool bland aerosol (LVN)|Addition of particulate water to the inspired gas of spontaneously breathing tracheostomy patients.
2531676|NCT02685917|Experimental|Microfracture with Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
2531692|NCT02685917|Active Comparator|Microfracture without Collagen Augmentation in HTO|Two groups, either collagen augmentation or not. Firstly, all patients underwent an arthroscopic examination and microfracture for bone marrow. Collagen augmentation included Cartifill insertion after arthroscopic microfracture.
2531728|NCT02685514|Experimental|HIFU Graves|Applying the High intensity Focused Ultrasound treatment to the relapsed Graves' disease Patients.
2531873|NCT02684409|Experimental|PROT-CL-NP101-015.01|
2530638|NCT02692976|Experimental|Plasmacytoid dendritic cells (pDC) vaccinations|Patients will be vaccinated intranodally three times biweekly with pDC (3x 106 cells; n=7, arm B). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA.
2530639|NCT02692976|Experimental|mDC and pDC vaccinations|Patients will be vaccinated intranodally three times biweekly with the combination of mDC and pDC (5x 106 mDC/ 3x 106 pDC; n=7, arm C). DC will be loaded with MHC class I binding peptides of tumor antigens and NY-ESO-1 and MUC1 PepTivator® which covers the complete antigen. DC will be stimulated with protamine/mRNA and loaded with KLH (mDC only) as an immune control.
2530668|NCT02692638|Experimental|Early laparoscopic enterolysis|Patient randomized to the early laparoscopy arm will undergo diagnostic laparoscopy within 24 hours of admission (depending on surgeon and operating room availability). Standard laparoscopy will be performed including supine positioning, sequential compression devices, and appropriate pre-incision antibiotics. Trocar placement will be at the surgeon's discretion and as appropriate for the patient's previous incisions. The necessity for conversion will be left to the discretion of the attending surgeon. Post operative management will conform to the standards of care. Nasogastric tubes will not be routinely placed.
2530673|NCT02692638|Active Comparator|trial of nonoperative management|Patients randomized to the trial of nonoperative management arm will undergo standard therapy including nil per os (NPO), nasogastric decompression only if actively vomiting, intravenous fluids while awaiting return of bowel function. Patients who do not achieve return of bowel function within 72 hours of admission will undergo attempted laparoscopic enterolysis with the understanding that conversion to open procedure may be necessary.
2530722|NCT02692352|Experimental|Experimental|8 sessions of Goal Management Training
2530732|NCT02692352|Active Comparator|Active control group|8 sessions of Brain Health Workshop
2530796|NCT02692027|Active Comparator|Standard of care|Standard of care in Lesotho. ART-initiation after at least two clinic visits for pre-ART counseling and monthly follow-up visits at the clinic thereafter.
2530802|NCT02692027|Experimental|Same-day ART initiation with less frequent follow-up visits|Proposition of same-day ART initiation with less frequent follow-up visits thereafter.
2530837|NCT02691390|Experimental|study group|alcoholics - dTMS group
2530839|NCT02691390|Sham Comparator|control group|alcoholics - sham group
2530915|NCT02691169|Experimental|18F-DCFPyL Injection|The subjects will receive the 18F-DCFPyL Injection (less than or equal to 9 mCi (333 MBq)) at visits 2 and 3.
3200846|NCT00894855|Experimental|education plus biometric feedback|In addition to the educational program, participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
3200847|NCT00894868|Experimental|Vildagliptin|
2531025|NCT02690259|Experimental|Sentinel node procedure|Enrolling all eligible endometrial cancer patient to the Sentinel node concept using indocyanine green.
2531042|NCT02689999|Experimental|Dexrabeprazole 10 mg Enteric-Coated Tablets|Dexrabeprazole 10 mg Enteric-Coated Tablets / once daily
2531145|NCT02689791|No Intervention|Control (SWF)|Standard Wheat Flour (SWF) Muffins
2531152|NCT02689791|Experimental|Resistant Starch Type 4|Resistant Wheat Starch Muffins
3200848|NCT00894868|Placebo Comparator|Placebo|
3200849|NCT00894881||1 group|patients before colonoscopy
2531258|NCT02688647|Experimental|KD025 400 mg Daily|Two 200 mg tablets (400 mg) KD025 QD. Subjects will take 2 tablets with their morning meal or within 5 minutes of completing a meal.
2531260|NCT02688647|Other|Best Supportive Care (BSC)|Best supportive care is treatment and/or drug determined by each subject's prescribing physician.
2531314|NCT02688179||Cardiac surgery patients|
2531380|NCT02688023|Experimental|single-arm Irinotecan-Oxaliplatin-5-Fluorouracil/leucovorin|Irinotecan,oxaliplatin and 5-fluorouracil/leucovorin(5-fluorouracil/leucovorin can be substituted with Capecitabine or S-1)
2531541|NCT02686931||Control|Control: Normal developmental children with orthopedic disease
2531542|NCT02686931||Experimental|Experimental: Developmental delayed children
2531566|NCT02686619|Active Comparator|Mycophenolate Mofetil + Cyclosporine|Participants will receive mycophenoate mofetil, daclizumab, cyclosporine, and corticosteroids (prednisolone) for 3 to 12 months.
2531575|NCT02686619|Experimental|Mycophenolate Mofetil + Sirolimus|Participants will receive mycophenoate mofetil, daclizumab, and corticosteroids (prednisolone) for 3 to 12 months. Participants will also receive cyclosporine which will be replaced with sirolimus at later stage of the study.
2531701|NCT02685644||Laparoscopic removal|Patients with endometrioma who will undergo laparoscopic removal of cysts.
2531780|NCT02685124|Experimental|Bahia orange juice|250 ml twice daily for 7 days
2531782|NCT02685124|Experimental|Cara Cara orange juice|250 ml twice daily for 7 days
2531783|NCT02685124|Placebo Comparator|Isocaloric control drink|250 ml twice daily for 7 days
2531828|NCT02684773||Incentre Nocturnal Hemodialysis|These are patients who converted to incentre nocturnal hemodialysis (8 hours/session, 3 sessions/week) from conventional hemodialysis (4 hours/session, 3 sessions/week) at the inception of this study and are eligible for the long-term follow-up phase of the study.
2531839|NCT02684773||Conventional Hemodialysis|These are patients treated with conventional hemodialysis (4 hours/session, 3 session/week) who elected to remain on this dialysis schedule at the inception of this study and are eligible for the long term follow-up phase of the study.
2531891|NCT02684513|Active Comparator|Oral Carbohydrate Beverage Group|Subjects assigned to this group will receive 710 mL of a preoperative beverage the evening prior to surgery and 355 mL the morning of surgery.
2531894|NCT02684513|Active Comparator|Rehydration Beverage Group|Subjects assigned to this group will receive 710 mL of re-hydration beverage the evening prior to surgery and 355 mL the morning of surgery.
2530739|NCT02692131||Speckle strain|All adult patients undergoing on pump CABG Surgery.
2530743|NCT02692131||Tissue doppler strain|All adult patients undergoing on pump CABG Surgery
2530775|NCT02692014||coronary heart disease|2,400 patients who are diagnosed with CHD and have received more than 2 times of coronary angiography within 12-24 months.
2530810|NCT02691728|Experimental|Treatment Arm|12 Week treatment with LDV/SOF FDC
2530840|NCT02691481|Active Comparator|Oatmeal breakfast|consuming 200 kcal of plain cooked oatmeal for breakfast
2530843|NCT02691481|Active Comparator|Glucerna formula|consuming 200 kcal of Glucerna shake for breakfast
2530846|NCT02691481|Active Comparator|Ultra Glucose Control formula|consuming 200 kcal of Ultra Glucose Control shake for breakfast
2530916|NCT02691065|Experimental|Integrase Inhibitor|Switch from protease inhibitor-based regimen to raltegravir-based regimen
2530917|NCT02691065|No Intervention|Protease inhibitor|Continuation of protease-inhibitor based regimen
3200850|NCT00894907|Experimental|PiCCO-group|Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids according to PiCCO-parameter-guided algorithm
3200851|NCT00894907|Other|2|Control: Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
2531112|NCT02689817|Experimental|Monitoring patch, no display|Participants in this condition will receive a padded bandage that monitors pressure over time. In this arm, healthcare providers will not be able to view the pressure data collected.
2531121|NCT02689414|Experimental|Remote ischaemic preconditioning|Four episodes of 5 minutes of ischaemia are performed. Between all the episodes there is a 5-minute period of reperfusion.
2531122|NCT02689414|Sham Comparator|Control to RIPC|Four episodes of 5 minutes during which the pressure in the cuff is equal to venous pressure are performed. Between all the episodes there is a 5-minute pause.
2531174|NCT02689323|Experimental|Open label|Participants will undergo 5 sessions of active rTMS
3200852|NCT00894920|Placebo Comparator|placebo|
3200853|NCT00894920|Active Comparator|biotin|
2531436|NCT02687373|Experimental|Part 1: Grp 1A - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination."
2531442|NCT02687373|Placebo Comparator|Part 1: Grp 1A - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination."
2531443|NCT02687373|Experimental|Part 1: Grp 1B - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531450|NCT02687373|Placebo Comparator|Part 1: Grp 1B - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 1A dose has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531456|NCT02687373|Experimental|Part 1: Grp 1C - PfSPZ Vaccine|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531459|NCT02687373|Placebo Comparator|Part 1: Grp 1C - Normal Saline|"Children aged 5-9 years (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531460|NCT02687373|Experimental|Part 1: Grp 2A - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
2531463|NCT02687373|Placebo Comparator|Part 1: Grp 2A - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after the 1st dose of Grp 1B has been shown to be well-tolerated and without safety concerns."
2531465|NCT02687373|Experimental|Part 1: Grp 2B - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
2531468|NCT02687373|Placebo Comparator|Part 1: Grp 2B - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2A has been shown to be well-tolerated and without safety concerns."
2531470|NCT02687373|Experimental|Part 1: Grp 2C - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2531512|NCT02687074|Experimental|Intubation rate on 28 days|patients with respiratory failure treat with HFNC or NIV and intubation rate on 28 days
2531539|NCT02686892||Cohort|Incident cases diagnosed with IBD over 12 months in the Spanish territory
3200854|NCT00894946|Experimental|Recurrent IVF implantation failure|
3200855|NCT00894946|Experimental|Endometriosis|
3200856|NCT00894959|Experimental|1|Heparin Sodium Blausiegel 1
3200857|NCT00894959|Experimental|Active Comparator|heparin sodium - APP 5.000 USP
3200858|NCT00894972|Active Comparator|1|General exercise. Participants in this group will perform aerobic exercise, range of motion exercise and general strengthening exercise.
3200859|NCT00894972|Experimental|2|Specific exercise. Participants in this group will perform aerobic exercise, range of motion exercise, and specific motor control exercises.
3200860|NCT00894985|Experimental|1|Heparin 5.000UI
3200861|NCT00894985|Active Comparator|2|Heparin 5.000USP - APP
3200862|NCT00894998|Experimental|1|Heparin sodium 5.000 UI - Cristália
2530805|NCT02691715|Experimental|Endometrial saline plus curettage|5 cc saline infused to the endometrial cavity and aspirated. Then routine endometrial curettage performed for same participant.
2530809|NCT02691715|Active Comparator|Endometrial curettage|Only routine endometrial curettage performed
2530841|NCT02691403|Sham Comparator|Placebo QL block|30 ml single shot QL block with saline 0.9%
2530845|NCT02691403|Active Comparator|Active QL block|30 ml single shot QL block with 0.25% levo-bupivacaine
2530895|NCT02691156||Premature Infants|Premature infants GA 24 to ≤34 wks at risk for hyperbilirubinemia will have BBC, ETCOc, and COHbc measured during 0-7 days of life.
2530973|NCT02690896|Experimental|UCF Behavioral Intervention Group|The intervention group will be the UCF Caregiver Support. Participants will receive a 90 minute group session, once a week, for a period of 6 consecutive weeks.
2530977|NCT02690896|Active Comparator|Community Comparison Group|Comparison group members will come from potential local support groups include, but are not limited to, the support group at the Faith Assembly of God church, the caregiver support group at the First Baptist Church of Orlando, and the caregiver support group at the Alzheimer's and Dementia Resource Center.
2531027|NCT02690428|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2531045|NCT02690064|Experimental|Acute Antioxidant Treatment|Following an overnight fast, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) (post only) will be performed at baseline and 2 hours following either a single dose oral 1) antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) 2) Resveratrol (1500 mg) 3) Mitoquinol (10 mg) or placebo on two days separated by at least 72 hours.
2531049|NCT02690064|Experimental|Chronic Antioxidant Treatment|Following the completion of Arm 1, blood samples, flow-mediated dilation, lung function, and exercise capacity (VO2 peak) will be performed, only in patients with CF, at baseline, 4 weeks, 8 weeks, and 12 weeks following one of the following: 1) an anti-oxidant cocktail (vitamin C 1000 mg, vitamin E 400 IU, and alpha lipoic acid 600 mg) taken once a day, 2) 1500 mg Resveratrol once a day or 3) 10 mg Mitoquinol once a day.
2531114|NCT02689557|Other|measures of the volumes|Measures of the volumes of the lower limbs. A measure to rest, a measure of effort (walk) and a measure recovery. Intervention.
2531155|NCT02689375|Experimental|Patients to receive spinal cord stimulator|
2531177|NCT02689180|Placebo Comparator|Withdraw of furosemide|Withdraw of of 40 or 80 mg of furosemide per day
2531186|NCT02689180|Active Comparator|Maintenance of furosemide|Maintenance of 40 or 80 mg of furosemide per day
2531247|NCT02688725|Experimental|Ultrasound|post mastectomy ultrasound
2531265|NCT02688478|Active Comparator|Filtered air|Exposure for 3 hours to filtered air followed by subject specific inhaled allergen challenge
2531271|NCT02688478|Experimental|Phthalate|Exposure for 3 hours to dibutyl phthalate followed by subject specific inhaled allergen challenge
2531342|NCT02688205||Shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
2531345|NCT02688205||Without shoulder pain group|The participants receive Cyriax's functional examination after history taking, and will be examined by ultrasound in one week.
3200863|NCT00894998|Active Comparator|2|Heparin Sodium 5.000 USP - APP
3200864|NCT00895024||Caregivers|
3200865|NCT00895050||1|Patients diagnosed with RA
3200866|NCT00895063|Experimental|Vocal Exercise|Subject will speak continually for one hour following injection of botulinum toxin.
3200867|NCT00895063|Placebo Comparator|Silence|Subject will remain silent for one hour following injection of botulinum toxin.
3200868|NCT00895076|Experimental|1|dexamethasone iontophoretic patch
3200869|NCT00895076|Active Comparator|2|dexamethasone intramuscular injection
3200870|NCT00895089|Experimental|A: Moxifloxacin|Moxifloxacin 400mg IV once daily for 14 days, then 400mg PO once daily for 7 days.
3200871|NCT00895089|Active Comparator|B: Ceftriaxone|Ceftriaxone 2gm IV every 12 hours for 14 days, then cephalexin 1gm PO every 6 hours for 7 days.
3200872|NCT00895102|Active Comparator|1. ABT-333 Capsule vs ABT-333 Tablet|400mg ABT-333 Tablet, QD, single dose vs eight 50mg ABT-333 Capsules, QD, single dose
3200873|NCT00895102|Active Comparator|2. ABT-333 Tablet|ABT-333 400mg Tablet, QD, single ascending doses (1200mg, 1600mg, 2400mg)
3200874|NCT00895102|Placebo Comparator|3. Placebo|Placebo tablets, QD, single ascending doses
3200875|NCT00895115|Sham Comparator|Arm I|Patients receive no supplementation.
3200876|NCT00895115|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 1 week.
3200877|NCT00895115|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E supplementation once daily for 2 weeks.
3200878|NCT00895128|Experimental|Erlotinib + Dasatinib|Erlotinib starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients. Dasatinib starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
3200879|NCT00895141|Experimental|Low saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 8%E saturated fat
2531677|NCT02685930||Pneumonia without ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Antibiotic choice and duration of therapy will not be influenced by the dedicated ICU stewardship team.
2531693|NCT02685930||Pneumonia with ICU stewardship involvement|Patients receiving >24 hours of invasive mechanical ventilation for pneumonia-related respiratory failure. Recommendations for antibiotic choice and duration of therapy will be provided by the dedicated ICU stewardship team (consisting of pulmonary fellows and ICU pharmacists)
3200880|NCT00895141|Experimental|High saturated fat diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
2531776|NCT02684955||Cerebral spectroscopy + pupillometry|During CPR, rSO2 will be monitored continuously as well as quantitative measurements of the pupillary light reaction every 5 minutes.
2531804|NCT02684799|Experimental|Part 1 Group 1 (Cenicriviroc)|Part 1 Group 1 (12 subjects) will receive CVC 150 mg on Days 1, 7 and 13.
3200881|NCT00895167|Experimental|curcumin|every subject receives 12 g of oral curcumin
2530747|NCT02692144|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
2530750|NCT02692144|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
2530753|NCT02692144|Placebo Comparator|White-bread|47g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
2530789|NCT02691884||Patients before/after Pressure Exertion|100 pregnant patients at term in low risk pregnancies, undergoing a routine cardiotocography, will experience different amounts of manual pressure on their abdomen. The amount of pressure applied will be recorded and the fetal heart rate will be compared before and at the time of maternal abdominal pressure.
2530855|NCT02691585|Experimental|Music intervention group 1|Raga 1 will be given
2530867|NCT02691585|Experimental|Music intervention group 2|Raga 2 will be given
2530868|NCT02691585|Experimental|Music intervention group 3|Raga 3 will be given
2530872|NCT02691585|No Intervention|Control Group 4|No raga. Just collection of electrophysiological parameters will be done.
2530921|NCT02691000|Experimental|Bright White Light (BWL) Litebook|Participants will be instructed to use the BWL Litebook for an hour every day for 8 weeks.
2530922|NCT02691000|Placebo Comparator|Dim Red Light (DRL) Litebook|Participants will be instructed to use the DRL (comparison condition) Litebook for an hour every day for 8 weeks.
3167204|NCT00535106|Active Comparator|Delayed defib|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation. Data is being collected on this population as well, thereby providing a cohort population for comparative purposes.
3167205|NCT00535119|Experimental|Treatment (enzyme inhibitor therapy and chemotherapy)|Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 3 and veliparib PO twice daily on days 1-7 until the recommended phase II dose is determined. Treatment repeats every 3 weeks for at least 6 courses in the absence of disease progression or unacceptable toxicity.
2531002|NCT02690311|Sham Comparator|LED with bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
2531010|NCT02690311|Experimental|LED without bluelight|Two types of smartphone were used. One type had a conventional LED display with the full range of blue light. The LED in the other type newly developed by Samsung Display was suppressed for the blue light portion of the spectrum (wavelength 450 ~ 470 nm). The smartphones were indistinguishable from each other with the naked eye, because other wavelengths mimicked blue light in the suppressed LED.
2531158|NCT02689427|Experimental|Treatment (enzalutamide, paclitaxel)|"Patients receive enzalutamide PO daily on days 1-7 and paclitaxel IV over 2 hours on day 1. Cycles repeat every 7 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: After 12 cycles of therapy, patients undergo surgical resection of primary tumor with or without lymph node biopsy or complete axillary dissection."
2531212|NCT02688972|Experimental|cold water immersion|
2531213|NCT02688972|Other|control|13 volunteers
2531268|NCT02688530|Placebo Comparator|0mg IV Dexamethasone|0mg IV Dexamethasone
2531270|NCT02688530|Experimental|4mg IV Dexamethasone|4mg IV Dexamethasone
2531274|NCT02688530|Experimental|6mg IV Dexamethasone|6mg IV Dexamethasone
2531275|NCT02688530|Experimental|8mg IV Dexamethasone|8mg IV Dexamethasone
2531403|NCT02687698|Experimental|Ketogenic diet|Patients will be suggested to follow a ketogenic diet for 8 weeks.
2531405|NCT02687698|No Intervention|Control|Usual diet.
2531452|NCT02687334||Standard general anesthesia induction|Patients scheduled for elective surgery at the First Hospital of China Medical University will be recruited for the study beginning in February 2016.We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia
2531520|NCT02687048|Active Comparator|EX protocol|Participants will receive a revised version of the Otago exercise program (OEP) - an individualized home-based exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week. The exercises are for strength and balance and are gradually progressed over the course of the study to meet the individual's abilities.
2531523|NCT02687048|Experimental|EX Plus protocol|"These participants will receive mindful meditation coaching via 6 one-hour small group sessions with an experienced meditation instructor. They will also be expected to practice mindful meditation at home following online audio recordings (free of charge from University of California, Los Angeles; http://marc.ucla.edu/body.cfm?id=22) and written instructions a minimum of five times per week for 30 minutes. Participants will complete a meditation log to record their practice.~These participants will also receive the same revised version of the Otago exercise program; a trained physiotherapist will make 5 home visits throughout the 12-week intervention. The participants will be expected to complete the home exercises as prescribed three times per week."
2531605|NCT02686554||AD patients|
2531606|NCT02686554||AD patients immunized|
2531639|NCT02686190|Experimental|Luxtherapy|Luxtherapy exposition
3167206|NCT00535197|Experimental|CD34+ stem/progenitor cell therapy|Patients presenting within 7 days of onset with severe anterior circulation ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score≥8). CD34+ cells were collected from the bone marrow of the subjects before being delivered by catheter angiography into the ipsilesional middle cerebral artery.
3167207|NCT00535210|Other|1|
3167208|NCT00535210|Other|2|
3167209|NCT00535275|Experimental|A|
3167210|NCT00535275|Active Comparator|B|Docetaxel monotherapy
3167211|NCT00535314|Experimental|RTA 402 Dose1|Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
3167212|NCT00535314|Experimental|RTA 402 Dose2|Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
3167213|NCT00535366|Experimental|Tiotropium+salmeterol+fluticasone|
3167214|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide low|
3167215|NCT00535366|Experimental|Tiotropium+salmeterol+ciclesonide high|
2530784|NCT02692001|No Intervention|Current MealTrain menu|This is the current menu being employed for food ordering in the pediatric inpatient wards.
2530788|NCT02692001|Experimental|Intervention MealTrain menu|The intervention menu included child-friendly labeling (attractive characters, fun food names and traffic light system) to encourage healthier choices.
2530812|NCT02691598|Experimental|Group A|Dexmedetomidine Hydrochloride 4ug/ml；0.05ml/kg.h infusion for 24hours
2530815|NCT02691598|Placebo Comparator|Group B|Normal Saline 0.05ml/kg.h infusion for 24hours
2530852|NCT02691286||Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI complicated with cardiogenic shock
2530862|NCT02691286||No Cardiogenic Shock STEMI|Patients admitted to the hospital with the diagnosis with STEMI without cardiogenic shock
2530899|NCT02691117|Experimental|Garlic concentrate|Garlic gel concentrate- once a day topical application
2530972|NCT02690857|Experimental|Docosahexaenoic acid|"Each capsule of DHA contains 100 mg DHA in triglycerides from algal oil, 0.125 mg alpha-tocopherol and 0.125 mg ascorbic acid.~Subjects receive an orally and daily ingestion of DHA capsules (5mg/kg for 15 days followed by 10 mg/kg for another 15 days without interruption between the 2 periods)."
2530974|NCT02690857|Placebo Comparator|Sunflower oil|Placebo capsules contain the same quantities of antioxidants and triglycerides of sunflower oil. Subjects receive an orally and daily ingestion of placebo capsules for 28 days.
2531022|NCT02690480|Experimental|PD-0332991(Palbociclib)+fulvestrant(FaslodexTM)|Fulvestrant 500mg, on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
2531023|NCT02690480|Active Comparator|Placebo+fulvestrant(FaslodexTM)|Fulvestrant 500mg on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days) in combination with Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
2531134|NCT02689778|Experimental|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg with dinner for 12 months.
2531138|NCT02689778|Placebo Comparator|Placebo|Oral placebo with breakfast and with dinner for 12 months.
2531180|NCT02689258|Experimental|Part A Cohort A|200 mg of HTX-011A by infiltration
2531192|NCT02689258|Placebo Comparator|Part A Cohort B|Saline Solution by infiltration
2531200|NCT02689258|Experimental|Part A Cohort C|200 mg of HTX-011B by infiltration
2531203|NCT02689258|Experimental|Part A Cohort D|400 mg of HTX-011B by infiltration
2531205|NCT02689258|Experimental|Part A Cohort E|600 mg of HTX-011B by infiltration
2531207|NCT02689258|Experimental|Part B Cohort A|Subjects will be enrolled in Part B following completion of enrollment in Part A to evaluate HTX-011 and HTX-002, with or without saline solution.
2531209|NCT02689258|Experimental|Part C Cohort A|Subjects will be enrolled in Part C following completion of Part B to evaluate 400 mg HTX-011B via instillation, bupivacaine HCl 100 mg via injection and saline placebo via injection
2531210|NCT02689258|Experimental|Part D Cohort A|Up to 300 mg of HTX-011B
2531211|NCT02689258|Placebo Comparator|Part D Cohort B|Saline Solution
3167216|NCT00535366|Placebo Comparator|Placebo|
3167217|NCT00535379|Experimental|1|
2531389|NCT02687841|Experimental|AST-120 and PTX|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days Pentapentoxifylline 400mg QD for 10 days
2531392|NCT02687841|Active Comparator|PTX|Pentapentoxifylline 400mg QD for 10 days
3167218|NCT00535418|Experimental|Letrozole|
3167219|NCT00535431|Experimental|A|AER 001
2531509|NCT02686944|Experimental|Intuvax (ilixadencel)|"Intuvax (ilixadencel) will be administered 2 or 3 times. First injection Day 1 (pat 1-12), second injection 14 days after the first vaccination (pat 1-12), third injection 28 days after the second vaccination (only pat 7-12).~Max 10 000 000 allogeneic dendritic cells/ml per injection."
2531668|NCT02686021|Experimental|Metamizole and Ibuprofen|all patients (n=42) will receive metamizol and ibuprofen in one session. In the other session half will receive metamizol and placebo (n=21) and the other half will receive ibuprofen and placebo. The order will be randomized (balanced).
2531678|NCT02686021|Active Comparator|Metamizole and Placebo|"This is one of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
2531690|NCT02686021|Active Comparator|Ibuprofen and Placebo|"This is the second of the two comparators for the Arm Metamizol and Ibuprofen. n=21"
2531725|NCT02685384||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
3167220|NCT00535431|Placebo Comparator|P|sterile saline
3167221|NCT00535444|Active Comparator|Control|assisted appointment with physician
3167222|NCT00535457|Experimental|1|"Children will watch tricks (magic) before anesthesia induction"
3167223|NCT00535470|Experimental|1|Open label 0.04% Mechlorethamine gel
3167224|NCT00535522|Experimental|TAK-285|
3167225|NCT00535561|Active Comparator|1|Oral iron treatment only- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
3167226|NCT00535561|Active Comparator|2|Oral iron plus levothyroxine treatment- for iron deficiency anemia and subclinical hypothyroidism coexisting patients
3167227|NCT00535574|Placebo Comparator|Bexarotene (Targretin LGD1069)|
3167228|NCT00535574|Active Comparator|placebo|
3167229|NCT00535665|Experimental|1: 10 ug, 14 days|
3167230|NCT00535665|Experimental|2: 5 ug, 28 days|
3167231|NCT00535665|Experimental|3: 10 ug, 28 days|
3167232|NCT00535665|Experimental|4: 15 ug, 28days|
3167233|NCT00535691|Active Comparator|1|Tacrolimus ointment 0.03% once daily, placebo once daily
3167234|NCT00535691|Active Comparator|2|Tacrolimus ointment 0.03% twice daily
3167235|NCT00535704|Experimental|1|The Strong AFrican American FAmilies-Teen program is a five part educational program has been designed to help teens and their parents create successful futures and avoid the risky behaviors that sometimes keep teens from reaching their goals.
3167236|NCT00535704|Other|2|The FUEL program is a family-based adaptation of a curriculum designed to assist teens to develop lifestyles that prevent health problems such as heart disease, diabetes, and being overweight. This program deals with diet and exercise, the influence of TV and magazines on eating habits, and handling stress.
3167237|NCT00535756|Experimental|1|
2530817|NCT02691650||polytrauma patients|Patients with severe traumatic injury, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
2530819|NCT02691650||burns patients|Patients with burns trauma, admitted to the emergency unit. Serum cholinesterase activity measurement using 10 µl whole blood, otherwise obtained through routine blood gas analysis upon arrival to the hospital.
2530863|NCT02691351||non-Hodgkin T-cell Lymphoma|
2530897|NCT02691104|Experimental|Intervention|"Use of the app and Fitbit alongside 5-7 week pulmonary rehabilitation programme (plus goal-setting help from physiotherapist), and then app and Fitbit plus intermittent contact with physiotherapist for 8 weeks after pulmonary rehabilitation~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
2530898|NCT02691104|Other|Control|"Attend 5-7 week pulmonary rehabilitation programme (usual care) and wear blinded Fitbit during pulmonary rehabilitation and for 8 weeks afterwards~NB Randomisation is being deployed to test the practicality / acceptability of randomising for a larger RCT. It is not being used to assess the efficacy of the intervention in the current study"
2530979|NCT02690792|Placebo Comparator|NAFLD/NASH - Placebo|"In NAFLD/NASH Group: Identically appearing Placebo capsules given as double-blinded, randomized intervention as a comparator to Vitamin E intervention.~Dosage: Placebo capsules. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
2530980|NCT02690792|Active Comparator|NAFLD/NASH - Vitamin E|"In NAFLD/NASH Group: Vitamin E capsules given as double-blinded, randomized intervention as a comparator to Placebo capsules intervention.~Dosage: Vitamin E 200 IU/capsule. Two capsules by mouth each morning and two capsules by mouth each evening for 4 months."
2531007|NCT02690402|Experimental|adapted physical activity|a personalized care will be offered in terms of adapted physical activity
2531054|NCT02690142|Experimental|ABY-035 i.v.|Part A: SAD (single ascending dose) including five different dose cohorts. ABY-035 given as intravenous injections. 6 ABY-035 and 2 placebo in each cohort.
2531058|NCT02690142|Experimental|ABY-035 s.c.|Part B: Bioavailability study where 6 subjects will receive ABY-035 as a single subcutaneous injection.
2531063|NCT02690142|Experimental|ABY-035 i.v. in psoriasis patients|Part C: Up to 12 psoriasis patients will receive ABY-035 as a single intravenous injection.
2531068|NCT02690142|Experimental|ABY-035 s.c. in psoriasis patients|Part D: Up to 18 patients will receive 3 or 7 biweekly doses of ABY-035 as s.c. injections
2531148|NCT02689583|Experimental|Successful treatment|The patients with H. pylori infection have successful treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
2531153|NCT02689583|Experimental|refractory infection|The patients with H. pylori infection have failed treatment based on the results from antibiotic susceptibility testing，CYP2C19 gene polymorphism，drug resistance gene sequencing and 16SrRNA sequencing.
2531282|NCT02688595|Experimental|Seldinger|Use a 23 gauge introducer needle for ultrasound-guided central venous catheterization
2531286|NCT02688595|Experimental|Modified Seldinger|Use a 22 gauge Angiocath Plus catheter for ultrasound-guided central venous catheterization
2531318|NCT02688140|Experimental|Arm A|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1 and 3, oral tretinoin twice daily on day 1-28 (max. up to day 60) and arsenic trioxide i.v. over 2 hours on day 5-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation therapy: Patients receive oral tretinoin twice daily on day 1-14. Treatment with tretinoin repeats every 4 weeks for up to 7 courses. Patients also receive arsenic trioxide i.v. over 2 hours on days 1-5 in week 1-4. Treatment with arsenic trioxide repeats every 8 weeks for up to 4 courses."
2531328|NCT02688140|Active Comparator|Arm B (standard chemotherapy)|"Induction therapy: Patients receive idarubicin i.v. over 20 minutes on day 1,3,5 and 7, oral tretinoin twice daily on day 1-28 (max. up to day 60).~In case of morphological CR and regenerated blood counts, consolidation therapy should be started within 2-4 weeks after documented CR.~Consolidation I:~IDA 5 mg/m2 i.v. day 1-4 Ara-C 1000 mg/m2/3h i.v. day 1-4 ATRA 45 mg/m2 p.o. day 1-15~Consolidation II:~MTZ 10 mg/m2 i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Consolidation III:~IDA 12 mg/m2 i.v. day 1 Ara-C 150 mg/m2 every 8h i.v. day 1-5 ATRA 45 mg/m2 p.o. day 1-15~Maintenance (duration 7 cycles = 2 years; one cycle lasts 106 days):~6-MP 50 mg/m2 p.o. Cycle 1-7: day 1-91 (followed by 15 days of ATRA on days 92-106)~MTX 15mg/m2 i.m./p.o. Cycle 1-7: once weekly for 91 days (followed by 15 days of ATRA on days 92-106)~ATRA 45 mg/m2 p.o. Cycle 1-6: day 92-106 Cycle 7: without ATRA Administration~(treatment break of 6-MP and MTX during ATRA administration)"
2531384|NCT02687724|Active Comparator|Standard treatment as per SmPC|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. They will then receive 100mgs/ 50mgs depending on their weight as per SmPC. Patients will report their modified partial mayo score and SHS score every 4 weeks (PRO) and provide it to the investigator site via a web based application.
2531387|NCT02687724|Experimental|Intervention Arm|Patients will receive standard loading dose of GLM of 200/100 mgs at WKS 0 & 2. As with Group 1, Patients will report their modified partial mayo and SHS score every four weeks ( the window for this will be +/- one week) and provide it to the investigator site via a web based application. In addition FCP, GLM DL and ADA shall be measured every four weeks.
3167238|NCT00535756|Placebo Comparator|2|
3167239|NCT00535795|Active Comparator|1|Conventional Radiation Therapy (XRT), one fraction per day, from Sunday to Thursday every week.
3167240|NCT00535795|Experimental|2|Conventional Plus accelerated boost Radiation Therapy (XRT), from Sunday to Thursday every week.
3167241|NCT00535808|Experimental|1|Administration of nitroprusside
3167242|NCT00535808|Experimental|2|Administration of nitroglycerine
3167243|NCT00535808|Experimental|3|Administration of sevoflurane
3167244|NCT00535860|Experimental|50 mcg|ViaDerm transdermal delivery
3167245|NCT00535860|Experimental|80 mcg|Add Via-Derm transdermal delivery
3167246|NCT00535860|Active Comparator|20 mcg|Subcutaneous injection
3167247|NCT00535886|Active Comparator|Elaidic Acid|
3167248|NCT00535886|Experimental|Vaccenic Acid|
3167249|NCT00535886|Placebo Comparator|Oleic Acid|
2530833|NCT02691559|Active Comparator|normal pregnancy group|Amniotic fluid analysis by blood gas device: The control group will consist of infants born to mothers without infection/inflammation. In all deliveries amniotic fluid will be taken and will be analyzed by blood gas device.
2530901|NCT02691195|Placebo Comparator|group control|group control :Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
2530904|NCT02691195|Experimental|group SPB|group SPB:Before induction of intravenous anesthesia, patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
2530965|NCT02690766|Other|Physical Activity Group|The Success Study's Standard Behavioral Weight Change Intervention consists of 75 minute group sessions held monthly which include 30 minutes of physical activity with a licensed Physical Activity Instructor. Web Lessons that include information on Physical Activity, Nutrition and Healthy Behaviors will also be provided to participants on the study's website.
3167250|NCT00535912|No Intervention|A|¨Chemotherapy by 12 courses of CHOP
2531091|NCT02689843|Active Comparator|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone acetate 2mg+Ethinyl estradiol 35 mcg) once daily + Spironolactone 50 mg twice daily
2531093|NCT02689843|Active Comparator|Metformin|Metformin 1500 mg daily
2531094|NCT02689843|Active Comparator|Pioglitazone|Pioglitazone 30 mg daily
2531166|NCT02688998|Active Comparator|Venous access PORT or PICC|Participants will receive a central line placement either a PORT or a PICC prior to the initiation of chemotherapy.
2531170|NCT02688998|No Intervention|No intervention|Participants will only receive a central line if required once chemotherapy has been initiated.
2531280|NCT02688439|Active Comparator|Leg in a neutral position|Sciatic nerve block, with leg kept in a neutral position after anesthesia (control group)
2531288|NCT02688439|Experimental|Leg raised 30°|Sciatic nerve block, with leg raised 30° by placing the back of the foot over a support placed on the OR table and maintained in that position for 15 min
2531289|NCT02688439|Experimental|Distal tourniquet placed on the lower part of the leg|Sciatic nerve block, and distal tourniquet placed on the lower part of the leg (upper part of the tourniquet being about 4-6 inches from the ankle) with the leg in a neutral position.
2531336|NCT02688088|Active Comparator|Drug Cocktail|Single dose of drug cocktail (caffeine, warfarin, dextromethorphan, and midazolam) administered orally on Day 1 of Period 1.
2531339|NCT02688088|Experimental|Abemaciclib + Drug Cocktail|Abemaciclib administered orally every 12 hours on Days 1 - 12 of Period 2 with a single dose of drug cocktail administered orally on Day 8 of Period 2.
2531341|NCT02688088|Experimental|Abemaciclib - Period 3|Abemaciclib administered orally every 12 hours on Days 13 to 28 of Period 3. Participants may continue to receive abemaciclib until discontinuation criteria are met.
2531346|NCT02688088|Experimental|Abemaciclib - Period 4|Abemaciclib administered orally every 12 hours on Days 1 to 28 of Period 4. Participants may continue to receive abemaciclib until discontinuation criteria are met.
2531363|NCT02687802||Mechanical ventilation|Patients under mechanical ventilation for more than 24h
2531411|NCT02687620||AS patients receiving Anti-TNF treatment|Three hundred and fifty consecutive AS patients fulfilling the modified New York criteria for the classification of AS (5), and with a new anti-TNF agent prescription (either for the first time or switched) in the last two weeks period will be included. Treatment with anti-TNF agents will be in accordance with the regulations of Turkish Social Security Agency (SGK) on the initiation and continuation of anti-TNF agents in AS, as well as ASAS/EULAR recommendations for the management of AS (29, 30).
2531469|NCT02687230|Experimental|Cohort 1|Subjects receive 3 mg of MVT-2163 without the addition of prior MVT-5873.
2531472|NCT02687230|Experimental|Cohort 2|Subjects receive 17 mg of MVT-5873 followed by 3 mg of MVT-2163.
2531474|NCT02687230|Experimental|Cohort 3|Subjects receive 47 mg of MVT-5873 followed by 3 mg of MVT-2163.
2531527|NCT02686905|Experimental|Topical vitamin patch|Dietary Supplement: PatchMD Vitamin D3/Calcium Patch Dietary Supplement: PatchMD Multivitamin Patch Dietary Supplement: PatchMD B12 Energy Plus Patch
2531528|NCT02686905|Experimental|Oral vitamins|Dietary Supplement: Chewable Multivitamin with Iron Dietary Supplement: Chewable Calcium Dietary Supplement: Quick Dissolve B12
2531572|NCT02686528|Experimental|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
2531580|NCT02686528|Active Comparator|Hip Precautions|Patients will receive the following hip precautions: no hip flexion past 90º, no crossing the legs, and no twisting at the waist for the first six weeks after surgery.
2531696|NCT02685683|Experimental|GED-0301 Induction (160mg) followed by intermittent 160 mg|"GED-0301 160 mg by mouth (PO) daily (QD) for 12 weeks, followed by alternating GED 0301 160 mg QD for 4 weeks and no IP for 4 week, up to Week 100"
3167251|NCT00535912|Active Comparator|B|¨Chemotherapy by 3 courses of CHOP, intensification and autograft
3167252|NCT00535951|Experimental|LBH589|
3167253|NCT00535964||1|Psychologically healthy adolescents, evenly divided across the various stages of smoking uptake
3167254|NCT00535977|Experimental|1|Dietary intervention of ITC-enriched broccoli
3167255|NCT00535977|Experimental|2|Dietary intervention of frozen peas
3167256|NCT00536003|Experimental|1|
3200882|NCT00895206|Experimental|1|individual adapted immunosuppression
3200883|NCT00895206|Active Comparator|2|golden standard therapy
2530968|NCT02690831|Active Comparator|Inspiratory Muscle training (IMT)|"The IMT program consisted of supervised and domiciliary exercises:~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 6 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 50% MIP~Fifth week: 60% MIP~Sixth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen."
2530970|NCT02690831|Experimental|IMT + Manual Therapy and Motor Control Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thrust dorsal~Cervical postero-anterior mobilization~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
2531013|NCT02690441|Experimental|CBT augmented with physical exercise|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of physical exercise pre-treatment, and 10 weeks of physical exercise alongside CBT. Both treatment and physical exercise is administered individually.
2531018|NCT02690441|Active Comparator|CBT and placebo control|Patients receive 10 sessions of cognitive behavioural therapy for generalized anxiety disorder. Patients also receive 5 weeks of placebo control (15 minutes telephone follow-up call each week) pre-treatment, and 10 weeks of attention placebo alongside CBT. Both treatment and placebo control is administered individually.
3200884|NCT00895219|Active Comparator|1|Breathing re-training
3200885|NCT00895219|Active Comparator|2|Breathing re-training and musculoskeletal physiotherapy techniques
3200886|NCT00895258|Experimental|IPS-CT|Participants will receive individual placement and support (IPS) plus cognitive training (CT).
3200887|NCT00895258|Active Comparator|IPS-ES|Participants will receive individual placement and support (IPS) plus enhanced support (ES).
2531163|NCT02689401|Experimental|Ferumoxtyol (Feraheme) with MRI|Patients will undergo a pre-contrast MRI followed by a pre determined dose of of IV Ferumoxyto. Post-contrast MRI imaging will be performed immediately following Ferumoxytol infusion and 48 hours after Ferumoxytol administration with subsequent image analysis.
2531198|NCT02689037|Experimental|stenting+medical treatment|Patients in PTAS+MT group will receive Percutaneous transluminal angioplasty and stenting and medical treatment (aspirin 100mg daily and clopidogrel 75mg daily)
2531201|NCT02689037|Active Comparator|Aspirin plus clopidogrel|Patients in aspirin plus clopidogrel group will receive aspirin 100mg daily and clopidogrel 75mg daily for 90 days.
2531235|NCT02688738|No Intervention|Control|Standard of care
2531237|NCT02688738|Active Comparator|Treatment|Oral doxycycline
2531272|NCT02688634||Treatment|Participants in this group are randomize to receive post-operative antibiotic of Amoxicillin x7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
2531273|NCT02688634||Non-Treatment|Participants in this group will be randomize to no post-operative antibiotic. They will be evaluated for infection, fistula formation, and dehiscence upon discharge and at 30-day follow-up based on standards of care.
2531364|NCT02688049|Experimental|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients receive NeuroRegen scaffold with mesenchymal stem cells transplantation after spinal cord injury.
2531365|NCT02688049|Experimental|NeuroRegen scaffold/neural stem cells transplantation|Patients receive NeuroRegen scaffold with neural stem cells transplantation after spinal cord injury.
2531430|NCT02687594||single group|sucroferric oxyhydroxide
3200888|NCT00895349|Experimental|1|CT Abdomen and Pelvis + whole body PET-CT
3200889|NCT00895349|Active Comparator|2|CT Abdomen and Pelvis
3200890|NCT00895362|Experimental|Erlotinib + Cetuximab|Erlotinib in Combination with Cetuximab
3200891|NCT00895375||Psoriasis patients|40 subjects (male or female) age 18 or older with psoriasis covering >10% BSA and without a diagnosis of depression.
3200892|NCT00895375||Patients without psoriasis|40 subjects without psoriasis matched for age, sex and BMI, as a control population.
2531798|NCT02684812|Active Comparator|Tranexamic Acid|Eligible subjects are randomly assigned to immediate administration of TXA (1 g i.v.) after a diagnosis of SAH, as confirmed by CT-scan of the brain, continued by continuous infusion of 1 g per 8 hours to a maximum of 24 hours after start of medication. A maximum of 4 g TXA (1 g bolus + 3x 1 g continuous infusion) can be administered to one patient.
2531799|NCT02684812|No Intervention|Control|Standard care
2531876|NCT02684682|Other|12h Group|Intervention 'Frequency of mechanical control of plaque (12h)'
3200893|NCT00895388|Other|Structured Rehabilitation program|
3200894|NCT00895388|No Intervention|Controls|
3200895|NCT00895401|Active Comparator|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
3200896|NCT00895401|Experimental|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available nutritional supplement designed to meet the nutritional needs of malnourished hemodialysis patients. The serving size is 8 oz which provides 425 kcal and 19 g protein
3200897|NCT00895427||1|Male ages 45-54, without diabetes, CAC score from 0 to >1000
3200898|NCT00895427||2|Male ages 55-64, without diabetes, CAC score from 0 to >1000
3200899|NCT00895427||3|Male ages 65+, without diabetes, CAC score from 0 to >1000
3200900|NCT00895427||4|Male ages 45-54, with diabetes and CAC score from 0 to >1000
3200901|NCT00895427||5|Male ages 55-64, with diabetes, CAC score from 0 to >1000
3200902|NCT00895427||6|Male ages 65+, with diabetes, CAC score from 0 to >1000
2531050|NCT02690103|Active Comparator|Group 1|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
2531055|NCT02690103|Experimental|Group 2|Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.
2531102|NCT02689739||Obese Pregnant cohort|Women will be consented to participate and then separated into a study group of obese women (BMI >/= 30).
2531104|NCT02689739||Non-obese Pregnant cohort|This will be the control group of non-obese women (BMI <30).
2531149|NCT02689453|Experimental|1A|IL-15 for 10 doses over two weeks followed byalemtuzumab for 4 weeks per dosing schema to determine the maximum tolerated dose (MTD)
2531154|NCT02689453|Experimental|1B|IL-15 for 10 doses over two weeks followed by alemtuzumab for 4 weeks at the maximum tolerateddose (MTD)
2531165|NCT02689115||Clinical activity|Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
2531168|NCT02689115||Clinical remission|Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
2531277|NCT02688543|Experimental|RF treatment|Patients treated with radio frequency of the genicular nerves
2531440|NCT02687425|Experimental|pioglitazone|The patients under the long-term treatment of imatinib mesylate acquire pioglitazone additionally.
2531513|NCT02687022|Experimental|Myopia (Peramis)|Peramis aberrometry: 30 consecutive LASIK candidates with myopia and regular astigmatism who agree to participate in the study will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer.
2531514|NCT02687022|Active Comparator|Myopia (iDesign)|iDesign aberrometry: The same 30 consecutive LASIK candidates scanned in the Myopia (Peramis) arm will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
2531515|NCT02687022|Experimental|Irregular astigmatism (Peramis)|Peramis aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will have up to 4 aberrometry scans acquired consecutively using the Peramis (test) aberrometer
2531516|NCT02687022|Active Comparator|Irregular astigmatism (iDesign)|iDesign aberrometry: 30 consecutive cases with stage II-III keratoconus or post corneal transplantation cases with irregular astigmatism will also have up to 4 aberrometry scans acquired consecutively using the iDesign aberrometer (control) aberrometer. The order of scans (Peramis and iDesign) will be randomised.
2531581|NCT02686684||Dimethyl Fumarate|MS patients who started treatment with dimethyl fumarate
2531585|NCT02686684||Healthy Control|
2531618|NCT02686411||Participant in Palliative Care Unit (PCU)|"Participants complete 2 questionnaires after being transferred to the PCU.~Two (2) weekdays after completion of first set of questionnaires, 2 more questionnaires completed."
2531619|NCT02686411||Caregiver of Participant in Palliative Care Unit (PCU)|"Caregiver of participant complete 2 questionnaires after participant transferred to the PCU.~Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed."
2531669|NCT02685631||Observational/data registry collection|Patients receiving Yttrium-90 resin microspheres as part of care
2531767|NCT02685241||General population|General population
2531807|NCT02685020|Experimental|Group 1A|Participants will receive Ad26.Mos.HIV vaccine at Week 0 and 12; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 microgram (mcg) of total protein mixed with adjuvant (aluminum phosphate) at Week 24 and 48.
2531810|NCT02685020|Placebo Comparator|Group 1B|Participants will receive placebo at weeks 0, 12, 24 and 48.
2531818|NCT02685020|Experimental|Group 2A|Participants will receive Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 0, 12 and 24.
2531820|NCT02685020|Placebo Comparator|Group 2B|Participants will receive placebo at weeks 0, 12 and 24.
2531822|NCT02685020|Experimental|Group 3A|Participants will receive Ad26.Mos.HIV vaccine at Week 0; followed by Ad26.Mos.HIV vaccine + Clade C glycoprotein 140 vaccine containing 250 mcg of total protein mixed with adjuvant (aluminum phosphate) at Week 8 and 24.
2531824|NCT02685020|Placebo Comparator|Group 3B|Participants will receive placebo at weeks 0, 8 and 24.
2531897|NCT02684448||Robotic-Assisted Inguinal Hernia Repair|Subjects who have undergone robotic-assisted (da Vinci) inguinal hernia repair from the initiation of robotic-assisted hernia repair at site through December 2015.
2531905|NCT02684448||Open Inguinal Hernia Repair|Subjects who have undergone open inguinal hernia repair from the day prior to initiation of robotic-assisted hernia repair through 5 years prior to initiation.
2531932|NCT02684149|Experimental|A|Relational touch before the first arterial puncture and the second arterial puncture without relational touch
2531933|NCT02684149|Experimental|B|First arterial puncture without relational touch and relational touch before the second arterial puncture
2532060|NCT02683356|Active Comparator|OCT-guided PCI|OCT before and after Stent implantation
2532061|NCT02683356|Active Comparator|Angiography-guided PCI|OCT after Stent implantation
3167257|NCT00536003|Placebo Comparator|2|
3167258|NCT00536029||A|Subject with pigmented skin lesion suspect for malignant melanoma
3167259|NCT00536042|Experimental|minocycline|addition of minocycline to standard asthma care as add-on therapy: 150 mg bid to 250 mg bid for up to one year
3167260|NCT00536068|Experimental|1, 2, 3, 4|"acetylsalicylic acid 100 mg/po,acetaminophen 3x1g/po~acetylsalicylic acid 100 mg/po,diclofenac 3x50mg/po~acetylsalicylic acid 100 mg/po,naproxen 3x250mg/po~acetylsalicylic acid 100 mg/po,placebo 3x1/po"
3167261|NCT00536081|Active Comparator|A|Pegfilgrastim during all 6 cycles of chemotherapy
3167262|NCT00536081|Experimental|B|Pegfilgrastim during the first two cycles of chemotherapy
3167263|NCT00536094|Experimental|1|Participants will receive cognitive behavioral therapy for anxiety that includes exposure
3167264|NCT00536094|Active Comparator|2|Participants will receive treatment as usual as delivered by school-based clinicians
2531075|NCT02690012|Active Comparator|Drug Magnesium oxide|Participants will be given standard dose levels of Magnesium oxide according to the level of magnesium in blood.
2531081|NCT02690012|Active Comparator|Drug Magnesium citrate|Participants will be given standard dose levels of Magnesium citrate according to the level of magnesium in blood.
2531144|NCT02689570||type 1 diabetic patients|Adult T1DM patients, aged 18-75 years, regularly attending the out-patient diabetes clinic of the Antwerp University Hospital are recruited starting from June 2011. Patients had to have a diabetes duration of ≥5 years and be in general good health to be included. Exclusion criteria were a history of a major adverse cardiovascular event (myocardial infarction, stroke), other cardiovascular complaints, pregnancy or a glomerular filtration rate ≤30 ml/min/1.73 m2.
2531167|NCT02689141|Experimental|Bendamustine + Ofatumumab + Ibrutinib|Bendamustine: 70mg/m² i.v. Ofatumumab: 1000 mg i.v. Ibrutinib: 420 mg po
3200903|NCT00895427||7|Female ages 50-59, without diabetes, CAC score from 0 to >1000
2531309|NCT02688244|Active Comparator|Irrigation|Irrigation of the area with at least 300ml normal saline using the power suction/irrigator
2531323|NCT02688244|Active Comparator|No irrigation|Only suction with the power suction/irrigator without saline attached
2531373|NCT02687893|Experimental|Aerobic Exercise Week|Subjects will complete 45 minutes of aerobic exercise twice during a 7 day period. Exercise will be graded based on the participant's relative capacity determined at the screening visit. Each exercise session will be followed by 60 minutes of monitored resting recovery.
2531383|NCT02687893|Experimental|Resistance Exercise Week|Subjects will complete 45 minutes of anaerobic exercise twice during a 7 day period. Each exercise session will be followed by 60 minutes of monitored resting recovery.
2531388|NCT02687893|No Intervention|No Exercise Week|Subjects will perform no exercise during this week.
2531420|NCT02687477|Sham Comparator|Sham procedure|Patients in the sham group will take sham procedure like PADN.
2531423|NCT02687477|Experimental|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
3200904|NCT00895427||8|Females ages 60-69, without diabetes and CAC score from 0 to >1000
2531623|NCT02686255||Children 0-18 months post heart surgery|complete blood count for all children 0-18 months going through cardiac surgery
3200905|NCT00895427||9|Females ages 70 +, without diabetes, CAC score from 0 to >1000
3200906|NCT00895427||10|Female ages 50- 59, with diabetes, CAC score from 0 to >1000
2531826|NCT02684929|Experimental|vegan|Vegan subjects interveinted with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
2531837|NCT02684929|Active Comparator|omnivor|Omnivorous subjects iterveined with oral capsules of BCAA, 15 (women) or 20 (men) grams daily for 3 months
2531879|NCT02684539|Experimental|tilt table Erigo®|observation of physiological parameters, tilting table with onset of syncope
2531916|NCT02684292|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 3-week cycle for up to 35 cycles.
2531918|NCT02684292|Active Comparator|Brentuximab vedotin|Participants receive BV 1.8 mg/kg (maximum 180 mg per dose) IV on Day 1 of each 3-week cycle for up to 35 cycles.
2531952|NCT02683980|Experimental|Ablation of the prostate|ablation of the prostate will be performed using the study device: Lumenis Pulse P120H Holmium Laser
2531995|NCT02683850|Experimental|Omega-3 SPM|"Intervention: Study participants will be instructed to take 3 Omega-3 SPM™ softgel supplements in the morning and 3 Omega-3 SPM™ soft gel supplements in the evening for two weeks.~At weeks two participants whose PROMIS-43 Pain Intensity score indicates a reduction in pain levels weeks, will take 2 Omega-3 SPM™ soft gel supplements in the morning and 2 in the evening for the remaining 2 weeks of the study.~Participants whose PROMIS-43 Pain Intensity score remained the same after two weeks, or increased will take 4 Omega-3 SPM™ soft gel supplements in the morning and 4 SPM™ softgels in the evening for the remaining two weeks of the study."
2532025|NCT02683655|Experimental|Apatinib 500mg qd p.o.|Apatinib Mesylate Tablets 500 mg qd p.o. after the failure of chemotherapy or radiotherapy
2532028|NCT02683655|Experimental|Apatinib 750mg qd p.o.|Apatinib Mesylate Tablets 750 mg qd p.o. after the failure of chemotherapy or radiotherapy
2532064|NCT02683369|Experimental|Iron Supplement|Participants will consume one tablet of Blood Builder®/Iron Response®, once per day, every day, for 8 weeks.
2532106|NCT02683005|Experimental|Ledipasvir/Sofosbuvir|Hepatitis C treatment will be initiated with ledipasvir (400 mg) and sofosbuvir (90mg) fixed dose combination, one pill, once daily for 12 weeks.
2532145|NCT02682745|Experimental|R-T1-T2|First period: administration of reference drug, Second period: administration of test drug l, Third period : administration of test drug ll
2532146|NCT02682745|Experimental|R-T2-T1|First period : administration of reference drug, Second period : administration of test drug ll, Third period : administration of test drug l
2532147|NCT02682745|Experimental|T1-T2-R|First period : administration of test drug l, Second period : administration of test drug ll, Third period : administration of reference drug
2532148|NCT02682745|Experimental|T1-R-T2|First period : administration of test drug l, Second period : administration of reference drug, Third period : administration of test drug ll
2532150|NCT02682745|Experimental|T2-R-T1|First period : administration of test drug ll, Second period : administration of reference drug, Third period : administration of test drug l
2532152|NCT02682745|Experimental|T2-T1-R|First period : administration of test drug ll, Second period : administration of test drug l, Third period : administration of reference drug
2532212|NCT02682446||Negative H. pylori group|The participants revealed negative findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
3200907|NCT00895427||11|Female ages 60-69, with diabetes, CAC score from 0 to >1000
3200908|NCT00895427||12|Female age 70+, with diabetes, CAC score from 0 to >1000
3200909|NCT00895440||1|Diabetic patients without neuropathy
3200910|NCT00895440||2|Diabetic patients with painless neuropathy
2531082|NCT02689921|Experimental|Neoadjuvant Biological Therapy|"Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).~Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).~Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)"
2531147|NCT02689505|Experimental|BI 836880|
2531164|NCT02689193||Salmonella|Patients for whom blood cultures grew Salmonella species.
2531169|NCT02689193||No pathogen|Patients for whom blood cultures did not grow a pathogen and no pathogen was detected using other routine care diagnostics (e.g. malaria with the use of a malaria rapid test).
2531171|NCT02689193||Another pathogen|Patients for whom blood cultures grew with another pathogen or a pathogen was detected using other routine care diagnostics (e.g. malaria with the use of malaria rapid test).
2531173|NCT02689193||Healthy controls|Healthy controls. Patients without fever but from whom blood is drawn for another reason (e.g. check of cholesterol).
2531261|NCT02688582|Experimental|TCI group|Patients who receive cefepime based on TCI for a maximum of 5 days with a target concentration of cefepime of 16 mg/L.
2531305|NCT02688361|Experimental|Fluimucil® (reference) then Acetylcysteine (test) 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Acetylcysteine (test).
2531316|NCT02688361|Experimental|Acetylcysteine (test) 2% solution then Fluimucil® (reference)|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test) following a wash out period of at least a week then administration of by 10ml of 2% oral solution of Fluimucil® (reference).
2531386|NCT02687958|Experimental|A Everolimus 10mg (every cycle) until PD|Patients with stable disease, partial response or complete response after 4- 6 cycles of induction chemotherapy with Cisplatin or Carboplatin plus Etoposide or alternative first line chemotherapy according with local practice will receive maintenance therapy with Everolimus 10mg every cycle (28days) until PD or unacceptable toxicity.
2531390|NCT02687958|No Intervention|B Observational|Patients in this arm will meet observation criteria
2531439|NCT02687438|Experimental|Treatment|Steroid-releasing sinus implant placement following ethmoidectomy in addition to post-op standard of care (i.e. debridement, irrigation, and topical steroids)
2531529|NCT02686957||women closed|"This cohort will include women who underwent repair for obstetric fistula at three fistula repair hospitals in Guinea and who had a closed fistula at hospital discharge.~no intervention will be done."
2531570|NCT02686710|Active Comparator|VIMA|Patiens receiving volatile induction and maitenance of anesthesia
2531579|NCT02686710|Active Comparator|TIVA|Patiens receiving total intravenous anesthesia based on propofol
2531584|NCT02686710|Active Comparator|Combi|Patiens receiving total intravenous induction and volatile anesthesia
2531629|NCT02686359|Experimental|Burning Mouth Syndrome Patients|saliva, blood and urinary samples
2531631|NCT02686359|Active Comparator|controls|saliva, blood and urinary samples
2531667|NCT02685904|Experimental|ENIA11|25 mg of ENIA11 subcutaneously administered twice weekly
2531679|NCT02685904|Placebo Comparator|Placebo|25 mg of Placebo subcutaneously administered twice weekly
2531738|NCT02685462|Active Comparator|Group 1 (Rosuvastatin)|Group 1 (12 subjects) will receive Rosuvastatin on Days 1 and 13.
2531744|NCT02685462|Active Comparator|Group 1 (Digoxin)|Group 1 (12 subjects) will receive Digoxin on Days 1 and 13.
2531747|NCT02685462|Active Comparator|Group 1 (Caffeine)|Group 1 (12 subjects) will receive Caffeine on Days 1 and 13.
2531748|NCT02685462|Active Comparator|Group 2 (Atorvastatin)|Group 2 (12 subjects) will receive Atorvastatin on Days 1 and 13.
2531750|NCT02685462|Experimental|Cenicriviroc|"Subjects in Group 1 and Group 2 will receive Cenicriviroc on Days 3-12.~Subjects in Group 3 will receive Cenicriviroc on Days 2-12."
2531753|NCT02685462|Active Comparator|Group 3 (Simvastatin)|Group 3 (12 subjects) will receive Simvastatin on Days 1 and 12.
2531813|NCT02684903|No Intervention|Services As Usual (SAU)|Participants receive all the usual services provided by DHS- Children's Services.
2531817|NCT02684903|Experimental|Parent Child Interaction Therapy (PCIT)|"Participants receive Parent Child Interaction Therapy (PCIT). PCIT is designed to improve child functioning by interrupting patterns of harsh, coercive interaction and enhancing parents' warm, positive parenting, autonomy support, and competent child management skills.~."
3200911|NCT00895440||3|Diabetic patients with painful neuropathy
3200912|NCT00895440||4|Diabetic patients with Charcot neuroarthropathy
2531971|NCT02684006|Experimental|Avelumab in combination with axitinib|Avelumab administered at 10 mg/kg IV every two weeks in combination with axitinib, 5 mg PO BID.
2531972|NCT02684006|Active Comparator|Sunitinib|Sunitinib given at 50 mg PO QD on schedule 4/2
2532295|NCT02681978|Active Comparator|Ivabradine group|Ivabradine 5 mg twice daily + standard medical therapy
2532296|NCT02681978|Other|Control group|Standard medical therapy
2532329|NCT02681588|Experimental|Obese group|
2532331|NCT02681588|Active Comparator|Normal Weight group|
2532401|NCT02681328||Afirma GEC|single molecular test GEC of collected tissue
2532416|NCT02681328||ThyroSeq v.2|single molecular test ThyroSeq v.2 of collected tissue
2532419|NCT02681328||Afirma GSC|single molecular test GSC of collected tissue
2532422|NCT02681328||ThyroSeq v.3|single molecular test ThyroSeq v.3 of collected tissue
2532488|NCT02680626|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine in their bilateral transversus abdominis plane blocks
3200913|NCT00895440||5|Control non-diabetic subjects
3200914|NCT00895479|Experimental|Trinam|Graft placement plus Trinam therapy
3200915|NCT00895479|No Intervention|Control|Graft placement surgery alone
3200916|NCT00895492||Sotero del Rio|Emergency Room and Hospital based surveillance
3200917|NCT00895492||Van Buren|Emergency Room and Hospital based surveillance
2531083|NCT02689895|Other|Intervention|Research assistants visit participants at home, and send SMS texts on scheduled days for 3 months to encourage adherence to ART. Pill charts, visit charts and text charts are completed. this is called modified directly administered anti-retroviral therapy (mDAART). In addition to the intervention, participants receive standard care at their usual clinic which comprises 3 monthly doctor reviews and adherence counseling at each review visit.
2531085|NCT02689895|No Intervention|Control|Participants get usual care at their clinic, which comprises 3 monthly doctor review visits and adherence counseling at each visit.
2531113|NCT02689609||Single arm|All patients will receive intensity-modulated radiation therapy (IMRT) with or without adjunct chemotherapy as standard of care. They will have baseline pre-treatment and post-IMRT serum thyroid function test at least yearly after IMRT.
2531136|NCT02689362|Experimental|Evogliptin 2.5mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 2.5 mg. The participants randomized to this group will receive 1 tablet daily of EVO 2.5 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2531139|NCT02689362|Experimental|Evogliptin 5.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 5.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 5.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2531140|NCT02689362|Experimental|Evogliptin 10.0mg+Placebo Sitagliptin|Evogliptin (EVO) will be administered orally at a daily dose of: 10.0 mg. The participants randomized to this group will receive 1 tablet daily of EVO 10.0 mg + 1 tablet of sitagliptin (SITA) placebo for 12 weeks.
2531141|NCT02689362|Active Comparator|Sitagliptin 100mg+Placebo Evogliptin|SITA at a daily oral dose of 100 mg. The participants randomized to this group will receive 1 tablet daily of SITA 100 mg + 1 tablet of EVO placebo for 12 weeks.
2531190|NCT02689050||Patients with lymphadenopathy|Patients ≥ 18 years of age, with (suspected) NSCLC or suspected sarcoidosis, and at least one suspected mediastinal/hilar lesion that are scheduled for standard diagnostic endosonographic workup will undergo additional needle based confocal laser endomicroscopy (nCLE) measurements of suspected lesions.
2531249|NCT02688894||Small cell lung cancers|To provide molecular characteristics of Small cell lung cancers to proceed SUKSES trial, To assess success rate of molecular profiling of Small cell lung cancers
2531269|NCT02688465|Experimental|Apomorphine pump|
2531307|NCT02688335|Experimental|Cloud9 Snoring Treatment|Snoring participants will be instructed to use the device as much as possible for 2 weeks.
2531367|NCT02687997|Experimental|Diagnostic|Patients enrolled in lung cancer screening subjected to a sleep study.
2531369|NCT02687997|No Intervention|Contro|Patients enrolled in lung cancer screening not included in the diagnostic intervention arm
2531473|NCT02687243|Experimental|Interactive Virtual Application|Online application
2531477|NCT02687243|No Intervention|Standard of Care|No intervention and Hospital Standard of Care
2531503|NCT02686918|Experimental|consultation by Advanced Practice Nurse.|During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
2531589|NCT02686840|Experimental|sublingual misoprostol|Group A (100 patients): will be treated with sublingual misoprostol
2531593|NCT02686840|Active Comparator|vaginal misoprostol|Group B (100 patients): will be treated with vaginal misoprostol
2531628|NCT02686307||ICD Implant|All patients receiving a dual chamber ICD
2531694|NCT02685943|Experimental|CAMS treatment|Psychotherapy using the Collaborative Assessment and Management of Suicidality framework
2531703|NCT02685943|Active Comparator|Treatment as usual|Ordinary treatment for suicidal patients
2531740|NCT02685475||Diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
2531742|NCT02685475||Non-diabetic patients|Patients received ultrasound-guided axillary brachial plexus blocks (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
3200918|NCT00895505|Active Comparator|oral anticoagulants|Experimental intervention: Extension of OAT in VTE patients showing high plasma levels of D-Dimer after end of routine secondary prophylaxis.
3200919|NCT00895505|No Intervention|2|Control: Withdrawal of OAT in VTE patients after end of routine secondary prophylaxis and receiving low molecular weight heparin in risk situations.
2531935|NCT02684071|Experimental|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
2531996|NCT02683811|Experimental|Intervention group|Diario della Salute (DDS-2), a school-based program aimed to promote psychological well-being and to prevent cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity in preadolescents aged 11-13 years. The program is composed by 5 highly standardised interactive units led by previously trained teachers during school hours (15 hours total). Units focus on emotional and social issues related to adolescent developmental tasks. The goal is to promote the adolescent emotional and social skills.
2531997|NCT02683811|No Intervention|Control group|No intervention aimed at preventing cigarette smoking, alcohol abuse, unhealthy eating habits, physical inactivity and promoting emotional and social well-being is administered at school by teachers.
2532037|NCT02683590|Experimental|sternum by a ceramic implant|The replacement of the sternum by a ceramic implant
2532132|NCT02683278|Experimental|Cognitive-Behavioral Therapy|Group-based cognitive-behavioral manualized treatment
2532133|NCT02683278|Experimental|Mindfulness-acceptance Therapy|Group-based mindfulness-acceptance manualized treatment
2532134|NCT02683278|Active Comparator|Education|Group-based manualized pain education
2532160|NCT02682576|Experimental|Brachial artery ultrasound imaging|Brachial artery ultrasound imaging is a non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery using high resolution continuous electrocardiogram-gated B-mode (2D) ultrasound imaging during reactive hyperemia.
2532224|NCT02682407|Experimental|OMS721 (narsoplimab)|Administration of OMS721 (narsoplimab)
3200920|NCT00895518|No Intervention|1|Participants will receive assessments only.
2532347|NCT02681666|Active Comparator|FODMAPs CONTROL arm|Dietary intervention in this cohort with irritable bowel syndrome will be administered a low Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols diet by a dietician.
3200921|NCT00895518|Experimental|2|Participants will receive prolonged exposure therapy.
3200922|NCT00895544|Experimental|1|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose B of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
2531196|NCT02689024|Experimental|Continuous FICB with local anesthetics|"With ultrasound guidance, a Fascia Iliaca Compartment Block will be administered and a catheter left in the compartment underneath the iliac fascia. This catheter will remain in place until two days after surgery.~Initial pain treatment in the Emergency Department will be with 40 mL bupivacaine 0.25% or equipotent dosages of levobupivacaine or ropivacaine. Thereafter, until removal of the catheter, pain is treated by titrating local anesthetics according to pain scores."
2531202|NCT02689024|Active Comparator|Traditional care with systemic analgesia|"Traditional care (usual care) will be on the discretion of the treating physician or hospital protocols and will comprise of systemic opioids such as fentanyl or morphine.~Usually, these opioids are combined with several other drugs, such as: paracetamol, NSAIDs (diclofenac or ibuprofen or naproxen) or dipyrone. (Inter)national guidelines advice morphine as first line agent in elderly patients with hip fractures, as longer acting analgesics are usually required."
2531266|NCT02688608|Experimental|Pembrolizumab|200 milligrams of Pembrolizumab will be given intravenously every 3 weeks.
2531308|NCT02688283|Experimental|Test-cluster|56g of optimized savory cluster made through a proprietary process with slowly digestible carbohydrates and fiber
2531317|NCT02688283|Placebo Comparator|Control-cluster|56g of control cluster made from general baking process with typical ingredients commonly used in commercially available energy snacks or bars
2531325|NCT02688283|Placebo Comparator|White-bread|45g of white bread containing equivalent amount of available carbohydrate in 56g of optimized savory cluster
2531377|NCT02688010|No Intervention|Control|No specific noise reduction strategies to restrict noise exposure less than 45 dB combined with either continuous bright light or continuous near darkness or unstructured combination of the two during the hospitalization.
2531381|NCT02688010|Experimental|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
2531412|NCT02687555|Experimental|Intervention|Computerized Cognitive Bias Modification of Appraisals (CBM-App), developed from that used by Woud et al. (2012,2013). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
2531413|NCT02687555|Sham Comparator|Control|Computerized Peripheral Vision Task (PVT), developed from that used by Calkins et al. (2015). The intervention comprises 8 sessions completed over a period of 2 weeks. The training takes place while participants are also receiving specialized inpatient treatment for PTSD at the Clinic for Psychosomatic Medicine and Psychotherapy, LWL University Clinic of Ruhr University of Bochum.
2531446|NCT02687256|Experimental|Protocol 1: Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
2531449|NCT02687256|Experimental|Protocol 1: Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 400 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
2531454|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 1|Participants will wear the control (standard) infusion set for 1 week, then the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4).
2531458|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 2|Participants will wear the Extended Wear infusion set with heparin at 40 IU (week 1), 80 IU (week 2), 120 IU (week 3), and 200 IU (week 4), then the control (standard) infusion set (week 5).
2531461|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 3|Participants will wear the Extended Wear infusion set with heparin at 80 IU (week 1), 120 IU (week 2), and 200 IU (week 3), then the control (standard) infusion set (week 4), then the Extended Wear infusion set with heparin at 40 IU (week 5).
2531462|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 4|Participants will wear the Extended Wear infusion set with heparin at 120 IU (week 1), and 200 IU (week 2), then the control (standard) infusion set (week 3), then the Extended Wear infusion set with heparin at 40 IU (week 4), and 80 IU (week 5).
2531464|NCT02687256|Experimental|Protocol 2 (Part 1): Sequence 5|Participants will wear the Extended Wear infusion set with heparin at 200 IU (week 1), then the control (standard) infusion set (week 2), then the Extended Wear infusion set with heparin at 40 IU (week 3), 80 IU (week 4), and 80 IU (week 5).
2531466|NCT02687256|Experimental|Protocol 2 (Part 2): Standard then Extended Set|Participants will wear the control (standard) infusion set for 1 week, then switch to the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then will repeat the cycle for a total of 4 weeks.
2531467|NCT02687256|Experimental|Protocol 2 (Part 1): Extended then Standard Set|Participants will wear the experimental Extended Wear infusion set in combination with Heparin 80 IU for 1 week, then switch to the control (standard) infusion set for 1 week, then will repeat the cycle for a total of 4 weeks.
2531591|NCT02686853|Experimental|Intrathecal administration group|
2531630|NCT02686385|Experimental|Prednisolone + N-Acetylcysteine|Prednisolone for 20 days with NAC (N-Acetylcysteine) NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
2531633|NCT02686385|Active Comparator|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
2531702|NCT02685839|Active Comparator|Traditional rehabilitation|"Each subject will do traditional rehabilitation work two times per week and one hour at a time~, lasting 24 weeks."
2531704|NCT02685839|Experimental|Power rehabilitation|Each subject will do Power rehabilitation work with motion tracking and biofeedback recording two times per week and one hour at a time, lasting 24 weeks.
2531115|NCT02689622|Experimental|Evaluation of disease prognostic factors|Research of disease-related factors, research of comorbidities, geriatric assessment (Mini Mental Status Examination (MMSE), Geriatric Depression Scale-15, Mini Nutritional Assessment, Short Physical Performance Battery, grip strength, Fried criteria, Activities of Daily Living (ADL), Instrumental-ADL, G8, self-reported health status, quality of life Quality of Life Questionnaire-C30, Elderly Cancer Patients-14, EQ5D) at inclusion. At 3 months ADL and physical performance. Grade 3/4 toxicities and serious adverse events will be assessed during 6 months after inclusion (using NCI-COMMON TERMINOLOGY CRITERIA version 2.0) whatever treatment type (chemotherapy, supportive care).
2531182|NCT02689102||ILD patients|ILD patients scheduled for diagnostic bronchoscopy with biopsy and/or broncho-alveolar lavage will undergo additional imagaing with probe based optical techniques.
2531251|NCT02688881|Experimental|sirolimus|sirolimus 1mg will be administered orally daily
2531281|NCT02688452|Active Comparator|Group 1|Young Healthy Adults
2531285|NCT02688452|Active Comparator|Group 2|Young Healthy Adults
2531311|NCT02688127|Experimental|tranexamic acid group|tranexamic acid given as 1 gram intravenous dose dilute in 500 cc of ringer lactate 20 minute before cesarean section
2531321|NCT02688127|Placebo Comparator|placebo group|the control group will receive 500 cc of ringer lactate 20 minute before cesarean section
2531379|NCT02687971|Active Comparator|Thermotherapy alone|"Local heat will be applied using a Localized Current Field radio-frequency generating device manufactured by Thermo-Med Technologies, Inc. A wand with 2 electrodes is connected to the main housing by a thin wire. The electrodes are applied to the skin. We will use electrodes 6 mm long, separated by 4 mm. One single session at the site of the lesion(s) at 50°C for 30 applications will be used. Depending on the size of the lesion, more than one application may be administered."
2531385|NCT02687971|Experimental|Thermotherapy plus Miltefosine|"In addition to receiving one single session of thermotherapy as described above, subjects will receive oral miltefosine two or three capsules a day, which is the equivalent of 100 to 150mg respectively for 21 days. Miltefosine capsules will be taken after breakfast, lunch and dinner, in other words, after food.~The daily dose of miltefosine will depend on the weight of each patient. According to dosage instructions if the patient is taking the miltefosine twice a day, it must be taken in the morning and night (dose of 100mg/Kg/day). Whereas if the patient is taking miltefosine three times a day, it must be taken in the morning, noon and night (dose of 150mg/Kg/day)."
2531415|NCT02687503|Other|Daily dose of probiotic|All children enrolled into the study will receive a daily dose of probiotic
2531506|NCT02687178|Active Comparator|Canrenone 50 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
2531508|NCT02687178|Active Comparator|Canrenone 100 mg|Caucasian patients affected by uncomplicated, essential hypertension, not well controlled by concomitant administration of ACE-I or ARBs and diuretics at the maximum dosage.
3167265|NCT00536133|Experimental|Zinc group|children with recurrent acute lower respiratory infections receiving zinc supplementation
2531689|NCT02685891|Active Comparator|playing tones|During slow-wave sleep short tones (50ms, 50dB) will be played
2531698|NCT02685891|Sham Comparator|Playing no tones|During slow-wave sleep no tones will be played
2531734|NCT02685501||Combat women soldiers|Women soldiers in combat units
2531736|NCT02685501||Non combat women soldiers|Women soldiers in non-combat units
2531784|NCT02685137|Experimental|Active drug-Stannsoporfin|"Stannsoporfin, single dose 4.5mg/kg administered Intramuscular (parental injection in the thigh) for treatment of jaundice~20 mg/mL 1.5 mL/vial"
2531785|NCT02685137|Sham Comparator|Reference Therapy-Sham|Sham Injection, no injection followed by a Band-Aid to thigh
2531831|NCT02684747|Experimental|Treatment - Autologous Transfusion|Participants will be randomized to the treatment group (autologous transfusion)
2531841|NCT02684747|Placebo Comparator|Control - Normal Saline (Placebo)|Participants will either be randomized to the control group (saline transfusion)
2531890|NCT02684526|Active Comparator|Eovist Contrast agent|To determine if Eovist contrast agent induces a transient abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans.
2531893|NCT02684526|Active Comparator|Non Eovist Contrast agents|To determine if using non-Eovist contrast agents produce the same abnormal sensation at first pass, which prevents patients from holding their breath at end of arterial phase liver MRI scans. Determine if this event is exclusive to Eovist contrast.
3200923|NCT00895544|Experimental|2|Day 0: Single priming vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Vietnam strain) - Day 360: Randomization to booster vaccination with Dose A of whole virion, Vero cell-derived influenza vaccine (Indonesia strain)
3200924|NCT00895557|Active Comparator|chantix|
2532124|NCT02683044|Experimental|Li-ESWT 5 weeks|Consists of five sessions of Low-Intensity Extracorporeal Shock Wave Therapy , one per week, with 3000 pulses at 0,15 mg/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 2000 pulses to the body of the penis and 1000 pulses at its base. Total duration: 5 weeks.
2532125|NCT02683044|Active Comparator|Li-ESWT 3 weeks|Consists of six sessions of Low-Intensity Extracorporeal Shock Wave Therapy , two per week, with 1500 pulses each one at 0.1 mJ/mm2, at a frequency of 4 Hz. The distribution of the shocks will be 900 pulses to the body of the penis and 600 pulses at its base. Total duration: 3 weeks.
2532161|NCT02682628|Experimental|BAY987517|Each test site area is divided into test subsite areas that are approximately at least 0.5 cm*2. The application of test material is 2 mg/cm*2. Thus, each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
3200925|NCT00895570|Experimental|Modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
3200926|NCT00895570|Placebo Comparator|Placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
3200927|NCT00895596|Experimental|LB80380 30mg|LB80380 30mg
3200928|NCT00895596|Experimental|LB80380 60mg|LB80380 60mg
3200929|NCT00895596|Experimental|LB80380 90mg,|LB80380 90mg
3200930|NCT00895596|Experimental|LB80380 150mg|LB80380 150mg
3200931|NCT00895596|Experimental|LB80380 240mg|LB80380 240mg
3200932|NCT00895609|Experimental|Sugammadex|Sugammadex in doses: 0 (placebo), 0.0625, 0.125, 0.25, 0.5 and 1 mg/kg
3200933|NCT00895609|Active Comparator|Neostigmine|Neostigmine in doses: 0 (placebo), 5, 8, 15, 25, 40 mg/kg
3200934|NCT00895635|Experimental|Treadmill Exercise Training|Participants will take part in a 12-week supervised treadmill exercise training program.
2531313|NCT02688270|Experimental|Vascana® (0.9% nitroglycerin cream)|
2531322|NCT02688270|Placebo Comparator|Vehicle cream|
2531370|NCT02687984|Experimental|RBP-7000 PLGH A|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 21 kDa PLGH polymer.
2531376|NCT02687984|Experimental|RBP-7000 PLGH B|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 29 kDa PLGH polymer.
2531382|NCT02687984|Active Comparator|RBP-7000 PLGH C|A single subcutaneous injection of RBP-7000 containing 120 mg risperidone in the ATRIGEL® Delivery System formulated with 26 kDa PLGH polymer. This intermediate molecular weight treatment serves as the reference treatment.
2531418|NCT02687490|Experimental|Abraxane|Abraxane: 125 mg/m2, D1, D8, D15 every 28 days
3200935|NCT00895635|Experimental|Arm Ergometry Exercise Training|Participants will take part in a 12-week supervised aerobic arm ergometry exercise training program.
3200936|NCT00895635|Active Comparator|Usual Care Control Group|Participants will receive usual care for PAD from their doctor.
2531568|NCT02686567|Active Comparator|with TDT|with TDT
2531574|NCT02686567|Active Comparator|without TDT|without TDT
2531609|NCT02686320||Rheumatoid arthritis >65 years old|
2531610|NCT02686320||Rheumatoid arthritis <50 years old|
2531632|NCT02686151|Active Comparator|letrozole|2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days
2531634|NCT02686151|Other|Polygeline Injection|500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days
2531672|NCT02685748|Experimental|Aspirin & pantoprazole|"Aspirin 1000 mg/pd per os in two doses~Pantoprazole 40 mg/pd per os in two doses for gastric protection"
2531680|NCT02685748|Placebo Comparator|Placebo|"Two pills in the morning and two in the evening~All pills (aspirin, pantoprazole an placebo) will be the same looking- in the same capsules."
2531751|NCT02685332|Experimental|Stereotactic Radiation|"Single Fraction Stereotactic Radiation. Step No. Fractions Dose per fraction~-1 1 20 0 (starting) 1 22.5~1 26.5~1 30"
2531808|NCT02685085|Experimental|Misoprostol|in this group misoprostol 25 ug will be administrated for induction of labor every 6 hours
2531812|NCT02685085|Experimental|Foley's catheter|In this group foley's catheter 30 cc will be used for induction of labor
2531816|NCT02685085|Experimental|Combined|Both misoprostol 25 ug and foley's catheter will be used for induction
2531885|NCT02684552|Experimental|Non invasive ventilation|Patients perform physical test with non invasive ventilation
2531888|NCT02684552|Active Comparator|Oxygen|Patients perform physical test with oxygen with mask
2531943|NCT02684201|Experimental|Boston Scientific cord stimulator lead|"A Boston Scientific Stimulator Lead (PMA P030017) will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance."
2532000|NCT02683889|Experimental|One arm|One arm will receive acthar to measure rate of recurrence of FSGS after transplant. There are no other arms. We do have previous data that FSGS recurs in 23% of kidney transplants.
2532041|NCT02683551||Ligasure|Patients underwent to Sutureless Thyroidectomy with Ligasure SmallJaw
2532043|NCT02683551||Harmonic|Patients underwent to Sutureless Thyroidectomy with Harmonic FOCUS
2532080|NCT02683252|Experimental|Normal patients|Patients with normal bone appearance on conventional MR images
2532082|NCT02683252|Experimental|Carpal osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the carpal bones on conventional MR images (hypointensity on T1 weighted sequences, no contrast enhancement).
2532084|NCT02683252|Experimental|Femoral head osteonecrosis|Patients presenting signal anomalies compatible with osteonecrosis of the femoral head on conventional MR images (fat containing signal anomalies with geographic contours in the femoral epiphysis).
2532085|NCT02683252|Experimental|Pseudarthrosis|Patients presenting a non consolidated macroscopic bone fracture for over 6 months (clinical history and imaging findings).
2532086|NCT02683252|Experimental|Compartment syndrome|Patients with a confirmed compartment syndrome on intra-compartment pressure assessement
2532126|NCT02682927|Experimental|ZX008 - 0.8 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2532127|NCT02682927|Experimental|ZX008 - 0.2 mg/kg/day|ZX008 (fenfluramine HCl) is supplied as an oral solution in concentrations of 1.25, 2.5, and 5 mg/mL. ZX008 will be administered twice a day (BID) in equally divided doses with food.
2532129|NCT02682927|Placebo Comparator|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
2532179|NCT02682511|Experimental|Patients with dcSSc|Patients with dcSSc will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
2532181|NCT02682511|Experimental|Patients with SSc-PAH|Patients with SSc-PAH will be randomized to receive either oral ifetroban or oral placebo daily for 365 days
2532283|NCT02682082|Experimental|Neurolysis without Bupivacaine|Experimental Group: Endoscopic ultrasound guided celiac plexus Neurolysis without Bupivacaine so only with Absolute Alcohol 20 mL
2532287|NCT02682082|Active Comparator|Neurolysis with Bupivacaine|Endoscopic ultrasound guided celiac plexus Neurolysis with Bupivacaine (0.5% Bupivicaine 20mL + Absolute Alcohol 20 mL)
2532340|NCT02681601|Active Comparator|Diet + Nutrawell Powder with Fish Oil|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) including Nutrawell powder with fish oil.
2532345|NCT02681601|Active Comparator|Dietary Intervention Only|Subjects will be evaluated by a registered dietitian with a diet prescription (55% carbohydrate, 30% fat and 15% protein) not including servings of Nutrawell powder with fish oil.
2532387|NCT02681146|Experimental|Group1|Educational advice + physiotherapist treatment
2532405|NCT02681146|Experimental|Group2|Educational advice + physiotherapist treatment
3200937|NCT00895648|Experimental|Alimta plus Cisplatin|
3200938|NCT00895674||Group 1|
2531242|NCT02688790|Experimental|Cohort 2|One dose of intravenous dalbavancin infusion 22.5 mg/kg in term neonates (defined as gestational age at or greater than 37 weeks) aged up to 28 days
2531243|NCT02688790|Experimental|Cohort 3|One dose of intravenous dalbavancin infusion 22.5 mg/kg in preterm neonates (defined as gestational age of 32 weeks, up to 37 weeks) aged no more than 28 days
2531276|NCT02688504||serious road accidents|Drivers involved in serious road accidents (hospitalization > 24 hours)
2531278|NCT02688504||non-serious road accidents|drivers involved in non-serious road accidents (hospitalization < 24 hours).
2531310|NCT02688231|Experimental|High intensity group|
2531320|NCT02688231|Experimental|Low intensity group|
2531327|NCT02688231|Active Comparator|Control group - conventional treatment|
2531396|NCT02687867||Dabigatran|Non-valvular atrial fibrillation patients who were initiated on dabigatran for stroke prevention.
2531398|NCT02687867||Vitamin K antagonist|Non-valvular atrial fibrillation patients who were initiated on VKA for stroke prevention.
2531419|NCT02687399|Experimental|TT-173|It will be sprayed using this syringe and a nozzle tip couplet to it one time over the surgical lesion surfaces on the exposed tissues of the knee
2531422|NCT02687399|Placebo Comparator|placebo|It will be sprayed over the surgical lesion surfaces on the exposed tissues of the knee
2531522|NCT02687100|Experimental|Beclomethasone|Patients will receive beclomethasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning. The solution will be aspirated 15 minutes after the instillation.
2531526|NCT02687100|Placebo Comparator|Placebo|Patients will receive 8 mL of saline without any drug.
2531611|NCT02686502|No Intervention|Mode 1|Current guidelines. Subjects attending the examinations and the tests but not participating the individualized intervention. The subjects will receive general guidance on healthy exercise and diet.
2531612|NCT02686502|Active Comparator|Mode 2|Individualized lifestyle intervention. Exercise intervention will be based on submaximal ergometer test (estimated VO2max), clinical status, personal goals and preferences. Intervention also includes diet counseling, multiprofessional team support, peer support and use of mobile health applications.
2531613|NCT02686502|Active Comparator|Mode 3|Highly individual lifestyle intervention. In addition to Mode 2 arm intervention optimal intensity zones and volumes for individual exercise training will be determined based on advanced cardiopulmonary exercise test.
2531645|NCT02686099|Experimental|SternaLock 360|Sternal closure performed with SternaLock 360 as a primary closure system
2531646|NCT02686099|Active Comparator|Wire Cerclage|Sternal closure performed with standard wire cerclage as a primary closure system
2531684|NCT02685774|Other|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
2531691|NCT02685774|Other|TR group|T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
2531733|NCT02685410|Experimental|One Night Stan Pilot Testing Group|The pilot testing of the One Nigh Stan prototype intervention will utilize 20 young black women aged 18-24 as participants.
2531829|NCT02685189||0.75 mg/kg Previous exposure to stannsoporfin|Previous exposure 0.75 mg/kg
2531836|NCT02685189||1.5 mg/kg Previous exposure to stannsoporfin|Previous exposure 1.5 mg/kg
3167266|NCT00536133|Placebo Comparator|Placebo group|children with recurrent acute lower respiratory infections receiving placebo syrup
3167267|NCT00536159|Active Comparator|Community Care|Medicaid eligible/insured pregnant women and their infants are eligible for risk assessment and up to 18 home visits (9/pregnancy and 9/infancy) from community professional providers as part of a state-sponsored enhanced prenatal and postnatal Medicaid program.
2531955|NCT02684084|Active Comparator|Combination group (RBZ+DEX)|30 eyes will receive an intravitreal Lucentis (0.5 mg) injection followed by Ozurdex implant (0.7 mg) injection within 0 to 8 days.
2531961|NCT02684084|Active Comparator|Monotherapy group (DEX only)|30 eyes will receive Ozurdex implant (0.7 mg) injection only
2532001|NCT02683720|Experimental|ONS1|new product
2532006|NCT02683720|Active Comparator|ONS2|usual care
2532042|NCT02683538|Experimental|Separable cluster electrode|radiofrequency ablation (RFA) using separable cluster electrode in switching monopolar mode.
2532102|NCT02683213|Active Comparator|Fluoxetine|One capsule Fluoxetine 20mg once daily for 6 months.
2532107|NCT02683213|Placebo Comparator|Placebo|One matching capsule placebo once daily for 6 months.
2532155|NCT02682693|Experimental|Denosumab|Denosumab every 4 weeks for 6 cycles.
2532156|NCT02682693|Experimental|nab-Paclitaxel weekly|nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.
2532157|NCT02682693|Experimental|nab-paclitaxel 2 of 3 weeks|nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.
2532158|NCT02682693|Experimental|EC every two weeks or every three weeks|Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
2532242|NCT02682238|Experimental|BBI-4000, 15%|15% BBI-4000 (sofpironium bromide) topical gel
2532247|NCT02682238|Placebo Comparator|Vehicle|Vehicle (placebo) gel
2532306|NCT02681887|Placebo Comparator|Placebo|Placebo tablet identical to Circadin by mouth each day before bedtime for 12 weeks
2532307|NCT02681887|Experimental|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
3167268|NCT00536159|Experimental|Nurse-CHW Team|Nurse-CHW team provided both nursing care, with additional focus on mental health and stress, and intensive relationship-based support from a CHW similar in characteristics to women served in the context of state-sponsored Medicaid program.
3167269|NCT00536185|Experimental|1|
3167270|NCT00536185|Placebo Comparator|2|
3167271|NCT00536211|Experimental|1|Exercise
3167272|NCT00536211|Active Comparator|2|Metformin
3167273|NCT00536224|Active Comparator|2|Minimal counseling
3167274|NCT00536224|Experimental|1|Full counseling
3167275|NCT00536289|Active Comparator|1|Sharp needles
2531250|NCT02688712|Experimental|LY2157299 + Chemoradiation + Surgery|Patients will receive a 14 day course of LY2157299. On day 15 patients will begin chemoradiation treatment with Capecitabine or Fluorouracil. On day 29, patients will undergo another fourteen day course of LY2157299 concurrent with their ongoing chemoradiation treatment. Six to ten weeks after completing their neoadjuvant therapy, patient will undergo a tumor specific mesorectal excision as per standard of care.
2531298|NCT02688413|Experimental|MindMotionPRO|MindMotionPRO exercises in addition to standard practice for upper limb rehabilitation
2531299|NCT02688413|Active Comparator|Self-Directed Prescribed Exercises|Self-Directed Prescribed Exercises in addition to standard practice for upper limb rehabilitation
2531352|NCT02688062|Experimental|NeuroRegen Scaffold with BMMCs transplantation|
2531353|NCT02688062|Experimental|Surgical intradural decompression and adhesiolysis|
2531401|NCT02687659|Experimental|Study group using TEMIS system|using TEMIS system during physical exercises: walking, biking, running
2531416|NCT02687386|Experimental|Mitoxantrone packaged EDV|Mitoxantrone packaged EDV (EnGeneIC Dream Vector)
2531518|NCT02687113|Other|CT/US fusion|"patients undergo routine conventional feasibility planning ultrasound, and clinical decision of RFA feasibility is made based on conventional planning ultrasound.~Then additional planning ultrasound using CT/US fusion technique is immediately performed by the same operator, and clinical decision is made based on fusion imaging."
2531569|NCT02686697|Experimental|L-Carnosine|oral doses of 2000mg for 4 weeks total - 2 weeks medication phase only, and then 2 weeks combined treatment with cognitive training.
2531576|NCT02686697|Placebo Comparator|Placebo|matching placebo
2531642|NCT02686294|Experimental|T-R|First period : administration of test drug Second period : administration of reference drug
2531643|NCT02686294|Experimental|R-T|First period : administration of reference drug Second period : administration of test drug
2531670|NCT02685787|Experimental|Psychosocial Intervention|Every caregiver in this arm will be assigned to a permanent counselor.
2531675|NCT02685787|Active Comparator|Educational Intervention on AD|The caregiver enrolled in this arm will not be assigned to a counselor but will participate to group sessions on AD education.
2531739|NCT02685423|Experimental|Visual Deprivation - 10 days|10 days of visual deprivation followed by vision training
2531743|NCT02685423|Active Comparator|Vision Training Only|Vision training without visual deprivation
3200939|NCT00895687|Experimental|Erlotinib + Bortezomib|Up to 4 dose levels of study drug combination tested with 3-6 participants enrolled at each dose level. Erlotinib beginning dose of 150 mg taken by mouth daily for 21-day cycle. Bortezomib beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
3200940|NCT00895700|Experimental|Web-based behavioral intervention|
3200941|NCT00895700|No Intervention|Usual care|
3200942|NCT00895713|Experimental|im HBIG Grifols|
2532029|NCT02683564|Experimental|BOW015|Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
2532031|NCT02683564|Active Comparator|Remicade|Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.
2532057|NCT02683304|Experimental|The study population|The study population consists of consecutive headache patients (visual analogue scale > 3) presenting at the emergency department of the Nîmes University Hospital
2532119|NCT02683070|Experimental|The PNB group|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) will be performed after the completion of surgery before extubation.
2532123|NCT02683070|Active Comparator|The TRAM group|Intravenous tramadol of 1.5mg/kg will be administrated after the completion of surgery before extubation.
2532175|NCT02682615||requirement of norepinephrine|requirement of norepinephrine <0,1 µg/kgKG/min versus ≥0,1 µg/kgKG/min
2532244|NCT02682329|Active Comparator|CP 10% + HP 40%|Carbamide Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. CP at home and HP at office
2532249|NCT02682329|Active Comparator|CP 15% + HP 40%|Carbamide Peroxide 15% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
2532252|NCT02682329|Active Comparator|CP 20% + HP 40%|Carbamide Peroxide 20% + Hydrogen Peroxide 40% were administered to each patient on this group.CP at home and HP at office
2532253|NCT02682329|Active Comparator|HP 10% + HP 40%|Hydrogen Peroxide 10% + Hydrogen Peroxide 40% were administered to each patient on this group. HP at Home and HP at office
2532299|NCT02681861|Experimental|Part 1: ASP6294 Single Ascending Intravenous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo intravenously. If no dose limiting toxicities are observed escalation to the next higher dose is planned approximately every 3 weeks. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
2532300|NCT02681861|Experimental|Part 2: ASP6294 Single Ascending Subcutaneous Doses|A dose escalation design will be implemented. Successive cohorts of patients (8 participants/cohort) will each be started on a fixed dose of ASP6294 or Placebo subcutaneously. The subcutaneous cohorts may be done in parallel with part 1, using doses which have been proven to be safe and tolerable. Within the planned dose range, a dose lower than the next planned dose may be tested, or a dose level may be repeated, depending on emerging safety, tolerability and/or other relevant data, such as available pharmacokinetic and pharmacodynamic data of previous dose levels.
2532352|NCT02681536|Experimental|Minidose long protocol|Down-regulation started on day 20 of the previous cycle by GnRH agonist triptorelin (0.5 µg Decapeptyl; Ferring). On the second day of menstruation, when down regulation was confirmed (as evidenced by endometrial thickness <5 mm and/or E2 levels <50 pg/mL) using transvaginal sonography (TVS) by Voluson 730 Pro (GE, Fairfield, CT) apparatus, gonadotropin (Merional; IBSA) was commenced at an initial dose of 300-450 IU/day for the first 5 days followed by individual adjustment in Gn dose according to ovarian response and the dose of Decapeptyl 50µg/day was continued until day of HCG administration.
3200943|NCT00895726|Experimental|APD209|
3200944|NCT00895778|Experimental|NMB|muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
2531324|NCT02688296||High Risk Patients|Patients who are implanted with Fibulock and are at high risk of complications from ankle surgery due to conditions such as diabetes, advanced age or osteoporosis
2531329|NCT02688296||Otherwise Healthy Patients|Patients implanted with Fibulock who are healthy other than their ankle fracture
3200945|NCT00895778|Placebo Comparator|no NMB|no muscle relaxation (neuromuscular block) during laparoscopic cholecystectomy
3200946|NCT00895791|Active Comparator|1|AXXESS Biolimus A9-eluting bifurcation stent
2531486|NCT02687204|Active Comparator|Enoxaparin prophylaxis|All enrolled patients will receive twice daily enoxaparin prophylaxis. Patients with identified out of range peak anti-Xa levels will receive real time dose adjustment and will be considered as the experimental arm.
2531489|NCT02687204|Experimental|Real time dose adjustment|Patients with identified out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment
2531530|NCT02686879|No Intervention|Natural progession|Following the natural progression of axial growth and refractive error.
2531532|NCT02686879|Experimental|Anisohyperopes - intervention eye|The more hyperopic eye will be fitted with a centre-near multifocal contact lens
2531534|NCT02686879|Experimental|Hyperopes|Both eyes will be fitted with centre-near multifocal contact lenses.
2531537|NCT02686879|Experimental|Anisohyperopes - fellow eye|The less hyperopic eye will be fitted with a single vision contact lens if required.
2531562|NCT02686606|Experimental|Vital 1.5|200ml orally over 30 minutes
2531567|NCT02686606|Active Comparator|Ensure Plus|200ml orally over 30 minutes
2531607|NCT02686463|Experimental|the laparoscopy group|Patients who are randomized to the laparoscopy group.
2531608|NCT02686463|Experimental|the laparotomy group|Patients who are randomized to the laparotomy group.
2531650|NCT02686177|Experimental|1: Liraglutide|Liraglutide 1,2 mg once daily subcutaneous injection for 1 month (4 weeks)
2531653|NCT02686177|Active Comparator|2: Add on oral antidiabetic medication|Metformin or sulfonylurea depending on monotherapy
2531665|NCT02685722|Experimental|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
2531673|NCT02685722|Experimental|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.treatment period and follow-up period.In accordance with chronic wound criteria for the patient,By producing the principle of random number,Were randomly divided into UC-MSCs Gel group or Gel group,The researchers according to the situation of wound healing time and decided to use the secondary treatment,to observe the clinical efficacy and safety.
2531788|NCT02685150|Experimental|Functional dyspepsia|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice and those who fulfill with Rome III criteria for functional dyspepsia are to be classified into this group.
2531791|NCT02685150|Experimental|Acid reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging, Omeprazole test and Analysis of gastric juice. Participants with acid reflux are to confirmed by Omeprazole test, one kind of proton-pump inhibitor (PPI) tests.
2531793|NCT02685150|Experimental|Bile reflux disease|Participants are to undergo Endoscopic Tri-Modal Imaging and Analysis of gastric juice. Participants with bile reflux are to be confirmed by Analysis of gastric juice.
2531795|NCT02685150|Experimental|Health volunteers|Health volunteers for routine checkup. Participants are to undergo Endoscopic Tri-Modal Imaging as well as Analysis of gastric juice and those who show no abnormal findings are to be classified into this group.
2531898|NCT02684643|Experimental|enhanced individualised therapy|Patients' dialysis dosage, medication as well as dietary plan will be modified.
2531906|NCT02684643|Experimental|non-enhanced individualised therapy|Patients' medication as well as dietary plan will be modified without alteration of dialysis dosage.
2531910|NCT02684643|Experimental|regular intervention|Phosphate binders and calcitriol will be prescribed and adjusted without altering patients' diet habit.
3200947|NCT00895791|Active Comparator|2|culotte stenting with use of 2 drug eluting stents
3200948|NCT00895804|Other|Pindolol, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
2532036|NCT02683616|Experimental|OSA + T2DM|CPAP treatment
2532038|NCT02683616|Experimental|OSA no T2DM|CPAP treatment
2532039|NCT02683616|No Intervention|T2DM no OSA|Standard care
2532040|NCT02683616|No Intervention|Healthy controls no ÓSA|no intervention
2532320|NCT02681718|Experimental|Community Health Worker education|During a six-month intervention period, the CHWs will conduct six home-based visitations and provide individualized diabetes education using an intensive diabetes lifestyle curriculum called Diabetes Learning Circle (DLC), developed and used by the Sinai Diabetes Education Program. At each visit, lasting for approximately one hour, the participants will be motivated to set SMART behavioral goals for diabetes self-management. At each visit after the initial visit, CHWs will follow-up with each participant to check their progress on their behavioral SMART goals. In addition, the CHWs will conduct intermittent phone calls (at least one monthly) and home visits as needed.
2532322|NCT02681718|Experimental|Cell phone text messaging|The participants in the text messaging group will receive weekly text messages through CareMessage. Each participant will receive 3-4 text messages per week for 6 months.
2532323|NCT02681718|No Intervention|Control|The participants in the control group will receive education as determined by the hospital's diabetes educator, dietitian, physician, or the participant's managed care provider. No additional education will be provided by the research team.
2531331|NCT02688374|Other|Treatment C:Treatment A:Treatment B|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment A(Nicorette 2 mg coated mint gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531333|NCT02688374|Other|Treatment A: Treatment C:Treatment B|Participants will be administered with Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531337|NCT02688374|Other|Treatment B:Treatment A: Treatment C|Participants will be administered with Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum) followed by Treatment C (Nicotinell 2 mg coated fruit flavor gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531340|NCT02688374|Other|Treatment C:Treatment B:Treatment A|Participants will be administered with Treatment C (Nicotinell 2 mg coated fruit flavor gum) followed by Treatment B (Nicotinell 2 mg coated mint gum) followed by Treatment A (Nicorette 2 mg coated mint gum). Administration of each treatment will be separated by clinical furlough period of at least 7 days and not more than 10 days.
2531361|NCT02687750|Experimental|MRI|"Eppendorf tubes containing 10% fluorine-19 diluted in agar were taped to the upper thigh of participants. Investigational device was used to image the phantom with Magnetic resonance imaging (MRI). Imaging was performed for anatomical (proton) and fluorine (agent detection). Total scan time was under 1 hour.~Objectives:~Verify RF coil functionality~Obtain preliminary detection threshold limits using a human coil loading"
2531409|NCT02687685|Experimental|Skin to skin contact immediate|At birth, the baby will be placed and dried on the breast of his mother where thermoregulation manoeuvres will be applied and once the cord clamping procedure has taken place; the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least one hour or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, it will be allowed again after these interventions. During immediate SSC, mother and baby receive continuous monitoring by the health staff
2531410|NCT02687685|Active Comparator|skin to skin contact early|At birth, the baby will be dried and placed on the abdomen and chest of his mother where thermoregulation manoeuvres are applied once there is an indication that the cord clamp procedure has been completed. At this time the baby will go to the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby who has 60 minutes of life, will proceed with the initiation of SSC for at least one hour or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC the mother and baby will receive monitoring by health personnel
2531447|NCT02687269|Experimental|Ranolazine|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, Ranolazine at a dose of 375 mg twice daily.
2531455|NCT02687269|Placebo Comparator|Placebo|The patients undergoing elective and complete CABG revascularization performed by the same surgeon, will be randomized in two different groups to receive, in the three days before surgery, placebo twice daily.
2531507|NCT02686996|Active Comparator|Intervention|Each participant will be given a daily oral dose 2 g of carnosine (2 tablets twice daily) for 14 weeks
2531510|NCT02686996|Placebo Comparator|Control|Each participant will be given a daily oral dose 2 g of identical placebo tablets ( 2 tablets twice daily) for 14 weeks
2531582|NCT02686723|Experimental|ACL injury|Subjects who has ACL injury repaired and who were allowed to return to sport
2531588|NCT02686723|Active Comparator|Healthy subjects|Subjects who has never been injured in ACL and who practice sports with cutting task (soccer, handball)
2531620|NCT02686372|Experimental|HBV/TCR-T cell|Biological: HBV antigen specific TCR redirected T cell infusion.
2531682|NCT02685982|Experimental|Rhythmic Sensory Stimulation|Participants in this group will undertake 30 minutes of daily Rhythmic Sensory Stimulation, for 5 day per week, for a total of 5 weeks. The stimulation consists of specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range. The intervention is conducted at the participant's home using a portable device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit. This device is a low-voltage consumer product device that has built in low frequency (subwoofer-type) speakers. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration that is synchronized with the relaxing musical track.
2531869|NCT02684695||Group A|Patients with enthesitis-related arthritis
2531870|NCT02684695||Group B|Patients with other forms of juvenile idiopathic arthritis (extended oligoarticular JIA and polyarticular JIA)
2532096|NCT02683057||IPAQ HIgh|Excessive physical activity:IPAQ quantifying the activity physical according vigorous intensity activities at least 3 days per week adding a minimum total physical activity of at least 1500MET-minutes / week or 7 or more days any combination of walking, moderate intensity or vigorous intensity activities a total minimum of physical activity of at least 3,000 MET-minutes / week
2532101|NCT02683057||IPAQ Moderate|Ideal Physical activity: IPAQ quantifying the activity physical according 3 days or more of vigorous intensity physical activity at least 20 minutes per day or 5 or more days of moderate intensity and / or walk at least 30 minutes per day or 5 or more days of any combination of walking, moderate-intensity activity and activity vigorous intensity for a total minimum of physical activity of at least 600 MET-minutes / week.
2532104|NCT02683057||IPAQ Low|IPAQ quantifying the activity physical according Insufficient physical activity: Individuals who can not put on the criteria of the above categories.
3167276|NCT00536289|Experimental|2|Blunt tipped needles
3167277|NCT00536302|Experimental|1|Collagen Hydrolysate
3167278|NCT00536302|Placebo Comparator|2|
3167279|NCT00536315||COPD|Patients with cough and/or shortness of breath who may have windpipe collapse.
3167280|NCT00536315||Healthy adults|Subjects without symptoms for comparison.
3167281|NCT00536315||Tracheomalacia|Patients with cough and/or shortness of breath who may have windpipe collapse.
3167282|NCT00536367||Patients seen for ADHF at OSUMC|
3200949|NCT00895804|Other|MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3200950|NCT00895856||Old-aged people|
3200951|NCT00895882|Experimental|1|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
2531661|NCT02686047|Experimental|the HYAJOINT Plus group|the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
2531662|NCT02686047|Active Comparator|The Synvisc-One group|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
2531666|NCT02685696|Experimental|Alexis O Retractor|Group 1 received the Alexis-O-Retractor at thet time of first Caesarean Section
2531674|NCT02685696|Active Comparator|Metal Retractor|Group 2 received the traditional self retaining metal Retractor at thet time of first Caesarean Section
2531752|NCT02685553|Experimental|1|Use of NIR
2531786|NCT02685111|Active Comparator|A. Pegfilgrastim|D2 once a cycle pegfilgrastim arm
2531789|NCT02685111|Experimental|B. Filgrastim|Intermittent Every Other Days of 5 Shot (D3-11) filgrastim arm
2531861|NCT02684734||Patients on no immunosuppressant|This includes patients on no medication or mesalamine.
2531864|NCT02684734||Patients on immunosuppressants|This includes patients on biologics, azathioprine (AZA), 6-mercaptopurine (6-MP), or corticosteroid. These patients will be sub-analyzed to: a) Patients on one immunosuppressive therapy with AZA, 6-MP, biologic or corticosteroid; b) Patients on combination therapy with AZA or 6-MP and biologic; c) Patients on triple therapy with corticosteroid, AZA or 6-MP, and biologic; d) Patients on corticosteroid and one other immunosuppressive therapy such as AZA, 6-MP, or biologic.
2531908|NCT02684422||Cystic Fibrosis with MRSA infection|"Cystic Fibrosis patients that are admitted to the hospital for IV therapy targeting MRSA will give a sputum sample and complete symptom diaries at the beginning and end of therapy. There will be no intervention administered.~Inclusion criteria are ability to produce sputum and having a chronic i.e. > 2 years of positive respiratory cultures, MRSA CF lung infection."
2531958|NCT02684123|Active Comparator|Apremilast|Apremilast 30mg twice daily
2531966|NCT02684123|Placebo Comparator|Placebo|Placebo pills twice daily
2532011|NCT02683733|Active Comparator|Treatment Arm|"Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:~Starting dose: 50 mg BID of Bio-enhanced Curcumin Soft Gelatin Capsule Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
2532014|NCT02683733|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicylic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
2532047|NCT02683460|Experimental|patella resurfacing group|Procedure: Patellar component Resurfacing with onlay technique
2532051|NCT02683460|Active Comparator|patella retention|Procedure: patellar retention Trimming of osteophytes when appropriate
3200952|NCT00895882|Experimental|2|vaniprevir 300 mg b.i.d. + peg-IFN + RBV for 24 weeks
3200953|NCT00895882|Experimental|3|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 12 weeks, followed by placebo to vaniprevir + peg-IFN + RBV for 12 weeks
3200954|NCT00895882|Experimental|4|vaniprevir 600 mg b.i.d. + peg-IFN + RBV for 24 weeks
3200955|NCT00895882|Experimental|5|vaniprevir 600 mg q.d. + peg-IFN + RBV for 24 weeks
2532275|NCT02682095||Patients: achieved BP control|Patients who have achieved blood pressure control (≤140/90 mmHg)
2532276|NCT02682095||Patients: not achieved BP control|Patients who have not achieved blood pressure control (>140/90 mmHg)
2532277|NCT02682095||Individual interviews|Hypertensive patients who have considered changing lifestyle regarding one or more of the areas of tobacco, alcohol, diet, physical activity or stress.
2532278|NCT02682095||Focus-group interviews|Hypertensive patients
2532311|NCT02681744|No Intervention|Control Group|These participants will be instructed to maintain their habits during 24 weeks. Before and after the aforementioned period, they will be asked to perform body composition and strength assessments, using DXA and isokinetic dynamometer, respectively.
2532313|NCT02681744|Experimental|Experimental group|Participants from the experimental group will assign to the resistance training program undergo physician screening at rest and under cardiopulmonary exercise test conditions before starting the program. Following a three-week familiarization process, participants undergo one repetition maximum (1-RM) testing for each of the exercises of the training program. This procedure intended to determine exercise load and will be systematically repeated in four-week intervals. Volunteers will train thrice per week during 24 weeks. The training program will involve the following exercises: chest press, lat pulldown, knee extension, hamstrings curl, leg press, hip abduction.
2532365|NCT02681445||Group 1 Healthy Non Smokers|No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray Non-Smoker
2532367|NCT02681445||Group-2 Smokers|No TB History No TB Symptoms No TB History Negative Mantoux test Smoker 10 + Cigarettes/day
2532368|NCT02681445||HIV Positive|"No TB Symptoms No TB History Negative Mantoux test Normal Chest X-ray HIV Positive~CD4 count >200"
2532369|NCT02681445||TB Suspect Group|WHO Screening Recommendation Protocls Unexplained Cough Sputum production Fever Weight Loss or loss of appetite Night Sweats
2532371|NCT02681445||Lower Respiratory Track Infection|TB Lab test Negative Ab Normal Chest X-ray HIV Negative
2532491|NCT02680626|Active Comparator|Non-magnesium|Participants in this arm will receive saline + ropivacaine in their bilateral transversus abdominis plane blocks
3200956|NCT00895882|Placebo Comparator|6|Placebo to vaniprevir + peg-IFN + RBV for 24 weeks, followed by peg-IFN + RBV for 24 weeks
3200957|NCT00895908|Experimental|Friendship Group Intervention|"Participants will receive the Friendship Groups intervention."
3200958|NCT00895908|Active Comparator|Individual Tutoring|Participants will receive individual academic tutoring.
3200959|NCT00895960|Experimental|Dasatinib Plus RT + TMZ|Dasatinib (Sprycel) with Radiotherapy (RT) and 6 weeks of concomitant Temozolomide (TMZ)
3200960|NCT00895973|Experimental|Stirrups delivery|Mom will be assigned to deliver with legs positioned in stirrups
3200961|NCT00895973|Experimental|Bed delivery|Mom will be assigned to deliver with the legs positioned in bed in the supine position
3200962|NCT00895986|Experimental|1|Conversation Maps Diabetes Education
2531417|NCT02687516|Experimental|Family-based behavioral social facilitation therapy.|The FBSFT condition includes 17 weekly family-based treatment sessions at the hospital obesity clinic followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital every third month for 2 years.The treatment targets both child and parent life-style; eating habits, physical activity, sedentary activity and sleep habits. Behavior modification techniques are systematically employed; such as self-monitoring, goal setting, reward systems, problem solving and stimulus control. In addition, FBSFT focuses on facilitating lifestyle change across different settings (family, friends, school and community) and harnessing social support for healthy habits, which is considered important for long-term weight control.
2531421|NCT02687516|Active Comparator|Treatment as usual|The TAU condition involves an assessment day with the multidisciplinary team (pediatrician, dietician, physical therapist and psychologist) at the hospital obesity clinic. Further a session with the nurse at the hospital clinic making a plan for behavioral lifestyle changes followed by monthly follow-up sessions with their local nurse and follow-up sessions at the hospital clinic every third month for 12 months. After 12 months they will be offered treatment by family-based behavioral social facilitation therapy (as in the other treatment arm).
2531604|NCT02686580|Experimental|Collagen paste|Injection of Permacol Collagen paste into the fistula tract.
2531624|NCT02686268||Individuals diagnosed with known positive C9ORF72 ALS|Individuals diagnosed with known positive C9ORF72 ALS
2531664|NCT02685852|Active Comparator|Arm 1: Exenatide (5mcg) + Acarbose Placebo|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal
2531671|NCT02685852|Active Comparator|Arm 2: Exenatide (5mcg) + Acarbose (25mg)|Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
2531687|NCT02685852|Placebo Comparator|Arm 3: Exenatide Placebo + Acarbose (25mg)|Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal
2531732|NCT02685345|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablets, orally, once daily (QD) for up to 28 days
2531735|NCT02685345|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg tablets, orally, once daily (QD) for up to 28 days
2531737|NCT02685345|Placebo Comparator|placebo|placebo tablets, orally, once daily for up to 28 days
2531833|NCT02685046|Experimental|Intervention|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
2531881|NCT02684500||aneurysmal subarachnoid hemorrhage|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) using abdominal ultrasound in order to evaluate the potential additional risk of non-occlusive mesenteric ischemia (NOMI) and non occlusive bowel necrosis (NOBN) for a aneurysmal subarachnoid hemorrhage in subjects undergoing hypertensive therapy for cerebral vasospasm in SAH, to justify the withholding of enteral nutrition.
2531917|NCT02684266|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen
2531953|NCT02683993|Experimental|Stone breaking|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with low frequency parameters.
2531963|NCT02683993|Experimental|Stone dusting|Lithotripsy will be performed using the Lumenis Pulse 120H holmium laser system with high frequency parameters.
2532002|NCT02683824|Experimental|pancreatic cancer patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
2532008|NCT02683824|Experimental|healthy patients|Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
2532077|NCT02683317|Experimental|DHA group|Experimental group will receive 75 mg of docosahexaenoic acid per kilo of baseline weight in one dose per day, administered by enteral feeding throughout 14 days.
2532079|NCT02683317|Sham Comparator|Control group|"Control group will receive sunflower oil, the excipient of the DHA in our intervention.~They will receive it once a day, administered by enteral feeding throughout 14 days."
2532093|NCT02682953|Experimental|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
2532166|NCT02682810|Active Comparator|DNA PCR HIV diagnostic test|SOC or control arm through existing PMTCT program, with DBS samples sent to an off-site laboratory for DNA PCR testing.
2532167|NCT02682810|Experimental|Alere Q POC nucleic acid-based platform|POC test to provide same-day diagnosis
2532256|NCT02682225|Experimental|Sequence 1: Qualification Session|Participants will receive Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 1 and Treatment B (0.5 milligram per kilogram (mg/kg) of intravenous racemic ketamine and intranasal placebo concurrently) on Day 2.
2532260|NCT02682225|Experimental|Sequence 2: Qualification Session|Participants will receive Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo concurrently) on Day 1 and Treatment A (intravenous placebo and intranasal placebo concurrently) on Day 2.
2532262|NCT02682225|Experimental|Sequence 3: Treatment Phase|Participants in Sequence 3 will receive Treatment A (intravenous placebo and intranasal placebo) on Day 1 of period 1, Treatment D (intravenous placebo and intranasal 112 milligram (mg) of esketamine as 4 devices, each with 28 mg esketamine) on Day 1 of period 2, Treatment B (0.5 mg/kg of intravenous racemic ketamine and intranasal placebo) on Day 1 of period 3, Treatment C (intravenous placebo and intranasal 84 mg esketamine as 3 devices, each with 28 mg esketamine followed by 1 device with placebo) on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2532264|NCT02682225|Experimental|Sequence 4: Treatment Phase|Participants in Sequence 4 will receive Treatment B on Day 1 of period 1, Treatment A on Day 1 of period 2, Treatment C on Day 1 of period 3, Treatment D on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2532265|NCT02682225|Experimental|Sequence 5: Treatment Phase|Participants in Sequence 5 will receive Treatment C on Day 1 of period 1, Treatment B on Day 1 of period 2, Treatment D on Day 1 of period 3, Treatment A on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2532266|NCT02682225|Experimental|Sequence 6: Treatment Phase|Participants in Sequence 6 will receive Treatment D on Day 1 of period 1, Treatment C on Day 1 of period 2, Treatment A on Day 1 of period 3, Treatment B on Day 1 of period 4. Periods 1, 2, 3 and 4 will be separated by 7 to 14 days.
2531429|NCT02687308|Active Comparator|1Retrograde radical prostatectomy RRP|This opem surgical prostatectomy techniques described by Patrick Walsh is made through prostatic dissection, from apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
2531433|NCT02687308|Experimental|2Anterograde radical prostatectomy RRP2A|This opem surgical prostatectomy techniques dissect the prostate, bladder neck and the neurovascular bundle, in an antegrade way, from bladder neck to the apex. With careful bladder neck dissection and preservation, careful nervesparing procedures with meticulous retroprostatic dissection of the posterior layer of Denonvilliers' fascia, and urethrovesical anastomosis performed through a monofilament running suture.
2531511|NCT02687009|Experimental|Niclosamide|
2531590|NCT02686749|Active Comparator|AF catheter Ablation|Pulmonary Vein Isolation catheter ablation for treatment of AF. AF catheter ablation is an FDA approved treatment for AF
2531594|NCT02686749|Active Comparator|FDA approved anti arrhythmic drug|FDA approved anti arrhythmic drug for the treatment of AF will be based on treating physicians' preference in accordance to guidelines.
2531637|NCT02686242||spinal anesthesia|patients receive spinal anesthesia before general anesthesia
2531640|NCT02686242||general anesthesia|patients receive general anesthesia
2531757|NCT02685605|Experimental|Experimental Arm (A)|Standard surgery plus intraoperative radiotherapy (20-30 Gy) followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
2531760|NCT02685605|Active Comparator|Control Arm (B)|Standard surgery followed by radiochemotherapy (EBRT: 60 Gy, 75 mg/m2/d temozolomide) and adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
2531801|NCT02684825|Experimental|Continuous plus standard cardiac monitoring|Continuous cardiac monitoring by Reveal LINQTM- LNQ11 Internal Loop Recorder (ILR) plus standard cardiac monitoring
2531803|NCT02684825|No Intervention|Standard cardiac monitoring|Routine cardiac monitoring with follow-up at the same frequency, but with no Implantable Loop Recorder
2531892|NCT02684656|Active Comparator|Hemodialysis|Intervention: Patients will be switch to hemodialysis and basal plasma oxalate levels as well as oxalate removal by hemodialysis will be determined after two weeks of treatment.
2531895|NCT02684656|Active Comparator|Hemodiafiltration|Intervention: Patients will be switch back to hemodiafiltration and basal plasma oxalate levels as well as oxalate removal by hemodiafiltration will be determined after two weeks of treatment.
2531938|NCT02684175|Active Comparator|In-Person CI Counseling Session|Participants (n=6) randomized to receive an in-person CI counseling session will receive what normally occurs with patients pursuing cochlear implantation. The counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, an explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
2531940|NCT02684175|Experimental|Remote CI Counseling Session|Participants (n=6) randomized to receive a remote CI counseling session will be receiving the counseling session remotely. The participants will be counseled remotely by the audiologist located in Lexington, KY via the telemedicine system (intervention). This counseling will last 30-45 minutes and consists 5 key components: an explanation of the patient's hearing testing results, a discussion of the impact of hearing loss on the patient's life, treatment options for hearing loss including hearing aid amplification and cochlear implantation, explanation of how CIs function and the necessary steps in candidacy and rehabilitation, and an outline of the expected outcomes following cochlear implantation.
3200963|NCT00895986|Experimental|2|Heart Healthy Living Diabetes Education
3200964|NCT00895999|Experimental|1|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to 8 individual sessions of IPT adapted for depression and pain.
2532062|NCT02683343||carpal tunnel syndrome|No intervention
2532065|NCT02683343||normals|no intervention
2532159|NCT02682732|Experimental|FDG-PET/CT|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be performed at diagnosis and at the end of induction chemotherapy (like cytarabine and daunorubicin). Then, patients will be followed to assess their response, and imaging-guided bone marrow sampling will be repeated in the likely event of disease relapse.
2532217|NCT02682433|Experimental|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same position, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
2532220|NCT02682433|Experimental|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, and in the same positionabdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
2532272|NCT02682017|Placebo Comparator|Treatment 1|Pork meat from pigs feed with a standard feed
2532273|NCT02682017|Experimental|Treatment 2|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix
3200965|NCT00895999|Other|2|Female patients (n=30) who meet criteria for major depression and chronic pelvic pain will be randomly assigned to Enhanced Support and Connection to Counseling (ESCC).
3200966|NCT00896077|Active Comparator|Subcutaneous|Subcutaneous administration of LSF
2531565|NCT02686593|Other|Clofarabine, AraC, mitoxantrone (CLAM)|This is the single arm with the intervention using Clofarabine, AraC, Mitoxantrone
3200967|NCT00896077|Active Comparator|IV|IV administration arm
3200968|NCT00896129||Study population|
2531683|NCT02685670|Experimental|Mixed CD19CAR transfer|All subjects will be infused with αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T cells in equal number
2531758|NCT02685371||Breathing effort type|Current known criteria for constrictive pericarditis will be test under: 1- spontaneous breathing 2- Breathing with a negative pressure of -15 to - 30 cm of water 3- Breathing with a negative pressure of more than - 30 cm of water.
2531832|NCT02685098|Experimental|Active/Treatment Group|Amputation performed at 7 days post allogeneic bone marrow derived mesenchymal stem cell injections.
2531840|NCT02685098|No Intervention|Observation Group 1|Amputation performed with no MSC administration. Subjects will be followed for incidence of infection and wound healing status to week 24 as a comparator to the Active/Treatment group.
2531844|NCT02685098|No Intervention|Observation Group 2|"Tissue Collection Group:~Amputation performed with no MSC administration. Subjects will not be followed after amputation is performed. Tissue collection will occur at time of amputation."
2531847|NCT02685098|No Intervention|Observation Group 3|Patients undergoing lower extremity bypass grafting procedure. Skeletal muscle samples of the sartorius and anterior tibial muscle will be collected for comparison to treatment group. No study testing, nor follow up visits will occur.
2531850|NCT02685098|No Intervention|Control Group 4|Patients undergoing a standard of care surgical procedure under anesthesia. Core needle biopsies will be collected from the anterior tibial muscle at the time of surgical procedure. No study testing, nor follow up visits will occur.
2531871|NCT02684487|Active Comparator|vitamin D3|Patients will be given single dose of vitamin D3 within 24 hours of new-onset severe sepsis, followed by weekly doses of vitD3 (25,000 IU) up to 90 days to assess clinical outcomes and key biomarkers.
2531872|NCT02684487|Sham Comparator|Placebo|Patients will be given placebo intervention within 24 hours of new onset severe sepsis followed by or placebo for up to 90 days to assess clinical outcomes and key biomarkers.
2531951|NCT02684240|Experimental|Nitazoxanide|Participants with drug-sensitive tuberculous randomized to the NTZ arm will receive nitazoxanide 1000 mg po twice daily for 14 days. After this time point, participants will be switched to WHO standard tuberculosis therapy with isoniazid, rifampin, pyrazinamide and ethambutol.
2531959|NCT02684240|Other|Control|Participants with drug-sensitive tuberculosis randomized to the standard therapy arm will receive WHO standard tuberculosis therapy involving isoniazid 300 mg po daily, rifampin 600 mg po daily, pyrazinamide 25 mg/kg po daily and ethambutol 15 mg/kg po daily.
3200969|NCT00896155|Experimental|Concurrent Tamoxifen and Radiotherapy|ARM 1 will receive Tamoxifen given concurrently with radiotherapy. Tamoxifen will continue for a period of 5 years.
3200970|NCT00896155|Active Comparator|Sequential radiotherapy and tamoxifen|ARM-2 shall receive radiotherapy followed by tamoxifen sequentially. Again tamoxifen will continue for a period of 5 years.
3200971|NCT00896194|Active Comparator|1: Standard Behavioral Treatment (SBT)|This group receives standard behavioral treatment for weight loss as described below.
2532282|NCT02681822||Healthy young subjects|Healthy young Chinese Han subjects aged 18-30
2532321|NCT02681679|Experimental|0.1% bromfenac ophthalmic solution|Patients received 0.1% bromfenac ophthalmic solution twice a day for 3 days before surgery.
2532324|NCT02681679|Placebo Comparator|control physiological normal saline|Patients received control physiological normal saline twice a day for 3 days before surgery.
2532388|NCT02681354|Experimental|A additional BioRescue training|Using a playful rehabilitation, BioRescue
2532406|NCT02681354|No Intervention|Regular training|
3200972|NCT00896194|Experimental|2: Modified SBT + Self-Efficacy|This group receives modified SBT with an additional self-efficacy component as described below.
2532557|NCT02680197|Experimental|CHF5259 12.5 μg total daily dose|"CHF5259 or Placebo administration:~Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI matched placebo twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2534016|NCT02670486|No Intervention|standard of care|Usual urodynamics with no intervention.
3200973|NCT00896207|Experimental|Arm I|Participants complete an overnight fast of ≥ 10 hours, eat a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800-1,000 calories) meal, and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
3200974|NCT00896207|Experimental|Arm II|Participants complete an overnight fast of ≥ 10 hours and then receive a single dose of oral SR13668 in a PEG400/Labrasol® liquid formulation with 8 ounces of water. Participants may not eat for ≥ 4 hours after study drug administration.
3200975|NCT00896207|Experimental|Arm III|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol® self-emulsifying solid dispersion capsule formulation.
3200976|NCT00896207|Experimental|Arm IV|Participants receive a single dose of oral Akt inhibitor SR13668 in a Solutol®/vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
3200977|NCT00896207|Experimental|Arm V|Participants receive a single dose of oral Akt inhibitor SR13668 in a vitamin E TGPS self-emulsifying solid dispersion capsule formulation.
3200978|NCT00896207|Experimental|Arm VI|Participants receive a single dose of oral Akt inhibitor SR13668 in a Myrj 53 self-emulsifying solid dispersion capsule formulation.
3200979|NCT00896220||ICU Survivors and Their Family Caregiver|ICU Survivors who required one week or more of mechanical ventilation during their critical illness and their primary family caregiver
3200980|NCT00896246|Active Comparator|Klean-Prep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Klean-Prep® (4 L) containing 99mTc-DTPA administered as a divided dose.
2531471|NCT02687373|Placebo Comparator|Part 1: Grp 2C - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2531475|NCT02687373|Experimental|Part 1: Grp 2D - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531476|NCT02687373|Placebo Comparator|Part 1: Grp 2D - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531478|NCT02687373|Experimental|Part 1: Grp 2E - PfSPZ Vaccine|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531479|NCT02687373|Placebo Comparator|Part 1: Grp 2E - Normal Saline|"Children aged 13-59 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 2D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531481|NCT02687373|Experimental|Part 1: Grp 3A - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 1.35 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2531483|NCT02687373|Placebo Comparator|Part 1: Grp 3A - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 2B has been shown to be well-tolerated and without safety concerns."
2531484|NCT02687373|Experimental|Part 1: Grp 3B - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 2.7 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
2531487|NCT02687373|Placebo Comparator|Part 1: Grp 3B - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3A has been shown to be well-tolerated and without safety concerns."
2531490|NCT02687373|Experimental|Part 1: Grp 3C - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Dose of 4.5 x 10^5 PfSPZ Vaccine administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
2531492|NCT02687373|Placebo Comparator|Part 1: Grp 3C - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Normal saline administered DVI, as a single vaccination. This dose will be administered 2 weeks after Grp 3B has been shown to be well-tolerated and without safety concerns."
2531493|NCT02687373|Experimental|Part 1: Grp 3D - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 9.0 x 10^5 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531494|NCT02687373|Placebo Comparator|Part 1: Grp 3D - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3C has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531495|NCT02687373|Experimental|Part 1: Grp 3E - PfSPZ Vaccine|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=8; Two doses of 1.8 x 10^6 PfSPZ Vaccine administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531496|NCT02687373|Placebo Comparator|Part 1: Grp 3E - Normal Saline|"Children aged 5-12 months (inclusive) of age will be enrolled in this group.~N=4; Two doses of normal saline administered DVI, 8 weeks apart. The 1st dose will be administered 2 weeks after Grp 3D has been shown to be well-tolerated and without safety concerns. The 2nd dose will be administered 8 weeks after the 1st dose in this group does not show any safety signals."
2531497|NCT02687373|Experimental|Part 2: Group 1 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the highest dose that is determined to be safe and well tolerated in the Part 1 trial, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 1.8 x 10^6 PfSPZ per dose."
2531499|NCT02687373|Experimental|Part 2: Group 2 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; the second highest dose, which is half of the highest dose, administered in 3 doses by DVI at 0, 8 and 16 weeks. Likely dosage will be 9.0 x 10^5 PfSPZ per dose."
2531501|NCT02687373|Experimental|Part 2: Group 3 - PfSPZ Vaccine|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a lower dose (half of the second highest dose) administered in 3 doses by DVI at 0, 8, 16 weeks. Likely dosage will be 4.5x 10^5 PfSPZ per dose."
2531502|NCT02687373|Placebo Comparator|Part 2: Group 4 - Normal Saline|"Infants aged 5-12 months (inclusive) of age at vaccination will be enrolled in Part 2.~N=104; a placebo arm, will receive normal saline by DVI, 3 times at 8 week intervals."
2531577|NCT02686632|Experimental|Palate Brushing|"In this group the intervention is palatal brushing, performed by the participants following each meal for a period of 6 months. This will be performed using the provided toothbrush (device). The results will determine if brushing the palate in an efficient intervention for reducing the microbial count and inflammation associated with denture stomatitis."
2531519|NCT02687087|Experimental|Visco-ease|Visco-ease is a suspension of multilamellar vesicles comprising lipids in ratios which mimic the lipidic composition of endogenous extra-alveolar lamellar bodies. Visco-ease is suspended in physiological saline (0.9% NaCl) to provide a final dose concentration of 19.6 mg/mL. Visco-ease is a white to off-white turbid suspension. The device under evaluation in this clinical investigation is Visco-ease at a concentration of 19.6 mg/mL.
2531525|NCT02687087|Placebo Comparator|RIX-Placebo|Physiological Saline (sodium chloride 0.9% (w/v)
2531587|NCT02686658|Experimental|Dose Group 1|Zimura Dose Administration 1
2531592|NCT02686658|Experimental|Dose Group 2|Zimura Dose Administration 2
2531595|NCT02686658|Sham Comparator|Dose Group 3|Sham Administration 1
2531597|NCT02686658|Experimental|Dose Group 4|Zimura Dose Administration 3
2531599|NCT02686658|Experimental|Dose Group 5|Zimura Dose Administration 4
2531601|NCT02686658|Sham Comparator|Dose Group 6|Sham Administration 2
2531647|NCT02686073||Group A|Underweight participants whose body mass index is less than 18.5 kg/m2
2531649|NCT02686073||Group B|Control group, in which the participants belong to the normal body mass index range , from 18.5 to 29.9 kg/m2
2531654|NCT02686073||Group C|Obese participants whose body mass index is more than or equal to 30 kg/m2.
2531706|NCT02685761|No Intervention|Low Transverse|Patients in this arm will undergo their cesarean section using the standard low transverse skin incision location
2531709|NCT02685761|Experimental|Midline Vertical|Patients in this arm will undergo their cesarean section using a midline vertical skin incision
2531715|NCT02685761|Experimental|High Transverse|Patients in this arm will undergo their cesarean section using a high transverse skin incision, above the pannus
2531729|NCT02685319|Experimental|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
2531857|NCT02684721|No Intervention|Control group|Patients in the control group receive usual care as a minimum. This includes 3-5 days of hospitalisation where the anticoagulant treatment is initiated. The patient and the relatives receive general information about the disease and the course of treatment, the medication and future prevention of embolism. In the year following discharge the patient is booked for a check-up of their anticoagulant treatment with a physician or a nurse as required.
2531858|NCT02684721|Experimental|Exercise group|8-week home-base exercise programme: Patients in the intervention group receive the same usual care as patients in the control group. In addition the patients participate in an 8 week home-based exercise programme, including follow-up telephone calls with the physiotherapist after 1 week, 2 weeks and 4 weeks. Briefly put, the patients are required to exercise for a minimum of 3 times per week for 30-60 minutes, and with 3-4 intervals of approximately 1 minute at a high intensity level. Total exercise time and intervals increase during the 8 week programme. The patients can choose whatever type of exercise they prefer, and they are generally encouraged to choose something they already do, or something that they have previously had positive experiences doing.
3200981|NCT00896246|Experimental|Moviprep®|1 x gelatin capsule containing not more than 1 MBq 111In radiolabelled ion exchange resin plus Moviprep® (2 L) containing radiolabelled 99mTc-DTPA administered as a divided dose.
2531998|NCT02683902|Active Comparator|Active tDCS + Diet|The participants will receive active tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
2531999|NCT02683902|Sham Comparator|Sham tDCS + Diet|The participants will receive sham tDCS treatment every day for 5 days per week, a total of 20 sessions. They will also be prescribed a hypocaloric dietary during these 4-week treatment.
2532078|NCT02683382|Experimental|Moisturizing Eye Product (product in development)|Moisturizing eye product in liquid form (medical device product in development). Part 1 of the study: Administered to both eyes 4 times/day for 1 day. Part 2: to one eye 4 times/day for 9 days. Part 3: to one eye 4 times/day for 45 days. Parts 2 & 3: treatment eyes randomized.
2532081|NCT02683382|Active Comparator|Moisturizing Eye Product, Comparison|Moisturizing eye product in liquid form (medical device CE-marked). Part 2 of the study: Administered to one eye 4 times/day for 9 days. Treatment eyes randomized.
2532083|NCT02683382|No Intervention|No treatment|Part 3 of the study: other eye is a control eye with no treatment for 45 days.
2532097|NCT02682966||PMI|Postoperative Myocardial injury, postoperative troponin levels ≥ 60 ng/L
2532099|NCT02682966||Control|postoperative troponin levels < 60 ng/L
2532173|NCT02682836|Experimental|single arm|Walk with Ease physical activity intervention
2532223|NCT02682316|Active Comparator|usual standard dry gauze used for wound management|Patients who are randomized to the standard dry gauze arm will have the standard dry gauze placed at time of wound closure. Their dressing will be removed on post-operative day 2 as per routine departmental practice.
2532225|NCT02682316|Experimental|Prevena Negative Pressure Wound Therapy System (NPWT)|Patients who are randomized to the Prevena Therapy System arm will have the Prevena Incision Management System device placed at time of wound closure. The device will be removed on day of discharge from the hospital or post-operative day 7, whichever comes first.
2532298|NCT02682043|Experimental|Toy car|The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
2532335|NCT02681562|Experimental|Olaparib triple negative|Olaparib short administration in triple negative breast cancer
2532342|NCT02681562|Experimental|Olaparib BRCA mutated|Olaparib short administration in BRCA mutated patients
2532474|NCT02680704|Other|PEEP Titration Arm|PEEP titrated mechanical ventilation
2532541|NCT02680353|Active Comparator|Study group|Patients received bilateral superficial cervical plexus block before operation
2532542|NCT02680353|No Intervention|Control group|Patients received no intervention before operation
2532555|NCT02679937|Experimental|Fit4Duty|6-week weight gain prevention group
2532564|NCT02679937|Active Comparator|Nutrition Education|Two, 50 minute educational videos.
2534058|NCT02670278||Peru|healthy breastfeeding women and their infants
3200982|NCT00896259||THA control|those with THA not participating in exercise and education program
3200983|NCT00896259||THA exercise|those with THA and participating in exercise and education program
2531558|NCT02686775|Experimental|Patient coach|Standard care and patient coach. 5 face-to-face sessions of approximately 1-2 hours duration and 3 phone calls from inclusion to one month after end of first line treatment. Deviations from this schedule might depend on the treatment modules and on the wishes and needs of the patient. Several patients will continue directly into palliative care and the coach will thus support this transition.
2531559|NCT02686775|Active Comparator|Standard treatment|Standard care.
2531616|NCT02686476|Active Comparator|Empagliflozin dose group|Patient Receive Standard of Care with Empagliflozen
2531617|NCT02686476|No Intervention|Standard dose group|Standard care for Type 2 Diabetes Mellitus upgraded without Empagliflozin
2531648|NCT02686086|Placebo Comparator|Standard hospital jet nebuliser|"Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a standard hospital jet nebuliser.~Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation."
2531651|NCT02686086|Active Comparator|Vibrating mesh nebuliser|Patients admitted to hospital with an acute exacerbation of COPD and prescribed nebulised bronchodilator therapy (combined short-acting salbutamol 2.5mg and ipratropium 0.5mg) will receive their prescribed medication via a vibrating mesh nebuliser (Aerogen Solo) rather than the standard hospital nebuliser Spirometry, lung volume measurement and symptom score (Borg breathlessness scale) will be recorded pre-nebulisation and at one hour post-nebulisation.
2531700|NCT02685709|Experimental|Run-in phase|Oral octreotide capsules
2531705|NCT02685709|Experimental|RCT phase - Oral|Oral octreotide capsules
2531711|NCT02685709|Active Comparator|RCT phase - Injectables|Injectable somatostatin analogs (octreotide or lanreotide)
2531714|NCT02685709|Experimental|Combination phase (sub-study)|Octreotide capsules plus cabergoline
3200984|NCT00896259||healthy control|Healthy control, people with no lower limb gait abnormalities
3200985|NCT00896285|Active Comparator|1|
2531936|NCT02684019|Active Comparator|Dexmedetomidine|1microgram/kilogram loading dose followed by 0.5 microgram/kilogram/hour IV
2531939|NCT02684019|Active Comparator|Magnesium sulphate|40milligram/kilogram loading dose followed by 10milligram/kilogram/hour IV
2532005|NCT02683863|Other|Group 1|"There will be 4 CSF sampling groups at the Week 6 visit for PK assessment:~1. Four subject for CSF samples 3 hours after dosing"
2532010|NCT02683863|Other|Group 2|2. Four subjects for CSF samples 5 hours after dosing
2532012|NCT02683863|Other|Group 3|3. Four subjects for CSF samples 7 hours after dosing
2532013|NCT02683863|Other|Group 4|4. Four subjects for predose CSF samples
2532094|NCT02683200|Experimental|Treatment (MRI-guided Tri-60Co teletherapy SBRT)|Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks.
2532177|NCT02682771|Active Comparator|Control|Individuals were treated with Conventional Respiratory Physiotherapy (CRP), twice in immediate postoperative day and three times in first postoperative day.
2532182|NCT02682771|Experimental|Bilevel positive airway pressure|Individuals were treated with positive pressure, in the BIPAP mode (bilevel positive airway pressure, with inspiratory pressure:12 cmH20 and expiratory pressure: 8 cmH20) twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each
2532185|NCT02682771|Experimental|Load inspiratory breathing exercises|Individuals were treat with PowerBreathe, a device for inspiratory muscle, with 40% maximal inspiratory pressure, measured at preoperative, twice in the immediate postoperative day and three times in first postoperative day, in sessions 1 hour each.
2532230|NCT02682199||Whole Brain Radiation|Patients scheduled to receive whole brain radiation with or without chemotherapy/targeted therapy.
3200986|NCT00896285|Active Comparator|2|
2532362|NCT02681692|Active Comparator|MEI colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system
2532363|NCT02681692|No Intervention|Standard colonoscopy Group|Patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) without the assistance of magnetic scope navigation system
2532364|NCT02681692|Active Comparator|MEI colon model Group|"Colonoscopist would be randomized to perform colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part.~All force variation data would be recorded by a image storage device."
2532366|NCT02681692|No Intervention|Standard colon model Group|Colonoscopist would be randomized to perform conventional colonoscopy on a colon model without an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
3200987|NCT00896285|Active Comparator|3|
3200988|NCT00896285|Active Comparator|4|
3200989|NCT00896311|Active Comparator|1|Treatment solution consisted of 100 micrograms/mL of nitroglycerin. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
2532598|NCT02679846|Experimental|Standardized protocol of AEDs withdrawal|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
2532601|NCT02679846|No Intervention|Current practice|Centers will continue their current practice
2532684|NCT02679443|No Intervention|Delayed Arm|Participants are started on folate and vitamin B12 supplementation for 5-7 days prior to initiation of chemotherapy
2532746|NCT02678962|Active Comparator|SBL-3 group|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
3200990|NCT00896311|Placebo Comparator|2|Placebo solution was saline. After an initial 1ml dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL
3200991|NCT00896324|Active Comparator|Cognitive Rehabilitation (Breast Cancer(BC) with chemotherapy)|Cognitive rehabilitation is a very low-risk method of treatment for cognitive deficits that involves restoring impaired function and/or training the individual to compensate for the area of deficit. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
2531560|NCT02686788|Experimental|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
2531621|NCT02686398|Active Comparator|Fluad|88 CKD patients were vaccinated with Fluad.
2531626|NCT02686398|Active Comparator|Agrippal|86 CKD patients were vaccinated with Agrippal.
2531681|NCT02685969||18F-Flutemetamol & 18F-FDG PET scans|All study participants will be assessed by PET scan with 18F-Flutemetamol & 18F-FDG PET scans.
2531805|NCT02685176|Experimental|No Heat|No active heating will be provided post cooling
2531809|NCT02685176|Experimental|Head|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the head following cooling
2531814|NCT02685176|Experimental|Torso|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, Vancouver) will be applied to the torso following cooling
2531899|NCT02684565|Active Comparator|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
2531902|NCT02684565|Active Comparator|BCAA Low Protein Supplement|Subjects will be randomly assigned to take low BCAA protein a day for 4 weeks after a 2-week washout will switch to the other arm.
2531987|NCT02683915||Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
2531988|NCT02683915||Non-cooled group|Infants in the non-cooled group received the current standard of care and will be placed under radiant heaters or in incubators, which are servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.
3200992|NCT00896324|Active Comparator|Active Neurofeedback (BC pre-chemotherapy)|"In active Neurofeedback session subjects will be trained to increase brain activation in regions associated with executive function (EF) function deficits (as determined by neuroimaging measures) by viewing their own brain activation in real-time. The dose will be 2-3 sessions, each lasting approximately 30 minutes."
3200993|NCT00896324|Sham Comparator|Neurofeedback placebo (Sham) (BC pre-chemotherapy)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
3200994|NCT00896350|Experimental|BOLD MRI|Determine the amount of oxygen supply to tumors.
3200995|NCT00896376|Experimental|trastuzumab|
3200996|NCT00896402|Active Comparator|Chlorhexidine|skin antisepsis with chlorhexidine
3200997|NCT00896402|Active Comparator|Povidone-iodine|skin antisepsis with povidone-iodine
2532338|NCT02681705|Experimental|Study Treatment|All subjects will undergo routine surgical staging of their tumor. Treatment must begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with Temozolomide. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as Temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
2532379|NCT02681198|Experimental|Lofexidine and paroxetine|Lofexidine in the presence of paroxetine
2532440|NCT02680899|Experimental|Curricular Intervention|The intervention is a novel science education curriculum in mental health and addiction called My Mind, My Body.
2532480|NCT02680522|Active Comparator|Control Group|composed of healthy volunteers who underwent training with virtual reality. Exercises with game through virtual reality
2532482|NCT02680522|Experimental|Parkinson's Group|composed of patients with Parkinson's disease and who underwent training with virtual reality. exercises with game through virtual reality
2532530|NCT02680275|Experimental|Doxycycline,Dead Sea Peloid Gel,placebo|"Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by Dead Sea Peloid Gel , 60 ml per day fo 12 days, intravaginally~Group -1 stage: Doxycycline 100mg 2 times per day 10 days; followed by placebo gel, 60 ml per day fo 12 days, intravaginally"
2532552|NCT02680015|Experimental|Experimental Group|Immediate enrollment in the PEERS group.
2532553|NCT02680015|No Intervention|Waitlist Group|Research measures while waiting for PEERS; will receive PEERS within one year.
2532639|NCT02679833|Placebo Comparator|Placebo|A toothpaste, with the same matrix, all components, and appearance like the active arm but not containing vitamin B12.
2532644|NCT02679833|Active Comparator|Cyanocobalamin|A toothpaste with cyanocobalamin 100 µg cyanocobalamin per 1 g.
3200998|NCT00896428|Experimental|1|16 patients with a diagnosis of severe asthma under gallopamil treatment
3200999|NCT00896428|Placebo Comparator|2|16 patients with a diagnosis of severe asthma under placebo treatment
2532766|NCT02678871|Other|All study participants|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.
2532808|NCT02678546||patients in outpatients departments|patients from outpatients departments in teaching hospital
2532813|NCT02678546||General|participants from center of continuing education in China Medical University
3201000|NCT00896493|Experimental|Total lymphoid irradiation & anti-thymocyte immunoglobulin|TLI is administered from a 6 MeV linear accelerator in 80c- 120c Gy fractions. Anti-thymocyte-Globulin (ATG) is administered intravenously for a total dose of 7.5 mg/kg.
3201001|NCT00896545|Experimental|5-keys feeding program|Counseling in small groups aimed at enhancing children's self control over eating
3201002|NCT00896545|Active Comparator|Healthy lifestyle counseling|Counseling in small groups aimed at achieving healthy eating patterns aimed at both the family and young children
3201003|NCT00896558|Experimental|Cohort A|A single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
2531561|NCT02686762|Active Comparator|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
2531564|NCT02686762|Active Comparator|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
2531571|NCT02686762|Placebo Comparator|Matching Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
2531657|NCT02686060|Experimental|in-line filters|0.2 micron positively charged PALL Corporation filters for parenteral nutrition (Posidyne® NEO Intravenous Filter Set) and 1.2 micro IV in-line filters used for lipid administration (Lipipor™ NEO Filters for Neonatal Parenteral Nutrition)
2531660|NCT02686060|No Intervention|without in-line filters.|
3167283|NCT00536393|Active Comparator|Doxorubicine|CHOP 8 courses every 21 days
3167284|NCT00536393|Experimental|Doxorubicine pegylated|CLOP 8 courses every 21 days
2531800|NCT02684994|Other|Cognitive Processing Therapy|Cognitive Processing Therapy
2531928|NCT02684669|Experimental|High-dose naloxone|naloxone 4 mg/ml i.v. infusion, total 3.25 mg/kg, target controlled infusion with three infusion rates (0.25 mg/kg; 0.75 mg/kg; 2.25 mg/kg) each of 25 min duration.
2531931|NCT02684669|Placebo Comparator|Normal saline|0.9% physiological saline, i.v. infusion, total 0.81 ml/kg, target controlled infusion with three infusion rates (0.06 ml/kg; 0.19 ml/kg; 0.56 ml/kg) each of 25 min duration.
2531981|NCT02683967|Active Comparator|Acupuncture|These patients received acupuncture during the follicular development phase and on the day of egg collection.
2531983|NCT02683967|No Intervention|Control|Patients received standard care, no acupuncture.
3167285|NCT00536406|Experimental|A|Participants will receive the BE-ACTIV treatment
3167286|NCT00536406|Active Comparator|B|Participants will receive treatment as usual
2532091|NCT02682992|Experimental|Low Level Laser Therapy|Patients meeting the eligibility criteria will be enrolled to receive prophylactic LLLT in addition to standard of care measures for oral mucositis or other toxicity of therapy. The radiation and chemotherapy dose, schedule, modality, technique, and any required adjustments will not be influenced by this protocol and will follow standard existing institutional practices.
2532138|NCT02682862|Experimental|Spiolto Respimat|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
2532139|NCT02682862|Active Comparator|Striverdi Respimat|olodaterol 2.5mcg 2 puffs OD (once daily) for 2-4 weeks. Participants then enter washout period and receive alternative treatment arm
2532183|NCT02682537||Female, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 Years
2532186|NCT02682537||Female, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
2532188|NCT02682537||Female, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
2532190|NCT02682537||Female, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
2532191|NCT02682537||Female, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
2532193|NCT02682537||Female, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
2532194|NCT02682537||Female, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
2532197|NCT02682537||Female, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
2532199|NCT02682537||Female, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
2532203|NCT02682537||Male, BMI: 14,00-16,49 kg/m²|Age: 18 - 100 years
2532204|NCT02682537||Male, BMI: 16,50-18,49 kg/m²|Age: 18 - 100 years
2532205|NCT02682537||Male, BMI: 18,50-19,99 kg/m²|Age: 18 - 100 years
2532206|NCT02682537||Male, BMI: 20,00-24,99 kg/m²|Age: 18 - 100 years
2532207|NCT02682537||Male, BMI: 25,00-29,99 kg/m²|Age: 18 - 100 years
2532208|NCT02682537||Male, BMI: 30,00-34,99 kg/m²|Age: 18 - 100 years
2532209|NCT02682537||Male, BMI: 35,00-39,99 kg/m²|Age: 18 - 100 years
2532210|NCT02682537||Male, BMI: 40,00-44,99 kg/m²|Age: 18 - 100 years
2532211|NCT02682537||Male, BMI: 45,00-49,99 kg/m²|Age: 18 - 100 years
2532239|NCT02682134|Experimental|"Xylocaine X"|Patients received xylocaine gel as lubricant on endotracheal tube
2532243|NCT02682134|Experimental|"Dexamethasone D"|Patients were given dexamethasone 8 mg intravenously
2532248|NCT02682134|Experimental|"xylocaine and dexamethasone XD"|Patients were given both xylocaine gel and dexamethasone 8 mg intravenously
2532356|NCT02681874|Experimental|Group A (Treatment Arm)|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Sessions are 90 minutes. Groups consist of a maximum of five parents. Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions. Parent Leaders receive a week-long leadership training to deliver the program and will be supervised by the PI who is a licensed clinical psychologist.
2532359|NCT02681874|Active Comparator|Group B (Control Arm)|Parents in the control condition will receive the Smart and Secure Children (SSC) program's written handouts. Handouts include didactic curriculum content and instruct parents to write goals and document goal progress.
3167287|NCT00536419|Placebo Comparator|2|4 days of placebo
3167288|NCT00536419|Experimental|1|MPH-SODAS at day 1 (0.3/mg/kg/day); day 2 (0.7/mg/kg/day);days 3 and 4 (1.0 mg/kg/day)
3167289|NCT00536458|Experimental|radiotherapy|minichep + radiotherapy
3167290|NCT00536458|Active Comparator|B|MINI CHEP
3167291|NCT00536523||Patients Receiving Chemotherapy|Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned
3167292|NCT00536536|Active Comparator|Hospital|Care of Childhood Obesity Clinic (COCO)
2531583|NCT02686632|No Intervention|Regular Oral Hygiene|The participants in this study arm will not be prescribed or allocated any intervention. The participants will be asked to continue with the regular hygiene and denture maintenance practices for the duration of the trial.
2531697|NCT02686008|Experimental|HPV negative tumors|10 patients with HPV negative tumors: Non-oropharyngeal tumors or p16 negative and HPV negative oropharyngeal tumors
2531708|NCT02686008|Experimental|HPV positive tumors|10 patients with HPV positive tumors: p16 positive and HPV positive tumors
3201004|NCT00896558|Experimental|Cohort B|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3201005|NCT00896558|Experimental|Cohort C|Subjects in the probe cohort will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12. All subjects will receive a single dose of midazolam alone on Day -1, and co-administered with the morning dose of GSK1322322/placebo on Day 1 and Day 12.
2531834|NCT02684890||Tinnitus patients|Patients with tinnitus lasting over 3 months
2531842|NCT02684890||Non-tinnitus patients|Patients without tinnitus
3201006|NCT00896558|Experimental|Cohort D|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
3201007|NCT00896558|Experimental|Cohort E|Subjects will receive a single AM dose of GSK1322322/placebo on Day 1, no dosing on Day 2, and BID dosing on Days 3-12.
2531934|NCT02684162|Experimental|Treatment (guadecitabine, DLI)|Patients receive guadecitabine SC QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive DLI IV over 10-30 minutes on day 6 of cycles 2, 4, and 6 in the absence of disease progression or unacceptable toxicity.
3201008|NCT00896571|Experimental|Arm 1|
3201009|NCT00896597|Experimental|NRL972|A single dose of 2 mg NRL972 will be administered on four occasions over a period of up to 6 weeks.
3201010|NCT00896610||Diabetes|Individuals who have been diagnosed with or are at risk for developing diabetes
3201011|NCT00896636||Luteal|Pre-menopausal women who undergo rFNA procedure during the luteal phase of their menstrual cycle.
3201012|NCT00896636||Follicular|Pre-menopausal women who undergo rFNA procedure during the follicular phase of their menstrual cycle.
2532520|NCT02680496|Experimental|Lokomat - Treadmill - Overground|Walking order: lokomat walking, treadmill walking, overground walking
2532523|NCT02680496|Experimental|Lokomat - Overground - Treadmill|Walking order: lokomat walking, overground walking, treadmill walking
2532525|NCT02680496|Experimental|Treadmill - Lokomat - Overground|Walking order: treadmill walking, lokomat walking, overground walking
2532526|NCT02680496|Experimental|Treadmill - Overground - Lokomat|Walking order: treadmill walking, overground walking, lokomat walking
2532528|NCT02680496|Experimental|Overground - Lokomat - Treadmill|Walking order: overground walking, lokomat walking, treadmill walking
2532529|NCT02680496|Experimental|Overground - Treadmill - Lokomat|Walking order: overground walking, treadmill walking, lokomat walking
2532592|NCT02679859|Experimental|B-type natriuretic guided medical therapy optimisation|B-type natriuretic guided medical therapy optimisation
2532596|NCT02679859|No Intervention|Normal medical management|
2532627|NCT02679586|Experimental|Diffusion weighted MRI Group|"All patients will receive a double baseline diffusion weighted MRI (performed on the same day as the Baseline MRI).~Patients participating in Part I will receive another MRI approximately 1 week (day 8-11) after the first dose of Chemotherapy (chemotherapy will be determined by the treating physician and is not assigned as part of this trial).~Patients participating in Part II will receive a single MRI 1-2 weeks after the first dose of Chemotherapy A (chemotherapy will be determined by the treating physician and is not assigned as part of this trial). A second MRI will be repeated within 2 weeks prior to the start of Chemotherapy B."
2532669|NCT02679417|Active Comparator|aerobic exercise|Each participant reach a minimum of 50 minutes of some form of aerobic exercise including running on a treadmill 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
2532670|NCT02679417|Active Comparator|resistant exercise|Each participant reach a minimum of 50 minutes of some form of strength training involving repetitions of a resistance training exercise for each major muscle group at an intensity for at least 60% of a one-repetition max, 5 to 7 days per week for 12 weeks under the supervision of fitness center trainers.
2532710|NCT02679170||Routine clinical practice group (NSCLC ALK+, ROS1)|Patients diagnosed and treated following routine clinical practice, for their NSCLC ALK+ or ROS1
3201013|NCT00896636||Menopause|Women who have entered menopause.
3201014|NCT00896675||patients treated with EGFR inhibitors and/or VEGF inhibitor|
2532913|NCT02677857|Active Comparator|Lifestyle|Participants will be educated on the relationship between MVPA and improved health outcomes, including weight management, and cancer survivorship. The goal will be to increase MVPA to > 40 min/day 5 times/wk As participants will be overweight/obese, inactive, and coming into the program with different levels of baseline fitness and time since last cancer treatment, participants will shape their MVPA to meet the targeted goals. Initially, participants will be encouraged to complete MVPA > 10 min/day 5 times/wk, and then progressively increase MVPA by 5 min/day every week until reaching the intervention goal (week 7 of the 12 week intervention). Participants will be encouraged to do brisk walking and be allowed to accumulate time spent being physically active by engaging in multiple short bouts (i.e., > 10 min in length). Any MVPA in bouts of > 10 min in length will be counted towards the MVPA goal. Participants will self-monitor their MVPA using the Polar® Loop tracking system.
2532915|NCT02677857|Active Comparator|Lifestyle + SB|Participants will receive everything that is described in Lifestyle. Additionally, they will be educated on the relationship between SB and weight management, and cancer survivorship risk. The goal will be to reduce sedentary time by > 2 hrs/day or > 14 hrs/wk. Participants will shape towards the goal. Baseline measures will be used as the starting point from where to calculate the 2 hrs/day reduction, providing participants with a total SB goal per day. For example, if baseline measures indicate that a participant has a mean daily SB amount of 9.75 hrs, the participant's SB goal will be 7.75 hrs/day. To achieve that goal, participants will reduce SB by 20 minutes a day, starting week 2, with a decrease of an additional 20 minutes/day occurring weekly until the SB goal is achieved (week 7 of the 12 week intervention. Participants will self-monitor their SB using the Polar® Loop tracking system.
3201015|NCT00896675||NOT treated with EGFR inhibitors and/or VEGF inhibitor|
2531586|NCT02686645|Experimental|Fecal Microbiota Therapy|Vancomycin 125 mg po qid for 7 days or metronidazole 500 mg po tid for 7 days pre-treatment. Loperamide 4 mg po after morning prep and 2 mg post treatment. The route of administration fecal microbiota will be by retention enema via a rectal tube.
2531635|NCT02686281|Experimental|Cohort A (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo"
2531638|NCT02686281|Experimental|Cohort B (Part A)|"Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo~Interventions:~Drug: GMC-252-L-Lysine Other: Placebo~The dose administered in Part A (fed) was based on the outcome of Part A (fasted)."
2531867|NCT02684708|Active Comparator|COPDAC-28|cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3
2531868|NCT02684708|Experimental|DECOPDAC-21|patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
3167293|NCT00536536|Active Comparator|Primary Care|Primary care clinics (x2)
2532226|NCT02682368||POCUSS Trial-1 Acute Biliary Disease|Patients with suspected biliary pathology which will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
2532227|NCT02682368||POCUSS Trial-2 Acute Diverticulitis|Patients with suspected diverticulitis will undergo POCUS. The results will be compared to the subsequent findings by imagistic means or at time of surgery.
2532228|NCT02682368||Radiology Report|Departmental imaging and reports.
2532229|NCT02682368||Surgical diagnostic|Intraoperative findings of patients that undergo emergency surgery.
2532294|NCT02681991|Experimental|test|Renamezin capsule 2g, tid, PO
2532349|NCT02681640|Experimental|uPAR PET|One injection of 68Ga-NOTA-AE105 followed by Positron Emission Tomography (PET/CT scan) to evaluate possible axillary lymph node metastatic lesions
2532392|NCT02681276|Experimental|Irrigation with 3% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 3 % NaOCl irrigation during instrumentation. If the patient's first visit was on an uneven date the concentration of the irrigant was 3 %.
2532412|NCT02681276|Active Comparator|Irrigation with 0.5% NaOCl|After informed consent the patient was randomly assigned to have the root canal treatment performed with a 0.5 % NaOCl irrigation during instrumentation. If the patient's first visit was on an even date the concentration of the irrigant was 0.5 %.
2532458|NCT02680769|Experimental|Magnesium|300 mg of citrate Mg/daily
2532461|NCT02680769|Placebo Comparator|Placebo|placebo group
2532498|NCT02680418|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
2532499|NCT02680418|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
2532501|NCT02680418|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
2532503|NCT02680418|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
2532504|NCT02680418|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
2532508|NCT02680418|Experimental|Multiple dose|Repeat doses of FDL169 to be administered at a dose level to be determined
2532579|NCT02680093||Cervical length in pregnant women.|"Pregnant Women beyond the date of birth in conservative monitoring and prenatal follow-up. will be followed while coming to routine monitoring.~physiological parameter of cervical length will be measured as the differential predictor to determine their due date."
2534059|NCT02670278||Kenya|healthy breastfeeding women and their infants
3167294|NCT00536549|Experimental|A|Guardina RT monitoring
3167295|NCT00536549|Active Comparator|B|
3167296|NCT00536562|No Intervention|Usual Care|Usual Care as provided through the Stroke Prevention Clinic
3167297|NCT00536562|Active Comparator|Cardiac Rehabilitation|Usual Care plus Comprehensive Cardiac Rehabilitation Program
3167298|NCT00536588|Experimental|SCH 721015 with SCH 209702|
3167299|NCT00536614|No Intervention|A|arm A) gemcitabine/cisplatin in combination with Cetuximab arm B) gemcitabine/cisplatin alone
3167300|NCT00536627|Experimental|1|Patients will receive 5 injections of DNA vaccine at weeks 0, 8, 16, 40, 44.
3167301|NCT00536627|No Intervention|2|
3167302|NCT00536640|Experimental|Arm A (Erlotinib, Bevacizumab)|
3167303|NCT00536640|Active Comparator|Arm B (Gemcitabine, Cisplatin, Bevacizumab)|
3167304|NCT00536653|Active Comparator|Osteporosis Group|Patients with a presenting T score < -2.5 (osteoporosis), treated with bicalutamide and Ca/VitD
3167305|NCT00536653|Active Comparator|Osteopenia Group|Patients with a presenting T score between -1.0 and -2,4 (osteopenia), treated with LHRH agonists and Ca/VitD
3167306|NCT00536653|Active Comparator|Normal Group|Patients with a presenting T score > -1.0(normal BMD), treated with LHRH agonists
3167307|NCT00536666|Other|1|Iron oligosaccharide
3167308|NCT00536679|Experimental|Sequence ABC|Subjects will be randomized to sequence ABC, where A=1 milligram (mg) GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3167309|NCT00536679|Experimental|Sequence ACB|Subjects will be randomized to sequence ACB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
2531603|NCT02686515|Experimental|Dual-task balance training group|Participants in the dual-task training group will also participate in a 12-session program conducted 60 minutes per session, 3 days a week, for a total of 4 weeks. They will perform a cognitive task or motor task concurrently with the balance/gait task. The framework of progressive balance exercises in the dual-task training group will be progressed from simple to more complex tasks as outlined for the single-task training group. In addition, a variety of added tasks will be progressively integrated into the dual-task balance training program.
2531636|NCT02686216|Experimental|F-18 THK-5351|F-18 THK-5351 imaging
2531707|NCT02685618|Experimental|Iloprost + M1006B offset by -10 mmHg|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Iloprost + M1006B offset -10mmHg"
2531710|NCT02685618|Experimental|Iloprost + M1006B, No offset|"Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Iloprost + M1006B, No offset"
2531713|NCT02685618|Placebo Comparator|Placebo + M1006B offset by -10 mmHg|"Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg~Intervention: Drug: Placebo + M1006B offset -10mmHg"
2531716|NCT02685618|Placebo Comparator|Placebo + M1006B, No offset|"Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset~Intervention: Drug: Placebo + M1006B, No offset"
2531730|NCT02685280|Experimental|DBS for psychiatric disorders patients|Patients on deep brain stimulation for either obsessive-compulsive disorder or major depression, undergoing rechargeable neurostimulator implantation as intervention
2531779|NCT02685163|Experimental|Antioxidant Ice-cream|Natural antioxidant Ice-cream
2531781|NCT02685163|Placebo Comparator|Control Ice-cream|Natural control ice-cream
2531835|NCT02684760|Experimental|Cohort 1: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2531845|NCT02684760|Experimental|Cohort 2: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2531849|NCT02684760|Experimental|Cohort 3: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2531852|NCT02684760|Experimental|Cohort 4: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2531854|NCT02684760|Experimental|Cohort 5: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
2531856|NCT02684760|Experimental|Cohort 6: PF-06651600|Single dose of PF-06651600 50 mg tablet (under fasted condition and following high fat meal) and 50 mg oral formulation (under fasted condition) to evaluate bioavailability.
3167310|NCT00536679|Experimental|Sequence BAC|Subjects will be randomized to sequence BAC, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
2532087|NCT02683395|Experimental|Treatment Group A|Open label, sequential PLX51107 dose escalation in approximately 30 solid tumor subjects.
2532088|NCT02683395|Experimental|Treatment Group B|Open label, sequential PLX51107 dose escalation in approximately 30 subjects with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
2532141|NCT02682888|Experimental|high trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
2532142|NCT02682888|Experimental|low trait anxiety group|experiment 1: identified according to scores of the trait anxiety scale.
2532143|NCT02682888|Experimental|oxytocin group|experiment 2: intranasal administration of oxytocin
2532144|NCT02682888|Placebo Comparator|placebo control group|experiment 2: intranasal administration of placebo
2532192|NCT02682485|Experimental|Cipro, metronidazole, neomycin combo|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with a direct topical antibiotics solution composed of metronidazole, ciprofloxacin and neomycin.
2532195|NCT02682485|Placebo Comparator|Saline|As part of each serial endoscopic surveillance, a second lavage of the anastomosis will be performed prior to removing the endoscope. In this arm, the lavage will be with direct topical saline.
2532267|NCT02682173|Active Comparator|Laparoscopic gastric bypass|MR Abdomen in morbidly obese patients receiving gastric bypass
2532268|NCT02682173|Active Comparator|Laparoscopic sleeve gastrectomy|MR Abdomen morbidly obese patients receiving sleeve gastrectomy
2532354|NCT02681796|Experimental|Study: Bupivacaine Epidural + standard of care pain regimen|-The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
2532358|NCT02681796|No Intervention|Control: Standard of care pain regimen|-The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
2532394|NCT02681224|Active Comparator|Active Product with Occlusion|TR987 Gel with Silon Bandage
2532413|NCT02681224|Active Comparator|Active Product without Occlusion|TR987 without Silon Bandage
2532421|NCT02681224|Placebo Comparator|Placebo Gel with Occlusion|Placebo Gel with Silon Bandage
3201016|NCT00896688||Healthy Volunteers|It will involve 5 volunteers and they will undergo C arm fluoroscopic guided cervical medial branch blocks (C2-C7) on unilateral position and then followed by the 3D ultrasound machine for visualization of needle position.
3201017|NCT00896688||Candidates for upper and lower cervial medical branch blocks|This will involve 25 patients and they will follow the same procedures as the healthy volunteers.
2531761|NCT02685254|Experimental|Initial group therapy|'Structural skills training group' - Start up with weekly structured skills training group for 14 weeks supplemented by homework training
2531764|NCT02685254|Other|Initial control condition|Treatment as usual/clinical management the first 15 weeks pending deferred start of group therapy (partially cross-over)
2531774|NCT02684968|Experimental|Colorectal Surgery with QL block having anesthetic|Bilateral QL catheter with local anesthetic infusion + intravenous patient controlled narcotic medication
2531775|NCT02684968|Placebo Comparator|Colorectal Surgery with QL block having saline|Bilateral QL catheter with normal saline infusion + intravenous patient controlled narcotic medication
3201018|NCT00896701||Patient samples from C9621, C9720 and C19808|This is a CALGB Leukemia Tissue Bank project that makes use of tissue from patients who have previously provided their consent. Diagnostic and follow-up samples from acute myeloid leukemia (AML) patients treated on CALGB protocols 9621, 9720 and 19808, and who have been registered on the mandatory companion Leukemia Tissue Bank Protocol CALGB 9665 will be used.
3201019|NCT00896714|Experimental|Closed loop anesthesia|
3201020|NCT00896753||patients with metastatic colon cancer|
3201021|NCT00896831|Active Comparator|L-ornithine-L-aspartate|5 g L-ornithine-L-aspartate (1 sachet) three times per day for 60 days
3201022|NCT00896831|Placebo Comparator|placebo|5 g (1 sachet) of placebo comparator three times per day for 60 days
2532054|NCT02683434|Experimental|KT|Kinesio Taping Application
2532055|NCT02683434|No Intervention|CONTROL|
3201023|NCT00896844|Experimental|emotional disclosure|writing about emotional events from the past
3201024|NCT00896844|Placebo Comparator|placebo writing|writing about how they spent their time the previous day
2532137|NCT02682849||Retrospective cohort|
2532140|NCT02682849||Prospective PleuralFlow cohort|
2532178|NCT02682589|Active Comparator|Open surgery|Patients undergo open CME. A standard midline incision carefully protected is made through the abdominal wall and the abdominal cavity is explored. A colectomy with CME is performed with the removal of the afflicted colon and its accessory lymphovascular supply at their origins by resecting the colon and mesocolon in an intact envelope of visceral peritoneum and mesenteric fascia.
2532184|NCT02682589|Experimental|Laparoscopic surgery|Patients undergo laparoscopic CME. A small infraumbilical incision is made through the abdominal skin and the abdominal cavity is insufflated with carbon dioxide to allow access and visualization. The abdominal cavity is explored. A colectomy with CME is performed using laparoscopic-assisted techniques. A 6-8cm midline auxiliary incision is made for specimen extraction and anastomosis.
2532240|NCT02682251|Experimental|Heart Failure Patients with CRT-CIED|PHR Messaging to notify patient of device transmitted information (i.e. percentage LV pacing)
2532301|NCT02681952|Active Comparator|Renamezin->Kremezin|
2532302|NCT02681952|Active Comparator|Kremezin->Renamezin|
3201025|NCT00896883|Experimental|Middle Turbinate Implant|Subjects to receive Middle Turbinate Implant
3167311|NCT00536679|Experimental|Sequence BCA|Subjects will be randomized to sequence BCA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3201026|NCT00896961|Experimental|Observational (EF5)|Approximately 24-48 hours prior to surgical resection or biopsy, patients receive EF5 IV over no more than 2½ hours. Tissue samples are analyzed by immunohistochemistry for EF5 binding. Blood samples are analyzed for genetic markers and cytokines associated with hypoxia and EF5 concentration.
2532471|NCT02680678|Active Comparator|Colloid preload|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) 15 minutes before spinal anesthesia.
2532472|NCT02680678|Active Comparator|Colloid Co-load|20 patients each patient receives 7 ml/kg of gelatin solution (gelofusin) beginning with spinal anesthesia.
2532475|NCT02680678|Active Comparator|Crystalloid Preload|20 patients each patient receives 20 ml/kg of Ringer's lactate solution 15 minutes before spinal anesthesia.
2532478|NCT02680678|Active Comparator|Crystalloid Co-load|20 patients each patient receives 20 ml/kg of Ringer's lactate solution beginning with spinal anesthesia.
2532531|NCT02680262|Experimental|Intervention group 1|HPV self-sampling kit mailed directly
2532532|NCT02680262|Experimental|Intervention group 2|HPV self-sampling kit on demand
2532535|NCT02680262|Experimental|Intervention group 3|second reminder
2534060|NCT02670278||Ethiopia-rural|healthy breastfeeding women and their infants
3201027|NCT00896974|Experimental|Arm I|Participants receive a single dose of oral 9cUAB30 on day 1.
3201028|NCT00896987|Experimental|1|lamotrigine
3201029|NCT00896987|Active Comparator|2|carbamazepine
3201030|NCT00897026||Group 1|Tissue samples are collected from patients. Tissue samples are analyzed by immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
3201031|NCT00897117||Resectable non-small cell lung cancer|Patients with clinical stage I or II invasive lung cancer that can be completely removed by surgery and who have not undergone chemotherapy or radiotherapy before surgery
3201032|NCT00897130|Experimental|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted.
3201033|NCT00897169|Experimental|A|
3201034|NCT00897169|Experimental|B|
3201035|NCT00897182||Group 1|This is a CALGB Leukemia Tissue Bank project makes use of tissue from patients who have previously provided their consent. Diagnostic samples from patients enrolled on CALGB AML treatment studies (eg, CALGB 9621, 9710, and 19808) and who have been registered on the companion Leukemia Tissue Bank Protocol CALGB 9665 were used.
3201036|NCT00897221|Experimental|Dose 1|Deferiprone oral solution 20 mg/kg/day
3201037|NCT00897221|Experimental|Dose 2|Deferiprone oral solution 40 mg/kg/day
3201038|NCT00897234||Healthy Volunteers|Non-smoking healthy volunteers
2531731|NCT02685397|Experimental|LHRH agonist + Enzalutamide + SBRT|Subjects will receive LHRH agonist in combination with the new generation of hormone therapy (enzalutamide, 40mg) plus the additional SBRT treatment
2531830|NCT02684877||Intensive care survivors|Observational study
3201039|NCT00897234||Non-Small Cell Lung Cancer|Patients with non-small cell lung cancer.
3201040|NCT00897260|Experimental|1|
3201041|NCT00897286||Tumor/Tissue Sample|Tumor material collected prospectively from a clinically well characterized patient cohort
3201042|NCT00897325||Ancillary-Correlative (Collecting and banking ALL specimens)|Patients undergo collection of bone marrow and peripheral blood at diagnosis of relapse and/or at the end of the first month of treatment.
3201043|NCT00897377|Experimental|Total resection with early radiation|Total resected LGGs treated with early radiation
2532067|NCT02683408|Experimental|diosmiplex|diosmiplex 630 mg BID administered orally
2532068|NCT02683408|Placebo Comparator|placebo|placebo BID administrered orally
2532120|NCT02682940|Other|Usual Care Patients on MDI or CSII|Usual care patients on multiple daily injections of insulin (MDI) or insulin pumps (CSII) will be their own controls against baseline and will use the Vigilant Diabetes Management Application in conjunction with a wireless blood glucose meter for three months.
2532180|NCT02682654|Experimental|Ankle/Knee brace|Dr. Scholl's Prototype Ankle or Knee Brace
3201044|NCT00897377|No Intervention|Total resection without radiation|Total resected LGGs treated without radiation
3201045|NCT00897377|Experimental|Residual LGGs with radiation|Residual LGGs treated with early radiation
2532433|NCT02680977|Experimental|MP-Equivalent; MP-Low; MP+DDCI|"MP-Equivalent: Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI (for example 100mg of Madopar corresponds to 500mg of Levodopa in MP).~MP-Low: Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 350mg of Levodopa in MP) MP+DDCI: Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI (for example 100mg of Madopar corresponds to 100mg of Levodopa in MP plus 25mg of Benserazide)"
2532434|NCT02680977|Active Comparator|LD+DDCI; LD-DDCI|"LD+DDCI: Levodopa plus Benserazide (dispersible formulation). The dose is calculated as 3.5mg per kg of body weight.~LD-DDCI: Levodopa without any dopa decarboxylase inhibitor (galenic formulation). The dose is 5-fold than LD+DDCI."
2532436|NCT02680977|Placebo Comparator|Placebo|Powder of groundnuts
2532506|NCT02680535|Experimental|AuroShell particle infusion|Single intravenous infusion of AuroShell particles 12 to 36 hours prior to ultrasound-guided laser irradiation using a FDA cleared laser and an interstitial optical fiber.
3201046|NCT00897377|Experimental|Residual LGGs with chemo|Residual LGGS treated with temozolomide
2532659|NCT02679521|Active Comparator|rESWT|Radial extracorporeal shock wave therapy (rESWT).
2532660|NCT02679521|Placebo Comparator|Placebo|Placebo treatment.
2532712|NCT02679183|Placebo Comparator|Control 0|No Intervention. This group received Premature Milk Formula. This group did not receive any Medically-Graded Honey.
2532716|NCT02679183|Experimental|Group 1|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 5 gram/day) for 2 weeks
2532720|NCT02679183|Experimental|Group 2|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 10 gram/day) for 2 weeks
2532722|NCT02679183|Experimental|Group 3|This group received Premature Milk Formula. This group received Medically-Graded Honey (dose = 15 gram/day) for 2 weeks
2532794|NCT02678806|Experimental|Postoperative radiotherapy group|Patients hospitalized in Affiliated Tumor Hospital of Guangxi Medical University from 1st November 2017, who were diagnosed as BCLC-A stage hepatocellular carcinoma, accepted hepatocellular carcinoma resection, pathologically confirmed as narrow margin (the closest distance from margin to tumor capsule < 1cm) and microvascular invasion was found in tumor capsule and adjacent tissues junction were selected and received margin postoperative radiotherapy.
2532795|NCT02678806|Active Comparator|Postoperative TACE group|
2532842|NCT02678403|Experimental|1 - TENS group|The treatment will consist of Transcutaneous electrical nerve stimulation (TENS): stimulation of the leg (frequency of 10 Hz, Biphasic, with a pulse width of 200 µs, maximal intensity below motor threshold), 45 minutes per day, in the morning before the exercise rehabilitation programme, for 3 weeks, 5 days per week.
2532845|NCT02678403|Sham Comparator|2 - SHAM group|SHAM Transcutaneous electrical nerve stimulation (TENS) : the stimulation placebo will be delivered according to the same modalities as for the TENS group but with a voltage level that vanishes automatically after 10 seconds of stimulation.
2532867|NCT02677974||On-X Aortic Heart Valve replacement|Patients with On-X Aortic Valve maintained on low dose warfarin anticoagulation with an INR target of 1.5 to 2.0, with or without home monitoring.
2533026|NCT02677259|Experimental|Estradiol + Standard Luteal Phase Support|"17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation~Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation"
3201047|NCT00897429||Ancillary-Correlative (laboratory biomarker analysis)|Previously collected tissue samples are analyzed for K-ras mutations; COX-2, phospho-AKT, and VEGF overexpression; microvessel density; association of genomic instability with microsatellite instability and p53 mutations; and methylation status of MLH1, MGMT, and WRN and to identify prognostic biomarkers by LINE-1 hypomethylation, PIK3CA mutation, BRAF mutation, FASN expression, and VDR expression via immunohistochemistry, PCR, RT-PCR, and microarray.
3201048|NCT00897442||Ancillary-Correlative (biomarker sampling and analysis)|Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.
3201049|NCT00897468||breast cancer patients|
3201050|NCT00897637||Observational|Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An additional 300 specimens are examined for gene expression and categorized according to the classifiers.
3201051|NCT00897650||Lung cancer|Patients with a diagnosis of invasive lung cancer.
2531746|NCT02685449|Placebo Comparator|group A|"On the first study day, insulin bolus was not given before a standardized pure protein meal. On the second day, pre-breakfast insulin was given as a square-wave bolus before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
2531749|NCT02685449|Active Comparator|group B|"On the first study day, pre-breakfast insulin was given as a square-wave bolus before a standardized pure protein meal. On the second day, insulin bolus was not given before the same standardized pure protein meal.~The fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
3201052|NCT00897663||Single group|Tissue samples from patients enrolled on clinical trials NCCTG-N0177 or NCCTG-N0074 are analyzed by microarray analysis and immunohistochemistry for biological markers predicting progression-free survival and overall survival. Biological markers include epidermal growth factor expression, vIII mutant p53 gene, P-AKT, p7056k, S6, 4EBP1, STAT-3, PLC-g, Erk, ErbB2, ErbB3, ErbB4, platelet-derived growth factor receptor, IGF1R, interleukin-6, FADD, and MGMT.
3201053|NCT00897793||patients with epithelial cancers|Patients with head and neck cancer, and lung, breast, colorectal, and prostate cancers who are to undergo radiation therapy
3201054|NCT00897806||Genetic Markers|
3201055|NCT00897832||pancreatic cancer|Patients with pancreatic cancer
3201056|NCT00897858||Pediatric CNS tumor patients|Newly diagnosed pediatric patients with CNS tumor and no prior irradiation or chemotherapy
3201057|NCT00897884|Experimental|Metformin|Patients will take metformin three times a day for two to three weeks prior surgery.
2531874|NCT02684383|Experimental|rDEN3∆30 vaccine|Participants will receive the rDEN3∆30 vaccine at Day 0.
2531878|NCT02684383|Placebo Comparator|Placebo|Participants will receive placebo at Day 0.
2531957|NCT02684253|Experimental|Nivolumab 3mg/kg IV every 2 weeks|Nivolumab 3mg/kg IV every 2 weeks
2531965|NCT02684253|Experimental|Stereotactic Body Radiotherapy & Nivolumab|"Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions given every other day) to a single lesion to start by study day 14 (study day 1 is day of first dose of Nivolumab).~Nivolumab 3mg/kg IV starting day 1 and then every 2 weeks thereafter. Treatment with Nivolumab will continue until progression or unacceptable toxicity."
2532027|NCT02683694|Other|study arm|iOCT is performed
3201058|NCT00897962||Metastatic Breast Cancer|Patients with metastatic breast cancer receiving treatment with chemotherapy, endocrine therapy or targeted therapy
3201059|NCT00897962||Non-cancer medical illness|Patients with non-cancer medical condition
3201060|NCT00897962||Healthy Controls|Healthy patients being seen for an annual exam
3201061|NCT00897975|Experimental|red yeast rice (RYR) plus phytosterol|arm will take red yeast rice and phytosterol supplement
2532187|NCT02682550||Ctrl|healthy volunteers, sex- and age matched Blood drawing at one time point: 20 ml
2532189|NCT02682550||PT|"polytrauma patients fulfilling the following criteria:~injury severity score ≥25~age ≥ 18 Blood drawing at admission to the emergency room, 8 h, 24h, 48 h, 120 h and 240 h post trauma: 20 ml"
2532231|NCT02682212|Experimental|Physiotherapy intervention|Intensive pelvic floor muscle training (PFMT) given by a physiotherapist with vaginal/rectal pressure feedback once a week for 12 weeks.
3201062|NCT00897975|Placebo Comparator|red yeast rice plus placebo|
3201063|NCT00897975|Active Comparator|TLC plus red yeast rice plus placebo|subjects attend 12 week therapeutic lifestyle program and take above supplement
3201064|NCT00897975|Experimental|TLC plus RYR plus phytosterol|Therapeutic lifestyle program for 12 weeks plus red yeast rice plus phytosterol
3201065|NCT00898053||Correlative studies|Previously archived tumor samples are analyzed for p53 mutations and p16 deletion by immunohistochemistry, FISH, PCR, and DNA sequencing.
3201066|NCT00898079||Observational|Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
3201067|NCT00898092||Group 1|Peripheral blood and bone marrow samples are analyzed to assess gene expression using polymerase chain reaction (PCR) or reverse transcriptase-PCR assays and microarray assays. Genes to be studied include BAALC, ERB, EVI1, MLL, FLT3, NPM1, and CEBPA.
3201068|NCT00898170|Experimental|myoma, with or without hypertension|those with myoma with or without hypertension in holter monitoring
3201069|NCT00898209||Health Volunteers|Blood and exhaled breath condensate will be collected.
3201070|NCT00898209||Patients at risk or already identified as having lung cancer|Blood and exhaled breath condensate will be collected.
3201071|NCT00898274||High risk for developing prostate cancer|Male subjects age 45-65 at high risk for developing prostate cancer.
3201072|NCT00898274||Healthy participants|Aged matched healthy participants
2531754|NCT02685592|Experimental|Lentigo maligna patients|All the participants with histologically confirmed lentigo maligna will receive photodynamic therapy three times with 2 weeks' intervals. The borderline of treatment area is delineated with Wood's lamp and hyperspectral imaging system using 5 millimeter margins. Before applying the 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) light sensitizing gel the skin of treatment area is prepared with fractional ablative CO2-laser to enhance absorption. Ameluz® is spread as a 1 millimeter thick layer on the skin. After light sensitizer absorption the treatment area is illuminated with artificial red light (Aktilite CL128 lamp) using a light dose of 90 J/cm2. Finally 4 weeks after the last PDT treatment LM is excised surgically using 5 mm margins.
3167312|NCT00536679|Experimental|Sequence CAB|Subjects will be randomized to sequence CAB, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
3167313|NCT00536679|Experimental|Sequence CBA|Subjects will be randomized to sequence CBA, where A=1 mg GSK163090 Capsule, Fasted, B=1 mg GSK163090 Tablet, Fasted and C=1 mg GSK163090 Tablet, Fed. In each of the 3 treatment periods, subjects will receive a single oral dose of GSK163090 in the fed or fasted state, followed by a 7-day wash-out period between each dose.
2532063|NCT02683330|Experimental|Mindfulness-based intervention (MBI)|Participants randomly assigned to the MBI group will receive 8 sessions over an 8-week period. The sessions will last 1 hour and will be held via video-conference through Skype, an online application.
2532066|NCT02683330|No Intervention|Wait-list control (WLC)|Participants randomly assigned to the WLC group will be discouraged from any new mindfulness related activities during the trial. The WLC group will be offered the opportunity to take part in the MBI at the end of the 20-week follow-up.
3167314|NCT00536770|Placebo Comparator|A|Placebo + gemcitabine
3167315|NCT00536770|Placebo Comparator|B|Placebo + gemcitabine + erlotinib
3167316|NCT00536770|Active Comparator|C|DN-101 + gemcitabine
2532447|NCT02680951|Experimental|Dose Level 1|"Study participants #1 - #6 receive dose level 1 of dasatinib (60/mg/m2/day) in addition to the standard treatment, for up to 2 courses. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2532449|NCT02680951|Experimental|Dose Level 2|"Study participants # 7 - # 12 receive dose level 2 of dasatinib (80/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 1 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2532450|NCT02680951|Experimental|Dose Level 3|"Study participants # 13 - # 18 receive dose level 3 of dasatinib (100/mg/m2/day) in addition to the standard treatment (up to 2 courses), if the participants receiving Dose Level 2 did not experience intolerable side effects. Each treatment course is 29 days.~Treatment course 1 consists of:~Fludarabine at a dose of 30mg/m2, intravenously once daily on days 1-5~Cytarabine at a dose of 2000mg/m2, intravenously once daily on days 1-5~Idarubicin at a dose of 8mg/m2, intravenously once daily on days 3-5~Intrathecal cytarabine on day 1 according to standard age specific dosing guidelines~Dasatinib orally, once daily on days 6-29~Participants achieving a response of standard disease or better are eligible for course 2 consisting of dasatinib with fludarabine and cytarabine alone."
2532640|NCT02679820|Experimental|PostPlacental IUD insertion|Copper T intrauterine device will be inserted immediately following delivery of the placenta in cases of cesarean section deliveries.
2532643|NCT02679820|No Intervention|Control|IUD will be offered as a method of contraception after puerperium
2532689|NCT02679313|Experimental|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit).
2532752|NCT02678962|Active Comparator|LS-313 MF30 group|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
3167317|NCT00536770|Active Comparator|D|DN-101 + gemcitabine + erlotinib
3167318|NCT00536796||Patients at very high risk|
3167319|NCT00536796||Patients at high risk|
3167320|NCT00536796||Patients at medium risk|
3167321|NCT00536796||Patients at low risk|
3167322|NCT00536835|Experimental|Stage A|Stage A will identify maximum tolerated doses for either Schedule 1 - GSK461364 given once weekly on Day 1, 8 and 15 every 28 days; Schedule 2 - GSK 461364 given twice weekly Days 1, 2, 8, 9, 15 and 16; Schedule 3 Daily on Day 1 to Day 15 every 21 days.
3167323|NCT00536835|Experimental|Stage B|Evaluate safety, PK, pharmacodynamic (PD) & tumor response in expanded cohorts at the MTD for at least one schedule from Stage A.
3167324|NCT00536848|Experimental|A|Metronidazole for 10 days, probiotics for 6 months
3167325|NCT00536848|Placebo Comparator|B|Metronidazole for 10 days, placebo for 6 months
3167326|NCT00536861|Experimental|1|
3167327|NCT00536900|Experimental|1|Advisor-Teller Money Manager
3167328|NCT00536900|Active Comparator|2|FIT (finance instruction therapy)
3167329|NCT00536926|Active Comparator|A|home spirometry alone
3167330|NCT00536926|Experimental|B|Home spirometry with data transfer via cellphone to clinical database
3167331|NCT00536952|Experimental|Arm 1|Pulmozyme
3167332|NCT00536952|Placebo Comparator|Arm 2|Placebo
3167333|NCT00537004||PPA (Primary Progressive Aphasia)|Individuals with primary progressive aphasia
3167334|NCT00537004||Control|Individuals with no diagnosis of any type of dementia
3167335|NCT00537108|Experimental|HV|Intervention arm.
3167336|NCT00537108|No Intervention|Cntr|Usual care control
2531768|NCT02685228|Experimental|decitabine & gemcitabine|"This group was treated by low dose decitabine combinated with gemcitabine regimen. decitabine: 5mg/m2 d1-d5; gemcitabine: 1.0g/m2,d8,d15,d22. 28days for one cycle.~every 28days for one cycle"
2531769|NCT02685228|Active Comparator|gemcitabine|This group was treated by gemcitabine only. Gemcitabine: 1.0g/m2, d8,d15,d22; 28 days for one cycle. every 28days for one cycle
2531777|NCT02684916|Experimental|Chiropractic treatment|Visit with active treatment.
2531778|NCT02684916|Placebo Comparator|Placebo|Visit without active treatment.
2531802|NCT02684786|Experimental|Prior right heart catheterization|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status.
2531806|NCT02684786|Experimental|Scheduled for right heart catheterization|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
3201073|NCT00898287|Experimental|P276-00 plus Gemcitabine|"Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/m2/day x 5 q 3 weeks Level 2 - 140 mg/m2/day x 5 q 3 weeks Level 3 - 185 mg/m2/day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.~Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity."
3201074|NCT00898300||Patients with confirmed or suspected head and neck cancer|
2531937|NCT02684032|Experimental|Letrozole Cohort|Letrozole combination cohort in dose escalation
2531941|NCT02684032|Experimental|Fulvestrant cohort|Fulvestrant combination cohort in dose escalation
2531942|NCT02684032|Experimental|ARM A|Gedatolisib + palbociclib + letrozole in dose expansion
2531947|NCT02684032|Experimental|ARM B|Gedatolisib + palbociclib + fulvestrant in dose expansion
2531948|NCT02684032|Experimental|ARM C|Gedatolisib + palbociclib + fulvestrant in dose expansion
2531949|NCT02684032|Experimental|Arm D|Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion
2532056|NCT02683447||CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
2532069|NCT02683135|Active Comparator|High-carbohydrate diet|
2532070|NCT02683135|Experimental|Low-carbohydrate diet|
2532071|NCT02683135|Experimental|Low-carbohydrate diet with post-meal walking|
2532117|NCT02682979||Geriatric patients|100 consecutive geriatric patients admitted in the Emergency Department of the Brugmann Hospital, Horta site, from 01/04/2015.
2532163|NCT02682680|Experimental|Colesevelam|Colesevelam 3.75 g daily (tablets or oral suspension) for 24 weeks
2532165|NCT02682680|Active Comparator|Ezetimibe|Ezetimibe 10 mg once daily for 24 weeks
2532234|NCT02682186|No Intervention|Control group (1)|The PECS Blocks are not (1) performed.
2532235|NCT02682186|Experimental|PECS group (2)|The PECS Blocks are performed (2): A single injection of Ropivacaine after dilution with sodium chloride 0.9% per fascial plane and per side.
2532270|NCT02682004||Women with postpartum depression|
2532271|NCT02682004||Women without postpartum depression|
2532377|NCT02681393|Experimental|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
2532378|NCT02681393|Active Comparator|Brochure Only|Participants will receive the Aerobic Exercise After Stroke educational brochure only.
2532429|NCT02680990|Active Comparator|Exercise Education|Distribution of exercise education materials
2532431|NCT02680990|Experimental|Band Together|A strength-training and walking program with or without an exercise partner throughout neoadjuvant therapy.
2532469|NCT02680600|Experimental|Study arm|"Cefepime dosing~Blood sampling~Urine sampling~Determination of renal markers~Population pharmacokinetic modeling~Covariate screening~Monte Carlo simulations"
3201075|NCT00898313||Sample Collection|
3201076|NCT00898326||Biopsy 36 month after breacchytherapy|Biopsy 36 month after breacchytherapy on protocol JUSMH-BRI-GU05-01.
3201077|NCT00898378||Colorectal Cancer Patients|Patients with stages I/II, III and IV colorectal cancer
3201078|NCT00898378||Colorectal Polyps Patients|Patients with adenomatous polyp(s) after colonoscopy.
3201079|NCT00898378||Healthy Controls|No abnormalities after colonoscopy.
3201080|NCT00898391||Ancillary-Correlative|Circulating DNA is extracted from serum. PCR amplification of MYCN is performed and analyzed by agarose gel electrophoresis. Real-time quantitative PCR is also performed.
2532749|NCT02678910|Experimental|Ovarian Cryopreservation|Removal of the ovary for cryopreservation is an investigational procedure. 100% of the tissue will be used for the participant's future use.
2532788|NCT02678741|Active Comparator|No clinical response|No clinical response (PD de novo) after a minimum of 3 months on CPI monotherapy
2532789|NCT02678741|Active Comparator|Develop PD|Develop PD after initial clinical response to CPI monotherapy
2532791|NCT02678741|Active Comparator|Stable Disease|Stable disease for at least 6 months on CPI monotherapy
2531811|NCT02684799|Active Comparator|Part 1 Group 1 (Omeprazole)|Part 1 Group 1 (12 subjects) will receive Omeprazole 20 mg from Days 2-7, and Omeprazole 40 mg from Days 8-13.
2531815|NCT02684799|Experimental|Part 1 Group 2 (Cenicriviroc)|Part 1 Group 2 (12 subjects) will receive CVC 150 mg on Days 1, 5, 9 and 13.
2531819|NCT02684799|Active Comparator|Part 1 Group 2 (Famotidine)|Part 1 Group 2 (12 subjects) will receive Famotidine 40 mg on Days 5, 9 and 13.
2531821|NCT02684799|Experimental|Part 2 (Cenicriviroc)|Part 2 (24 subjects) will receive Cenicriviroc from Days 1-10 and Days 11-20.
2531823|NCT02684799|Active Comparator|Part 2 (Omeprazole)|Part 2 (24 subjects) will receive Omeprazole from Days 11-20.
2531945|NCT02684331||T2DM|
2531993|NCT02683837|Active Comparator|Standard practice|"Remifentanil infusion guided by usual clinical signs (heart rate, blood pressure).~Pupillometry blindly recorded. Anesthesia maintenance with sevoflurane."
2531994|NCT02683837|Experimental|Pupillometry|Remifentanil infusion guided by changes in pupillary diameter. Anesthesia maintenance with sevoflurane.
2532044|NCT02683603|Active Comparator|aerosolised (AS) colistin group|"the intervention was: AS colistin and imipenem. the drug administered was colimycin (colistin) powder 1 million units (MU) by a flakon (Sanofi Winthrop Industry) at the dosage of 4 million units (MU) for 30 minutes 3 times per day for at least 14 days in addition to IV imipenem 1 g three times per day. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland). Inhaled colimycin® requires specific settings of the ventilator to limit turbulence inspiratory flow. The adjustment consisted in a volume controlled mode with a Tidal volume <8 ml / kg, respiratory rate at 12 cycles / min, I / E: 1/1 and an end inspiratory break > 20%."
2532045|NCT02683603|Active Comparator|intravenous (IV) colistin goup|"the intervention was: IV colistin and imipenem. the intravenous (IV) colistin goup received IV colimycin (colistin) as a loading dose of 9 MU during 60 minutes followed by 4.5 million units 2 times per day in addition to IV imipenem 1 g three times per day."
2532115|NCT02683096||SGA Infants|
2532121|NCT02683096||Failed Hearing Screen Infants|
2532255|NCT02682303|Experimental|elastic bandage|In this study, Idealplast C® (6cm*2.5m) was used.
2532257|NCT02682303|Placebo Comparator|Non-standardized tape (NST)|In the NST group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used.
2532309|NCT02681913|No Intervention|standard cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 500 ml normal saline (0.9% NaCl) infusion bag. Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives standard intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: n/a"
2532312|NCT02681913|Experimental|adenosine enriched cardioplegia|"Delivery of cardioplegic solutions will be according to the standard protocol (Amphia hospital, Breda, the Netherlands). Oxygenated blood and cardioplegic maintenance solution is delivered in a 20:1 ratio. Cardioplegic solutions will be administered at 20-minutes intervals. The flow of the cardioplegia must be at 300 ml/min, the duration is approximately 1 minute.~The cardioplegic maintenance solution consists of a 1000 mg = 500 ml adenosine infusion bag (2 mg/ml). Potassiumchloride (20 mmol) and magnesiumsulphate (1000 mg) is added according to standard protocol.~This arms receives adenosine enriched, intermittent 20:1 diluted warm blood cardioplegic solution.~Intervention: Drug: Adenosine"
2532355|NCT02681432|Experimental|HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
2532360|NCT02681432|Active Comparator|No HIPEC|Primary ovarian cancer FIGO stage II, III or IV or recurrent
2532402|NCT02681133||patients with knee pain|
2532441|NCT02680873|Other|SASI bypass|sleeve gastrectomy done and gastro-ileum anastomosis 2.5 meter from the ileocecal valve . the anastomosis is less than 3cmm in diameter . the concept to push undigested food early to the ileum to stimulate intestinal hormones secretion to control diabetes .
2532484|NCT02680548|Active Comparator|0.9% saline (salt water)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.9% saline injection per nerve (20cc max)
2532489|NCT02680548|Active Comparator|local anesthetic (freezing)|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine per nerve (20cc max)
2532492|NCT02680548|Active Comparator|local anesthetic (freezing) and steroid|0.5mL 0.25% bupivacaine subcutaneous injection, 2-6cc 0.25% bupivacaine and 4mg/cc methylprednisolone per nerve (20cc max)
2532519|NCT02680210|Other|cognitive measures and questionnaires|the material of the study will consist of cognitive measures and questionnaires in order to (1) compare the cognitive performances and behavioral manifestations between patients with TBI and volunteers without neurological disorders and (2) to analyze the links between cognitive and behavioural measures in the TBI population
3201081|NCT00898404||Arm I|Tumor diagnostic specimens from patients who subsequently failed therapy within 4 years of diagnosis or who did not fail therapy within 4 years of diagnosis (control patients) are obtained from the Children's Oncology Group cellbank. Specimens are studied for molecular determinants of human reduced folate carrier (hRFC) gene expression and gene sequence alterations using reverse transcriptase-polymerase chain reaction (RT-PCR), thymidylate synthase inhibition assay, Rnase protection assay, or 5'RACE. Multidrug resistance proteins are also studied by RT-PCR.
3201082|NCT00898430||Head and neck squamous cell carcinoma patients (HNSCC)|
2532666|NCT02679508|Experimental|Vonoprazan group|Vonoprazan 20 mg administered orally once daily in the healing phase + vonoprazan 10 mg (as the initial dose and adjusted to vonoprazan 10 mg or 20 mg) administered orally once daily in the maintenance phase
2532668|NCT02679508|Active Comparator|Lansoprazole group|Lansoprazole 30 mg administered orally once daily in the healing phase + lansoprazole 15 mg (as the initial dose and adjusted to lansoprazole 15 mg or 30 mg) administered orally once daily in the maintenance phase
2532739|NCT02678962|Active Comparator|SN6AD1 group|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
2531838|NCT02685059|Placebo Comparator|Placebo|part 1: Placebo (for the first two weeks) part 2: Placebo for 20 weeks
2531843|NCT02685059|Active Comparator|Taxane|Nab-Paclitaxel 125 mg/m² weekly for 12 weeks
2531846|NCT02685059|Active Comparator|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
2531848|NCT02685059|Active Comparator|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
3201083|NCT00898456||Group 1|Leukemia blast cells obtained from bone marrow aspirate or peripheral blood at diagnosis are used to study polymorphisms and haplotypes of ATP-binding cassette (ABC) B1, ABCC1, ABCG2, and other candidate genes. Multidrug resistance (MDR) protein expression and function are also analyzed using leukemia blast cells from patients enrolled on CALGB-9760.
3201084|NCT00898482||Healthy individuals|
3201085|NCT00898482||At risk individuals|
3201086|NCT00898482||Cancer patients|
3201087|NCT00898508||Normal benign breast disease or ductal carcinoma in situ|
3201088|NCT00898508||Invasive breast cancer|
2532004|NCT02683759|Active Comparator|Treatment Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take Bio-enhanced curcumin twice daily after meals as per the following regimen:
2532009|NCT02683759|Placebo Comparator|Control Arm|Patients will receive 5-Aminosalicyclic acid as per their current treatment regimen and will also take a placebo pill twice daily after meals
2532050|NCT02683486|Experimental|Activities of daily living on iO2t|Patients will complete simulated activities of daily living on intelligent oxygen therapy (an auto-titrating oxygen system)
2532053|NCT02683486|Active Comparator|Activities of daily living on LTOT|Patients will complete activities of daily living on their usual long-term oxygen therapy.
2532110|NCT02683148|Experimental|Arm 1: DHEA Dose Level 1|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2532111|NCT02683148|Experimental|Arm 2: DHEA Dose Level 2|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2532112|NCT02683148|Experimental|Arm 3: DHEA Dose Level 3|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
2532114|NCT02683148|Experimental|Arm 4: DHEA Phase II|-DHEA is an oral supplement which will be administered on an outpatient basis at the prescribed dose daily on a 28-day cycle.
3201089|NCT00898521|Experimental|DGD|
3201090|NCT00898534|Experimental|Immediate Feedback|Subjects receive point-of-care hemoglobin A1c testing prior to their diabetes clinic visit, with results made available to the provider during the visit.
2532261|NCT02682121|Placebo Comparator|Placebo|Patients on placebo.
2532263|NCT02682121|Active Comparator|Active drug|Patients on Metformin, 850mg twice daily for 6mos.
3201091|NCT00898534|No Intervention|Conventional Feedback|Subjects receive laboratory hemoglobin A1c testing at the clinic visit, with results made available to the provider several days later.
2532400|NCT02681367|No Intervention|fresh embryo transfer|Patient with RIF underwent ICSI cycle followed by Day 5 fresh embryo transfer.
2532411|NCT02681367|Experimental|Freeze all|Patient with RIF. All of them underwent ICSI cycle, all their embryos were cryopreserved at Day 5 and transferred in a consecutive natural cycle.
3201092|NCT00898547||Group 1|Serum samples previously obtained from patients on protocol CALGB-30107 are tested for levels of thrombospondin I serum, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin using enzyme-linked immunosorbent assays (ELISA).
3201093|NCT00898599|Placebo Comparator|Maltodextrin|
2532539|NCT02680106|Experimental|SPINNER|All patients in this arm will be treated with the SPINNER dressing.
2532540|NCT02680106|Active Comparator|JELONET|All patients in this arm will be treated with JELONET dressing, regarded as the standard of current care for split-skin donor-site wounds.
2532594|NCT02679924|Experimental|Restylane Silk|Micro-injections of Restylane® Silk Hyaluronic Acid filler for correction of mid to low cheek fine lines and wrinkles.
2532599|NCT02679924|Sham Comparator|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
3201094|NCT00898599|Experimental|Prebiotic|Inulin type fructooligosaccharides
3201095|NCT00898716|Experimental|BMS-754807|
3201096|NCT00898742||head and neck cancer patients|
3201097|NCT00898755||Ancillary-Correlative (tissue sample collection)|"Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:~NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5 RETINOBLASTOMA: interphotoreceptor retinoid-binding protein ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1 ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry"
2532942|NCT02677532|Active Comparator|Epidural infusion|Thoracic epidural bolus of 10 ml levobupivacaine 0.25% plus sufentanil 0.15 mcg/kg before end of surgery, followed by continuous epidural infusion of 0.12% levobupivacaine plus 0.4 mcg/ml at 5 ml/h infusion rate for 48 hours.
2532950|NCT02677532|Experimental|Wound infusion plus morphine bolus|Intravenous slow bolus of 10 mg morphine, wound infiltration with 10 ml levobupivacaine 0.5%, followed by pre-peritoneal continuous wound infusion of levobupivacaine 0.25% at 4 ml/h infusion rate for 48 hours.
2533029|NCT02677129|Experimental|home-based exercise intervention|"home-based exercise intervention:~Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems."
2533035|NCT02677129|No Intervention|Waiting control group|The wait list control group receives usual care over the study period. Usual care depends on the hospital guidelines as well as oncologists' and physicians' consideration.
2534061|NCT02670278||Ethiopia-urban|healthy breastfeeding women and their infants
3201098|NCT00898768|Other|capsule endoscopy|capsule endoscopie at baseline and after 2 years
2531880|NCT02684682|Other|24h Group|Intervention 'Frequency of mechanical control of plaque (24h)'
2531882|NCT02684682|Other|48h Group|Intervention 'Frequency of mechanical control of plaque (48h)'
2531944|NCT02684214|Experimental|Food secure families|high and marginal household food security
2531946|NCT02684214|Experimental|Food insecure families|low and very low household food security
2532003|NCT02683798|Active Comparator|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
2532007|NCT02683798|Experimental|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
2532049|NCT02683499|Experimental|Ultrasonic tips|Prepared surfaces will be finished with ultrasonic tips
2532052|NCT02683499|No Intervention|Conventional|Prepared surfaces will be finished with ordinary burs
2532168|NCT02682524|Active Comparator|test|
2532172|NCT02682524|Active Comparator|reference|
2532259|NCT02682290|Other|rheological measurement of sputum|"patients with COPD and patient with cystic fibrosis will perform a spontaneous expectoration.~Then all participants will have an induced expectoration with hypertonic salin solution."
2532305|NCT02681926||Average force group|A recent tool, called VISITAG, has been developed (and approved by EMEA) for Biosense Webster Navistar Smart Touch catheter in order to allow collection of ablation points with pre-determined characteristics, such as stability of catheter during ablation, mean contact force, drop in impedance. In the Average Force group, the operators decided to use the mean contact force as target parameter indicating a good lesion.
2532308|NCT02681926||Force Time Integral group|In the Force Time Integral (FTI) group, the operators decided to use the FTI as target parameter indicating a good lesion.
2532344|NCT02681471|Active Comparator|Monopolar TURP|Patients in Group M (Monopolar) were used monopolar resectoscope (Karl Storz, Tottling, Germany) and 5% Mannitol as an irrigation fluid.
2532351|NCT02681471|Active Comparator|Bipolar TURP|Patients in Group B (Bipolar) were used bipolar resectoscope TURis (OLYMPUS, Tokyo, Japan) and 0,9% Sodium chloride as an irrigation fluid.
2532396|NCT02681042|Experimental|SentreHeart Lariat|Left atrial appendage closure with SentreHeart Lariat device
2532473|NCT02680821|Other|Isolated ACL-revision|The standard operation with an isolated Anterior cruciate ligament.
2532476|NCT02680821|Other|Combined ACL and ALL surgery|An operation with an Anterior cruciate ligament combined with an anterolateral ligament.
2532573|NCT02680067|Experimental|Developmental arm - Healthy or rheumatoid arthritis subjects|Subjects in the developmental arm will have a minimum of two study visits to determine the optimal conditions for visualizing lymphatic transport in the upper extremities. Concentrations of 0.1 mg/ml of Indocyanine Green (ICG) will be injected intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). An ultrasound of the upper extremities may be performed after the ICG fluorescence is observed. The exam will help identify the location of the lymphatic vessels and nodes in the areas fluoresced.
2532574|NCT02680067|Experimental|Clearance arm - Healthy individuals|Subjects in the clearance arm will have an initial study visit that involves injections of 0.1 mg/ml of Indocyanine Green (ICG) intradermally into the web spaces of the hands in both upper extremities. Multispectral video and still images will be recorded using the MultiSpectral Imaging System (MSImager). Follow up imaging sessions will occur weekly for three weeks for a minimum of four study visits total.
2532645|NCT02679638||Kaplan Hospital|Breast cancer survivors recruited at the Kaplan Medical Center
2532648|NCT02679638||Rambam Hospital|Breast cancer survivors recruited at the Rambam Medical Center
2532649|NCT02679638||Sheba|Breast cancer survivors recruited at the Sheba Medical Center
2532650|NCT02679638||Barzilai|Breast cancer survivors recruited at the Barzilai Medical Center
2532729|NCT02679248|Experimental|Neo40 Daily®|
2532738|NCT02679248|Experimental|Placebo|
2532799|NCT02678455|Experimental|TV005 vaccine|Participants will receive one dose of TV005 vaccine at study entry (Day 0).
2532800|NCT02678455|Placebo Comparator|Placebo|Participants will receive one dose of placebo at study entry (Day 0).
3167337|NCT00537134|No Intervention|1|Conservative management (watchful observation)
3167338|NCT00537134|Active Comparator|2|Endovascular treatment
3167339|NCT00537147|Experimental|1|1 vaccination of a 10^4 plaque-forming units (PFU) dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
2532939|NCT02677558||CFOP obese|"Transthoracic Echocardiography in pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of greater or equal 40kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia."
2532945|NCT02677558||CFOP control|"Transthoracic Echocardiography pregnant women with a gestational age of greater or equal 36 weeks who have a BMI of less or equal 30kg/m2 at the time point of inclusion into the study.~Exclusion criteria: cardiac disease, on any cardiovascular drugs, pre-eclampsia or eclampsia"
2533019|NCT02677298|Experimental|Botulinum toxin A|Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
2533023|NCT02677298|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
2533092|NCT02676804|Experimental|High-intensity aerobic exercise|Subjects will participate in a 16 week high-intensity aerobic exercise program.
3167340|NCT00537147|Experimental|2|1 vaccination of a 10^5 PFU dose of WN/DEN4delta30 vaccine administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
3167341|NCT00537147|Placebo Comparator|3|1 vaccination of a placebo administered as 0.5 ml subcutaneously in deltoid at study entry and Day 180.
3167342|NCT00537173||Arm 1|Paclitaxel 90 mg/m2 IV D1, 8, and 15 + Avastin 10 mg/kg IV, day 1 and 15
3167343|NCT00537186|Other|1|Iron oligosaccharide
3167344|NCT00537212|Active Comparator|1|"Subjects will receive phototherapy and dietary counselling consistent with The South Beach diet."
3167345|NCT00537212|Active Comparator|2|"Subjects will receive phototherapy and dietary counselling consistent with The Ornish Diet."
3167346|NCT00537212|Sham Comparator|3|Subjects will receive phototherapy alone, without dietary counselling.
2531896|NCT02684513|No Intervention|Fasted Controls|Subjects assigned to this group will fast for ≥8 hours prior to surgery.
2532030|NCT02683629|Experimental|NTCELL|NTCELL Implantation
2532032|NCT02683629|Sham Comparator|Sham Surgery|Sham Surgery
2532128|NCT02683291|Active Comparator|Tacrolimus + Mycophenolate|"The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
2532131|NCT02683291|Experimental|Tacrolimus + Sirolimus|"The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).~Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %"
2532170|NCT02682472|Experimental|SettleIN|SettleIN - Adjustment to care programme intervention
3167347|NCT00537225|Experimental|A-Exercise group|Home based exercise
2532316|NCT02681783|Active Comparator|neovascular AMD group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2532317|NCT02681783|Experimental|CSR group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2532318|NCT02681783|Experimental|iPCV group with PED|Patients in this group will be administered aflibercept intravitreal injection 2 mg (0.05 mL), administered at baseline, month 1, and month 2, for a total of 3 injections. Study will end for these patients at month 4, where no injection will be given. A clinical exam and OCT imaging will be performed each visit.
2532319|NCT02681783|No Intervention|cataract patients|Patients diagnosed with cataracts requiring cataract surgery will serve as study controls. No intervention will be applied to these patients.
2532373|NCT02681406|No Intervention|Treatment as Usual|Participants randomized to this condition will continue their schedules and treatments as they had been and just come in to see research staff for research visits.
2532374|NCT02681406|Experimental|Telephone Monitoring and Counseling|TMC - participants receive brief (20 minute) telephone counseling once weekly, then biweekly, etc for 12 months.
2532375|NCT02681406|Experimental|ACHESS|Participants are signed up for an addiction based smart phone application that connects them in an anonymous fashion to a social network of other people in the study who are also struggling with alcohol addiction and sober living.
2532376|NCT02681406|Experimental|TMC + ACHESS|Participants in this arm receive both interventions - the telephone counseling plus the ACHESS phone application.
2532383|NCT02681016|Experimental|"Sirolimus-eluting stent Calypso"|"Commercially approved coronary stent system Calypso (Angioline, Russia) Coating - Sirolimus(rapamicine) Stent diameters: 2.0, 2.25, 2.5, 2.75, 3.0, 3.5, 4.0, 4.5 mm. Stent lengths: 8, 13, 15, 18, 23, 28, 33, 38 mm."
2532385|NCT02681016|Active Comparator|"Everolimus-eluting stent Xience Prime"|Commercially approved XIENCE PRIME, (Abbott Vascular, USA) Coating - Everolimus with concentration Stent diameters: 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm. Stent lengths: 8, 12, 15, 18, 23, 28, 33, 38 mm.
2532708|NCT02679430|Other|Prostate Arterial Embolization|"Intervention: Patients will undergo prostatic artery embolization.~The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms."
2532727|NCT02678936|Experimental|PRP|The operation will be performed with application of platelet rich plasma
2532733|NCT02678936|No Intervention|non-PRP|The operation will be performed without addition of platelet-rich plasma
2532790|NCT02678780|Experimental|Cohort A|"Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of the pancreas after progression to a previous targeted agent.~Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)"
2532792|NCT02678780|Experimental|Cohort B|Patients with advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of 2010 WHO (World Health Organization) classification neuroendocrine tumors of gastrointestinal tract after progression to somatostatin analogues Treatment: Dosing schedule of 24 mg once a day of Lenvatinib (two 10-mg capsules + one 4-mg capsule)
3167348|NCT00537225|No Intervention|B- Usual Care|Exercise as usually prescribed by provider
3167349|NCT00537264|Experimental|Computer|Health-related quality of life questionnaires will be administered using a computerised multimedia touchscreen system.
3167350|NCT00537264|Experimental|Interviewer|Health-related quality of life questionnaire will be administered via face-to-face interviews.
3167351|NCT00537342|Experimental|A|Biological Vaccine
3167352|NCT00537342|Placebo Comparator|B|
3167353|NCT00537355|Active Comparator|TOLAMBA™|
3167354|NCT00537355|Sham Comparator|Histamine|Histamine simulates mild redness/swelling effect seen with active comparator, TOLAMBA™. Prevents study staff from easily identifying subjects who received active comparator.
3167355|NCT00537420|Placebo Comparator|1|Nasal Placebo
3167356|NCT00537420|Placebo Comparator|2|Capsule Placebo
3167357|NCT00537420|Experimental|3|Nasal PYY3-36 200 ug
3167358|NCT00537420|Experimental|4|Nasal PYY3-36 400 ug
2531954|NCT02684318|Experimental|Dose Level 1|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 100 mg BID
2531964|NCT02684318|Experimental|Dose Level 2|PM01183 + olaparib PM01183: 1 mg/m² IV olaparib 150 mg BID
2531968|NCT02684318|Experimental|Dose Level 3|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 200 mg BID
2531970|NCT02684318|Experimental|Dose Level 4|PM01183 + olaparib PM01183: 1.5 mg/m² IV olaparib 250 mg BID
2531973|NCT02684318|Experimental|Dose Level 5|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 250 mg BID
2531974|NCT02684318|Experimental|Dose Level 6|PM01183 + olaparib PM01183: 2 mg/m² IV olaparib 300 mg BID
2531976|NCT02684318|Experimental|Dose Level 7|PM01183 + olaparib PM01183 3 mg/m² IV olaparib 300 mg BID
3201099|NCT00898781||Metastatic Breast Cancer|
3201100|NCT00898781||Metastatic Ovarian Cancer|
3201101|NCT00898781||Metastatic Pancreatic Cancer|
2532098|NCT02683226|Experimental|metformin and alogliptin|Vipdomet 12.5 mg/1000 mg tablets
2532105|NCT02683226|Experimental|pioglitasone and alogliptin|Incresync 12,5 mg/30 mg tablets
2532171|NCT02682797||1|At all study visits a complete ophthalmic examination, visual acuity and refractive error, Spectralis OCT, Cirrus OCT, Topcon OCT, PS-OCT, Optomap Fundus photography will be performed.
2532236|NCT02682355||Study cohort|Patients receiving IV polymyxin B for treatment of bacteremia and/or urinary tract infection and/or respiratory tract infection (including tracheobronchitis) or sepsis
2532289|NCT02681965|Experimental|LEAN|Participants randomized to the weight loss program will initially receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity. Written instructions in the LEAN book will include recording daily diet and exercise in the logs. At the end of the study, participants will return, via a stamped addressed envelope, the logs to the study office so compliance can be assessed.
2532292|NCT02681965|No Intervention|Waitlist Control|Participants randomized to the waitlist control study arm will be mailed the six-month questionnaires, which will include reporting of weight. On return of the 6-month questionnaires each woman will be provided with the entire weight loss program packet.
2532341|NCT02681653|Active Comparator|Statin|Atorvastatin, 40 mg for 7 days in patients of septic shock admitted to ICU
2532348|NCT02681653|Placebo Comparator|Placebo|Matched placebo, 40 mg for 7 days in patients of septic shock admitted to ICU
2532398|NCT02681185|Experimental|Interventional Group|The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
2532410|NCT02681185|Active Comparator|Standard of Care|The recruited participants will receive the standard of diabetes care as offered by the services in their community.
2532448|NCT02680717|Active Comparator|Treatment 1|Calcipotriene 0.005% ointment
2532451|NCT02680717|Active Comparator|Treatment 2|Clobetasol 0.05% ointment
2532453|NCT02680717|Active Comparator|Treatment 3|Tacrolimus 0.1% ointment
3201102|NCT00898781||Metastatic Colon Cancer|
3201103|NCT00898781||Stage 3 Ovarian Cancer|
2532657|NCT02679534|Experimental|hand massage|"Patients will receive a 20 minute hand massage by a trained nurse in addition to the standard ICU care. Before administering the massage, a favorable environment will be created that promotes calmness such as dampening the light, reducing the alarm intensity, closing the curtains and the door and posting the notice do not disturb, and a comfortable positioning of the patient will be ensured. The interventionist will hold each hand for 5-10 seconds, and apply 5-10 ml of unscented hypoallergenic cream to both hands and wrists. Then, she will perform massage using moderate pressure, and the stroking and kneading techniques during ten minutes on the palm and back of each hand."
2532658|NCT02679534|Active Comparator|hand holding|The active control group will receive hand holding by the same trained nurse in addition to standard ICU care. The same hand hygiene and environmental adjustments will be made as for those receiving massage. Patients will have their hands held for 5-10 seconds and unscented hypoallergenic cream applied to both hands. Then, the interventionist will hold each of the patients' hand in her hand for ten minutes without performing any tissue manipulation. The hand holding procedure will last for a total of 20 minutes.
2532661|NCT02679534|Other|rest group|The passive control group will have a 20 minutes rest period including the same environmental adjustments as the massage and hand holding groups in addition to the standard care administered in the ICU. The standard care includes the pharmacological and non-pharmacological treatments used to promote recovery and symptom relief. In the study ICU, cardiac surgery patients are automatically prescribed a pain management protocol that includes the regular administration of morphine, unless extraordinary patient circumstances require different prescriptions. Patients might equally receive breakthrough doses of analgesia in addition to regular opioids. Of the existing non-pharmacological interventions, repositioning and back rubs are commonly employed in the study ICU to provide patient comfort.
3201104|NCT00898781||Locally Advanced Pancreatic Cancer|
3201105|NCT00898833||Group 1|Previously collected plasma and urine samples are analyzed for VEGF via ELISA, plasma samples are analyzed for CgA and IL-6 via ELISA, hK2 via immunometric assay, plasma samples are analyzed for PSA via Tandem-R PSA kit, plasma samples are analyzed for TNF-alpha, sTNF-R1, and IL-8 via quantikine IL-8 immunoassay.
3201106|NCT00898846||UFT adjuvant therapy group|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year. During protocol treatment, clinical findings and laboratory values are evaluated every month. After the completion of protocol treatment, patients are followed-up, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3201107|NCT00898846||Observation group|Patients are followed-up without adjuvant treatment, according to the schedule defined in the study protocol, for 5 years until recurrence, other malignancy or death is confirmed.
3201108|NCT00898859||1|Healthy, non-smoking
3201109|NCT00898859||2|healthy, ex-smoking
3201110|NCT00898859||3|healthy, current-smokers
3201111|NCT00898859||4|COPD, ex-smokers
3201112|NCT00898859||5|COPD, smokers
3201113|NCT00898885||Bone Marrow Transplantation|
3201114|NCT00898898||Arm I|Tissue samples from protocol NCCTG-N9831 are obtained for immunohistochemistry and fluorescence in situ hybridization analysis of MYC, IGF- 1R, PTEN, and TOP2A genes. Exons 9 and 20 of PIK3CA gene are amplified via polymerase chain reaction; mutations in exons 9 and 20 of PIK3CA gene are identified.
2531962|NCT02684305|Experimental|Intravenous oxytocin infusion + balloon|"All women who failed induction of labor using vaginal insert slow release of dinoprostone 10 mg (Propess), defined as bishop score ≤ 7 24 hours after propess insertion will be randomized to one of the following treatment arms:~2. Intravenous oxytocin infusion combined with intracervical balloon administration, inflated with 60cc of saline."
3201115|NCT00898924||Group 1|Tissue samples were collected from patients on Day 1, Cycle 1. Whole blood and serum samples were collected on Day 1 (Cycle 1), Day 1 (Cycle 3), post-radiotherapy ZD1839 and at progression.
3201116|NCT00898950|Experimental|Aspirin low dose|Effects of using aspirin 75 mgs/day for 2 weeks.
3201117|NCT00898950|Experimental|Aspirin medium dose|Effects of using aspirin 300 mgs/day
3201118|NCT00898950|Experimental|aspirin high dose|aspirin 900mgs QID orally for 2 weeks
2532291|NCT02682108|Other|Diffusion-weighted imaging|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
2532336|NCT02681627|Active Comparator|endometrial scratch|Patient will be randomised to the intervention arm which is the luteal phase endometrial scratch
2532343|NCT02681627|Sham Comparator|touching cervix|Patient will have a speculum examination and cleaning of the cervix with cotton tip with saline but no scratch
2532397|NCT02681211|Experimental|Auricular Acupuncture|If assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint.
2532407|NCT02681211|Active Comparator|Medication and Fluid|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
2532481|NCT02680574|Experimental|vadadustat|
2532485|NCT02680574|Active Comparator|darbepoetin alfa|
2532959|NCT02677545|Experimental|Ticagrelor & Aspirin|Participants will receive a loading dose of 180 mg ticagrelor 1-3 days before stenting followed by a maintenance dose of 90 mg twice daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
2532961|NCT02677545|Active Comparator|Clopidogrel & Aspirin|Participants will receive a loading dose of 300 mg clopidogrel 1-3 days before stenting followed by a maintenance dose of 75 mg once daily until 28-32 days after stenting. All participants will receive 75-100 mg aspirin per day throughout the study period.
2533013|NCT02677025|Experimental|Young Women's Health CoOp (YWHC)|This is an adapted behavioral intervention for young women in Cape Town South Africa who dropped out of school, who use alcohol and other drugs and are at risk for HIV.
2533018|NCT02677025|Active Comparator|HIV Counseling/Testing|Provide age and gender appropriate standard HIV counseling and testing.
2533109|NCT02676817||Group 1|Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
2533114|NCT02676817||Group 2|Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.
2533127|NCT02676362|Experimental|the first day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 5., 10., 30.
2533129|NCT02676362|Experimental|the 2nd day|Gingival crevicular fluid collection with filter paper the length of sampling time in seconds: 10., 30., 5.
2533132|NCT02676362|Experimental|the 3rd day|Gingival crevicular fluid collection with filter paper the length of sampling time in second: 30., 5., 10.
2533236|NCT02676089|Experimental|CHF 5993 200/6/12.5 µg|"Treatment A:~CHF 5993 200/6/12.5 µg: 2 inhalations bid Total daily dose: 800/24/50 µg BDP/FF/GB"
2533238|NCT02676089|Active Comparator|CHF 1535 200/6 µg|"Treatment B:~CHF 1535 200/6 µg: 2 inhalations bid Total daily dose: 800/24 µg BDP/FF"
2533239|NCT02676089|Active Comparator|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|"Treatment C (open-label arm):~CHF 1535 200/6 µg: 2 inhalations bid~+ Tiotropium Respimat 2.5 µg: 2 inhalations od Total daily dose: 800/24 µg BDP/FF + 5 µg Tio"
2533501|NCT02674009||laBCC Participants|Participants with laBCC who received at least one dose of Vismodegib in routine clinical practice for 32 months (between 02 Aug 2013 and 31 Mar 2016).
2533539|NCT02673775|Placebo Comparator|Clean Air|Subjects will be exposed to clean air for 3 hours.
2533546|NCT02673775|Experimental|Ozone|Subjects will be exposed to 0.2 ppm ozone for 3 hours.
2533578|NCT02673476|Placebo Comparator|Placebo|Identical Placebo Comparator
2533589|NCT02673476|Experimental|ALS-008176|ALS-008176 tablets
2533685|NCT02672956|Experimental|Intraumbilical entry group|Umbilical port will be insert to intra umbilical area.
3201119|NCT00898950|Placebo Comparator|placebo|
3201120|NCT00898976||Group I|Immunohistochemistry is performed on tumor samples to analyze the following molecular markers: estrogen receptor, progesterone receptor, c-erbB2, p53, Ki-67, Bcl-2, Bax, cyclin D-1, and insulin-like growth factor-1R. PROJECTED ACCRUAL: A total of 300 tissue samples (150 from Native American women and 150 from Caucasian women) will be accrued for this study.
3201121|NCT00898989||Inclusion Body Myositis|
3201122|NCT00898989||Control|
3201123|NCT00899041|Active Comparator|Standard knee prosthesis|'standard' knee prosthesis (Sigma FB, J&J, UK).
2532100|NCT02683031|Experimental|With Ca2+ ionophore|Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
2532169|NCT02682758|Other|Patients of normal weight|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index of less than 30.
2532174|NCT02682758|Other|Obese patients|Patients undergoing routine xenon-based general anaesthesia for surgery with a body mass index equal to or more than 30.
2532245|NCT02682277|Active Comparator|Medical device polyglucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
2532250|NCT02682277|Placebo Comparator|Placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity
2532310|NCT02681939|Experimental|Tulsi|One capsule of Tulsi (Ocimum sanctum) orally, every morning and evening in empty stomach for 60 days regularly.
2532314|NCT02681939|No Intervention|No Tulsi|No intervention
2532339|NCT02681484|Experimental|Hypertensive|Patients diagnosed with hypertension (I10, either on drug therapy or verified by 24h blood pressure measurements) administered to anthroposophic speech therapy (intervention).
2532350|NCT02681484|Active Comparator|Normotensive|Patients diagnosed with tension headache (G 44.2) or anxiety disorders (F41) administered to anthroposophic speech therapy (intervention).
2532395|NCT02681263|Experimental|Temocillin|"Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.~Total antibiotic treatment between 10 and 14 days according to local guidelines (up to 21 days in immunosuppressed patients)."
2532556|NCT02680249|Experimental|CTP-656 Fed, low fat|Single dose of CTP-656 150 mg administered after a low-fat breakfast
2532560|NCT02680249|Experimental|CTP-656 Fasted|Single dose of CTP-656 150 mg administered fasted
2532566|NCT02680249|Experimental|CTP-656 Fed, high fat|Single dose of CTP-656 150 mg administered after a moderate-fat breakfast
3201124|NCT00899041|Active Comparator|High flexion knee prosthesis|'high flexion' knee prosthesis (Sigma RP-F, J&J, UK).
2532774|NCT02678858|Experimental|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) shall target expressive and interactional behavior skills together with those social cognitive domains (facial and prosodic affect recognition, social perception, theory-of-mind) known to be most impaired (Savla, 2012) and most closely associated with functional outcome (Fett, 2012) in schizophrenia.
2532775|NCT02678858|Active Comparator|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Therapy (NCRT) shall target impairments in attention, memory, and executive functions as an active comparator to the ISST.
3201125|NCT00899054|Experimental|P276-00 plus Radiation|"P276-00:~Level 1:100 mg/m2/day x 5 q 3 weeks, level 2:140 mg/m2/day x 5 q 3 weeks, level 3: 185 mg/m2/day x 5 q 3 weeks.~External beam radiotherapy (EBRT):~2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 2 cycles (6 weeks)followed by upto 10 additional Gy if required"
3201126|NCT00899093||Ancillary-Correlative (serum collection for YKL-40 and CA125)|Patients undergo collection of serum samples for analysis of YKL-40 via ELISA and CA125 via chemiluminometric sandwich immunoassay at the following time-points: at baseline; prior to beginning each course of chemotherapy (courses 1-6); at completion of chemotherapy; every 3 months during years 1-2 post-chemotherapy; every 6 months during years 3-5 post-chemotherapy; every year during years 6-10 post-chemotherapy; and at time of disease recurrence or progression.
2532994|NCT02677363|Experimental|Older adults|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
2533025|NCT02677038|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2533061|NCT02676752||Skin/soft tissue elasticity assessment|Participants will be evaluated for LEF status using the HN-LEF Grading Criteria and neck range of motion using the Cervical Range of Motion Device. Participants also complete study questionnaires, including VHNSS and LSIDS-H&N. Participants undergo ultrasound shear wave elastography over 20-25 minutes. Participants' cancer disease and treatment information will be gathered from their medical records.
2533144|NCT02676505||1|"Group (I)(Coached group):~It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds."
2533152|NCT02676505||2|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth.
2533189|NCT02676024|No Intervention|Control|Resuscitation teams will participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR without being provided cognitive aids. Participants in this group will be allowed to use any cognitive aid that they happen to keep with them and would normally use in their practice, for example, flash cards or smart phone apps.
3167359|NCT00537420|Experimental|5|Nasal PYY3-36 600 ug
2532251|NCT02682459|Experimental|Lisinopril|Patients will receive, in addition to standard immunosuppressive therapy, lisinopril starting with 5 mg/day, then progressively up-titrated to reach the maximum tolerable dose (target dose) for 18 months.
2532254|NCT02682459|No Intervention|No intervention|Patients will receive only the standard immunosuppressive therapy.
2532332|NCT02681900|Experimental|Self-affirmation|Participants in the self-affirmation arm write about their most important value, reasons why is important and an example of when they enacted that value. This is the Self-affirmation manipulation task as described in the intervention.
2532333|NCT02681900|Active Comparator|Control|Participants in this arm complete a control equivalent of the self-affirmation task, where they write about their least important value, reasons why is may be important to someone else and an example of when another person may have enacted that value. This is the Control task as described in the intervention.
2532430|NCT02681289|Experimental|physiotherapy group|Early goal directed neuromotor therapy applied by physiotherapist
2532432|NCT02681289|Experimental|family group|Early goal directed neuromotor therapy applied by family
2532533|NCT02680288|Placebo Comparator|Oral Placebo|Oral inert treatment
2532534|NCT02680288|Experimental|Active Treatment, Low-Dose|Lorcaserin 10 mg, single dose
2532536|NCT02680288|Experimental|Active Treatment, High-Dose|Lorcaserin 20 mg, single dose
2532583|NCT02679950||Initial diagnosis|The initial diagnosis only cohort will include 3 patients with germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and one tissue sample will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis.
2532587|NCT02679950||Late relapse|"The late relapse cohort will include 3 patients with late relapse germ cell tumor (GCT) who meet the inclusion criteria and have adequate tissue samples available in storage at the Pathology Department. One prospective blood and two tissue samples will be collected from each patient in this cohort. Tissue samples will come from the orchiectomy or virgin retro-peritoneal lymph node dissection (RPLND) that was done at initial diagnosis and the other will come from the site of late relapse.~Patients in this cohort will have biopsies at the site of late relapse as part of their routine cancer treatment. No biopsies will be performed specifically for the purposes of this study. Tissue from the site of late relapse will also be requested from the Pathology Department."
2532631|NCT02679677|Sham Comparator|Control|Whole body vibration training as sham procedure (5Hz) 3 times a week, 3x2 minutes, for 6 weeks.
2532633|NCT02679677|Experimental|Intervention|Whole body vibration training (12 Hz up to 30 Hz) 3 times a week, 3x2 minutes, for 6 weeks.
2532679|NCT02679352|Experimental|SMR stemless|Patients requiring a primary anatomic or reverse shoulder arthroplasty, due to symptomatic painful degenerative joint diseases with good bone stock
2532726|NCT02679092|Active Comparator|Dilapan (14wks 0days-15wks, 6days)|The clinician will place 1 to 2 osmotic cervical dilators (Dilapan-S) (4mm x 65mm) the day before the participant's procedure.
2532736|NCT02679092|Active Comparator|Dilapan (16wks 0days-18wks, 6days)|The clinician will place 3 to 5 osmotic cervical dilators (Dilapan-S) (4mm x 65mm). Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2532744|NCT02679092|Experimental|Mifepristone (14wks 0days-15wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2532751|NCT02679092|Experimental|Mifepristone (16wks 0days-18wks, 6days)|The patient will be administered mifepristone (200mg) orally with juice or water by the clinician or study investigator. Patients in this arm will also receive 200 mg misoprostol PO 30-90 minutes prior to their procedure.
2532952|NCT02677519|Experimental|10 mg Aptensio XR|10 mg methylphenidate, extended release
2532955|NCT02677519|Experimental|15 mg Aptensio XR|15 mg methylphenidate, extended release
2532956|NCT02677519|Experimental|20 mg Aptensio XR|20 mg methylphenidate, extended release once daily
2532957|NCT02677519|Experimental|30 mg Aptensio XR|30 mg methylphenidate, extended release
2532958|NCT02677519|Experimental|40 mg Aptensio XR|40 mg methylphenidate, extended release
2532960|NCT02677519|Experimental|50 mg Aptensio XR|50 mg methylphenidate, extended release
2532962|NCT02677519|Experimental|60 mg Aptensio XR|60 mg methylphenidate, extended release
2532997|NCT02677155|Experimental|Intranodal immunotherapy and anti-PD1|"Induction phase: 3 cycles of sequential intranodal immunotherapy (SIIT), every second week:~Radiotherapy 8 Gy single dose day 2, Rituximab 5 mg intranodal day 1 and 3, Autologous dendritic cells 1x 10 e8 intranodal day 4 and 5, GM-CSF 50 ug subcutaneously day 4 and 5, Pembrolizumab 200 mg intravenous day 5,~Consolidation phase:~Pembrolizumab 200 mg intravenous every third week for 8 cycles"
2533033|NCT02676947|Experimental|Open Label|Intravenous Tocilizumab 8mg/kg monthly (up to a maximum dose 800mg) for 6 months
2533315|NCT02675270|Experimental|Phonological, Orthographic, Untrained|
3167360|NCT00537420|Active Comparator|6|Sibutramine 10 mg
3167361|NCT00537433|No Intervention|Standard counseling|Families in the control group receive standard care, including routine counseling regarding medications prescribed from their physician and post-visit counseling by the pediatric nursing staff. Dosing instruments are given at the discretion of the physician or nurse.
3167362|NCT00537433|Experimental|Pictogram|Parents randomized to the pictogram-based intervention group receive medication counseling utilizing the pictogram-based medication instruction sheets. These sheets help to facilitate medication counseling, including teaching about dosage and adherence.
3167363|NCT00537472|Experimental|I|
3167364|NCT00537472|Active Comparator|II|
3167365|NCT00537498|Experimental|1|Interventional group
3167366|NCT00537524|Experimental|Arm 1|0.5mL of H5N1 vaccine 7.5ug
3167367|NCT00537524|Active Comparator|Arm 2|0.25 or 0.5mL of H5N1 vaccine
3167368|NCT00537537|Active Comparator|1|Telbivudine
3167369|NCT00537537|Active Comparator|2|Telbivudine
3167370|NCT00537537|Active Comparator|3|Telbivudine
3167371|NCT00537602|Experimental|A|Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
2532213|NCT02682446||Previous H. pylori infection group|The participants revealed positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2532215|NCT02682446||Eradicated H. pylori group|The participants revealed to success for H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2532218|NCT02682446||Persistent H. pylori group|The participants revealed to fail in H. pylori eradication in those who were positive findings of H pylori IgG and other invasive methods (rapid urease test or histology) at the time of ESD for EGC
2532274|NCT02682160|Other|Use of Protein Assistant|patients can use the Protein Assistant during 2 months to evaluate the quantity of protein's intake.
3201127|NCT00899145||Ancillary-Correlative (biomarker sampling and analysis)|Previously collected DNA samples and associated clinical information obtained from BRCA mutation-positive participants enrolled on GOG-0199 are studied. DNA samples are analyzed by mutation testing for variants (i.e., SNPs) in candidate genes of interest. Once genetic testing for a given set of variants has been completed, the coded laboratory data file is merged with selected demographic, clinical, and epidemiological data obtained from the GOG-0199 baseline questionnaire and submitted to the CIMBA Central Database to analyze and publish the data. The epidemiological and SNP data contributed to the central database are then distributed to the investigators responsible for analysis of a particular SNP or set of SNPs from a candidate gene or genetic pathway.
3201128|NCT00899223||Group 1|Previously untreated patients on a CALGB treatment protocol for leukemia (acute or chronic) or myelodysplasia are eligible. Patients must be registered to CALGB 9665 prior to receiving any therapy for their disease.
2532326|NCT02681419|Active Comparator|Needle fenestration|Needle fenestration
2532327|NCT02681419|Active Comparator|Suture wick|suture wick using 10-0 vicryl
2532404|NCT02681315|Experimental|6 liter/min group|Infants will be extubated to a HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) at ﬂow rate of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
2532417|NCT02681315|Active Comparator|3 liter/min group|Infants will be extubated to HHHFNC (Fisher and Paykel Healthcare , Auckland, New Zealand) a ﬂow rate of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
2532494|NCT02680808|Experimental|midazolam with F901318|Pharmacokinetic profile of midazolam 2 mg orally when given after dosing with F901318 to steady state.
2532558|NCT02680236||Breast Cancer Patients|"This pilot study proposes to explore the effect of art therapy on breast cancer patients' perception of pain, and its impact on daily functioning by offering four sessions of individual art therapy, spaced between one to three weeks apart.~The study will be open to breast cancer patients over the age of 18, who have been assessed by the Royal Marsden (RM) Pain Team, and who report having persistent post treatment pain of at least moderate intensity for the preceding two weeks despite having been optimally treated for their pain already, and who fulfil the inclusion criteria."
2532725|NCT02678949|Experimental|Inhaled Fluticasone 50 mcg/twice day|Group 2; Inhaled fluticasone. 50 mcg/twice day for a period of 4 weeks.
2532737|NCT02678949|Experimental|Inhaled Fluticasone 100 mcg/twice day|Group 3;Inhaled fluticasone. 100 mcg/twice day for a period of 4 weeks
2532748|NCT02678949|Experimental|Inhaled Albuterol|Group 2 and group 3, inhaled albuterol one dose of 400 mcg.
2532805|NCT02678663|Experimental|Injection-assisted cold snare polypectomy (I-CSP)|Polyps in this group will be resected with the cold snare technique after pre-lift of the lesion with a submucosal injection of methylene blue-tinted normal saline solution. The polyp and a small rim of normal tissue will be then snared closely and removed in a single piece without the use of electrocautery.
2532806|NCT02678663|Active Comparator|Endoscopic mucosal resection (EMR).|"Polyps in this group will be removed in a single piece by using an inject-and-cut EMR technique. Methylene blue-tinted normal saline solution will be injected into the submucosal space followed by the application of snare cautery for lesion resection."
2532862|NCT02678273|Experimental|Intervention group|Intervention
2532863|NCT02678273|No Intervention|Control group|Standard care when patient is in the hospital. At discharge, patients may be referred to community services as deemed necessary by the hospital team. This is not restricted.
2532905|NCT02677922|Experimental|Oral AG-120 + Subcutaneous (SC) azacitidine|Subjects with an IDH1 mutation will receive AG-120 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2532906|NCT02677922|Experimental|Oral AG-221 + Subcutaneous (SC) azacitidine|Subjects with an IDH2 mutation will receive AG-221 at the RP2D orally QD on Days 1-28 of each 28-day cycle + azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2532908|NCT02677922|Experimental|Subcutaneous (SC) azacitidine|Subjects with either an IDH1 or IDH2 mutation will receive azacitidine 75 mg/m2/day SC for 7 days of each 28-day cycle.
2533010|NCT02677337|No Intervention|No intervention|
2533011|NCT02677337|Other|Educational Program|chart abstraction will be conducted post education intervention component.
2533251|NCT02675790|Active Comparator|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
2533253|NCT02675790|Active Comparator|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
2533322|NCT02675387|Active Comparator|Traditional Group|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine
2533325|NCT02675387|Experimental|Buzzy|Children will be administered buccal infiltration anesthesia using a 21mm needle and 1.8ml of 2%Lidocaine after sensitizing the area with a vibrating device
2533397|NCT02674893|Experimental|type 2 diabetics treated with GLP1 analogue|
2533404|NCT02674893|Active Comparator|Type 2 diabetics not treated with incretins|
2533407|NCT02674893|Other|Healthy subjects|
2533441|NCT02674451|Active Comparator|RIPC|Participants will receive remote ischemic preconditioning within one hour of coronary angiography. This involves blood pressure cuff inflation to 200mmHG for three-5 minute periods, each separated by 5 minute intervals.
2532237|NCT02682147|Experimental|Hypoxia Administration study group|40 subjects will be recruited to study normoxia oxygen compared to hypoxia oxygen. 20M and 20F subjects will be evaluated under normoxia oxygen with low dose non-contrast CT scans at total lung capacity (TLC) and 20% vital capacity (VC) and then with contrast using dual energy CT scans to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normixia scans, hypoxia administration will be administered by breathing an inspired FIO2 of 15% oxygen and the non-contrast and contrast using DECT scans to evaluate heterogeneity of perfused blood volumen will be completed.
2532241|NCT02682147|Experimental|Hyperoxia Administration study group|40 subjects will recruited to study normoxia oxygen scans compared to hyperoxia scans. 20M and 20F subjects will be evaluated under normoxia with low dose non-contrast CT scans at TLC and 20% vital capacity (VC) and then with contrast scans using DECT to evaluate heterogeneity of perfused blood volume (PBV). For the intervention, following the normoxia scans, hyperoxia administration will be administered by breathing an inspired FIO2 of 100% oxygen and the non-contrast and contrast using DECT to evaluate heterogeneity of perfused blood volumen will be completed.
2532246|NCT02682147|Experimental|Sildenafil|40 subjects (20M and 20F) will be recruited to study non-contrast imaging at TLC and 20%VC and with contrast using DECT scans to assess perfused blood volume. For the intervention, the subject will be administered 20 mg of sildenafil and then the same scanning will be repeated one hour after sildenafil administration.
2532286|NCT02681835|Experimental|Position 1|Standard position during intubation. Intubator is behind head of the victim, propped up on both elbows
2532288|NCT02681835|Experimental|Position 2|Intubator is behind head of the victim, lies on the left side
2532293|NCT02681835|Experimental|Position 3|Intubator stands astride the victims, intubated using the face-to-face
2532361|NCT02681575|Experimental|Cog-Fun A|Metacognitive-Functional occupational therapy intervention (Cog-Fun - A) includes enhancing self awareness in occupational context, acquiring executive strategies and skills and implementation across multiple occupational domains.
2532399|NCT02681250|Experimental|Titanium-zirconium|Patients receiving titanium-zirconium implants
2532408|NCT02681250|Active Comparator|Titanium|Patients receiving titanium implants
2532463|NCT02680730|Experimental|Intervention only|Participants will be included in 1 pre-intervention and 2 post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
2532466|NCT02680730|Experimental|Intervention + Stability|Participants will be included in 2 pre-intervention and 2 post-assessment measures. The additional pre-intervention assessment will allow for assessment of stability of measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 60 minutes per day, for 5 consecutive days.
2532568|NCT02680405||Atopic Dermatitis|Subjects with Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
2532571|NCT02680405||Non Atopic Dermatitis|Subjects with no Atopic Dermatitis will have blood draw, skin biopsies and tape stripping
2532629|NCT02679703|Experimental|High voltage|The applied parameters of high voltage electrical stimulation are medium voltage of 100 volts, an increase in the course of the session, frequency of 10 Hz, with application in the donor areas of thigh or scalp for 40 minutes, 25% above of level engine daily until complete epithelialization, and removal of the dressing type rayon.
2532632|NCT02679703|Experimental|Neuromuscular transcutaneous electrical stimulation (TENS)|10 Hz, 40 min, 200 μs and 25% above of motor level
2532635|NCT02679703|Experimental|Control Group|There will be no intervention
2532674|NCT02679378||ClearSight™ System|To assess the ability of the ClearSight™ System to detect malignant tissue less than or equal to 1 mm of margins of excised breast specimen in breast conserving surgery when compared to histopathological assessment.
2532724|NCT02679118|Experimental|Sentire|The patients will undergo their laparoscopic gastric bypass, during the operative period at pre-defined time points, a small amount of gas from the abdomen will be withdrawn and analyzed for the device. The laparoscopic gastric bypass will proceed without interference or effect from the device.
2532796|NCT02678767|Experimental|HIV+ with neurocognitive disorder|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2532797|NCT02678767|Active Comparator|HIV+ without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2532798|NCT02678767|Active Comparator|HIV- without neurocognitive impairment|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2532825|NCT02678338|Experimental|Hu5F9-G4|Dose Escalation: CD47 blocking antibody Hu5F9-G4
2532888|NCT02678169||Penumbra Aspiration System|Penumbra Aspiration System with the ADAPT technique
2533034|NCT02677103|Experimental|RSWT group|The RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder. RSWT will be performed once per week, and will be continued for 3 weeks.
2533039|NCT02677103|Experimental|USNP group|All needle punctures will be guided by ultrasound (US). The puncture needle is a 3.8cm 22# needle attached on a 5ml syringe. Before puncture, the skin of the puncture site will be sterilized with better iodine, and the transducer will be covered with a sterilized plastic bag. After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed. The needle tract will be monitored by ultrasound to make sure the needle penetrated through the calcific plaque, but does not penetrate the rotator cuff.
2533318|NCT02675270|Experimental|Semantic, Lexical, Untrained|
3201129|NCT00899275||Ancillary-correlative|After the initial submission of blood samples, patients may undergo open or closed biopsy in order to obtain fresh and frozen tissue samples as well as paraffin embedded material. Patients who are enrolled at the time of initial diagnosis but then have a definitive surgery or develop recurrent disease may submit additional samples (paraffin block, frozen and fresh tumor tissue, or slides together with blood samples). Autopsy tumor samples may also be submitted.
2532370|NCT02681549|Experimental|pembrolizumab plus bevacizumab|
2532389|NCT02681029|Experimental|Blastocyst transplantation|The infertile women who underwent intra- uterus transferring of blastocyst from thawed cleavage embryo
2532414|NCT02681029|Placebo Comparator|Control|The infertile women who underwent intra- uterus transferring of thawed cleavage embryo.
2532452|NCT02680743|Experimental|Intervention Group|"Patients who fail newborn hearing screen will be screened for CMV by saliva PCR. If positive they will be referred for early hearing screen follow-up and early intervention.~They will also receive a consult with PEdiatric Infectious Disease to evaluate need for treatment.~Intervention:Education of parents to pursue prompt hearing screening."
2532497|NCT02680470|Experimental|Virtual Observed Therapy|Intervention = Virtual observed therapy of participants taking TB therapy
2532581|NCT02679989|Experimental|Intermittent Energy Restriction|Weight loss intervention: Intermittent Energy Restriction
2532585|NCT02679989|Active Comparator|Continuous Energy Restriction|Weight loss intervention: Continuous Energy Restriction
2532628|NCT02679651||Control group|Healthy Adults without foot pain
2532630|NCT02679651||DIsease group|Adults diagnosed with fat pat atrophy and report symptoms of foot pain and have participated in clinical trial to treat fat pad atrophy.
2532680|NCT02679339|Experimental|CNTX-2022 (lidocaine gel, 40%)|Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
2532681|NCT02679339|Placebo Comparator|Placebo|Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
3201130|NCT00899288|Experimental|tamoxifen and no bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have not had a bone fracture.
3201131|NCT00899288|Experimental|Letrozole and no bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have not had a bone fracture.
2532864|NCT02678260|Experimental|PDR001|PDR001 will be administered i.v. every two weeks until a patient experiences unacceptable toxicity, progressive disease as per irRC and/or treatment is discontinued at the discretion of the investigator or the patient. The treatment period will begin on Cycle 1 Day 1. For the purpose of scheduling and evaluations, a treatment cycle will consist of 28 days. During the study, cohorts of patients will be treated with PDR001 until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
2532910|NCT02677870|Other|Diet treatment|In part 1 of the study, patients will not receive any medication. Each patient will DIET treatment alone. They will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week. Based on these diaries, average weekly Phe intake and Phe tolerance will be calculated and recorded.
2532911|NCT02677870|Active Comparator|Standard dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin dihydrochloride (Kuvan) or high-dose saproterin dihydrochloride (Kuvan)  groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Standard-dose saproterin dihydrochloride will be 20mg/kg (rounded up to the nearest 100mg) provided in the form of 100mg tablets. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
2532912|NCT02677870|Experimental|High dose saproterin dihydrochloride|"Study numbers will be randomized into standard-dose saproterin or high-dose saproterin groups (treatment group A or treatment group B). Both groups will receive a trial of both standard and high dose saproterin dihydrochloride before the end of the study. Goal high-dose saproterin dihydrochloride dosing will be 40mg/kg (rounded up to the nearest 500mg), provided in the form of pre-packaged 500mg packets of powder. Labeled dosing on these packets will be covered by the investigational drug pharmacy and unidentifiable to patients. Dosing of the tablets will be unidentifiable to patients. Medication will be given orally once daily."
2532963|NCT02677506|Experimental|Supraclavicular|Supraclavicular brachial plexus block will be done.
2532966|NCT02677506|Active Comparator|Infraclavicular|Infraclavicular brachial plexus block block will be done.
2533000|NCT02677233||preeclamptic group|"Blood pressure: greater than or equal to 140 mmHg systolic or greater than or equal to 90 mmHg diastolic on two occasions at least 4 hours apart after 20 weeks of gestation (Roberts et al., 2013).~Proteinuria: protein/creatinine ratio greater than or equal to 0.3~In the absence of proteinuria, a new-onset hypertension with new onset of the following:~thrombocytopenia: platelet count less than 100.000/microliter~renal insufficiency: serum creatinine greater than 1.1 mg/dl~impaired liver function: elevated concentration of liver transaminases~pulmonary edema~cerebral or visual symptoms~Severe right upper quadrant or epigastric pain unresponsive to medication."
2533004|NCT02677233||non preeclamptic group|All are normotensive with blood pressure <140/90 with no proteinuria.
2533050|NCT02676934|Experimental|Et group|applying end tidal concentration as a control target for delivery of sevoflurane
2533051|NCT02676934|No Intervention|FGF group|using Fresh gas control for sevoflurane delivery
2533086|NCT02676583|Active Comparator|Billateral tonsil fossa closure|tonsillectomy
2533094|NCT02676583|Active Comparator|No closure of tonsil fossa|tonsillectomy
2533098|NCT02676583|Active Comparator|Unilateral tonsil fossa closure|tonsillectomy
2533141|NCT02676349|Experimental|Arm B|Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy
2533153|NCT02676349|Active Comparator|Arm A|Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy
2533276|NCT02675621|Placebo Comparator|Control|Mix 1 flavored still beverage
2532353|NCT02681666|Experimental|MB-IBS-EAT INTERVENTION STUDY arm|Irritable Bowel Syndrome eating awareness training intervention will be started in a comprehensive 8 weekly sessions of Mindfulness eating training.
3201132|NCT00899288|Experimental|Tamoxifen and bone fracture|Patients randomized to Arm A of Study BIG 1-98 (tamoxifen for 5 years) who have had a bone fracture.
2532470|NCT02680509|Experimental|All|All patient will undergo a unilateral sympathicotomy R3. After this left and right will be compared
2532545|NCT02680366|Experimental|collagen/ABMNC scaffold|collagen/ABMNC scaffold covered on Foley catheter balloon inserted after hysteroscopic adhesiolysis
2532546|NCT02680366|Active Comparator|Foley catheter balloon|Foley catheter balloon inserted after hysteroscopic adhesiolysis
2532692|NCT02679456|Active Comparator|Treatment Group 1 (Fluconazole)|Fluconazole
2532694|NCT02679456|Experimental|Treatment Group 2: (SCY-078)|Dose regimen 1
2532696|NCT02679456|Experimental|Treatment Group 3 (SCY-078)|Dose regimen 2
2532742|NCT02678988|Experimental|A1: Tocilizumab AI followed by PFS-NSD in abdomen|Participants will receive two single doses of 162 milligrams (mg) tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in abdomen.
2532747|NCT02678988|Experimental|A2: Tocilizumab AI followed by PFS-NSD in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2) in thigh.
2532753|NCT02678988|Experimental|A3: Tocilizumab AI followed by PFS-NSD in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via AI on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via PFS-NSD on Day 43 (Period 2), in upper arm.
2532754|NCT02678988|Experimental|B1: Tocilizumab PFS-NSD followed by AI in abdomen|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in abdomen.
2532757|NCT02678988|Experimental|B2: Tocilizumab PFS-NSD followed by AI in thigh|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
2532760|NCT02678988|Experimental|B3: Tocilizumab PFS-NSD followed by AI in upper arm|Participants will receive two single doses of 162 mg tocilizumab SC, first dose via PFS-NSD on Day 1 (Period 1) followed by a washout period of 6 weeks, thereafter second dose via AI on Day 43 (Period 2), in thigh.
2532811|NCT02678520|Experimental|3-D conformal radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using a 3-D conformal radiation technique (3-D CRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
2532815|NCT02678520|Active Comparator|Intensity modulated radiation therapy|"Intervention: Radiation therapy delivered to a total dose of 6600 centigray (cGy) at 200 cGy/fraction (fx) once daily using intensity modulated radiation therapy (IMRT). The volume of radiation will encompass the prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement. Hormonal therapy will be required for patients with high risk disease (both the adjuvant and salvage groups). For patients with low risk disease, hormonal therapy will be as per standard of care. Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months. Hormonal therapy regimen will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg sc once every 3 months x 2 injections) or Lupron (22.5 mg im once every 3 months x 2 injections) to start on day 1 once the subject has been enrolled to the clinical trial."
2532874|NCT02678104|Experimental|Chlorhexidine mouth wash|Tooth extraction. The patients will start using Chlorhexidine mouthwash on 2nd day of extraction twice daily for 7 days.
2532877|NCT02678104|Experimental|Manuka Honey|intra-alveolar application of Manuka Honey after tooth extraction.
2532949|NCT02677662|Sham Comparator|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise or rest.
2532954|NCT02677662|Experimental|Diesel exhaust exposure|2 hour exposure to dilute diesel exhaust (approximate PM10 (particulate matter<10um) concentration 300 mcg/m3) during intermittent exercise or rest.
2533081|NCT02676596|Other|Cohort 1|Japanese and Non-Japanese subjects receiving K-312 50 mg QD
2533091|NCT02676596|Other|Cohort 2|Japanese and Non-Japanese subjects receiving K-312 100 mg QD
2533097|NCT02676596|Other|Cohort 3|Japanese and Non-Japanese subjects receiving K-312 200 mg QD
2533102|NCT02676596|Other|Cohort 4|Japanese and Non-Japanese subjects receiving K-312 400 mg QD
2533105|NCT02676596|Other|Cohort 5|Japanese and Non-Japanese subjects receiving K-312 25 mg QD
2533108|NCT02676596|Other|Cohort 6|Japanese and Non-Japanese subjects receiving K-312 10 mg QD
2533142|NCT02676193|Experimental|Australian Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using standard Australian marketing for three months.
2533150|NCT02676193|Experimental|Blank Packs|The intervention to be administered to participants randomized to this group is the purchase of their US brand of cigarettes packaged using blank packaging for three months. Blank packaging will indicate participants brand and will not have any brand-related images or labels.
2533156|NCT02676193|No Intervention|American Packs|Participants assigned the nonintervention group will purchase their US brand of cigarettes in the standard American packaging for three months.
3201133|NCT00899288|Experimental|Letrozole and bone fracture|Patients randomized to Arm B of Study BIG 1-98 (letrozole for 5 years) who have had a bone fracture.
3201134|NCT00899301||Patients with Breast Cancer|
2533282|NCT02675621|Active Comparator|Phenolic beverage 1|Mix 2 flavored still beverage with a high dose phenolic extract
2532357|NCT02681536|Experimental|microdose flare protocol|OCPs drospirenone /ethinyl estradiol (Yasmin, BAYER) for not less than 21 days before starting ovarian stimulation, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by HMG IM daily (Merional, 75 IU, IBSA) 3 days later. Then the same cycle adjustment was done as the minidose long protocol.
2532391|NCT02681081|Other|Control|For sessions 2 through 4, maintain normal eating patterns.
2532409|NCT02681081|Active Comparator|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
2532418|NCT02681081|Active Comparator|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
2532507|NCT02680691|Experimental|Robot, then conventional training|Robot assisted gait training 4 weeks after conventional gait training
2532509|NCT02680691|Active Comparator|Conventional, then robot training|Conventional gait training 4 weeks after robot assisted gait training
2532575|NCT02680132|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2532576|NCT02680132|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
3201135|NCT00899301||Patients without breast cancer|
2532732|NCT02679040|Experimental|Immediate Mammary Reconstruction|Chemotherapy, radiation therapy, mastectomy with immediate mammary reconstruction
2532836|NCT02678598||Micafungin group|
2532884|NCT02677948|Experimental|Pacritinib and Ibrutinib|"Phase I: Patients will receive Pacritinib 100-200 mg twice daily along with Ibrutinib 420mg/day.~Phase II Lead-In: Pacritinib at MTD daily continuous x 2 months followed by Pacritinib at MTD twice daily along with Ibrutinib 420mg/day."
2532935|NCT02677688|Experimental|Autologous EBV specific CTL infusion|
2532967|NCT02677402|Experimental|cold water immersion|Participants immersed their lower limbs in water of ~12°C
2532969|NCT02677402|Experimental|contrast water therapy|Participants immersed their lower limbs in water : alternated every 2 min between ~12°C and ~35°C for CWT
2532970|NCT02677402|Experimental|thermo neutral immersion|Participants immersed their lower limbs in water of ~35°C
3201137|NCT00899457||Healthy, non-smokers|
2533119|NCT02676518||polycystic ovary syndrome women|PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
2533138|NCT02676258|Experimental|Si-Hy soft contact lens|olifilon B daily disposable soft contact lens
2533149|NCT02676258|Active Comparator|Vistakon soft contact lens|narafilcon A daily disposable soft contact lens
2533211|NCT02675959|Experimental|Defibrotide prophylaxis|defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
2533284|NCT02675569|Active Comparator|Catheter|Catheter is a method of vascular access for hemodialysis. It consists of a long, thin plastic tube and may be either tunnelled or non-tunnelled.
2533288|NCT02675569|Experimental|Fistula|Fistula is a type of vascular access strategy for hemodialysis in which a direct connection of an artery to a vein is created. It is intended to provide an access with good blood flow that can last for decades.
2533344|NCT02675036|Experimental|Primary canine tooth|Extraction of primary canine tooth
2533345|NCT02675036|Experimental|Primary canine and primary molar teeth|Extraction of primary canine and primary first molar teeth
2533408|NCT02674828|Experimental|Reinforcement treatment|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
2533410|NCT02674828|Active Comparator|Standard Treatment|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
2533428|NCT02674425||Young adults (18-40)|Healthy adult volunteers, aged between 18 and 40, with no prior/current eye problems or family history of genetic eye diseases and good general health.
2533432|NCT02674425||Older adults (50-70)|Healthy adult volunteers, aged between 50 and 70, with no prior/current eye problems or family history of genetic eye diseases and good general health.
2533509|NCT02674217|Experimental|Multiple sclerosis autografted patients|Individuals with a relapsing-remitting (RRMS) course, secondary progressive (SPMS) or primary progressive (PPMS) were included. Patients should have a Karnofsky performance status (18) above 70% and a EDSS score (1) of 6 or below. The study is approved by the Etichs Committee of the Clinica RUIZ and all patients signed a consent form after being fully informed about procedure an possible complications. Patients included will de treated with Hematopoietic stem cell transplantation
3201138|NCT00899483|Active Comparator|1|Administered with glucose potassium insulin solution to achieve euglycaemia 4.0-6.0 mmol/L
3201139|NCT00899483|No Intervention|2|Normal departmental practice using dextrose insulin infusion
2532380|NCT02681380|Experimental|Relation learning|Participants of this group will benefit form a specific learning on relation, Balint like. They will have 7 sessions during 3 months.
2532381|NCT02681380|Placebo Comparator|Control group|Participants of this group will have no learning related to relation with patient.
2532442|NCT02680938|Active Comparator|oxytocin group|10 units of oxytocin will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
2532443|NCT02680938|Placebo Comparator|control group|1 mL normal saline will be injected into the umbilical vein at the most proximal site to the placenta after clamping and cutting of the umbilical cord.
2532516|NCT02680483||AF cohort|AF consecutive patients
2532548|NCT02680119|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2532550|NCT02680119|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
2532593|NCT02679872||VATS team 1|Video-assisted thoracoscopic surgery team, from institution/hospital 1.
2532597|NCT02679872||VATS team 2|Video-assisted thoracoscopic surgery team, from institution/hospital 2.
2532602|NCT02679872||VATS team 3|Video-assisted thoracoscopic surgery team, from institution/hospital 3.
2532604|NCT02679872||VATS team 4|Video-assisted thoracoscopic surgery team, from institution/hospital 4.
2532622|NCT02679599|Other|Cardiac rehabilitation as usual|Participants will receive cardiac rehabilitation as usual (i.e., as offered in the clinical setting).
2532625|NCT02679599|Experimental|Cardiac rehabilitation plus B-MOBILE-CARDIAC smartphone app|Participants will receive cardiac rehabilitation as usual, plus access to the B-MOBILE-CARDIAC smartphone application through 4 weeks post-rehabilitation.
2532764|NCT02678884|Experimental|HNSCC Patients receiving RT|
2532818|NCT02678650|Experimental|volatile anesthetics group|10min after intubation, begin to sevoflurane wash-in / wash-out operation: sevoflurane administration was interrupted for at least 10 min, by washout with a high fresh gas flow (10 l/min) to achieve a MAC value below 0.2. Following the interruption, sevoflurane was again washed in with a high fresh gas flow (6 l/min) to achieve 1 MAC end-tidal concentration as soon as possible, and repeated twice periods of 10 minutes. Discontinuation of the halogenated agent for at 15 minutes during the last wash out time.
2532820|NCT02678650|Placebo Comparator|propofol intravenous anesthesia group|propofol infusion 3-5μg / kg / h
2532873|NCT02678195|Experimental|3 days amoxicillin + 2 days placebo|3 days amoxicillin DT + 2 days placebo DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
2532875|NCT02678195|Active Comparator|5 days amoxicillin|5 days amoxicillin DT in two divided doses based on age bands (500 mg/day for children 2 months up to 12 months, 1000 mg/day for children 12 months up to 3 years, and 1,500 mg/day for children 3 years up to 5 years of age).
3201140|NCT00899535||Group 1|This research study is looking at the cancer genome using tumor samples from patients with stage I or stage II non-small cell lung cancer treated on clinical trial ACOSOG-Z0030. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
3201141|NCT00899587|Experimental|Oxygen|
2532973|NCT02677454|Experimental|Flash Glucose Monitor|"Each patient with Type 1 diabetes will have a subcutaneous tissue FGM sensor inserted. The sensor will produce a maximum of 1440 tissue fluid glucose measurements per 24 hours and 20160 measurements during the 14 day study. The FGM data (Abbott Freestyle Libre) will be compared to the time-matched reference blood glucose measurements.~Each ambulatory patient will sample capillary blood with the HemoCue meter and measure the concentration of glucose 6 to 10 times per day for 14 days. The concentration of finger-stick capillary blood glucose will be measured using the self-monitoring blood glucose (SMBG) hemocue meter in their daily living. The subjects will record SMBG, in a written diary. Subjects will dose insulin according to their routine methods throughout the 14 day study."
2533043|NCT02677207|Experimental|JNJ-39393406|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
2533046|NCT02677207|Placebo Comparator|Placebo|2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial.
2533069|NCT02676661||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
2533071|NCT02676661||peri-implant disease|The subjects who suffered from peri-implant disease.
3201142|NCT00899587|Experimental|Enalapril|
3201143|NCT00899587|Placebo Comparator|Control|
3201144|NCT00899652||All Patients|Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.
3201145|NCT00899704||Group 1|Patient tissue samples are screened using polymerase chain reaction (PCR) for human papilloma virus-specific primers. Samples are analyzed to identify a nodal-metastasis signature for oral squamous cell carcinoma. Samples also undergo microarray analysis to quantify expression levels for targeted genes. Initial data analysis is performed using Affymetrix® Microarray Suite 5.0 to quantify expression levels for targeted genes.
3201146|NCT00899782||Ancillary-Correlative (lung cancer tissue bank)|Grossly viable tumor and grossly normal lung tissue are identified and removed from patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue Bank for future use in research. Blood specimens are also collected prior to surgery and at 4-12 weeks post-surgery (before the start of adjuvant therapy) and shipped immediately to the Tissue Bank.
3201147|NCT00899834||Tumor Samples|fresh-frozen and fixed tumor samples and correspondent normal tissue from patients affected with this tumor.(peripheral blood is applicable only to patients with focal brainstem gliomas and patients who undergo biopsy of a diffuse brainstem glioma at diagnosis)
3201148|NCT00899860||patients with renal cell cancer|
3201149|NCT00899951||Cohort 1|receiving fentaly citrate
3201150|NCT00899964|Active Comparator|1|automated tailored feedback per E-mail
3201151|NCT00899964|Active Comparator|2|1 + active contact per E-mail possible
3201152|NCT00899964|Active Comparator|3|2 + active contact by trainer in case of exercise-related problems
3201153|NCT00899964|Active Comparator|4|3 + regular active contact by trainer
3201154|NCT00899977|Placebo Comparator|Placebo|Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.
2532382|NCT02681107|Experimental|Single Arm|Single cohort to receive Accelerated Partial Breast Irradiation (APBI) 27Gy in 5 fractions
2532439|NCT02680886||Novosyn® Quick|Skin closure using rapid absorbable suture material
3167372|NCT00537602|Placebo Comparator|B|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
3167373|NCT00537654|Experimental|Fasted state|Subjects will be required to fast overnight. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
3167374|NCT00537654|Experimental|Fed state|Subjects will be served high fat breakfast 30 minutes prior to dosing. Subjects will participate in 3 treatment periods and assigned to one of 12 treatment sequences ( ABC, ACB, BAC, BCA, CAB, CBA, ABD, ADB, BAD, BDA, DAB, DBA) in accordance with the randomization schedule. The three treatment periods will be separated by a minimum washout period of 28 days
2532554|NCT02680028|Active Comparator|Standard length intramedullary nail|220mm intramedullary nail
2532561|NCT02680028|Experimental|Short length intramedullary nail|175mm intramedullary nail
2532642|NCT02679794|Experimental|Egg consumption|Consuming sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
2532647|NCT02679794|Placebo Comparator|Control|Consuming sautéed vegetables and 3g canola oil without eggs
2532765|NCT02678897|No Intervention|Pain management in early pregnancy MTOP|Patients in early pregnancy (pregnancy weeks <9weeks) undergoing medical termination of pregnancy gets Ibuprofen (tbl 600mg 3 times a day) and Paracetamol (tbl 1000mg 3 times a day).
2532768|NCT02678897|Experimental|Patient controlled analgesia (PCA)|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get pain medication (Oxynorm) via PCA"
2532769|NCT02678897|Active Comparator|Oxynorm on-demand|"Pregnancy weeks 9-20. All patients get baselineanalgesics: Ibuprofein 600mg and Paracetamol 1000mg both x3 a day.~Patients get extra pain medication (Oxynorm) on-demad from the nurse."
2532848|NCT02678585|Active Comparator|Nalbuphine|53 patients received intravenous regional lidocaine plus Nalbuphine
2532849|NCT02678585|Other|Control group|53 patients received intravenous regional lidocaine
2532868|NCT02678026|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early).~Women will receive pessary soon after UIC"
2532869|NCT02678026|No Intervention|No intervention|No treatment
2533001|NCT02677051|Placebo Comparator|Placebo|About 15 subjects will be randomized into this arm, receiving pills with an inactive placebo.
2533005|NCT02677051|Experimental|Sulforaphane|"About 30 subjects will be randomized into this arm, receiving pills with glucoraphanin rich broccoli seed powder containing active myrosinase resulting in sulforaphane once ingested Doses will be weight dependent with each pill resulting in ~ 50 µmol sulforaphane.~Body weight Dose of sulforaphane 34 kg ~ 50 µmol 68 kg ~ 100 µmol 102 kg ~ 150 µmol"
2533075|NCT02676908|No Intervention|4 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for four weeks (usual care)
2533080|NCT02676908|No Intervention|4 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for four weeks (usual care)
2533089|NCT02676908|Experimental|2 weeks & EVLT|After endovenous laser therapy and avulsions, patients will wear compression socks for two weeks (trial group)
2533095|NCT02676908|Experimental|2 weeks & RFA|After radiofrequency ablation therapy and avulsions, patients will wear compression socks for two weeks (trial group)
2533299|NCT02675725||Post cardiac surgery|Patients after cardiac surgery with signs of decreased organ perfusion and the need of fluid therapy.
2533314|NCT02675127|Experimental|A Test|Test drug (Daktavira, European Egyptian Pharmaceutical Industries)1 tablet contains 60 mg Daclatasvir
2533319|NCT02675127|Active Comparator|B Reference|Reference drug (Daklinza, (Bristol-Myers Squibb Pharma, UK)) 1 tablet contains 60 mg Daclatasvir
3167375|NCT00537667|Active Comparator|A|anakinra
3167376|NCT00537667|Experimental|B|anakinra and PEGsTNF-R1
3167377|NCT00537693|Active Comparator|1|CRRT via Convection
3167378|NCT00537693|Active Comparator|2|CRRT via Diffusion
3167379|NCT00537719|Active Comparator|GSK716155|albiglutide subcutaneous injection
3167380|NCT00537719|Placebo Comparator|placebo|placebo injection
3167381|NCT00537732|Active Comparator|control group|3 tablets, only 20 mg omeprazole, genotype independent
3167382|NCT00537732|Active Comparator|intervention group|20 vs. 60 mg daily, genotype dependent
3167383|NCT00537758|Experimental|1|Cognitive Behavior Therapy
3167384|NCT00537758|Experimental|2|Behavioral Weight Loss Treatment
3167385|NCT00537758|Experimental|3|CBT + BWL
3167386|NCT00537784|Active Comparator|1|Injection of autologous platelet concentrate into repair site
3167387|NCT00537784|Placebo Comparator|2|No injection
3167388|NCT00537797|Experimental|Arm 1|"18-FDG-PET exam with SUV determination~Thyroid operation to remove nodule~Pathologic confirmation of nodule histology~Determine sensitivity and specificity of FDG-PET, correlative studies"
3167389|NCT00537836|Experimental|ZK 283197, 3 mg|Postmenopausal women with hot flushes received 3 mg (3 x 1 mg tablets) ZK 283197, administered orally once daily over 8 weeks
3167390|NCT00537836|Placebo Comparator|Matching placebo|Postmenopausal women with hot flushes received placebo (3 tablets) orally once daily over 8 weeks
3167391|NCT00537836|Experimental|ZK 283197, 2 mg|Postmenopausal women with hot flushes received 2 mg (2 x 1 mg tablet) ZK 283197 plus 1 placebo tablet, once daily orally over 8 weeks
3167392|NCT00537836|Active Comparator|17ß-estradiol|Postmenopausal women with hot flushes received 1 mg (2 x 0.5 mg tablet) 17ß-estradiol plus 1 placebo tablet, once daily orally over 8 weeks
3167393|NCT00537875|Active Comparator|1|
3167394|NCT00537875|Placebo Comparator|2|
3167395|NCT00537914|Other|1|single-arm non-comparative somatropin safety study (PASS)
3167396|NCT00537927|Active Comparator|0|fixation of mesh with a single crown of tacks and absorbable sutures
3167397|NCT00537927|Active Comparator|1|fixation of mesh with a double crown of tacks and no sutures
2532390|NCT02681055|Experimental|open label arm|All 40 subjects will receive MN-001 for the first 4 weeks. At Week 4 subjects will increase their dosage frequency for remaining 8 weeks. Subjects will receive MN-001 for a total of 12 weeks.
2532464|NCT02680782|Experimental|X4P-001 QD|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug once daily in the first period, followed by twice daily in the second dosing period.
2532467|NCT02680782|Experimental|X4P-001 BID|Subjects will receive study drug in two dosing periods. In this arm subjects will receive drug twice daily in the first period, followed by once daily in the second dosing period.
2532495|NCT02680392|Experimental|Pulsed and Continuous Radiofrequency|In this group of patients undergoing total knee arthroplasty (allocation of patients is randomized), Pulsed radiofrequency (PRF) is applied to the saphenous nerve of the knee, associated to Continuous Radiofrequency (TRF) applied to the genicular nerves of the knee . A sham catheter is inserted in the mid-tigh to simulate a continuous adductor canal block, and connected to an infusion of normal saline (assessor and patient blinded to the treatment)
2532496|NCT02680392|Active Comparator|Continuous adductor canal block|"Continuous Adductor Canal Block~Continuous adductor canal block is performed in this group of patients, with a catheter infusing ropivacaine 0.2% in the first 48 hours after surgery.~The solutions bags are labelled in order to make assessor and patients, blinded to the treatment (Ropivacaine vs Normal Saline)"
2532547|NCT02680184|Experimental|Part 1: Dose-Escalation - CMP-001 and Pembrolizumab|Participants will receive up to 5 escalating dose levels (1 milligram [mg], 3 mg, 5 mg, 7.5 mg and 10 mg) of CMP-001 via intratumoral injection according to one of 2 schedules (Schedule A: once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued; Schedule B: once weekly for 2 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule.
2532549|NCT02680184|Experimental|Part 1: Dose-Expansion - CMP-001 and Pembrolizumab|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued) in combination with pembrolizumab at its labelled dose and schedule. As of 05 October 2018, the dose and schedule for Part 1 Dose Expansion Phase was selected based on all available safety, efficacy and pharmacodynamic data from the Part 1 Dose Escalation Phase. Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses less than (<) 10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A in combination with pembrolizumab.
2532551|NCT02680184|Experimental|Part 2: CMP-001 Monotherapy and Crossover to Combination|Participants will receive CMP-001 10 mg via intratumoral injection by Schedule A (once weekly for 7 weeks, followed by every 3 weeks thereafter until participant is discontinued). Participants who were enrolled prior to 05 October 2018 to receive CMP-001 doses <10 mg will have the option to receive CMP-001 doses up to 10 mg on Schedule A. Participants with documented progression while on CMP-001 monotherapy treatment will have the option to crossover to the combination treatment of CMP-001 10 mg plus pembrolizumab, at the discretion of the Investigator.
2532618|NCT02679716|Other|study group|MRI of the cerebral arteries ist performed
2532662|NCT02679482||Selective laser trabeculoplasty (SLT)|Patients who underwent to Selective laser trabeculoplasty
2532665|NCT02679482||Pattern laser trabeculoplasty (PLT)|Patients who underwent to Pattern laser trabeculoplasty
3201155|NCT00899977|Experimental|1 mg TC-5214|Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.
2532833|NCT02678507||Patients with chronic pain on opioids|
2532882|NCT02678156||LYoplant ONlay|Primary objective of the study is the generation of clinical data in patients receiving Lyoplant® Onlay for dura repair to assess its safety.
2533020|NCT02677311|Other|Cases|Participants who will receive gonadotoxic chemoradiation therapies to include the alkylating agents, heavy metals and plant alkaloids as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
2533024|NCT02677311|Other|Controls|Participants who will receive chemoradiation therapies presumed to be low risk for gonadotoxicity as determined by the literature and the patient's oncolologist as a standard part of their cancer treatment. Participants will also receive the GnRHa for menstrual suppression as part of standard of care. Baseline blood draws and pelvic ultrasound will be the intervention. Repeat blood draws and pelvic ultrasound at 6 and 12 months will also be interventions.
3167398|NCT00537927|Active Comparator|2|fixation of mesh with a single crown of tacks and non-absorbable sutures
3167399|NCT00537966|No Intervention|Control|Patients with primary HIV-1 infection who do not want to undergo early combination antiretroviral treatment
2533449|NCT02674295|Experimental|Cohort 1|50 milligram (mg) of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration.
2533454|NCT02674295|Experimental|Cohort 2|20 mg of intravenous esketamine in 30 milliliter (mL), fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
2533495|NCT02674152|Experimental|BI 836880|
2533541|NCT02673762||Normal glucose metabolism|Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
2533544|NCT02673762||Pre-diabetes|Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
2533550|NCT02673762||Type II diabetes|Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
2533649|NCT02673294|Experimental|Intervention (12-24 months)|Participants with a chronicity between 12-24 months
3167400|NCT00537966|Active Comparator|Intervention|In this arm patients with primary HIV-1 infection will receive early combination antiretroviral therapy with standard drugs approved by Swiss Medic.
3167401|NCT00538031|Active Comparator|Arm I|Patients receive oral cyclophosphamide once daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3167402|NCT00538031|Experimental|Arm II|Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3167403|NCT00538044|Experimental|1simvastatin group|before the operation, the patient start the simvastatin medication on the dosage of 40mg per day
2532415|NCT02681146|Experimental|Group3|Educational advice + physiotherapist treatment
2532420|NCT02681146|Experimental|Group4|Educational advice + physiotherapist treatment
2532424|NCT02681146|Experimental|Group5|Educational advice + physiotherapist treatment
2532425|NCT02681146|Experimental|Group6|Educational advice + physiotherapist treatment
2532426|NCT02681146|Experimental|Group7|Educational advice + physiotherapist treatment
2532428|NCT02681146|Experimental|Group8|Educational advice + physiotherapist treatment
2532510|NCT02680613|Experimental|Motivational SMS|This arm will receive 15 motivational SMS about cervical cancer and screening.
2532511|NCT02680613|Experimental|Travel Voucher|This arm will receive a voucher covering return transport from the screening clinic. This arm will also receive identical 15 motivational SMS about cervical cancer and screening as the Motivational SMS arm.
2532513|NCT02680613|No Intervention|Control|This arm will receive standard sensitization during study period (church announcements, screening promotion by key community leaders and posters in community, as well as sensitization by the research assistants conducting the door-to-door household recruitment) during the study and follow-up period. They will also receive one SMS message with the location of screening services during the study period. At the conclusion of the study, participants in the arm will receive identical motivational SMS as the other two arms.
2532559|NCT02680080|Active Comparator|Positive control group|"subjects will receive a single 400 mg tablet of Moxifloxacin - the most commonly used positive control in thorough QTc (TQT) studies. Subjects will be continuously recorded by a Holter monitor for 24 hours"
2532563|NCT02680080|Active Comparator|Grapefruit group|subjects will drink one liter of fresh pink-grapefruit juice as fast as possible. The pink-grapefruit juice will be squeezed in the morning of the experiment in the cardiology department. ECG will be performed immediately pre dose and at 1, 2, 3, 4, 6, 8, 12, 24 after fresh pink-grapefruit juice administration. In addition, subjects will be continuously recorded by a Holter monitor for 24 hours
2532634|NCT02679781|Active Comparator|oral sedation|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
2532636|NCT02679781|Active Comparator|nasal sedation|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
2532677|NCT02679326|Experimental|study group|will receive stretching guidance and high level active Ultrasound
2532678|NCT02679326|Placebo Comparator|control group|will receive stretching guidance and very low level of Ultrasound
2532728|NCT02679105|Placebo Comparator|ALK diluent|Human albumin
2532734|NCT02679105|Active Comparator|ALK Alutard birch or 5-grasses|Grass pollen suspension or birch pollen suspension
2532782|NCT02678702|Experimental|CBT-I|Behavioral intervention: CBT-I
2532784|NCT02678702|Active Comparator|Treatment as usual|Intervention: Control group receiving treatment as usual
3201156|NCT00899977|Experimental|2 mg TC-5214|Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.
3201157|NCT00899977|Experimental|4 mg TC-5214|Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.
2532907|NCT02677883|Experimental|Arm I: Manometry-guided thoracentesis|Intervention Group - Patients undergo fine needle- aspiration, called therapeutic thoracentesis, to drain fluid accumulated around the lung. Unlike Arm II, the intervention group will have their pleural pressure monitored during the procedure.
2532909|NCT02677883|Active Comparator|Arm II: Symptom-guided thoracentesis|Comparison Group - Patients undergo symptom-guided thoracentesis, the current standard-of-care is to drain fluid until 1) it is all gone or 2) a symptom occurs that indicates the lung may take longer to fully re-expand and drainage should be stopped.
2532931|NCT02677597|Experimental|Cisplatin Combined With S-1|Cisplatin 75mg/m2 ivgtt d1 S-1 BSA<1.5 50mg bid，BSA≥1.5 60mg bid po d1-14
2532932|NCT02677597|Experimental|Cisplatin Combined With Paclitaxel|Cisplatin 75mg/m2 ivgtt d1 Paclitaxel 175mg/m2 d1 ivgtt 3h
3201158|NCT00899977|Experimental|8 mg TC-5214|Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.
3201159|NCT00899990||Observational (biomarker sampling)|Patients undergo collection of tumor specimens, bone marrow, and peripheral blood at diagnosis. Associated demographic and clinical data are collected and archived. Patients who are not enrolled on a therapeutic clinical trial are followed annually.
2533067|NCT02676830|Experimental|K-312|
2533167|NCT02676479|Experimental|Uterine Lavage Group|"The study will involve up to 30 pairs of male and female sexually intimate partners who are carriers for a genetic disease (e.g Sickle Cell Disease or Thalassemia) and at high risk of transmitting the gene.~The female partner will be superovulated to mature multiple oocytes which can be fertilized, inseminated with her partner's sperm through intra-uterine insemination (IUI). Four to six days after IUI, the female partner will undergo a non-surgical uterine lavage procedure (Previvo Uterine Lavage System™, CA, U.S.A.) to recover preimplantation embryos."
3201160|NCT00900003||pancreatic cancer patients|pancreatic cancer patients with excess tissue collected at the time of standard of care surgery
3201162|NCT00900224||Group 1|Previously procured and archived bone marrow aspirate samples, blood and buccal cell samples, and bone marrow biopsy slides are analyzed for FLT3 ITD, MLL PTD, NPM1, KIT, KRAS, NRAS, CEBPA, WT1, JAK2, RUNX1, TET2, ASXL1, IDH1 and IDH2, CBL, and DNMT3A mutations, CBF fusion genes, levels of BAALC, ERG, EVI1, MN1, and APP microarray gene-expression, microRNA gene-expression signature, levels of methylation of genes silenced in AML, and genomic DNA by PCR amplification, RT-PCR, and denaturing high-performance liquid chromatography.
2532423|NCT02681224|Placebo Comparator|Placebo Gel without Occlusion|Placebo Gel without Silon Bandage
2532569|NCT02680431||Neurofibromatosis 1|10 mL venous blood sample taken from patients with type 1 neurofibromatosis
2532572|NCT02680431||Control|10 mL venous blood sample taken from age- and gender-matched healthy controls
2532637|NCT02679768|Active Comparator|Circadian Reinforcement Therapy|Circadian reinforcement therapy
2532638|NCT02679768|Placebo Comparator|Standard treatment|Standard treatment
2532683|NCT02679300|Experimental|Virtual reality group|During a single intervention session, participants will perform 2 sets of 2 minutes of pelvic tilt exercises using serious games. These serious games have to be controlled by pelvic tilts. Patients will perform the exercises in a standing position in front a TV-screen, on which the games will be displayed. Wireless motion sensors will be mounted to the patient's spine and pelvis to track the movements of the pelvis.
2532690|NCT02679300|Active Comparator|Control group|During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
2532714|NCT02679014|Placebo Comparator|Placebo|Participants will receive placebo capsules (2 capsules) twice daily for 28 days.
2532719|NCT02679014|Experimental|RO5459072|Participants will receive RO5459072 100 milligrams (mg) capsules (2*50 mg capsules) twice daily for 28 days.
2532780|NCT02678832||Cancer patients|
2532783|NCT02678832||Physicians|
2532786|NCT02678832||Oncology nurses|
2532834|NCT02678468||high-risk group|children with birth history of pre-term, low birth weight children with develop delay
2532838|NCT02678468||normal group|children with normal birth history and normal development
2532886|NCT02678117|Active Comparator|Pregabalin & placebo|: will receive single dose oral Pregabalin 300 mg one hour preoperative and 200 ml of normal saline over 20 min.
2532890|NCT02678117|Active Comparator|Magnesium sulphate & Placebo|will receive preoperative single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline and a placebo capsule similar to pregabalin 300 mg.
2532893|NCT02678117|Active Comparator|Pregabalin & Magnesium sulphate|: will receive single dose oral pregabalin 300mg one hour preoperative and single dose IV Magnesium Sulphate 50mg /kg infused over 20 minutes diluted in 200 ml normal saline.
2532897|NCT02678117|Placebo Comparator|Placebo|will receive placebo medications at the same time and route of administration of other groups.
2532938|NCT02677610|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
2532943|NCT02677610|Placebo Comparator|Vehicle|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
2533014|NCT02677285||Skin graft|The bioimpedance measurement is done with a purpose built patch that has electrodes in contact with the wound and reference electrodes.
2533017|NCT02677285||Operation wound|The bioimpedance measurement is done with commercial electrodes places in healthy skin surrounding the wound.
2533136|NCT02676232|Experimental|Intervention|Participants in this arm will follow DARWeb: an online psychosocial intervention for children with recurrent abdominal pain and their parents. This is composed by 7 units for parents and 7 units for children, that have been developed from the cognitive-behavioral model, including setting goals, relaxation and distraction techniques, changing maladaptive thoughts and assertive communication training. The team under the program only contact with families for sending reminders and to answer potential technical problems or doubts
2533145|NCT02676232|No Intervention|Control|Participants allocated in this arm will not receive intervention. However, they will be invited to participate once the families allocated to the experimental group complete the program.
2533230|NCT02676076|Experimental|CHF 5993 100/6/12.5 µg|"Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB"
2533233|NCT02676076|Active Comparator|CHF 1535 100/6 µg|"Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF"
2533326|NCT02675283|Other|coeliac disease point of care test|Patients will be consented for a finger prick point of care test, Simtomax, at the pharmacy.
2533367|NCT02674945||Wireless Activity tracker: Fitbit|Patients with brain tumor(s) will be give a wireless activity tracker (fitbit flex) to use during treatment. They will complete quality of life surveys and a sleep survey.
2533386|NCT02674724|Experimental|Gym Group|With gym equipments, twice per week for 12 weeks.
2533392|NCT02674724|Active Comparator|Free Weights Group|With dumbbells, elastics, twice per week for 12 weeks.
2533399|NCT02674724|Placebo Comparator|Control Group|The control group will be instructed to perform stretching exercises at home in the same 12-week period, according to an illustrated booklet.
2533453|NCT02674438|Experimental|Active Intervention|"Two components to the intervention: (1) clinical algorithm for prognostication, and (2) post-discharge follow-up in the RAPID-HF clinic~Intervention #1 - Clinical algorithm: the EHMRG 7-day and EHMRG30-ST risk scores, which will be used to categorize patients as high, intermediate, or low risk. The clinical algorithm will be used to guide clinicians to decide on admission to hospital, observation, or emergency department discharge.~Intervention #2 - Referral to RAPID-HF (Rapid Ambulatory Program for Investigation and Diagnosis of HF) transitional care clinic: visit to RAPID-HF within 48 hours of discharge. Care provided in RAPID-HF by cardiologist + nurse for up to 30 days from date of discharge."
2533457|NCT02674438|No Intervention|Control|Usual care without access to the EHMRG/EHMRG30-ST scoring system, decision algorithm, or RAPID-HF clinic.
2533506|NCT02674126|Placebo Comparator|Control group|Control group
2533515|NCT02674126|Active Comparator|Maternal sound group|Maternal sound
2533650|NCT02673294|Experimental|Intervention (>24 months)|Participants with a chronicity >24 months
2532454|NCT02680925|Placebo Comparator|Conventional ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 10 ml/kg without PEEP during two-lung ventilation and TV of 8 ml/kg without PEEP during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
2532455|NCT02680925|Active Comparator|Lung protective ventilation group|Mechanical ventilation is maintained with tidal volume (TV) of 6 ml/kg with PEEP 6 cmH2O during two-lung ventilation and TV of 4 ml/kg PEEP 6 cmH2O during one-lung ventilation. Alveolar recruitment is performed 3 times; after intubation, before one-lung ventilation and after lung resection.
2532500|NCT02680444|Experimental|Reappraisal-Only Intervention|Participants were instructed to independently practice the Self-Administered Reappraisal-Only Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the positive reappraisal instructions available online. This involved thinking about how one could grow, learn or benefit from the negative event in any way possible.
2532502|NCT02680444|Experimental|Mindful-Reappraisal Intervention|Participants were instructed to independently practice the Self-Administered Mindful-Reappraisal Exercise in the evening for five days. First, participants recalled a negative event from that day and then followed the Mindful-Reappraisal instructions available online. This involved thinking about the negative event in an objective, non-judgmental way, then following the Reappraisal-Only instructions, and closing off with a brief mindfulness breathing technique.
2532505|NCT02680444|Active Comparator|Event Recall Active Control|Participants were instructed to independently practice the Self-Administered Event Recall Exercise in the evening for five days. In this condition, participants were only instructed to recall a negative event from that day with no reappraisal exercise.
3201163|NCT00900250||Ancillary-correlative (specimen collection and baking)|"Patients enrolled on HL therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.~Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.~Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation."
3201164|NCT00900328||Ancillary-Correlative (biomarkers in resected AC specimens)|Previously collected tissue samples from patients enrolled in CALGB 140202 are assessed for mutation analysis of c-Met, EGFR, Kras, p53, and c-CBL via standard PCR and sequencing; gene amplification of c-Met via real time quantitative PCR; LOH analysis of c-CBL; expression levels of met/HGF protein in serum via ELISA; and expression levels of c-Met, EGFR, p53, c-CBL, DUB3, ALK, and EMT via IHC.
3201165|NCT00900406||Recipients of stem cells with graft versus host disease|
3201166|NCT00900406||Recipients of stem cells at risk of graft versus host disease|
3201167|NCT00900406||Donator of stem cells|
3201168|NCT00900445||Basic science (pharmacokinetics)|Patients receive anticancer therapy as prescribed by their treating clinicians. Patients receive prednisone/prednisolone orally twice on either day 1 or day 8. Patients also receive daunorubicin hydrochloride IV over 30 minutes and vincristine IV once on the same day.
2532723|NCT02679209|Experimental|Bone allograft|commercially available demineralized bone matrix putty allograft will be used to fill in the defect after opening a periodontal flap
2532731|NCT02679209|Experimental|Amnion chorion membrane|Amnion chorion commercially available allograft bioresorbable membrane as a guided tissue regeneration technique will be used to in the defect after opening a periodontal flap
2532776|NCT02678715|Experimental|Sequence SB-CA-SM|Solubrux®+ Customized Appliance + Somatics®
2532777|NCT02678715|Experimental|Sequence SB-SM-CA|Solubrux®+Somatics®+Customized Appliance
2532779|NCT02678715|Experimental|Sequence CA-SB-SM|Customized Appliance+Solubrux®+Somatics®
2532781|NCT02678715|Experimental|Sequence CA-SM-SB|Customized Appliance+Somatics®+Solubrux®
2532785|NCT02678715|Experimental|Sequence SM-SB-CA|Somatics®+Solubrux®+Customized Appliance
2532787|NCT02678715|Experimental|Sequence SM-CA-SB|Somatics®+ Customized Appliance+Solubrux®
2532844|NCT02678364|Placebo Comparator|Control egg group|Two or less control (non-biofortified) eggs per week
2532846|NCT02678364|Active Comparator|Vitamin D3-eggs group|Seven vitamin D3-biofortified eggs per week
2532847|NCT02678364|Active Comparator|25-Hydroxyvitamin D-eggs group|7 25-hydroxyvitamin D-biofortified eggs per week
2532870|NCT02677987|Experimental|Intervention light|30 minutes of intervention systematic light exposure daily for 4 weeks.
2532872|NCT02677987|Active Comparator|Comparison light|30 minutes of comparison systematic light exposure daily for 4 weeks.
2532929|NCT02677818||experimental group|The risk of bleeding adverse reactions when FVIII below the normal level.
2532930|NCT02677818||control group|The risk of bleeding adverse reactions when FVIII in normal level.
2532975|NCT02677441|Experimental|Conservative management|Conservative management includes a sling for 10 days, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
2532979|NCT02677441|Active Comparator|Surgery|Surgical fixation of ACJD with coracoclavicular and acromioclavicular fixation, followed by specific standardized validated rehabilitation that includes range of motion recovery and progressive reinforcement.
2533041|NCT02677103|Experimental|RSWT plus USNP|In this group, each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs
2533084|NCT02676726|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
3201169|NCT00900458|Active Comparator|1|formerly preeclamptic women with low plasma volume
3201170|NCT00900458|Active Comparator|2|formerly preeclamptic women with normal plasma volume
3201171|NCT00900458|Other|3|Healthy controls
3201172|NCT00900497|Experimental|White Blood Cells/Granulocytes|Fresh, non-irradiated granulocytes from ABO-Rh compatible, HLA-mismatched donors
3201173|NCT00900510|Experimental|Drainage and placebo|Incision and drainage with placebo.
2532456|NCT02680795|Experimental|Wild Type UGT1A1|Cohort A: Open for Enrollment Wild Type UGT1A1, Belinostat IV
2532457|NCT02680795|Experimental|Heterozygous UGT1A1*28|Cohort B: Closed For Enrollment Heterozygous UGT1A1, Belinostat IV
2532459|NCT02680795|Experimental|Homozygous UGT1A1*28|Cohort C: Open For Enrollment Homozygous UGT1A1, Belinostat IV
2532543|NCT02680379|Experimental|Minocycline, then Minocycline/Lovastatin|Participants will take minocycline then a combined treatment of minocycline/lovastatin for 3 months.
2532544|NCT02680379|Experimental|Lovastatin, then Minocycline/Lovastatin|Participants will lovastatin then a combined treatment of minocycline/lovastatin for 3 months
2532595|NCT02679898|No Intervention|Lean Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
2532600|NCT02679898|No Intervention|Overweight/Obese Control|This arm involves not making any changes to the subject's lifestyle at the moment of the start of the intervention and for 6 weeks.
2532603|NCT02679898|Experimental|Unloaded-Whole Body Vibration (WBVT)|Lower-body exercise training on a vibration platform
2532605|NCT02679898|Experimental|Loaded-Whole Body Vibration (WBVT)|Externally loaded lower-body exercise training on a vibration platform
2532730|NCT02679131|Experimental|Cohort A|Normal Renal function, Belinostat IV, Dose A
2532735|NCT02679131|Experimental|Cohort B|Mild Impairment, Belinostat IV, Dose A
2532743|NCT02679131|Experimental|Cohort C|Moderate Impairment, Belinostat IV, Dose B
2532750|NCT02679131|Experimental|Cohort D|Severe Impairment, Belinostat IV, Dose B
3167404|NCT00538044|No Intervention|2contral group|just do routin operation with no use of simvastatin, other medication is exact the same as the simvastatin group
3167405|NCT00538057|Experimental|arm 1|study drug
3167406|NCT00538070|Placebo Comparator|Placebo|You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
2532858|NCT02678208|Active Comparator|Tranexamic acid|received tranexamic acid containing 1 g/10mL tranexamic acid diluted with 20 mL of 5% glucose over a 5 minute period
2532860|NCT02678208|Other|placebo|received 30 mL of 5% glucose over the same period of time.
2532904|NCT02677935|Experimental|Intervention|community support program
2533042|NCT02676921||GROUP 1|Ten samples of sinus membrane where harvested from fifteen patients during a surgical nasal approach for treatment of chronic rhinosinusitis.
2533062|NCT02676765|Experimental|Allergen|Subjects will be administered either Timothy Grass or Short Ragweed sublingual allergen tablets, depending on their individual allergic sensitization.
2533064|NCT02676765|Placebo Comparator|Placebo|Subjects will be administered placebo sublingual tablets
2533166|NCT02676453|Experimental|Intervention|Dental hygienist support
2533173|NCT02676453|No Intervention|control|Care as usal
2533186|NCT02675920||High risk group of HCC|"known high risk group of HCC according to AASLD guideline. And patients whose risk index is equal to or higher than 2.33.~Risk Index = 1.65 (if the prothrombin activity is <=75%) + 1.41 (if the age is 50 years or older) + 0.92 (if the platelet count is <=100x10(3)/mm3) + 0.74 (if the presence of anti-hepatitis C virus [HCV] or hepatitis B surface antigen [HBsAg] is positive).~Patients undergo ultrasonography and LDCT using non-ionic monomer iodinated CT contrast media biannually and the interval between ultrasound and LDCT is within 30 days."
2533258|NCT02675712||Adults with acute mood disorders|Adults aged over 18 diagnosed with an acute episode of a mood disorder using DSM-V criteria
2533320|NCT02675374|Experimental|Treatment group|24 patients
2533321|NCT02675374|Placebo Comparator|Control group|24 patients
2533373|NCT02674971|Active Comparator|INCREASE|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) per day.
2533376|NCT02674971|Active Comparator|COMBINATION|This condition will be identical to the INCREASE condition, except it will also have a goal regarding the number of high-ED foods to consume and substituting low-ED foods for high-ED foods. Thus, this condition will have ED goals to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day. Foods with an ED >1.0 kcal/g but < 3.0 kcal/g will be unlimited; however, lower ED foods will be strongly encouraged. Furthermore, additions to beverages (i.e., sugar, cream) will count toward the > 3.0 kcal/g goal if the additions meet that ED criteria.
2533442|NCT02674594||Patient treated with Dabigatran|
2533445|NCT02674594||Patient treated with Rivaroxaban|
2533451|NCT02674594||Patient treated with Apixaban|
2533456|NCT02674594||Patient treated with Warfarin|
2533488|NCT02674243|Experimental|Iodopovidone group|Patients who will be randomized for using iodopovidone solution for pleurodesis.
2533491|NCT02674243|Active Comparator|Talc group|Patients who will be randomized for using Talc for pleurodesis.
2533540|NCT02673723|Experimental|Dezocine|Dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
2533547|NCT02673723|Placebo Comparator|Controlled|The same amount of saline is given for 10 seconds after surface anesthesia
2533574|NCT02673463|Experimental|Spironolactone|Spironolactone 25 mg once daily for 2 years
2533580|NCT02673463|Placebo Comparator|Placebo|Matched placebo once daily for 2 years
2534062|NCT02670278||The Gambia-rural|healthy breastfeeding women and their infants
3167407|NCT00538070|Experimental|Sarcosine|You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
3167408|NCT00538083|Experimental|1, 2|acute phase, solid dark chocolate, placebo
3167409|NCT00538083|Experimental|3, 4, 5|acute phase, sugared cocoa, sugar-free cocoa, placebo
3167410|NCT00538083|Experimental|6, 7, 8|sustained phase, sugared cocoa, sugar-free cocoa, placebo
2532477|NCT02680912|Experimental|Warm needle acupuncture|"Warm needle acupuncture (wenzhen; 温针) is where moxa cones are placed on the handle of the needle, after the needle has been inserted. Once lit, heat transmits along the shaft of the needle to the acupuncture point.~Moxa refers to the herb mugwort (Artemisia vulgaris) that is burnt to warm specific parts of the body, including acupuncture points."
2532479|NCT02680912|Active Comparator|Basic needle acupuncture|Basic needle acupuncture is the use of acupuncture needles alone, without other methods of stimulation.
3201174|NCT00900510|Active Comparator|Drainage with TMP/SX|Drainage with Bactrim
2532641|NCT02679547||Appendicitis|The patients with appendicitis
2532646|NCT02679547||Control|The participants without appendicitis
2532699|NCT02679261|Experimental|Atorvastatin|Oral administration Atorvastatin 20 mg per day
2532703|NCT02679261|Placebo Comparator|Control|Oral administration of Placebo
3201175|NCT00900523||Known or suspected ovarian cancer|Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer
3201176|NCT00900549|Experimental|CRT|
2532826|NCT02678494|Experimental|Neurofeedback training|Neurofeedback training: self-administered at home for 3 months. 3-5 sessions per week initially, then at least once a week. Each session consists of 5-6 blocks of 5 minute training.
2532887|NCT02678182|No Intervention|A1: Surveillance|Patients in this Arm will follow current UK standard of care for this setting and will be reviewed every 4 weeks
2532894|NCT02678182|Experimental|Arm A2: Capecitabine Maintenance|1250 mg/M2/DAY on days 1-21
2532898|NCT02678182|Experimental|Arm A3: MEDI4736 (Durvalumab)|IV treatment on day 1 +15, on a 28 day cycle.
2532901|NCT02678182|Active Comparator|Arm B1: Trastuzumab Maintenance|6mg/kg on day 1 every 21 days
2532902|NCT02678182|Experimental|Arm A4: Rucaparib|600mg PO twice daily
2532903|NCT02678182|Experimental|Arm A5: Capecitabine and Ramucirumab|capecitabine 1250 mg/m2/day PO in two divided doses continuously from days 1-21 of each 21 day cycle (see section 12) and ramucirumab 8mg/kg IV day 1 and day 8
2532940|NCT02677571|Experimental|PVB|51 patients receiving US guided homolateral paravertebral thoracic block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
2532946|NCT02677571|Experimental|PECS|51 patients receiving US guided pectorals nerve block with 30ml of 0.25% levobupivacaine, before general anesthesia (TCI-TIVA).
2533028|NCT02677246|Experimental|Denosumab|Phase 1, 3+3 design with inter-patient dose escalation from 1mg/kg/dose to 2mg/kg/dose, and possibility of a dose de-escalation of 0.5mg/kg/dose, A modification of 3+3 design is implemented to take into account the achievement of bone resorption blockade by Denosumab. CTX is a biologic marker of bone resorption. Provided a decrease of CTX blood level will be observed under the lower limit (2,5th percentile) for age and sex, or under 20% of the pre-treatment level, there will be no reason to continue escalating the dose. This modified 3+3 design prevents exposure of children to dose escalations that would not be needed regarding the medical and biological aims of this trial.
2533113|NCT02676791|Experimental|A (Povidone-Iodine)|Esophageal washout will be performed via a nasogastric tube with approx. 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) during esophageal resection.
2533116|NCT02676791|No Intervention|B (Control)|Esophageal resection will be performed without esophageal washout.
2533139|NCT02676310|Experimental|Cohort 1: Bimatoprost 0.3% (Formulation B)|0.25 mL of bimatoprost 0.3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2533151|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation A)|0.25 mL of bimatoprost 1% (Formulation A) applied onto pre-specified area on the scalp once daily for 28 days.
2533157|NCT02676310|Experimental|Cohort 2: Bimatoprost 1% (Formulation B)|0.25 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2533158|NCT02676310|Experimental|Cohort 3: Bimatoprost 1% (Formulation B)|1 mL of bimatoprost 1% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2533159|NCT02676310|Experimental|Cohort 4: Bimatoprost 3% (Formulation B)|1 mL of bimatoprost 3% (Formulation B) applied onto pre-specified area on the scalp once daily for 28 days.
2533220|NCT02675894|Active Comparator|RFA with cooled-wet electrode|RFA is performed using three cool-wet electrodes in switching bipolar mode under the fused US guidance.
2533223|NCT02675894|Active Comparator|RFA with separable clustered electrode|RFA using separable clustered electrode in switching monopolar mode under the fused US guidance
2533347|NCT02675088|Experimental|high-dose TRT|high-dose thoracic radiotherapy X-ray RT
2533350|NCT02675088|Active Comparator|standard-dose TRT|standard-dose thoracic radiotherapy XRT
2533377|NCT02674750|Experimental|CUDC-907|RR-DLBCL, including with MYC alterations detected by FISH or by >=40% MYC by IHC
3201177|NCT00900549|Sham Comparator|No CRT|
2533606|NCT02673359|Active Comparator|Progesterone group|Vaginal progesterone suppositories will be given
2533608|NCT02673359|Active Comparator|Cerclage group|Cervical cerclage will be performed.
2533651|NCT02673060|Experimental|dose escalation of MBC-11|MBC-11 was administered in 5 consecutively recruited cohort in dose 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg,10 mg/kg accordingly. The dose escalation is aimed at determining the maximum tolerated dose (MTD)
2533665|NCT02672735|Experimental|Corrective Exercise Program|Participants in the Corrective Exercise Program (CEP) group (n = 28) will be given a four-week corrective exercise programming intervention.
2533667|NCT02672735|No Intervention|Control|The participants in the Control (CON) group (n = 28) will have their four-week corrective exercise programming intervention deferred for 4 weeks, and as such, will serve as the comparative group for the CEP group.
3201178|NCT00900575|Experimental|Duke Arm|Patients referred for GYN procedures. Specifically, patients will be referred for Pap smear, colposcope or LEEP. The intervention for this arm is the use of the bench-top, miniature optical spectrometer or trans-vaginal colposcope
3201179|NCT00900588|Experimental|10 ug|10 microgram split-virion vaccine per dose
3201180|NCT00900588|Experimental|15 ug|15 microgram split-virion vaccine per dose
3201181|NCT00900588|Experimental|30 ug|30 microgram split-virion vaccine per dose
3201182|NCT00900588|Active Comparator|5 ug|5 microgram whole-virion vaccine per dose
2532521|NCT02680223|Active Comparator|Precision tinted lenses|Precision tinted lenses will be provided for one month.
2532522|NCT02680223|Sham Comparator|Non-beneficial tinted lenses|Tinted lenses at a colour different from but not easily distinguishable from the precision tinted will be provided for one month.
3201183|NCT00900640||ERCP group|All patients who have been scheduled for an ERCP due to medical necessity will be considered for this study.
3201184|NCT00900653|Experimental|Gynoflor|
2532709|NCT02678975|Active Comparator|Control|Alkylating chemotherapy
2532711|NCT02678975|Experimental|Experimental|Alkylating chemotherapy + disulfiram + copper
2532772|NCT02678728|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12hr of aortic cross clamp off
2532773|NCT02678728|Placebo Comparator|Normal saline|IV loading and infusion of same volume of normal saline after induction until 12hr of aortic cross clamp off
2532835|NCT02678481|Experimental|MR-targeted biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MR imaging two targeted biopsy cores will be taken.
2532837|NCT02678481|Experimental|TRUS-guided biopsy|Patients of arm B receive a saturation TRUS-guided prostate biopsy.
2532871|NCT02678065|Experimental|InPact Admiral|Patients treated with the InPact Admiral balloon for popliteal lesions
3201185|NCT00900653|No Intervention|Control|
3201186|NCT00900692|Experimental|Dynasplint Group|Along with the standard of care Botox and manual therapy, patients will use the Supination Dynasplint every day
2533045|NCT02676973|Active Comparator|Sacral Colpopexy|Sacral Colpopexy performed via open, robotic, or laparoscopic procedure.
2533047|NCT02676973|Active Comparator|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair: Sacrospinous Ligament Suspension (SSLS) and Uterosacral Ligament Suspension (USLS)
2533048|NCT02676973|Active Comparator|Apical Transvaginal Mesh Repair|Uphold™ LITE
2533078|NCT02676557||LASIK|
2533164|NCT02676492||Tic Disorder|Boys with a diagnosis of Tourette Syndrome (TS) or chronic tic disorder (CTD) aged 11-14 years
2533170|NCT02676492||Control|Boys aged 11-14 years without a diagnosis of TS/CTD (i.e. typically developing)
2533191|NCT02675803|Experimental|VAY736|VAY736 active
2533196|NCT02675803|Placebo Comparator|Placebo|VAY736 placebo
2533269|NCT02675660|Experimental|L-Homoarginine|125 mg of L-homoarginine
2533270|NCT02675660|Placebo Comparator|Placebo|placebo capsules
2533310|NCT02675309|Experimental|MT-8554, rosuvastatin and simvastatin|Subjects will be administered a single dose of rosuvastatin followed on Day 4 by a single dose of simvastatin. MT-8554 will be administered from Days 6 to 12 with co-administration of rosuvastatin and simvastatin on Days 9 and 12, respectively.
2533364|NCT02675023|Experimental|Auto-injector (AI)|M923 administered via AI
2533366|NCT02675023|Experimental|Prefilled syringe (PFS)|M923 administered via PFS
2533383|NCT02674698|Other|VA Integrated Service Networks Group 1|Access to the CNH Dashboard Step 1
2533387|NCT02674698|Other|VA Integrated Service Networks Group 2|Access to the CNH Dashboard Step 2
2533393|NCT02674698|Other|VA Integrated Service Networks Group 3|Access to the CNH Dashboard Step 3
2533400|NCT02674698|Other|VA Integrated Service Networks Group 4|Access to the CNH Dashboard Step 4
3167411|NCT00538096|Experimental|1|MEDI-538
2533492|NCT02674074|Experimental|measurement of corneal temperature by infrared thermography|
2533551|NCT02673814|Experimental|Arm A (durvalumab)|10 mg/kg durvalumab alone every two weeks
2533552|NCT02673814|Experimental|Arm B (bavituximab + durvalumab)|3 mg/kg bavituximab weekly in combination with 10 mg/kg durvalumab every two weeks
2533553|NCT02673814|Experimental|Arm C (bavituximab + durvalumab)|3 mg/kg bavituximab in combination with 10 mg/kg durvalumab both every two weeks
2533575|NCT02673385||Brazelton scale|Procurement across Brazelton scale
2533585|NCT02673385||No test|usual care
2533630|NCT02673229|Active Comparator|Collagenase Santyl|Applied topically (2 mm thickness once daily)
2533636|NCT02673229|Sham Comparator|Bacitracin|Applied topically (2 mm thickness) once daily
2533661|NCT02672800|Experimental|Writing intervention|
2533662|NCT02672800|No Intervention|Control|
2533726|NCT02672644|Experimental|Emervel Classic|Subjects treated with Emervel Classic (moderate NLFs; WSRS = 3/3). Subjects receiving bilateral treatment of NLFs following approved product labeling.
2533727|NCT02672644|Experimental|Emervel Deep|Subjects treated with Emervel Deep (severe NLFs; WSRS = 4/4). Subjects receiving bilateral treatment of NLFs following approved product labeling.
3201187|NCT00900692|No Intervention|Standard of care|Patients in the standard of care group will have the standard Botox treatments and manual therapy with no additional interventions.
3201188|NCT00900718|Experimental|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
2533868|NCT02671383|Active Comparator|Darunavir|Darunavir/Ritonavir 400/100mg once daily
2533871|NCT02671383|Active Comparator|Lopinavir|Lopinavir/Ritonavir 400/100mg twice daily
2533930|NCT02671045||A - Genomic profile by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified and the patient/physician agree to receive the targeted therapy
2533937|NCT02671045||B - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and an actionable target has been identified. However, the patient does not receive the targeted therapy.
2533939|NCT02671045||C - Genomic profiling by FoundationOne|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling using FoundationOne and no actionable target has been identified.
2533940|NCT02671045||D - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified and the patient/physician agrees to receive the targeted therapy.
3167412|NCT00538096|Experimental|2|MEDI-538
2532562|NCT02680197|Experimental|CHF5259 25 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 6.25μg + 1 puff of CHF5259 DPI 6.25μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2532565|NCT02680197|Experimental|CHF5259 50 μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 1 puff of CHF5259 DPI 12.5 μg + 1 puff of CHF5259 DPI 12.5 μg twice a day~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2532567|NCT02680197|Experimental|CHF5259 100μg total daily dose|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment :1 puff of CHF5259 DPI 25 μg + 1 puff of CHF5259 DPI 25 μg twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, Haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2532570|NCT02680197|Placebo Comparator|CHF5259 matched Placebo BID|"CHF5259 or Placebo administration: Patient receives during 4 weeks (28 days) the following treatment : 2 puffs of CHF5259 DPI matched placebo twice a day~Interventions :~Day 1 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram~Day 14: pre-dose spirometry~Day 28 : pre-dose spirometry, serial spirometry, haematology/chemistry sample and analyses, BDI/TDI (Baseline and transition dyspnea Indexes), Electrocardiogram"
2532663|NCT02679495|Active Comparator|Lifestyle intervention|A better lifestyle that are supposed to prevent gastric cancer occurrence are advised to patients. Measures includes dietary change and cessation of smoking and alcohol abuse. Behavioural and cognitive strategies from investigators are performed to patients to ensure adherence to established intervention.
2532667|NCT02679495|No Intervention|No intervention|No meassures are taken to change life style of enrolled patients.
3201189|NCT00900718|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
2532839|NCT02678611|Experimental|Basis 250|
2532840|NCT02678611|Experimental|Basis 500|
2532841|NCT02678611|Placebo Comparator|Placebo|
2532891|NCT02678052||Cohort 1: No Chronic Disease|Pregnant women without a current diagnosis of any chronic disease with no exposure to any biological agent and at any time from first day of last menstrual period (LMP) will be observed for up to 1 year.
2532896|NCT02678052||Cohort 2: UC/CD Prospective Cohort|Pregnant women with current diagnosis of UC or CD with exposure to Entyvio or other biologic agents during pregnancy at any dose, and at any time from first day of LMP will be observed for up to 1 year.
2532987|NCT02677649|Active Comparator|cranberry|30 grams/day freeze dried whole cranberry powder added to a basal diet comprising meats, dairy products, simple sugars, and stevia
2532989|NCT02677649|Placebo Comparator|placebo|30 grams/day placebo powder [made with maltodextrin (CPC Maltrin M-180), citric acid, artificial cranberry flavor (Lorann oils), fructose, red color (Lorann oils), and grape shade] added to a basal diet comprising meats, dairy products, simple sugars, and stevia
3201190|NCT00900744||Tamoxifen|20mg daily
3201191|NCT00900770||PIB+ NC|PIB positive, cognitively normal individuals with foci of elevated PIB retention in cortical regions typically affected in AD
3201192|NCT00900770||PIB- NC|PIB negative, cognitively normal individuals without amyloid deposition
3201193|NCT00900783|Experimental|2|FV-100, 400 mg once daily AND valacyclovir placebo, three times a day, for seven days
3201194|NCT00900783|Active Comparator|3|Valacyclovir, 1 gram, three times a day AND FV-100 placebo, once daily, for seven days
3201195|NCT00900783|Experimental|1|FV-100, 200 mg once daily AND valacyclovir placebo, three times a day, for seven days
3201196|NCT00900809|Experimental|Neukoplast™ (NK-92)|Neukoplast™ will be infused in three doses.1 x 10e9 cells/m2 dose, 3 x 10e9 cells/m2 dose, 5 x 10e9 cells/m2 dose.
3201197|NCT00900848||8|8 patients
3201198|NCT00900861||1|Asthmatic patients above 18 y, treated with ICS or bronchodilators
2534063|NCT02670278||The Gambia-urban|healthy breastfeeding women and their infants
3201199|NCT00900874|Active Comparator|1|Salbutamol + steroid
3201200|NCT00900874|Active Comparator|2|Formoterol + steroid
3201201|NCT00900887|Active Comparator|Ketorolac|ocular topic ketorolac used 3 times a day for a week after the selective photocoagulation
3201202|NCT00900887|Active Comparator|Nepafenac|ocular topic nepafenac 3 times a day during one week after selective photocoagulation
3201203|NCT00900887|Placebo Comparator|Polietilenglicol 400, propilenglicol|ocular lubricant drops 3 times a day for a week after selective photocoagulation
3201204|NCT00900900|Experimental|Dehydroepiandrosterone (DHEA)|
3201205|NCT00900900|Experimental|Pregnenolone|
3201206|NCT00900900|Placebo Comparator|Placebo|
3201207|NCT00900939|Experimental|Low-fat, vegan diet|
3201208|NCT00900939|Placebo Comparator|Control|
3201209|NCT00900952||1|Infected elderly patients
3201210|NCT00900965|Active Comparator|Electroacupuncture treatment|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
3201211|NCT00900965|Sham Comparator|Sham acupunture treatment|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
3201212|NCT00900978|Experimental|7v-PCV (Prevenar)|Biological/vaccine
3201213|NCT00900991|Experimental|10 ug|10 microgram per dose
3201214|NCT00900991|Experimental|15 ug|15 microgram per dose
2532584|NCT02679963|Experimental|Maintenance Olaparib|Olaparib (experimental arm): 600 mg daily (2 doses of 300 mg (2*2 tablets of 150 mg) taken approximately 12 hours apart) po, administered until disease progression or toxicity requiring its interruption. Olaparib has to be started no later than 6 weeks after the last administration of induction chemotherapy, and no later than 3 weeks after the CT scan confirming response to induction chemotherapy
2532589|NCT02679963|Placebo Comparator|Placebo|Placebo (control arm): 2 doses of 300 mg per day (2*2 tablets of 150 mg) taken approximately 12 hours apart
2532621|NCT02679664|Experimental|Treatment group|20 mg tablet of rosuvastatin PO once-a-day starting at the time of randomization until the completion of follow-up at 6 months.
2532624|NCT02679664|No Intervention|Control group|Standard medical care only. No rosuvastatin group.
2532682|NCT02679365|Experimental|group a|This arm will have lower segment cesarean section done with double locking technique for closure of Rectus Sheath.
2532688|NCT02679365|Active Comparator|group b|This arm will have lower segment cesarean section done with continuous non-locking technique for closure of rectus sheath.
2532819|NCT02678559|Experimental|TEE monitory system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
2532821|NCT02678559|Experimental|mini-invasive monitoring system|comparison between TEE and mini-invasive monitoring systems in accuracy of measurement of stroke volume variation during ARM.
3167413|NCT00538096|Experimental|3|MEDI-538
2533040|NCT02676986|Active Comparator|Cohort I (ER positive cohort)|Approximately 180 patients with ER positive breast cancer will be randomised 2:1 in favour of enzalutamide to receive enzalutamide plus exemestane or exemestane alone.
2533044|NCT02676986|Active Comparator|Cohort II (AR positive, TNBC cohort)|55 patients with AR positive, TNBC will receive single agent treatment with enzalutamide.
2533083|NCT02676531|Experimental|Walking Meditation|"Walking Meditation program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking while listening to the sound Budd and Dha and squeeze rubber balls according to the sound in order to practice mindfulness while walking. In phase 1 (week 1-6), Walking Meditation will be conducted at initial moderate intensity (41-50% heart rate reserve) 3 sets, 10 minutes per set and rest 3 minutes between set In phase 2 (week 7-12), the training intensity will be increased to ultimate moderate intensity (51-60% heart rate reserve) 3 sets, 15 minutes per set and rest 3 minutes between set. In both phases of the training, the frequency of Walking Meditation training is three times a week."
2533090|NCT02676531|No Intervention|No Walking meditation|keep regular activities, sedentary life style.
2533176|NCT02676440|Other|Treatment|Toothpaste containing 1.11% Fluoride as Sodium Monofluorophosphate and Zinc Citrate Trihydrate Serum containing 0.17% Fluoride as Sodium Monofluorophosphate and Zinc Sulphate Heptahydrate
2533178|NCT02676440|Other|Comparator|Silica toothpaste 1350ppm F as Sodium Fluoride
2533193|NCT02675868|Experimental|Norepinephrine|The noradrenaline group: a group of 10 subjects that will receive noradrenaline 0.05 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2533199|NCT02675868|Active Comparator|Vasopressins|The vasopressin group: a group of 10 subjects that will receive vasopressin 0.04 IU/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2533203|NCT02675868|Active Comparator|Phenylephrine|The phenylephrine group: a group of 10 subjects that will receive phenylephrine 0.5 μg/kg/min infusion for 5 hours, starting 60 minutes before endotoxin administration.
2533205|NCT02675868|Placebo Comparator|Placebo|The placebo group: a group of 10 subjects that will receive NaCl 0.9% infusion for 5 hours, starting 60 minutes before endotoxin administration.
2533272|NCT02675556|Experimental|Allogeneic hMSCs|Forty (40) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2533274|NCT02675556|Placebo Comparator|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
2533278|NCT02675556|Experimental|Pilot - Allogeneic hMSCs|Eight (8) subjects will be treated with a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
2533330|NCT02675166||Pediatric cancer young adult survivors|544 patients alive and that are min 18 years old, included in the ARCERRA population register, for a primary cancer (not leukemia), diagnosed between 15 years old, between January the 1st 1993, and December the 31st 1999, in Rhône-Alpes.
2533370|NCT02674906|Active Comparator|citrate|A quantity of 20 ml ACD-A per 100 ml of collected blood is used to prevent coagulation in the cell savage process. Pre-prepared ACD-A solutions is available (composition of ACD-A solution used: 22.0 g sodium citrate dehydrate, 24.5 g glucose monohydrate, 8.0 g citric acid monohydrate per 1000 ml of water
2534064|NCT02670278||Ghana|healthy breastfeeding women and their infants
3167414|NCT00538122||Thioridazine Group|Patients must have been treated with (Mellaril) thioridazine at least three months at time of enrollment.
3167415|NCT00538135|Experimental|1|"Cognitive Behaviour Therapy plus Treatment as Usual (CBT plus TAU) for borderline personality disorder.~CBT is a structured, time limited, psycho-social intervention developed to treat Cluster B personality disorder. Patients are encouraged to engage in treatment through a formulation of their problems within a cognitive framework. Interventions focus on the patient's beliefs and behaviour that impair social and adaptive functioning. Thirty sessions of CBT over one year, each lasting up to one hour, are required to work on long-standing problems and develop new ways of thinking and behaving. Priority is given to behaviours that cause harm to self or others. In addition, participants received the usual treatment they would have received if the trial had not been in place"
3167416|NCT00538135|Active Comparator|2|"Treatment as Usual.~All participants received the standard treatment (TAU) they would have received if the trial had not been in place. Although standard treatment may vary across the three sites, and depend on the specific problems of the individual participant, it was thought that all participants would be in contact with mental health services and would have some contact with Accident and Emergency services for repeated self-harm episodes. TAU will be documented carefully after each patient exits the trial."
3167417|NCT00538161|Experimental|Low tidal volume arm|
3167418|NCT00538161|Active Comparator|Conventional tidal volume arm|
2532623|NCT02679742|Experimental|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program
2532626|NCT02679742|Placebo Comparator|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program
2532671|NCT02679391||A|69 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2011. All post weight loss. , 96% female, BMI by the time of operation 26, mean age 41 (SD 9.5). Their mean weight loss in BMI units: 17.8 (SD 5.12).
2532672|NCT02679391||B|70 consecutive operated patients by plastic surgeons at Karolinska University Hospital 2010-2012. All post weight loss. 86% female, BMI by the time of oepration 26, mean age 38.6 (SD 11.4). Their mean weight loss in BMI units: 17.4 (SD 4.8).
2532673|NCT02679391||C|70 consecutive operated patients by general surgeons at Capio S:t Görans Hospital 2013-2014. All post weight loss. 90% female, BMI by the time of operation 26, mean age 46.8 (SD 10.1). Their mean weight loss in BMI units: 16.3 (SD 5.11)
2532702|NCT02679196|Experimental|KA2237|Open label treatment with KA2237
2532713|NCT02679001||RA participants treated with a TNF inhibitor or TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling will be observed.
2532793|NCT02678793|Other|Subjects who have completed Study 4975-MN-202 will be eligible|Subjects who have completed Study 4975-MN-202 will be eligible to receive open-label treatment with CNTX-4975 200 μg in Study 4975-MN-203 if they meet the inclusion/exclusion criteria.
2532812|NCT02678377|Active Comparator|OnabotulinumtoxinA injections|100 units of OnabotulinumtoxinA (Botox®) injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
2532814|NCT02678377|Sham Comparator|Saline injections|100 units of saline injected into the detrusor (large muscle of the bladder) at the time of sling surgery.
2532878|NCT02678221|Active Comparator|Sildenafil citrate with Aspirin|will receive sildenafil citrate 20mg ̸ 8hours plus low dose aspirin 150mg/day
2532880|NCT02678221|Other|placebo with Aspirin|will receive placebo plus low dose aspirin 150mg/day
2532983|NCT02677792|Experimental|Behavioral Family Intervention (BFI)|
2533012|NCT02677194|Experimental|Exposition LED|The patient is his own witness. This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm. Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act : exposition to LED 590nm (4 or 12sec) or 630nm(4min30 or 15 min) or 830 nm (6 or 12 min).
2533016|NCT02677194|Other|Control|Device without any LED exposition : This is a randomization for the allocation of treatments (LED parameters) on 6 mini-zones of 1,5x1,5 cm at the level of forearm or control (1 mini-zone)
2533120|NCT02676869|Experimental|IMP321 dose escalation|IMP321 administered fortnightly in addition to SOC pembrolizumab.
2533128|NCT02676245|Experimental|Viewing NBS + DBS Educational Movies|Group A: pregnant women who will view the NBS and residual specimen movies and printed materials during one visit between 30 and 40 weeks gestation.
2533130|NCT02676245|Experimental|Viewing NBS Educational Movie only|Group B: pregnant women who will view the NBS movie only and printed materials at one visit between 30 and 40 weeks. The movies will be presented on a tablet PC.
2533134|NCT02676245|No Intervention|No Educational Interventions|Control Group: pregnant women who will receive no experimental intervention during pregnancy or the postpartum period but will receive whatever information is routinely provided by their OB clinic and/or delivery center.
2533216|NCT02676050|Experimental|Imaging agents and imaging devices|All participants in Cohort 1 will be dosed on one occasion with the optical imaging agents and Cohort 2 can be dosed twice per agent. The final dosage will be <100ug per agent. The agents will be delivered using a novel delivery catheter and imaged with a novel imaging fibre and microendoscopy system.
3167419|NCT00538174|Experimental|Arm 1|2.5 mg
2533382|NCT02674997||Study participants|Participants with Hemophila A
2533486|NCT02673970||observational arm|From start treatment till date of death or date of cure, the patient will be followed for survival and adverse events on pembrolizumab
2533584|NCT02673593|Placebo Comparator|Placebo|Taken orally as a single dose (Cohorts 1 - 4) Taken orally as a multiple daily dose for 28 days (Cohorts 5 - 7)
2533590|NCT02673593|Experimental|DS102 100mg Single Dose|Taken orally once by Cohort 1
2533592|NCT02673593|Experimental|DS102 500mg Single Dose|Single Dose taken orally on three separate occasions by Cohort 2 (second and third dose assessing food effect)
2533596|NCT02673593|Experimental|DS102 1000mg Single Dose|Taken orally once by Cohort 3
2533599|NCT02673593|Experimental|DS102 2000mg Single Dose|Taken orally once by Cohort 4
2533600|NCT02673593|Experimental|DS102 500mg Multiple Dose|Taken orally once a day for 28 days by Cohort 5
2533601|NCT02673593|Experimental|DS102 1000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 6
2533603|NCT02673593|Experimental|DS102 2000mg Multiple Dose|Taken orally once a day for 28 days by Cohort 7
2533631|NCT02673073|Placebo Comparator|Control_Education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
2533682|NCT02672969|Experimental|Smoke evacuation uses|Smoke evacuation uses means using RapidVac Smoke Evacuator with electrosurgical unit during coagulation and cutting surgery. (Experimental group)
3167420|NCT00538174|Experimental|Arm 2|10 mg
3167421|NCT00538174|Experimental|Arm 3|20 mg
3167422|NCT00538174|Placebo Comparator|Arm 4|
3167423|NCT00538187|Experimental|Treatment (obatoclax mesylate, bortezomib)|Patients will receive a 3-hour infusion of obatoclax and an infusion of bortezomib once a week for 4 weeks
3167424|NCT00538200|Other|1|Dietary Advice
3167425|NCT00538200|Other|2|Supplements
3167426|NCT00538239|Experimental|Ridaforolimus|
3167427|NCT00538239|Placebo Comparator|Placebo|
3167428|NCT00538265|Active Comparator|A|tacrolimus + steroids
3167429|NCT00538265|Experimental|B|ATG+ tacrolimus without steroids in maintenance therapy
3167430|NCT00538265|Experimental|C|ATG+ Mycophenolate Mofetil + tacrolimus a reduced dosage without steroids in maintenance therapy
3167431|NCT00538317|Experimental|1|tirofiban bolus + perfusion started at the site of caring
3167432|NCT00538317|Active Comparator|2|tirofiban bolus + perfusion started at the beginning of coronarography (usual use of tirofiban)
2532686|NCT02679443|Experimental|Immediate Arm|Participants are started on folate and vitamin B12 supplementation simultaneously with chemotherapy (within 24 hours of initiation of chemotherapy)
2532715|NCT02679027|Active Comparator|Easy intubation|Intubation difficulty score <5
2532718|NCT02679027|Active Comparator|Difficult intubation|Intubation difficulty score >5
2532803|NCT02678845|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
2532804|NCT02678845|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
3201215|NCT00901004||1|Reflux esophageal minimal change in the endoscopic finding
3201216|NCT00901030||Patients with PCI on blood thinners|Patients have a coronary stent and are taking anti-clotting (anti-platelet) drug and are having non-cardiac surgery.
2532922|NCT02677636|Experimental|MSRD-100|MSRD-100 is a topical gel with an active ingredient in a vehicle. Excipients are purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. Application is twice daily for 28 days.
2532923|NCT02677636|Placebo Comparator|Placebo Comparator|The vehicle is a topical gel and contains excipients of the formulation: purified water, propylene glycol, polysorbate 20, benzyl alcohol, edetate disodium, diethylene glycol monoethyl ether and hydroxyethyl cellulose. It does not contain the active ingredient MSRD-100. Application is twice daily for 28 days.
2532971|NCT02677467||Spontaneous epistaxis|A participant enroll if their age is over 18 with spontaneous epistaxis and their cause of visiting ER is spontaneous epistaxis. Exclusion criteria is that they needs immediately treatment for hypertensive urgency. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
2532976|NCT02677467||Bleeding of wound|A participant enroll if their age is over 18 with bleeding of wound and their cause of visiting ER is to bleed on wound. Exclusion criteria is that their wounds' condition is serious or their pain is much severe. And, they don't want to participate in this investigation. Investigators examine their blood-pressure variability and cardiovascular risk throughout their blood sample analysis.
2532998|NCT02677168|Experimental|cNEP|Subjects with OSA will be treated with cNEP (continuous negative external pressure) at home for three weeks
3201217|NCT00901043|Experimental|Walnut supplementation|Eight weeks with walnut supplementation to an ad lib diet
3201218|NCT00901043|Active Comparator|Ad lib diet|Eight weeks ad lib diet without walnut supplementation
2533187|NCT02675933|No Intervention|Standard of Care|"The control arm participants will receive only a satisfaction survey once disposition is determined by the physician provider. The satisfaction survey will be collected by the research associated and kept in a protected location, along with all other study materials.~All patients will receive standard of care, which at this institution is the help of Child Life Specialists, when they are available and requested by the physician. Physicians will be instructed to request Child Life Specialists with the same discretion as with all patients."
2533188|NCT02675933|Active Comparator|Questionnaire|"Participants who are randomized to the questionnaire arm will receive a patient-centered questionnaire at the beginning of their visit. This single page document will ask questions about their child including, but not limited to, diagnoses, suggestions for distraction, sensory issues that may affect their visit, and method to best administer medications. The research associate will ask them to fill it out to the best of their ability and will collect the questionnaire prior to a physician provider seeing the patient. At least one physician provider must review the questionnaire prior to seeing the patient.~Once disposition is determined, the satisfaction survey will be distributed by the research associate along with an envelope for the parent to seal their survey within."
2533263|NCT02675699|Experimental|Optimisation + HENRY|
2533266|NCT02675699|Active Comparator|HENRY as standard|
2533329|NCT02675322|Experimental|Danlou Tablets|Danlou tablets (4.5 g oral dose taken once daily) for 90 days
2533333|NCT02675322|Placebo Comparator|placebo|matching placebo for 90 days
2533416|NCT02674919|Experimental|Nordic Hamstring|The Nordic Hamstring group performs a progressive strengthening program (Mjolsnes et al., 2004) comprising of the Nordic Hamstring exercise during a period of 10 weeks. The training load increases from one session per week in week 1 to 3 sessions per week in week 3-10. Number of sets and repetitions progressively increase from 2 to 3 and 5 to 12, respectively. The exercise program is performed in the end of a regular football training session.
2533420|NCT02674919|Other|Control|The control group are asked not to perform the exercise or any other specific strength training for the hamstring muscles and to continue to play football as usual.
3201219|NCT00901056|Active Comparator|Treated Group|This group will receive actual shockwave treatment
3201220|NCT00901069|Other|Azacitidine|
3201221|NCT00901082|Active Comparator|information and relaxation|will receive the intervention that consist of information and relaxation
2533543|NCT02673840|Experimental|Ketotifen|
2533548|NCT02673840|Placebo Comparator|Placebo|
2533559|NCT02673424|Active Comparator|FFR-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by FFR-guided strategy.
2533560|NCT02673424|Active Comparator|IVUS-guided stenting|Percutaneous coronaryintervention using drug-eluting stent(s) will be performed by IVUS-guided strategy.
2533648|NCT02673294|Experimental|intervention (6-12 months)|Participants with a chronicity between 6-12 months
3201222|NCT00901082|No Intervention|No intervention|No specific intervention before the medial branch block.
3201223|NCT00901095|No Intervention|Control|Usual Care
3201224|NCT00901095|Experimental|Lifestyle intervention|The Lifestyle intervention group consists of in-person meetings co-led by an exercise specialist and dietician as well as follow-ups with an interventionist by phone.
3201225|NCT00901108|Active Comparator|Trabectome-IOL|Combined Trabectome and cataract extraction with intraocular lens insertion
3201226|NCT00901108|Active Comparator|Trab-IOL|Combined Trabeculetomy with Mitomycin C and cataract extraction with intraocular lens insertion
3201227|NCT00901121|Experimental|BoneCeramic|Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).
3201228|NCT00901121|Active Comparator|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
3201229|NCT00901134||hypothermia|Patients with therapeutic hypothermia after cardiac arrest in hospitals
3201230|NCT00901147|Experimental|panobinostat and bortezomib|Oral Panobinostat and intravenous bortezomib
3201231|NCT00901160||Surgical patients|Blood will be taken from patients who are on anti-platelet medication and are having surgery that requires an overnight stay. This is a pilot study to see if Thromboelastography® and Platelet Mapping Assay™ will be able to predict if a patient is at risk for a bleeding or a clotting problem after surgery.
3201232|NCT00901212|Active Comparator|LV Pacing|left univentricular pacing
2532822|NCT02678572|Experimental|Melphalan/HDS|3 mg/kg ideal body weight of melphalan for infusion administered directly to the liver via percutaneous hepatic perfusion (PHP) over 30 minutes followed by a 30 minute washout. Treatment cycles are to be repeated every 6-8 weeks until disease progression.
3201233|NCT00901212|Active Comparator|BV Pacing|biventricular pacing
3201234|NCT00901251||1|
2532986|NCT02677389|Experimental|Arm I (Enhanced SCP)|See Detailed Description
2532988|NCT02677389|Active Comparator|Arm II (SCP)|"Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on Healthy Habits at 1, 2, 4, and 8 weeks. Specific topics in emails include positive self-talk, daily relaxation breathing techniques, better sleep, and ways to find pleasure."
2532999|NCT02677012||Arm I (RESOLVE TM)|Patients undergo AFG reconstructive surgery comprising washing and low velocity spinning using a commercially available system that washes the lipoaspirate with lactated Ringer's solution separates non-fat material from the fat with gentle centrifugal force and suction.
2533003|NCT02677012||Arm II (Cytori PureGraft TM)|Patients undergo AFG reconstructive surgery comprising gravity filtration using a commercially available system in which the lipoaspirate is rinsed with lactated RL and the non-fat material is filtered through mesh.
2533007|NCT02677012||Arm III (Coleman technique)|Patients undergo AFG reconstructive surgery comprising standard centrifugation at 3200 rpm for 3 minutes with the resulting oil and aqueous layers discarded.
2533100|NCT02676700|Active Comparator|Pelvic floor muscle training and Kaatsu|"Participants are instructed in the PFMT program by primary investigator and instructed in Kaatsu training by a research nurse. The Kaatsu training is performed 4 times a week before PFMT. The program includes 2 x 15 knee extensions with partly occlusion of the blood supply to the thigh. Training level is >12 RM. Training is performed sitting on a chair and rubber bands are used to increase resistance. Training adherence and bother with the training is reported in a training diary. At week 6 the research nurse adjusts the training program.~The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
2533106|NCT02676700|Active Comparator|pelvic floor muscle training|"Participants perform the same PFMT program as the intervention group. The PFMT program includes three sets of 10 contractions with an intensity of >12 RM and is to be performed 4 times a week.~Training adherence and any bother with the training is reported in a training diary."
2533148|NCT02676323|Experimental|Treatment|Participants will be given panobinostat in combination with fludarabine and cytarabine. Treatment consists of one course of therapy given over 12 days. Participants will also receive intrathecal triples and leucovorin
3201235|NCT00901264||1|Patients with pathological diagnoses of cancer or leukemia
3201236|NCT00901264||2|3.1.3 Patients for whom chemotherapy is planned.
2533296|NCT02675413|Experimental|Dimethyl Fumarate|Open label dimethyl fumarate (Tecfidera) at the US approved dose of 120mg BID for 7 days and then 240mg BID thereafter for 12 months.
2533362|NCT02675140|Experimental|ZENTEL|Children in intervention group 1 was received 400 mg single-dose albendazole administration, by mouth, for once.
2533363|NCT02675140|Experimental|ZENTEL and Vitamin A Soft Capsules|Children in intervention group 2 was received a 200,000 IU vitamin A capsule combined 400 mg single-dose albendazole once initially, by mouth.
2533365|NCT02675140|No Intervention|No drug adminitrated|Children in this Group were received no intervention as control group
2533381|NCT02674672|Experimental|VenaTech Retrievable arm|VenaTech Retrievable arm
3201237|NCT00901277|No Intervention|Control|Usual Care
3201238|NCT00901277|Experimental|Web Intervention|Web-based: interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
3201239|NCT00901277|Experimental|Nurse Intervention|Nurse: an interactive web-based tool based on Microsoft's HealthVault technology for data transmission, tracking and communication of cardiac risk factors (e.g. home BP monitors for all in this intervention arm)
3201240|NCT00901290|Experimental|1|monophasic oral contraceptive
3201241|NCT00901290|Experimental|2|AZD7325
2533673|NCT02672956|Experimental|Supraumbilical entry group|Umbilical port will be insert to supra umbilical area.
3201242|NCT00901329|Experimental|1: Gender prosthesis|
3201243|NCT00901329|Active Comparator|2: LPS flex prosthesis|
3201244|NCT00901368|Experimental|1|CHF1535 (beclometasone dipropionate plus formoterol, 400/24 µg daily)
3201245|NCT00901368|Active Comparator|2|Seretide® Diskus® (fluticasone plus salmeterol, 500/100 µg /daily)
3201246|NCT00901381|Experimental|G-CSF|
3201247|NCT00901381|No Intervention|Control|
3201248|NCT00901407|Experimental|1|lamotrigine
3201249|NCT00901407|Placebo Comparator|2|placebo
3201250|NCT00901420||Prostatectomy|
3201251|NCT00901420||Prostatectomy After Radiation Therapy|
3201252|NCT00901433||A|Usability study of the Personal Wheezometer
3201253|NCT00901446||Imaging|Subjects who receive intracoronary imaging with the investigative device.
3201254|NCT00901472||Stable type 2 Diabetes (ST2D)|Adults with Type 2 diabetes who receive medical care at the University of Chicago
2532717|NCT02679053|Experimental|Exercise (IG)|Aerobic exercise three times per week on indoor bicycles at 60 to 75% of maximal heartrate aiming at a weekly total of 17.5kcal/kg bodyweight for 6 consecutive weeks. The exercise will take place under supervision. At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
2532721|NCT02679053|Placebo Comparator|Control (CG)|Basic stretching and mobilisation program 3 times per week each for approx. 40 minutes, also under supervision for 6 consecutive weeks. At the end of every week physical fitness is evaluated by the queens step test.At the end of every week physical fitness is evaluated by the queens step test.No other activities with moderate or high intensity are allowed throughout the intervention time.
2532801|NCT02678819|Experimental|Digital Aid|The digital cognitive aid is designed as a smartphone app. Intervention : cognitive aid during anesthesia and intensive care crises management.
2532802|NCT02678819|No Intervention|No digital aid|Anesthesia and intensive care crises managed without any cognitive aid.
3167433|NCT00538343|Experimental|RTA 744|
3201255|NCT00901498|Experimental|Treatment A (Reference)|
2533110|NCT02676544|Experimental|Embosphere microspheres|Embospheres are calibrated microspheres which will be percutaneously delivered intra-arterially via a microcatheter under fluoroscopic guidance to occlude the prostatic arteries.
2533160|NCT02676401|Experimental|MT-3995 Low|
2533163|NCT02676401|Experimental|MT-3995 Middle|
2533169|NCT02676401|Experimental|MT-3995 High|
2533206|NCT02675829|Experimental|Cohort 1: Lung cancers, HER2 mutant|
2533209|NCT02675829|Experimental|Cohort 2: Lung cancers, HER2 amplified|
2533213|NCT02675829|Experimental|Cohort 3: Colorectal cancers|
2533217|NCT02675829|Experimental|Cohort 4: Endometrial cancers|
2533222|NCT02675829|Experimental|Cohort 5: Salivary gland cancers|
2533225|NCT02675829|Experimental|Cohort 6: Other solid cancers|
2533313|NCT02675257|Experimental|Cognitive-behavioural group treatment|"Five group sessions of diabetes-Specific cognitive-behavioural group treatment for diabetes patients with depressive symptoms and/or diabetes distress and suboptimal glycaemic control.~Interventions:~Diabetes-related affective problems analysis~Goal setting towards improvement of glycaemic control~Diabetes-specific problem-solving therapy~Interventions to increase diabetes treatment motivation~Activation of personal and social resources~Reduction of barriers to self-care/glycaemic control~Cognitive restructuring of diabetes-related problems~Goal definition regarding self-care/glycaemia/well-being"
2533317|NCT02675257|Active Comparator|Treatment-as-usual|"Standard diabetes education.~Interventions:~Health care and specific topics (e. g. blood pressure)~Healthy foods, cooking recommendations, recipes~Sports, activities and exercise~Foot care: exercises, care & control, injuries, neuropathy~Diabetes complications~Social aspects of living with diabetes"
2533388|NCT02674711|Experimental|Educational Video|Evidence-based video: Best Advice for People Taking Opioid Medication
2533395|NCT02674711|No Intervention|Usual Care|Usual care education provided at time of pre-operative appointment.
2533459|NCT02674503|Experimental|Intensive|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay.
2533464|NCT02674503|Placebo Comparator|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
2533498|NCT02674087||Expectant women|
2533542|NCT02673749|Experimental|RP-G28 Dose 1|
2533545|NCT02673749|Experimental|RP-G28 Dose 2|
2533549|NCT02673749|Placebo Comparator|Placebo|
2533646|NCT02673307|No Intervention|Controle|The volunteer does not chew gum during the study period
2533647|NCT02673307|Experimental|Chewing gum|The volunteer chews gum during the first 45 min after ingestion of 250 ml water
2533657|NCT02672787|Active Comparator|ED usual care plus education|ED usual care plus education
2533660|NCT02672787|Experimental|Intervention|Subjects will receive the ED-based behavioral intervention
2533741|NCT02672631||Median Nerve injury hand|Participants will be randomly called; and that 10 participants which had unilateral median nerve transection totally and repaired primely in our clinic at 2014. In the sample, correlations between physical examination (Tinnel Test, motor strength assessment (Medical Research Council (MRC) Scale), static two-point discrimination test (S2PD), Semmes-Weinstein (SW) monofilament test, the Disability of the Arm, Shoulder and Hand (DASH) test), ENMG with the DTI results will be assessed.
2533745|NCT02672631||Healthy Hand|Control group will be taken from patients other hand which had not injured before. And we will compare with first group's results.
2533775|NCT02671929|Experimental|self-help program + feedback|Patients in this arm receive access to the internet-based self-help program and get feedback on their progress in the program.
2533778|NCT02671929|Active Comparator|self-help program|Patients in this arm receive access to the internet-based self-help program and don't get any therapeutic feedback
2533839|NCT02671682|Experimental|Immunoadsorption|Immunoadsorption on 5 consecutive days with protein A columns and 2,5-fold patient's plasma volume
2533842|NCT02671682|Active Comparator|Plasmapheresis|Plasmapheresis on 5 consecutive days with 2l plasma exchange
2533893|NCT02671201||Group A|Theoretical training will be scheduled for 2 hours with lectures in basics of emergency ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 4 hours.
2533898|NCT02671201||Group B|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound. After the theoretical education the students will obtain a bedside-teaching on intensive care unit for 3 hours.
3201256|NCT00901498|Active Comparator|Treatment B|
3201257|NCT00901498|Active Comparator|Treatment C|
2532740|NCT02679144|Experimental|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study.
2532827|NCT02678325|Active Comparator|Standardized normal protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 20% of the total caloric intake
2532830|NCT02678325|Experimental|Standardized high protein enteral nutrition formula|Standardized enteral nutrition formula with a caloric density of 1.2 kcal/ml and protein percentage 33% of the total caloric intake
2532889|NCT02678130|Active Comparator|InterFuse Group|Patients are randomized based on last digit (odd) of social security number to be treated with an InterFuse T device
2532892|NCT02678130|Active Comparator|Control Group: Standard of care TLIF|treated with a standard of care TLIF (Transforaminal Lumbar Interbody Fusion) device (e.g. Stryker's AVS Unilif)
2532941|NCT02677675|Experimental|Intervention (reminder module)|"A reminder module which included standardized weekly SMS medication reminders (sent at 9am every Monday); SMS reminder 3 days prior to scheduled clinic appointments (individualized and sent at lunch time), and an average of 90sec lunch hour telephone call reminders a day prior to scheduled clinic appointment (in addition to standard care - routine adherence counselling) was delivered consistently for 24 weeks to respondents in the intervention group by two trained PLHIV (research assistants)"
2532947|NCT02677675|No Intervention|Control (standard care)|Control group received standard care only (routine adherence counselling and paper-based appointment scheduling)
2533036|NCT02677350|Experimental|Pilot|Twenty (20) subjects will be treated with 20 million (2 x 10^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.
2533079|NCT02676713|Experimental|TCM Sequential Treatment|"After conservative surgery, patients start to take pre-ovulation decoction for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found LUFS or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles.~Pre-ovulation decoction is HuoXueXiaoYi decoction, and post-ovulation decoction is BuShenZhuYun decoction. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~All drugs are tcm formula granules, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
2533088|NCT02676713|Placebo Comparator|Placebo|"After conservative surgery, patients start to take pre-ovulation decoction(placebo) for 14 days. Each menstrual period 2～5 days, patients start to take pre-ovulation decoction. If ultrasonography found ovulation, change to take post-ovulation decoction. If having taken 14 days, ultrasonography found luteinized unruptured follicle syndrome (LUFS) or no follicle develop maturity, change to take post-ovulation decoction. Taking post-ovulation decoction(placebo) for 14 days, or continue to next time menstruation. Taking medication for six menstrual cycles. 2 bags each time, 2 times a day, fused with hot water, 1 hour after dinner.~Pre-ovulation decoction and post-ovulation decoction is placebo, manufactured by Jiangyin Tianjiang Pharmaceutical Co. ltd"
2533168|NCT02676206|Experimental|Music intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. Classical music will be played until the subject is fully awake.
2533171|NCT02676206|No Intervention|Non intervention|Subjects will have headphones placed on 1 minute prior to procedural sedation. No music will be played. The headphones will be removed when the subject is fully awake.
2533192|NCT02675881|Active Comparator|RFA DSM|Eligible patients who undergo RFA using DSM and separable clustered electrodes.
2533197|NCT02675881|No Intervention|RFA SSM|Historical control group consisted of patients underwent RFA in our institution with single switching mode (SSM) and single/ or multiple clustered electrodes.
2533355|NCT02675361|Experimental|Intervention group: transition program|Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
2533356|NCT02675361|No Intervention|Comparison group|"Participants allocated to this group will receive usual care, which includes follow-up visits according to the complexity of the congenital heart disease. Usual care can vary across clinics, however, they all include meeting with a nurse and a physician.~This is established as a comparison group since there is the risk of contamination in this group."
2533359|NCT02675361|No Intervention|Control group|"Participants in this group will receive usual care. Follow-up visits will depend on the complexity of the disease.~Five clinis comprise this section of the study and will be part of an longitudinal, observational study, which investigators will use as a control group."
2533478|NCT02674269|Experimental|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
2533480|NCT02674269|Experimental|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
2533482|NCT02674269|Placebo Comparator|TC-3 Gel|One intravesical instillation of 60 ml TC-3 gel
2533483|NCT02673983|Experimental|Patients undergoing endoscopic full-thickness biopsy|
2533521|NCT02673905|Experimental|N-TEC (tissue engineered product)|N-TEC is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 weeks to allow the cells to produce extracellular matrix containing cartilage specific Proteins. The IMP is implanted in the knee joint and secured by sutures.
2533523|NCT02673905|Experimental|N-CAM (tissue engineered product)|N-Cell activated Matrix (CAM) is based on autologous nasal chondrocytes expanded and further cultured on type I/III collagen membrane for 2 days only to allow the cells to adhere. The IMP is implanted in the knee joint and secured by sutures.
3201258|NCT00901498|Active Comparator|Treatment D|
3201259|NCT00901498|Active Comparator|Treatment E|
3201260|NCT00901511|Experimental|WLL/GM-CSF|Whole lung lavage followed by inhaled GM-CSF
3201261|NCT00901511|Active Comparator|WLL alone|
3201262|NCT00901524|No Intervention|PegIFN- alpha 2a + RBV|
2532755|NCT02678962|Active Comparator|AT LISA tri 839 MP group|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
2532759|NCT02678962|Active Comparator|ART group|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
2532761|NCT02678962|Active Comparator|LS-313 MF30T group|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
2532850|NCT02678624|Experimental|Treatment according to the Collabri model|Participants in this group will recive treatment according to the Collabri model which is a Danish model for collaborative care between primary and secondary care for depression, social phobia, generalized anxiety and panic disorder
2532853|NCT02678624|No Intervention|Treatment as usual|Control group. Participants in this group will recive treatment as usual. This means that participants will recive treatment corresponding to what their GP normally would offer as treatment. E.g. this could be refferal to a psychologist or psychiatrist and/or medicine.
2532876|NCT02678013|Experimental|Radiofrequency ablation(RFA)|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
2532879|NCT02678013|Active Comparator|RFA+CTL|RFA was performed the same as RFA Arm.Peripheral blood (20-30mL) for manufacturing the individualized highly-purified CTL agent was collected from the respective patients who were randomized to the immunotherapy group before starting treatment. The highly-purified CTL agent was prepared at a central manufacturing facility. Patients in the immunotherapy group received 5*10E9 of the highly-purified CTL agent intravenously over 60 minutes without any premedication and then were observed for at least 30 minutes. They were scheduled to receive highly-purified CTL: 4-6 treatments at a frequency of once two-week during 6 months after receiving RFA, followed by 6-9 treatments during 6 months to 2 years after receiving RFA.
2532936|NCT02677805|Experimental|Botulinum toxin A|Botulinum Toxin A will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into glabellar area.
2532937|NCT02677805|Placebo Comparator|Placebo|Placebo will be administered in double blind fashion in cycle 1 divided in five 0.1 mL injections into the glabellar area.
2533032|NCT02677077||Czech Republic|Approximately 230 participants with RRMS receiving commercial natalizumab in Czech Republic
2533037|NCT02677077||Belgium|Approximately 70 participants with RRMS receiving commercial natalizumab in Belgium
2533082|NCT02676622|Experimental|Stem-cell mobilization and Leukapheresis|"Stem-cell mobilisation will be achieved using Cyclophosphamide (CY) 4g/m² (2g/m2 on 2 consecutive days) followed 5 days later by filgrastim (G-CSF) 10 mg/kg injection. This will be done daily until the day before the last day of leukapheresis. The PBSCs will be harvested usually between day +9 and +11 of completing CY.~Leukapheresis will be performed to a target cell dose of 3-8 x106 CD34+ cells/kg Approximately 1 month later patients will undergo HSCT"
2533182|NCT02676115|Active Comparator|Control Group|Standard Post Operative Skin Care
2533183|NCT02676115|Experimental|Treatment Group|Medipore Tape will be applied to ACL reconstruction Incision
2533241|NCT02675777|Experimental|Quality Improvement Intervention|"Quality improvement intervention: 4 months during which a practice facilitator supports the clinic in implementing routine, population-based screening, assessment, treatment, and follow-up for unhealthy alcohol use and AUDs (see Intervention) as part of behavioral health integration."
2533242|NCT02675777|No Intervention|Usual Care|Care received after 2/2016 but before active implementation begins, which includes passive access to tools in the EHR and 2 months of preparation in each clinic (team building and local pretesting by a local implementation team supported by the external practice facilitator).
2533280|NCT02675491|Experimental|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
2533343|NCT02675218||Patients with rheumatoid arthritis.|Rheumatoid arthritis diagnosis according to ACR (American College of Radiology)/EULAR 2010 classification criteria.
2533390|NCT02674841|Experimental|Feedback group|Receives live feedback on TUT and pulling force during exercises.
2533396|NCT02674841|Active Comparator|Control group|Receives no feedback on TUT but on pulling force during exercises.
3201263|NCT00901537|Experimental|Azacitidine and Cisplatin|Every 4 weeks, azacitidine is given daily as subcutaneous injection for 5 days from day 1 to day 5, and cisplatin is given as intravenous injection on day 8. The dose of azacitidine will be dose escalated among each group of 3-6 patients, and the dose of cisplatin is fixed.
3201264|NCT00901550|Active Comparator|Methotrexate|A drug for RA patient
2533484|NCT02673957||Blood pressure cuff protocol|All participants receive a baseline control blood test, and all participants receive the blood pressure cuff inflation protocol and blood sampling following the cuff protocol.
2533522|NCT02673879|Active Comparator|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
2533524|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated.
3167434|NCT00538356|Experimental|Home Monitoring|ICD or CRT-D with Home Monitoring feature activated Home Monitoring data will be analyzed regularly and patients will be contacted and scheduled for additional follow-up after predefined events
2533628|NCT02673112|Experimental|STEP-mhc + LS|Subjects will be asked to perform exercise at 80% of the heart rate threshold determined using the Balke protocol for 5 minutes greater than their measured minutes of MVPA/day at baseline (Subthreshold exercise program). They will also be given a light stretching protocol (5 stretches). The exercise intervention will last for 6 weeks and will be supported by weekly health coaching.
2533632|NCT02673112|Active Comparator|LS alone|Subjects will be given a light stretching program alone (5 stretches). The exercise program will last for 6 weeks.
2533655|NCT02672813|Experimental|Pectoral Nerve I and II block|Under Ultrasound guidance, Pectoral nerve I block is given for every breast surgery using 10ml of 0.25 % Ropivacaine ( without added preservatives). Similarly Pectoral nerve II block is also given using 20 ml of 0.25% Ropivacaine ( without added preservative) in same group of patient.
2533656|NCT02672813|No Intervention|No block|Pectoral nerve block is not given in this group of patients undergoing breast surgery
2534132|NCT02669732|Placebo Comparator|Placebo|tablets, orally, once daily for up to 28 days
3201265|NCT00901550|Active Comparator|Infliximab|for RA treatment
3167435|NCT00538356|Active Comparator|Control|ICD or CRT-D with Home Monitoring feature deactivated Patients will be treated as per standard of care in each participating clinic
3167436|NCT00538369|Active Comparator|standard-of-care|The standard-of-care group will receive sedation assessment and monitoring with the Ramsay scale, which is the accepted tool at this university
2533137|NCT02676167|Other|Intervention|
2533277|NCT02675582|Placebo Comparator|Control|Mix 1 flavored still beverage
2533281|NCT02675582|Experimental|Herbal beverage 1|Mix 2 flavored still beverage with a botanical extract(1)
2533286|NCT02675582|Experimental|Herbal Beverage 2|Mix 3 flavored still beverage with a botanical extract(2)
2533289|NCT02675582|Experimental|Combined Herbal Beverage|Mix 4 flavored still beverage with 2 botanical extracts (1,2)
3167437|NCT00538369|Experimental|standard + BIS|Subjects in the standard-of-care + BIS group will receive sedation assessment and monitoring using the Ramsay scale and values from the bispectral index (BIS) monitor.
2533493|NCT02673996||Postural Tachycardia Syndrome (POTS)|Patients with postural tachycardia syndrome; patients will receive both IV phenylephrine and IV isoproterenol
2533500|NCT02673996||Healthy (control) Subjects|Healthy volunteers that are gender and age-matched (by groups) to the POTS patients; healthy subjects will receive both IV phenylephrine and IV isoproterenol
2533730|NCT02672618||chronic heart failure|18-85years old,having symptoms of heart failure,New York Heart Association（NYHA） class II or above American College of Cardiology/American Heart Association（ACC/AHA） class B, C, including hypertensive heart disease, rheumatic heart disease, ischemic cardiomyopathy and idiopathic cardiomyopathy
2533732|NCT02672618||normalCardiac function|18-85years old,no symptoms of heart failure,NYHA class I or above ACC/AHA class A, including controled hypertension,stability coronary heart disease and rheumatic heart disease
2533735|NCT02672618||healthy volunteers|18-85years old,Without basic cardiovascular diseases
2533784|NCT02671942|Active Comparator|roflumilast:250μg|Drug: Roflumilast Roflumilast tablets Roflumilast 250 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2533798|NCT02671942|Active Comparator|roflumilast:375μg|Drug: Roflumilast Roflumilast tablets Roflumilast 375 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2533808|NCT02671942|Active Comparator|roflumilast:500μg|Drug: Roflumilast Roflumilast tablets Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2533810|NCT02671942|Placebo Comparator|placebo|Drug: placebo placebo tablets placebo tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive
2533847|NCT02671617|No Intervention|Control|Control: This group of patients will receive 'current best practice' as per UK NHS recommendations for their specific cancer management prior to surgery.
2533855|NCT02671617|Experimental|High intensity interval training|"Exercise: Participants in this group will attend 3-4 times per week to complete HIIT training during the period from diagnosis to surgery.~High intensity interval training (HIIT)"
2533885|NCT02671214|Placebo Comparator|Control|100 g high fibre flour
2533886|NCT02671214|Active Comparator|Active 1|85 g high fibre flour + 15 g legume flour
2533889|NCT02671214|Active Comparator|Active 2|98 g high fibre flour + 2 g guar gum
2533896|NCT02671214|Active Comparator|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
2533899|NCT02671214|Active Comparator|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
2533902|NCT02671214|Active Comparator|Active 5|96 g high fibre flour + 4 g guar gum
2533903|NCT02671214|Active Comparator|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
2533904|NCT02671214|Active Comparator|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
2533905|NCT02671214|Active Comparator|Active 8|94 g high fibre flour + 6 g guar gum
2533906|NCT02671214|Active Comparator|Active 9|98 g high fibre flour + 2 g konjac mannan
2533907|NCT02671214|Active Comparator|Active 10|96 g high fibre flour + 4 g konjac mannan
2533908|NCT02671214|Active Comparator|Active 11|100 g low fibre flour
3167438|NCT00538382|Experimental|Case|Cases are defined as parasitemic pregnant women during the second trimester (22-26 weeks gestation) and the third trimester (32-36 weeks gestation).
3167439|NCT00538382|Active Comparator|Non-pregnant Control|Non-pregnant controls are defined as parasitemic non-pregnant women recruited from the same community as the cases.
3167440|NCT00538382|Active Comparator|Internal Control|Internal controls are defined as the same women(cases)at three months postpartum.
3167441|NCT00538421|Active Comparator|1|
3167442|NCT00538421|Active Comparator|2|
3167443|NCT00538486|Experimental|Group T|Telmisartan
3167444|NCT00538486|Experimental|Group T+M|Telmisartan plus Metformin
3167445|NCT00538486|Experimental|Group C|Candesartan
3167446|NCT00538486|Experimental|Group C+M|Candesartan pus Metformin
3167447|NCT00538486|Active Comparator|Group A|Amlodipine
3167448|NCT00538486|Experimental|Group A+M|Amlodipine plus Metformin
3167449|NCT00538499|Other|Fentanyl citrate|
3167450|NCT00538499|Experimental|bupivcaine hydrochloride|
3167451|NCT00538499|Other|videothoracoscopy|
3167452|NCT00538525|Active Comparator|Arm 1|Doxorubicin, Docetaxel, Cisplatin
3167453|NCT00538538|Active Comparator|A|Does not receive Gas bubble
3167454|NCT00538538|Active Comparator|B|Does receive gas bubble
3167455|NCT00538564|Experimental|Tadalafil|Participants assigned to this arm were given oral 10 mg tadalafil tablets to take 3 times a week for 16 weeks.
3167456|NCT00538564|Placebo Comparator|Placebo|Participants assigned to this arm were given a placebo pill 3 times a week for the first 8 weeks, and then Tadalafil 10 mg 3 times a week for weeks 9-16.
3167457|NCT00538655|Experimental|modafinil|
3167458|NCT00538668|Experimental|1|20 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3167459|NCT00538668|Experimental|2|25 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
2532881|NCT02678234|Experimental|Theraflu Aktiv powder for oral solution|Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
2532885|NCT02678234|No Intervention|No Treatment|Participants in this arm will not receive any medication
3201266|NCT00901563|Active Comparator|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
3201267|NCT00901563|Placebo Comparator|Saline|Saline will be infused through-out the study.
2533002|NCT02677090|Placebo Comparator|Placebo|Placebo
2533006|NCT02677090|Active Comparator|Dose 1 - Promitor®|Investigational product Dose 1
2533008|NCT02677090|Active Comparator|Dose 2 - Promitor®|Investigational product Dose 2
2533009|NCT02677090|Active Comparator|Dose 3 - Promitor®|Investigational product Dose 3
2533077|NCT02676856|Experimental|CR group|For the patients in CR group(CR status of AML at microtransplantation), the conditioning regimen is high-dose (HD) Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with long-term course.
2533085|NCT02676856|Experimental|Non-CR group|For the patients in Non-CR group (PR or NR status of AML at microtransplantation), the conditioning regimens include: IAC or HD Ara-C. Hematopoietic stem cell microtransplantation will be given to these patients with short-term course.
2533131|NCT02676297|Experimental|Test product A|tiotropium
2533133|NCT02676297|Experimental|Test product B|tiotropium
2533143|NCT02676297|Active Comparator|reference product|tiotropium
2533210|NCT02675985|Experimental|Intervention arm|Early intensive physical therapy will be the intervention arm. There is not a control group.
2533267|NCT02675647|Experimental|Intervention group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the dosage of 340 UI/kg based on ideal body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on ideal body weight, to maintain this target during the CPB."
2533268|NCT02675647|Active Comparator|Control group|"Obese patients, randomized to receive an initial IV bolus of Heparin, before beginning of the cardiopulmonary bypass, at the usual dosage of 300 UI/kg based on total body weight of the obese patients.~The objective is to obtain an ACT target ≥ 400 s before the beginning of CPB. If necessary, additional boluses of heparin are administered at the dose of 100 UI/kg based on total body weight, to maintain this target during the CPB."
3167460|NCT00538668|Experimental|3|30 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3167461|NCT00538668|Experimental|4|35 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3201268|NCT00901589|Active Comparator|Premenopausal women-fishoil|
3201269|NCT00901589|Placebo Comparator|Premenopausal-placebo|
2533496|NCT02673931|Experimental|GLP-1|"700 patients will be randomized to GLP-1, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes. A set dose of 17.4 microg will be given."
2533504|NCT02673931|Placebo Comparator|Placebo|"20% Human Albumin is given as placebo. 700 patients will be randomized to placebo, that will be administered as follows:~248.5 mL of isotonic sodium chloride added 1.5 mL of 20% human albumin.~The placebo infusion is initiated immediately before open heart surgery and ended after 6 hours and 15 minutes at the same rate as the study drug."
2533511|NCT02673931|Experimental|Restrictive Oxygenation|"The intervention is FiO2 of 50%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 50% as long as the arterial O2 saturation (Sa02) remains above 91% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
2533517|NCT02673931|Active Comparator|Liberal Oxygenation|"The intervention is a FiO2 of 100%, given as 'Conoxia (AGA, oxygen)'. 700 patients will be randomized to a FiO2 of 100% during cardiopulmonary bypass, when weaning from and the following hour after weaning from cardiopulmonary bypass. The oxygenation strategy is discontinued and the patient is treated at the discretion of the attending physician after~a maximum of 1 hours of intervention or~the patient is slid from the operating table to a hospital bed for transfer to the intensive care unit, whichever comes first."
2533563|NCT02673606|Experimental|Estradiol 2mg Dose|2mg dose of estradiol (oral administration)
2533565|NCT02673606|Experimental|Estradiol 4mg Dose|4mg dose of estradiol (oral administration)
2533566|NCT02673606|Placebo Comparator|Placebo|placebo (oral administration)
2533617|NCT02673164|Active Comparator|CSCC_ASC|Cardiology Stem Cell Centre_adipose derived stem cells (CSCC_ASC)
2533619|NCT02673164|Placebo Comparator|Placebo|Saline
2533679|NCT02672995|Experimental|Single arm dose-escalation|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break.~Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
3201270|NCT00901589|Active Comparator|Postmenopausal women-fishoil|
3201271|NCT00901589|Placebo Comparator|Postmenopausal-placebo|
3201272|NCT00901615|Experimental|Lenalidomide and R-CHOP|Escalating Lenalidomide dose from 2.5 to 25 mg Lenalidomide and R-CHOP
2532917|NCT02677857|No Intervention|Newsletter|Participants in this condition will receive standard care and every month they will receive a newsletter that provides information and tips about healthy eating and activity behaviors. This newsletter will include information on myPlate,28 activity guidelines,29 reading food labels, healthy recipes, and seasonal activity suggestions.
2532933|NCT02677584|Active Comparator|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
2532934|NCT02677584|Active Comparator|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
2532990|NCT02677415|Other|Local anesthesia|local anesthesia and spontaneous breathing will be maintained.
2532991|NCT02677415|Other|General anesthesia|Intravenous anesthetics and controlled ventilation will be used .
3167462|NCT00538668|Experimental|5|40 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
2533072|NCT02676687|Active Comparator|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
2533074|NCT02676687|Experimental|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
2533147|NCT02676414|Other|Education program|"Group of patients participating in the interactive hypertension education program of the DHL© My blood pressure - OK!"
2533155|NCT02676414|No Intervention|Controls|"Group of patients not participating in the interactive hypertension education program of the DHL© My blood pressure - OK! (usual care)"
2533219|NCT02676063||neonatal Hypoxic Ischemic encephalopathy|moderate or severe HIE among term and late preterm newborn
3167463|NCT00538668|Experimental|6|45 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3167464|NCT00538668|Experimental|7|50 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3167465|NCT00538668|Experimental|8|55 mCi/m2 of 177Lu-J591 will be given in 2 doses, 2 weeks apart.
3167466|NCT00538668|Experimental|9|25 mCi/m2 of 177Lu-J591 will be given every 2 weeks.
3167467|NCT00538707|Experimental|Young subjects|
3167468|NCT00538707|Experimental|Older subjects|
3167469|NCT00538720|Experimental|Vitamin D|Vitamin D starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
2533391|NCT02674737|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both sedative and analgesic(dexmedetomidine, tramadol and flurbiprofen) are applied to this group of patients.
2533401|NCT02674737|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(tramadol and flurbiprofen) are applied to this group of patients.
2533430|NCT02674490|Experimental|A-tDCS & SALT|A-tDCS (1 mA) plus Speech and Language Treatment (SALT) for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. The electrical current will be administered to a pre-specified region of the brain. The stimulation will be delivered at an intensity of 1mA for a maximum of 20 minutes. SALT will be a computer-delivered naming + picture matching task .
2533438|NCT02674490|Sham Comparator|Sham-tDCS & SALT|Sham-tDCS plus SALT for 15 sessions (20-minutes per each 45-minute treatment session) over the course of 3 weeks. Current will be administered in a ramp-like fashion, but after the ramping, the intensity will drop to 0 mA. SALT will be a computer delivered oral naming + picture naming task.
2533564|NCT02673671||Subjects with unknown POI status consented pre-surgery|Up to 100 subjects may be consented prior to surgery who are planned to undergo gastrointestinal surgery or a planned surgery that does not involve the abdominal cavity. The investigator does not change the routine medical care of study participants.
2533567|NCT02673671||Subjects with known/unknown POI status consented post-surgery|Up to 50 subjects who have undergone gastrointestinal surgery or surgery not involving the abdominal cavity may be consented post- operatively during their hospital stay for this study.The investigator does not change the routine medical care of study participants.
2533625|NCT02673268|Experimental|Patients with breast cancer|
2533676|NCT02672904|Active Comparator|CO2 laser|Patients undergoing endoscopic treatment with CO2 laser
2533688|NCT02672904|Active Comparator|KTP laser|Patients undergoing endoscopic treatment with KTP laser
2533737|NCT02672397|Experimental|Hispanic Intervention|Hispanic subjects that receive additional epidural education [44 patients]
2533743|NCT02672397|No Intervention|Hispanic Control|Hispanic subjects that receive standard of care [44 patients]
2533749|NCT02672397|Experimental|Non-Hispanic Intervention|Non-Hispanic subjects that receive additional epidural education [44 patients]
2533753|NCT02672397|No Intervention|Non-Hispanic Control|Non-Hispanic subjects that receive standard of care [44 patients].
2533790|NCT02671955|Experimental|Part 1: Dose Escalation|Participants with advanced solid tumors will receive intravenous infusions of JNJ-61610588 until disease progression. Dose escalation will continue until the maximum tolerated dose is reached.
2533799|NCT02671955|Experimental|Part 2: Biomarker Evaluation|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at or below the recommended Phase 2 dose (RP2D) until disease progression.
2533816|NCT02671903|Active Comparator|Pacemaker: AV optimised, His pacing|Subjects will remain in this arm for 6 months before being crossed-over. See below intervention details.
3167470|NCT00538746|Experimental|1|BIPAP (Bilevel Positive Airway Pressure) targeted on: TV 6-8 ml/kg, total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92% (with spontaneous RR between 20-40%)
3167471|NCT00538746|Experimental|2|PSV (pressure support ventilation) targeted on: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated.
3167472|NCT00538746|Experimental|3|PSV+CPAP (continuous positive airway pressure) targeted on: PSV: TV 6-8 ml/kg,total RR 10-30/min, PEEP and FiO2 regulated on Sat greater than 92, a minimum of 7 cmH2O of PS is tolerated, CPAP (5-10 cmH2O) at least 2 hours a day. If during the CPAP periods at least 1 of the criteria T tube test failure occurs, the patients will come back immediately to PSV.
2532972|NCT02677480|Active Comparator|Test group, probiotic tablets and gel|Test group, probiotic tablets and gel: tablets with probiotic bacteria (10exp8/tablet) and pH-rising components and gel (with probiotic bacteria and pH-rising components) in trays on the teeth once a week.
2532977|NCT02677480|Placebo Comparator|Placebo group, placebo tablets and gel|Placebo group, placebo tablets and gel: placebo tablets without probiotic bacteria and pH-rising components and gel (with no probiotic bacteria but with pH-rising components) in trays on the teeth once a week.
2533015|NCT02677181|Experimental|ATG combined regimen|"ATG combined regimen for prophylaxis of GVHD, includes ATG, MMF(Mycophenolate mofetil ),CsA (cyclosporin A) and MTX (methotrexate).~All recipients in this arm received ATG, CsA, mycophenolate mofetil, and short-term methotrexate for GVHD prophylaxis. ATG (Thymoglobuline, rabbit) was used as 1.5 mg/kg/d on day -5 and 3.5 mg/kg/d on day -4. CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11."
2533022|NCT02677181|Active Comparator|no-ATG|regimen for prophylaxis of GVHD without ATG. The regimen includes MMF,CsA and MTX.CsA (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered. From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30. After graft infusion, MTX was given for all patients at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6 and +11.
2533099|NCT02676609|Active Comparator|Use of smart phone application (device glucal)|"Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio.~During the first month, then during the second month they'll use as usual their traintement and meal without the apllication"
2533103|NCT02676609|Active Comparator|Use of smart phone application (second month)|"During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin.~Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio."
2533161|NCT02676388|Experimental|Freeze-dried, Capsulized FMT|Patients included will receive bowel lavage and subsequent Freeze-dried, Capsulized FMT, and then will be followed up for 3 months.
2533162|NCT02676388|Experimental|Fresh FMT|Patients included will receive bowel lavage and subsequent Fresh FMT, and then will be followed up for 3 months.
2533252|NCT02675855|Experimental|GrafixPRIME®|GrafixPRIME® is cryopreserved human placental membrane Patients will be fitted with off-loading devices
2533254|NCT02675855|Active Comparator|Active Comparator|Wound cover, Dressing Application Patients will be fitted with off-loading devices
2533308|NCT02675400|Active Comparator|Medication Arm|Vyvanse Arm: 3-week open-label titration beginning at 20 mg Vyvanse (a class II drug), and be increased weekly during the titration period until an optimal response is obtained and then continue for 5 weeks. Optimal response is defined as a clinician Clinical Global Impression-Improvement score (CGI-I) ≤ 2 with minimal associated adverse events. Fathers will remain on optimal dose through the course of the study. In cases of poor tolerability or loss of efficacy the dose can be changed. If an optimal response is not achieved a trial with a long acting methylphenidate will be initiated based upon the Texas algorithm for stimulant medication. The study physician will be available by phone 24 hours/day; participants will be instructed to call with any safety concerns.
2533309|NCT02675400|Active Comparator|Behavioral Parent Training Arm|"Behavioral Parent Training (BPT) Arm: Fathers in the BPT group will receive weekly parent training sessions based on the Barkley manual, Defiant Children, Third Edition. The child participants will also come to several sessions at the clinician's and supervisor's discretion."
2533369|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES|ENDOSCOPIC BIOPSEIS TAKEN FROM BOTH ANTRUM AND CORPUS FOR H PYLORI DETECTION
3201273|NCT00901641|Experimental|cognitive training|CogniFit Personal Coach® computer cognitive training program. The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®). The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
3201274|NCT00901654|Experimental|ACE527|
2533487|NCT02674230||Extreme obesity|BMI ≥35kg/m2
2533489|NCT02674230||Obesity|BMI 24-34.9kg/m2
2533490|NCT02674230||Normal subjects|BMI <24kg/m2. No systemic disease, including hypertension, diabetes, liver cirrhosis, chronic kidney disease, and psychiatric disease.
2533554|NCT02673827|No Intervention|Group control|Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
2533555|NCT02673827|Experimental|experimental group|"Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation.~They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation."
2533602|NCT02673398|Experimental|Treatment (neratinib)|Patients receive neratinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2533671|NCT02672748|Experimental|Gardening|Receiving two years of technical, labor and financial support in starting, growing, and harvesting from a home food garden.
2533677|NCT02672748|No Intervention|Control|The control families receive a garden as a delayed intervention after two years.
2533713|NCT02672488|Experimental|Sorafenib and Metformin|Sorafenib 400μg tablet by mouth and Metformin 500mg tablet by mouth with meal, twice per day
2533721|NCT02672488|Active Comparator|Sorafenib Alone|Sorafenib 400μg tablet by mouth, twice per day
3201275|NCT00901654|Placebo Comparator|Placebo comparator|
2533901|NCT02671201||Group C|Theoretical training will be scheduled for 3 hours and included lectures in echocardiography, lung ultrasound and abdominal ultrasound.
2533027|NCT02677259|Active Comparator|Standard Luteal Phase Support|1. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
2533096|NCT02676674|Experimental|Dose 1|Three topical applications of 100,000 units for a total of 300,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
2533101|NCT02676674|Experimental|Dose 2|Three topical applications of 300,000 units for a total of 900,000 units of vitamin D3 in a newly formulated ointment will be applied to the upper arms over three weeks.
2533175|NCT02676128|Experimental|Mobile Health ART Adherence Application (mARTAA)|mARTAA will use a smartphone-delivered application developed by Twine Health, Inc.
2533177|NCT02676128|Active Comparator|Face-to-Face ART Adherence Intervention|A single face-to-face ART adherence intervention will be administered.
2533195|NCT02675816|Other|Inspire® (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
2533260|NCT02675673|Active Comparator|GJ-Tube arm|Patients randomized to his arm would usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made into the stomach through the frozen skin. The feeding tube is placed through this puncture into the stomach and the tube tip is placed in the small bowel. Once the GJ-tube has been inserted, the tube in the nose is removed.
2533264|NCT02675673|Active Comparator|G-Tube arm|Patients who are randomized to this arm will usually have a small tube is inserted through the nose into the stomach first, so that air can be used to fill the stomach to make it visible on X-ray. A fine needle is then used to inject freezing medicine (local anesthetic) into the skin of the abdomen. Using an x-ray machine for guidance, a puncture is made through the frozen skin. A small guiding tube or catheter is placed through this puncture into the stomach, and is advanced up the esophagus and out of the mouth. The feeding tube is then pulled into the mouth, down the esophagus, and positioned through the abdomen with its inside tip in the stomach.
2533328|NCT02675348|Experimental|Dietary Supplement: Beef Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of beef protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2533332|NCT02675348|Experimental|Dietary Supplement: Whey Protein|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of whey protein powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2533335|NCT02675348|Active Comparator|Dietary Supplement: CHO|"All the groups will perform a similar endurance training involved 4 to 6 workout per week with a total percentage distribution of 75 to 80% at low intensity; 10% at moderate intensity, and 15 to 10% at high intensity. Training session will last from 45 min to a maximum of 120 min.~Intervention will last for 10 weeks. Participants will ingest 20g of maltodextrin powder mixed with 250ml of water at post workout (training days) or before breakfast (non training days)."
2533385|NCT02674867|Experimental|Early treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART before 6 months-of-age (early treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
2533394|NCT02674867|Other|Late treatment group|"Vertically-HIV-1-infected children, between 5 and 17-year-of-age, who started cART after 24 months-of-age (late treatment group) with an initial virologic success (HIV-1 RNA <400 copies / mL reached no later than 24 months after the start of cART), whatever the later evolution of the viremia."
2533460|NCT02674373||Localized gastric cancer|resectable tumor receiving a curative intent treatment.
2533463|NCT02674373||advanced gastric cancer|unresectable tumor treated with palliative chemotherapy
2533494|NCT02674139|Active Comparator|IUD insertion 6 Weeks after delivery|Subjects randomized to interval placement will have their Copper T 380A IUD placed in the office at six weeks postpartum or later
2533499|NCT02674139|Experimental|Immediate Post-placental insertion|Subjects randomized to receive the Copper T 380A IUD within 10 minutes of delivery of the placenta during caesarean section.
2533561|NCT02673736|Experimental|PLX73086|"Part 1: Open-label, sequential PLX73086 dose escalation in approximately 36 solid tumors subjects.~Part 2: Extension cohort at the recommended phase 2 dose (RP2D) of PLX73086 in approximately 30 subjects with histologically confirmed, unresectable, locally advanced or refractory TGCT (including metastatic disease)."
3201276|NCT00901693|Experimental|AL-46383A|AL-46383A Ophthalmic Solution, 1 drop in each eye, 8 times a day for 10 days
2533675|NCT02672891|Experimental|Device|condom balloon catheter which is composed of a latex condom (SURE natural latex condom, Shanghai) and a 16-20 F, 2 ways silicon coated Foley catheter (Egypt). The catheter was introduced inside the condom and tied over tightly several times with a silk suture, to prevent air escape.
2533712|NCT02672527|Experimental|TRA|"At Day 1 (D1), premedication with dexamethasone (20 mg) and a 5-HT3 receptor antagonist anti-emetic agent will be intravenously administered 30 minutes prior to trabectedin administration. Trabectedin will be administered through a central venous catheter at a starting dose of 1.5 mg/m² over 24 hours, diluted in at least 500 mL of normal saline solution or of glucose 5% injectable solution.~Each treatment cycle will last 21 days. Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal, or toxicities.~In case of disease progression, the further treatments will be based on investigator's judgement."
2533720|NCT02672527|No Intervention|BSC|"Treatment:~Patients will receive the best supportive care (BSC) in order to alleviate their symptoms and improve their Quality of Life (QoL).~Antineoplastic agents (including surgery, radiotherapy, thermotherapy, chemotherapy, immunotherapy, hormonal treatment or antibodies-based treatments) are prohibited.~Treatment duration: the treatment might be pursued until disease progression according to RECIST 1.1, or patient refusal.~In case of disease progression, a treatment with trabectedin will be proposed (cross-over). In case of patient refusal, the further treatments will be based on investigator's judgement."
2533031|NCT02677142|Active Comparator|Attention Control Group (CG)|Behavioural: CG: Social Skills Activities: Participants in this arm will experience an 8-week manualized intervention program with activities and games. Sessions will NOT be designed around a specific social skill and activities and games will NOT have a specific focus. Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2533038|NCT02677142|Experimental|Experimental Group (EG)|Behavioral: Structured social skills training program, SSIP. Participants in this arm will experience an 8-week manualized intervention program that addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion). Sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
2533063|NCT02676648|Experimental|Experimental: Condition 1|1) core program; 2) breath meter; 3) text messages; 4) diet-appropriate food and cookbooks
2533065|NCT02676648|Experimental|Experimental: Condition 2|1) core program
2533066|NCT02676648|Experimental|Experimental: Condition 3|1) core program; 2) breath meter
2533068|NCT02676648|Experimental|Experimental: Condition 4|1) core program; 2) text messages
2533070|NCT02676648|Experimental|Experimental: Condition 5|1) core program; 2) diet-appropriate food and cookbooks
2533073|NCT02676648|Experimental|Experimental: Condition 6|1) core program; 2) breath meter; 3) text messages
2533076|NCT02676648|Experimental|Experimental: Condition 7|1) core program; 2) breath meter; 3) diet-appropriate food and cookbooks
2533087|NCT02676648|Experimental|Experimental: Condition 8|1) core program; 3) text messages; 4) diet-appropriate food and cookbooks
2533140|NCT02676154|Other|Fesoterodine|Open-Label
2533184|NCT02675972||patient with poor outcome|modified Rankin scale≥3
2533185|NCT02675972||patients with favorable outcome|modified Rankin scale<3
2533357|NCT02675049|Placebo Comparator|0.9% saline|Patients were assigned to receive 0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
2533358|NCT02675049|Experimental|dexmedetomidine 1 µg.kg-1|Patients were assigned to receive 1µg.kg-1dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2533360|NCT02675049|Experimental|dexmedetomidine 1.5 µg.kg-1|Patients were assigned to receive 1.5µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2533361|NCT02675049|Experimental|dexmedetomidine 2 µg.kg-1|Patients were assigned to receive 2µg.kg-1 dexmedetomidine intranasally 45 min before surgery using a computer-generated random number table.
2533398|NCT02674646|Experimental|Group A: Verum Acupuncture|Group A: Verum Acupuncture (Needle Acupuncture) Needlepoints Bilateral PC 6, S 36, L 8, L 9 Unilateral R4, R 6 Acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
2533405|NCT02674646|Sham Comparator|Group B: Sham Acupuncture|Group B: Sham Acupuncture (Needle Acupuncture) Needlepoints 8 needles in the medioaxillary line below the 6th rib, bilateral 2 needles unilateral Sham-acupuncture will be applied for approx. 20 min. with 10 needlepoints. Standard radiotherapy
3167473|NCT00538772||Biomarker|
3167474|NCT00538811|Experimental|1|Interferon alpha, ribavirin, interferon gamma
2533503|NCT02674022|Active Comparator|Mothers of Children with ASD|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
2533510|NCT02674022|Active Comparator|Mothers of Typically Developing Children|Initial treatment with standard prenatal supplement in mothers with abnormal homocysteine levels; additional treatment with optimized prenatal supplement in mothers not responding adequately to initial treatment.
2533562|NCT02673710||Participants with metastatic colorectal cancer|Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study
2533623|NCT02673099|Other|HDF online|All patients were started on HF (high-flux) hemodialysis. After 6 months they were then treated by HDF online.
2533695|NCT02672943|No Intervention|Normal|30 normal volunteers with age, sex and BMI-match as control group
2533706|NCT02672501|Experimental|anti-CD19-CAR-T cells|patients receive chemotherapy(CF, cyclophosphamide and Fludarabine) on day -6 to day -1, then infusied with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity.
2533758|NCT02672228|Experimental|MalariaSense device|This study will involve the evaluation of a medical diagnostic device. All participants enrolled in the study will be assessed for malaria using MalariSense Technology and will aslo get rapid diagnostic tests (RDTs), microscopy, PCR
3167475|NCT00538811|Active Comparator|2|Interferon alpha, ribavirin, amantadine
3167476|NCT00538928|Experimental|1|Intervention: Implantation of the iLA - adaptation of the ventilation strategy, explantation of the iLA after corresponding improvement (see treatment plan for details) - weaning from the ventilation and extubation according to specified criteria.
3167477|NCT00538928|Active Comparator|2|no device: Ventilation strategy based on the concept of lung-protective ventilation without extracorporeal support, weaning from the ventilation and extubation according to specified criteria (see treatment plan for details).
3167478|NCT00538941|Active Comparator|1|daily intake of 40gr chocolate (Nestlé Noir intense) in the morning and 40gr chocolate in the evening.
3167479|NCT00538941|Placebo Comparator|2|Nestlé Placebo Chocolate 40gr in the morning and 40gr chocolate in the evening.
3167480|NCT00538954|Active Comparator|1|Follow a standard Enhanced Recovery After Surgery protocol
3167481|NCT00538954|Experimental|2|Follow a standard Enhanced Recovery After Surgery protocol and will receive 1 g of Magnesium Oxide laxative twice daily from the day after surgery until discharge
3167482|NCT00538954|Experimental|3|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days
2533093|NCT02676726|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
2533207|NCT02676102|Active Comparator|Control Group|Participant will watch an educational video produced in partnership with the community of black men including customers, employers and owners of BOBs.
2533214|NCT02676102|Active Comparator|Targeted Intervention|Participants will watch an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
2533218|NCT02676102|Active Comparator|Tailored Intervention|Participants will watch videos with content individualized to participant's pre-intervention ODBI scores representing their organ donation beliefs
2533283|NCT02675608||Year 1 Group 1|They are between 18-65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
2533287|NCT02675608||Year 1 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; have no history of immunodeficiency or weakened immunologic function; do not have diabetes; and do not have chronic HIV or hepatitis B or C infection.
2533291|NCT02675608||Year 1 Group 3|They are between 18-65 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2533292|NCT02675608||Year 1 Group 4|They are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2533293|NCT02675608||Year 1 Group 5|They are between 35-50 years of age, meet the criteria listed above for non-diabetic subjects in Group 1, with the exception of chronic HIV with or without hepatitis B or C infection, and have current medical history of CD4 T-cell counts 300-800.
2533294|NCT02675608||Year 2 Group 1|They are between 18-64 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
2533295|NCT02675608||Year 2 Group 2|They are ≥65 years of age, are medically stable and ambulatory; have no active systemic or serious concurrent illness; do not have diabetes.
2533297|NCT02675608||Year 2 Group 3|If they are between 18-64 years of age, are currently diabetic, and meet the criteria listed above for not diabetic subjects in Group 1, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
2533298|NCT02675608||Year 2 Group 4|If they are ≥65 years of age, are currently diabetic, and meet the criteria listed above for non-diabetic subjects in Group 2, with the exception of having pre-diagnosed type-2 diabetes mellitus (e.g., a history of hemoglobin A1C or HbA1C scores of > 6.5%).
3201277|NCT00901693|Placebo Comparator|Vehicle|AL-46383A Ophthalmic Solution Vehicle, 1 drop in each eye, 8 times a day, for 10 days
2533421|NCT02674607|Experimental|patients|thirty children with beta thalassemia major will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
2533424|NCT02674607|No Intervention|controls|thirty healthy children of matched age and sex
2533458|NCT02674347|Experimental|Cohort 1: 3 g or 6 g of Zidebactam|"Cohort 1 (Zidebactam): 3 g of Zidebactam (1 g every 8 hours [q8h]) (n=8) IV infusions administered over 60 minutes.~Cohort 2 (Zidebactam or placebo): 6 g of Zidebactam (2 g q8h) (n=8) IV infusions administered over 60 minutes."
2533462|NCT02674347|Placebo Comparator|Placebo|"Cohort 1: Placebo every 8 hours [q8h] (n=2) IV infusions administered over 60 minutes.~Cohort 2: Placebo every q8h (n=2) IV infusions administered over 60 minutes."
2533572|NCT02673580|Other|Open Access telePRO|Intervention: In open access, contact to the outpatient clinic is initiated by the patient by filling in a PRO questionnaire.
2533576|NCT02673580|Other|Standard telePRO|No intervention: In standard telePRO, outpatient follow-up activity is determined by a clinician and patients receive a questionnaire at fixed intervals.
2533643|NCT02673216||Spontaneous abortion|Women attending for suspected spontaneous abortion
2533645|NCT02673216||Normal pregnant women|Normal pregnant women attending for nuchal translucency scan
2533658|NCT02672774|Other|Gastric cancer|Consecutive patients with gastric cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
2533659|NCT02672774|Other|Colorectal cancer|Consecutive patients with colorectal cancer will be examined using magnification endoscopy with narrow band imaging and probe based confocal laser endomicroscopy.
2533705|NCT02672579||Children 4-7 years|Pediatric subjects between the ages of 4 and 7 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
2533709|NCT02672579||Children 8-17 years|Pediatric subjects between the ages of 8 and 17 who have had pruritus for 6 weeks or longer will complete surveys to assess the severity of pruritus.
2533715|NCT02672579||Parents|Parents of pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of their child's severity of pruritus.
2533724|NCT02672579||Clinicians|Clinicians treating pediatric subjects between the ages of 4-17 years with chronic pruritus (for 6 weeks or longer) will complete surveys to assess their perception of the child's severity of pruritus.
2533766|NCT02672241|Experimental|radio-chemotherapy plus nimotuzumab|Radiotherapy: The total radiation dose is 52.2Gy (1.8Gy fractions). Chemotherapy: Nimotuzumab, given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression. Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation therapy are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles.
2533821|NCT02671851||Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs at the level of T3-T4 with 20 mL bupivacaine 0.375% as an adjunct to general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
2533104|NCT02676635|Experimental|Ergonomics Training Only|Participants in this arm receive Ergonomics training only
2533111|NCT02676635|Experimental|Ergonomics and Safety Voice Training|Participants in this arm receive training on both Ergonomic principles and Safety Voice training
2533115|NCT02676635|No Intervention|Control Group|Participants in this arm will receive no additional Ergonomics or Safety Voice training
2533165|NCT02676336|Active Comparator|Violet™ Iodine|3mg molecular iodine (I2) daily
2533172|NCT02676336|Placebo Comparator|Placebo|3mg placebo daily
2533174|NCT02676336|Active Comparator|Cross-over|Subjects on placebo will be offered 3 months of active post-treatment
3167483|NCT00538954|Experimental|4|Follow a standard Enhanced Recovery After Surgery protocol and will receive preconditioning with carbohydrate and fluid loading prior to surgery (800ml of Nutricia Preop the evening before surgery and 400 the morning of surgery 2 hours prior to anaesthesia) and postoperative nutritional supplements (200 ml Nutricia Fortisip twice daily) after surgery for 30 days and will receive postoperative laxative in the form of 20 ml of Magnesium Oxide twice daily form the day after surgery until discharge
3167484|NCT00538967|No Intervention|1|
2533300|NCT02675530|Experimental|healthy control|Healthy controls will receive electrophysiological assessments before and after NMDA antagonist administration.
2533403|NCT02674802||Retrospective study|People who has successfully eradicated helicobacter pylori more than six months detected helicobacter pylori by the C-urea breath test in order to evaluate the reinfection.
2533406|NCT02674802||Prospective study|People who has infected helicobacter pylori received regular eradication therapy after the 4 weeks, 8 weeks and 6 months detected helicobacter pylori by the C-urea breath test in order to prospect the reinfection .
2533434|NCT02674529|Active Comparator|Antidepressant Treatment|20mg of escitalopram will be taken over an 8-week period, starting with 10mg for the first week.
2533443|NCT02674529|Placebo Comparator|Placebo|A placebo pill will be taken over an 8-week period.
2533507|NCT02674165|Experimental|Intervention|"The pregnancy prevention intervention to be tested is an adaptation of Becoming a Responsible Teen (BART), an evidence-based (proven to work by research) HIV prevention curriculum designed primarily for African American adolescents, ages 14-18, in community-based settings.~The culturally-adapted version HART consists of nine sessions, lasting about 2 hours each, and includes interactive group discussions and role plays that are -performed by adolescents. Unlike BART, one PTSD awareness session has been added to address what happens to people who have been exposed to mental trauma and natural disasters."
2533513|NCT02674165|No Intervention|Control or nutrition|Nutrition/fitness curriculum will teach students about ingredients in food that are good for the body and will keep it in good health
2533581|NCT02673801||Patient referred to orthopedic clinic|Orthopedic assessment in the outpatient clinic as well as a new algorithm (using patient-reported symptoms and radiographic evaluation) will be applied
2533653|NCT02673281|Experimental|Walnut shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
2533654|NCT02673281|Placebo Comparator|Placebo shake|"All subjects will have 2 5-day visits to the BIDMC clinical research center, one where they will receive active milkshake containing 48g of walnuts daily in a single morning meal instead of breakfast, and another where they will receive a placebo milkshake without nuts"
2533672|NCT02672696|Experimental|FluoroMap group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use the FluoroMap 3D reconstruction system (Stryker Inc) with the standard fluoroscopy to help him place the cephalic screw in the femoral head."
2533683|NCT02672696|No Intervention|Test group|"Adult patients with a proximal femoral fracture eligible for intramedullary nailing with a Gamma 3 nail (Stryker Inc).~In this group, the surgeon will use only the standard fluoroscopy to help him visualize the position of the cephalic screw in the femoral head."
2533718|NCT02672475|Experimental|Treatment (Paclitaxel, Galunisertib)|Patients receive Paclitaxel IV on days 1, 8, and 15. Patients also receive GalunisertibPO BID on days 1-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2533785|NCT02672046||Patients with knee injuries|Patients referred to assessment at the Clinic of Sports Injuries
2533846|NCT02671721|No Intervention|Conventional Strategy|Patients will receive usual and prudent PEEP and tidal volume settings.
2533852|NCT02671721|Experimental|Maximal Compliance Strategy|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
2533860|NCT02671721|Experimental|Transpulmonary Pressure Strategy|Personal PEEP titration using transpulmonary pressures obtained from a naso/orogastric tube containing an esophageal balloon port
2533928|NCT02671188|Experimental|GSK3050002 100 mg/mL|Subjects will be administered GSK3050002 intravenously (IV) over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion. On Day 1, loading dose of GSK3050002 10 milligrams per kilogram (mg/kg) will be administered intravenously, followed by maintenance doses of 5mg/kg IV administered at Day 15 and Day 29. Each subject will receive a cumulative dose of 20 mg/kg.
2533934|NCT02671188|Placebo Comparator|Placebo|Subjects will be administered normal saline (0.9% sodium chloride) intravenously over the period of approximately 2 hours on Day 1, Day 15 and Day 29 (total of 3 doses) in a clinical facility with regular monitoring of vital signs. Monitoring of vital signs will continue for a minimum of 2 hours after completion of Infusion.
2533988|NCT02670746||Nab-paclitaxel in combination with gemcitabine (AG)|The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).
2534049|NCT02670278||US-Washington, Idaho|healthy breastfeeding women and their infants
2534053|NCT02670278||US-California|healthy breastfeeding women and their infants
2534056|NCT02670278||Sweden|healthy breastfeeding women and their infants
2534057|NCT02670278||Spain|healthy breastfeeding women and their infants
2533112|NCT02676739|Placebo Comparator|Placebo|Capsule with no active medical ingredients to be taken orally once a day for 12 weeks.
2533117|NCT02676739|Active Comparator|Adderall XR 10mg|10mg Adderall XR capsule to be taken orally once a day for 12 weeks.
2533118|NCT02676739|Active Comparator|Adderall XR 20mg|20mg Adderall XR capsule to be taken orally once a day for 12 weeks.
2533146|NCT02676219|Experimental|RS01|oral care product containing containing sodium monofluorophosphate and sodium fluoride
2533154|NCT02676219|Placebo Comparator|Water|Water
2533190|NCT02676011|Active Comparator|Group A|Intramuscular (IM) atropine (0.01 mg/kg) (1 ml) 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2533198|NCT02676011|Active Comparator|Group B|1 ml normal saline IM 30 minutes before induction of anesthesia, intravenously (IV) atropine (0.01 mg/kg) in 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2533201|NCT02676011|Active Comparator|Group C|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and 1mg/kg atropine mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
2533204|NCT02676011|Placebo Comparator|Group D|IM normal saline 1 ml normal 30 minutes before induction of anesthesia, IV normal saline 10 ml 3 minutes before induction of anesthesia and normal saline mixed with second dose succinylcholine (1mg/kg) in 5 ml syringe with normal saline
3167485|NCT00538967|Active Comparator|2|doxycycline 50 mg/day
3167486|NCT00538967|Active Comparator|3|doxycycline 100 mg
2533349|NCT02675153|Experimental|Upper gastrointestinal strictures|Patients with upper gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
2533352|NCT02675153|Experimental|Lower gastrointestinal strictures|Patients with lower gastrointestinal strictures were treated with rapamycin (2mg/day, Sirolimus, Roche) for at least six months.
2533372|NCT02674763|Experimental|Dose Escalation Schedule A|IMGN779 administered on days 1 and 15 of a 28-day cycle
2533374|NCT02674763|Experimental|Dose Escalation Schedule B|IMGN779 administered on days 1, 8, 15 and 22 of a 28-day cycle
2533378|NCT02674763|Experimental|Dose Escalation Schedule C|IMGN779 administered on days 1 and 8 of a 21-day cycle
2533380|NCT02674763|Experimental|Dose Expansion Cohort|Patients with Relapsed AML; IMGN779 administered at dose and schedule selected as the putative RP2D.
2533497|NCT02674256|Active Comparator|CRH injection|Intervention: intravenous injection of CRH 100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together then the solution will be injected IV over the course of 1 minute
2533505|NCT02674256|Placebo Comparator|placebo injection|"Intervention: intravenous saline injection~1mL of saline will be injected intravenously over the course of 1 minute"
2533593|NCT02673658|Active Comparator|Motor + problem solving|This method focuses on spontaneous movement (rather than facilitated movement). Self-initiated, functionally directed movement is emphasized. Intervention includes guidance and cues, which gently call the child's attention to the support surface, and a set-up of the environment for small increments of movement so that the child can solve a movement problem. Passive movements are not used. Each small increment of movement to advance sitting skill or other motor skills is paired with a specific object or toy that challenges a cognitive concept for spatial problem solving. In this approach, the parent will adjust toys and supports to encourage changes of position from sitting, to transitions in and out of sitting to crawling or standing, but will not assist the child physically.
2533598|NCT02673658|Active Comparator|Body weight support training|In this approach, infants will be supported physically by their parents to take steps, sit, crawl, or reach, in practice sessions focused simply on the motor skill. Toys or problem solving will not be part of this intervention, but the child will be assisted (lifted by the parent) through movement to improve strength and learn specific movements and new positions. The child will be able to perform as much of the movement as possible, but the parents will initiate the activity if the child does not initiate, and the parent will lift the child passively through the task if the child is unable to move.
2533626|NCT02673125|Experimental|Double embryo transfer|Patients with both MitoGrade normal and Mitograde elevated PGS normal embryos will have two embryos replaced- one Mitograde normal and one Mitograde elevated.
2533697|NCT02672878|Experimental|BVS implantation in patients with ISR|
2533779|NCT02672137|Experimental|knowledge translation|knowledge translation 12-month multi-facet intensive knowledge translation measures that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
2533788|NCT02672137|No Intervention|Usual care|no intervention
2533845|NCT02671734|No Intervention|control|Subjects in this arm received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
2533854|NCT02671734|Active Comparator|intervention|Subjects in this arm viewed a video detailing key elements of informed consent. Subjects in this arm also received the standard consent form to read and underwent standard discussions with the procedurist prior to the procedure.
2533891|NCT02671279|Other|Low calorie diet|Dietary intervention group
2533925|NCT02670980|Experimental|Retina Implant|Intelligent Retinal Implant System
2533959|NCT02670681|Active Comparator|Aerobic Exercise Mild Intensity|The subjects engage in aerobic exercise training (8 weeks) of mild intensity (continuous). The intensity is controlled by a corresponding heart rate at anaerobic threshold.
2533960|NCT02670681|Active Comparator|Aerobic Exercise Moderate Intensity|The subjects engage in aerobic exercise training (8 weeks) of moderate intensity (continuous). The intensity is controlled by a corresponding heart rate between anaerobic threshold and respiratory compensation point.
2533961|NCT02670681|Active Comparator|Aerobic Exercise High Intensity|The subjects engage in aerobic exercise (8 weeks) of high intensity interval training. The intensity is controlled by a corresponding heart rate above respiratory compensation point.
3167487|NCT00538967|Active Comparator|4|doxycycline 300 mg
3167488|NCT00538993|Experimental|1|Provider receives cue sheet to assist with counseling.
3167489|NCT00538993|No Intervention|2|Provider does not receive cue sheet.
3167490|NCT00539019||A, observed|measure REE via indirect calorimetry at various time points post burn
2533194|NCT02676024|Experimental|Knowledge-based cognitive aid|"Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. However, they will be trained in using a knowledge-based cognitive aid, which will be used by a dedicated team member (the cognitive aid reader)."
2533200|NCT02676024|Experimental|Cognitive aids with roles defined (CARD)|Resuscitation teams participate in a simulated pediatric cardiac arrest scenario, and provide standard CPR. Participants will be trained to use the cognitive aids with roles defined (CARD) system. However, they will not be given knowledge-based cognitive aids and there will be no dedicated cognitive aid reader in the team.
2533202|NCT02676024|Experimental|Integrated cognitive aids|Participants will be trained to use the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid, which will be used by a dedicated cognitive aid reader.
3201278|NCT00901706|Experimental|CGA plus APS Usual Care|Comprehensive geriatric assessment coupled with Adult Protective Services (APS) usual care for elders with self-neglect.
3201279|NCT00901706|Active Comparator|APS Usual Care|APS usual care consisting of social, medical, and legal interventions.
3201280|NCT00901719|Experimental|Sodium depletion|Subjects will be randomised to normal diet or sodium depleted diet. The sodium depletion protocol comprises of a single oral dose of 40 mg of furosemide followed by an out-patient diet containing >2000 kcal of energy, >60 g of protein, <12 mmol of sodium and <70 mmol of potassium per day for 3 days prior to study. This diet is know to increase the activity of the renin-angiotensin system.
3201281|NCT00901719|Placebo Comparator|Normal diet|Subjects will be randomised to a normal diet, with no restriction on sodium intake during the three days prior to the study.
2533346|NCT02675101|Active Comparator|Whole nuts|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume a combination of whole almonds and walnut pieces, a total of 110 g per day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Walnuts and almonds will be provided to participants for the duration of the study.
2533348|NCT02675101|Experimental|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 18 g olestra/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Fat free Pringles will be provided to participants for the duration of the study.
2533351|NCT02675101|Placebo Comparator|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet by a Registered Dietitian. During the 6-month intervention, study subjects will consume 29 potato crisps per day, which is approximately 17.4 g oil/day. Participants will pick up supplies and be weighed 1-2 times per month for six months. Participants will also maintain a diary of their intake using an automated system. Original Pringles will be provided to participants for the duration of the study.
2533384|NCT02674789|Experimental|Exercise day|Behavioral intervention: 90min bike ergometer test at 70% of VO2max. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
2533389|NCT02674789|No Intervention|Non exercise day (Rest day)|No exercise protocol. Estimating daily variation of magnesium concentration. Blood samples are collected at set time points (08:30, 11:00, 12:30, 13:30, 15:00, 16:00 and 18:30). Blood samples are analyzed on the pHOx analyzer for their ionized magnesium concentration. And on the Dimension Vista 1500 from Siemens for their total magnesium concentration.
2533474|NCT02674555|Experimental|ASP8273|Two Parts - Part A: 14C-radio labeled; Part B: non radio labeled (optional)
2533530|NCT02674035|Active Comparator|Device: 2-0 monofilament nylon suture|Plication of the anterior rectus sheath (correction of diastasis of the rectus abdominis muscles) was performed in two layers with Device 2-0 monofilament nylon suture (control group). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2533532|NCT02674035|Active Comparator|Device: Single layer 2-0 monofilament|Single layer with a Device 2-0 monofilament nylon suture (correction of diastasis of the rectus abdominis muscles) (group I). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2533534|NCT02674035|Active Comparator|Device: Barbed suture Quill Nylon 1|Using a continuous Device Barbed suture Quill Nylon 1 (correction of diastasis of the rectus abdominis muscles) (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
2533556|NCT02673528||Directly underwent TLA|Patients with the diagnosis who underwent directly total laparoscopic appendectomy
2533557|NCT02673528||Lap Assisted App|Patients with the diagnosis of acute appendicitis who underwent a successful laparoscopic assisted appendectomy
2533558|NCT02673528||Advanced to TLA|Patients with the diagnosis of acute appendicitis in whom laparoscopic assisted appendectomy attempted; however, because it fail advanced to total laparoscopic appendectomy.
2533614|NCT02673346||employees|YKHC employees
2533627|NCT02673086|Active Comparator|coracoid approach|Patients in this group will be randomized to receive an coracoid approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2533633|NCT02673086|Active Comparator|retroclavicular approach|Patients in this group will be randomized to receive an retroclavicular approach to Ultrasound Guided Infraclavicular Brachial Plexus Nerve Block .
2533689|NCT02672865|Experimental|HIPEC|The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of the abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.
2533208|NCT02675946|Experimental|CGX1321 alone and with pembrolizumab|"Dose Escalation Phase: Ascending doses of CGX1321 once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle~Dose Expansion Phase: CGX1321, at the MTD (identified in the Dose Escalation Phase), once daily, orally, for 3 weeks (21 days) followed by a one-week (7-day) washout period in each 28-day cycle.~Roll-over Cohort: CGX1321 at a dose identified in Phase 1b, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle).~Phase 1b: Ascending doses of CGX1321, once daily, orally, for 2 weeks (14 days) followed by a one-week (7-day) washout period in combination with pembrolizumab administered IV once every three weeks (in each 21-day cycle)."
2533279|NCT02675478|Experimental|AC220|This study will follow a mCRM (modified continual reassessment method) + EWOC (Escalation with Overdose Control) design.
3201282|NCT00901745|Experimental|Infusion of apelin|Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3201283|NCT00901745|Active Comparator|Sodium nitroprusside infusion|Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
3201284|NCT00901758|Placebo Comparator|2|Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
2533528|NCT02673866|Experimental|DS-1971a 400 mg TID|DS-1971a 400 mg three times per day (TID)
2533531|NCT02673866|Experimental|DS1971a 400 mg BID|DS1971a 400 mg twice per day (BID)
2533533|NCT02673866|Experimental|DS1971a 100 mg BID|DS1971a 100 mg BID
2533535|NCT02673866|Placebo Comparator|Placebo|Placebo
2533536|NCT02673866|Active Comparator|Pregabalin|Pregabalin
3201285|NCT00901758|Active Comparator|1|Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.
2533674|NCT02672917|Experimental|Group C|MVT-5873 is administered in Group C every 4 weeks by intravenous infusion. Each cycle is 28 days. During dose escalation, doses of MVT-5873 will be increased to define the MTD. Up to 30 patients will be treated at the RP2D.
2533686|NCT02672917|Experimental|Group D|MVT-5873 is administered in Group D every 2 weeks by intravenous infusion. During dose escalation, doses of MVT-5873 will be increased to defined he MTD. Up to 30 patients will be treated at the RP2D.
2533691|NCT02672917|Experimental|Group E|MVT-5873 is administered in combination with mFOLFIRINOX every 2 weeks. Both MVT-5873 and mFOLFIRINOX will be administered by intravenous infusion. During dose escalation, doses of MVT-5873, will be increased to define the MTD in combination with mFOLFIRINOX. mFOLFIRINOX will be administered according to institutional standards in compliance with the package insert for each drug. Up to 30 patients will be treated at the RP2D.
2533748|NCT02672319|Experimental|EUS-guided glue injection|Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
2533752|NCT02672319|No Intervention|Historical control|A historical control group of HCC patients with gastroesophageal variceal bleeding who underwent conventional cyanoacrylate injection by OGD for index variceal bleeding based on de-identified data from an existing prospective GI bleed database from 2009-2013 would also be included to allow a more meaningful interpretation of the rebleeding rate from gastroesophageal varices from this study.
2533774|NCT02671994|Experimental|A (experimental group)|Oncologic treatment decision based on G8 screening followed by geriatric assessment and subsequent MDT, if needed, in addition to standard assessment (ECOG Performance Status + clinical assessment).
2533777|NCT02671994|No Intervention|B (control group)|Oncologic treatment decision based on standard assessment (ECOG Performance Status + clinical assessment).
2533836|NCT02671695|Experimental|Group 1|chelation therapy plus Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
2533837|NCT02671695|Experimental|Group 2|chelation therapy plus Amlodipine in a dose of 5 mg/day orally for 3 months
2533895|NCT02671240||- Patients with behavioral addiction|
2533900|NCT02671240||- Patients with no behavioral addiction|
2533927|NCT02670993|Experimental|Control group : Singing sessions.|Patients will participate to singing working sessions. They will continue to take their usual treatments during the study period.
2533932|NCT02670993|Active Comparator|Control group : Painting sessions.|Patients will continue to participate to painting work sessions, and to take their usual treatments during the study.
2533963|NCT02670733||high responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, intracranial pressure (ICP) increases above the median for the study population.
2533967|NCT02670733||low responsiveness of ICP to PEEP|After increasing positive end-expiratory pressure (PEEP) from 5 cmH2O to 15 cmH2O, the level of intracranial pressure (ICP) increases below the median for the study population.
3201286|NCT00901784|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
2534081|NCT02670135|Placebo Comparator|triclosan free toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
2534089|NCT02670135|Active Comparator|Triclosan containing toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
2534127|NCT02669732|Experimental|DS-8500a 75 mg once daily (QD)|tablets, orally, once daily for up to 28 days
3201287|NCT00901784|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
3201288|NCT00901797|Active Comparator|Arthroscopic Bankart repair|
3201289|NCT00901797|Active Comparator|ABR+ARIC|
2533323|NCT02675335|Active Comparator|Sitagliptin|Sitagliptin tablets, 100mg per day, 12 weeks treatment
2533324|NCT02675335|Placebo Comparator|Placebo|Placebo tablets, 1 tablet per day, 12 weeks treatment
2533412|NCT02674932|Experimental|Signature Strengths|"Patients will complete the Values in Action Youth Survey (VIA-Youth) and will receive a list of his/her top character strengths (signature strengths). The patient will then participate in the Identifying and Using Signature Strengths Intervention."
2533413|NCT02674932|Active Comparator|Coping Skills + Memory Aid|Patients will complete the VIA-Youth but will not receive any results. The patient will then participate in the Identifying and Writing Down Coping Skills Intervention.
2533414|NCT02674932|Other|Coping Skills (Treatment as Usual)|Patients will complete the VIA-Youth but will not receive any results. After completing the VIA-Youth, the study team member and patient will have a treatment-as-usual discussion about coping skills. (This is equivalent to treatment as usual that is already provided on the psychiatric unit-doctors and nurses on the unit already have this a discussion about coping skills with patients).
2533437|NCT02674360|Active Comparator|SDM Online Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of a web-based SDM online Training (intervention group I). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The SDM online training works on the modeling principle.
2533447|NCT02674360|Active Comparator|Face-to-Face SDM Training|The intervention consists of a SDM training for oncologists, which is conducted in the form of an individualized, context-based SDM individual face-to-face training at the workplace of the participants (intervention group II). During training, the oncologists are guided to use decision aids for breast and colon cancer patients in their consultations, which were developed and evaluated in a previous project. The SDM training has the same duration (one session à 120 minutes) in both intervention groups. Doctors in the intervention group receive decision aids for breast cancer and colorectal cancer patients during training. The training contents are based on an already developed, evaluated and published SDM manual. The individual training works on the coaching principle.
2533450|NCT02674360|No Intervention|Control Group|The Control Group receives no SDM Training. All participants of the Control Group will be offered to participate in the SDM Online Training after T2.
2533514|NCT02674178|Active Comparator|Age <35|< 35 years old included 201 women who are further subdivided according o FSH/LH ratio into G1A (201 patients) with FSH/LH ratio <2 and G1B (37 patients) with FSH/LH ratio ≥2.
2533518|NCT02674178|Active Comparator|Age ≥ 35|. Group 2 ≥ 35 years old included 34 women who are further subdivided according o FSH/LH ratio into G2A (25 patients) with FSH/LH ratio <2 and G2B (9 patients) with FSH/LH ratio ≥2
2533595|NCT02673697|Experimental|Perceval|The Perceval sutureless aortic heart valve (Perceval valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The Perceval valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
2533597|NCT02673697|Active Comparator|other Stented biological valves|The comparator will be other commercially approved standard biological sutured stented valves, both bovine and porcine. The choice of the comparator tissue valve will be at the discretion of the participating investigators.
2533684|NCT02672826|Experimental|adipose tissue surgery|The adipose tissue surgery (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated.
2533710|NCT02672540|Experimental|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
2533722|NCT02672540|Placebo Comparator|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
2533782|NCT02672150|No Intervention|Control|During the Baseline Control data is collected in all 36 sites at the agency, staff, and youth level on the 6 months prior to the interventions in Arms 2 & 3 to document what practice was before the study.
2533791|NCT02672150|Active Comparator|Core|"In the second phase (after baseline) all 36 sites receive a Core condition that includes five interventions: (1) JJ-TRIALS Orientation Meetings, (2) Needs Assessment, (3) Behavioral Health Training, (4) Site Feedback Report, (5) Goal Achievement Training, (6) Monthly Site Check-ins, and (7) Quarterly Reports. As part of Goal Achievement Training, sites receive assistance in using their Site Feedback Reports to select goals to meet their local needs. Sites are trained on using Data-Driven Decision Making (DDDM) to inform decisions (e.g., selecting a goal, monitoring progress) and enlisting DDDM templates and tools (developed as part of the project) to plan and implement proposed changes.~these principles to their improvement efforts during the implementation phase."
3201290|NCT00901810|Active Comparator|Apex Locator|Working length for cleaning and shaping of the canal is measured by Electronic Apex Locator in this group.
3201291|NCT00901810|Active Comparator|Radiography|Working length for cleaning and shaping of the canal is measured by Radiography in this group.
3201292|NCT00901823|Experimental|Sequence 1|Single dose of low dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
3201293|NCT00901823|Experimental|Sequence 2|Single dose of high dose DCCR followed by a 14 day washout, then re-randomized to either low or high multiple dose DCCR
3201294|NCT00901836|Experimental|Preoperative Proton Therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
3201295|NCT00901836|Active Comparator|Surgery|Standard of care surgery will be performed 4-6 weeks after the completion of radiation.
3201296|NCT00901862|Active Comparator|1 Active PEFs|The pulsed electromagnetic fields were directed to the wrist. The model used has the form of a bracelet called Quantum MH-2MR which uses, as a source of power, an alkaline battery of 1.5 volts connected to an electronic circuit formed by two hybrid circuits of magnetic oscillation and a control system of all the generating frequency system.
2533285|NCT02675621|Active Comparator|Phenolic beverage 2|Mix 3 flavored still beverage with a high dose phenolic extract1 and a fruit extract
2533290|NCT02675621|Active Comparator|Phenolic beverage 3|Mix 4 flavored still beverage with a low dose phenolic extract3 and a fruit extract
2533340|NCT02675205|Active Comparator|clopidogrel-aspirin|clopidogrel: 75mg and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery.
2533341|NCT02675205|Experimental|ticagrelor-aspirin|Ticagrelor: 90 mg bid and aspirin 250 mg once a day for 15 weeks; prescribed 3 weeks before surgery
2533402|NCT02674815|Experimental|Intervention|Patients within this arm will perform two weeks of high intensity interval training prior to colorectal/thoracic surgery. Exercise intensity will be 100% of the peak power output (PPO) during maximal cardiopulmonary exercise testing. Patients will exercise for 15 seconds at 100% PPO and rest for 15 seconds (passive) for 30 minutes or until exhaustion. This will be performed 5 days a week for 2 weeks.
2533436|NCT02674516|Experimental|Anodal stimulation|Participants in the active stimulation group will undergo 3 sessions of anodal bilateral transcranial direct stimulation (tDCS) of the dorsolateral prefrontal cortex (DLPFC) on three consecutive days. tDCS will be delivered by a battery-driven, constant-current stimulator connected to three saline-soaked surface sponge electrodes. Two anodal electrodes (25cm2) will be placed over the DLPFC bilaterally and one cathodal electrode (35cm2) will be placed at the back of the neck. Scalp electrodes will be positioned over the F3 and F4 according to the 10-20 EEG international system. A current of 2mA (1mA at each DLPFC site) will be applied for 20 minutes and the current will be ramped up and down at the beginning and end of the stimulation period.
2533444|NCT02674516|Sham Comparator|Sham stimulation|The sham transcranial direct current stimulation condition will involve the same placement of the electrodes, current intensity, and ramp time as the real tDCS condition, but stimulation will only last for 30 seconds.
2533512|NCT02674191|Experimental|Group 1|Device: mini-plates supported molar intrusion (Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence Procedure/Surgery: Application of ULTRACARE benzocaine 20%, topical anesthesia (Ultradent Products, Inc) Procedure/Surgery: Administration of , Mepivacaine-l local anesthesia Procedure/Surgery: BETADINE povidone-iodine 10% a local disinfectant Drug: (150g Clindamycin/tds) for 1 week Postoperative antibiotic Drug: (Cataflam 25mg), are prescribed post-operatively an analgesic
2533516|NCT02674191|No Intervention|Group 2|hyperdivergent adolescence with no intervention
2533569|NCT02673554|Experimental|Oral glucose tolerance test|An oral glucose challenge (75 g)
2533573|NCT02673554|Active Comparator|GIP Bolus|Hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l) with two repeated intravenous bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
2533583|NCT02673554|Active Comparator|GIP Infusion|Hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
3167491|NCT00539045||A|The study population will consist of patients who are admitted to The New York Presbyterian Hospital-Weill Medical College of Cornell University (NYP-WMC) with ST elevation myocardial infarctions (STEMI). STEMI will be established based on standard clinical and ECG criteria.
3167492|NCT00539071|Active Comparator|Conventional dose|All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks (given as two injections - active 50 mg plus placebo injection).As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 3 unless symptoms warrant a quicker titration) along with the injections.Any oral risperidone the patients receive will be discontinued after Week 4.At Week 6, psychopathology will be assessed with a PANSS. Dose will remain at 50 mg q 2 weeks for those in the conventional Consta dose group.
2533698|NCT02672709|Experimental|Anticoagulation|Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.
2533739|NCT02672371|Experimental|active eMNS|Subjects with receive active eMNS for 20 minutes.
2533744|NCT02672371|Sham Comparator|sham eMNS|Subjects with receive sham eMNS for 20 minutes.
2533989|NCT02670499|Experimental|GAP-FLEX|Study Device will be used up to 6 times per day for up to 6 minutes to aid in the recovery and improve the degree of flexion from TKR
2533991|NCT02670499|Active Comparator|CPM|Control Device will be used up to 2 hours per day for up to 3 times per day to aid in the recovery and improve the degree of flexion from TKR and be compared to the Study Device
2534079|NCT02670096|Experimental|Reference therapy|"Baseline evaluation of subjects without acetazolamide administration~Follow up evaluation of subjects one hour after acetazolamide administration"
2534200|NCT02669381|Other|Experimental: phenylalanine intake|Dietary supplement: phenylalanine intake
2534236|NCT02669108|Other|PET/MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
2534311|NCT02668562|Experimental|Early CABG|Patients to undergo early CABG
2534312|NCT02668562|Active Comparator|Delayed CABG|Patients to undergo delayed CABG
2534318|NCT02668263|Active Comparator|Surgery and Drain|Group 1 will be allocated to receive a drain intra-operatively.
2534322|NCT02668263|Other|Surgery alone|Group 2 will not receive a drain and no further intervention.
2534325|NCT02668263|Experimental|Surgery and quilting sutures|Group 3 will not receive a drain but will receive quilting sutures
2534607|NCT02667041|Experimental|rTMS treatment (Monophasic vs. biphasic)|Safety and efficacy
3167493|NCT00539071|Active Comparator|High Dose group|Those who are randomized to high dose Consta will receive Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose after consent. As advised by the package insert for Consta, oral risperidone will be given (3-4 mg qd x 3 days followed by 6mg qd up to Week 4 unless symptoms warrant a quicker titration) along with the injections. Any oral risperidone the patients receive will be discontinued after Week 4.Psychopathology will be assessed with a PANSS at Week 6. If no improvement since baseline, dose will be increased to two 50 mg injections q 2 weeks for the remainder of the study.
3167494|NCT00539084|Experimental|1|Intradermal injection of Lidocaine followed by a painful stimulus (venipuncture)
3167495|NCT00539084|Placebo Comparator|2|Intradermal injection of placebo followed by a painful stimulus (venipuncture)
3167496|NCT00539097|Experimental|A, treated|treated with Juven po supplement x 3 weeks postop
2533568|NCT02673437||Rivaroxaban group|Patients who have been prescribed rivaroxaban and antiplatelet therapy for the prevention of atherothrombotic events following ACS.
2533570|NCT02673437||Alternative dual antiplatelet therapy|Patients who have been prescribed alternative dual antiplatelet therapy for the secondary prevention of atherothrombotic events following ACS
2533629|NCT02673255|Experimental|Sanofi Pasteur (Tenivac)|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
2533634|NCT02673255|Experimental|MassBiologics|Tetanus and Diphtheria (Td) Vaccine, Manufacturer: MassBiologics, Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration: 5 doses, 1 year.
2533815|NCT02671799|Experimental|VenTouch System Implant|The VenTouch System is indicated for patients who have moderately severe or severe functional mitral regurgitation (grade 3 or 4 MR).
2533833|NCT02671526|Experimental|Computerized Plasticity-based Adaptive Cognitive Training|
2533955|NCT02671006||Patients|Patients with an active Chronic Urticaria according to the EAACI criteria will be included. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
2533956|NCT02671006||Volunteers|Volunteers must no have history of immediate allergy (patients under medical follow up for melanoma in remission for at least 3 months, age (+/- 5 years) and sex matched). Controls should have no history of atopy, urticaria or immediate allergy declared (rhinitis, urticaria, asthma) at the time of the test. The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
2533999|NCT02670616|Experimental|ibrutinib in combination with r-CHOP|Ibrutinib560 mg daily on day 1-21 per each cycle ,Rituximab375 mg/m2, Cyclophosphamide750 mg/m2, doxorubicin 50 mg/m2, vincristine1.4 mg/m2 on day 1; Prednisolone 100mg per day on day 1-5 ,cycle length: 21 days ,Six cycles of treatment
2534078|NCT02670057|Experimental|Transnasal SPG block|
2534138|NCT02669823||Children <15y|no intervention
2534140|NCT02669823||Adults >=15y|no intervention
2534193|NCT02669459|Active Comparator|LLETZ|LLETZ (Large Loop excision of the transformation zone) treatment conform current guidelines, which is also the current gold standard in the Netherlands
2534195|NCT02669459|Other|Imiquimod 5% cream|intervention group
2534434|NCT02667873|Experimental|SL-801|The starting dose regimen of SL-801 (i.e., the dose regimen in Cohort 1) is 5 mg/day on Days 1-4 and 8-11 every 21 days. In the 2nd portion of the dose escalation stage, patients receive SL-801 PO once daily on days 1-2, 8-9, 15-16 and 22-23 of a 28-day cycle. The starting dose will be 70 mg/day (the next planned dose level).The SL-801 dose regimen for a particular patient is dependent on the cohort in which the patient is enrolled
2534496|NCT02667379|Other|Diagnostic skin testing|Diagnostic skin testing with cat dander samples on volar forearms.
2534570|NCT02667054|Active Comparator|Active 4%|One dose of 4mL of RX0041 4% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
2534572|NCT02667054|Placebo Comparator|Placebo|One dose of 4mL of RX0041 placebo for one day in the mucous membrane prior to a diagnostic or surgical procedure.
2534573|NCT02667054|Active Comparator|Active 8%|One dose of 4mL of RX0041 8% for one day in the mucous membrane prior to a diagnostic or surgical procedure.
3167497|NCT00539097|No Intervention|B, control|Usual nutrition therapy received postop
3167498|NCT00539123|Experimental|NCB|Participants receive Physician Management (PM) and non-contingent provision of take-home doses of buprenorphine-naloxone (NCB).
3167499|NCT00539123|Experimental|ACB|Participants receive Physician Management (PM) and abstinence-contingent provision of take-home doses of buprenorphine-naloxone (ACB).
3167500|NCT00539149|Active Comparator|1|
2534736|NCT02665754|Experimental|Active group|In active group, extract of causal allergen will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
2534740|NCT02665754|Placebo Comparator|Placebo group|In placebo group, normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
2535130|NCT02663167|Experimental|Internet-delivered Cognitive-Behavioral Therapy|
3167501|NCT00539149|Placebo Comparator|2|
3167502|NCT00539162|Experimental|CA 125 Analysis|"Participants will have blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers.~Depending on CA-125 level:~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year.~Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR Blood (about 2-3 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks.~Questionnaires completed at baseline and during each follow up visit."
3167503|NCT00539175|Active Comparator|2|active treatment with infrared light
3167504|NCT00539175|Placebo Comparator|1|sham (placebo) treatment without infrared light
3167505|NCT00539227||NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC). Questionnaires taking about 20-30 minutes to complete.
3167506|NCT00539266|Active Comparator|1|non diabetic patients with Fontaine IIb-IV peripheral artery disease
3167507|NCT00539266|Placebo Comparator|2|non diabetic patients with Fontaine IIb-IV peripheral artery disease
3167508|NCT00539266|Active Comparator|3|diabetic patients with Fontaine IIb-IV peripheral artery disease
3167509|NCT00539266|Placebo Comparator|4|diabetic patients with Fontaine IIb-IV peripheral artery disease
3167510|NCT00539292|Experimental|1|Silastic Spring-Loaded Silo
3167511|NCT00539292|Active Comparator|2|Primary Closure of Abdomen
3167512|NCT00539318||GI Cancer|
3167513|NCT00539331|Placebo Comparator|1|Paclitaxel/Carboplatin
3167514|NCT00539331|Experimental|2|Paclitaxel/Carboplatin + AZD2171
3167515|NCT00539344|Experimental|1|
3167516|NCT00539357|Experimental|1|All patients self-administered stimulation for 60 consecutive minutes each day. Participants self-administered the treatment for a period of 6 weeks, 7 days a week between the hours of 15:00 and 19:00. Assessments took place every 2 weeks during the treatment period.
3167517|NCT00539383|Experimental|1|
2533371|NCT02674906|Active Comparator|heparin|A heparinised saline solution of 25,000 IU of heparin per 1 litre of intravenous normal saline (0.9% NaCl) solution is used with a dosage of 20 ml of solution per 100 ml of collected blood. This type of solution is not commercially available and is made locally. This solution is used in the cell salvage process to prevent coagulation.
2533375|NCT02674620|No Intervention|Conservative|Standard conservative care of concussion
2533379|NCT02674620|Experimental|Treadmill|Aerobic exercise treatment for concussion
2533435|NCT02674581|Experimental|Healthy Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2533440|NCT02674581|Experimental|Mild Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2533446|NCT02674581|Experimental|Moderate Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2533452|NCT02674581|Experimental|Severe Renal Impairment Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2533455|NCT02674581|Experimental|End Stage Renal Disease Subjects|A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.
2533502|NCT02674113|Active Comparator|regional anesthesia bupivacaine|regional anesthesia (a single shot fascia iliaca block using bupivacaine) prior to hip arthroscopy
2533508|NCT02674113|Placebo Comparator|regional anesthesia placebo|subcutaneous injection procedure placebo (0.9% sodium chloride in water)
2533579|NCT02673645|No Intervention|Control group|These youth will receive standard mathematics instruction and support, but not the intensive tutoring offered through the intervention.
2533587|NCT02673645|Experimental|SAGA Innovations|These youth will receive the intensive mathematics tutoring by SAGA Innovations, with students randomized to tutors.
3201297|NCT00901862|Sham Comparator|2 Sham|The sham machines were identical to the machines in actual operation in both phases of the study. The only difference was that the hybrid circuits crucial for the generation of the electromagnetic field had been removed.
3201298|NCT00901875|Experimental|Suboxone, maximum 8mg|
2533703|NCT02672670|Experimental|Coping-oriented supportive programme|Coping-oriented supportive programme: education of the SCI disease information, learning from role model by watching a well-established DVD, discussion about how to break down stressors and used appropriate coping strategies (problem-solving training, cognitive re-constructing, relaxation exercises, and activity scheduling) to manage the stressors relating to SCI. Social skills training and ways of maintaining and improving social support will also be discussed and practiced in the COSP.
2533704|NCT02672670|Active Comparator|A didactic group|Usual rehabilitation care--routine inpatient rehabilitation care and brief education in groups (structured by both the rehabilitation nurses and the researcher), which will consist of similar professional contacts as the intervention (COSP) group, and thus can balance between the two study groups for the effect of social contacts and attention to SCI patients during group sessions. The intervention in the comparison group will be conducted by a rehabilitation nurse in the SCI wards. The knowledge/didactic education presented to the patients in the comparison group will be the basic health education and relevant information provided by the rehabilitation nurses in their routine care (mainly including knowledge of SCI, nutritional needs, skin care, bowel and bladder training, and other physical and psychological care of patients with SCI provided by the inpatient rehabilitation wards).
2533803|NCT02672267|Experimental|Stem Cells|Experimental: Stem Cells ALLOGENEIC LOW OXYGEN MESENCHYMAL BONE MARROW CELLS Intervention: Biological: Stem cells
2533809|NCT02672267|Placebo Comparator|Placebo|Lactated Ringer's Solution
2533869|NCT02671591|Experimental|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP. The control condition is a one-hour, theory-based, one-to-one session that will help YBMSM think more about using condoms consistently and correctly with every sex partner.
2533872|NCT02671591|Active Comparator|control|"This condition will include the provision of free condoms and lubricants - selected from a buffet of condoms and lubricants designed to offer men a broad selection of high quality products that can optimize the fit and feel of condoms during sex."
2533970|NCT02670512|Experimental|Telehome Monitoring|Patients in this arm will use the telehome monitoring device (a mobile tablet) to support them with their peritoneal dialysis (communication, treatment tracking, supply tracking, appointment reminders, educational content).
2533972|NCT02670512|No Intervention|Standard of Care|Patients in this arm use the standard of care for peritoneal dialysis, which is simple telephone communication and using pen and paper log to track their treatments and supplies.
3201299|NCT00901875|Experimental|Buprenorphine + naloxone|
3201300|NCT00901875|Experimental|Buprenorphine + naloxone (Suboxone)|
3201301|NCT00901888|Experimental|Angiotensin II infusion|Using forearm venous occlusion plethysmography angiotensin II will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
2534110|NCT02669953||AMD patients previously teated with Lucentis|"Adults ≥ 50 years; Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS; Willingness and ability to comply with regular visits; Signed informed consent form;~The patient can take his medicine in the prescribed manner. The prescribed drugs do not constitute an exclusion criteria."
2534111|NCT02669953||treatment naive AMD patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2534112|NCT02669953||DME patients previously teated with Lucentis|Adults ≥ 50 years; Patients who have been treated with ranibizumab due to DME for up to one year; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2534113|NCT02669953||treatment naive DME patients|Adults ≥ 50 years; Patients who have a BCVA score better than 20/400 in the study eye using ETDRS;
2534152|NCT02669628||Surgical technique|Laparoscopic ovarian cystectomy
2534159|NCT02669628||Alcohol sclerotherapy|US-aspiration and alcohol sclerosis
2534224|NCT02669303|Experimental|platelet-rich plasma group|Autologous platelet-rich plasma subacromial injection
2533409|NCT02674880|Experimental|HMW-HA|HMW-HA (Yabro - 5 ml of saline containing 0.3% hyaluronic acid sodium salt) via nebulizer b.i.d.
2533411|NCT02674880|Placebo Comparator|Placebo|5 ml of saline via nebulizer b.i.d.
3201302|NCT00901888|Active Comparator|Noradrenaline|Using forearm venous occlusion plethysmography noradrenaline will be infused to cause reduction in forearm blood flow. Infusion of apelin and sodium nitroprusside will given and vasodilatation will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
2533519|NCT02673892|Experimental|PODS intervention|The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
2533520|NCT02673892|No Intervention|Usual Care|Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.
2533696|NCT02672722|Experimental|Healthy Test Subjects|We will be using the drug Definity that is an approved medication for cardiac contrast enhanced ultrasound to measure the changes in kidney blood flow with exercise in healthy subjects.
2533733|NCT02672293|Experimental|Phosphate|500 mg of oral phosphate is administered after an overnight fast.
2533793|NCT02672059||Peripheral Neuropathy|Patients with peripheral neuropathy (observational study, no interventions)
2533850|NCT02671669|Active Comparator|Usual Care (UC)|
2533853|NCT02671669|Active Comparator|Movn application (MVN)|
2533888|NCT02671227|Active Comparator|intrathecal bupivacaine + Mg sulfate|intrathecal bupivacaine 15 mg + intrathecal Mg sulfate 50 mg. in gynecologic laparoscopic surgeries.
2533894|NCT02671227|Active Comparator|intrathecal bupivacaine|intrathecal bupivacaine 15 mg in gynecologic laparoscopic surgeries.
2534003|NCT02670694||Rett Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Rett Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2534008|NCT02670694||Angelman's Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Angelman's Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2534015|NCT02670694||Prader-Willi Syndrome|Children and adolescents, age between 0-19 years, with clinical diagnosis of Prader-Willi Syndrome; currently enrolled in the Rare Disease Clinical Research Network registry.
2534023|NCT02670694||Control|Siblings of RTT, AS and PW subjects will serve as control subjects.
2534092|NCT02670148|Experimental|Chiropractic Care (CC)|Participants in the CC group will receive evaluation and treatment (chiropractic manipulative therapy) from a doctor of chiropractic over a 4 week period.
2534101|NCT02670148|No Intervention|Waitlist control group (WC)|Participants allocated to the waitlist control group will not receive any chiropractic treatment during the active study period. These individuals will be scheduled for one additional study visit following allocation. This final study visit will be scheduled 4 weeks after allocation (± 7 days). WC participants are not restricted from receiving any other healthcare during study participation. However, participants in the WC group will be asked not to receive any chiropractic care or spinal manipulation by any other provider during the 4 week intervention period. After WC participants complete the final study visit, they will be offered chiropractic care. This treatment will not be part of the study and no data will be collected at these visits.
2534125|NCT02669745||Women of Chinese Descent|Females of Chinese descent, aged 18 year to 70 year, diagnosed with Stage 1 or Stage 2 (excluding those involving more than 3 lymph nodes) breast cancer.
2534156|NCT02669524|Active Comparator|T2D + OGTT + LY2409021|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
2534166|NCT02669524|Placebo Comparator|T2D + OGTT + placebo|Type 2 diabetes patients + 50 oral glucose tolerance test 4 hours + placebo comparator to the human antagonist of the glucagon receptor.
2534172|NCT02669524|Active Comparator|T2D + IIGI + LY2409021|Type 2 diabetes patients + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
2534175|NCT02669524|Placebo Comparator|T2D + IIGI + placebo|Type 2 diabetes patients + isoglycaemic iv glucose infusion + placebo comparator to the human antagonist of the glucagon receptor.
2534177|NCT02669524|Active Comparator|T2D + MEAL + LY2409021|Type 2 diabetes patients + Standardised liquid meal + the human antagonist of the glucagon receptor.
2534178|NCT02669524|Placebo Comparator|T2D + MEAL + placebo|Type 2 diabetes patients + Standardised liquid meal + placebo comparator to the human antagonist of the glucagon receptor.
2534179|NCT02669524|Active Comparator|CTRL + OGTT + LY2409021|Healthy controls + 50 oral glucose tolerance test 4 hours + the human antagonist of the glucagon receptor.
2534180|NCT02669524|Placebo Comparator|CTRL + OGTT + placebo|Healthy controls + 50 oral glucose tolerance test 4 hours + placebo comparator of the human antagonist of the glucagon receptor.
2534181|NCT02669524|Active Comparator|CTRL + IIGI + LY2409021|Healthy controls + isoglycaemic iv glucose infusion + the human antagonist of the glucagon receptor.
2534184|NCT02669524|Placebo Comparator|CTRL + IIGI + placebo|Healthy controls + isoglycaemic iv glucose infusion + placebo comparator the human antagonist of the glucagon receptor.
2534185|NCT02669524|Active Comparator|CTRL + MEAL + LY2409021|Healthy controls + Standardised liquid meal + the human antagonist of the glucagon receptor.
2534186|NCT02669524|Placebo Comparator|CTRL + MEAL + placebo|Healthy controls + Standardised liquid meal + placebo comparator of the human antagonist of the glucagon receptor.
2533417|NCT02674776|Experimental|HuZhen Capsule|The main elements of HuZhen Capsule include Polygonum cuspidatum, Ligustrum lucidum etc.
2533419|NCT02674776|Placebo Comparator|Placebo Capsule|Placebo appearance, content color and taste should be consistent with HuZhen Capsule.
2533461|NCT02674308||Vedolizumab|
2533465|NCT02674308||Other Biologic Agents|
2533740|NCT02672462|Experimental|Renal denervation|
2533795|NCT02672085|Experimental|PRP infiltration|Supraspinatus interstitial lesion needling and infiltration with PRP
2533805|NCT02672085|Active Comparator|Needling|Supraspinatus interstitial lesion needling and infiltration with NaCl
2533883|NCT02671305|Experimental|placental circulation intact|preterm newborns assisted bedside with placental circulation intact
2533884|NCT02671305|Active Comparator|cord milking|preterm newborns who receive cord milking before assistance performed in a routine setting
3201303|NCT00901914|Placebo Comparator|1|Placebo
3201304|NCT00901914|Experimental|2|12.5 µg rBet v 1
3201305|NCT00901914|Experimental|3|25 µg rBet v 1
2534329|NCT02668237|Experimental|Experimental group|The intervention for this group will be the use of a OptiPAC. A molecular technique and urinary tests will be performed to test a panel of infectious agents : the results will allow the children to benefit from an adapted treatment.
2534335|NCT02668237|Active Comparator|Control Group|The children will benefit from the usual care : an antibiotic prevention treatment.
2534417|NCT02667964|Other|Healthy controls|Spiroergometry
2534420|NCT02667964|Other|Patients with T2DM|Spiroergometry
2534425|NCT02667964|Other|Patients with T1DM|Spiroergometry
2534440|NCT02667613|Experimental|HABIT-ILE|HABIT-ILE (Hand and arm bimanual intensive therapy including lower extremities) will be applied over 2 weeks.
2534441|NCT02667613|Active Comparator|Control|A two weeks period of usual customary care.
2534516|NCT02667366|Experimental|Tel-PT|Tel-PT receives a manualized short-term CBT. Treatment consists of one initial face-to-face appointment and 8-12 subsequent telephone sessions between patient and licensed therapist. Each telephone contact lasts between 20 and 30 minutes and take place on a weekly and later biweekly basis.
2534521|NCT02667366|Active Comparator|TAU and text messages|Control Group receives treatment as usual and additionally weekly text messages containing general information about depression.
2534597|NCT02666872|Experimental|Motivational interviewing on vaccination|An educational strategy based on motivational interviewing of approximately 15 minutes to promote vaccination, in maternity ward.
2534602|NCT02666872|No Intervention|Brochure about vaccines for infants|Parents in the control group only received a brochure about vaccines for infants. This brochure is given to all fathers and mothers giving birth to the CHUS, participating or not at our study.
2534642|NCT02666300|Experimental|TaperGuard ETT|tracheal intubation with the TaperGuard ETT，the ETT cuff is Taper-shangped.
2534689|NCT02666053|Experimental|Treatment A|Single BMS-663068 tablet under fasted conditions
2534690|NCT02666053|Experimental|Treatment B|Single BMS-663068 tablet with a high fat meal
2534691|NCT02666053|Experimental|Treatment C|Single BMS-663068 tablet after a single famotidine tablet under fasted conditions
3201306|NCT00901914|Experimental|4|50 µg rBet v 1
2534775|NCT02665416|Experimental|Part I: Selicrelumab, Vanucizumab/Bevacizumab|Participants will receive a fixed dose of vanucizumab, 2 grams via IV infusion on Days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC in ascending dose levels on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part I of the study (expected 24 months). Due to the discontinuation of Vanucizumab development, Participants ongoing in Part I will switch from Vanucizumab to Bevacizumab. All the dose escalation has been performed using Vanucizumab.
2534778|NCT02665416|Experimental|Part II: Selicrelumab, Bevacizumab|Bevacizumab will be administered via IV infusion on days 1 and 15 of every 28-day cycle. Selicrelumab will be given SC after the Bevacizumab infusion at the dose determined in the Part I of the study on Day 2 of Cycles 1 to 4 and every third cycle thereafter. Treatment will continue as long as the participant experiences clinical benefit or until unacceptable toxicity, withdrawal of consent, or the end of Part II of the study (expected 18 months).
2534907|NCT02664870||Shoulder Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
2534909|NCT02664870||Hip Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy (with or without periacetabular osteotomy (PAO)) or arthroplasty
2534910|NCT02664870||Knee Patients|Patients (1) without evidence of cartilage damage, (2) with molecular change, (3) physiologic change, or (4) with end-stage osteoarthritis, who require arthroscopy or arthroplasty
2534945|NCT02664194|Active Comparator|Control Group|Primary percutaneous coronary intervention only
2534946|NCT02664194|Experimental|03 Hours Hypothermia Group - Proteus® Cooling System|03 hours of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
2534947|NCT02664194|Experimental|01 Hour Hypothermia Group - Proteus® Cooling System|01 hour of intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters using Proteus® Cooling System.
2535005|NCT02663934|Experimental|Exercise (EXS)|All EXS sessions will be at an exercise facility at the WUSTL medical campus. Sessions will be offered weekdays. Each session will start with range of motion exercises. Participants will follow an individualized exercise training prescription based on baseline cardiovascular testing. Individual aerobic exercise intensity is based on % of maximum heart rate achieved during the baseline cardiorespiratory fitness test. The target exercise HR will start at 50% and progress to 85% HR reserve. During aerobic exercise, a battery-operated HR monitor will monitor HR. Exercise intensity & duration will be increased as the participant acclimates to the exercise prescription. Adaptation is determined when a given exercise intensity yields a lower HR than prior sessions conducted at the same intensity.
2533422|NCT02674958|Active Comparator|Aspirin|Aspirin 325mg orally bolus followed by 162mg orally daily during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
2533423|NCT02674958|No Intervention|No aspirin|No aspirin allowed during alcohol septal ablation for hypertrophic obstructive cardiomyopathy until day 7.
2533468|NCT02674282|Experimental|ACL-injured|ACL injured professional soccer players submitted to ACL reconstruction.
2533472|NCT02674282|No Intervention|Control|Healthy professional soccer players
3201307|NCT00901940|Active Comparator|MenACWY Plain Polysaccharide (ACWY Vax)|The MenACWY Plain Polysaccharide Vaccine, which is already licensed and is used as a travel vaccine, is known as the MenACWY plain polysaccharide (ACWY Vax). Participants in this arm will receive 1 dose of the MenACWY plain polysaccharide (ACWY Vax) and 1 dose of the MenACWY conjugate (MenACWY).
3201308|NCT00901940|Active Comparator|MenACWY conjugate|The MenACWY conjugate vaccine was licensed in the UK in March 2010, and is known as the MenACWY conjugate vaccine (Menveo). Participants in this arm will receive 2 doses of the MenACWY conjugate vaccine.
2533771|NCT02672280|Experimental|Medical Collagen Membrane with MSC|Applications of medical collagen membrane with umbilical cord derived mesenchymal stem cells (MSC).
2533772|NCT02672280|Active Comparator|Medical Collagen Membrane|Application of medical collagen membrane only.
2533849|NCT02671552|Experimental|Diagnostic (contrast-enhanced ultrasound)|Patients receive perflutren protein-type A microspheres IV and then undergo contrast-enhanced ultrasound imaging the morning prior to cryosurgery and at 3-4 months post treatment during Magnetic Resonance Imaging (MRI) or computed tomography (CT) follow up.
2533926|NCT02671149|Experimental|Drink water|Participants will receive two 150ml drinks of water during the dehydration protocol
2533933|NCT02671149|No Intervention|Drink nothing|Participants will drink nothing during the dehydration protocol
2533993|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.003 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2533994|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.01 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2533995|NCT02670785|Experimental|Estradiol Vaginal Capsule 0.02 mg|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
2533996|NCT02670785|Placebo Comparator|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
3201309|NCT00901953||1|migrainous vertigo
2534170|NCT02669576|Experimental|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
2534174|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
2534226|NCT02669199|Experimental|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
2534260|NCT02668900|Experimental|Decision support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
2534263|NCT02668900|No Intervention|Usual care|The control group will not receive the decision support intervention prior to consultation with the physician.
2534367|NCT02668588|Experimental|LF-PB 30 mg|extended release of octreotide
2534368|NCT02668588|Placebo Comparator|Placebo|extended release of placebo
2534399|NCT02667925|Experimental|Intervention arm|Patients will receive an intraperitoneal chemotherapy (cisplatin) combined to a radiotracer (nanocis) in order to assess the intraperitoneal distribution of the chemotherapy
3201310|NCT00901953||2|migraine without vertigo
3201311|NCT00901966||Agricultural workers and spouses|Melanoma risk factors among Ag workers and spouses who use pesticides.
2534539|NCT02667158||No shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2534542|NCT02667158||Minimal shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2534543|NCT02667158||Marked shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2534544|NCT02667158||Extensive shopping behavior|Patients will be grouped into one of the categories based on the most recent 18 months of data available at the time the patient sample is identified
2534591|NCT02666794|Active Comparator|Puncture epidural|Women in labor the epidural group will receive epidural bupivacaine with vasoconstrictor 0.125% 10 ml plus 20 micrograms sufentanil, followed by the placement of the epidural catheter
2534596|NCT02666794|Active Comparator|Puncture combined spinal-epidural|The mothers of the combined spinal-epidural analgesia group will receive intrathecal hyperbaric bupivacaine solution 0.5% 2.5 mg plus 5.0 micrograms of sufentanil and plus 60 micrograms of morphine, followed by placement of an epidural catheter to the catheter through technical needle
2534669|NCT02666196|Experimental|DAA-I 6mg|Subjects given solid compound in vials containing 6mg per vial
2534673|NCT02666196|Experimental|DAA-I 50mg|Subjects given solid compound in vials containing 50mg per vial
2534676|NCT02666196|Experimental|DAA-I 110mg|Subjects given solid compound in vials containing 110mg per vial
2534678|NCT02666196|Placebo Comparator|Placebo|Subjects given 25ml placebo dissolved in 200ml water
3201312|NCT00901979|Experimental|LCQ908 Dose 1|
3201313|NCT00901979|Experimental|LCQ908 Dose 2|
3201314|NCT00901979|Experimental|LCQ908 Dose 3|
3201315|NCT00901979|Experimental|LCQ908 Dose 4|
3201316|NCT00901979|Experimental|LCQ908 Dose 5|
3201317|NCT00901979|Placebo Comparator|Placebo|
3201318|NCT00901979|Active Comparator|Sitagliptin|
2533448|NCT02674451|Sham Comparator|Controls|Participants will have routine blood pressure measurements will be obtained.
3201319|NCT00901992|Experimental|MEDIAS 2 ICT|MEDIAS 2 ICT - education program for the initiation of intensive conventional insulin treatment (ICT) in type 2 diabetic patients
2533622|NCT02673242|No Intervention|Control|No treatment other than medical
2533624|NCT02673242|Experimental|Intervention|Inspiratory muscle training
2533707|NCT02672592|Active Comparator|Anakinra|Anakinra//Kineret® 100mg s.c. bid
2533711|NCT02672592|Placebo Comparator|Placebo|Sodium Chloride 0.9% s.c. bid
2533831|NCT02672163|Experimental|AACD-Therapy group|6 patients are recruited to the AADC-therapy group. Autologous atrial appendage derived cells (AADCs) are harvested from the appendage tissue removed during the venal cannulation of bypass. The cells and their extracellular matrix are placed with tissue clue to Cormatrix-sheet and further on top of the myocardium in the area of infarction scar. The procedure is done simultaneously with CABG surgery. The patients will be carefully monitored after the operations and cardiac MRI and echocardiogram will be performed previously to surgery as well as during the follow ups.
2533832|NCT02672163|Active Comparator|Control group|20 patients are recruited to form the control group. They are patients scheduled for elective CABG surgery and they meet the same inclusion and exclusion criteria as the therapy group. There patients are followed as the hospital protocol with out any additional imagination or blood tests.
2533911|NCT02671344||IAD group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation IAD group 'Determination of gene profiles using arrays semen'
2533912|NCT02671344||FIV group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation FIV group of gene profiles using arrays semen'
2533914|NCT02671344||ICSI group|Sperm donors from donation program who have obtained three pregnancies Sperm donors from donation program that have not generated gestation 'Determination of gene profiles using arrays semen'
2533957|NCT02670863|Experimental|Experimental Infant Formula|Experimental Infant Formula containing a prebiotic
2533958|NCT02670863|Active Comparator|Standard Infant Formula|Standard bovine milk-based term infant formula
2534065|NCT02669992|Experimental|Stapled anastomosis|Stapled anastomosis by the use of commercially available linear stapler device
2534068|NCT02669992|Active Comparator|Hand-sewn anastomosis|Hand-sewn by the use of a resorbable monofilament suture
2534069|NCT02669992|Experimental|Abdominal wall mesh closure|Closure by the use of a mesh low-weight net device
2534072|NCT02669992|Active Comparator|Abdominal wall suture closure|Closure by the use of slowly absorbing monofilament suture
2534128|NCT02669719|Experimental|chemotherapy followed dendritic cells|pemetrexed and carboplatin chemotherapy followed dendritic cells infusion from Cycle 3
2534133|NCT02669719|Active Comparator|chemotherapy|pemetrexed and carboplatin chemotherapy only
2534163|NCT02669485|Experimental|ICG|Administering indocyanine green during surgery and the use of ICG fluorescence imaging to assess bowel perfusion during surgery
2534288|NCT02668809|Experimental|Experimental Group 1|consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence.
2534293|NCT02668809|Experimental|Experimental group 2|Consent, oral health assessment, questionnaires, Educational Program, clinical exam, microbiological sampling, monitoring adherence, varnish application
2534297|NCT02668809|Placebo Comparator|Control Group|Consent,clinical exam, microbiological sampling, questionnaires
2534344|NCT02668328|Experimental|Behavioral Intervention|The proposed study involves a 2-phase randomized clinical trial in adults with recently diagnosed T2D. Participants will be randomized to a wait-list Control group, BI, or Tailored-BI. In Phase 1, wait-list Control participants will receive 6 months of standard care; BI and Tailored-BI participants will receive 6 months of Active Intervention. In Phase 2, wait-list Control group participants will cross-over to the delayed Tailored-BI, and the BI and Tailored-BI participants will enter a 6-month observation phase to examine maintenance effects of the intervention.
2534389|NCT02668146|Experimental|perampanel|Perampanel administration
2534400|NCT02668146|Placebo Comparator|placebo|Placebo administered to subjects.
2534445|NCT02667717|Experimental|Experimental group : Mirror Therapy|Experimental group will perform mirror therapies during 16 weeks, added to the usual care. Therapy mirror sessions will take place at hospital units but also at home.
2534452|NCT02667717|Active Comparator|Control group : Usual care|The control group will benefit from the usual care during 16 weeks. No mirror therapies will be performed to this group.
2534517|NCT02667314|Experimental|Jigsaw Puzzle Group|Jigsaw puzzles & Cognitive health counseling
2534520|NCT02667314|Active Comparator|Cognitive Health Counseling Group|Cognitive health counseling only
2534578|NCT02666859|Experimental|Unilateral Transradial Amputation|This group includes people with a unilateral transradial amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
2534580|NCT02666859|Experimental|Unilateral Transhumeral Amputation|This group includes people with a unilateral transhumeral amputation. Potential subjects must use a body-powered or myoelectric prosthetic device. This group will be exposed to virtual reality therapy and non-virtual reality therapy.
2533582|NCT02673502|Experimental|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
2533588|NCT02673502|Experimental|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery.
2533618|NCT02673177|Experimental|Robot-assisted total mesorectal excision|Robot-assisted total mesorectal excision (RTME) for rectal cancer. Two different RTME procedures were chose to personalized patients. Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
2533620|NCT02673177|Active Comparator|Laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed. The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
2533664|NCT02673008|Experimental|MRD-directed DLI|For patients with MRD+ and without grade II/>II aGVHD by day +60 post-transplantation, DLI was given once by day +60 and was then administered based on MRD and GVHD status. If patients were MRD negative, DLI was not given again; if patients were MRD positive and without GVHD, DLI was given monthly until GVHD occurred or MRD became negative or for a total of four times. For patients with NR or PR pre-transplantation and with MRD negative by day +60 post-transplantation, DLI was given once by day +90 regardless of MRD, and was then administered when MRD became positive. For patients with CR pre-transplantation and with MRD negative post-transplantation, DLI was not given unless MRD became positive.
2533716|NCT02672566|Experimental|Experimental group : enoxaparin|Experimental group will take enoxaparin (4000 Ui / Day) and will benefit from the usual care.
2533723|NCT02672566|Active Comparator|Control group|The control group will only benefit from the usual care.
2533773|NCT02672007|Other|Included patients|All included patients will have respiratory rates measured by a research assistant using a criterion standard approach, by the SensiumVitals device and by the ward staff.
2533858|NCT02671773||BTS Step 2 Asthmatic patients|Group of 20 asthmatic patients on British Thoracic Society (BTS) treatment step 2 - regular low dose inhaled corticosteroids (dose of <400 micrograms/day BDP equivalent)
2533862|NCT02671773||BTS Step 4 Asthmatic patients on treatment with fluticasone|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled fluticasone (dose of >500 micrograms/day)
2533864|NCT02671773||BTS Step 4 Asthmatic patients on treatment with budesonide|Group of 15 asthmatic patients on British Thoracic Society (BTS) treatment step 4 - high dose inhaled budesonide (dose of >800 micrograms/day)
2533920|NCT02671110|Experimental|Transforming Your Life|The TYL program emphasized: 1) helping participants develop and maintain healthy habits and disrupt unhealthy habits, 2) enabling participants to create a personal food and exercise environment that increases exposure to healthy eating and physical activity and encourages automatic responding to goal-related cues, and 3) facilitating participants' weight loss motivation.
2533921|NCT02671110|Active Comparator|Diabetes Prevention program|The DPP recommends that participants set a weight loss reduction goal of 7% or more of their baseline body weight, reduce consumption of high fat foods as a means to reduce caloric intake, and engage in brisk walking or other moderate intensity physical activity for 150 minutes per week. Sessions include information on changing energy intake and energy output through diet and exercise, and addressing psychological, social, environmental, and motivational challenges to health behavior change.
3201320|NCT00901992|Active Comparator|Current ICT program (ACC)|This education program consists of 10 lessons combining an insulin education program with an hypertension program
3201321|NCT00902005||Rheumatic patients|"Three groups:~RA patients: 30 starting on Methotrexate, 30 starting on combination of Methotrexate and TNFalpha inhibitor.~PSA patients: 20 starting on Methotrexate, 20 starting on combination of Methotrexate and TNFalpha inhibitor.~AS patients: 20 starting on TNFalpha inhibitor"
2534109|NCT02669966|Experimental|Study Arm|Donor candidates with their intended recipients who meet criteria will be enrolled into this, the sole arm of our study. Donor-recipient pairs will be screened to meet criteria, and will proceed to kidney transplantation and post-transplant monitoring
2534160|NCT02669654|Experimental|Day-care management of Severe Pneumonia|management in Day-care clinic
2534171|NCT02669654|No Intervention|Existing Treatment Centre (ETC)|Severe Pneumonia management in Existing Treatment Centre
2534229|NCT02669238|Experimental|Implant|Subcutaneous insertion of an progestative implant containing 68mg of etonogestrel
2534235|NCT02669238|Active Comparator|Oral treatment|Continuous oral administration of second generation monophasic oestro-progestative (ethinyl-oestradiol)
2534267|NCT02668835||Cohort 1|Idiopathic Parkinson's Disease as defined by the UK brain bank criteria and history of resting tremor.
2534271|NCT02668835||Cohort 2|Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist
2534313|NCT02668536|Experimental|UV Filter + BNP|A UV filtering agent and bioadhesive nanoparticles (BNPs) will comprise the experimental condition in this study. Participants will have 5 sites on their torso where they will have these placed.
2534316|NCT02668536|Sham Comparator|BNP only|A placebo bioadhesive nanoparticles (BNPs) (strips with no UV filtering) will comprise the sham comparison in this study. Participants will have 5 sites on their torso where they will have these placed.
2534320|NCT02668536|Active Comparator|Standard|As the active comparator, participants will have 5 sites on their torso where they will have standard sunscreen applied.
2534324|NCT02668536|No Intervention|Control|Participants will have 5 sites on their torso where no agent will be applied.
2534398|NCT02668159|Experimental|Fish peptide|
2534408|NCT02668159|Experimental|Vitamin D|
2534410|NCT02668159|Experimental|Fish peptide + Vitamin D|
2534411|NCT02668159|Placebo Comparator|Control|
2534442|NCT02667600||Cesarean Section Group|Patients undergoing cesarean section
3201322|NCT00902031|Experimental|Docusate + Sennoside|
3201323|NCT00902031|Placebo Comparator|Sennoside + Placebo|
2533669|NCT02672982|Experimental|new combined NUTPSY treatment|2-month combined nutrition and psychosocial intervention
2533680|NCT02672982|Active Comparator|standard NUT treatment|2-month of standard nutritional treatment only
2533781|NCT02671864|Other|1: incretin-based therapy|Patients with incretin-based therapy
2533787|NCT02671864|Other|2: other antidiabetic|Patients with other antidiabetic
2533841|NCT02671630|No Intervention|Control group|Patients receive only usual hospital care
2533844|NCT02671630|Experimental|Experimental group|Patients receive only usual hospital care and community-based computerized cognitive training program
2533890|NCT02671292|Experimental|Interpersonal Psychotherapy (IPT-WG)|IPT-WG targets the difficult social functioning and stressful events that are associated with loss of control eating and that are highly relevant to the adolescent children of military personnel.
2533897|NCT02671292|Active Comparator|Health Education (HE)|HE improves knowledge on various health topics including, alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence.
3201328|NCT00902057|Active Comparator|desmopressin 1.5|
3201329|NCT00902057|Active Comparator|desmopressin 3|
3201330|NCT00902057|Active Comparator|desmopressin 15|
2534130|NCT02669797|Experimental|EMI|EMI (Arm 1): (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; and (2) a 8-week maintenance phase with EMI tips delivered on high stress days.
2534134|NCT02669797|Experimental|EMI + HV|"EMI + HV (Arm 2) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) a 8-week maintenance phase with EMI tips delivered on high stress days."
2534135|NCT02669797|Experimental|EMI + HV + Video feedback|"EMI + HV + Video Feedback (Arm 3) includes: (1) tailored ecological momentary intervention (EMI) prompts sent to parents targeting momentary behaviors (e.g., stress) around family meal quality and quantity for 16 weeks; (2) bi-weekly in-home educational visits (total of 8) with a community health worker (CHW) focusing on family meal quality (i.e., dietary quality, interpersonal quality) and quantity (i.e., frequency of family meals), and 8 weeks Try it Yourself activities that reinforce the messages and skills taught by a CHW (for a total of 16 weeks); (3) video feedback on a video-taped family meal delivered every other week during the in-home visit with the CHW; (4) a 8-week maintenance phase with EMI tips delivered on high stress days."
3201331|NCT00902057|Placebo Comparator|placebo|
3201332|NCT00902070||1|Patients to whom Eslax has been administered to relax muscles at the time of anesthesia or tracheal intubation
3201333|NCT00902083|Experimental|surgery plus p53 gene|using p53 gene therapy before surgery
2534261|NCT02668666|Experimental|Investigational Treatment|"71 subjects will be enrolled to determine progression-free survival (PFS) in subjects with HR(+)/HER2(-) advanced breast cancer who have not received prior systemic anti-cancer therapies.~Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.~Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously)."
2534347|NCT02668406||Burkholderia pseudomallei|Patients for whom blood cultures grew Burkholderia pseudomallei
2534357|NCT02668406||No pathogen|Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis
2534363|NCT02668406||Another pathogen|Patients for whom blood cultures grew another pathogen
3201334|NCT00902083|Active Comparator|surgery alone|Surgery without pre-p53 gene therapy
3201335|NCT00902083|Experimental|p53 plus chemotherapy|p53 gene therapy with concurrent chemotherapy
2534498|NCT02667470|Experimental|Solifenacin|
3201336|NCT00902083|Experimental|p53 gene therapy alone|Intra-tumor injectio of rAd-p53 gene with no concurrent treatment
3201337|NCT00902096||Prenatal factors|Prenatal factors to predict cord blood IgE
3201338|NCT00902109||perimetry, HRT, OCT|perimetry, HRT, OCT
3201339|NCT00902122|Experimental|1|Five times of p53 gene intratumoral injection are given before surgery,then radical surgery will be conducted.
3201340|NCT00902122|Active Comparator|2|surgery
3201341|NCT00902122|Experimental|3|p53 gene therapy
3201342|NCT00902122|Active Comparator|4|p53 gene therapy plus radioactive iodine
3201343|NCT00902135||Group 1|
3201344|NCT00902135||Group 2|
3201345|NCT00902135||Group 3|
3201346|NCT00902148|No Intervention|Control Group|Colorectal Surgery without use of SurgiWrapTM
3201347|NCT00902148|Active Comparator|Test Group|Colorectal Surgery with use of SurgiWrapTM film secured directly below the abdominal incision
3201348|NCT00902187|Other|Reference|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Zwickau (Reference)
3201349|NCT00902187|Other|Test|fesoterodine (Toviaz™ 4 mg) tablet manufactured at Vega Baja (Test)
3201350|NCT00902200|Placebo Comparator|Vehicle|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3201351|NCT00902200|Experimental|AR-12286 0.05%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3201352|NCT00902200|Experimental|AR-12286 0.1%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
3201353|NCT00902200|Experimental|AR-12286 0.25%|q.d. (AM) x 7 days, then q.d. (PM) x 7 days, then b.i.d. x 7 days.
2533663|NCT02673021|Experimental|Microwave Ablation|Microwave Ablation
2533714|NCT02672605|No Intervention|Control|Participant completes a survey measuring abortion stigma prior to receiving the mandatory Pennsylvania State consent for their abortion.
2533719|NCT02672605|Experimental|Investigational|Participant completes a survey measuring abortion stigma after receiving the mandatory Pennsylvania State consent for their abortion.
2533783|NCT02672254||Shams|Samples without any type of treatment
2533792|NCT02672254||Samples with 1 treatment|These samples will be treated with only one therapy: chemical agents such as cisplatin or other metallic compounds, or with superficial radiotherapy. These results will help us understand the effectiveness of each treatment by itself on cSCC cells.
2533802|NCT02672254||Samples with 2 treatments|These samples will be treated with both, chemical agents followed by superficial radiotherapy. These results will provide us information concerning the effectiveness of both treatments, wich is expected to be enhanced by the concomitant effects.
2533874|NCT02671747|Experimental|Pilot workshop|Participants attend intervention. No control arm
2533922|NCT02671058|Active Comparator|Cortenema|Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.
2533923|NCT02671058|Experimental|Hydrocortisone acetate|Hydrocortisone acetate suppository 90 mg administered rectally as a single dose with the Sephure Rectal Suppository Applicator
2534006|NCT02670772|Active Comparator|Stavudine|Stavudine 20mg twice daily for 96 weeks
2534013|NCT02670772|Active Comparator|Tenofovir Disoproxil Fumarate|Tenofovir 300mg once daily for 96 weeks
2534084|NCT02670109|Experimental|Unique|"Patients will receive a high dose chemotherapy regimen, consisting in the administration of three medications: Carmustine (BCNU) 300mg/m2 or Busulfan 16 mg/kg (according to availability), Cyclophosphamide 80mg/kg, and Carboplatin 1400/m2.~Then they will undergo an Autologous Hematopoietic Stem Cell Transplantation."
2534157|NCT02669589|Active Comparator|heparin anticoagulation|"Systemic anticoagulation of the continuous renal replacement therapy with heparin.~Dose will be titrated to maintain aPTT (activated partial thromboplastin time) between 45-60s)"
2534164|NCT02669589|Experimental|citrate anticoagulation|"Regional anticoagulation of the continuous renal replacement therapy with citrate.~Target posthemofilter ionized calcium level: 0.25-0.35 mmol/l"
2534221|NCT02669056|Experimental|preterm babies|preterm babies (less than 28 weeks)
2534225|NCT02669056|Other|term babies|term babies with blood test prescription
2534278|NCT02668705|No Intervention|Human RA|A sham research informed consent form will be explained by a research assistant
2534283|NCT02668705|Experimental|ECA|A sham research informed consent form will be explained by an ECA (embodied conversational agent as presented on a touch screen computer)
2534291|NCT02668705|Experimental|ECA + Human RA|A sham research informed consent form will be explained by an ECA and then questions will be answered by a research assistant
2534354|NCT02668523|Experimental|Raindrop|A single arm study to evaluate the effectiveness of a 2mm Raindrop Near Vision Inlay for the treatment of presbyopia in pseudophakic subjects. This corneal inlay is placed under a LASIK flap or in a corneal pocket, and is designed to change the anterior curvature of the cornea, resulting in the ability to reduce spectacle dependency for near and intermediate tasks.
2534381|NCT02667899|Active Comparator|DBS group|Besides routine treatment, Doc patients in this group will accepted deep brain stimulation treatment.
2534384|NCT02667899|Active Comparator|TMS group|Besides routine treatment, Doc patients in this group will accepted transcranial magnetic stimulation treatment.
2534394|NCT02667899|Placebo Comparator|Control group|This Doc patients will accepted routine treatment.
2534436|NCT02667665||Alzheimer's Disease Dementia|
2534438|NCT02667665||non-Dementia|
2534505|NCT02667483|Experimental|DS-5141b|"DS-5141b, Subcutaneous injection~Part 1: DS-5141b will be injected subcutaneously once a week for 2 weeks at the following dose levels. Dose escalation will be performed. DS-5141b will be administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Level 1: 0.1 mg/kg~Level 2: 0.5 mg/kg~Level 3: 2.0 mg/kg~Level 4: 6.0 mg/kg~Part 2: Two doses of DS-5141b will be selected based on the results obtained in Part 1. Each selected dose will be administered subcutaneously once a week for 12 weeks.~Part 2-Extension: Two doses, 2.0 mg/kg or 6.0 mg/kg, of DS-5141b will be administered subcutaneously once a week for 48 weeks."
2534554|NCT02666976|Experimental|ilaprazole group|ilaprazole 20mg once daily for 4 weeks.
2534567|NCT02666703|Experimental|Study (CytoSorb)|In the study group (20 patients) the CytoSorb filter will be installed in the CPB in a parallel circuit. An additional roller pump will drive the blood through the filter with a constant flow of 400 ml/min (max flow).
2534569|NCT02666703|No Intervention|Control|In the control group (20 patients) no filter will be installed on the CPB.
2534571|NCT02666703|Active Comparator|Corticosteroid|In the corticosteroid group (20 patients), 1 gram of methylprednisolone will be added in the priming solution of CPB machine. No filter will be installed on the CPB.
2534666|NCT02666274||RK Group|participants colonised with Klebsiella spp. resistant to either 3GC or carbapenems (RK cohort of index carriers of Resistant Klebsiella)
2534714|NCT02665923||Newborn (gastric emptying)|A total of 50 healthy newborns who will be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying. Follow up of these newborns at two later time intervals will be performed (between ages 4-6 months, and 9-12 months).
3201354|NCT00902213|No Intervention|Minimal movement|Minimal movement group with usual care non-intervention.
3201355|NCT00902213|Active Comparator|Physical Therapy|
3201356|NCT00902252|Experimental|Usual/Natura®/Vitala™|All subjects will wear usual product for 21 days, followed by Natura® for 14 days and followed by Vitala™ for 159 days.
3201357|NCT00902291|Active Comparator|1. Gemcitabine monotherapy|
3201358|NCT00902291|Experimental|2. Gemcitabine plus AGS-1C4D4|
2533635|NCT02673073|Experimental|Intervention_Diary|All patients will receive patient's information/education booklet on the heart failure including life style modification. In addition, patients also receive a patient's diary for self-recording of 6 parameters: body weight, blood pressure, heart rate, number of remaining pills, degree of pitting edema, and degree of dyspnea.
2533668|NCT02672839|Experimental|Period 1 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
2533678|NCT02672839|Experimental|Period 1 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
2533687|NCT02672839|Experimental|Period 2 Treatment A|Healthy subjects will receive a single dose orally of LGD-6972 capsules fasted
2533692|NCT02672839|Experimental|Period 2 Treatment B|Healthy subjects will receive a single dose orally of LGD-6972 solution fasted
2533731|NCT02672345||Sevoflurane Group|Group of patients receiving sevorane during extracorporeal circulation period.
2533734|NCT02672345||Not Sevoflurane Group|Group of patients who did not receive the sevorane during extracorporeal circulation period.
2533780|NCT02672098|Experimental|HIPEC|A procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
2533915|NCT02671019|Experimental|Internet-based treatment|A five-module Internet-based treatment program for harmful alcohol use (including therapist support) based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
2533916|NCT02671019|Active Comparator|Face-to-face treatment|Same treatment content as in the Internet-based treatment delivered via face-to-face treatment sessions in specialized addiction treatment.
2534022|NCT02670850|No Intervention|Control group|Patients received only routine hospital care
2534027|NCT02670850|Experimental|Intervention group|Patients received regular hospital routine care and model-based intervention program
2534094|NCT02670252|Experimental|BUCY|For standard-risk ALL undergoing HLA-matched allo-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2534100|NCT02670252|Active Comparator|TBICY|For standard-risk ALL undergoing HLA-matched allo-HSCT，TBICY conditioning regimen was 4.5 Gy TBI/day on days -5 and -4；CY 60 mg/kg/day on days -3 and -2.
3201359|NCT00902317|Active Comparator|Boston Scientific|The PolarCath peripheral balloon catheter (CryoVascular Systems, Inc., Los Gatos, CA) is a novel angioplasty system that simultaneously dilates and cools the plaque and vessel wall in the area of treatment. Cooling is achieved by inflating the balloon with nitrous oxide rather than the usual saline/contrast mixture.
2534298|NCT02668978|Experimental|Hemopatch™|Hemopatch™ sealing hemostat
2534300|NCT02668978|Active Comparator|Control|Standard surgical technique
2534332|NCT02668445|Experimental|Low carbohydrate|Subjects will eat a low carbohydrate diet
2534355|NCT02668445|Experimental|High carbohydrate|Subjects will eat a high carbohydrate diet
2534416|NCT02668120||Cases|Patients with chronic histiocytic intervillositis during pregnancy followed at University Hospital of Lille. Alkaline phosphatase assay was performed during pregnancy and is documented in the medical record. The cases are included retrospectively.
2534419|NCT02668120||Low-risk pregnancy|Patients with a low risk pregnancy followed at University Hospital of Lille and recruited prospectively in prenatal consultation. These patients have no pathological obstetric history.
2534424|NCT02668120||High-risk pregnancy|Patients with severe pregnancy complication (IUGR, Preeclampsia or Death in Utero), but without chronic intervillositis, and hospitalized in the maternal-fetal pathology department of the University Hospital of Lille. They are recruited prospectively.
3201360|NCT00902317|Active Comparator|Spectranetics|The excimer laser has unique properties that make it ideally suited to debulk atheromatous and thrombotic arterial blockages. LASER is an acronym for Light Amplification by Stimulated Emission of Radiation. However, there are many types of lasers, each distinguished by the wavelength of the emitted light, the effective power of the light beam, and whether the light is pulsed (like a flashbulb) or continuous (like a light bulb). The effectiveness of a given laser for intraarterial applications depends on how the light interacts with tissue inside an artery.
3201361|NCT00902317|Active Comparator|Fox Hollow|"The SilverHawk peripheral catheter system and cutter driver (FoxHollow Technologies, Redwood City, CA) are designed for the treatment of de novo and restenotic atherosclerotic lesions located in the native peripheral arteries. The catheter consists of a flexible shaft designed to track over a 0.014 guidewire. At the distal end of the catheter is a small cutting assembly comprised of a rotating inner blade contained within a tubular housing. The proximal end of the catheter contains a connector and Positioning Lever designed to fit into a small, disposable, battery-driven Cutter Driver which powers the device."
2534535|NCT02667119|Experimental|Prolonged Exposure + Contingency Management|Standard services plus Prolonged Exposure and Contingency Management
2534540|NCT02667119|Active Comparator|Standard Care|Standard substance abuse treatment services
2534598|NCT02666807|Experimental|Ginger|Ginger (Zingiber officinale Roscoe) 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
2534603|NCT02666807|Placebo Comparator|Placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks Placebo twice daily
2534735|NCT02665715|Experimental|Low carbohydrate/Standard carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
2534738|NCT02665715|Experimental|Standard carbohydrate/Low carbohydrate|10 Roux-en-Y gastric bypass operated subjects are tested two days with mixed-meal tests. Each studytest day consist of both breakfast and lunch.
3201362|NCT00902317|Active Comparator|WL Gore|Viabahn Endoprosthesis (W.L. Gore & Associates, Flagstaff, AZ) is a flexible self-expanding endoluminal device consisting of expanded polytetrafluoroethylene (ePTFE) lining with an external Nitinol (NiTi=Nickel:Titanium) support extending along its entire length. The device is compressed and attached to a catheter delivery system. The Gore Viabahn Endoprosthesis is available in a wide range of diameters and lengths.
2533637|NCT02673151|Experimental|Diagnostic (68Ga-PSMA-11 PET/CT)|Patients receive gallium Ga 68-labeled PSMA-11. Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA 11 Beginning 50-100 minutes later, a low dose CT will be obtained from vertex to mid thighs; followed by a static PET emission scan over the same .
2533717|NCT02672436|Experimental|ENERGI-F703|ENERGI-F703, topical application, 2 times daily for 12 weeks
2533725|NCT02672436|Placebo Comparator|Placebo|ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks
3201363|NCT00902317|Placebo Comparator|Control Group, Guidant|Balloon angioplasty is a treatment that uses a catheter with a tiny balloon mounted on the end. The balloon is positioned through the narrowing/blockage in your leg artery, and then it is inflated to push the narrowing apart and restore a channel for blood flow. The balloon is then deflated and removed from your body. A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface. The FDA has approved the use of certain stents for the treatment of narrowing in the leg arteries. Stents have been widely used in various parts of the body, including blocked blood vessels in the arms, legs, heart (coronary arteries), and kidneys (renal arteries).
3201364|NCT00902343|Experimental|1|nomogram-based selection for acute normovolemic hemodilution
2533851|NCT02671565||Hyaluronic acid (HA) injection users|Patients with at least one procedure claim for intra-articular administration of hyaluronic acid (procedure codes: J7320, J7322, J7325, Q4084, J7317, Q4083, J7321, Q4085, J7323, Q4086, J7324, J7327, J7326) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as HA users.
2533857|NCT02671565||Corticosteroids (CS) injections users|Patients with at least one procedure claim for intra-articular administration of corticosteroids (procedure codes: J1020, J1030, J1040, J1094, J1100, J2920, J2930, J0702, J0704, J3300, J3301, J3302, J3303, J1700, J1710, J1720, J2650, J2920, J2930) within 90 days after their first specialist (physical medicine, physical therapy, orthopedic surgeon, rheumatologist or orthopedic) visit will be considered as CS users.
2533863|NCT02671565||HA non-users|Patients who do not have any claims for procedural or surgical intervention including HA and CS injections in first 90 days after their first specialist visit will be considered as HA non-users
2533924|NCT02671162|Placebo Comparator|Wheat|Placebo capsule/ 2 capsule 3 times per day
2533931|NCT02671162|Active Comparator|Fumaria|Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.
2533990|NCT02670759|Experimental|Paravertebral analgesia|A paravertebral nerve block will be performed under ultrasound guidance by the anaesthesiologist prior to the induction of general anesthesia. A catheter will be inserted and a continuous infusion of bupivacaine will be administered.
2533992|NCT02670759|Active Comparator|Intercostal analgesia|An intercostal nerve block using a single dose of bupivacaine will be performed by the surgeon at the end of surgery before skin closure.
2534029|NCT02670317|Experimental|G CHOP 21 + Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
2534076|NCT02669979|Experimental|Intervention|"Intervention in the research groups is professional oral care with tooth brush, ordinary fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month."
2534082|NCT02669979|No Intervention|Control|Care as usual. Common oral hygiene help administered by nursing staff.
2534122|NCT02669810|Experimental|PROTHERACYTES|The interventional investigators will perform the ProtheraCytes® cardiac injections using a catheter introduced via the femoral route up to the left ventricle cavity for intraventricular injections (Helix/Biocardia) or a catheter introduced via the femoral / radial route up to coronary arteries for epicardiac injections (BullFrog/Mercator).
2534124|NCT02669810|Active Comparator|Standard of Care|Patients will be treated as standard treatment for CHF post - AMI.
2534187|NCT02669446||Ectoin containing Lozenges|treatment with Ectoin containing lozenges
2534190|NCT02669446||Hyaluronic acid containing lozenges|treatment with hyaluronic acid containing lozenges
2534191|NCT02669446||Saline solution for gargling|Subjects in were requested to gargle with salt water
2534214|NCT02669134|Active Comparator|SonR optimization|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
2534216|NCT02669134|Placebo Comparator|Fixed settings|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming device programming: sensed AV delay of 125 ms, VV delay of 0 ms (simultaneous); SonR CRT Optimization programmed Off)."
3201365|NCT00902343|Active Comparator|2|standard selection for ANH based on a planned resection of 3 or more segments.
3201366|NCT00902356|Active Comparator|B|Six female subjects in each of cohorts 1 to 5 will receive AMG 167; six male subjects in each of cohorts 6 and 8; three female subjects in each of cohorts 7 and 9.
2534336|NCT02668289|Other|interventional|consent, screening, xrays, PVS impressions, photographs, CBCT, anesthesia, extraction, clinical measurements
2534385|NCT02667938|Experimental|Treatment 1|HCP1303 capsule 5/0.2mg + HCP1303 capsule 5/0.4mg placebo+ HGP1201 placebo
2534393|NCT02667938|Experimental|Treatment 2|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg + HGP1201 placebo
2534405|NCT02667938|Active Comparator|Active Comparator|HCP1303 capsule 5/0.2mg placebo+ HCP1303 capsule 5/0.4mg placebo+ HGP1201
2534447|NCT02667574|Other|open-label|Enrolled patients will receive continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg per administration (in accordance with the product SmPC). One cycle of therapy will be defined as 28 days of treatment. The treatment will be renewed once a month depending on the product tolerance
3201367|NCT00902356|Placebo Comparator|A|Two female subjects in each of cohorts 1 to 5 will receive placebo; two male subjects in each of cohorts 6 and 8; and 1 female subject in each of cohorts 7 and 9.
3201368|NCT00902369|Experimental|AK106-001616|
2534599|NCT02666651|Experimental|Test group|Administration of oral tolvaptan (15-60mg PO titration) during admission for decompensated heart failure
3201369|NCT00902369|Placebo Comparator|Placebo|Part1: AK106-001616 and Placebo
3201370|NCT00902369|Active Comparator|Active comparator|Part2: AK106-001616 and Active comparator
2533652|NCT02673047||Botox®|Patients prescribed botulinum toxin Type A (Botox®) injection for the treatment of urinary incontinence associated with neurogenic detrusor overactivity or overactive bladder as per standard of care in clinical practice.
2533746|NCT02672306|Experimental|UCMSCs|Subjects with Alzheimer's Disease Intervention: UCMSCs
2533750|NCT02672306|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Placebo (normal saline)
2533786|NCT02671968|Experimental|CGM group|
2533797|NCT02671968|No Intervention|Control group|
2533861|NCT02671539|Experimental|open label injection of rAAV2.REP1|This is an open label, single arm interventional trial with subretinal injection of rAAV2.REP1 and fellow eye comparison
3201371|NCT00902382||1|Infertile women who conceive spontaneously
3201372|NCT00902382||2|Infertile women who conceive on various ovulation stimulation medications
3201373|NCT00902395|Active Comparator|Midazolam|Oral midazolam
3201374|NCT00902395|Experimental|Midazolam/ketamine|Combined midazolam and ketamine
3201375|NCT00902395|Other|Protective stabilization|No drug or placebo administered
2534188|NCT02669472|Experimental|F&V Intervention|Housing complexes randomized to the intervention arm received a multicomponent intervention comprised of a year-round, discount, mobile fresh fruit and vegetable market ('Fresh To You') that was paired with nutrition education interventions including educational newsletters, recipe cards, campaigns, taste-testings and videos in both English and Spanish.
2534189|NCT02669472|Experimental|Control Intervention|Housing complexes randomized to the comparison arm received a year-long intervention on physical activity and stress reduction including educational campaigns and materials in both English and Spanish.and a YMCA membership for those who joined the campaigns.
2534217|NCT02669160|Experimental|Experimental|Group of communicating CP children receiving a 30 minutes daily session of verticalization with a motorized orthosis reproducing walking movement (PS Innowalk)
2534222|NCT02669160|Other|Control|Group of communicating CP children receiving a 30 minutes daily session of verticalization with their conventional passive stander.
3201376|NCT00902408|Experimental|Lutein|Lutein enriched eggs
3201377|NCT00902408|Placebo Comparator|Placebo|Non enriched
2534314|NCT02668315|Experimental|Cohort 1|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 1.0-4.9 x 10E5/kg and TNC superior or equal to 2.0 x 10E7/kg
2534317|NCT02668315|Experimental|Cohort 2|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.5-4.9 x 10E5/kg and TNC superior or equal to 1.5 x 10E7/kg
2534321|NCT02668315|Experimental|Cohort 3|Intervention name: Transplantation of cord blood expanded with UM171 Prethaw CB cell count prior to manipulation: CD34+ cell count 0.25-4.9 x 10E5/kg and TNC superior or equal to 1.25 x 10E7/kg
3201378|NCT00902421|Active Comparator|Antimuscarinics|
3201379|NCT00902421|Experimental|Selective serotonin reuptake inhibitors|Selective serotonin reuptake inhibitor
2534545|NCT02667080|Active Comparator|Ejaculate 1|Semen sample after 2-7 days of sexual abstinence
2534546|NCT02667080|Active Comparator|Ejaculate 2|Semen sample after 2 hours of sexual abstinence
2534733|NCT02666014|Active Comparator|Sugammadex group|"Sugammadex 2 mg/Kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation.~The drug is to be diluted with normal saline to make up to 5 ml volume to maintain blinding."
2534737|NCT02666014|Active Comparator|Neostigmine group|"Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg, diluted in normal saline to make up 5 ml total volume to maintain blinding.~Neostigmine 0.040 mg/Kg, along with Atropine 0.015 mg/kg will be administrated as a single dose via intravenous injection upon completion of surgery and guided by peripheral nerve stimulation for reversal of neuromuscular blockade produced during surgery.~Atropine sulfate-diphenoxylate hydrochloride combination will be an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered."
2534807|NCT02665390|Experimental|treatment|Patients who are medically inoperable peripheral lung cancer will enroll in this study.They will receive percutaneous cryoablation and follow-up according to schedule.
3201380|NCT00902447||Human Blood Cell Disorders|Human Blood Cell Disorders Tissue Bank
3201381|NCT00902460|Experimental|Treatment Sequence 1|
3201382|NCT00902460|Experimental|Treatment Sequence 2|
3201383|NCT00902473|Experimental|1|25 mg Topiramate tablets of Ranbaxy Laboratories, Ltd
2534911|NCT02664545|Experimental|Bridge-Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to grow into.
2534913|NCT02664545|Active Comparator|Tendon Graft|ACL reconstruction is when a tendon graft (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee) is taken and used to replace the torn ACL.
2535033|NCT02663596|Experimental|Vancomycin|Patients with vancomycin mixed in the CRRT solution(s)
3201384|NCT00902473|Active Comparator|2|(Topamax®) 25 mg Topiramate tablets of Ortho-McNeil Pharmaceutical, Inc. New jersey 08869
3201385|NCT00902499||NC|Normal older controls, not cognitively impaired; MMSE 27-30 and performance above education adjusted cutoff scores on the Logical Memory II subscale (LM-II Delayed Paragraph Recall) of the Wechsler Memory Scale
3201386|NCT00902499||vMCI|Very mild cognitive impairment; less severe objective memory deficit, scoring .5 to 1.5 S.D. (standard deviation) below education adjusted norms on the LM-II
3201387|NCT00902499||sMCI|significant mild cognitive impairment; objective cut off of 1.5 S.D. level below education adjusted norms on the LM-II
3201388|NCT00902499||AD|Mild Alzheimer's disease; meet NINCDS/ADRDA criteria for probable AD with mild dementia severity (CDR Total = 1), MMSE 20-26
3201389|NCT00902512|Active Comparator|Treatment A|Viagra® 100 mg tablet, administered with water
3201390|NCT00902512|Active Comparator|Treatment B|Sildenafil 100 mg CT administered with water
2533666|NCT02672761|Experimental|MBSR|Subjects enrol and complete a standardized and licensed meditation program developed by Jon Kabat-Zinn. The program includes a weekly 200 min group session, daily meditation training from 20-40 min and one 4 h retreat within the study period. The individual daily and overall training volume is noted in min.
2533670|NCT02672761|Experimental|MBT|Subjects while being on the waiting list for MBSR are allocated to a web-based training program (MBT- My Brain Training) for working, episodic and general memory functions. The individual daily and overall training volume is noted in min.
2533681|NCT02672761|Active Comparator|Wellness|Subjects while being on the waiting list for MBSR are allocated to a free accessable wellness program including sessions in a computerized chair delivering Shiatzu massage and relaxation music. The individual daily and overall training volume is noted in min.
2533690|NCT02672761|Placebo Comparator|Control|Subjects while being on the waiting list for MBSR are requested to do no special program for stress reduction or memory improvement. The individual daily and overall training volume of sports or recreational activity is noted in min.
2533736|NCT02672358|Experimental|Dabrafenib +Trametinib|Oral Dabrafenib plus Oral Trametinib
2533776|NCT02672020|Experimental|patients with adrenal tumor|
3201391|NCT00902512|Active Comparator|Treatment C|Sildenafil 100 mg CT administered without water
2534010|NCT02670577||stage I or II HR-positive, HER2-negative|"Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive & HER2 negative~& Axillary lymph node status: 0-3 involved"
2534018|NCT02670577||HER2+|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative or positive~& HER2 positive~& Axillary lymph node status: 0-1 involved"
2534025|NCT02670577||Triple Negative|"Histologically proven invasive T1a or T1b breast cancer~& Hormone receptor negative~& HER2 negative~& Axillary lymph node status: 0-1 involved"
2534028|NCT02670577||Neoadjuvant|Stage I or II patients receiving neoadjuvant therapy.
2534066|NCT02670031||Newly Diagnosed Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2534071|NCT02670031||Well-Controlled Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2534073|NCT02670031||Resistant Essential Hypertension|Patients will undergo the following studying procedures: electrocardiogram, echocardiogram, cardiovascular magnetic resonance imaging and 24-hr ambulatory blood pressure monitoring.
2534165|NCT02669602||No intervention|No Intervention
2534211|NCT02669342|Active Comparator|Group A: Sharklet Catheter for 2 weeks first|"Arm A will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks"
2534212|NCT02669342|Active Comparator|Group B: Sharklet Catheter for 4 weeks first|"Arm B will have catheters inserted according to the schedule below:~Sharklet catheter inserted for 4 weeks~Standard catheter inserted for 4 weeks~Sharklet catheter inserted for 2 weeks~Standard catheter inserted for 2 weeks"
3201392|NCT00902525|Experimental|90Y-Ibritumomab Tiuxetan double dose|90Y-Ibritumomab Tiuxetan administered at 0.4 mCi/kg at phase 2 and then at 0.2 mCi/kg at phase 3
3201393|NCT00902551||1|Subjects underwent cervical sample DNA image cytometry
3201394|NCT00902551||2|Subjects underwent cervical sample conventional cytology
2534497|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 1|Low FODMAP Oral Nutrition Supplement
2534500|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 2|Low FODMAP Oral Nutrition Supplement
2534504|NCT02667184|Experimental|Low FODMAP Oral Nutrition Supplement 3|Low FODMAP Oral Nutrition Supplement
2534507|NCT02667184|Experimental|FOS Supplement|Supplement containing fructooligosaccharides
3201395|NCT00902590||1|Patients with urothelial cancer
3201396|NCT00902590||2|unrelated adults accompanying patients to clinic
2534672|NCT02666144||Glaucoma|
2534674|NCT02666144||Normal|
2534716|NCT02665845|Experimental|5-ASA group|Patients will receive corticosteroids with optimized 5-ASA.
2534721|NCT02665845|Active Comparator|Control group|Patients will receive corticosteroids alone.
2534819|NCT02665403|Experimental|play intervention|30 minutes of hospital play interventions
2534822|NCT02665403|Placebo Comparator|control|usual care
2534854|NCT02664818||Heart failure|Hospitalized patients with primary discharge diagnosis of heart failure and who were aged 18 years or older.
2534902|NCT02664623|Experimental|Dietary advice sheet|"Patients in this arm will receive a dietary advice sheet at the beginning of the study.~Intervention: Dietary advice sheet"
2534903|NCT02664623|Experimental|Dietary advice sheet + consults with dietician|"In addition to receiving a dietary advice sheet at the beginning of the study, patients randomized to this arm will have individual consultations with a dietician at inclusion, month 1 and month 3.~Intervention: Dietary advice sheet Intervention: Individual dietary consultations"
3201397|NCT00902603||1|Patients with WHO Group I pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3 months.
3201398|NCT00902616|Active Comparator|1. L-arginine|3 gm TDS for 3 months
3201399|NCT00902616|Placebo Comparator|2. Placebo - Lactose powder|3 gm TDS for 3 months
3201400|NCT00902629|Experimental|Intervention|Intervention group contains the patients randomized for early treatment of their epiretinal fibrosis.
3201401|NCT00902629|No Intervention|Control|Control contains patients not randomized for early surgery.
3201402|NCT00902642|No Intervention|control group|
3201403|NCT00902642|Active Comparator|Course on psychosocial factors|an eight day university training course for physical therapists designed to integrating psychosocial factors in clinical practice on a patient level
3201404|NCT00902655|Experimental|Desmopressin|
3201405|NCT00902681|Other|Reference|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Zwickau
3201406|NCT00902681|Other|Test|a single dose of 8 mg fesoterodine (Toviaz™ 8 mg) tablet manufactured at Vega Baja (Test)
3201407|NCT00902694|Experimental|ACHIEVE Intervention|Group and individual weight counseling and group physical activity classes for 18 months.
2533693|NCT02672969|No Intervention|no smoke evacuation uses|No smoke evacuation uses means using only the regular electrosurgical unit during coagulation and cutting surgery. (Control group)
2533708|NCT02672449|Experimental|External beam radiotherapy|A total of 65 consecutive newly diagnosed prostate cancer patients with 2013 NCCN high risk category will be consecutively enrolled in a prospective phase II trial on Carbon Ions Boost Followed by Pelvic Photon Radiotherapy .
2533755|NCT02672202|Active Comparator|Duloxetine|Treatment
2533756|NCT02672202|Active Comparator|Pregabalin|Treatment
2533760|NCT02672202|Placebo Comparator|Placebo|
3201408|NCT00902694|Other|Control|Control arm receives group health classes quarterly with topics not related to weight
3201409|NCT00902707|Experimental|Mucinex 1200mg|Pill
3201410|NCT00902707|Placebo Comparator|Placebo|Pill
2533973|NCT02670876|Experimental|Anti-bullying intervention|An anti-bullying intervention target to perpetrators of school bullying was conducted. The program consisted of 8 sessions over 4 weeks and was conducted by a board-certified psychiatrist and a therapist with previous training in psychosocial treatments. The intervention was based on cognitive-behavioral therapy (CBT) principles and addressed various factors that have been associated with perpetrators of school bullying, including impulse control, perspective taking (empathy), and the enhancement of communication skills.
2534067|NCT02670018|Active Comparator|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets
2534070|NCT02670018|Experimental|C|Combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets
2534117|NCT02669888|Experimental|Indigo naturalis ointment|"Form: ointment~Dose: each gram of ointment contains 200µg of indirubin~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
2534118|NCT02669888|Placebo Comparator|Placebo|"Form: ointment~Dose: vehicle~Dosing schedule: apply 0.5g of ointment per 10 x 10 dermatitis lesion twice daily"
2534145|NCT02669537|Experimental|GOPRO resident|Residents will use the gopro during a vaginal procedure, review the case with the attending after, and perform a 2nd case of the same type. The VVSI and GRS will be used to assess any changes in surgical skill
2534148|NCT02669537|No Intervention|Control Resident|Residents will use standard surgical education practices, direct instruction from attending, surgical atlas, online videos. They will perform 2 cases of the same type and the difference in VVSI and GRS will be assessed
2534151|NCT02669537|Experimental|GOPRO medical student|Medical students will be allowed to watch the surgery on an iPad with the GoPro app. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
2534161|NCT02669537|No Intervention|Control Medical Student|Medical students will be taught using standard practices, i.e instruction by residents/attendings. Their assessment of the educational value of the surgery will be assessed at the end of the procedure. They will also take a pre and post-test focusing on surgical instruments and steps used in the procedure.
2534238|NCT02669368|Active Comparator|Standard dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.6 mg/kg at induction of anesthesia.
2534243|NCT02669368|Active Comparator|Low dose Rocuronium|Pretreatment of saline 100ml then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
2534246|NCT02669368|Active Comparator|Low dose Rocuronium + Magnesium Sulfate|Pretreatment of Magnesium sulfate 30 mg/kg then giving Rocuronium 0.45 mg/kg at induction of anesthesia.
2534258|NCT02668718|Other|Adjuvant radiotherapy|Patients who were randomized to adjuvant radiotherapy following radical prostatectomy
2534262|NCT02668718|No Intervention|Watchful waiting|Patients who were randomized to watchful waiting following radical prostatectomy
2534333|NCT02668601||GDM Exposed|Children exposed to gestational diabetes in utero
2534352|NCT02668601||Non-GDM Exposed|Children not exposed to gestational diabetes in utero
2534404|NCT02668172|Experimental|Pasireotide LAR 60 mg monotherapy week 12|"After enrollment, acromegaly patients on combination treatment will half their regular weekly dose of pegvisomant (PEGV) for 12 weeks (run-in period).~When insuline-like growth factor 1 (IGF-I) remains within the age adjusted normal limits after 12 weeks, PEGV and the LA-SSA (Octreotide Long Acting Release (LAR) or Lanreotide Autogel) with Pegvisomant (PEGV) are discontinued and patients are switched to pasireotide LAR 60 mg for 12 weeks."
2534409|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 12|When IGF-I rises above the adjusted normal limits after 12 weeks (run-in period), these subjects will switch their LA-SSA to Pasireotide LAR 60 mg every 4 weeks and continue with the reduced PEGV dose of the run-in period, for the remaining 12 weeks.
2534413|NCT02668172|Experimental|Pasireotide LAR 60 mg and Pegvisomant week 24|"Between week 12 and 24 dose adaptations of PEGV are not permitted unless IGF-I drops below the age adjusted normal limits, then the dose of PEGV will be decreased stepwise with 20 mg weekly until IGF-I is within the age adjusted normal limits.~At week 24, efficacy will be assessed, as the number of patients with a normal IGF-I in the two different groups; the combination Pasireotide LAR 60 mg / PEG V dose and monotherapy Pasireotide LAR 60 mg.~From week 24 patients will continue with Pasireotide LAR 60 mg monotherapy, or Pasireotide LAR will be combined with 50% of the original dose of PEGV, or with an increasing dose of PEGV every 8 weeks depending on the treatment arm."
2534466|NCT02667561|Experimental|Testosterone gel 1% 2.2 mg|Testosterone gel 1% Topical use 2.2 mg (220 mg of gel) once daily duration of treatment: 28 days
2534469|NCT02667561|Experimental|Testosterone gel 1% 4.4 mg|Testosterone gel 1% Topical use 4.4 mg (440 mg of gel) once daily duration of treatment: 28 days
2534472|NCT02667561|Experimental|Testosterone gel 1% 8.8 mg|Testosterone gel 1% Topical use 8.8 mg (880 mg of gel) once daily duration of treatment: 28 days
2534474|NCT02667561|Placebo Comparator|Placebo of Testosterone Gel 1%|Placebo of Testosterone Gel 1% Topical use Approximately 550 mg of gel Once daily duration of treatment: 28 days
2534568|NCT02666729||AF Ablation Procedure|Patients with AF who are schedule for a first time pulmonary vein isolation (PVI) for AF using the TactiCath catheter. Patients will have four pulmonary veins ablated during procedure. The researcher will perform AF Ablation with contact force information on two veins. The research will perform AF Ablation without contact force information on the other two veins.
2533694|NCT02672956|Experimental|Infraumbilical group|Umbilical port will be insert to infra umbilical area.
3201411|NCT00902720|Experimental|Cryopreservation|The ovarian tissue is frozen and banked at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
3201412|NCT00902759|No Intervention|Usual Care Group|"Participants randomized to the usual care group will be encouraged to return to their usual or pre-surgical levels of activity. Usual care of post-surgical PC and peri-ampullary patients typically includes encouragement to walk and be active as they can be by the surgeons, surgical nurses and the nurse practitioners. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry. The usual care group will perform a baseline walk. Participants in the usual care group will not receive an individual Exercise Prescription at the time of entry nor will they will a telephone call every month. Repeat questionnaires will be performed at 6 months."
3201413|NCT00902759|Experimental|Walking Program|Participants in the intervention arm will participate in a walking program consisting of a 6 week graduated walking program. There are three phases to the walking program, Phase 1 is Warm-up, Phase 2 is Brisk Walking and Phase 3 is Cool Down. Phase 1 is the same for all 6 weeks, and consists of a slow 5 minute walk. In Months 1 and 2, Phase 2 is a 10 minute brisk walk. In Months 3 and 4, Phase 2 is a 20 minute brisk walk. In Months 5 and 6, Phase 2 is a 25 - 30 minute brisk walk. Phase 3 is the same for all 6 weeks and consists of a 5 minute rest/cool down period.
2533820|NCT02671838|Other|Musculoskeletal ultrasound program|Participants will receive the musculoskeletal ultrasound program
2533825|NCT02671838|No Intervention|Control|Participants will not be receiving the musculoskeletal ultrasound program.
2533829|NCT02671487|Experimental|Mind-Body Skills Groups|Mind-body skills groups will be administered for 2 hours once a week for 10 weeks and then once a month for 10 months.
2533830|NCT02671487|No Intervention|Wait List Control|No intervention will be administered. Students will have the opportunity to receive the intervention at the end of the study.
2533867|NCT02671396|Experimental|Virtual reality based intervention|Virtual reality based balance training
2533870|NCT02671396|Active Comparator|Conventional intervention|Conventional balance training
2533946|NCT02671097|Experimental|BAY1841788 (ODM-201) + Rosuvastatin|All subjects will receive a single dose BAY1841788 (ODM-201) (600 mg) followed by multiple doses BAY1841788 (ODM-201) (600 mg BID) as well as 2 times a single dose rosuvastatin (5 mg), once alone and once in combination with BAY1841788 (ODM-201).
2533983|NCT02670655|Experimental|Group A (short-time iontophoresis group)|Group A was treated with iontophoresis-assisted AFL-PDT with a short incubation time (2 h)
2533985|NCT02670655|Active Comparator|Group B (short-time conventional group)|Group B was treated with conventional AFL-PDT with a short incubation time (2 h)
2533987|NCT02670655|Active Comparator|Group C (long-time conventional group)|Group C was treated with conventional AFL-PDT with a standard incubation time (3 h)
2534035|NCT02670291|Active Comparator|active cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); active cTBS (80% of RMT);
2534038|NCT02670291|Sham Comparator|Sham cTBS|Determination of resting motor threshold (RMT); Coil position: temporoparietal cortices halfway between T3/P3 and T4/P4 (EEG 10/20 system); sham cTBS;
2534074|NCT02670070|Active Comparator|Coadministration of G+R|Coadministration of gemigliptin 50mg and rosuvastatin 20mg
2534075|NCT02670070|Experimental|Combination G/R|Combination of gemigliptin 50mg / rosuvastatin 20mg
3201414|NCT00902772|Placebo Comparator|A|Placebo
3201415|NCT00902772|Active Comparator|B|Lorazepam
2534255|NCT02669004|Active Comparator|Intermittent bolus epidural morphine|"Patients who received epidural morphine with patient- controlled intermittent bolus epidural analgesia (PCIEA) represented Group 1. Epidural catheter was inserted by surgeon under direct visualization at the midpoint of the incision and advanced 5-6 cm cephalad to thoracic 4-5 before surgical closure.~Patients received morphine 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion."
2534256|NCT02669004|Active Comparator|Continuous epidural morphine|epidural morphine with patient- controlled continuous epidural analgesia (PCCEA) represented Group 2. Infusion the following initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
2534341|NCT02668614|Experimental|WR-22 model microwave sensor|
3201416|NCT00902772|Active Comparator|C|Lorazepam
2534484|NCT02667444|Experimental|SB204 4%|SB204 4% topically once daily
2534486|NCT02667444|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
2534576|NCT02667028||patients receiving PCI|patients receiving percutaneous coronary intervention(PCI)
2534665|NCT02666443|Placebo Comparator|Control (C)|Control intervention (no dexamethasone)
2534667|NCT02666443|Experimental|Peri-neural (N)|Peri-neural Dexamethasone 1 mg
2534668|NCT02666443|Experimental|Intravenous|Intravenous Dexamethasone 1 mg
3201417|NCT00902772|Active Comparator|D|Lorazepam
3201418|NCT00902772|Experimental|E|AZD7325
3201419|NCT00902772|Experimental|F|AZD7325
2534815|NCT02665169|Experimental|Exercise intervention group|Supervised exercise intervention of 12 months. One Taiji and one gym training per week for first six months followed by 6 months free independent use of municipal facilities, including gym, swimming hall and weight room. Written and oral health counselling provided.
2534817|NCT02665169|Active Comparator|Control group|Control group, without any induced exercise intervention. Written and oral health counselling provided.
2534856|NCT02664792|Experimental|Diagnosis or suspicion of non-small cell lung carcinoma|SUS patients with diagnosis or suspicion of non-small cell lung carcinoma with an indication for mediastinoscopy
3201420|NCT00902772|Experimental|G|AZD7325
3201421|NCT00902785||no drug|no drug
2534979|NCT02664168|Active Comparator|Aquacel Ag Surgical Dressing|
2534981|NCT02664168|Active Comparator|Single-Use Negative Pressure Wound Therapy (PICO)|
2533699|NCT02672943|Active Comparator|treatment group|The Rehabilitation treatment group will receive rehabilitation training once per day, 3 days per week, for 12 weeks. The duration of each session is about 1 hour. Participants will first receive relaxation exercises, positioning and self-stretch exercises (emphasizing on spinal mobility and flexor muscle groups of limbs and trunk) for 15 minutes. Then they will have balance training for 20 minutes. The investigators will use goal-directed tasks, such as different types of ball games, for balance training. At the end, participants will receive walking exercise for 20 minutes, and cool down exercises for 5 minutes.
2533700|NCT02672943|Sham Comparator|non-treatment group|The group will not receive non-rehabilitation treatment, before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
2533742|NCT02672332|Experimental|SB204 4%|SB204 4% topically once daily
2533747|NCT02672332|Placebo Comparator|Vehicle Gel|Vehicle Gel topically once daily
2533817|NCT02671825|Experimental|PUR0217a|PUR0200 formulation 1
2533818|NCT02671825|Experimental|PUR0228a|PUR0200 formulation 2
2533822|NCT02671825|Experimental|PUR0228b|PUR0200 formulation 3
2533824|NCT02671825|Experimental|PUR0228c|PUR0200 formulation 4
2533826|NCT02671825|Experimental|PUR0230c|PUR0200 formulation 5
2533827|NCT02671825|Active Comparator|Reference Product 1|Reference Product formulation with active charcoal
2533828|NCT02671825|Active Comparator|Reference Product 2|Reference Product without active charcoal
2533838|NCT02671448||Homebound After Stem Cell Transplantation|The primary research outputs and measurements are the instruments/surveys, assessments, and video diaries to be completed by the patients, their caregivers and the healthcare providers during the time of the home transplantation care.
2533936|NCT02671175|Active Comparator|dihydroartemisinin-piperaquine|dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
2533938|NCT02671175|Placebo Comparator|dihydroartemisinin-piperaquine Placebo|Placebo comparator (matching tablets containing no active ingredients)
2534000|NCT02670603|Experimental|Experimental arm|In experimental arm, each patient painted EVONAIL® solution on nails and periungual areas once a day till developing onycholysis grade 2 or more.
2534005|NCT02670603|Other|Control arm|"In control arm, each patient painted EVONAIL® solution on nails and periungual area twice a day after developing onycholysis grade 2.~This study design allowed cross-over. Therefore, this control arm would give EVONAIL® solution after developing onlycholysis grade 2 in spite of control arm."
2534077|NCT02670200|Experimental|intervention arm / verum arm|Participants can work on ten modules specialized cognitive behavior treatments to learn and deal with mindfulness, acceptance and commitment. They should learn to handle their emotions, to accept the situation and to get in an active future. The participants can direct contact a psychotherapist via email, Chat or Skype/tokbox. The modules based on Cognitive Behavior Therapy.
2534091|NCT02670200|Active Comparator|non-intervention arm / control group|Participants can work on six modules with information und education goals for learning something about their possibilities to become a better mood, better psychovegetative or psychosocial situation as cancer patient. This modules are based on Cognitive Behavior Therapy. The non-intervention arm will only allow contact to the platform, no direct contact to a psychotherapist (in opposite to the intervention arm) is available.
2534131|NCT02669771||Enzalutamide group|oral
2534274|NCT02668679|Active Comparator|Children and their parents with the presence of Dream Doctors|The DD will use various methods for entertaining the child and alleviate stress . The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
2534277|NCT02668679|Placebo Comparator|Children and their parents without the presence of DD|No DD during the gastroscopy. The parents and the children will be given anxiety and satisfaction questionnaires. The children and parents will perform Pre-Pulse inhibition (PPI) test and GSR. In addition, stress hormones will be assessed (cortisol, epinephrine, and norepinephrine) and the following physical indices will be measured: blood pressure, pulse, saturation and body temperature. The amount of drugs given for deep sedation will be evaluated.
2534340|NCT02668367|Active Comparator|BTA-C585 oral capsules|100 mg capsules; Multiple ascending doses (MAD) from 100 mg to 600 mg
2534349|NCT02668367|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
2534379|NCT02668042|Experimental|liveness tissue skin|
2534456|NCT02667808||Focus Group|Participants with HIV and receiving antiretroviral therapy (ART) will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
2534457|NCT02667808||Questionnaire|Participants with HIV will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
2534511|NCT02667340|Experimental|Superstarch|Supplementation with Superstarch before a simulated soccer game
2534518|NCT02667340|Placebo Comparator|Placebo|Supplementation with placebo before simulated soccer game.
2534559|NCT02666898|Experimental|Obinutuzumab and Ibrutinib CLL treatment|"3 parts~PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:~GA101:~C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v~Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO~PART 2: 4 cycles / 28 days~After evaluation at D1 month 9:~patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily~patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, / 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days~Ibrutinib 420mg/day PO~PART 3 (only in GAI-FC+Ibru arm) :~After evaluation at D1 of M16:~patients CR with BM MRD< 10-4, treatment stopped~patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative."
2534605|NCT02666573|Experimental|Photodynamic therapy protocol|In addition to scaling and root debridement, test sites received PDT according to manufacturer's instructions.
2533738|NCT02672384|Experimental|patients in ICU|"Dental examination will be performed to diagnose CP based on the Centre for Diseases Control definition.~A point of care P. gingivalis test (Denka Seiken Co (Japan) ) on saliva and detection of antibodies against P. gingivalis in sera will be performed.~In case of discrepancies between both diagnoses methods, RT-PCR for identification of P. gingivalis and other pathogens will be performed on samples of periodontal pocket performed in routine."
2533789|NCT02672072||Control group|5-day specific training with dedicated scenario done by an ICU expert simulation team after the period of the study
2533800|NCT02672072||Simulation group|5-day specific training with dedicated scenario done by an ICU expert simulation team
3201422|NCT00902798|Experimental|Cognitive Enhancement Therapy|"This research treatment aims to help with problems in thinking, planning, and socialization. Participants begin with cognitive training using computer software programs. They also participate in a small social-cognitive group to learn about their condition and how to act wisely in social situations by developing the abilities needed to understand another person's perspective, evaluate social contexts, and be foresightful.~Time commitment: about 3½ hours per week; Location: Pittsburgh, PA only"
3201423|NCT00902798|Active Comparator|Enriched Supportive Therapy|"This research treatment uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.~Time commitment: about 1 hour per week; Location: Pittsburgh, PA only"
2533965|NCT02670707|Experimental|"Cytarabine (experimental) arm"|On this arm, patients will receive single therapy with cytarabine.
2533969|NCT02670707|Active Comparator|"Vinblastine/prednisone (standard) arm"|On this arm, patients will receive standard-of-care therapy with vinblastine and prednisone.
2534034|NCT02670356|Experimental|Fish oil|fish oil, 1500 mg/day, EPA:DHA ratio of 4:1, each capsule containing 750 mg total EPA+DHA, 2 capsules/day for 10 weeks
2534037|NCT02670356|Experimental|krill oil|krill oil, 300 mg/day, each capsule containing 74 mg total EPA+DHA , 1 capsule/day for 10 weeks
3201424|NCT00902811|Active Comparator|AM(LT)|Artesunate (Arsumax®, Sanofi)
3201425|NCT00902811|Experimental|AM(FDC)|Artesunate-mefloquine fixed dose combination
2534315|NCT02668341||psoriasis patients in Denmark|non-interventional survey study in psoriasis patients in daily practice care
2534319|NCT02668341||psoriasis patients in Spain|non-interventional survey study in psoriasis patients in daily practice care
2534323|NCT02668341||psoriasis patients in Poland|non-interventional survey study in psoriasis patients in daily practice care
2534326|NCT02668341||psoriasis patients in Germany|non-interventional survey study in psoriasis patients in daily practice care
2534386|NCT02668107|Active Comparator|Intervention Group (Hammock positioning)|Babies in the intervention group (IG), will be positioned supine in a hammock in the incubator, with the appropriate postural adjustments.
2534395|NCT02668107|No Intervention|Control Group|Those selected for the control group (CG) will be placed in the incubator following the service routine.
2534502|NCT02667249||check list|clinical pathway using a paper based check-list
2534506|NCT02667249||integrated clinical pathway|clinical pathway in form of a clinical pathway integrated into the paper based medical treatment and nursing documentation
2534550|NCT02666989|Active Comparator|open placebo|8 weeks of open placebo treatment
2534552|NCT02666989|No Intervention|waitlist group|4 weeks of waiting list followed by 4 weeks of open placebo treatment
2534654|NCT02666404|Experimental|Volume Resuscitation|We would like to establish new endpoints for guidance of volume resuscitation by implementing new measurements (body impedance, renal resistive index).
3201426|NCT00902811|Experimental|AL|artemether 20 mg - lumefantrine 120 mg co-formulated tabs
3201427|NCT00902811|Experimental|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/Piperaquine 160 mg tablets
2534790|NCT02665208|Active Comparator|Treatment As Usual (TAU)|Participants will receive informational pamphlets and information for a 1800 quit line, and a prescription for a nicotine replacement therapy (NRT) for 7 Days
2534792|NCT02665208|Active Comparator|Nicotine Replacement Therapies|Participants will receive a prescription for a nicotine replacement therapy (NRT) for 7 Days.
2534793|NCT02665208|Active Comparator|Text Message Intervention|Participants will receive up to 5 messages a day with message content informed by principles of cognitive behavioral therapy using software developed and maintained by the National Cancer Institute.
2534886|NCT02665000|Experimental|Study arm: Structured training programme|"The participants in study arm will undergo 5 days training program in laparoscopic appendectomy using the Box and Wet Trainer as intervention. Each training session will take up to 2 hours. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~After the above training, they will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and graded based on a validated GOALS scoring system 6. The Primary Outcome will be the difference of the GOALS results between the 2 groups. Secondary outcomes will include OSAT score, patient outcome, residents' feedback score as well as conversion rates to open surgery."
2534894|NCT02665000|No Intervention|Control arm: non-training|"Participant in study arm will not receive any additional training during the training week. The participant will then be exposed to the standard training in current practice over 5 supervised cases of laparoscopic appendectomy.~They will be required to perform another 5 cases of laparoscopic appendectomy as performing surgeon under supervision by a trained surgeon. The operation will be recorded and then graded based on a validated GOALS scoring system 6"
2534962|NCT02664389|Experimental|Genetic analysis of patient with early-onset breast cancer|Sequencing of 200 selected genes in patient with early-onset breast cancer without genomic alterations of BRCA1, BRCA2 or TP53
2534963|NCT02664389|Experimental|Genetic analysis of patient with early-onset ovarian cancer|Sequencing of 200 selected genes in patient with early-onset ovarian cancer without genomic alterations of BRCA1, BRCA2
2534965|NCT02664389|Experimental|Genetic analysis of patient with pediatric cancer|Sequencing of 200 selected genes in patient with pediatric cancer without genomic alteration of TP53
2533759|NCT02672189|No Intervention|Waiting list control group|Women in the waiting list control group will receive usual care. They will complete questionnaires during a period of 6 months. After completion of the last questionnaire they will be offered the opportunity to follow the EVA-Online program.
2533763|NCT02672189|Experimental|EVA-Online guided group|"The CBT/Relaxation program (EVA-Online) consists of 6 online sessions intended to be completed weekly over a 6 week period. The program comprises the following elements: (1) information and advice about symptoms (e.g., hot flushes, night sweats and sexual functioning); (2) monitoring and modifying precipitants; (3) relaxation and stress reduction; (4) cognitive restructuring of unhelpful thoughts and (5) encouraging helpful behavioral strategies (e.g., pacing activities). Throughout the program women will be asked to spend an hour a week to read the session and fill in the assignments and to spend 30 minutes per day on homework exercises (eg, filling in a hot flush/night sweats diary, practicing relaxation techniques).~Participating women will first undergo a 30 minute phone interview with a trained therapist before they start the online program. The same therapist will provide weekly feedback and support."
2533768|NCT02672189|Experimental|EVA-Online self-management group|The content of the self-management CBT/Relaxation program is the same as the guided version of the program as described above, but without weekly guidance by a trained therapist. The women allocated to the self-management intervention will work through the program independently.
3167518|NCT00539409|No Intervention|1|Diabetic patients will complete quality of life questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions.
3167519|NCT00539409|Active Comparator|Pulsatile Intravenous Insulin Therapy|
3167520|NCT00539422||I|group I of 15 women with benign breast lesion
2533865|NCT02671409|Placebo Comparator|Control group|The exercise program will be drawn from the recommendations of the American College of Physicians and the American Pain Society for the treatment of low back pain. The exercise protocol consist of: Strengthening the abdominal muscles and erector spinae: will be three sets of 15 repetitions for each exercise with rest time between 2 minutes series; - Proprioceptive Neuromuscular Facilitation (PNF). The PNF technique will be the contract-relax the hamstrings by 6/2. Stretching the erector muscles of the spine, iliopsos, hamstrings, quadriceps and sural triceps: will be three three repetitions, with 30 seconds support time each stretch and rest time between sets 1 minute.
2533866|NCT02671409|Experimental|MOB Group|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
2533929|NCT02671084|Experimental|Sevoflurane Group|Sevoflurane Group called group A patients will receive sevoflurane. The patients of group A will receive facial mask properly attached to your face, inspiratory fraction of sevoflurane 3%, with therapeutic target of 1.2% expired fraction into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. This procedure is sufficient to induce the pre anesthetic conditioning in the group exposed to sevoflurane. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
2533935|NCT02671084|Placebo Comparator|Control Group|Control Group called group B patients who will not receive sevoflurane. The patient of group B will receive facial mask properly attached to your face into spontaneously breathing.This exposure will during 30 min. Than, the mask will remove of the face and the patient will spontaneously breathing in ambient air during 10 min. After the end of this exhibition, patients will be allowed to enter the catheterization laboratory for angioplasty, no more any anesthetic agent will be administer until the end of his procedure.
2533974|NCT02670720|Experimental|avoralstat|Five avoralstat capsules (100 mg) to be taken three times daily by mouth
2534021|NCT02670395|Experimental|JNJ-54416076|Participants will receive single dose of JNJ-54416076 (in ascending dose) in Part 1 and 2 doses of JNJ-54416076 (one dose in the fasted state and an identical dose in the fed state) in Part 2. The dose selected for Part 2 will be selected based on the preliminary safety and PK data in Part 1.
2534026|NCT02670395|Experimental|Placebo|Participants will receive single dose of placebo in Part 1.
2534085|NCT02670174|Active Comparator|Traditional training|A home exercise program consisting of rotator cuff and scapular muscle training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2534095|NCT02670174|Experimental|Separate kinetic chain training|A home exercise program consisting of traditional training exercises as well as separate exercises focusing on core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2534103|NCT02670174|Experimental|Integrated kinetic chain training|A home exercise program consisting of traditional training exercises while integrating core and lower limb training will be performed during 6 weeks (4 sessions/week). To monitor progress and control load progression, a physical therapist will visit the subject every week.
2534266|NCT02668991||Cohort 1|It will consist of planned 100 children and adults with Autism Spectrum Disorder (ASD) aged 6 years and older with no requirements regarding concurrent therapies or treatments.
3167521|NCT00539422||II|group II of 16 women with breast cancer
3167522|NCT00539422||III|13 women were taken as a control group
3167523|NCT00539435|Active Comparator|1|Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
2533796|NCT02671916||all patients|questionnaire for patients with ICU stay at least 5 days or longer without interruption at the ICU
2533840|NCT02671708|Experimental|IDA+BUCY|For intermediate-risk AML undergoing auto-HSCT，IDA+BUCY conditioning regimen was IDA 15mg/m2/day on days -12 and -10；BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days -3 and -2.
2533843|NCT02671708|Active Comparator|BUCY|"For intermediate-risk AML undergoing auto-HSCT，BUCY conditioning regimen was BU 3.2 mg/kg/day on days -7 and -4；CY 60 mg/kg/day on days~-3 and -2."
2533917|NCT02671123|Active Comparator|Coronary PCI with OCT with Co-Registration|Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
2533918|NCT02671123|Placebo Comparator|Coronary PCI with OCT without Co-Registration|"Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted.~I"
2533966|NCT02670798|No Intervention|Control|Standard of care hematologic management in the operating room
2533971|NCT02670798|Experimental|Study|Standard of care hematologic management plus additional monitoring with the intervention of Thromboelastography laboratory testing and use of a thromboelastography-guided transfusion protocol.
2534030|NCT02670434|Experimental|NK-104-CR|Controlled release NK-104
2534032|NCT02670434|Placebo Comparator|Placebo|Livalo Placebo
2534033|NCT02670434|Active Comparator|Livalo® Immediate Release IR|Immediate Release Livalo®
3201428|NCT00902811|Experimental|AA (FDC)|Artesunate-amodiaquine fixed dose combination
2534197|NCT02669420|Experimental|extra amniotic misoprostol|misoprostol dissolved in warm saline , become dissolute misoprostol saline solution(200 microgram every 4 hours)
2534199|NCT02669420|Experimental|vaginal misoprostol|misoprostol tablet soaked with distilled water and inserted in the posterior fornix of the vagina( 200 microgram every 4 hours)
3201429|NCT00902824|Active Comparator|Group A|"ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months~Number of volunteers: 12"
3201430|NCT00902824|Active Comparator|Group B|"TBC-M4 at 0,1,6 months~Number of volunteers: 12"
3201431|NCT00902824|Placebo Comparator|Placebo|Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
2534328|NCT02668250|Experimental|Experimental group : OPTI-AGED|The OPTI-AGED group will receive a combined optimization strategy of anesthesia concerning hemodynamic, ventilation, and depth of anesthesia.
2534331|NCT02668250|Active Comparator|Control Group :|The control group will not benefit from the OPTI-AGED intervention but patients will receive the usual care.
2534387|NCT02667886|Experimental|Part A|X4P-001 + axitinib dose escalation
2534396|NCT02667886|Experimental|Part B|"Randomized assignment to one of two regimens:~X4P-001 at the Part A maximum tolerated dose (MTD), in combination with axitinib~X4P-001 at 0.5x Part A MTD, in combination with axitinib"
2534406|NCT02667886|Experimental|Part C|X4P-001 monotherapy
2534480|NCT02667522|Experimental|Parenting Intervention|Parenting Intervention: Parent-Child Interaction Therapy (PCIT)
2534482|NCT02667522|No Intervention|Waitlist Control|Waitlist Control Condition
2534503|NCT02667197||Opioid overdose and poisoning|
2534560|NCT02667015|Experimental|Anxiety Sensitivity Intervention|Group receives the 3-week, 6-session Anxiety Sensitivity Intervention. This is a 6-session psychotherapy occurring twice weekly (60-90 minutes) for three weeks. This psychotherapeutic treatment is focused on reducing anxiety sensitivity and includes many components, but primarily consists of psychoeducation about the relationship between anxiety and substance use disorders, interoceptive exposures, in vivo exposures, and cognitive challenging.
2534561|NCT02667015|No Intervention|Control Group|Receives only treatment as usual
2534574|NCT02666612|Other|Patients with metastatic cancer|
2534662|NCT02666482|Experimental|Stop Smoking SF Web App - baseline|"Online Study 1 will test the data gathering aspects of the proposed web app using a baseline, usual care intervention consisting of a static smoking cessation guide, the Guía para Dejar de Fumar, tested in printed form in the Muñoz et al. (1997) study. The print version of the guide yielded an 11% quit rate at 3 months. The investigators will utilize the content of the guide as the main element of the baseline app, so it will serve to estimate baseline utilization and quit rates when this already tested intervention is provided in a web app format. Participants can join the study online by going to: https://stopsmokingsf.org"
2534715|NCT02665910|Experimental|SHR0302|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets
2534724|NCT02665910|Placebo Comparator|SHR0302 placebo comparator|Multiple ascending doses (2, 5, 10, 25 mg), oral tablets (matching corresponding study medication)
3201432|NCT00902837|Active Comparator|oxycodone Tablet|OxyCodone Prolonged release tablets
2534942|NCT02664285|Other|closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section.
2534943|NCT02664285|Other|No closure of subcutaneous tissue|in diabetic patients, the subcutaneous fat will not sutured after cesarean section.
2535013|NCT02664012|Active Comparator|Own Brand Menthol Cigarette|Own Brand Menthol Cigarette
2535014|NCT02664012|Experimental|Electronic Menthol Cigarette #1|VUSE® (menthol flavor, 14 mg nicotine)
2535016|NCT02664012|Experimental|Electronic Menthol Cigarette #2|VUSE® (menthol flavor, 29 mg nicotine)
2535018|NCT02664012|Experimental|Electronic Menthol Cigarette #3|VUSE® (menthol flavor, 36 mg nicotine)
2535019|NCT02664012|Active Comparator|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
2535071|NCT02663427|Experimental|PG(-) and Hp(-) Group|PG negative （pepsinogen（PG）Ⅰ > 70ng/ml or PGⅠ/PGⅡ >7.0）and Hp (helicobacter pylori) negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
3201433|NCT00902837|Experimental|oxycodone naloxone tablet|Oxycodone naloxone prolonged release tablets (OXN)
3201434|NCT00902863|Experimental|YOGA patients|Patients assessed for chronic pain at our Pain Management Centre
2533801|NCT02672150|Experimental|Enhanced|While the core intervention and DDDM are expected to facilitate change, organizations may need additional support to apply these principles to their improvement efforts during the implementation phase. In the third phase (after Core), 1/2 of the sites are randomly assigned to an Enhanced condition that provides continuing support for the use of DDDM tools by adding research staff facilitation of DDDM over a 12-month period and formalized Local Change Teams (LCTs) featuring representation from the JJ agency and a local BH provider, with meetings facilitated by research staff).
2533835|NCT02671513|Experimental|SHR6390|Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen.
2533976|NCT02670837|Experimental|Graft from HCT donor|Cells are harvested from a donor using Cellutome, then transferred via Adaptic dressing to the recipient's wound with up to 3 donor harvest sites/treated wound sites on day 0.
2533979|NCT02670837|Experimental|Self donor from intact skin patch|Cells are harvested from the subject using Cellutome, then transferred via Adaptic dressing to that subject's wound with up to 3 harvest sites/treated wound sites on day 0.
2534001|NCT02670369|Experimental|Sitting time prompt|All participants will receive a prompting device (one-arm intervention).
2534080|NCT02670265|Active Comparator|Parenteral nutrition|Active Comparator: Olimel peri 2.5% ® 1l/d (700 kcal/d) (Baxter GmbH, Unterschleißheim, Germany)
2534090|NCT02670265|Placebo Comparator|Isotonic fluid|Isotonic fluid 1l/d (E153, Berlin-Chemie AG, Berlin, Germany)
2534237|NCT02669277|No Intervention|group A|no platelet enhancing therapy
2534242|NCT02669277|Active Comparator|group B|Standard IVIG single dose 1.0 gm /kg/dose
2534245|NCT02669277|Experimental|group C|minipool IVIG product single dose 1.0 gm /kg/dose
2534273|NCT02668757|Other|HeartHab application arm|Patients in the HeartHab application arm will receive the mobile application during study period.
2534353|NCT02668575|No Intervention|Usual Care|Patients randomized to the control arm of this study will continue to receive the standard of high-quality CF care provided to all patients at the UPMC CF Center.
2534361|NCT02668575|Experimental|Supportive Care Intervention|Patients randomized to the intervention arm will receive a protocolized supportive care intervention from a palliative care nurse practitioner.
2534377|NCT02668081|Experimental|Endoscopic papillary balloon dilation|For EPBD group, after selective cannulation of the common bile duct by the catheter, cholangiography will be performed to confirm the diagnosis of bile duct pathology. A 0.025-0.035-inch guidewire will then be inserted into the bile duct through the catheter. A dilating balloon (The controlled radial expansion (CRE) balloon dilation catheter, CRE balloon 5.5 cm (centimeter) in length, 1-1.2 cm/1.2-1.5 cm/1.5-2.0 cm in diameter) will be passed via the pre-positioned guidewire into the bile duct. Using fluoroscopic and endoscopic guidance, the balloon will be inflated with contrast medium up to the optimal size and duration (normally 5min (minutes)) after the waist on the balloon disappeared according to the patients' condition and tolerance.
2534380|NCT02668081|Active Comparator|Endoscopic sphincterotomy|"For EST group,endoscopic sphincterotomy(EST) will be done as large as possible with a pull type sphincterotome (The TRUEtome, Biliary sphincterotomy sphincterotome, Single-use sphincterotome CleverCut2V)~Other interventions: surgical intervention, endoscopic stenting, percutaneous transhepatic cholangiogram with balloon dilation"
2534444|NCT02667691|Experimental|SODB Dimpless-caloric restriction|This arm receives daily two capsules of SODB Dimpless 40mg containing 480 UI of superoxide dismutase (SOD), associated with a moderate caloric restriction.
2534450|NCT02667691|Placebo Comparator|Placebo-caloric restriction|This arm receives daily two capsules Placebo containing excipients only, associated with a moderate caloric restriction.
2534532|NCT02667353|Other|electroconvulsive therapy|only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
2534592|NCT02666781||Pilot Group|Postoperative surgical Patients with or without Obstructive Sleep Apnea
3167524|NCT00539448|Experimental|1|combination of insulin Glargine & insulin Glulisine as basal bolus regimen
3167525|NCT00539474|Active Comparator|1|Wireguided localisation
2534693|NCT02666027|Experimental|FIVA ON|The FIVA will be turned on for cases randomized to an even number. The ON light will be covered by tape. Routine induction and maintenance of anesthesia and rate and manner of delivery of IV fluid will be administered at the discretion by the anesthesiologist. The FIVA monitor will only monitor the first IV fluid bag since the study will be unblinded once the FIVA monitor alarm is triggered. When the IV bag is empty and the FIVA alarm is triggered, the anesthesiologist will turn off the FIVA and change the IV bag. The following will be recorded by the anesthesiologist: Type of surgical procedure; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA during the procedure; VAS assessment of ease of use of the FIVA; Loudness of audial alarm of the FIVA.
2534694|NCT02666027|Placebo Comparator|FIVA OFF|The FIVA will be off for cases randomized to odd numbers. The indicator lights will be covered by tape. Routine induction and maintenance of anesthesia and rate/manner of delivery of IV fluid will be administered at the discretion of the anesthesiologist. The IV bag may run dry with or without being noticed by the anesthesiologist. When they detect the empty bag, it will be changed after the removal of the FIVA. The anesthesiologist will record the presence or absence of air in the IV tubing following the termination of the study. The following will be recorded by the anesthesiologist: Type of surgery; Duration of surgery; Presence of air in the IV; Number of false alarms triggered by the FIVA device; VAS assessment of ease of use of the FIVA; Assessment of audial alarm of the FIVA.
3167526|NCT00539474|Experimental|2|Radioguided occult lesion localisation
3167527|NCT00539565|Active Comparator|A|oral corticosteroids
3167528|NCT00539565|Placebo Comparator|B|as for active regimen
3167529|NCT00539643|Active Comparator|Bead Arm|Hepatic arterial embolization with Bead Block microspheres, beginning with 100 - 300 micron beads, and using larger particles if necessary until stasis is evident.
3167530|NCT00539643|Active Comparator|Bead + Dox Arm|Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
3167531|NCT00539708|Experimental|NIV|Non-invasive ventilation
3167532|NCT00539708|Active Comparator|Control|Oxygen therapy
3167533|NCT00539721|Experimental|Rolapitant Dose 1|
3167534|NCT00539721|Experimental|Rolapitant Dose 2|
2533807|NCT02671955|Experimental|Part 3: Dose Expansion|Participants with metastatic Non-small Cell Lung Cancer (NSCLC) will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
2533811|NCT02671955|Experimental|Part 4: Dose Expansion|Participants with advanced solid tumors will receive intravenous infusion of JNJ-61610588 at the recommended Phase 2 dose (RP2D) until disease progression.
2533834|NCT02671578|Experimental|Nitrous oxide|Nitrous oxide sedation
2533913|NCT02671357||ERAMIP with EEN|Minimally invasive pancreaticoduodenectomy (MIPD) with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES). All patients are submitted to an ERAS trajectory with EEN
2533964|NCT02670902|Experimental|Critical Time Intervention-Residential|CTI-R is a 9-month, assertive outreach and linkage program.
2533968|NCT02670902|Active Comparator|Enhanced Usual Discharge-Residential|The enhanced usual discharge condition includes usual discharge services plus three telephone recovery check-up calls post-discharge.
2534007|NCT02670421|Active Comparator|Face to face Heart SMART program|Stress management program presented in a face to face meeting of 90-100 minutes with daily printed program instructions to follow over the next 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
2534012|NCT02670421|Active Comparator|Online Heart SMART program|Stress management program in the form of 10- minute videos completed weekly by participant on-line for 12 weeks, accompanied by reading from a book entitled The Mayo Clinic Guide to Stress Free Living.
2534093|NCT02670161|Active Comparator|Treatment A (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2534102|NCT02670161|Active Comparator|Treatment B (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2534108|NCT02670161|Active Comparator|Treatment C (see interventions description)|The investigators will conduct 11 pragmatic trials using the EMR: brain tumors (prevent seizures), epilepsy (prevent other seizure types), mild cognitive impairment (improve memory), migraine (prevention), migraine (abortive), mild traumatic brain injury (prevent post concussion syndrome), multiple sclerosis (attenuate relapses), neuropathy (pain management), Parkinson's (treat motor symptoms), restless legs syndrome (treat sensory symptoms), stroke (secondary prevention). For each trial they will compare up to three medications or treatments either FDA approved for the indication, or commonly employed. The pragmatic trials will be small and primarily to demonstrate the feasibility of subgroup based adaptive assignment of treatments, electronic consenting, and data capture at the point of care using the EMR. The focus is on the development of the study design and methodology and not on the treatments per se.
2534149|NCT02669693|Placebo Comparator|bread without olives|Intervention (no olives): Subjects will consume a meal of 109 g white bread and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
2534150|NCT02669693|Active Comparator|bread with olives|Intervention (olives 100 g): Subjects will consume a meal of 109 g white bread, 100 g of olives and 200 of ml water, and post-prandial blood glucose measured over a 3 hour period.
2534227|NCT02669290|Experimental|Guided|Guided LV lead placement for CRT.
2534231|NCT02669290|Active Comparator|Non-Guided|Non-guided LV lead placement for CRT.
2534276|NCT02668861|Experimental|Vitamin D+Budesonide Nasal Spray|Vitamin D 4000IU/day for 8 weeks + Budesonide Nasal Spray 128ug/d for 8 week
2534281|NCT02668861|Placebo Comparator|placebo+Budesonide Nasal Spray|Placebo for 8 weeks + Budesonide Nasal Spray128ug/d for 8 week
2534327|NCT02668419|Active Comparator|Usual Care|Patients in this group were subject to regular Physical Therapy Sessions in the hospital and each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise.
2534334|NCT02668419|Experimental|Neuromuscular Electrical Stimulator|Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
2534397|NCT02668055|Experimental|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells in wound, stick with wound edge skin suture, with vaseline gauze bandaging, controlled side not adding slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes
2534604|NCT02666651|Other|Control group|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority
2534610|NCT02667041|Active Comparator|EEG/ERP biomarkers|Investigation of pre- and post-treatment cognitive biomarkers
2533819|NCT02671903|No Intervention|No pacing|Subjects will remain in this arm for 6 months before being crossed-over. The pacemaker will be programmed to VVI 30 bpm. Dynamic AV delay will be programmed off throughout the study.
2533848|NCT02671435|Experimental|Part 1 -Dose escalation with 5 dose escalation cohorts|Durvalumab and monalizumab
2533856|NCT02671435|Experimental|Part 2 - Dose expansion with 4 dose expansion cohorts|Durvalumab with monalizumab
2533859|NCT02671435|Experimental|Part 3 -Dose Exploration with 10 dose exploration cohorts.|Durvalumab and monalizumab and standard of standard of care systemic therapy with or without a biologic agent and monalizumab in combination with biologic agent in CRC.
2534011|NCT02670824|Experimental|CN-105 Active Drug|"The CN-105 drug administered via IV at an escalating scale of mg/kg.~A1-0.01 mg/kg A2-0.03 mg/kg A3-0.1 mg/kg A4-0.3 mg/kg A5-1.0 mg/kg B1-1.0 mg/kg"
2534017|NCT02670824|Placebo Comparator|Placebo|Normal Saline
2534087|NCT02670187|Experimental|GLS-5300|GLS-5300 at 0.67 mg DNA/dose
2534099|NCT02670187|Experimental|GLS-5300 at 2 mg DNA/dose|GLS-5300 at 2 mg DNA/dose
2534107|NCT02670187|Experimental|GLS-5300 at 6 mg DNA/dose|GLS-5300 at 6 mg DNA/dose
2534129|NCT02669706||IV pentamidine|Pentamidine 4mg/kg IV every month (maximum 300mg)
2534144|NCT02669511|Other|PQR309|A single arm study with PQR309, a phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), 60mg/80mg given once a day, orally.
3201435|NCT00902876|Experimental|Mucograft + CAF|Mucograft in combination with coronally advanced flap (CAF)
2534241|NCT02669030|Experimental|Suvorexant|suvorexant 10mg/day, 15mg/day or 20mg/day augmentation of FDA-approved antidepressant treatment
2534244|NCT02669030|Placebo Comparator|Placebo|no augmentation of FDA-approved antidepressant treatment
2534257|NCT02668744|Experimental|Intervention|TX Sprouts
2534265|NCT02668744|Placebo Comparator|Control|Delayed Intervention
2534350|NCT02668380||Apatinib|Apatinib Tablets: 850 mg,po, once daily , 28 days for a cycle
2534383|NCT02668068|Active Comparator|Control Group|Large volume whole-lung lavage (WLL) only
2534390|NCT02668068|Experimental|Experimental Group|Combined large volume WLL with clinical grade umbilical cord mesenchymal stem cells transplantation
2534435|NCT02667678|Experimental|Cohort HIVOL, patients infected by HIV|Patients enrolled in HIVOL cohort (study performed between 2011 and 2013) will be contacted to participate to HIVOL-2. The intervention will be blood and urinary samples, with the use of iohexol (Omnipaque®) to have an idea on renal plasmatic clearance.
2534537|NCT02667496|Experimental|Leukine|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
2534541|NCT02667496|Placebo Comparator|Placebo|"Administered SC in treatment cycles up to 24 weeks~Florbetapir administered for PET scans to examine baseline brain imaging pathology and changes on treatment."
3201436|NCT00902876|Experimental|CAF|Coronally advanced flap (CAF) alone
3201437|NCT00902889|Experimental|1|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation with GPE (upper cranial two contacts).
2534679|NCT02666092||Fish allergy|"51 subjects presenting allergic manifestations after digestive, cutaneous, or respiratory contact with fish will be recruited.~Interventions will include:~A questionnaire on domestic exposure to fish, and on the characteristics of clinical manifestations~A detection of anti-Anisakis and anti-fish antibodies"
2534680|NCT02666092||Control|"51 subjects presenting no allergic manifestations after contact with fish.~Interventions will include:~A questionnaire on domestic exposure to fish~A detection of anti-Anisakis and anti-fish antibodies"
2534730|NCT02665767|No Intervention|On-site sonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert.
2534731|NCT02665767|Active Comparator|Smartphone-based Telesonography|The subjects(n=15) performed ultrasonography for the identification of the appendix under mentoring by an offsite expert.
2534827|NCT02665442|Experimental|Stylet|This group will receive an Esophageal stylet; EsoSure during the ablation procedure in attempt of moving the esophagus away from the ablation site.
2534829|NCT02665442|No Intervention|Non-Stylet|This group will receive the ablation procedure without any modifications or interventions. No esophageal stylet will be used in this group.
2534898|NCT02664701|Active Comparator|Individual supportive therapy|"Patients randomized to this arm will have individual supportive therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Individual supportive therapy~Intervention: Evaluations with a psychiatrist"
2534901|NCT02664701|Experimental|Cognitive behavioural group therapy|"Patients randomized to this arm will have cognitive behavioural therapy.~Intervention: Baseline evaluation with a psychiatrist~Intervention: Cognitive behavioural group therapy~Intervention: Evaluations with a psychiatrist"
2534944|NCT02664207|Experimental|Fetal Surgery in Women with ex|"Fetal myelomeningocele repair surgery will be offered to pregnant women meeting the criteria for surgery (as set by the MOMS trial) with the exception of the following:~a BMI greater than 35 (but less than or equal to 40 kg/m2)~(minor) Fetal structural abnormality~(well-controlled) Diabetes~Previous preterm delivery (followed by a full term delivery)~Maternal red cell alloimmunization (must NOT be associated with fetal disease, OR fetus must have negative red cell antigen status as determined by amniocentesis).~Intervention: Open Fetal Repair of Myelomeningocele"
2534990|NCT02663986|Experimental|Organizational Skills Training (OST) Intervention|"To improve children's organizational functioning, OST focuses on four key skills.~Tracking Assignments~Managing Materials~Time Management~Task Planning"
2535015|NCT02663713|Experimental|Ticagrelor|Ticagrelor 60 mg twice daily
2535017|NCT02663713|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily
2535060|NCT02663479|Experimental|Cardiopressin|A 5 capsule proprietary blend of herbal extracts and nutrients
2535061|NCT02663479|Placebo Comparator|Placebo|A 5 capsule placebo matched in color and size to the Experimental supplement
2535124|NCT02663193||Enzalutamide Group|Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
2535126|NCT02663193||Abiraterone Acetate plus Prednisone group|Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
2533823|NCT02671851||IV metamizole sodium, paracetamol|Patients received only standardized general anaesthesia. IV metamizole sodium and paracetamol were rescue analgesics.
2533887|NCT02671318|Active Comparator|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
2533892|NCT02671318|Active Comparator|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
2533944|NCT02670941|Experimental|Ginger|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2533945|NCT02670941|Experimental|Lavender|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2533949|NCT02670941|Experimental|Orange|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2533953|NCT02670941|Placebo Comparator|Jojoba|Subjects will use the aromatherapy inhalers through three chemotherapy treatment cycles (i.e., Study Cycle 1, Study Cycle 2, and Study Cycle 3). During each Study Cycle, subjects will start the aromatherapy inhaler on the day before the start of their chemotherapy treatment cycle (Day 0) and continue using the inhaler for the next six consecutive days (Day 1-Day 6), including the day he/she starts their chemotherapy treatment cycle. The subjects will remove the cover of the aromatherapy inhaler, place the aromatherapy inhaler under their nose and inhale three times with deep breathing (i.e., three sniffs). After use, the inhaler should be capped to minimize dispersal of the scent. Subjects will take 3 sniffs of the aromatherapy inhaler four times daily (morning, noon, evening, bedtime).
2533978|NCT02670564|Experimental|Total body irradiation (TBI)|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
2533980|NCT02670564|Experimental|Busulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
2533981|NCT02670564|Experimental|Treosulfan|"The Pharmacogenomics add-on requires 2X 5ml blood EDTA for further DNA analyses.~Note this is an add-on study to NCT 01949129, THE ALL SCTped FORUM study. Please refer to the main study for further details."
3201438|NCT00902889|Experimental|2|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
3201439|NCT00902902||1|
3201440|NCT00902902||2|
3201441|NCT00902915|Experimental|Lenalidomide - Dexamethasone|
2534196|NCT02669394|Experimental|Resistance Training (RT)|"The RT program will be a twice-weekly program. A pressurized air system and free weights will be used . The pressurized air system exercises will consist of biceps curls, triceps extension, seated row, latissmus dorsi pull downs, leg press, hamstring curls, and calf raises. Other exercises, with free weights, will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
2534230|NCT02669303|Active Comparator|Methylprednisolone group|Methylprednisolone subacromial injection
3201442|NCT00902928|Experimental|1. YM150, Dose X, twice daily|
2534259|NCT02668796|Experimental|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
2534264|NCT02668796|Active Comparator|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
3201443|NCT00902928|Experimental|2, YM150, Dose X, once daily|
3201444|NCT00902928|Experimental|3. YM150, Dose Y, twice daily|
3201445|NCT00902928|Experimental|4. YM150, Dose Y, once daily|
3201446|NCT00902928|Active Comparator|5. Enoxaparin|
3201447|NCT00902941|Experimental|Rasagiline|
3201448|NCT00902941|Placebo Comparator|Placebo|
3201449|NCT00902954|Experimental|A|anastrozole/letrozole 2-3 years switching to exemestane 3-2 years
3201450|NCT00902954|Active Comparator|B|anastrozole/letrozole 5 years
3201451|NCT00902967|Active Comparator|1|Tablet Atorvastatin 10 mg once daily for 5 weeks (1 week before operation till 2 weeks after the operation)
3201452|NCT00902967|Placebo Comparator|2|Placebo tablets of similar shape and color given at night time dosing
3201453|NCT00902980||1. Community Based Clinics|Patient charts from community based nephrology clinics
2533875|NCT02671786|Experimental|Intervention Arm|"Intervention area: Provision of community based health care to severely malnourished children 6 months age in 16 tribal villages by trained semi-literate village health workers.~Treatment of severely malnourished children through MAHAN RUTF & MAHAN Vit-Min mix~Growth monitoring of all children below the age of 5 years~Treatment of associated diseases like Diarrhea, Pneumonia, Malaria, etc.~Management of resistant or relapsed severely malnourished cases by pediatrician.~Intensive behavior change communication of parents of children below the age of 5 years for proper nutrition.~Dose: 46 gms of proteins/kg/day & 100170 calories/kg/day with gradual escalation with micro nutrient supplementation Route: Oral Frequency: 4 times a day Duration: 12 weeks"
2533877|NCT02671786|No Intervention|Control Arm|Control area: In control area, the V.H.W. and supervisor records weight of all under 5 children. They also collect data related to birth, deaths and verbal autopsy.
3201454|NCT00902980||2. Regional Clinics|Patient charts from regional transplant clinics
2534009|NCT02670642|Experimental|On demand 20 mg esomeprazole|On demand treatment with 20-mg esomeprazole once daily when needed
2534019|NCT02670642|Active Comparator|Continuous 20 mg esomeprazole|Continuous treatment with 20 mg esomeprazole once daily
2534119|NCT02669901|Other|Patients with opioid substance abuse disorders|All participants will receive Naloxone autoinjector as a preventative tool for accidental opioid overdose
2534162|NCT02669563|Experimental|Stage 1|"Subjects (n = 4 to 10) will be injected once with 20 mCi of [13N]ammonia and receive a 20 minute PET scan. They will then be injected once with 6.5 mCi of one of the two new drugs under study, [18F]4F-MHPG or [18F]3F-PHPG, and receive a 60 minute PET scan.~On a second visit to the clinic, subjects will be injected once with 6.5 mCi of [18F]3F-PHPG or [18F]4F-MHPG (whichever was not used for the first visit) and receive a 60 minute PET scan."
2534173|NCT02669563|Experimental|Stage 2|"Subjects (n = 20 to 26) will be injected with 20 mCi of [13N]ammonia and receive a 20 minute PET scan.~They will then be injected once with 6.5 mCi of [18F]4F-MHPG or [18F]3F-PHPG (whichever was chosen based on Stage 1 of the study) and receive a 60 minute PET scan. On a second visit to the clinic, subjects will be injected once with 20 mCi of [11C]HED and receive a 40 minute scan."
2534219|NCT02669173|Experimental|Treatment: Capecitabine + Bevacizumab|Capecitabine, PO dose to be determined by phase 1 dose escalation, cycle length 28 days. Treated with Bevacizumab, IV, 10 mg/kg days 1, 15 every 28 days, until progression.
2534268|NCT02668848|Experimental|urine monitoring group|Patients of urine monitoring group will be checked for urine specific gravity (USG) once between 6a.m. to 12 m.d. in the first 5 days after admission. Patients will be advised to have water according to the level of USG.
2534345|NCT02668549||Patients with Opioid dispensings|Patients receiving two or more opioid dispensings within 18 months
2534360|NCT02668549||Patients with Diuretic dispensings (neg control)|Patients receiving two or more Diuretics dispensings within 18 months will serve as negative control
2534423|NCT02668094|Active Comparator|Group L|Lidocaine 40mg was given intravenously before injection of propofol
2534426|NCT02668094|Active Comparator|Group LP|Pregabalin 75 mg was given orally 2 hour before surgery
2534429|NCT02668094|Active Comparator|Group HP|Pregabalin 150 mg was given orally 2 hour before surgery
2534468|NCT02667548||patients receiving PCI|patients receiving PCI
2534566|NCT02666690|Experimental|Patients with metastatic cancer treated with anti angiogenics|
2534682|NCT02666157|Active Comparator|Dabigatran|oral dabigatran etexilate capsule 110 or 150 mg (110 mg in specific population) bid for entire study period
2534684|NCT02666157|Active Comparator|Rivaroxaban|oral rivaroxaban film-coated tablet 15 or 20 mg (10 or 15 mg in specific population) qd for entire study period
2534688|NCT02666157|Active Comparator|Apixaban|oral apixaban 5 mg (2.5 mg in specific population) bid for entire study period
2534734|NCT02665702|Experimental|Endostar Combined With NVB and DDP|Endostar15mg/m2 NVB25 mg/m2 DDP75 mg/m2
2534768|NCT02665351|Active Comparator|Peramivir 300mg Q12H|Peramivir 300 mg, administered intravenously, twice daily (every 12 hours)
2534769|NCT02665351|Active Comparator|Peramivir 600mg Q24H|Peramivir 600 mg, administered intravenously, once daily (every 24 hrs)
2534805|NCT02665104||patients without neurological symptoms|carotid endarterectomy patients who dont'have any neurological symptoms after carotid clamping
2534808|NCT02665104||patients with neurological symptoms|carotid endarterectomy patients who have new neurological symptoms after carotid clamping
3167535|NCT00539721|Experimental|Rolapitant Dose 3|
3167536|NCT00539721|Experimental|Rolapitant Dose 4|
3167537|NCT00539721|Active Comparator|Ondansetron|
2535037|NCT02663739||Aortic Dissection|Treating patients with acute complicated Stanford Type B aortic dissection with the Zenith® TXD
3167538|NCT00539721|Placebo Comparator|Placebo|
3167539|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive GSK1827771 with the starting dose of 0.3 milligram (mg)
3167540|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xa (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3167541|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
3167542|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xb (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3167543|NCT00539760|Experimental|Subjects receiving GSK 1827771 in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive GSK1827771 via injection
3167544|NCT00539760|Placebo Comparator|Subjects receiving placebo in sub-cohort Xc (Cohort 1-5)|Eligible subjects will receive placebo matching to GSK1827771
3167545|NCT00539799|Active Comparator|1|Long-term low-dose prednisolone (5 - 7.5 mg/day)
3167546|NCT00539799|Placebo Comparator|2|
3167547|NCT00539812|Other|1|Standard Care only (standard batterer intervention program)
3167548|NCT00539812|Other|2|Brief alcohol intervention combined with standard care
3167549|NCT00539916|Experimental|Jus d'orange|
3167550|NCT00539916|Placebo Comparator|Boisson contrôle|
3167551|NCT00539929|Experimental|E6201 0.005% BID|Participants applied E6201 0.005% cream to a pre-identified marker lesion twice a day (BID) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
2533941|NCT02671045||E - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target has been identified. However, the patient does not receive targeted therapy.
2533942|NCT02671045||F - Genomic profile by other methods|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has been sent for genomic profiling but NOT using FoundationOne and an actionable target NOT has been identified.
2533943|NCT02671045||G - No genomic profiling|The patient's lung cancer specimen which was obtained at the time of documented metastatic disease has not been sent for genomic profiling.
2533962|NCT02670590|Experimental|NAFLD|diet
2534014|NCT02670460|Experimental|Temporary diaphragmatic pacing|There is no comparator for this study. Single site and all patients are in the treatment allocated group of temporary diaphragmatic pacing with the LIVE Catheter which is inserted via the left subclavian vein.
2534105|NCT02670213||NovoThirteen®|
2534158|NCT02669641|Experimental|Steatosis|Patients with diagnosed steatosis in treatment with combination Silimarin, Phyllanthus Niruri and Choline
3201455|NCT00902993|Experimental|1|Part A single and multiple dose and part B fractionated dose
3201456|NCT00902993|Placebo Comparator|2|
2534403|NCT02668211|Other|PROFEMUR Preserve RSA|Single cohort of subjects prospectively implanted with PROFEMUR® Preserve Classic femoral components
2534443|NCT02667769|Other|Fasting day without any food|Complete fasting: On a fast day under this Protocol no solid food may be eaten unless it is solid, medically prescribed part of a bedtime snack just before falling asleep (which must sometimes be to prevent nocturnal hypoglycaemia with injection of basal insulin before going to sleep) , Otherwise, the patient have ad libitum access to mineral water and unsweetened tea (possibly a fluid intake restriction should be considered for other diseases).
2534449|NCT02667769|Other|Fasting day with calorie- & carbohydrate-free food|During a fasting day for this protocol, patients may calories in unlimited quantity and (with calorie-free dressing) Take carb food like tomatoes, cucumbers, lettuce to be, both during meal periods and in between, if desired.
3201457|NCT00903019|Experimental|1|Participants will receive problem-solving therapy (PST) delivered via teleconferencing (tele-PST).
3201458|NCT00903019|Active Comparator|2|Participants will receive problem-solving therapy (PST) delivered in-person.
2534581|NCT02666625||Patients treated for cancer in childhood|
2534634|NCT02666391|Experimental|UCMSCs|Intracoronary infusion of umbilical cord mesenchymal stem cells (UCMSCs)
2534636|NCT02666391|No Intervention|controls|Standard medical treatment without umbilical cord mesenchymal stem cells (UCMSCs) infusion
2534727|NCT02665832|Experimental|AB|Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin) followed by DWJ1351
2534729|NCT02665832|Experimental|BA|DWJ1351 followed by Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
2534788|NCT02665429|No Intervention|Control|Providers who are subject only to the routine implementation of clinical practice guidelines without additional experimental intervention
2534789|NCT02665429|Experimental|Intervention|"Providers who are subject to routine clinical practice guideline implementation AND receive provider's own individual prescribing data profile intervention (Individual prescribing data profile and self-assessment)"
2534865|NCT02665039|Experimental|Vinflunine + gemcitabine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
2534866|NCT02665039|Active Comparator|Carboplatin + gemcitabine|"Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5~Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2"
3167552|NCT00539929|Experimental|E6201 0.01% BID|Participants applied E6201 0.01% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3201459|NCT00903019|Placebo Comparator|3|Participants will receive monitoring phone calls.
2535068|NCT02663401|No Intervention|Control|Control situation in campus cafeterias where no labelling of food is proposed
2535070|NCT02663401|Experimental|Front-of-pack labelling (5-CNL)|Introduction of the 5-CNL front-of-pack nutrition label on shelf display tags for every food and beverage sold in the campus cafeteria. Communication campaigns accompanying the introduction of the label
2535117|NCT02663154|Experimental|Aromatherapy|Aromatherapy inhaler (QueaseEASE, Soothing Scents Inc, Enterprise, AL) applied to nauseous post surgical paediatric patients in the postanesthetic care unit
2535120|NCT02663154|Placebo Comparator|Placebo|Saline inhaler applied to nauseous post surgical paediatric patients in the postanesthetic care unit
2535259|NCT02662166|Experimental|MRI and biomarkers in bladder cancer|Utilization of MR-imaging and biomarkers to stage bladder cancer and in estimation of chemosensitivity
2535294|NCT02661841|Experimental|LI-Guided Therapy|One hundred and fifty chronic heart failure patients treated based on guidelines and LI-Guided Therapy.
2535296|NCT02661841|Active Comparator|Control|One hundred and fifty chronic heart failure patients treated based on guidelines only.
3201460|NCT00903045|Experimental|1|
3201461|NCT00903045|Placebo Comparator|2|
3201462|NCT00903071|Active Comparator|REAL PPL|REAL+PPL profiles PCP performance using real electronic medical record derived data to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
3201463|NCT00903071|Active Comparator|SIM PPL|SIM+PPL, profiles PCP performance using simulated cases to identify each PCP's specific failures of decision making in HT care antecedent to the personalized learning intervention.
3201464|NCT00903071|No Intervention|Control|No intervention -control group
3201465|NCT00903084|Active Comparator|1|Participants will receive 7 doses per week, then 4 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3201466|NCT00903084|Active Comparator|2|Participants will receive 7 doses per week, then 2 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
2533950|NCT02670954|Experimental|Dexmedetomidine,tramadol and flurbiprofen|Both routine analgesic and sedation(dexmedetomidine,tramadol and flurbiprofen) are applied for this group of patients.
2533954|NCT02670954|Active Comparator|Tramadol and flurbiprofen|Only routine analgesic(Tramadol and flurbiprofen) is applied for this group of patients.
3201467|NCT00903084|Active Comparator|3|Participants will receive 4 doses per week, then 7 doses per week, then 2 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3201468|NCT00903084|Active Comparator|4|Participants will receive 4 doses per week, then 2 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
2534041|NCT02670304|Experimental|letrozole|letrozole for the first day after ovum picked up at least for 5 days.
2534045|NCT02670304|Active Comparator|aspirin|asprin for the first day after ovum picked up at least for 5 days.
2534154|NCT02669550|Experimental|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
2534167|NCT02669550|Experimental|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
2534286|NCT02668965|No Intervention|control|intrauterine infusion with standard embryo culture media 10 microliters before embryo transfer
2534292|NCT02668965|Experimental|intrauterine hCG|intrauterine infusion with hCG (500 IU) 10 microliters before embryo transfer
2534356|NCT02668497|Experimental|De-novo PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
2534364|NCT02668497|Experimental|L-dopa PD|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined by biomechanical analysis of tremulous movements for tremor therapy in both upper extremity every 12 weeks over 42 weeks. BoNT-A dose will range from 50-300 U per arm
3201469|NCT00903084|Active Comparator|5|Participants will receive 2 doses per week, then 7 doses per week, then 4 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
3201470|NCT00903084|Active Comparator|6|Participants will receive 2 doses per week, then 4 doses per week, then 7 doses per week (each for 6 weeks) of tenofovir, with a break in between dosing periods.
2534530|NCT02667132||medical treatment|In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate
2534533|NCT02667132||surgical treatment|lumpectomy, mastectomy, abscess drainage
2534534|NCT02667132||surgical+medical treatment|first medical, after surgical treatment or first surgical, after medical treatment
2534583|NCT02666885|Experimental|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
2534670|NCT02666417|Active Comparator|MNP+iron and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as FeFum and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
2534675|NCT02666417|Active Comparator|MNP+iron+GOS and test meal|"The MNP contains 400 μg Vitamin A, 5 μgVitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 μg Folic Acid,6 mg Niacin, 0.9 μg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 μg, Iodine, 17 μg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, plus 7.5 g of galacto-oligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)~Iron compound added to the test meal: Test meal A will contain 2.5 mg 57Fe as ferrous fumarate and 2.5 mg of iron as NaFeEDTA (given as 1.5 mg 56Fe and 1 mg 58Fe). Test meal B will contain 5 mg iron in form of FeSO₄ (3 mg 56Fe and 2 mg 54Fe)."
2534698|NCT02665806|Experimental|Ciclesonide|
2534700|NCT02665806|Active Comparator|Fluticasone|
3201471|NCT00903149||MITP exposure or not|Mothers of children born preterm and term.
3201472|NCT00903188|Active Comparator|Cyclosporine|Simulect + cyclosporine + Myfortic + steroid stop at 3 months
3201473|NCT00903188|Active Comparator|Everolimus|Simulect + cyclosporine (decrease dose in one week at month 3 and replace by Everolimus (Certican)) + Myfortic + steroid maintenance
3201474|NCT00903227|Experimental|Low Dose|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg) and 1 puff of inhaled Placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
3201475|NCT00903227|Experimental|Combined|One puff of inhaled fluticasone propionate Evohaler pMDI 50 µg twice a day (Total daily FP dose 100 µg) and 1 puffs of Placebo twice a day with intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts each nostril once a day (i.e. total intranasal FP daily dose 200ug).
3201476|NCT00903227|Experimental|High dose|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg) and 1 puff of inhaled placebo twice a day with placebo intranasal spray 2 squirts each nostril once a day.
3201477|NCT00903266|Experimental|MIT|Melodic Intonation Therapy
2534146|NCT02669875|Active Comparator|Serelaxin|IV infusion of serelaxin (RLX030) for 2 hours
2534147|NCT02669875|Placebo Comparator|Placebo|IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours
3167553|NCT00539929|Experimental|E6201 0.03% BID|Participants applied E6201 0.03% cream to a pre-identified marker lesion BID for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3201478|NCT00903266|Active Comparator|SRT|Speech-Repetition-Therapy
3201479|NCT00903266|No Intervention|NTC|No-Therapy Control; Patients in this arm will be re-randomized to the two active arms at the end of the NTC period.
3201480|NCT00903279|Placebo Comparator|Placebo|
3201481|NCT00903279|Experimental|Altabax|
3201482|NCT00903292|Active Comparator|A, erlotinib|If EGFR mutation found then assigned to thyrosine kinase inhibitor (erlotinib)
2534375|NCT02667860|Experimental|Intracorporeal anastomosis|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
2534376|NCT02667860|Active Comparator|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Rel Stapler
2534462|NCT02667795|Experimental|Monitored walking based exercise|Participants will be given a personalised daily exercise target. Participants will be given an activity tracker (a Fitbit ZipTM). The participants will be asked to wear the device all day to monitor their activity. Once a day the participants will be asked to complete the walking target they have been given at completion of their baseline assessment. This target should be completed in one go. The walking programme will last a minimum of 2 weeks and a maximum duration of 4 weeks. The length of time will depend on the length of time between recruitment and when the participant is scheduled to have their surgery.
2534464|NCT02667795|No Intervention|Control|No intervention
2534512|NCT02667327|Active Comparator|Granexin gel plus Standard of Care|Granexin gel is comprised of 100 μM aCT1 peptide plus hydroxyethyl cellulose.
2534522|NCT02667327|Placebo Comparator|Vehicle gel plus Standard of Care|Vehicle gel is hydroxyethyl cellulose without active pharmaceutical ingredient.
2534526|NCT02667327|No Intervention|Standard of Care|Standard of Care includes cleaning and irrigating ulcer, non-surgical debridement, pain management, ulcer dressing, off-loading, and nutritional assessment.
2534606|NCT02666638|Active Comparator|Control Volunteers|MRI on up to a 7T scanner without contrast.
2534608|NCT02666638|Experimental|Clinical Patients|MRI on up to a 7T scanner without contrast.+ 10 minutes of research development imaging added onto their clinical MRI scans.
2534656|NCT02666261||Breast Cancer Pathology Samples|Data on the epidemiology and HER2 testing of breast cancer will be collected from pathology routine diagnostics.
2534741|NCT02665650|Experimental|AFM13 + Pembrolizumab|Participants receive AFM13 in escalating doses intravenously (IV) for up to 25 weeks, pembrolizumab as a fixed dose intravenously (IV) for up to 52 weeks.
2534800|NCT02665247|Experimental|C-SIP|Participants assigned to the C-SIP group will attend sessions where information about sleep is presented. In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
2534802|NCT02665247|Other|Control Session|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
2534867|NCT02664948|Experimental|Intervention group|Early geriatric follow-up after discharge from hospital in the patient's home
2534874|NCT02664948|No Intervention|Control group|Usual care with follow-up home-visits conducted by home care and the GP after discharge, if they consider it as necessary
3201483|NCT00903292|Active Comparator|B, pemetrexed|If EGFR wild type found then assigned to chemotherapy (pemetrexed)
3201484|NCT00903305|Experimental|Group II (SNIP)|Patients undergo SNIP comprising four visits over 2 months and four monthly telephone calls from the APN. The APN will provide 24 hour access during the study. Patients complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
3201485|NCT00903305|Active Comparator|Group I (usual care intervention)|Patients undergo usual care and complete questionnaires about satisfaction with care, perceived preparedness with self-care, and helpfulness of patient teaching at baseline, 3 months and 6 months.
3201486|NCT00903318||Mexican American Men and Women|Rural and urban Mexican American men and women , aged 18 to 40, in urban Baytown, TX and rural Rio Grande Valley (Hidalgo County) communities along the Texas-Mexico border
2535199|NCT02662634|Experimental|Sequential, no radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin Area Under Curve (AUC) 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
3201487|NCT00903422|Active Comparator|Eltrombopag|Eltrombopag
3201488|NCT00903422|Placebo Comparator|Placebo|Placebo
2533997|NCT02670668|Experimental|Mutation analysis- NACwith PCR|consisting of 50 patients undergoing NACwith pathological compete response
2534004|NCT02670668|Experimental|Mutation analysis-NAC with SD/PD.|consisting of 50 patients undergoing NAC with SD/PD
2534086|NCT02670239||EVLP group|All lungs from brain dead donors that were considered at high-risk for transplantation and underwent EVLP in the Turin lung transplantation program
2534182|NCT02669836|Experimental|Posterior fossa decompression surgery|The bone is surgically removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected
2534183|NCT02669836|Experimental|Dural augmentation surgery|The bone is removed from the suboccipital region of the skull and Cervical 1 lamina so the constricting epidural band can be resected. Then, the dura is opened. Microsurgical dissection is performed and the dura is sewn closed.
2534213|NCT02669186|Experimental|'Bupivacaine + Fentanyl' (Opioid Group)|Group 1 (opioid group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
2534215|NCT02669186|Active Comparator|Bupivacaine (Local Anesthetic Group)|Group 2 (local anesthetic group) will receive general endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
2534287|NCT02668913|Experimental|Diagnostic Analysis|This arm will be subject to Caris Molecular profiling.
2534343|NCT02668484|Experimental|repositionable valve prosthesis|Lotus
2534359|NCT02668484|Active Comparator|balloon-expandable valve prosthesis|Sapien
2534378|NCT02667990|Experimental|orthopaedic stilettoe|orthopaedic stilettoe will be compared to standard stilettoe and comfy trainer
2534454|NCT02667730|Placebo Comparator|Physiotherapy only|This group will receive non-pharmacological advice and physiotherapy only
2534455|NCT02667730|Experimental|Acetaminophen + physiotherapy|This group will receive acetaminophen 500mg 4 times daily for 7 days in addition to standardized physiotherapy
2534458|NCT02667730|Experimental|Naproxen + physiotherapy|This group will receive naproxen 500mg twice daily for 7 days in addition to standardized physiotherapy
2534460|NCT02667730|Experimental|Celecoxib + physiotherapy|This group will receive celecoxib 100mg twice daily for 7 days in addition to standardized physiotherapy
2534508|NCT02667210||No shopping behavior|
2534509|NCT02667210||Minimal shopping behavior|
2534510|NCT02667210||Marked shopping behavior|
2534515|NCT02667210||Extensive shopping behavior|
2534585|NCT02666924|Experimental|Cooking class|The addition of diabetes cooking educational classes to standard diabetes education classes. Cooking classes are a series of four, four-hour sessions. These cooking classes will be led by a registered dietitian, a registered nurse and a chinese chef. Conducted in Mandarin or Cantonese. The cooking education focus is culturally specific teaching for Chinese-Canadian persons living with diabetes.
2534587|NCT02666924|Active Comparator|Control|Type 2 diabetes educational classes, consisting of two sessions, one week apart, four-hour classes. These classes are taught by a registered dietitian and nurse, in Mandarin or Cantonese.
2534804|NCT02665143|Experimental|Nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Based on the phase I dose, in the randomized phase II, the combination will be compared with chemotherapy+placebo. Nintedanib or placebo will be added at day 8 and continued until end of cycle .
3167554|NCT00539929|Experimental|E6201 0.03% QD|Participants applied E6201 0.03% cream to a pre-identified marker lesion once a day (QD) for 8 weeks. Participants applied matching placebo cream to another pre-identified marker lesion at the same treatment regimen.
3167555|NCT00539955|Other|1|Standard 40 hour state-mandated batterer intervention
2535106|NCT02663310|Experimental|Surgery with Rehabilitation|Surgically removed cysts, and collected intracystic fluids and cerebrospinal fluid for histological and molecular analyses. Samples will be collected during the surgery and will be cryo-protected for further analyses. All subjects will enroll for intensive rehabilitation 60 days after surgery.
2535109|NCT02663310|Active Comparator|Rehabilitation|All subjects will enroll for intensive rehabilitation everyday as instruction.
2535209|NCT02662751|Active Comparator|Routine Imaging|"Patients randomized to this arm will have routine post-stroke/TIA imaging assessments.~Intervention: Routine Imaging Assessment"
2535211|NCT02662751|Experimental|LDWBA first|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~Intervention: LDWBA first followed by Routine Imaging Assessment if required."
3167556|NCT00539955|Other|2|Brief alcohol intervention combined with standard batterer intervention
3167557|NCT00539968|Experimental|Docetaxel plus lonafarnib (single arm)|Docetaxel plus lonafarnib
3167558|NCT00540020|Experimental|Cognitive-Didactic|Developed by Sohlberg & Mateer to target four cognitive domains often impaired by TBI: attention, memory, executive functions, and pragmatic communication. Subjects practiced progressively more difficult paper-and-pencil or computerized cognitive tasks in 1:1 cognitive therapy sessions (1.5-2.5 hours daily).
3167559|NCT00540020|Experimental|Functional-Experiential|The works of Giles and Clark-Wilson and Hartley guided the basic concepts and treatment of the functional-experiential arm (Functional). The objective of the functional protocol was to use real life performance situations and common tasks to remediate or compensate for functional deficits after brain injury. Functional protocol treatment interventions (1.5-2.5 hours daily) typically occurred in group settings and natural environments (hospital recreation areas, group rooms, simulated home environments in the dining room, community outings, etc.).
3167560|NCT00540033|Experimental|2|Study arm was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks; the control arm was fed with breast milk or mixed feeding without probiotics.
3167561|NCT00540085|Active Comparator|A|Rocuronium dosed after ideal body weight
3167562|NCT00540085|Active Comparator|B|Rocuronium dosed after corrected body weight 20%
3167563|NCT00540085|Active Comparator|C|Rocuronium dosed after corrected body weight 40%
3167564|NCT00540098|Experimental|1|Paroxetine + aerobic exercise
3167565|NCT00540098|Active Comparator|2|Paroxetine + relaxation
2534024|NCT02670486|Active Comparator|Audiovisual intervention|Audiovisual stimulus during urodynamic testing.
2534096|NCT02670226|Other|Case group|The intervention, specific to the study, is to take samples at baseline on patients with Amyotrophic Lateral Sclerosis
2534104|NCT02670226|Other|Control group|The intervention, specific to the study, is to take samples at baseline on patients without neurological disease
2534153|NCT02669680|Experimental|G-CSF + Standard therapy|Standard care of acute-on-chronic liver failure and application of G-CSF
2534168|NCT02669680|Active Comparator|Standard therapy|Standard care of acute-on-chronic liver failure
2534282|NCT02668653|Experimental|Chemotherapy plus quizartinib|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by the experimental drug quizartinib~Consolidation: up to 4 cycles of cytarabine followed by the experimental drug quizartinib and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with the experimental drug quizartinib"
2534290|NCT02668653|Active Comparator|Chemotherapy plus placebo|"Induction: up to 2 cycles with cytarabine and daunorubicin/idarubicin, followed by placebo~Consolidation: up to 4 cycles of cytarabine followed by placebo and/or hematopoeitic stem cell transplant~Continuation: up to 36 cycles with placebo"
2534499|NCT02667145|Experimental|Intervention|Self care program focusing on the assistive device, For 4 weeks (1 to week lasting 90 minutes).
2534501|NCT02667145|No Intervention|Control group|receive only a brochure with orientations of joint protection.
2534549|NCT02667002|Experimental|Bilateral Abdominal Sacral Hysteropexy|Bilateral abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2534551|NCT02667002|Experimental|Classic Abdominal Sacral Hysteropexy|Conventional abdominal sacral hysteropexy will be perform in 10 patients. One month after patients will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2534553|NCT02667002|Active Comparator|Women with no uterovaginal prolapsed|Ten nulliparous participants with no uterovaginal prolapsed will be evaluate by MRI and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) form.
2534646|NCT02666456||Cross-sectional cohort|Patients with chronic peripheral neuropathic pain
2534649|NCT02666456||Longitudinal cohort|Painless patients before and after potential chronic neuropathic pain-inducing interventions (chemotherapy, Operation)
2534696|NCT02666040|Experimental|U - ULTRAPRO|Inguinal Hernia Surgery with ULTRAPRO® meshes, a new ULTRAPRO® mesh will be implanted in patients in the group (AG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment.
2534697|NCT02666040|Active Comparator|P - Prolene|"Inguinal Hernia Surgery with Prolene® meshes, the conventional mesh in polypropylene Prolene® will be implanted in patients in the control group (CG). The surgery will be evaluated in terms of procedure, detecting the mode of admission to hospital, the duration of surgery, anesthesia volume and type used, composition of the surgical equipment."
2534763|NCT02665585|Experimental|C-Guard carotid stent|Carotid stenting procedure by C-Guard stent implantation (InspireMD, Boston, MA, USA)
2534764|NCT02665585|Active Comparator|Wallstent carotid stent|Carotid stenting procedure by Wallstent implantation (BostonScientific, Marlborough, MA, USA)
2534812|NCT02665130|Active Comparator|Tai-Chi group|Tai-Chi exercise plus Indacaterol 150ug/day
2534813|NCT02665130|Placebo Comparator|Pulmonary rehabilitation group|Conventional exercise plus Indacaterol 150ug/day
2534918|NCT02664571|Other|ACA with isolated hemosiderosis|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with isolated hemosiderosis.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2534919|NCT02664571|Other|ACA with lobar hematoma(s)|"This group is composed of patients with amyloid cerebral angiopathy (ACA) with lobar hematoma(s).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2534920|NCT02664571|Other|Alzheimer's without ACA|"This group is composed of Alzheimer's type dementia without MRI signs in favor of amyloid cerebral angiopathy (ACA).~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2534925|NCT02664571|Other|Healthy volunteers|"This group is composed of healthy volunteers.~Intervention: Pet scan with FBB~Intervention: MRI scan~Intervention: APO E genotyping"
2534975|NCT02664064|Experimental|online Diabetes Prevention Program|Participants will receive access to a 12-month online diabetes prevention program modeled after the CDC DPP curriculum. Participants receive online curriculum, access to a live health coach, interactive group message forums, and connected weight and activity monitoring devices.
2534977|NCT02664064|No Intervention|Matched Control|A de-identified dataset of control subjects matched on age, gender, prediabetes diagnosis, body mass index, comorbidities and socioeconomic status will be cultivated for comparison to the active intervention arm.
3167566|NCT00540098|Active Comparator|3|Placebo + aerobic exercise
3167567|NCT00540098|Placebo Comparator|4|Placebo + relaxation
3167568|NCT00540111|Other|1|"Study of intervention, prospective,uncontrolled Group Number: 1~Group Type:Other - the subjects of group were compared the initial moment (M0 - moment without soluble fiber supplementation)with the others two moments: M1 (one month after soluble fiber supplementation) and M2 (four months after soluble fiber supplementation).~Group Description - HIV-positive individuals with hypertriglyceridemia (serum levels ≥ 200 to ≤ 500 mg/dL),who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study.~Intervention:Received 20g/day of soluble fiber® (partially hydrolyzed guar gum) for 4 months at pre-established times."
3167569|NCT00540137|Active Comparator|NRTIs plus NNRTI arm|nevirapine 400 mg once daily (after 12 weeks induction)with a nucleoside backbone
3167570|NCT00540137|Active Comparator|NRTIs plus PI arm|atazanavir 300 mg once daily, ritonavir 100 mg once daily with a nucleoside backbone
3167571|NCT00540150|Active Comparator|1|Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
3167572|NCT00540150|Active Comparator|2|Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
3167573|NCT00540176|Experimental|Cohort A|Recurrent disease with previous surgery, radiation therapy and/or chemotherapy
3167574|NCT00540176|Experimental|Cohort B|Newly diagnosed disease with no previous therapy
2534098|NCT02670005||FFR-PCI group|patients with ST-segment elevation myocardial infarction (STEMI) who received fractional flow reserve (FFR)-guided selective percutaneous coronary intervention (PCI)
2534106|NCT02670005||angiography-PCI group|patients with STEMI who received angiography-guided selective PCI
2534275|NCT02668926|Experimental|Lisdexamfetamine, d-amphetamine, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2534280|NCT02668926|Experimental|d-amphetamine, Placebo, Lisdexamfetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2534285|NCT02668926|Experimental|Placebo, Lisdexamfetamine, d-amphetamine|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 3 arms with three treatment conditions in the same subject. The three treatment conditions are placebo, lisdexamfetamine, and d-Amphetamine sulfate.
2534432|NCT02667847||Preoperative patients|Preoperative patients were asked to verbally rate their anxiety 1=on a scale from 0-10 and 2=using the new smiley scale
2534471|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% healthy|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Healthy volunteers
2534475|NCT02667535|Experimental|Isosorbide Mononitrate 0.5% anal fissure|Isosorbide Mononitrate gel 0.5% - 2g Anorectal usage Once daily Participants with anal fissure
2534476|NCT02667535|Experimental|Isosorbide Mononitrate 1.0% anal fissure|Isosorbide Mononitrate gel 1.0% - 2g Anorectal usage Once daily Participants with anal fissure
2534478|NCT02667535|Experimental|Isosorbide Mononitrate 2.0% anal fissure|Isosorbide Mononitrate gel 2.0% - 2g Anorectal usage Once daily Participants with anal fissure
2534514|NCT02667262||Extended Release and/or Long-Acting Opioids|
2534588|NCT02666937||ICU-patients (prospective)|Critically ill patients (18 years and older) on mechanically ventilation who have an arterial line and require bloodgasanalysis for medical reasons
2534590|NCT02666937||Emergency Department (prospective)|Patients (18 years and older), who are presented to the Emergency Department, and require bloodgasanalysis for medical reasons
2534595|NCT02666937||Pulmonary department (prospective)|Patients (18 years and older) who visit the outpatient clinic of the pulmonary department for different pulmonary functional test and require bloodgasanalysis for medical reasons
2534600|NCT02666937||Pulmonary department (retrospective)|Patients (18 years and older) who visited the outpatient clinic of the pulmonary department in the past of the VU medical centre in Amsterdam or the Medical Centre Alkmaar for different pulmonary functional test and required bloodgasanalysis for medical reasons
2534660|NCT02666365|Active Comparator|Bolus infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion
2534661|NCT02666365|Active Comparator|Continuous Infusion of Cefazolin|Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion
2534712|NCT02665858|Active Comparator|IIH Patients|Patients diagnosed with Idiopathic Intracranial Hypertension who undergo OCT imaging
2534718|NCT02665858|Active Comparator|Control Group|Patients diagnosed with headache with ruled out Idiopathic Intracranial Hypertension who undergo OCT imaging
2534754|NCT02665546||Case|Patients with diagnosis of LCH based on histopathological or clinical and radiological findings.
2534757|NCT02665546||Controls|Current or ex smokers matched with cases for age, gender and smoking history.
2534857|NCT02664896||Knee Osteoarthritis Cohort|Subjects with knee osteoarthritis will be asked to participate in the knee osteoarthritis testing session. This group will participate in 1 three hour testing session.
2534859|NCT02664896||Healthy Subject Cohort|Healthy subjects will be asked to participate in the healthy control testing session. This group will participate in 1 two hour testing session.
3167575|NCT00540189|Other|Initial appendectomy|children with complicated appendicitis will undergo initial appendectomy
3167576|NCT00540189|Other|Interval appendectomy|children with complicated appendicitis will undergo initial antibiotic treatment followed by an interval appendectomy
2534952|NCT02664259|Experimental|UTB-VBN-EBUS group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
3167577|NCT00540202|Experimental|1.Oral quinine|Patients will be given oral quinine at the dose of 10mg/kg 8 hourly for 7 days
3167578|NCT00540202|Active Comparator|2. Coartem|Tablets
3167579|NCT00540215|Active Comparator|1|450 nmol GLP-2 SC
3167580|NCT00540215|Placebo Comparator|2|1 ml isotonic saline SC
3167581|NCT00540241||Second-line pemetrexed treatment in NSCLC|Patients with NSCLC who will start second-line treatment with pemetrexed.
3167582|NCT00540254|Active Comparator|Arm 1|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
3167583|NCT00540254|Active Comparator|Arm 2|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
3167584|NCT00540267||Schizophrenia|Chronic schizophrenia with aged 18-80 years
3167585|NCT00540280|Active Comparator|Surgery alone|Surgery alone
3167586|NCT00540306||Diagnostic Tool|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
3167587|NCT00540332|Placebo Comparator|Placebo|"Approximately 17 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
3167588|NCT00540332|Experimental|Palifermin|"Approximately 23 subjects to receive palifermin. Subjects will be enrolled as follows:~PK cohort will be randomized in a 3:1 ratio [palifermin: placebo] in at least 12 subjects~Non-PK cohort will be randomized in a 1:1 ratio [palifermin: placebo] in up to 28 subjects."
2534155|NCT02669498|Active Comparator|Surgery with fallopian tube removal|Patients receiving routine fallopian tube removal during pelvic surgery after randomization.
2534169|NCT02669498|No Intervention|Surgery without fallopian tube removal|Fallopian tubes are not removed during pelvic surgery after randomization.
3167589|NCT00540345|Active Comparator|A, RVR LD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV A, RVR LD RBV B, RVR SD RBV
3167590|NCT00540345|Active Comparator|B, RVR SD RBV|Patients who have a RVR will be randomized into two groups with a ratio of 1:1 (Arm A & B)B, RVR SD RBV
2534279|NCT02668874|Active Comparator|Isolite® technique Device|The Isolite® technique differs in that it utilizes a flexible plastic dental adapter to separate the teeth from the cheek and tongue. The resident dentist will show the child the Isolite® before it is placed in the mouth. The resident with whom the child is scheduled will then apply the sealants.
2534284|NCT02668874|Active Comparator|cotton roll technique Device|The resident dentist with whom the child is scheduled with apply the sealants after the cotton roll technique has been placed.
2534330|NCT02668458|Experimental|NIV|NIV group, preoxygenation by NIV: pressure support set for an exhaled tidal volume of 6-8 ml / kg of ideal body weight, PEEP of 5 cm H2O and FiO2 at 100%.
2534342|NCT02668458|Active Comparator|HFNC|High-flow nasal canula oxygen therapy. NHFC group, preoxygenation by NHFC: oxygen flow rate of 60 L / min and 100% FiO2
2534564|NCT02666911|Experimental|4D Ultrasound|4D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury. The same patients will be imaged with both 2D and 4D transducers.
2534565|NCT02666911|Active Comparator|2D ultrasound|2D ultrasound imaging of the carpal tunnel. 20 healthy volunteers between the ages of 18 and 80, who have no history of carpal tunnel syndrome or wrist injury.The same patients will be imaged with both 2D and 4D transducers.
2534589|NCT02666547|Other|68Ga-NODAGA-RGD,18F-FDG,18F-FET PET/CTs|Active Comparator: 68Ga-NODAGA-RGD radiotracer All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT or a 18F-FET PET/CT
2534699|NCT02666001|Experimental|Part 1 (BMS-663068+methadone)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of methadone
2534701|NCT02666001|Experimental|Part 2 (BMS-663068+buprenorphine and norbuprene)|Effect of multiple doses of BMS-663068, 600mg ER on the exposure of buprenorphine and norbuprenorphine
2534753|NCT02665559||Hypogonadism group|a cross-sectional and prospective study, in HIV-infected men less than 50 years old, with HIV-RNA ≤ 50 cop/mL under ART who had never presented AIDS
2534818|NCT02665325||TSHsuppressive therapy group|TSH-suppressive therapy group: newly diagnosed differentiated thyroid carcinoma and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
2534820|NCT02665325||Negative control group|Healthy volunteers (normal T3,T4,FT3,FT4,TSH, TG-ab,TPO-ab,TG) are recruited to match the patients with age, gender, education level, ect.
2534823|NCT02665325||Positive control group|Newly diagnosed nodular goiter and undergone thyroidectomy according to the China thyroid association guidelines for the management of thyroid nodule and thyroid cnacer; followed by L-T4 replacement therapy 6/12 months.
2534882|NCT02664766|No Intervention|Control condition|Control condition with no intervention. Participants will be recording their daily alcohol consumption. No lifestyle modification during this period.
2534890|NCT02664766|Experimental|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
2534923|NCT02664454|Experimental|Systematic nurse-led GA|Interactive educational seminar for GPs and nurses, and focused on geriatric assessment in primary care combined with Systematic nurse-led GA and dedicated hotline for GPs seeking geriatric advice
2534929|NCT02664454|Experimental|GP-led GA on a case-by-case basis, as decided by the GP|Interactive educational seminar for GPs, and focused on Geriatric assessment in primary care combined with a GP-led GA on a case-by-case basis, as decided by the GP, and a dedicated hotline for GPs seeking geriatric advice
2534930|NCT02664454|No Intervention|No intervention|No educational seminar Usual care
2534986|NCT02664103|Experimental|SAR439281(Cohort 1)|Regimen 1: one full-dose tablet containing capecitabine and cyclophosphamide, given BID without interruption
2534992|NCT02664103|Experimental|SAR439281(Cohort 2)|Regimen 2: two tablets containing capecitabine and cyclophosphamide, given OD without interruption
2534997|NCT02664103|Experimental|SAR439281(Cohort 3)|Regimen 3: one tablet containing capecitabine and cyclophosphamide, given OD without interruption
2535020|NCT02663661|Other|Autoantibody negative subjects|Subjects who are relatives of persons with T1DM and have tested negative for autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test.
2535021|NCT02663661|Other|One autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for one autoantibody will have a Metabolic Challenge Admission followed by a CGM home test..
2535022|NCT02663661|Other|Two or more autoantibody subjects|Subjects who are relatives of persons with T1DM and have tested positive for two or more autoantibodies will have a Metabolic Challenge Admission followed by a CGM home test..
2535069|NCT02663414|Experimental|Atlas device|Each patient in this arm will receive the Atlas Knee System device on the medial side of the symptomatic knee.
2535123|NCT02663141|Experimental|Losartan|Oral losartan 50 mg daily for 6 months
2535125|NCT02663141|Placebo Comparator|Placebo|Oral placebo daily for 6 months
2535183|NCT02662829|Experimental|Community-based intervention (CBI)|"Nurse training and mentorship in TB prevention using clinical algorithm based on national guidelines.~Health education using a treatment literacy curriculum for parents and guardians.~Community outreach by trained village health workers."
2535195|NCT02662738|Other|Glucose solution|A solution of 50g glucose of which 2% 13C-universally-labeled glucose (2%) and unlabeled glucose (98%) in 250 mL water.
2535233|NCT02662335|Experimental|Arm I (computer-assisted cognitive training)|Patients complete a computerized working memory training program (Cogmed) over 35 minutes a day, 5 times a week for 6 weeks.
2534198|NCT02669394|Active Comparator|Stretching and Relaxation (CON)|"The CON program will be a twice-weekly program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.~To meet the public health mandates of COVID-19, when it is necessary, training will occur at home. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance."
2534218|NCT02669069|Active Comparator|PS1|
2534223|NCT02669069|Active Comparator|PS2|
2534232|NCT02669069|Active Comparator|PS3|
3167591|NCT00540345|Active Comparator|C, non-RVR 24w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D) (C, non-RVR 24w) (D, non-RVR 48w)
3167592|NCT00540345|Active Comparator|D, non-RVR 48w|For patients who do not have a RVR will be randomized into two groups with a ratio of 1:1 (Arm C & D)(C, non-RVR 24w) (D, non-RVR 48w)
3167593|NCT00540358|Active Comparator|Arm G/C|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
3167594|NCT00540358|Experimental|Arm G/C/I|Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
2534373|NCT02668224|Experimental|Vibrasens : Test group|Training programme: vibration training 3/week from Day 1 to Day 60 + Usual activities from day 60 to Day 75.
2534374|NCT02668224|Active Comparator|Control group|Control: Usual activities from day 1 to Day 75.
2534421|NCT02667834|Experimental|Social Cognition and Interaction Training (SCIT)|SCIT Social cognition and interaction training program.
2534427|NCT02667834|Active Comparator|Therapeutic education program (ETP)|Therapeutic education program
3167595|NCT00540371||Port wine stain Birthmark|Port wine stain Birthmark
3167596|NCT00540384|Experimental|NESP - Schedule 1 Part A|Part A - 4.5, 6.75, 9.0 or 13.5 mcg/kg Q3W for 12 weeks
2534577|NCT02666586|Placebo Comparator|Control smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
2534579|NCT02666586|Experimental|Faba Bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder.
2534582|NCT02666586|Experimental|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
2534584|NCT02666586|Experimental|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
2534586|NCT02666586|Experimental|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
2534635|NCT02666170|Experimental|therapy with alpha-lipoic acid daily for six months|
2534671|NCT02666079|Experimental|Treatment arm|Wide local excision (WLE) for breast cancer with intra-operative use of the LightPath® Imaging System.
2534728|NCT02665780|Experimental|Treatment|Periodontal debridement, tongue cleaning, mouth rinsing with 20ml Cetylpyridium Chloride daily for 24 weeks
2534879|NCT02664974|Experimental|HEN group|Home Enteral Nutrition
2534880|NCT02664974|Active Comparator|Control group|Dietary Counseling
2534922|NCT02664467|Experimental|Bright light therapy (BLT)|Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
2534927|NCT02664467|Placebo Comparator|Placebo dim light|Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
2534938|NCT02664116|Experimental|Cambia|Diclofenac postassium powder for oral solution and placebo injection
2534939|NCT02664116|Active Comparator|ketorolac|ketorolac intramuscular injection and placebo oral solution
2535010|NCT02663999|Experimental|diazepam nasal spray (AB)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
2535011|NCT02663999|Experimental|diazepam nasal spray (BA)|Each subject will receive two single doses of investigational product (DL1, DL2) with a 14-day washout between the doses. The order in which the doses are administered will be randomized, with subjects assigned to 1 of 2 treatment sequences: DL1 (A) followed by DL2 (B), or the reverse order (BA).
2535054|NCT02663531|Experimental|Mild cognitive impairment|Patients with mild cognitive impairment
2535055|NCT02663531|Experimental|Alzheimer Disease|Patients with Alzheimer Disease
2535058|NCT02663531|Experimental|Healthy|Healthy volunteers
2535145|NCT02663063|Experimental|SSP treatment group|Case on SSP treatment
2535150|NCT02663063|Sham Comparator|Non-SSP treatment group|Sham SSP treatment
2535179|NCT02662738|Active Comparator|A wheat product|A wheat product (containing 2% 13C-universally-labeled wheat) with natural fruit extract added.
2535190|NCT02662738|Placebo Comparator|Control|A wheat product (containing 2% 13C-universally-labeled wheat) without natural fruit extract added.
3167597|NCT00540384|Experimental|NESP - Schedule 2 Part A|NESP 9.0, 12.0, 15.0 or 18.0 mcg/kg Q4W for 12 weeks
3167598|NCT00540384|Placebo Comparator|Placebo - Schedule 1 Part A|Placebo Q3W for 12 weeks
3167599|NCT00540384|Experimental|NESP - Schedule 1 Part B|Open-label NESP at the dose of study drug administered at the end of Part A. Increase dose at week 19 if hgb < 13.0g/dL and/or RBC transfusion in previous 2 weeks.
3167600|NCT00540384|Placebo Comparator|Placebo - Schedule 2 Part A|Placebo Q4W for 12 weeks
3167601|NCT00540384|Experimental|NESP - Schedule 2 Part B|Open-label NESP at the dose of study drug administered at the end of Part A
3167602|NCT00540410|Experimental|1|
3167603|NCT00540410|Active Comparator|2|
3167604|NCT00540462|No Intervention|1|Medical Group
3167605|NCT00540462|Active Comparator|2|Surgical Group with gastric bypass
3167606|NCT00540462|Active Comparator|3|Sugical Group with Sleeve gastrectomy
3167607|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 50mg/hour|Oseltamivir1 150mg PO q12h for 5 doses + Zanamivir IV continuous infusion at 50mg/hour for 72 hours
3167608|NCT00540501|Experimental|Zanamivir IV 50mg/hour|Zanamivir IV continuous infusion 50mg/hour for 16 hours (total dose of 800mg)
3167609|NCT00540501|Experimental|Oseltamivir 150mg and zanamivir 600mg|Oseltamivir 150mg PO q12h for 5 doses + Zanamivir 600mg IV q12h
3167610|NCT00540501|Active Comparator|Oseltamivir 150mg|Oseltamivir 150mg PO q12h for 3 days
2534269|NCT02668991||Cohort 2|It will consist of planned 50 children and adults aged 6 and older who, as part of their standard care, happen to be beginning a behavioral intervention within 2 weeks after the baseline visit of the study. This intervention can be an applied behavior analysis (ABA) program or similar or a social skills program or a school-based autism program and must be intended to last at least throughout the duration of the study.
2534272|NCT02668991||Cohort 3|It will consist of planned 30 normally developing children and adults. These participants will only have a single visit wherein they will undergo a single session with the task battery and biosensors. There should be 5 participants aged 6-9 years, 5 aged 10-12 years, 5 aged 13-17 years, and 5 aged 18 years and older. This cohort should approximate the male:female ratio in Cohorts 1 & 2, with approximately 1 female for every 5 males.
2534338|NCT02668471|Experimental|Ultrasound guided|Radial artery catheters will be placed with the assistance of bedside ultrasound.
2534351|NCT02668471|Active Comparator|traditional method|Radial artery catheters will be placed by the palpation technique only.
2534431|NCT02668029|Experimental|oxygen|oxygen administered through a nasal cannula at a personalized, fixed flow
2534433|NCT02668029|Placebo Comparator|medical air|Medical air administered through a nasal cannula at the same flow
2534557|NCT02667067|Other|Ant cervical discectomy & fusion (ACDF)|
2534558|NCT02667067|Experimental|Simplify Disc|Simplify Disc
2534575|NCT02666599|Experimental|18F-FDG PET/CT|18F-FDG radiotracer All patients will undergo a 18F-FDG PET/CT and a surgery with probe detection of β+''
2534657|NCT02666469|Active Comparator|Group A Hyperbaric Oxygen Therapy and Exercise Program|Group A: Hyperbaric Oxygen Therapy (HBOT) and Exercise with HBOT sessions for 90 minutes, once daily, 5 times a week for 8 consecutive weeks. HBOT will be provided with 100% oxygen at 2.0 ATA. Patients will exercise in the multiplace hyperbaric chamber while receiving hyperbaric oxygen.
2534659|NCT02666469|Active Comparator|Group B Exercise Program|Group B: Exercise Program in the hyperbaric medical unit without exposure to HBOT
2534702|NCT02665884||Glaucoma EX-PRESS|Glaucoma patients who underwent glaucoma surgery between the years 2014-2015 and had diurnal intraocular pressure measurements over 24 hours.
2534704|NCT02665884||Control Group|Glaucoma patients who had been treated with anti-glaucoma drops and had diurnal intraocular pressure measurements over 24 hours.
2534869|NCT02664714|Active Comparator|PFMT Individualized|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s) 4(5s/10s), 5(5s/5s), 6(5s/5s), 7(6s/6s),8(6s/6s), 9(8s/8s) 10(8s/8s), 11(10s/10s),12(10s/10s)
2534873|NCT02664714|Experimental|PFMT individualized with group|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
2534877|NCT02664714|Active Comparator|12 group PFMT|12 Individualized pelvic floor muscle training:FAST CONTRACTIONS(repetitions) weeks 1(5x),2(10x),3(15x), 4(20x),5(30x),6(40x) 7-12(50x)SUSTAINED CONTRACTIONSNumber of series:weeks: 1 and 2(2), 3-6(3), 7-12(4)Repetitions:week 1(6) week 2(8), weeks 3-12 (10)Sustained contraction time/Resting time: weeks 1(2s/4s),2(3s/6s), 3(4s/8s)
2534921|NCT02664480||study group|Reproductive age women with polycystic ovary syndrome and irregular menses (Salivary Alpha-amylase Levels of 3rd and 24th day of menstrual cyclus)
2534926|NCT02664480||control group|Reproductive age women with regular menses (Salivary Alpha-amylase level of 3rd and 24th day of menstrual cyclus)
2534989|NCT02664129|Experimental|Experimental group with video|30 patients will watch the video of them in acute decompensation phase
2534994|NCT02664129|Sham Comparator|Control group without video|30 patients will not watch the video of them in acute decompensation phase, they pass a standard interview with psychometric scales
2535552|NCT02660307|Experimental|PROGRESS group|this group received the intervention based in meditation in the first 8 weeks. They were instructed to practice at least 5 times a week for up to half an hour a day. During the second 8 week period this group were left to manage their practice on their own.
2535556|NCT02660307|Other|control group|this group received no intervention in the first 8 weeks. During the second 8 week period, this group received the same intervention based in meditation that received PROGRESS group.
3167611|NCT00540527|Experimental|1|local intraarterial recombinant tissue plasminogen activator
3167612|NCT00540527|Active Comparator|2|intravenous (IV) rt-PA
3167613|NCT00540566||Optical Biopsy|Optical Biopsy imaging
3167614|NCT00540605|Experimental|1|4g tenofovir 1% gel applied vaginally 2 hours prior to expected time of cesarean delivery
2535651|NCT02659579|Experimental|The Reader Organisation's Shared Reading Programme|In the Reader Organisation's Shared Reading Programme, parents and children will attend The Reader Organisation's weekly shared reading programme for 8 weeks. The programme consists of two different modules. Parents will attend 'Magical Storytimes' with their children, in which a collection of shared book reading sessions are led by a project worker. Parents will also attend sessions on their own ('Stories for you and Yours') in which they will be informed how to choose books and read interactively with their child.
2535904|NCT02657980|Experimental|YBand(YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (total of 10 applications)
3167615|NCT00540618|Active Comparator|1|MEDI-507
3167616|NCT00540618|Placebo Comparator|2|
3167617|NCT00540618|Active Comparator|3|MEDI-507
3167618|NCT00540618|Active Comparator|4|MEDI-507
3167619|NCT00540631|No Intervention|P|subcutaneous treatment with placebo Placebo- physiological saline containing histamine-dihydrochloride 0.1mL, 0.2mL, 0.4mL, 0.6mL of strength A(1000TU/mL) followed by 0.1mL, 0.4mL, 0.6mL by strength B (10000TU/mL) in weekly intervals
3167620|NCT00540631|Experimental|A|Active treatment with house dust mite extract
3167621|NCT00540657|Experimental|1|
3167622|NCT00540657|Placebo Comparator|2|
3167623|NCT00540670|Experimental|1|
3167624|NCT00540670|Experimental|2|
3167625|NCT00540670|Experimental|3|
3167626|NCT00540670|Placebo Comparator|4|
3167627|NCT00540696|Experimental|darbepoetin alfa|
2534270|NCT02668796|Placebo Comparator|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
2534362|NCT02668510|Experimental|Platelet Rich Plasma Injection Group|shockwave therapy within standard of care using Ossatron system with intervention injection of platelet rich plasma (PRP) using Arthex system, into the plantar fascia at the calcaneal origin
2534365|NCT02668510|Placebo Comparator|Placebo injection group|shockwave therapy with placebo normal saline injection
2534382|NCT02667977|Active Comparator|Group 1|These patients will receive Dextrose 5% and 0.9 NS in their maintenance IV fluids
2534391|NCT02667977|Active Comparator|Group 2|These patients will receive Dextrose 5% and 0.45 NS in their maintenance IV fluids
2534459|NCT02667743|Experimental|Paclitaxel Micelles for Injection + Cisplatin|"In the First Period, 230 mg/m2 of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.~In the Second Period, 300 mg/㎡ of Paclitaxel Micelles for Injection was intravenously administrated for three hours without special infusion device to patients whose minimum neutrophil ≥1.0 × 109 /L and minimum platelet count ≥80 × 109 /L and with no hematologic toxicity of grade II to IV occurred in the First Period. Then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment."
2534461|NCT02667743|Active Comparator|Paclitaxel Injection + Cisplatin|175 mg/m2 of conventional Paclitaxel Injection was intravenously administrated for three hours, then 70 mg/m2 of Cisplatin was intravenously administrated for two hours. Three weeks constituted one course of treatment.
3201489|NCT00903461|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Subjects will receive a total of up to 7 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive a total EGFR AS dose of 1.92 milligrams in 1.78 milliliters on each weekly treatment. This dose may be delivered equally in the same tumor site per weekly session, the primary tumor or cervical lymph nodes.
3201490|NCT00903526||candidemia|
3201491|NCT00903552|Experimental|Low Dose|
2534826|NCT02665182|Experimental|Up-positioning of the testes|Patients receive standard medical therapy and supportive therapy
2534828|NCT02665182|No Intervention|Medical therapy only|Patients receive standard medical therapy only
2534862|NCT02664727|Experimental|Heavy drinkers|The effects of acute exercise in heavy drinkers. Participants will cycle on ergometer for 30 min at 50-60% of Heart Rate Reserve (HRR).
2534863|NCT02664727|Experimental|Alcoholic patients|The effects of acute exercise in alcoholic patients. Participants will cycle on ergometer for 30 min at 55-60% of Heart Rate maximal (HRmax).
2534924|NCT02664584||Cross-sectional cohort|Cohort who took part in the cross-sectional study (n=5186)
2534928|NCT02664584||Cross-sectional cohort + follow-up|Cohort who took part in both the cross-sectional and follow-up study (planned n=500 (on-going))
2534969|NCT02664142|Experimental|BIS Group|"BIS monitor will be used during the GA monitoring, the BIS value will be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the BIS values of 40-60%, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
2534971|NCT02664142|Experimental|Non-BIS Group|"BIS monitor will be used during the GA monitoring, however the BIS value will not be known to the anaesthetist (investigator)~GA induction (Phase 1):~inhalation introduction (Sevorane, 02,AIR (flow 2:2 l/min)) or~intra-venous introduction: (Suphentanil: (0.1-0.3 ug/kg iv.), Propofol (2-2,5 mg/kg iv.), or Mivacron (0.15-2mg/kg ),Tracrium (0.3-0.6mg/kg)~anaesthesia (Phase 2, Phase 3):~hypnotic component: titration of Sevorane concentration, with the aim of achieving the MAC value appropriate for the age of the child, bearing gas mixture: O2/AIR (in proportion of 1:1, with 0.5:0.5 flows)~analgesic component: Suphentanil (continuous dose of 0.1-0.3ug/kg iv. every 20-30 min)~relaxation: Mivacron (continuous dose of 0.1mg/kg iv.), Tracrium(0.3-0.6 mg/kg) Patients in this group will be administered anaesthetic, in order to achieve and maintain the required general anaesthesia."
2535081|NCT02663505||Group 1|Patients receiving either elective or emergency surgery.
2535133|NCT02663024|Experimental|Arm 1|0.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2535136|NCT02663024|Experimental|Arm 2|1.0 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2535141|NCT02663024|Experimental|Arm 3|1.5 mg/kg, iv, weekly infusion of idursulfase beta for 24 weeks
2535147|NCT02663024|Active Comparator|Arm 4|0.5mg/kg, iv, weekly infusion of idursulfase for 24 weeks
2535214|NCT02662465|Experimental|mucositis grade 1, laser 660|Group 1 will include patients with oral mucositis grade 1. Sera used wavelength of 660nm, power 100mW and lluencia of 4 J / cm².
2535217|NCT02662465|Experimental|mucositis grade 2, laser 660|Group 2 included patients with oral mucositis grade 2. Sera used with a wavelength of 660nm, power 100mW and lluencia of 8 J / cm².
2535220|NCT02662465|Experimental|mucositis grade 3, laser 790|Group 3 included patients with oral mucositis grade 3 Sera used laser diode AsGaAl operating in continuous mode, with a wavelength of 790 nm, power of 100mW and fluency of 8 J / cm².
2535274|NCT02662153||Long-term opioid-use cohort|Persons who have received 70 or more days of Schedule II opioid dispensed in a 90-day period, after at least 183 days with no opioid dispensing.
2535275|NCT02662153||IR/SA to ER/LA Switchers|Persons who have switched to or added on an ER/LA product after stable use of an IR/SA opioid regimen.
2535276|NCT02662153||IR/SA to IR/SA Switchers|Persons who have switched to or added on a new IR/SA opioid after stable use of a different IR/SA opioid regimen.
2535331|NCT02661659|Other|Weekly Vaccination|Maintenance multipeptide vaccine (S-588210) administered every week
2535333|NCT02661659|Other|Every other Week Vaccination|Maintenance multipeptide vaccine (S-588210) administered every other week
3167628|NCT00540735|Experimental|1|PDT
3201492|NCT00903552|Placebo Comparator|PBS|
2534337|NCT02668276|Placebo Comparator|Standard NCCN counseling|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment.
2534346|NCT02668276|Experimental|Standard NCCN counseling and Oncotype DX results|National Comprehensive Cancer Network (NCCN) counseling uses recommendations based on currently-accepted approaches to cancer treatment. The result provided by the Oncotype DX prostate test is called a Genomic Prostate Score (GPS). The GPS provides important information about how aggressive a man's cancer is based on the biology of the man's individual tumor.
2534392|NCT02668016|Experimental|Atorvastatin 20mg Daily|Atorvastatin 20mg daily for 1 month
2534401|NCT02668016|Placebo Comparator|Placebo|Placebo daily for 1 month
2534407|NCT02668016|No Intervention|No Treatment|No Atorvastatin or placebo for 1 month
2534437|NCT02667652|Active Comparator|short biliarypancreatic limb|short biliarypancreatic limb
2534439|NCT02667652|Active Comparator|long biliarypancreatic limb|long biliarypancreatic limb
2534485|NCT02667405|Experimental|Whirlpool|Immersion in Whirlpool during therapy
2534487|NCT02667405|Active Comparator|Hot Pack|Hot Pack Application during therapy.
2534513|NCT02667171|Active Comparator|Control group|The control group will receive standardized conventional supervised COPD rehabilitation, delivered in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks.
2534523|NCT02667171|Experimental|Online COPD rehabilitation|Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks.
2534594|NCT02666820|Active Comparator|Large balloon dilatation|Patients underwent clearance of common bile duct stones using a papillary large balloon dilatation.
2534601|NCT02666820|Active Comparator|Mechanical lithotripsy|Patients underwent clearance of common bile duct stones using a mechanical lithotripsy.
2534655|NCT02666326|No Intervention|Conventional diagnostic strategy|"Standard Diagnostics for suspected myocardial infarction, including standard biochemical analysis: min. two measurements of high sensitive troponin T with an interval of minimum 3 hours.~A normal value of high sensitive cardiac troponin-T in both blood samples rules out AMI and the patients can be discharged immediately if no other conditions are suspected."
2534658|NCT02666326|Experimental|Accelerated diagnostic strategy|'Accelerated, combined biomarker rule-out strategy for MI'. Copeptin measurement in a prehospital blood sample combined with high sensitive cardiac troponin T measurement in the first blood sample upon hospital admission, A normal value of both copeptin and cardiac troponin rules out AMI and the patients can be discharged immediately if no other conditions are suspected.
2534703|NCT02665936|Active Comparator|group L|Epidural levobupivacaine 0.125% (Chirocaine) in normal saline in a total volume of 10 ml will be administered epidurally in active stage of labor
2534705|NCT02665936|Active Comparator|group LD4|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 4 mg in a total volume 10 ml
2534708|NCT02665936|Active Comparator|group LD8|Epidural levobupivacaine 0.125%(Chirocaine) in normal saline combined with dexamethasone 8 mg in a total volume 10 ml
2534749|NCT02665572|No Intervention|renal transplant without bladder recycling|the patients allocated to this arm and met inclusion criteria will undergo renal transplant without prior recycling of the bladder
2534751|NCT02665572|Active Comparator|renal transplantation with bladder recycling|the patients allocated in this arm will undergo bladder recycling prior to renal transplantation
2534765|NCT02665338|Sham Comparator|Sham rTMS|The sham TMS system will be connected to an electrical generator on a 9 V battery and electrodes will be placed over the prefrontal cortex. The regulator is triggered by the TMS machine to allow brief, microsecond, pulses of the electrical current through to the skin on the subjects' forehead. Electrical stimulation will be triggered by the TMS machine to correspond to the sham TMS pulses.
2534767|NCT02665338|Active Comparator|Active rTMS|Stimulation frequency for all active subjects: 10 Hertz - Pulse train duration (on time) 5 seconds, Inter-train interval (off time) 10 seconds (15 second cycle time), Power (intensity) level 100% rMT, Total 60 trains, 15 minutes, Total pulses 3000.
2534806|NCT02665117|Active Comparator|KMgCit + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.
2534809|NCT02665117|Active Comparator|KCl + Chlorthalidone|After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.
2534868|NCT02664740|Experimental|Phage therapy|"Patients randomized to this arm will have phage therapy.~Intervention: Topical anti-Staphylococcus bacteriophage therapy"
2534871|NCT02664740|Placebo Comparator|Placebo|"Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm.~Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy"
2534964|NCT02664337|Experimental|Decision tool|"A decision tool will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
2534966|NCT02664337|Active Comparator|Standard treatment information|"Standard treatment information will be provided to participants who currently or previously have had one of the following 12 musculoskeletal conditions: hip arthritis, knee arthritis, ankle arthritis, hip labral tears and femoroacetabular impingement (FAI), osteochondritis dissecans, Achilles tendon rupture, patellofemoral dislocation, distal radius fracture, and fractures of the hip, ankle, tibia, and proximal humerus."
2535001|NCT02663869||HIV Aging-Young|200 patients
2535002|NCT02663869||HIV Aging-Old|200 patients
2535008|NCT02663869||controls|1200 patients
2535040|NCT02663570|Experimental|open|therapy with melatonin 2 mg daily for six months
3201493|NCT00903552|Experimental|High Dose|
2535343|NCT02661425||Standard of Care|
2535345|NCT02661425||EnteraGam|
2535383|NCT02661152|Experimental|Radio-/Chemoradiotherapy + nimorazole|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole but receiving the drug, which is normal standard radiotherapy of HNSCC in Denmark.
3201494|NCT00903578||Kidney transplant recipients|
2534388|NCT02668133|Active Comparator|lipid-based nutrient supplement SQ-LNS|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
2534402|NCT02668133|Experimental|lipid-based nutrient supplement SQ-LNS with phytase|"• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution~1 mg isotopically enriched 68Zn intravenously"
2534536|NCT02667106|Experimental|Single-dose, open label RX0041-2|Active Drug
2534726|NCT02665962|Other|Calorie Restricted (CR) program|The intervention will provide individualized CR program, meal replacement products and nutritional counseling sessions.
2534758|NCT02665533|Active Comparator|Dexamethasone|Dexamethasone 8 mg, one capsule single preoperative dose.
2534760|NCT02665533|Experimental|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg, one capsule single preoperative dose.
2534881|NCT02664779|Experimental|Arrhythmia diagnosis with the 10 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias.
2534885|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 6 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
2534891|NCT02664779|Active Comparator|Arrhythmia diagnosis with the 4 steps method|Of participants whom attending the workshop, we will take 84 whom agree to participate and sign the informed consent. They will be divided into subgroups according to their degree of medical training (nursing technicians, university nursing students, university medical students, nurse practitioners graduates, Professional medical graduates, residents of medical specialties and specialists) and randomly assigned one by one from each educational subgroup to 3 intervention groups A, B or C (A = 10 STEPS method, B = 6 STEPS method, C = 4 STEPS method ) so that each group has the third participants of each level of education ensuring matched groups on the level of training of participants in each group. Following this, an equal theoretical test will be performed for all groups to determine the knowledge base in arrhythmias
2534976|NCT02664025|Active Comparator|simulation group|Interns will carry out 10 VE on a simulator
2534978|NCT02664025|No Intervention|Control group|Interns who will not perform any simulated VE
2535029|NCT02663778|Active Comparator|Standard|The standard arm consists of strength, endurance and flexibility exercises 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
2535030|NCT02663778|Experimental|Standard-plus|The standard-plus arm consists of strength, endurance and flexibility exercises plus task specific timing and coordination exercises to improve gait 2 times per week for 12 weeks. Will also receive a physical activity behavioral intervention.
3167629|NCT00540735|No Intervention|2|
2535376|NCT02661334|Placebo Comparator|Placebo|30g white rice flour
3167630|NCT00540748|Experimental|A1|
3167631|NCT00540748|No Intervention|A2|
3167632|NCT00540761|Experimental|OFDI imaging|OFDI catheter advanced to the distal coronary artery
3167633|NCT00540761|Experimental|Intravenous Ultrasound|Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
3167634|NCT00540774||Oral tissue|detection of oral pathology
3167635|NCT00540787|Active Comparator|Drug Treatment|
3167636|NCT00540787|Active Comparator|ThermoCool Radiofrequency Catheter|Radiofrequency catheter used.
3167637|NCT00540800|Active Comparator|A|Three-weekly chemotherapy
3167638|NCT00540800|Experimental|B|Weekly chemotherapy
3167639|NCT00540813|Experimental|Drug Eluting Balloon|
3167640|NCT00540826||A|A: ADHD-patients receiving non-stimulants (e.g. atomoxetine)
3167641|NCT00540826||B|B: ADHD-patients receiving stimulants
3167642|NCT00540839|Experimental|Montelukast|Participants receive montelukast 4 mg oral granules (OG) or 4 mg chewable tablets (CT) once daily (QD) for 24 weeks and placebo to fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks. Participants aged >6 months to <2 years receive montelukast 4 mg packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive montelukast 4 mg CT QD for 24 weeks.
3167643|NCT00540839|Active Comparator|Fluticasone|Participants receive fluticasone 50 mcg inhalation aerosol twice daily (BID) for 24 weeks and placebo to montelukast 4 mg QD for 24 weeks. Participants aged >6 months to <2 years receive placebo packet of OG QD for 24 weeks. Participants aged >2 years to <64 months receive placebo CT QD for 24 weeks.
3167644|NCT00540852|Other|Diagnostic Tool|Diffuse Optical Spectroscopy Imaging
3167645|NCT00540865|Experimental|A|Participants will receive problem-solving therapy and case management
3167646|NCT00540865|Active Comparator|B|Participants will receive case management
3167647|NCT00540904|Active Comparator|sodium bicarbonate|Solution 154 mEq/L of sodium bicarbonate
2534477|NCT02667782|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is developed by Jon Kabat-Zinn in 1979 (Kabat-Zinn, 1990). It is an eight-week Program that includes practices such as gentle mindful movement (awareness of the body), a body scan (to systematically nurture awareness of the body region by region), and sitting meditation (awareness of the breath to include the four foundations of mindfulness, namely, body, feeling tone, mental state, and mental content) (Cullen, 2011).
2534479|NCT02667782|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT), developed by Zindel Segal, Mark Williams and John Teasdale, employs a cognitive theoretical framework (Cullen, 2011; Segal, Williams, & Teasdale, 2002). It is also delivered as an eight-session group treatment. The first four sessions teach the fundamental concepts and skills of the practice of mindfulness. The remaining four sessions teach the individual how to notice his/her own thoughts and the impact of such thoughts on his/her own physical and emotional experiences.
2534519|NCT02667223|Experimental|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2534524|NCT02667223|Active Comparator|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered subcutaneously to healthy volunteers
2534527|NCT02667223|Experimental|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2534528|NCT02667223|Experimental|Cohort 5: bococizumab 450 mg + rHUPH20|bococizumab 450 mg co-mixed with rHuPH20 and administered subcutaneously to healthy volunteers
2534531|NCT02667223|Experimental|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg co-mixed with rHuPH20 and administered subcutaneously to subjects with hypercholesterolemia receiving a statin
2534593|NCT02666768|Experimental|gamma interferon-1b|Gamma interferon-1b 100 mcg SC 3 times weekly for 12 months
2534706|NCT02665897||Eclampsia|pregnant women with eclampsia will be diagnosed by the occurrence of seizures on top of preeclampsia.
2534710|NCT02665897||severe preeclampsia|pregnant women with severe preeclampsia will be diagnosed according to blood pressure ≥160/110 mmHg with proteinuria detection by boiling method +3,+4.
2534711|NCT02665897||healthy|matched normotensive pregnant women.
2534766|NCT02665624|Active Comparator|Stewed apricot juice + senna group|68 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. Additional one liter of stewed apricot juice (made with dried apricot) were told to be drunken until 2 h before colonoscopy.
2534770|NCT02665624|Active Comparator|senna alone group|60 patients received 250 ml of Senna solution (containing 500 mg sennoside A+B calcium) (X-M solution, Yenisehir Pharmaceuticals, Turkey) at 6 PM on the day before colonoscopy, and at 6 AM on the day of the procedure. 1 patient was dropped out due to obstructive sigmoid colon cancer.
2534816|NCT02665091|Experimental|Peer Education Group|Group was self compared after the intervention
2534870|NCT02664857|Active Comparator|vitamin D|After per orally vitamin D supplementation during 12 weeks, serum Vitamin D level will evaluate with laboratory testing. 600 IU vitamin D will apply to 30 subject during 12 weeks. At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
2534872|NCT02664857|Sham Comparator|Placebo|Grup P will not take vitamin D during 12 weeks. This group just only will follow by researchers.At first day end end of the 12 weeks serum vitamin D level will analyse with laboratory testing.End of the 12 weeks, the children will be perform dental treatment under general anaesthesia. Postoperative pain, anxiety and sedation will evaluate.
2534915|NCT02664506|Experimental|Word repetition after a tiem delay|People with Aphasia and Short-Term Memory impairment will receive a behavioral treatment: Word repetition after a time delay. This is the intervention: repetition of words after a 5 or 10 second delay.
2534988|NCT02664233|Experimental|Connected group|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
2534993|NCT02664233|No Intervention|Usual diabetes education and care|Participants will receive standard diabetes education and care; each of the recruiting clinics offers diabetes self-management education programs.
2535031|NCT02663700|Experimental|1.8x10^6 sporozoites 2 doses|To be completed after safety data from Cohorts 1 and 2 are reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 3 and 11. n=8
2535034|NCT02663700|Experimental|2.7x10^6 sporozoites 2 doses|To be completed after safety data from Cohort 3 is reviewed. Vaccination with 1.8x10^6 sporozoites on study weeks 5 and 13. n=8
2535039|NCT02663700|Experimental|2.7x10^6 sporozoites 3 doses|Subjects to be assigned 1:1 to either PfSPZ vaccine (pending safety data from cohort 4) or placebo. Subjects will be administered the intervention on a 0, 8, and 16 week schedule (study days 1, 57, and 113). n=80
2535045|NCT02663700|Experimental|4.5x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 4.5x10^5 sporozoites on study weeks 1 and 9. n=8
2535046|NCT02663700|Experimental|9x10^5 sporozoites 2 doses|Initial vaccination arm. Vaccination with 9x10^5 sporozoites on study weeks 1 and 9. n=8
2535095|NCT02663271|Experimental|Optune+Pulsed Bevacizumab|The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.
2535102|NCT02663271|Other|Historical Controls|Historical controls treated with continuous bevacizumab alone or in combination with standard chemotherapy will be compared with the Optune arm. Information will be collected: Bevacizumab or additional chemotherapy, physical examination and quality of life questionnaires performed and brain MRI.
2534555|NCT02666963|Experimental|RTA 901 10 mg or 40 mg or Placebo|RTA 901 capsules (10 mg or 40 mg) or placebo taken orally in a single dose. Group 1: RTA 901 10 mg or matching placebo Group 2: RTA 901 20 mg or matching placebo Group 3: RTA 901 ≤ 40 mg or matching placebo Group 4: RTA 901 ≤ 80 mg or matching placebo Group 5: RTA 901 ≤ 160 mg or matching placebo Group 6: RTA 901 ≤ 320 mg or matching placebo Group 7: RTA 901 ≤ 640 mg or matching placebo Dose selection will be based on the safety, tolerability and available pharmacokinetics observed in prior study groups.
2534556|NCT02666963|Experimental|RTA 901 Dose TBD or Placebo|RTA 901 capsules, Dose TBD mg or placebo taken orally once daily for 14 days. Group 8: RTA 901 X mg or matching placebo Group 9: RTA 901 ≤Y mg or matching placebo Group 10: RTA 901 ≤Z mg or matching placebo The actual doses for Arm 2 will be selected based on the safety and available pharmacokinetic data obtained from Arm 1.
3201495|NCT00903591||1|All women will be interviewed by telephone using the a similar questionnaire as used in the parent study. DNA samples will be obtained either via blood samples drawn during a home or clinic visits, or an Oragene Saliva DNA Self-Collection Kit sent to the participant's home.
3201496|NCT00903604|Experimental|AP214|Infusions of sequential ascending dosages of AP214
2534814|NCT02665156|Experimental|Robotic Stapled orthotopic neobladder|Intracorporeal stapled neobladder using robotic staplers: Partly stapled orthotopic neobladder: robotic staplers applied to create the neobladder neck and to suture the left side of the posterior aspect of neobladder. Right side of the posterior aspect of neobladder and the anterior aspect of the neobladder hand sewn.
2534876|NCT02664844|Experimental|Obese adolescent|
2534931|NCT02664519|Experimental|Exercise training followed by no exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
2534932|NCT02664519|Experimental|No exercise training followed by exercise training|CKD subjects will be randomized to exercise training (to squeeze a tennis ball repeatedly for at least 30 min/day) or no exercise training for 28 days. Procedures in baseline visit will be repeated followed by cross over to alternate group for 28 days followed by repeat of baseline procedures.
2534933|NCT02664519|No Intervention|Normal Control|Control subjects without CKD will undergo baseline assessment as above.
2534950|NCT02664051|Placebo Comparator|placebo|mannitol
2534951|NCT02664051|Active Comparator|disodium cromoglycate|disodium cromoglycate
2534987|NCT02663960|Experimental|fixed citrate doses protocol|Fixed citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which was set to meet a circuit citrate concentration of 4 mmol/l (duration: the maximum time is 72 hrs).
2534995|NCT02663960|Active Comparator|adjusted citrate doses protocol|Adjusted citrate doses protocol: Anticoagulant Citrate Dextrose Solution ( Na+ 224, citrate 113, bicarbonate 203mmol/l, Fresenius Kabi, Italy) was administered in the prefilter ahead of the blood pump, which the starting infusion rate be set 2.5 % of blood flow ( dosage range: 160-250ml/h) and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l (duration: the maximum time is 72 hrs. )
3201497|NCT00903604|Placebo Comparator|Placebo|Infusions of saline solution
3201498|NCT00903643||Healthy subjects|
2535152|NCT02662907|Experimental|Aspirators Group|"Participants receive modified barium swallow at baseline and after 8 weeks of using the expiratory muscle strength training (EMST) device. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.~Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.~Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device."
2535154|NCT02662907|Other|Non-Aspirators Group|Participants receive modified barium swallow at baseline. Participants given neurocognitive exams at baseline. Questionnaires completed about symptoms and quality of life at baseline and at 12 months.
3201499|NCT00903643||PBS subjects|
3201500|NCT00903656|Experimental|Caelyx/Lapatinib|
3201501|NCT00903669||Peripheral Facial Paralysis (PFP)|Patients who are diagnosed with peripheral facial paralysis.
3201502|NCT00903708|Experimental|LY2275796|
2535502|NCT02660515|Active Comparator|ORIF|The operation has to be performed within 3 weeks after the initial trauma. According to the current standard, antibiotic prophylaxis (Cefazoline, 1000 milligram intravenous) will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis and the arteria radialis. After the fracture site is exposed, the fracture will be reduced and an appropriate volar locking plate will be positioned. The type and brand of the plate are at discretion of the treating surgeon. When a dorsal approach is deemed necessary the distal radius will be approached between the third and fourth dorsal extensor tendon compartments. To evaluate the quality of articular reduction, fluoroscopic images will be obtained. Wound closure will be performed using standard techniques.
2535503|NCT02660515|Active Comparator|ORIF with additional wrist arthroscopy|Surgery will be performed by a certified trauma surgeon, with experience in wrist arthroscopy. A delay of minimal 5 days before performing arthroscopy is mandatory to enable visualisation due to the organisation of the hematoma. During wrist arthroscopy, the forearm will be positioned upright and in neutral position, the elbow flexed by 90° and axial traction of 4-6 kg will be performed. Four portal entrees are created by superficial stab incisions and blunt preparation through the joint capsule; one midcarpal radiair and one midcarpal ulnar portal and the 3-4 and 6-R portal. A shaver is used for removal of fracture haematoma and osteocartilaginous debris. Cartilage damage will be graded using the Outerbridge classification system. With the 1 mm hook probe assessment of the quality of reduction and ligamentous injuries (TFCC, scapholunate and lunotriquetral) will be performed. Wound closure will be performed using standard techniques.
3201503|NCT00903721||1|Patients with perennial allergic rhinitis
3201504|NCT00903721||2|Patients with seasonal allergic rhinitis (including patients who also have perennial allergic rhinitis)
3201505|NCT00903734|Experimental|Erlotinib Hydrochloride|Those eligible for umbrella of studies and have not received Erlotinib hydrochloride in past, will first receive Erlotinib hydrochloride alone.
3201506|NCT00903747|Experimental|1|Prucalopride
2534609|NCT02666573|Other|SRP|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
2534645|NCT02666287|Experimental|Sequence 1|"Each subject will receive all the 9 treatment regimens in the following order: A,G/B/F/C,H/E/D,I with a washout period of 7 days between each treatment period administered via the ELLIPTA inhaler. Where Treatment A= BAT/FF 900/300 microgram (mcg) (3 inhalations of 300/100 mcg).~Treatment B= BAT 900 mcg (3 inhalations of 300 mcg) concurrently with FF (lactose) 300 mcg (3 inhalations of 100 mcg) from separate inhalers.~Treatment C= BAT 900 mcg (3 inhalations of 300 mcg). Treatment D= FF (lactose) 300 mcg (3 inhalations of 100 mcg). Treatment E= FF (magnesium stearate [MgSt]) 300 mcg (3 inhalations of 100 mcg). Treatment F= FF/VI 300/75 mcg (3 inhalations of 100 mcg/25 mcg). Treatment G= 7-day repeat doses: BAT/FF 300/100 mcg (1 inhalation). Treatment H= 7-day repeat doses: BAT 300 mcg (1 inhalation). Treatment I= 7-day repeat doses: FF (lactose) 100 mcg (1 inhalation)."
2534648|NCT02666287|Experimental|Sequence 2|Each subject will receive all the 9 treatment regimens in the following order: B/C,H/A,G/D,I/F/E with a washout period of 7 days between each treatment period.
2534650|NCT02666287|Experimental|Sequence 3|Each subject will receive all the 9 treatment regimens in the following order: C,H/D,I/B/E/A,G/F with a washout period of 7 days between each treatment period.
2534651|NCT02666287|Experimental|Sequence 4|Each subject will receive all the 9 treatment regimens in the following order: D,I/E/C,H/F/B/A,G with a washout period of 7 days between each treatment period.
2534652|NCT02666287|Experimental|Sequence 5|Each subject will receive all the 9 treatment regimens in the following order: E/F/D,I/A,G/C,H/B with a washout period of 7 days between each treatment period.
2534653|NCT02666287|Experimental|Sequence 6|Each subject will receive all the 9 treatment regimens in the following order: F/A,G/E/B/D,I/C,H with a washout period of 7 days between each treatment period.
3201507|NCT00903747|Placebo Comparator|2|Placebo/moxifloxacin
3201508|NCT00903799|Other|1|"Gastric electrical stimulation using Enterra Therapy. Device activated during 4 months then device in 'OFF' position the 4 following months.~After the cross-over period, device activated until the end of the trial"
2534803|NCT02665195||Prospective Registry of Multiplex Testing|This is a prospective ascertainment study that will obtain medical information and biospecimens from two different types of families: 1) Families transmitting sequence variants in non-BRCA predisposition genes that are either functionally deleterious or likely to be functionally deleterious based upon the interpretation of the laboratory that performed the testing on the Index Participant (Initial PROMPT enrollee), and 2) Families transmitting variants of uncertain significance (usually rare missense variants) in non- BRCA predisposition genes. Attempts will be made to collect a biospecimen and a completed risk factor questionnaire from each participant.
2534831|NCT02664805|Active Comparator|LEO 124249 ointment|Twice daily cutaneous application for 8 weeks
2534833|NCT02664805|Placebo Comparator|LEO 124249 ointment vehicle|Twice daily cutaneous application for 8 weeks
2534895|NCT02664675||Periimplantitis|"patients formerly treated with a non surgical procedure without antibiotics with at least one functional dental implant with at least on pocket deeper than 5 mm with bleeding on probing and radiographical alveolar bone loss.~These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis."
2534896|NCT02664675||Periodontitis|patients formerly treated with a non surgical procedure without antibiotics for a generalized severe chronic periodontitis (in accord to Armitage 2009) and needing a resective surgical procedure (periodontal pockets deeper than 5 mm with bleeding on probing) These patient will be treated by open flap debridement nd the granulation tissue xill be harvested for analysis.
2534899|NCT02664675||Healthy patient|healthy patients needing crown lengthening allowing collection of gingival explants
2534954|NCT02664350|Experimental|Genotype Arm|Participants in this arm will have genotyping performed for CYP2D6 variants. Based on the CYP2D6 the treating physicians will be provided with an interpretation of genotype results, and a recommendation will be provided by a pharmacist on the UF Health Personalized Medicine team through one-on-one consultation with the physician for the type of pain medication. These participants will also be genotyped for OPRM1 variants at the end of the study which is performed for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
2534955|NCT02664350|Active Comparator|Traditional Arm|Participants in this arm will have genotyping for CYP2D6 and OPRM1, however this information will not be provided to the physicians for treatment of the analgesic therapy but will be used for research purposes only. In addition, they will fill out the following questionnaires Brief Pain Inventory-Short Form (BPI-SF) and M.D. Anderson Symptom Inventory (MDASI).
2535024|NCT02663830|Experimental|(Sildenafil & clomiphene citrate group)|105 Patients will receive 25 mg sildenafil citrate 6 hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
2535025|NCT02663830|Active Comparator|clomiphene only|105 patients will receive only clomiphene citrate 100mg/day (day 2 to 6) orally (2 tablets at same time daily).
2535067|NCT02663440|Experimental|IMRT|Hypofractionated IMRT With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor
3201509|NCT00903799|Other|2|"Gastric electrical stimulation using Enterra Therapy. Device in 'OFF' position during 4 months then device activated the 4 following months.~After the cross-over period, device activated until the end of the trial"
3201510|NCT00903812||A|No intervention - observational study
3201511|NCT00903825|Active Comparator|Manual palpation|Local anesthetic before femoral artery puncture will be injected with the classic manual palpation technique
3201512|NCT00903825|Experimental|Ultrasound guidance|Local anesthetic before femoral artery puncture will be performed with the use of duplex ultrasound guidance
3201513|NCT00903838|Experimental|1|
3201514|NCT00903838|Active Comparator|2|
3201515|NCT00903851|Experimental|(1) Lidoderm|(1)Commercially available Lidoderm® (lidocaine patch 5%), up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain
3201516|NCT00903864||stethoscopy|
3201517|NCT00903864||BPM|blood pressure monitor
2534611|NCT02667041|Active Comparator|Blood biomarkers|Investigation of pre- and post-treatment protein biomarkers
2534663|NCT02666235|Active Comparator|Remote ischaemic conditioning|Intermittent inflation of a forearm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a curtain.
2534664|NCT02666235|Sham Comparator|Control group|Sham intervention: Arm cuff placement but without inflation during a 40 minute period. A curtain will obscure the patient from the clinical team during this time. Arm cuff placement, no inflation.
2534695|NCT02665819||Pediatric cancer women survivors|Women diagnosed for a cancer between 01/01/87 and 31/12/99 before the age of 15 years old living in Rhône-Alpes, will incur a blood taking for DNA tests (hormone tests) to see their fertility capacity.
2534744|NCT02665637|Active Comparator|CT-P6|Trastuzumab
2534745|NCT02665637|Active Comparator|US-licensed Herceptin|Trastuzumab
2534772|NCT02665377|Active Comparator|ANP|Infusion of h-ANP at dose of 50ng/kg/min fore 5 days, starting at the induction of anesthesia.
2534774|NCT02665377|Placebo Comparator|Placebo|Infusion of NaCl at the same volyme as for ANP for 5 days.
2534864|NCT02665078||Thoracoscopic Ultrasound|Patients who undergo lobectomy or an anatomical segmental resection for malignant lung tumors will be enrolled in the study. After lung resection, the lung will be evaluated by XLTF-UC180 for localization of the tumor. The ultrasound probe will be put on the lung surface in several different directions to obtain the cross section with maximum diameter. The ultrasound image with size measurement of the tumor will be recorded using an ultrasound scanner (EU-Y0008, OLYMPUS MEDICALSYSTEMS CORP., Tokyo, Japan). After ultrasound evaluation, the specimen will be delivered directory to the pathology laboratory and the actual tumor size and histological diagnosis will be determined. In addition, we will evaluate the differences between US image and pathological morphology using HE slides of lung tumor.
2534935|NCT02664558|Experimental|ubenimex|ubenimex capsules 150 mg three times a day (TID), administered orally for a total of 24 weeks.
2534936|NCT02664558|Placebo Comparator|placebo|placebo capsules TID, administered orally for a total of 24 weeks
2535004|NCT02663947||ultrasound group|ultrasonographic measure for optic nerve sheath diameter
2535175|NCT02662725|Experimental|ipilimumab + Stereotactic Radiosurgery|ipilimumab combined with a Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases
2535284|NCT02661971|Active Comparator|FLOT alone|"Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
2535285|NCT02661971|Experimental|FLOT + Ramucirumab|"Pre-operative therapy with FLOT + ramucirumab followed by surgical resection followed by post-operative therapy with FLOT + ramucirumab~Ramucirumab 8mg/kg, d1~Docetaxel 50 mg/m², d1~Oxaliplatin 85 mg/m², d1~Calciumfolinat 200 mg/m², d1~5-Fluorouracil 2600 mg/m², d1"
3167648|NCT00540904|Active Comparator|Sodium chloride|Solution of 154 mEq/L of NaCl
3167649|NCT00540917|Experimental|cooling spray|cooling spray during laser treatment
2535516|NCT02660619||Low-risk patients|These will be patients with a prescription for opioids for chronic pain for at least 30 days, recruited from university-affiliated pain and rehabilitation medicine clinics that routinely employ precautions to avoid prescribing such medication to individuals seeking it for non-therapeutic reasons
2535520|NCT02660619||High-risk patients|These patients will be in treatment for addiction to opioids and have (or have had) a prescription of opioids to treat pain.
2535771|NCT02658695||Group 1|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) <10 mm.
2535773|NCT02658695||Group 2|The distance between the fundal endometrial surface and air bubbles (air bubbles depth) >10 mm.
2535936|NCT02657642||Cohort 1 (exposed)|cohort 1: patients who will receive the OMAGE-P transitional care in geriatric or internal medicine departement of the Eaubonne Hospital
2535939|NCT02657642||Cohort 2 (non exposed)|Cohort 2: : patients included in the usual care arm of the OMAGE RCT study in 2007-2008
2535983|NCT02657382|Experimental|Heart Rate Variability (HRV) Biofeedback (BF)|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests. Participants in this group will also participate in heart rate variability (HRV) biofeedback (BF) during the first six weeks of the study.
2535986|NCT02657382|Experimental|Waitlist Control|Participants with coronary artery disease randomized to this group will complete myocardial blood flow (MBF) imaging and mental stress tests.Participants in this group will receive the heart rate variability (HRV) biofeedback (BF) intervention between the week 6 and week 12 study visits.
2536013|NCT02656914|Experimental|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
2536016|NCT02656914|Placebo Comparator|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
2536130|NCT02656056|Experimental|Obese Adults|Adults with a BMI between 32-37 will consume 8 oz of the fermented soybean beverage, twice daily.
2536180|NCT02655926|Active Comparator|STN Arm|Participants would only have STN deep brain stimulation switched at optimal settings for that participant on for 12 weeks.
2536358|NCT02654899|Placebo Comparator|Part 1_Cohort 2_Placebo|Single dose of placebo
3167650|NCT00540943|Experimental|Single Arm|irinotecan and cetuximab in combination with pazopanib.
3167651|NCT00541047|Experimental|RADICALS-RT: Early RT|
3167652|NCT00541047|Experimental|RADICALS-RT: Salvage RT|
3167653|NCT00541047|Experimental|RADICALS-HD: Radiotherapy Alone|
3167654|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 6 months|
3167655|NCT00541047|Experimental|RADICALS-HD: Radiotherapy + 24 months|
3167656|NCT00541060|Active Comparator|A|250 young patients presenting several carious lesions
3167657|NCT00541060|Placebo Comparator|B|160 young adults totally caries free
3167658|NCT00541086|Experimental|A - anastrozole|Up-front adjuvant anastrozole for 5 years
3167659|NCT00541086|Experimental|B - exemestane|Up-front adjuvant exemestane for 5 years
3167660|NCT00541086|Experimental|C - letrozole|Up-front adjuvant letrozole for 5 years
3167661|NCT00541086|Active Comparator|D - tamoxifen followed by anastrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by anastrozole for 3 years
2534612|NCT02666534|Experimental|AFL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
2534614|NCT02666534|Active Comparator|MAL-PDT|Forty-five Korean patients were enrolled in this study. Patients were randomly assigned to receive either AFL-PDT or MAL-PDT in a 1:1 ratio. As result, the patients were randomized to treatment with AFL-PDT (21 patients) or MAL-PDT (24 patients)
2534638|NCT02666183|Experimental|Closer|"The full intervention (Closer) is a tested intervention that uses videoconferencing technology (WebEx) for delivery and delivers the highest dose of the intervention. This arm of the intervention will deliver personalized information to the DCG (aimed at enhancing self-efficacy) and emotional support via nurse coaching as well as the opportunity for the DCG to talk with the oncologist and patient in real time during a minimum of four patient-oncologist office visits over a 4-month period (at least once/month). For patients who have more than one oncologist-patient meeting/month, the study will use the videoconference technology to allow the DCG to join as many of the join in as many of the oncologist-patient office visits as desired."
2534641|NCT02666183|Active Comparator|Video-C Only|"This arm will involve the delivery of information solely via the use of videoconference technology during the patient-oncologist-DCG visit. There is always the possibility that the DCG will receive emotional support from the oncologist during the office visit (as would potentially occur during a face-to-face meeting) - but this will not be delivered systematically as in the Closer intervention. As with the Closer intervention, the DCG will be able to participate in the patient-oncologist visit in real time during a minimum of four office visits over the 4-month study period (total dose ~5 hours). The procedure for these meetings will be the same as outlined for Closer but will not involve having the nurse involved in the videoconference sessions with the oncologist, patient, and DCG."
2534644|NCT02666183|Active Comparator|Web-Only|"This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association, etc.), b)Resources for DCGs (links to the Caregiving from a Distance, etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention."
3201518|NCT00903890||A|Individuals who have previously received radiation therapy and anthracycline chemotherapy for their Hodgkin's or non-Hodgkin's lymphoma.
3201519|NCT00903903||1|RA patients with at least one active synovitis
2534791|NCT02665234|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
2534794|NCT02665234|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
2534835|NCT02665013|Experimental|Tailored|Participants will complete surveys at each intervention time point. Based on survey responses, they will receive vaccine information on the study website tailored to their vaccine concerns and values
2534836|NCT02665013|Placebo Comparator|Untailored|Participants will complete surveys at each intervention time point and receive vaccine information on the study website. The vaccine information will NOT be tailored to their concerns and values.
2534837|NCT02665013|No Intervention|Usual Care|Participants will complete surveys at each intervention time point. They will receive vaccine information sheets that are provided in the well child visits at enrollment in the study.
2534884|NCT02664662|Experimental|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
2534888|NCT02664662|No Intervention|standard education|Only provide one paper of post operation and give education of rehabilitated exercise
2534958|NCT02664441|Active Comparator|Exenatide once weekly extended-release|Injections of glucagon-like peptide (GLP)-1 agonist exenatide once weekly extended-release (Bydureon®) for 36 weeks in randomized intervention followed by 18 weeks open label exenatide once weekly extended-release.
2534960|NCT02664441|Placebo Comparator|Matching placebo|Weekly injections of placebo for 36 weeks followed by 18 weeks open label exenatide once weekly extended-release.
2535038|NCT02663583||Intensity-Modulated Proton Therapy or( IMPT) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
2535044|NCT02663583||TransOral Robotic Surgery (TORS) Group|"Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months.~Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months.~Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits."
2535100|NCT02663258|Experimental|Pembrolizumab arm|All participants treated with Pembrolizumab, 200mg iv, 3weekly
2535157|NCT02662972|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards the sphenopalatine ganglion in the affected side (ipsilateral to the pain)
3201520|NCT00903903||2|Non-RA patients with at least one active synovitis
2535279|NCT02662127|Experimental|SIGVARIS®. Class 2 - RAL: 23-32|Graduated elastic compression stockings
2535324|NCT02661646||Advanced Pneumatic Compression Group|All study participants will receive treatment using an advanced pneumatic compression device.
2535573|NCT02660008|Active Comparator|GlucaGen|GlucaGen (native glucagon) Planned doses: 0.5, 1.0 mg s.c.
3201521|NCT00903955||Chronic Obstructive Pulmonary Disease|Subjects diagnosed with COPD are classified according to standards set forth by the Global Initiative on Obstructive Lung Disease. This study recruits subjects in each of three GOLD categories.
2534633|NCT02666378|Experimental|CMR/ECHO|"Prior to starting chemotherapy treatment, the participant will undergo the following procedures:~Cardiac Magnetic Resonance Imaging (CMR)~Echocardiogram (ECHO) in patients with no clinically indicated scans~Each imaging procedure will be repeated at predetermined times during the protocol~Simple blood collection for plasma biomarker analysis"
2534692|NCT02666105|Experimental|Exemestane Therapy|
2534746|NCT02665663|Other|healthy volunteers|"Constitution of a control group consisting of 20 healthy volunteers, matched for age and sex to establish a normal pressure force of the language depending on the age and sex value"
2534747|NCT02665663|Other|Patients with Amyotrophic Lateral Sclerosis|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis (ALS), included at diagnosis of the disease on clinical and electromyographic arguments addressed in speech pathology consultation without a complaint swallowing.
2534748|NCT02665663|Other|patients with Amyotrophic Lateral Sclerosis and swallowi|Constitution of a group of 20 patients with Amyotrophic Lateral Sclerosis ( ALS) and swallowing disorders clinically objectified in the ENT consultation.
2534842|NCT02665026|Experimental|stoma closure at different times|choose different times to do stoma closure after surgery for rectal cancer
2534883|NCT02664636|Experimental|The study population|"The study population consists of patients 20 and 75 years of age who have had a supra-tentorial ischemic or hemorrhagic stroke. The study covers consulting or hospitalized patients at the neurological rehabilitation service (NHS) of Grau du Roi Medical Center, part of the Nîmes University Hospital. Most patients originate from a 2-4 week stay in the neurological acute care, cardiac or polyvalent departments of the University Hospitals of Montpellier or Nîmes.~Intervention: Physiotherapy~Intervention: Occupational therapy~Intervention: Functional near-infrared spectroscopy"
3201522|NCT00903981|Experimental|Avanafil 100mg|
2535023|NCT02663635|Other|Single Arm|
2535072|NCT02663466||Recurrent Group|Patients with clinically confirmed recurrence of sacrococcygeal pilonidal sinus following Limberg flap surgery were eligible (recurrent group, RG). They were evaluated for erroneous off-midline closures as an exposure variable.
2535073|NCT02663466||Nonrecurrent Group|Patients who underwent same surgery from the January 2008 to July 2015 but have not had recurrence in the five-year follow-up period (non-recurrent group, NRG) were accepted eligible. They were evaluated for erroneous off-midline closures as an exposure variable.
2535128|NCT02663089|Experimental|[14C]-GSK961081 IV+GSK961081 inhalation; [14C]-GSK961081 oral|On Day 1 of Treatment Period 1, after an overnight fast of at least 8 hours, each subject will receive [14C] GSK961081 4 micrograms (mcg) by IV infusion over 1 hour. Within 5 minutes after the start of infusion, subjects will take 1200 mcg non-radiolabelled GSK961081 by inhalation. After Treatment Period 1, there will be a washout of at least 2 weeks. On Day 1 of Treatment Period 2, after an overnight fast of at least 8 hours, each subject will take 200 mcg [14C]-GSK961081 as an oral solution.
2535184|NCT02662790|Experimental|Preterm|
2535224|NCT02662426|Experimental|Drugs for experimental group|Lingdancao granules, 4 packs per time (3g/pack), three times per day; analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
2535225|NCT02662426|Active Comparator|Drugs for positive control group|Oseltamivir phosphate capsule (tamiflu), 1 capsule per time (75mg), twice per day; analogous Lingdancao granules, 4 packs per time, three times per day.Drugs must be used on the day of fever and last for five days continuously.
2535226|NCT02662426|Placebo Comparator|Drugs for placebo control group|Analogous Lingdancao granules, 4 packs per time, three times per day, analogous oseltamivir phosphate capsule, 1 capsule per time, twice per day.Drugs must be used on the day of fever and last for five days continuously.
2535326|NCT02661724|Experimental|Take Charge Burn - Pain (TCBR-Pain)|The TCBR-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress.
2535328|NCT02661724|No Intervention|Education attention control|The attention group receives an educational materials that is matched to the TCBR-Pain intervention in terms of session length and time on the web-based program. The web-based Education attention condition includes 7 sessions delivered over 7 weeks. The Education Attention Control is education materials commonly employed in rehabilitation centers and has been successfully used in several studies as a comparison to active rehabilitation interventions
2535342|NCT02661386|Other|Manometry Device|"During the last 10 minutes of subjects waking up from anesthesia, the motility procedure will be performed."
2535384|NCT02661243|Other|Dentate Sjogren's syndrome arm|30 human adults affected by SS with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2535386|NCT02661243|Other|Dentate healthy controls arm|30 healthy human adults with the need of replacement of missing premolars or molars in the upper or lower jaw. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2535391|NCT02661243|Other|Edentulous Sjogren's syndrome arm|30 human edentulous adults affected by SS with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
2535395|NCT02661243|Other|Edentulous healthy controls arm|30 healthy human edentulous adults with the need of stabilization of the dentures. Intervention: insertion of Biohorizons Laser-lok bonelevel dental implants
3167662|NCT00541086|Active Comparator|E - tamoxifen followed by exemestane|Switch adjuvant treatment with tamoxifen for 2 years followed by exemestane for 3 years
2535545|NCT02660177|Experimental|metamizole|single IV metamizole (10mg/kg) administration
3201523|NCT00903981|Experimental|Avanafil 200mg|
3201524|NCT00903981|Placebo Comparator|Placebo|
2535671|NCT02659319|Experimental|FL + Peer Group (FL+PG; n = 124)|This arm includes the Family Food & Lifestyle intervention plus the 12-session, Peer Group intervention.
3201525|NCT00903994|Other|Single Arm|Single Arm
3201526|NCT00904020|Experimental|(1) Lidoderm|(1) Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
2534707|NCT02665793|Experimental|DBPCFC to peanut cookie, then single-dose DBPCFC x 2|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions"
2534709|NCT02665793|Experimental|Single dose DBPCFC x 2, then DBPCFC to peanut cookie|"Patients will undergo 3 sets of double-blind, placebo-controlled food challenge (DBPCFC):~DBPCFC to a single dose of peanut (or placebo) equivalent to 1 dosing interval below that to which that patient reacted at the baseline DBPCFC to gain entry to the study, on two separate occasions~DBPCFC to incremental doses of peanut (or placebo) baked into a cookie biscuit"
2534777|NCT02665481|Experimental|MBSR|Mindfulness-Based Stress Reduction consists of a brief introductory meeting, eight weekly 2.5-hour classes, and a retreat, followed by monthly booster sessions for approximately 15 months. Content includes instruction in mindfulness meditation practices, gentle mindful movement, and exercises to enhance mindfulness in everyday life.
2534779|NCT02665481|Experimental|Exercise|The exercise protocol is optimal for improving aerobic fitness and insulin sensitivity in older adults, as well as improving strength and balance and reducing indices of frailty.It consists of classes twice weekly for 6 months, building up to 1.5 hr, under the direct supervision of trained exercise instructors, followed by once weekly classes for 12 months.
2534783|NCT02665481|Experimental|MBSR + Exercise|"This condition will receive both MBSR and exercise as described above. Participants in this condition will come in once weekly to receive MBSR and twice weekly to receive exercise classes, with at-home exercise the other two days as well as daily, at-home mindfulness practice. After the initial classes participants will also attend additional weekly or monthly sessions until completion of the study.~Note that at each site a pilot group is undergoing MBSR + Exercise (not randomized, separate from the RCT)."
2534787|NCT02665481|Active Comparator|Health Education|Health Education is a group-based intervention that increases health-related knowledge and action. Health Education improves chronic disease management.Health Education consists of ten weekly 2.5-hour classes, followed by monthly classes for approximately 15 months.
2535032|NCT02663726|Experimental|Yoga intervention group|10 weekly 75-min sessions of specialised yoga plus written advice about physical activity for older adults
2535035|NCT02663726|Active Comparator|Waiting list control group|Usual care plus written advice about physical activity for older adults
3167663|NCT00541086|Active Comparator|F - tamoxifen followed by letrozole|Switch adjuvant treatment with tamoxifen for 2 years followed by letrozolefor 3 years
2535132|NCT02663011||5YR boy|
2535134|NCT02663011||5YR girl|
2535138|NCT02663011||4YR boy|
2535144|NCT02663011||4YR girl|
2535148|NCT02663011||3YR boy|
2535181|NCT02662712|Experimental|Part 1: Single Dose Escalation|The single dose escalation phase of the study will consist of 6 dosing sessions (Sessions I to VI) evaluated in 2 panels (Panels 1 and 2). The dose of JNJ-56136379 will be consecutively escalated over 5 levels, alternating between the 2 panels. Panel 1 will receive 3 single doses (SD1, SD3 and SD3fed) in Sessions I, III and V, respectively. Panel 2 will receive 3 single doses (SD2, SD4 and SD5) in Sessions II, IV and VI, respectively. There will be a washout period of at least 14 days between consecutive JNJ-56136379/placebo dosing in each individual participant.
2535192|NCT02662712|Experimental|Part 1: Multiple dose session|After completion of the fifth single dose session another panel of healthy participant (panel 3) receive multiple doses of JNJ-56136379 at one dose level (MDx) or placebo for 12 or 19 consecutive days (Session VII) in fed or fasted conditions.
2535194|NCT02662712|Experimental|Part 2: Multiple dose escalation|Multiple dose levels will be given in Panel 4 in Session VIII (European sites), Sessions IX and X (European and/or Asian sites) Session XI (Asian sites) for 28 consecutive days in fed conditions. Optional Sessions A-B-C (Panel 4) used for further dose evaluations at European and/or Asian sites. Per session, participants will receive JNJ 56136379 or placebo. Dose progression to the next multiple dose level may be adapted based on the emerging safety and PK outcome of the previous dosing levels.
2535288|NCT02661906|Experimental|SKY Pre|Sudarshan Kriya Yoga is provided to all the enrolled participants. The baseline characteristics of patient is compared with that of their characteristics after yoga intervention. All the participants were provided with yoga training for 6 days and then asked to perform the SKY at home daily till 12 week. The questionnaire on anxiety, depression and quality of life were administered at the baseline and at the end of 6 days of yoga. Biochemical parameters such as HbA1c, lipid profile, fasting glucose and post meal glucose were measured at baseline and after 12 week of intervention.
2535289|NCT02661906|Active Comparator|SKY post|The enrolled participants were provided with SKY intervention and their pre and post data were recorded.
2535341|NCT02661568||Population with condition and with exposure|
2535371|NCT02661282|Experimental|Arm I (temozolomide, CMV-specific T cells, surgery)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer IV over 1-5 minutes on day 22. Patients undergo surgery on day 30 of cycle 1. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-21. Treatment repeats every 42 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2535385|NCT02661334|Experimental|Low dose|5g/day Creatine Monohydrate (25g white rice flour) for 28 days
2535389|NCT02661152|No Intervention|Radio-/Chemoradiotherapy|Hypoxia profile guided non-responder (less hypoxic tumour) to nimorazole and not receiving the drug, that is normally part of standard radiotherapy of HNSCC in Denmark.
3167664|NCT00541125|Other|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire|FOLFIRI-bévacizumab avec G-CSF en prophylaxie primaire
3167665|NCT00541164|Experimental|1|300 mg CoQ10 chewable wafer twice a day
3167666|NCT00541164|Placebo Comparator|2|Chewable placebo wafer twice a day for 24 weeks with crossover to 300mg CoQ10 twice a day for weeks 24-48.
3167667|NCT00541177|Experimental|1|use 0.25% atropine once a week
3167668|NCT00541177|Active Comparator|2|use 0.5% tropicamide everyday
3167669|NCT00541268|Experimental|A|Heart Failure nonischemic etiology
3167670|NCT00541268|Active Comparator|B|
3167671|NCT00541281|Active Comparator|A|weekly docetaxel and prednisone
3167672|NCT00541281|Active Comparator|B|weekly docetaxel (35mg/m&) plus prednisone 10mg a day associated with estramustine form day 1to 5 and 8 to 12
2534713|NCT02665871|Experimental|one dose of Influenza Vaccine in aged 18 years and older|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 18 years and older
2534720|NCT02665871|Experimental|One dose of Influenza Vaccine in aged 3-17 year|One dose of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in aged 3-17 years
2534722|NCT02665871|Placebo Comparator|placebo in aged 18 years and older|placebo in 10 subjects aged 18 years and older on day 0
2534725|NCT02665871|Placebo Comparator|placebo in aged 3-17 years|placebo in 10 subjects aged 3-17 years on day 0
3201529|NCT00904059|Experimental|Treatment Group A|
3201530|NCT00904059|Experimental|Treatment Group B|
2534875|NCT02664753|Experimental|L-Carnitine group|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Intervention: 56 days of weight-adjusted L-Carnitine treatment"
2534878|NCT02664753|Placebo Comparator|Placebo then open group|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Intervention: 10 days of intravenous placebo (isotonic saline)"
2535003|NCT02663804|Active Comparator|Implant design 1|Journey II, BCS, Smith&Nephew
2535006|NCT02663804|Active Comparator|Implant design 2|Persona, Zimmer
2535009|NCT02663804|Active Comparator|Implant design 3|Unity, Corin
2535056|NCT02663544|Active Comparator|Limited dairy diet|Three 8 oz. servings per week of non-fat milk. Participants will otherwise eat their usual diet, but will be asked not to consume any dairy products not provided by the study.
2535057|NCT02663544|Experimental|Low-fat dairy diet|3.3 daily servings of non-fat and low-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
2535059|NCT02663544|Experimental|Full-fat dairy diet|3.3 daily servings of full-fat dairy products in the form of fluid milk, cheese and yogurt. Participants will otherwise eat their usual diet, and will be asked not to consume any dairy products not provided by the study.
2535127|NCT02663180|Experimental|Intervention group|they will be enrolled in an educational program and video contact.
2535129|NCT02663180|No Intervention|Control group|No intervention
2535196|NCT02662842||FlowSmart Infusion set, then current set|Subjects will use the FlowSmart Infusion Set for a period of 9 to 11 days, then switch to their current infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period then - Subjects will use their current infusion set for a period of 9 to 11 days, then switch to the FlowSmart infusion set for another period of 9 to 11 days. Subjects must use at least 3 sets during each Study Period.
2535245|NCT02662283|Active Comparator|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
2535246|NCT02662283|Experimental|Reh-acteoside|Oral take reh-acteoside (0.4g bid) for 8 weeks
2535247|NCT02662283|Experimental|Reh-acteoside+Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) and reh-acteoside (0.4g bid) for 8 weeks
2535303|NCT02661880|Experimental|listening to preferred music choices|All patients will be invited to complete the McGill Quality of Life Questionnaire - Revised (McGill QOL-R) upon admission to the unit. The Questionnaire will not be part of the permanent medical record and the participants will remain anonymous. Afterwards participants will be asked if they would like to listen to music during their stay in the hospital. Music will be selected according to their choices from an i-Tunes playlist. Participants will be invited to listen to music at their own discretion. Prior to discharge from the hospital or after 3 days all willing participants will be again invited to complete the McGill QOL-R questionnaire.
2535373|NCT02661542|Experimental|Phase 1: Lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535380|NCT02661542|Experimental|Phase 1: 1.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535387|NCT02661542|Experimental|Phase 1: 2.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535392|NCT02661542|Experimental|Phase 1: 3.375x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535396|NCT02661542|Experimental|Phase 1: 5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535397|NCT02661542|Experimental|Phase 1: 7.5x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535401|NCT02661542|Experimental|Phase 1: 11.25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535402|NCT02661542|Experimental|Phase 1: 16.875x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535570|NCT02660008|Experimental|ZP4207|ZP4207 (peptide analogue of human glucagon) Planned doses: 0.1, 0.3, 0.6, 1.0 mg s.c.
2534719|NCT02665923||Infants (4-6mons)|Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
2534723|NCT02665923||Infants (9-12 months)|Patients will undergowill be given formula feeding of known volume, and then serial ultrasound imaging of gastric antral volume will be performed until gastric emptying.
2534782|NCT02665520|Active Comparator|stem cells injection in penis|Treatment Injection of adipose derived cells into penis experimental;randomised
2534785|NCT02665520|No Intervention|controled arm|
2534843|NCT02665065|Experimental|Iomab-B|Iomab-B in conjunction with a Reduced Intensity Conditioning (RIC) regimen containing Fludarabine and low-dose Total Body Irradiation (TBI) prior to allogeneic HCT
2534845|NCT02665065|Active Comparator|Conventional Care|Defined as Investigator's choice of salvage chemotherapy with any combination of the following agents: Azacitidine (not allowed as a single agent), Carboplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin, Decitabine (not allowed as a single agent with the exception of patients with documented TP53 mutations who have not previously received 10-day regimens of single agent decitabine), Doxorubicin, Enasidenib, Etoposide, Fludarabine, Gemtuzumab ozogamicin, Idarubicin, Ivosidenib (for subjects with IDH1 mutation), L-Asparaginase, Midostaurin (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Mitoxantrone, Sorafenib (for FLT3 mutant or FLT3-ITD subjects only, not allowed as single agent), Thioguanine, Topotecan, Venetoclax (in combination with a hypomethylating agent). Chemotherapy agents not listed above may be administered after providing clinical justification and receiving medical monitor approval prior to initiation of treatment.
2534959|NCT02664428|Active Comparator|PREBIOIL TEST|Product tests prepared with olives flour, buckwheat flour, pea flour, chestnut flour, oil chemical leavening agents, salt, sucrose. Baked
2534961|NCT02664428|Placebo Comparator|CONTROL|Product control prepared with wheat flour, oil, chemical leavening agents, salt, sucrose. Baked
3201531|NCT00904059|Experimental|Treatment Group C|Treatment Groups A and B are followed by Treatment Group C: A combination of BMS-650032 (200 mg) and BMS-790052 (30 mg)
3201532|NCT00904072||accepted|The suggestions provided by the CDSS which were accepted by the physicians.
3201533|NCT00904072||denied|The suggestions provided by the CDSS which were denied by the physicians.
3201534|NCT00904085|Active Comparator|Oxymorphone|
3201535|NCT00904085|Placebo Comparator|Placebo|
2535304|NCT02661867||VD|Vaginal delivery group - women who gave birth of offspring through the vagina without the use of special instruments such as forceps or a vacuum extractor (instrumental vaginal delivery)
2535309|NCT02661867||CS|Cesarean section group - women delivered by surgical procedure in which one or more incisions are made through a mother's abdomen and uterus to deliver a baby. Cesarean section is performed when a vaginal delivery would put the baby's or mother's life or health at risk.
2535350|NCT02661516||Vitamin K Antagonists|Vitamin K Antagonists dose as specified
2535382|NCT02661191|Other|asthma severity and disease exacerbation|intramuscular cholecalciferol 100,000 IU, followed by oral cholecalciferol 5000 IU weekly plus 400 IU daily for one year
2535446|NCT02660957|Experimental|self-determination smoking cessation|Subjects in the intervention group will be allowed to select their own schedules of quitting after discussing their situation with the counsellor (quit immediately (QI), or quit progressively (QP) with the ultimate goal of completing cessation over an acceptable period). Subjects in the intervention group will receive a self-help quitting leaflet published by the Hong Kong Council on Smoking and Health plus a series of brief interventions using the AWARD model.
2535452|NCT02660957|Placebo Comparator|health life|Subjects in the placebo control group will receive a smoking cessation leaflet published by the Hong Kong Council on Smoking and Health (COSH), as will the intervention group. Moreover, subjects in the placebo control group will undergo a similar schedule of telephone follow-up as those in the intervention group. They will receive a 'placebo' intervention with a 'placebo booster' of the same duration on increasing physical activity and fruit and vegetable intake.
3201536|NCT00904098|Experimental|Frovatriptan|Frovatriptan 2.5 mg oral tablet
3201537|NCT00904098|Active Comparator|Usual Care|Usual care includes the current treatment used to treat all episodes of migraine headache
3201538|NCT00904111|Experimental|Lidocaine 5% Patch|Lidocaine 5% patch (Lidoderm®,Endo Pharmaceuticals Inc.), 2 patches applied directly to the most painful area of the low back once daily (q24h)
3201539|NCT00904111|Placebo Comparator|Placebo Topical Patch|Matching placebo patch, 2 patches applied directly to the most painful area of the low back once daily (q24h)
3201540|NCT00904124|Placebo Comparator|Control|No regular flour replaced
2535757|NCT02659046||FH30|Patients treated by Pirkanmaa physician-staffed emergency medical service (EMS) unit
2535759|NCT02659046||FH10|Patients treated by Helsinki and Uusimaa physician-staffed emergency medical service (EMS) unit
2535815|NCT02658604||Home visit by pharmacist|Patients of participating pharmacies age 65 or older, who are on 5 or more chronic prescription medications, and who have a need for, and agree to, a home visit by a pharmacist for a medication review.
2535849|NCT02658253|Experimental|Group A1:Primvac 20 µg +alhydrogel|"Group A1: 3 European volunteers 0.5 ml intramuscular injection: 20 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2535852|NCT02658253|Experimental|Group A2:Primvac 20 µg +GLA-SE|Group A2: 3 European volunteers 0.5 ml intramuscular injection:20 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
2536145|NCT02656030|Active Comparator|usual care|Usual care 2 times/week, 6 weeks duration
3201541|NCT00904124|Experimental|5% Cellulose|5% regular flour is replaced by cellulose
3201542|NCT00904124|Experimental|2.5% Alginate|2.5% regular flour is replaced by Alginate
3201543|NCT00904124|Experimental|5% Alginate|5% regular flour is replaced by Alginate
3201544|NCT00904124|Experimental|2.5% Guar gum|2.5% regular flour is replaced by Guar gum
3201545|NCT00904124|Experimental|1.25% Guar gum|1.25% regular flour is replaced by Guar gum
3201546|NCT00904137|Active Comparator|Cast|Above elbow fiberglass cast with a collar-and-cuff
3201547|NCT00904137|Active Comparator|Splint|Long arm posterior plaster splint with a collar-and-cuff
3201548|NCT00904137|Active Comparator|Tape|Elastoplast tape applied to keep the elbow in flexion, with a collar-and-cuff
3201549|NCT00904176|Active Comparator|Dapagliflozin + Warfarin|
3201550|NCT00904176|Active Comparator|Warfarin|
2534761|NCT02665611|Experimental|intervention group|"intervention for improvement of treatment adherence Intervention group- This group will be followed by the MOMA call center (By the MOMA nures every couple weeks and by the study coordinatore and the treating Doctor at special visits as the study required.) The group will be monitored according to number of parameters, including treatment Adherence."
2534762|NCT02665611|Experimental|control group|"treatment as usual Control group- Treatment will continue as usual by the Doctor.(This group will allso be followed by the Study Coordinator at the same visits as the Intervention group.The group will be monitored according to number of parameters, including treatment Adherence."
3167673|NCT00541294||B|M.tb unexposed HIV-infected and uninfected children <15 years of age
3167674|NCT00541294||A|M.tb exposed HIV-infected and uninfected children <15 years of age
3167675|NCT00541333|Active Comparator|Copaxone|
3167676|NCT00541333|Sham Comparator|Sham|
3167677|NCT00541359|Experimental|Arm I|"PART I (completed as of 09/06/06; all patients enrolled in study after 09/06/06 are enrolled in part II): Patients receive escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8 followed 6 hours later by bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~PART II: Patients receive bortezomib IV on days 1, 4, 8, and 11 followed 6 hours later by escalating doses of topotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.~In both parts of the study, patients who achieve a response may receive additional courses of treatment."
3167678|NCT00541372|Experimental|1|Needle 5 mm
3167679|NCT00541372|Active Comparator|2|Needle length 8 mm
3167680|NCT00541398|Experimental|A|
3167681|NCT00541398|No Intervention|B|
3167682|NCT00541424||PET/CT Scanning|Patients that have newly diagnosed mantle cell lymphoma will first undergo CT colonography (CT or CTC) and PET followed by conventional colonoscopy.
2534999|NCT02664077|Experimental|Group 1: Regorafenib|Patients receive regorafenib orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
2535000|NCT02664077|Placebo Comparator|Group 2: Placebo|Patients receive placebo orally once daily for 21 days of a 28 day cycle for a total of 26 cycles.
2535094|NCT02663206|Other|Botulinum toxin injection|"Drug/Device: Botulinum toxin injection; Endoscopic Botulinum toxin (BTX) injection at lower esophagus; Upper endoscopy with Botulinum toxin injection.~The procedure will be performed as an outpatient basis by an endoscopist. Sedation can be in form of conscious sedation, monitored anesthesia care or general anesthesia. An upper endoscope will be inserted into the patient's mouth and advanced into lower esophagus. Botulinum toxin (Botox@) 100 units 8-10 (25 units/mL) will be injected in 1-ml portion in each of four quadrants about 1 cm above the Z-line (the LES region).~At 1 month follow-up, patients who do not response to the first botox injection (Eckardt score > 3) will receive the second botox injection.~At 3-month follow-up, POEM will be offered as a rescue therapy to both non-responders (Eckardt score > 3 at 3-month follow-up after the procedure) and relapsers (Eckardt score ≤ 3 at 3-month follow-up but becomes > 3 during the follow-up)"
2535101|NCT02663206|Other|peroral endoscopic myotomy|"Procedure/Surgery: peroral endoscopic myotomy.~The procedure will be performed by an endoscopist (gastroenterologist or surgeon). General anesthesia will be started and upper endoscope will be inserted into the patient's mouth and advanced into the stomach. Endoscopic myotomy will be performed. Mucosal entry will then be closed using endoscopic clips or endoscopic suturing.~All patients will recover from their procedures according to standard practice. They will remain nothing per oral (NPO) the night after the procedure and started on intravenous proton pump inhibitors. A gastrografin esophagram will be obtained the next day and if no evidence of leak, the diet will be advanced to a soft diet for two weeks. The patients will be evaluated by study coordinator/PI on a daily basis during their hospitalization."
2535158|NCT02662959|Experimental|Irinotecan|In the experimental arm, patients receive single agent of irinotecan as third line treatment in metastatic gastric cancer.
2535174|NCT02662595|No Intervention|Control|
2535178|NCT02662595|Active Comparator|Text message|Subjects in this arm will receive a text message reminder in due time for measles vaccination.
2535186|NCT02662595|Active Comparator|Text message and voice call|Subjects in this arm will receive a voice call in addition to a text message reminder in due time for measles vaccination.
2535262|NCT02662374|Active Comparator|Control|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid
2535263|NCT02662374|Experimental|Group 1|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Extra soft toothbrush, brushing with saline bd
2535264|NCT02662374|Experimental|Group 2|0.02% Chlorohexidine Gluconate: Mouth Rinse, 5ml, qid 3% Sodium Bicarbonate, Mouth Rinse, 5ml, qid Nystatin 10000U/ml : Mouth rinse, 5ml, qid Supersaturated Calcium Phosphate Spray, 5ml qid
3167683|NCT00541489|Placebo Comparator|1|
3167684|NCT00541489|Active Comparator|2|Naproxen 500 mg
3167685|NCT00541489|Experimental|3|Naproxcinod 750 mg
3167686|NCT00541515|Experimental|closed loop system|Device: continuous glucose sensors and insulin pump
3167687|NCT00541567|Placebo Comparator|1|
3167688|NCT00541567|Experimental|2|
3167689|NCT00541567|Experimental|3|
3167690|NCT00541567|Experimental|4|
3167691|NCT00541606|Experimental|Intervention|Received collaborative care including a clinical pharmacist practitioner.
3167692|NCT00541606|Active Comparator|Control|Patients received usual care directed by their physician.
3167693|NCT00541619||A|hypertensives with proteinuria
3167694|NCT00541710|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3167695|NCT00541710|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3201551|NCT00904176|Active Comparator|Dapagliflozin + Digoxin|
2534887|NCT02664688|Experimental|Lumbar stabilization exercises|Home exercise program to perform daily for 6 months
2534892|NCT02664688|Active Comparator|Flexor Exercises|Home exercise program to perform daily for 6 months
2534934|NCT02664376||Geriatric ward population|Every patient aged over 65 admitted in the unit 83 of the Geriatry Department, CHU Brugmann Hospital, undergoes a global geriatric evaluation at the end of its hospitalisation stay, including sarcopenia detection.
3201552|NCT00904176|Active Comparator|Digoxin|
3201553|NCT00904202|Placebo Comparator|placebo capsules + placebo patch|Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
2534998|NCT02663921|Experimental|Healthy volunteers|Healthy volunteers without cutaneous disorders associated with pigmentary changes
3201554|NCT00904202|Experimental|placebo capsules + Lidoderm patch (Lidocaine Group)|Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing
3201555|NCT00904202|Active Comparator|Gabapentin capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain
3201556|NCT00904202|Other|Gabapentin capsules 1800 mg/day + Lidoderm patch|Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
3201557|NCT00904228|Experimental|Plastic Cap|Plastic lined stockinet cap (polyethylene bag)
2535182|NCT02662803|Experimental|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
2535188|NCT02662803|Placebo Comparator|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
2535227|NCT02662361||no peri-implant disease|The subjects who did not suffer from peri-implant disease.
2535228|NCT02662361||peri-implant disease|The subjects who suffered from peri-implant disease.
2535249|NCT02662114||Tresiba®|
2535293|NCT02661893|Experimental|JNJ-42847922 and Rifampin|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ-42847922 on Day 1; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed with one oral dose of rifampin 600 mg (2*300 mg) on Day 5; A single oral dose of 40 mg (=2*20 mg) dose of JNJ-42847922 dosed on Day 12, following once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5-12.
2535339|NCT02661529|Active Comparator|Transesophageal Echocardiogram|Patients undergoing an Transesophageal Echocardiogram (TEE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
2535340|NCT02661529|Active Comparator|Transthoracic Echocardiogram|Patients undergoing an Transthoracic Echocardiogram (TTE) for diagnostic purposes to detect a cardiac shunt abnormality, using Saline/Air Mixture and Saline/Blood Mixture for vessel contrast
3201558|NCT00904228|Active Comparator|Stockinet Cap|Usual practice
3201559|NCT00904241||Ancillary-Correlative (cytology specimen collection)|Patients undergo collection of blood, tissue, and bone marrow samples for analysis via RT-PCR, quantitative PCR, flow cytometry, and FISH.
2535461|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
2535491|NCT02660567|Experimental|Amr Maneuver|Active management of third stage plus Amr's maneuver
2535492|NCT02660567|No Intervention|Active management alone|Active management of third stage alone
2535543|NCT02660268|Experimental|Clinical pathway|Patients in the experimental group will be followed according to the clinical pathway
2535544|NCT02660268|No Intervention|Control|Patients in the control group will receive standard care
2535638|NCT02659865|Placebo Comparator|Part A: Placebo|Single oral dose of placebo administered in one of three study periods
2535644|NCT02659865|Experimental|Part A: LY3039478 new formulation|Escalating single oral dose of LY3039478 administered in two of three study periods
2535647|NCT02659865|Experimental|Part B: LY3039478 original formulation|Single oral dose of LY3039478 administered in one of two study periods
2535649|NCT02659865|Experimental|Part B: LY3039478 new formulation|Single oral dose of LY3039478 administered in one of two study periods
2535669|NCT02659319|Experimental|Family Lifestyle (FL; n = 117)|This arm includes the Family Food & Lifestyle intervention (FL). Parents and children meet for 12 weekly, 90-minute psychoeducational groups in children's schools. They meet separately for 45 minutes and then conjointly for 45 minutes.
2535670|NCT02659319|Experimental|FL + Family Dynamics (FL+FD; n = 88)|This arm includes the Family Food & Lifestyle + Family Dynamics interventions (FL+FD). Parents and children meet separately for the full 90-minute psychoeducation sessions. The first 45 minutes are devoted to the Family Food & Lifestyle intervention and the second 45 minutes to the Family Dynamics intervention.
2535726|NCT02659007|Experimental|yoga|yoga, 2 times a week for 8 weeks
3201560|NCT00904254|Experimental|1, diagnostic comparison|EP 1645/Solution For Injection
3201561|NCT00904280|Experimental|Oxymorphone ER|
3201562|NCT00904293|Experimental|Genotype-guided warfarin dosing|A dosing algorithm including clinical factors and genotype information (VKORC1 and CYP2C9) will be used to determine initial warfarin doses.
3201563|NCT00904293|Active Comparator|Non-genotype guided warfarin dosing|Initial warfarin dosing will be determined using the same algorithm as in the experimental group, but only including the clinical factors and not including the genotype information
3201564|NCT00904306|Placebo Comparator|Sugar pill|6 months treatment with placebo
3201565|NCT00904306|Active Comparator|low dose|600ug/day chromium picolinate for 6 months
3201566|NCT00904306|Active Comparator|high dose chromium picolinate|1000 ug/day
3201567|NCT00904319|Experimental|Aquatic|Aquatic Power Training
3201568|NCT00904358||cross sectional area|internal jugular cross sectional area measured by ultrasound
3201569|NCT00904384||HIV+|Patients with HIV infection living in the Autonomous Community of the Balearic Islands (CAIB), Spain
3201570|NCT00904384||Reference group|Same determinations as in HIV+ cases will be obtained in the control group of COPD patients without HIV infection as part of the study PAC-EPOC (FIS 05/2082)
2534916|NCT02664493|Experimental|SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Methylprednisolone 0.5 g daily for 3 days will be administered in (Steroid pulse therapy) SPT group."
2534917|NCT02664493|No Intervention|non-SPT group|"The patients who will show borderline change in 2-week protocol biopsy with stable graft function will be included in this study.~Steroid pulse therapy (SPT) will not be applied and no additional treatment will be added in non-SPT group"
3201571|NCT00904397|Experimental|Lidoderm|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 2 patches applied once daily (q24h) directly to the most painful area of the low back
3201572|NCT00904397|Active Comparator|Celecoxib|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
2535062|NCT02663492|Experimental|TEAS group|Patients with transcutaneous electrical acupoint stimulation (TEAS) group receive electrical stimulation of acupoints including Dazhui (DU14), Geshu (BL17), Zusanli (ST36), Sanyinjiao (SP6), and Hegu (LI4).
2535063|NCT02663492|Active Comparator|Medication group|On the basis of routine nursing care, patients need to take Sanguisorba officinalis L., named Diyu Shengbai Pian (a Traditional Chinese Medicine) 3 times per day.
2535064|NCT02663492|No Intervention|Control group|The patients of control group receive routine nursing care, including (1) to be observed the changes in patient condition, (2) to eat high-calories, high-protein, high-vitamin, easy-to-digest foods during chemotherapy, (3) to be treated by psychological care, (4) to be prevented against the occurrence of phlebiti, and (5) to use Ondansetron and Omeprazole as direction.
2535119|NCT02663115||Arm 1|Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy
2535122|NCT02663115||Arm 2|Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%)
2535213|NCT02662439|Experimental|BCM group|The patients are measured by Body Composition Monitor (BCM) and both the patient and the physician know the results and adjust the diuretic therapy accordingly.
2535216|NCT02662439|Placebo Comparator|Control group|The patients are measured by Body Composition Monitor (BCM) but neither the patient nor the physician know the results, the physician adjusts the diuretic therapy as usual, according to the protocols.
2535269|NCT02662205|Active Comparator|Traditional Group|Traditional process psychotherapy group
2535270|NCT02662205|Experimental|Yoga Therapy Group|Psychotherapy group integrating yoga and process dialogue
2535271|NCT02662205|Active Comparator|Yoga Class|Yin yoga class
2535321|NCT02661711|Experimental|Aflibercept (Eylea)|All patients recruited to the study will receive 3 loading intravitreal injections of Aflibercept (Eylea) at monthly intervals followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow-up will occur when there is evidence of OCT stability in the view of the investigator i.e. there is no further reduction in macular fluid compared to the previous visit. All patients will receive 5 injections before considering them non-responders.
2535413|NCT02661087|Experimental|Bipolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy
2535416|NCT02661087|Active Comparator|Monopolar energy|Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy
3201573|NCT00904410|Experimental|1|
3201574|NCT00904436|Experimental|1|Spinal Cord Injury: subjects who have cervical spinal cord injury and complaints of dyspnea
2535532|NCT02660424|Experimental|VX-150, placebo|Sequence 1: VX-150 in Treatment Period 1→washout→ placebo in Treatment Period 2
2535534|NCT02660424|Experimental|placebo, VX-150|Sequence 2: placebo in Treatment Period 1→washout→ VX-150 in Treatment Period 2
2535593|NCT02659761|Experimental|dolutegravir/abacavir/lamivudine|All study subjects will receive triumeq (600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine) single tablet that will be taken orally, once daily, during 96 weeks
3201575|NCT00904436|No Intervention|2|Controls
3201576|NCT00904449|Experimental|Open Label|
2535803|NCT02658721|Experimental|lidocaine+adjunct tramadol|In the first group (LDC+TRA group), IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation.
2535854|NCT02658253|Experimental|Group B1:Primvac 50 µg +alhydrogel|"Group B1: 6 European volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
3201577|NCT00904462|Experimental|Lidocaine 5% patch|Lidocaine 5% patch (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied on each affected knee once every 24 hours
3201578|NCT00904462|Placebo Comparator|Placebo patch|Matching placebo patch, 1⅓ patches applied on each affected knee once every 24 hours
3201579|NCT00904475|Experimental|1- Lidoderm®|Lidoderm (lidocaine patch 5%), up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
3201580|NCT00904475|Placebo Comparator|2-Placebo|Matching placebo, up to three patches applied topically once daily (q24h) to the area of maximal peripheral pain
3201581|NCT00904501|Placebo Comparator|A|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL). A placebo cell-product (30 mL saline with 4 ml peripheral blood) is implanted and the BM-MNC are cryo-conserved. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted. After 6 months, it is possible to use previously cryo-conserved BM-MNC.
3201582|NCT00904501|Experimental|B|A bone marrow harvest (500 mL under general anaesthesia) is performed and BM-MNC are separated and concentrated (30mL) . The BM-MNC are implanted on the same day. Only the cell therapy unit, neither the patient, nor the clinician, know whether BM-MNC or placebo is implanted
3201583|NCT00904527|Experimental|Relaxation|Relaxation (Schultz)+ medical treatment (beta-bloquant or Oxetorone)+ patient's education
3201584|NCT00904527|No Intervention|without relaxation|Patients have no relaxation (only medical treatment+ education)
2534897|NCT02664649|Experimental|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
2534900|NCT02664649|Active Comparator|Standard of care|VKA or Antiplatelet therapy
2535105|NCT02663245|Experimental|Intervention 1|Diabetes specific consultation + multicomponent intervention aimed at professionals and patients
2535108|NCT02663245|Experimental|Intervention 2|Multicomponent intervention aimed at professionals and patients minus the diabetes specific consultation.
2535111|NCT02663245|No Intervention|Control group|No intervention. Data of the control groups will be retrieved from the SIDIAP.
2535159|NCT02662946|Experimental|ICG- angiography|"Colonic resection margins and colo-rectal anastomosis are intraoperatively assessed using fluorescence angiography to evaluate colonic perfusion. If perfusion at the resection margin is judged insufficient the colon is re-resected to obtain a satisfactory perfusion"
2535160|NCT02662946|Active Comparator|No angiography|Subjective measures are employed to determine anastomotic perfusion
3201585|NCT00904540|Experimental|Lidoderm®|Commercially available Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain
3201586|NCT00904553||Novalis Shaped Beam Surgery|Patients with limited brain metastases (mostly solitary brain metastasis) treated with Novalis Shaped Beam Surgery followed by planned craniotomy and resection of the metastases.
2535356|NCT02661360|Experimental|Starting condition of swaddled|
2535357|NCT02661360|Experimental|Starting Condition of Unswaddled|
2535412|NCT02661074||Fishermen|"Fisherman followed by the Service de Santé des Gens de Mer of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
2535417|NCT02661074||Fish processing factories|"Workers of fish processing factories who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France (occupational exposure to fish).~A questionnaire will be completed."
2535420|NCT02661074||Control|"Workers who are followed by the Service de Santé au Travail (ASTIL) of Boulogne-sur-Mer, France, but do not work in fish processing factories.~A questionnaire will be completed."
2535513|NCT02660593|Experimental|SanGrow|Patients will be given SanGrow Decoction 150 ml per day for 3 months.
3201587|NCT00904579||1|Cancer patients who have had organ transplants identified through the transplant and cancer registries.
2535642|NCT02659644|Experimental|Oral citrulline|
2535682|NCT02659397|Experimental|ETC-1002 + Atorvastatin|ETC-1002 180 mg treatment, oral once daily added-on to Atorvastatin 80 mg once daily
2535684|NCT02659397|Placebo Comparator|Placebo + Atorvastatin|Placebo treatment, oral once daily added-on to Atorvastatin 80 mg once daily
3167696|NCT00541723|Experimental|IncobutolinumtoxinA (Xeomin), 4-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 4 x 0.06 mL (4 x 3 units = 12 units); mode of administration: intramuscular injection."
3201588|NCT00904592|Experimental|Qi ming granula|"Study group(combined therapy with Intervention of TCM): Basic therapy ＆ treating both on deficiency and stasis of blood.~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management, exercise and education.~Qi ming granula, Usage: 4.5g，po，tid."
2535850|NCT02658058|Active Comparator|Landmark technique|As intervention, patients in this group are administered landmark guided midline spinal anesthesia.
2535856|NCT02658058|Experimental|Ultrasound-guided paramedian technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided paramedian technique using parasagittal oblique view
2535858|NCT02658058|Experimental|Ultrasound-guided midline technique|As intervention, patients in this group are administered spinal anesthesia based on preprocedural ultrasound-guided midline technique using transverse median view
2535898|NCT02657824||measuring ejection fraction|ejection fraction in an acute dyspneic patients
2535964|NCT02657681|Experimental|tSMS|30 min of tSMS, one session per day, for 9 days over 2 weeks
2535966|NCT02657681|Placebo Comparator|sham|30 min of sham, one session per day, for 9 days over 2 weeks
2536012|NCT02657122|Experimental|TD-1473 for SAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
2536015|NCT02657122|Placebo Comparator|Placebo for SAD|2 of out 8 subjects per cohort will be randomized to receive placebo
2536018|NCT02657122|Experimental|TD-1473 for MAD|6 of out 8 subjects per cohort will be randomized to receive TD-1473
2536019|NCT02657122|Placebo Comparator|Placebo for MAD|2 of out 8 subjects per cohort will be randomized to receive placebo
2536071|NCT02656758|Experimental|Executive function training|the experimental group will receive 12 sessions of intensive Executive function training weekly immediately
2536075|NCT02656758|Other|the waitlist group|the waitlist group will wait 12 weeks before receiving intensive executive function training for comparison.
2536194|NCT02655822|Experimental|Cohort 1 - Closed|Ciforadenant
2536196|NCT02655822|Experimental|Cohort 2 - Closed|Ciforadenant
2536202|NCT02655822|Experimental|Cohort 3 - Closed|Ciforadenant
2536205|NCT02655822|Experimental|Cohort 4|Ciforadenant + atezolizumab
2536208|NCT02655822|Experimental|Cohort 5 - Closed|Ciforadenant
2536288|NCT02655276|Experimental|100 mg microencapsulated Glycine and then Placebo tablets|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the first three weeks and then Placebo t.i.d. from Biotiki® for the second three weeks.
2536290|NCT02655276|Experimental|Placebo tablets and then 100 mg microencapsulated Glycine|Placebo t.i.d. from Biotiki® for the first three weeks and then 100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d. for the second three weeks.
2536351|NCT02654899|Experimental|Part 1_Cohort 1_Active;|Single ascending dose of PF-06815345
2534953|NCT02664259|Active Comparator|UTB-VBN-EBUS-X-ray group|Bronchoscopes with a 3.0-mm distal end diameter and a 1.7-mm working channel diameter are used (BF-Y0058;Olympus).The EBUS probe is confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
3201589|NCT00904592|Placebo Comparator|placebo comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
2535098|NCT02663284|Experimental|Perineural block|Perineural block with Ropivacaine 0.5%
2535180|NCT02662530|Active Comparator|Botulinum toxin type A clinical|Initial and optimization of BoNT-A injection parameters will be conducted by clinical visual assessment
2535191|NCT02662530|Active Comparator|Botulinum toxin type A kinematic|Initial and optimization of BoNT-A injection parameters will be conducted by kinematic assessment
2535232|NCT02662322|Experimental|HYPNOSIS|hypnotic communication, confusion procedure during peripheral intravenous catheterization
2535234|NCT02662322|Active Comparator|NOCEBO|negative connotation communication during peripheral intravenous catheterization
2535235|NCT02662322|Placebo Comparator|NEUTRAL|neutral connotation communication during peripheral intravenous catheterization
2535280|NCT02661997|Experimental|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
2535282|NCT02661997|Active Comparator|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
2535358|NCT02661607|Other|Point of care echocardiography after central venous catheter|Point of care echocardiography plus chest radiography
2535414|NCT02661035|Experimental|Reduced Intensity Conditioning|Non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related or unrelated donor stem cell infusion
2535477|NCT02660671|Active Comparator|Usual care|Email outreach
2535478|NCT02660671|Experimental|Active choice|Email outreach + active choice
2535479|NCT02660671|Experimental|Financial incentive + Active choice|Email outreach + active choice + financial incentive
2535512|NCT02660398|No Intervention|Controls|Our control group will consist of an observational cohort of 40 patients in whom we will make quantitative assessments of the Train-of-four ratio (TOF ratio). This is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
2535518|NCT02660398|Other|Intervention|The intervention consists of a protocol for intraoperative management of neuromuscular blockade with rocuronium and reversal with neostigmine. A train-of-four count of 4 at the thumb will be confirmed prior to administration of an adjusted dose of neostigmine. TOF ratio is measured in the same manner as for the Control group, it is done using the TOF-Watch SX monitor. The monitor will be calibrated after induction of general anesthesia, measurement of the TOF ratio will be obtained at time of extubation and again at the time of arrival to the Post Anesthesia Care Unit (PACU).
2535563|NCT02660125|Active Comparator|endometrial scratch injury|endometrial scratch done before ICSI cycle
2535565|NCT02660125|No Intervention|control|IcSI cycle without prior endometrial injury
2535648|NCT02659852|Experimental|Side by side group|
2535650|NCT02659852|Active Comparator|Stent in stent group|
2535674|NCT02659345|Experimental|Art Therapy|The art therapy intervention will be executed by an art therapist at the Cancer Center. The same art therapy practices that are utilized in daily practice will be employed in this study. The intervention will include assessment of patient's needs and goals in addition to utilization of various art modalities. Sessions will conclude with processing of the art and supportive counseling as appropriate. Pilot testing of the intervention has been performed informally at Maroone Cancer Center with positive feedback provided by patients and their support systems to the physicians, nurses, and art therapist. Change in pain, emotional distress, depression, adn anxiety will be measured by the emotions thermometer.
2535702|NCT02659163|Experimental|intervention|Intervention subjects will receive feedback on their health behaviors along with clinical recommendations.
2535704|NCT02659163|Active Comparator|control|Control subjects will receive feedback on their health behaviors for self-guided care.
2535867|NCT02658045||Normal healthy volunteers|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in healthy volunteers during 6 min walking test
2535871|NCT02658045||COPD patients|Measurement of oxygen saturation simultaneously by standard oximeter and Oxitone oximeter in COPD patients during 6 min walking test
2534967|NCT02664389|Experimental|Genetic analysis of patient with early-onset colorectal cancer|Sequencing of 200 selected genes in patient with early-onset colorectal cancer without genomic alteration of APC, MUTYH, SMAD4, BMPR1A, PTEN or STK11 in case of adenomatous polyposis or hamartoma presentation or without genomic alteration of MSH2, MLH1 or MSH6 in case of HNPCC presentation
2534968|NCT02664389|Experimental|Genetic analysis of patient with multiple primary tumors|Sequencing of 200 selected genes in patient with Multiple primary malignant tumors without syndromic presentation
2535036|NCT02663843|Experimental|i-gel airway|I-gel inserted for the low skill fibreoptic intubation technique
2535042|NCT02663843|Experimental|air-Q airway|Air-Q inserted for the low skill fibreoptic intubation technique
2535077|NCT02663349|Experimental|Supported SCIT|Social Cognition and Interaction Training is a manualized intervention that focuses on emotion recognition training, perspective taking, and strategies to avoid jumping to conclusions. One hour group sessions will be offered twice a week for 12 weeks. In addition, one hour of individual training will be provided weekly by an instructor.
2535121|NCT02663102||Fluarix Tetra Group|Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).
2535173|NCT02662621|Other|ill patient|Patient with a cancer disease
2535176|NCT02662621|Other|Healthy volunter|Subject without any cancer pathology
2535231|NCT02662400|Experimental|MNCs GROUP|Patients with Type 2 Diabetes mellitus
2535250|NCT02662088||Laparoscopic-lavage|Patients with colonic diverticulitis submitted to laparoscopic lavage
2535272|NCT02661919|Experimental|Emfit mattress sensor|
2535322|NCT02661698|Placebo Comparator|Placebo 1|"Placebo~All participants will be given a placebo for the first visit. The other 3 arms will be randomised in a counterbalanced order."
2535323|NCT02661698|Placebo Comparator|Placebo 2|Placebo
2535325|NCT02661698|Active Comparator|DHA rich oil|Omega-3 oil: DHA enriched
2535327|NCT02661698|Active Comparator|EPA rich oil|Omega-3 oil: EPA enriched
2535367|NCT02661347|Active Comparator|Active comparator: tDCS & Risperidone|In the active arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2 milliampere (mA) for 20 minutes, twice a day for five consecutive days, for a total of 10 sessions.
2535372|NCT02661347|Sham Comparator|Sham comparator: tDCS & Risperidone|In the sham arm, active tDCS will be applied using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator at a current of 2mA for 1 minute, twice a day for five consecutive days, for a total of 10 sessions.
2535429|NCT02660879|Placebo Comparator|Written Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given written educational materials, and given 5 minutes to read these materials. They were then re-taped for their inhaler technique.
2535431|NCT02660879|Experimental|Online Video Education|These patients were video taped before they had any inhaler education using their own inhalers. They were then given online video education located at use-inhalers.com, and were asked to complete the education (took on average 5 minutes). They were then re-taped for their inhaler technique.
2535467|NCT02660684|Experimental|Prograf + MTX|
2535469|NCT02660684|Active Comparator|Cyclosporine + MTX (historical control)|
2535524|NCT02660437|Active Comparator|Effect of PR in MCI-group|Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of MCI-Group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR). Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques.
2535530|NCT02660437|Placebo Comparator|Effect of PR in control-group|"Evaluation of the acute effect of a 3-week Pulmonary Rehabilitation (PR) program in cognitive function of control-group using SMMSE, ACE-R, MoCA, TICS and Stroop test clinical instruments in reference to potential changes in pCO2 oscillation patterns (post-PR).~Intervention: Pulmonary Rehabilitation program; 12 sessions of exercise training/breathing techniques."
2535578|NCT02660073|Experimental|NMES+FES group|NMES+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of surface NMES and ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks +3 weeks for measurements.
2535582|NCT02660073|Experimental|Control+FES group|Control+FES group (n=24; 2 days/week for 24 weeks); this group will undergo twice weekly of 12 weeks of passive leg extension/flexion with no ankle weights followed by 12 additional weeks of twice weekly of progressive FES-LEC using the RT300 bike. The total participation duration is 24 weeks+3 weeks for measurements.
2535617|NCT02659657|Experimental|Interleukin-2 interventions|Patients with standard risk hematologic malignancies undergoing an unmodified haploidentical HCT will be eligible. Once patients achieved neutrophil engraftment will be given IL-2, 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days).
2535653|NCT02659488|Other|Lisdexamfetamine|During the Treatment Phase, subjects will be evaluated after 1, 2, 3, 4, 6, 8, 10, and 12 weeks (see Figure 2). The morning after completing the first fMRI scan, LDX will be started at 30 mg q AM (Baseline). After 1 week, LDX will then be increased to 50 mg q AM (Visit 1); after another week, LDX will be increased to 70 mg q AM (Visit 2). A single downward dose titration to 50 mg is allowed during week 3 if 70 mg/d is not tolerated. LDX dose at week 4 (50 or 70 mg/d) will be maintained for the next 8 weeks. Patients who do not tolerate 50 or 70 mg/day will be terminated. For patients who complete the 12-week treatment phase, LDX will be stopped at week 12 visit.
2535746|NCT02658799|Experimental|diclofenac potassium|"Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
2535806|NCT02658721|Experimental|lidocaine+systemic tramadol|In the second group (LDC+SysTRA group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation.
2535007|NCT02663934|Active Comparator|Social Interaction Stretching (SIS)|This group will serve as a control group against which to gauge the effects of aerobic and resistance training on cognitive function. Participants in this group will follow the same schedule and format as the EXS group. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program. These SIS participants will receive instructions on stretching, range of motion, limbering, and toning; but the intensity will be far less than that achieved in the EXS classes. Activities will focus on flexibility enhancement. As the participant's level of flexibility increases, stretches with increasing levels of difficulty will be incorporated into the program.
2535041|NCT02663557||non-hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP<140 mmHg; 2. Systolic blood pressure-coefficient variation (SBP-CV) < Median SBP-CV
2535043|NCT02663557||non-hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP< 140 mmHg; 2. SBP-CV > Median SBP-CV
2535047|NCT02663557||hypertension with lower BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV < Median SBP-CV
2535048|NCT02663557||hypertension with higher BPV|patients meeting to flowing two criteria: 1. mean SBP> 140 mmHg; 2. SBP-CV > Median SBP-CV
2535131|NCT02663050|Experimental|Kinesio taping group|only Kinesio taping treatment group
2535135|NCT02663050|Active Comparator|NSAID treatment group|only NSAIDs taking group
2535139|NCT02663050|Active Comparator|Combination treatment group|NSAIDs plus Kinesio taping group
2535167|NCT02662673|Other|Localized prostate cancer, Focal treatment.|
2535198|NCT02662491|Experimental|vitamin D and calcium|daily oral vitamin D(3) (2000 IU) and calcium (600 mg) for 6 months
2535200|NCT02662491|Experimental|Calcium supplement|daily oral calcium (600 mg) for 6 months
2535204|NCT02662491|Experimental|vitamin D supplement|daily oral vitamin D(3) (2000 IU) for 6 months
2535206|NCT02662491|Placebo Comparator|Placebo|daily placebo tablet for 6 months
2535248|NCT02662218||Patients with superficial wounds|A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible.
2535311|NCT02661984||Healthy (no pulmonary disease)|Healthy children 4 - 6 years old with no pulmonary disease and not exhibiting respiratory illness or sinusitis.
2535315|NCT02661984||Asthmatic (physician diagnosed)|Asthmatic children 4 - 6 years old not exhibiting acute asthma symptoms, respiratory illness or sinusitis.
3167697|NCT00541723|Placebo Comparator|Placebo 4-injection scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 4 x 0.06 mL placebo solution; mode of administration: intramuscular injection.
2535408|NCT02661100|Experimental|CDX-1401 + Poly-ICLC + Pembrolizumab followed by Pembrolizumab|Patients receive CDX-1401, Poly-ICLC and Pembrolizumab for 4 cycles (Q 3 weeks) followed by Pembrolizumab alone (Q 3 weeks) until disease progression.
2535444|NCT02660814|Placebo Comparator|Healthy periodontium without obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
2535448|NCT02660814|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
2535455|NCT02660814|Placebo Comparator|Healthy periodontium with obesity|"GCF samples were taken at baseline~Intervention: Gingival crevicular fluid collection"
2535458|NCT02660814|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non-surgical periodontal treatment (SRP and oral hygiene instructions)"
3201590|NCT00904605|Experimental|1- Lidoderm®|Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
3201591|NCT00904605|Active Comparator|2-Celecoxib 200mg|Celecoxib (Celebrex®, G.D. Searle & Co., Chicago, IL), one 200 mg oral capsule QD
2535604|NCT02659800|Experimental|Arm A - Low Dexamethasone (LD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
2535609|NCT02659800|Experimental|Arm B High Dexamethasone (HD)|"Patients receive single dose of NT-I7 IM. Treatment continues in the absence of disease progression or unacceptable toxicity. Dose Escalation~Laboratory Biomarker Analysis Correlative Studies"
2535612|NCT02659800|Experimental|Arm A1 (LD) Control - Placebo|"Patients receive single dose Placebo IM (blinded). Patients also on Dexamethasone </=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
2535614|NCT02659800|Experimental|Arm A2 (LD) MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm A (Blinded) . Patients also on Dexamethasone <=0.75mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
2535621|NCT02659800|Experimental|Arm B1 HD MTD|"Patients receive single dose MTD NT-I7 IM determined in Arm B (Blinded) . Patients also on Dexamethasone >= 4mg daily Treatment continues in the absence of disease progression or unacceptable toxicity. Pilot~Laboratory Biomarker Analysis Correlative Studies"
2535691|NCT02659228|Placebo Comparator|Control 1 (negative control)|Individuals with a diagnosis of UWS without neural markers of consciousness
2535692|NCT02659228|Active Comparator|Control 2 (positive control)|Individuals with a diagnosis of MCS, who are behaviourally responsive and who present neural markers of consciousness
2535693|NCT02659228|Experimental|Target Population|Individuals with a clinical diagnosis of UWS, but who possess some neurophysiological signatures of conscious awareness
3201592|NCT00904631|Experimental|Treatment|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
2535078|NCT02663323|Experimental|MeRes100 - BRS|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System
2535140|NCT02663037||1|"Subjects will be recruited from a pool of elderly patients who present to the Emergency Department.~To be eligible for participation in the study, patients must meet ALL of the following criteria:~Age ≥ 55 years old~Triaged as P2 or P3 in the Emergency Department~Singapore citizen or Permanent Resident~Provision of Informed consent~Not previously already enrolled in this study"
2535193|NCT02662777||Eso-SPONGE® vacuum treatment|leakage after esophagectomy and gastrectomy, perforation of the esophagus
2535268|NCT02662179||Elderly patients with solid tumors|The group will include elderly patients with a malignant solid tumor: ovary cancer, breast cancer, digestive cancer (colo-rectal, pancreas), lung cancer or urinary tract cancer (including bladder cancer).
2535329|NCT02661685|Experimental|autologous IKDC-like cell|Received autologous IKDC-like cells
2535351|NCT02661373|Experimental|Treatment Arm|Participants will receive SJ733, an investigational drug developed at St. Jude Children's Research Hospital, and cobicistat.
3201593|NCT00904644||Salvage group|In this group patients are enrolled that have failed previous antiretroviral drug regimens and qualify for Raltegravir treatment according to the approved indication of this drug in Switzerland.
3201594|NCT00904644||Switch group|In this group, patients are enrolled which have to switch to Raltegravir due to drug toxicity or adverse events caused by other antiretroviral drugs.
3201595|NCT00904683|Experimental|LY2062430|
2535683|NCT02659514|Experimental|Poziotinib, oral tablets|
2535780|NCT02658760|Experimental|Bupivacaine|30cc of 0.25% bupivacaine
2535781|NCT02658760|Active Comparator|Dexmedetomidine and bupivacaine|30cc of 0.25% bupivacaine and 2mg/kg dexmedetomidine
2535826|NCT02658435|Experimental|Tafenoquine 300 milligram (mg) single dose|Participants will receive single dose of TQ (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
2535828|NCT02658435|Placebo Comparator|Matched Placebo 300mg single dose|Participants will receive single dose of matched placebo (2 tablets of 150mg) after standard meal. Participant will be randomized in a 2:1 ratio to 300mg TQ (n=300) or matched-placebo (n=150).
2535874|NCT02658097|Experimental|Single Fraction Radiation Therapy (SFRT) + pembrolizumab|200mg Pembrolizumab by IV infusion on day 1 of each 3 week cycle. 8Gy will be given in a single fraction on the first day of treatment
2535930|NCT02657759|Experimental|CARDICHOL|Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.
2535932|NCT02657759|Placebo Comparator|Placebo|"placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances.~2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch."
2535959|NCT02657395|Experimental|PriMatrix|Use of PriMatrix as a substitute for a subepithelial connective tissue graft under a coronal positioned flap for root coverage.
3201596|NCT00904683|Placebo Comparator|Placebo|
3201597|NCT00904709|Experimental|Tranexamic acid, Menorrhagia, Bleeding|Tranexamic acid with titrated doses. All women with menorrhagia will take .
3201598|NCT00904735|Experimental|Arm I|Patients receive oral hydroxyurea twice daily and oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.
3201599|NCT00904735|Experimental|Arm II|Patients receive oral hydroxyurea twice daily in the absence of disease progression or unacceptable toxicity.
3201600|NCT00904761|Experimental|exercise|arm: intervention
3201601|NCT00904774||premature neonates|gestational age less than 28 weeks
3201602|NCT00904787|Experimental|1|
3201603|NCT00904800|Experimental|1|Low dose
2536284|NCT02655198|Experimental|fenfluramine|"Experimental : one armed open label study :~Add-on fenfluramine in refractory Lennox Gastaut patients. Starting dose 0.2mg/kg/day. In non-responders (<50% seizure frequency decrease), dose will be uptitrated every 4 weeks from 0,2 to 0,4 and max 0,8 mg/kg/day (max 30 mg). Total duration study and max exposure to the drug 20 weeks"
3201604|NCT00904800|Experimental|2|Middle dose
3201605|NCT00904800|Experimental|3|High dose
2536636|NCT02653066|No Intervention|Control|Participant is recruited via usual avenues including flyers and physician referral. This includes participants who received a HealtheRx with advertisement for phone survey but did not call in based on advertisement.
2536638|NCT02653066|Experimental|Intervention with consent form|After completing survey, participant in HealtheRx+ group receives $5 bill with their survey check and blank registry consent form.
3201606|NCT00904800|Placebo Comparator|4|placebo
3201607|NCT00904852|Experimental|Tandutinib, bevacizumab, and temozolomide|tandutinib in combination with temozolomide and bevacizumab following concurrent radiation therapy and temozolomide treatment.
3201608|NCT00904865|Other|1|SPA cholecystectomy
3201609|NCT00904865|Other|2|laparoscopic cholecystectomy
3201610|NCT00904891|Experimental|1|Participants will receive a cognitive-behavioral group intervention.
3201611|NCT00904891|Active Comparator|2|Participants will receive cognitive-behavioral bibliotherapy.
3201612|NCT00904891|No Intervention|3|Participants will only complete study assessments.
2535074|NCT02663427|Experimental|PG(-) and Hp(+) Group|PG negative and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2535075|NCT02663427|Experimental|PG(+) and Hp(-) Group|PG positive (PGⅠ ≤ 70ng/ml and PGⅠ/PGⅡ≤7.0) and Hp negative. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2535076|NCT02663427|Experimental|PG(+) and Hp(+) Group|PG positive and Hp positive. A questionnaire survey are accomplished in 40-70 years old candidates. Eligible subjects are detected PG I and II, Hp-IgG antibody through serological examination. Gastroscope also accomplished in all participants.
2535137|NCT02663076||VKA - Vitamin K antagonist group|VKAs used in correspondence with the national guidelines for therapy of NVAF in the respective country.
2535143|NCT02663076||Rivaroxaban group|Rivaroxaban used in correspondence with the national guidelines for therapy of NVAF in the respective country.
2535149|NCT02663076||noAC group|noAC used in correspondence with the national guidelines for therapy of NVAF in the respective country.
2535257|NCT02662062|Experimental|Pembrolizumab|Pembrolizumab to be administered via IV 200mg 3 weekly commenced concurrently with chemoradiotherapy, and continuing until 12 week cystoscopy.
2535354|NCT02661581|Experimental|Peer Support|Peer support intervention group: During the first 3 months of DSME, participants in the DSMS intervention group will be invited to attend 6 lifestyle change sessions delivered a 2-person peer leader team and conducted bi-weekly. Immediately following the 3 months of DSME, participants are invited to attend 9 months of weekly DSMS sessions (60-minutes per session) delivered by a Peer Leader. These sessions are designed to sustain the self-management gains achieved in the 3 months of DSME.
2535355|NCT02661581|No Intervention|Wait-list Control|Immediately following the 6 bi-weekly DSME sessions, participants randomized to the Wait-list control group will have completed their participation in the study.
3201613|NCT00904904|Experimental|Indomethacin|Indomethacin ophthalmic solution 0.1% for post-surgical inflammation
2535515|NCT02660333|Placebo Comparator|Placebo|Maltodextrin
2535519|NCT02660333|Active Comparator|Prebiotic|Fructooligosaccharide
2535526|NCT02660333|Active Comparator|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
2535572|NCT02660060|Experimental|Pramipexole Dexa Medica|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
2535577|NCT02660060|Active Comparator|Pramipexole Boehringer Ingelheim Pharma|Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate. An oral single dose of the tablet was administered at the first day of each treatment period.
2535660|NCT02659423||Green Dot BIC 1|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have Green Dot versus those that don't have Green Dot. (BIC 1)"
2535661|NCT02659423||Online BIC 2|"Bystander Intervention Components Clusters will include at least a component of online bystander training.~E.g. Comparisons will be made across schools that have online bystander training versus those that do not. (BIC 2)"
2535663|NCT02659423||Alternative programs BIC 3|"Bystander Intervention Components Clusters will include at least a component of Green Dot.~E.g. Comparisons will be made across schools that have alternative program versus those that do not. (BIC 3)"
2535707|NCT02659215|Experimental|Hyalofast with BMAC|A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.
2535708|NCT02659215|Active Comparator|Microfracture|Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.
2535829|NCT02658409|Experimental|GC3106(quadrivalent)|0.5ml, intramuscular, a single dosing
2535830|NCT02658409|Active Comparator|Fluarix™tetra Syringe Inj.(Quadrivalent)|0.5ml,intramuscular,a single dosing
3201614|NCT00904904|Active Comparator|Ketorolac|Ketorolac ophthalmic solution 0.5% for post-surgical inflammation
3201615|NCT00904930||no periodontal disease|33 dental students (13 male, 20 female) with a mean age of 24.7 years (min. 19.8; max. 36.5) with no periodontal disease or dental trauma
2535979|NCT02657356|Placebo Comparator|Placebo capsules|Placebo capsules will be administered orally once a day for 24 weeks.
2535982|NCT02657356|Experimental|Bardoxolone methyl capsules|Each patient will receive bardoxolone methyl capsules administered orally once a day for 24 weeks. Starting dosage for each patient is 5 mg and will dose-escalate to 10 mg at Week 4, unless contraindicated clinically.
2536070|NCT02656550|Experimental|Uterine Transplant|Women will undergo uterine transplantation after IVF. Donor uterus will be from either a living donor or cadaveric.
2536137|NCT02656355|No Intervention|Stage 1:Healthy people|To establish baseline and reliability.
2536141|NCT02656355|No Intervention|Stage 2:Healthy people|To establish stage 3 training protocol.
2536146|NCT02656355|No Intervention|Stage 2:PD people|To establish stage 3 training protocol.
2536148|NCT02656355|Experimental|Stage 3:PD APA training group|Weight shift training and APA feedback.
2536150|NCT02656355|Experimental|Stage 3:PD Balance training group|Weight shift training without APA feedback.
2536152|NCT02656355|No Intervention|Stage 3:PD Control group|Control group
3201616|NCT00905008||DES|Patients underwent percutaneous coronary intervention and received at least one drug-eluting stent during their index hospitalisation.
3201617|NCT00905008||BMS|Patients underwent percutaneous coronary intervention and received at least one uncoated stent during their index hospitalisation.
3201618|NCT00905047|Other|XELODA|
3201619|NCT00905047|Other|UFT|
3201620|NCT00905073|Experimental|cyclosporin+Methotrexate|cyclosporin treatment at 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for on year and methotrexate 5 mg/kg/day for one year.
3201621|NCT00905112|Experimental|MOMS|Receives manual therapy, stabilization exercise and patient education
3201622|NCT00905112|Active Comparator|STOB|Receive standard obstetrical care
3201623|NCT00905138|Experimental|1|single ascending doses
2535156|NCT02662933|Experimental|Bedside Assessment Measures|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
2535168|NCT02662686|Active Comparator|Control|Embryo selection for transfer will be based initially on chromosomally normal embryos and secondly on embryo morphology criteria (specific of IVF lab, as standard practice).
2535169|NCT02662686|Experimental|MitoScore|Embryo selection for transfer will be based initially on chromosomal normality and secondly on the MitoScore value, trying to transfer chromosomally normal embryos which contain the lowest number of mitochondrial DNA copies.
2535210|NCT02662478||primary gastric GIST|Consisted of all consecutive cases of primary gastric stromal tumors (PGST) that underwent laparoscopic surgery (LS).
2535255|NCT02662257|Active Comparator|Sevoflurane group|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
2535256|NCT02662257|Experimental|Propofol group|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
2535297|NCT02661763||Schoolchildren in Zambia|Schoolchildren in grades 7-12 in fifteen randomly selected schools in Lusaka area
2535344|NCT02661555|Experimental|Aerobic exercise|Aerobic exercise two times per week for 24 weeks.
2535346|NCT02661555|No Intervention|Habitual lifestyle|Habitual lifestyle the first 24 weeks. Will be offered the same exercise intervention after 24 weeks.
2535361|NCT02661230|Experimental|COGNIPLUS|Exercise-Gaming
3201624|NCT00905138|Placebo Comparator|2|single dose placebo
2535485|NCT02660554|No Intervention|Usual care|In the usual care arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be given at the discretion of the care team. If bacterial cultures are negative for MRSA at 72 hours, the treating physician will be prompted to discontinue MRSA therapy.
2535487|NCT02660554|Experimental|Polymerase Chain Reaction|In subjects randomized to the polymerase chain reaction (PCR) arm, antibiotic therapy against methicillin resistant Staphylococcus aureus (MRSA) will be determined by the results of the PCR test. In subjects who are clinically stable, results from the PCR must be available prior to the administration of MRSA therapy. Subjects with a positive MRSA PCR will be administered MRSA therapy. In subjects with a negative MRSA PCR, MRSA therapy will be withheld. In subjects randomized to the automated PCR arm who are clinically unstable, empiric MRSA therapy will be allowed until the PCR is completed. In these cases of unstable subjects, empiric MRSA therapy will be discontinued if the PCR is negative.
3167698|NCT00541723|Experimental|IncobotulinumtoxinA (Xeomin), 3-injection scheme|"IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150kD), free of complexing proteins' (active ingredient:~Clostridium Botulinum neurotoxin Type A free of complexing proteins) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% sodium chloride (NaCl); total volume 0.24 mL per side, i.e. 3 x 0.08 mL (3 x 4 units = 12 units); Mode of administration: intramuscular injection."
3167699|NCT00541723|Placebo Comparator|Placebo 3-injection Scheme|Placebo to IncobotulinumtoxinA (Xeomin) powder for solution for injection; dose: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; total volume 0.24 mL per side, i.e. 3 x 0.08 mL placebo solution; mode of administration: intramuscular injection.
2535911|NCT02657980|Sham Comparator|Sham-Yband(YDT-201N)|sham-tDCS application 5 days a week for 2 weeks (total of 10 applications)
3167700|NCT00541736|Experimental|Patients|GTN-infusion
3167701|NCT00541736|Active Comparator|Controls|GTN-infusion
3167702|NCT00541762|Other|A, 3; B, 3; C, 3|A, 3: Fat with and without orlistat or placebo. B, 3: LCF vs MCF vs placebo. C, 3: LCF with and without DEXLOX or placebo.
3167703|NCT00541788|Experimental|1|Administration of Common Sage
3167704|NCT00541814|Active Comparator|1|CNI [Cyclosporine] minimisation Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to target blood level of 50-100 ng/ml.
3167705|NCT00541814|Experimental|2|CNI [Cyclosporine] withdrawal Group. Conversion from azathioprine to Myfortic followed by a three month period of cyclosporine weaning to the point of withdrawal.
3167706|NCT00541853|Active Comparator|A|ADPKD patients with blood pressure above 130/85 are enrolled. The patients whose blood pressure is controlled under 130/85 by Candesartan alone are classified into group A.
3167707|NCT00541853|Experimental|B|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group B, blood pressure is controlled by Candesartan plus Cilnidipine. If blood pressure is not lowered by Candesartan plus Cilnidipine alone, another antihypertensive agents except CCB and ACEI are allowable.
2535218|NCT02662452|Experimental|GLPG2222 single dose|Single dose of GLPG2222 oral suspension
2535221|NCT02662452|Placebo Comparator|Placebo single dose|Single dose of placebo oral suspension
2535222|NCT02662452|Experimental|GLPG2222 multiple doses|Multiple doses of GLPG2222 oral suspension
2535223|NCT02662452|Placebo Comparator|Placebo multiple doses|Multiple doses of placebo oral suspension
2535265|NCT02662075|Experimental|E-cigarette/tobacco Smoking Exposure|
2535273|NCT02661802|Experimental|Oxygen Supplementation|Two six-minute walk tests, one with oxygen supplementation and another without were performed on different days. During the test with oxygen supplementation the delivery was continuous by mask at 40% and technician walked behind the patient with the oxygen source.
2535368|NCT02661308|Experimental|Systematic bright light exposure|Systematic bright light exposure for 30 min. for 4 weeks
2535378|NCT02661308|Active Comparator|Systematic dim light exposure|Systematic dim light exposure for 30 min. for 4 weeks
2535424|NCT02660970|Active Comparator|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
2535425|NCT02660970|Placebo Comparator|Placebo-band|Children will have to wear a 'placebo-wristband'
2535427|NCT02660970|Active Comparator|Iberogast|Children will have to take Iberogast drops
2535430|NCT02660970|Placebo Comparator|Placebo-drops|Children will have to take placebo-drops
2535481|NCT02660658|Other|Intrathecal dexmedetomidine|"Up-down sequential allocation~The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance"
2535523|NCT02660411|Active Comparator|Sevoflurane group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.~Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
2535527|NCT02660411|Experimental|Propofol group|"Anesthesia will be induced intravenously with midazolam (0.015-0.03 mg/kg), sufentanil, propofol and rocuronium.~Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
2535599|NCT02659904|Active Comparator|Less than 2 mm|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: Less than 2 mm remaining palatal tissue thickness
2535603|NCT02659904|Active Comparator|2 mm or more|Palatal mucosa thickness was measured from baseline to 1, 3 and 6 months after graft harvesting Intervention: 2 mm or more remaining palatal tissue thickness
2535697|NCT02659527|Active Comparator|standardized needle biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~According to the randomization, the standardized 12 core TRUS (TransRectal UltraSound)-guided biopsy is performed without knowledge of imaging findings by the urologist. If the biopsy is negative patients will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
2535700|NCT02659527|Experimental|image-guided biopsy|"All enrolled patients are examined by means of dual tracer PET / MRI. Images will be interpreted by 4 designated readers. The readers are blinded of the respective results among each other. A consensus of the two principal readers of nuclear medicine and radiology will serve as reference for the guided needle biopsy. Additionally the readers are blinded to any result of the pathological workout until the recruitment of the last patient is finished.~Patients will have a standardized 12 core TRUS-guided biopsy without knowledge of imaging findings by the urologist. Patients randomized in this arm will have an additional image-guided biopsy with 4 more cores samples. After a positive biopsy the subjects be treated according to normal clinical practice."
2535730|NCT02658929|Experimental|bb2121|bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy
2535787|NCT02658617||patients|20 patients were enrolled. Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire). 1-2 days after the imaging patients started the treatment with duloxetine: 30mg for the first three days, then 60-90mg.
2535789|NCT02658617||healthy controls|Subjects were investigated with magnetic resonance spectroscopy (MRS), functional magnetic resonance imaging (fMRI) and also underwent a psychodiagnostic assessment (evaluating the severity of depression: Hamilton Depression Rating Scale and Beck Depression Inventory; measuring hopelessness: Beck Hopelessness Scale; measuring Alexithymia: Toronto Alexithymia Scale; measuring self-perception: Body Perception Questionnaire).
2535860|NCT02658253|Experimental|Group B2:Primvac 50 µg +GLA-SE|Group B2: 6 European volunteers 0.5 ml intramuscular injection:50 µg Primvac+ 2.5 µg GLA-SE Vaccination schedule: D0, D28 and D56
2536178|NCT02655809|Other|Physica KR|Patients who have received a Physica KR total knee implant.
2535118|NCT02663375||ACURATE TA™ Transapical Aortic Biorposthesis|Patients implanted with ACURATE TA™ Transapical Aortic Biorposthesis and Delivery System
2535170|NCT02662647|Experimental|DCAG plus HLI|Patient will be treated with decitabine and modified CAG regimen followed by HLA haploidentical peripheral mononuclear blood cells infusion.
2535171|NCT02662647|Experimental|DCAG|Patient will be treated with decitabine combining modified CAG regimen without other treatments.
2535253|NCT02662101|Experimental|Single arm, exsalt application|
2535307|NCT02661958|Experimental|S6G5T-3|topical cream
2535310|NCT02661958|Experimental|S6G5T-1|topical cream
2535313|NCT02661958|Active Comparator|S6G5T-5|topical cream
2535316|NCT02661958|Active Comparator|S6G5T-7|topical cream
2535318|NCT02661958|Active Comparator|S6G5T-6|topical cream
2535320|NCT02661958|Placebo Comparator|S6G5T-8|topical cream
3201625|NCT00905138|Experimental|3|multiple dose, 5 days, oral solution
3201626|NCT00905138|Placebo Comparator|4|multiple dose, 5 days, oral solution
2535646|NCT02659592|Experimental|infertile cancer survivors|infertile cancer survivors who seek to conceive and had frozen ovarian tissue when diagnosed years before
2535678|NCT02659371|Experimental|Low energy diet|Low energy diet (800 kcal/d) for eight weeks, following 4 weeks on reintroduction supplying 1200 kcal/d.
2535713|NCT02659176|Active Comparator|Transperineal repair with PIS|transperineal repair of anterior rectocele with limited internal sphincterotomy
2535715|NCT02659176|Active Comparator|Transperineal repair without PIS|transperineal repair of anterior rectocele only
3201627|NCT00905190|Experimental|Fed|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast
2535811|NCT02658500|Experimental|Infant Formula|200 newborns just consume the infant formula from 0-42 days to six months age.
2535813|NCT02658500|Other|Breast Milk|100 newborns were just fed with breast milk from after birth to six months age.
3201628|NCT00905190|Experimental|Fasting|A single oral dose of ondansetron (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
3201629|NCT00905203|Experimental|1|moderate exercise training (three times/ week including one home-based training and two supervised training)
3201630|NCT00905203|Experimental|2|intensive exercise training (four times/ week including one home-based training and three supervised training)
3201631|NCT00905216|Experimental|Test|Heparin sodium - Bergamo
3201632|NCT00905216|Active Comparator|Comparator|Heparin APP
2536055|NCT02656849|Experimental|BAY 1000394|"After the screening procedures confirm eligibility to participate in the research study:~Each treatment cycle lasts 4 weeks.~Participants will take the study drug orally at predetermined times and dosage per cycle."
2536089|NCT02656472|Active Comparator|Tranexamic Acid Arm|TXA arm will include 10 subjects who will receive TXA for duration of surgery.
2536090|NCT02656472|Active Comparator|Epsilon Aminocaproic Acid Arm|EACA arm will include 10 subjects who will receive EACA for the duration of surgery.
2536115|NCT02656108|Experimental|omiited controlled cord traction|neither controlled cord traction nor fundal pressure will be applied. The placenta will be delivered physiologically and signs of placental separation will be awaited
2536125|NCT02656108|Active Comparator|controlled cord traction|the cord will be held in one hand and the other hand will be placed just above the woman's pubic boneto stabilize the uterus during cord traction
2536193|NCT02655939|Active Comparator|Reflex Plus|Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
2536201|NCT02655939|Placebo Comparator|Placebo|Placebo Sachets to be taken once in a day Before breakfast for the study duration
2536252|NCT02655536|Active Comparator|erlotinib|erlotinib 150mg per day
3201633|NCT00905229|Active Comparator|PO (by mouth)|2.5 mg P.O Vitamin K
3201634|NCT00905229|Active Comparator|IV (intravenous )|0.5 mg IV Vitamin K
3201635|NCT00905281|Experimental|Action Group|
3201636|NCT00905281|Other|Standard care|
3201637|NCT00905294||coronary artery disease|Subjects with coronary artery disease undergoing percutaneous coronary intervention
3201638|NCT00905320|Active Comparator|Metallic Fasteners and Sutures|Laparoscopic ventral hernia repair with mesh fixation using both metallic fasteners and transabdominal sutures
3201639|NCT00905320|Experimental|Metallic Fasteners Alone|Laparoscopic ventral hernia repair with mesh fixation using metallic fasteners alone
3201640|NCT00905333|Other|Single-arm|3 treatments, 6 sequences, 3 periods, cross-over, single dose arm (Willians' Plan)
3201641|NCT00905372|Experimental|LY2062430|
3201642|NCT00905372|Placebo Comparator|Placebo|
3201643|NCT00905385|Experimental|Low Dose: 3,200 CFU|5 subjects inoculated with 3,200 colony forming units (CFU).
3201644|NCT00905385|Experimental|High Dose: 32,000 CFU|5 subjects inoculated with 32,000 colony forming units (CFU).
3201645|NCT00905398|Experimental|nilotinib|single arm study
3201646|NCT00905411|No Intervention|Attention Control / Usual Care|
3201647|NCT00905411|Experimental|Intervention|
3201648|NCT00905463||Transplantation|Lung transplantation candidates
3201649|NCT00905476||NPPV|Patients with chronic respiratory failure receiving domiciliary NPPV
3201650|NCT00905502|Experimental|1: Restricted protocol (RG) group|Received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period.
3201651|NCT00905502|Active Comparator|2: Liberal protocol (LG) group|Received 10 ml/kg•hr of RL solution intraoperatively.
3201652|NCT00905528||A|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
3201653|NCT00905528||B|Subjects with type 2 diabetes mellitus, eGFR > 80, hypertension, no overt proteinuria
3201654|NCT00905541|No Intervention|No treatment|Phase A: No treatment
3201655|NCT00905541|Experimental|simvastatin chronic|Phase B: 40 mg/day simvastatin
3201656|NCT00905541|Experimental|simvastatin acute-on-chronic|Phase C: 80 mg simvastatin acute-on-chronic
3201657|NCT00905619||Control|No kidney disease
3201658|NCT00905619||PreHD kidney disease|Kidney disease stage 4 or below
2535161|NCT02662894|Experimental|Valsartan 160mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (160mg) + rosuvastatin (20 mg), oral, once daily.
2535162|NCT02662894|Experimental|Valsartan 320mg + Rosuvastatin 20mg|Fixed-dose combination of valsartan (320 mg) + rosuvastatin (20 mg), oral, once daily.
2535163|NCT02662894|Active Comparator|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
2535164|NCT02662894|Active Comparator|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
2535202|NCT02662543||Hospitalized AGE patients|Children less than 18-years-old hospitalized due to acute gastroenteritis to seven Estonian hospitals participating in this study
2535254|NCT02662309|Experimental|MPDL3280A|Patients receive 2x 3-weekly cycles of MPDL3280A (one infusion on the first day of each cycle) prior to cystectomy surgery.
2535332|NCT02661789|Active Comparator|GnRHa|Goserelin 3.6 mg implant
2535334|NCT02661789|Placebo Comparator|Placebo|Injection of saline
2535369|NCT02661295|Other|Ferric Citrate|Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.
3201659|NCT00905619||Hemodialysis|Kidney disease receiving hemodialysis
3201660|NCT00905645|Experimental|Primary Augmentation|Silimed Gel-Filled Mammary Implant
3201661|NCT00905645|Experimental|Primary Reconstruction|Silimed Gel-Filled Mammary Implant
2535615|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer|Pit and fissure sealing using conventional glass-ionomer cement
2535622|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement|Pit and fissure sealing using conventional glass-ionomer cement
2535626|NCT02659917|Active Comparator|Ketac Molar® (3M/ESPE) - Glass ionomer -|Restoration using conventional glass-ionomer cement
2535630|NCT02659917|Experimental|Maxxion® (FGM) - Glass ionomer cement -|Restoration using conventional glass-ionomer cement
2535690|NCT02659358||Biosensor + Patient Reported Outcomes (PRO)|Participants will wear a biosensor (Fitbit Charge HR®) continuously for a period of 15 days and respond to PROMIS questionnaires. This is not a chemotherapy or treatment-intervention trial.
2535765|NCT02658786||Hepatitis B patients|Biopsy proven Hepatitis B virus infected cases will be followed for the period of 5 years
2535767|NCT02658786||Hepatitis C patients|Biopsy proven Hepatitis C virus infected cases will be followed for the period of 5 years
2535769|NCT02658786||Non Alcoholic Fatty liver Disease patients|Biopsy proven Non Alcoholic Fatty liver Disease patients cases will be followed for the period of 5 years
2535788|NCT02658565|No Intervention|Low-risk for nodal involvement|No lymphadenectomy recommended
2535790|NCT02658565|Experimental|High-risk for nodal involvement|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
2535836|NCT02658370|Experimental|animated home-based exercises (Wii-fit)|using the Wii game console by Nintendo
2535840|NCT02658370|Active Comparator|conventional home-based exercise program|by using a compilation with 31 exercises especially for rheumatoid arthritis patients
2535926|NCT02657733|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and Nellcor Bedside Respiratory Patient Monitoring System
2535955|NCT02657447|Experimental|Arm 1: Betalutin with lilotomab dose 1|Betalutin 15 MBq/kg b.w. with lilotomab pre-dosing
2535957|NCT02657447|Experimental|Arm 2: Betalutin with lilotomab dose 2|Betalutin 15MBq/kg b.w. with lilotomab pre-dosing
2536020|NCT02657148||Immediate postpartum Nexplanon|Participants who choose to enroll in the immediate postpartum Nexplanon arm will have a etonogestrel contraceptive implant (68 mg) (Nexplanon) placed in the immediate postpartum period (2-4 days following delivery), prior to hospital discharge.
2536021|NCT02657148||Control|Participants who choose to enroll in the control arm will receive standard postpartum contraceptive care: condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
3201662|NCT00905645|Experimental|Revison|Silimed Gel-Filled Mammary Implant
3201663|NCT00905658|No Intervention|Arm I|Patients are monitored via standard follow-up assessments every 3 weeks.
3201664|NCT00905658|Experimental|Arm II|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks.
3201665|NCT00905658|Experimental|Arm III|Patients receive nutritional supplements and are monitored via standard follow-up assessments every 3 weeks with additional biweekly assessments completed at home by a service provider.
2536275|NCT02655263|No Intervention|Control|12 hours of fasting
2536281|NCT02655263|Experimental|GH infusion|12 hours of fasting
2536282|NCT02655263|Experimental|GH and ketone bodies infusion|12 hours of fasting
2536354|NCT02654964|Experimental|Treatment Arm|"A Drug Combination Treatment will be determined through High Throughput Screening. The classes of drugs this combination therapy will be comprised from are:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
3201666|NCT00905671|Experimental|LCP+ Bifurcation Lesion|Bifurcating lesions that are positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
3201667|NCT00905671|Experimental|LCP- Bifurcation Lesion|Bifurcating lesions that are not positive for lipid core plaque, as detected by LipiScan Coronary Imaging, prior to angioplasty.
3201668|NCT00905684||Group 1|
3201669|NCT00905684||Group 2|
3201670|NCT00905697||Living donor lung transplantation|Living lung transplantation donors
3201671|NCT00905710|No Intervention|1|Conventional colonoscopy
3201672|NCT00905710|Experimental|2|Colonoscopy using chromoendoscopy
3201673|NCT00905723|Experimental|Estrogen|Women randomized to this group will receive daily pills containing 1 mg of estradiol
3201674|NCT00905723|Experimental|Isoflavone|Women randomized to this group will receive daily pills of 150 mg isoflavone
3201675|NCT00905723|Placebo Comparator|Placebo|Women randomized to this group will be administered daily placebo pills
2535165|NCT02662855|Active Comparator|Control|WHO-recommended therapies, mainly symptomatic and supportive treatments. Briefly: body fluid management (intravenous or oral, depending on patient status), balanced nutrition (including glucose, electrolytes, vitamin, et al.), preventing intravascular volume depletion, correcting profound electrolyte abnormalities, avoiding the complications of shock, defervesce, anti-diarrheal, acesodyne, anti-anxiety. For patients with positive Plasmodium detection or bacterial infection, apply artemether-lumefantrine or antibiotics respectively. Details refer to 'Manual for the care and management of patients in Ebola Care Units/Community Care Centres, Interim emergency guidance' and 'Clinical Management of Patients with Viral Haemorrhagic Fever: A Pocket Guide for the Front-line Health Worker' by WHO.
2535166|NCT02662855|Experimental|Treatment|WHO-recommended therapies plus oral administration of Favipiravir
2535197|NCT02662504|Experimental|multimodal treatment + intrapleural PDT|"surgery of the MPM: extended pleurectomy/decortication (eP/D)~intra-operative (intrapleural) photodynamic therapy (PDT). Briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~then:~prophylactic chest radiotherapy of surgical scars to prevent tumor seeding (3 x 7 Gray)~adjuvant standard chemotherapy by (cis)platin 75 mg/m2 and pemetrexed 500 mg/m2 up to 6 cycles (1 cycle every 3 weeks), with oral folic acid (400 μg daily) and vitamin B12 (1000 μg Q9W) supplementation"
2535258|NCT02662270||Cases|Patients with a fibromyalgia diagnosis established according to the American College of Rheumatology current criteria by a trained physician.
2535261|NCT02662270||Controls|Healthy subjects paired by age and gender to the subjects in the cases group.
2535298|NCT02661854|Experimental|MM09 Mannosylated 5.000 subcutaneous|5.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2535300|NCT02661854|Experimental|MM09 Mannosylated 10.000 subcutaneous|10.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2535302|NCT02661854|Experimental|MM09 Mannosylated 30.000 subcutaneous|30.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2535305|NCT02661854|Experimental|MM09 Mannosylated 50.000 subcutaneous|50.000 MTU/ml of subcutaneous immunotherapy and sublingual placebo.
2535308|NCT02661854|Experimental|MM09 Mannosylated 5.000 sublingual|5.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2535312|NCT02661854|Experimental|MM09 Mannosylated 10.000 sublingual|10.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2535314|NCT02661854|Experimental|MM09 Mannosylated 30.000 sublingual|30.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2535317|NCT02661854|Experimental|MM09 Mannosylated 50.000 sublingual|50.000 MTU/ml of sublingual immunotherapy and subcutaneous placebo.
2535319|NCT02661854|Placebo Comparator|Placebo Sublingual Placebo subcutaneous|Sublingual and subcutaneous placebo.
2535377|NCT02661204||Population A|Consecutive women in the age range 20 to 40 years, with a strong family history of breast cancer or a predisposing gene mutation such as BRCA1 or BRCA2, referring to our department for breast evaluation with ultrasound, will be invited to participate to the study. During the interview, before imaging examination, women will be questioned about family history as well as other relevant personal information (e.g. previous surgery or biopsy for benign breast disease).
2535388|NCT02661204||Population B|Consecutive women with a new breast cancer diagnosis and undergoing pre-operative MRI examination for local staging will be invited to participate to the study. ABUS will be performed within two weeks before the scheduled surgery.
2535393|NCT02661204||Population C|Consecutive women with BI-RADS 3 and 4 lesions detected in a routine breast imaging examination will be invited to participate to the study. ABUS will be performed just after the routine HH-US examination.
2535399|NCT02661204||Population D|Consecutive women undergoing breast MRI examination for the evaluation of breast implants integrity will be invited to participate to the study. ABUS will be performed just after the breast MRI.
2535437|NCT02660905|Experimental|Active Treatment|E/C/F/TAF Ledipasvir-Sofosbuvir/TAF
2535489|NCT02660632|Placebo Comparator|Thoracic epidural analgesia (TEA)|Patients who will be subjected for midline laparotomy, will receive epidural analgesia through an inserted thoracic epidural catheter before induction of general anesthesia
2535490|NCT02660632|Active Comparator|Rectus sheath catheter block|After insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected on each side, then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
2535535|NCT02660294|Experimental|Platlet rich plasma|For those with endometrial thickness less than 7 mm intrauterine injection of platlet rich plasma (PRP) for enhancing endometrial thickness and receptivity
2535537|NCT02660294|No Intervention|Hormone replacement therapy|Oral intake of estradiol valerate for those with endometrial thickness less than 7 mm will improve endometrial receptivity
2535580|NCT02660099|Experimental|Internet-delivered CBT|12 weeks of internet-delivered cognitive behavior therapy provided through a secure internet platform and online clinician contact
3201676|NCT00905736|Experimental|current controlled|a current controlled microcurent device providing a primarily monophasic waveform of typical amplitude 40 microamps
2535716|NCT02659267|Experimental|Interventions Group=|Group of change behavior including physical activity and healthy eating habits promotion.
2535717|NCT02659267|No Intervention|Control Group=|Group that will not receive the VAMOS program as intervention, only participate in the Health Academy Program Activities.
2535739|NCT02658838|Experimental|full amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with full amount low molecular weight heparin until they leave hospital.
2535749|NCT02658838|Experimental|half amount low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with half amount low molecular weight heparin until they leave hospital.
2535755|NCT02658838|Experimental|No low molecular weight heparin|Patients were treated with ticagrelor one year，After PCI， the patients are treated with no low molecular weight heparin.
2535809|NCT02658721|Active Comparator|lidocaine|In the third group (LDC group), IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL.
3201677|NCT00905736|Experimental|voltage controlled|constant voltage amplitude delivering high frequency AC waveform
2535172|NCT02662660|Experimental|Port-sites infiltration:Bupivacaine0,25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
2535177|NCT02662660|Experimental|Epidural analgesia:Levobupivacaine0.125%|"Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.~Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours."
2535185|NCT02662660|Active Comparator|Metamizole and Acetaminophen iv|Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
2535252|NCT02662296|Experimental|Treatment (ibrutinib or idelalisib)|Patients receive ibrutinib PO QD on days 1-28 or idelalisib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3201678|NCT00905762|Experimental|Besifloxacin|Besifloxacin one drop instilled into study eye.
3201679|NCT00905762|Active Comparator|Gatifloxacin|Gatifloxacin one drop instilled into study eye.
3201680|NCT00905762|Active Comparator|Moxifloxacin|Moxifloxacin one drop instilled into study eye.
3201681|NCT00905775||1 Isoflurane|The first group (G1) will be submitted to inhalational general anesthesia with isoflurane (1 CAM, evaluated by expired concentration of isoflurane)
3201682|NCT00905775||2 Propofol|The second group (G2) to targeted venous general anesthesia controlled with propofol. The targeted concentration of propofol will be kept at the predicted plasma concentration from 1 to 2 µg.ml-1 by means of a Diprifusor® infusion pump. During the interval from 10 minutes preceding ECC initiation to 10 minutes after ECC, the propofol concentration will be increased to 2 or 3 µg.ml-
3201683|NCT00905788|No Intervention|Control Group|Embryo transfer without any intervention
2535533|NCT02660320|Active Comparator|Dermabrasion|Dermabrasion using dermaroller: The dermaroller is applied on the treated areas, this dermabrasion technique is based on micro holes performed using 540 micro needles (200µm depth) which should allow the penetration of the suspension cells or hyaluronic acid alone. Twelve passages will be performed on the treated area in order to achieve 60% of coverage.
2535536|NCT02660320|Placebo Comparator|Laser|To prepare the graft recipient site, the upper layer of epidermis is removed by superficial dermabrasion using Erbium or CO2 ablative laser. The test area is ready to receive suspension cells when the dermis will appeared. The cells suspension will be applied on the wound.
2535639|NCT02659605|Experimental|Delayed cord clamping above the perineum|
2535643|NCT02659605|Active Comparator|Delayed cord clamping below the perineum|
2535680|NCT02659306|Experimental|Metformin|Assessment will be done at the baseline, during and after 12 week of metformin use.
2535719|NCT02659085|Active Comparator|Electroconvulsive Therapy (ECT)|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly. Each participating clinic decides for each patient whether the treatment is given uni- or bilateral, as well as the exact stimulation parameters. Choice of anesthetic drug (e.g. thiopental of propofol) and muscle relaxant is done by local anesthesiologist. The procedure differs in no way from how a given patient would have been treated if he or she were not included in the study.
2535720|NCT02659085|Experimental|Ketamine IV Infusion|Ketamin intra venous infusions of racemic ketamine (0.5mg/kg), delivered over a period of 40 minutes thrice weekly, as ECT (Monday, Wednesday and Friday).
2535777|NCT02658773|Active Comparator|lidocaine-Prilocaine cream|lidocaine-Prilocaine anesthetic cream placed into their cervix prior to having the IUD inserted
2535778|NCT02658773|Placebo Comparator|placebo cream|an inert placebo cream placed into their cervix
2535844|NCT02658305||transoral group|orthognathic patients that were treated with a transoral surgical approach
2535847|NCT02658305||transbuccal group|orthognathic patients that were treated with a transbuccal surgical approach
3201684|NCT00905788|Experimental|Embryo Expulsion|
3201685|NCT00905801|Other|Arm A CT Perfusion|"Arm A Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~CTP imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Subject will stand up and walk around, and then lay back down~CT Perfusion imaging: Second single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from their clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
2536022|NCT02657044|Active Comparator|EMR|In the EMR-arm, endoscopic resection will be performed using the (p)EMR technique.
2536023|NCT02657044|Active Comparator|ESD|In the ESD-arm, endoscopic resection will be performed using the (h)ESD technique.
2536053|NCT02656667|Experimental|neuromuscular electrical stimulation|conventional pulmonary rehabilitation including exercise training on treadmill and neuromuscular electrical stimulation with a medical device for quadriceps muscle strengthening
2536054|NCT02656667|Experimental|cycle ergometer training|conventional pulmonary rehabilitation including exercise training on treadmill and quadriceps strenghthening on cycle-ergometer
2536120|NCT02656056|Experimental|Lean Adults|Adults with a BMI between 21-25 will consume 8 oz of the fermented soybean beverage, twice daily.
3201686|NCT00905801|Other|Arm B CT Perfusion|"Arm B Procedure~On the first required study visit, subject will undergo one SOC CT scan followed by the research component:~- CT Perfusion imaging: Single bed position CTP examination, which includes injection of 30 cc of contrast agent, over the predetermined lesion from clinical scan~Procedures will be repeated at optional second study visit ~6-8 weeks later."
2535187|NCT02662816|Experimental|glutathion|The study will validate the detection and the quantification of glutathione in muscle and liver using 1H MRS
2535229|NCT02662348|Experimental|Interleukin-2 Transfusion|Patients receive low-dose Recombinant Human Interleukin-2 SC daily beginning 3 days before the first HER2Bi armed T cell infusions infusion.
2535230|NCT02662348|Experimental|T Cells Transfusion|Patients receive HER2Bi-Armed T Cells IV weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2535366|NCT02661269||Septic patients|Septic patients with fluid overload (fluid balance + 4 L)
2535375|NCT02661269||Post-cardiac surgery patients|Patients after cardiac surgery, at arrival on ICU.
2535463|NCT02660892|Experimental|Protein Intake|Threonine intake - Dietary supplement
2535484|NCT02660541|Active Comparator|Betafoam|Brand name: Betafoam® This is a medicated device (dressing) consisting of 3% povidone iodine.
2535486|NCT02660541|Active Comparator|Allevyn Silver dressing|Brand name: Allevyn® Silver
2535517|NCT02660372|Experimental|Imonogas|Imonogas 120 mg, 1 capsule three times daily for 8 weeks
2535525|NCT02660372|Active Comparator|Espumisan|Espumisan 40 mg, 2 capsules four times daily for 8 weeks
3167708|NCT00541853|Active Comparator|C|The patients whose blood pressure is not controlled under 130/85 with ARB alone are randomized into group B or C. In group C, blood pressure is controlled by Candesartan plus non-CCB agents such as beta- or alpha- adrenergic blockers or another ARB. Any CCB and ACEI are not allowable.
3167709|NCT00541879|Experimental|I|Elementary school children -grades 2-6 participating in Program ENERGY
2535675|NCT02659436|Active Comparator|Verbal-linguistic CBT|Participants will receive 4 sessions of verbal cognitive restructuring and exposure therapy delivered in an individual therapy format.
2535676|NCT02659436|Experimental|Imagery-based CBT|Participants will receive 4 sessions of imagery-based cognitive work and behavioural experiments delivered in an individual therapy format.
2535731|NCT02658955|Experimental|Short stitch|Patients in which abdominal wall is closed by short stitch technique
2535732|NCT02658955|No Intervention|Large stitch|Patients who didn't receive properly closure according with the protocol
3167710|NCT00541879|Sham Comparator|II|Elementary school children in grades 2-6 matched to the intervention classes not receiving any intervention
3167711|NCT00541892|Experimental|1|Medium with no human serum albumine added
2535845|NCT02658214|Experimental|Cohort 1|ovarian/peritoneal/fallopian tube cancer and squamous cell carcinoma of the head and neck (SCCHN)
2535848|NCT02658214|Experimental|Cohort 2|Small-cell lung cancer (SCLC)
2535851|NCT02658214|Experimental|Cohort 3|Triple-negative breast cancer (TNBC)
2535855|NCT02658214|Experimental|Cohort 4|Triple-negative breast cancer (TNBC)
2535859|NCT02658214|Experimental|Cohort 5|Gastric/gastro-esophageal junction (GEJ)
2535862|NCT02658214|Experimental|Cohort 6|Pancreatic ductal adenocarcinoma (PDAC)
2535863|NCT02658214|Experimental|Cohort 7|Esophageal squamous cell carcinoma (ESCC)
2536110|NCT02656394|Active Comparator|GL101|GL101 topical gel
2536112|NCT02656394|Placebo Comparator|Placebo|Placebo topical gel
2536189|NCT02655991|Experimental|Telephone Case Monitoring|Telephone care management augmenting treatment as usual
2536195|NCT02655991|Active Comparator|Treatment as Usual|Case management, psychotherapy, and pharmacotherapy as usual
2536286|NCT02655445|Active Comparator|Mini-craniotomy|"Intervention: Bone flap > 30mm and replaced, placement of Jackson-Pratt drain~A linear incision located over the biggest bulk of the hematoma is made. Dura is opened and a wide opening of the pseudomembrane is done. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
2536291|NCT02655445|Active Comparator|Twist Drill Craniostomy|"Intervention: twist drill burr hole <5mm, placement of Integra basket-type drain~A stab incision to the scalp is made, at the approximate location of the thickest diameter of hematoma. The twist-drill hole <5mm is placed obliquely to the surface of the skull, at an angle of about 45° until perforation of the dura. No irrigation is performed. A basket-type drain (Integra) is placed in the subdural space and tunneled underneath the skin"
2536292|NCT02655445|Active Comparator|Burr Hole Craniostomy|"Intervention: 2 Burr Holes >5mm and <30mm, placement of Jackson-Pratt drain~First burr hole at the site of maximal diameter, second anterior and superior to that point. The scalp incisions are so planned that they can be incorporated into a craniotomy if necessary. Visible membranes are opened with a sharp hook until the pia is visualized. Gentle irrigation is performed and continued until the returning liquid is clear. Two burr holes are placed to facilitate drainage. A closed system subdural drain (Jackson-Pratt catheter) is inserted after irrigation until clear liquid return"
2536323|NCT02654873||Benign|Benign pathology specimens with macroscopically
2536324|NCT02654873||Suspicious|Suspicious group includes the conditions such as increasing of the gallbladder wall thickness, having calcifications or polyps in the gallbladder.
2536326|NCT02654873||Malign|Malign group includes the conditions such as detecting mass or irregularities in the gallbladder wall.
2536400|NCT02654678|Experimental|Enalapril Orodispersible Minitablets|Individually adapted dose of enalapril consisting of 1 to maximum 4 enalapril ODMTs of 0.25 mg and/or 1 mg and/or other prescribed treatment of heart failure.
2536443|NCT02654184|Active Comparator|Supine group|Anesthesia induction with sevoflurane for the patient while he is in supine position.
2536452|NCT02654184|Active Comparator|Right lateral group|Anesthesia induction with sevoflurane for the patient while he is in right lateral position position.
2536524|NCT02653963|Experimental|Triamcinolone adjuctival AGV|Subtenon Periplate 10 mg triamcinolone acetonide around the AGV plate after fixation of AGV Plate to the sclera
2536641|NCT02653066|Experimental|Intervention with return of consent form|After returning signed consent form, participant in HealtheRx++ group is mailed $5 bill.
3167712|NCT00541892|Active Comparator|2|Conventional medium
3167713|NCT00541905|Experimental|NT 201 (50-300 Units)|"NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3167714|NCT00541918|Active Comparator|1|propofol
3167715|NCT00541918|Experimental|2|sevoflurane
2535189|NCT02662829|Active Comparator|Standard of Care (SOC)|At SOC clinics, patients will receive usual care for management of contact tracing, screening, and IPT provision. Childhood TB in Lesotho is managed by nurses in health centers. Per national guidelines, TB patients are asked to bring in child contacts, who are screened using a simple symptom questionnaire. Children who screen negative are assessed for IPT eligibility. Absent contra-indications (eg, active hepatitis, regular alcohol consumption, peripheral neuropathy), nurses counsel children and guardians on IPT benefits, potential side effects, and importance of adherence. Children requiring chest x-rays or gastric lavage and HIV-infected children under age 1 are referred to the hospital. After initiation, patients and guardians return to the clinic monthly for monitoring for side effects, TB symptoms, adherence, and 30-day supply of isoniazid. If adherence problems are noted, the nurse counsels patient and guardian as appropriate.
2535291|NCT02661750||Step 1|Patients who had inadequate preparations for colonoscopy with a standard dose of bowel cleansing agent.
2535295|NCT02661750||Step 2|Patients who had inadequate preparations for colonoscopy with a step 1 dose of bowel cleansing agent.
2535299|NCT02661750||Step 3|Patients who had inadequate preparations for colonoscopy with a step 2 dose of bowel cleansing agent.
2535301|NCT02661750||Step 4|Patients who had inadequate preparations for colonoscopy with a step 3 dose of bowel cleansing agent.
2535306|NCT02661750||Step 5|Patients who had inadequate preparations for colonoscopy with a step 4 dose of bowel cleansing agent.
2535362|NCT02661438|Other|Placebo to Ciprofloxacin DPI|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
2535440|NCT02661022|Experimental|SL-401/Pomalidomide/ Dexamethasone|SL-401 in combination with Pomalidomide and Dexamethasone
3167716|NCT00541957|Other|2|Medication prescribed by PCP
2535546|NCT02660190|Experimental|PDD|PDD at flexible cystoscopy
2535548|NCT02660190|Experimental|WL|WL only at flexible cystoscopy
2535619|NCT02659891|Active Comparator|Group 1 (Treatment)|Intravenous immune globulin (IVIg; Privigen®) 1g/kg monthly for 2 months with immunosuppression reduction.
2535625|NCT02659891|Placebo Comparator|Group 2 (Control)|Placebo infusion monthly for 2 months with immunosuppression reduction
2535725|NCT02659033|Active Comparator|ceftriaxone|healthy volunteer who receive ceftriaxone
2535728|NCT02659033|Active Comparator|cefotaxime|healthy volunteer who receive cefotaxime
3167717|NCT00541957|Experimental|1|Medication prescribed by PCP + behavior therapy
3167718|NCT00541983|Active Comparator|1|
2535954|NCT02657460|Experimental|MTX-ATMPs|methotrexate-autologous tumor derived microparticles
2535956|NCT02657460|Sham Comparator|cisplatin|Cisplatin is a traditional treatment for lung cancer
2535989|NCT02657239|Experimental|MOVE UP Intervention|Subjects will participate in a healthy lifestyle weight management intervention focused on healthy eating and increasing physical activity
2536084|NCT02656940|Experimental|Group 1 - diet rich in n-3 and n-6 PUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 1 received diet rich in n-3 and n-6 polyunsaturated fatty acids (PUFA). The volunteers were asked to consume daily a mixture of virgin olive oil and soybean oil, totaling 35.2g to 52.8g, and 2 g of fish oil."
2536085|NCT02656940|Experimental|Group 2 - diet rich in MUFA|"Assigned intervention: The dietary intervention was conducted by 60 days. Were prescribed normocaloric diets with similar macronutrient composition, varying only the type of lipids offered.~Group 2 received diet rich in monounsaturated fatty acids (MUFA). The volunteers were asked to consume daily virgin olive oil, totaling 35.2g to 50.6g, and 1 capsule of 1g of soybean oil."
2536087|NCT02656940|Experimental|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming 1 sachet of 2g of soybean oil and 1 capsule of 1g of soybean oil by day.
2536118|NCT02656212|Experimental|(+)-epicatechin 30mg|10 subjects will be randomized to a 30mg dose of synthetic (+)-epicatechin
2536131|NCT02656212|Placebo Comparator|placebo|5 subjects will be randomized to a placebo
2536192|NCT02655874|Experimental|Six-monthly influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and 180
2536200|NCT02655874|Active Comparator|Annual influenza vaccine|Standard dose trivalent inactivated seasonal influenza vaccine will be administered at day 1 and an active-comparator (Tetanus-diphtheria-pertussis) at day 180
2536508|NCT02653924|Active Comparator|silk suture|silk suture
2536513|NCT02653924|Active Comparator|vicryl suture|vicryl suture
2536520|NCT02653924|Active Comparator|nylon suture|nylon suture
2536525|NCT02653924|Active Comparator|polypropylene suture|polypropylene suture
3167719|NCT00541983|Placebo Comparator|2|
3167720|NCT00542009|Experimental|CE-326,597 100 mg QD|
3167721|NCT00542009|Experimental|CE-326,597 50 mg QD|
3167722|NCT00542009|Experimental|CE-326,597 25 mg QD|
3167723|NCT00542009|Placebo Comparator|Placebo|
3167724|NCT00542009|Experimental|CE-326,597 5mg QD|
3167725|NCT00542035|Experimental|ARRY-371797|
3167726|NCT00542035|Experimental|Placebo, ARRY-371797|
3167727|NCT00542035|Placebo Comparator|Placebo|
3167728|NCT00542048|Experimental|1|
3167729|NCT00542061|Experimental|A|Device: monitoring services
3167730|NCT00542061|No Intervention|B|Control group: no monitoring procedures
3167731|NCT00542074|Experimental|1|
3167732|NCT00542074|Active Comparator|2|
3167733|NCT00542100|Experimental|1|
3167734|NCT00542100|Experimental|2|
3167735|NCT00542113|Experimental|1|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 1
3167736|NCT00542113|Experimental|2|Parents of elementary school children in grades 2-6 participating in Program ENERGY -Intervention 2
3167737|NCT00542113|Sham Comparator|3|Parents of elementary school children in grades 2-6 participating in Program ENERGY matched to the intervention groups
3167738|NCT00542126|Active Comparator|1|GnRH analog administration following embryo transfer
3167739|NCT00542126|No Intervention|2|
3167740|NCT00542139|Experimental|1|
3167741|NCT00542139|Active Comparator|2|
2535201|NCT02662634|Experimental|Concurrent, no radiation|"AGS-003-LNG dosing initiated concurrently or subsequent to 3rd cycle of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses will then be administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G)."
2535203|NCT02662634|Experimental|Sequential, radiation|"AGS-003-LNG initiated after completion of platinum doublet chemotherapy. AGS-003-LNG induction = 1 dose administered every 3 weeks for 5 doses. Booster doses will then be administered every 12 weeks. A dose of AGS-003-LNG consists of (1.2 x 10-7 Dendritic cells.) Platinum-doublet chemotherapy can be any of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI"
2535205|NCT02662634|Experimental|Concurrent, radiation|"AGS-003-LNG dosing initiated concurrently during or subsequent to the 3rd cycle (3-week cycle) of platinum doublet chemotherapy & radiation therapy. AGS-003-LNG induction = 1 dose administered every 3 wks for 5 doses. Booster doses administered every 12 wks. A dose of AGS-003-LNG =1.2 x 10-7 Dendritic cells.~Platinum-doublet chemotherapy choice of the following determined by PI~Carboplatin/Abraxane:~ABRAXANE is 100 mg/m2 i.v. over 30 minutes on Days 1, 8, & 15 of each 21-day cycle; carboplatin AUC 6 (C&G) on Day 1 of each 21-day cycle immediately after ABRAXANE.~Carboplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day cycle in combination with carboplatin AUC 6 (C&G) i.v. 30 minutes after ALIMTA.~Cisplatin/Alimta ALIMTA is 500 mg/m2 i.v. on Day 1 of each 21-day with cisplatin 75 mg/m2 i.v., 30 minutes after ALIMTA.~Carboplatin/Taxol TAXOL administered i.v. over 24 hrs at a dose of 135 mg/m2 followed by carboplatin, AUC 6 (C&G).~Radiation therapy per PI."
3201687|NCT00905814|Other|Sequence 1 (BABA)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
3201688|NCT00905814|Other|Sequence 2 (ABAB)|Treatment A: One 5-mg FCIR tablet Treatment B: Five 1-mg FCIR tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B -> A -> B
2535426|NCT02661009||Plasma and tissue matching|
2535428|NCT02661009||predicting clinical efficacy|
2535462|NCT02660697|Active Comparator|Test - Extraction site development group|In the test group 29 healthy patients presenting 33 single rooted teeth scheduled for extraction with Extraction Defect Sounding (EDS) Class 3-4 type buccal bony dehiscences were included. 29 maxillary single rooted teeth and 4 single rooted teeth in the mandible (27 incisors, 2 canines and 4 premolars) were removed and treated by the novel extraction site development method. Pre- and postoperative ConeBeam Computer Tomography (CBCT) data were collected for further analysis.
2535464|NCT02660697|No Intervention|Control - Spontaneous healing group|In the control group. pre- and postextraction CBCT data sets of 14 patients with 21 extracted teeth were collected. 11 maxillary single rooted teeth and 10 single rooted teeth in the mandible (13 incisors, 2 canines and 6 premolars) were extracted and left for spontaneous healing.
2535493|NCT02660502|Experimental|BioChaperone insulin lispro 0.1 U/kg|
2535495|NCT02660502|Experimental|BioChaperone insulin lispro 0.2 U/kg|
2535496|NCT02660502|Experimental|BioChaperone insulin lispro 0.4 U/kg|
2535498|NCT02660502|Active Comparator|Humalog®|
3201689|NCT00905853|Active Comparator|Ventricular Tachycardia Ablation|Catheter ablation for Ventricular tachycardia will be performed within 14 days of randomization.
2535640|NCT02659618||Severe Persistent Asthma|All subjects will have severe persistent asthma diagnosed by a doctor.
2535681|NCT02659410|Experimental|Heat stress|4h exposure to heat stress alone or in combination with different solvents. Solvent concentrations are equal to their TLV. Heat conditions are 21, 25 and 30°C (WBGT). Inhalation exposure for all solvents and demal exposure for toluene.
2535738|NCT02658825|Experimental|Panel 1: Dose level 1|Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
2535745|NCT02658825|Experimental|Panel 1: Dose level 2|Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
2535754|NCT02658825|Experimental|Panel 2: Treatment EFG|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535756|NCT02658825|Experimental|Panel 2: Treatment FGE|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535758|NCT02658825|Experimental|Panel 2: Treatment GEF|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535236|NCT02662335|Active Comparator|Arm II (wait-list)|Patients undergo standard follow-up care for 6 weeks. Following standard follow-up care, patients may complete Cogmed as in the Intervention Group in weeks 7-13.
3201690|NCT00905853|Active Comparator|Escalated Antiarrhythmic Drug Therapy|Patients are prescribed a loading dose of amiodarone or the addition of mexiletine to their current anti-arrhythmic medication which is stratified by the dose and type of antiarrhymic medication at the time of the index arrhythmic event.
3201691|NCT00905866||Quality of life|All participants undergoing parathyroidectomy
2535374|NCT02661477|Other|pegylated interferon + placebo|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ). Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will receive subcutaneous placebo (0,9% NaCl) injection once a week, two times.
2535379|NCT02661477|Other|placebo + pegylated interferon|Patients with primary hypogammaglobulinemia and confirmed respiratory rhinovirus infection will receive will receivesubcutaneous placebo(0,9% NaCl) injection once a week, two times. Washout period is 8 weeks. When the same patient gets next rhinovirus infection, he/she will subcutaneous pIFNα2a (pegylated interferon alfa 2, Pegasys, 180 ug s.c. injection once a week, two times ).
2535457|NCT02660866|Placebo Comparator|SMT+APT+Placebo|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy."
2535460|NCT02660866|Active Comparator|SMT+APT+Vorapaxar|"Standard Medical Therapy (SMT): Presence of any two of the listed classes of agents [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), statin therapy and beta-blocker drugs] + ability to perform at least 15 min of home walking a day, at least 3 times/week, at ≥20 steps/min~Background Antiplatelet Therapy (APT) :At least one aspirin dose within 5 days prior to randomization at 325 mg dose in aspirin naïve patients (0-5 days of prior aspirin use) or at least one aspirin dose within 5 days prior to randomization at 81 mg dose in patients on chronic (>5 days of prior use) aspirin therapy.~Vorapaxar: Vorapaxar 2.08mg/day"
2535558|NCT02660385|Experimental|Cognitive Behavioral Therapy|Cognitive behavioral therapy for insomnia (CBT-I) will be provided in a group format, led by an interventionist. CBT-I includes strategies for modifying thoughts and behaviors about sleep. Participants will be instructed on and practice methods for modifying their thoughts and behaviors about sleep and insomnia. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
2535561|NCT02660385|Active Comparator|Heart Failure Self-Management Education|Heart Failure Self-management education is an intervention that will be provided by a nurse in a group format. This includes standard components, such as education about fluid and sodium management, heart failure medications, diet and physical activity. Participants will participate in four sessions, conducted every other week for 8 weeks. They will receive a call from the interventionist on intervening weeks.
2535597|NCT02659826|Experimental|anodal tsDCS and gait training|Volunteers will be submitted to anodal transcutaneous spinal cord stimulation and gait training
2535600|NCT02659826|Experimental|cathodal tsDCS and gait training|Volunteers will be submitted to cathodal transcutaneous spinal cord stimulation and gait training
2535606|NCT02659826|Sham Comparator|sham tsDCS and gait training|Volunteers will be submitted to sham transcutaneous spinal cord stimulation and gait training
2535608|NCT02659826|Experimental|High frequency rTMS and gait training|Volunteers will be submitted to high frequency transcranial magnetic stimulation and gait training
2535611|NCT02659826|Experimental|Low frequency rTMS and gait training|Volunteers will be submitted to low frequency transcranial magnetic stimulation and gait training
2535613|NCT02659826|Sham Comparator|sham rTMS and gait training|Volunteers will be submitted to sham transcranial magnetic stimulation and gait training
2535703|NCT02659293|Active Comparator|Lenalidomide (Control)|Treatment with lenalidomide only
2535706|NCT02659293|Experimental|Experimental Combination Regimen|Experimental arm using a combination of Carfilzomib, Lenalidomide and Dexamethasone
2535744|NCT02658812|Experimental|Treatment (talimogene laherparepvec)|Patients receive talimogene laherparepvec IT on day 1. Cycles repeat every 3 weeks in cycle 1 and every 2 weeks thereafter in the absence of disease progression or unacceptable toxicity.
2535814|NCT02658552|Experimental|HIFU treatment|To collect the data after HIFU treatment
3201692|NCT00905879||Group 1|
3201693|NCT00905905|Experimental|Ezetimibe-Simvastatin 10/40 mg|
2535981|NCT02657278|Other|Symptomatic Peripheral arterial disease|Patients scheduled to undergo surgery or angioplasty of the iliofemoral segment for intermittent claudication.
2536044|NCT02657018|Experimental|Intervention|MOBIGAME group
2536047|NCT02657018|Active Comparator|Control|Lifestyle counseling group
2536093|NCT02656524||Cohort1/Regorafenib|All patients with at least 1 treatment with regorafenib
3201694|NCT00905905|Active Comparator|Simvastatin 40 mg|
3201695|NCT00905918|No Intervention|Arm I|Patients receive no intervention before undergoing planned surgery.
2536329|NCT02654925||Young Men|men 21-40 years of age
2536332|NCT02654925||Young Women|women 21-40 years of age; young women will be premenopausal and eumenorrheic, not on hormonal contraceptive therapy.
2536338|NCT02654925||Older Men|men 55-100 years of age
3201696|NCT00905918|Experimental|Arm II|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 1 week before undergoing planned surgery.
3201697|NCT00905918|Experimental|Arm III|Patients receive oral high γ-tocopherol vitamin E mixture supplementation once daily for 2 weeks before undergoing planned surgery.
3201698|NCT00905931|Experimental|Active|
3201699|NCT00905931|Placebo Comparator|Placebo|
3201700|NCT00905944|No Intervention|Control|
3201701|NCT00905944|Experimental|Intervention|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
2535243|NCT02662192|Experimental|Intervention|Exercise + health education + auditory rehabilitation 10 weeks of exercise, interactive health education, socialization and auditory rehabilitation program
2535244|NCT02662192|Active Comparator|Auditory rehabilitation alone|"auditory rehabilitation alone~1 hour of group auditory rehabilitation once a week for 10 weeks"
2535290|NCT02661945|Experimental|Near focus with narrow band imaging|Near focus with narrow band imaging is used for marking the tumor margin.
2535292|NCT02661945|No Intervention|Indigo carmin|After indigo carmine was sprayed over the lesion, marking is performed.
2535352|NCT02661503|Active Comparator|BEACOPP|4 or 6 cycles of BEACOPP (21-day cycles) Bleomycin (B) Etoposide (E) Doxorubicin (A) Cyclophosphamide (C) Vincristine (O) Procarbazin (P) Prednisone (P). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will bev given a total of six cycles.
2535353|NCT02661503|Experimental|BRECADD|4 or 6 cycles of BRECADD (21.day cycles) Brentuximab Vedotin (BR) Etoposide (E) Cyclophosphamide (C) Doxorubicin (A) Dacarbazine (D) Dexamethasone (D). If FDG-PET is negative after two cycles patients will be given a total of four cycles. If FDG-PET is positive after two cycles patients will be given a total of six cycles.
3201702|NCT00905957|Active Comparator|Transversus abdominis plane (TAP) Group|Patients will receive a TAP block using a local anaesthetic agent after induction of anaesthesia
3201703|NCT00905957|Placebo Comparator|Control Group|Patients will receive a TAP block using a placebo after induction of anaesthesia
2535522|NCT02660346|Active Comparator|Group A - Daptomycin or Vancomycin|Standard of Therapy of physician's choice, usually daptomycin 6-8 mg/kg IVPB daily or vancomycin IVPB adjusted dose per site protocol with a goal vancomycin trough level: 15-20 mcg/mL.
2535529|NCT02660346|Experimental|Group B - Daptomycin with Ceftaroline|Daptomycin (6-8 mg/kg/day IVPB daily) with Ceftaroline (600 mg IVPB q8hr) to start within 72hrs of hospital admission. Daptomycin will be renally adjusted per package insert. Ceftaroline will be renally adjusted per institutional renal dosing recommendations for Q8h.
2535616|NCT02659748|Experimental|Milk fat|A 21-day low-fat (E%) experimental diet including milk fat with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single (bioactive) fatty acids.
2535620|NCT02659748|Experimental|Control Fat|A 21-day low-fat experimental diet. Eucaloric diet to Arm #1 with macronutrient and fatty acid class profiles differing only in type of fat and, thus, the proportion of single fatty acids. A control fat is used to replace dairy fats.
2535677|NCT02659475|Experimental|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
3201704|NCT00905970||1|Patients with LTBI recently diagnosed under prophylactic chemotherapy treatment.
3201705|NCT00905970||2|Patients with LTBI recently diagnosed not following any prophylactic chemotherapy treatment.
2535843|NCT02658136|Other|1 arm study: CCT estimated right ventricular function.|
3201706|NCT00905970||3|Patients with LTBI diagnosed time ago.
2536101|NCT02656719|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
2536102|NCT02656719|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
2536121|NCT02656121|Experimental|Vitamin D|1st subgroup will be tested and treated with vitamin D together with Clomiphene Citrate for induction of ovulation
2536132|NCT02656121|Active Comparator|control|2nd subgroup will be treated with Clomophene Citrate only
2536174|NCT02655835|Experimental|Internet Mindfulness Meditation Intervention|Six-week internet mindfulness meditation training program including handouts and daily guided meditations
2536175|NCT02655835|Experimental|Access|Written information handouts on mindfulness meditation and access to guided daily meditations
2536241|NCT02655575|Experimental|BI + VR + CBT|"Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Vestibular Rehabilitation (VR) includes active exercises that provokes dizziness, Balance exercises and body awareness exercises in a group format.~Cognitive Behavioral Therapy (CBT) includes conversation and reflection about factors that may be a barrier to Activity and participation"
2536242|NCT02655575|Active Comparator|BI + phone calls|Brief Intervention (BI) consists of an individual clinical examination, education/information and advice about being active Phone Calls as follow-up at week 2 and 6 to reassure
2536276|NCT02655211|Active Comparator|CO2-CO2-Med|Participants will receive two blocks of CO2 laser treatment, followed by one block of usual care.
2536280|NCT02655211|Active Comparator|Med-CO2-CO2|Participants will receive one block of usual care, followed by two blocks of CO2 laser therapy.
2536285|NCT02655211|Active Comparator|CO2-Med-CO2|Participants will receive one block of CO2 laser therapy, one block of usual care, and finally one more block of CO2 laser therapy.
2536289|NCT02655211|Active Comparator|PDL-PDL-MED|Participants will receive two blocks of PDL laser therapy, followed by one block of usual care.
2536293|NCT02655211|Active Comparator|Med-PDL-PDL|Participants will receive one block of usual care, followed by two blocks of PDL laser therapy.
2536295|NCT02655211|Active Comparator|PDL-Med-PDL|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
2536297|NCT02655211|Active Comparator|PDL-CO2-Med|Participants will receive one block of PDL laser therapy, followed by one block of CO2 laser therapy, followed by one block of usual care.
2536298|NCT02655211|Active Comparator|CO2-PDL-Med|Participants will receive one block of CO2 laser therapy, followed by one block of PDL laser therapy, followed by one block of usual care.
2536301|NCT02655211|Active Comparator|Med-PDL-CO2|Participants will receive one block of usual care, followed by one block of PDL laser therapy, followed by one block of CO2 laser therapy.
2536303|NCT02655211|Active Comparator|Med-CO2-PDL|Participants will receive one block of usual care, followed by one block of CO2 laser therapy, followed by one block of PDL laser therapy.
3201707|NCT00905970||4|Positive control for the Exhaled Breath condensate assay only. Patients with active TB will conform this group. The n of this group is determined, as it will only be used as a positive control to prove the bacilli's DNA can be detected in the exhaled breath condensate.
3201708|NCT00905983|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
2535251|NCT02662140|Experimental|Mobile Health Application Group|"emobile health application will enhance the existing evidence informed curriculum of a Multiple Family Group model (called 4 Rs and 2 Ss for Strengthening Families Model) for families with children who have disruptive behavior disorders. This mobile application consists of two primary components that will support engagement and integration of the model's core concepts in family life. The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
2535281|NCT02661932|Experimental|Letrozole associated COS|"Breast cancer patients undergo fertility preservation with letrozole associated COS for oocyte collection.~Letrozole is administered orally (5mg/day) during the entire stimulation protocol until ovulation triggering."
2535347|NCT02661633||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
2535348|NCT02661633||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
3201709|NCT00905996|Active Comparator|Endoscopic Cyanoacrylate injection|Endoscopic injection of cyanoacrylate in the gastric varix until obturation
3201710|NCT00905996|No Intervention|No Intervention|No treatment offered for gastric varix
2535666|NCT02659384|Experimental|Bevacizumab|Bevacizumab monotherapy treatment in arm 1 will be discontinued upon RECIST documented progression or upon treatment withdrawal, whichever occurs first. Patients will cross-over to the combination of bevacizumab and atezolizumab upon progression as long as they meet cross-over criteria.
2535667|NCT02659384|Experimental|atezolizumab + bevacizumab + placebo|The randomized treatment regimen (atezolizumab + bevacizumab + placebo) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
2535668|NCT02659384|Experimental|atezolizumab + bevacizumab + acetylsalicylic acid|The randomized treatment regimen (atezolizumab + bevacizumab + acetylsalicylic acid) will be continued until treatment failure or upon treatment withdrawal, whichever occurs first. Patients then go off protocol treatment and further treatment is left to the investigator's decision.
2535879|NCT02658292|Active Comparator|NAFT900|NAFT900 (Naftifine hydrochloride foam, 3%)
2535881|NCT02658292|Placebo Comparator|Vehicle|Vehicle Foam
2535927|NCT02657746|No Intervention|usual care|Usual care comprises existing services for hypertension control in the community without any additional training
2535928|NCT02657746|Experimental|multi-component interventions|: The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
2535962|NCT02657486|Experimental|BGJ398|BGJ398 will be administered at a dose of 125 mg orally once daily on a three weeks on, one week off schedule.
2535994|NCT02657213|Experimental|Minimed 640G with smartguard activated|"Group SmartGuard On: Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640G insulin pump with SmartGuard activation"
2535996|NCT02657213|Active Comparator|Minimed 640G with smartguard off|"Group SmartGuard Off Patients will be equipped with a sensor augmented pump (SAP) therapy Minimed 640 insulin pump without SmartGuard activation"
2536037|NCT02656888|Experimental|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
2536039|NCT02656888|Placebo Comparator|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
2536078|NCT02656602|No Intervention|Nurse Counseling|A trained endoscopy nurse provided patients with all information on their scheduled colonoscopy.
2536082|NCT02656602|Experimental|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI.All elements of informed consent for colonoscopy (risks, alternatives) were included.
2536123|NCT02656342|Experimental|250 mg DCS|64 patients receive 250 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2536134|NCT02656342|Experimental|100 mg D-Cycloserine|64 patients receive 100 mg D-Cycloserine two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2536138|NCT02656342|Active Comparator|Placebo|32 patients receive placebo two consecutive days in combination with therapist assisted concentrated exposure therapy (cET)
2536182|NCT02655718|Other|Patients with ACS|Patients with ACS who underwent coronary angiography within 72 hours from the onset of disease. In identifying nonobstructive coronary atherosclerosis , patients underwent cardiac contrast MRI.
2536250|NCT02655536|Experimental|bevacizumab plus erlotinib|bevacizumab 15mg/kg every 3 weeks plus erlotinib 150mg per day
3201711|NCT00905996|Other|Beta-blocker (propranolol)|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
2535442|NCT02660736|Experimental|Regimen AB|"Subjects will be receive Regimen A treatment in Session 1 followed by Regimen B treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
2535449|NCT02660736|Experimental|Regimen BA|"Subjects will be receive Regimen B treatment in Session 1 followed by Regimen A treatment in Session 2.~Regimen A: 50 mg Albiglutide Liquid Auto-injector + Placebo lyophilized DCC Pen injector.~Regimen B: 50 mg Albiglutide lyophilized DCC Pen injector + Placebo Liquid Auto-injector.~A minimum of an 8-week washout period between study treatment administration of Session 1 and Session 2."
2535559|NCT02660164||Cohort A: High-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where high-risk of concussion is anticipated: football, soccer, lacrosse, hockey, basketball, ice hockey, field hockey, rugby, cheerleading, boxing, and gymnastics.
2535560|NCT02660164||Cohort B: Low-Risk of Concussion|Middle school, high school and college athletes of either gender participating in sports where low-risk of concussion is anticipated: swimming, track, volleyball, baseball, softball and golf.
2535594|NCT02659839||Cancer patients admitted to the ICU|Patients with cancer admitted to the ICU. No intervention will be administered.
2535722|NCT02658981|Experimental|A1 Anti-LAG-3|"Patients receive Anti-LAG-3 monoclonal antibody BMS-986016 IV over 60 minutes and on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
2535723|NCT02658981|Experimental|A2 Anti-CD137 (Urelumab)|"Patients receive Anti-CD137 (Urelumab) IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity~Pharmacological Study~Laboratory Biomarker Analysis"
2535724|NCT02658981|Experimental|B1 Anti-LAG3 + Anti-PD-1 (nivolumab)|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes and anti-LAG-3 monoclonal antibody BMS-986016 IV on days 1 and 15. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Pharmacological Study~Laboratory Biomarker Analysis"
2535727|NCT02658981|Experimental|B2 Anti-CD137 + Anti-PD-1|"Patients receive Anti-PD-1 (nivolumab) IV over 60 minutes on days 1 and 15 and Anti-CD137 (urelumab) IV on day 1. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~(2pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)~Pharmacological Study~Laboratory Biomarker Analysis"
2535729|NCT02658981|Experimental|Intratumoral Studies|"Patients pre-operatively receive either anti-LAG-3 monoclonal antibody BMS-986016 (Arm A1), or urelumab (Arm A2), or nivolumab and anti-LAG-3 monoclonal antibody BMS-986016 as in Part B (B1)), or nivolumab and urelumab as in Part B (B2). Within 45 days of surgical resection, patients post-operatively receive drug from one of the four arms.~(3pts enrolled before the Anti-CD137 antibody (BMS-663513 - urelumab) treatment arm closed by BMS on 10/16/18 due to closure of BMS Urelumab development program. Subjects currently on treatment may continue.)"
2535818|NCT02658422|Experimental|Sequence A-B (Test Montelukast then Reference Montelukast)|Subjects will receive Treatment A- Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 1 and then Treatment B - Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 2.
2535819|NCT02658422|Experimental|Sequence B-A (Reference Montelukast then Test Montelukast)|Subjects will receive Treatment B- Reference montelukast sodium 10 mg tablets (innovator product) in Treatment Period 1 and then Treatment A Test montelukast sodium 10 mg tablets (GW483100) in Treatment Period 2.
2535865|NCT02658110|Sham Comparator|Non Protein Trial|Mixed Macronutrient Breakfast Meal and Mixed Macronutrient Lunch Meal served without additional whey protein
2535868|NCT02658110|Experimental|Preload Trial|Whey protein (20g) administered 15 minutes prior to Mixed Macronutrient Breakfast Meal
2535869|NCT02658110|Experimental|With Meal Trial|Whey protein (20g) administered alongside Mixed Macronutrient Breakfast Meal
2535872|NCT02658110|Experimental|Post Meal Trial|Whey protein (20g) administered 15 minutes after Mixed Macronutrient Breakfast Meal
2535947|NCT02657707|Experimental|Single-arm, open label|To evaluate the safety and effectiveness of MicroVention, Inc. Roadsaver™ Carotid Stent System used in conjunction with the Nanoparasol® embolic protection system for the treatment of carotid artery stenosis in patients with elevated risk for adverse events following carotid endarterectomy.
2536031|NCT02656901|Active Comparator|Auto Total endovenous anesthesia|The closed loop delivering as already approved by ClinicalTrials.gov Identifier: NCT00392158
2536032|NCT02656901|Sham Comparator|Manual Desflurane anesthesia|The anesthesia will be maintained with desflurane to target the BIS of 50.
2536033|NCT02656901|Sham Comparator|Manual sevoflurane anesthesia|The anesthesia will be maintained with sevoflurane to target the BIS of 50.
2536034|NCT02656901|Sham Comparator|Manual total endovenous anestesia|In ManualTIVA group, the anesthesia will be maintained with propofol to target the BIS of 50
2536062|NCT02656563|Experimental|Radium 223 Arm|Radium 223 Dichloride (Xofigo®)
2536064|NCT02656563|No Intervention|Non Treatment Arm|Control Arm
3201712|NCT00906022|Experimental|Astron Pulsar Stent|Device: Astron Pulsar Stent
3201713|NCT00906022|Active Comparator|PTA alone|Device: Balloon angioplasty alone
3201714|NCT00906048|Experimental|1|Levofloxacin and Rifampicin
2536135|NCT02656030|Experimental|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise 2 times/week, 6 weeks duration
2536140|NCT02656030|Experimental|cranio-cervical flexion exercise|cranio-cervical flexion exercise 2 times/week, 6 weeks duration
2535381|NCT02661282|Active Comparator|Arm II (temozolomide, CMV-specific T cells)|Patients receive temozolomide PO QD on days 1-21 and CMV-specific T cell transfer intravenously IV over 1-5 minutes on day 22. Treatment repeats every 42 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2535466|NCT02660762|Experimental|Modified MRCUKALLⅫ/ECOGE2993 Regimen|"All patients received phase 1 of induction therapy, which consisted of daunorubicin,vincristine,Pegaspargase,prednisone and methotrexate (intrathecally).Patients went on to phase 2 at the end of phase 1.Phase 2 therapy consisted of cyclophosphamide,cytarabine,6-Mercaptopurine and methotrexate intrathecally. After Induction therapy, all patients received intensification therapy with high-dose methotrexate followed by Pegaspargase. After intensification therapy,patients received consolidation(cytarabine, etoposide,Pegaspargase,dexamethasone,vincristine,cyclophosphamide,daunorubicin,thioguanine)and maintenance therapy(vincristine,6-mercaptopurine,methotrexate~,prednisone). Intrathecal methotrexate and intrathecal cytarabine were given as CNS prophylaxis."
3167742|NCT00542152|Active Comparator|CICLO|"Cyclosporine will be administered by continuous intravenous infusion at the initial dose regimen of 2mg/kg per day.~After 24 hours of treatment, cyclosporine trough level will be measured and the dose adapted in order to obtain a cyclosporinaemia level between 150 and 250 ng/ml. Cyclosporinaemia will be reassessed every 48 hours for the duration of the continuous intravenous treatment."
3167743|NCT00542152|Active Comparator|INFLIXIMAB|"INFLIXIMAB (REMICADE) Infliximab in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution, and slowly infused at the dose of 5mg/kg in 2 hours.~In patients with clinical response at D7 (Lichtiger Index score < 10 for 2 consecutive days), two additional infliximab infusions will be administered at the dose of 5mg/kg at D14 and D42."
3167744|NCT00542204|Experimental|Online disease management|The PAMFOnline-mediated Personalized Health Care Program, which couples a multidisciplinary diabetes care management team with an EHR-integrated Online Disease Management (ODM) system.
3167745|NCT00542204|No Intervention|Usual care|Usual medical care. No access to the PHCP electronic system and self-management tools supporting this care management.
3167746|NCT00542217|Placebo Comparator|Cohort 1|Single dose of 0.5 mg/kg Imprime PGG administered over 1 hr
3201715|NCT00906061|Experimental|Gemcitabine and Docetaxel|Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.
2535816|NCT02658682|Experimental|ABM +|Attention Bias Modification
2535817|NCT02658682|Sham Comparator|ABM -|Sham Attention Bias Modification
2535838|NCT02658188|Experimental|ASP8825 group|
2535912|NCT02657902||Gamma 3 Nail|Fractures that were treated with a Gamma 3 nail
2535918|NCT02657902||Gamma 3 Nail + U-Blade|Fractures that were treated with a Gamma 3 nail and additional with antirotation U-blade lag screws.
2535937|NCT02657603|Active Comparator|LAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the adductor canal
2535940|NCT02657603|Active Comparator|SAX insertion of catheter|Lidocaine 10mg/ml, 15 ml injected into the contralateral adductor canal
3167747|NCT00542217|Placebo Comparator|Cohort 2|Single dose of 1.0 mg/kg Imprime PGG administered over 1 hr
3167748|NCT00542217|Placebo Comparator|Cohort 3|Single dose of 2.0 mg/kg Imprime PGG administered over 1 hr
2536048|NCT02656979|Other|Blood flow pre&post IOP lowering|After measurement of blood flow with MRI and measurements of ocular parameters the patient receives the IOP lowering eye drop latanoprost once daily in one eye for approximately one week and then the measurements are are repeated in the same manner.
2536049|NCT02656979|No Intervention|Blood flow|The subjects will do blood flow measurements with MRI and measurements of ocular parameters only once. No intervention with IOP lowering drops.
2536096|NCT02656498|Experimental|Cognitively Healthy Subjects|Cognitively healthy subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2536098|NCT02656498|Experimental|MCI Subjects|MCI Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2536099|NCT02656498|Experimental|AD Subjects|AD Subjects will receive an IV injection, [18F]THK-5351 at baseline and also receive an IV injection, [18F]THK-5351 at 24 months.
2536100|NCT02656498|Experimental|Subjects with other neurodegenerative disease|Subjects with other neurodegenerative disease will receive an IV injection, [18F]THK-5351 at baseline.
2536204|NCT02655965|Experimental|Ropivacaine + Clonidine|"A pecs block of Ropivacaine 3.5 mg/ml and Clonidine 5 µg/ml will be injected to the patients prior surgery. 10 ml of the drug combination will be injected between pectoral muscles and 20 ml of the drug combination will be injected between the muscles pectoralis minor and serratus anterior.~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
2536207|NCT02655965|Placebo Comparator|Sodium Chloride|"A pecs block of Placebo (Sodium Chloride 0.9%) will be injected to the patients prior surgery. 10 ml of the Sodium chloride solution will be injected between pectoral muscles and 20 ml of the Sodium chloride solution will be injected between the muscles pectoralis minor and serratus anterior).~After surgery, subjects in both arms will receive one dose of Paracetamol (1g) and Diclofenac (75 mg) and one dose 0.05 mg/kg Piritramide as well as PCIA (Patient Controlled Intravenous Analgesia)-Piritramide for 24 hrs post-surgery."
2536251|NCT02655380|Experimental|ketamine 1|Anesthesia induction with ketamine 1 mg followed by remifentanil.
2536255|NCT02655380|Experimental|ketamine 2|Anesthesia induction with ketamine 2 mg followed by remifentanil.
2536342|NCT02655055|Experimental|Intervention|high frequency voluntary apheresis blood donation (i.e. 20 - 26 donations in one year period)
2536348|NCT02655055|No Intervention|Control|no voluntary (or paid) apheresis blood donation (whole blood donation allowed during one year period)
3167749|NCT00542217|Placebo Comparator|Cohort 4|Single dose of 4.0 mg/kg Imprime PGG administered over 2 hr
3167750|NCT00542217|Placebo Comparator|Cohort 5|Single dose of 6.0 mg/kg Imprime PGG administered over 3 hr
2535390|NCT02661334|Experimental|Loading dose|Creatine Monohydrate 20g/day (10g white rice flour) for 7 days, followed by maintenance dose of Creatine Monohydrate 5g/day (25g white rice flour) for the remaining 21 days
2535394|NCT02661334|Experimental|High dose|High dose of Creatine Monohydrate 20g/day (10g white rice flour) for the entire 28 day period
2535434|NCT02660840|Experimental|0.5 mg Test, then 0.5 mg reference|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)
2535435|NCT02660840|Experimental|0.5 mg reference, then 0.5 mg Test|14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)
2535436|NCT02660840|Experimental|1 mg Test, then 1 mg reference|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)
2535438|NCT02660840|Experimental|1 mg reference, then 1 mg Test|14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)
2535439|NCT02660840|Experimental|5 mg Test, then 5 mg reference|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)
2535441|NCT02660840|Experimental|5 mg reference, then 5 mg Test|14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)
2535499|NCT02660450|Experimental|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
2535500|NCT02660450|Experimental|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
2535501|NCT02660450|Experimental|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
2535547|NCT02660203|Experimental|forced expiration|2 daily sessions of forced expiration on ipsilateral decubitus from day 1 after surgery until chest tube removal
2535550|NCT02660203|No Intervention|control|No session of forced expiration
2535596|NCT02659774|Experimental|Group A|Health talk + workshop (Motivational intervention) + booklet + Short Message Service (SMS)
2535601|NCT02659774|Placebo Comparator|Group B|Face to Face counseling (Motivational intervention) + Booklet + SMS
2535605|NCT02659774|Placebo Comparator|Group C|Phone counseling (Motivational intervention) + Health talk + booklet + SMS
2535610|NCT02659774|Placebo Comparator|Group D|Phone counseling (Motivational intervention) + booklet + SMS
2535699|NCT02659280|Active Comparator|Standard of Care Therapy|Home Health or Outpatient Physical therapy services (a minimum of 1x/week).
2535701|NCT02659280|Experimental|Adjunct Therapy|"Home Health or Outpatient Physical therapy services (a minimum of 1x/week) with an adjunct Home Exercise Program given up to 1x/wk via Store and Forward tele-health through the Hudl Technique app."
2535721|NCT02658968|Experimental|Betalutin|10 MBq/kg b.w., in escalated doses with lilotomab pre-dosing
2535802|NCT02658643|Experimental|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
2535805|NCT02658643|Active Comparator|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
2535841|NCT02658279|Experimental|Pembrolizumab (MK-3475)|Pembrolizumab 200 mg will be administered as an approximately 30 minute (-5/+10 mins) IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. Patients will be followed with DCE perfusion MRI done at baseline and every 9 weeks (+/- 7 days). Patients will be allowed to stay on treatment in spite of increase in tumor size, provided the patient has no, or manageable, new neurologic symptoms, and at the discretion of treating physician. In that situation, tumor resection should be encouraged for the distinction between tumor progression and immunologic reactions. Patients undergoing surgical resection will have tissue collected for collateral studies. All collected tissue will be stored in the Pathology Core Tissue bank at MSK.
2535897|NCT02657798||Depressed patients taking sertraline|Patients with depression who have been randomised to the sertraline arm in the PANDA trial
2535899|NCT02657798||Depressed patients taking placebo|Patients with depression who have been randomised to the placebo arm in the PANDA trial
2535914|NCT02657798||Healthy controls|Healthy participants with no history of depression
2535942|NCT02657655|Experimental|Kinesia 360 Users|Parkinson's patients will be monitored continuously using wearable Kinesia 360 sensors.
2535970|NCT02657291|Experimental|Costoclavicular|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the costoclavicular approach
2535974|NCT02657291|Active Comparator|Paracoracoid|Ultrasound-guided infraclavicular block using Ropivacaine 0.5% 35 mL using the paracoracoid or standard approach
2536041|NCT02656966|Active Comparator|Auricular acupuncture + standard therapy|Patients, who will wish acupuncture, will receive this intervention, in addition to standard therapy
2536045|NCT02656966|No Intervention|Standard therapy alone|Patients who do not wish acupuncture will be asked if they will fill in the study questionnaire
2536079|NCT02656576|Other|patient with suspected lesions of the tonsillar region|patients will have a tonsil biopsy and a smear
2536114|NCT02656251|Active Comparator|0.12% Clorhexidine with alcohol|0.12% Clorhexidine with alcohol, 15ml every 12 hour for 4 days
2536124|NCT02656251|Experimental|0.12% Clorhexidine without alcohol|0.12% Clorhexidine without alcohol, 15ml every 12 hour for 4 days
2536133|NCT02656251|Placebo Comparator|control|placebo 15ml every 12 hour for 4 days
2536190|NCT02655770|Active Comparator|Liraglutide arm|Patients will be treated with liraglutide (up to 1.8 mg s.c. once daily). Total treatment period will be 18 weeks.
2536197|NCT02655770|Placebo Comparator|Placebo arm|Patients will be treated with placebo (up to equal to 1.8 mg drug dose s.c. once daily). Total treatment period will be 18 weeks. The study will be placebo-controlled with placebo as an add-on to conventional diabetes treatment. Thus, no patient will receive a sub-standard treatment.
2536253|NCT02655458|Experimental|autologous PBMC reconstitution, Elotuzumab, Lenalidomide|Max number of cycles is 12. Elotuzumab will be administered IV 20 mg/kg on Day 1 of each cycle. Lenalidomide dosing will start with cycle 4 at 10 mg orally daily days 1-21.
2536339|NCT02654990|Experimental|Arm A - 20mg PAN TIW|20mg panobinostat three times a week, 2 weeks on/1week of in combination with s.c. bortezomib and p.o. dexamethasone
2536346|NCT02654990|Experimental|Arm B - 20mg PAN BIW|20mg panobinostat twice a week, 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
2535403|NCT02661542|Experimental|Phase 1: 25x lowest dose of FF-10502-01|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535404|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Pancreatic Cancer|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535405|NCT02661542|Experimental|Phase 2a: FF-10502-01 at MTD in Solid Tumors|FF-10502-01 will be administered intravenously (IV) on Days 1, 8, and 15 of a 28 day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
2535445|NCT02660775|Experimental|schizophrenia|this project is to assess relevance of ClaCoS in schizophrenia compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
2535450|NCT02660775|Experimental|autism|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
2535454|NCT02660775|Placebo Comparator|healthy controls|this project is to assess relevance of ClaCoS in autism compared to healthy controls, and to analyze links between social cognition and both neurocognition and symptoms, (2) to collect data in a large sample of healthy controls in order to establish appropriate standards for tools composing ClaCoS battery.
3201716|NCT00906113|Experimental|Intra-arterial melphalan|The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma
2535551|NCT02660151|Experimental|Treatment A-B|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
2535555|NCT02660151|Experimental|Treatment B-A|Treatment A: Hyper-CL™ lens + salt solution + antibiotics drops (7 days) Treatment B: Regular soft contact lens +salt solution+ antibiotics drops (7 days) One week (7 days) of washout without any treatment will be between treatments.
3201717|NCT00906126|Experimental|Oral Misoprostol 1|Oral misoprostol 25 micrograms every 4 hours for up to two doses.
3201718|NCT00906126|Experimental|Oral Misoprostol 2|Oral misoprostol 50 micrograms every 4 hours for up to two doses.
2535694|NCT02659462||patients post Fontan palliation for single ventricular hear|Cardio Pulmonary Exercise Testing
2535695|NCT02659462||Subjects post surgical correction of congenital heart disease|Cardio Pulmonary Exercise Testing
2535696|NCT02659462||Healthy patients|Cardio Pulmonary Exercise Testing
3201719|NCT00906126|Experimental|Oral Misoprostol 3|Oral misoprostol 100 micrograms every 4 hours for up to two doses.
3201720|NCT00906126|Experimental|Oral Misoprostol 4|Oral Misoprostol 50 micrograms every 2 hours for up to two doses.
2535833|NCT02658383|Experimental|Cleaner cookstove received after visit 2|This arm receives the cleaner cookstove earlier in the study (after visit 2 which is approximately after 6 months)
2535834|NCT02658383|Experimental|Cleaner cookstove received after visit 4|This arm receives the cleaner cookstove later in the study (thus acting as a control arm until after visit 4 which is after approximately 1 yr and 6 months)
2535902|NCT02658006||Cardiac surgical patients|Adult patients having a cardiac surgery at the Montreal Heart Institute
2535938|NCT02657616||No anticoagulation with VKA/NOAC|No prescriptions of vitamin-k-antagonists/novel anticoagulants in all observational period; No prescriptions of low molecular weight heparins/Clopidogrel during observation period to the extent of more than 30 days.
2535941|NCT02657616||Anticoagulation with vitamin-k-antagonists|The patient should be treated stable during the observation period with vitamin-k-antagonists (at least one prescription per half-year). The patient should be not been around on other anticoagulants during the observation period. This means that no prescriptions of novel anticoagulants and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year.
2535944|NCT02657616||Anticoagulation with novel oral anticoagulants|The patient should be treated stable during the observation period with a novel anticoagulant (at least one prescription per half-year). This means that no vitamin-k-antagonists prescriptions and not more than 30 days should be observable prescriptions of low molecular weight heparins/Clopidogrel per year from the start of the observation period.
2535969|NCT02657330|Experimental|SBP-101|SBP-101 is administered as a subcutaneous injection once daily, Monday through Friday for 3 weeks (total of 15 doses) followed by a 5-week rest period (3 weeks on, 5 weeks off = 1 treatment cycle). Dose escalation in phase 1a will continue until the maximum tolerated dose is determined.
3201721|NCT00906126|Experimental|Oral Misoprostol 5|Oral Misoprostol 75 micrograms every 4 hours for up to two doses.
3201722|NCT00906139|Active Comparator|Propofol|To receive propofol (0.5 mg/kg up to 400 mg) and fentanyl (0.05 mg);
2536116|NCT02656277|Experimental|Decision tool|The decision tool includes a questionnaire and statistical model used to determine how patient preference regarding shoulder pain, physical limitations, physical therapy, recovery period, prognosis, and cost impact choice of surgical versus non-surgical intervention.
2536126|NCT02656277|Active Comparator|Information on Shoulder Dislocation|Subjects in this arm will receive the standard of care information available to patients to make this treatment decision.
2536353|NCT02654899|Placebo Comparator|Part 1_Cohort 1_Placebo;|Single dose of placebo
3201723|NCT00906139|Active Comparator|Midazolam|To receive midazolam (0.1 mg/kg) and fentanyl (0.05 mg).
3201724|NCT00906152||Subacute low back pain; chronic low back pain|Patients with subacute or chronic low back pain seen in the Primary Care Centers participating in the study.
3201725|NCT00906191|Experimental|1|Single oral dose
3201726|NCT00906217||elderly patients|patients older than 70 years with normal renal function
3201727|NCT00906256|Active Comparator|AZD7295|AZD7295
3201728|NCT00906256|Placebo Comparator|Placebo capsule|Placebo
3201729|NCT00906269|Active Comparator|1|
3201730|NCT00906269|Sham Comparator|2|
3201731|NCT00906295|Active Comparator|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
3201732|NCT00906295|Experimental|Allowed drop in hemoglobin to 5.6-6.5 mmol/L|Transfusion with red blood cells to level between 5.6-6.5 mmol/L
3201733|NCT00906308|Placebo Comparator|Placebo|
3201734|NCT00906308|Experimental|MF101 5 g/day|
3201735|NCT00906308|Experimental|MF101 10 g/day|
3201736|NCT00906334|Experimental|800 mg/m^2 ON 01910.Na|800 mg/m^2 ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 48 hours (i.e. 2 consecutive 24-hour infusions) every week for the first 3 weeks of 4-week cycle.
3201737|NCT00906334|Experimental|1800 mg ON 01910.Na|1800 mg ON 01910.Na administered as a continuous intravenous infusion (CIV) over 24 hours for 72 hours (i.e., 3 consecutive 24-hour infusions) every 2 weeks for the first four 2-week cycles and every 4 weeks afterwards.
2535779|NCT02658747||Cohort Docetaxel|Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)
3201738|NCT00906360|Experimental|Treatment (enzyme inhibitor and monoclonal antibody therapy)|Patients receive sunitinib malate orally or by percutaneous gastrostomy tube once daily, cetuximab IV over 60-120 minutes once weekly, and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 7-9 weeks in the absence of disease progression or unacceptable toxicity. Patients with persistent disease undergo surgical resection.
3201739|NCT00906386|Experimental|1|
2535992|NCT02657187|Experimental|rocuronium 1|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.24mg per muscle mass(kg).
2535993|NCT02657187|Experimental|rocuronium 2|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.32mg per muscle mass(kg).
2535995|NCT02657187|Experimental|rocuronium 3|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.40mg per muscle mass(kg).
2535997|NCT02657187|Experimental|rocuronium 4|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) and the dose of rocuronium is 0.48mg per muscle mass(kg).
3201740|NCT00906386|Placebo Comparator|placebo|
3201741|NCT00906412||ET Group|Total of 25 participants with ET
3201742|NCT00906412||Controls|25 controls without ET
2536210|NCT02655783|Active Comparator|control|normal saline, 250 ml/h, until expulsion of placental
2536213|NCT02655783|Experimental|intervention|normal saline + 5% dextrose, 250 ml/h, until expulsion of placental
2536248|NCT02655367|Experimental|Milled followed by flaked oats|Participant consumes test meal consisting of porridge made from milled oats on study day 1, followed by porridge made from flaked oats on study day 2
2536249|NCT02655367|Experimental|Flaked followed by milled oats|Participant consumes test meal consisting of porridge made from flaked oats on study day 1, followed by porridge made from milled oats on study day 2
2536314|NCT02655133|Active Comparator|Pentaglobin®|Patients will receive Immunoglobulins IgGAM (Pentaglobin®) at dosage of 250 mg/kg IV (5 mL/kg) per day (rate of 0.4 mL/kg/h), for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®).
2536316|NCT02655133|Placebo Comparator|Physiologic Solution|Patients will receive physiologic solution (NaCl 0.9%) at a dosage of 5 ml/Kg per day for 72 hours. Microcirculation will be monitored with sublingual microcirculation device (Cytocam®) and Near InfraRed Specrotcopy (NIRS, Hutchinson®)
3201743|NCT00906438|Placebo Comparator|Control|
3201744|NCT00906438|Experimental|Treated|
3201745|NCT00906451|No Intervention|No lipid-lowering|No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
3201746|NCT00906451|Experimental|Simvastatin 20 mg|Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
3201747|NCT00906451|Experimental|Simvastatin 40 mg|Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
3201748|NCT00906451|Experimental|Simvastatin 80 mg|Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment
3201749|NCT00906477|Experimental|Early intervention|Modified CI therapy starting between 7 and 28 days post stroke.
2536612|NCT02653118||Cohort 1: V503 in the Base Study|Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
2536640|NCT02653040|Experimental|Dynamic lighting|Indoor lighting with low-lux no-blue wavelengths at night.
3201750|NCT00906477|Active Comparator|Delayed intervention|Modified CI Therapy starting 6 months post stroke
3201751|NCT00906516|Experimental|Neuradiab in combination with Avastin|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
3201752|NCT00906529|Active Comparator|Conservative Blood Glucose Control|Goal Pre-prandial blood glucose <180 mg/dl.
3201753|NCT00906529|Active Comparator|Aggressive Blood Glucose Control|Pre-prandial goal blood glucose <110 mg/dl
3201754|NCT00906542||Acute ischemic stroke patients|Acute ischemic stroke patients admitted to the neurological intensive care unit or stroke unit within 24 hours after stroke onset in whom ischemic brain lesion was clearly assessed on CT and/or MRI
3201755|NCT00906555|No Intervention|1|hemodialysis patients with baseline Kt/V between 1.2 and 1.7 (1.2 ≤ Kt/V < 1.7)
3201756|NCT00906555|Experimental|2|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
3201757|NCT00906568||Sensitized vs non-sensitized|CF with and without SAD defined by MEF25 <50%
2535423|NCT02661048|Experimental|Open label|Non-randomized, open label clinical trial that intends to treat 10 subjects with refractory ventricular tachycardia with the CyberHeart system using standard radiosurgical techniques.
3201758|NCT00906581|Experimental|Behavioral|Behavioral
2535494|NCT02660476||QUDOS 1|Aims to recruit 1,700 diabetic patients (including 200 with type 1 diabetes mellitus (independent of healthcare setting)) attending the hospitals and primary care
2535497|NCT02660476||QUDOS 2|To further characterise 500 patients, from the total 1500 patients with T2DM recruited in QUDOS 1, who accept to continue with QUDOS 2 (a more detailed study and assessment).
3201759|NCT00906581|No Intervention|Waitlist control|Waitlist control
3201760|NCT00906594|Active Comparator|Latanoprost|Latanoprost mono therapy
2535705|NCT02659332|Experimental|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of1ms)
2535764|NCT02658942|Active Comparator|Ureteroscopy|Intervention: Flexible ureteroscopy for removal of lower calyceal stones using holmium:YAG laser lithotripsy
2535766|NCT02658942|Active Comparator|Shockwave lithotripsy|Intervention: Shockwave lithotripsy for lithotripsy of lower calyceal stones using Siemens Lithostar Lithotriptor
2535820|NCT02658526||control|children without anesthesia / surgery
2535822|NCT02658526||anesthesia|children with anesthesia for diagnostic reason
2535825|NCT02658526||surgery|children with anesthesia / surgery
2535835|NCT02658123|Active Comparator|Group A: Standard of care|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
2535837|NCT02658123|Experimental|Group B: Phone call|"Standard of care pre-operative education~Standard of care home health visits~Standard of care follow-up post-operative visits with surgeon and CWOCN~Telephone call 48-72 hours post-discharge from CWOCN/PA to evaluate tolerability to foods/fluids, activity level, screen for red-flags, review/assess for medication, reviewing pouching of ostomy, review patient's ability to obtain supplies, provide continued education, discuss proper use of durable medical equipment/frequency of pouch changes, and complete Patient Assessment Form.~At 30-days post hospital discharge, the participant will:~See the physician~Turn in Patient Data Collection Form~Turn in Healthcare Utilization Form~Complete The City of Hope QOL Survey for Ostomy Patients~Ostomy assessment with a CWOCN, including photo of ostomy site"
2535900|NCT02657850||control cohort - study subject self-reporting|Participants who have another cancer (not head and neck cancer) and undergoing treatment will self-report their dysphagia symptoms.
2535910|NCT02657850||study cohort - study subject self-reporting|Participants who have head and neck cancer and undergoing treatment will self-report their dysphagia symptoms.
2535917|NCT02657850||study cohort - provider reporting|Participants who have head and neck cancer and undergoing treatment will have their dysphagia symptoms reported by the provider.
3201761|NCT00906594|Experimental|Latanoprost + Fixed combination|Latnoprost + Fixed combination
3201762|NCT00906607||Group I|10-18 years
2536219|NCT02655627|Experimental|Group A|Usual Care Group: A brochure which emphasis the importance of physical activity and exercise in Type 2 DM will be given to the patients in this group after the evaluation.
2536222|NCT02655627|Experimental|Group B|Supervised Clinical Exercise Training Group: Patients in this group will continue group exercise training includes aerobic and resistance training, 1 hour in a day, 3 times in a week for 8 weeks with the supervision of a researcher physiotherapist.
2536223|NCT02655627|Experimental|Group C|Internet Based Exercise Training Group. the patients to this group will be a member of the web site named www.diyabetvehareket.com. The participation of the patients will be provided with the videos directing them to 1 hour in a day, 3 times in a week for 8 week both aerobic and resistance exercise training from the researcher physiotherapist.
2536260|NCT02655302|Other|Bacterial exacerbations|Patients with at least 10^7 UFC/ml bacteria in their sputum during their first COPD exacerbation.
2536267|NCT02655302|Other|Non-bacterial exacerbations|Patients without detected bacteria or below 10^7 UFC/ml in sputum during their first COPD exacerbation.
2536318|NCT02654886|Experimental|Resistance Exercise Training|Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
3201763|NCT00906607||Group II|20-35 years
3201764|NCT00906607||Group III|45-60 years
2536507|NCT02653937|Experimental|Kampo medicine|7.5g per day of Tsumura's shigyakusan ( Tsumura & Co ) was administered to each of 110 cases.
3201765|NCT00906607||Group IV|65-75 years
3201766|NCT00906620|Experimental|QPR intervention|"QPR intervention (Question, Persuade & Refer): The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
3201767|NCT00906620|Experimental|Awareness program|The awareness programme is comprised of a leaflet, six posters and four seminars. The seminars are made up of one introductory lesson, and two interactive follow-up lessons with role play and one final meeting as a closing/debriefing lesson.
3201768|NCT00906620|Experimental|ProfScreen|The program's primary objective is to help young people and their parents through the early identification of mental health problems, such as anxiety, depression, substance abuse, and suicide. Screening strategies are based on the valid premise that suicidal adolescents are under-identified, suffer from an active, often treatable mental illness such as depression and exhibit identifiable risk factors (Gould et al. 2003). A potential shortcoming of screening programs is that asking about suicide could increase suicidal ideation and behaviour. About this issue a recent study (Gould et al . 2005) on over 2300 students reported no evidence of iatrogenic effects of suicide screening and that screening in high schools is a safe component of youth suicide prevention efforts.
2535443|NCT02660931|Experimental|AKI Risk Notification|Patients randomized to this arm will be eligible for an acute kidney injury risk notification, if their calculated risk exceeds the threshold during their inpatient encounter.
2535451|NCT02660931|No Intervention|Usual Care|These patients will receive usual clinical care, with no acute kidney injury risk notification.
2535514|NCT02660606||Group 1: Opioid abusers|
2535521|NCT02660606||Group 2: Abusers of other substances|
2535528|NCT02660606||Group 3: Non-opioid abusers|
2535531|NCT02660606||Group 4: Non-opioid users|
2535571|NCT02660047|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
2535576|NCT02660047|Placebo Comparator|Liraglutide - Placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dose: same as Liraglutide~Duration: 26 weeks"
2535592|NCT02659683|Experimental|Test|Torrent's Esomeprazole Magnesium DR Capsules 40 mg
2535595|NCT02659683|Active Comparator|Reference|Nexium 40 mg DR Capsules of AstraZeneca LP, USA
2535662|NCT02659553||mild steatosis|5% - 30% of hepatocytes have fatty infiltration
2535664|NCT02659553||moderate steatosis|30% - 60% of hepatocytes have fatty infiltration
2535665|NCT02659553||No steatosis|No or less than 5% of hepatocytes have fatty infiltration
2535714|NCT02659202|Experimental|Precision Spinal Cord Stimulator System|Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.
2535768|NCT02658903|Experimental|Study arm with Oxys-Cathter|The study group is treated with a modified urinary catheter, which delivers electromagnetic therapy to prevent and treat bacterial colonization during the study period. The intervention is the insertion of the study urinary catheter (foley) into the bladder.
2535770|NCT02658903|Other|Control-arm with commercial catheter|The control group is treated with a commercial urinary catheter. The intervention is the insertion of the control urinary catheter (foley) into the bladder,
2535793|NCT02658513||All Patients|"All patients will undergo both of the following interventions:~Lancet blood sampling Standard intravenous blood sampling"
2535853|NCT02658318||Pierre Robin Syndrome (PRS)|Cleft palate patients with the Pierre Robin Syndrome.
2535857|NCT02658318||non-PRS|Cleft palate patients without the Pierre Robin Syndrome.
2535905|NCT02657876|Experimental|ExpressGraft-C9T1 Skin Tissue|Enrolled participants receive one application of ExpressGraft-C9T1 skin tissue
2535943|NCT02657668|Experimental|Treatment Group|Emotion focused therapy: EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
2535945|NCT02657668|No Intervention|Control Group|Control group: For control group interactions to be effective in therapeutic outcomes, the psycho-educational group was assigned as control group. The Psycho-educational group was conducted in four sessions (without pretest and posttest sessions). They became familiar with etiology and role of psychological factors in IBS, without any psychotherapy. Eight members were removed (because of being absent more than three sessions).
2535972|NCT02657317|Experimental|FORT-A|"has been labeled FORT-A. FORT-A is provided on an outpatient basis and includes 12 daily group pain management and physical therapy sessions spanning three weeks. Group interventions are supplemented by individual psychotherapy, biofeedback, and case staffings. CBT sessions were decreased in favor of CAM components. FORT-A participants will receive 270 minutes (4½ hours) of intervention a day for 12 days over 3 weeks."
2535975|NCT02657317|Active Comparator|VA Treatment As Usual|"Treatment As Usual (TAU) represents usual VA Care based on as usual appointments and referrals from VA providers. TAU can include active medical interventions, psychosocial intervention, and other rehabilitation strategies."
2536043|NCT02656953|Experimental|VDU lenses|VDU lenses provide a clear vision of the intermediate zone at a distance of approximately 70 centimeters, which is closer than distant vision at a distance of more than 2 meters (e.g. driving), but further than near vision at a distance of 40 centimeters (e.g. reading), so the computer screen is seen clear without the need for excessive focusing effort or bad postures. In this study Zeiss® Officelens Plus lenses with a Silhouette® frame were used.
2536046|NCT02656953|Active Comparator|Progressive lenses|Progressive lenses or multifocal lenses provide a continuous range of focal power between near and far distances.Progressive lenses have some lens power for the intermediate zone as well, but this zone might not be large enough for comfortable and ergonomic computer work. In this study Zeiss® Multifocal Precision Plus lenses with a Silhouette® frame were used.
2536066|NCT02656537|Experimental|EnSite™ HD Grid Catheter AF/AT Mapping|
2536159|NCT02656017|Experimental|Metformin|"Participants will be started on 500 mg of metformin once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
2536161|NCT02656017|Placebo Comparator|Placebo|"Participants will be started on 500 mg of placebo once daily, with the following scheduled dose titrations:~Increase to 500mg twice daily at week 2~Increase to 1000mg qAM, 500mg qPM at week 4~Increase to 1000mg twice daily at week 6 for the duration of their participation (26 months).~Increased titrations based on tolerability"
2536215|NCT02655744||newly-diagnosed patients with primary CNS lymphoma|
3167753|NCT00542243|Active Comparator|Finasteride|"The recommended dosage of PROSCAR© is one 5 mg tablet daily with or without food. If a tablet is missed at its usual time, an extra dose should not be taken. The next dose should be taken as usual.~PROSCAR© 5 mg tablets are blue, apple-shaped; film coated with the code MSD 72 on one side and PROSCAR on the other. They will be provided in bottles of 35 tablets."
2536355|NCT02654899|Experimental|Part 1_Cohort 2_Active|Single ascending dose of PF-06815345
2535623|NCT02659735|Experimental|Panel 1: Treatment ADBC|Participants will receive Treatment A (600 milligram [mg] JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 1; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 2; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 3; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2535627|NCT02659735|Experimental|Panel 1: Treatment BACD|Participants will receive Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 1; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 2; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 3; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2535629|NCT02659735|Experimental|Panel I: Treatment CBDA|Participants will receive Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 1; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 2; followed by Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 3; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2535632|NCT02659735|Experimental|Panel I: Treatment DCAB|Participants will receive Treatment D (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #3 [test 3] under fed conditions) in Period 1; followed by Treatment C (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #2 [test 2] under fed conditions) in Period 2; followed by Treatment A (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fed conditions) in Period 3; followed by Treatment B (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1 [test 1] under fed conditions) in Period 4. A washout period of 7 days will be maintained between each treatment period.
2535634|NCT02659735|Experimental|Panel 2: Treatment EFG|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535635|NCT02659735|Experimental|Panel 2: Treatment FGE|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535636|NCT02659735|Experimental|Panel 2: Treatment GEF|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535637|NCT02659735|Experimental|Panel 2: Treatment GFE|Participants will receive Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 1; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 2; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535641|NCT02659735|Experimental|Panel 2: Treatment FEG|Participants will receive Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 1; followed by Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 2; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535645|NCT02659735|Experimental|Panel 2: Treatment EGF|Participants will receive Treatment E (600 mg JNJ-63623872 formulated as the 300 mg oral tablet [reference] under fasted conditions) in Period 1; followed by Treatment G (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 5] under fed conditions) in Period 2; followed by Treatment F (600 mg JNJ-63623872 formulated as the 600 mg oral concept formulation #1, #2 or #3 [test 4] under fasted conditions) in Period 3. A washout period of 7 days will be maintained between each treatment period.
2535709|NCT02659111|Experimental|High-intensity physical exercise, HIFE|
2535710|NCT02659111|Active Comparator|Physical training advice|
2535903|NCT02657811|Active Comparator|Bench Incubation|These embryos will be randomized to the bench incubator.
2535908|NCT02657811|Active Comparator|Time Lapse Incubation|These embryos will be randomized to the Time Lapse Incubator.
2535920|NCT02657811|Active Comparator|Time Lapse Incubation - Modified|These embryos will be randomized to the bench incubator.
2535961|NCT02657512|Experimental|Arm A|"Period  rivaroxaban alone~Washout period (at least 6 days)~Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 5 hours after rivaroxaban administration"
2535963|NCT02657512|Experimental|Arm B|". Period  rivaroxaban and activated charcoal 5 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration"
2535652|NCT02659579|Active Comparator|Shared Reading control|In the Shared Reading control parents and children will attend a weekly shared reading group at a library for 8 weeks where parents/children will read in a shared reading group which will be coordinated by a group facilitator.
2535689|NCT02659254|Experimental|Firesorb Implantation|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）in patients with coronary artery lesions.
2535895|NCT02657993|Experimental|Hypnosis|The hypnosis intervention involves three, face-to-face, hypnosis sessions delivered by doctoral-level psychology professionals
2535896|NCT02657993|Active Comparator|Attention Control (Non-Hypnosis)|The attention control intervention is matched to the hypnosis intervention in terms of the amount of professional time received by patients.
2535946|NCT02657694||Sofosbuvir+Ledipasvir|Following patients treating with Sofosbuvir+Ledipasvir
2535949|NCT02657694||Sofosbuvir+Daclatasvir|Following patients treating with Sofosbuvir+Daclatasvir
2535951|NCT02657694||Sofosbuvir+Velpatasvir|Following patients treating with Sofosbuvir+Velpatasvir
3167754|NCT00542243|Placebo Comparator|Placebo|Patient will receive a placebo comparator each day for 6 months.
2536069|NCT02656511|Experimental|Dolutegravir+Emtricitabine/Tenofovir|Dolutegravir 50 mg PO daily plus Emtricitabine 200 mg/Tenofovir alafenamide 25 mg
2536183|NCT02655692|Placebo Comparator|Placebo|Saline dose
2536184|NCT02655692|Experimental|Low Dose Ketamine|Low Dose Ketamine (.20 mg/kg)
2536187|NCT02655692|Experimental|High Dose Ketamine|High Dose Ketamine (.50 mg/kg)
2536263|NCT02655471|Experimental|HTLV-1 plus Tropical Spastic paraparesis|"Patients with recent onset of Tropical Spastic paraparesis due HTLV-1 will receive combination of Raltegravir and Zidovudine during 48 weeks"
2536336|NCT02655042||RCT-01|Participants in previous clinical trial that received blinded injection of RCT-01
2536340|NCT02655042||Placebo|Participants in previous clinical trial that received blinded injection of placebo
2536388|NCT02654730|Experimental|G6PD deficient 0.25 mg/kg PQ + DHAP|
2536389|NCT02654730|Experimental|G6PD deficient 0.4 mg/kg PQ + DHAP|
2536390|NCT02654730|Active Comparator|G6PD deficient DHAP only|
2536391|NCT02654730|Active Comparator|G6PD normal 0.25 mg/kg PQ + DHAP|
2536392|NCT02654730|Active Comparator|G6PD normal 0.4 mg/kg PQ + DHAP|
2536473|NCT02654288||single arm|The pancreatic cancer patients without history of chemotherapy who will receive gemcitabine-based chemotherapy will be recruited and the sera IgG4 and IL-10 will be detected before and after chemotherapy.
2536498|NCT02653833|Experimental|Healthy Controls (HC)|Healthy men currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. This is repeated at baseline and shortly after taking beetroot juice extract.
2536499|NCT02653833|Experimental|Becker Muscular Dystrophy (BMD)|"currently taking no medications will be asked to perform graded hand-grip exercise while a contrast enhanced ultrasound (CEU) probe is placed over their forearm to measure blood flow. Using a lower body negative pressure (LBNP) chamber, the subjects are tested for impaired exercise induced vasodilation to the skeletal muscle or functional sympatholysis. This is repeated at baseline and shortly after taking beetroot juice extract."
2536589|NCT02653586|Experimental|"program In Favor of Resilience Self"|"The program In Favor of Resilience Self was delivered to adolescence aged 15-17, over 2 months. The program contained nine weekly, 90-min lessons that focus on enhancing self- resilience, self-esteem, self-image, body image. All students completed a self-report questionnaire at baseline, conclusion and 3 months after program conclusion."
2536592|NCT02653586|No Intervention|control group|The control group didn't receive the intervention program, instead they received a lecture on wised nutrition. In addition the control group completed the same self-report questionnaire as the intervention group at baseline, conclusion and 3 months after program.
2536658|NCT02653014|Experimental|Cohort 1|Healthy Volunteers will receive multiple dose of KBP-5074
2536660|NCT02653014|Experimental|Cohort 2|Healthy Volunteers will receive multiple dose of KBP-5074
2536661|NCT02653014|Experimental|Cohort 3|Healthy Volunteers will receive multiple dose of KBP-5074
2536662|NCT02653014|Experimental|Cohort 4|Healthy Volunteers will receive multiple dose of KBP-5074
2536665|NCT02653014|Experimental|Cohort 5|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
2536669|NCT02653014|Experimental|Cohort 6|Subjects with mild to moderate renal impairment will receive multiple dose of KBP-5074
2536730|NCT02652494||Patients receiving Apremilast per daily clinical practice|Dutch patients receiving Apremilast according to daily clinical practice
2536858|NCT02651844|Experimental|Mifepristone|Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria
3167755|NCT00542256|Active Comparator|1|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each of the 10 weekday training sessions, participants will receive 40 minutes of active tDCS over the primary motor cortex.
3167756|NCT00542256|Sham Comparator|2|Each subject will receive 14 days (2 week period: 10 weekdays and 2 weekends) of constraint induced movement therapy. In addition, on the 10 weekdays during the treatment period, the subjects will come into the laboratory and receive up to 6 hours per day of training of the affected arm in a variety of tasks. At the beginning of each training day tDCS will be applied for 40 minutes with the current active for only 30 seconds over the primary motor cortex.
2537088|NCT02649530|Experimental|WNT974|Patients will receive 10 mg of WNT974 daily by mouth.
2537152|NCT02649335|Active Comparator|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study.
2537188|NCT02648802|Experimental|Cavity shaving and CM assessment|Standardized BCS with additional cavity shaving before CM assessment.
3167757|NCT00542282||1, 2, 3|known moderate to severe COPD, known moderate or severe Asthma, suspected obstructive moderate to severe airways disease
3167758|NCT00542295|Experimental|A|
3167759|NCT00542295|Placebo Comparator|B|
3201769|NCT00906620|Experimental|Control group|The control group will comprise 250 subjects. After the baseline assessment, subjects will be randomized in one of the three intervention arms or in the control group. Individuals in the control group will undergo the same baseline and follow-up evaluations as subjects in the intervention arms and will receive the same leaflet about healthy lifestyles with information about the possibility to seek help for unhealthy, suicidal behaviour and mental health problems. In this arm, no additional intervention will be performed although the possibility of seeking help from mental health resources will be available.
3201770|NCT00906633||Outcome of combination antifungal therapy|
3201771|NCT00906646|Experimental|Metabolic therapy|Metabolic therapy with antioxidants and cellular energisers
3201772|NCT00906646|Placebo Comparator|Placebo|Placebo tablets
2535741|NCT02658864|Experimental|10-mg group|Twelve healthy subjects were administered a single oral dose of 10 mg lafutidine tablets in fasted state.
2535748|NCT02658864|Experimental|20-mg group|Twelve healthy subjects were administered a single oral dose of 20 mg lafutidine tablets in fasted state.
2535752|NCT02658864|Experimental|40-mg group|Twelve healthy subjects were administered a single oral dose of 40 mg lafutidine tablets in fasted state.
2535800|NCT02658591|Active Comparator|Control|Crackers/pasta with no faba bean fraction
2535804|NCT02658591|Experimental|Faba bean protein concentrate|Crackers/pasta with added faba bean protein concentrate
2535807|NCT02658591|Experimental|Faba bean protein isolate|Crackers/pasta with added faba bean protein isolate
2535810|NCT02658591|Experimental|Faba bean flour|Crackers/pasta with added faba bean flour
2535812|NCT02658591|Experimental|Faba bean starch|Crackers/pasta with added faba bean starch
2535876|NCT02658162|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
2535878|NCT02658162|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
2535922|NCT02657785|Experimental|R-IDARAM plus intrathecal chemotherapy|Patients will be treated with systemic R-IDARAM plus intrathecal immunochemotherapy
2535967|NCT02657499||Medicaid Expansion States|Patients receiving care in community health centers in states that expanded Medicaid (intervention group)
2535968|NCT02657499||Non Medicaid Expansion States|Patients receiving care in community health centers in states that did not expand Medicaid (control group)
2536036|NCT02657070|Experimental|Experimental Group|Virtual reality based therapy with augmented visuomotor feedback.
2536038|NCT02657070|Active Comparator|Control Group|Virtual reality based therapy without augmentation.
2536092|NCT02656615|Experimental|Abiraterone|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
2536166|NCT02656004|Experimental|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
2536167|NCT02656004|Experimental|Control|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
2536186|NCT02655757|Active Comparator|Sitagliptin|Sitagliptin 100mg QD
2536188|NCT02655757|Placebo Comparator|Placebo|Placebo
2536261|NCT02655497|Experimental|Cognitive Training|Cognitive training intervention. The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The experimental group will receive real-world strategy training, a cognitive strategy based approach that trains people to improve their level of independence on meaningful activities of daily life with which they are having difficulty.
2536268|NCT02655497|Active Comparator|Psychosocial education|The intervention includes seven 2-hour group sessions interspersed with four individual 45-minute sessions for a total of 17 hours of intervention over an 8-week period. The control group will receive brain-health education.
3201773|NCT00906659||diabetic macular edema|type 2 patients who had been treated with selective photocoagulation for clinically significant macular edema
3201774|NCT00906672|Experimental|INTEGRA®|
2536441|NCT02654340||Participants with Tuberous Sclerosis Complex (TSC)|Üarticipants diagnosed with Tuberous Sclerosis Complex (TSC) aged between 2 months and 50 years.
2536519|NCT02653976|Experimental|SP-02L (darinaparsin for injection)|
3201775|NCT00906672|Active Comparator|Flap technique|
3201776|NCT00906685|Active Comparator|Intravitreal bevacizumab|
2536709|NCT02652598|Experimental|Open-Label|Each patient will receive a two-week specified dosing amount of tolcapone (100mg TID on Day 1; 200mg TID on Days 2-14). The patient will be instructed to take the study drug three times daily. Tolcapone will be tapered after Day 14 to avoid potential withdrawal reactions.
2536746|NCT02652351|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
2536790|NCT02652052|Other|Group 1: Observational|Observational only
2536794|NCT02652052|Experimental|Group 2: Dasatinib & Quercetin|Interventional: The drugs dasatinib and quercetin will be used in this arm
2536860|NCT02651662|Experimental|Open label (cemiplimab)|Experimental cohorts will consist of multiple dose levels of cemiplimab administered intravenously (IV) every 2 weeks (Q2W)
2536862|NCT02651662|Experimental|Open label (cemiplimab and REGN1979)|Experimental cohorts will consist of a single dose level of cemiplimab administered intravenously (IV) and multiple dose levels of REGN1979 administered intravenously (IV)
2536916|NCT02650973|Experimental|Sequence A|3 doses of CHS-1701 or Neulasta, random order
2536925|NCT02650973|Experimental|Sequence B|3 doses of CHS-1701 or Neulasta, random order
2536926|NCT02650973|Experimental|Sequence C|3 doses of CHS-1701 or Neulasta, random order
2536969|NCT02650622||Cohort 1-Newborns aged 1-2 days|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the state-mandated newborn screening test.
3201777|NCT00906685|Sham Comparator|Sham injection|
3201778|NCT00906711||Group I|(G1): 10 - 18 years old
3201779|NCT00906711||Group II|(G2): 20 - 35 years old
3201780|NCT00906711||Group III|(G3): 45 - 60 years old
3201781|NCT00906711||Group IV|(G4): 65 - 85 years old
2535672|NCT02659319|Experimental|FL + FD + Peer Group (FL+FD+PG; n = 130)|This arm includes the Family Food & Lifestyle intervention plus the Family Dynamics Intervention plus the Peer Group intervention.
2535673|NCT02659319|No Intervention|Control (n = 82)|Non-intervention control group
2535712|NCT02659124|Other|Standard of Care plus AmnioFix|All patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face.
2535734|NCT02658916|Experimental|Panel 1: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
2535735|NCT02658916|Experimental|Panel 2: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
2535742|NCT02658916|Experimental|Panel 3: BIIB092|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
2535751|NCT02658916|Experimental|Panel 4: BIIB092 (Expansion Panel)|BIIB092 administered by intravenous (IV) infusion, once every four weeks.
3201782|NCT00906724||aerobic exercise|Aerobic exercise in Insulin Resistant Minority Adolescents
3201783|NCT00906737|Experimental|Ankle-Bot Training|Subjects in this group receive focused ankle training using the ankle-bot device.
3201784|NCT00906737|Active Comparator|Conventional Therapy|Subjects in this group will receive conventional focused ankle physical therapy.
2535906|NCT02657941|Experimental|Motivational group|psycho-education program inspired by motivational interviewing and behavioral psychotherapy
2535915|NCT02657941|Active Comparator|educational group|exclusively informative psycho-education program
2535960|NCT02657551|Experimental|Regorafenib|Regorafenib tablets orally, once daily at predetermined dosage for 21 days per cycle
2536008|NCT02657161|Active Comparator|Group A|"Comparator vaccine RABIPUR®~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
2536009|NCT02657161|Experimental|Group B|"PIKA Rabies vaccine~Healthy volunteers received rabies vaccination intramuscularly on days 0,3,7 and 14"
2536010|NCT02657161|Experimental|Group C|"PIKA Rabies vaccine with an accelerated regimen~Healthy volunteers received rabies vaccination intramuscularly on days 0 (2 Doses), 3 (2 Doses), and day 7 (1 Dose)"
2536068|NCT02656797|Experimental|AM-B|Topical Amphotericin-B 0.4% liposomal gel
2536074|NCT02656797|Placebo Comparator|Placebo|Placebo gel preparation
3201785|NCT00906737|No Intervention|Control|Subjects in this group will not receive treatment; they will continue their usual care.
2536262|NCT02655289|Experimental|Modulated TENS|
2536269|NCT02655289|Placebo Comparator|Placebo TENS|
2536480|NCT02654028|Experimental|Autotransfusion group|These group of patients will receive autotransfusion before liver resection.
2536483|NCT02654028|Active Comparator|Control group|These group of patients will not receive autotransfusion before or after liver resection.
3201786|NCT00906750|Experimental|1|
3201787|NCT00906750|Active Comparator|2|
2536582|NCT02653235|Active Comparator|Typhoid vaccination|Salmonella typhi vaccination
2536583|NCT02653235|Placebo Comparator|Placebo|0.9% sodium chloride
2536639|NCT02653027|Experimental|Lumacaftor Ivacaftor|Subjects will get an OGTT before and after starting the combination therapy lumacaftor-ivacaftor.
2536710|NCT02652728|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
2536745|NCT02652286|Other|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
2536830|NCT02651753|Experimental|A|"Period 1: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.~Period 2: Test drug(CKD-337), 1 capsule administered under fed conditions."
2536831|NCT02651753|Experimental|B|Period 1: Test drug(CKD-337), 1 capsule administered under fed conditions. Period 2: Reference drug (Lipitor+ Lipidil supra), 2 tablets administered under fed conditions.
2536871|NCT02651376|Experimental|Conventional plus AAIT|Participants received conventional treatment (anti-opportunistic infections and ART) plus a dose (3 times of MNCs) of AAIT.
2536900|NCT02651142|Experimental|SLNB with para-SLN dissection|patients receive sentinel lymph node biopsy patients receive para-sentinel lymph node dissection
2536904|NCT02651142|Experimental|SLNB without para-SLN dissection|patients received sentinel lymph node biopsy
2536965|NCT02650817|Experimental|Elacestrant (formerly RAD1901)|To receive daily oral elacestrant
2536992|NCT02650427|Experimental|DPPIV Inhibition|The study will include 3 weeks administration (± 7 days) of sitagliptin as monotherapy (taken orally). The study will use 3 doses: the first five patients will receive 100 mg/day, the next five 200 mg/day and the last five patients 600 mg/day. During this time, arrangements will be made for surgical resection, as per the standard of care treatment of patients. Blood samples will be obtained for immunology studies. The study will end one week after surgery. Patients will continue their treatment for HCC as prescribed by the clinician.
3201788|NCT00906763|Active Comparator|Dark Chocolate (85% cocoa)|Oral Intake of dark chocolate (85% cocoa) over 15 minutes.
3201789|NCT00906763|Active Comparator|White chocolate (0% cocoa)|Oral intake of 200 grams of white chocolate (0% cocoa) over 15 Minutes.
3201790|NCT00906802|Experimental|R-Y reconstruction|the reconstruction was performed by R-Y anastomosis
3201791|NCT00906802|No Intervention|conventional reconstruction|the anastomosis was performed by B-II
3201792|NCT00906828|Active Comparator|1. Duodopa, optimised dose|
3201793|NCT00906828|Experimental|2. 80% Duodopa + entacapone|80% of optimised Duodopa dose + two tablets of entacapone at t=0 hours and at t= 6 hours
3201794|NCT00906828|Experimental|3. 80% Duodopa + tolcapone|80% of optimised Duodopa dose + two tablets of tolcapone at t=0 hours and at t= 6 hours
3201795|NCT00906841|Experimental|90Y-DOTA-hLL2|Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
3201796|NCT00906854||Group I|practice of weight training exercises
3201797|NCT00906854||Group II|aerobic exercises as part of lessons jump, step and dance classes
3201798|NCT00906854||Group III|swimming (crawl mode)
3201799|NCT00906867||Vocal cord dysfunction|Patients with suspicion of VCD
3201800|NCT00906893|Experimental|1|
3201801|NCT00906906||1|Patient to receive CPB
3201802|NCT00906919|Active Comparator|Regular diabetes patient education|Regular professionally-led diabetes patient education
2535753|NCT02658799|Active Comparator|placebo|"or placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (placebo) was administered from 2 to 4 months, then diclofenac potassium therapy was reinstituted (b.i.d.) from 4 to 6 months.~To promote compliance, each patient was recalled monthly."
2535791|NCT02658578|Active Comparator|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
2535792|NCT02658578|Placebo Comparator|Sham PNS|In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
2535831|NCT02658344|Experimental|Jointstem|Autologous Adipose Tissue derived MSCs
2535832|NCT02658344|Placebo Comparator|Saline solution|Sodium chloride
2535880|NCT02658032|Other|Standard Care/No Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the non bio feedback arm.
2535883|NCT02658032|Other|Standard Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the standard care arm and then those enrolled in the bio feedback arm.
2535885|NCT02658032|Other|Personalized Care/ No Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the non bio feedback arm.
2535886|NCT02658032|Experimental|Personalized Care/ Bio Feedback|This arm will consist of those first randomized to be enrolled in the personalized care arm and then those enrolled in the bio feedback arm.
2535935|NCT02657720|Other|Healthy volunteers|Respiration rate will be measured using several medical devices: Radical-7, Capnostream20p and PTAF2 (flow meter)
2535980|NCT02657304|Experimental|Coaching group|PPC + Coaching
2535984|NCT02657304|Active Comparator|Control group|PPC
2536072|NCT02656992|Experimental|High-IMT group|Intervention group receive supervised training sessions three times per week for 8 weeks. Each sessions lasted 21 minutes and comprised seven cycles of 2 minutes of breathing on an inspiratory threshold device followed by 1 minute of rest. High-IMT was performed at the maximal load tolerable for each 2-minute work interval and was progressively increased over the training period.
2536076|NCT02656992|Sham Comparator|Control group|Control group was prescribed at 10% of baseline maximal inspiratory pressure, and remained at this level during all training sessions for 8 weeks.
3201803|NCT00906919|Experimental|Augmented Diabetes Patient Education|Regular professionally-led diabetes patient education augmented by participation in the Stanford Chronic Disease Self-Management Program
3201804|NCT00906932||Trachview videoscope, direct laryngoscopy|Each subject served as their own control - the Trachview videoscope and direct laryngoscopy was performed on by all subjects in a sequential fashion.
3201805|NCT00906932||See above|See above
2536394|NCT02654509|Experimental|EEE vaccine|Eastern Equine Encephalitis Vaccine will be administered as primary doses of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area and booster doses of 0.1 mL given intradermally in the volar aspect of the forearm. The primary series will be administered on Days 0 and 26-35 with a booster at 6 months. Titers will be collected 28-35 days after the second primary vaccine is < 1:40, the subject will receive a booster dose 28- 90 days of obtaining the titer result.
2536439|NCT02654327|No Intervention|Standard Care|Standard care with conventional lung protective mechanical ventilation
2536440|NCT02654327|Experimental|ECCO2R to enable lower tidal volume mechanical ventilation|VV-ECCO2R to enable lower tidal volume mechanical ventilation (target tidal volume of ≤ 3ml/kg predicted body weight and a Pplat ≤ 25cmH20)
3201806|NCT00906984|Other|TheraSphere® treatment|TheraSphere® treatment will be performed in the outpatient setting. The effect on the tumor and any side effects of TheraSphere® HUD treatment will be examined. This is not a research study and there are no comparison or experimental treatments being used. Within 14 days of initial treatment, reverification of eligibility will be confirmed. If review of eligibility indicates an uncorrectable risk of flow to the gastrointestinal organs or risk of shunting to the lungs, treatment will not be administered. In this event, the patient will receive alternative treatment (chemoembolization) or no treatment. If the patient remains eligible, TheraSphere® will be administered within 14 days. All patients will be evaluated at 30 days post-treatment to assess clinical experience and adverse effects. Subsequently, patient status will be followed via communication with the referring oncologist to determine disease status and survival. Survival surveillance will continue up to 24 months.
3201807|NCT00906997|Active Comparator|Fecal occult blood testing|
3201808|NCT00906997|Active Comparator|Colonoscopy|
3201809|NCT00907010||Group I|11 to 18 years - composed of 12 adolescent with six women and six men
3201810|NCT00907010||Group II|20 to 26 years - composed of 12 young with six women and six men
3201811|NCT00907010||Group III|45 to 60 years - composed of 12 adult with six women and six men
3201812|NCT00907010||Group IV|66 - 82 years - composed of 12 aged with six women and six men
3201813|NCT00907023||SOT|Patients that have had a solid organ transplant
3201814|NCT00907049||Subacute neck pain; chronic neck pain|Patients with subacute or chronic neck pain seen in the Primary Care Centers participating in the study.
3201815|NCT00907062|Experimental|Gingko biloba|60 mg of Ginkgo biloba (standardized to 15 mg ginkgofavonglycosides) given 2 times per day, with food, for 12 weeks.
2536693|NCT02652975|Experimental|Category 1|Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2537062|NCT02649933||Watch PAt 200|obese pregnant women, pregnancy between 12 and 15 weeks
3201816|NCT00907075|Active Comparator|NES With Energy Restriction|
3201817|NCT00907075|Active Comparator|NES Without Energy Restriction|
3201818|NCT00907114|Active Comparator|Ketorolac tromethamine|ocular topic ketorolac used 4 times a day during a week after panphotocoagulation
3201819|NCT00907114|Placebo Comparator|Polivynilic alcohol|ocular lubricant drops 4 times a day during one week after panphotocoagulation
3201820|NCT00907127|Active Comparator|Mediterranean Diet and Exercise|Mediterranean Diet and Exercise
3201821|NCT00907140|Other|Chemoradiation therapy|
3201822|NCT00907166|Experimental|Phase I, Arm A|CPI-613 + Gemcitabine
2535761|NCT02658825|Experimental|Panel 2: Treatment GFE|Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535762|NCT02658825|Experimental|Panel 2: Treatment FEG|Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535763|NCT02658825|Experimental|Panel 2: Treatment EGF|Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
2535842|NCT02658266|Experimental|Resistance training|Home based resistance training 12 weeks home based resistance training 3 times per week, 10-12 reps, 2 sets
2535846|NCT02658266|No Intervention|Control group|No instructed exercise training. Continue with habitual physical activity.
2535907|NCT02657863||Healthy volunteer|Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
2535913|NCT02657863||Prostate cancer patients being treat with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
2535919|NCT02657863||Prostate cancer patients being treated with radiation therapy|Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
2535971|NCT02657343|Experimental|Cohort A|Ribociclib will be given orally once day (day 5-18) at a pre-determine dose for two weeks of a 21 day cycle. T-DM1 will be given as IV infusions on Day 1 of a 3 week cycle at a pre-determined dose over pre-determined period of time.
2535976|NCT02657343|Experimental|Cohort B|Ribociclib will be given orally once day continuously for a 21-day cycle of treatment (except at Dose Level -2, when Ribociclib is given Days 1-14 of a 21 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose.
2535978|NCT02657343|Experimental|Cohort C|Ribociclib will be given orally once a day continuously for a 28-day cycle of treatment (except at Dose Level -1, when Ribociclib is given Days 1-21 of a 28 day cycle). Trastuzumab will be given as IV infusions over a pre-determined period of time and dose. Fulvestrant will be dosed approximately every 28 days as per standard of care.
3201823|NCT00907166|Experimental|Phase II, Arm A|CPI-613 + Gemcitabine
2536109|NCT02656407|Experimental|Ultrasensitive Doppler|Intraoperative ultrasensitive Doppler acquisitions by using an ultrasound device for functional area detection
2536117|NCT02656043|Active Comparator|XPF-005|Active treatment: XPF-005 Gel
2536129|NCT02656043|Placebo Comparator|Vehicle gel|Placebo: XPF-005 Vehicle Gel
2536185|NCT02655731|Other|Treatment|PVI with HeartLight
2536265|NCT02655549|Experimental|Cohort 1 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2536270|NCT02655549|Experimental|Cohort 2 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2536273|NCT02655549|Experimental|Cohort 3 of Px563L, RPA563, or placebo|Intramuscular injections of Px563L, RPA563, or placebo
2536335|NCT02655003|Experimental|INH (Intervention Nursing Homes)|TIME consists of a manual based multicomponent program which includes a rigorous assessment, the treatment, and the evaluation of NPS. The staff, physicians and nursing home managers in the intervention nursing homes will receive a one-day education program. Three nurses from each unit will receive further education including practical and theoretical training for three hours.
2536344|NCT02655003|Active Comparator|CNH (Control Nursing Homes)|A brief two hours education-only intervention about dementia and NPS will be given to the staff in for the control nursing homes (CNH). The staff and physicians in the control nursing homes continue practice as usual.
2536423|NCT02654587|Experimental|OSE2101|OSE2101 will be administered as a 1 mL-subcutaneous injection on Day 1 every three weeks for six cycles, then every eight weeks for the remainder of year one and finally every twelve weeks beyond year one until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal. Should pseudo progression or delayed response to treatment suspected in arm A, investigator may continue treatment beyond the time of RECIST-defined progression, if the patient is perceived to be experiencing clinical benefit. OSE2101 dose will be 5 mg of peptide (0.5 mg for each peptide).
2536426|NCT02654587|Active Comparator|Docetaxel or Pemetrexed|"Patients receiving docetaxel: Docetaxel 75 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of a 21-day cycle.~Patients receiving pemetrexed: Pemetrexed, 500 mg/m2, will be administered by intravenous infusion over 10 minutes on Day 1 of a 21-day cycle.~Docetaxel and pemetrexed will be continued until unequivocal RECIST 1.1-defined disease progression as determined by the investigator, unacceptable toxicity, or consent withdrawal."
2536536|NCT02653651|Active Comparator|Ketamine|Ketamine infused at 0.1 mg/kg/hour
2536538|NCT02653651|Experimental|Lidocaine|Lidocaine infused at 1 mg/kg/hour
2536540|NCT02653651|Placebo Comparator|Placebo|An equal volume of saline
2536585|NCT02653365||Non-invasive ventilation|All patients eligible for inclusion in the study were treated with Non-invasive ventilation.
3201824|NCT00907166|Active Comparator|Phase II, Arm B|Gemcitabine
2535772|NCT02658708|Experimental|Arm 1: Bright blue-green light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, -21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
2535774|NCT02658708|Active Comparator|Arm 2: Dim red light|Complete the MEQ at screening, the day before 2nd cycle of chemo, and on the day of 3rd cycle of chemo, 21 day light intervention at home for 30 min once a day during 2nd cycle of chemo, Scores of ≤41 (evening types) on MEQ will have light delivered within 30 minutes of waking for 21 consecutive mornings. Score of ≥59 (morning types) on MEQ will have light delivered between 1900-2000 hours for 21 consecutive evenings. Light therapy will be self-administered using a light visor cap. On 2 days randomly selected days ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter, Continuous ambulatory PSG for 24 hours at the participant's home before and after the light intervention, Complete the fatigue and sleep log on a daily basis and two visual analog scales (VAS) (diurnal fatigue and daytime sleepiness) within half an hour upon awakening, at 1200 hours, 1600 hours, 2000 hours, and within half an hour before going to bed
2535875|NCT02658201|Other|MRI group|Ultrafast MRI
2535929|NCT02657837||Cystic Fibrosis|Children 2.5 to 18 years old with confirmed diagnosis of cystic fibrosis
2535931|NCT02657837||Children with other respiratory disease|Children 2.5 to 18 years old with confirmed diagnosis of respiratory disease including but not limited to asthma, transplant, and sickle cell anemia.
2535933|NCT02657837||Healthy Children|Children and adults 2.5 to 30 years old with no history of chronic disease
2536006|NCT02657174|Experimental|G1- experimental active comparator group|G1 - (Experimental) 40 third molars surgeries will be performed in a conventional manner. At the end of surgery low level laser in auricular acupuncture points will be applied for prevention of inflammation and pain in a split-mouth design.
2536007|NCT02657174|Placebo Comparator|G2- control group|G2 - (Control) 40 third molars surgeries will be performed in the conventional manner, identically to the G1. At the end of surgery low level laser device off in auricular acupuncture points will be applied. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1, with split-mouth design.
2536056|NCT02656810|Experimental|Sequence A|Single subcutaneous injection of two teriparatide products (PF708 and Forteo)
2536057|NCT02656810|Experimental|Sequence B|Single subcutaneous injection of two teriparatide products (Forteo and PF708)
2536143|NCT02656082|Experimental|Etanercept|Intradermal injection of etanercept. The dosage is determined based on discoid lesion radius. Weekly injection up to 12 weeks.
2536172|NCT02655848|Active Comparator|@ Cuff repair with LHB tenodesis|In case of pathologic changes of the long Head Biceps tendon, a tenodesis is performed in adjunct to performing an arthroscopic rotator cuff repair.
2536173|NCT02655848|Active Comparator|@ cuff repair with LHB tenotomy|In case of pathologic changes of the long Head Biceps tendon, a tenotomy is performed in adjunct to performing an arthroscopic rotator cuff repair.
2536220|NCT02655614|Experimental|SAD Stage: GDC-0134|Participants in multiple cohorts and treatment periods will receive single doses of GDC-0134 oral capsules under fed/fasting conditions. To study the effect of proton pump inhibitor (PPI) medication rabeprazole on PK properties of GDC-0134, few participants may receive rabeprazole 20 milligrams (mg).
2536221|NCT02655614|Placebo Comparator|SAD Stage: Placebo|Participants in multiple cohorts and treatment periods will receive placebo matching to GDC-0134 under fed/fasting conditions. Few participants may receive rabeprazole 20 mg.
2536224|NCT02655614|Experimental|MAD Stage: GDC-0134|Participants will receive multiple doses of GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
2536225|NCT02655614|Placebo Comparator|MAD Stage: Placebo|Participants will receive placebo matching to GDC-0134 for 28 days. To study the interactions between GDC-0134 and other drugs, some participants may receive single doses of midazolam and caffeine at various time points.
2536227|NCT02655614|Other|Open-Label Safety Expansion (OSE)|Participants will receive GDC-0134 at a dose determined by the corresponding MAD cohort.
3201825|NCT00907179|Experimental|Dose escalation|"Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.~Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given"
3201826|NCT00907192||Opioids|Personal Interview and Questionnaire of Advanced cancer patients, taking narcotic pain drugs (opioids).
2536427|NCT02654418|Experimental|SIC 8000, 10 mL ampoules|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with SIC 8000 injectate solution.
2536428|NCT02654418|Active Comparator|reference comparator|Procedure/Surgery: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size) with Reference Comparator Injectate solution (site standard of care injectate solution).
2536450|NCT02654106|Experimental|Refractory Brain Metastases|Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases
2536518|NCT02653963|No Intervention|Conventional AGV|A limbus-based conjunctival peritomy was created 4mm posterior to the limbus and Tenon's capsule was dissected. The AGV Plate was secured to the sclera 8 mm posterior to the limbus. The tube was trimmed to an appropriate length and inserted into the anterior chamber through a corneoscleral track. The tube was fixed to the episclera with a 10-0 nylon mattress suture. A donor sclera was fashioned to cover the exposed part of the tube and was secured to the sclera using 10-0 nylon sutures. The conjunctiva and Tenon were closed using 10-0 nylon suture.
3167760|NCT00542347|Active Comparator|1|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
3167761|NCT00542347|Active Comparator|2|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
2536026|NCT02657096|Experimental|Hybenx treatment|Both quadrants included maxillary teeth 11-16 and 21-26. Each selected subject underwent randomly, without anaesthesia, at the same time and after recording periodontal parameters, the two following treatments: in one, maxillary quadrants were treated as conventional SRP + desiccant (Hybenx). In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the marginal gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
2536029|NCT02657096|Sham Comparator|Scaling and Root Planing|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
2536083|NCT02656628||Fractures of humerus femur tibia|Dynamic Locking Screw 3.7mm and 5.0mm
2536122|NCT02656316|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
2536128|NCT02656316|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
2536217|NCT02655640||Lupus|Characteristics of patients with Systemic Lupus Erythematosus. No interventions will be administered. Patients will be asked to complete questionnaires.
2536218|NCT02655640||Scleroderma|Characteristics of patients with Systemic Sclerosis. No interventions will be administered. Patients will be asked to complete questionnaires.
2536257|NCT02655341||Consecutive STEMI Patients|All patients with AMI referred for primary PCI in a single centre
2536319|NCT02654912|Experimental|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
2536321|NCT02654912|No Intervention|Reactive Focal Test and Treat|This is the current standard of care in Southern Province and is described by a reactive response to passively detected index case of malaria. The reactive response consists of testing all individuals within a defined radius of each RDT-confirmed incident malaria case with an RDT and treating all positive individuals with artemether-lumefantrine (AL).
2536368|NCT02654743|Experimental|SF|"Sulforaphane (SF) will be administered in an approximate dosage of 1 µmol SF/lb (2.2 kg µmol/kg) body weight. This dosage roughly approximates the dosage that was used in the Singh et al, (2014; PNAS) clinical trial of sulforaphane in male adolescents and adults with autism. The sulforaphane will be supplied as glucoraphanin (GR)-enriched broccoli seed extract tablets (manufacturing details follow). Each active tablet will contain 125 mg broccoli seed extract (containing 37 µmol GR, which is equivalent to about 15 µmol SF), 50 mg dried broccoli sprouts (a source of myrosinase, the enzyme that converts GR to SF), 15 mg ascorbic acid, 55.90 mg microcrystalline cellulose, and other minor GRAS excipients used for tablet forming.~The total dose per day will depend of study participants' body weight."
2536413|NCT02654457||Women with Breast Cancer #1|IVD Study
2536416|NCT02654457||Women with Breast Cancer #2|IVD Study
2536418|NCT02654457||Women with Breast Cancer #3|IVD Study
2536624|NCT02653105|Experimental|OLFM4|Patient have a blood test every 6 months at the same time of the clinical exam planned in the following. The OLFM4 will be dose in the blood sample and the rate of OLFM4 compared to the result of imaging.
2536714|NCT02652754|Other|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
2536738|NCT02652338|Active Comparator|MNC-01|potassium, magnesium, and vitamins (MNC-01)
2536743|NCT02652338|Placebo Comparator|Placebo|cellulose, microcrystalline [NF], HPMC E15,
2536786|NCT02652065|Active Comparator|Healthy skin|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on healthy skin.~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
2536791|NCT02652065|Experimental|Psoriasis plaque|"Local vasodilators (acetylcholine, sodium nitroprussiate and ppi water as control) will be delivered to patients by iontophoresis on a psoriasis plaque (on the patient's back).~The skin blood flow in response to these molecules will be followed by laser Doppler recordings."
3167762|NCT00542360|Experimental|Social marketing program|Behavioral: Social marketing program to motivate exercise class participation
3167763|NCT00542360|No Intervention|Control|Control: No intervention
3167764|NCT00542373|Experimental|Diagnostic (fluorescent/reflectance imaging, spectroscopy)|Participants' oral cavities are inspected by a clinician using a standard white light headlamp. Participants then undergo oral mucosa examination using wide-field reflectance and fluorescence imaging, and/or fluorescence spectroscopy imaging. Standard oral brush biopsies are also performed and examined microscopically. Participants may undergo repeated imaging procedures and biopsy during subsequent follow up visits.
3167765|NCT00542399|Experimental|1|once a day
3167766|NCT00542399|Experimental|2|twice a day
3167767|NCT00542438|Active Comparator|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
3167768|NCT00542438|Active Comparator|Environmental Assessment|Environmental assessments on a palm pilot either 3 times a day or once a day. Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
3167769|NCT00542464|Placebo Comparator|Cohort 1|1.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
3167770|NCT00542464|Placebo Comparator|Cohort 2|2.0 mg/kg Imprime PGG administered daily over 1 hr for 7 consecutive days
3167771|NCT00542464|Placebo Comparator|Cohort 3|4.0 mg/kg Imprime PGG administered daily over 2 hr for 7 consecutive days
3167772|NCT00542516|Experimental|HES 130/04|Pre-expansion with HES
2535839|NCT02658396|Experimental|GO-203-2C|"Patients who fulfill eligibility criteria will be entered into the trial to receive Bortezomib and GO-203-2C.~After the screening procedures confirm participation in the research study:~The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have multiple myeloma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.~Bortezomib~GO-203-2C"
2535901|NCT02657954|Experimental|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training
2535916|NCT02657954|Active Comparator|Holistic Cognitive Education (HCE)|Holistic Cognitive Education
3201827|NCT00907205|Experimental|SF1126|Twice weekly IV infusion
2536081|NCT02656706|Experimental|Adjuvant treatment|Ipilumumab:1mg/kg q6weeks (1 dose per cycle, 4 planned treatments over 6 months total) Nivolumab:3mg/kg q2weeks (3 doses per cycle, 12 planned treatments over 6 months total)
2536111|NCT02656225|Experimental|Ejiao compound|The participants in experimental group receive Ejiao compound (20ml, twice daily) orally for 4 weeks.
2536113|NCT02656225|Active Comparator|Niferex|The participants in control group receive Polysaccharide Iron Complex(Niferex)(150mg per tablet, once daily) orally after breakfast over 4 weeks.
2536176|NCT02655978||Healthy Volunteers|These participants will not have any psychiatric disorder as assessed by a structured clinical interview for psychiatric disorders.
2536177|NCT02655978||Medically Treatment-Responsive BD|This group will be composed of participants who have BDI or BDII and have most recently been depressed but are currently in remission with evidence-based treatments for bipolar disorder
2536179|NCT02655978||Treatment-Refractory BD|This group will be composed of participants who have BDI or BDII, are currently depressed with their current episode lasting at least 12 months and not responding to 4 adequate evidence-based treatments for BDI or BDII and who have failed, been intolerant to, or were unwilling to try electroconvulsive therapy (ECT).
2536244|NCT02655562|Experimental|biomarker treatment arm|Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO<25ppb were given placebo (p.o., 10mg, qd).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
2536246|NCT02655562|Placebo Comparator|standard treatment arm|Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO<25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
2536312|NCT02655146|Experimental|GnRHa protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 (Progynova) 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2.In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .A single dose of Triptorelin 0.1mg is administrated on the 3rd day after embryo implanted with routine luteal phase support.
2536313|NCT02655146|Other|routine luteal phase protocol|All subjects are artificially preparing endometrium starting on day 3-5 of the cycle with oral E2 4-10mg/day at least 14 days. After ultrasound and hormone tests, progesterone 100mg/day intramuscular injection is allocated with E2. In the meanwhile, if the subjects have a fail history of hormonal artificially preparing endometrium, such as an early ovulation, a singal dose of triptorelin 3.75mg would be intramuscular injected before E2 was used as a pretreatment. Then a maximum of two embryos are transferred when endometrium is perfectly prepared. All subjects receive routine luteal phase support with E2 and progesterone .
2536360|NCT02654795|Placebo Comparator|Patients without stroke|This group will consists of patients scheduled for atrial fibrillation ablation without history of stroke.
2536362|NCT02654795|Experimental|Patients with history of stroke|This group will consists of patients after ischemic stroke and history of atrial fibrillation.
2536412|NCT02654496||Group 1 (Successful weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had successful weight loss
2536414|NCT02654496||Group 2 (Suboptimal weight loss)|3-5 years post Roux-en-Y gastric bypass patients who had suboptimal weight loss
2536415|NCT02654496||Group 3 (Control group)|A control group who has not had Roux-en-Y gastric bypass surgery and are of similar age, gender, body mass index as the gastric bypass groups.
2536445|NCT02654249|Other|THD and mucopexy|Patients will undergo to transanal hemorrhoidal dearterialization with mucopexy (THD)‪ under generla anesthesia.
2536451|NCT02654249|Active Comparator|Ligasure hemorroidectomy|Patients will undergo to Ligasure™ hemorroidectomy under generla anesthesia.
3201828|NCT00907270|Active Comparator|Cholecalciferol: 400 IU/day|Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)
2536611|NCT02653157||Burn patients with VAT or VAP with MDR-GNB|Adult patients with burn and/or inhalation injury requiring intubation
2536680|NCT02652936|Experimental|AF-130 capsule|AF-130 oral capsules administered as a single dose or once daily for 7 days
2536684|NCT02652936|Placebo Comparator|AF-130 matching placebo capsule|Oral placebo capsules to match AF-130 administered as a single dose or once daily for 7 days
3201829|NCT00907270|Experimental|Cholecalciferol 4000 IU/day|Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D
3201830|NCT00907283|Experimental|deferiprone|15 mg/Kg/twice for 1 year
3201831|NCT00907309|No Intervention|Treatment as usual|Participants will receive treatment as usual from their provider.
3201832|NCT00907309|Experimental|iMET|Participants will receive the iMET intervention.
3201833|NCT00907309|Experimental|iMET/TE|Participants will receive the iMET intervention and Technological Extenders (TEs).
3201834|NCT00907322|Experimental|Dimbeon 20 mg|
3201835|NCT00907322|Experimental|Dimebon 40 mg|
3201836|NCT00907322|Experimental|Dimebon 60 mg|
3201837|NCT00907322|Experimental|Placebo|
3201838|NCT00907348|Experimental|Cohorts 1 - 2 - 3 - 4|Chemiotherapy
2535861|NCT02658253|Experimental|Group C1:Primvac 50 µg +alhydrogel|"Group C1: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2535864|NCT02658253|Experimental|Group C2: Primvac 50 µg +GLA-SE|"Group C2: 10 African volunteers 0.5 ml intramuscular injection: 50 µg Primvac+ 2.5 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
2535866|NCT02658253|Placebo Comparator|Group C3: Placebo|"Group C3: 5 African volunteers 0.5 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
2535870|NCT02658253|Experimental|Group D1:Primvac 100 µg +alhydrogel|"Group D1: 10 African volunteers 0.6 ml intramuscular injection: 100µg Primvac+ 0.85 mg Alhydrogel®~Vaccination schedule: D0, D28 and D56"
2535873|NCT02658253|Experimental|Group D2: Primvac 100 µg +GLA-SE|"Group D2: 10 African volunteers 0.6 ml intramuscular injection: 100 µg Primvac+ 2.56 µg GLA-SE~Vaccination schedule: D0, D28 and D56"
2535877|NCT02658253|Placebo Comparator|Group D3: placebo|"Group D3: 5 African volunteers 0.6 ml intramuscular injection: NaCl 0.9% (placebo)~Vaccination schedule: D0, D28 and D56"
3201839|NCT00907387|Active Comparator|Dose A|Dose A RT001
3201840|NCT00907387|Active Comparator|Dose B|Dose B RT001
2536011|NCT02657135|Experimental|History of Traumatic Brain Injury|All participants have a history of TBI. At study outcome participants are provided treatment recommendations that are the result of a consensus meeting of all physician investigators. Follow up care is not provided by this clinical trial.
2536065|NCT02656732|Experimental|coronally advanced flap with amnion chorion membrane|coronally advanced flap was reflected and amnion chorion allograft membrane was placed under the flap as a guided tissue regeneration barrier.
2536067|NCT02656732|Active Comparator|subepithelial connective tissue graft|coronally advanced flap was reflected and subepithelial connective tissue graft was harvested from the palate and placed under the flap.
2536119|NCT02656368|Experimental|Interventional, open label, Safety/Efficacy Study|SEBORRHEAMEDIS Face Cream Interventional 30
2536209|NCT02655952|Experimental|Foxy-5|"Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.~There will be a maximum of 8 dose cohorts. Cohorts 1-4 will be conducted in the United Kingdom and Denmark whereas cohorts 5-8 will only be conducted in Denmark. As doses in cohort 1 and 2 have been investigated in the previous phase I study, cohorts 1+2 and 3 can be run in parallel with dose escalation approved by the DSMB at all times.~DK+UK: Cohort 1: 0.8 mg/kg DK+UK: Cohort 2: 1.3 mg/kg DK+UK: Cohort 3: 1.8 mg/kg DK+UK: Cohort 4: 2.3 mg/kg DK only: Cohort 5: 3.0 mg/kg DK only: Cohort 6: 4.0 mg/kg DK only: Cohort 7: 5.3 mg/kg DK only: Cohort 8: 7.0 mg/kg"
2536264|NCT02655432||Spot photoscreener|Automated vision screener: Spot Vision Screener VS 100, Welch-Allyn. This photoscreener is a portable device, using an infrared light. It is built to detect amblyogenic risk factors. First of all, the spot photoscreener produces a sounds which attracts the child's attention and helps him shift his gaze towards the device, held at 1 meter in front him. The spot then evaluates for refractive errors, anisocoria, strabismus, ptosis and media opacity. The ophthalmologic evaluation consists of the measure of the visual acuity, ocular alignment, anterior and posterior segment. The patient will be cyclopleged with cycloplegic drops and will be refracted to obtain a cyclopleged refraction. This will determine his refractive error.
2536320|NCT02654951|Experimental|Visual + Force Feedback|Participants will complete a set of trials while receiving visual feedback only. After finishing, participants will continue to a new set of trials while receiving force feedback only.
2536322|NCT02654951|Experimental|Force + Visual Feedback|Participants will complete a set of trials while receiving force feedback only. After finishing, participants will continue to a new set of trials while receiving visual feedback only.
2536399|NCT02654704||Healthy Young Adults|Healthy young adults aged 18-25. Vaccination in all cohorts/groups.
2536402|NCT02654704||Asthma Young Adults|Young adults aged 18-25 with asthma. Vaccination in all cohorts/groups.
2536404|NCT02654704||Immunocompromised Young Adults|"Young adults aged 18-25 that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
2536405|NCT02654704||Healthy Older Adults|Healthy older adults aged 55+ Vaccination in all cohorts/groups.
2536408|NCT02654704||Asthma Older Adults|Older adults 55+ with asthma. Vaccination in all cohorts/groups.
2536410|NCT02654704||Immunocompromised Older Adults|"Older adults aged 55+ that are immunocompromised (e.g. following treatment for leukemia).~Vaccination in all cohorts/groups."
2536471|NCT02654197||H.pylori positive children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
2536476|NCT02654197||H.Pylori negative children|Healthy children, 6-12 years old, will undergo screening for H. pylori infection by measuring anti-H. pylori and CagA IgG antibodies in the serum. The status of H. pylori infection will be confirmed using breath test (UBT). Children will be classified as i) H. pylori negative, if they test negative on UBT ii) H. pylori positive- CagA negative, if they test positive on UBT, but lack serum CagA IgG antibodies iii) H. pylori positive- CagA positive, if they are positive for H. pylori on UBT and CagA IgG antibodies.
2536556|NCT02653430|Experimental|Bariatric Surgery|Sleeve Gastrectomy
2536600|NCT02653274|Active Comparator|OATS PORRIDGE|Oats breakfast porridge
2536607|NCT02653274|Active Comparator|RYE PORRIDGE|Rye breakfast porridge
2536614|NCT02653274|Active Comparator|FINGER (RAGI) MILLET PORRIDGE|Finger (ragi) millet breakfast porridge
2536620|NCT02653274|Active Comparator|PEARL (BAJRA) MILLET PORRIDGE|Pearl (bajra) millet breakfast porridge
2536672|NCT02652858|Experimental|Pulse wave's speed observational arm|Whole patients for who the pulse wave's speed are measured during a cardiopulmonary bypass during cardiac surgery
2536739|NCT02652572|Experimental|Granexin® gel plus standard-of-care|Granexin® gel will be applied topically to diabetic foot ulcer(s) on Day 0 (baseline), Day 3, and Day 7. In addition, standard-of-care treatment will be applied to the ulcer(s) at Screening, Day 0, Day 3, and Day 7.
3201841|NCT00907387|Placebo Comparator|Dose C|Dose C Placebo
3201842|NCT00907400|Experimental|1|PN400
3201843|NCT00907400|Active Comparator|2|Naprosyn E
2536025|NCT02657083|Experimental|Glucose control using DreaMed MD-AID|In this group the subjects use a closed loop system (DreaMed Substance Administration Device) that combines glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™), which provides real-time interstitial glucose values, with a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) and computer algorithm, which directs insulin delivery in response to glucose sensor data.
2536028|NCT02657083|Active Comparator|Glucose control using SAP|In this group the subjects use a standard treatment (Sensor Augmented Pump), characterised by glucose monitoring system (S.C wired sensor, named Sof® Sensor™ or Enlite® Sensor™) which provides real-time interstitial glucose values and a modern insulin pump (MiniMed® Paradigm® Veo™, Medtronic) without computer algorithm decisions.
2536136|NCT02656147|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2536139|NCT02656147|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2536144|NCT02656147|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.
2536212|NCT02655861||Ichthyosis|
2536243|NCT02655406|Active Comparator|Compression stockings|Patients randomised to group A will be asked to wear compression stockings for 1 week
2536245|NCT02655406|No Intervention|No compression|Patients randomised to group B will be provided with bandages to wear for 24 hours only, with no further compression afterwards
2536287|NCT02655185||Heart failure|
2536341|NCT02655081|Experimental|Dietary supplement|Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
2536401|NCT02654626|Experimental|KBP-7072: Cohort 1|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2536403|NCT02654626|Experimental|KBP-7072: Cohort 2|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2536406|NCT02654626|Experimental|KBP-7072: Cohort 3|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2536407|NCT02654626|Experimental|KBP-7072: Cohort 4|Healthy Volunteers will receive multiple dose of KBP-7072 and placebo
2536464|NCT02654158||Low-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
2536468|NCT02654158||High-dose of Fuganlin Oral Liquid|"oral~less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
2536500|NCT02653820|Experimental|Chemotherapy patients|Chemotherapy patients will receive reflexology treatment
2536557|NCT02653599|Experimental|TTP273 300 mg daily (150 mg BID)|Two 75 mg tablets of TTP273 administered orally twice daily for 12 weeks
2536560|NCT02653599|Experimental|TTP273 150 mg daily|Two 75mg tablets of TTP273 administered orally once daily and two placebo tablets administered orally once daily for 12 weeks
2536561|NCT02653599|Placebo Comparator|Placebo|Two matching placebo tablets administered orally twice daily for 12 weeks
2536609|NCT02653131|Experimental|DPP-4|The administration of the DPP-4 inhibitor in the form of a pill once per day
2536617|NCT02653131|No Intervention|NO DPP|no therapy
2536675|NCT02652884|Experimental|Group 1|will receive single dose intramuscular corticosteroid deltoid deposit (as phosphate and betamethasone acetate, 2 mL) for immediate postintubation.
2536677|NCT02652884|Placebo Comparator|Group 2|will receive 2 ml saline 0.9% NaCl in deltoid immediately postintubation.
3167773|NCT00542516|Active Comparator|Ringer's lactate|Pre-expansion with Ringer's lactate
2536979|NCT02650635|Experimental|Treatment (CTX, pegfilgrastim, TLR8 agonist VTX-2337)|Patients receive cyclophosphamide IV over 30 minutes on day 1, pegfilgrastim SC on day 2, and TLR8 agonist VTX-2337 SC on day -6 of course 1 only and on days 9 and 16. Patients achieving CR, PR, or SD may continue therapy every 21 days for 3 additional courses. Treatment may then continue in the absence of disease progression or unacceptable toxicity.
3167774|NCT00542529|Placebo Comparator|Cohort 1|Placebo or 2.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
3167775|NCT00542529|Placebo Comparator|Cohort 2|Placebo or 4.0 mg/kg of Imprime PGG dosed in 7 different treatment regimens in combination with G-CSF for up to 4 consecutive days.
3167776|NCT00542555|Placebo Comparator|Placebo bid|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
3167777|NCT00542555|Experimental|Naproxcinod 375 mg bid|
3167778|NCT00542555|Active Comparator|Naproxen 500 mg bid|
3167779|NCT00542555|Experimental|Naproxcinod 750 mg bid|
3167780|NCT00542568|Experimental|1|Cohort 1 (Low Dose group) 18-25 IU/kg/day
3167781|NCT00542568|Experimental|2|Cohort 2 (Intermediate Dose group): 35-45 IU/kg/day
3167782|NCT00542568|Experimental|3|Cohort 3 (High Dose group): 55-65 IU/kg/day
3167783|NCT00542581|Experimental|The Acrysof toric SN60T3 IOL|Multifocal Intraocular Lens
3167784|NCT00542633|Experimental|A|VIAject™
3167785|NCT00542633|Active Comparator|B|Regular Human Insulin
3167786|NCT00542685|Experimental|PD 0332334 300 mg BID|
3167787|NCT00542685|Placebo Comparator|Placebo BID|
3167788|NCT00542685|Experimental|PD 0332334 225 mg BID|
3167789|NCT00542685|Experimental|PD 0332334 175 mg BID|
3167790|NCT00542698|No Intervention|Control|Control group uses 90 minutes of standard diabetes education/ 7 days using the International Diabetes Center curriculum & update phone call at 4 weeks.
3167791|NCT00542698|Experimental|Intervention|Interventional group received standard diabetes education, CGMS monitor, and extra educational topics including CGMS counceling.
3167792|NCT00542724|Experimental|A|VIAject™
3167793|NCT00542724|Active Comparator|B|Regular Human Insulin
3167794|NCT00542737|Active Comparator|Early Intervention Group|
3167795|NCT00542737|Active Comparator|Delayed Intervention Group|
3167796|NCT00542776||1|IBD patients on immunosuppressive therapy
3201844|NCT00907413|Experimental|ERCP and PDT|Endoscopic Retrograde Cholangio Pancreatography (ERCP) and stenting combined with Photodynamic Dynamic Therapy ERCP and PDT
2536004|NCT02657109|Active Comparator|Control|Participants are submitted to cardiac rehabilitation protocol of the hospital where it will be conducted the study, which consists in respiratory exercises of 3 series Inspirations Maximum Sustained for 10 reps, 3 sets of 20 repetitions metabolic exercises with dorsiflexion and plantar flexion and ankle and wrist extension and fingers of the upper limbs. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of postoperative and on the fifth postoperative day
2536005|NCT02657109|Active Comparator|Early mobilization|Participants performed exercise in cycle ergometer of lower Limbs, pedaling for 20 consecutive minutes at a moderate level with Heart Rate Assessment and the Borg scale to evaluate the Voluntary Comfort. Assessment of heart rate varibility and oxidative stress carried out before the heart valve replacement surgery , the first day of oepratório post and on the fifth postoperative day
2536091|NCT02656823|Other|ANKYLOS C/X 6.6 mm implants|ANKYLOS C/X 6.6 mm implants
2536142|NCT02656186|Experimental|Single-arm pretest-posttest|In this study, the subjects served as their own controls. Subjects who were eligible based on inclusion criteria first entered into a 2-week pre-intervention period, during which they received nutrition counseling to keep their routine dietary habits. This was followed by an intervention period, during which an oral nutritional supplement was used over a period of 2 weeks.
3201845|NCT00907413|Active Comparator|ERCP alone|Endoscopic Retrograde Cholangio Pancreatography (ERCP) with stenting alone
2536304|NCT02655172|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
2536307|NCT02655172|Active Comparator|Control group|healthy patients who will perform cognitive tasks
2536325|NCT02654847|Active Comparator|Norepinephrine 3 micrograms/mL|1mL of a solution of norepinephrine, containing 3 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536327|NCT02654847|Active Comparator|Norepinephrine 4 micrograms/mL|1mL of a solution of norepinephrine, containing 4 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536331|NCT02654847|Active Comparator|Norepinephrine 5 micrograms/mL|1mL of a solution of norepinephrine, containing 5 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536337|NCT02654847|Active Comparator|Norepinephrine 6 micrograms/mL|1mL of a solution of norepinephrine, containing 6 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536343|NCT02654847|Active Comparator|Norepinephrine 7 micrograms/mL|1mL of a solution of norepinephrine, containing 7 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536347|NCT02654847|Active Comparator|Norepinephrine 8 micrograms/mL|1mL of a solution of norepinephrine, containing 8 micrograms/mL in normal saline, will be given intravenously to a patient if her blood pressure decreases from baseline.
2536444|NCT02654093|Experimental|Group A|A → B → C / A: Cholecalciferol, B: Raloxifene, C: Cholecalciferol+Raloxifene
2536448|NCT02654093|Experimental|Group B|A → C → B
2536455|NCT02654093|Experimental|Group C|B → A → C
2536456|NCT02654093|Experimental|Group D|B → C → A
2536457|NCT02654093|Experimental|Group E|C → A → B
2536458|NCT02654093|Experimental|Group F|C → B → A
2536527|NCT02653716|Active Comparator|Case Management|CM
2536532|NCT02653716|Experimental|New Orleans Intervention Model|NIM
2536586|NCT02653378|Active Comparator|DIET ARM|A 25% energy depletion (daily for 3 days) induced by reducing the amount of energy intake that would otherwise keep the individual in energy balance.
2536588|NCT02653378|Active Comparator|EX ARM|A 25% energy depletion (daily for 3 days) induced by performing aerobic exercise at 50% of V02max.
2536679|NCT02652988|Active Comparator|Active-tDCs|17 patients will receive Active-tDCS intervention (2mA, 30 min) at home.
2536683|NCT02652988|Sham Comparator|Sham-tDCS|17 patients will receive Sham-tDCS intervention (2mA, 30 min) at home.
3201846|NCT00907452|Active Comparator|melphalan-prednisone-thalidomide|
3201847|NCT00907452|Active Comparator|lenalidomide-dexamethasone|
3201848|NCT00907465||Calibration study|These individuals were used to develop cut points for sedentary behavior using accelerometers and a metabolic chamber.
3201849|NCT00907491||A|
3201850|NCT00907504|Experimental|CP-751,871 + Gemcitabine + Cisplatin|investigational arm
3201851|NCT00907504|Active Comparator|Gemcitabine + Cisplatin|standard of care
2536899|NCT02651311|Experimental|Block|"ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg.~Fentanyl in postanesthesia care unit(PACU), Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4."
2536903|NCT02651311|Placebo Comparator|No block|Fentanyl in PACU, Ibuprofen in ward when pain scale (FLACC) is equal to or more than 4.
2536964|NCT02650739||SS-OCTdetermined group|Eyes with macular hole surgery that the postoperative prone positioning was discontinued after detecting a closure by SS-OCT
2536967|NCT02650739||Control group|Eyes with macular hole surgery that the halting of the prone position was determined by the surgeon
3201852|NCT00907530|Active Comparator|MULTIHANCE|gadobenate dimeglumine
2537095|NCT02649517|Other|chronic inflammation|All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
2537149|NCT02649244|Experimental|The Family Caregiver Training Program|The experimental group received a 2 hour intervention training on activities of daily throughout the early, middle, and late stages of dementia including communication, eating/feeding, nutrition, bathing, grooming, dressing, toileting, and transferring.
2537159|NCT02649244|No Intervention|Standard Care|The control group received a 1 1/2 hour training, however the information was based on what has been deemed standard care by the Alzheimer's Association.
2537197|NCT02649075|Active Comparator|SBI 10 g BID|Serum-derived Bovine Immunoglobulin / Protein Isolate (SBI) 10.0 grams twice per day
2537202|NCT02649075|Placebo Comparator|Placebo BID|Placebo w/control protein
3201853|NCT00907530|Active Comparator|GADOVIST|gadobutrol
2535965|NCT02657512|Experimental|Arm C|". Period  rivaroxaban and activated charcoal 2 hours after rivaroxaban administration~Washout period (at least 6 days)~Period   rivaroxaban and activated charcoal 8 hours after rivaroxaban administration~Washout period (at least 6 days)~Period  rivaroxaban alone"
2536014|NCT02657057|Experimental|Transcutaneous Tibial Nerve Stimulation|TENS SNS therapy is performed as follows; patient is asked to sit with legs slightly bent and an adhesive electrode is attached transcutaneously 5cm cephalic to either the right or left medial malleolus (subject choice). A surface electrode is placed on the medial surface of the ipsilateral calcaneum and both electrodes are connected to a low voltage electronic stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
2536017|NCT02657057|Active Comparator|Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; patient is asked to sit with legs slightly bent. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial surface of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage electrical stimulator. The current is then set to the highest level tolerable to the subject (0-20 mA) and the subject undergoes therapy for 30 minutes and 12 weeks (once-a-week session). Data are completed at baseline, after half therapy and after 12 weeks therapy.
2536059|NCT02656771|Active Comparator|Echo Bi-Metric THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It is a relatively new implant that is now in routine clinical use. The stem uses many of the features of the known and used Integral® and Bi-Metric® hip stems while integrating new design features to further enhance clinical performance such as a reduced neck geometry to allow for increased ROM and decreased risk of neck impingement, a polished neck designed to reduce debris should impingement occur and a polished bullet-shape distal tip to reduce distal stresses."
2536061|NCT02656771|No Intervention|Bi-Metric Porous Primary THA stem|"Uncemented titanium alloy press-fit stem with a proximal plasma spray porous titanium coating designed for bone ingrowth and the distal part of the stem has a roughened titanium surface for bone on-growth.~It was introduced in 1984 and have shown good clinical results and excellent stem survival in register studies"
2536107|NCT02656433|Placebo Comparator|Placebo Group|Receive treatment with physiotherapy
2536108|NCT02656433|Experimental|Experimental or tRNS Group|Receive treatment with physiotherapy plus Transcranial Random Noise Stimulation (tRNS)
3201854|NCT00907543|Other|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy treatment
3201855|NCT00907543|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy treatment
2536230|NCT02655601|Experimental|Radiation Therapy, TMZ and BMX-001|Patients will receive standard of care radiation therapy plus temozolomide (TMZ). BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly maintenance doses at half the loading dose for a total of 8 weeks. A total of 80 subjects will receive BMX-001 in this phase.
2536232|NCT02655601|Active Comparator|Radiation Therapy and TMZ|In this arm, one-half of the study subjects will not receive BMX-001 but will undergo all components of standard therapy (radiation therapy plus temozolomide [TMZ]). A total of 80 subjects will be in this study arm.
3201856|NCT00907582|Experimental|ASCT in relapsed APL|autologous hematopoietic cell transplantation for patients with relapsed APL after achieving molecular remission
3201857|NCT00907595|Active Comparator|Ramelteon|Subjects randomized to Ramelteon
2536494|NCT02653898|Active Comparator|Focused Screening and Treatment + ITU|Approved antimalarial based on the malaria species identified on the monthly follow ups, following national treatment guidelines in Cambodia AND Insecticide Treated Uniform with 40% Permethrin; DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
2536495|NCT02653898|Active Comparator|Focused Screening and Treatment + sITU|Approved antimalarial based on the malaria species identified at the monthly follow up and following national treatment guidelines in Cambodia AND sham treated uniform. DHA-PIP or Artesunate + Mefloquine based on the malaria species, single dose Primaquine 15 mg in subjects with P.f uncomplicated malaria or Primaquine 45 mg weekly x 8 weeks in G6PD-deficient volunteers, or Primaquine 15 mg daily for 14 days in G6PD-normal volunteers.
2536496|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + ITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive insecticide treated uniforms with 40% Permethrin
2536497|NCT02653898|Active Comparator|Monthly Malaria Prophylaxis + sITU|Monthly DHA-PIP + weekly Primaquine 22.5 mg for 3 months; All subjects will also receive sham treated uniforms
2536559|NCT02653612|Experimental|Experimental Arm|This cohort will receive the contrast agent
2536598|NCT02653248|Experimental|Cohort 1|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 8Gy. Total Dose: 40Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
2536603|NCT02653248|Experimental|Cohort 2|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 9Gy. Total Dose: 45 Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
3201858|NCT00907595|Placebo Comparator|Placebo|Subjects randomized to placebo
3201859|NCT00907608|Experimental|1|Receive Darbepoetin alfa
3201860|NCT00907608|No Intervention|2|
3201861|NCT00907660|Active Comparator|Full Dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 2 meals per day of portion-controlled foods (shakes and entrees)
3201862|NCT00907660|Experimental|Half dose|Provision of 8 weight loss counseling sessions, calorie guide, pedometer, meal plan, and 1 meal per day of portion-controlled foods (shakes and entrees)
3201863|NCT00907673|Active Comparator|Patient condition pre-implant|
3201864|NCT00907686||LBWIs of CMV-positive mother|LBWIs born to CMV-positive mothers
2535973|NCT02657473|Active Comparator|TIS 300mg once daily|Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months
2535977|NCT02657473|Placebo Comparator|Placebo once daily|Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months
2536040|NCT02656927|Experimental|Yoga Condition|
2536042|NCT02656927|Placebo Comparator|Wait-list Control Condition|
2536086|NCT02656589||Herceptin probable sensitive group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable sensitive group
2536088|NCT02656589||Herceptin probable resistant group|Plasma microRNAs will be collected using microRNA extraction kit according to manufacturer's instructions; and their expression levels are analyzed by quantitative polymerase chain reaction (qPCR).According to microRNAs - herceptin predictive model(reported by our team), the patients will be considered as Herceptin probable resistant group
2536211|NCT02655705|Active Comparator|Cyclosporine A|Cyclosporine 200 mg/day (male) and 150 mg/day (female) orally, divided twice daily for 16 weeks
2536214|NCT02655705|Active Comparator|Methotrexate|Methotrexate was started with 10 mg/week orally as a single dose, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
2536277|NCT02655328|Experimental|athlete under asthma treatment|athlete suffering from asthma blood sample urine sample
2536372|NCT02654665|Experimental|Liraglutide|Liraglutide will be administered once daily by subcutaneous injection at a starting dose of 0.6 mg, increasing at 0.6 mg/week increments to a maximum of 3.0 mg over the next 6 weeks, as tolerated.
2536377|NCT02654665|Active Comparator|Bariatric Surgery|Subjects will have outcomes measured within 28 days before surgery. Post-operative management and frequency of follow-up visits will be decided by the bariatric surgeon. Study visits for biochemical and endothelial function testing; MRI and liver biopsy and / or fibroscan will follow the same schedule as that of the lifestyle and liraglutide arms. Target weight loss for the first 26 weeks post-surgery is at least 30% of excess body weight.
2536378|NCT02654665|Active Comparator|Diet modification and exercise|Exercise will be used to induce and maintain weight loss in a 26-week Weight Management Program. Each subject will follow an aerobic exercise prescription of moderate intensity (60-75% maximum heart rate) to expend 2000-3000 kcal/week, lasting 30-60 minutes each session (over 5-7 sessions). Subjects will be instructed by sports trainers, compliance reviewed and adjusted if necessary to maintain the targeted total energy expenditure to produce weight loss of at least 7% over 26 weeks.
2536430|NCT02654405|Experimental|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
2536432|NCT02654405|Placebo Comparator|Placebo|Placebo capsule with 2 mg of sodium butyrate for making taste or odor, (9 mg/day)
3167797|NCT00542776||2|IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
3167798|NCT00542802|Experimental|LEV|Levetiracetam
2536510|NCT02653742|Experimental|Ketorolac|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use.
2536517|NCT02653742|Experimental|Fentanyl|Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
2536523|NCT02653742|Experimental|Ketorolac and Fentanyl|Ketorolac 1mg/kg sublingual, in the form of Ketorolac Tromethamine solution for intravenous/intramuscular use and Fentanyl 2mcg/kg intranasal, in the form of Fentanyl Citrate solution for intravenous/intramuscular use.
2536566|NCT02653404||Cases|"A blood sample necessary to perform QFT-GIT will be taken, together with other routine blood samples, from children with following diagnosis:~latent tuberculous infection: active TB contact, TST positive, lack of clinical and RX signs of active-TB~active TB: clinical and radiologic evidences of active-TB, positivity to microbial tests to BK~not infected: patients evaluated as TB contacts, with negative TST and negative clinical/radiological/microbial results for TB."
2536618|NCT02653222|Experimental|Renal sympathicolysis|"The patient will have:~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography~Blood test~Renal sympathicolysis~Ambulatory Blood Pressure Monitoring~Magnetic Resonance Angiography"
2536674|NCT02652793|Experimental|Experimental|All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.
2536731|NCT02652507|Other|Anesthesia for MRI|"All patients will receive the same drugs.~A loading dose of dexmedetomidine of 2 mcg/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h. Bolus dose 2 mg/kg of ketamine will be given after the initial set of research images have been taken."
2536798|NCT02652130|Experimental|Safety population|All subjects who participated in Protocol MSB-GVHD001 and received at least one remestemcel-L infusion in that protocol.
2536869|NCT02651441|Experimental|D-CIK|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines,patients will receive 3 cycles of D-CIK treatment.
2536878|NCT02651441|Active Comparator|Chemotherapy|After accepting chemotherapy of Gemcitabine and Cisplatin according to NCCN guidelines, patients will just regularly follow up.
2536912|NCT02651051|Sham Comparator|High Fat Breakfast Meal|High fat breakfast meal served without addition of whey protein isolate
2536920|NCT02651051|Experimental|High Fat Breakfast Meal + Whey Protein|High fat breakfast meal served with addition of whey protein isolate
2536953|NCT02650687||Elective Non Cardiac Surgical Patients|65 years of age and older
2536985|NCT02650518|No Intervention|Control|Subject receives the standard of care that is provided by the primary team taking up his/her case.
2536988|NCT02650518|Experimental|Catheter change+Short-course Antibiotics|
2537067|NCT02650180|Other|Soberlink Cellular Device|Soberlink Cellular Device: a Breath Alcohol Analyzer
3167799|NCT00542802|Active Comparator|CAR|Carbamazepina
3167800|NCT00542841|Experimental|1|
3167801|NCT00542854||MP3|4 different brands of MP3 players will be tested at 3 distances from pacemakers and ICDs.
3167802|NCT00542893|Experimental|Group 1|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
3167803|NCT00542893|Experimental|Group 2|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
3167804|NCT00542906|Other|1|healthy volunteers
3167805|NCT00542932|No Intervention|I|
3167806|NCT00542932|Active Comparator|II|Exercise
2536024|NCT02656784|Experimental|Trial-Based Cognitive Therapy (TBCT)|"Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach, based on the work of Franz Kafka The Trial and developed by Professor Irismar Reis de Oliveira at Federal University of Bahia, Brazil. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All individuals in the group will be submitted to MRI"
2536027|NCT02656784|Experimental|Behavioral Therapy (ERP)|The Behavioral Therapy is an intervention of first choice for treatment of OCD , which employs the technique of Exposure and Response Prevention (ERP) , considered the gold standard to the disorder. The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All individuals in the group will be submitted to MRI
2536030|NCT02656784|No Intervention|Control Group|The control group consisted of individuals without OCD, matched with the experimental group in terms of gender,age and education. In this group are not included in individuals in psychotherapeutic care and with a history of neurological or psychiatric disorder; however, all them will be submitted to MRI .
2536073|NCT02656641|No Intervention|Control|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will not complete any scales during other sessions.
2536077|NCT02656641|Experimental|Continuous Client Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will review and discuss their results and at the beginning of each session.
2536080|NCT02656641|Experimental|Continuous Self Feedback|Clients will complete symptom and quality of life scales before their first session and before their last or tenth session, whichever occurs first. Clients will then complete symptoms scales, specifically the Patient Health Questionnaire-9 and Generalized Anxiety Disorder 7-Item Scale before each other session. The treating clinician will not have access to these results.
3201865|NCT00907686||CMV Sero-negative & Sero-postive LBWIs|LBWIs of CMV sero-negative & sero-positive mothers
3201866|NCT00907712|No Intervention|cardiovascular|cardiac echo
3201867|NCT00907725|Other|1|serum BhCG follow-up
3201868|NCT00907725|Other|2|ultrasonographic follow-up
3201869|NCT00907751|Experimental|1|Microangiopathic hemolytic anemia (< 12 g/dL) with thrombocytopenia (<50 G/L)
3201870|NCT00907764|Experimental|Regadenoson alone|
2536330|NCT02654938|Experimental|Mobilan (M-VM3)|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Investigational Drug Product
2536333|NCT02654938|Placebo Comparator|Placebo|Patients with histologically verified non-metastatic prostate cancer (stage 1 or 2) treated with Placebo (Glucose 5%)
2536373|NCT02654561|Placebo Comparator|Saline|
2536375|NCT02654561|Experimental|Heparin|If severe sepsis with suspected DIC is diagnosed, the Heparin sodium(2ml:12500 units) will be administered intravenously continuously for 24 hours. The course of treatment will last 7 days or until the death or discharge.
2536446|NCT02654236|Placebo Comparator|Placebo|Heavy Drinkers on placebo
2536449|NCT02654236|Experimental|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 4 weeks.
2536454|NCT02654236|No Intervention|Non-drinking Controls|Non-drinking healthy controls
2536502|NCT02653950|Active Comparator|Traditional|a control arm of patients undergoing traditional septoplasty for DNS
2536505|NCT02653950|Experimental|Endoscopic|patients undergoing endoscopic septoplasty.
2536558|NCT02653573|Experimental|Intervention|Telephone health coaching over 3 months with supporting education materials.
2536587|NCT02653261|Experimental|Tranexamic Acid|Tranexamic Acid (TXA): bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
2536590|NCT02653261|Placebo Comparator|Placebo|An equal volume of saline
3201871|NCT00907764|Experimental|Regadenoson with exercise|
2536770|NCT02652169|Experimental|Study arm 1 - PRF plus amikacin and teicoplanin|PRF mixed with amikacin and teicoplanin is sprayed on the patients' ulcer
2536771|NCT02652169|Experimental|Study arm 2 - PRF plus normal saline|PRF mixed with normal saline is sprayed on the patients' ulcer
2536772|NCT02652169|Experimental|Study arm 3 - PRF mixed with PHMB plus Macrogolol|PRF mixed with polyhexanide and macrogolol is sprayed on the patients' ulcer
2536773|NCT02652169|Active Comparator|Study arm 4 - Acticoat 7|A silver gauze (Acticoat 7®) is applied to the patients' ulcer
2536861|NCT02651649|Experimental|Parturients with FGR/OSA who use CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for Continuous Positive Airway Pressure (CPAP). Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
2536864|NCT02651649|No Intervention|Parturients with FGR/OSA and no CPAP|Subjects who meet criteria for FGR and OSA will be referred to a pulmonologist for referral for CPAP. Women who agree with CPAP and comply with therapy will be compared to women who do not wear CPAP (eg. non-compliance).
3201872|NCT00907764|Experimental|Regadenoson with contrast agent|
2536986|NCT02650557||CSF group|consecutive patients with angiographically documented CSF
2536989|NCT02650557||control group|age- and gender-matched control subjects
2537043|NCT02650232|Other|Young Healthy Volunteers|We will evaluate in this group (18 - 40 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
2537048|NCT02650232|Other|Old Healthy Volunteers|We will evaluate in this group (50 - 80 y) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
2537051|NCT02650232|Other|Patients with heart failure|We will evaluate in this group (50 - 80 y + Heart failure) the use of the SOMNOtouch system to quantify the spontaneous baroreflex sensitivity
3201873|NCT00907764|Experimental|Regadenoson with contrast agent (perfusion)|
3201874|NCT00907790|Experimental|Comprehensive Self-Management (CSM)|"Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS~--------------------------------------------------------------------------------"
2536181|NCT02655926|Active Comparator|VC/VS Arm|Participants would only have VC/VS deep brain stimulation switched on at optimal settings for that participant for 12 weeks.
2536233|NCT02655523|Active Comparator|Bupivacaine+Triamcinolone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 40 mg of triamcinolone.
2536234|NCT02655523|Active Comparator|Bupivacaine+Dexamethasone|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL 4 mg of dexamethasone.
2536235|NCT02655523|Placebo Comparator|Bupivacaine+Saline|An ultrasound-guided C2 nerve block with 2 mL of 0.5% bupivacaine plus 1 mL of preservative free normal saline.
2536328|NCT02655120|Experimental|Bone Marrow +BMP7|The drilling is completed by a joint supply of autologous marrow unconcentrated and recombinant BMP7 (OP1)
2536334|NCT02655120|Placebo Comparator|Drilling|Group I: a simple drill is practiced
3201875|NCT00907790|Other|Usual Care (Control Group)|Includes the usual care provided by the person and their health care provider.
2536433|NCT02654379||Cohort|Cohort consisting of participants who are in the center to receive an infusion for rituximab for a non-oncology indication.
2536528|NCT02653729|Experimental|Espidone, Olepra, Donu & C.B.T|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day and Olepra tablet 5 mg by mouth at night and C.B.T 6 session program 45 minutes session after every 15 days
2536533|NCT02653729|Active Comparator|Espidone, Olepra & Donu|Espidone tablet 2 mg and Donu 10 mg by mouth twice a day Olepra tablet 5 mg by mouth at night
2536610|NCT02653313|Experimental|ParvOryx|ParvOryx given intravenously on four consecutive days (day 1 to 4) and intrametastatic six to thirteen days thereafter (day 7, 10 or 14).
2536644|NCT02652910|Experimental|IL-2 programmed CD19.CAR-T cells|Administrated with IL-2 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2536647|NCT02652910|Experimental|IL-7/IL-15 programmed CD19.CAR-T cells|Administrated with IL-7/IL-15 programmed CD19.CAR-T cells on day 0,1,2 in the lympho-depleted patients
2536695|NCT02652637|Experimental|Mechanical and oral antibiotic bowel preparation|Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.
2536698|NCT02652637|No Intervention|No bowel preparation|No mechanical bowel preparation or oral antibiotics.
2536751|NCT02652377|Experimental|EDP-494 SAD Cohorts|EDP-494, oral 50 mg, 100mg, 200mg, 400mg and 800 mg, capsules, once daily in one single administration
2536753|NCT02652377|Experimental|EDP-494 MAD/POC Cohorts|EDP-494, oral 200mg, 400mg and 800 mg, capsules, once daily for 14 days
2536758|NCT02652377|Placebo Comparator|EDP-494 SAD Placebo Cohort|
2536759|NCT02652377|Placebo Comparator|EDP-494 MAD/POC Placebo Cohort|
2536789|NCT02651961|Active Comparator|One stage exchange|One stage exchange of the chronically infected implant
2536795|NCT02651961|Active Comparator|Two stage exchange|Two stage exchange of the chronically infected implant
2536875|NCT02651714|Placebo Comparator|Placebo|Oral
2536877|NCT02651714|Experimental|Tradipitant|Oral
2536896|NCT02651090|Experimental|sonazoid|treatment arm with sonazoid
2536913|NCT02650934||Adverse remodelling|EF below 40% following MI and remain below 40% after reperfusion
2536921|NCT02650934||not adverse remodelling|EF below 40% following MI and remodelling after reperfusion or EF above 40 % following MI
2536949|NCT02650674|Experimental|Product A: NP-0148|Cereal product belVita Milk & Cereals - High in SDS
2536956|NCT02650674|Experimental|Product B: NP-0149|Cereal product belVita Honey & Nuts - High in SDS
2536958|NCT02650674|Experimental|Product C: NP-0150|Cereal product belVita Mixed Berry - High in SDS
2536960|NCT02650674|Experimental|Product D: NP-0151|Cereal product Kellogg's Corn Flakes - Low in SDS - Low in fat
2536961|NCT02650674|Experimental|Product E: NP-0152|Cereal product Kellogg's Trésor Duo Choco - Low in SDS
2536962|NCT02650674|Experimental|Glucose reference|Glucose solution performed on three occasions
2537001|NCT02650375|Experimental|Metatinib Tromethamine|
2537022|NCT02650076|Experimental|Healthy|
2537060|NCT02649920|Experimental|Cervical ripening balloon|Prospective
2537063|NCT02649920|Active Comparator|Dinoprostone|Retrospective
2537083|NCT02649673|Experimental|LCL161+topotecan+Pegylated GCSF (PEG-GCSF)|"Dose Escalation: Groups of 3-6 patients per dose level (DL) will initiate treatment in escalating doses until the maximum tolerated dose (MTD) is reached. MTD is defined as the highest combination of doses that results in dose-limiting toxicities for 2 of 6 patients per dosing group.~LCL161: orally, on Days 1, 8, 15 of each 21-day cycle. Maximum dose not to exceed 1200 mg/week.~topotecan: orally, for first 5 days of each 21-day cycle. Maximum dose not to exceed 2.3 mg/m2 per day.~Pegylated GCSF (PEG-GCSF) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.~Dose Expansion: 24 additional patients will be treated at the MTD in 2 cohorts (SCLC-12 patients; ovarian cancer-12 patients)"
2537150|NCT02649270|Experimental|Group1|10 Psoriasis patients,T1h 0.2mg/kg,only single dose administration at week 1.
2537160|NCT02649270|Experimental|Group2|10 Psoriasis patients,T1h 0.4mg/kg ,first administration at week 1 and continous administration from fifth week for 9 weeks.
2537165|NCT02649270|Experimental|Group3|10 Psoriasis patients,T1h 0.8mg/kg,first administration at week 1 and continous administration from fifth week for 9 weeks.
2537167|NCT02649270|Experimental|Group4|"10 Psoriasis patients,T1h 1.6mg/kg,first administration at week 1 and biweekly from fifth week for 9 weeks.~."
3167807|NCT00542945|Experimental|A|Heart Failure nonischemic ethiology
3167808|NCT00542945|Active Comparator|B|
2537481|NCT02647229|Active Comparator|Isosmotic bowel cleansing preparation|Isosmotic solution ingested prior to colonoscopy
3173966|NCT00618085|Active Comparator|2|"All patients will receive the occupational therapy and physiotherapy normally given in their setting.~In addition; the control group will receive 2 DVDs for 35 minutes in total. These will show background information on their condition, explaining the importance of practice of activities, and on the principles of motor learning and phased movement which underlie most therapy.The research therapist will also attend the first session with the physiotherapist and with the occupational therapist to control for attention. The total amount the physiotherapist and occupational therapist spend with the patients should be the same in both groups."
2536191|NCT02655913|Experimental|vitamin C+ mEHT+ supportive care|"Patients will be allocated into 3 Vitamin C infusion dosage groups:~1g/kg.d,1.2g/kg.d,1.5g/kg.d;3 times a week for 8 weeks(25 infusions);concurrent with Modulated Electro-Hyperthermia (mEHT): 150W x 60 min/session,3 times a week for 8 weeks (25 sessions);together with supportive care."
2536199|NCT02655913|Placebo Comparator|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
3201876|NCT00907816||intervention|PCPs at MGH who receive display of utilization and quality during computer order entry
3201877|NCT00907816||control|
2536436|NCT02654366|Experimental|Community Supported Risk Reduction Group|Six weekly sessions will be scheduled during daytime and evening hours to accommodate the daily schedules of BNEP registrants and their CSPs. Each session meets for 60 minutes. Groups will consist of 5-6 BNEP registrant-CSP dyads (10-12 individuals). While BNEP registrants and CSPs attending the group together will receive an attendance incentive, BNEP registrants attending without a CSP will not earn one. The group leader will follow a manual that includes a structured outline. The group manual content combines risk reduction / treatment readiness and community outreach approaches. Following the introduction, each group session is divided into two components: 1) Risk Reduction and Treatment Readiness (30 min) and 2) Community Outreach skills (20 min).
3201878|NCT00907829|Active Comparator|Arm 1|persons with severe hand impairment following hemiparetic stroke
3201879|NCT00907829|Active Comparator|Arm 2|persons with severe hand impairment following hemiparetic stroke
3201880|NCT00907842|Experimental|mesh placement|
2536676|NCT02652871|Experimental|LY2510924 + Idarubicin + Cytarabine|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients. On Day 8, LY2510924 administered after bone marrow aspiration and/or biopsy is performed.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase.~Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days.~Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
3201883|NCT00907894|Experimental|Stratum 1|
2536802|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
2536809|NCT02651870|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
2536814|NCT02651870|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
2536848|NCT02651519|Sham Comparator|Control|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with saline.
2536852|NCT02651519|Experimental|stellate-ganglion block|All patients undergoing breast cancer operation will be the treatment intervention with general anesthesia as an adjunct to stellate-ganglion block with 0.25% ropivacaine hydrochloride.
2536910|NCT02651207||local anaesthetic spray group|women will either chose the above, ethyl chloride spray prior to having their contraceptive implant fitted or the below injection. This comes in a canister and a maximum of 5 spray for 5 seconds will be applied topically to the skin at the site of the contraceptive implant insertion
2536918|NCT02651207||local anaesthetic injection group|women will either chose ethyl chloride spray prior to having their contraceptive implant fitted or the injection, subcutaneous 1% lidocaine, usually a dose of about 1-2 mls to the area skin where the contraceptive implant is to be inserted.
2536941|NCT02650752|Experimental|Lapatinib in Tandem With Capecitabine|A minimum of one patient at each dose level will be enrolled. Patients will receive a 4 week treatment cycle consisting of lapatinib 3 day on/11 day off in tandem with capecitabine 7 day on/7 day off with lapatinib. Both drugs will be administered orally as outpatient. Safety, toxicity, and DLT will be assessed weekly during the cycle 1 (first 4 weeks). Each patient will be monitored during cycle 1 prior to enrolling the next patient to the next higher dose level. Dose escalation will take place if no DLT or less than two occurrences of grade 2 toxicity (except those listed below) is observed within a given patient. In the event that a second instance of separate grade 2 toxicity (except those listed below) is noted, the cohort will be expanded to 3 patients at the same dose level and the study will revert to the standard 3+3 design with 3 patients per cohort. There will be no intra-patient dose escalation.
2537004|NCT02650492|Experimental|imILT|Immunostimulating Interstitial Laser Thermotherapy (imILT)
2537173|NCT02649452|Experimental|vibration|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between. After exercise, this group had to undergo vibration exercise by using whole body vibration machine.
2537175|NCT02649452|Active Comparator|Exercises|Flexibility test of Active Chest Flexibility and Shoulder Reach Flexibility tests will be performed before and after the experiment to determine their improvement in the flexibility of the pectoral muscles. After measuring the flexibility, two stretching exercises of one-arm doorway stretch and office chest stretch will be performed. it will be done twice, 30 second each with 10 second rest in between
3201884|NCT00907894|Experimental|Stratum 2|
3321414|NCT02018679|Experimental|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
3201885|NCT00907894|Experimental|Stratum 3|
2536198|NCT02655796|Experimental|Moderate/High Risk|Participants assessed as moderate/high risk of falling according to the CDC Algorithm for Fall Risk Assessment
2536203|NCT02655796|Experimental|Low Risk|Participants assessed as low risk of falling according to the CDC Algorithm for Fall Risk Assessment
3201886|NCT00907920||Correlative studies|"Tumor DNA samples are examined by mutation analysis for germline and somatic mutations in the ALK tyrosine kinase domain. Samples are analyzed by whole genome amplification using polymerase chain reaction and then sequenced for DNA alterations in the entire ALK coding sequence. Samples are also examined for SNPs by polymorphism analysis. Exploratory multivariable analysis is performed to test for the prognostic ability of ALK mutations in the presence of other known prognostic variables (i.e., age, International Neuroblastoma Staging System stage, MYCN status, International Neuroblastoma Pathology Classification, and diploidy).~A subset of tumor DNA samples from high-risk patients will be resequenced for DNA alterations to determine whether or not additional regions in ALK, outside of the tyrosine kinase domain, are prone to mutations and should be sequenced in a larger panel."
2536356|NCT02654834||Pediatric Operating Room (OR) Staff|OR Staff exposed to nitrous oxide, and other volatile anesthetics
2536357|NCT02654834||Pediatric Intensive Care Unit (ICU) Staff|ICU Staff unexposed to any volatile anesthetics
2536371|NCT02654574|Experimental|Face-to-face collection followed by collection by phone|Reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, followed by the collection of IADL by phone, one month later.
2536376|NCT02654574|Experimental|Collection by phone followed by face-to-face collection|Collection of IADL by phone, followed by the collection of the IADL questionnaire using the reference procedure i.e IADL collected during a face-to-face interview at the Memory Clinic, one month later.
2536417|NCT02654431||Breast Cancer patients|Breast cancer patients
2536420|NCT02654431||women with breast cancer|women with breast cancer
2536424|NCT02654431||Cancer patients|Cancer patients
2536453|NCT02654119|Experimental|Treatment (cyclophosphamide, paclitaxel, trastuzumab)|"SYSTEMIC THERAPY: Patients receive cyclophosphamide IV over 1 hour, paclitaxel IV over 3 hours, and trastuzumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE TRASTUZUMAB THERAPY: Beginning in course 6, patients receive trastuzumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 52 weeks in the absence of disease progression or unacceptable toxicity.~Patients may undergo radiation therapy at the discretion of the radiation oncologist and medical oncologist and patients with estrogen/progesterone receptor positive tumors receive hormonal therapy as determined by the medical oncologist per standard NCCN guidelines."
2536569|NCT02653547|Experimental|standard multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
2536571|NCT02653547|Experimental|high-frequency multisite four weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; complete treatment of four weeks
2536572|NCT02653547|Experimental|standard multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
2536573|NCT02653547|Experimental|high-frequency multisite two weeks|Combined high-frequency dorsolateral prefrontal (unilateral) and high-frequency temporoparietal (bilateral) stimulation; discontinuation after two weeks
3201887|NCT00907933|Experimental|Part 1 - Arm 1|HVTs
3201888|NCT00907933|Placebo Comparator|Part 2 - Arm 3|HVTs
3201889|NCT00907933|Experimental|Part 1 - Arm 2|HVTs
2536755|NCT02652546|Active Comparator|A|CC-11050 200mg (2 capsules) BID with food
2536760|NCT02652546|Placebo Comparator|B|Placebo (2 capsules) BID with food
2536806|NCT02651935|Experimental|Intellivent ASV|Patients in this arm will be ventilated with Intellivent ASV. Intellivent ASV is an automatic close loop ventilation mode. FiO2 setting will be automatically adjusted according to patients SpO2 and minute volume will be automatically adjusted according to patients EtCO2.
2536813|NCT02651935|No Intervention|PCV+PSV|PCV+PSV is a conventional ventilation strategy of pressure controlled ventilation PCV) and pressure support ventilation (PSV).In this arm, FiO2, pressure control levels, respiratory frequency and all the ventilator settings will be manually adjusted by the physicians in charge.
2536850|NCT02651597|Experimental|Low Viscous|Low Viscous Beta Glucan Oatmeal
2536853|NCT02651597|Experimental|Medium Viscous|Medium Viscous Beta Glucan Oatmeal
2536855|NCT02651597|Experimental|High Viscous|High Viscous Beta Glucan Oatmeal
2536945|NCT02650882|Placebo Comparator|placebo|Placebo group (PG) Nine athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a fixed load at 15% MIP, placebo protocol.
2536948|NCT02650882|Experimental|Experimental|Experimental group (EG) Ten athletes who maintained their regular sporting activities and were submitted to the IMT program for 12 weeks with a progressive load at 60%, 70% and 80 % of MIP.
2537035|NCT02650310|No Intervention|Conventional transfer|This arm is the control group (conventional embryo transfer protocol) where there is no intervention.
2537036|NCT02650310|Experimental|Thermostable device transfer|This arm is the study group: embryo transfer protocol using a new thermostable device.
3201890|NCT00907933|Experimental|Part 1 - Arm 3|HVTs
2537123|NCT02649465|Active Comparator|SGLT2 inhibitor|N=20 SGLT2 inhibitor dosage (Tofogliflozin): a dose of 20mg once daily for 48 weeks.
2537124|NCT02649465|Active Comparator|Sulfonylurea|N=20 Sulfonylurea (Glimepiride): an initial dose of 0.5 mg once daily for 48 weeks.
2537137|NCT02649153|Experimental|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus.
2537143|NCT02649153|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
2537153|NCT02649153|No Intervention|empty control|This group patients will not receive gum chewing or smoked plum.
2537560|NCT02646722||severe pain|patients show generalized movement because of pain
3201891|NCT00907933|Experimental|Part 1 - Arm 4|HVTs
3201892|NCT00907933|Experimental|Part 1 - Arm 5|HVTs
3201893|NCT00907933|Placebo Comparator|Part 1 - Arm 6|HVTs
2536226|NCT02655588|Experimental|ImbPST|"ImbPST Arm: Participants in this arm will interact with imbPST program which provides a simulated therapy session based on the Problem Solving Treatment-Primary Care (PST-PC) treatment manual used in depression clinical trials . imbPST via a virtual therapist (presented via audio and video) provides programmed instructions on the steps and skills of problem solving, emotional support, and tailored feedback to the user's input."
2536228|NCT02655588|No Intervention|Control Group|Control Arm: Participants in this group will not receive any treatment for their depression and their depressive symptoms will be monitored for 6 to 9 weeks
2536272|NCT02655315|Active Comparator|DEFERIPRONE|Half of participants will receive the deferiprone (DFP) to 15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
2536279|NCT02655315|Placebo Comparator|PLACEBO|Half of participants will receive the placebo twice daily morning and evening. The treatment lasts nine months.
2536509|NCT02653677|Active Comparator|commercial bread, wheat flour|Intake of the specific kind of bread
2536512|NCT02653677|Experimental|wheat, organic flour|Intake of the specific kind of bread
2536515|NCT02653677|Experimental|wheat, supermarket flour|Intake of the specific kind of bread
2536522|NCT02653677|Experimental|einkorn, organic flour|intake of the specific kind of bread
3167809|NCT00542958|Experimental|NK012|"This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.~For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.~UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.~Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study."
3167810|NCT00542984|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
3167811|NCT00542984|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
3167812|NCT00543023|Experimental|A|teriparatide 20 micrograms/day subcutaneous
2536696|NCT02652715|Experimental|Basic science (Salvia hispanica seed)|Patients receive Salvia hispanica seed PO QD for 12 weeks.
2536735|NCT02652312|Active Comparator|Group 'D'|"Dexmedetomidine group Patients received dexmedetomidine (2 ml diluted in 18 ml of saline) IV in a dose of 1 mcg/kg over 10 minutes. A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour was infused.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
2536742|NCT02652312|Placebo Comparator|Group 'P'|"Placebo group Patients received similar volume of normal saline as the bolus and maintenance infusion as group D.~Ondansetron: 0.15 mg/kg intravenous preoperative. Fentanyl: 1.5 μg/kg intraoperative Propofol: 10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia.~Atracurium: 0.5 mg/kg IV. Desflurane: 1 MAC concentration. Diclofenac sodium: 1 mg/kg for postoperative analgesia."
2536810|NCT02651831||1A: Content Validation|"Up to 4 focus groups of 6-10 cancer patients each will be conducted each lasting approximately 90 mins. An additional 10 to 15 patients will undergo individual semi-structured interviews each lasting around 60 minutes.~10-12 expert clinicians experienced in treating patients with ICMs or managing ICM toxicities will participate in a survey, and group or individual interviews."
2536816|NCT02651831||1B: Face Validity|Patients who have been and are being treated with ICMs to complete draft questionnaire (FACT-ICM). Some patients who were involved in the first round of interviews will be re-interviewed, and interview naïve patients will also be included.
2536817|NCT02651831||2A: To measure test-retest reliability|Patients to complete FACT-ICM at at two time points separated by 5 to 14 days.
2536818|NCT02651831||2B: To confirm construct validity|To evaluate discriminative properties of FACT-ICM, scores will be compared between pre-defined groups of patients where differences are expected.
2536819|NCT02651831||2C: To determine responsiveness and MCID|"Responsiveness testing: Patients will complete FACT-ICM within a week of starting treatment, then while on treatment and within 30 days after end of treatment (EOT) with ICMs.~MCID testing: In addition to the FACT-ICM score, patients undergoing serial assessment for responsiveness will also indicate how much better or worse they are using a 5-point rating scale."
2536846|NCT02651480|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, plant-based diet for 14 weeks, and will attend nutrition classes in the form of a weekly support group.
2536849|NCT02651480|Active Comparator|Control Group|The control group will follow an unrestricted diet with no instruction.
2537189|NCT02648802|Placebo Comparator|CM assessment|Standardized BCS with CM assessment.
3167813|NCT00543023|Active Comparator|B|salmon calcitonin 100 IU/day subcutaneous
3167814|NCT00543049|Other|1 non-continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 50.0 mg once daily. After 28 days, treatment will be paused for 14 days and cycle one is completed, followed by resumption of therapy as cycle one for up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
3167815|NCT00543049|Other|2 continuous|Subjects will receive open-label sunitinib = SU11248 at a dose of 37.5 mg once daily continuously. Treatment period up to one year (therapy can be continued in case of tumor response and benefit for the patient for more than one year).
3173967|NCT00618098|Experimental|Octaplex (human prothrombin complex concentrate)|Participants to receive1 or more Octaplex infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
2536247|NCT02655484|Other|COPD patients|Oxygen was delivered to the face mask by a tube at a constant rate (5L/min) to keep the fingertip oxygen saturation at 90% or above. Ventilatory assistance was delivered using a BiPAP® Vision® ventilator (Respironics, Murrysville, Pennsylvania, USA) in BiPAP mode applied via a tightly fitting full face mask (Curative, Suzhou, China). A symptom-limited cycle exercise test was performed while assisted by non-invasive ventilation (NIV). All measurements were recorded at inspiratory pressure of 14 cmH2O, expiratory pressure of 4 cmH2O during rest and exercise. Breathing pattern, mean exhalation flow, mean plateau exhalation valve flow, the mean inspiratory fraction of CO2 (tidal FiCO2) reinsufflated from the circuit between the mask and the exhalation valve was measured for each breath.
2536309|NCT02655159||Abraxane® treatment in patients with metastatic breast cancer|Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.
2536350|NCT02654821|Experimental|TCR treatment|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
2536442|NCT02654275|Active Comparator|Proprioceptive Intervention|Strength training on a non-stable surface
2536447|NCT02654275|No Intervention|No Proprioceptive Intervention|Conventional strength training
2536488|NCT02653989|Experimental|MDV9300|
3167816|NCT00543114|Experimental|Lenalidomide, fludarabine and rituximab|Lenalidomide-Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period fludarabine- Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days Rituximab- Given intravenously on Day 1 of each 28 day cycle
3167817|NCT00543153||Patients diagnosed with cancer|
2536562|NCT02653443|Experimental|Day 6|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
2536563|NCT02653443|Experimental|Day 7|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
2536595|NCT02653196|Experimental|Allogeneic Hematopoietic Stem Cell Transplant|"Matched Unrelated Donor HSCT (minimum 9/10 human leukocyte antigen [HLA] match) OR Matched Related Donor HSCT (10/10 HLA match). Conditioning regimen begins 12 days prior to stem cell infusion and includes the following drugs:~Keratinocyte Growth Factor Alemtuzumab Thiotepa Etoposide Melphalan Fludarabine Tacrolimus (Cyclosporine A may be substituted for Tacrolimus) Mycophenolate mofetil"
2536715|NCT02652663||ECA-MRI group|ECA-MRI group (patients who underwent conventional MRI using extracellular contrast agent [ECA])
2536716|NCT02652663||Gd-EOB-MRI group|Gd-EOB-MRI group (patients who underwent gadoxetic acid-enhanced MRI)
2536783|NCT02652143|Experimental|sibling oocytes in vivo|randomized oocytes assigned to in vivo culture
2536785|NCT02652143|Active Comparator|sibling oocyte in vitro|randomized oocytes assigned to in vitro culture
2536844|NCT02651727|Experimental|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 1- IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
2536845|NCT02651727|Experimental|Part B, Cohort 2- VS-4718, nab-paclitaxel, gemcitabine|Part B, Cohort 2- IV treatment for the first 2 cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15), followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
2536847|NCT02651727|Experimental|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
2536902|NCT02651168|Other|aflibercept|aflibercept treatment aflibercept, 40 mg/mL Solution for Intravitreal Injection
3167818|NCT00543166|Placebo Comparator|2|180 patients divided to two separate groups (each containing 90 patients). This study has a cross-over, wash-out design, which consists of two 4 month treatment period separated by a one month long wash-out period. During one treatment period the patient gets placebo and during one of the treatment periods the patient gets 50mg of dehydroepiandrosterone (DHEA) in the morning.
2536982|NCT02650596|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg liraglutide once daily for 1 week, then 1.2 mg liraglutide for another 1 week, and then 1.8 mg liraglutide to the end.
2536983|NCT02650596|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 3 months. After admission, the patients were treated with 0.6 mg placebo once daily for 1 week, then 1.2 mg placebo for another 1 week, and then 1.8 mg placebo to the end.
2537023|NCT02650245|Experimental|Moderate protein and 10gm lactulose|40% of daily recommended intake of protein based on weight
2537075|NCT02649855|Experimental|A/Sequential docetaxel followed by PROSTVAC|Standard ADT followed by sequential docetaxel + prostvac
2537076|NCT02649855|Experimental|B/ Combined docetaxel with PROSTVAC|Standard ADT followed by combined docetaxel + prostvac
2537077|NCT02649855|Experimental|C/ PROSTVAC prior to docetaxel|Standard ADT followed by prostvac, then docetaxel
2537302|NCT02648334|Active Comparator|IN.PACT drug coated balloon|IN.PACT drug coated balloon
2537305|NCT02648334|Experimental|Lutonix drug coated balloon|Lutonix drug coated balloon
2537351|NCT02647853|Experimental|TAT4 Gel concentration A|TAT4 Gel concentration A applied once daily to 50 cm2 for 14 days.
2537579|NCT02646527|Experimental|DT+|Dignity Therapy is conducted with patients and partners
3167819|NCT00543218|Active Comparator|A|teriparatide 20 micrograms/day subcutaneous
3167820|NCT00543218|Active Comparator|B|
3167821|NCT00543244||1|Patients with chronic hepatitis C who receive pegylated interferon plus ribavirin for 24 weeks (genotype 1 or 2) and for 48 weeks (genotype 1)
3167822|NCT00543257||Parents|Parents of children with ADHD will be recruited from the greater Boston community. We are interested in enrollment of parents with a range of educational and technical backgrounds, and specifically will look to enroll parents who may not have much computer experience.
3167823|NCT00543270|Experimental|Endovascular Repair - EVAR (Powerlink System)|EVAR (Powerlink System)
3167824|NCT00543270|Active Comparator|Open Surgical Control|Open Surgical Control
3167825|NCT00543335|Experimental|Sorafenib + Radiation Therapy|Sorafenib starting dose 200 mg orally daily + 45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
3167826|NCT00543348|Active Comparator|1|CUTTING BALLOON
3167827|NCT00543348|Placebo Comparator|2|
2536460|NCT02654171|Experimental|AK0529|Subjects will receive single or multiple doses of AK0529 at different dose levels within different cohorts.
2536461|NCT02654171|Placebo Comparator|Placebo|Patients who are randomized to the control arm within each cohort will receive the corresponding placebo to AK0529.
3167831|NCT00543413|Experimental|1|Arm 1: Drug 250 mg
3167832|NCT00543413|Experimental|2|Arm 2: Drug 500 mg
3167833|NCT00543413|Active Comparator|3|Arm 3: Active Comparator
2536580|NCT02653352|No Intervention|Control|The control group received two one-hour general sessions on health issues and printed general advices regarding healthy diets.
2536581|NCT02653352|Experimental|Lifestyle modification|Intervention was focused on the reduction in consumption of sugar-sweetened carbonated beverages by students. During seven months of one school year, a healthy lifestyle education programme was implemented using simple messages encouraging water consumption instead of sugar-sweetened carbonated beverages. Education was delivered via classroom activities; banners were hung promoting water consumption, and water bottles with the logo of the campaign were given to children and schoolteachers.
2536634|NCT02653079||Study Cohort|Blood draw and Questionaire from patients suffering from chronic inflammatory diseases of the joints, namely painful shoulder syndrome (periarthritis humeroscapularis), painful elbow syndrome (Epicondylopathia humeri), benign achillodynia, and benign calcaneodynia, Arthrosis (finger- and Rhizarthrosis, Gonarthrosis, Anklearthrosis), and Arthritis with an planned local low dose radiation therapy (LDRT) at the Department of Radiation Oncology, Universitätsklinikum Erlangen.
2536694|NCT02652819|Experimental|FG-4592|Intervention is investigational treatment FG-4592
2536699|NCT02652819|Placebo Comparator|Placebo|Double blinded placebo control
2536754|NCT02652234|Experimental|Endostar-subcutaneous injection/Chemotherapy|
2536787|NCT02652013|Experimental|40 patients with multiple sclerosis|The study sample will consist of 40 patients with multiple sclerosis. MS patients and control subjects will be recruited on the Rennes (Centre Hospitalier Universitaire and Pôle de Médecine Physique et de Réadaptation Saint-Hélier) and Angers sites (Centre Hospitalier Universitaire) participating in COGNISEP project
2536792|NCT02652013|Other|40 healthy subjects|All the performance of the 40 MS patients will be compared to 40 control subjects matched in age, gender and sociocultural level. Subjects with a history of neurological and psychiatric condition or substance abuse will be excluded from the study. Control subjects will receive an honorary as a token for their time.
2536894|NCT02651298|Experimental|Fractional CO2-laser|3 treatments with fractional co2-laser
2536895|NCT02651298|No Intervention|Untreated control|untreated control side of caesarean section scar
2536928|NCT02650947|Experimental|Sucralose|Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
2536930|NCT02650947|Placebo Comparator|Placebo|Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
2537017|NCT02650336||CIN proup|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
2537019|NCT02650336||control group|The occurrence of CIN was defined as an increase in serum creatinine of 0.5 mg/dL above the baseline value within 48-72 h after PCI. Follow-up SCr and BUN levels were measured 1, 2, and 3 days after the procedure.
3167834|NCT00543413|Placebo Comparator|4|Arm 4: Pbo Comparator
3167835|NCT00543426|Experimental|1|Fuzheng Huayu Tablets
3167836|NCT00543426|Sham Comparator|2|sham Fuzheng Huayu Tablets
3167837|NCT00543452|Active Comparator|oxygen|4 liters of oxygen a minute
3167838|NCT00543452|Placebo Comparator|air|4 liters of room air
3167839|NCT00543478|Active Comparator|1|Receive active drug Saccharomyces boulardii 250mg twice a day for 8 weeks.
3167840|NCT00543478|Placebo Comparator|2|Placebo will be given twice a day for 10 weeks
3167841|NCT00543504|Experimental|Bevacizumab + Sunitinib|Arm 1: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sunitinib 12.5 mg orally daily for 4 weeks, then 2 weeks off.
3167842|NCT00543504|Experimental|Bevacizumab + Sorafenib|Arm 2: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Sorafenib 200 mg by mouth daily for 28 Days
3167843|NCT00543504|Experimental|Bevacizumab + Erlotinib + Cetuximab|Arm 3: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Erlotinib 50 mg By Mouth Daily for 28 Days + Cetuximab loading dose 100 mg/m² IV and maintenance 75 mg/m² on Days 1, 8, 15, 22.
3167844|NCT00543504|Experimental|Bevacizumab + Trastuzumab + Lapatinib|Arm 4: Bevacizumab starting dose 2.5 mg/kg intravenous (IV) over 90 minutes + Trastuzumab loading dose 2 mg/kg IV then maintenance dose 1 mg/kg IV on Day 1 + Lapatinib 250 mg By Mouth Daily for 21 Days.
3167845|NCT00543582|Experimental|1|
3167846|NCT00543608|Experimental|1|Dose 1 iclaprim
3167847|NCT00543608|Experimental|2|Dose 2 iclaprim
3167848|NCT00543608|Active Comparator|3|vancomycin
2536305|NCT02655211|Active Comparator|PDL-Med-CO2|Participants will receive one block of PDL laser therapy, followed by one block of usual care, followed by one block of CO2 laser therapy.
2536308|NCT02655211|Active Comparator|CO2-Med-PDL|Participants will receive one block of CO2 laser therapy, followed by one block of usual care, followed by one block of PDL laser therapy.
2536422|NCT02654613|Active Comparator|Quality Improvement Intervention|In intervention clinics, staff will follow QI methodology to undertake a detailed assessment of their HIV-TB care and to prioritize the steps to improve treatment outcomes. A senior nurse will be identified to be the QI champion and will be trained by the study team to fulfil this role. The QI champion in the clinic then provides peer-leadership, mentorship and support for the implementation of the prioritized changes until the checklist is complete and all integrated HIV-TB service components meet the required standard.
2536425|NCT02654613|No Intervention|Control Standard of Care|The control arm will continue with the usual support that is received for HIV-TB service integration
3167849|NCT00543634|Active Comparator|1|
3167850|NCT00543634|Active Comparator|2|
3167851|NCT00543647|Experimental|1|
3167852|NCT00543647|Placebo Comparator|2|
3167853|NCT00543660|Experimental|Intervention arm DSEK|Intervention: DSEK
3167854|NCT00543673|Experimental|Milk based formula A|Experimental milk based infant formula
3167855|NCT00543673|Active Comparator|Standard formula|standard milk based infant formula
3167856|NCT00543673|Other|Reference|Human milk
3167857|NCT00543673|Experimental|Milk based formula C|Experimental milk based infant formula
2536574|NCT02653534|Experimental|Intervention Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
2536576|NCT02653534|No Intervention|Control|Routine visits by government health workers
2536682|NCT02652676|Experimental|Reversible Pulmonary Artery Banding|"The addition of afterload Reversible Pulmonary Artery Banding to a normal-functioning right ventricle (in the setting of end-stage dilated cardiomyopathy) shifts the inter-ventricular septum toward the midline, thus significantly improving left ventricular geometry and function. It permits the infant or young child to operate from a much improved position on Starling's curve with gradual resolution of congestive heart failure and the potential for lethal ventricular dysrhythmia. An abundance of progenitor myocytes known to exist within the myocardium of this patient age group may then contribute to permanent left ventricular restoration."
2536749|NCT02652429|Experimental|Inhaled Nitric Oxide (iNO)|Pulsed iNO 75 mcg/kg IBW/hour
2536799|NCT02651883|Active Comparator|Screening invitation (with education)|Participants will receive a phone call providing (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic.
2536800|NCT02651883|Experimental|Self-collection for HPV testing|Participants in the intervention arm will receive a kit to self-collect a sample and return it for HPV testing. Participants will then receive a phone call providing their HPV results plus (i) education on cervical cancer, and (ii) assistance scheduling an appointment for free cervical cancer screening at a study-affiliated clinic, if desired.
2536833|NCT02651532||IBS + Confocal Laser Endomicroscopy|Outpatients with irritable bowel syndrome according to Roma III classification: recurrent abdominal pain or discomfort, at least 3 days per month, in the last 3 months and symptoms begin at least 6 months before diagnosis, associated with 2 or more of: improvement with defecation, start associated with changes in the bowel frequency, start associated with changes in stool consistency. Absence of alarm symptoms: gastrointestinal bleeding, weight loss, anemia, night-time symptoms, fever, family history of colorectal cancer or celiac disease, elevated erythrocyte sedimentation rate, positive fecal occult blood test.
2536835|NCT02651532||Control + Confocal Laser Endomicroscopy|Outpatients without IBS symptoms, undergoing colonoscopy for colorectal cancer screening
2536889|NCT02651324|Experimental|Treatment Group|A ketamine bolus of 0.5mg/kg will be given and then the ketamine infusion of 0.2 mg/kg/hr will be initiated prior to incision. Intra-operative opioids will be at the discretion of the attending anesthesiologist. Postoperative management will include continuation of the study drug as well as a standardized morphine patient-controlled analgesia (PCA) and acetaminophen 15 mg/kg IV every 6 hours. On postoperative day 1, patients are started on ketorolac 0.5 mg/kg up to 15 mg IV q8h. On postoperative day 2 they are transitioned to ibuprofen 10 mg/kg up to 600 mg. The ketamine infusion will continue for 48 hours post operatively at which point the PCA is discontinued and patients are transitioned to oral pain medications (Roxicet or Lortab and Flexeril) as per the current protocol.
2536890|NCT02651324|Placebo Comparator|Placebo|A placebo (saline) will be given in place of ketamine
2536915|NCT02651025|Experimental|Resistance Exercise Program|Patients included in intervention group will submit to resistance exercise training during hemodialysis, three times a week, for twelve weeks. This program includes exercises for the upper and lower limbs.
2536922|NCT02651025|No Intervention|Passive Stretching Program|Patients included in control group will submit to passive stretching program of lower limbs, during hemodialysis, three times a week, for twelve weeks.
2536963|NCT02650726|Placebo Comparator|control group|The participants in this group are instructed to consume placebo capsules every day during the trial period.
2536966|NCT02650726|Experimental|treatment group|The participants in this group are instructed to consume anthocyanin capsules every day during the trial period.
2537307|NCT02648347|Active Comparator|darbepoetin alfa|
3167858|NCT00543686|Active Comparator|1|Montelukast
3167859|NCT00543686|Active Comparator|2|Fluticasone
3167860|NCT00543790|Experimental|1|
3167861|NCT00543829|Experimental|1|4 cycles of doxorubicin and docetaxel with tamoxifen
3167862|NCT00543829|Active Comparator|2|4 cycles of doxorubicin and docetaxel without tamoxifen
3167863|NCT00543842|Experimental|Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy|Bevacizumab 5 mg/kg intravenous (IV) every 2 weeks for 3 Doses (Weeks 1, 3, 5). Erlotinib starting dose 50 mg orally daily Weeks 1-3. Capecitabine starting dose 650 mg/m^2 orally twice daily Monday-Friday for 6 Weeks. Radiation Therapy 30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments. At least 8 weeks after radiation therapy, surgical removal of rectal tumor.
3167864|NCT00543881|Experimental|1|Interventional group
2536315|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
2536317|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
2536434|NCT02654392|Placebo Comparator|placebo|This group will receive isoenergetic carbohydrate (corn syrup) supplement daily for 5 weeks
2536435|NCT02654392|Other|Polyunsaturated fatty acid group|This group will receive a plant essential fatty acid food supplement, Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils, containing a 2.5:1 omega-6 to omega-3 ratio (1.5 g per 70kg body mass plus an additional 0.5 g on exercise days)
2536479|NCT02654041|Experimental|Hypothyroxinemia induced patients|Combined T3 and Methimazole treatment will be administered. This experimental treatment will be administered adjunct to standard oncological treatment for newly-diagnosed GBM patients e.g. radiation followed by Temozolomide.
2536526|NCT02653807|Experimental|mobilization with movement|MWM at the talocrural joint during active weight bearing ankle dorsiflexion with the belt
2536530|NCT02653807|Active Comparator|osteopathic mobilization|passive mobilization of the talo-crural joint
2536689|NCT02652689|Experimental|Diagnostic ultrasound|Recording Doppler ultrasound signals noninvasively from the right chest wall
2536870|NCT02651506|Experimental|Electromagnetic Navigation Bronchoscopy|
2536881|NCT02651506|Active Comparator|Transthoracic Needle Biopsy|
2537037|NCT02650050|Experimental|Micropulsed laser photocoagulation|
2537038|NCT02650050|Sham Comparator|Sham micropulsed laser photocoagulation|
3167865|NCT00543881|Active Comparator|2|Usual care group
3167866|NCT00543907||Pre programmatic development|Patients who have undergone mastectomy for breast cancer prior to implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
3167867|NCT00543907||Post programmatic development|Patients who have undergone mastectomy for breast cancer after implementation of the deep inferior epigastric perforator flap microsurgical breast reconstruction program
3167868|NCT00543933|Experimental|iNO administered|iNO administered at 40 ppm via a non-rebreather mask
3167869|NCT00543959|Experimental|Part1 - Arm 1|Part1: Arm 1: drug
3167870|NCT00543959|Placebo Comparator|Part1 - Arm 2|Part1 - Arm 2: Pbo comparator
3167871|NCT00543959|Placebo Comparator|Part 2 - Arm 1|Part 2 - Arm 1: Pbo
3167872|NCT00543959|Experimental|Part 2 - Arm 2|Part 2- Arm 2: drug 5mg
3167873|NCT00543959|Experimental|Part 2 - Arm 3|Part 2 - Arm 3: drug 15mg
3167874|NCT00543959|Experimental|Part 2 - Arm 4|Part 2 - Arm 4: drug 30mg
3167875|NCT00543959|Active Comparator|Part 2 - Arm 5|Part 2 - Arm 5: active comparator
3167876|NCT00543998||Optical Measurement transillumination|Optical Measurement of sinus
3167877|NCT00544024||Reference|Lariam was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3167878|NCT00544024||T1|Mephaquin was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3167879|NCT00544024||T2|Mefloquine-AC Farma was administered as whole tablets with food and water at a dose of 25 mg/kg (15 mg/kg on the first day and 10mg/kg on the second day) along with artesunate at a dose of 4 mg/kg/day for three days under supervision by clinical staff
3167880|NCT00544037||Group 1|
3167881|NCT00544115|Active Comparator|Regimen I|Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.
3167882|NCT00544115|Active Comparator|Regimen II|Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.
3167883|NCT00544115|Active Comparator|Regimen III|Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.
3167884|NCT00544115|Active Comparator|Regimen IV|Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.
3167885|NCT00544115|Active Comparator|Regimen V|Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.
3167886|NCT00544115|Active Comparator|Regimen VI|Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.
3167887|NCT00544128|Active Comparator|Epzicom Arm|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
3167888|NCT00544128|Active Comparator|Truvada Arm|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg
3167889|NCT00544206|Experimental|#1|Diabetes specific enteral feeding product
3167890|NCT00544206|Active Comparator|#2|Standard enteral feeding product
3167891|NCT00544219|Other|R-Chop 14|Standard treatment
3167892|NCT00544232|Experimental|epirubicin, paclitaxel and CMF +/- darbepoetin|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
3173968|NCT00618098|Active Comparator|Fresh frozen plasma|Participants to receive1 or more fresh frozen plasma infusions intravenously until their International Normalized Ratio (INR) was < 1.5.
2536345|NCT02654925||Older Women|women 55-100 years of age; older women will be postmenopausal who are at least 12 months past the final menstrual period (FMP).
2536393|NCT02654444||GenASIs HiPath IHC #1|Expression of HER2 antibody. Semi-Quantitative value
2536395|NCT02654444||GenASIs HiPath IHC #2|Expression of HER2 antibody. Semi-Quantitative value
2536396|NCT02654444||GenASIs HiPath IHC #3|Expression of HER2 antibody. Semi-Quantitative value
2536429|NCT02654353|Other|Group A: stepwise ablation|Stepwise ablation of persistent atrial fibrillation (conventional treatment arm) In this arm, patients will be treated with the conventional stepwiese ablation approach
2536431|NCT02654353|Active Comparator|Group B: sequential substrate ablation|Sequential substrate ablation of persistent atrial fibrillation (novel procedure) In this arm, patients will undergo an ablation procedure that consist of PVI, cardioversion, linear ablation and atrial fibrillation re-induction after blocked lines, followed by electrogram-guided ablation
3167893|NCT00544232|Experimental|EC followed by paclitaxel +/- darbepoetin|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
3167894|NCT00544258|Experimental|1|Two days consecutive days of application of 0.05% PEP005 Topical Gel to a 100cm2 contiguous AK treatment area of the arm.
2536667|NCT02652923|Experimental|Part 1 - volunteers|Subdermal low (1.0 ml) or high (2.0 ml) dose injection of the ultrasound contrast agent Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around a 2 cm in diameter region in the mid-upper outer quadrant of the left breast, followed a week later by the other dose injected in the same fashion into the right breast.
2536670|NCT02652923|Experimental|Part 2 - patients|Subdermal injection of the ultrasound contrast agent of Sonazoid divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock) around the breast cancer. Subjects will receive an injection of either a low (1.0 ml) or a high (2.0 ml) dose of Sonazoid depending on the outcome of the Part 1 safety and tolerability study.
2536805|NCT02651909||Rivaroxaban Cohort|Evidence of Rivaroxaban use with-in the last 48hours Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
2536812|NCT02651909||Control cohort not taking Rivaroxaban|Not taking Rivaroxaban - matched to Rivaroxaban group by age gender, type of injury or illness requiring urgent surgery Participating subjects will not undergo any procedures associated with this study except data collection and minimal blood sampling of which results will not be become part of the medical record and no clinical decisions will be made using the results of research lab results. Blood samples are for TEG analysis and for Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
2536901|NCT02651181|Experimental|Closed Loop System|
2536975|NCT02650830||1) Normal control|metabolically healthy with no obesity
2536978|NCT02650830||2) prediabetes|defined in 'inclusion criteria'
2536980|NCT02650830||3) type 2 diabetes|defined in 'inclusion criteria'
2537008|NCT02650362|Experimental|spinal cord stimulation|
2537098|NCT02649504|Active Comparator|R+3D, MMF|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Mycophenolate mofetil (MMF) will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
2537105|NCT02649504|Placebo Comparator|R+3D, Placebo|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study. Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study. Placebo will be given starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
2537135|NCT02649179|Experimental|local infiltration with ropivacaine|patients were to receive 0.75% ropivacaine
2537139|NCT02649179|Placebo Comparator|local infiltration with 0.9% saline|patients were to receive placebo
2537196|NCT02649023||A: Patients with deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a positive finding will be grouped in arm A"
2537200|NCT02649023||B: Patients without deep venous thrombosis|"All patients will be screened for deep venous thrombosis on postoperative day 3. Patients with a negative finding will be grouped in arm B"
2537355|NCT02647853|Experimental|TAT4 Gel concentration B|TAT4 Gel concentration B applied once daily to 50 cm2 for 14 days.
3167895|NCT00544284|Experimental|Treatment (temozolomide, bortezomib)|GROUP A: Patients receive oral temozolomide once a day on days 1-5 and bortezomib IV on days 2, 5, 9, and 12. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. GROUP B: Patients receive temozolomide and bortezomib as in group A. Cohorts of patients in both groups receive escalating doses of both study drugs until the maximum tolerated doses are determined. All patients undergo blood sample collection periodically for pharmacokinetic studies. Samples are analyzed for bortezomib concentration (groups A and B) and trough levels of anticonvulsants (group A only).
3167896|NCT00544297|Experimental|PEP005 gel administration|0.05% PEP005 Topical Gel administered for two consecutive days to a 25cm2 contiguous AK treatment area on the top of the hand
3167897|NCT00544310|Experimental|1|Post surgery adhesion prevention treatment
3167898|NCT00544336||Supportive|
3167899|NCT00544362|Experimental|Neoadjuvant chemoradiotherapy|Weekly cetuximab (400 mg/m2 one week before start of radiotherapy RT and 250 mg/m2 during radiotherapyRT), and 5 FU (500 mg/m2 per day D1-D4) combined with cisplatin CDDP (40 mg/m2 D1) on week 1 and 5
3167900|NCT00544375||Neonatal Tissues|Optical measurement neonatal tissues
3167901|NCT00544401|Experimental|1|Hypnopuncture Treatment
3167902|NCT00544401|No Intervention|2|Conventional IVF/ICSI treatment only
3173969|NCT00618124|Experimental|A|
3173970|NCT00618150|Experimental|A|
3173971|NCT00618176|Experimental|B|
2536349|NCT02654990|Experimental|Arm C - 10mg PAN TIW|10mg panobinostat three times a week 2 weeks on/1 week off in combination with s.c. bortezomib and p.o. dexamethasone
3173972|NCT00618176|Experimental|A|
2536501|NCT02653703|Placebo Comparator|Vehicle, topical ethanol 96%|Exposure: 10 % topical trans-cinnamaldehyde [CAS Number: 14371-10-9] Vehicle: 96% ethanol
2536504|NCT02653703|Experimental|Topical L-menthol 40%|Exposure: 10 % trans-cinnamaldehyde [CAS Number: 14371-10-9] Intervention: 40% l-menthol [CAS Number: 2216-51-5] Vehicle: 96% ethanol
2536568|NCT02653521|Experimental|adaptive radiation therapy (ART)|40 patients treated with ART, using dose adaptation method to match the change of PTV and movement of OARs and achieve an optimal dose distribution using online CBCT images.
2536570|NCT02653521|No Intervention|the control group|40 patients treated with original plan for full treatment course.
2536596|NCT02653209|Experimental|Sitagliptin - DPP4i|
2536601|NCT02653209|Experimental|Canagliflozin - SGLT2i|
2536606|NCT02653209|Experimental|Pioglitazone - TZD|
2536686|NCT02652806|Experimental|FG-4592|Intervention is investigational treatment FG-4592
2536690|NCT02652806|Active Comparator|EPO|Intervention is subject's current dose of Li Xue Bao (epoetin alfa)
2536976|NCT02650609|Experimental|Methylprednisolone|"Methylprednisolone will be supplied as powder and stored in capsules containing 16 mg with lactose as excipient.~Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
2536977|NCT02650609|Placebo Comparator|Placebo|"Placebo capsules will only contain lactose. Capsules will be administered orally in the morning, during breakfast with a glass of water.~Dose is adapted according to the weight of the patient (1mg/kg):~<60 kg: 3 pills of 16 mg/day~60-80kg: 4 pills of 16 mg/day~>80kg: 5 pills of 16 mg/day The duration of the treatment is 21 days."
2537009|NCT02650167|Experimental|Colostrum|
2537011|NCT02650167|Experimental|Witness|
2537044|NCT02649985|Experimental|Relapsing-Remitting Multiple Sclerosis|"Subjects meeting the definition for RRMS by the International Panel Criteria, who are active, as defined by at least one MS relapse in the past 12 months, at least one gadolinium enhancing lesion on a MRI within 12 months of enrollment, or at least one new FLAIR bright lesion on MRI within 6 months of enrollment.~The study will be performed in two phases. In the early pilot phase, 8 subjects with multiple sclerosis will undergo both [C-11]PBR28 PET scan and [F-18]PBR06 PET scan. At the end of this phase, a formal interim analysis will be performed and if imaging characteristics of [F-18]PBR06 are found non-inferior to or better than [C-11]PBR28, the rest of the study will be completed using [F-18]PBR06. On the other hand, if [F-18]PBR06 is found to be inferior to [C-11]PBR28, the rest of the study will be pursued using [C-11]PBR28."
2537050|NCT02649985|Experimental|Progressive Multiple Sclerosis|Subjects meeting the definition for SPMS/PPMS (Primary Progressive Multiple Sclerosis) by International Panel Criteria and who have demonstrated deterioration in EDSS score in last 1 year.
2537052|NCT02649985|Active Comparator|Alzheimer's Disease|Subjects meeting the definition for probable AD based on NINDS-ADRDA criteria. In terms of severity of disease, the investigators will select subjects with mild AD, as defined by Mini-Mental Status Examination (MMSE) score of 20-26.
2537056|NCT02649985|Other|Healthy Control|This group will serve as non disease population.
2537057|NCT02649985|Experimental|Multiple Sclerosis Ocrelizumab|"Subjects who have been prescribed Ocrelizumab by their treating MS neurologist but have not yet started the first Ocrelizumab infusion.~Subjects will undergo two separate visits for [F-18]PBR06 PET scans, once before starting Ocrelizumab and the second visit 3 months after completion of the initial Ocrelizumab doses."
2537096|NCT02649647|Active Comparator|Conventional Resection|Patients receive conventional resection with standard proximal excision margin. The sigmoid colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
2537102|NCT02649647|Experimental|Proximally Extended Resection|Patients receive proximally extended resection. The whole sigmoid colon and rectum proximal to the tumor is removed, and the descending colon is anastomosed to the rectum or anus. A defunctioning ileostomy is routinely performed.
2537138|NCT02649296|Other|Treatment with Skanlab Bodywave|Treatment with Skanlab Bodywave twice a week for four weeks at the affected knee.
2537147|NCT02649296|No Intervention|No treatment|Treatment with Skanlab Bodywave without function twice a week for four weeks.
2537221|NCT02649101|Experimental|thalidomide plus chemotherapy|thalidomide tablet 100mg qn po
2537224|NCT02649101|Active Comparator|chemotherapy|Physician's choice chemotherapy. No constraints of the choice of chemotherapy drugs and regimens.
2537268|NCT02648451|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of AYMES Rome for a period of 9 days
2537308|NCT02648282|Experimental|Cyclophosphamide, Pembrolizumab, GVAX, SBRT|
2537333|NCT02647879||Hepatitis C infected|All patients diagnosed with hepatitis C in Iceland
2537399|NCT02647736|Experimental|Copeptin values in normo- to hyperosmolar states|
2537419|NCT02647398|Experimental|A: Supervised combined training|INTERVENTION: Two supervised 75 min-vigorous aerobic training & strength training
2537585|NCT02646527|Experimental|DT|Dignity Therapy is conducted only with patients
2537587|NCT02646527|No Intervention|SPC|standard palliative care
3173973|NCT00618176|Experimental|C|
3173974|NCT00618215|Experimental|I|"ROE Group~Interventions:behaviorial"
3173975|NCT00618215|Experimental|2|"MIM Group~Interventions:behaviorial"
3173976|NCT00618241|Experimental|A|"Group A: day 1-5 Raltegravir 400 mg oral BD (twice daily). Lamotrigine one oral dose 100 mg on day 4. Wash-out 6-31. Followed by one oral dose Lamotrigine 100 mg on day 34.~5 days Raltegravir 400 mg oral BD. Lamotrigine one oral dose 100mg on day 34."
2536359|NCT02654899|Experimental|Part 2|Single dose of solid dosage formulation (test) versus liquid dosage formulation (reference) of PF-06815345
2536419|NCT02654522|Experimental|Filler|Each subject will have one product in one forearm and another product in the other. Products: JUVEDERM Ultra Plus (24 mg/mL of HA) and VOLUMA (20 mg/mL of HA). Subjects will be randomized as to which forearm will receive which product. In one forearm, subject will receive four injections of the assigned HA filler (0.2mL). HA injections will be placed along a line from the wrist to the antecubital fossa. The initial 0.2mL HA injection will be placed in the deep dermis 5 cm from the wrist and the subsequent three 0.2mL HA injections will be place in 5 cm increments in the deep dermis along the line noted above. Same process will be used on the contralateral forearm using the other HA filler.1-3 hours post injection, these 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
2536421|NCT02654522|No Intervention|Scale Validation|"One forearm of one of three subjects will be randomized to the scale control forearm. The opposite forearm of this subject as well as the forearms of the two remaining subjects will receive treatment in this study. The forearm that has been designated as the scale control forearm will be injected with VOLUMA in a straight line into the mid-dermis in the following manner: 0.05ml of VOLUMA will be injected 5 cm proximal to the wrist, 0.1ml of VOLUMA will be injected 10 cm proximal to the wrist, 0.15ml of VOLUMA will be injected 15 cm proximal to the wrist and 0.2ml of VOLUMA will be injected 20 cm proximal to the wrist. The remaining randomized forearms (the non-injected forearm from the subject above and the forearms from the two additional subjects) will be injected in a similar fashion to the control forearm as noted above; however, the dose at each location will be randomized. Control subject will receive no Hylenex until after pertinent data is collected for the study."
2536546|NCT02653638|Experimental|Drug|"Control-Hypercapnic Trials: Three stepwise CO2 elevations will be applied to the patient by adding fractional concentration of inspired CO2 (FICO2) at 2%, 4%, and 6% each time, balanced with room air. The end tidal CO2 (PetCO2) will be elevated and maintained constant for three minutes at each target level. Breath-by-breath changes in minute ventilation (VE) and PetCO2 will be measured.~Drug-Indomethacin: Healthy volunteers, indomethacin suspension will be orally administered at 1.2 mg/kg. After drug administration, the patient will rest quietly for 90 minutes."
2536604|NCT02653339|Experimental|Qufeng Shengshi Fang and Loratadine|Qufeng Shengshi Fang is a traditional Chinese medicine form 8 kinds of herbs. Loratadine is the second generation antihistamines, after converted into its active metabolite Carrie period (carebastine), its antihistamines and allergy effect has been demonstrated in vitro and in vivo tests, also received data from clinical trials.
2536613|NCT02653339|Active Comparator|Loratadine|Loratadine (INN) is a second-generation H1 histamine antagonist drug used to treat allergies. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.Loratadine is marketed by Schering-Plough[needs update] under several trade names (e.g., Claritin) and also by Shionogi in Japan. It is available as a generic drug and is marketed for its nonsedating properties. In a version named Claritin-D or Clarinase, it is combined with pseudoephedrine, a decongestant; this makes it useful for colds, as well as allergies but adds potential side effects of insomnia, anxiety, and nervousness.
2536648|NCT02652832|Active Comparator|Depression Electroconvulsive therapy|40 patients with major depression receiving a mean of 12 sessions of Electroconvulsive therapy
2536650|NCT02652832|Active Comparator|Depression active repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
2536652|NCT02652832|Sham Comparator|Depression sham repetitive transcranial magnetic stimulation|40 patients with major depression receiving a mean 4 weeks of sham 1 Hz repetitive transcranial magnetic stimulation applied over the right dorsolateral prefrontal cortex - DLPFC
2536653|NCT02652832|Active Comparator|Schizophrenia active transcranial magnetic stimulati|40 patients with schizophrenia and predominant negative symptoms receiving 20 sessions of intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
2536654|NCT02652832|Sham Comparator|Schizophrenia sham transcranial magnetic stimulation|patients with schizophrenia and predominant negative symptoms receiving 20 sessions of sham intermittent theta burst simulation (iTBS) applied over the left dorsolateral prefrontal cortex - DLPFC
2536655|NCT02652832|Active Comparator|Schizophrenia active transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
2536656|NCT02652832|Sham Comparator|Schizophrenia sham transcranial Direct Current Stimulation|40 patients with schizophrenia and auditory verbal hallucinations receiving 10 sessions of sham transcranial Direct current stimulation (tDCS) applied with the anode over the left dorsolateral prefrontal cortex - DLPFC- and the cathode over the left temporoparietal junction
2536659|NCT02652832|No Intervention|Healthy volunteers|80 healthy volunteers receiving no stimulation
2536740|NCT02652520|Experimental|Kidney transplantation|HEMO2Life® use in organ preservation solution. Grafts removed and transplanted locally within the 6 kidney transplant centers participating in the study will be preserved with Hemo2life.
2536784|NCT02652039||cancer patients|
2536828|NCT02651766|No Intervention|Waiting List control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
2536829|NCT02651766|Experimental|Cupping massage treatment|Received the 5 cupping treatments, application twice a week on the upper back and neck
3201894|NCT00907933|Experimental|Part 2 - Arm 1|HVTs
3201895|NCT00907933|Experimental|Part 2 - Arm 2|HVTs
2537061|NCT02649998|Active Comparator|Group 1|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV saline placebo, followed by IV saline placebo 6 mL/h
2537064|NCT02649998|Active Comparator|Group 2|Each patient will initially receive a bolus of IV saline placebo and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
2536397|NCT02654548|Experimental|PCOS women and babies|Sebum output using Sebutape on post-partum PCOS women and new born babies.
2536398|NCT02654548|Active Comparator|Non-PCOS women and babies|Sebum output using Sebutape on post-partum non-PCOS women and new born babies.
2536459|NCT02654301|Placebo Comparator|Control group|sucrose drink (Control, sucrose 50g + deionized water 100g)
2536462|NCT02654301|Active Comparator|5 g xylose group|5 g xylose (Test 1, sucrose : xylose = 10:1),
2536463|NCT02654301|Active Comparator|3.33 g xylose group|3.33 g xylose (Test 2, sucrose : xylose = 15:1)
2536466|NCT02654301|Active Comparator|2.5 g xylose group|2.5 g xylose (Test 3, sucrose : xylose = 20:1)
2536503|NCT02653781|Experimental|Realistic simulation; Performance|Student participation in the study will happen on demand by enrollment in activities of dialogue-exhibition (workshop) on realistic simulation in the context of patient safety. Check the performance of students in face of simulation workshop for test realistic simulation.
2536506|NCT02653781|Other|theoretical-practical classes|Will be to give a theoretical-practical classes for students of control group the provision of similar opportunities
3201896|NCT00907946|Experimental|NT prior to PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one week prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
3201897|NCT00907946|No Intervention|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
2536663|NCT02652702|Experimental|Circular Stapler-assisted Colostomy|Using Circular Stapler-assisted Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
2536666|NCT02652702|Experimental|Hand-stitching Colostomy|Using Conventional Hand-stitching Technique to Finish Colostomy after colorectal carcinoma surgery when patient need permanent sigmoid stoma.
2536723|NCT02652559|Experimental|Home initiation|Home initiation of long-term NIV will be compared with standard in-hospital initiation. NIV at home will be titrated by a specialised nurse of our home mechanical ventilation centre (HMV) on transcutaneously measured gas exchange and respiratory electromyography and will be adjusted with the use of telemedicine.
2536725|NCT02652559|Active Comparator|Inhospital initiation|Inhospital initiation of NIV is standard care and in the study will be set as the control arm.
3201898|NCT00907972|Experimental|Vitamin D3 supplementation|1000 IU/day of Vitamin D3
3201899|NCT00907972|Placebo Comparator|Placebo|Placebo
3201900|NCT00907985|Experimental|Treatment sequence A|Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
2537026|NCT02650141|Experimental|ziyinxiehuo Granules|Children of ziyinxiehuo granules group will be treated with chinese herbal granules,3 times a day, for 6 months.
2537028|NCT02650141|Active Comparator|zishenqinggan Granules|Children of zishenqinggan granules group will be treated with chinese herbal granules, 3 times a day, for 6 months.
2537171|NCT02649426|Experimental|Ultrasound Renal Denervation|Subjects in the TRIO or SOLO cohorts that are randomized to treatment, will receive renal denervation following a renal angiogram
2537172|NCT02649426|Sham Comparator|Sham Procedure|For subjects in TRIO or SOLO cohorts that randomize to the sham procedure, the diagnostic renal angiogram intervention will be considered the sham procedure.
2537231|NCT02648776||Estazolam|Exposure to sedative-hypnotic drugs; Patients who have taken estazolam for at least one week before the first date of enrollment
2537232|NCT02648776||Lorazepam|Exposure to sedative-hypnotic drugs; Patients who have taken lorazepam for at least one week before the first date of enrollment
2537234|NCT02648776||Diazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Diazepam for at least one week before the first date of enrollment
2537235|NCT02648776||Alprazolam|Exposure to sedative-hypnotic drugs; Patients who have taken Alprazolam for at least one week before the first date of enrollment
2537237|NCT02648776||Flunitrazepam|Exposure to sedative-hypnotic drugs; Patients who have taken Flunitrazepam for at least one week before the first date of enrollment
2537238|NCT02648776||Zolpidem|Exposure to sedative-hypnotic drugs; Patients who have taken Zolpidem for at least one week before the first date of enrollment
2537241|NCT02648776||Zopiclone|Exposure to sedative-hypnotic drugs; Patients who have taken Zopiclone for at least one week before the first date of enrollment
2537242|NCT02648776||Control Group|Patients not taking any of the included or any other anxiety-hypnotic agents
2537262|NCT02648399|Placebo Comparator|control group|only unilateral center lymph node dissection
2537265|NCT02648399|Experimental|experimental group|bilateral center lymph node dissection
3201901|NCT00907985|Experimental|Treatment sequence B|Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
2537426|NCT02647515|Experimental|ranibizumab|
2537474|NCT02647190|Experimental|Erwinia Chrysanthemi asparaginase|This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.
3201902|NCT00907985|Experimental|Treatment sequence C|Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
3201903|NCT00907985|Experimental|Treatment sequence D|Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3201904|NCT00907985|Experimental|Treatment sequence E|Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
3201905|NCT00907985|Experimental|Treatment sequence F|Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
3201906|NCT00907985|Experimental|Treatment sequence G|Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.
3201907|NCT00907985|Experimental|Treatment sequence H|Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.
2536762|NCT02652195|Placebo Comparator|Placebo|Each participant will be studied using fMRI following self-administration of placebo.
2536765|NCT02652195|Experimental|Oxytocin|Each participant will be studied using fMRI following self-administration of oxytocin.
2536823|NCT02651896||HypoIGRT|"Low Risk (T1-T2a, Gleason score 6, and PSA < 10 ng/mL)~Intermediate Risk (T1-T2c, Gleason 7, and PSA 10-20 ng/mL)~High Risk (T3 - 4 , Gleason 8-10, and/or PSA > 20 ng/mL) Neoadjuvant hormone therapy is allowed on groups 2 and 3"
2536873|NCT02651493|Active Comparator|Down syndrome|photographs of individuals less than 18 yo with Down syndrome
2536879|NCT02651493|Active Comparator|Control group|photographs of individuals less than 18 yo with a genetic referral (not Down syndrome) or a healthy sibling to a child with Down syndrome
3201908|NCT00907985|Experimental|Treatment sequence I|Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
2536950|NCT02650713|Experimental|Dose-Escalation (Part IA): RO6958688 + Atezolizumab|Participants will receive RO6958688 weekly (QW) at escalating doses starting at 5 mg, in combination with a fixed dose (1200 mg) of atezolizumab every 3 weeks (Q3W). RO6958688 dosage will not exceed the MTD if defined in the BP29541 study.
2536954|NCT02650713|Experimental|Dose/Schedule Finding (Part IB): RO6958688 + Atezolizumab|"Part IB will explore different RO6958688 administration schedules in combination with atezolizumab, consisting of:~Cohort A: will compare the QW vs Q3W dosing schedules at a flat dose of RO6958688.~Step Up dosing schedules: RO6958688 dose will start at 40 mg and increase with each administration up to the MTD or 1200 mg, whichever occurs first."
2537027|NCT02650297|Experimental|CDT and pneumatic compression pump|combined decongestive therapy consists of the pressure of bandage, manual lymphatic drainage, and exercises that increase the flow of lymph and skin care are used. Intermittent pneumatic pump is not as a part of CDT, but it can be used as an adjunct method. This device according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk.
2537032|NCT02650297|No Intervention|not CDT and pneumatic compression pump|Patients in the control group received no treatment for lymphedema but were placed on the waiting list for CDT as soon as possible after the 8 weeks follow-up period.
2537082|NCT02649829|Experimental|Single Arm|dendritic cell vaccination plus chemotherapy
2537151|NCT02649283|Other|Breast symmetrisation with OrbiSymm|Standard surgical intervention of up to 30 patients including placement of the OrbiSymm device
2537161|NCT02649283|Other|Breast symmetrisation without device|Standard surgical intervention of up to 30 patients without the Orbix device; only routine reduction/symmetrisation intervention
2537222|NCT02648945|Active Comparator|high intensity exercise|"high intensity exercise on a treadmill according to Balke's Protocol.~high intensity of exercises for each group of 15 participants were set at 80-85% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
2537226|NCT02648945|Active Comparator|low intensity exercise|"low intensity exercise on a treadmill according to Balke's Protocol. low intensity of exercises for each group of 15 participants were set at 50-55% VO2 max (Schneider, S., et al., 2009). To determine the targeted HR for low and high intensity aerobic exercise for each participant, the needed VO2 max percentages were subbed into the Swain equation as follows: %VO2 max = (%HRmax - 37)/0.64 Exercise HR/HRmax = %HRmax~After rearrangement, it will be:~%HRmax = %VO2 max x 0.64 + 37 Exercise HR = %HRmax x HRmax During the experimental session, each participant performed physical exercise training on the treadmill according to Balke's Protocol. The reliability of this protocol was tested by Leddy, et. al. (2011)."
3201909|NCT00907985|Experimental|Treatment sequence J|Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3201910|NCT00907985|Experimental|Treatment sequence K|Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.
2537691|NCT02646007|Experimental|BM-MSC|Bone marrow derived mesenchymal stromal/stem cells injection during decompressive surgery in patients with Kienböck's disease.
2536511|NCT02653911|Experimental|acupuncture group|"Bilateral ST25, EX-CA1, CV4 and SP6 will be selected for treatment. After routine sterilization of the local skin, bilateral ST25, EX-CA1, CV4 and SP 6 will be inserted by the needles (0.30 mm in diameter, 40 mm in length) to a depth of 25-30 mm to the abdominal muscle layer with the manipulation of lifting, thrusting and rotating until de qi. Each session will last for 30 minutes, and the manipulation of lifting, thrusting and rotating evenly three times will be used for CV 4 and SP 6 every 10 minutes. If the date of treatment is during the menstrual circle, the treatment will be continued as usual. Participants will be treated three times a week for 12 weeks with 36 sessions."
2536516|NCT02653911|Sham Comparator|Sham-acupuncture group|The sham ST25, EX-CA1, CV4 and SP 6, which are 1 cun (25 mm) outward to ST25, EX-CA1, CV4 and SP 6, will be inserted to 2-3 mm with needles with a diameter of 0.30 mm and a length of 13 mm. The needles will be inserted without de qi or any manipulation. The treatment sessions will be the same as those in the acupuncture group.
3201911|NCT00907985|Experimental|Treatment sequence L|Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3201912|NCT00907985|Experimental|Treatment sequence M|Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
3201913|NCT00907985|Experimental|Treatment sequence N|Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3201914|NCT00907985|Experimental|Treatment sequence O|Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.
3201915|NCT00907985|Experimental|Treatment sequence P|Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.
3201916|NCT00907985|Experimental|Treatment sequence Q|Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
2536826|NCT02651779|Active Comparator|Closed reduction and plasterimmobilisation|The control group will be treated with closed reduction and cast immobilization. This will take place under local anaesthesia by means of a haematoma block with 20 cc Lidocaine 1%. Closed reduction will be preferably performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilizing wrist and hand in the reduced position. Additional radiographs will be performed to verify the success of the reduction. After this has been confirmed, the wrist will be immobilized initially in a split plaster and later changed into a circular cast for five to six weeks immobilization in total.
2536827|NCT02651779|Other|Open reduction and internal plate fixation|The surgery will be performed by a certified trauma surgeon. According to the current standard treatment protocol, antibiotic prophylaxis will be administered thirty minutes preoperatively. The distal radius will be approached according to Henry, which beholds an incision between the tendon of the flexor carpi radialis muscle and the radial artery. After the fracture site is exposed, the fracture will be reduced and provisionally fixed under fluoroscopy with K-Wires/reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Fracture reduction and screw placement will be confirmed by radiographic images. Additionally, fixation can be supported by a dorsal plate or radial column plate. This will be at discretion of the surgeon and depends on the fracture configuration and the position of the fragments. Wound closure will be performed at the discretion of the surgeon using standard techniques.
2536865|NCT02651402|Active Comparator|FRIENDS for Life Train-the-Trainer|Therapists implement FRIENDS (a CBT protocol for students with anxiety) in the school setting, while supported by their supervisor assigned to the Train-the-Trainer (TT) implementation strategy (supervisors participate in training workshops on conducting supervision with active therapists).
2536867|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer|Therapists implement an adapted version of FRIENDS (aFRIENDS) in the school setting while supported by their supervisor assigned to the TT strategy.
2536874|NCT02651402|Experimental|Adapted FRIENDS Train-the-Trainer Plus|Therapists implement aFRIENDS in the school setting while supported by their supervisor assigned to the Train-the-Trainer Plus (TT+) implementation strategy (supervisors participate in training workshops and receive further/on-going consultation on conducting supervision with active therapists).
2536909|NCT02651038|Experimental|Micafungin|Micafungin is administered per clinical need and the pharmacokinetic parameters are analyzed
2536990|NCT02650570||Head/Neck Cancer|Subjects diagnosed with advanced (stages III or IV), persistent (recurrence within 6 months) or recurrent head and neck squamous cell carcinoma (HNSCC)
2536991|NCT02650570||Healthy Control|Healthy controls age matched to the Head/Neck cancer group.
2537025|NCT02650258||Young Adult|80 Adults 21-40 years of age: 10 Male and 10 Female in each 5 year increment (21-25, 26-30, 31-35, 36-40).
2537029|NCT02650258||Middle Aged Adults|80 Adults 41-60 years of age: 10 Male and 10 Female in each 5 year increment (41-45, 46-50, 51-55, 56-60).
2537034|NCT02650258||Older Adults|100 Adults 61-85 years of age: 10 Male and 10 Female in each 5 year increment (61-65, 66-69, 70-75, 76-80, 81-85).
2537085|NCT02649803|Other|community hospital|"During the study, subjects who diagnosed as asthma according to Guideline for the diagnosis and optimal management of asthma in children will be assigned to the nearest community hospital or Shanghai Children's Medical Center, and receive 12 months standard treatment, prescribed by the investigators according to Guideline for the diagnosis and optimal management of asthma in children. The patient's caregiver will be instructed to install asthma APP at their smart phone to follow up."
2537169|NCT02649413|Experimental|Early response to prednisone treatment|intervention -children that will have a remission in 8 days (response) will get an adjusted steroids dose treatment.children that have a remission between 9-28 days will get a regular steroid dose.
2537306|NCT02648347|Experimental|vadadustat|
2536584|NCT02653469||Augmented ventilation with fluid loading|This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
2536657|NCT02653001|Experimental|Experimental arm|Stool sample collection: Stool samples collected from study participants will be introduced into the colon model to enhance our understanding of the colonic bacterial ecosystem in response to various food components, drugs or biological therapies, and/or to allow investigation the impact of the bacterial ecosystem itself on these added components
2536712|NCT02652611|Experimental|Screw Removal|Patients enrolled in the SI screw removal treatment group will undergo the surgery 5-9 months after the initial SI screw stabilization surgery. The surgeon will remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
2536713|NCT02652611|Experimental|Non-screw Removal|Patients enrolled in the Non-SI screw removal treatment group will not undergo surgical intervention to for removal of their SI screws. remove all screws that he/she is able and feels is appropriate for the patient. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments as per standard of care to determine if the injury continues healing properly. If complications arise and/or the patient requires screw removal surgery, crossover will be allowed and recorded within study follow0up forms.
2536750|NCT02652325|Active Comparator|povidone-iodine|
2536752|NCT02652325|Active Comparator|3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP swabs|
2536756|NCT02652325|Placebo Comparator|Saline|
2536801|NCT02652026|Experimental|Treatment Group|The Treatment Group (TG) received full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron, Acteon, Merignac, France) and Gracey curettes (Hu- Friedy, Chicago, USA).Also received Oral Hygienic Instructions
2536807|NCT02652026|Active Comparator|Control Group|The Control Group (CG) received periodontal prophylaxis at baseline, by removal of supragingival deposits (plaque and calculus) with ultrasonic scaler. Also received Oral Hygienic Instructions
2536942|NCT02650804|Experimental|BPM31510 plus gemcitabine|"BPM31510 Nanosuspension Injection (40 mg/mL) will be administered IV over 144 hours at the starting dose of 110 mg/kg. Each patient will receive 2 consecutive 72-hour infusions per week (Tuesday-Friday and Friday-Monday). The patient will be subsequently treated with gemcitabine IV once weekly at a starting dose of 1000 mg/m2.~Cycle 1 of combination therapy is 6 weeks in duration for patients with BPM31510 administered twice weekly on Tuesdays and Fridays for 6 weeks and gemcitabine administered on Mondays, Days 21, 28 and 35. Cycles 2-12 are 4 weeks in duration with BPM31510 administered twice weekly on Tuesdays and Fridays for 4 weeks and gemcitabine administered on Mondays, Days 7, 14 and 21."
3167903|NCT00544414|Experimental|Treatment|"Patients receive neoadjuvant induction chemotherapy comprising docetaxel IV over 1 hour on day 1 and cisplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on days 1-4. Induction chemotherapy repeats every 28 days for 3 courses.~Patients with partial response at the primary site may undergo radical or functional resection of the primary tumor within 3 weeks of completion of neoadjuvant therapy.~Beginning within 4 weeks of completion of neoadjuvant therapy, patients with persistent disease or complete response after chemotherapy at the primary or neck then undergo radiotherapy 5 days a week for 7 weeks and receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 60 minutes on day 1 of each week of radiotherapy."
3167904|NCT00544466|Experimental|Treatment (enzyme inhibitor, radiation therapy, transplant)|PREPARATIVE REGIMEN*: Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. Patients also undergo helical tomotherapy twice daily on days -7 to -4. TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. NOTE: *Treatment begins 2 days earlier in patients receive tacrolimus and/or sirolimus for GVHD prophylaxis.
3167905|NCT00544492|Experimental|A1|Buttonhole cannulation technique
3167906|NCT00544492|Active Comparator|A2|Rope ladder cannulation technique
3167907|NCT00544492|Experimental|B1|Catheter with bevel point
3167908|NCT00544492|Active Comparator|B2|Catheter with cylindrical point
3167909|NCT00544518|Experimental|2|
2537199|NCT02648815|Active Comparator|Percutaneous catheter drainage group|Percutaneous catheter drainage (PCD) of necrotic tissue and pathological collections formed during acute pancreatitis
2537206|NCT02648815|Active Comparator|Abdominal paracentesis evacuation group|Abdominal paracentesis drainage (APD) of peritoneal fluid during acute pancreatitis
2537275|NCT02648633|Experimental|Nivolumab & Valproate Following G.K.|Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion. Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
2537357|NCT02648035||Subcutaneous Tocilizumab|Participants receiving treatment for rheumatoid arthritis (RA) with subcutaneous Tocilizumab alone or in combination with conventional disease-modifying antirheumatic drugs (DMARDs) according to approved label.
2537768|NCT02645461|Active Comparator|Riluzole|Riluzole 50 mg twice daily in ALS patients
3167910|NCT00544518|Active Comparator|1|
3167911|NCT00544583|Active Comparator|A|Interrupted closure with Vicryl equivalent sutures (USP 2, 45 cm)
3167912|NCT00544583|Experimental|B|Continuous closure with PDS II equivalent sutures (USP 1, 150 cm loops)
3167913|NCT00544596|Experimental|Treatment (R-(-)-gossypol acetic acid, cisplatin, etoposide)|"Patients receive oral R-(-)-gossypol twice daily on days 1-3, cisplatin IV over 60 minutes on day 1*, and etoposide IV over 30 minutes on days 1*-3. Treatment repeats every 21 days for up to 6 courses during the dose escalation and 4 courses in the expanded extensive stage small cell lung cancer cohort, in the absence of disease progression or unacceptable toxicity.~Blood samples are collected on day 1 of courses 1 and 2 for pharmacokinetic analysis, biomarker assays, and correlative studies.~After completion of study treatment, patients are followed for 30 days.~[Note: *Cisplatin and etoposide will be started on day 2 during course 1; they will be given on day 1 during all subsequent courses.]"
2536591|NCT02653508|Experimental|Diet and Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, while the nutritional education comprised of a supplementary 15 minutes of group-based sessions that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2536593|NCT02653508|Experimental|Activity|60 overweight and obese adolescents aged 13-15 years old took part in the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. The activity intervention included a 45 minutes, three-day per week supervised training programme, that could be also attended by the parents. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2536594|NCT02653508|No Intervention|Control|61 overweight and obese adolescents aged 13-15 years old were the control group of the clinical trial and remained at the end of the 3 months intervention program and also at the 6 months follow up. All adolescents were assessed for anthropometric measures, fitness and activity and family habits along with their parents.
2536681|NCT02652962|Experimental|Gelesis200 x 2, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
2536685|NCT02652962|Experimental|Gelesis200 x 2, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2536688|NCT02652962|Placebo Comparator|Placebo x 2, 10 min|3 x Placebo capsules administered 10 minutes before each of 2 meals (breakfast, lunch).
2536692|NCT02652962|Placebo Comparator|Placebo x 2, 30 min|3 x Placebo capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2536697|NCT02652962|Experimental|Gelesis200 x 3, 10 min|3 x 0.70g Gelesis200 capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
2536701|NCT02652962|Experimental|Gelesis200 x 3, 30 min|3 x 0.70g Gelesis200 capsules administered 30 minutes before each of 2 meals (breakfast, lunch).
2536704|NCT02652962|Placebo Comparator|Placebo x 3, 10 min|3 x Placebo capsules administered 10 minutes before each of 3 meals (breakfast, lunch, dinner).
2536706|NCT02652962|Placebo Comparator|Placebo x 3, 30 min|3 x Placebo capsules administered 30 minutes before each of 3 meals (breakfast, lunch, dinner).
2536736|NCT02652299||Early Rheumatoid Arthritis group|Following informed written consent, 20 patients with early RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
2536741|NCT02652299||Longstanding Rheumatoid Arthritis group|Following informed written consent, 20 patients with longstanding RA will be enrolled from Odense University Hospital (OUH) during a 12 month period
2536747|NCT02652299||Control group: Synovial tissue and peripheral blood|20 Non-RA patients who are referred to arthroscopy in a joint of the hand at OUH Department of Orthopedics, Section of hand surgery, are asked to participate by the surgeon at the first ambulatory consultation. Following informed written consent, MRI of hand, a blood sample and synovial biopsies, will be used as control for synovial and plasma fibrocyte levels. The synovial biopsies will be obtained during the planned arthroscopy.
2536808|NCT02652078|Sham Comparator|Control|Sham treatment in identical format to treatment arm but without shockwave production
2536815|NCT02652078|Experimental|Shockwave|Active shockwave treatment to calf muscle bulk
2536854|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the chest
2536857|NCT02651558|Experimental|OBPM 2015-MD-0022 - CHEST & FINGER|Cohort of 10 patients undergoing general anesthesia, monitored by optical signals at the chest and at the fingertip
2536859|NCT02651558|Experimental|OBPM 2015-MD-0022 - FINGER|Cohort of 30 patients undergoing general anesthesia, monitored by optical signals at the fingertip
3201917|NCT00907985|Experimental|Treatment sequence R|Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
3201918|NCT00907985|Experimental|Treatment sequence S|Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.
3201919|NCT00907985|Experimental|Treatment sequence T|Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.
2537223|NCT02648984|Other|Patient group|Patients with ventricular septal defect
2537227|NCT02648984|Other|Control group|Healthy control subjects
2537269|NCT02648542|Active Comparator|CAS vs. tDCS|Assess the efficacy of compensatory auditory stimulation (CAS) versus transcranial direct current stimulation (tDCS)
2537271|NCT02648542|Sham Comparator|Combined CAS+tDCS vs. Sham|Assess the efficacy of combined compensatory auditory stimulation (CAS) + transcranial direct current stimulation (tDCS) versus sham stimulation
2537353|NCT02648061||After cardiac arrest syndrome (ACAS)|adult patients after out-of-hospital cardiac arrest
2537402|NCT02647671|Experimental|Aquamin®|Experimental: Aquamin® (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2537772|NCT02645227|Active Comparator|Group 2|OFD with Platelet rich fibrin (PRF)
3201920|NCT00907998|Experimental|APL180 (first dose level)|
3201921|NCT00907998|Experimental|APL180 (second dose level)|
3201922|NCT00907998|Placebo Comparator|Placebo|
3201923|NCT00908024|Experimental|BMS-754807 + cetuximab|Combination
3201924|NCT00908050|Placebo Comparator|Placebo|Placebo arm
3201925|NCT00908050|Active Comparator|botulinum toxin type A|Active arm
3201926|NCT00908063|Experimental|Oxycyte|"Single intravenous infusion of Oxycyte (Perfluoro(t-butylcyclohexane) Intravenous Emulsion 60% w/v)~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
3201927|NCT00908063|Placebo Comparator|Normal Saline|"Single intravenous infusion of Normal Saline~One of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury."
2536608|NCT02653248|Experimental|Cohort 3|Patients will receive 5 fractions of Stereotactic Body Radiation Therapy (SBRT). Dose per fraction is 10Gy. Total Dose: 50Gy. To escalate the dose of stereotactic radiotherapy to a tumoricidal dose without exceeding the maximum tolerated dose in patients with organ confined prostate cancer.
2536645|NCT02652845|Experimental|Intervention-Wellness Engagement Program|"The group assigned to the intervention arm will receive treatment as described below for a twelve week period:~Weekly lessons related to healthy eating and physical activity Biweekly check-in calls with a trained peer support coach Access to neighborhood wide physical activity and nutritional education events"
2536646|NCT02652845|No Intervention|Delayed treatment control group|The delayed treatment control group will not receive the intervention for measurement purposes; however the intervention as described will be administered to this group upon conclusion of the 12 week period for the intervention group.
2536678|NCT02652650|Experimental|Ethinylestradiol/Norethindrone|During the first oral contraceptive (OC) cycle participants will receive ethinylestradiol/norethindrone 35 microgram (mcg)/1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in). During the second OC cycle (from Day 29 to Day 56), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg alone qd for 21 days on Days 29 to 49 (Cycle II: OC alone, reference). During the third OC cycle (from Day 57 to Day 84), participants will receive ethinylestradiol/norethindrone 35 mcg/1 mg qd for 21 days on Days 57 to 77 and in addition JNJ-63623872, 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test).
3167914|NCT00544609|Other|Sorafenib|2 weeks:Sorafenib, 6 weeks and a half:Sorafenib with radiotherapy, 4 weeks:Sorafenib
2536804|NCT02651857|Experimental|Endoscopy exploratory single arm|
2536837|NCT02651623|Experimental|Sertraline|Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
2536839|NCT02651623|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
2536841|NCT02651623|Placebo Comparator|Drug - Placebo|placebo - placebo administered on Days 1 through 14
2536911|NCT02651285|Experimental|G-CSF|The embryos obtained with IVF in patients included iin this arm will be incubated after fertilization with medium supplemented with G-CSF
2536919|NCT02651285|Placebo Comparator|CONTROL|The embryos obtained by women undergoing IVF included in this arm will be incubated with a standard medium for IVF, and utilized as control group.
2536951|NCT02650661|Experimental|Online program & Health coaching|"This group is provided with Online health management program, Health coaching and Workshop."
2536957|NCT02650661|Experimental|Online program|"This group is provided with Online health management program."
2536959|NCT02650661|Active Comparator|Enhanced Usual Care|"This group is provided with Standard health educational booklet."
2537013|NCT02650388|Other|Post TAVI neurocognitive outcome|"TAVI with CoreValve will be done for all the patients and outcome will be assessed as Cognitive fuction, quality of life, Gait speed, Hand grip strength, Activities of daily living (ADL), Instrumental activities of daily living (IADL), Short- Form Mini Nutritional assessment (SF-MNA), Serum albumin level, Hemoglobin level, BMI, Montreal cognitive Assessment (MOCA), EQ-5D-3L-questionnaire, Ferreans and Powers Quality of life Index (QLI), MOCA, RBANS, Wisconsin test, Stroop test, Fluency test, Subjective Eyeball test, Serial Transcranial Doppler (TCD) during TAVI. Finally, Hungarian frailty score will be deduced."
2537072|NCT02649907|Experimental|Weight loss|3 months weight loss intervention by behavioral intervention
2537089|NCT02649543|Active Comparator|Primary Closure|Primary Closure is made after surgery.
2537097|NCT02649543|Active Comparator|Delayed Primary Closure|Delayed Primary Closure is made after at least 7 days.
2537104|NCT02649543|Active Comparator|Vacuum Assisted Closure|Vacuum Assisted Device is used in the wound.
2537140|NCT02649205||Chronic kidney disease (pre-dialysis)|Observational study: Supplemented protein-restricted diet
2537208|NCT02649062|Experimental|NGM282 Dose 1|NGM282
2537211|NCT02649062|Experimental|NGM282 Dose 2|NGM282
2537216|NCT02649062|Placebo Comparator|Placebo|Placebo
2537415|NCT02647463|Experimental|Attachment and Biobehavioral Catch-up|10-session intervention for parents and infants aimed at increasing parents' nurturance and following the lead, and reducing frightening behavior
2537417|NCT02647463|No Intervention|Waitlist Control|Waitlist Control
2537441|NCT02647294|Experimental|Polyunsaturated omega-3 fatty acids|Patients will receive n-3 fatty acids (Maxicor) 3,6 g/day.
2537443|NCT02647294|Placebo Comparator|Placebo|Patients will receive placebo (soya oil)
2537492|NCT02647034||pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
2537494|NCT02647034||non-pulmonary hypertension|The two groups were defined by catheterization result. (no intervention)
2537518|NCT02646774|Experimental|Micafungin group|Injection
2537735|NCT02645682|Experimental|anti-infection CVC (Certofix®protect)|intervention group
2537740|NCT02645682|Active Comparator|normal CVC (Certofix®)|control group
2537770|NCT02645227|Active Comparator|Group 1|Open flap debridement (OFD)
3167915|NCT00544635|Experimental|A|scars will be treated with light
3167916|NCT00544635|Placebo Comparator|B|no intervention
3167917|NCT00544687|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
3167918|NCT00544687|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
3167919|NCT00544687|Active Comparator|3|0.1% mometasone furoate
3167920|NCT00544687|Active Comparator|4|0.1% nortriptyline HCl
3167921|NCT00544687|Active Comparator|5|Karison® Creme (clobetasol-17-propinate 0.05%)
3167922|NCT00544687|Placebo Comparator|6|Vehicle (placebo)
3167923|NCT00544700|Active Comparator|Arm A: Bevacizumab monotherapy|Bevacizumab maintenance monotherapy
3167924|NCT00544700|Other|Arm B: No maintenance|No antitumor treatment until progression
3167925|NCT00544726|Active Comparator|1|Physical training
3167926|NCT00544726|Placebo Comparator|2|No physical training
3167927|NCT00544739||1|323 women with established coronary artery disease before 55 year of age
2536619|NCT02653118||Cohort 2: GARDASIL in the Base Study|Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
2536649|NCT02652897||Exposure to glioma resection surgery|Patients undergoing elective glioma resection
2536651|NCT02652897||Exposure to colon resection surgery|Patients undergoing elective colon cancer resection
2536687|NCT02652585|Active Comparator|Naltrexone|"1 capsule naltrexone 25 mg per day, oral use, day 1 to day 3;~1 capsule naltrexone 50 mg per day, oral use, day 4 to day 28"
2536691|NCT02652585|Placebo Comparator|Placebo|1 capsule placebo, oral use, day 1 to day 28
2536721|NCT02652403|Active Comparator|Complete conventional dentures|Complete dentures fabricated by conventional technique.
2536722|NCT02652403|Active Comparator|Complete simplified dentures|Complete dentures fabricated by simplified technique
2536763|NCT02652182||1|patients with acute ST (S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Huai'an first people's hospital
2536767|NCT02652182||2|patients with acute ST(S- and T-wave)-segment elevation myocardial infarction who received emergent percutaneous coronary intervention in Nanjing Drum Tower hospital
2536803|NCT02651948|Experimental|Transperineal prostate biopsy (TPB)|Transperineal prostate biopsy MRI-guided
2536811|NCT02651948|Active Comparator|Transrectal prostate biopsy (TRB)|Transrectal prostate biopsy echo-guided
2536834|NCT02651610|Active Comparator|Taxane|Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
2536836|NCT02651610|Experimental|Bavituximab plus taxane|Bavituximab 3 mg/kg weekly PLUS Docetaxel on Day 1 of 21-day cycles OR Paclitaxel on Days 1, 8, and 15 of 28-day cycles
3201928|NCT00908089|Active Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 35 mg/kg/week)+ Prednisolon 7.5 mg/day + infliximab 3 mg/kg at weeks 4, 6, 10, 18, 26
3201929|NCT00908089|Placebo Comparator|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|Combination therapy with 3 DMARDs (starting with methotrexate 10-25 mg/week, sulphasalazine 1-2 g/day and hydroxychloroquine 25 mg/kg/week)+ Prednisolon 7.5 mg/day + placebo at weeks 4, 6, 10, 18, 26
2537042|NCT02650102|Experimental|antipsychotics|This group was treated with one of 5 antipsychotics(risperidone/olanzapine/aripiprazole/quetiapine/ziprasidone) randomly.
2537047|NCT02650102|No Intervention|health control|This group was treated with no invention
2537101|NCT02649621|Experimental|Amniotic Membrane Extract Eye Drop recipient|patients with limbal stem cell Deficiency who receive amniotic membrane transplantation and amniotic membrane extract eye drop as eye drop.
2537148|NCT02649348|Other|pre-operative prehabilitation|Patients in the pre-operative prehabilitation group required the exercise intervention protocol, which included climbing six flights of stairs at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction following abdominal surgery by using a full elastic breathable abdominal bandage.
2537157|NCT02649348|No Intervention|Comparator|Patients in the control group did not need to undergo this pre-rehabilitation protocol and prepared conventionally.
2537205|NCT02649036||Emergency call population|Citizens over 18 years old from the Capital Region of Denmark with a first time emergency call within a two-year study period (1/12-2011-30/11-2013)
2537213|NCT02649036||Background population|Citizens over 18 years old from the Capital Region of Denmark with no emergency call within a two-year study period (1/12-2011-30/11-2013)
3201930|NCT00908102|Active Comparator|BB|"Subjects received the back book booklet, which is an self-information booklet about managing low back symptoms.~Included in the Mild and Mild vs. NC interventions."
3201931|NCT00908102|Experimental|BB+A|"Subjects received a back book booklet and also oral advice based on the back book by the occupational health professional (OH Nurse or OH Physician in mild or moderate intervention, respectively).~Included in the Mild and Mild vs. NC interventions. Arm was also used as a control at the Moderate and Moderate vs. NC interventions."
2537317|NCT02647996||Conscious patients|"group: TBI patients awoken from comatose state with normal level of consciousness.~intervention: fMRI (resting state) and structural (DTI)"
2537320|NCT02647996||DOC patients|"group: TBI patients awoken from comatose state with abnormal level of consciousness~intervention: fMRI (resting state) and structural (DTI)"
2537366|NCT02647814|Experimental|Salud al Día|The participants in the intervention group will receive interactive text-messages with a link to support if needed for: clinic appointment reminders, follow-up on medicine and referral adherence, and illness care needs and use. Participants will additionally receive reminders for insurance renewal, food stamp applications, and health-promoting community events. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
2537368|NCT02647814|No Intervention|Usual Care|The participants in the usual care group will receive the clinic's usual care in terms of receiving no text messages. Participants in this arm will complete a baseline survey when their infant is ≤ 2 months of age, a mid-point survey at 7-9 months, and a follow-up survey at by age 15 months.
2537434|NCT02647593||gallstone hepatitis group,|gallstone hepatitis group (Among patients diagnosed as CBD stone who displayed above 400 IU/L of aminotransferase without cholangitis),
2537436|NCT02647593||control group|control group (Among patients diagnosed as CBD stone who showed the normal value of aminotransferase)
3201932|NCT00908102|Experimental|DBC|A graded activity back school program was carried out in a physiotherapy out-patient clinic that consisted of one-hour session twice or three times per week, lasting for 12 weeks, supervised by a specially trained physiotherapist. Arm is included in the MOderate and Moderate vs. NC interventions.
2537551|NCT02646722||No pain|patients show no pain on rocuronium injection
2537552|NCT02646722||mild pain|patients move a hand only on rocuronium injection
2537555|NCT02646722||moderate pain|patients move a arm on rocuronium injection
2536643|NCT02653040|No Intervention|Treatment as usual|Characterized by full white light with little variation through a day cyclus.
2536717|NCT02652741|Experimental|Drug administration|Enalapril Orodispersible Minitablet (ODMT), 0.25 mg or 1 mg, administered 1x/day or 2x/day for up to 8 weeks
3201933|NCT00908102|Experimental|PMU|An intensive, multidisciplinary LBP rehabilitation program was carried out in a physical medicine out-patient unit at the local Central Hospital. The program included a 3-week pre-course of 1,5 hour session at 3 days per week, closely followed by a 3-week intensive rehabilitation course of 6.5 hours per day for 5 days per week. A personal graded activity training program was made for each subject and patients were later called for follow-up visit within 1 year of the initial course. Arm is included in the MOderate and Moderate vs. NC interventions.
3201934|NCT00908102|Placebo Comparator|NC|Natural course of low back pain
2536876|NCT02651350|Experimental|Methylprednisolone|Participants will receive methylprednisolone from week 0 through week 48 study visit in combination with standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) in the first 12 weeks. Participants will then be followed until week 72 study visit.
2536882|NCT02651350|Active Comparator|Standard Treatment|Participants will only receive standard treatment (namely,routine liver protection drugs) including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72 study visit.
2536917|NCT02651077||Case Group|38 women with severe and deep endometriosis, aged 18 to 45 years old and hospitalized at Nantes University Hospital for surgical indication of endometriosis lesions ablation.
2536924|NCT02651077||Control Group|38 women aged 18 to 45 years old without suggestive signs of endometriosis
2536943|NCT02650791|No Intervention|Prophylactic Platelet Transfusions|Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 10^9/L.
2536946|NCT02650791|Experimental|Prophylactic Tranexamic Acid|Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral dose of Tranexamic Acid 1 gram three times daily. Tranexamic Acid will start when Platelet count is less than 50 x 10^9/L and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions
2536994|NCT02650479|Other|IV exenatide - pilot study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2536995|NCT02650479|Experimental|Treatment Group A - core study|IV Exenatide Infusion 0.1250 mcg/kg/hour for 0.5 hours followed by 0.0625 mcg/kg/hour for 5.5 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2536997|NCT02650479|Experimental|Treatment Group B - core study|IV infusion of placebo over 6 hours, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2536998|NCT02650479|Experimental|Treatment Group C - core study|IV infusion of placebo over 6 hours and a single oral dose of 400 mg moxifloxacin within 1 min of start of infusion, preceded by IV Palonosetron 0.25 mg for nausea/vomiting prophylaxis.
2537039|NCT02650089|Experimental|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
2537041|NCT02650089|Experimental|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 8 repetitions were performed for each exercise, with an interval of 90 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
2537046|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
2537090|NCT02649712|Active Comparator|Unilateral stent|Patients undergo placement of unilateral biliary stent on day 1.
2537100|NCT02649712|Active Comparator|Bilateral stents|Patients undergo placement of bilateral biliary stents on day 1.
2537144|NCT02649257|Experimental|MC 6125 AS IOL + CTR|All patients received the same procedure: cataract surgery with phakoemulsification, implantation of a capsular tension ring (CTR13/11) and implantation of an intraocular lens (MC 6125 AS).
2537298|NCT02648386|Sham Comparator|Laparoscopic surgery|Patients receive no interventions after rectal cancer treatment.
2537299|NCT02648386|Experimental|NeuroRegen scaffold transplantation|Patients receive NeuroRegen scaffold transplantation after rectal cancer treatment.
2537301|NCT02648386|Experimental|NeuroRegen scaffold/BMMCs transplantation|Patients receive autologous bone marrow mononuclear cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
2537304|NCT02648386|Experimental|NeuroRegen scaffold/HUC-MSCs transplantation|Patients receive allogeneic human umbilical cord mesenchymal stem cells with NeuroRegen scaffold transplantation after rectal cancer treatment.
3201935|NCT00908154|Other|Cohort 1|
3201936|NCT00908154|Other|Cohort 4|
3201937|NCT00908154|Other|Cohort 3|
3201938|NCT00908154|Other|Cohort 2|
3201939|NCT00908167|Other|Research Participants|Participants treated with sorafenib, cytarabine and clofarabine.
3201940|NCT00908193|Experimental|1|robot-assisted coelioscopy
3201941|NCT00908193|Active Comparator|2|conventional coelioscopy
3201942|NCT00908206|Placebo Comparator|Placebo|Placebo to match GSK598809.
3201943|NCT00908219|Experimental|Bevacizumab IV|All subjects will be treated with an intravenous infusion of the experimental drug (Bevacizumab 15 mg/kg) every 3 weeks for a total of twelve (12) weeks on study.
3201944|NCT00908245|Experimental|Preconditioning|Surgery with ischemic preconditioning
3201945|NCT00908245|Active Comparator|Control|Surgery without preconditioning ischemia
3201946|NCT00908271|Other|Dapagliflozin|PO and IV
2536788|NCT02651974|Active Comparator|Control condition|A control invitation letter similar to the previous standard (non-incentive) invitation with slight wording and grammatical improvements will be mailed to patients randomly assigned to this group.
2536793|NCT02651974|Active Comparator|Cost condition|A control invitation letter with the addition of one line informing participants of the average value of the KIT procedure will be mailed to patients randomly assigned to this group.
2536796|NCT02651974|Active Comparator|Cost/Future condition|An invitation letter with the average value of the KIT procedure and a sentence assuring participants that should a follow-up test be requested, it will also be provided free of charge will be mailed to patients randomly assigned to this group.
2536832|NCT02651675|Experimental|AAV directed hLDLR gene therapy|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
2536866|NCT02651363||Patients treated with Dolocordralan|
3201947|NCT00908284|Active Comparator|Control Group|Participants will take part in a 12-week control group.
3201948|NCT00908284|Experimental|Exercise Program|Participants will take part in a 12-week exercise program.
3201949|NCT00908323||A|Participants receiving the JS7 DNA and MVA/HIV62 vaccinations in HVTN 205
3201950|NCT00908323||B|Participants receiving the placebos of the JS7 DNA and MVA/HIV62 vaccines in HVTN 205
3201951|NCT00908336|Experimental|Docetaxel and Erlotinib|"Patients in the experimental arm will receive sequential treatment of intermittent erlotinib and docetaxel up to 4 cycles in the absence of disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.~After 4 cycles, participants will receive 150 mg of erlotinib per day until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment."
2537180|NCT02649114|Active Comparator|Cognitive-Behavioural Therapy|This version of CBT is based on techniques employed in evidence-based approaches to a transdiagnostic sample. The programme includes; individualized formulation, taking into account different maintaining factors across cases (e.g., nutritional and/or emotional drivers for binging); agenda setting; homework; change in diet (particularly to improve carbohydrate intake); diary-keeping; exposure; behavioral experiments; cognitive restructuring; and surveys. The behavioral change is maintained as a focus, along with changes in mood and cognitions.
2537181|NCT02649114|Experimental|Compassion-Focused Therapy|There are four main treatment elements to the program. Two of these are linked to the experience of being a therapy group. This involves patients providing compassionate support to other group members.The third treatment element involves compassionate mind training which mainly focuses on activating the soothing system via imagery and related practical exercises.The final element of the program aims to help patients improve their ability to use their wider social network to access support.
2537225|NCT02648828||Intern|Interns are in their first year of residency.
2537229|NCT02648828||Residents|Residents are in their 2nd or 3rd year of residency.
2537230|NCT02648828||Attendings|Attendings are physicians who have completed their residency.
2537272|NCT02648490|Experimental|HLX07, in patients with solid cancers.|"Each cycle of treatment consists of 4 weeks. Patients who enroll into this study will receive weekly infusion of assigned dose of HLX07. No intra-patient dose escalation is allowed.The proposed dose escalation sequence is 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg.~Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07, followed by dexamethasone 10 mg intravenous infusion for 10 minutes, and followed by diphenhydramine 30 mg intravenous infusion for 10 minutes. If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions."
2537338|NCT02647970|Experimental|Group A|Dietary intervention
2537341|NCT02647970|Active Comparator|Group B|Dietary intervention
2537455|NCT02647697|Experimental|Radiprodil|Subjects will receive a single dose of Radiprodil 30 mg in suspension form, orally via a syringe in the morning of Day 1.
2537514|NCT02647021|Active Comparator|Therapeutic Exercise|"Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function."
2537519|NCT02647021|Experimental|Therapeutic + Lower Body Exercise|"The Therapeutic Exercise Program (standard care) will include:~Neck range of motion and strengthening, and posture retraining.~Shoulder specific progressive resistance exercise program that focuses on spinal accessory nerve dysfunction and rehabilitation of trapezius muscle function.~The Resistance Exercise component will target 6-8 muscle groups of the lower extremities and core including gluteal, quadriceps, hamstrings, abdominals, and gastrocnemius muscles. A progressive introduction of exercises will occur over the first 3 weeks.~a personalized program of lower extremity resistance exercises~core strengthening exercises"
2537692|NCT02645747||Group 1|The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.
2537745|NCT02645643|Experimental|intervention group|Medical students rolled into this group would accept education of medical humanities.
2537750|NCT02645643|No Intervention|control group|Medical students rolled into this group would not gain education of medical humanities.
2537775|NCT02645240|Experimental|Heparin injection|Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
2537895|NCT02644460|Experimental|Stratum A|Appropriate dose RT will be administered in 30-33 fractions over approximately 6 weeks for Stratum A patients. Treatment with abemaciclib (LY2835219) will start on the same day as RT and continue twice daily during and after RT for a maximum treatment duration of 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib (LY2835219) starting with dose level 1 (80% of adult dose). A cycle is defined as 28 days and the first 6 weeks of therapy will constitute the dose-limiting toxicity (DLT)-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
2536700|NCT02652975|Experimental|Category 2|Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2536703|NCT02652975|Experimental|Category 3|Examination of participants one year after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
2536733|NCT02652273|Experimental|Abatacept|Abatacept 125mg administered via subcutaneous injection once a week for 24 weeks
2536797|NCT02652091||Interferon beta-1b|Patients diagnosed with relapse-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are injecting Betaseron via the Betaconnect device.
3201952|NCT00908336|Active Comparator|Erlotinib|Erlotinib (Tarceva®) 150 mg/day po daily until disease progression, unacceptable toxicity, patient refusal or investigator's decision to discontinue the treatment.
3201953|NCT00908362|Active Comparator|A|Inhalation of Fluticasone (via discus) twice daily for 28 days
2536952|NCT02650700|Experimental|Chemotherapy plus spleen radiotherapy|Chemotherapy plus spleen radiotherapy are performed, simultaneously, to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). The intervention is spleen radiotherapy.
2536955|NCT02650700|Other|Chemotherapy alone|Chemotherapy is performed to the subjects with advanced lung cancer who experienced chemotherapy induced thrombocytopenia (≧grade II CIT). When severe CIT (≧grade III) occurs, the subjects should receive chemotherapy plus spleen radiotherapy. The intervention is spleen radiotherapy.
2536999|NCT02650544|Experimental|mirtazapine|Mirtazapine arm will be orally administered with mirtazapine 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
2537000|NCT02650544|Placebo Comparator|Placebo|Placebo arm will be orally administered with placebo 15mg, QD, consecutive medication for 8 weeks; along with palliative chemotherapy regimen decided by investigators.
2537071|NCT02649881||isolated heart from heart transplantation|
2537084|NCT02649582|Experimental|Single Arm|Dendritic cell vaccine plus temozolomide chemotherapy
2537142|NCT02649387|Experimental|Treatment (ibrutinib)|"Patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 4 weeks* for up to 36 courses in the absence of disease progression or unacceptable toxicity.~Note: *The last course may last up to 56 days to accommodate the study drug discontinuation visit."
2537207|NCT02648893|Experimental|MBFC-Exp|The MBFC-Exp (Multiple biofortified food crops - Experimental) arm will consume meals based on biofortified food crops.
2537209|NCT02648893|Active Comparator|MBFC-C|The MBFC-C (Multiple biofortified food crops - Control) arm will consume the same meals based on non-biofortified (commercially available) food crops.
2537273|NCT02648529|Experimental|Patients with BCECTS|Patients with BCECTS on which MRI, fMRI and neuropsychological assessment will be performed
2537281|NCT02648529|Other|Healthy volunteers|Healthy volunteers on which MRI, fMRI and neuropsychological assessment will be performed
2537316|NCT02648048|Experimental|Vismodegib and Pirfenidone|Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.
2537375|NCT02647749|Experimental|Group 1 : Cardiac rythm radiofrequency ablation|Prospective recruitment
2537376|NCT02647749|Experimental|Group 1: Implantation or programming of a pacemaker|Prospective recruitment
2537380|NCT02647749|Experimental|Group 1: Risk of serious arrhythmias or sudden death|Prospective recruitment
2537383|NCT02647749|Active Comparator|Group 2: Cardiac rythm radiofrequency ablation|Retrospective recruitment
2537388|NCT02647749|Active Comparator|Group 2 : Implantation or programming of a pacemaker|Retrospective recruitment
2537390|NCT02647749|Active Comparator|Group 2 : Risk of serious arrhythmias or sudden death|Retrospective recruitment
2537428|NCT02647437|Experimental|Levetiracetam, Then Placebo|2 weeks of levetiracetam administration (125 mg pill, bid), followed by a 1-2 week washout, then 2 weeks of placebo pill administration (bid).
2537432|NCT02647437|Experimental|Placebo, Then Levetiracetam|2 weeks of placebo pill administration (bid), followed by a 1-2 week washout, then 2 weeks of levetiracetam administration (125 mg pill, bid).
2537509|NCT02647112|Experimental|Bladder EpiCheck|Urine sample will be tested with the Bladder EpiCheck in conjunction with cystoscopy and cytology
2537512|NCT02647112|No Intervention|Practice of medicine|Practice of medicine including cystoscopy and cytology
2537578|NCT02646605||patients initiating ART|HIV positive men and women initiating ART
2537583|NCT02646605||patients on established ART|HIV positive men and women on established ART
3201954|NCT00908362|Active Comparator|B|Inhalation of Fluticasone and Salmeterol (via discus) twice daily for 28 days
3201955|NCT00908362|Placebo Comparator|C|Inhalation of Placebo (via discus) twice daily for 28 days.
2537712|NCT02645695|Active Comparator|routine pulmonary rehabilitation|routine pulmonary rehabilitation consisted of position giving technique
2537714|NCT02645695|Active Comparator|chest wall vibration technique|chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours.
2537761|NCT02645448|Other|Resistance Exercise Low intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
2537763|NCT02645448|Other|Resistance Exercise High intensity|"Day 1 (Control Session)~Day 2 (Resistance Exercise)~Day 3 (Duration of effect)"
2537829|NCT02644980|Experimental|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
2537831|NCT02644980|Experimental|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
2537878|NCT02644603|Experimental|Enhanced Recovery After Surgery|Patients underwent ERAS protocol
2537879|NCT02644603|No Intervention|Conventional Treatment|Patients underwent conventional treatment
3201956|NCT00908401|Active Comparator|sucrose|This group will receive oral sucrose for procedural pain
3201957|NCT00908401|Experimental|breastmilk|this group will receive breastmilk as analgesic product to avoid procedural pain
3201958|NCT00908414|Experimental|Panel 1: Single Dose Escalation|Panel 1 will receive doses of 40 milligram (mg) (Session Ia), 100 mg (Session IIa), 200 mg (Session IIIa) and 400 mg (Session IVa) of TMC589337 or placebo.
2536821|NCT02651805|Experimental|Mechanical Insufflation-Exsufflation Group|Patients will receive usual care except suctioning or cough augmentation techniques+Mechanical Insufflation-Exsufflation
2536824|NCT02651805|Active Comparator|Usual Care Group|Patients will receive the usual care provided by the hospital, all interventions to control respiratory secretion will be verified in patient chart
2536868|NCT02651454|Experimental|Daesiho-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2536872|NCT02651454|Experimental|Jowiseungcheung-tang|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2536880|NCT02651454|Placebo Comparator|Placebo|Dose: 6g, three times a day, each taken before or between meals for 12 weeks
2536905|NCT02651064|Experimental|HIP|Received a 30% rebate on targeted fruits and vegetables (TFV) purchased using SNAP benefits in participating retailers. TFV earning the rebate included fresh, canned, frozen, and dried fruits and vegetables without added sugars, fats, oils, or salt, excluding white potatoes, mature legumes (dried beans and peas), and 100% juice.
2536906|NCT02651064|No Intervention|Non-HIP|Received SNAP benefits as usual.
2536993|NCT02650583|Experimental|Supportive care (Enhancing Connections Program)|Patients participate in Enhancing Connections Program comprising of anchoring patients to help their child, adding to listening skills, building on listening skills, being a detective of their child's coping, and celebrating success for 5 sessions. Patients also receive workbook which includes text from the sessions, handouts, and at-home assignments to be completed between sessions.
2537015|NCT02650154||Pre-ketamine group|Blood samples are taken prior to the administration of ketamine.
2537018|NCT02650154||Post-ketamine group|Blood samples are taken several hours after the administration of ketamine.
3167928|NCT00544739||2|347 clinically healthy, age matched women selected from the National Health Survey WOBASZ study with negative history of CVD or negative exertional chest pain.
2537103|NCT02649738|Experimental|Corneal tissue inlay|The treated cornea will be implanted with a thin disc of preserved corneal tissue
2537134|NCT02649309|Experimental|RIPre + RIPost|Intervention: RIPre 200 mmHg + RIPost 200 mmHg
2537136|NCT02649309|Experimental|RIPre + Sham|Intervention: RIPre 200 mmHg + Sham 10 mmHg
2537141|NCT02649309|Experimental|Sham + RIPost|Intervention: Sham 10 mmHg + RIPost 200 mmHg
2537154|NCT02649309|Sham Comparator|Sham + Sham|Intervention: Sham 10 mmHg + Sham 10 mmHg
2537194|NCT02648854|Other|Group 1|<Group 1> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition)
2537195|NCT02648854|Other|Group 2|<Group 2> Period 1: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (High fat meal fed condition) 7 days for wash out Period 2: administered CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T to oral (Fasting condition)
2537280|NCT02648672|Experimental|BPN14770|A single oral dose of BPN14770.
2537286|NCT02648672|Placebo Comparator|Placebo|A single oral dose of placebo matching BPN14770
2537480|NCT02647216|Active Comparator|Mindfulness Based Cognitive Therapy (MBCT)|MBCT is a structured 8-week group intervention which integrates aspects of cognitive behavioral therapy (CBT) with components of the Mindfulness Based Stress Reduction (MBSR) program.
2537485|NCT02647216|Active Comparator|Treatment as Usual (TAU)|Subjects randomized to TAU will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study. All treatments received over the course of the study (for the TAU group) and outside of the study (for the MBCT group) will be assessed at the 3-month follow up (Visit 3).
2537545|NCT02646865|Experimental|Self-Compassion Enhanced Cognitive-Behavioral Therapy|Group Cognitive-Behavioral Therapy for social anxiety enhanced with exercises targeting self-compassion
2537549|NCT02646865|Active Comparator|Cognitive-Behavioral Therapy|Standard Group Cognitive-Behavioral Therapy for social anxiety
2537577|NCT02646514|Experimental|RFA with RF catheter (ELRA®) with stenting|
2537581|NCT02646514|Active Comparator|stenting|
2537774|NCT02645227|Active Comparator|Group 3|OFD with PRF and 1.2% Rosuvastatin
3167929|NCT00544752|Experimental|16|indoor temperature of 16 degrees celcius
3167930|NCT00544752|Experimental|20|indoor temperature 20 degrees celcius
3167931|NCT00544752|Experimental|24|indoor temperature of 24 degrees celcius
3167932|NCT00544765|Experimental|resp: 4xTAC|Patients sufficiently responding (iPR, iCR) will recieve 4 further cycles of TAC
3167933|NCT00544765|Experimental|resp: 6xTAC|Patients sufficiently responding (iPR, iCR) will recieve 6 further cycles of TAC
3167934|NCT00544765|Experimental|nonResp: 4xTAC|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of TAC
3167935|NCT00544765|Experimental|nonResp: 4xNX|Patients non-sufficiently responding (iNC) will recieve 4 further cycles of NX
3167936|NCT00544791|Experimental|A|melatonin 5 mg, daily dose for 6 months
3167937|NCT00544791|Placebo Comparator|B|
3167938|NCT00544804|Experimental|Lapatinib|Dose Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy With Biomarker Analysis in Patients With HER2-Overexpressing Breast Cancer
3167939|NCT00544830|Experimental|Treatment (androgen therapy, radiation therapy)|"ADT: Patients not currently on ADT receive goserelin acetate SC or leuprolide acetate via injection once every 4 or 12 weeks and bicalutamide PO QD. Treatment repeats every 12 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients already receiving ADT at the time of enrollment continue treatment until they have received 36 weeks of therapy.~RADIATION THERAPY: Patients achieving PSA normalization after initiation of androgen deprivation therapy undergo intensity-modulated radiation therapy daily for 2-7 weeks during or after completion of androgen deprivation therapy."
3167940|NCT00544856|Experimental|1|cognitive intervention
3167941|NCT00544856|Placebo Comparator|2|
3167942|NCT00544921|Experimental|50 mg|
3167943|NCT00544921|Experimental|100 mg|
3167944|NCT00544921|Experimental|250 mg|
3167945|NCT00544921|Experimental|500 mg|
3167946|NCT00544921|Experimental|750 mg|
3167947|NCT00544921|Experimental|1000 mg|
3167948|NCT00544921|Placebo Comparator|Placebo|
3201959|NCT00908414|Experimental|Panel 2: Single Dose Escalation|Panel 2 will receive doses of 40 mg (Session Ib), 100 mg (Session IIb), 200 mg (Session IIIb) and 400 mg (Session IVb) of TMC589354 or placebo.
2536822|NCT02651792|Active Comparator|ketamine- propofol|IV Ketamine 1mg/kg + Propofol 1.2 mg/kg will be given for sedation.
2536825|NCT02651792|Active Comparator|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
3201960|NCT00908414|Experimental|Panel 3: Multiple dosing|AA mg (Final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. (twice daily) during 7 days (Session Va) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIa).
3201961|NCT00908414|Experimental|Panel 4: Multiple dosing|BB mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session Vb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session VIIIb).
3201962|NCT00908414|Experimental|Panel 5: Multiple dosing|CC mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) b.i.d. during 7 days (Session VIa) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXa).
2536944|NCT02650869|Experimental|Standard care + Breast milk+ Probiotics|The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.
2536947|NCT02650869|Active Comparator|Standard care|The control group will be given standard care without the addition of probiotics
2536984|NCT02650505|Experimental|LEO 43204|LEO 43204 will be applied topically to the skin under open conditions 10 times
2536987|NCT02650505|Placebo Comparator|LEO 43204 vehicle|LEO 43204 vehicle will be applied topically to the skin under open conditions 10 times
2537031|NCT02650271|Experimental|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
2537033|NCT02650271|Active Comparator|Tenofovir|Patients will be received tenofovir (1#/d) after 3 days of liver resection.
2537093|NCT02649764|Experimental|Treatment (fludarabine phosphate, cytarabine, prexasertib)|Patients =/< 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-4, cytarabine IV over 4 hours on days 1-4, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Patients > 65 years of age: receive fludarabine IV over approximately 2 hours on days 1-3, cytarabine IV over 4 hours on days 1-3, and prexasertib (LY2606368) IV over approximately 2 hours on days 1, 3, and 4 or on days 1-4. Treatment for both age groups repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
2537146|NCT02649127|Experimental|Imaginal Therapy Only|The imaginal exercise of exposure therapy will be manualized (Rothbaum, Foa & Hembree, 2007) and adapted with the permission of Dr. Foa for combat-related stress disorders (Peterson, Cigrang & Riggs, 2008). While traditional exposure therapy includes both imaginal exposure and in vivo exposure, this study will use only the imaginal exposure components. Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes.
2537156|NCT02649127|Experimental|Exercise Only|The aerobic exercise regimen will be standardized according to the American College of Sports Medicine recommendations: frequency of a minimum of 5 sessions per week, at a vigorous intensity [>60% of oxygen uptake reserve (VO2R)], time of 20-25 minutes per exercise session. To determine the exercise heart rate intensity, the Karvonen formula for heart rate reserve will be used. The mode of exercise will be purposeful walking or jogging. The goal of the exercise is not training, but rather to keep the participant's heart rate >60% of their individually-determined heart rate reserve.
2537162|NCT02649127|Experimental|Imaginal Therapy & Exercise Combined|Participants will meet with a therapist the first week of treatment and every-other week for a total of five appointments over eight weeks. During the second session, the therapist will help the participant make an approximately 20-minute voice tape recording of their traumatic experience which they will listen to 5-days/week. A new recording will be made with the therapist during sessions 3 and 4 also, for a total of three tapes. Participants will exercise listening to their tape at least 5-times/week outside of scheduled unit Physical Training. Participants will wear the heart rate monitor to record their exercise activity.
3201963|NCT00908414|Experimental|Panel 6: Multiple dosing|DD mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589354 (n=6) b.i.d. during 7 days (Session VIb) ) plus a single oral dose of 300 mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg TMC310911, single dose (Session IXb).
2537233|NCT02648841|Active Comparator|Adjuvant Chemotherapy|The interventions of adjuvant chemotherapy group is 8 cycles of SOX(S-1+Oxaliplatin) chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
2537362|NCT02647853|Placebo Comparator|Placebo|Placebo product once daily to 50 cm2 for 14 days.
3201964|NCT00908414|Experimental|Panel 7: Multiple dosing|EE mg (final doses will be selected based upon data obtained in the single dose sessions (i.e., Sessions I, II, and III) TMC589337 (n=6) or YY mg TMC589354 (n=6) b.i.d. or q.d. during 7 days (Session VII) ) plus a single oral dose of 300 mg or 600mg of TMC310911 on Day 7. After at least 14 days following Day 7 of multiple dosing, participants will receive 300 mg or 600 mg TMC310911, single dose (Session X).
3201965|NCT00908427|Active Comparator|1|PVP group
3201966|NCT00908427|Active Comparator|2|TURP group
3201967|NCT00908453|Experimental|15mg/kg of loading dose|
3201968|NCT00908453|Experimental|18mg/kg of loading dose|
3201969|NCT00908453|Experimental|22.5mg/kg of loading dose|
3201970|NCT00908479|Experimental|LE|Leg Exercise group
3201971|NCT00908479|Experimental|LM|Leg Management (Control group)
2536863|NCT02651636|Experimental|Open label|Therapy with alpha-lipoic acid (800 mg), myoinositol (2000 mg) and folic acid (400 mcg) daily for six months
3167949|NCT00544934|Experimental|250 mg|
3167950|NCT00544934|Experimental|500 mg|
2537054|NCT02650063|Experimental|DE-117 ophthalmic solution|
2537078|NCT02649751|Experimental|Group 1|"200 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
2537079|NCT02649751|Experimental|Group 2|"400 mg roscovitine (8) or placebo (4) once daily for 4 cycles of 7 days (4 days on and 3 days off)"
2537080|NCT02649751|Experimental|Group 3|"400 mg roscovitine (8) or (4) placebo twice daily for cycles of 7 days (4 days on and 3 days off)"
2537277|NCT02648503|Experimental|Deep neuromuscular block|PTC=1-2
2537284|NCT02648503|Active Comparator|Moderate neuromuscular block|TOF=1-2
2537312|NCT02648139|Experimental|Experimental dentifrice|Dentifrice containing the extract of Eugenia uniflora rip fruit. Each 10 ml of E. uniflora L. dentifrice comprises the following components: Hydroalcoholic extract of the ripe fruit of E. uniflora L. (3.0%), preservatives (parabens; 0.02 g), and dentifrice base (silicon dioxide, sodium lauryl sulfate, white dye, aromatic compounds, sodium saccharin, and Gangrez sodium salt; q.s.p.). Intervention protocol: three times per day (pea-like amount), for seven consecutive days.
2537314|NCT02648139|Active Comparator|Control Dentifrice|"Control dentifrice - Colgate total 12 (fluoride, 1500 ppm and triclosan, 0.3%)~Intervention protocol: three times per day (pea-like amount), for seven consecutive days."
2537457|NCT02647502|Active Comparator|Continuous calorie restriction|Participants will be provided with a diet that includes approximately 78% of calories each day that would be needed to maintain current BMI.
2537458|NCT02647502|Experimental|Intermittent calorie restriction|Participants will be provided a diet that with a daily calorie intake required to maintain current BMI, except only 25% of this calorie intake will be provided for 2 days a week.
2537465|NCT02647502|Placebo Comparator|Control calorie intake|Participants will be assigned to consume enough calories each day required to maintain current BMI
2537523|NCT02647008|Experimental|ACTIVE TENS|ACTIVE TENS
2537531|NCT02647008|Placebo Comparator|PLACEBO|INACTIVE TENS
2537538|NCT02647008|No Intervention|CONTROL|NO TENS
2537573|NCT02646579|Experimental|Spinal and Peripheral Dry Needling|Participants will receive dry needling to the low back and painful areas in the leg.
2537574|NCT02646579|Active Comparator|Peripheral Dry Needling|Participants will receive dry needling to painful areas in the leg.
2537653|NCT02646345||Pre Checklist|All surgical encounters before surgical checklist implementation
2537661|NCT02646345||Post Checklist|All surgical encounters after surgical checklist implementation
2537696|NCT02645942|Experimental|Intervention group|L-carnitine 1400 mg daily for 8 weeks
2537700|NCT02645942|Placebo Comparator|Placebo group|Placebo
2537754|NCT02645539|Experimental|Single Arm|All patients are treated with the intravascular ventricular assist system (iVAS).
2537824|NCT02644993|Experimental|Proton beam therapy|
2537845|NCT02644720|Experimental|multifocal intraocular lens group|
2537847|NCT02644720|Active Comparator|monofocal intraocular lens group|
2538046|NCT02643602|Experimental|Bicarbonate and theophylline|Hydration with bicarbonate in addition to theophylline
2538049|NCT02643602|Active Comparator|Sodium and theophylline|Hydration with sodium chloride in addition to theophylline
2538117|NCT02643134|Other|Group 1|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
2538124|NCT02643134|Other|Group 2|Patients in Group 2 undergo external physical vibration lithecbole for the treatment after extracorporeal shockwave lithotripsy(ESWL).A multi-dimensional physical harmonic vibration inertial guidance technology
2538199|NCT02642692|Experimental|Patellar Tendon Graft|Kind of graft that will be used for acl reconstruction
2538203|NCT02642692|Experimental|Hamstring Graft|Kind of graft that will be used for acl reconstruction
2538242|NCT02642133|Other|Intervention|All patients were in the same arm - this is a cohort study where the group serves as their own control. Patients who did not undergo the procedure were not included in this outcomes study.
2538286|NCT02641938|Experimental|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
2538292|NCT02641938|Placebo Comparator|Normal Saline|IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
3167951|NCT00544934|Experimental|750 mg|
3167952|NCT00544934|Placebo Comparator|Placebo|
3167953|NCT00544947||D, F|"Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.~Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section."
3167954|NCT00544960|Experimental|1|AT-101 and docetaxel
3167955|NCT00544960|Placebo Comparator|2|placebo and docetaxel
3167956|NCT00545090|Experimental|1|
3167957|NCT00545116|Experimental|a|Active carrier 1: biscuit providing 250 mg hesperidin per piece(6g)
3167958|NCT00545116|Experimental|b|Active carrier 2: liquid skim milk providing 250 mg hesperidin/serve (200 ml) and containing around 300 mg calcium/serving
3167959|NCT00545116|Placebo Comparator|c|Placebo carrier 1: biscuit with the same nutrient composition and appearance as the active biscuit carrier but minus hesperidin
3167960|NCT00545116|Placebo Comparator|d|Placebo carrier 2: liquid skim milk with the same nutrient composition and appearance as the active milk carrier but minus hesperidin
3167961|NCT00545129|Experimental|Tanezumab 10 mg IV + opioids|
3167962|NCT00545129|Placebo Comparator|Placebo + opioids|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
3167963|NCT00545194|Active Comparator|A|sustained release preparation of prostaglandin E2
3167964|NCT00545194|Active Comparator|B|short-acting (instant-released) preparation of prostaglandin E2
3167965|NCT00545207|Experimental|1|
3167966|NCT00545207|Placebo Comparator|2|
3167967|NCT00545220|Experimental|1|PST
3201972|NCT00908492|Active Comparator|Education Control|
3201973|NCT00908492|Experimental|Environmental Skill Building|
2537118|NCT02649478|Experimental|Fluticasone / Salmeterol|"fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura lever operated multidose inhaler (LOMI) inhaler device twice a day by inhalation throughout the study"
2537119|NCT02649478|Active Comparator|Advair Diskus 100/50|Advair Diskus (fluticasone propionate and salmeterol xinafoate) twice a day by inhalation throughout the study
2537120|NCT02649478|Placebo Comparator|placebo inhaler|placebo inhaled powder twice a day by inhalation throughout the study
2537260|NCT02648464|Experimental|Hydroxychloroquine|Hydroxychloroquine 300 mg tablet by mouth daily for 6 months. Patients under the weight of 60 kg: hydroxychloroquine 300 mg tablet daily for 5 days per week for 6 months.
2537264|NCT02648464|Placebo Comparator|Placebo|Placebo tablet by mouth daily for 6 months. Patients under the weight of 60 kg: placebo tablet daily for 5 days per week for 6 months.
2537324|NCT02648113|Experimental|Restrictive transfusion strategy|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
2537326|NCT02648113|Experimental|Liberal transfusion strategy|Transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL.
2537379|NCT02647775|Other|multi-port VATS|Multi-port VATS is an operative method
2537384|NCT02647775|Other|single-port VATS|Single-port VATS is an operative method
2537445|NCT02647489|Experimental|1A - 20 µg PAMVAC + Alhydrogel|The study participant will get 20 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2537449|NCT02647489|Experimental|2A - 20 µg PAMVAC + GLA-SE|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2537453|NCT02647489|Experimental|3A - 20 µg PAMVAC + GLA-LSQ|The study participant will get 20 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
2537454|NCT02647489|Experimental|4A - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2537456|NCT02647489|Experimental|5A - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2537459|NCT02647489|Experimental|6A - 50 µg PAMVAC + GLA-LSQ|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-LSQ administrated three times with each time 28 days interval (day 0-28-56)
2537462|NCT02647489|Experimental|1B - 50 µg PAMVAC + Alhydrogel|The study participant will get 50 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2537466|NCT02647489|Experimental|2B - 50 µg PAMVAC + GLA-SE|The study participant will get 50 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2537467|NCT02647489|Experimental|3B - 100 µg PAMVAC + Alhydrogel|The study participant will get 100 µg of PAMVAC adjuvanted with Alhydrogel administrated three times with each time 28 days interval (day 0-28-56)
2537468|NCT02647489|Experimental|4B - 100 µg PAMVAC + GLA-SE|The study participant will get 100 µg of PAMVAC adjuvanted with GLA-SE administrated three times with each time 28 days interval (day 0-28-56)
2537469|NCT02647489|Placebo Comparator|5B - Placebo|The study participant will get Placebo (physiological saline solution) administrated three times with each time 28 days interval (day 0-28-56)
2537554|NCT02646748|Experimental|pembrolizumab + itacitinib|"Part 1a Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group A-1 and Group A-2 will evaluate the MTD or PAD of itacitinib in combination with pembrolizumab in subjects with select solid tumors."
2537557|NCT02646748|Experimental|pembrolizumab + INCB050465|"Part 1a Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.~Part 1b Group B-1 and Group B-2 will evaluate the MTD or PAD of INCB050465 in combination with pembrolizumab in subjects with select solid tumors.~Part 2 will evaluate the combination of INCB050465 in combination with pembrolizumab in subjects with small cell lung cancer, non-small lung cancer and urothelial cancer."
3201974|NCT00908505|Experimental|physiotherapy|
3201975|NCT00908518||Total Intravenous Anesthesia|Propofol based anesthesia
2537739|NCT02646020|Experimental|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28;
2537741|NCT02646020|Active Comparator|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28
2537787|NCT02645162|Experimental|Preschool|"This arm will receive the community-based preschool intervention.~The preschool sessions will include 2 groups per day (3 years 6months to 4 years 6 months in the morning session and 4 years 7 months to 5 year 6 months in the afternoon session at the time of enrolment)~Each session will last 3 hours for 5 days per week.~The expected CYL-to-child ratio will be 1:15; however, given the expected high level of local demand it may exceed to a maximum of 1:20 ratio."
2537794|NCT02645162|No Intervention|Control|The control group will receive standard services available in the community.
2537960|NCT02644135|Experimental|Halo Oral Spray|Based upon the preliminary studies that assessed the duration of the antimicrobial effects of Halo as reported in the preliminary studies and feasibility, subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
2537989|NCT02643563|Active Comparator|Ropivacaine 1%|Low volume (5 ml) Interscalene Block with Ropivacaine 1%
3201976|NCT00908518||Inhaled anesthesia|Isoflurane based anesthesia
3201977|NCT00908531|Active Comparator|Postoperative letrozole|Definitive surgery without preoperative AI treatment
3201978|NCT00908531|Experimental|Preoperative letrozole|Treatment with letrozole for 4 months before definitive surgery.
2536972|NCT02650622||Cohort 2-Children aged 0-18 years|No intervention will be applied specifically for this cohort. Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care.
2536973|NCT02650622||Cohort 3-Diseased childrens and families|Blood samples will be collected from this cohort by piggybacking the blood draw of patient's standard of care. Skin biopsy will be performed on the proband children with the agreement from parents or guardians.
2537003|NCT02650349|Experimental|spinal cord stimulation|The Vectris® SureScan® MRI lead will be connected to a RestoreSensor® SureScan® MRI neurostimulator.
2537066|NCT02650011||ACLF cohort|Patients who have chronic liver disease and admitted for acute deterioration of liver function
2537081|NCT02649686|Experimental|Durvalumab plus Trastuzumab|Durvalumab q3w until PD Trastuzumab q3w x 6
2537158|NCT02649400||Diastolic Heart Failure|Women with diastolic heart failure and previous coronary artery disease
2537294|NCT02648685||normal glycaemic metabolism|100 subjects
2537295|NCT02648685||Type 2 Diabetes|300 subjects
2537347|NCT02648100||A|120 patients from Carte d'Identité des Tumeurs (CIT), Henri Mondor and Foch hospitals.
2537352|NCT02648100||B|510 cystectomy patients operated between 2005 and 2010 in Henri Mondor and Foch hospitals.
2537359|NCT02648100||C|188 patients treated by cystectomy and adjuvant chemotherapy for locally advanced bladder cancer from a national multicentric study.
2537365|NCT02648100||D|93 patients from the clinical trial GETUG 19 (UNICANCER)
2537450|NCT02647554|Experimental|Ulinastatin group|Ulinastain treatment group：400,000 IU ulinastatin will be reconstituted in 10 mL of 0.9% normal saline, and then dissolved in 100 mL of 0.9% normal saline every 8 hours for 10 days in a double-blind fashion.
2537451|NCT02647554|Placebo Comparator|Placebo group|Placebo control group：Matching with medication
2537503|NCT02646982|Experimental|Candesartan|Candesartan will be given orally once a day in a stepwise manner as follows: All participants will be initiated on 8 mg candesartan. The dose will be increased in 2 week increments to 16 mg and 32 mg as long as the systolic blood pressure (SBP) >100 mm Hg, diastolic blood pressure (DBP) >40 mm Hg and participant reports no symptoms of hypotension (dizziness or weakness). The highest achievable dose will be the Maximal Tolerated Dose (MTD) and the participant will receive this dose for the remaining duration of the study (participants will be treated for 1 year).
2537504|NCT02646982|Placebo Comparator|Placebo|Participants will receive a matched placebo once a day orally for 12 months.
2537558|NCT02646709|Experimental|Ketamine 1|Ketamine 1 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
2537561|NCT02646709|Experimental|Ketamine 1.5|Ketamine 1.5 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
2537565|NCT02646709|Experimental|Ketamine 2|Ketamine 2 mg/kg will be injected during induction. Low dose rocuronium (0.3 mg/kg) will be injected for muscle relaxation.
3201979|NCT00908557|Experimental|1|Patients receiving an information and consent form that has been modified using the LISYCOM methods.
3201980|NCT00908557|Active Comparator|2|Patients receiving a standard information and consent form.
2537734|NCT02645981|Experimental|Donafenib|Drug:Donafenib; Dose:200mg,bid,po.
2537736|NCT02645981|Active Comparator|Sorafenib(Nexavar)|Drug:Sorafenib; Dose:400mg,bid,po.
3201981|NCT00908570|Experimental|1Topical estriol cream|
3201982|NCT00908570|Placebo Comparator|2Placebo cream|
3201983|NCT00908609||1|Patients who undergo routine ultrasound guided biopsy will be studied by optical imaging technique.
3201984|NCT00908609||2|Patients who have advanced breast cancers and are under neoadjuvant chemotherapy treatment will be studied by optical technique.
2537961|NCT02644057|Active Comparator|M-group|Will be given milrinone as an intravenous infusion at 0.2-0.6 mcg/kg/min for a maximum period of 72 hours and adjusted based on creatinine clearance measured by cockcroft-gault equation. It would be titrated based on hemodynamic response , urine output and at the discretion of the treating physician
2537966|NCT02644057|Active Comparator|D-group|Will be given dobutamine as an intravenous infusion at a maximum rate of 20 mcg/kg/min depending on patient tolerance and would adjusted based on hemodynamic response, urine output and at the discretion of treating physician
2537981|NCT02643641|Experimental|BM32-3|2 placebo injections will be given followed by 3 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
2537982|NCT02643641|Experimental|BM32-4|1 placebo injections will be given followed by 4 injections with 20 micrograms each of BM321, BM322, BM325 and BM326
2537983|NCT02643641|Experimental|BM32-5|5 injections with 20 micrograms each of BM321, BM322, BM325 and BM326 will be given
2537984|NCT02643641|Placebo Comparator|Placebo|5 placebo injections (alhydrogel only) will be given
3201985|NCT00908622|Experimental|Skeletal myoblasts|Percutaneous autologous myoblast implantation
3201986|NCT00908622|Placebo Comparator|No cells|Percutaneous culture medium without cells implantation
2538183|NCT02642744|Other|Attending nurse model|The attending nurse model of in-hospital care delivery aims to improve patient understanding, shared decision making, medication adherence, and reduce early readmissions after discharge to improve quality of life. On the inpatient stroke unit, the attending nurse will take ownership of essential aspects of an individual stroke patient's care, education, and transition out of the hospital. To further contribute to the patient's plan of care, the attending nurse will be present on daily teaching rounds.
3201987|NCT00908635||survivor|survivors of patients
3201988|NCT00908635||fatalities|non-survivors of patients
3201989|NCT00908661|Active Comparator|Prophylactic mesh|All patients will have a permanent ostomy and a randomisation with prophylactic mesh
3201990|NCT00908661|No Intervention|without prophylactic mesh|All patients will have a permanent ostomy and a randomisation without prophylactic mesh
3201991|NCT00908674||Group 1|
3201992|NCT00908700|Experimental|Occlusion arm|Surgical intervention: Occlusion of the left atrial appendage (LAA) using 'cut-and-sew' technique appendage occlusion.
3201993|NCT00908700|Active Comparator|Medical arm|Medical arm: The comparator is best medical practice for atrial fibrillation related stroke prevention as per guidelines.
3201994|NCT00908713|Experimental|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
3201995|NCT00908713|Placebo Comparator|Placebo|
3201996|NCT00908726|Experimental|Microemulsion propofol|
2536981|NCT02650648|Experimental|Humanized Anti-GD2 Antibody Hu3F8|This is a phase I study to assess the safety and feasibility of combining HLA-mismatched (KIR ligand incompatible) NK cells with hu3F8 in high-risk NB patients. Following chemotherapy, patients will be treated in sequential groups with a minimum of 3 patients/ dose of NK cells. Three dose levels of NK cells, starting at dose level 1, will be evaluated in this treatment protocol. The goal dose for each dose level is the high boundary (e.g. 9.9x10^6/kg in level 1; 14.9x10^6/kg in level 2, etc), but a range is provided to allow for cases where the goal dose cannot be achieved.
3201997|NCT00908726|Active Comparator|Lipid emulsion propofol|
3201998|NCT00908752|Active Comparator|Brivanib|Adjuvant treatment with TACE Therapy
2537091|NCT02649569||Observational (continuous activity monitoring, questionnaires)|Patients wear an activity monitor throughout and up 4 weeks after completion of radiation therapy. Patients who are willing may continue to wear the monitor through routine follow up appointments. Patients also complete questionnaires at evaluations, which take place prior to radiotherapy initiation, weekly during radiotherapy, and then 2 and 4 weeks after the completion of radiotherapy.
3201999|NCT00908752|Placebo Comparator|Brivanib Placebo|Placebo adjuvant treatment with TACE Therapy
3202000|NCT00908765|Active Comparator|Aerobe Interval Training|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
3202001|NCT00908765|Active Comparator|Moderate Continous Training|Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks
3202002|NCT00908778|Experimental|Vitreosolve I|Intravitreal injection
2537249|NCT02648737|Experimental|Cognitive Behavioural Therapy (CBT)|Patients who will receive CBT plus clinical monitoring will receive 10 weekly individual sessions (60-75 minutes), tailored to the preferences and needs of each patient. In each session, a registered psychologist will address specified aspects of (coping with) anxiety and related concerns with a specific focus on behaviour and thoughts associated with anxiety.
2537251|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status. Patients who receive clinical monitoring only will be given the option to receive CBT once the trial is completed.
2537296|NCT02648360|Experimental|Text Messaging Intervention Arm|Participants will be enrolled in either a dietary or physical activity text messaging program. The dietary program will include nutritional education, reading nutrition labels, portion control, making lifestyle changes, finding social support, and identifying triggers. The physical activity program will provide information on the benefits of physical activity, exercise tips, and encouragement to live more active lifestyles. The programs have limited interactive capability; patients will be asked to respond to specific questions, but questions asked by the participants will be answered with an automated message asking them to contact their health care provider.
2537335|NCT02648074|Experimental|Allergic asthma|Bronchial asthma and sensitization to D. pteronyssinus allergen Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation.
2537339|NCT02648074|Active Comparator|Healthy subjects|"Healthy subjects without allergic and other chronic respiratory diseases (control group).~Interventions: Bronchial challenge with allergen; Eosinophil and linear bronchial smooth muscle cell co-culture formation."
3202003|NCT00908778|Experimental|Vitreosolve|Intravitreal injection
3202004|NCT00908804|Active Comparator|open appendectomy|
3202005|NCT00908804|Active Comparator|laparoscopic appendectomy|
3202006|NCT00908817|Active Comparator|triamcinolone|
3202007|NCT00908817|Placebo Comparator|chlorhexidine|
3202008|NCT00908843|Experimental|(I) BICARBONATE INTRAVENOUS INFUSION|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
3202009|NCT00908843|Active Comparator|(II) ORAL SODIUM SOLUTION|Oral hydration with Sodium solution (Casen solution of rehydratation) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
3202010|NCT00908856|Placebo Comparator|Placebo|Placebo
3202011|NCT00908856|Active Comparator|autologous mononuclear cells|a single intravenous autologous bone marrow mononuclear cell transfusion
3202012|NCT00908856|Active Comparator|autologous marrow stromal cells|a single intravenous autologous marrow stromal cell transfusion
3202013|NCT00908921|Experimental|1|"The treatment period is 16 weeks with 5 visits: at weeks 2, 4, 8, 12, 16. At every visit if Fasting Blood Glucose (FBG) >7.0mmol/L the Glimepiride dosage is increased from 1mg to 2mg or 2mg to 4mg.~At every visit if FBG<3.9mmol/L the Glimepiride dosage is decreased from 4mg to 2mg or 2mg to 1mg.~Patients who have been on 4mg for 4 weeks and FBG>11.0mmol/L at visit, another treatment can be added at the physician's discretion."
2537746|NCT02645656|Experimental|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals.
2537811|NCT02645188|Experimental|Experimental|Cueing
2537815|NCT02645188|No Intervention|Control|
2537885|NCT02644746|Experimental|Acupuncture group|Acupuncture has a long time used for chronic pain including low back pain, sciatica, and other pain related to spina via stimulating specific acupuncture points.
2537887|NCT02644746|Placebo Comparator|Placebo needle group|The placebo needle using in this trial will be unpenetrated needles. Based on our previous research, the placebo needle is a valid control for acupuncture research and may eliminate the placebo effect of acupuncture.
2537897|NCT02644200|No Intervention|ORS|Controls treated with oral rehydration solution (standard therapy)
2537900|NCT02644200|Active Comparator|ORS+GT|Group treated with oral rehydration solution plus gelatin tannate
3202014|NCT00908934|Experimental|1|50 or 400 mg AZD9056, Test formulation
3202015|NCT00908934|Experimental|2|50 or 400 mg AZD9056, Reference formulation
3202016|NCT00908973||Good responders|Excess weight loss of > 60% 1 year after gastric bypass surgery
3202017|NCT00908973||Poor responders|Excess weight loss of =< 50% 1 year after gastric bypass surgery
2537024|NCT02650206|Experimental|Liraglutide group|"Drug with diet control intervention: Subjects assigned to this group receive blinded pens containing liraglutide (commonly known as Victoza), manufactured by Novo Nordisk. Subjects will inject 0.6 mg daily into abdomen during the first week of the study, and if tolerated, will increase dose to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
2537030|NCT02650206|Placebo Comparator|Placebo group|"Diet control-only intervention: Subjects assigned to this group receive blinded pens containing placebo (normal saline) instead of liraglutide (commonly known as Victoza). Subjects will inject 0.6 mg of placebo daily during the first week of the study, will increase to 1.2 mg the second week of the study, and then up to 1.8 mg daily from the third week until the end of the 12-week study. Any adverse symptoms as well as fasting blood glucose will be monitored weekly for safety.~Subjects, with the guidance of the study's dietitian, will remain weight-stable for the first four weeks of the study, and then will be allowed to lose weight for the remaining eight weeks of the study."
3202018|NCT00908973||Lean controls|Non-gastric bypass operated lean individuals, matched for age and sex
3202019|NCT00908986|Experimental|Rituximab|Subjects receive rituximab in an open label manner
2537257|NCT02648373|Experimental|Education|Patients receive an educational video about low back pain based on the Consumer Reports Choosing Wisely recommendation for patients with back pain to avoid early imaging and remain as active as possible. After the video the evaluator and patient discussed key themes from the video and the patient was able to ask any questions. Previously scheduled physical therapy then began with treatment at the therapist's discretion.
2537259|NCT02648373|Active Comparator|Control|Previously scheduled physical therapy was provided with treatment at the therapist's discretion. No educational intervention was provided before beginning physical therapy
2537309|NCT02648269|Experimental|SEL-110|Single intravenous dose of SEL-110
2537310|NCT02648269|Experimental|SEL-212|Single intravenous dose of SEL-110 plus SEL-037 (pegsiticase)
2537311|NCT02648269|Experimental|SEL-037|Single intravenous dose of SEL-037 (pegsiticase)
2537332|NCT02647892|Active Comparator|Arm A|10 mg/mL lidocaine; Frequency: 1
2537334|NCT02647892|Active Comparator|Arm B|9 mg/mL of 10% sodium bicarbonate-90% lidocaine; Frequency: 1
2537337|NCT02647892|Active Comparator|Arm C|7.5 mg/Ml of 25% sodium bicarbonate-75% lidocaine Frequency: 1
2537340|NCT02647892|Active Comparator|Arm D|5 mg/mL 50% sodium bicarbonate-50% lidocaine Frequency: 1
2537421|NCT02647567|Experimental|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
2537422|NCT02647567|Placebo Comparator|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
2537517|NCT02646943||Cohort of patients with chronic chagas cardiomyopathy|"We have established a prospective cohort of 1,959 patients with chronic Chagas cardiomyopathy (CCC) to evaluate if a clinical prediction rule based on electrocardiogram (ECG), Brain Natriuretic Peptide (BNP) levels and other biomarkers can be useful in clinical practice.~The study is being conducted in 21 cities of the northern part of Minas Gerais state in Brazil, and includes a follow up of at least two years. The baseline evaluation included collection of socio-demographic information, social determinants of health, health-related behaviours, comorbidities, medicines in use, history of previous treatment for Chagas Disease (ChD), symptoms, functional class, quality of life, blood sample collection and ECG."
2537612|NCT02646657|Other|Early UC|Patients with 'early UC' defined as disease duration < 4 years and no other treatments than aminosalicylates and/or corticosteroids
2537617|NCT02646657|Other|Late UC|Patients with 'late UC' defined as active disease despite treatment with immunosuppressives (IS) and/or anti-TNF. Patients wih intolerance to IS AND anti-TNF will also be allowed in the latter group.
2537641|NCT02646085|Experimental|Intervention|C11 Methionine positron emission tomography (PET/CT) studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 10 millicuries of C11 Methionine will be injected intravenously. Approximately 60 minutes following tracer injection, the patient will be positioned on a Siemens Biograph PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first with while the patient is free breathing. PET will be acquired at 3 minutes per bed position using the 3D mode, approximately 6-7 bed positions. C11 Methionine PET/CT imaging will take less than 60 minutes.
2537686|NCT02646033||robotic surgery|all those patients aged 40 - 60 years undergoing robotic surgeries, who does not have any ophthalmic complains.
2537723|NCT02645708|Other|Retrograde Intrarenal Surgery (RIRS)|Patients in Group 1 undergo Retrograde Intrarenal Surgery
2537725|NCT02645708|Other|EPVL after RIRS|"Patients in Group 2 undergo external physical vibration lithecbole after Retrograde Intrarenal Surgery.~with the help of changing the position and direction of the extracorporeally physical vibration machine, the urinary stone was discharged from the urinary collecting system"
2537942|NCT02644525|Placebo Comparator|2|Subjects given vitamin placebo
2537944|NCT02644525|Experimental|imatinib|Subjects given drug (200 mg, 400 mg, or 600 mg)
2537995|NCT02643797|Experimental|Intervention Group: MA Health Coaching|"Patients in the intervention group will receive the MA Health Coaching intervention during their primary care visits, as well a follow-up calls to encourage/monitor progress and offer support."
2537999|NCT02643797|No Intervention|Usual Care|"Patients in this group will receive treatment as usual during their primary care visits."
3202020|NCT00908999||Controls|The control group have to be medically and cognitively healthy(MMSE ≥ 28; Hopkins Verbal Memory Test-Revised raw score within 1.5 SD of normative values for age and gender). These individuals are recruited from the community and all attempts will be made to match them on age and education to individuals recruited for groups of AD and aMCI.
2538186|NCT02642744|No Intervention|Conventional inpatient nursing care|Standard of care nursing care patients receive while inpatient
2537065|NCT02649998|Active Comparator|Group 3|Each patient will initially receive a 40 mg bolus of IV furosemide (10 mg/mL) and a 2 mL bolus of IV isosorbide dinitrate (1 mg/mL), followed by IV isosorbide dinitrate 6 mL/h
2537086|NCT02649595|Other|Red Cross respite care|A 2 week free stay at a Red Cross respite center after hospitalization.
2537087|NCT02649595|No Intervention|Streets/communal programmes|Homeless being discharged from hospital to the streets and communal programmes.
2537145|NCT02649374|No Intervention|Gestational diabetes mellitus|women diagnosed with GDM during pregnancy, either treated by diet or pharmacological therapy
2537155|NCT02649374|Active Comparator|No GDM, Dietary Modifications|Women without GDM, will be advised and monitored for dietary, Exercise and lifestyle modifications
2537163|NCT02649374|No Intervention|No GDM, free diet|Women without GDM, for whom diet. exercise are continued regulary without any modifications
2537198|NCT02649010|Active Comparator|Group A|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
2537203|NCT02649010|Active Comparator|Group B|Subjects will be randomly assigned to 2 groups (Group A & Group B) that will determine when they will be participating in the in-clinic YSI frequent sample testing.
2537270|NCT02648607|Experimental|Customised Orthosis|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)
3167968|NCT00545220|Sham Comparator|2|Attention Control
3167969|NCT00545246|Experimental|aflibercept + docetaxel|
2537476|NCT02647255|Experimental|PE and methylprednisolone pulse|Plasma exchange(PE) and methylprednisolone pulse therapy: plasma exchange >7 within 3ws, Volume: 60ml/kg/course; Replacement fluid: 5% albumin or fresh frozen plasma and methylprednisolone pulse therapy Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
2537478|NCT02647255|Active Comparator|Methylprednisolone pulse|Methylprednisolone pulse alone: methylprednisolone 7-15mg/kg/d 3 times on consecutive or alternate days Basic treatment: Oral prednisone was tapered from 1 mg/kg/d for 6wks, then diminish 5mg/d every 10d, stop at the sixth month; cyclophosphamide 1.5 mg/kg/d for 3 months, 50mg /d at 3 months and stopped at 6 month.
2537508|NCT02646800|Experimental|Micafungin group|Intravenous (IV)
2537588|NCT02646501|Experimental|group A+PSGB|(Antiarrhythmic drug + percutaneous stellate ganglion block) group
2537593|NCT02646501|Active Comparator|group A|Antiarrhythmic drug group
2537646|NCT02646241|Experimental|unroofing biopsy|
2537655|NCT02646241|Active Comparator|EUS-FNB|
2537699|NCT02645955||Control group, disease history|people who didn't have disease history of Maintenance Hemodialysis
2537704|NCT02645955||The MHD patient group, diseases history|Maintenance Hemodialysis Patients
2537743|NCT02645591|Experimental|Nerve Sparing RARP + AmnioFix®|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
2537747|NCT02645591|Active Comparator|Nerve Sparing RARP|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
2537814|NCT02645110|Experimental|MC Hand soap|For bacterial removal trial: Hand washing with the tested soap following bacterial application
2537821|NCT02645110|Sham Comparator|Water|For bacterial removal trial: Hand washing with tap water alone following bacterial application
2537925|NCT02644369|Experimental|Pembrolizumab|Pembrolizumab will be given by intravenous infusion (IV, given by vein) at a dose of 200 mg, once every 3 weeks.
2538006|NCT02643823|Experimental|hUC-MSC + DMARDs|Patients will be treated in combination with hUC-MSC and DMARDs with a 12 months follow-up.
2538009|NCT02643823|Active Comparator|DMARDs|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) with a 12 months follow-up.
2538097|NCT02643290|Other|Patients|Adult patients with low back pain secondary to an high degree scolisis are treated by fiting with a brace 2-4 hours a day and tracked for 6 months.
2538150|NCT02642939|Experimental|mifepristone|mifepristone 300 mg capsule per day, orally in 28-day cycles
2538167|NCT02642549|Experimental|Girls for Health Intervention (G4H)|G4H will integrate proven girls' education strategies with innovative vocational interventions to build 1350 girls' career aspirations and academic achievement
2538168|NCT02642549|No Intervention|Control Condition|standard of care to support school attendance among girls (i.e., school tracking of attendance and reaching out to truant girls).
2538211|NCT02642328|Experimental|HIIT Training|Circuit training with strength and power. The chosen exercises were (random order): Sit-Ups, Mountain Climbers, Plank, Side Skater, Push Ups, Ground Support with Vertical Jump, Overhead Squat, Box Jump.Time total = 4 minutes
2538217|NCT02642328|Active Comparator|Control|Running aerobic exercise at 65% of VO2Max
2538604|NCT02639793|Active Comparator|manual radiofrequency ablation|Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
2538611|NCT02639793|Active Comparator|magnet navigation ablation|Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
3167970|NCT00545259|Experimental|1|AEB071
3167971|NCT00545285|Active Comparator|1|Total hip Arthroplasty E-Poly™ liner in a titanium plasma sprayed RingLoc® shell
3167972|NCT00545285|Active Comparator|2|Total hip Arthroplasty ArcomXL® polyethylene liner in a titanium plasma sprayed RingLoc® shell
3167973|NCT00545285|Active Comparator|3|Total hip Arthroplasty E-Poly™ liner with Regenerex Ringloc +™ shell
3167974|NCT00545285|Active Comparator|4|Total hip Arthroplasty ArcomXL® polyethylene liner with Regenerex Ringloc +™ shell
3167975|NCT00545311|Experimental|1|NVA237
3167976|NCT00545311|Experimental|2|NVA237
3167977|NCT00545311|Experimental|3|NVA237
3167978|NCT00545311|Experimental|4|NVA237
3167979|NCT00545311|Placebo Comparator|5|Placebo
3167980|NCT00545350|No Intervention|1|Usual activity / care
3167981|NCT00545350|Experimental|2|"Physical exercise classes plus home exercises:~Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home. The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
3167982|NCT00545376|No Intervention|1|This group will leave after the first visit without additional instruction and will be asked to return in two weeks for a follow up lung assessment.
3167983|NCT00545376|Experimental|2|This group, at the first visit, will be taught three home OMT techniques that a family member or friend can administer to them. They will be asked to do these techniques at least 4 times a week, up to every day, for two weeks before returning for a follow up lung assessment.
2537133|NCT02649166|Experimental|Deep brain stimulation|All participants will undergo unilateral deep brain stimulation (DBS) implantation for essential tremor. Medtronic Summit RC+S devices will be used because these are capable of recording brain signals, as well as delivering DBS. Participants will receive continuous (open-loop) and closed-loop deep brain stimulation interventions, which will be compared for efficacy.
2537217|NCT02649049||Patients with NAFLD|Patients with NAFLD are the cases.
2537219|NCT02649049||control group|Healthy people without NAFLD are controls.
2537287|NCT02648659|Experimental|triple with clarithromycin|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin bid for 2 weeks
2537290|NCT02648659|Experimental|triple with metronidazole|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Metronidazole 500mg tid for 2 weeks
2537292|NCT02648659|Experimental|quadruple|Ilaprazole 10mg qid, Amoxicillin 500mg qid, Clarithromycin 500mg bid, Metronidazole 500mg tid for 2 weeks
2537358|NCT02647957|Experimental|Group A|Hospital using Code Stroke
2537363|NCT02647957|No Intervention|Group B|Hospital not using Code Stroke
2537437|NCT02647632|Experimental|16 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 16 weeks
2537439|NCT02647632|Experimental|24 weeks of treatment|Drug : Grazoprevir/Elbasvir + Sofosbuvir + Ribavirin during 24 weeks
2537525|NCT02646995|Experimental|Active|modified lipid formulation
2537534|NCT02646995|Active Comparator|Control|fish oil
2537778|NCT02645214|Placebo Comparator|Control scrubs (non-antiseptic)|subject will wear control scrubs for the duration of a 12-hour ICU shift
2537780|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 1|subject will wear antiseptic impregnated scrubs-type 1 for the duration of a 12-hour ICU shift
2537783|NCT02645214|Active Comparator|Antiseptic Impregnated Scrubs Type 2|subject will wear antiseptic impregnated scrubs-type 2 for the duration of a 12-hour ICU shift
2537861|NCT02644824|Experimental|Biventricular Pacing (BiVp)|Consented infants with wide QRS randomized to receive standard of care and BiVp.
2537862|NCT02644824|No Intervention|Control (wide QRS)|Consented infants with wide QRS randomized to receive standard of care alone.
2537863|NCT02644824|No Intervention|Control (narrow QRS)|This is an observation control group. Consented infants with narrow QRS will enter control group 2 without randomization.
2537901|NCT02644330|Active Comparator|surgical group|The patients in Group A (surgical group) underwent surgical repair with cardiopulmonary bypass
2537902|NCT02644330|Experimental|closure group|The patients in Group B (closure group) underwent minimally invasive transthoracic device closure.
2537932|NCT02644044|Experimental|Treatment|Treatment with IT methotrexate
2538110|NCT02643147|Experimental|CA125 guided strategy|In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels
2538114|NCT02643147|Active Comparator|Conventional strategy|Standard treatment strategy Therapy is based on established european guidelines
2538174|NCT02642666|Experimental|Yoga intervention|While in the yoga intervention arm of the study participants will practice yoga at home and at school for six weeks with the goal of practicing yoga daily during that time period. Yoga classes will be held twice a week at school. On the days that the children do not practice yoga at school, they will practice yoga at home with the use of a children's yoga video that mirrors the yoga class that they attend at school.
2538175|NCT02642666|No Intervention|Normal school and home activities|While in the wait-list group the children will continue with their regular activities both at home and at school.
2538232|NCT02642276|Active Comparator|Maximal walking group|Patients to be randomized to the 'maximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to the point of pain-free walking distance.
2538234|NCT02642276|Active Comparator|Submaximal walking group|Patients to be randomized to the 'submaximal walking group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo an exercise training programme consisting of 60 minutes of repetitive interval muscle training/walking up to 2/3 of pain-free walking distance.
2538236|NCT02642276|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
2538270|NCT02642016|Experimental|CDX-0158|
2538636|NCT02639377|Experimental|Chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
3167984|NCT00545376|Experimental|3|This arm is the physicians that I will recruit participants through. They will be exposed to education about the use of OMT for asthma.
3167985|NCT00545415|Experimental|1|
3167986|NCT00545415|Experimental|2|
3167987|NCT00545415|Experimental|3|
3167988|NCT00545415|Experimental|4|
3167989|NCT00545415|Experimental|5|
3167990|NCT00545415|Experimental|6|
3167991|NCT00545428|Experimental|1|Rhinoplasty
3167992|NCT00545454|Experimental|SSR150106 QD|90 micro grams oral solution once daily (QD)
3167993|NCT00545454|Experimental|SSR150106 OEQD|90 micro grams oral solution once every other day (OEQD)
3167994|NCT00545454|Placebo Comparator|Placebo|oral solution QD or OEQD
3167995|NCT00545467|Active Comparator|1|fast tapering of the previous medication within 1 week after initiating aripiprazole for 2 weeks
3167996|NCT00545467|Active Comparator|2|slow tapering of the previous medication within 4 weeks after initiating aripiprazole for 2 weeks
3167997|NCT00545480|Experimental|1|
3167998|NCT00545480|Active Comparator|2|
3167999|NCT00545493|Experimental|Group 1|"Tacrolimus capsules (Prograf; dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter)"
2537092|NCT02649699|Other|Additional 3D MRI scans|Participating patients will receive additional 3D MRI scans during pre and post RT planning for their primary brain tumors.
2537191|NCT02649361|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2537192|NCT02649361|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2537274|NCT02648568|Active Comparator|Hypnosis plus relaxation|Ericksonian hypnosis, based on sensations when awakening partially during N3 ; Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
2537282|NCT02648568|Active Comparator|Relaxation|Jacobson relaxation, based on flexion and relaxation of muscles (serves here as a control procedure)
2537400|NCT02647918|Experimental|Group 1|Subjects with normal renal function
2537401|NCT02647918|Experimental|Group 2|Subjects with mild renal impairment
2537403|NCT02647918|Experimental|Group 3|Subjects with moderate renal impairment
2537405|NCT02647918|Experimental|Group 4|Subjects with severe renal impairment
2537407|NCT02647918|Experimental|Group 5|Subjects with ESRD requiring HD
3202021|NCT00908999||amnestic Mild Cognitive Impairment|Participants who have expressed interest to take part in the study. A consensus from the study clinicians regarding the diagnosis will be required before a subject is enrolled. The criteria for MCI include 1) observation of memory decline by informant, 2) Mini Mental Status Exam (MMSE) score between 24 and 30, 3) objective memory impairment on neuropsychological tests, 3) intact functional abilities, and 4) no diagnosis of dementia.
2537591|NCT02646397|Experimental|Fosinopril,benidipine combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus benidipine (4/8 mg）once daily for 6 months.
2537596|NCT02646397|Experimental|Fosinopril,hydrochlorothiazide combination|254 CKD patients with HTN will take oral tablets of fosinopril (20 mg) plus hydrochlorothiazide (12.5/25 mg）once daily for 6 months.
2537650|NCT02646163|Experimental|REP 2055|Treatment with REP 2055
2537732|NCT02645903|Active Comparator|transversus abdominis plane block|"Patients who received a tranversus abdominis plane block with ultrasound after standard general anesthesia represented Group 1.~The tranversus abdominis plane block was performed bilaterally by obtaining an image with real time ultrasound guidance with a 6-13 MHz linear probe.~The block was placed with a 22 G 80 mm needle while obtaining real-time images via an in-plane technique.~Two 20 mL syringes were prepared after preparing a local anesthetic concentration of 1.5 mg/kg of 0.5% bupivacaine to 40 mL with saline. These were administered to the left and right abdominal walls.~Postoperative analgesia was administered through a morphine the patient-controlled analgesia device."
2537737|NCT02645903|Placebo Comparator|nonblocked|Patients who received standard general anesthesia alone made up Group 2. Postoperative analgesia was administered through a morphine the patient-controlled analgesia device.
2537799|NCT02645279|Active Comparator|oral 30% glucose|oral 30% glucose total 200 mg/kg with 0.5-1 mL increments
2537802|NCT02645279|Active Comparator|IV midazolam|intravenous administration of midazolam 0.1 mg/kg
2537868|NCT02644811|Experimental|Group A - Miniscrews|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal). Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with miniscrews (Spider Screw K1 short neck). Miniscrews are placed buccally between the maxillary second premolar and the first molar after topical anesthesia (buccal) and injection (buccal). Miniscrews are placed when space closure starts. Space closure is performed as en masse retraction. Miniscrew are immediately loaded with 150g Nickel Titanium coil springs."
2537870|NCT02644811|Active Comparator|Group B - Molarblock|"Topical anesthesia (buccal and palatal) followed by local anesthesia (buccal and palatal. Extraction of the maxillary first premolars.~Fixed appliance in the maxilla or maxilla and mandible.~Anchorage reinforcement with molarblocks - a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar. Molarblocks are installed from the beginning of leveling and alignment. Space closure is performed as en masse retraction with type one active tie-backs."
2537928|NCT02644187|Other|Left side first -Aktilite CL128|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
2537934|NCT02644187|Other|Right side first -Aktilite CL128|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that Aktilite CL128.
2537936|NCT02644187|Other|Left side first -BF-RhodoLED|Randomized left side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
2537939|NCT02644187|Other|Right side first -BF-RhodoLED|Randomized right side first with application of 5-aminolevulinic acid under occlusion during 3h. After that BF-RhodoLED.
2537987|NCT02643745|Experimental|Nephrology Intervention|Nephrology intervention before surgery:
2537990|NCT02643745|No Intervention|Standard of Care|No nephrology intervention before surgery (standard of care)
2538050|NCT02643485||Study group|Patients undergoing forefoot reconstruction of hallux valgus or hallux rigidus
2538056|NCT02643485||Control group|Healthy volunteers (Students)
2538099|NCT02643121||children with sepsis, SIRS|Data will be collected and analyzed from childrens with SIRS or septic state who will be admitted to the Department of Anesthesia and Intensive Care of the University Children´s Hospital Brno, Czech Republic. Infections, sepsis, severe sepsis, septic shock and multiple organ dysfunction syndrome (MODS) will be defined according to commonly used criteria - by International pediatric sepsis consensus conference.
2538100|NCT02643121||control group, healthy children|The samples children undergoing elective surgery will be used as a controls, i.e. samples from patients without signs of infection.
2538142|NCT02642926|Active Comparator|Monopolar endoscopic endometrial ablation|
2538145|NCT02642926|Experimental|Bipolar endoscopic endometrial ablation|
2538198|NCT02642588|Experimental|energy gel|women will be given 22 g of carbohydrates every 45-60 minutes for up to 8 hours or until delivery during the active phase of labor
2538202|NCT02642588|No Intervention|control|women will be given only clear liquids during labor
2538640|NCT02639377|Placebo Comparator|Placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
3168000|NCT00545493|Experimental|Group 2|"Intravenous immunoglobulins (IVIG) infusions (Octagam; dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months)."
2537168|NCT02649140|No Intervention|Group 1|Group1 is control group and participants do not need intervention.
2537170|NCT02649140|Experimental|Group 2|Group 2 is vinegar Group and participants in this group are asked to drink 15ml vinegar(Ninghuafu, Sanxi, China)after dinner at noon and evening respectively for a period of four weeks.
2537204|NCT02648906|Experimental|Choline alfoscerate|"Drug: Choline alfoscerate and Donepezil~concomitant administration"
2537212|NCT02648906|Placebo Comparator|Placebo|Drug: Donepezil only
2537266|NCT02648620|Experimental|SurVeil Drug Coated Balloon catheter|Paclitaxel Coated Balloon catheter for angioplasty
2537313|NCT02648191|Experimental|Active stimulation|
2537315|NCT02648191|Sham Comparator|Inactive stimulation|
2537473|NCT02647177||Pancreatic Cyst Group|Only the eligible participant in the study are considered for inclusion in this group.
2537521|NCT02646904|Experimental|Beclometasone Dipropionate (BDP)|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of Nasal Beclomethasone Dipropionate for 21 days.
2537530|NCT02646904|Active Comparator|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
2537609|NCT02646592|Experimental|alfentanil|"Children under general anesthesia for elective surgery. Induction with sevoflurane or propofol according to the preference of the patient.~Maintenance with sevoflurane. 5 minutes before skin incision, first assessment of the pupillary pain index. Then injection of 10 µg/kg of alfentanil. After 5 minutes second assessment of pupillary pain index. End of study period, beginning of surgery."
2537657|NCT02646228||molecular profiling, patient derived cells|
2537697|NCT02645916|Experimental|DSGOST|admission to Danggui-Sayuk-Ga-Osuyu-Saenggang-tang granule
2537702|NCT02645916|Placebo Comparator|Placebo|admission to placebo
2537800|NCT02645175|Experimental|TW1025|TW1025 oral solution, 20ml, 3 times per day (daily dose: 60 ml)
2537801|NCT02645175|Placebo Comparator|Placebo|TW1025 oral solution matched placebo, 20ml, 3 times per day
2537884|NCT02644538|No Intervention|nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) are still using the original treatment for 72 weeks
2537886|NCT02644538|Active Comparator|PegIFN alfa-2a + nucleot(s)ides treated|patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir), then will add PegIFN alfa-2a to the original nucleot(s)ides for 48 weeks, then follow up for 24 weeks
2537930|NCT02644226||Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
2537935|NCT02644226||Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
2538094|NCT02643238|Experimental|Group A - Blind|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
2538095|NCT02643238|Active Comparator|Group C - Control|Subjects will be trained to ambulate through a 40-foot obstacle course by the occupational therapy colleagues at Akron Children's Hospital after which they will be scored on their performance while using the BrainPort® system.
2538193|NCT02642380|Experimental|4 cycles|Oral administration of dexamethasone 40 mg for four consecutive days every 14 days for 4 courses
3168001|NCT00545519|Experimental|Dose Level 1|Thymoglobulin 2.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3168002|NCT00545519|Experimental|Dose Level 2|Thymoglobulin 3.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3168003|NCT00545519|Experimental|Dose Level 3|Thymoglobulin 4.0 mg/kg over 8 hours on day 1 and over 6 hours on days 2-4.
3168004|NCT00545545|Experimental|Arm 1, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3168005|NCT00545545|Experimental|Arm 1, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3168006|NCT00545545|Experimental|Arm 1, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with combination therapy of cetuximab and irinotecan.
3168007|NCT00545545|Experimental|Arm 2, Cohort 1|2.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3168008|NCT00545545|Experimental|Arm 2, Cohort 2|4.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3168009|NCT00545545|Experimental|Arm 2, Cohort 3|6.0 mg/kg Imprime PGG administered weekly with concomitant cetuximab.
3168010|NCT00545558|Experimental|1|Participants will receive ART consisting of efavirenz and the co-formulation of emtricitabine and tenofovir disoproxil fumarate. If participants are unable to tolerate the treatment, a different regimen will be prescribed.
3168011|NCT00545610||Test 1 (n=50)|1 x 10^5 (+/-10%) CD34+ cells/kg of body weight
3168012|NCT00545610||Test 2 (n=50)|5 x 10^5 (+/-10%) CD34+ cells/kg of body weight
3168013|NCT00545610||Placebo (n=50)|Saline plus 5% autologous plasma
3168014|NCT00545649|Experimental|1|Exercise and education
3168015|NCT00545649|Active Comparator|2|Education only
3168016|NCT00545675|Experimental|1|Abilify(aripiprazole) + Depakote(divalproate)
3168017|NCT00545675|Placebo Comparator|2|Divalproate + Placebo
3168018|NCT00545701|Experimental|1|
2537164|NCT02649335|Active Comparator|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy (SMT) .
2537190|NCT02648958|Placebo Comparator|Control group|The control group received saline instead of dexmedetomidine.
2537193|NCT02648958|Experimental|Dexmedetomidine group|The dexmedetomidine group received the dexmedetomidine.
2537247|NCT02648724|Experimental|Part 1: Dose-Escalation|Sym015 will be tested in four dose titration cohorts. A substitute or an additional dose level could potentially be evaluated.
2537248|NCT02648724|Experimental|Part 2: Basket Cohort|Patients with KRAS WT advanced solid tumor malignancies with MET-amplification will receive Sym015 at the RP2D. Included in this group will be a subset of patients who have received prior therapy with a MET-targeting TKI.
2537250|NCT02648724|Experimental|Part 2: NSCLC MET-Amplified Cohort|Patients with advanced NSCLC with MET-amplification will receive Sym015 at the RP2D. Patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents.
2537252|NCT02648724|Experimental|Part 2: NSCLC METex14del Cohort|Patients with advanced NSCLC with METex14del will receive Sym015 at the RP2D. Tumors need not be MET-amplified, and patients may have received prior therapy with MET-targeting and/or EGFR-targeting agents. mutation.
2537323|NCT02648126|Other|Pure red cell aplasia participants|Group of participants with pure red cell aplasia and chronic kidney disease, that have resistance criteria to treatment with epoetin alfa produced by Bio-Manguinhos / Fiocruz. The Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation.
2537371|NCT02647840|Other|Voice therapy|All participants will receive voice therapy based on the Estill model. This is very similar to our usual intervention.
2537423|NCT02647541|Experimental|Nutritional intervention|Consultation with a dietitian, including nutritional recommendations and supplementation.
2537427|NCT02647541|No Intervention|Standard therapy|No specific nutritional recommendations.
2537482|NCT02647151|Active Comparator|METHYLAMINOLEVULINATE HYDROCHLORIDE|METHYLAMINOLEVULINATE HYDROCHLORIDE (MAL)cream 160mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
2537486|NCT02647151|Experimental|AMINOLEVULINIC ACID HYDROCHLORIDE|AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy
2537529|NCT02646787|Experimental|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
2537535|NCT02646787|Experimental|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
2537539|NCT02646787|No Intervention|Control|No intervention during the subject's standard wound care session
2537627|NCT02646540|Experimental|Tolvaptan 30 mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 30 mg of tolvaptan concomitantly with their standard dose of diuretics.
2537629|NCT02646540|Active Comparator|Metolazone 5mg and IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive 5mg metolazone concomitantly with their standard dose of diuretics.
2537630|NCT02646540|Active Comparator|IV Lasix|Participants admitted to the hospital and diagnosed with acutely decompensated heart failure (ADHF) will receive two and a half (2.5) times their standard dose of diuretics.
2537640|NCT02646111|Experimental|Genotype 1b without cirrhosis|12 weeks without Ribavirin
2537642|NCT02646111|Experimental|Genotype 1b with cirrhosis|12 weeks with Ribavirin
2537643|NCT02646111|Experimental|Genotype 1a without cirrhosis|12 weeks with Ribavirin
2537644|NCT02646111|Experimental|Genotype 1a with cirrhosis|24 weeks with Ribavirin
2537688|NCT02645890|Active Comparator|CKD-397|Tadalafil/ Tamsulosin Fixed dose combination
2537689|NCT02645890|Experimental|TD+TM|Tadalafil/ Tamsulosin Coadministration
2537791|NCT02645292|Experimental|1 mile Walk using treadmill|Walking for 1 mile on treadmill (American Motion Fitness, 8800D) as fast as participant can, without any inclination
2537795|NCT02645292|Experimental|Stair Climbing|30 meters of vertical distance to be covered (14 flights of stairs with a total of 154 steps)
2537849|NCT02644863|Experimental|DC-CIK|After accepting chemotherapy according to guidelines,patients will receive 3 cycles of autologous DC-CIK treatment.
2537851|NCT02644863|Sham Comparator|Chemotherapy|After the Chemotherapy by Paclitaxel and Cisplatin, patients will just regularly follow up.
2537985|NCT02643563|Experimental|Ropivacaine 0.5%|Low volume (5 ml) Interscalene Block with Ropivacaine 0.5%
3168019|NCT00545727|Other|HGI|High/standard glycemic index diet
3168020|NCT00545727|Experimental|LGI|Low glycemic index diet
3168021|NCT00545805|Experimental|OM group|
3168022|NCT00545805|Active Comparator|CT group|Control group
3168023|NCT00545831|Experimental|A|Use of taurolidine in prevention of bloodstream infection related to central venous access
3168024|NCT00545831|Placebo Comparator|B|Use of Physiologic Serum to compare to arm A
3168025|NCT00545857|Experimental|Pioglitazone|
3168026|NCT00545857|Placebo Comparator|Placebo control|
3168027|NCT00545870|Experimental|A|Bevacizumab treatment
3168028|NCT00545870|Active Comparator|B|Ranibizumab treatment
3168029|NCT00545909|Experimental|1|
3168030|NCT00545909|Active Comparator|2|
3168031|NCT00545922|Experimental|A|7 weekly sessions of group cognitive behavioral therapy
3168032|NCT00545922|Active Comparator|B|Minimal Telephone Contact
3168033|NCT00545935|Active Comparator|1-Methylenblue-Amodiaquine|
3168034|NCT00545935|Active Comparator|2-Methylenblue-Artesunate|
3168035|NCT00545935|Active Comparator|3-Artesunate-Amodiaquine|
3168036|NCT00545961|Placebo Comparator|1|placebo Ora-Plus (registered trademark) mixture with an strawberry sweetening agent to make the placebo mixture similar in appearance and taste to active drug
3168037|NCT00545961|Active Comparator|2|amoxicillin-clavulanate acid
2537166|NCT02649127|Active Comparator|Nurse-led Self-Care|The Self-Care Group will use written materials that outline the benefits of thinking about problems the individual is facing as well as the benefits of exercise, however doing the two activities together will not be advocated as part of the material. A fact sheet prepared by the National Center for PTSD, Returning from the War Zone: A Guide for Military Personnel as well as a list of coping strategies and self-care behaviors adapted from the National Center for PTSD guide, Self-Care and Self-Help Following Disasters, will be used to guide the discussion. The research nurse will meet with the participant five times over 8-weeks at weeks 1, 2, 4, 6, and 8 to encourage use of the self-care fact sheet and assess the participant for safety.
2537218|NCT02648867|Experimental|Patients receiving PushCoach feedback|Patients will receive continuous maternal feedback from the PushCoach device, which includes both audio and visual feedback of fetal head movement during the second stage of labor
2537220|NCT02648867|Active Comparator|Patients blinded to PushCoach feedback|Patients will not receive continuous maternal feedback from the PushCoach device (it will be in place and collect data), but will receive normal feedback from the clinician during the second stage of labor.
2537278|NCT02648555|No Intervention|Standard follow-up (controls)|Given that depressive disorders may increase the risk of spontaneous abortions, antidepressants will be not discontinued. However, expectant mothers on paroxetine or sertraline, which have been reported to increase the incidence of cardiac malformations, will be switched to fluoxetine.
2537283|NCT02648555|Experimental|W+D protocol (lifestyle intervention)|Daily walking and dietary recommendations. Expectant mothers on paroxetine or sertraline will be switched to fluoxetine
2537342|NCT02648165|Experimental|ABM +|Attention Bias Modification
2537343|NCT02648165|Sham Comparator|ABM -|Sham Attention Bias Modification
2537345|NCT02648165|Experimental|ABM + and ACT|Attention Bias Modification followed by Group Acceptance and Commitment Therapy
2537346|NCT02648165|Sham Comparator|ABM - and ACT|Sham Attention Bias Modification followed by Group Acceptance and Commitment Therapy
2537446|NCT02647528|Experimental|Treatment|Patients in this arm receive treatment
2537448|NCT02647528|Placebo Comparator|Placebo|Patients in this arm do not receive treatment
2537491|NCT02647047|Experimental|Spinal|Patients will receive spinal analgesia (morphine 0.2 mg) before general anesthesia for minor laparotomic liver resection.
2537493|NCT02647047|Active Comparator|Epidural|Patients will receive epidural analgesia (bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL) before general anesthesia for minor laparotomic liver resection.
2537559|NCT02646696||Children with Autism Spectrum Disorder|Boys between the age of 4 to 11 years old with Autism Spectrum disorder will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2537562|NCT02646696||Typically Developing Children|typically developing boys between the age of 4 to 11 years will participate in the Sensory Challenge Protocol which will measure electrodermal activity in response to sensation.
2537576|NCT02646488|Active Comparator|Cluster 1|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2537582|NCT02646488|Active Comparator|Cluster 2|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2537584|NCT02646488|Active Comparator|Cluster 3|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2537586|NCT02646488|Active Comparator|Cluster 4|Consists of 80 sites chosen by block randomization in four waves every three months (80 in the first three waves and 60 in the last wave).
2537675|NCT02646059|Experimental|Text group|Text messages containing reminds of blood donation information would be sent to donors in this group.
2537677|NCT02646059|Experimental|Telephone group|Investigators would give telephone calls to the donors in this group, ask the reasons why they stopped donating blood.
2537680|NCT02646059|No Intervention|Control group|No intervention will be giving to this group.
2537706|NCT02645786||Case|"Differentiated thyroid cancer group:~who received total- or near-total thyroidectomy, and thereafter regularly visited the endocrine out-patient department (OPD) of Chuncheon Sacred Heart Hospital.~1) age less than 45 years old when receiving total or near-total thyroidectomy, 2) serum level of TSH<0.1 mU/L in the intermediate recurrence-risk or TSH<0.3 mU/L in the low recurrence-risk group13, 14 over 2 years before study entry, 3) receiving TSH suppressive therapy for 5 to 9 years with fixed dose of LT4 more than 2 years before study entry, and 4) no history of structural heart disease, arrhythmia, or cardiac symptoms (palpitation, exertional dyspnea and chest discomfort) during therapy."
2537708|NCT02645786||Control|"Control group As each DTC patient was enrolled, control subjects were selected from patients who visited endocrinology department for thyroid nodule work-up. The control group had to meet the following criteria~1) the subject matched to a patient by age (±2 years), sex, and body mass index (BMI) (±2 kg/m2), 2) within the reference range of serum TSH (0.3-4.6 mU/L), 3) no history of structural heart disease, arrhythmia, or cardiac symptoms, 4) no history of comorbid diseases which affect thyroxine metabolism and cardiac structure, including hepatic or renal disease, anemia, and hypertension."
2537757|NCT02645552|Experimental|Tranexamic acid|Focused intervention
2537759|NCT02645552|Placebo Comparator|Sodium chloride|Placebo control
2537779|NCT02645045||Dry eye|Patients with dry eye syndrome
2537782|NCT02645045||normal|Patients without dry eye
2537842|NCT02644954|Active Comparator|Metformin|Topical coal tar and topical calcipotriol + oral metformin 850mg twice daily
2537843|NCT02644954|Placebo Comparator|Placebo|Topical coal tar and topical calcipotriol
2537889|NCT02644551|Experimental|CELEXT07|suspension that is applied topically to the infected nail(s) daily.
2537890|NCT02644551|Placebo Comparator|placebo|placebo is a suspension that simulates the physical properties of the experimental agent CELEXT07. It is applied topically to the infected nail(s) daily.
2537891|NCT02644551|Active Comparator|Penlac|Is a standard of care for the condition and is applied topically to the infected nail(s) daily.
2537968|NCT02644135|Placebo Comparator|Halo Placebo|The placebo will consist of purified sterile water without CPC - the active antiseptic. Subjects assigned to both study arms will be asked to spray the product intra-orally 3 times daily (Three sprays per use, total = 9 sprays per day).
2537236|NCT02648841|Experimental|Adjuvant Chemo-radiotherapy|The interventions of adjuvant chemo-radiotherapy group is concurrent chemo-radiotherapy to be give after 4-6 cycles of chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral. Six cycles of SOX chemotherapy to be given. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
2537253|NCT02648425|Experimental|Regimen A / Amended Regimen A|"Regimen A: Cisplatin + 5-fluorouracil~ASLAN001 daily in combination with:~Cisplatin 80 mg/m2 IV infusion for 1 day and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks for up to 6 cycles.~Or~Amended Regimen A: Cisplatin + 5-fluorouracil + leucovorin~ASLAN001 daily in combination with:~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks for up to 6 cycles."
2537254|NCT02648425|Experimental|Regimen B|"Regimen B: Cisplatin + capecitabine~ASLAN001 daily in combination with:~Cisplatin 60-80 mg/m2 IV infusion on Day 1 and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks for up to 6 cycles."
2537319|NCT02648009|Other|Healthy Volunteers|"Arm 1~Group 1A: control male volunteers between 19 and 50 years of age.~Group 1B: control female volunteers between 19 and 50 years of age.~Group 1C: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice~Group 1D: control male volunteers between 19 and 50 years of age.~Group 1E: control female volunteers between 19 and 50 years of age.~Group 1F: control male or female volunteers between 19 and 50 years of age, with the MRI scan performed twice"
2537321|NCT02648009|Other|Hypertension Hypertrophy Volunteers|"Arm 2~Group 2A: patients aged 30 to 75 with hypertension and hypertrophy~Group 2B: patients aged 30 to 75 with non-obstructive hypertrophic cardiomyopathy (HCM).~Group 2C: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~Group 2D: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents.~Group 2E: patients aged 30 to 75 with hypertrophy~Group 2F: patients aged 30 to 75 with hypertrophic cardiomyopathy (HCM).~Group 2G: stable outpatients with NYHA class 1-3 heart failure who have evidence of elevated LV mass (LVH), irrespective of LVEF.~Group 2H: stable patients with type 2 DM who have a HcA1c between 6.5-9% on oral hypoglycemic agents."
3202022|NCT00908999||Alzheimer's disease|Patients with probable Alzheimer's disease according with the NINDS-ADRDA and DSM-IV diagnostic criteria. An additional criterion is a MMSE score between 16 and 27. All AD patients must have capacity to provide informed consent as judged by the referring physician.
2537429|NCT02647424|Other|PCOS group|PCOS women with anovulation
2537433|NCT02647424|Other|Ovulatory group|Ovulatory group planned for intra-uterine insemination
2537528|NCT02647099|Active Comparator|Aspirin|One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
2537536|NCT02647099|Placebo Comparator|Placebo|One tablet placebo orally once daily for three years
2537615|NCT02646384|Experimental|Ovarian tissue cryopreservation|Children faced with a fertility threatening diagnosis or treatment plan will be offered ovarian tissue cryopreservation, particularly if pre menarchal and without other options to preserve fertility. Although considered experimental, there are over 120 live births worldwide using this technique
2537649|NCT02646215|Active Comparator|Inspiratory muscle training group|Threshold inspiratory muscle training
2537651|NCT02646215|No Intervention|Control group|No training
2537698|NCT02645994|Experimental|Target Controlled Infusion|Propofol is administered through a target controlled infusion pump based on Marsh model to achieve a BIS of 50 and manually adjusted to maintain BIS between 40 and 60
2537703|NCT02645994|Active Comparator|Closed Loop Anesthesia Delivery System|Propofol is administered through Closed Loop Anesthesia Delivery System which is titrated automatically to achieve a target BIS of 50 and maintain it between 40 and 60.
2537733|NCT02645487|Experimental|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Dose-Escalation
2537806|NCT02645331|Experimental|Remind-to-move|RTM involved a wristwatch device worn on more-affected arm which emitted sensory cueing continuously to remind the children to use the more-affected hand to engage in daily activities or complete bimanual tasks intensively, 5 hour per day, 5 days every week, for 3 consecutive weeks.
2537813|NCT02645331|Active Comparator|Modified constraint induced movement therapy (mCIMT)|children were encouraged to wear a customer-made volar resting splint that extended from below the elbow to the fingertips on their noninvolved hands for 5 hour daily except for toileting, writing and specific physical sports, for 3 weeks. Each child was supervised by one therapist to complete structured unimanual practice with the affected hand during the supervised session, 5 days every week, for 3 consecutive weeks.
2537822|NCT02645331|Placebo Comparator|Conventional rehabilitation|Conventional splinting, muscle strengthening, stretching, and neurodevelopmental facilitation techniques for 1hr daily, 2 day per week for 3 weeks.
2537846|NCT02644707|Experimental|L-selenomethionine|A group randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
2537848|NCT02644707|Placebo Comparator|Placebo|A group randomized to receive placebo (control group) for 6 months
2537919|NCT02644421|Experimental|VVZ-149|"The following doses will be administered intravenously:~Loading Dose: 1.8 mg/kg VVZ-149 over 0.5 hours~Maintenance infusion: 1.3 mg/kg/hr VVZ-149 over 7.5 hours"
2537924|NCT02644421|Active Comparator|Lidocaine|"The following doses will be administered intravenously:~Lidocaine 4mg/kg LBM over 0.5 hours~Normal saline over 7.5 hours"
2537926|NCT02644421|Placebo Comparator|Placebo|Normal saline administered intravenously over 8 hours
2538031|NCT02643810|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak heart rate) and low-intensity intervals (50-70% of peak heart rate).
2538032|NCT02643810|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. They will undergo moderate continuous exercise training at 70-75% of peak heart rate.
2538034|NCT02643810|No Intervention|Usual care group|Patients to be randomized to the 'usual care group' will undergo standard care for 12 weeks.
2538188|NCT02642731||Patients for elective TKA|patients with normal or near normal plasma creatinine who come for elective total knee arthroplasty
3202023|NCT00909012|Placebo Comparator|1|
3202024|NCT00909012|Experimental|2|
2537300|NCT02648321|Experimental|Motivational Interviewing|Motivational Interviewing
2537303|NCT02648321|Active Comparator|Health Education|Health Education
2537360|NCT02647983|Experimental|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection to be used a MRI contrast agent.
2537438|NCT02647619|Active Comparator|Needle aponeurotomy|percutaneous transection or pretendinous palmar dupytren cord
2537440|NCT02647619|Active Comparator|Xiapex|Injection of 0.58 mg collagenase into pretendinous palmar dupytren cord
2537515|NCT02647086|Experimental|Period 1|Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprololin) in period 1 (day 1)
2537524|NCT02647086|Experimental|Period 2|Patients will receive dupilumab starting in Period 2 (day 8) and continue weekly through day 50; Patients will receive selected Cytochrome P450 substrates (Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol) in period 2 (at day 36).
2537621|NCT02646410|Other|FPD+NDOT|Fixed-point delivery (FPD) combined with non directly observed treatment (NDOT)
2537624|NCT02646410|Other|FPD+DOT|Fixed-point delivery (FPD) combined with directly observed treatment (DOT)
2537626|NCT02646410|Other|DDD+NDOT|door-to-door delivery (DDD) combined with non directly observed treatment (NDOT)
2537628|NCT02646410|Other|DDD+DOT|door-to-door delivery (DDD) combined with directly observed treatment (NDOT)
2537652|NCT02646098|Active Comparator|CD34+ cell selection|CD34+ cell selection applying CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany)
2537660|NCT02646098|No Intervention|No CD34+ cell selection|No CD34+ cell selection
2537695|NCT02645864|Experimental|Apatinib and Irinotecan|"This study will include a sequential evaluation of 3 subjects per cohort. Cohort 1: apatinib 250 mg per day and irinotecan 150mg q2w. Cohort 2: apatinib 500 mg per day and irinotecan 150mg q2w. Cohort 3: apatinib 750 mg per day and irinotecan 150mg q2w.~A dose limiting toxicity (DLT) event is defined as any of the following events:~CTCAE Grade 4 event~Grade 3 non-hematologic toxicity including fever, nausea, vomiting, and diarrhea that continues despite optimal medical management) If a DLT is experienced in any cohort, the cohort will be expanded to 6 subjects. If two (2) DLTs are experienced in any cohort, the study will stop and the dose of combination treatment in this cohort will be documented."
2537756|NCT02645500|Experimental|Physical activity message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to physical activity.~The training workshop include one core session and one booster session at one month.~Daily messages in relation to physical activity will be sent to the participants."
2537758|NCT02645500|Active Comparator|Healthy diet message|"Participants will receive training on healthy living style focusing on positive psychology, physical activity and healthy diet, and health messages related to healthy diet .~The training workshop include one core session and one booster session at one month.~Daily messages in relation to healthy diet will be sent to the participants."
2537784|NCT02645097|Active Comparator|Proximal saphenous nerve block|The anesthesiologist will administer a saphenous proximal nerve block if specified in the randomization envelope.
2537789|NCT02645097|Active Comparator|Distal saphenous nerve block|The anesthesiologist will administer a saphenous distal nerve block if specified in the randomization envelope.
2537858|NCT02644889||Patients advanced NSCLC EGFR mutated|This is an observational study, there is no intervention.
2537914|NCT02644473|Experimental|Tranexamic acid|Investigators will administer topical (1.5g) TXA during total knee arthroplasty and total hip arthroplasty
2537915|NCT02644473|Placebo Comparator|Control|
2537962|NCT02643966|Experimental|Whole breast ultrasound|All women will receive both 3D mammography and whole breast ultrasound for breast cancer screening; the order of interpretation will vary for each of two radiologists
2538044|NCT02643654|Placebo Comparator|Placebo|The placebo product is manufactured following the same procedures and batch records used to manufacture the MABp1 drug product. The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
2538045|NCT02643654|Active Comparator|MABp1|MABp1 is a recombinant human IgG1 monoclonal antibody specific for human interleukin-1α (IL-1α). The entire MABp1 heavy and light chain sequences are identical to those found in naturally-occurring human IgG1κ, with the light and heavy chain variable regions being identical to those originally expressed by a peripheral blood B lymphocyte that was obtained from a healthy individual. It is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
2538118|NCT02643186|Active Comparator|misoprostol group|preoperative vaginal misoprostol in decreasing blood loss in transabdominal myomectomy
2538122|NCT02643186|Active Comparator|uterine artery ligation group|bilateral uterine artery ligation in decreasing blood loss in transabdominal myomectomy
2538159|NCT02642718|Placebo Comparator|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision
3202025|NCT00909012|Experimental|3|
3202026|NCT00909012|Experimental|4|
3202027|NCT00909012|Experimental|5|
3202028|NCT00909025|Experimental|Claudiximab|
3202029|NCT00909051||Group 1|
3202030|NCT00909077|Active Comparator|1|Combination therapy with Dexamethasone and Rituximab
3202031|NCT00909077|Active Comparator|2|Dexamethasone as monotherapy
3202032|NCT00909103||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histological confirmation
3202033|NCT00909103||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
3202034|NCT00909116||Chronic constipation - ODS|Adult Patients with ODS
3202035|NCT00909129|Experimental|HIV-1 HCV coinfected patients|HIV-1 HCV coinfected patients undergoing HCV therapy
3202036|NCT00909142||Group1|
3202037|NCT00909168|Experimental|Efficacy of FLAIMy|
3202038|NCT00909194|Experimental|Intervention|Educational Seminar on Juvenile Primary Fibromyalgia Syndrome and CD-guided total body relaxation technique
2537245|NCT02648750|Experimental|Rehabilitation Assistant|Bridges stroke self-management programme. Delivered by rehabilitation assistants. Participants will receive a minimum of 4 sessions over a 4-6 week period.
2537246|NCT02648750|Active Comparator|Therapist|"Bridges stroke self-management programme. Delivered by registered stroke therapists (Occupational therapists or physiotherapists).~Participants will receive a minimum of 4 sessions over a 4-6 week period."
2537297|NCT02648412|Experimental|Ketamine sedation|"Procedure scheduled under ketamine sedation. Baseline pupillary diameter measurement in alert subjects. Injection of a bolus of 1 mg/kg of ketamine. Every minute, tetanic stimulations of incremental intensities (10-20-30-40-60 milliamps), during 5 seconds.~Pupillary diameter measurement before and after each stimulation. End of study period, beginning of procedure."
3202039|NCT00909194|No Intervention|Control|Control Arm consisted of an educational seminar on skin care
3202040|NCT00909207||Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
2537396|NCT02647723|Experimental|Oral supplement for pregnant women|450 mg/daily of DHA beginning at 10-16 weeks of gestation through the end of pregnancy
2537398|NCT02647723|Placebo Comparator|Sugar pill|450 mg/daily of sugar pill beginning at 10-16 weeks of gestation through the end of pregnancy
2537425|NCT02647385|Experimental|General Anesthesia|Interventions: include pain assessment, inflammatory response and opioid consumption.
2537431|NCT02647385|Experimental|General Anesthesia SAM and PEC I block|Interventions: include pain assessment, inflammatory response and opioid consumption.
2537483|NCT02647138|Experimental|White Noise|Subject will have white noise machine placed in room.
2537510|NCT02646878|Other|Harmony 1 Sensor Group A|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 90 minutes after sensor insertion.
2537511|NCT02646878|Other|Harmony 1 Sensor Group B|Subjects wearing Harmony 1 Sensor will be assigned this group which will participate in the in-clinic YSI frequent sample testing 12 hours after sensor insertion.
2537614|NCT02646670|Active Comparator|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml . This group will be five about patients about any age, with diabetic macular edema randomly chosen
2537618|NCT02646670|Active Comparator|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml. This group will be about five patients about any age, with diabetic macular edema randomly chosen
2537619|NCT02646670|Active Comparator|Ranibizumab and Aflibercept|- In this group will be held two applications of 0.1 ml Aflibercept(the first and the third doses) interspersed with one application of Ranibizumab 0.1 ml(the second dose). This group will be about five patients about any age, with diabetic macular edema randomly chosen
2537620|NCT02646670|Active Comparator|Aflibercept and Ranibizumab|- This group will be held two applications of Ranibizumab 0.1 ml(the first and the third doses) interspersed with one application of Aflibercept 0.1 ml(the second dose). This group will be five about patients about any age, with diabetic macular edema randomly chosen
2537648|NCT02646150||critical limb ischemia|
2537786|NCT02645344|Experimental|Repetitive Transcranial Magnetic Stimulation (rTMS)|Low frequency rTMS at 1 Hz was applied over P5 of the contralesional hemisphere in addition to conventional rehabilitation
2537790|NCT02645344|Experimental|rTMS combined with sensory cueing (SC)|Vibration cueing was emitted using a wristwatch device on the hemiplegic arm combined with low frequency rTMS in addition to conventional rehabilitation
2537797|NCT02645344|Active Comparator|Conventional rehabilitation|Physical therapy and occupational therapy
2537881|NCT02644499|Active Comparator|Combination therapy|Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
2537882|NCT02644499|Active Comparator|Monotherapy|Methotrexate (up to 25 mg once a week) for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop) will be given as bridging therapy.
2538067|NCT02643368|Active Comparator|mOPV2 at 6 and 7 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 7 weeks of age
2538069|NCT02643368|Active Comparator|mOPV2 at 6 and 8 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 8 weeks of age
2538071|NCT02643368|Active Comparator|mOPV2 at 6 and 10 weeks of age|Participants enrolled in this arm would receive a dose of monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age
2538073|NCT02643368|Active Comparator|mOPV2 at 6 and 10 week of age and IPV at 6 weeks of age|Participants enrolled in this arm would receive a dose monovalent type 2 oral polio vaccine (mOPV2) at 6 and 10 weeks of age. In addition, the participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age
2538128|NCT02643030|Experimental|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
2538132|NCT02643030|Active Comparator|hypercapnia|Tidal volume (6ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
2538209|NCT02642705|Experimental|High intensity interval training N|High intensity interval training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing ambient air (normoxia)
2538215|NCT02642705|Experimental|High intensity interval training H|High intensity interval training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a high intensity interval training protocol (1 min ON at 100% maximal power output, 1 min OFF), breathing hypoxic air (about 3 500 m of altitude)
2538246|NCT02642250|Experimental|Entoban Capsules|Entoban is the combination of Holarrhena antidysenterica, Berberis aristata, Symplocos racemosa, Querecus infectoria and Helicteres isora.
3202041|NCT00909233||Group 1|
3202042|NCT00909259|Experimental|Phrenic Stimulation|
3202043|NCT00909272||US-guided lumbar medial branch block|Patients who have low back pain and/or leg pain due to possible lumbar facet joint disease .
3202044|NCT00909272||Cadavers for Ultrasound landmarks|Cadavers donated to the Department of Anatomy in McMaster University will be used to determine the landmarks for ultrasound.
3202045|NCT00909285|Experimental|Treatment Group (#1)|
2537350|NCT02647931|Experimental|Voice Therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia patients.
2537397|NCT02647684|Experimental|Self- Direced Triple P|Self-directed Triple P workbook to be completed over 10 weeks. Over the course of the workbook parents will think about the changes they would like to make to their child's behaviour. They are taught strategies to enhance their relationship with their child, and promote desirable behaviours. They learn about options for managing problem behaviours and have the opportunity to decide if they would like to use any of these approaches with their child in a clear and consistent way. Parents have practice period to use the approaches they have learnt in weeks 1-3. By the end of week 6 they will have had practice in using their chosen positive parenting approaches, learnt to set goals and monitor their own behaviour when using these strategies. The final weeks aim to help parents identify times when the strategies may not be working and provide survival tips on what to do at these times.
2537447|NCT02647411||Projeto Boa Visão|Review of records between 1995 and 2000, in totality of 16.806 patients between 2 and 40 years old
2537452|NCT02647411||Projeto Olhar Brasil|Review of records between March and September 2014, in totality of 163 patients between 6 and 18 years old
2537487|NCT02647125|Experimental|Huachansu Arm|Patients in this arm will receive a treatment of Huachansu combined with thoracic radiotherapy.
2537488|NCT02647125|Active Comparator|Control Arm|Patients in this arm will receive thoracic radiotherapy alone.
2537505|NCT02646813|Active Comparator|Intraluminal Placement|These patients will have the Arndt endobronchial blocker placed within the endotracheal tube for lung isolation during their thoracic surgery. The observer will measure time required to place blocker correctly prior to surgery.
2537506|NCT02646813|Experimental|Extraluminal Placement|These patients will have the Arndt endobronchial blocker placed outside of the endotracheal tube for lung isolation during their thoracic surgery. The investigator will measure the time required for placement.
2537571|NCT02646683|Other|Early Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
2537572|NCT02646683|Other|Late Crohn's disease|"VEDOLIZUMAB 300 mg at week 0,2,6, (10), 14, 22, 30,(34), 38, (42), 46, (50)~week 10 = only required for subjects not responding week 34, 42 and 50- only required for subjects who have no endoscopic improvement at week 26"
2537664|NCT02646267|Experimental|standard intensity warfarin group|standard intensity warfarin group， target international normalised ratio(INR) was 2.1-3.0, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(2.1-3.0)
2537666|NCT02646267|Experimental|low intensity warfarin group|low intensity warfarin group， target international normalised ratio(INR) was 1.7-2.2, warfarin baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range(1.7-2.2)
2537669|NCT02646267|Active Comparator|dabigatran etexilate group|110mg dabigatran etexilate was administrated twice a day
2537805|NCT02645305|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be transfused into 20 COPD patients.
3202046|NCT00909285|Sham Comparator|Control group (#2)|
3202047|NCT00909298|Experimental|1|TTP889 300 mg
3202048|NCT00909298|Placebo Comparator|2|TTP889 Placebo
2538004|NCT02643680|Experimental|The novel biocellulose wound dressing|
2538005|NCT02643680|Active Comparator|Bactigras|
2538092|NCT02643316|Active Comparator|Same day 4 L preparation of PEG|Receive 1 gallon (4 L) of Polyethylene Glycol (PEG) preparation on the morning of the colonoscopy.
2538093|NCT02643316|Active Comparator|Split dose 4 L preparation of of the PEG|Receive the split-dose regimen. Will take half (2 L) of the PEG preparation the evening before colonoscopy and half (2 L) of the PEG preparation on the morning of the procedure.
3202049|NCT00909311|Active Comparator|1|Non-fasting
2538341|NCT02641444||Efavirenz|Receiving efavirenz as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2538342|NCT02641444||Atazanavir|Receiving atazanavir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2538344|NCT02641444||Raltegravir|Receiving raltegravir as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2538346|NCT02641444||Maraviroc|Receiving maraviroc as part of their HIV regimen. Will undergo blood plasma collection, cervical and vaginal biopsy, and colonoscopy with ileal and rectal biopsy.
2538377|NCT02641158|Other|Control Group|
2538378|NCT02641158|Experimental|Care Facilitation Group|
2538425|NCT02640846|Active Comparator|Norepinephrine|Doser
3202050|NCT00909311|Active Comparator|2|Fasting
3202051|NCT00909337|Other|Bosentan|"In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the therapy period can be compared with the changes in the follow up period."
3202052|NCT00909350||No treatment|genetic research project; to meet inclusion criteria, participants must have normal upper GI tract upon upper endoscopy, for study biopsies to be taken
3202053|NCT00909376||1 - transabdominal sonography|Women who will have a transabdominal sonography done in the early second trimester.
3202054|NCT00909376||2 - transvaginal sonography|Women who will have a transvaginal sonography done in the early second trimester.
3202055|NCT00909402|Experimental|All Subjects|
3202056|NCT00909441|Experimental|SNB + ALND|Intervention: Sentinel Lymph Node Biopsy followed by Axillary Node Dissection.
3202057|NCT00909454|Experimental|Daily 2000 IU vitamin D supplement|
3202058|NCT00909454|Active Comparator|Daily Vitamin D supplement 400 IU|
3202059|NCT00909467||myeloproliferative, -dysplastic disease|
3202060|NCT00909493|Experimental|Access to Pain Specialist|Network
2537258|NCT02648711|Experimental|CRLX101 alone|Subjects will receive weekly infusion of CRLX101 alone. Starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2 (or 10 mg/m^2 if 12 mg/m^2 is not well tolerated. No other dose levels will be explored.
2537261|NCT02648711|Experimental|CRLX101 in combination with bevacizumab|Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2. No other dose levels will be explored.
2537263|NCT02648711|Experimental|CRLX101 in combination with mFOLFOX6|Subjects receive weekly infusion of CRLX101 for 3 of every 4 weeks in combination with bi-weekly mFOLFOX6 (oxaliplatin 85 mg/m^2, leucovorin 400 mg/m^2 and 5FU 400 mg/m^2 bolus followed by 2400 mg/m^2 continuous infusion). The starting dose is 12 mg/m^2 and the next dose level is 15 mg/m^2.
2537329|NCT02648087|Other|With and without SDB|comparison of patients with and without sleep-disordered breathing
2537377|NCT02647762|Experimental|CF101 1mg|CF101 1mg, orally q12 hours
2537378|NCT02647762|Experimental|CF101 2mg|CF101 2mg, orally q12 hours
2537382|NCT02647762|Active Comparator|MTX once weekly|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.
2537387|NCT02647762|Placebo Comparator|Placebo|Placebo control , orally q12 hours
2537461|NCT02647372|Experimental|Endocrinological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be endocrinological evaluation including metabolic measures, calorimetric parameters.
2537463|NCT02647372|Experimental|Neurological approach|Parkinson patient submitted to DBS surgery target to globus pallidus nucleus or the subthalamic nucleus. Those patients will be neurological evaluation including UPDRS scale.
2537522|NCT02646956||Age Group-Children|Children between ages of 7 and 14
2537532|NCT02646956||Age Group-Adults|Healthy adults who are the parent of the children
2537589|NCT02646631|Experimental|Usual Treatment|
2537592|NCT02646631|Experimental|MORE|
2537597|NCT02646631|Active Comparator|MORE + MI|
2537676|NCT02646072|Active Comparator|Diabetes mellitus patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
2537678|NCT02646072|No Intervention|Diabetes mellitus control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
2537681|NCT02646072|Active Comparator|Non diabetic patients|Ketorolac tromethamine ophthalmic solution 0.45% four times a day for 3 days prior to cataract surgery
2537683|NCT02646072|No Intervention|Non diabetic control patients|Topical refresh plus four times a day for 3 days prior to cataract surgery
2537710|NCT02645734|Active Comparator|Injection intravitreous bevacizumab|Injection intravitreous bevacizumab at a dose 1.25mg
2537713|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 1.25 mg|Injection ziv-aflibercept at dose of 1.25 mg
2537716|NCT02645734|Active Comparator|Injection ziv-aflibercept at dose of 2.5 mg|Injection ziv-aflibercept at dose of 2.5 mg
2537792|NCT02645435|Active Comparator|Hip direct anterior approach|Patients with hip arthritis
2537796|NCT02645435|Active Comparator|Lateral hip approach|Patients with hip arthritis
2537866|NCT02644915|Experimental|study group|"Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
2537871|NCT02644915|Placebo Comparator|control group|"100ml 0.9%%NaCl solution,but without edaravone, will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg."
2537946|NCT02644291|Experimental|mebendazole|oral mebendazole as dose escalation (three groups), or l oral mebendazole at maximum dose for extended cohort. Given in 3 divided doses with meals as chewable 500 mg tablets based on calculated patient surface area.
2538015|NCT02643758|Experimental|Bifocal soft contact lenses|Device: Bifocal soft contact lenses Use of bifocal contact lenses with nasally decentered optical zone to control the progression of myopia
2538016|NCT02643758|No Intervention|Single vision spectacles|Control: Single vision spectacles
2538087|NCT02643329|Experimental|BF-Gliclazide Tablet 80mg|During the study session, healthy male subjects will be administered a single oral dose of BF-Gliclazide Tablet 80 mg after an overnight fast of approximately 10 hours.
2538088|NCT02643329|Active Comparator|Diamicron 80mg Tablet|During the study session, healthy male subjects will be administered a single oral dose of Diamicron 80 mg Tablet after an overnight fast of approximately 10 hours.
3202061|NCT00909506|Placebo Comparator|Placebo|Placebo
3202062|NCT00909506|Active Comparator|Metformin 500 mg/d|Metformin 500 mg/d
2538268|NCT02642029|Experimental|Intermittent TBS (iTBS)|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
2538269|NCT02642029|Active Comparator|Continuous TBS (cTBS)|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
2538271|NCT02642029|Sham Comparator|Sham TBS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
2538314|NCT02641639|Active Comparator|Fosbretabulin tromethamine|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and CA4P
2538321|NCT02641639|Placebo Comparator|Placebo|Physician's choice chemotherapy (weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) plus bevacizumab and placebo
2538610|NCT02639806||Retrospective - Local Anesthetic with Sedation|The retrospective group will have received local anesthetic from the surgeon using lidocaine injected subcutaneously and received sedation using fentanyl and midazolam as needed to achieve the desired level of sedation.
3202063|NCT00909506|Active Comparator|Metformin 1000 mg/d|Metformin 1000 mg/d
3202064|NCT00909519|Active Comparator|naproxen|
3202065|NCT00909519|Experimental|naproxcinod|
3202066|NCT00909519|Placebo Comparator|placebo|
3202067|NCT00909571|Experimental|1. FK506E high dose group|
2537267|NCT02648516|Experimental|Conventional plus AAIT|Participants will receive ART plus a dose of allogenic adoptive immune transfusion (3 times of MNCs transfusions) from day 0 through the week 2 study visit.
2537318|NCT02648243|No Intervention|Control|Patients will receive routine discharge instructions and medication information by the nurses and treating physicians at hospital discharge: Patients will not have any contact with the clinical pharmacists.
2537322|NCT02648243|No Intervention|Pharmacist delivered usual care at discharge|Patients will receive the usual counseling at discharge by the clinical pharmacists.
2537325|NCT02648243|Experimental|structured intervention at discharge and tailored follow up|The pharmacist will deliver a structured personalized discharge intervention in addition to 2 follow-up session (around 30 minutes each session) at 4 weeks of discharge and 8 weeks of discharge.
2537364|NCT02647827|Active Comparator|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization.
2537367|NCT02647827|Active Comparator|Acupuncture + lifestyle management|Three treatment per week (4 weeks) and thereafter 2 times per week during 12 weeks.
2537369|NCT02647827|Active Comparator|Metformin + lifestyle management|Oral metformin 500 mg three times daily, in total 1500 mg per day.
2537442|NCT02647476|Experimental|Study group|Immunomodulating nutrition (Reconvan)
2537444|NCT02647476|Active Comparator|Control group|Standard nutrition (Peptisorb)
2537489|NCT02647060||idiopathic pulmonary hypertension|"diagnose as idiopathic pulmonary arterial hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
2537490|NCT02647060||secondary pulmonary hypertension|"diagnose as pulmonary hypertension~clinical stable over 3 months~able to walk and can do bicycle cardiopulmonary exercise testing"
2537662|NCT02646280|Experimental|Massage therapy and contact experience|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading associated with a preparation to the contact phase of the massage using the typical elements of neurocognitive rehabilitation such as motor imagery, dynamic state during which a person mentally simulates an action, and language, necessary to understand the way of perceiving and organizing sensory, cognitive and phenomenological informations by the patients and so to interpretate pain in a more articulate way.
2537663|NCT02646280|Active Comparator|Massage therapy|Traditional massage therapy consisting of different phases: surface touch, deep touch, static pressures, dynamic pressures and kneading.
2537760|NCT02645383|Active Comparator|PASCAL group|Patients undergone PASCAL laser photocoagulation
2537762|NCT02645383|Active Comparator|Conventional group|Patients undergone conventional laser photocoagulation
2537808|NCT02645084|Active Comparator|Intervention|Intervention: offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
2537816|NCT02645084|No Intervention|Control|Control: Hospital-based standard practice for the detection of colorectal cancer patients with hereditary or familial colorectal cancer, informed by the referral criteria that are being used in the intervention group
2537906|NCT02644408|Experimental|Megestrol and chemoradiotherapy|"Megestrol（Yining）：160mg/d，po,5 weeks in total，oen week before chemoradiotherapy and one week after chemoradiotherapy.~chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w."
2537909|NCT02644408|Active Comparator|chemoradiotherapy|chemoradiotherapy：chemotherapy and radiotherapy： 50Gy in total，2 Gy/d，5d/w.
2538039|NCT02643511|Experimental|Prostate biopsy,Hemiablative focal Brachytherapy|This is a non-randomized, Phase II study examining the efficacy in terms of postimplant dosimetry (primary endpoint) as well as the secondary endpoints of QOL changes, toxicity, local control with post-treatment biopsy outcomes and comparison with historical whole-gland cohorts in men with early stage low volume prostate cancer treated with hemiablative focal brachytherapy
2538125|NCT02643212|Placebo Comparator|Placebo|
2538131|NCT02643212|Experimental|Rivaroxaban|Rivaroxaban 10mg, 1 once a day
3168038|NCT00545987|Active Comparator|intramuscular injection|administration of an HIV-1 vaccine by conventional intramuscular injection
3168039|NCT00545987|Experimental|TriGrid Delivery System|electroporation-mediated intramuscular delivery using the TriGridTM device by Ichor Medical Systems, Inc.
3168040|NCT00546013||AAA group, control group|AAA group : with AAA Control group: without AAA
3168041|NCT00546026|Active Comparator|Active group|Receive assessment of placental function
3168042|NCT00546039|Active Comparator|1|
3168043|NCT00546039|Placebo Comparator|2|
3168044|NCT00546065|Other|ablation of Barretts with concomitant esomeprazole therapy|comparison of recurrence-free survival
3168045|NCT00546065|No Intervention|non ablation|non ablation only surveillance
2537276|NCT02648594|Experimental|Intervention: Hook wire CT guided|"There is only one arm. When patient undergo surgery , the radiologist will place a CT-guided Hook wire in order to localize it in patient lung. The intervention consists to place a CT-guided hook wire in contact with the pulmonary nodule under local anesthesia.~Then, the thoracoscopy will be realised. Then, the surgery piece will be examined to confirm if the node is in the surgery piece"
2537336|NCT02648256|Experimental|Oropharyngeal rinse|"Polymerase Chain Reaction on Oropharyngeal rinse:~Dosage of Pneumocystis jiroveci will be performed on the broncho-alveolar lavage following the usual routine diagnosis.~Polymerase Chain Reaction will be performed on the broncho-alveolar lavage and the oropharyngeal rinse (not communicated to the clinician result) in the same series, in order to compare the results of the fungal quantification."
2537412|NCT02647710|Experimental|PHAT Life Intervention|PHAT Life: Preventing HIV/AIDS Among Teens, is a uniquely-tailored intervention designed for recently-arrested juvenile offenders on probation. The program will teach teens about HIV/AIDS, sexually transmitted infections, and safer decision-making. PHAT Life draws on social learning theory and a Social-Personal Framework to address individual and social mechanisms related to HIV-risk, including emotion regulation, peer norms, partner communication, relationship characteristics, and HIV/AIDS/STI and substance use knowledge, attitudes, and beliefs.
2537413|NCT02647710|Active Comparator|Health Promotion Control|A health promotion program focusing on nutrition, physical activity, substance use, and sexual health.
2537470|NCT02647307|Experimental|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg).
2537540|NCT02646969|Active Comparator|Formula regimen 1|"Product Control from enrollment to transition phase 1 (blinded administration), followed by open label administration for 2 months.~Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old"
2537544|NCT02646969|Active Comparator|Formula regimen 2|Product Test 1 from enrollment to transition phase 1 (blinded administration) Product Control for 2 months(open label) Product Test 2 from transition phase 2 to 1 year old (open label) Commercial follow up formula from 1 year old
2537546|NCT02646969|No Intervention|Reference group|Infants fed HM exclusively through at least 4 months of age. Once breastfeeding is over and if wished Infant will receive Product test 2 until 1 year old followed by the commercial follow-up formula
2537656|NCT02646254|Active Comparator|blood cardioplegia|these patients received blood cardioplegia
2537659|NCT02646254|Active Comparator|del nido cardioplegia|these patients received del nido cardioplegia
2537687|NCT02645877||Prehospital care|All pre-hospital service data were collected from January 2005 to December 2014 from the Beijing Emergency Center and Beijing Red Cross Emergency Center, which oversee all pre-hospital care in Beijing. The major illnesses were classified into 34 disease spectrum categories according to the Medical Priority Dispatch System (MPDS) which total includes 34 diseases. Data on pre-hospital emergency demand and first aid-related time intervals were analyzed to determine trends over the period.
2537730|NCT02645669|Experimental|Study site|Scaling and Root planing (SRP) was followed by placement of S boulardii-FOS mixture
2537731|NCT02645669|Placebo Comparator|Control site|Only Scaling and Root planing (SRP) was performed
2537852|NCT02644759|Experimental|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
2537905|NCT02644434|Active Comparator|Conventional Strategy|Patients randomized to the conventional strategy group would undergo either jailed wire technique (diameter of side branch<2.5mm and ≥2.0mm) or provisional two-stent strategy (diameter of side branch≥2.5mm).
2537908|NCT02644434|Experimental|Intentional Strategy|Patients randomized to the intentional strategy group would undergo either jailed balloon technique (diameter of side branch<2.5mm and ≥2.0mm) or elective two-stent strategy (diameter of side branch≥2.5mm).
2538027|NCT02643732|Experimental|Methylphenidate|"Methylphenidate 10mg (one tablet) twice daily, increasing to 20mg (two tablets) twice daily following assessment 2 weeks into trial.~24 weeks duration"
2538028|NCT02643732|Placebo Comparator|Placebo|"Identical, over-encapsulated placebo tablets manufactured to be identical to the experimental tablets. One tablet twice daily, increased to two tablets twice daily following assessment 2 weeks into trial.~24 weeks duration."
3202068|NCT00909571|Experimental|2. FK506E low dose group|
3202069|NCT00909584|Experimental|1|4-Week dose equilibration period with Telintra followed by 4 month treatment period
2538297|NCT02641964||ARDS group|patients with acute necrotizing pancreatitis complicated by ARDS
2538298|NCT02641964||non-ARDS group|acute necrotizing pancreatitis patients without ARDS
2538327|NCT02641535|Experimental|research arm|"12 healthy volunteers from the border guard of the police forces will participate in this study. The subjects will undergo 4 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3.2 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC membrane protective garment + NBC mask"
2538362|NCT02641145|Experimental|Active AL cardiac amyloidosis|75 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of blood of the heart, as well as the heavy metal analysis of the blood at baseline, 6 months and 12 months after initiation of chemotherapy. 25 of these individuals will also undergo a N-13 ammonia PET scan of the heart following supine bicycle stress at baseline and at 6 months after initiation of chemotherapy.
2538612|NCT02639793|Active Comparator|cryoablation|Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
3168046|NCT00546130|Experimental|1|Irinotecan hydrochloride + Cisplatin + Krestin Therapy
3168047|NCT00546143|Experimental|1|Omalizumab 900 mg
2537356|NCT02647801|Experimental|Mindfulness intervention|The experimental group comes to weekly laboratory meetings and practices mindfulness. Participants also fill out self-report questionnaires which assess self-control and mindfulness.
2537361|NCT02647801|No Intervention|Control group|The control group comes to weekly laboratory meetings and fills out self-report questionnaires which assess self-control and mindfulness. No mindfulness training is carried out.
2537424|NCT02647606|Experimental|McGrath Group|MgGrath videolaryngoscope will be used for nasotracheal intubation with MILS
2537430|NCT02647606|Experimental|Pentax-AWS Group|Pentax-AWS videolaryngoscope will be used for nasotracheal intubation with MILS
2537435|NCT02647606|Experimental|Macintosh Laryngoscope Group|Macintosh Laryngoscope will be used for nasotracheal intubation with MILS
2537564|NCT02647073|Experimental|Mobile monitoring device arm|Canary 01 Mobile Vital Signs Monitoring Device
2537726|NCT02645578|Experimental|RMNS group|Focus intervention: right median nerve stimulation plus standard management
2537727|NCT02645578|No Intervention|Control group|Standard management
2537764|NCT02645357|Experimental|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
2537766|NCT02645357|Other|Control group|No on-screen, point-of-care computer reminders on clinical practice.
2537807|NCT02645032|Experimental|Test group|Two doses of Vi-DT (typhoid conjugate vaccine) will be administrated intramuscularly 4 weeks apart (Day 0 and Day 28).
2537820|NCT02645032|Active Comparator|Comparator group|"Biological/Vaccine:~One dose of Typhim Vi® will be administrated intramuscularly at 1st dose (Day 0).~One dose of VAXIGRIP® will be administrated intramuscularly at 2nd dose (Day 28)."
2537880|NCT02644655|Experimental|CD19-specific chimeric antigen receptor|After pretreatment, cluster of differentiation antigen 19 (CD19)-specific chimeric antigen receptor will be transfused.
3202070|NCT00909584|No Intervention|2|4 Month observation period with standard of care treatment and option to crossover to Telintra treatment for 4 week dose equilibration followed by 4 week treatment period
2538047|NCT02643342|No Intervention|Single-vision glasses|Subjects wearing single-vision glasses CR-39 of refractive index 1.56.
2538051|NCT02643342|Sham Comparator|Orthokeratology with normal compression factor|Subjects wearing orthokeratology lenses of normal compression factor about 0.50-0.75D.
2538055|NCT02643342|Active Comparator|Orthokeratology with increased compression factor|Subjects wearing orthokeratology lenses of increased compression factor about 1.50-1.75D.
2538103|NCT02643108|Experimental|Lateral episiotomy|Lateral episiotomy (left or right) is performed by the attending physician or assisting midwife at crowning of the fetal head in operative vaginal delivery by vacuum extraction. Regular manual perineal support is applied.
2538104|NCT02643108|No Intervention|No episiotomy|No episiotomy is performed during operative vaginal delivery, unless vitally indicated (for example severe fetal distress). The woman may tear spontaneously. Regular manual perineal support is applied.
2538169|NCT02642510|Experimental|DVD Structured Education|Participants in this group will watch an educational DVD in addition to standard teaching by nursing staff.
2538170|NCT02642510|Active Comparator|Standard Educational Teaching|Participants in this group will receive educational teaching by their assigned nursing staff.
2538212|NCT02642315|Other|open-label|"open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days."
3168048|NCT00546143|Experimental|2|Omalizumab 1050 mg
3168049|NCT00546143|Experimental|3|Omalizumab 1200 mg
2538279|NCT02641873|Experimental|BBI608 + FOLFIRI +Bevacizumab|
2538310|NCT02641600|Active Comparator|Elastic stockings|Class 1 elastic stockings (18-21 mmHg)
2538316|NCT02641600|Placebo Comparator|Placebo stockings|Placebo stockings (0 mmHg)
2538355|NCT02641301|Experimental|Subjects Roux-en-Y-gastric bypass (RYGB)|Sustained release morphine sulfate, 30 mg
2538359|NCT02641301|Active Comparator|Control volunteers matched with RYGB|Sustained release morphine sulfate, 30 mg
2538417|NCT02640976|Active Comparator|Poor responders|"This group will include women who underwent IVF/ICSI cycle and produced 4 oocytes or less.~intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (300 IU).~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~Finally, when at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
2538427|NCT02640846|Active Comparator|Milrinone|Doser
2538430|NCT02640846|Active Comparator|Levosimendan|Doser
2538475|NCT02640599|Experimental|Vestibular Rehabilitation + Areobic Exercise|
2538477|NCT02640599|Active Comparator|Vestibular Rehabilitation|
3168050|NCT00546169||A|
3168051|NCT00546208||1|adolescents and young adults who underwent, as newborns, unilateral low loop cutaneous ureterostomy for severe bilateral hydro-ureteronephrosis, and that, afterwards, underwent stomal closure
3168052|NCT00546221|Experimental|Psychosocial support|Comprising 22 participants engaging in the experimental exercise programme, exercising with psychosocial support.
3168053|NCT00546221|Active Comparator|Prescribed exercise|Comprising 21 participants engaging in a programme of typical prescribed exercise.
3168054|NCT00546234|Active Comparator|1|
3168055|NCT00546234|Active Comparator|2|
3168056|NCT00546247|Experimental|1|
3168057|NCT00546286|Experimental|1|dorzolamide HCl/timolol maleate
3168058|NCT00546286|Experimental|2|dorzolamide hydrochloride/timolol maleate + prostaglandin
3168059|NCT00546325|Experimental|1|Rimonabant
3168060|NCT00546325|Placebo Comparator|2|Placebo
3168061|NCT00546403|Placebo Comparator|Placebo|Adjunctive treatment with placebo
3168062|NCT00546403|Experimental|Modafinil|Treatment with titrated dose of study drug, modafinil.
3168063|NCT00546442|Placebo Comparator|2|Placebo of metformine 850-2550 mg/daily for 48 weeks
3168064|NCT00546442|Experimental|1|Metformine 850-2550 mg/daily for 48 weeks
3202071|NCT00909597|Active Comparator|pioglitazone|
2537776|NCT02645526|Experimental|KMC with woolen cap|In this group, the head of the patients will be covered with a woolen cap during KMC.
2537777|NCT02645526|No Intervention|KMC without woolen cap|In this group, the head of the patients will be uncovered during KMC.
2537940|NCT02644161|Active Comparator|Combination acupuncture treatment (CAI)|Post stroke depression patients will receive Dense Cranial Electroacupuncture Stimulation (DCEAS) and body acupuncture. Patients will continue their existing antidepressant and rehabilitation therapy as usual.
2537945|NCT02644161|Sham Comparator|Least acupuncture stimulation (LAS)|Post stroke depression patients will receive Least acupuncture stimulation (LAS). Patients will continue their existing antidepressant and rehabilitation therapy as usual.
3168065|NCT00546468|Experimental|Laparoscopy assisted distal gastrectomy|Laparoscopy assisted distal gastrectomy with D2 lymph node dissection.Surgery will be done in similar operative extent with control open distal gastrectomy. Omentectomy will be omitted.
3168066|NCT00546468|Active Comparator|Open Distal Gastrectomy|Conventional standard D2 open distal gastrectomy without omentectomy.
2538197|NCT02642445|Experimental|Renal Sympathetic Denervation|Renal sympathetic Denervation are conducted from the adventitia of renal artery
2538201|NCT02642445|No Intervention|Control Group|Renal Sympathetic Denervation are not conducted in control group.
2538250|NCT02642211|Active Comparator|phako|eyes receiving phakoemulsification for cataract surgery
2538251|NCT02642211|Active Comparator|MSICS|Eyes undergoing manual small incision cataract surgery
2538293|NCT02641860|Other|Mesenchymal progenitor cells Dosage 1|Mesenchymal progenitor cells low-dose group
2538295|NCT02641860|Other|Mesenchymal progenitor cells Dosage 2|Mesenchymal progenitor cells mid-dose group
2538296|NCT02641860|Other|Mesenchymal progenitor cells Dosage 3|Mesenchymal progenitor cells high-dose group
2538329|NCT02641496|Experimental|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
2538332|NCT02641496|Active Comparator|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
2538413|NCT02641002|Experimental|Dose escalation of CC-90002|CC-90002 by intravenous (IV) infusion on a 28 day cycle
2538618|NCT02639741|Active Comparator|Oral Melatonin Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of melatonin (6 mg) or placebo tablet will be given one hour before the start of anesthesia.
2538620|NCT02639741|Active Comparator|Oral Vitamin C Tablet|Melatonin, Vitamin C and placebo tablet Preoperative single oral dose of vitamin C (2 gr) or placebo tablet will be given one hour before the start of anesthesia.
2538621|NCT02639741|Placebo Comparator|Oral Placebo Tablet|Preoperative single oral dose of placebo tablet will be given one hour before the start of anesthesia.
3168067|NCT00546507|Placebo Comparator|A|placebo
3168068|NCT00546507|Active Comparator|B|celecoxib 200 mg qd p.o.
3168069|NCT00546507|Experimental|C|TDS-943 40 mg bid topically
3168070|NCT00546546|No Intervention|control = conventional treatment|conventional treatment: use of immunosuppressants only if steroid dependency or chronic active disease
3168071|NCT00546546|Experimental|Immunossuppresive treatment|Switch to different immunosuppresive treatment in case of relapse.
3168072|NCT00546585|Experimental|90 mcg of Influenza A/H7N7|25 subjects to receive 90 mcg of Influenza A/H7N7.
3168073|NCT00546585|Experimental|15 mcg of Influenza A/H7N7|25 subjects to receive 15 mcg of Influenza A/H7N7.
3168074|NCT00546585|Experimental|7.5 mcg of Influenza A/H7N7|25 subjects to receive 7.5 mcg of Influenza A/H7N7.
3168075|NCT00546585|Experimental|45 mcg of Influenza A/H7N7|25 subjects to receive 45 mcg of Influenza A/H7N7.
3168076|NCT00546585|Placebo Comparator|Saline placebo|25 subjects to receive placebo.
3168077|NCT00546611|Active Comparator|1|Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.
3168078|NCT00546650|Experimental|A|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
3168079|NCT00546650|Active Comparator|B|Sumatriptan succinate (Imitrex®) tablet: 100 mg orally.
3168080|NCT00546650|Active Comparator|C|Sumatriptan succinate (Imitrex®) injection: 6 mg subcutaneously (SQ).
3168081|NCT00546650|Active Comparator|D|Sumatriptan (Imitrex®) nasal spray: 20 mg (one spray) intranasal (IN) into one nostril.
3168082|NCT00546650|Experimental|E|NP101 patch applied to the upper arm and left in place for 4 hours. The NP101 patch is designed to deliver ~ 10 mg of sumatriptan utilizing up to 600 mA minutes.
3168083|NCT00546663|Experimental|Open-label|
3168084|NCT00546689||1 , 2|those with HIV
3168085|NCT00546741|Experimental|1|
3168086|NCT00546741|Active Comparator|2|
3168087|NCT00546741|Active Comparator|3|
3168088|NCT00546767|Experimental|Mail and Live Phone|
3168089|NCT00546767|Experimental|IVR|
3168090|NCT00546767|Experimental|Computer Kiosk|
3168091|NCT00546767|Active Comparator|Traditional|
3168092|NCT00546780|Active Comparator|Arm A|Tanespimycin + Bortezomib
3168093|NCT00546780|Active Comparator|Arm B|Bortezomib
2537404|NCT02647671|Active Comparator|Calcium Carbonate|Active Comparator: Calcium Carbonate (4 capsules per day) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2537406|NCT02647671|Placebo Comparator|Placebo|Placebo (Maltodextrin) - 4 capsules; 2 to be taken in the morning and 2 in the evening
2537460|NCT02647333|Experimental|Omega-3 fatty acid|Omega-3 fatty acids for 8 weeks, dosage are 3 and 4 g/day for women and men, respectively.
2537464|NCT02647333|Experimental|Omega-6 fatty acid|Omega-6 fatty acids for 8 weeks, dosage are 20 and 27 g/day for women and men, respectively.
3202072|NCT00909597|Experimental|taspoglutide 10mg|taspoglutide 10mg sc weekly
3202073|NCT00909597|Experimental|taspoglutide 10mg/20mg|taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly
2537633|NCT02646358|Experimental|Cohort 1: Normal Renal Function|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2537635|NCT02646358|Experimental|Cohort 2: Mild Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2537637|NCT02646358|Experimental|Cohort 3: Moderate Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2537638|NCT02646358|Experimental|Cohort 4: Severe Renal Impairment|Vepoloxamer Injection, 100 mg/kg for 1 hour followed by 30 mg/kg/hr for 5 hours
2537639|NCT02646358|Experimental|Cohort 5: End Stage Renal Disease|Vepoloxamer Injection, 50 mg/kg for 1 hour followed by 15 mg/kg/hr for 5 hours
2537684|NCT02646046|Experimental|Combi lone-CPR|"Intervention group~: Newly developed method"
2537685|NCT02646046|Active Comparator|Conventional lone-CPR|Conventional CPR group
2537720|NCT02645721|Experimental|Extended self-help program with guidance|The program is a comprehensive CBT program lasting 12 weeks, with as many modules. The modules are quite extensive. A guide with basic education in psychotherapy assists and counsels participants online.
2537722|NCT02645721|Active Comparator|Briefer Self-help program, no guidance|This self-help program also lasts 12 weeks but contains only 9 modules; a pause occurs during the final weeks of the program for self-testing of acquired skills. The modules are quite brief. Participants receive no guidance.
2537724|NCT02645721|Other|WL: Extended self-help program, choice of guidance intensity|Participants will be put on a waiting list. After 12 weeks on the waiting list, participants will receive access the the extended self-help program used in the experimental arm. However, participants will be offered a choice between three guidance options of varying intensity: proactive guidance, reactive guidance (only at participant request) or no guidance.
2537765|NCT02645370|Active Comparator|Active Comparator:Topiramate|The treatment with TPM is initiated at a 50 mg daily dose and sequentially increase every 7 days, as tolerated, in 25 mg increments up to a target dose of 150 mg total/day.
2537767|NCT02645370|Experimental|Experimental:Danzhen|The treatment with Danzhen is 3 tablets triple daily.
3202074|NCT00909636|Active Comparator|1. ABT-333 Tablet|Three 400mg ABT-333 Tablets, BID
3202075|NCT00909636|Active Comparator|2. ABT-333 Tablet|Four 400mg ABT-333 Tablets, BID
3202076|NCT00909636|Placebo Comparator|3. Placebo|Three or four placebo tablets, BID
3202077|NCT00909662||Patients|Female patients with operable breast cancer intending to undergo adjuvant chemotherapy
3202078|NCT00909662||Participants|Female control subjects will be recruited, consisting predominantly of age-matched (i.e.+/- 10 years of age) friends or family members of the patients.
2537888|NCT02644564||Ultrasonography|Patients will undergo structured clinical examination and ultrasonography of both shoulders on the day of inclusion. They also fill out an injury registration form, Oxford Shoulder Score and QuickDASH. Follow-up at 3, 6 and 12 months will be identical, but without ultrasonography and injury registration form.
2537918|NCT02644213|Experimental|research arm|"12 young, healthy civilian volunteers will participate in this study. The experiment will take place in a dome room.~The experiment will be performed according to the protocol of using CAREN and MOTEK systems:~CAREN high (Computer Assisted Rehabilitation Environment) which screens virtual scene in the dome.~MOTEK (Motek Medical©, the Netherlands) which is a two track treadmill (for each leg) placed on a rotatable platform.~each subject will undergo the same experiment protocol."
2537978|NCT02643927|Experimental|standard 8-weeks MBSR|8-week program
2537979|NCT02643927|Experimental|4-week shortened MBSR|Short 4 sessions intervention
2537980|NCT02643927|No Intervention|Control Group|control group: No intervention
2538018|NCT02643524|Active Comparator|Nutrition and Exercise Counseling|CAM boot prescribed as standard of care Nutritional counseling provided Upper body exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit Patients in this arm compared with patients in control arm
2538021|NCT02643524|Active Comparator|Control|CAM boot prescribed as standard of care No nutritional or exercise counseling provided Blood drawn for Albumin level at enrollment and final visit Height and weight measured at enrollment and final visit
2538105|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
2538106|NCT02643277|Experimental|Mobile phone text messaging|The intervention will receive text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring. The messages provide tips and suggestions, and positive reinforcement or encouragement, for improving lifestyle behaviors and compliance with therapy.
2538155|NCT02642848|Active Comparator|HTO with micro fracture|High tibial osteotomy(HTO) with micro fracture is an common treatment for the correction of malalignment of the knee treating osteoarthritis.
2538156|NCT02642848|Experimental|HTO with bone marrow stem cell|High tibial osteotomy(HTO) with transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone.
2538158|NCT02642848|Experimental|HTO with adipose derived stem cell|High tibial osteotomy(HTO) with autologous adipose-derived stromal vascular fraction transplantation using LipoSculptor collecting from abdominal fat tissue.
2537418|NCT02647450||GIANT Clinic Group|Patients are required to have been refereed to the GI and Nutrition team Clinic at the Royal Marsden Hospital. In the clinic they will be assessed for their symptoms using the Gastrointestinal Symptom Rating Scale (GSRS).
2537475|NCT02647268|No Intervention|Control (no oxytocin) pretreatment|The myometrial samples are bathed in physiological saline solution (PSS).
2537477|NCT02647268|Active Comparator|Magnesium Sulphate|The myometrial samples are bathed in a 3.5mM magnesium sulphate solution.
2537479|NCT02647268|Active Comparator|Magnesium Sulphate + oxytocin|The myometrial samples are bathed in a 3.5mM magnesium sulphate plus 10-5M oxytocin solution.
2537507|NCT02646839|Experimental|KIR Favorable Transplant|To assess in a multi-center setting whether the disease-free survival (DFS) at one-year post-HCT for children with high-risk ALL, AML and MDS can be improved following favorably KIR-mismatched haplo-HCT using a graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells from CliniMacs TCR alpha-beta-Biotin system
2537613|NCT02646553||Children refered to the obesity clinic.|All children refered to the obesity clinic for examination and optionally treatment are invited.
2537667|NCT02646202|Active Comparator|Sclerotherapy group|thirty patients treated by sclerotherapy for OV using ethanolamine oleate 5%.
2537671|NCT02646202|Active Comparator|Endoscopic band ligation group|thirty patients treated by endoscopic banding using the Euro-Ligator system.
2537673|NCT02646202|Experimental|Sclero-ligation (SL) group|thirty patients treated by intra variceal endoscopic sclerotherapy combined with band ligation.
2537711|NCT02645773|Experimental|Pre-laser|non-ablative laser Laser Pre-wounding low dose laser Pre-wounding medium dose laser Pre-wounding high dose
2537715|NCT02645773|Experimental|Immediate-laser|non-ablative laser Laser low dose - immediate after wounding Laser medium dose - immediate after wounding Laser high dose - immediate after wounding
2537717|NCT02645773|Experimental|Post-laser|non-ablative laser Laser low dose - post wounding Laser medium dose - post wounding Laser medium dose - post wounding
2537718|NCT02645773|No Intervention|Control|Untreated control wound
3202079|NCT00909688|Experimental|1|BLI-489
3202080|NCT00909688|Placebo Comparator|2|placebo
3202081|NCT00909701|Experimental|Test|PreOP Booster (Fresenius Kabi, Bad Homburg, Germany)
2537916|NCT02644577|Experimental|metformin group|Metformin 1000mg/day
2537917|NCT02644577|Placebo Comparator|placebo group|starch
2537964|NCT02643953|No Intervention|Control Group|This arm includes women who are eligible and give birth (including cases of fetal or infant death) in the intervention period in comparative health wards, who will not receive the interventions and who will continue to receive their usual pattern of utilization of maternity care.
2537965|NCT02643953|Experimental|Other|The intervention will need to be multi-faceted, and will consist of provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; conditional cash transfers to promote uptake of services and targeted community health education and advocacy activities
2538007|NCT02643706||CIN|CIN was defined as an absolute increase in serum creatinine concentration of at least 0.5 mg/dL (44.2umol/l) or a relative rise of at least 25% from baseline on the follow-up blood sample drawn 24 to 72 hours after the operation.
2538011|NCT02643706||Control|The enrolled patients without CIN.
3202082|NCT00909701|Active Comparator|Comparator|PreOP (Nutricia Clinical Care, Trowbridge, UK)
3202083|NCT00909714|Experimental|Anodal tDCS|Direct Current (DC)-Stimulator to apply tDCS + Training
3202084|NCT00909714|Sham Comparator|Sham tDCS|Direct Current (DC)-Stimulator to apply Sham tDCS (Placebo) + Training
2538231|NCT02642289|Experimental|Probiotic1: Lactobacillus acidophilus|Dietary Supplement: Probiotics 1. 8-week probiotic food-supplement intervention with Lactobacillus acidophilus (Daily intake: 24 millions)
2538233|NCT02642289|Placebo Comparator|Placebo|Inactivate substance
2538235|NCT02642289|Experimental|Probiotic2: Lactobacillus Rhamnosus GG ®|Dietary Supplement: Probiotics 2 8-week probiotic food-supplement intervention with Lactobacillus Rhamnosus (Daily intake: 24 millions)
2538288|NCT02641808|Experimental|follicular flushing group|Monofollicular IVF therapy with follicular flushing up to five times after aspiration of the follicule at the time to the oocyte pick-up
2538291|NCT02641808|Active Comparator|aspiration group|Monofollicular IVF therapy with aspiration only at the time of the oozyte pick-up
3202085|NCT00909740|Experimental|1|
3202086|NCT00909766|Active Comparator|Panel A|
2538397|NCT02641119||Albumin|Patients receiving any amount of 5% albumin during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician.
2538398|NCT02641119||Saline-only|Patients receiving only saline during large volume resuscitation (defined as ≥ 60ml/kg in a single 24 hour period), as prescribed by treating clinician
2538454|NCT02640872||HAPPY Cohort|A elderly cohort for chronic diseases
2538488|NCT02640456||Para- or retropharyngeal abscess|Patients with para- or retropharyngeal abscess.
2538490|NCT02640456||Neck abscess|Patients with neck abscess without relation to the pharynx or salivary glands.
2538550|NCT02640079|Experimental|Cognitive behavioral therapy|Cognitive behavioral therapy aimed at reducing pain catastrophizing.
2538579|NCT02639858|Experimental|Docetaxel-PM|Docetaxel-PM 75mg/m2 IV infusion
2538628|NCT02639624|Experimental|Low bicarbonate dialysate First|Dialysis with low bicarbonate dialysate (expected normal for an adult ~24 mEq) for the first half of dialysis then switched over to normal bicarbonate dialysate for the second half.
2538630|NCT02639624|Active Comparator|Normal bicarbonate dialysate First|Dialysis with normal (37 mEq) for the first half of dialysis then switched over to low bicarbonate dialysate
3202087|NCT00909766|Active Comparator|Panel B|
3202088|NCT00909766|Active Comparator|Panel C|
3202089|NCT00909766|Active Comparator|Panel D|
3202090|NCT00909766|Active Comparator|Panel E|
3202091|NCT00909766|Active Comparator|Panel F|Low Dose
3202092|NCT00909766|Active Comparator|Panel G|High Dose
3202093|NCT00909766|Placebo Comparator|Panel H|
3202094|NCT00909805|Experimental|Cutaneous suture with glue|Inguinal surgical incision closing using Dermabond® glue instead of cutaneous suture with surjet
2537420|NCT02647398|Active Comparator|B: Supervised strength training|ACTIVE COMPARATOR: Two supervised 45-minute sessions of strength training & Participants will be advised to comply with international recommendations of physical activity (150 min pf MVPA)
2537501|NCT02646930|Experimental|Incidence of CE|To determine rates of CE in women undergoing initial IVF and outcomes
2537563|NCT02646735|Experimental|Fulvestrant|Fulvestrant 500 mg
2537566|NCT02646735|Active Comparator|Exemestane|Exemestane 25mg
2537622|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method - presence of recent abdominal surgery (less than 30 days); multiple previous abdominal surgery (more than two); presence of fibrosis or peritoneal adhesions; fungal peritonitis; severe respiratory insufficiency (FiO2> 70%); abdominal infections; severe hyperkalemia with changes characteristic in EKG; and acute pulmonary edema - will be treated with HD.
2537625|NCT02646436|Other|PD treatment|Patients stage 5 (creatinine clearance < 15 ml/min) requiring dialysis treatment immediately without absolute contraindication to the PD method will receive unplanned PD treatment. High volume PD (HVPD) will be used during the first 7 days of PD in order to achieve metabolic and fluid control. The procedure for acute PD has been published recently by our team . At this point, patients will be discharged from hospital and they will be treated by intermitent PD at the dialysis unit of the University Hospital.until their family be trained and home be prepared for the implementation of technique.
2537647|NCT02646137|Active Comparator|Transarterial chemoembolization (TACE)|treated by transarterial chemoembolization
2537654|NCT02646137|Experimental|Radiofrequency ablation with TACE|Radiofrequency ablation combined with TACE
2537658|NCT02646137|Experimental|Microwave ablation combined with TACE|Microwave ablation combined with TACE.
2537707|NCT02645838|Experimental|Motivational interviewing group|"Structural motivational interviewing for one section (about 20 mins)，provided by family physician~Follow-up telephone call，provided by family physician"
2537709|NCT02645838|No Intervention|Brief advice group|Brief advice without motivational interviewing (about 5 mins), provided by family physician
2537744|NCT02645513|Experimental|Malaria-only text messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to malaria diagnosis and treatment.
2537748|NCT02645513|Experimental|Malaria, pneumonia, and diarrhea messages|Health workers at facilities in this arm receive twice-daily text message reminders for six months on key reminders related to diagnosis and treatment of malaria, pneumonia, and diarrhea
2537751|NCT02645513|Placebo Comparator|Control|No text message reminders to health workers, just the usual health system supports.
2537785|NCT02645136|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
2537793|NCT02645136|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation (AES) associated with Pelvic Floor Muscle Training (PFMT), supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
2537798|NCT02645136|Placebo Comparator|Control|Control Group
2537865|NCT02644798||ARDS patients|ARDS patients in Han nationality
2537921|NCT02644317|Experimental|with modified shoe inserts|wear the modified shoe inserts and shoes for balance test.
2537922|NCT02644317|No Intervention|without modified shoe inserts|only wear the shoes for balance test.
2537996|NCT02643901|Experimental|Ic-GW003 150ug/kg 4-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2537998|NCT02643901|Experimental|Ic-GW003 300ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2538000|NCT02643901|Experimental|Ic-GW003 500ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2538001|NCT02643901|Experimental|Ic-GW003 650ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2538002|NCT02643901|Experimental|Ic-GW003 850ug/kg 6-8subjects|Biological/Vaccine:GW003 freeze-dried powder single SC injection
2538107|NCT02643017|Placebo Comparator|normal saline|
2538109|NCT02643017|Experimental|Dex|
2538213|NCT02642367|Experimental|no use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection without use of stylet with McGrath videolaryngoscope after endotracheal tube was rolled up circularly for 3 min
2538219|NCT02642367|Active Comparator|use of stylet|Endotracheal intubation was performed 2 min after rocuronium injection using a styletted endotracheal tube with McGrath videolaryngoscope
3202095|NCT00909805|Active Comparator|Conventional suture|Inguinal surgical incision closing with conventional cutaneous suture (surjet)
2538966|NCT02637466|Experimental|Vortioxetine|In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
2538970|NCT02637466|Placebo Comparator|Placebo|"In cycle I of the study, 80 eligible depressed women with breast cancer will be randomized into an 8-week, double-blind, placebo-controlled, flexible-dose vortioxetine (10-20 mg) treatment arm versus placebo arm.~Responders to placebo treatment will complete their study participation at the end of Cycle I, and will not proceed to Cycle II."
2539007|NCT02637167|Active Comparator|Rifaximin|Rifaximin: one tablet (550 mg) morning and evening for three months
3202096|NCT00909818|Active Comparator|standard fractionated radiotherapy|50 Gy/25 fractions, 2.00 Gy/fraction, 5 fractions per week
2537484|NCT02647229|Active Comparator|Colonic Hyrdrotherapy|Colonic hydrotherapy is an FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician.2 There
2537520|NCT02646852|Experimental|PLX038 Q3W|intravenous infusion once every 3 weeks
2537527|NCT02646852|Experimental|PLX038 QW ×2|intravenous infusion once weekly for 2 consecutive weeks of a 4-week cycle
2537623|NCT02646644||Metastasized intestinal NET|We will select the 18F- DOPA-PET scans conducted in the Universtiy Medical Center of Groningen (UMCG) of adult patients with a metastasized intestinal NET between February 2014 until November 2015. Only patients of whose clinical data are available within the UMCG are included.
2537665|NCT02646189|Experimental|REP 2139-Ca + immunotherapy|"REP 2139-Ca is the calcium chelate complex formulation of REP 2139.~Zadaxin is thymosin alpha 1~Pegasys is pegylated interferon alpha 2a~Patients initially receiving REP 2139-Ca with no Grade 3 adverse events at week 20 are eligible to transition to combination therapy with Zadaxin if serum HBV DNA is > 2000 copies / ml.~After 10 weeks of REP 2139-Ca / Zadaxin combination therapy, patients not experiencing a measurable improvement in serum antiviral response can further transition to combination therapy with REP 2139-Ca and Pegasys."
2537690|NCT02645799|Active Comparator|LABR-312|"LABR-312 will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> 0.01 mg LABR-312 Group 2: Intermediate dose-> Up to 0.03 mg LABR-312 Group 3: High dose-> Up to 0.08 mg LABR-312 The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
2537693|NCT02645799|Placebo Comparator|saline|"Placebo will be administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent. Target lesions will be treated with the Resolute Integrity Drug Eluting Stent during the index PCI.~Three (3) doses will be tested:~Group 1: Low dose -> placebo (saline) equivalent to 0.01 mg LABR-312. Group 2: Intermediate dose-> placebo (saline) equivalent to up to 0.03 mg LABR-312 Group 3: High dose-> placebo (saline) equivalent to up to 0.08 mg LABR-312. The duration of subject participation will be 1 year; clinical follow-up will be performed at 30 days, 9 months, and 1 year post randomization.~OCT follow-up will be performed at 9 months."
2537749|NCT02645630|Experimental|Right Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the right side.
2537752|NCT02645630|Experimental|Left Cervical Manipulation|Patients assigned to this group will receive a cervical spine manipulation targeting the C3/C4 segment on the left side.
2537753|NCT02645630|Active Comparator|Sham Cervical Manipulation|Patients assigned to this group will receive a sham cervical spine manipulation targeting the C3/C4 segment on both sides. No therapeuthic thrust will be applied.
3168094|NCT00546793|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.
3168095|NCT00546806|Experimental|1|"AVIVA Soft Tissue Injury Care Model"
3168096|NCT00546806|Experimental|2|Pre-approved Framework Guideline for Grade I and II Whiplash Associated Disorders (PAF)
3168097|NCT00546806|Active Comparator|3|Physician-based Education and Activation
2537883|NCT02644590|Experimental|Melatonin treatment|Adolescents with Type 1 Diabetes will undergo baseline 24 hour ambulatory blood pressure monitoring, followed by treatment with Melatonin for 3 weeks, using a single tablet at bed time, and repeat of the 24-hour blood pressure test following treatment period.
2537929|NCT02644252|Experimental|Performance status 0-1, Arm A|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.
2537933|NCT02644252|Experimental|Performance status 0-1, Arm B|Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.
2537937|NCT02644252|Experimental|Performance status 2, Arm A|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression
2537941|NCT02644252|Experimental|Performance status 2, Arm B|Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression
2537992|NCT02643589|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
2537993|NCT02643589|Active Comparator|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
2538059|NCT02643446||G1: IPV+OPV, 1 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV.
2538063|NCT02643446||G2: IPV+OPV, 1 m+7d followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV.
2538068|NCT02643446||G3: IPV+OPV, 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
3168098|NCT00546832|Placebo Comparator|1|placebo
3168099|NCT00546832|Active Comparator|2|celecoxib 200 mg qd p.o.
3168100|NCT00546832|Experimental|3|TDS-943 40 mg bid topically
3168101|NCT00546858||Survey|Patients with interstitial cystitis
3168102|NCT00546936|Experimental|ranibizumab intravitreal injection|0.5 mg intravitreal injection of ranibizumab
3168103|NCT00546936|Active Comparator|Photodynamic Therapy|Photodynamic therapy with Visudyne
3168104|NCT00546949|Active Comparator|decompression|Minimal invasive decompression
3168105|NCT00546949|Experimental|x-stop|X-stop, an interspinous decompression device
3168106|NCT00546975|Experimental|1|Resource Support® Novartis
3168107|NCT00546975|Active Comparator|2|Resource Protein®, Novartis
3168108|NCT00546975|Placebo Comparator|3|
3168109|NCT00546988|No Intervention|Standard risk IFN|Administration of interferon alpha as a maintenance treatment following autologous stem cell transplantation
3202097|NCT00909818|Experimental|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
3202098|NCT00909896||Robotic Surgery candidates|Group of patients receive Robotic approach for endometrial cancer staging
3202099|NCT00909896||Open Laparotomy Surgical Candidates|Patients receiving open laparotomy for endometrial cancer surgical staging
2537728|NCT02645565|Active Comparator|Low dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 500 mg intravenous 2 weekly for 3 months followed by azathioprine 2 mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
2537729|NCT02645565|Active Comparator|High Dose Cyclophosphamide|Intravenous Cyclophosphamide therapy 750mg/m2 intravenous 4 weekly for 6 months followed by azathioprine 2mg/kg. Injectable methylprednisolone 1 gm pulse will be given for 3 days before starting the first pulse of cyclophosphamide followed by oral prednisolone 1 mg/kg for 4 weeks and then tapering 5 mg every 2 weeks till 7.5 mg/day.
2537771|NCT02645201|Active Comparator|Probiotic|Children in probiotic group will receive chewable tablets containing 4x108 CFU of Gastrus. Subjects will take 1 tablet twice a day for 21 days
2537773|NCT02645201|Placebo Comparator|Placebo|Children in placebo group will receive placebo tablets of similar appearance and taste as Gastrus tablets. Subjects will take 1 placebo tablet twice a day for 21 days
2537826|NCT02644967|Experimental|Arm 1|IMO-2125 intratumoral injection plus ipilimumab
2537828|NCT02644967|Experimental|Arm 2|IMO-2125 intratumoral injection plus pembrolizumab
2537872|NCT02644616|Active Comparator|trial group(tolvaptan group)|trial group (tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv,n=20)
2537876|NCT02644616|Placebo Comparator|control group|control group(placebo 15mg/d po(10 days) +torasemide 20mg/d iv,n=20)
2537903|NCT02644304|Active Comparator|Clomiphene citrate plus cabergoline|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus cabergoline 0.25 mg from second day every 3 days (4 doses only)
2537904|NCT02644304|Active Comparator|Clomiphene citrate plus placebo|This group will receive Clomiphene citrate 50 mg tablet twice daily from the second day of menses to the sixth day plus placebo tablets from second day every 3 days (4 doses only)
2537957|NCT02644031|Experimental|Mtwo rotary system|( continuous rotation system)
2537963|NCT02644031|Experimental|safe-sider rotary system|(reciprocating system)
2537967|NCT02644031|Experimental|hand files|k-files
3202100|NCT00909909|Active Comparator|A|3DCRT/IMRT lumpectomy bed boost followed by accelerated whole breast irradiation (AWBI)
3202101|NCT00909909|Active Comparator|B|Accelerated whole breast irradiation (AWBI) followed by 3DCRT/IMRT lumpectomy bed boost
2538111|NCT02643173||Volatile|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using volatile anesthetics as maintenance agents.
2538115|NCT02643173||Intravenous|The investigators retrospectively reviewed and analyzed the electrical medical records of patients who underwent surgery for HCC under the general anesthesia using intravenous anesthetics as maintenance agents.
2538157|NCT02642796|No Intervention|Group I (control)|Patient controlled analgesia (epidural fentanyl): PCA only
2538160|NCT02642796|Experimental|group II|PCA plus lumbar plexus & sciatic nerve transcutaneous electric nerve stimulation (LS-TENS)
2538163|NCT02642796|Experimental|group III|PCA plus surgical wound transcutaneous electric nerve stimulation ( SW-TENS)
2538182|NCT02642484|Active Comparator|Gabapentin|Gabapentin twice daily
2538185|NCT02642484|Placebo Comparator|PLacebo|Calcium carbonate twice daily
2538252|NCT02642172|Experimental|ITF (Inulin/OFS 75/25)|16 gram/day of ITF (Inulin/OFS 75/25)
2538253|NCT02642172|Placebo Comparator|placebo|16 gram/day of maltodextrin (placebo)
2538301|NCT02641769|Other|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
2538330|NCT02641457|Experimental|Aflibercept x Ranibizumab|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab
2538357|NCT02641197|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after brachial artery occlusion by a standard upper arm pneumatic blood pressure cuff. The procedure is non-invasive and does not employ ultrasound.
2538445|NCT02640703|Active Comparator|morning vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 am
2538449|NCT02640703|Active Comparator|evening vaccination|Vaccination with Infanrix + Prevenar 13 between 7 and 10 pm
2538485|NCT02640495||Study subjects|Patients admitted with malaria, caused by Plasmodium falciparum, treated with parenteral artesunate.
3202102|NCT00909922||Lower Limb Amputees|Unilateral Above knee amputees
3202103|NCT00909948|Active Comparator|Fludarabine|The patients in this cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
2538635|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538638|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
3202104|NCT00909948|Active Comparator|TBI only|Patients will be given 200 centiGray (cGy) total body irradiation (TBI) in one fraction. TBI will be given on day 0, 4 to 6 hours prior to HCT.
3202105|NCT00909961|Experimental|Zoledronic acid|
3202106|NCT00909974|Experimental|Food supplement (FS)|Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
2537645|NCT02646319|Experimental|Treatment (nanoparticle albumin-bound rapamycin)|Patients receive nanoparticle albumin-bound rapamycin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 24 weeks in the absence of disease progression or unacceptable toxicity.
3202107|NCT00909974|Active Comparator|UNIMMAP|UNIMMAPin tablet form: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
3202108|NCT00909987|Experimental|Single arm|"Neoadyuvant chemotherapy with XELOX: Xeloda 1000mg/m2/12h dayly, day one in the afternoon until day 15 in the morning; plus oxaliplatin 130mg/m2 (day 1); and Bevacizumab 7.5 mg/kg (day 1)during 3 cycles (each cycle of 3 weeks).~Followed by a selective use of chemoradiotherapy with radiotherapy (50.4Gy, 28 sesions of 1.8Gy during 5 weeks) plus Xeloda 825mg/m2/12h dayly."
2537853|NCT02644642|Experimental|DLT(Double Lumen Tube) group|disconnection technique will be applied
2537857|NCT02644642|Experimental|BB(Bronchial Blocker) group|disconnection technique will be applied
2537898|NCT02644447|Experimental|HUC-MSCs Transplantation|
2537899|NCT02644447|Experimental|HUC-MSCs with Injectable Collagen Scaffold Transplantation|
2537938|NCT02644070|Experimental|alveolar bone preservation with mp3|Extraction sockets grafted with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy) with graft particle size between 600 and 1000 µm and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
2537943|NCT02644070|Experimental|alveolar bone preservation with apatos|Extraction sockets grafted with cortical porcine bone with particle size between 600 and 1000 µm (Apatos, Osteobiol, Coazze, Italy ) and a collagen membrane (Evolution, Osteobiol, Coazze, Italy) used to stabilize the biomaterial into the socket.
2537947|NCT02644070|No Intervention|NO_graft|extraction sockets with spontaneous healing
2537986|NCT02643784|Experimental|Rosuvastatin|Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).
2537988|NCT02643784|No Intervention|Control|Control group(don't take rosuvastatin until 14th day), as directed by the study physician.
3202109|NCT00910013|Experimental|Ropivacaine + femoral block|After the surgery is proceeded and after the closure of the joint capsule, 20 cc of ropivacaine 0.5% is inserted intra-articular through a catheter.
3202110|NCT00910026|Experimental|low tidal volume ventilation|6 ml/kg tidal volume ventilation
2538129|NCT02642978|Experimental|RSRCLM|robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).Three different liver resection procedures were chose to personalized patients. Generally, when the size of liver metastasis was ≤ 3 cm, a wedge resection was chose without Hilar vessels blocking. The segmentectomy was performed using the Glissonian approach when tumor size was among 3-5 cm, and Hilar vessels was blocked, if necessary. For resection of Couinaud's segments II and III, left lateral sectionectomy (LLS) was performed commonly. Intraoperative ultrasound can help us find intrahepatic pedicles and follow the proper resection line. When liver tumor size was more than 5 cm or more than 3 tumors with the size over 3cm, hemicolectomy was applied usually.
2538134|NCT02642978|Active Comparator|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis. The DFS and safety event were evaluated.
3202111|NCT00910026|Experimental|high tidal volume ventilation|12 ml/kg tidal volume ventilation
3202112|NCT00910052|Experimental|Fibrin sealant|received intraoperative fibrin sealant
2538300|NCT02641795|Experimental|Experimental|Minimally invasive robotic cochlear implantation with custom device
2538328|NCT02641470|Experimental|DA9301|Orally administration of DA9301 (Vaccinium uliginosum extract) pills (1000 mg/day) for 4 weeks.
2538331|NCT02641470|Placebo Comparator|Placebo|Orally administration of placebo pills (1000 mg/day) for 4 weeks.
2538361|NCT02641236|Active Comparator|Gut Decontamination with vancopoly|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will receive non-absorbable, oral vancomycin-polymyxin B as per our institutional standard practice."
2538366|NCT02641236|No Intervention|No Gut Decontamination|"All eligible participants will be randomized to either Arm A: Gut Decontamination or Arm B: No Gut Decontamination.~Participants assigned to this arm will not receive oral vancomycin-polymyxin B, but all other HSCT supportive care will be the same as for patients in Arm A."
2538431|NCT02640963|Experimental|Intervention: the GrACE programme|The programme included several weight-bearing exercises (using body weight and dumbbells) and a range of seated, non-resisted upper- and lower-body dynamic and reaching movements. While developed for respite care older adults, the GrACE programme was slightly modified for the RAC setting; using reduced range of motion and resistance, and an extended conditioning/familiarisation phase. The conditioning phase lasted for three weeks and focus on the development of correct technique. After concluding the conditioning phase, participants started to use light dumbbells. Participants performed the exercises twice per week for 12 weeks. Training sessions lasted approximately 45 minutes, were separated by at least 48 hours and were delivered by an experienced allied health professional.
2538432|NCT02640963|Placebo Comparator|Control Group|All subjects assigned to the control group were given the option to engage in other activities that were offered by the facility during the 12-week intervention period. Activities were facility specific, and included Zumba aerobic exercise and walking, however no specific resistance exercises were offered.
3202113|NCT00910052|No Intervention|Control|No fibrin sealant
2538540|NCT02640105||Patient with Cluster headache|Prospective follow-up of patient with Cluster headache
2538606|NCT02639806||Prospective - General Anesthetic|The prospective treatment group will have an anesthetic induction according to the anesthetic provider's preference that will include propofol and fentanyl as IV induction agents and rocuronium as a muscle paralytic. Maintenance of anesthesia for the treatment group will include sevoflurane with a target end tidal concentration of 1-1.5%, rocuronium as a paralytic as needed, opioids and any other standard medication deemed necessary by the provider.
3202114|NCT00910065|Experimental|Arm 1|
3202115|NCT00910065|Experimental|Arm 2|
3202116|NCT00910065|Active Comparator|Arm 3|
3202117|NCT00910104|Experimental|Omegaven|1g/kg/day for duration of study participation for all participants
2537679|NCT02646306||Shoulder Impingement Syndrome|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
2537682|NCT02646306||Healthy Subjects|Execution of two tests in succession with the use of the shoulder proprioceptive rehabilitation tool (SRPT), each oriented to indicate a specific discriminative and integrative mode in the movement of the scapulothoracic. Will be required to each subject to perform recognition tasks that include both retraction movements of the hand, starting from a start position, and approaching movements of the hand, starting from an end position. First test: ability to integrate visual and proprioceptive informations. Second test: discriminative proprioceptive capacity of the subject, thus excluding the contribution of the view.
3202118|NCT00910117|Experimental|nimotuzumab|nimotuzumab plus PF regimen
3202119|NCT00910130||End Stage Renal Disease|Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes
2537781|NCT02645266|Experimental|Aflibercept Injection [Eylea] group|Intervention: Subjects will be receiving a (2mg/ml) dose of VEGF-Trap, injected intravitreally at the start of every month, for the 4 months duration of the trial.
2537850|NCT02644876|Experimental|Penehyclidine group|Penehyclidine inhalation will be administered (penehyclidine hydrochloride 0.5 mg/0.5 ml + normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
2537854|NCT02644876|Placebo Comparator|Control group|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml + normal saline 5.5 ml ) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation will be performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
2537948|NCT02644382||Key Informant interviews|20 in-person or phone qualitative interviews with patients.
2537949|NCT02644382||Focus Groups|four qualitative focus groups of 6-10 women each.
2537950|NCT02644382||Physician Interviews|physician qualitative interviews over the telephone.
2537952|NCT02644382||Usual care cohort (pilot)|50 women who will be surveyed before and after their surgical consult
2537953|NCT02644382||Decision aid cohort (pilot)|50 women who will be surveyed before and after their surgical consult and will also be sent a web-based decision aid
3202120|NCT00910130||Control|"Healthy people, with normal Renal Function and without Diabetes, matched with ESRD group for age, gender, BMI"
3202121|NCT00910143||1|patients operated before summer 1995, that is before the introduction of TME
3202122|NCT00910143||2|patients operated after summer 1995, that is after the introduction of TME.
2538149|NCT02642874|Experimental|Methocarbamol|Methocarbamol twice daily
2538152|NCT02642874|Placebo Comparator|placebo|Calcium carbonate twice daily
2538178|NCT02642523|Placebo Comparator|Saline Infusion|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2538179|NCT02642523|Experimental|Insulin Clamp|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2538180|NCT02642523|Experimental|BNP Infusion (Nesiritide)|All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).
2538245|NCT02642185||Ablation|Patients that are primarily treated with microwave ablation of colorectal liver metastases
2538247|NCT02642185||Resection|Patients identified in the Swedish liver registry during the same time frame subjected to liver resection, propensity score matched to the ablation group
3202123|NCT00910156|Active Comparator|Airtraq|
3202124|NCT00910156|Active Comparator|Glidescope|
2538440|NCT02641054|Experimental|CVXL-0107 then cross-over to placebo|"Study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa.~Cross-over to placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa"
2538443|NCT02641054|Placebo Comparator|Placebo then cross-over to CVXL-0107|"Placebo 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of placebo on top of supraoptimal dose of levodopa.~Cross-over to study drug (CVXL-0107) 4 times per day for 2 weeks on top of usual treatment for Parkinson disease, followed by one challenge test day: one intake of study drug on top of supraoptimal dose of levodopa"
2538489|NCT02640508|Experimental|Combination Eribulin and lenvatinib|Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.
2538532|NCT02640144|Active Comparator|Treatment group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of Sodium Hyaluronate 1% - ARTHREASE TM
2538534|NCT02640144|Placebo Comparator|Control group|Randomized, patients that are going for knee arthroscopy for any indication including pain and cartilage damage or osteoarthritis. After surgery - will receive 3 injections of BPS - Buffer Phosphate Solution - as a placebo
3202125|NCT00910156|Active Comparator|Macintosh|
3202126|NCT00910169||inpatient treatment|naturalistic treatment no modification: observational study
3202127|NCT00910182||1|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 and treated non-operatively
2537769|NCT02645461|Experimental|PEA plus Riluzole|Riluzole 50 mg twice daily plus Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily in ALS patients
2537810|NCT02645006|Experimental|Intervention arm- 3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
2537818|NCT02645006|Other|Control arm- 1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention
2537844|NCT02644694|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
2537911|NCT02644486|Experimental|A Group|
2537912|NCT02644486|Experimental|B Group|
2537913|NCT02644486|Active Comparator|C Group|
2538020|NCT02643771|Experimental|Diabetic group|Subjects with Chronic Periodontitis and Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
2538022|NCT02643771|Experimental|Nondiabetic group|Subjects with Chronic Periodontitis and without Type 2 Diabetes Mellitus treated with non surgical periodontal therapy (Full Mouth Scaling and Root Planing)
2538096|NCT02643264|Experimental|rTMS 10 Hz|Deep Repetitive Transcranial Magnetic Stimulation (rTMS, 10 Hz) of the insula ,15 stimulation sessions (1 daily, 5 days / week).
2538098|NCT02643264|Sham Comparator|rTMS Sham|Sham Repetitive Transcranial Magnetic Stimulation (rTMS, Sham),15 stimulation sessions (1 daily, 5 days / week).
2538141|NCT02642900|Experimental|Nystatin 100.000 units|Patients were treated with a topical antifungal nystatin oral suspension(1000.000 units) 5mL every six hours/14 days. Patients were instructed to rinse the solution for 5 minutes and then to spit the solution out. Samples were collected on days 7, 14 and 30 after the end of treatment (follow-up).
2538144|NCT02642900|Active Comparator|Photodynamic Therapy|Patients used mouthwash with methylene blue 0.005% for 20 minutes (pre-irradiation time). The palatal mucosa was irradiated using a low level laser with the following settings: wavelength of 660 nm, energy density of 120 J/cm ², output power of 40 milliwatt, 2 minutes per point. PDT was performed in two sessions (one session per week). Samples were collected immediately after each clinical procedure and 30 days after the second procedure (follow-up).
2538205|NCT02642601|Experimental|indomethacin|one dose of indomethacin 100 mg rectal suppository;will be adminstrated1-2 hours before embryo transfer
2538207|NCT02642601|No Intervention|no medication|no indomethacine before embryo transfer
2538262|NCT02642068||ADHD group|Drug-naïve adult ADHD Probands
2538264|NCT02642068||Sibling group|Unaffected Siblings of Drug-naïve Adult ADHD
2538265|NCT02642068||Control group|Age-, sex-, handedness-, and IQ-matched controls without lifetime ADHD or a family history of ADHD
2538494|NCT02640391||Quiescent UC|Patients with quiscent UC who will undergo colonoscopy for surveillance or mucosal healing check up
2538627|NCT02639611|Active Comparator|Immediate Post Operative Acupuncture Treatment|
2538629|NCT02639611|Active Comparator|Acupuncture Treatment After 6 Weeks of Recovery|
2538683|NCT02639260|Experimental|Cohort A|3,000 mg/day
2538684|NCT02639260|Experimental|Cohort B|10000 mg/day
2538713|NCT02639000|Experimental|Blastocyst|Embryo transfer of at maximum 2 embryos at blastocyst stage
2538717|NCT02639000|Active Comparator|Cleavage|Embryo transfer of at maximum 2 embryos at cleavage stage
2538770|NCT02638701|Experimental|Infliximab treatment|Administer infliximab intravenously to patients with DVB aneurysms (3 mg/kg at 0, 3 and 7 weeks, then at 8-week intervals x 7) for a total of 12-months. Patients will undergo MR imaging at 0, 12, and 24-month time points.
2538799|NCT02638350|Experimental|Intervention lung ultrasound|All patients will have strategy with lung ultrasoundlung ultrasound
3168110|NCT00546988|No Intervention|Standard risk PEGIFN|Maintenance treatment with pegylated interferon following autologous stem cell transplantation
2538942|NCT02637570|Experimental|Hibiscus tea|420 mg Hibiscus 2 hour after dinner with 1 glass of cool water every day
3168111|NCT00546988|Experimental|High risk allo|Allogeneic stem cell transplantation from an HLA identical related or unrelated donor
3168112|NCT00546988|No Intervention|High risk auto|Second cycle of high-dose melphalan in subjects without an HLA-identical donor
3168113|NCT00547001|Active Comparator|1|Group A will be tapered over 4 weeks, starting at baseline (week 0). Subjects in this group will take one tablet of ET daily (effective dose, 0.75 mg) for week 1, then one 0.50 mg tablet daily for week 2, then one 0.25 mg tablet daily for week 3, and finally one 0.125 mg tablet daily for week 4.
3168114|NCT00547001|Placebo Comparator|2|Group B will be administered placebo. These tablets will appear identical to those administered to subjects in Group A, but the tablets will contain no estrogen. Subjects in this group will be instructed to take one pill every day for the 4 weeks. Thus, while patients will, in effect, be stopped abruptly from their therapy, there is still the potential of a placebo effect.
3168115|NCT00547001|No Intervention|3|"Group C will have their therapy discontinued acutely at baseline (week 0); i.e., these subjects will not take any tablets after the 8-week stabilization phase ends. While we recognize that this group will not be blinded to the regimen they are receiving, we feel that group C will be important to include in light of the consistent decrease in vasomotor symptoms experienced by women taking placebo. Because women taking placebo have approximately a 35% decrease in vasomotor symptoms, it will be important to compare our taper regimen to the real life scenario of stopping medication abruptly."
3168116|NCT00547014|Experimental|Cohort 1 1mg|
3168117|NCT00547014|Experimental|Cohort 2|
3168118|NCT00547014|Experimental|Cohort 3|
3168119|NCT00547014|Experimental|Cohort 4|
3168120|NCT00547014|Experimental|Cohort 5|
3168121|NCT00547040||A|incident renal transplant patients
3168122|NCT00547066|Experimental|veltuzumab|veltuzumab is a humanized CD20 antibody administered subcutaneously.
2537788|NCT02645071|Experimental|Physical activity|The experimental arm is a 15-20 min interactive session, which aims to reduce participants' sedentary behavior and increase physical activity by increasing their motivation, self-efficacy, and knowledge of different types of easy exercises.
2537855|NCT02644902|Experimental|Technology Arm|5 days training of health workers in THP through avatar assisted cascade training and supervision
2537859|NCT02644902|Active Comparator|Specialist Arm|5 days training and supervision of health workers in THP by specialists
2537893|NCT02644395|Active Comparator|Amlodipine|Current treatment of choice
2537894|NCT02644395|Experimental|Chlorthalidone|Testing new indication for approved drug
2538008|NCT02643576|No Intervention|Control|Usual SNAP-like food benefits
2538010|NCT02643576|Experimental|Rewards|Usual SNAP-like food benefits, plus a modification to this food benefit program that entails a 30% bonus on eligible fruit and vegetable purchases (i.e. F&V bonus)
2538012|NCT02643576|Experimental|Restrictions|Usual SNAP-like food benefits, plus a modification that requires no sugar-sweetened beverages, candy, or sweet baked goods be purchased
2538014|NCT02643576|Experimental|Rewards plus restrictions|Usual SNAP-like food benefits, plus two modifications to this food benefit program: one modification includes a 30% bonus on eligible fruit and vegetable purchases and the other modification is that sugar-sweetened beverages, candy, or sweet baked goods are not allowed to be purchased (i.e. Bonus & Restriction)
3168123|NCT00547092|Active Comparator|1|tadalafil given the first 12 weeks and after a 4 week washout sildenafil is given for 12 weeks.
3168124|NCT00547092|Active Comparator|2|sildenafil given the first 12 weeks and after a 4 week washout tadalafil is given for 12 weeks.
3168125|NCT00547144|Experimental|Gemcitabine|
3168126|NCT00547170|Experimental|1|Half of enrolled women will be randomly assigned to group 1.
2538138|NCT02642887|Experimental|The test group|This group included 30 recession defects treated with mTA + SCTG
2538139|NCT02642887|No Intervention|The control group|This group included 30 recession defects treated with cTT + SCTG
2538313|NCT02641548|Experimental|Silicone sock+heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet and a sock of silicone is used every night.
2538315|NCT02641548|Active Comparator|Heel cream|Every evening a cream (Footmender, Auxilum Cura Innovatio, Dublin, Ireland, European Patent 2522342) is applied to the feet
2538354|NCT02641275|Experimental|Intervention|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions.
2538358|NCT02641275|No Intervention|Control group|no intervention other than existing support (see exclusion criteria). However, intervention will be offered and studied secondary as well (after 1 1/2 year of no intervention).
2538479|NCT02640430|Active Comparator|standard treatment|"Control group will be made of 20 COPD patients with severe and very severe airflow obstruction, mucus hypersecretion and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Control group will b treated with PEP-bottle over 10 daily sessions (20 minutes twice a day). Patients are asked to breath against a positive expiratory pressure determined by a column of water in a bottle (PEP Bolltle). PEP is one of the validated treatment used in the clearance of bronchial secretions in COPD patients.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
2538481|NCT02640430|Experimental|Free Aspire|"Experimental group will be made of 20 COPD patients with severe and very severe airflow obstruction , mucus hypersecretion , and reduced cough efficiency referred to standard pulmonary rehabilitation after acute exacerbation.~Patients are asked to use FREE ASPIRE Free Aspire is an electro-medical device which removes bronchopulmonary secretions noninvasively, without using a suction catheter and without generating airway pressure, positive or negative.~All patients will receive regular treatment with inhaled bronchodilators and inhaled steroids according to current guidelines for their disease stage. Each patient will sign an informed consent form."
2538513|NCT02640196|Placebo Comparator|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
2538515|NCT02640196|Placebo Comparator|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope laryngoscope followed with intubating the difficult airway simulator
2538521|NCT02640196|Active Comparator|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq laryngoscope followed with intubating the difficult airway simulator
2538526|NCT02640196|Active Comparator|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
2538573|NCT02639923||Minor head injury CCT pos. group|Tbi patients with acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
2538574|NCT02639923||Minor head injury CCT neg. group|Tbi patients without acute lesion on early cranial computed tomography. Patients consent to have 7ml peripheral blood to be drawn.
2538575|NCT02639923||Control Group (healthy volunteers)|Volunteers without history, signs or symptoms of acute traumatic injuries. Volunteers consent to have 7ml peripheral blood to be drawn.
2538668|NCT02639364|Active Comparator|conventional ventilation strategy|The conventional ventilation strategy use volume-controlled ventilation (VCV) or pressure-controlled ventilation (PCV) mode, combination with low tidal volume and adequate PEEP level.
3168127|NCT00547170|Active Comparator|2|Half of enrolled women will be randomly assigned to group 2
3168128|NCT00547183|Active Comparator|2|2.5 mg tadalafil
3168129|NCT00547183|Active Comparator|3|5 mg tadalafil
3168130|NCT00547183|Placebo Comparator|1|
3173977|NCT00618241|Active Comparator|B|"Group B: day 4 Lamotrigine one oral dose on day 4. Wash-out day 6-28 followed by Raltegravir 400 mg oral BD day 29-33. One dose Lamotrigine 100 mg oral on day 32.~One dose Lamotrigine 100 mg oral."
3173978|NCT00618280|Active Comparator|1|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
3173979|NCT00618280|Placebo Comparator|2|schizophrenic and non schizophrenic patient stratified by smoking and non smoking will get nicotine and placebo on first day on the second day placebo and nicotine
2537809|NCT02645058|Experimental|RIRS (retrograde intrarenal surgery)|In the first arm (RIRS) the patients will be treated by a standard retrograde ureterorenoscopy and Holmium laser lithotripsy. Preoperative exams will be abdomen ultrasound and Xray (CT in case of stones > 15 mm), urine analysis and culture (according to all the more recent guidelines). Surgeries will be performed under general or spinal anesthesia, according to anesthesiologist evaluation. According with standard technique, ureteroscopy will be performed using both rigid and flexible ureteroscope. Lithotripsy will be performed by Holmium laser. Major stone fragments will be removed at the end of the procedure. Finally a double J ureteral stent will be push in specific cases depending on intraoperative findings (length of the procedure, macroscopic view of the ureter, residual stones etc.). RIRS will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
2537817|NCT02645058|Experimental|ESWL (extracorporeal shockwaves lithotripsy)|In the second arm (ESWL) the patients will be treated by a standard extracorporeal shock waves lithotripsy (ESWL). Preoperative exams will be the same as first arm. No general or spinal anaesthesia will be used, but just intravenous medications if required. Ultrasound and/or X-Ray will be used to locate the stone. Power and number of shock waves will consist in 20-24 KV and 3000-3500 sw respectively, according to individual tolerance. ESWL will be an outpatients procedure with an hospital stay <23 hours. Some patients may require a longer hospital stay due to specific pre-operative diseases or intra/post-operative events.
2537864|NCT02644629|Active Comparator|Active IV|Will receive IV Ketamine, along with IN placebo.
2537867|NCT02644629|Active Comparator|Active IN|Will receive IN Ketamine, along with IV placebo.
2537907|NCT02644239|Active Comparator|Group control|classical ketogenic diet
2537910|NCT02644239|Active Comparator|Group case|Group case: modified ketogenic diet to reduce at least 20% saturated fat, up> 50% of the acid supply monounsaturated, increasing> 50% polyunsaturated fatty acid content and a lower ratio w6 / w3 at least 50% compared to classic diet used by the control group
2537927|NCT02644018|Experimental|Ingavirin|Ingavirin (Imidazolyl ethanamide pentandioic acid), capsules 30 mg daily for 5 days. The contents of one capsule of Ingavirin, capsules 30 mg should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
2537931|NCT02644018|Placebo Comparator|Placebo|Placebo, capsules daily for 5 days. The contents of one capsule of placebo should be dissolved in 50-70 ml of water at room temperature or apple juice at room temperature with mandatory stirring for 20 seconds and administered orally 1 time a day regardless of the meal.
2538017|NCT02643719|Active Comparator|Topiramate|
2538019|NCT02643719|Active Comparator|Behavioral intervention|
2538023|NCT02643719|Active Comparator|topiramate and behavioral intervention|
2538025|NCT02643719|Active Comparator|Standard of Care|
2538176|NCT02642640|Other|melatonin-placebo|subjects will receive melatonin first and placebo second
2538177|NCT02642640|Other|placebo-melatonin|subjects will receive placebo first and melatonin second
2538307|NCT02641652|Active Comparator|Sertraline|sertraline, 25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
2538308|NCT02641652|Placebo Comparator|Placebo|placebo
2538365|NCT02641340|Experimental|Cycle 1, Cohort 1|Fentanyl Sublingual Spray (FSS) low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2538373|NCT02641340|Experimental|Cycle 1, Cohort 2|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2538380|NCT02641340|Experimental|Cycle 1, Cohort 3|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2538382|NCT02641340|Experimental|Cycle 1, Cohort 4|FSS low dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
2538384|NCT02641340|Experimental|Cycle 2, Cohort 1|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2538385|NCT02641340|Experimental|Cycle 2, Cohort 2|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2538386|NCT02641340|Experimental|Cycle 2, Cohort 3|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2538387|NCT02641340|Experimental|Cycle 2, Cohort 4|FSS medium dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
2538388|NCT02641340|Experimental|Cycle 3, Cohort 1|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every four hours for a maximum of three doses.
2538391|NCT02641340|Experimental|Cycle 3, Cohort 2|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every two hours for a maximum of three doses.
2538394|NCT02641340|Experimental|Cycle 3, Cohort 3|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every hour for a maximum of three doses.
2538396|NCT02641340|Experimental|Cycle 3, Cohort 4|FSS high dose (n=6) or Fentanyl Citrate IV 50 mcg (n=2) will be administered once every 30 minutes for a maximum of three doses.
3173980|NCT00618293|Active Comparator|1|intravenous infusion of Haemate (dosage dependent on body weight)
3173981|NCT00618293|Placebo Comparator|2|intravenous infusion of 0.9% NaCl solution
2538537|NCT02640092|Experimental|[18F]GTP1|Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
3173982|NCT00618319|Experimental|1|BIIB021
3173983|NCT00618358|Experimental|Vascular Sealant)|
3173984|NCT00618358|Active Comparator|Gelfoam/Thrombin|
3173985|NCT00618384|Active Comparator|1|Patients with TACE therapy will be treated with Sorafenib (2 x 400 mg/day) until progressive disease
3173986|NCT00618397|Experimental|Arm 1|Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.
3173987|NCT00618423|Placebo Comparator|Physiologic saline|
2537869|NCT02644837|Active Comparator|i-Gel and AuraGain|"In this arm of the crossover study, patients will undergo insertion of Ambu AuraGain laryngeal mask airway and iGel and will undergo initial management with the iGel. Primary and Secondary outcomes will be assessed. The initial device will be removed and subsequent Airway management will then be undertaken with the Ambu AuraGain and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
2537873|NCT02644837|Active Comparator|AuraGain and i-Gel|"In this arm of the crossover study, patients will undergo insertion of the Ambu AuraGain laryngeal mask airway and i-Gel and will undergo initial management with the Ambu AuraGain.. Primary and Secondary outcomes will be assessed. Airway management will then be undertaken with the iGel device and the same outcomes will be assessed.~Interventions with both devices will be~Insertion of the laryngeal mask airway~Assessment of ease of insertion~Ability to perform positive pressure ventilation~Measurement of OLP~Fibreoptic assessment with Ambu A-scope~Ability to insert nasogastric tube~Record number of manipulations~An assessment of device related trauma"
2537920|NCT02644148|Other|Conventional Roux-en-Y anastomosis|Conventional Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
2537923|NCT02644148|Experimental|Uncut Roux-en-Y anastomosis|Uncut Roux-en-Y Gastrojejunostomy will be used after laparoscopic distal gastrectomy for early gastric cancer.
2537994|NCT02643836|Experimental|Treatment PEMF|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The experimental group will contain 38 subjects. Each study subject will receive two hats, which contain the integrated PEMF device, this will be done to ensure continuity of treatment in case that one of the hats stops working due to the battery running out. The subjects will receive PEMF treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
2537997|NCT02643836|Sham Comparator|Sham Treatment|The investigators will recruit and enroll 76 patients (between 18 and 30 years of age) who have had persistent symptoms consistent with PCS for at least 4 weeks, but not more than 6 months, after the initial injury. The sham group will contain 38 subjects. Each study subject will receive two hats, which contain a de-activated PEMF device, the device will still be blinking to show sham treatment activity. The sham subjects will receive the sham treatment for 15 minutes three times per day for 6 weeks. Upon enrollment and at the end of the 6-week treatment period, all subjects will undergo a comprehensive assessment that will include symptom inventories, neuropsychological tests, qEEG measurement and near-infrared spectroscopy. The investigators will conduct a 3-month follow-up to assess longer-term outcomes.
2538053|NCT02643420|Experimental|SPI-2012|"SPI-2012 (13.2 mg/0.6 mL fixed dose, equivalent to 3.6)~Supplied in prefilled single-use syringes for subcutaneous injection~Administered on Day 2 of each cycle"
2538058|NCT02643420|Active Comparator|Pegfilgrastim|"Pegfilgrastim (6 mg/0.6 mL) (Neulasta® [NDC 55513-190-01] manufactured by Amgen)~Single-dose subcutaneous injection administered on Day 2 of each cycle"
2538137|NCT02643043|Other|UC Subjects|Subjects with confirmed metastatic urothelial cancer willing to participate in biospecimen collection (tissue and blood) for genetic studies.
3202128|NCT00910182||2|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 who underwent emergency surgical treatment
3202129|NCT00910182||3|all adult patients with splenic rupture after blunt abdominal injuries admitted to Bern University Hospital between January 2002 and December 2008 treated non-operatively plus transcatheter arterial embolisation
3202130|NCT00910195|Experimental|CPAP before Bi-Level-APAP|receiving CPAP treatment during the first night and then Bi-level-APAP treatment during second night
2538520|NCT02640326|Active Comparator|Active Comparator|The catheterized arm will have Standard of care Foley urinary catheter insertion according to usual institutional care pathways in the operating room prior to surgery initiation. The urinary catheter will be assessed for removal on the morning of post-operative day 1, and patients will be monitored for urinary complications once catheter is removed until patient has successfully voided spontaneously within 8 +/- 2 hours.
2538523|NCT02640326|Experimental|Experimental Arm|The non-catheterized arm will have standard of care Foley urinary catheter insertion, with no Foley Urinary Catheter inserted prior to, during, or after surgery unless the patient is showing signs of urinary retention after surgery. Patient will be monitored for urinary complications starting in the recovery room until patient has successfully voided spontaneously within 8 +/- 2 hours
2538588|NCT02639949|Experimental|Group CBT|
2538593|NCT02639949|Active Comparator|Standard Care|
2538643|NCT02639572|Experimental|Siloss® bone graft|Based on the sequence, in the test site,Siloss® was placed.
2538647|NCT02639572|Placebo Comparator|Hydroxyapatitie Bone graf|Based on the sequence, the control site which was treated by Hydroxyapatite graft only.
2538702|NCT02639130|Active Comparator|Vildagliptin|"After a screening examination, patients were treated with vildagliptin and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
2538710|NCT02639169|Experimental|music|Apply live music through techniques music therapy in group experimental and evaluation through the visual analog scale (VAS) and numeric.
2538712|NCT02639169|No Intervention|Comparative|Apply the visual analog scale (VAS) and numeric.
2538774|NCT02638766|Other|Unique arm|Regorafenib 160mg once a day, frequency: 3 weeks on/1 week off in cycles of 28 days
3202131|NCT00910195|Experimental|Bi-Level-APAP before CPAP|receiving Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
3202132|NCT00910221|Active Comparator|1|
2537896|NCT02644460|Experimental|Stratum B|Abemaciclib (LY2835219) will be administered orally on a twice daily basis continuously for 28 days, which defines one cycle. The maximum treatment duration will be 2 years. Investigators plan to treat a maximum of 4 cohorts of research participants (dosage levels 1, 2, 3, and 4) with escalating doses of abemaciclib starting with dose level 1 (80% of adult dose). Dose escalation will be independent of Stratum A escalation. A cycle is defined as 28 days and the first 4 weeks of therapy will constitute the DLT-evaluation period. Participants must take abemaciclib by mouth as intact capsules.
2537975|NCT02643914|Experimental|Nicotine Cravings|
2538036|NCT02643550|Experimental|Dose escalation|Dose escalation of monalizumab in combination with cetuximab
2538037|NCT02643550|Experimental|Expansion cohort 1|monalizumab + cetuximab expansion cohort
2538041|NCT02643550|Experimental|Expansion cohort 2|monalizumab + cetuximab expansion cohort in patients with prior exposure to PD-(L)1 blockers
2538042|NCT02643550|Experimental|Expansion cohort 3|monalizumab + cetuximab + anti-PD(L)1
3202133|NCT00910221|Placebo Comparator|2|
3202134|NCT00910234|Active Comparator|Drug: rhEpo, low dose|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
3202135|NCT00910234|Active Comparator|Drug: rhEpo, high dose|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
2538353|NCT02641171||Entire Cohort|This is an observational/validation study and there is no intervention involved. Exhaled air samples, blood samples, and fecal samples will be obtained.
2538410|NCT02641041|Experimental|Cohort 1|A single IV dose of 10 mg/kg BIIB033 or placebo given on Day 1
2538412|NCT02641041|Experimental|Cohort 2|A single IV dose of 30 mg/kg BIIB033 or placebo given on Day 1
2538415|NCT02641041|Experimental|Cohort 3|One IV dose of 100 mg/kg BIIB033 or placebo given on Days 1 and 15
2538541|NCT02640118|Active Comparator|Pancreatectomised + Lixisenatide|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
2538545|NCT02640118|Placebo Comparator|Pancreatectomized + lixisenatide-placebo|"During the experimental day the patient will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously."
2538548|NCT02640118|Active Comparator|Healthy + Lixisenatide|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a Lixisenatide-injection will be given subcutaneously"
2538549|NCT02640118|Placebo Comparator|Healthy + lixisenatide-placebo|"During the experimental day the subject will ingest a standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).~Before the meal a placebo-injection will be given subcutaneously"
2538700|NCT02639117|Other|Vismodegib|Vismodegib 150 mgs po qd. Open label.
2538763|NCT02638857|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization(TACE) treatment:patients will receive lipiodol,Mitomycin (MMC),Epirubicin（EADM） hepatic arterial infusion,3 cycles.
2538767|NCT02638857|Experimental|DC-PMAT cells|After accepting concurrent TACE treatment,patients will receive 3 cycles of Dendritic Cell -Precision Multiple Antigen T (DC-PMAT) cells treatment.
2538921|NCT02637726|Experimental|TIVA0|Propofol : TIVA guided by clinical signs. Remifentanil
2538930|NCT02637726|Experimental|TIVA BIS|propofol : TIVA guided by EEG Monitoring. Remifentanil
2538937|NCT02637726|Experimental|TCI KBIS|Propofol : TCI Kataria guided by EEG Monitoring. Remifentanil.
2538939|NCT02637726|Experimental|TCI SBIS|Propofol : TCI Schnider guided by EEG Monitoring. Remifentanil.
2539013|NCT02637128|Experimental|artemether-lumefantrine (AL)|"20mg artemether/120 mg lumefantrine per tablet, Coartem-D™; Novartis, Basel, Switzerland administered following manufacturer's prescribed weight-based dosing, twice daily for 3 days.~5-14 kg: 1 tablet; 15-24: 2 tablets; 25-34 kg: 3 tablets; >34 kg: 4 tablets per dose"
2539014|NCT02637128|Experimental|artesunate-amodiaquine (ASAQ)|25mg artesunate/67.5 mg amodiaquine or 50 mg artesunate/135mg amodiaquine per tablet, Coarsucam™; Sanofi-Aventis, Paris, France administered following manufacturer's prescribed weight-based dosing, once daily for 3 days 4.5-8.9 kg: 1 25mg/67.5 mg tablet; 9-17.9 kg: 1 50mg/135 mg tablet; 18-35.9 kg 2 50mg/135 tablets; >36 kg: 4 50mg/135mg tablets per dose
2539069|NCT02636803|Experimental|oxfendazole 6 mg/kg|patients receive 6 mg/kg oxfendazole once
2539072|NCT02636803|Experimental|oxfendazole 30 mg/kg|patients receive 30 mg/kg oxfendazole once
2539076|NCT02636803|Experimental|oxfendazole 6 mg/kg 3 times|patients receive 6 mg/kg oxfendazole three times
2539079|NCT02636803|Active Comparator|albendazole 400 mg|patients receive 400 mg albendazole once
2539115|NCT02636517|Other|C. Difficile without IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile
2539116|NCT02636517|Other|C. Difficile with IBD|Fecal Microbiota transplant in pediatric patients with recurrent C. Difficile with Inflammatory Bowel Disease
2539166|NCT02636205|Experimental|Armeo|Group receiving Armeo therapy
2539217|NCT02635867|Active Comparator|Indirect pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal Resin-based dentin bonding agent
2539229|NCT02635867|Active Comparator|Direct pulp capping therapy|Resin-modified calcium silicate - TheraCal LC Calcium hydroxide - Dycal
2539276|NCT02635360|Experimental|Following chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. After chemoradiation is complete, subjects will receive the study drug, pembrolizumab.
2538040|NCT02643498|Experimental|Stereotactic Body Radiotherapy (SBRT)|"Cohorts 1-3 After completion of induction chemotherapy, stereotactic body radiotherapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.~Cohorts 4-6 For cohort 4, dose prescription will start at 7 Gy x 6 fractions (42Gy, isoeffective to 11 Gy x 3), followed by 4.8 Gy x 12 (54Gy) and 4.5Gy x 15 (67.5Gy)."
2538113|NCT02643160|Experimental|Functional Trunk Training Group|Functional Trunk Training which includes strengthening of trunk muscle and functional activities including trunk region.
2538120|NCT02643160|No Intervention|Control Group|No intervention, the continued their regular physical therapy
2538172|NCT02642783|Other|Descriptive analysis|panelists were asked to rate different sensory attributes for different laxative bowel cleansing solutions on a 15 cm line scale.
2538173|NCT02642783|Other|Acceptability test|panelists were asked to rate the acceptability of different laxative bowel cleansing solutions using the 9-point hedonic scale.
2538206|NCT02642302|Experimental|HIIT With 60 sec Rest|The experimental (1) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 60 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
2538210|NCT02642302|Experimental|HIIT With 120 sec Rest|The experimental (2) group will be submitted at Six reps of 30 seconds of high intensity interval training (all out) with 120 seconds of interval rest for a total of 30 sessions of training. Dependents variables such as VO2Max and performance parameters are estimated before and after training sessions
2538216|NCT02642302|Active Comparator|Control|Continuous exercise at 50-55% of VO2max with similar total work
2538260|NCT02642055|Experimental|Neuro+ Intervention|30 sessions (900 minutes) of Neuro+ Attention Training administered over 10 weeks.
2538261|NCT02642055|Active Comparator|Treatment as Usual|Continuation of current treatment for ADHD
2538303|NCT02641743|Experimental|Inslow|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) Inslow at 7:00 AM.
2538304|NCT02641743|Placebo Comparator|standard balanced formula|Each participant was requested to consume one of is energetic test meals (200 kcal per serving 200ml) standard balanced formula at 7:00 AM.
2538356|NCT02641431|Experimental|mapping/ablation|Epicardial substrate identification consisted in mapping the entire RV epicardial surface under baseline conditions and after ajmaline infusion (1mg/kg in 5 minutes).We obtained 3 groups of RV epicardial maps using CARTO3 system: 1) bipolar/unipolar voltage map, 2) local activation time map (LAT), and 3) potential duration map (PDM), in which abnormal long-duration bipolar electrograms were defined as low-frequency (up to 100 Hz) prolonged duration (> 200 ms) bipolar signals with delayed activity extending beyond the end of the QRS complex. Epicardial ablation was performed during sinus rhythm using a stepwise strategy in a descending order of abnormal potential duration as displayed on the map and beginning from the longest potentials.
2538420|NCT02640924|Experimental|Proton radiotherapy|Proton radiotherapy will be totally 66 cobalt gray equivalent (CGE) in 10 fractions and delivered once daily, 5 fractions per week, over 2 weeks for HCC more than 1 cm away from the alimentary tract.
2538421|NCT02640924|Experimental|Radiofrequency Ablation|Multiple-electrode radiofrequency with switch-controller system (ME-SWC RFA) can create a large coagulation necrosis volume and successful treat HCC sized more than 3 cm, extending to 8.5 cm. ME-SWC RFA system uses up to 3 electrodes parallel insertion to inside of the tumors with an equilateral triangular confirmation before initiation of ablation. The distances between electrodes are about 1.5-2 cm, estimated by ultrasound measuring. The switching machine is set on the auto-mode, and all electrodes work alternately and switching each other automatically after impendence surge.
3173988|NCT00618423|Active Comparator|Ketamine|
3173989|NCT00618462|Experimental|1|Participants will receive psychoeducation therapy plus case management and a referral to Gamblers Anonymous.
3173990|NCT00618462|Experimental|2|Participants will receive cognitive behavioral therapy plus contingency management and a referral to Gamblers Anonymous.
2538589|NCT02639767|Experimental|pemetrexed/cisplatin with pleural IMRT|This is a single institution phase I study of pemetrexed/cisplatin given concurrently with pleural intensity modulated radiation therapy (IMRT) in patients with unresectable malignant pleural mesothelioma (MPM). All patients will receive pleural intensity modulated radiation therapy (IMRT). Patients will be enrolled in cohorts of 3-6 at each dose level of pemetrexed/cisplatin, and dose escalation will proceed in a standard 3+3 fashion until the maximum tolerated dose (MTD) is identified.
2538766|NCT02638545|Experimental|dexmedetomidine|
2538800|NCT02638389|Experimental|Patients with vascular malformations|Patients with venous, lympathic or complex vascular malformations (KTS, PTEN, etc.) will receive sirolimus after completion of inclusion criteria
3173991|NCT00618462|Experimental|3|Participants will receive cognitive behavioral therapy and a referral to Gamblers Anonymous.
3173992|NCT00618475|Experimental|Treatment|Individual cognitive behavioral therapy (CBT)
3173993|NCT00618475|Other|Wait-list control|Individual cognitive behavioral therapy (CBT) after 3 month wait-list period
3173994|NCT00618488|Experimental|1|Bifidobacterium lactis
3173995|NCT00618488|Placebo Comparator|2|Placebo
3173996|NCT00618527|Experimental|1|Rebif with Cellcept
3173997|NCT00618527|Placebo Comparator|2|Rebif alone
3173998|NCT00618553|Experimental|Pulmonary Rehabilitation|Pulmonary Rehabilitation - Rehabilitation treatment given over about 3-4 weeks. Questionnaire regarding quality-of-life that lasts about 30 minutes.
3173999|NCT00618566|Experimental|Oregon|
3174000|NCT00618579|Experimental|LMWH arm - active LMWH|
3174001|NCT00618579|Placebo Comparator|LMWH arm - placebo|
3174002|NCT00618579|Experimental|Warfarin arm - active warfarin|
3174003|NCT00618579|Other|Warfarin arm - control|
3174004|NCT00618592|Experimental|CHO|
3174005|NCT00618592|No Intervention|FAST|
3174006|NCT00618605|Experimental|1|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^9 virus particles (VP) given at Days 0, 28, and 168
3174007|NCT00618605|Experimental|2|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^10 VP given at Days 0, 28, and 168
2537991|NCT02643563|Active Comparator|Bupivacaine 0.5% + epinephrine 1:200,000|Low volume (5 ml) Interscalene Block with Bupivacaine 0.5% + epinephrine 1:200,000
2538048|NCT02643433|Experimental|MR and JE coadministration group|Infants aged 8 months are vaccinated measles-rubella combined vaccine (MR) and Japanese Encephalitis alive vaccine (JE) in different sites at same time.
2538052|NCT02643433|Active Comparator|MR administration alone group|Infants aged 8 months are vaccinated measles-rubella combined vaccine alone
3202136|NCT00910234|Placebo Comparator|Control Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
3202137|NCT00910286|Other|VENTILATOR WEANING|Two ventilators with different flow termination criteria (TC) were compared: Servo 300 (Siemens-Elema, Sweden) with fixed TC (5% of peak inspiratory flow) and Newport E500 (Newport Medical Instruments, CA) with automatic TC (varies between 5% to 55%). Each patient remained three hours in the protocol, one hour in each ventilator, after been randomized to one of two sequences of 3 steps: Fixed 5% / Automatic / Fixed 5% or Automatic / Fixed 5% / Automatic . The PS, the positive end expiratory pressure (PEEP), the inspiratory oxygen fraction (FiO2) and the pressure trigger sensitivity levels were unchanged during the protocol.
2538189|NCT02642419|Experimental|Rivaroxaban|
2538191|NCT02642419|Experimental|Rivaroxaban and single antiplatelet drug|
3202138|NCT00910312|Experimental|Breast Fibroadenoma|
3202139|NCT00910338|Experimental|PFMT with Extracorporeal Biobeedback|
2538499|NCT02640352|Active Comparator|Probi Defendum|Dietary supplement (tablet) with probiotics
2538501|NCT02640352|Placebo Comparator|Placebo|Dietary supplement (tablet) without probiotics
2538542|NCT02640131|Experimental|BSHR Intervention|"Couples will attend 30-minute clinic consultations with an Urologist and a Sexual Health Counsellor and receive session-specific chapters of the Kindness, Intimacy, Sexuality and Satisfaction manual over the course of the intervention.~The BSHR Intervention involves two complementary components; the bio-medical, and the psychosocial. The bio-medical component for both arms intervention includes an urologist consultation at a pre-operative appointment and 5 f/u appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.~The psychosocial component aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive sexual health counseling and manualized support."
2538546|NCT02640131|Active Comparator|Attention Control|"Survivorship Counseling: Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) and receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You Manual. The bio-medical component is the same in both arms.~The core topics discussed during over 7 counseling sessions include: preparation for immediate post-surgery recovery, Kegel exercises, nutrition and prostate cancer, exercise and prostate cancer, and maintaining healthy lifestyle change."
2538607|NCT02639845||Patients Prescribed Eye Drops|Patients who are scheduled to receive prescription eye drops due to complications such as cataract surgery, glaucoma, retina surgery, or eye-related condition.
2538653|NCT02639455|No Intervention|Athlete group|Participants wo regularly exercise and are student athletes.
2538656|NCT02639455|No Intervention|Non-exercise group|Participants who are not student athletes.
2538659|NCT02639455|Experimental|Exercise group|Participants are not student athletes but commit to modest exercise for 5 weeks as part of this study.
2538711|NCT02639208|Experimental|PatientsLikeMe (PLM)|"After the screening procedures confirm eligibility.~Baseline Survey Assessment and PatientsLikeMe Introduction~Treatment Evaluation on PLM website at predetermined times per protocol~Final Survey"
2538748|NCT02638779|Experimental|Blood sampling|Blood sampling will be performed in all patients and healthy volunteers
2538791|NCT02638506|Experimental|Intranasal Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
2538792|NCT02638506|Placebo Comparator|Salinex|All patients will receive a 1.5 mcg⁄kg dose of fentanyl or an equivalent volume of similar looking placebo. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe.
3202140|NCT00910351|Experimental|Arm 1|
3202141|NCT00910364|Experimental|Exercise testing|Feasibility study; all participants receive intervention
2538893|NCT02637791|Experimental|Intervention|The virtual glove in their homes for a period of 8 weeks and advised to try to build up to using the system for a maximum of 20 minutes 3 times a day for 8 weeks.
2538894|NCT02637791|No Intervention|Control|Usual care
3202142|NCT00910377|Experimental|visit with grandmother|Teenagers mothers and their grandmothers receive counseling sessions about breastfeeding and complementary feeding.
3202143|NCT00910377|Experimental|visit without grandmother|Teenagers mothers don´t live with their grandmothers and receive counseling sessions about breastfeeding and complementary feeding.
2539501|NCT02633683|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
2539575|NCT02633397|Experimental|Riociguat|Treatment Arm
2539579|NCT02633397|Placebo Comparator|Placebo|Placebo Arm
2539639|NCT02632851||Ectoin inhalation solution|treatment according to instructions for use
2539640|NCT02632851||Pari NaCl inhalation solution (0.9%)|treatment according to instructions for use
2539668|NCT02632604|Active Comparator|Bottom-up to top-down cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes
2539670|NCT02632604|Active Comparator|Top-down to bottom-up cognitive training|Participants are given 20 hours of cognitive training with exercises that involve essentially top-down cognitive processes, followed by 20 hours of cognitive training with exercises that involve essentially bottom-up cognitive processes
2539671|NCT02632604|Placebo Comparator|Computer games|Participants are given 40 hours of computer games commonly found on the internet and which do not involve a high demand in cognitive functions (e.g. fishing game, pinball game, tetris, etc).
2538003|NCT02643537||Luxation erecta|All patients with Inferior shoulder dislocation in fixed abduction, also known as luxatio erecta humeri (LEH)
2538062|NCT02643407|Experimental|Docetaxel plus Nedaplatin|docetaxel 60mg/m2 and nedaplatin 80mg/m2, d1 every 3 weeks
2538066|NCT02643407|Active Comparator|Docetaxel plus Cisplatin|docetaxel 60mg/m2 and cisplatin 75mg/m2, d1 every 3 weeks
2538121|NCT02643069|Experimental|Intervention Geriatric Program|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, according to the treating physicians (s) surgeon and the performance of a geriatrician . This management will consist of the therapeutic plan, access to geriatric levels of care, coordination with primary and social care, rehabilitation, and discharge plan.
2538126|NCT02643069|No Intervention|Usual clinical practice|A comprehensive management plan of the frail patients, covering both in-hospital and postdischarge time, agreed with the treating physicians (s) surgeon.
2538165|NCT02642757|Experimental|Brief intervention|AUDIT brief intervention
2538166|NCT02642757|Sham Comparator|Control group|Pamphlet on alcohol use
3202144|NCT00910377|No Intervention|no visit with grandmother|Teenagers mothers live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
3202145|NCT00910377|No Intervention|no visit without grandmother|Teenagers mothers don´t live with their grandmothers and don´t receive counseling sessions about breastfeeding and complementary feeding.
2538364|NCT02641132|Experimental|Pterygium surgery: Head and body.|Application of Mitomycin C 0.02% after excision of the body and the head of the pterygium.
2538372|NCT02641132|Active Comparator|Pterygium surgery: Body.|Application of Mitomycin C 0.02% after excision of the body only of the pterygium.
2538452|NCT02640781|Experimental|covered stent|newly designed covered stent group
2538453|NCT02640781|Active Comparator|uncovered stent|currently used uncovered stent group
2538480|NCT02640417|Experimental|Nucleotides + B12|Nucleotides + Vitamin B12 Dose: two capsules, three times per day + placebo corresponding to Group B treatment
2538482|NCT02640417|Active Comparator|B vitamins|Vitamin B1 + Vitamin B6 + Vitamin B12 Dose: one tablet, three times daily + placebo corresponding to Group A treatment
2538516|NCT02640222||AC-naive treated with VKA|AC-naive treated with VKA
2538522|NCT02640222||AC-naive treated with apixaban|AC-naive treated with apixaban
2538525|NCT02640222||AC-naive treated with dabigatran|AC-naive treated with dabigatran
2538527|NCT02640222||AC-naive treated with rivaroxaban|AC-naive treated with rivaroxaban
2538529|NCT02640222||AC-experienced treated with VKA|AC-experienced treated with VKA
2538533|NCT02640222||AC-experienced treated with apixaban|AC-experienced treated with apixaban
2538535|NCT02640222||AC-experienced treated with dabigatran|AC-experienced treated with dabigatran
2538536|NCT02640222||AC-experienced treated with rivaroxaban|AC-experienced treated with rivaroxaban
3202146|NCT00910390|Placebo Comparator|Slow Freezing|Standard freezing protocol (slow freezing) of preimplantation embryos
2538776|NCT02638558|Experimental|written + oral explanation|patients will undergo both written and oral explanation for preparation with split dose
2538781|NCT02638558|Experimental|written explanation|patients will receive only a written explanation for preparation with split dose
3202147|NCT00910390|Experimental|VIT-Irvine|Vitrification with Irvine solution (rapid freezing) of preimplantation embryos
3202148|NCT00910390|Experimental|VIT-Vitrolife|Vitrification (rapid freezing) with Vitrolife solution
3202149|NCT00910416||patients receiving iv anesthesia|
2539127|NCT02636439|Active Comparator|dietary, and aerobic exercise|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training."
2539128|NCT02636439|Active Comparator|dietary, aerobic and resistance training|"Intervention for diet-A hypocaloric diet will be developed to achieve a 2800 kcal/week deficit, which should produce about 0.4 kg (1 lb.) weight loss per week.~Intervention for aerobic exercise-Based on initial evaluations and the stress testing results, (HR, VO2, RPE) an individual exercise prescription will be developed for aerobic training.~Intervention for resistance training- Additional weight resistant exercise will be added to this arm."
2539231|NCT02635789|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
2539233|NCT02635789|Placebo Comparator|Placebo gel|Placebo gel is matched ingredient with NPC-12G gel
3202150|NCT00910416||patients receiving balanced anesthesia|
3202151|NCT00910442|Experimental|Patient Group|Dietary supplement:N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
3202152|NCT00910442|Active Comparator|Control Group|Healthy HIV negative subjects submitted to the same dietary supplement than experimental group: N-acetylcysteine 1g/day and Glutamine 20g/day for 7 consecutive days. The dietary supplements were intermediated by 7 days of washout with usual diet.
3202153|NCT00910455|Experimental|Active|Single oral dose of SRX246 capsule
3202154|NCT00910455|Placebo Comparator|Placebo|Single oral dose of placebo capsule
2539434|NCT02634255|Active Comparator|Rocuronium elective surgery|patients undergoing inguinal herniorrhaphy
2539435|NCT02634255|Experimental|Rocuronium emergency surgery|patients undergoing appendectomy
2539455|NCT02633943||Subjects with hemoglobinopathies|Subjects treated with ex vivo gene therapy product in a bluebird bio-sponsored clinical trial who agree to participate in this study
3202155|NCT00910468||Robot Assisted Laparoscopic Myomectomy|
3202156|NCT00910468||Myomectomy via Laparotomy|
2539563|NCT02633202|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone: Patients receive intensity modulated-radiotherapy (IMRT) alone
2539572|NCT02633202|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
2539822|NCT02631616|Experimental|Treatment arm|Monthly injections of Somatostatin (Sandoatatin LAR - 30mg)
3202157|NCT00910494|Experimental|12 Gray IORT|
3202158|NCT00910494|Experimental|15 Gray IORT|
2538273|NCT02642003|Experimental|GCSF+SMT|5-day course of GCSF (5 μg/kg/d) plus standard medical therapy for 6 months
2538274|NCT02642003|No Intervention|SMT|
2538622|NCT02639663|Experimental|women whom are interested in breastfeeding and have not begun.|"Post-partum primi and multiparous women Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
2538624|NCT02639663|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
2538956|NCT02637492||ICCMI|Patient hospitalized for lower limb arterial disease and suspected to have critical ischaemia
2539151|NCT02636374|Experimental|Guided Imagery|Participants listened to a pregnancy-specific guided imagery recording on four separate occasions during their pregnancies. Perceived stress was measured immediately pre and post each listening session using the Perceived Stress Measure-9 (PSM-9).
2539207|NCT02635945|Experimental|PBF-680 10 mg|2 capsules: PBF-680, 5 mg capsules for oral administration (excipient: 76 mg microcrystalline cellulose).
2539211|NCT02635945|Placebo Comparator|Placebo|2 capsules: Placebo to PBF-680, as 95.12 mg microcrystalline cellulose capsules.
2539268|NCT02635503|Experimental|transrectal specimen extraction|Laparoscopic colorectal resection with natural orifice specimen extraction will be performed for patients in this group.
2539272|NCT02635503|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
2539371|NCT02634645||Patients with Barrett's Esophagus|Patients with non-dysplastic Barrett's esophagus, patients with Barrett's related dysplasia which includes low-grade dysplasia, high-grade dysplasia and intramucosal cancer who will be evaluated and treated with endoscopic eradication therapies (EET).
2539375|NCT02634645||Patients with invasive esophageal cancer|Patients with invasive esophageal cancer who will be treated with surgery (esophagectomy), chemotherapy, radiation, and palliative treatment modalities.
2539428|NCT02634281|Experimental|group A|Subjects in Group A will receive varenicline for six weeks .During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2539431|NCT02634281|Active Comparator|group B|group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2539475|NCT02633995||preeclampsia|spinal anaesthesia will be given for cesarean section
2539478|NCT02633995||normotensive|spinal anaesthesia will be given for cesarean section
2539505|NCT02633644|Experimental|Treated with Harmony System|Implantation and activation of the Harmony endovascular neurostimulator
3174008|NCT00618605|Experimental|3|3 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at 1 x 10^11 VP given at Days 0, 28, and 168
3174009|NCT00618605|Experimental|4|2 injections of Ad26.ENVA.01 HIV-1 vaccine or placebo at a dose to be determined by the safety data from Arms 1, 2 and 3 given at Days 0 and 168
3174010|NCT00618644|Experimental|1|Ranibizumab injection
3174011|NCT00618657|Experimental|Arm I (HER-2 positive)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, carboplatin IV over 60 minutes, and trastuzumab IV over 90 minutes , then weekly over 30-60 minutes. Treatment repeats every week for 12 weeks in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
3174012|NCT00618657|Experimental|Arm II (HER-2 negative)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as in Arm I. Patients also receive bevacizumab IV over 90 or 60 or 30 minutes once every two weeks for 5 doses in the absence of disease progression or unacceptable toxicity. In both arms, beginning 21-40 days later, patients undergo surgery.
3174013|NCT00618670|Experimental|1|Home-based program with progressive increases in exercise duration and intensity (i.e., cadence); walking duration will be longer for the home-based group because the intensity of walking will be lower than the graded treadmill walking performed by the supervised group
3174014|NCT00618670|Experimental|2|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes, and progressive increments in exercise intensity from 50 to 70% of exercise capacity
3174015|NCT00618670|Active Comparator|3|Light resistance training without any walking exercise
3174016|NCT00618683|Other|Study Arm|Mapping and Ablation
3174017|NCT00618696|Experimental|AHN-12|2.0, 5.0, 7.5, 10.0 or 12.5 mCi/m^2 of ^90Y-AHN-12 at Day 7/8
3174018|NCT00618709|Experimental|Cohort 1|ATX-101 (1 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
3174019|NCT00618709|Experimental|Cohort 2|ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid
3174020|NCT00618709|Experimental|Cohort 3|3 subgroups in Cohort 3: 3a: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 3b: ATX-101 (2 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 3c: ATX-101 (2 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
3174021|NCT00618709|Experimental|Cohort 4|3 subgroups in Cohort 4: 4a: ATX-101 (8 mg/cm2) at a volume of 0.2 ml on a 1.0 cm grid 4b: ATX-101 (4 mg/cm2) at a volume of 0.2 ml on a 0.7 cm grid 4c: ATX-101 (4 mg/cm2) at a volume of 0.4 ml on a 1.0 cm grid
3174022|NCT00618735|Experimental|1|Subjects in Schedule A will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (Beginning at midnight).
2538070|NCT02643446||G4: IPV+OPV, 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 5 months of age, that is one month after the second dose of OPV.
2538072|NCT02643446||G5: OPV, 3 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 5 months of age, that is one month after the third dose of OPV.
2538074|NCT02643446||G6: OPV, 1 m followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months of age, that is one month after the first dose of OPV and just before the second dose of OPV.
2538075|NCT02643446||G7: OPV, 1 m+7d followup|Using 3 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of OPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of OPV.
2538076|NCT02643446||G8: IPV+IPV, 1 m+7d followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV.
2538078|NCT02643446||G9: IPV+IPV, 2 m followup|Using 2 doses of IPV and 1 doses of OPV at 2, 3,4 months of age; Collecting two blood samples: one sample just before the first dose of IPV, another sample at 4 months of age, that is one month after the second dose of IPV and just before the first dose of OPV.
2538080|NCT02643446||G10: IPV+OPV, 1 m and 3 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months of age, that is one month after the first dose of IPV and just before the first dose of OPV;the third sample at 5 months of age, that is one month after the second dose of OPV.
2538081|NCT02643446||G11: IPV+OPV, 1 m+7d and 2 m followup|Using 1 dose IPV and 2 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the first dose of OPV,the third sample at 4 months of age, that is one month after the first dose of OPV.
2538083|NCT02643446||G12: IPV+IPV,1 m+7d and 2 m followup|Using 2 dose IPV and 1 doses of OPV at 2, 3 and 4 months of age; Collecting three blood samples: one sample just before the first dose of IPV, another sample at 3 months and 7 days of age, that is 7 days after the second dose of IPV,the third sample at 4 months of age, that is one month after the second dose of IPV.
2538146|NCT02642861|Active Comparator|Cyclobenzaprine|Cyclobenzaprine administration for 2 weeks
2538147|NCT02642861|Placebo Comparator|PLacebo|Calcium carbonate for 2 weeks
2538287|NCT02641821|Experimental|Nifedipine GITS|
2538312|NCT02641574||previous 1|women who have had in their past one cesarean section
2538318|NCT02641574||previous 2|women who have had in their past 2 cesarean sections
2538320|NCT02641574||previous 3|women who have had in their past 3 cesarean sections
2538323|NCT02641574||previous 4|women who have had in their past 4 cesarean sections
2538371|NCT02641327||Internal ward|Patients hospitalized in Internal Medicine unit with unstable blood pressure that need regulation/ stabilization of their blood pressure (e.g., CHF, post surgical, hypotension or Hypertension patients, patients with kidney failure, heart disease, stroke)
2538379|NCT02641327||ICU|Patients hospitalized in intensive care with arterial line that allow continuous blood pressure measurement
2538436|NCT02640950|Experimental|Open-Label TMS|Active Transcranial Magnetic Stimulation
2538469|NCT02640560||Children with food allergy|"Children with food allergy to nuts, hazelnuts, walnuts, shellfish and mollusks (1-14 years old).~The Parents of the cases children will compile a Food allergy questionnaire"
2538471|NCT02640560||Healthy Children|Healthy Children (1-14 years old) The Parents of the control children will compile a Control questionnaire
2538506|NCT02640339||Parkinson Disease|Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, with alpha-synuclein deposits in neurons which aggregate into Lewy bodies.
2538507|NCT02640339||Mutiple system atrophy|is a degenerative neurological disorder. MSA is associated with the degeneration of nerve cells in specific areas of the brain. This cell degeneration causes problems with movement, balance, and autonomic functions of the body such as bladder control or blood-pressure regulation. Neuronal death probably occurs as a consequence of alpha-synuclein aggregation in oligodendroglia.
2538508|NCT02640339||REM sleep behavior disorder|a sleep disorder in which you physically act out vivid, often unpleasant dreams with vocal sounds and sudden, often violent arm and leg movements
2538509|NCT02640339||dementia with Lewy bodies|"causes a progressive decline in mental abilities.~It may also cause visual hallucinations, which generally take the form of objects, people or animals that aren't there. This can lead to unusual behavior such as having conversations with deceased loved ones.~Another indicator of Lewy body dementia may be significant fluctuations in alertness and attention, which may include daytime drowsiness or periods of staring into space. And, like Parkinson's disease, Lewy body dementia can result in rigid muscles, slowed movement and tremors."
2538510|NCT02640339||Pure autonomic failure|Pure autonomic failure is dysfunction of many of the processes controlled by the autonomic nervous system, such as control of blood pressure•Blood pressure may decrease when people stand, and they may sweat less and may have eye problems, retain urine, become constipated, or lose control of bowel movements
2538511|NCT02640339||Healthy controls|Healthy normals with no neurological involvement
2538553|NCT02640066|Experimental|acupuncture|acupuncture treatment with Supportive care
2538555|NCT02640066|No Intervention|standard treatment|Supportive care measures only
2538605|NCT02639819|Experimental|Treatment|Study drug
2538676|NCT02639481|Active Comparator|Control group standard physiotherapy|Patients will receive standard physiotherapy for 60 minutes, including the goal of verticalization and stimulation of the patient but without the use of the robotic Erigo®Pro device.
2538148|NCT02642913|Experimental|Enzalutamide without Sorafenib|Will get enzalutamide, at the dose approved by the FDA for prostate cancer. If this dose has serious side effects, a lower dose will be given to new patients as they take part in the study. At the end of this part of the study, the recommended dose of enzalutamide will be set for all patients on this study. More patients will then be treated with this dose.
2538151|NCT02642913|Experimental|Enzalutamide with Sorafenib|Will get enzalutamide and sorafenib. The first group of patients will get the recommended dose of enzalutamide with sorafenib by mouth either once or twice daily. The dose of sorafenib you receive will depend on when the patient starts the study. At the beginning of the study, patients will be treated with a lower dose of sorafenib. If this dose does not have serious side effects, a higher dose will be given to new patients as they take part in the study.
2538181|NCT02642497|Active Comparator|local ketamine group|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
2538184|NCT02642497|Placebo Comparator|control group|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure, with closure of suction drain tube for 30 min. postoperatively.
2538187|NCT02642497|Active Comparator|systemic ketamine group|Intra-muscular injection of ketamine at a dose of 1 mg/kg before wound closure.
2538275|NCT02641886|Experimental|Jian Pi Yi Shen Hua Tan Granules group|Treat with the prescription of Jianpi Yishen Huatan Granules and conventional treatment of ischemic stroke.
2538276|NCT02641886|Placebo Comparator|the Placebo Group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin and conventional treatment of ischemic stroke.
2538311|NCT02641626|Experimental|Urgent Coronary Angiography|Urgent Coronary Angiography: as soon as possible, when the patient is randomized.
2538319|NCT02641626|Active Comparator|Deferred coronariography|Deferred coronary angiography: after extubation if the patient has a good neurologic prognosis.
2538360|NCT02641314|Experimental|metronomic therapy|Treatment consists of eight alternating 28-day-cycles of propranolol, celecoxib, cyclophosphamide, vinblastine, etoposide (PCCVE) and of propranolol, celecoxib, cyclophosphamide, vinblastine (PCCV) followed by five cycles PCCV resulting in a total of 13 cycles (364 days of treatment)
2538447|NCT02640859||Normal cohort|Normal cohort for biobank
2538493|NCT02640534|Experimental|Enzalutamide + Metformin|Enzalutamide 160 mg od + metformin 850 mg bid until disease progression
2538495|NCT02640534|Active Comparator|Enzalutamide|Enzalutamide 160 mg od until disease progression
3202159|NCT00910507|Experimental|Exercise counseling|Each participant in the experimental group receives exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
3202160|NCT00910507|Active Comparator|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
2538691|NCT02639065|Experimental|Investigational Treatment|Durvalumab 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
2538739|NCT02638909|Experimental|ceritinib|Phase II, single-arm study of oral ceritinib in adult patients with ALK and ROS1 activated gastrointestinal malignancies
2538805|NCT02638584|Experimental|Ilaprazole|Ilaprazole tab 10mg, 2 tablets once daily for 8 weeks.
2538806|NCT02638584|Active Comparator|Rabeprazole|Rabeprazole tab 20mg, 1 tablet once daily for 8 weeks.
2538838|NCT02637960|Experimental|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
2538839|NCT02637960|Experimental|Placebo matched to fedovapagon|One daily dose of placebo (matched to fedovapagon) for 12 weeks
2538948|NCT02637505|Active Comparator|Arthroscopic microfracture (MF)|"The AM group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The cartilage is cut sharp forming a rim of 90 degrees. The calcified layer is removed using a curette before an arthroscopic awl is then used to perform multiple holes (microfractures) from the periphery towards the center. The microfractures are 3 - 4 mm apart and 2 - 4 mm deep into the subchondral bone. The correct and successful technique is confirmed by direct visualization: while reducing the fluid pump pressure, the release of marrow fat droplets and blood will be observed."
2538953|NCT02637505|Sham Comparator|Arthroscopic debridement (AD)|The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. The lesion is stabilized, debriding all loose or marginally attached cartilage from the surrounding rim to form a stable edge of healthy cartilage around the defect using a ring curette, where cartilage slops down to the defect.
2539053|NCT02636894|Other|Restylane Silk|Restylane Silk
3202161|NCT00910533|Active Comparator|Early Lyme neuroborreliosis patients|
2539178|NCT02636075||Upper 1/3 of thyroid tissue|
2539179|NCT02636075||Middle 1/3 of thyroid tissue|
2539180|NCT02636075||Lower 1/3 of thyroid tissue|
2539182|NCT02636075||Below thyroid tissue|
3202162|NCT00910533|No Intervention|control subjects|Control subjects without a history of Lyme borreliosis.
2539264|NCT02635529|Active Comparator|OFD + DFDBA|Intrabony defects treatment was carried out with OFD + DFDBA
2539270|NCT02635529|Active Comparator|OFD+DFDBA+AM|Intrabony defects treatment was carried out with OFD + DFDBA+ AM
2539328|NCT02635022||FLS|Patients with new hip fracture or newly identified vertebral fractures
2539330|NCT02635022||MMS|Patients prescribed with anti-osteoporosis medications but not fit FLS requirements
2538162|NCT02642718|Experimental|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision. (a single dose).
2538192|NCT02642471|Experimental|Arm 1|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2538195|NCT02642471|No Intervention|Arm 2|patients with negative sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 1 or Arm 2 Arm 1: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 2: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2538200|NCT02642471|Experimental|Arm 3|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2538204|NCT02642471|No Intervention|Arm 4|patients with positive sentinel nodes confirmed by pathological examination of frozen section will be randomly assigned to Arm 3 or Arm 4 Arm 3: patients undergo radical hysterectomy±salpingo-oophorectomy (no systematic pelvic lymphadenectomy) Arm 4: patients undergo radical hysterectomy±salpingo-oophorectomy+pelvic lymph node dissection
2538281|NCT02641925|Active Comparator|Omentum preserving|Omentum preserving: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed.
2538282|NCT02641925|Experimental|Total omentectomy|Total omentectomy: Whole omentum will be removed.
2538325|NCT02641509|Experimental|NBI to perform the polipectomy|this arm will undergo polypectomy with the use of NBI to define the margins of the lesion
2538326|NCT02641509|Experimental|no NBI to perform the polypectomy|this arm will undergo polipectomy without the use of NBI to define the margins of the lesion
3202163|NCT00910546|Experimental|Implantation of gold marker|CT guided implantation of gold marker into early stage lung tumors. Extra 4DCT scans and fluoroscopies during planning and the 3 fraction radiotherapy course.
3202164|NCT00910585|Experimental|Active coaching|Telephone and in person coaching
2538448|NCT02640794|Active Comparator|Aspirin +clopidogrel|Patients would be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d) + clopidogrel (75 mg/d)
2538451|NCT02640794|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin/acetylsalicylic acid (80-325 mg/d)
2538585|NCT02639975|Experimental|100 mg PBF-677|
2538586|NCT02639975|Experimental|200 mg PBF-677|
2538587|NCT02639975|Experimental|400 mg PBF-677|
2538592|NCT02639975|Experimental|600 mg PBF-677|
2538594|NCT02639975|Placebo Comparator|Placebo 100 mg|
2538598|NCT02639975|Placebo Comparator|Placebo 200 mg|
2538599|NCT02639975|Placebo Comparator|Placebo 400 mg|
2538601|NCT02639975|Placebo Comparator|Placebo 600 mg|
2538642|NCT02639403|Experimental|RT for Obstructing Rectal Cancer|Conformal three-dimensional RT was planned (3D-RT) in patients with obstructing rectal cancer not amenable for curative resection
2538707|NCT02639221|Experimental|PXT002331|
2538709|NCT02639221|Placebo Comparator|Placebo|
2538749|NCT02638792|Experimental|Internet-based exposure therapy|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
2538751|NCT02638792|Active Comparator|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
2538753|NCT02638792|No Intervention|Waitlist|When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, and 4, 12 months later using the same questionnaires as the treatment group. The participants will be able to choose which treatment they receive i.e. no randomization.
2538795|NCT02638467|Experimental|Bosutinib and Bone Marrow Transplant|Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI. Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow. Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
2538861|NCT02638090|Experimental|Phase I Dose Escalation|"Level 1: Vorinostat 200mg by mouth (PO) Daily; Pembrolizumab 200 mg intravenously (IV) every (Q) 3 weeks.~Level 2: Vorinostat 400 mg PO Daily; Pembrolizumab 200 mg IV Q3 weeks"
2538864|NCT02638090|Experimental|Phase Ib Expansion|"Pembrolizumab plus Vorinostat.~Level 1: Maximum Tolerated Dose (MTD)"
2538865|NCT02638090|Active Comparator|Arm A: Pembrolizumab|"Pembrolizumab treatment only.~Level 1: Pembrolizumab 200 mg Q3 wks"
2538868|NCT02638090|Active Comparator|Arm B: Pembrolizumab plus Vorinostat|"Pembrolizumab plus Vorinostat treatment.~Level 1: MTD"
2538960|NCT02637583|Active Comparator|Sequential vaccination PCV13 and PPV23|PCV13 0.5 ml intramuscular injection once on day 0 PPV23 0.5 ml intramuscular injection once 6 months later
2538962|NCT02637583|Experimental|Simultaneous vaccination PCV13 and PPV23|PCV13 0.5ml intramuscular injection once on day 0 followed by PPV23 0.5ml intramuscular injection on day 0
2538964|NCT02637583|Active Comparator|Single vaccinationPPV23|PPV23 0.5ml intramuscular injection on day 0
2539321|NCT02634866||Group D_HF|The subjects with symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
3202165|NCT00910585|Active Comparator|Usual care|Return to PCP for usual care
3202166|NCT00910598|Experimental|glatiramer acetate|glatiramer acetate 20 mg s.c. daily for 1 year
3174023|NCT00618735|Experimental|2|Subjects in Schedule B will take BIIB021 in the morning at approximately 0800 with at least 6 ounces of water following an overnight fast (beginning at midnight). The second dose will be taken, following at least a 2-hour fast, 12 hours (+/- 2 hours) after the first dose, except on Day 1 of Cycle 1 and Day 1 of Cycle 2.
2538350|NCT02641613|Active Comparator|supraclavicular|patients receive a supraclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
2538352|NCT02641613|Experimental|retroclavicular block|patients receive a retroclavicular block for forearm or hand surgery with 30 ml of a mixture of ropivacaine 0.5 % and mepivacaine 1 %
2538514|NCT02640261||Group 1|Single embryo transfer on day 5, according to standard embryo morphological criteria
2538519|NCT02640261||Group 2|Single embryo transfer on day 5, chosen on the basis of both embryo morphological criteria and levels of cytokines measured in the individual FF.
2538565|NCT02640040|Experimental|combined surgery|combined surgery for enrolled patients with CPT(Congenital Pseudarthrosis of Tibia): sleeve resection of the pathological soft tissues, intramedullary rod fixation, packaged lilac bone autograft,and llizarov external fixation device installation.
2538614|NCT02639676||Group 1: Infants born to mothers with preeclampsia|Infants with expected delivery at 26+0 weeks gestation or greater .
2538616|NCT02639676||Group 2: Infants born to mothers with normotensive pregnancies|Infants with expected delivery at 26+0 weeks gestation or greater.
2538632|NCT02639416|Active Comparator|Standard management|Standard management consists of F-100 and/or ready-to-use therapeutic food (RUTF) according to usual practice for 14 days
2538633|NCT02639416|Experimental|Polymeric formula|Exclusive polymeric formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
2538637|NCT02639416|Experimental|Elemental formula|Exclusive elemental formula supplemented with micronutrients in equivalent volume to F-100 for 14 days
2538689|NCT02639143|Experimental|ticagrelor|Ticagrelor, 180 mg, oral administration. followed by 90 mg bid
2538690|NCT02639143|Active Comparator|Clopidogrel|Clopidogrel 600 mg loading dose taken orally, followed by 75 mg qd.
2538736|NCT02638922||no treatment|girls who never received estradiol treatment
2538737|NCT02638922||Estradiol treatment|girls who received estradiol treatment
2538778|NCT02638649||subjects who call 911 for dyspnea|All subjects who call 9-1-1 for difficulty breathing will have the potential to be enrolled in the study.
2538815|NCT02638285|Experimental|HCG group|HCG group
2538819|NCT02638285|Experimental|LH group|LH group
2538820|NCT02638285|Experimental|clomiphene citrate|clomiphene citrate
2538852|NCT02637908|Experimental|Mindfulness training|The mindfulness training (experimental condition) will receive 6-weeks of mindfulness training for parents provided in a group setting.
2538855|NCT02637908|No Intervention|Wait-list control|The wait-list control group will receive no intervention during the course of the study. The control group will be offered training following the completion of the study.
2538905|NCT02637778|Experimental|Cardioprotective diet|The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).
2538908|NCT02637778|Experimental|Cardioprotective diet + 3 g EPA+DHA/d|"The study participants receive defined personal nutrition counselling every two weeks and they get daily menu plans (with optimised nutrient profiles) over an entire period of 20 wks (follow-up 20 wks).~Participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)."
2538915|NCT02637453|Active Comparator|PVI|Pulmonary vein isolation (PVI)
2538917|NCT02637453|Experimental|PVI+6L|PVI plus 6 additional lines at 1, 3 and 6 o'clock (from internal view) of left PV and 6, 9 and 11 o'clock of right PV
2539070|NCT02636790|Active Comparator|Surgery wait time (< 8 weeks)|Outcomes of patients with sinus surgery of less than 8 weeks.
2539078|NCT02636790|Active Comparator|Surgery wait time (> 1 year)|Outcomes of patients with sinus surgery of more than 1 year.
2539105|NCT02636543||Group 2a-patient|75 patients who attended a genetic counselling consultation.
2539106|NCT02636543||Group 2a-public|75 persons belonging to general population.
2539107|NCT02636543||Group 2b-patient|75 patients who attended a genetic counselling consultation (those patients are different than patients from group 2a-).
2539108|NCT02636543||Group 2b-public|75 persons belonging to general population (those persons are different than patients from group 2a).
2539109|NCT02636543||Group 2b-professional|75 genetic professionals.
2539161|NCT02636166|Other|Pregnancy test|"Clearblue investigational Pregnancy test~Clearblue Marketed pregnancy test~Professional pregnancy test"
2539189|NCT02635802|Experimental|Remifentanil|injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished.
2539190|NCT02635802|Experimental|Lidocaine|injection form concentration 10mg/ml loading dose 100-400mg local anesthesia
2539191|NCT02635802|Experimental|Remifentanil+Lidocaine|"injection form concentration 20μg/ml loading dose 1.0-2.0μg/kg intravenous injection slowly,time >1min,then 5μg/kg·h pumping until the operation is finished~+ injection form concentration 10mg/ml loading dose 100-400mg local anesthesia"
2539295|NCT02635295|No Intervention|Standard cooperation|Nursing student - nurse teacher standard cooperation during the clinical practicum.
3174024|NCT00618761|Experimental|1|kidney-pancreas recipients
3174025|NCT00618761|Active Comparator|2|kidney recipients
3174026|NCT00618761|Active Comparator|3|healthy controls
3174027|NCT00618761|Active Comparator|4|beta-cell recipients
3174028|NCT00618800|Experimental|Pharmacist Care|Pharmacist Intervention
3174029|NCT00618800|Active Comparator|Control|Written information only group
3174030|NCT00618852|Experimental|1|Furosemide
3174031|NCT00618852|Placebo Comparator|2|
3174032|NCT00618865|Experimental|1|omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
3174033|NCT00618865|Placebo Comparator|2|Placebo (olive oil ethyl esters)
3174034|NCT00618878|Active Comparator|1|Electroacupuncture
3174035|NCT00618878|Active Comparator|2|Laser Therapy
3174036|NCT00618904|Experimental|1|Probiotic containing Lactobacillus and Bifidobacterium
2538196|NCT02642380|Active Comparator|1 cycle|Oral administration of dexamethasone 40 mg for four consecutive days
2538239|NCT02642120|Experimental|Receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
2538240|NCT02642120|No Intervention|Do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
2538277|NCT02641951|Placebo Comparator|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
2538278|NCT02641951|Active Comparator|Pecs II block|Ultrasound guided Pecs II block
2538363|NCT02641366||Tremor kinetics after DBS|This group have already undergone Deep Brain Stimulation (DBS) placement and will have measurements of tremor kinetics by using the electromagnetic tracking. The electromagnetic sensors will be placed on the arm and hand while the routine outpatient neurologic examinations are being performed. The testing will be performed with the DBS system in both the on and off settings.
2538369|NCT02641366||Tremor kinetics before and after DBS|This group will have measurements of tremor kinetics by using electromagnetic tracking prior to being scheduled to undergo Deep Brain Stimulation (DBS) placement. A total of two testing sessions will be performed: the first session will be performed during the routine preoperative visit, the second session will be performed during the routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
2538434|NCT02640898|Active Comparator|FU-based chemoradiotherapy|patients will be treated with the INT0116 regimen.
2538437|NCT02640898|Experimental|docetaxel-based chemoradiotherapy|patients will be treated with modified DCF chemotherapy in combination with docetaxel-based chemoradiotherapy.
3202167|NCT00910598|No Intervention|no treatment|No disease modifying treatment allowed
2538609|NCT02639754|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be trained to endorse frequent HIV testing, compliance with medical guidelines, and effective ways to communicate these concepts to social network members.
2538613|NCT02639754|Active Comparator|Routine Counseling|Members of social networks randomized to this arm will receive HIV counseling at baseline sessions.
2538631|NCT02639442|Experimental|ClearRing™|subjects will undergo general/spinal/local block anesthesia and cystoscopy and/or x-ray evaluation. One to three implants will be transplanted into the patient prostate, followed by cystoscopy for results evaluation
3202168|NCT00910637|Experimental|Arm 1|
3202169|NCT00910676|Experimental|DIPROSONE|
2538797|NCT02638233|Other|Sofosbuvir 400mg/Ledipasvir 90 mg|Subjects will receive sofosbuvir 400mg q.d p.o and ledipasvir 90 mg q.d p.o (FDC) for 8 weeks
2538840|NCT02638064|Experimental|Surgiflo injection|Injection of surgiflo in the pilonidal sinus cavity after curettage of its content
2538886|NCT02637817||Control Group|Neonates with no evidence of brain lesions on conventional MRI.
2538888|NCT02637817||Patients Group|Neonates with PWML diagnosed by conventional MRI.
2538919|NCT02637648|Experimental|Sodium oxbate|oral administration of sodium oxybate, 6-18ml per night, starting with 6ml in two nightly dosages of 1.5g each, increased by steps of 1.5g every second or third night until treatment response
2538929|NCT02637648|Placebo Comparator|Placebo|oral administration of placebo, 6-18ml per night, starting with 6ml in two nightly dosages
2538980|NCT02637271|Experimental|Total Meal Replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
2538981|NCT02637271|Active Comparator|Typical Diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
3202170|NCT00910702|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
3202171|NCT00910741|Experimental|Nanoplatin|"Nanoplatin (NC-6004) had to be administered once every 3 weeks, on Day 1, Day 22 and Day 43 etc.~Gemcitabine had to be administered to every patient 2 times on Day 1 and Day 8 every 3 weeks after the infusion of Nanoplatin (NC-6004)."
3202172|NCT00910754|Experimental|Abiraterone acetate|Patients will take 1000 mg of abiraterone acetate once daily plus prednisone 5 mg twice daily orally (by mouth) until disease progression.
2539121|NCT02636491|Experimental|investigational device|"MD-Logic-Automated Insulin Delivery System, Version 01.05.02~The device is being used continuously over 60 hours for insulin therapy"
2539122|NCT02636491|Placebo Comparator|MiniMed Paradigm® Veo™ System|"sensor augmented insulin pump~The device is being used continuously over 60 hours for insulin therapy"
2539163|NCT02636127|Experimental|Systemic Sclerosis (SSc) patient|15 patients whose diagnosis of SSc is made according to the revised ACR/EULAR ( American College of Rheumatology ) criteria 2013 will be recruited and blood samples will be obtained
2539168|NCT02636127|Other|healthy patient|15 healthy patients will be recruited and blood samples will be obtained
2539220|NCT02635854|Experimental|Test group|The test group (Septic choc group) includes 15 patients suffering from septic shock in intensive care unit.
2539228|NCT02635854|Other|Control group|The control group (Orthopedic surgery group) includes 15 patients recruited from the orthopedic surgical anesthesia consultation programmed for a prosthetic hip or knee pose.
2539266|NCT02635451||study group|Study group included 20 pregnant women with PPROM and fulfilled the inclusion and exclusion criteria.
2539273|NCT02635451||control group|Control group also included 20 pregnant women without PPROM following every recorded case of PPROM and matched for gestational age.
3202173|NCT00910767|Experimental|Closed loop (algorithm)|
3202174|NCT00910767|Placebo Comparator|Open loop|
3202175|NCT00910780|Active Comparator|Staying on Risperdal|
3202176|NCT00910780|Active Comparator|Risperdal switched to Abilify|
3202177|NCT00910780|Active Comparator|Staying on Zyprexa|
3202178|NCT00910780|Active Comparator|Zyprexa switched to Abilify|
2538208|NCT02642458||trastuzumab plus chemotherapy|Treatment with trastuzumab plus chemotherapie as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
2538214|NCT02642458||pertuzumab plus trastuzumab plus chemotherapy|Treatment with with pertuzumab plus trastuzumab plus chemotherapy as first line therapy, administered intravenously/subcutaneously in a three weekly frequency. Docetaxel is recommended as chemotherapy, however, any treatment choice or change in regimen is performed at the discretion of the treating physician.
2538283|NCT02641899|Experimental|Experimental Treatment|ITCA 650 20/60 mcg/day Acetaminophen 1000 mg Atorvastatin 40 mg Lisinopril 20 mg Warfarin 25 mg Digoxin 0.5 mg
2538333|NCT02641483|Experimental|Colonic Motility|Study participants will act as their own controls, first providing data using their usual digital rectal stimulation intervention for bowel care, then providing data using electrical stimulation for bowel care.
2538401|NCT02641106|Experimental|Video Directly Observed Therapy|VDOT arm participants use a smartphone to make a video recording of each weekly medication dose ingested using the VDOT mobile phone app. The VDOT app is programmed to send encrypted, time/date stamped videos to a HIPAA-compliant server as soon as the video recorder is stopped. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken. Dose 1 is observed in-person; doses 2-12 are observed via videos.
2538402|NCT02641106|Active Comparator|In-Person DOT|In-Person DOT arm participants follow standard-of-care procedures for monitoring ingestion of all medication doses. Participants take their first medication dose at the enrollment visit and return to the clinic once weekly to be observed taking the remaining 11 doses of medication until they complete the 12-dose regimen.
2538446|NCT02640820|Experimental|Sensitization Phase|Up to two doses of Sensitizing DPCP Ointment will be applied and subjects who exhibit a sensitization response will enter the Treatment Phase. Pharmacokinetics (PK) of Sensitizing DPCP Ointment will be measured in a subset of subjects. For PK, blood will be collected prior to application of the Sensitizing DPCP Ointment and again at 1, 2, and 24 hours after application.
2538450|NCT02640820|Experimental|Treatment Phase|In the Treatment Phase, subjects will receive doses of Treatment DPCP Ointment weekly for 10 weeks. Subjects who at the end of the Treatment Phase have exhibited partial clearance of warts may be given the option to continue with an additional 10 weekly treatments.
2538492|NCT02640443|Experimental|Treatment|Treatment with sulfamethoxazole. Subjects will serve as their own control, by using the data from baseline and after treatment stop.
3174037|NCT00618904|Placebo Comparator|2|Placebo
2538571|NCT02640027|No Intervention|Treatment in the Clinic Only|Patients in Group A will receive their follow-up care entirely at the investigators institution
2538572|NCT02640027|Experimental|Treatment in the Clinic and at Home|Cast removal at home using a telemedicine tool
2538603|NCT02639702|Experimental|Switch group|Participants will receive clozapine once daily at evening or bedtime throughout the study period. If a participant takes ≥200 mg of clozapine at a time other than evening/bedtime, half of this dose will be switched to an evening/bedtime regimen on day 0 (baseline), then another half dose will be switched on day 7 (week 1). Participants will receive placebo in place of the clozapine dose that was switched to evening/bedtime.
2538608|NCT02639702|No Intervention|Maintenance group|Participants will continue to take clozapine twice daily throughout the study period.
2538725|NCT02638961|Placebo Comparator|Standard treatment|Only standard medical treatment
2538727|NCT02638961|Active Comparator|IMT group|Standard medical treatment associated to Inspiratory muscle training
2538729|NCT02638961|Active Comparator|FES group|Standard medical treatment associated to functional electrostimulation of both legs for 45 minutes a day, 2 days per week for a total of 12 weeks.
2538732|NCT02638961|Active Comparator|IMT+FES group|Standard medical treatment associated to combination of inspiratory muscle training and functional electrostimulation of both legs
2538754|NCT02638636|Experimental|Internet-based exposure therapy|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
2538756|NCT02638636|No Intervention|Waitlist|Waitlist control, i.e. no active active intervention during waiting list period. Will be offered treatment when the first group has finished (i.e. week 10).
2538808|NCT02638454|Active Comparator|HL-YNG|"Healthy young sedentary males and females 20-30 yrs old~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
2538813|NCT02638454|Experimental|FL-OLD|"Functionally-limited older sedentary males and females without sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
2538818|NCT02638454|Experimental|SR-OLD|"Functionally-limited older sedentary males and females with clinically defined sarcopenia (70-85 yrs old)~Participants will undergo an acute bout of resistance exercise at 80% of their 1 repetition maximum (1RM, maximum strength) and will undergo muscle biopsies before, immediately after and 4 hours after the exercise."
3174038|NCT00618930|Experimental|1|
3174039|NCT00618930|Active Comparator|2|Use of Fleet
3174040|NCT00618969|Experimental|Haploidentical allogeneic PBSC transp|Non-myeloablative preparative regimen (reduced-intensity) of busulfan, melphalan and alemtuzumab followed by a haploidentical-related peripheral blood stem cell transplant.
3174041|NCT00619008|Experimental|1|Ad libitum low carbohydrate diet
3174042|NCT00619008|Experimental|2|Ad libitum high complex carbohydrate diet
3174043|NCT00619008|Experimental|3|Energy-restricted high complex carbohydrate diet
3174044|NCT00619021|Experimental|Cohort 1|Patient receives gemcitabine 600 mg/m^2.
3174045|NCT00619021|Experimental|Cohort 2|Patient receives gemcitabine 800 mg/m^2.
3174046|NCT00619021|Experimental|Cohort 3|Patient receives gemcitabine 1000 mg/m^2.
3174047|NCT00619021|Experimental|Cohort 4|Patient receives gemcitabine 1200 mg/m^2.
3174048|NCT00619034|Experimental|latanoprost|Medical intervention cross-over
2538218|NCT02642705|Active Comparator|Constant load exercise training N|Constant load exercise training N: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing ambient air (normoxia)
2538221|NCT02642705|Experimental|Constant load exercise training H|Constant load exercise training H: The intervention consists in 8-week exercise training, 3 times a week for one hour, according to a constant load training protocol (50% maximal power output), breathing hypoxic air (about 3 500 m of altitude)
2538223|NCT02642705|Experimental|Hypoxic conditioning at rest|Hypoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, hypoxic breathing for one hour (about 4500 m of altitude) while seating quietly
2538224|NCT02642705|Sham Comparator|Normoxic conditioning at rest|Normoxic conditioning at rest : The intervention consists in 8-week conditioning period, 3 times a week, normoxic breathing for one hour (ambient air) while seating quietly
2538255|NCT02641990|Experimental|Group 1|ITCA 650 20/60 mcg/day, ITCA placebo
2538258|NCT02641990|Experimental|Group 2|ITCA placebo, ITCA 650 20/60 mcg/day
2538305|NCT02641756|Experimental|Study Population|"This is a single arm study. The investigators will include 10 HIV positive patients under chronic CART (combined antiretroviral therapy).~The intervention will consist on treatment interruption after in depth sampling under CART"
2538368|NCT02641405|Experimental|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
2538375|NCT02641405|Placebo Comparator|Placebo|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
2538435|NCT02640885|Experimental|Foley's cather tamponade|Balloon tamponade with 2-way Foley's Cather was successfully used during cesarean section due to sever postpartum haemorrhage after failure of medical treatment.
2538783|NCT02638532|Other|Foot Fat Pad Grafting|All subject who enter into the study will undergo the fat pad grafting procedure to either the Heel or Forefoot based on the discretion of the PI, Co-investigator and the study subject.
2538809|NCT02638324|Active Comparator|Renal nervous denervation.|Renal nervous denervation is performed to the patients who do not response properly to conventional therapy. The patients are randomised according to the waiting list principle.
2538814|NCT02638324|Active Comparator|Renal nervous denervation (delayed)|Renal nervous denervation is performed after six months on the waiting list
2538867|NCT02637973|Experimental|Empagliflozin|Empagliflozin, film-tablet, 25mg once daily
2538872|NCT02637973|Placebo Comparator|Placebo|Placebo, once daily
2538916|NCT02637609||Likert Scale|Priority elicitation survey using a Likert scale method.
2538918|NCT02637609||Best-Worst Scaling (Case 1)|Priority elicitation survey using a best-worst scaling method.
2539004|NCT02637349|Experimental|POST SCP|Patient receives Survivorship Care Plan (SCP) after active treatment ends. It will be discussed with the patient. SCP includes medical and psychosocial history, medical contact information, 5-year follow-up plan and educational materials.
2539005|NCT02637349|Active Comparator|POST TAU|Patient receives treatment as usual (TAU) after active treatment ends.
2539034|NCT02636920|Other|TEP-CASES|"25 Case Patients will follow the Therapeutic Education to the Patient (TEP).~In addition the following procedures will be performed:~Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~Children Asthma Control Test (C-ACT);~Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
2539039|NCT02636920|No Intervention|TEP-CONTROLS|"25 Control Patients will follow the usual care program:~The Pediatric Asthma Quality of Life Questionnaire (PAQLQ);~The Children Asthma Control Test (C-ACT);~the Pediatric Caregiver Asthma Quality of Life Questionnaire (PCAQLQ);~Functional respiratory tests: forced expiratory volume in one second (FEV1), forced expiratory flow between 25% and 75% (FEF 25-75), forced vital capacity (FVC) and Peak expiratory flow (PEF)"
2539357|NCT02634723||Previously Untreated Patients (PUPs)|PUPs in China with Moderate to Severe Hemophilia A
3168131|NCT00547196|Experimental|Regimen I (age < 50 years, no contraindication to FTBI)|Patients undergo FTBI 2-3 times a day on days -9 to -6 for a total of 11 fractions. Patients also receive cyclophosphamide IV over 2 hours on days -5 and -4 and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3174049|NCT00619034|Active Comparator|diclofenac|medical intervention
2539533|NCT02633579|Active Comparator|Erythromycin lactobionate|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %
2539576|NCT02633449|Active Comparator|cognitive behavioral therapy + sham-tDCS|Group cognitive behavioral therapy combined with sham-tDCS
3174050|NCT00619034|Experimental|dorzolamide|dorzolamide eyedrops twice daily in one week
3174051|NCT00619047||Observation|
3174052|NCT00619086|Placebo Comparator|A, 1|Placebo 45 minutes prior to surgery
3174053|NCT00619086|Active Comparator|A, 2|8 mg Dexamethasone 45 minutes prior to surgery
3174054|NCT00619125||A|20 patients with IBS C
3174055|NCT00619125||D|20 Subjects without IBS
3174056|NCT00619125||B|20 patients with IBS D
3174057|NCT00619125||C|20 patients with IBS M
3174058|NCT00619138|Active Comparator|1|
3174059|NCT00619138|Active Comparator|2|
3174060|NCT00619164|Experimental|1|
3174061|NCT00619164|Experimental|2|
3174062|NCT00619164|Experimental|3|
3174063|NCT00619164|Placebo Comparator|4|
3174064|NCT00619203|Active Comparator|A|Two active ingredients
3174065|NCT00619203|Active Comparator|B|One active ingredient
3174066|NCT00619203|Active Comparator|C|One (other) active ingredient
3174067|NCT00619203|Placebo Comparator|D|
3174068|NCT00619268|Experimental|A|
2538249|NCT02642250|Experimental|Metronidazole DS|Metronidazole DS(400 mg) is commonly used to treat diarrhea.It eliminates bacteria and other microorganisms that cause infections of the reproductive system, gastrointestinal tract, skin, vagina, and other areas of the body.
2538284|NCT02641847|Experimental|High risk group A|TA(E)C x 4 cycles to GP x 4 cycles (docetaxel + doxorubicin (epirubicin) + cyclophosphamide to gemcitabine + cisplatin), docetaxel: 75 mg/m2 IV on day 1; doxorubicin: 50 mg/m2 IV on day 1 or epirubicin 75 mg/m2 IV on day 1; cyclophosphamide: 500 mg/m2 IV on day 1; gemcitabine: 1250 mg/m2 IV on day 1 and 8; cisplatin: 75 mg/m2 IV on day 1, dosing interval is 21 days.
2538285|NCT02641847|Active Comparator|High risk group B|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
2538290|NCT02641847|Other|Low risk group C|A(E)C x 4 cycles to T x 4 cycles (doxorubicin (epirubicin) + cyclophosphamide to docetaxel), doxorubicin: 60 mg/m2 IV on day 1 or epirubicin 90 mg/m2 IV on day 1; cyclophosphamide: 600 mg/m2 IV on day 1; docetaxel: 100 mg/m2 IV on day 1, dosing interval is 21 days.
2538349|NCT02641418|Other|Exercise|only 1 arm to trial
2538407|NCT02641093|Experimental|Pembrolizumab|Pembrolizumab in combination with standard of care surgery followed by radiation therapy with or without cisplatin
3202179|NCT00910793|Other|Inuvair|
3202180|NCT00910806|Experimental|TMC207, nevirapine|
2538538|NCT02640287|Experimental|Waldenström macroglobulinemia|Patients with diagnosis of Waldenström macroglobulinemia
2538539|NCT02640287|Experimental|Others B-cell malignancies|Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma
2538544|NCT02640287|Other|Healthy subjects|Control healthy subjects without B-cell malignancy
2538591|NCT02639871||healthy volunteers|31P-MR Spectroscopy and CEST for Validation of MRI/MRS methods
2538595|NCT02639871||HD presymptomatic individuals|General medical exam Clinical assessment with illness rating scales: Unified Huntington's Disease Rating Scale Total Motor Score (UHDRS) and Total Functional Capacity (TFC), 31P-MR Spectroscopy and CEST
2538597|NCT02639871||early affected HD patients|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
2538600|NCT02639871||Controls|General medical exam Clinical assessment with illness rating scales: UHDRS and TFC, 31P-MR Spectroscopy and CEST
2538634|NCT02639533|Experimental|Pregabalin|Pregabalin 150 mg PO single dose
2538639|NCT02639533|Placebo Comparator|Placebo|Placebo (a pill of same physical characteristics as the one used for the experimental arm, containing starch) PO single dose
3174069|NCT00619268|Active Comparator|B|
3174070|NCT00619268|Active Comparator|C|
3202181|NCT00910832|Experimental|Eductyl suppository|
3202182|NCT00910832|Placebo Comparator|Placebo suppository|
2539029|NCT02636933||59 prematurely born children|Lung function assessment of 59 prematurely born children (of both sex and 3-5 years old) attending as outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR)
2539032|NCT02636933||93 full-term born children|Lung function assessment of a Control group of full-term born children (N=93), recruited by a collaborative Pediatricians network within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
3174071|NCT00619281||Oberservation|600 consecutive patients undergoing cardiac surgery
3174072|NCT00619320|Experimental|Safer Sex Skill Building (SSB)|Safer Sex Skill Building Intervention (SSB) A five session behavioral intervention focused on HIV/STD prevention and safer sex negotiation skills
2539155|NCT02636322|Experimental|Arm I (RLI WITH EPOCH)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive etoposide IV over 24 hours on days 1-4, prednisone PO QD on days 1-5, vincristine sulfate IV over 24 hours on days 1-4, doxorubicin hydrochloride IV over 24 hours on days 1-4, and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
2539157|NCT02636322|Experimental|Arm II (RLI WITH R-CHOP)|"SMART START: Patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~After SMART START therapy, patients receive rituximab IV over 4-6 hours on day 1, lenalidomide PO QD on days 1-10, and ibrutinib PO QD on days 1-21. Patients also receive prednisone PO QD on days 1-5, vincristine sulfate IV over 1 hour on day 1, doxorubicin hydrochloride IV over 1 hour on day 1, and cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity."
2539346|NCT02634970|Experimental|Ranibizumab at 0.5 mg|Single arm, intravitreal injection
2539383|NCT02634541|Active Comparator|DMARD-naive|Sulfasalazine will be given as the initial therapy.
2539388|NCT02634541|Experimental|Post-sulfasalazine|Sulfasalazine contraindicated or not efficient, adalimumab will be given as the initial therapy.
2539429|NCT02634268|Active Comparator|Lifestyle intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
3174073|NCT00619320|Active Comparator|2|one group session focused on standard HIV/STD education
3174074|NCT00619333|Other|1|
3174075|NCT00619346|Placebo Comparator|1|Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
3174076|NCT00619346|Active Comparator|2|Pafuramidine maleate, 100 mg tablet, BID X 14 days
3174077|NCT00619372|Experimental|B|Low dose OKT3 with GC
3174078|NCT00619372|Experimental|C|Mid dose OKT3
3174079|NCT00619372|Experimental|D|Mid OKT3 dose with GC
3174080|NCT00619372|Experimental|E|High dose OKT3
3174081|NCT00619372|Experimental|F|GC only
3174082|NCT00619372|Experimental|A|Low dose OKT3
3174083|NCT00619398|Active Comparator|1|
3174084|NCT00619398|Experimental|2|
3174085|NCT00619411|Experimental|I|
2538254|NCT02642263|No Intervention|Oxytocin|Oxytocin 20 IE in 500 ml G Na intravenous infusion over 6 hours (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%), Sintetica-Bioren, Switzerland, after birth of the baby. For blinding purposes a 3ml NaCl 0.9% syringe is administered intravenously after birth of the baby as well.
2538256|NCT02642263|Experimental|Carbetocin|100 mcg of Carbetocin, Ferring, Switzerland, as iv administration after birth of the baby. For blinding purposes an intravenous infusion of 500 ml G Na (GlucoSalin 2:1; 2/3 glucose 5%+1/3 NaCl 0.9%) is administered over 6 hours.
2538299|NCT02641782|Active Comparator|Standard Arm|Standard IL-2 i.v. together with antibody ch14.18, GM-CSF and retinoic acid
2538302|NCT02641782|Experimental|Experimental Arm|IL-2 s.c. together with antibody ch14.18, GM-CSF and retinoic acid
2538367|NCT02641288|Experimental|Ropivacaine irrigation|Using a standard irrigation device, 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
2538374|NCT02641288|Placebo Comparator|Normal saline irrigation|Using a standard irrigation device, 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
2538433|NCT02640937||Orthopaedic device related infections|"Inclusion Criteria:~infections after fracture fixation or prosthetic joint surgery~Affected bone or joint: Long bones of the lower extremity; hip joint, knee joint;~Bacterial growth of S. epidermidis at the site of interest~Written consent~Age: 18 and older"
2538473|NCT02640638|Experimental|CenteringPregnancy group prenatal care|Pregnant women who were randomized to receive CenteringPregnancy group prenatal care
2538474|NCT02640638|No Intervention|Traditional individual prenatal care|Pregnant women who were randomized to receive traditional individual prenatal care
2538528|NCT02640313|Experimental|18F-choline PET-MR imaging|"Intervention: 18F-choline PET-MR imaging.~Drug: 18F-choline, dosis 4 MBq/kg body-weight (maximum 360 MBq), administered intravenously as a single dose.~Procedure: dynamic and static 18F-choline PET-MR."
2538576|NCT02639962||NSTEMI|patients hospitalized with NSTEMI diagnosed according to the national Danish guidelines, and are scheduled to coronary angiography.
2538577|NCT02639962||patients with stable angina pectoris|Patients in this group have stable angina symptoms and had verified plaques by earlier CAG or Cardiac CT
2538644|NCT02639598|Experimental|flunarizine|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 5 mg/day flunarizine once daily in the first week, followed by 10 mg/day flunarizine in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
2538648|NCT02639598|Active Comparator|topiramate|"This study consisted of two periods: a prospective baseline screening period lasting up to 2 weeks (week -2 to week 0, T0), and a treatment period lasting 8 weeks after enrollment (weeks 0-8, T1-T4).~The treatment phase consisted of a 2-week titration period (T1) and a 6-week maintenance period (T2-T4). During the titration period, subjects were given 25 mg/day topiramate once daily in the first week, followed by 50 mg/day topiramate in divided doses (twice daily) in the second week. When subjects could not tolerate this target dose, the initial dose was continued through T4."
2538694|NCT02639104|Experimental|Cervical postural related neck pain|Patients recruit in this group who has a neck pain without radiculopathy. If the patient examination shows neurologic deficits, this patient will exclude in this study. All patients will undergo lateral cervical spine spot radiography and serratus anterior needle electromyography. Cervical segmental angle measurements will be done in all patients.
2538696|NCT02639104|Sham Comparator|Control group|The healthy volunteers recruit in this group. All inviduals will undergo lateral cervical spot radiography and serratus anterior needle electromypography
2538775|NCT02638831|Experimental|Ketorolac Tromethamine|Ketorolac 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
2538779|NCT02638831|Active Comparator|Ketoprofen|Ketoprofen gel 2.5% for external application. Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
2538810|NCT02638298|Experimental|NPWT dressing|
2538816|NCT02638298|Placebo Comparator|Standard dry gauze dressing|
3174086|NCT00619424|Experimental|pazopanib + erlotinib|Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
2538926|NCT02637661||Initial AMI|To study the sensitivity, specificity, positive predictive value, and negative predictive value of different earlobe crease as risk factors of AMI
2538934|NCT02637661||No coronary heart disease|To study the characteristics of earlobe crease
2539110|NCT02636673||Robotic-assisted sigmoid resection|Patient that have undergone robotic-assisted sigmoid resection for benign or malignant disease between 2010 and 2015
2539111|NCT02636673||Laparoscopic sigmoid resection|Patient that have undergone laparoscopic sigmoid resection for benign or malignant disease between 2010 and 2015
2539131|NCT02636231|Active Comparator|IMRT and concurrent Endostar|"IMRT and concurrent Endostar (Endostatins) to treat locally recurrent NPC patients; Endostar is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.~IMRT is to give GTV 60Gy in 27 fractions."
2539133|NCT02636231|Experimental|IMRT alone|IMRT alone to treat locally recurrent NPC patients. IMRT is to give GTV 60Gy in 27 fractions.
2539243|NCT02635906|Experimental|2 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for two hours
2539245|NCT02635906|Active Comparator|4 hours|after coronary arteriography or coronary angioplasty, will be removal the introducer and the patient will be in bed rest for four hours
2539294|NCT02635295|Experimental|Mobile cooperation|Nursing student - nurse teacher mobile cooperation during the clinical practicum.
2538267|NCT02642094|Experimental|The effect of short-term rapamycin treatment|Subjects will be given a low dose of rapamycin at 2 mg/day for 5-7 days of treatment. A surgical specimen will be taken 3-7 days after the last dose of rapamycin. The specimens will be evaluated for lesion size, nuclear grade, presence of necrosis in each patient's core biopsy and surgical specimens, as well as IHC (ImmunoHistoChemistry) for biomarkers including p16, COX2 (cyclooxygenase-2), and Ki-67. Specimens will also be tested for rapamycin treatment on the properties of mammary stem/progenitor cells as another biomarker for gauging the efficacy of rapamycin treatment.
2538309|NCT02641717|Experimental|All subjects|All patients enrolled in this study will self-collect a vaginal swab (experimental) then have a physician collected vaginal swab (gold standard)
3202183|NCT00910884||Arm I|Patients receive oral GRAS supplements daily for 12 months or as possible within the patient's parameters.
3202184|NCT00910884||Arm II|Patients do not receive supplements.
3202185|NCT00910897|Active Comparator|Velcade-Dexamethasone|
2538472|NCT02640586|Experimental|Assessing response with MRI|"Preoperative chemo-radiotherapy as standard treatment. Neoadjuvant therapy (long course intensity modulated radio-chemotherapy, GTV 50.6Gy, totally 22 fractions; Capecitabine 825mg/m2 /bid by oral administration).~Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.~All patients are scheduled to receive total mesorectal excision surgery 12-14 weeks after the completion of preoperative chemo-radiotherapy."
2538517|NCT02640274|Experimental|Intervention group|The intervention is an individual nurse-led counselling programme in addition to usual care.
2538524|NCT02640274|Other|Control group|usual care
2538590|NCT02639988||rheumatoid arthritis and type 2 diabetes|
2538596|NCT02639988||osteoarthritis and type 2 diabetes|
3202186|NCT00910897|Active Comparator|Velcade-Thalidomide-Dexamethasone|
3202187|NCT00910936|Experimental|Intervention|
2538771|NCT02638727|Active Comparator|Drug Arm|This group treat with L-Citrulline (3 grams per day)
2538772|NCT02638727|Placebo Comparator|Placebo Arm|this group treat with placebi every day
2538849|NCT02638142||Continuous Furosemide Infusion|continuous intravenous furosemide infusion
2538853|NCT02638142||Intermittent Furosemide Infusion|bolus intermittent intravenous furosemide infusion
2538924|NCT02637622||Best-Worst Scaling (Case 2)|Preference elicitation survey using a best-worst scaling method.
2538933|NCT02637622||Discrete Choice Experiment|Preference elicitation survey using a discrete choice experiment method.
2538982|NCT02637284|Experimental|Intervention 1a (cohort 1)|Single dose of 1 oral tablet of PCO-02 containing 1 mg of Bepecin (12 subjects)
2538984|NCT02637284|Experimental|Intervention 1a (cohort 2)|Single dose of 3 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
2538986|NCT02637284|Experimental|Intervention 1a (cohort 3)|Single dose of 6 oral tablets of PCO-02 containing 1 mg of Bepecin (12 subjects)
2538988|NCT02637284|Placebo Comparator|Control group 1a (cohort 1)|Single dose of 1 oral tablet of PCO-03 as placebo (2 subjects)
2538992|NCT02637284|Placebo Comparator|Control group 1a (cohort 2)|Single dose of 3 oral tablets of PCO-03 as placebo (2 subjects)
2538993|NCT02637284|Placebo Comparator|Control group 1 a (cohort 3)|Single dose of 6 oral tablets of PCO-03 as placebo by mouth (2 subjects)
2538994|NCT02637284|Experimental|Intervention 1b|Multiple dose regime of 3 oral tablets of PCO-02 containing 1 mg Bepecin every 8 hours during 2 weeks (36 subjects)
2538995|NCT02637284|Placebo Comparator|Control group 1b|Multiple dose regime of 3 oral tablets of PCO-03 as placebo every 8 hours during 2 weeks (6 subjects)
2539146|NCT02636335|Experimental|Bright Light|"8 a.m. study participants will be exposed to Bright Light (4500 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
2539148|NCT02636335|Experimental|Control|"8 a.m. study participants will be exposed to a Control Light Condition (230 lx) Phillips Energy Light HF3319 for 30 minutes prior and during a 30 minute lasting exercise test with self-chosen exercise intensity on a bicycle ergometer.~The light exposure and time-trial will be performed in three repetitive exercise sessions 48h apart."
2539192|NCT02635958||Group 1|BMI 18.5 to 24.9
2539195|NCT02635958||Group 2|BMI 25 to 29.9
2539198|NCT02635958||Group 3|BMI 30 to 34.9
2539199|NCT02635958||Group 4|BMI ≥ 35
2539240|NCT02635633|Experimental|continuous thetaburst stimulation|Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
2539259|NCT02635334|Experimental|Montelukast 10 mg daily for 8 weeks|Study subjects will take montelukast 10 mg orally daily for 8 weeks
2539262|NCT02635334|Placebo Comparator|Placebo daily for 8 weeks|Study subjects will take placebo orally daily for 8 weeks
2539336|NCT02635061|Experimental|ACY-241 in combination with nivolumab|
2539380|NCT02634567|No Intervention|Treatment as Usual|This group will not any training with the Cogmed training program.
2539382|NCT02634567|Experimental|Training Group|This group will receive intervention with the Cogmed training program and coach over a period of 5 weeks.
3202188|NCT00910936|No Intervention|Control|
2539567|NCT02633449|Experimental|cognitive behavioral therapy + tDCS|Group cognitive behavioral therapy combined with tDCS
2539577|NCT02633449|Placebo Comparator|cognitive behavioral therapy|Group cognitive behavioral therapy only
3202189|NCT00910949||Painfree|Thoracotomy patients without chronic pain
3202190|NCT00910949||With Pain|Thoracotomy patients with chronic pain
3202191|NCT00910975|Active Comparator|Standard of care|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment is given for 24, 48 or 72 weeks depending on the time point (week 4, 12 or 24) when HCV RNA becomes undetectable by the Cobas Taqman assay. If HCV RNA has not declined 2 logs by week 12 or is detectable at week 24, treatment is stopped.
3202192|NCT00910975|Experimental|Tailored treatment|Treatment with Pegasys 180 µg/week and ribavirin 1000/1200 mg per day. Treatment duration is flexible, 24-72 weeks, depending on the time point when the HCV RNA level is calculated to be 1 copy/mL. If the decline between day 14 and 28 is poor, treatment is stopped after 5 weeks.
3202193|NCT00911001||Group 1|
2538272|NCT02642224|Experimental|Social work intervention|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
2538306|NCT02641704||Multidisciplinary program|Multidisciplinary program designed and administered by the Competence- and Integration Center in Sonderborg Municipality
3202194|NCT00911014||Vesicovaginal fistula repair|Women undergoing repair of vesicovaginal fistula
3202195|NCT00911027|Experimental|SonoVue guided biopsy|
3202196|NCT00911027|Other|Systematic biopsy|
3202197|NCT00911066|Experimental|MLN4924|
3202198|NCT00911066|Experimental|Azacitidine|
3202199|NCT00911079|Experimental|Hyperthermia with HDR brachytherapy|Hyperthermia will be delivered within approximately 2 hours of (HDR) brachytherapy associated with the implant session
3202200|NCT00911105||Patients with multiple myeloma|Patients with multiple myeloma receiving second line therapy or higher.
2538773|NCT02638610|Experimental|Sensation measurement|patients with eyelid pathology going through eyelid surgery.
2538801|NCT02638376|Active Comparator|KXL treatment only|
2538803|NCT02638376|Active Comparator|KXL and topography-guided PRK|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)
2538851|NCT02637986|Experimental|ARM A - suffered from one episode of UTI|Women who suffered from one episode of UTI during pregnancy before recruitment
2538856|NCT02637986|Placebo Comparator|ARM A - suffered from one episode of UTI - placebo|Women who suffered from one episode of UTI during pregnancy before recruitment
2538860|NCT02637986|Experimental|ARM B -suffered from more than one episode of UTI|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
2538863|NCT02637986|Placebo Comparator|ARM B -suffered from more than one episode of UTI - placebo|women who suffered from more than one episode of UTI or one episode of pyelonephritis during pregnancy before recruitment
2538928|NCT02637700|Experimental|Intravenous Immunoglobulin|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive intravenous immunoglobulin.
2538935|NCT02637700|Placebo Comparator|Placebo (Saline 0.9%)|Patients with skin biopsy proven idiopathic Small Fiber Neuropathy in this arm will receive placebo (saline 0.9%).
2539016|NCT02637245||Patients with Diabetic Macular Edema|Patients with Diabetic Macular Edema. There will be no intervention in this cohort, only observation of standard of care.
2539068|NCT02636829|Experimental|Multiple Sclerosis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
2539074|NCT02636829|Experimental|Rheumatoid Arthritis patients|"Patients (Multiple Sclerosis, Rheumatoid Arthritis) will be recruited during specialized consultations or hospital admissions for monitoring their chronic disease at the University Hospital of Nimes and will be divided into two distinct groups.~Intervention: QALCIMUM questionnaire~Intervention: Determination of calcium intake by a dietician interview"
2539123|NCT02636530|Experimental|Ground Reaction Forces|Participants will have an individualized exercise program that includes walking, jogging, stair climbing, and box jumping.
2539125|NCT02636530|Experimental|Joint Reaction Forces|Participants will have an individualized exercise program that includes weight lifting and aerobic rowing.
2539154|NCT02636140|Experimental|Light|Randomized amount and color of light
2539205|NCT02635971|Experimental|TAI chemotherapy|Patients in this arm will receive transcatheter arterial infusion of chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
2539209|NCT02635971|Active Comparator|Chemotherapy|Patients in this arm will receive intravenous chemotherapy with gemcitabine and oxaliplatin every 2 weeks, until progression of disease or adverse effects leading to treatment termination. Each 4-week period is one cycle of treatment.
2539274|NCT02635412|Placebo Comparator|Scheduled delivery at 34 weeks|Scheduled delivery at 34 weeks (range 33 weeks 5 days to 34 weeks 3 days)
2539281|NCT02635412|Active Comparator|Scheduled delivery at 36 weeks|Scheduled delivery at 36 weeks (range 35 weeks 5 days to 36 weeks 3 days)
2539310|NCT02635074|Experimental|Treatment (ibrutinib, idarubicin, cytarabine)|"INDUCTION: Ibrutinib daily on days 1 to 21, idarubicin intravenously (IV) over 15 minutes on days 1 to 3 and cytarabine IV continuously on days 1 to 4.~CONSOLIDATION: Patients achieving CR or CRi may receive ibrutinib daily on days 1 to 21, idarubicin IV over 15 minutes on days 1 to 2 and cytarabine IV continuously on days 1 to 3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients maintaining a CR/CRi may receive ibrutinib daily on days 1 to 28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
2539358|NCT02634749|Experimental|Nordic diet|The participant in the Nordic diet group will experience three interventions: a) a systematic introduction of taste portions, b) Protein reduced complementary foods (milk cereal drinks, porridge and baby milk with reduced protein content), and c) homemade and industry manufactured main meals with a predominance of Nordic ingredients.
2539400|NCT02634528|Experimental|Julphar Insulin N|Julphar Insulin N, human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
2539432|NCT02634268|No Intervention|Usual Care|Participants continue with usual diet and exercise activities as they desire
3202201|NCT00911118|Experimental|Radiation|Patients enrolled in the study will undergo image-guided, intensity-modulated radiotherapy using the same equipment, techniques, and treatment-planning procedures as currently practiced as MSKCC. MSKCC patients will have the option of continued follow-up through MSKCC's established Prostate Survivorship Clinic for an indefinite period of time, meaning patients enrolled in the protocol will be encouraged to remain at MSKCC for life-long follow-up after their treatment. The standard assessments obtained in the Survivorship Clinic will not be altered. All protocol relevant data collected at these visits through month 60 will be used for protocol analysis.
3202202|NCT00911131|Active Comparator|Screening esophagoduodenoscopy (EGD)|"EGD will be performed utilizing conscious sedation. During EGD, the endoscopist will capture pictures of the esophageal body, Z-line, lower esophagus and proximal gastric folds. Grading of esophageal varices will be performed by all investigators using the Italian Liver cirrhosis project.~Patients who are found to have small grade varices and meet the inclusion and exclusion criteria will be enrolled in the study."
2538408|NCT02640989|Experimental|Group 1|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Anflu®"
2538411|NCT02640989|Experimental|Group 2|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, VAXIGRIP"
2538414|NCT02640989|Active Comparator|Group 3|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Seasonal trivalent influenza vaccine, Fluarix"
2538441|NCT02640729|Experimental|Nelotanserin|Nelotanserin 40mg then nelotanserin 80 mg
2538444|NCT02640729|Placebo Comparator|Placebo|Placebo
3202203|NCT00911131|Active Comparator|Capsule Endoscopy|The capsule endoscope will be swallowed by the participant with 100cc of water and simethicone in the supine position. Recording is done for 2 minute in this position and then the head will be elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient will sip10cc of water and after 15 seconds, they will sit upright and sip water again. They can then walk and resume normal activity for 15 minutes. The videos will be reviewed and graded by a gastroenterologist experienced with capsule endoscopy and will be blinded to the patient's clinical and procedural history as well as the most recent EGD. The varices will be graded using the Given Imaging software that grades varices as no varices (C0), small varices or < 25% of esophageal circumference (C1), and large varices or > 25% of esophageal circumference (C2).
3202204|NCT00911131|Active Comparator|Capsule Endoscopy with abdominal binder|Before swallowing the capsule endoscope, an inflatable girdle is wrapped around the waist above the umbilicus and held in place by a an abdominal binder. The pressure is increased by 10mmHg for 10 minutes. The PillCam ESO is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
2538560|NCT02639936||Immunocompetent controls|Control persons without immunodeficiency with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538562|NCT02639936||Solid organ transplant recipients|Patients after solid organ transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538564|NCT02639936||Stem cell transplant recipients|Patients after stem cell transplantation with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538566|NCT02639936||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538567|NCT02639936||Patients with chronic renal failure|Patients with chronic renal failure with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538568|NCT02639936||Individuals with HIV infection|Individuals with HIV infection with and without active tuberculosis, with and without risk factors for prior exposure with M. tuberculosis
2538672|NCT02639585|Experimental|Treatment arm|Daclinza and Sunvepra
3202205|NCT00911183|Experimental|Arm I (R-COP regimen)|Patients receive rituximab IV, cyclophosphamide IV, and vincristine sulfate IV on day 1. Patients also receive oral prednisone on days 1-5 and filgrastim subcutaneously (SC) on days 8-14 or pegfilgrastim SC on day 2. Treatment repeats every 21 days for at least 3 courses.
2538782|NCT02638571|Sham Comparator|Usual education|Households in the control clusters (kebeles) will receive usual nutrition education from Health extension workers, about complementary foods, over 9 months.
2538784|NCT02638571|Experimental|Enhanced Education|Additional education sessions from Health extension workers (HEWs) trained on use of pulses for complementary foods (CF). HEWs provide nutrition education programs and counseling about pulse-cereal mix complementary foods, over 9 months.
2538811|NCT02638272|Other|spine surgery|The objective was to compare the outcomes of radical debridement versus no debridement under different surgical procedures for the treatment of thoracic and lumbar tuberculosis.
2538841|NCT02638038|Experimental|Oral INT 131 3 mg|Oral INT-131 Double blind study
2538842|NCT02638038|Experimental|Oral INT-131 1 mg|Oral INT-131 Double blind
2538843|NCT02638038|Placebo Comparator|Placebo|Oral placebo Double blind
2539017|NCT02637102||Patients undergoing cardiac or vascular surgery|
2539075|NCT02636842|Other|Location|Deltoid or Gluteal Muscle
2539134|NCT02636218|Active Comparator|0.9% NaCl control|Normal saline
2539136|NCT02636218|Experimental|Ketamine|Anesthetic
2539183|NCT02635932|Experimental|Functional Splint group|Patient will be using the functional splint during their activity daily life
2539184|NCT02635932|Active Comparator|Night Splint group|Patients will use the night splint during the sleep time
2539238|NCT02635698|Experimental|Intervention group, Optifast|OPTIFAST, medically supervised weight-management program
2539242|NCT02635698|Active Comparator|Control group, Low-energy, low-fat|Food-based program, current standard of care for weight management
2539267|NCT02635269|Experimental|Sugar|The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
2539425|NCT02634424|Experimental|MyPKFiT|Personalized prophylaxis : Treatment is adjustment according to PK modeling
2539444|NCT02634060|Experimental|Home Based Fecal Calprotectin|"IBDoc® at week 0, 4 and 8 using smartphone. All material will be provided by the third party The same stool sample of the home base faecal calprotectin will be brought to the hospital and used for ELISA faecal calprotectin measurement at week 0, 4 and 8 for UC patients and week 0 and 4 for CD patients.~IBDoc® results will be forwarded to the patient and the health care professional."
2538348|NCT02641210|Experimental|Periodontal Treatment|The experimental group underwent nonsurgical periodontal therapy, performed by a single professional who performed the scaling and root planing procedures under local anesthesia using an ultrasonic device and Gracey and mini Gracey curettes, with Robson polishing brush and prophylactic paste. This therapy was performed in two sessions at seven day intervals, with no time limit, according to the needs of each periodontal condition. In each session, subjects received oral hygiene instruction (OHI) for use of toothbrushes for the modified Bass technique, dental floss and other complementary means (interdental brush, single tuft brush, electric toothbrush, etc.) when necessary. Supportive periodontal therapy was performed in 30, 60 and 90 days. Albendazole administration.
2538351|NCT02641210|No Intervention|No Periodontal Treatment|Individuals in the control group underwent only the polishing of tooth surfaces with Robson brush and prophylactic paste fine-grained and topical fluoride application. After 90 days, they were reassessed with the same parameters of clinical examination of the baseline.
2538406|NCT02641028|Experimental|CERC-501|Administered orally once daily, 15mg daily, 8 days.
2538409|NCT02641028|Placebo Comparator|Placebo|Administered orally daily, 8 days.
2538438|NCT02640768|Experimental|educational training|educational training
2538439|NCT02640768|No Intervention|no educational training|no educational training wards
2538486|NCT02640521|No Intervention|Control Parents|
2538491|NCT02640521|Active Comparator|Treatment Parents|Chart reminders (paper or electronic medical records, depending on clinic wishes) to prompt providers to ask about in home smoking at every medical visit; establishing a New York State Quit line referral system in the pediatric practice; and amending the training curriculum for providers and the patient education materials that are part of a provider toolkit, to focus on the negative impact of second hand smoke (SHS) on their children,and specifically, asthma outcomes.
2538512|NCT02640209|Experimental|Arm 1|
2538561|NCT02640014|Experimental|Study 1: Milk OIT follow up|Follow up on patient with severe milk allergy how have participated to milk OIT.
2538563|NCT02640014|No Intervention|Study 1: Follow up|Follow up on patient with severe milk allergy how have not participated to milk OIT.
2538663|NCT02639520|Active Comparator|Group Canephron® N|Canephron® N & fosfomycin trometamol-placebo
2538667|NCT02639520|Active Comparator|Group Fosfomycin Trometamol|Canephron® N-placebo & fosfomycin trometamol
3168132|NCT00547196|Experimental|Regimen II (age < 50 and unable to tolerate FTBI)|Patients receive a test dose of busulfan on day -10 and then dose adjusted busulfan IV 3-4 times daily on days -9 to -6, melphalan IV on days -5 and -4, and fludarabine phosphate IV on days -5 to -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3168133|NCT00547196|Experimental|Regimen III (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -8 to -4 and cyclophosphamide IV over 2 hours on day -3 and undergo TBI (single dose) on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
2538750|NCT02638688||2D ultrasound|2D-US measurements are the most accurate method for measuring fibroid volumes
2538752|NCT02638688||3D ultrasound|3D-US measurements are the most accurate method for measuring fibroid volumes
2538755|NCT02638688||postoperative|actual volume using change in water path measurements are the most accurate method for measuring fibroid volumes
2538804|NCT02638480|No Intervention|Control|The control subjects will be treated with only the current SOC including NSAIDs and physical therapy.
2538807|NCT02638480|Experimental|Experimental|The experimental subjects will be treated with current SOC and will also use a kneeMD splint 3 times a day for 20 minutes per session
2538873|NCT02637830|Experimental|Fluoride varnish and fluoride toothpaste|Application of fluoride varnish (Duraphat) at the begining of the study. Application of fluoride toothpaste (Crest) twice a day for 3 days.
2538878|NCT02637830|Placebo Comparator|placebo toothpaste|Application of placebo toothpaste twice a day for 3 days
2538879|NCT02637830|Active Comparator|Fluoride toothpaste|Application of fluoride toothpaste (Crest) twice a day for 3 days
2538923|NCT02637674|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF
2538997|NCT02637310|Experimental|N02RS1 1200mg|Combination of Broussonetia spp and Lonicera spp
2538999|NCT02637310|Placebo Comparator|Placebo|sugar pill
3202206|NCT00911183|Experimental|Arm II (R-COPY regimen)|Patients receive rituximab, cyclophosphamide, vincristine sulfate, prednisone, and filgrastim or pegfilgrastim as in arm I. Patients also receive liposome-encapsulated doxorubicin citrate IV on day 1. Treatment repeats every 21 days for at least 3 courses.
3202207|NCT00911196||Group A|
3202208|NCT00911209|Experimental|Intervention|The Intervention group at each session will receive information on Heart healthy diet, lifestyle recommendations and diet and exercise counseling with a dietitian in order to achieve at least 7% weight loss (for example a person weighing 200 pounds will be encourage to lose at least 14 pounds).
2539193|NCT02635659|Experimental|Encapsulated nutrients|The investigational product will be a shot of sterile water (80 ml) mixed with a total of 21.6 grams encapsulate consisting of 13 grams of sucrose (60% of the total) encapsulated whey protein (<5% of total). On top of the encapsulated sucrose, 6.44 grams of casein (30% of total) encapsulated in whey protein (<5% of total) will be mixed with the shot of water. The micro-beats of encapsulated sucrose and casein are 150 µm and the ratio active (sucrose and casein) : whey is 95:5%, this means that the shot of water contains 13 grams of encapsulated sucrose, 6.44 grams of encapsulated casein and 1.3 grams of whey protein required for the encapsulation.
2539282|NCT02635360|Experimental|Concurrent to chemoradiation|Subjects will receive standard chemotherapy weekly and 4-6 fractions of brachytherapy radiation for 5-6 weeks. While subjects are receiving chemotherapy and radiation, they will also receive the study drug, pembrolizumab.
2538370|NCT02641145|Active Comparator|Remission AL cardiac amyloidosis|25 individuals with light chain systemic amyloidosis with cardiac involvement and plasma cell dyscrasia in hematological remission (complete hematological remission or very good partial response-differential free light chain (dFLC)<40 mg/dL for > 1 year prior to enrollment) will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI scan of the heart as well as a heavy metal analysis of the blood at baseline.
2538376|NCT02641145|Experimental|Active AL Pre-CMP|36 individuals with light chain systemic amyloidosis with active plasma cell dyscrasia and without cardiac involvement will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline. At 6 months they will undergo a research MRI of the heart and at 12 months they will have a clinical follow up. Subjects with contraindications to Cardiac MRI or gadolinium contrast may still be eligible for study participation.
2538381|NCT02641145|No Intervention|Multiple Myeloma Controls|25 individuals with diagnosis of multiple myeloma without concomitant amyloidosis by standard criteria will undergo urine and blood testing only.
2538383|NCT02641145|Experimental|Heart Failure|10 individuals with diagnosis of heart failure without amyloidosis by standard criteria will undergo a research F-18 florbetapir PET, C-11 acetate PET, and MRI of the heart, as well as a heavy metal analysis of the blood at baseline..
2538442|NCT02640833|Experimental|Duvelisib+Venetoclax|
3202209|NCT00911209|No Intervention|No Intervention|The standard of care group will receive information on Heart healthy diet at baseline visit and will return to a final visit about 28 weeks later.
3202210|NCT00911222||antiemetic treatment|epidemiological registry
3202211|NCT00911235|Experimental|Fesoterodine Alone|Reference treatment
2538602|NCT02639689|Experimental|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
2538662|NCT02639468|Experimental|Tomographie par impédance électrique|Tomographie par impédance électrique
2538719|NCT02639091|Experimental|BAY 94-9343 + Pemetrexed + Cisplatin|Investigating the combination of anetumab ravtansine (BAY 94-9343) with Pemetrexed (500 mg/m2) and Cisplatin (75 mg/m2) in Part 1 (dose escalation cohorts) and Part 2 (two MTD expansion cohorts)
2538746|NCT02638675|Experimental|Wellness program, accelerometer, incentives|During the intervention period (weeks 1 to 12), intervention participants will be eligible to earn daily reward points contingent on step count goal achievement. Intervention participants will earn 100 reward points (i.e. $1) for each day that specific step count goals are reached. During weeks 13 to 24, participants will no longer receive daily reward points for completing specific step count goals.
2538747|NCT02638675|Active Comparator|Wellness program and accelerometer|During the 24 week trial, control participants will receive no additional incentives when step count goals are reached.
3202212|NCT00911235|Other|fesoterodine plus fluconazole|Test treatment
3202213|NCT00911248|Experimental|PTC299|PTC299 administered at 100 mg/dose twice per day
3202214|NCT00911261|Experimental|Single Arm|
2538869|NCT02637843|Active Comparator|Slender arm|Uses the terumo slender sheath for radial angiography or angioplasty
2538876|NCT02637843|No Intervention|Standard arm|Uses the terumo standard sheath (Routine) for radial angiography or angioplasty
2538904|NCT02637713|Experimental|Radiofrequency Energy to the Lower Esophageal Sphincter (LES)|All patients that have undergone sleeve gastrectomy as treatment for obesity that have developed severe reflux symptoms will be treated with Stretta (FDA approved device for the management of GERD) and evaluated prospectively for resolution/improvement of reflux symptoms.
2538925|NCT02637414|No Intervention|Control App|Initially this control group will have access to a Control App and after 8 weeks this goup will receive the intervention (Flourishing App Program).
2538931|NCT02637414|Experimental|Flourishing App Program|This group will receive the intervention Flourishing App Program and after that it will not receive any other intervention.
2538998|NCT02637362|Active Comparator|Ankle + Sham metatarsal|Ankle block + sham metatarsal block
2539000|NCT02637362|Active Comparator|Ankle + Metatarsal|Ankle block + metatarsal block
2539001|NCT02637362|Active Comparator|Metatarsal + sham ankle|Metatarsal block + sham ankle block
2539030|NCT02636959|Active Comparator|high volume saline irrigation (HVSI)|High volume nasal spray, NeilMed® Sinus Rinse, is a high saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
2539033|NCT02636959|Active Comparator|low volume saline irrigation (LVSI)|Low volume nasal spray, Salinex Rinse, is a low saline nasal rinse that is a safe, nonpharmacologic treatment. Randomized participants will be asked to use the rinse for one month (twice daily) by following the manufacturer's guidelines and use of the squeeze bottle provided. Preoperative and one month Postoperative sinus surgery, the participants will complete subjective questionnaires and at one-month after surgery, endoscopic sinonasal photos will be taken. These data will be used to assess the quality of postoperative improvements after treatment.
2539103|NCT02636647|Active Comparator|FMT|Fecal transplant via enema once
2539104|NCT02636647|No Intervention|No treatment|No transplant performed
3202215|NCT00911287|Experimental|Single Arm|
3202216|NCT00911313|Experimental|Letrozole|
3202217|NCT00911313|Active Comparator|Metformin-CC|
2539305|NCT02635087||high risk group|"the miRNA tool predict this group of patients as high risk"
2539352|NCT02634840|Experimental|Surgical intervention|"Patients receiving our modified bilateral sagittal split osteotomy procedure during orthognathic surgery, intervention arm in prospective cohort study"
3202218|NCT00911339|Active Comparator|Atorvastatin 10 mg|
3202219|NCT00911339|Active Comparator|Atorvastatin 80 mg|
3202220|NCT00911352|Experimental|Frozen gel glove (Elasto-Gel Mitten)|Cryotherapy hand
2538419|NCT02640976|Active Comparator|Good responders|"This group will include women who produced (5 or more oocytes) after COH.~Intervention:~fixed daily morning dose of Human menopausal gonadotrophin (HMG) Merional® intra-muscular injection ,starting on cycle day 2 and will be maintained for 9-11 days according to each individual ovarian response,at a dose of (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml~On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg Cetrotide® will be introduced as daily subcutaneous injections and continued till the day of ovulation triggering.~When at least 3 follicles will reach 17 mm in diameter, ovulation will be triggered by a single intra-muscular injection of 10,000 IU of Human chorionic gonadotrophin (hCG) Choriomon®."
2538456|NCT02640651|Experimental|DC-Stimulator (PLUS version)|For tDCS stimulation, anodal stimulation of the right dorsolateral prefrontal cortex will be performed for twenty minutes at 2mA. The current will be applied by a battery-driven tDCS stimulator via a pair of saline-soaked sponge electrodes (25 cm2 surface). The anodal electrode will be placed on the scalp at the F4 position according to the international 10-20 EEG coordinate system. 20 minute tDCS sessions will be conducted ten times over a two week period
2538483|NCT02640469|Active Comparator|Chlorhexidine with water rinse|This is a traditional method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2538484|NCT02640469|Experimental|Chlorhexidine without water rinse|This is an experimental method of disinfection. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2538487|NCT02640469|Active Comparator|Chlorhexidine + sterillium hand rub|This is a standard method of disinfection used at NYU Hospital for Joint Disease. Following disinfection protocol, each subject will have hand cultured three times using a cotton swab culture and sent to microbiology for processing.
2538558|NCT02640183|Experimental|Group A (EMLA)|3 mL EMLA® cream 5% will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
2538559|NCT02640183|Placebo Comparator|Group B (Placebo)|3 mL of ultrasonic gel will be applied in the endocervical canal 7 min before procedure, with a 5-mL needleless syringe. A subsequent application will be made with a swab at ectocervix level, using a vaginal speculum, which will be then withdrawn.
2538615|NCT02639728|Experimental|Regular coffee|Will receive a 4oz cup coffee, three times daily (at 8:00, 12:00, and 16:00 hours)and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
2538617|NCT02639728|Experimental|Decaffeinated coffee|Will receive a 4oz cup of decaffeinated coffee (at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
2538619|NCT02639728|Experimental|Warm water|Will receive a 4oz cup of warm water at 8:00, 12:00, and 16:00 hours) and instructed to consume the entirety of its liquid contents. This liquid consumption will begin on the morning of POD #1 at 8:00 hours. Duration of experimental treatment will last until first flatus or bowel movement or 7 days, whichever comes first.
3202221|NCT00911352|No Intervention|No frozen glove therapy|Usual care
2538687|NCT02639195||Treatment, retrospective|Retrospective analysis on patients treated with manual physical therapy in quality of life outcomes as measured by pre and post treatment questionnaires. Chart review.
2538688|NCT02639195||Untreated control|Prospective data collection via questionnaire of subjects with a history of small bowel obstruction in an observational manner. No treatment is performed.
3202222|NCT00911365|Placebo Comparator|normal saline|
3202223|NCT00911365|Experimental|autologous mesenchymal stem cells|
3202224|NCT00911378|Active Comparator|Pressure support ventilation|Patients in this arm are weaned by gradual reduction of pressure support
2538903|NCT02637635|Experimental|Breast reconstruction with implant|The patients will undergo breast reconstruction with an expander prosthesis.
2538907|NCT02637635|Experimental|Autologous fat transplantation|The patients will undergo lipofilling as a pre-treatment before they will undergo breast reconstruction with an expander prosthesis.
3202225|NCT00911378|Active Comparator|Spontaneous breathing trials|Patients in this arm are weaned by T piece trials
3202226|NCT00911391|Active Comparator|Fluid restriction|Current best practice of intraoperative fluid restriction
2539037|NCT02636946|Experimental|Bimatoprost Sustained-Release (SR)|"Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2).~Contralateral Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2)."
2539042|NCT02636946|Active Comparator|Selective Laser Trabeculoplasty (SLT)|"Assigned Primary Eye: SLT administered on Day 1 followed by up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).~Contralateral Eye: Sham SLT administered on Day 1 followed by up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2)."
2539137|NCT02636309|No Intervention|control group|control group only filled up the questionnaires. They didn't receive intervention
2539141|NCT02636309|Experimental|intervention group|physical therapy at work
3202227|NCT00911391|Experimental|Oesophageal Doppler|Oesophageal Doppler-guided fluid administration
2539250|NCT02635516|Experimental|Treatment|Only one arm was used and this arm received Near-Infrared Phototherapy.
2539256|NCT02635256|Experimental|Hypofractionated Radiosurgery|5 fractions with 7 Gy, total dose 35 Gy
2539342|NCT02634918||Ultrasound|3 groups of hemophilia patients - Those with > 20 bleeds into a joint, those with < 2 bleeds into a joint and those with no bleeds into a joint will be enrolled into the study
3202228|NCT00911404|Experimental|Low CHO|Diet with 40% total calories from carbohydrates.
3202229|NCT00911404|Active Comparator|High CHO|Diet with 55% total calories from carbohydrates.
2538498|NCT02640365|Experimental|GROUP A / GROUP B (two differents cohorts)|"GROUP A (Patients with unresectable advanced non-colorectal cancer ) - irinotecan + MM-398 dose escalation (3-18 patients)~Level 1 : initial DOUBLIRI dose 60/90 (0-3 patients)~MM-398 : 60mg/m²~Irinotecan (CPT-11) : 90mg/m²~Level 2: DOUBLIRI dose 80/90 (9 - 18 patients)~MM-398 : 80mg/m²~CPT-11: 90mg/m²~Level 3A: DOUBLIRI dose 60/120 (12-18 patients)~MM-398 : 60mg/m²~CPT-11: 120mg/m²~Level 3B: DOUBLIRI dose : 80/120 (12-18 patients)~MM-398 : 80mg/m²~CPT-11 : 120 mg/m²~GROUP B (Patients with unresectable metastatic colorectal cancer)- LV/5FU-bevacizumab+irinotecan+MM-398 dose Escalation (3-18 patients)~same level as group A + LV/5FU - bevacizumab regimen :~Bevacizumab : 5mg/kg(day (d) 1)~Leucovorin (LV) : 400mg/m² (d1)~5-fluorouracile infusion (5 FU) :2400mg/m² (d1,2)"
2538625|NCT02639650|Active Comparator|control group|etoposide, methotrexate ,actinomycin D,vincristine, cyclophosphamide(EMA-CO), two weeks a cycle
2538626|NCT02639650|Experimental|study group|paclitaxel + cisplatin or carboplatin，two weeks a cycle
2538708|NCT02639156|Experimental|intervention|Patients established on an oral nutritional supplement, being prescribed 1-2 ONS providing at least 300kcal/day will be changed onto an equivalent prescription of AYMES LONDON for a period of 9 days.
2538762|NCT02638805|Experimental|Group 1|ITCA 650 20/60 mcg/day
2538765|NCT02638805|Experimental|Group 2|ITCA 650 60 mcg/day
2538871|NCT02638077||Group 1|2000 DTC patients undergo the first-time thyroidectomy and identified as intermediate or high risk of recurrence will be recruited. Doctors can treat the patients based on disease conditions. Investigators will record data which are related to study endpoints.
2538913|NCT02637752|Active Comparator|Lifestyle counseling|Intervention: Lifestyle counseling or nutrition/physical counselling
2538914|NCT02637752|No Intervention|No Intervention|To ensure that both groups benefited equally from the study, the control group received the counselling and the handouts at the end of the study.
2538977|NCT02637388|Placebo Comparator|Placebo Comparator: Control Breakfast|Breakfast cereal and yoghurt only (placebo, negative control)
2538978|NCT02637388|Experimental|Experimental: beta-Glucan Breakfast|Breakfast cereal and yoghurt with the addition of 4g beta-glucan (14.7g Oatwell28 powder)
3202230|NCT00911469|Experimental|1|
3202231|NCT00911469|Placebo Comparator|2|
2539160|NCT02636244|Experimental|SHAPE Gel|1% SHAPE Gel applied twice daily for 12 weeks.
3202232|NCT00911482||Diabetes/weight loss|12 individuals with type 2 diabetes and hypertriglyceridemia
2539278|NCT02635282|Active Comparator|IN fentanyl and midazolam|group of patients who are randomized to receive intranasal fentanyl and midazolam
2539283|NCT02635282|Experimental|IN ketamine|group of patients who are randomized to receive intranasal ketamine
2539348|NCT02634957|Experimental|3 day absolute voice rest|participants would begin initiation of voice/speaking 3 days post phonomicrosurgery for benign vocal fold lesions
2539351|NCT02634957|Experimental|7 day absolute voice rest|participants would begin initiation of voice/speaking 7 days post phonomicrosurgery for benign vocal fold lesions
2539408|NCT02634463|Other|Antipsychotic Immunoassay Development Participants|No study agent will be administered as a part of this study. Participants must be on Aripiprazole or Olanzapine, or Paliperidone or Risperidone, orally, daily or long-acting injectable versions, as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for use in the development of antipsychotic immunoassays. Participants may also be on long acting injectable versions of the medication.
2539503|NCT02633852|Experimental|Aflibercept (EYLEA) 2mg /0.05 ml|Aflibercept (EYLEA) 2mg /0.05 ml
2539603|NCT02633514|Experimental|Radiochemotherapy|adjuvant radiochemotherapy after incomplete resection: Cisplatin + Etoposide + Radiotherapy (60Gy / 30FX)
2539607|NCT02633514|Sham Comparator|radiotherapy|adjuvant radiotherapy after incomplete resection: Radiotherapy (60Gy / 30FX)
2539695|NCT02632500|Experimental|30 compressions and 2 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 30 compressions and 2 seconds of pause protocol (30 chest compressions followed by 2 seconds of pause) on a manikin connected to the Personal Computer."
2539696|NCT02632500|Experimental|50 compressions and 5 seconds of pauses|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 50 compressions and 5 seconds of pause protocol (50 chest compressions followed by 5 seconds of pause) on a manikin connected to the Personal Computer."
2539704|NCT02632500|Experimental|100 compressions and 10 seconds of pause|"After the randomization the participant will be asked to perform 8 minutes of CPR following the 100 compressions and 10 seconds of pause protocol (100 chest compressions followed by 10 seconds of pause) on a manikin connected to the Personal Computer."
2539710|NCT02632500|Experimental|hands-only|"After the randomization the participant will be asked to perform 8 minutes of CPR following the hands-only protocol (continuous chest compressions without any pauses) on a manikin connected to the Personal Computer."
2539763|NCT02632097|Experimental|Histoacryl|Intervention: Lichtenstein Hernioplasty with Histoacryl™(cyanoacrylate glue 0.5 ml) for mesh fixation (Optilene™ mesh 60 g/m2 (B. Braun))
2539768|NCT02632097|Experimental|Suture|Intervention: Lichtenstein Hernioplasty with Sutures (polypropylene 2/0) to fix the Optilene™ mesh 60 g/m2 (B. Braun)
3202233|NCT00911482||Nondiabetic/hypertriglyceridemic|10 insulin resistant nondiabetic individuals with dyslipidemia
2539914|NCT02631239|Active Comparator|MESA|Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
2539915|NCT02631239|Experimental|ESA|Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
2539977|NCT02630836|Experimental|XCEL-MT-OSTEO-BETA|Adult ex-vivo expanded mesenchymal stromal cells from allogeneic bone marrow, cryopreserved, to combine with fibrin glue and cancellous human bone tissue + endomedullary nailing
2539979|NCT02630836|Other|Standard treatment|Standard surgical treatment with isolated endomedullary nailing
3202234|NCT00911482||Normotensive/nondiabetic|10 insulin resistant, normotensive, nondiabetic individuals
3202235|NCT00911482||Insulin resistant/dyslipidemic|14 insulin resistant nondiabetic individuals with dyslipidemia
3202236|NCT00911521|Active Comparator|Vaccine arm|subjects receiving vaccination
2538530|NCT02640300|Experimental|Immediate discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules at week 3. All capsules contained placebo (i.e., the antipsychotic drugs were abruptly discontinued). Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
2538531|NCT02640300|Experimental|Gradual discontinuation group|The antipsychotic drugs that patients took at baseline were prepared in unmarked capsules, with the dose adjusted to provide a 25% reduction weekly over the next 3 weeks. The dose tapering schedule was as follows: 3 capsules at baseline, 2 capsules at week 1, 1 capsule at week 2, and 0 capsules (i.e., the antipsychotic drugs were discontinued) at week 3. Clozapine was gradually increased to 300 mg/day according to the following schedule: 12.5 mg/day at day 0 and increased by 25 mg/day to 300 mg/day at day 12, with this dose maintained for three weeks and thereafter adjusted according to clinical judgment. Concomitant medications were kept constant throughout the study period.
3202237|NCT00911560|Experimental|vaccine group one|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a inimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to in Group 1 will receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
3202238|NCT00911560|Experimental|vaccine group two|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Patients assigned to Group 2 will receive oral β glucan (40 mg/kg/day) starting week 1 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination .
2538761|NCT02638714|Experimental|Stem Cells|Intervention: Transplantation of autologous purified stem cells
2538812|NCT02638415|Experimental|HVPG group|HVPG-guided therapy
2538817|NCT02638415|Other|non-HVPG group|routine therapy
2538845|NCT02637882|Experimental|First intervention (ear plug)|"Other: ear plug~Other Name: eastnova ear plug"
2538847|NCT02637882|Other|Second intervention (eye mask)|"Other: eye mask~The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~Other Name: Sleeping mask"
2538848|NCT02637882|Other|Ear plug and eye mask|The patients will receive the mixed intervention (eye mask) and (ear plug ) in the first night (N1) from 9 pm to 6 am.
2538912|NCT02637739|Experimental|Pregnancy of unknown location|pregnant women of at least 5 weeks by last menstrual period and transvaginal ultrasound did not revealed intra-uterine pregnancy or ectopic pregnancy Intervention: hysteroscope
2538979|NCT02637401||Therapy group|Dialectical behaviour therapy: a psychological therpay involving 16 group sessions plus approximately 5 individual meetings over 4 months.
2539022|NCT02637089||PD-non-MCI|Patients with Parkinson's disease, no mild cognitive impairment
2539025|NCT02637089||PD-MCI|Patients with Parkinson's disease with mild cognitive impairment
2539026|NCT02637089||MCI (non-PD-MCI)|Patients with mild cognitive impairment, no Parkinson's disease
2539027|NCT02637089||HC (non-PD-non-MCI)|Healthy Controls (age-matched to patients)
2539089|NCT02636764|Active Comparator|exercise group|An exercise protocol drawn up with the objective will be held to strengthen the musculature: flexor and extensor of the knee; extension, abduction, hip side rotator, using the weight and the elastic band.
2539091|NCT02636764|Placebo Comparator|exercise group + Ultrasound therapy|Apart from intervening in the exercise group, an ultrasound device is used .
2539092|NCT02636764|Experimental|exercise group + interferential current|Besides the intervention of the exercise group after the exercises will be applied to interferential current through the device. Will be positioned 4 electrodes (8x5 cm), two upper and two lower (forming a square) around the center of the knee.
2539093|NCT02636764|Experimental|exercise group + short-wave diathermy|Besides the intervention of the exercise group after the exercises will be applied diathermies short wave in continuous mode. For that will be used apparatus, 27.12 megahertz, by means of vulcanized rubber electrodes (12x17 cm) with gentle warming for 30 minutes.
2539094|NCT02636764|Experimental|exercise group + Low level laser therapy|Apart from intervening in the exercise group, will be applied to Low level laser therapy, through the laser unit, Class 3b, gallium-aluminum-arsenide, continuous mode, wavelength: 830 nanometer, power: 30 watts.
2539153|NCT02636413|Experimental|LacTEST|0,45 g of gaxilose po, once, per diagnostic test performed.
2539156|NCT02636413|Active Comparator|Hydrogen Breath Test|25 to 50 g of lactose po, once, per diagnostic test performed.
2539216|NCT02635750|Experimental|BI 409306|
2539223|NCT02635750|Experimental|Donepezil low dose|
2539230|NCT02635750|Experimental|Donepezil high dose|
2539263|NCT02635399|Placebo Comparator|conventional group|Conventional PPPD
2539269|NCT02635399|Experimental|DJ-pexy group|PPPD with additional DJ-pexy to anchor DJ to transverse colon
2539307|NCT02635048|Other|Group 1|Patients in Group 1 undergo mini percutaneous nephrolithotomy
2539309|NCT02635048|Other|Group 2|Patients in Group 2 undergo percutaneous nephrolithotomy
2539401|NCT02634528|Active Comparator|Huminsulin® Basal|Huminsulin® Basal, neutral protamine hagedorn (NPH), human isophane insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/kg body weight
2538641|NCT02639546|Experimental|Phase I (Tablet) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538645|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.6 mg/kg)|Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538652|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (0.8 mg/kg)|Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538654|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1 mg/kg)|Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538657|NCT02639546|Experimental|Phase I (Suspension) Cobimetinib (1.33 mg/kg)|Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538661|NCT02639546|Experimental|Phase II (Suspension) Cobimetinib (1 mg/kg)|Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.
2538728|NCT02638935|Other|BI-RADS 3|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2538730|NCT02638935|Other|BI-RADS 4a|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2538734|NCT02638935|Other|BI-RADS 4b|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
2538735|NCT02638935|Other|BI-RADS 4c|Intervention: Ultrasound- Virtual Touch Tissue Imaging Quantification
3202239|NCT00911560|Experimental|vaccine group three|Patients will receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8 , 20 , 32 , and 52. Minor schedule adjus tment s are permitted , as needed Vaccines must occur a minimum of 6 days apart. The last three vaccine s can be administered up to one week earlier or later than indicated without representing a protocol violation.Group 3 will include patients who have previously received vaccine and oral β glucanglucan. Patients in this group will not be randomized using the MSK CRDB system. They will be treated as patients in Group 1 and receive o ral β glucan (40 mg/kg/day) starting at week 6 or 7 and continue with approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination . They will not be eligible for primary endpoint.
3202240|NCT00911573|Experimental|A|Tigecycline
2538824|NCT02638181|Experimental|trabeculectomy|
3202241|NCT00911573|Active Comparator|B|Clindamycin (or Vancomycin if needed)
2538941|NCT02637518||Hospital Universitario de Getafe|"Assessment of frailty tools in elderly people~The Geriatric Department attends patients:~1800/year - acute unit. 800/year - Orthogeriatrics and Interconsultation Unit. 300/year - Day Hospital. 4000/year - Outpatient office. 1200/year - Domiciliary Care."
2538944|NCT02637518||Diabetes Frail Ltd.|Assessment of frailty tools in elderly people Has significant experience in managing research studies in older people.
2538950|NCT02637518||Università Cattólica del Sacro Cuore|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~24 beds of Acute Care Ward 46 beds of Intensive Rehabilitation Unit 20 beds of Day Hospital Outpatient clinic"
2538955|NCT02637518||Gérontopole de Toulouse|"Assessment of frailty tools in elderly people~The Geriatric Unit is compounded by:~5 Acute Care Units - 100 beds. 3 Rehabilitation Unit - 75 beds. Long term care Unit - 140 beds. 2 Day Hospitals Outpatient Clinic"
2538959|NCT02637518||Jagiellonian University Medical College|Assessment of frailty tools in elderly people The Department of Internal Medicine and Gerontology is the largest centre in Poland limited to the Geriatric market.
2539009|NCT02637193|Experimental|Venlafaxine|Maximum dose of 450 mg/day (225 mg BID given at approximately 12 hours apart) Venlafaxine, dose titrated from a starting single dose (QD) of 75 mg venlafaxine in the morning of Days 1 and 2, followed by BID escalating doses administered on Days 3 through 10, followed by 450 mg/day (BID) on Days 11 through 13, and on Day 14 only the morning dose of 225 mg will be administered, then 3 days (Days 15, 16 and 17) of down titration
2539011|NCT02637193|Active Comparator|Moxifloxacin|400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
2539012|NCT02637193|Placebo Comparator|Drug -- placebo|Placebo administered on Days 1 through 13 and on Days 15 to 17
2539066|NCT02636816|Experimental|Infusion|carbetocin is given slowly
2539071|NCT02636816|Active Comparator|Bolus|carbetocin is given quickly
2539112|NCT02636556|Experimental|chemoradiation|concurrent chemoradiation.
2539130|NCT02636257|Experimental|Recessive Spherical Headed Silicone Intubation|The silicone nasolacrimal intubation under nasal endoscopy can restore natural drainage pathway in tears and as an out-patient surgery, it is more simple,cheap and mini-invasive.Recessive Spherical Headed Silicone Intubation is safe,convenient and almost unpainful for no trauma.It has no facial scar and no damage for structure and function of lacrimal duct.Besides,silica gel is non-toxic and nonirritating.Nasal endoscopy handed by otorhinolaryngologist helps intraoperative visualization about anatomy of the nasal cavity,understanding and management of congenital nasolacrimal duct obstruction and is the only method that confirms the correct anatomic position of the catheterization and in real time,avoiding traditionally the blind raking-out wire by the ophthalmologist alone.Compare to the classic DCR,its short therapeutic effects are equal but more convenient and fewer time and money-cost.
2539132|NCT02636257|Other|Dacryocystorhinostomy|Nasolacrimal duct obstruction is common among patients with epiphora,which is seriously affect the quality of life. The treatment principle is to restore or rebuild the lacrimal duct drainage channel. The classic operation type is dacryocystorhinostomy(DCR), which is complex for face-section particularly.After surgery the lacrimal passage can't siphon the tear out physically any more so that it will effect the patients' life.Besides,the operating time,bleeding volume,hospitalization time and total cost for the surgery is higher.
2539202|NCT02636023|Experimental|SPhENo-Cardiograph / ECG|SPhENo-Cardiograph and ECG
2539241|NCT02635581|Experimental|DELTA TT|
2539265|NCT02635321||Patients with LGMD 2T|Four patients over 18 years old with genetically verified LGMD 2T.
2539306|NCT02635139|Experimental|Breakfast Skipping|Effect of breakfast skipping on metabolism
2539308|NCT02635139|Experimental|Dinner Skipping|Effect of dinner skipping on metabolism
2539369|NCT02634632|Experimental|Subjects with cancer|choose to write advance directives
3202242|NCT00911599|Active Comparator|Conserve Total Hip with BFH|CONSERVE® A-Class Total Hip with BFH technology. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
3202243|NCT00911599|Active Comparator|Metal with Polyethylene Liner|Metal on polyethylene total hip replacement. Blood and urine samples will be collected and blood metal ion levels will be analyzed and compared to samples from the other group.
3202244|NCT00911638|Experimental|1: Patient decision aid|Patient decision aid focused on treatment options for osteoarthritis of the hip or knee and preference report for surgeons. The patient decision aid used is from the Informed Medical Decisions Foundation
3202245|NCT00911638|Active Comparator|2: Usual care|Usual patient educational resources for patients undergoing hip or knee replacement surgery.
2538764|NCT02638662||First time IVF patients. Observational|Those who are doing IVF for the first time.
2538768|NCT02638662||Donors Observational|Those who are doing IVF for the sole purpose of donating their eggs.
2538769|NCT02638662||2 or more IVF cycles Obervational|Those who have done IVF 2 or more times with no success.
3202246|NCT00911651|Active Comparator|salbutamol|6 patients with moderate (GOLD 2) and severe (GOLD 3) COPD
3202247|NCT00911651|Active Comparator|ipratropium bromide|COPD patients GOLD stage II and III
3202248|NCT00911664|Placebo Comparator|1|
2538947|NCT02637440|No Intervention|Conservative|After the index primary PCI. The control group will receive best medical therapy and regular follow up and only PCI for recurrent angina with evidence of inducible ischaemia.
2538952|NCT02637440|Active Comparator|FFR guided|FFR group will undergo FFR at 4 weeks of the index primary PCI as OPD. If FFR is less than 0.8, then PCI will be performed
2538957|NCT02637440|Active Comparator|angiogram guided|The group will undergo PCI for all significant lesions more than 50
2539006|NCT02637180||patients with low-energy fracture(s)|"The study will include patients from pre-defined groups of individuals (postmenopausal, perimenopausal, male, and steroid induced osteoporosis) who would be anyway eligible to receive treatment for their condition according to standard medical practice and Greek treatment guidelines.~Drug: anti-osteoporotic medication (bisphosphonates, denosumab, strontium ranelate, teriparatide, SERMs)"
2539054|NCT02636881|Active Comparator|Autologous Chondrocyte Implantation|A diagnostic arthroscopy of the knee joint.The lesion is stabilized down to the subchondral bone, but not through it. Cartilage biopsy is taken from the medial femoral notch. The harvested cartilage is transported to the cell culture Laboratory and cultured for two weeks. The chondrocyte implantation: A mini-open arthrotomy is performed and the lesion is curetted down to subchondral bone, avoiding bleeding. The lesion is measured and a template of sterile aluminum foil is used to cut out a matching piece of collagen sheet which is used to contain the cells in the defect. The flap is sutured to the lesion and sealed with fibrin glue, leaving and opening at the upper part for injection of the cells. The last opening is then closed with a last stitch and fibrin glue.
2539055|NCT02636881|Sham Comparator|Arthroscopic Debridement|"The AD group will be subjected to a diagnostic arthroscopy with a full inspection of the knee joint to ensure the inclusion criteria are fulfilled. Lose bodies are removed, any meniscal pathology is addressed. Inflamed synovium is debrided. The lesion is stabilized by debridement around the edges and down to the subchondral bone using a ring curette, but not through it. Microfracture or any other cartilage treatment will not be performed.~No intra-articular local anesthetics will be used due to the possible harmful effect on cartilage [41-43].~All the operating surgeons will receive proper training in the operative procedure before study start."
2539113|NCT02636569|Active Comparator|diclofenac once daily|Topical diclofenac, will will be applied onto the skin of one arm, every day for 30 days. Enough medication will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The medications will come in a tube. The medications will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
2539114|NCT02636569|Placebo Comparator|placebo|The topical medication will will be applied onto the skin of one arm, once daily for 30 days. Enough placebo will be used to cover an area of approximately 4 square inches( a 2 inch by 2 inch square). The placebo will come in a tube. The placebo will be applied to the same sun exposed site on the arm every day. The research team will provide instructions for the correct application of the treatment.
2539165|NCT02636192||Cohort 1|Cohort 1 included participants who were exposed to sodium-glucose co-transporter 2 (SGLT2) inhibitor (canagliflozin, dapagliflozin and empagliflozin).
2539171|NCT02636192||Cohort 2|Cohort 2 included participants who were exposed to other non-SGLT2 antihyperglycemic agents (AHA).
3202249|NCT00911664|Experimental|2|
3202250|NCT00911664|Experimental|3|
2539277|NCT02635230||Patients with chronic oral anticoagulation and P2Y12 inhibitor|Patients with chronic indication for chronic oral anticoagulation (OAC) because of a heart valve prosthesis and/or atrial fibrillation undergoing coronary revascularisation (by PCI or CABG) and requiring concomitant treatment with P2Y12 inhibitors.
2539318|NCT02634866||Group N|The subjects with no symptoms of HF and normal left ventricular diastolic function (no less than 40 subjects)
2539320|NCT02634866||Group D|The subjects with no symptoms of HF and left ventricular diastolic dysfunction (no less than 40 subjects)
3202251|NCT00911677||Open Aortic Repair|Patients 60 years of age and older undergoing open repair of the abdominal aorta
3202252|NCT00911690||Cognitively Impaired|Patients in this cohort with be diagnosed with mild to moderate cognitive impairment, Alzheimers disease, Dementia, or any other form of cognitive impairment.
3202253|NCT00911690||Non-cognitively impaired|Patients in this cohort will be normal healthy adults over the age of 60 years that have no cognitive impairment.
3202254|NCT00911703||Acute heart failure|Subjects with an ED diagnosis of acute decompensated heart failure .
3202255|NCT00911716|Experimental|cyclophosphamide, Docetaxel, bevacizumab|
3202256|NCT00911755|Other|Laryngoscopy|
3202257|NCT00911755|Other|Videolaryngoscopy|
3202258|NCT00911781||Infants with infantile hemangiomas|
3202259|NCT00911794|Experimental|Written Disclosure Therapy|
3202260|NCT00911794|Sham Comparator|Controls|
3202261|NCT00911846||Buprenorphine|opioid-dependent patients with buprenorphine substitution
3202262|NCT00911846||methadone|opioid-dependent patients substituted with methadone
3202263|NCT00911846||no substitution|opioid-dependent patients without substitution
2538671|NCT02639364|Experimental|BILEVEL-APRV protocol|According to our BILEVEL-APRV protocol, BILEVEL-APRV APRV mode with specific settings,combination with spontaneous breathing.
2538695|NCT02639039|Active Comparator|Cortisone Injection|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
2538697|NCT02639039|Active Comparator|Trigger Point Dry Needling|Fifty patients with GTPS will be randomized into a CI or TDN group. Treatment will be carried out at the 1st visit following consent according to SOC. Treatment will be administered according to standard of care for up to 6 weeks.
2538743|NCT02638896|Experimental|Dose reduction arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every other weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
2538744|NCT02638896|Active Comparator|Dose maintenance arm|AS patients who achieved remission will receive etanercept 50 mg subcutaneous injections every weeks plus sulfasalazine (2g/d) oral administration till week24. Celecoxib will be the background therapy.
2538745|NCT02638896|Other|Etanercept discontinuation arm|AS patients who achieved remission will take sulfasalazine (2g/d) till week24. Celecoxib will be the background therapy.
2538785|NCT02638519|Other|Healthy Volunteers|Healthy volunteers will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
2538787|NCT02638519|Other|Alzheimer's Disease Participants|Alzheimer's disease participants will inhale NeuroXene using various breathing methods. The CMRS 1H-129Xe dual-tuned quadrature head coil will be used to acquire MRI images of the human brain after inhalation of NeuroXene. The coil permits the acquisition of both conventional proton and HP xenon gas images. Two types of MRI scans will be performed: Traditional proton fMRI and Hyperpolarized Xenon-129 fMRI. The order of scans will be randomized to account for bias caused by scan order.
2538825|NCT02638194|Active Comparator|Hookah Smoking Group|10 participants will smoke tobacco hookah for 2 hours
2538828|NCT02638194|Active Comparator|Hookah Secondhand Smoke Group|10 individuals will be exposed to secondhand hookah tobacco smoke for 2 hours
2538866|NCT02637869||Control Group - non-intervention|Clinics that did not participate in the APM project
2538874|NCT02637869||Alternative Payment Model -intervention|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
3168134|NCT00547196|Experimental|Regimen IV (unable to tolerate regimen I or II)|Patients receive fludarabine phosphate IV on days -7 to -3 and melphalan IV on day -2. UCB transplantation: Patients receive 2 combined units of UCB IV on day 0. Patients also receive G-CSF IV or subcutaneously beginning on day 5 (or later) and continuing until blood counts recover. GVHD prophylaxis: Patients receive cyclosporine IV twice daily beginning on day -1 followed by a taper according to institutional guidelines. Patients also receive mycophenolate mofetil orally or IV beginning on day 0 and continuing until day 27 (or as clinically indicated).
3168135|NCT00547209|Active Comparator|1|ventilation with air and oxygen
3168136|NCT00547209|Experimental|2|ventilation with nitrous oxide and oxygen
3168137|NCT00547261|Experimental|Arm A|1 hour IV infusion D1
3168138|NCT00547261|Experimental|Arm B|1 hour IV infusion D1, D8, D15
3168139|NCT00547287|Active Comparator|1|Currently prescribed dosage of sildenafil is continued until wash-out period.
2539020|NCT02637154|Active Comparator|Motivational Interviewing|With 30 patients Motivational Interviewing method will be used during each visit
2539021|NCT02637154|Active Comparator|Standard Education|With 30 patients Standard Education material will be used during each visit
2539102|NCT02636738|Experimental|experiment|Vela XL thulium laser, laser fiber and accessories
2539158|NCT02636387||Desmopressin|0.2mg tablets, dose titrated to effect
2539159|NCT02636387||Placebo|Placebo Comparator
2539338|NCT02634931|Experimental|NPC-12G gel|NPC-12G gel is containing 0.2% Sirolimus
2539368|NCT02634593|No Intervention|Control|Control
2539370|NCT02634593|Active Comparator|Low glycemin load snacks|Low glycemic load snacks, consumed during specific times
2539403|NCT02634359|Other|IVF Treatments- Frozen Embryo transfer|Consenting women that arrive to IVF clinic for frozen embryo transfer on spontaneous cycle Study Intervention: Ultrasound and Blood test to detect Ovulation. At home, HR, RR and movements will be contactlessly measured using EarlySense home device
2539404|NCT02634359|Other|IVF Treatments- Clinical Evaluation|"Consenting women that arrive for cycle evaluation or insemination on spontaneous cycle (infertile women).~Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device"
2539405|NCT02634359|Other|No IVF|Healthy women volunteers with regular menstrual cycles - not using contraceptives Study Intervention: Ultrasound and Blood test to detect Ovulation At home, HR, RR and movements will be contactlessly measured using EarlySense home device
3168140|NCT00547287|Active Comparator|2|20 mg tadalafil given after one week sildenafil wash-out period.
3168141|NCT00547326|Experimental|1|Treatement with osteopatic cranial techniques
3168142|NCT00547326|Placebo Comparator|2|Treatment with placebo
3168143|NCT00547352|Active Comparator|1|sildenafil treatment for at least 10 weeks prior to a 1 week wash out
3168144|NCT00547352|Active Comparator|2|Tadalafil treatment for 8 weeks following the 1 week washout period.
3168145|NCT00547391|No Intervention|1|patients on waiting list for a minimum of 5 months. These patients receive no prophylactic intervention for their recurrent pharyngitis episodes.
3168146|NCT00547391|Active Comparator|2|Tonsillectomy as soon as possible after randomization (within 2-3 weeks).
3168147|NCT00547417|Active Comparator|1|tadalafil
3168148|NCT00547443|Active Comparator|Arm I|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and high-dose external beam radiotherapy (HDRT) as in phase I. Patients also receive consolidation therapy comprising paclitaxel and carboplatin as in phase I.
2538678|NCT02639481|Active Comparator|Erigo®Pro group without FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device but without functional electrical stimulation (FES) of the leg muscles.
2538679|NCT02639481|Active Comparator|Erigo®Pro group with FES|Patients will receive 60 minutes of therapy with the robotic Erigo®Pro verticalization device including functional electrical stimulation (FES) of the leg muscles.
2538738|NCT02639013|Experimental|ttransducer technique|the nurses will measure intraabdominal pressure at each shift during the day by using transducer technique
3202264|NCT00911846||therapists|therapists of the patients
3202265|NCT00911872|Experimental|aging|
3202266|NCT00911885|Experimental|High Fiber Diet|A single dietary change condition that focuses exclusively on increasing fiber.
3202267|NCT00911885|Active Comparator|AHA Diet|The AHA Diet is the current recommendation for patients with the metabolic syndrome.
2538938|NCT02637531|Experimental|Part A/B: IPI-549 Dose Escalation|Participants receive IPI-549 orally (PO) once a day (QD) for Part A and twice a day (BID) in Part B until disease progression.
2538940|NCT02637531|Experimental|Part C: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538943|NCT02637531|Experimental|Part D: IPI-549 Monotherapy|Participants receive IPI-549 (dose determined from Part A/B) orally until disease progression.
2538946|NCT02637531|Experimental|Part D Annex: IPI-549 and nivolumab|Participants receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538949|NCT02637531|Experimental|Part E: NSCLC: IPI-549 and nivolumab|Participants with NSCLC receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538954|NCT02637531|Experimental|Part E: Melanoma: IPI-549 and nivolumab|Participants with melanoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538958|NCT02637531|Experimental|Part E: SCCHN: IPI-549 and nivolumab|Participants with squamous cell cancer of the head and neck receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538961|NCT02637531|Experimental|Part F: TNBC: IPI-549 and nivolumab|Participants with triple negative breast cancer receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538963|NCT02637531|Experimental|Part G: ACC: IPI-549 and nivolumab|Participants with adrenocortical carcinoma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538965|NCT02637531|Experimental|Part G: Mesothelioma: IPI-549 and nivolumab|Participants with mesothelioma receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2538968|NCT02637531|Experimental|Part H: High-circulating MDSCs: IPI-549 and nivolumab|Participants with high-circulating MDSCs receive IPI-549 (dose determined from Part A/B/C) orally in combination with nivolumab IV infusion (240 mg) every 2 weeks.
2539018|NCT02637024|Experimental|APBI: 30 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 30 Gy in 5 daily fractions of 6 Gy
2539019|NCT02637024|Experimental|APBI: 27.5 Gy|Radiotherapy of 3 Dimensional Conformal Radiation Therapy (3DCRT) Accelerated Partial Breast Irradiation (APBI) 27.5 Gy in 5 daily fractions of 5.5 Gy
2539129|NCT02636270|Experimental|PAPP-A2 deficient patients|Patients deficient in PAPP-A2 with short stature will be treated with Increlex (rhIGF-1)
2539187|NCT02636062||Follow-up CAC > 0|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients that develop incident CAC.
2539188|NCT02636062||Follow-up CAC zero|All patients with CAC scores of zero > 5 years previous will be invited to enroll and undergo repeat CAC scanning. This group will include all patients who continue to have a CAC of zero.
3202268|NCT00911911|Experimental|FEC 100 + TAXOTERE|"FEC 100 = Fluoro-uracile + Epirubicin + Cyclophosphamide Fluoro-uracile : 500 mg/m²/cycle Epirubicin : 100 mg/m²/cycle Cyclophosphamide : 500 mg/m²/cyle 1 cycle = 21 days. For a total of 6 cycles or 3 cycles followed by 3 cycles of TAXOTERE~TAXOTERE 100 mg/m²/cycle~1 cycle = 21 days. For a total of 3 cycles following 3 FEC 100"
3202269|NCT00911924|Experimental|iStent|
2539334|NCT02635100|Experimental|MNT Algorithm|All participants will be monitored using an existing (FDA approved) CPAP machine that has been modified to be externally controlled by a computer with the MNT algorithm, for titration.
3202270|NCT00911963|Experimental|Part A|This will be a 4 dose escalation study comparing VCH-222 to placebo treatment.
3202271|NCT00911963|Experimental|Part B|VCH-222 + peginterferon alfa-2a + ribavirin (12 weeks) followed by peginterferon alfa-2a + ribavirin for 36 weeks
3202272|NCT00911976|Experimental|Xience V|Implantation of the Xience V stent in saphenous vein graft lesions
3202273|NCT00912041|Other|BrainGate|BrainGate Neural Interface System
3202274|NCT00912054|Experimental|1|DuoTrav APS
3202275|NCT00912054|Active Comparator|2|Xalacom
3202276|NCT00912067||hematopoietic stem cell transplantation|
3202277|NCT00912080|Experimental|good signature|"Patients who have a good signature for the genomic analysis. They will receive the standard chemotherapy."
3202278|NCT00912106||HA injection|Patients with osteoarthritis of knee. They are going to received HA injection 1 vial per week for 5 weeks.
3202279|NCT00912119|Experimental|Group A|Group A - Low Dose
3202280|NCT00912119|Experimental|Group B|Group B - Intermediate Dose
3202281|NCT00912119|Experimental|Group C|Group C - High Dose
3202282|NCT00912119|Experimental|Group D|Group D - Extra Low
3202283|NCT00912132||Low risk singleton cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
2538692|NCT02639234|Experimental|Vigil™ + Nivolumab|Patients meeting study eligibility criteria will receive doublet therapy comprising of (i) Vigil™ 1 x 10^7 cells by intradermal injection every 2 weeks (for a minimum of 4 and a maximum of 12 doses) and (ii) nivolumab 3 mg/kg by intravenous infusion over 60 minutes every 2 weeks.
2538757|NCT02638818||minimally invasive whipple|Surgical technique (minimally invasive vs open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
2538759|NCT02638818||traditional whipple|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
2538798|NCT02638428|Experimental|Refractory/relapsed solid tumor or AML|Conventional chemotherapy (Ifosfamide carboplatin etoposide for solid tumor and fludarabine cytarabine for AML) with matched single-targeted agent (axitinib, crizotinib, dasatinib, erlotinib, everolimus, imatinib, pazopanib, ruxolitinib, sorafenib, vandetanib, vemurafenib, or trastuzumab) or multi-targeted receptor tyrosine kinase inhibitor (pazopanib or sorafenib) according to the result of CancerSCAN™
3202284|NCT00912132||Obese cohort|Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
3202285|NCT00912145|Experimental|1|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)
2539036|NCT02636972||Group 1|Mild or absent dysmenorrhoea and no other pelvic pain symptoms without contraceptive pill use.
2539040|NCT02636972||Group 2A|History of mild or absent dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
2539044|NCT02636972||Group 2B|History of severe dysmenorrhoea prior to pill use and no other pelvic pain symptoms with contraceptive pill use (Participants already using contraceptive pills).
2539047|NCT02636972||Group 3|Severe dysmenorrhoea but without chronic pelvic pain and without contraceptive pill use.
2539049|NCT02636972||Group 4|Severe dysmenorrhoea but without chronic pelvic pain and with contraceptive pill use (Participants already using contraceptive pills).
2539050|NCT02636972||Group 5|Chronic pelvic pain and severe dysmenorrhoea without contraceptive pill use
2539052|NCT02636972||Group 6|Chronic pelvic pain and severe dysmenorrhoea with contraceptive pill use (Participants already using contraceptive pills).
2539124|NCT02636582|Experimental|Arm I (nelipepimut-S plus GM-CSF vaccine)|Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
2539126|NCT02636582|Active Comparator|Arm II (sargramostim)|Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
2539232|NCT02635893|Active Comparator|D-Cycloserine/Placebo + Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation.
2539234|NCT02635893|Active Comparator|Training+Med/Placebo+Stimulation|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation followed by training.
2539235|NCT02635893|Active Comparator|Training+Med+Stimulation/Placebo Stim|Participant will be given a single dose of 100 mg of D-Cycloserine or placebo before receiving stimulation or placebo stimulation followed by training.
2539279|NCT02635217|Experimental|Group A1|EGD performed before the Colonoscopy with Carbon Dioxide insufflation.
2539284|NCT02635217|Experimental|Group A2|EGD performed before the Colonoscopy with room air insufflation.
2539288|NCT02635217|Experimental|Group B1|Colonoscopy performed before the EGD with Carbon Dioxide insufflation.
2539290|NCT02635217|Experimental|Group B2|Colonoscopy performed before the EGD with room air insufflation.
2539333|NCT02634892|No Intervention|Standard of Care (SOC)|Patients receive usual or standard of care regarding management of early stage pressure ulcers
2539337|NCT02634892|Experimental|SOC plus PRO-TECT|Patients receive usual or standard of care plus the addition of PRO-TECT.
2539372|NCT02634619|Active Comparator|Ventral Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
2539376|NCT02634619|Active Comparator|Dorsal Buccal Mucosa Graft Onlay|Standard of care method for repairing urethral strictures
3202286|NCT00912145|Active Comparator|2|Alprazolam Tablets, 2 mg, Xanax (The Upjohn Company)
2539476|NCT02633904|Active Comparator|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
2539480|NCT02633904|Experimental|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
2539519|NCT02633657|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
2539565|NCT02633436||cancer tissues|SLC1A5 expression of esophageal cancer tissues from patients
2539574|NCT02633436||paired adjacent tissues|SLC1A5 expression of paired adjacent esophageal tissues from patients
2539625|NCT02633007|Experimental|CVT-301 then Placebo (AB)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
2539628|NCT02633007|Experimental|Placebo then CVT-301 (BA)|All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.
2539687|NCT02632565|Active Comparator|intra-articular 0.5% lidocaine|intra-articular 7 mL 0.5% lidocaine injection for 3 times with one week intervals
2539689|NCT02632565|Active Comparator|intra-articular saline|intra-articular 7 mL saline injection for 3 times with one week intervals
2539772|NCT02632253|Active Comparator|Moderate intensity continuous exercise|"Patients perform two weekly supervised MICE session on a cycling ergometer per week plus one self monitored 30-60 min MICE training of choice at home.~MICE is performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down)."
3202287|NCT00912171|Active Comparator|Nasal steroid|
2538704|NCT02639130|Placebo Comparator|Placebo|"After a screening examination, patients were treated with placebo, and participated in meal tests (day 9 and 10, respectively), in a crossover design. Between the two treatment periods, there was a ≥ 5 week wash-out period.~Experimental procedures: Meal test, determination of the rate of gastric emptying. On days 9 and 10 of treatment, the volunteers underwent a mixed meal (one scrambled egg, a slice of ham, 10 g of butter, two slices of toast, 20 g strawberry jam, and 200 ml of unsweetened tea) test in the morning after fasting overnight. 13C-octanoic acid (110 µl/100 mg) was used as label.~Meal tests were performed (days 9 and 10), without and with a high dose intravenous infusion of exendin [9-39]."
2538777|NCT02638740|Active Comparator|SCALING AND ROOT PLANING (SRP)|Scaling and root planning with ultrasonic scalar
2538780|NCT02638740|Experimental|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
2538796|NCT02638246|Experimental|Contingent|Participants in this group received incentives contingent on meeting pre-specified daily blood-glucose testing adherence goals.
2538802|NCT02638246|Active Comparator|Noncontingent|Participants in this group received incentives independent of meeting pre-specified daily blood glucose testing adherence goals.
2538857|NCT02638116|Experimental|Ibrutinib + Omeprazole|Participants will receive a dose of Ibrutinib 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7 and Omeprazole at a dose of 40 mg tablets orally once on Days 3 through 7.
2538927|NCT02637765|No Intervention|Control Group|Usual Physical Activity
2538936|NCT02637765|Experimental|Intervention Group|8-week increased physical activity program
2538983|NCT02637336|Experimental|Acupuncture|acupuncture session were inserted, and maintained for 20 minutes in paragraph 6 of the channel the pericardium (Neiguan).
2538985|NCT02637336|Experimental|Aerobic Exercise|The aerobic exercise session was conducted through 20 minutes.
2538989|NCT02637336|Experimental|Aromatherapy|Eucalyptus essential oil was inhaled by volunteers for 20 minutes
2538991|NCT02637336|No Intervention|Control|In the control session the volunteers remained seated at rest for 20 minutes without performing therapy.
2539028|NCT02637050||CTEPH Patients|Patients with confirmed diagnosis of CTEPH
2539088|NCT02636621|Active Comparator|Brazilian Dental Appliance|The device increases the volume of the airway by mandibular traction.
2539090|NCT02636621|Placebo Comparator|Placebo|Oral device that does not change the volume of the airway
2539117|NCT02636465||obese healthy adults|persons with BMI> 30 kg/m2
2539118|NCT02636465||obese COPD patients|COPD-patients (GOLD I-IV Group A-D) with BMI> 30 kg/m2
2539120|NCT02636465||OHS-patients|patients with defined OHS: BMI>30 kg/m2 and sleep related breathing disease, no COPD
2539162|NCT02636153|Experimental|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
2539169|NCT02636153|Experimental|Restricted Phosphorus Diet|Diet containing 500mg of phosphorus per day
2539215|NCT02635815||Group I|twenty six patients with history of bleeding or had an attack of bleeding during one year follow-up. All underwent upper gastrointestinal endoscopy.
2539224|NCT02635815||Group II|thirty four patients without bleeding. All underwent upper gastrointestinal endoscopy.
2539271|NCT02635490||prophylactic antibiotics|
2539324|NCT02635178|Experimental|Active|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects on the mind and body. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and that they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
2539325|NCT02635178|Placebo Comparator|Control|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
2539355|NCT02634671|Other|22Q11|24 patients with 22Q11DS to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
2539359|NCT02634671|Other|SCHIZOPHRENIA|24 patients with schizophrenia to determine whether the severity of the two disorders' symptoms is correlated with the cerebral response to facial expressions. To answer this question, a set of clinical and neuropsychological tests will be conducted for each patient.
2539406|NCT02634372|Experimental|EMDR Therapy|EMDR: 20 individual sessions 60 minutes each for 6 months
2539409|NCT02634372|Active Comparator|Supportive therapy|Supportive therapy: 20 individual sessions 60 minutes each for 6 months.
3202288|NCT00912171|Active Comparator|Anti-leukotrienes|
3202289|NCT00912171|Active Comparator|Nasal steroid + anti-leukotrienes|
3202290|NCT00912184|Experimental|1|CVVH with high cut-off polyamide membrane (P2SH) using standard continuous veno-venous hemofiltration (CVVH) settings
3202291|NCT00912184|Active Comparator|2|CVVH using standard high flux membrane with standard CVVH settings
2539896|NCT02631382|Experimental|wet cupping : double cupping|wet cupping: (traditional cupping technique): cupping (suction) - Scarification - cupping (suction)
2539899|NCT02631382|Experimental|wet cupping: single cupping|wet cupping:(Asian cupping): Puncture by needles then cupping (suction):
2539952|NCT02631044|Experimental|JCAR017 1-dose schedule|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 1 intravenous (IV) injection
3202292|NCT00912210|Active Comparator|Higher protein|
3202293|NCT00912210|Placebo Comparator|Higher carbohydrate|
2538758|NCT02638753|Active Comparator|Education|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology.
2538760|NCT02638753|Experimental|Education combined with hypnosis|Patients will receive 4 sessions (1 hour each) of education on pain neurophysiology combined with hypnosis.
2538793|NCT02638402||Stage I, II, III, IV ovarian cancer|Stage I, II, III, IV ovarian cancer receive treatment in National Taiwan University Hospital
2538794|NCT02638402||Stage I, II, III, IV endometrial cancer|Stage I, II, III, IV endometrial cancer receive treatment in National Taiwan University Hospital
3202294|NCT00912236||1|BMI 20-25 kg/m2
3202295|NCT00912236||2|BMI > 30 kg/m2 with low TG (<150) and normal HDL (>50 for females, >40 for males)
3202296|NCT00912236||3|BMI > 30 kg/m2 with high TG (>150) and low HDL (<50 for females, <40 for males)
2538967|NCT02637479|Experimental|Pituitary radiosurgery group|Subjects will receive a pituitary radiosurgery by GammaKnife® during a brief hospitalization associated with standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
2538969|NCT02637479|Active Comparator|Control group|Subject will receive standards of care for pain according to recommendations (Standards, Options and Recommendations about drug analgesic treatments for nociceptive cancer pain in adults)
2539035|NCT02637115|Placebo Comparator|Placebo|Placebo corresponds to a solution of Phosphate buffer saline (PBS) and glycerol, that is the carrier used in the 3 other groups receiving the bacteria (active arms)
2539041|NCT02637115|Experimental|Live Akk 9|Live Akkermansia muciniphila (Akk) at the dose of 10exp9 live bacteria (one billion of live bacteria) per day
2539043|NCT02637115|Experimental|Live Akk 10|Live Akkermansia muciniphila (Akk) at the dose of 10exp10 live bacteria (ten billion of live bacteria) per day
2539046|NCT02637115|Experimental|Killed Akk|This group corresponds to Akkermansia muciniphila that have been heat-killed. The initial quantity of bacteria before the heating procedure was of 10exp10 bacteria.
3202297|NCT00912249|Experimental|Horticultural Therapy|
2539142|NCT02636348|Experimental|Calcium/Vitamin D Bar|Dietary supplement consumed as 2 calcium and vitamin D fortified snack bars per day
2539145|NCT02636348|Experimental|Calcium/Vitamin D Pill|Dietary supplement consumed as several capsules per day
2539147|NCT02636348|Placebo Comparator|Placebo Bar|Placebo consumed as 2 isocaloric, unfortified snack bars per day
2539149|NCT02636348|Placebo Comparator|Placebo Pill|Placebo consumed as several capsules per day
2539214|NCT02635919|Experimental|mSMART|Smokers in this group will have the mSMART application installed on their smartphones. The mSMART application will provide information about varenicline (Chantix) and reminders when it's time to take the medication.
2539222|NCT02635919|No Intervention|Control|Smokers in this group will not be given the mSMART application.
2539285|NCT02635438|Experimental|Arm A|Test Product: Clotrimazole troche/ lozenges USP, 10 mg (Unique Pharmaceutical Laboratories, India) 10mg troche 5 times a day for 14 consecutive days
2539289|NCT02635438|Active Comparator|Arm B|Reference Product: Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) troche 5 times a day for 14 consecutive days
2539365|NCT02634775|Experimental|CKD - no dialysis|Change in treatment strategy: Start on dialysis, transplantation
2539366|NCT02634775|Experimental|Patients on PD|Change in treatment strategy: Change of PD prescription, start on HD, transplantation
2539367|NCT02634775|Experimental|Patients on HD|Change in treatment strategy: Change of HD prescription, transplantation
2539402|NCT02634385|No Intervention|Small Renal Mass|Patient's with a small renal mass will be undergoing embolization prior to laparoscopic partial nephrectomy.
2539456|NCT02634203|Experimental|Balloon Pulmonary Angioplasty (BPA)|Non-operable patients with CTEPH allocated to BPA arm
2539457|NCT02634203|Active Comparator|Riociguat|Non-operable patients with CTEPH allocated to Riociguat arm
2539522|NCT02633761|Active Comparator|Group 1|200mg mifepristone followed in 24 hours by repeated doses of 200mcg buccal misoprostol given every 3 hours
2539524|NCT02633761|Placebo Comparator|Group 2|placebo followed in 24 hours by 200mcg buccal misoprostol given every three hours.
2539548|NCT02633384|Experimental|SMOFlipid|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a new generation intravenous lipid emulsion
2539549|NCT02633384|Other|Lipofundin|infants subjected to corrective surgery for congenital abnormalities and needing prolonged PN using a current intravenous lipid emulsion
2539600|NCT02633111||Patients with aggressive B-cell Non-Hodgkin lymphoma|This is a non-therapeutic protocol aimed to assess the ability of Adaptive clonoSEQ® MRD assay to detect clinical relapse in DLBCLwhen compared to conventional approaches for detecting relapse such as patient-reported symptoms, clinical exams, and CT scans.
2539682|NCT02632734|Experimental|CoreBone Cone device|Experimental: CoreBone Cone device After extraction intervention will include the placement of CoreBone Cone device derived from coral that its dimensions is 4-5mm width and 8-10mm height. One cone for each extraction socket.Its advantage is that it fits well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month. We predict that CoreBone Cones are more effective than particulate device.
2539684|NCT02632734|Experimental|CoreBone 500 device|After extraction intervention will include the placement of CoreBone500 device derived from coral that is particulate. 0.3-0.5cc for each extraction socket.Its advantage is that it fills well the socket site.Measurements from models taken at different times will be analysed for bone loss. Changes in width and height of alveolar bone will be studied at 3 and 6 month.
2539761|NCT02632279|Experimental|TRP depleted|TRP depleted protein drink
2539765|NCT02632279|Placebo Comparator|Placebo|Balanced protein drink (+1.21g of TRP)
3202298|NCT00912262|Active Comparator|Low and High Concentration Capsaicin Topical Liquids|
3202299|NCT00912275|Experimental|Lapatinib plus Oral Vinorelbine|Oral vinorelbine on day 1 and day 8 q3w plus lapatinib 1000mg/day.
3202300|NCT00912314|Active Comparator|Monthly Maintenance PTNS|After 12 weeks of PTNS, patients will be randomized to either the monthly PTNS arm, or the no maintenance PTNS arm.
3202301|NCT00912314|No Intervention|No maintenance PTNS|After 12 weeks of PTNS, patients will either be randomized to the Monthly PTNS arm or the No maintenance PTNS arm.
3202302|NCT00912327||Stage 1|
3202303|NCT00912327||Stage 2|
2538826|NCT02638155||Food Addiction Group|Those participants identified as having food addiction by the Yale Food Addiction Scale.
2538829|NCT02638155||No Food Addiction Group|Those participants with no identified food addiction
2538850|NCT02637921|Active Comparator|Hypoxic ambulatory|Participants ambulatory in normobaric hypoxia with standardised nutritional intake
2538854|NCT02637921|Experimental|Hypoxic Bed rest|Participants are on bed rest in normobaric hypoxia with standardised nutritional intake
2538859|NCT02637921|Active Comparator|Normoxic bed rest|Participants are on bed rest in normobaric normoxia with standardised nutritional intake
2538920|NCT02637596|Experimental|RFA group|Twenty-fourth consecutive patients with histologically proved pancreatic cancer [stage IIb (n=4), III (n=15), IV (n=5) ]underwent intraoperative RFA of primary tumor.
2538996|NCT02637375|Experimental|Therapy|Patients will receive ganetespib monotherapy for two weeks followed by twelve weeks of ganetespib/paclitaxel therapy followed by 4 bi-weekly doses of doxorubicin/cyclophosphamide therapy followed by surgery.
2539031|NCT02636998||Normal weight|BMI <85th percentile
2539038|NCT02636998||Obese|BMI > 95th percentile
2539099|NCT02636751|Experimental|In-person prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment. General information about pain control, such as ice application and medication usage will also be provided
2539100|NCT02636751|Experimental|Tele-prehabilitation group|The participants in this group will receive a 12-week rehabilitation program (2x/week) including, education, stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities, in addition to walking aid adjustment using a telecommunication software (Reacts®, Facetime® or Skype®). General information about pain control, such as ice application and medication usage will also be provided.
2539101|NCT02636751|Active Comparator|Usual care group|The participants in this group will be provided with the hospital's usual documentation before total joint arthroplasties, consisting of information regarding the pre- and post-surgery course and medication.
2539138|NCT02636296|Experimental|Pilates|Group received 12 week of inspired-Pilates intervention (2 days/week, 60 minutes duration).
2539140|NCT02636296|Other|Control|Control group was oriented to maintain the habitual activities during 12 weeks
2539210|NCT02636010|Experimental|MK-3475 Pembrolizumab|MK-3475 at a dose of 200 mg every three weeks for 1 year with a potential expansion of 1 additional year of treatment in case of clinical benefit and patient agreement
2539339|NCT02635113|Experimental|PD Shoe|40 subjects will wear the shoe in order to test abnormal gait patterns that increase likelihood of falls and the effectiveness of a gait synchronized vibration system to plantar surface to reduce fall risk.
3202304|NCT00912353|Experimental|AZD7268|
3202305|NCT00912353|Placebo Comparator|Placebo|
3202306|NCT00912366||Group A|VATS
3202307|NCT00912366||Group B|Open Surgery
2539589|NCT02633163|Experimental|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution
2539590|NCT02633163|Experimental|High Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution
2539591|NCT02633163|Placebo Comparator|Plasma Lyte A Solution|Placebo Infusion (Plasma-Lyte A solution only)
3202308|NCT00912379||hemoglobin determination|ICU and emergency unit patients
3202309|NCT00912392|Experimental|Etoposide-Carboplatin with Endostar|Endostar® 7.5mg/m2 on day 1 to day 14, etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
2539699|NCT02632461|Experimental|Podcast (+Bite Counter)|Participants in this group will receive podcasts twice weekly in conjunction with using a wearable wrist device called a Bite Counter. The Bite Counter tracks the number of bites/calories per bite. (Podcasts plus Bite Counter)
2539705|NCT02632461|Active Comparator|Podcast (+Mobile App)|Participants in this group will receive podcasts twice weekly in conjunction with using a mobile application to track their diet. (Podcasts plus Mobile Diet Application)
2539777|NCT02632136|Active Comparator|TAP block group|"This group will receive 30 ml of 0.25% Bupivacine given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine.~They will also receive normal saline injections at port sites, which will be injected before the ports are inserted. 15 ml of normal saline will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports."
2539784|NCT02632136|Placebo Comparator|Peri-Portal block Group|"They will receive 0.5% Bupivacaine injections at port sites, which will be injected before the ports are inserted. 15 ml of 0.5% Bupivacaine will be divided in aliquots of 7, 4 and 4 ml. 7 ml will be injected at sub-umblical port side and 4 ml each at the site of other two ports.~This group will also receive 30 ml of Normal Saline Injection given as Transversus Abdominus Plane Block under direct Laparascopic view. The TAP block will be injected in the angle of Petit above the anterior superior iliac supine."
2539859|NCT02631603|Active Comparator|Prednisolone|"Oral prednisolone, anticipated dose:~first month after steroid pulse 0.5 mg/kg bw/d, second month 0.25 mg/kg bw/d, and third month 0.125 mg/kg bw/d in a single morning dose.~Individual capsules will be prepared using rounded dose."
3202310|NCT00912392|Active Comparator|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
3202311|NCT00912431|Experimental|1|
3202312|NCT00912431|Placebo Comparator|2|
3202313|NCT00912444|Experimental|TAC Arm|six cycles of neoadjuvant Docetaxel, Anthracycline and Cyclophosphamide
3202314|NCT00912444|Experimental|TC Arm|six cycles of neoadjuvant Docetaxel and Cyclophosphamide
3202315|NCT00912457|Experimental|Donepezil|Donepezil-treated sleep apnea patients
3202316|NCT00912457|Placebo Comparator|Placebo|Placebo-treated sleep apnea patients
3202317|NCT00912483|Experimental|Test|Heparin Sodium 5.000UI/0.25mL
3202318|NCT00912483|Active Comparator|Ative comparator|Heparin Sodium 5.000USP/mL
3202319|NCT00912496|Experimental|Group 9: 2 dose prime|Received two doses of A/Vietnam/1203/04 90mcg vaccine as prime (on Days 0, 28 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
3202320|NCT00912496|Experimental|Group 8: 1 dose prime|Received A/Vietnam/1203/04 90mcg vaccine as prime (Day 0 in DMID 07-0019), will receive a booster dose of A/Anhui/05 vaccine (A) with or without MF59 adjuvant in DMID 08-0013 on Day 0.
2538922|NCT02637544|Active Comparator|Verum|"Acupuncture therapy.~For this study arm following acupuncture points suitable for facial pain, according to traditional chinese medicine, were chosen:~F2, F3, F34, IT3, IT19, S7, T21 and temporomandibular joint ear acupuncture points. Only intervention is the acupuncture therapy."
2538932|NCT02637544|Placebo Comparator|Placebo|Placebo acupuncture therapy. For this study arm points outside of the meridians according to traditional chinese medicine, were chosen. Only intervention is the acupuncture therapy.
2538987|NCT02637297|Experimental|Group I (immediate intervention group)|Participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
2538990|NCT02637297|Active Comparator|Group II (wait-list control group)|At week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. The hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.
3202321|NCT00912496|Experimental|Group 10: unprimed control/dose response group|Unprimed control and dose response group of H5 vaccine naive volunteers will be added in DMID 08-0013 to receive two doses of A/Anhui/05 vaccine (A) with or without MF59 adjuvant or placebo on Day 0 and Day 28.
3202322|NCT00912522|Active Comparator|LT PFC HIGH FREQ TMS|
3202323|NCT00912522|Active Comparator|LT PFC LOW FREQ TMS|
3202324|NCT00912522|Active Comparator|RT PFC HIGH FREQ TMS|
3202325|NCT00912522|Active Comparator|RT PFC LOW FREQ TMS|
3202326|NCT00912522|Sham Comparator|SHAM STIMULATION|
3202327|NCT00912535|Active Comparator|Quetiapine extended release tablet|Quetiapine orally at a flexible dose fo 50-300mg/day according to the judgment by the investigator for 8 weeks, as adjunct to the same antidepressant at the same dose.
3202328|NCT00912535|Placebo Comparator|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
2539181|NCT02636088|Experimental|Cetuximab|Cetuximab is administered once a week. The initial dose is 400 mg/m2 body surface area. First Cetuximab infusion should start day 15 in cycle 1.The subsequent weekly doses are 250 mg/m2.
2539237|NCT02635711|Experimental|Adapted Taekwondo training|An adapted TKD training regime which was developed by our research team [16] will be used in this study. This training programme is designed to train balance control, eye-hand coordination and facilitate skeletal development for children with DCD. The high-impact striking techniques (e.g., punching and blocking) incorporated in the programme may stimulate bone growth [15]. Subjects who are assigned to the TKD training group will attend a weekly 1-h session of TKD training that will be held at the University of Hong Kong for 12 weeks. All TKD training sessions will be conducted by a qualified World Taekwondo Federation black belt coach.
2539239|NCT02635711|Active Comparator|Control|Subjects who are assigned to the DCD-control group will receive no TKD training during the study period. Instead, they will participate in jogging exercise daily (one hour per day) for 12 weeks. Participants will be encouraged to jog to school or other places every day, as appropriate. Pedometers will be used to monitor their exercise level and enhance habitual physical activity. The pedometer count (steps per day) will be documented in a log book by the parents. Signed log books will be returned to our research personnel after the intervention period. In addition, children with DCD in this group will receive an adapted TKD training menu and 12 training/demonstration sessions immediately after the follow-up testing is completed.
3202329|NCT00912548|Experimental|TAM+OFS(E) group|"Patients should be premenopausal women ,prior to the start of chemotherapy, less than or equal to 45 years of age with oestrogen receptor positive ± progesterone receptor positive who have undergone a primary mass excision, received an neo-/adjuvant chemotherapy ± radiotherapy for their stage I, II or III breast cancer. This arm is ovarian suppression group which have a various starting time of ovarian function suppression after neo-/adjuvant chemotherapy.~Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. After that, the patients will complete taking tamoxifen 20mg/day for 5 years."
2539397|NCT02634476|Experimental|cognitive bias modification training|Participants complete four sessions of the alcohol approach/avoidance task.
2539399|NCT02634476|Sham Comparator|sham training|Participants complete four sessions of the sham approach/avoidance task.
2539464|NCT02634164|No Intervention|control|"Control Treatment with Oral Glucose Tolerance Test:~Blood glucose and insulin will be obtained following the protocol of Eicher et al (4). Participants will ingest a Placebo (inert, calorie free, stevia sweetener) with blood collections at 0,2,4,6,8,10,30 prior to a standard 75 g glucose solution, followed by blood collections at 0,2,4,6,8,10,30,60,90,120 minutes post glucose ingestion. A total of 16 blood collections will be taken."
2539466|NCT02634164|Experimental|Leucine Supplement|Control Treatment with Oral Glucose Tolerance Test:
2539469|NCT02634164|Experimental|Isoleucine Supplement|Isoleucine Combined with Oral Glucose Tolerance Test:
2539471|NCT02634164|Experimental|Leucine and Isoleucine Supplement|Leucine and Isoleucine Combined with Oral Glucose Tolerance Test:
2539504|NCT02633696|Active Comparator|Legalón Sil i.v 350 mg|8 healthy volunteers received 1 vial of 350 mg iv of sylibin lyophilisate for solution for infusion (legalon sil) in two hours (single dose).
2539509|NCT02633696|Experimental|Silybin-phosphatidylcholine oral 360 mg|8 healthy volunteers received 9 capsules of 40 mg of sylibin each one (360 mg in total) orally.
3202330|NCT00912548|Active Comparator|TAM(D) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 0, 6, 12, 18 and 24 months since the baseline asTsessment(0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. The latter will complete taking tamoxifen 20mg/day for 5 years.
2539608|NCT02633137|Experimental|Chemotherapy|Lenalidomide + R-CHOP x 4 cycles R-HiDAC x 2 cycles R-Len maintenance x 6 months
2539119|NCT02636426|Experimental|sorafenib|In this phase I study patients are treated with high-dose, pulsatile sorafenib in escalating AUC0-12h cohorts.
2539164|NCT02636179||448 children|Children aged 11-15 years from a historical cohort born after In Vitro Fertilization or Intracytoplasmic Sperm Injection at Hospital Saint Joseph of Marseille
2539170|NCT02636179||1344 children|Children aged 11-15 years born spontaneously schooling in the same geographic area as case
2539219|NCT02635763|Other|PNBs1|Femoral nerve and the lateral cutaneous nerve block combined with general anesthesia
2539227|NCT02635763|Other|PNBs2|Lumbar plexus and sacral plexus nerve block combined with general anesthesia
2539347|NCT02634879|No Intervention|Control|Control Group
2539350|NCT02634879|Active Comparator|Loss Aversion|Each physician in this arm will have access to funds prior to earning them.
2539353|NCT02634879|Active Comparator|Group Incentive|Each physician will receive 50% of their potential incentive based on group performance. Physicians will also receive information on the performance of physicians on key CI measures in their group.
2539424|NCT02634515|Experimental|Julphar Insulin R|Julphar Insulin R, soluble human insulin, biosimilar, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
2539426|NCT02634515|Active Comparator|Huminsulin® Normal|Huminsulin® Normal, soluble human insulin, reference, 100 IU/mL, single subcutaneous injection of 0.3 IU/kg body weight
2539460|NCT02634021|Active Comparator|dexmedetomidine group|dexmedetomidine 1 mcg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
2539461|NCT02634021|Experimental|midazolam group|midazolam 0.1 mg/kg intravenous loading followed by dexmedetomidine continuous infusion at the rate of 0.5 mcg/kg/hr
2539520|NCT02633722|Experimental|TRF-b|Participants are instructed to eat between 8am-5pm
2539523|NCT02633722|Experimental|TRF-d|Participants are instructed to eat only between 12-9pm
2539525|NCT02633722|No Intervention|Baseline|No lifestyle instruction given
2539601|NCT02633423|Experimental|PEEP and CPAP|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
2539604|NCT02633423|Experimental|ZEEP and CPAP|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB continous positive airway pressure(CPAP) will be adopted.
2539609|NCT02633423|Experimental|PEEP and NO VM|Patients will be ventilated with positive end-expiratory pressure(PEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
2539611|NCT02633423|Placebo Comparator|ZEEP and NO VM|Patients will be ventilated without PEEP(ZEEP) before and after cardiopulmonary bypass(CPB); during CPB no mechanical ventilation will be adopted(no VM)
2539663|NCT02632617||CTA Group|Participants in CTA group will primarily receive computed tomographic angiography examination before surgery. Those with positive findings in CTA (≥50% diameter stenosis in main coronary artery) or uncertain diagnosis caused by motion artifact or calcium artifact are required to undergo ICA, and coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis according to the ICA result. Participants with negative findings in CTA do not need further coronary artery evaluation, and CABG won't be performed during the surgery.
2539664|NCT02632617||ICA Group|Participants in ICA group will undergo ICA as guideline recommend before surgery, coronary artery bypass grafting (CABG) is recommended in patients with significant stenosis
3168149|NCT00547443|Experimental|Arm II|Patients receive chemoradiotherapy comprising paclitaxel, carboplatin, and HDRT as in phase I. Patients also receive consolidation therapy comprising paclitaxel, carboplatin, and sorafenib tosylate at the MTD as in phase I, as well as maintenance therapy comprising sorafenib tosylate at the MTD as in phase I.
2539773|NCT02632032|Other|Insulin therapy and diabetes education|Children and adolescents living with type 1 diabetes already on insulin therapy received collective diabetes education during a five days camp.
2539814|NCT02631759|Experimental|Lévétiracetam|52 patients will be recruited over 2 years in the experimental group
2539817|NCT02631759|Placebo Comparator|Placebo|52 patients will be recruited over 2 years in the control group
2539877|NCT02631473|Active Comparator|1st Stage-Group A|"Day 1: 50 mg NANO-efavirenz single dose~Days 4-21: 50 mg NANO-efavirenz OD (once daily)"
2539878|NCT02631473|Active Comparator|1st Stage-Group B|"Days 1-7: 400mg NANO-lopinavir BID (twice daily)~Days 8-21: Wash-out period~Days: 22-28: 200mg NANO-lopinavir BID plus 100mg Ritonavir (Norvir) BID"
2539879|NCT02631473|Active Comparator|2nd Stage-Group A-Group 1-Dose level 1|"21 Days: 300mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 600mg Sustiva OD"
3168150|NCT00547482|Sham Comparator|Control|They will all be implanted but not activated for the Initial Study Period (24 weeks), followed by all subjects assigned to treatment (Control Group with device activation) in the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA.
3168151|NCT00547482|Active Comparator|Treatment|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation). They will be followed for the Initial Study Period (24 weeks), followed by the Study Extension Period (an additional 24 weeks). Subjects will remain in the study (Safety Monitoring Period) with semi-annual evaluations until a determination of safety and efficacy is made by the FDA."
3168152|NCT00547495|Placebo Comparator|1|Placebo tablet
3168153|NCT00547495|Active Comparator|2|5 mg tadalafil
3168154|NCT00547495|Active Comparator|3|10 mg tadalafil
3168155|NCT00547495|Active Comparator|4|20 mg tadalafil
3168156|NCT00547508|Placebo Comparator|1|Placebo
3168157|NCT00547508|Placebo Comparator|2|Placebo
3168158|NCT00547508|Active Comparator|3|tadalafil
3168159|NCT00547508|Active Comparator|4|tadalafil
3168160|NCT00547508|Active Comparator|5|tadalafil
3168161|NCT00547508|Active Comparator|6|tadalafil
3168162|NCT00547547|Experimental|Treatment (high-selenium therapy and chemotherapy)|
3168163|NCT00547560|Other|GSI+Placebo|
3168164|NCT00547573|Active Comparator|2|10 mg tadalafil tablet
3168165|NCT00547573|Active Comparator|3|20 mg tadalafil tablet
3168166|NCT00547573|Placebo Comparator|1|placebo tablet
3168167|NCT00547599|Active Comparator|1|20 mg tadalafil tablet
3168168|NCT00547625|Placebo Comparator|1|Placebo run in followed by 5 mg treatment phase 1 and then 20 mg treatment phase 2 which both include a placebo control.
2539135|NCT02636400|No Intervention|expectant|7 menstrual cycles of expectant management
2539139|NCT02636400|Experimental|postop IUI|4 IUI cycles within 7 menstrual cycles
2539200|NCT02635997||patients on antiresorptive therapy|Ibandronate 150 mg per month + Vitamine D 400-800 IU and Calcium 500-1000 mg per day
2539212|NCT02635620||e-cigarette group|Probands are smokers who intend to start vaping for the first time. The probands are recruited in e-cigarette shops. It is aimed to include 60 persons who start vaping. A baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking/vaping behaviour and health status at the beginning and after 1, 2 and 3 months.
2539218|NCT02635620||smoking cessation group|Probands are smokers who intend to quit smoking within a clinical conducted smoking cessation program. It is aimed to include 20 persons who stop smoking. Like in the e-cigarette group, a baseline visit at the beginning will measure conventional lung function parameters, mannitol provocation, FeNO and exhaled CO. The measurement will be repeated after 3 months to evaluate changes in these parameters. In addition there will be questionnaires concerning smoking behaviour and health status at the beginning and after 1, 2 and 3 months.
2539286|NCT02635477|Experimental|Intervention Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with an actigraphy device that displays an adaptive personalized daily step count goal and audible alerts to increase physical activity
2539291|NCT02635477|Experimental|Control Group|frail elderly patients discharged from a cardiovascular hospitalization; provided with a matching actigraphy device that has a blacked-out screen and does not display step count goals or provide audible alerts (functions in silent monitoring mode only)
2539536|NCT02633592|Active Comparator|HRARM|Patients and healthy volunteers are subjected to position change ( LLP to SP) during pressure measurements with HR-ARM.
2539540|NCT02633592|Active Comparator|MRI Defecography|Patients and healthy volunteers are subjected to position change during MRI Defecography
2539554|NCT02633280||COPD-Untreated (Group 1)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that did not receive COPD treatment in the last 6 months (beta 2 agonists, corticosteroids, anticholinergics).
2539556|NCT02633280||COPD-uncontrolled (Group 2)|In this Group will be enrolled patients of both sex and older than 40-years with COPD stage GOLD 2 and 3 that receive a COPD treatment (e.g. beta 2 agonists, corticosteroids, anticholinergics) but with a post-bronchodilator FEV1< 80% and an FEV1/FVC < 0.7 or with 1-2 exacerbation/year
2539558|NCT02633280||Control subjects (Group 3)|In this Group will be enrolled patients of both sex and older than 40 years; (2) will be free from lung disease as determined by a physician; (3) will have a normal spirometry (FEV1> 85% and FEV1/FVC > 0.7)
3168169|NCT00547625|Active Comparator|2|Treatment phase 1 includes 5 mg tadalafil 6 weeks then treatment phase 2 which includes 20 mg tadalafil for 6 weeks.
2539672|NCT02632773|Experimental|Parent Learning Style 1|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2539673|NCT02632773|Experimental|Parent Learning Style 2|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2539676|NCT02632773|Other|Learning Style 1 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2539679|NCT02632773|Other|Learning Style 2 (Parent)|Mothers with Learning Style 2 will be randomly assigned to either the responsive intervention or directive intervention group.
2539752|NCT02632318|Experimental|Light|Dawn simulation for 30 minutes prior to habitual wake time
2539756|NCT02632318|No Intervention|No light|Darkness for 30 minutes prior to habitual wake time
2539796|NCT02631928|Experimental|Julphar Insulin 30/70|human biphasic insulin, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
2539798|NCT02631928|Active Comparator|Huminsulin® Profil III|human biphasic insulin, reference, 100 IU/mL, single subcutaneous injection of 0.6 IU/ kg body weight
2539857|NCT02631603|Experimental|Placebo|Capsules of placebo will be taken for 3 months.
3168170|NCT00547651|Experimental|Amrubicin|Amrubicin
3168171|NCT00547651|Active Comparator|Topotecan|Topotecan
3168172|NCT00547664|Experimental|A|
3168173|NCT00547664|Placebo Comparator|B|
3168174|NCT00547690|Experimental|1|Acupuncture and strength training
3168175|NCT00547690|Other|2|Strength training
3168176|NCT00547716|Experimental|1.|Omega-3 Fatty Acids 4 grams/day
3168177|NCT00547716|Placebo Comparator|2.|Placebo comparator along with interferon.
3168178|NCT00547794||CRT-D + AVJ Ablation|
3168179|NCT00547794||Single-Chamber ICD + Pharmacological Therapy|
3168180|NCT00547820|Experimental|A|with application of urinary sensor
3168181|NCT00547820|Placebo Comparator|B|without use of urinary sensor
3168182|NCT00547833||Experimental|Children with language-learning disabilities reading at approximately a 6th grade level
3168183|NCT00547833||Age-Matched|Typical language learners each of whom is pair match to an experimental participant by age and gender.
3168184|NCT00547833||Language-Matched|Typical language learners, each of whom is pair-matched to an experimental participant by reading comprehension skills and gender.
3168185|NCT00547872|Experimental|1|Best medical/behavioral treatment according to guidelines suggestions plus CAD screening by ECG tolerance testing followed by revascularization in case of coronary stenosis.
3168186|NCT00547872|No Intervention|2|Best medical/behavioral treatment according to guidelines suggestions
3168187|NCT00547885|Active Comparator|1|Active dihydrocodeine, long acting and Placebo dihydrocodeine short acting
3168188|NCT00547885|Active Comparator|2|Placebo dihydrocodeine, long acting and active dihydrocodeine short acting.
2538945|NCT02637570|Experimental|green tea|450 mg green tea 2 hour after dinner with 1 glass of cool water every day
2538951|NCT02637570|Placebo Comparator|control group|450 mg placebo (dextrose) 2 hour after dinner with 1 glass of cool water every day
2539023|NCT02637206|Experimental|Part 1 (Single Application)|All subjects will have two sets (left and right) of 4 semi-occlusive test patches applied to randomized test sites on their upper backs on Day 1. Test patches on left back will be for simple-patch test and those on right back will be for photo-patch test. Each set will consist of approximately 150 micro liter (0.15 mL) of the following study treatments: GSK2894512 0.5% cream, GSK2894512 1% cream, placebo (cream vehicle without the active ingredient) and an empty patch. The test patches will be applied for 24 hrs (photo-patch test) or 48 hrs (simple-patch test).
2539024|NCT02637206|Experimental|Part 2 (Repeat Application)|All subjects will have repeat applications of GSK2894512 0.5%, 1% cream and placebo twice a day for 7 days on both side (left and right, 3 in total) of their upper back (approximately 5 centimeter (cm) in diameter >10 cm away from another application area) under non-occlusive conditions and covered with gauze using adhesive. GSK2894512 0.5% and 1% cream and placebo will be randomized according to the randomization code in the same manner as Part 1.
2539087|NCT02636634|Other|diagnostic imaging strategy|PET-FET (positron emission tomography using 1-Fluoro-Ethyl-Tyrosine) and MSR (magnetic resonance spectroscopy) before biopsy
2539143|NCT02636478||reference group|therapy naive patients with a sleep related breathing disorder
2539144|NCT02636478||therapy group|patients with devices treating their sleep related breathing disorder
3202331|NCT00912548|No Intervention|Permanent postmenopausal(A) group|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. Eligible patients except for premenopausal status at the baseline will be followed up until 2 years after the baseline assessment for evaluating the menopausal status. This group still remains to postmenopausal status and will taking tamoxifen 20mg/day for 5 years if they remain in the study.
3202332|NCT00912548|Active Comparator|TAM(B)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized into the additional ovarian function suppression group or tamoxifen only group. This group, patients are premenopausal women, they will be randomized into tamoxifen only group, complete taking tamoxifen 20mg/day for 5 years.
2539257|NCT02635243|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
2539260|NCT02635243|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
2539261|NCT02635243|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions and under induced hypoglycemia. Novolin^®R will be used to induce hypoglycemia.
3202333|NCT00912548|Experimental|TAM+OFS (C)|Patients, less than or equal to 45 years of age with hormone receptor positive breast cancer will be enrolled. Included All the patients have already treated by surgery, neo- or adjuvant chemotherapy ±and/or radiotherapy before enrolment. At 6, 12, 18 and 24 months since the baseline assessment (0), the ovarian function status will be evaluated by menstruation status or serum FSH level. If the patients are regarded as the premenopausal women, they will be randomized. This group, patients are premenopausal women, they will be randomized into the additional ovarian function suppression group. Ovarian function suppression will be done by administration of LHRH agonist (ZOLADEXTM) for 2 years. Then, Patients will complete taking tamoxifen 20mg/day for 5 years.
3202334|NCT00912561|No Intervention|Sedentary|patients who train after an 8 week observational period
2539807|NCT02631889|Experimental|Transcollation technology|the use of transcollation technology for hilium dissection during Lung surgery
2539808|NCT02631889|Active Comparator|Traditional Electrocautery|The use of electrocautery for hilium dissection during lung surgery
3202335|NCT00912561|Active Comparator|patients who train immediately after enrollment|patients who train immediately after enrollment
3202336|NCT00912574|Active Comparator|Saline|first of 4 arms: injection: 1 ml saline
3202337|NCT00912574|Active Comparator|GM-CSF|Second of 4 arms: injection: specified dose of GM-CSF in 1 ml saline
3202338|NCT00912574|Active Comparator|0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline|Third of 4 arms: injection: 0.5 ml Montanide ISA-51 adjuvant and 0.5 ml saline
2539991|NCT02630823|Experimental|Arm 1: MK-3475|"Patients will undergo endometrial biopsy followed by 2 doses of MK-3475 3 weeks apart. 3-4 weeks after the second dose of MK-3475, the standard of care surgical resection will take place, followed by standard of care adjuvant therapy. Tissue and blood will be collected at the time of surgical resection for immune analysis. For patients whose pathology confirms high-risk features and advanced stage, MK-3475 will be given every 3 weeks starting 4 -6 weeks after completion of adjuvant therapy for a maximum of 4 doses post-surgery.~MK-3475 will be given intravenously at a dose of 200 mg over the course of 30 minutes.~The standard of care chemotherapy will consist of 6 cycles of paclitaxel and carboplatin AUC 5 every 3 weeks for 6 cycles.~The decision to administer radiation therapy will be per the treating physician. If the patient does not receive radiation therapy, then the patient will start MK-3475 every 3 weeks x 4 doses after the completion of chemotherapy."
3202339|NCT00912574|Active Comparator|GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant|Fourth of 4 arms: injection: specified dose of GM-CSF in 0.5 ml slaine plus 0.5 ml Montanide ISA-51 adjuvant
3202340|NCT00912600||1|Elderly individuals presenting to one of 15 emergency departments and possibly qualifying for admission to an ICU
2540257|NCT02628977|Experimental|OSA Health Education & Support Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer educator.
2540260|NCT02628977|Active Comparator|Attention Control Group|Participants in the attention control group will receive standard sleep literature, providing information about Obstructive Sleep Apnea and access to available sleep services.
2540304|NCT02628834|No Intervention|Healthy Volunteers|Healthy individuals will only be evaluated with no intervention
2539008|NCT02637167|Active Comparator|Saccharomyces boulardii|S. boulardii: two capsules (500 mg) morning and evening for three months
2539010|NCT02637167|No Intervention|Control group|The third group receives no intervention
3202341|NCT00912613|No Intervention|Discussion with nurse|Brief discussion with ICU follow-up nurse about the patients' critical illness
3202342|NCT00912613|Experimental|ICU Diary|Receipt of ICU Diary at 1 month post critical illness
3202343|NCT00912626|Experimental|FU-1 feedback|
2539201|NCT02635685|Experimental|Intervention group|Intervention with Clinical Decision Support tool installed on units.
2539203|NCT02635685|No Intervention|Control group|Control group without intervention with Clinical Decision Support tool installed on units.
2539253|NCT02635555|Experimental|Adjusted Spinal Dose|"Patients in this group receive height and weight adjusted dose for spinal anesthesia.During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
2539254|NCT02635555|Active Comparator|Standard Spinal Dose|"Patients in this group receive a fixed standard dose for spinal anesthesia. During surgery, phenylephrine/ephedrine is given to maintain blood pressure as necessary.~Episodes of hypotension will be treated with these vasopressors ."
2539311|NCT02635191|Experimental|Tailored Group|In tailored therapy, medications will be adjusted according to the antimicrobial susceptibility testing (including Clarithromycin sensitivity) and cytochrome P450 isoenzyme 2C19 genotype. 10 days regimen will be prescribed.
2539312|NCT02635191|Active Comparator|Standard group|In standard triple therapy, children will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) for 10 days.
3202344|NCT00912626|No Intervention|control group|
3202345|NCT00912639|Experimental|Genexol-PM|"All the patients are recurrent breast cancer after taxane treatment. Patients with a measurable lesion (at least 1 measurable lesion)~Spiral CT : lesion ≥ 10mm (unidimension)~X-ray, MRI, ultrasound : lesion ≥ 20 mm (unidimension)"
3202346|NCT00912652|Experimental|High Intensity Lifestyle Intervention|High intensity group will receive 48 sessions of lifestyle intervention over a two-year period
3202347|NCT00912652|Experimental|Mod. Intensity Lifestyle Intervention|Moderate intensity group will receive 32 sessions of lifestyle intervention over a two-year period.
2539470|NCT02633930|Experimental|berberine quadruple therapy|Berberine 300 mg, three times daily for 14 days,lansoprazole 30 mg,amoxicillin 1000 mg, and Bismuth 220 mg by mouth, twice daily for 14 days.
2539472|NCT02633930|Active Comparator|clarithromycin quadruple therapy|Bismuth 220 mg, lansoprazole30 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
2539527|NCT02633605||First Sense Breast Exam|
2539544|NCT02633410|Active Comparator|Transtibial|Transtibial technique used to create femoral tunnel
2539545|NCT02633410|Active Comparator|Anteromedial|Anteromedial technique used to create femoral tunnel
2539581|NCT02633189|Experimental|erlotinib and bevacizumab|
2539583|NCT02633189|Active Comparator|erlotinib|
2539691|NCT02632643|Experimental|lifestyle counseling|
2539782|NCT02632188|Active Comparator|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
2539790|NCT02632188|Experimental|DC-PMAT treatment|On the basis of postoperative routine treatment, patients will receive 3 cycles of dendritic cell-precision multiple antigen T (DC-PMAT) cells treatment.
2539844|NCT02631629|Placebo Comparator|Non-fortified foods SA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of South Asian (SA) origin
2539847|NCT02631629|Placebo Comparator|Non-fortified foods CA|Non-fortified foods (eggs, cheese, yoghurt, crips bread) (placebo), women of Caucasian (CA) origin
2539850|NCT02631629|Active Comparator|Vitamin D fortified foods SA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of South Asian (SA) origin
2539852|NCT02631629|Active Comparator|Vitamin D fortified foods CA|Vitamin D fortified foods (eggs, cheese, yoghurt, crips bread), women of Caucasian (CA) origin
2539891|NCT02631317||rt-PA|patients treated with rt-PA, followed strategies were used: advance hospital notification by EMS, stroke team notification, key performance indicators feedback form, standard informed consent procedures, performance of thrombolysis at CT-room.
2539937|NCT02631031|Other|morning administration|administration of single oral dose valsartan (160 mg) in the morning
2539939|NCT02631031|Other|evening administration|administration of single oral dose valsartan (160 mg) in the evening
2540024|NCT02630680||Colorectal diseases patients|
2540105|NCT02630108|Experimental|Thermal Ablation & TACE|"Transarterial chemoembolization (TACE) is performed immediately following thermal ablation.~EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE."
2540107|NCT02630108|Active Comparator|TACE alone|Only TACE is performed. EADM, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
2540174|NCT02629692|Experimental|Vodobatinib (K0706) capsules|
2540370|NCT02628353|Placebo Comparator|Placebo|control group
2540372|NCT02628353|Experimental|Phenolic compound|treated group
2540426|NCT02627950|Active Comparator|Isotonic sodium chloride + Ticagrelor|46 patients with NaCl i.v. and 180 mg ticagrelor orally pre revascularization plus medical standard therapy
2540429|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor|46 patients with 5 mg morphine i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
2540432|NCT02627950|Experimental|Morphinhydrochloricum + Ticagrelor + Metoclopramide|46 patients with 5 mg morphine i.v. and 10 mg MCP i.v. and 180 mg ticagrelor pre revascularization plus medical standard therapy
2540485|NCT02627521|Experimental|PRU Guided CABG|Timing of CABG surgery within 24 hours of reaching a normalized platelet function (NPF). NPF defined as a PRU value >235 or a PRU value between >170 and <235 for two consecutive days as documented by VerifyNow assay.
2540486|NCT02627521|Active Comparator|CABG per standard of care|Timing of CABG per standard of care
2540647|NCT02626338|Experimental|Arm B|"Mitoxantrone~Etoposide~Cytarabine~Crenolanib"
3202348|NCT00912652|Experimental|Low Intensity Lifestyle Intervention|Low intensity group will receive 16 sessions of lifestyle intervention over a two-year period.
3202349|NCT00912652|Active Comparator|Health Education Control|Health education control group will receive 16 sessions of health education related to diet and exercise over a two-year period.
3202350|NCT00912665|Experimental|Healthy Volunteer|
2539167|NCT02636114|Active Comparator|scaling and root planing|this was an international study in which scaling and root planing was done in systemically healthy patients patients with chronic periodontitis
2539173|NCT02636114|No Intervention|control group|Scaling and planing was not done that no intervention is carried out in this group
2539225|NCT02635776|Experimental|AR101 powder provided in capsules & sachets|Study product provided in pull-apart peanut protein capsules or sachets
2539226|NCT02635776|Placebo Comparator|Placebo powder provided in capsules & sachets|Placebo formulation in pull-apart capsules or sachets containing only inactive ingredients
2539340|NCT02634905|Experimental|Individual session therapeutic education|The children included in the active arm will undergo, along with their parents (by child's age and wish), a structured individual TPE session between W0 and W2. This session will be conducted by the nurse trained in TPE. The session will be one hour long.
2539341|NCT02634905|No Intervention|Control|
2539418|NCT02634437|Experimental|Normal Renal Function|Ulipristal acetate, 10 mg, oral administration
2539419|NCT02634437|Experimental|Moderate Renal Impairment|Ulipristal acetate, 10 mg, oral administration
2539420|NCT02634437|Experimental|Severe Renal Impairment|Ulipristal acetate, 10 mg, oral administration
2539445|NCT02634034|Experimental|NK-104-CR (8mg), Pitavastatin IR (4mg), Pitavastatin IR (8mg)|
2539446|NCT02634034|Experimental|Pitavastatin IR (4mg), Pitavastatin IR (8mg), NK-104-CR (8mg)|
2539448|NCT02634034|Experimental|Pitavastatin IR (8mg), NK-104-CR (8mg), Pitavastatin IR (4mg)|
2539526|NCT02633826||kidney transplant recipients|kidney transplant recipients of an allograft from a living donor, no intervention
3202351|NCT00912678|Active Comparator|MMF and Steroid Group|Group of Patients randomized to MMF and Steroid maintenance immunosuppression after 3 months (Tacrolimus withdrawal)
3202352|NCT00912678|Active Comparator|Low-Dose Tacrolimus Group|Patients randomized to withdrawal of MMF after 3 months and maintenance immunosuppression with low-dose tacrolimus and Steroids
2539619|NCT02632968|Active Comparator|Pinhole surgery with orthodontic buttons|Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
2539621|NCT02632968|Active Comparator|Pinhole surgery without buttons|Pinhole surgery without orthodontic buttons The selected participants were assigned in test and control. In the control group, after administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions till the recession defects were covered. No sutures or orthodontic buttons were used in the control site.
2539650|NCT02632708|Experimental|AG-120 with cytarabine and daunorubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in complete response (CR) or complete remission with incomplete hematologic recovery (CRi) (including CR with incomplete platelet recovery [CRp]) may continue on maintenance therapy and receive daily treatment with AG-120.
2539652|NCT02632708|Experimental|AG-120 with cytarabine and idarubicin|Daily AG-120 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-120. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-120.
2539653|NCT02632708|Experimental|AG-221 with cytarabine and daunorubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2539681|NCT02632656||Patients with congestive heart failure|Patients with congestive heart failure (CHF) who are followed in the hospital or clinic setting, with optimization of medical therapy
2539730|NCT02632370||Gliolan®|Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials. The formulation contains 1.5 g 5-aminolevulinic acid hydrochloride corresponding to 1.17 g of 5-aminolevulinic acid. The oral solution is intended for single (partial) use.
3202353|NCT00912691|Experimental|1|CM-AT
3202354|NCT00912717||Pancreatic Cancer|individuals who have been diagnosed with pancreatic cancer
3202355|NCT00912717||Unaffected|individuals who have not been diagnosed with pancreatic cancer
3202356|NCT00912756|Experimental|1cilostazol|Cilostazol group: Treatment with cilostazol 200 mg/day BID (morning and evening) and aspirin at 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
3202357|NCT00912756|Active Comparator|2aspirin|Non-cilostazol group: Treatment with aspirin 100 mg/day will be started 3 to 7 days prior to EVT and continued until the end of the 2-year follow-up period.
3202358|NCT00912769||subvastus approach/ midvastus approach|subvastus: vastus medialis oblique was not cut during operation midvastus: vastus medialis oblique was cut during operation
2539197|NCT02635659|Placebo Comparator|Placebo|The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
2539213|NCT02635594|Experimental|Carnipure® tartrate|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
2539221|NCT02635594|Placebo Comparator|Placebo|1000mg cellulose + 475mg L-tartaric acid
2539275|NCT02635464|Experimental|hUC-MSCs+Injectable collagen scaffold+CABG|
2539280|NCT02635464|Active Comparator|hUC-MSCs+CABG|
2539287|NCT02635464|Active Comparator|CABG|
2539502|NCT02633813|Experimental|Naftifine hydrochloride 2%|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2539508|NCT02633813|Active Comparator|Naftin® 2% (Naftifine hydrochloride 2%)|A thin layer of sufficient quantity of Naftifine hydrochloride cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2539511|NCT02633813|Placebo Comparator|Placebo vehicle cream.|A thin layer of sufficient quantity of vehicle cream need to be applied to the affected areas plus an approximate ½ inch margin of healthy surrounding skin once daily consecutively for 2 weeks.
2539562|NCT02633267|Experimental|Usual Vocational Services + CBT|This is the experimental intervention - Usual vocational services at a vocational services center plus additional cognitive behavioral therapy at vocational service center.
2539566|NCT02633267|Active Comparator|Usual Vocational Services|This is the care as usual intervention - Vocational services as usually delivered to service seeking clients
2539688|NCT02632539|Active Comparator|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
2539690|NCT02632539|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
2539776|NCT02632240|Active Comparator|Control group|Surgery:The tunnel technique for covering gingival recession. Graft: connective tissue.
2539786|NCT02632240|Active Comparator|Study group|Surgery:The tunnel technique for covering gingival recession.Graft: xenogenic collagen matrix (Mucoderm).
2539823|NCT02631681|Experimental|Men with prostate cancer on androgen deprivation therapy|Group based supervised combined aerobic and resistance training for 12 weeks.
2539894|NCT02631434|Experimental|sit-to-stand|To perform a sit-to-stand test
2539897|NCT02631434|Active Comparator|six minute walking test|To perform a six minutes walking test
2539916|NCT02631122|Active Comparator|Supraclavicular BPNB|Patients in this group will be randomized to receive an Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
2539917|NCT02631122|Active Comparator|Retroclavicular BNPB|Patients in this group will be randomized to receive an Ultrasound Guided Retroclavicular Brachial Plexus Nerve Block and outcomes will be measured over the perioperative and 1day time period.
2539965|NCT02630888|Active Comparator|Memantine|Patients randomized to this group will receive a dose of 15 mg / day of memantine during the first week (V0); all have the dose of memantine increased on the second week (V1) at the dose of 30 mg / day (in two divided doses of 15 mg).
2539973|NCT02630888|Placebo Comparator|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine.
2540025|NCT02630602|Active Comparator|Functional goat cheese|The functional cheese is rich in conjugated linoleic acid (CLA) and omega-3. It was used for obese and overweight people, who need a special diet advice to control of lipid profile. 9,3% of polyunsaturated fatty acids 60 g per day during 12 weeks
2540033|NCT02630602|Placebo Comparator|Control cheese|Control cheese, not enriched with conjugated linoleic acid (CLA) and omega-3 4.1% of polyunsaturated fatty acids. 60 g per day during 12 weeks
2540085|NCT02630264|Experimental|Combination therapy|"E10A+chemotherapy group (360 subjects):~E10A (Endostatins) of 1.0×1012VP on day 1 and 6~Paclitaxel Injection 160mg/m2 on day 3~Cisplatin Injection 25mg/m2 on day 3, 4, and 5. Repeat every 21 days."
2540087|NCT02630264|Experimental|Chemotherapy|"Chemotherapy-alone group (180 subjects):~Paclitaxel Injection 160mg/m2 on day 1~Cisplatin Injection 25mg/m2 on day 1, 2, and 3. Repeat every 21 days"
3168189|NCT00547937|Sham Comparator|Sham-CPAP|The sham CPAP device consisted of a conventional CPAP device, in which the area of the exhalation port was amplified, thereby nearly cancelling nasal pressure; an orifice resistor was connected between the tubing and the CPAP unit that loads the blower with the same airflow resistance as in effective CPAP
2540238|NCT02629380|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (Hymovis, Fidia Farmaceutici SpA, Padova, Italy) at the end of the arthroscopic meniscectomy
2540243|NCT02629380|Other|meniscectomy alone|Arthroscopic meniscectomy alone
2540293|NCT02628795|Experimental|PRT + FM|Progressive resistance training + functional mobility training 3 d/wk x 16 wk
2540303|NCT02628795|Active Comparator|Usual Care|Post-surgical usual care including physical therapy
2540349|NCT02628405|Experimental|Treatment (R2-ICE)|Patients receive lenalidomide PO daily on days 1-14, rituximab IV on day 1, ifosfamide IV over 24 hours on day 2, carboplatin IV over 1-2 hours on day 2, and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for 2 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CMR, PMR, or NMR may receive 2 more cycles per physician discretion. After completion of 2 cycles of R2ICE treatment, patients achieving objective status of CMR, PMR or NMR may proceed to SCT during the event monitoring phase.
2540508|NCT02627365|Experimental|Individualized, interactive SMS|Individualized, interactive SMS intervention plus Standard care. Messages sent automatically using the Text-IT system.
3168190|NCT00547937|Active Comparator|CPAP|
3168191|NCT00547950|Experimental|1|drug
3168192|NCT00547963|Experimental|1|two brief counseling sessions delivered to ED patients who report conjoint alcohol and marijuana use
3168193|NCT00547989|Active Comparator|1|control
2539206|NCT02635607|Other|Fixed Protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start fixedly on stimulation Day 5. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
2539208|NCT02635607|Other|Flexible protocol|Patients will start Follitropin beta stimulation on menstrual cycle day 3 and the daily dose will be fixed for the first 5 days of stimulation, a modification of the rFSH dose will be allowed from stimulation day 6 onward. Ganirelix will start flexibly by the promissory criterion in the flexible group. rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed, and triptorelin trigger will be used as a replacement in case of OHSS high risk
2539304|NCT02635308|Experimental|Experimental|"High-Intensity, Unilaterally-Biased Resistance training 3x/wk x 12wk MOVE"
2539322|NCT02634853|Active Comparator|Tavilermide Ophthalmic Solution|1% Tavilermide Ophthalmic Solution
2539323|NCT02634853|Placebo Comparator|Vehicle Ophthalmic Solution|Placebo Ophthalmic Solution
3202359|NCT00912769||Cybex|Knee extension/ flexion isometric and isokinetic performance of all cases were tested using Cybex
3202360|NCT00912821|Active Comparator|8 L dialysate|8 L peritoneal dialysis solution
2539458|NCT02634138|Experimental|Intervention|Revitive IX Neuromuscular Electrical Stimulation Device
2539506|NCT02633774|Active Comparator|Rhythm control group|1. Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation 2. check the echo, brain perfusion CT and K-MOCA on baseline 3. confirm a thrombus through the TEE 4. Cardioversion after 1 month 5. Rhythm FU schedule (2012 ACC/AHA/ESC guidelines) 6. If AF recur, RFCA 7. check the brain perfusion CT, K-MOCA after 3M and 12M
2539510|NCT02633774|Active Comparator|Rate control group|1. No AAD, just anticoagulation 2. HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin) 3. check the echo, brain perfusion CT and K-MOCA on baseline 4. check the brain perfusion CT and K-MOCA after 3M and 12M 5. Without the treatment about antiarrythmia and rhythm control, diffication of rate control, the subject will be drop out for study.
2539564|NCT02633475||CONTROL: women no miscarriage|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than one successful pregnancy without miscarriage. Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
2539570|NCT02633475||CASE: patients with IRM|Group of patients who referred to the Fourth Affiliated Hospital of Guangxi Medical University or Liuzhou Maternity and Child Healthcare Hospital, who have more than three consecutive miscarriages without clear cause (Idiopathic Recurrent Miscarriage, IRM). Then the blood sample will be collected and the IL-10 Polymorphism will be analyzed.
3202361|NCT00912821|Experimental|6 L dialysate|6 L peritoneal dialysis solution
3202362|NCT00912834||1|tract and field athletes
2539702|NCT02632422|Experimental|Non-ambulatory - dAIH|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
2539708|NCT02632422|Sham Comparator|Non-ambulatory - dSHAM|Non-ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) 10 treatment visits at a frequency of 5 days each week for 2 weeks.
2539709|NCT02632422|Experimental|Ambulatory - dAIH+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily acute intermittent hypoxia (dAIH) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
2539711|NCT02632422|Sham Comparator|Ambulatory - dSHAM+Walk|Ambulatory subjects will be randomly assigned to receive 10 sessions of daily room air (dSHAM) coupled with 60 minutes of walking practice at a frequency of 5 days each week for 2 weeks.
2539714|NCT02632422|Other|Ambulatory-Walk|Ambulatory subjects will be randomly assigned to 10 sessions of walking practice only for 5 consecutive sessions/week x 2 weeks.
2539733|NCT02632019|Active Comparator|gemcitabine|Gemcitabine treatments will be performed once a week with a total of six times
2539734|NCT02632019|Experimental|Dendritic cell-precision T cell for neo-antigen|Dendritic cell-precision T cell for neo-antigen (DC-PNAT) combined with gemcitabine treatment: Gemcitabine: once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: once per 3 weeks with a total of three periods.
2539795|NCT02631941|Experimental|Z7200|single dose (two inhalations)
2539797|NCT02631941|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
2539799|NCT02631941|Experimental|Z7200 with charcoal|single dose (two inhalations)
2539800|NCT02631941|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
2539801|NCT02631941|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
3202363|NCT00912834||2|swimming athletes
3202364|NCT00912834||3|tennis athletes
3202365|NCT00912834||4|football athletes
3202366|NCT00912834||5|basketball athletes
3202367|NCT00912834||6|Badminton athletes
3202368|NCT00912834||7|control group
3202369|NCT00912847||JHC|AFP > 20 ng/ml and USG positive
3202370|NCT00912847||Non JHC|patient without AFP > 20 or USG negative
3202371|NCT00912860|Experimental|1|serum-free avonex given IM
3202372|NCT00912886||1: Case|Patients with early and moderate AD
3202373|NCT00912886||2: Controls|AD free volunteer-controls matched for gender and age
3202374|NCT00912899|Experimental|One|Noscapine HCl
3202375|NCT00912938|Experimental|Zoledronic acid|Patients with advanced breast cancer with radiographic confirmation of bone metastases. This arm will be receiving zoledronic acid administration. The primary endpoint is to find the correlation between bone turnover markers and the frequency of skeletal-related-events for one year. Skeletal related events are defined as pathologic fractures, the need for radiation therapy, orthopaedic surgery, hypercalcemia of malignancy and spinal cord compression. A total of 237 patients will be included.
3202376|NCT00912977||Group 1|Groups are defined by another study
3202377|NCT00912977||Group 2|Groups are defined by another study
3202378|NCT00912977||Group 3|Groups are defined by another study
3202379|NCT00913016||letrozole (Femara)|
2539313|NCT02635165|Active Comparator|Surgical treatment with Stracos|The patient was placed in the lateral decubitus position. The procedure involved a curvilinear thoracic incision overlying the center of the fractured segments. The intercostal muscles were dissected off the rib on its superior aspect away from the fracture site, and the fracture was then reduced. The investigators then chose the most suitable Stracos, which is to be found in two available sizes, 6 or 9 claws, according to the length of the fracture. The clip chosen was molded according to the shape of the corresponding rib and the claws were crimped using special pliers on and around the fractured rib.The investigators treated only one rib out of two with Stracos, and as for displaced or comminuted fractures, the adjacent rib was wrapped using vicryl suture on the osteosynthesis rib.
2539314|NCT02635165|No Intervention|Medical treatment|
2539360|NCT02634736|Experimental|Exergame plus usual treatment|Exergame programme plus usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
2539363|NCT02634736|No Intervention|Usual treatment|No exergame programme, just usual falls prevention treatment including assessment and exercises (prescribed by the physiotherapists).
2539427|NCT02634450|No Intervention|Control|Current practice of Early Infant Diagnosis in Mozambique: using conventional system of collecting blood on Dried Blood Spot and sending it to central laboratory for PCR processing and receiving result by SMS printer.
2539430|NCT02634450|Active Comparator|Intervention|Point Of Care Device (Alere q) is used for Early Infant Diagnosis, with the sample collected and processed in the consultation room with the device
2539463|NCT02634008|Experimental|Cohort 1|Paritaprevir/ritonavir/ombitasvir (75mg/50mg/12.5mg) and dasabuvir (250mg) with or without ribavirin (1000-1200mg) daily taken orally for 8 weeks.
2539465|NCT02634008|Experimental|Cohort 2|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 6 weeks
2539468|NCT02634008|Experimental|Cohort 3|Three tablets of glecaprevir/pibrentasvir (100mg/40mg) daily taken orally for 4 weeks
2539530|NCT02633566|Active Comparator|Functional plantar orthoses|Functional plantar orthoses in polypropylene with Medial Heel Skive technique
2539532|NCT02633566|Placebo Comparator|Placebo plantar orthoses|Plantar orthoses made in Ethil Vinyl Acetate (22º Shore) without correction of the pronation
2539630|NCT02632877|Experimental|Pirfenidone with MODD|"Active ingredients: Pirfenidone 8% with modified oxide diallyl disulfide (MODD) 0.016%.~Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every eight hours for 6 months."
2539632|NCT02632877|Active Comparator|Ketanserin|"Active ingredients: Ketanserin 2%. Dosage form: gel. Dosage: standar finger tip unit (0.5g for an area of 100 to 120 square centimeters).~Frequency and duration: topically applied every 12 hours for 6 months."
3168194|NCT00547989|Experimental|2|PVB with ropivacaine and postoperative pump 5ml/h
3168195|NCT00547989|Experimental|Experimental 1|PVB with ropivacaine, 10 patients included but not analysed
3168196|NCT00548002||1 and 2|Patients were randomly assigned to receive either 1) standard treatment or 2) standard treatment combined with a fluoroquinolone (trovafloxacin or levofloxacin).
2539818|NCT02631824|Active Comparator|Standard treatment|open reduction and internal fixation TFNA
2539819|NCT02631824|Experimental|Augmentation|open reduction and internal fixation TFNA Augmentation (Cement)
2539885|NCT02631356|Placebo Comparator|Ringer's lactate solution|Infusion of Ringer's lactate solution (10ml/kg) in the control group
2539887|NCT02631356|Active Comparator|Succinylated gelatin|Infusion of Succinylated gelatin (10ml/kg) in the test group
2539932|NCT02631161|Experimental|EQUIA forte|Dental non-carious cervical restorations are being restored with a glass hybrid restorative system (Medical product: EQUIA forte).
2539935|NCT02631161|Active Comparator|Filtek Supreme XT/Clearfil SE Bond|Dental non-carious cervical restorations are being restored with a composite resin based material/Adhesive combination (Medical product: Filtek Supreme XT/Clearfil SE Bond).
2540383|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
2540421|NCT02627872||COPD patients (GOLD I-II)|Participants with mild-to-moderate COPD (GOLD I-II)
2540424|NCT02627872||Smoker Control Group|Actively smoking participants with normal lung function (do not have COPD)
2540428|NCT02627872||Healthy Never-smoker Control Group|Healthy participants that never have smoked
3168197|NCT00548015|Active Comparator|State of the Art strategy|education, reminders, performance feedback,
3168198|NCT00548015|Experimental|extended strategy|state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
3168199|NCT00548054|Experimental|Vaccine Group for Vibriocidal Assay|Killed whole cell cholera vaccine bled at day 42 for vibriocidal assay
2540558|NCT02627131|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
3168200|NCT00548054|Experimental|Vaccine Group for EPI Assay|Killed whole cell cholera vaccine bled at day 56 for EPI immunogenicity testing
3168201|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal Assay|Placebo bled at day 42 for vibriocidal assay
3168202|NCT00548054|Placebo Comparator|Placebo Group for EPI Assay|Placebo bled at day 56 for EPI immunogenicity testing
3168203|NCT00548054|Experimental|Vaccine Group for Vibriocidal and Measles Assay|Killed whole cell cholera vaccine bled at day 14 and 28 for measles immunogenicity testing
3168204|NCT00548054|Placebo Comparator|Placebo Group for Vibriocidal and Measles Assay|Placebo bled at day 14 and 28 for measles immunogenicity testing
3168205|NCT00548067|Active Comparator|1|
3168206|NCT00548067|Active Comparator|2|
3168207|NCT00548067|Active Comparator|3|
3168208|NCT00548067|Experimental|4|
3168209|NCT00548093|Experimental|1|descriptive: adenocarcinoma histology
3168210|NCT00548093|Experimental|2|descriptive: non-adenocarcinoma histology
3168211|NCT00548106|Experimental|1|Infants will be fed the new hydrolyzate formula.
3168212|NCT00548106|Placebo Comparator|2|Nan HA infant formula
3168213|NCT00548119|Experimental|NeoCart|
3168214|NCT00548119|Active Comparator|microfracture|
3168215|NCT00548223|Experimental|Dengzhan Shengmai capsule|Dengzhan Shengmai capsule 0.18g by mouth twice a day for 1year
2539315|NCT02634944|Experimental|mTBI|mTBI (concussed) participants will be administered the VOMS after concussive event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2539316|NCT02634944|Sham Comparator|Healthy Control|Healthy controls will be administered the VOMS tool. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2539317|NCT02634944|Experimental|BLAST mTBI|Blast mTBI (concussed) participants will be administered the VOMS after concussive blast event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2539319|NCT02634944|Experimental|BLUNT mTBI|Blunt mTBI (concussed) participants will be administered the VOMS after concussive blunt event. The VOMS- which requires only a small target with 14 point font text and takes only 5 min to administer- includes assessments in five domains: (1) smooth pursuits, (2) horizontal and vertical saccades, (3) near point of convergence (NPC) distance, (4) horizontal and vertical VOR, and (5) VMS.
2539361|NCT02634697|Experimental|3RP Intervention Group|"AF Patients will undergo the 3RP intervention which will comprise of the following:~i. One-one-one session: each subject will spend an hour with a clinician to set specific goals for the intervention. They will also answer questionnaires.~ii. ECG monitoring: Enrolled subjects may be monitored with an ECG at some point after the time of consent up to the day of the one-on-one session, and again after completing the 8 weeks.~iii. Weeks 1 - 8: subjects will meet with the clinician/staff member as a group once a week for 1.5 hours each where they will be taught a variety of techniques to elicit the relaxation response as well as other cognitive skills.~At the end of the 4th (mid-point) and 8th (last) weekly session, subjects will answer questionnaires.~iv. 6 month follow up: 3 months after the final 3RP session to answer questionnaires.~v. Subjects will be asked to keep track of their AF episodes during the course of the study."
2539364|NCT02634697|Active Comparator|3RP Waitlist Control Group|The Control Group will wait for 6 months (from the time the Intervention group starts the 3RP intervention) and then will undergo the same study procedures as the intervention group - except for the 6 month follow up.
3168216|NCT00548223|Placebo Comparator|Placebo|Placebo 0.18g by mouth twice a day for 1year
3168217|NCT00548236|Experimental|1|Immediate participation in a 16-week exercise program
2539692|NCT02632578||HIV-positive|
2539693|NCT02632578||HIV-negative|
2539762|NCT02632227||Hypovolemia|patients with hypovolemic signs including hypotension, decreased central venous pressure (less than 5mmHg), and decreased urine output
2540026|NCT02630589|Experimental|ABI implantation|All 10 patients included in the study will be neurosurgically implanted with the ABI. This is open label, not blinded. The implant is permanent, but can be switched off.
2540094|NCT02630277|Experimental|Arm 1|1:1 Intravitreal Aflibercept Injection once every 4 weeks
2540095|NCT02630277|Experimental|Arm 2|Intravitreal of Aflibercept once every 4 weeks for 4 months then as needed (PRN)
2540128|NCT02629848|Experimental|Motesanib + Paclitaxel + Carboplatin|Motesanib 125 mg, (5 x 25 mg) tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target Area Under the Curve (AUC) of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib 125 mg, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
2540131|NCT02629848|Placebo Comparator|Placebo + Paclitaxel + Carboplatin|Motesanib placebo-matching tablets, orally, once daily and paclitaxel 200 mg/m^2, intravenous, once on Day 1 and carboplatin at a dose to achieve a target AUC of 6.0 mg/mL x minute, once on Day 1 of a 3 week Cycle for up to 6 Cycles. After 6 Cycles, motesanib placebo-matching, tablets, orally, once daily alone until disease progression, drug intolerability, study withdrawal or death for up to 36 months.
2540232|NCT02629172||Chronic infection of hepatitis C virus (HCV) Genotype 1 (GT1)|Participants with confirmed chronic hepatitis C genotype 1, receiving paritaprevir/ritonavir/ombitasvir according to standard of care and in line with the current local label
2540532|NCT02627105|Experimental|Beef group|Subjects in this group are asked to consume 4 or more servings of beef per week and to exclude all other red meats from their diet for the 6 month study.
3168218|NCT00548236|No Intervention|2|Control population; will receive exercise plan after 16-week control period
3168219|NCT00548275|Experimental|1|Enhanced Sexual Risk Management (ESRM): Patients assigned to ESRM will attend 4 individual gender-specific interactive counseling sessions, once weekly over a four-week period. They will attend 2 sessions (20 minutes, weeks 2 and 3) followed by 2 sessions (40 minutes, weeks 4 and 5) that will be gender-specific to the patient and gender-matched with the study physicians (one female and one male) who will be trained in HIV testing and risk counseling. Sessions will include skill-building in condom use, safer sex negotiation, self-control of triggers and coping skills, didactic materials, and distribution of written material and address self-perception of risk, barriers to risk reduction, and negotiation of a risk-reduction plan.
3168220|NCT00548275|Active Comparator|2|Standard Sexual Risk Management (SSRM): In SSRM, patients will attend two 10-minute gender non-specific individual educational sessions about HIV/AIDS provided by one of the study physicians who will be trained in HIV testing and risk counseling. Session 1 will coincide with the physician visit at the time of randomization. The patient will receive pre-test counseling at this time and undergo HIV antibody testing. Session 2 will take place 7 days later when the patient returns to receive their HIV test results and post-test counseling. In addition, subjects will receive didactic prevention messages about HIV relevant to their reported risks and will be asked if they have questions regarding this information.
3168221|NCT00548314|Experimental|1|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
3168222|NCT00548314|Experimental|2|After excision and adequate hemostasis, the selected wound will be treated with the dermal substitute Matriderm, a split skin graft (SSG), mesh 1:1.5.
2539326|NCT02635152|Experimental|Interpretation Bias Modification (IBM)|"Treatment consists of eight brief sessions. In Task 1, participants read unique scenarios (You notice someone pointing in your direction). A sentence meant to resolve the ambiguity will appear (This person thinks they reco_nize you). After filling in the missing letter, the interpretation is reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is this person mocking you?). In Task 2, participants are shown a word denoting a threatening (mocking) or benign (cheerful) interpretation. Participants are presented with an ambiguous scenario (You hear people at a nearby table laughing) and asked to denote whether the word and the sentence are related. Participants will receive positive or negative feedback based on their response."
2539327|NCT02635152|Active Comparator|Progressive Muscle Relaxation (PMR)|Participants will receive eight brief sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups.
2539374|NCT02634658|Experimental|Medical ICU Subjects|All Medical ICU subjects that meet eligibility criteria and are enrolled in the study will receive muscle Ultrasounds, Nerve Conduction Studies and Electromyography (EMG).
2539378|NCT02634658|Experimental|Neuro ICU Subjects|All Neuro ICU subjects that meet eligibility criteria and are enrolled in the study will receive Nerve Conduction Studies and Electromyography (EMG).
2539421|NCT02634294|Experimental|Peg interferon alfa-2b|Pegylated Interferon α-2b (PEG INTRON®) , 1~1.5μg/kg qw, subcutaneous injection, 1 to 12 months, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
2539447|NCT02634047|Active Comparator|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
2539451|NCT02634047|Experimental|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
2539498|NCT02633878|Experimental|CHM+MP|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
2539499|NCT02633878|Placebo Comparator|CHM Placebo+MP Placebo|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
2539500|NCT02633878|Experimental|CHM+MP Placebo|CHM one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP Placebo 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
2539507|NCT02633878|Experimental|CHM Placebo+MP|CHM Placebo one dose in the morning and in the evening respectively until 12 weeks of gestations (84 days); MP 100mg tablet by mouth, every 8 hours until 12 weeks of gestations (84 days).
3168223|NCT00548314|Experimental|3|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5 and VAC therapy. The VAC system will be set at 125mmHg, continuous mode, for 3-5 days.
2539606|NCT02632929||Diabetic Foot Ulcers at Amputation Risk|Patients at high risk for limb amputation from a diabetic foot ulcer will be treated with comprehensive, interdisciplinary approach (usual care) in combination with early application of advanced therapy; dehydrated human amniotic membrane allografts (AMNIOEXCEL®, Derma Science, Princeton, New Jersey).
2539781|NCT02631980|Experimental|IV iron|Postoperative iv iron administration (Ferinject) upon arrival in after surgery recovery room
2539788|NCT02631980|Placebo Comparator|IV placebo|Postoperative iv placebo administration upon arrival in after surgery recovery room
2539826|NCT02631655|Other|device 18FDOPA|impact of device 18F-FDOPA PET on treatment decisions
2539900|NCT02631395|Other|Training group|Six teams, consisting of 13 to 25 players each, were randomized into two groups throughout their competition season; the training Group (intervention Group) and the Control Group.The intervention group completed strength training exercises Three times a week the Whole competition season.
2539904|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
2540207|NCT02629419|Experimental|CAMB (Encochleated Amphotericin B)|Encochleated Amphotericin B (200 mg, 400 mg, 800 mg)
2540231|NCT02629042|Active Comparator|Control|
2540242|NCT02629042|Experimental|Experimental|
2540381|NCT02628197|Active Comparator|CONTROL GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.Scaling and root planing was not done in this group.
2540382|NCT02628197|Active Comparator|TEST GROUP|34 osteopenic postmenopausal women with chronic periodontitis who received scaling and root planing along with calcium (500mg) and vitamin D (250I.U.) supplementation twice a day for 6 months.
2540434|NCT02627885|Active Comparator|ICBT|Internet-based CBT for Parkinsons Disease with therapist contact added to standard medical treatment
2540435|NCT02627885|Other|SMT|Standard Medical Treatment for Parkinsons Disease only
2540506|NCT02627456|Active Comparator|4|(n=SS), will be group- matched (age, sex, village) controls for Arm 2 for the duration study. Subjects previously enrolled in Arm 3 may re-enroll in Arm 4. All subjects will receive antimalaria treatment at enrollment
3168224|NCT00548314|Active Comparator|4|After excision and adequate hemostasis, the selected wound will be treated with a split skin graft (SSG), mesh 1:1.5.
3168225|NCT00548353|Experimental|1|MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
3168226|NCT00548353|Placebo Comparator|2|MK3207 placebo as tablets will be Orally administered to patients with water. During each period (with and without acute migraine).
3168227|NCT00548366|Experimental|1|4 gram sodium diet
3168228|NCT00548366|Active Comparator|2|2 gram sodium diet
3168229|NCT00548379|Active Comparator|1|Vitamin D
3168230|NCT00548379|Placebo Comparator|2|
3168231|NCT00548444|Experimental|Group 1|Volunteers will receive a single dose of MVA85A followed by regular blood tests to measure the resulting cellular immune response.
3168232|NCT00548444|Experimental|Group 2|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
2539343|NCT02634918||those with < 2 bleeds into a joint and|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
2539344|NCT02634918||those with no bleeds into a joint will be enrolled into the st|3 groups of hemophilia patients Group I - Those with > 20 bleeds into a joint, Group II - those with < 2 bleeds into a joint and Group III - those with no bleeds into a joint will be enrolled into the study
2539386|NCT02634489|Active Comparator|Tamsulosin HCl and Solifenacin Succinate|Participants will receive daily doses of tamsulosin HCL and Solifenacin Succinate (3 dose strengths) as single tablets.
2539390|NCT02634489|Active Comparator|EC905 (tamsulosin HCI and solifenacin succinate)|Participants will receive a fixed combination tablet (3 dose strengths).
2539438|NCT02634229||Diabetic family members|(i) probands negative for GCK/MODY2 , HNF1A/MODY3 genes and HNF4A/MODY1; (ii) dominant inheritance of diabetes (three consecutive affected generations, or two generations with at least 2 diabetic patients in a generation); (iii) Diagnosis of diabetes before age 40 years in at least 3 diabetic family members; (iv) negative testing for anti-GAD and IA2-antibodies; and (v) body mass index < 30 kg/m2 (to avoid inclusion of patients with insulin-resistant type 2 diabetes).
2539440|NCT02634229||Healthy relatives|Healthy subjects whose relationship is relevant for genetic analysis and necessary for the validation step (family cosegregation study)
2539462|NCT02633969|Experimental|Indomethacin Capsules low dose|Indomethacin Capsules low dose twice daily for up to three days
2539467|NCT02633969|Experimental|Indomethacin Capsules high dose|Indomethacin Capsules high dose twice daily for up to three days
2539513|NCT02633709|Placebo Comparator|Part 1: Single Ascending Dose: Placebo|Participants will receive a single dose of matching placebo orally on Day 1 of Part 1.
2539515|NCT02633709|Experimental|Part 1: Single Ascending Dose: Risdiplam|Participants will receive a single ascending dose (SAD) of Risdiplam orally on Day 1 of Part 1.
2539517|NCT02633709|Experimental|Part 2: Food Effect: Fasted-Fed|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fasted state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fed state on Day 1.
2539518|NCT02633709|Experimental|Part 2: Food Effect: Fed-Fasted|This arm consists of two periods. In Period 1 participants will receive one oral dose of Risdiplam in the fed state on Day 1. In Period 2 participants will receive one oral dose of Risdiplam in the fasted state on Day 1.
2539521|NCT02633709|Experimental|Part 3: Itraconazole Interaction|In Period 1 a single oral dose of Risdiplam will be administered. After a wash-out period in Period 2 participants will be administered oral doses of itraconazole twice daily from Day 1 to Day 8. On Day 4 participants will receive a single oral dose of Risdiplam in the fed state in combination with itraconazole.
2539561|NCT02633345|Experimental|Probiotic|The probiotic tablets contain Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2 at a dose of 1 * 109 CFU/tablet. The participants will take two tablets a day for four weeks.
2539569|NCT02633345|Placebo Comparator|Control|Placebo tablets. The participants will take two tablets a day for four weeks.
3202380|NCT00913029|Active Comparator|Stent|One hundred patients will be randomized to implantation of two G2 stents in at least one eye.
2539724|NCT02632383|Experimental|Test Group|"Intervention: Young with Diabetes - app The test group receives standard care and the mHealth app Young with Diabetes - app to support young people to self-manage their diabetes.~The young people's parents are also invited to download the app. The diabetes team (doctors, nurses and dieticians) also have the app and uses the app in their consultations with the young people."
2539726|NCT02632383|No Intervention|Control Group|The control group receives standard care
2540054|NCT02630394|Experimental|Azithromycin prophylaxis|Azithromycin will be supplied as a 250-mg tablet. Participants weighing less than 40 mg will be instructed to take 1 tablet 3 days a week (Monday, Wednesday, and Friday), and participants who weigh more than 40 kg will be instructed to take 2 tablets on the same 3 days per week.
2540116|NCT02630095|Other|Control.|No anticoagulation，just routine follow up.
2540118|NCT02630095|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
3168233|NCT00548444|Experimental|Group 3|Volunteers will receive a single dose of MVA85A followed by an infusion of labelled (deuterated) glucose and regular blood tests.
3168234|NCT00548457||A|
3168235|NCT00548483|Active Comparator|1|dexamethasone 5mg was administered every 6 hour for 1 day
3168236|NCT00548483|Active Comparator|2|dexamethasone 10mg was administered every 6 hour for 1 day
3168237|NCT00548496|Experimental|Placebo-Controlled based on the two Intervention Groups below|Placebo-Controlled based on the two Intervention Groups below.
3168238|NCT00548522||1|Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
3168239|NCT00548522||2|Pregnant women (34-38 wks gestation) with Type 1 diabetes
3168240|NCT00548522||3|Post partum women with Type 1 diabetes
3168241|NCT00548522||4|Non pregnant women with Type 1 diabetes
3168242|NCT00548587|Active Comparator|1|Participants will receive one 50 mg E5555 tablet and two 100 mg placebo tablets, once daily for 12 weeks.
3168243|NCT00548587|Active Comparator|2|Participants will receive one 50 mg placebo tablet, one 100 mg E5555 tablet, and one 100 mg placebo tablet, once daily for 12 weeks.
3168244|NCT00548587|Active Comparator|3|Participants will receive one 50 mg placebo tablet and two 100 mg E5555 tablets, once daily for 12 weeks.
3168245|NCT00548587|Placebo Comparator|4|Participants will receive one 50 mg placebo tablet and two 100 mg placebo tablets, once daily for 12 weeks.
3168246|NCT00548600|Experimental|1|Iridium implant plus external beam irradiation
3168247|NCT00548600|Active Comparator|2|Standard external beam irradiation alone
3168248|NCT00548613|Experimental|A|Patients with documented acute myocardial infarction (heart attack) occurring within 4-24 hours after onset of symptoms
3168249|NCT00548613|Experimental|B|Candidates for coronary artery bypass grafting that suffered a myocardial infarction (heart attack) within the past 12 months
3168250|NCT00548626|Active Comparator|A|Patients assigned to simple needle group (SN) will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
2539345|NCT02634710|Experimental|Hypofractionated Radiation Therapy|Radiation treatment in which the total dose of radiation is divided into large doses and treatments are given every other day. Hypofractionated radiation therapy is given over a shorter period of time (fewer days or weeks) than standard radiation therapy.
2539417|NCT02634502|Experimental|Treatment|Patients will receive radiofrequency ablation for liver metastatic lesions, as well as two weeks of oral S-1 treatment every three weeks, until progression of disease or adverse effects leading to termination of treatment. Each 3-week period is one cycle of treatment.
2539459|NCT02634099|Other|hemoglobine monitoring|3 different techniques will be used for hemoglobine monitoring : hemocue, pulse co-oxymeter (SpHb) and blood measurement
2539512|NCT02633748|Other|Intervention|The twenty participants in the intervention arm will undergo a pre-assessment, post assessment, and a three month follow-up assessment. The pre and post assessments will ask participants to 1) fill out questionnaires to measure lifestyle, stress, meditations habits, and sleep impairment, 2) take a blood sample, 3) use a BodyMedia's Sensewear® armband for a week, and 4) provide salivary cortisol levels. The three month follow-up will repeat everything done if the first two assessments, excluding the blood sample. The intervention arm will also attend the weekly two and a half hour Mindfulness-Based Cancer Survivorship (MBSC) four-week program between the pre and post assessments.
2539514|NCT02633748|No Intervention|Control|The twenty participants in the control arm will undergo the same pre assessment as the intervention arm, receive a presentation on breathing exercises, and undergo the same post and three-month follow-up assessments. The control arm will also be offered the same Mindfulness-Based Cancer Survivorship program given to the intervention arm following the three month follow-up.
2539555|NCT02633462|Active Comparator|Test Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis and treated with scaling and root planing(SRP) along with Myo-inositol supplementation
2539557|NCT02633462|Active Comparator|Control Group|Polycystic ovarian syndrome(PCOS) women who have periodontitis treated with Myo-inositol along with oral hygiene instructions.
2539642|NCT02632825|Experimental|Nasal High Flow|NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen
2539644|NCT02632825|No Intervention|Control|Control is no NHF intervention
2539685|NCT02632513|Experimental|continuous ultrasonic irrigation|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
2539686|NCT02632513|No Intervention|Syringe irrigation|In the syringe irrigation group, irrigation was done using 27 gauge syringe.
2539764|NCT02632292|Experimental|Absorb GT1|Bioresorbable everolimus-eluting scaffolds
2539767|NCT02632292|Active Comparator|Promus|Everolimus-eluting stents
2539816|NCT02631798|Experimental|Dye staining|Food grade dye mucosal staining
2539864|NCT02631512|Other|Woulgan Gel|Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)
2539866|NCT02631512|Other|Intrasite Hydrogel|Primary dressing with Intrasite Hydrogel
2539902|NCT02631252|Experimental|Open-label, Single-arm|"Hydroxychloroquine + Mitoxantrone + Etoposide~Hydroxychloroquine is given up to 21 days, started concurrently with both Mitoxantrone, administered by IVPB over 15 minutes each day for 5 days and Etoposide, administered intravenously over 2 hours each day for 5 days"
2539933|NCT02630979||No treatment|Clinical and medical oncology physicians.
2540007|NCT02630758|Experimental|Mindfulness-based Yoga|"Participants in the 12-week mindfulness-based yoga condition were guided by a gentle yoga DVD that included postures (asanas), pranayama (breathing exercises), and relaxation (meditation). Participants were asked to complete 60-75 minutes of the DVD twice per week and were encouraged to do more if they were interested.~Following the initial baseline assessment and randomization telephone interview, participants in the yoga group completed weekly 15-minute telephone sessions for the first month and bi-weekly telephone sessions for the second and third for a total of eight sessions over the 12 weeks. The mindfulness telephone sessions were modified from the Mindfulness-Based Stress Reduction."
2540012|NCT02630758|Active Comparator|Walking Control Group|"The 12-week walking control condition included twice-weekly home practice with a 65-minute walking DVD (Sansone, 2008) and eight telephone sessions with the telephone counselor.~Participants were asked to complete 60 minutes of the DVD (or other walking) twice weekly and encouraged to do more if they were interested.~Participants received telephone sessions on the same schedule as the yoga condition. The education sessions covered a variety of health and wellness related topics."
2540115|NCT02630329|Experimental|vNOTES adnexectomy|Vaginal Natural Orifice Transluminal Endoscopic Surgery
2540117|NCT02630329|Active Comparator|LSC adnexectomy|Laparoscopic adnexectomy
2540156|NCT02629744|Experimental|Etrolizumab|Participants will self-administer single SC dose of etrolizumab using prefilled auto-injector, into the abdomen or the anterior thigh.
2540178|NCT02629510|Experimental|Tachosil|The group composed of patients whose surgical margin of cervix will be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
2540184|NCT02629510|No Intervention|No Tachosil|The group composed of patients whose surgical margin of cervix will NOT be treated with Tachosil® after a loop electrosurgical excisional procedure (LEEP)
2540223|NCT02629315|Active Comparator|10% neutral buffered formaldehyde|Specimens will be fixed for 24-48hours in 10% neutral buffered formaldehyde and then dissected for lymph nodes.
2540236|NCT02629315|Experimental|Carnoy's solution|Specimens will be fixed for 24-48hours in Carno'ys solution and then dissected for lymph nodes.
2540279|NCT02628847|Experimental|Drug|Sildenafil citrate 25mg once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
2540295|NCT02628847|Placebo Comparator|control|placebo capsule once per day for 14 days starting day 5-9 post stroke while undergoing usual rehabilitation
2540334|NCT02628392|Experimental|DS-8500a 25 mg QD|DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule
2540339|NCT02628392|Experimental|DS-8500a 50 mg QD|DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
2540345|NCT02628392|Experimental|DS-8500a 75 mg QD|DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule
2540351|NCT02628392|Placebo Comparator|placebo|placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.
3202381|NCT00913029|Active Comparator|Medication|One hundred patients will be randomized to receive a fixed combination ocular hypotensive medication.
2539436|NCT02634242|Experimental|Si-Wu-Tang (SWT)|Subjects are recommended to drink 125 mL of SWT (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
2539437|NCT02634242|Placebo Comparator|placebo|Subjects are recommended to drink 125 mL of Placebo (n=30) for 6 continuous days per month during the following 6 months and vice versa with one month of washout period in between.
3202382|NCT00913042||1|febrile neutropenia patient
3202383|NCT00913055|Experimental|One hydrated 84mg Octreotide implant|hydrated implant
2539598|NCT02632916|Active Comparator|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg
2539599|NCT02632916|Experimental|Denosumab|Subcutaneous denosumab 1.0mg/kg
2539641|NCT02632799|Experimental|NHF small cannula|NHF 8 L/min (Airvo2) , Smaller cannula (neonatal, yellow)
2539643|NCT02632799|Experimental|NHF big cannula|NHF 8 L/min (Airvo2) , Bigger cannula (neonatal, purple)
2539645|NCT02632799|Experimental|Mask CPAP|CPAP 5cm H2O
2539646|NCT02632799|No Intervention|no intervention|control
2539697|NCT02632487|Active Comparator|Exercise|This group will receive 8 weeks of center-based exercise followed by recommendations to remain physically active.
2539703|NCT02632487|Experimental|Exercise + Non-Exercise Physical Activity (NEPA)|This group will receive 8 weeks of center-based exercise combined with behavioral counseling and a technology intervention designed to increase daily Exercise + Non-Exercise Physical Activity (NEPA).
2539750|NCT02632149|Experimental|Vagus nerve Stimulation is on|
2539809|NCT02631863|Experimental|ALA|Patients will receive 3 topical treatments of aminolaevulinic acid 500mg
2539810|NCT02631863|Placebo Comparator|Placebo|Patients will receive 3 topical treatments of placebo 500mg
3202384|NCT00913055|Experimental|One non-hydrated 84mg Octreotide implant|
3202385|NCT00913094||ICG|Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
2539921|NCT02631187|Experimental|Balloon Eustachian Tuboplasty|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
2539945|NCT02630875|Active Comparator|A4250 1|Dose I
2539950|NCT02630875|Active Comparator|A4250 2|Dose 2
2539955|NCT02630875|Active Comparator|A4250 3|Dose 3
2539961|NCT02630875|Active Comparator|A4250 4|Dose 4
2539968|NCT02630875|Active Comparator|A4250 5|Dose 5
2539974|NCT02630875|Active Comparator|A4250 6|Dose 6
2540006|NCT02630524|Experimental|Low Carbohydrate Diet|
2540010|NCT02630524|Active Comparator|Standard Diet|
2540098|NCT02630342|Experimental|Group 1: preparation materials only|This group will receive preparation materials for a clinical MRI scan. These include links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur only at home.
2540104|NCT02630342|Experimental|Group 2: Materials with review|This group will receive in preparation for a clinical MRI scan links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan. Preparation for this group will occur at home and include a visit with research team to review preparation materials with the research team
2540108|NCT02630342|Experimental|Group 3: Mock MRI scanner|This group will receive the same materials as training group 1. In addition they will attend the mock scanner where the research team will utilise a mock MRI scanner to practice lying down in a scanner, staying still , wearing headphones and watching a movie/video on the mirror system.
2540109|NCT02630342|No Intervention|Neuro-oncology retrospective controls|A retrospective control group of neuro-oncology patients from the 3 years prior to the study initiation. This group will be used to determine the age at which patients were able to complete a diagnostic MRI without GA
2540112|NCT02630342|Experimental|Neuro-oncology prospective|Child life specialist preparation will be provided to these patients. This preparation for Diagnostic MRI scanning in which utilise the Mock MRI scanner as preparation for the scan.
2540160|NCT02629705|Other|Group A|"Placebo intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Carrageenan intervention~Assessment block (3 days)"
2540161|NCT02629705|Other|Group B|"Carrageenan intervention~Assessment block (3 days)~Washout-phase of 21-35 days~Placebo intervention~Assessment block (3 days)"
2540206|NCT02629432||Cosyconet COPD Cohort|MRI and CT of the lung will be performed in a multi-centre cohort of 625 COPD-patients from the main COSYCONET cohort.
2540227|NCT02629029|Other|Surgical - therapeutic free flap|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will be imaged using two systems: (i) pre-operative CTA with IV contrast; (ii) intra-operative fluorescence endoscopy with ICG.
2540285|NCT02628834|Experimental|Fascial mobilization|First day intervention: Patients will take fascial mobilization techniques to management of plantar flexor spasticity
2540298|NCT02628834|Experimental|Stretching exercise|Second day intervention:Patients will take fascial mobilization techniques to management of plantar flexor spasticity
2540565|NCT02627209|Active Comparator|serum lysozyme|radial immunodiffusion
3202386|NCT00913107|Experimental|Lamictal®|"Lamictal® was used as the active medication in this study."
3202387|NCT00913107|Active Comparator|Tegretol®|"Tegretol® was employed as the control for comparative purposes in order to check and evaluate the efficacy (pain-relief) and occurrence of side- effects of Lamictal®."
3202388|NCT00913120|Experimental|YM150 group-1|YM150 low dose group
3202389|NCT00913120|Experimental|YM150 group-2|YM150 high dose group
3202390|NCT00913120|Placebo Comparator|Placebo group|
3202391|NCT00913120|Active Comparator|Enoxaparin group|
3202392|NCT00913146||index|child with fever and a negative malaria RDT
3202393|NCT00913146||control|apparently healthy child with a negative RDT
2539362|NCT02634749|No Intervention|Regular diet|The participants will be given the current advice on infant feeding issued by the Swedish National Food Agency. They will also be given regular, commercially available milk cereal drinks, porridge, baby milk and industry manufactured main meals. No advice or recipes on meals will be given apart from the current recommendations.
2539422|NCT02634398||Treated subjects|All subjects recruited and treated wiht the Axium neurostimulator
2539452|NCT02634086||Percutaneous coronary intervention|Patients with triple-vessel coronary artery disease underwent percutaneous coronary intervention.
2539453|NCT02634086||Coronary artery bypass graft|Patients with triple-vessel coronary artery disease underwent coronary artery bypass graft.
2539454|NCT02634086||Optimal medication therapy|Patients with triple-vessel coronary artery disease underwent optimal medication therapy only.
2539531|NCT02633839|Experimental|Adults who smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
2539535|NCT02633839|Experimental|Adults who don't smoke|"Day -1, subjects begin pre-treatment of oral dose regimen of carbidopa every 8 hours.~Day 1, subjects receive a final dose of carbidopa and 1 hour later, a single dose of CVT-301."
2539553|NCT02633254|Experimental|Single arm|Treatment group Magentic Resonance guided High Intensity Focused Ultrasound will be employed on uterine fibroids
3202394|NCT00913159|Active Comparator|Using HM3 lithotripter|This is an older generation lithotripter
3202395|NCT00913159|Active Comparator|F2 lithotripter|This is a newer generation lithotripter
3202396|NCT00913172||Intervention group|Directly Observed Treatment under Health Extension Workers
3202397|NCT00913172||Control group|Directly observed treatment under general health workers
3202398|NCT00913198|Experimental|IV CP-4126|
3202399|NCT00913211|Experimental|rTMS only|brain stimulation to non-stroke primary motor area
3202400|NCT00913211|Experimental|Finger tracking training|Motor learning training using finger flexion/extension tracking movements toward a target.
3202401|NCT00913211|Experimental|rTMS and finger tracking|Combination of rTMS and tracking
3202402|NCT00913211|Placebo Comparator|Sham|Sham rTMS treatment
3202403|NCT00913224|Experimental|1|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
3202404|NCT00913224|Active Comparator|2|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)
3202405|NCT00913237|Experimental|1|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
3202406|NCT00913237|Active Comparator|2|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
3202407|NCT00913250|Experimental|Sequence 1|Serum containing Avonex followed by serum free Avonex
3202408|NCT00913250|Experimental|Sequence 2|Serum free Avonex followed by serum containing Avonex
3202409|NCT00913276|Other|Sevoflurane anesthesia|
3202410|NCT00913276|Other|Propofol anesthesia|
3202411|NCT00913289|Other|adipose tissue derived stromal cells|
3202412|NCT00913302|Experimental|Training|cardiovascular training
2539983|NCT02630784|Experimental|Homecare ventilator|NIV with a dedicated ventilator for homecare, functioning with a turbine and with vented mask (exhalation by a calibrated leak)
2539986|NCT02630784|Active Comparator|ICU ventilator|NIV with a dedicated ICU ventilator, functioning with non-vented masks and an exhalation valve.
2540084|NCT02630303|Experimental|LED-RL Phototherapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2540086|NCT02630303|Sham Comparator|Mock Therapy|"The protocol for dose escalation requires subjects be enrolled sequentially in groups of five (three subjects randomized to LED-RL phototherapy and two subjects randomized to mock therapy).~After either a maximally tolerated dose (MTD) has been established, or the study endpoint of 640 J/cm2 has been achieved, an additional 27 LED-RL phototherapy subjects (for a total of 30) and 18 mock therapy subjects (for a total of 20) (determined randomly) will be enrolled to satisfy Hanley's Rule of Three, such that it can be concluded with 95% confidence that fewer than 1 person in 10 will experience an adverse event."
2540136|NCT02629913|Experimental|Intervention|mementor somnium
2540139|NCT02629913|Other|Waitlist|
2540169|NCT02629614|Experimental|TAPS Stimulation|Temporal Afferent Patterned Stimulation (TAPS) is alternating bursts of TENS stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
2540175|NCT02629614|Sham Comparator|Sham Stimulation|0 amplitude stimulation applied to the radial and median nerves of a subject's wrist using the Cala ONE device.
2540280|NCT02628652|Experimental|Gluco-Galacto-Oligosaccharide (GOS)|Subjects randomized to this treatment arm will ingest GOS once per day for a total of 14 days. One level of GOS will be taken during Phase I and 2 levels of GOS will be taken during Phase II.
3202413|NCT00913315|Experimental|tolterodine + tamsulosin|
3202414|NCT00913315|Active Comparator|tamsulosin + placebo|
3202415|NCT00913328|Active Comparator|Montelukast|Oral montelukast 10 mg once daily for 12 weeks
3202416|NCT00913328|Placebo Comparator|Placebo|Oral placebo once daily for 12 weeks
3202417|NCT00913341|Experimental|1|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
3202418|NCT00913341|Active Comparator|2|Alprazolam Tablets, 1 mg (The Upjohn Company)
3202419|NCT00913354|Experimental|1|30 minutes of acupuncture just before and just after embryo replacement
3202420|NCT00913354|Placebo Comparator|2|Sham acupuncture for 30 minutes just before and just after embryo transfer
3202421|NCT00913367|Active Comparator|Amaryl group|
3202422|NCT00913367|Experimental|Amaryl M group|
3202423|NCT00913393|Placebo Comparator|1|Placebo IV
3202424|NCT00913393|Experimental|2|3 mg/kg FG-3019 IV
3202425|NCT00913393|Experimental|3|10 mg/kg FG-3019 IV
3202426|NCT00913406|Experimental|1|Experimental=Standard formula with lutein added to the formula
3202427|NCT00913406|Active Comparator|2|Active Comparator=Standard formula
3202428|NCT00913419|Experimental|1|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories
3202429|NCT00913419|Active Comparator|2|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme
3202430|NCT00913432|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day
2539635|NCT02632890||Patients survey|Adult patients treated with abatacept for rheumatoid arthritis
2539637|NCT02632890||HCP survey|HCP with at least 1 patient taking abatacept
2539638|NCT02632890||Retrospective chart review study|Adult patients treated with abatacept for rheumatoid arthritis
2539701|NCT02632474|Experimental|Low-dose|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
2539757|NCT02632201|Experimental|PIK-HER2 cells|PIK-HER2 cells treatment will be performed every 3 weeks with a total of three periods.
2539760|NCT02632201|Active Comparator|DC-PMAT|DC-PMAT treatment will be performed every 3 weeks with a total of three periods.
3202431|NCT00913432|Experimental|masitinib 6 mg|masitinib 6 mg/kg/day
3202432|NCT00913445|Active Comparator|surgery, absorbable stitches|wound healing after absorbable and nonabsorbable stitches are compared
2539883|NCT02631265|Active Comparator|Reduction of insulin basal rate at the time of exercise|
2539886|NCT02631265|Active Comparator|Reduction of insulin basal rate 20 minutes prior to exercise|
2539889|NCT02631265|Active Comparator|Reduction of insulin basal rate 40 minutes prior to exercise|
2539922|NCT02631135|Placebo Comparator|Group 1 (TIVA)|Only propofol (started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1)
2539923|NCT02631135|Active Comparator|Group 2 (TIVA+D)|Propofol started as firstly 12 mg. kg-1 for the 30 minutes, the second 30 minutes 9 mg. kg-1) and remifentanil infusion (0.5 μg.kg-1),and also dexmedetomidine infusion (started as 0.5 μg.kg-1 without making the loading dose and the dose change was not made during the operation)
2539992|NCT02630771||PDAP only|Persistent dentoalveolar pain disorder patients who do not fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
2539993|NCT02630771||PDAP + TMD|Persistent dentoalveolar pain disorder patients who also fit criteria for TMD. Pressure pain threshold before/during conditioned pain modulation.
2539994|NCT02630771||Painfree controls|Painfree subjects. Pressure pain threshold before/during conditioned pain modulation.
2540005|NCT02630511|Experimental|Asthma Group|Asthma group to receive mannitol, methacholine or placebo challenge tests
2540011|NCT02630511|Experimental|Control Group|Control group to receive mannitol, methacholine or placebo challenge tests
2540110|NCT02630121|Placebo Comparator|Placebo/Fluticasone Propionate|Placebo Spray 2 Sprays QHS Fluticasone Propionate 1 spray BID
2540113|NCT02630121|Active Comparator|Oxymetazoline Hydrochloride /Fluticasone Propionate|Oxymetazoline Hydrochloride 2 Sprays QHS Fluticasone Propionate 1 spray BID
2540159|NCT02629757|Experimental|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles.
2540194|NCT02629497|Experimental|Healthy subjects for Omega-6 protection|Platelets from healthy donors will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
2540195|NCT02629497|Experimental|T2DM patients for Omega-6 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Primrose Oil (omega-6 fatty acid).
2540197|NCT02629497|Active Comparator|Healthy control for Omega-3 protection|Platelets from healthy donors will be assessed for regulation by Fish Oil (omega-3 fatty acid).
2540200|NCT02629497|Active Comparator|T2DM for Omega-3 protection|platelets from Type 2 diabetes mellitus (T2DM) patients will be assessed for regulation by Fish Oil (omega-3 fatty acid).
3202433|NCT00913445|Active Comparator|surgery, nonabsorbable stitches|
2540271|NCT02628717||SOF/SMV|SOF/SMV 400mg/150mg QD 12-24 weeks
2540273|NCT02628717||SOF/DCV|SOF/DCV 400mg/60mg QD 12-24 weeks
2540274|NCT02628717||SOF/LDV|SOF/LDV 400mg/90mg QD 12-24 weeks
2540282|NCT02628717||treatment duration|12 - 24 weeks
2540343|NCT02628561|Active Comparator|Active tdcs/M1|Anodal tDCS on primary motor cortex and CIMT (constraint induced movement therapy)
2540350|NCT02628561|Experimental|Active tdcs/Premotor|Anodal tDCS on premotor cortex and CIMT (constraint induced movement therapy)
2540353|NCT02628561|Sham Comparator|Sham tdcs|Sham tDCS and CIMT (constraint induced movement therapy)
2540400|NCT02628015||preschool children preterm|born 2010 or 2011 Birthweight <1500g
2540402|NCT02628015||preschool children full-term|born 2010 or 2011 born after 38 weeks
2540403|NCT02628015||school children preterm|same children from the preschool group will be tested 2 years later again
2540404|NCT02628015||school children full-term|same children from the preschool group will be tested 2 years later again
2540405|NCT02628015||youths preterm|born 2001 or 2002 Birthweight <1500g
2540406|NCT02628015||youths full-term|born 2001 or 2002 born after 38 weeks
2540408|NCT02628015||adults preterm|Birthweight <1500g
2540412|NCT02628015||adults full-term|born after 38 weeks
2540478|NCT02627768||Cohort 1: Ustekinumab Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
2540481|NCT02627768||Cohort 2: TNFi Treatment|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy.
2540563|NCT02626962|Experimental|Nivolumab and Ipilimumab|Nivolumab and Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
3202434|NCT00913471||Acute-Longitudinal SCI|
3202435|NCT00913471||Chronic SCI|
3202436|NCT00913471||Healthy volunteers|
3202437|NCT00913484|Experimental|Disulfiram|Disulfiram 250 mg per day
3202438|NCT00913484|Placebo Comparator|Placebo|Placebo
3202439|NCT00913497|Active Comparator|insulin glulisine|
3202440|NCT00913497|Active Comparator|insulin aspart|
3202441|NCT00913536|Experimental|Cone beam CT in Bladder Cancer|
3202442|NCT00913549|Experimental|1|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
3202443|NCT00913549|Experimental|2|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
2539443|NCT02634216|Experimental|Type 1 Diabetics using CGM|Type 1 diabetics using Continuous Glucose MonitoringCGM to take 500 mg daily of Capros supplement (250 mg twice a day) at lunch and dinner.
3202444|NCT00913562|Active Comparator|Patients with diabetes|Rosuvastatin
3202445|NCT00913562|Active Comparator|Patients with glaucoma|Rosuvastatin
3202446|NCT00913562|Placebo Comparator|Control patients with diabetes|Placebo
3202447|NCT00913562|Placebo Comparator|Control patients with glaucoma|Placebo
2539580|NCT02633176|Active Comparator|cisplatin and docetaxel|"Induction chemotherapy: Patients receive cisplatin and docetaxel intravenously on day 1 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
2539582|NCT02633176|Experimental|cetuximab, cisplatin, and docetaxel|"Induction chemotherapy: Patients receive cetuximab 400mg/m^2 intravenously over at least 120 minutes on day 1 followed by 250 mg/m^2 intravenously over at least 60 minutes every week. Cisplatin and docetaxel will be administered intravenously on day 2 repeated every 3 weeks for 6 cycles.~Concurrent chemoradiation: Patients who achieve complete response or partial response receive radiotherapy for primary and/or metastatic lesions with concurrent cetuximab 250mg/m^2 intravenously followed by cisplatin 30mg/m^2 intravenously every week.~Maintenance treatment: Capecitabine will be given at a dose of 1000mg/m^2 orally twice a day starting on day 1 and continuing for days 1 to 14 of each 21 day cycle for at least 2 years or until progression."
2539627|NCT02632864|Experimental|Proton arm|Proton beam therapy
3202448|NCT00913575|Experimental|preoperative neuromuscular training|preoperative neuromuscular training
3202449|NCT00913575|Placebo Comparator|education|knee school
3202450|NCT00913588|Experimental|1|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)
3202451|NCT00913588|Experimental|2|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)
3202452|NCT00913588|Active Comparator|3|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
3202453|NCT00913601|Experimental|Dextra|Unilateral sacral nerve stimulation dextra for 4 weeks
2539959|NCT02631174|No Intervention|cohort 1|Cohort 1 (Aim 1) - 6 participants Cohort 1 will be comprised of 6 neonates (≤28 days of age) admitted to the CICU or NICU who are neither undergoing ECMO nor CPB. Cohort 1 will receive a single dose of ATIII by short 15 minute infusion.
2539963|NCT02631174|Active Comparator|cohort 2.1|"• Cohort 2.1 - 6 neonates undergoing ECMO.~Three participants will receive a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume followed by a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume~Three participants will receive a single dose 15 minute infusion of hpATIII that is not dose adjusted to account for circuit volume followed by a single dose 15 minute infusion of hpATIII that is dose adjusted to account for additional circuit volume"
2539970|NCT02631174|Active Comparator|cohort 2.2|"• Cohort 2.2 - 12 neonates who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
2539976|NCT02631174|Active Comparator|cohort 2.3|"• Cohort 2.3 - 12 infants who will undergo open-heart surgery with CPB~Six participants will receive a single dose 15 minute infusion of ATIII that is dose adjusted to account for additional circuit volume.~Six participants will receive a single dose 15 minute infusion of ATIII that is not dose adjusted to account for circuit volume"
3202454|NCT00913601|Experimental|Sinistra|Unilateral sacral nerve stimulation sinistra 4 weeks
2540597|NCT02626806||patients without hemodynamic significant CAD|
3202455|NCT00913601|Experimental|Bilateral|Bilateral sacral nerve stimulation 4 weeks
3202456|NCT00913614|Experimental|Age Group 6-11 year old - Dose level 1|
3202457|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 2|
3202458|NCT00913614|Experimental|Age Group 6-11 year old - Dose Level 3|
3202459|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 1|
3202460|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 2|
3202461|NCT00913614|Experimental|Age Group 12-17 year old - Dose level 3|
3202462|NCT00913640||PD Group|
3202463|NCT00913640||Control Group|
3202464|NCT00913653|Experimental|Stable heart failure patients|
3202465|NCT00913666|No Intervention|Group 1|Healthy Volunteers
3202466|NCT00913666|Experimental|Group 2|MS patients previously naïve to interferon therapy
3202467|NCT00913666|Experimental|Group 3|MS patients on Interferon beta-1a treatment with no history of breakthrough disease (clinically stable)
3202468|NCT00913666|Experimental|Group 4|MS patients on interferon beta-1a treatment with a history of breakthrough disease.
3202469|NCT00913679|Active Comparator|Posterior approach|Posterior surgical approach in hip resurfacing arthroplasty
3202470|NCT00913679|Active Comparator|Anterolateral approach|Anterolateral surgical approach in hip resurfacing arthroplasty
3202471|NCT00913705|Experimental|1|The patients will be randomized to receive taxol (Paclitaxel) and carboplatin as adjuvant or as neoadjuvant regimen or to surgery alone
3202472|NCT00913718|Experimental|1|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)
3202473|NCT00913718|Active Comparator|2|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)
3202474|NCT00913731||psychotic patients|psychotic patients, acute ward, symptom rating scale.
3202475|NCT00913757||Group 1|400 patients with primary HCC (Hepatocellular carcinoma)
3202476|NCT00913757||Group 2|800 patients with chronic liver disease (high risk non-cancer cases)
3202477|NCT00913757||Group 3|800 population-based controls, identified through a OMV database that will match cases by age, gender, race, and county of residency
3202478|NCT00913783|Experimental|1|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)
3202479|NCT00913783|Active Comparator|2|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)
3202480|NCT00913796|Experimental|Postassium citrate|Aim: correction of metabolic acidosis
2539449|NCT02634190||Triple negative women|Women 30 years of age or older coming for routine cervical screening who tested triple negative at baseline with the interventions: Thinprep® LBC, HR HC2® HPV DNA and APTIMA® HPV Assay
2539450|NCT02634190||Women tested positive|Women who tested positive in any of the tests Thinprep® LBC, HR HC2® HPV DNA or APTIMA® HPV Assay will undergo colposcopy and be followed up over a ten year period and subjects who tested positive during the follow up assessment will be followed up over a 5 year period on a yearly basis
3202481|NCT00913796|Active Comparator|Potassium chloride|Potassium chloride is given to compensate for any possible effects of potassium in potassium citrate (primary treatment).
3202482|NCT00913809|Experimental|1|Desipramine HCL 100 mg Tablets Cord Laboratories
2539713|NCT02632448|Experimental|Part A: LY2880070|Multiple oral doses of LY2880070 during 21-day cycles
2539716|NCT02632448|Experimental|Part A: LY2880070 with Gemcitabine|Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles
2539717|NCT02632448|Experimental|Part A: LY2880070 (Metabolism Phenotype)|Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
2539718|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Breast)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539719|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Colorectal)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539720|NCT02632448|Experimental|Part B:LY2880070 and Gemcitabine (Ovarian)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539721|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Endometrial)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539725|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539727|NCT02632448|Experimental|Part B: LY2880070 and Gemcitabine (Pancreatic)|Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)
2539769|NCT02631967|Experimental|Kono anastomosis|Patients receiving Kono anastomosis
2539771|NCT02631967|Experimental|Stapled side-to-side anastomosis|Patients receiving stapled side-to-side anastomosis
2539813|NCT02631720||Adult Lung Transplant Recipients|Adult lung transplant recipients undergoing lung transplant at each of the participating centers.
2539944|NCT02631447|Experimental|Arm A: Combo Target/Combo Immuno|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD; then Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD
2539949|NCT02631447|Experimental|Arm B: Como immuno/Combo Target|Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
2539960|NCT02631447|Experimental|Arm C: Sandwich|Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) for 8 weeks followed by Combo Immuno (nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks) until PD; then Combo Target (LGX818 450 mg p.o. od + MEK162 45 mg p.o. bid) until PD
2540045|NCT02630407|Experimental|Hyaluronic acid group|Single injection of 3 ml HA (product name: Hymovis, Fidia Spa, Padova, Italy) the day after ACL reconstruction (after drainage removal)
2540047|NCT02630407|Placebo Comparator|Placebo group|Single injection of 3 ml saline solution the day after ACL reconstruction (after drainage removal)
2540069|NCT02630147|Experimental|Night-vanilla|Intervention = exposition to vanilla scent A quantity of 2 ml of a saturated vanilla solution (2% vanillin) will be applied on premature pyjamas infant's, close to his face (on each shoulder and on the upper chest).
2540071|NCT02630147|No Intervention|Night-no vanilla|The only difference with the experimental arm is the absence of vanilla (usual, standard care)
2540120|NCT02630004|Experimental|Melatonin|Melatonin oral gel 3%
2540122|NCT02630004|Placebo Comparator|Placebo|Placebo oral gel
2540183|NCT02629627|Experimental|cojugated ALC/Leucine+Metformin|Intervention with conjugated linoleic acid/Leucine + 500mg in individuals with METS
2540188|NCT02629627|Active Comparator|Metformin+placebo conjugatedALC/leucine|active comparator with Metformin 500mg + Placebo of ACL/Leucine in individuals with METS
2540191|NCT02629627|Placebo Comparator|Placebo of Metformin|Active comparator with ACL/Leucine + Placebo of Metformin in individuals with METS
2540193|NCT02629627|Placebo Comparator|ACL/Leu placebo|Placebo comparator with ACL/Leu placebo + Metformin placebo in individuals with METS
2540217|NCT02629081||Controls & Cases|Controls (participants without heartburn or other GERD symptoms undergoing standard upper endoscopy for the following: anemia, weight loss, diarrhea, and screening for esophageal varices) and Cases (participants with heartburn or other GERD symptoms undergoing standard endoscopy for heartburn or other GERD symptoms.)
3202483|NCT00913809|Active Comparator|2|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc
3202484|NCT00913822|Experimental|1|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
3202485|NCT00913822|Active Comparator|2|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
2540442|NCT02627898|Experimental|Green tea extract|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
2540446|NCT02627898|Placebo Comparator|Placebo|Individuals with T2DM controlled with metformin or glibenclamide, or both; with no hypertension neither treated with insulim
2540487|NCT02627547|Experimental|Experimental tests|2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training
2540561|NCT02627235|Experimental|DIAL Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes daily IVR-system call feedback and monthly graphic-based feedback delivered in the mail. In addition, social support, outcome expectations and perceived physical activity enjoyment variables will be assessed at baseline, 30, 60, and 90 days. Responses will be used to select appropriate tailored feedback modules.
2540646|NCT02626338|Experimental|Arm A|"Mitoxantrone~Cytarabine~Crenolanib"
2539477|NCT02633917|Experimental|Motor control exercises|One group should perform motor control exercises
2539481|NCT02633917|Active Comparator|Standard exercises|the other group should perform standard physiotherapy exercises
3168251|NCT00548626|Experimental|B|Patients assigned to multiple needle group (MN) will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
3168252|NCT00548639|Experimental|Statin Choice|Statin Choice Decision Aid The provider will introduce the patient to the choice of statins using the decision aid. The patient may make a choice then or defer this choice; in all cases, the patient goes home with the Statin Choice decision aid and pamphlet.
3168253|NCT00548639|Sham Comparator|Usual Care|Control Pamphlet the provider meets with the patient to discuss treatment options in the usual fashion.
3168254|NCT00548665|Experimental|1|Carotid plaque screening and brief advice for smoking cessation: Smokers with at least one carotid plaque will receive pictures of their own plaques with a structured explanation on the general significance of plaques.
3168255|NCT00548665|Active Comparator|2|Brief advice for smoking cessation (without carotid ultrasound for plaque screening): to ensure equal contact conditions, smokers not undergoing ultrasound will receive a relevant explanation on the risks associated with tobacco smoking.
2539665|NCT02632630|Active Comparator|Amino Acids w/Electrolytes in Dextrose|Peripheral parenteral nutrition (PPN)
2539666|NCT02632630|Active Comparator|Ensure product|Calorie and protein dense oral nutritional supplement for patients with elevated nutritional needs.
2539667|NCT02632630|Active Comparator|Crystalloid solutions|Standard care intravenous maintenance fluids.
2539669|NCT02632630|Active Comparator|Oral nutritional supplementation|Nutrient-enhanced drink products that provide macronutrients and micronutrients with the aim of increasing oral nutritional intake.
2539783|NCT02632071|Active Comparator|80 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2539787|NCT02632071|Active Comparator|120 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2539792|NCT02632071|Active Comparator|180 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
2539794|NCT02632071|Active Comparator|240 mg|Subject will receive ACY-1215 (ricolinostat) orally once daily for 21 consecutive days (Day 1 to Day 21) at the assigned dose, followed by a 7-day non-dosing period (Day 22 to Day 28). 100 mg/m2 Nab-paclitaxel will be administered intravenously on Days 1, 8, and 15.
3168256|NCT00548678|Experimental|A|intravenous diclofenac sodium
3168257|NCT00548678|Active Comparator|B|intravenous ketorolac
2539941|NCT02630849|Experimental|IMF group|intercostal muscle flap and pericostal no-compression suture of the intercostal space
2539946|NCT02630849|Active Comparator|IINB group|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
3202486|NCT00913848|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
3202487|NCT00913848|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
2540250|NCT02629003|Active Comparator|[11C]Cimbi-36|"[11C]Cimbi-36~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
2540254|NCT02629003|Active Comparator|[11C]Cimbi-36-5|"[11C]Cimbi-36-5~Maximum of 600 Mega Becquerel (MBq) or 1.5 micrograms, single dose intravenous (I.V.)"
2540287|NCT02628678|Other|Fructooligosaccharide (FOS)|Subjects will be required to take 8 grams of FOS per day for a total of 10 days.
2540330|NCT02628548|Experimental|Cognitive training program 1|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
2540331|NCT02628548|Experimental|Cognitive training program 2|This 8-week program will meet once per week for 1.5 hours. Participants will be trained in performing various cognition enhancing techniques at each class, and will practice these techniques both in class and at home each day for 45 minutes.
2540419|NCT02627859|Experimental|Durolane SJ|Durolane SJ intra-articular injection; device
2540449|NCT02627716|Experimental|SOS Intervention Group|Subjects benefit from the SOS Plan in addition to the usual follow-ups
2540450|NCT02627716|No Intervention|Control Group|Subjects receive no additional intervention (tracking the continuation of psychiatric care according to the standard care terms)
2540501|NCT02627469|No Intervention|Control|Common oral hygiene help administered by nursing staff
2540504|NCT02627469|Experimental|Intervention|Extended professional oral hygiene care Electric toothbrush (Oral-B Professional Care 7000) 1100 ppm sodium fluoride dentifrice (Zendium Classic, Opus Health Care AB/Zendium)
3168258|NCT00548678|Active Comparator|C|oral diclofenac (Cataflam)
3168259|NCT00548678|Active Comparator|D|oral aspirin
3168260|NCT00548730||Observation|Patients with known or suspected malignancies of the lung and with a medical indication for a bronchoscopy
3168261|NCT00548743|Experimental|1|Intervention arm
3168262|NCT00548743|Placebo Comparator|2|Usual care
3168263|NCT00548756|Experimental|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy
3168264|NCT00548756|Other|Observation|Observation
2539479|NCT02633891|Experimental|Balance exercise program|Participants will attend weekly group training sessions and will keep an exercise log of home activity during a three month exercise program designed to improve balance. Balance exercises will be performed three times per week in a home-based training program.
2539482|NCT02633891|Active Comparator|standard care|Participants will meet in person on a weekly basis for a general education class regarding health and fall prevention but will not participate in an exercise class.
2539495|NCT02633631||Women seeking family planning services|Women seeking family planning and gynecological services will be enrolled in our study.
2539528|NCT02633553|Experimental|radiotherapy group|complete resection and adjuvant radiotherapy
2539529|NCT02633553|No Intervention|observation group|complete resection
3202488|NCT00913861|Active Comparator|standard sedation|propofol and fentanyl
2539596|NCT02632942|Experimental|HAQ Criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
2539597|NCT02632942|Active Comparator|Current Recommendation|Obliteration of accessory vein which satisfy the current recommendations only defined as accessory vein with a diameter greater than 25% of the AVF diameter.
3202489|NCT00913861|Active Comparator|structured attention-standard sedation|structured attention
3202490|NCT00913861|Experimental|hypnosis-standard sedation|hypnosis
3202491|NCT00913874|Experimental|1|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)
3202492|NCT00913874|Active Comparator|2|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)
2539931|NCT02631005|Experimental|Walk With Ease Participants|"Participants will receive a copy of the Walk With Ease workbook. This workbook provides guidance on walking safety and on how to start and maintain a regular walking program. It is designed to help participants increase their physical activity over a six-week period. Participants will complete self-reported outcomes questionnaires before and after completion of the program."
2540020|NCT02630732|Active Comparator|Brain School|Pain Neuroscience Education Program
2540022|NCT02630732|Active Comparator|Back School|Classical Back School
3202493|NCT00913887|Experimental|1|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
2540199|NCT02629549|Experimental|OTL38|Dosage calculated by weight of individual
2540211|NCT02629185||normal weight|BMI 18.5 to 25.0 Healthy men and women ages 25-40 and 55-75
2540212|NCT02629185||overweight|BMI 25.0 to 30.0 Healthy men and women ages 25-40 and 55-75
2540213|NCT02629185||obese|BMI over 30.0 Healthy men and women ages 25-40 and 55-75
3202494|NCT00913887|Experimental|2|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
3202495|NCT00913887|Active Comparator|3|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
3202496|NCT00913900|Active Comparator|Autologous Stem cells (CD133+)|Intramuscular injection
3202497|NCT00913900|Placebo Comparator|Control|Intramuscular Injection
3202498|NCT00913926||Group 1|
2540493|NCT02627664||observational study|natural history of non dopaminergic signs
2540523|NCT02627222|Active Comparator|Treatment|Daily consumption of two cassava-based meals prepared with pro-vitamin A rich biofortified cassava
2540525|NCT02627222|Placebo Comparator|Control|Daily consumption of two cassava-based meals prepared with common white cassava
2540566|NCT02626923||Patients on once daily Maraviroc|Maraviroc tablet 600 mg once daily 48 weeks
2540603|NCT02626689||β-thalassemia transfusion dependent subjects|Participants will complete 3 quality of life instruments (i.e. FACT-AN, the SF-36v2, and the TranQol) once every 3 weeks, in addition to a TranQol instrument on the day of a RBC transfusion. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
2540604|NCT02626689||β-thalassemia Non Transfusion Dependent (NTD) subjects|Participants will complete 2 quality of life instruments (i.e. FACT-An and the the SF-36v2l) once every 3 weeks, in addition to completing the non-transfusion dependent Patient Recorded Outcome (PRO) tool on a daily basis. Continuous monitoring of Healthcare Resource Utilization will be conducted throughout the course of the study at each clinical visit.
2540659|NCT02626221||Single|Single Cohort Study
2540711|NCT02625701|Experimental|Goal-Directed-Therapy (GDT)|"Besides the basal infusion of crystalloids at 3-6 ml/kg/h, colloids (200 ml) or crystalloids (200 ml) are given over 10 min in the presence of signs of absolute/relative hypovolemia as detected by a fall in cardiac output/stroke volume (CO/SV) or if Pressure Pulse Variation (PVV) or Stroke Volume Variation (SVV) exceeds 10-12%, particularly in the presence. Fluid filling is interrupted when SV fail to increase > 10% (or PVV/SVV =< 10%) Otherwise, vasopressors can be used to achieve appropriate mean arterial pressure (MAP>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1)."
2540713|NCT02625701|Active Comparator|Restrictive strategy|"Crystalloids are given at a fixed rate of 3-6 ml/kg/h. Otherwise, vasopressors can be used to achieve appropriate MAP (>70 mmHg, within ±20% of baseline).~Blood losses are replaced with colloids (1:1) or crystalloids (2:1). Clinicians in charge of the patients are free to use hemodynamic parameters such as PVV or SVV, always attempting to limit the amount of fluid infusion and to maintain normovolemia"
2540756|NCT02625506|Placebo Comparator|Levobupivacaine|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine
2540758|NCT02625506|Active Comparator|Levobupivacaine and Tramadol|Patients will be subjected for radical mastectomy surgery and pectoral nerve block with levobupivacaine and tramadol
3202499|NCT00913939|Active Comparator|1: Salvage After EBRT|Patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C).
3202500|NCT00913939|Active Comparator|2: Boost to EBRT|Patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy.
3202501|NCT00913952|Experimental|1|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
3202502|NCT00913952|Experimental|2|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
3202503|NCT00913952|Active Comparator|3|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
2539602|NCT02633124|Experimental|Edelvaiss Multiline NEO|The Edelvaiss Multiline NEO design allows to position the access to the infusion line outside of the incubator, without increasing the residual volume and this device has been validated by the manufacturer as part of CE marking for a period of 21 days.
2539605|NCT02633124|Other|Standard Infusion Set|The infusion set used for the standard group is the infusion set usually used.
2539674|NCT02632760|Active Comparator|ferric carboxymaltose|ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously
2539677|NCT02632760|Placebo Comparator|Placebo|Placebo intravenous infusion
2539766|NCT02632305|Experimental|Treatment|"Eligible patients will receive nab-paclitaxel in combination with gemcitabine + cisplatin at the recommended phase II dose based on the phase I study completed in metastatic pancreas cancer patients.~The doses of study drugs will be as follows:~nab-Paclitaxel 100 mg/m2 day 1 and 8 every 21 days~Cisplatin 25 mg/m2 day 1 and 8 every 21 days~Gemcitabine 800 mg/m2 day 1 and 8 every 21 days~Nab-paclitaxel will be administered first followed by cisplatin and then gemcitabine on day 1 and 8 of each treatment cycle. Cycles will be 3 weeks in length (21 days)."
2539820|NCT02631811|Experimental|Supportive /palliative care intervention|patients will be supported by a multidisciplinary palliative specialist team
2539821|NCT02631811|No Intervention|usual medical follow up|patients will be supported by the support care team if asked by the oncologist
2539908|NCT02631460|Experimental|S1 and Carboplatin|S1 80-120 mg/d+Carboplatin AUC=5 Patients without progression received maintenance until disease progression with S1
2539910|NCT02631460|Active Comparator|pemetrexed and Carboplatin|pemetrexed 500 mg/m2+ Carboplatin AUC=5 Patients without progression received maintenance until disease progression with pemetrexed
3202504|NCT00913965|Experimental|1|Atenolol Tablets 100 mg (Cord Laboratories)
2540032|NCT02630420|Experimental|cetuximab and savolitinib|Following assessment in Part 1 of dose-limiting toxicity and maximum tolerated dose, this drug combination will be administered in Part 2 of the study to assess safety, tolerability, response rate, and progression-free survival.
2540088|NCT02630290|Placebo Comparator|Ropivacaine|After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle tip repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under continuous ultrasound monitoring.
2540089|NCT02630290|Experimental|Ropivacaine + Dexmedetomidine|After skin infiltration with 1-2 mL of lidocaine 2%, a 21-gauge 90-mm spinal needle will be inserted into the brachial plexus sheath using in-plane technique. After a careful aspiration, 1 to 2 mL of normal saline is injected for a distribution in and around the brachial plexus. Additional needle repositioning and injections may be needed when the distribution is not attained. Then the study drug (0.5% ropivacaine plus 30 microg dexmedetomidine in a total volume of 20 mL) will be injected with additional fine adjustment of the block needle under realtime ultrasound monitoring.
2540149|NCT02629874|Active Comparator|EA-230 (30mg/kg)|Subjects will receive EA-230, 30 mg/kg
2540151|NCT02629874|Active Comparator|EA-230 (90mg/kg)|Subjects will receive EA-230, 90 mg/kg
2540153|NCT02629874|Active Comparator|EA-230 (180mg/kg)|Subjects will receive EA-230, 180 mg/kg
2540154|NCT02629874|Placebo Comparator|Placebo|subjects receive placebo
2540196|NCT02629471|Experimental|response time due to light flashs pulses|light flashing effects on response time to random target appearance
2540219|NCT02629250|Placebo Comparator|SV maximization|Goal-directed fluid therapy with stroke volume maximization. Device: The Volume-View system from Edwards Co.
2540221|NCT02629250|Experimental|supernormal DO2|"Goal-directed fluid therapy with stroke volume maximization and supernormal oxygen delivery.~Device: The Volume-View system from Edwards Co."
2540284|NCT02628730|Active Comparator|Ablation Index Group|PVI using radiofrequency ablation (RFA) guided by Ablation Index.
2540300|NCT02628730|Other|Reference Group (Contact Force Group)|That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
2540374|NCT02628379||Class 1, 2, or 3 alterations, with targeted therapy|Patients put on targeted therapies matched to specific genomic alterations.
2540375|NCT02628379||Site-specific therapy determined by tissue of origin testing|Patients put on therapy determined by tissue of origin testing (e.g., CancerTYPE ID)
2540376|NCT02628379||Empiric CUP therapy|Patients put on empiric treatment at physician discretion
2540423|NCT02627989||Diflucortolone valerate (Nerisona/Texmeten)|Adult patients with atopic dermatitis switching from diflucortolone-valerate fatty ointment to ointment (water/oil emulsion) during autumn/ winter (Nov to Feb) or spring/ summer (May to Aug)
2540461|NCT02627625|Experimental|test product A|tiotropium
2540462|NCT02627625|Experimental|test product B|tiotropium
2540463|NCT02627625|Experimental|test product C|tiotropium
2540464|NCT02627625|Active Comparator|Commercial product D|tiotropium
2540465|NCT02627625|Active Comparator|commercial product E|tiotropium
2540515|NCT02627378|Active Comparator|Extracorporeal Membrane Oxygenation|Patients received Extracorporeal Membrane Oxygenation (ECMO) support
2540516|NCT02627378|Placebo Comparator|Non Extracorporeal Membrane Oxygenation|Patients did not receive Extracorporeal Membrane Oxygenation (ECMO) support
2540536|NCT02627040|Active Comparator|InterTan Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail with an InterTan device (two-integrated screws)
2540540|NCT02627040|Active Comparator|Gamma 3 Intertrochanteric Nail|'Surgical fixation' of intertrochanteric fracture with a cephalomedullary nail and Gamma 3 locking nail (single screw)
2540596|NCT02626806||patients with hemodynamic significant CAD;|
3202505|NCT00913965|Active Comparator|2|Atenolol Tablets 100 mg (Stuart Pharmaceutical)
3202506|NCT00913991|Experimental|Stress Management #1|8 weeks of individual stress management training sessions
3202507|NCT00913991|Active Comparator|Stress Management #2|8 weeks of individual stress management training sessions
3202508|NCT00914004|Experimental|1|Desipramine HCl 50 mg Tablets Cord Laboratories
2539534|NCT02633618|Experimental|Analgecine|3ml, 2 times per day, continuous infusion for two weeks.
2539539|NCT02633618|Active Comparator|Neurotropin|3ml, 2 times per day, continuous infusion for two weeks.
2539559|NCT02633319|Experimental|Parenting Training|Skilful Parenting: 12-week group-based parent intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages.
2539560|NCT02633319|Experimental|Agricultural Training|Agrics: Initial 3-month agricultural training intervention with ongoing support afterwards.
2539568|NCT02633319|Experimental|Parenting and Agricultural Training|Village farmer groups receiving both Skilful Parenting and Agrics interventions.
2539573|NCT02633319|No Intervention|Control|6-month wait-list control group
2539629|NCT02632903|Experimental|Intravenous Zoledronic Acid|Intravenous Zoledronic Acid 0.025mg/kg at baseline and 6 months
2539675|NCT02632695|Experimental|FOOTFIT Plus|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports and allows regular communication with the wound care provider on progress.
2539678|NCT02632695|Experimental|FOOTFIT|The intervention consists of: 1) a prescribed, evidence-based, phased, non-exertive physical activity conditioning activities for lower leg function (CALF) movements that are to be performed daily at home; 2) a low-cost, tri-axial Bluetooth® enabled highly sensitive motion-sensing accelerometer and tracking device (BEAT) worn on the foot during CALF to capture frequency and intensity of foot movements; and 3) a Smartphone that receives foot movement data, provides automated educational/motivational messages, and reports. There is not regular communication with the wound care provider on progress.
2539731|NCT02632331|Experimental|Fasted dosing preceding group|
2539732|NCT02632331|Experimental|Fed dosing preceding group|
2539785|NCT02632006|Experimental|PIK-PD-1 cells|PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.
2539793|NCT02632006|Active Comparator|DC-PMAT|DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.
2539834|NCT02631668|Experimental|ferrous succinate and vitamin C|In this group, the patients received 100mg ferrous succinate and 200mg vitamin C three times per day for 3-4 months
2539838|NCT02631668|Active Comparator|ferrous succinate with normal dosage|In this group, the patients received 100mg ferrous succinate three times per day for 3-4 months
2539841|NCT02631668|Active Comparator|ferrous succinate with double dosage|In this group, the patients received 200mg ferrous succinate three times per day for 3-4 months
2539884|NCT02631330|Experimental|Falls prevention group|"Intervention group that will receive a monthly talk (individual or collective) of 30 minutes on the advantages of having a free fall hazards environment and multiple physical exercise component: balance,muscle strength and aerobic capacity and risk polypharmacy and abuse of drugs, especially benzodiazepines). In the same monthly meeting, subjects will be train Multicomponent physical activity program during 60 minutes. 15 minutes of gait and balance training; 15 minutes of endurance training; 30 minutes of aerobic training according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459"
2539888|NCT02631330|No Intervention|Control group|Subjects will receive the same information provided at the beginning to Falls prevention group. They will not receive further information during the follow-up period.
3202509|NCT00914004|Active Comparator|2|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc
3202510|NCT00914017|Experimental|Atorvastatin|40 mg of Lipitor (atorvastatin) daily for 1 year
3202511|NCT00914017|Placebo Comparator|Sugar Pill|Sugar pill daily for 1 year
3202512|NCT00914030||A1|Patients with schizophrenia
3202513|NCT00914030||A2|Control subjects matched individually with patients with schizophrenia
2540162|NCT02629640||Research Participants|Medical history questionnaire; clinical assessment and review; participant follow-up; blood or buccal sample; post mortem examination.
2540209|NCT02629393|Experimental|ORGN001 (formerly ALXN1101)|
2540255|NCT02629016|Experimental|Mindfulness|Education and experiential exercises for mindfulness including movement, thoughts and meditation
2540258|NCT02629016|Active Comparator|Wellness|Education and experiential exercises for general wellness including sleep hygiene, goal setting and power poses.
2540259|NCT02629016|No Intervention|Waitlist|Students receive regular health class instruction without intervention.
2540290|NCT02628665|Experimental|24 to 48 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 24 to 48 hours: The injection of photosensitizer(photofrin) 24 to 48 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
2540299|NCT02628665|Active Comparator|48 to 72 hours group|"photosensitizer(photofrin): 2mg/kg, Diomed Surgical Diode Laser:400mv/cm irridiation 750 seconds, 48 to 72 hours: The injection of photosensitizer(photofrin) 48 to 72 hours light irradiation power.~630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds."
3202514|NCT00914030||B1|Adult subjects with autism
3202515|NCT00914030||B2|Control subjects matched individually with adult subjects with autism
3202516|NCT00914030||C1|Children with autism
3202517|NCT00914030||C2|Control subjects matched individually with children with autism
3202518|NCT00914056|Experimental|Lactulose withdrawal|Patients who were started on lactulose as a result of a precipitated HE episode underwent analysis while they were on lactulose; after this they underwent a controlled lactulose withdrawal with 3 visits post-withdrawal at 2 days, 14 days and 30 days after lactulose withdrawal
3202519|NCT00914082|Experimental|antenatal classes in self hypnosis|3 antenatal classes in self hypnosis. 3 audio compact discs for homework in self hypnosis and 1 audio compact disc for birth
3202520|NCT00914082|Active Comparator|relaxation and awareness|3 antenatal classes including training in relaxation methods and mindfulness.3 audio compact discs for homework and 1 for birth.
3202521|NCT00914082|Other|Control|Only receive ordinary antenatal care and no additional interventions
2539537|NCT02633579|Active Comparator|Erythromycin lactobionate with atropine|40 mg erythromycin lactobionate was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min
2539541|NCT02633579|Placebo Comparator|Atropine|"Atropine sulfate was given as an i.v. bolus (15 µg/kg) followed by a continuous infusion of 15 µg/kg/h over 30 min.~Infusion of saline as a placebo for erythromycin was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %"
2539543|NCT02633579|Placebo Comparator|Placebo|Infusion of saline was administered over a 20 min period in a volume of 100 ml sodium chloride 0.9 %; also placebo for atropine was given as an i.v. bolus of saline followed by a continuous infusion over 30 min
2539613|NCT02633059|Experimental|Treatment (ixazomib citrate, idasanutlin, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and idasanutlin PO QD on days 1-5 every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 every 28 days for 12 courses at the discretion of the treating physician.
2539770|NCT02632175|Experimental|Subjects receiving Adalimumab|Subjects receiving Adalimumab up to 288 weeks
3202522|NCT00914095|Active Comparator|methylphenidate|methylphenidate 10 mg tablets (1 mg /kg /day) 3 time a day
2539926|NCT02630940||Idiopathic pulmonary fibrosis sufferers|Male or female idiopathic pulmonary fibrosis (IPF) sufferers over the age of 40, with a confirmed diagnosis of IPF against international guidelines. Patients are devoid of significant other medical, surgical or psychiatric illnesses that may affect respiratory symptoms or disease progression.
2539962|NCT02630797|Placebo Comparator|Blueberry baseline|No blueberry products provided as part of the usual dietary intake
2539971|NCT02630797|Active Comparator|Blueberry Low|One blueberry product per day containing an equivalent of 0.75 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2539978|NCT02630797|Active Comparator|Blueberry Medium|Two blueberry products per day containing an equivalent of 1.5 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2539980|NCT02630797|Active Comparator|Blueberry High|Four blueberry products per day containing an equivalent of 3 cups of fresh blueberries provided as part of usual dietary intake for 42 days
2540013|NCT02630550||Aortic Aneurysm Repair|The impact of large abdominal retractors and an abdominal aortic cross-clamp on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
2540016|NCT02630550||Femoral Endarterectomy|The impact of the clamping of a large peripheral arterial vessel on the validity of the Cheetah NICOM's measurements will be evaluated in this group.
3168265|NCT00548769|Experimental|Sequence ADBC|Subjects will be administered formulation A, formulation D, formulation B and formulation C across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3168266|NCT00548769|Experimental|Sequence BACD|Subjects will be administered formulation B, formulation A, formulation C and formulation D across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
2540261|NCT02628990|Experimental|1.6 g plant stanols|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols), consumed with a meal daily for 4 weeks
2540262|NCT02628990|Experimental|2 g plant stanols|A yoghurt drink containing plant stanol ester (2 grams plant stanols), consumed with a meal daily for 4 weeks
2540263|NCT02628990|Experimental|1.6 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (1.6 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
2540264|NCT02628990|Experimental|2 g plant stanols and camelina oil|A yoghurt drink containing plant stanol ester (2 grams plant stanols) and camelina oil (2 g), consumed with a meal daily for 4 weeks
2540265|NCT02628990|Placebo Comparator|Placebo|A placebo yoghurt drink, consumed with a meal daily for 4 weeks
2540320|NCT02628639|Experimental|electroencephalography recording|Cerebral measurements from high-density electroencephalography after the presentation of personalized stimulations
2540371|NCT02628301|Active Comparator|Hypercaloric diet|Hypercaloric diet (1.6x REE) for 30 days
2540373|NCT02628301|Placebo Comparator|Normal diet|Normocaloric diet (1.0xREE)
3202523|NCT00914095|Placebo Comparator|placebo|tablets of placebo 3 time a day
3202524|NCT00914121|Experimental|1|SKI-606 alone
2540638|NCT02626429|Experimental|Active, Young Adult Famale|Participants will complete a bout of exercise and then consume a randomly assigned amino acid intake prior to measuring whole body 13CO2 excretion and phenylalanine oxidation.
2540685|NCT02626117|Active Comparator|CAF+ SCTG+ laser depithelialisation|CAF + SCTG and Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium.
2540687|NCT02626117|Sham Comparator|CAF+SCTG+ sham laser depithelialisation|CAF+ SCTG+ sham LASER deepithelialisation was applied to remove the sulcular epithelium.
2540764|NCT02625467|Experimental|Penetrating keratoplasty|Conventional penetrating keratoplasty technique
2540767|NCT02625467|Experimental|PALK|Pachymetry and Excimer laser assisted lamellar keratoplasty
2540802|NCT02625155|Other|Standard of Care (SOC Arm)|Standard of Care UDT
2540810|NCT02625155|Other|Selective PGx Testing (Test Arm)|Standard of Care UDT with selective PGx testing
2540875|NCT02624908|Active Comparator|canagliflozin|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
2540880|NCT02624908|Placebo Comparator|placebo|Subjects randomized to this arm will start with 100 mg tablet and increase to 300 mg tablet at Visit 4 if well tolerated.
2540940|NCT02624544|Experimental|Group A|Proton Pump Inhibitor esomeprazole 40 mg twice a day
2540941|NCT02624544|Active Comparator|Group B|desonide
2541028|NCT02623972|Experimental|Arm A: Eribulin > AC|"Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Two research breast biopsies~Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
3168267|NCT00548769|Experimental|Sequence CBDA|Subjects will be administered formulation C, formulation B, formulation D and formulation A across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3202525|NCT00914121|Placebo Comparator|2|Placebo
3202526|NCT00914121|Active Comparator|3|Moxifloxacin
2539698|NCT02632435|Other|Peripherally inserted central catheter|PICC line will be inserted for the delivery and duration of chemotherapy.
2539706|NCT02632435|Other|portacath|PORT will be inserted for the delivery and duration of chemotherapy and trastuzumab.
2539774|NCT02632162||cardiac surgery|active Group screening
2539778|NCT02632162||orthopedic surgery|control Group screening
3202527|NCT00914121|Experimental|4|SKI-606 plus ketoconazole
2539919|NCT02631200|Experimental|Advance care plan|Participants will be offered the opportunity to complete an advance care plan.
2539920|NCT02631200|No Intervention|Usual care|Participants will be offered usual care for 12 weeks (and only then be offered the opportunity to complete an advance care plan).
2539942|NCT02630862|Active Comparator|aspirin|acetylsalcylic acid 100 mg per day give orally for six months, starting the day of carotid endoartherectomy
2539948|NCT02630862|Active Comparator|aspirin plus dipyridamole|acetylsalicylic acid 25 mg plus dipyridamole extended release 200 mg, combined in a capsule, per day starting the day of carotid endoartherectomy
2540019|NCT02630628|Experimental|Tacrolimus|route: oral duration: 96 weeks
2540021|NCT02630628|Active Comparator|Mycophenolate Mofetil|route: oral duration: 96 weeks
2540097|NCT02630225|Experimental|Intervention|"Participants in this arm will receive three intervention services in addition to treatment as usual services:~A brief intervention including a feedback session utilizing principles of Motivational Interviewing (MI).~Extended outreach services (6 months) using the Critical Time Intervention (CTI) approach.~Multi-agency attention."
2540103|NCT02630225|Other|Treatment as Usual|Participants in this arm will receive the usual care offered to victims of gun shot wounds.
2540201|NCT02629562|Experimental|Arm 1|first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously
2540204|NCT02629562|Experimental|Arm 2|first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously
2540237|NCT02629146|Experimental|Midazolam|Drug: Midazolam (experimental)
2540245|NCT02629146|Placebo Comparator|Isotonic saline|Drug: Isotonic saline (placebo)
2540247|NCT02629146|Active Comparator|Fentanyl|Drug: Fentanyl (active comparator)
2540276|NCT02628691||HCV coinfection with no-to-moderate fibrosis|
2540337|NCT02628535|Experimental|MGD009|Orlotamab; Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein
2540427|NCT02627911|Other|Usual System (open-loop)|"In open loop, the patient will be provided with its usual pump and a CGM. To estimate rest and physical activity in patients being sedentary situation ( Centers : Caen, Nancy & Strasbourg) or in situations of physical activity ( Centers : CHSF Marseille and Besancon ) , the usual system will be complemented by an accelerometer  ActiGraph  and a  ActiHeart  heart rate monitor."
2540430|NCT02627911|Experimental|DIABELOOP System (closed-loop)|In the closed loop, the patient's pump will be replaced by the Diabeloop system consisting of insulin pump Cellnovo driven by remote control augmented by Diabeloop software and connected to the CGM.
2540459|NCT02627508|Experimental|Pregnenolone (up to 500 mg per day)|"Twice daily intake of orally administered Pregnenolone will occur on a schedule as described below.~Weeks 1 and 2: 30mg twice daily (total 60mg per day)~Weeks 3 and 4: 60mg twice daily (total: 120mg per day)~Weeks 5 and 6: 90mg twice daily (total: 180mg per day)~Weeks 7 and 8: 150mg twice daily (total: 300mg per day)~Weeks 9 and 10: 210mg twice daily (total: 420mg per day)~Weeks 11 to 14: 250mg twice daily (total: 500mg per day)"
2540460|NCT02627508|Placebo Comparator|Placebo|Placebo
2540511|NCT02627417|Experimental|Dapsone: (Disulone®)|Dapsone: Disulone® given orally at 100 mg per day
2540513|NCT02627417|Active Comparator|"Prednisone (Cortancyl®) alone and standard of care"|"Prednisone (Cortancyl®) alone at 1 mg/kg for 3 weeks followed by monitoring and standard of care (control arm)"
2540522|NCT02627053|Experimental|rivaroxaban|
2540554|NCT02626936|Active Comparator|Dual-hormone CL with overestimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be overestimated by one category, which will result in a meal insulin bolus for a meal of 95g of carbohydrates.
2540556|NCT02626936|Active Comparator|Dual-hormone CL with adequate estimation of meal size category|A large size standardized meal of 75g of carbohydrates will be provided to the patient and the meal size will be adequately estimated, which will result in a meal insulin bolus for a meal of 65g of carbohydrates.
2540609|NCT02626637|Experimental|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
2540641|NCT02626260|Experimental|Cohort 1b|The subject test one adhesive strip on the peristomal area
2540692|NCT02626078||observation and interview of residents|residents will be observed over lunch and an interview will be held with each resident after lunch
2540727|NCT02625662||iFSHD group|First recruitment group
2540854|NCT02625051|Active Comparator|Ureteroscopy|Kidney stone of participants in this arm will be treated with ureteroscopy (URS). A ureteral stent will be inserted at the end of the procedure.
2540934|NCT02624479|Experimental|Medium first|Sodium thiosulfate medium release formulation first, followed by slow and fast
3202528|NCT00914121|Placebo Comparator|5|Placebo plus ketoconazole
2539614|NCT02632981|Active Comparator|chronic periodontitis patients|gingival crevicular fluid and saliva collecion were taken before and after nonsurgical periodontal treatment
2539617|NCT02632981|Placebo Comparator|periodontally healthy controls|gingival crevicular fluid and saliva collection were taken at baseline after oral hygiene instructions
3168268|NCT00548769|Experimental|Sequence DCAB|Subjects will be administered formulation D, formulation C, formulation A and formulation B across four study days each separated by a washout period of at least seven days. Subjects will fast overnight prior to dosing. Blood samples will be collected at intervals over a period of 24 hours post-dose.
3168269|NCT00548782|Active Comparator|A|Subjects will be placed on Paleolithic diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. a paleolithic diet excludes dairy, grains, legumes and processed foods.
3168270|NCT00548782|Active Comparator|B|Subjects will be placed on ADA ( American Diabetes Association) recommended diet and markers of insulin resistance, lipid profiles and vascular reactivity will be measured. An ADA diet is lower fat and more whole grains.
3168271|NCT00548821|Experimental|2|ARM 2: Weekly cisplatin 40mg/m2, concurrent with radiotherapy.
2539728|NCT02632357|Experimental|AS group|Subjects with ULNTT asymmetry > 10°
2539729|NCT02632357|No Intervention|S group|Subjects with ULNTT symmetry
2540090|NCT02630160|Active Comparator|Intraarticular Catheter with anesthesic|Intraarticular infusion with Bupivacaine Hydrochloride
2540091|NCT02630160|Placebo Comparator|Intraarticular Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by intraarticular catheter
2540092|NCT02630160|Active Comparator|Perifascial Catheter with anesthesic|Perifascial infusion with Bupivacaine Hydrochloride
2540093|NCT02630160|Placebo Comparator|Perifascial Physiological Saline|Infusion of Physiological Saline [Flebobag Salina Fisiologica Grifols 0.9%] Sterile Solution by Perifascial catheter
2540141|NCT02629809|Experimental|Treatment (iFCG)|See Detailed Description.
2540216|NCT02629211|Experimental|NaviAid™ AB|NaviAid™ AB device procedure
2540309|NCT02628925||Recovery room|10 medical staff working in the recovery room
2540310|NCT02628925||Orthopedic ward|10 medical staff working on the orthopedic ward
2540336|NCT02628431||General anesthesia|Patients that will recieve general anesthesia for elective surgery
2540344|NCT02628431||Regional or neuraxial anesthesia|Patients that will revieve regional or neuraxial anesthesia for elective surgery
2540399|NCT02628119|Experimental|Intra-procedural access flow|"Management of access dysfunction based on intra-procedure access flow monitoring.~Criteria for target access flow:~Within 90% of baseline access flow if known 180% increase from pre-intervention flow if access flow not known 600ml/min for thrombosed grafts and 500 ml/min for thrombosed arteriovenous fistula in case baseline access flow not known"
2540401|NCT02628119|Active Comparator|Standard Angioplasty|Intervention based on current standards of care i.e. 2 dimensional angiographic views.
2540448|NCT02627781||suspected appendicitis|This group includes all patients with suspected appendicitis, who are admitted to our University Hospital.
2540518|NCT02627157||myopia patients|20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
2540533|NCT02627014|Experimental|INTERVENTION|Manual Therapy in temporomandibular joint and cervical region. Home physical therapy in temporomandibular joint and cervical region.
2540537|NCT02627014|Active Comparator|CONTROL|Manual therapy in cervical region Home physical therapy in cervical region
2540632|NCT02626299|Placebo Comparator|200 mg/day DHA|Participants will receive 2 placebo pills/day that do not contain DHA. Like the experimental group, they will be given a supplement of Docosahexaenoic acid - 200mg/day , a common amount in prenatal vitamins.
2540635|NCT02626299|Experimental|1000 mg/day DHA|The intervention includes Docosahexaenoic acid - 800mg/day per day provided in two 400 mg capsules. The intervention group as well as the active comparator group will be given 1-200 mg/capsule per day of DHA that is a common amount in prenatal vitamins.
2540719|NCT02625779|Active Comparator|Valproate and Placebo|Valproate: 300mg/day for 8 weeks Placebo: for 8 weeks
2540721|NCT02625779|Experimental|Valproate and Cytidine-containing Drug|Valproate: 300mg/day for 8 weeks Cytidine-containing Drug: 2g/day for 8 weeks
2540723|NCT02625779|Experimental|Valproate and Creatine-containing Drug|Valproate: 300mg/day for 8 weeks Creatine-containing Drug: 3g/day for the first week 5g/day for week 2-8
2541062|NCT02623738|Experimental|DE-117 ophthalmic solution high|Eyedrop
2541069|NCT02623738|Active Comparator|Latanoprost ophthalmic solution 0.005%|Eyedrop
2541299|NCT02622204||Corrective osteotomy|patients with knee osteoarthritis undergoing corrective osteotomy
3168272|NCT00548821|Experimental|1|ARM 1: 5-day 3 weekly cisplatin 20mg/m2 for 5 days, concurrent with radiotherapy
3168273|NCT00548899|Other|Sorafenib|Single Arm: All patients receive sorafenib in addition to the established chemotherapy
3168274|NCT00548925|Experimental|1|
3168275|NCT00548925|Placebo Comparator|2|
3168276|NCT00548951|Active Comparator|1|Subject receives Snoezelen sessions once per week.
3168277|NCT00548951|Active Comparator|2|Subject receives Snoezelen sessions three times per week.
3168278|NCT00548951|Other|3|Subject receives no sessions per week.
3168279|NCT00548964|Experimental|Ketamine + Lithium|All participants receive the study drug, IV ketamine, open-label
3168280|NCT00548964|Active Comparator|Ketamine + Placebo|All participants receive the study drug, IV ketamine, open-label
3168281|NCT00548990|Experimental|1|a 10-month moderate aerobic exercise training program
3168282|NCT00548990|Placebo Comparator|2|flexibility/balance control group
3168283|NCT00549016|Experimental|1|
3168284|NCT00549029||1,2|Group 1 for the patients with rhabdomyolysis Group 2 for the control without any myopathy
3168285|NCT00549081|Experimental|1|IVF patients who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
3168286|NCT00549081|No Intervention|2|IVF patient who had a low ovarian response in a previous hormonal-stimulation treatment, treated with recombinant FSH and LH.
3168287|NCT00549107|Experimental|1|
3168288|NCT00549107|Active Comparator|2|
3168289|NCT00549120|Experimental|Propranolol alone|Propranolol 80 mg (5 doses at 6 hourly intervals)
2539623|NCT02632955|Experimental|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
2539626|NCT02632955|Sham Comparator|Regular Angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
2539694|NCT02632669|Experimental|Hemigland focal LDR brachytherapy|Hemigland focal LDR brachytherapy using permanent iodine 125 seed implantation
2539780|NCT02632214|Experimental|Deaf|Group of early profound deaf participants fMRI measure
2539789|NCT02632214|Experimental|Hearing signers|Group of hearing signer controls fMRI measure
2539791|NCT02632214|Sham Comparator|Hearing non signers|Group of hearing non signer controls fMRI measure
2539824|NCT02631694|Experimental|Fear reactivation with propranolol|
2539830|NCT02631694|Placebo Comparator|Fear reactivation with placebo|
2539835|NCT02631694|Placebo Comparator|No fear reactivation with propranolol|
2539901|NCT02631343|Experimental|Intervention KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
2539906|NCT02631343|Other|Control|Routine visits by government health workers
2539924|NCT02631018|Experimental|Physical Activity Enhanced Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations. This arm, uniquely, will receive a culturally based physical activity component.
2539925|NCT02631018|Active Comparator|Standard Weight Loss Intervention|Participants will engage in 18 weight loss intervention group sessions over 6 months. Sessions will occur weekly for the first 3 months, and biweekly for the latter 3 months. Participants will receive a behavioral weight loss curriculum, calorie and physical activity recommendations.
2539966|NCT02630810|Experimental|Early oral hydration|Early oral intake of 100 ml clear unsweetened water 1 hour following the Cesarean Section, then upon patient's desire, then starting semisolid, solid food when participant passed flatus.
2539972|NCT02630810|Active Comparator|Delayed oral hydration|Oral intake of 100 ml clear unsweetened water after 6 hours from the end of CS then upon patient's request,then starting semisolid, solid food when participant passed flatus.
2540037|NCT02630667|Experimental|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response.
2540038|NCT02630667|Experimental|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response.
2540041|NCT02630667|Experimental|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response.
2540042|NCT02630667|Placebo Comparator|Non-Caloric Placebo|Non-caloric placebo consisting of artificial sweeteners
2540099|NCT02630134|Experimental|Baeta|These patients receive the Baeta device and take it home.
3168290|NCT00549120|Experimental|Propranolol + salbutamol|Propranolol 80 mg (5 doses at 6 hourly intervals) + salbutamol 600 μg (4 doses at 6 hourly intervals)
3168291|NCT00549120|Experimental|Salbutamol alone|Salbutamol 600 μg (4 doses at 6 hourly) + placebo (5 doses at 6 hourly intervals)
3168292|NCT00549120|Placebo Comparator|Placebo|Placebo (5 doses at 6 hourly)
2540440|NCT02627807|Experimental|Individualized CTV|Patients receive IMRT using individualized CTV based on disease extension risk atlas and computer-aided delineation. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
2540443|NCT02627807|Active Comparator|Traditional CTV|Patients receive IMRT using traditional CTV. Gemcitabine and cisplatin induction chemotherapy or docetaxel and cisplatin induction chemotherapy and cisplatin 100mg/m² concurrent chemotherapy or cisplatin 80mg/m² concurrent chemotherapy are optional based on clinical classification.
2540497|NCT02627456|Experimental|1A|(n=5), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (4.5x105) via DVI. All 5 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination.
2540499|NCT02627456|Experimental|1B|(n=S), will be a safety group. Subjects will receive 1 dose of PfSPZ Vaccine (9.0x10S) via DVI. All S subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to PfSPZ Vaccine. Subjects will be followed for approximately 3 months post vaccination
2540500|NCT02627456|Experimental|1C|(n=30), will be the targeted dose for the Pilot Safety Group. Subjects will receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. 15 subjects will receive antimalarial treatment with artesunate /amodiaquine (ASAQ) prior to each administration of PfSPZ Vaccine, while 15 will not, except prior to PfSPZ Vaccine #3 when all 30 subjects will receive antimalarial treatment with ASAQ.
2540502|NCT02627456|Experimental|1D|(n=15), will be the CHMI control group. Subjects will not receive any PfSPZ vaccinations but will serve as infectivity controls for CHMI. All 15 subjects will receive antimalarial treatment with ASAQ prior to PfSPZ Challenge.
2540503|NCT02627456|Experimental|2|(n=60), will be the targeted vaccine dose arm and receive 3 doses of PfSPZ Vaccine (18x105) via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the pilot study indicate otherwise.
2540505|NCT02627456|Placebo Comparator|3|(n=60), will be the placebo arm and receive vaccinations with normal saline via DVI on Day 1, 57, 113. All subjects will receive antimalarial treatment prior to Vaccination #1 and #3 unless results obtained and analyzed from the Pilot Study indicate otherwise.
2540509|NCT02627365|No Intervention|Standard care|Standard care according to Kenyan guidelines, including clinic-based adherence education and counseling.
2539654|NCT02632708|Experimental|AG-221 with cytarabine and idarubicin|Daily AG-221 administered orally in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2539660|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and daunorubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2539662|NCT02632708|Experimental|AG-221 (starting on Day 8) with cytarabine and idarubicin|Daily AG-221 administered orally starting on Day 8 of induction cycle 1 in combination with standard Induction therapy and consolidation therapy. After 1 cycle of induction therapy, participants may undergo a second induction cycle given as per institutional practice. Participants who achieve an adequate response at the end of induction therapy will go on to receive consolidation therapy (mitoxantrone/etoposide or up to 4 cycles of cytarabine) in combination with AG-221. Participants who complete consolidation therapy and are in CR or CRi (including CRp) may continue on maintenance therapy and receive daily treatment with AG-221.
2539758|NCT02632045|Experimental|Ribociclib (LEE-011)/Fulvestrant|LEE-011 is administered orally, 600mg, daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
2539759|NCT02632045|Placebo Comparator|Placebo/Fulvestrant|Placebo is administered orally, 600mg daily for 3 weeks and 1 week off. Fulvestrant is administered intramuscularly, 500mg, every 2 weeks x 3, then every 4 weeks.
2539863|NCT02631486|Experimental|Early|"The first group will use sling for comfort only. Active assisted exercises in closed chain and in safe zone are allowed in the first 4 weeks.~The rehabilitation stages will start from active assisted progressing to more active stages phases until full recovery. The whole program will last about 3 months."
2539865|NCT02631486|Active Comparator|Conservative|The second group will use a sling for 6 weeks. The rehabilitation stages will start with active assisted/closed chain movements with short levers, it will progress to more active stages phases until full recovery. The whole program will last about 3 months.
2539890|NCT02631291|Experimental|Lifestyle|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet.
2539892|NCT02631291|No Intervention|Usual Care|Participants randomized to this condition will receive the written education provided to all participants.
2539893|NCT02631291|Experimental|LIfestyle + coaching|Behavioral self-monitoring of daily physical activity, dietary, and sleep behaviors, for 12 weeks, into an electronic tablet; and behavioral self-monitoring + motivational interviewing lifestyle coaching.
2539990|NCT02631109|Experimental|L-DEP|Pegaspargase 2000U/m2 day5; doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered once on the first day of every week; methylprednisolone 15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
2540028|NCT02630498|Experimental|study (first group)|The first group will include those who receive a single shot brachial plexus block with or without general anesthesia.
2540035|NCT02630498|No Intervention|Controlled (second group)|The second group will be the control group and include those patients who receive general anesthesia only, without any block whether due to the preference of patient or the surgeon.
3202529|NCT00914134|Experimental|Levodopa Infusion|Patients with advanced Parkinson's disease and motor fluctuations that cannot be adequately controlled with oral medication.
3202530|NCT00914147|Other|Pulmonary Function Test (PFT)|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization. PFT measurements will be reported as absolute values (e.g. liters) and percentage of predicted. The predicted normal values will be calculated according to sex, age, height and race using the Third National Health and Nutrition Examination Survey (NHANES III) reference equation. Predicted values for diffusion capacity will be calculated using the Morris/Polgar equation. DLCO values will be adjusted to anemia (hemoglobin levels)
3202531|NCT00914160|Experimental|1|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
3202532|NCT00914160|Experimental|2|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
2540664|NCT02626234|Experimental|INC280|
3202533|NCT00914160|Active Comparator|3|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
3202534|NCT00914173|Experimental|Pain/No Pain Stimuli|One Arm is used in this trial. The comparator is within the arm. The different types of stimuli levels and types are compared.
3202535|NCT00914199|Experimental|Kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent using kissing balloon dilatation
3202536|NCT00914199|Experimental|No kissing balloon post-dilatation|Percutaneous coronary intervention with implantation of stent and not using kissing balloon postdilatation
3202537|NCT00914212|Active Comparator|1|Sibutramine
3202538|NCT00914212|Placebo Comparator|2|Placebo
3202539|NCT00914225||Intervention|Cohort 1 is the intervention group who received long-lasting insecticide treated bednets and a water filtration device
3202540|NCT00914225||Comparison|"Cohort 2 is the comparison group included from the control arm of the study, Empiric therapy of helminth coinfection to reduce HIV-1 disease progression ClinicalTrials.gov identifier: NCT00507221~As part of the RCT (NCT00507221), we have enrolled 948 HIV infected ART naïve individuals to compare HIV disease progression in those receiving standard of care versus empiric deworming. Subjects are followed for 24 months and have serial measurements of HIV disease progression, and are evaluated serially for evidence of malaria, diarrhea and other co-morbidities. Participants in this study will have been consented for the collection of data on the frequency of malaria and diarrheal disease, their use of a bednet and water filtration and their compliance with TMP/SMX."
2539751|NCT02632266|Active Comparator|Powder HMF|Once patient has reached 80ml/kg/day of enteral feedings, 1 pack of powder HMF will be added to 50 ml of human or donor breast milk, then increased to a maximum of 2 packs for 50 ml following the unit feeding advancement protocol and this will be continued up until 48 hours prior to discharge.
2539754|NCT02632266|Active Comparator|Liquid HMF|Once patient has reached 80ml/kg/day of enteral feedings, researchers will add 1 packet (5 ml) of liquid HMF to 50 ml of human or donor breast milk, then increase to 2 packs to 50 ml following the unit feeding protocol and this will be continued up until 48 hours prior to discharge.
2539804|NCT02631902|Experimental|Exercise|Community-based exercise program
2539805|NCT02631902|Experimental|Exercise plus dietary intervention|Community-based exercise and dietary intervention program
2539806|NCT02631902|No Intervention|Control|Habitual physical activity and habitual dietary pattern
2539913|NCT02631304||Patients undergoing cardiac surgery|Elderly patients scheduled to undergo elective cardiac surgery (coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery) with the use of cardiopulmonary bypass.
2539934|NCT02630914|Experimental|Intervention|All patients will have the hybrid procedure of ablation of atrial fibrillation.
2540002|NCT02630745|Active Comparator|Immediate periodontal surgery (Group 1)|periodontal surgical procedure in the form of open flap debridement will be performed immediately( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) after obturation of the root canal system( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
2540004|NCT02630745|Active Comparator|Delayed periodontal surgery (Group 2)|periodontal surgical procedure in the form of open flap debridement( in which after debridement mucoperiosteal flaps will be repositioned and secured by using 3-0 non-absorbable black silk surgical suture) will be performed 3 months after obturation of the root canal system ( using calcium hydroxide intracanal medicament placed with the help of 27 gauge endodontic syringe for 10 days and access cavity will be sealed with suitable sealer).
2540057|NCT02630368|Experimental|Experimental phase I dose escalating|"Prospective open-labeled phase I trial.~Combination of cyclophosphamide and JX-594 dose escalation. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 14"
2540058|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 1.~Experimental phase II soft-tissue sarcoma :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 48"
2540059|NCT02630368|Experimental|Control group soft-tissue sarcoma, treatment by JX-594 + Metronomic cyclophosphamide|"Randomized non comparative phase II clinical trial : Arm 2.~Control-arm phase II soft-tissue sarcoma :~Patients will be treated by metronomic cyclophosphamide. Cyclophosphamide will be administered 50 mg twice daily orally, one week on/one week off. One cycle consits of 28 days.~Number of subjects : 24"
2540060|NCT02630368|Experimental|Experimental group breast cancer, treatment by JX-594 + Metronomic cyclophosphamide|"Single-arm phase II clinical trial.~Experimental phase II Group breast cancer :~Combination of cyclophosphamide and JX-594. Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.~Number of subjects : 32"
2540061|NCT02630368|Experimental|Experimental group soft-tissue sarcoma, treatment by Avelumab + ITJX-594 + Metronomic CP|"Experimental phase II soft-tissue sarcoma :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 47"
2540062|NCT02630368|Experimental|Experimental group breast cancer, treatment by Avelumab + IT JX-594 + Metronomic CP|"Experimental phase II breast cancer :~Combination of avelumab in combination with intratumoral JX-594 and metronomic cyclophosphamide.~Avelumab will be administered by intravenous infusion every 2 weeks, starting at Day 15 of cycle 1.~Cyclophosphamide wil be administered orally, 50 mg twice daily, one Week on/one Week off, starting 7 days prior to cycle 1 day 1 (impregnation phase).~JX-594 will be administered by intratumoral injection on day 1 of cycle 1, every 2 weeks, for a maximum of 4 injections.~Number of subjects : 32"
3202541|NCT00914238|Experimental|5 year|5 years OPUS treatment
3202542|NCT00914238|Active Comparator|2 years of OPUS treatment|2 years OPUS treatment and 3 years of treatment as usual
2540241|NCT02629198||normal weight|Healthy men and women ages 25-40 and 55-75. BMI 18.5 to 25.0
2540248|NCT02629198||overweight|Healthy men and women ages 25-40 and 55-75. BMI 25.0 to 30.0
2540249|NCT02629198||obese|Healthy men and women ages 25-40 and 55-75. BMI over 30
2540302|NCT02628899|Other|Prospective TAVR Arm|200 patients prospectively undergoing transfemoral TAVR
2540306|NCT02628899|Other|Historical SAVR Controls|Historical controls will be selected from among patients at the same site who have undergone isolated bioprosthetic SAVR within the previous 36 months. TAVR patients will then be matched to SAVR patients using STS database variables to perform propensity matching, including (but not limited to) age, gender, race, ethnicity, STS score, and valve prosthesis size.
2540308|NCT02628899|Other|Low-Risk TAVR with Bicuspid Aortic Valve|The third arm of the trial will comprise a registry of TAVR in up to 100 low-risk patients with bicuspid aortic valve. The results from the registry arm will be analyzed independently.
2540332|NCT02628314||Osteoarthritis|Study population to include adult men and women with osteoarthritis.
3202543|NCT00914264||COPD with OSA with CPAP treatment|COPD with OSA: CPAP treatment
3202544|NCT00914264||COPD without OSA|COPD without OSA, not treat with CPAP
2539779|NCT02632253|Experimental|High intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min.~Additionally patients perform one self monitored 30-60 min MICE training of choice per week at home."
2539825|NCT02631707|No Intervention|Control Standard Protein Diet|Control Arm Ministry of Health guidelines percentage energy from carbohydrate (50-55%), protein (10-15%) and fat (30%).
2539829|NCT02631707|Experimental|Intervention High Protein Diet|Intervention Arm Percentage energy from carbohydrate (40%), protein (30%) and fat (30%).
2539909|NCT02631408|No Intervention|Control Group|No additional treatment. Routine iv. antibiotic prophylaxis only.
2539912|NCT02631408|Experimental|Vancomycin Group|Vancomycin powder is applied before wound closure. Routine iv. prophylaxis stays unchanged
3202545|NCT00914264||COPD with OSA but without CPAP treatment|COPD with OSA but patient refused CPAP treatment
3202546|NCT00914277|Experimental|Sequence 1|"Period 1: placebo~Period 2: sildenafil~Period 3: SAR407899 dose level 2~Period 4: SAR407899 dose level 1"
2540014|NCT02630485|Experimental|Graceful Lifestyle Changes & MYO|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
2540015|NCT02630485|Experimental|Graceful Lifestyle Changes|"The 12-week lifestyle intervention will incorporate three lifestyle changes: a low-glycemic diet, increased exercise, and stress reduction through meditation and mindfulness.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
2540017|NCT02630485|Placebo Comparator|Letrozole & MYO|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take myo-inositol (6 grams in juice or water every morning)."
2540018|NCT02630485|Placebo Comparator|Letrozole|"The women assigned to the fertility medication group will be prescribed letrozole. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.~In addition, this group will take a white powder placebo (6 grams in juice or water every morning)."
2540101|NCT02630199|Experimental|AZD6738 + paclitaxel|The PART A will be in combination with paclitaxel; the starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity. The PART B will be an independent parallel PK expansion cohort with cycle 0 of AZD6738 on D1, D8~D21 monotherapy followed by combination therapy with weekly paclitaxel from cycle 1.
2540135|NCT02629835|Active Comparator|Intravenous dexamethasone 8 mg|patients receiving intravenous 8 mg of dexamethasone in parallel to ultrasound guided axillary nerve block with a standardized local anesthetic solution
2540140|NCT02629835|Active Comparator|Perineural dexamethasone 8 mg|patient receiving perineural 8 mg of dexamethasone in a mixture with a standardized local anesthetic solution for ultrasound guided axillary block
2540181|NCT02629588||Persons in coma or vegetative state|People who survived TBI have a period of complete unconsciousness or coma with no awareness of themselves or their surroundings received multimodal or unimodal sensory stimulation.People in a coma are unaware and unresponsive, but not asleep as there is no sleep-wake cycle. While in a coma, people are unable to speak, follow commands or open their eyes. The person in coma may have a simple reflex in response to touch or pain, but essentially there is no meaningful response to external stimuli. There is an absence of awareness of self and the environment, even under conditions of vigorous external stimulation. Coma can last from hours to days, depending on the severity of the brain damage, and sometimes a person can remain in a comatose state for months and even years.
2540215|NCT02629068|Experimental|PURPOSE|"Parents in the PURPOSE group will join a secret Facebook group for 2 months. Groups will be lead by 2 peer leaders and include 20 parent participants."
2540218|NCT02629068|No Intervention|Treatment as Usual (TAU)|Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
2540301|NCT02628912||long-term survivors of HPV-related oropharyngeal cancer|This is a cross-sectional pilot study of long-term survivors of HPV-related oropharyngeal cancer treated with CTRT who are at least three years from treatment completion. This study consists of a onetime assessment of cardiopulmonary fitness, physical function status, measurement of lean body mass, endothelial function quality of life assessment, medical history and blood laboratory evaluation for traditional cardiac risk factors, endocrine derangement and inflammation.
3202547|NCT00914277|Experimental|Sequence 2|"Period 1: sildenafil~Period 2: SAR407899 dose level 1~Period 3: placebo~Period 4: SAR407899 dose level 2"
2540422|NCT02627820|Experimental|Experimental Drug|Isis 420915/GSK 299872, an antisense oligonucleotide. Administered subcutaneously three times per week for the first week, and then weekly for 18 months. Each dose shall contain 300 mg of active drug.
2540559|NCT02627326|Active Comparator|Group 1|Interventions done in 30 patients and included conventional endodontic treatment (ET) and periodontal surgery . After 3 months of completion of endodontic therapy without using 2%chlorhexidine gluconate gel intracanal medicament , periodontal surgery in the form of open flap debridement (OFD) was performed.
2540560|NCT02627326|Active Comparator|Group 2 Chlorhexidine|Interventions done in 30 patients and included intracanal medicament . After biomechanical preparation of root canal, 2%Chlorhexidine gluconate gel as an intracanal medicament was placed in root canal from pulp chamber to apex for 3 months (replacing every month). After 3 months,periodontal surgery in the form of open flap debridement (OFD) was performed in the respective tooth and medicament was changed and placed further for 3 months (replacing every month). Obturation was done after 3 months of OFD.
2540587|NCT02626676|Experimental|Educational Programme Group|Stage 5D Chronic Kidney Disease Patients on high-efficiency hemodialysis programme - 4-hour sessions, 3 times a week will be followed up
2539811|NCT02631785|Experimental|Anxious group|Youth diagnosed with anxiety disorder will receive Cognitive Behavioral Therapy for reducing anxiety symptoms.
2539812|NCT02631785|No Intervention|Control group|Healthy youth will be recruited for comparison but their participant in the study will not include intervention.
2539867|NCT02631499|Experimental|Adjuvant TACE|TACE will be performed 4-6 weeks after hepatectomy in patients with preoperative CTC ≥2 Epirubicin, lipiodol and gelatin sponge articles are used in TACE.
2539868|NCT02631499|No Intervention|Control|no interventions were assigned after hepatectomy
2539918|NCT02631226||Pregnant women colonized by resistant enterobacteria|
2539953|NCT02630901|Experimental|PRX003|
2539956|NCT02630901|Placebo Comparator|Placebo|
2539999|NCT02630576|Experimental|Men - Left Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
2540000|NCT02630576|Experimental|Men - Right Hand|5 healthy male volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
2540001|NCT02630576|Experimental|Women - Left Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the left hand
2540003|NCT02630576|Experimental|Women - Right Hand|5 healthy female volunteers undergoing 4 types of neuromuscular stimulation protocols on the right hand
2540076|NCT02630355|Sham Comparator|Control|Inflation of blood pressure cuff in lower limb to 40mmHg for four cycles of 5 minutes inflation and then deflation
2540079|NCT02630355|Active Comparator|Low Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for two cycles of 5 minute inflation and then deflation.
2540080|NCT02630355|Active Comparator|Standard Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and then deflation.
2540082|NCT02630355|Active Comparator|High Intensity|Inflation of blood pressure cuff in lower limb to 200mmHg for four cycles of 5 minute inflation and deflation on weekly basis for four consecutive weeks.
2540121|NCT02629978|Experimental|radiofrequency ablation|In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation，the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
2540163|NCT02629718|Experimental|A(NACT)|Neoadjuvant Chemotherapy followed by Radical Surgery
2540165|NCT02629718|Active Comparator|B(RS)|Radical Surgery alone
2540205|NCT02629406||Diabetes typ 1|Patients with typ 1diabetes with a duration of the disease between 10-20 years (HbA1C >65 mmol/l) and age 20-50 will be exposed to intermittent hypoxia.
2540208|NCT02629406||Healthy controls|Healthy controls, age 20-50 will be exposed to intermittent hypoxia.
2540228|NCT02629055|Experimental|Respiratory EMG|Additional EMG measurements whilst on NIV will be used to guide the titration of NIV.
2540239|NCT02629055|No Intervention|Care as usual|NIV will be initiated according to standard care protocol.
2540289|NCT02628821||Preterm Infants treated with non-invasive ventilation|"Preterm Infants of less than 32 weeks of Gestational age treated with synchronized non-invasive ventilation (SNIPPV) to prevent intubation or extubation failure based in a prospective protocol:~nCPAP failure: Preterm infants supported with nCPAP that meet intubation criteria if they are in a stable situation.~Electively For extubation:~Preterm infants in which nCPAP extubation has previously failed or Prolonged mechanical ventilation (more than 15 days) with high respiratory parameters (PMAP > 10 cmH2O and FiO2>35%)."
2540341|NCT02628509||cardiac devices|patients receiving mechanical circulatory support patients undergoing transaortic valve replacement
3202548|NCT00914277|Experimental|Sequence 3|"Period 1: SAR407899 dose level 1~Period 2: SAR407899 dose level 2~Period 3: sildenafil~Period 4: placebo"
2540494|NCT02627534|Active Comparator|Ultrasonic Debridement (UD)|Ultrasonic Debridement (UD) (n=20)
2540498|NCT02627534|Experimental|UD + Antimicrobial Photodynamic Therapy|Ultrasonic Debridement + aPDT (UD+aPDT) (n=20)
2540544|NCT02627170||Healthy adults group|Age 20 to 40 years of age and have myopia with a spherical equivalent (SE) between 0.00 and -11.00 diopters (D)
2540599|NCT02626832|Experimental|Healthy Control|This group is represented by healthy controls
2540600|NCT02626832|Experimental|Depression|This experimental group is represented by subjects with depression
2540601|NCT02626832|Experimental|Schizophrenia|This experimental group is represented by subjects with schizophrenia
2540602|NCT02626832|Experimental|Prodromal subjects|This experimental group is represented by subjects with prodromal symptoms for schizophrenia
2540643|NCT02626286|Other|HIV quarterly global care|HIV quarterly global care including i) data collection on health status, symptoms of sexually transmitted infections (STI) and sexual behavior, ii) a clinical examination, iii) STI diagnosis and treatment, iv) prevention counselling adapted for MSM, v) the provision of condoms and lubricants, and vi) HIV screening test at each quarterly visit for HIV-negative MSM or immediate support of HIV infection including antiretroviral therapy for HIV-positive MSM.
3202549|NCT00914277|Experimental|Sequence 4|"Period 1: SAR407899 dose level 2~Period 2: placebo~Period 3: SAR407899 dose level 1~Period 4: sildenafil"
3202550|NCT00914290|Other|IPX056-Baclofen IR-IPX056|Following 2 weeks of run-in period, subjects were randomized to IPX056 and Placebo IR for 2 weeks and then to Baclofen IR and Placebo IPX056 for 2 weeks.
3202551|NCT00914290|Active Comparator|IPX056-IPX056-Baclofen IR|Following 2 weeks of run-in period, subjects were randomized to Baclofen IR and Placebo IPX056 for 2 weeks and then to IPX056 and Placebo IR for 2 weeks.
3202552|NCT00914303|Experimental|AZD3241|AZD3241 Tablets
3202553|NCT00914303|Experimental|Placebo|Placebo Tablets
3202554|NCT00914329|Experimental|Gelsemium 5CH|Globules of Gelsemium sempervirens 5CH
2540818|NCT02625077|Experimental|Laparoscopic valvuloplasty|Via laparoscopy, using three sutures a part of the esophagus is folded (similar to the way parts of a telescope slide in each other) into the stomach, creating a valve on the inside to prevent gastric acid to enter the esophagus.
3202555|NCT00914329|Experimental|Gelsemium 15CH|Globules of Gelsemium Sempervirens 15CH
3202556|NCT00914329|Placebo Comparator|Placebo|Globules of placebo
2539827|NCT02631642|Experimental|HMPL-689|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
2539833|NCT02631642|Placebo Comparator|HMPL-689 placebo|Subjects will receive a single dose of HMPL-689 or matching placebo on Day 1. The planned dose levels in ascending order are: 1, 2.5, 5, 10, 20, 25 and 30 mg (7 dose cohorts with 8 subjects in each cohort). Within each cohort, randomization ratio of 3:1 is followed to dose 6 subjects with HMPL-689 and 2 subjects with placebo.
2539895|NCT02631369|Experimental|inter- & intrarater reliability study|pre-study: inter- and intrarater reliability study in 30 healthy subjects, interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2539898|NCT02631369|Experimental|cyclotorsion in forth nerve palsy|measurement of cyclotorsion on SLO-fundusphoto in 20 patients forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2539905|NCT02631369|Experimental|cyclotorsion in healthy subjects|measurement of cyclotorsion on SLO-fundusphoto in 30 healthy subjects to be compared to patients with forth nerve palsy interventions: SLO-fundus photographs using the integrated algorithm by Heidelberg Spectralis OCT (optical coherence tomography) device
2539940|NCT02631096|Experimental|0.2 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.2 mg/kg versus placebo once a month for 3 months
2539943|NCT02631096|Experimental|0.4 mg/kg ARB-001467 or Placebo|HBeAg-negative subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
2539947|NCT02631096|Experimental|ARB-001467 or Placebo|HBeAg-positive subjects randomized 3:1 to receive ARB-001467 at 0.4 mg/kg versus placebo once a month for 3 months
2539954|NCT02631096|Experimental|0.4 mg/kg ARB-001467|HBeAg-negative subjects receive ARB-001467 at. 0.4 mg/kg (open label) bi-weekly for 5 treatments and then subjects with HBsAg ≤1000 IU/mL AND ≥1.0 log10 decrease from baseline at Day 71 will continue monthly dosing through 48 weeks
2540055|NCT02630381|Experimental|Shock wave arm|Unfocused extracorporeal shock wave therapy will be applied on the distal radius on one site when the patient is receiving general anaesthesia for surgery on the lower extremity or spine.
2540056|NCT02630381|No Intervention|Contra-lateral arm|The distal radius and/or wrist that did not receive UESWT will not be treated
2540134|NCT02629926||Patients to receive GH replacement|30 patients will be recruited to the study who wishes to continue receiving growth hormone replacement, all of whom will receive NutorpinAq Recombinant growth hormone
2540138|NCT02629926||Patients who will not receive GH replacement|An additional 30 patients who elect not to receive growth hormone replacement will provide a parallel control data.
2540172|NCT02629601|Experimental|Active Rewards|Participant will receive the standard active rewards incentives.
2540179|NCT02629601|Active Comparator|Active Rewards Doubled|Participant will receive the standard active rewards doubled in magnitude.
2540182|NCT02629601|Active Comparator|Active Rewards & Lottery 1|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward.
2540186|NCT02629601|Active Comparator|Active Rewards & Lottery 1 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 1 with a 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward. Includes broadcasting winners (number) each week.
2540190|NCT02629601|Active Comparator|Active Rewards & Lottery 2 & Broadcast|Participant will receive the standard active rewards incentives plus a lottery 2 with a 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward. Includes broadcasting winners (number) each week.
3202557|NCT00914342||Upper-GI symptoms in primary-care patients|
2540286|NCT02628808||Autism Spectrum Disorder|For all patients included in the study, core assessment carried out by either collaborating partners consists of diagnosis using the Autism Diagnostic Interview-Revised (ADI-R) criteria for autism and Autism Diagnostic Observation Schedule (ADOS-G) criteria for autism or Autism Spectrum Disorders. Patients with profound intellectual disability or with a known medical cause of autism, such as neurocutaneous syndromes, Fragile X, metabolic disorders, extreme prematurity, congenital rubella and other prenatal or postnatal neurological infections or gross dysmorphology, will be excluded.
2540296|NCT02628808||controls|Age 6 to 40 Healthy individuals with or without idiopathic surgical or urological conditions (e.g. orthopaedic conditions, hernia repairs, renal malformations, pre- or post-circumcision, phimosis, balanitis, scoliosis, congenital hip dislocation, adenoid or tonsil removal, dental procedures such as wisdom tooth extraction, cosmetic procedures such as removal of skin tags or cleft lip repairs, non-head injuries such as fractures, drainage of subungual or perichondrial haematomata).
2540361|NCT02628483|Experimental|Ultimate Omega|5 capsules of Ultimate Omega fish oil daily in the morning with food
2540364|NCT02628483|Active Comparator|Meg-3|5 capsules of Meg-3 fish oil daily in the morning with food
2540420|NCT02628080|Experimental|Cohort 1|Atovaquone suspension, 750mg/5ml bd and 1000mg (6.25ml) bd for 7-17 days. Device: PET-CT, Device: DWI-MRI
2540425|NCT02628080|No Intervention|Cohort 2|Device: PET-CT, Device: DWI-MRI
2540474|NCT02627638|Other|Osteopathic treatment|
2540541|NCT02627313|Experimental|GammaPod|GammaPod tumour bed boost
2540593|NCT02626845|Active Comparator|Rituximab Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional rituximab infusions at week 16 and week 32.
2540595|NCT02626845|Placebo Comparator|Placebo Arm|All subjects in this arm will receive standard of care induction therapy, and then will receive two additional placebo infusions at week 16 and week 32.
2540620|NCT02626364|Experimental|Treatment|crenolanib 100mg PO TID
3202558|NCT00914355|Experimental|SBRT for Hepatocellular Carcinoma|
3202559|NCT00914368|Active Comparator|1|Patients with previously experienced stent thrombosis while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
3202560|NCT00914368|Active Comparator|2|Patients with previously experienced myocardial infarction while on dual antiplatelet treatment within 6 months after coronary stenting for coronary artery disease
2539880|NCT02631473|Active Comparator|2nd Stage-Group A-Group 2-Dose level 2|"21 Days: 200mg NANO-efavirenz OD~4 weeks: Wash-out period~21 days: 400mg Sustiva OD"
2539881|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 1|"7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD~2 weeks: Wash-out period~7 days: NANO-lopinavir (200mg +/- ritonavir®)"
2539882|NCT02631473|Active Comparator|2nd Stage-Group B-Arm 2|"7 days: NANO-lopinavir (200mg +/- ritonavir Norvir)~2 weeks: Wash-out period~7 days: Kaletra® (lopinavir400mg/ritonavir100mg) BD"
2539951|NCT02630927|Placebo Comparator|Part 1 Single-Ascending (SAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. A single dose of AG-519 will be administered by mouth (orally).
2539957|NCT02630927|Placebo Comparator|Part 2 Multiple-Ascending (MAD Phase)|A range of doses of AG519 will be tested based on the assessment of safety and tolerability. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
2539964|NCT02630927|Experimental|Part 3 Bioavailability & Food Effect|The dose to be assessed in Part 3 will be selected based on emerging safety, tolerability and PK/PD data from preceding cohorts in Part 1 and Part 2, which will be reviewed during a dose decision meeting.
2539969|NCT02630927|Experimental|Experimental Part 4 (Subjects of Japanese Origin)|Two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3
2539975|NCT02630927|Experimental|Experimental Part 5 Open-label Multiple-Ascending (MAD)|Up to two dose levels of AG-519 will be tested based on the assessment of safety and tolerability in preceding cohorts in Part 1, Part 2, and Part 3. AG519 will be administered by mouth (orally) each day for a period up to 14 days.
2540083|NCT02630043|Experimental|Tolcapone and Oxaliplatin|"Subjects will receive oral tolcapone at their assigned dose level on each day of this 21-day cycle.~Oxaliplatin will be given at 100 mg/m2 IV on Day 1 of Cycle 2 through 5 and any subsequent 21-day cycle."
2540127|NCT02629900|Experimental|Intermittent fasting group|Participants will restrict their daily food intake (time restricted feeding) to an 8-hour time period between 1200 to 2000 hours. During the remaining 16-hour intermittent fasting period (2000 to 1200 hours) participants will be allowed to drink zero calorie beverages (diet soda pop, black coffee, tea, water, etc) in order to maintain normal hydration. There will be no attempt to restrict food intake. Rather simply to restrict the time period each day when food is consumed.
2540164|NCT02629653|Other|Single arm|The endovascular cooling system will be Zoll IVTM. This system consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585)
2540321|NCT02628587|Experimental|Generic clopidogrel|Patients are assigned to take generic clopidogrel
2540322|NCT02628587|Active Comparator|Patent clopidogrel|Patients are assigned to take patent clopidogrel (Plavix)
2540347|NCT02628275|No Intervention|Control|Continued inactivity
2540355|NCT02628275|Active Comparator|Moderate to vigorous physical activity|MVPA (55-90% of maximum heart rate) for 150 min/week (current recommendations)
2540358|NCT02628275|Active Comparator|Light physical activity|LPA (40-55% of maximum heart rate) for 150 min/week
2540409|NCT02628054|Active Comparator|Typhoid Vaccine|Typhoid vaccination in single 0.5mL injections into the non-dominant deltoid muscle in the arm
2540411|NCT02628054|Placebo Comparator|Placebo|A single 0.5mL injection of 0.9% sodium chloride saline solution into the non-dominant deltoid muscle in the arm
2540471|NCT02627729|Active Comparator|Linear cutter-Circular stapler J pouch|J pouch anal anastomosis after laparoscopic low anterior resection
2540472|NCT02627729|Active Comparator|Circular stapler Side-to-end anastomosis|side to end coloanal anastomosis after laparoscopic low anterior resection
2540520|NCT02627352|Experimental|Transscleral Cyclophotocoagulation|Subjects undergo a Micropulse Transscleral Cyclophotocoagulation(TSCPC) laser surgery, where a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
2540552|NCT02626988|Experimental|Intervention|The intervention group will receive capacity building sessions on the 'Promotion of a biodiverse diet' and will include both Agriculture and Nutrition topics, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal. 5 Sessions will be held in each village over 12 months.
2540555|NCT02626988|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
2540577|NCT02626741|Experimental|meal replacement group|the participants receive a meal replacement plus life style modification
2540578|NCT02626741|Experimental|control group|the participants receive life style modification only.
3168293|NCT00549120|Experimental|Propranolol + ipratropium + salbutamol|Propranolol 80 mg (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
3168294|NCT00549120|Experimental|Placebo + ipratropium + salbutamol|Placebo (2 doses at 6 hourly intervals) + ipratropium bromide 40 μg (2 doses at 6 hourly interval) + salbutamol 600 μg (1 dose)
2540786|NCT02625103|Experimental|Clozapine|treatment as usual: administration of clozapine between 9 and 12 pm. Blood sampling 10 -14 hours post drug administration
2540947|NCT02624557|Experimental|Moderate hepatic impairment group|Subjects with moderate hepatic impairment with Child-Pugh score 7 - 9
2540953|NCT02624557|Experimental|Severe hepatic impairment group|Subjects with severe hepatic impairment with Child-Pugh score 10 - 15
2540957|NCT02624557|Experimental|Matching healthy control group|Subjects with apparent normal liver function matched to the hepatic impairment subjects by sex, race, age, and weight.
2540985|NCT02624076|Experimental|Acupuncture plus expectant management|
2540988|NCT02624076|Active Comparator|expectant management|
2541058|NCT02623738|Placebo Comparator|Placebo ophthalmic solution|Eyedrop
2541060|NCT02623738|Experimental|DE-117 ophthalmic solution low|Eyedrop
3168295|NCT00549159|Experimental|Cavaterm|
3168296|NCT00549159|Active Comparator|TCRE|Transcervical resection of the endometrium
3168297|NCT00549237|Active Comparator|Nutrition|Pre-operative Glucose load and post-operative immediate enteral nutrition
3168298|NCT00549237|No Intervention|Control|No pre-operative glucose load. No early post-operative nutrition
2539903|NCT02631421||Pulmonary Arterial Hypertension|Clinical diagnosis of pulmonary arterial hypertension
2539907|NCT02631421||Healthy subjects and patients with other causes of PH|Patients referred for right heart catheterization who do not have PAH
2539936|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (high GI)|Subjects will consume meals which are high glycemic index for breakfast (Honey stars cereal), lunch (glutinous rice meal) and snack (white bread and jam) in the whole body calorimeter. A take-away high glycemic index dinner will be provided.
2539938|NCT02631083|Experimental|Breakfast, lunch, snack and dinner (low GI)|Subjects will consume meals which are low glycemic index for breakfast (All bran cereal), lunch (basmati rice meal) and snack (multigrain bread and sugar-free jam) in the whole body calorimeter. A take-away low glycemic index dinner will be provided.
3202561|NCT00914368|Active Comparator|3|Patients without previously experienced myocardial infarction or stent thrombosis 6 within months after coronary stenting for coronary artery disease(matched controls for group 1 and 2)
3202562|NCT00914381|Active Comparator|CRA + CM|Community Reinforcement Approach (CRA) combined with Contingency Management (CM)
2540073|NCT02630069|Experimental|CDP-choline+supportive psychotherapy|CDP-choline 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
2540075|NCT02630069|Placebo Comparator|Placebo+supportive psychotherapy|Placebo 500mg once a day for 12 weeks / Supportive psychotherapy 1 session/2 weeks for 12 weeks
2540077|NCT02630069|No Intervention|Healthy control|No intervention
2540125|NCT02629952|Experimental|Blueberry Tea|3 cups of blueberry tea per day x 4 weeks
2540126|NCT02629952|No Intervention|No Treatment|No Treatment
2540198|NCT02629666|Active Comparator|Exercise Referral Scheme (ERS)|In the Exercise Referral Scheme (ERS) intervention participants will undergo a physical activity program of 16 weeks, with two sessions per week (60 minutes each session). Participants will be asked to perform the activity in a moderate to vigorous intensity (according to each individual's progression) during the central part of each session. Intensity will be estimated using the modified Borg Scale of Perceived Exertion (e.g. moderate intensity activity will be considered as a 4 to 6 and vigorous-intensity activity as a 7 to 9) or with training loads (i.e. ankle weights and dumbbells) corresponding to 70-80% of maximum, adjusted progressively during the training period. ERS programs will be based on a combination of aerobic, strength-based, balance and flexibility activities, with a specially trained PA specialist. These sessions will be always performed under the supervision of the same trainer. The PA intervention is adapted to the participants' functional status.
2540202|NCT02629666|Experimental|ERS + Self-management Strategies|"Participants will undergo the aforementioned Physical Activity program plus 11 sessions of Self-Management Strategies (SMS).~SMS start with a face-to-face session in an indoor primary-care facility. The next 6 sessions are further implemented in a group format. SMS are aimed at increasing self-efficacy in reducing sedentary behaviour and at adopting/maintaining an active behaviour as complement to a standard physical activity program (ERS). SMS group sessions will be conducted during week 3 to 11 of the ERS, after the PA sessions (6 sessions: 3 once a week, 3 once every second week). There will be 4 telephone contacts during the adherence phase, at week 15, 20, 25 and 30."
2540203|NCT02629666|No Intervention|Control group|Researchers will give to all participants during the first informative meeting (prior assessment) a written general booklet standardized across sites with WHO recommendation regarding PA regular practice for health. During the intervention, a health advice meeting with standardized topics about healthy lifestyle and feedback on some outcomes regarding their results will be held twice in the Primary Health Centre (at week 5, and at week 11). Researchers will send a letter or phone call prior to each follow up reminding the next assessment.
3202563|NCT00914381|Active Comparator|TSF + CM|Twelve-Step Facilitation (TSF) combined with Contingency Management (CM)
3202564|NCT00914381|Active Comparator|CRA + VC|Community Reinforcement Approach (CRA) combined with Voucher Control (VC)
2540317|NCT02628613|Active Comparator|Paclitaxel plus Epirubicin|Paclitaxel plus Epirubicin for 4 cycles, paclitaxel 80 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
2540319|NCT02628613|Experimental|Vinorelbine plus Epirubicin|Vinorelbine plus Epirubicin for 4 cycles, vinorelbine 25 mg/m2 IV on day 1, 8 and 15, epirubicin 90 mg/m2 IV on day 1, and dosing interval is 21 days.
2540338|NCT02628288|Active Comparator|PCI with Axxess device + AbsorB BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with AXXESS device and additional Absorb BVS.
2540346|NCT02628288|Active Comparator|PCI with Modified T with Absorb BVS|Bifurcation lesion will be treated percutaneously by performing coronary stenting with a modified T stenting technique using Absorb BVS.
2540416|NCT02628041|Active Comparator|Permanent Iodine-125 seed implant|Prostate brachytherapy using Iodine-125 seed implant to a prescription dose of 144 Gy delivered to the Target volume defined as Clinical Target volume (CTV)+ 0-3 mm margin.
2540418|NCT02628041|Experimental|High-dose-Rate Prostate brachytherapy|"Prostate brachytherapy implant using Iridium-192 to a prescription dose of 19 Gy delivered to the CTV in one fraction. Greater than 95% coverage of the CTV with the prescription dose is considered per protocol, 90-95% coverage is considered a minor deviation and, < 90% coverage is considered a major deviation.~Attempts should be made to achieve these other dosimetric values:~D90: 105-115%~V150 ≤ 35%~V200 ≤ 12%"
2540488|NCT02627599||Chronic Obstructive Pulmonary Disease|"More than 12 million adults are diagnosed with COPD~COPD is the 3rd leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization are associated with higher costs~Oximetry is an important tool for assessing need for Long-Term Oxygen Therapy~LTOT has been proven to improve survival and quality of life~Patients provided with a breath responsive variable bolus oxygen conserving device:~support increased activity~improve quality of life~increase functional capability~reduce portable oxygen source utilization~maintain and/or improve oxygen saturation"
2540564|NCT02627209|Active Comparator|serum angiotensin converting enzyme|spectrophotometric assay
3202565|NCT00914381|Active Comparator|TSF + VC|Twelve-Step Facilitation (TSF) combined with Voucher Control (VC)
3202566|NCT00914394|Active Comparator|NG-monomethyl-L-arginine (L-NMMA)|
3202567|NCT00914394|Active Comparator|Phenylephrine|
3202568|NCT00914394|Placebo Comparator|Physiological saline solution|
3202569|NCT00914407|Experimental|Healthy subjects|
3202570|NCT00914420|Experimental|Intrepide|Group A- Primary stenting with Intrepide trapidil eluting stent
3202571|NCT00914420|Experimental|Taxus|Group B Stenting with Taxus DES
3202572|NCT00914433|Experimental|TPI 1100|Drug to be given by inhalation.
2540031|NCT02630433|Experimental|Index cholecystectomy|Cholecystectomy within 48 hours after inclusion.
2540039|NCT02630433|Active Comparator|Scheduled cholecystectomy|Cholecystectomy 6 weeks after inclusion.
2540078|NCT02630212||Control|Chinese Han people undergoing coronary angiography in Qilu Hospital in corresponding period whose coronary arteries narrowing less than 50 percent.
2540081|NCT02630212||Aortic dissection|Chinese Han people diagnosed with aortic dissection in Qilu Hospital
3202573|NCT00914446|Other|morbid obese subject|
3202574|NCT00914446|Other|overweight and NASH subjects|
2540189|NCT02629484|Active Comparator|Focused Cardiac Ultrasound|participants randomised to receive focused cardiac ultrasound prior to surgery for hip fracture
2540192|NCT02629484|No Intervention|Standard care (clinical assessment)|Participants randomised to standard care receive clinical assessment of the patient
2540220|NCT02629224|Experimental|Renal impairment|
2540230|NCT02629224|Experimental|Haemodialysis|
2540272|NCT02628756|Experimental|Endometrial injury|Hysteroscopic-guided endometrial injury (Karl Storz, Tuttlingen, Germany).
2540326|NCT02628574|Experimental|TRX518 monotherapy (Parts A and B)|Subjects receive an assigned dose of TRX518 administered intravenously one time per week or one time per cycle on a 21-day cycle
2540327|NCT02628574|Experimental|TRX518 with gemcitabine (Part C)|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with gemcitabine (dosed two times per cycle) on a 21-day cycle
2540328|NCT02628574|Experimental|TRX518 with pembrolizumab (Part D|Subjects receive an assigned dose of TRX518 (dosed one time per cycle) intravenously administered in combination with pembrolizumab (dosed one time per cycle) on a 21-day cycle
2540329|NCT02628574|Experimental|TRX518 with nivolumab (Part E)|Subjects receive an assigned dose of TRX518 (dosed two times per cycle) intravenously administered in combination with nivolumab (dosed two times per cycle) on a 28-day cycle
3202575|NCT00914446|Other|control subjects|
3202576|NCT00914472|Experimental|Test|Heparin - Hipolabor
2540437|NCT02627833||Subject Group|Patients suffering from Bronchiolitis Obliterans
2540438|NCT02627833||Control Group|Age and sex matched control group
2540475|NCT02627573|Experimental|Thymoglobulin|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -6 through -5 Busulfan 1 mg/kg po qid x 2 days Days -4 through -3 Thymoglobulin 2,5 mg/kg po qd x 2 days Days -1 through +30: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days -1 through +150: Tacrolimus 0.03 mg/kg/day with further correction by concentration
2540477|NCT02627573|Experimental|PTCy|Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
3202577|NCT00914472|Active Comparator|Ative comparator|Heparin - APP
3202578|NCT00914498|Experimental|Xylocaine|Participants will receive local injection of 20 ml 1% Xylocaine to the skin incision site
3202579|NCT00914498|Placebo Comparator|Controls|Participants will receive injection of 0.9% NaCl 20 ml to the incision site
3202580|NCT00914511|Experimental|Healthy young males|Healthy young males age 18-45, inclusive
3202581|NCT00914511|Experimental|Elderly males|Elderly males 65 years of age and older
2540630|NCT02626546||Major surgical procedures|All patients selected to follow up
2540681|NCT02626130|Experimental|Arm A (tremelimumab)|Patients receive tremelimumab IV over 60 minutes at weeks 1 and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q4W for 3 doses, and then every Q12W in the absence of disease progression or unacceptable toxicity.
2540683|NCT02626130|Experimental|Arm B (tremelimumab and cryoablation)|Patients undergo cryoablation and receive tremelimumab IV over 60 minutes at weeks 1 (2-6 days after cryoablation) and 5. Within 4-6 weeks later, patients undergo surgery or biopsy. After surgery or biopsy, patients receive tremelimumab IV Q34W for 3 doses, and then Q12W in the absence of disease progression or unacceptable toxicity.
2540741|NCT02625636|Experimental|SAR438544 dose 1|Single dose of SAR438544 given SC under fasting conditions
2540746|NCT02625636|Experimental|SAR438544 dose 2|Single dose of SAR438544 given SC under fasting conditions
2540748|NCT02625636|Experimental|SAR438544 dose 3|Single dose of SAR438544 given SC under fasting conditions
2540749|NCT02625636|Placebo Comparator|Placebo|Single dose of placebo given SC under fasting conditions
2540751|NCT02625636|Active Comparator|Glucagon|Single dose of glucagon given SC under fasting conditions
2540752|NCT02625636|Experimental|SAR438544 Optional Dose|Optional lower, intermediate, or higher dose of SAR438544 given SC under fasting conditions
3202582|NCT00914524|Experimental|Treatment|16 weeks of treatment starting with 5 mg of olmesartan medoxomil. If tolerated, the dose was increased to the next higher dose at weeks 4, 8, and 12.
3202583|NCT00914537||1|Human immunodeficiency virus (HIV) positive adult men who have sex with men that are members of KPNC (Kaiser Permanente Northern California) and do not have a current anal cancer diagnosis.
2540844|NCT02624804|Experimental|Stem Cell Educator Therapy|"Patients will have apheresis performed and then have their own blood returned to them with the educated lymphocytes"
2540902|NCT02624674|Experimental|Multi-spectral Imaging Group|All subjects in this group will undergo baseline Near Infrared Spectroscopy (NIRS) measurement points with the Multi-spectral imaging device, baseline vascular studies (including ankle-brachial index (ABI), vascular doppler (arterial and venous), and toe pressures. At the one month mark (from baseline), NIR measurement point and vascular studies will again be performed. All measurements are incorporated into the routine wound care and will not require extra trips in hospital for wound care.
2540932|NCT02624479|Experimental|Fast first|Sodium thiosulfate fast release formulation first, followed by medium and slow
3202584|NCT00914550||Procalcitonin level, caregiver informed|Procalcitonin level for patients with lung infiltrates:caregivers know/ do not know results
2539958|NCT02631044|Experimental|JCAR017 2-dose schedule (no longer accruing)|Each cycle of JCAR017 (lisocabtagene maraleucel) will be administered as 2 intravenous (IV) injections
2540027|NCT02630446|Experimental|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
2540034|NCT02630446|No Intervention|standard dementia care|Control group receiving all types of standard dementia care except in-home respite care of the Baluchon type.
2540072|NCT02630238|Experimental|Branched-Chain Amino Acid group|The branched-chain amino acid group will be on a hypocaloric diet, exercise and receive 0.342g/kg of BCAA per day, partially accounted for through their diet with the rest provided by a BCAA supplement
2540074|NCT02630238|Placebo Comparator|Placebo Group|The placebo will be on a hypocaloric diet, exercise and receive isoenergetic beverage with carbohydrate instead of branched-chain amino acids
2540130|NCT02629939|No Intervention|questionnaires|"Questionnaires will be distributed to families of heart patients to test the theoretical knowledge to perform CPR The questionnaires were distributed to internal, cardiology clinics and clinic T by a doctor, Paramedic or medical student. The family will be asked to fill out the questionnaire independently.~The questionnaires will be distributed in Hebrew, Arabic, Russian and English The research questionnaire will include questions about able to perform basic CPR"
2540132|NCT02629939|Experimental|to participate in a short course for learning CPR|": The investigators will offer patients and their relatives to participate in a short course for learning CPR.~Relatives will receive a prescription Containing a proposal for participation in the course~Prescription will be awarded in four places:~-.Family physicians as a suggestion during a routine visit / presentation of cardiac problem~Heart Rehabilitation Institute - cardionegev~Doctors internal medicine department as part of a patient's discharge letter with heart disease~Doctors in cardiology clinic The prescription will be accompanied by several minutes of explanation about the program and its importance The investigators consider the level of responsiveness and participation, find out which arm yielded the highest number of participants (actual turnout of the total prescriptions distributed) And how to expand their activities"
2540173|NCT02629679||Males nonathletes|Boys non-involved in organized sport and exercising
2540177|NCT02629679||Females nonathletes|Girls non-involved in organized sport and exercising
2540185|NCT02629679||Males athletes|Athletic boys (involved in sports)
2540187|NCT02629679||Females athletes|Athletic girls (involved in sports)
2540225|NCT02629237|Experimental|Multifaceted education group|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
2540233|NCT02629237|No Intervention|control group|Subjects will not be asked to watch education film and not participate in counseling session before and after surgery.
2540288|NCT02628886|Experimental|maternal group|13-valent pneumococcal conjugate vaccine [Prevenar13®] (PCV13) vaccine, 0.5ml, once, stat, plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
2540297|NCT02628886|Placebo Comparator|control group|placebo sterile 0.9% sodium chloride, 0.5ml, once, stat plus tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV13 at 8, 12 and 16 weeks according to normal EPI vaccination in country
2540307|NCT02628886|Experimental|neonatal group|tetanus toxoid to pregnant women between 28-34 weeks and their infants will get PCV 13 0.5ml at birth, 8 weeks and 16 weeks
2540335|NCT02628366|Experimental|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention arm will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
2540340|NCT02628366|No Intervention|Fixed Dialysate Temperature at 36.5°C|Dialysis centres in the control group will provide usual care, which is standard dialysis using a fixed dialysate temperature of 36.5°C
3202585|NCT00914563|Experimental|LIDCO|The extensively burnt patients (age range 18-75 years) with second and the third degree burns, with TBSA above 15%, with or without inhalation injury will be included to the study. We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. We will use in the LIDCO group the continuous real-time hemodynamic monitoring through transpulmonal lithium dilution additionally. The monitor Lithium Dilution Cardiac Output (LIDCO) Plus permits, through analysis of the arterial blood pressure trace, to acquire items about CO, SVR and DO2. In fluid resuscitation, we will use a combination of the balanced crystalloids and synthetic colloids (of the middle molecular weight) in the ratio 2 ml/kg/% TBSA: 1 ml/kg/% TBSA.
3202586|NCT00914563|No Intervention|Standard care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
2540517|NCT02627430|Experimental|Treatment (talazoparib and Hsp90 inhibitor AT13387)|Patients receive talazoparib PO QD on days 1-7 (course 0). Beginning in course 1, patients receive talazoparib PO QD on days 1-28 and HSP90 inhibitor AT13387 IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3202587|NCT00914576|Active Comparator|1|
3202588|NCT00914576|Placebo Comparator|2|
3202589|NCT00914602|Active Comparator|Treatment Period A|Treatment Period A: Sinemet® 25-100 treatment After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
2539981|NCT02631174|Active Comparator|cohort 3|Cohort 3 (Aim 3) - 6 participants Six participants (neonates or infants) who will undergo ECMO and receive ATIII as standard of care will be enrolled and have a baseline ATIII level measured within 6 hours of ATIII administration and repeated within 15 minutes of initiation of extracorporeal support. If post-support level is < 80% normal activity then an ATIII level will be repeated and participants will be assigned to one of two hpATIII dosing regimens in which one formula accounts for additional circuit volume and one formula does not account for additional circuit volume, as described in section 7.4. Upon completion and 120 hr follow up after the first dose, participants still having ATIII activity less than 80% will then receive a second dose
2540111|NCT02630082|Other|Intervention|Circumcision and flexible sigmoidoscopy
2540144|NCT02629783|Experimental|Physiotherapy + Corticosteroid injection + Psychomotor therapy|Usual care + intervention
2540145|NCT02629783|Active Comparator|Physiotherapy + Corticosteroid injection|Usual care
2540170|NCT02629536|Experimental|Active-verum-NAC tablet|Intervention: Twice-daily administration of N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablets
2540176|NCT02629536|Placebo Comparator|Sham-placebo tablet|Intervention: Twice daily administration of sham/placebo tablet
2540226|NCT02629302|Experimental|animal assisted therapy|"Standard therapy (speech therapy, occupational therapy and physiotherapy) that is done in the presence and with Integration of an animal."
2540235|NCT02629302|Active Comparator|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
2540283|NCT02628782|Experimental|InSeal VCD|InSeal's Vascular Closure Device Use of the experimental VCD to close the access site of the artery
2540362|NCT02628522|Experimental|ADRCs therapy|"Infiltration with 20mL Lidocaine 2% and Epinephrine 1:100 000. Liposuction will be done from the abdomen using Tulip cannulas. Fat will be processed with Celution system.~Isolated ADRCs will be administered in chronic anal fissures."
2540431|NCT02627976|Active Comparator|breast edema vest|
2540483|NCT02627651|Experimental|brain injury|children post brain injury
2540484|NCT02627651|Active Comparator|controls|children typically developed age matched
2540526|NCT02627287|Experimental|DV3316 pen-injector|
2540527|NCT02627287|Active Comparator|FlexPen®|
2540605|NCT02626650|Active Comparator|Check symptoms one has experienced|This is the baseline condition. When asked to indicate concussion symptoms (or most other kinds of symptoms for medical conditions), people usually place a check mark next to each symptom they have experienced.
2540606|NCT02626650|Experimental|Check symptoms one has not experienced|Participants place a check mark next to each symptom they have NOT experienced in the most recent sports season.
2540607|NCT02626650|Experimental|Uncheck symptoms one has experienced|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have experienced in the most recent sports season.
2540610|NCT02626650|Experimental|Uncheck symptoms one has not experienced.|To begin, all symptoms will be automatically checked. Participants are told to remove a check mark from each symptom they have NOT experienced in the most recent sports season.
2540640|NCT02626247|Active Comparator|Vitamin A + Long chain PUFA|The test product is a food supplement containing Vitamin A + Long chain Poly Unsaturated Fatty Acids (PUFA). It is presented as a hard shell capsule containing lipophylic nutrients.
2540642|NCT02626247|Placebo Comparator|Placebo|The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
2540738|NCT02625740|Experimental|Study group|After crossing the lesion with a guidewire, patients will be treated with intravascular high intensity, low-frequency ultrasound followed by local administration of liquid mixture of Paclitaxel and Iopromide-370 with predetermined dosage of 1.0 µg/mm
2540745|NCT02625740|Active Comparator|Control group|After crossing the lesion with a guidewire, patients will be treated with drug eluting ballon angioplasty with the In.Pact Admiral ballon (Medtronic)
2541191|NCT02622880|Active Comparator|: IMPACT|along 10 days before surgery
2541193|NCT02622880|Experimental|immunomodulatory supplement|along 10 days before surgery
2541215|NCT02622490|Active Comparator|Low carb. one meal|Intervention: One meal of 750 kcal with 20 % of energy content from carbohydrates
2541224|NCT02622490|Active Comparator|Low Carb. 5 small meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 20 % of energy content from carbohydrates.
3168299|NCT00549315|Experimental|1|
3168300|NCT00549341|Active Comparator|1|
3168301|NCT00549341|Placebo Comparator|2|
3168302|NCT00549367|Other|1|Clients in the control arm of the study will receive nutrition assessment only for the first 24 weeks and the be transferred to nutrition counselling group
3168303|NCT00549380|Experimental|1|
3168304|NCT00549406|Experimental|1|computer-based visual-training program UFOV
3168305|NCT00549406|Experimental|2|video-game based visual training
3168306|NCT00549406|Placebo Comparator|3|computerized word puzzles
3168307|NCT00549419|Experimental|1|In the Treatment group, the traditional vital signs and APCO are made continuously available for fluid and catecholamine optimization and clinical decision making.
3168308|NCT00549419|Active Comparator|2|
3168309|NCT00549432|Experimental|1|
3168310|NCT00549471|Experimental|BG|cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment. BG children will be given Botulinum Toxin A, as clinically required, in addition to an equivalent program of intensive therapy
3168311|NCT00549471|No Intervention|Control Group|control group: Twenty cooperative quadriplegic CP children ages 8-11 years, gross motor function level 4 with troublesome hypertonia that will respond to treatment.CG children will undergo a program of intensive therapy.
3168312|NCT00549484||1|10 mL/kg platelet transfusion
3168313|NCT00549484||2|15 mL / kg platelet transfusion
3168314|NCT00549497|Other|GW870086X|
3168315|NCT00549523|Placebo Comparator|Placebo|Placebo (capsule filled with inert materials)
3168316|NCT00549523|Experimental|Low Dose|400 mg bid Lessertia Frutescens
3168317|NCT00549523|Experimental|Mid Dose|800 mg bid Lessertia Frutescens
3202590|NCT00914602|Experimental|Treatment Period B|Multiple-Dose XP21279 (with Lodosyn®) treatment. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
2540146|NCT02629887|Active Comparator|Face Mask|Standard Face Mask with T piece resuscitator for neonatal resuscitation. Face mask placement per Neonatal Resuscitation Program resuscitation guideline.
2540147|NCT02629887|Active Comparator|Non-inflatable supraglottic airway|Use of non-inflating supraglottic airway with T-piece resuscitator instead of Standard Face Mask with T piece resuscitator for neonatal resuscitation, replacing standard of care face mask in Neonatal Resuscitation Program guideline.
2540171|NCT02629523|Experimental|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
2540234|NCT02629341|Active Comparator|Functional yogurt powder|This arm will receive one daily serving of the functional yogurt which is enriched in Calcium, D, K, C vitamins, Zn, Mg, L-leucin and the Lactobacillus plantarum 3547 probiotic
2540246|NCT02629341|Placebo Comparator|Control yogurt powder|This arm will receive one daily serving of the control yogurt which consists of a regular yogurt not enriched
3202591|NCT00914615|Experimental|SBRT for liver mets from colorectal cancer|
3202592|NCT00914641|Other|Apixaban Cross-over|
2540360|NCT02628249|Experimental|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid made after egg protein.
2540365|NCT02628249|Experimental|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid made after egg protein.
2540366|NCT02628249|Experimental|Base + BCAA|Base protein intake + Branched chain amino acids
2540368|NCT02628249|Experimental|Base + EAA|Base protein intake + essential amino acids.
2540369|NCT02628249|Experimental|Base + NEAA|Base protein intake + non essential amino acids
2540413|NCT02627937||pediatric sleep apnea|The children were confirmed to have OSAHS by comprehensive polysomnography (PSG).
2540466|NCT02627755|Active Comparator|Glide group|Device: Glidescope® use
2540467|NCT02627755|Experimental|Glide+aScope group|Device: combined use of two airway devices Glidescope® + aScope®
2540510|NCT02627391|Experimental|Early surgery|Surgical aortic valve replacement
2540512|NCT02627391|Active Comparator|Delayed surgery according to guidelines|Surgical aortic valve replacement
2540551|NCT02627066|Active Comparator|Volume Control|This group of patients will receive a volume reduction protocol that includes two primary components: 1) persistent ultrafiltration to slowly reduce patient's post-dialysis weight; and 2) persistent dietary education focused on reducing intake of dietary sodium and phosphorus additives
2540557|NCT02627066|Active Comparator|Volume Control + Exercise|This group of patients will receive the volume control intervention in addition to intensive counseling to increase their physical activity levels.
2540611|NCT02626533||Total knee arthroplasty patients|Patients undergoing total knee arthroplasty for osteoarthritis are enrolled in the study. Blood and joint fluid samples will be obtained from patients, and questionnaires will be administered to assess pain and stiffness.
2540666|NCT02626273|Experimental|intervention group|an intervention group who will undergo the management program combining physical activity and restrictive diet at Tza Nou Medical House for 10 months
2540667|NCT02626273|Other|a control group|a control group who will not undergo any intervention
2540697|NCT02625896|Experimental|Intervention|A sequence of free fall manoeuvres performed using the human body: A free fall velocity reduction prior to main parachute deployment followed by a head high body attitude prior to main parachute extraction.
2540699|NCT02625896|No Intervention|Control|Normal main parachute extraction performed in a manner that is typical for the study participant.
3202593|NCT00914654|Other|Healthty|10 healthy men
3202594|NCT00914654|Other|Asthmatics|10 male asthmatic subjects
2540904|NCT02624661|Experimental|Glycerol injection|The patients will be injected with glycerol using a new neuronavigation-based technique in the trigeminal ganglion.
2540964|NCT02624440|Experimental|Clarithromycin|p.o. clarithromycin 250 mg twice daily for 180 days
2540967|NCT02624440|Experimental|Sulfamethoxazole/trimethoprim|p.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily for 180 days
2540970|NCT02624440|Experimental|Observation|Observation without prophylactic antibiotic treatment
2541031|NCT02623868|Experimental|Group 1|A-B-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541035|NCT02623868|Experimental|Group 2|B-C-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541037|NCT02623868|Experimental|Group 3|C-A-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541039|NCT02623868|Experimental|Group 4|A-C-B (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541041|NCT02623868|Experimental|Group 5|B-A-C (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541042|NCT02623868|Experimental|Group 6|C-B-A (Drug A: CKD-519 50mg 2Tabs. /Drug B: CKD-519 100mg 1Tab. /Drug C: CKD-519 100mg 1Cap.)
2541112|NCT02623296|Experimental|GLPG1205 and single CYP450 substrate cocktail dose|Daily GLPG1205 administration from Day 1 to Day 12 Single GLPG1205 co-administration on Day 13 with CYP450 substrate cocktail
2541232|NCT02622490|Active Comparator|High carb. one meal|Intervention: One meal of 750 kcal with 50 % of energy content from carbohydrates
3202595|NCT00914654|Other|Elite asthmatics|10 male elite athletes with asthma
3202596|NCT00914667|Experimental|Warfarin Alone|Reference treatment
3202597|NCT00914667|Experimental|Warfarin Concomitantly With Fesoterodine|Test treatment
3202598|NCT00914680|Experimental|MST|
3202599|NCT00914693|Experimental|Arm 1|
3202600|NCT00914719|Active Comparator|Information only|
3202601|NCT00914719|Active Comparator|sexual risk reduction intervention|
3202602|NCT00914719|Experimental|SRRI+ETOH|
3202603|NCT00914758||MS patients on Campath®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Campath® treatment arm of the Care-MS II trial, for which this study is a sub-study
2540029|NCT02630615||Cohort A (one-time blood sample)|"Blood samples will be collected from eligible patients only once at baseline. These samples will be immediately processed for CTCs and CTC derived xenografts.~For Cohorts A & B: Patients can participate in both cohorts simultaneously, or only one cohort per patient preference."
2540036|NCT02630615||Cohort B (multiple blood samples)|Blood samples will be collected from eligible patients at baseline just prior to initiation of therapy. Samples will also be collected on day 1 of every cycle of therapy for 4 cycles (typical cycles are 21 days for chemotherapy, 28 days for targeted therapy and 14 days for immune therapy). At the time of initiation of the treatment break, blood samples will be collected. During the treatment break, patients will be followed every 6-12 weeks with imaging studies, and we will collect blood samples at each visit. At the time of disease progression in the event patient goes on best supportive care, the last blood draw will be at the time of this decision as there will unlikely be any further imaging studies going forward. If a patient is found to have disease progression while on active therapy, the next blood draw will be on the first day of the next therapy and time point of subsequent blood draws will depend on the type of therapy the patient receives.
2540040|NCT02630615||Cohort C (healthy volunteers)|Blood samples will be collected from eligible health volunteers only once. These samples will be used to test the CTC chip system. Two tubes of peripheral blood will be collected and taken to the PI's lab for processing.
2540096|NCT02630173|Experimental|Non vital teeth with apical radiolucency|Endodontic treatment was performed in non vital teeth with periapical radiolucency. Local anesthesia was provided (2% Novocaine with 1:80,000 epinephrine), isolation with rubber dam and standard access cavity preparation was done.Using 3 % sodium hypochlorite, canal negotiation was done & apical patency was achieved with #10 or #15K-files. Coronal flaring with # 2 and #3 Gates-Glidden drills was done.Calcium hydroxide was filled in the canals with the help of a lentulo spiral.At the second appointment,calcium hydroxide paste was removed and copious irrigation with 3% sodium hypochlorite was followed by 5.0 mL 17% ethylenediaminetetraacetic acid with a final rinse of 5.0 mL of 3% sodium hypochlorite. The canals were obturated with gutta-percha and ZOE sealer.
2540102|NCT02630173|Active Comparator|Vital teeth|Only scaling and root planing will be done in contralateral vital tooth with pocket depth >5mm .Non surgical periodontal treatment in the form of scaling and root planing was provided in minimum of two sessions using ultrasonic scaler (Satelec P5 Booster Suprasson) and hand instruments (Hu-friedy scalers and curettes).
2540180|NCT02629458|Experimental|Patients requiring surgery|
2540222|NCT02629289|Other|Treatment A|HSP-130, 6 mg, single subcutaneous (SC) injection in the deltoid region
2540229|NCT02629289|Other|Treatment B|US-approved Neulasta, 6 mg, single SC injection in the deltoid region
2540244|NCT02629289|Other|Treatment C|EU-approved Neulasta, 6 mg, single SC injection in the deltoid region
2540275|NCT02628704|Experimental|Selinexor, carfilzomib and dexamethasone|60 mg of selinexor and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, selinexor will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
2540281|NCT02628704|Placebo Comparator|Placebo, carfilzomib and dexamethasone|Placebo (for 60 mg of selinexor) and and 20 mg of dexamethasone will be taken twice weekly. On days coinciding with carfilzomib administration, Placebo (for 60 mg of selinexor) will be given between 30 minutes and 4 hours after the end of the carfilzomib infusion.
2540333|NCT02628327||Glaucoma subjects|Survey given to all glaucoma subjects agreening to study.
2540414|NCT02628145|Experimental|Resistance Training Intervention|The RT intervention will take place three times per week for approximately 12 weeks on non-consecutive days using 8-10 exercises for major muscle groups utilizing free weights and machines follow American College of Sports Medicine and National Strength and Conditioning Association guidelines for RT in older adults.
2540415|NCT02628145|Active Comparator|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
2540473|NCT02627690||Islet transplanted|patients who underwent islet transplantation
2540476|NCT02627690||non islet transplanted|patients who refused or were non selected for islet transplantation for a non nephrologic reason
2540534|NCT02627261||patients with multiple myeloma|blood samples and bone marrow aspirates will be collected in patients at different time point
2540625|NCT02626793||Patients with ≤ 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for ≤ 1 conventional, systemic pre-treatment
2540627|NCT02626793||Patients with > 1 conventional, systemic pre-treatment|After failure (inadequate response/intolerance) to or contraindication for > 1 conventional, systemic pre-treatment
3168318|NCT00549523|Experimental|High Dose|1200 bid Lessertia Frutescens
3168319|NCT00549536|No Intervention|2|
2540969|NCT02624323|Experimental|Axillary catheterization|Real-time ultrasound-guided axillary vein catheterization, in plain technique.
2540973|NCT02624323|Experimental|Jugular catheterization|Real-time ultrasound-guided jugular vein catheterization, out of plain technique.
2541064|NCT02623634||observation|this study measure the cuff leak volume and cuff leak ratio according to the cuff leak test with different positions and waveform,, at the same time observe the patient general condition, vital signs, oxygen saturation, cuff leak test results under different conditions and the breathing machine parameters, the diameter of the airway, the use of sedatives and hormones, after extubation stridor and intubation is happening again, the use of NPPV after extubation, patient outcomes
3168320|NCT00549536|Active Comparator|1|Patients on calcium supplementation
3168321|NCT00549575|Experimental|A|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories). Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
3168322|NCT00549575|Placebo Comparator|B|After double blind randomization, patients received a placebo. Doppler ultrasound examination of the uterine, umbilical and cerebral circulation, and of ductus venous was performed prior to inclusion, after 7 days of treatment, and the day before delivery. Ultrasound examination was performed upon randomization, and weekly until birth. Venous blood and urine samples were collected before initiation and after 7 days of treatment, and both maternal and umbilical venous samples were obtained at delivery for nitrate and nitrite (NO2-/ NO3-) determination.
2540240|NCT02629328|Other|CardioCel|Treatment with CardioCel implant
2540291|NCT02628860|Experimental|Ferinject|"Ferinject to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® must be diluted only in sterile 0.9% sodium chloride.~Strength/Packaging: 10 mL vials containing 500 mg iron as iron per vial."
2540352|NCT02628470|Experimental|group cervical manipulation|The patient is supine without a pillow and physiotherapist standing in the ipsilateral corner of the hand of the thrust.
2540357|NCT02628470|Placebo Comparator|Placebo group|Participants will receive a protocol of domiciliary cervical control exercises.
2540363|NCT02628470|Active Comparator|Group cervical mobilization|Oscillatory mobilization technique. With the patient in prone, the investigator applies an oscillatory motion in the most painful cervical segment for three minutes
2540631|NCT02626572|Experimental|S47445 5mg|
2540634|NCT02626572|Experimental|S47445 15mg|
2540637|NCT02626572|Experimental|S47445 50mg|
2540639|NCT02626572|Placebo Comparator|Placebo|
2540753|NCT02625597|Experimental|Dental Materials|
2541004|NCT02623907||AS group|Severe AS patients, without severe AR
2541005|NCT02623907||AR|Severe AR patients, without severe AS
2541046|NCT02623790|Experimental|Test meal (butter)|Subjects will eat one test meal containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2541048|NCT02623790|Experimental|Test meal (cheddar cheese)|Subjects will eat one test meal containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2541049|NCT02623790|Experimental|Test meal (cream cheese)|Subjects will eat one test meal containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
2541118|NCT02623400||Preterm infants and their parents|Preterm infants born before 34 weeks gestational age and/or with a birth weight lower than 1500g and their parents.
2541159|NCT02623049||octogenarians patients - Apixaban|octogenarians patients who will be treated with Apixaban
2541162|NCT02623049||younger than 70 years patients - Apixaba|younger than 70 years patients who will be treated with Apixaba
2541164|NCT02623049||octogenarians patients - Rivaroxaban|octogenarians patients who will be treated with Rivaroxaban
2541166|NCT02623049||younger than 70 years patients - Rivaroxaban|younger than 70 years patients who will be treated with Rivaroxaban
2541167|NCT02623049||octogenarians patients - Dabigatran|octogenarians patients who will be treated with Dabigatran
2541168|NCT02623049||younger than 70 years patients - Dabigatran|younger than 70 years patients who will be treated with Dabigatran
2541251|NCT02622607|Experimental|ZOL|Zoledronic acid 4 mg intravenous infusion over at least 15 minutes every 3 months for 12 months.
2541256|NCT02622607|No Intervention|Control|No investigational treatment
2541284|NCT02622165|Experimental|The REWARD serious game intervention|A mobile 4-week serious game intervention will be administered.
2541289|NCT02622165|No Intervention|Control group|School curriculum as usual
3168323|NCT00549614|Experimental|1|
3168324|NCT00549614|Placebo Comparator|2|
3168325|NCT00549666|Experimental|Lurasidone 40 mg|
3168326|NCT00549666|Placebo Comparator|Placebo|
2541590|NCT02620033|No Intervention|Standard Care|Those assigned to the standard care group will follow the routine pre- and post-operative care for patients whose undergoing radical prostatectomy.
2541615|NCT02619968|Sham Comparator|Group control|Will be held the same isometric and isotonic concentric ambulatory and home with the same duration, frequency and intensity, except is not to apply the tourniquet.
2542630|NCT02613377||Transfused critically ill children|Any infusion of RBC, plasma or platelets will be considered a transfusion.
3168327|NCT00549666|Active Comparator|Ortho Tri-Cyclen|
3168328|NCT00549679|Experimental|25 mcg|25 microgram inhaled once daily
3168329|NCT00549679|Experimental|87.5 mcg|87.5 microgram inhaled once daily
3168330|NCT00549679|Placebo Comparator|Placebo|Placebo inhaled once daily
3168331|NCT00549692|Experimental|Omacor|
3168332|NCT00549692|Placebo Comparator|Placebo Omacor|
3168333|NCT00549731||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study."
3168334|NCT00549731||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
3168335|NCT00549796|Active Comparator|1|PCI performed at a hospital with co-located (on-site) cardiac surgery
3168336|NCT00549796|Other|2|PCI performed at a hospitals without co-located (on-site) cardiac surgery
3168337|NCT00549809|Active Comparator|IMV, SIMV|
3174087|NCT00619424|Experimental|pazopanib + pemetrexed|Pazopanib and pemetrexed are to be combined at different specified dose levels until an optimally tolerated dose regimen is identified. Combination of an anti-VEGF therapy (such as bevacizumab) with systemic chemotherapy has demonstrated increased clinical efficacy in comparison with systemic chemotherapy alone in several malignancies. Hence, pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit, was chosen to be combined with pemetrexed, a chemotherapeutic agent that inhibits the enzyme thymidylate synthase, in an effort to determine if an anti-angiogenesis inhibitor would enhance the activity of the approved chemotherapeutic agent pemetrexed.
3174088|NCT00619463|Experimental|exercise then monitor|8 weeks of aerobic exercise followed by 16 weeks of monitoring
2540277|NCT02628951|Experimental|Ramucirumab + Paclitaxel|"Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.~Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason."
2540342|NCT02628496|Experimental|Arm 1: CLM|"On the day of surgery, participants will have placement of laser-safe endotracheal tube and a rigid laryngoscope will be introduced into the oral cavity to gain access to the laryngeal introitus and then placed into suspension (standard of care)~Fluorescein dye will be administered intravenously~Confocal laser probe will be introduced through the rigid laryngoscope and touched first on the lesion of concern and put into scanning mode in order to obtain photos and video footage of the lesions. The probe will then be placed on normal appearing vocal fold tissue to obtain a control sample.~The remainder of the procedure is standard excisional biopsy and KTP laser photoablation"
2540397|NCT02628002|Experimental|Test arm|The subjects randomized to the anti-gravity treadmill arm will be instructed on the safe use of the Alter-G treadmill by the study staff. After this instruction, subjects will be exercised on the Alter-G anti-gravity treadmill using the conventional Bruce protocol with unweighting to 75% of their body weight to reach target heart rate. If the subject is unable to reach the target heart rate, they will be further unweighted to 50% of their body weight to enable the subject to reach target heart rate on the Bruce protocol. If the subject is still unable to reach target heart rate with 50% unweighting, the patient's subsequent SPECT images will be excluded from use in the research comparison to control subject images.
2540398|NCT02628002|Active Comparator|Control arm|The control arm subjects will undergo the conventional treadmill/regadenoson pharmacological stress SPECT. Consistent with standard practice, these patients will perform adjunctive low-intensity walk on a conventional treadmill prior to regadenoson and Tc-99m injection if tolerated.
2540584|NCT02626897|Other|Sarcoidosis - GENEActiv device first|Six patients start with the GENEActiv wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the ActiGraph GT3X device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
2540588|NCT02626897|Other|Sarcoidosis - ActiGraph device first|Six patients start with the ActiGraph GT3X wrist-worn accelerometer which is needed to be worn for a 7 day period. Participants then switch to the GENEActiv device for a 7 day period. At the end of this second period they complete a short exit questionnaire detailing their experience and their device preference.
2540624|NCT02626377|Experimental|Interventional arm|'Support provided by social worker'
2540626|NCT02626377|Other|Non-interventional arm|'Information booklet receipt'
2540653|NCT02626143|Experimental|Investigational nutrient-rich whey protein formula|
2540654|NCT02626143|Active Comparator|Cow's milk based formula|
2540655|NCT02626143|No Intervention|Breast milk|
2540689|NCT02625948|Active Comparator|tranexamic acid|tranexamic acid
2540691|NCT02625948|Placebo Comparator|Placebo|0.9% NaCl
2540693|NCT02625948|No Intervention|observation(spot sign -)|regular clinical treatment
2540766|NCT02625649||RYGB|RYGB-operated type 2 diabetic patients
2540769|NCT02625649||non-RYGB|non-RYGB-operated type 2 diabetic controls
2540793|NCT02625168|Experimental|Afatinib|Afatinib 30 or 40 or 50mg daily orally after study recruitment until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
2540800|NCT02625168|Experimental|Erlotinib|Erlotinib 150mg daily until radiologically documented disease progression, intolerable side effects as judged by investigators or patient withdrawal.
2540850|NCT02624856|Experimental|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
2540852|NCT02624856|Active Comparator|Standard bupivacaine plus dexamethasone|Bupivacaine 0.5% 10 mL plus 2 mg dexamethasone for quadriceps sparing femoral nerve block and bupivacaine 0.25% 20 mL plus 2 mg of dexamethasone for posterior knee compartment periarticular injection.
3174089|NCT00619463|Experimental|monitor than exercise|8 weeks of monitoring followed by 16 weeks of aerobic exercise
3174090|NCT00619528|Experimental|1|No separate arms: All Enrolled Receive Same Treatment
2540980|NCT02624297|No Intervention|Control Group|Healthy control group for comparisons with coronary artery disease groups.
2540981|NCT02624297|No Intervention|CAD without OSA - Control|Clinical follow-up.
2540983|NCT02624297|Experimental|CAD without OSA - Intervention|Aerobic exercise training.
2540984|NCT02624297|No Intervention|CAD with OSA - Control|Clinical follow-up.
2540987|NCT02624297|Experimental|CAD with OSA - Intervention|Aerobic exercise training.
2541024|NCT02623816|Experimental|Sub-optimal/optimal dosing|Patients will not change sub-optimal dosing regimen of omeprazole 20 mg for 6 weeks after which they will receive optimal dosing of omeprazole for 4 weeks. Rescue antacid use is permitted. Total duration of 10 weeks.
2541027|NCT02623816|No Intervention|Sub-optimal dosing|No change will be made to the sub-optimal dosing regimen of omeprazole 20 mg. Rescue antacid use is permitted. Total duration of 10 weeks.
2541029|NCT02623816|Experimental|Optimal dosing|Patients will be administered optimal dosing of Omeprazole 20 mg for 4 weeks starting at week 2. Rescue antacid use is permitted. Total duration of 6 weeks.
2541084|NCT02623517||Registry Subjects|The Registry Subjects group will comprise of screened patients who do not exhibit symptoms of atrial fibrillation at the time of screening. The already collected data from the patient's device during the screening visit will be kept and put into a registry.
3174091|NCT00619541|Experimental|A|"5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days~Sorafenib 400 mg bid orally continuously~5-FU will be administered for a maximum of 12 cycles.~Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease."
2540292|NCT02628652|Experimental|Gluco-Oligosaccharide (GLOS)|Subjects randomized to this treatment arm will ingest GLOS once per day for a total of 14 days. One level of GLOS will be taken during Phase I and 2 levels of GLOS will be taken during Phase II.
2540305|NCT02628652|Active Comparator|FructoOligosaccharide (FOS)|Subjects randomized to this treatment arm will ingest FOS once per day for a total of 14 days. One level of FOS will be taken during Phase I and 2 levels of FOS will be taken during Phase II.
3202604|NCT00914758||MS patients on Rebif®|This group is comprised of patients diagnosed with relapsing remitting multiple sclerosis who were assigned to the Rebif® treatment arm of the Care-MS II trial, for which this study is a sub-study
3202605|NCT00914758||Control group|This group is comprised of non-MS, non-CNS compromised control participants matched in age, education level, and socioeconomic status to the participants in the 2 MS treatment groups
3202606|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 3.75µg|
3202607|NCT00914771|Active Comparator|H5N1 pandemic Influenza vaccine 7.5µg|
3202608|NCT00914797|Active Comparator|asthmatics|10 male asthmatic subjects
3202609|NCT00914797|Active Comparator|healthy|10 male healthy volunteers
3202610|NCT00914797|Active Comparator|elite athletes with asthma|10 elite athletes with asthma.
3202612|NCT00914836|Active Comparator|1 cc - Betamethasone Sodium Phosphate|1 cc - Betamethasone Sodium Phosphate
2540579|NCT02626949|Experimental|MBSR Course|Mindfulness-Based Stress Reduction Course (MBSR) consisting of 8 weekly sessions, 2.5 hours each, and a 5 hour silent retreat during the 6th week of the program.
2540582|NCT02626949|Experimental|HEP Course|Health Enhancement Program (HEP) consisting of 8 weekly sessions, 2.5 hours each, and 1.5 hour monthly educational sessions after the 8 week intervention.
2540649|NCT02626403|Active Comparator|anodal tDCS|Patients will receive anodal tDCS (bilateral fronto-parietal stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
2540652|NCT02626403|Sham Comparator|sham tDCS|Patients will receive sham tDCS (15 second of stimulation) during 20 minutes preceded and followed by a clinical assessment (Coma Recovery Scale-Revised) and neurophysiological assessment (8 channels EEG).
2540678|NCT02625961|Experimental|Pembrolizumab|Participants receive pembrolizumab, 200 mg, intravenously, every 3 weeks (Q3W) for up to 24 months.
2540734|NCT02625831||SLE patients|"165 SLE patients. Subgroup : 77 with active lupus and 88 in disease remission. in the active subgroup : 36 with lupus nephritis and 41 without.~Biological analysis were performed."
2540742|NCT02625831||healthy patients|48 healthy patients. Biological analysis were performed.
2540796|NCT02625350|Experimental|Instant noodle without soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes and drained
2540804|NCT02625350|Experimental|Instant noodle with soup|Instant noodle with 50 gram available carbohydrate per serving; cooked with 500 ml of water for 6 minutes, drained, and given additional 250 ml of water as soup
2540812|NCT02625350|Experimental|Glucose reference|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
2540848|NCT02624895||mCRC: Anti-EGFR MAbs + FOLFOX 1st line|• Adult (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFOX plus panitumumab or FOLFOX plus cetuximab as upfront treatment as per clinical practice.
2540851|NCT02624895||mCRC: Anti EGFR MAbs + FOLFIRI 1st line|Adults (>= 18 years old) RAS wild-type metastatic colorectal cancer patients candidate to receive FOLFIRI plus panitumumab or FOLFIRI plus cetuximab as upfront treatment as per clinical practice
2540945|NCT02624453|Experimental|IMMY LFA positive patients|HIV positive patients who will be positive for cryptococcal antigen (by the IMMY LFA test) would be consented for lumbar puncture in search of cryptococcal meningitis (CM). If CM is not confirmed, they would be prescribed pre-emptive fluconazole based therapy at 800mg/day for two weeks (placed on antiretroviral therapy two weeks after screening for cryptococcal antigen), then 400mg/day for 8 weeks and thereafter 200mg/day until CD4 counts increases beyond 200cells/ml. (CM confirmed cases will be referred to the ACTA trial ISRCTN45035509)
2540949|NCT02624453|Active Comparator|IMMY LFA negative patients|HIV positive patient who will be negative for cryptococcal antigen (by the IMMY LFA test) would not be consented for lumbar puncture, will be placed immediately on antiretroviral therapy immediately after screening for cryptococcal antigen and would not be placed on fluconazole pre-emptive therapy.
2540978|NCT02624063|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 60 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
2540979|NCT02624063|Experimental|Simeprevir + Sofosbuvir|Simeprevir 150 mg tablet + Sofosbuvir 400 mg tablet oral dosing once daily for 12 weeks
2541043|NCT02623842|Experimental|Radiofrequency|
2541082|NCT02623517||Enrolled Subjects|The Enrolled Subjects group will comprise of 75 individuals who will be followed for 12 months for their atrial fibrillation condition. Data will be collected from subjects' devices for 12 months, and any needed changes or additions to therapy will be done. (ie: ablation, pacemaker setting changes, medication control).
3202613|NCT00914836|Active Comparator|2 cc - Betamethasone Sodium Phosphate|2 cc - Betamethasone Sodium Phosphate
3202614|NCT00914875||group tramadol plus ketorolac|
3202615|NCT00914875||group tramadol plus dypirone|
3202616|NCT00914888|Experimental|A|Tigecycline
3202617|NCT00914888|Active Comparator|B|Ceftriaxone regimen
3202618|NCT00914901|Other|Healthy|10 healthy men
3202619|NCT00914901|Other|Asthmatics|10 male asthmatic subjects
3202620|NCT00914901|Other|Elite athletes with asthma|10 male elite athletes with asthma
3202621|NCT00914914|Experimental|p28 Phase I Safety|A total of 15 patients were administered p28 i.v. as a short infusion three times per week for 4 weeks followed by a 2-week rest under an accelerated titration 3þ3 dose escalation design.
3202622|NCT00914953|Experimental|oxytocin|
3202623|NCT00914979|Experimental|1|Single Arm - Interventional
3202624|NCT00915044||IBD patients|Approximately 40 patients (adults and children) suffering from IBD will be enrolled.
3202625|NCT00915044||Controls|Approximately 100 healthy controls
3202626|NCT00915057|Experimental|NRL972|Single 2mg intravenous dose of NRL972, administered on up to seven occasions
2540348|NCT02628457||Mild Subgroup|patients with supraspinatus tendon retracted upto medial 1/3rd of humerus head and arthroscopic rotator cuff repair done by single row.
2540354|NCT02628457||Moderate Subgroup|patients with supraspinatus tendon retracted between medial 1/3rd of humerus head and glenoid,and arthroscopic rotator cuff repair done by single row.
2540359|NCT02628457||Severe subgroup|patients with supraspinatus tendon retracted beyond glenoid and arthroscopic rotator cuff repair done by single row
3174092|NCT00619567|Experimental|Cognitive Stimulation|Subjects will be given Internet access to the Smartbrain cognitive stimulation program. They will complete exercises for ~30 minutes, at least three times per week, for a period of 24 weeks.
3174093|NCT00619567|No Intervention|Control|"These individuals will receive usual care during the 24 week follow-up period."
2540480|NCT02627742|Experimental|METANEB|Patients will receive standard care with the addition of therapy with The MetaNeb® System.
2540623|NCT02626507|Experimental|Gedatolisib ER+/HER2- Breast Cancer|"Gedatolisib at escalating doses of 180, 215 and 260 mg via a 3-6 dose-escalation scheme is administered once weekly on the first day for each of the four weeks during the four 4-week cycles.~Faslodex at 500 mg is administered IM into the buttocks slowly (over 1 - 2 minutes per injection) as two 5-mL injections, one in each buttock, on Days 1 and 15 of Cycle 1 and on Day 1 of the remaining three 4-week treatment cycles.~Palbociclib at 125 mg is administered PO with food daily on Days 1-21 for each of the four 4-week cycles~Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment."
2540686|NCT02626091|Experimental|Perfusion evaluation of anastomosis|During left-sided colonic resections, anastomosis perfusion will be estimated by the visual appreciation of the surgeon and the ICG fluorescence-based enhanced reality. These two approaches will be compared.
2540737|NCT02625727|Experimental|hyaluronic acid group|hyaluronic acid injection
2540744|NCT02625727|Active Comparator|hyaluronic acid and corticosteroid group|hyaluronic acid combined corticosteroid injection
2540809|NCT02625337|Active Comparator|Pembrolizumab mono|Pembrolizumab monotherapy
2540813|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib short|Pembrolizumab combined with a short scheme of dabrafenib+trametinib
2540816|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib intermediate|Pembrolizumab combined with an intermediate scheme of dabrafenib+trametinib
2540817|NCT02625337|Experimental|Pembrolizumab with dabrafenib+trametinib long|Pembrolizumab combined with a long scheme of dabrafenib+trametinib
2540898|NCT02624752|No Intervention|Standard of Care|"Standard of care could include liberalized diet consisting of 3 meals and snacks served daily or the standard oral nutrition supplementation (ONS) routinely used in the hospital, as prescribed by the medical team.These routine meals and snacks are the standard of care."
2540901|NCT02624752|Experimental|Ensure|Patients randomized to Enhanced Oral Nutritional Supplementation (ONS) will receive the standard of care hospital menu (3 meals and snacks per day) plus 2 cans of Ensure (or similar product) per day while in hospital and will continue 2 cans per day of Ensure when discharged home until they have been receiving the enhanced ONS for a total of 90 days.
2540929|NCT02624505|Placebo Comparator|Placebo Product|One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2540930|NCT02624505|Active Comparator|90 mcg Reference Product|Drug : 90 mcg Reference Product One actuation each from the Reference inhalation aerosol and the placebo Reference inhalation aerosol and one actuation each from two different placebo Test inhalation aerosols
2540931|NCT02624505|Active Comparator|180 mcg Reference Product|Drug: 180 mcg Reference Product One actuation each from two different Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols
2540933|NCT02624505|Experimental|90 mcg Test Product|Drug: 90 mcg Test Product One actuation each from the Test inhalation aerosol and the placebo Test inhalation aerosol and one actuation each from two different placebo Reference inhalation aerosols
2541012|NCT02624167|Active Comparator|NW-3509A|Patients will start on NW-3509A 15 mg BID and be up-titrated to 20mg, and 25mg BID dependent on tolerability.
2541013|NCT02624167|Placebo Comparator|Placebo|Patients will receive matching placebo BID
3202627|NCT00915070|Active Comparator|BQ-123|
3174094|NCT00619580||positive E coli|positive E coli at UPMC
3174095|NCT00619593|Active Comparator|2|Standard follow-up in patients without appropriate ICD therapy
2540356|NCT02628392|Active Comparator|Sitagliptin|capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet
2540507|NCT02627404|Other|Main module|Blood sample
2540545|NCT02627092|Experimental|Copper linen exposure|"Subjects will use copper linens during their hospital stay, consisting of copper hospital gowns, copper bed sheets (top and bottom sheets), and copper pillow covers.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
2540547|NCT02627092|No Intervention|Non-copper linen exposure|"Subjects will not have exposure to copper linens during their hospital stay. They will use the usual hospital linens provided by hospital, not containing copper.~A subset of 50 subjects from this arm will be recruited to provide three types of swabs to calculate the microbial burden on copper linens. Linen swabs, anatomical swabs and environmental swabs will be collected from subjects and subject hospital rooms will be collected to do bacteria counts."
2540590|NCT02626767|Experimental|Intervention|Participants were required to complete a high-intensity interval exercise training intervention, which took place three time per week for 10 weeks. The exercise sessions comprised of 4 to 7 repetitions of 45 s maximal effort exercise, based on boxing, dance, soccer and basketball drills), interspersed with 90-s rest. During each repetitions participants were encouraged to reach >90% of their individual maximal heart rate. Participants were asked to maintain their dietary habits throughout the intervention period.
2540592|NCT02626767|No Intervention|Control|Participants were asked to maintain their usual diet, physical education and physical activity habits during the intervention period and were not aware that an exercise intervention was taking place at other study sites.
2540614|NCT02626468||Normal|Participants with no diagnosis of respiratory disease between the ages of 0 and 80
2540615|NCT02626468||COPD|Patients from different diagnostic groups between the ages of 0 and 80
2540657|NCT02626208|Experimental|Nestorone®/ Estradiol 75|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 75 ug/day of estradiol
2540658|NCT02626208|Experimental|Nestorone®/Estradiol 100|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 100 ug/day of estradiol
2540660|NCT02626208|Experimental|Nestorone®/ Estradiol 200|Device: Nestorone®/Estradiol Contraceptive Vaginal Ring with 200 mcg/day of NES and 200 ug/day of estradiol
3174096|NCT00619593|Experimental|1|Following 1st appropriate ICD therapy, the patients have to be called to the clinic for intensified clinical diagnostics and, if necessary or useful, intensified therapy.
3174097|NCT00619632|Experimental|1|LC- Primary-care based lactation consultant meeting women pre- and post-natally.
2540785|NCT02625090|Experimental|UCB0942|"UCB0942 400 mg bid or a tapered UCB0942 dose of 200 mg bid.~The Investigator will be allowed to increase or decrease the dose of UCB0942 to optimize tolerability and seizure control for each subject. Increases or decreases to the dose of UCB0942 should be made in steps not exceeding 200 mg/day per week; an exception is Taper Week 1 where a step of 800 mg/day to 500 mg/day is allowed. A faster decrease of the dose than 200 mg/day per week is allowed when it is clinically appropriate in the Investigator's medical judgment. Daily UCB0942 doses during this study may be 100 mg (50 mg bid), 200 mg (100 mg bid), 400 mg (200 mg bid), 600 mg (300 mg bid), or 800 mg (400 mg bid); intermediate doses will not be allowed except for tapering and titration unless agreed by the UCB Study Physician or PRA Medical Monitor. The dose of UCB0942 must always be administered as bid morning and evening doses, approximately 12 hours apart."
2540926|NCT02624466||CKD - no dialysis|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2540927|NCT02624466||Patients on PD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and PD fluid, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2540928|NCT02624466||Patients on HD|Follow-up of CKD progress by frequent assessment of: concentration of uraemic toxins in blood, urine and spent dialysate, anthropometry, cardio-vascular parameters, body composition monitoring, dietary assessment, psycho-social questionnaires, sleep disorders, stool, nails.
2540976|NCT02624258|Experimental|RNA CART19 cells|CD19 RNA redirected autologous T-cells (RNA CART19 cells)
2541032|NCT02623933|Experimental|MRI assisted HDR monotherapy|HDR monotherapy to the whole prostate gland (19Gy/1) with MRI assisted focal boost to intraprostatic nodule up to 22.5Gy
2541100|NCT02623595|Experimental|SBRT+GM-CSF|Metastasis lesion will be treated with a SBRT of 50Gy/5F from day 1 to day 5 in a cycle of 21 days.Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
2541136|NCT02623075|Experimental|Transplant recipients (Chimeric)|Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
2541138|NCT02623075|Experimental|Transplant recipients (IS)|Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
2541140|NCT02623075|Active Comparator|Controls|Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
3174098|NCT00619632|Experimental|2|Provider Prompt
3174099|NCT00619632|Experimental|3|LC+Provider Prompt
3174100|NCT00619632|No Intervention|Control|
3174101|NCT00619658|Experimental|1|All women undergoing medical abortion will have telephone follow-up approximately one week after using mifepristone and misoprostol.
3174102|NCT00619710|Experimental|1|Meropenem
3174103|NCT00619710|Active Comparator|2|Imipenem-cilastatin
3174104|NCT00619736|Experimental|NSA-789|
3174105|NCT00619736|Placebo Comparator|Placebo|
3174106|NCT00619749|Experimental|1|
3174107|NCT00619749|Placebo Comparator|2|
3174108|NCT00619788|Experimental|1|Patients receiving 4.0-5.0mm AngioSculpt Scoring Balloon Catheter (AngioScore, Inc.) for femoropopliteal use
3174109|NCT00619814|Other|Cohort group|Cohort group of asymptomatic patients 50-80 years old with a positive fecal occult blood test done for colorectal cancer screening.
2540384|NCT02628171|Other|Control|Participants will receive a controlled diet (base diet), typical of an American diet, with 0 g/day of cashew nuts (control).
2540385|NCT02628171|Active Comparator|Cashew|Participants will receive a controlled diet, typical of an American diet, with 42 g/day of cashew nuts (base diet with cashew nuts).
2540407|NCT02627846|Active Comparator|EndoVenous Laser Ablation|EndoVenous Laser Ablation (EVLA) involves the delivery of laser light through a glass fibre placed into the lumen of a refluxing vein. This energy is converted into heat inducing a permanent, non-thrombotic occlusion.
2540410|NCT02627846|Active Comparator|MechanoChemical Ablation (ClariVein®)|Mechanochemical ablation (MOCA) is performed by a device called ClariVein® which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip.
2540479|NCT02627560|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
2540482|NCT02627560|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
2540543|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide (TEC)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
2540548|NCT02627248|Experimental|Docetaxel, Epirubicin and Cyclophosphamide + Huaier (TEC+HE)|Six cycles of docetaxel (75 mg/m²), epirubicin (70 mg/m²) and cyclophosphamide (600 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
2540550|NCT02627248|Experimental|Epirubicin and Docetaxel (ET)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be not be administrated.
2540553|NCT02627248|Experimental|Epirubicin and Docetaxel+Huaier (ET+HE)|Six cycles of epirubicin (70 mg/m²) and docetaxel (75 mg/m²). Patients will be treated with chemotherapy every 3 weeks (+/- 2 days ) in total. Huaier Granule will be administrated from the first cycle of chemotherapy until time of definitive surgery.
3202628|NCT00915070|Placebo Comparator|Physiological saline solution|
3202629|NCT00915083|Experimental|Amrubicin 40mg/m^2|Amrubicin 40mg/m^2 given as a 5 minute IV infusion on Days 1, 2 & 3 of a 21 day cycle
3202630|NCT00915096||High Tumor Burden Follicular Lymphoma|
2540754|NCT02625584|Other|Shared Reading Control|Reading Together - Shared Reading Control. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will not be trained to read with their child. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2540755|NCT02625584|Experimental|Dialogic Reading|Reading Together - Dialogic Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a dialogic reading style. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2540757|NCT02625584|Experimental|Pausing for Reading|Reading Together - Pausing for Reading. The intervention will run for six weeks and the caregivers will be provided with books to read with their children. Caregivers will be trained to read with their child using a style which involves pausing, recasting and open questioning. The caregivers will be asked to read two books to their child five times a week. Caregivers will keep a reading diary and audio record all shared book reading sessions with their child.
2540803|NCT02625246|Experimental|Group 1|3 patients will receive a single administration of allogeneic hMSCs: 20 x106 (20 million) cells delivered via peripheral intravenous infusion
2540808|NCT02625246|Experimental|Group 2|3 patients will receive a single administration of allogeneic hMSCs: 1 x108 (100 million) cells delivered via peripheral intravenous infusion
2540855|NCT02624869|Experimental|evolocumab (AMG 145)|Single arm all subjects receive evolocumab (AMG 145) every 4 weeks (QM)
2540963|NCT02624349|Active Comparator|Transplant|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
2540965|NCT02624349|Active Comparator|Control|Intervention: Quadravalent human papillomavirus vaccine 0.5ml intramuscular injection at 0, 2, and 6 months and/or post administration antibody titers as described in methods
2541018|NCT02623985|Experimental|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia which is rapid test.
2541020|NCT02623985|Experimental|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue which is rapid test.
2541021|NCT02623985|Experimental|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture which is gold standard.
3202631|NCT00915109||vascular|People with a unilateral below-knee amputations due to a vascular reason
3202632|NCT00915109||nonvascular|People with a below-knee amputation due to nonvascular reasons
3202633|NCT00915109||Control|People with no gait impairments.
3202634|NCT00915122|Experimental|IMRT in prostate cancer|
3202635|NCT00915135|Experimental|Ramelteon QD and Placebo QD (25 possible combinations total)|
3202636|NCT00915187|Active Comparator|Control|
3202637|NCT00915187|Experimental|CCS/C (Adjuvant Formulation)|
3202638|NCT00915200|Placebo Comparator|Placebo|N-acetylcysteine placebo + silibin placebo
3202639|NCT00915200|Experimental|N-acetylcysteine|N-acetylcysteine active + silibin placebo
3202640|NCT00915200|Experimental|silibin|N-acetylcysteine placebo + silibin active
3202641|NCT00915200|Experimental|N-acetycysteine + silibin|N-acetylcysteine active + silibin active
3202642|NCT00915200|Experimental|N-acetylcysteine + high-dose silibin|N-acetylcysteine active + high-dose silibin active
3202643|NCT00915213||Repeat Prostate Biopsy|Men who undergo repeat prostate biopsy
3202644|NCT00915239|Active Comparator|Pantoprazole|
2540417|NCT02628132|Experimental|Durvalumab and Paclitaxel|After one cycle of paclitaxel, durvalumab will be given concurrently with paclitaxel. Once paclitaxel cycles are completed, durvalumab will be continued alone until disease progression or unacceptable toxicity.
2540468|NCT02627612|Experimental|TM RWB PLUS Pro Vetus|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this group and request that they voluntarily join TM RWB and receive mentorship from their matched and assigned mentor. In addition to TM RWB membership, research participants will also receive approximately four months of mentorship from a ProVetus mentor to assist them in further transitioning within the five domains.
2540469|NCT02627612|Active Comparator|TM RWB ONLY|Research participants will receive an introductory email from the research team informing them that they were randomly assigned to this arm and request that they voluntarily join TM RWB. Weekly emails will provide lists of voluntary physical/social activities available to all Chapter members. No participation is required in these activities.
2540470|NCT02627612|No Intervention|Control Group (Waitlist)|Research participants (recent Veterans) will be placed on a waitlist for approximately sixteen months. Based on their desires, the research participants in this group will have opportunity to belong to TM RWB plus receive approximately four months of mentorship from trained, peer-mentors (who are TM RWB volunteers).
2540530|NCT02627339||Healthy controls|Healthy controls age 10 to 90 years
2540591|NCT02626858|Other|extra treatment planning CT-scan|Extra pre-operative CT-scan for treatment planning in RT
2540679|NCT02626442|Experimental|Group Exercise Class|6 month group balance/exercise class, three days a week - up to one hour. Exercise program includes walking around a track, bodyweight/balance exercises, and an obstacle course.
2540680|NCT02626442|No Intervention|Testing|Subjects enrolled in other MERCE exercise and robotics interventions will receive balance/walking tests, MRI with famous name recognition task, and cognitive testing pre and post their intervention.
2540729|NCT02625805|Experimental|Participants diagnosed with ADD/ADHD|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
2540732|NCT02625805|Experimental|Healthy participants|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv) and Methylphenidate administration
2540791|NCT02625285||G6PD Deficient Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD deficient at SMRU clinic"
2540799|NCT02625285||G6PD Intermediate or Heterozygous Volunteers|"Subjects with age ≥ 18 years~Female~Previously tested G6PD intermediate or heterozygous for G6PD variants at SMRU clinic"
2540807|NCT02625285||G6PD-Normal Volunteers|"Subjects with age ≥ 18 years~Male and female~Previously tested G6PD normal at SMRU clinic"
2540846|NCT02624947|Placebo Comparator|Treatment Group A|Formulation buffer (0.5mL injection)
2540847|NCT02624947|Active Comparator|Treatment Group|RSV F vaccine with adjuvant (0.5mL injection)
2541015|NCT02624089|Experimental|Ropivacaine Group|This group will receive nebulized ropivacaine 0.5% based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered once at the onset of pneuomoperitoneum during appendectomy.
2541017|NCT02624089|Placebo Comparator|Placebo group|This group will receive placebo (normal saline) based on ideal body weight at a dose of 0.5 mg/kg with a maximum total dose of 30 mg. This will be administered at the onset of pneuomoperitoneum during appendectomy.
2541019|NCT02624089|No Intervention|Non-enrolled group|This group will not receive either intervention (ropivicaine) or placebo (normal saline), but will have primary and secondary endpoints evaluated.
2541065|NCT02623569|Experimental|Ivabradine|Ivabradine 5 mg twice a day for first 4 weeks and 7.5mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR（heard rate）>80times/min of subjects.
2541071|NCT02623569|Active Comparator|Atenolol|Atenolol 12.5 mg twice a day for first 4 weeks and 25mg twice a day when positive ETT and HR（heard rate）>60times/min or negative ETT and HR （heard rate）>80times/min of subjects.
2541127|NCT02623270|Experimental|Noninvasive Ventilation|After induction of anesthesia, checking of ability to bag mask ventilating the patient, the manual bag ventilation will be replaced by a Noninvasive Ventilator, V60 (Philips)
2541145|NCT02622984|Experimental|RBIRT|Telehealth model or the remote administration of SBIRT, a short term, brief intervention and referral to treatment for alcohol abuse.
2541147|NCT02622984|Active Comparator|SBIRT|Face-to-face intervention and referral to treatment for alcohol abuse.
2541214|NCT02622789||Controls|Age-matched Healthy Controls
2541225|NCT02622789||General Exercises|Low Back Pain Participants Receiving General Exercises
2541233|NCT02622789||Pilates Exercises|Low Back Pain Participants Receiving Pilates Exercises
3202645|NCT00915239|Placebo Comparator|Placebo|
3202646|NCT00915252|Experimental|5-azacytidine|Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.
3202647|NCT00915252|Active Comparator|standard chemotherapy|Patients enrolled in this arm will receive standard chemotherapy treatment.
2541353|NCT02621827|Experimental|Non-pregnant, non-lactating (NPNL)|"NPNL women are age and parity matched to pregnant women. Each NPNL women is studied twice, approximately 3 months apart.~At each study period the participant receives (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3."
3202648|NCT00915291|No Intervention|Usual education|"Participants randomized into the no intervention arm were not exposed to the web-based educational modules"
3202649|NCT00915291|Experimental|Web-based educational modules|Participants randomized into the intervention arm were exposed to the web-based educational modules
3202650|NCT00915330|Active Comparator|TBNA alone|Arm A: TBNA alone.
3202651|NCT00915330|Experimental|TBNA with ROSE|Arm B: TBNA with ROSE.
3202652|NCT00915382|Active Comparator|3 weekly regimen of S-1 and cisplatin|
3202653|NCT00915382|Active Comparator|5 weekly regimen of S-1 and cisplatin|
3202654|NCT00915408|Experimental|CRD|
3202655|NCT00915421||Prehospital hypothermia group|All patients included to the study
3202656|NCT00915447||Cat Allergic Rhinitis|Individuals with cat allergic rhinitis, yet without routine cat exposure
3202657|NCT00915460|Experimental|1|Patients previously enrolled in BIogen Idec study C95-812.
2540489|NCT02627586|Active Comparator|Moderate intensity continuous exercise|Moderate intensity continuous exercise (MICE) is performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group will perform MICE training three times per week. Cycling resistance will be adjusted weekly according to heart rate and Borg scale.
2540491|NCT02627586|Experimental|High-intensity interval training|"High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. Moderate intensity continuous exercise (MICE) is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-85% of peak heart rate for 38 min (including a 5 min warm-up and 3 min cool-down). This group performs two HIIT sessions and one MICE session per week.~In both training forms cycling resistance will be adjusted weekly according to heart rate and Borg scale."
2540568|NCT02627196|Experimental|Device and Medical Management|Subjects will be implanted with the BAROSTIM NEO System and receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
2540569|NCT02627196|Active Comparator|Medical Management|Subjects will receive optimal, stable, Guideline Directed Medical Therapy (GDMT) for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
2540688|NCT02625987|Experimental|Continuous intradermic stitch|Closure was did with a continuous intradermic stitch.
2540690|NCT02625987|Sham Comparator|Separated stitches|Like comparator was used a closure with separated stitches.
2540717|NCT02625688|Placebo Comparator|Early cord clamping|Cord clamping will be applied after 30 seconds post delivery.
2540720|NCT02625688|Active Comparator|Delayed cord clamping|Cord clamping will be applied after 3 minutes post delivery.
2540722|NCT02625688|Active Comparator|Cord milking|The baby will be placed below the level of the placenta, between the mother's thighs (during a vaginal delivery) or at the side of the mother swaddled in sterile towels (during a caesarian delivery).
2540794|NCT02625363|Experimental|Glucose Ref - Std|250 ml glucose solution with 50 gram available carbohydrate per serving, used as reference
2540801|NCT02625363|Experimental|Glucose Ref and 450 ml water|250 ml glucose solution with 50 gram available carbohydrate per serving. Sample was consumed with additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
2540811|NCT02625363|Experimental|White Bread with 250 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption
2540814|NCT02625363|Experimental|White Bread and 700 ml water|White bread with 50 gram available carbohydrate was consumed with 250 ml water immediately after meal consumption. Moreover, subjects given additional water intake @150 ml at 45, 75, and 105 minutes after meal consumption
2540815|NCT02625363|Experimental|White Bread with 125 ml water (twice)|Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
2540862|NCT02624817|Experimental|Drug: Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to glucagon have been tested.
3174110|NCT00619840|Active Comparator|1|
3174111|NCT00619840|Placebo Comparator|2|
2541059|NCT02623582|Experimental|Cohort 1|The first 3 subjects to receive RNA CART123 cells will receive up to 3 doses of RNA CART123 cells, with no lymphodepleting chemotherapy prior to infusion.
2541061|NCT02623582|Experimental|Cohort 2|"The remaining 12 subjects of the study will receive up to six IV doses of RNA CART123 cells.~Subjects in Cohort 2 may be given lymphodepleting chemotherapy 4 days (+/- 1 day) prior to the first CART123 cell infusion (if ALC> 500/uL).~Lymphodepleting chemotherapy may be repeated before the fourth dose of RNA CART123 cells (if ALC> 500/uL).~Lymphodepleting chemotherapy includes a single dose of cyclophosphamide (1g/m2) Weight used for dosing will be the weight obtained prior to the apheresis procedure Cell numbers are based on CAR+ cells with CAR expression determined by flow cytometry Based on the product release criteria, at least 20% of the total cells will be RNA CART123 cells.~Dosing will not be changed for changes in subject weight The indicated doses are +/- 20% to account for manufacturing variability."
2541223|NCT02622477||Participants with idiopathic pulmonary fibrosis|Participants with idiopathic pulmonary fibrosis receiving Pirfenidone will be observed for treatment responses.
2541431|NCT02621359|Experimental|Quadruple therapy|Nitazoxanide (500mg bid), Levofloxacin (500 mg once daily), Omeprazole (40 mg bid) and doxycyclin (100 mg twice daily) were prescribed for 14 days.
3174112|NCT00619905|Experimental|1|
3174113|NCT00619905|Placebo Comparator|2|
3174114|NCT00619931||1|APD791 or placebo
3174115|NCT00619931||2|APD791 or placebo
3174116|NCT00619931||3|APD791 or placebo
3174117|NCT00619931||4|APD791 or placebo
3174118|NCT00619931||5|APD791 or placebo
3174119|NCT00619944|Experimental|1|Lumefantrine lopinavir drug interaction arm
3174120|NCT00619944|Active Comparator|2|lumefantrine only arm
3174121|NCT00619996|Experimental|1|
3174122|NCT00620009|No Intervention|Control|Therapists and patients record their estimates of the patient's Global Assessment of Functioning, but do not discuss these estimates in therapy sessions.
3174123|NCT00620009|Experimental|Empathy Feedback|Therapists and patients record their ratings of the patient's Global Assessment of Functioning and discuss these ratings.
3174124|NCT00620048|Experimental|Low dose of autologous CD34-positive cells (stem cells)|
3174125|NCT00620048|Experimental|High dose of autologous CD34-positive cells (stem cells)|
2540528|NCT02626975||ACL reconstruction ballooning|"ACL reconstruction with short hamstring tendon autograft~arm ballooning~arm no ballooning"
2540572|NCT02626884|Experimental|Ibrutinib|All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
2540598|NCT02626598||Treated patients|Patients treated with blended Belotero for etched-in fine lines of the cutaneous lip, and/or radial cheek area, and/or nasolabial folds, and/or melolabial folds, and/or forehead area will be evaluated with photographs, physician ratings, and patient improvement assessments.
2540656|NCT02626312|Experimental|Treatment (radiation therapy)|Patients undergo radiation therapy 5 days a week for a total of 15 or 25 fractions in the absence of disease progression or unacceptable toxicity.
2540739|NCT02625818||acute psychiatric condition|
2540776|NCT02625454|Experimental|Intravenous Acetaminophen|Subjects will receive 1000 mg of intravenous Acetaminophen q 6 hours, up to two doses and an oral placebo resembling oral acetaminophen
2540779|NCT02625454|Active Comparator|Oral Acetaminophen|Subjects will receive 1000 mg of oral Acetaminophen q 6 hours, up to two doses and an intravenous placebo resembling intravenous acetaminophen
3202658|NCT00915460|Experimental|2|Patients previously enrolled in Biogen Idec study C96-823.
2541099|NCT02623530|Active Comparator|Control group|Control group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), not based on the Active Learning Model for Critical Thinking (MEAPC).
2541101|NCT02623530|Experimental|Experimental group|Experimental group: to implement educational intervention focusing on first aid for developing critical thinking (CT) skills and disposition, through the Problem Based Learning (PBL), based on the Active Learning Model for Critical Thinking (MEAPC).
2541146|NCT02623127|Experimental|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily in 3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment.
2541213|NCT02622776|Other|Vaginal DNA Collection|Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.
2541290|NCT02622399|Experimental|Project NOW|Participants in the intervention arm receive access to free mobile communications and a web-based informational platform supported by txtwire.
2541293|NCT02622399|No Intervention|Control|Participants in the control arm do not receive access to the txtwire platform.
2541329|NCT02621944|Experimental|Participants 1-10|"This group will receive a 0.5 mg/kg enteral dose of Melatonin. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
2541332|NCT02621944|Experimental|Participants 11-20|"This group will the Melatonin dose of 3 mg/kg enteral, only if the group Participants 1-10 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
2541354|NCT02621827|Experimental|Pregnant/Lactating|Pregnant women receive (as the intervention) a single oral dose of stable isotope labeled 25(OH)D3. The same women are followed-up in lactation to repeat the same protocol.
3174126|NCT00620087|Other|Diagnostic Arm|Women with core-biopsy proven atypia, LCIS, or radial scar who have not yet undergone surgical excision were enrolled in the diagnostic arm. A molecular breast imaging study will be obtained.
3174127|NCT00620087|Other|Surveillance arm|Women with a diagnosis of ADH, ALH, or LCIS within the past 5 years were enrolled in the surveillance arm. A molecular breast imaging study was done at enrollment (Year 0) and repeated at Yer 2 and Year 4. Patients continued with routine screening mammography during this time period.
3174128|NCT00620139||A|Some patients presenting with suspicious lesions of the oropharynx or oral cavity will need to undergo transoral biopsy in the clinic to confirm the diagnosis of carcinoma. Of those patients who choose to participate in the study, an extra piece of tumor will be harvested for investigational purposes related to this trial.
3174129|NCT00620152|Experimental|1|Low glycemic load diet
3174130|NCT00620152|Active Comparator|2|Low fat diet
3174131|NCT00620165|Experimental|1|
3174132|NCT00620165|Placebo Comparator|2|
3174133|NCT00620178||1|Candesartan
3174134|NCT00620178||2|Losartan
3174135|NCT00620204|Experimental|A|Atorvastatin group
3174136|NCT00620204|No Intervention|B|Control group
3174137|NCT00620217|Experimental|1|intramyocardial injection of bicistronic VEGF-A165/bFGF plasmid
3174138|NCT00620217|Placebo Comparator|2|intramyocardial injection of placebo plasmid
3174139|NCT00620230|Experimental|1|
3174140|NCT00620230|Placebo Comparator|2|
3174141|NCT00620243|Experimental|1|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
3174142|NCT00620256|Experimental|AL-37807|AL-37807 ophthalmic suspension, 0.1%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
3174143|NCT00620256|Active Comparator|Timolol|Timolol gel forming solution, 0.5%, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
2540529|NCT02627079|Active Comparator|Cohort 1|"Cohort 1 will include 15 sedentary participants who have completed all cancer therapy except adjuvant hormonal therapy.~All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity level for 12 weeks.."
2540531|NCT02627079|Active Comparator|Cohort 2|Cohort 2 will include 15 sedentary participants in active treatment. All participants will be provided a Fitbit. Participants will then be provided daily SMS text messaging tailored to their activity levels for 12 weeks.
3202659|NCT00915460|Experimental|3|Patients previously enrolled in Biogen Idec study C97-830.
3202660|NCT00915486|Experimental|Good Standard of Care (GSoC)|Twice per week
2540709|NCT02625883||Survivors|Patients with out-of-Hospital resuscitation and return of spontaneous circulation. Structured interview for quality of life (questionnaire) one year after resuscitation.
2540736|NCT02625519|Experimental|Urinary follicle-stimulating hormone|Controled Ovarian stimulation with urinary follicle-stimulating hormone
2540743|NCT02625519|Experimental|Recombinant follicle-stimulating hormone|Ovarian stimulation with recombinant follicle-stimulating hormone
2540777|NCT02625272|Experimental|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
2540780|NCT02625272|No Intervention|Group B|novel laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were divided at the beginning of the operation intracorporeally.
2540783|NCT02625272|No Intervention|Group C|the traditional laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer.
2540863|NCT02625012||Vitiligo|A serial of vitiligo patients under treatment with UVB-NB
2540909|NCT02624622|Active Comparator|CHW applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. The community health worker is given the chlorhexidine to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
2540911|NCT02624622|Experimental|Mother applies chlorhexidine|Intervention: Chlorhexidine gel 7.1% topical 3 gm applied to the umbilical cord stump in one application. Mother is given the chlorhexidine during the first prenatal care visit to apply to the umbilical cord stump within 24 hours of delivery of the newborn infant.
3202661|NCT00915486|Experimental|GSoC + vehicle|Twice per week
3202662|NCT00915486|Experimental|GSoC + I-020201 (33microg)|Twice per week
3202663|NCT00915486|Experimental|GSoC + I-020201 (100microg)|Twice per week
2541204|NCT02622750|Experimental|triple-branched stent graft|The triple-branched stent graft was a branched 1-piece graft and included a main stent graft and 3 sidearm stent grafts (Yuhengjia Science and Technology, Corp, Ltd, Beijing, China). The main stent graft and sidearm stent grafts were individually mounted on 4 catheters and restrained by 4 silk sutures .The triple-branched stent graft was inserted into the true lumens of the aortic arch and proximal descending aorta; the three vascular stent branches were then grafted into the corresponding true lumens of the aortic arch branch vessels followed by the sequential release of the vascular stent backbone and the branch stents in the left subclavian artery, the left common carotid artery, and the innominate artery.
2541207|NCT02622750|Active Comparator|four-branched Dacron graft|"A four-branched Dacron graft (Boston Scientific Inc, Boston, MA) and a stent graft (MicroPort Medical Co Ltd, Shanghai, China) were used in total arch replacement combined with stented elephant trunk (SET) implantation.The SET was inserted into the true lumen of the descending aorta.The proximal edge of the residual aorta was trimmed to match the proximal end of the stent graft.The anastomosis between the four-branched prosthetic graft and the distal aorta containing the intraluminal stented graft was carried out using open aortic technique."
2541269|NCT02622308|Experimental|single-case design|"The study design will be a non-randomized clinical trial with single-subject baseline design (also called single-case baseline design) where each patients act as their own controls:~Observations (A) will be taken before and after a 8-week intervention period. We plan to introduce a 4-week INP-treatment period ('FlowOx™) (B) using the same outcome variables that were used as baseline measures. If the patient demonstrates improvements in outcome variables after the first treatment period (B1), the patient will be asked to continue INP therapy for another 4-week period, before a final assessment after a total of 8-week intervention period (B2) (A-B-B design)."
3202664|NCT00915486|Experimental|GSoC + I-020201 (300microg)|Twice per week
3202665|NCT00915512|Experimental|Paliperidone extended-release (ER)|
2541419|NCT02621398|Experimental|Treatment (paclitaxel, carboplatin, radiation, pembrolizumab)|Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Patients undergo 3D CRT or IMRT QD 5 days a week for 6 weeks. Beginning 2-6 weeks after, 2 weeks before the end, or at the start of chemotherapy and radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3202666|NCT00915564|Experimental|TMC435 + methadone|Supervised intake of individualized methadone dose (range, 30 to 150 mg once daily) from Day -14 to Day -1; followed by addition of 150 mg dose of TMC435 once daily from Day 1 to Day 7 along with methadone; and later followed by continued intake of individualized methadone 30 to 32 days follow-up.
2541544|NCT02620592|Active Comparator|ZYDPLA1 tablet|ZYDPLA1 tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
3202667|NCT00915577|Experimental|1st Injection|Manual injection with pre-filled syringe.
3202668|NCT00915577|Experimental|Single-use autoinjector|Single-use autoinjector with Avonex pre-filled syringe
3202669|NCT00915616|No Intervention|control|9 healthy normal subjects.
3202670|NCT00915616|Active Comparator|Group II|Included 9 patients suffering from GERD; receiving melatonin alone for treatment of GERD in a dose of 3 mg once daily at the bed time.
3202671|NCT00915616|No Intervention|Group III, combined group|Included 9 patients suffering from GERD; receiving omeprazole alone for treatment of GERD in a dose of 20 mg twice daily.
3202672|NCT00915616|Active Comparator|Group IV|Included 9 patients suffering from GERD receiving omeprazole and melatonin for treatment of GERD in the same dose of each of them.
2540535|NCT02627027|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T) T: Test drug(CKD-395 0.25/750 mg 2T)
2540538|NCT02627027|Experimental|TR group|T: Test drug(CKD-395 0.25/750 mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucodaun OR Tab. 750mg 2T)
2540581|NCT02626754|Experimental|Sunitinib|Sunitinib malate, 12.5mg/capsule, 50mg/day
2540618|NCT02626416|Experimental|telemedicine group|Congenital cataract patients use telemedicine to pursue and adjust the time of follow-up under non-clinical settings
2540619|NCT02626416|No Intervention|non-telemedicine group|Congenital cataract patients pursue and adjust the time of follow-up through outpatient visit in the hospital
2540650|NCT02626169|Active Comparator|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
2540651|NCT02626169|Active Comparator|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
2540735|NCT02625792|Experimental|Endo-Clot(TM)|The intervention group
3202673|NCT00915629|Experimental|Probiotic|Dietary supplement
3202674|NCT00915642||Normal volunteers|Volunteers, body mass index 17 to 25
3168338|NCT00549835|Active Comparator|Real Acupuncture|Participants will have acupuncture performed at a rate of 3 times (Mon, Wed, Fri) / week for total of 2 weeks (total of 6 sessions). We will follow Saam Acupuncture methods, which have been the mainstream of acupuncture methodology in most Korean Oriental Medical Colleges and among clinical practitioners >400 years. Standardized acupuncture prescriptions for mucositis will be acupuncture points tonifying Spleen Meridian (R side) and Small Intestine Meridian (L side). In Oriental Medicine, the spleen has functions of promoting water metabolism, transporting nutrients, and controlling blood. Mouth belongs to the spleen system according to Five element theory. Small intestine is related with mucositis symptoms including thirst and tongue ulcers. We will use sterile, disposable, filiform needles, size 0.16 (40Gauge) - 0.30 mm (30Gauge) in diameter and 15-40 mm long. Total number of acupuncture needles will be 8 (4 needles each side) and needles will be retained for 20 minutes.
3202675|NCT00915642||Obese volunteers|Volunteers body mass index higher than 30
2540975|NCT02624271|Experimental|GastroPanel|GastroPanel test on blood samples
2541068|NCT02623660|Experimental|Experimental|This group will receive treatment from the ODIN1 device in conjunction with standard care and diagnostic device testing.
2541073|NCT02623660|Active Comparator|Control|This group will receive the standard care and the diagnostic device testing.
2541131|NCT02623244||ovarian endometrioma|Women with ovarian endometrioma noted by ultrasonography.
2541133|NCT02623244||The control group|Women with age and body mass index matched and without ovarian endometrioma in ultrasonography
2541153|NCT02622932|Experimental|Anlotinib and 14C-labeled Anlotinib|each participant will be given a single dose of 14C-labeled gilteritinib.
2541222|NCT02622802|Experimental|ex-vivo placenta perfusion|ex vivo placenta perfusion study with exposure to paracetamol, erythromycin and azithromycin
2541297|NCT02622217|Experimental|Sleep deprived|Participants undergo a simulation session after an on call night
2541303|NCT02622217|No Intervention|Rested|Participants undergo a simulation session after a night of normal sleep at home
2541351|NCT02621853|Other|MRI+RAMAN|Patients will undergo an MRI for assessment of the fat content of the liver. Then during surgery, their livers will be illuminated (for a few seconds) by Raman spectroscope (the device in question) to see if MRI findings correlate well with Raman spectroscopy findings.
2541417|NCT02621567|Experimental|Bright Light Therapy Group|Participants in this group will receive bright light therapy lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
2541418|NCT02621567|Placebo Comparator|Dim Light Group|Participants in this group will receive modified dim lamps and will be instructed to use them for 30 minutes every morning within an hour of waking up, everyday for 4 weeks.
2541502|NCT02620761|Placebo Comparator|Control|Infants in the Placebo arm will receive 0.9% sodium chloride (0.1 ml/hr). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion (in this arm the placebo) will be increased to 0.2 ml/kg/hr. This rate will be continued throughout the remainder of the study.
2541504|NCT02620761|Experimental|Fenoldopam|Infants in the experimental arm will receive fenoldopam (60 ug/ml; 0.1 ml/hr to provide 0.1ug/kg/min). If, after 6 hrs there is not a clinically concerning decrease in blood pressure, as determined by attending physician, the rate of infusion will be increased to 0.2 ml/kg/hr (0.2 ug/kg/min for infants receiving fenoldopam). This rate will be continued throughout the remainder of the study.
2541568|NCT02620163|Experimental|YH22162|YH22162 40/5/12.5 mg (telmisartan 40/amlodipine 5mg/chlorthalidone 12.5mg) for the first 2 weeks, then force titrated to YH22162(telmisartan 80mg/amlodipine 5mg/chlorthalidone 25mg) for the remaining 6weeks
2541570|NCT02620163|Active Comparator|telmisartan/amlodipine|Twynsta(telmisartan 40/amlodipine 5mg) for the first 2 weeks, then force titrated to Twynsta(telmisartan 80mg/amlodipine 5mg) for the remaining 6weeks
2541638|NCT02619916|Experimental|MBCT|Mindfulness-Based Cognitive Therapy
2541639|NCT02619916|Experimental|CBT|Cognitive Behavioral Therapy
2541640|NCT02619916|No Intervention|TAU|Treatment as usual
2541698|NCT02619526|Experimental|Nebivolol|Nebivolol 10mg, once a day
2541702|NCT02619526|Active Comparator|Carvedilol|Carvedilol 25mg, twice a day
2541771|NCT02619097|Experimental|0.08mg/kg|Pegol-sihematide injection, 0.08mg/kg, single-dose
2541773|NCT02619097|Experimental|0.2mg/kg|Pegol-sihematide injection, 0.2mg/kg, single-dose
2541777|NCT02619097|Experimental|0.33mg/kg|Pegol-sihematide injection, 0.33mg/kg, single-dose
2541786|NCT02619097|Experimental|0.5mg/kg|Pegol-sihematide injection, 0.5mg/kg, single-dose
2541794|NCT02619097|Experimental|0.7mg/kg|Pegol-sihematide injection, 0.7mg/kg, single-dose
2542724|NCT02612480|Experimental|Ticagrelor and acetylsalicylic acid|7 day treatment with ticagrelor 2x90mg after a loading dose of 180 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg.
2540539|NCT02627105|Other|Non-beef group|Subjects in this group are asked to avoid all red meats from their diet for the 6 month study.
3202676|NCT00915681|Experimental|Legalon SIL|Silibinin: loading dose of one hour infusion of 5 mg/kg, followed by 20 mg/kg/day infused continuously via pump
2540682|NCT02626104|Experimental|A - Lactoferrin|Bovine lactoferrin orally - 100 mg twice a day, for whole antibiotic treatment period.
2540684|NCT02626104|Placebo Comparator|B - Maltodextrin|Maltodextrin orally - 100 mg twice a day, for whole antibiotic treatment period.
2540726|NCT02625714|Other|A group|Renexin® → SID142
2540731|NCT02625714|Other|B group|SID142 → Renexin®
2540771|NCT02625415|Experimental|Vitamin B6|Topical application of B6 cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
2540772|NCT02625415|Placebo Comparator|Placebo|Topical application of B6 Placebo cream to the hand or/and feet 1-2 ml applied to the hand or /and feet three times a day for 4 weeks.
2540842|NCT02624999|Experimental|Immunotherapy|Subjects in this arm will receive immunotherapy (AlloVax™: CRCL + AlloStim™) twice a week for 4 weeks and then every 4 weeks for an additional 12 weeks
2540843|NCT02624999|Active Comparator|Standard chemotherapy|Subjects in this arm will receive up to six three-week cycles of chemotherapy consisting of cisplatin on day 0 of the 3-week cycle at dose 80-100 mg/m2 IV followed by 1000 mg/m2 IV 5FU on days 1-4 of the cycle
3202677|NCT00915694|Experimental|Single arm|NFV-RT-Tem
3202678|NCT00915707|Experimental|Baseline|Subjects are tested under normal sleep conditions for carbohydrate metabolism and appetite regulation.
2540966|NCT02624232||Patients with anorectal malformations|"Participants are identified through relevant diagnostic codes in ICD-10(Q 42) and ICD-9(75.120, 75.121) in patients which underwent surgery for ARM in the years 1985-2005 are included if informed consent is obtained.~Relevant questionnaires regarding symptoms and QoL are completed before the following examinations:anorectal manometry, endoanal ultrasonography, pudendal nerve conduction velocity, colon transit time, Magnetic resonans(MR)-scan of the pelvis and uroflowmetry."
2541010|NCT02624037|Experimental|Individualized Dosage Precision IFX Dashboard|A clinician will select a dose and dosing frequency that is populated by a pharmacokinetic dashboard system that monitors and aims to dose patients to maintain a target trough infliximab concentration. Dosage and dosing frequency may vary from each patient.
2541074|NCT02623699|Experimental|Single Ascending Dose|Part A: Randomized single ascending dose
2541075|NCT02623699|Experimental|Multiple Ascending Dose|Part B: Randomized multiple ascending dose
2541076|NCT02623699|Experimental|Fixed Dose|Part C: Fixed Dose
2541182|NCT02622958|Experimental|PH94B Nasal Spray|Water based solution of 16 ppm PH94B. Each nasal spray delivers .8 micrograms PH94B in 50 microliters
2541185|NCT02622958|Placebo Comparator|Placebo Nasal Spray|Water based solution, each nasal spray delivers 50 microliters of droplets.
2541205|NCT02622529||Screening through Questionnaires|All of the patients within this single existent Arm will receive the questionnaires.
2541270|NCT02622412|Experimental|Intervention Group|Patients randomised to the intervention group will get immediate access to the Multi-professional breathlessness service (MBS).
2541272|NCT02622412|Other|Control Group|Patients randomised to the control group will get delayed MBS intervention. They will receive standard care and get access to the service after a waiting time of eight weeks.
2541327|NCT02621970|Experimental|IC plus CC plus IMRT plus AC|Induction chemotherapy: TP -- Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 2 cycles; Concurrent chemotherapy: PX -- Cisplatin 25 mg/m2, D1-3 and Xeloda 2000mg/m2, D1-14, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy; Adjuvant chemotherapy: Xeloda 2500mg/m2, D1-14, every 3 weeks for 2 cycles
2541331|NCT02621970|Active Comparator|CC plus IMRT|Concurrent chemotherapy: Cisplatin 100 mg/m2, D1, every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2541408|NCT02621489|Experimental|Bydureon 2 mg Once Weekly|Patients randomised to Bydureon will be treated with Metformin 1g BID, and only receive 10U of Humulin kwickpen QD at bedtime, with no more up-titration of insulin during the study.
2541409|NCT02621489|Active Comparator|Humulin kwickpen|Patients randomised to the comparator group will be treated with Meformin 1g BID and Humulin kwickpen to reach a fP-glucose level of 6 mmol/l. For that reason patients will be instructed to increase the bedtime Insulin dose of 2-4U every third day until this goal is reached.
3202679|NCT00915707|Experimental|Sleep restriction|Subjects are tested under sleep restriction for carbohydrate metabolism and appetite regulation.
3202680|NCT00915707|Experimental|Reduced sleep quality|Subjects are tested under a poor sleep quality condition for carbohydrate metabolism and appetite regulation.
2541535|NCT02620670|Active Comparator|Individuals with obesity|Body mass index (BMI) is 30.0 to 39.9 kg / m2 and a waist circumference greater than 80 cm in women and 90 cm for men Physical activity of moderate intensity for 3 days
2541542|NCT02620670|Active Comparator|Individuals with normal weight|Body mass index BMI is 18.5 to 24.9 kg / m2 with lower waist circumference of 80 cm for women and 90 cm for men Physical activity of moderate intensity for 3 days
2541612|NCT02619968|Experimental|Experimental group|"Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application.~Application of the tourniquet Will be held in conjunction with exercises for the experimental group.~Tennis ball: will initially be 3 sets, where one series with 10 grips, increasing 5 grips every week, 60 seconds rest every series.~Halter: are performed with load of 1 kg, 2 kg and 3 kg. Handgrip: they will be performed 3 sets of dynamic manual hold exercises in the intensity of 40% of MVC.~Home program: at home will be performed isometric exercises with tennis ball on the same frequency as in performing ambulatory without applying the tensiometer."
3202681|NCT00915733|Active Comparator|triple group|"Additive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) in patients with acute myocardial infarction (AMI).~Received cilostazol 100 mg twice daily in addition to aspirin 100 mg and clopidogrel 75 mg once daily."
3202682|NCT00915733|Active Comparator|high maintenance dose group|"High maintenance dose dual antiplatelet therapy in patients with acute myocardial infarction (AMI).~Received clopidogrel 150 mg/day with aspirin 100 mg once daily."
3202683|NCT00915785|Experimental|5 azacytidine|
3202684|NCT00915811|Experimental|FBATG|Haematopoietic stem cell transplantation utilising conditioning with Fludarabine, Busulphan and Thymoglobuline
2540562|NCT02627235|Active Comparator|Wait List Control|Access to the intervention 12 weeks following baseline assessment.
2540580|NCT02626663||aHUS|atypical Hemolytic Uremic Syndrome
2540583|NCT02626663||TTP|Thrombotic thrombocytopenic purpura
2540586|NCT02626663||MAHA|other microangiopathic hemolytic anemias
2540633|NCT02626494|Experimental|Cocaine Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
2540636|NCT02626494|Active Comparator|Healthy Control Group|n-AC and placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 4 doses of n-AC/placebo over 2 consecutive days (total dose=4800mg; individual dose=1200mg). Subjects will take the first 2 doses of n-AC/placebo 5 days after the screening assessment (one in the morning, one in the evening), and the last 2 dose 1h prior to scanning, with 12 hours dosing intervals in between. 14 days later n-AC/placebo will be administered analogously as described above. Preparation and blinding of n-AC and placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
2540675|NCT02626065|Experimental|Nivolumab, patients with BRAF mutation|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
2540677|NCT02626065|Experimental|Nivolumab, patients with BRAF wild type|"Nivolumab (dose equal to 3mg/kg), 10 mg/ml solution for infusion. injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.~Blood sampling at different time"
2540733|NCT02625766|Experimental|Operative|Patients enrolled in the operative treatment group will undergo surgical intervention for their pelvic fracture. The surgeon will decide the best surgical technique as per standard of care for the patient's injury. The patient will mobilize as per the surgeon's instructions and x-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly. If additional surgery is required or other complications arise, this will be recorded within the study follow-up forms.
2540740|NCT02625766|Experimental|Non-operative|Patients enrolled in the non-operative treatment group will not undergo surgical intervention for their pelvic fracture. They will mobilize as per the surgeon's instructions according to standard of care of for this injury. X-rays will be taken at follow-up clinic appointments to determine if the injury is healing properly or if the pelvis has shifted and may warrant surgical intervention. If complications arise and/or surgery is required, crossover will be allowed and recorded within study follow-up forms.
2540788|NCT02625311|Experimental|MIS|Minimal invasive surgery for placement total knee prosthesis
2540792|NCT02625311|Active Comparator|conventional approach|"conventional open surgery for placement total knee prosthesis."
2540903|NCT02624635|Active Comparator|Manual Therapy|The treatment for this group will be manual therapy.
2540905|NCT02624635|Experimental|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip.
3168339|NCT00549835|Sham Comparator|Sham Acupuncture|Newly diagnosed leukemia patients will be recruited from the large patient population on the Leukemia Inpatient Services who will be receiving high dose preperative regimens such as Busulfan + Cytarabine for marrow transplantation.
2540986|NCT02624102|Experimental|Cognitive therapy|Major depressive disorder treated with cognitive therapy (Trial Based Cognitive Therapy plus Drug).
2540989|NCT02624102|Experimental|Behavioral Therapy|Major depressive disorder treated with behavioral therapy (Behavioral Activation plus drug).
2540990|NCT02624102|Other|Antidepressants|Major depressive disorder treated only with antidepressants (Drug alone).
2541045|NCT02623764||MCI due to Alzheimer´s disease|Individuals with MCI diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or Cerebro Spinal Fluid (CSF) analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2541047|NCT02623764||Mild dementia due to Alzheimer´s disease|Individuals with mild dementia and diagnosed with Alzheimer´s disease on the basis of cognitive decline and positive biomarkers by MRI and/or CSF analysis. The intervention is donepezil in recommended doses, 5mg/day for a month and then 10mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2541050|NCT02623764||Mild dementia due to Lewy body disease|Individuals with mild Lewy body dementia. The intervention is Exelon patches in recommended doses, 4.6mg/day for a month and then 9.5mg/day. Cholinergic index in EEG will be measured before initiating treatment, after 3 and 6 months and related to clinical response of treatment
2541095|NCT02623491|Experimental|Part 1: Single Ascending Dose (SAD)|Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
2541096|NCT02623491|Experimental|Part 2: Multiple Ascending Dose (MAD)|Participants will receive JNJ-55375515 (at doses determined based on the data from the SAD part) or Placebo from Day 1 to 10.
2541148|NCT02623140|Experimental|Biofreedom|Biofreedom stent treatment at index procedure
2541150|NCT02623140|Active Comparator|Orsiro|Orsiro stent treatment at index procedure
2541218|NCT02622737|Experimental|Functional Training|Functional exercise training program
2541231|NCT02622737|Experimental|Stationary Bike|Stationary bike training program
2541237|NCT02622737|Experimental|Exergaming|Virtual Reality Exposure Therapy
3168340|NCT00549848|Experimental|HD PEG|"Participants randomized to receive higher dose PEG-asparaginase during the continuation phase.~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
3202685|NCT00915824|Experimental|STOPP/START intervention|STOPP/START intervention group
3168341|NCT00549848|Active Comparator|CD PEG|"Participants randomized to receive conventional dose PEG-asparaginase during the continuation phase..~Interventions:~Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine~Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib"
3168342|NCT00549861|No Intervention|A1|CMR study for the assessment of irreversible tissue damage
2540674|NCT02626390|Experimental|Implicit Learning|Physiotherapy delivered based on implicit treatment guidance - achieved primarily by reducing the frequency of verbal coaching statements and promoting an external focus of attention.
2540676|NCT02626390|Active Comparator|Explicit Learning|Physiotherapy delivered based on explicit treatment guidance - achieved primarily by giving frequent verbal coaching statements and promoting an internal focus of attention.
2540747|NCT02625870|Experimental|Omega-3-Acid Ethyl Esters 90 Soft Capsules|
2540750|NCT02625870|Placebo Comparator|Corn Oil|
2540773|NCT02625389|Experimental|Embolization with Lipiodol Ultra Fluid and glue|
2540798|NCT02625129||Pharmacist-provided travel care|
2540845|NCT02624960|Experimental|Accucinch Implant|Accucinch Implant procedure is completed
2541023|NCT02624245|Experimental|Experimental: Conventional Physical Therapy|Strength, this arm will receive hip and knee muscle strengthening with and without weight bearing.
2541026|NCT02624245|Active Comparator|Movement control training|Movement control training, this arm will receive movement control training associated to muscle strengthening.
2541114|NCT02623387|Active Comparator|Standard Paravertebral Block|Patients receiving a conventional paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered using anatomical landmarks
2541116|NCT02623387|Active Comparator|Ultrasound Guided Paravertebral Block|Patients receiving paravertebral block of dilute local anaesthetic (eg. 5ml of 0.5% bupivacaine or similar) administered under ultrasound guidance
2541151|NCT02623036|Active Comparator|Enalapril arm|Patients randomized to this group will receive equivalent dose enalapril to their current ACEI therapy and change the administration time to bedtime.
2541154|NCT02623036|Active Comparator|Lisinopril arm|Patients randomized to this group will receive equivalent dose lisinopril to their current ACEI therapy and change the administration time to bedtime.
2541211|NCT02622672|Experimental|Placebo|glycerin.soy-lecithin, and water
2541219|NCT02622672|Experimental|Supplement|water-soluble Ubiquinol 100 mg/d
2541281|NCT02622282|Experimental|Experimental Group|Participants will receive text messages and telephone calls during the length of their participation. Participants will receive a handout with information on PAD and physical activity.
2541286|NCT02622282|Active Comparator|Control Group|Participants will receive a handout with information on PAD and physical activity.
2541334|NCT02621866|Experimental|Active|UVA irradiation.
2541337|NCT02621866|Sham Comparator|Sham UVA irradiation|
2541401|NCT02621645|Experimental|Early intervention|Intervention between 12.0 and 14.0 weeks. Early selective reduction of TRAP mass.
2541402|NCT02621645|Active Comparator|Late intervention|Intervention between 16.0 and 19.0 weeks. Late selective reduction of TRAP mass. This is the standard timing of the intervention. One of two possible techniques for late reduction is chosen by the treating physician.
2541459|NCT02620943||Exposed Group|Pregnant mothers reporting inadequate (<4) dietary diversity during pregnancy
2541465|NCT02620943||Unexposed group|Pregnant mothers reporting adequate (>=4) dietary diversity during pregnancy
2541578|NCT02620358|Experimental|High Work of Breathing|"If patient has weaning criteria, a Spontaneous Breathing Trial (SBT) with T Tube for 2 hours will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
2541579|NCT02620358|Experimental|Low Work of Breathing|"If patient has weaning criteria a Spontaneous Breathing Trial (SBT) with Pressure Support Ventilation of 8 cmH2O for 30 minutes will be done.~The patient will be extubated after the SBT if he has no criteria of SBT failure."
2541614|NCT02619955||Rare iron overload with hepcidin deficiency|clinical, biological, and genetic analysis of rare iron overlaod phenotype (except C282Yhomozygisity), samples with DNA
2541658|NCT02619604|Other|Clinician education|
2541775|NCT02618811||Group 1|not sarcopenic
2541779|NCT02618811||Group 2|sarcopenic
2541788|NCT02618811||Group 3|not myosteatotic
2541796|NCT02618811||Group 4|myosteatotic
2541845|NCT02618629|Experimental|14C-Z-215|
2542798|NCT02612298|Experimental|arotinolol|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks
3168343|NCT00549874|Experimental|1|
3168344|NCT00549874|Experimental|2|
3168345|NCT00549887||Rapid acting to short acting|Patients on rapid-acting analog insulins who switch to short-acting human insulin
3168346|NCT00549887||Short acting to rapid acting|Patients on short-acting human insulins who switch to rapid-acting analog insulin
3168347|NCT00549913|Experimental|1|10 subjects to receive lowest dose of NeoFuse (MPCs)
3168348|NCT00549913|Active Comparator|2|4 subjects standard posterolateral spinal fusion with instrumentation
3168349|NCT00549913|Experimental|3|10 subjects to receive middle dose of NeoFuse
3168350|NCT00549913|Active Comparator|4|3 subjects standard posterolateral spinal fusion with instrumentation
3168351|NCT00549913|Experimental|5|10 subjects to receive highest dose of NeoFuse
3168352|NCT00549913|Active Comparator|6|3 subjects with standard posterolateral spinal fusion with instrumentation
3168353|NCT00549926|Active Comparator|1|
3168354|NCT00549926|Active Comparator|2|
3168355|NCT00549926|Active Comparator|3|
3168356|NCT00549926|Active Comparator|4|
3168357|NCT00549978|Other|1|Two compartments with cross-over and parallel
3168358|NCT00549978|Other|2|Two compartments with cross-over and parallel
3168359|NCT00550004|Active Comparator|Arm 1|RP101 and Gemcitabine
3168360|NCT00550004|Placebo Comparator|Arm 2|Placebo and Gemcitabine
3168361|NCT00550017|Experimental|1|
3168362|NCT00550030|Experimental|left/right|half-body comparison
3168363|NCT00550056|Experimental|1|NET
3168364|NCT00550056|Experimental|2|TC
3168365|NCT00550056|No Intervention|3|Monitoring Group
3168366|NCT00550095|Experimental|1|valsartan
2540613|NCT02626585|No Intervention|Control|Control group (n=20): Following removal of nasal cast on postoperative first week, no additional taping was applied to this group.
2540616|NCT02626585|Experimental|2-weeks of PRT|2-weeks of PRT (n=17): Following removal of nasal cast on postoperative first week, 2 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 3rd week).
2540617|NCT02626585|Experimental|4-weeks of PRT|4-weeks of PRT (n=20): Following removal of nasal cast on postoperative first week, 4 weeks of additional postrhinoplasty taping was applied to this group (form 1st to 5th week).
2540663|NCT02626195|Experimental|nutritional support program apply|Preoperative nutritional support program is given for 5 or more days preoperatively by nutritional support program.
2540665|NCT02626195|No Intervention|historical control group|Historical control group is that did not receiving
3202686|NCT00915837|Experimental|Slow release formulation|Slow release formulation, helical intravitreal triamcinolone implant
3202687|NCT00915837|Experimental|fast release formulation|fast release formulation, helical intravitreal triamcinolone implant
2540724|NCT02625532|Active Comparator|Follicular phase|Controlled ovarian stimulation starts during follicular phase on day 2-3 of the menstrual cycle
2540730|NCT02625532|Experimental|Luteal phase|Controlled ovarian stimulation starts during luteal phase on day 3 to 5 after first LH positive urine test
2540789|NCT02625376|Experimental|Trans-Resveratrol|capsule of 250 mg of resveratrol. two capsules daily : one in the morning and evening for 24 months
2540795|NCT02625376|Active Comparator|Resvega|"capsule composed of antioxydant, omega 3, carotenoid, 15 mg of resveratrol, zinc and copper.~two capsules daily : one in the morning and evening for 24 months"
2540806|NCT02625376|Placebo Comparator|Placebo|capsule of medium chain triglyceride. two capsules daily : one in the morning and evening for 24 months
2540891|NCT02624882|Experimental|Positive rapid Group A Streptococcus (GAS) test|In case of positive rapid GAS test, patients will be treated by antibiotics: amoxicillin 50mg/kg/d during 10 days or cefpodoxime 8mg/kg/d during 10 days in case of betalactamine allergy
2540893|NCT02624882|Active Comparator|Negative rapid GAS test|If case of negative rapid GAS test, usual care: local antiseptic or surgical intervention
2540946|NCT02624531|Other|fertility-sparing surgery|NACT with Taxane combined with cisplatin and Fertility-sparing Treatment Strategy
3202688|NCT00915850|Experimental|Anticancer drug|docetaxel, cisplatin and 5-FU
3202689|NCT00915863|Active Comparator|Billroth-II-type|Billroth-II-type reconstruction after pancreaticoduodenectomy
3202690|NCT00915863|Experimental|Isolated Roux-en-Y|Isolated Roux-en-Y type reconstruction after pancreaticoduodenectomy
3202691|NCT00915889|Active Comparator|Group I|Patients receive a survivorship booklet in the mail that contains information about cervical cancer. Patients then receive a follow-up telephone call at 3 months to clarify any issues relevant to the survivorship booklet.
3202692|NCT00915889|Experimental|Group II|Patients are randomly assigned to receive either 6 or 8 weekly telephone sessions that address managing medical issues, health education, and cancer resources; balancing emotions and managing stress; coping skills and problem solving; family and social concerns; relational, intimacy, and sexual concerns; and financial and employment concerns. Patients also receive a survivorship booklet as in group I.
3202693|NCT00915915|Experimental|Arm 1|
3202694|NCT00915915|Experimental|Arm 2|
2541259|NCT02622451|Other|Youth Behavioral Intervention|Teen Intervene
2541260|NCT02622451|Other|Parent Education|Everyday Parenting
2541298|NCT02622087|Experimental|Hormonal contraceptive|Women who receive one-session-treatment while they are on the hormonal contraceptive pill
2541301|NCT02622087|Experimental|Naturally cycling- high estradiol|Naturally cycling women who receive one-session-treatment during a period of high estradiol
2541307|NCT02622087|Experimental|Naturally cycling-low estradiol|Naturally cycling women who receive one-session-treatment during a period of low estradiol
2541350|NCT02621749|Active Comparator|CRRT group|the CRRT group receives continuous renal replacement therapy for acute kidney injury
2541352|NCT02621749|Active Comparator|IRRT group|the IRRT group receives intermittent renal replacement therapy after termination of CRRT.
2541387|NCT02621541|Experimental|Preoperative diagnosis|Preoperative diagnosis
2541433|NCT02621294|Experimental|Measuring protein requirement|Measuring protein requirement of athletes by feeding different amount of protein in the form of amino acid mixture and measuring their oxidation through expired CO2
2541477|NCT02620969||Patients on haemodialysis|During a midweek session of a patient on haemodialysis, blood and dialysate sampling is performed at different time points.
2541533|NCT02620644|Other|G1 Diabetics with no retinpathy|Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
2541543|NCT02620644|Other|G2 Non diabetics|Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
2541589|NCT02620267|Experimental|tDCS Stimulation|Each subject will receive all three types of stimulation on separate days- anodal, cathodal, and sham stimulation
2541632|NCT02619851|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
2541633|NCT02619851|Active Comparator|Conventional Therapy|Typical therapy conducted for burn injury patients
3202695|NCT00915980||Patients without diabetes undergoing gastric bypass|
3202696|NCT00916019|Experimental|exercise|mild exercise training
2542725|NCT02612480|Active Comparator|Clopidogrel and acetylsalicylic acid|7 day treatment with clopidogrel x75 mg after a loading dose of 300 mg and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
3202697|NCT00916045|Other|Myeloblative conditioning regimen|
3202698|NCT00916045|Other|Reduced intensity conditioning regimen - FluCyTBI|
3202699|NCT00916045|Other|Reduced intensity conditioning regimen - FluMel|
3202700|NCT00916071||Eating Disorders|Study subjects will be individuals with a history of eating disorder(s) diagnosis
3202701|NCT00916084|Experimental|Group A|
3202702|NCT00916084|Experimental|Group B|
3202703|NCT00916097|Experimental|1|docetaxel 75mg/m2 in combination with cisplatin 75mg/m2 given every 3 weeks for 3 cycles
3202704|NCT00916110|Experimental|1.5mgSC|ATN-103
3202705|NCT00916110|Experimental|4mgSC|ATN-103
3202706|NCT00916110|Experimental|10mgSC|ATN-103
2540857|NCT02624973|Experimental|A|ER/PGR>50% TP53 wt
2540858|NCT02624973|Experimental|B|ER/PGR>50% TP53 mutated
2540861|NCT02624973|Experimental|C|ER/PGR<50% TP53 wt
2540866|NCT02624973|Experimental|D|ER/PGR<50% TP53 mutated
2540869|NCT02624973|Experimental|E|HER2+ TP53 wt
2540872|NCT02624973|Experimental|F|HER2+ TP53 mutated
2540873|NCT02624973|Experimental|G|Triple negative breast cancer TP53 wt
2540879|NCT02624973|Experimental|H|Triple negative breast cancer TP53 mutated
3168367|NCT00550108|No Intervention|A|Observation of pancreatic cysts
2541011|NCT02623881|Active Comparator|Cervical pessary|Cervical pessary (Arabin) will be inserted to participants at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
2541014|NCT02623881|Active Comparator|Vaginal Progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort.
2541055|NCT02623647|Other|A single-arm, nonrandomized|stereotactic body radiotherapy SBRT, 40 Gy for 3 fractions
2541097|NCT02623374|Experimental|SH-CBT|This intervention will be a tailored CBT intervention adapted from the previously validated (Ayres, et al., 2012) self-help CBT intervention that comprises of a self-help booklet containing information, advice, a relaxation CD and daily diaries. This intervention lasts 4 weeks (approx. 4 hours per week) and the materials guide the individual through each chapter and exercise, including the homework set out for each chapter.
2541098|NCT02623374|No Intervention|No Treatment-Wait Control (NTWC)|Women will be offered no intervention but will complete questionnaires at the same assessment points as the intervention/treatment arm participant group (i.e. baseline (A0), 6 weeks (A1), 20 weeks (A2) post randomisation). They will be offered the SHCBT intervention off trial following the final assessment (i.e. A2).
2541169|NCT02623153|Active Comparator|capecitabine and oxaliplatin|capecitabine of 1000 mg/m2, orally administered twice a day on days 1-14 and oxaliplatin at 130 mg/m2on day 1, as intravenous 2 h infusion
2541170|NCT02623153|Experimental|S1, oxaliplatin and docetaxel|S1 of 40 mg/m2, orally administered twice a day on days 1-14,oxaliplatin 130 mg/m2 and docetaxel 40 mg/m2on day 1 as intravenous
2541234|NCT02622581||NSCLC, Non-squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.~3,250 patients with non-squamous cell carcinoma will be tested for molecular alterations. (CRISP)"
2541240|NCT02622581||NSCLC, Squamous cell carcinoma|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.~1,750 patients with squamous cell carcinoma that possibly will be tested for molecular alterations. (CRISP)"
2541243|NCT02622581||NSCLC, Non-squamous cell carcinoma (not tested)|"Patients with locally advanced or metastatic NSCLC at the start of palliative first-line systemic therapy.~Not tested for molecular alterations (CRISP satellite untested patients stage IIIB/IIIC/IV).)."
2541246|NCT02622581||NSCLC, Stage II/III|800 patients with NSCLC stage II, or stage IIIA, or with NSCLC stage IIIB/C if they are eligible for curative surgery and/or radiochemotherapy
2541247|NCT02622581||Small cell lung cancer (SCLC)|Up to 1200 patients with SCLC (limited stage (LD) or extensive stage (ED)) if they are eligible for surgery and/or radio(chemo)therapy and/or systemic therapy, or are receiving best supportive care
2541420|NCT02621437|Experimental|Intervention group (osteopathy)|Patients will have three sessions of osteopathy and 6 phone questionnaires.
2541421|NCT02621437|Other|control group|Patients will have 6 phone questionnaires.
2541446|NCT02621125|Experimental|Fertilix|Fertilix supplementation
2541447|NCT02621125|Placebo Comparator|Placebo|Placebo
2541497|NCT02620839|Experimental|Cohort 1A|Alpelisib: 200 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2541501|NCT02620839|Experimental|Cohort 2A|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2541505|NCT02620839|Experimental|Cohort 2B|Alpelisib: 250 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2541506|NCT02620839|Experimental|Cohort 3A|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2541509|NCT02620839|Experimental|Cohort 3B|Alpelisib: 300 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2541512|NCT02620839|Experimental|Cohort 4A|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 30 mg/m^2, intravenously, days 1, 8, 15
2541513|NCT02620839|Experimental|Cohort 4B|Alpelisib: 350 mg/day, orally, days 1-21 Cisplatin: 35 mg/m^2, intravenously, days 1, 8, 15
2541571|NCT02620371|Placebo Comparator|(bupivacaine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine)
2541573|NCT02620371|Active Comparator|(bupivacaine, ketamine)|30 patients were given preoperative ultrasound guided, modified pectoral block (pecs II block) with local anesthetic(0.25% bupivacaine plus ketamine 1 mg/kg) .
2541613|NCT02619994|Active Comparator|Control Arm|"Regimen is the locally-used WHO-approved MDR-TB regimen in Korea based on 2014 Korean guideline of TB management.~Intensive phase regimen consists of four effective second-line anti-TB drugs (including injectables) and pyrazinamide.~Treatment duration: for at least 20 months"
2542726|NCT02612740|Experimental|Test Group|The bone defect was filled with granules of deproteinized bovine bone (Bio-Oss, Geistlich Pharm, AG Wolhausen, Switzerland)
3168368|NCT00550108|Experimental|B|Ethanol lavage of pancreatic cysts
3168369|NCT00550121|Experimental|1|
3168370|NCT00550121|Placebo Comparator|2|
3168371|NCT00550160|Active Comparator|1|The Home Management of Malaria (HMM) is a strategy aimed at improving access to prompt and effective antimalarial treatment of all fevers in children under 5 years. Community Drug Distributors (CDD) have been trained and equipped for this task.
3168372|NCT00550160|Experimental|2|An Intermittent Preventive Treatment (IPTc) schedule for asymptomatic pre-school children during high malaria transmission seasons alongside an ongoing Home Management of Malaria programme
3168373|NCT00550186|Placebo Comparator|1|No preload
3168374|NCT00550186|Active Comparator|2|Preload with cristalloid infusion
3168375|NCT00550186|Active Comparator|3|Preload with collid infusion
3168376|NCT00550199|Experimental|LBH589 and Gemcitabine|Phase I dose escalation study
2540644|NCT02626351|Experimental|Receiving/ received QI intervention|A clinic which is presently receiving the Intensive Phase of the QI intervention, or is in the Maintenance Phase
2540645|NCT02626351|Active Comparator|Not yet received QI intervention|A clinic which has not yet received the QI intervention
3202707|NCT00916110|Experimental|25mgSC|ATN-103
3168377|NCT00550212|Experimental|1|240 mg
2540819|NCT02625064||1: patient at High risk for ARDSp|Severe pneumonia and（PaO2/FIO2）>300mmHg
2540823|NCT02625064||2: patient at High risk for ARDSexp|Severe sepsis and without ARDS
2540824|NCT02625064||3: mild ARDS|PaO2/FiO2=201～300 mmHg，and PEEP or CPAP≤5 cm
2540826|NCT02625064||4: moderate ARDS|PaO2/FIO2=101～200 mmHg，且PEEP≥5 cm H2O
2540827|NCT02625064||5: severe ARDS|PaO2/FIO2≤100 mmHg，且PEEP≥10 cm H2O
3202708|NCT00916110|Experimental|25mgIV|ATN-103
3202709|NCT00916110|Experimental|50mgSC|ATN-103
2540952|NCT02624388|Experimental|Arm A: Genistein followed by Placebo|Genistein daily throughout chemotherapy cycles 1 and 2, and placebo daily during chemotherapy cycles 3 and 4
2540955|NCT02624388|Experimental|Arm B: Placebo followed by Genistein|Placebo daily throughout chemotherapy cycles 1 and 2, and genistein daily during chemotherapy cycles 3 and 4
2541016|NCT02624024||Acute chest pain or equivalent ischemic symptoms|acute chest pain or equivalent ischemic symptoms suggestive of acute coronary syndromes (ACS) or acute myocardial infarction (MI)
2541067|NCT02623686|Experimental|Aroma group|"two massages delivered within a two day period~the patient will choose the essential oils used from blend A and blend B (if no choice is made, therapist will choose blend A and B alternately). One drop of the essential oil blend will be added to 5 mls of grapeseed base oil.~an Inhalation Patch with the same blend of oils as used in the massage will be left by the therapist for use on each of the two nights following the aromatherapy massage intervention. Its use will be explained to the patient and to the member of nursing staff. The Inhalation Patch will be applied to the patient's upper chest when it is time to sleep at approximately 11 pm and will be removed the following morning at approximately 6 am."
2541070|NCT02623686|No Intervention|Control Group|Normal Care
3202710|NCT00916110|Experimental|100mgSC|ATN-103
3202711|NCT00916110|Experimental|200mgSC|ATN-103
3202712|NCT00916110|Experimental|200mgIV|ATN-103
3202713|NCT00916123|Experimental|Dose Level 1|177Lu-J591 at 20 mCi/dose
3202714|NCT00916123|Experimental|Dose Level 2|177Lu-J591 at 25 mCi/dose
3202715|NCT00916123|Experimental|Dose Level 3|177Lu-J591 at 30 mCi/dose
2541439|NCT02621580|No Intervention|Control|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and do not require laser or anti-VEGF treatment in at least one eye.
2541440|NCT02621580|Experimental|Treatment: Pan-Retinal Photocoagulation|Patients with type 1 or type 2 diabetes mellitus (according to ADA or WHO guidelines) that have severe preproliferative or proliferative diabetic retinopathy and require PRP laser in at least one eye.
2541515|NCT02620696|Experimental|Treatment 1|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-42"
2541520|NCT02620696|Experimental|Treatment 2|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14, and from Days 29-42"
2541523|NCT02620696|Experimental|Treatment 3|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 25 mg daily for 14 days (Days 29-42)~netazepide placebo daily from Days 1-28"
2541524|NCT02620696|Experimental|Treatment 4|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide placebo daily from Days 1-28"
2541525|NCT02620696|Experimental|Treatment 5|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 1 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
2541526|NCT02620696|Experimental|Treatment 6|"esomeprazole 40 mg daily for 28 days (Days 1-28)~netazepide 5 mg daily for 14 days (Days 15-28)~netazepide placebo daily from Days 1-14"
2542728|NCT02612480|Placebo Comparator|Placebo and acetylsalicylic acid|7 day treatment with placebo and acetylsalicyclic acid 1x80mg after a loading dose of 160 mg
3168378|NCT00550225|Experimental|Sequence 1|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
3168379|NCT00550225|Experimental|Sequence 2|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
3168380|NCT00550225|Experimental|Sequence 3|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by placebo in session 2. The subjects will receive 1500 micrograms of GSK961081edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
3168381|NCT00550225|Experimental|Sequence 4|In session 1, subjects will receive 300 microgram GSK961081 succinate followed by 1500 micrograms of GSK961081 edisylate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
3168382|NCT00550225|Experimental|Sequence 5|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and placebo in session 4.
3202716|NCT00916123|Experimental|Dose Level 4|177Lu-J591 at 35 mCi/dose
3202717|NCT00916123|Experimental|Dose Level 5|177Lu-J591 at 40 mCi/dose
3202718|NCT00916175|Placebo Comparator|P1&P2|Food product P1&P2 is composed of: placebo1(mimic aloe vera gel) 30ml and placebo2 (mimic Cnidoscolus chayamansa infusion) 200ml;
3202719|NCT00916175|Experimental|P1&CC|Food Product P1&CC contains: placebo1 (mimics liquified aloe vera gel) 30ml and Cnidoscolus Chayamansa infusion 200ml;
3202720|NCT00916175|Experimental|AG&P2|Food product AG&P2 contains (liquified aloe vera gel) 30ml and placebo2 (mimic CC infusion) 200ml.
3202721|NCT00916175|Experimental|AG&CC|Food product AG&CC is composed of: liquified aloe vera gel 30ml and Cnidoscolus Chayamansa infusion 200ml
3202722|NCT00916175|Experimental|TA (concentrated 5:1 aloe vera gel)|Food product TA contains concentrated 5:1 aloe vera gel by total process30 ml and purified water 200 ml.
2540648|NCT02626338|Experimental|Arm C|"Fludarabine~Cytarabine~G-CSF~Idarubicin~Crenolanib"
2540725|NCT02625857|Experimental|Dose Cohort 1A and 1B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
2540728|NCT02625857|Experimental|Dose Cohort 2A and 2B|JNJ-64041809 will be administered intravenously (IV) once every 21 days.
3202723|NCT00916175|Placebo Comparator|P3|Food product Placebo 3 contains stabilizers and preservative used for TA 30 ml and purified water 200 ml.
3202724|NCT00916188|Experimental|Black Tea-Four Doses|One, 2, 3 and 4 cups (150 ml/cup) of Black tea/day for week 1, 2, 3, and 4, respectively.
2540882|NCT02624726|Experimental|FOLFIRI/Aflibercept|5 Fluorouracil/Leucovorin/Irinotecan/Aflibercept
2540936|NCT02624427|Experimental|Glaucoma Eyes|Measurement of intraocular pressure (IOP)
2540937|NCT02624427|Active Comparator|Healthy Eyes|age-matched healthy eyes as controls will undergo Measurement of intraocular pressure (IOP)
2540992|NCT02624219|Experimental|Group 1|N = 55 receive 7.5 mcg A/H5N8 + AS03 on Day 1, 22
2540994|NCT02624219|Experimental|Group 2|N = 55 receive 7.5 mcg A/H5N8 + MF59 on Day 1, 22
2540995|NCT02624219|Experimental|Group 3|N = 55 receive 15 mcg A/H5N8 unadjuvanted on Day 1, 22
2540996|NCT02624219|Experimental|Group 4|N = 55 receive 15 mcg A/H5N8 + AS03 on Day 1, 22
2540997|NCT02624219|Experimental|Group 5|N = 55 receive 15 mcg A/H5N8 + MF59 on Day 1, 22
2541066|NCT02623712|Active Comparator|More Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
2541072|NCT02623712|Active Comparator|Less Frequent CT Surveillance|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
2541119|NCT02623309|Experimental|HAPLO graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 4 days: from D-5 à J-2.~Busulfan IV : 130 mg/m2/day for 2 days : drom D-4 to D-3. + 1 day of Thiotepa : 5mg/kg at D-6.~Prophylaxis regimen for GVHD~F CSA and MMF (starting day +5)~Additional immunosuppression: PT-HDCy (50 mg/kg/day) on days +3 and +4~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg GCSF (Neupogen ®) during 4 to 5 days (D-4 to D-1): SC 10 µg/kg/d."
2541120|NCT02623309|Active Comparator|MUD graft|"Conditioning regimen~Fludarabin : 30 mg/m2/day for 5 days: from D-6 to D-2.~Busulfan IV : 130 mg/m2/day for 2 days: from D-4 to D-3.~Prophylaxis regimen for GVHD~CSA and MMF will be used from day -1 after UD~Additional immunosuppression: Rabbit ATG (2.5 mg/kg/day) on days -3 and -2~Hematopoietic Stem Cell Graft PBSC graft will be preferred for a minimal targeted cell dose of 4 x 106 CD34+cells/kg"
2541149|NCT02622971|Active Comparator|PBMT and Cryotherapy|Volunteers allocated in this group received phototherapy (PBMT - applied in six points of quadriceps) and cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2541152|NCT02622971|Active Comparator|Cryotherapy and PBMT|Volunteers allocated in this group received cryotherapy (20 minutes in PRICE protocol) and phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2541155|NCT02622971|Active Comparator|PBMT (active phototherapy)|Volunteers allocated in this group received active phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol.
2541156|NCT02622971|Placebo Comparator|PBMT (placebo phototherapy)|Volunteers allocated in this group received placebo phototherapy (PBMT - applied in six points of quadriceps) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. The placebo PBMT device was identical to the active devices and displayed the same settings and emitted the same sound regardless of the comparator.
2541158|NCT02622971|Active Comparator|Cryotherapy|Volunteers allocated in this group cryotherapy (20 minutes in PRICE protocol) as a treatment three minutes and 24h, 48h and 72h after exercise protocol. Two flexible ice packs filled with ice cubes and water (with a volume of 1.15 liters each) were used in order to cover the entire quadriceps. Rubber belts were used to apply compression and to affix the packs tightly to the volunteers' quadriceps.
2541250|NCT02622659|Experimental|Fuganlin Oral Liquid|"Fuganlin Oral Liquid:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day~Xiaoer Jiebiao Oral Liquid placebo:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
2541254|NCT02622659|Active Comparator|Xiaoer Jiebiao Oral Liquid|"Xiaoer Jiebiao Oral Liquid:oral~1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day~Fuganlin Oral Liquid placebo:oral~less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
2541277|NCT02622126|Active Comparator|Normotensive pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
2541279|NCT02622126|Active Comparator|Mild preeclampsia pregnant women group|"Preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6% 130/0.4) (Voluven).~Sub arachnoid 10-12 mg hyperbaric bupivacaine Sub arachnoid 200 meg morphine Isotonic 0.9 sodium chloride (NaCl) solution (NaCl) solution ( 10 ml/kg) will be used as co loading during the duration of the operation Ephedrine 6 me intravenous will be used to treat severe hypotension (fall of > 20% of mean arterial pressure from baseline) Atropine 0.5 mg intravenous will be used to treat bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension)"
2541381|NCT02621710||Minimally invasive hysterectomy|Patients undergoing scheduled minimally invasive hysterectomy (vaginal, laparoscopic, robotic) for benign condition
2541382|NCT02621710||Abdominal hysterectomy|Patients undergoing scheduled abdominal hysterectomy for benign condition
2542729|NCT02612740|No Intervention|Control Group|No filling material was used in the bone healing
2540668|NCT02626481|Experimental|Daratumumab + Dexamethasone|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
3202725|NCT00916188|Active Comparator|Black Tea-One Dose|One cup (150 ml) of Black tea/day during study.
2540778|NCT02625194|Experimental|Oxygen|Oxygen is supplied through suction port in bronchoscope during bronchoscope-guided intubation.
2540781|NCT02625194|No Intervention|Control|Bronchoscope-guided intubation is performed without oxygen supply.
2540835|NCT02625038|Experimental|Interventional|3D-planned osteotomies with patient-specific guides
2540860|NCT02624778|Experimental|LY3002813 Single dose 1|LY3002813 administered intravenously (IV) once
2540865|NCT02624778|Experimental|LY3002813 Single dose 2|LY3002813 administered IV once
2540868|NCT02624778|Experimental|LY3002813 Single dose 3|LY3002813 administered IV once
2540871|NCT02624778|Experimental|LY3002813 Multiple dose 1 x 24 wks|LY3002813 administered IV for 24 wks
2540874|NCT02624778|Experimental|LY3002813 Multiple dose 2 x 24 wks|LY3002813 administered IV for 24 weeks
2540878|NCT02624778|Experimental|LY3002813 Multiple dose 3 x 72 wks|LY3002813 administered IV for 72 wks
2540881|NCT02624778|Experimental|LY3002813 Multiple dose 4 x 72 weeks|LY3002813 administered IV for 72 wks
2540883|NCT02624778|Placebo Comparator|Placebo given once|Placebo administered IV once
2540884|NCT02624778|Placebo Comparator|Placebo x 24 weeks|Placebo administered IV for 24 wks
2540886|NCT02624778|Placebo Comparator|Placebo x 72 weeks|Placebo administered IV for 72 wks
2540950|NCT02624401|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion.
2540954|NCT02624401|Experimental|Propofol|Intravenous propofol using target controlled infusion.
2540958|NCT02624401|Experimental|S-ketamine|Intravenous S-ketamine using target controlled infusion.
2540959|NCT02624401|Experimental|Sevoflurane|Inhalational sevoflurane using target controlled inhalation.
2540960|NCT02624401|Placebo Comparator|Placebo|Intravenous saline.
3202726|NCT00916201|Experimental|Intranasal Insulin|Intranasal administered insulin
3202727|NCT00916201|Experimental|Cannabidiol CR|Cannabidiol is the main non psychoactive compound of the Cannabis sativa plant.
2541102|NCT02623465|Experimental|Part A:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin once in each of 3 periods
2541104|NCT02623465|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin once in each of 3 periods
2541106|NCT02623465|Experimental|Part B:Insulin Lispro Test|Individualized doses of insulin lispro test formulation administered by injection under the skin with each meal for 14 days
2541109|NCT02623465|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of insulin lispro reference formulation administered by injection under the skin with each meal for 14 days
2541172|NCT02623101|Active Comparator|Standard of care procedure|"Clinical suspected basal cell carcinomas, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most clinical suspicious part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. Hematoxylin/eosin stained sections of the punch biopsies will be evaluated by an experienced pathologist. Subjects will receive surgical excision according to subtype.~When there is any doubt by reflectance confocal microscopic diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma."
2541175|NCT02623101|Experimental|Reflectance confocal microscopy (RCM)|The Vivascope 1500 and Vivascope 3000 (handheld divice) will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed on clinical suspected basal cell carcinomas, of all subtypes. When there are signs of a basal cell carcinoma imaged by RCM, subjects will receive surgical excision according to subtype. When there is any doubt by RCM diagnosis, a punch biopsy will also be obtained and the lesion will be excized when the biopsy reveals a basal cell carcinoma.
2541212|NCT02622516|Active Comparator|Intervention Group (IG)|Participants in the intervention group subjects (IG) will receive physiotherapy treatment in vestibular rehabilitation based on multisensory exercises consisting of the group of therapeutic proposals that stimulation of the vestibular, proprioceptive and visual associated with manual therapy treatment proposed by the techniques cervical global pompage and classic massage therapy on neck and shoulder girdle .
2541216|NCT02622516|Experimental|Control Group (CG)|Participants in the control group subjects (CG) will receive physiotherapy treatment in vestibular rehabilitation based on Cawthorne and Cooksey Exercises, consisting of eye movements in different directions, slowly and quickly; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
2541356|NCT02621840|Experimental|Intervention|Patients in the intervention group will be mandated to complete the PAT with Dr. Koka. After scheduling the surgery with the surgical coordinator, intervention patients will be required to go directly to Dr. Koka's office, to complete all necessary pre-operative steps.
2541398|NCT02621593|Experimental|Treatment of dry eye secondary to MGD|Intervention: Treatment of dry eye symptoms secondary to MGD with the M22-IPL system
3202728|NCT00916201|Experimental|URB597|URB597 is a selective inhibitor of the Fatty acid amide hydrolase enzyme.
3202729|NCT00916214|Experimental|Intervention|
3202730|NCT00916227|Experimental|ARRY-614|
3202731|NCT00916240|Experimental|1|Participants will receive Multisystemic Therapy (MST).
3202732|NCT00916240|Active Comparator|2|Participants will receive home-based, non-directive family support.
3202733|NCT00916253|Experimental|Modafinil First|Treatment by Modafinil during first condition then placebo during second condition
3202734|NCT00916253|Experimental|Placebo First|Treatment by Placebo during first condition then Modafinil during second condition
3202735|NCT00916253|No Intervention|H|Healthy Volunteers
3202736|NCT00916266|Experimental|stem cell transplantation|Patients with refractory temporal lobe epilepsy that are transplanted with autologous bone marrow stem cells in order to provide seizure control.
2540765|NCT02625558|Active Comparator|Riociguat|Active drug
2540768|NCT02625558|Placebo Comparator|Placebo|placebo
2540782|NCT02625142|Experimental|Family-centered rounds checklist|"During the post-intervention period, health care team members on two pediatric inpatient services received the Family-centered Rounds Checklist tool, as well as training in how to use the checklist in the delivery of effective family-centered rounds"
2540784|NCT02625142|No Intervention|Usual care|Two pediatric inpatient services were not provided the Family-centered rounds checklist tool, and delivered morning rounds in their usual manner. These services served as a control.
2540849|NCT02625025|Experimental|Low pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Low Pression Pneumoperitoneum (8 mm Hg)
2540853|NCT02625025|Experimental|Standard pression pneumoperitoneum|Patients undergoing Single Port Access Laparoscopy for benign adnexal pathology with use of Standard Pression Pneumoperitoneum (12 mm Hg)
2540914|NCT02624609|Placebo Comparator|Control without pomegranate juice|Control meal will be white bread and a glass of water containing the same amounts of sugars naturally present in the pomegranate juice.
2540915|NCT02624609|Experimental|Test with pomegranate juice|Test meal will be white bread with a glass of pomegranate juice
2540951|NCT02624362|Experimental|Odor+ Positive belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor improves asthma symptoms (therapeutic suggestion)
2540956|NCT02624362|Experimental|Odor + Negative belief|Participants receive 15 minute odor presentation (Phenylethyl Alcohol odor) accompanied by the suggestion that this odor worsens asthma symptoms (asthmogenic suggestion)
2540982|NCT02624011|Experimental|Physical inactivity|Study arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
3202737|NCT00916292|Experimental|Low dose|Four subjects will receive low dose FGF-1
3202738|NCT00916292|Experimental|High Dose|Four subjects will receive high dose FGF-1
2541130|NCT02623205|Active Comparator|Escitalopram|Active Comparator: Escitalopram (Lexapro) 10mg Week 1, 20mg Weeks 2 and 3, and 30mg for Weeks 4 to 8 (or until 12 for patients close to remission)
2541132|NCT02623205|Placebo Comparator|Placebo|Lactose pill manufactured to mimic Escitalopram pill
2541180|NCT02622906|Placebo Comparator|Placebo|1 injection per month during 6 months of the placebo product
2541184|NCT02622906|Active Comparator|Pasireotide|1 injection per month during 6 months of the Pasireotide LP (60mg/injection)
2541210|NCT02622555||Mirabegron treatment|Women with overactive bladder syndrome eligible for Mirabegron treatment
2541266|NCT02622360||Dyslexia|Individuals with confirmed dyslexia.
2541267|NCT02622360||Control|Healthy control subjects.
2541321|NCT02622022|Active Comparator|Morphine|18 patients treated with oral morphine hydrochloride linctus 5 mg 4 four times daily and as needed up to 4 times daily
2541323|NCT02622022|Placebo Comparator|Placebo|18 patients treated with oral linctus corresponding to 5 mg morphine hydrochloride, four times daily and as needed up to 4 times daily
2541393|NCT02621684|Experimental|Arm 1: Aerobics|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week walking program at the WellAware Center~required to check in with gym staff to check attendance~advised to walk at own pace for 3 days per week~15 minutes per day for the first 2 weeks~30 minutes per day for the next 2 weeks~50 minutes or more for remaining weeks"
2541395|NCT02621684|Experimental|Arm 2: Resistance training|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations.~Require physical evaluation and orientation to the WellAware gym~12 week weight lifting program at WellAware Center~exercise physiologists will work with each patient to develop a custom routine~exercise load will start at 60% of one-repetition maximum and progress from 8 to 12 repetitions~2-4 sets of repetition exercises will be performed to target upper & lower muscle groups~resistance load will be added by 5 pounds when patients can complete more than 12 repetitions"
2541397|NCT02621684|Active Comparator|Arm 3: Usual care|"Complete baseline questionnaires either online or on paper~Questionnaires will also be completed at 6 weeks, 12 weeks, and 16 weeks after baseline~Participants will be asked to wear an accelerometer for 7 days at baseline, 12 weeks, and 16 weeks.~Receive printed materials from the American Cancer Society about cancer management and standard physical activity recommendations."
2541452|NCT02621177|Experimental|NBP607|Trivalent Inactivated Cell Culture-derived Influenza Vaccine
2541455|NCT02621177|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
2541482|NCT02620813|No Intervention|No Acne|Healthy subjects without acne between the ages of 15-45
2541487|NCT02620813|Experimental|Acne Subjects on Topical Tretinoin Treatment|Subjects with acne before and after topical retinoid therapy
2541488|NCT02620813|Experimental|Acne Subjects on Systemic Isotretinoin Treatment|Subjects with acne before and after isotretinoin therapy
3202739|NCT00916318|Experimental|A: experimental|"(A) internet based information and communication tool Sundabarn.se("
3202740|NCT00916318|Experimental|(B): experimental|(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A
3202741|NCT00916318|Experimental|(c): experimental|(C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A
3202742|NCT00916318|Active Comparator|(D): control group|
3202743|NCT00916331|Experimental|subcutaneous group|Vacuum drainage is indwelled in subcutaneous layer
3202744|NCT00916331|Experimental|intraarticular group|Vacuum drainage is indwelled in intraarticular space
3202745|NCT00916396|Active Comparator|real drug|
2540716|NCT02625753|Active Comparator|Codeine plus paracetamol|Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
2540718|NCT02625753|Placebo Comparator|placebo|Placebo every 6 hours for 72 hours after photorefractive keratectomy.
3202746|NCT00916396|Placebo Comparator|placebo|
2540912|NCT02624648|Placebo Comparator|Placebo Group|"The effects of Placebo on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
2540913|NCT02624648|Experimental|Maca (Lepidium Meyenii Walp) Group|"The effects of Lepidium Meyenii Walp on sexual function, desire and depression in postmenopausal women.~The Female Sexual Function Index (FSFI) and the Female Intervention Efficacy Index Questionnaire (FIEI).~The Beck Depression Inventory II will be used to ward off depression"
2540961|NCT02624310|Experimental|Droxidopa First, Placebo Second|Participants in this arm will receive droxidopa first, then cross over and receive placebo
2540962|NCT02624310|Experimental|Placebo First, Droxidopa Second|Participants in this arm will receive placebo first, then cross over and receive droxidopa
2541022|NCT02623998|Experimental|Intervention|Drug: insulin glargine - sc injection Drug: sitagliptin/metformin - oral administration Behavioral: lifestyle therapy
2541025|NCT02623998|No Intervention|Standard Care|Standard glycemic care as informed by the current clinical practice guidelines
2541113|NCT02623478|Experimental|Insulin Lispro - Test Formulation|Novel formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2541117|NCT02623478|Active Comparator|Insulin Lispro - Reference Formulation|Marketed formulation of insulin lispro delivered via an insulin pump as a continuous infusion under the skin, with intermittent bolus doses during meals for two 3-day periods
2541143|NCT02623062|Active Comparator|Compound Sodium Alginate Oral Suspension sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
2541144|NCT02623062|Placebo Comparator|Matching placebo sachets|Each patient will be instructed to take Compound Sodium Alginate Oral Suspension sachet or matching placebo as a 2x10ml sachets four times daily regimen. Prior to dosing, all patients will be instructed by the Investigator on how they will take the medication. Patients will be instructed to start taking their medication the day after their randomisation visit (Day 1) for seven days (20ml taken four times a day: 30 minutes after breakfast, 30 minutes after lunch, 30 minutes after dinner and immediately before lying down for bed. Shake well before use).
2541217|NCT02622763|Experimental|10 millions dose|a total of 10 millions tolerogenic dendritic cells
2541230|NCT02622763|Experimental|100 millions dose|a total of 100 millions tolerogenic dendritic cells
2541262|NCT02622334|Experimental|Part A|Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days.
2541265|NCT02622334|Experimental|Part B|Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days.
2541341|NCT02621918|Experimental|Progressive Resistance Training (PRT)|For the progressive resistance training we use 11 exercises. The exercises for upper limbs were held in the waiting room before the hemodialysis session. Resistance exercise was carried out in two sets of 15-20 repetitions, the intensity were determined by the method of maximal repetitions, where series were run until exhaustion to momentary exercises (15-20 repetitions) with specific load. The load adjustments or volume were managed when necessary, but necessarily for every 4th week of training. The effort perception should be situated between 12 and 16 on the Borg scale (Borg and Noble, 1974), as proposed by The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995).
2541343|NCT02621918|Experimental|Aerobic Exercise (AER)|Aerobic exercise was conducted with a mini ergometer cycling (Mini Bike E5 Acte Sports) attached to the patient chair. Patients exercised 50-60 minutes of continuous workout with increased load. The workload was adjusted when necessary, according to the perceived effort made by the patient. The scale of perceived exertion, Borg scale (Borg and Noble , 1974), was used in accordance with the proposed By The Life Options Rehabilitation Advisory Council: Exercise for the Patient Dialysis (1995), which defines the values of perceived exertion between 12 and 16.
2541346|NCT02621918|Placebo Comparator|NEPLA|The control group performed active mobilization of members, circumduction of cervical, scapular girdle and extremities, breathing exercises with no loads, set on three to five repetitions only and no stretch exercises. The exercises were performed during the hemodialysis session, three times per week and did not exceed 5 minutes.
3202747|NCT00916409|Experimental|NovoTTF-100A device in combination with Temozolomide|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3202748|NCT00916409|Active Comparator|Temozolomide alone, as the best known standard of care|Patients will be treated with Temozolomide, as the best known standard of care for Glioblastoma Multiforme patients.
2541517|NCT02620709|Experimental|Hula intervention|"Participants randomized to the intervention arm will receive the 6-month KaHOLO Program within 1 week of baseline data collection. The first 3 months of the KaHOLO was designed and standardized as a culturally-based PA, which includes 12 weeks of hula lessons. These hula lessons consist of two 60 minute classes per week over 12 weeks. Each hula lesson will consist of 15 participants, providing with the opportunity to engage in social support network.~The last three months of the program will be reduced to once a week sessions. One week will consist of hula lessons for 60 minutes. The remaining 3 weeks will consist of the intervention group meeting for 45 minutes with the community-peer educator."
2542731|NCT02612480|Placebo Comparator|Placebo|7 day treatment with 2 placebos
2540763|NCT02625493||study population|All patients who underwent elective coronary procedures belonged to the one group, they received standard care without any additional interventions, but were asked to fill in a questionnaire.
2540942|NCT02624336|Active Comparator|DTC1 mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2540943|NCT02624336|Placebo Comparator|Oradex mouth wash|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2540944|NCT02624336|Placebo Comparator|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
2541063|NCT02623673||bevacizumab plus dexamethasone 0.7mg|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg
2541226|NCT02622815||Healthy blood donors|10,000 highly controlled blood donors in the age range 30-70 years
2541236|NCT02622815||Moli-sani subjects|A sample of 1,000 tumor cases have been identified so far and samples from these participants will be analyzed compared to 1,000 controls from randomly extracted from the Moli-sani cohort (parent cohort).
2541242|NCT02622815||Cancer patients|4,000 Patients with breast, lung, and gastrointestinal tumors.
2541276|NCT02622152|Active Comparator|Right lateral position group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for 30 minutes period on the supine position Repositioning the patients for 30 minutes period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
2541278|NCT02622152|Active Comparator|Routine hospital care group|After weaning from mechanical ventilation in the postoperative Intensive Care Unit (ICU patient underwent Repositioning the patients for two-hours period on supine position Repositioning the patients for two-hours period on the left lateral position Repositioning the patients for two-hours period on the right lateral position This period of repositioning in both groups repeated during the period of ICU stay
2541360|NCT02621775|Experimental|Computer-based stress management program|Immediate e-learning condition with minimal contact (n =40),
2541363|NCT02621775|Experimental|Stress management in face-to-face|Immediate treatment in face - to- face (n = 40)
2541365|NCT02621775|Other|Waiting list|Waiting list (n=40)
2541396|NCT02621385|Experimental|Tradipitant|One dose of midazolam followed by tradipitant dosing for days 3-16. Midazolam is also given on day 16
2541442|NCT02621255|Active Comparator|General anesthesia|General Anesthesia: Effect of general anesthesia will compare with regional anesthesia without use of nonsteroid antiinflammatory drug usage. Propofol 2mg/kg and rocuronium will be administered to patients for anesthesia induction. Anesthesia maintenance will ensure with sevoflurane %2 and N2O/O2 %50/50 mixture.
2541445|NCT02621255|Active Comparator|bupivacaine|Regional Anesthesia: Effect of regional anesthesia will compare with general anesthesia without use of nonsteroid antiinflammatory drug usage. Combined epidural-spinal anesthesia will be performed to patients. %5 bupivacain and 20µg fentanyl will apply for spinal anesthesia. Anesthesia maintenance will ensure with bupivacain.
2541552|NCT02620449|Experimental|single arm study|
2541588|NCT02620176|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve.
2541594|NCT02620176|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation stimulation. The stimulator is attached to the left ear, but rotated 180 degrees, so that it is not stimulating the auricular branch of the vagal nerve.
2541674|NCT02619760|Active Comparator|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists , followed by 59-month clopidogrel monotherapy
2541677|NCT02619760|Active Comparator|12-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists with 11-month DAPT composed of aspirin and clopidogrel, followed by 48-month aspirin monotherapy
2541720|NCT02619240||patients suspected of TB|patients suspected of TB requiring to undergo bronchoscopy as part of the investigation
3168383|NCT00550225|Experimental|Sequence 6|In session 1, subjects will receive placebo followed by 900 micrograms of GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 succinate in session 3 and 1500 micrograms of GSK961081 edisylate in session 4.
3168384|NCT00550225|Experimental|Sequence 7|In session 1, subjects will receive 1500 micrograms of GSK961081 edisylate followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive placebo in session 3 and an additional dose of GSK961081 succinate in session 4.
2541992|NCT02617485|Experimental|MabionCD20®|"A course of MabionCD20® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
2541994|NCT02617485|Active Comparator|MabThera®|"A course of MabThera® consists of intravenous infusions in dose 375 mg/m2 body surface area, administered on day 1 of each chemotherapy cycle for 8 cycles.~Intervention: Drug: Rituximab"
2542801|NCT02612337|Experimental|OTO-104|12 mg dexamethasone
3168385|NCT00550225|Experimental|Sequence 8|In session 1, subjects will receive placebo followed by 900 microgram GSK961081 succinate in session 2. The subjects will receive 1500 micrograms of GSK961081 edisylate in session 3 and an additional dose of GSK961081 succinate in session 4.
3168386|NCT00550251|Active Comparator|Acupressure Bands|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
3168387|NCT00550251|Placebo Comparator|Placebo|Elasticated wrist bands without active bead.
3168388|NCT00550264|Experimental|1|
3168389|NCT00550264|No Intervention|2|
3168390|NCT00550342|Experimental|Rituximab|Rituximab (375 mg/m2) will be administered intravenously as per current package label in a facility capable of handling infusion reactions. Subjects would be pre dosed with diphenhydramine and acetaminophen. Solu-Medrol, 1.5 mg/kg would be dosed 1 hour prior to the first dose of rituximab. Three subsequent doses of rituximab will be given at weekly intervals.
3168391|NCT00550355|Experimental|1|
3168392|NCT00550355|Experimental|2|
3168393|NCT00550355|Experimental|3|
3168394|NCT00550355|Placebo Comparator|4|
3168395|NCT00550381|Placebo Comparator|1|10mg
3168396|NCT00550381|Placebo Comparator|2|20mg
3168397|NCT00550381|Placebo Comparator|3|40mg
3168398|NCT00550381|Placebo Comparator|4|80mg
3168399|NCT00550381|Placebo Comparator|5|160mg
2540820|NCT02625077|Active Comparator|Laparoscopic Toupet fundoplication|Via laparoscopy, the entire stomach is mobilized and folded around itself posteriorly, creating a partial (270 degrees) fundoplication.
2540897|NCT02624830|Experimental|Drug, Sulfonylurea|Sulfonylurea tablets (glibenclamide, other forms of sulfonylureas) were administered at the time of intervention (before November 1, 2006). The patients have been prospectively followed up. Sulfonylurea dose, insulin requirement, death of all causes, episodes of severe hypoglycemia, ketoacidosis, development of discoloured teeth and diarrhea have been recorded. For a small number of subjects, increment of insulin and C-peptide after either an oral or intravenous glucose load and/or response to intravenous glucagon have been tested.
2540939|NCT02624518|Experimental|Diagnostic (68Ga-RM2 PET/MRI)|Patients receive 68Ga-RM2 IV and beginning 45 minutes later undergoing PET/MRI scan. The 68Ga-RM2 PET/MRI may be repeated at the completion of treatment to evaluate response to therapy, if requested by the treating physician. Imaging with PET/MRI is the intervention.
2541009|NCT02624141|Experimental|Epoetin Beta 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks.
3202749|NCT00916422|Experimental|Depigoid Phleum pratense 1000DPP/Ml|Depigmented and Polymerized Allergen extract of Phleum Pratense.Subcutaneous Immunotherapy in an up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years.
3202750|NCT00916422|Placebo Comparator|2|Placebo. Dosing regimen: An up-dosing cluster regimen for 4 weeks, followed by monthly injections for 2 years
2541195|NCT02622854|Experimental|plasma exchange|plasma exchange, with 1.5 estimated plasma volume exchanged with albumin solution, using citrate anticoagulation, performed daily until triglycerides <=10 mmol/l
2541196|NCT02622854|Active Comparator|conservative treatment|infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l
2541228|NCT02622464|Experimental|micro injection of SVF in vocal cords|micro injection of Stromal Vascular Fraction extracted from autologous adipose tissue in vocal cords
2541274|NCT02622386|Experimental|Riboflavin|Riboflavin (Vitamin B2) 400 mg oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive Riboflavin but matching placebo capsule for additional 12 weeks.
2541275|NCT02622386|Placebo Comparator|Placebo|Placebo oral capsule taken once daily for 12 weeks, followed by 4 week washout period before crossover. At crossover, patients will no longer receive placebo but 400 mg Riboflavin (Vitamin B2) capsule for additional 12 weeks.
2541339|NCT02621905|Active Comparator|Sporanox|100 mg
2541340|NCT02621905|Experimental|Lozanoc|50 mg
3202751|NCT00916448|Placebo Comparator|Placebo|placebo medication: 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
3202752|NCT00916448|Active Comparator|Atazanavir|Atazanavir 150 mg, 2 capsules taken twice daily for 4 consecutive days and thereafter infusion of 2 ng/kg E.coli endotoxin intravenously
3202753|NCT00916461|Active Comparator|Minocycline|
3202754|NCT00916461|Placebo Comparator|Sugar Pill|
3202755|NCT00916474||Cohort A|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
3202756|NCT00916474||Cohort B|Observational follow-up study to assess long-term response to telaprevir and to evaluate changes in Hepatitis C virus over time
3202757|NCT00916487|Experimental|Arm1|single arm of study in cross-over design
3202758|NCT00916500|Experimental|CISPLATIN|Patients With Locally Advanced Cervical Cancer Who Underwent Concurrent Chemoradiation; Cisplatin 75mg/m2 IV Every 3 Week For 3 Cycles; External Pelvic Radiation 40 Gy; Brachytherapy Up to 85-90 Gy To Point A
2541800|NCT02618993|Placebo Comparator|Control group|Control group: Realization of the V3 block with a placebo in maxillofacial surgeries
2541801|NCT02618993|Experimental|Loco-regional anesthesia (LRA) group|Loco-regional anesthesia (LRA) group: Realization of the V3 block with Ropivacaine in maxillofacial surgeries
2541815|NCT02618434|Experimental|Low dose SPN-810|Subjects will be treated with low dose of SPN-810
2541817|NCT02618434|Experimental|High dose SPN-810|Subjects will be treated with high dose of SPN-810
2541819|NCT02618434|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
2541901|NCT02618005|Experimental|LcS group|Consuming probiotic capsule
2541906|NCT02618005|No Intervention|Control group|
2541951|NCT02617745|Experimental|Stupp protocol|Blood assessment of the platelet level every week during the radiotherapy phase and every cycle during the chemotherapy
2542036|NCT02617394|Active Comparator|Control group|
2542039|NCT02617394|Experimental|Study group|
2542069|NCT02616796|Experimental|Social gaze training|Appropriate social gaze behavior will be reinforced using the principles of Applied Behavior Analysis.
2542074|NCT02616796|No Intervention|No Training|Appropriate social gaze behavior will not be reinforced.
2542141|NCT02616536|Active Comparator|Flipped classroom|The flipped classroom is new pedagogical method, which employs asynchronous video lectures and practice problems as homework and active, group-based problem solving activities in the classroom.
2542148|NCT02616536|Active Comparator|traditional classroom|The classroom lecture is a special form of communication in which voive, gesture. Movements, facial expression and eye contact can either complement or detract from the content. No matter what your topic, your delivery and manner of speaking immeasurably influence your student's' attentiveness and learning.
2542732|NCT02612675|Active Comparator|Standard ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
3202759|NCT00916513||1|Patients ³ 40 years old, with T2DM diagnosed and followed up in the participating site at least 1 year prior to entry in the study, treated with diet, OADs and/or insulin for at least the past three months
3202760|NCT00916526|Experimental|bronchial provocation test with mannitol|"Patients referred for evaluation of a chronic cough (without treatment or after stopping inhaled corticosteroids for 2 weeks) will perform a measure of FeNO, a bronchial provocation test with mannitol, will fill out a questionnaire of quality of life for the cough (Leicester Cough Questionnaire) and the intensity of coughing on a 10-cm visual scale.~After 6 weeks after treatment with inhaled corticosteroids patients will perform the same tests."
3202761|NCT00916552|Experimental|Erythropoeitin|40.000 IU, epoetin alfa; Janssen-Cilag
3202762|NCT00916565||Experimental milk-based infant formula|
2540856|NCT02625051|Active Comparator|Percutaneous nephrolithotomy|Kidney stone of participants in this arm will be treated with percutaneous nephrolithotomy (PNL). A percutaneous nephrostomy tube will be inserted at the end of the procedure.
2541079|NCT02623608|Experimental|High fat meal|Subjects eat a high fat breakfast (reference breakfast) at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h.
2541083|NCT02623608|Experimental|High fat meal + Active Ingredient 1|"Subjects eat the same high fat breakfast with the active ingredient 1 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2541085|NCT02623608|Experimental|High fat meal + Active Ingredient 2|"Subjects eat the same high fat breakfast with the active ingredient 2 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2541088|NCT02623608|Experimental|High fat meal + Active Ingredient 3|"Subjects eat the same high fat breakfast with the active ingredient 3 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2541092|NCT02623608|Experimental|High fat meal + Active Ingredient 4|"Subjects eat the same high fat breakfast with the active ingredient 4 at 7:30 am. The meal contains 50 g fat and 900 kcal. Blood samples are taken before the breakfast and every 30 min postprandial for 4 h."
2541171|NCT02623114|Experimental|Methylphenidate|ADHD patients with methylphenidate administration Generic names include concerta, metadata and penid. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
2541176|NCT02623114|Experimental|Atomoxetine|ADHD patients with atomoxetine administration Generic names include strattera. The initial dosage was fixed for 2 weeks and then adjusted according to the clinician's judgement. The patients visited the hospital at week 2,4,6,8,16,24, 9months, 12,15,18,21,24 months.
2541206|NCT02622594|Active Comparator|1|Treatment 1 will include microneedling performed prior to ALA application to their right face and ALA application only to the left face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2541209|NCT02622594|Active Comparator|2|Treatment 2 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2541221|NCT02622594|Active Comparator|3|Treatment 3 will include microneedling performed prior to ALA application to their right face and ALA application only to the left side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2541227|NCT02622594|Active Comparator|4|Treatment 4 will include microneedling performed prior to ALA application to their left face and ALA application only to the right side of their face 30 minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds).
2541305|NCT02622061||PCD Subjects|Participants 5 and older with PCD.
2541306|NCT02622061||Healthy Subjects|Participants 5 and older without any pulmonary disease.
2541359|NCT02621788|Experimental|First Year Residents|Stress Management and Resiliency Training for Residents (SMART-R) delivered to first year residents in the departments of medicine and psychiatry at Massachusetts General Hospital
2541385|NCT02621528|Other|CeraFlex occluder|The Lifetech CeraFlex™ study is a triple-arm study.
2541436|NCT02621307|Experimental|Salba|50g glucose 25g ground Salba (Salba Corporation Ltd, Buenos Aires, Argentina) 200ml water
2541438|NCT02621307|Experimental|Flax|50g glucose 31g ground Flax (Bob's Red Mill Natural Raw Whole Flaxseed) 200ml water
2541441|NCT02621307|Placebo Comparator|Control|50g glucose 200ml water
2541490|NCT02620891|Active Comparator|experimental group|Using helium oxygen mixture
2541492|NCT02620891|No Intervention|matched group|Using air oxygen mixture
2541532|NCT02620618|Experimental|Intravitreal Infliximab|Patients with refractory behcets uveitis.
2541603|NCT02620280|Active Comparator|Carbo-abrax, surgery, anthra|Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
2541605|NCT02620280|Experimental|Carbo-abrax-MPDL3280A, surgery, anthra|Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy
2541667|NCT02619461|Experimental|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes.
2541670|NCT02619461|No Intervention|Control|Resting
2541783|NCT02619006||Immediate Cord Clamping|Healthy term infants who were previously randomized or assigned at birth to the control group known as immediate cord clamping. The cord was clamped and cut within10 seconds after birth.
2541795|NCT02619006||Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
2541814|NCT02618551|Experimental|Intervention|Patients will be treated by three bronchial thermoplasty sessions.
3202763|NCT00916565||Control milk-based infant formula|
3202764|NCT00916565||Breastfed Reference Group|
2541975|NCT02617758|Experimental|Treatment AB|Participants will receive Treatment A (single application of DURAGESIC fentanyl transdermal system 100 microgram per hour (µg/h) dose) as Reference in Period 1; followed by Treatment B (single application of Fentanyl transdermal system [JNJ-35685-AAA-G021] 100 µg/h dose) as test in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
2541976|NCT02617758|Experimental|Treatment BA|Participants will receive Treatment B [single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose] as test in Period 1; followed by Treatment A (single application of DURAGESIC fentanyl transdermal system 100 µg/h dose) as Reference in Period 2. A washout period of at least 8 days and no more than 14 days will be maintained between each treatment period.
3202765|NCT00916604|Experimental|A|3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
3202766|NCT00916604|Placebo Comparator|B|Placebo oral suspension given to 3 groups (2 on placebo in each group)
3202767|NCT00916630|Other|Single-arm treatment|Dose finding study
3202768|NCT00916656|Experimental|Prospective Arm|
3202769|NCT00916656|Other|Historical Control|
3202770|NCT00916669|Active Comparator|Group A|Cisplatin and Etoposide
3202771|NCT00916669|Experimental|Group B|Cisplatin and etoposide, plus low-dose enoxaparin sodium
3202772|NCT00916669|Experimental|Group C|Cisplatin and etoposide, plus high-dose enoxaparin sodium
3202773|NCT00916682||Cystic Fibrosis|
3202774|NCT00916695|Active Comparator|Complex PCI strategy for bifurcation coronary lesions|Stenting main vessel and T-stenting for the side branch
2541103|NCT02623452|Experimental|Part A:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin once in each of 3 periods
2541105|NCT02623452|Active Comparator|Part A:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin once in each of 3 periods
2541108|NCT02623452|Experimental|Part B:Insulin Lispro Test|Individualized doses of Insulin Lispro test formulation administered by injection under the skin with each meal for 14 days
2541111|NCT02623452|Active Comparator|Part B:Insulin Lispro Reference|Individualized doses of Insulin Lispro reference formulation administered by injection under the skin with each meal for 14 days
2541142|NCT02623088||PAP therapies|Patients with sleep apnea syndrome treated by CPAP after respiratory and vascular assessment and followed 5-7 years, as part of a clinical research.
2541252|NCT02622841|Experimental|BLEND|Combination of stereotactic bodyradiotherapy and surgical stabilization within 48 hours for the treatment of unstable spinal metastases.
2541282|NCT02622243|Experimental|tiotropium|2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
2541288|NCT02622243|Experimental|glycopyrronium|1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge
2541357|NCT02621762|Experimental|Mg first|Receives MgCl2 first, MgCl2 and Bicarbonate in second phase
2541364|NCT02621762|Experimental|Bicarbonate first|Receives Bicarbonate first, MgCl2 and Bicarbonate in second phase
2541423|NCT02621450|Placebo Comparator|standart dialysate|dialysate sodium 140 mEq/L
2541425|NCT02621450|Other|low sodium dialysate|dialysate sodium will be reduced from 140 mEq/L to 137 mEq/L
2541449|NCT02621112|Experimental|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccination with topical imiquimod pretreatment. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical imiquimod ointment pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2541450|NCT02621112|Active Comparator|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccination with topical aqueous cream. Subjects to receive intradermal 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2541451|NCT02621112|Active Comparator|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccination with topical aqueous cream. Subjects to receive intramuscular 10mcg of recombinant hepatitis B vaccine at two separate sites (5mcg) with topical aqueous cream pretreatment 5 minutes before injection at 0, 1, 3, 6 months
2541529|NCT02620605|Active Comparator|Late administration of Cabirgoline 0.5 mg|Cabergoline 0.5mg (Dostinex®, Pfizer Australia Pty Ltd ) administrated once daily started on day of HCG triggering and continued for 8 days.
2541530|NCT02620605|Experimental|Early administration of Cabirgoline 0.5mg|Cabergoline 0.5mg(Dostinex®, Pfizer Australia Pty Ltd ) once daily stared once patients fulfilling the inclusion criteria at any day of cycle and continued for 8 days post HCG trigger.
2541618|NCT02620306|Experimental|Fimasartan(A)|
2541619|NCT02620306|Experimental|Fimasartan(B)|
2541621|NCT02620306|Active Comparator|Losartan(A)|
2541623|NCT02620306|Active Comparator|Losartan(B)|
2541689|NCT02619630|Experimental|High-Risk (HR) patients|Nelarabine during consolidation and maintenance
3202775|NCT00916695|Active Comparator|Simple PCI strategies for bifurcation coronary lesions|Stenting main vessel, with provisional stenting for the side branch.
3202776|NCT00916708|Experimental|Intensive follow up|Intensive follow up in low-risk patients Intensive follow up in high-risk patients
3202777|NCT00916708|Experimental|Minimalist follow up|Minimalist follow up in low-risk patients Minimalist follow up in high-risk patients
3202778|NCT00916734|Experimental|Spinal Manipulation Group|Subjects who received spinal thrust manipulation as an intervention.
3202779|NCT00916734|Active Comparator|McKenzie MDT Group|
3202780|NCT00916747|Experimental|Treatment arm|All patients will receive zoledronic acid, pravastatin and lonafarnib
3202781|NCT00916760|Experimental|1|A Subcutaneous Depigmented and Polymerized Allergen extract of Parietaria Judaica 1000 DPP/ml. Depigoid Parietaria judaica 1000 DPP/ml.
3202782|NCT00916760|Placebo Comparator|2|
3202783|NCT00916786||OROS-methylphenidate|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
3202784|NCT00916786||Atomoxetine group|The patients will be randomly assigned to two treatment groups, the OROS-methylphenidate group (n=80) and the atomoxetine group (n=80), respectively.
3202785|NCT00916786||Control group|Healthy controls matching for the distribution of age and sex of the case groups
3202786|NCT00916799|Experimental|Oximeter arm and non-oximetry arm|
3202787|NCT00916825|Experimental|3-week family oriented rehabprogramme|waiting control group
3202788|NCT00916838||Type 1 Diabetes Mellitis|Children with Type 1 Diabetes Mellitis (T1DM) between 4 and 16 were recruited.
3202789|NCT00916838||Non diabetic Control|62 healthy siblings also enrolled in the study between the ages of 4 and 17.
3202790|NCT00916851||Control group|Normally developing children and adolescents
3202791|NCT00916851||ADHD group|Children and adolescents with ADHD
2540935|NCT02624479|Experimental|Slow first|Sodium thiosulfate slow release formulation first, followed by fast and medium
2541002|NCT02624206|Active Comparator|Juice A|Half of the group to receive Juice A, a novel juice flavor.
2541003|NCT02624206|Active Comparator|Juice B|Half of the group to receive Juice B, a novel juice flavor different from Juice A.
2541044|NCT02623751|Experimental|KHK2375 PO and Exemestane PO|KHK2375 and Exemestane
2541087|NCT02623413||Sites implementing contact precautions|"Centers isolating for VRE may only participate if complying with the following standards:~Contact precautions triggered by the initial detection of VRE~Patients discharged as a VRE-carrier must be placed in contact isolation upon readmission~Termination of contact precautions after at least two consecutive VRE-negative consecutive fecal screening cultures~Resumption of contact isolation on first subsequent VRE-positive culture~Contact precautions must encompass the following measures:~Patients: Placement in single rooms. Cohorting is only permitted, in case of unavailability of single rooms~Staff and visitors: Wearing of gloves and gowns when entering the room.~Patients: Wearing of gloves and gowns when leaving the room."
2541091|NCT02623413||Sites not implementing contact precautions|Only VRE colonized or infected patients with urinary or fecal incontinence or diarrhea (defined as > 3 loose bowel movements/day), must be isolated in single rooms at any time during the study.
2541181|NCT02622893|Active Comparator|Transperitoneal laparoscopic nephrectomy|Patients in this group underwent transperitoneal laparoscopic nephrectomy in 45-60º modified flank position after receiving epidural catheter in the sitting position before the surgery.
2541183|NCT02622893|Active Comparator|Retroperitoneal laparoscopic nephrectomy|Patients in this group underwent retroperitoneal laparoscopic nephrectomy in lateral decubitis position after receiving epidural catheter in the sitting position before the surgery.
2541200|NCT02622542|Active Comparator|BMT Alone|Patients in this group will be managed with the best medical therapy (BMT) alone
2541202|NCT02622542|Experimental|BMT+TEVAR|Patients in this group will be managed with thoracic endovascular aortic repair (TEVAR) in addition to the best medical therapy (BMT)
2541294|NCT02622269|Experimental|Patient-regulated compression|Patient-regulated compression device
2541295|NCT02622269|Active Comparator|Standard compression|Standard compression device
2541355|NCT02621879|Experimental|Bilateral Gluteal Advancement Flap|Advancement of both gluteal muscles to the midline after release incisions in their fascia.
2541390|NCT02621554|Experimental|resveratrol supplementation|Dietary Supplement: Resveratrol
2541391|NCT02621554|Placebo Comparator|placebo supplementation|Dietary Supplement: Placebo
2541435|NCT02621268|Experimental|Indocyanine Green|Dosage calculated by weight of individual, 5mg/kg.
2541480|NCT02620956|Active Comparator|obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
2541484|NCT02620956|Experimental|asthmatic obese nebulizer|would be used to inhale an aerosol with technetium labeled diethylenetriaminepente-acetic acid (99mTc - DTPA) with an activity of 1 mCi in a total dose volume with normal saline of 2,5 ml and heliox using a vibrating mesh inhaler.
2541545|NCT02620631|Placebo Comparator|Placebo|Subjects receive intrathecal injection of saline at time of spinal anesthesia
2541549|NCT02620631|Experimental|Morphine|Subjects receive intrathecal injection of morphine sulfate 0.2mg at time of spinal anesthesia
2541566|NCT02620150|Experimental|Experimental|CCBT plus Escitalopram, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
2541567|NCT02620150|Placebo Comparator|Placebo|CCBT plus Placebo, oral, for 10 weeks, once daily, starting at 10mg/day. Tapered up or down, based on tolerability and clinical response, to 20mg/day max.
2541630|NCT02620007|Experimental|Experimental arm|oral Ciprofloxacin 500 mg bid and oral Rifaximin 800 mg bid for 12 weeks
2541631|NCT02620007|Placebo Comparator|Control arm|a placebo of Ciprofloxacin bid and a placebo of Rifaximin bid for 12 weeks
2541687|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2541691|NCT02619552||Anti-TNF (Remicade, Humira or Cimzia)for perianal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2541692|NCT02619552||Steroid (Prednisone or budesonide) for luminal CD|All participants are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
2541774|NCT02619045|Other|Solid tumors|Patients with solid tumor starting a intra venous chemotherapy with 21 days cycles.
2541842|NCT02618655||Fever，none definite diagnosis|Those who have fever，but the doctor can not make definite diagnoses with the diagnostic methods available.
2541871|NCT02618200|Experimental|3D prostate ultrasound|3D prostate ultrasound will be performed in patients the day before radical prostatectomy
2541929|NCT02617940|Experimental|fissure sealant|single placement of resin-based sealant on occlusal surface and oral hygiene orientation
2541933|NCT02617940|Placebo Comparator|oral hygiene orientation|single application of water on occlusal surface and oral hygiene orientation
2542005|NCT02617173|Experimental|Transcutaneous electrical nerve stimulation|Low current electrical stimulator
2542085|NCT02616991|Experimental|Cohort|computed tomography venography
2542135|NCT02616471|Experimental|High-fat cheese (HFC) group|"The subjects in the HFC group will be supplied with equal amounts of two types of regular/high fat cheeses. The cheeses are normal-fat Danbo (Riberhus, 25% fat, Arla, DK) and normal-fat Cheddar (Sharp Cheddar, 32% fat, Cabot, US).~No further dairy and cheese consumption is allowed"
3202792|NCT00916851||ASD group|Children and adolescents with ASD
2541034|NCT02623920|Experimental|Brentuximab, Bendamustine, Rituximab|Brentuximab Vedotin in Combination with Bendamustine and Rituximab
2541121|NCT02623439|Experimental|cyclophosphamide post BMT|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
2541174|NCT02623010|Experimental|Single arm|Imbruvica (ibrutinib) will be given as maintenance treatment until relapse or toxicity to 30 elderly PCNSL patients after achieving response to first line treatment
2541203|NCT02622633|Experimental|Stimulation|One week after implantation of the device, participants randomized in this arm will receive continuous magnetic stimulation of high frequency (50Hz) with epidural electrode for 12 weeks. And then, the epidural electrode will be turned off for more 12 weeks in a crossover fashion.
2541208|NCT02622633|Sham Comparator|Sham Stimulation|One week after implantation of the device, participants randomized in this arm will receive sham stimulation for 12 weeks and then continuous magnetic stimulation with epidural electrode of high frequency (50Hz) stimulation for more 12 weeks.
2541268|NCT02622373||Birth Between 23-32 Weeks Gestation|Babies born between 23-32 weeks of gestational age will have their body composition determined using PEA POD Infant Body Composition System at 34 weeks, 36 weeks and 40 weeks of corrected age.
2541271|NCT02622373||Birth Between 34-36 Weeks Gestation|Babies born at 34 weeks and 36 weeks of gestational age will have their body composition measured using PEA POD Infant Body Composition System as soon as they are off parenteral nutrition and receiving full enteral nutrition.
2541273|NCT02622373||Birth at Term|Body composition will be measured using PEA POD Infant Body Composition System in this group will be obtained prior to discharge.
2541325|NCT02621957|Experimental|Female Healthy Volunteers|Healthy volunteer female subjects of non-childbearing potential will be administered pravastatin once on Day 1 during Period 1 (Day -1 to Day 4). During Period 2 (Days 5-28) GDC-0810 will be administered daily on Days 5-8. Pravastatin will be co-administered on Day 7.
2541376|NCT02621671|Experimental|Arm 1: Cognitive Interviews|"Participants will complete several survey items, view 1 of 8 disease risk pictures (selected at random), and then complete further survey questions.~Participants will then be recorded giving their opinions on the remaining 7 disease risk pictures which depict the hypothetical risk of disease.~The entire visit will take no more than 90 minutes with no follow-up.~The first 10-20 participants will be randomized to this arm."
2541378|NCT02621671|Experimental|Arm 2: Experimental survey|"Participants will be randomly assigned by GfK's computer to one of the 12 experimental conditions.~After completing questions about information seeking and physical activity, the participants will read a short scenario that describes the purpose of a risk assessment tool and ask them to imagine that they had just entered their information into such a tool.~Participants will see whichever risk ladder corresponds to the experimental condition to which they were assigned.~The hypothetical display will be consistent with a display generated for an individual whose risk profile includes risk increasing and decreasing factors, but does not engage in the recommended amount of physical activity."
2541559|NCT02620475|Active Comparator|Gold standard of care|The usual gold standard of wound treatment to prevent scarring is to cover the incision with a self adhesive gauze type dressing (Mepore) covered by paper tape.
2541563|NCT02620475|Experimental|SutureSafe dressings|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
2541595|NCT02620098|Experimental|Size Matters Handwriting Program|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The intervention group consisted of 23 kindergarten students comprising all students in two kindergarten support classrooms, one in each of two neighboring schools. All students in the group received the Size Matters Handwriting Program.
2541597|NCT02620098|No Intervention|Control|All participants were receiving educational support in the form of IEP and/or RtI tier 2 interventions, and were participating in a support classroom where those services where being delivered. The control group consisted of 12 kindergarteners comprising all students in a kindergarten support classroom at a third school. They received no additional interventions.
2541680|NCT02619838||Aptus CCS 5.0 or/and 7.0 screws|Procedure/Surgery: Subtalar, Double or Triple Arthrodesis of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint of the foot with the Aptus CCS 5.0 or/and 7.0 screws
3168400|NCT00550381|Placebo Comparator|6|240mg
2542252|NCT02615795|Experimental|Intervention|Best practice + Tele Monitoring of physiological parameters (heart frequence, oxygen saturation, weight, FEV1), and answers to disease specific questions, using Tunstall monitoring device.
2542335|NCT02615379|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 weeks + standard wound care
3168401|NCT00550381|Placebo Comparator|7|400mg
3168402|NCT00550381|Placebo Comparator|8|640mg
3168403|NCT00550381|Placebo Comparator|9|960mg
3168404|NCT00550381|Placebo Comparator|10|placebo
3168405|NCT00550472|Experimental|Probiotic|intervention
3168406|NCT00550485|Other|1|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype A)
3168407|NCT00550485|Other|2|Healthy subjects with a single nucleotide polymorphism (SNP) of the ABCB1-gene (Genotype B)
3168408|NCT00550498|Experimental|A|Behcet's Disease with ocular lesions
3168409|NCT00550511|Other|Ultrasound|Surgeon-performed ultrasound as intervention, as a complement to clinical investigation and standardized laboratory testing.
3168410|NCT00550511|No Intervention|Control|Control group examined with clinical examination including standardized laboratory tests.
3168411|NCT00550524|Experimental|A|Knee osteoarthritis
3168412|NCT00550563|Experimental|Oral Cholecalciferol|Patients receive oral cholecalciferol 2000 IU once daily for 1 year
3168413|NCT00550576|Experimental|digibind|Injection of digibind and psychological tests
3168414|NCT00550628||resection of a non-sarcomatous primary colon neoplasm|The surgically removed colon will undergo ex-vivo imaging after examination in pathology. A PET scanner will be used to acquire a scan of the whole specimen.
3168415|NCT00550641|Active Comparator|1|
3168416|NCT00550641|Experimental|2|
3168417|NCT00550693|Placebo Comparator|A|The patients in this arm continued with the local catheter care protocol.
2540991|NCT02624193|Experimental|MBSR Program|"MBSR Program:~The MBSR intervention is a nine-week program designed to cultivate mindfulness, a focused non-judgmental awareness of the present moment. It consists of eight 2-hour weekly sessions and one 3-hour retreat and the content includes three main components: 1) material related to mindfulness, meditation, yoga, and the mind-body connection; 2) experiential practice of mindful meditation (sitting, lying down, walking), gentle mindful yoga, and body scan during group meetings and encouragement of home practice; and 3) group discussion focused on problem-solving related to barriers to effective practice. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
2540993|NCT02624193|Placebo Comparator|HT Program|"Healthy Topics Program:~The health education program Healthy Topics (HT) will serve as an attention control group. The HT program is focused on providing age-appropriate health information and education. There is minimal content overlap in the MBSR and HT programs regarding self-care and healthy eating; however, the style, structure, and content of the MBSR and HT programs are distinct. HT participants will receive no training in MBSR or meditation. Topics covered include physical activity, nutrition, managing weight, building health, personal care, understanding adolescence, tobacco, alcohol, and other drugs. HIV disease will not be discussed as a group topic, unless it is brought up by participants."
2541033|NCT02623777|Experimental|AXOS as first intervention|AXOS as first intervention
2541036|NCT02623777|Experimental|SCFA as first intervention|SCFA as first intervention
2541107|NCT02623504|Experimental|Equetro|200-1200 mg of Equetro (carbamazepine) by mouth given in divided doses in the morning and in the evening. Dosage is titrated in 200 mg increments weekly as needed according to subject response.
2541110|NCT02623504|Placebo Comparator|Placebo|Placebo dosage to match the active Equetro treatment given in 2 daily doses in the morning and in the evening.
2541137|NCT02622997|Active Comparator|Refrigerated|Sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
2541139|NCT02622997|Experimental|Incubated at 25oC for 1 week|Sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
2541141|NCT02622997|Experimental|Incubated at 25oC for 2 weeks|Sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
3202793|NCT00916890|Active Comparator|Oral extended-release morphine|
3202794|NCT00916890|Active Comparator|Oral extended-release oxycodone|
3202795|NCT00916890|Active Comparator|Transdermal fentanyl|
3202796|NCT00916890|Active Comparator|Transdermal buprenorphine|
3202797|NCT00916903||1|Patients with genetic condition being studied.
3202798|NCT00916903||2|Matched controls
2541644|NCT02619864|Experimental|AZD2014 plus temozolomide|Patients will receive single agent AZD2014 for 2 days immediately prior to surgery at a fixed dose of 125 mg bid po (i.e. on days -2, -1, and on morning of day 0 [day of surgery]). After recovery from surgery, patients will start the dose escalation (within 7-21 days after tumour resection).
2541668|NCT02619448|Experimental|Chemotherapy with hypofractionated RT|Carboplatin AUC 2 + Paclitaxel 50 mg/m2 given weekly x 4 concurrently with radiation therapy (70 Gy in 20 fractions) over 4 weeks
2541738|NCT02619266|Experimental|Acupuncture+Placebo|Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
2541739|NCT02619266|Active Comparator|Megestrol Acetate+Sham acupuncture|Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
2541740|NCT02619266|Placebo Comparator|Placebo+Sham acupuncture|Placebo tablet by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
2541784|NCT02618785|Experimental|Hyoscine|The experiment group receive Hyoscine 10 mg 2 tablets by mouth before hysterosalpingography procedure
2541792|NCT02618785|Placebo Comparator|Placebo|The control group receive placebo by mouth before hysterosalpingography procedure
2541822|NCT02618486|Experimental|Obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
2541823|NCT02618486|Active Comparator|Non obese with CP|Procedure/Surgery Non surgical periodontal therapy Received OHE, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine rinse thrice a day
2541862|NCT02618291|Experimental|Active Geriatric Evaluation (AGE tool)|The Active Geriatric Evaluation is a comprehensive assessment and management tool consisting of a 20-minute clinical screening instrument (Brief Assessment Tool, BAT) to identify 8 geriatric syndromes, and complementary diagnostic evaluations and propositions of management & treatment for each syndrome.
2541863|NCT02618291|Active Comparator|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
3202799|NCT00916916||Lanreotide|Patients taking lanreotide for the treatment of acromegaly.
3202800|NCT00916942|Experimental|NGX-4010 patch|
3202801|NCT00916942|Experimental|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
2541987|NCT02617446|Placebo Comparator|Placebo|i.v. infusion for 24 hours
2541989|NCT02617446|Active Comparator|treatment|The 2 doses of istaroxime (0.5 and 1.0 µg/kg/min) will be infused i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.
2541999|NCT02617121|Active Comparator|Gabapentin|oral gabapentin 300 mg 1 hours before induction of anesthesia
2542002|NCT02617121|Active Comparator|ramosetron|ramosetron 0.3 mg iv at end of surgery
3202802|NCT00916955||Individuals with 22q11.2 deletions|Individuals confirmed with the diagnosis of velo-cardio-facial syndrome by positive FISH or CGH microarray confirming the diagnosis and deletion of 22q11.2
3202803|NCT00916968|Active Comparator|Standard CR-Flex|
3202804|NCT00916968|Experimental|Gender specific CR-Flex|
3202805|NCT00916994|Experimental|SpaceGuard Balloon implantation|
3202806|NCT00917007||ABO compatible|
3202807|NCT00917007||ABO incompatible, antiglobulin positive|
3202808|NCT00917007||ABO incompatible, antiglobulin negative|
3202809|NCT00917020|Experimental|Active: CO2 Gas|
3202810|NCT00917020|Placebo Comparator|Inactive Placebo Gas|
2541030|NCT02623972|Experimental|Arm B: AC > Eribulin|"Adriamycin (doxorubicin) via iv a predetermined dosage and schedule per cycle~Cyclophosphamide (AC) via iv a predetermined dosage and schedule per cycle~Two research breast biopsies~Eribulin-Administered via iv, at predetermined dosage and schedule per cycle~Surgical Removal of the breasts (Mastectomy) and axillary lymph node dissection~Radiation Therapy~Endocrine Therapy (if applicable)~Optional 5 Patient-Optional DCE-MRI (Dynamic Contrast Enhanced-Magnetic Resonance Imaging) scans"
2541090|NCT02623426|Active Comparator|Dexamethasone intravitreal implant 0.7mg|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at study visit M03 (8 weeks) if re-treatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Re-treatment criteria:~Central subfield thickness greater than 1.1X upper limit of normal (330 μm for Zeiss and Topcon SD OCT and 352 μm for Heidelberg OCT) and/or cystoid space(s) within 1 mm central subfield.~IOP of <25 mm Hg (treatment with ≤3 IOP-lowering agents permitted)~Minimum time between treatments: minimum target is 8 weeks after last injection but re-injection permitted as early as 51 days after last injection;"
2541093|NCT02623426|Active Comparator|Intravitreal methotrexate 400µg in 0.1mL|"Eligible eye(s) treated at study visit M01 (week 0).~Retreatment required at M02 (4 weeks) and M03 (8 weeks) if retreatment criteria met.~Retreatment permitted at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection."
2541094|NCT02623426|Active Comparator|Intravitreal ranibizumab 0.5mg in 0.05mL|"Eligible eye(s) treated at study visits M01 (week 0), M02 (4 weeks), and M03 (8 weeks).~Retreatment permitted at M04 (12 weeks) and at later time points if retreatment criteria met.~Minimum time between treatments: minimum target is 4 weeks after last injection but re-injection permitted as early as 23 days after last injection.~Re-treatment permitted at later time points if re-treatment criteria met."
2541253|NCT02622698|Placebo Comparator|Control|The patients in the control group did not receive any supplementation, and were directed to follow the dietary guidelines of their surgeon.
2541255|NCT02622698|Experimental|Treatment|Patients were instructed to consume one ounce (containing 16 grams of protein) of the supplement three times daily. No other modifications were made to the patient's diet. Patients were provided with a total of 60 doses, which would last 20 days if they consumed each dose as instructed.
2541296|NCT02622230|Experimental|Mianhuahua Flavonoids Tablets|Mianhuahua Flavonoids Tablets, oral administration
2541300|NCT02622230|Placebo Comparator|Placebo|Placebo, oral administration
2541358|NCT02621801|Experimental|Intervention|Stress Management and Resiliency Training for Residents (SMART-R)
2541362|NCT02621801|Active Comparator|Waitlist Control|The control group will receive the same intervention (SMART-R) after the experimental group.
2541405|NCT02621502|Experimental|Quinoa variety 1|1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2541406|NCT02621502|Experimental|Quinoa variety 2|1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2541407|NCT02621502|Experimental|Quinoa variety 3|1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2541410|NCT02621502|Experimental|Quinoa variety 4|1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
2541413|NCT02621502|Active Comparator|Anhydrous Glucose|1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product.
3168418|NCT00550706||1Pediatric Dept A|Children's files from this department will be analysed once weekly and medication prescription data will be registered
3168419|NCT00550706||2 Pediatric Dept B|Children's files from this department will be analysed once weekly and medication prescription data will be registered
2541601|NCT02620332|Placebo Comparator|Placebo injection|Water for injection
2541602|NCT02620332|Experimental|MultiPepT1De injection low dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2541606|NCT02620332|Experimental|MultiPepT1De injection medium dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2541609|NCT02620332|Experimental|MultiPepT1De injection high dose|Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)
2541663|NCT02619721|Experimental|Sacral Neuromodulation is on|Sacral Neuromodulation is on as soon as implantation
2541664|NCT02619721|Placebo Comparator|Sacral Neuromodulation is off|Sacral Neuromodulation is off after implantation
2541696|NCT02619357|Experimental|Cohort 1|10 subjects diagnosed with COPD (GOLD stages 2 and 3). Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
3168420|NCT00550797|Experimental|No.1 ASM8 (oligonucleotide)|TPI ASM8 1mg/mL in phosphate buffered saline (PBS) solution; 1 mg will be administered daily (morning) by inhalation
3168421|NCT00550797|Placebo Comparator|Phosphate Buffer solution|Placebo solution (PBS) will be administered daily in the form of 1 mL of PBS (phosphate buffered saline) by inhalation
3168422|NCT00550823|Experimental|A,1|
3168423|NCT00550849|Experimental|1|RTA 402
3168424|NCT00550849|Experimental|2|RTA 402
2541078|NCT02623556|Experimental|TB subjects|"720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method.~360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h."
2541080|NCT02623556|Experimental|non-TB subjects with lung disease and suspected TB subjects|360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.
2541161|NCT02623179|Active Comparator|A-Culture and Sensitivity group|Diagnosis by Culture and Sensitivity group-Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
2541165|NCT02623179|Active Comparator|B-Diagnosis by Molecular Testing|Diagnosis by Molecular Testing-Treatment based on the results of the PathoGenius molecular testing - Even Numbers on randomization table
2541220|NCT02622711|Experimental|DI Dietary Intervention|Individualized dietary counselling to reduce body weight
2541229|NCT02622711|Experimental|PAI Physical Activity Intervention|Individualized physical activity counseling to reduce body weight
2541235|NCT02622711|Experimental|PADI Physical Activity+Diet Intervention|Individualized dietary and physical activity counseling to reduce body weight
2541239|NCT02622711|Experimental|LII Less Intensive Intervention|Materials and guidelines available to general public
2541304|NCT02622100||Bioresorbable Vascular Scaffold|
2541386|NCT02621632|Other|Healthy subjects and patients|To done a novel compression system. 20 healthy subjects and 20 patients done a novel compression system termed Socknleg and a compression class III stocking as a comparator.The Socknleg compression system was developed by the investigator and produced by Sigvaris AG, St. Gallen, Switzerland.
2541443|NCT02621320|Experimental|Vitamin D|alcohol-based (Ethanol 65%) Vitamin D3 (Vi-De 3®. WILD) solution 6000IU per day.
2541444|NCT02621320|Placebo Comparator|Placebo|Same alcohol-based solution (Ethanol 65%) as intervention product but without cholecalciferol
2541560|NCT02620436|Experimental|Core Mother Shelter Model|Existing mother shelters will be renovated, and mother shelters will be built at intervention sites, to meet the Core Mother Shelter Model. This model includes ensuring a safe infrastructure with four walls, a roof, doors and windows that lock, a toilet, running water, and beds.
2541564|NCT02620436|No Intervention|Standard of Care|Existing mother shelters with no changes made, except to ensure that they can provide standard of care.
2541591|NCT02620085||Graves' disease|Patient had been diagnosed of Graves' disease and now under euthyroid status
2541709|NCT02619370|Experimental|Intervention|Play 'My Gift of Grace,' a conversation card game for 4-6 players (the game consists of 20 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues); all game sessions will be audio recorded and transcribed.
2541713|NCT02619370|Active Comparator|Control|"Review and discuss a brochure on ACP called Advance Care Planning: Tips from the National Institute of Aging. Discussion will be prompted by the researcher asking participants to discuss the information they've just read with the group. However, there will not be a formal structure to this discussion."
2541754|NCT02619110|Other|backward walking treadmill training|The intervention group not only received four weeks of conventional physical therapy but also accepted additional four weeks of backward walking treadmill training at the same time
2541762|NCT02619110|Other|conventional physical therapy|The conventional physical therapy training focused on strengthening, postural control, functional mobility and forward gait training program but excluded backward walking training
2541811|NCT02618668|Experimental|Ketamine / Propofol Admixture|Ketamine / Propofol Admixture: I.V propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+ 4 ml saline in a 20-ml syringe which resulted in 0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol.
2541812|NCT02618668|Active Comparator|Propofol|I.V propofol 2 mg/kg
2541825|NCT02618395|Experimental|Treatment A|
2541830|NCT02618395|Experimental|Treatment B|
2541834|NCT02618395|Experimental|Treatment C|
2541858|NCT02618252|Experimental|Zonare|108 patients are randomized to receive the intervention of using ultrasound machine (Zonare ZS3 machine) for IV cannulation. These patients will first undergo IV cannulation with assistance of the ultrasound machine.
2541861|NCT02618252|Experimental|Veinviewer|108 Patients are randomized to receive the Intervention of using the Veinviewer Flex machine for IV cannulation. These patients will first undergo IV cannulation with assistance of the Veinviewer Flex machine.
2542265|NCT02615561|Experimental|Phase 1 (Cure phase)|Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)
2542273|NCT02615561|Experimental|Phase 2 (Care phase) / Arm 1|Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD
2542277|NCT02615561|Active Comparator|Phase 2 (Care phase) / Arm 2|Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD
2542802|NCT02612337|Placebo Comparator|Placebo|
3168425|NCT00550849|Experimental|3|RTA 402
3168426|NCT00550875|Experimental|1|
3168427|NCT00550875|Experimental|2|10* concentration of arm 1
3168428|NCT00550875|Placebo Comparator|3|
3174144|NCT00620256|Placebo Comparator|AL-37807 vehicle|AL-37807 ophthalmic solution vehicle, one drop in the study eye(s) at 8 AM, with latanoprost ophthalmic solution, one drop in the study eye(s) at 8 PM, for four weeks
3174145|NCT00620269|Experimental|study arm 1|Induction (with Erlotinib X 3 cycles) -> CCRT with Erlotinib (X 2 cycles) -> continue Erlotinib (X 6 cycles)
2541086|NCT02623543|Experimental|OrthoK|OrthoK lenses will be prescribed for subjects randomly and followed for 2yrs throughout wearing the lenses. There will be an enrollment appointment, dispense appointment, 1-day, 1-week, 1-month, 6-month, 12-month, and 24-month follow-ups.
2541089|NCT02623543|Placebo Comparator|Control|Subjects in the randomly assigned control will continue to wear their glasses throughout the 2yr follow-up period. There will be an enrollment appointment, 6-month, 12-month, and 24-month follow-ups.
2541157|NCT02623192||ARDS|
3202811|NCT00917033|Experimental|GlideScope|Orotracheal intubation using the GlideScope videolaryngoscope
3202812|NCT00917033|Active Comparator|Macintosh|Orotracheal intubation using the Macintosh direct laryngoscope
2541565|NCT02620410|Other|Axonics SNM System|Axonics SNM Therapy for urinary control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.
2541624|NCT02620072|Experimental|oral insulin capsule (dose escalation using 2 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 67.5 mg rH-insulin crystals. Insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) contained in hard gelatine capsules given orally.
2541626|NCT02620072|Placebo Comparator|Placebo capsule|Daily administration of placebo capsules containing filling substance (microcrystalline cellulose).
2541675|NCT02619656|Experimental|Treatment|"Patients randomized to insufflation with CO2.~Intervention: CO2 Insufflation with CO2Efficient Endoscopic Insufflator on managed flow setting at 3.4 L/min"
2541678|NCT02619656|Active Comparator|Control|"Patients randomized to insufflation with ambient air.~Intervention: Ambient air insufflation with Evis Exera 111 CLV-190 on medium air flow setting 0.68 L/min"
2541747|NCT02619214|Experimental|Oxygen 30%|Patient receives 1 hour of general anesthesia with a 30% oxygen concentration.
2541748|NCT02619214|Experimental|Oxygen 60%|Patient receives 1 hour of general anesthesia with a 60% oxygen concentration.
2541826|NCT02618746|Experimental|Group A, Telerehabilitation|The 12-month home care/rehabilitative program will include the following components: a) individualized action plan; b) educational session on self management; c) physical exercise sessions to remote monitoring; d) access to the call centre; e) professional weekly calls by physiotherapists, dietician and physician with remote connection as a response to possible incidents; f) remote monitoring selectively and temporarily.
2541827|NCT02618746|Active Comparator|Group B, Hospital based Rehabilitation|Patients assigned to the hospital based program will visit the hospital twice weekly for 12 months in order to participate in a multidisciplinary rehabilitation program including exercise, physiotherapy dietary and psychological advice by the staff of the rehabilitation centre based at the University clinic.
2541833|NCT02618746|No Intervention|Group C, Usual care Group|The control group will follow the usual care not involving the initial 8-week rehabilitation program neither maintenance hospital rehabilitation sessions or home telemonitoring of vital signs.
2541865|NCT02618278|Experimental|Intervention|Patients randomised to the intervention arm will receive a individual, goal -orientated physiotherapy management package within 2 weeks G.P referral for physiotherapy.
2541867|NCT02618278|Active Comparator|Usual care|Patients randomised to usual care will receive the same individual, goal-orientated physiotherapy management as the intervention arm but at 6 weeks post G.P referral, as is usual care.
2541926|NCT02617927||Vedolizumab Cohort|"Group 1a Mothers exposed to Vedolizumab at any time during pregnancy (and up to 3 months prior to last menstrual period [LMP], if this information is available).~Group 1b Infants born to Group 1a patients."
2541930|NCT02617927||Anti-TNF Agents Cohort|"Group 2a Patients with IBD who were exposed to anti-TNFs at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~Group 2b Infants born to Group 2a patients."
2541932|NCT02617927||Conventional therapy only Cohort|"Patients with IBD who were exposed to conventional therapy only any time during pregnancy (and up to 3 months prior to LMP, if this information is available).~• Group 3b Infants born to Group 3a patients."
3174146|NCT00620269|Experimental|study arm 3|Induction (IP X 3 cycles) -> CCRT with IP (X 2 cycles)
2542101|NCT02617095|Experimental|T2762|One drop of T2762 in each eye 3 to 6 times daily
2542102|NCT02617095|Active Comparator|Optive|One drop of Optive in each eye 3 to 6 times daily
2542143|NCT02616289|Experimental|Emollient|Topical emollient (Sun Flower seed oil) in addition to routine standard of care for severe acute malnutrition.
2542150|NCT02616289|No Intervention|Control|Routine Standard of care only for severe acute malnutrition.
2542177|NCT02616094|Experimental|Treatment Seeking Alcohol Dependent Adults|Group consists of 100 treatment seeking alcohol dependent (AD) men and women (ages 18-60). AD subjects will complete either 8 weeks of outpatient treatment at the Yale Stress Center, or the first 4 weeks as inpatient treatment at the CNRU, followed by 4 weeks of outpatient treatment at the Yale Stress Center. While in outpatient treatment, AD subjects may be admitted to the CNRU or HRU for the 1-5 days prior to one or both of their scans, to ensure abstinence for their scans.
2542182|NCT02616094|Active Comparator|Social Drinking Controls|Group consists of demographically and handedness matched 50 socially drinking controls. Healthy controls will be moderate and binge/heavy social drinkers who will participate in a single MRI session after baseline assessments. Healthy controls may be admitted to the HRU overnight prior to their scan.
2542190|NCT02616094|Active Comparator|Prazosin/Placebo Group|This is a separate group of 60 treatment seeking AD subjects in a NIAAA-funded RCT of Prazosin vs placebo for alcohol dependence ( PI: Sinha, Hic protocol 0705002691, NCT00585780) to assess target primary and secondary predictors of alcohol treatment outcomes in the context of a currently ongoing RCT. AD subjects enrolled in the PZ/PL RCT will NOT be given drugs as part of this study. That study and intervention is listed elsewhere (NCT00585780). Subjects will participate in a baseline scan and a second scan between weeks 10-12 of the 12-week RCT with follow-ups. PZ/PL is only given to subjects enrolled in 0705002691, not the current protocol.
3174147|NCT00620269|Active Comparator|control arm|CCRT with IP (X 2 cycles) -> consolidation IP (X 3 cycles)
3202813|NCT00917046|Experimental|1 Interval training|high-intensity Interval Training
3202814|NCT00917046|Experimental|2 Moderate Training|Moderate continuous training
3202815|NCT00917046|Active Comparator|3 Recommendation of exercise|Recommendation of regular exercise at moderate intensity at individual choice
2541115|NCT02623296|Placebo Comparator|Placebo and single CYP450 substrate cocktail dose|Daily Placebo administration from Day 1 to Day 12 Single Placebo co-administration on Day 13 with CYP450 substrate cocktail
2541173|NCT02623023|Experimental|Combigan group|Combigan will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
2541177|NCT02623023|Placebo Comparator|Refresh tears|Refresh tears will be administered twice a day on the day before the intraocular injection and once in the morning of the injection
2541199|NCT02622620||Patients with glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
2541313|NCT02622035|Experimental|1|Gain frame; Anger
2541315|NCT02622035|Experimental|1b|high visual perception load high interactive
2541318|NCT02622035|Experimental|2|Gain frame; Fear
2541320|NCT02622035|Experimental|2b|high visual perceptual load
2541322|NCT02622035|Experimental|3|Loss frame; Anger
2541324|NCT02622035|Experimental|3b|low visual preceptual load
2541328|NCT02622035|Experimental|4|Loss frame; Fear
2541412|NCT02621476|Experimental|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
2541415|NCT02621476|Experimental|Usual care|Usual care
2541460|NCT02621164|Experimental|NBP607-QIV|Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine
2541463|NCT02621164|Active Comparator|Agrippal S1|Trivalent Inactivated Egg-derived Influenza Vaccine
3202816|NCT00917059|Active Comparator|1|Participants will receive a 1-week treatment of escitalopram and then an 8-week treatment with escitalopram.
3202817|NCT00917059|Active Comparator|2|Participants will receive a 1-week treatment with escitalopram and then an 8-week treatment with bupropion XL.
2541600|NCT02620293|Experimental|Eczema Emollient|Eczema Repair Emollient
2541655|NCT02619747|Active Comparator|Compound Sodium Alginate Oral Suspension sachet|Single dose of contents of two 10 ml sachets of Compound Sodium Alginate Oral Suspension
2541657|NCT02619747|Placebo Comparator|Matched placebo|Single dose of contents of two 10 ml sachets of matched placebo
3202818|NCT00917072|Experimental|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
3202819|NCT00917072|Experimental|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center.
3202820|NCT00917072|Placebo Comparator|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
3202821|NCT00917085|No Intervention|Control group|Control infants received the same standard care as infants who were not in the study. Infants were kept warm in incubators or warmer beds and were wrapped in blankets when held by their mothers. Hospital staff was responsible for providing standard care.
3202822|NCT00917085|Experimental|Skin-to-Skin group|
3202823|NCT00917098|Experimental|Behavior Therapy|Participants will receive behavior therapy during Phases 1 and 2.
2541885|NCT02618096|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
2541887|NCT02618096|Active Comparator|Oxytocin & Dinoprostone|"Women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
2541954|NCT02617810|Experimental|JNJ-42847922 Plus Midazolam Plus Warfarin|Participants will receive Treatment A (midazolam 4 milligram [mg] syrup once on Day 1 and warfarin 25 mg tablet once on Day 3) followed by Treatment B (JNJ-42847922 20 mg once daily from Day 1 to Day 9, midazolam 4 mg syrup once on Day 7 and warfarin 25 mg tablet once on Day 9). A washout period of 14 to 21 days will be maintained between each treatment period.
2542007|NCT02617212|Experimental|Definitive abutment|Implant surgery. No abutment dis-/reconnections.
2542009|NCT02617212|Active Comparator|Conventional treatment|Implant surgery. Three abutment dis-/reconnections.
2542077|NCT02616822|Experimental|trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
2542081|NCT02616822|Placebo Comparator|Placebo|Used for placebo substance single dose
2542159|NCT02616549|Experimental|Sudarshan Kriya Yoga|
2542161|NCT02616549|No Intervention|Waitlist Control|
2542186|NCT02616042|Experimental|Centella asiatica and bamboo salt|Participants received a dentifrice which contains Centella asiatica, bamboo salt, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime). All participants used the assigned dentifrices for 4 days in each trial cycle.
2542191|NCT02616042|Experimental|Centella asiatica|Participants received a dentifrice which contains Centella asiatica, dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
2542194|NCT02616042|Placebo Comparator|Control dentifrice|Participants received a plain dentifrice which contains dental-type silica, sodium fluoride and aminocaproic acid. Each participant brushed their teeth using only the assigned dentifrices for 3 minutes twice a day (after breakfast and before bedtime).
2542241|NCT02615769|Experimental|Invitation with focused information of spirometry|
2542242|NCT02615769|Active Comparator|Standard invitition|
2542734|NCT02612675|Experimental|Low Carbohydrate ONS|Nutritional beverage (Oral Nutrition Supplement) designed for oral consumption
2541160|NCT02623231|Experimental|escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
2541163|NCT02623231|Placebo Comparator|placebo|Group number 2 will include 50 patients, who will receive Placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
2541197|NCT02622646||Well controlled patients|Patients with an adequate disease control with the routine clinical practice (AJBR≤2, non-severe ABR≤5 and severe ABR≤2) (Ministerio de Sanidad, Servicios Sociales e Igualdad. Gobierno de España; 2012)
2541198|NCT02622646||Poor controlled patients|Patients with poor disease control, based on the international guidelines: AJBR>2, ABR>2 for severe BE or ABR >5 for non-severe BE
2541263|NCT02622425|Active Comparator|PD01|Carotenoid-producing Bacillus strain PD01
2541264|NCT02622425|Placebo Comparator|Placebo|Maltodextrin
2541317|NCT02621996|Experimental|Hammock group|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
2541319|NCT02621996|Active Comparator|control group|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
2541383|NCT02621697|Experimental|Cognitive motor training|Evaluate the effectiveness of a 12-week training based on dual-task (motor and cognitive) in institutionalized elderly.
2541384|NCT02621697|Active Comparator|Control Group|kinesiotherapeutic conventional treatment
2541428|NCT02621346|Experimental|Imagery Group|The imagery group, will sit on the leg press and image completing 3 sets of leg press. The imagery group will be asked to fill out the Movement Imagery Questionnaire -revised as this gives us a measure of imagery ability. The imagery group will be given an imagery script prior to imaging. Weekly manipulation checks will be completed to ensure that participants are imagining what they are supposed to.
2541429|NCT02621346|Active Comparator|Maintenance Group|The maintenance group will continue to perform the leg press three times per week at 1/3rd of final strength assessment. This is the percentage of intensity recommended to maintain muscle mass and strength gains by the American College of Sports Medicine.
2541430|NCT02621346|Active Comparator|Control Group|Control group will come in 3 times per week for 20 minutes and complete 3 sets of 8-12 of a bicep curl 1/3 of predicted 1 RM
2541458|NCT02620995|Experimental|hypertensive patients|Hypertensive patients will receive a single oral dose of sildenafil citrate (100 mg) - acute protocol - and a chronic 30-day treatment with sildenafil citrate (50 mg twice daily) - chronic protocol. Penile and systemic microvascular function will be evaluated before and one hour after acute sildenafil administration and in the end of each treatment period.
2541464|NCT02620995|Sham Comparator|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
2541491|NCT02620735|Active Comparator|Exercise Only|Participants receive 12-weeks PA training (1x/week - 60 min) group sessions with a CEP/RKin, and a progressively structured home-based exercise program based on the American College of Sports Medicine (ACSM) guidelines.It combines aerobic-resistance exercise with flexibility training, and progresses towards increased in intensity and improved fitness. The goal is at least 150 min/week of moderate-intensity aerobic activity. Participants are also asked to complete 3-5 additional home-based sessions of aerobic, and resistance activities each week. Initial intensity is based on the performance of the exercises during a group session and is self-monitored via the 10-point rating of perceived exertion, with a prescribed training zone of 4-7.
2541493|NCT02620735|Experimental|Exercise + iMOVE|Participants will receive the same exercise program at the Exercise Only group + 1) one-on-one telephone-based counselling (10 x 30-minute telephone: weeks 1, 2, 3, 4, 5, 6, 8, and 12 (during the exercise program) and at weeks 20,28 (post-exercise program booster sessions)); 2) supportive software on smart-phone devices (the HealthCoach program), 3) use of Fit-bit and corresponding software. The iMOVE intervention was designed to enhance sustained behavior change. The theoretical constructs employed are based on promoting motivation and establishing: a) exercise self-efficacy, b) social support for exercise and c) positive exercise-induced feelings during the acute intervention (12 weeks) and post-exercise program period (6 months).
2541537|NCT02620501|Placebo Comparator|Placebo|Patients will receive 10cc of 1/2 normal saline to gargle prior to EGD
2541541|NCT02620501|Experimental|Experimental|Patients will receive 10cc of 2% topical lidocaine to gargle prior to EGD
2541584|NCT02620215|Experimental|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
2541586|NCT02620215|Active Comparator|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
2541636|NCT02619773|Experimental|Mupirocin dressing|"Mupirocin + island dressing applied to surgical incision until postoperative day 5.~Intervention: mupirocin ointment applied to extrication incision."
2541637|NCT02619773|No Intervention|Island dressing|Island dressing applied to surgical incision until postoperative day 2. This arm will not undergo any intervention.
2541669|NCT02619539||Trauma patients|All patients having / suspected to have severe trauma injuries admitted to participating centers.
2541737|NCT02619331|Experimental|Atopic volunteers|Allergy tests will be performed in allergic patients with rhinoconjunctivitis and allergy test reading measured following two different methodologies. 1) test reading based on conventional wheal and flare measurement (wheal diameter in mm, CWFM), 2) test reading based on high speed laser doppler imaging (HS-LDI). Both type of tests reading will be compared.
2541178|NCT02622945|Experimental|Active tDCS plus Speech-Language Therapy|Active tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
2541179|NCT02622945|Sham Comparator|Sham plus Speech-Language Therapy|Sham tDCS will be applied at the beginning of 45min speech-language therapy session. Language therapy will be oral and written naming. This is a cross-over study so all participants will receive this arm but the order will be randomized.
3202824|NCT00917098|Placebo Comparator|Supportive Counseling|Participants will receive supportive counseling during Phase 1 and will not participate in Phase 2.
3202825|NCT00917111|Experimental|CO2 Gas|
2541326|NCT02622009||COPD I|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE I
2541330|NCT02622009||COPD II|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE II
2541333|NCT02622009||COPD III|BRONCHOSCOPIC PROCEDURE IN COPD PATIENTS STAGE III
2541336|NCT02622009||NONSMOKERS|BRONCHOSCOPIC PROCEDURE IN NONSMOKERS
2541338|NCT02622009||CURRENT OR EXSMOKERS|BRONCHOSCOPIC PROCEDURE IN CURRENT OR EXSMOKERS
2541388|NCT02621658|Active Comparator|Clear Liquid Diet|Clear Liquid Diet the day before colonoscopy.
2541389|NCT02621658|Experimental|Full Liquid Diet|Full Liquid Diet the day before colonoscopy.
2541422|NCT02621281|Active Comparator|cold storage|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
2541424|NCT02621281|Active Comparator|Kidney Transporter machines|In this randomized clinical trial, 200 kidney pairs from deceased donors will be included in the study, which will be randomly assigned, one kidney to machine perfusion and the other to cold storage. In machine perfusion group, patients will be analyzed by two subgroups based on pressure, resistance index and perfusion time duration.
2541453|NCT02621086|Experimental|Level 1|10g of Cellodextrin
2541457|NCT02621086|Experimental|Level 2|20g of Cellodextrin
2541461|NCT02621086|Experimental|Level 3|30g of Cellodextrin
2541462|NCT02621086|Experimental|Level 4|50g of Cellodextrin
2541495|NCT02620748|Experimental|Tranexamic Acid|This arm will receive an injection of Tranexamic Acid
2541499|NCT02620748|Placebo Comparator|Saline|This arm will receive an injection of Saline Solution
2541534|NCT02620553|Experimental|Human Insulin|Oral Insulin at 2.5 mg, 7.5 mg, 22.5 mg, or 67.5 mg per day
2541540|NCT02620553|Placebo Comparator|Placebo|Oral Placebo
2541585|NCT02620228|Experimental|BIP Biopsy System|Biopsy system that enables real-time bioimpedance measurement from the tip of the biopsy needle.
2541634|NCT02619890||Patients with glioma requiring treatment|Patients with glioma requiring treatment, who undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent
2541682|NCT02619565|Other|Blood samples if evolution of the disease|blood samples at Day 0 and also if there is an evolution of the disease
2541718|NCT02619188||Hyperemesis gravidarum|Hyperemesis gravidarum patients admitted to hospital PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis), Intervention at discharge : PUQE-form, Nutritional form and Blood sampling
2541719|NCT02619188||Control: Healthy pregnant women|Outpatients NOT subjected to severe nausea and emesis (PUQE-score <13). PUQE-form inclusion (PUQE-score), Nutritional form inclusion, Blood sampling inclusion (Prealbumin analysis).
2541759|NCT02618876|Active Comparator|Nalbuphine group|30 children will be given Caudal Bupivacaine plus Nalbuphine.
2541766|NCT02618876|Other|Control group|30 children will be given Caudal Bupivacaine.
2541891|NCT02618694|Experimental|Group 1|patient had posterior retroperitoneoscopic adrenalectomy
2541893|NCT02618694|Active Comparator|Group 2|patient had Transperitoneal laparoscopic adrenalectomy
2541957|NCT02617693|Other|Standard of care|
2541966|NCT02617693|Experimental|Life style intervention|
2542037|NCT02617316|Other|barefoot first|Ten runners carried on barefoot test first and then in-shoes.
2542038|NCT02617316|Other|in shoes first|Ten runners carried on in-shoes test first and then barefoot.
2542071|NCT02616744|Experimental|Arm A: Ibandronic acid|Ibandronic acid 150 mg per os per month for two years
2542075|NCT02616744|Placebo Comparator|Arm B: Placebo|Placebo per os per month for two years
2542131|NCT02616445|Placebo Comparator|MAD Study|
2542133|NCT02616445|Placebo Comparator|Fed-Fasted|
2542140|NCT02616445|Experimental|CSF|
3202826|NCT00917111|Placebo Comparator|Inactive Placebo Gas|
3202827|NCT00917137||Peripheral pulmonary lesions|
3202828|NCT00917163|Experimental|Supralimus(R) Sirolimus Eluting Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
3202829|NCT00917163|Active Comparator|Xience V™ Everolimus Eluting Stent|The XIENCE V™ Everolimus Eluting Coronary Stent System consisting of the MULTI-LINK VISION® Coronary Stent System coated with a formulation containing everolimus, the active ingredient, embedded in a non-erodible polymer., Drug Load: 100 µg/cm2
3202830|NCT00917176|Experimental|Effective stimulation|Effective stimulation at sub-threshold level
3202831|NCT00917176|Placebo Comparator|Placebo stimulation|Stimulation at non-effective strength
3202832|NCT00917189|Experimental|Computerized Cognitive Skills Training|Participants will receive the Challenging Our Minds intervention, delivered in-person in Phase 1 and remotely in Phases 2 and 3.
3202833|NCT00917202|Experimental|MB3|3 days
3202834|NCT00917202|Experimental|MB5|5 days
3202835|NCT00917202|Experimental|MB7|
3202836|NCT00917215|Experimental|Active acupuncture|
3202837|NCT00917215|Sham Comparator|Sham acupuncture|
3202838|NCT00917215|No Intervention|Waiting list control|
3202839|NCT00917228||Feedback|Subjects of this group are equipped with the biofeedback system
3202840|NCT00917228||Control|Subjects of this group are not equipped with the biofeedback system
2541187|NCT02622867|Experimental|Lactobacillus plantarum 3547|1 capsule/daily during 12 weeks with Lactobacillus plantarum 3547 (10x109 cfu/d). The capsule contains 77 mg probiotic Lp3547 and 390 mg maltodextrin
2541189|NCT02622867|Placebo Comparator|Maltodextrin|1 daily capsule of maltodextrin (425 mg) during 12 weeks
2541201|NCT02622503||Patients with rheumatoid arthritis|Patients with rheumatoid arthritis receiving rituximab will be observed for treatment responses.
2541316|NCT02622048|Experimental|Stage 2 Parents experiencing psychosis|Parents all receive the self-directed Triple P Positive Parenting Programme
2541426|NCT02621333|Experimental|CIK combined chemotherapy group|autologous CIK combined chemotherapy group Drugs: platinum combined doublets; After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-indued killer cells are transfused into the vein of patients in one hour.
2541427|NCT02621333|Active Comparator|chemotherapy group|platinum combined doublets Drugs: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/ m2，D1-3 or carboplatin AUC=5, D1.
3168429|NCT00550914||Control arm|The conventional therapy arm will undergo debridement with either a powered microdebrider or cold instrumentation excision as per the preference of the individual surgeon. Debridement will be deemed complete after removal of gross papilloma to the extent that the individual surgeon feels can be safely accomplished. Standard microsurgical principles of the larynx will guide debridement in that no opposing mucosal surfaces of the true vocal folds, laryngeal ventricle or inter-arytenoid space will be simultaneously debrided
3168430|NCT00550914||Experimental Arm|Patients enrolled into the conventional therapy plus PDL treatment arm will undergo debridement of the supraglottis and subglottis via conventional techniques as per the individual surgeons preferences followed by therapy to anterior commissure, true vocal folds, laryngeal ventricle and inter-arytenoid space with the pulsed dye laser. Standard laser settings will be a 450 microsecond pulse width, 5 J per pulse maximum of 1Hz, 1 mm spot fiber, 1-2 mm spot size and fluences of 38-255 J/cm2.
2541598|NCT02620345|Experimental|Dydrogesterone M/ Women Pregnancy|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Women Pregnancy~Dosage:~1tablet/24 hours/day/ (when seeing fibroids to 4 weeks after postpartum). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids throughout pregnancy after 48 weeks."
2541599|NCT02620345|Experimental|Dydrogesterone M/ Reproductive Age|"Reducing the size of fibroids with medication~Drug: Dydrogesterone M 15mg/Fibroids/Reproductive Age~Dosage:~1tablet/24 hours/day/24 weeks ( from discovered fibroids through 24 weeks). Dydrogesterone 15mg/day Beta Carotene 4000 IU/day Ascorbic Acid 100 mg/day Cholecalciferol 400 IU/day Dl-Alpha Tocopheryl Acetate 11IU Thiamin Mononitrate 1.5 mg/day Riboflavin 1.7 mg/day Niacinamide 18 mg/day Pyridoxine Hydrochloride 2.6 mg/day Folic Acid 400 mcg/day Cyanocobalamin 4mcg/day Calcium Carbonate 150 mg/day Ferrous Fumarate 27 mg/day Zinc Oxide 25 mg/day~The lost in size of fibroids after 24 weeks."
2541676|NCT02619734|No Intervention|Control|Conventional treatment established by the good clinical practice Patients received standard local care dressing method (compresses) to heal leg ulcers
2541679|NCT02619734|Experimental|Stem Cell Injection|Intramuscular implantation of Autologous bone marrow-derived mononuclear cells
2541717|NCT02619292|Experimental|Mindful Movement Program|"Mindfulness is moment-to-moment, present-centered, purposive non-judgmental awareness; Dance/movement therapy is a multidimensional approach that integrates body awareness, expression and acceptance to facilitate physical, emotional, cognitive, social and spiritual integration of individuals"
2541806|NCT02618707||Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
2541813|NCT02618408|Experimental|Low dose SPN-810|Subjects will be treated with low dose SPN-810
2541816|NCT02618408|Experimental|High dose SPN-810|Subjects will be treated with high dose SPN-810
2541818|NCT02618408|Placebo Comparator|Placebo|Subjects will be treated with a Placebo
2541900|NCT02618044||Obese patients without preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass without preoperative GER at 24h-impedance pH monitoring (Group G-)
2541905|NCT02618044||Obese patients with preoperative GER|Obese patients selected for laparoscopic Roux-en-Y Gastric Bypass with preoperative GER at 24h-impedance pH monitoring (Group G+)
2541944|NCT02617797|Experimental|Radiofrequency|Experimental group: women with urinary incontinence are subjected to standard treatment cinesiotherapy perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic in beyond the RF application in the genital area once a week to total 5 sessions.
2541946|NCT02617797|Sham Comparator|Radiofrenquency Off|Control group: women with stress urinary incontinence will be submitted to the treatment of cinesioterapia standard perineal ( pelvic muscle exercises ) every day in home and one session per week in the clinic beyond the application of radiofrequency off in genital area once a week with the total of 5 sessions.
2542013|NCT02617355|Other|Prototype vs Covidien magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs Covidien magnetic drape
2542017|NCT02617355|Other|Prototype vs 4 commercial drapes|"New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax vs 4 commercially available magnetic drapes:~Green Covidien Magnetic Drape Jac-Cell Medic Reusable Magnetic Pad DeRoyal Magnetic Pad size 10 x 16 DeRoyal Magnetic Pad size 20 x 16"
2542082|NCT02616731|Active Comparator|Tranexamic acid|
2542088|NCT02616731|Active Comparator|Diosmin|
2542160|NCT02616419|Experimental|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
2542162|NCT02616419|Active Comparator|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
2542742|NCT02612506|Experimental|Hepalatide|Hepalatide 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
2541238|NCT02622490|Experimental|High carb. 5 meals|Intervention: Five meals every 30 minutes of 150 kcal/each with 50 % of energy content from carbohydrates.
2541280|NCT02622256|Experimental|Health System: HTN Intervention|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys.
2541285|NCT02622256|No Intervention|Health System: HTN Control, survey only|Investigators will identify patients with known hypertension (ICD-9 code 401.9), from the Penn Data Store (PDS). Participants will be asked to complete 3 short surveys. Participants in this arm will be exposed to daily messages about heart health and asked to tweet about health.
3174148|NCT00620269|Experimental|study arm 2|Induction (Erlotinib X 3 cycles) -> CCRT with IP (X 2 cycles) -> recurrence -> Erlotinib (until PD)
3174149|NCT00620295|Experimental|Gemcitabine / Bortezomib|"Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose on day 1 and day 8 of a 21 day cycle.~Bortezomib will be given 1 hour after gemcitabine by IVP over 3 to 5 seconds followed by a standard saline on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles."
3174150|NCT00620308|Experimental|CD-NP low-dose study drug|
2541741|NCT02619227|Experimental|Immediate treatment|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2541743|NCT02619227|No Intervention|Delayed treatment|Participants will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
2541782|NCT02618850|Other|Advanced CRC patients undergoing first-line chemotherapy|single cohort
2541864|NCT02618330|Experimental|retainer: 0.75-mm-thick film|
2541866|NCT02618330|Experimental|retainer: 1.00-mm-thick film|
2542047|NCT02617056||Observational group|Subjects with dementia
2542063|NCT02616692||HCC patients / Cohort 1|Patient preferences associated with oral anti-cancer therapy (Sorafenib), repeated TACE, and HAIC and their perceptions regarding the respective treatment characteristics
2542134|NCT02616575||Silver link|Patients enrolled in NTUH hospital and its Behui branch
2542203|NCT02616224||Participants with unresectable LA/mBC|
2542263|NCT02615808|Experimental|Oxygen saturation data visualization|During intervention periods staff in both units will have access to the data visualization tool in the electronic health record.
2542272|NCT02615808|No Intervention|Control|During control periods, the staff will not have access to the data visualization and will continue to use standard of care electronic health record and monitor data to understand oxygen status and trends.
2542319|NCT02615327|Experimental|Active Treatment 1|8g Polydextrose
2542324|NCT02615327|Experimental|Active Treatment 2|12 g Polydextrose
2542329|NCT02615327|Experimental|Active Treatment 3|16 g Polydextrose
2542331|NCT02615327|Placebo Comparator|Placebo|0 g Polydextrose
2542405|NCT02614846|Experimental|Hetrombopag Olamine|All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
2542452|NCT02614391|Experimental|Active distraction using a tablet|Children were admitted in a comfortable room with a parent and started to play with a videogame suitable for their age three minutes before procedure. They continued to play the videogame during venipuncture. The use of a computer tablet permitted to play with one hand only.
2542460|NCT02614391|Active Comparator|Passive distracion|Children were admitted in a comfortable room with a parent and received various kinds of passive distractions: nurses singing a song, reading a book, blowing bubbles and playing a puppet show. The technique that most engaged the child, was continued during procedure.
2542897|NCT02611609|Experimental|Cohort 1|Low dose MultiStem
2542901|NCT02611609|Experimental|Cohort 2|High dose MultiStem
2542906|NCT02611609|Experimental|Cohort 3|Highest safe MultiStem dose (from Cohorts 1 and 2) or Placebo
2542954|NCT02611271||Piperacillin/Tazobactam|Critically ill patients teated with piperacillin/tazobactam undergoing renal replacement therapy and cytosorb absorption during sepsis
2542958|NCT02611271||Imipenem/Cilastatin|Critically ill patients teated with imipenem/cilastatin undergoing renal replacement therapy and cytosorb absorption during sepsis
2542992|NCT02610985|Active Comparator|2-Dimensional laparoscopic hysterectomy|traditional 2-D laparoscopy
2542994|NCT02610985|Experimental|3-Dimensional laparoscopic hysterectomy|experimental 3-D laparoscopy
2543027|NCT02610751||Smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
3174151|NCT00620308|Experimental|CD-NP high-dose study drug|
3174152|NCT00620308|Placebo Comparator|Placebo|
3174153|NCT00620334||1|"ASTHMA:~PREVOUSLY DIAGNOSED MILD ASTHMA PATIENTS"
3174154|NCT00620334||2|"CONTROL:~PATIENTS WHO HAVE NEVER BEEN DIAGNOSED WITH ASTHMA"
3174155|NCT00620347|Experimental|Single arm|Single arm (sunitinib arm) until PD, unacceptable toxicity, patients refused
3174156|NCT00620360|Experimental|fructose|acute fructose administration
3174157|NCT00620386|Experimental|1|Intubation with Bonfils intubating fiberscope
3174158|NCT00620386|Active Comparator|2|Intubation with Macintosh laryngoscopy
3174159|NCT00620399|Experimental|1|brace
3174160|NCT00620399|Placebo Comparator|2|no brace
3174161|NCT00620412|Active Comparator|treatment|
3174162|NCT00620412|Placebo Comparator|placebo|
3174163|NCT00620438|Experimental|1|nevirapine arm
3174164|NCT00620438|Experimental|2|efavirenz arm
3174165|NCT00620438|Experimental|3|Rifampicin arm
3174166|NCT00620451|Experimental|Larazotide acetate 4 mg|larazotide acetate capsules 4 mg TID
3174167|NCT00620451|Experimental|Larazotide acetate 8 mg|Larazotide acetate capsules 8 mg TID
3174168|NCT00620451|Placebo Comparator|Placebo|Placebo capsules
3174169|NCT00620477|Experimental|1|injection in the knee joint with 20 ml of chirocaine 0.125%
2541241|NCT02622685|Experimental|DWP10292|"Drug: DWP10292 DWP10292 tablets, oral administration, multiple administration~Arms: DWP10292"
2541244|NCT02622685|Placebo Comparator|DWP10292 Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
2541245|NCT02622685|Experimental|Ursodeoxycholic acid (UDCA)|"Drug: Ursodeoxycholic acid (UDCA) UDCA tablets, oral administration, multiple administrations~Arms: Ursodeoxycholic acid (UDCA)"
2541249|NCT02622685|Placebo Comparator|Ursodeoxycholic acid (UDCA) Placebo|"Drug: Placebo Placebo tablets, oral administration, multiple administrations~Arms: Placebo"
2541302|NCT02622139|Experimental|Multispectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography (MSOT) for the evaluation of disease activity in inflammatory bowel diseases (IBD)
2541366|NCT02621814|Experimental|Experimental 1|Formula feeding
2541367|NCT02621814|Experimental|Experimental 2|Formula feeding
2541434|NCT02621411||Substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are found current use of the certain substance(s).
2541437|NCT02621411||Non-substance abuser group|After preoperative screen by application of ICG test cassette, this group of patients are not found use of any substance.
2541503|NCT02621008|Experimental|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
2541539|NCT02620566|Active Comparator|Bupivacain -Caudal|Single shot Caudal Block will receive Group C with 1ml per kg Bupivacain 0,25%.
2541546|NCT02620566|Active Comparator|Bupivacain- Local|Single shot Local Infiltration will receive Group L with 0,2ml per kg Bupivacain 0,25%.
2541641|NCT02619903|No Intervention|COPD Control|Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention.
2541642|NCT02619903|Active Comparator|COPD Test|Subjects with COPD that do get the additional dental cleaning, as well as dental examination.
2541652|NCT02619513|No Intervention|General anesthesia group(Group GA)|Group GA received general anesthesia only and intravenous analgesia pump.
2541653|NCT02619513|Experimental|TEB group(Group GE)|Group GE received continuous thoracic epidural block(TEB) combined with general anesthesia and postoperative continuous thoracic epidural analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
2541654|NCT02619513|Experimental|PVB without DEX group (Group GT)|Group GT received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block(PVB) combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia, and only added ropivacaine in PVB as an postoperative adjuvant.
2541656|NCT02619513|Experimental|PVB with DEX group(Group GTD)|Group GTD received ultrasound-guided(Mindray M7 series) continuous thoracic paravertebral nerve block combined with general anesthesia and continuous thoracic paravertebral nerve block patient-controlled analgesia,but with dexmedetomidine 0.5μg/kg added to ropivacaine in PVB as an adjuvant.
2541694|NCT02619383|Experimental|HBOT|All patients were treated with 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
2541725|NCT02619162|Experimental|Letrozole+Nintedanib|Letrozole+Nintedanib
2541778|NCT02618889|Active Comparator|CBT plus botox|Participants will be randomized to receive BoNT (onabotulinumtoxinA). Patients will undergo study assessments four weeks later. We will inject a total of 250 units of onabotulinumtoxinA, as the average optimal dose in cervical dystonia,11 using a 100:1 dilution with normal saline. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
2541787|NCT02618889|Placebo Comparator|CBT plus placebo|Participants will be randomized to receive normal saline (placebo). We will inject a total of 250 units of normal saline, as this is the average optimal dose of onabotulinumtoxinA in cervical dystonia. The target muscles will be the ones deemed most active in the cervical region or in any of the affected limbs. If several limbs are affected, only up to two will be targeted in similar fashion, with a total dose not to exceed 400 units altogether (250 +150 units, if involvement is asymmetric or unilateral [leg and arm, respectively]; 200 + 200 units, if involvement is symmetric).
2541832|NCT02618564|Active Comparator|2 TABS QHS|Sennosides 2 tabs, taken two nights before the colonoscopy
2541835|NCT02618564|Active Comparator|3 TABS QHS|Sennosides 3 tabs, taken two nights before the colonoscopy
2541837|NCT02618564|Active Comparator|2 TABS AM|Sennosides 2 tabs, taken the morning before the colonoscopy
2541838|NCT02618564|Active Comparator|3 TABS AM|Sennosides 3 tabs, taken the morning before the colonoscopy
2541839|NCT02618564|Active Comparator|2 TABS AM & QHS|Sennosides 2 tabs taken the morning before and 2 tabs taken the evening before the colonoscopy.
2541892|NCT02617992||EMR Surveillance|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions undertaking a surveillance visit will be included in this cohort.
2541923|NCT02617823|No Intervention|semi-recumbent|rutine positioning at the hospital today
2541925|NCT02617823|Experimental|lateral position|experimental position to be evaluated against rutine
2541959|NCT02617602|Experimental|Goal directed therapy|Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals
2541968|NCT02617602|Active Comparator|Control|Conventional therapy
2541997|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
2541998|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group.
2542006|NCT02617082||partial breast irradiation|
2542094|NCT02616718|Experimental|Ventral incisional hernia|Repeated computed tomography scan of abdomen
3174170|NCT00620477|Placebo Comparator|2|injection in the knee joint with 20 ml of physiological fluid
3174171|NCT00620490|Experimental|1|Ropivacaine 0.5% 0.1 ml/kg per hour
2541335|NCT02621944|Experimental|Participants 21-30|"This group will receive Melatonin dose of 5 mg/kg enterally, only if the group Participants 11-20 has meet the safety goals. The first dose will be administered via enteral route within 12 hours of life with a target of 6 hours of life.~The melatonin will be administered as a single dose for the first 5 participants in allowing the investigators to determine if the dosing frequency has the potential to decrease in the elimination with hypothermia. The next 5 subjects who will receive multiple doses if there are not any safety concerns.~Additionally, the participants will have the following test performed: Magnetic Resonance Imaging (MRI), Neurological Outcome Assessment, Pharmacokinetics, and safety monitoring."
3202841|NCT00917241|Experimental|MMI+IID group|MMI,methimazole；IID,intrathyroid injection of dexamethasone
2541479|NCT02621138||cerebral palsy|Age 6-12 years Gross Motor Function Classification System I-II
2541481|NCT02621138||control|Age 6-12 years
2541531|NCT02620657||Non interventional study|The patients with advanced NSCLC who have the medical records from Jan 1st 2014 to Dec 31st 2014 will be recruited .
2541617|NCT02620319|Experimental|biodegradable stent|endoscopic implantation of biodegradable airway stent, the SX-ELLA Stent DV Tracheal (DV Stent)
2541643|NCT02619669|Experimental|TAK-228 followed by TAK-228 plus Letrozole|"Eligible subjects will have a research biopsy and baseline blood and urine studies done within two weeks prior to start of study treatment. Subjects will then be treated with TAK-228 for 10 days, and a repeat biopsy and pharmacokinetics will be done on day 11.~The subject will then be treated with the combination of TAK-228 and letrozole for an additional 110 days, before undergoing resection of the primary tumor. Subjects will be treated at the recommended Phase II dose of TAK-228 of 3 mg once daily, and a dose deescalation to 2 mg daily will be performed if dose-limiting toxicity is seen in 1/3 or more of the subjects at the first dose level. The maximum tolerated dose cohort will be expanded to include six to ten subjects."
2541693|NCT02619487|Experimental|8-12 years old, parent receiving text|text message to parent only
2541697|NCT02619487|Active Comparator|13-18 years old, parent receiving text|text message to parent only
2541701|NCT02619487|Active Comparator|13-18 years, both receiving text|Text message to parent and adolescent
2541704|NCT02619487|No Intervention|No text|No text will be sent
2541767|NCT02619084|Experimental|STN DBS ON First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
2541769|NCT02619084|Experimental|STN DBS OFF First|"The study will be performed according a randomized, double-blind, crossover design with two 3-month phases, during which the stimulation could be switched on or off, separated by a 1-month washout period, At the end of the second double-blind phase, a further open period of 6 months with stimulation switched on will follow."
2541820|NCT02618525|Active Comparator|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
2541821|NCT02618525|Active Comparator|Jaw thrust maneuver|Jaw thrust maneuver is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
2541886|NCT02618317|Active Comparator|Heparin Lock Solution|Patients on Heparin 1,000 U/ml locking solution, administered at the end of each dialysis session during a 15-week period .
2541888|NCT02618317|Experimental|Trissodium Citrate 30%|Patients on trissodium citrate 30% locking solution, administered at the end of each dialysis session during a 15-week period .
2541890|NCT02618317|Experimental|Minocycline-EDTA 30 mg/ml - 3 mg/ml|Patients on Minocycline 30 mg/ml/EDTA 3 mg/ml locking solution, administered at the end of each dialysis session during a 15-week period.
2541958|NCT02617706|Experimental|Transdermal Continuous Oxygen Therapy|EPIFLO® working study unit, all day, every day for 2 - 4 weeks + standard wound care
2541967|NCT02617706|No Intervention|Standard of care|standard wound care for 4 weeks
2542020|NCT02617342|Experimental|Robot-mediated Intervention|Families assigned to the robot condition will be asked to complete pre-test assessments and post testing as well as to participate in the robot intervention. The intervention will last for a 8-14 week period in which families will bring their child in 2-3 times a week on average for approximately 30 minutes until 24 treatment sessions have been completed. Children will receive one-on-one intervention with an interventionist facilitating the child's interactions with the robot.
2542029|NCT02617342|No Intervention|Treatment as Usual|Families assigned to the TAU condition will be asked to complete pre-test assessments and approximately 8-14 weeks later return to complete post-test assessments where the social emotions activity will be retested. During the 8-14 weeks between the testing assessments, families in the TAU condition will also receive a weekly email asking about their child's media use.
2542090|NCT02616861|Experimental|IW-1973|1973 Escalating Doses
2542092|NCT02616861|Placebo Comparator|Placebo|Matching Placebo
2542137|NCT02616458|Experimental|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours. The research assistant provided and reviewed proper dosing instructions for acetaminophen and ibuprofen, and provided a prescription for antipyrine/benzocaine analgesic ear drops to each family to use as pain relief if their child did develop ear pain in the subsequent 12 months.
2542149|NCT02616458|Active Comparator|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
2542212|NCT02616068|Experimental|transdermal patch & placebo|transdermal patch 100 mg once a day for 7 days and placebo (for loxoprofen sodium 60 mg tablet) by mouth, every 8 hours for 7 days
2542219|NCT02616068|Active Comparator|loxoprofen sodium & placebo|loxoprofen sodium 60 mg by mouth, every 8 hours for 7 days and placebo (for transdermal patch 100 mg) once a day for 7 days
2543774|NCT02605811|Experimental|temozolomide|temozolomide oral 150mg/m2 d1-5/28d for 12 cycles
3202842|NCT00917241|Active Comparator|MMI Group|MMI,methimazole
3202843|NCT00917254|Experimental|YM150 group-1|YM150 low dose group
3202844|NCT00917254|Experimental|YM150 group-2|YM150 high dose group
2541683|NCT02619500|Experimental|Thrust Manipulation|Subjects in this arm will receive spinal thrust manipulation to both the cervical and thoracic spines.
2541686|NCT02619500|Active Comparator|Non-thrust Mobilizations|Subjects in this arm will receive spinal non-thrust mobilizations to both the cervical and thoracic spines
2541799|NCT02619058|Experimental|Arm 1（NKT cells single low dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 1×10^9 on d1, 2×10^9 on d3, 4×10^9 on d29, 8×10^9 on d31.
2541802|NCT02619058|Experimental|Arm 2（NKT cells single high dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3, 5×10^9 on d29, 5×10^9 on d31.
2541803|NCT02619058|Experimental|Arm 3（NKT cells multiple dose）|Patients will receive intravenous administration of autologous NKT cells, the dose level is 5×10^9 on d1, 5×10^9 on d3 of each 28 days-cycle, the dosing will be ended after 8 cycles.
2541836|NCT02618421||Participants Aged 40 Years or Over|Cross-section of general population of males and females in China, Taiwan, and South Korea
2541874|NCT02618304|Experimental|moderate to severe meibomian gland dysfunction|
3202845|NCT00917254|Placebo Comparator|Placebo group|
2541986|NCT02617472|Experimental|Pelvic floor exercise|Pelvic floor exerciser, daily use
2542022|NCT02617108|Experimental|Foley balloon|Foley balloon following TCRS: a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
2542028|NCT02617108|No Intervention|control groups|control groups: women will not receive any therapy of the treatment (comparison group).
2542031|NCT02617108|Experimental|postoperative estrogen therapy groups|Subjects received postoperative hormone therapy as per the protocol in use in our center for Asherman Syndrome. Immediately after the operation, the subjects were started on a 3- month course of cyclical hormonal therapy, consisting of orally administrated oestradiol valerate 2-4mg/day for 21 days, orally administrated medroxyprogesterone acetate 8mg /day from day 12 to 21 of the oestradiol valerate therapy. The second treatment cycle started one week after the completion of the first cycle, and the third treatment cycle started one week after the second cycle.
2542096|NCT02616848|Experimental|Everolimus, Eribulin|
2542120|NCT02616354|Active Comparator|Group I|"Group I received intravenous imipenem/cilastatin 1 g every 8 h (q8h) or 0.5g every 6 h (q6h) with optimized two-step infusion therapy (OTIT; rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours) Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
2542125|NCT02616354|Placebo Comparator|Group II|"group II received intravenous imipenem/cilastatin 1g q8h or 0.5g q6h with extended infusion therapy (2-hours continuous infusion in a constant speed).~Group I is more informative than Group II from PK parameters(%T>MIC,AUC/MIC)."
3202846|NCT00917254|Active Comparator|Enoxaparin group|
3202847|NCT00917280||Parkinson's Disease|Parkinson Disease participants without dementia
2542290|NCT02615444|Experimental|Beta-glucan enriched oatcake|Oatcakes which have been enriched with beta-glucan. Each participant will consume 5 oatcakes daily in order to ingest 4g of oat-beta glucan.
2542291|NCT02615444|Placebo Comparator|Isocaloric control|Control: Wheat based snack, equicaloric and matched to intervention product for macronutrient content. Contains no oat-beta glucan. Each participant will consume 6.5 Krackawheats daily.
3202848|NCT00917280||Control|Non-PD participants, matched for age, education and gender.
3202849|NCT00917293|Experimental|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate, enteric-coated 2x 250mgs po bid.
2542633|NCT02613377||Non-transfused critically ill children|For each transfused patient (index patient), one matched non-transfused control will be identified and included in the control group. The matching will be conducted using four criteria in hierarchical order: gender; age ± 10%; baseline Hemoglobin level (± 15 g/L); and Pediatric Risk of Mortality III score (PRISM III score ± 10%).
3202850|NCT00917293|Placebo Comparator|Placebo|Placebo 2 pills, po bid.
3202851|NCT00917306|Experimental|PEP005 gel|PEP005 gel, 0.05% administered once daily for 2 consecutive days
3202852|NCT00917319|Experimental|Infection control measure|Bundling Infection Control Interventions
3202853|NCT00917332|Experimental|intervention|"55 third trimester women will receive a CD of relaxation and guided imagery (of safe place), to practice daily at home until childbirth"
3202854|NCT00917332|No Intervention|control|55 third trimester women who does not receive the relaxation and guided imagery CD.
3202855|NCT00917345||aldosteronism, hypertension|
3202856|NCT00917345||hypertension|
3202857|NCT00917358|Experimental|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
3202858|NCT00917358|No Intervention|Observation|Retrospectively chart review of dialysis patients with acute hepatitis C who did not receive any intervention
3202859|NCT00917371||atomoxetine group|
3202860|NCT00917371||methylphenidate group|
3202861|NCT00917371||psychological counseling group|
3202862|NCT00917397|Experimental|psychotherapy|Trauma-focused cognitive behavioral therapy
3202863|NCT00917397|Experimental|Drug|drug treatment and psychoeducation
3202864|NCT00917397|No Intervention|Waiting list|subjects randomized to waiting list
3202865|NCT00917397|Experimental|Combination|Both drug and psychotherapy
3202866|NCT00917410|Experimental|SMS intervention|
3202867|NCT00917423||Inpatients with anorexia nervosa|Hospital inpatients with anorexia nervosa
3202868|NCT00917423||Normal weight controls|Healthy, normal-weight volunteers
3202869|NCT00917449|Active Comparator|L-arginine|L-arginine (3.2 gr bid) plus lifestyle counselling vs placebo plus lifestyle counselling
3202870|NCT00917449|Placebo Comparator|placebo|placebo plus lifestyle counselling for 18 months
3202871|NCT00917475||Preterm infants|birth weight<1500 grams and gestational age<30 weeks
3202872|NCT00917488|Experimental|A|Four concentrations of Glycyphagus domesticus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, was tested in every patient in duplicate on the volar surface of the forearm.
2541361|NCT02621840|No Intervention|Usual Care|Patients in the usual care group will be treated with the standard protocol that is currently utilized in the Wills Eye Hospital Cataract and Primary Eye Care (CPEC) Service. After scheduling the surgery with the surgical coordinator, the patient will be given pre-admission testing (PAT) paperwork to be completed. The patient schedules the PAT on his or her own with the primary care physician.The patient will be given the information for Dr. Koka's cardiology office if he or she has any problem getting the PAT done.
2541394|NCT02621515|Experimental|Nivolumab|All patients in this trial will receive treatment with nivolumab for 24 months. Treatment will be discontinued if confirmed disease progression has been demonstrated, if unacceptable toxicity or intercurrent illness prevents further treatment, and when informed consent is withdrawn. After discontinuation of treatment, follow-up will start. Duration of follow-up depends on survival of patients, with a maximum of 24 months. Therefore the end of this study is determined as 24 months after the last patient in this trial has started follow-up, has died, withdraws consent or is lost to follow-up for a different reason
2541432|NCT02621242|Other|Cohort|All subjects will undergo all procedures
2541470|NCT02620982|Experimental|ARIES Application|Low intensity Extracorporeal Shockwave Application utilizing the Dornier Aries
2541514|NCT02620722|Experimental|LOP Measurement|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument and the gold-standard technique with the handheld Doppler ultrasound.
2541556|NCT02620488|Active Comparator|Healthy Control|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
2541561|NCT02620488|Experimental|Sickle Cell Disease|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
2541569|NCT02620111|Experimental|Whey protein high leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein high in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
2541572|NCT02620111|Active Comparator|Whey protein normal leucine|Subjects are supplemented water in a fasted state for 180 minutes while the isotopic tracer 15Nphenylalanin is infused. Subjects are supplemented with whey protein normal in leucine from 180 - 360 minutes while the isotopic tracer 15Nphenylalanin is infused.
2541604|NCT02619981|Active Comparator|Father present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Father present
2541607|NCT02619981|Active Comparator|Mother Present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , Mother present
2541608|NCT02619981|Active Comparator|Both parents present|Child seated at the dental chair, buccal maxillary infiltration anesthesia with 2%Lidocaine administered using a 27 gauge 21mm needle , restorative procedure completed , both parents present
3174172|NCT00620490|Placebo Comparator|2|
2541761|NCT02619032|Active Comparator|Remifentanil|Drug: Remifentanil (Ultiva). Intraoperative intravenous infusion of remifentanil 0.5-1 μg/kg/min for up to 1 h.
2541764|NCT02619032|Active Comparator|Fentanyl|Drug: Fentanyl (FNT). Intraoperative administration of fentanyl given as one single bolus dose of 50 μg at the time of induction of anesthesia.
2541849|NCT02618603|Experimental|BoNT-A treatment group|Ultrasound guided sub-acromial bursa injection with BoNT-A (100 u);
2541851|NCT02618603|Active Comparator|Triamcinolone acetonide treatment group|Ultrasound guided sub-acromial bursa injection with Triamcinolone acetonide (40mg)+1% Lidocaine 2 ml;
2541879|NCT02618135|Experimental|Intervention Group|10 child participants in the intervention group will take part in a total of 24 sessions spread over an 8-week period, and a final follow-up review 1 month after the completion of the training session. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy.
2541881|NCT02618135|Other|Control Group|10 child participants in the control group will not receive BCI training during the first 8 weeks of their study participation; they will act as controls. At week 9, subjects in this group will go through the BCI training similar to the intervention group. If sessions are missed during the 8-weeks period due to unforeseen circumstances (e.g. sickness, travel plans), arrangements will be made for participants to attend up to 5 BCI-based therapy sessions per week. All participants will have to complete a minimum of 20 sessions within the 8-weeks period for treatment efficacy. They will take part in a total of 24 sessions spread over an 8-week period, followed by a final follow-up review 1 month after the completion of the training sessions.
2541942|NCT02617849|Experimental|Pembrolizumab, Carboplatin, Paclitaxel|Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
2542008|NCT02617407|Experimental|Livionex® Dental Gel|Study patients assigned to this arm will use Livionex toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
2542010|NCT02617407|Active Comparator|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Study patients assigned to this arm will use PreviDent 5000 plus or Tom's of Maine Children's (age 6 years and younger) toothpaste for daily teeth brushing from day 1 to day 14. Study participants will be encouraged to continue use study toothpaste and monitored up to 44 days after study enrollment.
2542051|NCT02616809|Experimental|Sitting|Participants will sit continuously for 8 hours in a simulated office environment
2542054|NCT02616809|Experimental|slow cycling|Participants will cycle at regular hourly intervals during an 8-hr simulated office environment
2544345|NCT02602275|Placebo Comparator|Placebo|3 tablets, 40-60 minutes before the second MRI
3174173|NCT00620529|Experimental|1|20/50 fish oil, 1000mg capsules, Ocean Nutrition 2050,4g/day.
3174174|NCT00620529|Placebo Comparator|2|olive oil capsules
3174175|NCT00620568|Experimental|1|
3174176|NCT00620568|Experimental|2|
3174177|NCT00620568|Experimental|3|
3174178|NCT00620568|Experimental|4|
3174179|NCT00620581|Placebo Comparator|Paroxetine 10mg;paroxetine 20mg; Placebo|
3202873|NCT00917527|Placebo Comparator|Control|
3202874|NCT00917527|Experimental|Atorvastatin|
3202875|NCT00917566|Active Comparator|Airtraq group|Use Airtraq for intubation
3202876|NCT00917566|Active Comparator|Macintoch gorup|Use Macintoch laryngoscope for intubation
3202877|NCT00917592|Experimental|Short intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic 48 hours followed by oral antibiotic for 10 days
3202878|NCT00917592|Active Comparator|Long intravenous amoxicillin plus clavulanic acid|Intravenous antibiotic for 7 days followed by oral antibiotic for 5 days
3202879|NCT00917618|Active Comparator|Exercise intervention|Patients began the exercise intervention after randomization for 12 weeks
2541635|NCT02619786|Experimental|inhaled colistin|Inhaled colistin 75 mg mixed with normal saline up to 4 ml every 12 hours at least 5 days
2541685|NCT02619578|Other|TEAS Group|TEAS consisted of 30 min of stimulation (12-15 mA, 2/100 Hz) at the Hegu (L14) and Neiguan (PC6) before anesthesia. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
2541688|NCT02619578|Other|Con Group|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation. Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v. Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
2541768|NCT02619123|Active Comparator|invitation to mammography screening|44-45 years old women in this arm are invited to attend for a mammography screening every 1 year. After the age of 50, all women will continue to be screened in the usual service screening programme.
2541770|NCT02619123|Experimental|invitation to tailored screening|44-45 years old women in this arm with a dense breast (3-4 categories in BI-RADS) at the baseline mammography are invited again after 1 year, while the lower-density group in the intervention arm are invited after 2 years. After the age of 50, all women will continue to be screened in the usual service screening programme.
2541841|NCT02618473|No Intervention|seloken|"In seloken arm, patients performs the cardiac CT procedure regarding the national scan guidelines, ande receive 5-10 intravenous seloken, until heart rate below 60 beats pr minit is achieved."
2541848|NCT02618473|Experimental|non-seloken|"Patients randomized to non-seloken, do not receive any medication."
2541869|NCT02618213|Active Comparator|Continous Positive Airway Pressure|CPAP is administered through a binasal tube fitted with a Benveniste gas jet administered with humified airflow. Start flow is 12-14 l/min and can be changed to maximum 15 or minimum 12 l/min. Oxygen can be supplied as needed to keep SpO2 (peripheral capillary Oxygen saturation) within acceptable limits.
2541872|NCT02618213|Active Comparator|High Flow Oxygenation Therapy|HFOT is administered by optiflow Junior ( Fisher&Paykal Healthcare® Auckland, New Zealand) Start flow 12-14 l/min. Oxygen can be supplied as needed to keep Sp02 within acceptable limits
2541941|NCT02617875|Active Comparator|Conventional EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a conventional EMS physician, if this is the result of the randomization software.
2542745|NCT02612701|Experimental|E-cigarettes (nicotine free e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking nicotine free e-cigarette liquid.
3202880|NCT00917618|Placebo Comparator|Control|Patients were asked not to change their baseline exercise program
3202881|NCT00917631|Experimental|Co-bedding|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
3202882|NCT00917631|No Intervention|Standard care|For infants who are randomized to receive standard care, the twin pair will remain in separate incubators as per current NICU policy. The infant will be nested in boundaries consistent with neonatal care practices. The heelstick may occur at any time following randomization (within 10 days) to maintain consistency between groups.
3202883|NCT00917683||1|Autistic patients.
3202884|NCT00917683||2|Matched controls
3202885|NCT00917696|Active Comparator|1|ATP
3202886|NCT00917696|Placebo Comparator|2|Saline
3202887|NCT00917709|Experimental|DLB with extrapyramidal syndrome|patients dementia with Lewy bodies with extrapyramidal syndrome
3202888|NCT00917709|Other|DLB without extrapyramidal syndrome|patients dementia with Lewy bodies without extrapyramidal syndrome
3202889|NCT00917709|Sham Comparator|healthy volunteers|healthy volunteers
3202890|NCT00917748|Experimental|1|docetaxel chemotherapy + modafinil 100 mg capsules
3202891|NCT00917748|Placebo Comparator|2|docetaxel chemotherapy + placebo (lactose) capsules (matched to modafinil drug)
3202892|NCT00917761|Experimental|Entecavir and peginterferon (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
3202893|NCT00917761|Experimental|Peginterferon (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
3202894|NCT00917761|Active Comparator|Peginterferon (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
3202895|NCT00917774|Active Comparator|Standard LPS Flex|Nexgen LPS-Flex total knee design used for TKA
3202896|NCT00917774|Experimental|Gender specific LPS-Flex|Gender specific LPS flex design used for TKA in female patients
3202897|NCT00917787||Healthy, Non-asthmatic|
3202898|NCT00917787||Asthma|
3202899|NCT00917800||suspected coronary artery disease|patients referred to angiography because of suspected coronary artery disease
3202900|NCT00917813|Experimental|KD-247|
3202901|NCT00917813|Placebo Comparator|Placebo|
2541454|NCT02621190|No Intervention|A|patients without CTCs or AR-V7 negative CTCs are treated according to their physician's discretion
2541456|NCT02621190|Experimental|B|patients with AR-V7 positive CTCs are treated with cabazitaxel 25mg/m2 q3w
2541478|NCT02620800|Experimental|FABLOx|5 fluorouracil (5-FU ) (180 mg/m^2/day for 14 days), by continuous intravenous infusion (CIVI) via ambulatory pump, nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15, bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15, calcium leucovorin (20 mg/m^2) IV bolus on Days 1, 8, 15, and oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15. First bevacizumab infusion is given over 90 minutes.
2541557|NCT02620462|Experimental|Wearable sensor-based exercise training|The intervention group in addition to standard of care, will receive 6 weeks of sensor-based balance training that provides real-time visual feedback of lower extremities during exercise. The visual feedback is provided on computer screen.
2541562|NCT02620462|No Intervention|Control Group|The control group only receives standard of care.
2541577|NCT02620137|Experimental|Multicentrum® 3 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 3 months
2541580|NCT02620137|Active Comparator|Multicentrum® 12 months|Patients maintaining the multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) during 12 months
2541712|NCT02619474|Experimental|Experimental|Patients who have been admitted to the 3F or 3M wards under the care of the clinical teaching unit (CTU) after the introduction of the new, labelled whiteboard.
2541714|NCT02619474|No Intervention|Control|Patients who have been admitted to the 3R surgical ward under the care of any of the nursing groups without the introduction of the new labelled whiteboard.
2541772|NCT02619071|Experimental|Refractory or relapsed acute myeloid leukemia|
2541824|NCT02618577|Experimental|Edoxaban|"Edoxaban will be applied in NOAH at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
2541828|NCT02618577|Active Comparator|ASA or Placebo|Either one tablet of ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg or one placebo tablet matching in colour, weight, form and size to ASA 100 mg plus one placebo tablet matching in colour, form and size to edoxaban 60 mg will be administered per day depending on the indication for use of antiplatelet therapy as assessed by the responsible investigator
2541907|NCT02618070|Experimental|Functional dyspepsia patient|Yogurt ingestion
2541909|NCT02618070|Experimental|Healthy|Yogurt ingestion
2541947|NCT02617680|Experimental|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Concentration of oxygen should be 50%.
2541950|NCT02617680|Experimental|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially.Concentration of oxygen should be 50%.
2542104|NCT02617303|Experimental|OTAGO'S program arm|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive OTAGO'S exercise program during three months, followed by adherence phase. Falls and fractures will be quarterly followed during 15 months.
2542105|NCT02617303|Active Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. Normal medical treatment will be provided by family physicians and nurses. Falls and fractures will be quarterly followed during 15 months.
3168431|NCT00550966|Active Comparator|1|"Randomized controlled trial with a 12-month follow-up involving two groups, one of which is the intervention group that includes patients receiving a psychoeducative program and the other is the control group formed by patients treated for FM in the usual way.~Setting. Three urban PC centers in the province of Barcelona (Spain) Sample. The total sample comprises 218 patients (over 18 years of age) suffering FM, selected from a database (Rheumatology service-Viladecans hospital) of patients with this illness. Only those patients introduced in the database between the years 2005 and 2007 are included in the selection. Selected patients are asked for written informed consent to participate in the study."
3168432|NCT00550979||1|Black women with history of pregnancy/ies complicated by gestational diabetes mellitus
3168433|NCT00550979||2|Black women with history of normal, uncomplicated pregnancy/ies
3168434|NCT00550979||3|White women with a history of pregnancy/ies complicated by gestational diabetes.
3168435|NCT00550979||4|White women with a history of normal, uncomplicated pregnancy/ies.
2542338|NCT02615028|Other|Closed eyes double-leg stance|Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
2542389|NCT02614859|Active Comparator|A|
2542391|NCT02614859|Experimental|B|
2542427|NCT02614482|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 1 month and 4 months.
2542470|NCT02614235|Experimental|Pocket-ECG III System|After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
2542746|NCT02612714|Other|medication status|Rosuvastatin 5 mg qd for 6 months, Quitted rosuvastatin for 6 months, Re-administrated rosuvastatin for 6 months
3168436|NCT00551018|Experimental|Vicriviroc + Reyataz + ritonavir|vicriviroc 30 mg tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
3168437|NCT00551018|Active Comparator|Truvada® + Reyataz + ritonavir|Truvada® 200/300 combination tablet QD + Reyataz® (atazanavir sulfate) 300 mg (1x300 mg capsule or 2x150 mg capsules) QD + Norvir® (ritonavir) 100 mg capsule QD
3168438|NCT00551044|Active Comparator|Bicalutamide|Osteoporotic patients (T score ≤ -2.5) on bicalutamide
3168439|NCT00551083|Experimental|CDSS-D|Computer Decision Support System for Depression (CDSS-D) - This arm provided physicians with a computerized treatment algorithm and a decision support system to treat their patients suffering Major Depressive Disorder
2541485|NCT02620865|Experimental|Treatment (anti-CD3 x anti-EGFR BATs)|Patients receive one of the following standard chemotherapy regimens at the discretion of the treating physician: gemcitabine hydrochloride IV over 30 minutes; gemcitabine hydrochloride IV over 30 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes; oxaliplatin IV over 2 hours, fluorouracil IV over 46 hours and leucovorin calcium IV over 2 hours; or fluorouracil IV over 46 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV, and oxaliplatin IV over 2 hours. Approximately 2 weeks after standard chemotherapy completion, patients receive anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV over 5-30 minutes twice weekly for 4 weeks. Patients also receive aldesleukin SC and sargramostim SC on day -3 before the first anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells infusion and continuing twice weekly until the final infusion.
2541681|NCT02619695|Experimental|Ketoprofen|Interventional arm: ketoprofen gel 2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
2541684|NCT02619695|Placebo Comparator|Placebo|Placebo arm: placebo gel form of ketoprofen
2541745|NCT02619149|Active Comparator|Intervention|Piperacillin-tazobactam combination product
2541746|NCT02619149|Placebo Comparator|Control|Saline solution
2541793|NCT02618837|Active Comparator|Downstream strategy arm|downstream administration strategy of P2Y12 receptor blockers (prasugrel or ticagrelor)
2541798|NCT02618837|Active Comparator|Upstream strategy arm|upstream administration strategy (ticagrelor only)
2541856|NCT02618499|Active Comparator|oxytocin inmediately at birth|Intervention: Timing of administration of postpartum Oxytocin. 10 international Units (IU) immediately at birth will be given intravenously (IV) to the mother.
2541857|NCT02618499|Experimental|oxytocin at 3 minutes|Intervention: Timing of administration of postpartum Oxytocin. 10 IU IV at 3 minutes immediately after the cord is clamped
3202902|NCT00917826|Experimental|Arginine Butyrate + Ganciclovir/Valganciclovir|
3202903|NCT00917839|Experimental|lamotrigine|7 weeks initial phase with increasing dose beginning with 25 mg oral 12 months treatment phase with fixed dose of 100 mg oral
2541971|NCT02617459|Experimental|Levobetaxolol eye drops|Levobetaxolol eye drops 5ml/25mg per bottle
2541974|NCT02617459|Active Comparator|Betaxolol eye drops|Betaxolol eye drops 5ml/12.5mg per bottle
2542023|NCT02617199|Experimental|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
2542030|NCT02617199|Active Comparator|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
2542060|NCT02616770|Experimental|S1226 (4%)|S1226 (4%) dosed as single dose for 2 minutes
2542065|NCT02616770|Placebo Comparator|Saline (for 4%)|3 mL saline and medical air as single dose for 2 minutes
2542070|NCT02616770|Experimental|S1226 (8%)|S1226 (8%) dosed as single dose for 2 minutes
2542073|NCT02616770|Placebo Comparator|Saline (for 8 %)|3 mL saline and medical air as single dose for 2 minutes
2542078|NCT02616770|Experimental|S1226 (12%)|S1226 (12%) dosed as single dose for 2 minutes
2542083|NCT02616770|Placebo Comparator|Saline (for 12%)|3 mL saline and medical air as single dose
2542115|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
2542119|NCT02616302|Experimental|≤30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh ≤30 kg.
2542121|NCT02616302|Experimental|>30 kg: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
2542124|NCT02616302|Experimental|>30 kg: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, once, daily, for 12 weeks. Participants weigh >30 kg.
2542178|NCT02616120|Placebo Comparator|Placebo|placebo identified to SQJZ herbal mixtures, 29.375g, 2 times per day.for 12 weeks.
2542183|NCT02616120|Active Comparator|SQJZ herbal mixtures|SQJZ herbal mixtures 29.375g, 2 times per day.for 12 weeks.
2542262|NCT02615821|Experimental|Affective Mental Contrasting|"Before the goal formation or mental contrasting activities, participants will receive information about the affective benefits of exercising (e.g. regular physical activity has been shown to reduce stress, physical activity is enjoyable), and related research support including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit affective judgements. Specifically, the affective condition will include the additional prompts Why might you find exercise to be enjoyable, pleasant, exciting, or fun? for eliciting outcomes, and Why might you find exercise to be unenjoyable, unpleasant, boring, or miserable? for eliciting obstacles."
2542267|NCT02615821|Active Comparator|Instrumental Mental Contrasting|"Before the goal formation or mental contrasting activities,participants will receive information about the instrumental benefits of exercising (e.g., regular physical activity reduces the risk of developing cancer) and related research support, again including appropriate references. During the mental contrasting component of the activity the prompts will remain the same as the standard condition, with minor variations in questions in order to elicit either instrumental judgements. Specifically, the instrumental conditions will include the prompts Why might you find exercise to be useful, advantageous, beneficial, or important? for eliciting outcomes, and Why might you find exercise to be unimportant, useless, inconvenient, or detrimental? for eliciting obstacles."
2542270|NCT02615821|Active Comparator|Standard Mental Contrasting|In the standard condition, the space where the affective and instrumental benefits of physical activity were listed in the instrumental and affective conditions, will be left blank in the standard condition, and no additional prompting questions will be given, allowing for the idiosyncratic identification of obstacles and outcome.
2542347|NCT02615262|Experimental|Experimental|Dexamethasone 1 mg per 1 kg of body weight intravenously immediately after induction of anesthesia
2542352|NCT02615262|Placebo Comparator|Control|0.9% Sodium Chloride 0.25 ml per 1 kg of body weight intravenously immediately after induction of anesthesia
3202904|NCT00917839|Placebo Comparator|Placebo|300mg Mannitol with 2% Aerosil
3202905|NCT00917878|Experimental|Milk|500 mL low-fat milk added to high-fat meal
3202906|NCT00917878|Experimental|Protein|Milk protein in 500 mL water added to high-fat meal
3202907|NCT00917878|Experimental|Calcium|Milk calcium in 500 mL water added to high-fat meal
2541521|NCT02620709|No Intervention|Wait-List Control|After baseline data collection and education, participants randomized to the wait-list control arm will not receive the KaHOLO Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not receive the intervention for 6 months until after the intervention arm is completed and their 6 month follow-up data collection is completed. They will not receive any other intervention from us during the 6 month period but they will be instructed to continue with their routine medical care as usual.
2541536|NCT02620514|No Intervention|Health-literacy Assessment|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with low adherence will continue to one or more intervention groups that address needs based on the results of the survey.
2541538|NCT02620514|Experimental|Health-literacy Assessment + Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants with then complete a 24-week intervention aimed to improve education about inflammatory bowel disease and scheduled nurse phone call reminders.
2541547|NCT02620514|Experimental|Health-literacy Assessment + Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education about IBD.
2541550|NCT02620514|Experimental|Health-literacy Assessment + Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive education regarding their medications.
2541551|NCT02620514|Experimental|Health-literacy Assessment + Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will then receive financial support for medications.
2541574|NCT02620124|No Intervention|Natural cycle, control|Treatment cycles with normal luteal support with progesteron
2541575|NCT02620124|Experimental|Natural cycle, intervention|Treatment cycles with normal luteal support with progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days: Intervention is the additional 0.1 mg triptorelin as described in the previous sentence.
2541576|NCT02620124|No Intervention|Hormone replacement cycle, control|Standard hormone replacement cycle with estrogen and progesteron
2541581|NCT02620124|Experimental|Hormone replacement cycle, intervention|Standard hormone replacement cycle with estrogen and progesteron and a single dose of 0.1 mg triptorelin when the age of the embryo was 6 days
2541628|NCT02619942|Active Comparator|D2 radical operation group|In D2 radical operation group(D2), the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes, which along the feeding vessels.
2541629|NCT02619942|Experimental|CME group|In complete mesocolic excision group (CME), in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodesmshould be entirely removed.
3202908|NCT00917878|Experimental|Control|Lactose in 500 mL water added to high-fat meal (control condition)
3202909|NCT00917891|Placebo Comparator|vehicle placebo gel|
2541781|NCT02618863|Active Comparator|1 , cricoid pressure|30 male
2541790|NCT02618863|Active Comparator|2,cricoid pressure|30 female
2541855|NCT02618369|Other|MR-HIFU treatment|"The interventional radiologist will locate the target lesion and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan."
2541913|NCT02618109|Other|Relapse Group|"Collection of blood samples will be done in newly diagnosed relapse of B-ALL children at the time of relapse diagnosis.~Children aged from 1 to 18 years at the time of first B-ALL relapse diagnosis."
2541915|NCT02618109|Other|Control Group|"Collection of blood samples will be done at the same stage of treatment as the relapse group has been collected.~Children aged from 1 to 18 years enrolled into FRALLE (protocol of treatment) or EORTC (European Organisation for Research and Treatment of Cancer) treatment protocols, treated for B-ALL and who are in complete molecular remission.~These control patients will be recruited at the same time from the beginning of B-ALL treatment as paired-relapsed control patients."
2541955|NCT02617498|Active Comparator|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
2541964|NCT02617498|Active Comparator|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler. The clearly exposed vessels were ligated by 5/0 proline or clipped according to their size.
2542032|NCT02617290|Experimental|Ticagrelor Arm|Ticagrelor is an oral antiplatelet agent which was approved for use in the European Union by the European Commission on December 3, 2010. The drug was approved by the US Food and Drug Administration on July 20, 2011. It is available as round, yellow tablets (90 mg). The standard dose is 90 mg twice a day during the maintenance phase and 180 mg once for the loading dose. It is approved for duration of 12 month in ACS patients and will be used for duration of one month in the ALPHEUS Study.
2542035|NCT02617290|Active Comparator|Clopidogrel Arm|Clopidoprel is an oral antiplatelet agent which was approved for use in the European Union by the European Commission in 1997 and available as generic since 2007. The standard dose of clopidogrel is one 75 mg tablet once a day. The dosage for the loading dose is normally 300 mg but 600 mg is also used. Clopidogrel is the standard of care for PCI at the moment.
3202910|NCT00917891|Experimental|dapivirine gel|
3202911|NCT00917904|Placebo Comparator|vehicle placebo gel|
2542180|NCT02615938|Experimental|Start HCQ block Verum|During trial: Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
2542188|NCT02615938|Placebo Comparator|Start HCQ block Placebo|At the beginning of the trial: Placebo for 4 weeks then Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg bw/d, p.o., one daily dose in the evening for 7 days, then reduction to 6,5 mg/kg bw/d for 3 weeks; the maximum daily dose is 400mg.
2542748|NCT02612506|Placebo Comparator|Placebo|Placebo 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg
3202912|NCT00917904|Experimental|dapivirine gel|
3202913|NCT00917930||physical training|
3202914|NCT00917943|Experimental|Tailored Counseling Intervention Arm|Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
2541610|NCT02620046|Experimental|Group A: Vedolizumab SC 108 mg Q2W|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:~Completed the Maintenance Period (Week 52), or~Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6."
2541611|NCT02620046|Experimental|Group B: Vedolizumab SC 108 mg QW|"Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.~•Participants from current study who experience treatment failure while on study."
2541914|NCT02618018|Experimental|intraocular lens|AT TORBI 709M toric intraocular lens
3202915|NCT00917943|No Intervention|Control Arm|Women randomized to the control arm receive the booklet, Forever Free for Baby and Me: A Guide to Remaining Smoke Free and usual prenatal and postpartum care.
3202916|NCT00917982|Other|Vision therapy|
3202917|NCT00917995|Experimental|Colostomy with a prophylactic mesh|
3202918|NCT00917995|No Intervention|Colostomy without a prophylactic mesh|
2542044|NCT02617069|Experimental|Group 1 (Cardiac surgery+botulinum toxin)|All patients underwent conventional cardiac surgery. After the main stage of the surgery botulinum toxin (50 U/1 mL) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right ganglionated plexi (GP); second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior pulmonary vein (PV) and left inferior PV (between the PVs and left atrial appendage (LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2542046|NCT02617069|Active Comparator|Group 2 (Cardiac surgery+placebo)|All patients underwent conventional cardiac surgery. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP
2542062|NCT02616679||Cognitively Normal|Participants will be deemed cognitively normal based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
2542068|NCT02616679||Amnestic Mild Cognitive Impairment (aMCI)|Participants will be deemed aMCI based on criteria set forth by the National Alzheimer's Disease Coordinating Center/Alzheimer's Disease Centers (ADCC/ADC).
3202919|NCT00918008||Blood sample|the blood sample only collected prior to surgery
3202920|NCT00918021|Active Comparator|olanzapine (B)|Group B: In addition to clozapine, the participants receive their normal dosage of olanzapine (=the same as on the hospital ward) for 12 weeks, next the decreasing dosage of olanzapine for four weeks and subsequently placebo for 8 weeks.
3202921|NCT00918021|Placebo Comparator|placebo (A)|Group A: : In addition to clozapine the participants receive the decreasing dosage of olanzapine for four weeks, next placebo for 8 weeks, after that the increasing dosage of olanzapine for four weeks and subsequently the normal dosage of olanzapine for 8 weeks.
2542261|NCT02615782|Experimental|A group|"Period 1: CKD-397 1T single oral administration under fasting condition~Period 2: CKD-397 1T single oral administration under fed condition (high fat meals)"
2542266|NCT02615782|Experimental|B group|"Period 1: CKD-397 1T single oral administration under fed condition (high fat meals)~Period 2: CKD-397 1T single oral administration under fasting condition"
2542316|NCT02615275|Experimental|Supportive Care (bioelectrical impedance analysis, RT)|Patients undergo bioelectrical impedance analysis with seca mBCA and CT or PET at baseline, weekly for 6-7 weeks during standard of care RT, and at 10-12 weeks after completion of RT.
2542411|NCT02614625||Normal subjects|Patient with healthy, normal eyes
2542412|NCT02614625||Eyes with corneal disease|"Subjects that have any of the following conditions~Corneal dystrophy or degeneration~Corneal scarring~Corneal ulcer~Corneal injury~Keratoconus~Patients who had undergone corneal surgery~Patients with other corneal disease"
2542413|NCT02614625||Eyes with retinal disease|"Subjects that have any of the following conditions:~Diabetic macular edema~Cystoid macular edema~Age related macular degeneration~Retinal vascular disorders (e.g. retinal artery occlusion)~Epiretinal membrane~Choroidal nevus~Macular hole~Patients who had undergone retinal surgery~Patients with other retinal disease"
2542414|NCT02614625||Eyes with glaucoma|Eyes diagnosed with glaucoma of any type and any stage
2542451|NCT02614352|Experimental|AG1502|
2542453|NCT02614352|Active Comparator|Candesartan + Atorvastatin|
2542771|NCT02612467|Active Comparator|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
3202922|NCT00918034|Experimental|LS11 (talaporfin sodium)|
3202923|NCT00918047|Experimental|SPN-804O 150mg/Day|Subjects who weighed 15.0 to 29.9 kg dosed with SPN-804O 150mg/Day
3202924|NCT00918047|Experimental|SPN-8040 300mg/Day|Subjects who weighed 30.0 to 44.9 kg dosed with SPN-8040 300mg/Day
3202925|NCT00918047|Experimental|SPN-8040 450mg/Day|Subjects who weighed 45.0 to 59.9 kg dosed with SPN-8040 450mg/Day
3202926|NCT00918047|Experimental|SPN-8040 600mg/Day|Subjects who weighed 60.0 kg and above dosed with SPN-8040 600mg/Day
3202927|NCT00918060|Experimental|gel a|
3202928|NCT00918060|Placebo Comparator|gel b|
3202929|NCT00918073||HIV positive smokers|50 HIV infected patients who enroll in a parent protocol to quit smoking and elect to participate in this sub-study.
3202930|NCT00918086|Experimental|Vitamin D pill|
3202931|NCT00918086|Placebo Comparator|Placebo|
3202932|NCT00918099|Active Comparator|Avaulta mesh|Avaulta mesh
3202933|NCT00918099|Active Comparator|Anterior repair|Anterior repair
2541548|NCT02620592|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage (Single Ascending Study): 1 mg, 5mg, 20mg, 50mg, 100mg, 200mg Multiple Ascending Study: 100mg, 200mg Food effect and Gender effect study: 200mg
2541587|NCT02620241|Other|sitting position|infants are in a sitting position for 20 minutes
2541650|NCT02619877|Experimental|ALLO-ASC-DFU|Allogeneic mesenchymal stem cells
2541651|NCT02619877|Active Comparator|Standard therapy|Standard therapy for patients with diabetic foot ulcer
2541708|NCT02619422|Other|Intensivo|intensive cardiac rehabilitation program in less time
2541711|NCT02619422|No Intervention|Convencional|standard cardiac rehabilitation program
2541780|NCT02619136|Experimental|Restrictive Transfusion Strategy|We will permit but not require red cell transfusions once a hemoglobin value falls below 80 g/L (required below 70 g/L) during the 30 days following randomization
2541789|NCT02619136|Active Comparator|Liberal Transfusion Strategy|We will transfuse at a transfusion threshold of 100 g/L for up to 30 days after randomization.
2542004|NCT02617134|Experimental|CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific chimeric antigen receptor targeting MUC1 antigen by infusion.
2542052|NCT02617017|Experimental|Buspirone|
2542057|NCT02617017|Placebo Comparator|Placebo|
3168440|NCT00551083|Active Comparator|UC|Usual Care (UC) - This group of physicians treated their patients suffering from Major Depressive Disorder with their standard treatment as usual, and received no algorithm support with regard to treatment decisions
3168441|NCT00551096|Experimental|Gemcitabine, capecitabine and ZD6474|"Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.~Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off .~ZD6474 administered orally at 300 mg/day once daily. One cycle will consist of 28 days."
3168442|NCT00551109|Placebo Comparator|P|Placebo
3168443|NCT00551109|Experimental|A1|SA4503
2542239|NCT02615912|Other|Surfactant Exposure|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5% Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5% Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5% Silwet* DA-63 (Momentive) 1.5% Sodium lauryl sulfate (Sigma Aldrich) 1.0% Water
2542288|NCT02615431||MitraClip Intervention|the influence of MitraClip on Apnoea Asleep
2542305|NCT02615210|No Intervention|Standard|Standard of care biopsies with optional SOC-directed biopsy afterwards
2542306|NCT02615210|Experimental|Study|SOC-directed biopsies using the SpyGlass System plus standard of care biopsies
2542348|NCT02614989|Experimental|MRI guided Focused Ultrasound treatment|"MRI guided focused ultrasound thalamotomy~Patients will undergo unilateral thalmotomy using MRI guided Focused Ultrasound intervention for the treatment of the tremor"
2542408|NCT02614833|Experimental|Paclitaxel + IMP321 at the RPTD|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, either IMP321, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (IMP321) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
2542410|NCT02614833|Active Comparator|Comparator: Paclitaxel + Placebo|The chemo-immunotherapy phase consists of 6 cycles of 4 weeks. Patient will receive weekly paclitaxel at Days 1, 8 and 15 with adjunctive treatment of study agent, placebo, on Days 2 and 16 of each 4-week cycle. After completion of the 6-cycle chemo-immunotherapy phase, responding or stable patients will receive study agent (placebo) every 4 weeks during the maintenance phase for an additional period of up to 12 injections
2542690|NCT02613026|Experimental|Combined therapy group|pirarubicin 50mg/m2, iv, d1; docetaxel 75mg/m2, div, d1. 21 days were a cycle of treatment, with a total of 4-8 cycles.
2542692|NCT02613026|Experimental|Sequential therapy group|cyclophosphamide 600mg/m2, iv, d1; Pirarubicin 60mg/m2, iv, d1, 21 days were a cycle of treatment, with a total of 4 cycles. Then followed by Docetaxel 75- 100mg/m2, div, d1, 21 days were a cycle of treatment, with a total of 4 cycles.
2542789|NCT02612363|Experimental|Early goal directed sedation group|"Dexmedetomidine for sedation in early goal directed sedation group~Analgesia~Dexmedetomidine start at 0.7ug/kg/hour~Dose range: 0.2- 0.7 u/kg/hour~Supplemental other sedatives at lowest effective dose Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal in EGDS group"
2542790|NCT02612363|Placebo Comparator|Standard sedation|"Control drug for sedation in early goal directed sedation group~Analgesia~Control drug~Supplemental other sedatives at lowest effective dose for standard sedation Target Richmond Agitation-Sedation Scale score of -2 to +1 to achieve sedation goal"
2542811|NCT02612038|Experimental|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
3168444|NCT00551109|Experimental|A2|SA4503
3168445|NCT00551122|Experimental|Paclitaxel, gemcitabine, cisplatin, ifosfamide|"Day 1 Dexamethasone sodium phosphate 25mg I/V ) before Chlorphenamine 10mg I/V 30 - 60 mins ) paclitaxel Ranitidine 50mg I/V ) Paclitaxel - 175 mg m2 I/V in 500ml normal saline over 3 hours Gemcitabine - 1200mg per m2 I/V in 500ml normal saline over 30 mins Days 1-5 Cisplatin 20mg per m2 in 1 litre normal saline over 4 hours 2 litres normal saline over 16 hours, each litre containing 10 mmol MgSO4 and 20mmol KCL.~If urine output is insufficient (less than 600ml per 6 hours) or if excessive weight gain (greater than 2kg) 100 - 200ml 10% mannitol should be used. Alternatively, low dose frusemide (20mg I/V) can be used.~Days 2 - 6 Ifosfamide 1G per m2 + MESNA 0.5G m2 in 500 ml normal saline over 1 hour after the cisplatin infusion.~MESNA 0.5G m2 to be included in first 1 litre post cisplatin hydration bag Pegylated G-CSF will be given on day 7 as an alternative to daily G-CSF."
3168446|NCT00551148|Experimental|15 mg|
3168447|NCT00551148|Experimental|30 mg|
3168448|NCT00551148|Experimental|5 mg|
3168449|NCT00551148|Experimental|60 mg|
3168450|NCT00551148|Placebo Comparator|Placebo|
3168451|NCT00551187|Experimental|1|V504 + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3168452|NCT00551187|Placebo Comparator|2|Placebo + Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
3168453|NCT00551226||1|Patients with tuberculosis
3168454|NCT00551226||2|Healthy controls
3168455|NCT00551239|Active Comparator|Arm I (control)|Patients receive rituximab IV on day 1 and fludarabine phosphate IV on days 2-4. Treatment repeats every 28 days for up to 6 courses.
2541592|NCT02620059|Experimental|Lifestyle Intervention|"Behavioral: Lifestyle Intervention These women will receive the Healthy Lifestyle Intervention. This intervention will have been delivered during 12 weeks, which will be Distance learning program (multimedia or internet). During the intervention (12 weeks) and follow up period, women will receive not only motivational messages through the Short Message System (SMS) but also a pedometer to record their steps.The intervention will focus on women increasing physical activity (walking) to 10'000 steps per day and receiving healthy eating guidelines.~This intervention curriculum will cover topics related to healthy eating, physical activity, and stress management during postpartum. General information about postpartum period will also be provided."
2541596|NCT02620059|No Intervention|Control|These women will receive general information via pamphlet about postpartum period and tips for stress management.
2541645|NCT02619825|Other|"Group 1 healthy volunteers"|Echography and Elastography To determine physiological standards across age classes of myocardial stiffness estimated by Elastography in ultrafast (estimated right ventricular stiffness [VD] and left ventricular [LV]). This will be done in groups of children without heart condition, age group (10 children per group, four age groups [0-1mois, 1 month-1 year 1 year-5 years, 5 years-15years]).
2541646|NCT02619825|Other|Group 2 Patients CMH primitive|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Hypertrophic Cardiomyopathy (HCM) non obstructive primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
2541647|NCT02619825|Other|Group 3 Patients primitive CMD:|Echography and Elastography To evaluate myocardial stiffness Elastography (RV and LV) on different groups of children (same age group) with Dilated Cardiomyopathy primitive and examine correlations with the conventional parameters of systolic and diastolic function of both ventricles and with myocardial strain values.
2541672|NCT02619435|Experimental|regorafenib|
2541723|NCT02619279|Experimental|Immediate treatment|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2541726|NCT02619279|No Intervention|Delayed treatment|Participants' mothers will receive no intervention but will be placed on a waitlist to receive the intervention after a 12-month delay.
2541752|NCT02618954|Other|Study patient|Articular ultrasound at each study follow-up
2541844|NCT02618720|Experimental|ornidazole|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
2541850|NCT02618720|Placebo Comparator|placebo|oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
2541896|NCT02618174|Placebo Comparator|Neutral Control Condition|Message about age of University of Birmingham
2541898|NCT02618174|Placebo Comparator|Food-based Control Condition|Message about variety of vegetables in the world
2541902|NCT02618174|Active Comparator|Health Condition|Message about the health benefits of eating vegetables
2541904|NCT02618174|Active Comparator|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
2541910|NCT02618174|Experimental|Liking Social Norm|Message suggesting most people like eating vegetables
2541945|NCT02617615|Experimental|MB-110|oral hard-gel capsule formulation. One dose strength, 25 mg of MB-110, will be filled into the #00 hard-gel capsule.
2541948|NCT02617615|Placebo Comparator|Placebo|in the same #00 hard-gel capsules.
2542024|NCT02617264|Experimental|Axillary lymph node FNA Biopsy|A carbon compound ink (SPOT) is injected to the axillary lymph node suspected to be infected with cancer
2542049|NCT02616887||Vertebral metastases|Selected patients with spine metastases are treated with ablative single dose SBRT and VMAT technique in various solid tumors .
2542130|NCT02616627||chronic dialysis|Patient enrolled at the National Taiwan University Hospital Jinshan branch
3202934|NCT00918112||Parkinson's Disease|Meets criteria for definite Parkinson's Disease
3202935|NCT00918112||Healthy Controls|- Must be in good health
2542320|NCT02615041|Experimental|1 g by bolus injection|1 g of meropenem with bolus injection every 8 h regimen
2542325|NCT02615041|Experimental|1 g by 3 h infusion|1 g of meropenem with 3 h infusion every 8 h regimen
2542327|NCT02615041|Experimental|2 g by 3 hinfusion|2 g of meropenem with 3 h infusion every 8 h regimen
2542393|NCT02614820|Experimental|treatment group|inflation of a blood pressure cuff on the bilateral thighs to 150 mm Hg for four 5-minute intervals
2542394|NCT02614820|Other|control group|inflation of a blood pressure cuff on the bilateral thighs to 40 mm Hg for four 5-minute intervals
2542437|NCT02614417||Polysomnography|Patients undergo an one-night in-hospital polysomnography to diagnose sleep-disordered breathing
3202936|NCT00918151||A|
3202937|NCT00918164|Experimental|Healthy adult volunteers|Standard Phase 1 normal healthy adult volunteers, age range 21-55 years and of either sex
3202938|NCT00918177|Experimental|Early patients|
3202939|NCT00918177|Experimental|Moderate Patients|
3202940|NCT00918190|Active Comparator|Ondansetron-Dexa group|Use 2 different antiemetics
3202941|NCT00918190|Active Comparator|Midazolam, Dexa group|use of midazolam and dexamethasone
3202942|NCT00918190|Placebo Comparator|Placebo|Saline will be given
3202943|NCT00918268|Experimental|Influenza vaccine|
3202944|NCT00918294|Experimental|QuickOpt|QuickOpt is an optimization algorithm to program the AV, PV and VV delays
3202945|NCT00918307|Experimental|Varenicline|Varenicline titrated to 2 x 0.5 mg twice daily for 12 weeks
2541616|NCT02619994|Experimental|Experimental Arm|"Regimen consists of only oral medication using delamanid, linezolid, levofloxacin, and pyrazinamide, for nine or twelve months depending on the time of sputum culture conversion to negative.~Delamanid (100 mg bid for the entire treatment period)~Linezolid (600mg/day for 2 months and 300mg/day afterwards until the end of treatment)~Levofloxacin (750 ~1000 mg/day)~Pyrazinamide (1000~ 2000 mg/day)"
2541695|NCT02619643|Experimental|Primed PAS 1A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2541700|NCT02619643|Experimental|Unprimed PAS 1B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
2541703|NCT02619643|Sham Comparator|Sham PAS|A single session of sham paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied
2541705|NCT02619643|Experimental|Primed PAS 2A|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2541706|NCT02619643|Experimental|Unprimed PAS 2B|A single session of active paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied.
2541707|NCT02619643|Experimental|Primed PAS 1C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2541710|NCT02619643|Experimental|Primed PAS 2C|Two sessions of paired associative stimulation (PAS) using transcranial magnetic stimulation will be applied consecutively (within minutes).
2541753|NCT02619019|Active Comparator|Dexamethasone group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
2541760|NCT02619019|Active Comparator|Pethidine group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
2541763|NCT02619019|Placebo Comparator|Control group|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
2541840|NCT02618681||AMI with earlobe crease|To observe the prognosis for AMI with earlobe crease
2541847|NCT02618681||AMI without earlobe crease|To observe the prognosis for AMI without earlobe crease
3168456|NCT00551239|Experimental|Arm II|Patients receive rituximab and fludarabine phosphate as in arm I. Patients also receive pixantrone IV on day 2. Treatment repeats every 28 days for up to 6 courses.
3168457|NCT00551252|Experimental|I|
2541949|NCT02617641|Experimental|TAVIEenM@RCHE intervention|The experimental group will receive a web-based tailored nursing intervention. Between 3 and 4 sessions of 15 to 25 minutes each are completed within 4 weeks. A booster session is delivered at 8 weeks post randomization.
2541953|NCT02617641|Active Comparator|Publicly available websites|The control group will receive hyperlinks to four publicly available websites and one online booklet on the topic of walking.
2542066|NCT02616666|Experimental|Dapagliflozin 10 mg|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
2542072|NCT02616666|Active Comparator|Standard of Care (SOC)|Patients will be randomized to receive either dapagliflozin or SOC. As this is a pragmatic trial, there will be no additional interventions (apart from collection of PROs and occurrence of hypoglycaemias) and there will be no restriction on how GPs change the randomized treatment regimen (e.g., switch or add drugs). Patients will be followed up for 2 years (+ 12 weeks = 116 weeks) after randomization, regardless of the status of medication.
2542223|NCT02615899|Active Comparator|Matched|Administer Targeted (specific) balance exercise interventions
2542225|NCT02615899|Active Comparator|Mismatched|Administer Untargeted (non-specific) balance exercise interventions
3174180|NCT00620594|Experimental|BEZ235 Alone, Dose Escalation|
3174181|NCT00620594|Experimental|BEZ235 + trastuzumab, Dose Escalation|
3174182|NCT00620594|Experimental|BEZ235 Alone, MTD Expansion|
3174183|NCT00620594|Experimental|BEZ235 + Trastuzumab, MTD Expansion|
3174184|NCT00620620|Placebo Comparator|Inhaled Placebo|Staccato Placebo
2541671|NCT02619708|No Intervention|Standard Preoperative Experience|The preoperative visit will be performed, as it would be normally. Patients will be given a description of the preoperative experience, they will be told what to expect, they will be given brochures detailing what will happen on the day of the surgery, and will be given the opportunity to ask questions. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
2541673|NCT02619708|Experimental|Immersive Preoperative Experience|The preoperative visit will be performed, as it would be normally, with the only addition of a 5-minute video for the patients randomized to the intervention group. Patients will be given a few minutes to watch the video, and will have the chance to ask questions. The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. Patients will fill out questionnaires immediately preoperatively on the day of the procedure, on the day after the procedure, and 30-days after the operation (only for patients undergoing surgery for degenerative spine disease).
2541729|NCT02619318|Experimental|The Balancing Everyday Life (BEL) intervention|The BEL was developed on the basis of previous research on lifestyle interventions made by our own group and other researchers [1, 2]. It is a group-based programme (5-8 participants) with 12 sessions, one session a week, and 2 booster sessions with two-week intervals. The themes for the group sessions are, e.g., activity balance, healthy living, work-related activities, and social activities. Each session contains a main group activity and a home assignment to be completed between sessions. The main group activity starts with analysing the present situation and proceeds with identifying desired goals and finding strategies for how to reach them. The home assignment is aimed at testing one of the proposed strategies. Self-analysis, setting goals, finding strategies and evaluating the outcome of tested strategies form a process for each session, but also for the BEL intervention as a whole.
2541731|NCT02619318|Active Comparator|Care as usual (standard occupational therapy)|Standard occupational therapy involves support to open-market employment and support in managing everyday life in general.
2541755|NCT02618902|Experimental|tolerogenic dendritic cells (tolDC)|Each vaccine (5x106, 10x106 , or 15x106cells in 500 µL NaCl 0.9% solution supplemented with 5% human albumin) will be administered through intradermal injection at 5 sites (100 µL/site) in the subclavicular region (5-10 cm from the cervical lymph nodes). Injection sites will alternate between left and right sides.
2541889|NCT02618733|Experimental|Ticagrelor|Ticagrelor 90mg, twice a day
2541894|NCT02618733|Active Comparator|Clopidogrel|Clopidogrel 75mg, once a day
2541965|NCT02617771|Active Comparator|Vit D|Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
2541973|NCT02617771|No Intervention|Control|
2542015|NCT02617381|Experimental|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
2542097|NCT02616952|Experimental|Chinese herbal therapy group|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks.
2542098|NCT02616952|Other|Pelvic floor muscle training group|Pelvic floor muscle training includes intensive exercises and home exercises. Intensive exercises are conducted in hospital once a week while home exercises are performed three times daily for 12 weeks.
2542136|NCT02616341|Experimental|Team ERP (T-ERP) Intervention|The ERP team intervention (T-ERP) consists of 25 sessions over 20 weeks with four components: (a) 3-4 pretherapy individual session with therapist, (b) 12 weekly group sessions (90-mins) led by a therapist and, (c) 10 individual coaching sessions with a case manager during weeks 2-11 of the group, and (d) 2 booster group sessions to reinforce relapse prevention
2542145|NCT02616341|Active Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes standard community treatment consisting of a personalized treatment plan and assistance with treatment referrals to available community resources
2542226|NCT02616172|Experimental|Autologous bone marrow infusion|One time administration of autologous bone marrow mononuclear cells intravenously, minimum dose of 6 million cells per kg Total nucleated cells.
2542247|NCT02615600|Experimental|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
2542281|NCT02615457|Experimental|Arm I|Patients taking Huaier Granule for adjuvant treatment after the triple negative breast cancer has been surgically removed. The Huaier Granule (Qidong Gaitianli Medicines Co., Ltd.) should be given orally from the 3rd day after surgery up to 5 years after surgery or until study termination.
2542283|NCT02615457|No Intervention|Arm II|Patients not taking Huaier Granule after the triple negative breast cancer has been surgically removed.
2542301|NCT02615418|Active Comparator|Fully active treatement|
2542303|NCT02615418|Sham Comparator|partially active|first 2.5 weeks will receive sham treatment followed by active
2542312|NCT02615223|Experimental|Arm1|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
2542314|NCT02615223|Experimental|Arm2|Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.
2542339|NCT02615080|Active Comparator|CRD007|CRD007 (containing pemirolast sodium) tablets given twice daily for 14 weeks
2542342|NCT02615080|Placebo Comparator|Placebo|Matching placebo tablets given given twice daily for 14 weeks
2542387|NCT02614872|Experimental|GLASSIA®|Glassia® IV treatment additional to Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
2542388|NCT02614872|No Intervention|Institution standard of care (SOC)|Institution standard of care (SOC) for first lung transplant subjects according to Investigator discretion.
2542401|NCT02614638|Active Comparator|1st observational period (before experimental intervention)|"Patients in this arm are included during a first month of observation before the intervention is implemented.~Intervention: One month of department-wide observation"
2542773|NCT02612389|Experimental|MM Intervention taught via DVD|Receive Meditative Movement training via DVD with pre and post interventional testing.
2541699|NCT02619357|Experimental|Cohort 2|10 subjects diagnosed with asthma. Subjects will wear multiple devices simultaneously (SenseWear Armband Gecko, SenseWear Armband MF, Actigraph GT9x wristband and waistband and Garmin Vivofit 2 wristband) up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests.
2541750|NCT02618941|Experimental|AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/adjuvanted
2541756|NCT02618941|No Intervention|Control|Untreated control group
3202946|NCT00918307|Placebo Comparator|Placebo|placebo titrated to 2 pills twice daily for 12 weeks
3202947|NCT00918320|Experimental|Toptecan + temozolomide|
2541979|NCT02617719||Primary care|Staff, patients aged 75 years and older and their carers associated with a single, participating United Kingdom primary care practice.
2542011|NCT02617225||DHaAL Intervention|The group receives standard Ailment-free Life (DHaAL) DHaAL intervention
2542012|NCT02617225||DHaAL +CFSS Intervention|This group received the standard DHaAL intervention and additional support under another UNICEF program named Child Friendly School System (CFSS).
2542014|NCT02617225||Control|This group receive the standard / business-as-usual support from the Education Department, but does not receive DHaAL or CFSS Interventions.
3202948|NCT00918359||HI|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Intolerance .
3202949|NCT00918359||HT|Subjects who experienced heat exhaustion or heat stroke in their past and will be identified by heat tolerance test (HTT) as Heat Tolerance .
2542227|NCT02615860|Experimental|Topical 85% trichloroacetic acid (TCA)|AIN lesions are treated with trichloric acid
2542230|NCT02615860|Active Comparator|Surgical electrocautery (ECA)|AIN lesions are treated with electrocautery
2542279|NCT02615548|Experimental|Community exercise class|Regular community exercise class is the intervention. It is an exercise class that incorporate PWR moves( UP,ROCK,STEP,TWIST) and cardiovascular training.
2542285|NCT02615548|Active Comparator|self-directed exercise activity|Self-directed exercise.
2542310|NCT02615314||BPPV without migraine|Two hundred and sixty-three patients with BPPV (2009-2014), confirmed by videonystagmography (VNG), were enrolled in the study. Patients' charts were reviewed. They were grouped as those with or without migraine. Distribution of gender, age, duration of symptoms and affected side were reviewed. Two hundred and thirty-one patients with no migraine were identified.
2542313|NCT02615314||BPPV with migraine|Thirty-two patients (11.4%) with migraine were identified. Diagnosis and classification of migraine and its differentiation from other type of headaches was based on third edition of International classification of headache disorders (ICHD-III beta) by international headache society (IHS). All patients with migraine had migrainous headache with or without aura and they all were diagnosed in our institution and followed by our neurology staff.
2542318|NCT02615184|Experimental|Healing Period: Dexlansoprazole 60 mg|Dexlansoprazole 60 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of erosive esophagitis [EE] confirmed by endoscopy).
2542323|NCT02615184|Experimental|Healing Period: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, capsules, orally, once, daily, for 8 to 12 weeks (healing of EE confirmed by endoscopy).
2542328|NCT02615184|Experimental|Maintenance: Dexlansoprazole 30 mg|Participants in the Healing Period: Dexlansoprazole 60 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 30 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2542330|NCT02615184|Experimental|Maintenance: Dexlansoprazole 15 mg|Participants in the Healing Period: Dexlansoprazole 30 mg treatment arm with healed EE confirmed by endoscopy will be re-randomized to receive dexlansoprazole 15 mg, capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2542332|NCT02615184|Placebo Comparator|Maintenance: Placebo|Participants who are eligible to enter the Maintenance of Healing period as confirmed by endoscopy will be re-randomized to receive placebo-matching capsules, orally, once, daily, for 16 weeks in the Maintenance Period.
2542380|NCT02614937|Experimental|Squalamine and ranibizumab to Week 10|"All eyes received an initial 10 week mandatory loading period of topical Squalamine Lactate Ophthalmic Solution, 0.2% therapy.~All eyes received mandatory intravitreal injections of ranibizumab 0.5mg at the conclusions of weeks 2 and 6.~Randomize at Week 10 to 2 different groups - Squalamine and No Squalamine, continue PRN ranibizumab in both groups"
2542381|NCT02614937|Experimental|Continue Squalamine, ranibizumab PRN|Continue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
2542382|NCT02614937|Experimental|Stop Squalamine, ranibizumab PRN|Discontinue use of Squalamine Lactate Ophthalmic Solution, 0.2% after Week 10; continue ranibizumab 0.5 mg IVT PRN
2542416|NCT02614599|Experimental|BP22042013|This group of patients receive 2.000 kilocalories diet(60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
2542418|NCT02614599|Experimental|Low carbohydrate Diet|the second group of patients receive diet of 2.000 Kilo calories without rapidly absorbed carbohydrates and without proteins supplements
3202950|NCT00918372||Extreme fitness|Female competitive long distance runners
3202951|NCT00918372||Control|Age and Risk matched controls
2542464|NCT02614300|Active Comparator|Pulmonary Rehabilitation|These sessions will be individually designed and they will be a combination of global aerobic interval training using a cycloergometer. The aim is to achieve a training intensity of 80% HR or greater of the obtained during the ISWT. This intensity will be progressively increased during the firsts four weeks until achieving the target. The duration will be of about 45 minutes per session. Oxygen Saturation, HR and Borg scale for dyspnoea and fatigue will be measured before, during and at the end of the session in order to monitories the effort.
2542466|NCT02614300|Active Comparator|Chest Physiotherapy|"The ELTGOL technique (total slow expiration with glottis open in lateral decubitus) for airways clearance will be used in order to move respiratory secretions from the distal bronchial tree. It will be applied during 15 minutes each side (right and left lungs) assuming an approximate session length of 30 minutes. The patient could perform the cough technique when it's necessary."
2542750|NCT02612701|Experimental|E-cigarettes (low nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking low concentration(4-6 mg/mL) e-cigarette liquid.
3202952|NCT00918398|Experimental|1|AZD1981, 100 mg iv infusion
3168458|NCT00551265|Experimental|Arm I|Patients undergo delayed-type hypersensitivity (DTH) skin testing with oregovomab and a standard anergy panel (i.e., mumps, Candida, and tetanus toxoid) on day 0 (at baseline) and at week 14. The skin test response is measured 48 hours later. Patients receive cyclophosphamide IV on day 6 and oregovomab IV over 20 minutes on day 9 or 10. Patients then receive oregovomab alone at weeks 6 and 10 and then every 12 weeks for up to 2 years (10 doses) in the absence of disease progression or unacceptable toxicity.
2541791|NCT02618824|Active Comparator|HTK Solution|Hearts will be arrested with HTK solution during cardiac operation
2541797|NCT02618824|Active Comparator|HTK Solution + TWBC|Hearts will be arrested with HTK solution during cardiac operation and received terminal warm blood cardioplegia before aortic cross clamp removal.
2541846|NCT02618460|Experimental|Whole Group|
2541859|NCT02618226||Optic nerve ultrasound|Optic nerve sheath diameter (ONSD) measurement will be performed in subjects with concomitant measurement of Intracranial Pressure (ICP) from an invasive ICP monitor. The operator measuring ONSD will be blinded to concomitant ICP.
2541903|NCT02617953|Experimental|Active rTMS(A)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
2541908|NCT02617953|Experimental|Active rTMS(B)|Temporal low frequency repetitive transcranial magnetic stimulation
2541911|NCT02617953|Sham Comparator|Sham condition(C)|low frequency frontal and temporal repetitive transcranial magnetic stimulation
2541977|NCT02617654|Active Comparator|Liraglutide treatment|Liraglutide treatment in the dose of 1.8 mg daily for 52 weeks
2541978|NCT02617654|Placebo Comparator|Placebo treatment|Treatment with placebo once daily for 52 weeks
3168459|NCT00551265|Active Comparator|Arm II|Patients undergo DTH skin testing and receive oregovomab as in arm I.
3168460|NCT00551278||1|Patients with previous diagnosis of breast cancer scheduled for sentinel lymph node dissection.
2542138|NCT02616328||Participants with confirmed rheumatoid arthritis|
2542176|NCT02616198|Active Comparator|EquiaFil G-coat|EquiaFil G-coat combination was applied on one randomly selected cavity to be restored
2542181|NCT02616198|Active Comparator|EquiaFil Fuji Varnish|EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored
2542187|NCT02616198|Active Comparator|Riva SC G-coat|River SC G-coat combination was applied on one randomly selected cavity to be restored
2542192|NCT02616198|Active Comparator|Riva SC Fuji Varnish|River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored
2542259|NCT02615626||Group 1|Periodontal healthy
2542268|NCT02615626||Group 2|Gingivitis, Non-surgical Periodontal Treatment
2542275|NCT02615626||Group 3|Chronic Periodontitis, Non-surgical Periodontal Treatment
2542317|NCT02615288|Active Comparator|High Dose Vitamin D3 (10,000 IU daily)|
2542321|NCT02615353|Experimental|Lifestyle Intervention|6 months of a bi-weekly Nutrition Education, Physical Activity, and Behavioral Modification program
2542322|NCT02615288|Placebo Comparator|Low Dose Vitamin D3 (1000 IU daily)|
2542326|NCT02615353|Placebo Comparator|Usual Care Control|Medical screening and dietary counseling with a Endocrinologist and Registered Dietitian
2542383|NCT02614911||Sick patients|Biological sampling of blood for all patients. Biological sampling of saliva, biopsies (skin and endoscopic), feces, for some patients
2542384|NCT02614911||Healthy relatives|Biological sampling of blood for all healthy relatives
2542399|NCT02614885||Prophylactic Mastectomy|Females undergoing prophylactic mastectomy with RFA performed on the excised tissue.
3202953|NCT00918398|Experimental|2|AZD1981, 514 mg oral solution
2542438|NCT02614456|Experimental|Interferon-gamma and nivolumab|"Interferon-gamma (IFN-γ): starting dose 50 mcg/m2 subcutaneously Nivolumab: 3 mg/kg intravenously~Induction phase: IFN-γ every other day alone for 1 week Combination phase: IFN-γ every other day & Nivolumab every 2 weeks for 3 months Single agent phase: Nivolumab every 3 weeks up to 1 year"
2542471|NCT02614118|Active Comparator|Ketorolac tromethanine|10 mg oral Ketorolac tromethanine 45 minutes before root canal treatment
2542474|NCT02614118|Active Comparator|Acetaminphen & Ketorolac tromethamine|1000 mg Acetaminophen and 10 mg Ketorolac tromethamine oral 45 minutes before root canal treatment
2542476|NCT02614118|Placebo Comparator|Placebo|placebo 45 minutes before root canal treatment
2542528|NCT02614040|Active Comparator|0.9% Saline|Patients in a month randomized to physiologically-balanced isotonic fluid will receive 0.9% Saline whenever isotonic intravenous fluid administration is ordered by the treating provider.
2542531|NCT02614040|Active Comparator|Physiologically-balanced|Patients in a month randomized to physiologically-balanced isotonic fluid will receive physiologically-balanced isotonic crystalloid (Plasma-Lyte© A or Lactated Ringer's) whenever isotonic intravenous fluid administration is ordered by the treating provider.
2542551|NCT02613559|Experimental|TK001 0.1mg|Injection:single Intravitreal Injection
2542556|NCT02613559|Experimental|TK001 0.5mg|Injection:single Intravitreal Injection
2542564|NCT02613559|Experimental|TK001 1.0mg|Injection:single Intravitreal Injection
2542569|NCT02613559|Experimental|TK001 2.0mg|Biological: TK001 Injection:single Intravitreal Injection
2542570|NCT02613559|Experimental|TK001 2.5mg|Biological: TK001 Injection:single Intravitreal Injection
2542571|NCT02613559|Experimental|TK001 3.0mg|Injection:single Intravitreal Injection
2542775|NCT02612389|No Intervention|MM Intervention Waitlist Control|Testing at same frequency as Meditative Movement interventional subjects.
3168461|NCT00551330|Experimental|1|Vicriviroc 30 mg QD
3168462|NCT00551330|Placebo Comparator|2|Placebo
3168463|NCT00551343|Other|PWS|
3168464|NCT00551343|Other|Controls|
3168465|NCT00551356|Active Comparator|2|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
3168466|NCT00551356|Active Comparator|1|Lispro mix 25 SC twice-daily in conjunction with oral antidiabetic medications.
3168467|NCT00551382|Experimental|A|
3168468|NCT00551382|Placebo Comparator|B|
3168469|NCT00551395|Experimental|SLT Early Completion (Arm 1)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degree on Day 2
3168470|NCT00551395|Active Comparator|SLT Late Completion (Arm 2)|Intervention: 180 degrees of laser on Day 1, 180 degrees of laser on the other 180 degrees at 1 month follow up appointment.
3202954|NCT00918398|Experimental|3|AZD1981, 500 mg oral tablet A
2541981|NCT02617537|Experimental|BAY86-5300|Patients suffering from dysmenorrhea, treated with Yaz
2541983|NCT02617537|Placebo Comparator|Placebo|Patients suffering from dysmenorrhea,treated with placebo
2542045|NCT02617043|Experimental|HF-WBI|Hypofractionated whole breast irradiation for early breast cancer with prescription dose 40Gy in 15 fractions in 3 weeks. Tumor bed is simultaneously integrated boosted to 48Gy.
2542055|NCT02616705||IgG4-related sclerosing cholangitis|Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)
2542059|NCT02616705||Controls|cholangiocarcinoma, PSC, and other patients with biliary strictures
2542144|NCT02616588|Experimental|Intervention Arm|All participants are enrolled into the intervention arm and receive the Veteran Patient Navigator and Social Work Intervention.
2542264|NCT02615496||Educational materials: Physicians|
2542271|NCT02615496||Educational materials: Patients|
2542311|NCT02615236|Experimental|PERINEAL ULTRASOUND|Perineal ultrasound with a bedside scanner by inserting a the probe into the perineum and reviewed in real-time
2542315|NCT02615236|Active Comparator|Clinical diagnosis|Diagnosis of OASIS will be clinically
2542343|NCT02615379|No Intervention|Standard of care|standard wound care for 2 weeks
3202955|NCT00918398|Experimental|4|AZD1981, 500 mg oral tablet B
3202956|NCT00918411|Experimental|Ramosetron group|oral
2542396|NCT02614807|Experimental|Intervention|All recruited patients will receive a standard endorsement of lower fluid intake (<1.5 Litres/day) by a hypertension nurse and physician and an additional treatment consisting of a bottle (237 ml) of Nepro (a low sodium, low potassium content protein supplement) a day (supply for 4 weeks will be provided).
2542428|NCT02614443|Experimental|Depression Condition|Participants in this group will be offered the Space from Depression programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2542429|NCT02614443|Experimental|Anxiety Condition|Participants in this group will be offered the Space from Anxiety programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2542430|NCT02614443|Experimental|Stress Condition|Participants in this group will be offered the Space from Stress programme to be completed over an 8 week period. The programme is delivered through the online SilverCloud platform.
2542435|NCT02614378|Active Comparator|Subject receiving treatment|participant receiving air insufflation
2542436|NCT02614378|Placebo Comparator|Subject receiving placebo|participant not receiving air insufflation
3202957|NCT00918411|Placebo Comparator|Placebo group|oral
3202958|NCT00918437||RAUP treatment|Patients referred to the hospital for a snoring problem
3202959|NCT00918450|Experimental|1|
3202960|NCT00918476|Experimental|1. filibuvir + Oral Contraceptives|
3202961|NCT00918489|Experimental|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
3202962|NCT00918515|Experimental|AZD3043|Intravenous solution
2542557|NCT02613546|Experimental|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
2542559|NCT02613546|Other|Control|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
2542592|NCT02613455|Active Comparator|Kenalog (triamcinolone )|Patients assigned to the corticosteroid arm will receive an intratendinous injection of 1cc Kenalog-40 (triamcinolone-40mg) + 2cc lidocaine 1% by an attending orthopaedic hand surgeon in clinic. They will be provided a home stretching regimen for lateral epicondylitis. They will be discouraged from using nonsteroidal anti-inflammatory drugs . No additional physical or occupational therapy will prescribed.
2542595|NCT02613455|Active Comparator|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either Walter Reed National Military Medical Center (WRNMMC) or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24 kilovolts, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
2542629|NCT02613325|Experimental|Arm 1: fPAM imaging & Single cell PAM imaging|"fPAM imaging will be performed prior to scheduled excision. The time to excision will not be extended longer than 2 weeks for imaging purposes.~When the participant presents for imaging, the area of the thickest lesion depth will be determined by fPAM. The area of deepest thickness will be marked perpendicular to the longest axis of the lesions and a clinical photo will be taken and placed in the image storage database.~Surgical excision will be performed as standard of care and fPAM depth will be compared with histological examination.~To image CTCs in cutaneous blood vessels, a small cuticle area on a finger will be imaged (Single cell PAM imaging) and the most distal cutaneous metastasis or metastasis of largest diameter will be imaged"
2542639|NCT02613156||laparoscopic group|patients in the laparoscopic group underwent laparoscopic resection of recurrent HCC
2542644|NCT02613156||control group|patients in the control group underwent conventional open surgery
2542680|NCT02612961|Experimental|Saline Instillation|3mL normal saline from pink sodium chloride bullet instilled into tracheostomy immediately prior to suctioning.
2544973|NCT02598037|Other|FTO gene polymorphism|test meal after fasting for 12 hours
3202963|NCT00918528|Active Comparator|1. Internal urethrotomy|
3202964|NCT00918528|Experimental|2. Internal urethrotomy + mitomycin C|
3202965|NCT00918541||A|asymptomatic patients with mild to moderate carotid artery stenosis
3202966|NCT00918554|Experimental|Methotrexate|
3202967|NCT00918554|Placebo Comparator|Placebo|
3202968|NCT00918593|Experimental|Electrochemotherapy|
3202969|NCT00918593|Active Comparator|radiotherapy|
3202970|NCT00918606|Experimental|LIPO-102|
3202971|NCT00918619|Experimental|Sangustop|
3202972|NCT00918619|Active Comparator|Tachosil|
2541776|NCT02619305|Experimental|Immediate treatment|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises
2541785|NCT02619305|No Intervention|Delayed treatment|Participants will be social network ties of women receiving no intervention but who will be placed on a waitlist to receive the intervention after a 12-month delay.
3202973|NCT00918632|Other|Sequence 1 (ABC)|"The following treatments will be administered in the following order A -> B-> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3202974|NCT00918632|Other|Sequence 2 (ACB)|"The following treatments will be administered in the following order A -> C -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3202975|NCT00918632|Other|Sequence 3 (BCA)|"The following treatments will be administered in the following order B -> C -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3202976|NCT00918632|Other|Sequence 4 (BAC)|"The following treatments will be administered in the following order B -> A -> C~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3202977|NCT00918632|Other|Sequence 5 (CAB)|"The following treatments will be administered in the following order C -> A -> B~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
3202978|NCT00918632|Other|Sequence 6 (CBA)|"The following treatments will be administered in the following order C -> B -> A~Treatment A = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered after overnight fasting~Treatment B = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a high-fat, high-calorie meal.~Treatment C = AG-013736 polymorph Form XLI film-coated immediate release (FCIR) tablet administered with a moderate-fat, standard-calorie meal."
2542107|NCT02616640|Experimental|Durvalumab monotherapy|Intravenous (IV) durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle
2542108|NCT02616640|Experimental|Durvalumab + pomalidomide (POM)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle and Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle
2542109|NCT02616640|Experimental|Durvalumab + pomalidomide (POM) + dexamethasone (dex)|IV durvalumab at assigned dose level (750, 1500, 2250, or 3000 mg) over 1 hour on day 1 of a 28-day cycle with Oral POM 4 mg/day on Days 1 to 21 of each 28-day treatment cycle and Oral dex 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle
3202979|NCT00918658||Patients with hematologic cancer|Patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, or multiple myeloma
3202980|NCT00918658||Patients without cancer|Patients who do not have cancer.
2542284|NCT02615483|Experimental|Web-based platform|Access to a web-based platform
2542286|NCT02615483|No Intervention|Control|Conventional
2542307|NCT02615197|Active Comparator|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014).
2542308|NCT02615197|Experimental|Dialectical Behavior Therapy + DBT Prolonged Exposure protocol|Standard Dialectical Behavior Therapy (DBT) as described in the 2 DBT treatment manuals (Linehan, 1993; 2014) plus an adapted version of Prolonged Exposure therapy for PTSD.
2542346|NCT02615132|Experimental|Treatment Group|The study SLP will instruct the patient to use the ipad apps as intervention for at least one-hour per day, until they are admitted to outpatient SLP services or for a maximum of 8 weeks, whichever comes first. Throughout the telemedicine treatment phase, patients' progress will be monitored remotely by a study SLP through Apps/Skype/Facetime/Telephone consultation on a weekly basis.
2542350|NCT02615132|No Intervention|Control|Patients will be sent home with standard of care.
2542374|NCT02614950|Experimental|Treatment interuption|
3202981|NCT00918697|Active Comparator|Mechanical debridment|In this arm, corneal epithelium was removed during PRK using conventional mechanical method.
3202982|NCT00918697|Experimental|Alcohol-asstisted debridement|In this arm, corneal epithelium was removed using ethanol 20% during PRK.
3202983|NCT00918710||1|Patients with oropharyngeal squamous cell carcinomas
3202984|NCT00918762|Experimental|daVinci® Robotic Surgical System|Participants will undergo a planned surgical procedures via the robotic approach.
3202985|NCT00918775||Observational (follow-up)|After metastasectomy, patients are followed up every 6 months for up to 5 years.
3202986|NCT00918801||Type 1 Diabetes Mellitus|Adolescents ages 13-18 with T1DM
3202987|NCT00918801||Non Controls|Healthy adolescents ages 13-18 without T1DM
3202988|NCT00918814|Experimental|LIPO-102|LIPO-102
3202989|NCT00918814|Experimental|Placebo|Placebo
2542699|NCT02612792|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2545028|NCT02597608|Experimental|UPPR: Control|No interventions are provided.
2541831|NCT02618447|Experimental|Arm 1: 4D phase contrast MR scan|"Each patient will undergo a total of 3 MRI/MRA scans (lasting 30-60 minutes):~Scan 1: Baseline (pre-portal vein embolization (PRE))~Scan 2: Early after PVE (within 48 hours)~Scan 3: Late after PVE (at 3-8 weeks).~Scans 1 and 3: routine liver MR sequences with/without contrast (Gadoxetic acid, Eovist) and 4D phase contrast of the portal venous system. The 4D phase contrast sequence will be repeated twice at each time point, adding about 15-30 minutes to each scan.~Scan 2: 4D phase contrast sequences and imaging for localization."
2541860|NCT02618239|Experimental|Healthy subjects|Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
2541918|NCT02618057|Experimental|Steroid|Prednisolone, 1.0 mg/kg/day, PO, for 5 days Levofloxacin, 10mg/kg/day, IV, for 5days
2541919|NCT02618057|Active Comparator|Control|Levofloxacin, 10mg/kg/day, IV, for 5days
2541952|NCT02617576||Flavored contrast|This group of patients will have the choice to flavor their contrast.
2541961|NCT02617576||Unflavored contrast|This group of patients will drink the contrast without flavoring.
2542033|NCT02617433|Experimental|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours.
2542091|NCT02616874|Experimental|MVA.HIVconsv plus romidepsin|MVA.HIVconsv plus romidepsin
2542114|NCT02616406||Open repair|Repair group to be monitored with wearable activity monitors pre and post op.
2542117|NCT02616406||Laparoscopic group|Laparoscopic surgical repair group to be monitored with wearable activity monitors pre and post op.
2542197|NCT02616237|Experimental|Intervention Group|"Lifestyle Intervention: The interventions include participation in a private research group on Facebook for health education, self monitoring and social support. Participants will receive 12 weekly lessons related to nutrition, physical activity, Chinese food therapy, acupressure, weight loss. A registered nutritionist and a registered Chinese medicine practitioner will join the Facebook group as health partners. Both of them are also registered nurses.~Besides the Facebook contents, the participants will also receive government printed health information on healthy eating, physical activity, obesity and cancers."
2542199|NCT02616237|No Intervention|Control Group|The participants randomized into the Control Group will only receive government printed health information on healthy eating, physical activity, obesity and cancers.
2542240|NCT02615756|Experimental|Physical exercise|
3168471|NCT00551408||A|20 patients with idiopathic pulmonary arterial hypertension in the WHO functional class II to III, and had a mean pulmonary artery pressure >30 mm Hg on right heart catheterization able to walk >50 m during a standardized 6-min walk test.
3168472|NCT00551434|Experimental|1|
3168473|NCT00551434|Experimental|2|
3168474|NCT00551434|Experimental|3|
3168475|NCT00551434|Placebo Comparator|4|
3168476|NCT00551486||1|Patients with thyroid incidentaloma underwent ultrasound-guided fine needle aspiration biopsy
2542390|NCT02614651|Experimental|The study population|"The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute.~Intervention: Find visual comfort threshold related to light intensity~Intervention: Find the size of the visual field~Intervention: Effectiveness of brightness control~Intervention: Performance of color correction~Intervention: Vuzix Wrap 1200DX virtural reality glasses"
2542433|NCT02614430|Active Comparator|Vocational training|Participants are randomized into the intervention group (training) where they are offered a training course of 4-9 weeks of physical training three times a week with a physiotherapist.
2542434|NCT02614430|No Intervention|Control|Participants are randomized into the control group where they are offered the standard treatment.
2542479|NCT02614105|Experimental|Pelvic floor muscle training|Participants in the pelvic floor muscle training group will receive group exercise sessions (1 hour) at the physiotherapy out-patient department of the hospital once a week for 16 weeks with guidance from an experienced pelvic floor physiotherapist. The group exercise sessions will focus on pelvic floor muscle training, relaxation and breathing techniques. Participants in the pelvic floor muscle training group will also receive an individually adapted pelvic floor muscle training program for daily home use.
2542481|NCT02614105|Experimental|Cough-suppression|Participants in the cough-suppression group will receive a group education session with general information about cough-suppression therapy and advice about how to distinguish between unproductive and productive cough to enable them to perform airway clearance techniques when required. In addition, participants will receive one to two individual sessions (30-60 minutes) of cough-suppression therapy tailored to the individual needs based on symptoms and underlying disease activity
2542485|NCT02614105|Experimental|Control group|Participants in the group will receive guidance and instruction in terms of correct contraction of the pelvic floor muscles at clinical assessment. Control group participants will receive brief written information about pelvic floor muscle training and cough-suppression therapy, but no other form of regular follow-up or intervention throughout the intervention period.
3168477|NCT00551499|No Intervention|CRT for patients with CSA|Patients suffering from HF with central Sleep Apnea (CSA) programmed to DDD/45 (CRT) for 12 weeks. Intervention is CRT.
3168478|NCT00551499|Active Comparator|CRT + AOP for patients with CSA|Patients suffering from HF with central Sleep Apnea programmed to DDD/+15 bpm nocturnal rate (CRT + AOP) for 12 weeks. Intervention is the AOP in addition to CRT.
3168479|NCT00551512|Experimental|CBP501 and Cisplatin|Dose escalation study
3168480|NCT00551538|Active Comparator|1|Lispro mixture 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
3168481|NCT00551538|Active Comparator|2|Glargine, once-daily, SC injection, given in conjunction with oral antidiabetic medications.
3168482|NCT00551551|Experimental|Rééducation|Standardized pelvic floor muscle training program with a physiotherapist in 8 sessions (20-30 minutes each) between 24 and 36 weeks of gestation AND Written instructions about personal (Kegel) pelvic floor exercises
3168483|NCT00551551|Active Comparator|Control|Written instructions about personal (Kegel) pelvic floor exercises
3168484|NCT00551564|Experimental|Subjects in healthy normal and overweight control arm|Subjects in the Healthy Normal or Overweight Control Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
3168485|NCT00551564|Experimental|Subjects in healthy obese with T2DM arm|Subjects who are in the Healthy Obese or T2DM Population will be included in this arm and they will receive Rosiglitazone 4 milligram twice daily.
2541927|NCT02618161|Experimental|Arm A|HDR Brachytherapy single dose of 15 Gy followed by EBRT of 46 Gy in 23 fractions and Androgen deprivation therapy 6 months to 3 years, (sequencing of HDR followed by EBRT)
2541931|NCT02618161|Active Comparator|ARM B|External Beam Radiotherapy (EBRT) of 46 Gy in 23 fractions, followed by single dose of HDR brachytherapy of 15 Gy boost and Androgen deprivation therapy 6 months to 3 years (timing of HDR Brachytherapy Treatment is changed compared to ARM A)
2541963|NCT02617524|Experimental|Valve Medical Dedicated Sheath|Valve Medical Dedicated Sheath version 00
2542018|NCT02617368||KC group|KC group included patients those were diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system
2542021|NCT02617368||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
2542026|NCT02617368||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
2542093|NCT02616939||Patients with suspected cardiac disease|"Patients eligible for cardiac CT will be included with a focus on symptomatic patients with low-intermediate risk for obstructive coronary artery disease.~Patients will undergo Cardiac CT scanning (with the SpotLight CT)."
3168486|NCT00551577|Active Comparator|A1|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
3168487|NCT00551577|Experimental|A2|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
2542232|NCT02615847|Experimental|Memantin arm|Memantinhydrochlorid, administered once per day during 12 month. Dosage is from 0-20 mg.
2542356|NCT02615015||ST elevation myocardial infarction patient cohort|Patients who suffered from ST elevation myocardial infarction since 2006, referred to the General Hospital of Vienna and received primary percutaneous coronary intervention.
2542359|NCT02615015||Healthy proband cohort|Age matched healthy individuals who voluntarily participate in the study.
2542404|NCT02614638|Experimental|2nd obs. period (during experimental intervention)|"Following a one-month wash-out period, patients in this arm are included during a second month of observation during which the intervention is implemented.~Intervention: Pharm Tech participates in department"
2542454|NCT02614365|Experimental|Aerobic Exercise|6-month 3-time/week aerobic exercise, and a 12-month passive follow-up.
2542461|NCT02614365|Active Comparator|Stretch Exercise|6-month 3-time/week stretch exercise, and a 12-month passive follow-up.
2542480|NCT02614508|Experimental|Cohort A (buparlisib, ofatumumab)|Patients receive buparlisib PO QD on days 1-28 and ofatumumab IV on days 1, 8, 15, and 22 during of courses 1-2; and day 1 of courses 4-7. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2542483|NCT02614508|Experimental|Cohort B (buparlisib, ibrutinib)|Patients receive buparlisib as in Cohort A and ibrutinib PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2542515|NCT02613806|Experimental|D group (dexmedetomidine)|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion with microperfusion pump at the beginning of the surgery,and continued till end of surgery.
2542518|NCT02613806|Active Comparator|C group (saline)|The patients received equal volume normal saline by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
2542521|NCT02613975|Experimental|on positional device|patients who could not tolerate cpap will be provided with positional device for treatment of OSA which will vibrate when patients lie in prone position
2542522|NCT02613975|Experimental|patients on dental device|patients on dental devices but not optimally treated for OSA will be provided positional device for optimization of treatment for OSA, which will vibrate when patients lie in prone position
2542547|NCT02613663|Experimental|immediate implants with nanobone graft|Nano-hydroxyapatite bone graft fill the gap between immediate implant and labial bone wall.
2542549|NCT02613663|Active Comparator|immediate implants with autogenous bone graft|Autogenous graft fill the gap between immediate implant and labial bone wall.
2542562|NCT02613702|Experimental|Modified Free Gingival Graft|Twenty patients will receive the modified free gingival graft technique at the inferior incisors area. In this technique, the graft is covered by a flap, similarly to what is done in a connective tissue graft surgery.
2542568|NCT02613702|Active Comparator|Original Free Gingival Graft technique|Twenty patients will receive the original technique of free gingival graft at the inferior incisors area.
2542623|NCT02613260|No Intervention|Usual Care|Patients in this study arm will receive usual care from their primary care clinic.
2542624|NCT02613260|Experimental|FIT Outreach + Usual Care|Patients in this study arm will receive usual care at their primary care clinic and the intervention.
2542628|NCT02613351|Experimental|scooting|incremental test to establish the relationship between leg and breathing heaviness with increasing demand (speed) during scooting
2542667|NCT02612948|No Intervention|Standard Care|Standard care for delerium
2542668|NCT02612948|Active Comparator|Quetiapine|Quetiapine therapy was initiated at 12.5 mg twice daily a. After thefirst dose of quetiapine 12.5 mg, the regimen could then be adjusted by the rounding surgeon. If the surgeon felt benefit from receiving a higher dose of quetiapine the dose could then be increased. Quetiapine was discontinued if adverse events (torsades de pointes or other ventricular tachycardias) occurred. All patients receiving at least one dose of quetiapine were included in the final intention-to-treat analyses. All prescribing decisions were left to the discretion of the rounding surgeon and were not mandated as part of the study.
2542674|NCT02612974|Experimental|Group A|Hirudinaria granulosa and Qurse mafasil are given
2542681|NCT02612974|Active Comparator|Group B|Qurse mafasil only given
2545033|NCT02597608|Experimental|UPPR: Livelihoods only|Livelihoods programmes offered by UPPR.
3168488|NCT00551590|Placebo Comparator|1|placebo PO (placebo control for sitagliptin) for three days. Saline IV (placebo control for exendin(9-39) on two consecutive study days.
3168489|NCT00551590|Experimental|2|Sitagliptin 100 mg PO for three days. Saline IV (placebo control for exendin(9-39)) on two consecutive study days
3168490|NCT00551590|Experimental|3|Sitagliptin 100 mg PO for three days. Exendin(9-39) IV on two consecutive study days.
2541868|NCT02618265|Experimental|Mobile terminal|Stroke received mobile terminal management for secondary prevention administration, as the same time platelet reactivity modified drug selection was performed. Mobile application management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
2541870|NCT02618265|Active Comparator|traditional management|Stroke received traditional management for secondary prevention administration
2541873|NCT02618265|Active Comparator|website platform management|Stroke received website platform management for secondary prevention administration. Website platform management conducts the control and regulation for anti hypertension, statin and antiplatelet therapy to increasing drug compliance.
2541935|NCT02617862|Experimental|PCI imaging system|
2541960|NCT02617511|Experimental|Omega-3 Supplementation|This groups will supplement their regular diet with 2.97 grams of combined omega-3 fatty acid (EPA/DHA) supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
2541970|NCT02617511|Placebo Comparator|Placebo|This group will supplement their regular diet with 3.0 grams of a combined omega-3-6-9 supplement in soft gel form on a daily basis for 12 weeks. This group will also complete a whole body progressive resistance training program 3 days per week for 12 weeks.
2542019|NCT02617238|Active Comparator|PWV group|"Cardiovascular risk management based on PWV will include altogether~the implementation of international guidelines,~the normalisation of blood pressure, and~the normalisation of arterial stiffness"
2542027|NCT02617238|No Intervention|Conventional group|These patients will be treated according to the 2007 (and then 2013) ESH-ESC Guidelines for the management of hypertension
2542079|NCT02616835|Experimental|theta-burst TMS|Theta-Burst protocol for transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
2542084|NCT02616835|Sham Comparator|sham theta-burst TMS|Sham protocol for theta-burst transcranial magnetic stimulation on dorsolateral prefrontal cortex (exact location to be determined using neuronavigation guided by Magnetic Resonance Imaging)
2542155|NCT02616510||PCOS|Rotterdam criteria (at least 2 out of three criteria present) oligo-anovulation polycystic ovarian morphology hyperandrogenism
2542156|NCT02616510||POI|amenorrhea of at least 4 months prior to age 40 years, with follicle stimulating hormone (FSH) levels above 40 IU/L
3202990|NCT00918840||DermaVir + HAART|"Dosage: 0.4 mg DNA~Dosage form: 3.2 mL DNA/PEIm nanomedicine~Administration with 4 DermaPrep patches~Frequency: every 4 weeks~Duration: 8 weeks (3 DermaVir treatments)"
3202991|NCT00918840||Placebo + HAART|"Dosage form: 3.2 mL Placebo~Administration with 4 DermaPrep patches~Frequency: every four weeks~Duration: 8 weeks (3 Placebo treatments)"
2542361|NCT02614976|No Intervention|Control|No padding before application of blood pressure cuff
2542363|NCT02614976|Experimental|Padding|Padding before application of blood pressure cuff
2542398|NCT02614742|Active Comparator|SFX-01|300mg bid for up to 28 days.
2542403|NCT02614742|Placebo Comparator|Placebo|300mg placebo bid for up to 28 days
2542415|NCT02614768|Experimental|Glucose Sensor|Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
2542440|NCT02614313|Active Comparator|Fructose double-blind|Fructose during breath test, double-blind 35g
2542442|NCT02614313|Active Comparator|Fructose open|Fructose during breath test, open 35g
2542444|NCT02614313|Placebo Comparator|Sweet placebo double-blind|Assugrin during breath test double-blind
2542446|NCT02614313|Placebo Comparator|Neutral placebo double-blind|Water during breath test double-blind
2542457|NCT02614326|Experimental|Memory Flexibility (MemFlex) Training|MemFlex training draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014). MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks used throughout the workbook, and guides the participant in completion of the tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive a phone call at the beginning of week three to check progress, and clarify any difficulties.
2542465|NCT02614326|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. The workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The participant will receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties.
3202992|NCT00918853|Experimental|resection for adenocarcinoma|quality standard resection for adenocarcinoma of the head of the pancreas
2542513|NCT02613949|Active Comparator|12-week RINCE mode 1|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 1
2542516|NCT02613949|Active Comparator|12-week RINCE mode 2|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device at treatment mode 2
3202993|NCT00918905|Experimental|1 Telemonitor|Within 24 hours after the patient was discharged the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with a doctor. The patient was planned to have the equipment for approximately one week and had at least one follow-up phone call within the four weeks period. Telemonitoring video conferences could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period of time (hot-line).
3202994|NCT00918905|No Intervention|Control group|No tele-monitor at home. The COPD patients discharged after an acute exacerbation living outside Svendborg or Faaborg-Midtfyn municipalities in the recruiting area were included in the control group and assigned to conventional care.
2541895|NCT02617979|Experimental|Arm 1: SAFECARE at Home|"Patients randomized to the intervention arm will be assigned a username and password to access a SAFECARE at Home account via the internet. They will also be emailed a link to the site with their username and password.~The investigators have worked directly with SAFECARE at Home to create customized lessons for patients undergoing pancreatectomy. These lessons are comprehensive and encompass preoperative preparation as well as postoperative recovery and care. This includes videos, printed material, web-based material, and modules that focus on the pre-treatment, treatment, and follow-up care of patients undergoing surgery for pancreatic cancer.~All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients."
2541899|NCT02617979|No Intervention|Arm 2: Standard of Care|-All patients will receive standard pre- and post-operative instructions and care. This will include verbal education about the procedure by the surgeon as well as standard educational patient handouts, which are routinely provided preoperatively to pancreatectomy patients.
2541956|NCT02617732|Experimental|Tianqi capsule|a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
2541969|NCT02617732|Placebo Comparator|placebo|a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
2542016|NCT02617251||neonatology patients|neonatology patients
2542025|NCT02617251||paediatric patients|paediatric patients
2542056|NCT02616913|Experimental|R,R-monatin|150 mg single dose
2542061|NCT02616913|Active Comparator|Moxifloxacin|400 mg tablet single dose
2542067|NCT02616913|Placebo Comparator|Placebo|placebo single dose
3202995|NCT00918918|Experimental|Treatment B|Vodka + orange juice
3202996|NCT00918918|Placebo Comparator|Treatment A|Orange juice
3202997|NCT00918944|Other|Control arm|Practices with the EHR implemented will be randomized have the asthma disease management tools available passively (the control group).
2542229|NCT02615873|Experimental|AP CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
3202998|NCT00918944|Other|Intervention arm|The intervention sites will have decision support alerts and reminders activated to guide providers toward these tools in the appropriate situations.
2542467|NCT02614300|Active Comparator|Pulmonary Rehabilitation and Chest Physiotherapy|"This group will perform a combination of the two programs in the same session with a total duration of 1h and 15 minutes. The session will be divided in different parts: First, we will execute 15min of chest physiotherapy (7.5min for each side); second, the pulmonary rehabilitation session (45min) and finally, another 15min of chest physiotherapy (7.5min for each side). The patient will have a rest when it's necessary and we will continue with the session when there is a decrease of 2 points in the Borg scale.~Intensity of physiotherapy exercises and drainage techniques will be maintained similar to the PR and CP programs."
2542469|NCT02614300|No Intervention|Control Group|"For the control group, participants will attend educational sessions to improve patients' understanding and awareness of the respiratory diseases. These sessions will be performed at beginning and at 12 weeks by the physiotherapist and the pulmonologist.~The physiotherapist will also do monthly telephone calls for patient's monitoring."
2542487|NCT02614092|Experimental|Water based Activity+ Cognitive Training|water-based physical activity + classroom based cognitive training
2542512|NCT02613845||Cardiac surgery|Study subjects are all patients who underwent cardiac surgery with cardiopulmonary bypass at the University Hospital Basel during the year 2013.
2542535|NCT02613936|Experimental|Active anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of active tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
2542538|NCT02613936|Sham Comparator|Placebo anodal tDCS + cognitive training|In this arm, 40 patients with mmTBI will undergo 10 sessions of placebo tDCS x 30 minutes combined with simultaneous cognitive training on consecutive weekdays.
2542555|NCT02613728|Active Comparator|Standard of Care Arm|Standard enhanced care following minimally invasive colorectal cancer surgery
2542560|NCT02613585|Experimental|Permethrin Impregnated Clothing|Uniforms and work clothing (including pants, shorts, shirts, socks, and hats) treated with long-lasting permethrin by Insect Shield.
2542563|NCT02613728|Experimental|Intervention (RecoverMI) Arm|Routine care with Accelerated Recovery Plan, Early Discharge, and Telemedicine following minimally invasive colorectal cancer surgery
2542565|NCT02613585|No Intervention|Untreated Clothing|Uniforms and work clothing sent to Insect Shield, washed and refolded (no permethrin applied).
2542640|NCT02613234|Experimental|Experimental Group|Active Intervention on brain waves by cathode tDCS
2542645|NCT02613234|Sham Comparator|Control Group|Sham Intervention on brain waves by cathode tDCS
2542672|NCT02612883||Esophagus|Measuring of tissue perfusion of the esophagus
2542673|NCT02613052|Placebo Comparator|Agitated Normal Saline|Agitated saline is the current standard of care contrast agent used for bubble studies. 10 mL of agitated normal saline will be used for the bubble study.
2542675|NCT02612883||Liver|Measuring of tissue perfusion of the liver
2542679|NCT02613052|Active Comparator|Albumin only|10 mL of agitated 5% albumin will be used for the bubbly study.
2542682|NCT02612883||Stomach|Measuring of tissue perfusion of the stomach
2542684|NCT02613052|Experimental|Albumin and Propofol|7 mL of 5% albumin and 3 mL of propofol (10 mg/mL) will be agitated together and used for the bubble study.
2542686|NCT02612883||Pancreas|Measuring of tissue perfusion of the pancreas
2542688|NCT02612883||Colon|Measuring of tissue perfusion of the colon
2542694|NCT02612987|Experimental|iCBT|
2542737|NCT02612597|Experimental|Bedrest|4 days of bedrest
2542740|NCT02612701|Experimental|Cigarettes|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking two standard cigarettes
2542741|NCT02612597|Experimental|Exercise Training|6 weeks of aerobic endurance exercise training with 4 supervised sessions per week at an average intensity of 65 % of maximal heart rate
3202999|NCT00918970||SNA group|This group will have a real-time analysis of autonomic nervous system activity during its intensive care hospitalisation
2541943|NCT02617875|Other|Tele-EMS physician|The dispatching personnel will evaluate the emergency call severity and after exclusion of the life-threatening cases listed in a written procedure instruction, they will dispatch a tele-EMS physician, if this is the result of the randomization software.
2542034|NCT02617420||Intervention|All patients will be enrolled in one arm. These patients will have monitoring devices placed on their asthma controller and rescue medication, with data transmitted both to their smartphones and a dashboard accessed by their primary pediatric pulmonary provider.
2542087|NCT02616926|Experimental|Hepatic resection|"Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.~Intervention: Hepatic resection"
2542089|NCT02616926|Active Comparator|TACE + RFA|"TACE is performed as a primary treatment for hepatocellular carcinoma. RFA will be performed two weeks later if necessary.~Intervention: TACE; RFA"
2542163|NCT02616315|Placebo Comparator|Group A: Placebo|Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
2542164|NCT02616315|Experimental|Group B: Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).
2542253|NCT02615639|Experimental|HPDC-T cells & entecavir|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks , and entecavir(ETV) 0.5mg tablet by mouth, every night.
2542254|NCT02615639|Active Comparator|entecavir|entecavir 0.5mg tablet by mouth, every night.
2542255|NCT02615639|Experimental|HPDC-T cells & IFN-a-2a|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
2542256|NCT02615639|Active Comparator|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection， every week for 9 months.
2542257|NCT02615639|Experimental|HPDC-T cells & Telbivudine|HPDC-T cells 1-5×10^5 intravenous injection, every 2 weeks for 24 weeks ,and Telbivudine 600mg tablet by mouth, every night.
2542258|NCT02615639|Active Comparator|Telbivudine|Telbivudine 600mg tablet by mouth, every night.
3203000|NCT00918970||Clinical group|This group will have a conventional clinical analysis during its intensive care hospitalisation
3203001|NCT00918983|Experimental|NX-1207|
3203002|NCT00918983|Placebo Comparator|Placebo|
2542458|NCT02614339|Experimental|metformin|
2542463|NCT02614339|Active Comparator|control|
2542472|NCT02614157|Experimental|LLND+TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo lateral lymph node dissection and total mesorectal excision(LLND+TME)
2542475|NCT02614157|No Intervention|TME group|advanced rectal cancer patients after neoadjuvant chem-radiation with suspicious lateral lymph nodes involvement undergo total mesorectal excision (TME)solely, without LLND
2542529|NCT02613962|Experimental|relapsed or refractory pediatric tumor|This is a prospective, international, multicentric clinical proof-of-concept study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory pediatric tumors. The molecular screening will be done on a newly biopsied or resected tumor sample obtained at the time of relapse/progression, using high-throughput technologies, primarily WES and RNA Sequencing, and bioinformatics analysis.
3203003|NCT00918996|Experimental|No Bladder Flap Group|Uterine incision made 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
3203004|NCT00918996|No Intervention|Bladder Flap Group|Standard cesarean section technique with incision and dissection of a bladder flap prior to uterine incision.
3203005|NCT00919009|Experimental|Sorafeinb|Oral sorafenib (400 mg BID) will be start the 3 day after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination.
2542652|NCT02613104|Experimental|Sad to Happy|emotion recognition modification - sad>happy
2542653|NCT02613104|Placebo Comparator|Sad control|emotion recognition modification - sad>happy control
2542655|NCT02613104|Experimental|Angry to Happy|emotion recognition modification - angry>happy
2542657|NCT02613104|Placebo Comparator|Angry control|emotion recognition modification - angry>happy control
2542658|NCT02613078|Experimental|Gut-Directed Hypnotherapy (GDH)|Gut-Directed Hypnotherapy on a daily basis (20 min each day, at least 4 times/week)
2542659|NCT02613078|Experimental|Probiotic (NS)|Nutritional supplement SymbioLact B once a day diluted in water or tea
2542660|NCT02613078|Active Comparator|Active Controls (AC)|AC group keeps a symptom dairy (self-monitoring)
2542706|NCT02612753|Experimental|Aphasics Patients|Patients which have difficulties to speak. Improvement of language for aphasics patients.
3203006|NCT00919022||Group 1|
3203007|NCT00919048||Urodynamic patients|Uroflow studies of patients who underwent urodynamics as part of an incontinence work-up.
2542003|NCT02617121|Active Comparator|Gabapentin and ramosetron|oral gabapentin 300 mg 1 hours before induction of anesthesia ramosetron 0.3 mg iv at end of surgery
2542095|NCT02616965|Experimental|Treatment|Treatment consists of the combination of Romidepsin given 10mg/m2 or 14mg/m2 on days 1, 8 and 15 every 28 days and Brentuximab vedotin given 0.9mg/kg or 1.2mg/kg on days 1 and 15 every 28 days for 16 cycles.
2542126|NCT02616367|Experimental|liposomal bupivacaine Periarticular injection|Will consist of 100 mL (one syringe with 50 mL total: 40 mL 0.25% bupivacaine, 300 mcg epinephrine, 1 mL ketorolac, 2.5 mL morphine, 6.5 mL normal saline) (one syringe with 50 mL total: 20 mL liposomal bupivacaine 30 mL normal saline).
2542128|NCT02616367|Active Comparator|Ropivacaine Periarticular Injection|Will consist of 100 mL (1 mL ketorolac, 2.5 mL morphine, 28.95 mL normal saline, 300 mcg of epinephrine, and 200 mg ropivacaine
2542196|NCT02616159|Experimental|Oatmeal 1|40 g cereal
2542200|NCT02616159|Experimental|Oatmeal2|40 g cereal
2542202|NCT02616159|Experimental|Oatmeal 3|40 g cereal
2542208|NCT02616159|Placebo Comparator|Ready to eat cereal|32.2 g cereal
2542213|NCT02616159|Placebo Comparator|Hot cereal|28.8 g cereal
2542243|NCT02615704||Active APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP with MEMS
2542244|NCT02615704||Active APP without MEMs|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using active APP without MEMS
2542245|NCT02615704||Control APP with MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP with MEMS
2542246|NCT02615704||Control APP without MEMS|ACS patients 18 years or older with access to an electronic device (compatible with the patient support tool), diagnosed with STEMI, NSTEMI or UA treated with twice daily Brilique(ticagrelor) co administered with low dose acetylsalicylic acid according to the prescription recommendation using control APP without MEMS
2542309|NCT02615067|Experimental|99mTc-MIP-1404 Injection|20 ± 3 millicurie (mCi) intravenous (IV) injection of 99mTc-MIP-1404
2542425|NCT02614573|Experimental|The study population|The clinical phases of this study will be held in the nursing home (EHPAD; principal building + 2 annexes) of Pont-Saint-Esprit, located in France. Patients are elderly dependents treated by anti-vitamin K for more than 6 months.
2542473|NCT02614235|Active Comparator|Conventional Holter|Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
2542523|NCT02613923|Experimental|GO! To Sleep|Participants in the intervention group will be provided with a code and website address to participate in this program. This program includes reminder emails and is 6 weeks in duration. Participants will be given a blood draw to measure biomarkers.
2542527|NCT02613923|Active Comparator|informational control|Participants in the control group will receive weekly emails with sleep information and the health benefits of sleep for 6 weeks.Participants will be given a blood draw to measure biomarkers.
2542540|NCT02613819|Experimental|Stereotactic Ablative Body Radiotherapy|"Stereotactic Ablative Body Radiotherapy (SABR)~Treatment schedule 1: 26 Gray (Gy) in 1 fraction, for tumours of less than or equal to 4cm in size.~Treatment schedule 2: 42 Gray (Gy) in 3 fractions, for tumours of greater than 4cm in size"
2542550|NCT02613533|Experimental|Narrow Angle Glaucoma Study Group|Subjects will be given 10ml/kg of water over 15 min prior to surgery and Intra-ocular pressure measurement (IOP) is checked every 15 min before and after surgical procedure.
2542578|NCT02613520|Experimental|Group 1a (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 9 x 10^5 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2542580|NCT02613520|Placebo Comparator|Group 1a (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2542581|NCT02613520|Other|Group 1a (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1a. Volunteers will be injected with PfSPZ Challenge (for CHMI).
2542584|NCT02613520|Experimental|Group 1b (PfSPZ Vaccine)|18- 45 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2542586|NCT02613520|Placebo Comparator|Group 1b (normal saline)|18- 45 years; n=3; 3 doses of normal saline given 8 weeks apart. Volunteers will undergo CHMI with PfSPZ Challenge 3 weeks after the last immunization.
2542588|NCT02613520|Other|Group 1b (CHMI controls)|18- 45 years; n=6; volunteers will not receive any intervention, but will serve only as infectivity controls; 3 volunteers each, for CHMI 1 and for CHMI 2 in Group 1b. Volunteers will be injected with PfSPZ Challenge (for CHMI).
2542589|NCT02613520|Experimental|Group 2a (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542590|NCT02613520|Placebo Comparator|Group 2a (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
2542591|NCT02613520|Experimental|Group 2b (PfSPZ Vaccine)|11-17 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
2542593|NCT02613520|Placebo Comparator|Group 2b (normal saline)|11-17 years; n=3; 3 doses of normal saline given 8 weeks apart.
2542596|NCT02613520|Experimental|Group 3a (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542598|NCT02613520|Placebo Comparator|Group 3a (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
2545136|NCT02596802|Experimental|FETO therapy|Intervention name: FETO therapy
2542058|NCT02616809|Experimental|standing|Participants will change posture (from sitting to standing) during hourly intervals for an 8-hr period in a simulated office environment
2542064|NCT02616809|Experimental|slow walking|Participants will transition from sitting to slow walking on a treadmill desk at regular hourly intervals during an 8-hr period in a simulated office environment
2542152|NCT02616497|Active Comparator|Aspirin|100mg/day
2542157|NCT02616497|Active Comparator|Triflusal|300mg twice or 600mg once daily
2542174|NCT02616003|Other|Super-super Obese Patients|Multimorbid, super-super obese patients that need preoperative conditioning therapy (intervention 1: Liraglutide, intervention 2: aminosteril hepa 8%, intervention 3: Caloric diet with 1000 kcal) for weight loss surgery to achieve technical operability.
2542237|NCT02615886|Experimental|Observational Control|Randomized participants will be observed for diarrhea incidences throughout the 6 month trial with no intervention.
2542238|NCT02615886|Experimental|Rice Bran|Randomized participants will consume a measured dose of rice bran daily throughout the 6 month trial.
3203008|NCT00919074|Active Comparator|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
3203009|NCT00919074|Active Comparator|Pancreatic wire|Placement of a guidewire into the pancreatic duct to facilitate bile duct cannulation.
2542368|NCT02614963|Experimental|Clostridium Butyricum group|Irritable bowel syndrome patients treated with Clostridium Butyricum
2542371|NCT02614963|Placebo Comparator|Placebo group|Irritable bowel syndrome patients treated with placebo
3203010|NCT00919165||control and study group|severe carotid artery stenosis in asymptomatic patients defined as greater than 80% stenosis angiographically or greater than 400 cm/sec peak systolic velocity on carotid doppler evaluation
3203011|NCT00919178|Experimental|1|Participants will receive a single immunization for Dengue virus serotype 4 (DEN4)
3203012|NCT00919178|Placebo Comparator|2|Participants will receive a single immunization in the form of placebo resembling vaccine for DEN 4
3203013|NCT00919204|Experimental|Cohort 1|
3203015|NCT00919230|No Intervention|no treatment|no iron given
3203016|NCT00919230|Experimental|ferrous sulphate|iron given
3203017|NCT00919243|Experimental|prednisone|
3203018|NCT00919243|Active Comparator|allopurinol|
2542544|NCT02614014|Experimental|Psychological intervention|Cognitive-behavior interventional program
2542546|NCT02614014|No Intervention|Control|No intervention
3203019|NCT00919269||Ancillary-Correlative (specimen collection)|Surgical tissue, bone marrow, and blood specimens are collected at diagnosis (initial or relapse) and, if applicable, at the development of a second primary tumor. Specimens are used for research purposes. A certificate of confidentiality protecting the identity of research participants in this project has been issued by the National Cancer Institute.
3203020|NCT00919282|Experimental|Gemcitabine/folinic acid/5-FU|Gemcitabine 1g/m² 5-FU 750mg/m² FS 500 mg/m²
3203021|NCT00919295|Placebo Comparator|placebo|placebo
3203022|NCT00919295|Placebo Comparator|mirtazapine 15|mirtazapine 15 mg
3203023|NCT00919295|Placebo Comparator|mirtazapine 30|mirtazapine 30mg
2542677|NCT02613013|Active Comparator|single LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
2542683|NCT02613013|Experimental|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure
3203024|NCT00919308||Control, traditional bedside training|Postgraduate year 1 and 2 residents who are trained in central venous catheter insertion according to the traditional, bedside apprenticeship model.
3203025|NCT00919308||Simulation training|Postgraduate year 1 and 2 residents who complete a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by: the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous cannulator on a partial task training simulator with no technical errors.
3203026|NCT00919321|Other|PPV|
3203027|NCT00919334|No Intervention|single vision soft contact lens|Single vision soft contact lenses with same materials of the DISC lens
3203028|NCT00919334|Experimental|Defocus Incorporated Soft Contact (DISC) lens|The use of DISC lens to slow down the progression of myopia
3203029|NCT00919360||Controls|Gravidas without history of hypertension of any kind, and matched to cases for parity, gestational age, labor status, mode of delivery, maternal age, and race.
3203030|NCT00919360||Preeclamptics|Gravidas at 32-42 weeks gestation, delivered by Caesarean Section, who have preeclampsia as defined by Sibai et al, 1997.
3203031|NCT00919373|Active Comparator|ICD-Implantation|Implantation of an Implantable Cardioverter Defibrillator (ICD) alone.
3203032|NCT00919373|Active Comparator|ICD + Ablation|Stratified Catheter Ablation of Ventricular Tachycardia and ICD Implantation
3203033|NCT00919386||1 Direct ureteric measurement|This is determined by using a 5 French Pollack Open-Ended Flexi-Tip Ureteral catheter (Cook, Spencer, Indiana) to cannulate the ureteral orifice. A retrograde pyelogram will be done at the conclusion of the procedure and the Pollack will be advanced to the pyeloureteral junction (PUJ) under fluoroscopy. At this point the length of the distance between the PUJ and vesicoureteral junction (VUJ) will be recorded and stent length determined based on this measurement.
2542076|NCT02616757|Active Comparator|Simple Bone Cyst Patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline and once annually for 2 years.~There will also be optional blood samples taken o measure bone alkaline phosphatase."
2542080|NCT02616757|Active Comparator|Fracture patients|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at future follow-up visits as clinically indicated or at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
2542086|NCT02616757|Placebo Comparator|Health volunteers|"Z-score measurements will be taken from the mid-shaft tibia and distal third of the radius of both extremities where possible using quantitative ultrasound at baseline, after 3 months and at a one year follow-up visit.~There will also be optional blood samples taken to measure bone alkaline phosphatase."
2542151|NCT02616484|Active Comparator|Dichloroacetate, then Placebo|"This group will start on the Dichloroacetate (DCA) treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the placebo treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
2542153|NCT02616484|Placebo Comparator|Placebo, then Dichloroacetate|"This group will start on the placebo treatment which will last for 4 months. After 4 months a 1 month washout period will occur. After the 1 month the group will crossover to the Dichloroacetate (DCA) treatment for 4 months.~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens"
2542224|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation, it is proposed by one of the investigators, patients that clinical data from this psychiatric examination, conducted as part of their usual care, are recorded as part of the research that their is proposed and explained. An information note is then distributed and not collected their opposition
2542274|NCT02615691|Experimental|Previously untreated patients (PUPs)|"Part A (Main Study): Participants age <3 years and not experienced two joint bleeds will receive on- demand treatment of 10-80 international unit per kilogram (IU/kg) of BAX 855 intravenously depending on the severity of the bleeding episode and age <3 years or after a maximum of two joint bleeds will receive prophylaxis treatment with dose of 25-80 IU/kg of BAX855 IV (based on investigator discretion) once weekly for up to 100 EDs.~Part A (Surgery): In participants, the administration of BAX 855 will be individualized based on the participants IR and half-life. For major surgery to achieve the target level of 80-100% FVIII in plasma of normal FVIII level and for minor surgery >=30-60% FVIII levels for dental or other invasive surgery.~Part B (Immune tolerance induction [ITI]): Participants will receive prophylaxis treatment of 100-200 IU/kg BAX 855 IV daily or 50 IU/kg three time in a week and will be reduced to twice weekly to maintain FVIII trough level of 1% for further 3 months."
3203034|NCT00919386||2 Based on patient height|"We will use the height measurement criteria used by Lee et al in their study. Patients less than 5'2 will receive a 22 cm stent, 5'3-5'7 will get a 24 cm stent, 5'8-5'10 will get a 26 cm stent, 5'11 to 6'1 will get a 28 cm stent, and all patients greater than 6'2 will receive a 30 cm stent."
3203035|NCT00919386||3 Based on a predetermined formula|We will use the formula described by Wieder. Stent length in cm= patients height in inches - 42.
2542519|NCT02613949|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
2542558|NCT02613676|Experimental|TcB screening before discharge|Participants in this group will be screened for jaundice using the JM 105 transcutaneous device. The TcB value will be plotted on the Bhutani nomogram to assess the risk category. Infants who are categorised as high risk according to the nomogram will require blood sampling for TsB and assessment for need for phototherapy.
2542566|NCT02613676|Other|Standard care (visual inspection)|Participants in this group will be managed routinely according to the current standard of care where babies are assessed for jaundice by visual inspection. Babies in this group will require blood draw for TsB if there are visibly jaundiced
3203036|NCT00919412||Preterm delivery (< 37 weeks)|
2542626|NCT02613286|Experimental|Extrafascial Hysterectomy|Type A hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
2542627|NCT02613286|Active Comparator|Modified radical hysterectomy|Type B2 hysterectomy with 1 - 2cm of vaginal cuff plus level 1 pelvic lymph-node dissection according to Querleu and Morrow classification.
2542638|NCT02613247|Experimental|Immediate-start group|Hylan G-F 20 6 mL intra-articular knee injection
2542643|NCT02613247|Other|Delayed-start group|Washout control group which then becomes an experimental group (Hylan G-F 20 6 mL intra-articular knee injection) at 6 weeks post-enrolment
2542685|NCT02612961|Sham Comparator|Placebo|Pretend to instill 3mL of normal saline using empty pink sodium chloride bullet immediately prior to suctioning.
2542687|NCT02613000||All enrolled patients/Group A|500 consecutive adult patients will be enrolled in Part A (clinical data)
2542689|NCT02613000||Patients with blood and urine sampling/Group B|Patients with informed consent signed (anticipated 200 out of 500 patients) will participate in Part A (clinical data) and B (intestinal-specific biomarkers from blood and urine)
3203037|NCT00919412||Term delivery (>=37 weeks)|
3203038|NCT00919438||Dialysis|
3203039|NCT00919451|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
2542736|NCT02612649||Ramosetron group|Female patients with diarrhea-predominant irritable bowel syndrome
2542751|NCT02612701|Experimental|E-cigarettes (high nicotine e-liquid)|Healthy chronic dual cigarette and e-cigarette smokers will undergo myocardial contrast echocardiography before and after smoking high concentration (18-24 mg/mL) e-cigarette liquid.
2542777|NCT02612376||AD, DS, Mild Cognitive Impairment|Persons with age-related Mild Cognitive Impairment (MCI) or Alzheimer Disease (AD) according to clinical diagnosis, consistent with Alzheimer's Association (AA) and the National Institute on Aging (NIA) diagnostic criteria. Individuals with Down Syndrome (DS) according to clinical diagnosis, with cognitive ability sufficient to follow directions.
3203040|NCT00919464|Other|Needle Insertion into Femur|Data gathering with monitoring of pressures in the thigh via via needle in femur.
3203041|NCT00919490|Experimental|Group 1|Single dose of 400 mg
2542103|NCT02617160|Experimental|MD Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
2542106|NCT02617160|Active Comparator|Control Group-Medical guided recommendations|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
2542129|NCT02616276|Active Comparator|Control|Control breakfast
2542132|NCT02616276|Experimental|Intervention 1|High glycemic index breakfast
2542139|NCT02616276|Experimental|Intervention 2|Low glycemic index breakfast
2542260|NCT02615730|Experimental|Paclitaxel & GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily) in combination with a fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
2542334|NCT02615340|Active Comparator|Enteral melatonin 0.5 mg|Melatonin 0.5 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration of 0.1 mg/mL; final volume in the oral syringe will be 5 mL)
2542336|NCT02615340|Active Comparator|Enteral melatonin 2 mg|Melatonin 2 mg from the 1mg/mL oral suspension qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0.4 mg/mL; final volume in the oral syringe will be 5 mL)
2542341|NCT02615340|Placebo Comparator|Enteral matched placebo|Melatonin 0 mg qs to 5 mL with Oral Mix SF (sugar-free flavoured suspending vehicle) (final concentration 0 mg/mL; final volume in the oral syringe will be 5 mL)
2542407|NCT02614716|Experimental|LY3090106|LY3090106 given subcutaneously (SC) in escalating dose cohorts once every 2 or 4 weeks for 16 weeks.
2542409|NCT02614716|Placebo Comparator|Placebo|Placebo given subcutaneously (SC) once every 2 or 4 weeks for 16 weeks.
3168491|NCT00551590|Placebo Comparator|4|placebo PO (placebo control for sitagliptin) for three days. Exendin(9-39)IV on two consecutive study days.
2542574|NCT02613468|Placebo Comparator|Periodontally healthy|"Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.~Intervation: Collection of periodontal records and pregnancy parameters."
2542576|NCT02613468|Placebo Comparator|Periodontally diseased, untreated|"This group is comprised of individuals who do not accept treatment Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Birth weight was recorded at the end of pregnancy."
2542579|NCT02613468|Active Comparator|Periodontally diseased, treated|"This group is comprised of individuals who agree to treatment. Some periodontal measurements (attachment level, probing depth, gingival index, plaque index, and bleeding on probing) were performed in periodontally healthy pregnant. These measurements were performed at the end of each trimester.~Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit were evaluated.~Initial Periodontal Therapy is completed (calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.~Birth weight was recorded at the end of pregnancy. Intervation: Collection of periodontal records and pregnancy parameters."
2542691|NCT02612922|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets orally twice daily (b.i.d.) for 5 days
2542695|NCT02612922|Placebo Comparator|Placebo|Two Placebo tablets orally twice daily (b.i.d.) for 5 days
2542754|NCT02612636|Active Comparator|ear plug and eye mask|"The patients will not receive the intervention in the first night (N1) from 9 pm to 6 am~The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.~The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.~The patients will receive the intervention (eye mask and ear plug) in the fourth night (N4) from 9 pm to 6 am."
2542755|NCT02612636|No Intervention|control|The researcher will assess and observe the patients who are receiving the routine hospital nursing care during the four nights.
2542765|NCT02612402|Experimental|Learning algorithm|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT the Patients will receive daily messages, a learning algorithm will study the exercise response to each type of message and personalize the best message sequence for each patient.
2542768|NCT02612402|Active Comparator|control|The app will be installed on the patients's phone. The app will measure the amount of activity performed. THE INTERVENTION IS THAT THE Patients will receive a weekly reminder to exercise.
3168492|NCT00551603|Experimental|1|Group Epo will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-weekly SC epoetinum beta during the first phase, then will be switched to receive SC once-fortnightly darbepoetinum. Anaemia treatment schedule will continue according to the Romanian Best Practice Guidelines recommendations, with the same dose. A conversion factor of 1:200 will be used.
3168493|NCT00551603|Active Comparator|2|Subjects in the Darbepo Group will receive anaemia treatment according to the Romanian Best Practice Guidelines recommendation, with once-fortnightly or once-monthly darbepoetin SC administration, continuing their previous schedule and will continue their previous schedule of anaemia treatment during the second phase of the study
3168494|NCT00551616|Experimental|1|
3168495|NCT00551616|Active Comparator|2|
3168496|NCT00551629|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3168497|NCT00551629|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3168498|NCT00551629|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6, 10) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3168499|NCT00551629|Experimental|PR51 (6, 15)|Participants were vaccinated with 0.5 ml of PR51 (6, 15) formulation via intramuscular injection as a primary series at 2, 3, and 4 months of age, and as a booster at 12 to 14 months of age.
3168500|NCT00551668|Experimental|1|Operative
2542205|NCT02616055|Experimental|50mg Daily|One 50mg tesevatinib tablet per day
2542210|NCT02616055|Experimental|100mg Daily|Two 50mg tesevatinib tablets per day
2542216|NCT02616055|Experimental|150mg M/Th|Three 50mg tesevatinib tablets every Monday and Thursday.
2542220|NCT02616055|Experimental|150mg MWF|Three 50mg tesevatinib tablets every Monday, Wednesday and Friday.
2542280|NCT02615574|Experimental|αDC1 vaccine + CKM|all subjects enrolled in study
2542510|NCT02613793||Preterm pre-eclampsia (cases)|Pregnant patients diagnosed with pre-eclampsia prior to 35 weeks gestation
2542511|NCT02613793||Pregnant patients (controls)|Age- and gestation-matched pregnant patients who are not suffering with pre-eclampsia, hypertensive disease or any other neuropsychiatric condition
2542525|NCT02614001|Experimental|inspiratory muscle training, stroke rehabilitation|Inspiratory muscle training with a pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) will be start at a resistance equal to 30% of their MIP or at a load which patient can tolerate, and then the loading will be gradually increased 2cm H2O per week or as symptom tolerated and according to the RPE scale. Each patient will receive regular post-stroke rehabilitation program.
2542530|NCT02614001|Other|control group|stroke rehabilitation.
2542543|NCT02613741|Experimental|Intervention|12 weeks of lifestyle-based physical activity intervention
2542545|NCT02613741|No Intervention|Control|12 weeks of no intervention
2542603|NCT02613429|Active Comparator|Cranial horizontal|identification of the airway by from the cranial end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination from the cranial end at the level of the thyroid catilage , horizontally and thereafter moving caudally
2542607|NCT02613429|Active Comparator|caudal longitudinal|identification of the airway from the distal end. Marking of the airway, including the cricothyroid membrane, on the skin, by starting the examination caudally, and then moving cranially
3168501|NCT00551668|Experimental|2|Nonoperative
3168502|NCT00551681|Active Comparator|1|Epicardial left ventricular lead placement
3168503|NCT00551681|Active Comparator|2|transvenous left ventricular lead
3168504|NCT00551720|Experimental|Standard Care|
3168505|NCT00551720|Experimental|Motivational Enhancement|
3168506|NCT00551733|Experimental|Arm I|Patients receive paclitaxel poliglumex IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3168507|NCT00551733|Active Comparator|Arm II|Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3168508|NCT00551785||1|Women prescribed Intrinsa and estrogen therapy
3168509|NCT00551785||2|Women prescribed estrogen therapy
3168510|NCT00551811|Experimental|Subjects receiving treatment sequence 1|Eligible subjects will receive single doses of placebo in period 1, SB-656933-AAA with a dose of 50 milligrams in period 2 and 150 milligrams in period 3.
3168511|NCT00551811|Experimental|Subjects receiving treatment sequence 2|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, placebo in period 2 and SB-656933-AAA 150 milligrams in period 3.
3168512|NCT00551811|Experimental|Subjects receiving treatment sequence 3|Eligible subjects will receive single doses of SB-656933-AAA with a dose of 50 milligrams in period 1, 150 milligrams in period 2 and placebo in period 3.
3168513|NCT00551824|Experimental|1|"First dilation session with topical mitomycin applied over esophageal mucosa after dilation.~Second dilation session (after 14 days): standard dilation without topical mitomycin."
3168514|NCT00551824|Experimental|2|"First dilation session: standard dilation without topical mitomycin.~Second dilation session (after 14 days) with topical mitomycin applied over esophageal mucosa after dilation."
3168515|NCT00551850|Experimental|1|
3168516|NCT00551863|Active Comparator|IVPT|Intervention based on Motivational Interviewing and CBT
3168517|NCT00551902|Experimental|1|Trabeculectomy with anterior chamber infusion system
3168518|NCT00551902|Active Comparator|2|Trabeculectomy without anterior chamber infusion system
3168519|NCT00551915|Experimental|AR51 (12, 10)|Participants were vaccinated with 0.5 ml of AR51 (12,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3168520|NCT00551915|Experimental|PR51 (3, 10)|Participants were vaccinated with 0.5 ml of PR51 (3,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3168521|NCT00551915|Experimental|PR51 (6, 10)|Participants were vaccinated with 0.5 ml of PR51 (6,10) formulation via intramuscular injection as a primary series at 2, 4, and 6 months of age, and as a booster at 12 to 14 months of age.
3168522|NCT00551915|Active Comparator|PENTACEL™ + RECOMBIVAX HB™|Participants were vaccinated with 0.5 ml each of PENTACEL™ + RECOMBIVAX HB™ via intramuscular injection as a primary series at 2, 4, and 6 months of age, and with 0.5 ml PENTACEL™ as a booster at 12 to 14 months of age.
3168523|NCT00551928|Active Comparator|A|Oral therapy with Lenalidomide Melphalan and Prednisone.
3168524|NCT00551928|Active Comparator|B|High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)
3168525|NCT00551941|Active Comparator|2|non-union of diaphysary tibial fractures will be treated with allograft together with DBM
3168526|NCT00551941|Experimental|1|non-union of diaphysary tibial fractures will be treated with BMP-7 in adjunct to fresh frozen allograft
3168527|NCT00551954|Experimental|1|20 weeks of treatment with acarbose (100 mg t.i.d.)
3168528|NCT00551954|Placebo Comparator|2|20 weeks of treatment with placebo (one tablet t.i.d.)
3168529|NCT00551967|Active Comparator|E1 polyethylene|All patients received an E1 polyethylene liner which is the material being monitored in this study.
3174185|NCT00620620|Experimental|Inhaled Zaleplon 0.5 mg|Staccato Zaleplon 0.5 mg
2542146|NCT02616471|Experimental|Low-fat cheese (LFC) group|The subjects in the LFC group will be supplied with equal amounts of two types of reduced/low fat cheeses. The cheeses are reduced-fat Danbo(Cheasy, 13% fat, Arla, DK) and reduced-fat Cheddar (Sharp Light Cheddar, 16% fat, Cabot, US). No further dairy/cheese consumption is allowed.
2542154|NCT02616471|Active Comparator|No-cheese/carbohydrate group (CTR)|For subjects in the CTR group, cheese is replaced by simple and starchy carbohydrates in jam and white bread, which will be supplied by the department. The daily energy and sodium contents will be matched to those of the cheese in the HFC group. No dairy/cheese consumption is allowed.
2542175|NCT02616016|Other|MRI guided High Intensity Focused Ultrasound Treatment|"Intervention Group The interventional radiologist will locate the target tissue and mark the volume to be treated using MRI images.~The operator starts the treatment and monitors the progress of the treatment with MR thermal and dose maps to ensure adherence to treatment plan.~An individual treatment sonication will last approximately 30 seconds."
2542235|NCT02615834|No Intervention|Control group|
2542236|NCT02615834|Active Comparator|Study group|
2542298|NCT02615366|Active Comparator|Tranexamic Acid|Tranexamic acid will be provided as an intravenous infusion (1g in 100mL 0.9% NaCl solution [1% TXA] at 5 ml/min) 20 minutes pre-operatively, followed by an additional intravenous dose of the same dosing parameters postoperatively. Oral tablet doses containing 1 g of TXA (2x 500mg tablets) per dose will be administered to the patient to be taken orally by the patient according to a standard regimen; the first tablet dose will be taken on the same day as the surgery, in the evening. The patient will then take one tablet dose three times a day for a total of five days following the surgery (one dose in the morning, one dose mid-day, and one dose in the afternoon) for a 6 day total regimen.
2542299|NCT02615366|Placebo Comparator|Placebo Control|Placebo control will be either 100 ml of 0.9% NaCl solution or tablets of similar appearance containing no medicinal ingredients; placebo will be administered according to the same regimen as the intervention group.
3168530|NCT00551980|Experimental|Cognitive and physical program|Randomized group of workers of the same institution ( City of Turin, Italy).
3168531|NCT00551980|No Intervention|Control group|Randomized group of workers of the same institution ( City of Turin, Italy).
3168532|NCT00551993|Active Comparator|2|Robotic Sacral Colpopexy
2542392|NCT02614664||Single ventricle|Patients with single ventricle physiology presenting for laparoscopic procedures.
2542426|NCT02614495|Experimental|Surufatinib|300mg once-daily
2542477|NCT02614248|Experimental|Coconut Oil|Participants in this group will receive a generous layer of organic, unrefined coconut oil applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
2542478|NCT02614248|Active Comparator|Standard of Care|Participants in this group will receive the standard of care for preventing and treating diaper dermatitis at Genesis. This includes no treatment until a diaper dermatitis appears. If diaper dermatitis appears, participants will receive a generous layer of Medline Remedy Phytoplex Z-Guard Skin Protectant applied to the diaper area (buttocks and creases between thighs and hips) at each diaper change. This will continue until the patient is discharged or reaches the primary safety endpoint (skin that is eroded and/or blistered in the diaper area with bleeding).
2542533|NCT02613780|Active Comparator|Sequential group|Photorefractive keratectomy will be performed 12-18 months after participants had crosslinking
2542536|NCT02613780|Active Comparator|Simultaneous group|Photorefractive keratectomy and crosslinking will be performed on the same day
2542641|NCT02613130|Experimental|Two-Step stannous fluoride toothpaste|Two-Step stannous fluoride toothpaste
2542646|NCT02613130|Active Comparator|Potassium nitrate toothpaste|Potassium nitrate toothpaste
2542671|NCT02612844|Experimental|NNC0143-0406|
2542676|NCT02612844|Active Comparator|Insulin Aspart|
2542703|NCT02612792|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2542704|NCT02612792|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin for treating furcation defect
3168533|NCT00551993|Active Comparator|1|Laparoscopic Sacral Colpopexy
3168534|NCT00552006|Experimental|NET|
3168535|NCT00552006|Active Comparator|AC|
3168536|NCT00552006|No Intervention|WL|Waiting list
3168537|NCT00552045||subject|individuals with epilepsy
3168538|NCT00552097|Experimental|EZ/Simva|
3168539|NCT00552097|Placebo Comparator|Placebo/Simva|
3168540|NCT00552149|Active Comparator|1|GEMOX
3168541|NCT00552149|Experimental|2|GEMOX + CETUXIMAB
3168542|NCT00552162|Active Comparator|1|NOTES Transvaginal cholecystectomy The gallbladder will be dissected free and will be removed through an incision in the vagina.
3168543|NCT00552162|Active Comparator|2|NOTES Transvaginal Appendectomy. The appendix will be dissected free and will be removed through an incision in the vagina.
3168544|NCT00552214|Other|Human Blood Donor Plasma Specimens|
3168545|NCT00552227|Experimental|1|
3168546|NCT00552227|Placebo Comparator|2|
3168547|NCT00552253|Experimental|1|under eltroxin
3168548|NCT00552331|Active Comparator|LISS|Treatment of distal femur fracture with less invasive stabilization system
3168549|NCT00552331|Active Comparator|Standard Treatment|Treatment of distal femoral fractures using locking condylar plates or dynamic condylar screws
3168550|NCT00552435|Experimental|1|Micropulse 810nm diode laser
3168551|NCT00552435|Active Comparator|2|Argon laser photocoagulation
3168552|NCT00552461|Experimental|1|
3168553|NCT00552474|Placebo Comparator|Group B|Implanted but no active stimulation
3168554|NCT00552474|Experimental|Group A|Active Stimulation
3168555|NCT00552487|Other|1|healthy people without Hashimoto disease receive a 1µg ACTH stimulation test
3168556|NCT00552487|Other|2|patients with Hashimoto disease with well being receive a 1 µg ACTH stimulation test
3168557|NCT00552487|Other|3|patients with Hashimoto disease an impaired well-being receive a 1 µg ACTH stimulation test
3168558|NCT00552487|Other|4|patients with Hashimoto disease and negative TPO antibodies receive a 1µg ACTH stimulation test
2542193|NCT02615938|Experimental|Stop HCQ block Verum|Individual dose, usually Hydroxychloroquine Sulfate (HCQ, Quensyl) 6-10 mg/kg bw/d, p.o., one daily dose in the evening; the maximum daily dose is 400 mg. The dose, on which the patient is included into the trial, should be continued for 3 months. After therapy of 3 months the medication will be stopped. The patients will be followed up for additional 3 months.
2542195|NCT02615938|Placebo Comparator|Stop HCQ block Placebo|Patients will receive Placebo for 3 months and will be followed up for additional 3 months.
2542248|NCT02615613|Experimental|High acceptability meal|A custard recipe was used as the high acceptability meal
2542251|NCT02615613|Experimental|Low acceptability meal|The regular custard recipe was reformulated to yield a low acceptability version
2542296|NCT02615392|Experimental|Park prescription|The participants in this group will receive a brief counseling on physical activity together with a park prescription that highlights the importance of engaging in at least 150 minutes of physical activity per week and the possibility of engaging in physical activity in the park. In addition, they are invited to join in a structured and supervised physical activity program in the park. The structured physical activity program will take place in public parks located in the participants' neighbourhood. Participants will receive text messages for reminder and registration purposes approximately once a week. Also, participants will receive a sheet to monitor their weekly physical activity, information about parks in their neighborhood, and a counseling phone call half-way through the study.
2542297|NCT02615392|No Intervention|Control|The participants in this group will not be given any park prescription or be invited to participate in the weekly program in the park. However, they will receive all the information materials provided to the experimental group after the study has ended.
2542340|NCT02615106|Experimental|Endostar Combined With Radiotherapy|Drug: Endostar Endostar 7.5 mg/m2/day, day 1-14 Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
2542456|NCT02614534|Experimental|Proactive cytoreductive surgery + HIPEC|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC (Mytomicin C - 60 minutes).
2542459|NCT02614534|Active Comparator|Proactive cytoreductive surgery|Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women).
2542514|NCT02613832|Experimental|EPAP Group|The EPAP devices increase the alveolar pressure. This effect is obtained through valves that generate a resistance to airflow during expiration.
2542517|NCT02613832|Experimental|Breath Stacking Group|The Breath Stacking consists on the implementation of subsequent inspiratory efforts through a one way valve, which allows stacked volume of gas during each inspiration, until it reaches a maximum lung volume.
2542541|NCT02613754|Experimental|Contingency Management|Contingency Management (CM+): This procedure is designed to reinforce treatment attendance, non-gambling behaviour, and study completion. Participants will earn points that will be recorded on vouchers that could be subsequently redeemed for gift cards at a variety of local businesses. Submission of evidence of gambling behaviour or non-attendance re-sets the point value for future vouchers to the starting level. This intervention is in addition to Treatment as Usual.
2542542|NCT02613754|Active Comparator|Treatment as Usual|Treatment as Usual (TAU): This is typically a semi-structured approach for delivering cognitive behavioural therapy addressing the participant's experiences, thoughts, and emotions relating to their gambling.
2542561|NCT02613689|Experimental|Scheduled Gradual Reduction (SGR)|Subjects will receive the Scheduled Gradual Reduction (SGR) intervention, as well as SMS support text messages.
2542567|NCT02613689|Active Comparator|Control Group|Subjects will receive SMS support text messages
2542614|NCT02613390|Experimental|MRI-Based Image Guidance|"MRI images of the spine taken of anesthetized participant in the operative prone position. These images are exported into a computer navigation program, and used to help the doctor perform surgery.~Pain and symptom questionnaires completed at baseline and at follow up."
2542625|NCT02613143||Surgery|
2542661|NCT02613091|Experimental|Clemastine|This group will receive 8mg of clemastine daily.
2542678|NCT02613039|Other|female outpatient subjects|Patients requiring combined Oral Contraceptives therapy.
2542698|NCT02612831|Other|Early bariatric surgery|patient receive their procedure early (within 3 months)
2542701|NCT02612831|Other|Delayed bariatric surgery|Patient receive their procedure later (in 12 - 15 months), following a year of optimal medical treatment
2542705|NCT02612766|Other|Single Arm|This is a single-arm interventional study, in which each patient gets 50 grams/day of pure, uncontaminated oats
2542757|NCT02612519|Experimental|Alfapump - Substudy 1|Alfapump implantation
2542759|NCT02612584|Experimental|Pinhole soft contact lens|
2542760|NCT02612532|Experimental|LuCID|"Standardised exhaled volatile organic compound collection by ReCIVA breath sampler (http://www.owlstonenanotech.com/medical/products/reciva) for analysis of volatile organic compounds by Lonestar (http://www.owlstonenanotech.com/medical/products/lonestar)"
2542763|NCT02612519|Active Comparator|TIPS - Substudy 1|TIPS implantation
2542764|NCT02612519|Experimental|Alfapump - Substudy 2|Alfapump implantation
2542766|NCT02612519|No Intervention|Standard - Substudy 2|Standard treatment
2542209|NCT02615977|Experimental|Intervention|"In the verum treatment condition, i.e. Zooming Joystick Task, 90% of all alcohol-related pictures appear in the landscape format and hence are trained to be pushed away."
2542218|NCT02615977|Placebo Comparator|Placebo Intervention|In the placebo condition, i.e. Zooming Joystick Task (Placebo), alcohol picture are as often pushed away as pulled towards the subject.
2542249|NCT02615587||AF patients in Denmark / Cohort 1|"The base population of AF patients for diagnosis and health care utilization / resource use will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code will be identified.~Further Data sources used:~Registry of Medicinal Product Statistics: for determining the individuals' use of prescription medicine DREAM database: for investigation of sickness benefit and productivity loss Statistics Denmark's databases: on social services from municipalities Cause of Death Registry: AF-patients or controls who died during the study period (2000-2013) Danish Civil Registry: used for identification of controls, holds information about age, gender"
2542300|NCT02615405|Experimental|EPA|3.5 g/day in Studies 1 & 2
2542302|NCT02615405|Active Comparator|DHA|1.75 g/day in Studies 1 & 2
2542304|NCT02615405|Placebo Comparator|Placebo capsules|oleic oil in Study 1
2542360|NCT02615002|Experimental|piromelatine 5 mg|5 mg tablets once daily
2542362|NCT02615002|Experimental|piromelatine 20 mg|20 mg tablets once daily
2542364|NCT02615002|Experimental|piromelatine 50 mg|50 mg tablets once daily
2542365|NCT02615002|Placebo Comparator|Placebo|Placebo tablet once daily
2542455|NCT02614404|Experimental|Imatinib combination therapy|Administration of imatinib (400 mg/day) plus dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
2542462|NCT02614404|Active Comparator|dihydroartemisinin plus piperaquine|Administration of dihydroartemisinin (40 mg/day) plus piperaquine (320 mg/day) to uncomplicated adult male malaria patients. Normal health parameters will be monitored continuously to evaluate safety and the decrease in peripheral blood parasitemia with time will be quantitated to assess efficacy.
3203042|NCT00919490|Experimental|Group 2|Single dose of 800 mg after safety evolution of Group I
2542553|NCT02613715|Experimental|Blackberry juice with 12% ethanol|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml alcohol beverage (38%) and 17 g sugar.
2542554|NCT02613715|Experimental|Blackberry juice|250 ml of blackberry juice freshly prepared with 250 g fresh blackberries, 80 ml water and 17 g sugar.
2542572|NCT02613494|Active Comparator|Hyoscine|Hyoscine hydrobromide
2542573|NCT02613494|Active Comparator|Glycopyrrolate|Glycopyrronium bromide
2542577|NCT02613494|Placebo Comparator|Placebo|Placebo
3203043|NCT00919490|Experimental|Group 3|Single dose of 1200 mg after safety evolution of Group 2
2542636|NCT02613195|Experimental|Hydrogen-rich Celsior solution|Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.
2542642|NCT02613195|No Intervention|Celsior solution|Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.
2542707|NCT02612805|Experimental|Aerobic training group|This group perform aerobic hydrogymnastics.
2542708|NCT02612753|Sham Comparator|Aphasics Patients control|Patients which have difficulties to speak will receive Sham tDCS +SLT for aphasics patients control
2542709|NCT02612870|Active Comparator|Sienna+ retro and Technetium 1|"Sienna+® is administered retro-mamillary 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2542710|NCT02612805|Active Comparator|Combined training group|This group perform combined hydrogymnastics.
2542711|NCT02612805|Placebo Comparator|Training placebo|This group perform stretching and relaxation in aquatic environment.
2542712|NCT02612870|Active Comparator|Sienna+ peri and Technetium 1|"Sienna+® is administered peri-tumorally 1 day before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2542713|NCT02612870|Active Comparator|Sienna+ retro 4-6 and Technetium 1|"Sienna+® is administered retro-mamillary 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2542714|NCT02612870|Active Comparator|Sienna+ peri 4-6 and Technetium 1|"Sienna+® is administered peri-tumorally 4-6 days before surgery for sentinel node marking.~Technetium as standard technique is employed according to the gold standard protocol one day before surgery.~The Sentimag device is used during surgery to detect the lymph nodes in parallel to the standard technique."
2542727|NCT02612454|Experimental|Body weight ≥60 kg|Administered every two weeks (Q2W)
2542730|NCT02612454|Experimental|Body weight 30 kg to <60 kg|Administered Q2W
2542735|NCT02612454|Experimental|Body weight 15 kg to <30 kg|Administered every 4 weeks (Q4W)
2542747|NCT02612454|Experimental|Body weight 5 kg to <15 kg|Administered Q4W
2542756|NCT02612441|Experimental|1 real Acupuncture group-intervention|real Acupuncture Needles
2542758|NCT02612415|Experimental|High flow nasal cannula (HFNC)|Heated humidified high flow nasal cannula therapy delivered at 2 L/kg/min gas flow rate (for children older than 10 kg in weight, an additional 0.5 L/kg/min per kilogram over 10 kg). Any approved device can be used to deliver HFNC
2542761|NCT02612441|Sham Comparator|2 sham Acupuncture group|sham Acupuncture Needles
2542762|NCT02612415|Active Comparator|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure delivered using any interface (hood, mask or prongs)
2542767|NCT02612467|Experimental|Stratified care|Patients are stratified into low, medium, high risk of poor outcome. Stratified care are delivered by special trained physiotherapists according to risk group
3203044|NCT00919490|Experimental|Group 4|Single dose of 1600 mg after safety evolution of Group 3
2542215|NCT02616107|Experimental|Intervention|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the intervention group and will receive the booklet, Managing Cancer Care: A Caregiver's Guide (MCC-CG) (N=18)
2542221|NCT02616107|Active Comparator|Control|Family caregivers of breast cancer patients who consent to participate in the study have a 50/50 chance of being randomized to the control group and will receive the Symptom Management Toolkit (N=17)
2542337|NCT02615301|Experimental|Salmon (HD+HK)|Tailor-made salmon with high levels of vitamin D3 and K1
2542345|NCT02615301|Experimental|Salmon (LD+HK)|Tailor-made salmon with low levels of vitamin D3 and high K1
2542349|NCT02615301|Experimental|Salmon (HD+LK)|Tailor-made salmon with high levels of vitamin D3 and low K1
2542353|NCT02615301|Experimental|Supplement (vitamin D + Calcium)|Supplement with vitamin D and Calcium
3203045|NCT00919490|Placebo Comparator|Group 5|Single dose of placebo
3203046|NCT00919516|Experimental|Stem Cell Implantation|
2542526|NCT02613988|Other|MR imaging and standard treatment|Patients with glioblastoma undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and perfusion (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) at pre-CCRT; 4 weeks after completion of the CCRT; and every 2 or 3 months during the adjuvant temozolomide therapy.
2542600|NCT02613520|Experimental|Group 3b (PfSPZ Vaccine)|6-10 years; n=6; 3 doses of 1.8 x 10^6 PfSPZ Vaccine given 8 weeks apart.
2542604|NCT02613520|Placebo Comparator|Group 3b (normal saline)|6-10 years; n=3; 3 doses of normal saline given 8 weeks apart.
2542608|NCT02613520|Experimental|Group 4a (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542610|NCT02613520|Placebo Comparator|Group 4a (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
2542612|NCT02613520|Experimental|Group 4b (PfSPZ Vaccine)|1-5 years; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542613|NCT02613520|Placebo Comparator|Group 4b (normal saline)|1-5 years; n=3; 3 doses of normal saline given 8 weeks apart.
2542615|NCT02613520|Experimental|Group 5a (PfSPZ Vaccine)|6-11 months; n=3; 1 dose of 2.7 x 10^5 PfSPZ Vaccine.
2542616|NCT02613520|Experimental|Group 5b (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 4.5 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542617|NCT02613520|Placebo Comparator|Group 5b (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
2542618|NCT02613520|Experimental|Group 5c (PfSPZ Vaccine)|6-11 months; n=6; 3 doses of 9.0 x 10^5 PfSPZ Vaccine given 8 weeks apart.
2542619|NCT02613520|Placebo Comparator|Group 5c (normal saline)|6-11 months; n=3; 3 doses of normal saline given 8 weeks apart.
2542635|NCT02613416|Experimental|Denosumab|6 monthly subcutaneous injections of denosumab
2542693|NCT02612896|Experimental|Elimination arm|"Both human and porcine interventions at four-monthly intervals in the first two study years, for a total of six iterations (only human interventions will be detailed here):~Human: Mass drug administration, praziquantel 10mg/kg, according to the list of WHO recommended anthelmintic drugs for use in preventive chemotherapy for taeniasis. And Health Education"
2542696|NCT02612896|Experimental|Control intervention arm|Human: yearly health education, for a total of five iterations. The intervention on the pig host will not be detailed here)
3203047|NCT00919542|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
3203048|NCT00919542|Experimental|Ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
3203049|NCT00919555|Active Comparator|Tretionoin and Pioglitazone HCL|20 patients will be randomized blindedly to Tretinoin and Pioglitazone HCL
3203050|NCT00919555|Placebo Comparator|Sugar Pill|10 Patients will randomly receive placebo
2542722|NCT02612545|Active Comparator|ACT|Patients randomized to ACT will receive DHA-PPQ only
2542723|NCT02612545|Experimental|TACT|Patients randomized to TACT will receive DHA-PPQ plus MQ
2542738|NCT02612571||Wind instrument players|A wind instrument is defined as any instrument that contains a resonator, in which a column of air is set into resonation by the player blowing into a mouthpiece at one end of the resonator.
2542744|NCT02612571||Non-wind instrument players|A non-wind instrument is defined as any instrument that does not contain a resonator.
2542769|NCT02612558|Experimental|Fostamatinib 150 mg|Fostamatinib 150 mg bid (morning and evening) over the course of 24 weeks
2542779|NCT02612376||Healthy Controls|"Non-DS community-dwelling controls~Non-pregnant mothers and fathers of DS individuals (controls)~An Informant (study partner) available to complete functional interviews/survey measures annually."
3203051|NCT00919581||Healthy controls|
3203052|NCT00919581||Subjects with spinal cord injury|
3203053|NCT00919594|Experimental|Interpersonal Psychotherapy for Mothers|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
3203054|NCT00919594|Active Comparator|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
3203055|NCT00919607|Active Comparator|1|quetiapine fumarate extended-release 300mg,administered once-daily Day1~5
2542831|NCT02611973|Experimental|HU without aspirin|
3203056|NCT00919607|Experimental|2|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2~6,administered once-daily
3203057|NCT00919607|Experimental|3|quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3~7,administered once-daily
3203058|NCT00919620|Experimental|case management (4 yrs)|4-year case management and standard care
3203059|NCT00919620|Active Comparator|case management (2 yrs) and standard care (2 yrs)|2-year case management and standard care
2541593|NCT02620033|Active Comparator|Yoga therapy group|Those assigned to the yoga therapy group will be asked to participate in yoga session three times in a week for 6 weeks prior to the scheduled surgery and then re-initiated 3 weeks after the surgery for another 6 weeks. Each session will be approximately 60 - 75 minutes. These yoga session will be held at Nydia's Yoga Therapy Studio, located in San Antonio, TX, under the guidance of certified yoga instructor, Dr. Nydia Tijerina Darby, PT, DPT, MS, who's the owner of the studio and co-investigator of this study. The yoga exercise will be tailored to patient's comfort level.
3203060|NCT00919620|No Intervention|standard care (4 yrs)|standard care for 4 years
3203061|NCT00919659|Experimental|parenteral nutrition|25kcal/kg/bw /day via parenteral support
3203062|NCT00919672|Active Comparator|Sacral nerve stimulation ON-OFF|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
3203063|NCT00919672|Active Comparator|Sacral nerve stimulation OFF-ON|As previously described the patients will be randomized in a blinded design to receive either ON-OFF or OFF-ON stimulation in a 2 month period.
2541721|NCT02619201|Experimental|ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
2541722|NCT02619201|Active Comparator|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) Diluted in 20 ml of saline and administer intravenously in 5 minutes
3203064|NCT00919698||Sedated mechanically ventilated patients|
3203065|NCT00919737|Experimental|NPC-08|
2541854|NCT02618356|Experimental|combined use Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA(body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 - <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
2541897|NCT02618083|Experimental|retinal detachment|color Doppler ultrasound of the eye
3203066|NCT00919750||Ancillary-Correlative (tissue and blood sample collection)|Brain tumor tissue and blood specimens are collected from patients and banked for future study.
3203067|NCT00919776|Experimental|ciclosporin|ciclosporin reducing regimen lasting 16 weeks (additional prednisolone given for the first four weeks)
2542050|NCT02616653|Active Comparator|Sitting followed by lateral position|First half of participants will be assigned to have their L3-L4 intervertebral space located first in the sitting position followed by the lateral position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
2542053|NCT02616653|Active Comparator|Lateral followed by sitting position|Second half of participants will be assigned to have their L3-L4 intervertebral space located first in the lateral position followed by the sitting position using the palpation method confirmed by US. (L3-L4 location: Palpation method confirmed by US)
3203068|NCT00919776|Active Comparator|Prednisolone|standard course of prednisolone given in a reducing regimen over 16 weeks
3203069|NCT00919815|Experimental|ciclosporin arm|ciclosporin reducing regimen lasting 24 weeks (additional prednisolone given for the first four weeks)
3203070|NCT00919815|Active Comparator|prednisolone|standard course of prednisolone given in a reducing regimen over 24 weeks
2542282|NCT02615678|Experimental|Acupuncture|Acupuncture including scalp needling will be applied to selected points based on literature
3203071|NCT00919841||Postpartum women|Women who deliver a singleton vaginally
2542397|NCT02614612|Experimental|Itacitinib (200 mg)|Itacitinib (200 mg) + prednisone or methylprednisolone (corticosteroids)
2542402|NCT02614612|Experimental|Itacitinib (300 mg)|Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)
3203072|NCT00919880|Experimental|Experimental|
3203073|NCT00919880|Active Comparator|Active Comparator|
2542532|NCT02613767||Obese|"BMI >30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2542534|NCT02613767||Overweight|"BMI >25 and < 30 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2542537|NCT02613767||Healthy-Weight|"BMI >18 and < 25 kg/m2, Protein meal,~L-[ring 13C6]Phenylalanine infusion"
2542620|NCT02613273|Experimental|Experimental: Arm 1 (Aerobic Exercise)|Arm 1 will engage in a periodized program consisting of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
2542621|NCT02613273|Experimental|Experimental: Arm 2 (Resist. Exercise)|Arm 2 will engage in a periodized program consisting of 3 resistance exercise sessions per week comprised of various loads and volumes. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
2542622|NCT02613273|No Intervention|No Intervention: Arm 3 (Control)|Arm 3 will follow their usual exercise and lifestyle routine. A physical assessment, physical function and strengths tests, and questionnaires will be completed at baseline and 3 months.
2542669|NCT02613065|Experimental|Eggwhite protein shake|Participants drink a NOW Foods protein shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
2542670|NCT02613065|Active Comparator|Maltodextrin carbohydrate shake|Participants drink a NOW Foods carbohydrate shake (~20% daily energy requirements) at the beginning of each of the three daily meals. Kcals/meal are dependent upon participant's baseline Resting Metabolic Rate value.
3203074|NCT00919906|No Intervention|Handwriting without Tears|Standard practice
3203075|NCT00919906|Experimental|Haptic guidance|
3203076|NCT00919919|Experimental|Progesterone vaginal tablet|Group A - Daily use of Endometrin 100 mg progesterone vaginal tablet, and Estrofem orally.
3203077|NCT00919919|Other|Activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
3203078|NCT00919945|Experimental|1|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
3203079|NCT00919945|Experimental|2|The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.
3203080|NCT00919958|Experimental|PLX-PAD low dose|
3203081|NCT00919958|Experimental|PLX-PAD intermediate dose|
3203082|NCT00919958|Experimental|PLX-PAD high dose|
2542856|NCT02611947||Healthy Volunteers|"Inclusion criteria:~Aged 18 or more.~Never smoked.~No respiratory infection in the 4 weeks before the begin of the study.~No history of pulmonary resection.~No active malignancy or malignancy of any organ system within the past 5 years."
2542874|NCT02611726|Active Comparator|Acupuncture treatment|Individualized acupuncture needle insertion according to traditional Chinese and Japanese medicine on top of standard medical care during In-Vitro-Fertilization. Acupuncture needles will be inserted to body surface points following traditional diagnosis (anamnesis, tongue, pulse and abdomen inspection) according to practitioner discretion.
2542877|NCT02611726|No Intervention|Control|Standard medical care during In-Vitro-Fertilization.
2542931|NCT02611492|Active Comparator|Intensive Arm (A)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
2542932|NCT02611492|Experimental|Light Arm (B)|"4 cycles + 2 interphases +Hematopoietic Stem Cell Transplantation (SCT)~+ Post-SCT Maintenance"
2543008|NCT02611102|Experimental|MCT oil + Butter in Coffee|This group will be provided with MCT oil and butter to add to their daily coffee intake.
2543012|NCT02611102|Placebo Comparator|Low calorie coffee|This group will continue to drink their normal daily coffee with < 50kcal of creamer and/or sweetener.
3203083|NCT00919984|Experimental|IP Chemotherapy|Patients with optimally debulked advanced (stage 3 or 4) epithelial ovarian cancer; IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
3203084|NCT00919997||Specimen collection|Single group study. Blood, saliva, anal cytology, and penile cytology samples, and questionnaire responses will be collected from participants at a single study visit.
3203085|NCT00920036|Experimental|Arm 1|Eight subjects were trained to utilize a handheld biofeedback device
3203086|NCT00920036|No Intervention|Arm 2|usual care
2543313|NCT02609165|Active Comparator|study group|rhNGF 180 µg/ml eye drops solution
2543314|NCT02609165|Placebo Comparator|control group|vehicle eye drops solution
3203087|NCT00920088|Experimental|Cohort 1|GSK2248761 with LPV/RTV arm and probes
3203088|NCT00920088|Experimental|Cohort 2|GSK2248761 with DRV/RTV
2543574|NCT02607332|Experimental|Paclitaxel|paclitaxel 80mg/m2/day on a Cycle1Day1, Cycle1Day8,Cycle1Day15 off 1 week schedule
2543628|NCT02606942||Dancers with knee injury|A cohort of dancers with reported knee injury. Questionnaires, physical exam, US of the knee
2543629|NCT02606942||Dancers with no knee injury|A cohort of dancers without reported knee injury. Questionnaires, physical exam, US of the knee
2543631|NCT02606942||Non-dancers athletes|A cohort of non-dancers athletes without knee injuries. Questionnaires, physical exam, US of the knee
2543658|NCT02606539|Active Comparator|surgery and methotrxate|The patient will be treated by total abdominal hystrectomy(after written consent laparatomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg alternating with calcium folinate 0.1 mg/kg until normalization of B-HCG
2543663|NCT02606539|Active Comparator|methotrxate|The patient will be treated by multiple courses of methotrexate( antifolate) 1mg/kg every 14 days each one alternating in every otherday with calcium folinate 0.1 mg/kg till normalization of B-HCG
2543702|NCT02606175|Other|Admitted for renal transplantation|"Patients who are hospitalised on the abdominal transplantation surgery ward at the University Hospitals of Leuven (UZLeuven) and undergo a kidney transplantation during this hospitalisation.~Intervention: taking questionnaires and tests at predefined timepoints:~at discharge: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~1 month after kidney transplantation: BAASIS, medication knowledge test~3 months after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test~1 year after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire~2 years after kidney transplantation: NVS-D, FCCHL, BAASIS, medication knowledge test, demographic factors questionnaire"
3203089|NCT00920101|Active Comparator|Atorvastatin|
3203090|NCT00920101|Placebo Comparator|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
2543846|NCT02605278|Experimental|Clinical program for pain and depression|Structured program with integrated management for depression and chronic musculoskeletal pain with three main components: 1) Optimized care of major depression on the basis of a Clinical Guideline 2) Care Management, and 3) Group psychoeducational intervention.
2543847|NCT02605278|Active Comparator|Control|Care as usual
2543942|NCT02604784|Experimental|cohort A|Cohort A: For patients that have indication for systemic therapy with standard chemotherapy. This cohort has a phase II design; the Objective Response Rate (ORR) will be evaluated according to the RECIST criteria (version 1.1) after 2 and 3 cycles of PIPAC with Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m2 ) or Oxaliplatin (92 mg/m2) according to the primary cancer, in association with standard systemic chemotherapy.
2543959|NCT02604498|Experimental|Liver function impaired|Subject with Moderate Impaired Hepatic Function. Nemonoxacin Malate Capsules 500mg single dose oral.
3203091|NCT00920114|Experimental|Lupus disease|
3203092|NCT00920114|Active Comparator|Healthy witnesses|
3203093|NCT00920114|Active Comparator|Healthy witnesses with an other auto-immune disease|
3203094|NCT00920127|Placebo Comparator|Placebo|
3203095|NCT00920127|Active Comparator|AKL1|
3203096|NCT00920153|Experimental|Group 1 (favorable prognosis)|Patients receive ABVD and VABEM chemotherapy.
3203097|NCT00920153|Experimental|Group 2 (intermediate prognosis)|Patients receive ABVD and VABEM chemotherapy.
3168559|NCT00552500|Active Comparator|Schizophrenics|i) meets DSM-IV criteria for schizophrenia, any type, treated with atypical or high potency typical neuroleptics for at least 3 months; ii) aged 18 to 60 years; iii) able to give informed consent; iv) no antipsychotic medication changes for 3 months, and no other medication changes for 2 weeks prior to Baseline Evaluations.
3168560|NCT00552526|Active Comparator|Ketogenic diet|
3168561|NCT00552526|Active Comparator|AED|Most appropriate antiepileptic drug
3168562|NCT00552539|Experimental|1|pre test survey, educational video, post test survey
2542948|NCT02611297|Other|Transbronchial lung biopsy with cryoprobe|
3168563|NCT00552539|No Intervention|2|no intervention
2543038|NCT02610595|Experimental|experimental group|Jianpixiaozhong particles and Wuse Dietotherapy
2543104|NCT02610348|Experimental|Group A|Toddlers vaccinated with Hexaxim®/Hexyon®/Hexacima® in study A3L12
2543105|NCT02610348|Experimental|Group B|Toddlers vaccinated with Infanrix hexa® in study A3L12
2543145|NCT02609945|Experimental|CVT-427 (zolmitriptan inhalation powder)|"Periods 1-2: Subjects will receive Zomig oral tablet in Period 1 and Zomig nasal spray in Period 2, 1 hour apart.~Periods 3-6: Subjects will receive CVT-427 (dose levels (DL) 1, 2, 3 and 4), administered in ascending order provided that safety and tolerability data are observed to be adequate to allow dose escalation, approximately 24 hours after preceding DL."
2543432|NCT02608138||1|Urinary iodine will be measured at one point in time in school children aged 6-12. A sample of salt used at home and schools will be collected to estimate iodine levels.
2543460|NCT02607839|Placebo Comparator|normal saline|normal saline intravenous infusion
2543463|NCT02607839|Active Comparator|glucose|glucose intravenous infusion
2543531|NCT02607774|Experimental|Secukinumab|Secukinumab over 24 weeks
2543563|NCT02607241|Active Comparator|BRS|"OCT-guided BRS implantation: implantation of a bioresorbable scaffold (BRS) under OCT guidance.~Note: Absorb™ from Abbott Vascular has been used as BRS until this product became unavailable in April 2017. Currently the recruitment is stopped due to this issue, until the use of another BRS gets final approval."
2543564|NCT02607241|Experimental|DCB-only|FFR-guided DCB-only PCI: PCI using DCB (SeQuent Please™, B Braun Melsungen GmBH) without stent implantation und FFR guidance
2543733|NCT02605915|Experimental|Cohort 1A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks.
2543734|NCT02605915|Experimental|Cohort 1B: Atezolizumab/Trastuzumab emtansine 3.6 mg|Participants will receive atezolizumab in combination with trastuzumab emtansine (3.6 mg/kg) every 3 weeks.
2543735|NCT02605915|Experimental|Cohort 1C: Atezolizumab/Trastuzumab emtansine 3.0 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (3.0 mg/kg) every 3 weeks.
2543737|NCT02605915|Experimental|Cohort 1D: Atezolizumab/Trastuzumab emtansine 2.4 mg|Participants will receive atezolimumab in combination with trastzumab emtansine (2.4 mg/kg) every 3 weeks.
2543738|NCT02605915|Experimental|Cohort 1E: Atezolizumab/ doxorubicin/ cyclophosphamide|Participants with HER2-negative breast cancer will receive atezolizumab (every 2 weeks) in combination with doxorubicin (every 2 weeks) and cyclophosphamide for four cycles. After the completion of four cycles of combination atezolizumab /doxorubicin / cyclophosphamide, atezolizumab will be continued as a single-agent at a dose of 1200 mg every 3 weeks.
2543740|NCT02605915|Experimental|Cohort 1F: Atezolizumab/Trastuzumab/Pertuzumab/ Docetaxel|Participants will receive atezolizumab in combination with trastuzumab, pertuzumab, and docetaxel every 3 weeks.
2543742|NCT02605915|Experimental|Cohort 2A: Atezolizumab/Trastuzumab/Pertuzumab|Participants will receive atezolizumab in combination with trastuzumab and pertuzumab every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
2543744|NCT02605980||Male|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
2543750|NCT02605980||Female|Community-dwelling healthy older adults over the age of 70 years. Must be ambulatory, with or without walking aids
3168564|NCT00552539|Experimental|3|educational video and post test survey
3168565|NCT00552539|No Intervention|4|post test survey
3168566|NCT00552552|Experimental|1|
3168567|NCT00552552|Other|2|waiting control group
3168568|NCT00552565|Placebo Comparator|1|
3168569|NCT00552565|Experimental|2|
3168570|NCT00552565|Experimental|Rezular 37.5mg|
3168571|NCT00552565|Experimental|Rezular - 75mg|
3168572|NCT00552591|Experimental|1|Family Heart Health Program
3168573|NCT00552591|No Intervention|2|Usual Care
3168574|NCT00552604|Experimental|1|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
3168575|NCT00552604|Placebo Comparator|2|matching placebo capsules, twice daily
3168576|NCT00552630|Experimental|1|This group will receive d-penicillamine for 6 weeks
3168577|NCT00552630|Placebo Comparator|2|This group will receive placebo for 6 weeks
3168578|NCT00552643|Experimental|1|Treatment with Polyheal 1
3168579|NCT00552643|Active Comparator|2|Saline
3168580|NCT00552656||1|the group of patients with angiographic results of complex coronary lesions(refer to the definition of protocol)are enrolled and given a clinical follow up and angiographic follow up during the following one year.
3168581|NCT00552682|Experimental|A|Duloxetine 60 mg, 1 tablet/day
3168582|NCT00552682|No Intervention|B|To continue with the antidepressive treatment if exist
3168583|NCT00552721|Experimental|A|Physical therapy with strength training.
3168584|NCT00552721|Active Comparator|B|Physical therapy without strength training.
3168585|NCT00552734||Control|The other half of the patients were randomized to the control group who were followed for their routine diabetes care and had to visit the clinic on the same schedule as the experimental group.
3168586|NCT00552734||Experimental|Half of the subjects were randomized to this group using insulin guidance software on a PDA to adjust their insulin dose at home based on the prescription provided by the provider.
3168587|NCT00552747|Active Comparator|1|fenofibrate 160 mg capsules (QD) Taken once daily with the largest meal of the day
2542792|NCT02612272|Active Comparator|Corticosteroid|"This arm will receive intra-articular betamethasone.~4cc of 1% lidocaine, 1cc of 0.9% normal saline and 1cc (6 mg) of betamethasone.~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
2542794|NCT02612272|Experimental|Ketorolac|"This arm will receive intra articular ketorolac.~2cc (60 mg) of ketorolac and 4cc of 1% lidocaine~An 18 gauge needle connected to a syringe filled with the study drug will be administered. If there is no effusion, a 22 gauge needle with 6cc of the study drug will be injected into the administration site~Please see detailed description of study for further information."
2542839|NCT02612025|Experimental|Exercise group|Exercise training during intensive medical treatment
2542846|NCT02612025|No Intervention|Control group|Usual Care
3203098|NCT00920153|Experimental|Group 3 (poor prognosis)|Patients receive VABEM, CEO, BEAM, and MINE chemotherapy. Patients also undergo allogeneic or autologous stem cell transplantation.
3203099|NCT00920166|Experimental|Modilac Pétunia 1|Formula with reduced total protein concentration, enriched in alpha-lactalbumin and containing a symbiotic
3203100|NCT00920166|Active Comparator|Modilac 1|Regular milk
3203101|NCT00920179||Dry eye group|Dry eye patients with Primary Sjogren's syndrome
2543209|NCT02609477|Experimental|Istradefylline 40 mg|40 mg istradefylline (1 × 40 mg tablet + 3 × placebo tablets + 3 × placebo capsules)
2543216|NCT02609477|Experimental|Istradefylline 80 mg|80 mg istradefylline (2 × 40 mg tablets + 2 × placebo tablets + 3 × placebo capsules)
2543221|NCT02609477|Experimental|Istradefylline 160 mg|160 mg istradefylline (4 × 40 mg tablets + 3 × placebo capsules)
2543224|NCT02609477|Active Comparator|Phentermine 45 mg|45 mg phentermine (4 x placebo tablets + 3 × 15 mg phentermine hydrochloride capsules)
2543227|NCT02609477|Active Comparator|Phentermine 90 mg|90 mg phentermine (4 × placebo tablets + 3 × 30 mg phentermine hydrochloride capsules)
2543228|NCT02609477|Placebo Comparator|Placebo|Placebo (4 × placebo tablets + 3 × placebo capsules)
2543288|NCT02609061|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating furcation defect
2543290|NCT02609061|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating furcation defect
2543293|NCT02609061|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating furcation defect
2543352|NCT02608580|Other|Patients with sicke cell disease|"Adult sickle cell disease patients will fill in a survey about the quality of their hospital care, in the transition period between the pediatric to an adult hospital care system.~Since filling in this survey is not part of the standard of care, this study has been defined as interventional."
2543401|NCT02608320|Experimental|Treatment Sequence (ACB) Position (RLR)|Participants will receive treatment A (Duragesic 12.5 microgram per hour [mcg/h]) applied to right paraspinal side in period 1, then treatment C (aged JNJ- 35685-AAA-G016 12.5 mcg/h) applied to left paraspinal side in period 2 and then treatment B (New JNJ-35685- AAA-G016 12.5 mcg/h) applied to right paraspinal side in period 3.
2543405|NCT02608320|Experimental|Treatment Sequence (BAC) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
2543413|NCT02608320|Experimental|Treatment Sequence (CBA) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
2543416|NCT02608320|Experimental|Treatment Sequence (BCA) Position (RLR)|Participants will receive treatment B applied to right paraspinal side in period 1, then treatment C applied to left paraspinal side in period 2 and then treatment A applied to right paraspinal side in period 3.
2543419|NCT02608320|Experimental|Treatment Sequence (CAB) Position (RLR)|Participants will receive treatment C applied to right paraspinal side in period 1, then treatment A applied to left paraspinal side in period 2 and then treatment B applied to right paraspinal side in period 3.
2543420|NCT02608320|Experimental|Treatment Sequence (ABC) Position (RLR)|Participants will receive treatment A applied to right paraspinal side in period 1, then treatment B applied to left paraspinal side in period 2 and then treatment C applied to right paraspinal side in period 3.
2543421|NCT02608320|Experimental|Treatment Sequence (ACB) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
2543422|NCT02608320|Experimental|Treatment Sequence (BAC) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
2543423|NCT02608320|Experimental|Treatment Sequence (CBA) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
2543424|NCT02608320|Experimental|Treatment Sequence (BCA) Position (LRL)|Participants will receive treatment B applied to left paraspinal side in period 1, then treatment C applied to right paraspinal side in period 2 and then treatment A applied to left paraspinal side in period 3.
3203102|NCT00920179||Controls|Healthy subjects without dry eyes
3203103|NCT00920192|Experimental|Foretinib|Phase I starting dose of 30 mg/day escalated to 45 mg/day, de-escalated to 30 mg/day; MTD for Phase II was 30 mg/day
3203104|NCT00920257|Experimental|GSK2141795|Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified.
3203105|NCT00920270|Active Comparator|antibiotic|conventional antibiotics
3203106|NCT00920270|Experimental|colistin group|nebulized colistin
3203107|NCT00920283|Experimental|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
3203108|NCT00920283|Active Comparator|Driver, Cobalt Alloy Coronary Stent|
3203109|NCT00920296|Experimental|Cohort 1|All subjects
3203110|NCT00920322|Active Comparator|five times weekly|Patients will receive rTMS on each weekday for 4 weeks (5 x weekly)
2542813|NCT02612012||Axillary radiotherapy|
2542881|NCT02611856||monochorial-biamniotic pregnancies|
2542938|NCT02611505|Experimental|Cohort 1|Participants with moderate hepatic impairment will receive esketamine solution (containing 14 milligram [mg] of esketamine base per 100 microliter [mcl]) by intranasal route into each nostril using nasal spray pump at 0 hour (h) on Day 1.
2542941|NCT02611505|Experimental|Cohort 2|Participants with mild hepatic impairment will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
2542942|NCT02611505|Experimental|Cohort 3|Participants with normal hepatic function and no evidence of liver damage will receive esketamine solution (containing 14 mg of esketamine base per 100 mcl) by intranasal route into each nostril using nasal spray pump at 0h on Day 1.
2542970|NCT02611128||Peripubertal girls|Peripubertal girls with varying androgen concentrations will have careful phenotype/genotype assessment, primarily to assess the relationship between urinary exosomal DENND1A.V2 and serum free testosterone concentrations.
2543011|NCT02610894|Experimental|mHealth application|Participants will be provided an iPad Mini tablet computer loaded with an mHealth application (PoCAH) to provide enhanced post-operative pain care management. The app will utilize algorithms tailored to the patient's needs and symptoms in an attempt to reduce poor outcomes related to post-operative pain management.
2543014|NCT02610894|Active Comparator|Control Group|Participants will be provided an iPad Mini tablet computer loaded with a PDF of the As usual standard discharge and care instructions for post-operative pain care management.
2543037|NCT02610621|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and chemotherapy.
2543080|NCT02610361|Experimental|BGB-283|
2543142|NCT02609932|Other|SD or SS|In this study, IFN- γ-1b will be subcutaneously administered a total of 30 subjects in one of two cohorts; Single Dose (SD) or Steady State (SS) dosing. Dosing of IFN- γ-1b will be based upon the time subject became eligible and started study. In this non-randomized, open-label study, subjects will be enrolled on the SD cohort first, and once that cohort has been filled, enrollment to the SS cohort will begin. Although not required, subjects in the SD cohort may also volunteer to participate in the SS cohort if they still meet eligibility criteria. Separate consents will be used for the SD and SS cohorts. In the event not all the SD subjects choose to continue onto the SS cohort, we will plan to recruit new participants from our local campus community.
2543172|NCT02609646||linezolid|patients treated with linezolid
2543173|NCT02609646||meropenem|patients treated with meropenem
2543174|NCT02609646||piperacillin/tazobactam|patients treated with piperacillin/tazobactam
2543175|NCT02609646||vancomycin|patients treated with vancomycin
2543270|NCT02609295|Placebo Comparator|Placebo|Individuals who consumed 1.2 g (two capsules) of medium-chain triglyceride (MCT) oil daily
2543272|NCT02609295|Experimental|ALA group|Individuals who consumed 1.2 g (two capsules) of perilla oil daily
2543309|NCT02608775|Experimental|Metrodoloris Medical System|Application of a skin electrode
2543311|NCT02608775|Active Comparator|Aisys® care station, Acertys|SPI calculated from photoplethysmography
2543548|NCT02607592|Experimental|Nadaplatin and Pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
2543551|NCT02607592|Active Comparator|Cisplatin/Pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
2543582|NCT02607137|Experimental|Health Education|Health information related to physical activity
2543729|NCT02606513|Experimental|Comparison of CTU vs MRU|CTU is the primary test of choice for the evaluation of the UUT. The performance of MRU will be compared to that of CTU in the same patient population
3168588|NCT00552747|Placebo Comparator|2|placebo (capsules identical to those of fenofibrate) taken once daily (QD)with the largest meal of the day
2543815|NCT02605616|Experimental|Active drug AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
2543824|NCT02605616|Placebo Comparator|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
2543873|NCT02605200|Other|Participants|Participants will complete tests of glucose tolerance and psychosocial assessments, and will undergo medical history screening. Those children identified with diabetes and/or abnormal glucose tolerance will receive both diabetes self-management education and psychosocial support from a pediatric Certified Diabetes Educator (CDE) and a psychologist, respectively.
2543964|NCT02604576|Experimental|Group 1|FDC Bromopride 10 mg and Simethicone 80 mg
2543966|NCT02604576|Active Comparator|Group 2|Bromopride 10 mg (Digesan ® - Sanofi Aventis)
2544004|NCT02604251|Experimental|Treatment with KLOX BioPhotonic WoundGel System|One breast will be randomized to be treated with KLOX BioPhotonic WoundGel System.
2544007|NCT02604251|Active Comparator|Treatment with silicone sheets|The second breast will be randomized to be treated with silicone sheets.
2544121|NCT02603471|Experimental|Text Messaging CBT (TXT-CBT)|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
2544129|NCT02603471|Active Comparator|Informational group|A pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
3168589|NCT00552773|Experimental|Cyclamen Europaeum|
3168590|NCT00552773|Placebo Comparator|Placebo|
3168591|NCT00552799|Experimental|1|Penicillin VK 250 mg b.d.
3168592|NCT00552799|Placebo Comparator|2|placebo tablet b.d.
3168593|NCT00552825||1|all were in a single group
3168594|NCT00552838|No Intervention|A|Physicians in this arm did not have any intervention with the AUT. Antimicrobial prescriptions were based on hospital guidelines or on the physician's medical knowledge.
2542799|NCT02612298|Active Comparator|Metoprolol|Metoprolol succinate sustained-release tablet, oral, 23.75-71.25mg, qd for 12 weeks.
2542933|NCT02611986|Experimental|McGrath MAC|tracheal intubation using the McGrath MAC
2542935|NCT02611986|Experimental|Macintosh Laryngoscope|tracheal intubation using the Macintosh Laryngoscope
2542973|NCT02611219|Experimental|Arm 1: Pediatric patients|"Patients will wear a Fitbit Flex during hospitalization~Completion of Demographic Data Form at baseline, discharge from hospital, and at the six week clinic visit~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out (some with help of parents) applicable questionnaires: Child Health Ratings Inventories-General Health Module (5-12 years), General Health Module-Baseline Adolescent-Self Report (13-18 years), General Health Module-Follow Up Adolescent-Self Report (13-18 years) at baseline, discharge from hospital, and at six week clinic visit~Patients will be assessed using standard physical therapy assessment tools to determine functioning, muscle strength, endurance, and mobility: The Functional Independence Measure for Children and Manual Muscle Testing is done weekly, discharge from hospital, and at six week clinic visit. The 3-Minute Step Test is done at admission, discharge from hospital, and at six week clinic visit."
2542974|NCT02611219|Experimental|Arm 2: Parents of pediatric patients|"Parents will be considered participants as they will be completing study questionnaires.~Completion of Demographic Data Form at baseline~Assist in recording time out of bed using the SCT Daily Activity Log~Fill out applicable questionnaires: General Health Module-Baseline Parent Report -Adolescent (13-18 Years), General Health Module-Follow Up Parent Report-Adolescent (13-18 years), General Health Module-Baseline Parent Report-School Age (5-12 years), and General Health Module Follow Up Parent Report-School Age (5-12 years), HSCT Module-Follow UP Parent Report School Age (5-12 years), HSCT Module-Follow Up Parent Report Adolescent (13-18 years), HSCT Module-Follow Up Adolescent-Self Report (13-18 years), HSCT Module-Follow Child-Self Report (5-12 years) at baseline, discharge from hospital, and at six week clinic visit.~Assist child with Child Health Ratings Inventories-General Health Module (5-12 years) at baseline, discharge at hospital, and at six week clinic visit"
2543046|NCT02610569|Active Comparator|standart endoscopy|Intervention: 2 standard endoscopy during anti-TNFalpha or vedolizumab treatment
2543047|NCT02610569|Experimental|PillCamCOLON (C2)|Intervention : 2 PillCamCOLON (C2) during anti-TNFalpha or vedolizumab treatment
2543094|NCT02610309|Experimental|Family-Based Crisis Intervention|The Family-Based Crisis Intervention (FBCI) is a single-session intervention that takes place in the Emergency Department. Adolescents randomized to the experimental condition received a standard psychiatric evaluation followed by the experimental intervention. FBCI was administered by licensed psychiatric social workers who were trained in the intervention. The research clinician provided FBCI to the suicidal adolescent and his/her parent(s)/guardian(s) in a 60-90 minute session in which she helped the adolescent and family develop a joint crisis narrative of the problem and taught them cognitive-behavioral skill-building, therapeutic readiness, psycho-education about depression, and safety planning.
2543097|NCT02610309|No Intervention|Treatment As Usual|Treatment as usual included an emergency psychiatry evaluation (standard care).
2543115|NCT02610010|Experimental|IMRT alone|Intensity-modulated radiotherapy without cisplatin-based concurrent chemotherapy
2543119|NCT02610010|Active Comparator|IMRT plus concurrent chemotherapy|Intensity-modulated radiotherapy with cisplatin-based concurrent chemotherapy
2543188|NCT02609789|Experimental|Part A: Dose 1|Drug JNJ-55920839 or Placebo administered IV infusion Dose 1.
2543189|NCT02609789|Experimental|Part A: Dose 2|Drug JNJ-55920839 or Placebo administered IV infusion Dose 2.
2543193|NCT02609789|Experimental|Part A: Dose 3|Drug JNJ-55920839 or Placebo administered IV infusion Dose 3.
2543197|NCT02609789|Experimental|Part A: Dose 4|Drug JNJ-55920839 or Placebo administered IV infusion Dose 4.
2543199|NCT02609789|Experimental|Part A: Dose 5|Drug JNJ-55920839 or Placebo administered IV infusion Dose 5.
2543202|NCT02609789|Experimental|Part A: Dose 6|Drug JNJ-55920839 or Placebo subcutaneous injection Dose 6.
2543205|NCT02609789|Experimental|Part B|Participants will receive 6 doses of JNJ-55920839 or placebo (every 2 weeks) as an IV infusion.
2543260|NCT02609022|Experimental|CV-MG01|The therapeutic vaccine candidate, CV-MG01 comprises two short synthetic peptides separately conjugated to a carrier protein for the potential treatment of myasthenia gravis
2543262|NCT02609022|Placebo Comparator|Placebo|Aluminium hydroxide adjuvant alone
2543351|NCT02608658|Experimental|Interventional Arm|The experimental arm of this study will involve all patients in this study. Subjects will be evaluated in a clinical setting and undergo a brief healthcare questionnaire, blood work, and a breath test. Subjects will then take a medical food (EnteraGam) twice daily for 8 weeks total, after which they will be seen in clinic at 4 weeks for follow up and then at 8 weeks to repeat the healthcare questionnaire, breath tests, and blood draw.
3168595|NCT00552851|Other|Pegvisomant|patients with active acromegaly and impaired cardiac function
3168596|NCT00552864|Active Comparator|R|
3168597|NCT00552864|Active Comparator|L|
2543457|NCT02607969|Experimental|seen once every six weeks|Parents will be educated about home program and they will be asked to control once every six weeks.
2543461|NCT02607969|Experimental|seen once a week.|Parents will be educated about home program and they will be asked to control once a week.
3168598|NCT00552877|Active Comparator|1|Cypher Select plus stent
2543575|NCT02607319|Experimental|Low molecular weight heparin|Bemiparin sodium 3,500 IU anti Xa/0.2 ml solution (Hibor; Laboratories Rovi Pharmaceuticals) for injection in pre-filled syringes.
2543576|NCT02607319|No Intervention|No intervention group|Control group receiving standard care.
2543630|NCT02606916|Experimental|SMART & S-1/DDP|Patients in experimental group receive daily simultaneous modulated accelerated radiotherapy combined with DDP and S-1.
2543656|NCT02606552|Active Comparator|Dabigatran plus aspirin|Medical treatment with dabigatran plus aspirin after 3months triple therapy (Dabigatran plus DAPT (dual-antiplatelet therapy))
2543665|NCT02606552|Experimental|Dabigatran plus clopidogrel|medical treatment with dabigatran plus clopidogrel after 3months triple therapy (Dabigatran plus DAPT)
2543669|NCT02606552|Other|Amplazter Cardiac Plug (ACP)|Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure
3168599|NCT00552877|Active Comparator|2|Xience V stent
3168600|NCT00552890|Experimental|ATK|modified Atkins diet
2542800|NCT02612350||Increased Risk for Cancer Development|The group is to include at least 1000 individuals who are at high risk for the development of cancer. Risk is assessed through the completion of a clinical history questionnaire. Examples of such subjects include those with known hereditary cancer syndrome pathogenic variants without a diagnosis of cancer, with significant family history of breast, ovarian, colon, or lung cancer or melanoma, or another strong history of cancer but no prior molecular diagnosis, heavy smokers or those exposed to carcinogens and mutagens. The individuals who meet criteria for inclusion will undergo cell-free DNA isolation and circulating-tumor DNA (ctDNA) analysis for the detection of genetic mutations associated with the possible development of a malignancy.
2542857|NCT02611934|Experimental|Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
2542860|NCT02611934|No Intervention|no-Mild Therapeutic Hypothermia|OHCA survivors with diagnosed or suspected ACS
2542887|NCT02611648|No Intervention|standard HLD|Standard high-level disinfectant (metricide ortho-phthalaldehyde) currently performed at BIDMC (standard HLD)
2542890|NCT02611648|Experimental|double HLD|Double the exposure time of the standard high level disinfectant (metricide ortho-phthalaldehyde)
2542892|NCT02611648|Experimental|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
2542951|NCT02611427|Active Comparator|Education/Self-efficacy|Booklet about physical activity, movement monitoring device, encouragement
2542953|NCT02611427|Active Comparator|Education|Booklet about physical activity
3168601|NCT00552890|Experimental|ADA|subjects assigned to follow ADA recommended diet for 1 year
3168602|NCT00552903|Experimental|1|Active intervention - personal health coaching provided
2543049|NCT02610582|Other|Treatment arm|single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
2543053|NCT02610582|Other|Waiting group Arm|Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
2543081|NCT02610296|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
2543085|NCT02610296|Placebo Comparator|Placebo|isotonic saline
2543271|NCT02608944|Experimental|MRI perfusion vs. PET Imaging perfusion|Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging
2543326|NCT02608710|Experimental|Single Dose|Single dose of RDEA3170 4.5 mg, RDEA3170 6 mg or RDEA3170 12 mg on Days 1, 5 and 9.
2543329|NCT02608710|Experimental|Multiple Dose|RDEA3170 12 mg once daily (qd)
2543334|NCT02608710|Experimental|Single Dose Food Effect|Since dose of RDEA3170 6 mg administered in fed or fasted state on Day 1 and Day 8.
2543385|NCT02608372|Experimental|Sequence A|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-UP-CTR
2543391|NCT02608372|Experimental|Sequence B|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence LD-CTR-UP
2543394|NCT02608372|Experimental|Sequence C|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-LD-CTR
2543397|NCT02608372|Experimental|Sequence D|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence UP-CTR-LD
2543399|NCT02608372|Experimental|Sequence E|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-LD-UP
2543403|NCT02608372|Experimental|Sequence F|The meal study was performed with Laminaria digitata (LD), Undaria pinnatifida (UP) or pea protein drink (CTR) in the sequence CTR-UP-LD
2543640|NCT02606760|Experimental|P-3073|P-3073
2543642|NCT02606760|Placebo Comparator|vehicle of P-3073|vehicle of P-3073
2543661|NCT02606448|Active Comparator|Femoral Nerve Block|Patients in this group received preoperative ultrasound guided femoral nerve blocks by senior anesthesiologist using ropivicaine.
2543666|NCT02606448|Experimental|Liposomal Bupivacaine|Patients in this group received local infiltration of Liposomal bupivacaine before the end of surgery.
2543897|NCT02604914|Experimental|ND0612L (LD/CD solution)|3 doses of the investigational ND0612L (LD/CD solution) for subcutaneous (SC) infusion 0.24ml per hour.
2543899|NCT02604914|Experimental|ND0612H (LD/CD solution)|3 doses of the investigational ND0612H (LD/CD solution) for subcutaneous (SC) infusion 0.64ml per hour.
2543901|NCT02604914|Active Comparator|LCIG (Levodopa-carbidopa intestinal gel)|Active Comparator: LCIG subjects who completed the ND0612H arm will be administered with 3 doses of LCIG, directly to the jejunum.
2543951|NCT02604641|Placebo Comparator|Placebo group|0 mg CoQ10 daily
2543952|NCT02604641|Active Comparator|Quvital LD group|50 mg CoQ10 daily
2543955|NCT02604641|Active Comparator|Quvital HD group|150 mg CoQ10 daily
2544146|NCT02603458|Experimental|NRX-1074 Dose Group|Group of enrolled subjects receiving two infusions of intravenous NRX-1074 (10 mg)
3168603|NCT00552903|No Intervention|2|Control arm - no intervention, data on health outcomes collected at baseline (entry to the study) and during the 12 month follow-up
3168604|NCT00552916|Other|1|Participants will be randomized to either an intervention arm where they will receive 'true' FES and the other control arm where they will receive 'false' FES. The sham group will receive 'false' FES.
3168605|NCT00552916|Other|2|The intervention group will receive 'true' FES
3168606|NCT00552942|Experimental|1|surgery plus omentectomy
3168607|NCT00552942|No Intervention|2|standard gastric bypass
3168608|NCT00552981|Active Comparator|1|
3168609|NCT00552981|Sham Comparator|2|
3168610|NCT00552994|Active Comparator|1|Cypher Select plus stent
3168611|NCT00552994|Active Comparator|2|Xience V stent
3168612|NCT00553033||A|
3168613|NCT00553046||family burden|chronich respiratory failure home ventilated patients
3168614|NCT00553072|Active Comparator|Magnesium sulphate, neurological outcome|Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
3168615|NCT00553072|Placebo Comparator|Placebo|Placebo every 24 hours for 3 doses starting from 6 hours after birth
3168616|NCT00553085||Anx group|
3168617|NCT00553085||ADHD group|
3168618|NCT00553085||Nonanx/nonadhd group|
3168619|NCT00553111|Experimental|1|pre survey, intervention, post test survey
2542803|NCT02612181|Experimental|Dexmedetomidine group|Dexmedetomidine group: Dexmedetomidine infusion for dexmedetomidine group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Dexmedetomidine doses 0-0.7 mcg/kg/h
2542808|NCT02612181|Placebo Comparator|Control group|Control group: Placebo infusion for control group to the goal of sedation: Richmond agitation-sedation scale 0 to -2 Control drug doses 0-0.7 mcg/kg/h
2542885|NCT02611869|Experimental|Cryoballoon|
2542888|NCT02611869|Active Comparator|RF ablation|
2542962|NCT02611414|Experimental|anodal tDCS|TDCS will be delivered with two saline-soaked sponge electrodes. The main electrode to anodal stimulation will be placed over the motor cortex, M1. The second electrode is neutral and will be placed on the skin overlying the supraorbital region The current will be delivered at the intensity of 2mA for 20 minutes. The procedure will be repeated at five consecutive days.
2542964|NCT02611414|Sham Comparator|Sham tDCS|Two electrodes are positioned at M1 and supra-orbital área. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes. The procedure will be repeated at five consecutive days.
2542993|NCT02610946|Placebo Comparator|Paper-based|Use of paper-based calenders, reminders, medication list, and blood pressure, fluid intake tracking methods in adolescent renal transplant care
2542997|NCT02610946|Experimental|Electronic application|Use of electronic apps (iphone or i-Pad mini) to determine whether it can improve compliance with transplant care and readiness to transition to adult care.
2543034|NCT02610738|Experimental|Junior KICk-OFF education programme|Participants will attend an age appropriate self management programme (Junior KICk-OFF) designed to improve their knowledge and understanding of type 1 diabetes
2543073|NCT02610400|Experimental|RACD without RAVC|In this arm, subjects will receive RACD without the addition of RAVC.
2543074|NCT02610400|Experimental|RACD+RAVC|"In this arm, subjects will receive both:~(i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)"
2543075|NCT02610400|Experimental|rfMDA without RAVC|In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
2543076|NCT02610400|Experimental|rfMDA+RAVC|"In this arm, subjects will receive both:~(i) reactive focal mass drug administration (rfMDA) and (ii) RAVC."
3168620|NCT00553111|No Intervention|2|pre test survey and post test survey
3168621|NCT00553111|Experimental|3|video intervention and post test survey
3168622|NCT00553111|No Intervention|4|post test survey
2543249|NCT02609087|Experimental|Sevoflurane|adjust the end-tidal sevoflurane (sevofran inhaler, Hana pharmacy, Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
2543250|NCT02609087|Experimental|Propofol|adjust propofol (FRESOFOL MCT INJ 2% (vial), Fresinus Kabi Korea) concentration maintaining the 40 ~ 50 BIS (bispectral index) with 3 ng/ml of remifentanil using TCI (target controlled infusion) pump
2543276|NCT02608918|Experimental|BMS-955176|BMS-955176 specified dose on specified days
2543355|NCT02608723|Active Comparator|Standard shock waves device|3 sessions were applied: one per week.
2543359|NCT02608723|Active Comparator|Austere shock waves device|3 sessions were applied: one per week.
2543361|NCT02608723|Active Comparator|Sophisticated shock waves device|3 sessions were applied: one per week.
2543410|NCT02608216|Experimental|FLT PET/CT|All subjects will receive an [18F]FLT PET/CT scan.
2543474|NCT02607852|Other|Arm A|Patients between the ages of 5-18 years. They will complete the 5-18 version of the BOQ on iPads or through the HTTPS Tonic link.
2543479|NCT02607852|Other|Arm B|Patients between the ages of 0-4 years. They will complete the 0-4 version of the BOQ and appropriate Pediatric Symptom Checklists (i.e. baby or preschool) on iPads or through the HTTPS Tonic link.
2543513|NCT02607631|Experimental|Single arm|Pembrolizumab 200mg IV every 3 weeks until tumor progression or unacceptable toxicity
2543555|NCT02607488|Placebo Comparator|Placebo|Patients will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
2543556|NCT02607488|Active Comparator|Lidocaine 1%|"Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight-IBW)]"
2543557|NCT02607488|Active Comparator|Lidocaine 1.5%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1,5% solution which will be continued for 24 hours after surgery.
2543558|NCT02607488|Active Comparator|Lidocaine 2%|Patients will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
2543579|NCT02607072|Experimental|Aspirin 200 mg daily|Aspirin 200 mg daily
2543580|NCT02607072|Experimental|Aspirin 100 mg daily|Aspirin 100 mg daily
2543585|NCT02607072|Placebo Comparator|Placebo control|Placebo control
2543616|NCT02606773|Experimental|600 mg Novo C plus|Single dose of oral 600 mg Novo C plus dietary supplement (contains 600 mg ascorbic acid in liposomal formulation)
2543618|NCT02606773|Experimental|900 mg Novo C Plus|Single dose of 900 mg oral Novo C plus dietary supplement (contains 900 mg ascorbic acid in liposomal formulation)
2543620|NCT02606773|Active Comparator|500 mg intravenous vitamin C|Single dose of 500 mg intravenous ascorbic acid (Vitamin C 100 mg/ml injection; EGIS)
2543622|NCT02606773|Active Comparator|500 mg oral vitamin C|Single dose of 500 mg oral ascorbic acid (Cetebe 500 mg retard capsules; GlaxoSmithKline Consumer Healthcare - GSK Export)
2543693|NCT02606344|Experimental|Intervention Group (IG)|Loans were provided to poor women who enrolled in the intervention group. A participatory learning and action curriculum was integrated into loan meetings, which took place every 2 weeks.
3168623|NCT00553137|Active Comparator|1|single dose fluconazole (750 mg) and placebos 150 mg tablets once daily for 14 days
3168624|NCT00553137|Active Comparator|2|150 mg fluconazole once daily for 14 days and placebos (5 placebos tablets) 750 mg once
3174186|NCT00620620|Experimental|Inhaled Zaleplon 1 mg|Staccato Zaleplon 1 mg
3174187|NCT00620620|Experimental|Inhaled Zaleplon 2 mg|Staccato Zaleplon 2 mg
2542804|NCT02612129|Experimental|arimoclomol|arimoclomol capsules for oral administration (3 times daily). Doses:150-600 mg/day (based on weight)
2542806|NCT02612129|Placebo Comparator|Placebo|Matching placebo capsules
2542872|NCT02611700|Experimental|experimental group|Nimotuzumab+TP(paclitaxel+cisplatin)
2542873|NCT02611700|Placebo Comparator|control group|Placebo + TP(paclitaxel+cisplatin)
2542975|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (1 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
2542978|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (3 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
2542980|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (6 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
2542982|NCT02611167|Experimental|Bone marrow-derived MSC transplantation (10 x 10 6 MSC/kg)|Allogeneic bone marrow-derived MSCs will be delivered intravenously.
2543028|NCT02610829|Experimental|Gamma Tocopherol|Subjects will ingest 1400 mg gamma tocopherol, orally administered in 3 doses separated by 12 hours.
2543067|NCT02610439||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2543122|NCT02610205||Caring touch interventions|The study was conducted as a mixed-methods design. A recruitment of potential study participants was made up from a list of incoming patients arriving at the emergency department following an MVA, and who upon medical examinations were given an injury severity score between 0-3 and subsequently discharged straight home. ISS is a 0-8 point scale rating injury severity, where a rating of 0 indicates no physical injury; 1-3 represents minor physical injuries. The patients were informed about the study by mail during the week after the MVA, and those interested in participating in the caring touch intervention were asked to contact the investigator and subsequently completed a written informed consent form during the first encounter with the therapist.
3168625|NCT00553176||Patients with Crohn's disease|The Registry is an observational research program featuring clinical, economic, and humanistic measures characterizing the treatment of Crohn's disease
3168626|NCT00553228|Experimental|group I|Tdap
2543212|NCT02609529|Experimental|SBI|Entergam 10 g/day PO
2543215|NCT02609529|Placebo Comparator|Placebo|Placebo 10 g/day PO
2543275|NCT02609126|Experimental|EP-104IAR|15mg EP-104IAR in 4 mL carrier fluid
2543281|NCT02609126|Placebo Comparator|Vehicle|4 mL carrier fluid
2543339|NCT02608697|Experimental|Group 1: CAT-2054 or Placebo Dose 1|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
2543341|NCT02608697|Experimental|Group 2: CAT-2054 or Placebo Dose 2|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo QD and open label 40 mg atorvastatin tablet administered daily.
2543344|NCT02608697|Experimental|Group 3: CAT-2054 or Placebo Dose 3|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 250 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
2543348|NCT02608697|Experimental|Group 4: CAT-2054 or Placebo Dose 4|A run-in phase with 40 mg atorvastatin tablet administered daily for at least 28 days, followed by a 28-day blinded treatment phase with 400 mg CAT-2054 or placebo BID and open label 40 mg atorvastatin tablet administered daily.
2543412|NCT02608151|Active Comparator|Touch massage without oil|massage without oil
2543418|NCT02608151|Experimental|touch massage with oil|massage with an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil)
2543909|NCT02604875||observational|Blood samples will be taken for measuring copeptin levels in healthy subjects.
2543977|NCT02604654|Experimental|Yiqitongluo group|Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.
2544013|NCT02604238|Experimental|Group A|"Administered a safe dose of Alteplase. All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin in addition it is administered a safe dose of Alteplase."
2544016|NCT02604238|No Intervention|Group B|All patients are treated with low molecular weight heparin ( LMWH ) according to the Guidelines ESC2014 heparin. It not added any treatment.
2544074|NCT02603939||Participants with Advanced Knee OA|People with advanced knee osteoarthritis requiring joint replacement surgery are being assessed for their pain responses before and after joint replacement surgery
2544075|NCT02603939||Participants with Early Knee OA|Participants with osteoarthritis with early disease who do not require joint replacement surgery are being assessed for pain
2544120|NCT02603627||With lung cancer|Patients who have a new diagnosis of lung cancer will be invited to undergo spirometry to enable us to gather data on the prevalence of COPD in this group.
2544125|NCT02603627||Without lung cancer|Smokers who are referred to the smoking cessation clinic will be invited to undergo spirometry to ascertain the prevalence of COPD in this group.
2544208|NCT02603276|Active Comparator|Plant sterols|Plant sterols 800 mg per dose, 1 liquid stick per day, per 8 weeks
2544214|NCT02603276|Active Comparator|Red Yeast Rice|Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
2544216|NCT02603276|Experimental|Red Yeast Rice plus Plant sterols|lant sterols 800 mg per dose + Red Yeast Rice 200 mg containing 5 mg monacolin K per daily dose, 1 liquid stick per day, per 8 weeks
2544261|NCT02602678|Experimental|PRONE-Supine|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
2544262|NCT02602678|Experimental|SUPINE - Prone|We test the hypothesis that in infants with severe bronchiolitis, prone position reduces the work of breathing (WOB) and the intrinsic Positive End Expiratory Pressure (PEEP).
2544282|NCT02602379||Tetanic stimulation|Single arm study. See Study description for a through description of the intervention.
2544344|NCT02602275|Experimental|Neurexan®|0.6 mg / tablet, 3 tablets, 40-60 minutes before the second MRI Intervention: Drug: Neurexan®
3168627|NCT00553228|Active Comparator|group 2|Td
3174188|NCT00620620|Experimental|Inhaled Zaleplon 4 mg|Staccato Zaleplon 4 mg
3203111|NCT00920322|Experimental|three times weekly|Patients will receive rTMS three times weekly for four weeks
2542894|NCT02611635||VKA treatment of AF / Cohort 1|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
2542903|NCT02611635||NOAC treatment of AF / Cohort 2|A sample of about 200 patients with non-valvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
2542939|NCT02611895|Experimental|HIV DNA|Blood test : Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
2542947|NCT02611284|Experimental|Treatment Cohort (LISA)|All preterm infants born at < 32 WG between October 2013 and November 2014 who met inclusion criteria were managed by the new LISA technique.
2542952|NCT02611284|Other|Historical Cohort (INSURE)|The control group was collected from the period immediately before the study's initiation (from Jun 2012 to September 2013). This cohort was comprised of preterm infants of less than 32 WG who met the inclusion criteria.
2542976|NCT02611206|Experimental|Open Label rTMS|All participants who qualify will undergo 6 weeks of open-label rTMS.
2543007|NCT02611089||Radial dysplasia patients|Recruited participants will have 2-3 small tissue biopsy samples taken during 1-2 of their planned reconstructive surgical procedures for radial dysplasia, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
2543013|NCT02611089||Control patients|Recruited participants will have 2-3 small tissue biopsy samples taken during their planned reconstructive surgery for hand trauma, whilst under general anaesthesia in the operating theatre. Samples will be taken by scalpel or scissors, by the operating surgeon, from within the surgical site in the forearm and hand. The skin incision and deep dissection will have to be made as part of the normal course of reconstructive surgery, regardless of participation in this study.
2543020|NCT02610881|Experimental|Iron and Folic Acid (IFA)/Micronutrient Powders (MNP)|Participants will receive iron and folic acid (IFA) drops for one month followed by a two week washout period. Participants will then receive micronutrient powders (MNP) for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
2543022|NCT02610881|Experimental|Micronutrient Powders (MNP)/Iron and Folic Acid (IFA)|Participants will receive micronutrient powders (MNP) for one month followed by a two week washout period. Participants will then receive iron and folic acid (IFA) drops for one month. Mothers of participants will receive counseling on the benefits of iron intake, side effects of IFA, and preservation of IFA bottles and MNP sachets.
2543045|NCT02610608||Women undergoing ART|Observation of the incidence of venous and arterial thrombosis following ovarian stimulation
2543078|NCT02610504|Experimental|Durolane 3ml|Single intra-articular injection into shoulder
2543084|NCT02610270|Experimental|2 Gums|Athletes that continued their usual training and diet, who took 2 gums of omega 3 (DHA 760 mg) during the experimental period.
2543088|NCT02610270|Experimental|3 Gums|Athletes that continued their usual training and diet, who took 3 gums of omega 3 (DHA 1140 mg) during the experimental period.
2543089|NCT02610270|No Intervention|Control|Athletes and coaches that continued their usual training and diet, but did not take any supplements during the experimental period.
2543109|NCT02610062|Experimental|AGS67E 1.2 mg/kg Schedule 1|Participants will receive 1.2 mg/kg of AGS67E as an intravenous infusion once every three weeks (Q3).
2543110|NCT02610062|Experimental|AGS67E 1.8 mg/kg Schedule 1|Participants will receive 1.8 mg/kg of AGS67E as an intravenous infusion once every three weeks.
2543113|NCT02610062|Experimental|AGS67E 2.4 mg/kg Schedule 1|Participants will receive 2.4 mg/kg of AGS67E as an intravenous infusion once every three weeks.
2543117|NCT02610062|Experimental|AGS67E 0.6 mg/kg Schedule 2|Participants will receive 0.6 mg/kg of AGS67E once weekly for three weeks.
2543120|NCT02610062|Experimental|AGS67E 0.9 mg/kg Schedule 2|Participants will receive 0.9 mg/kg of AGS67E once weekly for three weeks.
2543138|NCT02610114|Experimental|Z-Score and computer algorithm|
2543139|NCT02610114|Active Comparator|Z-Score|
2543170|NCT02609750|Experimental|Structured care & workplace intervention|Through a flow chart the investigators in detail specify the medical and work place interventions (all according to evidence-based guidelines). Red, yellow and blue flags, and motivational factors are identified in a screening investigation. The aim of the screening is to individually tailor the rehabilitation interventions. Physiotherapy interventions are based on a bio-psychosocial and cognitive behavioural therapy perspective. Behavioural medicine treatment principles include careful examination and treatments such as advice to stay active, instructions, OMI, OMT, MDT. The investigators apply interventions based on ergonomics, motivational factors and work place changes according to Convergence Dialogue Meetings (CDM).
2543171|NCT02609750|Active Comparator|Treatment as Usual|Patients follows the PHCs standard schedule and procedures including the so called rehabilitation guarantee
2543213|NCT02609412|Experimental|Static compression of LMTRP|static compression of most sensitive LMTRP with the foam roll for 90 seconds
2543219|NCT02609412|Experimental|Dynamic self-myofascial release of calf|dynamic self-myofascial release rolling back and forth on the entire calf for 90 seconds with the foam roll
2543222|NCT02609412|Placebo Comparator|Placebo laser acupuncture of LMTRP|placebo laser acupuncture applied on most sensitive LMTRP of the calf, light and acoustic sounds provided, but laser remains switched off, 90 seconds
2543236|NCT02609230|Experimental|A|For the first arm (A), dose escalation will use the following single patient dose-escalation cohorts based on 'Design 4' proposed by Simon and colleagues: 125, 250, and 500 mg. every 3 weeks.
2542812|NCT02612233|Active Comparator|Pregabalin|Pregabalin 150mg ON week 1 increased to Pregabalin 300mg ON weeks 2-11 then decrease to Pregabalin 150mg ON week 12 then STOP
2542822|NCT02612233|Active Comparator|Duloxetine|Duloxetine 30mg ON week 1 increase to Duloxetine 60mg weeks 2-11 then decrease to Duloxetine 30mg ON week 12 then STOP
2542832|NCT02612233|Placebo Comparator|Placebo|1 capsule ON week 1- increase to 2 capsules ON week 2-11 then decrease to 1 capsule ON week 12 then STOP.
2542967|NCT02611245|Experimental|Indocyanine green|This group of patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. Before systematic lymphadenectomy, four-point of ICG with 10mg was injected in normal lung tissue around the tumor. After 3-5 minutes, fluorescence and white-light images were collected and recorded in real-time. With the guidance of intraoperative images, all fluorescent lymph nodes were removed and sent to routine pathological confirmation.
2542990|NCT02610907|Experimental|Cohort 01a|"This is a sub-study testing three patches consisting of an adhesive patch and a sleeve. The sleeve can contain one of three solutions:~Buffer Own output Simulated output (digestive enzymes)~All subjects will test the three solutions at the same time, hence the three patches with different solutions will be placed on the peristomal skin simultanously."
2543030|NCT02610751||Non-smoking|No interventions were applied to this group. Measurements of female fetal testosterone, maternal cotinine and testosterone levels, newborn anogenital distance, second digit to fourth digit (2D:4D) finger length ratio, newborn length and birth weight are collected.
2543061|NCT02610790||Connected bracelet|Patients with a colorectal surgery planned will be included. Fifteen days before surgery, patients will have a connected bracelet permitting to quantify the number of steps and distance achieved each day before surgery.
2543083|NCT02610283|Active Comparator|QPI-1002|QPI-1002 Injection, single dose
2543087|NCT02610283|Placebo Comparator|Placebo|isotonic saline
2543112|NCT02610036||neuropathic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
2543116|NCT02610036||neuroischemic type 2 diabetic patients|the foot ulcer of 30 neuropathic and 30 neuroischemic type 2 diabetic patients
3168628|NCT00553241||1|"Dept. of Neurology, Beijing Anzhen Hospital, Capital Medical University Beijing 100029, P.R.China~Every patient admitted to Beijing anzhen hospital with transient ischemic attack will be enrolled in this study, from 06/2007 to 12/2008. duration of the symptom not larger than 1 hour."
3168629|NCT00553293|Active Comparator|A,1|rFSH + rLH arm
2543154|NCT02609867|Experimental|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter (TaeWoong Medical Co., Ltd. Korea)
2543178|NCT02609594|Active Comparator|Standard of Care|Subjects randomized to this group will receive standard of care (multi-layer compression therapy).
2543180|NCT02609594|Experimental|Weekly application of Amnioband|Weekly application of Amnioband plus standard of care.
2543181|NCT02609594|Experimental|Biweekly application of Amnioband|Biweekly application of Amnioband plus standard of care.
2543198|NCT02609568||Control Group 1|Children with non-trauma complaints
2543200|NCT02609568||Control Group 2|Children with non TBI and musculoskeletal trauma
2543203|NCT02609568||Cases|Children admitted to hospital with moderate/severe isolatedTBI
2543237|NCT02609243|Active Comparator|intensive consulting, conventional diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat ) - dietary intervention without supplement
2543239|NCT02609243|Active Comparator|conventional consulting, low-carb diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
2543241|NCT02609243|Active Comparator|conventional consulting, conventional diet|subjects receive 8 units of nutritional consulting, first 3 weeks of intervention phase are designed as a conventional hypocaloric low-fat diet referring to DGE guidelines (below 30 % fat), followed by 11 months of isocaloric-to-moderate-hypocaloric low-fat diet (below 30 kcal% fat) - dietary intervention without supplement
2543243|NCT02609243|Active Comparator|intensive consulting, low-carb diet|subjects receive 16 units of nutritional consulting, first 3 weeks of intervention phase are designed as a very-low calory ketogenic (low-carb) diet (< 40 g CH / day), following 11 months are restricted to not more than 40 % energy intake by carbohydrates under isocaloric-to-moderate-hypocaloric conditions - dietary intervention without supplement
2543252|NCT02609269||Decipher GRID Patients|Patients who have been tested with any of the Decipher suite of genomic solutions.
2543299|NCT02608996|Active Comparator|Subcutaneous BNP|Patients will receive gradually increasing doses (10-25 µg/kg) of subcutaneously administered nesiritide (BNP) twice daily for two days, to determine the feasibility, safety and blood pressure lowering effect of BNP so as to identify the optimal dose.
2543300|NCT02608996|Placebo Comparator|Subcutaneous placebo|Patients will receive subcutaneously administered placebo twice daily for two days for determination of the effect of BNP.
2543321|NCT02608853||Liraglutide-like Cohort|
2543323|NCT02608853||LEADER™-like Cohort|
2543481|NCT02608073|Experimental|Capecitabine + Cisplatin|Participants with metastatic nasopharyngeal cancer will receive combination treatment with capecitabine (1000 milligrams per meter square [mg/m^2] tablets twice daily [BID] orally) and cisplatin (100 mg/m^2/day intravenous [IV] infusion) for up to 8 cycles.
2543537|NCT02607566|Experimental|Iyengar Yoga|Iyengar Yoga Intervention twice weekly for 60 minutes for 12 weeks.
3168630|NCT00553293|Placebo Comparator|A,2|rFSH alone
3168631|NCT00553306|Experimental|Arm I|Beginning 48 hours before T-cell infusion, patients receive cyclophosphamide IV. Patients then receive antigen-specific CD8+ T cells IV alone or with CD4+ T helper clones over 1-2 hours on day 0. Patients also receive aldesleukin subcutaneously twice daily on days 0-13. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3168632|NCT00553397||Live Lung Donors|Participants had a living donor lobectomy at one of the two participating study centers, the University of Southern California and the Washington University Medical Center between 1993 and 2006.
2542814|NCT02612142|Experimental|aerobic exercise (AE)|Intervention type: Behavioral. Intervention name: Aerobic exercise Intervention description: 10 days of daily aerobic exercise (brisk walking, jogging); duration: 30 minutes per session; intensity: 65%-75% of age-predicted maximal heart rate. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
2542826|NCT02612142|Sham Comparator|stretching exercise (ST)|Intervention type: Behavioral. Intervention name: Stretching exercise Intervention description: 10 days of daily stretching exercise; duration: 30 minutes per session. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
2542835|NCT02612142|No Intervention|no intervention (NI)|No behavioral intervention. All participants were treated with either paroxetine (20-50mg/day), fluoxetine (20-80mg/day) or bupropion (100-200mg/day).
3203112|NCT00920348||Group 1|COPD moderate-severe(GOLD2-4)(post-BD FEV1/FVC<0.70 and FEV1<80% of pred.)
3203113|NCT00920348||Group 2|COPD mild (GOLD1)(post-BD FEV1/FVC<0.70 AND FEV1>=80% of pred.)
2543153|NCT02609854|Experimental|Sham Sustained Acoustic Medicine Device|Sham Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
2543155|NCT02609854|Experimental|3 MHz Sustained Acoustic Medicine Device|3 MHz Sustained Acoustic Medicine device - the device is to be used 4 hours/day, ≥4 days per week for 8 weeks.
2543192|NCT02609542||STOL group|"STOL children will be recruited in the neuropediatric unit at the GHICL in Lille. Children will be followed and we will determine if capacities of verbal memory of the children presenting STOL diagnosed at an early stage of their development (before 6 years) are predictive of the evolution of the disorder according to their cognitive profile and more specifically, their language profile as well as their tests performances. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.~Patients with a persistent STOL will be identified at the end of the follow up."
2543196|NCT02609542||Control group|Children with no language development disorder willing to participate in the study will be recruited at school. The participants' eye movements ( visual world paradigm or eye tracking) will be recorded in order to determine the interplay between linguistic and visual information processing.
2543238|NCT02609230|Experimental|B|Following completion of Arm A dose escalation, subsequent cohorts will be tested in a minimum of 3 patients, the Arm B dose cohort will consist of dose levels administered every week (planned dosing of 250, 375, 500 and 625 mg).
3203114|NCT00920348||Group 3|COPD at risk (ever smoker with post-BD FEV1/FVC>=0.70)
2543287|NCT02609048|Placebo Comparator|Placebo Dose|Placebo Capsule Two Capsules Daily
2543291|NCT02609048|Experimental|Seladelpar / MBX-8025 50 mg Dose|MBX-8025 50 mg capsule One Capsule Daily
2543294|NCT02609048|Experimental|Seladelpar / MBX-8025 200 mg Dose|MBX-8025 100 mg capsules (2 taken once daily)
2543317|NCT02608762||pediatric/adolescent patients with brain tumors|A prospectively recruited of newly-diagnosed pediatric/adolescent patients with brain tumors or head/neck cancers
2543364|NCT02608502|Experimental|Treatment Group A|RSV-F Vaccine (0.5mL Injection)
2543365|NCT02608502|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
3203115|NCT00920348||Group 4|"Healthy control never smokers without respiratory disease (post-BD FEV1/FVC>=0.70."
3203116|NCT00920361||1|Patients who underwent IVF
2543453|NCT02607904|Experimental|GWP42003-P|"Administered orally, twice daily (morning and evening), commencing with titration of 100 mg/mL GWP42003-P to 20 mg/kg/day over 10 days in a blinded manner (i.e., only participants taking placebo in the blinded phase will up-titrate; doses will remain unchanged for those taking GWP42003-P in the blinded phase).~Participants remain on the maintenance dose for the remainder of the 48-week treatment period, until early withdrawal or at an early study conclusion date defined by the sponsor. However, investigators may subsequently decrease or increase the participant's dose (to a maximum of 30 mg/kg/day) until the optimum dose is found.~Dosing is tapered (10% each day) for participants who do not immediately continue to use GWP42003-P once market authorization is granted, or for those who withdraw early."
2543518|NCT02607696|Experimental|Zolpidem 1.75 mg|Zolpidem Hemitartarate 1.75 mg Orodispersible Tablets Once daily
2543522|NCT02607696|Experimental|Zolpidem 3.50 mg|Zolpidem Hemitartarate 3.50 mg Orodispersible Tablets Once daily
2543535|NCT02607527|Other|Device Implantation|Transcatheter IRIS placement
2543543|NCT02607436|Experimental|Sarpogrelate + Aspirin|Sarpogrelate as an active drug
2543544|NCT02607436|Active Comparator|Aspirin alone|Aspirin as an active comparator
2543567|NCT02607293||Subjects undergoing ART treatment with long GnRH-a or GnRH-ant|Subjects undergoing ART treatment with long GnRH-a protocol or GnRH-ant protocol + Gn + human chorionic gonadotropin (hCG) as per routine clinical practice. No visits or intervention(s) additional to the routine practice of the Investigators will be performed during this observational study.
2543590|NCT02607176|Experimental|Heweizhixie capsule|Heweizhixie capsule, 0.33g/#, 3 #, Tid, Oral
3203119|NCT00920413|Active Comparator|vitamin C|vitamin C 500mg orally once a day
3203120|NCT00920413|Placebo Comparator|placebo|
3203121|NCT00920465|Experimental|one-visit|
3203122|NCT00920465|Active Comparator|two-visit|
3203123|NCT00920478|Active Comparator|Control Group|Inflammatory disease activity assessed using DAS28
3203124|NCT00920478|Experimental|Ultrasound Group|Inflammatory disease activity assessed using musculoskeletal ultrasound (gray scale and power doppler)
3203125|NCT00920491||patients with non-specific complaints|patients who do not have specific presenting symptoms (e.g. dyspnea, chest pain etc.)
3203126|NCT00920504|Experimental|German PRO-SELF(c) Plus PCP|Group receives 10 weeks German PRO-SELF(c) Plus PCP intervention program
3203127|NCT00920504|Active Comparator|Standard Care|control group receives attention control and standard care
3203128|NCT00920517|Active Comparator|1|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 180
2542815|NCT02612103||Active Crohns disease|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index > 4.
2542825|NCT02612103||Crohns disease in remission|Verified Crohns disease diagnosis according to clinical, endoscopic and histological standard criteria and Harvey Bradshaw index ≤ 4.
2542836|NCT02612103||Active ulcerative colitis|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index > 3.
2542843|NCT02612103||Ulcerative colitis in remission|Verified ulcerative colitis diagnosis according to clinical, endoscopic and histological standard criteria and Simple Clinical Colitis Activity Index ≤ 3.
2542849|NCT02612103||Irritable bowel syndrome|Verified irritable bowel syndrome according to standard criteria.
2542851|NCT02612103||Healthy controls|No known chronic diseases which needs continuously medication.
2542918|NCT02611804|Experimental|Diclofenac Sodium Gel, 3%|Diclofenac Sodium Gel, 3%, applied twice daily for 60 days
2542920|NCT02611804|Active Comparator|Solaraze®|Solaraze® (diclofenac sodium) Gel, 3%, applied twice daily for 60 days
2542922|NCT02611804|Placebo Comparator|Vehicle of Test Product|Vehicle of Test Product, Gel, applied twice daily for 60 days
3203129|NCT00920517|Active Comparator|2|Participants will receive 1 injection of rDEN2/4delta30(ME) or placebo vaccine on Days 0 and 120
2543050|NCT02610543|Experimental|UCB5857|UCB5857 once daily for 12 weeks
2543054|NCT02610543|Placebo Comparator|Placebo|Placebo once daily for 12 weeks
3203130|NCT00920530||Real time PCR monitoring|Women giving birth at the St Etienne Teaching Hospital
2543218|NCT02609438|Active Comparator|Short breaks|Participants instructed to stand/move for 1-2 minutes every half hour throughout the workday
2543220|NCT02609438|Active Comparator|Long breaks|Participants instructed to take two 15-minute activity breaks during each workday
2543255|NCT02609347|Experimental|Manual Therapy Group|Participants in the manual therapy group will receive 3 treatment sessions of joint mobilization based on the physical therapist's clinical decision making.
2543256|NCT02609347|Sham Comparator|Control Group|Participants in the control group will receive a sham manual therapy treatment consisting of soft tissue mobilization and Grade I mobilizations at the proximal tib/fib joint.
2543264|NCT02609139|Experimental|<=400mg Modified Release Tablets, Fasted|Up to 400 mg PF-06650833 modified release tablets administered under fasted conditions
2543265|NCT02609139|Experimental|100mg Modified Release Tablets, Fasted|100 mg PF-06650833 modified release tablets administered under fasted conditions
2543266|NCT02609139|Experimental|20mg Modified Release Tablets, Fasted|20 mg PF-06650833 modified release tablets administered under fasted conditions
2543267|NCT02609139|Experimental|<= 400mg Modified Release Tablets, Fed|Up to 400 mg PF-06650833 modified release tablets administered with high fat meal food intake
2543268|NCT02609139|Experimental|100mg Modifed Release Tablets, Fed|100 mg PF-06650833 modified release tablets administered with high fat meal food intake
2543269|NCT02609139|Experimental|20mg Modified Release Tablets, Fed|20 mg PF-06650833 modified release tablets administered with high fat meal food intake
2543308|NCT02608749|Experimental|IC|Integrated care (IC)
2543310|NCT02608749|Experimental|LEE|Lower extremity exercise (LEE)
2543312|NCT02608749|Experimental|HC|Home care (HC)
2543320|NCT02608866|Experimental|SF-SSRS|Single-Fraction (SF) Stereotactic Spine Radiosurgery
2543322|NCT02608866|Experimental|MF-SSRS|Multiple-Fraction (MF) Stereotactic Spine Radiosurgery
2543384|NCT02608411|Experimental|ARQ-197|ARQ-197 360 mg twice/day by mouth (PO), with meals, continuously as maintenance treatment until disease progression or unacceptable toxicity.
2543434|NCT02608125|Experimental|PRN1371|Drug: PRN1371
2543471|NCT02608047||dengue patients|Dengue patients confirmed by Non-structural protein and RNA
2543476|NCT02608047||Healthy controls|Healthy population without any diseases
2543484|NCT02607826|Experimental|Intervention arm|
2543487|NCT02607826|No Intervention|Standard of Care|
2543517|NCT02607657|Experimental|Eplerenone 25 mg|Eplerenone 25 mg Tablet Oral Once daily
2543519|NCT02607657|Experimental|Eplerenone 50 mg|Eplerenone 50 mg Tablet Oral Once daily
2543521|NCT02607657|Experimental|Eplerenone 100 mg|Eplerenone 100 mg (2 tablets of 50 mg) Tablet Oral Once daily
2543524|NCT02607657|Experimental|Eplerenone 50 mg x 2|Eplerenone 50 mg Tablet Oral Twice daily
2543525|NCT02607657|Experimental|Eplerenone 25 mg x 2|Eplerenone 25 mg Tablet Oral Twice daily
3203131|NCT00920543|Active Comparator|Fluticasone propionate|
3203132|NCT00920543|Active Comparator|Fluticasone propionate/salmeterol combination|
3203133|NCT00920582|Experimental|1|
2543571|NCT02607358||Clopidogrel|Clopidogrel non-responders (HOTPR) Blood sampling for HOTPR-testing
2543573|NCT02607358||Acetacylicacid|Acetcylicacid non-responders (HOTPR), Blood sampling for HOTPR-testing
3203134|NCT00920582|Experimental|2|
2543644|NCT02606981|Experimental|Chlorination|Device: Water chlorination by the Flogenic Primary drinking water source will be outfitted with automatic dosing device supplied with chlorine tablets. The device is called the Flogenic.
2543645|NCT02606981|Placebo Comparator|Control|Active control: Vitamin C dosing into water. Primary drinking water source will be outfitted with automatic dosing device supplied with vitamin C tablets. The device is not commercially available.
2543675|NCT02606383|Experimental|Dapaconazole|Dapaconazole 2% Cream Topical
2543677|NCT02606383|Active Comparator|Ketoconazole|Ketoconazole 2% Cream Topical
3203135|NCT00920582|Experimental|3|
3203136|NCT00920582|Placebo Comparator|4|
3203137|NCT00920595|Experimental|1|CEP-9722 alone and in combination therapy with temozolomide.
3203138|NCT00920608|Experimental|A|AZD9056 400 mg and Methotrexate
2542817|NCT02612246|Experimental|GLPG1972 single dose|Single oral dose of GLPG1972 solution - ascending doses
2542829|NCT02612246|Placebo Comparator|Placebo single dose|Single oral dose of placebo solution
2542837|NCT02612246|Experimental|GLPG1972 multiple doses|Multiple oral doses of GLPG1972 solution - ascending doses
2542847|NCT02612246|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo solution
3168633|NCT00553423|Experimental|1|Lactulose 30 ml q6h for 48 hrs
3168634|NCT00553423|Placebo Comparator|2|Placebo 30 ml q6 hrly for 48hrs
2542934|NCT02611518|Experimental|Panel 1|Participant will be administered a single oral dose of rosuvastatin 10 milligram (mg) on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 17.
2542936|NCT02611518|Experimental|Panel 2|Participant will be administered a single oral dose of metformin 500-mg on Day 1 and Day 14 and JNJ-54861911 at a dose of 25 mg once daily from Day 8 until Day 16.
2543133|NCT02610166|Experimental|Game|Access to the game.
2543137|NCT02610166|Active Comparator|Usual Care|Control group.
2543244|NCT02609360|Active Comparator|0.9% NaCl|Circuit priming will be performed with 0.9% NaCl solution
2543245|NCT02609360|Active Comparator|Ringer Lactate|Circuit priming will be performed with Ringer Lactated
2543246|NCT02609360|Experimental|Balanced Solution|Circuit priming will be performed with a Balanced Solution created by mixing 0.9% NaCl, Sodium bicarbonate (8.4%) and injectable sterile water, in order to obtain a solution with constant sodium concentration (140 mEq/l) and SID equal to patient's bicarbonate level.
2543289|NCT02608983|Experimental|Treatment 1|
2543292|NCT02608983|Experimental|Treatment 2|
2543296|NCT02608983|Placebo Comparator|Treatment 3|
2543349|NCT02608619||PET Imaging|This study will enroll patients who have a clinical diagnosis of a systemic histiocytic disorder, and who are scheduled to undergo confirmatory biopsies of the systemic lesions, that were identified by standard imaging modalities.
2543368|NCT02608294|Experimental|Experimental Group|Kinesio Taping Procedure application with 35% strain.
2543369|NCT02608294|Sham Comparator|Sham Group|Kinesio Taping Sham procedure application without strain.
2543402|NCT02608203|Experimental|patients with gastroenteropancreatic neuroendocrine tumors|
2543467|NCT02607995||low key intervention|for the whole group
2543469|NCT02608086|Other|Control|"Flyer What can I do facing a crisis?"
2543472|NCT02608086|Experimental|Psychological First Aid|"Psychological First Aid according to an adapted protocol based on the WHO PFA Operation Guide 2012 Brochure Network and Services Flyer What can I do facing a crisis?."
2543502|NCT02607709|Placebo Comparator|Nephroureterektomy|scheduled to receive routine standard open or robot assisted nephroureterectomy without lymphadenectomy
2543504|NCT02607709|Experimental|Nephroureterektomy + Lymphadenectomy|scheduled to received mapped lymphadenectomy in conjugation with nephroureterectomy
2543532|NCT02607553|Experimental|Experimental: G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
2543546|NCT02607449|Experimental|A|Standard TB treatment+ treatment regiment with FS-1 drug. Study drug was given to the patients orally once per day in dose of 2.5 mg/kg along with other prescribed TB drugs.
3168635|NCT00553488|Active Comparator|1|Regular insulin SC at -17 mins
3168636|NCT00553488|Active Comparator|2|Regular insulin ID at -17 mins
3168637|NCT00553488|Active Comparator|3|Regular insulin ID at -2 mins
3168638|NCT00553488|Active Comparator|4|Insulin lispro given SC at -2 mins
3168639|NCT00553488|Experimental|5|Insulin lispro given ID at -2 mins
3168640|NCT00553527|Other|1|Patient will receive standard of care humeral stem replacement. Only a data collection study. There will be no changes in standard of care for diagnosis.
3168641|NCT00553553|Active Comparator|1|IV morphine group
3168642|NCT00553553|Experimental|2|Remifentanil-intrathecal morphine group
3168643|NCT00553579||DE|All subjects will have clinically significant dry eye.
3168644|NCT00553592|Experimental|Drug|Bicifadine
3168645|NCT00553592|Experimental|Drug: 2|Bicifadine
3168646|NCT00553592|Placebo Comparator|Control|Placebo of Bicifadine
3168647|NCT00553618|Experimental|Proleukin/DTIC Arm|Adjucant proleukin and DTIC
3168648|NCT00553670||1|Patients with elective coronary intervention for LAD-diagonal bifurcation lesion with provisional side branch intervention strategy with successful intravascular ultrasound and fractional flow reserve measurement
3168649|NCT00553683|Experimental|poly ICLC|
3168650|NCT00553709|Experimental|Nicotine patch|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
3168651|NCT00553709|Placebo Comparator|Placebo patch|Placebo patch 10 cm2
2542818|NCT02612038|Sham Comparator|Sham expiratory resistance|Sham resistance will be added to the patient's respiratory circuit
2542876|NCT02611791|Experimental|Radiofrequency|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genitalia.
2542882|NCT02611791|Sham Comparator|Radiofrenquency Off|Eight RF sessions were performed, with an interval of seven days between them. The application of Radiofrequency in the external genital which was turned off, but a water-soluble gel was used
2542995|NCT02611050|Experimental|Option Grid|Patients randomized to the Option Grid arm will receive the Multi-vessel Coronary Artery Disease Option Grid at the time of enrollment. The treating physician will then discuss the patient diagnosis and treatment choice reviewing the Option Grid within the conversation to facilitate patient understanding and shared decision making
2542998|NCT02611050|Other|Usual Care|Patients randomized to usual care will discuss the patient diagnosis and treatment options typical to the physician's routine care.
2543025|NCT02610712|Experimental|TRD patients|Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
2543071|NCT02610452|Experimental|The study population|"The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.~Intervention: Clown therapy"
2543191|NCT02609516||Healthy|Patients without any of the pre-specified chronic diseases
2543194|NCT02609516||Multimorbid|Patients having any two or more of the pre-specified chronic diseases
2543240|NCT02609282|Experimental|Prompt group|Following an education session on the health benefits of breaking prolonged sitting, the prompt group will receive hourly prompts on their PC to stand. The prompts will be delivered by Microsoft Outlook and will run for a period of 10 weeks. The messages will be short in length, varied and centre around the key message of breaking prolonged sitting by standing.
2543242|NCT02609282|No Intervention|Control group|The control group will receive the same education session as the prompt group, but will receive no prompts on their PC.
2543273|NCT02609035|Experimental|Intervention|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive a telephonic prompt to get a vaccination.
2543278|NCT02609035|No Intervention|Control|Patients who are either appointment-based medication synchronization calls, refill ready calls, or refill reminder calls at the pharmacy who have been identified as missing at least one vaccination. These patients will receive usual pharmacy care.
2543324|NCT02608736|Experimental|Valproic Acid|Valproic acid will be orally administered in a total dose of 1500mg per day (500mg, every 8 hours), for three months.
2543330|NCT02608736|Placebo Comparator|Placebo|Placebo will be orally administered in a total dose of three capsules per day (every 8 hours), for three months.
2543375|NCT02608424|Experimental|Foot Mechanical Stimulation|"Intervention: Foot Mechanical Stimulation (FMS) will be performed on enrolled patients every 72 hours (total 5 stimulation sessions) by a pressure-controlled mechanical stimulator (Gondola®, European Community (CE) marking n° 0476) .~The sites of the stimulation will be the tip of the hallux and the lower big toe first metatarsal joint plantar surface. The FMS procedure consists in the application of the patient's calibrated pressure for 6 seconds, over the selected sites. Each of the 2 cutaneous sites of both feet will be mechanically stimulated. The procedure will be automatically repeated for 4 times in every subject so that the overall time of stimulation will be approximately 2 minutes."
3168652|NCT00553722|Experimental|Eplerenone|Administer Eplerenone, 25 mg, orally twice daily for 4 weeks.
2543452|NCT02607917|Experimental|Mass Media plus clinic intervention.|These geographic areas will receive the media plus clinic intervention over a two year period.
2543454|NCT02607917|Experimental|Media|These geographic areas will receive the media intervention over a two year period.
2543456|NCT02607917|No Intervention|No Intervention|Adjacent states will receive no intervention.
2543470|NCT02608021||Amnestic mild cognitive impairment|
2543475|NCT02608021||Cognitively normal|
2543509|NCT02607761|Experimental|Intervention Group|2 minutes video with information and images on age-related fertility, infertility definitions, infertility risk factors, probabilities of fecundity according to age and cycle.
2543512|NCT02607761|No Intervention|Control|No intervention
2543515|NCT02607761|Active Comparator|Control 1|2 minutes video with same images but information on work-family balance.
2543516|NCT02607748|Experimental|18F-NaF PET and coronary CTA imaging|18F-NaF PET and coronary CTA imaging
2543540|NCT02607475|Experimental|Robotic telesonography compared to conventional sonography|All participants will receive two imaging studies: (1) Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix), and (2) conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare).
2543570|NCT02607371||Cohort 1 / VKA treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with VKAs for at least three months at date of study inclusion
2543572|NCT02607371||Cohort 2 / NOAC treatment|A sample of about 200 patients with nonvalvular atrial fibrillation who are treated with NOACs for at least three months at date of study inclusion
3168653|NCT00553722|Placebo Comparator|placebo|Administer a placebo tablet orally twice daily for 4 weeks
3168654|NCT00553748|Experimental|I|
3168655|NCT00553774|Experimental|Flavanol|Cocoa Flavanol
3168656|NCT00553774|Placebo Comparator|Placebo|
3168657|NCT00553800|Experimental|Bevacizumab & Erlotinib|bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
3168658|NCT00553852|Experimental|1|The clinical examination will determine anthropometric indexes (weight, height, BMI, waist circumference). The biochemical evaluation will include the measurement of lipid profile, fasting plasma glucose and insulin, liver test function, FT3, FT4, GHRH + Arginine test to detect GHD, plasma IGF-I levels. The instrumental evaluation will include DEXA Total Body and bioimpedance analysis to determine body composition, and liver ultrasounds.
3174189|NCT00620633|Experimental|1|Patients with leukemia or myelodysplastic syndrome (MDS) who, following an HLA-matched allogeneic hematopoietic cell transplant, have relapsed with leukemia as demonstrated morphologically on peripheral blood smear or bone marrow aspirate
2542819|NCT02611999|No Intervention|Control|Physicians in this Arm received only a paper memo with a list of common imaging tests and procedures.
2542828|NCT02611999|Experimental|Single Price|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
2542840|NCT02611999|Experimental|Paired Inside/Outside Prices|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
3203139|NCT00920634||1|Patients with anovulation and oligoovulation due to hypothalamus-pituitary dysfunction (amenorrhea first grade, anovulatory cycle, polycystic ovary syndrome, oligoamenorrhea) who underwent ovulation induction
3203140|NCT00920660|Experimental|Treatment Group|"Subjects will be required to attend the research unit in a fasted state (at least 10 hours without food) on six separate occasions (treatment visits) during the study. At approximately the same time every morning, subjects will consume a standard, non-high-fat meal (approximately 650 kcal with 30% of calories derived from fat). Test material (per treatment) will be administered within 15-30 minutes following the meal. There will be at least a 7-day washout period between treatment visits.~During the first five treatment visits, subjects will receive one of the following treatments in the form of 8 capsules: 0.25g SRT2104, 0.5g SRT2104, 1g SRT2104, 2g SRT2104, or placebo.~During the last treatment visit, subjects will receive 30 mg of open-label prednisolone tablets."
2543062|NCT02610517|Other|Provider Training|Training providers to offer alcohol pharmacotherapy to at-risk drinkers interested in quitting or reducing their drinking as part of overall HIV care could be an important strategy to reduce hazardous alcohol use in this medically-ill population.
2543063|NCT02610517|Other|Patient Intervention|Determine the effectiveness of a computer-delivered brief intervention (CBI) for reducing hazardous drinking in the HIV clinical care setting at two intervention clinics: University of Alabama at Birmingham (UAB) and the University of Washington (UW).
2543107|NCT02610179|Active Comparator|Standard Glucola GCT|A prospective cohort of 617 women who will undergo screening for gestational diabetes with the standard glucola GCT between 24 and 28 weeks gestational age.
2543108|NCT02610179|Experimental|Twizzlers challenge|At a later date, the same prospective cohort of 617 women Participants will receive their Twizzlers challenge between 24 and 28 weeks gestational age.
2543141|NCT02609893|Active Comparator|Modified Directly Observed Therapy|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) observed daily dosing (modified for non-observed Saturday and Sunday dosing) for 8 weeks
2543143|NCT02609893|Active Comparator|Unobserved Dosing|Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV-SOF) tablet (LDV 90mg/SOF 400mg) provided weekly (7 tablets) for unobserved daily dosing for 8 weeks
2543185|NCT02609620|Experimental|Treatment|In the treatment group: The LunGuard Peristaltic Feeding Tube (PFT) will be positioned in the ICU and positioning will be verified by X-ray. Nutritional formula will be fed into the stomach via the feeding lumen of the PFT
2543187|NCT02609620|Active Comparator|Control|Patients in the control group will have a Convatec Levin Duodenal Tube inserted according to standard procedure, which is considered the gold standard.
3203141|NCT00920712|Experimental|Weiqi decoction|
3203142|NCT00920712|Placebo Comparator|low dose of Weiqi decoction|
2543327|NCT02608593||Implant reconstruction with Strattice|Women having immediate breast reconstruction with partial or total Strattice cover
2543332|NCT02608593||Implant reconstruction without Strattice|Women having immediate implant based breast reconstruction where no Strattice has been used
2543409|NCT02608164|Active Comparator|Vitamin D oral spray solution|An oral spray solution containing 3000IU (75micrograms) vitamin D3 per spray
2543415|NCT02608164|Active Comparator|Vitamin D capsules|A capsule containing 3000IU (75micrograms) vitamin D3 per capsule
2543520|NCT02607644|Experimental|Laryngeal Tube (LT)|VBM Laryngeal Tube (Intervention)
2543523|NCT02607644|Active Comparator|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA)
2543541|NCT02607410|Active Comparator|sitagliptin|100mg every day of sitagliptin in patients that were previosly using metformin and glyburide
2543542|NCT02607410|Active Comparator|NPH insulin|NPH insulin will be applied bedtime every night in patients that awere previously using metformin and glyburide,The insulin dosage will be adjusted to fasting glycemia between 90 and 100 mg / dL
2543559|NCT02607384|Experimental|Vision problems|Children with refractive error will be prescribed eyeglass wearing, and children with convergence insufficiency will be given orthoptic exercises. Children with any other vision problem will be given a specialist referral to a pediatric eye specialist.
2543583|NCT02607202|Experimental|Arm A|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes. Treatment to be repeated Q21 days.
2543587|NCT02607202|Experimental|Arm B|nab-paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration over 30 minutes without premedication, followed by carboplatin AUC 2 on Day 1 and 8 by IV administration over 60 minutes. Treatment to be repeated Q21 days.
2543621|NCT02606786|Experimental|stabilization exercises|Lumbopelvic stabilization exercises have been shown to decrease pain and disability in those with low back pain. The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
2543623|NCT02606812|Experimental|Traditional-food|During the 3 months, a dish containing traditional food will be provided 5 days per week. The food will contain an average of 600 Kcal, ≤ 50 mg of cholesterol, ≥ 10 g of fiber, ≥ 130 g of vegetables, and ≤ de 200 mg of sodium. Each dish will be accompanied with 3 standard-sized corn tortillas.
2543625|NCT02606812|No Intervention|Control|Is the group who will intake the cafeteria fast food. The control group will receive habitually consumed fast food provided by the cafeteria of the campus at a similar caloric proportion.
2543639|NCT02606747||Diabetes mellitus with DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes with DPN.
2543641|NCT02606747||Diabetes mellitus without DPN|Aged from 40 to 80. Normal cognitive ability. Right handed. Able to walk without any other kinds of central nervous system disorder. Confirmed diabetes without DPN.
2543654|NCT02606630|Experimental|ABT-555|ABT-555 will be administered at Visit 4 for Part 2 only
2543698|NCT02606344|No Intervention|Control Group (CG)|
2542820|NCT02612116|Active Comparator|pulverized ticagrelor sublingually|Pulverized ticagrelor 180 mg (Brilique) administered sublingually
2542830|NCT02612116|Active Comparator|pulverized ticagrelor orally|Pulverized ticagrelor 180 mg (Brilique) administered orally
2542838|NCT02612116|Active Comparator|Integral ticagrelor orally|Ticagrelor 180 mg (Brilique) administered orally in integral tablets
2542880|NCT02611661|Other|Stratum 1: Observe|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~No further treatment just observation"
2542886|NCT02611661|Experimental|Stratum 2: Percutaneous ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation"
2542889|NCT02611661|Experimental|Stratum 3: SBRT|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
2542891|NCT02611661|Experimental|Stratum 4: SBRT + Percutaneous Ablation|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Percutaneous ablation can be radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation~The planned SBRT dose will be 30 Gy in 5 fractions of 6 Gy each. It is recommended that each fraction be separated by a minimum of 12 hours and a maximum of 8 days."
2542893|NCT02611661|No Intervention|Stratum 5: Referral for systemic therapy|"PET/MRI within 36 hours of standard of care hepatic radioembolization received off study~Referred for further systemic therapy and are not candidates for further locoregional therapy on study."
2542944|NCT02611375|Experimental|tDCS + FTP group|This group of individuals with tetraplegia will receive transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1). Stimulation at 2mA will be applied for 20 minutes while subjects complete a total of 1 hour of functional task practice (FTP) per session. (Only 20 minutes of functional task practice be be performed with stimulation on). 3 sessions will be completed per week for 4 weeks.
2542949|NCT02611375|Active Comparator|PNSS + FTP group|This group of individuals with tetraplegia will receive peripheral nerve somatosensory stimulation (PNSS) to the median nerve of the primary hand being trained. Stimulation will be set to elicit a sensory - not motor - response. Stimulation will be performed concurrently with the entire functional task practice (FTP) session. 3 sessions will be completed per week for 4 weeks.
2542955|NCT02611375|Active Comparator|sham tDCS + FTP group|This group of individuals with tetraplegia will receive sham transcranial direct current stimulation (tDCS) over the hand area of their primary motor cortex (M1) alongside functional task practice. Stimulation will be briefly turned on at the beginning of FTP and again after 20 minutes of practice in order to create a sham effect and maintain blinding of the participants. 3 sessions will be completed per week for 4 weeks.
2543002|NCT02610959|Experimental|Intervention group|Intervention with cod 200 grams two times the week for four months.
2543004|NCT02610959|Experimental|Control group|Control group which will continue to eat their habitual diet.
2543039|NCT02610686|Other|Chloroquine|Single treatment arm
2543095|NCT02610335|Active Comparator|Control group (C)|Kyphosis reeducation + patient education + auto-reeducation at home
2543098|NCT02610335|Other|Test group (M)|Spinal mobility reeducation + patient education + auto-reeducation at home.
2543140|NCT02609971|Experimental|Vibration group|The vibration group (Vibration at 50 Hz) will hold an exercise protocol on the vibration platform (model Power Plate® pro5 ™), which is to stay on on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
2543144|NCT02609971|No Intervention|Control group|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on affected limb, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
2543251|NCT02609373|Other|Sleep intervention|Sleep intervention
2543304|NCT02608931|Experimental|Dranabinol Capsules|The initial dose will be 2.5 mg BID (5 mg/day), and the maximum dose will be 10 mg TID (30 mg/day).
2543305|NCT02608931|Placebo Comparator|Placebo Capsules|placebo
2543357|NCT02608554|Experimental|Taichi|The 24 forms of simplified TCC recommended as the popular health sport by the General Administration of Sport of China were applied.
2543363|NCT02608554|Active Comparator|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise.
2543367|NCT02608255|Experimental|acute coronary syndromes|
2543428|NCT02608320|Experimental|Treatment Sequence (CAB) Position (LRL)|Participants will receive treatment C applied to left paraspinal side in period 1, then treatment A applied to right paraspinal side in period 2 and then treatment B applied to left paraspinal side in period 3.
2543430|NCT02608320|Experimental|Treatment Sequence (ABC) Position (LRL)|Participants will receive treatment A applied to left paraspinal side in period 1, then treatment B applied to right paraspinal side in period 2 and then treatment C applied to left paraspinal side in period 3.
2543433|NCT02608320|Experimental|Treatment Sequence (DFE) Position (RLR)|Participants will receive treatment D (Duragesic 100 mcg/h) applied to right paraspinal side in period 1, then treatment F (aged JNJ-35685-AAA-G021 100 mcg/h) applied to left paraspinal side in period 2 and then treatment E (new JNJ-35685-AAA-G021 100 mcg/h) applied to right paraspinal side in period 3.
2543435|NCT02608320|Experimental|Treatment Sequence (EDF) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
2543437|NCT02608320|Experimental|Treatment Sequence (FED) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
3203143|NCT00920725|Active Comparator|Subcutaneous Insulin|Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours
3203144|NCT00920725|Active Comparator|IV Regular Insulin|Intravenous Regular Insulin 0.1 units/kg/hour
2542904|NCT02611557|Other|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
2542961|NCT02611388|Experimental|2/10HZ TEAS pretreatment|Patients were given 30min of 2/10HZ TEAS before anesthesia
2542963|NCT02611388|Experimental|10/50HZ TEAS pretreatment|Patients were given 30min of 10/50HZ TEAS before anesthesia
2542966|NCT02611388|Sham Comparator|fake stimulation|Patients were only attached electrodes without electric current
2542989|NCT02610920|Experimental|Iron-tracer Injection and Biopsy|Single injection of 30mg of iron sucrose followed by axillary ultrasound-guided biopsy of lymph node within 2 hours.
2543035|NCT02610764|Experimental|Experimental diagnostic test|"Evaluation and enumeration of circulating Tumor cells from the blood with two different CTC-detection platforms: one established test (CellSearch) and one experimental test (ScreenCell).~Control diagnostic test: CT-Scan of the Chest and the Abdomen, Endoscopy and Endosonography, Clinical response and histo pathologic response. (% Of vital tumor Cells in the histologic specimen)."
2543070|NCT02610387|Active Comparator|Arm 1:tDCS|Transcranial direct current stimulation (tDCS) Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days
2543072|NCT02610387|Sham Comparator|Arm 2: Sham tDCS|Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days
2543106|NCT02610153||Cohort 1|Adult patients, diagnosed with no-valvular atrial fibrillation and who have recently initiated or are going to initiate VKA treatment, that attend the Cardiology Units
2543132|NCT02609906|Other|PhilosTM with augmentation (Depuy-Synthes)|The intervention group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)
2543136|NCT02609906|Other|MultiLoc®-Nail (Depuy-Synthes)|The comparison group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
2543177|NCT02609737|Experimental|68Ga-DOTA-JR11 and 177Lu-DOTA-JR11|Pts get a PET/CT study with approx.150-200 MBq of 68Ga-DOTA-JR11. Lesions with focal radiotracer uptake not explained by physiologic sstr2 expression will be interpreted as metastatic disease. If 68Ga-DOTA-JR11 uptake by metastases with a diameter of more than 2 cm is less than the physiologic radiotracer uptake by the liver, no further imaging & therapy will be performed as part of the study, as it is unlikely that pts with this low radiotracer uptake will benefit from PRRT (2). All other pts will undergo a dosimetric study with 1850 MBq (less than 100 μg peptide) of 177Lu-DOTA-JR11. Results of the dosimetry study, will determine the balance of activity of 177Lu-DOTA-JR11 that can be administered without exceeding the radiation dose limits. This activity will be split into 2 equal amounts to be delivered in 2 cycles, approximately 3 months apart. After each therapy cycle, pts will be followed clinically for 3 months.
3203145|NCT00920725|Active Comparator|Intravenous Novolog Insulin|Intravenous Novolog Insulin 0.1 units/kg/hour
3203146|NCT00920738||Cancer Survivors|Subjects who are cancer survivors must have survived childhood cancer (diagnosed < or = 18 years) for a minimum of 5 years and be in remission.
2543295|NCT02608957|Experimental|Latella Knee Implant System|
2543358|NCT02608632|Experimental|Group 1 (RDN guided by HFS)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access. After that high-frequency stimulation (HFS) was used before the initial and after each radiofrequency (RF) delivery within the renal artery. RDN was considered to have been achieved when the sudden increase of blood pressure (> 15 mm Hg from invasive arterial monitoring) was eliminated in response to HFS.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery."
2543362|NCT02608632|Active Comparator|Group 2 (RDN as standard procedure)|"Renal arteries were assessed for suitability of ablation by renal angiography. The real-time 3-dimensional aorta-renal artery maps were reconstructed with the use of navigation system and ablation catheter via femoral artery access.~RF ablations of 8-12 watts (impedance drop >10%) were applied discretely from the first distal main renal artery bifurcation all the way back to the ostium. The duration of each RF delivery was 60-120 sec, and up to 6 lesions (separated by > 5 mm) were performed both longitudinally and rotationally within each renal artery. High-frequency stimulation (HFS) was performed before and after RDN to just to verify the response of BP"
2543374|NCT02608242|Experimental|YH22189|YH22189 FDC tablet of Yuhan Corporation
2543380|NCT02608242|Active Comparator|Twynsta 80/10mg|Telmisartan/Amlodipine 80/10mg (FDC)
2543388|NCT02608242|Active Comparator|Crestor 20mg|Rosuvastatin 20mg
2543438|NCT02608320|Experimental|Treatment Sequence (EFD) Position (RLR)|Participants will receive treatment E applied to right paraspinal side in period 1, then treatment F applied to left paraspinal side in period 2 and then treatment D applied to right paraspinal side in period 3.
2543442|NCT02608320|Experimental|Treatment Sequence (FDE) Position (RLR)|Participants will receive treatment F applied to right paraspinal side in period 1, then treatment D applied to left paraspinal side in period 2 and then treatment E applied to right paraspinal side in period 3.
2543443|NCT02608320|Experimental|Treatment Sequence (DEF) Position (RLR)|Participants will receive treatment D applied to right paraspinal side in period 1, then treatment E applied to left paraspinal side in period 2 and then treatment F applied to right paraspinal side in period 3.
2543444|NCT02608320|Experimental|Treatment Sequence (DFE) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
3203147|NCT00920738||Healthy Siblings of Cancer Survivor|Healthy populations similar in age and gender distribution, derived from a frequency matched control population of 350 healthy siblings.
3203148|NCT00920751|Experimental|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
3203149|NCT00920751|Active Comparator|Air insufflation|Conventional air insufflation colonoscopy
2542823|NCT02612090|Active Comparator|Active Treatment Beverage|Strawberry
2542834|NCT02612090|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
2542879|NCT02611739|Experimental|Intervention Group|"Children in the experimental treatment condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a pre-programmed series of behaviours to distract the child before, during, and after the SCP needle insertion. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
2542883|NCT02611739|Active Comparator|Control Group|"Following consent and randomization, children in the (control) usual care condition will sit in front of the nurse and beside (or on the lap) of a parent. Medi-Port (humanoid robot) will be positioned beside the child (at eye-level) and will execute a standard set of dancing movements only. The nurse will insert the needle according to hospital procedures, using minimal distraction (e.g., What's on TV?). The estimated time for port procedures and completion of the needle insertion will range from 10-30 minutes. The total estimated time which includes the completion of surveys and questionnaires on the pain intensity of the SCP needle insertion procedure and acceptability of Medi-port will be approximately 1 hour. There will be no follow-up visits."
2542984|NCT02611466|Experimental|ASP7962|Participants receive 100 mg of ASP7962 orally twice daily for 4 weeks.
2542986|NCT02611466|Active Comparator|Naproxen|Participants receive 500 mg of naproxen orally twice daily for 4 weeks.
2542988|NCT02611466|Placebo Comparator|Placebo|Participants receive placebo orally twice daily for a period of 4 weeks.
2543051|NCT02610530||Non-Surgery|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2 who have been on medical treatment for glycemic control.
2543055|NCT02610530||Surgery-A|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with ileal transposition
2543056|NCT02610530||Surgery-B|Overweight diabetic, type 2 diabetes diagnosis longer than 3 years; BMI:25-29.9 kg/m2. who underwent sleeve gastrectomy with transit bipartition
2543079|NCT02610257|Active Comparator|Vibration Relevant|Vibration applied on the muscle belly after 'motor block' onset
2543082|NCT02610257|Active Comparator|Neutral Vibration Relevant|Vibration applied on a bony mark after 'motor block' onset
2543086|NCT02610257|Active Comparator|Neutral Vibration Non-Relevant|Vibration applied on a bony mark before 'motor block' onset
2543090|NCT02610257|Active Comparator|Vibration Non-Relevant|Vibration applied on the muscle belly after 'motor block' onset
2543092|NCT02610257|No Intervention|No Vibration|
2543114|NCT02610049|Active Comparator|Control|Subjects will receive 8 sessions of Cognitive Processing Therapy.
2543118|NCT02610049|Experimental|Experimental|Subjects will receive 8 sessions of CPT + Art Therapy 8 sessions of individual therapy.
2543121|NCT02610049|Experimental|Experimental 2|Subject to receive 8 sessions of individual therapy for Art + CPT Cognitive Processing Therapy intervention pre-specified to be administered separately.
2543163|NCT02609802|Experimental|Sevoflurane|Anesthesia was maintained with sevoflurane.
2543164|NCT02609802|Experimental|Desflurane|Anesthesia was maintained with desflurane.
2543206|NCT02609464|Active Comparator|Inturrupted Knotte Sutures|
2543207|NCT02609464|Active Comparator|Barbed Sutures|
2543247|NCT02609256|Experimental|Stereotactic infarct tissue aspiration|Patients receive the stereotactic infarct tissue aspiration 24-48 hours after cerebral infarction beside medical therapy.
2543248|NCT02609256|Sham Comparator|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc;
2543297|NCT02608970|Experimental|BMS-986177|BMS-986177 specified dose on specified days
2543298|NCT02608970|Other|Placebo|Placebo specified dose on specified days
2543353|NCT02608606|No Intervention|oral administration of tacrolimus|Oral administration of tacrolimus (FK506) in the usal dose and measuring plasmatic levels at hours 0, 0.5, 1, 2, 3, 4 and 6. Measuring AUC.
2543354|NCT02608606|Active Comparator|sublingual administration of tacrolimus|sublingual administration of tacrolimus (FK506) in the dose that allows similar plasmatic level at time 0 compared with the oral administration, and measuring plasmatic levels at hours 0, 0.5, 1 , 2, 3 , 4 and 6. Measuring AUC.
2543408|NCT02608281|Other|CEDEM|diagnostic contrast enhanced Dual Energy mammograms after Iodine based contrast media administration compared to CE MRI
2543440|NCT02608112||Participants with Moderate to Severe RA|Participants with moderate or severe RA, naïve to TCZ treatment (IV or SC), and who have no contra-indication to TCZ SC therapy as per the local label are included.
3203150|NCT00920764|Active Comparator|A|
3203151|NCT00920764|Active Comparator|B|
3203152|NCT00920764|Active Comparator|C|
2543565|NCT02607267||laparoscopic Roux en Y Gastric Bypass|patients undergoing LRYGB, being the first surgical treatment for severe obesity
2543568|NCT02607267||laparoscopic Sleeve Gastrectomy|patients undergoing LSG, being the first surgical treatment for severe obesity
2543603|NCT02607020|Experimental|Physical exercise|
2543606|NCT02607020|Active Comparator|Relaxation|
2543624|NCT02606864|Experimental|BAYa2502 without food|Oral intake of a single 120 mg nifurtimox dose under fasted conditions
2543627|NCT02606864|Experimental|BAYa2502 with food|Oral intake of a single 120 mg nifurtimox dose under fed conditions after ingestion of a high calorie and high fat breakfast
3203153|NCT00920764|Placebo Comparator|D|
3203154|NCT00920777|Experimental|8 weeks CBT|
3203155|NCT00920777|Active Comparator|Control group|
3203156|NCT00920777|Experimental|16 weeks CBT|
2542824|NCT02612168|Experimental|All patients|Each patient will have any pigmented lesions (PLs) which are due to be biopsied, two PLs not due for biopsy and one patch of healthy skin photographed. Each will be photographed using three cameras: A standard DSLR and two smartphones with a dermoscopic lens attachment. Photographic images will be analysed by Melanoma Image Analysis Algorithm (MIAA)
2543009|NCT02611076|Experimental|Stop Smoking for Good Intervention in Spanish|Study II: Stop Smoking for Good Intervention in Spanish (SS-SP) will comprise a series of 10 booklets distributed over 18 months, plus additional monthly contacts via 9 supportive pamphlets developed in Study I. Behavioral: Stop Smoking for Good Intervention in Spanish (SS-SP) Assessments will occur at six-month intervals, through 24 months.
2543016|NCT02611076|Active Comparator|Usual Care|Study II: Usual Care (UC) will comprise a single, Spanish-language, smoking cessation booklet developed by the National Cancer Institute (NCI). Behavioral: Usual care (UC) Assessments will occur at six-month intervals, through 24 months.
2543126|NCT02610101|Active Comparator|Traditional SCD Diet|7 subjects will be randomized to a traditional SCD diet
2543127|NCT02610101|Active Comparator|Modified SCD Diet|"7 subjects will be randomized to a modified SCD diet, which includes oatmeal and rice"
2543130|NCT02610101|Active Comparator|Whole Foods Diet|"7 subjects will be randomized to a Whole foods diet without added sugars"
2543190|NCT02609698|Experimental|Coroflex ISAR 3 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 3 months
2543195|NCT02609698|Active Comparator|Coroflex ISAR 6 months DAPT|Patients who have received a Coroflex ISAR stent procedure to treat coronary arterial lesions, and administered the drug for 6 months
2543257|NCT02609191|Experimental|The study population: first 30 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR~Intervention: Second whole body exam using the Stratos DR"
2543258|NCT02609191|Experimental|The study population: last 20 patients|"The study population consists of adult patients referred to the Nuclear Medicine and Medical Biophysics Department of the Nîmes University Hospital for the performance of an osteodensitometric examination.~Intervention: Whole body exam using the Discovery A~Intervention: First whole body exam using the Stratos DR"
2543315|NCT02608840|Experimental|MCI auditory stimulation|MCI patients receiving auditory stimulation during sleep (crossover arm 1)
2543316|NCT02608840|Sham Comparator|MCI sham stimulation|Sham intervention: MCI patients sleeping with headphones but sounds not played (crossover arm 2)
2543318|NCT02608840|Experimental|Older adult auditory stimulation|healthy older adults receiving auditory stimulation during sleep (crossover arm 1)
2543319|NCT02608840|Sham Comparator|older adult sham stimulation|Sham intervention: healthy older adults sleeping with headphones but sounds not played (crossover arm 2)
2543373|NCT02608437|Experimental|SGI-110 and Ipilimumab|SGI-110 in combination with Ipilimumab
2543446|NCT02608320|Experimental|Treatment Sequence (EDF) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
2543448|NCT02608320|Experimental|Treatment Sequence (FED) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
2543449|NCT02608320|Experimental|Treatment Sequence (EFD) Position (LRL)|Participants will receive treatment E applied to left paraspinal side in period 1, then treatment F applied to right paraspinal side in period 2 and then treatment D applied to left paraspinal side in period 3.
2543450|NCT02608320|Experimental|Treatment Sequence (FDE) Position (LRL)|Participants will receive treatment F applied to left paraspinal side in period 1, then treatment D applied to right paraspinal side in period 2 and then treatment E applied to left paraspinal side in period 3.
2543451|NCT02608320|Experimental|Treatment Sequence (DEF) Position (LRL)|Participants will receive treatment D applied to left paraspinal side in period 1, then treatment E applied to right paraspinal side in period 2 and then treatment F applied to left paraspinal side in period 3.
2543465|NCT02607982|Experimental|Concurrent Chemoradiotherapy Arm|Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks. Concurrent paclitaxel (135mg/m², d1) and oxaliplatin (125mg/ m², d1) were administered on Days 1 and Day 29 of radiotherapy.
2543506|NCT02607683|Experimental|XAF5 (concentration A: 0.1%)|Participants will apply XAF5 Ointment (concentration A: 0.1%) to the lower eyelids once daily.
2543508|NCT02607683|Experimental|XAF5 (concentration B: 0.035%)|Participants will apply XAF5 Ointment (concentration B: 0.035%) to the lower eyelids once daily.
2543511|NCT02607683|Placebo Comparator|Placebo|Participants will apply Placebo Ointment to the lower eyelids once daily.
2543617|NCT02606799|No Intervention|Standard Care|intensive care therapy according to international standards and following local SOPs, including fluid therapy, mechanical ventilation, catecholamine therapy and other pharmacotherapy as required
2543619|NCT02606799|Experimental|CytoSorb|all of the above, plus extracorporeal hemadsorption therapy (CytoSorbents Adsorber cartridge) using continuous veno-venous hemofiltration (citrate anticoagulation) CytoSorb cytokine elimination
2542833|NCT02612220|Experimental|Experimental Group|Complete hemostasis will be achieved using BioFoam® Surgical Matrix
2542842|NCT02612220|Active Comparator|Control Group|Complete hemostasis will be achieved without the use of topical agents, using conservative hemostasis
3203157|NCT00920803|Active Comparator|5g SRT501|5.0 g of SRT501 will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, SRT501 will be administered approximately 15-30 minutes following the consumption of a standardized breakfast. On all other days, SRT501 will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of SRT501 administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive SRT501 for a minimum of 10 days and a maximum of 21 days.
3203158|NCT00920803|Placebo Comparator|Placebo|Placebo will be administered once daily as an oral reconstituted powder, for 14 days at the same time each day. On Days 1 and 2, placebo will be administered approximately 15-30 minutes following the consumption of a standardized breakfast to allow for PK sample collection. On all other days, placebo will be administered approximately 15-30 minutes following the consumption of the evening meal. Following the course of placebo administration, subjects will undergo scheduled surgical removal of their metastatic liver disease as well as non-diseased tissue. Due to scheduling and surgical availability, subjects can receive placebo for a minimum of 10 days and a maximum of 21 days.
2543023|NCT02610699|Active Comparator|Smartphone otoscope/Conventional otoscope|Participating clinicians will use a smartphone otoscope for one month followed by a conventional otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
2543024|NCT02610699|Active Comparator|Conventional otoscope/Smartphone otoscope|Participating clinicians will use a conventional otoscope for one month followed by a smartphone otoscope for one month, alternating monthly, for a total of 6 months to examine children between 6 months and 18 years of age who have clinical signs of acute otitis media (AOM).
2543077|NCT02610426||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2543128|NCT02610127||OBIZUR - Prospective Participants|Participants enrolled and treated with Obizur after the prospective study start date
2543131|NCT02610127||OBIZUR - Retrospective Participants|Retrospective chart review of participants treated with OBIZUR from product approval date until prior to the prospective study start date
2543214|NCT02609425|Other|STRATAFIX|Anastomosis of esophagus to stomach
3203159|NCT00920868|Experimental|Dasatinib 50mg|Cohort 1
3203160|NCT00920881||Diabetes|
2543455|NCT02607943|Experimental|Insulin Glargine|subcutaneous long acting basal insulin (insulin glargine) with added short acting regular insulin to correct hyperglycemic events
2543458|NCT02607943|Active Comparator|Regular Insulin|short acting regular insulin pre-meal with added NPH at bed time if start eating
2543510|NCT02607670|Experimental|TAT4 Gel|The participant will apply TAT4 Gel to the nasolabial fold area once daily.
2543514|NCT02607670|Placebo Comparator|Placebo|The participant will apply Placebo Gel to the nasolabial fold area once daily.
2543526|NCT02607787|Experimental|Exercise Group|As well as usual care, this group receive a behavioural change session and intervention information regarding the exercise programme. The home-based walking and strengthening intervention is individually tailored for each participant. They receive a booklet, diary and pedometer to guide them as well as weekly phone calls for 12 weeks to monitor their progress.
2543527|NCT02607787|Other|Control Group|This group attends and participates in the same assessment outcomes as the intervention group and receives usual care for the duration of the study. However they are not given any exercise instructions and do not receive the intervention information until their final assessment at week 24. They are aware of their group allocation throughout the duration of the study.
2543566|NCT02607462|Experimental|PRP|Platelet-rich plasma taken made from centrifuged venous blood.
2543569|NCT02607462|Placebo Comparator|Saline|Sodium chloride 0.9% used as placebo.
2543577|NCT02607345|Active Comparator|Glucomedics®|25gr Glucomedics®
2543578|NCT02607345|Experimental|Zusto®|25gr Zusto®
2543598|NCT02607033|Experimental|Exercise and Weight Loss|Individuals assigned to this group will be asked to complete both the exercise and weight loss intervention for six months
2543599|NCT02607033|Active Comparator|Exercise|Individuals assigned to this group will be asked to complete the exercise intervention for xic months
2543638|NCT02606721||Challenge Subjects|Male or female subjects aged 5 - 35 with suspected food allergy and an upcoming scheduled clinical food challenge
2543646|NCT02606487||CF pulmonary exacerbation group|Patients with cystic fibrosis admitted for inpatient treatment of a pulmonary exacerbation
2543660|NCT02606591|Experimental|Electroencephalograph (EEG) + Testing|Participants complete an electroencephalograph (EEG) cognitive tests, and provide a hair sample shortly after entering the study and again near the end of the school year. Hair sample tested to measure a stress hormone called cortisol.
2543688|NCT02606526|Experimental|Intervention arm: BCG at birth|Infants randomized to this arm will receive an intra-dermal administration of 0.05 ml of BCG vaccine within 24h of birth
2543689|NCT02606227|Experimental|Experimental group:financial incentives|Vouchers for show up + Vouchers at increasing amount to reward tobacco abstinence
2543691|NCT02606526|Active Comparator|Control arm: BCG at 14 weeks of age|Infants randomized to this arm will receive intra-dermal administration of 0.05 ml of BCG vaccine at 14 weeks of age
2543695|NCT02606357|Experimental|HOE901|HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
2543696|NCT02606227|Other|Control group:no financial intervention|Vouchers for show up only, no financial incentive for rewarding tobacco abstinence
2543701|NCT02606214|Experimental|Dose Level 3: 200 mg TBA-354|200 mg TBA-354 for 14 days (two 100 mg once daily)
2543704|NCT02606214|Placebo Comparator|Dose Level 3: Placebo|Placebo cohort for Dose Level 3
2543706|NCT02606331|Experimental|Piezosurgery|In one half of the dental arch, piezosurgery will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
2544225|NCT02602951|Experimental|Control|Pilot subjects
2542841|NCT02611973|Active Comparator|HU + aspirin maintenance|
2542845|NCT02611973|Other|HU + AAG|Observational arm
2542937|NCT02611622|Active Comparator|Arm 1: Control|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the control group will proceed to filling out Demographic Survey and Patient Satisfaction Survey~Once completed, they will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist"
2542940|NCT02611622|Experimental|Arm 2: LUMA ENT™|"Participants will be presented with envelopes labeled with a unique block-randomization code and asked to pick one~Once the participant selects an envelope, the research coordinator will verify whether the code assigns the patient to the control or the intervention group, without the knowledge of the otolaryngologist who will be blinded to participant randomization at this point.~Participants in the intervention group will proceed to viewing the LUMA ENT™ videos pertinent to their thyroid condition using either of the two iPADS (the videos should not last longer than 10 minutes)~Once video viewing is complete, participants will be given the opportunity to discuss any further questions or concerns about their thyroid condition with their otolaryngologist, especially as relates to questions that arise as a result of viewing the video~Subsequently, the participants will proceed to filling out Demographic Survey and Patient Satisfaction Survey"
2542977|NCT02611193|Experimental|Manipulative treatment|Manipulative Treatment
2542979|NCT02611193|Sham Comparator|Simulated manipulative treatment|Simulated manipulative treatment
2543018|NCT02610855|Active Comparator|Spinal Fusion Surgery|The surgical participants recruited from the pediatric orthopaedic clinic and have severe scoliosis curves requiring posterior spinal fusion. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before and one year after spinal fusion surgery.
2543019|NCT02610855|Active Comparator|Brace Treatment|The bracing participants have scoliosis curves that require treatment with a spinal brace for at least the next year. All braces will have monitors to record hours of brace wear, as is current standard of care. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified before bracing and after one year.
2543021|NCT02610855|Other|Control Arm|The control group are participants who do not have scoliosis. Physical activity measured using Tri-axial accelerometers and paraspinal muscle stiffness measured by Shear Wave Elastography (SWUE) ultrasound will be quantified at baseline and one year after enrollment.
2543096|NCT02610491|Placebo Comparator|Placebo|Cellulose
2543099|NCT02610491|Active Comparator|Hesperidin|Citrus peel extract
2543146|NCT02609997|Experimental|Single-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a single-piece IOL
2543147|NCT02609997|Experimental|Three-piece IOL Group|Age-related cataract patients receive in-the-bag implantation of a three-piece IOL
2543186|NCT02609555|Experimental|TEM perineal Rectopexy|TEM perineal rectopexy: triple repair technique , Perineal rectopexy with a polyprolene mesh assisted by TEM technique, postanal repair to close the postanak space then finally anal cerclage to hold the rectum in place for one month.
2543232|NCT02609321|Experimental|Thoracic Paravertebral Block|to identify the thoracic T3, a parallel line 2.5 cm from the spinous process is drawn and in this place the ultrasound sensor is placed. Ultrasonograph image identifies the transverse process, the intercostal cost-transverse ligament, the pleura and lung. We proceed to insert a needle between the two corresponding transverse processes and positions after passing the cost-ligament posterior intercostal and transverse to the parietal pleura. After negative aspiration for blood, 0.5% bupivacaine anesthetic is administered at doses of 1.5 mg/kg slowly. The volume is defined by the anesthesiologist. The injection of anesthetic is displayed, as well as confirmation of the correct location of the needle because the volume injected above pushes the pleura.
2543233|NCT02609321|Active Comparator|Surgical Wound Infiltration|before the close of the skin, it proceeds to infiltrate the subcutaneous tissue and skin with 0.5% bupivacaine at doses of 1.5 mg/kg, generating the widest possible dissemination of the bupivacaine in the surgical area.
2543274|NCT02609074|Experimental|CPC/rhBMP-2|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC/rhBMP-2 microffolds (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
2543279|NCT02609074|Active Comparator|CPC|"All operations were done by doctors titled with associate chief physician or above. Procedures were performed under general anesthesia in a tertiary care medical center.~A minimally invasive internal fixation method had been applied in the surgeries. In brief, the patients with fracture were treated by reduction of fracture first of all, the correction of displacement, and the angle of the deformity, and the use of metal implants were fixed, and the collapse of the cancellous bone was filled with CPC paste (product of Shanghai Rebone Biomaterials Co., Ltd, following the manufacturer's instruction), which was compacted and prevented from filling material into the joint cavity."
2543370|NCT02608671|No Intervention|Continuous skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
2543371|NCT02608671|Experimental|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
3203161|NCT00920894|Experimental|yoghurt type minidrink containing plant stanol ester|
2543632|NCT02606994|Experimental|Oral Defense Toothpaste|The experimental group will brush with Oral Defense Toothpaste three times per day during the study
2543752|NCT02606097|Experimental|regorafenib|regorafenib 160 mg daily, 3 weeks on/1 week off
3203162|NCT00920894|Placebo Comparator|yoghurt type minidrink without plant stanol ester|
3203163|NCT00920933|Experimental|AIN457|
3203164|NCT00920933|Placebo Comparator|Placebo|
2542844|NCT02612051|Experimental|Part A, Cohort 1: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2542848|NCT02612051|Experimental|Part A, Cohort 2: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2542850|NCT02612051|Experimental|Part A, Cohort 3: GSK3008348 1-3000 mcg/Placebo|Healthy subjects will receive single 3 ascending doses of GSK3008348 (ranging from 1 to 3000 microgram [mcg]) and matching placebo by nebulisation in one of the four treatment period according to randomization. There will be washout period of at least 6 days between the doses. Actual doses may involve either an increase or a decrease in the planned dose as well as a repeat of the previous.
2542853|NCT02612051|Experimental|Part B, Cohort 4: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2542854|NCT02612051|Experimental|Part B, Cohort 5: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2542858|NCT02612051|Experimental|Part B, Cohort 6: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2542859|NCT02612051|Experimental|Part B, Cohort 7: GSK3008348/Placebo, IPF, Period 2 PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per cohort 1 to 3) or Placebo in two treatment periods according to randomization. There will be washout period of 6 to 28 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in period 2.
2542861|NCT02612051|Experimental|Part C, Cohort 8: GSK3008348, IPF, PET Scan|IPF subject will receive single dose of GSK3008348 (safe and tolerated dose as per Part B) in two treatment periods. There will be washout period of 6 to 14 days between the doses. Subjects will receive up to three microdose administrations of [18F]-FBA-A20FMDV2 for the PET scanning in both periods.
2542878|NCT02611570||LDCT and follow-up|LDCT(1.5 mSV) at enrollment. If subjects with positive result of LDCT, then subjects will be under surgery, resection or followed by every 3-12 months for their possible occurrence of lung cancer.The frequency of follow-up depends on their pathological status and changes of nodules.
2543036|NCT02610803||Patients with ischemic stroke|Patients admitted with ischemic stroke from August 2008 to April 2011 (Retrospectively defined).
2543064|NCT02610374|Other|Cohort A|HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2543066|NCT02610374|Other|Cohort B|HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2543068|NCT02610374|Other|Cohort C|HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
2543123|NCT02610088|Active Comparator|Dapagliflozin|Dapagliflozin will be started in patient with type 2 diabetes mellitus
2543124|NCT02610088|Active Comparator|Gliclazide|Gliclazide will be started in patient with type 2 diabetes mellitus
2543210|NCT02609451|Experimental|2 weeks|Ileostomy closure after 2 weeks
2543217|NCT02609451|Experimental|12 weeks|Ileostomy closure after 12 weeks
2543277|NCT02609152|Experimental|Continuous perfusion of esmolol|Intervention: Drug: Continuous perfusion of esmolol
2543280|NCT02609152|Placebo Comparator|Continuous perfusion of saline|Intervention: Continuous perfusion of saline
3168659|NCT00553852|Placebo Comparator|2|PHASE II: In the medical treatment protocol very severe obese patients with persistent GHD after LASGB will be inclosed. Starting from 15-day, GHD patients were re-evaluated by GHRH + Arginine test. After evaluation, the patients with persistent GHD will be randomized to be treated with Recombinant GH replacement therapy (Group A: Recombinant GH replacement therapy at the initial dose 0.15-0.30 mg/die; dose adjustment will be made according to IGF-I levels; Group B: no GH treatment).
3168660|NCT00553865|Experimental|Group 1|OJP-2028 1mg/day
3168661|NCT00553865|Experimental|Group 2|OJP-2028 2mg/day
3168662|NCT00553865|Experimental|Group 3|OJP-2028 4mg/day
3168663|NCT00553865|Placebo Comparator|Group 4|Placebo
3168664|NCT00553865|Other|Group 5|Reference drug
3168665|NCT00553878|Placebo Comparator|dutasteride|
3168666|NCT00553891|Experimental|Nasonex Nasal Spray|
3168667|NCT00553891|Placebo Comparator|Placebo Nasal Spray|
3168668|NCT00553917||1|Pregnant women currently taking Prozac for the treatment of depression
3168669|NCT00553917||2|Pregnant women currently taking Zoloft for the treatment of depression
3168670|NCT00553917||3|Pregnant women not currently using medication for the treatment of depression
3168671|NCT00553917||4|Pregnant women with no history of, symptoms of, or treatment for depression
3168672|NCT00553930|Experimental|G 2/3|Patients with chronic hepatitis or compensated cirrhosis by hepatitis C virus, genotypes 2 or 3, and HIV-coinfected.
3168673|NCT00553943|Experimental|Rituximab + Cytarabine|
3168674|NCT00553956|Experimental|1|Intervention group A treatment combination of Narrative Exposure Therapy and Interpersonal Psychotherapy (5 individual sessions NET in addition to 3 individual sessions IPT)
3168675|NCT00553956|No Intervention|2|Waiting list control
3168676|NCT00553982|Experimental|1|Patellar resurfacing
3168677|NCT00553982|Active Comparator|2|Patellar retention
2542852|NCT02612324|Experimental|Pono Choices|Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program for Middle School Youth in Hawaii. The program includes 9.5 hours of scripted lessons or modules.
2542855|NCT02612324|Active Comparator|Business as Usual|Middle school sexual health content or programs chosen by control group schools.
2542928|NCT02611440|Experimental|Pharmacist Intervention|It will be a semi -structured interviews with patient and pharmacist over various time after the stroke (at Month0, M3, M6, M9) combined with patient's therapeutic follow-up from various healthcare professionals.
2542930|NCT02611440|No Intervention|Control|No pharmacist intervention planned.
2542971|NCT02611232|Active Comparator|Victoza®|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with Victoza® (liraglutide)
2542972|NCT02611232|Placebo Comparator|Placebo|Subjects with preclinical type 1 diabetes aged 18-30 years are treated with placebo
3203165|NCT00920933|Active Comparator|oral corticosteroid|
2543301|NCT02609334|Placebo Comparator|Placebo|Matching placebo tables are given as a single dose
2543302|NCT02609334|Active Comparator|CRD007 Low dose|"Low dose of CRD007 (pemirolast sodium) given as a single dose"
2543303|NCT02609334|Active Comparator|CRD007 High dose|"High dose CRD007 (pemirolast sodium) given as a single dose"
2543378|NCT02608541||Retrospective rib fracture fixation|patients presenting since 2006 with multiple rib fractures or flail chest, managed operatively or non-operatively
2543382|NCT02608541||Prospective rib fracture fixation|patients presenting from October 2015 to October 2017 with multiple rib fractures or flail chest, managed operatively or non-operatively
2543477|NCT02608034|Experimental|Part 1: Vemurafenib+Itraconazole|Part 1: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with itraconazole orally once in the morning from Days 21 to 40 (Period B).\nPart 2: Participants will receive vemurafenib orally BID up to Day 20 (Period A) followed by vemurafenib orally BID along with rifampin orally once in the morning from Days 21 to 40 (Period B).
3203166|NCT00920946|Placebo Comparator|Placebo|
2543536|NCT02607540|Experimental|Two cycles PF-radiotherapy|"2 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.~radiotherapy： 50Gy，2 Gy/d，5d/w."
2543538|NCT02607540|Active Comparator|Four cycles PF-radiotherapy|"4 cycles cisplatin-5-fluorouracil: cisplatin: 75mg/m2 d1，29, 57, 85；5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50Gy，2 Gy/d，5d/w."
2543560|NCT02607215|Experimental|Vinorelbine Plus DDP|"Vinorelbine:25 mg/m2, D1, D8 every 21 days~DDP:75 mg/m2, D1 every 21 days"
2543561|NCT02607215|Active Comparator|Vinorelbine|Vinorelbine:30 mg/m2, D1, D8 every 21 days
2543586|NCT02607098||Males diagnosed with male-factor infertility|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
2543589|NCT02607098||Female partners|This study will recruit a convenience sample of 10 men and their partners seeking consultation from a fertility urologist following the detection of male-factor infertility.
2543610|NCT02607007|Experimental|2% M.F. Milk|Breakfast meal: 250 mL 2% M.F. milk, 75 g white toast, 23.2 g strawberry jam, 100 mL water
2543612|NCT02607007|Experimental|2% M.F. Plain Greek Yogurt|Breakfast meal: 175 g 2% plain Greek yogurt, 75 g white toast, 23.2 g strawberry jam, 100 mL + 75 mL water
2543613|NCT02607007|Experimental|31% M.F. Cheddar Cheese|Breakfast meal: 30 g 31% M.F. cheddar cheese, 75 g white toast, 27.0 g strawberry jam, 100 mL + 220 mL water
2543614|NCT02607007|Experimental|Soy Beverage|Breakfast meal: 250 mL soy beverage, 75 g white toast, 19.3 g strawberry jam, 100 mL water
2543615|NCT02607007|Experimental|Water (control)|Breakfast meal: 250 mL + 100 mL water
2543633|NCT02606994|Placebo Comparator|Crest Toothpaste/Magic Mouth Rinse|The placebo group will brush with Crest Toothpaste three times per day during the study. Participants in the placebo comparator group who require additional management of their oral mucositis pain will be provided Magic Mouth Rinse.
3203167|NCT00920946|Experimental|Dimebon|
3203168|NCT00920959|Experimental|Fluticasone propionate/salmeterol combination|study drug
2543653|NCT02606409|Active Comparator|Dexmedetomidine|Dexmedetomidine intravenous sedation at 0.2-0.7 µg/kg/h for >24h.
2543657|NCT02606409|Active Comparator|Propofol|Propofol sedation at 10-70µg/kg/h for >24h.
2543668|NCT02606669|Experimental|Intermittent Fasting|"The intervention of interest here is the Intermittent Energy Restriction (IER) or the Intermittent Fasting approach, specifically, the 5:2 diet, where adherence to this dietary intervention consists of fasting for two consecutive days and consuming enough to meet energy requirements for the remaining five non-fasting days. In this study, fasting will be achieved by using a meal replacement product (Optifast®) supplemented by two scoops of protein powder (Propass®) and a multivitamin, making a total of 540kcal (54g protein, 60g carbohydrates) for each fasting day."
2543671|NCT02606669|No Intervention|Control|Diet and Physical Activity advice only. No treatment plan.
2543699|NCT02606240||Mild to Moderate ARDS on PRISMALUNG|Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device in patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS).
3203169|NCT00920959|Experimental|Fluticasone propionate|study drug
2543707|NCT02606331|Experimental|ER:YAG Laser|In one half of the dental arch, ER:YAG laser irradiation will be performed for canine retraction, whereas in the other half ordinary canine retraction procedure will be followed.
2543708|NCT02606292|Experimental|Arm 1: PAE assessment|-The PAE-EUS assessment will be performed in the operating room by the after induction of general anesthesia and following strict sterile technique while the patient is being positioned and prepped for esophageal surgery.
3203170|NCT00920959|Experimental|Placebo|placebo
3203171|NCT00920972|Experimental|Stratum 1|Recipients with non-malignant disorders, excluding thalassemia. Related or unrelated 8/8 HLA-matched bone marrow
3203172|NCT00920972|Experimental|Stratum 2|Recipient with transfusion dependent thalassemia. Related or unrelated. 8/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
3203173|NCT00920972|Experimental|Stratum 3|Recipient with hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
3203174|NCT00920972|Experimental|Stratum 4|Recipient with non-malignant disorder, excluding hemoglobinopathy Related or unrelated. 7/8 HLA-matched bone marrow or 5-8/8 HLA-matched UCB
3203175|NCT00920985|Experimental|Arm 1|
2542899|NCT02611544|Active Comparator|Acceptance and Commitment Therapy|6 weeks, the ACT group will meet weekly for 2 hours at one of three facilities.
2542905|NCT02611544|Active Comparator|Survivorship Education|6 weeks, SE group will meet weekly for 2 hours at one of three facilities.
2542910|NCT02611544|Active Comparator|Enhanced Usual Care|"Continue to meet with their health care team + receive a variety of readings at each data collection point on coping with common survivorship concerns, including a booklet from the National Cancer Institute entitled Facing Forward: Life After Cancer Treatment."
2542960|NCT02611310||Participants with HER2-positive unresectable LA/mBC|
2543058|NCT02610556|Experimental|TP plus IMRT|Concurrent chemotherapy: TP - Docetaxel 60mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2543059|NCT02610556|Active Comparator|DDP plus IMRT|Concurrent chemotherapy: DDP - Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles; Radiation: Intensity-modulated radiotherapy
2543125|NCT02610218||histo-HER2+ gastric cancer patients|Histologically HER2 positive gastric cancer patients treated with HER2 targeted therapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
2543129|NCT02610218||histo-HER2- gastric cancer patients|Histologically HER2 negative gastric cancer patients treated with chemotherapy. Interventions: peripheral blood samples of 12.5 mL for CTC and cfDNA analysis will be collected before targeted therapy, at the time that they achieve the optimal response and when they suffer progressive disease.
3168678|NCT00553995|Experimental|Salsalate|Salsalate
3168679|NCT00553995|Placebo Comparator|Placebo|Placebo
2543338|NCT02608788|Active Comparator|S.L.® & Difflam Forte ®|"1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg and 3.0 mg/ml Benzydamine ,Difflam Forte ® 5.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
2543343|NCT02608788|Placebo Comparator|placebo ( for Acular® )|placebo(distilled water)spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
2543345|NCT02608788|Active Comparator|Acular® & S.L.®|"5％ Ketorolac Tromethamine , Acular® 8.0 mg and 1.5 mg/ml Benzydamine , S.L.® Spray Solution 2.5 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
2543347|NCT02608788|Experimental|Difflam Forte ® & Acular®|"3.0 mg/ml Benzydamine , Difflam Forte ® 5.0 mg and 5％ Ketorolac Tromethamine Acular® 8.0 mg spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
3168680|NCT00554008|Active Comparator|1|children randomized to open appendectomy
3168681|NCT00554008|Active Comparator|2|children randomized to laparoscopic appendectomy
3168682|NCT00554021||1|Department of Traumatology and Critical Care Medicine, National Defense Medical College
3168683|NCT00554047|Experimental|1|Multidisciplinary Memory Clinic
3168684|NCT00554047|Active Comparator|2|General practitioner
3168685|NCT00554112|Active Comparator|1|Exercise
3168686|NCT00554112|Active Comparator|2|Exercise
3168687|NCT00554112|No Intervention|3|Control
3168688|NCT00554125|Active Comparator|2, III ,intervention|
3168689|NCT00554138|Placebo Comparator|1|
3168690|NCT00554138|Experimental|2|
3168691|NCT00554164|Active Comparator|B1|Six cycles of the (R-)CHOP regimen.
2543539|NCT02607566|Active Comparator|Standard Exercise Program|professionally supervised program of aerobic exercise including use of an indoor walking track, treadmills, stationary bicycles and elliptical machines, held for 60 minutes twice weekly for 12 weeks
2543647|NCT02606617|Active Comparator|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
2543648|NCT02606617|Placebo Comparator|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
2543676|NCT02606695||NuvaMap and NuvaMap OR in Thoracolumbar Spinal Fusion|
3168692|NCT00554164|Experimental|B2|Six blocks of the B-ALL protocol.
3168693|NCT00554164|Active Comparator|A1|Four cycles of the (R-)CHOP regimen.
3168694|NCT00554164|Active Comparator|A2|Four cycles of the (R-)CHOP regimen plus two additional doses rituximab.
3168695|NCT00554177|Experimental|1|Medicane (mifepristone)
3168696|NCT00554177|Placebo Comparator|2|Placebo
3168697|NCT00554268|Experimental|PBI-05204|PBI-05204 starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle.
3168698|NCT00554281|No Intervention|A|Run in period
3168699|NCT00554281|Experimental|B|
3168700|NCT00554307||Indo|Infants that are treated with indomethacin
3168701|NCT00554307||Neo|Infants treated with neoprofen
3168702|NCT00554307||Control|Infants without PDA
3168703|NCT00554320|Active Comparator|A|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
3168704|NCT00554320|Placebo Comparator|C|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
3168705|NCT00554333|Experimental|1|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
3168706|NCT00554333|Active Comparator|2|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
3168707|NCT00554346|Active Comparator|1|Etoricoxib 90mg
3168708|NCT00554346|Placebo Comparator|2|placebo
3168709|NCT00554359|Experimental|I5NP drug|
3168710|NCT00554359|Placebo Comparator|Placebo|
3168711|NCT00554385|Experimental|1|
3168712|NCT00554398|Experimental|A|MK-0518 400mg twice a day
3168713|NCT00554398|No Intervention|B|No intervention
3168714|NCT00554424|Active Comparator|LA|Intravaginal and pre-peritoneal injection of 1% lignocaine into each side of the upper vagina under ultrasound guidance immediately prior to ultrasound guided transvaginal oocyte retrieval
2542865|NCT02611908|Experimental|ibrutinib +obinutuzumab|
2542875|NCT02611596|Experimental|Ranolazine|Subjects will take one 500mg tablet twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
2542884|NCT02611596|Placebo Comparator|Placebo|Subjects will take one placebo tablet (identical to the 500mg Ranolazine tablet) twice daily (500mg BID) for seven days and then increase to two 500mg tablets twice daily (1000mg BID) for the remainder of the study, for a total of 24 weeks. Subjects taking moderate CYP3A4 inhibitors will not participate in upward titration and will remain on 500mg tablet twice daily (500mg BID) for the duration of the trial.
2542929|NCT02611453|Experimental|Single arm|"All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. Air contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium."
2542965|NCT02611258|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
2542996|NCT02610933|No Intervention|Vitamin K antagonist|Vitamin K antagonist treatment targeting an international normalized ratio of 2 to 3 for 18 months
2543000|NCT02610933|Active Comparator|rivaroxaban|Rivaroxaban 10 mg tablet by mouth once daily for 18 months
2543001|NCT02610933|Active Comparator|rivaroxaban and vitamin K2|Rivaroxaban 10 mg tablet by mouth once daily and MK-7 2000 microgram tablet by mouth thrice weekly for 18 months
2543043|NCT02610647|Other|Control group|"Subjects randomized to this group will have a tapping test with no sensory blocking.~Intervention: Tapping test"
2543044|NCT02610647|Experimental|Wrist anesthesia|"Subjects randomized to this group will have an axillary block / regional anesthesia followed by a tapping test.~Intervention: Wrist anesthesia~Intervention: Tapping test"
2543048|NCT02610647|Experimental|Wrist anesthesia, masked|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Tapping test"
2543052|NCT02610647|Experimental|Wrist anesthesia, helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Anti-noise helmet~Intervention: Tapping test"
2543057|NCT02610647|Experimental|Wrist anesthesia, masked & helmet|"Subjects randomized to this group will have an axillary block / regional anesthesia, will wear a blinding mask, will wear an anti-noise helmet, and then will perform a tapping test.~Intervention: Wrist anesthesia~Intervention: Blinding mask~Intervention: Anti-noise helmet~Intervention: Tapping test"
3203176|NCT00920985|Active Comparator|Arm 2|
3203177|NCT00920998|Experimental|1. Z-338|3-way cross-over study (drug administration 3-times in fasted and 2 fed conditions)
2543286|NCT02608801||Patients from NoFRACT|Patients from NoFRACT who consent to participate in this sub-study, will be offered examination and treatment with anti-osteoporotic drugs cf. treatment algorithm in the main-study. I.e. if osteoporosis is present clinically or at DXA scan, treatment is started.
2543366|NCT02608346|Other|Blood sampling|
2543411|NCT02608190|Experimental|Active training|Patients will undergo active working memory training (see description of protocol).
2543417|NCT02608190|Active Comparator|Passive training|Patients will undergo passive working memory training (see description of protocol).
2543459|NCT02607891|Experimental|STP + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early.~STP Arm: Last patient completion October 2018"
2543462|NCT02607891|Placebo Comparator|STP + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~STP Arm: Last patient completion February 2018"
2543464|NCT02607891|Experimental|VPA + GWP42003-P|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion February 2018"
2543466|NCT02607891|Placebo Comparator|VPA + Placebo|"Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days.~Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early.~VPA Arm: Last patient completion January 2018"
2543533|NCT02607579|Active Comparator|Ropivacaine|This group is given an adductor canal block with Ropivacaine which is the previous gold standard medication.
2543534|NCT02607579|Experimental|Exparel|This group is given an adductor canal block with Exparel which is believed to last longer and provide a better pain relief post-operatively.
2543549|NCT02607449|Placebo Comparator|B|Standard TB treatment + treatment regiment with a placebo. Instead of study drug the placebo was given to the patients orally once per day along with other prescribed TB drugs (in quntity equal to study drug).
2543581|NCT02607111|Experimental|open label|Dalteparin injected as a bolus into the arterial port of the hemodialysis machine every dialysis session for four weeks
3203178|NCT00921011||Perimenopausal women|Women at the beginning stages of menopause
3203179|NCT00921037|Experimental|Erbium YAG Laser|Patients with Neurofibromatosis Type 1 (Recklinghausen)
2542866|NCT02611921|Experimental|Crossover Group: Ketamine verses Placebo|"Phase 1: Two ascending doses of intranasal ketamine~Two week washout~Phase 2: Two doses of placebo"
2542867|NCT02611921|Experimental|Crossover Group: Placebo verses Ketamine|"Phase 1: Two doses of placebo~Two week washout~Phase 2: Two ascending doses of intranasal ketamine"
2542914|NCT02611583|Active Comparator|Ibuprofen and TENS plus|Patients will receive 45 minutes of TENS therapy. All patients will receive ibuprofen.
2542917|NCT02611583|Placebo Comparator|Ibuprofen and Sham TENS plus|Patients will receive 45 minutes of sham TENS therapy. All patients will receive ibuprofen.
2542950|NCT02611323|Experimental|Dose-Escalation Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at escalating doses to identify the recommended Phase 2 dose (RP2D) for polatuzumab vedotin and venetoclax when combined with a fixed dose of obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
2542956|NCT02611323|Experimental|Dose-Escalation Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at escalating doses to identify the RP2D of venetoclax when combined with fixed doses of polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
2542957|NCT02611323|Experimental|Expansion Cohort: FL|Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
2542959|NCT02611323|Experimental|Expansion Cohort: DLBCL|Participants with relapsed or refractory DLBCL will receive 18 weeks of induction treatment. Venetoclax will be administered at the RP2D identified during the dose-escalation phase, in addition to polatuzumab vedotin and rituximab. Those who achieve CR or PR at the EOI will be eligible to receive an 8-month consolidation regimen consisting of venetoclax and rituximab.
3203180|NCT00921050|Experimental|Levothyroxine|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
2543091|NCT02610322|Experimental|Whole soy group|Whole soy replacement diet: to incorporate 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods.
2543093|NCT02610322|Placebo Comparator|Control group|Usual diet: to receive a conventional lifestyle education on MetS.
2543135|NCT02610075|Experimental|AZD1775|This is a single-arm study in which all patients will receive AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
2543182|NCT02609724|Experimental|Fluoroscopy-guided MLD|Information, skin care, compression therapy, exercises and fluoroscopy-guided MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
2543183|NCT02609724|Active Comparator|Traditional MLD|Information, skin care, compression therapy, exercises and traditional MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
2543184|NCT02609724|Placebo Comparator|Placebo MLD|Information, skin care, compression therapy, exercises and placebo MLD 3 weeks (14 sessions of 60 minutes) of intensive treatment 6 months (18 sessions of 60 minutes) of maintenance treatment 6 months of follow-up
3203181|NCT00921050|Placebo Comparator|Placebo|Half of participants randomly assigned, take a pill daily, bimonthly thyroid test
3203182|NCT00921063|Experimental|PD 0332334 250 mg|
2543337|NCT02608567||Preserved LV GLS|"Patients will be compared according to the level of LV global longitudinal strain (GLS) as derived from transthoracic echocardiography and speckle tracking analysis.~Two groups will be compared regarding outcome: preserved LV GLS vs. reduced LV GLS. The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data."
2543340|NCT02608567||Reduced LV GLS|The definition use for reduced LV GLS will be >-16%. An optimal threshold would also be calculated and derived from the pooled data.
2543376|NCT02608385|Experimental|Dose Escalation Cohort|Patients will be enrolled to receive specific doses of radiation (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects. Enrollment will continue until best safe dose of SBRT is determined for each organ type.
2543379|NCT02608385|Experimental|Large Volume Tumors Cohort|Patients with large tumors will be enrolled and their tumors will be partially treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
2543390|NCT02608385|Experimental|Oligometastatic Cohort|Patients with few tumors (4 or less) will be enrolled and their tumors treated with (stereotactic body radiotherapy) given over 1 week followed by treatment with pembrolizumab. Pembrolizumab dosing will continue for up to 2 years or until patients have disease progression or unacceptable side effects.
3203183|NCT00921063|Experimental|PD 0332334 100 mg|
3203184|NCT00921063|Placebo Comparator|placebo|
3203185|NCT00921063|Active Comparator|Alprazolam extended release|
2543650|NCT02606565|Experimental|Intervention arm: 4% chlorhexidine|Neonates randomized to the chlorhexidine arm will have umbilical stump cleansing with a single application of 4% chlorhexidine solution at birth
2543681|NCT02606370|Experimental|Unstable shoes|Wearing unstable shoes during 1 month
3203186|NCT00921076|Active Comparator|Ankle Arthoplasty|Patients will undergo a Total Ankle Replacement procedure
3203187|NCT00921076|Active Comparator|Ankle fusion|Patients will undergo an Ankle Arthrodesis procedure
3203188|NCT00921089||Hemodialysis group|End stage renal disease patients aged lower than 70 years, treated for more than 6 months with hemodialysis
3203189|NCT00921089||Control group|Normotensive healthy controls
3203190|NCT00921102|Placebo Comparator|Control|Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator.
2542911|NCT02611531|Experimental|Video Module Education (VME)|The RE will provide participants with a tablet device and will demonstrate how to access VME and complete the pre/post e-learning assessments. The RE will provide technical support but will neither participate directly in the education nor help with the self-assessments. The participants will first complete the pre-assessment e-learning tool on the tablet. They will then watch the video instruction that will provide a complete demonstration with verbal instructions on correct inhaler technique. Next the participants will complete the post-assessment e-learning tool. Based on participants' performance, they will be directed to further tailored video-instruction. The cycle of self-assessment and video instruction will continue until sufficient mastery has been achieved.
2542915|NCT02611531|Active Comparator|Teach-To-Goal (TTG)|Participants assigned to the TTG condition will be provided with an intensive, iterative education and evaluation strategy that consists of the following steps.
2542946|NCT02611336|Experimental|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
2543017|NCT02611011||Women|Women seeking health services will perform the Congo Red Dot test (GV-005) individually by following the the test instructions
2543103|NCT02610413||Ancillary-Correlative (whole exome sequencing)|Previously collected germline DNA samples are analyzed via whole exome sequencing.
2543148|NCT02609958|Experimental|Treatment Arm A|Varlitinib (ASLAN001) tablets
3203191|NCT00921102|Experimental|Intrathecal Atropine|Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding.
3203192|NCT00921102|Active Comparator|IV Atropine|Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding.
2543259|NCT02609009|Experimental|Spinal Manipulation Therapy|Active chiropractic care for this RCT will consist of diversified technique prone, side posture and supine manipulations with soft-tissue therapy
2543261|NCT02609009|Other|Usual Medical Care|Control group patients will follow the usual medical visit scheduled according to their attending orthopaedists. Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises.
2543325|NCT02608827|Active Comparator|Slow breathing group (GRL)|After randomization and have done aerobic exercise, patients allocated in this arm of the study, using the device-guided breathing - Slow breathing group (GRL), for 15 minutes during the experimental session.
2543331|NCT02608827|Placebo Comparator|Music group (GC)|After randomization and have done aerobic exercise, patients allocated in this study arm will hear slow music - Music group (GC), for 15 minutes during the experimental session.
2543386|NCT02608398||overweight children at weight-loss camp|This is an observational study there is no intervention. The investigators will carry out metabolic profiling on a cohort of overweight or obese children who are attending a commercial weight loss camp for 2-5 weeks.
2543482|NCT02608060|Experimental|Epoetin Beta - 30000 IU|Dosage at Initiation: Subcutaneous injection of 30000 IU epoetin beta administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
2543545|NCT02607501|Other|eCLIPs BRS|Implant eCLIPs BRS at target aneurysm
2543562|NCT02607423|Experimental|Diagnostic (18F-FDG PET/CT)|"Patients undergo fludeoxyglucose F-18 PET/CT at baseline and after course 1 of chemotherapy. Patients undergo 1 of 3 chemotherapy regimens at the discretion of the investigator.~CHEMOTHERAPY REGIMEN 1: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, and 8. Patients also receive cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 2: Patients receive docetaxel IV over 60 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.~CHEMOTHERAPY REGIMEN 3: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity."
2543584|NCT02607163|Experimental|dexmedetomidine|dexmedetomidine, 0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
2543588|NCT02607163|Placebo Comparator|control|saline, same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
2543652|NCT02606565|No Intervention|Control arm: Dry cord care|Neonates randomized to the control arm will receive the current standard of cord care (dry cord care)
2543680|NCT02606422|Experimental|Active HD-tDCS plus Speech-Language Therapy|Active HD-tDCS will be applied at the beginning of 45min speech-language therapy session and will last for 20 min.
2543683|NCT02606370|No Intervention|Control Group|Not Wearing unstable shoes
2543684|NCT02606422|Sham Comparator|Sham plus Speech-Language Therapy|Sham HD-tDCS will be applied at the beginning of 45min speech-language therapy session.
2543705|NCT02606214|Experimental|Dose Formulation Comparison Cohort|"All subjects in this cohort will receive two doses of the active drug. The first dose in three subjects will be a 100 mg TBA-354 tablet, followed 14 days later by a 100 mg dose of the TBA-354 suspension formulation. The first dose in the other three subjects will be 100 mgs of the TBA-354 suspension formulation, followed 14 days later by a 100 mg TBA-354 tablet dose. Placebo formulations will not be used in the dose formulation comparison cohort.~Each dose will be administered orally with 200 ml of water after a minimum 8 hour overnight fast. Food will be given two hours after each dose."
2543746|NCT02606123|Experimental|EPI-506|Part I: Ascending doses of EPI-506 administered orally to define the maximum tolerated dose.
2542896|NCT02611843|Experimental|Peer-Supported Web CBT|Semi-structured brief sessions conducted weekly for the 12 weeks of study treatment by a certified peer support specialist. Sessions focus on helping participants use the skills they are learning in the Web CBT treatment in their daily lives. Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
2542898|NCT02611843|Experimental|Self-Managed Web CBT|Self-managed Web CBT consists of 24 brief (i.e., 20-minute) modules. Participants will be asked to complete two modules per week. Module topics include The Connection Between PTSD and Substance Use, Motivational Enhancement, Relaxation, Identifying, Evaluating and Challenging Automatic Thoughts, Functional Analyses of Substance Use, Substance Use Refusal Skills, Communication, Anger Management, Pain Management, and Insomnia.
2542943|NCT02611401|Experimental|Mindulness Based Intervention|intervention with group-based Mindfulness Based Intervention
2542945|NCT02611401|Active Comparator|Active Control|intervention with group-based Psychoeducation and Relaxation
3168715|NCT00554424|Placebo Comparator|P|Intravaginal saline placebo injection into each side of upper vagina under ultrasound guidance immediately prior to transvaginal oocyte retrieval
2543176|NCT02609490|Experimental|Treatment-Azilsartan|Azilsartan tabelts
2543179|NCT02609490|Active Comparator|Positive Control-olmesartan medoxomil|olmesartan medoxomil tablets
2543230|NCT02609386|Experimental|Regimen 1|IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.
2543231|NCT02609386|Active Comparator|Regimen 2|Regimen 1 but without IRX-2
2543381|NCT02608333|Experimental|ESDM-12|ESDM -12 : 60 children will receive 12 hours a week of ESDM ( Early Start Denver Model)intervention delivered by trained therapists during 2 years.ESDM is a comprehensive relational, developmental and behavioral intervention.It's described in a manual for Professional and parents.
2543389|NCT02608333|Active Comparator|Control group|control group: 120 children will receive heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period
2543468|NCT02608008||Data analysis transfemoral aortic valve implantation|Periinterventional data analysis during structural heart procedures like transfemoral aortic valve implantation with and without the use of EchoNavigator System Release II.
2543473|NCT02608008||Data analysis MitraClip|Periinterventional data analysis during structural heart procedures like MitraClip Implantations with and without the use of EchoNavigator System Release II.
2543478|NCT02608008||Data analysis PFO|Periinterventional data analysis during structural heart procedures like PFO implantations with and without the use of EchoNavigator System Release II.
2543480|NCT02608008||Data analysis ASD|Periinterventional data analysis during structural heart procedures like ASD implantations with and without the use of EchoNavigator System Release II.
2543597|NCT02606955|Experimental|BIA REST|BIA DW assessment
2543649|NCT02606435|Experimental|thrombus aspiration with PCI|patient will receive manual thrombus aspiration with percutaneous coronary intervention (PCI)
2543651|NCT02606435|Active Comparator|PCI alone|patients will receive percutaneous coronary intervention (PCI) alone including stent implantation
2543655|NCT02606682|Experimental|NPT200-11 - Cohort 1, Dose 1|Single ascending dose of orally administered capsule(s) NPT200-11: 15 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543662|NCT02606682|Experimental|NPT200-11 - Cohort 2, Dose 2|Single ascending dose of orally administered capsule(s) NPT200-11: 30 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543667|NCT02606682|Experimental|NPT200-11 - Cohort 3, Dose 3|Single ascending dose of orally administered capsule(s) NPT200-11: 60 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543670|NCT02606682|Experimental|NPT200-11 - Cohort 4, Dose 4|Single ascending dose of orally administered capsule(s) NPT200-11: 120 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543672|NCT02606682|Experimental|NPT200-11 - Cohort 5 ,Dose 5|Single ascending dose of orally administered capsule(s) NPT200-11: 240 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543673|NCT02606682|Experimental|NPT200-11 -Cohort 6, Dose 6|Single ascending dose of orally administered capsule(s) NPT200-11: 360 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543674|NCT02606682|Experimental|NPT200-11 - Cohort 7, Dose 7|Single ascending dose of orally administered capsule(s) NPT200-11: 480 mg OR Single dose of orally administered placebo capsule(s) to match dose
2543690|NCT02606201|Experimental|IPSMA|Injection Peri Sphincter Myofibers Autologous
2543692|NCT02606214|Experimental|Dose Level 1: 50 mg TBA-354|50 mg TBA-354 for 14 days (two 25 mg once daily)
2543694|NCT02606214|Placebo Comparator|Dose Level 1: Placebo|Placebo cohort for Dose Level 1
2543697|NCT02606214|Experimental|Dose Level 2: 100 mg TBA-354|100 mg TBA-354 for 14 days (one 100 mg tablet once daily)
2543700|NCT02606214|Placebo Comparator|Dose Level 2: Placebo|Placebo cohort for Dose Level 2
3168716|NCT00554437|Experimental|1|Intermediate-intensity, community-based, multifactorial falls intervention
3168717|NCT00554437|Active Comparator|2|Occupational therapist home safety evaluation
3168718|NCT00554450|Experimental|Arm 1|50 mg single dose
3168719|NCT00554450|Experimental|Arm 2|20 mg up to 7 days
3168720|NCT00554502|Active Comparator|A|
3168721|NCT00554502|Active Comparator|B|
3168722|NCT00554528|Other|A|patient receiving cervical disc prosthesis with a mobile insert named Mobi-C and product by LDR médical
3168723|NCT00554528|Other|B|patient receiving intersomatic cage
3168724|NCT00554541||Normal Body-Mass|BMI Index: 18.5-24.9 Ankle Brachial Index Venous physiologic study
3168725|NCT00554541||Obese Body-Mass|BMI Index: 30.0-39.9 Ankle Brachial Index Venous physiologic study
3168726|NCT00554541||Morbidly Obese Body-Mass|BMI Index: ≥ 40 Ankle Brachial Index Venous physiologic study
3168727|NCT00554567|Experimental|Intervention Arm|Fully Decentralized HIV Testing and Care Services
3168728|NCT00554580|Active Comparator|A|Usual care of pulmonary acute oedema
2542805|NCT02612259|Experimental|TRYPTOPHAN|"tryptophan 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
2542807|NCT02612259|Placebo Comparator|PLACEBO|"lactose capsules 3.5 mg / kg / day divided in 2 doses, one before breakfast and another one before dinner. Oral administration.~Total treatment duration for each patient is 6 months."
3203193|NCT00921141||study population|Patient with cancer requiring a long-term central venous catheter
3203194|NCT00921154|Experimental|Ivermectin|Ivermectin
3203195|NCT00921167|Experimental|Bevacizumab/Irinotecan|
2542981|NCT02611141|Other|Patient with Retromolar Gap|20 patients with a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
2542983|NCT02611141|Other|Patient without a Retromolar Gap|20 patients without a retromolar gap between the last erupted molar and the ascending ramus at the right lower mandible.
3203196|NCT00921180|Experimental|Entecavir and peginterferon|Entecavir 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
2543101|NCT02610244|No Intervention|Treatment As Usual|Standard treatment as usual as directed by the physician.
2543102|NCT02610244|Experimental|Modified Cogmed Training|10 weeks of computerized training (3x weekly for 35-minutes each session) that targets thinking skills that are often impaired in individuals diagnosed with ADHD.
3203197|NCT00921180|Active Comparator|Placebo and peginterferon|Placebo 0.5 mg/day at week 1-4, followed by peginterferon alfa-2a 180 ug/week at week 5-52
3203198|NCT00921206|Active Comparator|VAX102 given i.m.|Universal influenza candidate vaccine
2543253|NCT02609217||Multiparous|12 multiparous women and their partners, planned to undergo elective term cesarean section.
2543254|NCT02609217||Nulliparous|12 nulliparous women and their partners, planned to undergo elective term cesarean section.
3203199|NCT00921206|Active Comparator|VAX102 given s.c.|Universal influenza candidate vaccine
3203200|NCT00921219|Experimental|Ivermectin|ivermectin
3203201|NCT00921232|Other|dyad|life-ending patient and its caregiver
3203202|NCT00921245||Group 1|
3203203|NCT00921258||control group|Patient with latent prostate cancer who agree to be controled instead of to be treated
3203204|NCT00921271||At risk for compartment syndrome.|"Patients admitted to Selly Oak Hospital, Birmingham, Uk, meeting one or more of the following inclusion criteria:~Patients with one or more of the following injuries:~tibial fracture.~crush injury/soft tissue injury to lower limb without fracture.~pelvic fracture.~major vascular injury below the aortic bifurcation.~2 or more long bone fractures.~Any patient sustaining a traumatic injury with a base deficit ≥ 6 mEq/L within 12 hours of Hospital admission.~Any patient receiving ≥ 6 units packed red blood cells within 12 hours of hospital admission."
2543552|NCT02607514|Experimental|immediate yoga arm|participants will immediately start the 8-week hyperthermic yoga intervention
2543554|NCT02607514|Other|delayed yoga arm|participants will wait 8-weeks to start the 8-week hyperthermic yoga intervention
3203205|NCT00921284|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
3203206|NCT00921284|Experimental|dexmedetomidine|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine
2543749|NCT02606032|Active Comparator|Metronidazole+doxycylcine+terbinafine|Metronidazole 500 mg BID, Doxycycline 100 mg BID, Terbinafine 250 mg once daily all for 14 days
2543760|NCT02606032|Placebo Comparator|Placebo|Placebo Metronidazole, Placebo Doxycycline, and Placebo Terbinafine all BID for 14 days
2543822|NCT02605525|Experimental|SM101 12 mg/kg|Human soluble recombinant Fcγ Receptor IIB
2543826|NCT02605525|Experimental|SM101 24 mg/kg|Human soluble recombinant Fcγ Receptor IIB
2543827|NCT02605525|Placebo Comparator|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 2
3203207|NCT00921297|Active Comparator|Immediate Cataract Surgery|Subjects randomly selected into the Immediate Surgery group will have their cataract surgery scheduled one month from the time their initial study visits are completed. The subjects will be followed monthly for a period of 6 months for surgical and non-surgical adverse events. At the 6-month point, subjects will receive a final comprehensive eye exam and neuropsychological testing. The research partners will complete final activities of daily living and resource utilization questionnaires.
3203208|NCT00921297|No Intervention|Delayed Cataract Surgery|Subjects selected into the Delayed Surgery group will be asked to delay their surgery for 6 months after their initial study visits. At 6 months, this group will also undergo the same testing as the Surgery Group.
3203209|NCT00921323|Placebo Comparator|Control|The control group will be advised to continue to be physically active and record daily steps
3203210|NCT00921323|Active Comparator|Goal-setting group|This intervention group would be instructed to increase their daily step count by at least 20% above their baseline gradually over 3 months.
2544093|NCT02603770|Experimental|XueZhiKang (XZK)|XueZhiKang (XZK) 1200 mg
2544094|NCT02603770|Active Comparator|Lovastatin|Lovastatin 20 mg
2544144|NCT02603458|Placebo Comparator|Placebo|Group of enrolled subjects receiving two infusions of intravenous placebo (5% glucose solution)
3203211|NCT00921336|Experimental|KW-2450|
3203212|NCT00921349|Experimental|Ligation+Nadolol|"Multi-ligators were applied. Patients received regular ligation treatment at an interval of 3-4 weeks until variceal obliteration.~Intervention; ligation of varices plus beta blockers (Nadolol)."
3203213|NCT00921349|Active Comparator|Nadolol only|
3203214|NCT00921362||1|Schizophrenia patients under Seroquel treatment
3203215|NCT00921375|Experimental|Tuly, uric acid lowering drug|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
3203216|NCT00921388|Experimental|1|Exercise program
3203217|NCT00921388|Other|2|Relaxation program
2543710|NCT02606266|Experimental|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension), at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
2543712|NCT02606266|No Intervention|Control group|Control group with standard care who do not receive the investigational medicinal product
2543993|NCT02604485|Other|Cohort|XOMA 358 dose level A, dose level B, dose level C, and dose level D.
2544049|NCT02604082|Active Comparator|Vibocompression (VB)|Grup 1 - Vibrocompression: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration
2544050|NCT02604082|Active Comparator|Hyperinflation (HMV)|Grup 2 - Hyperinflation with Mechanical ventilator: Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the increase in inspiratory pressure ventilator .
2544051|NCT02604082|Experimental|HMV+VB|Grup 3 - Hyperinflation with mechanical ventilator and vibrocompression:Is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation. Through the thoracic compression during expiration and the increase in inspiratory pressure ventilator.
2544084|NCT02603744|Experimental|5 million MSC|The patients with POF who underwent intraovarian injection of 5 million mesenchymal stem cells.
2544088|NCT02603744|Experimental|10 million MSC|The patients with POF who underwent intraovarian injection of 10 million mesenchymal stem cells.
2544090|NCT02603744|Experimental|15 million MSC|The patients with POF who underwent intraovarian injection of 15 million mesenchymal stem cells.
2544133|NCT02603445|Experimental|Follicular lymphoma (FL)|
2544139|NCT02603445|Experimental|Mantle cell lymphoma (MCL)|
2544173|NCT02603068|Experimental|Individual Maximum Tolerated Dose (iMTD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 12 mg TID.
2544174|NCT02603068|Experimental|Fixed Dose (FD)|Subjects are allowed to titrate oral treprostinil up to a maximum dose of 1 mg TID.
2544237|NCT02602886|Experimental|Exposure and Response Prevention Therapy|
2544286|NCT02602548||Open Shoulder Surgery|Culture
2544289|NCT02602548||Arthroscopic Shoulder Surgery|Culture
2544336|NCT02602249|No Intervention|Experimental Group A(control group)|saline infusion and follow up
2544338|NCT02602249|Experimental|Experimental Group B|MUC1-gene-DC-CTL will be used against tumor cells.
2544339|NCT02602249|Experimental|Experimental Group C|MUC1-peptide-DC-CTL will be used against tumor cells.
2544451|NCT02601274|Experimental|Single Group Assignment|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 7 dose cohorts,including120mg/160mg/200mg/220mg/300mg/400mg/500mg, QD in the dose escalation stage .
2544520|NCT02601079|Active Comparator|Conventional biopsy|"4 out of 8 biopsies taken with a conventional biopsy forceps from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
2544522|NCT02601079|Active Comparator|Endodrill biopsy|"4 out of 8 biopsies taken with the Endodrill instrument from the tumor tissue in the distal esophagus and cardia. The biopsies will be taken in random order blinded for the person performing the examination. 1 additional biopsy will be taken from the tumor tissue in order to be evaluated for appropriateness of further genetic analysis. Both type of biopsies will be taken from the same patient. In total 10 biopsies per patient."
2544540|NCT02600728|Experimental|experimental group (EG)|The experimental training (ET) consisted of eight gait training sessions, twice a week, using the declarative memory cues strategy (DMCS).
2544541|NCT02600728|Active Comparator|control group (CG)|The control training (CT) consisted of a similar gait training without DMCS.
2544609|NCT02600533|No Intervention|Standard care/control group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the standard of care group will be provided standard educational resources (booklet and DVD), with no additional instructions. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
2544612|NCT02600533|Experimental|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
2544654|NCT02600091|Experimental|MBCT Intervention|Participants in the Mindfulness-based Cognitive Therapy Intervention arm will receive an 8-week programme in mindfulness-based cognitive therapy
2544655|NCT02600091|No Intervention|Waiting List Control|The participants who are allocated to the waiting list control group will receive usual care. They will receive the MBCT intervention 3 months after the intervention group complete their MBCT programme.
2544720|NCT02599740|Placebo Comparator|Placebo|Rice only
2544722|NCT02599740|Active Comparator|Assumed active|Assumed key active consumed with rice
2544725|NCT02599740|Active Comparator|Natural fruit extract|Natural fruit extract consumed with rice
2544828|NCT02599090|Experimental|Dose Level 1|"Temozolomide + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle~Temozolomide 75mg/m^2 daily during radiation therapy, and 150mg/m^2 in the first cycle of adjuvant therapy. Dose Level 1 will receive sorafenib in the adjuvant phase (following radiation therapy) at the dose of 400mg BID in combination with standard dose temozolomide 150-200 mg/m^2 two days out of 28 day cycle. Radiotherapy 2.0 Grey (Gy)/day given daily 5 days per week for total of 60.0 Gy over 6 weeks."
2544829|NCT02599090|Experimental|2|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Higher Dose Temozolomide in a Shorter Cycle + Higher Dose Sorafenib
2544830|NCT02599090|Experimental|3|Temozolomide + Lower Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Lower Dose Sorafenib
2543812|NCT02605499|Experimental|UV-C light disinfection|During intervention UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
2543818|NCT02605499|No Intervention|Control|During control period there will be standard discharge and daily room cleaning only, with no UV-C light disinfection.
2543874|NCT02605239|Experimental|bleaching teeth|Group of patients will be bleaching with 10% peroxide carbamide , and them will be assessed the impact on dental confidence , impact psychosocial and esthetic perception
2543936|NCT02604797|Experimental|Nalbuphine|Nalbuphine group: nalbuphine 100 mg, ramosetron 0.3mg, background dose 1ml/h,patient-controlled analgesia(PCA) 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
2543939|NCT02604797|Experimental|Sufentanil|Sufentanil group: sufentanil 100ug, ramosetron 0.3mg, background dose 1ml/h, PCA 1ml/time, lockout time 10 min, flurbiprofen axetil 50mg 6h after operation.
2543979|NCT02604316|Experimental|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate
2543982|NCT02604316|No Intervention|Control- Non Arabinoxylan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
2543985|NCT02604316|Experimental|Beta-Glucan|10 days of weight loss diet calculated as 100% RMR AND 6g Beta-Glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
2543987|NCT02604316|No Intervention|Control Non Beta glucan|10 days of weight loss diet calculated 100% RMR using a heterogeneous natural fibre for food ingredients, 30% protein, 30% fat, 40% CHO.
2544022|NCT02604134|Other|conventional treatment group|The child will receive a prophylaxis and fluoride varnish. Parents will fill out a parent and a child questionnaire.
2544024|NCT02604134|Other|Silver Nitrate group|The child will receive a prophylaxis, then silver nitrate and then fluoride varnish. Parents will fill out a parent and a child questionnaire.
2544080|NCT02603835|Experimental|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
3168729|NCT00554580|Experimental|B|CPAP + usual care of pulmonary acute oedema
3168730|NCT00554606|Experimental|Canakinumab|Participants received one single dose of 600 mg canakinumab via intravenous infusion on Day 1 and thereafter every 6 weeks until completion of the 54-week treatment period.
2544579|NCT02600572|Experimental|Isometric exercise|Subjects performing the isometric exercises intervention
2544581|NCT02600572|Experimental|Eccentric exercise|Subjects performing the eccentric exercises intervention
2544719|NCT02599792|Experimental|CTP-656, 150 mg|Single Oral Dose
2544724|NCT02599792|Active Comparator|Kalydeco, 150 mg|Single oral dose
2544726|NCT02599792|Experimental|CTP-656, 75 mg or matching placebo|Subjects will be administered 75 mg CTP-656 for 7 days.
2544728|NCT02599792|Experimental|CTP-656, 150 mg or matching placebo|Subjects will be administered 150 mg CTP-656 for 7 days.
2544733|NCT02599792|Experimental|CTP-656, high dose or matching placebo|Subjects will be administered up to 300 mg CTP-656 for 7 days.
2544792|NCT02599155|Placebo Comparator|Crystalloid group|Crystalloid group receive only crystalloid for intravenous volume expansion. The same transfusion protocol is applied in both groups.
2544794|NCT02599155|Active Comparator|Colloid group|Colloid group receive colloid preferentially for intravenous volume expansion, until 30 ml/kg. The same transfusion protocol is applied in both groups.
2544821|NCT02598830|Experimental|Vitamin D3+str.training, COPD & Healthy|"Vitamin D3 capsules for 30 weeks:~weeks 1-2: 10000 IU/day (equivalent to 250 ug), accompanied by 1000 mg Ca2+~weeks 3-30: 2000 IU/day (equivalent to 50 ug), accompanied by 1000 mg Ca2+~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
2544822|NCT02598830|Placebo Comparator|Placebo+str.training, COPD & Healthy|"Placebo capsules for 30 weeks (the number of capsules ingested each day match those of the vitamin D3 group)~Progressive unilateral strength training of the legs for 3+10 weeks (weeks 15-28); leg 1 = high-load training, leg 2 = low-load training, allocated to left and right foot in a randomized manner:~weeks 15-17, familiarization period~week 18, test period~weeks 19-28, intervention period~weeks 29-30, test period"
2544893|NCT02598635|Placebo Comparator|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
3168731|NCT00554632|Active Comparator|1|Use of transdermal hormonal contraceptive
3168732|NCT00554632|Active Comparator|2|Use of oral hormonal contraceptive
2543714|NCT02606318|Experimental|Adjusted the challenge-skill balance|This group received 10-session occupational therapy with adjustment of challenge-skill balance.This intervention aimed at improving the skill level for the activity has started once the balance were balanced.
2543718|NCT02606318|Other|Non-adjusted the challenge-skill balance|This group received 10-session occupational therapy without adjustment of challenge-skill balance. That is conducted the therapy in the normal manner for the day care center.
2543820|NCT02605408||Cataract surgery|Phacoemulsification and artificial IOL implantation with and without LenSx® laser system
2543871|NCT02605226|Experimental|Arm I|"Patients receive oral bicalutamide once daily on days 1-28. Patients also receive luteinizing-hormone releasing-hormone (LHRH) agonist treatment intramuscularly (IM) on day 8. Treatment with LHRH agonist repeats every 12 weeks for 24 weeks.~Patients receive cryoablation therapy."
2543872|NCT02605226|Experimental|Arm II|Patients receive androgen ablation as in arm I. Patients receive external beam radiation therapy.
2543932|NCT02604719|Experimental|tanexamic acid and Ethamsylate|10 ml of the study drugs (1 gm Tranexamic acid and 1 gm Ethamsylate ) slowly (over 30-60 sec ) in the 2 minutes after birth
2543934|NCT02604719|Placebo Comparator|placebo|10 ml normal saline will be administered intravenously just after birth
3168733|NCT00554645|Experimental|1|Multi-disciplinary group intervention
3168734|NCT00554645|Active Comparator|2|traditional information
3168735|NCT00554658|Active Comparator|A|Patients will be taken quetiapine for the treatment of first episode schizophrenia.
2544152|NCT02603380||Clinical staff|Clinicians in the Royal Infirmary of Edinburgh.
2544154|NCT02603380||Patients|Patients in intensive care units and general wards in the Royal Infirmary of Edinburgh.
2544176|NCT02603159|Experimental|Capecitabine-5 weeks-radiotherapy|Capecitabine 5 weeks : 625mg/m2, bid d1-5; q1w, po,5 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
2544178|NCT02603159|Active Comparator|Capecitabine-10 weeks-radiotherapy|Capecitabine 10 weeks : 625mg/m2, bid d1-5; q1w, po,10 weeks in total, radiotherapy： 50Gy ，2 Gy/d，5d/w.
2544240|NCT02602873||good efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can reach effective outcome.
2544242|NCT02602873||poor efficacy|using therapeutic drug monitoring to adjust the dose of tacrolimus. patients can not reach effective outcome.
2544292|NCT02602587|Experimental|blood samples and bone marrow samples|The patients included in this study will be processed according to the standard treatment in force for their disease. This study does not in any way interfere with this treatment regimen, and is only based on additional samples of blood and bone marrow in acts planned in the prognostic or follow-up protocols. Treatment shall start within the 15 days following inclusion and first sampling.
2544326|NCT02602210|Active Comparator|group A|Group A: treated with intravenous hydrocortisone in addition to standard therapy (= treatment group)
2544327|NCT02602210|Placebo Comparator|group B|Group B: IV treatment with NaCL 0.9% in addition to standard therapy (= placebo group)
2544381|NCT02601911|Active Comparator|Ketorolac tromethanine|This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.
2544385|NCT02601911|Active Comparator|Acetaminophen|This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.
2544390|NCT02601911|Placebo Comparator|Placebo|This group receive a caplet including placebo, before applying the injection.
2544513|NCT02601222|Experimental|Runzao zhiyang capsule|Runzao zhiyang capsule: 4 pills each time, 3 times a day, oral， Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
2544518|NCT02601222|Placebo Comparator|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation:4 pills each time, 3 times a day, oral, Urea Cream (topical application, apply to the affected area and gently rub) 2 times a day.
2544554|NCT02600676|Active Comparator|TENS, 10 weeks (active) 2 hours a day.|26 children.
2544571|NCT02600676|Placebo Comparator|TENS, 10 weeks (placebo) 2 hours a day.|26 children.
2544643|NCT02600104|Experimental|all subjects|will receive up to four (4) facial treatments in 3-8 weeks interval, with the PicoWayTM device-fractional hand piece 1064nm and/or 532nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
2544685|NCT02599831|Experimental|Electrical pudendal nerve stimulation|"Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum).~Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 times per week for 8 weeks."
2544696|NCT02599870|No Intervention|Control|The medical provider for the control group will not receive the NeuroIDgenetix Test Panel results and will make post-operative pain management recommendations based as usual. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
3168736|NCT00554697||1|
3168737|NCT00554697||2|
3168738|NCT00554710|Experimental|1|Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
3174190|NCT00620646|Experimental|A|Aspirin plus increasing clopidogrel group
3174191|NCT00620646|Experimental|B|Aspirin, clopidogrel plus cilostazol group
2543715|NCT02606188|Active Comparator|Modified High-flow nasal cannula therapy|Patients undergoing bronchoscopy are given Modified High-flow nasal cannula oxygen therapy all the time.
2543719|NCT02606188|Active Comparator|Nasal cnnnula therapy|Patients undergoing bronchoscopy are given nasal cannula oxygen therapy all the time.
3203218|NCT00921401|Experimental|Asthma Feedback|Each month and before all visits with their asthma care provider, participants will be encouraged to go online and answer a series of questions regarding the types of asthma medications they use and how often they use them, asthma symptoms they have experienced, emergency department visits in the past year, the care they have received for their asthma (e.g., specialist visits) in the past year, and the planned date of their next visit with their asthma care provider. Participants will receive tailored feedback about what questions they should ask their doctor during a subsequent visit, whether or not they should schedule a visit sooner, and links to read more about each recommendation.
3203219|NCT00921401|Active Comparator|Preventive Feedback|Each month and before all visits with their primary care provider, participants will be encouraged to go online and answer a series of questions regarding their preventive care. They will receive tailored feedback regarding preventive services, such as pap testing, cancer screenings, and flu shots. Participants will receive tailored feedback regarding preventive services (e.g., cancer screening) that they should discuss with their primary care provider.
3203220|NCT00921414|Active Comparator|1|observation : 3 years maintenance period with assesments and surveillance every 2 months
3203221|NCT00921414|Experimental|2|maintenance period infusions of Rituximab 375 mg/m2/2 months and assessement and surveillance
3203222|NCT00921427|Active Comparator|VRT and active tDCS|Patients will receive tDCS (noninvasive brain stimulation) concurrently with vision restoration therapy. TDCS is delivered using a small battery-operated device. Electrical leads from the device are connected to saline soaked sponges that are placed at strategic locations on the skull corresponding to areas of the brain that need to be stimulated (in this case, the visual cortex). The dosage will be set to 2 mA/min for 30 minutes, twice a day for 3 days a week for 12 weeks.
3203223|NCT00921427|Sham Comparator|VRT combined with sham tDCS|Patients will receive sham tDCS concurrently with vision restoration therapy. Electrical leads from the tDCS device will be connected to saline soaked sponges placed at strategic locations on the skull, in a similar maner as in the active tDCS group. Current will be turned on for 30 seconds but will be slowly ramped down and turned off. Treatment will continue for 3 days a week for 12 weeks.
2544078|NCT02603783|Active Comparator|Capsaicin|1,5 mg capsaicin in 30 minutes
2544082|NCT02603783|Placebo Comparator|Placebo|75 ml placebo (0,9 % saline) in 30 minutes
2544118|NCT02603588|Experimental|active acupuncture|intervention: subjects in the active acupuncture group received active sphenopalatine ganglion acupuncture
2544119|NCT02603588|Sham Comparator|sham acupuncture|intervention: subjects in the sham acupuncture group received sham sphenopalatine ganglion acupuncture
2544212|NCT02603250||Wicking|50% of the 132 children enrolled in the study will have their Hb measured using the wicking method of HemoCue® 201+ blood collection.
2544218|NCT02603250||Gravity|50% of the 132 children enrolled in the study will have their Hb measured using the gravity method of HemoCue® 201+ blood collection.
2544305|NCT02602509|Experimental|Celecoxib plus rifampicin group|Visit 1: Celecoxib 400mg Visit 2: Rifampicin 10mg/kg Visit 3: Celecoxib 400mg PLUS rifampicin 10mg/kg
2544309|NCT02602509|Experimental|Celecoxib plus pyrazinamide group|Visit 1: Celecoxib 400mg Visit 2: Pyrazinamide 25mg/kg Visit 3: Celecoxib 400mg PLUS pyrazinamide 25mg/kg
2544341|NCT02602054|Experimental|Surgical treatment|Implement surgical treatment for closure of patent ductus arteriosus
2544343|NCT02602054|Active Comparator|Control group|"- Indomethacin: Administer 1 full cycle (3 doses) of indomethacin (1 dose every 12 hours) for 2 days Dose 0.1 - 0.25 mg / kg~- Ibuprofen: Administer 1 full cycle (3 doses) of ibuprofen (1 dose every 24 hours) for 2 days Dose 05 - 10 mg / kg~- Acetaminophen: Administer 1 full cycle (12 doses) of acetaminophen (1 dose every 6 hours) for 3 days Dose 15 mg / kg"
2544365|NCT02601794|Experimental|App-based Mindfulness Training|12 week mindfulness training delivered remotely through mobile app
2544369|NCT02601794|No Intervention|Waitlist Control|No intervention provided during study period. 12 week mindfulness training will be delivered through mobile app once all study assessments have been completed
2544405|NCT02601599|Experimental|Intervention|Motivational interviewing The medical student will deliver a 15 minute consultation with the patient. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, educate the patient about effective behavioral and pharmacological cessation strategies, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy. Patients who elect to receive this consult with have a coloured sticker placed by the medical student on the medical chart requesting a consultation.
2544406|NCT02601599|No Intervention|Usual care|This group will not receive student contact, but may be counselled by the smoking cessation officer or other Connolly staff as per normal procedures.
3203224|NCT00921453||Intervention 1|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
3203225|NCT00921453||Control 1|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a common kind of headache.
2544832|NCT02598843|Active Comparator|Standard treatment protocol|Cast immobilisation with 4 weeks in equinus cast (non-weight bearing) followed by 4 weeks in semi-equinus cast (non-weightbearing) and 2 weeks in neutral cast (full weightbearing). At this point, the cast is removed and patients mobilise fully weightbearing for a further 2 weeks out of cast, with internal shoe insert heel raise. Commence physiotherapy at 10 weeks, when cast removed.
2544834|NCT02598843|Experimental|Accelerated rehabilitation|4 weeks in Ossur rebound walking boot with 2 heel wedges (3cm), 2 weeks in Ossur rebound walking boot with 1 heel wedge (1.5cm) and 2 weeks in Ossur rebound walking boot with no heel wedges (neutral position). Fully weightbearing throughout. Commence physiotherapy at 8 weeks.
2544970|NCT02598063|Active Comparator|ADV + Lamivudine|Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
3203226|NCT00921453||Intervention 2|Participants using the prototype to receive expert system guided tailored internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
3203227|NCT00921453||Control 2|Participants using search engines and portals to gather internet information about the type of headache of a family member who provided anamnesis data for a less common kind of headache.
2543775|NCT02605772|Experimental|metformin+Saxagliptin|metformin 0.5g tablet Saxagliptin 5mg tablet metformin 0.5g three times a day for three months Saxagliptin 5mg one time a day for three months
2543780|NCT02605772|Experimental|acarbose+Saxagliptin|acarbose 50mg tablet Saxagliptin 5mg tablet Saxagliptin 5mg one time a day for three months acarbose 100mg three times a day for three months
2543797|NCT02605460|Other|Unique|Patients will receive reduced Busulfan and Cyclophosphamide (BUCY) 2 conditioning regimen, consisting in the administration of two medications: Busulfan and Cyclophosphamide Plus: CXCR4 Antagonist. Then they will undergo a Hematopoietic Stem Cell Transplantation (Autologous or Allogeneic)
2543853|NCT02605291|Experimental|Experimental arm 1|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2543855|NCT02605291|Experimental|Experimental arm 2|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2543858|NCT02605291|Experimental|Experimental arm 3|One of three 7-day study arms consisting of 3 days of standardised diet followed by 3 days of dietary macronutrient manipulation and 1 day of experimental testing.
2543907|NCT02604849||Received therapy desconolizacion against Klebsiella pneumoniae|
2543908|NCT02604849||Patients who do not receive the therapy|
2543947|NCT02604615|Experimental|Capecitabine-oxaliplatin 2 cycles|oxaliplatin：65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
2543949|NCT02604615|Active Comparator|Capecitabine-oxaliplatin 4 cycles|oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
2543989|NCT02604277|Experimental|Group Intervention Program|Patients diagnosed with Bipolar Disorder will receive therapy in a group setting of 4 to 12 male and female participants.
2544092|NCT02604069|Experimental|Continuous Glucose Monitor|Application of CGM for 6 days following free flap reconstruction in conjunction with clinical monitoring
2544108|NCT02603536|Experimental|Vulnerable or pilot participant|"In addition to standard care, WelTel will send a weekly text message to participants in this arm for a one year period. Participants will be requested to respond to the outgoing message How are you? within 48 hours; they may respond that they are doing well or that they have a problem. A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
3203228|NCT00921466||Hospital Patients/Hospital Employees|
3203229|NCT00921466||Hospital employees|A group of 10 hospital employees used as baseline
2544219|NCT02603042||Observation|Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease
2544281|NCT02602717|Experimental|thyroid cancer|
2544335|NCT02602262||HIV D+/R+|HIV-infected individuals who accept an organ from an HIV-infected deceased donor
2544337|NCT02602262||HIV D-/R+|HIV-infected individuals who accept an organ from an HIV-uninfected deceased donor
2544432|NCT02601651|Experimental|Lidocaine|Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
2544434|NCT02601651|Placebo Comparator|Normal saline|Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
2544497|NCT02601144|Experimental|VFS|variable frequency deep brain stimulation (VFS)
2544499|NCT02601144|Active Comparator|HFS|high frequency deep brain stimulation (HFS)
2544501|NCT02601144|Active Comparator|LFS|low frequency deep brain stimulation (LFS)
2544505|NCT02601144|No Intervention|DBS off|deep brain stimulation off
2544551|NCT02600780|Active Comparator|Allopurinol|Allopurinol 300mg Tablets once daily for 90 days
2544561|NCT02600780|Experimental|Febuxostat|Febuxostat 40mg Tablets once daily for 90 days
2544676|NCT02599922|Experimental|Group 1: 2.0 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544677|NCT02599922|Experimental|Group 2: 4.0 x 10^10 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544678|NCT02599922|Experimental|Group 3: 1.2 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544679|NCT02599922|Experimental|Group 4: 3.6 x 10^11 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544680|NCT02599922|Experimental|Group 4a: 3.6 x 10^11 vg/mL of AGTC-401|Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544681|NCT02599922|Experimental|Group 5: 1.1 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544682|NCT02599922|Experimental|Group 5a: 1.1 x 10^12 vg/mL of AGTC-401|Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544683|NCT02599922|Experimental|Group 6: 3.2 x 10^12 vg/mL of AGTC-401|Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.
2544684|NCT02599922|Experimental|Group 7: MTD of AGTC-401|Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.
2544860|NCT02598921|Other|Office hysteroscopy|Office hystrescopy evaluated the uterine cavity for cavitary lesions
2544887|NCT02598492||Imputation of SF to PF|Patients required invasive mechanical ventilation within 6 hours after intubation
2544936|NCT02598232|Experimental|1,414nm Nd:YAG laser|It has high absorption coefficient in water and a short pulse width.
3203230|NCT00921479||Females|Norwegian females Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar.
3203231|NCT00921479||Males|Norwegian males of Caucasian origin, between the age of 18 and 45, who are candidates for surgical removal of one mandibular 3. molar
2543720|NCT02606084|Experimental|Cohort 1|Participants with mild renal impairment (Measured Creatinine Clearance [CLCR,m] greater than or equal to >= 50 to 79 milliliter/minute [mL/min]) will self-administer esketamine 28 milligram (mg) intranasally on Day 1.
2543725|NCT02606084|Experimental|Cohort 2|Participants with moderate renal impairment (CLCR,m >=30 to 49 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
2543726|NCT02606084|Experimental|Cohort 3|Participants with severe renal impairment (CLCR,m less than [<] 30 mL/min), not on dialysis will self-administer esketamine 28 mg intranasally on Day 1.
2543727|NCT02606084|Experimental|Cohort 4|Participants with normal renal function and no evidence of kidney damage (CLCR,m >= 80 mL/min) will self-administer esketamine 28 mg intranasally on Day 1.
2543763|NCT02605798|Experimental|T test|Test drug (Elbanovir)1 tablet contains 400 mg Sofosbuvir
2543766|NCT02605798|Active Comparator|B reference (first dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2543768|NCT02605798|Active Comparator|B reference (second dose)|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
3203232|NCT00921492|Experimental|Low-frequency electro-acupuncture|
3203233|NCT00921492|Active Comparator|Meeting a therapist - attention|
2543863|NCT02605083|Experimental|eFT508|Escalation cohort
2543911|NCT02604888|Other|Volunteers|20 volunteers both men and women with an age between 18 and 70 years suffering from Alopecia Areata in several types apply on the scalp drops of the MEXIS/M6S PATENT - lotion against Alopecia
3203234|NCT00921505|Active Comparator|Ibuprofen 400 mg|Ibuprofen oral single dose
3203235|NCT00921505|Active Comparator|Ibuprofen 1200 mg|Ibuprofen oral single dose
3203236|NCT00921505|Active Comparator|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) oral single dose
2544047|NCT02604004|Active Comparator|Period 1|Epivir ® tablet 150-mg single dose (drug reference)
2544048|NCT02604004|Experimental|Period 2|Lamivudine 150-mg tablet single dose (drug test)
2544060|NCT02603757|Active Comparator|Group A|Standard-dose of 2,000 IU Vitamin D3, daily
2544064|NCT02603757|Experimental|Group B|Higher-dose of 50,000 IU of Vitamin D3, weekly
2544123|NCT02603614|Experimental|Cenderitide-Placebo|"Infusion Period A: Cenderitide Infusion Period B: Placebo~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
2544132|NCT02603614|Experimental|Placebo-Cenderitide|"Infusion Period A: Placebo Infusion Period B: Cenderitide~This is a randomized, double-blind, placebo-controlled, cross-over trial. The sequence was either cenderitide crossed over to placebo or placebo crossed over to cenderitide, with the sequence divided into two 7-day infusion periods (Infusion Period A and Infusion Period B)."
3203237|NCT00921505|Active Comparator|Ibuprofen 400 mg + paracetamol 1000 mg|Paracetamol (acetaminophen) + ibuprofen oral single dose
3203238|NCT00921531|Experimental|Thalidomide and TACE|Thalidomide is used for adjuvant therapy for TACE
3203239|NCT00921531|Active Comparator|TACE only|
3203240|NCT00921544|Active Comparator|Oral Sucrose|Oral sucrose administered 2 mins prior to eye exam
3203241|NCT00921544|Placebo Comparator|Sterile water|0.2 mls of sterile water
2544400|NCT02601742|Active Comparator|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
2544401|NCT02601742|Placebo Comparator|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
2544421|NCT02601417|No Intervention|Control|Group which considers both blood culture and bile culture for antibiotics choice
2544424|NCT02601417|Experimental|Trial|Group which considers only blood culture and ignore bile culture for antibiotics choice. Patients in this arm would undergo bile culture but ignore the result when choosing antibiotics
2544519|NCT02601248|Experimental|Theliatinib|Theliatinib investigational product once a day (QD) will be orally administrated on a 28-day cycle There are 5 dose cohorts,including120mg/160mg/200mg/220mg/300mg, QD in the dose escalation stage .
2544545|NCT02600793|Experimental|Arm 1|Single dose IV ceftaroline will be administered
2544599|NCT02600494|Experimental|40 mg ITI-007 (Lumateperone)|40 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
2544601|NCT02600494|Experimental|60 mg ITI-007 (Lumateperone)|60 mg ITI-007 (Lumateperone) administered orally as capsules once daily for 6 weeks
2544603|NCT02600494|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
2544697|NCT02599727|Experimental|Active Isometric exercise|Subjects performing the isometric exercises intervention
2544698|NCT02599727|Active Comparator|No exercise|Subjects not performing the isometric exercises intervention
3203242|NCT00921570|Experimental|Amlodipine|
3203243|NCT00921570|Experimental|Valsartan|
3203244|NCT00921570|Experimental|Valsartan+Amlodipine|
3203245|NCT00921583||1|Examination of dental implants 20 years in function
3203246|NCT00921596|Other|Totally endoscopic cardiac operation|Patients with cardiac diseases undergo cardiac operations with totally endoscopic and cardiopulmonary bypass
3203247|NCT00921609||Acromegaly patients|All patients will undergo oral glucose tolerance test at postoperative day 1, 6 weeks, 3 months, and 1 year
3203248|NCT00921622|Active Comparator|Vitamin D|1000 IU twice daily for up to 10 days
3203249|NCT00921622|Active Comparator|Vitamin C|500 mg twice daily for up to 10 days
3203250|NCT00921635|Experimental|Maintain hemoglobin level above 120 g/L|Hemoglobin level from 120 g/L to 130 g/L
3203251|NCT00921635|Active Comparator|Maintain hemoglobin level above 100 g/L|Hemoglobin level from 100 g/L to 110 g/L
3203252|NCT00921648||Mr Q, 40 years old|Dementia, sensory aphasia, irritability, hallucination MRI showed cortical lesion, mesial temporal lobe atrophy.
3203253|NCT00921648||Mr Guo,35 years old|Dementia, sensory aphasia, tremor, gait disturbance MRI showed cortical lesion, enlarged ventricle, white matter lesion, cerebral atrophy
3203254|NCT00921648||Mr Zhang,40 years old|Dementia, apraxia of speech, gatism , irritability, insomnia, gait disturbance MRI showed white matter lesion, cerebral atrophy.
3203255|NCT00921648||Mr Liu,40 years old|Dementia, apraxia of speech, irritability, insomnia MRI showed normal.
3203256|NCT00921648||Mr Zhang,54 years old|Dementia, apraxia of speech MRI showed white matter lesion, cerebral atrophy.
2543721|NCT02606149|Active Comparator|Standard of information|Information on chemotherapy as done in routine practice following national and international guidelines
2543724|NCT02606149|Experimental|Truthful information on chemotherapy risks|Information on the potential role of anticancer chemotherapy in worsening life-threatening conditions
2543736|NCT02605850|Placebo Comparator|Ground beef patty + Water|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2543739|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Extract|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2543741|NCT02605850|Active Comparator|Ground beef patty + Pomegranate Juice|32 healthy subjects, ages 18-35 years who meet all the eligibility criteria in the screening phase of the study will receive the ground beef patty + water to evaluate the clinical efficacy of pomegranate on vascular health.Then subjects will be randomized to consume pomegranate juice or extract. At visit 2, subjects will be tested before and after meal with pomegranate juice or extract, then take pomegranate product daily for 4 weeks. At visit 3, subjects will tested before and after test meal with pomegranate products.
2543795|NCT02605655|Experimental|AMP-1915|Instant noodles contained AMP-1915 2 g/pc with meal, 1 pc/day for 3 months.
2543796|NCT02605655|Placebo Comparator|Placebo|Instant noodles with the same sharp and color as Experimental noodles with meal, 1 pc/day for 3 months.
2543833|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 1]|Phase 1: Radium-223 dichloride; 30 kiloBecquerel (kBq)/kg body weight (33 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2543836|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 2]|Phase 1: Radium-223 dichloride; 50 kBq/kg body weight (55 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2543838|NCT02605356|Experimental|Radium-223 dichloride [Phase 1, dose 3]|Phase 1: Radium-223 dichloride; 80 kBq/kg body weight (88 kBq/kg after implementation of NIST update) every 4 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.
2543840|NCT02605356|Placebo Comparator|Placebo +SoC [Phase 2]|Phase 2: Matching placebo (isotonic saline) every 4 weeks for a total of 6 doses plus SoC (Standard of care) bortezomib/dexamethasone.
2543843|NCT02605356|Experimental|Radium-223 dichloride + SoC [Phase 2]|Phase 2: Phase 1b-selected dose of radium-223 dichloride every 4 weeks for 6 doses plus SOC bortezomib/dexamethasone
2543983|NCT02604537|Active Comparator|Betamethasone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml betamethasone (Celestone)
2543986|NCT02604537|Experimental|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac (Toradol)
2544023|NCT02604147|Sham Comparator|Simulated inspiratory muscle training|Inspiratory muscle training with load of 15% of maximal inspiratory pressure.
2544025|NCT02604147|Experimental|Inspiratory muscle training group|Inspiratory muscle training with initial load of 50% of maximal inspiratory pressure.
2544127|NCT02603562|Experimental|ATYR1940|Intrapatient dose escalation ATYR1940: ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg for up to 12 Weeks. The dose level in this study will not exceed 3.0 mg/kg.
2544134|NCT02603562|Placebo Comparator|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
3203257|NCT00921661|Experimental|AVE0005 (aflibercept)|
3203258|NCT00921674|Experimental|Ivermectin|ivermectin
3203259|NCT00921700|Experimental|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg
2544447|NCT02601326|Active Comparator|Laparoscopic ventral mesh Rectopexy|Fixation of the rectum to the sacrum using laparoscopy and mesh
3203260|NCT00921700|Experimental|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg + paracetamol (acetaminophen) 1000 mg + codeine 60 mg
3203261|NCT00921700|Active Comparator|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg + codeine 60 mg
3203262|NCT00921700|Placebo Comparator|Placebo|Single oral dose of lactose as placebo
2543745|NCT02605759|Experimental|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation for the treatment of esophageal squamous cell dysplasia
2543817|NCT02605629|Experimental|CG428|Patients will self-administer the study product twice per day (morning, evening) for 6 months, for the efficacy assessment
2543823|NCT02605629|Placebo Comparator|Placebo|Patients will self-administer the study placebo twice per day (morning, evening) for 6 months, for the efficacy assessment
3203263|NCT00921713|Active Comparator|Enhanced Usual Care|An extensive packet of information including cancer education materials and treatment resources will be mailed to patients.
3203264|NCT00921713|Experimental|Oncology Nurse Care Management|In addition to this mailed information packet, patients in OCNM will be contacted by an experienced Oncology nurse with additional training in self-management support and psychosocial care. The intervention nurse, supported by a Medical Oncologist and Clinical Psychologist, will work closely with patients, their primary care physicians, and other clinicians to assure that patient needs discussed are met. The nurses will be trained in and employ proven counseling and psychotherapeutic approaches-behavioral activation and problem-solving treatment. The multi-component intervention will be based on the Chronic Care Model's six elements (health care organization, community resources, self-management support, delivery system design, decision support, and clinical information system).
3203265|NCT00921726|Experimental|1|Participants will receive treatment in the following order: Study Regimens A, B, C, D
3203266|NCT00921726|Experimental|2|Participants will receive treatment in the following order: Study Regimens B, A, C, D
2544055|NCT02603965|Experimental|Diagnostic (Cu 64 TP3805 PET/CT)|Patients receive copper Cu 64 TP3805 IV and undergo PET/CT at 30 minutes and 2 hours post-injection. Patients then undergo radical prostatectomy within 1 to 3 weeks after scans.
2544142|NCT02603497|Experimental|Control (Subjects with normal renal function)|Oral
2544145|NCT02603497|Experimental|Mild renal impairment|Oral
2544149|NCT02603497|Experimental|Moderate renal impairment|Oral
2544151|NCT02603497|Experimental|Severe renal impairment|Oral
2544206|NCT02603133|Other|Cohort 1|The intervention will begin for all NICUs, with baseline surveys as necessary pre-work. For those unable to attend, a link to the baseline survey will be emailed with site champion instructions to complete in groups at staff meetings and during shift change. Two weeks later, three randomly (random number generator) assigned NICUs (block 1) included in the first block webinar will then receive Module 1 of the intervention with Modules 2-6 being rolled out monthly. The second block of three NICUs starts approximately six-month later.
2544210|NCT02603133|Other|Cohort 2|This second block of 3 NICUs will start approximately six-months after roll-out of group 1. At time point 0 this NICUs in this group will receive a lecture on safety culture, unrelated to the burnout intervention.
2544215|NCT02603133|Experimental|Cohort 3 (July cohort) WISER 2.0|"Individually randomized to one of two cohorts. Cohort 1 to start will serve as the waitlist control 1 before starting their version of the intervention. Each cohort will experience modified versions of WISER, which only differ by the spacing of intervention. Participants will receive 10-day sequential or 10-day non-sequential rollout of the resilience tools. Seq will receive the tools on ten consecutive days. NSeq will receive messages daily noThursdays, Fridays and Saturdays.~Days 1 through 3 will be offered 3GT. Day 4 will continue with 3GT but add a single day activity for Gratitude. Day 5 adds a single activity for Awe. Day 6 adds a single day activity for RAK. Days 7 -10 the participant is offered the choice of Gratitude, Awe or RAK to accompany their daily 3GT. At 1 month follow-up time point, participants will receive 8 days of the 1 Good Chat tool, as a booster. At 6 month follow-up, participants will receive a gratitude exercise."
2544456|NCT02601365|Experimental|Aerosolized Sargramostim|A self-controlled, open-label study to evaluate safety of Sargramostim administered by nebulization
2544613|NCT02600286|Experimental|1|"Arm (1) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2544616|NCT02600286|Experimental|2|"Arm (2) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2544621|NCT02600286|Experimental|3|"Arm (3) will be randomised to receive either :~5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
2544721|NCT02599532|Other|Nephrotic syndrome|Subjects with nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
2544727|NCT02599532|Other|Non-nephrotic syndrome|Subjects without nephrotic syndrome will receive a single dose of apixaban 10 mg and will subsequently have blood drawn at 0, 0.5, 1, 3, 4, 6, 8, 24 hours after drug administration.
2544758|NCT02599233||The study population|"The study population consists of adult surgery patients at the Nîmes University Hospital, with recruitment based on the operating theater program for a predefined six month period and for a predefined list of surgeries. The latter list of surgical acts was established according to the Medicalization of Information Systems Progam (PMSI) database. Patients are recruited either the day before or the day after surgery, in their respective departments.~Interventions:~In hospital pain evaluation~In hospital questionnaires~Telephone conctact at 3 months"
2544803|NCT02598947|Experimental|Posterior shoulder tightness group|As well as receiving a strengthening program for the scapular and rotator cuff musculature, subjects allocated to the 'posterior shoulder tightness' treatment group will also receive specific manual therapy and home stretches to address stiffness of the posterior shoulder
2544831|NCT02599090|Experimental|4|Temozolomide + Higher Dose Sorafenib + Radiation, Followed by Lower Dose Temozolomide in a Longer Cycle + Higher Dose Sorafenib
2544923|NCT02598466||Abatacept|
2543743|NCT02605915|Experimental|Cohort 2B: Atezolizumab/Trastuzumab emtansine|Participants will receive atezolizumab in combination with trastuzumab emtansine every 3 weeks for 2 cycles, followed by docetaxel, carboplatin, trastuzumab and pertuzumab every 3 weeks for 6 cycles. Breast surgery will be performed no later than 6 weeks after neoadjuvant therapy. Upon the completion of surgery, participants will receive 12 cycles of single-agent trastuzumab every 3 weeks.
2543747|NCT02605915|Experimental|Cohort 2C: Safety Expansion|Participants with HER2-positive metastatic breast cancer/unresectable locally advanced breast cancer who received prior treatment with trastuzumab and a taxane chemotherapy will receive atezolizumab in combination with trastuzumab emtansine at the dose determined from stage 1, every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
2543755|NCT02605915|Experimental|Cohort 2D: Safety Expansion|Participants with HER2-positive metastatic breast cancer recently progressed on an HP containing regimen will receive atezolimumab in combination with trastuzumab and pertuzumab every 3 weeks until disease progression, lack of clinical benefit, or unacceptable toxicity.
2544182|NCT02603016|Experimental|GLSE compound group|GLSE compound 2g each time by mouth,twice a day for 42 days.
2544184|NCT02603016|Experimental|Maitake mushroom extract compound group|Maitake mushroom extract compound 2 tables each time by mouth,twice a day for 42 days.
2544188|NCT02603016|Experimental|Ginseng compound group|Ginseng compound 2 tables each time by mouth,twice a day for 42 days.
2544193|NCT02603016|No Intervention|blank control group|Take nothing.
2544249|NCT02602808||Severe acute pancreatitis group|Severe acute pancreatitis is characterised by persistent organ failure.
2544251|NCT02602808||Moderately severe acute pancreatitis|Moderately severe acute pancreatitis is characterised by the presence of transient organ failure or local or systemic complications in the absence of persistent organ failure.
2544253|NCT02602808||Mild acute pancreatitis|Mild acute pancreatitis is characterised by the absence of organ failure and the absence of local or systemic complications.
2544254|NCT02602808||post-ERCP pancreatitis|Patients with new onset of epigastric pain, an increase in pancreatic enzymes of at least three times the upper limit of the normal range within 24 hours after ERCP, and hospitalization for at least 2 nights.
2544313|NCT02602457|Experimental|Moderate-intensity continuous exercise|Moderate-intensity continuous exercise training
2544317|NCT02602457|Experimental|High-Intensity Interval Training|High-Intensity Interval Training
2544340|NCT02602106|Experimental|Intervention group|"The aquatic exercise program included a total of three 50-55 minutes session per week. Pregnant women started at 9 weeks and finished at 38-39 weeks.~Each session included 10 minutes of warm up and 10 minutes of cool down including an specific pelvic floor muscle training. The core section of the session included aerobic and strength moderate exercise in water during 25 to 30 minutes"
2544342|NCT02602106|No Intervention|Control group|Sedentary healthy pregnant women
3174192|NCT00620672|Other|1|The dietary supplement is 400 mg/day of the omega 3 fatty acid docosahexaenoic acid . The docosahexaenoic acid is provided in triglycerides from Martek Biosciences, Maryland. The supplement is a blend of soybean and canola oil, blended to resemble the usual fat composition of the diet. Both the supplement and placebo provide a total of about 10 calories per day to the diet.
3174193|NCT00620672|Other|2|Dietary supplement is vegetable oil, the placebo.
2544514|NCT02600962||STEMI|Patients discharged with STEMI
2544517|NCT02600962||NSTEMI|Patients discharged with NSTEMI
2544532|NCT02600884|Experimental|Families Talking Together Plus (FTT+HPV)|Parents in the experimental group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the experimental intervention includes parent-child sexual health communication and HPV vaccination navigation.
2544533|NCT02600884|Active Comparator|Brief motivational interviewing (BMI)|Parents in the brief motivational interviewing (BMI) group will attend a 1-hour intervention session, receive program materials to use with youth at home, and receive 2 booster phone calls post-intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
2544555|NCT02600650|Experimental|Experimental|Receive daily authentic Testosterone boosting supplement
2544565|NCT02600650|Placebo Comparator|Placebo|Receive daily placebo supplementation
2544695|NCT02599870|Experimental|NeuroIDgenetix Test Panel Intervention|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, length of hospital stay and number of medical visits will be measured throughout the study.
3174194|NCT00620685|Placebo Comparator|1|
3174195|NCT00620685|Experimental|2|
3174196|NCT00620685|Experimental|3|
3174197|NCT00620724|Placebo Comparator|A|Placebo three times daily
3174198|NCT00620724|Experimental|B|20 mg of slow-release Nifedipine three times daily
3174199|NCT00620737|Experimental|Active Arm|Active Treatment
3174200|NCT00620737|Placebo Comparator|Control Arm|Placebo treatment
3174201|NCT00620789|Active Comparator|1|Cognitive-Behavior Therapy for insomnia (CBT-I) + Antidepressant medication
3174202|NCT00620789|Placebo Comparator|2|Cognitive Behavior Therapy for Insomnia (CBT-I) + placebo medication
3174203|NCT00620789|Sham Comparator|3|Antidepressant medication + Sleep Hygiene Control (SH)
3174204|NCT00620802|Experimental|A|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg)
3174205|NCT00620802|Active Comparator|B|Plavix (clopidogrel 75 mg)
3174206|NCT00620841||A|Patients treated with tacrolimus and experiencing a drug interaction
3174207|NCT00620867|Experimental|Ibuprofen|
3174208|NCT00620867|Experimental|Celecoxib|
3174209|NCT00620867|Placebo Comparator|placebo|
3174210|NCT00620893|Active Comparator|1|1. PEG-400 based artificial tear
3174211|NCT00620893|Active Comparator|2|2. Systane
3174212|NCT00620906|Other|A|Manipulation
3174213|NCT00620919|Experimental|1|Drug + MDCT
3174214|NCT00620932|No Intervention|Control Group|These patients will continue with whatever routine exercise they already engage in.
3174215|NCT00620932|Experimental|Exercise Arm|These patients will participate in a controlled, supervised exercise program.
3174216|NCT00620958|Experimental|1|Participants will receive individual cognitive behavioral therapy with parent reinforcement training.
2543748|NCT02606006|Active Comparator|Non-AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. None of the sessions will include use of a canine for AAT. This group will include the intervention of Standard of Care Physical Therapy
2543753|NCT02606006|Experimental|AAT Group|Inpatients in this group will receive 3-5 brief afternoon physical therapy sessions over 3-5 successive days. The session on the middle day will include use of a canine for AAT. This group will receive a behavioral intervention of Canine Animal-Assisted Therapy.
2543891|NCT02605265|Active Comparator|Capecitabine Alone|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 825mg/m2 bid Monday-Friday per week~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
2543894|NCT02605265|Experimental|Capecitabine with Irinotecan|"Concurrent Chemoradiotherapy:~Radiation: 50Gy/25Fx; Capecitabine: 625mg/m2 bid Monday-Friday per week; Irinotecan: 80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)~Chemotherapy in Interval Between CRT and Surgery:~Capecitabine: 1000mg/m2 bid d1-14; Irinotecan: 200mg/m2 d1~Surgery:~Scheduled 6-8 weeks after the completion of CRT~Adjuvant Chemotherapy:~Capecitabine: 1000mg/m2 bid d1-14; Oxaliplatin: 130mg/m2 d1; q3w, 5cycles"
2543968|NCT02604602||PPH|
2543970|NCT02604602||non-PPH|
3203267|NCT00921739|Experimental|IMRT concurrent with chemotherapy|6 fractions of esophageal sparing IMRT weekly for 5-6 weeks (dependent on dose cohort) concurrent with standard chemotherapy: Cisplatin 50 mg/m2 /d intravenously (IV) on days 1, 8, 29, and 36. Etoposide 50 mg/m2 /d IV on days 1 through 5 and 29 through 33.
3203268|NCT00921752||Patients at high cardiovascular risk|
3203269|NCT00921765|Placebo Comparator|Placebo + Placebo|Saline single bolus dose iv + saline single bolus dose iv
3203270|NCT00921765|Active Comparator|Placebo + Ketamine|Saline single bolus dose followed by single bolus dose of ketamine 0.2 mg/kg bw
3203271|NCT00921765|Active Comparator|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
3203272|NCT00921765|Active Comparator|Naloxone + Ketamine|Single bolus dose of ketamine 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
3203273|NCT00921791|Experimental|Home Blood Pressure Monitoring|Automatic oscillometric device for blood pressure measurement at home plus usual care.
3203274|NCT00921791|Experimental|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists plus usual care.
2544318|NCT02602353|Experimental|Loxoprofen Pain Patch|One Active Pain Patch containing loxoprofen applied once daily for 3 days
2544319|NCT02602353|Placebo Comparator|Placebo Patch|One Placebo Patch applied once daily for 3 days
2544320|NCT02602353|Other|No Treatment|No Treatment for 3 days
2544332|NCT02602067|Experimental|131I-Tenatumomab|"Diagnostic: each patient will receive one single i.v. infusion of 370 MBq±10% 131I-Tenatumomab in 10 ml of saline (conveyed by 10 ±10%, 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333 ° µl / min).~Therapeutic: each patient will receive one single i.v. infusion, escalating 131I-Tenatumomab dose starting at 2.5 GBq±10%,with escalation steps of 1 GBq, up to 5.5 GBq±10% in 10 ml of saline, (conveyed by 10 ±10% , 20 ±10%, 40 ±10% mg of Tenatumomab). It will be administered as a short infusion in approximately 30 minutes (333° µl / min)"
2544380|NCT02601859|Experimental|Phase 3|Administration of Lithium to 11 individuals with MCI (non-randomised) for 9 weeks. Lithium dose escalates from 100mg to 200mg to 400mg, then a 3 week wash out period, total study duration 12 weeks. Blood samples taken at regular intervals throughout trial and analysed for GSK-3 enzyme activity in blood.
3203275|NCT00921791|Active Comparator|Pharmaceutical care|Consultations with the pharmacists plus usual care.
3203276|NCT00921791|Active Comparator|Control|Usual care: participants are instructed to keep on their current antihypertensive medication and receive non-pharmacological recommendations for hypertension treatment.
3203277|NCT00921804|Experimental|1|AZD8529 40 mg
3203278|NCT00921804|Placebo Comparator|2|Placebo
3203279|NCT00921804|Other|3|Risperidone 4 mg (2mg on Day 1)
3203280|NCT00921830|Experimental|Ibuprofen|ibuprofen
3203281|NCT00921856|No Intervention|CAD|Patients admitted with suspicion of CAD and proof of CAD after coronary angiography.
3203282|NCT00921856|Experimental|No-CAD|Patients admitted with suspicion of CAD but without proof of CAD after coronary angiography will undergo intracoronary acetylcholine provocation test.
2544631|NCT02600260|Other|enoxaparin|A prospective study that will evaluate all pregnant women admitted for clinical treatment and / or surgery through the application of a thromboprophylaxis protocol with risk assessment score.The patient in whom prophylaxis would be indicated are those with scores greater than or equal to 3. The drug to be used is enoxaparin and the dose to be used depends on the weight of the patient.It will be further assessed: adverse effects of treatment with enoxaparin, protocol failure in the group treated and untreated (without anticoagulation) and bleeding incidence in both groups.
2544633|NCT02600260|Other|no intervention|Pregnant women admitted in hospital for clinical treatment and/or delivery and that does not score for thromboprophylaxis.
2544661|NCT02599883|Experimental|MulticenterRecruitment|COPD phenotypization by Low-Dose Computed Tomography
2545168|NCT02596581|No Intervention|diabetics with periodontally healthy group|Control group
3203283|NCT00921869|Experimental|1|
3203284|NCT00921882||Oral glucose tolerance test|oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.
3203285|NCT00921908||epidural catheter|subfascial placement of a triple-orifice epidural catheter
3203286|NCT00921908||multiholed catheter|subfascial placement of a multi-orifice 15 cm catheter
3203287|NCT00921921|Experimental|Extra-fine particle steroid inhaler|
3203288|NCT00921921|Placebo Comparator|Placebo control|
3203289|NCT00921960|No Intervention|Usual Care|Usual Care will involve ongoing management from the general practitioner, nurse-led assessment of cardiovascular risk at the general practice and referral to specialist services as deemed necessary.
3203290|NCT00921960|Other|Intervention|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate
2543751|NCT02606058|No Intervention|Early cord clamping (Control Arm)|Immediate cord clamping (< 10 seconds after birth). The cord is clamped 6 cm from the umbilicus within ten seconds of delivery of the baby.
2543758|NCT02606058|Experimental|Deferred cord clamping|Deferred cord clamping. Investigator/Research personnel holds the baby as low as possible below the level of the introitus or placenta for 60 seconds and not to exceed 80 seconds, then clamps the cord about 6 cm from the umbilicus.
2543828|NCT02605434|Experimental|AP-CD/LD|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d and Placebo IR Carbidopa/ levodopa
2543829|NCT02605434|Active Comparator|SINEMET®|IR Carbidopa/ levodopa tablets 25/100 mg at least 4 times a day and placebo AP-CD/LD
2543991|NCT02604420||Transplant, no TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant but do not meet the criteria for a thrombotic microangiopathy in the one year follow up period. No interventions anticipated.
2543992|NCT02604420||Transplant, +TMA|Adult patients who undergo an allogeneic hematopoietic stem cell transplant and meet the criteria for a thrombotic microangiopathy in the one year follow up period. Possible interventions include observation, treatment of an underlying infection or GvHD, use of plasma exchange, or use of anti-complement therapy (eculizumab or other anti-complement drug). Eculizumab is used as a 900mg intravenous infusion over 35 minutes, given weekly for 4 weeks, then 1200mg every other week. Patients must be vaccinated against meningococcus 2 weeks before starting drug or, if that is not feasible because of the physician's assessment of the severity of the TMA, given prophylactic antibiotics for the 2 week period before immunization has taken hold.
2544033|NCT02604095|Experimental|Melatonin|Take one table at bedtime.
2544073|NCT02603822|Experimental|Healthy Volunteers|Subjects will receive a saccharide solution of 12C mannitol 100 mg, 13C mannitol 100 mg, and lactulose 1 g in 250ml of water at visits 2, 5, and 7 prior to permeability testing. The subjects will also receive Indomethacin capsules prior to visit 5.
2544122|NCT02603575|Experimental|Caspofungin and corticosteroids|patients treat with caspofungin and corticosteroids on the base of sulfanilamide
2544128|NCT02603575|Active Comparator|Caspofungin and no corticosteroids|patients treat with caspofungin on the base of sulfanilamide
2544136|NCT02603575|Active Comparator|corticosteroids and no caspofungin|patients treat with corticosteroids on the base of sulfanilamide
2544141|NCT02603575|Active Comparator|no corticosteroids and no caspofungin|patients treat with sulfanilamide only
2544194|NCT02603081|Placebo Comparator|Placebo|0 mg SPI-1005 bid po x 21d
2544200|NCT02603081|Active Comparator|Low dose|200 mg SPI-1005 bid po x 21d
2544201|NCT02603081|Active Comparator|Mid dose|400 mg SPI-1005 bid po x 21d
2544203|NCT02603081|Active Comparator|High dose|600 mg SPI-1005 bid po x 21d
2544257|NCT02602691|Active Comparator|Endomyocardial biopsy|Systematic endomyocardial biopsies performed according to a planned monitoring schedule in usual care for patients with a heart transplantation.
2544258|NCT02602691|Experimental|AlloMap® test|Noninvasive gene expression profiling blood test (AlloMap®) performed instead of endomyocardial biopsies when planned in the monitoring schedule for patients with a heart transplantation.
2544363|NCT02602158|Active Comparator|Octanoic acid (1-13C, 99%)|100 µL 13C Octanoic acid (Cambridge isotope laboratories)
2544364|NCT02602158|Active Comparator|TRIOCTANOIN (1,1,1-13C3, 99%)|100 µL 13C Trioctanoin (Cambridge isotope laboratories)
2544439|NCT02601612|Experimental|Group 1: D46cpΔM2-2 Vaccine|RSV-seropositive children will receive a single dose of 10^6 PFU D46cpΔM2-2 vaccine at study entry (day 0).
2544442|NCT02601612|Placebo Comparator|Group 1: Placebo|RSV-seropositive children will receive a single dose of placebo at study entry (day 0).
2544444|NCT02601612|Experimental|Group 2: D46cpΔM2-2 Vaccine|RSV-seronegative infants and children will receive a single dose of 10^5 PFU D46cpΔM2-2 vaccine at study entry (day 0).
2544446|NCT02601612|Placebo Comparator|Group 2: Placebo|RSV-seronegative infants and children will receive a single dose of placebo at study entry (day 0).
2544515|NCT02601092|Experimental|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
2544516|NCT02601092|Active Comparator|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
2544542|NCT02600754|Experimental|IT-PST|IT-PST refers to problem-solving therapy that will be tele-delivered by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More).
2544543|NCT02600754|Experimental|IT-SCM|IT-SCM refers to self-care management support that will be tele-delivered by trained lay advisers (TLAs) co-located in an aging-service agency (Meals on Wheels and More).
2544546|NCT02600754|No Intervention|Wait-list control (Usual Care or UC)|Participants who will serve as controls with telephone safety calls
2544602|NCT02600455||Patients who are treated with ORENCIA|Patients who are treated with ORENCIA according to the approved indications, and dosage and administration
2544630|NCT02600156|Experimental|Single arm study|MR guided focal laser ablation of prostate cancer using the Visualase Thermal Therapy System.
2544658|NCT02599935|Experimental|educational intervention and supplements|structured educational intervention and dietary supplements
2544660|NCT02599935|Active Comparator|usual interventions|Usual treatment without nutritional supplements or structured assessment
2544741|NCT02599506||breast cancer radiation therapy|Observation over a period of all treatment sessions for radiotherapy
2544789|NCT02599181|Experimental|WITH-Group: alcoholic skin disinfection|In the WITH-group, the skin is disinfected with an aerosolized alcoholic solution propanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland prior to perineural catheter removal.
2543756|NCT02605902|Active Comparator|iCBIT|internet-delivered Comprehensive Behavioral Intervention for Tics (iCBIT) consisting of psychoeducation, habit reversal training (HRT), function-based assessment and intervention, and relaxation training
2543761|NCT02605902|Placebo Comparator|Control intervention/reference test|internet-delivered psychoeducation and relaxation training.
2543764|NCT02605902|Active Comparator|face-to-face CBIT-treatment|face-to-face CBIT-treatment
2543809|NCT02605538|Active Comparator|Cystic Fibrosis|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
2543813|NCT02605538|Active Comparator|Healthy volunteers|Vaccination with Twinrix (TM), 3 doses within 6 months according to the manufacturer's instruction. The response will be studied in a time frame of 6 months.
2543854|NCT02605161||Parkinson's disease group|"patients diagnosed with Parkinson's disease by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
2543856|NCT02605161||Control group|"patients diagnosed with either essential tremor or cervical dystonia by a movement disorder specialist from the deep brain stimulation program at The Ottawa Hospital, Civic Campus~to undergo pre-operative MRI with contrast"
2543876|NCT02604953||Ocular Hypertension patients|Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2543879|NCT02604953||Healthy Controls|Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2543882|NCT02604953||Glaucoma patients|Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service. Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
2543918|NCT02604680|Experimental|BLI1100-1|Topical gel
2543919|NCT02604680|Experimental|BLI1100-2|Topical gel
2543923|NCT02604680|Experimental|BLI1100-3|Topical gel
2543926|NCT02604680|Experimental|BLI1100-4|Topical gel
2543929|NCT02604680|Placebo Comparator|Placebo|Topical gel
3174217|NCT00620958|Experimental|2|Participants will receive individual cognitive behavioral therapy with parent relationship training.
3174218|NCT00620958|Active Comparator|3|Participants will receive individual cognitive behavioral therapy alone.
2544052|NCT02603848|Experimental|Ibuprofen suspension|Ibuprofen suspension (Advil) will be administered orally at a dose of 10mg/kg every 6 hours for 72 hours post-surgery.
2544053|NCT02603848|Active Comparator|Morphine Sulfate suspension|Morphine sulfate suspension will be administered orally at a dose of 0.02 - 0.04 mg/kg every 6 hours for 72 hours post-surgery.
2544124|NCT02603640|Experimental|epileptic patient|
2544179|NCT02603237|Other|Glucose tolerance test|All participants will receive an oral standardized glucose tolerance test
2544180|NCT02603237|Other|Fat tolerance test|The same participants will receive an oral standardized fat load test
2544235|NCT02602899|Experimental|PINS Deep Brain Stimulator|Deep Brain Stimulator is on,continuous stimulation to the brain,
2544268|NCT02602600|Experimental|Liraglutide|Liraglutide up to 3.0 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks followed by 2 weeks of weight maintenance diet. Before initiating treatment participants will serve as their own controls for 4 weeks.
2544321|NCT02602340|Experimental|Behavioral Activation therapy|Participants will complete 10, 90-minute sessions of Behavioral Activation therapy, conducted using a group format. Each group will include 8-12 participants. Behavioral Activation therapy seeks to target behaviors that might maintain or worsen the depression.
2544423|NCT02601339||GM-IVH|Premature infants who developed germinal matrix-intraventricular hemorrhage. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
2544426|NCT02601339||Posthemorrhagic hydrocephalus (PHH)|"Premature infants with complications of hydrocephalus secondary to intraventricular hemorrhage and have the potential to receive endoscopic third ventriculostomy (ETV) with choroid plexus cauterization (CPC) and/or ventriculoperitoneal (VP) shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
2544428|NCT02601339||Healthy Control (HC)|Premature infants without diagnosed brain injuries. FDNIRS-DCS measures will be performed up to once a day if clinically feasible.
2544430|NCT02601339||Ventriculomegaly Control (VC)|"Infants who have symptomatic hydrocephalus of any etiology except post-hemorrhagic etiology and have the potential to receive ETV/CPC and/or VP shunting for clinical treatment.~FDNIRS-DCS measures will be performed up to once a day if clinically feasible. Additional FDNIRS-DCS measures will be performed on the day of hydrocephalus treatment to monitor the treatment response if clinically feasible. These additional measures are limited to up to four times a day."
2544624|NCT02600273|Active Comparator|Usual brand cigarettes|During one session, participants will smoke their usual brand cigarettes
2544625|NCT02600273|Experimental|Lower nicotine content cigarettes|During one session, participants will smoke SPECTRUM Research Cigarettes
2545169|NCT02596581|No Intervention|systemically and periodontally healthy group|Control group
3174219|NCT00620971|Experimental|1|NC/Avastin->DG/Avastin
3174220|NCT00620971|Experimental|2|DG/Avastin
3174221|NCT00620997|Experimental|1|"patients randomized to 0.05% Proparacaine drops on a PRN basis for up to 7 days~Acetaminophen with Codeine for breakthrough pain~topical Gatifloxacin drops"
3174222|NCT00620997|Placebo Comparator|2|"placebo drops on a PRN basis for up to 7 days post injury~Acetaminophen with Codeine for breakthrough pain~Gatifloxacin drops"
3174223|NCT00621010|Experimental|Cohort|
3174224|NCT00621036|Experimental|methotrexate IV once every 2 weeks|
3174225|NCT00621062|Active Comparator|High Ligation of the GSV|
3174226|NCT00621062|Active Comparator|Endovenous Laser Ablation|
3174227|NCT00621062|Active Comparator|Radiofrequency ablation|
3174228|NCT00621062|Active Comparator|Foam Sclerotherapy|
3174229|NCT00621075||1|Pulmonary Arterial Hypertension
3203291|NCT00921973|Active Comparator|VAX102|Simultaneous administration of VAX102 1 ug i.m. plus TIV
2543808|NCT02605551|Active Comparator|OMT Group|During the initial visit, the subject will have his BP recorded manually by the osteopathic physician in a standardized fashion. The subject will then undergo the OMT protocol and have his BP recorded again immediately afterwards. This will represent the conclusion of the initial visit. There will be 2 subsequent visits about 2-3 weeks apart that will be identical to this visit. Following the third visit, the next follow-up will be 2 months afterwards. However, the patient will only have his BP checked, and will not undergo an OMT treatment. The final visit will be another 2 months afterwards and will also be a simple BP check with no OMT treatment. The principles of lifestyle modification (diet/exercise/weight loss) will also be discussed at each visit.
2543819|NCT02605551|Placebo Comparator|Control Group|Patients in this arm will only receive lifestyle modification recommendations at each visit, along with a BP check. No antihypertensive medication changes will be made unless indicated by the guidelines.
2543866|NCT02605096|Experimental|MRI group|"This arm assess the use of MRI as the first line examination of suspected scaphoid fracture (replacing conventional plain x-ray).~Patients with negative findings will receive a splint and contact card to a specialist wrist clinic if the pain persists for ten to fourteen days after initial presentation.~Patients with positive findings will receive a plaster cast and undergo a CT scan (to evaluate displacement) and will be referred to the fracture clinic. Furthermore, if the CT scan confirms a displaced fracture, that might require surgery, the patient should be seen by a Hand Specialist at fracture clinic.~All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
2543868|NCT02605096|Active Comparator|X-ray group|"This arm is the current standard of care pathway for the diagnosis of patients with suspected scaphoid fracture. This includes an initial clinical assessment on arrival to the Emergency Department of Urgent Care Centre followed by a plain x-ray (using a 4-view scaphoid protocol).~Patients with negative/positive findings for scaphoid fracture in the initial X-ray will be immobilised with a splint/plaster cast.~All patients will be referred to an initial fracture clinic and a proportion of patients are likely to require additional imaging scans (usually CT but also MRI) and follow-up appointments in the fracture clinic. All patients enrolled in the pilot should undergo a 4-view plain x-ray 3 months after the initial ED/UCC presentation."
3203292|NCT00921973|Placebo Comparator|Placebo|
3203293|NCT00921986||Arrhythmias|Patients with arrhythmias
3203294|NCT00921986||Control Subjects|Subjects that do not have a history of cardiac arrhythmias.
3203295|NCT00922012|Experimental|Electromagnetic stimulation|Electromagnetic stimulation therapy
3203296|NCT00922025||1|Male patients with non-small cell lung cancer (NSCLC) of adeno histology
3203297|NCT00922038|Experimental|High reward|
2544181|NCT02603029|Placebo Comparator|Placebo cream|Cream with 0% Silver fir wood extract (Belinal)
2544183|NCT02603029|Active Comparator|Belinal cream|Cream with 2% Silver fir wood extract (Belinal)
2544243|NCT02602860|Experimental|Levetiracetam|"Cohort 1: Half of the subjects will receive LEV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2: Half of the subjects will receive LEV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of LEV (500 mg to 2500 mg) or BRV (50 mg to 200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session (Visit 4), 7 to 28 days after completion of their first session (Visit 3) to enter the BRV arm."
2544244|NCT02602860|Experimental|Brivaracetam|"Cohort 1:Half of the subjects will receive BRV as a 5 minute iv infusion during the second Positron Emission Tomography (PET) scan, 60 minutes after the start of [11C]UCB-J administration.~Cohort 2:Half of the subjects will receive BRV as a 5 minute iv infusion during the first PET scan, 60 minutes after the start of [11C]UCB-J administration. The dose of BRV (50-200 mg) will be decided based on the data obtained in Cohort 1. Subjects will return for a second PET imaging session,7 to 28 days after completion of their first session to enter the LEV arm.~Cohort 3:void Cohort 4:Subjects will take oral BRV (25-100 mg bid) for 4 days and a single dose of BRV on Day 5. Pre-/post-block scans will be obtained at the first dose, one post-block scan after the last dose. Additional post-block scans may be obtained 8-10 and 28h or later after last dose; if last scan not needed, subject will return 7 to 28 days later for a post-block scan. Dose range for LEV in Cohort 4 will be 250 to <1500mg."
2544301|NCT02602444||STEMI|ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
2544302|NCT02602444||NSTEMI|non-ST-elevation myocardial infarction patients receiving 180 mg ticagrelor loading dose
2544372|NCT02602132|Experimental|Clamping group|Indwelling urinary catheter is clamped before removal and unclamped when the patient expresses his desire to urinate.
2544375|NCT02602132|No Intervention|Free drainage group|The urinary catheter will be removed without prior clamping.
3203298|NCT00922038|Experimental|Low reward|
3203299|NCT00922038|No Intervention|Control|
3203300|NCT00922051|Experimental|Group 1|Application of Acu-TENS
3203301|NCT00922051|Placebo Comparator|Group 2|
2544598|NCT02600429|Experimental|RGN-259|It is a preservative-free, sterile eye drop solution containing Tβ4
3203302|NCT00922064|Experimental|ECT|
3203303|NCT00922103|Experimental|INRA|Patients treated for medical refractory Ulcerative Colitis
3203304|NCT00922103|Active Comparator|IPAA|Patients treated for medical refractory Ulcerative Colitis
3203305|NCT00922129|Experimental|Conversion to sirolimus|
3203306|NCT00922129|Active Comparator|Calcineurim inhibitor reduction|
3203307|NCT00922155|No Intervention|EBUS|After the PPLs been localized by endobronchial ultrasound(EBUS), patients in the EBUS group received transbronchial biopsy and bronchial washing at the bronchus located by EBUS.
3203308|NCT00922155|Active Comparator|EBUS-GS|After PPLs been localized by EBUS, the EBUS and guide sheath were then inserted to localize the lesion again. Transbronchial biopsy and brushing were done through the guide sheath after the probe been removed.
3203309|NCT00922168||Cardiac Surgeries: CABG, valve replacements|
3203310|NCT00922181|Experimental|MWA|Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease
3203311|NCT00922181|Active Comparator|RFA|Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
2543765|NCT02606045|Active Comparator|Group I|Subjects randomized to Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
2543767|NCT02606045|Active Comparator|Group II|Group II will receive Arm B, tranexamic acid 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
2543831|NCT02605382|Experimental|chlorhexidine gluconate|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2543835|NCT02605382|Placebo Comparator|placebo|15 ml of solution every 12 hours, twice a day, 30 minutes after brushing, for 14 days
2543869|NCT02605070|Experimental|Infertility group|Patients referred will be evaluated to participate in the study and then asked to take part.In this visit,the normal protocol for infertility patients will be followed and at least 2 spermiograms and a blood test analyzing the following parameters:FSH, LH,Estradiol,Total testosterone,SHBG, Albumin,Calculation of bioavailable testosterone,Prolactin.If these tests have not been performed,a second baseline visit will be scheduled.Should the patient meet all the inclusion criteria and after the patient has signed an informed consent form agreeing to participate in the study,the physician will prescribe the medication and schedule visits.Before initiating the treatment, they will provide a semen sample.This sample will be sent to the Center for Reproductive Biology,where the sample will be subjected to epigenetic analysis.The patient will be given samples of Bravelle.It is administered subcutaneously.The dose will be 150 IU 3times a week for 3months
2543870|NCT02605070|No Intervention|Fertily group|"Patients who volunteer will be informed of the nature of the study and asked to sign the informed consent form. At least two spermiograms will be performed along with a blood test analyzing the following parameters:FSH,LH,Estradiol,Total testosterone,SHBG,Albumin,Estimation of bioavailable testosterone,Prolactin.~A second baseline visit will be scheduled to evaluate the test results and to check whether these subjects meet all the inclusion criteria for the control group. Those subjects will provide a semen sample which will be stored at -20º C.~Outpatient visit: week twelve: a physical exam will be carried out to identify any adverse reactions. A blood test and a semen sample will also be obtained."
2543946|NCT02604836|Experimental|Ibandronate|Participants will receive 150 milligrams (mg) of ibandronate as a film-coated tablet once-monthly.
2544095|NCT02603718|Experimental|Standard physical therapy treatment with feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured, and provided to both therapist and patient on-line during one of the two treatments.
2544097|NCT02603718|Experimental|Standard physical therapy treatment without feedback|Standard physical therapy rehabilitation is administered to stroke patients. Attention level of the patient gathered with an EEG tool is measured but feedback is not provided.
2544373|NCT02601807|Active Comparator|Active|Subjects given active ActiPatch device before or after crossover (randomised)
2544376|NCT02601807|Placebo Comparator|Placebo|Subjects given placebo ActiPatch device before or after crossover (randomised)
2544448|NCT02601547|Experimental|intervention|"PET-FDG brain imaging and NPT should be performed at T0 (within the 15 days before chemotherapy), at Tf (within 1 month after chemotherapy termination), T+12 (Tf+12 months: within the first month after one year of achievement of chemotherapy). Several PET parameters should be calculated: minimal Standard Uptake Value (SUV), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.~NPT scores (3 values) should be correlated with the five better values on PET-FDG.~Each patient will be monitored along a time period of 18 months.~Duration of the study: one year to include the 15 patients with all the exams; 18 months follow-up for each; total of 30 months."
2544494|NCT02601118|Experimental|training group|41 training students were pre-tested before education with Micro Expression Training Tool (METT) and Subtle Expression Training Tool (SETT) at baseline and then, took second METT and SETT tests after a 1-hour class about interpreting micro and subtle expressions.
2544498|NCT02601118|No Intervention|control group|41 control students were pre-tested before education with METT and SETT at baseline and then, took the second tests without attend the training class.
3168739|NCT00554710|Active Comparator|2|Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.
3168740|NCT00554723|Experimental|A|NeuroAid
2544600|NCT02600429|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4.
3168741|NCT00554723|Placebo Comparator|B|NeuroAid matched Placebo
3168742|NCT00554736|Experimental|1|In the first phase, subjects with a history of grass pollinosis, with positive skin tests to grass, will be studied out of season and will be randomized to active treatment for 4 months.
3168743|NCT00554775|Experimental|erlotinib hydrochloride|WBRT plus Tarceva (OSI-774, erlotinib) PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
3168744|NCT00554775|Placebo Comparator|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride arm
3168745|NCT00554814|Experimental|3|Blédilait Biofer® milk (1,1mg/100kcal)
3168746|NCT00554814|Experimental|1|Blédilait Biofer® milk (2mg/100kcal)
3168747|NCT00554814|Active Comparator|2|Milk supplemented with ferrous sulphate (2mg/100kcal)
3174230|NCT00621088|Active Comparator|Intertan|
3174231|NCT00621101|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
3174232|NCT00621101|Active Comparator|B|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
2543771|NCT02605746|Experimental|2-4 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 2-4 hours prior to craniotomy for tumor resection.
2543772|NCT02605746|Experimental|4-8 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 4-8 hours prior to craniotomy for tumor resection.
2543778|NCT02605746|Experimental|22-26 hours|All patients will be orally-administered 10-14 doses of ceritinib 750mg with the final dose occurring at one of three intervals before brain tumor resection. This arm has the last ceritinib dose 22-26 hours prior to craniotomy for tumor resection.
2543816|NCT02605512|Other|Breast cancer patients with 3DCRT|Measures of subclinical functional and anatomical cardiac lesions and circulating biomarkers 'Subclinical cardiac lesions and biomarkers'
2543859|NCT02605213|Experimental|Vancomycin|Vancomyicn 250 mg every 6 hours for 12 weeks
2543861|NCT02605213|Placebo Comparator|Placebo|placebo every 6 hours for 12 weeks
2543896|NCT02604901|Experimental|Screening and Brief Intervention (BI)|Screening and Brief Intervention (BI) at initial prescription fill and at each additional refill.
2543898|NCT02604901|Experimental|Pill Box (PB)|Pill Box (PB) and information about their medications at the initial fill and at each additional refill.
2543900|NCT02604901|Experimental|Brief Intervention + Pill Box (BI+PB)|Screening and Brief Intervention (BI) and Pill Box (PB) at initial prescription fill and at each additional refill.
2543903|NCT02604901|No Intervention|Standard Care (SC)|The Standard Care (SC) arm administered traditional dispensing and counseling by Rite Aid® pharmacists.
2543931|NCT02604628|No Intervention|Control|Patients will be treated as standard of care.
2543933|NCT02604628|Experimental|Antibiotic Stewardship Intervention|Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.
2544010|NCT02604355|Experimental|Healthy Participants (Multiple-Ascending Dosing)|
2544011|NCT02604355|Experimental|Healthy Participants (Single-Ascending Dosing)|
2544014|NCT02604355|Experimental|Healthy Participants (Study of Food Effect)|
2544017|NCT02604355|Experimental|Participants with Chronic Hepatitis B (Proof of mechanism)|
2544087|NCT02603874|Experimental|Target Tape|Including target tape in the procedure
2544089|NCT02603874|No Intervention|Control|Without target tape in the procedure
2544110|NCT02603601|Active Comparator|Standard lifestyle intervention|The standard lifestyle intervention is a 1-hour individual nutritional counseling session with a registered dietician at BIDMC.
2544111|NCT02603601|Experimental|Mind-body lifestyle intervention|The mind-body lifestyle intervention is a 10-week mindfulness-based intervention that integrates mindfulness with traditional behavioral strategies to improve long-term weight maintenance.
2544165|NCT02603302|Experimental|Locally advanced rectal cancer|"RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV + Chemotherapy with 5-FU~Surgery 8 weeks after the neoadjvuant treatment."
2544220|NCT02602964|Experimental|Deep neuromsucular block|Deep neuromuscular block and low pressure pneumoperitoneum
2544221|NCT02602964|No Intervention|Standard neuromuscular block|Standard neuromuscular block and low pressure pneumoperitoneum
2544284|NCT02602730|Experimental|Break the Chain|Access during the evaluation study period to an Internet smoking cessation intervention that included digital coaching messages sent at prescribed times during the participant's quit process and as needed in response to participant questions or comments.
2544290|NCT02602730|Active Comparator|Clearing the Air PDF|"Control users were e-mailed a copy of the National Cancer Institute's PDF smoking cessation booklet, Clearing the Air."
2544323|NCT02602236|Experimental|AOS-C2000-B|A new 2-piece appliance composed with 2 parts : a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
2544350|NCT02601989|Experimental|Tadalafil|Per oral intake of tadalafil 20 mg o.d. for six weeks
2544353|NCT02601989|Placebo Comparator|Placebo|Per oral intake of placebo
2544410|NCT02601703|Experimental|Tacrolimus Ointment 0.1%|
2544412|NCT02601703|Active Comparator|Protopic® ointment, 0.1%|
2544414|NCT02601703|Placebo Comparator|Placebo of Tacrolimus Ointment|
2544539|NCT02600936||Registry|A retrospective and prospectively maintained registry of patients who have undergone or will undergo vein stent placement for proximal venous outflow obstruction
2544582|NCT02600585||Flublok|Recombinant influenza vaccine (RIV); Intramuscular injection of vaccine of recombinant uncleaved hemagglutinin (rHA0) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
2544583|NCT02600585||Inactivated Influenza Vaccine|Injectable, inactivated, egg-based influenza vaccines (IIV); Intramuscular injection of vaccine (whether trivalent or quadrivalent) derived from influenza A/H1N1, A/H3N2, and B viruses, as identified for the season by the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) in a total volume of 0.5 mL.
2544607|NCT02600299|Experimental|Intervention Arm|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship. This program is designed to take place on three individual days on a weekend. For each session, three major topics will be covered, with lectures and interactive workshop integrated. Sessions will be conducted by healthcare professionals who are experts/well-versed in their respective domains.
2544610|NCT02600299|Placebo Comparator|Usual Care|No active intervention provided.
2544651|NCT02600078|Active Comparator|Moderate Hypoxia|Subjects will be exposed to moderate hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2544717|NCT02599545||Maternal/VLBW Infant Pairs|One-hundred-fifty mother-VLBW infant pairs, a total of 300 participants, will be recruited for the final sample size of 120 pairs.
2543807|NCT02605421|Experimental|Patients Treated for Neuroblastoma|Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.
3168748|NCT00554827|Experimental|Pralatrexate Injection (FOLOTYN,PDX,Pralatrexate(R|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
3168749|NCT00554866|Experimental|VLBW between 6 and12 hours after birth|"Blood sample and buccal swab sample. One blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
2543941|NCT02604823|Experimental|Group A (Naïve Participants)|Participants who never received any HBV treatment, will receive peginterferon alfa-2a (180 micrograms [mcg]) subcutaneously once weekly for 48 weeks.
2543944|NCT02604823|Experimental|Group B (Conventional Interferon Pretreated Participants)|Participants who received conventional interferon treatment and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
2543945|NCT02604823|Experimental|Group C (Lamivudine Pretreated Participants)|Participants who received lamivudine and had relapse or did not respond, will receive peginterferon alfa-2a (180 mcg) subcutaneously once weekly for 48 weeks.
2543988|NCT02604368|Experimental|SC411|Omega-3 docosahexaenoic acid, soft gelatin capsule, administered once a day on a per weight basis.
2543990|NCT02604368|Placebo Comparator|Placebo|Soybean oil, soft gelatin capsule, administered once a day on a per weight basis.
2544030|NCT02604121|Experimental|transepithelial brushing|transepithelial brushing in liquid-based technology + biopsy
2544114|NCT02603406|Experimental|Group A|mechanical barrier disruption procedure + hrEPO manufactured by Dong-A pharmaceutics Multiple burrholes with local anesthesia after medication Drug: Erythropoietin 33,000u daily for 3 day via intravenous
2544115|NCT02603406|No Intervention|Group B|mechanical barrier disruption procedure Drug: no-specific intervention
2544231|NCT02603289||Teen|< 17 years of age
2544232|NCT02603289||Adult|17 years of age or older
2544233|NCT02603289||Adult with Primer Aligners|17 years of age or older This group will get Primer Aligners
2544306|NCT02602418|Experimental|HIV Positive participants|Intervention; 90 HIV positive participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
2544310|NCT02602418|Other|Seronegative particpiants|Intervention; 90 seronegative participants will be trained. Half the participants will have the Adaptive WM Cogmed training, and half will have the non-adaptive WM Cogmed training.
2544356|NCT02602093|Active Comparator|Transforaminal Endoscopic Discectomy|Surgery: Patients will undergo Percutaneous Transforaminal Endoscopic Discectomy.
2544359|NCT02602093|Active Comparator|Open Microdiscectomy|Surgery: Patients will undergo conventional micro discectomy.
2544409|NCT02601664|Active Comparator|Combined Intervention|Combined intervention: pre-PCI intracoronary vasodilator and glycoprotein IIb/IIIa inhibitor administration, use of an EPD if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
2544411|NCT02601664|Active Comparator|Conventional PCI|Conventional PCI
2544575|NCT02600624||Participants|Women who are in active labor and their newborn infants.
2544620|NCT02600468||Patients who use ORENCIA|Patients who use ORENCIA for the approved indications and who at the start of treatment
2544674|NCT02600117|Other|Tenofovir disoproxil fumarate|300 mg, orally, once a day for 3 years or when sAg+ve seroconverts to sAb+ve whichever comes earlier
2544701|NCT02599584|Experimental|precritical staff|4 min of precritical team staff for anticipation of risk and role attribution during the critical events if they occur. athe staff will take place after briefing of the scenario and before the start of the scenario.
2544702|NCT02599584|No Intervention|control|screening of normal labs results during 4 min, after briefing of the scenario and before the start of the scenario
2544995|NCT02597816|Other|Three dimensional ultrasound|Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard.
2545025|NCT02597595|Experimental|patients|thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)
2545029|NCT02597595|No Intervention|controls|thirty healthy children of matched age and sex
2545062|NCT02597374|Experimental|Experimental|A 45 mn EEG for all the participants.
2545103|NCT02597166|Other|Ledipasvir/Sofosbuvir|Each tablet contains 90 mg ledipasvir and 400 mg sofosbuvir, given orally, once daily for 24 weeks.
2545147|NCT02596815|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 3 times a week during 6 continuous weeks.The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
2545148|NCT02596815|Active Comparator|Waiting list control group|Patients assigned to a 6 week waiting list to receive treatment
3168750|NCT00554879|Experimental|1|Acupuncture
3168751|NCT00554879|Sham Comparator|2|Sham Acupuncture
3168752|NCT00554892|Active Comparator|1|Bowel preparation
3168753|NCT00554892|Experimental|2|without bowel preparation
3168754|NCT00554905|Experimental|1|TACE first, then RFA within 2 weeks
3168755|NCT00554905|Active Comparator|2|RFA alone
3168756|NCT00554957||NBC|All dancers with the National Ballet of Canada will be given the opportunity to participate in the study.
3168757|NCT00554957||TDT|All dancers with the Toronto Dance Theatre will be given the opportunity to participate.
2543779|NCT02605811|Active Comparator|prophylaxis cranial radiotherapy|prophylaxis cranial radiotherapy,25-30Gy/10Fra
3168758|NCT00554957||KDC|All members of the Kibbutz Contemporary Dance company will be given the opportunity to participate.
2543857|NCT02605135||Continued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab and 10 mL of vaginal lavage at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months
2543860|NCT02605135||Discontinued Pessary Use|All participants will undergo clinical testing prior to placement of the pessary and the investigator will test their vaginal environment prior to pessary placement. Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage (Aim 2) at each study visit. The participant will then be followed, and repeat testing obtained at the standard clinical interval for pessary follow-up, every three months. Should the participant discontinue pessary use, we will additionally culture the microbes that are present on the pessary and compare those to the vaginal microbiota.
2543913|NCT02604927|Placebo Comparator|Placebo|800 mg of dextrose, four times per day, during 28 days.
2543914|NCT02604927|Experimental|Beta-alanine|800 mg of beta-alanine, four times per day, during 28 days.
2543963|NCT02604563||Arm A: Clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
2543965|NCT02604563||Arm B: No clonal hematopoiesis|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
2543967|NCT02604563||Arm C: No clonal hematopoiesis & no follow-up|"Complete several self-administered health assessments at baseline with no further follow-up~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline with no further follow-up~Peripheral blood draw will occur at baseline with no further follow-up~Buccal swabs will occur at baseline with no further follow-up"
2543969|NCT02604563||Arm D: Hip replacement|"Complete several self-administered health assessments at baseline and every 6 months until death.~Cognitive assessment, Gait Speed, grip strength, blood pressure, height, and weight will be performed by a member of the research team at baseline and every 6 months until death.~Participants with or without clonal hematopoiesis who are undergoing hip replacement~Peripheral blood draw will occur at baseline and no more than every 6 months until death.~Buccal swabs will occur at baseline and repeated as necessary, but not more than every 6 months until death~May be approached about optional bone marrow biopsy"
2543971|NCT02604563||Arm E: Trauma|-Blood sample at the time of admission with initial bloodwork. For inpatient participants, weekly follow-up samples will be drawn with morning phlebotomy. A follow-up sample collection will occur 4-7 weeks after discharge.
2544068|NCT02603796||Newborns requiring ncpap|3D scan of nares will be performed before and after administration of NCPAP for infants with Corrected Gestational Age greater than or equal to 24 weeks and less than or equal to 42 weeks.
2544113|NCT02603705|Experimental|Oxycodone extended-release|Egalet abuse-deterrent, extended-release oxycodone tablet
2544186|NCT02603003|Placebo Comparator|Cisplatin|Cisplatin
2544191|NCT02603003|Placebo Comparator|Pemetrexed|Pemetrexed
2544196|NCT02603003|Experimental|Jinfukang|Jinfukang
2544252|NCT02602743|Experimental|remifentanyl, ketamine|Experimental:Remifentanyl and ketamine Remifentanyl vial 2 mg, Ketamine vial 500mg/10 mlt by intravenous. 2 mg/kg ketamine and 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
2544255|NCT02602743|Active Comparator|propofol, ketamine|"Active comparator:Propofol and ketamine Propofol injectable emulsion vial 200 mg/20 mlt, Ketamine vial 500mg/10 mlt by intravenous.~2 mg/kg ketamine and 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started."
2544283|NCT02602366|Other|Month 1|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2544287|NCT02602366|Other|Month 2|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2544291|NCT02602366|Other|Month 3|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2544293|NCT02602366|Other|Month 4|In a cross-over design, women will be randomized to a sequence of product use. Each product will be tested by every participant for 1 month in a 4-period cross-over design.
2544352|NCT02602028|Experimental|once daily dosage schema of colchicine|The once daily dosage group was prescribed as once daily at 08:00 a.m. (Total 1mg)
2544357|NCT02602028|Experimental|twice daily dosage schema of colchicine|Twice daily dosage group received the treatment twice daily at 08:00 a.m. and 08:00 p.m. (Total 1mg)
2544407|NCT02601677|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
2544408|NCT02601677|Active Comparator|Standard Control|Fluoxetine
2544461|NCT02601287|Experimental|BOTOX® 100U|Botulinum Toxin Type A 100U into the detrusor muscle on Day 1 in patients with Overactive Bladder
2544464|NCT02601287|Experimental|BOTOX® 200U|Botulinum Toxin Type A 200U into the detrusor muscle on Day 1 in patients with Neurogenic Detrusor Overactivity
3168759|NCT00554957||BDC|All dancers with the Batsheva Dance Company or Ensemble will be given the opportunity to participate.
3168760|NCT00554957||RSB|All dancers with the Royal Swedish Ballet will be given the opportunity to participate.
3168761|NCT00554957||RDB|All dancers with the Royal Danish Ballet will be given the opportunity to participate.
3203312|NCT00922220|Active Comparator|stationary bike|Participants rode a stationary bike for five minutes
3203313|NCT00922220|Active Comparator|lumbar extension exercises|Participants performed four sets of fifteen lumbar extension exercises over five minutes
2543881|NCT02604966|Experimental|Artesunate (AS) group|P. falciparum infected patients randomly allocated to this arm will be treated with AS (50mg/tablet) 4 mg/kg body weight once daily for three days followed by DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
2543888|NCT02604966|Active Comparator|DHA - PPQ group|P. falciparum infected patients randomly allocated to this arm will be treated with the combination DHA-PPQ (40mg of DHA +320mg of PPQ/tablet) once daily for three days.
2543917|NCT02604693||Chronic Beryllium Disease|Those that have been diagnosed with the disease. No interventions will be administered.
2543920|NCT02604693||Beryllium Sensitization|Those that have been diagnosed with beryllium sensitization and do not have chronic beryllium disease. No interventions will be administered.
2543922|NCT02604693||normal controls|Those that do not have chronic beryllium disease or beryllium sensitization. No interventions will be administered
2543981|NCT02604472||CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received concurrent chemoradiotherapy
2543984|NCT02604472||IC+CCRT group|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and concurrent chemoradiotherapy
2544019|NCT02604186|Experimental|Botulinum Toxin Injections|Botulinum Toxin injections at adductors and triceps surae
2544021|NCT02604186|Placebo Comparator|Placebo Injections|Placebo injections at adductors and triceps surae
2544058|NCT02603913||Normal pregnancy|Normal uncomplicated pregnancy
2544061|NCT02603913||Pre-eclampsia|"Hypertension (>140 mmHg systolic or >90 mmHg diastolic) developing after 20 weeks gestation and the coexistence of one or more of the following new onset conditions:~Proteinuria (>300 mg/day)~Other maternal organ dysfunction~renal insufficiency (creatinine >90 μmol/L)~liver involvement (elevated transaminases - and/or severe right upper quadrant or epigastric pain)~neurological complications (eclampsia, altered mental status, blindness, stroke, hyperreflexia when accompanied by clonus, severe headaches when accompanied by hyperreflexia, persistent visual scotomata)~hematological complications (thrombocytopenia, disseminated intravascular coagulation, hemolysis)~Uteroplacental dysfunction"
2544065|NCT02603913||Pregnancy induced hypertension|New onset of hypertension (>140 mmHg systolic or >90 mmHg diastolic) after 20 weeks gestation, without proteinuria, in a previously normotensive woman.
2544069|NCT02603913||Preterm birth|Babies born alive before 37 weeks of pregnancy are completed.
2544071|NCT02603913||Intra-uterine growth restriction|Moderate IUGR is an estimated fetal weight and / or abdominal circumference < 10th percentile for its gestational age Severe IUGR is an EFW (estimated fetal weight) and/ or AC (abdominal circumference) < 5th percentile for its gestational age
2544138|NCT02603679|Active Comparator|A: Weekly Paclitaxel|Patients receive weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for a 12-week period. Thereafter, treatment is switched to endocrine treatment in combination with palbociclib. Pre- or perimenopausal women and all men are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during the second 12-week period
2544143|NCT02603679|Experimental|B: Tamoxifen + Palbociclib|Pre- or perimenopausal women and all men are treated with tamoxifen together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2544147|NCT02603679|Experimental|B: Aromatase Inhibitor + Palbociclib|Postmenopausal women receive an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2544150|NCT02603679|Experimental|B: Goserelin + Aromatase Inhibitor + Palbociclib|Pre- or perimenopausal women may be treated with goserelin and an aromatase inhibitor together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period, repeated twice during a 12-week period. Thereafter, treatment is switched to weekly paclitaxel 80mg/m2, eventually dose-adjusted in relation to side effects, for further 12 weeks.
2544202|NCT02602990||Cerebral AVM treated with SQUID™|
2544248|NCT02602756|Active Comparator|A|Protontherapy : 4 sessions of 13 Gy, total dosis 52 Gy
2544250|NCT02602756|Experimental|B|Protontherapy : 8 sessions of 6.5 Gy, total dosis 52 Gy
2544303|NCT02602470||Rosacea treated patients|Patients using topical rosacea treatment
2544346|NCT02602041||Patients with breast cancer and partners|We will invite 10 women with early stage breast cancer (BC) and their partners for a semi-structured interview.
2544347|NCT02602041||Patients with testicular cancer and partners|We will invite 10 men with disseminated testicular cancer (TC) and their partners for a semi-structured interview.
2544398|NCT02601768||ASD II|Transcatheter closure of ASD II
2544441|NCT02601495||Women in a court diversion program|Women enrolled in the court diversion program in Tulsa, Oklahoma called Women in Recovery who report symptoms related to anxiety or depressive symptoms (Patient Health Questionnaire score ≥ 10 and/or Overall Anxiety Severity and Impairment Scale ≥ 8), problematic eating behavior(Eating Disorder Screen score ≥ 2), problems related to substance use (Drug Abuse Screening Test score > 2), or post traumatic stress disorder symptoms (PTSD Checklist score ≥ 30).
3203314|NCT00922220|Experimental|spinal manipulative therapy|Participants received spinal manipulative therapy to the low back
3203315|NCT00922246|No Intervention|control group|Conscript used their own ankle boots instead of custom made insoles.
3203316|NCT00922246|Experimental|shoe insoles|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length. The insole was strong enough to fill the arch area thus providing support to the mid foot. It also influences the position of the foot. The insoles were individually customized by heating the polyethylene in form of individual foot with standing and walking in them. The conscripts were advised to use these insoles in their ankle boot.
3203317|NCT00922259|Experimental|H7N7 Vaccine|Participants will be administered two doses of the candidate live influenza A H7N7 vaccine
3203318|NCT00922285|Experimental|Art Therapy|
3203319|NCT00922311|Experimental|Aliskiren|
3203320|NCT00922324|Experimental|STP206|STP206 administered either as a single dose or as a daily dose for seven consecutive days
3203321|NCT00922324|Placebo Comparator|Vehicle Control|STP206 vehicle administered as either a single dose or as a daily dose for 7 consecutive days
2543915|NCT02604940|Experimental|dexmedetomidine|Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
2543916|NCT02604940|Active Comparator|Normal Saline|Control group will receive Normal saline over 15 minutes at the beginning of surgical closure
2543948|NCT02604511|Experimental|Ibrutinib|This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
2544003|NCT02604381|Experimental|Glucosamine Sulfate Potassium Chloride/Ginkgo Biloba Extract|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
2544005|NCT02604381|Placebo Comparator|Placebo|2 capsules daily, immediately following a meal. 1 capsule in the morning, and 1 capsule in the evening, at approximately the same time each day.
2544054|NCT02603978|No Intervention|Wait-list|This arm will receive no intervention for the first 6 months. At the conclusion of the 6-month period, this group will receive a brief alcohol intervention
2544057|NCT02603978|Active Comparator|Brief Alcohol Intervention|This arm will receive a brief (2-hour) alcohol intervention based on motivational interviewing
2544063|NCT02603978|Active Comparator|Bystander and Social Norms Intervention|This arm will receive a brief (2-hour) bystander and social norms intervention designed to increase healthy sexual behaviors
2544067|NCT02603978|Active Comparator|Combined Alcohol and Bystander Intervention|This arm will receive a combined (4-hour) alcohol and bystander/social norms intervention to target both alcohol and sexual behavior
2544130|NCT02603692||Pediatric group (ages 8-17)|PROMIS pediatric domains for emotional distress (anxiety and depression), physical function (fatigue, pain interference, mobility and upper extremity), and peer relations
2544137|NCT02603692||Adult group (ages 18-35)|PROMIS adult domains. To reduce respondent burden, the multi-form design will be used which includes the short form of physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference and pain intensity.
2544140|NCT02603692||Parent/guardian proxy|Parent/guardian will complete the parental proxy PROMIS instruments based on corresponding child age (ages 5 to 17 years)
2544175|NCT02603185|Experimental|Hemay007|"Part 1: Single ascending dose Group Hemay007 tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 2: Food effect group Hemay007 tablets will be taken orally in single dose with a high-fat, high-calorie meal or at overnight fasting.~Part 3: Multiple doses group Hemay007 tablets will be taken orally once daily in low, medium, high doses"
2544177|NCT02603185|Placebo Comparator|Placebo|"Part 1: Single ascending dose Group Placebo tablets will be taken orally once daily in doses of 0.2g, 0.6g,1.2g, 2g, 3g.~Part 3: Multiple doses group Placebo tablets will be taken orally once daily in low, medium, high doses"
2544224|NCT02602912|Experimental|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability.
2544269|NCT02602704|Active Comparator|Bazedoxifene & Calcium/Vit D|"Enrollment: 57~Drug: Bazedoxifene 20 mg/day (Viviant)~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
2544270|NCT02602704|Active Comparator|Calcium/Vit D|"Enrollment: 57~Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day)"
2544322|NCT02602327|Experimental|Tas-102 and radioembolization|Combination therapy with Tas-102 and radioembolization using 90Y resin microspheres
2544330|NCT02602002|Experimental|Active|Remifentanil 0.1 ug/kg/min to 0.10 ug/kg/min
2544333|NCT02602002|Placebo Comparator|Placebo|Saline (0.9%)
2544391|NCT02601898|Experimental|Lipoic acid|vaginal capsules of lipoic acid (10 mg, one capsule per day)
2544394|NCT02601898|Active Comparator|Progesterone|Vaginal soft gel of progesterone (200 mg, two capsules per day)
2544433|NCT02601521|Experimental|Internal coaching program|The internal coaching program uses a chronic disease management strategy to treat tobacco use and dependence. The program provides evidence-based treatment consisting of up to 12 months of services from a tobacco coach based at Partners HealthCare. The tobacco coach offers (1) repeated smoking cessation counseling delivered by proactive telephone calls, emails, and interactive voice response [automated phone calls] and (2) facilitated access to a new Partners HealthCare Inc., health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
3203322|NCT00922337||MGuard|eligible patients implanted with minimum one MGuard stent
3203323|NCT00922350|Experimental|heliox|The patients in this group underwent nebulization with heliox carried by the trunk erect
3203324|NCT00922350|Experimental|heliox+posture|The patients in this group carried out the mist carried by heliox and the trunk tilted forward
3203325|NCT00922350|Experimental|oxygen+posture|The patients in this group carried out the mist carried by oxygen and the trunk tilted forward
3203326|NCT00922350|Active Comparator|oxygen|The patients in this group carried out the mist carried by the oxygen and the trunk upright
3203327|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 alone|
3203328|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|
3203329|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|
3203330|NCT00922363|Experimental|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|
3203331|NCT00922376|Active Comparator|T+ Intervention|The intervention group patients will use the T+ telemedicine application whilst completing repeated measures aiming to compare them to a control group receiving standard care.
3203332|NCT00922376|No Intervention|Usual care|The control group will be receiving the standard care offered by the NHS to patients suffering from diabetes.
3203333|NCT00922389|Experimental|G-CSF + Stem cells|
3203334|NCT00922389|Other|No stem cell group|
2543793|NCT02605707|Experimental|Intravenous stem cell transplantation|Intravenous transplantation of autologous endothelial progenitor cells plus conventional treatment include rehabilitation
2543794|NCT02605707|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
2543834|NCT02605369|Experimental|Intervention arm: An integrated package|Pregnant women in the intervention clusters will receive an integrated package consisting of peer support for facility based births by pregnancy buddies, mama kits and mobile phone messages. These components will all aim at mitigating the three delays and increasing the proportion of facility based births.
2543837|NCT02605369|No Intervention|Control arm: Standard of care|Pregnant women in the control clusters will continue to receive the standard of care for pregnant women according to Ugandan Ministry of Health guidelines
2543884|NCT02605109||RiskMERS|Exposed to case-patients
2543978|NCT02604745||Degenerative Mitral Regurgitation|This cohort includes patients that have had mitral valve surgery for Degenerative Mitral Regurgitation (Type II)
2544001|NCT02604225|Experimental|Penthrox|Methoxyflurane
2544002|NCT02604225|Placebo Comparator|Placebo|Saline 0.9%
2544392|NCT02601885|Experimental|Group 2|Participants will receive multiple doses of ABT-555 or placebo
2544397|NCT02601885|Experimental|Group 3|Participants will receive multiple doses of ABT-555 or placebo
2544399|NCT02601885|Experimental|Group 1|Participants will receive multiple doses of ABT-555 or placebo
2544437|NCT02601404||Bioresorbable Scaffold|Patients receiving percutaneous coronary intervention (PCI) for coronary artery disease using Absorb™(Abbott Vascular)
2544509|NCT02601196|Other|Ulipristal acetate treatment|Women who receive UPA treatment before another IVF cycle.
2544628|NCT02600247|Experimental|Duloxetine group|"Experimental: Duloxetine group~Phase I (preemptive): 1day before operation (30mg for 1 day)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon"
2544629|NCT02600247|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
2544762|NCT02599480|Active Comparator|mirabegron|Patients will be orally administererd with 50 mg of mirabegron once a day during 12 months.
2544768|NCT02599480|Placebo Comparator|Placebo|Patients will be orally administererd with a placebo once a day during 12 months.
2544875|NCT02598791|Active Comparator|IIGI+GIP|4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
2544884|NCT02598791|Active Comparator|IIGI+GLP-1|4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
2544890|NCT02598791|Placebo Comparator|IIGI+NaCl (placebo)|4 hour i.v. NaCl (placebo) during isoglycemic conditions
2544896|NCT02598791|Active Comparator|IIGI+GIP+GLP-1|4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
2544901|NCT02598791|Other|50 g OGTT|50 g oral glucose tolerance test (OGTT)
2544958|NCT02598102|Experimental|Diclofenac sodium|Oral diclofenac 75 mg one hour prior to stent removal
2544964|NCT02598102|Placebo Comparator|Placebo|Placebo one hour prior to stent removal
2545010|NCT02597764|Active Comparator|Standard Urotherapy (SU)|Standard Urotherapy (SU): A non-invasive therapy combining cognitive, behavioral and physical therapy. The study team will explain the problem to the children and their parents and educate them on the following: proper voiding mechanics, sitting, standing positions, how and when to void, techniques on relaxing pelvic floor muscles, and avoiding straining. An assessment of bowel habits will be done and their diet and drinking/voiding habits will be modified to maintain proper hydration with timed voiding. Voiding diaries will be provided for the assessment of the bladder and bowel habits.
2545036|NCT02597608|Experimental|UPPR: Livelihoods plus nutrition|Livelihoods programmes offered by UPPR, plus nutrition programmes offered by UPPR.
2545038|NCT02597608|Experimental|CLP: Livelihoods only|Livelihoods programmes offered by CLP.
2545039|NCT02597608|Experimental|CLP: Livelihoods plus nutrition|Livelihoods programmes offered by CLP, plus nutrition programmes offered by CLP.
2545041|NCT02597608|Experimental|Shiree: Livelihoods only|Livelihoods programmes offered by Shiree.
3168762|NCT00554983|Placebo Comparator|2|
3168763|NCT00554983|Experimental|1|
3168764|NCT00555009|Experimental|Genotropin treatment arm|
3168765|NCT00555009|Placebo Comparator|Placebo|
3168766|NCT00555022|Experimental|All subjects|Eligible subjects will receive one of the following treatment in cohort I and cohort II in five different treatment periods; Placebo, GSK1160724 (10 micrograms, 50 micrograms or 125 micrograms) and tiotropium bromide
3168767|NCT00555074|Experimental|1|Sodium Tungstate
3168768|NCT00555074|Placebo Comparator|2|
3168769|NCT00555087|Experimental|A= Nebido|It is and intervention study with 1 arm
3168770|NCT00555113||1|pseudoxanthoma elasticum
3168771|NCT00555126|Active Comparator|Warming with Forced Air|Forced Air Warming
3168772|NCT00555126|Experimental|Endovascular Warming|Warming with Endovascular Catheter
3168773|NCT00555139|Experimental|GW876008|The subjects will be randomized to one of the six sequences A/B/D A/D/B B/A/D B/D/A D/A/B D/B/A across three treatment periods where A represents placebo, B represents GW876008 and D represents alprazolam.
3168774|NCT00555139|Experimental|GSK561679|The subjects will be randomized to one of the six sequences A/C/D A/D/C C/A/D C/D/A D/A/C D/C/A across three treatment periods where A represents placebo, C represents GSK561679 and D represents alprazolam.
3168775|NCT00555165|Experimental|I|
3168776|NCT00555178||1|Patients with polymorphic light eruption without medical photohardening treatment
3168777|NCT00555178||2|Patients with polymorphic light eruption treated with medical photohardening
3168778|NCT00555178||3|Patients with other disorders (including psoriasis) treated with phototherapy
3168779|NCT00555178||4|Normal healthy subjects
3168780|NCT00555191|Active Comparator|1|PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSE REDUCED DIET FOR A PERIOD OF 3 MONTHS
2543798|NCT02605577|Experimental|experimental group|"group of late preterm infants following new systemic nutritional management protocol during hospital stay,which including specific enteral and parenteral nutritional protocol and complication monitor, such as hyperglycemia,hypoglycemia,infection,hyperbilirubinemia and anemia(the intervention refers to thisnew systemic nutritional management protocol )"
2543800|NCT02605577|No Intervention|control group|group of late preterm infants using current nutritional management protocol during hospital stay
2543844|NCT02605343||NeuroIDgenetix-guided Pain Management|The medical provider for the NeuroIDgenetix-guided group will make post-operative pain management recommendations based on test results. Patient outcomes, narcotic consumption, opioid-related adverse effects, time to mobilization, number of adverse drug events and number of hospital and/or medical visits will be measured throughout the study.
2543845|NCT02605343||Historical Control|The retrospective chart review will utilize patient outcomes from patients meeting the study inclusion/exclusion criteria. The medical provider for the control group will not have received the NeuroIDgenetix Test Panel results and would have made post-operative pain management recommendations per standard of care.
2543893|NCT02605044|Experimental|Masitinib + FOLFIRI|masitinib + FOLFIRI
2543895|NCT02605044|Placebo Comparator|Placebo + FOLFIRI|Placebo + FOLFIRI
2543925|NCT02604667||Group 1: Cancer and Stroke|Patients with active solid tumor cancer and acute ischemic stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
2543928|NCT02604667||Group 2: Stroke and No Cancer|Patients with acute ischemic stroke and no cancer. Will undergo blood tests and transcranial Doppler microemboli detection study.
2543930|NCT02604667||Group 3: Cancer and No Stroke|Patients with active solid tumor cancer and no stroke. Will undergo blood tests and transcranial Doppler microemboli detection study.
3203335|NCT00922389|Active Comparator|Standerd theraphy|Any therapy for diabetic foot CLI which is routinely practiced and accepted in India
3203336|NCT00922402|Experimental|Treatment|All patients will be submitted to a shared intensive protocol of insulin infusion supported by continuous glucose monitoring
2544109|NCT02603523|Experimental|Senior Dance|The intervention group will attend a single educational class on fall risk factors and prevention, and will participate in a 12-week, twice-weekly group-based program of Senior Dance. Each dance class will last for an hour, and the number of participants per class will range from 10 to 15. Senior Dance-certified instructors will lead the classes. The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups.
2544112|NCT02603523|No Intervention|Control group|Participants in the control group will attend the same educational class on fall risk factors and prevention that intervention group participants will receive, and will be instructed not to take part in any regular exercise programs such as supervised group exercise, Tai Chi, Yoga, or any dance activity during the study period. At the end of the study, they will be offered Senior Dance classes, twice a week, during 12 weeks.
2544159|NCT02603341|Active Comparator|Photon|Photon therapy: once a day, 5 days a week, for 5 to 7 weeks
2544160|NCT02603341|Active Comparator|Proton|Proton therapy: once a day, 5 days a week, for 5 to 7 weeks
2544222|NCT02602925|Experimental|Dose decrease|Patients receive daily practice care, but doses of etanercept, adalimumab or ustekinumab will be lowered: intervals of drug-administration will be prolonged stepwise with tight control of disease activity and DLQI. First, the dose will be decreased to 66-70% of the normal dose (by interval prolongation with a factor 1.5). If patients remain in a state of low disease activity, the dose will be further reduced to 50% (by doubling the original interval). Each step will be analyzed after three months, or when the patient visits earlier due to complaints.
2544223|NCT02602925|Other|Usual care|Patients will continue treatment with the normal dose and treatment regimens will be based on usual daily practice care. Treatment decisions are made at the discretion of the treating physician.
2544280|NCT02602613|Experimental|AMEND|
2544377|NCT02602288|Experimental|AAR+Behavioral Intervention (EXP)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased tobacco counseling: Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke. Mobile phone smoking cessation application: Smartphone based application to support smoking cessation efforts. Nicotine polacrilex: Over the counter nicotine replacement therapy in gum or lozenge form.
2544379|NCT02602288|Active Comparator|AAR+Attention Control Intervention (CTL)|Ask Advise Refer (AAR): WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources. Telebased nutrition counseling: Telephone counseling to promote nutritious eating practices in the family. Mobile phone nutrition application: Smartphone based application to support healthy eating habits
2544454|NCT02601430|Experimental|BOLD-MRI|Blood Oxygen Level Dependent (BOLD)-MRI assessment of limb perfusion before and after standard of care endovascular therapy.
2544483|NCT02601131||AML, ALL and MDS|Patients receiving intensive chemotherapy with diagnoses of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) or myelodysplastic syndromes (MDS).
2544485|NCT02601131||Autologous stem cell transplantation|Patients undergoing autologous stem cell transplantation
2544487|NCT02601131||Allogeneic stem cell transplantation|Patients undergoing allogeneic stem cell transplantation including both myeloablative conditioning (MAC) and the reduced-intensity conditioning (RIC)
2544491|NCT02601131||Platelet transfusion prophylaxis|Patients receiving platelet transfusion prophylaxis before the intervention, such as insertion of a central venous catheter or lumbar puncture
2544495|NCT02601131||Control|Patients with AML, ALL or MDS that have low PLC (10-20 billion/L) and is not relevant for platelet transfusion. Samples taken in the same manner as in the other groups. Control is needed to rule out other causes of variation of the PLC than the platelet transfusion and thereby strengthen the causality between a given transfusion and increased PLC.
2544553|NCT02600858|Experimental|"Training off medication"|"Participants will train on the upper limb feeding task before taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while off dopamine replacement medication"
2544626|NCT02600273|Experimental|Electronic cigarettes 1|During one session, participants will use an electronic cigarette with 0 mg/mL nicotine e-liquid
2543799|NCT02605590|Experimental|1.25 mg|Part 1: single inhaled dose of 1.25 mg AIR-DNase followed by Part 2: once daily inhaled dose of 1.25 mg AIR DNase for 5 consecutive days.
2543802|NCT02605590|Experimental|2.5 mg|Part 1: single inhaled dose of 2.5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 2.5 mg AIR DNase for 5 consecutive days.
2543804|NCT02605590|Experimental|5 mg|Part 1: single inhaled dose of 5 mg AIR-DNase followed by Part 2: once daily inhaled dose of 5 mg AIR DNase for 5 consecutive days.
2543806|NCT02605590|Placebo Comparator|Placebo|Placebo comparator for each of the dose levels, administered accordingly as single inhaled dose in Part 1 followed by once daily inhaled dose for 5 consecutive days in Part 2.
3203337|NCT00922415||cases|patients at least 18 years of age, with confirmed Crohn's disease undergoing intestinal resection for complicated Crohn's disease
3203338|NCT00922454|Experimental|Talent Stent-Graft|
2543921|NCT02604706|Experimental|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2543924|NCT02604706|Experimental|LP Acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. BC-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2543927|NCT02604706|Active Comparator|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
2543999|NCT02604459|Active Comparator|Usual general anesthesia care|"Subjects will have their general anesthetic management directed at the discretion of the anesthesia provider.~General anesthesia with be maintained with propofol, fentanyl, sevoflurane"
2544000|NCT02604459|Experimental|Optimized general anesthesia care|The subjects will have general anesthesia with propofol, fentanyl, sevoflurane. In addition the subjects will be monitored with a depth of anesthesia monitor (BIS) and a cerebral oximeter (Foresight). These additional monitors will be used to direct care. BP management: Systolic BP will be maintained within 20% of baseline systolic BP variables.
2544076|NCT02603861|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once orally in one of four periods.
2544077|NCT02603861|Experimental|LY3154207 - Dose 1|LY3154207 administered orally in no more than one of the four periods.
2544079|NCT02603861|Experimental|LY3154207 - Dose 2|LY3154207 administered orally in no more than one of the four periods.
2544081|NCT02603861|Experimental|LY3154207 - Dose 3|LY3154207 administered orally in no more than one of the four periods.
2544085|NCT02603861|Active Comparator|Modafinil|200 mg modafinil administered orally in no more than one of the four periods.
2544116|NCT02603510|Experimental|SAR342434/Humalog|SAR342434 and Humalog will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
2544117|NCT02603510|Experimental|Humalog/SAR342434|Humalog and SAR342434 will be self-administered subcutaneously via insulin pump. The dose will be individually titrated and administered in a basal and bolus fashion.
2544227|NCT02603198|Active Comparator|mepivacaine chloridrato epinephrine|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:100.000 epinephrine, maximum of 4 cartridges
2544228|NCT02603198|Active Comparator|mepivacaine chloridrato levonordefrin|Side of operation that is going to receive anesthesia with 2% mepivacaine chloridrato with 1:20.000 levonordefrin, maximum of 4 cartridges
2544304|NCT02602483|Experimental|Triple combination|Powder for oral administration
2544307|NCT02602483|Active Comparator|Ibuprofen|Powder for oral administration
2544314|NCT02602483|Active Comparator|Magnesium + ascorbic acid|Powder for oral administration
2544316|NCT02602483|Placebo Comparator|Placebo|Powder for oral administration
3203339|NCT00922454|Experimental|Cook Zenith Stent-Graft|
2544449|NCT02601534|Experimental|Zero-time Exercise (PA) group|"The intervention arm (PA group) aims to improve family communication and well-being, reduce sedentary behavior and increase physical activity. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve dietary habits."
2544460|NCT02601534|Placebo Comparator|Healthy Eating (HE) group|"The control arm (HE group) aims to improve family communication and well-being and enhance healthy eating habits. Participants are required to engage their family members in their activities. The programme includes a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months after the first session as well as biweekly/monthly mobile messages.~The holistic health session is not a part of the cRCT, it aims to collect one-year feedback from participants and provides additional health information to improve physical activity habit."
2544480|NCT02601066|Experimental|EPS and ECG holter monitor|Electrophysiological study (EPS) and ECG holter monitor implantation
2544562|NCT02600858|Other|"Training on medication"|"Participants will train on the upper limb feeding task after taking their first daily dose of standard dopamine medication for Parkinson's disease, i.e. while on dopamine replacement medication"
3203340|NCT00922467|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
2543801|NCT02605668|Experimental|Intensified Psychological Intervention|Intensified psychological intervention (Cognitive Behavioral Therapy), based on optimized extinction learning
2543803|NCT02605668|Active Comparator|Treatment As Usual|Standard intervention (Cognitive Behavioral Therapy) without optimized extinction learning
2543865|NCT02605005||GA|general anesthesia
2543867|NCT02605005||ISB|interscalene block
2543910|NCT02604862|Experimental|FIB ONE administration|All participants in this clinical study will be dosed on one occasion with FIB ONE. The final dosage will be less than 100 µg.
2543912|NCT02604862|Experimental|AZD1236 administration|To quantify the change in mean FIB ONE fluorescence amplification gradient in the presence of AZD1236 in the fibroproliferative lung
2544056|NCT02604056|Active Comparator|Audit + Feedback|'Usual care' / standard quality improvement supports (including online Audit and Feedback reports for each prescriber in the home)
2544059|NCT02604056|Experimental|Audit + Feedback + Educational Outreach|'Active/full' intervention (featuring Educational Outreach offered to each prescriber and team members in the home)
2544368|NCT02601755|Experimental|iCanCope app and website|Intervention: Behavioral: iCanCope app and website
2544370|NCT02601755|Active Comparator|Attention control group|Intervention: Behavioral: Attention control group
2544452|NCT02601508|Active Comparator|Modarate Blockade Group|Neuromuscular blocking agent, cis-atracurium will be administered after skin incision and reversal agents, pyridostigmine & glycopyrrolate will be given for the recovery.
2544457|NCT02601508|Experimental|Deep Blockade Group|Neuromuscular blocking agent, rocuronium will be administered after skin incision and reversal agent, Sugammadex will be given for the recovery.
2544527|NCT02600988|No Intervention|Group 1: Control|Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
2544529|NCT02600988|Experimental|Group 2: 1000IU/day of Vitamine D|It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
2544530|NCT02600988|Experimental|Group 3: 5000IU/day of Vitamine D|It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.
2544576|NCT02600663||acute back pain|
2544608|NCT02600507|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as capsules once daily for 6 weeks
2544615|NCT02600507|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as capsules once daily for 6 weeks
2544619|NCT02600507|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
2544773|NCT02599350||1|Patients receiving mechanical ventilation
2544817|NCT02599051|Active Comparator|Monarc|Placement of a transobturator monarc sling for stress urinary incontinence
2544818|NCT02599051|Experimental|Mini-arc|Placement of a single incision mini-arc sling for stress urinary incontinence
2544903|NCT02598713|Experimental|Aspiration Markers|Aspiration marker solution will be composed as following: Quinine 83 mg/L suspended in sterile water. After enrollment patients will be challenged with 5 mL of the study solution nebulized in the retropharyngeal space twice a day for two consecutive days.
3168781|NCT00555191|No Intervention|2|these patients use their usual diet
2544960|NCT02597972|Active Comparator|Open Reduction Internal Fixation Proximal Humerus|The patients randomized into the ORIF group will receive standard surgical treatment of their proximal humerus fracture with a proximal humeral locking plate.
3168782|NCT00555204|Experimental|A|
3168783|NCT00555204|Experimental|B|
3168784|NCT00555204|Experimental|C|
3168785|NCT00555204|Experimental|D|
3168786|NCT00555204|Experimental|E|
3168787|NCT00555204|Experimental|F|
3168788|NCT00555204|Placebo Comparator|G|
3168789|NCT00555230|Experimental|1|Rosuvastatin
3168790|NCT00555230|Placebo Comparator|2|Placebo
3168791|NCT00555243|Experimental|1|Laparoscopic Simulation Education
3168792|NCT00555243|Placebo Comparator|2|
3168793|NCT00555256|Experimental|1|Patients will be instructed to take sunitinib and rapamycin every morning for 4 weeks, then to take 2 weeks off. The sunitinib dose will be 25mg in the first cohort and the rapamycin dose will be 2 mg.
3168794|NCT00555269||MB|
3168795|NCT00555269||IFCG|
3168796|NCT00555282|Experimental|1|coated central venous catheter
3168797|NCT00555282|Active Comparator|2|standard central venous catheter
3168798|NCT00555308|Experimental|one|undergo EDTU
3168799|NCT00555334|Experimental|1|nucleoid antiviral therapy after RFA
3168800|NCT00555334|Active Comparator|2|RFA only
3168801|NCT00555347|Active Comparator|Armnodafinil|Armodafinil
3168802|NCT00555347|Placebo Comparator|Placebo|
3168803|NCT00555373|Other|Sirolimus|Single arm
3168804|NCT00555386|Active Comparator|1|6g of chocolate (supplemented with selenium and isoflavones) per day for the duration of one menstrual cycle (25-35 days)
3168805|NCT00555386|Placebo Comparator|2|6g of chocolate (control) per day for the duration of one menstrual cycle (25-35 days)
3168806|NCT00555399|Experimental|Ph I: Arm 1|Vorinostat plus isotretinoin
3168807|NCT00555399|Experimental|Ph I: Arm 2|Temozolomide plus isotretinoin
3168808|NCT00555399|Experimental|Ph I: Arm 3|Vorinostat plus isotretinoin plus temozolomide
3168809|NCT00555399|No Intervention|Ph II: Arm 1|Non-Surgical
3168810|NCT00555399|Other|Ph II: Arm 2|Surgical Arm
3168811|NCT00555412|Experimental|A - 10 mg loxapine q 4 h x 3 (30 mg total)|
3168812|NCT00555412|Experimental|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|
3168813|NCT00555412|Experimental|C - 5 mg loxapine q 4 h x 3 (15 mg total)|
2543811|NCT02605681||septic patients|We recruited the patients admitted to the Department of Critical Care Medicine, Zhongda Hospital, a tertiary hospital, from November 2017 to March 2018. The inclusive criteria were adult patients (age > 18 years-old and < 80 years-old) diagnosed with sepsis, according the definition of the Surviving Sepsis Campaign (2016). Exclusive criteria included: 1. age < 18 years-old or > 80 years-old; 2. pregnancy or breastfeeding; 3. malignancy; 4. patients with potentially elevated plasma midkine apart from sepsis including acute myocardial infarction, stroke, limb thrombosis, chronic renal dysfunction (baseline plasma creatine ≥2 mg/dL), autoimmune diseases and Alzheimer syndrome; 5. patients deceased or discharge from ICU within 24 hours; or, 6. written consents could not be obtained.
2543877|NCT02605252|Experimental|CHB patients|Hepatitis B e antigen (HBeAg)-negative CHB patients who had received NAs for more than 12 months, with HBsAg <1500 IU/ mL and Hepatitis B virus DNA not detectable, are to receive peginterferon alfa-2b 80 micrograms/week for 48 weeks.
2543938|NCT02604758|Experimental|Tidal Model|the psychiatric nursing approach based on the Tidal Model
2543940|NCT02604758|No Intervention|control group|The control group received routine treatment and follow-up in the Alcohol and Substance Addiction Treatment Clinic.
3203341|NCT00922467|Experimental|Esmolol|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and esmolol
3203342|NCT00922506|Experimental|doxazosin plus tolterodine SR 2 mg|doxazosin plus tolterodine SR(2 mg, qd) for 12 weeks
2544211|NCT02602938|Experimental|aspirin|"The included patients will be administered with aspirin (100mg) orally once a day in 28-day cycles.~The CTC was evaluated at baseline, and every 28 days for 2 months."
2544259|NCT02602769||Cases of ROHHAD syndrome|"Children diagnosed with ROHHAD syndrome during the course of their clinical care by their physicians.~The investigators will perform transcriptome profiling in this group."
2544260|NCT02602769||Control cohort|Unaffected first degree family members. The investigators will perform transcriptome profiling in this group.
2544294|NCT02602392|Experimental|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
2544296|NCT02602392|Active Comparator|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
2544361|NCT02602184|Experimental|AR/101|Topically treatment with AR/101+Standard of Care once daily for up to 21 days. Daily treatment will include application of AR/101 drug to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with AR/101.
2544362|NCT02602184|Placebo Comparator|Placebo|Topically treatment with Placebo + Standard of Care once daily for up to 21 days. Daily treatment will include application of placebo control to the wound and coverage with dressing (SoC). Subjects who are scheduled for an elective abdominoplasty at the practice of the principal investigator will have superficial split thickness wounds created on their abdomen according to protocol about 4 weeks prior to their scheduled abdominoplasty. A total of 8 split thickness (5X5 cm, 0.0254 mm in thickness) wounds will be distributed on the abdomen between the umbilicus and the suprapubic hairline. 4 of the wounds will be treated with Placebo.
3203343|NCT00922506|Experimental|doxazosin plus tolterodine SR 4 mg|doxazosin plus tolterodine SR(4 mg,qd) for 12 weeks
3203344|NCT00922519||1|
3203345|NCT00922532|Experimental|Inhaled Nitric Oxide|Inhaled Nitric Oxide
3203346|NCT00922532|Placebo Comparator|Nitrogen|Nitrogen Placebo
3203347|NCT00922558|No Intervention|normal children|Normal children ages 5-12 years.
3203348|NCT00922558|Experimental|postural control|
2544531|NCT02600949|Experimental|Treatment (synthetic tumor-associated peptide vaccine therapy)|Patients receive personalized synthetic tumor-associated peptide vaccine therapy SC on day 1 of weeks 0, 1, 3, 4 and 6, then every 3 weeks until week 30, then at weeks 39 and 51. Beginning 30 minutes after each vaccine is administered, patients then receive imiquimod cream topically after 30 minutes. Patients also receive pembrolizumab IV over 30 minutes on day 1. Courses with pembrolizumab repeat every 3 weeks until week 51 in the absence of disease progression or unacceptable toxicity.
3203349|NCT00922571|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the OptiMedica Catalys™ Precision Laser System (Catalys System)
3203350|NCT00922584|Experimental|sorafenib|Patients with stage IIIB/IV NSCLC who failed EGFR-TKI therapy will receive oral sorafenib 400 mg twice daily until disease progression or unacceptable toxicity.
2544670|NCT02599909||1/ Cohort 1|Subjects with hepatocellular carcinoma
2544730|NCT02599623|Experimental|Local anesthesia|Patient operated in local anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
2544732|NCT02599623|Active Comparator|General anesthesia|Patient operated in general anesthesia, with a mesh repair in Lichtenstein if no bowel necrosis existed.
3203351|NCT00922597||Group 1|
2544864|NCT02598804|Experimental|Intervention group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
2544865|NCT02598804|Other|control group|"No single group but 2 groups :~Intervention group (5 educational workshop in addition to spa therapy)~Control group (Written information booklet in addition to spa therapy)"
2544939|NCT02598388|Experimental|Part 1 (US Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
2544941|NCT02598388|Experimental|Part 2 Group 1 (African Participants)|Participants will receive Ad26.ZEBOV or placebo on Day 1 followed by MVA-BN-Filo or placebo on Day 29.
2544944|NCT02598388|Experimental|Part 2 Group 2 (African Participants)|Participants will receive MVA-BN-Filo or placebo on Day 1 followed by Ad26.ZEBOV or placebo on Day 15.
2545012|NCT02597790||Group A (HIV/HCV coinfected)|
3203352|NCT00922610|Experimental|1|
3203353|NCT00922649|Other|A|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of ≥ 2 OAs
2543821|NCT02605694|Experimental|Arm 1|Duvelisib 25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity; and Rituximab (375 mg/m2) will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
2543825|NCT02605694|Active Comparator|Arm 2|"R-CHOP will be administered as follows:~IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2) Orally on Days 1-5 of Cycles 1-6 (21-day cycles)~Prednisone (100 mg) will be administered."
2543880|NCT02605057|Experimental|LEO 80185 gel|LEO 80185 gel will be allocated to 7 different test sites on each subject
2543887|NCT02605057|Experimental|Dovobet Ointment|Dovobet Ointment will be allocated to 7 different test sites on each subject
2543960|NCT02604732|Active Comparator|Patients who stop Aspirin|Patients need to stop Aspirin 1 week before the surgery
2543962|NCT02604732|Experimental|Patients who continue Aspirin|Patients will continue Aspirin
2544091|NCT02604043|Experimental|supraglottic impendence/pH probe|
2544126|NCT02603549||Surgery or Blood Patch|
2544209|NCT02603263||Workplace Restaurant Customers|"1 Group (Workplace Restaurant Customers) across 3 sites (data to be combined at end of study)~Study consists of three phases:~Pre Intervention~Intervention~Post Intervention~All phases lasted two weeks and included monitoring till receipts for meals (these were automatically generated and held on the tills electronically). The intervention phase consisted of posters being displayed in the restaurants, featuring a Social Norms Poster."
2544245|NCT02602795|Experimental|Distress Tolerance (DT)|Acceptance and Commitment Therapy based Distress Tolerance (DT) intervention to facilitate opioid detoxification delivered in six 50-minute individual telehealth sessions.
2544246|NCT02602795|Active Comparator|HIV/STI Intervention|Information Motivation Behavioral model based HIV/STI risk reduction intervention delivered in six 50-minute individual telehealth sessions.
2544247|NCT02602795|No Intervention|Treatment As Usual (TAU)|Traditional treatment given to patients who elect to transition to XR-NTX at the treatment sites.
2544311|NCT02602535|Experimental|M.O.R.E.|Participants will attend a Mindfulness-Oriented Recovery Enhancement (MORE) group weekly for eight weeks.
2544315|NCT02602535|Active Comparator|Support Group|Participants will attend a support group weekly for eight weeks.
2544331|NCT02602145||Peripheral artery disease patients|Patients with peripheral artery disease that were treated with a stent as part of their standard of care. Patients who meet the inclusion criteria (i.e. already have an SFA stent) will be consented after their endovascular repair, and those who choose to participate in the study will be followed for six months. At six months a standard post-operative contrast-enhanced CTA of the lower extremities will be obtained to assess for restenosis.
2544382|NCT02601924|Active Comparator|Topical Pressure Massage Block injection|Topical pressure massage at site of alveolar nerve block injection.
2544389|NCT02601924|Active Comparator|Topical Anesthetic Gel Block injection|Topical anesthetic gel (20% Benzocain) at site of inferior alveolar nerve block injection.
2544395|NCT02601924|Active Comparator|Topical Pressure Massage Infiltration|Topical pressure massage at site of maxillary anterior infiltration
2544396|NCT02601924|Active Comparator|Topical Anesthetic Gel Infiltration|Topical anesthetic gel (20% Benzocain) at site of maxillary anterior infiltration
2544443|NCT02601443|Experimental|Cervical Pessary|"Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.~Cervical pessary has been tried as a simple, non-invasive alternative that might replace the above invasive cervical stitch operation to prevent preterm birth."
2544445|NCT02601443|No Intervention|Routine care (watch and wait)|
2544474|NCT02601157|Experimental|Orsiro SES/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
2544475|NCT02601157|Active Comparator|Orsiro SES/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Orisro sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
2544476|NCT02601157|Experimental|CX-ISAR/3-months DAPT|As an one of experimental arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 3-month dual antiplatelet therapy (DAPT) schedule.
2544477|NCT02601157|Active Comparator|CX-ISAR/1-year DAPT|As an one of comparator arms in 2x2 factorial design, patients allocated to this group will be implanted with Coroflex ISAR (CX-ISAR) sirolimus-eluting stents for their coronary lesions, and then will be followed with 1-year dual antiplatelet therapy (DAPT) schedule.
2544547|NCT02600689|Experimental|Physical exercise training|Combined aerobic and resistance exercise for 30 or more minutes at least 3 times per week for 12 weeks using the Wii Fit Plus
2544549|NCT02600689|Active Comparator|Cognitive exercise training|Cognitive, brain-training, video gaming ~30 minutes per session, 3 times per week for 12 weeks
2544614|NCT02600442||main and unique cohort|
2544649|NCT02600052|Experimental|GPNF|Patients will be submitted to aerobic training, with prior application of PNF technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
2544652|NCT02600078|Sham Comparator|Sham|Subjects will be exposed to sham and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2544653|NCT02600078|Active Comparator|Mild Hypoxia|Subjects will be exposed to mild hypoxia and measures of balance, heart rate, pulse oxygen saturation, questionnaires, and coordination tasks will be examined at set time intervals during the hypoxic exposure.
2543848|NCT02605330||Fibrinogen plasma level in CABG|In all patients undergoing coronary artery bypass grafting (CABG) the investigators plan to measure the fibrinogen plasma level
2543849|NCT02605330||Fibrinogen plasma level in AVR|In all patients undergoing aortic valve replacement (AVR) the investigators plan to measure the fibrinogen plasma level
2543850|NCT02605330||Fibrinogen plasma level in AAR|In all patients undergoing aortic arch replacement (AAR) the investigators plan to measure the fibrinogen plasma level
2543875|NCT02604992|Experimental|Group 1 (A,B,C)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment B, and then Treatment C.
2543878|NCT02604992|Experimental|Group 2 (B,C,A)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment C, and then Treatment A.
2543883|NCT02604992|Experimental|Group 3 (C,A,B)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment A, and then Treatment B.
2543885|NCT02604992|Experimental|Group 4 (C,B,A)|With a 7-day washout between periods, participants are randomized to receive Treatment C, Treatment B, and then Treatment A.
2543889|NCT02604992|Experimental|Group 5 (A,C,B)|With a 7-day washout between periods, participants are randomized to receive Treatment A, Treatment C, and then Treatment B.
2543892|NCT02604992|Experimental|Group 6 (B,A,C)|With a 7-day washout between periods, participants are randomized to receive Treatment B, Treatment A, and then Treatment C.
2543950|NCT02604524|Experimental|Closed-Loop Control (CLC) System|Subjects will use the Closed-Loop Control system in an attempt to maintain blood glucose in a certain range during the day and at night during the trial.
2543954|NCT02604524|Placebo Comparator|Sensor Augmented Pump Therapy Group|Subjects will manage their own glucose levels during the trial.
2543980|NCT02604329|Experimental|intervention|"Radiation : use of Oncolase Digi therapy laser diode"
3203354|NCT00922649|Other|B|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen of basal insulin ± OAs
3203355|NCT00922649|Other|C|Insulin pump naïve subjects with type 2 diabetes who are not achieving glycemic targets (screening A1C ≥ 7.0%) on an established regimen basal-bolus insulin ± OAs
3203356|NCT00922675|Experimental|Postconditioning|Active arm:Postconditioning protocol before routine PCI/stenting of an occluded coronary artery
3203357|NCT00922675|Other|Control|Control arm: Routine PCI/stenting of an occluded coronary artery without postconditioning
2544153|NCT02603367|Experimental|Supportive care (COMFORT communication intervention)|"Participants receive the printed communication tool A Communication Guide for Caregivers, a guide developed from the COMFORT communication curriculum, a national training program for palliative care communication. After a 1 week period to review the material, participants undergo communication coaching with a research nurse by phone over approximately 1 hour."
2544226|NCT02603055|Experimental|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
2544229|NCT02603055|Active Comparator|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co., Ltd. three doses, 30μg/0.5ml per dose
2544334|NCT02602639|Experimental|Functional electrical stimulation rowing|Using an Odstock 4 channel neuromuscular stimulator with Concept 2 Rower
2544450|NCT02601482|Experimental|Control (CON)|No exercise intervention.
2544459|NCT02601482|Experimental|Normal Interval Walking (IW-60).|Sixty minutes with repeated cycles of 3 minutes of fast and 3 minutes of slow walking on a treadmill
2544465|NCT02601482|Experimental|Time-reduced Interval Walking (IW-45)|Forty-five minutes with repeated cycles of 3 minutes of fast and 1.5 minutes of slow walking on a treadmill
2544486|NCT02601053|Active Comparator|Dull (boring) movie|Participants will be exposed to a dull (i.e. boring) movie followed by a scary (i.e. horrifying) movie.
2544488|NCT02601053|Experimental|Scary (horrifying) movie|Participants will be exposed to a scary (i.e. horrifying) movie followed by a to a dull (i.e. boring) movie.
3203358|NCT00922688|Active Comparator|Dipeptiven Arm Enteral|
3203359|NCT00922688|Placebo Comparator|Placebo Arm Enteral and Intravenously|
2544668|NCT02599948||Patients hospitalised in ICU|Patients hospitalised in ICU
2544703|NCT02599701|Placebo Comparator|Placebo|A single dose of placebo with exactly the same characteristics of the active drug at bedtime.
2544705|NCT02599701|Experimental|Gabapentin|A single dose of Gabapentin 300mg at bedtime.
2544748|NCT02599389|No Intervention|Standard balloon|Angioplasty with use of standard balloons
2544749|NCT02599389|Experimental|Drug-coated balloons|Angioplasty with use of drug-coated balloons
2544750|NCT02599389|Experimental|Drug-coated balloons and laser|Angioplasty with use of drug-coated balloons in association with Excimer Laser
2544854|NCT02598869|Active Comparator|Intravitreal triamcinolone|subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)
2544858|NCT02598869|Active Comparator|posterior subtenon triamcinolone|subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)
2544917|NCT02598505|Experimental|Indacaterol|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
2544921|NCT02598505|Placebo Comparator|Placebo|Inside this arm we also compare the effect of Carvedilol to the effect of Bisoprolol
2544951|NCT02598336|Other|Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing followed by a forced respiratory manoeuvre. This sequence is repeated twice.
2544953|NCT02598336|Other|Agreement and repeatability Breathing Sequence|Simultaneous measurement using Structured Light Plethysmography and Pneumotachograph Spirometry during a period of tidal breathing. This sequence is repeated one further time at rest, and once further time after an exercise test to elevate respiratory rate.
3203360|NCT00922688|Active Comparator|Dipeptiven ARM Intravenously|
3203361|NCT00922714|Experimental|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
3203362|NCT00922714|Placebo Comparator|Control|saline
2543943|NCT02604784|Experimental|cohort B|Cohort B: For patients that have not indication for systemic therapy with standard chemotherapy. This cohort has a phase I design; with a dose-escalation design the maximum tolerated doses and recommended doses of Cisplatin + Doxorubicin and Oxaliplatin (according to the pathology) administered through PIPAC in patients with peritoneal carcinomatosis will be evaluated.
2543997|NCT02604394|Active Comparator|Rheolytic Thrombectomy with PCI|"Rheolytic Thrombectomy (RT) will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The single-pass antrograde thrombectomy technique will be used."
2543998|NCT02604394|Sham Comparator|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
2544072|NCT02604030|Experimental|Upper limb function|Assessment of scapular kinematics during arm elevation, perceived function, quality of life, range of motion and muscle strength for shoulder complex after a rehabilitation program focused on upper limb.
2544131|NCT02603653|Experimental|Patients|Virtual radial task in 3D
2544135|NCT02603653|Experimental|Controls|Virtual radial task in 3D
2544198|NCT02603224|Experimental|MRG-201|
2544199|NCT02603224|Placebo Comparator|Placebo|
2544238|NCT02602834|Experimental|HTx|Heart transplant recipients n=15
2544241|NCT02602834|Active Comparator|Control|Healthy controls n=5
2544295|NCT02602574||ERCP- induced acute pancreatitis|"All patients with indication for ERCP will be prepared for ERCP. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample.~Upon clinical and laboratory confirmation of acute pancreatitis according to ESGE guidelines for post-ERCP pancreatitis, will be further monitored during hospitalization for evaluation of the severity of the disease."
2544297|NCT02602574||non -ERCP acute pancreatitis|"All patients with acute pancreatitis according to Atlanta criteria admitted through Emergency Department will be taken 30 ml of heparinized peripheral venous blood and urine sample upon 24 hours after the clinical symptoms have started. 10 mL of collected blood samples will be examined in the Department of Laboratory Medicine. Other 20 mL of blood samples will be sent to Department of Physiology and Immunology, School of Medicine where immunologic analysis will be performed.~This group of patients will be further monitored during hospitalization for evaluation of the severity of the disease. Severity of the disease will be assessed according to the Atlanta criteria."
2544298|NCT02602574||Control group|"Control group will consist of patients who underwent ERCP but didn't develop acute pancreatitis. One hour before and 4-6 hours after the procedure 10 mL of blood sample and urine sample will be collected.~24 hours after the procedure all patients will be taken 30 ml of heparinized peripheral venous blood and urine sample."
2544354|NCT02602171|Experimental|dereverberation condition|Oldenburger Sentence test, localization test
2544358|NCT02602171|Experimental|reverberation condition|Oldenburger Sentence test, localization test
2544403|NCT02601729||RT-CGM population|Prospective data collection during standardized clinical follow-up and from filled out questionnaires.
2544404|NCT02601729||Pump only population|Retrospective data collection on demographic and clinical characteristics.
2544521|NCT02601261||Patients with some access to internet during stay|
2544523|NCT02601261||Patients without access to internet during stay|
2544618|NCT02600312|Active Comparator|oXiris|Continuous renal replacement therapy with filter that adsorbs cytokines/toxins.
2544622|NCT02600312|No Intervention|ST150|Continuous renal replacement therapy with filter that does not adsorb cytokines/toxins.
2544662|NCT02600065||Study cohort|"All patients who are suffering from brain tumor of brain metastases and are willing to participate.~The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy."
2544760|NCT02599259|Experimental|1. Monitored (M+)|Group receiving treatment as usual (TAU) and using the AiCure platform for monitoring and intervention platform on a mobile device being tested when taking their daily anticoagulation medication.
2544767|NCT02599259|No Intervention|Unmonitored (M-)|No Intervention. Group receiving TAU and not issued mobile device with the AiCure platform.
2544796|NCT02599012|Experimental|Subjects|
2544853|NCT02598765|Active Comparator|Standard Trabeculectomy|Patients in the Standard Trabeculectomy arm will undergo regular trabeculectomy
2544857|NCT02598765|Experimental|Microtrabeculectomy|Patients in the Microtrabeculectomy arm will undergo microtrabeculectomy
2544892|NCT02598518|Experimental|Integrating Combined Therapies|Integrating Combined Therapies (ICT) is a 10-session, manual-guided individual therapy. ICT has three phases designed to address substance use, psychiatric problems and their interactions. MET is the first phase (2 sessions) and is focused on assessment, feedback and securing motivation to address problems and take steps. CBT is the second phase (5 sessions) and incorporates patient education and functional analysis, develops coping skills, teaches methods to challenge beliefs, and activates alternative behaviors. TSF (3 sessions) is focused on maintaining recovery and engaging in community-based recovery activities. Although ICT has core components, its application is flexible to accommodate the unique needs and problems of individual patients (and their comorbidities).
2544898|NCT02598518|Active Comparator|Standard Care|Standard Care (SC) is the typical outpatient treatment that the patient would receive ordinarily at the identified addiction treatment program. SC service operates using the American Society of Addiction Medicine criteria (9 hours per week); group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
2544928|NCT02598284|Experimental|Point of Care (POC) Only|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies to accelerate performance on ABCS clinical measures. All strategies will focus on aspects of the clinical encounter.
2545016|NCT02597790||Group B (HIV monoinfected)|
2543961|NCT02604498|Experimental|Healthy Subjects|Healthy volunteers. Nemonoxacin Malate Capsules 500mg single dose oral.
2544006|NCT02604290|Experimental|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
2544008|NCT02604290|Sham Comparator|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
3203363|NCT00922727|Active Comparator|L. reuteri|Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment and maintenance of a well-functioning gastro-intestinal (GI) tract microflora and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment. The oil drops contain a dietary supplement of Lactobacillus reuteri DSM 17938.
3203364|NCT00922727|Placebo Comparator|Sunflower Oil|Placebo will be the equivalent number of drops of suspended sunflower oil (without LR), provided by Biogaia.
3203365|NCT00922740|Placebo Comparator|Sugar pill|
3203366|NCT00922740|Experimental|VA106483 1 mg|
2544207|NCT02602977|Experimental|multiple-dose RIPC|Multiple-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive 4 cycles of remote ischemic preconditioning of the upper limb per day in the 7 consecutive days before the endotoxemia experiment. The last dose will be applied 40 minutes before LPS administration.
2544213|NCT02602977|Experimental|single-dose RIPC|Single-dose Remote Ischemic Preconditioning. A group of 10 subjects that will receive a single RIPC dose, starting 40 minutes before LPS administration.
2544217|NCT02602977|Active Comparator|control group|Only LPS infusion. A group of 10 subjects that will be administered LPS without RIPC.
2544271|NCT02602665|Experimental|Shallow catheter tip placement|Patients randomized to shallow tip placement will have the tip of the catheter placed approximately one vertebral body above to even with the carina.
2544272|NCT02602665|Experimental|Deep catheter tip placement|Patients randomized to deep tip placement will have the tip of the catheter placed 1.5 to 2.5 vertebral bodies below the carina.
2544299|NCT02602314|Experimental|Imatinib + Nilotinib|
2544300|NCT02602314|Experimental|Nilotinib|
2544453|NCT02601638|Experimental|Arm 1|"Demographics and Health History Questionnaire (5-10 minutes to complete)~Pre-Class Laryngectomy Survey (5-10 minutes to complete)~Attend a preoperative counseling session with a speech pathologist. It will take 30-60 minutes~Attend the Total Laryngectomy Preoperative Education Class. Participants will attend within 1-2 weeks of providing written consent and prior to their scheduled surgery. The preoperative education class will take one hour.~Complete the Day of Hospital Discharge Laryngectomy Survey at the time of discharge from the hospital (5-10 minutes to complete)~Perform the day of discharge practicum assessing the minimal competency skills for laryngectomy care prior to discharge from the hospital.~Complete the Laryngectomy Education Study Exit survey. Participants will perform an exit survey at the first clinic appointment after 30 days after hospital discharge (15-30 minutes to complete)"
2544507|NCT02600975|Active Comparator|Group 1|10µg of R21 with AS01B on days 0, 28, and 56.
2544511|NCT02600975|Active Comparator|Group 2|50µg of R21 with AS01B on days 0, 28, and 56.
2544552|NCT02600806|Other|Azithromycin/levofloxacin|Azithromycin or levofloxacin are given according to serum procalcitonin levels
3203367|NCT00922740|Experimental|VA106483 2 mg|
2544663|NCT02600000|Experimental|Sympathetic myocardial activity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the modulation of sympathetic myocardial activity of patients with HF
2544664|NCT02600000|Experimental|Maximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the maximal functional capacity of patients with HF
2544666|NCT02600000|Experimental|submaximal functional capacity after IMT|Evaluate the effectiveness of Muscle Training Inspiratory associated with a cardiac rehabilitation program in the submaximal functional capacity of patients with HF
2544669|NCT02600000|Experimental|Thickness and mobility of the diaphragm after IMT|Assess the impact of Inspiratory Muscle Training in combination with a cardiac rehabilitation program on the thickness and mobility of the diaphragm in patients with heart failure.
2544743|NCT02599597|Experimental|Therapist-assisted iCBT|Internet-delivered cognitive behavioral therapy (iCBT), containing physical activity and sleep management for preventing depressive relapse. Monthly depression screening with therapist feedback.
2544745|NCT02599597|Active Comparator|Monthly screening with feedback|Monthly depression screening with therapist feedback.
2544747|NCT02599597|No Intervention|Control|No intervention, follow-up along with all participants at 6 and 12-months.
2544825|NCT02599142|Active Comparator|Group A: Closed-face shells|Cranial radiotherapy using the control closed-face immobilisation shell.
2544826|NCT02599142|Experimental|Group B: open-face shell|Cranial radiotherapy using the experimental open-face immobilisation shell
2544870|NCT02598648|Other|ALI( acute lung injury)|Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 40.0 kPa (300mmHg, ALI); 3.Chest X-ray showed that the double lung texture increased, the increase of crude, fuzzy, visible diffuse patchy infiltration shadow with compensatory emphysema, for the most early performance; B. double lung field large sheet, asymmetric, edge fuzzy infiltration shadow, the most dense in the lung；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of. FXR and RIPK3 were measured in neonate with ALI.
2544968|NCT02597972|Active Comparator|Reverse Total Shoulder Arthroplasty|The patients randomized into the RTSA group will receive standard surgical treatment of their proximal humeral fracture with a Reverse Total Shoulder Arthroplasty.
3203368|NCT00922740|Experimental|VA106483 4 mg|
3203369|NCT00922753|Active Comparator|BiPAP6 assisted preoxygenation|
2544155|NCT02603354|Active Comparator|3x12 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 3 times of 12 minutes session for in office bleaching teeth
2544156|NCT02603354|Experimental|1-36 m peroxide gel tooth bleaching 6%|bleaching with 6% hydrogen peroxide 1 time of 36 minutes session for in office bleaching teeth
2544190|NCT02603094|Experimental|clear fluids until premedication|allowed to drink until premedication, aprox 30 minutes before anaesthesia induction. Fasting for solids and non-clear fluids is six hours.
2544195|NCT02603094|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction clear fluid Ingestion. Fasting for solids and non-clear fluids is six hours.
2544234|NCT02602847||Patients with alcoholic or hepatitis C virus related disease|cccDNA assay on liver biopsy in patients with liver transplantation for alcoholic disease or hepatitis C virus (HCV) related disease, without contact with HBV
2544236|NCT02602847||Hepatitis B core antibody positive donors|cccDNA assay on liver biopsy in patients who receive liver from hepatitis B core antibody positive donors
2544239|NCT02602847||HBV patients|cccDNA assay on liver biopsy in patient with liver transplantation for chronic hepatitis B, with or without HBV replication
2544285|NCT02602561|Active Comparator|HMB|3 g HMB/day
2544288|NCT02602561|Placebo Comparator|Placebo|Placebo administered similar to the active comparator
2544324|NCT02602197|Active Comparator|Paracetamol|1 gr paracetamol received intravenously bolus 15 minutes after anesthetic induction and at the postoperative 6 th,12 th, 18 th and 24 th hours
2544325|NCT02602197|Active Comparator|Dexketoprofen|50 mg dexketoprofen received intravenous bolus 15 minutes after anesthetic induction and at the postoperative 8 th,16 th and 24 th hours.
2544383|NCT02601963|Experimental|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2544388|NCT02601963|Experimental|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2544393|NCT02601963|Placebo Comparator|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
2544455|NCT02601378|Experimental|LXS196 as a single agent|About 68 patients will be enrolled in dose escalation and expansion
2544462|NCT02601378|Experimental|LXS196 in combination with HDM201|about 44 patients to be enrolled in dose escalation and expansion
3168814|NCT00555412|Placebo Comparator|D - inhaled placebo q 4 h x 3|
2544641|NCT02600039|Experimental|ELTGOL|
2544642|NCT02600039|Active Comparator|Acapella|
2544673|NCT02599818|Experimental|NavSTAR|Participants in this arm will receive services from the NavSTAR Patient Navigation team. The Patient Navigator will work with patients for up to 3 months post-hospital discharge to resolve internal barriers (e.g., ambivalence about treatment; low motivation; competing life demands, etc.) and external barriers (e.g., lack of transportation; lack of ID card, etc.) to appropriate utilization and engagement in addiction treatment and medical care. Interventions include motivational interventions and patient navigation with proactive case management, tailored to participants' specific needs.
2544675|NCT02599818|No Intervention|TAU (Treatment as Usual)|Participants in this arm will receive usual care, which includes in-hospital services from a multidisciplinary substance use disorder consultation liaison team.
2544729|NCT02599571|Other|Very low nicotine content cigarettes|Reduced nicotine content cigarettes.
2544731|NCT02599571|Other|Conventional nicotine content cigarettes|Conventional nicotine content cigarettes.
2544791|NCT02599168|Active Comparator|Dexmedetomidine group|Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
2544793|NCT02599168|Placebo Comparator|Non-Dexmedetomidine group|Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
2544827|NCT02598817||Standard Infant Formula|Standard Infant Formula containing High Sn-2
2544879|NCT02598635|Experimental|Cholecalciferol|A capsule of pulverized cholecalciferol 4800 U will be administered once a day for 16 weeks. At serum calcium levels > 10.5 mg/dL (2.65 mmol/l) and/or at serum phosphorus levels > 7 mg/dL (2.26 mmol/L) capsule administration will be discontinued and restarted one month after when serum calcium levels or phosphorus levels declined to < 10.6 mg/dL and/or <7.1 mg/dL respectively.
2544971|NCT02598063|Experimental|Peginterferon alfa-2a + Lamivudine|Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
3168815|NCT00555490|Experimental|1|
3168816|NCT00555503||1|Patients who have risk-reduction mastectomy of any type, per protocol inclusion and exclusion criteria.
3168817|NCT00555516|Active Comparator|1|"The chemotherapy regimen of group 1 is restricted to AC or CAF during the first cycle~Group 1 will receive EW02 for 15 consecutive days during the second cycle~will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle."
3168818|NCT00555516|Placebo Comparator|2|"The chemotherapy regimen of group 2 is restricted to AC or CAF during the first cycle~Group 2 will receive 15 consecutive days of Placebo~Group 2 will receive EW02 at 700mg tid/day for 15 consecutive days during the third cycle"
3168819|NCT00555529||1|
3168820|NCT00555529||2|
3168821|NCT00555542|Experimental|1|Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15.
3168822|NCT00555555|Experimental|Coagulation FVIII/VWF|Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT
3168823|NCT00555594|Active Comparator|A|Patients with corneal neovascularization of infectious etiology, steroid reactors, and know glaucoma or glaucoma suspects. They received one dose of 0.1cc of subconjunctival Bevacizumab (Avastin™ Genentech, Inc, USA) in bulbar conjunctiva, 2 mm from the limbus, according to the location of the vessels.
3203370|NCT00922753|Active Comparator|BiPAP4 assisted preoxygenation|
2544308|NCT02602522|Experimental|Experimental|The patients in this arm will be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
2544312|NCT02602522|Active Comparator|controlled|The patients in this arm will be given 1 bag per time of Sichuan Danshen-Jiang-Fu Granule prepared, twice a day for 5 days before menorrhea and the first 2 days in the first menorrhea period. And then in the next menstrual cycle, the patients will in turn be given 1 bag per time of Shandong Danshen-Jiang-Fu Granule, twice a day for 5 days before menorrhea and the first 2 days in the second menorrhea period.
2544355|NCT02602119|Experimental|OTL38|Dosage calculated by weight of individual
2544413|NCT02601716|Experimental|Group 1|"Group 1 subjects (n=15) will receive 4 doses of PfSPZ Vaccine (4.5 x 10^5 PfSPZ/dose) every 2 days, followed by a single, boosting dose (same dose as before) given 16 weeks later, for a total PfSPZ dose = 22.5 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 4 priming immunizations and the boost scheduled for Group 1. Participants not protected after the first CHMI will be invited to receive a booster vaccination (4.5 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
2544415|NCT02601716|Experimental|Group 2|"Subjects (n=15) will receive 3 doses of PfSPZ Vaccine (9.0 x 10^5 PfSPZ/dose) every 8 weeks, total PfSPZ dose = 27 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by heterologous CHMI (7G8) Pf parasites at 28 and 40 weeks after first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 2. Participants not protected after the first CHMI will be invited to receive a booster vaccination (9.0 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week 40)."
2544416|NCT02601716|Experimental|Group 3|"Group 3 subjects (n=15) will receive 3 doses of PfSPZ Vaccine (18 x 10^5 PfSPZ/dose) every 8 weeks for a total PfSPZ dose of 54 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous (7G8, NF135.C10) Pf parasites at 40 and 66 weeks after the first immunization, along with 8 infectivity controls. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 3. All participants will be invited to receive a booster vaccination (18 x 10^5 PfSPZ) 21 days prior to the second CHMI. Subjects may participate in the second CHMI whether or not they were protected in the 1st CHMI, to serve as controls for the effect of the 1st CHMI on immunity.~Subjects will be followed for 56 days beyond the final CHMI (post-immunization week66)."
2544417|NCT02601716|Experimental|Group 4|"Subjects (n=15) will receive a single, priming dose of PfSPZ Vaccine (27 x 10^5 PfSPZ/dose), followed by 2 additional immunizations (9.0 x 10^5 PfSPZ per dose) every 8 weeks, total PfSPZ dose = 45 x 10^5. PfSPZ Vaccine administered by DVI.~Protective efficacy assessed by CHMI with heterologous 7G8 and NF135.C10 Pf parasites at 40 and 66 weeks, respectively, along with 8 infectivity controls at each CHMI. Subjects may proceed to CHMI if they have received at least 2 of 3 immunizations scheduled for Group 4. All participants will be invited to receive a booster vaccination (9.0x10^5 PfSPZ) 21 days prior to the second CHMI.~Subjects will be followed for 56 days beyond the final CHMI at (post-immunization week 66)."
2544418|NCT02601716|Other|Infectivity Controls, CHMI (7G8)|Infectivity controls (n=24) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for CHMI for all groups. 8 infectivity controls will undergo CHMI with each of two CHMIs (at 28 and 40) for Groups 1 and 2, and 8 infectivity controls will undergo CHMI with the 40 week CHMI for Groups 3 and 4. All CHMI will be conducted by exposure to the bites of 5 mosquitoes infected with heterologous (7G8) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 40 at the UMB site.
2544419|NCT02601716|Other|Infectivity Controls, CHMI (NF135.C10)|Infectivity controls (n=8) will not receive any PfSPZ Vaccine. They will serve as infectivity controls for the second CHMI at week 66 for Groups 3 and 4. CHMI will be conducted by exposure to the bites of 3-5 mosquitoes infected with heterologous (NF135.C10) Pf parasites. Subjects will be followed for 56 days beyond the last CHMI at week 66 at the NMRC site.
2544503|NCT02601235|Experimental|Naridrin|Naridrin: 2 drops in each nostril once daily as prescription
2544504|NCT02601235|Active Comparator|0.05 % Oxymetazoline Hydrochloride|2 pumps in each nostril every 12 hours
2544556|NCT02600741||Study group 1|Caregivers randomized to this group will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
2544566|NCT02600741||Study group 2|Caregivers randomized to this group will receive whatever caregiver support that is customarily available at the study site, if any. Each patient will be paired with a caregiver and patients will continue their routine antipsychotic treatments prescribed by their treating physician.
2544706|NCT02599675|Experimental|Vitamin D3|Vitamin D3 capsules for 12 weeks (2000 IU daily, equivalent to 50 ug)
2544709|NCT02599675|Placebo Comparator|Placebo|Placebo capsules for 12 weeks (the number of daily capsules will match that of the vitamin D-group)
2544757|NCT02599311|Other|the efficacy|transvaginal synthetic mesh
2544764|NCT02599311|No Intervention|the recurrence rate|transvaginal synthetic mesh
2544770|NCT02599311|No Intervention|the quality of life|transvaginal synthetic mesh
2544774|NCT02599311|Other|the rate of the LUTS|We use Tolterodine to improve patients' LUTS
2544859|NCT02598921|Other|Three dimensional ultrasound|Three dimensional ultrasound evaluated the uterine cavity for cavitary lesions
2544230|NCT02602951|Experimental|Patients|Patients with an intracranial disorder or needing a supraaortic trunk MRA
2544256|NCT02602652|Experimental|a live attenuated chimeric JE vaccine|Children were received JE-CV as a booster dose after vaccinated with SA14-14-2 vaccine as a first dose regimen 12-24 months before.
2544273|NCT02602431|Active Comparator|Extra-oral laser irradiation|infra-red wave laser, 660nm, 100mW, and 107J/cm2
2544274|NCT02602431|Placebo Comparator|Extra-oral placebo|Laser point will be placed in region without irradiation on.
2544275|NCT02602431|Active Comparator|Intra-oral laser irradiation|red wave laser, 660nm, 100mW, and 107J/cm2
2544276|NCT02602431|Placebo Comparator|intra-oral placebo|Laser point will be placed in region without irradiation on.
2544348|NCT02602301|Active Comparator|1|group A that included 109 women in whom labour was augmented by IV infusion of oxytocin using isotonic saline 0.9%,
2544349|NCT02602301|Active Comparator|2|group B that included 109 women in whom labour was augmented by IV infusion of oxytocin using glucose 5% .
2544351|NCT02602301|Placebo Comparator|3|Group C in which 109 women continued their labour course without any further augmentation.
2544402|NCT02601690||Blood Sampling|Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.
2544463|NCT02601391|Other|STEPPS within forensic services.|"Forensic inpatients attend the STEPPS-HI group. Consent will be obtained. Pre and post group psychometric questionnaires will be completed as well as each service user attending a short semi-structured interview following the conclusion of the group .~Primary nurse will fill in pre and post group questionnaires. Facilitators will complete short feedback forms each session and attend a focus group upon completion.~Psychology Assistants/Interns will collect records of self harm and violence/aggressive incidents for each service user as well as records of nursing observation level and leave status taken."
2544478|NCT02601040|Experimental|Attenuated Hepatitis A Vaccine, H2 Strain|Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.
2544479|NCT02601040|Experimental|Inactivated Hepatitis A Vaccine, Lu8 Strain|Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.
2544481|NCT02601040|Placebo Comparator|Group A Meningococcal Polysaccharide vaccine|Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.
2544558|NCT02600832|Experimental|AABM Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of real AABM training (16 subjects each) taking place over three weeks.
2544569|NCT02600832|Sham Comparator|Sham Training|Immediately following screening, patients will be randomly assigned to receive 9 sessions of sham training (16 subjects each) taking place over three weeks.
2544594|NCT02600416|Other|AV port reversal|Patients undergoing citrate CVVH.
2544665|NCT02600195|Experimental|EPIQ sites|Use Evidence-based Practice for Improving Quality (EPIQ) method to develop and implement evidence-based practice changes to reduce hospital-acquired infection
2544667|NCT02600195|No Intervention|Control sites|Continue current practices
2544765|NCT02599376|Active Comparator|BMI less than 30|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
2544769|NCT02599376|Experimental|BMI more than 40|The drop in cardiac output after spinal anaesthesia for LSCS at various intervals with LiDCORapid
2544795|NCT02599025|No Intervention|Supine position|Children tested while lying down
2544799|NCT02599025|No Intervention|Standing position|Children tested while standing
2544802|NCT02599025|Experimental|Cycling supine postion|Children lying down with APT cycling system
2544809|NCT02599025|Experimental|Cycling standing postion|Children standing with Innowalk cycling system
2544904|NCT02598752||functional performance testing|This observational study will evaluate the feasibility and safety of functional performance testing in patients undergoing HCT. In addition to standard of care procedures, participants will undergo a CPET with a rest and stress echo, pulmonary function, and patient reported outcome questionnaires within 30 days of HCT.
2544945|NCT02598245|Active Comparator|TOT 8/4|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 4 mm diameter is used (Hegar 4). An additional Hegar dilator sound of 8 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
2544946|NCT02598245|Experimental|TOT 6/3|"Transobturator sling (TOT) is placed according to the original description. Instead of a Metzenbaum Scissor which should guarantee the distance between the urethra and the sling a Hegar dilator sound of 3 mm diameter is used (Hegar 3). An additional Hegar dilator Sound of 6 mm is placed in the urethra before tightening the sling and suturing the vaginal skin."
3203371|NCT00922753|Active Comparator|Standard preoxygenation (VS)|
3203372|NCT00922792|Experimental|A|
3203373|NCT00922792|Experimental|B|
2545345|NCT02595619|Experimental|RRT plus ECCO2R|
2545382|NCT02595268|Experimental|Pitavastatin Then JNJ-63623872|Participants will sequentially receive single oral dose of pitavastatin 1 milligram (mg) on Day 1, followed by JNJ-63623872 600 mg twice daily on Days 4 through 12 with a single oral dose of pitavastatin 1 mg administered in the morning of Day 9. All study drug intakes will be taken orally, under fed conditions (within approximately 10 minutes after completion of a meal).
2545404|NCT02595021|Experimental|Total or Subtotal Colectomy|all patients who underwent total colectomy(removal of the large intestine from ileum to the rectum. After it is removed, the end of the small intestine is sewn to the rectum) or subtotal colectomy(removal of transverse colon, descending colon, sigmoid colon to the rectum. After it is removed, the end of the ascending colon is sewn to the rectum)as part of optimal cytoreductive surgery
2545405|NCT02595021|Active Comparator|Other Bowel Resection|all patients who underwent partial intestinal resection as part of optimal cytoreductive surgery
2545473|NCT02594839|Experimental|MSCs|2 intravenous infusions of suspension of 200 000 000 MSCs each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
2545480|NCT02594839|Placebo Comparator|placebo|2 intravenous infusions of 400 mL saline each at interval of 7 days. Infusions will be repeated every 3 months for 1 year.
2545545|NCT02594332|Experimental|Mepolizumab|100 mg SC every 4 weeks for 13 injections
2544366|NCT02601781|Experimental|Primary PCI (PPCI) with BVS|Primary percutaneous coronary intervention (PPCI) with bioresorbable vascular scaffold (BVS) implantation in STEMI patients. Following the arterial route, PPCI (performed according to the international guidelines) aims to recanalize an occluded coronary artery that is then maintained patent inserting an endovascular permanent prosthesis (stent). In this study we aim to assess the results following the use of a fully bioresorbable prosthesis (BVS) during PPCI using a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation). BVS has the theoretical advantage, as compared with a permanent stent, to disappear within 24-36 months from implantation restoring the native pristine vessel state.
2544435|NCT02601586|Experimental|PR oxycodone|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone : 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2544438|NCT02601586|Active Comparator|levodopa|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa : 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa : 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2544440|NCT02601586|Placebo Comparator|Placebo|"A titration phase of two weeks, in three steps:~Level 1 (from D1 to D5):~Oxycodone placebo : 10 mg PR/day bid (5 mg PR/5 mg PR)~Levodopa placebo 100 mg/day bid (50 mg/50 mg)~Level 2 (from D6 to D10):~Oxycodone placebo: 20 mg PR/day tid (10 mg/0 mg/10 mg)~Levodopa placebo: 150 mg/day tid (50 mg/50 mg/50 mg)~Level 3 (from D11to D15):~Oxycodone placebo: 40 mg PR/day tid (20 mg/0 mg/20 mg)~Levodopa placebo: 200 mg/day tid (100 mg/50 mg/50 mg)~A fixed dose period: the level 3 dose will be maintained for 8 weeks (from D16 to D71).~A withdrawal period:"
2544638|NCT02600234|Experimental|Treatment with Inter-Atrial Shunt Device|Once all study criteria have been met, if randomized to this arm, patients will receive the IASD implant.
2544640|NCT02600234|Placebo Comparator|Control|Once all study criteria have been met, if randomized to this arm, patients will not receive the implant. They will undergo an intracardiac echo only, with the option to crossover at 1 year.
2544755|NCT02599753|Experimental|18F-DTBZ for Parkinson's Disease|The participants qualify for the study will return to the clinic at a later date and will have catheter(s) placed for i.v. administration of 18F- DTBZ for injection. The participants will receive a single i.v. bolus of 18F- DTBZ, followed by brain PET imaging of 10 minutes duration, approximately 80 minutes post-dose injection. Vital signs will be obtained prior to and immediately after the administration of 18F- DTBZ, and at the completion of the imaging session. Adverse events will be continuously monitored during the imaging session. The participants experience any adverse event will not be discharged until the event has resolved or stabilized.
2544867|NCT02599103|Placebo Comparator|fat-free milkshake|
2544871|NCT02599103|Active Comparator|Olive oil|
2544881|NCT02599103|Experimental|soybean oil|
2544889|NCT02599103|Experimental|fried soybean oil|
2544894|NCT02599103|Experimental|palm oil|
2544900|NCT02599103|Experimental|fried palm oil|
2544906|NCT02599103|Experimental|camellia oil|
2544907|NCT02599103|Experimental|fried camellia oil|
2544909|NCT02599103|Experimental|tallow|
2544911|NCT02599103|Experimental|fried tallow|
2544955|NCT02598141|Other|Per-op biopsy around material|"Patients included in this study require biopsies for suspicion of infected osteo-articular materials (implants, protheses, nails, screw, plates).~Interventions:~Biological sampling grinding~Biological sampling with standard procedures"
2545005|NCT02597803|Experimental|High Dose RGN-259|High dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2545008|NCT02597803|Placebo Comparator|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
2545019|NCT02597803|Experimental|Low Dose RGN-259|Low dose RGN-259: It is a preservative-free, sterile eye drop solution containing Tβ4
2545066|NCT02597335|Experimental|IDH1/IDH2|
3174233|NCT00621101|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus)
2545438|NCT02595216|Experimental|all subjects|"All subjects in this study will receive a single Profound system treatment to the submental area with the profound device; subjects will return to four follow- up visits: 1 week post treatment, 1, 3 and 6 months post treatment.~Prior to treatment, tissue will be treated with injected tumescence or local dermal infiltration solution according to the protocol."
3174234|NCT00621114|Active Comparator|1|Patients in group 1 will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
3174235|NCT00621114|Experimental|2|Patients in group 2 will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
3174236|NCT00621166|Other|1|generic lopinavir/ritonavir
3174237|NCT00621218|Active Comparator|1|
3174238|NCT00621218|Placebo Comparator|2|
3174239|NCT00621231|Placebo Comparator|1|
3174240|NCT00621231|Experimental|2|
3174241|NCT00621270|Experimental|1|BCI-540 80 mg once a day (q.d.)
3174242|NCT00621270|Experimental|2|BCI-540 80 mg three times a day (t.i.d.)
3174243|NCT00621270|Placebo Comparator|3|Placebo
3174244|NCT00621283|Experimental|1|Drug + MR with MRCP
3174245|NCT00621361|Experimental|1|
3174246|NCT00621361|Active Comparator|2|Etoposide + Cisplatin
3174247|NCT00621374|Experimental|Random Order 1|Randomization Order 1= 1)CONT, 2)CBT, 3)HYP, 4) CBT-HYP
3174248|NCT00621374|Experimental|Random Order 2|Randomization order 2= 1)CONT, 2)HYP, 3)CBT, 4) CBT-HYP
3174249|NCT00621387|Experimental|1|ofloxacin and roxithromycin
3174250|NCT00621387|Placebo Comparator|2|placebo
2544436|NCT02601521|Active Comparator|External coaching program|The external coaching program consists of referral to the Massachusetts Tobacco Control Program's Smokers Helpline, a free program offering multi-session proactive telephone counseling for 3 months to individuals who are ready to quit smoking. Individuals in this arm also receive information about Partners HealthCare, Inc.'s new health insurance benefit that provides access to all FDA-approved smoking cessation medications without copay or prior approval.
2544508|NCT02601183||Ischemic stroke|The patients in the group are diagnosed as ischemic stroke by CT or MRA examination within 8h following stroke attack.
2544512|NCT02601183||Hemorrhagic stroke|The patients in the group are diagnosed as hemorrhagic stroke by CT or MRA examination within 8h following stroke attack.
3203374|NCT00922805|Active Comparator|fiber-enriched formula then fiber-free formula|Subjects first receive a fiber-enriched formula for one week but then will be crossed over and receive a fiber-free formula
2544646|NCT02600169||Patients treated with pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma. Patients will be included from all 14 WIN-O (Werkgroep Immunologie Nederland voor Oncologie) centers in the Netherlands. Patients are at least 18 years of age.
2544714|NCT02599857|Experimental|CONCOR smartphone application|Use of CONCOR smartphone application
2544716|NCT02599857|No Intervention|Standard care (no CONCOR smartphone application)|No CONCOR smartphone application
2544778|NCT02599324|Experimental|Renal Cell Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.~Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus."
2544781|NCT02599324|Experimental|Urothelial Carcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel."
2544784|NCT02599324|Experimental|Gastric Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.~Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel."
2544785|NCT02599324|Experimental|Colorectal Adenocarcinoma - Enrollment Closed|"Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.~Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab."
2544787|NCT02599324|Experimental|Urothelial Carcinoma Ibrutinib- Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b.
2544788|NCT02599324|Experimental|Urothelial Carcinoma with Pembrolizumab - Enrollment Closed|Phase 1b: Patients will receive ibrutinib at various dose levels in combination with pembrolizumab to determine the RP2D of ibrutinib Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with pembrolizumab.
2544918|NCT02598453|Experimental|Ibandronate IV|Participants will receive ibandronate 3 mg IV once every 3 months
2544922|NCT02598453|Experimental|Ibandronate Oral|Participants will receive ibandronate 150 milligrams (mg) tablet once monthly
2544975|NCT02597959||risk factors of musculoskeletal injuries|trainees for surgical assistants - determining the level of risk
2544979|NCT02597959||design wearable devices|Creating feedback mechanism to reduce surgical assistant musculoskeletal risk
2545011|NCT02597699|Active Comparator|Arm 1: Sufentanil + Lidocaïne|"For patients randomized to arm 1, as in the current practice, we will inject Sufentanil intra-cordially at the dose of 1.5 μg / kg of the estimated fetal weight, then the Lidocaïne 1% bolus of 10 ml (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of fetal asystole, we will inject 100mg of Lidocaïne 1% in bolus of 10 ml. In the event of failure of the procedure, we will inject 10ml of KCL 10% intra-cordial if the cord is always accessible, if not intra-cardiac."
2545018|NCT02597699|Experimental|Arm 2: Remifentanil + Lidocaïne|"For patients randomized to arm 2, we will inject 30 μg of intravenous Remifentanil (Ultiva®) followed by Xylocaine 1% in a 10 ml bolus (10 mg / ml).~If 2 minutes after the start of the injection of Lidocaïne, there is no obtaining of asystole, we will inject 100 mg of Lidocaïne 1% in bolus of 10 ml. In case of failure of the procedure, we will inject 10 ml of KCL 10% intra-cordial if the cord is still accessible, if not intra-cardiac."
2545061|NCT02597387|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
2545112|NCT02597179||Metastatic Breast Cancer, Young Breast Cancer|Patients with feasible biopsy site.
3203375|NCT00922805|Active Comparator|fiber-free formula then fiber-enriched formula|Subjects receive first formula only then will be crossed over and receive a fiber-enriched formula
3203376|NCT00922818||Radical perineal prostatectomy patients|Radical perineal prostatectomy patients
2545213|NCT02596399|Experimental|DSTA4637S|
2545215|NCT02596399|Placebo Comparator|Placebo|
2545235|NCT02596113||No pathological findings|blood and biopsy samples from normal colon mucosa
2545244|NCT02596113||>1 cm adenomatous polys|blood and biopsy samples from the polyp
2545248|NCT02596113||Colorectal cancer|blood (plasma) and biopsy samples from colorectal cancer
2545440|NCT02594891|Placebo Comparator|endoscopic nasobiliary drainage|Patients will undergo endoscopic nasobiliary drainage (ENBD) when bile duct stones were removed clearly with ERCP. The nose bile duct will be pulled out 3-5 days later if no cholangitis occurrence.
2545461|NCT02594865|Active Comparator|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
2545485|NCT02594800|Active Comparator|standard dose|Drug: Rosuvastatin rosuvastatin 10 mg daily for 52 weeks.
3203377|NCT00922844|Active Comparator|Sevoflurane|Administration of the volatile anesthetic Sevoflurane.
3203378|NCT00922844|Active Comparator|Isoflurane|Administration of the volatile anesthetic Isoflurane.
3203379|NCT00922857|Experimental|Respiratory rehabilitation|
3203380|NCT00922870|Active Comparator|Standard treatment|
3203381|NCT00922870|Experimental|Cascade|
3203382|NCT00922896|Experimental|GPE|Gemcitabine-Cisplatin-Erlotinib
2544458|NCT02601326|Active Comparator|delorme's procedure|excision of excess rectal mucosa under spinal anesthesia then plication of the rectal muscles with vicryl 2/0 sutures
2544560|NCT02600702|No Intervention|usual care|quadricep exercise
2544570|NCT02600702|Experimental|Siriraj home base exercise|Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
2544577|NCT02600702|Active Comparator|Modalities and exercise|Physical modalities for 6 weeks and Knee exercise protocol for 12 position for 3 months with low-impact aerobic exercise
2544593|NCT02600390|Experimental|SANGUINATE™ (4-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 4-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
2544596|NCT02600390|Experimental|SANGUINATE™ (6-week)|This is an Open-label, repeated-dose study. About five patients will be observed for 3 weeks continuing on standard of care therapy (for wound cleaning and bandaging). This will be followed by a 6-week treatment period to include once weekly doses of SANGUINATE provided via two-hour IV infusion. The final week of the study will include another observation period wherein all patients will receive standard of care therapy.
2544637|NCT02600182|Experimental|Bilevel Positive Airway Pressure (BiPAP)|The routine physical therapy will be performed in two groups (control and BiPAP). The BiPAP group will receive two daily sessions of 20 minutes, with positive expiratory pressure of 10cmH2O and inspiratory of 15cmH2O.
2544639|NCT02600182|No Intervention|Control|Routine physical therapy will be performed.
2544686|NCT02599896|Experimental|Group 1|5 mg/kg/IV on Day 0
2544688|NCT02599896|Experimental|Group 2|5 mg/kg SC on Day 0
2544689|NCT02599896|Experimental|Group 3|20 mg/kg IV on Day 0
2544690|NCT02599896|Experimental|Group 4|40 mg/kg IV on Day 0
2544691|NCT02599896|Experimental|Group 5|5 mg/kg SC on Day 0, Week 12 and Week 24
2544692|NCT02599896|Experimental|Group 6|20 mg/kg IV on Day 0, Week 12 and Week 24
2544693|NCT02599896|Experimental|Group 7|5 mg/kg SC on Day 0, Week 4
2544694|NCT02599896|Experimental|Group 8|20 mg/kg IV on Day 0, Week 4
2544808|NCT02598908||NHS staff volunteer donors|Interested staff working within the Pathology Department at SWBH NHS Trust will be provided with written information regarding the proposed EQA scheme and the sample collection procedure. A consent form will be given to staff members, who will be asked to return the signed form within 1 week if they wish to participate. Each participating staff member will be assigned a unique patient identifier to allow for sample results to be anonymised.
2544815|NCT02598908||SWBH outpatient donors|A list of SWBH NHS Trust patient TPMT results will be gathered from the Pathology computer system (Telepath). Those with a TPMT activity of interest, measured in the past five years, will be contacted with the agreement of their hospital consultant. Information and consent forms will be sent to the patient either through the post or via their hospital consultant. Each participating patient will be assigned a unique patient identifier to allow for sample results to be anonymised.
2544855|NCT02598726|Experimental|Supportive care (curcumin, piperine)|Patients receive curcumin PO BID or TID and piperine extract (standardized) PO on days 1-7 in the absence of disease progression or unacceptable toxicity.
2544929|NCT02598440|Experimental|Group A: Ibandronate Then Alendronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet) for 3 months followed by and once-weekly oral alendronate (70 mg tablet) in crossover design for 12 weeks.
2544932|NCT02598440|Experimental|Group B: Alendronate Then Ibandronate|Participants will receive once-weekly oral alendronate (70 mg tablet) for 12 weeks followed by once-monthly oral ibandronate (150 mg tablet) for 3 months.
2545104|NCT02597140|Experimental|Lidocaine group|Patients will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
2545107|NCT02597140|Placebo Comparator|Control group|Patients will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous normal saline infusion of 2 mg/kg/hr.
2545142|NCT02596763|Other|Baclofen|Patient with current alcohol use disorder included by any baclofen prescriber located in the French region of Nord - Pas-de-Calais - Picardie.
3168824|NCT00555594|Active Comparator|B|Patients with corneal neovascularization of any cause except for infectious disease. Patients of this group received one application of 0.1cc of subconjunctival Bevacizumab™ + 0.1cc of triamcinolone acetonide (ATLC; Grin laboratories, México city) in bulbar conjunctiva, 2 mm from de limbus, according to the location of the vessels.
3168825|NCT00555607|Active Comparator|steroid|Group receiving oral prednisolone (0.5 mg/kg bodyweight per day) during 14 days.
2545260|NCT02596126|Active Comparator|Treatment Prevention for Secondary CV|Patients allocated to the usual care arm will receive standard of care therapies for secondary prevention according to the ESC guidelines. Drugs and doses will be left at the discretion of the treating physicians..
2545266|NCT02596126|Experimental|Cardiovascular Polypill|Patients allocated to the experimental arm will receive a cardiovascular polypill containing aspirin 100 mg, atorvastatin (40 or 20 mg) and ramipril (2.5, 5 or 10 mg) taken orally once a day.
2545413|NCT02595125|Sham Comparator|Conventional technique|Intrauterine device (IUD) insertion by the conventional technique
2545418|NCT02595125|Experimental|Direct technique|Intrauterine device (IUD) insertion by the direct technique
3168826|NCT00555607|Placebo Comparator|placebo|Group receiving placebo tablets during 14 days, followed by an open prednisolone treatment (0.5 mg/kg bodyweight per day) during a following 14 days.
3168828|NCT00555685|Active Comparator|A|Group of patients that will receive hypertonic saline solution (NaCl 7,5%)
3168829|NCT00555685|Placebo Comparator|B|Group of patients that will receive placebo
3168830|NCT00555698|Experimental|DBS|DBS
3168831|NCT00555711||Modulated Imaging|Modulated Imaging
3168832|NCT00555724|Experimental|BIIB022|
3168833|NCT00555763|Active Comparator|1|
3168834|NCT00555776|Active Comparator|1|Randomly,half of the subjects are given Gabapentin.
3168835|NCT00555776|Placebo Comparator|2|Randomly,half of the subjects receive placebo.
3203383|NCT00922909|Active Comparator|2|Day 1 : morning : Medication on ; Stimulation : off afternoon : Medication : on ; Stimulation : on Day 2 : morning : Medication : off ; Stimulation : off afternoon : medication : off ; stimulation : on
2544572|NCT02600598|Experimental|LEO 43204 Group A|Group A - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
2544578|NCT02600598|Experimental|LEO 43204 Group B|Group B - Experimental LEO 43204, applied once daily for 3 consecutive days in patients with actinic keratosis
3203384|NCT00922909|Active Comparator|3|Day 1 : morning : Medication off ; Stimulation : on afternoon : Medication : off ; Stimulation : off Day 2 : morning : Medication : on ; Stimulation : on afternoon : medication : on ; stimulation : off
3203385|NCT00922909|Active Comparator|4|Day 1 : morning : Medication off ; Stimulation : off afternoon : Medication : off ; Stimulation : on Day 2 : morning : Medication : on ; Stimulation : off afternoon : medication : on ; stimulation : on
3203386|NCT00922909|Active Comparator|1|Day 1 : morning : Medication on ; Stimulation on afternoon : Medication on ; Stimulation off Day 2 : morning : Medication off ; Stimulation on afternoon : Medication off ; Stimulation off
3203387|NCT00922948|Experimental|Cryoablation|
2544754|NCT02599415|Other|TL01 light treatment|routine treatment with a CE marked device that has been used for this disease for many years
2544810|NCT02599077|Experimental|Dienogest|the patient handling with 2 mg dienogest / day.
2544813|NCT02599077|Active Comparator|Levonorgestrel + ethinylestradiol|The patient handling with levonorgestrel + ethinylestradiol (0,10 mg - 0,02 )
2544888|NCT02598687|Other|treatment|treatment arm: TH-302 pre-treatment day 4 and weekly during treatment. 5 x carboplatin and paclitaxel, radiotherapy: 23 x 1.8Gy HX4 scans day 1 and day 8,surgery 6-10 weeks after chemo-radiotherapy
2544956|NCT02598258|Experimental|Sauna + Cold Water Bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after , subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
2544991|NCT02597868|Active Comparator|Capecitabine|Capecitabine 1250mg per BSA by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.
2544992|NCT02597868|Experimental|endocrine therapy|endocrine therapy is be gived as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemotreatment,the medcine will be confirmed by the patient's past-treatment.
2545046|NCT02597556|Active Comparator|Albendazole|Albendazole will be administered as a single 400mg chewable tablet at 0, 3, 6, 9, and 12 months.
2545047|NCT02597556|Placebo Comparator|Placebo|Matching Placebo will be administered as a single chewable tablet at 0, 3, 6, and 9 months. At month 12, all participants will receive a single 400mg Albendazole tablet.
2545089|NCT02597270||Cohort 1|Brazilian participants with Genotype 1 HCV infection treatment naive participants or previously failed to double therapy (Peg-interferon-α and Ribavirin) will be included in the trial and will constitute the trial population.
2545188|NCT02596477|Experimental|Vepoloxamer - Low dose|Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
2545191|NCT02596477|Experimental|Vepoloxamer - High dose|Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
2545192|NCT02596477|Placebo Comparator|5% dextrose in water (D5W)|D5W administered intravenously over 3 hours
2545256|NCT02596152|Experimental|Mini-trampoline|participants allocated to this group will participate in a 12-week mini-trampoline group instructed training twice a week.
2545262|NCT02596152|Active Comparator|Nordic Walking|participants allocated to this group will participate in a 12-week Nordic Walking group instructed training twice a week.
2545296|NCT02595788||Supine position|Examination in the supine position
2545297|NCT02595788||Prone position|Change from supine to prone position
2545383|NCT02595203|Experimental|Part A: Cohort 1|Participants receive a single intravenous (IV) dose of 240 mg/3.7 megabecquerel (MBq) of [14C-pos 1]-Debio 1450 BES solution.
2545385|NCT02595203|Experimental|Part A: Cohort 2|Participants receive a single oral dose of 240 mg/3.7 MBq of [14C-pos 1]-Debio 1450 BES solution.
2545387|NCT02595203|Experimental|Part B: Cohort 3|Participants receive a single oral dose of 240 mg Debio 1450/37 kilobecquerel (kBq) of [14C-pos 25]-Debio 1450 BES solution.
2545428|NCT02594995|Experimental|NBP in thrombolysis group|NBP 25mg bid for 2 weeks administered after 24 hours after receiving recombinant plasminogenactivator(rt-PA) thrombolysis
2545431|NCT02594995|Experimental|NBP group|NBP 25mg bid for 2 weeks administered for the patients who do not receive rt-PA
2545432|NCT02594995|No Intervention|Control group|Control group not receiving rt-PA thrombolysis, receiving basic therapy for acute stroke, e.g. aspirin/clopidogrel and lipid-lowering therapy
2545434|NCT02594995|No Intervention|Control in thrombolysis group|Control group receiving rt-PA thrombolysis
2545451|NCT02594696|Experimental|Proactive Psychiatry Consultation (PPC)|"The patient is linked to a psychiatrist and case manager at cancer diagnosis who deliver team-based, patient-centered care. The psychiatrist collaborates with the oncologist to guide cancer treatment. The psychiatrist and case manager proactively monitor patient symptoms and potential barriers to care and remain in communication with the patient, oncology team, and community-based providers for the duration of the intervention.~Patients complete study assessments at baseline, 4 +/- 2 weeks after baseline, and post-intervention (12 +/-2 weeks after baseline)~Oncologists provide feedback about the usefulness of the intervention (12 +/- 2 weeks after baseline)"
2545551|NCT02594501|Experimental|COBRA PzF|Cobra PzF plus 14-day DAPT (dual antiplatelet therapy)
2545552|NCT02594501|Active Comparator|Drug Eluting Stent|standard FDA-approved DES (Xience/Promus or Resolute) plus 3 or 6-month DAPT (dual anti-platelet therapy)
2545610|NCT02593760|Active Comparator|Placebo + Ruxolitinib|Participants will receive placebo (PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
2545616|NCT02593760|Experimental|Vismodegib + Ruxolitinib|Participants will receive vismodegib (150 mg PO QD) in combination with ruxolitinib (dose will depend on the participant's baseline platelet count) for up to 48 weeks.
2545693|NCT02593487|Experimental|Rosuvastatin 10mg/d group|rosuvastatin 10mg table by mouth, qd
3203388|NCT00922948|Active Comparator|Radiofrequency ablation|Radiofrequency ablation
3203389|NCT00922961|Experimental|cellular apoptosis|
3203390|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g|
2544611|NCT02600520|Active Comparator|Rosuvastatin Group|SRP followed by RSV gel LDD
2544617|NCT02600520|Active Comparator|Atorvastatin Group|SRP followed by ATV gel LDD
2544623|NCT02600520|Placebo Comparator|Placebo group|SRP followed by placebo gel LDD
2544657|NCT02600026|Experimental|Video Camera: Intervention|DriveCam video event recorder with feedback
2544659|NCT02600026|Placebo Comparator|Video Camera: Monitoring|DriveCam video event recorder with no feedback
2544710|NCT02599662|Other|Group 1: 10 Gy Low-KV IORT|10 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
2544713|NCT02599662|Other|Group 2: 15 Gy Low-KV IORT|15 Gy Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
2544715|NCT02599662|Other|Group 3: 20 GY Low-KV IORT|20 GY Low Kilovoltage Intraoperative Radiation: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
2544775|NCT02599285||Fixation|Patients with a trimalleolar AO Weber C fracture with open reduction and fixation of the posterior malleolar fragment.
2544782|NCT02599285||No Fixation|Patients with a trimalleolar AO Weber C fracture without open reduction and fixation of the posterior malleolar fragment.
3203391|NCT00923000|Active Comparator|Nalbuphine|
3203392|NCT00923000|Active Comparator|Morphine|
2544934|NCT02598167||RRMS Population|Participants with a diagnosis of RRMS and being prescribed with a DMT for a period of at least 3 months according to standard local clinical practice will be included.
3203393|NCT00923000|Experimental|Morphine with Long dan xie gan tang|
3203394|NCT00923000|Experimental|Nubian with Long dan xie gan tang 3g tid|
2545217|NCT02596373|Experimental|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
2545218|NCT02596373|Active Comparator|Mitoxantrone Hydrochloride Injection|Mitoxantrone Hydrochloride Injection 14 mg/m2 will be infused intravenously once over 30 minutes in 150 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks
2545257|NCT02596074|Experimental|Omiganan (CLS001)|CLS001 topical gel, 2.5%
2545261|NCT02596074|Placebo Comparator|Vehicle|Vehicle topical gel
2545291|NCT02595801||Exposed|Exposure to surgery prior to completion of Early Development Instrument
2545293|NCT02595801||Reference|No exposure to surgery prior to completion of Early Development Instrument
2545335|NCT02595606|Experimental|treatment group|treatment with 0.3% Sodium Hyaluronate, by five times a day, one or two drop each time
2545336|NCT02595606|No Intervention|control group|without treatment
2545341|NCT02595359|Experimental|moxifloxacin intracameral|moxifloxacin injection given at conclusion of cataract intervention
2545394|NCT02595255||High risk|Conditioning therapy for bone marrow transplantation or pelvic irradiation. Fertility preservation is usually already proposed in this group of patients. No intervention.
2545395|NCT02595255||Moderate/low risk|"Pathologies treated with chemotherapy regimen with moderate or low risk of inducing ovarian function insufficiency: AML (Acute myeloide leukemia), osteosarcoma, Ewing sarcoma, neuroblastoma, non-Hodgkin lymphoma, Hodgkin lymphoma, soft tissue sarcoma, ALL (acute lymphoblastic hormone), Wilms tumour, retinoblastoma.~This is the study group we will compare with high risk and no risk patients. No intervention"
2545396|NCT02595255||No risk|"Patients with chronic benign diseases or malignancies who don't receive any chemotherapy or other gonadotoxic treatment.~No intervention"
2545443|NCT02594878|Experimental|Pamidronatdinatrium 3mg/ml|Pamidronatdinatrium 1 mg/kg max 60 mg for 3 days every 3 month in total of 3 series (0,3,6 month). First day first series 0,5mg/kg max 30 mg.
2545445|NCT02594878|Placebo Comparator|Natrium chloride 9 mg/ml|Natrium chloride 9 mg/ml volume equals experimental drug
2545484|NCT02594592||Younger Women|Younger Women (age ≤ 55 years),complete questionaire
2545488|NCT02594592||Younger Men|Younger Men (age ≤ 55 years),complete questionaire
2545490|NCT02594592||Older Men|Older Men (age > 55 years). complete questionaire
2545491|NCT02594592||Older Women|Older Women (age > 55 years),complete questionaire
2545529|NCT02594241|Active Comparator|Methylprednisolone|Patients in this arm will be given an intravenous infusion of 125 mg Methylprednisolone (Solu-Medrol) immediately after induction of general anesthesia.
2545532|NCT02594241|Placebo Comparator|Physiological saline|Patients in this arm will be given an intravenous infusion of saline immediately after induction of general anesthesia.
3203395|NCT00923039||Exposed/ Not exposed|
3203398|NCT00923182|Experimental|Alemtuzumab|The starting dose of alemtuzumab was 3 mg. The dose was gradually escalated on a daily basis (3 mg, 10 mg, and then 30 mg) until the patient tolerated a dose of 30 mg IV infusion over 2 hours. All subsequent doses of alemtuzumab were 30 mg IV 3 times a week (every other day).
3203400|NCT00923234|Experimental|Azacitidine and Lenalidomide|Azacitidine 75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles and Lenalidomide 10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
3203401|NCT00923247|Experimental|Phase 1 - vandetanib and bortezomib|Patients will be treated with vandetanib and bortezomib to find the maximally tolerated dose
3168836|NCT00555789|Active Comparator|1|mycophenolic and tacrolimus
3168837|NCT00555789|Experimental|2|mycophenolic and tacrolimus
3168838|NCT00555815||1|Extended hygiene measures
2544699|NCT02599844||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
2544700|NCT02599844||Sepsis without AKI|This group will have a history of a pediatric admission with sepsis which lead to no classification of sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
2544777|NCT02599337|Experimental|sorafenib|Sorafenib is the test product.In period 1, period 2 and period 3, 12 of 36 Subjects were given Single oral dose (1 x 200 mg) sarofenib.
2544780|NCT02599337|Active Comparator|Nexavar|Nexavar is the reference product.In period 1, period 2 and period 3, 24 of 36 Subjects were given Single oral dose (1 x 200 mg) Nexavar .
2544850|NCT02598882|Active Comparator|treadmill|patients will be 30 minutes of activity on treadmill, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
2544852|NCT02598882|Active Comparator|videogame|patients will be 30 minutes of activity with video games, before and after exercise the same shall be assessed as fatigue of quadriceps by surface electromyography
3203402|NCT00923247|Active Comparator|Phase 2 B - vandetanib alone|Patients will be treated with vandetanib alone.
3203403|NCT00923247|Active Comparator|Phase 2 A - vandetanib and bortezomib at the MTD|Patients will be treated with vandetanib and bortezomib at the maximally tolerated dose (MTD) of the Phase I study
2545064|NCT02597361|Active Comparator|Irbesartan|Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.
2545065|NCT02597361|Placebo Comparator|Placebo|Placebo once or twice per day for 2 years.
2545094|NCT02597075|Active Comparator|Arm A: with ST + PA|Standard therapy + structured Physical activity and pedometer
2545095|NCT02597075|Active Comparator|Arm B:|Standard therapy
2545159|NCT02596737|Other|workers|"Workers will fulfil a visual analog scale of Well-being regarding 3 main categories: Physically, Mentally, At Work."
2545175|NCT02596425|Experimental|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
2545176|NCT02596425|Experimental|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
2545182|NCT02596425|Experimental|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
2545242|NCT02596243|Experimental|GX-188E|GX-188E + EP
2545249|NCT02596243|Placebo Comparator|placebo|Placebo + EP
3203404|NCT00923299|Other|cetuximab, trastuzumab|
3203405|NCT00923312|Experimental|CV9201|CV9201 is composed of five formulated mRNAs (drug product components) encoding antigens that are overexpressed or exclusively expressed in NSCLC cells.
2545492|NCT02594735|Other|open label|A patient's participation in this study will last approximately 24 weeks ( screening visit and 5 intervention visits) with possible extension to 48 weeks. At screening, participants will have a physical exam, muscle strength assessment, blood and urine collection, and chest x-ray; they will also be asked to complete several questionnaires. All participants will receive each week subcutaneous injection of Abatacept. During intervention phase of the trial, muscle strength testing, physical exam, disease activity measurements, blood and urine collection, and muscle MRI will be performed. Participants will also be asked to complete several questionnaires. Participants will be also monitored closely for for serious drug related side effects.
2545538|NCT02594228|Experimental|Whey Protein and exercise training|Six meals per day of 20 grams of protein, two of which were whey protein and 4 days per week of exercise training..
2545543|NCT02594228|Experimental|Food Protein and exercise training|Six meals per day of 20 grams of protein, all of which were whole food protein and 4 days per week of exercise training.
2545553|NCT02593981|Active Comparator|Fruit/Honey Drink|Fruit/Honey Drink (2 canisters) will be taken orally twice a day. Subjects will consume the drink on days 1 through 28.
2545554|NCT02593981|Placebo Comparator|Placebo|Placebo (2 canisters) will be taken orally twice a day. Subjects will consume the placebo drink on days 1 through 28.
3168839|NCT00555815||2|Standard hygiene measures
3168840|NCT00555828|Experimental|A1|5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
3168841|NCT00555828|Other|A2|5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
3168842|NCT00555828|Experimental|B1|5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
3168843|NCT00555828|Other|B2|3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
3168844|NCT00555828|Experimental|C1|5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
3203406|NCT00923338|Experimental|Vesico-vaginal fistula plug|Vesico-vaginal fistula plug
2544559|NCT02600910||Manual Wheelchair User Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, chair type, health status, and job type."
2544568|NCT02600910||Matched Able-bodied Cohort|"Physical Exam. Screening exam performed by a licensed physical therapist to confirm inclusion/exclusion criteria.~Assessment of Shoulder Function in Everyday Life. Shoulder motion & hand loading data will be collected over a few days, twice per yr for 3-5 yrs in home & community environment.~Magnetic Resonance Imaging (MRI) of Shoulders. Imaging will use standard clinical protocol once per yr for 3-5 yrs.~Shoulder Strength Testing. Once per yr for 3-5 yrs. Additional Variables. Updated demographic info will be collected yearly including but not limited to weight, health status, and job type."
2544595|NCT02600481|Experimental|low-pressure pneumoperitoneum group|Subjects assigned to the low-pressure pneumoperitoneum group will receive 7-10 mm Hg carbon dioxide pneumoperitoneum, and the expected duration is longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
2544597|NCT02600481|Active Comparator|standard-pressure pneumoperitoneum group|Subjects assigned to the standard-pressure pneumoperitoneum group will receive 12-16 mm Hg carbon dioxide pneumoperitoneum, which is expected lasted longer than 3 hours to complete robot-assisted surgeries in the Trendelenburg position;
2544708|NCT02599805|Experimental|Natrox treatment group|In this group, all subjects will have the Natrox™ ODS will be applied to the ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. Dressings according to the standard practice guidelines will be used. Patients in this group will continue to receive treatment as described by the diabetic foot ulcer standard of care. The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software.
2544711|NCT02599805|No Intervention|Control group|"All subjects in this group will receive the Diabetic foot ulcer standards of care which include:~Full medical assessment in all cases.~Surgical operation/Intervention where indicated.~Local treatment of the ulcer (debridement followed by ulcer care according to modern ulcer healing standards and management of diabetes.) The ulcer will be photographed at biweekly intervals for a period of 8 weeks to analyze ulcer surface area using a standardized digital imaging software."
3168845|NCT00555828|Other|C2|2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
2544798|NCT02598999|Experimental|Part I, SAD|Single administration of OSCN- or bLF or Placebo in healthy male volunteers
2544801|NCT02598999|Experimental|Part II, SAD and MAD|Single and multiple administrations of ALX-009 or Placebo in healthy male volunteers
2544806|NCT02598999|Experimental|Part III, MAD|Multiple administrations of OSCN- or bLF or Placebo in CF patients in healthy volunteers
2544812|NCT02598999|Experimental|Part IV, MAD|Multiple administrations of ALX-009 or Placebo in healthy volunteers and in patients (CF and NCFBE)
3168846|NCT00555841|Experimental|ALC|I g three times daily
3168847|NCT00555841|Placebo Comparator|Placebo|1 g three times daily
3168848|NCT00555867||1|Standard routine care for breast cancer
2545486|NCT02594566|Experimental|Research Subjects|A total of 3 injections of the vaccine (CyMVectin) will be given at Days 0, 28 (+4 days), and 56 (+4 days).
2545515|NCT02594293|No Intervention|Controlled Group|Discontinue the NA treatment and follow up for 96 weeks
2545521|NCT02594293|Experimental|Pegasys 24 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks
2545526|NCT02594293|Experimental|Pegasys 48 weeks|Discontinue the NA treatment ,PegIFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks
2545606|NCT02593851|Experimental|Part 1: Cohort 1a|Participants (greater than or equal to [>=] 6 months and less than or equal to [<=] 24 months of age) will receive JNJ-53718678, 2 milligram per kilogram body weight (mg/kg) oral solution once daily on Day 1 to Day 7. Dose and/or dosing regimen may be adapted in subsequent cohorts based on the review of the safety/tolerability and full pharmacokinetic data from Cohort 1a.
2545611|NCT02593851|Experimental|Part 1: Cohort 1b|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 6 mg/kg JNJ-53718678 oral solution or placebo [either in once daily [qd] or twice daily [bid]) on Day 1 to Day 7.
2545619|NCT02593851|Experimental|Part 1: Cohort 1c|Participants (>= 6 months and <= 24 months of age) will receive total daily dose of 18 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2545694|NCT02593487|Active Comparator|Rosuvastatin 20mg/d group|rosuvastatin 20mg table by mouth, qd
3168849|NCT00555867||2|Standard + Intervention arm: standard routine care for breast cancer and additional information material via post
3168850|NCT00555919|Experimental|Arm 1|
3168851|NCT00555919|Experimental|Arm 2|
3168852|NCT00555932|Active Comparator|1|The research head ultrasound (HUS) will be performed at the bedside in the Neonatal Unit. The ultrasound examination will be performed within 10 hours time window of the MR and or CT study.
3168853|NCT00555945|Active Comparator|1|Gamma3 intramedullary nail
3168854|NCT00555945|Active Comparator|2|Sliding hip screw
3168855|NCT00555958|Experimental|A|All study subjects will be implanted with the Maestro System, and all will receive VBLOC therapy.
3168856|NCT00555984|Active Comparator|Total Intravenous anesthetic|Intravenous anesthetics (propofol + remifentanil) for maintenance of General Anesthesia
3168857|NCT00555984|Active Comparator|Volatile Anesthetic|Inhalational anesthetics (sevoflurane+remifentanil) for maintenance of General Anesthesia. Patients receive Sevoflurane as a volatile anesthetic and remifentanil as an IV agent for maintenance of general anesthesia.
3168858|NCT00556023|Experimental|CP-675,206 and gemcitabine|
3168859|NCT00556036||1|lean healthy women, age 18-45
3168860|NCT00556036||2|overweight healthy women, age 18-45
3168861|NCT00556036||3|women with hypothalamic amenorrhea (have not had a period in three months), age 18-45
3168862|NCT00556036||4|women with anorexia nervosa, age 18-45
2544627|NCT02600273|Experimental|Electronic cigarettes 2|During one session, participants will use an electronic cigarette with 18 mg/mL nicotine e-liquid
2544671|NCT02599987|Experimental|Inspiratory Muscle Training Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The training group will carry with IMT load of 50% of MIP. Weekly, patients attend the Cardiopulmonary Physical Therapy Laboratory for evaluation of MIP and load adjustment, performing a training session in the presence of the therapist, while other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
2544672|NCT02599987|Sham Comparator|Sham Group|Will use the breathing coach POWERbreathe® Classic Light. Participants will hold the workout three sets of 30 inspirations, 2 sessions per day, 7 days per week for 8 weeks. The sham group will carry without load, but will be subjected to the same procedures in the experimental group (simulation of load adjustment in the Cardiopulmonary Physical Therapy Laboratory) to ensure blinding of the study, other sessions will be held by the participant at home and registered in the diary training. The training took place with the patient sitting in chair with a back, with knees and hips flexed to 90 °, the participant will use a nose clip and the device coupled to the nozzle mouth, will be instructed to diaphragmatic breathing pattern.
2544718|NCT02599610|Active Comparator|Digital vaginal examination|Patients assigned to this group will be followed-up with digital vaginal examinations as described in intervention protocol.
2544723|NCT02599610|Experimental|Transperineal ultrasound examination|Patients assigned to this group will be followed-up with transperineal ultrasound examinations as described in intervention protocol.
2544820|NCT02599064|Experimental|RXI-109|Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses
2544933|NCT02598375||Children with feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have the feeding intolerance at least for12 hours or more.
2544937|NCT02598375||Children without feeding intolerance|Critically ill children having with respiratory or catecholamine support in PICU have not the feeding intolerance signs at least for 12 hours or less
2545024|NCT02597660|Active Comparator|Drug: Somatropin|Under ultrasound guidance, patients will receive an injection of somatropin (0.1mg in a volume of 0.2mL of bacteriostatic saline) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
2545027|NCT02597660|Placebo Comparator|Drug: Placebo|Under ultrasound guidance, patients will receive an injection of 0.2mL of bacteriostatic saline (which is an equivalent volume of diluent used in the active comparator arm) into the area of tendinopathic lesion. A series of three injections will be delivered one week apart. Vials will be blinded.
2545102|NCT02597257|Placebo Comparator|Normal Saline|"normal saline~total 250 ml~once a week~4 times"
2545105|NCT02597257|Active Comparator|Lidocaine HCl|"lidocaine 3 mg/kg mixed in normal saline~total 250 ml~once a week~4 times"
2545139|NCT02596776|Active Comparator|Fat biopsy|From each abdominal and thigh biopsy, between 0.5 - 3 g of tissue is obtained (often less from the thigh), which is used for immunohistochemistry and frozen for subsequent RNA or protein isolation.
2545144|NCT02596776|Experimental|Propranolol and Fat Biopsy|From each abdominal and thigh biopsy, tissue will be examined for gene expression, with a focus on genes believed to be involved in adipose beiging (PGC1α, UCP1, TMEM26, IL4, Metrnl, CPA3, Siglec 8, tyrosine hydroxylase, others), and with immunohistochemistry, with a focus on beige adipocytes, macrophages, eosinophils and mast cells.
2545146|NCT02596776|Active Comparator|Heavy Water and Fat Biopsy|The investigator will measure in vivo adipose lipolysis and triglyceride (TG) turnover in response to cold to physiologically demonstrate the impact of cold exposure on tissue function. The subjects will then be given 50 mL sterile containers of 70% 2H2O and consume two 50 mL vials per day during the remainder of the 5-week labeling period. Plasma and urine will be collected weekly so that body 2H2O can be measured.
2545193|NCT02596503|Experimental|Eribulin + Irinotecan|"Eribulin will be administered intravenously on days 1 and 8 of a 21-day cycle, while irinotecan will be administered orally on days 1-5. The oral antibiotic cefixime will be used to reduce irinotecan-associated diarrhea.~Eribulin dose will be assigned at time of enrollment using a 3+ 3 Phase 1 design (ranging from 0.8 - 1.4 mg/m2/dos). The dose of irinotecan will be fixed at 90 mg/m2/day x 5 days."
2545236|NCT02596165|Experimental|Pulse wave analysis measurement|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
2545314|NCT02595892|Active Comparator|Arm I (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm II.
2545321|NCT02595892|Experimental|Arm II (gemcitabine, ATR kinase inhibitor M6620)|Patients receive gemcitabine hydrochloride as in Arm I and ATR kinase inhibitor M6620 IV over 60-90 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2545376|NCT02595281|Experimental|Study arm|
3168863|NCT00556062|Experimental|1: Lot 1|
3168864|NCT00556062|Experimental|2: Lot 2|
3168865|NCT00556062|Experimental|3: Lot 3|
2545453|NCT02594670|Experimental|DU20 and HT7 combination|combination of two acupoints based on location and Heart meridian, including Baihui (DU20) and Shenmen(HT7).
2545459|NCT02594670|Other|DU20 and SP6 combination|combination of two acupoints based on location and Spleen meridian, including Baihui (DU20) and Sanyinjiao(SP6).
2545465|NCT02594670|Sham Comparator|DU20 and SA combination|combination of local acupoint Baihui (DU20) and a sham acupoint (SA) not belonging to any regular meridian or acupoint.
3168866|NCT00556062|Active Comparator|4: control vaccine|
3203407|NCT00923403|Placebo Comparator|Placebo Comparator|control dairy milk
2544650|NCT02600052|Active Comparator|GCONTROL|Patients will be submitted to aerobic training, with prior application of relax technique and after its completion. Aerobic training program will consist of walking on a treadmill for 30 minutes with 5 minute initial heating and 5-minute cool-down. The training intensity will correspond to 60% of maximal oxygen consumption (VO2max) or 70% of maximum heart rate (MHR) predicted by age is determined by the formula: HR max = 208 - (0.7 x age). The speed and incline of the treadmill will be adjusted according to the patient's performance, so that they maintain the same intensity throughout the course of the training.
2544707|NCT02599779|Experimental|Treatment arm A|"Arm-A: Pembrolizumab will be started and Stereotactic Body Radiation Therapy will be given at the time of progression on pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
2544712|NCT02599779|Experimental|Treatment arm B|"Arm B: Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued.~Pembrolizumab will continue until progression as per immune related response criteria (irRC)."
2544759|NCT02599272|Other|Rice with vegetables but no added spice|Control session - rice with control vegetables (tomatoes and aubergines) - no mixed spices
2544766|NCT02599272|Active Comparator|Rice with vegetables and low spice|Dose 1 mixed spice session - rice with 6 g powdered mixed spices and 40 g polyphenol rich vegetables (onions, ginger and garlic)
2544772|NCT02599272|Active Comparator|Rice with vegetables and high spice|Dose 2 mixed spice session - rice with 12 g powdered mixed spices and 80 g polyphenol rich vegetables (onions, ginger and garlic)
3203408|NCT00923403|Experimental|experimental|plant sterol enriched soymilk
3203409|NCT00923416||Prostate Cancer|
3203410|NCT00923429|Active Comparator|S-A|
3203411|NCT00923429|Active Comparator|S-A+stretch|
2545069|NCT02597439|Active Comparator|Omega-3 fatty acids|Subjects will be treated daily with 1.2 gram omega-3 polyunsaturated fatty acids (720 mg eicosapentaenoic acid (EPA) and 480 mg Docosahexaenoic acid(DHA)) for six months.
2545070|NCT02597439|Placebo Comparator|Placebo|Subjects will be treated daily with placebo for six months. Placebo capsules will contain a 1:1 combination of coconut oil and medium chain triglycerides because these do not contain polyunsaturated fatty acids and have no impact on omega-3 fatty acid metabolism. Placebo capsules also contain the same amount of vitamin E as the omega-3 capsules and 1% fish oil to mimic flavour and taste.
3203412|NCT00923429|Experimental|S-A+stretch+manther|
2545194|NCT02596633|No Intervention|Treatment as Usual|Participants carry on with their usual care
2545196|NCT02596633|Active Comparator|Intervention|ACT self help book with telephone support calls; Telephone-support Acceptance and Commitment therapy (ACT)
2545510|NCT02594423|Active Comparator|Fine needle Diathermy|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels.
2545518|NCT02594423|Active Comparator|Fine Needle Diathermy and Bevacizumab|Fine needle Diathermy(FND) will be applied under topical anaesthesia under an operating microscope. This involves the insertion of a fine corneal suture needle in the vicinity of the vessels and using this as an extension of the probe of a monopolar cautery to deliver the energy in the corneal tissue at the site at which it is required to occlude the vessels. Patients will receive subconjunctival injections of bevacizumab in the conjunctiva near the limbus in the quadrant(s) affected (total volume of between 0.2 ml-0.3 ml of the 2.5 mg/0.1 ml solution). The subconjunctival injections will be administered after FND in the same treated quadrants.
3174251|NCT00621426||Observation|Patients with end-stage renal disease (ESRD) treated with hemodialysis three (3) times per week for at least 3 continuous months
3174252|NCT00621439|Experimental|I|Receives 1 dose of Pegylated Interferon
2545687|NCT02593448|Active Comparator|Propofol|"General anaesthesia with Propofol use. Maintenance of anaesthesia in group P will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
2545690|NCT02593448|Experimental|Sevoflurane|"General anaesthesia with sevoflurane use. Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.~Intervention: NIRS during VOT on several timepoints."
2545753|NCT02593110|Active Comparator|Telmisartan + Supervised Treadmill Exercise Therapy|Participants in this group will receive both daily telmisartan and supervised treadmill exercise three days weekly for six months.
2545757|NCT02593110|Active Comparator|"Telmisartan + No Exercise Control Group"|Participants in this group will receive daily telmisartan and attend weekly educational lectures at the medical center for six months.
2545761|NCT02593110|Active Comparator|Placebo + Supervised Treadmill Exercise Therapy|Participants randomized to this group will receive daily placebo and supervised treadmill exercise three times weekly for six months.
2545763|NCT02593110|Placebo Comparator|"Placebo + No Exercise Control Group"|Participants randomized to this group will receive daily placebo and health education lectures weekly for six months.
2545823|NCT02592564|Experimental|Psychological treatment|Psychological treatment during 9 weeks.
2545866|NCT02592278|Experimental|Fluoride Varnish each 6 months|Fluoride Varnish application every 6 months.
3174253|NCT00621439|Placebo Comparator|II|Receives placebo
3174254|NCT00621452|Experimental|Treatment (autologous CD20 specific T-cells)|"CHEMOTHERAPY: Patients receive cyclophosphamide IV over 60 minutes.~IMMUNOTHERAPY: Beginning 2 days after completion of cyclophosphamide, patients receive autologous CD20-specific T-cells IV over 30 minutes. Treatment repeats every 2-5 days for 3 courses.~MAINTENANCE THERAPY: Beginning 2 hours after the last T-cell infusion, patients receive low-dose aldesleukin subcutaneously twice daily for 14 days.~Subjects who have achieved at least a partial remission lasting a minimum of 6 months may, on a case-by-case basis, receive additional stored T cells following relapse."
3174255|NCT00621465|Active Comparator|1|Participants will receive standard aftercare and community care services.
3174256|NCT00621465|Experimental|2|Participants will receive usual care and the Critical Time Intervention.
2544687|NCT02599831|Active Comparator|PFM training with Transanal ES|Electromyogram BF-assisted PFMT (using a nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co. Ltd, China) and following TES (using a neuromuscular stimulation therapy system (PHENIX USB4, Electronic Concept Lignon Innovation, France)) at a current intensity of < 60 mA (as high as possible within the patient's tolerance) and frequencies of 15 Hz and 85 Hz (alternate 3-minute periods of stimulation) were performed by a specially trained therapist, 20 minutes each time, respectively (a total of 40 minutes), 3 times a week for a total of 8 weeks. The patients were also required to conduct 30 maximal high-intensity PFM contractions for 2-6 seconds (with 2-6 seconds rest), 3 sessions every day at home for a total of 8 weeks.
2544739|NCT02599493|Experimental|Low dose|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
2544740|NCT02599493|Active Comparator|High dose|Patients will be randomly assigned to high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
2544856|NCT02599038|Experimental|Serine supplementation|Serine oral administration 20mg/kg/day
2544872|NCT02598531||Test Arm|Test Arm participants will be enrolled in the standard of care bariatric surgery program and will undergo surgical weight loss through Laparoscopic Sleeve Gastrectomy or Laparoscopic Gastric Bypass. Approximately 9-13 months post surgery, each participant will be evaluated to determine if he/she is still eligible for a total knee replacement or if their need has been removed. If still eligible, participants will be enrolled in the standard of care TKA program and will undergo a TKA procedure. Participants will complete nine (9) research visits over 3.5-4 years.
2544880|NCT02598531||Control Arm|Control Arm participants will be enrolled in the standard of care TKA program and complete six (6) research visits over 2.5-3 years. This group of participants will undergo a TKA procedure without any surgical weight loss intervention.
2545009|NCT02597751|Experimental|Treatment Arm|Participants are randomized to treatment group. After the first MRI scan, participants are assessed by an independent occupational therapist (before and after intervention) and participate in 10 treatment sessions with a treating occupational therapist. Following the post-treatment assessment, participants have a second MRI scan. Twelve weeks later, participants have a third, follow-up scan.
2545017|NCT02597751|No Intervention|Waitlist control|"Participants are randomized to the waitlist control group. After the first MRI scan, participants wait for 12 weeks and then have a 2nd MRI scan. Participants then have 10 treatment sessions with an occupational therapist and are assessed by an independent occupational therapist before and after treatment. Participants then have a third MRI scan to examine brain changes associated with intervention."
3168867|NCT00556088|Experimental|Part 1|"Part I Phase I dose escalation trial. LBH589 will be administered orally on Monday and Thursday or Tuesday and Friday each week (twice weekly). Paclitaxel and carboplatin will be administered intravenously every 21 days.~Part II LBH589, paclitaxel, and carboplatin dosing will be determined in the first phase of this study (Phase I). The drug dosages to be administered will be reduced one level from the determined Maximum Tolerated Dose (MTD). In addition, bevacizumab 15 mg/kg will be added to the second portion of this trial."
3168868|NCT00556114||Optical Coherence Tomography|Optical Coherence Tomography
2545119|NCT02597036|Experimental|Part A LY3127804|Dose escalation of LY3127804 given intravenously (IV) every 2 weeks (Q2W) for 28 day cycle.
2545122|NCT02597036|Experimental|Part B LY3127804 + Ramucirumab Dose 1|Dose escalation of LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
2545124|NCT02597036|Experimental|Part C LY3127804 + Ramucirumab Dose 2|LY3127804 in combination with Ramucirumab given IV Q2W for 28 day cycle.
2545126|NCT02597036|Experimental|Part D LY3127804 + Ramucirumab|LY3127804 and Ramucirumab given IV Q2W until participant qualifies for study discontinuation.
2545128|NCT02597036|Experimental|Part E LY3127804 + Ramucirumab + Paclitaxel|LY3127804 and Ramucirumab given IV Q2W and Paclitaxel given IV on day 1, 8, and 15 until participant qualifies for study discontinuation.
2545225|NCT02596334|Active Comparator|triple therapy|dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
2545228|NCT02596334|Experimental|monotherapy|dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.
2545292|NCT02595827|No Intervention|Universal|In this group, caretakers of children will receive the standard advice under current iCCM guidelines in DRC. Specifically, the CHW will advise that the child come back in 2-3 days.
2545294|NCT02595827|Active Comparator|Conditional|In this Conditional Advice group, caretakers will be given advice that is modified from the current iCCM guidelines. Specifically, the CHW will advise that the child come back in 2-3 days if the child's symptoms continue.
3168869|NCT00556127|Experimental|1|
3168870|NCT00556153||Phase I|Children, ages 5-15 years with brain tumors
2545358|NCT02595333|Experimental|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
2545364|NCT02595333|Experimental|Group S1|primary cesarean section+postoperative analgesia with sufentanil group
2545366|NCT02595333|Experimental|Group SF2|repeated cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
2545368|NCT02595333|Experimental|Group S2|repeated cesarean section+postoperative analgesia with sufentanil group
2545411|NCT02595099|Experimental|Mindfulness training|8 week programme of Mindfulness training
2545506|NCT02594215|Experimental|Experimental|Experimental
3168871|NCT00556179|Experimental|1|
3168872|NCT00556192|Active Comparator|1|Rituximab
3168873|NCT00556192|Active Comparator|2|Rituximab + Cyclophosphamide
3168874|NCT00556192|Active Comparator|3|Cyclophosphamide
3168875|NCT00556205|Active Comparator|1|Bevacizumab monotherapy 10 mg/kg IV q2 weeks
3168876|NCT00556205|Active Comparator|2|Combination Sunitinib & Bevacizumab Bevacizumab 10 mg/kg IV q2 weeks Sunitinib 50 mg PO QD on 4/2 schedule
3168877|NCT00556218|Other|Tibetan Meditation|
3168878|NCT00556218|Other|No Meditation|
2544734|NCT02599467|Experimental|case group 1: ALND|"Inclusion criteria: unilateral breast cancer surgery with Axillary lymph node dissection (ALND) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording."
2544735|NCT02599467|Experimental|case group 2: SLNB|"Inclusion criteria: unilateral breast cancer surgery with Sentinel Lymph Node Biopsy (SLNB) during the last year and a half. Exclusion criteria: bilateral breast cancer, ipsilateral shoulder pathology, neuropathy.~Procedure: ULNT 1 and EMG recording"
2544736|NCT02599467|Active Comparator|control group|"Matched by age and dominant arm to each case. Exclusion criteria: current painful conditions involving their neck or dominant upper-extremity, and chronic pain conditions or use of pain relievers.~Procedure: ULNT 1 and EMG recording."
2544779|NCT02599207|Experimental|Matched related umbilical cord blood|Six subjects will receive an infusion of HLA matched sibling umbilical cord blood cells.
2544783|NCT02599207|Experimental|Mismatched related umbilical cord blood|Nine subjects will receive an infusion of HLA-mismatched (≥3/6 match) or matched sibling umbilical cord blood cells.
2544804|NCT02598960|Experimental|BMS-986156: Dose Escalation|
2544805|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Escalation|
2544811|NCT02598960|Experimental|BMS-986156: Dose Expansion|
2544816|NCT02598960|Experimental|BMS-986156 + nivolumab (nivo): Dose Expansion|
2544819|NCT02598960|Experimental|BMS986156 + Nivo: Cohort Expansion|
2544916|NCT02598544|Other|lean men|
2544919|NCT02598544|Other|Obese men without type 2 diabetes|
2544920|NCT02598544|Other|Obese men with type 2 diabetes|
2544949|NCT02598180|Experimental|VergenixTM Flowable Gel|VergenixTM Flowable Gel
2544985|NCT02597894|Other|Prostate biopsy|Patients undergo two biopsies, the first at baseline before start of ADT and the second two months later during brachytherapy.
2545031|NCT02597621||M/XDR|The M/XDR-cohort will consist of patients with a suspected infection with an M/XDR-TB strain.The suspicion will be held on behalf of molecular biological methods (i.e. GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The suspected cases will be confirmed by culture (n= 20). Empirically, less than 10% of the cases have an XDR-TB
2545034|NCT02597621||Susceptible|The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
2545037|NCT02597621||Healthy Controls|Healthy controls.
2545082|NCT02597309|Active Comparator|Intervention Group|Subjects in this group will take canagliflozin in addition to their regular U-500 insulin dose and other antihyperglycemic medications. Canagliflozin dose will be titrated after 2 weeks from 100 mg once daily to 300 mg once daily. This dose will continue for 22 weeks.
2545085|NCT02597309|Placebo Comparator|Control Group|Subjects in this group will take a matched placebo in addition to their regular U-500 insulin dose and other antihyperglycemic medications for 2 weeks then another matched-placebo for 22 weeks.
3203413|NCT00923429|Experimental|S-A+stretch+manther+sterinject|
3203415|NCT00923494|Active Comparator|Group R20|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
3203416|NCT00923494|Active Comparator|Group R30|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
2545598|NCT02593955|Active Comparator|PD exercise group|Supervised exercise training, 3x per week for 16 weeks
2545600|NCT02593955|Active Comparator|PD sleep hygeine group|Tips for improved sleep hygiene, reading materials
2545603|NCT02593955|No Intervention|Healthy control|MRI sub-study only
2545661|NCT02593578||Biomarker group|Advanced cancer undergoing genomic profiling
2545699|NCT02593357|Experimental|COPD patients|measure of endothelial function with EndoPAT® in COPD patients
3203417|NCT00923494|Active Comparator|Group R40|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
2545787|NCT02592720|Experimental|Cocktail plus FFR guided group|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
2545789|NCT02592720|Placebo Comparator|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
2545977|NCT02591628|Active Comparator|Intervention|"Intervention is HCTZ prescription conversion to chlorthalidone. Intervention patients are defined as patients of physicians randomized to intervention. All these patients will have their current prescription of hydrochlorothiazide (HCTZ) switched to an equipotent dose of Chlorthalidone. These patients can choose to decline this intervention, and will be followed for 9 months with no other intervention to observe primary and secondary outcomes."
3203419|NCT00923520|Experimental|1|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
2546044|NCT02590874|Experimental|Duloxetine group|Active drug group
3203420|NCT00923533|Active Comparator|Part A|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
3203421|NCT00923533|Active Comparator|Part B|Hydrochlorothiazide (7day) Hydrochlorothiazide + Fimasartan (7day)
3203422|NCT00923572||Group 1|
3203423|NCT00923611|Placebo Comparator|Placebo|3 tablets of placebo will be taken 30minutes after breakfast for 8 weeks
3203424|NCT00923611|Active Comparator|Fimasartan 20mg|2 tablets of placebo and 1 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
3203425|NCT00923611|Active Comparator|Fimasartan 60mg|3 tablets of fimasartan 20mg will be taken 30minutes after breakfast for 8 weeks
3203426|NCT00923611|Active Comparator|Fimasartan 120mg|3 tablets of fimasartan 40mg will be taken 30minutes after breakfast
2544742|NCT02599454|Experimental|atezolizumab + SBRT|"DOSE ESCALATION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3.~EXPANSION PHASE: Patients receive atezolizumab IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Within 24-48 hours after receiving atezolizumab, patients also undergo 4-5 fractions of stereotactic body radiation therapy over days 1-5 of course 3."
2544924|NCT02598427|Experimental|Intrathecal Pertuzumab and Trastuzumab|"Four cohorts will enroll in a dose escalation of pertuzumab and a consistent dose of trastuzumab. The cohorts will be assigned as follows:~Cohort: Intrathecal Dose:~10mg pertuzumab, 80mg trastuzumab~20mg pertuzumab, 80mg trastuzumab~40mg pertuzumab, 80mg trastuzumab~80mg pertuzumab, 80mg trastuzumab"
2544959|NCT02598115|No Intervention|Before collarborative pharmaceutical care|"All clusters start in this arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
2544966|NCT02598115|Experimental|After collarborative pharmaceutical care|"All clusters start in the No Intervention arm for 15 days. Following the start of the study, 1 randomly chosen cluster will switch to the experimental arm every 15 days.~Days 1 to 15: all clusters in the before arm Days 16 to 30: 1 cluster in the Collaborative Pharmaceutical Care arm Days 31 to 45: 2 clusters in the Collaborative Pharmaceutical Care arm Days 46 to 60: 3 clusters in the Collaborative Pharmaceutical Care arm Days 61 to 75: 4 clusters in the Collaborative Pharmaceutical Care arm Days 76 to 90: 5 clusters in the Collaborative Pharmaceutical Care arm Days 91 to 105: all 6 clusters in the Collaborative Pharmaceutical Care arm"
2545007|NCT02597725||Urodynamics|There is no intervention in this study.
2545071|NCT02597491|Active Comparator|4 wk assessment + TLC monthly|4 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
2545072|NCT02597491|Active Comparator|4 week assessment + TLC quarterly|4 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
2545073|NCT02597491|Active Comparator|4 week assessment +TLC + MTM|4 week assessment, 4 weeks counseling, NRT, medication management (nonresponders)
2545074|NCT02597491|Active Comparator|8 week assessment + TLC monthly|8 week assessment, 8 weeks of counseling, NRT, monthly follow-up (responders)
2545075|NCT02597491|Active Comparator|8 week assessment + TLC quarterly|8 week assessment, 8 weeks of counseling, NRT, quarterly follow-up (responders)
2545076|NCT02597491|Active Comparator|8 week assessment + TLC + MTM|8 week assessment, 8 weeks counseling, NRT, medication management (nonresponders)
2545125|NCT02596919|Other|No arms|No randomisation therefore no arms. All patients will receive the same research treatment.
2545202|NCT02596659|Experimental|The experimental group|Participants in the experimental group received radial extracorporeal shock wave therapy (rESWT) plus physical therapy for 3 weeks.
2545204|NCT02596659|Sham Comparator|The control group|Participants in the control group received sham shockwave therapy plus physical therapy for 3 weeks.
2545267|NCT02596087|No Intervention|Normal Use of EHR|Sites will configure their EHR systems so that alerts will not be triggered for providers in the control arm if the patient does not have the condition on her/his problem list.
2545269|NCT02596087|Experimental|Intervention Arm|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. Each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
3168879|NCT00556231||1|Children with congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
3168880|NCT00556231||2|Children without congenital heart lesions - males/females, ages 6-20, scheduled for a regular stress test
2545357|NCT02595476|Experimental|BIS 55|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 55~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
2545363|NCT02595476|Active Comparator|BIS 25|"Induction:~TCI propofol (6 µg/ml) - remifentanil (4 ng/ml) Atracurium IV (0.5 mg/kg)~Orotracheal Intubation~Remifentanil target decreased to 1 ng/ml~Propofol target adjustment to reach BIS 25~10 minutes steady state~Tetanic stimulation (ulnar nerve): 100 Hz, 60 milliamps, 5 seconds~Pupillary dilation recording (videopupillometer Algiscan)"
2545483|NCT02594553|Experimental|Intervention|All GPs working at the participating GP out-of-hours centres that are in the intervention group will use the GP-parent information-exchange tool (interactive booklet).
2545487|NCT02594553|No Intervention|Control|All GPs working at the participating GP out-of-hours centres that are in the control group will provide care as usual.
2545513|NCT02594280||Selective Laser Trabeculoplasty (SLT)SLT|Monitor glaucoma patients that are scheduled to be treated with Selective Laser Trabeculoplasty (SLT) with VEP/PERG. The treatment is not dependent on the study.
3168881|NCT00556231||3|
3168882|NCT00556231||4|
3168883|NCT00556231||5|
3168884|NCT00556231||6|
3168885|NCT00556244|Active Comparator|2|
3168886|NCT00556257|Active Comparator|Treatment Arm 1|Treatment Arm 1 will also receive standard of care medications.
3168887|NCT00556257|Experimental|Treatment Arm 2|Treatment Arm 2 will also receive select standard of care medications.
3168888|NCT00556270||Matrix II|
3168889|NCT00556283|Experimental|1|STARR
3168890|NCT00556283|Active Comparator|2|Biofeedback
3168891|NCT00556296|Experimental|1|
3168892|NCT00556296|Experimental|2|
3168893|NCT00556296|Experimental|3|
3168894|NCT00556296|Placebo Comparator|4|
3168895|NCT00556309||Diagnostic Tool|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
2544836|NCT02598973|Active Comparator|Exercise|aerobic walking
2544839|NCT02598973|No Intervention|No exercise|normal activity
2544869|NCT02598596|Experimental|Pegloticase regimen <120 kg - Main Study|Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
2544876|NCT02598596|Experimental|Pegloticase regimen ≥120kg|Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
2544883|NCT02598596|Experimental|Pegloticase PK Sub-Study|Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses. Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
2544891|NCT02598596|Experimental|Pegloticase Imaging Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
2544897|NCT02598596|Experimental|Pegloticase FDG-PET-CT Sub-Study|A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
2544902|NCT02598596|Experimental|Pegloticase and Azathioprine|Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
2544976|NCT02598154||Study population|The study population consists of patients whose age is between 20 and 75 years and who experienced a supra-tentorial ischemic or hemorrhagic stroke. The study covers inpatients or patients consultating in the neurological rehabilitation service (NHS) at the Grau du Roi Medical Center, Nîmes University Hospital.
2545003|NCT02597686|Experimental|SD-PB training|
2545155|NCT02596685|Experimental|Arm A (electronic-cigarette)|"Patients receive nicotine-free and flavor-free electronic cigarettes and instructed to use them BID over a 2 hour period for 4 weeks.~Patients undergo a second bronchoscopy during week 5."
2545156|NCT02596685|Experimental|Arm B (control)|"Patients receive no intervention.~Patients undergo a second bronchoscopy during week 5."
2545157|NCT02596685|Experimental|Arm I (bronchoscopy of the left lung)|Patients undergo bronchoscopy of the left lung over 30-60 minutes.
2545158|NCT02596685|Experimental|Arm II (bronchoscopy of the right lung)|Patients undergo bronchoscopy of the right lung over 30-60 minutes.
2545214|NCT02596386||potassium level in saliva|Each willing participant will undergo Sialometry
2545216|NCT02596386||blood test|blood will be drawn from the dialysis connections for Biochemistry for potassium level evaluation
2545240|NCT02596100|Experimental|Tablet|80mg immediate release tablet
2545243|NCT02596100|Experimental|Capsule|80mg immediate release capsule
2545318|NCT02595840|Experimental|Arm A: Afatinib|Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)
2545323|NCT02595840|Experimental|Arm B: Pemetrexed|Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle
2545360|NCT02595489|Experimental|Vitamin D3|Single-arm, dose-escalation starting at 1,000 IU or 2,000 IU of vitamin D3 daily for a 6 month period, followed by a conditional titration up to 4,000 IU daily for at least 6 months thereafter. No placebo.
2545419|NCT02595164||Impulsive subjects|Subjects exhibiting impulsive symptoms Behavioral Task
2545421|NCT02595164||Non-impulsive subjects|Subjects which do not exhibit impulsive symptoms Behavioral Task
2545524|NCT02594410|Experimental|Treatment|patients receiving renal artery stenting and anti-hypertension drug for renal artery atherosclerosis
2545562|NCT02594059|Experimental|Pulmonary idiopathic fibrosis|Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria
2545679|NCT02593409|Other|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
2545785|NCT02592733||Historical Cohort|Patients who have undergone infrarenal endovascular repair at each centre in the past.
2545788|NCT02592733||Prospective Cohort|Patients undergoing infrarenal endovascular repair in the study using CYDAR in addition to the local angiography equipment.
2545868|NCT02592278|Experimental|Fluoride Varnish each 3 months|Fluoride Varnish application every 3 months.
2545870|NCT02592278|Active Comparator|Fluoride tooth paste|Control group. Twice a day brush with fluoride toothpaste.
3168896|NCT00556335|Experimental|manual aspiration|manual aspiration
3168897|NCT00556335|Active Comparator|conventional drainage|conventional drainage
3168898|NCT00556348|Experimental|1|
3168899|NCT00556361|Placebo Comparator|1|
3168900|NCT00556361|Experimental|2|
3168901|NCT00556387|Placebo Comparator|1|Placebo Group receiving Saline Infusion.
3168902|NCT00556387|Experimental|2|Case Group receiving Ketamine infusion.
3168903|NCT00556413|Experimental|ERBIRINOX|5FU + Irinotecan + Oxaliplatine + Cetuximab
3168904|NCT00556465|Experimental|A, 1,III|in this arm patients took 1200 mg N-acetylcysteine
3168905|NCT00556465|No Intervention|B,2, III|
3168906|NCT00556569|Experimental|Intervention|2 Intervention schools are cluster randomized to receive CHAM JAM (previously known as the Moving Smart Program) in Year 1
3168907|NCT00556569|No Intervention|Wait-Listed Control|2 Wait-Listed Control Schools will receive CHAM JAM (previously known as the Moving Smart Program) in Year 2 of the study
3168908|NCT00556595|Experimental|1|primary electrophysiological approach
3168909|NCT00556595|Active Comparator|2|primary anatomical approach
3168910|NCT00556608|Experimental|Sinovial|3 intra-articular injections of Sinovial®
3168911|NCT00556608|Active Comparator|Sinvisc|
3168912|NCT00556621|Other|gemcitabine, cisplatine, radiotherapy|
3168913|NCT00556634|Active Comparator|B|
3203427|NCT00923611|Active Comparator|Fimasartan 240mg|3 tablets of fimasartan 80mg will be taken 30minutes after breakfast for 8 weeks
3203428|NCT00923624|Active Comparator|staff emails|Attention control that includes staff sending emails with information about using health information technology system.
3203429|NCT00923624|Experimental|study nurse messages|A series of 6 proactive secure messages and 3 proactive booster messages (for a total of 9 secure and personalized messages) sent by the study nurse via the EMR patient web portal.
2544835|NCT02598778|Active Comparator|Chlorhexidine gluconate (.12%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
2544837|NCT02598778|Active Comparator|Sodium fluoride oral rinse (.05%)|An oral rinse given to pediatric patients in routine practice within the standard of care.
2544840|NCT02598778|Active Comparator|Coconut oil|A food product. In previous studies it has shown positive effects on the reduction of oral plaque and gingivitis as an oral rinse.
2544844|NCT02598778|Placebo Comparator|Deionized water|Water that has had the majority of its ions removed.
2544910|NCT02598479||IPTLD and nutrition therapy|Patients presenting to the Arizona Center for Advanced Medicine for the treatment of cancer using Insulin Potentiation Low Dose Chemotherapy and Nutrition Therapy
2544943|NCT02598323|Experimental|patients with active singleton pregnancy between 16 and 26 SA|
2544974|NCT02598011|Experimental|Toca 511/Toca FC at 170 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 170 mg/kg/day"
2544977|NCT02598011|Experimental|Toca 511/Toca FC at 220 mg/kg/day|"Toca 511: 4 mL administered by intracranial parenchymal injection into the walls of the resection cavity following tumor resection or, for those subjects who are not candidates for resection, via stereotactic injection into their tumor using a standard Nashold-type side cutting biopsy needle.~Toca FC: Approximately 4 to 6 weeks after tumor resection, subjects will begin temozolomide concurrent with radiation therapy. During concurrent chemoradiation at the start of the second and sixth week of concurrent chemoradiation and every 28 days thereafter, a 7-day course of oral Toca FC will be dosed at 220 mg/kg/day"
2545032|NCT02597634|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
2545035|NCT02597634|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose at 2 hours, and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose NRS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
3203430|NCT00923663|Experimental|Lenalidomide|Lenalidomide administered orally at a dose of 25 mg daily
2545239|NCT02596295||Mothers for term infants|Lactating mothers
2545245|NCT02596295||Mothers for preterm infants|Lactating mothers
2545319|NCT02595918|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes on days -56, -42, -28, and -14 in the absence of disease progression or unacceptable toxicity. Patients then undergo nephrectomy or metastasectomy on day 0.
2545343|NCT02595385|Active Comparator|RAP|Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
2545346|NCT02595385|Active Comparator|CS|Reinfusion of shed blood during the operation
2545348|NCT02595385|Active Comparator|RAP and CS|RAP and CS used in combination
2545350|NCT02595385|No Intervention|Control|No intervention
2545384|NCT02595190|Experimental|surgery group|sacral canal cyst microscopic tamponade treatment; resting state functional magnetic resonance imaging (rfMRI)
2545386|NCT02595190|Experimental|drug group|gabapentin + tramadol tablets; resting state functional magnetic resonance imaging (rfMRI)
2545388|NCT02595190|Placebo Comparator|control group|resting state functional magnetic resonance imaging (rfMRI)
2545436|NCT02594943|Active Comparator|Conventional Biopsy|"4 out of 8 biopsies taken with a Boston Scientific Large capacity with needle biopsy forceps from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
2545437|NCT02594943|Active Comparator|Endodrill Biopsy|"4 out of 8 biopsies taken with the Endodrill 1A instrument from the suspected tumor tissue in the stomach. They will be taken in random order blinded for the person performing the examination."
2545455|NCT02594657|Experimental|pedal rate ON 50 RPM|
2545460|NCT02594657|Experimental|pedal rate on 80 RPM|
2545541|NCT02594475|Experimental|Left lateral position|Endoscopic retrograde cholangiopancreatography is performed in left lateral position in this group.
2545544|NCT02594475|Active Comparator|Prone position|Endoscopic retrograde cholangiopancreatography is performed in prone position in this group.
2545560|NCT02593942|Experimental|group I|remifentanil
2545561|NCT02593942|Experimental|group II|remifentanil, propofol
2545614|NCT02593799||Patients with esophageal varices|"Esophageal varices were confirmed by endoscopy. They were divided into any grade and high-risk varices."
2545617|NCT02593799||Patients without esophageal varices|"Patients without esophageal varices were divided into patients without any grade or high-risk varices."
3203431|NCT00923676|Active Comparator|Fenofibrate|Fenofibrate pills
3203432|NCT00923676|Active Comparator|Rosuvastatin|Rosuvastatin pills
3203433|NCT00923676|Active Comparator|fenofibrate + rosuvastatin|fenofibrate pills + rosuvastatin pills
3203434|NCT00923702|Other|2 doses of vaccine|The participants will receive two doses of the vaccine at Day 1 and Day 180.
2544763|NCT02599298|Active Comparator|SGMT arm|Treatment of OSA requires a multidisciplinary approach, involving a sleep physician and paramedical staff with expertise in the management of sleep disorders. An initial medical assessment is needed to confirm the diagnosis of OSA, determine its severity and decide whether CPAP therapy is appropriate. As part of this evaluation, an objective overnight sleep study will be performed. This will be followed by an assessment, education, and counseling at the multidisciplinary therapy clinic.
2544771|NCT02599298|No Intervention|Control arm|The patients will be treated according to the standard treatment for acute coronary syndrome in Singapore, which is largely in accordance with the recommendations of the American College of Cardiology and the American Heart Association. Management includes, but is not limited to, antiplatelet and lipid-lowering therapy, early coronary revascularization, and cardiac rehabilitation, with the recommendation to follow the current practice and the most recent international guidelines.
2544843|NCT02598986|Placebo Comparator|white pita bread|Pita bread made of white wheat flour
2544846|NCT02598986|No Intervention|Whole grain pita bread|no macronutrient supplementation
2544848|NCT02598986|Experimental|Restored white pita bread|macronutrient supplementation
2544849|NCT02598986|Experimental|Fortified white pita bread|macronutrient supplementation 2
2544908|NCT02598570|Experimental|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
2544926|NCT02598271||Low SCr|Patients with a serum creatinine below or equal to 1.3mg/dL
2544930|NCT02598271||High SCr|Patients with a serum creatinine above to 1.3mg/dL
3203435|NCT00923702|Other|3 doses of vaccine|The participants will receive three doses of the vaccine at Day 1, Day 60, and Day 180.
3203436|NCT00923793|Active Comparator|Titanium|Titanium implant for cranioplasty. Titanium implants are used since 10 years in Germany because of their high biocompatibility and accuracy of fit.
3203437|NCT00923793|Experimental|Hydroxylapatite|Hydroxylapatite (CustomBone) implant Hydroxylapatite implants are used since about 3 years in Germany. As this material is very similar to human bone structure an improved osteointegration has been observed.
3203438|NCT00923806|Experimental|Gene Therapy Treatment|
3203439|NCT00923819|Experimental|Group A|Laparoscopic Gastric Bypass
3203440|NCT00923819|Active Comparator|Group B|Standard conservative treatment. Patients from Child Obesity Registry of Vestfold.
2545189|NCT02596568|Experimental|Active tDCS stimulation|Anodal tDCS will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
2545190|NCT02596568|Sham Comparator|Sham tDCS stimulation|tDCS electrodes will be applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor, however stimulation will never be turned on.
2545241|NCT02596217|Experimental|Stage 1 (low dose SC)|Low dose administered by subcutaneous (SC) injection
2545246|NCT02596217|Experimental|Stage 1 (medium dose SC)|Medium dose administered by subcutaneous (SC) injection
2545247|NCT02596217|Experimental|Stage 1 (high dose SC)|High dose administered by subcutaneous (SC) injection
2545250|NCT02596217|Experimental|Stage 2 (low dose IV)|Low dose administered by intraveneous (IV) infusion
2545251|NCT02596217|Experimental|Stage 2 (medium dose IV)|Medium dose administered by intraveneous (IV) infusion
2545252|NCT02596217|Experimental|Stage 2 (high dose IV)|High dose administered by intraveneous (IV) infusion
2545253|NCT02596217|Placebo Comparator|Placebo SC (Stage1)|Placebo administered by subcutaneous (SC) injection
2545254|NCT02596217|Placebo Comparator|Placebo IV (Stage2)|Placebo administered by intraveneous (IV) infusion
2545342|NCT02595645|Experimental|Polypectomy and NGS|All patients which underwent screening colonoscopy and fulfilling the inclusion criteria are eligible. Polyps were biopsied and underwent histopathological and genetic analyses
2545402|NCT02595229|Active Comparator|PQ (Pronator quadraus) repair|Following volar plate osteosynthesis the pronator quadratus muscle is sutured with 3 to 5 U-shaped stitches using a polyfilament absorbable synthetic suture.
2545403|NCT02595229|No Intervention|No PQ repair|Following volar plate osteosynthesis the pronator quadratus muscle is placed in its anatomical position without suture repair.
2545439|NCT02594891|Experimental|endoscopic retrograde biliary drainage|Patients will undergo endoscopic retrograde biliary drainage (ERBD) with 8.5 F plastic stent with proximal flap when bile duct stones were removed clearly with ERCP. The stent will be taken out with endoscopy three months later if not discharge self-driven.
2545452|NCT02594865|Active Comparator|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
3203441|NCT00923858||Control - participants from cycles 1 & 2|no intervention. Control group is composed of participants from Cohort I (recruited during our first grant cycle) and from Cohort II (recruited during our second grant cycle). Continued observation is planned for those controls, partial tears and full tears who enrolled in study at age 65 years or younger and have less than 11 years of follow up.
3203442|NCT00923858||Cuff Tear Cohort III|These participants are being recruited from our clinical population and have been scheduled to undergo a standard of care rotator cuff repair and post op therapy. One shoulder has been indicated for rotator cuff repair and the contralateral shoulder is asymptomatic. Both shoulders will be monitored.
3203443|NCT00923871|Experimental|Cone Beam CT|
3203444|NCT00923897|Experimental|RT for Liver Mets and HCC|
3203445|NCT00923923|Experimental|levels of stress|
3203446|NCT00923962|Active Comparator|Type 2 Diabetes patients|
3203447|NCT00923962|Active Comparator|Healthy|
3203448|NCT00923962|Active Comparator|Artherosclerosis|
3203449|NCT00924014|Active Comparator|Conivaptan|Conivaptan will be given via IV bolus
3203450|NCT00924014|Active Comparator|Furosemide|Furosemide will be given via IV bolus
3203451|NCT00924014|Active Comparator|conivaptan and furosemide|on day 3 subjects will receive both study drugs
3203452|NCT00924079|Experimental|nalbuphine|
3203453|NCT00924105|Experimental|1|
3203454|NCT00924105|Placebo Comparator|2|
3203455|NCT00924183||Treatment-as-usual|All patients will receive treatment as usual: antidepressant medication and/or cognitive behavioral therapy (CBT). Patients' results will be compare to their own baseline measurements.
2544790|NCT02599181|No Intervention|WITHOUT: no alcoholic skin desinfection|"In the WITHOUT-group, the skin is NOT disinfected prior to perineural catheter removal."
2544841|NCT02598856|Experimental|Intranasal naloxone 1x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2544845|NCT02598856|Active Comparator|Intranasal naloxone 2x|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2544847|NCT02598856|Active Comparator|Intravenous naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2544851|NCT02598856|Active Comparator|Intramuscular naloxone|Each subject will receive one dose of IN naloxone 1.4 mg, IN naloxone 2 x 1.4 mg, IV naloxone 0.4 mg and IM naloxone 0.8 mg in a randomized order. The four doses will be given at four different visits with a washout period of at least 72 hours between. One follow-up visit will be conducted within one month after the last exposure.
2544925|NCT02598414|Experimental|Bowel Anastomosis Under ICG Guidance|Patients undergo robotic colon/rectal resection and anastomosis with near-infrared ICG fluorescence imaging.
2544927|NCT02598414|Active Comparator|Standard Bowel Anastomosis|Patients undergo robotic colon/rectal resection and anastomosis without near-infrared ICG fluorescence imaging.
2544972|NCT02598050||older surgical patients|Patients 65 years of age and older having lower extremity joint replacement surgery.
3168914|NCT00556634|Experimental|A|
3168915|NCT00556647||A|Fast-track diagnosis
3168916|NCT00556660|Experimental|1|SPECT imaging
3168917|NCT00556686||1|Individuals with a history of canker sores.
3168918|NCT00556686||2|Individuals with no history of canker sores.
3168919|NCT00556699|Experimental|1|
2545067|NCT02597283|Experimental|Biguard stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
2545068|NCT02597283|Active Comparator|Sirolimus-eluting stent system|PCI with regular sirolimus-eluting stent system
2545097|NCT02597114|Experimental|AGT-181|AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase) administered once weekly x 26 weeks at same dose level as subject received in core study
2545672|NCT02593552|Experimental|Video camera|DriveCam video event recorder with counseling feedback
2545713|NCT02593279|Active Comparator|asthma with proximal or diffuse lung damage|
2545718|NCT02593279|Experimental|asthma with small airway prevailing damage|
2545772|NCT02592811|Active Comparator|ESLBD|"Endoscopic Sphincterotomy plus Large Balloon Dilatation +/- lithotripsy~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Large Balloon Dilatation of Oddi Sphincter: with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
2545774|NCT02592811|Active Comparator|CONV|"Conventional treatment associating Endoscopic Sphincterotomy +/- Mechanical Lithotripsy (ES+/-LM)~ERCP with deep cancellation of BDS~Endoscopic large sphincterotomy~Stone extraction with dormia basket or extraction balloon~Mechanical Lithotripsy if needed"
2545847|NCT02592408|Active Comparator|Pf: ASP|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP)
2545853|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 2|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 2
2545859|NCT02592408|Active Comparator|Pf: ASP + SDPQ|In falciparum patients (Pf): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and a single dose of primaquine (SDPQ) on day 2
2545864|NCT02592408|Active Comparator|Pv: ASP + 14DPQ on day 42|In vivax patients (Pv): 3 days of artesunate + sulfadoxine/pyrimethamine (ASP) and 14 days of primaquine (14DPQ) starting on day 42
2545937|NCT02591888|Active Comparator|Liposomal bupivacaine|Subjects in this arm will received the drug - liposomal bupivacaine 30 ml.
2545938|NCT02591888|Placebo Comparator|Placebo|Subjects in this arm will received the placebo - normal saline 30 mL.
2545984|NCT02591394|Experimental|STEP Clinic|
3168920|NCT00556738|Experimental|nHFPV|Intrapulmonary Percussive Ventilation
3168921|NCT00556738|Active Comparator|nCPAP|Nasal Continuous Positive Airway Pressure ventilation
3168922|NCT00556764|Experimental|2 cohorts|"In this observational study 2 cohorts will participate. Cohort 1 will include people with Parkinson disease and Cohort 2 will include healthy volunteers.~A subset of twelve subjects (8 PD and 4 HC) will be enrolled in the [123I] IBVM and SPECT imaging portion of this study"
3168923|NCT00556790|Other|1|Standard Care
3168924|NCT00556790|Other|2|Fast Track Care
3168925|NCT00556803|Experimental|1|TACE after RFA within one month as an adjuvant therapy
3168926|NCT00556803|Active Comparator|2|RFA alone
3168927|NCT00556816|Active Comparator|Conventional outpatient clinic|Conventional outpatient clinic
3168928|NCT00556816|Experimental|On demand outpatient clinic|On demand outpatient clinic
3168929|NCT00556855|Experimental|A|applied on one hand
3168930|NCT00556855|Placebo Comparator|B|applied on the other hand
3168931|NCT00556868|Experimental|A|Breakfast on the first day of intervention, fasting (no breakfast) on the second day of intervention
3168932|NCT00556868|Experimental|B|Fasting (no breakfast) on the first day of intervention, breakfast on the second day of intervention
3168933|NCT00556907|Other|1|Patients will receive IORT
3168934|NCT00556959|Experimental|1|CLONICEL High Dose
3168935|NCT00556959|Experimental|2|CLONICEL Low Dose
3168936|NCT00556959|Placebo Comparator|3|Placebo
3168937|NCT00557011|Experimental|1|NRP104
3168938|NCT00557011|Active Comparator|2|Adderall XR
3168939|NCT00557011|Placebo Comparator|3|Placebo
3168940|NCT00557024|Experimental|1|radiotherapy after RFA
3168941|NCT00557024|Active Comparator|2|RFA alone
2544807|NCT02598947|Sham Comparator|Posterior shoulder tightness sham group|The 'sham posterior shoulder tightness' group will receive the same strengthening program for the scapular and rotator cuff musculature, in addition they will receive home stretches and manual therapy of similar durations to the 'posterior shoulder tightness' group, but delivered to structures that have no known direct structural influence on the posterior shoulder
2544866|NCT02598739|Experimental|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
2544873|NCT02598739|Other|Control group|Waiting list for the exercises.
2544947|NCT02598362|Other|intravenous|Participants who are treated with ciprofloxacin intravenously, at discretion of the treating physician.
2544948|NCT02598362|Other|oral|Participants who are treated with ciprofloxacin via the oral route, at discretion of the treating physician.
3203456|NCT00924222|Experimental|Sevoflurane|
3203457|NCT00924222|Experimental|Propofol|
2545077|NCT02597504|Active Comparator|Standardization|individuals assigned to this group will be healthy volunteers and will take the Quick Test.
2545078|NCT02597504|Experimental|Validity and Reliability|"Reliability:~Test-Retest~Validity:~Concurrent:Quick Test administered with ImPACT online Discriminant: Concussed patient administered Quick Test Construct: Determine agreement between Quick Test and and paper and pencil test."
2545113|NCT02596984|Experimental|caspofungin|Caspofungin will be administered according to the international recommendation.
2545221|NCT02596282|Active Comparator|Clinical Officer (CO),|COs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
2545223|NCT02596282|Experimental|Nurse Midwife (NMW)|NMWs were trained and provided neonatal male circumcision under topical anesthesia using the Mogen clamp
3168942|NCT00557037|Experimental|A|Patients with chemotherapy naïve androgen independent disease
3168943|NCT00557037|Experimental|B|Patients with rising PSA after radical prostatectomy or radiotherapy that are androgen dependent
2545327|NCT02595697|Experimental|J-EMT for Toddlers with Autism|The J-EMT intervention:(a) teach foundational social communicative behaviors, (b) teach related skills that predict long term language outcomes, (c) teach a range of communicative functions, (d) target specific spoken language skills as well as foundational skills, (e) incorporate instructional methods, contexts, and partners that increase social use of language in natural contexts, and (f) promote generalization and maintenance of newly learned skills to everyday activities and routines. In addition, because parents are essential partners for young children with ASD who are learning to communicate, studies are needed that (g) include parents and (h) specify the method and fidelity of parent instruction and fidelity and dosage with which parents use the trained strategies
2545328|NCT02595697|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
2545351|NCT02595424|Experimental|Arm A (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO QD on days 10-14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2545354|NCT02595424|Active Comparator|Arm B (cisplatin, carboplatin, etoposide)|Patients receive cisplatin IV on days 1-3 or carboplatin IV on day 1. Patients also receive etoposide IV on days 1-3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2546349|NCT02588963|Experimental|Experimental Group 1|Children whose caregivers were subjected to a health education session
2546351|NCT02588963|Experimental|Experimental Group 2|Children who were subjected to nasal clearance protocol
2546353|NCT02588963|Experimental|Experimental Group 3|Children whose caregivers were subjected to health education session and who were subjected to respiratory physiotherapy protocol
2546355|NCT02588963|Placebo Comparator|Control Group|Children who were not subjected to respiratory physiotherapy protocol for nasal clearance and whose parents were not subjected to health education session
2546487|NCT02588144|Active Comparator|[standard STN]|Device: standard stimulation on subthalamic (STN) contacts
2546492|NCT02588144|Experimental|[STN+SNr]|Device: Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr)
2546594|NCT02587442|Experimental|RadProtect®|RadProtect® is not a full-closed micelle, and uses ferrous iron to provide linkage between PEG-b-PGA and amifostine. Transferrin and other related proteins can chelate with ferrous iron and break the micelle releasing amifostine into the blood stream.
2546665|NCT02586714||Normal weight|
2546669|NCT02586714||Overweight|
2546672|NCT02586714||Obese|
2546716|NCT02586402|Experimental|Pegolsihematide|Participants received Pegolsihematide by intravenous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
2546719|NCT02586402|Active Comparator|Epoetin Alfa|Epoetin Alfa administration 1 to 3 times per week. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
2547155|NCT02583698|Experimental|Carvedilol|Tab Carvedilol 3.125 mg twice daily followed by 6.25 mg BD and finally 12.5 mg BD if SBP > 90 mmHg and HR >55/min
2547156|NCT02583698|Placebo Comparator|placebo|
3168944|NCT00557089|Other|1|This arm will receive the active treatment for 28 days, followed by a 28 day washout period and then the placebo treatment for 28 days.
3168945|NCT00557089|Other|2|This arm will receive the placebo treatment for 28 days, followed by a 28 day washout period and then the active treatment for 28 days.
3168946|NCT00557102|Other|cetuximab, FOLFIRI|
3168947|NCT00557115|No Intervention|Usual Care|Usual Care (UC): usual follow up care post acute COPD exacerbation
3168948|NCT00557115|Experimental|EPR|Early pulmonary rehabilitation (EPR): pulmonary rehabilitation commenced within 1-week of hospital discharge from an acute COPD exacerbation
2544833|NCT02599116|Other|Microbiome cohort|"Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.~Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires~Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires"
2544895|NCT02598609|Other|Cluster A|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster A. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 4 months. The intervention is implemented during 4 months. The length of the post interventional period is 12 months.
2544899|NCT02598609|Other|Cluster B|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster B. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 8 months. The intervention is implemented during 4 months. The length of the post interventional period is 8 months.
2544905|NCT02598609|Other|Cluster C|Out of the 12 participating NICUs, 4 NICUs are randomly assigned in Cluster C. The intervention (educational program for preventing adverse events and medical errors in the NICU) is implemented after a pre interventional period of 12 months. The intervention is implemented during 4 months. The length of the post interventional period is 4 months.
3203458|NCT00924248||Group 1|
2545096|NCT02597348|Experimental|Liver Transplantation|Arm LT+C: patients will be treated by experimental liver transplantation preceding the non experimental standard chemotherapy (according to usual practices).
2545098|NCT02597348|No Intervention|No intervention|Arm C: patients will receive non experimental standard chemotherapy according to usual practices in the context of definitively unresectable CLM.
2545120|NCT02596880|Experimental|Treatment|Subjects will receive sofosbuvir, daclatasvir and ribavirin
2545205|NCT02596594|Experimental|Port intervention|"The subcutaneous intraumbilical port-system will be implanted in IUGR patients with the cerebroplacental ratio less than 1 (cerebroplacental ratio= PI in the middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~The fetuses will receive AAs and glucose supplementation via a subcutaneously implanted intraumbilical perinatal port system till the delivery. Control by doppler and cardiotocogram"
2545210|NCT02596594|No Intervention|control|"IUGR patients with the cerebroplacental ratio less than 1 (CPR= PI middle cerebral artery / PI umbilical artery) between 24/0 and 30/0 weeks of gestation.~Control by doppler and cardiotocogram"
2545237|NCT02596178|Experimental|EIT Guided PEEP Therapy|
2545356|NCT02595515|Experimental|Chiropractic treatment|Manipulation and/or mobilisation. Intervention: Procedure: Chiropractic treatment.
2545361|NCT02595515|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
2545397|NCT02595138|Experimental|A|zoledronic acid received
2545398|NCT02595138|No Intervention|B|observation
2545447|NCT02594930|Experimental|undirected and directed biopsy|Via an antero-lateral incision of the knee samples are taken without visual control; Afterwards an arthroscope is inserted and samples are taken from 5 defined regions of the knee (suprapatellar pouch, medial and lateral gutter, notch, Hoffa's fat pad)
2545470|NCT02594605|Experimental|Platelet Rich Fibrin|Platelet Rich Fibrin was applied with conventional flap surgery for treatment of periodontal bone loss in test group.
2545478|NCT02594605|Active Comparator|Conventional Flap Surgery|Platelet Rich Fibrin was not applied to control groups. Only conventional flap surgery was applied to control groups.
2545498|NCT02594306|Experimental|Non operation|Recording the event related potential of drug addicts when they receive the stimulus of Emotional pictures stimulation system.
2545500|NCT02594306|Experimental|Deep brain stimulation|Recording the event related potential after the deep brain stimulation operation.Recording the local field potential of drug addiction people when we conduct a test of adjacent contact stimulation in the deep brain stimulation operation. Recording the waveform of bilateral NAc/ALIC after puting the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule
2545503|NCT02594306|Active Comparator|Standard Control|Recording the event related potential of normal people when they receive the stimulus of emotional pictures stimulation system.
2545581|NCT02594072|Experimental|SABR with androgen suppression|Stereotactic ablative radiotherapy (SABR) with a prescribed dose of 36.25 Gy in 5 fractions over 5 weeks (one treatment day per week). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
2545589|NCT02594072|Active Comparator|EBRT with androgen suppression|Conventional external beam radiation therapy (EBRT) with a prescribed dose of 73.68 Gy in 28 fractions (5 treatment days per week over 5.5 weeks). Zoladex ® for androgen suppression, taken for 6 months for patients with intermediate-risk prostate cancer, 18 months for patients with high-risk prostate cancer.
2545642|NCT02593591||Biomarker group|Advanced cancer undergoing genomic profiling
2545681|NCT02593474|Other|Detoxification / induction|The detoxification / induction procedure consists of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection. Participants then receive a second injection 4 weeks after the first.
2545721|NCT02593136|Experimental|Home Fortification and Counseling|Participants aged 6 to 18 months will receive a daily supplement of vitamins and minerals in dry powder form to be taken once daily for up to nine months or up to 240 sachets. Participant caregivers will also receive improved young child feeding practices (IYCF) counseling from a front line worker.
2545728|NCT02593136|Experimental|Improved Child Feeding Practices (IYCF) Counseling|Participants ages 6 to 18 months will receive improved young child feeding practices (IYCF) counseling from a front line worker.
3203459|NCT00924261|Experimental|Hip Stretching|Kneeling Hip flexor stretch - 3 minutes a day, daily, for 10 weeks
2545908|NCT02591901|Experimental|Uro Vaxom|Uro Vaxom, Once daily for 3 months
3203460|NCT00924261|Experimental|Shoulder Stretch|Shoulder Stretch - 3 minutes daily for 10 weeks
3203461|NCT00924274|Experimental|Lifestyle counseling|
3203462|NCT00924274|Active Comparator|sunflower oil|
2544868|NCT02598674||Sepsis with Severe AKI|"This group will have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI) which lead to classification of injury or failure. The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, renal plasma flow by using an injection of non-radioactive iodohippurate, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV)."
2544878|NCT02598674||Control|This group will not have a history of pediatric admission with sepsis-related Acute Kidney Injury (sAKI). The following test will be performed: urinary and serum studies to measure glomerular filtration rate by using gadolinium, followed by cardiovascular assessments using 24 hour ambulatory blood pressure monitoring, peripheral arterial tonometry and pulse wave velocities (PWV).
2544965|NCT02598206|Experimental|Experimental 1|"All subjects will receive 2 treatments in one of the indicated sequence orders:~A - B B - A"
2544993|NCT02597842|Experimental|shuangxuezu|Patients were given 30min of TEAS before induction until the end of the operation at two acupoints.
2544996|NCT02597842|Experimental|neiguanxuezu|Patients were given TEAS at neiguan acupoint.
2544997|NCT02597842|Experimental|zusanlixuezu|Patients were given TEAS at Zusanli acupoint.
2544998|NCT02597842|Sham Comparator|duizhaozu|Patients were not given TEAS at two acupoints.
2545056|NCT02597517||Intervention group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and positive stool antigen test for H pylori in whom gastric body mucosal will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
2545058|NCT02597517||Control group|(Digital chromoendoscopy and magnification) Patients with functional dyspepsia and negative stool antigen test for H pylori in whom gastric mucosal body will be evaluated with digital chromoendoscopy (OE system) and magnification technology in addition to white light
2545106|NCT02597205|Experimental|Mobile app|Multi-faceted intervention for physicians and patients respectively: physician-facing app and patient-facing messages
2545134|NCT02596789|Other|state dependency TMS|TMS performed at rest and during a cognitive/emotional task
2545233|NCT02596360|Experimental|Dextromethorphan|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
2545234|NCT02596360|Placebo Comparator|Placebo|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
3168949|NCT00557141||1|Age > 18 years, Asthma with irregular or regular use of short acting beta-agonists and / or: Asthma treatment with inhaled steroids, Ability to understand the questionnaire
2545339|NCT02595346|Experimental|hydroxychlorquine|hydroxychloroquine 200 mg twice a day for 6 months
2545340|NCT02595346|Placebo Comparator|control|placebo 2 pills a day for 6 months
2545399|NCT02595242|Experimental|Mitoxantrone 12 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 12 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2545400|NCT02595242|Experimental|Mitoxantrone 16 mg/m2|Mitoxantrone Hydrochloride Liposome Injection 16 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2545401|NCT02595242|Experimental|Mitoxantrone 20mg/m2|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 1 hours in 250 ml 5％ glucose injection on the first day during a treatment phase of 3 weeks.
2545441|NCT02594904|Experimental|G-6-PD normal group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2545442|NCT02594904|Experimental|G-6-PD mild deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2545444|NCT02594904|Experimental|G-6-PD moderate deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2545446|NCT02594904|Experimental|G-6-PD sever deficiency group|Drug: Yinzhihuang Oral Liquid, dose: 3ml each time, 3 times every day, during the period, measuring bilirubin from skin one time every 24 hours.
2545462|NCT02594579|Active Comparator|Vitamin D|Dietary Supplement: Vitamin D3
2545466|NCT02594579|Placebo Comparator|Placebo|Dietary Supplement: Placebo
2545568|NCT02593890|Active Comparator|Intervention|Arm A: Participants will be fitted with the THEYA Recovery bra
2545574|NCT02593890|No Intervention|Control|Arm B: Participants will be recommended or fitted with current recommended bra used in each hospital by the Breast Care Nurse Specialist
2545650|NCT02593721|Experimental|Median Nerve Neural Mobilization|15 minute Median Nerve Neural Mobilization sessions 5 times a week (monday to Friday) during 6 continuous weeks The maximum degree of elbow extension applied in the Median Nerve neural mobilization procedure was determined through the use of a Universal Goniometer Device.
2545651|NCT02593721|Active Comparator|Ibuprofen|A single daily 400 mg dose of oral Ibuprofen that can be increased depending on patient tolerance to a maximum dose of 1200 mg/day equally divided in 3 oral intakes of the drug every 8 hours during 6 continuous weeks.
2545704|NCT02593292|Active Comparator|PROSPERO group (intervention group)|
2545705|NCT02593292|Placebo Comparator|control group|
3168950|NCT00557154|Experimental|1|Ultrasound used to visualize peripheral venous anatomy. This guides subsequent attempts at venipuncture.
2544877|NCT02598648|Other|ARDS(respiratory distress syndrome)|"ARDS :Diagnostic criteria: 1.Acute onset；2.FiO2/ PaO2< 26.7 kPa (200mmHg, ARDS); 3.Chest X-ray showed that the double lung transparent brightness is generally lower, the glass sample, with bronchial inflatable sign, and even double lung field common density increased, the heart shadow is not clear, a white lung, as the most important performance；4. Echocardiography, left atrial hypertension; 5.The gestational age >35 week, have maternal age cholestasis (severe), sepsis or meconium aspiration syndrome (MAS) understanding of history, and with the exception of the primary pulmonary surfactant (PS) lack of；6.Need to use a ventilator.~FXR and RIPK3 were measured in neonate with ALI.were measured in another group neonate with ARDS"
2544885|NCT02598648|Other|control|Control group: Patients with mechanical ventilation due to external causes of the lung, no ALI-ARDS performance,FiO2/ PaO2< 40.0 kPa (300 mmHg), such as premature apnea or HIE. FXR and RIPK3 were measured in neonate with HIE
2545115|NCT02597023|Experimental|MitoQ|MitoQ, 20 mg per day for six weeks
2545116|NCT02597023|Placebo Comparator|Placebo|Placebo, inert excipient, one time per day for six weeks
2545172|NCT02596672|Experimental|Intervention|They will complete a 12-week peer-led walking programme. Participants will be paired together as walking partners and will be given a pedometer and step count logs for self-monitoring. The walking co-ordinators will facilitate walking groups two times a week in the local areas, lasting for 30 minutes. The nature of the walks will be tailored to the participants stated preferences of types of activity. Participants will also receive local walking route maps. After 12 weeks, the formal peer-led component will finish and participants will be encouraged to continue walking with their walking partners other activity programmes organised in the fold in order to maintain activity levels.
2545173|NCT02596672|No Intervention|Control|"Folds assigned to the control group will not receive any additional support to change their physical activity behaviour over the course of the intervention period.~At the six-month data collection point they will be offered a referral to a local walking group in their area or advice on beginning a self-directed walking programme (similar to Public Health Agency www.choosetolivebetter.com/content/getting-active). They will be asked to complete outcome measures at baseline and follow up time-points. Post-study a sample of control participants will be asked to attend a focus group, exploring their views on social activity as form of physical activity for older adults in folds."
2545222|NCT02596308|Experimental|15µg vaccine|15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
2545224|NCT02596308|Experimental|30µg vaccine|30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.
3168951|NCT00557154|Active Comparator|2|Routine venipuncture using standard methods.
3168952|NCT00557180||BASALT|Participants in the ACRN BASALT study
2546042|NCT02590965|Placebo Comparator|Control Group|Placebo is a capsule in the form of 1mg and 5 mg, orally, once daily, 3 weeks on/1week off with best supportive care.
2546045|NCT02590965|Experimental|Treatment Group|The subjects will receive oral Fruquintinib at fasting state 5mg+best supportive care, once daily for the first 3 consecutive weeks and dose holiday for 1 week according to their dose regimens until the occurrence of disease progression, unacceptable toxicity, or withdrawal of consent
2546109|NCT02590601|Active Comparator|Bromocriptine + Guideline-driven medical therapy|"In addition to heart failure treatment described above, patients will be administered bromocriptine 2.5 mg orally twice daily for 14 days, followed by 2.5 mg orally daily for 42 days.~Although not a study procedure, we recommend anticoagulation with prophylactic doses of subcutaneous low-molecular weight heparin during the whole duration of bromocriptine therapy."
2546111|NCT02590601|Other|Guideline-driven medical therapy|New onset PPCM will be managed according to the principles of guideline-driven medical therapy for new-onset heart failure as per the position statement for treatment of PPCM published by the European Society of Cardiology (ESC) and the Canadian Cardiovascular Society (CCS) update on heart failure and pregnancy . The choices and administration of GDMT will be left at the discretion of the treating physician
2546154|NCT02590224|Active Comparator|Ferrous bis-glycinate group|The patients will receive oral ferrous bis-glycinate fully reacted amino acid 27 mg tablets (Pharaferro 27 tablets) once daily for eight consecutive weeks.
2546155|NCT02590224|Active Comparator|Ferrous glycine sulphate group|The patients will receive 567.6 mg of ferrous glycine sulphate capsules (Ferrosanol duodenale capsules, Schwarz) once daily for eight consecutive weeks.
2546248|NCT02589457|Active Comparator|Viread® tablet|Tenofovir Disoproxil Fumarate
2546251|NCT02589457|Experimental|CKD-390|Tenofovir Disoproxil Fumarate
2546350|NCT02589301|Experimental|Pegfilgrastim|Pegfilgrastim (Hematopoietic Growth Factor) injectable solution 6 mg / 0,6mL in a single subcutaneous application.
2546352|NCT02589301|Active Comparator|Neulastim (pegfilgrastim)|Neulastim injectable solution 6 mg / 0,6mL in a single subcutaneous application.
2546411|NCT02588651|Experimental|Brentuximab vedotin|Brentuximab vedotin 1.8 mg/kg intravenously (IV) once every 3 weeks
2546486|NCT02588118||male group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
2546541|NCT02587312|Active Comparator|Normal Nicotine Content Cigarettes|SPECTRUM cigarette: 0.8 mg nicotine with 10.5 mg tar (standard nicotine and tar yields of commercially available cigarettes; control condition)
2546544|NCT02587312|Experimental|Very Low Nicotine Content Cigarettes|SPECTRUM cigarette: 0.03 mg nicotine with 9 mg tar
2546608|NCT02587182|Experimental|Dry needling|Dry needling in the masseter and temporalis muscles
3168953|NCT00557180||TALC|Participants in the ACRN TALC study
3168954|NCT00557206|Experimental|1|This is a single arm trial.
3168955|NCT00557219|Placebo Comparator|Placebo|Control group receiving placebo
3168956|NCT00557219|Experimental|Ketanserin|patients receiving ketanserin infusion
3168957|NCT00557219|Experimental|Fenoldopam|patients receiving fenoldopam infusion
3168958|NCT00557375||1|Brain tumor patients
3168959|NCT00557375||2|Caregivers of brain tumor patients
3168960|NCT00557388|Experimental|1|Young men 18-30 years, BMI < 27 kg/m2
3168961|NCT00557388|Experimental|2|Young men 18-30 years, BMI < 27 kg/m2
2544931|NCT02598284|Experimental|POC + Population Managment (PM)|Clinics will receive facilitation to implement point-of-care (POC) quality improvement strategies as well as population management (PM) strategies to accelerate performance on ABCS clinical measures. Strategies in this arm will occur both at the clinical encounter and strategies aimed at the time between clinical encounters.
2544957|NCT02598024|Experimental|Narrative Exposure Therapy (NET-R)|Revised Narrative Exposure Therapy (NET-R) is a 4-session manual-based treatment, each session lasting 60-90-minutes, and first three sessions delivered daily and the last session after a gap of 1-2 days
2544962|NCT02598024|Experimental|Control Focused Behavioural Treatment|CFBT is an intervention to facilitate natural recovery process by restoring sense of control over anxiety, fear, or distress. For this study in Nepal, a monitoring session will be added to the one-session group CFBT used by Basoglu and Salcioglu (2011), and the revised CFBT would be delivered to groups of 20-30 survivors. Each treatment session would be delivered within 1- 2 hours (90 minutes on average), at the interval of two weeks.
2544969|NCT02598024|No Intervention|Waiting List Control|The waiting list participants will receive the treatment of choice (NET-R or CBFT-R) after 3 months.
2545013|NCT02597777|Placebo Comparator|Side of face receiving placebo vehicle|One half of the face (left or right side) will be randomized to receive the placebo lotion. Subjects will be asked to apply a pea-sized amount of the lotion to half of the face at twice daily application for 4 weeks.
2545020|NCT02597777|Experimental|Side of face receiving AH8 lotion|One half of the face (left or right side) will be randomized to receive the 10% Acetyl Hexapeptide-8 containing (AH8) lotion. Subjects will be asked to apply a pea-size amount of the lotion to the half of the face twice daily application for 4 weeks.
2545090|NCT02597413||Before group|Women in this group are included before the implementation of a strategy of systematic catheterization (they will not be catheterized).
2545092|NCT02597413||After group|"Women in this group are included after the implementation of a department-wide strategy of systematic catheterization.~Intervention: catheterization"
2545117|NCT02596932|Other|Tight control|"Intervention Standard Care:~Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60 mg/dL"
2545118|NCT02596932|Experimental|Less tight control|"Intervention:~Less Tight glucose control protocol: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60mg/dL"
3203463|NCT00924300||patients|children and/or adolescents with psychiatric disorder
3203464|NCT00924300||controls|typically-developing children/adolescents
2545264|NCT02596048|Other|Iomeron|Patients will undergo a injection of Iomeron if they are scheduled to undergo an elective thoraco-abdominal aorta, carotid, pulmonary or peripheral MDCTA examination
2545306|NCT02595736|Placebo Comparator|Placebo (SC)|Single subcutaneous (SC) dose of placebo
2545310|NCT02595736|Experimental|LY3200327 (SC)|Single escalating subcutaneous (SC) dose of LY3200327
2545311|NCT02595736|Experimental|LY3200327 (IV)|Single intravenous (IV) dose of LY3200327
2545312|NCT02595736|Placebo Comparator|Placebo (IV)|Single intravenous (IV) dose of placebo
2545347|NCT02595463|Experimental|Lidocaine|Following intraoperative IV placement, a 1.5 mg/kg bolus does of lidocaine hydrochloride is given and is followed by a continuous infusion of 2 mg/kg/hr until discharge from the Phase 1 recovery period.
2545349|NCT02595463|Placebo Comparator|Placebo|Following intraoperative IV placement, a bolus of saline is given and is followed by a continuous infusion until discharge from the Phase 1 recovery period. The volume of the bolus and rate of infusion are equivalent to that which would have been given in the experimental arm.
2545389|NCT02595177|Experimental|Multifocal IOL|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, multifocal intraocular lens implantation in both eyes planning for emmetropia complete the intervention.
2545390|NCT02595177|Experimental|Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation planning for emmetropia in one eye (dominant) and a monofocal IOL planning for 1.50 D of myopia in the other eye (non-dominant) complete the intervention.
2545391|NCT02595177|Experimental|Hybrid Monovision|Cataract removal with topical anesthesia and phacoemulsification is performed. At the end, a monofocal intraocular lens implantation in the dominant eye and a multifocal IOL in the non-dominant eye complete the intervention.
2545422|NCT02594956|Active Comparator|With Nasogastric Decompression|This group will receive conventional care according to the protocol of the service in place with removal of the nasogastric tube the 3rd postoperative day if the flow is < 500ml / 24h, if not removal will take place on the 5th postoperative day.
2545423|NCT02594956|Experimental|Without Nasogastric decompression|The nasogastric tube will be take off at the end of the surgery, just after the extubation.
2545469|NCT02594722|Experimental|One single arm group|"COPD included in a pulmonary rehabilitation program~Intervention:~Investigators used a bedside cycloergometer with electrical stimulation. COPD perform 2 measure of oxygen uptake during exercise for compare aerobic capacities:~Functional Electrical Stimulation Cycling (FES-cycling)~Classic Cycloergometer endurance training with a sham electrical stimulation"
2545502|NCT02594397|Experimental|acupoints combination 1|acupoints comination 1 includes the specific acupoint ST36 (Zusanli) and a local acupoint CV12 (Zhongwan).
2545505|NCT02594397|Active Comparator|acupoints combination 2|acupoints comination 2 includes the specific acupoint ST36 (Zusanli) and a distal acupoint PC6(Neiguan).
2545507|NCT02594397|Sham Comparator|sham acupoints combination|sham acupoints combination includes the specific acupoint ST36 (Zusanli) and a sham acupoint.
2545583|NCT02594137|Experimental|Without Watertight Duraplasty|"After standard craniectomy (12x15cm) and dural opening, the intervention, which is to not perform watertight duraplasty is carried out. The exposed brain parenchyma is covered with Surgicel. Usual closure is then performed."
3168962|NCT00557388|Experimental|3|Old men 70-85 years, BMI < 27 kg/m2
3168963|NCT00557388|Experimental|4|Old men 70-85 years, BMI < 27 kg/m2
3203465|NCT00924339|Placebo Comparator|Rapeseed oil|Control-Group (n = 15) : Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
2544942|NCT02598310|Experimental|nab-paclitaxel plus trastuzumab|Four cycles of nab-PTX 260 mg/m2 with trastuzumab 6 mg/kg (8 mg/kg as the loading dose). One year of adjuvant trastuzumab will be administrated. Anthracycline regimens may be administered by physician's choice for the case expected to have a high risk of recurrence based on the pathological findings of surgical specimen. Adjuvant endocrine therapy may be administrated for the case with weakly hormone-sensitive (1-9% of positive cells) tumor.
2544961|NCT02597998|Experimental|14C-BI 409306|14C-BI 409306 oral solution
2544994|NCT02597829|Other|Open Label Certolizumab Pegol|Active Treatment
2545044|NCT02597569||Historical Control|Patient participants will be recruited from an inpatient rehabilitation stroke unit prior to introducing CO-OP KT training to the stroke team. Patient participants will receive Usual Care from their stroke team.
2545045|NCT02597569||CO-OP KT Exposure group|Patient participants will be recruited from an inpatient rehabilitation stroke unit after the stroke team has been exposed to CO-OP KT training. Patient participants will receive Usual Care, augmented by CO-OP KT, from their stroke team.
2545099|NCT02597244|Experimental|Treatment group|Percutaneous Extraforaminotomy using BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea)
3203466|NCT00924339|Experimental|Soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
2545178|NCT02596542|Experimental|Water temperature|
3203467|NCT00924391|Active Comparator|dairy milk|Control phase with 1% milk.
3203468|NCT00924391|Experimental|phytosterol enhanced soy based beverage|Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.
2545299|NCT02595671|Active Comparator|Waiting Group|Patients will not receive a treatment during the actual intervention. This group will receive the digital super coach as an incentive at the end of the trial.
2545302|NCT02595671|Active Comparator|Conventional face to face PA & dietitian|Participants will receive both dietary and physical activity advice. The advice is provided my medical trained staff (eg. dieticia, physiotherapist) according to a standardised protocol. The number of consultations are respectively three and four for diet and physcial activity.
2545303|NCT02595671|Active Comparator|Digital Super Coach|Only receive coaching via digital super coach.
2545307|NCT02595671|Active Comparator|Digital Super Coach + minimal coaching|Receive digital super coach and only have a few appointments with a physical activity coach and a dietitian.
3203469|NCT00924417|Experimental|Distraction|"Parent given brief teaching session on concept of distraction, and parent and child given 3 distraction toys/tools to assist with peripheral intravenous line placement."
2545410|NCT02595112|Experimental|Patient undergoing otorhinolaryngologic surgery|Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure.
2545474|NCT02594852|Experimental|Intervention (+ laser)|+ laser therapy
2545479|NCT02594852|Placebo Comparator|Non-intervention (- laser)|- laser
2545540|NCT02594345|Experimental|Intervention group|
2545572|NCT02593994||Onyx Drug Eluting Stent|
2545695|NCT02593370|Experimental|Suprasacral Parallel Shift guided by US/MR image fusion|Use of ultrasound/MR image fusion guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
2545696|NCT02593370|Active Comparator|Suprasacral Parallel Shift guided by US|Use of ultrasound guided Suprasacral Parallel Shift technique to place a lumbar plexus block (20 mL 2% lidocaine with epinephrine added gadoterate meglumine).
2545708|NCT02593071|Experimental|Treatment Group A|RSV-F Vaccine ( 0.5mL Injection)
2545711|NCT02593071|Placebo Comparator|Treatment Group B|Phosphate Buffer Placebo (0.5mL Injection)
2545779|NCT02592759|Experimental|Smart Glove Group|The subjects will be treated with conventional occupational therapy for 30 minutes and smart glove treatment for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
2545780|NCT02592759|No Intervention|Homework group|The subjects will be treated with conventional occupational therapy for 30 minutes and upper extremity rehabilitation homework which means the self training at bedside, for 30 minutes. 5 treatments per week will be conducted a total of 2 weeks.
2545850|NCT02592499|Experimental|HM III|Patients randomized to mechanical circulatory support will be treated with the HeartMate III (HM III) left ventricular assist device system.
2545858|NCT02592499|Active Comparator|OMM, Optimal Medical Management|"Patients randomized to OMM will be treated according to international guidelines.~ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J. 2012 Jul;33(14):1787-84"
2545930|NCT02591862|Other|Coversin|"This is an open label, non-comparator study.~Patient will be given a single ablating dose of 0.57mg/kg per subject followed by daily repeat maintenance doses. The initial repeat dose will be 25% of the ablating dose. If this is insufficient to maintain complement inhibition at ≤10% of baseline (pre-treatment) level after 5 days of treatment the daily dose will be increased by doubling until that level of inhibition is achieved. In the event of 100% inhibition being achieved the dose may be titrated downwards at the PI's discretion until a satisfactory clinical result is obtained. If at any point in treatment complement inhibition falls to less than 50% of baseline a further ablating dose of 0.57mg/kg should be given."
2546001|NCT02591433|Experimental|Supportive care (JeffQuit group therapy)|Patients undergo three, 1-hour group therapy sessions held by a JeffQuit practitioner over a 1-month period. Patients receive strategies for managing the psychological, habitual, and physiological components of smoking and help with developing a planned quit date. Patients are also provided with advice on how to switch to cigarette brands with less nicotine and then how to substitute the nicotine patch and gum for cigarettes. The JeffQuit counselor is available for additional individual support as needed.
2546062|NCT02590991||Prebiotics group|No intervention since is a follow-up study
2546064|NCT02590991||Prebiotics & Probiotics group|No intervention since is a follow-up study
2546065|NCT02590991||Control group|No intervention since is a follow-up study
3203470|NCT00924417|Other|Routine care|Patient managed as routine care.
3203471|NCT00924430|Other|1|
3203472|NCT00924430|Other|2|
3203473|NCT00924456|Experimental|Transcendental Meditation program|a natural effortless mental technique practiced sitting quietly 20 minutes twice a day
2545026|NCT02597647|Experimental|Live attenuated influenza vaccine|Healthy adult volunteers given intranasal FluMist (Live Attenuated Influenza vaccine). Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after LAIV.
2545030|NCT02597647|Placebo Comparator|Saline nasal spray|Healthy adult volunteers given intranasal saline nasal spray. Subjects will undergo nasal swabs, nasopharyngeal washes, and nasal epithelial brushings at baseline, 1-2 weeks, and 4-6 weeks after saline administration.
2545114|NCT02597322|Experimental|AXITINIB|
3203474|NCT00924495|Active Comparator|Cortical function|Activity/inhibition of the cortex
3203475|NCT00924495|Active Comparator|Cortical regulation|
3203476|NCT00924521|Active Comparator|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
3203477|NCT00924521|Experimental|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
3203478|NCT00924534|Placebo Comparator|1|
2545325|NCT02595632||Healthy|Healthy subjects with no apparent lung disease and normal lung function testing.
2545355|NCT02595541|Active Comparator|milrinone group|milrinone
2545359|NCT02595541|Active Comparator|sildenafil and milrinone group|milrinone and sildenafil
2545406|NCT02595151||gastric intestinal metaplasia|Those fulfilling the criteria of GIM by CLE according to the study by Yuting Guo et al were included.
2545416|NCT02595151||normal gastric|diagnosed during routine colonoscopy procedures.
2545475|NCT02594774|Experimental|Osteopathic treatment|Manipulative osteopathy (and standard medical treatment)
2545481|NCT02594774|No Intervention|Standard medical treatment|Standard medical treatment
2545547|NCT02594319|Active Comparator|Control|Daily reporting of fruit and vegetable consumption
2545548|NCT02594319|Experimental|Daily reward|Incentives for fruit and vegetable consumption delivered daily
2545550|NCT02594319|Experimental|Delayed reward|Incentives for fruit and vegetable consumption delivered in a lump sum at the end of the intervention
2545605|NCT02593747|Experimental|Loratadine oral solution/syrup then Claritin peach syrup|Subjects received a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
2545613|NCT02593747|Experimental|Claritin peach syrup then Loratadine oral solution/syrup|Subjects received a single oral dose of 10 mg loratadine-claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in treatment period 1, followed by a single oral dose of 10 mg loratadine-oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in treatment period 2. A wash-out period of at least 10 calendar days was maintained between the 2 treatments.
3203479|NCT00924534|Experimental|2|
2545828|NCT02592538|Experimental|RFA+stent+S-1|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement, and be treated with S-1 began within 1 month after RFA.
2545829|NCT02592538|Placebo Comparator|RFA+stent|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Patients will only receive endobiliary radiofrequency ablation ( RFA) followed by plastic stent(s) placement
2545856|NCT02592200|Experimental|Lactobacillus gasseri|Lactobacillus gasseri DSM 27123 capsules, 1×109 CFU (divided in two doses)
2545862|NCT02592200|Placebo Comparator|Placebo|Placebo capsules (two doses)
2545954|NCT02591667|Experimental|Active treatment|"Patients will first undergo upfront staging laparoscopy with retrieval of tumor tissue for standard pathology.~Two to 4 weeks after initial surgical exploration, patients will receive 4 cycles of FOLFOXIRI + bevacizumab, q2w. The last chemotherapy cycle will be given without bevacizumab.~Five to 7 weeks after the last administration of bevacizumab (i.e., 3 to 5 weeks after completion of chemotherapy), patients will undergo surgery with the intent to perform complete surgical cytoreduction of all peritoneal tumor deposits. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, will be given at the discretion of the investigator."
3203480|NCT00924534|Experimental|3|
3203481|NCT00924534|Experimental|4|
3203482|NCT00924547|Experimental|Docosahexanoic Acid Supplement|In this arm, participants took two different doses of a DHA supplement. Each dose of the DHA supplement was taken for 4 weeks.
3203483|NCT00924547|Placebo Comparator|Placebo|In this arm, participants took a placebo pill that did not contain any DHA.
3203484|NCT00924573|Experimental|1|"Metformin on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 500-750mg of daily dose for metformin for 24 weeks"
3203485|NCT00924573|Placebo Comparator|2|"Placebo on top of glimepiride~Twice a day with 2-6 mg of daily dose for glimepiride and 2-3 tablets of placebo for 24 weeks"
3203486|NCT00924586|Placebo Comparator|P|
3203487|NCT00924586|Experimental|E|
2545015|NCT02597764|Experimental|Standard Urotherapy (SU) + Diaphragmatic Beathing (DB)|"Standard Urotherapy (SU) with the addition of Diaphragmatic Breathing (DB):~A non-invasive breathing technique that is performed by a marked expansion of the abdomen (contracting diaphragm) rather than chest cavity during inspiration and tightening of the stomach muscles during expiration. Participants will lie on their back on a flat surface. Head is supported with a pillow and knees are bent forward supported by another pillow. Participants will place one hand on chest and the other on the abdomen, then start inhalation by moving their abdomen out against their hand, breathing in through their nose while keeping their chest and the other hand as still as possible. During expiration, the participants will tighten their abdominal muscles by forcing them inward and breathe out through pursed lips while keeping the hand on the chest as still as possible. Participants will be asked to perform this exercise for 10 minutes 3 times daily for 3 months."
2545063|NCT02597400|Experimental|HMS5552 and Metformin|"All subjects will receive the following:~Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
2545109|NCT02597153|Experimental|Mitoxantrone HCL Liposome Injection|Each treatment cycle lasts for 28 days with 20mg/m2
2545131|NCT02596828|Experimental|RIST|
2545198|NCT02596555|Experimental|Dabigatran treatment|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
3168964|NCT00557388|Experimental|5|Old men 70-85 years, BMI < 27 kg/m2
3168965|NCT00557388|Experimental|6|Old men 70-85 years, BMI < 27 kg/m2
3168966|NCT00557388|Experimental|7|Old men 70-85 years, BMI < 27 kg/m2
3168967|NCT00557388|Experimental|8|Old men 70-85 years, BMI < 27 kg/m2
2545313|NCT02595775|Experimental|Round 1: Intervention arm|"Half of the endoscopists in Ontario will receive an individualized audit & feedback report.~Individualized A/F report."
2545316|NCT02595775|No Intervention|Round 1: Control|Half of the endoscopists in Ontario will NOT receive an individualized audit & feedback report.
2545320|NCT02595775|Other|Round 2: Month 12|"All endoscopists in Ontario will receive an individualized audit & feedback report at month 12.~Individualized A/F report"
2545324|NCT02595775|Other|Round 2: Poor performers|"In Round 2, selected 60 poorer performers will be randomly assigned to receive one of the following interventions at month 12:~A/F report plus a high intensity intervention~A/F report plus a low intensity intervention~A/F report alone"
3203488|NCT00924599|Experimental|Intervention Group-English|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
2545424|NCT02594969|Active Comparator|Healthy Group|These subjects do not have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
2545426|NCT02594969|Experimental|Atopic Dermatitis Group|These subjects have atopic dermatitis and are considered healthy. They will participate in the bleach bath and the moisturizer application.
2545456|NCT02594709|Experimental|ONSM Multisession Radiosurgery|Multisession Radiosurgery
2545504|NCT02594488|Active Comparator|Remote monitoring|Remote cardiac monitoring by the Reveal® LINQ implantable cardiac monitor
2545508|NCT02594488|No Intervention|Control arm|Follow-up at the same frequency, but with no implantable cardiac monitor
3203489|NCT00924599|Experimental|Intervention Group-Spanish|Intervention Group will be learning how to lose weight through healthy eating and moderate exercise. The goal is to get participants to lose 7% of body weight and increase physical activity to 2 1/2 hours per week. This group will be meeting one time per week for twelve weeks, and then one time per month until conception.
2545659|NCT02593526|No Intervention|No Diuretic and 37°C dialysate|Standard of care, no diuretic
2545662|NCT02593526|Experimental|No Diuretic and 35.5°C dialysate|Cool dialysate only, no diuretic
2545664|NCT02593526|Experimental|Diuretic and 37°C dialysate|Isothermic dialysate (37°C) and bumetanide (diuretic)
2545667|NCT02593526|Experimental|Diuretic and 35.5°C dialysate|Cool dialysate (35.5°C) and bumetanide (diuretic)
2545720|NCT02593253|Experimental|Intervention Audit and Feedback Bundle|Access to the electronic dashboard and weekly feedback rounds
2545727|NCT02593253|Active Comparator|Bi-weekly audit and feedback emails|Access to biweekly feedback emails with performance on selected quality measures (current practice).
3203490|NCT00924599|Active Comparator|Lifestyle education-English|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
2545911|NCT02591914|Experimental|Altering regimens of Fovista™and Anti-VEGF Therapy|"All subjects will be treated with Fovista™ 1.5 mg/eye in combination with anti-VEGF therapy.~The following doses of Anti-VEGF therapy will be delivered based on the Investigator's discretion:~Lucentis® 0.5 mg/eye~Avastin® 1.25 mg/eye~Eylea® 2 mg/eye~Subjects will be treated with Fovista™ and Anti-VEGF therapy every month for the first three months.~The regimen for administration of each intravitreal agent will be as follows:~Injection Day #1-Administration of Fovista™ 1.5mg/eye~Injection Day #2-Administration of Fovista™ 1.5mg/eye followed by anti-VEGF therapy after Fovista™ injection~The same regimen will be delivered monthly until the subject reaches maximum visual acuity benefit. Maximum visual acuity is defined as no increase in ETDRS visual acuity at two consecutive visits.~Subsequent re-treatment with the Anti-VEGF therapy will use a PRN (as-needed) regimen based on protocol specified retreatment criteria."
2545934|NCT02591615|Active Comparator|Arm A|"For Squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
2546028|NCT02591108|Experimental|Safety and Efficacy|Parallel treatment; use of standard TOF peripheral Stimulator to Novel Train of Four Device
3168968|NCT00557388|Experimental|9|Old men 70-85 years, BMI < 27 kg/m2
2545043|NCT02597608|Experimental|Shiree: Livelihoods plus nutrition|Livelihoods programmes offered by Shiree, plus nutrition programmes offered by Shiree.
2545086|NCT02597218||Patients following hepatectomy|"Patients following hepatectomy of any type, any gender. Roughly, we will describe: type of resection, presence of cancer,use of mechanical/pharmacological prophylaxis, major/minor bleedings ocurring during observation period.~Outcomes: Venous thromboembolism (VTE)[deep vein thrombosis (DVT) and pulmonary embolism (PE)] and portal thrombosis (PT)."
3203491|NCT00924599|Active Comparator|Lifestyle education-Spanish|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
3203492|NCT00924625|Experimental|Neuromuscular electrical stimulation|NMES will be used as in clinical practice based on an evidence-based approach. NMES will be applied at the participant's maximum tolerance. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions.
3203493|NCT00924625|Active Comparator|Volitional exercises|VE will be used as in clinical practice based on an evidence-based approach. VE program will be the one shown to positively affect muscle hypertrophy and will follow the resistance training principles. Participants will receive 3 treatments/week for 12 weeks with at least 48h between training sessions
3203494|NCT00924677|Sham Comparator|lidocaine|Local injection with lidocaine through the RF cannula without activation of RF generator.
3203495|NCT00924677|Active Comparator|lidocaine, radiofrequency current|After lidocaine injection through the RF cannula, the temperature of the electrode tip was raised to 70℃ for 90 seconds by RF generator.
3203496|NCT00924690|Experimental|1|Behavioral Message Arm
2545333|NCT02595580|Experimental|GlucoPred|
3203497|NCT00924690|Active Comparator|2|Generic Message Arm
2545425|NCT02595034|Experimental|Clindamycin/BP Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
2545429|NCT02595034|Active Comparator|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
2545433|NCT02595034|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
2545449|NCT02594631|Active Comparator|ESWL Group|Patients in this arm will receive ESWL as treatment for acute calcular urinary retention
2545450|NCT02594631|Active Comparator|Endoscopy group|Patients in this arm will receive endoscopic treatment for acute calcular urinary retention
2545511|NCT02594436||Ingenol mebutate gel 0.015 percent|Topical treatment of face or scalp once daily for three consecutive days
2545516|NCT02594436||Ingenol mebutate gel 0.05 percent|Topical treatment of trunk or extremities once daily for two consecutive days
3203498|NCT00924742|Experimental|Test drug|
3203499|NCT00924768|Experimental|Endotoxin|Inhalation of 20K EU CCRE
3203500|NCT00924794||Cohort A|Women aged 18 years and above, diagnosed with high grade lesions or microinvasive cervical carcinomas in primary conization performed and registered in the Cancer Registry of Norway, and presenting with recurrent conization with high grade lesions or microinvasive cervical carcinoma or invasive cervical carcinoma.
3203501|NCT00924846|Active Comparator|HFOV plus iNO|HFOV plus iNO: high frequency oscillatory ventilation plus inhaled nitric oxide
2545791|NCT02592746|Experimental|Palbociclib + Exemestane + GnRH agonist|
2545795|NCT02592746|Active Comparator|Capecitabine|
2545865|NCT02592304|Other|dual energy ct|
2545909|NCT02592044|Experimental|Aromatherapy with lavender essential oil|The 2 drops of lavender essential oil will put on 5x5 cm gauze and the patient will inhale it for 5 minutes and during peripheral venous cannulation.
2545912|NCT02592044|Placebo Comparator|Placebo|The 2 drops water will put on 5x5 cm gauze ant the patient will inhale it for 5 minutes and during peripheral venous cannulation.
2545940|NCT02591589|Experimental|Normoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For normoxic oxygenation FiO2 will be set at 0.35 (35%) ideally to maintain PaO2 above 70mmHg (or saturations greater than or equal to 92%), and titrated up if need be to prevent potentially injurious hypoxemia (saturations below 92%). During cardiopulmonary bypass, blended air/ oxygen mixture will be titrated to arterial blood gas analysis with maintenance of PaO2 between 100mmHg and 150mmHg.
2545942|NCT02591589|Active Comparator|Hyperoxic group|To standardize key aspects of ventilator support, tidal volume will be set to 6-8ml/kg and PEEP levels will be set to 0-5cm H2O, allowing flexibility for provider preference. For hyperoxic oxygenation FiO2 will be set at 1.0 (100%) throughout the intraoperative period, including cardiopulmonary bypass.
2545999|NCT02591355|Experimental|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma injection
2546006|NCT02591355|Placebo Comparator|Saline|Saline solution injection
2546049|NCT02591030|Placebo Comparator|GEMCIS|
2546050|NCT02591030|Experimental|mFOLFIRINOX|
3203502|NCT00924846|Active Comparator|CMV plus iNO|CMV (conventional mechanical ventilation) iNO (inhaled nitric oxide)
3203503|NCT00924859||1|Patients with clinical suspicion of CVT
3203504|NCT00924872|Experimental|intervention|receive wheelchair skills training
3203505|NCT00924872|No Intervention|control|no formalized wheelchair skills training provided
3203506|NCT00924911|Experimental|Part 1|A 4 way crossover of three GSK1322322 tablet formulations and GSK1322322 powder in bottle
2546178|NCT02590081|Active Comparator|Normal saline|Normal saline will be used for wash back procedure at the end of hemodiaysis.
2546180|NCT02590081|Experimental|dextrose 5%|Dextrose 5% will be used for wash back procedure at the end of hemodiaysis.
3203507|NCT00924911|Experimental|Part 2|A 3 way crossover of a GSK1322322 tablet with a high fat meal, with Ranitidine, and with Ranitidine and Vitamin C.
3203508|NCT00924924|Experimental|Act Healthy!|Immediate treatment group of six-weeks of classes in self-management training for healthy behaviors
3203509|NCT00924924|Active Comparator|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
2545048|NCT02597530|Experimental|Long-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.Patients in Long-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and continued until the end of the surgery with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
2545050|NCT02597530|Other|Short-term stimulution group|According to ancient Chinese medical books, acupoints Hegu and Zusanli are chosen and identified.The patients in Short-term stimulation group received electrical stimulation with the 'disperse-dense' waves.TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia with dilatational wave(2-15HZ).All patients will remove electrodes on surgery over.
2545052|NCT02597530|Placebo Comparator|Sham group|Patients in sham group will be pasted electrodes 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
2545079|NCT02597231|Experimental|Melatonin Group|Patients in this group will receive melatonin 3mg orally at 9pm.
2545081|NCT02597231|Placebo Comparator|Placebo Group|Patient in this group will receive a matching placebo pill orally at 9pm.
2545121|NCT02597010|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
2545123|NCT02597010|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
2545180|NCT02596646|Active Comparator|Group A|Early Precut
2545183|NCT02596646|Active Comparator|Group B|Prolonged cannulation attempts
2545274|NCT02596256|Experimental|control group|Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
2545277|NCT02596256|Active Comparator|contrast group|Docetaxel (60mg/m2, i.v. d1 q21d)
2545298|NCT02595658|Experimental|1|Carbohydrate only meal: Participants will consume a standardised carbohydrate meal (80 g of carbohydrates, 25 g protein, 0 g fat: meal composition, white rice, chicken, curry sauce; 420 kcal) and will self-administer (into the subcutaneous tissue of the abdomen, as per their regular routine) a rapid-acting insulin dose calculated as per the carbohydrate-counting ratio (e.g. 1 IU of insulin per 10 g of carbohydrates).
2545301|NCT02595658|Experimental|2|Participants will replicate Trial 1, but on this occasion the meal consumed will have an additional 50 g of fat (via addition of Ghee). This fat will be added to the sauce within the meal (80 g of carbohydrates, 25 g of protein, 50 g of fat; 735 Kcal). Participants will administer their rapid-acting insulin as per the carbohydrate counting method (i.e. the same IU of insulin as per Trial 1).
2545304|NCT02595658|Experimental|3|Trial 3) Participants will replicate Trial 2, but will administer a rapid-acting insulin dose that has been increased by 30%.
2545308|NCT02595658|Experimental|4|Participants will replicate Trial 2, but will administer an additional rapid-acting insulin dose of 30% 3 hrs post-meal.
2545435|NCT02594982|Other|intervention bundle|An intervention bundle consisting of optimized sedation, pain assessment and treatment, early mobilization and sleep.
3168969|NCT00557388|Experimental|10|Old men 70-85 years, BMI < 27 kg/m2
3168970|NCT00557401|Experimental|XP19986 SR3, 20 mg QD|XP19986, 20 mg QD for approximately 32 days
3168971|NCT00557401|Experimental|XP19986 SR3, 40 mg QD|XP19986, 40 mg QD for approximately 32 days
2545556|NCT02594033|Experimental|3 mm needle|
2545558|NCT02594033|Experimental|3.5 mm needle|
2545559|NCT02594033|Active Comparator|4 mm needle|
2545604|NCT02593812|Experimental|"Training off medication"|"Participants will train on the postural stepping task before taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while off dopamine replacement medication"
2545609|NCT02593812|Other|"Training on medication"|"Participants will train on the postural stepping task after taking their first daily dose of standard Parkinson's medication (dopamine), i.e. while on dopamine replacement medication"
2545670|NCT02593565||Intervention|Woman, 18 years of age or older, currently pregnant, and have a diagnosis of vasculitis.
2545751|NCT02593240|Experimental|Human Performance Institute©|These participants will be part of the intervention sites and will receive the Human Performance Institute© intervention for the duration of the study (18 months).
2545755|NCT02593240|Experimental|The iDiet® with Voucher|These participants will be part of the intervention sites and will receive the iDiet® with Voucher for the duration of the study (18 months).
2545758|NCT02593240|Experimental|The iDiet® with Food|These participants will be part of the intervention sites and will receive the iDiet® with Food for the duration of the study (18 months).
2545760|NCT02593240|No Intervention|Wait-listed control|These participants will be part of the control sites and will participate in outcome assessments for a 6-month period only.
2546047|NCT02590874|Placebo Comparator|Placebo group|Inactive drug group
3168972|NCT00557401|Experimental|XP19986 SR3, 60 mg QD|XP19986, 60 mg QD for approximately 32 days
3168973|NCT00557401|Experimental|XP19986 SR3, 30 mg BID|XP19986, 30 mg BID for approximately 32 days
3168974|NCT00557401|Placebo Comparator|Placebo|Placebo for approximately 32 days
3168975|NCT00557427|Experimental|A|hypericum 250mg tablets twice daily for 8 weeks
3168976|NCT00557427|Active Comparator|B|fluoxetine 20mg - 40mg daily for 8 weeks
3168977|NCT00557453||A|Antibiotic treatment
3168978|NCT00557453||B|Non antibiotic treatment
3168979|NCT00557518|Active Comparator|1|
3168980|NCT00557518|Placebo Comparator|2|
3168981|NCT00557531|Experimental|BL-1040|
3168982|NCT00557544|Experimental|1|metoclopramide 0,15 mg/kg and Ketoprofen 1 mg/Kg per os in single dose
3168983|NCT00557544|Active Comparator|2|metoclopramide 0,15 mg/Kg + placebo per os
3168984|NCT00557544|Active Comparator|3|ketoprofen 1 mg/Kg and placebo in single dose
3168985|NCT00557557|Experimental|IHP with Oxaliplatin and 5-Fluorouracil (5-FU)|Isolated Hepatic Perfusion with Oxaliplatin and 5-Fluorouracil (5-FU)
3168986|NCT00557648|Experimental|1|CBT for children only
3168987|NCT00557648|Experimental|2|CBT for children with parental involvement
3168988|NCT00557648|No Intervention|3|No intervention control group: families free to seek treatment on their own
3168989|NCT00557700|Placebo Comparator|2|Administration of placebo
3168990|NCT00557700|Experimental|1|Administration of inhaled tiotropium bromide
3203510|NCT00924937|Active Comparator|Low Fat Diet|Dietary Intervention with a Low fat diet: <30% fat (12% monounsaturated fatty acids; 6-8%polyunsaturated fatty acids; <10% saturated fatty acids)
3203511|NCT00924937|Experimental|Mediterranean Diet|Dietary Intervention with a Mediterranean Diet: 35-38% fat (22% monounsaturated fatty acids; 6% polyunsaturated fatty acids; <10% saturated fatty acids).
3203512|NCT00924963|Experimental|Jet injection lidocaine|J-Tip jet injection of 1% buffered lidocaine
3203513|NCT00924963|Placebo Comparator|Jet injection saline|J-Tip jet injection of sterile saline
3203514|NCT00924963|Active Comparator|Lidocaine cream|Lidocaine 4%cream applied for 30 minutes prior to IV insertion or venipuncture
2545195|NCT02596438||Asian Americans|Foreign born or children of foreign born Asian American from Hepatitis B endemic areas residing in Sacramento, CA.
2545255|NCT02596204|Active Comparator|Data Upload|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. Subjects will continue to receive usual diabetes care. Phone calls and emails to the diabetes clinic will be initiated by the family.
2545263|NCT02596204|Experimental|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. FitBit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (diabetes educator, nurse practitioner and/or physician) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
2545322|NCT02595762||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
3203515|NCT00924976|Experimental|1|Subjects will be offered the Steps for Achieving Financial Empowerment (SAFE) which helps facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
3203516|NCT00924976|No Intervention|2|Representative payeeship as usual
3203517|NCT00924989|Experimental|Arm A: OSI-906|150 mg twice daily
3203518|NCT00924989|Placebo Comparator|Arm B: Placebo|Matching placebo twice daily
3203519|NCT00925028|Experimental|Group A|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. After four months the groups will switch to the alternate management strategy.
3203520|NCT00925028|Experimental|Group B|Patients of group B will continue to be managed by their physician. After four months the groups will switch to the alternate management strategy.
3203521|NCT00925041|Experimental|Kxl Vedera|
3203522|NCT00925067|Experimental|lightweight TiMesh|
3203523|NCT00925067|Experimental|lightweight VyproII|
3203524|NCT00925067|Experimental|Heavyweight Marlex|
3203525|NCT00925080||A|
3203526|NCT00925093|Active Comparator|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
3203527|NCT00925093|Active Comparator|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
3203528|NCT00925093|Active Comparator|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
3203529|NCT00925106|Active Comparator|Celebrex capsule|Commercial capsule
3203530|NCT00925106|Experimental|D1|Test formulation D1
3203531|NCT00925106|Experimental|D2|Test formulation D2
3203532|NCT00925106|Experimental|D3|Test formulation D3
3203533|NCT00925145||1|
3203534|NCT00925158|Experimental|Surgical instrument (DAME)|Surgical dissector instrument created to malar elevation.
3203535|NCT00925171|Experimental|Pulmonary Rehabilitation Group|Intervention with exercise management
3203536|NCT00925171|No Intervention|Control Group|"Patients will receive the standard advice to undertake strength and endurance exercises at home and invitation to attend the Norwich Breath Easy Group~Patients will be stratified according to whether the initial programme took place in the outpatient hospital or community setting"
3203537|NCT00925184||medical students, graduate year,|medical students at graduate year will be invited to participate in this study.
3203538|NCT00925210|Experimental|Sequential pEBUS - ENB|
3203539|NCT00925223||irritable bowel syndrome|patients with diarrhea-predominant IBS will be enrolled in this group.
3203540|NCT00925223||control group|patients with colon cancer or colon polyp will be enrolled as control group.
3203541|NCT00925249||1|The study group will consist of RA patients of the Walter Reed Army Medical Center (WRAMC) rheumatology clinic being considered for treatment with anti-TNF alpha therapy. We will enter patients into the study over a projected course of 12-24 months or until we reach the statistical requirement of 60 subjects.
3203542|NCT00925249||2|The control group will consist of healthy subjects without known immune-dysregulation or history of treatment with biologic agents who present to the WRAMC Allergy- Immunology clinic for routine screening TST as a part of current WRAMC policy.
3203543|NCT00925262|Experimental|Cognitive Processing Therapy|An adaptation of cognitive behavioral therapy, focusing on treatment for persons suffering mental health effects of trauma
3203544|NCT00925262|Experimental|Behavioral Activation|A form of counseling therapy that emphasizes enhancing pleasurable behaviors and minimizing negative behaviors as a means to reducing depression symptomatology.
3203545|NCT00925262|Experimental|non-specific counseling|a collection of counseling skills suitable for a broad range of mental health and psychosocial problems and not designed for specific disorders. This particular version was developed by a collaborator -Heartland Alliance - for use with torture survivors.
3203546|NCT00925262|No Intervention|wait control|persons in this study arm will not receive active treatment as part of the study but will be monitored during the study and offered treatment after 3-5 months of waiting.
3203547|NCT00925275|Experimental|Dosimetric|
2545100|NCT02597192|Active Comparator|Active test group|probiotic oral hygiene products with Bacillus (PIP, Chrisal)
2545101|NCT02597192|Placebo Comparator|Placebo group|oral hygiene products without Bacillus
2545179|NCT02596698||Adolescents with Mood Disorders|Teens aged 13-18 with a diagnosis of a mood disorder.
2545184|NCT02596698||Adolescents with no Mental Health Diagnoses|13-18, no psychiatric d/o diagnosis
2545272|NCT02596269|Experimental|Nefopam(NF) group|Received i.v. PCA with the same volume of solution containing 1250 µg fentanyl plus 120 mg of nefopam in normal saline (fentanyl 12.5 µg/ml and nefopam 1.2 mg/ml).
2545273|NCT02596269|Placebo Comparator|Saline(SF) group|Received i.v. PCA with 100 ml solution containing 1250 µg of fentanyl in normal saline (12.5 µg/ml),
2545295|NCT02595710||Biospecimen retention|Blood Collection Skin Punch Biopsy Collection Urine Sample Collection
2545337|NCT02595554|Active Comparator|Concurrent chemoirradiation (CCRT)|Concurrent chemoirradiation
2545338|NCT02595554|Experimental|NACT+Surgery|Neoadjuvant chemotherapy with Paclitaxel and Cisplatin (3 cycles), followed by radical surgery
2545373|NCT02595294|Experimental|Cervical Lateral Glide|"15 minutes Cervical Lateral Glide neural mobilization~5 times a week~During 6 weeks~Patient's adequate cervical spine linear alignment was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization."
2545377|NCT02595294|No Intervention|Waiting list control group|- Patients assigned to a 6 week waiting list to receive treatment
2545407|NCT02595047|Experimental|tissue/ organ prefabrication|in vivo generation of autologous tissue for joint replacement
2545472|NCT02594787|Active Comparator|Phosphorus|Intervention (500 mg of potassium phosphate) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
2545477|NCT02594787|Placebo Comparator|Placebo|Placebo (cellulose) will be administered with 75 g glucose solution and diet induced thermogenesis will be measured afterwards
2545496|NCT02594358|Active Comparator|Caffeine 20 mg|Patching plus once daily caffeine for 12 weeks
2545497|NCT02594358|Active Comparator|Caffeine 40 mg|Patching plus once daily caffeine for 12 weeks
2545578|NCT02594176|Experimental|Test Product|2.2 g FLEXISEQ® twice daily
2545579|NCT02594176|Placebo Comparator|Placebo|2.2 g placebo twice daily
2545660|NCT02593643|Experimental|ketamine+TAU - MDD|Ketamine + treatment as usual (TAU) in MDD inpatients with SI
2545663|NCT02593643|Active Comparator|midazolam + TAU - MDD|Midazolam + treatment as usual (TAU) in MDD inpatients with SI
2545665|NCT02593643|Experimental|ketamine + TAU - BD|Ketamine + treatment as usual (TAU) in BD inpatients with SI
2545668|NCT02593643|Active Comparator|midazolam + TAU - BD|Midazolam + treatment as usual (TAU) in BD inpatients with SI
2545736|NCT02593188||HYQVIA- Epoch 1|Participants receiving HYQVIA
2545738|NCT02593188||HYQVIA- Epoch 2|Participants with rHuPH antibody titers ≥160 (tested in Epoch 1)
2545792|NCT02592616|Experimental|CON|Control (CON).
2545796|NCT02592616|Experimental|CW|Continuous Walking (CW).
2545798|NCT02592616|Experimental|IW|Interval Walking (IW).
2545848|NCT02592395|Experimental|Electrochemotherapy with FOLFIRINOX|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with FOLFIRINOX . The schedule of administration of FOLFIRINOX will be administered as per standard of care.
3203548|NCT00925314|Experimental|Transgenic Lymphocyte Immunization|Open Label, Single Arm
3203549|NCT00925327|Experimental|Corneal collagen cross-linking with riboflavin and UVA light|
3203550|NCT00925340|Experimental|1 - Family Check Up|Brief family intervention that employs Motivational Interviewing.
2545947|NCT02591706|Active Comparator|Dental implant (C1)|"Internal Conical Connection: The C1 has a six-position cone index, except for the C1 narrow platform that has a four-position cone index. The conical connection is 2.00mm in depth, with a 12° cone. As a result of our meticulous manufacturing process a perfect fit between the implant and the abutment is achieved, eliminating micro-movements and minimizing bone resorption.~Patient will be randomly assigned to one of the two groups after flap opening."
2545951|NCT02591706|Experimental|Dental implant (V3)|"The unique triangular shape of the coronal portion of the V3 implant results in less titanium and more bone and soft tissue visible in the esthetic zone, for a restorative-driven approach and easier soft tissue management. The V3 provides doctors with a more advantageous starting point; where greater volume of bone and soft tissue is achieved at the onset of implant placement.~Patient will be randomly assigned to one of the two groups after flap opening."
2546016|NCT02591316||Breast cancer survivor|Inclusion criteria: Female breast cancer survivors (30-70yrs of age) that have completed primary treatment (chemotherapy, radiation therapy or both) within past 60 months
2546018|NCT02591316||Control|Females (30-70yrs of age) with no previous cancer diagnosis.
2546055|NCT02590952|Experimental|Epitinib|Epitinib is a capsule in the form of 5mg,20 mg, and 40 mg. Route: oral (daily)
2546114|NCT02590679|Experimental|PRAS|pulmonary regurgitation after surgical repair of congenital right ventricular outflow tract
2546169|NCT02590211|Other|non-poker players|(control group)
2546171|NCT02590211|Other|expert unproblematic poker players|(comparator)
2546172|NCT02590211|Other|pathological poker players|(comparator)
2546210|NCT02589886|Active Comparator|intervention|This arm will receive the education and self-help internet intervention added to usual care
2546212|NCT02589886|No Intervention|control|This arm will receive usual care only
2546254|NCT02589613|Placebo Comparator|PLACEBO|Single intragastric instillation of 300ml tap water via nasogastric tube
2546264|NCT02589613|Active Comparator|GLUCOSE|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
2546269|NCT02589613|Active Comparator|FRUCTOSE|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
2546376|NCT02588898||Patients with type 2 diabetes|Patients (both men and women) with diagnosed type 2 Diabetes for at least 5 years. Blood collection and electrophysiological tests were performed.
2546378|NCT02588898||Controls free of diabetes|Controls (both men and women) are people of the same age who are free of Diabetes. Blood collection and electrophysiological tests were performed.
3203551|NCT00925340|Active Comparator|2 - Psychoeducation|
2545197|NCT02596529|Experimental|Fixation|Patients with a medium-sized posterior fragment which will be treated by open reduction and internal fixation of all fractured malleoli.
2545201|NCT02596529|Active Comparator|No fixation|Patients with a medium-sized posterior fragment which will be treated bij open reduction and internal fixation of lateral and medial malleolus alone. No fixation of the posterior malleolus take place.
2545238|NCT02596139||Healthy people|
3203552|NCT00925366|Other|Shoulder rotator cuff tear|Shoulder rotator cuff tear
3203553|NCT00925392|Experimental|Doripenem 500 mg|
2546057|NCT02591095|Experimental|ABT-263|oral Navitoclax (ABT-263) daily
2546127|NCT02590510|Experimental|The small dose of group|The dose of methotrexate is 10 mg
2546130|NCT02590510|Active Comparator|The high dose of group|The dose of methotrexate is 15 mg
2546159|NCT02590120|Active Comparator|Enteral nutrition product : product A|Administration during 16 hours.
2546161|NCT02590120|Active Comparator|Enteral nutrition product : product B|Administration during 16 hours.
2546260|NCT02589353|Experimental|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
2546359|NCT02588846|Experimental|Stage 1: Optimise nodal treatment margin|During Stage 1: Optimise nodal treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. The nodal target position stability will be evaluated by the cone beam computed tomography (CBCT) imaging before and after each treatment session for the first 10 patients.
2546363|NCT02588846|Experimental|Stage 2: Use treatment margin|During Stage 2: Use treatment margin, Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring' will be used to reshape the radiation beam in real-time. At the same time, multi-leaf collimator (MLC) tracking will be used to reshape the radiation beam in real-time using the margin size determined in Stage 1.
2546403|NCT02588521|Experimental|AL-794|AL-794 administered orally in a suspension
2546404|NCT02588521|Placebo Comparator|Vehicle|Suspension vehicle alone
2546455|NCT02588235|Experimental|Ezetimibe and Atorvastatin Therapy|Atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
2546457|NCT02588235|Active Comparator|Atorvastatin Therapy|Atorvastatin (20 mg/day）
2546499|NCT02587871|Experimental|Treatment (cytarabine, G-CSF mobilized peripheral blood cells)|Approximately 4-6 weeks after completion of induction chemotherapy, patients receive cytarabine IV over 1-3 hours BID on days -7 to -2 and G-CSF mobilized peripheral blood cells (microtransplant) IV over 15-20 minutes on day 0. Treatment repeats every 8-10 weeks for 3 courses in the absence of disease progression or unacceptable toxicity.
2546575|NCT02587377|Other|Cohort 1|single cohort of patient
2546605|NCT02587130|Experimental|communicating and none-communicating patients|20 communicating patients (evaluated with the visual analogue pain scale (VAS)) and 20 none-communicating patients or patients presenting cognitive disturbance or vigilance (evaluated with the Algoplus scale)
3203554|NCT00925392|Experimental|Doripenem 1000 mg|
3203555|NCT00925405||Breast MRI Screening|
2546718|NCT02586259||Cortiment®|Treatment according to routine clinical practice.
2546764|NCT02586038|Experimental|MLN-DEX-CYCLO arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Cyclophosphamide: 300 mg/sqm orally on days 1, 8, 15"
2546765|NCT02586038|Experimental|MLN-DEX-THAL arm|"Patients will receive nine 28-days induction cycles.~MLN9708: 4,0 mg orally on days 1, 8, 15 Dexamethasone: 40 mg orally on days 1, 8, 15, 22. Thalidomide: 100 mg/day orally"
2546925|NCT02585323|Placebo Comparator|Delayed Intervention Group|Same intervention with a 3 month delay: The full intervention will be initiated in Month 4 and with a brief education session, use of a Fitbit Flex paired with the FitViz app, and counseling by a physiotherapist. In Months 6-9, participants will continue using Fitbit/FitViz without the PT phone calls.
3203556|NCT00925418|No Intervention|Without Glove|Patients do not use frozen glove during chemotherapy with Taxotere®
3203557|NCT00925418|Experimental|With Glove|Patients use frozen glove during chemotherapy with Taxotere®
3203558|NCT00925431|Experimental|Lifestyle Modification|Behavioral: cognitive-motivational enhancement to lifestyle management plus nutritional education.
3203559|NCT00925431|Active Comparator|Supportive education|General fibromyalgia education plus nutritional education.
3203560|NCT00925444|Experimental|FOREseal|
3203561|NCT00925444|Active Comparator|Stapling|
3203562|NCT00925457||001|Current Domperidone Current domperidone at any dose regardless of proton pump inhibitor status
3203563|NCT00925457||002|Current proton pump inhibitor (PPI) Current PPI and not current dapoxetine
3203564|NCT00925457||003|No Intervention Neither current domperidone nor current PPI
3203565|NCT00925470||1|
2545170|NCT02596581|Active Comparator|diabetics with chronic periodontitis group|non-surgical periodontal treatment was performed
2545171|NCT02596581|Active Comparator|chronic periodontitis group|non-surgical periodontal treatment was performed
2545219|NCT02596347||Beryllium Sensitization (BeS)|Blood draw
2545220|NCT02596347||Chronic Beryllium Disease(CBD)|blood draw BAL
3203566|NCT00925483|Experimental|daily long|daily long (4 hours, 6 times weekly) dialysis for 6 months
2545372|NCT02595307|Experimental|Pamphlet|Participant group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
2545375|NCT02595307|No Intervention|No Pamphlet|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
2545409|NCT02595086|Experimental|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy(LPPG) with D1+ lymphadenectomy is performed (exclude lymph node station No. 5) in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy. Extra-corporeal gastro-gastrostomy should be performed
2545415|NCT02595086|Active Comparator|Laparoscopic DG|"Laparoscopic distal gastrectomy(LDG) with D1+ lymphadenectomy in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.~Anastomosis method (extra-corporeal or intra-) and reconstruction type (Billroth I (gastroduodenostomy), Billroth II, or Roux-en Y gastrojejunostomy) are optional according to the surgeon's preference"
2545457|NCT02594748|Experimental|Experimental group|Intervention is administered to patients in this Arm. The intervention is self-management education based on the theory of planned behavior(TPB). The intervention of experimental group is individual guide and face to face education based on TPB.
2545463|NCT02594748|Active Comparator|Comparison group|The comparison group will receive routine care
2545530|NCT02594449|Active Comparator|low concentration Benzalkonium Chloride|To use low concentration Benzalkonium Chloride Solution to gargle
2545533|NCT02594449|Active Comparator|high concentration Benzalkonium Chloride|To use high concentration Benzalkonium Chloride Solution to gargle
2545535|NCT02594449|Placebo Comparator|Normal Saline|To use Normal Saline to gargle
2545555|NCT02594046|Experimental|stem cell group|stem cell group who apply 1.2 g of allogeneic human adipose derived stem cell component extract on their scalp for 16 weeks
2545557|NCT02594046|Placebo Comparator|placebo group|placebo group who apply a placebo on their scalp for 16 weeks
2545575|NCT02593838|Other|CTP and SPECT-MPI|Every patient enrolled will undergo CT-MPI and SPECT-MPI. The latter is clinically indicated,.
2545644|NCT02593708|Experimental|Cohort 0|"Neratinib: 80 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2545645|NCT02593708|Experimental|Cohort 1|"Neratinib: 120 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2545647|NCT02593708|Experimental|Cohort 2|"Neratinib: 160 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2545649|NCT02593708|Experimental|Cohort 3|"Neratinib: 200 mg, daily, oral~Paclitaxel: 80 mg/m2, weekly, intravenously~Pertuzumab: 840 mg loading dose, 420 mg every 3 weeks, intravenously~Trastuzumab: 4 mg/kg loading dose, 2mg/kg every week, intravenously"
2545731|NCT02593266|Experimental|Intervention Group|weekly sessions of PIP for depression.
2545734|NCT02593266|No Intervention|Waiting list control group|This is treatment as usual.
2545773|NCT02592824|Active Comparator|Intravenous glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
2545775|NCT02592824|Placebo Comparator|Intravenous saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
3203567|NCT00925483|Experimental|daily short|daily short (2 hours 6 times weekly) dialysis for 6 months
2545946|NCT02591836|Experimental|Gemcabene 300 mg|Gemcabene 300 mg QD
2545950|NCT02591836|Experimental|Gemcabene 600 mg|Gemcabene 600 mg QD
2545953|NCT02591836|Experimental|Gemcabene 900 mg|Gemcabene 900 mg QD
2545955|NCT02591836|Placebo Comparator|Placebo|
2545956|NCT02591836|Active Comparator|Atorvastatin 10 mg|
2545957|NCT02591836|Active Comparator|Atorvastatin 40 mg|
2545959|NCT02591836|Active Comparator|Atorvastatin 80 mg|
2545960|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 10 mg|
2545962|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 40 mg|
2545964|NCT02591836|Experimental|Gemcabene 300 mg & Atorvastatin 80 mg|
2545965|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 10 mg|
2545967|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 40 mg|
2545970|NCT02591836|Experimental|Gemcabene 600 mg & Atorvastatin 80 mg|
2545971|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 10 mg|
2545972|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 40 mg|
2545974|NCT02591836|Experimental|Gemcabene 900 mg & Atorvastatin 80 mg|
2546074|NCT02590926||Patients|"patients with stable angina and/or documented ischemia presenting with:~An angiographic stenosis of more than 50% and less than 90% of the left main~Any proximal descending anterior with a stenosis of more than 50% and less than 90%~Two or three vessel disease with a stenosis of more than 50% and less than 90% and a left ventricle ejection fraction less than 40%~Single remaining patent coronary artery with stenosis >50% and less than 90%"
2546102|NCT02590705|Experimental|Group 1|surface anesthesia with lidocaine
2546107|NCT02590705|No Intervention|Group 2|no anesthesia
2546131|NCT02590666|Active Comparator|Microscissors or graspers|Polyps resection with microscissors or graspers
2545203|NCT02596490|Experimental|Phase 1: Couple-Based Mindfulness Disclosure Group|"Phase 1:~Couples participate in 2 guided meditation sessions. During the sessions, participants do deep breathing and visualization exercises then asked to review the exercises. Participants also asked for feedback about the instructions. Participants complete a written review about the program and a questionnaire about their general health and well-being. Each session will last about 60-90 minutes."
2545206|NCT02596490|Experimental|Phase 2: Couple-Based Mindfulness Disclosure Group|"Phase 2:~Participants complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires. After completing the last session, about 4 weeks later, participants complete the same questionnaires again. Participants also complete a program review.~Couples participate in 4 guided meditation sessions with a trained meditation instructor. Participants do deep breathing and visualization exercises. All meditation and discussion sessions videotaped.~Participants continue daily meditation practice and some other short exercises at home."
2545208|NCT02596490|Experimental|Phase 3: Couple-Based Mindfulness Disclosure Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
2545211|NCT02596490|Experimental|Phase 3: Cancer-Related Discussion Program Group|"Participant completes 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.~Participant and partner take part in a discussion program, 1 discussion session each week for 4 weeks with a trained interventionist. These are one-on-one sessions. Issues discussed for couples coping with cancer. Each session will last about 60 minutes."
2545212|NCT02596490|Other|Phase 3: Attention Control (AC) Group|Participant completes 13 questionnaires at baseline and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. It should take about 45 minutes to complete these questionnaires.
2545259|NCT02596061|No Intervention|Control|These participants are made aware of all smoking cessation services offered by the clinic, for example group counseling or individual counseling, but are not offered any rewards for participating in these activities.
2545265|NCT02596061|Experimental|Intervention-Rewards Only|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for completing these activities and for utilizing counseling services at the clinic. At the 2 mo. mark, these participants come to the clinic for a biochemical verification of their smoking status. Their rewards are contingent on successfully passing this verification test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
2545268|NCT02596061|Experimental|Intervention-Pre-Commitment|Patients have access to a website where they can self-report smoking status, add supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. At enrollment, patients are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4 mos. and starts 2 mos. after the rewards contract. If, at the end of 6 mos., the patients pass the second verification test, their rewards are returned to them. At the 2 mo. mark, patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
2545270|NCT02596061|Experimental|Intervention-Commitment|Patients have access to a website where they can self-report smoking status, add virtual supporters, and submit journal entries. Patients receive incentives for these activities and for using clinic counseling services. After 2 mos., this group is offered the chance to set aside some of their rewards towards a deposit contract that lasts for 4 months. If, after the 4 mos., the patients pass the second cessation verification test, their rewards are returned to them. At the 2 mo. mark, these patients come to the clinic for a biochemical verification of their smoking status. Rewards are contingent on passing this test. They are also asked to return to the clinic 6 and 12 mos. after enrollment to complete the smoking tests and are compensated for these 2 visits.
3203568|NCT00925483|Experimental|alternate day conventional|alternate day conventional (4 hours, 3 times weekly) dialysis for 6 months
3203569|NCT00925483|Experimental|alternate day long|alternate day long (8 hours, 3 times weekly) dialysis for 6 months
3203570|NCT00925496||Standard PROMOS prosthesis|Patients receiving a standard PROMOS prosthesis
3203571|NCT00925496||Reverse PROMOS prosthesis|Patients receiving a reverse PROMOS prosthesis
2545499|NCT02594540|Experimental|Feet Mechanical Stimulation|The feet mechanical stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
3203572|NCT00925535|Active Comparator|Treatment A|Lersivirine
3203573|NCT00925535|Active Comparator|Treatment B|Rifabutin
3203574|NCT00925535|Experimental|Treatment C|Lersivirine and Rifabutin
3203575|NCT00925561||No treatment|
3203576|NCT00925613|No Intervention|Control|The double lumen tube is kept until extubation; there is no exchange with any tracheal tube or LMA.
3203577|NCT00925613|Active Comparator|Proseal|The double lumen tube is exchanged with a Proseal (LMA) before emergence according to the study protocol.
3168991|NCT00557713|Experimental|A|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
2545408|NCT02594917||Test Group|The study population will include ten patients (ages 18-60 yrs) with confirmed mutations of the iron-sulfur cluster biogenesis complex of proteins and experiencing dyspnea, heart failure, or exercise intolerance.
2545414|NCT02594917||Control Group|It will also include ten additional patients (ages 18-60 yrs) who are unaffected first-degree family members of the above subjects.
2545471|NCT02594761|Experimental|Treatment A|Hercules: 8 mg/kg i.v. infusion over 90 minutes
2545476|NCT02594761|Active Comparator|Treatment B|Herceptin EU: 8 mg/kg i.v. infusion over 90 minutes
2545482|NCT02594761|Active Comparator|Treatment C|Herceptin US: 8 mg/kg i.v. infusion over 90 minutes
2545509|NCT02594254|Experimental|Study Arm 1|Subjects in Study Arm 1 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush.
2545512|NCT02594254|Experimental|Study Arm 2|Subjects in Study Arm 2 will receive 4 ml of 800 µM study drug administrations for a total of 28 consecutive days. Subjects will receive 4 C16G2 Gel or placebo administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the subjects' home for 27 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
2545517|NCT02594254|Experimental|Study Arm 3|Subjects in open-label Study Arm 3 will receive 4 ml of 1600 µM study drug administrations for a total of 7 consecutive days. Subjects will receive 4 C16G2 Gel administrations at the clinic on the first day, followed by morning (AM) and evening (PM) study drug administrations at the clinic for 6 consecutive days. Study drug will be administered via a manual brush and custom dental trays.
2545522|NCT02594254|Experimental|Study Arm 4|Subjects in open-label Study Arm 4 will receive 4 ml 800 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
2545528|NCT02594254|Experimental|Study Arm 5|Subjects in open-label Study Arm 4 will receive 4 ml of 1600 µM C16G2 Gel on a single day. Subjects will receive 4 study drug administrations at the clinic. Study drug will be administered via manual toothbrush and custom dental trays.
2545531|NCT02594254|Experimental|Study Arm 6|If initiated, subjects in Study Arm 6 will receive 4 ml of 1600 µM study drug over a 7 day study drug administration period. Subjects will receive 4 C16G2 Gel or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
2545534|NCT02594254|Experimental|Study Arm 7|If initiated, subjects in Study Arm 7 will receive 4 ml of 800 µM or 1600 µM study drug on a single day once a week or once a month for a total of 4 days of C16G2 Gel or placebo administration. Subjects will receive 4 study drug administrations on the day of dosing. Study drug will be administered via manual toothbrush and custom dental trays.
2545563|NCT02593877|Experimental|VHA algorithm|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and VHA-guiding further resuscitation with blood products and procoagulant factors
2545564|NCT02593877|No Intervention|Control|Massive transfusion protocol resuscitation aiming at ratio 1:1:1 of blood components (RBC 1: plasma 1: platelets 1) and conventional coagulation tests guiding further resuscitation with blood products and procoagulant factors
2545612|NCT02593734|No Intervention|Control|No intervention
2545618|NCT02593734|Experimental|Experimental|The intervention is prescription and dispensing by a nurse of oral antipsychotic or antidepressant medication as clinically indicated. The mediations to be selected from include oral olanzapine, risperidone, amitryptaline or fluoxetine at doses prescribed by the treating psychiatrist.
2545673|NCT02593513|Experimental|Daifert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2545676|NCT02593513|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2545750|NCT02593227|Experimental|Low dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - single ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2545752|NCT02593227|Experimental|High dose FRα vaccine|FRα peptide vaccine with GM-CSF adjuvant - triple ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2545754|NCT02593227|Experimental|Low dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2545756|NCT02593227|Experimental|High dose FRα vaccine + cyclophosphamide|Cyclophosphamide 300 mg/sqm as a 1 hour IV infusion 3 days prior to first vaccination. Followed by FRα peptide vaccine with GM-CSF adjuvant - ID administration - monthly vaccinations repeated 6 times followed by boosters every 6 months until recurrence
2545830|NCT02592551|Experimental|MEDI4736|8 patients will receive an infusion of MEDI4736 (15 mg/kg intravenously, once), one to six weeks prior to surgical resection.
2545831|NCT02592551|Active Comparator|MEDI4736 + Tremelimumab|8 patients will receive an infusion of MEDI4736 (1500 mg intravenously, once) + tremelimumab (75mg intravenously, once), one to six weeks prior to surgical resection.
2545832|NCT02592551|Placebo Comparator|Untreated arm (control)|4 patients will not receive MEDI4736 or Tremelimumab.
2545910|NCT02591901|Placebo Comparator|Placebo|Placebo identical to main drug in shape and form
2545961|NCT02591602|Experimental|CASI|Teleradiology service for patients residing at home or in nursing homes
2545489|NCT02594800|Experimental|intensive dose|Drug: Rosuvastatin rosuvastatin 20 mg daily for 52 weeks.
2545549|NCT02594267|Experimental|Part 1: Dose Finding, Cohort 1|"Dose finding Phase Intervention: Folotyn (Pralatrexate Injection) CHOP: Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone~The first cohort will begin with three patients with dose A of pralatrexate plus CHOP at full dose.~The second cohort will begin with three patients with dose B of pralatrexate plus CHOP at full dose.~The third cohort will begin with three patients with dose C of pralatrexate plus CHOP at full dose.~The fourth cohort will begin with three patients with dose D of pralatrexate plus CHOP at full dose.~The fifth cohort will begin with three patients with dose E of pralatrexate plus CHOP at full dose.~Part 2: Dose Expansion, Additional ten patients will be enrolled at the MTD or MAD (if the MTD is not reached) plus CHOP at full dose in this part of the study. Blood samples for PK analysis of pralatrexate will be collected at various intervals pre and post pralatrexate injection during cycle 1, Dose 1."
3203578|NCT00925613|Active Comparator|Tracheal tube|The double lumen tube is exchanged with a tracheal tube before emergence according to the study protocol.
3203579|NCT00925626|Experimental|Sub - Vastus arthrotomy|Sub-vastus arthrotomy
2545674|NCT02593500|Experimental|Pulmictan+Test (Treatment Sequence AB)|"Treatment period 1:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs)per treatment period under fasting conditions.~Treatment period 2:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) per treatment period under fasting conditions."
2545677|NCT02593500|Experimental|Test+Pulmictan (treatment sequence BA)|"Treatment period 1:~Budesonide 200 µg (test product (B)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions.~Treatment period 2:~Budesonide 200 µg (Budesonida Pulmictan® 200 µg: reference product (A)). Pressurized inhalation suspension. Single dose of 600 µg (3 puffs) under fasting conditions."
2545717|NCT02593175|Experimental|Treatment (panitumumab, paclitaxel, carboplatin)|Patients receive panitumumab IV over 30 minutes and paclitaxel IV over 30 minutes on days 1, 8, and 15. Patients also receive carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
2545799|NCT02592603|Active Comparator|Endocuff-assisted Colonoscopy|Endocuff-assisted Colonoscopy with the ARC Endocuff-vision® attached at the distal tip of the scope.
2545800|NCT02592603|No Intervention|Standard Colonoscopy|Standard Colonoscopy without any additional device
2545845|NCT02592382|Placebo Comparator|Isotonic saline spray|Isotonic saline (0.9% of NACL) given as nasal spray 3 times a day ( one puff for each nostril) for a two months period
2545852|NCT02592382|Experimental|Xylitol spray|Solid Xylitol diluted in normal saline(0.9% NACL) to a concentration of 5%. given as a nasal spray 3 times a day(one puff for each nostril) for two months period
2545883|NCT02592083|Active Comparator|A: Endocrine treatment|Pre- or perimenopausal women are treated with tamoxifen, alternatively with an LHRH analogue in combination with an aromatase inhibitor (only women); postmenopausal women receive an aromatase inhibitor. The preoperative treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2545885|NCT02592083|Experimental|B: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, provided that re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2545888|NCT02592083|Experimental|C: Endocrine treatment + palbociclib|Patients receive the same endocrine treatment as in arm A together with palbociclib 125 mg orally days 1-21, followed by a 7-days rest period. The combined treatment is continued for further 12 weeks, if re-evaluation after 6 weeks, week 10 of the preoperative treatment, does not indicate progression. Upon progression (PD), individualized management, preferentially surgery, is the primary option
2545929|NCT02591693|Experimental|Caregiver Training|"Three home visits by a specialist occupational therapist, each lasting 1-2 hours. Assessment and training to confidently achieve up to three goals relating to practical activities of daily living identified by patient and caregiver.~On-going usual care from multi-professional team at hospice."
2545932|NCT02591693|No Intervention|Usual Care|On-going usual care from multi-professional team at hospice.
2546002|NCT02591459|Other|Autism|Using the app to assist routine anticipation for autistic children in Android mobile devices
3203580|NCT00925626|Active Comparator|Mid-Vastus arthrotomy|Mid-vastus arthrotomy
2546165|NCT02590237|Active Comparator|Direct Laryngoscopy|The trachea will be intubated via direct laryngoscopy using a traditional straight blade (Miller) laryngoscope.
2546166|NCT02590237|Experimental|KingVision Video Laryngoscope|The trachea will be intubated using the Ambu KingVision Video Laryngoscope size 1 pediatric blade.
2546219|NCT02589925|Sham Comparator|sham stimulation|ineffective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
2546221|NCT02589925|Active Comparator|NBM stimulation|effective neurostimulation of the Nucleus basalis Meynert combined with subthalamic nucleus (STN) stimulation using Vercise deep brain stimulation
2546262|NCT02589496|Experimental|pembrolizumab|"Cohort A :gastric cancer patients Cohort B : MSI-H gastric cancer patients All Chort receive the following treatment.~Pembrolizumab 200 mg every 3 weeks"
2546329|NCT02589236|Placebo Comparator|Placebo|Placebo Capsule
2546330|NCT02589236|Experimental|Cavosonstat (N91115) 200 mg|Cavosonstat (N91115) 200 mg twice daily (BID)
2546331|NCT02589236|Experimental|Cavosonstat (N91115) 400 mg|Cavosonstat (N91115) 400 mg BID
2546390|NCT02588456|Experimental|Single Arm|
3203581|NCT00925639|Experimental|Isoflavone|Patients will receive daily doses of 150 mg of concentrated extract of soy per os
3203582|NCT00925639|Placebo Comparator|Control|Patients will receive daily placebo pills
3203583|NCT00925652|Experimental|1. Diet Intervention Arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
3168993|NCT00557739|Experimental|1|CRx-191 (0.1% mometasone furoate + 0.05% nortriptyline HCl)
2545570|NCT02594020|Other|dental bur versus air abrasion|1 tooth prepared with air abrasion versus one prepared tooth with dental bur
2545573|NCT02594020|Other|sono abrasion versus dental bur|1 tooth prepared with sono abrasion ans 1 tooth prepared with dental bur
2545577|NCT02594020|Other|air abrasion versus sono abrasion|1 tooth prepared with air abrasion versus 1 tooth prepared with sono abrasion
2545703|NCT02593344|Experimental|endopat|measure of endothelial function with endopat
2545716|NCT02592993|Experimental|PicoWay treatment to all subjects|Subjects in this study will receive up to six (6) treatments in 3-8 weeks interval, with the PicoWay device-fractional handpiece 532nm and/or 1064nm according to the study protocol. Subjects will be followed by phone 7 days post first treatment by study staff, and will return for two follow-up (FU) visits at the clinic at: 6 weeks and 12 weeks following the last treatment.
2545776|NCT02592902|Active Comparator|Recurrent respiratory papillomatosis|Patients with recurrent respiratory papillomatosis (RRP) - surgical collection of histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin, HPV 6 and 11, herpes simplex virus (HSV) type 2, chlamydia trachomasis, and assessment of the dysplasia.
2545778|NCT02592902|Active Comparator|Laryngeal cyst - control group|Patients with laryngeal cyst - surgical collection of a histology specimen from the vocal cords and rear laryngeal commissure, performance of immunohistochemical analysis - proof of pepsin and HPV 6 and 11, herpes simplex virus (HSV) type 2 and chlamydia trachomasis.
3168994|NCT00557739|Experimental|2|CRx-191 (0.1% mometasone furoate + 0.1% nortriptyline HCl)
3168995|NCT00557739|Active Comparator|3|0.1% mometasone furoate
2545918|NCT02591823||Healthy Controls|Healthy subject who accompanying patients to rheumatology OPD or healthy subjects who are staff at Columbia Asia Hospital,Bangalore.
2545921|NCT02591823||Cases (patients on methotrexate)|Subjects attending the rheumatology OPD of Columbia Asia hospitals bengaluru, who are diagnosed as having Rheumatoid arthritis and fulfill the ACR/ EULAR 2010 classification criteria for rheumatoid arthritis and are started on low dose methotrexate will included as cases
2545998|NCT02591485|Experimental|Attention Control Training|Computerized attention modification training, comprised of six sessions that delivered by internet, in purpose of modulate biases in attention for threat stimuli.
2546005|NCT02591485|No Intervention|Follow-up only|In this condition, a follow-up interviews will be conducted 3 months since the traumatic event had occurred.
2546060|NCT02591043|Other|Follow-up|Patients have not received a structured follow up examination or evaluation of outcome after surgery. Therefore this study aims at conducting a follow up examination regarding functional outcome, pain and radiologic healing in these patients.
2546091|NCT02590653|Experimental|Group A|Group A patients will start atorvastatin at a dose of 80 mg/day between 24 and 96 hours after the onset of STEMI
2546093|NCT02590653|Active Comparator|Group K|Group K patients will start atorvastatin at a dose of 20 mg/day between 24 and 96 hours after the onset of STEMI
3168996|NCT00557739|Active Comparator|4|0.05% nortriptyline HCl
3168997|NCT00557739|Active Comparator|5|0.1% nortriptyline HCl
2546192|NCT02590029|Experimental|Mindfulness|15 minute mindfulness session
2546195|NCT02590029|Experimental|Suggestion|15 minute therapeutic suggestion session
2546197|NCT02590029|Active Comparator|Psychoeducation|15 minute psychoeducation session
2546237|NCT02589756|Experimental|The fatty fish group|Participants will eat fatty fish and avoiding nuts)
2546239|NCT02589756|Experimental|The nut group|Participants who will avoid fatty fish
2546240|NCT02589756|Placebo Comparator|The control group|Participants who will avoid both fatty fish and nuts
2546249|NCT02589431||Patients with severe sepsis|
2546250|NCT02589431||Controls|Healthy subjects
2546347|NCT02589327|Experimental|Exercise Intervention|Hight intensity resistance training group
2546348|NCT02589327|No Intervention|Control|No-exercise control group
2546413|NCT02588690||Women participating in screening|Community screening project targets women of color and/or low income women over 21 years of age in economically and ethnically diverse greater Los Angeles community. Women will be risk stratified based on ASCVD risk calculation and if labeled high risk will be referred to physician services. In 1 year, women will have their ASCVD re-risk stratify to see if seeing a physician/ health care provider reduced overall ASCVD risk scores.
2546470|NCT02588131|Experimental|tremelimumab plus MEDI4736|Tremelimumab in combination with MEDI4736
2546621|NCT02586961|Placebo Comparator|0.9% saline solution - oral betamethasone placebo|Control arm: 0.9% saline solution - oral betamethasone placebo
3168998|NCT00557739|Placebo Comparator|6|Vehicle (placebo)
3168999|NCT00557752|Active Comparator|1|Addition to the standard therapy of non-invasive mechanical ventilation. Continuously for the first 24 hours, then trials to discontinuation every 24 hours. Interface adjusted for the associated injuries.
3169000|NCT00557752|No Intervention|2|Standard therapy for severe post-traumatic hypoxia: pain control with epidural anesthesia and oxygen.
3169001|NCT00557778||1|Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
3169002|NCT00557778||Group 2|Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.
3169003|NCT00557791|Active Comparator|A|Lucentis® (0.5 mg) every 4 weeks.
3169004|NCT00557791|Experimental|B|Bevasiranib (1.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3169005|NCT00557791|Experimental|C|Bevasiranib (2.0 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3169006|NCT00557791|Experimental|D|Bevasiranib (2.5 mg) every 8 weeks beginning at week 12, after pre-treatment with 3 injections of Lucentis® and initial priming doses of bevasiranib at weeks 2 & 6.
3169007|NCT00557817|No Intervention|1|No medication given
3169008|NCT00557817|Active Comparator|2|Aranesp 300 µg/15 days
3169009|NCT00557817|Active Comparator|3|Aranesp 300 µg/15 days. Venofer 200 mg on days 28, 42, and 56 after the transplant.
2545495|NCT02594527|Experimental|Volunteer-led physical activity sessions|Patient will receive volunteer-led physical activity sessions twice a day during admission.
2545542|NCT02594189|Other|1|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
2545582|NCT02593968|Experimental|Treatment|subject were treated 3 periods with Yallaferon®; each period has interval 10 days ; one period included Yallaferon application for every other day for 10 times
2545587|NCT02593968|Placebo Comparator|Plcaebo|subject were treated 3 periods with Yallaferon® Plcaebo; each period has interval 10 days; one period included Yallaferon application for every other day for 10 times
2545641|NCT02593656|Experimental|High Protein|Ingestion of 2.0 grams of protein per kilogram of body weight per day combined with exercise training
2545643|NCT02593656|Active Comparator|Normal Protein|Ingestion of 1.0 gram of protein per kilogram of body weight per day combined with exercise training
2545685|NCT02593435||No treatment|There will be two groups, one is breast cancer patient group, another group inlude the first-degree relatives and second degree relatives of patients with BRCA1/2 mutation. All volunteers should provid tissue(s) and blood for NGS test.
2545709|NCT02593162|Experimental|Group 1|12 weeks of Faldaprevir plus low dose TD-6450 plus Ribavirin
2545712|NCT02593162|Experimental|Group 2|12 weeks of Faldaprevir plus high dose TD-6450 plus Ribavirin
2545784|NCT02592785|Experimental|BAY1163877|Cohort 1: Safety, tolerability and PK of 600 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 21 days after start of study treatment Cohort 2: Safety, tolerability and PK of 800 mg dose given twice daily
2545851|NCT02592512||NIV-NAVA|4 hour NIV-NAVA, followed by 4 hour NIV-PS/PC
2545857|NCT02592512||NIV-PS/PC|4 hour NIV-PS/PC, followed by 4 hour NIV-NAVA
2545893|NCT02591966||Biomarker group|"The patients who receive neoadjuvant systemic treatments:~The patients who have distant metastatic sites at first and recur from surgery:~The patients who are going to receive first-line chemotherapy:"
2545949|NCT02591784|Experimental|Nimotuzumab group|Nimotuzumab+radiotherapy
2545991|NCT02591277||Harvoni|Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.
2546135|NCT02590367|Experimental|FOLFOX regimen&HD6610 Granule|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the HD6610 Granule will be given 2 times a day.
2546136|NCT02590367|Placebo Comparator|FOLFOX regimen&HD6610 Granule placebo|Patients in this group will be given conventional oxaliplatin based chemotherapy recommended by treatment guidelines for colorectal cancer, and the placebo HD6610 Granule
2546193|NCT02590055|Experimental|Intervention arm|D1, 8 Gemcitabine 1000mg/m2 IV over 30 minutes D1, 8 Docetaxel 35mg/m2 IV over 1hr
2546225|NCT02589782|Experimental|Regimen 1|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated
2546227|NCT02589782|Experimental|Regimen 2|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks
2546231|NCT02589782|Experimental|Regimen 3|Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)
2546232|NCT02589782|Active Comparator|Control Regimen|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
2546292|NCT02589366|Experimental|Lymphoseek plus Vital Blue Dye|Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
3203584|NCT00925652|Experimental|2. Diet and exericise intervention arm|The dietary intervention will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber. Patients randomized to the diet and exercise groups will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
2546408|NCT02588677|Experimental|Masitinib (3.0) & Riluzole|masitinib 3 mg/kg/day + riluzole
2546414|NCT02588677|Experimental|Masitinib (4.5) & Riluzole|masitinib 4.5 mg/kg/day (2) + riluzole
2546418|NCT02588677|Placebo Comparator|Placebo & Riluzole|Matched placebo
2546491|NCT02588027|Active Comparator|Control|Ibuprofen 400mg by mouth three times daily. Patients will also receive the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
2546494|NCT02588027|Placebo Comparator|Placebo|Placebo tablet by mouth three times daily. Patients will also received the standard opiate medication (hydrocodone/acetaminophen 10mg/325mg) for the UCSF orthopaedic clinic for postoperative pain control.
2546549|NCT02587572|Experimental|LMSCs 10 million IV|A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.
2546554|NCT02587572|Placebo Comparator|Placebo (Plasmalyte A,HSA) IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.
2546559|NCT02587572|Experimental|LMSCs 20 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.
2546562|NCT02587572|Experimental|LMSCs100 million IV|10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.
2546731|NCT02586363|Active Comparator|Baraclude Tab. 0.5mg, fasting|Single dose Baraclude Tab. 0.5mg, fasting state
2546735|NCT02586363|Experimental|Cavir Tab. 0.5mg, fasting|Single dose Cavir Tab. 0.5mg, fasting state
2546740|NCT02586363|Experimental|Cavir Tab. 0.5mg, high fatty meal|Single dose Cavir Tab. 0.5mg, high fatty meal
2545501|NCT02594540|Sham Comparator|Sham Feet Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland). Intervention: Device: Foot Mechanical Stimulation (GONDOLA)
3203585|NCT00925652|Experimental|3. Bevicizumab, CM, and diet intervention|Participants will receive Bevacizumab treatment, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber.
3203586|NCT00925652|Experimental|4. Bevacizumab, CM, diet and exercise|Participants will receive bevacizumab, cyclophosphamide and methotrexate treatment and well as the dietary intervention that will focus on the Food Pyramid, emphasizing diet that is low in fat and high in fruits, vegetables and fiber and will also have a target physical activity goal of 180 minutes of moderate-intensity activity each week.
2545730|NCT02592954|Experimental|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
2545733|NCT02592954|Placebo Comparator|Jojoba oil|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
2545765|NCT02592863|Experimental|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
2545766|NCT02592863|Placebo Comparator|Placebo|Patients will take placebo 3 times per day for 12 weeks
3203587|NCT00925665||Glidescope|Patients intubated with the Glidescope technique
3203588|NCT00925665||Macintosh|Patients intubated via the conventional direct laryngoscopy with a Macintosh laryngoscope
3203589|NCT00925678|Experimental|1|
2545873|NCT02592213|Experimental|Treatment|Treatment of lymphedema with cell-assisted lipotransfer using autologous stromal vascular fraction
2545886|NCT02591992|Active Comparator|Cardiac CT|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo computed tomography angiography (cardiac CT) as the first-choice imaging diagnostics
2545891|NCT02591992|Active Comparator|Invasive coronary angiography|60 patients with high pre-test probability o coronary artery disease will be randomly chosen and undergo invasive coronary angiography
2545980|NCT02591524|Experimental|Cystic fibrosis airway colonization|Flexible bronchoscopy via the nasal route on the date of baseline visit, nasal lavage at baseline and after 6 month
2546043|NCT02591186|Experimental|Acupuncture arm|Participants receiving acupuncture during IVF process
2546048|NCT02591186|No Intervention|Control|Control arm not receiving acupuncture during IVF process
2546079|NCT02590718|Experimental|Group 1|optimized postoperative management(lying without the pillow for half an hour after lumbar puncture)
2546080|NCT02590718|No Intervention|Group 2|traditional postoperative management(lying without the pillow and fasting water and food for four hours after lumbar puncture)
2546132|NCT02590471|Active Comparator|Stenting of the femoral artery.|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted.
2546133|NCT02590471|Experimental|Stenting of the femoral artery and fasciotomy.|Under local anesthesia standard endovascular exposure is made and lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent of all the extension is mounted. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
2546252|NCT02589691|Experimental|Rocuronium|Intra-venous injection during induction anesthesia of 0.3 mg/kg (1 mL/kg) of rocuronium
2546253|NCT02589691|Placebo Comparator|Placebo|Intra-venous injection during induction anesthesia of 1 mL/kg of sodium chloride 0.9%
2546326|NCT02589275|Experimental|TNX-102 SL Tablet 2.8 mg|1x TNX-102 SL 2.8 mg sublingual tablet taken daily at bedtime for 3 months
2546409|NCT02588625|Experimental|Part A - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
2546416|NCT02588625|Experimental|Part B - BMS-986020|BMS-986020 or Placebo tablets specified dose on specified days
2546466|NCT02587936|Experimental|Collaborative model|Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator
2546467|NCT02587936|No Intervention|Standard Care|Group to receive regular care
2546595|NCT02587741|Experimental|oral drugs|oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid
3203590|NCT00925678|Placebo Comparator|2|
2545520|NCT02594280||Trabecular stent bypass microsurgery|Monitor glaucoma patients that are scheduled to be treated with trabecular stent bypass microsurgery with VEP/PERG.The treatment is not dependent on the study.
2545565|NCT02594150|No Intervention|usual care|Each FIT kit will include a tube in which to deposit the stool sample, directions on how to collect and mail the sample, a letter about colorectal cancer screening, a Labcorp requisition form, and a pre-paid return envelope.
2545566|NCT02594150|Experimental|unconditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will also receive a financial incentive in the form of a gift card and a note explaining that this gift card is a token of our appreciation for completing the kit.
2545567|NCT02594150|Experimental|conditional fixed incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
2545569|NCT02594150|Experimental|conditional lottery incentive|This arm will receive a FIT kit as described in the mailed FIT arm and will receive a note stating that they will be entered in a 1/10 chance lottery to receive a financial incentive in the form of a gift card if they return their completed FIT within two months of receiving the FIT kit.
2545646|NCT02593695|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
2545648|NCT02593695|Active Comparator|Standard Control|Fluoxetine
2545682|NCT02593422|Experimental|Expressive Writing|Writing about ovarian cancer: Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
2545686|NCT02593422|Active Comparator|Fact Writing (Control)|Writing about ovarian cancer: Participants will be asked to write about the facts of their experience with ovarian cancer
3169010|NCT00557843|Active Comparator|bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
3169011|NCT00557843|Placebo Comparator|Placebo|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
2545803|NCT02592694|Experimental|Cocktail with thrombus aspiration|Intracoronary cocktail (tirofiban, bivalirudin, tenecteplase) injection combined with thrombus aspiration
2545804|NCT02592694|Active Comparator|Thrombus aspiration|Thrombus aspiration alone
2545902|NCT02592057||SOF-based regimens|Adults with chronic HCV infection in India who are being treated with a SOF-based treatment regimen as per the approved prescribing information.
2545917|NCT02591563||Healthy children|6-36 months of age who will have the following study procedures: Venipuncture, Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis
2545996|NCT02591498|Active Comparator|Auditory|Administration of 40 hours of auditory training exercises
2546003|NCT02591498|Active Comparator|Visual|Administration of 40 hours of visual training exercises
2546007|NCT02591498|Placebo Comparator|Video Games|Administration of 40 hours of commercial video games
2546066|NCT02591004|Experimental|Magesium sulphate|"Patients in group A will receive Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first).~Doppler on fetal middle cerebral artery"
2546069|NCT02591004|Active Comparator|Nifedipine|"Patients in group B will receive Nifedipine ( Epilat 10mg ® EIPICO Egypt ), as there is no recommended dose for the use of nifedipine as neuroprotectant, the dose given in this study will be same as that used for tocolysis. Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses.~Doppler on fetal middle cerebral artery"
2546096|NCT02590497|Experimental|Diagnostic (MRI, tumor tissue analysis)|Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
2546184|NCT02590042|Experimental|ADSC-SVF-002|Cells will be administered at 1x10^6 cells/mL of defect. If administered with fat, the cells will be administered at 1.2x10^6 cells/mL of defect.
3203591|NCT00925691|Active Comparator|APICAL|implantation at the apex
2546281|NCT02589470|Experimental|COMETE|patients will attend a specific rehabilitation programme of memory
2546288|NCT02589470|No Intervention|CONTROL|the control group where patients will benefit from a standard treatment
2546317|NCT02589197||Group 1 (Medial-Pivot)|Group 1 will be implanted with the EVOLUTION® MP System with Cruciate Sacrificing (CS) tibial inserts.
2546324|NCT02589197||Group 2 (Posterior-Stabilized)|Group 2 will be implanted with the Zimmer® NexGen® PS TKA system.
2546327|NCT02589197||Group 3 (Control Group)|Non-implanted control subjects
2546373|NCT02588768|Active Comparator|Active PBMT|Active PBMT was applied employing MR4 Laser Therapy Systems outfitted with LaserShower 50 4D emitters (both manufactured by Multi Radiance Medical, Solon - OH, USA). The cluster style emitter contains 12 diodes comprising of four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode).
2546375|NCT02588768|Placebo Comparator|Placebo PBMT|Placebo PBMT was applied using the same device that emitted the same sounds and light, but with no effective irradiation.
2546452|NCT02588287|Experimental|Tenofovir PK before and after SOF/LDV|
2546609|NCT02587208|Active Comparator|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
2546623|NCT02586961|Experimental|adrenaline - oral betamethasone|Experimental arm : adrenaline and betamethasone
3169012|NCT00557908||VWF/FVIII product infusions|One to three infusions of factor replacement as needed to control bleeding.
3169013|NCT00557921|Experimental|1|
3169014|NCT00557921|Active Comparator|2|
3169015|NCT00557934|Experimental|1|
2545525|NCT02594462|Other|ENG-group|"Twenty-five women with homozygous sickle cell anemia (hemoglobin SS), aged between 18-40 years-old, who had at least one episode of sickle cell pain crisis in the last three months pre- enrollment; whom desire to use etonogestrel-releasing implant contraceptive without contraindications will be invited to inserted etonogestrel implant.~Etonogestrel implant is a single implant progestogen-only, with 4 cm in length and 2 mm diameter containing 68 mg etonogestrel (3- ketodesogestrel), the active metabolite of desogestrel, involved in a ethylene vinyl acetate membrane (Huber, 1998), which is released continuously in bloodstream for three years. It will be inserted subdermal, on the inner face of non-dominant arm between the first and seventh day of the menstrual cycle."
2545584|NCT02594085|Experimental|Patch 3/Patch4 + Patch1/patch2 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 1 and Patch 2 Test period 3: Patch 5 and Patch 6"
2545588|NCT02594085|Experimental|Patch 1/Patch2 + Patch3/patch4 + patch 5/patch 6|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2545590|NCT02594085|Experimental|Patch 1/Patch2 + Patch5/patch 6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2545591|NCT02594085|Experimental|Patch 3/Patch4 + Patch5/patch6 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 3 and Patch 4 Test period 2: Patch 5 and Patch 6 Test period 3: Patch 1 and Patch 2"
2545592|NCT02594085|Experimental|Patch 5/Patch 6 + Patch 3/patch 4 + patch 1/patch 2|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 5 and Patch 6 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 1 and Patch 2"
2545595|NCT02594085|Experimental|Patch 5/Patch 6 + Patch1/patch2 + patch 3/patch 4|"The subjects test 6 adhesive strips; two in each test period. The patches are tested in pairs i.e Patch 1 and patch 2 are a pair; Patch 3 and Patch 4 are a piar and patch 5 and patch 6 are a pair. The test order of the patch pairs is randomised between the three periods.~In this arm the the subjects test:~Test period 1: Patch 1 and Patch 2 Test period 2: Patch 3 and Patch 4 Test period 3: Patch 5 and Patch 6"
2545700|NCT02593331|Placebo Comparator|Placebo|Participants will receive placebo matching to BFKB8488A.
2545701|NCT02593331|Experimental|BFKB8488A SC|Participants will receive single ascending SC dose of BFKB8488A in each dose escalation cohort.
2545702|NCT02593331|Experimental|BFKB8488A IV|Participants will receive single IV dose of BFKB8488A.
2545920|NCT02591810|Active Comparator|Serial Casting|Participants will receive the intervention of the placement of serial casting/splinting for the injured wrist. This is not a surgical intervention.
2545924|NCT02591810|Active Comparator|Kirschner wires|Participants will receive the intervention of percutaneous fixation with Kirschner wires for the injured wrist. This will be performed surgically.
2545927|NCT02591810|Active Comparator|Foveal repair|Participants will receive the intervention of open anatomic foveal repair of the ligaments of the injured wrist. This is a surgical intervention.
2546010|NCT02591251|Active Comparator|The povidone-iodine group|The patients will be subjected to povidone-iodine (Betadine7.5%, Phama Care) for vaginal cleaning before the laparoscopic surgery
2546012|NCT02591251|Active Comparator|Normal saline group|The patients will be subjected to normal saline solution (Sod. Chloride 0.9%, Nile) for vaginal cleaning before the laparoscopic surgery.
2546051|NCT02591017|Other|morphine drops solo and placebo spray|"morphine 2% drops~daily fixed dose of morphine equivalents < 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards~daily fixed dose of morphine equivalents =/> 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards"
2546052|NCT02591017|Other|ketamine/chitosan spray nasal and placebo drops|5 mg ketamine all 5 minutes, maximal 4 times an hour
2546054|NCT02591017|Other|morphine drops and ketamine/chitosan spray nasal|see above
2546115|NCT02590575|Other|CO2 removal|
2546150|NCT02590263|Experimental|Arm A of Phase 1 portion|ABT-414 administered every other weeks monotherapy
2546151|NCT02590263|Experimental|Phase 2 portion|ABT-414 administered every other weeks in combination with temozolomide
2546152|NCT02590263|Experimental|Arm C of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
2546153|NCT02590263|Experimental|Arm B of Phase 1 portion|ABT-414 administered every other weeks in combination with radiation and temozolomide
2546207|NCT02589873|Active Comparator|In-Person Diabetes Prevention Program|An in-person group delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by the Young Men's Christian Association (YMCA). This group receives lifestyle coaching in a group setting, meeting weekly for 16 weeks followed by 3 biweekly sessions, and 5 monthly maintenance sessions.
2546209|NCT02589873|Active Comparator|Online Diabetes Prevention Program|An online delivery modality of a CDC recognized Diabetes Prevention Program (DPP), delivered by Canary Health's Virtual Lifestyle Management program. This group completes online learning sessions weekly for 16 weeks followed by 8 monthly maintenance sessions.
2546283|NCT02589561|Active Comparator|face to face fitting|face to face fitting of hearing aids
2546287|NCT02589561|Experimental|remote fitting|remote fitting of hearing aids
2546308|NCT02589119|Other|MSC-AFP|Single Treatment Group
2545536|NCT02594371|Experimental|Oraxol (paclitaxel + HM30181AK-US)|"Oraxol paclitaxel - supplied as 30-mg capsules~Oraxol HM30181 methansulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets"
2545539|NCT02594371|Active Comparator|IV paclitaxel|IV paclitaxel - supplied as Taxol or generic
2545571|NCT02593786|Experimental|Nivolumab monotherapy|Nivolumab specified dose on specified days
2545576|NCT02593786|Experimental|Cohort Expansion|Nivolumab specified dose on specified days
3203592|NCT00925691|Experimental|SEPTAL|implantation at the interventricular septum
3203593|NCT00925717||2500 patients|Who have records of clinic visit with endocrine internal medicines of nationwide secondary/tertiary hospitals within the last six months.
2545723|NCT02593045|Experimental|IPH4102|
2545790|NCT02592889|No Intervention|CONTROL|OPTIMIZED MEDICAL TREATMENT
2545794|NCT02592889|Active Comparator|DEVICE|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM + OPTIMIZED MEDICAL TREATMENT
2545861|NCT02592460|Experimental|poor-polyamines diet|
2545867|NCT02592460|Active Comparator|high-polyamines diet|
3203594|NCT00925730|Experimental|Pimecrolimus cream 1%|Pimecrolimus
3203595|NCT00925743|Experimental|1|"5, 15, 20 or 25 mg/m2~one injection of cabazitaxel on day 1 of each cycle (3 weeks)"
3203596|NCT00925795|Active Comparator|Group A (1. EVOO; 2. ROO)|
2546075|NCT02590887|Experimental|drink manufactured from lupine peptides|"Beverage drink containing 0.5mg/ml of protein hydrolysate extracted from food grade lupine flour. The drink will be formulated as 200 mL tetra brik subjected to a test of microbiological safety according to the Spanish law (RD 135/2010 of 12 February 2010).~The final beverage shall consist of:~Oily phase: refined sunflower oil 5% w/w of the emulsion~Aqueous phase (water) 95% w/w of the emulsion, containing equal volumes of solution A and B:~Solution A:~Hydrolyzed Lupine (1.17% w/w)~Sucrose (14.03% w/w)~Vanilla flavor (0.42% w/w)~Drinking water (84.38% w/v)~Solution B:~Xanthan gum (0.28% w/w)~Drinking water (99.72% w/v)~The samples will guard and kept by the investigator until the day of delivery to the volunteers.~The duration of treatment 4 weeks, during which the volunteers daily consume the contents of a tetra brik."
2546105|NCT02590523|Experimental|A: Vancomycin|Intracameral vancomycin injection given at conclusion of cataract case
2546108|NCT02590523|Experimental|B: Moxifloxacin|Intracameral moxifloxacin injection given at conclusion of cataract case
2546110|NCT02590523|Placebo Comparator|C: Placebo|Intracameral placebo injection with BSS given at conclusion of cataract case
2546177|NCT02590250||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
2546241|NCT02589730|Experimental|online mutual management|The patients received the online coaching of a doctor and diabetes educator via smart phone based welltang app.
2546242|NCT02589730|Experimental|online self-management|The patients received the online coaching of a doctor alone via smart phone based welltang app.
2546244|NCT02589730|No Intervention|hospital regular management|The patients received usual care and did not use smart phone.
2546282|NCT02589392|Experimental|Moisturizer + Body wash|Cetaphil® Restoraderm® moisturizer (2/day) + Cetaphil® Restoraderm® Skin body wash (1/day)
2546286|NCT02589392|Active Comparator|Body wash|Cetaphil® Restoraderm® body wash (1/day)
2546323|NCT02589080|Experimental|Non-invasive sensory feedback|
3203597|NCT00925795|Active Comparator|Group B (1. ROO; 2. EVOO)|
3203598|NCT00925808||Unsuspected VTE|Prevalence of unsuspected VTE in oncology patients on routine staging CT scans of the thorax, abdomen and pelvis
2546435|NCT02588365|Experimental|Brain Training (Active)|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
2546436|NCT02588365|Experimental|Brain Training (Passive)|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent level."
2546438|NCT02588365|Experimental|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
2546473|NCT02588014||Schizophrenia|Individuals with schizophrenia
2546477|NCT02588014||Control|Neurotypical individuals
2546610|NCT02587195|Experimental|Teriflunomide|Teriflunomide 14 mg Once Daily
2546645|NCT02586792|Experimental|Group 2|N up to 10 in prior receipt of a placebo in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
2546647|NCT02586792|Experimental|Group 1|N up to 40 in prior receipt of a monovalent inactivated influenza A/H7N7 virus vaccine in DMID Protocol 07-0023 will receive 45 mcg of HA/0.75 ml of Monovalent inactivated influenza A/H7N9 virus vaccine
2546694|NCT02586571||Exclusive Breastfeeding A|Mother/infant pairs with exclusive breastfeeding up to 6 months of age. Secondary outcome measure 2 (Metabolisable energy content of breast milk) measured in this group only.
2546696|NCT02586571||Exclusive Breastfeeding B|Mother/infant pairs with exclusive breastfeeding up to 6 months of age.
2546699|NCT02586571||Partial Breastfeeding|Mother/infant pairs with partial breastfeeding along with complementary foods at 6 months of age.
2546734|NCT02586350|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
2547312|NCT02582801|Experimental|breast cancer|Perform 18F-Alfatide Ⅱ PET/CT in breast cancer patients
3203599|NCT00925821|Experimental|Allogeneic stem cell transplant|Second scheduled transplantation performed from an HLA-matched MRD or MUD after conditioning with treosulfan and fludarabine
3203600|NCT00925821|Active Comparator|High-dose melphalan chemotherapy|Second high-dose melphalan therapy followed by transplantation of peripheral blood stem cells
3203601|NCT00925834|Placebo Comparator|Sodium chloride|"Control arm A: Hidden intracoronary infusion of 5ml sodium chloride"
2545546|NCT02594332|Experimental|Placebo|Amount of Placebo corresponding to mepolizumab dose SC every 4 weeks for 13 injections
2545602|NCT02593929|Experimental|ruxolitinib|Ruxolitinib will be taken orally for 14-21 days prior to surgery, every morning and every evening, and will be discontinued after the morning dose on the day of planned surgical resection.
2545653|NCT02593617|Other|University students who use alcohol|In Addiction Profile Index, university students who use alcohol in last year.
2545654|NCT02593617|Other|University students who don't use alcohol|In Addiction Profile Index, university students who don't use alcohol in last year.
2545655|NCT02593617|Other|University students who use energy drinks|In energy drink consumption questionnaire, university students who use energy drinks in last year.
2545656|NCT02593617|Other|University students who don't use energy drinks|In energy drink consumption questionnaire, university students who don't use energy drinks in last year.
2545657|NCT02593617|Other|University students who use substance|In Addiction Profile Index, university students who use substance in last year.
2545658|NCT02593617|Other|University students who don't use substance|In Addiction Profile Index, university students who don't use substance in last year.
2545722|NCT02593058|Experimental|PEPS+TAU|Eight one-hour weekly sessions of Positive Emotions Program for Schizophrenia (PEPS) + Treatment as Usual (TAU)
2545729|NCT02593058|Active Comparator|Treatment As Usual (TAU)|Treatment as usual - with no attempts to standardize this treatment as TAU is tailored to the patient's specific needs
2545767|NCT02592772|Experimental|Reduced Nicotine Non-Menthol (RNC)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine non menthol cigarettes (RNC: NRC 200; 0.07 mg nicotine yield cigarettes without menthol) during the 6 week experimental phase.
2545768|NCT02592772|Experimental|Reduced Nicotine Menthol (RNC-Men)|Study participants will be randomized from their own brand of menthol cigarettes to the reduced nicotine menthol cigarettes (RNC-Men: NRC 201; 0.07 mg reduced nicotine content menthol cigarettes) during the 6 week experimental phase.
2545769|NCT02592772|Experimental|Conventional Nicotine Non-Menthol (CN)|Study participants will be randomized from their own brand of menthol cigarettes to the regular/conventional nicotine non menthol cigarettes (CN: NRC 600; 0.8 mg nicotine content) during the 6 week experimental phase.
2545813|NCT02592577|Experimental|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
2545836|NCT02592226|Active Comparator|Control group|
2545837|NCT02592226|Experimental|Protocol Group|
2545881|NCT02592148||Health subjects|Male and female
2545892|NCT02591940||Aortic Coarctation|interventional treatment in heart catheter (stenting/angioplasty) surgical repair of coarctation
2545894|NCT02591940||Aortic Valve Disease|surgical repair in aortic valve disease (reconstruction/valve replacement)
2545916|NCT02591758||Stable Angina with coronary angiogram|This study aims to correlate the biometric data collected and derived from the Hexoskin with the standard physiological assessment, in patients referred for coronary angiography for limiting angina. Afterwards, the clinician will decide of the best treatment strategy for the patient: coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) or no revascularization.
2545966|NCT02591550||patients with normal cough sensitivity|
2545968|NCT02591550||patients with high cough sensitivity|
2545969|NCT02591550||healty controls|
2546008|NCT02591225|Experimental|Dabigatranetexilate|Dabigatran capsula 150 mg; oral; bid; treatment period 12 months
2546009|NCT02591225|Active Comparator|Phenprocoumon|Phenprocoumon INR adjusted; oral; once daily; treatment period 12 months
2546067|NCT02590978|Experimental|Early cholecystectomy|Cholecystectomy within the first 72 hours of admission.
2546070|NCT02590978|Other|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
3203602|NCT00925834|Experimental|Sodium chloride and verbal suggestions|"Experimental arm A: Open intracoronary infusion of 5ml sodium chloride plus the suggestion of a vasodilatory effect on coronary vessels"
2546290|NCT02589509|Experimental|Direct-Metacognitive|Direct attention training followed by metacognitive strategy training
2546291|NCT02589509|Experimental|Metacognitive-Direct|Metacognitive strategy training followed by direct-attention training
2546315|NCT02589093|Experimental|Stimulation|Subjects will receive progressive electrical stimulations with an external nerve stimulator over the ulnar nerve, from 0 mA to 30 mA in increments of 5 (2 Hz single twitch mode), for 3 minutes at each intensity. They will be asked to score their pain level (NRS 0-10) every minute. ANI will be recorded constantly.
2546380|NCT02588924||Second University of Naples|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
2546382|NCT02588924||Neuromed IRCCS|the present research project is aimed at measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
2546426|NCT02588417|Active Comparator|dexamethasone|dexamethasone 4 mg administered intrathecally during active stage of labor once only in combination with levobupivacaine
2546428|NCT02588417|Active Comparator|levobupivacaine|levobupivacaine 2.5 mg in 2 ml administered intrathecally during active stage of labor once and alone and then epidural levobupivacaine 7ml of 2.5 mg concentrationis administered till the end of labor
2546534|NCT02587728||Carpal Tunnel Blood Draw|Participants with confirmed diagnosis of Carpal Tunnel Syndrome who will undergo blood draw for laboratory analysis for amyloidosis.
2546633|NCT02586948|Experimental|extracorporeal CO2 removal|extracorporeal CO2 removal initiated shortly after intubation, using the veno-venous Hemolung device
3169016|NCT00557973|Experimental|XP19986 SR1 10 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 10 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
2545580|NCT02594007|Experimental|discharge home|SEEQ for 28 days. Cardiocom for 30 days
2545585|NCT02594007|Experimental|discharge to skilled nursing facility|SEEQ for 28 days, DocView for 30 days
3203603|NCT00925834|Active Comparator|Nitroglycerin|"Control arm B: Hidden intracoronary infusion of 0.01mg nitroglycerin in 5 ml sodium chloride"
3203604|NCT00925834|Experimental|Nitroglycerin and verbal suggestions|"Control arm B: Open intracoronary infusion of 0.01 mg nitroglycerin in 5 ml sodium chloride plus the suggestion of a vasodilatory effect on cardiac vessels"
2545719|NCT02592980|Experimental|Traditional anticoagulation|For the Traditional Anticoagulation group, the physician will adjust the dose according to the current INR value based on current guidelines
2545726|NCT02592980|Experimental|Pharmacogenetic anticoagulation|For the Pharmacogenetic Anticoagulation group, the dose will be prescribed based on data from each patient applied in a pharmacogenetic algorithm. In some cases, used algorithm may provide a counter-intuitive dose, i.e., a dose that is not adequate for adjusting the current patient' INR (for example, a higher dose for a patient that already has a high INR). In these cases, the physician will adjust the dose following clinical criteria based on published guidelines
2545781|NCT02592837|Experimental|Flex 19G EBUS-TBNA|Mediastinal and hilar lymph node sampling using the flexible 19G EBUS-TBNA needle
2545783|NCT02592837|Active Comparator|EBUS-TBNA|Mediastinal and hilar lymph node sampling using a standard 21G EBUS-TBNA needle
2545846|NCT02592473|Experimental|Embozene Microspheres|Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.
2545907|NCT02592070|Experimental|30 minute treadmill walking|All participants will walk on the treadmill for 30 minutes and perform a battery of cognitive tasks immediately prior, immediately after, and one hour after completion of the 30 minute walking period.
2545919|NCT02591719|Experimental|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS with language task: Perilesional Broca's area
2545923|NCT02591719|Sham Comparator|MagPro magnetic stimulator (sham)|Most activated area from fNIRS with language task: Perilesional Broca's area
2545925|NCT02591719|Active Comparator|MagPro magnetic stimulator (LF rTMS)|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
2545982|NCT02591381|Experimental|STANDARD AUS Placement|Standard placement of an artificial urinary sphincter involves a small incision made in the patient's perineum or scrotum and a fluid-filled cuff is placed around the bulbar urethra (the portion of the urethra between the bladder neck and penis). Connected to the cuff with tubing, is a balloon filled with fluid that is placed behind the pubic bone or in the space between the peritoneum and abdominal muscles. A control pump is placed in the scrotum and allows the device to cycle, thus either exerting pressure to close off the urethra or releasing pressure to allow the urethra to open and the patient to void.
2545983|NCT02591381|Experimental|TRANSCORPORAL AUS Placement|Transcorporal placement has been introduced as a way to reduce risk of erosion and involves tunneling the cuff through the erectile bodies. The same incision is made as for the standard approach, and then an incision is made in each corpus cavernosum (cylinders of tissue that allow for erection). This allows the cuff to be placed around both the urethra and through the lining of the corporal bodies, increasing the bulk of tissue behind the urethra to protect it from erosion.
2546068|NCT02591160|Other|HCTZ cessation|Patients will stop taking HCTZ for 3 months while submitting serial blood and 24 hour urine samples
2546118|NCT02590614|Experimental|800 IU Vitamin D|Participants will be taking 800 IU/d of vitamin D3 for two months
2546120|NCT02590614|Placebo Comparator|Placebo|Placebo made by Vital Nutrients, Inc. to look exactly like the 800 IU/d caplets by the same company.
2546158|NCT02590133|Experimental|Nedaplatin+5-Fu+Endostar|Drug: Recombinant Human Endostatin Injection (Endostar) Endostar, 15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
2546160|NCT02590133|Active Comparator|Nedaplatin+5-Fu|Drug: Fluorouracil (5-Fu) 5-Fu, 200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total Drug: Nedaplatin Nedaplatin, 80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
3203605|NCT00925847|Experimental|1|
3203606|NCT00925860|Experimental|non invasive ventilation approach|pure hypoxemic patients admitted to ICU treated by non-positive pressure mechanical ventilation
2546312|NCT02589314||root planning|
2546395|NCT02588547|Active Comparator|Granisetron 1|Intravenous granisetron 1 mg
2546397|NCT02588547|Active Comparator|Granisetron 0.7|Intravenous granisetron 0.7 mg
2546400|NCT02588547|Placebo Comparator|Placebo|intravenous 0.9% Sodium chloride (2 ml)
2546453|NCT02588209|Experimental|SMART Training|This group will receive the Strategic Memory Advanced Reasoning Training (SMART) program, twice a week for four weeks.
2546454|NCT02588209|Active Comparator|Health|This group will receive the Brain Health Workshop educational program, twice a week for four weeks.
2546497|NCT02587832|Active Comparator|HHHFNC|Randomized to HHHFNC
2546501|NCT02587832|Active Comparator|NCPAP|Randomized to NCPAP
2546526|NCT02587546|Experimental|laryngeal carcinoma|patients with T1-T2 (some T3) laryngeal carcinoma will undergo treatment using thulium contact laser surgery - tumour resection
2546527|NCT02587546|Experimental|bilateral vocal cord paralysis|patients with bilateral vocal cord paralysis treated with partial arytenoidectomy will be treated using thulium laser surgery and laterofixation
2546529|NCT02587546|Experimental|subglottic stenosis|patients with subglottic stenosis treated endoscopically (incisions and dilatation) will be treated with thulium laser surgery
2546571|NCT02587273|Other|Fentanyl|This is a pharmacokinetics study with a single arm. All participants will will undergo the intervention described under the intervention section
2546613|NCT02587000|Active Comparator|Ulipristal acetate|ESMYA® : 2 tablets of 5mg per day during 3 months, per os
2546614|NCT02587000|Placebo Comparator|Placebo|2 tablets of 5mg per day during 3 months, per os
2546681|NCT02586688|Active Comparator|Phase I TMS Active|Blinded Active TMS coil (Phase I). Active NeuroStar® Transcranial Magnetic Stimulation (TMS)
2545586|NCT02594137|No Intervention|With Watertight Duraplasty|After standard craniectomy (12x15cm) and dural opening, watertight duraplasty with pericranium or an artificial graft is performed. Usual closure is then performed. This kind of duraplasty is performed by most neurosurgeons and this group will be used as a control.
2545666|NCT02593669|Experimental|Neutral IOL|Phacoemulsification cataract surgery is performed with neutral IOL implantation.
2545669|NCT02593669|Experimental|Blue-blocking IOL|Phacoemulsification cataract surgery is performed with blue-blocking IOL implantation.
2545715|NCT02593201|Experimental|Treatment|One extra week of antibiotic therapy
2545724|NCT02593201|Sham Comparator|Control|No extra antibiotics
2545770|NCT02592915|Experimental|Test Group|Patients randomized in the Test Group will receive the clonidine hydrochloride
2545771|NCT02592915|Placebo Comparator|Control Group|Patients randomized in the Control Group will receive the Placebo
2545838|NCT02592525|Experimental|Cluster A|IP-SDM training for health professionals (intervention at 4 months)
2545839|NCT02592525|Experimental|Cluster B|IP-SDM training for health professionals (intervention at 11 months)
2545840|NCT02592525|Experimental|Cluster C|IP-SDM training for health professionals (intervention at 18 months)
2545843|NCT02592525|Experimental|Cluster D|IP-SDM training for health professionals (intervention at 25 months)
2545887|NCT02592122|Active Comparator|Atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Second, randomly selected into the atomization group
2545890|NCT02592122|Active Comparator|Without atomization inhalation|First of all, investigators need to give patients to do the test, the result is more than 12% is positive group, less than 12% is negative group.Secondly, the random selection is not the atomization group
2545928|NCT02591732||Patient treated with Apixaban|
2545931|NCT02591732||Patient treated with Rivaroxaban|
2545933|NCT02591732||Patient treated with Dabigatran|
2545935|NCT02591732||Patient treated with vitamin K antagonists|
2545997|NCT02591472|Active Comparator|Usual Care (UsCare)|This group will receive UsCare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
2546004|NCT02591472|Experimental|Integrated Care (ICare)|This group will receive ICare for orthopedic trauma involves surgical intervention, acute care therapies, post-acute rehabilitation and follow-up clinic visits after discharge, plus simultaneous psychosocial support via the Transform-10 Program.. Additionally, the following test will be performed: Lower Extremity Gain Scale (LEGS), dynamometer isometric handgrip strength, Active Range of Motion (AROM), Posttraumatic Stress Disorder (PTSD), Beck Depression Inventory-II, State-Trait Anxiety Inventory (STAI), Tampa Scale of Kinesiophobia-11 (TSK-11), and Patient-Reported Outcomes Measurement Information System (PROMIS).
2546081|NCT02590809|Experimental|Treatment group|20 patients
2546082|NCT02590809|Placebo Comparator|Placebo group|20 patients
2546122|NCT02590445|Active Comparator|Active stimulation|Stimulator on followed by off
2546123|NCT02590445|Sham Comparator|Sham stimulation|Stimulator off followed by on
2546157|NCT02590185|Experimental|cocktail probe drugs|"A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
3203607|NCT00925860|No Intervention|conventionally ventilated|pure hypoxemic patients treated by conventional ventilatory support
3203608|NCT00925873|Active Comparator|1|"Control arm without fludarabine~Induction course: Ara-C 100mg/m2 days 1-7, idarubicin 8mg/m2 days 1-5, GM-CSF (molgramostim, Novartis) 5 microg/kg days 1 to neutrophil recovery;~Consolidation course: Ara-C 1g/m2 q12h days 1-3, idarubicin 10mg/m2 days 2-3;~and 3 quarterly reinduction courses during maintenance including Ara-C 80mg/m2 days 1-5, CCNU 40mg and mitoguazone 350mg/m2 day 1, ± fludarabine days 1-2."
3203609|NCT00925873|Experimental|2|"Fludarabine arm~The same regimen with fludarabine 20 mg/m2/day IV for 30 minutes~induction course + fludarabine days 2-7;~consolidation course + fludarabine days 4-5;~during reinduction courses + fludarabine days 1-2."
2546280|NCT02589418|Experimental|Healthy subjects|All subjects participate at 3 experimental conditions (Acupuncture, Sham-Acupuncture and No Acupuncture) at 3 different days in a randomized order.
2546322|NCT02589106|Experimental|Anisotropic Textile Braces|The design of the anisotropic textile braces will provide different mechanisms with rigid, semi-rigid and flexible materials: a) axial elongation through a close fit of the brace supported with textile composites on the lateral sides of the trunk, b) 3-point pressure with push and counter-pushes through semi-rigid pads inserted inside the pocket lining, c) pulling or compression to correct kyphosis or lordosis in the sagittal plane with elastic bands, d) derotation between the pelvis and shoulders with uneven straps, and e) an active mechanism with sensors added to the brace to maintain correct posture.
2546441|NCT02588391|Experimental|Active Brain Training|"The children in this arm receive one type of Brain Training with online computer games that actively matches their skill level."
2546443|NCT02588391|Experimental|Passive Brain Training|"The children in this arm receive one type of Brain Training with online computer games that are at a consistent skill level."
2546444|NCT02588391|Other|Cross-over|"Following completion of the 6-month follow-up sessions after completion of Brain Training, each group is allowed to cross-over to the other arm of Brain Training (open-label extension)."
2546479|NCT02587988|Experimental|HCP1302+HGP0904Placebo|HCP1302+HGP0904Placebo for 12weeks
2546484|NCT02587988|Active Comparator|HCP1302Placebo+HGP0904|HCP1302Placebo+HGP0904 for 12weeks
3203610|NCT00925886|Experimental|Acrysof Toric intraocular lens|A One piece, acrylic intraocular lens is implanted in the lens bag.
3203611|NCT00925912|Active Comparator|1|"spinal anesthesia: Active Comparator~The SA group were received a subarachnoid block with 1.5-2.0 ml of 0.5% bupivacaine."
3203612|NCT00925912|Experimental|2|Perianal block with 0.25% bupivacaine
3203613|NCT00925925||Normal Birth Weight (NBW)|Term, healthy infants born at normal birth weights
3203614|NCT00925925||Low Birth Weight (LBW)|Infants born at > or equal to 34 0/7 weeks with a birth weight at < or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
3203615|NCT00925951|Experimental|Wet Cupping|
3203616|NCT00925951|No Intervention|Waiting Control|They can't use any other specific treatment except exercises and behavior modification (we'll offer a brochure which includes exercise method and directions about behavior modifications).
3203617|NCT00925964||Patients exposed|Patients with Systolic Pressure Index <0,9 ou >1,4.
3203618|NCT00925964||Patients not exposed|Patients with Systolic Pressure Index >0,9 ou <1,4.
2545809|NCT02592590|Experimental|Group A|
2545811|NCT02592590|Experimental|Group B|
2545812|NCT02592590|Experimental|Group C|
2545814|NCT02592590|Active Comparator|Group D|
2545841|NCT02592239|Experimental|Patients|Functional dyspepsia patients will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
2545842|NCT02592239|Experimental|Controls|Healthy subjects recruited by public advertisement will be studied using functional brain MRI before and after receiving a test meal. Cognitive and hedonic response will be evaluated using 10 score scales.
2545884|NCT02592109|Experimental|Enhanced Counseling using CFR based on LP|"The counseling will be done by individual face-to-face communications. The intervention's arm will get a counseling with an additional of 7-day cycle with adequate n-3 and optimal n-3/6 ratio for complementary feeding menu obtained from linear programming formulation.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet; definition, function, and source of omega-3; example of menu that contains adequate omega-3. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
2545889|NCT02592109|Active Comparator|General CFR Counseling|"The control's arm will get general counseling combining balance diet and IYCF principal, which already been used by Ministry of Health, with additional of 7-day cycle menu guidance modified from existing or available menu which can be downloaded for public on Ministry of Health official website.~The counseling consisted of nutritional status in children aged 12-23 months and how to determine the nutritional status; the principle of balanced diet based on Ministry of Health's Recommendation, and example of balanced diet menu. The duration of counseling is approximately 30 minutes, once a week for ten weeks. The mother or caregiver will also receive daily menu for seven days that should be followed during the intervention. The daily menu comprised of 3 main meals and 2 snacks."
2545944|NCT02591771|Experimental|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
2545985|NCT02591368|Active Comparator|Ligament reconstr. tendon interposition|Ligament reconstruction, tendon interposition.
2545987|NCT02591368|Active Comparator|Mini Tight rope with one-suture|Mini Tight rope with one suture
2545989|NCT02591368|Active Comparator|Mini Tight rope with two-suture|Mini Tight rope with two sutures
2546046|NCT02591069|Experimental|All patients will undergo the same procedure|
2546098|NCT02590731||Control group|Pfeiffer test 6 or above. No or mild cognitive impairment
2546100|NCT02590731||Cognitivt impaired|Pfeiffer test less than 6. Moderate to severe cognitive impairment.
3203619|NCT00925977|Active Comparator|insulin Glargine + insulin Apidra|insulin Glargine + insulin Apidra
2546266|NCT02589574|No Intervention|Control|Subjects of the control group will receive the usual announcement on the dates and times of offering free influenza vaccination, and reminder from hospital, and access to informational flyers posted at the hospital
2546273|NCT02589574|Experimental|Intervention|Subjects of the intervention group besides the usual information same as those stated in the control group, will receive four reminders on dates and details for free influenza vaccine. Together with the reminder, electronic text messages of educational information will be received
2546332|NCT02589210|Experimental|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
2546354|NCT02588807|Experimental|Spirit1|Patients will take a daily nutritional supplement for 8 months
2546412|NCT02588638||Adult patients|Unclear movement disorder, unclear cognitive decline
2546417|NCT02588638||Patients < 18 years|Patients with (penetrating) suspected cerebral neurogenetic diseases
2546468|NCT02588222||Healthy children|Healthy children, aged 6-18 years old.
2546547|NCT02587767|Experimental|577-MPL|"577nm micropulse laser(577-MPL) will be performed of the areas identified on hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein.Multiple laser spots will be applied, covering the leakage area."
2546548|NCT02587767|Active Comparator|HD-PDT|Half-dose photodynamic therapy (HD-PDT) is administered to the patients. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689nm, and a treatment duration of 83 seconds.
2546618|NCT02587156|Experimental|Meal serving at high dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount above 1.5 g protein/kg/day
2546620|NCT02587156|Active Comparator|Meal serving at low dietary protein|Test the handling of meal-served protein when habituated to high dietary protein at an amount below 0.8 g protein/kg/day
2546661|NCT02586701|Active Comparator|Prehabilitation Plus|Patients in this group will be enrolled in a multimodal program before surgery involving supervised exercise, nutrition counseling and relaxation strategies. Supervised exercise is provided once a week for four weeks before surgery as well as during the hospital stay post surgery. Patients are to continue with a home-based exercise program for 8 weeks after discharge.
2546666|NCT02586701|No Intervention|Rehabilitation|Patients in this group are provided with in-hospital supervised exercises with a kinesiologist post surgery until discharge. Patients, upon discharge are provided with a home-based exercise program, nutritional counseling and relaxation strategies for 8 weeks.
3203620|NCT00925977|Active Comparator|Insulin NPH + Insulin Apidra|12 weeks treatment with Insulin NPH + Insulin Apidra
3203621|NCT00926016|Active Comparator|pioglitazone|Treatment with pioglitazone 45 mg a day for 3 months
3203622|NCT00926016|No Intervention|No intervention|Monitoring period without pioglitazone for 3 months
2545680|NCT02593383|Experimental|Treat group 1|Group 1: 0.1% Adapalene + 1% Clindamycin Hydrochloride
2545683|NCT02593383|Experimental|Treatment group 2|Group 2: 0.1% Adapalene + 2% Clindamycin Hydrochloride
2545689|NCT02593383|Experimental|Treatment group 3|Group 3: 0.05% Adapalene + 0.5% Clindamycin Hydrochloride
2545691|NCT02593383|Experimental|Treatment group 4|Group 4: 0.05% Adapalene + 1% Clindamycin Hydrochloride
2545692|NCT02593383|Placebo Comparator|Placebo group|Placebo Group: Blank Gel
2545714|NCT02593084|Experimental|Higher Intensity Resistance Training|Participants will take part in a 12-week higher-intensity resistance training protocol.
2545725|NCT02593084|Active Comparator|Lower Intensity Resistance Training|Participants will take part in a 12-week lower-intensity resistance training protocol that will serve as the active comparator.
2545782|NCT02592850|Experimental|Osteopathic Manipulative Treatment|Active manipulative treatment.
2545786|NCT02592850|Sham Comparator|Sham Osteopathic Manipulative Treatment|Sham manipulative treatment.
3203623|NCT00926042||Healthy Control|Healthy control group for research on autoimmune diseases
3203624|NCT00926055|No Intervention|Control|
2546393|NCT02588729|Experimental|Pregnant+ app for smartphone (Gravid+)|The intervention consists of the Pregnant+app downloaded on women's smartphone. The app contains culturally adapted information about physical activity, diet and management of GDM. The Gravid+app will be available in Norwegain, Urdu and Somali. Women will have the opportunity to automatically transfer their blood glucose levels to their smartphones via Bluetooth.
2546394|NCT02588729|No Intervention|No admission to Pregnant+ app (Gravid+)|The control group will receive standard care at the outpatient departments. Participants to not receive the Pregnancy
2546459|NCT02588274|Experimental|Acupuncture|Zhongliao (BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyinjiao (SP 6) acupuncture points (Table 1). After patients are in prone position with relax, the investigators will use 75% alcohol pads to sterile the skin around the acupuncture points, and then insert steel needles (Huatuo, Suzhou, China 0.3mm*40mm/0.3mm*75mm) into the acupuncture points. For bilateral Zhongliao (BL 33), the needle will be inserted into about 50-60mm with 45 degree, for Huiyang (BL 35), the needle will be inserted into 50-60mm. for Shenshu (BL 23) and Sanyinjiao (SP 6), the needles will be inserted vertically to a depth of 25-30 mm. The treatment sessions are 24 after baseline, 3 times a week, and the each time the patients will accept a 30 minutes treatment.
2546460|NCT02588274|Placebo Comparator|placebo needle|The participants in placebo needle group will receive placebo needle at the same acupuncture points to treatment group. Investigators will use a sort of blunt needle that cannot penetrate skin and stimulate deep tissues while the thrusting and twisting manipulation will be used by acupuncturists to mock the treatment procedure and blind the patients. The duration and frequency of sessions are same to the treatment group.
2546495|NCT02587845|Active Comparator|IV group|Intravenous tranexamic acid injection Group IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
2546496|NCT02587845|Experimental|Topical group|Intra-articular tranexamic acid injection Group Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
2546518|NCT02587533|Active Comparator|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. No pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2546520|NCT02587533|Active Comparator|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Counteracting pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2546521|NCT02587533|Active Comparator|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation. No additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
2546522|NCT02587533|Active Comparator|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Additional pharmacologic suppression of chemoreflex afferents. Readout: Responses to electrical baroreflex stimulation.
3203625|NCT00926055|Active Comparator|Ezetimibe|
3203626|NCT00926055|Experimental|Ezetimibe/Simvastatin|
2546748|NCT02586246|Experimental|CDP870 group from Study 275-08-002|Subjects with active rheumatoid arthritis who are participating in Study 275-08-002 of CDP870
2546751|NCT02586246|Experimental|CDP870 group from Study 275-08-004|Subjects with active rheumatoid arthritis who are participating in Study275-08-004 of CDP870
2546781|NCT02585921|No Intervention|Health & Wellness|Following enrollment, participants will learn about health and wellness.
2546784|NCT02585921|Experimental|Organ Donation Video Education|Following recruitment, participants will watch and discuss videos about organ donation.
2546788|NCT02585921|Experimental|Organ Donation Discussion Education|Following recruitment, participants will learn techniques to introduce and discuss the topic of organ donation with parents or guardians.
2546792|NCT02585921|Experimental|Both Video and Discussion Education|Following recruitment, participants will watch and discuss videos about organ donation and then learn techniques to introduce and discuss the topic of organ donation with parents and guardians.
3203627|NCT00926068|Experimental|HO/03/03 10µg|
3203628|NCT00926068|Placebo Comparator|Placebo|
2546973|NCT02584881|Experimental|Intervention|A safe opioid prescription protocol will be implemented with these trauma patients
3203629|NCT00926081|No Intervention|Best medical treatment|Patients with peripheral artery disease receiving best medical treatment only
3203630|NCT00926081|Active Comparator|Supervised exercise training|Patients with peripheral artery disease receiving best medical treatment plus supervised exercise training
3203631|NCT00926094||1|
3203632|NCT00926094||2|
3203633|NCT00926120|Experimental|Mogroside sweetener|All subjects will received Mogroside. Mogroside sweetener administered at a dosage level of 5 g every 6 hours for 14 days.
3203634|NCT00926133||STEMI patients|Patients with acute STEMI treated by PCI without previously known type 2 diabetes.
3203635|NCT00926146|Experimental|NCMIT|Nurse Case Management Plus Contingency Management and Tracking and the HBV vaccine
3203636|NCT00926146|Active Comparator|SCMIT|Standard with Contingency Management and Tracking (SCMT) and HBV vaccine
2545622|NCT02593851|Experimental|Part 1: Cohort 1d|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1d is optional and may be included at the discretion of the sponsor.
2545624|NCT02593851|Experimental|Part 1: Cohort 1e|Participants (>= 6 months and <= 24 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 1e is optional and may be included at the discretion of the sponsor.
2545627|NCT02593851|Experimental|Part 1: Cohort 2a|Participants (>= 3 months and less than [<] 6 months of age) will receive total daily dose of 1.5 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
2545628|NCT02593851|Experimental|Part 1: Cohort 2b|Participants (>=3 months and < 6 months of age) will receive total daily dose of 4.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2545629|NCT02593851|Experimental|Part 1: Cohort 2c|Participants (>= 3 months and < 6 months of age) will receive total daily dose of 13.5 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7
2545630|NCT02593851|Experimental|Part 1: Cohort 2d|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2d is optional and may be included at the discretion of the sponsor.
2545632|NCT02593851|Experimental|Part 1: Cohort 2e|Participants (>= 3 months and < 6 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 2e is optional and may be included at the discretion of the sponsor.
2545634|NCT02593851|Experimental|Part 1: Cohort 3a|Participants (greater than (>) 1 month and < 3 months of age) will receive total daily dose of 1 mg/kg JNJ-53718678 oral solution [either in a qd or a bid regimen] on Day 1 to Day 7.
2545636|NCT02593851|Experimental|Part 1: Cohort 3b|Participants (> 1 month and < 3 months of age) will receive total daily dose of 3 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2545637|NCT02593851|Experimental|Part 1: Cohort 3c|Participants (> 1 month and < 3 months of age) will receive total daily dose of 9 mg/kg JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7.
2545638|NCT02593851|Experimental|Part 1: Cohort 3d|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3d is optional and may be included at the discretion of the sponsor.
2545639|NCT02593851|Experimental|Part 1: Cohort 3e|Participants (> 1 month and < 3 months of age) will receive JNJ-53718678 oral solution or placebo [either in a qd or a bid regimen] on Day 1 to Day 7. The cohort 3e is optional and may be included at the discretion of the sponsor.
2545640|NCT02593851|Experimental|Part 2: Cohort f|Participants of all age groups will receive daily dose of JNJ-53718678 oral solution or placebo, either in a qd or a bid regimen on Days 1 to 7.
2545710|NCT02593019|Experimental|AZD1775|AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
2545759|NCT02592928||Lleida Health Sector|"Lleida (168k inhabitants and 21 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2545762|NCT02592928||Vic Health Sector|"Vic (49k inhabitants and 11 Primary Care Centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2545764|NCT02592928||AISBE Health Sector|"Atenció Integral en Salut Barcelona Esquerra (AISBE) (540k inhabitants and 19 Primary Care centers). Primary Care centers from this health sector~Inclusion of the Forced Spirometry into the Electronic Health Records No interventions performed"
2545793|NCT02592642|Experimental|Group 1|Self-management Program, Workbook, Video, Pedometer
2545797|NCT02592642|Active Comparator|Group 2|Instructional Workbook, Video, and Pedometer
2545801|NCT02592642|Experimental|Group a|Para-spinal TENS
2545802|NCT02592642|Placebo Comparator|Group b|Para-spinal Placebo TENS
2545805|NCT02592642|Experimental|Group c|Prototype Spinal Stenosis Belt
2545808|NCT02592642|Sham Comparator|Group d|Sham spinal stenosis belt
2545878|NCT02592252|Experimental|Microfinance + gender training|Microfinance + 10 sessions of participatory gender training
2545879|NCT02592252|Experimental|Microfinance only|Receive microfinance only
2545880|NCT02592252|Experimental|Gender training only|10 sessions of participatory gender training for women and their male partners
2545882|NCT02592252|No Intervention|No intervention|No microfinance or participatory gender training
2545948|NCT02591849|Active Comparator|Glucagon-like peptide-1 (GLP-1)|Twelve eligible renal transplant recipients with PTDM and twelve age, gender, BMI and renal function-matched non-diabetic renal transplant recipients will be randomized to continuous unblinded intravenous infusion of GLP-1 with an infusion rate of 0.8 pmol/kg/min or isotonic saline (placebo) on two experimental days performed 2-4 weeks apart. The GLP-1 infusion will consist of 42.5 nmol/mL GLP-1 (7-36) amide, 12.5 mL 5% human albumin and isotonic saline added to a total volume of 50 mL. After 60 min, a 2 hour hyperglycemic clamp will be initiated, where plasma glucose will be elevated by 5 mmol/L from each individual fasting plasma glucose in both groups. This will be done to measure concentrations of glucagon and insulin in hyperglycemic conditions.
2545952|NCT02591849|Placebo Comparator|Isotonic saline|The included patients will receive concomitant intravenous infusion of isotonic saline on one of the two experimental days
2546020|NCT02591303|Experimental|Insomnia group|Patients with insomnia: sleep complaints, of more than 3 nights a week, more than 3 months, affected daytime functioning, objectified low sleep quality (Sleep Efficiency <85%) with 10 days actigraphy
2546021|NCT02591303|Experimental|Control group|No sleep problems either self reported or objectified through actigraphy (Sleep Efficiency >85%)
2546035|NCT02590913|Experimental|group fructose|Volunteer was randomized into either group fructose or glucose
2546037|NCT02590913|Experimental|group glucose|After one-week washout period, volunteer was crossed over for either group glucose or fructose.
2546090|NCT02590770|Active Comparator|gaze-contingent|attention modification: participants will receive gaze-contingent feedback according to their viewing patterns
2546129|NCT02590666|Experimental|Bipolar electrode|Polyps resection with bipolar electrode
2545671|NCT02593461|Experimental|Diafert|The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2545675|NCT02593461|Other|Control Group|The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2545749|NCT02593214|Experimental|Wondaleaf Arm|This is a single arm clinical trial, all subjects and their married couples were be recruited to the arm using investigational device Wondaleaf only.
2545806|NCT02592681|Experimental|verum acupuncture|Participants will receive real needle insertion. The needles will be left in the acupoint for 20 min, with a manual rotation at a ten-min interval. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian).
2545807|NCT02592681|Active Comparator|acupressure|Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Duration of each session will be 15 min.
2545810|NCT02592681|Sham Comparator|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan).
2545833|NCT02592330|Experimental|Cultivated Autologous Limbal Epithelial Cell (CALEC) graft|Participants will have a corneal biopsy in their non-diseased eye, which will provide cells for the creation of the CALEC graft. The CALEC will be made at the Good Manufacturing Practice (GMP) Laboratory, Dana Farber Cancer Institute and transported to Mass. Eye and Ear Infirmary for application to the participant's diseased eye during their standard corneal reconstruction procedure.
2545869|NCT02592187|Experimental|Experimental intervention|ReMemory-MCI training
2545872|NCT02592187|Active Comparator|Control intervention|Control intervention
2545896|NCT02591953|Experimental|Ultrasound-guided Injection|Injection performed with ultrasound-guidance
2545898|NCT02591953|Active Comparator|Landmark-guided Injection|Injection performed at point of maximal tenderness along biceps tendon
2545922|NCT02591641|Experimental|Standard of Care First, then Liquicell|Subjects were secured on a standard ambulance stretcher, with a shear and pressure sensors attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken during the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated with the LiquiCell® ASMO.
2545926|NCT02591641|Experimental|Liquicell First, then Standard of Care|Subjects were secured on a standard ambulance stretcher with an anti-shear mattress overlay placed on top of the stretcher, with a shear and pressure sensor attached to the body. Starting at 0 degrees head-of-bed (HOB) elevation, the ambulance traveled on a closed driver training course accelerating up to 30 mph and decelerating to a stop 5 times. Shear and pressure measurements were taken throughout the runs. The HOB was then elevated to 15 and 30 degrees respectively, and the procedure repeated. Subjects were asked to rate their comfort at each of the HOB elevations using a 0-10 scale. Following the first set of 15 runs, the course was repeated without the LiquiCell ASMO.
2546011|NCT02591407|Active Comparator|TAP Block- Exparel|Transversus abdominis plane block utilizing the medication Exparel®
2546014|NCT02591407|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia
3203637|NCT00926159||ICD eligible|Patients with Ejection Fraction (EF) of 35% or less as determined by cardiac echocardiogram or cardiac nuclear scan.
3203638|NCT00926250|Experimental|PS-IPC supplementation|
3203639|NCT00926250|Placebo Comparator|Placebo supplementation|
3203640|NCT00926276|Active Comparator|Surgical Treatment Group-Fundoplication|Re-evaluated 1 month post-op Re-evaluated 2 months post-op
2546201|NCT02590016|Experimental|Insulin-glucose-infusion|Insulin-glucose-infusion is administered once active labour begins and will be continued until birth.
2546202|NCT02590016|Active Comparator|Observation|Plasma glucose level is measured every 1-2 hours during active labour and insulin-glucose-infusion is started if plasma glucose level exceeds 7,5 mmol/l in two subsequent measurements.
2546357|NCT02589158|Experimental|Evotaz®, washout, then Rezolsta®|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days, undergo a ten-day wash out period and then take Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
3203641|NCT00926276|Active Comparator|Medical Therapy|Treated by primary clinician for GERD Re-evaluated 1 month Proceed to Fundoplication if GERD persist by pH-MII Re-evaluated at 2 months (1 month post-op) Worsening BPD will be given option of immediate surgery
3203642|NCT00926302|Experimental|Test drug|Levetiracetam one period
2546461|NCT02587910|Placebo Comparator|Non-invasive arm|Participants in this arm, who fit the inclusion criteria and have a GERD Q score of 3 or more, will be randomized to receive either Melanole, a herbal derived melanin, 300 mg, 2 capsules three times a day or placebo for 10 days.To assess the symptomatic improvement, GERD Q score will be calculated on day 0 (before administration of the product) and then on days 11 and 30 having taken the product for 10 days.
2546463|NCT02587910|Placebo Comparator|Invasive arm|Participants in this arm will undergo a 24-hour pH monitoring before administration of Melanole, the herbal melanin or placebo. They will then be randomized to receive either Melanole or placebo for 10 days. pH metry will be repeated between days 7 and 10 from the study product or placebo.
2546528|NCT02587676||denture liners|Evatouch Super (EVA; Neo Dental Chemical products, Washington, USA), GC RELINE (GCR; GC Dental Products Corp, Tokyo, Japan), Mucopren soft (MCP; Kettenbach GmbH & Co KG, California, USA) Soften (SFT; KAMEMIZU CHEM, Osaka, Japan), FD Soft (FDS; KAMEMIZU CHEM, Osaka, Japan), and Bio Liner (BIO; Nissin Dental Products, Kyoto, Japan).
2546703|NCT02586558|Placebo Comparator|Reference group|Milk-based infant formula without prebiotics
3203643|NCT00926302|Active Comparator|Reference drug|Keppra one period
3203644|NCT00926315|Experimental|calcitriol|calcitriol supplementation (0.25 mcg 2x/d)
3203645|NCT00926341|No Intervention|Active control|1. Active Control: (n=20), intervention: no intervention
3203646|NCT00926341|Active Comparator|PIO arm|PIO arm (n=30), Pioglitazone 30 mg/day, given for 24 weeks.
3203647|NCT00926341|Active Comparator|Telmi arm|Telmia arm (n=30): Tab. Telmisartan 40 mg/day given for 2 weeks.
3203648|NCT00926354|Experimental|AS101 infusion|Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
2545819|NCT02592668|Experimental|Active stimulation|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function. The total estimated time for the intervention is 66 weeks.
2545913|NCT02591927|Active Comparator|Glucose-Insulin-Potassium|Rackley's Glucose-Insulin-Potassium formula consisting of 30% glucose (300 mg/L), 50 units of regular insulin per liter and 80 mEqu of KCL per liter.
2545915|NCT02591927|Placebo Comparator|Glucose 5%|Glucose 5%
2545992|NCT02591576||ST-elevation myocardial infarction (STEMI)|
2545994|NCT02591576||non-ST-elevation myocardial infarction (NSTEMI)|
2546076|NCT02590822|No Intervention|Standard Care|The Standard Care group will be contacted weekly (where possible) to reinforce cognitive behavioural adaptations and encourage compliance to diet and exercise. They will be provided with standard lifestyle advice according to NICE guidance.
2546077|NCT02590822|Experimental|Total Dietary Replacement|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention contact & current medications will need to be adjusted initially and throughout the study."
2546078|NCT02590822|Experimental|Supervised Exercise|"The exercise group will attend thrice weekly 60minute supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. An initial assessment of cardiorespiratory fitness will be performed (VO2 max) to allow design of a tailored exercise programme.~Current medication will need to be adjusted initially and throughout the study."
2546126|NCT02590458|Experimental|Short Breast MRI (SBMRI)|Routine scheduled MRI with contrast performed on women at high risk of developing breast cancer. One day after routine MRI, short breast MRI (SBMRI) with contrast performed. After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan.
2546173|NCT02590107|Experimental|Supportive care (Boost Plus, Pro-Stat 101)|Participants receive Boost Plus PO BID or Pro-Stat 101 PO BID beginning one week before scheduled HSCT and continuing until hospital discharge. If participants do not tolerate the Boost Plus or Pro-Stat, they receive a milkshake PO QD as an alternative.
2546228|NCT02589769|Experimental|unsaturated fat|an intervention diet substituting unsaturated fats from oil and nuts for saturated fats from meat and dairy foods
2546229|NCT02589769|Active Comparator|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced.
2546278|NCT02589522|Experimental|Group I (VX-970, whole-brain radiation therapy)|Patients undergo whole-brain radiation therapy QD 5 days a week for 15 fractions. Patients also receive berzosertib IV over 60-90 minutes twice a week, 18-30 hours after first radiation therapy. Treatment continues for 3 weeks in the absence of disease progression or unacceptable toxicity.
2546285|NCT02589522|Experimental|Group II (VX-970, surgery, whole-brain radiation therapy)|Patients receive berzosertib IV over 60-90 minutes 2-4 hours prior to surgery. After surgery, patients undergo whole-brain radiation therapy and receive berzosertib as in Group I.
2546309|NCT02589002|Experimental|Sucralose|Ingestion of 15% of the ADI of sucralose daily during two weeks
2546311|NCT02589002|No Intervention|Control|Absence of sucralose ingestion
2546456|NCT02588183|Experimental|ArticFont Advance ST|Patients undergoing PV isolation with the ArticFont Advance ST Cryoenergy Balloon Catheter
3169017|NCT00557973|Experimental|XP19986 SR1 20 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 20 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
2546542|NCT02587754|Active Comparator|Verum acupuncture|10 sessions of verum acupuncture
2546545|NCT02587754|Placebo Comparator|Placebo acupuncture|10 sessions of placebo acupuncture via use of placebo acupuncture needles
2546649|NCT02586740||Pulmonary artery rehabilitation|Patients with pulmonary artery stenosis or small pulmonary arteries following surgical repair for tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals undergoing cardiac catheterization.
2546701|NCT02586558|Active Comparator|Experimental Infant Formula|Milk-based infant formula with prebiotics
2545741|NCT02592967|Experimental|Cohort 1A and 1B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
2545744|NCT02592967|Experimental|Cohort 2A and 2B|JNJ-64041757 will be administered intravenously (IV) once every 21 days.
3169018|NCT00557973|Experimental|XP19986 SR1 30 mg - Placebo|Following a 7 day run-in period in which participants take placebo twice a day (BID), participants are randomized to the cohort that will take XP19986 SR1 30 mg BID treatment crossing over to placebo treatment (or the reverse order). Each treatment segment follows the same pattern: 3-9 days of titration, 7 days at target dose, 3-9 days of tapering, followed by a 3-day placebo washout.
2545854|NCT02592356|Experimental|Cabozantinib or Lenvatinib|Patients treated with cabozantinib s-malate or lenvatinib mesylate are observed for body weight, skeletal muscle and adipose tissue changes. Patients complete 3 to 4 questionnaires every 2 weeks for 6 months and then monthly up to 12 months. Patients also undergo physical assessments and body composition measurements by DXA and CT scans at baseline, months 3, 6, and 12.
2545939|NCT02591680|Experimental|Neuromuscular training|Neuromuscular, this arm will receive neuromuscular training and muscle strengthening.
2545941|NCT02591680|Active Comparator|Strength|Strength, this arm will receive only muscle strengthening.
2545988|NCT02591329|Experimental|Experimental|The experimental condition (EXP) will receive the targeted intervention material developed and designed by the researchers using focus group discussions with parents. This information will include salient benefits of the consumption of calcium-rich products. In addition, self-regulatory strategies will be provided to encourage purchasing and consumption of calcium-rich products and address any potential barriers to purchase and consumption. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a grocery pad and a recipe book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
2545990|NCT02591329|Active Comparator|Standard Care|Individuals in the Control condition (CON) will receive general healthy eating materials including Canada's Food Guide, Healthier Grocery Shopping Guide and Cooking with Kids. Material will sent on four different occasions via mail. At time one (week 0) participants will be sent a 13-month calendar, at time 2 (week 8) participants will be sent a note pad and an activity book. At time 3 and 4 (week 16 and 22 respectively) participants will be sent a newsletter.
2546058|NCT02591134|Experimental|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages will be provided to participants using a home delivery system and they are expected to consume at least two portions (330ml) per day.
2546061|NCT02591134|Placebo Comparator|Control Water Beverages|Water beverages will be used as a comparator to NNS beverages during the trial. These beverages will encompass a range of water-based drinks that contain no NNS. Including water as a comparator is vital to understand whether NNS beverages are equally as effective as water during phases of weight loss and weight maintenance.
2546117|NCT02590627|Active Comparator|A|Artemether-lumefantrine
2546119|NCT02590627|Experimental|B|Dihydroartemisinin-piperaquine
2546183|NCT02590146|Experimental|Intervention Group|Patients in this group will participate in pain management counseling and choose non-pharmacologic pain control supports to use during their procedure in addition to the standard of care pain management offered in the office
2546189|NCT02590146|No Intervention|Control group|Patients in this group will receive standard of care pain management offered in the office.
2546220|NCT02589821|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
2546223|NCT02589821|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
2546284|NCT02589483|Experimental|Prospective pilot|Patient included prospectivly will be all treated according to study protocol.The rectal anastomosis will be reinforced with HemoPatch.
2546313|NCT02589132|No Intervention|Standard of Care|Families receiving Standard of Care
2546319|NCT02589132|Experimental|Mobile-Thrive application|Standard care plus Mobile-Thrive app
2546367|NCT02588911|Active Comparator|Conventional Surgery|Limb with GSV insufficiency in the same patient, randomised to conventional surgery
2546370|NCT02588911|Active Comparator|Radiofrequency Ablation|Limb with GSV insufficiency in the same patient, randomised to radiofrequency ablation
2546384|NCT02588508|Experimental|Warm packs|The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
2546385|NCT02588508|Experimental|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
2546388|NCT02588508|No Intervention|Hands off|Hands off group does not receive any perineal manipulation and they are only observed.
3169019|NCT00557986|No Intervention|A|Standard Systemic Therapy only group (no primary surgery)
3169020|NCT00557986|Other|B|Surgery group
2546472|NCT02588001|Experimental|Enzalutamide Group|
2546533|NCT02587689|Experimental|anti-MUC1 CAR T Cells|The subject's T cells will be modified in one or two different ways that will allow the cells to identify and kill the MUC1+ tumor cells.
2546574|NCT02587260|Active Comparator|Sequence I|Ticagrelor in the period I Prasugrel in the period II Clopidogrel in the period III
2546580|NCT02587260|Active Comparator|Sequence II|Ticagrelor in the period I Clopidogrel in the period II Prasugrel in the period III
2546582|NCT02587260|Active Comparator|Sequence III|Prasugrel in the period I Ticagrelor in the period II Clopidogrel in the period III
2546584|NCT02587260|Active Comparator|Sequence IV|Prasugrel in the period I Clopidogrel in the period II Ticagrelor in the period III
2546587|NCT02587260|Active Comparator|Sequence V|Clopidogrel in the period I Ticagrelor in the period II Prasugrel in the period III
2546589|NCT02587260|Active Comparator|Sequence VI|Clopidogrel in the period I Prasugrel in the period II Ticagrelor in the period III
2546650|NCT02586753|Experimental|Paclitaxel plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug Paclitaxel plus Cisplatin
2546651|NCT02586753|Experimental|S1 plus Cisplatin with radiotherapy|patients will receive concurrent chemoradiotherapy with drug S1 plus Cisplatin
2546779|NCT02585973|Other|open label, single-arm, Phase 1b|AZD1775 when added to standard of care concomitant chemotherapy (cisplatin) and radiation
3169021|NCT00557999|Other|Experimental group|Application of a weaning mechanical ventilation protocol
3169022|NCT00557999|No Intervention|Control group|
3203649|NCT00926354|No Intervention|Control group|Twenty patients who developed thrombocytopenia during chemotherapy course will be treated according to standard of care and will not receive the investigational product. Their medical condition will be followed and a complete blood count will be performed routinely once weekly.
3203650|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
2545875|NCT02592161|Experimental|Experimental|Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
2545877|NCT02592161|Placebo Comparator|Placebo comparator|Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks
2545943|NCT02591797|Experimental|"hand-eye-mouth technique"|"hand-eye-mouth (MOB) seeks to focus the patient in performing a sequence of movements in a fun way so that your attention is diverted from the puncture dental needle, also it seeks to the patient does not see the needle. The operator prior to infiltrate local anesthetic teaches the child a game to put the sleepy little water.After explain a first time, the sequence once or twice is repeated until the patient has mastered. We call this test. When we apply the anesthetic, the entire sequence must be repeated as in trials with the same tranquility and in the same tone of the game. The operator will use this technique during the inferior alveolar and lingual nerve block procedure"
2545945|NCT02591797|Active Comparator|Conventional technique|the operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child´s field of view by hand during the inferior alveolar and lingual nerve block
2545979|NCT02591342||CPT stem|Patients treated with a polished, tapered femoral stem as a hip arthroplasty for a displaced femoral neck fracture
2545981|NCT02591342||SP2 stem|Patients treated with a anatomic femoral stem as a hip arthroplasty for a displaced femoral neck fracture
2546025|NCT02591199|Experimental|URG101|A single 15 mL dose of URG101,a mix of buffered Lidocaine (200 mg) and Heparin (50,000 IU), delivered to the bladder via catheter.
2546026|NCT02591199|Placebo Comparator|Placebo|A single 15 mL dose of placebo delivered to the bladder via catheter.
2546030|NCT02591199|Experimental|Lidocaine|A single 15 mL dose of buffered Lidocaine (200 mg) delivered to the bladder via catheter.
2546031|NCT02591199|Experimental|Heparin|A single 15 mL dose of buffered Heparin (50,000 IU) delivered to the bladder.
2546083|NCT02590796||Hospitalised patients with delirium|hospitalised patients with delirium in general wards.
2546084|NCT02590796||Hospitalised patients with dementia/ no delirium|Hospitalised patients with a diagnosis of dementia who do not have delirium in general wards.
2546085|NCT02590796||Hospitalised patients with no delirium or dementia|Hospitalised patients with no delirium or dementia in general wards.
2546086|NCT02590796||Outpatients with dementia|People with a diagnosis of dementia who are living in the community.
2546087|NCT02590796||Healthy volunteers|Healthy volunteers who are living in the community who do not have a cognitive impairment.
2546088|NCT02590796||ICU delirium|Patients with delirium who are hospitalised in the intensive care units.
2546089|NCT02590796||ICU no delirium|Patients who do not have delirium who are hospitalised in intensive care units.
2546121|NCT02590419|No Intervention|Control Group|Control Group (involvement of BrightMatter™ Plan (BMP)): Patients with temporal lobe epilepsy, who have been identified as candidates for anterior temporal lobe resection (ATLR) will be recruited. All epilepsy patients will have clinical MRI scans that include a diffusion tensor imaging (DTI) protocol. Surgery will be carried out according to usual standard of care, without the use of processing for DTI tractography. Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out . Primary outcomes will be assessed to identify the baseline incidence of visual of postoperative visual field deficits.
2546124|NCT02590419|Experimental|Treatment Arm|Treatment group (involvement of all three products BrightMatter™ Plan (BMP), BrightMatter™ Bridge (BMB), and BrightMatter™ Guide(BMG): A treatment group (prospective enrollment) that uses the interventional technology will be recruited based on the same eligibility criteria as control cohort. All epilepsy patients will have clinical MRI scans that include a DTI protocol. For this treatment group of patients, the BrightMatter system (BMB,BMP, and BMG) will be employed pre-operatively and intra-operatively for planning before and guidance during anterior temporal lobe resection (ATLR). Additional clinical scanning with the same protocol will be carried out post-operatively at 6 months. Pre-operative and post-operative (6-month) visual field assessments (Estermann Perimetry and Humphrey Perimetry) will also be carried out. Primary outcomes will be assessed to evaluate the effect of surgical planning and guidance with DTI tractography on outcomes, by comparison against the control cohort.
2546186|NCT02590198||ANAES algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
2546190|NCT02590198||PCT algorithm|Each center will start the study by applying the usual ANAES algorithm. The date of implementation of the new algorithm based on PCT will be determined randomly. Therefore, within each center, there will be an initial period in which the standard algorithm is applied and a second one during which the PCT-based algorithm is applied
3203651|NCT00926419|Experimental|Varicella (1/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
3203652|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
3203653|NCT00926419|Experimental|Varicella (2/5 dose) - ID - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.25 ml, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
3203654|NCT00926419|Active Comparator|Varicella (full dose) - SC - Injector|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle-free Syringe Jet Injector
3203655|NCT00926419|Active Comparator|Varicella (full dose) - SC - Syringe|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain) reconstituted in 0.5 ml, Single dose, 0.5 ml Subcutaneous administration with Disposable Needle Syringe
3203656|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle-free Syringe Jet Injector
3203657|NCT00926419|Experimental|Hepatitis A (1/5 dose) ID - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.1 ml Intradermal administration with Disposable Needle Syringe
2546059|NCT02590848|No Intervention|Group with no intervention|This group will receive healthy recommendations of eating fresh fruits
2546063|NCT02590848|Experimental|Group with walnut intake|This group will receive healthy recommendation of eating fresh fruits + 30 g of walnut kernels per day during 6 months.
2546125|NCT02590640|Active Comparator|Inhibitory insular rTMS|Inhibitory (1 Hz) repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
2546128|NCT02590640|Sham Comparator|Sham insular rTMS|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
2546203|NCT02589990|Experimental|Strength training|Strength training, 4 rep of 4RM x 4 sets in leg press.
2546333|NCT02589028|Experimental|premeal protein bar first|"intervention: premeal protein-enriched bar intake~protein enriched bar(total serving: 30g, 43.28% carbohydrate; 1.29% fat; 40.39% protein; 42.63% fiber) will be given 30 minutes before breakfast~protein enriched bar is provided with 150 ml of water~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
2546334|NCT02589028|Other|breakfast first|"intervention: breakfast follows by protein bar~protein enriched bar is provided with 150 ml of water shortly after breakfast~amount of protein bar : 30g~breakfast : plain bagel, cream cheese, strawberry jam, orange juice 210ml"
2546365|NCT02588794|Active Comparator|intervention|Standart CVVHD plus CytoSorb 300 ml device (3804606CE01)
2546369|NCT02588794|No Intervention|control|Standart CVVHD
2546389|NCT02588534|Active Comparator|Treatment A-etanercept (ENBREL®) via auto-injector device|Single dose of etanercept (ENBREL®) in a pre-filled syringe administered with an auto-injector device manufactured by Scandinavian Health Limited (SHL)
2546391|NCT02588534|Other|Treatment B-etanercept (ENBREL®) via Manual injection|single dose of etanercept (ENBREL®) in a syringe given by manual injection (reference treatment)
2546446|NCT02588313|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
2546450|NCT02588313|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
2546451|NCT02588313|Placebo Comparator|Placebo formulation|Placebo formulation
2546464|NCT02587975|Experimental|Evogliptin 10 mg|Single oral administration of 2 tablets of evogliptin 5 mg with water 250 mL
2546506|NCT02587780||Inactive|people who perform < 30mins.day physical activity at a 'moderate' level of intensity.
2546507|NCT02587780||Active|people who perform 30mins-60 mins.day of physical activity at a 'moderate' level of intensity.
2546508|NCT02587780||Very active|People who perform > 60 mins.day of physical activity at a >moderate level of intensity.
2546567|NCT02587494|Active Comparator|Early cardiac catheterization|Cardiac catheterization performed as early as possible, within 12h post ROSC following OHCA, with possible PCI during mild therapeutic hypothermia or apyrexia
2546573|NCT02587494|No Intervention|Medical arm|Initial therapy does not include cardiac catheterization. Cardiac catheterization with possible PCI is allowed after completion of mild therapeutic hypothermia or apyrexia for >24h post ROSC.
2546615|NCT02587039|Placebo Comparator|Control: Usual care|This group will receive usual care and delirium assessments.
2546616|NCT02587039|Experimental|Treatment: Ischemic Pre-conditioning|Remote Ischemic pre-conditioning before cardiac surgery and delirium assessments.
3203658|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Injector|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle-free Syringe Jet Injector
3203659|NCT00926419|Active Comparator|Hepatitis A (full dose) IM - Syringe|Hepatitis A virus vaccine, inactivated, Single dose, 0.5 ml Intramuscular administration with Disposable Needle Syringe
2546732|NCT02586376|Sham Comparator|0J LLLT|The intervention will be made with the machine off.
2546737|NCT02586376|Experimental|4J LLLT|The Laser radiation will be made with 4J by spot.
2546741|NCT02586376|Experimental|6J LLLT|The Laser radiation will be made with 6J by spot.
2546743|NCT02586376|Experimental|8J LLLT|The Laser radiation will be made with 8J by spot.
2546780|NCT02585986|Active Comparator|Probiotic|daily intake of 1 capsule containing probiotic.
2546785|NCT02585986|Placebo Comparator|Placebo|daily intake of 1 capsule containing placebo
2546846|NCT02585739|Experimental|patient|patient with Cluster headache
2546855|NCT02585739|Other|healthy subject|patient without Cluster headache
2546934|NCT02585375|Experimental|Patients with glaucoma or ocular hypertension 1|35 patients with glaucoma or ocular hypertension
2546937|NCT02585375|Active Comparator|Patients with glaucoma or ocular hypertension 2|35 patients with glaucoma or ocular hypertension
3203660|NCT00926432|Other|Healthy volunteers|Small group of aged healthy volunteers
3203661|NCT00926432|Other|Patients|Patients consulting for spine disorders that may or may not have postural troubles
2547124|NCT02583997|Active Comparator|Routine third molar extraction|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care (i.e. with suturing of the lower alveoli).~Intervention: Suturing of lower alveoli"
2547129|NCT02583997|Experimental|Third molar extraction without suturing|"Patients randomized to this arm will have all four wisdom teeth removed according to usual, standard care, except that the resulting alveoli will not be sutured.~Intervention: Non suturing of lower alveoli"
2547190|NCT02583607|Experimental|Brava and fat transfer|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~Woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
3203662|NCT00926445||Preterm (BW < 1500 grams)|
3203663|NCT00926445||Critically ill term newborn|ventilation > 48 hours
3203664|NCT00926445||Healthy term newborn|
3203665|NCT00926471|Experimental|Cognitive Behavioral Therapy (CBT) Program|Participants will receive a treatment program involving CBT plus adjunctive group counseling and parent training.
2545899|NCT02592096|Experimental|0.1% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2545900|NCT02592096|Experimental|0.3% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2545904|NCT02592096|Experimental|0.5% Pazufloxacin Mesilate Ear Drops|10 drips for ear dropping, 10 minutes for ear bath
2545905|NCT02592096|Active Comparator|Pazufloxacin mesilate injection|0.3g, 30 minutes for ventricular injection
2545958|NCT02591654|Experimental|Pembrolizumab and FLT|Subjects will receive WB-DW MRI and FLT PET to assess disease burden after receiving pembrolizumab.
2546041|NCT02590861|Experimental|Dental implant|All participants will receive the same intervention, this is a single group study.
2546170|NCT02590302|Other|Dyads receiving the Implementation Phase|Dyad 1 (CHEO-YSB) Dyad 2 (CGH-CCH) Dyad 3 (WDMH-CCH) Dyad 4 (QCH-YSB)
2546257|NCT02589600|Experimental|Active Medication Group|Annual dose: intravenous zoledronic acid (Reclast) 5.0 mg; vitamin D (800 IU/daily) and calcium (approximately 1200 mg/daily, dietary + supplements)
2546261|NCT02589600|Placebo Comparator|Placebo Group|Annual dose: intravenous saline; vitamin D (800 IU/daily and calcium (approximately 1200 mg/daily, dietary + supplements)
3203666|NCT00926471|No Intervention|Wait list control|Participants will be placed on a 12-week wait list with no active treatment
2546447|NCT02588300|Experimental|Drug induced sleep endoscopy|Patients upper airway is assessed by drug induced sleep endoscopy
2546511|NCT02587702|Experimental|Improved Infant Formula Group|Containing β-Palmitate Content
2546512|NCT02587702|Placebo Comparator|General Infant Formula Group|Excluding β-Palmitate Content
2546513|NCT02587702|Active Comparator|Human Milk Group|Containing β-Palmitate Content Naturely in Human Milk
2546530|NCT02587429|Experimental|Patienteducation|(Patients with PCS>22). An education in pain coping delivered by physiotherapists. The education consist of seven sessions over a four months period. Each session is individual and will last 30 minutes. Focus will be on pain behaviour and pain coping based on Cognitive Behavioral Therapy.
2546531|NCT02587429|No Intervention|Control group 1|(Patients with PCS>22). Patients randomly assigned to this arm will undergo usual treatment for total knee arthroplasty.
2546532|NCT02587429|No Intervention|Control group 2|(Patients with PCS<12). Patients in this arm will undergo usual treatment for total knee arthroplasty. Patients in this arm are not randomized but matched by age, gender and BMI with patients in control group 1.
2546569|NCT02587286|Experimental|Gather app|Use of the Gather mHealth diabetes management system
2546578|NCT02587286|No Intervention|Control|Control group participants will be recruited from the same clinics and will also fit all study inclusion and exclusion criteria. Participants will be recommended to test their BG as per usual care in India. Providers will not contact control group participants between regular visits, though they will respond to queries directed at them in typical fashion.
2546601|NCT02587052||Tacrolimus|100 patients treated with generic tacrolimus
2546603|NCT02587052||Prograf|100 patients treated with Prograf
3203667|NCT00926484||Tooth Mousse|
2546883|NCT02585440|Experimental|Group A|CMX157, tablet, 5 mg, QD, 14 days versus CMX157 placebo, 5 mg, tablet, QD, 14 days
2546886|NCT02585440|Experimental|Group B|CMX157, tablet, 10 mg, QD, 14 days versus CMX157, placebo tablet, 10 mg, QD, 14 days
2546887|NCT02585440|Experimental|Group C|CMX157, tablet, 25 mg, QD, 14 days versus placebo CMX157, placebo tablet, 25 mg, QD, 14 days
2546889|NCT02585440|Experimental|Group D|CMX157, tablet, 50 mg, QD, 14 days versus CMX157, placebo tablet, 50 mg, QD, 14 days
2546891|NCT02585440|Experimental|Group E|CMX157, tablet, 100 mg, QD, 14 days versus CMX157, placebo tablet, 100 mg, QD, 14 days
2546939|NCT02585128|Other|Patients following TAVI|
3203668|NCT00926484||fluoride varnish|
2547054|NCT02584465|Active Comparator|A-Tamoxifen|Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression
2547055|NCT02584465|Experimental|B-Regorafenib|Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression
2547120|NCT02584062|Experimental|no-touch fluid-air exchange group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will not touch the macular area,especially the area of the macular hole and investigator will not have the fluid-air exchange of the macular area.
2547121|NCT02584062|Experimental|the tradional group|All patients in no-touch fluid-air exchange group will have a surgery of vitrectomy metrectomy and internal membrane peeling and gas tamponed.In this surgery ,investigator will touch the macular area and investigator will have the fluid-air exchange.
3203669|NCT00926484||Tooth Mousse + fluoride varnish|
3203670|NCT00926510|Experimental|Language Toolkit|Language toolkit composed of simple tools that parents can use to interact with child and help language acquisition.
3203671|NCT00926510|Placebo Comparator|2|Safety counseling and smoke detector
3203672|NCT00926523||Healthy Controls|Subjects are made up of healthy adults
3203673|NCT00926523||Affected|Subjects have Pulmonary Hypertension
3203674|NCT00926549|Experimental|spectral domain-OCT|Spectral domain-OCT scanning performed.
3203675|NCT00926562|Experimental|Iopromide|Drug: Ultravist 370 mgl/ml, injection of intra-artery during cardiac interventional operation
3203676|NCT00926562|Active Comparator|Iodixanol|Drug: Visipaque 320 mgl/ml, injection of intra-artery
3203677|NCT00926614|Experimental|Pioglitizone and Atorvastatin|Pioglitazone and Atorvastatin added to standard of care Pegasys and weight based ribavirin
3203678|NCT00926627|Placebo Comparator|Placebo|placebo b.i.d.
3203679|NCT00926627|Experimental|Bosentan|62.5 mg/125 mg bosentan b.i.d.
3203680|NCT00926640|Experimental|1|Belinostat dose escalation
3203681|NCT00926640|Experimental|2|Belinostat UGT1A1 wild type/*28 variant
3203682|NCT00926640|Experimental|3|Belinostat UGT1A1*60 or 2/3/4 variant
2545871|NCT02592174|Other|HIV subjects|"Evaluation of health-related quality of life and collection of social and demographic informations at the inclusion visit.~Neurocognitive assessment with neuropsychologist and walking speed, grasp force and one leg stand assessments at the neurocognitive visit.~Two substudies will be proposed:~cerebral images sub-study (80 patients in the centers of Montpellier and the centers of Nîmes)~sub-study on immune activating markers with sample's collection (plasma), 85 patients in the centers of Montpellier and the centers of Nîmes."
3169023|NCT00558038|Active Comparator|1|
3169024|NCT00558038|Experimental|2|
3169025|NCT00558051|Active Comparator|Intradermal administration|Intradermal administration
2546097|NCT02590692|Experimental|CPCB-RPE1 treatment|Subretinal implantation of CPCB-RPE1 in dry AMD patients
2546185|NCT02590315|Experimental|Digital Breast Tomosynthesis - DBT|Invitation for breast screening and random allocation. Participants randomised to DBT will be screened with bilateral, two-view combo mode (DBT images are obtained with DM images). DBT participants will have an additional radiation exposure for the combined DM and DBT examinations.
2546187|NCT02590315|Active Comparator|Conventional digital mammography - DM|Invitation for breast screening and random allocation. Participants randomised to DM will be screened with bilateral, two-view DM.
2546243|NCT02589743|Active Comparator|Fluroshield - F (Sealant)|Pit and fissure sealing using only sealant
2546245|NCT02589743|Experimental|Single Bond and F (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
2546246|NCT02589743|Active Comparator|Helioseal Clear Chroma - H (Sealant)|Pit and fissure sealing using only sealant
2546247|NCT02589743|Experimental|Excite and H (Adhesive and Sealant)|Pit and fissure sealing using adhesive and sealant
2546289|NCT02589379||Pancreatic Resection|All consecutive patients undergoing pancreatic resection for benign or malignant disease and meet inclusion criteria.
2546310|NCT02589184|Experimental|hypergravity WITH isometric load|Patient performing rehabilitation exercises under hypergravity as well as loaded isometric squats
2546318|NCT02589184|Experimental|hypergravity WITHOUT isometric load|Patient performing rehabilitation exercises under hypergravity
2546325|NCT02589184|Experimental|normal gravity WITH isometric load|Patient performing rehabilitation exercises under normal gravity as well as loaded isometric squats
2546328|NCT02589184|Active Comparator|normal gravity WITHOUT isometric load|Patient performing rehabilitation exercises under normal gravity
2546360|NCT02588781|Experimental|Pemetrexed|Pemetrexed 500 mg/m2 IV Q 3 weeks
2546386|NCT02588560||HCV lymphoma patients with chemotherapy|Lymphoma patients who are positive for anti-HCV and are planning to receive chemotherapy for lymphoma
2546431|NCT02588378||Early dry AMD (no GA)|multi-modal cSLO imaging
2546433|NCT02588378||Late dry AMD (with GA)|multi-modal cSLO imaging
2546434|NCT02588378||Reticular Pseudodrusen (RPD)|multi-modal cSLO imaging
2546437|NCT02588378||Polypoidal Choroidal Vasculopathy (PCV)|multi-modal cSLO imaging
2546439|NCT02588378||Retinal Angiomatous Proliferaion (RAP)|multi-modal cSLO imaging
2546440|NCT02588378||Central Serous Retinopathy (CSR)|multi-modal cSLO imaging
2546442|NCT02588378||RPE Detachment (RPED)|multi-modal cSLO imaging
2546445|NCT02588378||New onset CNVM (wet AMD)|multi-modal cSLO imaging
2546449|NCT02588378||Healthy (non-AMD) controls|multi-modal cSLO imaging
2546504|NCT02587806|Experimental|Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC)|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
2546538|NCT02587468|Experimental|Juice Plus+(R)|Check of phenolic absorption between baseline and after 8wks of intake before-after comparison
2546876|NCT02585453|Experimental|Patients with dry eye syndrome 1|20 Patients with dry eye syndrome
2546878|NCT02585453|Active Comparator|Patients with dry eye syndrome 2|20 Patients with dry eye syndrome
2546882|NCT02585453|Active Comparator|Patients with dry eye syndrome 3|20 Patients with dry eye syndrome
2546898|NCT02585193|Other|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
2546941|NCT02585115||Non-pregnant women with symptoms|Non-pregnant women with one or more symptoms of UTI. All women will make a paired urine sample (first void and midstream void) of the same urine sample.
2546977|NCT02584894|Placebo Comparator|rTMS 1Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 1Hz on dorsolateral prefrontal cortex (1Hz rTMS is describe in the literature to have no effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter . Heart rate measure With electrocardiogram
2546979|NCT02584894|Experimental|rTMS 10Hz|Subjects have 8 session of trauma exposure with repeated transcranial magnetic stimulation (rTMS) at 10Hz on dorsolateral prefrontal cortex (10Hz rTMS is describe in the literature to have effect on the dorsolateral prefrontal cortex). psychoneurological assessment. Electrodermal conductance measure With conductivity meter. Heart rate measure with electrocardiogram
2547042|NCT02584556|Experimental|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).
2547046|NCT02584556|Active Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).
2549181|NCT02570581|Active Comparator|jelly with zopiclone|Jelly with zopiclone
3169026|NCT00558051|Active Comparator|Intranodal administration|Intranodal administration
3169027|NCT00558051|Active Comparator|Intralymphatic infusion|Intralymphatic infusion
3169028|NCT00558077|Experimental|A|Metformin plus clomiphene citrate
3169029|NCT00558077|Active Comparator|B|Laparoscopic ovarian drilling
3169030|NCT00558090|Active Comparator|A|patients receive 2,5 mg morphine iv, before the first intervention on the day after admission in the ICU
2545936|NCT02591615|Active Comparator|Arm B|"MK-3475 200 mg/m2 IV every 21-days for up to 4 cycles~Patients with CR, PR, or SD by irRC will then be treated with:~For Squamous Carcinoma:~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Paclitaxel 200 mg/m2 IV day 1 every 21-days for up to 4 cycles~OR~For Non-squamous Carcinoma~Carboplatin AUC = 6 IV day 1 every 21-days for up to 4 cycles Pemetrexed 500 mg/m2 IV day 1 every 21-days for up to 4 cycles"
2546017|NCT02591212|Active Comparator|#ConnectDots|"Green Dot Intensive Bystander Training (INT Condition) (Randomized):~Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.~Administered by: UK VIP Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training."
2546019|NCT02591212|Placebo Comparator|#ConnectWell|"Wellness Initiatives for Student Empowerment delivered by UK's Student Wellness Office Programming: Addresses elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.~Administered by: UK VIP/Student Wellness Ambassadors Delivery Mode: Class or large groups of 100-150 students; training lasts 3 hours Required: Elective. All students randomized to this condition will be scheduled for training"
2546034|NCT02590900||at delivery|women who underwent cesarean at delivery, and needed iv paracetamol as part of multimodal analgesia. In these cases, paracetamol was administered q6h (2g loading dose, 1g q6h for 24 h), and blood and urine samples were collected to describe paracetamol disposition at delivery.
2546036|NCT02590900||postpartum|a subgroup of 8 women initially included in at delivery, underwent a second PK study 2-3 months postpartum and another PK study about 1 year after delivery. This PK study was based on a single iv paracetamol administration (2 g), and blood and urine samples were collected to describe paracetamol disposition in postpartum
2546039|NCT02590900||healthy female volunteers|"a group of 8 young healthy women not on oral contraceptives underwent a single PK study (2 g intravenous paracetamol) and blood and urine samples were collected to described paracetamol disposition in healthy female volunteers, not on oral contraceptives.~Raw data as published by Gregoire et al (Clin Pharm Ther 2007) were available in 14 young women, all on contraceptives."
3169031|NCT00558116|Experimental|1|Treatment with Dynasplint device
3169032|NCT00558116|No Intervention|2|Control group; does not receive conservative or surgical treatment.
2546175|NCT02590276|Experimental|Evaluation|Characterization
2546234|NCT02589834|Active Comparator|Quran group|The patients listened to Quran recitation by a compact disc player through an occlusive headphone, started after induction of spinal anesthesia and continued throughout the entire cesarean section duration.
2546235|NCT02589834|No Intervention|Non-Quran group|Those patients did not listen to Quran and subjected to operative room noise throughout the surgery.
2546256|NCT02589535||septic|Group Gb: postoperative septic patients in intensive care unit (ICU)] Gb1: the group of septic patients treated with extracorporeal hemoperfusion therapy and conventional therapy according to the Surviving Sepsis Campaign guidelines Gb2 group treated with conventional therapy according to the Surviving Sepsis Campaign guidelines
2546263|NCT02589535||no septic|Ga: postoperative patients in emergency surgical ward (ES)
2546270|NCT02589535||healthy|Healthy people
2546314|NCT02589288|Active Comparator|Continuous Infusion|Patients receive a postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
2546320|NCT02589288|Experimental|Automatic Intermittent Bolus|Patients receive a postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% and 4 ml PCA bolus, lockout 20 minutes every hour via electronic infusion pump (Micrel device, Greece).
2546356|NCT02588820|Experimental|Antiretroviral treatment|
2546482|NCT02588170|Experimental|Surufatinib|Surufatinib 300 mg, orally, once daily (QD)
2546488|NCT02588170|Placebo Comparator|Placebo|Placebo 300 mg, orally, once daily (QD)
2546551|NCT02587507|Placebo Comparator|Water|The subjects will ingest the HFHC meal with 500mL of water.
2546553|NCT02587507|Experimental|Orange juice|The subjects will ingest the HFHC meal with 500mL of orange juice.
2546558|NCT02587507|Active Comparator|Water with glucose|The subjects will ingest the HFHC meal with 500mL of water with glucose (isocaloric control of the orange juice).
2546596|NCT02587091|No Intervention|Control Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. There was no advertisement of portable ultrasound.
2546598|NCT02587091|Experimental|Intervention Arm|In this arm communities were told by word of mouth advertisement that a comprehensive antenatal care clinic would be held. In addition, it was advertised that portable ultrasound would be provided free of charge in addition to standard comprehensive antenatal care.
2546635|NCT02586935|Active Comparator|Tideglusib|
2546636|NCT02586935|Placebo Comparator|Placebo|
2546704|NCT02586636|Other|OCT1 -/-|Cohort of patients with two loss of function alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort.
2546705|NCT02586636|Other|OCT wt/wt|"Cohort of patients with two normal or wild type alleles for OCT1. The participants within this group will receive metformin at increasing dose to a maximum tolerated dose over two distinct four week treatment periods. The concurrent treatment order of omeprazole and placebo will be randomised within the cohort."
3169033|NCT00558129|Experimental|Investigational|X-STOP® PEEK IPD
3169034|NCT00558129|Active Comparator|Control|Laminectomy
3169035|NCT00558142|Active Comparator|1|Healthy volunteers will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
2545978|NCT02591628|No Intervention|Usual Care|"Usual care patients are defined as patients of physicians randomized to usual care. All these patients will keep their current prescription for HCTZ and work with their physician like normal. These patients will be followed for 9 months with no intervention to compare primary and secondary outcomes to the intervention group."
2546038|NCT02591173|Experimental|Angiotensin-(1-7)|Patients will receive an intravenous infusion of five ascending doses of Angiotensin-(1-7). The doses are: 1, 2, 4, 8 and 16 ng/kg/min. Each dose will be maintained for 10 minutes, for a total of 50 minutes.
2546040|NCT02591173|Placebo Comparator|Saline|Patients will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will be maintained for 50 minutes.
2546112|NCT02590744|Experimental|eye patch|cover the sick eye with eye patch for 3 hours preoperatively.
2546113|NCT02590744|Placebo Comparator|non-eye patch|do not cover the sick eye before surgery.
2546206|NCT02589964|Active Comparator|Probiotic|"Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The treatment is Florajen-3. The ingredients in Florajen-3 are:~Lactobacillus acidophilus-over 7.5 billion Bifidobacterium lactis-over 6.0 billion Bifidobacterium longum-over 1.5 billion"
2546208|NCT02589964|Placebo Comparator|Placebo|"Placebo will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days. The ingredients in the placebo are:~Rice maltodextrin"
2546255|NCT02589587|Active Comparator|sleeve gastrectomy|Morbidly obese patients scheduled for sleeve gastrectomy will be examined by endoscopy before and 3 months after surgery. Biopsies will be taken from stomach and duodenum.
2546258|NCT02589587|Other|no intervention|Lean, healthy controls will undergo endoscopy and biopsies will be taken from stomach and duodenum.
2546341|NCT02589249|Placebo Comparator|Placebo|placebo
2546343|NCT02589249|Active Comparator|AyuFlex1|AyuFlex1 (500 mg/d)
2546345|NCT02589249|Active Comparator|AyuFlex2|AyuFlex2 (1000 mg/d)
2546407|NCT02588703|Experimental|Cognitive Behavioral Therapy|9-session 2-hour group cognitive behavioral therapy
2546410|NCT02588703|Active Comparator|Usual Care|9-session 2-hour group counseling
2546474|NCT02588157|Active Comparator|İnsertion time|handling the device till the glottic visualisation of Macintosh, McGrath MAC X-Blade and Glidescope
2546478|NCT02588157|Active Comparator|intubation time|handling the device till seeing the endotracheal tube entering from the vocal cords Macintosh, McGrath MAC X-Blade and Glidescope
3203683|NCT00926653||Depressed|Elderly participants with depression
3203684|NCT00926653||Control|Elderly participants who have never experienced depression
3203685|NCT00926692||Healthy Subjects|All subjects are considered healthy
3203686|NCT00926705|Active Comparator|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
3203687|NCT00926705|Experimental|Dexmedetomidine and Fentanyl|This group received a combination of Dexmedetomidine (1 ug/kg) and Fentanyl (1.79 ug/kg). Total number of patients in this group 24.
3203688|NCT00926718|Experimental|Dose 1a|
3203689|NCT00926718|Experimental|Dose 2a|
3203690|NCT00926718|Experimental|Dose 3a|
3203691|NCT00926718|Experimental|Dose 1b|
3203692|NCT00926718|Experimental|Dose 2b|
3203693|NCT00926718|Experimental|Dose 3b|
3203694|NCT00926731|Experimental|1|AZD1152 variable dose in combination with 20 mg of LDAC. (The LDAC is given twice daily.)
3203695|NCT00926744|Experimental|Intervention|Physically inactive participants receiving both physical activity and dietary counseling
3203696|NCT00926744|No Intervention|Active|Physically active participants receiving only dietary counseling
3203697|NCT00926744|No Intervention|Control|Physically inactive participants receiving only dietary counseling
3203698|NCT00926757|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
3203699|NCT00926757|Active Comparator|Therapeutic arm|In patients with HBV reactivation and ALT flare > 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission
3203700|NCT00926770||Pretem infants (GG < 37+0)|
2546811|NCT02585856|Experimental|PDT+stent|Patients with unresectable CCA are performed PDT and biliary stent with ERCP
2546817|NCT02585856|Placebo Comparator|stent|Patients with unresectable CCA are performed biliary stent with ERCP alone
2546919|NCT02585414||85 healthy subjects with no history of DES|
2546921|NCT02585414||255 subjects with DES|
2546975|NCT02584946|Placebo Comparator|Low-AVA oat flour cookies|
2546978|NCT02584946|Experimental|High-AVA oat flour cookies|
3203701|NCT00926809|Active Comparator|Eradication|Helicobacter pylori eradication
3203702|NCT00926809|Placebo Comparator|No eradication|No eradication for Helicobacter pylori
2547169|NCT02583542|Experimental|Dose Expansion Phase (Phase IIa)|"Following the definition of the recommended Phase 2 Dose (RP2D), three NSCLC and one TNBC dose expansion cohorts are planned to perform a preliminary assessment of the anti-tumour efficacy in different molecular settings and to further establish the safety profile of the selected RP2D. These cohorts are:~Triple-negative breast cancer (TNBC)~Squamous cell lung cancers~Non-squamous cell lung cancers with KRAS mutations~Non-squamous cell lung cancers with wild-type KRAS"
3203703|NCT00926835|Experimental|Paroxetine|Paroxetine monotherapy
3203704|NCT00926835|Active Comparator|Escitalopram|Escitalopram monotherapy
3203705|NCT00926835|Active Comparator|Venlafaxine|Venlafaxine monotherapy
3203706|NCT00926835|Active Comparator|Paroxetine+Bupropion|
3203707|NCT00926835|Active Comparator|Paroxetine+Lamotrigine|
3203708|NCT00926835|Active Comparator|Paroxetine+Lithium|
3203709|NCT00926835|Active Comparator|escitalopram+mirtazapine|
3203710|NCT00926835|Active Comparator|Escitalopram+Aripiprazole|
3203711|NCT00926835|Active Comparator|Paroxetine + Venlafaxine|
3203712|NCT00926861||Dry AMD|male or female persons aged over 50 years with dry age-related macular degeneration
3203713|NCT00926874||1|patients who presented an ischaemic stroke(full stroke or TIA)
3203714|NCT00926874||2|patients who present an acute coronary syndrome (ACS).
2546029|NCT02591108|Active Comparator|Microstim|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
2546072|NCT02590835|Active Comparator|Control group|Treated with conventional orthodontics
2546073|NCT02590835|Experimental|Test group|subjected to piezo-assisted orthodontics
2546101|NCT02590536|Experimental|sildenafil citrate|Group A (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with sildenafil citrate 25 mg of sildenafil citrate every 8 hours starting at diagnosis of FGR until delivery
2546104|NCT02590536|Placebo Comparator|placebo|Group B (45 patients): pregnancies affected by Fetal Growth Restriction (FGR) being treated with placebo every 8 hours starting at diagnosis of FGR until delivery.
2546162|NCT02590289|Experimental|BBI-5000 Dose 1|Low dose of BBI-5000
2546164|NCT02590289|Experimental|BBI-5000 Dose 2|Middle dose of BBI-5000
2546167|NCT02590289|Experimental|BBI-5000 Dose 3|High dose of BBI-5000
2546168|NCT02590289|Experimental|BBI-5000 Dose 4|High dose of BBI-5000
2546217|NCT02589899||Needle placement in different tissue types|Needle placement and impedance measurements in different tissue types
3203715|NCT00926900|Active Comparator|D-cycloserine|
2546321|NCT02589054||Patients|
2546361|NCT02588950|Experimental|Part A: U-500R Single Injection|Bolus of U-500R administered via single subcutaneous (SC) injection in one of the two periods
2546362|NCT02588950|Experimental|Part A: U-500R CSII|Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII) in one of the two periods
2546368|NCT02588950|Experimental|Part B: U-500R TID|U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days
2546371|NCT02588950|Experimental|Part B: U-500R BID|U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days
2546387|NCT02588482|Experimental|electroencephalography recording|Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously
2546429|NCT02588352|Experimental|Healthy volunteers|Open label administration of salt tablets for one week
2546469|NCT02588066|Experimental|Index test|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
2546471|NCT02588066|No Intervention|Reference test|No Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
2546514|NCT02587715|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
2546566|NCT02587390|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2546572|NCT02587390|Active Comparator|Simvastatin 80 mg|Simvastatin 80 mg
2546643|NCT02586844||Neuroendocrine tumors (NETs)|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
2546646|NCT02586844||panNETs|Eligible consenting patients will undergo one-time biopsy, during which at least 3 tumors' core samples (total length of at least 6 cm) will be collected. Core tumor biopsies and 3 vials of whole blood and archived tumor specimens will be obtained for genomic testing analysis.
2546686|NCT02586610|Experimental|Neoadjuvant Treatment|"All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:~Pembrolizumab 200 mg IV Days 1, 22 and 43~Capecitabine 825 mg/m2 PO in twice daily doses (total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days~Radiation therapy 50.4 GY. Daily fractions of 1.8 Gy over a 6 week interval, excludes weekends"
2546725|NCT02586324|Other|global medium|
2546730|NCT02586324|Experimental|SSM|
2546760|NCT02586168|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2546762|NCT02586168|Placebo Comparator|Placebo|Placebo
3203716|NCT00926900|Placebo Comparator|Placebo|
3203717|NCT00926913||Group 1|
2546870|NCT02585466||BIS25|BIS 25 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 ofBIS 25 of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
2546874|NCT02585466||BIS50|BIS 50 levels were subsequently maintained via propofol TCI 0.2 microg mL-1 TCI adjustments. Stable BIS values that showed no further decline and remained within BIS ±5 of either BIS 50 levels of the previous BIS value were considered an indicator of pseudo-steady state plasma effect-site equilibration
2546922|NCT02585323|Active Comparator|Immediate Intervention Group|Education session, Fitbit/FitViz, PT counselling: Participants receive this intervention in Months 1-3. The session will include a presentation on physical activity, an individual goal-setting session with a registered physiotherapist, and an orientation to the Fitbit Flex and the FitViz app. In Months 1 and 2, participants will use the Fitbit/FitViz. The PT will review the progress with participants via 20-minute bi-weekly phone calls, and progressively modify their activities. In Month 3, participants will continue using the Fitbit/FitViz and have access to a PT via email as needed, but no bi-weekly phone calls. In Months 4-9, participants may continue using the Fitbit/FitViz without access to a PT.
2546976|NCT02584881|No Intervention|Control|Standard care at discharge will be implemented with these trauma patients
2547189|NCT02583438|Experimental|Lifestyle intervention|
3203718|NCT00926926|Experimental|Active OTG|
3203719|NCT00926926|Placebo Comparator|Placebo|
3203720|NCT00926939|Experimental|Abstinence Contingent (AC)|This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
3203721|NCT00926939|Experimental|Submission Contingent (SC)|This group receives vouchers for submitting videos of their CO breath test.
3203722|NCT00926965|Experimental|Olanzapine group|randomized to Olanzapine group with dose range of 2.5-30mg/day
2546092|NCT02590770|Placebo Comparator|non-gaze contingent|Placebo: participants will receive non-gaze-contingent feedback according to their viewing patterns
2546134|NCT02590393|Experimental|Nicotine + NNTAs|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks. E-cigarette cartridges will contain tobacco extract with nicotine + NNTAs in a vehicle of propylene glycol and vegtable glycerin, with tobacco or menthol flavor matched to each participant's preference. The yields of nicotine and NNTAs will be in the range of typical commercial cigarettes.
3203723|NCT00926965|Experimental|Amisulpiride group|the subjects were randomized to the amisulpiride group with dose range of 100 to 800mg/day
3203724|NCT00926965|Active Comparator|FGA group|The subjects were randomized to maintain the conventional antipsychotics
3203725|NCT00926978|Other|Radiopharmacokinetics|"1-2 mCi I-124 orally, once per day, twice total 0.9mg rhTSH intravenous injection, once per day, four total~After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
3203726|NCT00926991||traumatic rib fractures|
3203727|NCT00927004|Experimental|Etoricoxib 60 mg|
2546358|NCT02588755|Active Comparator|TACE+ Tegafur|Patients will be treated with Tegafur after resection soon, and TACE in 4 or 8 weeks after resection.
2546364|NCT02588755|Experimental|TACE|Patients will be treated with TACE alone in 4 or 8 weeks after resection.
2546405|NCT02588495|No Intervention|Fasting|Participant will remain fasted following initial gastric ultrasound
2546406|NCT02588495|Experimental|Food intake|Participant will ingest either 250mL of clear fluid (apple juice) or 250mL of coffee and a muffin following initial gastric ultrasound
2546476|NCT02588248|Experimental|Peppermint Oil|"Solution A) Peppermint oil solution (1.6% peppermint oil, which is 0.8% L-menthol)~Ingredients:~16mL of peppermint oil (provided by the NowFoods® company)~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone"
2546481|NCT02588248|Placebo Comparator|Placebo|"Solution B) Placebo solution~Ingredients:~0.4mL of Tween® 80 (i.e. Polysorbate 80) - this is a commonly used food additive that acts as a surfactant to bring the peppermint oil into solution~1L prepackage sterile water~2.6mL of undyed simethicone~Instructions to prepare:~Add tween and simethicone to sterile water. Then, shake vigorously.~Once solution has settled, and patient has been randomized, draw 20mL of solution into a plastic syringe"
2546561|NCT02587611|Experimental|Elemental liquid diet|"Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Elemental liquid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
2546563|NCT02587611|Active Comparator|Standard semi-solid diet|"Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and healthy subjects drink it within 5 min.~Standard semi-solid diet (200 kcal/200 mL) is labeled with 100 mg [13C]sodium acetate and is administered within 15 min using the gastrostomy tube."
2546604|NCT02587078|Active Comparator|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
2546606|NCT02587078|Active Comparator|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
2546747|NCT02586337|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration. Subjects who received Anlotinib will not be eligible for the open-label phase.
2546749|NCT02586337|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
2546783|NCT02585908|No Intervention|Experimental Group A(control group)|regular treatment and follow up
2546789|NCT02585908|Experimental|Experimental Group B|CIK will be used against tumor cells.
2546791|NCT02585908|Experimental|Experimental Group C|γδ T will be used against tumor cells.
2546793|NCT02585908|Experimental|Experimental Group D|CIK and γδ T will be used against tumor cells.
2546828|NCT02585648|Experimental|Patients with dry eye syndrome 1|20 patients with dry eye syndrome, they will receive intervention 1 for one week and then cross over to intervention 2
2546830|NCT02585648|Experimental|Patients with dry eye syndrome 2|20 patients with dry eye syndrome, they will receive intervention 2 for one week and then cross over to intervention 1
2546842|NCT02585531|Experimental|HS3% group|Administration of nebulized hypertonic saline for 4 days. Hypertonic Saline 3% 3 ml.
2546854|NCT02585531|Active Comparator|ED group|Administration of nebulized epinephrine and dexamethasone for 4 days. Epinephrine 1:1000 solution. Dexamethasone solution 8mg/2ml.
2546907|NCT02585258|Experimental|arm A|prednisolone 5 mg per day
2546909|NCT02585258|Placebo Comparator|arm B|placebo capsules once per day
2546998|NCT02584777|Experimental|Pacritinib|Oral administration
2546099|NCT02590549|Experimental|MyoRing Implantation combined with corneal cross linking|Surgical technique: Implantation of a MyoRing in a corneal pocket was performed by using a PocketMaker microkeratome a guided, vibrating diamond blade to create a stromal pocket 9 mm in diameter at a 300-μm depth via a 4- to 5-mm-wide corneal tunnel followed by Corneal Collagen Crosslinking (standard surface UVA irradiation (370 nm, 3 mW/cm2) using Ufalink device)
2546222|NCT02589795|Experimental|Group 1: ID/EP + IM|"0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly without electroporation, at Weeks 0, 4 and 8.~50 µg CN54gp140, intradermally without electroporation, at Week 20."
2546224|NCT02589795|Experimental|Group 2: ID + IM/EP|"0.6 mg DNA-C CN54ENV, intradermally without electroporation, at Weeks 0, 4 and 8.~2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20."
2546226|NCT02589795|Experimental|Group 3: ID/EP + IM/EP|0.6 mg DNA-C CN54ENV, intradermally with electroporation, at Weeks 0, 4 and 8. 2 mg DNA-C CN54ENV, intramuscularly with electroporation, at Weeks 0, 4 and 8. 50 µg CN54gp140, intradermally without electroporation, at Week 20.
2546265|NCT02589444|Experimental|Participants with vitamin D deficiency - treatment group|Participants with 25-hydroxyvitamin D (25(OH)D) ≤30 ng/mL taking oral high-dose vitamin D3 (50,000 IU) once a week and providing stool and sputum sample at screening and 3 months after screening.
2546268|NCT02589444|Sham Comparator|Participants with vitamin D deficiency - placebo group|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/mL taking a sham comparator (placebo) once a week and providing stool sample and sputum sample at screening and 3 months after screening.
2546276|NCT02589444|Other|Participants without vitamin D deficiency|Participants with 25-hydroxyvitamin D (25(OH)D) concentrations > 30 ng/mL with no intervention and providing stool sample and sputum sample at screening and 3 months after screening.
3203728|NCT00927004|Placebo Comparator|Sugar pill|
2546483|NCT02587858||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI, other clinical findings, and PANK2 gene sequencing.
2546489|NCT02587858||PLAN|This group consists of individuals diagnosed with PLAN using a combination of MRI, other clinical findings and PLA2G6 gene sequencing.
2546493|NCT02587858||BPAN|This group consists of individuals diagnosed with BPAN using a combinatino of MRI, other clinical findings, and WDR45 gene sequencing.
2546557|NCT02587663|Active Comparator|Group 1 (standard of care)|Patients undergo standard of care diagnostic imaging comprising bilateral mammography and targeted breast ultrasound.
2546560|NCT02587663|Experimental|Group 2 (bilateral whole-breast ultrasound)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral whole-breast ultrasound.
2546564|NCT02587663|Experimental|Group 3 (bilateral breast contrast-enhanced MRI)|Patients undergo standard of care diagnostic imaging as in Group 1. Patients also undergo bilateral breast contrast-enhanced MRI.
3169036|NCT00558142|Active Comparator|2|Volunteers with CKD III will be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3169037|NCT00558142|Active Comparator|3|Healthy volunteers will receive a single IV dose of 100mls Visipaque 320 (iodixanol, equivalent to 320 mg iodine/ml). They will then be randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3203729|NCT00927017|Active Comparator|Liquorice 66 g/day|Liquorice given 66 grams per day for two weeks
3203730|NCT00927017|Active Comparator|Liquorice 102 g/day|Liquorice given 102 grams per day for two weeks
2546873|NCT02585479|Experimental|systemic chemotherapy|Pirarubicin 30mg/m2 intravenously on Day 1 and Oxaliplatin 100 mg/m2 intravenously on Day 2 every 3 weeks until disease progression or limiting toxicity.
2546875|NCT02585479|Active Comparator|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using Gelfoam every 4 weeks until disease progression or limiting toxicity.
2546897|NCT02585180|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
2546900|NCT02585180|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
3203731|NCT00927030|Experimental|Pharmacokinetic|We hope to target 12 of the 30 children to be enrolled for this study to participate in a pharmacokinetic arm of the study. These 12 children would be receiving overnight sleep studies prior to receiving the first dose of melatonin and again at about every 3 week intervals each time the dose increases until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. During the sleep studies an intravenous catheter will be placed in the child's arm to sample small amounts of blood throughout the day (about 3 teaspoons of blood)to allow us to look at how melatonin is produced in children with autism who have sleep problems.
3203732|NCT00927030|Placebo Comparator|flavored inert liquid|Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
3203733|NCT00927043||1|
2547180|NCT02583802|No Intervention|Control group|Control group received regular hemodialysis treatment, no given Ear pills and Shengmai capsule completed in the treatment of the first stage. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
2547181|NCT02583802|Experimental|Ear pills and Shengmai capsule|On regular hemodialysis based on given auricular Ear pills and Shengmai capsule
2547242|NCT02583217||Ketamine|Ketamine+propofol
2547249|NCT02583217||Remifentanyl|Remifentanyl+propofol
2547292|NCT02582606|Experimental|Regular|Regular meal pattern
2547293|NCT02582606|Experimental|Irregular|Irregular meal pattern
3203734|NCT00927056|Active Comparator|Minimally Invasive Microdiscectomy|
3203735|NCT00927056|Active Comparator|Conventional Open Microdiscectomy|
3203736|NCT00927121|Active Comparator|Group 1 : G_1|G_1: stimulation for 4 - 6 hours a day, 4 tones per sequence
3203737|NCT00927121|Active Comparator|Group 2 :G_2|G_2: stimulation for 4 - 6 hours a day with 12-tone sequences
2546293|NCT02589340|Experimental|Buspirone|Two week titration up to 10 mg tablet/3 times a day for 7 days
2546294|NCT02589340|Placebo Comparator|Placebo|Two week titration up to 3 tablets/3 times a day for 7 days
2546342|NCT02589041|Experimental|Intraneural|Using an Up-and-down methodology, the first patient receives 15 ml ropivacaine 1% intraneural injection. If unsuccessful, following patient will receive an increased dose of LA (2 ml). If successful, following patient will be randomized to have either the same LA dose (9 out of 10 probability) or 2 ml reduction of LA dose (1 out of 10 probability)
2546399|NCT02588742|Experimental|melatonin group|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
2546401|NCT02588742|Placebo Comparator|control group|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
3203738|NCT00927121|Active Comparator|Group3 : G_3|G_3: stimulation for 4 - 6 hours a day, 4 tones per sequence with a signal controlled by EEG measurement
3203739|NCT00927121|Active Comparator|Group 4 : G_4|G_4: stimulation for 1 hour a day, 4 tones per sequence
2546746|NCT02586285|Active Comparator|S-Adenosyl Methionine Treatment|Patients will be treated with S-Adenosyl Methionine treatment after curative resection.
2546750|NCT02586285|No Intervention|Control group|Patients will be treated without S-Adenosyl Methionine treatment after curative resection.
3203740|NCT00927121|Placebo Comparator|Group5 : G_5|G_5: stimulation with placebo-tone
3203741|NCT00927147|Experimental|BNCT plus cetuximab|Patients treated with BNCT followed by cetuximab administration
3203742|NCT00927173|Sham Comparator|Sham|Sham treatment
3203743|NCT00927173|Active Comparator|Active|Active Deep Transcranial Magnetic Stimulation treatment
2547164|NCT02583789|Active Comparator|oral treprostinil|Dosing of oral treprostinil will be initiated at 0.125 mg three times daily. Dose escalations of oral treprostinil can occur every 72 hours (three consecutive doses) in 0.125 mg increments. Subjects will be titrated as tolerated to a goal dose of 2mg TID over a 6-week period.
2547170|NCT02583789|Placebo Comparator|Placebo|Placebo mimics oral treprostinil and will be taken three times a day
3203744|NCT00927199|Experimental|High-Oleic Canola Oil|
2547324|NCT02582593|Active Comparator|Cognitively Normal Group NIR|Transcranial Near Infrared Stimulation for cognitively normal participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2547331|NCT02582593|Sham Comparator|Cognitively Normal Group - Sham|Cognitively Normal Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
2547334|NCT02582593|Active Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic NIR|Transcranial Near Infrared Stimulation for amnestic and nonamnestic participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2547344|NCT02582502|Experimental|Treatment|This arm will receive Hyperbaric Oxygen Therapy immediately after consent into study.
2547350|NCT02582502|Other|Wait list Treatment|This arm will receive Hyperbaric Oxygen Therapy two months after consenting into study.
3203745|NCT00927199|Experimental|High-Oleic Canola/Flaxseed Oil Blend|
3203746|NCT00927199|Active Comparator|Western Diet|
3203747|NCT00927212|Experimental|Group 1|2% AS101 ointment
3203748|NCT00927212|Experimental|Group 2|4% AS101 ointment
3203749|NCT00927225|Active Comparator|active|subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
3203750|NCT00927225|Placebo Comparator|placebo|subcutaneous wound infiltration with 50 mL saline
3203751|NCT00927238|Experimental|XL TDR|The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
3203752|NCT00927238|Other|Outcomes from lumbar fusion study|
3203753|NCT00927277|Placebo Comparator|placebo laser|inactive light on the laser device.
3203754|NCT00927277|Active Comparator|Erchonia (R) LipoLASER PL|The Erchonia(R) LipoLASER PL is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
3203755|NCT00927290|Active Comparator|1|Pioglitazone, 16 weeks before and during antiviral combination therapy
3203756|NCT00927290|Placebo Comparator|2|Pioglitazone placebo, 16 weeks before and during antiviral combination therapy
3203757|NCT00927303||Group 1|Intervention 1 Sequence of observers: observer1, observer 2, observer 1, observer 2
3203758|NCT00927303||group 2|intervention 1 sequence of observers: observer 2, observer 1, observer 2, observer 1
3203759|NCT00927303||group 3|intervention 2 sequence of observers: 1,2,1,2
2546163|NCT02590328||Screened patients|SCID screening: some drops of blood are placed on a second Guthrie card when current screening is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
2546272|NCT02589652||Switch group|Patients who have been assigned to pegylated interferon alfa-2a.
2546275|NCT02589652||Sequential combination group (S-C group)|Patients who have been assigned to pegylated interferon alfa-2a plus entecavir.
2546277|NCT02589652||ETV group|Patients who have been assigned to entecavir monotherapy.
2546316|NCT02588989||transposition of the great arteries|Patients with a TGA
2546381|NCT02588937|Experimental|EntecaBell ODT.|
2546383|NCT02588937|Active Comparator|Baraclude Tab.|
2546480|NCT02588079|Experimental|Internet-based cognitive behavioral therapy|The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
2546485|NCT02588079|No Intervention|Wait list|Participants are not offered any active controlled psychological interventions but have free access to dental health services, which could involve exposure and other behavioral strategies applied by dental staff.
2546525|NCT02587624||RMN AF ablation|Consecutive patients with class I or class IIa indication for catheter ablation for symptomatic atrial fibrillation according to the current guidelines.
2546576|NCT02587325|Experimental|ABI-009|
2546619|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736. 4 cohorts of double combination (Selumetinib+MEDI4736).~The decision to escalate to the next dose level/cohort will be made by the Safety Review Committee (SRC) following the completion of the dose limiting toxicity (DLT) assessment period for at least 3 evaluable patients in each cohort."
2546622|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: Selumetinib+MEDI4736|One or more independent mandatory paired biopsy expansion cohorts for double combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for double combination, the tumor type will be determined from emerging data.
2546625|NCT02586987|Experimental|Dose escalation: Selumetinib+MEDI4736+tremelimumab|"An oral formulation of selumetinib will be administered in combination with an IV dose of MEDI4736 and an IV dose of tremelimumab.~For triple combination treatment, the starting dose of selumetinib (DL1) will be determined by the SRC based on emerging data from dose escalation cohorts of double combination treatment."
2546628|NCT02586987|Experimental|Mandatory paired biopsy expansion cohort: triple combination|One or more independent mandatory paired biopsy expansion cohorts for triple combination treatment will start after safety and tolerability have been established for the relevant dose. It will be tumour-type specific for triple combination, the tumor type will be determined from emerging data.
2546744|NCT02586545|Experimental|Shared care model|Four visits a year: one annual comprehensive check-up at the outpatient diabetes clinic and three quarterly visits at the general practitioner.
2546745|NCT02586545|No Intervention|Mono sectorial care|Treament as usual including four visits a year with the diabetes team at the outpatient clinic: an annual comprehensive check-up, identical to the one received by the intervention group, and three quarterly visits.
2546850|NCT02585622|Experimental|Bone marrow-derived Mesenchymal Stromal Cells|
2546856|NCT02585622|Placebo Comparator|Cryostor CS10|
3169038|NCT00558142|Active Comparator|4|Volunteers with CKD III will receive Visipaque 320 during coronary angiography. They will have been randomised to receive either placebo capsules PO plus an infusion of normal saline, acetylcysteine capsules PO plus an infusion of normal saline or placebo capsules PO plus an IV infusion of acetylcysteine in normal saline
3169039|NCT00558155|Experimental|SEN|standard enteral nutrition
2547103|NCT02584075|Experimental|Lifestyle intervention|
2547187|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 1|ISIS-GCGRRx - Dose Level 1
2547192|NCT02583919|Experimental|ISIS-GCGRRx - Dose Level 2|ISIS-GCGRRx - Dose Level 2
2547196|NCT02583919|Placebo Comparator|Placebo|Placebo
3169040|NCT00558155|Experimental|IMEN|immunostimulating enteral nutrition
3169041|NCT00558155|Experimental|SPN|standard parenteral nutrition
3169042|NCT00558155|Experimental|IMPN|immunostimulating parenteral nutrition
3169043|NCT00558181|Experimental|Rituximab, Methylprednisolone|
3169044|NCT00558194|Experimental|1|Standard behavioral weight loss treatment with cognitive and affective skills training
3169045|NCT00558194|Active Comparator|2|Standard behavioral weight loss treatment
3169046|NCT00558207|Experimental|1|ARQ 197
3169047|NCT00558207|Active Comparator|2|Gemcitabine
3169048|NCT00558220|Experimental|A|Intensive induction followed by high-dose consolidation with stem cell support ± radiotherapy
3169049|NCT00558233|Experimental|Intervention group|
3169050|NCT00558233|Placebo Comparator|Placebo group|
3169051|NCT00558311|Experimental|Clazosentan|A continuous intravenous infusion of clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
3169052|NCT00558311|Placebo Comparator|Placebo|A continuous intravenous infusion of placebo-matching clazosentan was started within 56 hours post-aSAH and was scheduled to continue during the hospitalization until Day 14 post-aSAH, or at least until Day 10.
3169053|NCT00558324|Experimental|I|Corneal flaps were created with mechanical microkeratome (Hansatome 160μm (Chiron Vision Corp, Claremont, Calif)
3169054|NCT00558324|Experimental|II|Corneal flaps were created with mechanical microkeratome K3000 130μm ( BD Ophthalmic Systems, Waltham, Mass) .
3169055|NCT00558324|Experimental|III|Corneal flaps were created with microkeratome femtoseconds laser (Intralase Corp, Irvine, Calif.)
3169056|NCT00558337|Active Comparator|A|
3169057|NCT00558337|Active Comparator|B|
3169058|NCT00558350||1|lobectomy / segmentectomy in patients with lung cancer
3169059|NCT00558376|Active Comparator|1|Ingestion of 3L polyethylene Glycol
3169060|NCT00558376|Active Comparator|2|Ingestion of 2 doses of sodium phosphate 45 cc
2546267|NCT02589678|Other|MMR/Tdap-IPV|Participants receiving MMR vaccine (Measles, mumps, and rubella) at 0 months/at enrollment, followed by Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 3 months.
2546274|NCT02589678|Other|Tdap-IPV/MMR|Participants receiving Tdap-IPV vaccine (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) at 0 months/at enrollment, followed by MMR vaccine (Measles, mumps, and rubella) at 3 months.
3203760|NCT00927303||group 4|intervention 2 sequence of observers: 2,1,2,1
3203761|NCT00927303||group 5|intervention 1 sequence of observers 1,1,2,2
2546419|NCT02588469|Experimental|Interventional group|Physical activity program coupled with compression socks wearing during 3 months.
2546421|NCT02588469|Active Comparator|control group|Physical activity program without compression socks during 3 months.
3203762|NCT00927303||group 6|intervention 1 sequence of observers 2,2,1,1
3203763|NCT00927303||group 7|intervention 2 sequence of observers: 1,1,2,2
2546641|NCT02586883|Experimental|Patients with multiple bronchi dilations|
2546642|NCT02586883|Active Comparator|Control patients without transport abnormality|
2546644|NCT02586883|Active Comparator|Patients with typical cystic fibrosis|
2546706|NCT02586389||Non-hematological Cancer Cohort|Eligible subjects will have been previously diagnosed with a non-hematological cancer with tumor present at baseline blood draw.
2546752|NCT02586220||normal pregnant women|150 normal pregnant women (28-32 weeks' gestation)
2546753|NCT02586220||pregnant women with gestational|100 pregnant women with gestational diabetes (28-32 weeks' gestation)
3203764|NCT00927303||group 8|intervention 2 sequence of observers: 2,2,1,1
3203765|NCT00927316|Active Comparator|Active arm|E. coli 83972 bacteriuria
3203766|NCT00927316|Placebo Comparator|Placebo arm|Monitoring
3203767|NCT00927329|Experimental|dust mite|
3203768|NCT00927342|Active Comparator|Vivostat|
3203769|NCT00927342|Active Comparator|BioGlue|
2546840|NCT02585544|Other|Genital prolapse|Single arm: i.e., all patients
2546915|NCT02585388|Active Comparator|Vinorelbine|Vinorelbine (metronomic) alone 3 times per week ( mondays, wednesdays, Fridays or Thursdays, Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.
2546917|NCT02585388|Experimental|Vinorelbine+Anastrozole or Letrozole|"Vinorelbine metronomic 3 times per week (mondays, wednesdays, Fridays or Thursdays,Tuesdays, Saturdays) at 50 mg per day, taken orally until progression of disease or toxicity.~And:~Letrozole 2,5 mg every day or Anastrozole 1 mg every day. Until progression of disease or toxicity"
2547044|NCT02584543|Experimental|HEV vaccine and HBV vaccine Co-administration group|
2547049|NCT02584543|Active Comparator|HEV vaccine control group|
2547050|NCT02584543|Active Comparator|HBV vaccine control group|
2547087|NCT02584244|Experimental|Patients with colorectal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547088|NCT02584244|Experimental|Patients with esophageal cancer|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547089|NCT02584244|Experimental|Pancreatic cancer patients receiving neoadjuvant chemotherapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547234|NCT02583165|Experimental|Monotherapy arm|MEDI1873
3203770|NCT00927381||Severe envenomation|Patients with a calculated severity score of 5 or 6 were included in this group.
3203771|NCT00927381||Minimal/Moderate Envenomation|Severity Score less than 5
3203772|NCT00927407|Experimental|Malathion gel 0.05%|Malathion gel 0.5% topical treatment for head lice
3203773|NCT00927407|Active Comparator|Malathion lotion 0.5%|Malathion lotion 0.5% treatment for head lice
3203774|NCT00927420||1|Patients diagnosed with bipolar disorder I or II (DSM-IV) in ambulatory settings
3203775|NCT00927433|No Intervention|Standard care|Patients received standard education about fatigue by clinicians.
3203776|NCT00927433|Experimental|Education arm|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions.
3203777|NCT00927446||Endoscopy screening|Patients with tissue diagnosis of head and neck cancer undergo endoscopy screening with conventional white light system first. Then the entire esophagus is examined under the NBI system by another endoscopist, who is blinded to the result of the conventional endoscopy.
3203778|NCT00927459|Experimental|PRO-040201|PRO-040201 with placebo control in each cohort
3203779|NCT00927459|Placebo Comparator|Placebo|PRO-040201 with placebo control in each cohort
3203780|NCT00927498|Active Comparator|Arm A Daunorubicin and Cytarabine|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
3203781|NCT00927498|Experimental|Arm B Daunorubicin and Cytarabine and Mylotarg|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
3203782|NCT00927511|Experimental|A - Dose Tritation|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity
3203783|NCT00927511|Active Comparator|B- Control|Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
3203784|NCT00927524|Active Comparator|Apidra (insulin glulisine)|Administration of Apidra at three meals during a 24 hour period.
3203785|NCT00927524|Active Comparator|70/30 insulin|Administration of 73/30 insulin at three meals during a 24 hour period.
3203786|NCT00927537||Group 1|
3203787|NCT00927537||Group 2|
3203788|NCT00927550|Experimental|lithium plus usual care|
2546509|NCT02587793||Barcelona Clinic Liver Cancer (BCLC) staging|The tumor stages of the patient are classified as BCLC stage 0, A, B, C, or D.
2546517|NCT02587455|Experimental|Low Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
2546519|NCT02587455|Experimental|High Dose Radiotherapy Arm|Pembrolizumab and radiotherapy
2546565|NCT02587364|Experimental|Gemcabene 50 mg|Gemcabene 50 mg
2546570|NCT02587364|Experimental|Gemcabene 150 mg|Gemcabene 150 mg
2546579|NCT02587364|Experimental|Gemcabene 450 mg|Gemcabene 450 mg
2546581|NCT02587364|Experimental|Gemcabene 750/600 mg|Gemcabene 750/600 mg
2546583|NCT02587364|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2546585|NCT02587364|Placebo Comparator|Placebo|Placebo
3203789|NCT00927550|Active Comparator|usual care without lithium therapy|
3203790|NCT00927602|Experimental|fondaparinux|
2546723|NCT02586454|Experimental|Transmuscular quadratus lumborum (QL) block|Bilateral QL block using 20 ml 0.375% ropivacaine in each side (to a maximum dose 3 mg/kg) plus patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
2546726|NCT02586454|Active Comparator|Control|Patient controlled analgesia morphine (1mg/bolus morphine, lockout time 5 minutes) post operative
2546777|NCT02586090|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
2546778|NCT02586090|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
2546838|NCT02585765|Experimental|Pioglitazone|Subjects will receive 8 weeks of daily pioglitazone (30mg/day).
2546845|NCT02585765|Placebo Comparator|Placebo|Subjects will receive 8 weeks of daily placebo capsules.
2546914|NCT02585362|Active Comparator|Intervention group|Participants will receive physical exercise, nutrition counseling and a whey protein Supplement over 12 weeks
2546916|NCT02585362|No Intervention|Control group|Participants will receive standard care
2546972|NCT02584920|Experimental|HLX01|375mg/m2 iv single dose
2546974|NCT02584920|Active Comparator|Rituximab|375mg/m2 iv single dose
3203791|NCT00927615|Experimental|intracoronary abciximab|intracoronary administration of abciximab (0.25 mg/kg body weight)
3203792|NCT00927615|Active Comparator|intravenous abciximab|intravenous administration of abciximab (0.25 mg/kg body weight)
2547102|NCT02584231|Experimental|Patients needing an urinary concentration test|Patients who need a urinary concentration test because of uro- or nephropathy (age: 6 months - 8 year)
2547109|NCT02584231|Experimental|Patients suffering from treatment resistant nocturnal enuresis|Patients suffering from treatment resistant nocturnal enuresis (age: 5 - 8 year)
2547143|NCT02583841|Active Comparator|Scaling and Root Planing( SRP)|This was an interventional study in which scaling and root planing was done in systemically healthy patients with chronic periodontitis
2547149|NCT02583841|No Intervention|Control Group|Scaling and root planing was not done , that is no intervention is carried out in the patients of this group.
2547167|NCT02583542|Experimental|Dose Escalation Phase (Phase Ib)|This phase will investigate two different dosing schedules of AZD2014: a continuous daily schedule (CC-Schedule) and an intermittent schedule of 2 days on and 5 days off treatment (IC-Schedule). The dose of Selumetinib (AZD6244) will remain unchanged in both schedules. The outcome of this investigation will determine whether an additional schedule of combined intermittent Selumetinib (AZD6244) (3 days on and 4 days off treatment) with intermittent AZD2014 will be considered (II-Schedule). The II-Schedule will be initiated following the completion of the corresponding continuous regimens and will only be investigated if escalation of the AZD2014 dose in the IC-Schedule is not feasible with the corresponding continuous Selumetinib (AZD6244) regimen. Up to three individual dose levels of Selumetinib (AZD6244) might subsequently be explored within the intermittent schedule of Selumetinib (AZD6244).
2547405|NCT02582086|Experimental|BOR15001L7 Cream|BOR15001L7 Cream with 5% 15019L0
3203793|NCT00927628||Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular hole. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
3203794|NCT00927641|Active Comparator|Ketoprofen Patch (HKT-500)|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
3203795|NCT00927641|Placebo Comparator|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
3203796|NCT00927654|Experimental|Iloprost|
3203797|NCT00927654|Placebo Comparator|Isotonic Sodium Chloride solution 0.9 %|
3203798|NCT00927667|Experimental|Arm 1|
3203799|NCT00927667|Experimental|Arm 2|
3203800|NCT00927667|Experimental|Arm 3|
2546344|NCT02589223|Active Comparator|Multisensory Stimulation Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
2546346|NCT02589223|Placebo Comparator|Control Group|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
2546415|NCT02588716|Active Comparator|Terlipressin|Terlipressin will be given at the beginning of surgery as an initial bolus dose of (1 mg over 30 mins) followed by a continuous infusion of 2μg/kg/h to be continued throughout the surgery then gradually withdrawn over 4 hours
2546420|NCT02588716|Placebo Comparator|Control|same volumes of normal saline with the same rate of infusion, throughout the operation then gradually withdrawn over 4 hours.
3169061|NCT00558402|Experimental|1|Meditation class, 90min/week for 8 weeks, with home assignments, adapted from MBCT program
2546652|NCT02586779|Experimental|whatsApp messages|consultations in the experimental group will be generated with whatsApp. Patients' all radiographies, laboratory results, electrocardiographs, tomography images, wound images and/or extremity pictures will be sent to consultant physician via whatsApp.
2546653|NCT02586779|Other|control group|consultations in the control group will be generated without whatsApp.
2546715|NCT02586467|Experimental|Gain-Framed|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products).
2546717|NCT02586467|Experimental|Loss-Framed|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products).
2546720|NCT02586467|Experimental|Self-Regulatory Efficacy|Participants receive messages that provide them with tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.)
2546721|NCT02586467|Experimental|Gain-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potential benefits of engaging in a specific behaviour (i.e., what positive outcomes they could experience from consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
2546727|NCT02586467|Experimental|Loss-Framed + Self-Regulatory Efficacy|Participants receive messages that highlight the potentially loses of not engaging in a specific behaviour (i.e., what they could lose from not consuming milk and milk products) and these messages also provide tips and strategies on how to engage in the consumption of milk and milk products (i.e., recipes, meal planning etc.).
2546923|NCT02585154|Experimental|Closed-loop Deep Brain Stimulation|Closed-loop Deep Brain Stimulation
2546926|NCT02585154|Active Comparator|Open loop Deep Brain stimulation|Open loop Deep Brain stimulation
2546929|NCT02585154|Other|No Deep Brain Stimulation|No Deep Brain Stimulation
2546999|NCT02584816|Experimental|Group 1 - BRV-PV Lot A|BRV-PV Lot A + DPT- HepB-Hib + OPV
2547000|NCT02584816|Experimental|Group 2 - BRV-PV Lot B|BRV-PV Lot B+ DPT- HepB-Hib + OPV
2547002|NCT02584816|Experimental|Group 3 - BRV-PV Lot C|BRV-PV Lot C + DPT- HepB-Hib + OPV
2547003|NCT02584816|Active Comparator|Group 4 - ROTARIX|ROTARIX + DPT-HepB-Hib + OPV
2547193|NCT02583750|Experimental|OGTT after deprived sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sleep deprivation, then another test after three nights of sufficient sleep
2547197|NCT02583750|Experimental|OGTT after sufficient sleep first|Participants came to the lab to perform the oral glucose tolerance test after three nights of sufficient sleep, then another test after three nights of deprived sleep
3169062|NCT00558402|Active Comparator|2|Education
3169063|NCT00558402|Active Comparator|3|Respite care only, 90 mins per week for 8 weeks
3169064|NCT00558441|Experimental|1|
3169065|NCT00558454|Placebo Comparator|1|Placebo
3169066|NCT00558454|Experimental|2|1 mg/kg/day from age 6 weeks to 6 months
3169067|NCT00558454|Experimental|3|2 mg/kg/day from age 6 weeks to 6 months
3169068|NCT00558480|Active Comparator|1|Vitamin A
3169069|NCT00558480|Placebo Comparator|2|Vitamin A placebo
3169070|NCT00558493|Experimental|1|switching treatment from lamivudine to clevudine
3169071|NCT00558506|Experimental|A|Abatacept
3169072|NCT00558532||Surgical|Those subjects undergoing bariatric surgery or abdominal surgery following a previous bariatric surgery.
3169073|NCT00558532||Control|Volunteers who have dietary habits similar to the subjects.
3169074|NCT00558584|Active Comparator|IA/IgG group|immunoadsorption using IA columns and subsequent IgG substitution
3169075|NCT00558584|Placebo Comparator|control group|pseudo-immunoadsorption followed by an intravenous infusion without IgG
3169076|NCT00558597||1|30 patients with stable graft function
3169077|NCT00558597||2|30 patients with acute rejection after lung transplantation
3169078|NCT00558623|Placebo Comparator|1|Placebo
3169079|NCT00558649|Experimental|1|Low dose flu vaccine delivered intradermally using microneedles
3169080|NCT00558649|Experimental|2|Medium dose flu vaccine delivered intradermally using microneedles
3169081|NCT00558649|Active Comparator|3|Standard dose flu vaccine delivered intramuscularly with a regular needle
3169082|NCT00558662|Active Comparator|1|Coban 2 Layer Compression System
3169083|NCT00558662|Active Comparator|2|Short-Stretch Bandage
3169084|NCT00558675|Experimental|1|Single intravenous infusion of AlloStim
3169085|NCT00558675|Experimental|2|Intravenous AlloStim infusion on day 1 and day 7
3169086|NCT00558675|Experimental|3|Intravenous AlloStim infusion on day 1, day 7 and day 14
3169087|NCT00558675|Experimental|4|Intravenous AlloStim infusion on day 1, day 7, day 14 and day 21
2546398|NCT02588443|Experimental|Arm1|Arm I provides one dose of RO70097890 as a single agent in the neoadjuvant setting. Patients will recover from any toxicities and will then have their disease surgically resected. After recovery from surgery patients will proceed to adjuvant therapy which will include nab-paclitaxel 125mg/m2 and gemcitabine 1000mg/m2 on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle. Four cycles of adjuvant therapy will be given. All medications are administered intravenously.
2546402|NCT02588443|Experimental|Arm2|Arm II provides one dose of RO7009789 two days after one dose of nab-paclitaxel and one dose of gemcitabine prior to surgery. Nab-paclitaxel and gemcitabine are given on day 1. RO7009789 will be given on day 3. Patients will recover from any toxicities and will then have their disease surgically resected. Patients will receive four cycles of these same medications in an adjuvant fashion after recovering from surgical resection. A cycle will consist of nab-paclitaxel (125mg/m²), gemcitabine (1000mg/m²) given on days 1,8 and 15 of a 28 day cycle along with RO7009789 0.2mg/kg on day 3 of each cycle.
2546458|NCT02588196|Experimental|treatment of dexamethasone group|
2546498|NCT02587884|Active Comparator|Group TACE|Patients will treated with TACE after resection.
2546500|NCT02587884|No Intervention|Group Control|Patients will treated without TACE after resection.
2546552|NCT02587585|Experimental|Feedback against tailored target|For each two hour epoch, the watch calculate the level of activity for the same epoch the day before, and adds 5% as the new target to be achieved.
2546556|NCT02587585|Sham Comparator|No Feedback|For participants assigned to the control group, the smart watch will not provide any activity feedback against a target; it simply shows which two hour epoch a person is in.
2546612|NCT02587104|Experimental|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
2546714|NCT02586532||1|Residents of towns participating in China Demonstration Project.
2546757|NCT02586194|Experimental|Control (Subjects with normal hepatic function)|Oral
2546758|NCT02586194|Experimental|Mild hepatic impairment|Oral
2546759|NCT02586194|Experimental|Moderate hepatic impairment|Oral
2546801|NCT02585882|Experimental|Communal preschool feeding with fluoridated salt|"According to the allocation concealment, subjects of the test group were preschool children at the Kindergarten Wattenscheid in Gambia, Brikama-Kabafita, West Coast Region, The Gambia."
2546802|NCT02585882|No Intervention|Communal preschool feeding with no fluoridated salt|"Subjects of the control group were preschool children at the Kindergarten Bottrop in Gambia, Brikama, West Coast Region, The Gambia."
2546829|NCT02585687|Experimental|liver Perfusion MRI|liver perfusion MRI will be performed in patients to assess the early response (7 days) to antiangiogenic treatments
2546843|NCT02585557|Experimental|Cluster A|50 practices randomly assigned to start intervention at month 9. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2546853|NCT02585557|Experimental|Cluster B|50 practices randomly assigned to start intervention at month 11. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2546859|NCT02585557|Experimental|Cluster C|50 practices randomly assigned to start intervention at month 12. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2546861|NCT02585557|Experimental|Cluster D|50 practices randomly assigned to start intervention at month 14. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
2546865|NCT02585557|Experimental|Cluster E|50 practices randomly assigned to start intervention at month 16. Assigned Intervention: Primary Care Practice Support. The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
3203801|NCT00927667|Experimental|Arm 4|
3203802|NCT00927667|Experimental|Arm 5|
2546982|NCT02584985|Other|ETAP : Endoscopic Transanal Proctectomy|"Primary transanal approach :~Careful positioning in Lithtomy, dilatation and anal exposure with standard retractor. Mucosa incision and internal sphincter dissection according to tumor extension. Primary conventional dissection up to circumferential exposure of fascia recti. Secondary implantation of transanal endoscopic device Begin mesorectal endoscopic dissection postero-anteriorly, then laterally with nerve-sparing dissection. Level assessment of posterior dissection (vertical segment). End with peritoneal opening anteriorly (Douglas).~Secondary transabdominal approach :~Type of laparoscopic approach multiport or singleport. Level of arterial section, extension of colonic mobilization, site for specimen extraction (transanal / transabdominal), type of colonic reconstruction."
2546983|NCT02584985|Other|Standard Transabdominal Laparoscopic proctectomy|Primary transanal conventional dissection (sphincter preservation assessment) or not, type of laparoscopic approach multiport or singleport, level of arterial section, extension of colonic mobilization, conditions of mesorectal excision and nerve preservation, site for specimen extraction (transanal / transabdominal) and type of colonic reconstruction.
2547069|NCT02584439|Other|ivabradine-placebo|Volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
2547071|NCT02584439|Other|placebo-ivabradine|Volunteers will receive, at meal, lactose capsule (placebo) morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8). A wash out period (12 to 16 days) will follow this first period of treatment. of wash-out . Then, volunteers will receive, at meal, ivabradine 5 mg morning and evening for the first period of treatment during 8 days (1 capsule on day 1 and then 1 capsule 2 times a day from day 2 to day 7 and 1 capsule on day 8).
2547241|NCT02583126|Experimental|Music Group|Prescribed medical/chemotherapy treatment plus standard care + Guided Imagery and Music
3203803|NCT00927680||Colorectal cancer cases|
3203804|NCT00927680||Controls|
3203805|NCT00927693|Experimental|Scan group|"Scan group undergoes complete cardiac risk assessment and CAC scanning at baseline."
3203806|NCT00927693|No Intervention|No scan group|"No scan group undergoes only complete cardiac risk assessment (without CAC scan) at baseline."
2546550|NCT02587403|Active Comparator|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
2546555|NCT02587403|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
3203807|NCT00927706|Experimental|Immediate intervention|Subjects and their caregivers randomized to this arm receive the intervention immediately after baseline data is collected.
3203808|NCT00927706|Experimental|Delayed Intervention|Subjects and their caregivers who are randomized to this group will receive the intervention after baseline measurements are administered twice (6 weeks apart).
2546722|NCT02586272|Experimental|Daifert|• Interventional Group: The embryo to be transferred is selected on the basis of both morphological assessment performed on Day 2 or 3 and FF G-CSF concentration. FF G-CSF concentration will be measured with the Diafert® immunoassay.
2546729|NCT02586272|Other|Control Group|Control Group: The embryo to be transferred is selected on the basis of morphological assessment performed on Day 2 or 3.
2546774|NCT02586142|Experimental|Botulinum toxin type A(BTX-A) injection|To inject Botulinum toxin type A on the spasticity lower extremities for participants by ultrasounds guidance.
2546776|NCT02586142|Active Comparator|BTX-A injection plus stretching exercise|Inject Botulinum toxin type A on the spasticity lower extremity for participants by ultrasounds guidance. After injection, arrange them to receive stretching exercise in Kaoshiung Chang Gung Memorial Hospital 3 time per week for 3 months.
2546826|NCT02585752|Experimental|Single centre, single arm|Noninvasive ventilation with expiratory modulation. Assessment of comfort and blood gases.
2546847|NCT02585583|Other|Radiosurgical thalamotomy|Patients will undergo to radiosurgical thalamotomy by Cyberknife system.
2546911|NCT02585349||First-ever and recurrent ischemic and hemorrhagic stroke|First-ever and recurrent ischemic and hemorrhagic stroke patients are enrolled in the study. Recurrent strokes are only included if the patient is fully recovered from the previous event, which occurred at least 3 years ago, without obvious residual symptoms.
2546986|NCT02585024|Experimental|1.5 mg cytisine|1.5 mg cytisine given as a single dose
2546988|NCT02585024|Experimental|3 mg cytisine|3 mg cytisine given as a single dose
2546990|NCT02585024|Experimental|4.5 mg cytisine|4.5 mg cytisine given as a single dose
2546991|NCT02585024|Experimental|1.5 mg cytisine six times a day|1.5 mg (1 capsule) is given six times a day (0, 2, 4, 6, 8 and 10 hours) for 5 days
2546993|NCT02585024|Experimental|3 mg cytisine three times a day|3 mg (2 capsules) are given three times a day (0, 4 and 8 hours) for 5 days
2546995|NCT02585024|Experimental|4.5 mg cytisine two times a day|4.5 mg (3 capsules) are given two times a day (0 and 6 hours) for 5 days
2547023|NCT02584530|No Intervention|Standard procedure group|PICC line insertion using anatomical landmarks guidance and tip placement confirmation by X-ray
2547026|NCT02584530|Experimental|Interventional group|Ultrasound guidance for PICC line placement and X-ray
2547060|NCT02584426|Experimental|Cefazolin Treatment|Subjects will receive antibiotic treatment with phonophoresis (i.e., hypodermoclysis) during test 1, and will be given standard of care for 8 weeks.
2547062|NCT02584426|No Intervention|Standard of Care Control|Subjects will not receive intervention and will receive standard of care for 8 weeks.
2547113|NCT02584179|Experimental|Biparametric MRI before biopsy|"Biparametric MRI is a reduced Multiparametric MRI using less scan sequences and no intravenous contrast.~All men will have standard transrectal ultrasound guided biopsies"
2547153|NCT02583815||Cancer Patients|This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.
3203809|NCT00927732|Experimental|hydroquinidine|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
2547309|NCT02582853||Patients diagnosed with GBS|"Patients will undergo a lumbar puncture as a part of the diagnostic procedure as soon as they are suspected to be suffering from GBS on clinical grounds with blood test. The procedure and a blood test will be repeated after 6 months.~Lumbar puncture Blood sample"
2547314|NCT02582853||Symptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study. We expect to include 40 symptomatic controls.
2547374|NCT02582385||Amyotrophic lateral sclerosis (ALS)|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.
2547377|NCT02582385||Control|Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.
2547404|NCT02582047|Active Comparator|Influenza vaccination with PPV23|concomitant vaccination with trivalent inactivated influenza vaccine and 23-valent polysaccharide pneumococcal vaccine
2547409|NCT02582047|Active Comparator|Influenza vaccination with PCV13|concomitant vaccination with trivalent inactivated influenza vaccine and 13-valent pneumococcal conjugate vaccine
2547457|NCT02581761|Experimental|Cytotec treatment group|patient with pregnancy of unkown location will receive cytotec 800 mcg per vaginal
2547460|NCT02581761|Placebo Comparator|Placebo treatment group|patient with pregnancy of unkown location will receive suppository which contain Whitepsol H-15 with no active material (Cytotec).
2549182|NCT02570581|Active Comparator|jelly with alprazolam|elly with alprazolam
3203810|NCT00927732|Placebo Comparator|capsules of sugar|As it is a cross-over study, patient will taken treatment 1 for 18 months (ex: hydroquinidine) and then treatment 2 (placebo in this case) for 18 months.
3203811|NCT00927745|Experimental|With AutoFlow|Assist-controlled ventilation with activation of AutoFlow mode
2546540|NCT02587416|Experimental|Gemcabene 300 mg|Gemcabene 300 mg
2546543|NCT02587416|Experimental|Gemcabene 900 mg|Gemcabene 900 mg
2546546|NCT02587416|Active Comparator|Atorvastatin 80 mg|Atorvastatin 80 mg
3203812|NCT00927745|Active Comparator|Without AutoFlow|Assist-controlled ventilation without activation of AutoFlow mode
3203813|NCT00927771|Experimental|Azelaic Acid|
2546967|NCT02585037|Experimental|Kinesio Taping for facilitation|To provide the facilitation of muscle activity (G1 group) a Kinesio Taping® bandage will be applied to the muscle starting at its origin up to the location of muscle insertion. Bandage in group G1 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2546970|NCT02585037|Experimental|Kinesio Taping for inhibition|For inhibition of muscle activity (G2 group), the Kinesio Taping® bandage will be placed over the muscle starting at the insertion location and ending at the muscle origin. Bandage in group G2 will be applied following the protocol proposed by method of technical, which defined the direction of the bandage and an applied tension of 10% to 15% (paper off). With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2546971|NCT02585037|Placebo Comparator|Kinesio Taping and Placebo|For the control group (G3 group) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis. Bandages in the G3 group will be applied laterally to produce a similar visual effect, which control for the placebo effect, but without tension so that a muscle stimulus will be not generated. With a dynamometer Jamar® pressure the grip strength will be messure in four stages: immediately before placing the Kinesio Taping®, 24 h, 48 h, and 72 h after its application.
2547025|NCT02584699|Experimental|SABR|SABR group includes patients receiving pre-identified fractionated Stereotactic Ablative Radiotherapy (SABR)
2547068|NCT02584400|Experimental|[18F]HX4 PET imaging|Injection with the hypoxia tracer [18F]HX4 and PET imaging at baseline for esophageal, rectal, prostate cancer, primary brain tumor (grade IV glioma) and brain metastases and after 2 weeks of radiotherapy for esophageal, rectal and brain metastases
2547118|NCT02584153|Experimental|Myoseal|The fibrin sealant and silver microparticles are sprayed onto the surface of the sutured myofascial incision following abdominal surgery.
2547239|NCT02582944|Experimental|Arm 1: Electromagnetic navigation|"The bronchoscope will be inserted transorally into the tracheobronchial tree and a standard airway inspection will be performed.~Following airway inspection, the bronchoscope will be removed and the tip tracked steerable catheter with optical system will be advanced transorally through the vocal cords and into the tracheobronchial tree.~Once the tip tracked catheter has been advanced to the peripheral pulmonary target lesion, the optical SpinView system will be removed from the tip tracked catheter and the 1.4mm radial endobronchial ultrasound mini-probe will be inserted through the tip-tracked catheter into the lung periphery to confirm the presence of a peripheral pulmonary lesion and accurate navigation.~Once target confirmation has been performed using radial probe endobronchial ultrasound, biopsy of the peripheral lesion will be performed using biopsy forceps, brushes and aspiration needles."
2547303|NCT02582736||Olanzapine|Exposure to olanzapine will be defined as a prescription for olanzapine on the date of cohort entry.
2547308|NCT02582736||Other atypical antipsychotics|Exposure to atypical antipsychotics will be defined as a prescription for an atypical antipsychotic other than olanzapine (clozapine, quetiapine, ziprasidone, paliperidone, or aripiprazole) on the date of cohort entry.
2547313|NCT02582736||Typical antipsychotics|Exposure to typical antipsychotics will be defined as a prescription for a typical antipsychotic (chlormezanone, chlorpromazine, chlorprothixene, flupenthixol, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, mesoridazine, methotrimeprazine, perphenazine, pimozide, pipotiazine, tetrabenazine, thiopropazate, thioproperazine, thioridazine, thiothixene, trifluoperazine or zuclopenthixol) on the date of cohort entry.
2547318|NCT02582736||Risperidone (reference)|Exposure to risperidone will be defined as a prescription for risperidone on the date of cohort entry.
3203814|NCT00927771|Active Comparator|Hydroquinone|
3203815|NCT00927797|Experimental|Immunochemotherapy, Maintencance|
2547489|NCT02581644||Patients survey|Adult patients treated with belatacept for renal transplantation
2547490|NCT02581644||HCP survey|HCP with at least 1 patient taking belatacept
2547492|NCT02581644||Retrospective chart review study|Adult patients treated with belatacept for renal transplantation
2547533|NCT02581215|Experimental|Arm A: Experimental Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm A will receive ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks."
2547737|NCT02579642|Placebo Comparator|Placebo|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with placebo (normal saline)
3203816|NCT00927836|Experimental|AX200|
3203817|NCT00927836|Placebo Comparator|Placebo|
3203818|NCT00927875|Experimental|All Subjects|
2546490|NCT02588118||female group|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
2546523|NCT02587559|No Intervention|Control|usual medical advice regarding symptomatic control and activity modification
2546524|NCT02587559|Experimental|Experimental|Six visits of physical therapy to provide manual therapy and therapeutic exercise
2546568|NCT02587338|Experimental|Verum tDCS|Left frontal anodal stimulation, supraorbital right cathodal stimulation
2546577|NCT02587338|Experimental|Sham tDCS|sham stimulation, same electrode positions
2546627|NCT02587013|Experimental|In situ uterine repair|The uterus is repaired in situ within the abdominal cavity, without exteriorization; intra-abdominal repair
2546631|NCT02587013|Active Comparator|Exteriorization of the uterus|The uterine incision is repaired with the exteriorization of the uterus; extra-abdominal repair
2546825|NCT02585661|Active Comparator|Dairy product + Salt 1|Dairy product fortified with enriched Fe-54 salt (1)
2546827|NCT02585661|Experimental|Dairy product + Salt 2|Dairy product fortified with enriched Fe-57 salt (2)
2546841|NCT02585570|Experimental|Low dose phenylephrine|phenylephrine 0.5 mcg/kg/min
2546852|NCT02585570|Experimental|High dose phenylephrine|phenylephrine 1.0 mcg/kg/min .
2546858|NCT02585570|No Intervention|Normal saline|normal saline for 5minutes
2546918|NCT02585284||vicenarian|20 to 29 years. Five males and five females
2546920|NCT02585284||tricenarian|30 to 39 years. Five males and five females
2546924|NCT02585284||quadragenarian|40 to 49 years. Five males and five females
2546927|NCT02585284||quinquagenarian|50 to 59 years. Five males and five females
2546930|NCT02585284||sexagenarian|60 to 69 years. Five males and five females
2546932|NCT02585284||septuagenarian|70 to 79 years. Five males and five females
2546935|NCT02585284||octogenarian|80 to 89 years. Five males and five females
2546942|NCT02585284||nonagenarian|90-99 years. Five males and five females
2546992|NCT02584907|Experimental|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
2546994|NCT02584907|No Intervention|Standered Enteral Nutrition|Diet in standard group will be 20% from protein, 30% from fat and 50% from carbohydrate
2547038|NCT02584582|Experimental|Liraglutide + Liquid meal test|Liraglutide 1.2 mg once daily for 14 days (0.6 mg/day for one week, escalated to 1.2 mg/day after one week)
2547041|NCT02584582|Experimental|Exenatide + Liquid meal test|Exenatide 10 mcg twice daily for 14 days (5 mcg twice daily for one week, escalated to 10 mcg twice daily after one week)
2547045|NCT02584582|Other|Baseline + Liquid meal test|Baseline day with no additional medication
2547101|NCT02584218|Experimental|Non-invasive resin based caries sealing|Application of resin based sealant after acid etching of carious occlusal surface
2547106|NCT02584218|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
2547142|NCT02583854|Active Comparator|Hemostasis achieved by TR Band|After the transradial procedure and randomization TR Band will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
2547147|NCT02583854|Experimental|Hemostasis achieved by RY Stop|After the transradial procedure and randomization, RY Stop will be applied to achieve hemostasis. Patient experience and complications after the application will be measured.
2547182|NCT02583529|Experimental|Back Tibial Nerve Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
2547183|NCT02583529|Placebo Comparator|Placebo Electrostimulation|They will be assessed before and after 12 weeks of treatment with home PTNE through specific form of questionnaires assessing incontinence, quality of life and voiding diary. After the end of treatment will be made up of patients to verify the effectiveness of treatment in 30 to 90 days.
2547233|NCT02583178|Experimental|Aegis Sierra Ligation System|The Aegis Sierra Ligation System is a series of devices designed for epicardial ligation of the Left Atrial Appendage through a minimally invasive transcatheter approach.
2547517|NCT02581358|Experimental|Scolioscan (Ultrasound imaging system)|This diagnostic study is a single arm study with all participants receiving investigation with the Scolioscan (a diagnostic ultrasound machine) for quantitative assessment of spinal deformity
2547657|NCT02580409|Other|Single-arm studies|Behavioral Intervention
2547685|NCT02580097||Stroke|Ischemic stroke patients with sympton onset in 24 hours and no contradiction to MRI scan
2547739|NCT02579824|Experimental|DS-3032b|"Dose Escalation Phase: DS-3032b administered once daily by mouth on Days 1 - 21 of a 28 day cycle. Starting dose level 90 mg/day.~Dose Expansion Phase: Starting dose level maximum tolerated dose from Dose Escalation Phase."
2547781|NCT02579499|Active Comparator|Fixed high-potent statin group|According to 2013 ACC/AHA guideline, patients will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels.
2547784|NCT02579499|Experimental|Targeted LDL-C goal statin group|Patients will be tiltrated statin intensity guided by follow-up LDL-C level
2547813|NCT02579213||women candidates for amniocentesis|pregnant women candidates for amniocentesis between 17-33 gestational weeks
2547852|NCT02579096|Active Comparator|Allopurinol / Sham Comparator (Febuxostat)|Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
3169090|NCT00558740||healthy volunteers|
3169091|NCT00558779|Experimental|1|
3169092|NCT00558779|Active Comparator|2|
3169093|NCT00558805|Active Comparator|1|Usual Care + Family Intervention for Suicide Prevention (FISP)
3169094|NCT00558805|Other|2|Usual Care
2546597|NCT02587741|Experimental|lantus|basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.
2546600|NCT02587741|Experimental|Novomix30|premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .
2546654|NCT02586766|Experimental|Behavioral: Project Sync|Brief 30 minute on-on-one private motivation interviewing intervention during emergency department care
2546656|NCT02586766|No Intervention|Comparison Group|This group did not receive an intervention, but did receive an informational pamphlet of resources in the area (enhanced usual care).
2547178|NCT02583503||Hindfoot alignment view x ray|Patients undergoing TKR for osteoarthritis will have an additional x ray (hindfoot alignment view) as well as the standard hip knee ankle x ray extended to include the heel.
2547227|NCT02583295|Active Comparator|Music group|Music sound
2547229|NCT02583295|Active Comparator|Maternal sound group|Maternal sound
3169095|NCT00558857|Active Comparator|DSM|Treatment using DSM to guide ablation
3169096|NCT00558883|Active Comparator|1|treatment with Acarbose: 2 weeks 1 x 50mg; 2 weeks 3 x 50mg; 16 weeks 3 x 100mg
3169097|NCT00558883|Placebo Comparator|2|treatment with placebo: 2 weeks 1 x 50mg 2 weeks 3 x 50mg 16 weeks 3 x 100mg
2547448|NCT02581813|Experimental|RDa (Recommended dairy group)|4 servings of dairy per day + exercise (3 times per week with combination of aerobic and resistance exercise).
2547449|NCT02581813|Experimental|LDa (Low dairy group)|0-1 serving of dairy per day + exercise (the same as the RDa group)
2547450|NCT02581813|No Intervention|GCon (growth controls)|This no-intervention group will serve as the control to account for growth during the study.
2547478|NCT02581553|Experimental|Sequence AB|Day 1: lesinurad/allopurinol FDC tablets (Treatment A); Day 8: lesinurad + allopurinol (Treatment B)
2547480|NCT02581553|Experimental|Sequence BA|Day 1: lesinurad + allopurinol (Treatment B); Day 8: lesinurad/allopurinol FDC tablets (Treatment A).
2547483|NCT02581553|Experimental|Sequence CD|Day 1: lesinurad/allopurinol FDC tablets (Treatment C [fasted]); Day 8: lesinurad/allopurinol FDC tablets (Treatment D [fed]).
2547485|NCT02581553|Experimental|Sequence DC|Day 1: lesinurad/allopurinol FDC tablets (Treatment D [fed]); Day 8: lesinurad/allopurinol FDC tablets (Treatment C [fasted]).
2547487|NCT02581553|Experimental|Sequence EF|Day 1: lesinurad/allopurinol 200/200 FDC tablets (Treatment E); Day 8: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2)
2547491|NCT02581553|Experimental|Sequence FE|Day 1: coadministered lesinurad 200 mg + allopurinol 200 mg (100 mg × 2) (Treatment F); Day 8: lesinurad/allopurinol 200/200 FDC tablets (Treatment E).
2547692|NCT02580006|Experimental|EPORON→EPREX|"EPORON PFS(PreFilled Syringe) 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPREX INJ.(Injection) 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
2547697|NCT02580006|Experimental|EPREX→EPORON|"EPREX INJ. 4000 IU(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 1.~And wash out for 4 weeks. EPORON PFS 4000 IU/0.4 mL(Erythropoietin alfa 4000 IU) will be administered subcutaneously after 10 hours fasting on Day 29."
2547768|NCT02579707|Active Comparator|Treatment A: Unfed|Treatment A: Single oral dose of AG-120 at Hour 0 on Day 1, following a 10-hour overnight fast.
3169098|NCT00558961|Experimental|I|Gleevec Chlorambucil
3169099|NCT00558987|Experimental|1|
3169100|NCT00558987|Sham Comparator|2|
3169101|NCT00559000|No Intervention|Waitinglist Control|
3169102|NCT00559000|Experimental|KIDNET|
3169103|NCT00559026|Active Comparator|1|
3169104|NCT00559026|Experimental|2|
3169105|NCT00559052|No Intervention|1|Baseline measurement. No drug with the liquid meal during perfusion procedure to establish baseline secretion.
3169106|NCT00559052|Experimental|2|The Viokase 16 is to be taken as 3 tablets with the liquid meal during perfusion procedure.
3169107|NCT00559065||Benzene Cohort|Benzene exposed and unexposed workers.
3169108|NCT00559078||CAH|Women diagnosed with CAH (either simple virilizing or salt-losing)
3169109|NCT00559091|Experimental|I|Ribavirin
3169110|NCT00559117|Experimental|Cohort|
3169111|NCT00559143|Active Comparator|1|DDD(R)-RV pacing
3169112|NCT00559143|Experimental|2|DDD(R)- BIV pacing
3169113|NCT00559182|Experimental|Parts A and B: MK-8033|Dose Escalation Study
3169114|NCT00559182|Experimental|Part C: MK-8033 +/- omeprazole|Crossover Study
3169115|NCT00559208||Children's Aid Societies|Comparing differential response (Wraparound) with usual care
3169116|NCT00559221|No Intervention|1|
3169117|NCT00559247|Experimental|or Placebo - Dose Panel 1|Oral Suspension, 10 mg
3169118|NCT00559247|Experimental|or Placebo - Dose Panel 2|Oral Suspension 50 mg
3169119|NCT00559247|Experimental|or Placebo - Dose Panel 3|Oral Suspension, 200 mg
3169120|NCT00559247|Experimental|or Placebo - Dose Panel 4|Oral Suspension or Solution, 2.5 to 600 mg
3169121|NCT00559286|Experimental|A|treatment with 80 mg Telmisartan per day for 30 days
3169122|NCT00559286|Active Comparator|B|treatment with 20mg Telmisartan per day for 30 days
3169123|NCT00559312|Experimental|FSC 250/50|fluticasone 250μg/salmeterol 50μg combination
3169124|NCT00559312|Placebo Comparator|Placebo|matched placebo inhaler
3169125|NCT00559338|Active Comparator|1|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
3169126|NCT00559338|Placebo Comparator|2|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
3169127|NCT00559351|Active Comparator|S|esophagectomy
3169128|NCT00559351|Experimental|CHTS|neoadjuvant chemotherapy followed by esophagectomy
3169129|NCT00559351|Experimental|CHRTS|neoadjuvant chemoradiotherapy followed by esophagectomy
2546611|NCT02587208|Active Comparator|plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
3203819|NCT00927914|Experimental|Ranirestat 80 mg|Two 80 mg Ranirestat tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
3203820|NCT00927914|Experimental|Ranirestat 40 mg|One 40 mg tablet of Ranirestat and a matching placebo, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
3203821|NCT00927914|Placebo Comparator|Placebo|Two placebo tablets, given orally, once daily, preferably in the morning with or without a light breakfast, for upto 24 months.
2546833|NCT02585817|Experimental|Remote CIED Management|Patients with a CIED will undergo remote monitoring with information technology.
2546863|NCT02585505|Active Comparator|Intravenous|stem cells will be injected through intravenously in the subjects
2546869|NCT02585505|Active Comparator|superior pancreaticoduodenal|stem cells
2546871|NCT02585505|Active Comparator|splenic artery|stem cells will be injected through splenic in the subjects
2546912|NCT02585271|Other|Transanal decompression tube|Patients undergo placement of the transanal decompression tube as a bridge to surgery
2546913|NCT02585271|Other|Stent|Patients undergo placement of the stent as a bridge to surgery
2546965|NCT02584972||children with Autism Spectrum Disorder|no intervention required
2546968|NCT02584972||heathy children|no intervention required
2547006|NCT02584751|Active Comparator|Able-Bodied non-GERD|Able-bodied patients who are not diagnosed with GERD during screening will act as controls.
2547008|NCT02584751|Active Comparator|SCI non-GERD|SCI patients who are not diagnosed with GERD during screening will act as controls
2547010|NCT02584751|Experimental|SCI GERD|For those SCI subjects who are identified with GERD, they will undergo a 8week treatment of Omeprazole to reduce GERD
2547011|NCT02584751|Active Comparator|Able-bodied GERD|For those AB subjects who are identified with GERD will act as controls. Note they will not receive treatment for GERD in this study. We will notify their primary care physician during the study so that they may receive treatment.
2547104|NCT02584296|No Intervention|Usual care control|Phase 1 will be observation only, and will be considered a usual care control group, activity at home.
2547108|NCT02584296|Experimental|Biobehavioral self management approach|Phase 2 participants will receive the Biobehavioral self management approach (BSMA) intervention aligned with the IMB model; introduced over three days of each five-day consolidation chemotherapy hospital admission.
2547272|NCT02582905|Placebo Comparator|Placebo|Matching placebo given beginning at 1 capsule BID increasing to 2 capsules BID at week 1, 3 capsules BID at week 2, and 4 capsules BID at weeks 3-12.
2547274|NCT02582905|Experimental|Citicoline|Citicoline will be given beginning at 250 mg BID with an increase to 500 mg BID at week 1, 750 mg BID at week 2, and 1000 mg BID at weeks 3-12.
2547275|NCT02582905|Experimental|Pregnenolone|Pregnenolone will be given beginning at 50 mg BID with an increase to 100 mg BID at week 1, 150 mg BID at week 2, and 250 mg BID at weeks 3-12.
2547338|NCT02582554|Experimental|Intervention|Intervention: NutriSTEP The intervention will be the administration of NutriSTEP, a nutrition risk screening questionnaire for preschoolers along with a nutrition education brochure called How to Build a Healthy Preschooler
2547341|NCT02582554|No Intervention|Control|Control: Wait-list control The wait-list control group will complete the NutriSTEP and receive the nutrition education information at the end of the 3 month study period
2547365|NCT02582424|Experimental|PDL-0101|EPA +astaxanthin
2547367|NCT02582424|Placebo Comparator|placebo|olive oil
2547453|NCT02581722|Experimental|Adolescent male population|Male circumcision using the PrePex device among healthy adolescent males and contraindicated subjects due to Preputial adhesions and /or narrow foreskin/Phimosis
2547496|NCT02581540||Suspected Cardiac Chest Pain|This cohort is observed for the incidence of MACE (death, non-fatal myocardial infarction and emergency revascularisation)
2547523|NCT02581293|Experimental|Only visceral peritoneum will be closed|Group1: Only visceral peritoneum will be closed
2547526|NCT02581293|Experimental|Only parietal peritoneum will be closed|Group 2: Only parietal peritoneum will be closed
2547527|NCT02581293|Experimental|Both of them will be closed|Group 3: Both of them will be closed
2547535|NCT02581293|Experimental|None of them will be closed|Group 4: None of them will be closed
2547594|NCT02580916|Experimental|Group 1 (Postal)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team and deemed 'low risk'; SCQOLIT questionnaires will be administered by post.
2547596|NCT02580916|Experimental|Group 2 (Clinic-based)|These are patients who will be identified from the histological diagnosis of their skin cancer by members of the direct care team, for whom all aspects of the study will be conducted in the Dermatology clinic. SCQOLIT questionnaires will be administered according to the protocol.
2547602|NCT02580916|No Intervention|Group 3 (Interviews)|A Qualitative Researcher (Co-Investigator) will undertake structured interviews with approximately 20 patients from both Group 1 and 2. Potential participants will be invited to volunteer their contact details at the time of consent to the Questionnaire study. This is optional; they may refuse to do so and still take part in the main questionnaire study. The patient will then be contacted by the Qualitative Researcher (Co-Investigator) at a later date and subsequently consented for the interview.
2547605|NCT02580916|No Intervention|Group 4 (Clinician focus group)|We aim to discuss the project at the end of the study period in the same setting, to establish staff perspectives on the study, to establish usefulness of the SCQOLIT tool and to identify any barriers to implementation.
2547631|NCT02580448|Experimental|Female Triple Negative Breast Cancer Patients|TNBC Patients - Enrollment is complete in this cohort
2547632|NCT02580448|Experimental|Female Estrogen Receptor (+) Breast Cancer Patients|Female ER(+) BC Patients - Enrollment is complete in this cohort
2547633|NCT02580448|Experimental|Male Breast Cancer Patients|Locally advanced or metastatic males with BC
2547775|NCT02579733|Active Comparator|Azathioprine|Azathioprine (1.5mg/kg) po for 1 year
2546617|NCT02587169|Experimental|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
2546767|NCT02586181|Placebo Comparator|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate"
2546768|NCT02586181|Experimental|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
2546908|NCT02585219||High-grade Glioma Patients|"Patients with suspicion of newly diagnosed high-grade glioma eligible for standard therapy (surgical resection followed by chemoradiotherapy).~Patients with a second brain tumor, brain surgery earlier or prior radiotherapy to the brain are excluded. Patients with only a biopsy be excluded.~The group will consist of 10 patients. This number may be adjusted for patients who are found to have a different diagnosis after histological examination or fall out. For a pilot feasibility study our experience that a number of 10 patients is sufficient for PET examination."
2546985|NCT02585063||Dual assessment|Where there is time and space, participants will be allocated to have a clinical assessment by the IP optometrist during their wait for the clinical assessment with the ophthalmologist. Both clinical assessments are needed to obtain measurement of agreement. There is no intervention. but participants have two clinical assessments rather than just one.
2547027|NCT02584647|Experimental|Phase 1: PLX3397 and Sirolimus|Cohort 1 (Phase 1): Subjects with unresectable or metastatic sarcoma will take orally PLX3397 (600 - 1000mg) in combination with Sirolimus (2-6mg) daily .
2547029|NCT02584647|Experimental|Phase 2: PLX3397 and Sirolimus|Cohort 2 (Phase 2): Subjects with unresectable or metastatic Malignant Peripheral Nerve Sheath Tumors (MPNSTs) will take PLX3397 and Sirolimus at the recommended Phase 2 dose (RP2D).
2547077|NCT02584283|Experimental|Dual hypothermic oxygenated perfusion|The liver is procured with a segment of supratruncal aorta. The intervention is restricted to the liver graft after arrival in the transplant center and before implantation. The donor liver is subjected to 2 hours of hypothermic oxygenated perfusion via the portal vein and the supratruncal aorta applied by the Liver Assist®. Before perfusion, the liver is flushed via the portal vein with 1 L Belzer machine perfusion solution. The perfusion is pressure controlled and set to a mean of 25 mmHg (arterial) and 5 mm Hg (portal). The perfusion fluid is 4 L Belzer machine perfusion solution with additional 3 mmol/L glutathione. The perfusion fluid is 12°C, when the temperature is set at 10°C. The oxygen flow is set at 0.5 mL/min of 100% oxygen on each of the two membrane oxygenators.
2547079|NCT02584283|No Intervention|Care as usual|The donor liver is procured with a segment of 5 cm circular supratruncal aorta left attached to the coeliac trunc. The patients randomized to the control group will receive a liver graft preserved by conventional SCS without any further intervention.
2547100|NCT02584023|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose after the endotracheal intubation and and at the end of surgery.
2547105|NCT02584023|Active Comparator|Alveolar recruitment|Perform lung ultrasound twice during the perioperative period after the endotracheal intubation and and at the end of surgery. Conduct alveolar recruitment maneuver after first lung ultrasound assessment.
2547123|NCT02583906|Other|cpap treatment|patients randomized to the 'no cpap' arm will not be treated by CPAP
2547128|NCT02583906|No Intervention|no cpap|patients randomized to the 'cpap' arm will be treated by CPAP
2547175|NCT02583620|Other|Emmetropic volunteers|Blood sample
2547176|NCT02583620|Other|High myopic volunteers|Blood sample
3203822|NCT00927966|Experimental|RAD001 in combination with figitumumab|
3203823|NCT00927979|Experimental|Ropivacaine|
3203824|NCT00927979|Placebo Comparator|Water for injection|
3203825|NCT00928005|Active Comparator|Weight loss diet|Participants will follow a low-calorie, low-fat weight loss diet for 6 months.
3203826|NCT00928005|Active Comparator|Weight loss diet plus exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
2547403|NCT02582203|Active Comparator|Ceftaroline|600 mg IV (over 1 hour) every 12 hours for renal function > 50 mL/min, adjusted for renal function based on package insert for no more than 14 days.
2547411|NCT02582203|Active Comparator|Vancomycin|Dosed by institutional pharmacy protocol to reach goal trough level of 10 - 20 mg/L steady state concentration for no more than 14 days.
2547472|NCT02581774||term isolated oligohydramnios|Labor Monitoring and normal delivery tracking
2547473|NCT02581774||prolonged pregnancies|Labor Monitoring and normal delivery tracking
2547505|NCT02581397|Experimental|Transpulmin suppository|"It is a rectal suppository that is manufactured by Aché S.A. and which is composed of camphor, eucalyptol, guaiacol and menthol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
3203827|NCT00928044||control groups|They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded.
3203828|NCT00928044||operation group|1. They had regular menstrual cycles and no history of pelvic surgery. None had any endocrine disorders (e.g. PCOS) and received any kind of medication that could affect the results within the preceding 6 months, and any woman who had a suspected pathologic lesion in the ovary or menopausal symptoms was excluded. 2. Operations were performed for benign ovarian tumors, leiomyoma or adenomyosis
3203829|NCT00928109|Experimental|Cognitive Behavioral Couples Therapy (CBCT)|CBCT is a 20-week program consisting of 1-hour sessions between a couple and a therapist. In this program, couples learn about ways to communicate about their relationship in the context of experiencing anorexia nervosa. CBCT focuses on couple-specific skills such as communication and targets relationship domains such as exercise, body image and sexuality, eating together as a couple, and broader relationship concerns outside of anorexia nervosa.
2546683|NCT02586688|Sham Comparator|Phase I TMS Sham|Blinded Sham TMS coil (Phase I) Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)
2546687|NCT02586688|Other|Phase II Open Label Active TMS|Open label active TMS coil. Open label active NeuroStar® TMS.
2546691|NCT02586688|Other|Phase III Long-Term Follow up TMS Active|Long term follow up with open label active TMS for retreatment as needed. Open label active NeuroStar® TMS.
2546834|NCT02585804|Experimental|Dapagliflozin (trade name Farxiga®)|Oral tablet, 10mg, PO, 8 weeks
2546888|NCT02585427|Experimental|low glycemic index rice with butter|50 g available low glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
2546890|NCT02585427|Experimental|low glycemic index rice with olive oil|50 g available low glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
2546892|NCT02585427|Experimental|low glycemic index rice with grapeseed oil|50 g available low glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
2546893|NCT02585427|Experimental|high glycemic index rice with butter|50 g available high glycemic index rice cooked with 48 g butter ( equal 40 g saturated fatty acid)
2546894|NCT02585427|Experimental|high glycemic index rice with olive oil|50 g available high glycemic index rice cooked with 44 g olive oil ( equal 40 g monounsaturated fatty acid)
2546895|NCT02585427|Experimental|high glycemic index rice with grapeseed oil|50 g available high glycemic index rice cooked with 40 g grapeseed oil ( equal 40 g polyunsaturated fatty acid)
2546950|NCT02585141|Experimental|aspiration|Aspiration of perianal abscess(MEDIPLAST® 13 G, 2,5 x 110 mm) under general anesthesia followed by antibiotic treatment with Clindamycin tablet 300 mg 3 times daily for 7 days
2546956|NCT02585141|Active Comparator|incision|Surgical incision of perianal abscess under general anesthesia.
2547059|NCT02584478|Experimental|Phase 3 -Active Treatment Arm|"Phase 3: AL3818 8 mg once daily in combination with one background chemotherapy in 21-day cycles. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
2547063|NCT02584478|Other|Phase 3-Control Treatment Arm|"Control Treatment Arm: Background chemotherapy treatment alone. Platinum resistant recurrent or metastatic ovarian, fallopian, or primary peritoneal cancer subjects will be enrolled into one of the following three background chemotherapy groups:~Weekly paclitaxel (default choice; if the subject is ineligible for paclitaxel, the investigator will select from PLD or topotecan)~Pegylated liposomal doxorubicin (PLD)~Topotecan"
2547064|NCT02584478|Experimental|Phase 1b: AL3818 plus carboplatin and paclitaxel|Phase 1b: Sequential deescalating dosing evaluation to determine the recommended Phase II dose (RP2D). For 21-day treatment cycles, cohort 1 (3 subjects) will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at an initial dose of 12 mg/day.
2547066|NCT02584478|Experimental|Phase 2a: AL3818 plus carboplatin and paclitaxel|Phase 2a: subjects will receive chemotherapy and oral AL3818 for 6 cycles (18 weeks, 21-day cycles of treatment) followed by continuous maintenance treatment of oral AL3818 for up to 12 months. Subjects will be administered carboplatin (AUC 5/6 over 30 minutes) and paclitaxel (175mg/m2 over 3 hours) intravenously on Day 1. AL3818 is orally administered daily starting on Day 8 until Day 21 (14 days) at the RP2D found in Phase 1b.
2547138|NCT02583958|Experimental|Device Urgo 3103166|Soft-adherent hydro-desloughing dressing
2547139|NCT02583958|Active Comparator|Device Aquacel Extra|Hydrofibre dressing
2547184|NCT02583555|Active Comparator|Active patient support|Interview followed by frequent telephone support Questionnaire every 3 months
2547185|NCT02583555|No Intervention|Controls|Questionnaire every 3 months
2547252|NCT02583204|No Intervention|Control - standard care|Participants will receive standard care regarding nail toxicity. This entails advice to keep nails trim and the provision of a nail oil to massage into the nail daily. Participants will also receive advice in relation to general healthy living.
2547254|NCT02583204|Experimental|Intervention - Oncolife drops|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive Onicolife nail drops to be applied twice daily.
2547258|NCT02583204|Experimental|Intervention - Nail polish|Participants will receive the same standard care as the control arm, except for the nail drops. The participants will also receive a dark coloured nail polish to be applied as instructed.
2547300|NCT02582710|Experimental|VASCAZEN|Patients treated with Vascazen
2547301|NCT02582710|Placebo Comparator|Placebo|Patients treated with a placebo
2547359|NCT02582489|Experimental|Meniscectomy with Bone Marrow Aspirate Concentrate (BMAC)|Subjects will undergo the scheduled meniscectomy procedure. Following the procedure the investigator will make a small incision and create the marrow access channel in the proximal tibia. The experimental group will then have bone marrow harvested and BMAC will be prepared using a BMAC harvesting system. The automated centrifuge system rapidly concentrates cellular contents and growth factors in bone marrow aspirate using flow cytometry. The BMAC will be injected intra-articularly.
2547360|NCT02582489|Placebo Comparator|Meniscectomy with Placebo|Subjects will undergo the same meniscectomy procedure and will also have an incision and marrow access channel made in the proximal tibia, however no bone marrow will be harvested. The control group will have a placebo injection of saline into the affected knee.
2547382|NCT02582229|Experimental|Interventionnal|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
2547429|NCT02581982|Experimental|Treatment (pembrolizumab, paclitaxel)|Patients receive pembrolizumab IV over 30 minutes on day 1 and paclitaxel IV over 60 minutes on day 1 and 8. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2547475|NCT02581579|Active Comparator|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis
2546685|NCT02586649|Experimental|Tiotropium Bromide group|The study participants will be randomly assigned to receive Tiotropium bromide,single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Tiotropium bromide capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
2546689|NCT02586649|Placebo Comparator|Placebo|The study participants will be randomly assigned to receive placebo , single dose (inhalation capsule - 18 mcg) over the course of 24 hours on day one of visit 1 or during visit 3.On the day of the first scheduled visit ( visit 1 ),study participants will be asked to arrive between 12-1 pm at the pulmonary laboratory at the JJPVAMC (7A-13). Baseline blood pressure (BP) and heart rate (HR) measurements will be obtained prior to drug administration. Placebo capsule containing active ingredients will be orally inhaled through a SPIRIVA HandiHaler. Measurements of exhaled nitric oxide, pulmonary function ( spirometry , static lung volumes and specific airway conductance) will be performed at 20 and 24 hours. The same schedule will be followed for visits 3 and 4;vists 3 and 4 will be scheduled between 14 and 21 days after visit 2.
2546736|NCT02586298|Experimental|ICSI with mitochondria|Half of the Metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and autologous mitochondria from the patient's ovarian cortex will be introduced into the oocyte during the intracytoplasmic sperm injection in the vitro fertilization treatment.
2546742|NCT02586298|Active Comparator|Control ICSI without mitochondria|The other half of the metaphase II oocytes retrieved after the controlled ovarian stimulation will be randomized to this group and will not receive autologous mitochondria during the intracytoplasmic sperm injection (ICSI) in the vitro fertilization treatment. Control Group
2546770|NCT02586129|Experimental|YH14755|PO, Once Daily, 16 weeks
2546772|NCT02586129|Active Comparator|Metformin|PO, Once Daily, 16 weeks
2546775|NCT02586129|Active Comparator|Rosuvastatin|PO, Once Daily, 16 weeks
3203830|NCT00928109|Active Comparator|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
3203831|NCT00928122|Experimental|1 / Presbyopia|Presbyopic patients, slightly hyperopes
2547177|NCT02583568|Experimental|Part 1|In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
2547179|NCT02583568|Experimental|Part 2|In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
3203832|NCT00928122|Experimental|2 / Myopia|Myopic patients without Astigmatism
3203833|NCT00928122|Experimental|3 / Hyperopia|Hyperope patients without Astigmatism
3203834|NCT00928122|Experimental|4 / Myopia with Astigmatism|Myopic patients incl. Astigmatism
3203835|NCT00928122|Experimental|5 / Hyperopia with Astigmatism|Hyperope patients incl. Astigmatism
3203836|NCT00928148|Experimental|SPD465 (50 or 75 mg)|
2547521|NCT02581254|Experimental|Thin Wire Snare Arm|Use of Thin Wire Snare to resect polyp <10mm
2547522|NCT02581254|Experimental|Thick Wire Snare Arm|Use of Thick Wire Snare to resect polyp <10mm
2547579|NCT02581007|Experimental|Reduced-Intensity Mismatched Transplant|Fludarabine, Melphalan & Post-transplant cyclophosphamide
2547635|NCT02580513|No Intervention|Control|3 days with normal circadian alignment.
2547636|NCT02580513|Experimental|Circadian Misalignment|3.5 days in which the subjects will undergo a maximal circadian misalignment of 12 hours by means of a midday nap during the second day, and a subsequent start of a new normal wake period, shifted 12 hours.
2547711|NCT02580149|Active Comparator|Ticagrelor|Loading dose of 180 mg on day one, followed by a regular intake (90 mg twice daily) for 14 days
2547712|NCT02580149|Active Comparator|Clopidogrel|Loading dose of 600 mg on day one, followed by a regular intake (75 mg once daily) for 14 days
2547829|NCT02579369|Experimental|ALLO-ASC-DFU|
2547833|NCT02579369|Active Comparator|Conventional Therapy|
2547882|NCT02578888|Active Comparator|Palliative Therapy|EORTCQLQ-30 and FAMCARE questionnaire every 6 weeks for 3 visits.
2547884|NCT02578888|Experimental|Palliative Therapy+ idiographic|EORTC QLQ-30, and FAMCARE questionnaire every 6 weeks for 3 visits plus patients undergo idiographic assessment.
2547934|NCT02578589|Active Comparator|surgery|
2547935|NCT02578589|Active Comparator|Conservative treatment|
2547939|NCT02578251|Experimental|Paracetamol|Patients will receive paracetamol intravenously (1 g in 100 mL) over 15 minutes (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2547944|NCT02578251|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2548025|NCT02578134|Sham Comparator|Sham US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of sham US-guided percutaneous electrolysis. In this case, the acupuncture needle will be inserted in the soft tissue, in this case the plantar fascia insertion without the application of the galvanic electrical current. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
3203837|NCT00928148|Active Comparator|Immediate Release Amphetamine salt (25 mg)|
3203838|NCT00928148|Placebo Comparator|Placebo|
3203839|NCT00928161|No Intervention|Group 1|Patients with no acid reflux.
3203840|NCT00928161|Active Comparator|Group 2|Patients with acid reflux.
3203841|NCT00928213|Experimental|1|Control not treated, no placebo
3203842|NCT00928213|Experimental|2|Patient treated with low molecular weight heparin after repeated pregnancy loss
3203843|NCT00928213|Experimental|3|Patient super from first trimester bleeding treated with progesterone
3203844|NCT00928226|Experimental|Arm 1 - 24 Grey SRS|24 Grey administered as 8 Gy x 3 fractions
2546711|NCT02586311|Experimental|CKD-330 16/5mg + Amlodipine 5mg placebo|CKD-330 16/5mg + Amlodipine 5mg placebo, po, q.d.
2546712|NCT02586311|Active Comparator|CKD-330 16/5mg placebo + Amlodipine 5mg|CKD-330 16/5mg placebo + Amlodipine 5mg, po, q.d.
2546761|NCT02586116|Active Comparator|nanOss|nanOss Cervical IBF System with nanOss BA Bone Void Filler
2546763|NCT02586116|Active Comparator|C-Plus|C-Plus PEEK IBF Device with autograft
3203845|NCT00928226|Experimental|Arm 2 - 27 Grey SRS|27 Grey administered as 9 Gy x 3 fractions
3203846|NCT00928226|Experimental|Arm 3 - 30 Grey SRS|30 Grey administered as 10 Gy x 3 fractions
2546867|NCT02585518||Obese|Children and adolescents with a BMI at or above the 85th percentile for age and sex
2546872|NCT02585518||Healthy control|Children and adolescents with a BMI below the 85th percentile for age and sex
2546896|NCT02585297||Control- semen|Semen of fertile men
2546899|NCT02585297||Control- vaginal discharge|Vaginal discharge of partners of fertile men
2546901|NCT02585297||Case-semen|Semen of infertile men
2546902|NCT02585297||Case- vaginal discharge|Vaginal discharge of partners of infertile men
2546981|NCT02585076||Cohort 1|Patients aged 60 years or older regardless of gender and race with a documented diagnosis of hypertension will be enrolled into this study after the decision for electrocardiographic screening for AF has been made by the investigator
2547117|NCT02584127|Experimental|High reinforcement cessation program|The High Reinforcement (HR) condition included five monthly, online interim surveys with financial incentives for these assessments and also for program completion. All participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
2547119|NCT02584127|Experimental|Low reinforcement cessation program|Participants in the Low Reinforcement (LR) condition participants completed an eligibility survey and a baseline survey. All participants were offered a financial incentive to complete the six-monh followup survey. All participants were provided access to a six step, cognitive-behavioral smoking cessation program self-administered online.
2547157|NCT02583737|Active Comparator|group lyophilized bone allograft|sinus lifting with tissue bank lyophilized bone filling
2547158|NCT02583737|Active Comparator|group freeze bone allograft|sinus lifting with freeze bone bank filling
3203847|NCT00928226|Experimental|Arm 4 - 33 Grey SRS|33 Grey administered as 11 Gy x 3 fractions
2547235|NCT02582931|Experimental|Arm 1: MRI-guided SBRT|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~Patients will be planned for an initial dose of 35Gy to the planning target volume (PTV), with dose adaptation and reduction allowed based on safety constraints that are generally accepted, up to a maximum allowed total dose of 50Gy in five fractions to the PTV.~All patients will undergo both CT and MRI simulation in positioning appropriate for the specific treatment site"
3203848|NCT00928239|Experimental|1|Arm1: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment to the caudal part of the vagina and the apex.
2547384|NCT02582164|Experimental|Adult|Duke Biomedical Engineering's long-working distance OCT system imaging of adult participants ages ≥18 year of age
2547388|NCT02582164|Experimental|Teenage minors|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥13-≤17 years of age
2547390|NCT02582164|Experimental|Children-pre teen|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥7-≤12 years of age
2547391|NCT02582164|Experimental|Target age group ≥6 months to ≤6 years|Duke Biomedical Engineering's long-working distance OCT system imaging of children ≥6 months to ≤6 years of age
3203849|NCT00928239|Active Comparator|2|Arm 2: Laparoscopic repair of vaginal vault prolapse. Laparoscopic sacropexy procedure as described in previous publication(Sarlos D, Brandner S, Kots L, Gygax N, Schaer G. Laparoscopic sacrocolpopexy for uterine and post-hysterectomy prolapse: anatomical results, quality of life and perioperative outcome-a prospective study with 101 cases. Int Urogynecol JPelvic Floor Dysfunct. 2008 Oct;19(10):1415-22. Epub 2008 Jun 7. PubMed PMID: 18536861) with attachment of the dorsal mesh at distal end of vagina at dorsal vaginal wall
3203850|NCT00928278|Experimental|Treatment A - PF-04764793|PF-04764793 using inhaler A
3203851|NCT00928278|Active Comparator|Treatment B - PF-04764793|PF-04764793 using inhaler B
2547609|NCT02580617|Experimental|ALLO-ASC|Group 1: 5.0 x 10^7 cells Group 2: 7.5 x 10^7 cells Group 3: 10.0 x 10^7 cells
2547630|NCT02580344|Other|Ibuprofen|
3203852|NCT00928278|Experimental|Treatment C - PF-04764793|PF-04764793 using inhaler A
2547756|NCT02579668|Experimental|Language therapy in BSL|Working with Deaf practitioners to provide language activities in British Sign Language aimed at developing children's language skills.
3203853|NCT00928278|Active Comparator|Treatment D - PF-04764793|PF-04764793 using inhaler B
3203854|NCT00928291|Experimental|Group 1 - PCT group|interventions on antibiotic therapy will be based on circulating PCT levels
3203855|NCT00928291|Active Comparator|Group 2 - Control group|antibiotic therapy will be guided by appropriate guidelines, and will be left at the discretion of caregivers.
3203856|NCT00928317|Experimental|ART621 A|ART621 0.75mg/kg per week
3203857|NCT00928317|Experimental|ART621 B|ART621 1.5 mg/kg per week
3203858|NCT00928317|Experimental|ART621 C|ART621 3.0mg/kg per week
3203859|NCT00928317|Placebo Comparator|Placebo arm|
3203860|NCT00928330|Experimental|A|
3203861|NCT00928330|Experimental|B|
3203862|NCT00928330|Experimental|C|
3203863|NCT00928343|Experimental|GLPG0187|Single dose
3203864|NCT00928343|Placebo Comparator|Placebo|
3203865|NCT00928356|Experimental|Hybrid CABG/PCI|Patients undergo hybrid, same sitting CABG/PCI as described.
2546782|NCT02585947|Experimental|tenofovir for 24 weeks|"prophylactic (preemptive) treatment~300mg for 24 weeks~once daily"
2546786|NCT02585947|Experimental|tenofovir for 48 weeks|"prophylactic (preemptive) treatment~300mg for 48 weeks~once daily"
2546839|NCT02585726|Active Comparator|Historical Control with Propensity Analysis|
2546849|NCT02585726|Experimental|VenaSeal Treatment Arm|
2546904|NCT02585336|No Intervention|Observation|
2546905|NCT02585336|Experimental|Brief intervention|
2546989|NCT02585050||patients alive discharged from hospital|patients alive discharged from hospital following CPR
2547032|NCT02584621|Experimental|Check Yourself App With Feedback|Participants complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their visit with their health provider. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Health providers receive a summary report of health risk behaviors from Check Yourself prior to the visit.
2547033|NCT02584621|No Intervention|Usual Care|Participants are asked to complete health risk screening questions on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
2547058|NCT02584374||Patients|with suspected iliac vein compression, but with no signs of compression on venography and if venography with balloon occlusion test is performed.
2547061|NCT02584374||Healthy controls|"Healthy subjects between 18-45 years of age~Venography with balloon occlusion test will be performed."
2547083|NCT02584166||Intervention group|38 maternity units with allocated to the intervention group: coordinating team disseminated protocols related to the management of cases, and organized mortality morbidity conferences (MMC) in each unit with staff concerned. These MMC were realized by the same outside medical binomial composed of a midwife and an obstetrician (outreach visit with a leader ship). Among the 38 maternity units, MMC were performed with the medical binomial and professionals of human science in 20 units to identify the defense mechanisms manifested by medical staff which could disturb the decision making. In the others 18 units, MMC were performed with only the outside medical binomial. Coordinating team defined with teams the area of improvement before each MMC. 3 or 4 MMC were performed according to their activity.
2547085|NCT02584166||Control group|No intervention in 57 maternity units
2547115|NCT02584036||Receiving Influenza Vaccine|Patients who receive an influenza vaccine at a participating pharmacy site will be eligible to: a) receive a vaccination forecast review, b) be evaluated for unmet vaccination needs, c) receive patient education, and d) have vaccination needs met.
2547160|NCT02583672|Experimental|N-acetylcysteine|The first 10 GD1 subjects will take 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days. An interim analysis will be performed to determine if this dose produces changes in systemic redox status and brain glutathione (GSH) levels. If no signal of a significant change is observed, the remaining 20 subjects will receive up to 3600 mg NAC orally twice a day (7200 mg/day).
3203866|NCT00928356|Other|Off-pump CABG|Standard of Care Off Pump CABG
2547262|NCT02582918|No Intervention|Group 1: Usual Care|Usual care with opportunistic visit-based HCC surveillance.
2547266|NCT02582918|Experimental|Group 2: Patient Education and Patient Navigation Services|Mailed HCC surveillance outreach with patient education and patient navigation services.
2547296|NCT02582723|Active Comparator|High protein/high fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
2547298|NCT02582723|Active Comparator|High protein/low fat hard cheese|Served for breakfast together with bread, juice and coffee, tea or water
2547299|NCT02582723|Experimental|Low protein/high fat creme cheese|Served for breakfast together with bread, juice and coffee, tea or water
2547406|NCT02582138|Experimental|Multicomponent intervention (MCI)|The multicomponent intervention will include a physical activity programme, a nutritional intervention and an information and communications intervention.
2547410|NCT02582138|Active Comparator|Healthy Aging Lifestyle Education (HALE)|The health aging lifestyle education programme will be based on workshops. Participants will receive information on a variety of topics of relevance to older persons (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
2547471|NCT02581748|Experimental|safety|Assessment of safety of HLX02 at different doses
2547474|NCT02581748|Active Comparator|PK comparative|Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess the safety and immunogenicity between HLX02 and Herceptin®(U.S. and German)
2547509|NCT02581371|Experimental|Cerebrolysin infusion|Cerebrolysin, solution for injection, 10 ml vials. Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
2547511|NCT02581371|Placebo Comparator|Placebo infusion|Sodium chloride 0.9%, solution for infusion, 100 ml. Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval.
2547556|NCT02581033|Experimental|Nucleoside analogue therapy cessation|To determine if a sustained virological response can be achieved after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
2547588|NCT02580773|Other|Prophylactic anticoagulation|
2547590|NCT02580773|Experimental|Curative anticoagulation|
2547645|NCT02580526|Active Comparator|V-E mask ventilation technique crossover C-E mask ventilation|
2547649|NCT02580526|Active Comparator|C-E mask ventilation technique crossover V-E mask ventilation|
2547717|NCT02579980|Experimental|DCE and DWI MRI group|Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.
3203869|NCT00928460||Regular preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to current protocol, including routine preoperative ECG.
2546724|NCT02586441|Experimental|Electroencephalography|"Standard monitoring included electrocardiogram, noninvasive arterial blood pressure, pulse oximetry, and BIS-VISTATM sensor at OR.~Raw EEG in a steady state was collected for 5 minutes.~Anesthesia was induced with intravenous 1% propofol (1.5-2.5 mg/kg) and rocuronium bromide (0.6 mg/kg)~Mechanical ventilation was initiated~Anesthesia was maintained with desflurane at an end-tidal concentration of 6-7 %, with a fraction of inspired oxygen of 0.5 (fresh gas flow; O2 1.5 L/min and air 2.5 L/min).~On completion of the surgery, all anesthetic gases were discontinued and the FiO2 was increased to 1.0.~After extubation, BIS-VISTA TM monitoring was stopped."
2546766|NCT02586103||MRI|Patients who undergo simulated practice MRI on the day of or prior to their scheduled MRI.
2546813|NCT02585869|Experimental|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
2546815|NCT02585869|Experimental|Gemcabene 300 mg|Gemcabene 300 mg once daily (QD)
2546818|NCT02585869|Experimental|Gemcabene 600 mg|Gemcabene 600 mg once daily (QD)
2546820|NCT02585869|Experimental|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
2546822|NCT02585869|Placebo Comparator|Placebo|Placebo once daily (QD)
2546848|NCT02585596|Experimental|YH23537 1000mg/day|YH23537 500mg 1 tab, placebo 500mg 2tab twice a day (before morning,evening meal) during 12 weeks
2546857|NCT02585596|Experimental|YH23537 2000mg/day|YH23537 500mg 2tab, placebo 500mg 1tab twice day (before morning,evening meal) during 12 weeks
2546860|NCT02585596|Experimental|YH23537 3000mg/day|YH23537 500mg 3tab a day twice day (before morning,evening meal) during 12 weeks
2546862|NCT02585596|Experimental|YH23537 3000mg/day loading 1000mg/day|YH23537 500mg 3tab twice a day (before morning,evening meal) during 4weeks and YH23537 500mg tab twice a day (before morning,evening meal) during 8weeks
2546866|NCT02585596|Placebo Comparator|Placebo|YH23537 500mg placebo 3tab twice a day
2546933|NCT02585167|Active Comparator|Operation|"the fistula will be excised after dividing the sphincter and primary reconstruction~."
2546938|NCT02585167|Experimental|VAAFT|the fistula tract will be visualized by scope, closing the internal opening with absorbable sutures.
2546996|NCT02584829|Experimental|Group 1 (avelumab and MHC class I up-regulation)|Patients who do not have a HLA type for which T cells can be generated or for whom T cells cannot be generated for technical issues receive avelumab intravenously (IV) over 1 hour every 2 weeks for 12 months. Within 7-10 days after completion of 1-3 doses of avelumab, patients receive MHC class I up-regulation intervention comprising either localized radiation therapy or recombinant interferon beta via intra-tumor injection.
2546997|NCT02584829|Experimental|Group 2 (avelumab, MHC class I up-regulation, T cells)|Patients who have an HLA type for which T cells can be generated receive avelumab IV over 1 hour every 2 weeks for 12 months. Patients also receive MHC class I up-regulation intervention as in Group 1 between 7-10 days after the first infusion of avelumab and 2-5 days before the first infusion of MCPyV TAg-specific polyclonal autologous CD8+ T cells. Patients receive two infusions of MCPyV TAg-specific polyclonal autologous CD8+ T cells IV over 60-120 minutes.
2547056|NCT02584387|Experimental|3D VVRET|"Behavioral: 3D Video Virtual Reality Exposure Therapy (VVRET)~1 30 minute 3D VRET treatment session for arachnophobia."
2547057|NCT02584387|No Intervention|Waitlist|Participants randomized to the waitlist group will complete all study procedures except the 3D VVRET. After the conclusion of their sessions, these participants will be offered the full 3D-VVRET treatment.
2547111|NCT02584205|Experimental|Powerbreathe|We will use the powerbreathe Classic light resistance in this intervention (inspiratory muscle training). Both groups will receive the equipment, but the intervention group will do the training with a load 40% of the maximum inspiratory pressure.
2547112|NCT02584205|Placebo Comparator|Control|"This group will also receive the equipment (powerbreathe classic light) but will do the training with a load less than 10% of the maximum inspiratory pressure (insufficient charge to train the muscles)."
2547145|NCT02583828|Active Comparator|Cyclophosphamide alone|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in this arm will receive cyclophosphamide 50 mg daily.
2547148|NCT02583828|Experimental|Cyclophosphamide plus letrozole for resistant patients|Patients who were resistant to letrozole will be randomized to receive cyclophosphamide alone or letrozole plus cyclophosphamide. Patients in the this will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
2547151|NCT02583828|Experimental|Cyclophosphamide plus letrozole for treat-naive patients|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive cyclophosphamide 50 mg daily plus letrozole 2.5 mg daily.
2547152|NCT02583828|Active Comparator|letrozole alone|Patients who haven't received letrozole hormonotherapy will be randomized to receive letrozole plus cyclophosphamide or letrozole alone. Patients in this arm will receive letrozole 2.5 mg daily.
2547188|NCT02583464|Experimental|Test-Reference|A new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) followed by a branded formulation (R).
2547194|NCT02583464|Experimental|Reference-Test|A branded formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (R) followed by a new formulation (T).
2547247|NCT02583152||MPS patient cohort|Participants with Mucopolysaccharidosis. types I-IV, VI and VII will be recruited from the paediatric and adult ophthalmology. Participants over the age of three who are able to comply and be investigated.
3203870|NCT00928460||New preanesthesia evaluation|Patients are evaluated by the anesthesiologist according to a new protocol, in which a routine preoperative ECG is no longer provided.
3203871|NCT00928473|Experimental|Lifestyle counseling|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
2547525|NCT02581228||Training Set|The objective of the Training stage is to assess the predictive potential of ML-PrediCare for melanoma patients' response to Ipilimumab, Pembrolizumab and Nivolumab.
2547528|NCT02581228||Validation Set|The objective of the Validation stage is to test the predictive power of ML -PrediCare in an independent set of patients diagnosed with melanoma.
2547628|NCT02580721|Experimental|Thickened mucosa with connective tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Soft tissue augmentation will be performed with sub epithelial connective tissue graft.
2546728|NCT02586597|Experimental|PAS 10: TMS and median nerve stimulation|Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation. The interval between median nerve stimulation and TMS was chosen to be 10 ms, which is called PAS10. PAS 10: TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2546733|NCT02586597|Experimental|PAS 25:TMS and median nerve stimulation|PAS 25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. PAS 25:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2546738|NCT02586597|Sham Comparator|PAS100:TMS and median nerve stimulation|PAS Control Paradigm: The interval between median nerve stimulation and TMS was chosen to be 100 ms, which is called PAS100. PAS100:TMS and median nerve stimulation: 240 paired median nerve stimulation and TMS during 20 minutes.
2546769|NCT02586051|Experimental|Cohort 1: Single Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Day 1 followed by high dose intravenous immunoglobulin (IVIG) on Days 22 and 43 of treatment period.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
2546773|NCT02586051|Experimental|Cohort 2: Repeated Dose Obinutuzumab|"Desensitization period: Participants will receive obinutuzumab on Days 1 and 15 followed by high dose IVIG on Days 22 and 43. An additional dose of obinutuzumab may be administered on Day 169 at investigator's discretion.~Transplantation period: Participants who are found to qualify for transplantation and receive a compatible kidney offer after inclusion will receive two additional infusions of obinutuzumab (one at the time of transplantation [within the first 48 hours of the transplantation] and second at Week 24 post-transplantation)."
2546844|NCT02585635||Families|Families of children with haemophilia
2546851|NCT02585635||Clinicians|Haemophilia physicians
2546910|NCT02585401||Eylea product and application information / Cohort 1|Physicians prescribing aflibercept in Canada will be selected to reflect the distribution of retinal specialists and ophthalmologists who prescribe aflibercept.
3203872|NCT00928525|Experimental|Imatinib Mesylate|Patients affected by Desmoid Tumor and Chondrosarcoma will receive Imatinib Mesylate 800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
3203873|NCT00928538|No Intervention|Usual NFP Care|Usual NFP care includes pregnancy planning and contraceptive advice during nurse home visits, with the prescription and dispensing of contraceptives provided through the women's primary care settings.
3203874|NCT00928538|Experimental|Enhanced NFP Care|Enhanced NFP intervention includes usual NFP care plus the intervention that includes contraceptive administration and distribution in the home
3203875|NCT00928551|Experimental|1|
3203876|NCT00928577||ACAM2000 Smallpox Vaccine Group|Participants are vaccinia vaccine-naive and have received ACAM2000 Smallpox vaccine as part of their Service Member readiness process.
3203877|NCT00928577||Other vaccinia vaccine Group|Participants did not receive ACAM2000 Smallpox vaccine as part of their Service Member readiness process because they are still protected by previous vaccinia vaccination or are ineligible for current ACAM2000 vaccination either because of recency of prior vaccinia vaccination or for reasons solely attributable to conditions or characteristics of their contacts (such as a healthy soldier who is married to someone with a contraindicated condition).
2547208|NCT02583386|Active Comparator|Free From Falls training group|Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.
2547250|NCT02583191|Experimental|Rivaroxaban|Arm A: Rivaroxaban
3203878|NCT00928590|Experimental|DuoTrav APS|Travoprost/Timolol Maleate Fixed Combination solution, 1 drop in the study eye(s) once daily, at 9 AM, for 12 months
3203879|NCT00928603|Experimental|cryotherapy|Focal Cryotherapy of localized tumor of prostate after spatial definition by in-house extended perineal core biopsy using a template biopsy strategy under local or general anesthesia
3203880|NCT00928616|Experimental|plant sterol esters|Participants consume plant sterol ester supplemented margarine (3 g/day)
3203881|NCT00928616|Placebo Comparator|Placebo|Placebo is a non-sterol ester supplemented margarine
3203882|NCT00928629|Other|All Subjects|ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease.
3203883|NCT00928655|Experimental|acetazolamide|combination of acetazolamide and nocturnal continuous positive airway pressure ventilation
3203884|NCT00928655|Placebo Comparator|placebo capsules|combination of placebo and nocturnal continuous positive airway pressure ventilation
3203885|NCT00928681|Other|0.03 mg/kg or placebo iv|
3203886|NCT00928681|Other|0.1 mg/kg or placebo iv|
3203887|NCT00928681|Other|0.3 mg/kg or placebo iv|
3203888|NCT00928681|Experimental|1.0 mg/kg or placebo iv|
3203889|NCT00928681|Other|3.0 mg/kg or placebo sc|
3203890|NCT00928681|Other|10 mg/kg or placebo iv|
3203891|NCT00928681|Other|0.3 mg/kg or placebo sc|
3203892|NCT00928681|Other|0.1 mg/kg or placebo iv (multiple dose)|
3203893|NCT00928681|Other|0.3 mg/kg or placebo iv (multiple dose)|
3203894|NCT00928681|Other|3.0 mg/kg or placebo iv|
3203895|NCT00928681|Other|0.1 mg/kg or placebo sc|
3203896|NCT00928681|Other|0.3 mg/kg or placebo sc (multiple dose)|
3203897|NCT00928733|Experimental|alcohol|Intraduodenal infusion of ethanol
3203898|NCT00928733|Other|Ethanol|
3203899|NCT00928733|Experimental|Placebo|Intraduodenal infusion of tap water
3203900|NCT00928759||peripubertal obese girls|Peripubertal obese girls, aged 8 - 16 years, who are obese (BMI-for-age percentile greater or equal to 95)
3203901|NCT00928785|Experimental|REPEVAX|
3203902|NCT00928785|Active Comparator|Monovalent tetanus vaccine|
3203903|NCT00928798|Experimental|rapamycin|one facial side rapamycin and one facial side placebo
2546739|NCT02586350|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.Subjects with confirmation of disease progression by independent imaging review, while receiving blinded study drug may request to receive open label Anlotinib and enter the Optional Open Label Anlotinib Treatment Period of the Extension Phase. Subjects who request to receive open label Anlotinib(at the time of confirmed progression) will be informed whether they received placebo or Anlotinib during the period of blinded study drug administration.
2547034|NCT02584712|No Intervention|Control|This group do not participated in the intervention protocol (exercise training), and was followed throughout the entire process. Autonomic activity was assessed before and after 4 weeks.
2547035|NCT02584712|Active Comparator|Exercise Training|This group undergone exercise training intervention during 4 weeks.
2547070|NCT02584361|Active Comparator|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
2547072|NCT02584361|Active Comparator|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA)
2547125|NCT02584101|Experimental|ACT|ACT therapy
2547130|NCT02584101|Active Comparator|Enhanced Treatment as Usual|Group support
2547163|NCT02583659||Combined chemotherapy|AGC patients treated with first-line combined chemotherapy
2547212|NCT02583373|Active Comparator|CAL02 Low-dose|Liposomal formulation
2547216|NCT02583373|Active Comparator|CAL02 High-dose|Liposomal formulation
2547218|NCT02583373|Placebo Comparator|Placebo|Saline
2547328|NCT02582528|Experimental|cognitive remediation treatment and MI|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS) and motivational interviewing, a client-centered, directive method for enhancing intrinsic motivation to change.
2547330|NCT02582528|Active Comparator|cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
2547383|NCT02582346|Experimental|MRI acquisition - no contrast agent|Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
2547677|NCT02580383||Group none|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When both needles were positioned inadequately for a facet joint."
2547679|NCT02580383||Group partial|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~when one of the needles for a facet joint medial branch was placed inadequately."
2547681|NCT02580383||Group complete|"According to the adequacy of RF needle position while performing radiofrequency neurotomy of lumbar medial branch.~When all needles were placed adequately.'"
3169130|NCT00559390||Pre-PCOS|First degree relatives, either sisters or daughters, of women with Polycystic Ovary Syndrome.
3169131|NCT00559390||Controls|Sisters and daughters of women who do not have PCOS
2547743|NCT02579512||Extra-corporeal ECG Signal Analysis|
2547789|NCT02579434|Experimental|Male young adults|Arm 1: Male healthy volunteers aged from 20 to 45 years Midazolam (IV) on day 1
2547790|NCT02579434|Experimental|Male elderly adults|Arm 2: Male healthy volunteers aged over 45 years Midazolam (IV) on day 1
2547793|NCT02579434|Experimental|Female elderly adults|Arm 3: Female healthy volunteers aged over 45 years Midazolam (IV) on day 1
2547795|NCT02579434|Experimental|Female young adults|Arm 4: Female healthy volunteers aged 20 to 45 years Midazolam (IV) on day 1, Day 15
2547837|NCT02579174|Other|Manual (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for both the tibia component and the femur component
2547840|NCT02579174|Other|Manual (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using manual instrumentation for the tibia component and custom instrumentation for the femur component
3169132|NCT00559403|Experimental|HIV/STD Sessions|The HIV/STD Risk-Reduction Intervention arm focuses on reducing the risk of STDs, including HIV.
3169133|NCT00559403|Active Comparator|Health Promotion Control Sessions|The Health Promotion Intervention arm focuses on physical activity, diet, and other behaviors linked to risk of heart disease, high blood pressure, stroke, diabetes, and certain cancers, which are all leading causes of morbidity and mortality among South Africans.
3169134|NCT00559429|Active Comparator|C1|
3169135|NCT00559429|Active Comparator|C2|
3169136|NCT00559429|Active Comparator|C3|
3169137|NCT00559429|Active Comparator|C4|
3169138|NCT00559442|Experimental|1|high altitude exposure without prior acclimatization
3169139|NCT00559455|Experimental|1|
3169140|NCT00559494|Experimental|Minocycline|
3169141|NCT00559494|Placebo Comparator|Placebo|
3169142|NCT00559494|Experimental|SCPP augmentation|
3169143|NCT00559494|Sham Comparator|SCPP control|
3169144|NCT00559520|Active Comparator|Impact|"patient receiving 3 drinks Impact a day during 5 days before surgery"
3169145|NCT00559520|Experimental|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
3169146|NCT00559533|Experimental|1|
3169147|NCT00559546|Active Comparator|1|3 weeks of Montelukast and 3 weeks of placebo treatment
3169148|NCT00559546|Active Comparator|2|3 weeks of placebo and 3 weeks of montelukast treatment
3169149|NCT00559559|Other|Control Group|Patient Notifier turned OFF
3169150|NCT00559559|Experimental|Treatment group|Patient Notifier turned ON
3169151|NCT00559572|Experimental|1|Exercise information group
3169152|NCT00559572|Active Comparator|2|General health information group
2547004|NCT02584764|Experimental|CBT with Internet support|16 sessions of Cognitive behavior therapy in group with Internet support between group sessions
2547047|NCT02584517||GCA|Patients referred with suspected GCA, whose final diagnosis is GCA
2547048|NCT02584517||Not GCA|Patients referred with suspected GCA, whose final diagnosis is another disorder
2547096|NCT02584335|Active Comparator|"Lidocaine solution (A)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of 0.5% lidocaine dilution when the wound treatment process is assigned to the letter A. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient)."
2547098|NCT02584335|Placebo Comparator|"Saline solution (B)"|"Two sterile gauzes will be dampen with the content of the second syringe (the content of the first syringe is always 20 ml of saline solution and it is the first sterile gauzes administrated always) that will contain 20ml of saline solution when the wound treatment process is assigned to the letter B. The nurse has a third syringe exactly like this second syringe to apply if necessary (process still painful to the patient). In this case, the three syringes supplied to the nurse, have saline solution."
2547132|NCT02583945|Experimental|kidney treatment bundle (KDIGO)|Consequent postoperative application of a kidney treatment bundle: Protocol based hemodynamic optimization and monitoring, regular screening of creatinine in serum and of urine output, no use of potential nephrotoxic medication and normoglycemia.
3169153|NCT00559611|Experimental|Endobronchial Ultrasound vs. Mediastinoscopy|"Endobronchial Ultrasound - A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.~Mediastinoscopy - Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS."
3169154|NCT00559650|Placebo Comparator|Arm 1|
2547257|NCT02583139|Experimental|Music Narrative Group|Prescribed medical/chemotherapy treatment plus standard care + Designed Music Narratives
2547261|NCT02583139|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
3169155|NCT00559650|Experimental|Arm 2|
3169156|NCT00559663|Active Comparator|GT|The green tea group is given initially green tea treatment and then after a washout period of four weeks switched to the dark chocolate treatment.
2547428|NCT02581969||Prophylaxis|Prophylaxis group: treatment is based on regularly repeated infusions of clotting factor, 20-30 IU/kg -3 times a week
2547431|NCT02581969||On-demand|On-demand group: treatment administered when bleeding episode occur
2547468|NCT02581670|Experimental|Oligometastatic breast cancer patients|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients medically inoperable, using VMAT RapidArc approach.
2547613|NCT02580539|Experimental|Autologous or allogenic (stem cell donor) T cells|Subjects receive an autologous anti-EBV T-cell line or a T-cell line derived from the patient's allogeneic (stem cell transplant) donor.
2547615|NCT02580539|Experimental|"Allogeneic third party T cells"|Subjects receive a T-cell line from a matched or partially matched related donor.
2547659|NCT02580305|Active Comparator|Experimental: SUVN-502 Low dose (50 mg)|SUVN-502 Low dose adjunct to base treatment with Donepezil and Memantine
2547663|NCT02580305|Active Comparator|Experimental: SUVN-502 High dose (100 mg)|SUVN-502 High dose adjunct to base treatment with Donepezil and Memantine
2547667|NCT02580305|Placebo Comparator|Placebo|Placebo adjunct to base treatment with Donepezil and Memantine
2547780|NCT02579473|Experimental|Cohort 0|"Subjects in Cohort 0 will receive a single subcutaneous injection of 20 mg SER-214, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2547783|NCT02579473|Experimental|Cohort 1|"Subjects in Cohort 1 will receive a single SC injection of 50 mg SER-214 at the beginning of each week for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2547785|NCT02579473|Experimental|Cohort 2|"Subjects in Cohort 2 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a weekly SC injection of 100 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine safety, tolerability and PK and terminal wash-out of rotigotine and pro-drug SER-214."
2549183|NCT02570581|Active Comparator|jelly with Oxazepam|Jelly with Oxazepam
3169157|NCT00559663|Active Comparator|DC|The dark chocolate group is given initially dark chocolate treatment and then after a washout period of four weeks switched to the green tea treatment.
3169158|NCT00559689||1|receive once-daily administration of inhaled glucocorticosteroids at bedtime
3169159|NCT00559689||2|receive twice-daily administration of inhaled glucocorticosteroids
3169160|NCT00559702|Experimental|1|Natalizumab IV (Participants with secondary progressive multiple sclerosis)
3169161|NCT00559702|Experimental|2|Natalizumab IM (Participants with secondary progressive multiple sclerosis)
3169162|NCT00559702|Experimental|3|Natalizumab SC (Participants with secondary progressive multiple sclerosis)
3169163|NCT00559702|Other|4|Standard of care as determined by the Investigator and Treating Neurologist (Participants with secondary progressive multiple sclerosis)
3169164|NCT00559702|Experimental|5|Natalizumab SC (Participants with relapsing forms of multiple sclerosis)
3169165|NCT00559702|Experimental|6|Natalizumab IV (Participants with relapsing forms of multiple sclerosis)
3169166|NCT00559715|Experimental|A|
3169167|NCT00559715|Active Comparator|B|
3169168|NCT00559780|Experimental|1|12 weeks of resistance training
3169169|NCT00559780|Experimental|2|12 weeks of neuromuscular electrical stimulation
3169170|NCT00559780|Other|3|12 weeks of standard rehabilitation
3169171|NCT00559806|Experimental|1|9 healthy elderly males
3169172|NCT00559806|Experimental|2|11 healthy young males
3169173|NCT00559819|Active Comparator|Alcohol|Alcohol
3169174|NCT00559819|Placebo Comparator|Placebo|Orange juice
3169175|NCT00559832|No Intervention|Normoxia|Sleeping in normoxia for 14 nights prior to one night at 4500 m
3169176|NCT00559832|Experimental|Hypoxia|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
3203904|NCT00928811|Other|Control|Standard of care administration with Simulect (basiliximab)being administered as per induction therapy on day of transplant and day 4.
3203905|NCT00928811|Experimental|Simulect|"Simulect (basiliximab) intravenously day of transplant and day 4.~Chronic Simulect (basiliximab) administration monthly for one year duration.~Concomitant decrease in Prograf administration."
2546966|NCT02585011|Experimental|Ropivacaine|Local infiltration anesthesia, single shot during surgery. 150 ml Ropivacaine (2mg/ml), added 0.5 ml Epinephrine (1mg/ml)
2546969|NCT02585011|Placebo Comparator|Placebo|Single shot during surgery.150 ml saline
2547012|NCT02584738|Experimental|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4.~Intravenous methylprednisolone or oral prednisolone"
2547013|NCT02584738|Placebo Comparator|Nebulized isotonic saline|Nebulized salbutamol and ipratropium bromide with 2.5 ml of isotonic saline. Intravenous methylprednisolone or oral prednisolone
2547067|NCT02584413|Experimental|Arm 1: MRI of brain with gadolinium contrast|-Eligible children whose guardians have consented to their participation will undergo routine clinical brain MRI with gadolinium contrast. The MRI scan will last no more than 45 minutes
3203906|NCT00928837|Active Comparator|flavocoxid 250 mg|Medical Food product
2547186|NCT02583451|Experimental|Treatment A|Treatment A is a placebo tablet matching lemborexant and placebo tablet matching zopiclone on nights in the clinic; placebo tablet matching lemborexant on nights at home.
2547191|NCT02583451|Experimental|Treatment B|Treatment B is zopiclone 7.5 mg tablet and placebo tablet matching lemborexant on nights in the clinic; placebo tablet matching lemborexant on nights at home.
2547195|NCT02583451|Experimental|Treatment C|Treatment C is lemborexant 2.5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 2.5 mg tablet on nights at home.
2547198|NCT02583451|Experimental|Treatment D|Treatment D is lemborexant 5 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 5 mg tablet on nights at home.
2547201|NCT02583451|Experimental|Treatment E|Treatment E is lemborexant 10 mg tablet and placebo tablet matching zopiclone on nights in the clinic; lemborexant 10 mg tablet on nights at home.
2547251|NCT02583009|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
2547253|NCT02583009|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
2547256|NCT02583009|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2547260|NCT02583009|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
3203907|NCT00928837|Active Comparator|Naproxen|antiinflammatory
2547387|NCT02582268|Experimental|TAS guided IUD insertion|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
2547389|NCT02582268|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound. the trans-abdominal probe will also be placed by an assistant on the suprapubic region ( the image would be on freeze mode) as it is not actually used , it is just to make the same settings for the participant females.
3203908|NCT00928837|Placebo Comparator|Placebo|Placebo
3203909|NCT00928837|Experimental|flavocoxid 500 mg|medical food product
2547557|NCT02581150|Other|Outpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during an ambulatory hospitalisation, with the use of an arterial closure device (ACD).~The patients treated for PAD (Peripheral Arterial Disease) are informed and prepared in the morning of D0. The surgical endovascular procedure is performed at D0 before 1:00 p.m. The patients leave the hospital in the evening at D0 after a systematic visit."
2547558|NCT02581150|Other|Conventional inpatient hospitalisation|"The intervention is the Treatment of Occlusive Arterial Disease, during a conventional hospitalisation, with or without ACD (ACD will be used at the discretion of the interventionalist).~The patients treated for PAD arrive at the hospital the day before surgery (D-1). The surgical endovascular procedure takes place the next day (D0). The day after (D1), the patients leave the hospital after a systematic visit."
2547643|NCT02580669|Experimental|Progressive Multiple Sclerosis|22 patients with Progressive Multiple Sclerosis will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
2547647|NCT02580669|Experimental|Multiple Sclerosis, Relapsing-Remitting|22 patients with Multiple Sclerosis, Relapsing-Remitting will be included and they get an Neuropsychological assessment, a Neurologic consultation and MRIs (with vasoreactivity testing)
2547651|NCT02580669|Experimental|Healthy volunteers (22 patients)|22 healthy volunteers will be included and they get an Neuropsychological assessment and MRIs (with vasoreactivity testing)
3203910|NCT00928850|Active Comparator|urethral irrigation but no fascial suturing, QOL forms|The anterior two-thirds of the urethra is divided exposing a Foley catheter that was placed at the beginning of the procedure. Irrigation of the urethra may prevent spread of prostate cancer cells to tissue that is not removed during surgery. The urethra is irrigated with 60 cc of sterile water as it is withdrawn from the patient to 'wash' the urethra.
2547760|NCT02579551|Experimental|Treatment (surgical excision)|Patients undergo surgical excision of the skin lesion consisting of 1 and 2 mm circumferential margins during visit 1.
2547898|NCT02578823|Experimental|TTM-36|"Participants assigned to TTM-36 Arm will be managed by Arcticgel™ and Arctic Sun® to maintain core temperatureTemperature at 36.0℃ for 72 hours.~After targeted temperature management(TTM), Fever will be controlled for remaining 7 days by conventional antipyretic treatment. (Treat core temperature ≥ 38.3℃).~A total of 40 participants will be enrolled."
2547903|NCT02578823|Active Comparator|Conventional treatment|"Participants who are assigned to this Arm will be treated with conventional antipyretic treatment regarding the occurrence fever for 7 days.(Treat core temperature ≥ 38.3℃).~A total of 20 participants will be enrolled."
2547960|NCT02578446|Experimental|Uncemented Triathlon Tritanium CR|Primary total knee replacement with Uncemented Triathlon Tritanium CR Total Knee System
2549184|NCT02570581|Active Comparator|jelly with donepezil|jelly with donepezil
2546831|NCT02585674|Experimental|MyStar DoseCoach|MyStar DoseCoach - Device-supported treat-to-target regimen. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
2546832|NCT02585674|Active Comparator|Routine Titration|Routine Titration - Routine titration defined by the Investigator. Insulin glargine is administered subcutaneously on top of potential background therapy using oral anti-diabetic drug(s) or GLP1 RA injectable antihyperglycemic drug(s).
2546864|NCT02585492|Active Comparator|head-of-bed elevated 15°|Mother's head-of-bead elevated 15°. Intervention: Head-of-bed elevated 15° during 2 hours after the delivery.
2546868|NCT02585492|Experimental|head-of-bed elevated 45°|Mother's head-of-bead elevated 45°. Intervention: Head-of-bed elevated 45°during 2 hours after delivery.
2546928|NCT02585206|No Intervention|Arm 1|"All 4 factors off - standard text message program~Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity OFF"
2546931|NCT02585206|Active Comparator|Arm 2|Personalization OFF Integration OFF Dynamic Tailoring OFF Message Intensity ON
2546936|NCT02585206|Active Comparator|Arm 3|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity OFF
2546943|NCT02585206|Active Comparator|Arm 4|Personalization OFF Integration OFF Dynamic Tailoring ON Message Intensity ON
2546945|NCT02585206|Active Comparator|Arm 5|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity OFF
2546948|NCT02585206|Active Comparator|Arm 6|Personalization OFF Integration ON Dynamic Tailoring OFF Message Intensity ON
2546949|NCT02585206|Active Comparator|Arm 7|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity OFF
2546952|NCT02585206|Active Comparator|Arm 8|Personalization OFF Integration ON Dynamic Tailoring ON Message Intensity ON
2546954|NCT02585206|Active Comparator|Arm 9|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity OFF
2546955|NCT02585206|Active Comparator|Arm 10|Personalization ON Integration OFF Dynamic Tailoring OFF Message Intensity ON
2546957|NCT02585206|Active Comparator|Arm 11|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity OFF
2546958|NCT02585206|Active Comparator|Arm 12|Personalization ON Integration OFF Dynamic Tailoring ON Message Intensity ON
2546959|NCT02585206|Active Comparator|Arm 13|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity OFF
2546960|NCT02585206|Active Comparator|Arm 14|Personalization ON Integration ON Dynamic Tailoring OFF Message Intensity ON
2546961|NCT02585206|Active Comparator|Arm 15|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity OFF
2546962|NCT02585206|Active Comparator|Arm 16|Personalization ON Integration ON Dynamic Tailoring ON Message Intensity ON
2546963|NCT02585206|No Intervention|WEB|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program."
2546964|NCT02585206|Active Comparator|WEB+OA_TXT|"Phase II arm.~Full access to standard BecomeAnEX.org web-based smoking cessation program PLUS optimal-adherence text message program from Phase I."
2547052|NCT02584491|Experimental|Functional gait-related training|16 session, 6-week intensive functional gait-related training intervention based on motor learning principles that includes a motor imagery practice component.
2547080|NCT02584270|Experimental|Prosthesis + Articulation Therapy|This arm will receive a palatal augmentation prosthesis with standard articulation therapy, and is the study arm.
2547081|NCT02584270|Other|No Prosthesis; Articulation Therapy Only|This arm will not receive a palatal augmentation prosthesis, but will receive standard articulation therapy, and is the control arm.
2547114|NCT02584049|Active Comparator|Osteopathy|3 sessions of Osteopathic treatment in addition to the usual follow
2547116|NCT02584049|Sham Comparator|Sham osteopathy|3 sessions of Sham osteopathy treatment in addition to the usual follow
2547168|NCT02583776|Experimental|Unblinded CGM|"CGM data will be unblinded, with Hypo/hyperglycemia alarms on. Data will be recorded from CGM every three hours and intervention to adequate glucose intake will be performed to keep glycemia in normal range (72-144mg/dl) if necessary."
2547171|NCT02583776|Other|Blinded CGM|Hypo/hyper alarms are off. CGM data will be blinded. Glucose intake will be adequate according to 2-3 capillary glycemic tests per day.
2547264|NCT02583282|Experimental|Doxycycline|Intrapleural doxycycline
2547268|NCT02583282|Active Comparator|Iodopovidine|Intrapleural iodopovidine
2547305|NCT02582645|Experimental|OWT - open window technique|In this arm, a palatally impacted canine will be exposed surgically and left for max 9 months. No traction will be applied during this time.
2547311|NCT02582645|Active Comparator|CWT - closed window technique|In this arm, a palatally impacted canine will be exposed surgically, an attachment will be bonded to the tooth and traction will be applied after healing period is complete (1-2 weeks).
2547370|NCT02582372|Experimental|dexmedetomidine|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 10 micrograms of dexmedetomidine, with needle 25 gauge
2547372|NCT02582372|Active Comparator|fentanyl|25 patients recieve subarachnoidal anesthesia with 12,5 mgrs of bupivacaine 0,5% plus 25 micrograms of fentanyl, with needle 25 gauge
2547401|NCT02582099|Active Comparator|Gentamicin|Gentamicin nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
2547413|NCT02582099|Placebo Comparator|Normal saline|Normal saline nasal irrigation in chronic rhinosinusitis amount 20 ml each pernostril
3169177|NCT00559871|Placebo Comparator|1|One placebo tablet administered tid from Day 1 to 28
3203911|NCT00928850|Active Comparator|fascial suturing but no urethral irrigation, QOL forms|For patients undergoing fascial suturing only, after the initial placement of the suture through the urethra a second bite is taken deeply into the fascia of the lateral pelvic fascia.
3203912|NCT00928850|Active Comparator|both urethral irrigation and fascial suturing, QOL forms|
2547598|NCT02580812|Experimental|MONALISA 5-years old children|Clinical and neuropsychological evaluation procedure 90 children
2547601|NCT02580812|Active Comparator|EPIPAGE 5 -years old children|Cohort of prematurely borne children and their controls Clinical and neuropsychological evaluation procedure 270 children
2547656|NCT02580474|Experimental|Daclatasvir plus Asunaprevir|
3169178|NCT00559871|Active Comparator|2|One 30-mg tablet of Fipamezole tid from Day 1 to 28
3169179|NCT00559871|Active Comparator|3|One 30-mg tablet of Fipamezole tid from Day 1 to 7; and one 60-mg tablet of Fipamezole tid from Day 8 to 28
2546835|NCT02585791|Experimental|vape NFEC containing 100% PG|Subjects will then be instructed how to use the NFEC (eGo-T® with light emitting diode (LED) display) for 1 week of regularly vaping NFEC containing 100% Propylene Glycol . Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2546836|NCT02585791|Experimental|vape 100% vegetable glycerin -VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 100% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 mAh battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2546837|NCT02585791|Experimental|vape PG+VG|Subjects will then be instructed how to use the NFEC (eGo-T® with LED display) for 1 week of regularly vaping NFEC containing 50% PG and 50% VG. Subjects will be given the eGo-T®, which contains a 1.2 ml refillable cartridge and a 1100 milliamp hours (mAh) battery with an LED display to record the number of puffs. Subjects will be asked to puff 100x per day (equivalent to ~10-11 cigarettes) for 7 days. We will accept a vaping range of 80-120 times a day.
2546940|NCT02585102|Other|Recommended Vegetables|Diet provided consisting of recommended vegetable intake per Dietary Guidelines for Americans amounts for 8 weeks.
2546946|NCT02585102|Other|Usual Vegetables|Diet consisting of usual vegetable intake amounts for 8 weeks.
2547267|NCT02583022|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2547269|NCT02583022|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
2547271|NCT02583022|Active Comparator|Elidel cream 1%|Elidel cream 1%, Twice daily for 4 weeks
3169180|NCT00559871|Active Comparator|4|One 30-mg tablet of Fipamezole tid from Day 1 to 7; one 60-mg tablet of Fipamezole tid from Day 8 to 14; and one 90-mg tablet of Fipamezole tid from Day 15 to 28
3169181|NCT00559910|Experimental|PH-797804|PH-797804 at four dose levels
3169182|NCT00559910|Placebo Comparator|Placebo|Placebo
3169183|NCT00559975|Active Comparator|1|
2547386|NCT02582320||Study patients|Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.
2547512|NCT02581501|Experimental|Gemcitabine, ABRAXANE®, and Xeloda|"Level-1~ABRAXANE® 75 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12.~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 1~ABRAXANE® 100 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 60 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 2~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 600 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day~Level 3~ABRAXANE® 125 mg/m2 over 30 min Days 5 and 12~GEMCITABINE 750 mg/m2 over 75 min Days 5 and 12~XELODA 500 mg/m2 BID D 1-14 capped at total dose of 2000 mg/day"
2547548|NCT02581124|Experimental|Experimental: JTZ-951 and Lapatinib|Tablets; JTZ-951, single dose on non-dialysis Days 1 and 5; Lapatinib, single dose on non-dialysis Day 5
2547567|NCT02580825|Active Comparator|Biofeedback gait retraining|The intervention program will take four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
2547574|NCT02580825|Active Comparator|Exercise|The control group will receive the same training program: four weeks while in each week their will be two exercise sessions and a total of 8 sessions. Each session length is about 9 minutes. Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). This group will not provide the biofeedback.
2547626|NCT02580721|Active Comparator|Thick mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
2547627|NCT02580721|Experimental|Thin mucosal tissue|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted.
3169184|NCT00559975|Active Comparator|2|
3169185|NCT00559975|Experimental|3|
3169186|NCT00559975|Experimental|4|
3169187|NCT00559975|Experimental|5|
3169188|NCT00560001|Experimental|A|Those subjects that receive an MD.2 Medication Dispenser
3169189|NCT00560001|No Intervention|B|Control subjects that do not receive an MD.2 Medication Dispenser, but continue to take their medications utilizing standard care, such as pill boxes, etc.
3169190|NCT00560014|Experimental|1|Arginine and Canola oil supplemented group
3169191|NCT00560014|Experimental|2|Arginine and Coromega
3169192|NCT00560014|No Intervention|3|Control
3169193|NCT00560079|Experimental|1|Lithium 900mg/day plus allopurinol 600mg/day
3169194|NCT00560079|Active Comparator|2|
3169195|NCT00560079|Placebo Comparator|3|
3169196|NCT00560092|Experimental|intrathecal magnesium sulfate|
3169197|NCT00560144|Experimental|1|
3169198|NCT00560144|Experimental|2|
3169199|NCT00560144|Experimental|3|
3169200|NCT00560157|Active Comparator|I|Sondalis HP
3169201|NCT00560157|Experimental|II|Crucial
3169202|NCT00560170|Experimental|high dose statin|40mg of Simvastatin (n=20)
3169203|NCT00560170|Active Comparator|combination arm|10mg/10mg of Ezetimibe/Simvastatin (n=20)
3169204|NCT00560183|Experimental|1|
3169205|NCT00560183|Placebo Comparator|2|
3169206|NCT00560196||1|Patients with panic anxiety disorder without pain
3169207|NCT00560196||2|Patients with depression without pain
3169208|NCT00560196||3|Healthy controls
3169209|NCT00560209|Placebo Comparator|P|
3169210|NCT00560209|Experimental|E2|
3169211|NCT00560209|Experimental|E1|
2546944|NCT02585089|Active Comparator|Spanish cured-pork ham|"One group will receive dry-cured pork ham of >10 months proteolysis (intervention product).~Intervention: Dietary intake Dry-cured pork ham contains high doses of bioactive peptides produced during more than 10 months of proteolysis."
2546947|NCT02585089|Placebo Comparator|Cooked pork ham|The other group will receive cooked, uncured ham (placebo product). Intervention: Dietary intake. Cooked ham does not display bioactive peptides as they are produced during proteolysis of pork ham.
3203913|NCT00928850|Active Comparator|neither urethral irrigation nor fascial suturing, QOL forms|
2547065|NCT02584348|Experimental|Gastric Ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed
2547082|NCT02584192|Experimental|the rehabilitation group|entailing an early home-based CR program
2547084|NCT02584192|Other|the control group|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
2547133|NCT02584010|Experimental|Kelofin Aerosol|Silicon-based Aerosol that will be applied over the postoperative scar two times a day
2547135|NCT02584010|Experimental|Kelofin Gel|Silicon-based Gel that will be applied over the postoperative scar two times a day
2547137|NCT02584010|No Intervention|Control|This group will not receive any intervention as a control group.
2547162|NCT02583594|Experimental|alemtuzumab (subcutaneous injection)|Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
2547166|NCT02583594|Experimental|alemtuzumab (intravenous infusion)|Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
3203914|NCT00928863||Haemorrhagia post partum|Women with a high risk for haemorrhagia post partum.
2547322|NCT02582827|Experimental|ABI-011|IDN 5404 protein-bound particles for injectable suspension
2547361|NCT02582411||Group 1: 18-34 years|Patients in age group 18-34 years
2547362|NCT02582411||Group 2: 35-49 years|Patients in age group 35-49 years
2547363|NCT02582411||Group 3: 50-64 years|Patients in age group 50-64 years
2547364|NCT02582411||Group 4: 65-80 years|Patients in age group 65-80 years
2547393|NCT02582190|Other|Colchicine group|Colchicine add on therapy in atrial fibrillation
2547519|NCT02581631|Experimental|Nivolumab+Brentuximab Vedotin|Nivolumab+Brentuximab Vedotin dose as specified
2547560|NCT02580838|Experimental|early OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected immediately when spasticity develop in early OnabotulinumtoxinA group.
2547562|NCT02580838|Active Comparator|late OnabotulinumtoxinA group|OnabotulinumtoxinA will be injected at 6 months after emergence of spasticity in late OnabotulinumtoxinA group.
2547571|NCT02580838|No Intervention|no OnabotulinumtoxinA group|OnabotulinumtoxinA will not be injected for this group.
2547660|NCT02580695|Experimental|Umbilical-cord mesenchymal stromal cells|"Umbilical-cord mesenchymal stromal cells (UC-MSCs)~Allogeneic UC-MSCs 20 x 10e6 diluted on 3 mL of saline solution + 5% of Plasma AB~Arm 2a: single infusion group. UC-MSCs at 0 month~Arm 2b: double infusion group. UC-MSCs at 0 and 6 months"
2547664|NCT02580695|Active Comparator|Hyaluronic Acid (HA)|Drug: Hyaluronic Acid 3 mL of HA intra-articular injection at baseline and 6 months
3203915|NCT00928876|Experimental|Anakinra group|Anakinra 150 mg/day during four weeks
3203916|NCT00928876|Placebo Comparator|Placebo|Placebo during four weeks
2547883|NCT02578966|Experimental|Motivational Interview|INTERVENTION GROUP: in this group, composed of 6 UBS, the children and their respective mothers/fathers/responsible adults will be attended by the dentists at least once a year with an approach based on the Motivational Interview.
2547885|NCT02578966|Active Comparator|Traditional health education|CONTROL GROUP: in this group, composed of 6 UBS, the children and their respective mother/fathers/responsible adults will be attended by the dentists at least once a year based on the recommendations by the Brazilian Ministry of Health (BRASIL,2008-a) and on SSC-GHC's protocol (BRASIL, 2008-b). Additionally, the professional guidance script and the parents' booklet of SSC-GHC's oral health Program may be used.
2547922|NCT02578641|Experimental|Arm A|"4 cycles* of combination IV Gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days, followed sequentially by T-cell immunotherapy (2 cycles) of autologous EBV specific Cytotoxic T cells every 2 weeks, followed by EBV-specific CTL immunotherapy (4 cycles) every 8 weeks after 6 weeks from the second cycle.~*Additional 1-2 chemotherapy cycles (up to total 6 chemo cycles) might be given upon discretion of Investigator, if EBV-specific CTL infusions are not available in time for the 1st scheduled infusion.~As of 1 May 2020, patients who have not received the first infusion of EBV-specific CTLs, will instead continue to receive a total of 6 cycles combination of Gemcitabine (1000 mg/m2) and carboplatin (AUC2) on Days 1, 8, 15 every 28 days"
2547925|NCT02578641|Active Comparator|Arm B|6 cycles of combination IV gemcitabine (1000 mg/m2) and IV carboplatin (AUC2) on Days 1, 8, 15 every 28 days.
2548040|NCT02577861|Experimental|Holoclar|Treatment with Holoclar (medicinal product), including biopsy, graft production and implantation of the graft containing stem cell
2548054|NCT02577471||During pregnancy|Pregnant ladies filled bowel function questionnaires
2548055|NCT02577471||After delivery|ladies within three weeks of delivery filled bowel function questionnaires
2548056|NCT02577471||Controls|Non pregnant ladies filled bowel function questionnaires
2548091|NCT02577393|Experimental|prophylactic EGCG group|
2548093|NCT02577393|Experimental|therapeutic EGCG group|
2548098|NCT02577393|Placebo Comparator|conventional therapy group|
2549185|NCT02570581|Active Comparator|Jelly with clopidogrel|jelly with clopidogrel
2547039|NCT02584569|Experimental|TAK-915|TAK-915 100 mg suspension, orally, once on Day 1. Additional TAK-915 dose levels may be incorporated based on dose level review meetings (DLRMs) following approximately every 2 participants and based on prior occupancy, duration of occupancy, safety, tolerability, and available pharmacokinetic (PK) data.
2547086|NCT02584322|Experimental|ERAS patients|Enhanced recovery pathway
2547127|NCT02583984||Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic Surgery with Lung Resection, such as lobectomy, segmentectomy
2547131|NCT02583984||Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic Surgery without Lung Resection, such as esophageal surgery, mediastinal surgery
2547172|NCT02583633|Active Comparator|Group one have received Transdermal nitroglycerin|transdermal GTN (Schwarz Pharma AG, Monheim, FRG) were prescribed and placed on the patient forearm. Each patch contained 37.4 mg of glyceryl trinitrate which was released in blood stream (10mg/24hour). After one hour of the first patch application, the uterine contractions were evaluated.
2547174|NCT02583633|Active Comparator|Group two have received nifedipine|"For the nifedipine group, nifedipine 5mg softgel (Daana Pharma Co., Tabriz, Iran) was prescribed. In this group, the order of medicine prescription was as below;~One softgel every 20 min (4 doses)~Two softgel every 6 hr (4 doses)~One softgel every 6 hr (4 doses)~One softgel every 8 hr (3 doses) Likewise, the uterine contractions were checked every one hour and if the contraction didn't subside or there was any change in dilation and effacement, the treatment were stopped and another tocolytic were applied."
2547228|NCT02583321|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
2547230|NCT02583321|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2547245|NCT02583035|Other|Nurse telephone contact|3 days of consultation, telephone follow-up of the patient by the nurse coordinator of the Geriatric Oncology Unit to validate
2547307|NCT02582762|Experimental|Nail gel|apply nail gel twice daily
2547385|NCT02582450||Patients with haemophilia|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
2547430|NCT02581943|Experimental|Arm I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2547433|NCT02581943|Experimental|Arm II (pembrolizumab, paclitaxel, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1, paclitaxel IV over 1 hour and carboplatin IV over 1 hour on days 1, 7 and 14. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
2547744|NCT02579525|Experimental|Targeted tissue perfusion guidance (TTP)|TTP-guidance based on clinical signs of peripheral perfusion.
2547745|NCT02579525|Active Comparator|Macrocirculatory - guidance (MCG)|MCG-guidance based on recommended macrocirculatory parameters.
2547826|NCT02579356|Experimental|Part1-A|The Part1-A of groups take Telmisartan once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
2547828|NCT02579356|Experimental|Part1-B|The Part1-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan once a day for 6 days in period 2.
2547834|NCT02579356|Experimental|Part2-A|The Part2-A of groups take Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Telmisartan and Atorvastatin once a day for 6 days in period 2.
2547836|NCT02579356|Experimental|Part2-B|The Part2-B of groups take Telmisartan and Atorvastatin once a day for 6 days in period 1. After wash-out period, they take Atorvastatin once a day for 6 days in period 2.
2547890|NCT02578836|Experimental|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
2547982|NCT02578329|Experimental|Med Diet|Intensively advised Mediterranean diet
2547987|NCT02578329|Active Comparator|Low Fat diet|usual low-fat dietary advice
2548026|NCT02577965|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
2548028|NCT02577965|Active Comparator|Male Arm|Male Gender with diagnose of ST segment Elevation Acute Myocardial Infarction (STEMI). Interventions: Angiography, thrombus aspiration, optical coherence tomography and percutaneous coronary intervention, implantation of XIENCE PRIME Everolimus Eluting Coronary Stent. Angiography and Optical Coherence Tomography follow up at 9 months.
2548146|NCT02577055|Active Comparator|myomectomy|Women will be treated with surgical removal of all fibroids, either by laparoscopic or abdominal route
2548147|NCT02577055|Experimental|embolisation|Women will be treated with fertility sparing uterine arteries embolization (i..e. with ultra thin catheter, and particles' diameter > 500µm)
2548157|NCT02576756||with difficult intubation|Control population
2548169|NCT02576756||without difficult intubation|Control population
2548207|NCT02576691||The PCI group|The PCI group was composed of patients who underwent PCI following the return of spontaneous circulation or after CA.
2548208|NCT02576691||Non-PCI group|Non-PCI group included patients who didn't undergo PCI or were subjected to PCI before CA
2548553|NCT02574585|No Intervention|Control group|Twenty subjects will be randomly assigned to be clinically followed, without any specific intervention.
3203917|NCT00928902|Active Comparator|Peptides with GM-CSF-in-adjuvant, with upfront IL-2|Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 1 and ending at week 7.
2547136|NCT02583971||Patients with AF|"Split into 3:~Those patients on treatment for AF involving blood thinning medicines (anticoagulants) +/- heart rate limiting drugs such as B blockers or digoxin. 100 patients in this group.~Patients undergoing direct current cardioversion (DCCV) to temporarily restore normal (sinus) rhythm. 100 patients in this group.~Patients undergoing an AF ablation to permanently restore sinus rhythm. 300 patients in this group."
2547200|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + ASV for 4 weeks.
2547203|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 4 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 2 will receive LDV/SOF + SMV for 4 weeks.
2547205|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + ASV for 6 weeks.
2547209|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 6 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <25 IU/ml by week 4 will receive LDV/SOF + SMV for 6 weeks.
2547210|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + ASV for 8 weeks.
2547215|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 8 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA > 2 log drop but ≥25 IU/ml by week 4 will receive LDV/SOF + SMV for 8 weeks.
2547219|NCT02583685|Experimental|PR4 + LDV/SOF + ASV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + ASV for 12 weeks.
2547221|NCT02583685|Experimental|PR4 + LDV/SOF + SMV 12 wk|Participants treated with 4 weeks pegylated interferon and ribavirin and plasma HCV RNA <2 log drop by week 4 will receive LDV/SOF + SMV for 12 weeks.
2547278|NCT02582892|Other|Vit D|Vit D 20 mg/day
2547302|NCT02582567|Experimental|Exercise intervention|3 times per week from the 17th week of gestation until delivery
2547304|NCT02582567|No Intervention|Control group|Usual care (control) group
2547427|NCT02581956|Experimental|Walking Exercise|For the exercise group, subjects were asked to follow a simple walking regimen. Walk normally with stable and comfortable stride rates during their exercise. The duration and frequency was initiated at a 30-minute or more daily exercise at least five days per week and gradually increased to a maximum of 60 minutes within subject's comfort zone.
2547432|NCT02581956|Placebo Comparator|No Intervention|No exercise required
2547458|NCT02581696|Other|Single arm|This is a follow-up study of BR-LAF-CT-101, a phase 1 study to evaluate the drug-drug interaction and safety of Lafutidine and Irsogladine maleate in healthy adult volunteers. Subjects judged to be appropriate to this study by screening.
2547520|NCT02581423|Experimental|Capecitabine|Participants will receive capecitabine for up to approximately 6 months.
2547575|NCT02580994|Experimental|Pembrolizumab + chemotherapy|Pembrolizumab, in combination with cis/carboplatin and etoposide for 4 cycles intravenous 200mg on day 1 (every 3 weeks), pembrolizumab continued alone as continuation maintenance until progressive disease
2547578|NCT02580994|Active Comparator|Chemotherapy|4 cycles of cis/carboplatin and etoposide
2547625|NCT02580396|Other|Patients eligible for CanADVICE+® (smart phone app)|
2547672|NCT02580214|Experimental|Acerto|Preoperative immune nutrition for 5 days (Impact, Nestle) Preoperative fasting of 2h with a drink containing 12% maltodextrine No intravenous fluids postoperatively
2547673|NCT02580214|No Intervention|Control|No immune nutrition Preoperative fasting of 6-8 h Crystalloid intravenous fluids until PO day 1
3203918|NCT00928902|Active Comparator|Peptides plus GM-CSF-in-adjuvant, delayed IL-2|"Peptides plus GMCSF-in-adjuvant, with delayed IL-2.~Each of the peptides plus tetanus toxoid peptide, plus GM-CSF in adjuvant, administered subcutaneously and intradermally. Systemic low-dose IL-2 will be administered daily for 6 weeks, beginning at week 4 and ending at week 10."
3203919|NCT00928915|Experimental|Prothrombin complex concentrate (PCC)|intravenously, 30 IU/kg
2547753|NCT02579564|Experimental|chemotherapy with Oncorine and Endostar|Systemic chemotherapy with standard schemes, such as GP (Gemcitabine/Cisplatin), NP (Vinorelbine/Cisplatin), TP (Paclitaxel/Cisplatin) or PP (Pemetrexed/Cisplatin). Thoracic cavity perfusion of recombinant human adenovirus type 5 injection 1.5ml and Endostar 30mg each time, twice a week for four times.
2547757|NCT02579564|Active Comparator|chemotherapy with cisplatin|Systemic chemotherapy with standard schemes without cisplatin, such as Gemcitabine, Vinorelbine, Paclitaxel or Pemetrexed. Thoracic cavity perfusion of cisplatin 30mg/m2 each time, twice a week for four times.
2547835|NCT02579148|Experimental|HUCMSC injection|once intracavernous injection of 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
2547838|NCT02579148|Experimental|collagen scaffolds/HUCMSC injection|once intracavernous injection of collagen scaffolds loaded with 15,000,000 Human Umbilical Cord Mesenchymal Stem Cells
3203920|NCT00928915|Experimental|Fresh frozen plasma (FFP)|intravenously, 20ml/kg
3203921|NCT00928928|Active Comparator|Open group|Group of patients operated with open approach for colorectal cancer
3203922|NCT00928928|Active Comparator|laparoscopic group|Group of patients operated with laparoscopic approach for colorectal cancer
3203923|NCT00928941|Experimental|Arm 1|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units.
3203924|NCT00928941|Active Comparator|Arm 2|A computer game control condition will be implemented for 3-4 training exercises a week for 40 hours.
3203925|NCT00928967||Group 1|
3203926|NCT00928980|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy and withdrawal of antidepressant medication between the 4th and 5th session, patients being off medication until the end of study period (15 months).
3203927|NCT00928980|Experimental|Combination|Mindfulness Based Cognitive Therapy combined with the use of antidepressant medication during the study (15 months).
2547090|NCT02584244|Experimental|Pancreatic cancer patients not receiving neoadjuvant chemo|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547091|NCT02584244|Experimental|Gastric cancer patients who have received neoadjuvant therapy|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547092|NCT02584244|Experimental|Patients with early stage gastric cancer or precancerous lesions|The first 3 patients will be injected at a dose of 0.5 mg/kg. If no or minimal activity is observed and no serious adverse events occur, the subsequent three patients will be injected with the second tier dose level of 1.0 mg/kg. If no or minimal activity is observed in in the second tier dosing group, and no serious adverse events occur, the following three patients will have the third tier dose of 1.5 mg/kg administered. An additional 2 patients will be recruited at the dose level that produces optimal LUM015 activity. All surgical specimens will be sent to the pathology suite for imaging with the LUM 2.6 Imaging Device and routine diagnostic assessment.
2547154|NCT02583893|Experimental|Sirolimus, MEC chemotherapy|Patients undergo collection of bone marrow samples prior to sirolimus dosing on day 4 and within 1 week and no later than day 45 of hematologic recovery. Patients receive sirolimus PO on days 2-9 (loading dose on day 1 only), and standard MEC chemotherapy comprising mitoxantrone hydrochloride IV over 15 minutes, etoposide IV over 1 hour, and cytarabine IV over 1 hour every 24 hours on day 4-8.
2547204|NCT02583412|Active Comparator|Group 1: Accelerated Schedule|
2547206|NCT02583412|Active Comparator|Group 2: Standard Schedule|
2547238|NCT02583100|Experimental|Intensive Feedback|Participants in this arm will receive intensive feedback on their complication rates, surgical technique, and peri-operative surgical management from peer surgeons participating in the study.
2547240|NCT02583100|Active Comparator|Routine Feedback|Participants in this arm will receive routine feedback on their complication rates.
3203928|NCT00928980|Active Comparator|Optimal Medical Care|Treatment with optimal medical care: therapeutic dose of antidepressant medication during at least 15 months, administered in accordance with current guidelines.
2547395|NCT02582177|Experimental|Candicort®/ Nizoral®|Candicort® is a cream composed by ketoconazole 20mg/g and betamethasone dipropionate 0,64 mg/g that will be dispensed to 80 participants of this group in the first stage. The cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Nizoral ® will be dispensed to the same participants. It´s a cream composed by ketoconazole 20mg/g that will be applied in the affected area once a day for 14 days. The total duration of treatment may be 28 (+1) days.
2547397|NCT02582177|Experimental|Baycuten N®/ Canesten®|Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage. he cream will be applied in the affected area twice a day for 14 (+1) days. In the second stage Canesten ® will be dispensed to the same participants. It´s a cream composed by clotrimazole 10mg that will be applied in the affected area once a day for 14 days.The total duration of treatment may be 28 (+1) days.
2547466|NCT02581683|Experimental|Magnesium|Participants in this arm will receive magnesium sulfate + ropivacaine via adductor canal block
2547467|NCT02581683|Active Comparator|Non-magnesium|Participants in this arm will receive ropivacaine via adductor canal block
2547469|NCT02581683|Sham Comparator|Sham|Participants in this arm will receive a sham adductor canal block
2547514|NCT02581319|Other|Periodontal treatment|Both groups of patients (smokers and non-smokers) will receive periodontal treatment consisting of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects will be made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
3203929|NCT00928993||Main group|pediatric patients receiving overnight sleep study
2547652|NCT02580370|Experimental|Dose A|Botulinum toxin type A
2547654|NCT02580370|Placebo Comparator|Dose B|Placebo comparator
2547695|NCT02580084|Active Comparator|aorta femoral bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
2547704|NCT02580084|Experimental|hybrid intervention|Iliac Arteries With Stenting and Plasty of the Common Femoral Artery
2547735|NCT02579746|Experimental|intervention|The intervention group received usual care plus the DASHNa-CC intervention.
2547736|NCT02579746|Active Comparator|control|The control group received usual care.
2547752|NCT02579538||Total Knee Arthroplasty|Patients undergoing unilateral total knee arthroplasty
2547754|NCT02579538||Thoracic/Breast Surgery|Patients undergoing mastectomy, thoracotomy, or video-assisted thoracoscopic surgery (VATS)
2547841|NCT02579174|Other|Custom (tibia) and custom (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for both the tibia component and the femur component
3203930|NCT00929006|Experimental|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
2547107|NCT02584114|Experimental|Memory training group|The intervention is self-administration of 4 hours of memory training over 4 days per week, for 3 weeks (12 hours total). Memory training will be done with the Peak app for memory training http://www.peak.net.
2547110|NCT02584114|Active Comparator|Non-memory training group|The intervention is self-administration of 4 hours of training of games that do not involve memory such as language and card games over 4 days per week, for 3 weeks (12 hours total).
2547165|NCT02583867|Experimental|Exercise|Participants will complete an exercise dose of 15 kilocalories per kilogram of bodyweight per week (KKW). This is equivalent to approximately 150 minutes/week of aerobic exercise. This dose will be completed in at least 3 sessions per week for 12 weeks.
2547319|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm A: HCT with 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and stem cell transplant without mesenchymal stem cell infusions.
2547323|NCT02582775|Experimental|CLOSED TO ACCRUAL Arm B: HCT plus MSC, 300 cGy of TBI|Epidermolysis bullosa patients treated per study regimen with chemotherapy and hematopoietic stem cell transplant with mesenchymal stem cell infusions using 300 cGY of TBI.
2547333|NCT02582775|Experimental|Arm C: Re-Transplant with 300 cGy of TBI|Epidermolysis bullosa patients treated regardless of original transplant arm with re-transplant using 300 cGy of TBI.
2547336|NCT02582775|Experimental|Arm D: HCT with 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGY BID of TBI (400 cGy total).
2547339|NCT02582775|Experimental|Arm E: HCT plus MSC, 200 cGy BID of TBI|HLA-matched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGY BID of TBI (400 cGy total)
2547343|NCT02582775|Experimental|Arm F: HCT Alone, 200 cGy BID of TBI|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant alone using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
2547349|NCT02582775|Experimental|Arm G: HCT plus MSC, 200 cGy|HLA-mismatched epidermolysis bullosa patients treated with hematopoietic cell transplant plus serial MSC infusions using 200 cGy BID of TBI (400 cGy total) + addition of low dose busulfan for recipients of HLA-mismatched bone marrow
2547462|NCT02581735||Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
2547494|NCT02581449|Experimental|omega-3 group|omega-3 soft gelatin capsules 1000 mg (500mg EPA+250mg DHA)once daily for four months
2547495|NCT02581449|Placebo Comparator|placebo group|empty soft gelatin capsules with matched size, color and shape once daily for four months
2547553|NCT02581176|Experimental|Apixaban|Apixaban 10 mg two times daily for 1 week, then apixaban 5mg two times daily for 6 months, then apixaban 2.5 mg two times daily for as long as the treating physician finds it necessary.
3203931|NCT00929006|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
2547700|NCT02580123|Experimental|Experimental group|Received the intervention program.
2547706|NCT02580123|No Intervention|Control group|received the standard care
2547765|NCT02579837|No Intervention|Usual Screening|Participants randomized to the Usual Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care).
2547771|NCT02579837|Experimental|On-Site Screening|"Participants randomized to the On-Site Screening group will be advised by their Endocrinologist during their Diabetes Clinic visit to arrange an eye examination with their usual eye care professional (as per current standard of care). However, they will also undergo non-mydriatic ultra-widefield (UWF) retinal imaging (both 100 and 200 degrees) using the Optos 200Tx UWF retinal imaging device in the Ophthalmology Department on the same day as their Diabetes Clinic visit.~Half of this group will by random allocation undergo optical coherence tomography (OCT) using the Zeiss Cirrus OCT, which may or may not be done on the same day (for practical reasons regarding availability of OCT at the hospital)."
2547830|NCT02579265|Experimental|Smoflipid 20%|"Smoflipid is a lipid emulsion containing soybean oil, MCTs (medium-chain triglycerides), olive oil, and fish oil. Smoflipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
2547832|NCT02579265|Active Comparator|Intralipid® 20%|"Intralipid is a long-chain triglyceride emulsion derived from purified soybean oil and egg yolk phospholipids. Intralipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions."
2547910|NCT02578810||Eclampsia|In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts.
2547911|NCT02578810||Control|In 24 control patients without Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts
2547956|NCT02578524||Accommodating Lenses|Patients who underwent surgery with an accommodating lens implant.
2547966|NCT02578524||Multifocal Lenses|Patients who underwent surgery with an multifocal lens implant.
2548023|NCT02578134|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks for 5 weeks of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the plantar fascia insertion. In addition, patients will be asked for conducting a best-evidence low-load exercise programs for the intrinsic foot musculature. The exercise program will be asked to be performed on an individual basis twice every day.
2548593|NCT02574221|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
2547122|NCT02584309|Experimental|Arm 1: dexrazoxane & standard of care doxorubicin|"Dexrazoxane will be given intravenously on an outpatient basis over 15 minutes on each day that doxorubicin is given.~Dexrazoxane should be given no more than 30 minutes prior to administration of doxorubicin, which is typically given on Day 1 of a 21-day cycle.~Dosing is a 10:1 ratio of dexrazoxane to doxorubicin; doxorubicin is typically given at 75 mg/m2, so dexrazoxane dosing would be 750 mg/m2.~In the event of a national shortage of dexrazoxane, 72-hour infusional doxorubicin can be used instead of dexrazoxane and bolus doxorubicin.."
2547126|NCT02584309|Active Comparator|Arm 2: control (standard of care doxorubicin)|"Doxorubicin is given as standard of care. Doxorubicin is typically given at 75 mg/m2 on Day 1 of a 21-day cycle.~The last 10 patients enrolled after completion of enrollment to Arm 1 (dexrazoxane & standard of care doxorubicin) will be enrolled to Arm 2 (control arm - standard of care doxorubicin only)"
2547173|NCT02583581|Experimental|Participants diagnosed with migraine|EEG monitoring (MindWave by NeuroSky and EPOC by Emotiv)
2547259|NCT02583308|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions
2547265|NCT02583308|Experimental|Period with endotracheal tubes allowing SSD|During this period of the DEMETER study (NCT02515617), patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2547327|NCT02582580|Active Comparator|Perineal Massage|Massage is made in the perineum and vagina using your fingers to promote stretching of pelvic floor structures, making them more flexible and distensíveis, avoiding trauma during vaginal birth.
2547329|NCT02582580|Active Comparator|Vaginal Dilator|This device consists of a silicone balloon in an eight shape that, after inserted into the vagina, is inflated by manual pumping, promoting a stretching of the structures around it (hymenal edge, connective tissues and muscles perivaginal). This equipment assists the stretching of tissues around the vagina and the pelvic floor muscles, minimizing the risk of injury from the birth canal during the passage of the baby.
2547335|NCT02582580|Active Comparator|Pelvic floor muscles training|Exercises emphasizing conscious muscle relaxation, i.e., considering a resting time based on the contraction time. The resting time was double of the sustaining time of each contraction up to the 38th week of pregnancy, after remaining fixed this relaxation time up to the moment of delivery. This time was chosen because during the expulsive labor phase, there is a need for the pelvic floor muscles to consciously relax during a long period, in order to facilitate the descendants and rotational movements of the baby's head and consequently, its passage. This exercises does not aim only muscle strength but also contraction promotion, which aims body and perineal awareness, muscle tone, coordination and appropriate motor control to allow an active muscle relaxation in the second labor stage.
2547380|NCT02582307|Experimental|Hyoscine butylbromide|Hyoscine butylbromide 10mg oral single dose
2547381|NCT02582307|Active Comparator|Acetaminophen|Acetaminophen 15mg/kg oral single dose (maximum 1000mg)
2547415|NCT02582008|Experimental|Arm A (bupropion hydrochloride)|Patients receive bupropion hydrochloride PO for 3 days and then BID for up to 1 year post RT/CRT.
2547416|NCT02582008|Active Comparator|Arm B (varenicline, NRT)|Patients receive smoking cessation treatment tailored to individual smokers based on preference, smoking history and contra-indications. Patients are given the choice of one of the NCCN-recommended first-line pharmacotherapy options for smoking cessation comprised of varenicline PO daily for 1 week and then BID for 12 weeks or combination of nicotine patch and acute NRT for 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Treatment with varenicline or NRT can be extended up to 6 months to 1 year as needed.
2547481|NCT02581566|Active Comparator|Intrathecal Dexmedetomidine Group|30 patients will be given Intrathecal Dexmedetomidine plus Intrathecal Bupivacaine
2547482|NCT02581566|Active Comparator|Intraarticular Dexmedetomidine Group|30 patients will be given Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
2547484|NCT02581566|Other|control Group|30 patients will be given Intrathecal Bupivacaine
2547540|NCT02581280||On ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel during ECMO
2547542|NCT02581280||Off ECMO|patients who are concomitantly receiving teicoplanin or levofloxacin or piperacillin/tazobactam or meropenem or vancomycin or remifentanil or cefepime or cefpirome or sufentanil or midazolam or clopidogrel or ticagrelor or prasugrel after removing ECMO
2547589|NCT02580929|Experimental|radiation|
2547591|NCT02580929|No Intervention|no radiation|
2547693|NCT02580175|Active Comparator|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation
2547702|NCT02580175|Active Comparator|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
2547776|NCT02579798|Experimental|PEEP 10 cmH20|In this group, a PEEP of 10 cmH20 is applied for the duration of the intervention and a recruitment maneuver is applied each time the SpO2 (oxygen pulsated saturation) drops below 95%.
2547779|NCT02579798|Active Comparator|optimal PEEP|"In this group, 10 cmH20 PEEP is applied immediately. Then the optimal PEEP is sought at three key moments. It is determined by the best value of lung compliance found in the patient. It is sought by increasing or decreasing the value of the PEEP by increments or decrements of 2 cmH20. If after 6 respiratory cycles, the value of the compliance is increased, the investigator continues to increase the value of the PEEP. On the other hand, if the value of compliance is reduced, the investigator reduces the value of PEEP. The value of the PEEP selected shall in no event exceed the set pressure range (maximum pressure plate of 30 cmH20 and maximum inspiratory peak pressure 40cmH20). A recruitment maneuver is applied each time the SpO2 drops below 95%, as in the PEEP 10cmH2O group."
2547827|NCT02579200|Active Comparator|Inspiratory Muscle Training (IMT)|POWERbreathe®KHA (IMT group)
2547831|NCT02579200|Sham Comparator|Sham Training|POWERbreathe®KH2 (sham group)
2547140|NCT02583763||Fetuses/Children with IUGR|"The moving sequences of the heart movement are collected at the regular ultrasound examinations during pregnancy. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyse the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
2547144|NCT02583763||Healthy Controls|"The moving sequences of the heart movement are collected at two occasions approximately 4 weeks apart. This takes place during gestational weeks 28-36. Following delivery the investigators plan to examine the baby with cardiac ultrasound, echocardiography, between 12 and 72 hours after delivery and again when the child is 3-4 months old and at 7 years of age.~Blood sample will be taken from the umbilical cord at birth and again at 7 years of age. The investigators will analyze the blood for growth factors and cardiac markers. An additional ethical approval was accepted 2015 for analysing epigenetic factors in the children's DNA."
2547207|NCT02583516|Experimental|A - Continuous Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle.
2547211|NCT02583516|Experimental|B - Intermittent Administration|960 mg of vemurafenib po, bid, days 1 to 28 and 60 mg of cobimetinib po, od, days 1 to 21, for each 28-days' cycle, during 12 weeks. After that period, patients will be treated with both drugs at the same doses indicated previously, but with an intermittent pattern: vemurafenib days 1 to 28 followed by 14 days off (4 weeks on and 2 weeks off) and cobimetinib days 1 to 21 followed by 21 days off (3 weeks on and 3 weeks off)
3203932|NCT00929019|Experimental|dendritic cell vaccination|HLA-A2.1 positive patient will receive 3 biweekly intradermal/intravenous vaccination with autologous mRNA transfected mature dendritic cells, followed by a DTH skin test for monitoring purposes. One such cycle is repeated every 6 months if no signs of progression, up to a total of 3 cycles.
3203933|NCT00929019|No Intervention|control arm|For comparison, HLA-A2.1 negative patients will be monitored for clinical response (secondary endpoint).
3203934|NCT00929032||Liver transplant recipient|Liver transplant recipient
2547375|NCT02582281|Experimental|Non touch technique|"the intrauterine device TCu 380A will be inserted in the conventional method as follows: First, insert the speculum and view the cervix. The position of the cervix will very often confirm if the uterus is anteverted or retroverted. Second, using the Allis forceps hold the back of a cotton-ball swab and dip it into a povidine-iodine disinfectant solution, or equivalent. Swab the cervix. Then cut the threads to the appropriate length and remove the speculum.~This technique omits the sounding of the uterus which is considered a quintessential procedure before IUD insertion for which there is no one established piece of evidence.The IUD is checked afterwards by transvaginal ultrasound."
2547378|NCT02582281|Experimental|Traditional IUD insertion|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
2547414|NCT02582034|Active Comparator|Standard dosimetry|Standard Internal Radiation Therapy : Dose of radiation delivered to the tumoral volume is fixed : 120 Gray (GY)
2547418|NCT02582034|Experimental|Optimized dosimetry|Optimized Internal Radiation Therapy : Dose of radiation absorbed by the tumor is > 205 GY, if possible 250 or 300 Gy.
3203935|NCT00929045|Experimental|Growth Hormone|
3203936|NCT00929058|Experimental|Bevacizumab|
3203937|NCT00929084|Other|Survivor Stories Arm|Women in the Survivor Stories intervention arm will be given the Survivor Stories Tablet to take home for two weeks at three different time points over a two year period.
3203938|NCT00929084|Other|Control Arm|Women in the Control Arm will receive standard care.
3203939|NCT00929097|Experimental|Implementation aids|
3203940|NCT00929097|Active Comparator|Control|
2547592|NCT02580890|Experimental|tDCS active|"Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline. The stimulator to be used will be the Chattanooga Ionto ISO 13485. Stimulation will be performed for 5 days, one time per day."
2547595|NCT02580890|Sham Comparator|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
2547610|NCT02580487||retrospective group|Patients whose pain evaluation, analgesics used and details of surgery were collected from patient files
2547612|NCT02580487||Prospective group|Patients who were interviewed before and after surgery when they were at the hospital
3203941|NCT00929123|Experimental|neural mobilization|manual therapy technique known to directly stress the median nerve
3203942|NCT00929123|Placebo Comparator|sham neural mobilization|manual therapy technique known to directly stress the median nerve without any stimulation.
3203943|NCT00929123|Active Comparator|Healthy Controls|People without carpal tunnel syndrome for comparison
2547778|NCT02579733|Placebo Comparator|Sugar pill|Placebo drug identical to azathioprine (1.5mg/kg) po for 1 year
3203944|NCT00929136|Experimental|Endotoxin|
3203945|NCT00929175|Active Comparator|active CPAP|auto-PAP with therapeutic pressure
3203946|NCT00929175|Sham Comparator|sham-CPAP|auto-PAP with pressure less than 1cm H2O
3203947|NCT00929188|Experimental|001|JNJ-42160443 Type=1 unit=mg number=10 form=solution for injection route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
3203948|NCT00929188|Placebo Comparator|002|Placebo Form=solution for injection route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
3203949|NCT00929214|Experimental|Standard Therapy + Local Therapy|Systemic Standard Therapy (chemotherapy and/or endocrine therapy) + Local Therapy (surgery and/or radiation)
2547141|NCT02583932|Experimental|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis. The MMi consists of 3-4 weekly sessions of 30-90 min each with an intervener (psychologist, social worker, or nurse) who provides the necessary ingredients to foster a good therapeutic alliance (i.e., trust, warmth, empathy, neutrality, and authenticity), encourages self-exploration and systematically addresses different levels of meaning (i.e., situational, global, existential, historical).
2547146|NCT02583932|Placebo Comparator|Empathic Visitor (EV)|Empathic visitors will meet with patients over 3-4 weekly sessions of 30-90 minutes as in the experimental group. They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic listener will be specifically instructed to avoid initiating discussions about meaning (e.g., perspective-taking, how the patient interprets his/her feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present). If the patient initiates discussions about these topics, the visitor will simply listen without further intervening.
2547150|NCT02583932|No Intervention|Usual Care Control Group|Treatment as usual in tertiary care hospital, typically medically-focused. All participants will be free to use hospital- or community-based supports, which will be tracked in all groups throughout the study by questionnaire and through a chart review. Both recruiting centres include well established psychosocial oncology services including psychiatrists, psychologists and social workers.
2547159|NCT02583490|Experimental|Low Pulse Amplitude ECT (LAP)|Right Unilateral LAP ECT
2547161|NCT02583490|Active Comparator|standard Right Unilateral ECT|standard Right Unilateral ECT
2547224|NCT02583334|Experimental|Verum Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the verum acupuncture group, participants will receive verum acupuncture (Device: 30# acupuncture needle) three times a week, for 4 weeks (12 treatment in total).
2547226|NCT02583334|Sham Comparator|Sham Acupuncture|After diagnosis by rheumatologist, participants will be randomized to receive verum acupuncture or sham acupuncture treatment. In the sham acupuncture group, participants will receive sham acupuncture (Device: Streitberger device) three times a week, for 4 weeks (12 treatment in total).
2547236|NCT02582996|Experimental|Cefalium®|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.
2547237|NCT02582996|Active Comparator|Tylenol®|Acetaminophen
3203950|NCT00929227||1|Stress MRI perfusion, and cardiac CT will have observed sensitivity, specificity, and accuracyof at least 0.80 in predicting CAD in a patient population with prior equivocal stress testing.
2547437|NCT02581878|Experimental|Cohort 1a|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (2 mg antibody chelator conjugate [ACC]).
2547438|NCT02581878|Experimental|Cohort 1b|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 1.5 MBq (10 mg ACC).
2547442|NCT02581878|Experimental|Cohort 2|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 3.1 MBq (10 mg ACC).
2547444|NCT02581878|Experimental|Cohort 3|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 4.6 MBq (10 mg ACC).
2547445|NCT02581878|Experimental|Cohort 4|Cancer patients with relapsed or refractory non-Hodgkin's lymphoma will be randomized to receive an injection of study drug (BAY1862864) with a dosage of 6.1 MBq (10 mg ACC).
2547493|NCT02581527|Active Comparator|Rifampicin 150mg (Control)|2 months daily 4FDC - Rifampicin 150mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 4 months daily 2FDC - Rifampicin 150mg and Isoniazid 75mg (continuous phase)
2547497|NCT02581527|Experimental|Rifampicin 1200mg (Regimen 1)|2 months daily 4FDC - high dose Rifampicin 1200mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1200mg and Isoniazid 75mg (continuous phase)
2547498|NCT02581527|Experimental|Rifampicin 1800mg (Regimen 2)|2 months daily 4FDC - high dose Rifampicin 1800mg, Isoniazid 75mg, Ethambutol 275mg and Pyrazinamide 400mg (intensive phase); followed by 2 months daily 2FDC - high dose Rifampicin 1800mg and Isoniazid 75mg (continuous phase)
3321415|NCT02018679|Active Comparator|MAL-PDT|Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
2547600|NCT02580760||Cosmetic silicone injection|People responding to inclusion criteria with a history of cosmetic silicone injection
2547617|NCT02580552|Experimental|Part A, MF|Intratumoral Injection of cobomarsen
2547619|NCT02580552|Experimental|Part B, MF|Subcutaneous, intravenous or a combination of systemic and intratumoral administration of cobomarsen with or without stable background therapy
2547620|NCT02580552|Experimental|Part C, MF|Subcutaneous or intravenous administration of cobomarsen as monotherapy
2547621|NCT02580552|Experimental|Part D, CLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
2547622|NCT02580552|Experimental|Part E, DLBCL, activated B-cell (ABC) subtype|Subcutaneous or intravenous administration of cobomarsen as monotherapy
2547623|NCT02580552|Experimental|Part F, ATLL|Subcutaneous or intravenous administration of cobomarsen as monotherapy
2547678|NCT02580227|Active Comparator|Tranexamic Acid|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
2547680|NCT02580227|Placebo Comparator|Placebo|Patients will be randomized 1:1 onto active TXA arm, or placebo arm.
2547970|NCT02578446|Active Comparator|Cemented Triathlon CR|Primary total knee replacement with Cemented Triathlon CR Total Knee System
2547213|NCT02583386|No Intervention|Wait-list control group|Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.
2547214|NCT02583386|Active Comparator|FFF training group w/ Fall Detector|"Subjects randomized to this group will receive an 8 week exercise and educational program on fall prevention (Free From Falls fall prevention program). They will have mobility and quality of life assessments taken at baseline, after the training program has been completed, and 3 and 6 months later. During this time, their falls will be recorded monthly using prospective falls calendars.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
2547217|NCT02583386|Other|Wait-list control w/ Fall Detector|"Subjects in this group will participate in the same mobility and quality of life assessments and completion of the falls calendars, but will receive no training classes during this time. These subjects will have the opportunity to receive the class sessions when all assessment visits have been completed.~In addition, this group will be asked to wear electronic fall detectors on their bodies for the first 10 weeks of their participation in the study."
2547244|NCT02583074|Experimental|Stimulation Group|Patients in 'Neurostimulation Group' will receive subthalamic nucleus deep brain stimulation for 3 months.
2547246|NCT02583074|Sham Comparator|Sham-stimulation Group|Patients in 'Sham-stimulation Group' will receive sham stimulation of subthalamic nucleus for 3 months.
2547566|NCT02580968|Experimental|electro-acupuncture|100hz, 2min. electro-acupoint: LI4(Large Intestine4) with LV3(Liver3).5times a week. lasting for 4 weeks.
2547569|NCT02580968|Active Comparator|routin medicine|one tablet of flunarizine hydrochloride tablet per day. lasting for 20days
2547624|NCT02580708|Experimental|Rociletinib and Trametinib|
2547662|NCT02580253|Experimental|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
2547665|NCT02580253|Active Comparator|mFOLFOX6|Oxaliplatin (85 mg/m2 )+Fluorouracil (2800 mg/m2 ) q2w
3169212|NCT00560222|Active Comparator|A|This group will receive daily lactoferrin supplementation
3169213|NCT00560222|Placebo Comparator|B|placebo
3169214|NCT00560248||I|Patients presenting to the Emergency Department with chest pain suspected to be of cardiac origin.
3169215|NCT00560261|Experimental|1:Children with sickle cell disease|"NO-CO inhalation and expiration:~Children with sickle cell disease"
3169216|NCT00560261|Active Comparator|2: Healthy volunteers|"NO-CO inhalation and expiration:~Healthy volunteers"
2547748|NCT02579590||DEMPA group|This group are using DMPA (Depot Medroxyprogesterone Acetate 150 mg) injection every 3 month for 6-12 month
2547749|NCT02579590||Implanon group|"This group are using Implanon  (etonogestrel implant) 68 mg implant for 6-12 month"
2547750|NCT02579590||Cerazette group|This group are using Cerazette pills (75 micrograms desogestrel) one pill every day for 28 days without pill-free interval for 6-12 month.
2547751|NCT02579590||Normal healthy group|Those women not using any method of contraception
2547889|NCT02578771|Experimental|ZuraPrep with 70% Isopropyl alcohol|Test Article ZuraPrep with 70% isopropyl alcohol (IPA) will be compared with reference positive control Chloraprep
2547892|NCT02578771|Experimental|ZuraPrep without 70% IPA|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline
2547894|NCT02578771|Active Comparator|ChloraPrep Teal Tint|Test Article ZuraPrep with 70% isopropyl alcohol will be compared with reference positive control ChloraPrep [Chlorhexidine gluconate(CHG)/IPA] Teal Tint
2547895|NCT02578771|Placebo Comparator|Normal Saline 0.85%|Vehicle test article ZuraPrep without isopropyl alcohol will be compared with normal saline 0.85%
2547959|NCT02578381|Experimental|Boston Scientific PW versus St Jude PW|Performance of Boston Scientific PW vs St Jude PW
2547971|NCT02578381|Experimental|Boston Sci PW vs Boston Sci PW|Boston Sci PW vs Boston Sci PW
2547976|NCT02578381|Active Comparator|St Jude PW versus St Jude PW|Performance of St Jude PW vs St Jude PW
2548084|NCT02577458|Experimental|CM082 plus everolimus|CM082 plus everolimus
2548167|NCT02577159|Experimental|Dapagliflozin|Diabetic patients who met the inclusion/exclusion criteria. Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
2548686|NCT02573571||Clostridium difficile infection|Patients with Clostridium difficile-associated diarrhea for development of biomarkers
2548886|NCT02572583|Active Comparator|Shufeng Jiedu Capsule Group|Shufeng Jiedu Capsule, take orally, 3 times a day, 4 capsules each time, for a course of five days.
3169217|NCT00560274|Experimental|1|
3169218|NCT00560287|Active Comparator|1|Volume assist non-invasive ventilation
3169219|NCT00560287|Active Comparator|2|Pressure Assist mode
3169220|NCT00560300|Experimental|1|Doxercalciferol + Calcium Carbonate
3169221|NCT00560300|Experimental|2|Doxercalciferol + Sevelamer
3169222|NCT00560300|Experimental|3|Calcitriol + Calcium Carbonate
3169223|NCT00560300|Experimental|4|Calcitriol + Sevelamer
3169224|NCT00560326|Experimental|1|
3169225|NCT00560378|Experimental|Tacrolimus Ointment 0.1%|
3169226|NCT00560430|Active Comparator|T1|Telmisartan 80 mg/d
3169227|NCT00560430|Active Comparator|T2|Telmisartan 160 mg/d
3169228|NCT00560430|Placebo Comparator|P|placebo
3169229|NCT00560443|Active Comparator|1|children 4-17 y. old with not compound bone fracture treated with ketorolac
2547248|NCT02583126|No Intervention|Control Group|Prescribed medical/chemotherapy treatment plus standard care
2547316|NCT02582788|Active Comparator|Bleach|Patients will use bleach added to their baths twice a week.
2547321|NCT02582788|Active Comparator|Vinegar|Patients will use vinegar (dilute acetic acid) added to their baths twice a week.
2547371|NCT02582437|Experimental|Chronic Opioid User|"The patients (ASA class I-III) who receive elective surgery s aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The Patients who use opioid medication daily and regularly immediately before the day of surgery for more than four weeks. The minimum criteria for opioid dose in the intervention goup is oral morphine 20mg per day: Morphine Equivalent Daily Dose(MEDD)"
2547373|NCT02582437|No Intervention|Opioid Naive patient|"The patients (ASA class I-III) who receive elective surgery aging between 41 and 69 and signed in informed consent to participate in this trial voluntarily.~The patients who do not use opioid medications immediately before the day of surgery for four weeks."
2547407|NCT02582060|Other|Severe Hemophilia A Subjects|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
2547452|NCT02581826|Active Comparator|Silodosin|"Silodosin capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Silodosin in the first intervention period and Placebo in the second period (after washout period of 14-21 days).~The patients received 4 mg of Silodosin 1 times a day, total dosage 12 mg for 14-21 days."
2547455|NCT02581826|Placebo Comparator|Placebo|"Placebo capsules of 4 mg, oral: 4 mg once daily with a meal, total dosage 12 mg for 14-21 days.~This arm received Placebo in the first period and Silodosin in the second period (after washout period of 14-21 days).~The patients received 4 mg of Placebo 1 times a day, total dosage 12 mg for 14-21 days."
2547515|NCT02581462|Experimental|FLOT alone|Pre-operative therapy with FLOT followed by surgical resection followed by post-operative therapy with FLOT
2547518|NCT02581462|Experimental|FLOT + Herceptin/Pertuzumab|Pre-operative therapy with FLOT + Herceptin/Pertuzumab followed by surgical resection followed by post-operative therapy with FLOT + Herceptin/Pertuzumab
2547559|NCT02581072|Experimental|SB204 4%|SB204 4% once
2547564|NCT02581072|Experimental|SB204 8% or 12 %|SB204 8 or 12 % (supratherapeutic) once
2547570|NCT02581072|No Intervention|Moxifloxacillin|Moxifloxacillin 400 mg orally
2547573|NCT02581072|Placebo Comparator|Vehicle Gel|Placebo
2547653|NCT02580656|Experimental|Metacognitive Therapy|Metacognitive Therapy (MCT) is a brief psychological intervention which will be delivered over a course of six, one hour weekly sessions. Treatment will follow a manualised protocol.
2547698|NCT02580032||Child Treatment Naïve group (Group A)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 7.0 ng/ml.
2547703|NCT02580032||Child Maintenance group (Group B)|Pre-pubertal boy or girl, ages of 9 to 13 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of equal or below 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
2547707|NCT02580032||Parent Treatment Naïve group (Group C)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 7.0 ng/ml.
2547709|NCT02580032||Parent Maintenance group (Group D)|Parents/guardians, who live with a pre-pubertal boy or girl, age 4 to 9 years with a confirmed diagnosis of GHD prior to enrolment as determined by one GH stimulation test, defined as a peak GH level of below or equal to 10.0 ng/ml who have been taking prescription treatment for GHD for 6 months or more.
2547759|NCT02579577||Decision making cohort|Any people identified as being important within the network of care for children with life-limiting illnesses.
2547805|NCT02579278||mrEMVI positive rectal tumours|20 patients will be registered whose rectal tumours are mrEMVI positive (i.e. EMVI is present in baseline and post-chemoradiotherapy MRI scans).
2547807|NCT02579278||mrEMVI negative rectal tumours|20 patients registered who were mrEMVI positive at baseline MRI but have become mrEMVI negative post-chemoradiotherapy.
3321416|NCT02018692|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|15 patients will first receive the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder (5mg/Kg) for 24 weeks. After 24 weeks of washout period they will receive capsule containing placebo (Starch) for 24 weeks.
3321417|NCT02018692|Placebo Comparator|Placebo (Starch)|The other 15 Patients will receive first the placebo (Starch) capsules for 24 weeks. After 24 weeks of washout period they will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
2547936|NCT02578550|Experimental|Treatment Sequence (AB)|Participant will receive a single oral tablet of darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF fixed dose combination [FDC]) (Treatment A) in period 1, then 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 2
2547937|NCT02578550|Experimental|Treatment Sequence (BA)|Participant will receive 1 tablet of DRV 800 mg + 1 tablet of COBI 150 mg + 1 tablet of FTC/TAF 200/10 mg FDC (Treatment B) in period 1, then a single oral tablet of D/C/F/TAF (800/150/200/10 mg) FDC (Treatment A) in period 2
2548041|NCT02577835||Hypertensive patients|No intervention. Patients will be sumbitted to standard tests required for hypertension management, including ambulatory blood pressure monitoring, and pharmacologically treated according to recommendations of international guidelines. The registry will include data from subjects fulfilling the inclusion criteria and whose data are contained in existing databases collected by the participating centers and who are regularly followed-up at the center. New subjects can be enrolled for this project, but they must be submitted to ambualtory blood pressure monitoring because it is required for evaluating their hypertension status, according to current recommendations.
2548104|NCT02577367|Experimental|Levothyroxine on empty stomach|Levothyroxine will be given on empty stomach, by holding enteral feeding for 2 hours before and 2 hours after Levothyroxine administration
2548106|NCT02577367|Active Comparator|Levothyroxine during feeding|Levothyroxine will be given while the enteral feeding is running
2548245|NCT02576444|Experimental|Group 1|Patients with cholangiocarcinoma harboring IDH 1/2 tumors will be treated with olaparib. Patients with tumors harboring mutation in HDR genes will be treated with olaparib.
2547255|NCT02583191|Active Comparator|low-molecular heparine|Arm B: standard treatment with low-molecular heparine
2547417|NCT02582073|Placebo Comparator|Placebo (0.5ml)|Six 0.5ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
2547420|NCT02582073|Placebo Comparator|Placebo (1.0ml)|Six 1.0ml injections of placebo consisting of L-Tyrosine, Ph. Eur 2%
2547422|NCT02582073|Experimental|Grass MATA MPL (0.5ml) 5100SU|Six 0.5 mL injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA with 50 µg/0.5 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
2547423|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 10200SU|Six 1.0 mL injections sequentially of placebo, placebo, 600, 1600, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 10200 SU).
2547424|NCT02582073|Experimental|Grass MATA MPL (1.0ml) 18200SU|Six 1.0 mL injections sequentially of placebo, 600, 1600, 4000, 4000, 4000 and 4000 SU of Grass MATA per 1.0 mL and 50 µg/1.0 mL of MPL® adjuvant adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 18200 SU).
2547425|NCT02582073|Active Comparator|Grass MATA (0.5ml) 5100SU|Six 0.5ml injections sequentially of placebo, placebo, 300, 800, 2000 and 2000 SU of Grass MATA adsorbed to L tyrosine (2%) and 0.5% phenol (cumulative dose 5100SU).
2547506|NCT02581618|Experimental|Study group|"Remote ischemic preconditioning arm~Blood pressure cuff will be inflated up to 200 mmHg in the non-dominant arm for 5 minutes before guiding catheter engagement."
2547507|NCT02581618|No Intervention|Control group|No intervention will be performed. Percutaneous coronary intervention will be performed without ischemic preconditioning.
2547857|NCT02579070|Experimental|DFUPS (visual and thermal images)|Visual and thermal imaging with DFUPS and standard foot care. The study investigator will have access to the thermal and visual images captured with DFUPS.
2547858|NCT02579070|Placebo Comparator|DFUPS ( visual images)|Visual and blinded thermal imaging with DFUPS and standard foot care. The study investigator will have access only to the visual images and will be blinded to the thermal images which will be captured at each visit but accessed only at the end of the study.
3169230|NCT00560443|Experimental|2|children 4-17 y. old with not compound bone fracture treated with tramadol
2547942|NCT02578537|Experimental|Ticagrelor group|ticagrelor 180mg loading, followed by 90mg bid for 30 days
2547953|NCT02578537|Active Comparator|Clopidogrel group|clopidogrel 600mg loading, followed by 75mg/d for 30 days
2548108|NCT02577432|Active Comparator|(S) separate.|fentanyl and hyperbaric bupivacaine (sequentially)
2548112|NCT02577432|Active Comparator|(M) mixed|fentanyl and hyperbaric bupivacaine.(mixed)
2548302|NCT02576236|Experimental|Triple therapy guided by result of the molecular resistance|"If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
2548307|NCT02576236|Active Comparator|Quadruple concomitant therapy|high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days
2548326|NCT02576028|Other|standard treathment|two sessions of 45 minutes of active exercises for 10 days
2548327|NCT02576028|Experimental|FM associated to standard treathment|the same intervention of CG except on days 2 and 7 where one session treatment was replaced with a FM treatment.
2548359|NCT02575846|Active Comparator|Human Milk|Neonates fed human milk
2548361|NCT02575846|Placebo Comparator|Formula|Neonates fed formula
2548429|NCT02575664|Experimental|Buprenorphine|Buprenorphine 5 microg/h/7days patch
2548432|NCT02575664|Placebo Comparator|Placebo|Placebo patch
2548506|NCT02575066|Other|radiotherapy combined with pazopanib|patients during the first part of the study received concurrent radiotherapy (25x2Gy) and pazopanib (QD 800 mg). The patients of the second part of the study will receive concurrent radiotherapy (18x2Gy) and pazopanib (QD 800 mg).
2548550|NCT02574585|Experimental|Treated group|Twenty subjects will be randomly assigned to receive two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
3169231|NCT00560456|Experimental|1|snorers
3169232|NCT00560456|Other|2|healthy volonters (control)
3169233|NCT00560456|Experimental|3|young subjects
3169234|NCT00560456|Experimental|4|mature subjects
3169235|NCT00560469||1|Men and Women over age 40 who are obese (BMI>30) and insulin-resistant.
3169236|NCT00560469||2|Men and women over age 40 who are obese (BMI>30) and insulin-sensitive.
3169237|NCT00560482|Active Comparator|A|
3169238|NCT00560482|Placebo Comparator|B|
3169239|NCT00560521|Active Comparator|1|
3169240|NCT00560547|Experimental|1|
3169241|NCT00560586|Experimental|Budesonide|Budesonide for 6 weeks followed by crossover to placebo
3169242|NCT00560586|Placebo Comparator|Placebo|Placebo for 6 weeks followed by crossover to treatment.
3169243|NCT00560599|No Intervention|1: Standard of care|Standard of care (no body decolonization regimen) and Standard of care (no environmental decolonization regimen)
3169244|NCT00560599|Experimental|2: Body decolonization regimen|Body decolonization regimen and Standard of care (no environmental decolonization regimen)
3169245|NCT00560599|Experimental|3 Environmental decolonization regimen|Standard of care (no body decolonization regimen) and Environmental decolonization regimen
3169246|NCT00560599|Experimental|4 Body and Environmental decolonization regimens|Body decolonization regimen and Environmental decolonization regimen
3169247|NCT00560638|Experimental|Loteprednol Etabonate TID|loteprednol etabonate ophthalmic suspension, 0.5%, TID
3169248|NCT00560638|Experimental|Loteprednol Etabonate QID|loteprednol etabonate ophthalmic suspension, 0.5%, QID
3169249|NCT00560638|Placebo Comparator|Vehicle|vehicle of loteprednol etabonate
3169250|NCT00560651||1|Cross linked eyes
3169251|NCT00560664|Experimental|1|Autologous chondrocytes transplantation
3169252|NCT00560664|Active Comparator|2|Mosaicoplasty
3169253|NCT00560690|Placebo Comparator|Placebo|standard treatment with pegylated interferon and ribavirin + placebo
3169254|NCT00560690|Experimental|Metformin|standard treatment with pegylated interferon and ribavirin + metformin
3169255|NCT00560729|No Intervention|I|
2547317|NCT02582801|Active Comparator|benign breast lesions|Perform 18F-Alfatide Ⅱ PET/CT in patients with benign breast lesions
2547368|NCT02582398|Experimental|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
2547369|NCT02582398|Placebo Comparator|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
3203951|NCT00929253|Active Comparator|Computer delivered CRA + CM + Suboxone|"In this arm, participants are administered Suboxone and therapy is delivered by a computer. Fluency training is provided. The participant then listens through headphones and reads the information on the screen. They progress through various modules that involve education regarding high risk situations for potential use drug and skills to deal with those situations. In addition, skills for dealing with anxiety and anger are also provided. Videos are displayed that have examples of real-left situations. HIV/AIDS education is also provided. The program is interactive with the participant being required to answer short questions at the end of each module and prompts for homework worksheets are provided. These participants receive vouchers for providing drug negative urine samples."
3203952|NCT00929253|Active Comparator|Therapist delivered CRA + CM + Suboxone|In this arm of the study, the participants receive vouchers for providing a drug negative urine sample. These participants, however, do not have computer deliver therapy, only therapist delivered therapy.
2547529|NCT02581514|Experimental|Algorithm|Eosinophilia is assessed following the diagnosis algorithm
2547552|NCT02581059|Experimental|Regorafenib + Ginseng|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle. Subjects will receive 1,000 mg ginseng orally twice daily every day for 4 weeks (2 cycles).
2547554|NCT02581059|Active Comparator|Regorafenib Only|Regorafenib will be administered 160 mg once daily for the first 21 days of each 28-day cycle for 2 cycles.
2547593|NCT02580786|Experimental|Breastfeeding peer support|Internet-based breastfeeding peer-support group in social media (Facebook). The mothers are allowed to use the group based on their individual needs from the recruitment to the first birthday of their child. Peer support is provided by three voluntary mothers. The mothers can discuss breastfeeding-related issues and ask questions. A midwife will moderate the group.
2547597|NCT02580786|No Intervention|Routine breastfeeding support|Routine breastfeeding support provided in the hospital and in the maternal and child health clinics
2547611|NCT02580604|Experimental|Calcium Infusion|Continuous calcium infusion during exercise
2547614|NCT02580604|Placebo Comparator|Saline Infusion|Continuous saline infusion during exercise
2547644|NCT02580331|Placebo Comparator|SRP and placebo|Oral prophylaxis followed by placement of placebo gel
2547650|NCT02580331|Active Comparator|SRP and 1% metformin|Oral prophylaxis followed by placement of 1% metformin gel
2547690|NCT02580019|No Intervention|conventional stroke treatment|Control group without intervention, whereas they receive conventional stroke treatment that including rehabilitation
2547696|NCT02580019|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation accompanied with conventional treatment including rehabilitation
2547764|NCT02579785|Experimental|mhealth intervention|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number. Also receives Mobile phone based intervention for post-abortion contraceptive uptake.
2547769|NCT02579785|No Intervention|Standard Care|Receives standard care which includes face to face post-MR family counselling and provision of existing hotline phone number.
2547846|NCT02579109|Other|autistic patient|patient with autistic trouble
2547849|NCT02579109|Other|healthy volunteers|healthy volunteers
2547879|NCT02578914|Experimental|NS2 Ophthalmic Drops (0.5%)|NS2 Ophthalmic Drops (0.5%)
2547881|NCT02578914|Sham Comparator|NS2 Ophthalmic Drops Vehicle (0.0%)|NS2 Ophthalmic Drops Vehicle (0.0%) control
2547916|NCT02578667|No Intervention|Gorbly Compression not needed|
2547919|NCT02578667|Experimental|Gorbly Compression may benefit|the use of the Gorbly device with the consent of the patient
2547964|NCT02578407|Experimental|Accommodative/Vergence Therapy|Accommodative/Vergence Therapy. No drug involved.
2548005|NCT02578108|Active Comparator|no diagnostic genicular nerve blocks|no diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
2548010|NCT02578108|Active Comparator|diagnostic genicular nerve blocks|Set of diagnostic genicular nerve blocks prior to genicular nerve ablation Intervention: genicular nerve radiofrequency ablation
2548128|NCT02577133|Active Comparator|Lactobacillus reuteri group|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
2548129|NCT02577133|Placebo Comparator|Placebo group|Placebo (5 drops) for 28 days
2548158|NCT02576886|Experimental|Supine/Prone Imaging|The patient will be imaged in the standard supine position and then an additional image will be acquired of the patient in the prone position.
2548377|NCT02575768||Severe AS: asymptomatic|Asymptomatic
2548378|NCT02575768||Severe AS: pure angina|Presence of exertional chest pain
2548380|NCT02575768||Normal controls|Healthy controls
2548422|NCT02575560||weekly use erolotinib vs history data|Drug: erolotinib erolotinib 1050mg, oral, once a week, continues to disease progression or death or stop by physician
2548459|NCT02575183|Experimental|Varenicline (Chantix)|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: 0.5 mg orally once a day Days 4 to 7: 0.5 mg orally twice a day Days 8 to end of treatment: 1 mg orally twice a day. Intervention 'Varinecline (Chantix)' and Intervention 'Behavioral Therapy'"
2548595|NCT02574221|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
2548663|NCT02574104||Institution 10|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2547325|NCT02582541|Active Comparator|SEMS alone|Endoscopic retrograde cholangiopancreatography (ERCP) was performed under standard operating conditions with a duodenoscope (TJF 260V, Olympus, Tokyo, Japan) to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) (Wallstent, Boston Scientific, USA) would be placed across the biliary stricture.
2547332|NCT02582541|Experimental|SEMS plus radiofrequency ablation|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The Habib EndoHBP catheter (Emcision, London, United Kingdom) was placed through the biliary stricture under fluoroscopic guidance. The RFA energy can be delivered repetitively at different tumor sites within one procedure, according to the stricture size. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
2547366|NCT02582359|Experimental|MLN9708|"Phase I dose escalation study of MLN9708 with induction chemotherapy~MLN9708 -oral on predetermined days per cycle~Cytarabine, continuous infusion for predetermined duration and dosage~Daunorubicin short IV infusion or rapid injection for predetermined~Phase I dose escalation study of MLN9708 with consolidation chemotherapy after establishment of MTD with induction"
2547394|NCT02582112|Active Comparator|Warming group|Active Comparator: Warming group
2547396|NCT02582112|Placebo Comparator|Control group|Control group
2547439|NCT02581904|Experimental|High Risk - Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
2547441|NCT02581904|Active Comparator|High Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
2547443|NCT02581904|Active Comparator|Low Risk - Dry Gauze Dressing Care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
2547477|NCT02581605||Osteotomy Arm|Patients due to undergo an osteotomy around the knee. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
2547479|NCT02581605||Partial Knee Replacement Arm|Patients due to undergo a partial knee replacement. To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
2547538|NCT02581332|Other|Behavioral: Mindfulness Meditation|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
2547568|NCT02580955|Experimental|LEGFLOW DCB|patients treated with the LEGFLOW Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter
2547616|NCT02580734|Placebo Comparator|placebo|tablet without melatonin
2547618|NCT02580734|Experimental|melatonin|tablet with melatonin
2547755|NCT02579889|Experimental|Active group - CLS ON|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON; Intervention: DDD+CLS
2547761|NCT02579889|Active Comparator|Control group - CLS OFF|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
2547869|NCT02578979|Experimental|ECG for 5 days|Patients will receive 12-lead electrocardiogram for 5 days during their hospitalization.
2547871|NCT02578979|Active Comparator|24-h Holter|Patients will receive a 24-h Holter during their hospitalization.
2547940|NCT02578420|Placebo Comparator|open-label placebo|"Participants (N=40) will have the information that they are receiving an inert cream (i.e. placebo). Placebo will be described as an inert or inactive cream, with no medication in it. Additionally, participants will be told that placebo has been shown in rigorous clinical testing to produce significant mind-body self-healing processes. The placebo administration will be combined with the following scientific rationale/verbal suggestion: (a) placebos are effective analgesics, (b) classical conditioning as a possible mechanism of this effect, (c) compliance is important for outcome and (d) positive expectations increase placebo effects, but are not necessary."
2547948|NCT02578420|Sham Comparator|deceptive placebo|"Participants (N=40) will have the information that they are receiving an analgesic cream (Antidolor, containing Lidocain), while in fact they will receive an inert cream, only. Antidolor will be described as an analgesic cream."
2547963|NCT02578420|Placebo Comparator|control group|Participants (N=40) will have the information that they are receiving an inert control cream.
2547972|NCT02578420|No Intervention|no treatment group|"Participants (N=40) will be told that they are in the no treatment group and that they will not receive an analgesic cream."
2548004|NCT02578017|Experimental|Mobile DOT|All Participants will utilize Mobile DOT for 6 months. The Mobile DOT intervention includes: reminder alerts, participant videos, research staff feedback on adherence, and contingency management.
2548009|NCT02578017|No Intervention|Post-intervention observation|All participants will not receive any additional adherenece intervention after completing the Mobile DOT arm. Participants will be observed for 6 months.
2548057|NCT02577783|Experimental|PDD arm|patients involved in PDD arm will accept chemotherapy of PDD regimen (doxorubicin hydrochloride liposome plus bortizomib and dexamethasone )
2548058|NCT02577783|Active Comparator|PAD arm|patients involved in PAD arm will accept chemotherapy of PAD regimen (doxorubicinplus bortizomib and dexamethasone )
3321418|NCT02018705||POEM|group of Achalasia patients treated with POEM (peroral endoscopic myotomy)
2548221|NCT02576470|Experimental|Videofluoroscopy (VF) and Barium|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium to provide biofeedback for targeted dysphagia swallowing maneuver.
2548229|NCT02576470|Active Comparator|Surface Electromyography (sEMG)|This group will receive the following types of procedures during visits. sEMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
2548234|NCT02576470|Active Comparator|Mixed VF and sEMG|This group will receive the following types of procedures during visits. Videofluoroscopy (VF) and Barium, and EMG images will be used to provide biofeedback for the targeted dysphagia swallowing maneuver.
2548238|NCT02576470|Experimental|VF with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2547337|NCT02582593|Sham Comparator|Amnestic MCI Groups - Amnestic and Nonamnestic - Sham|Amnestic and Nonamnestic Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
2547342|NCT02582593|Active Comparator|Parkinson Disease Group NIR|Transcranial Near Infrared Stimulation for Parkinson Disease participants who will attend a total of 6 treatment sessions over a two week period. During each session, stimulation via light emitting diode clusters will occur for a total of 60 minutes. Four light emitting diode (LED) clusters will be applied in 3 distinct configurations. There will be 20 minutes of stimulation at each of these 3 configurations. Each configuration will target 4 sites, for a total of 12 sites over the course of the 60 minute session. The power density used will be 500 milliwatts (mW) with a cumulative fluence (energy density) of 312 Joules/cm2 (26 J/cm2 applied at 12 sites). It is estimated that approximately 6 Joules/cm2 will reach the cortex with each daily treatment.
2547346|NCT02582593|Sham Comparator|Parkinson Disease Group Sham|Parkinson Disease Participants in the sham control group will undergo identical procedures as the intervention group - screening, baseline testing, and LED cluster placement procedures. However, during the near infrared (NIR) session, the MedX console will not be turned on and no active stimulation will be applied.
3169256|NCT00560729|Active Comparator|II|oral nutrition
2547440|NCT02581852|Other|Single arm assessment|Cross sectional assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning of rheumatoid arthritis patients with different disease activity levels.
2547486|NCT02581657|Experimental|PE0139 Injection|PE0139 Subcutaneous Injection - 6 weekly doses
2547488|NCT02581657|Placebo Comparator|Placebo Injection|Placebo Subcutaneous Injection - 6 weekly doses
2547532|NCT02581241|Experimental|drug-induced long QT syndrome|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 due to drug-induced long QT syndrome and the associated torsades de pointes, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
2547536|NCT02581241|Active Comparator|control|"20 adults aged above 18 years which were hospitalized in Tel Aviv medical center between January 2013 and June 2015 and were treated with specific drugs (antibiotics) that potentially prolong the QT interval but they do not have drug-induced long QT syndrome, have no exclusion criteria and provide informed consent to participate in the study.~Interventions. Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
2547580|NCT02580981|Experimental|Genomic Testing|"Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used).~In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs."
2547638|NCT02580630|Active Comparator|Training and glucocorticosteroid|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with glucocorticosteroid: 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
2547641|NCT02580630|Active Comparator|Training and local anesthetic|"Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then every month.~All patients are informed to a reduction in running and jumping sports for the first 3 months, thereafter slowly progressing to normal sports activity.~Ultrasound guided injection with local anaestethic: 1ml Lidocain 5 mg/ml and 1 ml intralipid (for blinding) in Kagers triangle underneath the thickest part of the achilles tendon. Injection is given every months until the tendon pain is markedly diminished (max 3 injections)."
2547715|NCT02579941|Experimental|Pregnant women at term, vaginal childbirth|
2547718|NCT02579941|Experimental|Pregnant women at term, cesarean delivery|
2547720|NCT02579941|Experimental|Female volunteers, age 18 to 40|
2547758|NCT02579655|Active Comparator|Copayment Elimination and Personalized Education|In this arm, participants would have copayment elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and free enrollment in a new personalized education program to help participants manage their chronic conditions
2547763|NCT02579655|Active Comparator|Copayment Elimination Only|In this arm, participant's would be randomized to Copayment Elimination (no cost for preventative medications for hypertension, diabetes, and cardiovascular disease) and receive some basic educational information about their chronic disease
2547770|NCT02579655|Active Comparator|Personalized Education Only|In this arm, participants would be randomized to free enrollment in a new personalized education program to help patients manage their chronic conditions
2547773|NCT02579655|No Intervention|No intervention|In this arm, participants will have access to some basic online educational information about their chronic disease. There is no intervention in this arm. The comparative group.
2547811|NCT02579226|Experimental|Part A|Part A dose-escalation will evaluate the safety and tolerability of AZD2811 monotherapy at increasing doses in patients with advanced solid tumours. Patients will receive AZD2811 on Days 1 and 4 of a 28-day cycle or Day 1 only in cycles of either 21 or 28 days.
3169257|NCT00560729|Experimental|III|oral nutrition
2547376|NCT02582333||Tenofovir|Chronic hepatitis B patients who receive tenofovir as their first anti-HBV therapy and are indicated for stopping tenofovir therapy
2547379|NCT02582333||Entecavir|Chronic hepatitis B patients who receive entecavir as their first anti-HBV therapy and are indicated for stopping entecavir therapy
2547402|NCT02582021||Women|Women undergoing clinically-ordered coronary angiography for signs and symptoms of ischemia who have no obstructive coronary artery disease (CAD)
2547408|NCT02582021||Women or men|Women and men hospitalized for signs and symptoms of ischemia and evidence of Heart Failure with preserved ejection fraction (HFpEF) who have not undergone a clinically-ordered coronary angiography
2547530|NCT02581592|Experimental|Hepatic Impairment|Eight subjects with Moderate Hepatic Impairment (Child-Pugh B). Drug: TD-4208 175mcg, inhaled, single dose.
2547534|NCT02581592|Experimental|Normal Hepatic Function|Eight healthy participants matched to participants with moderate hepatic impairment. Drug: TD-4208 175mcg, inhaled, single dose.
2547634|NCT02580500|Active Comparator|group 1|Pilonidal dermoid cyst surgery in Spinal anaesthesia
2547637|NCT02580500|Active Comparator|group 2|Pilonidal dermoid cyst surgery in Epidural anaesthesia
2547691|NCT02580110|Experimental|sucrose|14 days intervention with daily intake of a beverage (1000 ml) including 66g sucrose.
2547699|NCT02580110|Experimental|stevia glycosides|14 days intervention with daily intake of a beverage (1000ml) including 0.220 g stevia glycosides.
2547705|NCT02580110|Experimental|saccharin|14 days intervention with daily intake of a beverage (1000ml) including 0.216g saccharin.
2547762|NCT02579720||Group 1: Pollinex® Quattro Patients|Patients treated with Pollinex® Quattro
2547767|NCT02579720||Group 2: Control Patients|Patients who decided to use only anti-allergic drugs during the grass pollen season
2547809|NCT02579330|Experimental|Coloshield Group|In the Intervention group the Coloshield Device (double balloon system) will be introduced at the beginning of surgery followed by a washout of the rectum with 500ml of saline solution. The grade of macroscopic contamination will be assessed.
2547810|NCT02579330|Sham Comparator|Control Group|In the control Group the grade of macroscopic contamination will be assessed after rectal washout with 500ml of saline solution.
2547855|NCT02579083|Experimental|Segment A: Single MB66 Administration|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
2547859|NCT02579083|Placebo Comparator|Segment B: Repeated Administrations Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
2547860|NCT02579083|Experimental|Segment B: Repeated Administrations MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
2547900|NCT02578784|Placebo Comparator|POBA-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a standard, non-coated balloon (plain old balloon, POBA).
2547901|NCT02578784|Active Comparator|DCB-after-Cutting Balloon|After cutting balloon angioplasty, subsequent angioplasty is performed using a drug-coated balloon (DCB)
2547965|NCT02578485|Experimental|AVideogame|Session with active video game lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2547975|NCT02578485|Active Comparator|SVideogame|Session with active video sedentary lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2547978|NCT02578485|Placebo Comparator|EMIntensity|Session with walk on a treadmill with moderate intensity lasting 60 minutes performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
2547980|NCT02578485|Placebo Comparator|EISVideogame|Session with walk on a treadmill with intensity similar reached in session with VGA and lasting 60 minutes performing heart rate and perceived exertion measurements every 10 minutes.
2547981|NCT02578485|Sham Comparator|Control|Participants remained for 60 minutes at rest performing heart rate measurements every 10 minutes and evaluating the perceived exertion.
3203953|NCT00929266|Experimental|1|"The choice of conducting the study in healthy volunteers and not in patients is based on the necessity to have a healthy physiological context avoiding any situation which could lead to hemolysis. As the protocol requires mobilization with a growth factor, the donors of peripheral stem cells (PSC) receive G-CSF.~Direct intravenous injection of labeled cRBC in a volume of 1 mL will be administered to the subjects."
3203954|NCT00929279|Active Comparator|Abciximab bolus plus infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen.
3203955|NCT00929279|Experimental|bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
3203956|NCT00929292|Experimental|Modilac Dahlia 1|Formula enriched with alpha-lactalbumin and containing a probiotic
3203957|NCT00929292|Placebo Comparator|Modilac 1|Regular milk
2548134|NCT02576873||Hemodiafiltration|End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months
2548168|NCT02576821|Other|Patients with Hippocampal sclerosis non AD|Patients with Hippocampal sclerosis non AD (n=40)
2548175|NCT02576821|Other|Patients with Alhzeimer's Disase|Patients with Alhzeimer's Disase (n=40)
2548180|NCT02576821|Other|Patients with DLFT|Patients with DLFT (n=20)
2548182|NCT02576821|Other|Patients with CBD/PSP|Patients with CBD/PSP (n=20)
2548184|NCT02576821|Other|Normal controls|Normal controls (n=20)
2548300|NCT02576379||HEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Helicopter Emergency Medical System (HEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 36-month period from May 1st 2010 until April 30th 2013.
3203958|NCT00929318|Active Comparator|benign|patients after surgery because of a benign disease
3203959|NCT00929318|Active Comparator|DTC|Patients after thyroidectomy because of papillary carcinoma of the thyroid gland
3203960|NCT00929370|Experimental|GSK1018921|Glycine Transporter-1 inhibitor to modulate the NMDA receptor.
3203961|NCT00929396|Experimental|Latent TB infection group|The latent TB group will receive two injections of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart.
2547459|NCT02581800|No Intervention|Control group|The control group includes hospital consultations (usual care) on the hospital 2-3 times a week (1-2 hours) and the possibility to call the neonatal ward 24 hours a day all week until the infant gets full nutrition from the breast or bottle and gains weight. The parents register nutrition on a paper between the visits to the hospital.
2547461|NCT02581800|Experimental|App group/intervention group|The intervention group will receive the Smartphone application at inclusion time and learn to use it in the hos-pital. When the families go home they will use the application and receive planned video consultations 2-3 times a week and the possibility to call the neonatal ward 24 hours a day all week whenever needed, until the infant gets full nutrition from the breast or bottle and gains weight. Parents will borrow a baby weight to weigh the baby at home.
2547513|NCT02581436|Experimental|kSORT assay based follow-up|Post Transplant surveillance based on the result of the kSORT assay.
2547516|NCT02581436|Active Comparator|Standard follow-up|Post Transplant surveillance based on standard of care.
2547639|NCT02580682|Experimental|Sanfu herbal patch|one kind of acupoint application which used in hot dog days of summer,The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba asarum), Bai Jie Zi (Semen Sinapis Albae), and Rou Gui (Cortex Cinnamomi) at a ratio of 2:2:1:1:2:1.The bilateral Feishu (BL13), Pishu (BL20), Shenshu (BL23), Neiguan (PC6), and Guanyuan (CV4) acupoints were selected for treatment
2547642|NCT02580682|Experimental|Sanfu moxibustion|use moxibustion in hot dog days of summer,and adopting the indirect moxibustion box method at the bilateral BL13, BL20, and BL23 acupoints
2547646|NCT02580682|Experimental|Sanfu herbal patch and Sanfu moxibustion|use herbal patch and moxibustion together in hot dog days
2547648|NCT02580682|No Intervention|controlled|patients in this group will not accept herbal patch or moxibustion therapy in these 3 years. After the 3-year experimental period they will be offered corresponding treatments for free as well, so they are in our wait list.
3169258|NCT00560729|Experimental|IV|oral nutrition
2547896|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol|Intervention group that carries out the Transdiagnostic Internet-Based Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
2547902|NCT02578758|Experimental|Transdiagnostic Internet-Based Protocol+Positive Affect|Intervention group that carries out the Transdiagnostic Internet-Based Protocol+Positive Affect component and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages).
2547906|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the waiting list period.
2547949|NCT02578459|Experimental|Intrathecal Drug Delivery (ITDD)|These subjects will have a Prometra System implanted and managed with the appropriate drug regimen to treat their pain.
2547967|NCT02578459|Active Comparator|Conventional Medical Management (CMM)|These subjects will be treated with conventional medical management to treat their pain.
2548013|NCT02578030|Experimental|SHP465 12.5 mg|A single dose of SHP465 12.5 mg for Subjects aged 6-12 years
2548015|NCT02578030|Experimental|SHP465 25 mg|A single dose of SHP465 25 mg for Subjects aged 13-17 years
2548102|NCT02577666|Experimental|Ecologically-Based Therapy + TAU|receives Ecologically-Based Therapy which includes the Community Reinforcement Approach, Strengths-Based Case Management (6 months) and rental assistance for housing (3 months) + TAU
2548105|NCT02577666|Experimental|Housing Only + TAU|receives 3 months of rental assistance for housing only + TAU
2548107|NCT02577666|Other|treatment as usual (TAU)|receives usual treatments/interventions (TAU) within in the community
2548303|NCT02576288|Experimental|Sitagliptin|100mg will be administered by mouth daily for 28days
2548309|NCT02576288|Placebo Comparator|Matching Placebo|One placebo will be administered by mouth daily for 28days
2548328|NCT02576015|Experimental|Group L|Participants in group L will receive a single injection for femoral nerve block combined with continuous femoral nerve block intra-operatively. The femoral nerve block will be performed before the induction of anesthesia on the leg to be operated. Then the patients were given the 2% lidocaine 10 ml and 1% ropivacaine 10 ml as initial dose,then,the patients will receive a continuous infusion of 0.15% ropivacaine at 15 ml/h.Intra-operatively, bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 50-60.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
2548329|NCT02576015|Sham Comparator|Group D|Participants in group D will receive the placement of femoral nerve catheter preoperatively. The same dose of 0.9% saline was injected and infused as group L intra-operatively. Bispectral index score (BIS) was titrated with the adjusting of desflurane to maintain the index between 30-40.After the surgery,these patients will receive continuous femoral nerve analgesia till 3 days post-operatively( the loading dose was set at 5 ml of 0.15% ropivacaine followed by an infusion of 0.15% ropivacaine at 5 ml/h, with bolus of 5 ml and the lock time of 30 min).
2548391|NCT02575729|Experimental|Inject betamethasone by sonography|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease by sonography- guided. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
2549174|NCT02570581|Active Comparator|Jelly with Furosemide|Jelly with Furosemide
3169259|NCT00560742|Active Comparator|Control|
3169260|NCT00560742|Experimental|Intramuscular|
3169261|NCT00560742|Experimental|Intracoronary|
3169262|NCT00560768|Experimental|1|
3169263|NCT00560781|Active Comparator|1|Pregnenolone
3169264|NCT00560781|Placebo Comparator|2|Placebo
3169265|NCT00560807|No Intervention|A|Zero treatment/3 weeks
3169266|NCT00560807|Active Comparator|B|Frequency of Mobilization:1/week Duration of Mobilization Treatment: 3 weeks
3169267|NCT00560807|Active Comparator|C|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 6 weeks
3169268|NCT00560807|Active Comparator|D|Frequency of Mobilization: 1/week Duration of Mobilization Treatment: 12 weeks
2547508|NCT02581397|Experimental|Guaiacol suppository|"It is a rectal suppository that is manufactured by Aché S.A. and consists of guaiacol.~The rectal suppositories will be dispensed to 90 participants of this group within a cartridge. Each cartridge contains one strip with five suppositories.~The participant must manage 1 suppository in the morning and 1 at night via rectal suppository (12/12h).~The duration of treatment may be up to 03 or 07 days, depending on the visit discharge."
2547510|NCT02581397|Active Comparator|Transpulmin syrup|"It is a syrup which is manufactured by Aché S.A. and which is composed of guaifenesin.~Transpulmin syrup will be dispensed to 90 participants of this group in a bottle of 150ml plus a dosing cup.~The participant shall administer 7,5ml orally every 4 hours, The duration of treatment may be up to 07 days."
2547576|NCT02581046|Experimental|3 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation.
2547577|NCT02581046|Experimental|6 month surgical group|Phacoemulsification pediatric cataract surgery is performed at the age of 3 month of patients without IOL implantation..
3203962|NCT00929396|Experimental|BCG vaccinated group|The BCG vaccinated group will receive two vaccinations of 50 microgram antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)two months apart
3203963|NCT00929409|Active Comparator|Peroral iron - ferrous sulfate tablets|Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
3321419|NCT02018705||LHM|group of Achalasia patients treated with LHM (laparoscopic Heller myotomy)(+ fundoplication)
2547938|NCT02578264||All participants|All subjects enrolled in the study will provide tumor and normal tissue and blood samples.
2547995|NCT02578173||AVERT PLUS|The AVERT PLUS will be used on the first 10 patients enrolled in the study. The AVERT PLUS is a contrast monitoring system which is used to precisely measure the volume of contrast delivered to the patient.
2547996|NCT02578173||Non device group|The second group of 10 patients will undergo the scheduled angiography using the standard method of measuring contrast dye delivery.
2548095|NCT02577406|Experimental|AG-221 plus Best supportive care (BSC)|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days, plus BSC.
2548097|NCT02577406|Active Comparator|Conventional care regimen (CCR)|Continuous 28-day cycles of BSC only, azacitidine subcutaneously (SC) plus BSC, low-dose cytarabine (LDAC) SC plus BSC, or intermediate-dose cytarabine (IDAC) intravenously (IV) plus BSC. Subjects will be assigned by the investigator to one of the CCR treatment options based on the investigator's assessment of subjects' eligibility.
2548250|NCT02576418|Experimental|Partosure TTD Test|PartoSure TTD test will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
2548323|NCT02576327|Experimental|Aprepitant Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）+ Aprepitant125mg（Day1-2）、80mg（Day3-6）
2548324|NCT02576327|Active Comparator|Control Arm|Tropisetron 5mg（Day1-6）+ Dexamethasone 10mg（Day1-6）
2548355|NCT02575859|Experimental|Adjuvant HIPEC|Adjuvant HIPEC will be performed simultaneously with primary tumor resection in patients undergoing curative surgery for primary colorectal cancer associated with risk factors for the development of metachronous peritoneal metastases.
2548363|NCT02575859|No Intervention|Matched control|"Comparable controls will be retrospectively selected from patients undergoing curative surgery for colorectal cancer at the National Cancer Institute (Milan, Italy) during the same period.~Every single control patient will be matched with a.patient in HIPEC group according to the following criteria: i) risk-factor for metachronous PM (minimal synchronous PM vs. ovarian metastases vs. pathological tumor [pT] stage (pT4a/b); ii) pathological node (pN) stage (pN0 vs. pN1/2); iii) grading (well/moderately vs. poorly differentiated); iv) histological subtype (adenocarcinoma vs. mucinous/signet ring cell carcinoma); v) sex; vi) age (+/-5 years). The investigators will be blinded to patient outcomes during the process."
2548421|NCT02575638|Experimental|Treatment population|The study drug, CZ48, is administered orally in capsule form t.i.d. Capsules in 30mg and 50mg of drug are available for dosing. This is a dose escalation study so dosage has not yet been determined. Study drug is take on day 1 - 5 and then no drug on day 6 and 7. This is repeated for 4 weeks, or one course.
2548500|NCT02574923|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
2548543|NCT02574663|Experimental|TGR-1202|TGR-1202 daily dose
2548549|NCT02574663|Experimental|TGR-1202 + nab-paclitaxel + gemcitabine|TGR-1202 oral daily dose + nab-paclitaxel + gemcitabine both as an IV infusion
2548555|NCT02574663|Experimental|TGR-1202 + FOLFOX|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen)
2548558|NCT02574663|Experimental|TGR-1202 + FOLFOX + Bevacizumab|TGR-1202 oral daily dose + oxaliplatin IV infusion + leucovorin IV infusion followed by 5-fluorouracil IV bolus followed by 5-FU IV infusion (FOLFOX regimen) + bevacizumab IV infusion
2548630|NCT02574104||Institution 1|"McGill University Health Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2548633|NCT02574104||Institution 2|"Rochester University Medical Center NICU staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2548636|NCT02574104||Institution 3|"Parkland Memorial Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Complete"
2548639|NCT02574104||Institution 4|"Eastern Maine Medical Center NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2548644|NCT02574104||Institution 5|"Brigham and Women's Hospital NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2548654|NCT02574104||Institution 6|"Centre hospitalier universitaire Sainte-Justine NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Active"
2548659|NCT02574104||Institution 7|"Golisano Children's Hospital of Southwest Florida NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
2548661|NCT02574104||Institution 8|"Florida Hospital for Children NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Preparing"
2548662|NCT02574104||Institution 9|"Memorial Hospital of South Bend NICU Staff~Simulate a functional NICU prior to moving patients to preserve safety at transition~STATUS: Pending"
2547581|NCT02581085|Placebo Comparator|Placebo Vehicle|Subjects will take 2 placebo capsules following AM meal, 2 placebo capsules following PM capsules
2547582|NCT02581085|Active Comparator|Tocotrienol supplement|Subjects will take (2) 200 mg TCT capsules following AM meal, (2) 200 mg TCT following PM meal
2547608|NCT02580578||All Participants|Female patients who are diagnosed and treated for symptoms associated with their uterine fibroids per routine clinical practice. No intervention is administered in this study.
2547661|NCT02580279|Experimental|EGCG group|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution;The solution is sprayed three times a day at 0.05 ml/cm2 to the whole radiation field until two weeks after radiation completion; Patients who developed grade Ⅱ radiation-induced dermatitis have the option to either withdraw from the study or to continue with EGCG. Patients are follow general good skin care practices during radiation therapy, such as not applying water soaks to relieve itching or pain, not vigorously rubbing the irradiated area, or not erasing ink marks; patting the skin dry with a soft towel; avoiding exposure to the sun; and wearing loose and cotton clothes. They are advised not to use deodorant, lotion, cream, make up, perfume or any other product on the area during the course of radiation therapy.
2547666|NCT02580279|Placebo Comparator|placebo|The placebo is 0.9% saline solution.Patients are also to follow general good skin care practices which is same as the EGCG group.
2547687|NCT02580071|Experimental|Sheng-Yu-Tang|"Treatment group will receive standard of care, as well as:~2-3 months post-HSCT, patients will be administered the herbal formula Sheng-Yu-Tang (聖愈湯), which they will receive for 6 months. The herbal formula will be provided from a GMP herbal company and will be given in granulated form."
2547689|NCT02580071|No Intervention|Control|Control group will receive standard of care
2547983|NCT02578303|Experimental|Dementia group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
2547985|NCT02578303|Other|control group|"Assessed by the insertion of an interaction parameter between cerebral blood flow and the group label(dementia or no-dementia).~ROC method will be used to find a threshold value of IAH that separates the two groups.~Interventions:~Vascular flow measurement by PC-MRI~Neuropsychological assessment~Registration of sleep apnea~Registration of blood pressure~ECG holters~Blood test~Geriatric standard evaluation"
2548072|NCT02577380|Experimental|IPV/GBV HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to IPV/GBV HTC HIV testing.
2548073|NCT02577380|No Intervention|Standard HIV testing and counseling|For the randomized controlled trial, first-time antenatal care clients will be randomly assigned to Standard HIV testing and counseling.
2548122|NCT02577302|Experimental|CAN-Stim Group - CAN-Stim System|"Intervention: tibial medical device~Subjects randomized to this group will have the Protect CAN-Stim System tibial medical device implanted for the duration of the study."
2548123|NCT02577302|Active Comparator|SNS Group - Interstim® System|"Intervention: SNS Medical device~Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study."
2548163|NCT02576847|Experimental|Treatment|Omiganan gel applied once daily
3169269|NCT00560807|Active Comparator|F|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 3 weeks
3169270|NCT00560807|Active Comparator|G|Frequency of Mobilization: 2/week Duration of Mobilization Treatment:6 weeks
3169271|NCT00560807|Active Comparator|H|Frequency of Mobilization: 2/week Duration of Mobilization Treatment: 12 weeks
3169272|NCT00560807|Active Comparator|J|Frequency of Mobilization: 3/week Duration of Mobilization Treatment: 3 weeks
3169273|NCT00560807|Active Comparator|K|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:6 weeks
3169274|NCT00560807|Active Comparator|L|Frequency of Mobilization: 3/week Duration of Mobilization Treatment:12 weeks
3169275|NCT00560807|No Intervention|E|Zero treatment/6 weeks
3169276|NCT00560807|No Intervention|I|Zero treatment/12 weeks
3169277|NCT00560820|Experimental|Deferasirox|30 mg/kg/day
3169278|NCT00560846|Experimental|Nutrition|Pre-operative immunonutritrion, pre-operative glucose load, post-operative early immunonutrition
3169279|NCT00560846|No Intervention|Control|No immunonutrition, no glucose load, no early enteral immunonutrition
3169280|NCT00560872|Other|1|conventional ablation with manual catheter navigation
2548511|NCT02575196||Cardiac arrest|Consecutive adult cardiac arrest patients with sustained ROSC in an academic medical center
2548532|NCT02574559|Experimental|Caregiver of Child With Autism Spectrum Disorder|Caregivers attending eight weekly sessions of Cognitive Based Compassion Training Sessions and Meditation.
2548617|NCT02574351||obese asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
3169281|NCT00560872|Active Comparator|2|ablation with remote magnetic catheter navigation
3169282|NCT00560898|Experimental|2|contact lenses disinfected in multipurpose solution
3169283|NCT00560898|Experimental|3|contact lenses disinfected in multipurpose solution
3169284|NCT00560898|Experimental|4|contact lenses disinfected in multipurpose solution
3169285|NCT00560898|Experimental|1|contact lenses disinfected in multipurpose solution
3169286|NCT00560911|Other|1Self-management|
3169287|NCT00560911|Other|2 Routine control|
3169288|NCT00560963|Experimental|1 RAD001|
3169289|NCT00560976|Experimental|Iron Saccharate (Venofer)|IV Iron Saccharate (Venofer)100 mg
3169290|NCT00560989||1|CBD cases
3169291|NCT00560989||2|Beryllium-exposed, non-diseased control subjects
2547539|NCT02581215|Placebo Comparator|Arm B: Placebo Arm|"mFOLFIRINOX will be administered every 2 weeks, and consist of:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.~Arm B will receive a placebo infusion every 2 weeks. Due to the double-blinded nature of this study, the volume of placebo will be calculated as if it were ramucirumab"
2547561|NCT02580864||IBD patients|120 adult patients (Caucasian, male/female,18-65 years old) with moderate-severe active Crohns disease (220≤ CDAI ≤450; blood CRP ≥5 mg/L and/or fecal calprotectin ≥250mg/L) and with indication for anti-TNF therapy according to the normal clinical practice
2547565|NCT02580864||No-IBD patients|30 no-IBD controls with no GI disorders, as defined by medical history and standard clinical chemistry values, afferent to the out-patient clinic
2547606|NCT02580747|Experimental|anti-meso CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
3203964|NCT00929409|Active Comparator|Ferric carboxymaltose|Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.
3203965|NCT00929422||spinal cord injury 1|
3203966|NCT00929422||spinal cord injury 2|
3203967|NCT00929422||spinal cord injury 3|
3203968|NCT00929422||normal control|
3203969|NCT00929435||MRSA surveillance|Newly recruited resident physicians will be monitored for a year with nasal swabs monthly.
3203970|NCT00929448||Immunoglobulin|
2548033|NCT02577874||Chinese Subjects|7 blood glucose tests taken over a two hour period
2548037|NCT02577874||European Subjects|7 blood glucose tests taken over a two hour period
2548096|NCT02577588|Experimental|re-activated T cells|Ten patients with CRC stage UICC IV under routine first line FOLFOX 6/Bevacizumab therapy are planned to receive a singular treatment with an autologous T cell product at a dose of 5x10^7 (first three or six patients) or 5x10^8 (last four or seven patients) cells.
2548132|NCT02577120||Low TEWL|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.
2548133|NCT02577120||High TEWL - No treatment|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2548135|NCT02577120||High TEWL - Epiceram skin barrier function|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2548136|NCT02577120||High TEWL - Ceramiseal|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site
2548137|NCT02577120||High TEWL - Vaseline Petroleum Jelly|Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects
2548165|NCT02576795|Experimental|valoctocogene roxaparvovec|Single administration of valoctocogene roxaparvovec at escalating doses.
2548217|NCT02576600|Experimental|PUPILLO|Videopupillometer Algiscan peroperative remifentanil target concentration adapted every five minutes to pupillary diameter in patients under propofol and remifentanil TCI
2548225|NCT02576600|Sham Comparator|STANDARD|peroperative remifentanil target concentration as standard practice in patients under propofol and remifentanil TCI
2548301|NCT02576301|Experimental|Phase 2 AML|OXi4503 at MTD plus cytarabine 1g/m2/day
2548304|NCT02576301|Experimental|Phase 2 MDS|OXi4503 at MTD plus cytarabine 1g/m2/day
2548308|NCT02576301|Experimental|OXi4503 dose escalation|MTD for OXi4503 will be determined
2548312|NCT02576301|Experimental|OXi4503 + cytarabine dose escalation|MTD of the combination of OXi4503 + cytarbine will be determined
2548353|NCT02575937|Experimental|Diabetes group|During the trial period, the participants who are diagnosed of diabetes are instructed to consume low glycemic diet every day
2548354|NCT02575937|Experimental|Fatty group|During the trial period, the participants who are diagnosed of obesity are instructed to consume low glycemic diet every day
2548450|NCT02575586|Experimental|Dry Needling into MTrPs.|Intervention-Dry Needling: Deep Dry Needing into the medial Myofascial Trigger Point of the soleus muscle.
3203971|NCT00929461|Other|Omega-3 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
3203972|NCT00929461|Other|Omega 3 + Omega 6 group|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter.
3203973|NCT00929487|Experimental|Contact lens solution #1|
3203974|NCT00929487|Experimental|Contact lens solution #2|
3203975|NCT00929487|Experimental|Contact lens solution #3|
3203976|NCT00929487|Experimental|Contact lens solution #4|
3203977|NCT00929487|Active Comparator|Saline/blister pack solution|
3203978|NCT00929539|Experimental|Dose 1 JTT-130|
3203979|NCT00929539|Experimental|Dose 2 JTT-130|
3203980|NCT00929539|Experimental|Dose 3 JTT-130|
3203981|NCT00929539|Placebo Comparator|Placebo|
3321420|NCT02018718|Other|Marathoners|
2547599|NCT02580851|Other|Coronary angiography|Patients directly undergo diagnostic coronary angiography. A PCI is performed according to current guidelines in case of ≥70% stenosis in a coronary vessel with ≥2 mm diameter.
2547603|NCT02580851|Other|Cardiac magnetic resonance imaging|Patients receive adenosine perfusion CMR for functional testing, first. The examination is conducted on a 3.0 Tesla whole-body scanner with a 32-channel phased-array cardiac receiver coil according to a well-established standard protocol [21-23]. In case reversible ischemia can be detected, subjects are sent to coronary angiography and PCI afterwards.
2547655|NCT02580461|Experimental|Immediate Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the immediate exercise group. The immediate exercise group will receive a 12 week center based structured exercise program followed by a 12 week maintenance of exercise program.
2547658|NCT02580461|No Intervention|Delayed Exercise Group|One half of the participants enrolled in the 24 week center-based structured exercise and education program will be randomized to the delayed exercise group. This will be a wait list control group and the participants will receive no active intervention for 12 weeks. The wait list control group will then be enrolled in the 12 week structured exercise intervention.
2547688|NCT02579993|Experimental|Stem Cell Transplantation|Cultivated Limbal Stem Cell Transplantation
2547864|NCT02579005|Experimental|Patients with a living donor|Radiation + PBMC
2547868|NCT02579005|Experimental|Patients with a UCB donor|Radiation + UCB
2547984|NCT02578342||Healthy volunteers|healthy volunteer between age of 20 to 55 will undergo MRI examination.
2547986|NCT02578342||ADHD subjects without medication|Medication-naive subjects with ADHD (20-55 years) will undergo MRI examination.
2547988|NCT02578342||ADHD subjects with medication|Subjects with ADHD (20-55 years), under medication will undergo MRI examination.
2548027|NCT02577913||FC patch low|Women taking FC Patch low, a transdermal patch releasing 60 micrograms gestodene/24 hours + 13 micrograms ethinyl estradiol/24 hours
2548029|NCT02577913||LNG-COC|Women taking levonorgestrel-containing COCs: 1) monophasic preparations containing 20 - 30mcg of ethinylestradiol; 2) multiphasic preparations containing up to 40mcg of ethinylestradiol
2548087|NCT02577653|Other|subjects|participant undergoing posturographic evaluation
2548153|NCT02577185|Experimental|botulinum toxin type A|Experimental drug
2548154|NCT02577185|Placebo Comparator|sodium chloride 9 mg/ml|Vehicle drug
2548220|NCT02576457|Experimental|BMS-936559|BMS-936559 Intravenous infusion on specified days
2548227|NCT02576457|Other|Placebo|Placebo on specified days
2548347|NCT02576197|Active Comparator|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
2548348|NCT02576197|Placebo Comparator|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
2548408|NCT02575703|Experimental|[¹⁴C]-LY3023414|Single oral dose of [¹⁴C]-LY3023414 administered on Day 1
2548517|NCT02574871||Single Group|Psychological and biological data collection
2548533|NCT02574546||Surgery|Women undergoing mastectomy are eligible for enrollment.
2548567|NCT02574403|Experimental|without eculizumab|
2548642|NCT02574039|Experimental|Oat bran|66g oat bran made up in 350ml skimmed milk
2548649|NCT02574039|Placebo Comparator|Control|Refined grain product and 350ml skimmed milk
3169292|NCT00560989||3|Sarcoidosis cases
3169293|NCT00560989||4|Sarcoidosis control subjects
2548768|NCT02573168|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
2548776|NCT02573142|Experimental|Bull City Fit Intervention|Subjects in the Bull City Fit intervention will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and unlimited access to a community-based wellness program that includes physical fitness activities and cooking classes.
2548857|NCT02572869||segmental mandibulectomy and free fibular flap reconstruction|Patients who underwent segmental mandibulectomy and free fibular flap reconstruction at MSK between 1987 and 2014
3169294|NCT00561028||1|ST-elevation acute myocardial infarction.
3169295|NCT00561028||2|high-risk unstable angina or non-ST-elevation myocardial infarction.
3169296|NCT00561028||3|known coronary artery disease, either asymptomatic or with stable angina.
3169297|NCT00561028||4|blood donors without known coronary artery disease.
3169298|NCT00561041|Experimental|1|Brief phone aftercare intervention composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
3169299|NCT00561041|Experimental|2|Individual aftercare therapy - composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
3169300|NCT00561041|No Intervention|3|No intervention
3169301|NCT00561054|No Intervention|1|CISPLATIN gENCITABINE cETUXIMAB
3169302|NCT00561067|Active Comparator|1|Methylprednisolone
3169303|NCT00561067|Experimental|2|Erythropoietin
3169304|NCT00561093|Experimental|A|Group A (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3169305|NCT00561093|Experimental|B|Group B (n=25) Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3169306|NCT00561093|Experimental|C|Group C (n=25) Placebo dietary supplement to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3169307|NCT00561093|Placebo Comparator|D|Group D (n=25) Placebo to imitate Nepro (8 ounces) and Oxepa-similar anti-inflammatory module (2 ounces) AND Placebo to imitate pentoxiphylline (400 mg) while undergoing hemodialysis and the following non-dialysis day (6 days per week)
3169308|NCT00561106|Active Comparator|1|
2547563|NCT02580942|Experimental|Acupoint sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
2547572|NCT02580942|Sham Comparator|Sham sticking therapy group|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
2547640|NCT02580643||APS Injection|Autologous Protein Solution
2547694|NCT02580162|Active Comparator|Pro.Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Professionals interventionists and parents are NOT Peer Interventionists
2547701|NCT02580162|Experimental|Pro.Treatment, Peer|Families receive FBT for Pediatric Weight Management by Professionals and parents ARE Peer Interventionists
2547708|NCT02580162|Experimental|Peer Treatment, Not a Peer|Families receive FBT for Pediatric Weight Management by Peers and parents are NOT Peer Interventionists
2547710|NCT02580162|Experimental|Peer Treatment, Peer|Families receive FBT for Pediatric Weight Management by Peers and parents ARE Peer Interventionists
2547766|NCT02579681|Experimental|BG00012|BG00012 administered orally at 120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter.
2547843|NCT02579161|Active Comparator|Antibiotics for a 24 hour period|"Antibiotics for a 24 hour period~Intervention drug to be determined based on patient history etc."
2547847|NCT02579161|Active Comparator|Continued antibiotics|"Continued antibiotics until the removal of any external catheters~Intervention drug to be determined based on patient history etc."
2548020|NCT02577926|Experimental|Ruxolitinib|Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
2548021|NCT02577926|Active Comparator|Best available therapy (BAT)|BAT may include all currently used treatment options. BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc). BAT will be administrated for two consecutive years.
2548085|NCT02577484||Participants|Subjects who satisfy both general and angiographic inclusion/exclusion criteria, and who have the pressure measurement taken with the Navvus catheter.
2548159|NCT02576925||Eligible patients|Adults having had a transient diplopia during the last 8 days.
2548454|NCT02575274|Experimental|JHS COL-HAP91 + JHS HAP-91|Surgical flaps debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Bone defects will be treated with JHS COL-HAP91 (porous hydroxyapatite + collagen) + JHS HAP-91 (porous hydroxyapatite). Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day, and Nimesulide 100 mg 2 times/day will be prescribed.
2548456|NCT02575274|Other|surgical and mechanical debridement|Surgical flaps: All groups will receive the same surgical treatment for implant surface decontamination. Surgical intervention will be performed with full thickness mucoperiosteal flaps. Debridement with plastic curette Implacare Hu-Friedy, cleaning the surface with chlorhexidine gel 2% 3 minutes and irrigation with saline solution 0.9 %. Amoxicillin 500 mg 3 times/day 7 days, Tylenol 750 mg 3 times/day and Nimesulide 100 mg 2 times/day will be prescribed.
2548521|NCT02574910|Experimental|Abiraterone acetate 1 mg/kg/d|Abiraterone acetate will be administered orally at a daily dose of 1 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2548523|NCT02574910|Experimental|Abiraterone acetate 2 mg/kg/d|If the 1 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 2 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2548525|NCT02574910|Experimental|Abiraterone acetate 4 mg/kg/d|If the 2 mg/kg/d dosing does not result in androstenedione level normalization, abiraterone acetate will be administered orally at a daily dose of 4 mg/kg for 7 days in addition to the standard of care treatment of hydrocortisone and fludrocortisone.
2548562|NCT02574429|Experimental|Cognitive Processing Therapy|Individuals who have either completed Standard Dialectical Behavior Therapy (DBT) for Borderline Personality Disorder (BPD) and/or are currently enrolled in DBT who have co-occuring PTSD.
2548596|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 1|alveolar recruitment maneuvers by CPAP then alveolar recruitment maneuvers by eSigh
2548598|NCT02574169|Experimental|Alveolar recruitment maneuvers Group 2|alveolar recruitment maneuvers by eSigh then alveolar recruitment maneuvers by CPAP
2548650|NCT02573922|Experimental|Oxycodone-naloxone|Oxycodone-naloxone prolonged release tablet twice a day
2548660|NCT02573922|Active Comparator|Oxycodone|Oxycodone prolonged release tablet twice a day
3169309|NCT00561106|Placebo Comparator|2|
3169310|NCT00561119|No Intervention|Arm 1|Observation after 6 cycles of gemcitabine plus paclitaxel till progression
3169311|NCT00561119|Experimental|Arm 2|Maintenance chemotherapy with gemcitabine plus paclitaxel after 6 cycles of gemcitabine plus paclitaxel till progression
3169312|NCT00561132|Experimental|1|
3169313|NCT00561132|Placebo Comparator|2|
3169314|NCT00561158|Experimental|A|
3169315|NCT00561158|No Intervention|2|
3169316|NCT00561171|Experimental|1|high dose
3169317|NCT00561171|Experimental|2|lower dose
3169318|NCT00561184|Experimental|1|
3169319|NCT00561184|Experimental|2|
3169320|NCT00561210|Experimental|I|Total enteral tube feeding
3169321|NCT00561210|Active Comparator|II|Total enteral tube feeding
3169322|NCT00561223|Experimental|1|"This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.~It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD."
2547629|NCT02580721|Experimental|Thickened mucosa with ADM|Implants with platform switching (Astra Tech Implant System EV) will be placed and cover screws will be inserted. Acellular dermal matrix, thick 1 x 4 cm will be used for vertical soft tissue augmentation.
3203982|NCT00929552|Experimental|Fish oil|Daily dose = 6g fish oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day. The fish oil was micro-incapsulated.
3203983|NCT00929552|Active Comparator|Vegetable oil (Mix of canola, palm and soy oil)|Daily dose = 6g vegetable oil baked into rye bread and wheat rolls. Participants were asked to consume two slices of rye bread and one wheat roll pr day.
2547746|NCT02579902|Active Comparator|Vitamin D3|50000 IU vitamin D3 capsule, one capsule every 2 weeks for 6 months.
2547747|NCT02579902|Placebo Comparator|placebo|Placebo capsule, one capsule every 2 weeks for 6 months.
2547817|NCT02579395|Experimental|With spouse/romantic partner|
2547821|NCT02579395|Experimental|Without spouse/romantic partner|
2547823|NCT02579395|Other|Control|No Intervention
2547887|NCT02578953|Experimental|Sequence 1-Dutasteride test product and then Reference product|Participants will receive treatment A in period 1 and treatment B in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
2547888|NCT02578953|Experimental|Sequence 2-Dutasteride reference product and then test product|Participants will receive treatment B in period 1 and treatment A in period 2. Where treatment A= dutasteride 0.5 mg capsule test product, treatment B= dutasteride 0.5 mg capsule reference product.
2547926|NCT02578576||patients with flare-up|Disease flare-up is demonstrated by coloscopy at one month after resection.
2547927|NCT02578576||patients without flare-up|No flare-up is found by coloscopy at one month after resection.
2547968|NCT02578355||Coronary CT Angiography (CCTA)|Patients included in the OPeRA Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
2548030|NCT02577939|Experimental|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
2548071|NCT02577575|Experimental|Oxytocin|40 IU Oxytocin
2548074|NCT02577575|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2548138|NCT02577237|Experimental|Intervention Group: Caregiver education|The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
2548139|NCT02577237|Active Comparator|Control Group: educational booklet|The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
2548166|NCT02576769||Basal cell carcinoma|Basal cell carcinoma
2548209|NCT02576665|Experimental|Toca 511/Toca FC|"Toca 511: 14 mL intravenously daily for 3 days followed by up to 4 mL intratumorally or into resection cavity walls following biopsy or resection. Cutaneous melanoma patients may receive intralesional injections (up to 4 mL) daily for 5 days.~Toca FC: 220 mg/kg/day orally starting at Week 5-6. Cycles are 5- to 7- day courses of treatment every 4 to 6 weeks."
3203984|NCT00929565||Lung cancer|Comparison between individuals with and without pulmonary malignancy
3203985|NCT00929591|Active Comparator|tamoxifen for five years|tamoxifen for five years
2548444|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
2548446|NCT02575326|Other|Intervention|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
2548497|NCT02575001||Type 1 diabetes|"Children with Type 1 diabetes, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Cortisol release test, Procedure/Surgery: Saliva cortisol measurement."
2548498|NCT02575001||Healthy control|"Healthy primary school pupils, age from 8 to 15 years.~The following interventions/exposures will be administered:~Behavioral: Psychological background determinations, Genetic: Genetic susceptibility determination, Procedure/Surgery: Saliva cortisol measurement."
3203986|NCT00929591|Experimental|CAF followed by tamoxifen for five years|intermittent CAF X 6 courses followed by tamoxifen for five years
3203987|NCT00929591|Experimental|CAF with concurrent tamoxifen for five years|intermittent CAF X 6 courses with concurrent tamoxifen for five years
2548643|NCT02574026|Experimental|Psychomotor tasks|20 healthy subjects and 10 tetraplegic patients will participate to acquisition of MEG, EEG, MRI data during a motor tasks
2548706|NCT02573766|Experimental|Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
2548712|NCT02573766|Sham Comparator|Sham Neurofeedback Training|Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions. Participants asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback and again at the conclusion of the session. Participants complete assessments again at the end of treatment and 1 month (+/- 2 weeks) later. Participants undergo an EEG at baseline, during each neurofeedback session, and within 7 days of the conclusion of treatment. Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
2548716|NCT02573766|Other|Standard of Care|Seven questionnaires regarding symptoms and quality of life completed at baseline, at follow up, and again in one month. Participants receive EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month.
3321421|NCT02018731|Experimental|Metformin and Metformin & L-Citrulline|1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
3321422|NCT02018731|Experimental|L-Citrulline and Metformin & L-Citrulline|15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
2547897|NCT02578849||PD_no_LID|Patients with Parkinson´s disease without dyskinesia
2547904|NCT02578849||PD_LID|Patients with Parkinson´s disease with L-DOPA induced dyskinesia
2547905|NCT02578849||HC|Health controls, age-mathced.
2547957|NCT02578511|Experimental|Ixazomib (MLN9708) in combination with standard POMP/D|"Patients who are receiving maintenance therapy with the POMP/D (Methotrexate, 6-Mercaptopurine, Vincristine, Prednisone/Dexamethasone) will be enrolled. Each cycle will be 28 days. The patients will receive IV vincristine, dexamethasone or prednisone, methotrexate and 6 - Mercaptopurine. Ixazomib will be administered on days 1, 8 and 15.~Both prednisone and dexamethasone are acceptable drugs in maintenance therapy. For example, in the HyperCVAD regimen or the CALGB 8811 prednisone is used. Patients will continue the same maintenance regimen they are receiving and ixazomib will be added to that."
2547998|NCT02578043|Experimental|Clindamycin and BPO Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% applied to the face once daily for 84 days.
2548000|NCT02578043|Active Comparator|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) applied to the face once daily for 84 days.
2548002|NCT02578043|Placebo Comparator|Placebo|Placebo (vehicle of the test product) applied to the face once daily for 84 days.
2548066|NCT02577692|Experimental|Oxygen|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
2548067|NCT02577692|Experimental|Ambient|Day 1: breathing of 100% oxygen; Day 2: ambient air breathing
2548118|NCT02577276|Experimental|Tele-motion rehabilitation system|Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
3169323|NCT00561249|Experimental|1|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo.
3169324|NCT00561249|No Intervention|2|No intervention
2548310|NCT02576275|Experimental|Duvelisib + Rituximab + Bendamustine|"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.~Bendamustine is administered as an intravenous (IV) infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
2548311|NCT02576275|Placebo Comparator|Placebo + Rituximab + Bendamustine|"Placebo is administered orally and supplied as formulated capsules to match the active 5 mg and 25 mg capsules of duvelisib.~Bendamustine is administered as an IV infusion and is supplied for injection in single-use vials at two strengths, 25 mg and 100 mg.~Rituximab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg and 500 mg."
2548331|NCT02575963|Experimental|Phase 1 (Completed)|"Cytarabine + Lintuzumab-Ac225 Cytarabine days 1 to 10 of each cycle. Doses were divided into 2 equal fractions with the first fraction given approx. 4-7 days after 1 cycle of low dose cytarabine and the second fraction given 4-7 days after the first fraction, followed by up to 11 more cycles. Furosemide (Phase 1 only) and Spironolactone were administered after Lintuzumab-Ac225.~Experimental: Phase 2~Experimental: Lintuzumab-Ac225 The Phase II dose determined during the Phase I dose escalation was 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8. Spironolactone is administered after Lintuzumab-Ac225."
3169325|NCT00561288|Experimental|1|2000 mg acetaminophen per day
3169326|NCT00561288|Placebo Comparator|2|2000 mg cornstarch per day
3169327|NCT00561301|No Intervention|1|
3169328|NCT00561327||A|Patients chronically treated with drug losartan
3169329|NCT00561327||B|Patients not chronically treated with losartan
3169330|NCT00561366|Placebo Comparator|1|
3169331|NCT00561366|Experimental|2|
3169332|NCT00561379|Active Comparator|1|
3169333|NCT00561379|Active Comparator|2|
3169334|NCT00561405|Experimental|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner.
3169335|NCT00561405|Active Comparator|Body weight supported treadmill training|Body Weight Supported Treadmill Training. Participants walk on a treadmill while partially supported with an overhead harness system. Mass repetition of the normal gait cycle is encouraged through the support of the harness, the movement of the treadmill, and the assistance of one or two trainers to position limbs and trunk.
3169336|NCT00561444||Quality of Life Study|Prostate cancer patients
3169337|NCT00561483||Observation|Patients admitted to the hospital with decompensated heart failure
3169338|NCT00561496|Other|Twice daily|Tenofovir gel intravaginal twice daily for 14 days
3169339|NCT00561496|Other|Once daily|Tenofovir gel intravaginal once daily for 14 days
3169340|NCT00561509||A|SSRIs
3169341|NCT00561509||B|Dual antidepressants
3169342|NCT00561522|Experimental|Intervention treatment|Capecitabine
3169343|NCT00561522|No Intervention|No intervention treatment|No other preventive treatment
3169344|NCT00561535|Experimental|A|Lactobacillus FARCIMINIS
3169345|NCT00561535|Placebo Comparator|B|Placebo
3169346|NCT00561548|Other|A|Patients with active Crohn disease and with azathioprine treatment
3169347|NCT00561548|Other|B|Patient with active crohn disease and without azathioprine disease
3169348|NCT00561561|Experimental|1|Subjects with schizophrenia
3169349|NCT00561561|Active Comparator|2|Health controls
3169350|NCT00561561|Active Comparator|3|Family members of subjects with schizophrenia
3169351|NCT00561561|Active Comparator|4|Family members of healthy controls
3169352|NCT00561587|Active Comparator|1|
3169353|NCT00561587|No Intervention|2|
3169354|NCT00561613|Placebo Comparator|1|SILCS with K-Y Jelly
3169355|NCT00561613|Active Comparator|2|SILCS with N-9
3169356|NCT00561626|Experimental|A|
3169357|NCT00561626|Experimental|B|
3169358|NCT00561717|Experimental|Arm 1|
3169359|NCT00561717|Active Comparator|Arm 2|
3169360|NCT00561717|Active Comparator|Arm 3|
2547738|NCT02579642|Experimental|Ketamine|Propofol at usual induction doses for ECT (0.75 - 1 mg/kg IV bolus) with the addition of low-dose ketamine 0.2 mg/kg (or 0.5 mg/kg - see interim analysis)
2547815|NCT02579408||LDLT donor|Donors of living donor-related liver transplantation
2547886|NCT02579044|Other|Everolimus and Lonafarnib|Single arm. Phase I: Lonafarnib with escalating doses of everolimus to determine MTD Phase II: Lonafarnib plus everolimus at MTD (efficacy assessment)
2547943|NCT02578498|Placebo Comparator|High carbohydrate diet|high carbohydrate intake
2547954|NCT02578498|Active Comparator|Low carbohydrate diet|low carbohydrate intake
2548038|NCT02578121|Experimental|Ixazomib, Pomalidomide, Dexamethasone|Protasome/IMiD combination of Ixazomib 4mg days 1, 8, and 15, Pomalidomide 4mg days 1-21 amd Dexamethasone 20 mg days 1, 8, 15 and 22 of a 28 day cycle
2548063|NCT02577549|Experimental|Diet & Exercise|Participants will attend an exercise class 3 days/week for 18 months. The exercise program will consist of a 15-minute aerobic phase, a 20-minute strength training phase, a second 15-minute aerobic phase, and a 10 minute cool down phase. Participant's will also attend individual and group diet sessions. Each participant's minimum weight loss goal will be 10% of baseline body weight.
2548065|NCT02577549|Active Comparator|Attention Control|The attention control intervention will cover an 18-month period. There will be four total face to face group meetings over the 18 months, with one meeting each at months 1, 6, 12, and 18; and during the other months (months 2-5, 7-11, 13-17) participants will receive a combination of informational packets, webinars, and/or emails based on continued monitoring of participant needs and delivered via their preferred mode of contact.
2548119|NCT02577289|Active Comparator|Control group ( Hydroxyappetite)|Patients will undergo open sinus lift using nano crystalline hydroxyapatite as augmentation material and placing implants simultaneously then evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)
2548121|NCT02577289|Experimental|Test group (PRF)|Patients will undergo open sinus lift using PRF as sole augmentation material and placing implants simultaneously then Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)
2548160|NCT02576912|Experimental|Active Delta-9-THC and Placebo Pregnenolone|
2548170|NCT02576912|Experimental|Active Delta-9-THC and Active Pregnenolone|
2548176|NCT02576912|Experimental|Placebo Delta-9-THC and Active Pregnenolone|
2548181|NCT02576912|Placebo Comparator|Placebo Delta-9-THC and Placebo Pregnenolone|
2548299|NCT02576392|Experimental|Intervention|Informational letter mailed approximately 2 weeks prior to surgery, informational letter mailed approximately 2 weeks post surgery, pharmacist call if refill opioid medicine more than 28 days after surgery
2548306|NCT02576392|No Intervention|Control|Usual Care
3203988|NCT00929604|No Intervention|Standard of care|Standard of care arm: utilizes the current standard of care per Zambian national guidelines to determine treatment failure and eligibility for second-line ART. HIV-1 viral load measurement is performed if the criteria for either immunologic (i.e., CD4+ lymphocyte count-based) or clinical treatment failure are fulfilled. If both immunologic and clinical treatment failure criteria are fulfilled, the ART regimen is changed to second-line without VL testing.
3203989|NCT00929604|Experimental|Routine HIV-1 viral load testing|Routine viral load testing arm: Routine HIV viral load testing at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30 and 36 months thereafter.
2548430|NCT02575430||Subjects with IRD|IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
2548480|NCT02575040|Other|Fecal microbiota transplantation|Fecal microbiota transplantation only
2548542|NCT02574767|Experimental|Lifestyle counseling + PUFA supplement|Home-based Diet and Physical activity plus n3LC-PUFAs supplementation
2548545|NCT02574767|Experimental|Routine diet & PA + PUFA Supplementation|Routine Diet & Physical Activity counseling care plus n3LC-PUFAs supplementation.
2548552|NCT02574767|Experimental|Lifestyle counseling + PUFA placebo|Home-based Diet and Physical Activity plus placebo for n3LC-PUFAs supplementation.
2548556|NCT02574767|Placebo Comparator|Routine diet & PA + PUFA placebo|Routine Diet & Physical Activity counseling plus placebo for n3LC-PUFAs supplementation.
2548624|NCT02574117|Experimental|flap with corticotomy and bone allograft|Maxillary expansion with quad helix appliance was applied to posterior teeth with cross bite. Then corticotomy surgical procedure associated with addition of commercially available bone allograft; demineralized freeze-dried bone allograft on the buccal surface of maxillary 1st premolar, 2nd premolar and 1st molar areas.
2548703|NCT02573831|Placebo Comparator|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if needed
2548709|NCT02573831|Experimental|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
2548827|NCT02572804|Active Comparator|Rectus Sheath Catheter Group|Patients will have rectus sheath catheters surgically inserted with infusion of 0.125% Bupivicaine at 5mls an hour.
2548828|NCT02572804|Active Comparator|Epidural Group|Patients will have a standard epidural placement with infusion of 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response
2548878|NCT02572661|Other|Squamous Head and Neck Cancer|radiation
2548929|NCT02572349|Experimental|IW-1701|Single Dose
2548931|NCT02572349|Placebo Comparator|Matching Placebo for IW-1701|Single Dose
2548995|NCT02571959|Experimental|amoxicillin and clavulanic acid|All volunteers receive a dose of amoxicillin and clavulanic acid
2549145|NCT02570737||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
2549148|NCT02570737||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
2549225|NCT02570334|Experimental|HIV-infected children diagnosed before 7 months of life|HIV-infected children diagnosed before 7 months of life
2549230|NCT02570334|Experimental|HIV-exposed uninfected children|HIV-uninfected children born to HIV-infected mothers
2549234|NCT02570334|Experimental|HIV-unexposed uninfected children|Children born to HIV-uninfected mothers
2549296|NCT02569905|Active Comparator|Groups Parecoxib sodium|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2547772|NCT02579707|Active Comparator|Treatment B: Fed|Treatment B: Single oral dose of AG-120 at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
2547774|NCT02579707|Experimental|Part 2 Single Dose|PART 2 is an open-label study to determine the safety and PK parameters of a single 1000-mg oral dose of AG-120.
2547818|NCT02579291|Experimental|Dry needling|The experimental group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system. In addition, this group will receive a single session of dry needling into the tibialis posterior muscle with a disposable stainless steel needle (0.3mm x 50mm)
2547820|NCT02579291|Active Comparator|Bobath|This group will receive a single session of Bobath therapy including techniques targeting modulation of central nervous system.
3203990|NCT00929617|Experimental|1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
3203991|NCT00929617|Other|2. Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
2547958|NCT02578368|Experimental|Arm A: FLOT chemotherapy + surgery (OP)|"4 cycles (8 weeks) FLOT pre-OP - surgery - 4-8 cycles FLOT (8-16 weeks) post-OP~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
2547969|NCT02578368|Active Comparator|Arm B: FLOT chemotherapy alone|"4 cycles (8 weeks) FLOT followed by further 4-8 cycles FLOT (8-16 weeks)~Docetaxel (50 mg/m2) in 250 ml sodium chloride (NaCl) 0.9% i.v. for 1 h, d1; Oxaliplatin (85 mg/m2) in 500 ml G5% (glucose 5%) i.v. for 2 h, d1; Leucovorin (Ca-folinate) (200 mg/m2) in 250 ml NaCl 0.9% i.v. for 1 h, d1*; 5-FU (2600 mg/m2) continuous infusion for 24 h, d1; Repeated every two weeks (qd15).~* Leucovorin can be replaced by sodium folinate. Dose adjustment necessary if levo-leucovorin is used instead of racemic leucovorin mixture.~For HER-2 positive disease, trastuzumab should be added:~Trastuzumab 4 mg/kg body weight (6 mg loading dose at 1st administration), i.v. for 1 h, d1"
2548051|NCT02577809|Active Comparator|Morphine100|1.8ml 0.5% hyperbaric bupivacaine with 0.1mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
2548052|NCT02577809|Active Comparator|Morphine50|1.8ml 0.5% hyperbaric bupivacaine with 0.05mg preservative-free morphine (mixed in 0.4ml normal saline to a volume of 2.3ml) administered into the intrathecal space
2548053|NCT02577809|Active Comparator|Fentanyl25|1.8ml 0.5% hyperbaric bupivacaine with 25μg fentanyl (2.3ml volume) administered into the intrathecal space
2548109|NCT02577419|Experimental|Target Fortification|
2548111|NCT02577419|Experimental|Higher Initial Concentration|
2548114|NCT02577419|Active Comparator|Portagen Growth Reference|
2548155|NCT02576964|Experimental|Capecitabine + Peginterferon alfa-2a|Treatment-naive participants with advanced liver cancer will receive combination treatment with capecitabine (1000 milligrams per meter-squared [mg/m^2] twice daily orally on Days 1 to 14 of each 21-day cycle) and peginterferon alfa-2a (180 micrograms (mcg) subcutaneous [SC] every week during each 21-day cycle) until at least 6 cycles (18 weeks) or disease progression, intolerable toxicity, or consent withdrawal.
2548222|NCT02576548|Experimental|MEDI4276 0.05 mg/kg|Participants received IV dose of 0.05 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548228|NCT02576548|Experimental|MEDI4276 0.1 mg/kg|Participants received IV dose of 0.1 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548235|NCT02576548|Experimental|MEDI4276 0.2 mg/kg|Participants received IV dose of 0.2 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548239|NCT02576548|Experimental|MEDI4276 0.3 mg/kg|Participants received IV dose of 0.3 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548244|NCT02576548|Experimental|MEDI4276 0.4 mg/kg|Participants received IV dose of 0.4 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548247|NCT02576548|Experimental|MEDI4276 0.5 mg/kg|Participants received IV dose of 0.5 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548254|NCT02576548|Experimental|MEDI4276 0.6 mg/kg|Participants received IV dose of 0.6 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548260|NCT02576548|Experimental|MEDI4276 0.75 mg/kg|Participants received IV dose of 0.75 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548266|NCT02576548|Experimental|MEDI4276 0.9 mg/kg|Participants received IV dose of 0.9 mg/kg MEDI4276 every three weeks (Q3W) for 2 years.
2548339|NCT02576171|Experimental|Group-therapy + ICBT|This is an open trial with only one study arm
2548388|NCT02575755|Experimental|Efficacy Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
2548393|NCT02575755|Active Comparator|Efficacy Study Control: National Standard Treatment|At baseline, participants receive a single dose of sulfadoxine-pyrimethamine comprising 1,500 mg of sulfadoxine and 75 mg pyrimethamine in tablet form
2548394|NCT02575755|Experimental|Pharmacokinetic Study: Azithromycin plus piperaquine|At baseline, participants receive three daily doses (0, 24 and 48 hours) of i) 1 g azithromycin as 2 x film-coated 500 mg tablets ii) 960 mg piperaquine tetraphosphate tablets as 3 x 320 mg tablets
2548412|NCT02575456|Experimental|Group A|(4×10^10vp/vial, 4 vials): 1 ml sterilization injection water per dose to dilute 2 vials (4×10^10 vp/vial), one shot in each arm, total dose of 1.6×10^11vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2548413|NCT02575456|Experimental|Group B|(4×10^10vp/vial, 2 vials): 1 ml sterilization injection water per dose to dilute 1 vial (4×10^10vp/vial), total dose of 8×10^10vp, one shot in each arm. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2548414|NCT02575456|Placebo Comparator|Group C|(0 vp/ vial, 2 vials):1 ml sterilization injection water per dose to dilute 1 vial, total dose of 0 vp. The inoculation site was the central lateral deltoid in the upper arm, and inoculation route was intramuscular injection
2547782|NCT02579460|Experimental|Barrett's esophagus patients|Patients with Barrett's Esophagus will be enrolled. The intervention is cessation of acid-suppressing medications. Biopsies will be taken during endoscopy at Day 0, 7, and 14.
2547819|NCT02579239|Experimental|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
2547822|NCT02579239|Placebo Comparator|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
2547877|NCT02578927|Experimental|GT+Ex|Ingestion of one dose of 2 g of green tea (GT) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
2547878|NCT02578927|Placebo Comparator|PL+Ex|Ingestion of one dose 2 g of placebo (PL) ingested at 10 minutes after the period of rest. After the Ingestion, the volunteers practice aerobic exercise (EX) in treadmill.
2547880|NCT02578927|Active Comparator|Green Tea|Ingestion of one dose 2g of green tea (GT) at 10 minutes after the period of rest. In this section the volunteers does not practice aerobic exercise.
3203992|NCT00929630|Experimental|glue (Tissucol ) treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
3203993|NCT00929630|Active Comparator|Seton treatment|patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
3203994|NCT00929682|Experimental|Levobupivacaine 0.568mg.mL|
2548044|NCT02577848|Experimental|GLP-1 group|liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
2548047|NCT02577848|Placebo Comparator|placebo|placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
2548090|NCT02577497|Experimental|Beclomethasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
2548094|NCT02577497|Experimental|fluticasone|Subjects are being randomized to 8 weeks of beclomethasone or fluticasone treatment followed by a 4 week study drug washout with resumption of standard asthma medication regimen for 4 weeks, followed by 8 weeks of beclomethasone or fluticasone (whichever drug was not taken the first 8 weeks)
3203995|NCT00929682|Other|Levobupivacaine 1.136mg.mL|
2548202|NCT02576717|Experimental|1 mg RPC1063 (Ozanimod) oral capsule|1 mg RPC1063 (Ozanimod) oral capsule daily
2548485|NCT02575209||Women schiz.|Women with recent diagnosis of schizophrenia
2548486|NCT02575209||Men schiz.|Men with recent diagnosis of schizophrenia
2548490|NCT02575209||Women healthy|Women without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
2548491|NCT02575209||Men healthy|Men without diagnosis of schizophrenia or other neurological and/or psychiatric diagnosis
2548547|NCT02574689|Experimental|HIPP Intervention|The physical activity intervention emphasizes behavioral strategies for increasing activity levels (i.e., goal-setting, self-monitoring, problem-solving barriers, increasing social support, rewarding oneself for meeting physical activity goals), and includes regular mailings (three mailings in month 1, two mailings in months 2 and 3, one mailing in months 4, 5, 6, 8, and 10) of physical activity manuals that are matched to the participant's current level of motivational readiness and individually-tailored computer expert system feedback reports.
2548554|NCT02574689|Active Comparator|Wellness Contact Control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the ACS website (www.cancer.org) will be mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
3203996|NCT00929721|Other|Subjects with Community-Acquired Pneumonia|Subjects with Community-Acquired Pneumonia
3203997|NCT00929747|Active Comparator|Toric IOL|AcrySof IQ Toric IOL
3203998|NCT00929747|Active Comparator|Limbal Relaxing Incision|AcrySof IQ with Limbal Relaxing Incision
2548702|NCT02573753|Experimental|sleep restriction|Sleep restriction
2548705|NCT02573753|No Intervention|normal sleep|Normal sleep
2548710|NCT02573753|Experimental|weight gain|Weight gain
2548747|NCT02573415|Experimental|Uterus Transplantation|Women will undergo deceased donor uterine transplantation after IVF.
2548758|NCT02573090|Experimental|Non-invasive resin based fissure sealing|Application of resin based fissure sealing after acid etching of carious occlusal surface
2548763|NCT02573090|Active Comparator|Invasive resin based restoration|Application of resin based resin restoration after operative intervention of caries lesion, excavation and preparation on occlusal surface
2548833|NCT02572921|Experimental|Positive Psychotherapy|Experimental Group (Positive Psychotherapy)
2548842|NCT02572921|Active Comparator|Cognitive Behavioral Therapy|Active Control Group (Cognitive Behavioral Therapy)
3321423|NCT02018757|Experimental|As2O3|Subjects will be treated with TACE containing As2O3
3203999|NCT00929760|Active Comparator|nephrologists|Combined management PCP: nephrologists (at least 4 nephrology visits/year)
3204000|NCT00929760|Active Comparator|Primary Care Physicians|Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG
3204001|NCT00929786||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
3204002|NCT00929799|Experimental|Growth Hormone|Therapy with recombinant human GH (Genotropin® 1 mg = 3 IU, Pfizer Inc., NY, USA) daily by subcutaneous injection using a Genotropin pen at maximal GH dose of 0.003 mg/kg/day in patients with severe GHD
3204003|NCT00929812|Active Comparator|Glucagon hydrochloride|GlucaGen® 1 mg/1 ml intramuscularly
3204004|NCT00929812|Placebo Comparator|Placebo|1 ml NaCl 0.9%
3204005|NCT00929825|Experimental|Elastomers|Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
3321424|NCT02018757|Placebo Comparator|placebo|Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide
2547786|NCT02579473|Experimental|Cohort 3|"Subjects in Cohort 3 will receive a single SC injection of 50 mg SER-214 at the beginning of week one, followed by a single SC injection of 100 mg SER-214 at the beginning of week two, followed by a single SC injection of 200 mg SER-214 for two consecutive weeks, followed by a two week wash-out period, to determine PK and terminal wash-out PK of rotigotine and pro-drug SER-214."
2547839|NCT02579187|Placebo Comparator|control group|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). A biodegradable sponge (type I bovine collagen) to stabilize the blood clot will be placed.The site will be stabilized with a simple external, cross mattress suture. Blood , wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2547842|NCT02579187|Active Comparator|Experimental group 1|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2547845|NCT02579187|Active Comparator|Experimental group 2|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2547848|NCT02579187|Active Comparator|Experimental group 3|CBCT scan limited to the dental arch that includes the study site will be obtained. All subjects will receive local infiltrative anesthesia, following which minimally invasive tooth extraction will be performed. After tooth extraction clinical measurements of the site will also be obtained and recorded for both groups (i.e. keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness). 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) will be locally delivered. The site will be stabilized with a simple external, cross mattress suture. Blood, wound fluid, and saliva samples will be taken periodicallly. In addition, photos/videos, periapical xrays and PVS impressions will be obtained.
2547952|NCT02578290|Experimental|Treatment|Clinical Decision Support (CDS)
2547961|NCT02578290|No Intervention|Control|Will not receive Clinical Decision Support (CDS)
2548006|NCT02578095|Placebo Comparator|Placebo|Placebo QD
2548008|NCT02578095|Experimental|VK5211- 0.5mg|0.5mgQD
2548012|NCT02578095|Experimental|VK5211- 1.0mg|1.0mg QD
2548014|NCT02578095|Experimental|VK5211- 2.0mg|2.0mg QD
2548061|NCT02577536||1 All Subjects|No interventions
3204006|NCT00929825|Experimental|TENS|TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
3204007|NCT00929825|Experimental|Elastomers+TENS|Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
2548172|NCT02576834|Experimental|CTSP + SAU|10 sessions of Cognitive Therapy for Suicide Prevention (CTSP) provided over 6 months, with optional 9 booster sessions + SAU
2548179|NCT02576834|Other|Services as Usual (SAU)|client receives services they would normally receive within the community
2548223|NCT02576561|Experimental|TVGV-1 (cohort 1)|Antigen + Adjuvant - 0.6 mg lyophilized PEK fusion protein + 0.6 ml* GPI- 0100 (1:1 ratio)
2548231|NCT02576561|Active Comparator|GPI-0100 (cohort 1)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml* GPI- 0100 (1:1 ratio)
2548236|NCT02576561|Placebo Comparator|Placebo (cohort 1)|Placebo- 0 mg lyophilized PEK fusion protein. 0.6 mg lyophilized placebo cake + 0.6 ml placebo-diluent (1:1 ratio)
2548240|NCT02576561|Experimental|TVGV-1 (cohort 2)|Antigen + Adjuvant - 0.9 mg lyophilized PEK fusion protein + 0.9 ml* GPI- 0100 (1:1 ratio)
2548243|NCT02576561|Active Comparator|GPI-0100 (cohort 2)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml* GPI- 0100 (1:1 ratio)
2548249|NCT02576561|Placebo Comparator|Placebo (cohort 2)|Placebo - 0 mg lyophilized PEK fusion protein. 0.9 mg lyophilized placebo cake + 0.9 ml placebo diluent (1:1 ratio)
2548255|NCT02576561|Experimental|TVGV-1 (cohort 3)|Antigen + Adjuvant - 1.2 mg lyophilized PEK fusion protein + 1.2 ml* GPI- 0100 (1:1 ratio)
2548259|NCT02576561|Active Comparator|GPI-0100 (cohort 3)|Adjuvant Alone - 0 mg lyophilized PEK fusion protein + 1.2 mg lyophilized placebo cake 1.2 ml* GPI- 0100 (1:1 ratio)
2548264|NCT02576561|Placebo Comparator|Placebo (cohort 3)|Placebo - 0 mg lyophilized PEK fusion protein. 1.2 mg lyophilized placebo cake + 1.2 ml placebo-diluent (1:1 ratio)
3204008|NCT00929825|No Intervention|No therapy (control)|Patients will not receive intervention
2548424|NCT02575391|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
2548477|NCT02575157|No Intervention|Discontinuing usage|Patients will discontinue use of bisphosphonates. Bone markers and BMD will be monitored until a need for reinitiation of treatment within 2-years is identified or needed.
2548508|NCT02574819|Experimental|Drug|Methylnaltrexone (MNTX) nearly 0.15mg/kg administered every other day for 2 weeks.
2548510|NCT02574819|Placebo Comparator|Placebo|Placebo administered every other day for 2 weeks.
2548597|NCT02574208|Active Comparator|"HIV testing by ELISA"|Patients enrolled in this arm will be tested by usual HIV Elisa
2548600|NCT02574208|Experimental|"HIV testing by rapid test"|Patients enrolled in this arm will be tested by the new rapid HIV test
2547812|NCT02579226|Experimental|Part B|Part B will include patients with relapsed or refractory small-cell lung cancer (SCLC). Patients will receive AZD2811 monotherapy at the recommended Phase 2 dose (RP2D).
2547862|NCT02579018|Experimental|Anorexia Nervosa (AN)|Diagnosis of anorexia spectrum disorder and stable use of all medications ≥ three months.
2547865|NCT02579018|Experimental|Matched Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Also age (+/- 2 years) and gender matched to AN study participant and exercise regularly.
2547866|NCT02579018|Experimental|Healthy Controls|No diagnosis of anorexia spectrum disorder. Stable use of all medications ≥ three months. Do not exercise regularly.
2547908|NCT02578719|Placebo Comparator|drug: bupivacaine|Placebo comparator: bupivacaine first 3 months 0.5% 1 cc bupivacaine diluated with 1.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
2547909|NCT02578719|Placebo Comparator|placebo|first 3 months 2.5 cc saline enjection will be used in GON block once a month. If effectiveness is proved then blindness will be opened and all patients will be blocked by 0.5% 1 cc bupivacaine diluated with 1.5 cc saline once a month for 3 months.
2547946|NCT02578472|Experimental|Group 1 (Sequence ABC)|Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2547950|NCT02578472|Experimental|Group 2 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2547962|NCT02578472|Experimental|Group 3 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
2547973|NCT02578472|Experimental|Group 4 (Sequence ABC)|Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
2547977|NCT02578472|Experimental|Group 5 (Sequence BCA)|Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
2547979|NCT02578472|Experimental|Group 6 (Sequence CAB)|Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
3204009|NCT00929851|Experimental|BDP/FF|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose inhaler
3204010|NCT00929851|Active Comparator|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
2548161|NCT02577068|Active Comparator|nefopam group|
2548171|NCT02577068|Active Comparator|propacetamol group|
2548178|NCT02577068|Experimental|nefopam and propacetamol group|
3204011|NCT00929877|Experimental|Ketoprofen lysinate 12.5 mg|
3204012|NCT00929877|Experimental|Ketoprofen lysinate 6.25 mg|
2548350|NCT02575989|Active Comparator|1: control group|Classic - current management of trauma patients by French medical teams
2548352|NCT02575989|Experimental|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
2548409|NCT02575677||Parturients with oxycodone|Parturients who were given oxycodone
3204013|NCT00929877|Placebo Comparator|Matching placebo|
2548514|NCT02574780|Experimental|Grupo I TFC|Women with lymphedema , perform complex physical therapy with manual lymphatic drainage, compression bandaging and exercises linfomiocinéticos.
2548516|NCT02574780|Experimental|Grupo II TFC X PFM|Standard treatment for lymphedema perform complex physical therapy associated with a muscular strength protocol.Muscle-building arm with load
2548586|NCT02574286|Experimental|Velaglucerase alfa 60 U/kg|Participants will receive 60-minute intravenous infusion of 60 units per kilogram (U/kg) velaglucerase alfa every other week (EOW) and an oral daily dose of 800 IU vitamin D for 24 months (101 weeks).
2548634|NCT02573935|Experimental|Clarithromycin|Clarithromycin combined with VCD induction therapy
2548637|NCT02573935|Placebo Comparator|Placebo|Placebo combined with VCD induction therapy
2548715|NCT02573623||HIV-infected children with confirmed TB|Hospitalized children with TB confirmed by culture or GeneXpert
3204014|NCT00929890|Active Comparator|Lifestyle counseling|Patients will receive dietary counseling and a general advice on physical activity
3204015|NCT00929890|Experimental|Exercise training|patients will receive dietary counseling and will be enrolled in supervised exercise training
3204016|NCT00929903|Experimental|Treatment (pazopanib hydrochloride)|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3204017|NCT00929916||AM dosing of MoviPrep®|Take prep morning of exam
3204018|NCT00929916||PM/AM dosing of MoviPrep®|half of the volume of prep(1L) solution the evening prior, and half (1L) the morning of, colonoscopy.
3204019|NCT00929929|Experimental|L-Leucine|This arm receives a supplement of leucine along with a progressive resistance exercise program.
3204020|NCT00929929|Placebo Comparator|Maltodextrin|This arm receives a supplement of maltodextrin along with a progressive resistance exercise program.
3204021|NCT00929942|Experimental|DV Stent|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
2547814|NCT02579317|Experimental|Resonance Breathing|Breathing is paced to the cardiovascular resonance frequency where heart, respiratory, and brain signals become aligned. This can potentially positively impact cognitive-emotional functioning.
2547816|NCT02579317|Placebo Comparator|Non-Resonance Breathing|Breathing is paced at a non-resonance frequency. It does not align heart, respiratory, and brain signals, and thus does not impact cognitive-emotional functioning.
2547861|NCT02579031|Active Comparator|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent Orsiro
2547863|NCT02579031|Active Comparator|Xience|Durable-polymer everolimus-eluting stent Xience
2547918|NCT02578654|Experimental|Interventions|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
2547945|NCT02578433|Experimental|Mindful Self Compassion|Participants will receive a shortened form (6 weeks) of mindful self compassion meditation, once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
2547955|NCT02578433|Other|Progressive Muscle Relaxation|Participants will receive progressive muscle relaxation once a week for 75 minutes, furthermore they get an audio cd and a handout to practice during the week
2548016|NCT02578082|Experimental|Renal Impairment|Eight subjects with Severe Renal Impairment (eGFR <30 mL/min/1.73m2). Intervention is TD-4208, 175mcg, inhaled, single dose.
2548017|NCT02578082|Experimental|Normal Renal Function|"Eight healthy participants matched to participants with severe renal impairment.~Intervention is TD-4208, 175mcg, inhaled, single dose."
2548068|NCT02577705|Experimental|Self Empowerment Groups|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment and Peer Support curriculum, weekly for about 3 hours per week for 28 weeks.
2548069|NCT02577705|Experimental|Financial Empowerment|Intervention activities included helping participants to open savings accounts at a local federal credit union with 1:1 matches of up to twenty dollars per month for 12 months. Participants also received financial empowerment weekly for about 3 hours per week for 28 weeks.
2548070|NCT02577705|No Intervention|Control Group|The Control group did not receive assistance in opening a matched savings account, and were required by the County Assistance Office to participate in other Temporary Assistance for Needy Families (TANF) mandated work participation activities according to standard procedure.
2548149|NCT02577172|Experimental|Exercise group|Aerobic- and Strength Training program
2548151|NCT02577172|Active Comparator|Control group|One lifestyle counseling session
2548197|NCT02576730||Fratures|patient with foot and ankle fractures and surgery with ORIF
2548200|NCT02576730||healthy subjects|patients without foot and ankle fracture s
2548366|NCT02576093|Experimental|0.1% WOL071-007|Formulation containing 0.1% WOL071-007 for topical application
2548368|NCT02576093|Experimental|0.3% WOL071-007|Formulation containing 0.3% WOL071-007 for topical application
2548369|NCT02576093|Experimental|1.0% WOL071-007|Formulation containing 1.0% WOL071-007 for topical application
2548370|NCT02576093|Placebo Comparator|WOL071-007 Placebo|Formulation containing Placebo of WOL071-007 for topical application
2548405|NCT02575573||Admitted patients at the ED|
2548425|NCT02575378|Other|Metronomic chemotherapy|Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.
2548428|NCT02575378|Experimental|Metronimic chemotherapy plus Chinese Traditional Medicine|"Metronomic Chemotherapy for maintenance treatment with Capecitabine 300mg/m2 twice a day, everyday.~Chinese Traditional Medicine"
2548493|NCT02575092|Active Comparator|Group A, without hypertension|The patients who will not be taken the drugs of antihypertension and antihomocysteine.
2548494|NCT02575092|Experimental|Group B, hypertension|The hypertensive patients with their plasma Hcy levels <10 umol/L will be taken the drugs of antihypertension(Enalapril Maleate Tablets,as the program-based antihypertension)
2548495|NCT02575092|Experimental|Group C,hypertension and hyperhomocysteinemia|The hypertensive patients with their plasma Hcy levels ≥10 umol/L will be taken the drugs of antihypertension and antihomocysteine( Enalapril Maleate and Folic Acid Tablets,as the program-based antihypertension)
3204022|NCT00929955|Active Comparator|Ondansetron|
3204023|NCT00929955|Active Comparator|Simvastatin|
3204024|NCT00929955|Placebo Comparator|Placebo|
3204025|NCT00929968|Placebo Comparator|Placebo to VAK694|
2548618|NCT02574351||normal asthmatic|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group
3204026|NCT00929968|Experimental|VAK694|
3204027|NCT00929968|Active Comparator|Fluticasone propionate|
3204028|NCT00930007||Hyperandrogenemic|Girls with elevated free testosterone concentrations
3204029|NCT00930007||Controls|Girls with normal free testosterone concentrations
3204030|NCT00930020|Placebo Comparator|matching placebo pill|matching placebo
3204031|NCT00930020|Active Comparator|Oral minocycline|Minocycline 200mg
3204032|NCT00930033|Active Comparator|A|Nephrectomy + sunitinib
3204033|NCT00930033|Experimental|B|Sunitinib alone
3204034|NCT00930072|Experimental|Block|
3204035|NCT00930072|No Intervention|Standard Care|
3204036|NCT00930085|Experimental|SELDI-TOF MS|The proteic profiling is performed by SELDI-TOF mass spectroscopy.
3204037|NCT00930111|Active Comparator|2 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 2 weeks.
3204038|NCT00930111|Placebo Comparator|4 weeks|Attending physicians are physician-of-records for traditional inpatient ward team (housestaff and medical students) for 4 weeks.
3204039|NCT00930124|Experimental|1|Group 1 will receive Conventional orthognathic surgery
2547824|NCT02579252|Experimental|AADvac1|"AADvac1 is a suspension for subcutaneous injection. AADvac1 is provided in single-use vials. Dosage: 40 µg Axon peptide 108 (coupled to keyhole limpet haemocyanin (KLH)) using aluminium hydroxide (containing 0.5 mg Al3+) as adjuvant, in a phosphate buffer.~Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses."
2547825|NCT02579252|Placebo Comparator|Placebo|Placebo is a suspension for subcutaneous injection. Placebo is provided in single-use vials. Dosage: aluminium hydroxide (containing 0.5 mg Al3+), in a phosphate buffer. Patients receive 6 doses in 4-week intervals, and then 5 individual booster doses in 3-month intervals, for a total of 11 doses.
2547913|NCT02578628|Active Comparator|Active|These subjects will continue to receive Patient Engagement services.
2547917|NCT02578628|No Intervention|Control|These patients will have all Patient Engagement services discontinued.
3169361|NCT00561717|Placebo Comparator|Arm 4|
3169362|NCT00561756|Experimental|Vaccine Therapy|This single arm, open-label, phase I clinical trial of xenogeneic CD20 DNA vaccination is designed to evaluate its safety in patients with B cell lymphoma. The study is a dose escalation study at three test doses, 0.5 mg, 2 mg and 4 mg of purified plasmid DNA per injection. There will be an initial cohort of three patients receiving a pre-level 1 dose of 0.1 mg/vaccination before proceeding to the three test doses.
2548001|NCT02578004||100 patients suffering from pressure ulcer|100 subjects were having at least one wound of pressure ulcer (74 men and 26 women) middle-aged (55.5±20 years) and were recruited from many services of three University Regional hospitals of Tunisia.
2548007|NCT02578004||213 healthy subjects|213 healthy subjects (125 men and 88 women) middle-aged (51.5±17 years). Although, healthy individuals, were included as controls, followed in the outpatient services of the University Hospital Farhat Hached and they considered clinically free of pressure ulcer and tissue necrosis.
2548100|NCT02577770|Experimental|200mg caffeine plus acupuncture|In healthy subjects
2548101|NCT02577770|Experimental|400mg caffeine plus acupuncture|In healthy subjects
2548103|NCT02577770|Placebo Comparator|Decaffeinated plus acupuncture|In healthy subjects
2548381|NCT02575820||RBC_old|shelf life of red blood cells of 15 or higher days
2548382|NCT02575820||RBC_new|shelf life of red blood cells 14 or lower days
2548423|NCT02575547||NC+CCRT|Patients treated with neoadjuvant chemotherapy(NC) (cisplatin and docetaxel) and CCRT (cisplatin)
2548463|NCT02575144|Experimental|BiRd|"Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows:~Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min. Patients with a calculated creatinine clearance of <60 cc/min will receive 15 mgs PO daily on days 1-21 of a 28 cycle.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle."
2548464|NCT02575144|Active Comparator|Rd|"Subjects on the Rd arm will receive Revlimid, and dexamethasone in 28-day cycles. Dosing is as follows:~Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up. Vomited doses will not be made up.Patients with renal failure will recived an ajusted dose.~Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle. Missed or vomited doses will not be made up. If subject cannot tolerate oral dexamethasone, it will be given intravenously. In patients over 75 years old, dexametasona oral will be given at dose of 20mg on days 1, 8, 15, 22 ."
2548559|NCT02574611|Experimental|SCI observational|"Individuals with SCI will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
2548561|NCT02574611|Experimental|Able-bodied observational|"Able-bodied individuals (non SCI) will undergo a one day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during a typical day (eating, sleeping, mobility, etc.)."
2548566|NCT02574611|Active Comparator|SCI drug group|Individuals with SCI will undergo a second day observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of neostigmine and glycopyrrolate.
2548568|NCT02574611|Placebo Comparator|SCI placebo group|Individuals with SCI will undergo a second day of observation following elective colonoscopy and placement of the colonic catheter. Investigators will be monitoring colonic motility during the transdermal administration of normal saline solution (placebo).
2548621|NCT02574091|Experimental|Cohort 1-Experimental|"4 healthy adult participants will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2548622|NCT02574091|Placebo Comparator|Cohort 1-Placebo|"2 healthy adult participants will be randomized to receive placebo (blank cream), applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2548623|NCT02574091|Experimental|Cohort 2-Experimental|"4 healthy adult participants will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2548626|NCT02574091|Placebo Comparator|Cohort 2-Placebo|"2 healthy adult participants will be randomized to receive matching placebo, applied twice daily for 7 consecutive days (final dose on the morning of Day 8).~The drug will be used topically to the back of each participant within an area of 15cm x 25cm."
2548631|NCT02574091|Experimental|Cohort 3-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 1% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2548648|NCT02574182||MCI subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
3169363|NCT00561769||A|poor responder
3169364|NCT00561782||Group 1|Spinal cord injured with chronic central neuropathic pain.
3169365|NCT00561782||Group 2|Spinal cord injured without chronic central neuropathic pain.
2547844|NCT02579174|Other|Custom (tibia) and manual (femur)|Knee replacement with Medacta GMK Sphere implants using custom instrumentation for the tibia component and manual instrumentation for the femur component
2547941|NCT02578277|Experimental|Single sequence, 3-period DDI (drug-drug interaction)|Single sequence
3169366|NCT00561782||Group 3|Able-bodied without history of chronic pain of any type
3169367|NCT00561782||Group 4|Traumatically Brain Injured with a history of pain that onset after their TBI
3169368|NCT00561808|Experimental|Observational|
3169369|NCT00561860|No Intervention|1|This pathway represents our standard clinical protocol when a patient has been diagnosed with sleep apnea and CPAP therapy is initiated. After prescription of CPAP, all patients will be seen by our CPAP coordinator and oriented to the device during a 20 minute session. Patients are also provided the telephone number of the CPAP coordinator who can be contacted if any problems or questions arise.
2548193|NCT02576743||Healthy subjects|Subjects with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning. 7 Tesla MRI
2548195|NCT02576743||Patients|Patients with an unruptured brain aneurysm or an unruptured arteriovenous malformation (AVM) with no contraindications to magnetic resonance imaging will undergo 4D flow MRI scanning 7 Tesla MRI
3169370|NCT00561860|Experimental|2|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
3169371|NCT00561886|Experimental|1|Patients with COPD receiving once 24 µg formoterol
2548452|NCT02575248|Experimental|Group A|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
2548457|NCT02575248|Active Comparator|group B|patients diagnosed laparoscopically with Endometriosis Stage 1 and Stage 2
2548518|NCT02574936|Other|modified Karydakis,surgical technique|a new surgical technique(modified Karydakis) to be compared with standard Karydakis
2548684|NCT02573649|Active Comparator|CLS-ON first|Closed-loop Stimulation on first
2548685|NCT02573649|Active Comparator|CLS-OFF first|Closed-loop Stimulation off first
2548941|NCT02572180|Active Comparator|NIRS-based NF in 3D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 3D virtual reality classroom environment.
2548946|NCT02572180|Active Comparator|NIRS-based NF in 2D|A near-infrared spectroscopy (NIRS)-based neurofeedback training in which participants learn to increase the BOLD signal in prefrontal cortical regions will take place in a 2D (normal computer screen) classroom environment.
2548952|NCT02572180|Active Comparator|EMG-based BF in 3D|An electromyogram (EMG)-based biofeedback training in which participants learn to self-regulate activity of the musculi supraspinatus will take place in a 3D virtual reality classroom environment.
3169372|NCT00561899|Experimental|1|SP+AQ
3169373|NCT00561899|Experimental|2|Piperaquine plus SP arm
3169374|NCT00561899|Experimental|3|Du-Cotecxin
3169375|NCT00561964|Experimental|1|
3169376|NCT00561964|Placebo Comparator|2|
3169377|NCT00561990|Active Comparator|Nimotuzumab|Nimotuzumab
3169378|NCT00561990|Placebo Comparator|Placebo|Placebo
3169379|NCT00562016|Experimental|IMPELLA LP 2.5|
3169380|NCT00562016|Active Comparator|IABP Intra-aortic balloon pump|
3169381|NCT00562029|Experimental|DJB patient|Patient has undergone a duodeno-jejunal bypass
3169382|NCT00562042||1|Patients diagnosed with acute pulmonary embolism were enrolled in this study.
3169383|NCT00562055|Experimental|Arm A|
3169384|NCT00562055|Active Comparator|Arm B|
3169385|NCT00562081|Placebo Comparator|1|Patient does not have 24/7 access to a Certified Asthma Educator.
3169386|NCT00562081|Active Comparator|2|Patient has 24/7 access to a Certified Asthma Educator.
3169387|NCT00562107|Experimental|1|AAIsafeR /SafeR Patient randomized with the SafeR switched ON
3169388|NCT00562107|Experimental|2|DDD(R) mode. Patients randomized with the SafeR mode switched OFF
3169389|NCT00562133|Experimental|1|One Day Treatment with Insulin Glulisine
3169390|NCT00562133|Active Comparator|2|One day Treatment with Human insulin
3169391|NCT00562146||1|Successful progression of spiral tube to duodenum within 3 days
3169392|NCT00562146||2|Failure of progression to duodenum within 3 days
3169393|NCT00562172|Experimental|1|
3169394|NCT00562172|Active Comparator|2|
3169395|NCT00562198|Experimental|1|Investigational drug Stalevo 200
3169396|NCT00562211|Experimental|1|
3169397|NCT00562211|Active Comparator|2|
3169398|NCT00562224|Experimental|Arm 1|All study subjects will receive PCI-24781 (study drug).
3169399|NCT00562237|Placebo Comparator|1|
3169400|NCT00562237|Experimental|2|
3169401|NCT00562237|Experimental|3|
3169402|NCT00562237|Experimental|4|
3169403|NCT00562237|Experimental|5|
3169404|NCT00562237|Experimental|6|
3169405|NCT00562237|Experimental|7|
3169406|NCT00562250|Experimental|Arm 1|
3169407|NCT00562250|Active Comparator|Arm 2|
3169408|NCT00562250|Active Comparator|Arm 3|
3169409|NCT00562263|Experimental|Lifestyle Modification|Parents are randomized to attend 12 educational sessions covering strategies to manage children's health behaviors.
3169410|NCT00562263|No Intervention|Control|Teen participates in lifestyle intervention, but parent does not attend parent education sessions
3169411|NCT00562276|Experimental|1|Immediate IUD insertion following suction aspiration between 5 and 12 weeks gestation
3169412|NCT00562276|No Intervention|2|Delayed IUD insertion 2-6 weeks following suction aspiration between 5 and 12 weeks gestation
3169413|NCT00562289|Active Comparator|aspirin|aspirin use like antiplatelet
3169414|NCT00562289|Experimental|anticoagulant|Antivitamins K or rivaroxaban or dabigatran or apixaban
3169415|NCT00562289|Experimental|Devices for PFO closure|Devices for PFO closure
3169416|NCT00562341||bariatric surgery|description of enrollees
3169417|NCT00562393|Experimental|Overfeeding|4 weeks of 1250 kcal added daily
2547853|NCT02579096|Active Comparator|Febuxostat / Sham Comparator (Allopurinol)|Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat
2547933|NCT02578602|Experimental|Diagnostic (gadoxetate disodium MRI)|Patients receive gadoxetate disodium IV and then undergo enhanced liver MRI.
2547989|NCT02578212|Placebo Comparator|Control|"All participants will also be introduced to the control cream: This cream is a control cream."
2547990|NCT02578212|Sham Comparator|Placebo|"All participants will then be introduced to an analgesia expectation: This cream is a powerful pain killer, while receiving an inert cream. In this study participants will be told that they will receive a potent painkiller as well as a control cream. Making use of placebo cream is an established method to induce placebo expectations . Moreover, to increase the analgesic effect, heat pain stimuli intensity will be surreptitiously lowered for the placebo trials to a temperature corresponding to 30% of the VAS intensity and to 60% for the control trials. As the occurrence of a placebo response is highly dependent on expectations, the deceptive procedure described above is used in order to maximally enhance expectations and therefore placebo response. Participants will be debriefed after the completion of study participation."
2548031|NCT02577952||People with Lipodystrophy & family|People currently living with lipodystrophy and their family members.
2548077|NCT02577614|Experimental|FEIBA|Single dose of commercially available FEIBA
2548080|NCT02577614|Placebo Comparator|Normal Saline|Single dose of NaCl 0.9%
2548144|NCT02577198|Experimental|Intervention|Electronic Health Records with computerised decision support system activated Medilogy Decision Support System (MediDSS)
2548145|NCT02577198|Other|Control|Electronic Health Records with computerised decision support system silenced Medilogy Decision Support System (MediDSS) silenced
2548162|NCT02576782|Active Comparator|perineural dexamethasone group|21 patients received perineural dexamethasone plus bupivacaine 0.5%
2548173|NCT02576782|Active Comparator|systemic dexamethasone group|21 patients received systemic (intravenous) dexamethasone plus perineural bupivacaine 0.5%
2548177|NCT02576782|Sham Comparator|control group|21 patients received only perineural bupivacaine 0.5% plus intravenous saline
2548219|NCT02576613|Experimental|MPP-S|at least 30 weekly sessions of modified psychodynamic psychotherapy
2548226|NCT02576613|Experimental|standard therapy (TAU)|clinical standard treatment, including supportive therapeutic contacts, pharmacotherapy, creative and occupational therapies, psychoeducation, group therapies, excluding structured individual or group psychotherapy
2548297|NCT02576314|Active Comparator|Sofosbuvir and Daclatasvir|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
2548298|NCT02576314|Active Comparator|Ledipasvir/sofosbuvir|Participants will receive Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet daily for 12 weeks.
2548325|NCT02576002||Pediatric PAH patients|US pediatric population with PAH in MarketScan database during the period 2010-2013
2548349|NCT02575872|Experimental|Exercise Intervention|Participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. Participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks.
2548351|NCT02575872|No Intervention|wait-list for intervention|Participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. After 12 weeks, patients are invited to participate in the physical behavior intervention as in Group I.
2548406|NCT02575690|Placebo Comparator|Placebo group|Obese patients with well-treated hypertension that receive placebo (pure microcrystalline cellulose)
2548407|NCT02575690|Experimental|Spirulina group|Obese patients with well-treated hypertension that receive Hawaiian spirulina (Cyanotech Corporation, Hawaii, US)
2548496|NCT02575014|Experimental|Preoperative HBOT|25 out of 50 patients will receive 2 preoperative hyperbaric oxygen therapy treatments, one the day before their operation, the other within 5 hours preceding their operation. The participants will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator. Day 0 will be the first day of their HBOT treatment, Day 1 will be the day of their operation and second/final HBOT treatment.
2548499|NCT02575014|No Intervention|No HBOT|25 out of 50 patients will not receive preoperative hyperbaric oxygen therapy. Day 1 will be the day of the operation.
2548599|NCT02574338|Active Comparator|group - 1 Foley's Catheter|will have cervical ripening with intracervical extraamniotic Foley's catheter for 24 hours
2548601|NCT02574338|Active Comparator|Group - 2 Prostaglandin E1 Analogue|will have cervical ripening with intravaginal misoprostol inserted into the posterior fornix every six hours to a maximum of four doses (24 hours)
2548645|NCT02573961|Active Comparator|laser|Subjects will receive 24 activated laser acupuncture group treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points. In addition they will be instructed to take a tailored low caloric diet
2548653|NCT02573961|Active Comparator|high protein low carbohydrate diet|Subjects will be instructed to take a tailored high protein/low carbohydrate/low caloric diet.
2548658|NCT02573961|Sham Comparator|control|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. In addition they will be instructed to take a tailored low caloric diet .
2548748|NCT02573376|Other|Sofosbuvir/Ledipasvir with Directly Observed Therapy (DOT)|Participants randomized to vDOT will be provided a smart phone with cellular service and will be pre-programmed with the mobile phone-based video application and contact information for study personnel.
2548749|NCT02573376|Other|Sofosbuvir/Ledipasvir with Wirelessly Observed Therapy (WOT)|Participants on WOT will be provided the Wisepill portable medication dispenser.
2548858|NCT02572908|Active Comparator|Fermented wheat bread for 7 days|Long sourdough fermentation
2548859|NCT02572908|Placebo Comparator|Yeast baked wheat bread for 7 days|Regular toast bread
2548860|NCT02572908|Other|Run-in|Gluten-free diet for 7 days before entering either bread period
2548869|NCT02572531|Active Comparator|L. reuteri|L. reuteri DSM 17938/ATCC PTA L. reuteri DSM 17938/ATCC PTA lozenges three times daily for 2 weeks
2548872|NCT02572531|Placebo Comparator|Placebo|Placebo lozenges three times daily for 2 weeks
3204040|NCT00930124|Active Comparator|2|Group 2 will receive distraction osteogenesis
3204041|NCT00930137|Experimental|High dairy trans fat|a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal)
2548003|NCT02578160|Experimental|Tell-Show-Do Behavior Technique|This technique will involve verbal explanations related to the inferior alveolar and lingual nerve block procedure in phrases appropriate to the developmental level of the patient (tell);demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do).
2548011|NCT02578160|Active Comparator|"Conventional Technique"|The operator will explain how he/she will do the inferior alveolar and lingual nerve block procedure in phrases appropriates to the child. Then quietly cover the child's field of view by hand during the inferior alveolar and lingual nerve block.
2548059|NCT02577744|Active Comparator|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
2548060|NCT02577744|Active Comparator|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
2548130|NCT02577224|Experimental|Intervention|Participants randomized to the intervention group (patient-initiated treatment) will be asked to initiate their own treatment during the nine months they are taking part in the trial. Intervention group participants will receive information about when and how to initiate an appointment. Contact details for the service will be provided along with information on how quickly an appointment will be made, with whom and the procedure in the case of an emergency. All patients requesting an appointment will be booked in to the next available slot within the twice weekly ring-fenced nurse-led clinics. Any subsequent scheduled appointments will be cancelled and all future treatment will be initiated by the patient.
2548131|NCT02577224|No Intervention|Control|Participants in the control group will receive treatment as usual. This consists of scheduled appointments in the hospital-based nurse-led botulinum toxin clinic. The frequency with which these appointments takes place are based on clinical judgement, but tend to range between every 6 weeks to every 4 months.
2548183|NCT02576860|Experimental|Treatment|CLS001 (Omignan) gel applied once daily
2548185|NCT02576860|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
2548315|NCT02576262||HPV-positive women，30-65 years of age|
2548335|NCT02575976|Experimental|comprehensive CR|education and exercise-based cardiac rehabilitation
2548337|NCT02575976|Active Comparator|exercise-based CR|Exercise-based cardiac rehabilitation
2548338|NCT02575976|Other|wait list control|no cardiac rehabilitation
2548385|NCT02575742||Young women without chronic constipation|Healthy women without chronic constipation who are aged between 18-40 years
2548386|NCT02575742||Older women without chronic constipation|Healthy women without chronic constipation who are aged between 70-90 years
2548387|NCT02575742||Young women with chronic constipation|Women with symptoms of chronic constipation who are aged between 18-40 years
2548390|NCT02575742||Older women with chronic constipation|Women with symptoms of chronic constipation who are aged between 70-90 years
2548453|NCT02575313|Experimental|Whole Food Intervention Treated|Group of participants given the experimental WFI along with standard cancer treatment.
2548526|NCT02574975|Active Comparator|Methacholine diagnosing group|Methacholine bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2548527|NCT02574975|Experimental|Adenosine monophosphate diagnosing group|Adenosine monophosphate bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2548528|NCT02574975|Experimental|Leukotriene D4 diagnosing group|Leukotriene D4 bronchial provocation test was performed by using Jaeger spirometry with Aerosol Provocation System
2548529|NCT02574975|Experimental|Astograh diagnosing group|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
2548530|NCT02574975|Experimental|budesonide /formoterol treatment group|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three month
2548573|NCT02574377|Experimental|A: myDC vaccination|intranodal injection with tumor peptide-loaded myeloid dendritic cells
2548576|NCT02574377|Experimental|B: pDC vaccination|intranodal injection with tumor peptide-loaded plasmacytoid dendritic cells
2548577|NCT02574377|Experimental|C: combined myDC/pDC vaccination|intranodal injection with tumor peptide-loaded myeloid and plasmacytoid dendritic cells
3204042|NCT00930137|Active Comparator|Low dairy trans fat diet|a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)
3204043|NCT00930150|Experimental|Posit Science Intervention|Participants will receive targeted cognitive training and participate in a bridging group.
3204044|NCT00930150|Active Comparator|Control|Participants will play commercially available computer games and participate in weekly groups to discuss health and wellness.
3204045|NCT00930163|Experimental|1|
3204046|NCT00930163|Placebo Comparator|2|
3204047|NCT00930202|Experimental|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
3204048|NCT00930202|No Intervention|Standard Care|No intervention
3204049|NCT00930215|Experimental|D961H 40 mg gelatin capsule|2 way crossover
3204050|NCT00930215|Experimental|D961H 40 mg HPMC capsule|2 way crossover
3204051|NCT00930228|Experimental|Flutamide|Flutamide 250 mg taken by mouth twice a day for 4 weeks. Flutamide is an androgen-receptor blocker.
3204052|NCT00930228|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
3204053|NCT00930241|Experimental|Advagraf|Advagraf® (one daily dose of Tacrolimus)
3204054|NCT00930241|Active Comparator|Prograf|Prograf® (two daily doses of Tacrolimus)
3204055|NCT00930254|Experimental|Ultrasound|Vascular puncture guided by vascular ultrasound
3204056|NCT00930280||Hemorrhagic stroke cases|People who have had a hemorrhagic stroke, specifically an intracerebral hemorrhage, and live within a 100 mile radius of the University of Cincinnati.
3204057|NCT00930280||Healthy Control Subjects|Healthy volunteers who are randomly identified in the same 100 mile radius of the University of Cincinnati and have not had a hemorrhagic stroke.
3204058|NCT00930306|Experimental|1|12 AZD2066 Capsule, 2 mg & 8 mg 2 Caffeine Tablet, 2 x 50 mg 2 Tolbutamide Tablet, half of 500 mg 2 Omeprazole Tablet, 20 mg 2 Midazolam Tablet, 7.5 mg 2 Metoprolol Tablet, 100 mg 2 Bupropion Tablet, 150 mg
3204059|NCT00930319||1|Patients with Advanced Hormone-dependent Prostate Carcinoma treated with Firmagon according to SPC
2548046|NCT02577757|Other|healthy volunteers|achieving functional MRI
2548048|NCT02577757|Experimental|Eligible patients with awakened surgery|achieving functional MRI
2548062|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 1|Dosing Regimen 1 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 24 hours
2548064|NCT02577523|Experimental|ND0612 (Levodopa/Carbidopa solution) Dosing Regimen 2|Dosing Regimen 2 of ND0612 (Levodopa/Carbidopa solution) continuous SC infusion over 14 hours
2548120|NCT02577250|Experimental|Six ketamine infusions|Six infusions of 0.5 mg/kg ketamine hydrochloride solution over 2 weeks.
3204060|NCT00930332|Active Comparator|Arm A: Methadone|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
3204061|NCT00930332|Active Comparator|Arm B: Methadone|"Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
2548332|NCT02576119|Experimental|Part 1: Sentinal Cohorts|Study is in 2 sequential cohorts (BMS-955176 or placebo) each to evaluate the safety, tolerability, and PK following multiple-dose administration of BMS-955176.
2548334|NCT02576119|Experimental|Part 2: Main QTc Study|3 period nested crossover study.
3204062|NCT00930345|Other|SUTENT before nephrectomy|
3204063|NCT00930358|Experimental|MEOPA|MEOPA : equimolar nitrous oxide/oxygen mixture
2548460|NCT02575170|Experimental|Amino acid|Intravenous infusion of amino acid solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
2548462|NCT02575170|Placebo Comparator|Ringer's Lactate solution|Intravenous infusion of Ringer's lactate solution started approximately one hour prior to spinal anaesthesia after recording the baseline vital parameters. Each patient in experimental group received a total of 200 ml at 2 ml/kg/min.
3204064|NCT00930358|Active Comparator|General anesthesia|Gold standard
3204065|NCT00930384||Psoriasis group|All adult patients fulfilling inclusion criteria will be considered as cases in which psoriasis is detected and diagnosed by our principal investigator based on the clinical criteria accepted by American Academy of Dermatology. They will have an abdominal ultrasound performed by a radiologist to assess for the presence of nonalcoholic fatty liver disease. They will be referred to the research clinic to have a blood drawn.
3204066|NCT00930384||Control group|For every case an age, sex and body mass index (BMI range - kg/m2) matched control will be selected from the same dermatologic/radiologic clinic. The controls will be invited to voluntarily participate and informed consent will be obtained for performing ultrasonography and analytical tests to ensure the absence of manifest hepatic disease.
3204067|NCT00930397||Low risk women|Women without any personal risk.
3204068|NCT00930397||High risk women|Women at high risk for pre-eclampsia with personal of pre-eclampsia and/or IUGR in a previous pregnancy, diabetes, auto-immune syndrome such as lupus, hypertension, renal insufficiency and anti-phospholipid.
3204069|NCT00930410|Experimental|endomicroscopy|Utilisation of an intra-ductal confocal endomicroscopy during the endoscopic Retrograde Cholangio-Pancreatography
3204070|NCT00930423||cases|patients with endstage renal failure due to atypical uraemic syndrome treated with hemodialysis.
3204071|NCT00930423||controls|patiënts with endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.
2548875|NCT02572726|Active Comparator|active rTMS|active repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
2548876|NCT02572726|Sham Comparator|'sham' rTMS|'sham' repeated transcranial magnetic stimulation over primary motor cortex along 5-10 daily sessions
2548915|NCT02572336|Active Comparator|THR-18|Single administration of intravenous THR-18 solution
2548917|NCT02572336|Placebo Comparator|Placebo|Single administration of intravenous THR-18 lookalike solution
2548944|NCT02572037||Group I|Penile sensory hyperexcitability: Latencies of GPSEP and/or DNSEP of them are abnormal. They will receive treatment of Compound Lidocaine Cream-a kind of local anaesthetics that is widely used to treat PE.
2548947|NCT02572037||Group II|Sympathetic hyperexcitability: Latency of PSSR are abnormal.They will be treated with Dapoxetine(Priligy)-a kind of selective serotonin reuptake inhibitor(SSRI) which has been shown effective to PE.
2548953|NCT02572037||Group III|Mixed type: Both Latencies of GPSEP and/or DNSEP and Latency of PSSR are abnormal.They will receive both Compound Lidocaine Cream and Dapoxetine.
2548958|NCT02572037||Group IV|Others: Both Latencies of GPSEP, DNSEP and Latency of PSSR are normal.They will receive further tests. (This group is not the main objects to be observed in this study.)
2549005|NCT02571790|Experimental|Relaxation optimized virtual reality|six relaxation sessions with virtual reality
2549008|NCT02571790|Experimental|Classical relaxation (without Virtual Reality).|six relaxation sessions without virtual reality
2549053|NCT02571374|Experimental|symbiotic group|Symbiotic group
2549056|NCT02571374|Placebo Comparator|placebo group|placebo group
2549213|NCT02571036|Experimental|Escalation|Escalation Phase: DCC-2618 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours or once daily (QD) for repeated 28-day cycles. Participants may continue to receive study drug until discontinuation criteria are met. [Closed for Enrollment]
2549217|NCT02571036|Experimental|Expansion Cohort 1|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 3 prior therapies. [Closed for Enrollment]
2549220|NCT02571036|Experimental|Expansion Cohort 2|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received 4 prior therapies. [Closed for Enrollment]
2549222|NCT02571036|Experimental|Expansion Cohort 3|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST who have received at least one prior therapy and no more than 2 prior therapies. [Closed for Enrollment]
2547997|NCT02578056|Experimental|Mid-urethral sling|Patients randomized to anti-incontinence surgery will undergo TVT sling placement as the standard technique at the same time of genital prolapse surgery.
2547999|NCT02578056|Sham Comparator|POP|Patients randomized to the sham group will be submitted to genital prolapse surgery and sham incisions as if they had undergone the TVT procedure (two small incisions of 0.5 cm in the suprapubic region in a similar way to that used for the insertion of the sling). These incisions intended to keep the raters blind to the achievement or otherwise of the sling during the postoperative evaluation.
2548082|NCT02577731|Other|Severe Trauma|Bone marrow collection. Blood collection. Clinical data collection.
2548083|NCT02577731|Other|Elective Hip Repair|Bone marrow collection. Blood collection. Clinical data collection.
2548086|NCT02577731|Other|Healthy Young Bone Marrow Control|Deidentified freshly isolated bone marrow samples from healthy young control subjects will be purchased for a tissue bank.
3204072|NCT00930436|Active Comparator|Saline infusion|Saline will be given as an active control agent to compare with sodium bicarbonate. Each bag of solution will be blinded, and given in the same manner.
3204073|NCT00930436|Experimental|Sodium Bicarbonate|Infusion of sodium bicarbonate will be given prior to,during and after the contrast agent for a total of 6 to 10 hours
2548319|NCT02576223|Active Comparator|Ropivacaine hydrochloride|Ropivacain 7.5mg/ml, 5 ml injected perineural at the suprascapular nerve.
2548320|NCT02576223|Placebo Comparator|Isotonic Saline|0.9% Saline solution, 5 ml injected perineural at the suprascapular nerve.
3204074|NCT00930449|Experimental|Cogmed Working Memory Training Program|
2548436|NCT02575339|Experimental|Phase I MLN0128 Dose Escalation Study|"Subjects will receive MLN0128 orally on days 1, 8, 15 and 22 in successive cohorts.~Cohort 1 MLN0128 15mg each week (QW); Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW"
2548438|NCT02575339|Experimental|Phase II Arm A: MLN0128|Subjects randomized to experimental arm will receive MLN0128 orally at the recommended phase II dose (RP2D) once weekly.
2548440|NCT02575339|Active Comparator|Phase II Arm B: Sorafenib|Subjects randomized to control arm will receive sorafenib 400mg by mouth (PO) twice a day (BID) daily.
2548507|NCT02574897|Experimental|Electronic Symptom Survey|Patients randomized to the intervention arm will fill out the daily PRO-CTCAE electronic symptom survey. The intervention consists of sending the results of the surveys in the intervention arm to the clinical care team. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. Patients in the intervention arm will complete a satisfaction survey at discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
2548509|NCT02574897|Active Comparator|Blinded Electronic Symptom Survey|Patients in the control arm will only fill out the symptom survey at the time of admission and days 7, 10, and 14. The results of symptom surveys from the patients in the control arm will not be sent to providers, but will be used for data analysis purposes only. The four symptom-specific PROMIS subsets (Anxiety, Depression, Fatigue, and Sleep Disturbance) will be filled out weekly while patients are admitted to the hospital. Patients will again complete the 6 minute walk distance testing, HRQoL surveys, and PASS assessment at the time of discharge. HRQoL (by mail) and PASS (by telephone) will be assessed for a third time 30 days after discharge.
2548537|NCT02574572|Experimental|Single group|Patients with spinal cord injury that will undergo laminectomy and autologous mesenchymal cells intralesional injection
3204075|NCT00930449|Active Comparator|Academy of Math® program|
3204076|NCT00930449|Active Comparator|Special Education/Individualized Tutoring|
2548687|NCT02573818||SEDASYS System|
2548740|NCT02573441|Experimental|Math + Liaison Service|To help with mathematics, participants will be assigned to a workbook based version of the JUMP Math program which will be completed at home with a parent. This intervention focuses on mental math skills. In addition all participants will receive the liaison service program.
2548741|NCT02573441|Experimental|Working Memory + Liaison Service|To help with working memory, participants will be assigned to Cogmed, a game-like computer exercise focusing on improving working memory. In addition all participants will receive the liaison service program.
2548742|NCT02573441|Other|Liaison Services|Participants in this group will only receive the liaison service program for 12 weeks before being assigned to one of the intervention groups.
2548846|NCT02572999||Valvular heart disease|All patients aged 70 years or older, consecutively admitted for elective heart valve surgery or if admitted for elective transcatheter aortic valve implantation, or if a patient presents with symptomatic moderate to severe valvular heart disease on hospital admission as evidenced by moderate to severe valve regurgitation or stenosis will be included in this cohort. Participants will be observed up to 30 days post-hospital discharge
2548880|NCT02572674|Other|experimental arm|Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
2548919|NCT02572310|Experimental|HV Cement|Simplex High Viscosity Bone Cement
3204077|NCT00930462|No Intervention|Conventional colonoscopy|No cap fitted on the colonoscopes for this group.
2548983|NCT02571699|Active Comparator|Subgluteal sciatic block|Subgluteal block with similar volume
2548987|NCT02571699|Experimental|Subgluteal block|Subgluteal block with decreasing volume
2549041|NCT02571556|Experimental|Dexamethasone Phosphate Ophthalmic Solution|
3204078|NCT00930462|Experimental|Cap-assisted colonoscopy|
3204079|NCT00930488||Group 1|
3204080|NCT00930501||Cancer patients|women 5-45 yr olf pre and post chemotherapy
2549160|NCT02570581|Placebo Comparator|Plain jelly control|Plain jelly control
2549169|NCT02570581|Active Comparator|Jelly with: Paracetamol|"Jelly with:~Paracetamol"
3204081|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 1: Cohort A)|
3204082|NCT00930514|Active Comparator|Rituximab IV 375 mg/m^2 (Stage 2: Cohort E)|
3204083|NCT00930514|Experimental|Rituximab SC 1400 mg (Stage 2: Cohort F)|
3204084|NCT00930514|Experimental|Rituximab SC 375 mg/m^2 (Stage 1: Cohort B)|
3204085|NCT00930514|Experimental|Rituximab SC 625 mg/m^2 (Stage 1: Cohort C)|
3204086|NCT00930514|Experimental|Rituximab SC 800 mg/m^2 (Stage 1: Cohort D)|
3204087|NCT00930566|Experimental|Extracorporal Photopheresis|
3204088|NCT00930579|Experimental|Metformin|
2548018|NCT02578147|Experimental|Mighty Girls|Girls in this group complete 3 different activities after school: 6 classroom sessions, 4 DRAMA-RAMA game play sessions, and 4 short game experience surveys. Classroom sessions are 1 hour long, 3 days a week for 2 weeks. Topics include: goal setting, choices and their effects; defining what makes a behavior risky; learning how to not get talked into doing risky things by friends (e.g., going to a party at a house where parents are not home); and learning to be critical of TV shows and other media that make it seem like lots of teens are having sex. These sessions teach girls skills and strategies that help them score game points in DRAMA-RAMA. These are important skills and strategies that they can use in everyday life to make wise choices. Classroom sessions are designed to be fun.
2548019|NCT02578147|Active Comparator|Game Girls|Girls in this group take part in activities that can be done from home or anywhere they have Wi-Fi access: 4 Science Valley game play sessions and 4 short game experience surveys. Science Valley is a web based game in which girls explore a virtual world and experiment with objects in this world using a computer, tablet or cell phone. Girls will play this game for about 20-30 minutes. There are no classroom sessions required to be able to play Science Valley. Science Valley is designed to be fun and to give girls a chance to build skills important to doing well in school: her problem solving and critical thinking skills. Girls will be given a link to use to access Science Valley on the internet. At the end of the game, they do a short game experience survey that asks questions about how easy, how hard, how fun etc. it was to play Science Valley. This survey will appear on the screen at the end of the Science Valley game play session.
2548088|NCT02577341|Experimental|Nimotuzumab|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin, and concurrent weekly Nimotuzumab.
2548089|NCT02577341|Active Comparator|Control|Daily RT to the chest, concurrent chemotherapy of weekly docetaxel and cisplatin.
2548156|NCT02577081|Experimental|CAT scan|A CAT scan will be done for all participants. The scan will include the pelvis and 2 femurs.
3204089|NCT00930592||Children with Psoriasis|Children and adolescents from 10-17 years of age with moderate to severe psoriasis.
3204090|NCT00930592||Control: children with warts|Children and adolescents from 10-17 years of age with warts.
3204091|NCT00930605|Experimental|Alemtuzumab combination with CHOP and ESHAP|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
2548358|NCT02575885|Experimental|Arm I (different type of ENDS product at each visit)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with a different type of ENDS product at each visit (e-cigarette, disposable e-cigarette, eGo, personal vaporizer, e-cigar, and e-pipe) over 3.5-4 hours at least 7 days apart for 7 weeks. Participants are provided with cartridges of the same amounts of nicotine with regular (tobacco) or menthol flavor according to smoker's preference, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
2548364|NCT02575885|Experimental|Arm II (BLU e-cigarette ENDS product with different flavors)|Participants are asked to smoke ad lib a single cigarette of their own brand and provided with the BLU e-cigarette ENDS product with nicotine solution of one of five flavors over 3.5-4 hours at least 7 days apart for 6 weeks. Participants are provided with cartridges of maximum available amounts of nicotine and different flavors at each visit, instructed on how to use the product, asked to practice using it for 7 days, and return to the study center for their next visit.
2548419|NCT02575521|Placebo Comparator|Propofol-Dexmedetomidine group|this group is planned to receive intravenous anaesthesia only
2548420|NCT02575521|Active Comparator|Sevoflurane group|this group is planned to receive sevoflurane/fentanyl anaesthesia
2548465|NCT02575131|Experimental|TNO whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at TNO
2548466|NCT02575131|Active Comparator|TNO whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water. at TNO
2548468|NCT02575131|Experimental|TNO Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams of water and consumed with 307 grams of skimmed milk at TNO
2548470|NCT02575131|Active Comparator|TNO original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at TNO
2548471|NCT02575131|Experimental|TNO standard breakfast|"TNO breakfast: one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at TNO"
2548474|NCT02575131|Experimental|Home whole wheat bread yeast basis|NBC-1: four slices of whole wheat bread yeast basis (98 grams) spread with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
2548475|NCT02575131|Active Comparator|Home whole wheat sourdough bread|NBC-2- four slices of whole wheat sourdough bread (98 grams) with 3 cups low-fat margarine (total 30 grams) consumed with 200 mL of black coffee (without milk and sugar) or 200 mL tea (no sugar) or 200 mL of water at home
2548476|NCT02575131|Experimental|Home Oatmeal|PepsiCo, Inc.-1 - One portion of Steel Cut oatmeal: 66.8 grams of oats boiled for 25 minutes in 500 grams* of water and consumed with 307 grams of skimmed milk at home
2548478|NCT02575131|Active Comparator|Home original Cheerios|PepsiCo, Inc.-2 - One portion of original Cheerios (ready to eat cereal): 70 grams prepared with 307 grams of skimmed milk and consumed with about 275 grams of water at home
2548479|NCT02575131|Experimental|Home standard breakfast|"one slice of white bread with a fried egg and 200 mL orange juice. With spray oil a frying pan is prepared to fry an egg (medium size).~The breakfast is consumed at home"
2548535|NCT02574650|Experimental|Open Label|Non-randomized, open label clinical study that intends to treat up to 30 subjects with the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) using standard of care techniques and services that are typically used for structural heart procedures.
3204092|NCT00930618|Experimental|IMN|Isosorbide mononitrate
3204093|NCT00930618|Placebo Comparator|Placebo|Administration of placebo of IMN
3204094|NCT00930631|Other|Single Arm|Single arm PK study
3204095|NCT00930670|Experimental|Rosuvastatin-omeprazole|Rosuvastatin-omeprazole
2548078|NCT02577627||Training Set|The Training Set will be used to calibrate the Predicare models and algorithms and assess its predictive potential in a retrospective manner. Patients data will be collected according to the oncological indications (NSCLC, SCLC, Prostate cancer, Breast cancer and Colon cancer) and the applied treatment protocols, and their data will be integrated and processed by the PrediCare algorithm.
2548081|NCT02577627||Validation Set|The Validation Set will be used to validate the prediction power of the device in a prospective manner. The files of patients assigned to Validation Set of the study will be used for the blind prediction of TTP under each specific treatment, based on the baseline individual information. This will be done by inputting into PrediCare the information of each individual patient, available prior to treatment onset (baseline; clinical data, imaging data, histology/cytology, oncomarkers, genetic screening, hematology, biochemistry) for creating a personalized mathematical models and predicting TTP of this specific patient. These predictions will be then compared to the clinically observed TTP for all the patients.
2548140|NCT02577211|Experimental|Hipocaloric enteral nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
2548141|NCT02577211|Active Comparator|Normocaloric enteral nutrition|25 kcal per kg of body weight and 1.7 grams of protein per kg.
2548164|NCT02576808|Experimental|Ginger extract|Drug
2548174|NCT02576808|Active Comparator|Loratadine|Drug
2548230|NCT02576522|Experimental|brain metastatic patients|Patients with single, large brain metastases from solid tumors
2548295|NCT02576340|Active Comparator|study|drug was administered
2548296|NCT02576340|No Intervention|control|no drug administered
2548346|NCT02576106|Experimental|Cryoablation|Cryoablation of the tumor followed by a lumpectomy as practiced in standard care
2548389|NCT02575716|Experimental|Muscle relaxant|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg muscle relaxant use rocuronium 0.6 mg/kg
2548392|NCT02575716|Placebo Comparator|Placebo|Intubation with McGrath video laryngoscope after fentanyl 1.5 mcg/kg, xylocaine 1.5 mg/kg and propofol 3 mg/kg placebo use NSS 0.6 mg/kg
2548435|NCT02575495|Experimental|7 days course of antibiotic treatment|To assign the 7 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
2548439|NCT02575495|Active Comparator|14 days course of antibiotic treatment|To assign the 14 days course of antibiotic treatment, start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture
2548481|NCT02575027|Experimental|Treatment (4pi radiotherapy)|Patients undergo 4pi radiation simulation and planning followed by 5 to 10 daily fractions of 4pi palliative radiotherapy. If an acceptable plan cannot be achieved using 4pi planning, then the patient will be treated with standard radiation therapy planning for palliative re-irradiation.
2548519|NCT02574702|No Intervention|Control Group|Patients with primary loop ileostomy closure without drainage of the surgical wound
2548520|NCT02574702|Experimental|Drainage Group|"Patients with the application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure.~Intervention: application of a contralateral drainage in surgical wound closure."
3169418|NCT00562406|Active Comparator|1|laser photocoagulation to the retina at the area of edema
3169419|NCT00562406|Experimental|2|intravitreal injection of ranibizumab
2548765|NCT02573337|Experimental|Intradermal injection|Emervel Classic Lidocaine and/or Emervel Deep Lidocaine
2548832|NCT02572895|Active Comparator|Optimal dose|One capsule with a proanthocyanidins standardized cranberry extract of 18,5 mg twice a day, i.e. in the morning and at night.
2548838|NCT02572895|Placebo Comparator|Control dose|One capsule with a proanthocyanidins standardized cranberry extract of 1 mg twice a day, i.e. in the morning and at night.
2548951|NCT02572089|Experimental|2mg Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in one nostril
2548957|NCT02572089|Experimental|4mg(a) Intranasal Naloxone|Administer 0.1mL spray of the 20 mg/mL formulation in both nostrils
2548959|NCT02572089|Experimental|4mg(b) Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in one nostril
2548962|NCT02572089|Experimental|8mg Intranasal Naloxone|Administer 0.1mL spray of the 40mg/mL formulation in both nostrils
2548965|NCT02572089|Experimental|Intramuscular Naloxone|Administer 1mL of 0.4mg/mL formulation intramuscularly
2549011|NCT02571738|Active Comparator|CHAM|Cryopreserved Human Amniotic Membrane
2549012|NCT02571738|Placebo Comparator|Control|Standard of Care
2549150|NCT02570724|Active Comparator|Blood Patch arm|Standard of care arm: injection of autologous blood approximately 40 mL of blood sample into the epidural space at a rate of 1 ml / about 5 seconds.
2549159|NCT02570724|Active Comparator|"Drug: injection of HES  Voluven®  patch arm"|"Drug: injection of HES  Voluven®  into the epidural space of 15 to 30 ml at a rate of 1 ml / about 5 seconds"
2549221|NCT02570230|Placebo Comparator|Control|NSS infusion
2549228|NCT02570230|Experimental|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
2549278|NCT02570009|Active Comparator|TEAMS|
2549283|NCT02570009|Active Comparator|TEAMS+|
2549583|NCT02568098|Experimental|TMEC-14-022 (OxTREC 39-14)|Subjects had previously taken drug CQ and PQ
3169420|NCT00562406|Experimental|3|laser photocoagulation to the retina at the area of edema and intravitreal injection of ranibizumab
3169421|NCT00562419|Experimental|1|CT-322
3169422|NCT00562419|Experimental|2|CT-322 and irinotecan hydrochloride
3169423|NCT00562432|Experimental|Plexisyl-AF|Plexisyl-AF implants
3169424|NCT00562432|Sham Comparator|No Treatment|Surgery without experimental treatment
3169425|NCT00562445||1|Peptic bleeding
3169426|NCT00562445||2|Portal hypertension bleeding
3169427|NCT00562445||3|Severe acute pancreatitis
3169428|NCT00562471|Experimental|1|Adhesion Prevention Gel Arm
3169429|NCT00562471|Other|2|Standard of Care Comparator Arm (standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure)
3169432|NCT00562510|Experimental|Raltegravir|
3169433|NCT00562510|Placebo Comparator|Raltegravir matching placebo|
3169434|NCT00562523|Experimental|Arm 1|
2548340|NCT02575924|Active Comparator|sequential medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2548341|NCT02575924|Active Comparator|sequential medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2548342|NCT02575924|Active Comparator|sequential medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE-FERT medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE-CLEAVAGE medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day3~day3: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices and newer volumes of mineral oil to cover up the droplets till day5~day5: fitting volumes of SAGE-BLASTOCYSTS medium to replace all the culture devices without any mineral oil replacement till day7"
2548343|NCT02575924|Active Comparator|one step medium female age>=40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2548344|NCT02575924|Active Comparator|one step medium female age<40|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2548345|NCT02575924|Active Comparator|one step medium sperm testis retrieval|"day 0: suitable number of test tubes, each one filled with 1ml of SAGE 1-STEP medium to gather all the oocytes retrieved during the pick up (at most 3 oocytes/test tube)~1 or more culture dish with 6 droplets (35µl) of SAGE 1-STEP medium covered with mineral oil to culture the zygotes/embryos after ICSI procedure till day7"
2548418|NCT02575625|Experimental|Fibroscan exam|"Step 1: feasibility study of the method on 10 healthy volunteers Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an hepatic biopsy et whom the histological answer is clean steatosis (NAFLD).~Experimental procedures consist in:~Fibroscan measure, preceded by tracking sonography.~liver MRI (for substudy about MRI comparison, in step 2)~a blood test for biological assessment of liver functions"
2548483|NCT02575105||Pediatric Hydrocephalus|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
2548487|NCT02575105||Pediatric Control|In the first study 15 pediatric patients with hydrocephaly and 15 pediatric control patients at approximately the same age group will be included in the study.
2548489|NCT02575105||Adult Hydrocephalus|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
2548492|NCT02575105||Adult Control|In the second study 15 post cerebral hemorrhage adult patients undergoing ventriculo-peritoneal shunt placements and 15 adult control patients will be included in the study
2548564|NCT02574754|Experimental|warfarin|Subjects will receive a single dose of warfarin 10 mg PO at each of 3 visits. The study days will be separated by at least 14 days to allow adequate time for the drug to reach washout.
2548638|NCT02574182||Control subjects under 40 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
2548641|NCT02574182||Control subjects over 60 years|Brain MRI Simulated walking with Corvit boots Records gait parameters on Gaitrite carpet
3169435|NCT00562536|Experimental|A 1|Delayed umbilical cord clamping 30-45 seconds.
3169436|NCT00562536|No Intervention|A 2|Immediate umbilibcal cord clamping
3169437|NCT00562549|Experimental|1|SLx-2101
3169438|NCT00562549|Placebo Comparator|2|Matching Placebo Dose
3169439|NCT00562562|Other|MOT|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
3169440|NCT00562575|Experimental|1|SLx-4090
3169441|NCT00562575|Placebo Comparator|2|Matching Placebo Dose
3169442|NCT00562614|Experimental|1|SLx-2101
3169443|NCT00562614|Placebo Comparator|2|Comparative Placebo Dose
3169444|NCT00562640|Experimental|WT1-Specific T Cells|This is a phase I dose escalating trial designed to identify tolerable, clinically active doses of Wilms' tumor gene (WT1) peptide sensitized T cells when administered alone or with nonmyelosuppressive chemotherapy in patients with recurrent or persistent, evaluable WT1+ ovarian, primary peritoneal, or fallopian tube carcinomas.
3169445|NCT00562653||1|infective endocarditis patients before treatment
3169446|NCT00562653||2|infective endocarditis treatment after treatment
3169447|NCT00562653||3|control
3169448|NCT00562666|Experimental|1|Single hepatic intra arterial administration of 500 millions T gamma delta lymphocytes
3169449|NCT00562666|Experimental|2|Single hepatic intra arterial administration of 1000 millions T gamma delta lymphocytes
3169450|NCT00562666|Experimental|3|Single hepatic intra arterial administration of 2000 millions T gamma delta lymphocytes
3169451|NCT00562666|Experimental|4|Single hepatic intra arterial administration of 4000 millions T gamma delta lymphocytes
2548210|NCT02576626|Other|A|Participants start with Ultibro (indacaterol/glycopyrronium 110/50) + placebo nebulization , then after a new washout period of 7 days they will receive ipratropium/salbutamol nebulization and placebo Breezhaler Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation
2548211|NCT02576626|Other|B|"Participants start with ipratropium/salbutamol nebulization and placebo Breezhaler , then after a new washout period of 7 days they will receive Ultibro(indacaterol/glycopyrronium 110/50) + placebo nebulization.~Interventions: indacaterol/glycopyrronium 110/50 Breezhaler® ,Placebo by Breezhaler®, ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation, Placebo by nebulisation"
2548321|NCT02576366|Experimental|Voriconazole|Four hundred mg of voriconazole (2 tablets of 200 mg Vfend; Pfizer, Karlsruhe, Germany) will be administered twice daily on day 2. Two hundred mg of voriconazole (1 tablet of 200 mg Vfend) will be administered twice daily on days 3, 4, 5 and 6.
2548322|NCT02576366|Experimental|Rifampin|Six hundred mg of rifampicin (2 tablets of 300mg Rifadine; Sanofi, Belgium) will be administered once daily on days 7 through 13.
2548356|NCT02575898|Other|One|"Creative writing and questionnaires interventions:~First Session, Second Session, Third through Sixth Sessions"
2548416|NCT02575599|Active Comparator|Lifestyle counselling|Intervention group: Eighty six adults with type 2 diabetes will be recruited from the general practices where the trained nurses in Guided self-determination programme are working.
2548417|NCT02575599|No Intervention|Regular consultation|Control group: Eighty six adults with type 2 diabetes will be recruited from general practices with employed registered nurses without the Guided self-determination training.
2548467|NCT02575235|Experimental|1.5mg Cetylpyridinium Chloride (CPC)|1.5mg CPC will be taken daily for four weeks.
2548469|NCT02575235|Experimental|4.5mg Cetylpyridinium Chloride (CPC)|4.5mg CPC will be taken daily for four weeks.
2548472|NCT02575235|Placebo Comparator|Control|Placebo will be taken daily for four weeks
2548522|NCT02574806||Healthy newborn|Healthy newborn at term of healthy mother.
2548524|NCT02574806||Preeclamptic newborn|Newborn at term of mother with pre-eclampsia with severity features.
2548548|NCT02574468|Active Comparator|DPC+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
2548551|NCT02574468|Active Comparator|MP+Dexa|forty intact premolars were randomly assigned to 1 of 4 treatment groups (n=10): I) DPC, II) MP, III) DPC+dexamethasone, and IV) MP+dexamethasone. After administration of local anesthesia (3% mepivacaine plain; Septodont, Cedex, France) dental rubber dam was applied and tooth surface disinfected with 2% chlorhexidine gluconate. Occlusal cavity was prepared using high speed diamond fissure bur and buccal pulp horn was mechanically exposed (approximately 1.2 mm in diameter) using a sterile high speed carbide round bur. In MP, depth of penetration to the pulp was 0.5 mm
2548602|NCT02574234|Experimental|Patients with orthopedic surgery|"Patients will be included in the consultation of anesthesia. The usual laboratory tests will be carried out and a determination of apelin and inflammatory cytokines. Assessment of cognitive functions using the Informant Questionnaire on Cognitive Decline in the Elderly (ICQODE), Mini Mental State examination (MMS) and the scale of Instrumental activities of daily living (IADL).~Day of surgery: liquid sampling cerebrospinal. Day 1 to day 7 postoperatively: determination of inflammatory cytokines and apelin, postoperative delirium research (Confusion Assessment Method (CAM)), residual cognitive dysfunction research (MMS, IADL, IQCODE).~3 months after operation: evaluation of cognitive performance (IQCODE, IADL)"
2548647|NCT02573909|Experimental|Oxycodone intravenously|Oxycodone 0,1 mg/kg IV
2548656|NCT02573909|Experimental|Oxycodone epidurally|Oxycodone 0,1 mg/kg epidurally
2548762|NCT02573480|Experimental|Wraparound Care|Wraparound care initiated in the ED at the time of injury and continuing for approximately 1 year in the community.
2548848|NCT02572947|Experimental|Dolutegravir monotherapy|10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks
2548900|NCT02572648||Participants with Heart Failure|Participants with heart failure will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
2548904|NCT02572648||Healthy Controls|Healthy controls will complete neurocognitive tests and undergo magnetic resonance imaging (MRI).
2548942|NCT02572193|Experimental|Active case|POEM procedure
2549024|NCT02571621||Patients intubated with Combitube|Patients with Combitube intubation undergoing general anesthesia with ASA class I and II
3204096|NCT00930670|Experimental|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
3204097|NCT00930670|Experimental|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
2549135|NCT02570789|Experimental|patients with sunitinib or pazopanib|This will be a non-randomized, proof-of-concept, prospective, longitudinal, multi-center study in patients with metastatic clear cell renal cell carcinoma with good or intermediate risk (based on MSKCC criteria) treated with sunitinib or pazopanib in first line.
2549156|NCT02570503|Experimental|ROP/KET/CLON/EPI/SAL|Ropivacaine (ROP) (5mg/ml)- 50ml Ketorolac (KET) (30mg/ml)- 1ml Clonidine (CLON) (0.1mg/ml)- 0.8ml Epinephrine (EPI) (1mg/ml)- 0.5ml 0.9% sodium chloride SAL)--47.7 ml
2549167|NCT02570503|Placebo Comparator|Placebo|0.9% Sodium Chloride- 100ml
3204098|NCT00930670|Active Comparator|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300 mg for 11 months
3204099|NCT00930670|Experimental|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
2549319|NCT02569749||Group 1|Patients with pacemaker indication (pacemaker already implanted or to be implanted)
2549320|NCT02569749||Group 2|Patients with ICD or CRTD therapy indication (device already implanted or to be implanted)
3204100|NCT00930670|Experimental|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40mg for 11 months
3204101|NCT00930670|Experimental|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
2548401|NCT02575612|Experimental|vacuum-assisted biopy|All patients enrolled in this study received a vacuum-assisted biopsy before surgery.
2548431|NCT02575404|Experimental|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2548433|NCT02575404|Experimental|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2548434|NCT02575404|Experimental|8 mg/kg GR-MD-02|8 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
2548482|NCT02574962|Experimental|Acthar® Gel|For the first two weeks participants will receive 1 mL of study drug subcutaneously every other day. After that, participants will received 1 mL of study drug twice a week for up to 6 months.
2548563|NCT02574715||Levonorgestrel (Jaydess, BAY86-5028)|women aged 18 to 29 years following 6 (±1) months of Jaydess® use as their contraceptive method.
2548674|NCT02573844|Active Comparator|A: Proklama ( 1 sachet/ day)|"15 patients belonging to group A will receive drug A (Proklama: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group A, starting from visit 5, will receive drug B ( Placebo: 1 sachet/day)."
2548678|NCT02573844|Placebo Comparator|B: Placebo ( 1 sachet/ day)|"15 patients belonging to group B will receive drug B (Placebo: 1 sachet/ day). The treatment will be administred starting from visit 3 for a 2 weeks- treatment's period.~After a 2 weeks wash out's period, patients belonging to group B, starting from visit 5, will receive drug A ( Proklama: 1 sachet/day)."
2548736|NCT02573545|Experimental|Test group: with IFE|Patients treated with IFE software
2548738|NCT02573545|Active Comparator|Test group: without IFE|Patients treated with Numaris 4 software
2548935|NCT02572245|Active Comparator|PF-06410293 PFS (Prefilled Syringe)|PF-06410293 40 mg administered by Prefilled Syringe (PFS)
2548937|NCT02572245|Active Comparator|PF-06410293 PFP (Prefilled Pen)|PF-06410293 40 mg administered by Prefilled pen
2548978|NCT02571933||Grammar English|Patients who primarily speak Grammar English. Patients will answer the FPS-R in Grammar English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
2548979|NCT02571933||Pidgin English|Patients who primarily speak Pidgin English. Patients will answer the FPS-R in Pidgin English both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
2548981|NCT02571933||French|Patients who primarily speak French. Patients will answer the FPS-R in French both before and after administration of routine analgesia for pain (analgesia to be administered regardless of enrollment in study). Study participants will answer a series of questions - the cognitive interview - after second FPS-R to assess for ease of use and how well it is understood.
3169452|NCT00562679||2 groups|The cohort is grouped according to one group with sleep apnea and one group without sleep apnea
2549115|NCT02571140|Active Comparator|Active Comparator|Subcutaneous injection of Teriparatide
2549116|NCT02571140|Experimental|Oral PTH (1-34)|Oral administration of pill with API with different optimizations
2549178|NCT02570581|Active Comparator|Jelly with Levothyroxine sodium salt|Jelly with Levothyroxine sodium salt
3169453|NCT00562692|Experimental|A|Nesiritide
3169454|NCT00562692|Placebo Comparator|B|Placebo
3169455|NCT00562705|Experimental|1|Growth hormone and nutritional intervention
3169456|NCT00562705|Active Comparator|2|growth hormone
3169457|NCT00562744|Experimental|SIM|Participants complete training and assessment of performance in PALS scenarios using high-fidelity simulator
3169458|NCT00562744|No Intervention|MAN|Participants complete training and assessment of performance in PALS scenarios using mannequin
3169459|NCT00562757||A|Post myocardial infarction patients who received an ICD, stratified into low versus high WMI groups
3169460|NCT00562770|Active Comparator|1|Valacyclovir
3169461|NCT00562770|Active Comparator|2|Valganciclovir
3169462|NCT00562796||1|Participants with abdominal obesity without growth hormone deficiency
3169463|NCT00562796||2|Participants with abdominal obesity with growth hormone deficiency
3169464|NCT00562796||3|Participants who are lean controls
3169465|NCT00562822|Active Comparator|Arthroscopic Surgery|Arthroscopic surgery optimized with physical and medical therapy
3169466|NCT00562822|Active Comparator|Physical and medical therapy|treatment with physical and medical therapy alone
3169467|NCT00562835|Active Comparator|1|Methylprednisolone
3169468|NCT00562835|Placebo Comparator|2|
3169469|NCT00562848|Experimental|Subjects enrolled in single dose escalation cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
3169470|NCT00562848|Experimental|Subjects enrolled in gastric emptying cohort|Subjects will receive escalated doses of GSK962040 with a starting dose of 1 milligrams along with placebo in fasted state.
3169471|NCT00562848|Experimental|Subjects enrolled in gastro-enteral contractility cohort|Eligible subjects will receive GSK962040 and placebo in the fasted state in crossover manner.
3169472|NCT00562874|Experimental|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months.
3169473|NCT00562874|Active Comparator|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy flour as an ingredient for 5 days each week for 12 months.
3169474|NCT00562874|Sham Comparator|Wheat Biscuit|75 women and one of their children will receive a biscuit containing pm;u wheat flour as a source of protein as an ingredient for 5 days each week for 12 months.
3169475|NCT00562887|Placebo Comparator|1|
3169476|NCT00562887|Experimental|400 mg|
3169477|NCT00562887|Experimental|700mg|
3169478|NCT00562900|Active Comparator|A, robotic|
3169479|NCT00562900|Active Comparator|B, laparoscopic|
3169480|NCT00562913|Experimental|Arm 1|
3169481|NCT00562939|Experimental|A|1 mg CpG 7909 + pneumococcal vaccines
3169482|NCT00562939|Placebo Comparator|B|Pneumococcal vaccines
2548242|NCT02576470|Experimental|sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with anodal transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2548246|NCT02576470|Experimental|Mixed VF, sEMG with anodal tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with anodal transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The anodal tDCS will be applied to the lesioned hemisphere during training.
2548251|NCT02576470|Sham Comparator|VF with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium images without the transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2548257|NCT02576470|Sham Comparator|sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images without the transcranial direct current stimulation and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2548261|NCT02576470|Sham Comparator|Mixed VF, sEMG with sham tDCS|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images without transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS). The tDCS will be applied during training, however no stimulation will be received.
2548265|NCT02576470|Experimental|VF with reward|This group will receive the following the procedure outlined below for biofeedback. The biofeedback is based on the videofluoroscopy (VF) and Barium with financial reward.
2548268|NCT02576470|Experimental|sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3-days.
2548269|NCT02576470|Experimental|Mixed VF, sEMG with financial reward|This group will receive the following types of procedures for biofeedback. The biofeedback is based on videofluoroscopic (VF) and barium, and submental electromyography (sEMG) images with financial reward. The financial reward will only be done for 3 days.
2548372|NCT02575781|Experimental|SAR428926-Escalating cohort|SAR428926 will be administered intravenously up to disease progression or dose limiting toxicities
2548374|NCT02575781|Experimental|SAR428926 in triple negative breast cancer-Expansion Cohort 1|SAR428926 will be administered intravenously at maximum tolerated dose (MTD) up to disease progression or unacceptable toxicity
2548376|NCT02575781|Experimental|SAR428926 in solid tumors-Expansion Cohort 2|SAR428926 will be administered intravenously at the MTD up to disease progression or unacceptable toxicity
2548415|NCT02575534|Experimental|observational|"All patients will undergo 12-lead ECG and transthoracic echocardiography on the day of the study. These studies will be performed on patients as their previously implanted device is reprogrammed to pace in different modes. Patients will then receive an infusion of procainamide (12 mg/kg up to a maximum of 1 g) at a rate of 20 mg/min. Repeat ECG and echocardiograms will then be performed.~The patient's device will be programmed to a specific setting before and after the procainamide infusion."
2548473|NCT02575222|Experimental|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
2548546|NCT02574507|Experimental|Couples-Based Behavioral Weight and Symptom Management|Participants will receive 12 session (6 weekly and 6 biweekly) of a behavioral weight and symptom management intervention.
2548587|NCT02574273|Active Comparator|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) Program is an intervention which involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home. Parents will attend weekly parent support training sessions. 3 and 6 month booster sessions are conducted with both parents and children to help families with maintaining the skills that they have learned and to problem-solve new challenges that arise. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits, for both parent and child participants.
2548588|NCT02574273|Other|Waitlist Group / Treatment As Usual|Participants may be randomly allocated to the wait list control condition, where participants will receive treatment as usual during the 3 month period when the intervention group will participate in the SAS Program. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic. The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits.
2548679|NCT02574013|Experimental|sponge-assisted surgery group|Patients offered surgery with use of the retractor sponge
2548683|NCT02574013|No Intervention|Control group|Patients receiving standard care, i.e. surgery in Trendelenburg position
2548739|NCT02573506|Experimental|split-course radiotherapy|The radiotherapy is delivered using simultaneous integrated boost (SIB)-IMRT. Patients are irradiation at a palliative dose in the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated three weeks after the end of the initial course using CT. The patient without disease progression according to the RECIST criteria and had a recovery of lung function should get the additional boost. In the second course, the tumor is repositioned and scanned. The residual tumor is then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor. Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
2548772|NCT02573142|Active Comparator|Education-only|Subjects in the education-only control will receive standard of care clinical treatment in the Duke Healthy Lifestyles clinic and educational materials describing community-based resources for physical activity and how to access them.
2548882|NCT02572583|Experimental|Liugan Shuangjie Heji Group|Liugan Shuangjie Heji, take orally, 4 times a day, 100 ml each time (i.e. two doses per day), for a course of five days.
2548248|NCT02576444|Experimental|Group 2|Patients with tumors harboring PTEN, PIK3CA, AKT, or ARID1A mutations or other molecular aberrations leading to dysregulation of the PI3K/AKT pathway will be treated with AZD5363 plus olaparib.
2548252|NCT02576444|Experimental|Group 3|Patients with tumors harboring either TP53 or KRAS mutations or mutations in KRAS and TP53 will be treated with AZD1775 plus olaparib. TP53 mutations must be found on the TP53 mutation eligibility list.
2548256|NCT02576444|Experimental|Group 4|Patients with tumors harboring mutations in HDR genes, including ATM, CHK2, APOBEC, MRE11 complex, will be treated with AZD6738 and olaparib.
2548336|NCT02576158||Subjects will be women, 30-65 years of age|Patients who are at average risk of developing cervical intraepithelial neoplasia or cervical cancer who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT. Subjects with HPV positive will undergo colposcopy within 90 days of enrollment.
3204102|NCT00930670|Active Comparator|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
3204103|NCT00930683|Other|1|MEDI-546
3204104|NCT00930683|Other|2|MEDI-546
3204105|NCT00930683|Other|3|MEDI-546
3204106|NCT00930683|Other|4|MEDI-546
2548502|NCT02574884|Other|Recently infected subjects|Actual population of blood donors primo-infected with HCV with specific intervention for the study : one blood sample during the inclusion visit
2548504|NCT02574884|No Intervention|Retrospective cases|Population of infected blood donors in 2007, 2008 and 2009 No blood sample
2548505|NCT02574884|Other|Individuals sources|Specific intervention for the study : one blood sample during the inclusion visit
2548536|NCT02574624|Experimental|Intraocular Assistance|Intraocular assistance in patients undergoing standard of care vitreous surgeries
2548605|NCT02574325|Placebo Comparator|Placebo|Placebo
2548606|NCT02574325|Experimental|ARI-3037MO|ARI-3037MO
2548677|NCT02573974|Other|Case group|the intervention, specific to the study, is to take samples on patients with advanced gastrointestinal cancer
2548682|NCT02573974|Other|Control group|the intervention, specific to the study, is to take samples on non-undernourished patients supported for adjuvant chemotherapy as part of colorectal cancer
3204107|NCT00930683|Other|5|MEDI-546
3204108|NCT00930683|Other|6|MEDI-546
3204109|NCT00930683|Other|7|MEDI-546
3204110|NCT00930683|Other|8|MEDI-546
3204111|NCT00930683|Other|9|MEDI-546
3204112|NCT00930696|Experimental|Extensive Abdominal Lavage|women with full thickness excision of deep endometriosis involving the bowel
3204113|NCT00930696|Active Comparator|Standard Rinsing|women with full thickness excision of deep endometriosis involving the bowel
3204114|NCT00930709|Active Comparator|Active strength training and stretching|Active strength training and stretching
3204115|NCT00930709|Active Comparator|Botulinum toxin type A injections|Botulinum toxin type A injections
3204116|NCT00930722||quinapril|quinapril
3204117|NCT00930735||Myocardial fibrosis, outcomes|Groups with none and variable amounts of myocardial fibrosis
3204118|NCT00930800|Other|Exercise|Dance Dance Revolution (DDR)
3204119|NCT00930839||Controls|Normal, healthy controls, males and females, ages 30-80
3204120|NCT00930865|Active Comparator|Bumetanide|
3204121|NCT00930865|Active Comparator|Dapagliflozin|
3204122|NCT00930865|Active Comparator|Bumetanide + Dapagliflozin|
3204123|NCT00930878||Promus|Patients intended to be treated with a Promus™ stent system
3204124|NCT00930878||Endeavor|Patients intended to be treated with an Endeavor™ stent system (excluded the Endeavor™ Resolute™ stent)
2549059|NCT02571504|Experimental|Immediate cognitive training group|Plasticity-based Adaptive Cognitive Remediation (PACR) is an 8 week training to improve executive functions (e.g., working memory, flexibility, cognitive control) as well as attention. Participants in the immediate cognitive training group will receive the PACR intervention shortly after enrollment.
3204125|NCT00930878||Cypher|Patients intended to be treated with a Cypher™ stent system
3204126|NCT00930891|Active Comparator|Arm A|4 additional cycles of chemotherapy
3204127|NCT00930891|Experimental|Arm B|4 additional cycles of chemotherapy + bevacizumab
3204128|NCT00930917|Experimental|cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
3204129|NCT00930917|Active Comparator|wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
3204130|NCT00930917|Other|conventional group|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
3204131|NCT00930956|Active Comparator|Dextrose|30 g of carbohydrate via Sun-Dex OGTT beverage
3204132|NCT00930956|Experimental|RS Type 2|30g Resistant Starch Type 2 (Hi-Maize 260, National Starch)
3204133|NCT00930956|Experimental|RS Type 4 (cross linked)|30g of cross linked RS type 4 (Fibersym RW, MGP Ingredients, Inc.)
3204134|NCT00930995|Active Comparator|A|
3204135|NCT00930995|Placebo Comparator|B|
3204136|NCT00931008|Experimental|SID530|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
3204137|NCT00931008|Active Comparator|Taxotere|Study participants who meet eligibility criteria will be randomized to one of two treatment sequences, SID530 or Taxotere (i.e., SID530 on Day 1 followed by Taxotere on Day 21 or Taxotere on Day 1 followed by SID530 on Day 21)
3204138|NCT00931021|Active Comparator|Varenicline (Chantix)|
3204139|NCT00931021|Active Comparator|Nicotine Patch|
3204140|NCT00931034|Active Comparator|South Beach Diet with SBD Products|
3204141|NCT00931034|Active Comparator|ADA Diabetes meal plan|
3204142|NCT00931060|Experimental|Branched chain amino acids|Patients with cirrhosis. Healthy subjects age and sex matched
3204143|NCT00931073|Experimental|Period 1|
3204144|NCT00931073|Experimental|Period 2|
3204145|NCT00931073|Experimental|Period 3|
3204146|NCT00931099||Low risk pregnant women|300 women in the third trimester of a singleton uncomplicated pregnancy, who attend a low risk obstetric surveillance
2548285|NCT02576353|Experimental|Cohort 1|After a 10-hour fast, the 10 participants in this cohort are randomized to receive Fentanyl Sublingual (under the tongue) Spray (FSS) 100 mcg (n=8), or Fentanyl Citrate Intravenously (FCIV) 50 mcg (n=2).
2548286|NCT02576353|Experimental|Cohort 2|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 200 mcg (n=8), or FCIV 50 mcg (n=2).
2548287|NCT02576353|Experimental|Cohort 3|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 400 mcg (n=8), or FCIV 50 mcg (n=2).
2548290|NCT02576353|Experimental|Cohort 4|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 600 mcg (n=8), or FCIV 50 mcg (n=2).
2548292|NCT02576353|Experimental|Cohort 5|After a 10-hour fast, the 10 participants in this cohort are randomized to receive FSS 800 mcg (n=8), or FCIV 50 mcg (n=2).
2548441|NCT02575508|Experimental|Treatment (oxaliplatin, irinotecan, fluorouracil, BGJ398)|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously over 46 hours on days 1 and 15. Patients also receive pan FGFR kinase inhibitor BGJ398 PO QD on days 8-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2548534|NCT02574533|Experimental|Vigil™ + Pembrolizumab|"Biological: Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens.~Drug: Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter"
2548580|NCT02574364|Active Comparator|traditional incision|traditional incision : McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
2548582|NCT02574364|Experimental|modified incision|modified incision :The application of abdomen CT before surgery provides a new approach to the incision and new perception.
2548655|NCT02574052|Other|Behavioral|"The whole experiment was divided into three phases with each phase lasting two weeks.~First Stage-Behavioral: just record participants' food choices Second Stage-Behavioral: menu labelling without nutrition education Third Stage- Behavioral; menu labelling with nutrition education"
2548730|NCT02573727|Experimental|Nor Adrenaline + Albumin|"Intravenous continous infusion of terlipressin at the dose of 2 mg every 24 hours with the maximum daily cumulative dose of 12 mg/day.~In case of no response the dose of the terlipressin will be progressively increased to the maximum infusion dose of 12 mg/24 hour.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
2548731|NCT02573727|Active Comparator|Terlipressin + Albumin|"Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours designed to achieve an increase in MAP of at least 10 mmHg or an increase in 4-h urine output of more than 200 ml. When one of these goals was not achieved, the noradrenaline dose was increased every 4 h in steps of 0.5 mg/h, up to the maximum dose of 3 mg/h.~Patients will be given 1g/Kg of albumin per day, which will be discontinued if CVP is more than 18 cm H2O."
2548760|NCT02573272||Epileptic patients with AEDs and eslicarbacepine|
2548840|NCT02572986|Experimental|Permethrin cream 5%|Manufactured by Dr. Reddy's Laboratories, Ltd
2548850|NCT02572986|Active Comparator|Elimite™ Cream (permethrin) 5%|Manufactured by Prestium Pharma, Inc
2548898|NCT02572557|Experimental|Spray cryotherapy using liquid nitrogen|Device: TruFreeze Spray CryoTherapy Drug: Liquid nitrogen
2548939|NCT02572258|Experimental|Nutritional oats cookie and educational session|Nutritional cookie with oats and nuts
2548940|NCT02572258|No Intervention|Educational session only|
2548997|NCT02571894|No Intervention|Observational arm|Participants randomized to observational arm will receive standard oncological followup and care.
2549000|NCT02571894|Experimental|Intervention arm|Intervention arm receives standard oncological followup and care + subclinical cardiotoxicity surveillance and treatment.
2549076|NCT02571400||Patients scheduled to undergo surgery|Patients scheduled to undergo surgery at St Vincent's Private Hospital Sydney
2549144|NCT02570776||observation|Cohort of patients for Endoscopy & they are assessed for Helicobacter pylori through the histopathology & also throgh C14 C UBT.
2549204|NCT02570373|Experimental|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
2549430|NCT02568995|Experimental|LIA|Local infiltration analgesia using a combination of ropivacaine 300 mg + ketorolac 30 mg + adrenaline 0.5 mg
2549431|NCT02568995|Active Comparator|Femoral nerve block|Ultrasound guided 3-in-1 block using 30 ml of 0.75% ropivacaine
3169483|NCT00562952|Active Comparator|1|Patient will receive cardiac therapy to decrease NT-proBNP levels. This will be primarily RAAS-Antagonists and Betablocker. Blood pressure will be lowered to target values. A decrease of NT-proBNP is also known form life-style changes. Thus the patient will be educated to be trained
3169484|NCT00562952|Placebo Comparator|2|Patients will be followed 2 years. Care will be given by the responsible unit ( Dept.of Endocrinology) as clinical appropriate. Event rates will be obtained. After one year NT-proBNP will be measured.
3169485|NCT00562991||FeNO group|asthma patients, exhaled NO is used to monitor asthma
3169486|NCT00562991||Symptom group|asthma patients, exhaled NO is not used to monitor asthma
3169487|NCT00563004|Active Comparator|A|Patients receive the herbal medication DBCARE for 3 months
3169488|NCT00563004|Placebo Comparator|B|PATIENTS RECEIVE PLACEBO PILLS
3169489|NCT00563030||1|Patients undergoing CABG with CPB
3169490|NCT00563030||2|Patients undergoing off-pump CABG
3169491|NCT00563056|Experimental|Flutiform|2 puffs 50/5 or 125/5 mcg
3169492|NCT00563056|Active Comparator|Flixotide plus Foradil|Flixotide 2 puffs 50 or 125 mcg; Foradil 1 puff 12 mcg
3169493|NCT00563082||1|SLE participants positive for both APA and CHD
3169494|NCT00563082||2|Normal participants with a high titer of APA
3169495|NCT00563147|Experimental|A|tivozanib (AV-951) plus temsirolimus
3169496|NCT00563173|Other|1|Low dose
3169497|NCT00563173|Other|2|Medium dose
3169498|NCT00563173|Other|3|High dose
3169499|NCT00563212|Experimental|A1|
3169500|NCT00563238|No Intervention|Control|
3169501|NCT00563238|Active Comparator|Metoprolol|
2548305|NCT02576379||GEMS patients|Patients suspected of suffering from a vascular condition within the geographical area covered by both HEMS and GEMS, and were transported by Ground Emergency Medical System (GEMS) to the regional stroke unit at Copenhagen University Hospital Roskilde in a 40-month period from January 1st 2010 until April 30th 2013.
2548330|NCT02576080|Active Comparator|Standard Group|The Standard Group will receive adjuvant imatinib at a dose of 400 mg per day for a period of 3 years. Patients will be assessed for metastases every three months for three years with thoraco-abdominal and pelvic CT scan.
2548333|NCT02576080|Other|Experimental Group|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan. Surveillance
2548410|NCT02575443|Experimental|Moderate block (MB) group|
2548411|NCT02575443|Experimental|Deep block (DB) group|
2548451|NCT02575287||NERD group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a positive ph-impedanciometry for reflux
2548455|NCT02575287||Control group|(Digital chromoendoscopy with Optical Enhancement and without magnification; Digital chromoendoscopy with Optical Enhancement and with magnification; optical magnification without Digital chromoendoscopy: Optical Enhancement) Patients with reflux symptoms, without endoscopic lesions on the upper endoscopy with high definition white light or I-Scan and a negative ph-impedanciometry for reflux
3204147|NCT00931099||High risk pregnant women|100 women hospitalized at the Antenatal department due to pregnancy related hypertensive disorder, IUGR, diabetes mellitus or premature labor
2548707|NCT02573662||Case subjects|Physical active non-diabetic individuals of age 18 to 50 years, who are undergoing knee surgical procedures at the Arthroscopic Center at Amager/Hvidovre Hospitals are recruited as cases for this case-control study. OGTT, blood- and urine sampling and DXA scans will be performed 3 times throughout the study period.
2548713|NCT02573662||Control group|Non-diabetic individuals matched for age, gender and physical activity are recruited as control subjects to establish a reference level likely to image the cases before they experienced their knee injury. Blood- and urine sampling, OGTT and DXA scans will be carried out 1-3 times for each control subject. No lifestyle intervention is implemented.
3204148|NCT00931099||Pregnant women in labor|200 women of a singleton uncomplicated full term pregnancy will be recruited during labor at the delivery room
2548899|NCT02572466||ESRD group|"Aged 18 years or older.~was diagnosed as End-stage renal disease for more than one year.~Attend hemodialysis 3 times a week consistently for more than 6 months.~Hemodialysis with Kt/V > 1.2~No urine output or is less than 500 ml per day.~No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks."
2548903|NCT02572466||Control group|"Aged 18 years or older.~without kidney disease (eGFR > 60 ml/min/1.73m2)"
2548925|NCT02572232|Experimental|Combitube, Easytube, Laryngeal masks|Combitube, Easytube, Laryngeal mask airway are intubated in pediatric airway manikins by probands in randomized order.
2549081|NCT02571166|Experimental|HSV529|
2549125|NCT02570841|Active Comparator|Capsaicin|Treatment with Topical High dose Capsaicin
2549127|NCT02570841|Placebo Comparator|Placebo|Treatment with Topical Placebo
2549137|NCT02570542|Active Comparator|3-4 x 10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
2549138|NCT02570542|Experimental|6-8 x10^6 CD34+ stem cells/kg|Patients will receive standard supportive measures (including: growth factor support post-HDT/ASCT, antimicrobial prophylaxis, red blood cell and platelet transfusion and treatment for neutropenic fever) as per institutional guideline practices.
2549237|NCT02570321|Experimental|Bacterial ulcer cross-linking|Standard of care topical treatment for bacterial ulcer plus cross-linking
2549238|NCT02570321|Active Comparator|Bacterial ulcer control|Standard of care topical treatment for bacterial ulcer
2549244|NCT02570321|Experimental|Fungal ulcer cross-linking plus natamycin|Standard of care topical treatment for fungal ulcer with natamycin plus cross-linking
2549249|NCT02570321|Active Comparator|Fungal ulcer control with natamycin|Standard of care topical treatment for fungal ulcer with natamycin
2549252|NCT02570321|Experimental|Fungal ulcer cross-linking plus amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin plus cross-linking
2549254|NCT02570321|Active Comparator|Fungal ulcer control with amphotericin|Standard of care topical treatment for fungal ulcer with amphotericin
3169502|NCT00563264|Active Comparator|1|Participants receive monthly newsletter (for 10 months) including general health and reading information for child and mother and incentives for completing the baseline and 2 follow-up assessments
3204149|NCT00931099||Newborns|400 newborns belong to women in first two groups
2549341|NCT02569515|Experimental|Epoetin Beta|Patients will be administered 3 times (X) 30 International unis per kilogram(IU/Kg body weight per week of eopetin beta subcurtaneously using the device RecoPen. The dosage could be increased every 4 weeks by 3 X20 IU/Kg.
2549383|NCT02569242|Experimental|Nivolumab Arm|Nivolumab 240 mg/body solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
2549384|NCT02569242|Active Comparator|Active Comparator Arm （Docetaxel/Paclitaxel）|"Docetaxel: Intravenously administered at a dose of 75 mg/m2 every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends~OR~Paclitaxel: Intravenously administered at a dose of 100 mg/m2 weekly for 6 weeks followed by 2-week drug holiday until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends"
3204150|NCT00931112|Other|exercise|
3204151|NCT00931125|Active Comparator|vitrectomy with ranibizumab|Patients receiving adjunct preoperative intravitreal ranibizumab (3±1 days) before vitrectomy surgery
3204152|NCT00931125|Placebo Comparator|vitrectomy without ranibizumab|Patients receiving sham treatment before vitrectomy as a comparator arm
2548357|NCT02575937|Experimental|Impaired glucose tolerance group|During the trial period, the participants who are diagnosed of impaired glucose tolerance are instructed to consume low glycemic diet every day
2548400|NCT02575651|Experimental|Fluzoparib|Each subject will receive a single dose of fluzoparib on day 1, and then subject will receive fluzoparib twice daily for 28 days during cycle 1.
2548445|NCT02575417|Experimental|Patient Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Patient Only Groups:~are 18 years or older~speak and read English~have at least one chronic illness (cancer, chronic pulmonary disease, coronary artery disease, congestive heart failure, peripheral vascular disease, severe chronic liver disease, diabetes with end organ damage, renal failure)~have not completed an advance directive within the past 18 months~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys"
2548447|NCT02575417|Experimental|Caregiver Only|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Caregiver Only Groups:~are 18 years or older~speak and read English~have been an unpaid caregiver for an adult over the age of 18 in the last 12 months. Being an unpaid caregiver may include helping with personal needs or household chores, managing a person's finances, arranging for outside services, or visiting regularly to see how they are doing. This person need not live with participants in order for them to identify as caregivers;~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required survey~care recipient is capable of discussing medical issues~care recipient has not completed an AD in past 18 months"
2548448|NCT02575417|Experimental|Surrogate Decision Maker with Patient|"Individuals who meet the following criteria will play My Gift of Grace, a conversation game.~Eligibility Criteria for Surrogate Decision Maker and Patient Group:~considers themselves a surrogate decision maker for an adult with a chronic illness (defined in Patient Only Group)~are 18 years or older~speak and read English~are able to sit for about 2.5-3 hours~are able to focus on the game for about 1.5-2 hours~can complete required surveys~both patient and surrogate decision maker are able to attend study session together~patient must meet eligibility criteria defined in Patient Only group"
2548488|NCT02574988||SCAR Patients|Patients diagnosed with severe cutaneous adverse reactions with be recruited
3204153|NCT00931138|Active Comparator|Arm1 = Aracytine + Daunorubicin|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
2548646|NCT02574065|Experimental|L. reuteri DSM 17938 group|"L. reuteri DSM 17938 will be given at a dose of 100000000 colony forming units (CFU) per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.~Each day, at about the same time, the infants will be given 5 drops (1x100000000 CFU) of the study product in connection with feeding."
2548657|NCT02574065|Placebo Comparator|Placebo group|The placebo consists of an identical formulation without L. reuteri. Each day, at about the same time, the infants will be given 5 drops placebo in connection with feeding.
2548691|NCT02573688|Experimental|Interdisciplinary Therapy|The Therapy includes: Physical Exercise (three times week - 180 minutes); Nutrition, Psychology, Physiotherapy (once a week - 60 minutes each one)
2548743|NCT02573428||Autism Spectrum Disorder|Individuals who receive a clinical diagnosis of Autism Spectrum Disorder
2548744|NCT02573428||Developmental/Psychiatric Controls|Individuals who receive a clinical diagnosis of another developmental or psychiatric disorder
2548745|NCT02573428||Healthy Controls|Individuals who have no specific developmental or psychiatric diagnosis
2548766|NCT02573116|Experimental|Obstructive sleep apnea with chronic parodontis|patients with severe obstructive sleep apnea (OSA) and chronic parodontis treated for OSA by continuous positive airway pressure (CPAP) and intensive periodontal treatment
2548778|NCT02573116|No Intervention|Obstructive sleep apnea without chronic parodontis|patients with severe OSA treated by CPAP
2548831|NCT02572882|No Intervention|Pre-treatment|This arm is the 8-week observation period before the p-inulin treatment phase.
2548835|NCT02572882|Experimental|p-inulin|This arm is the 12 week p-inulin treatment phase (8 grams twice daily, oral).
2548843|NCT02572882|No Intervention|Post-treatment|This arm is the 8-week observation period after the p-inulin treatment phase.
2548891|NCT02572596|Experimental|rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed. rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
2548893|NCT02572596|Active Comparator|non- rhTPO treatment group|Subject will receive chemotherapy with intermediate-dose CTX 2.5/m2 for 2 days. 10 ug/kg/d of G-CSF was administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
2548943|NCT02572206|Other|PET/SPECT and MRI scans|"PET/SPECT scan will be used to evaluate the utility of mGluR5 binding as a biomarker of the CNTNAP2 mutation and related mTOR kinase pathway dysregulation.~30 minute structural MRI will be obtained to permit co-registration of PET images."
2548984|NCT02571855|Experimental|Part A: ACT-541468 multiple ascending doses|Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day
2548986|NCT02571855|Placebo Comparator|Part A: Placebo|For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)
2548988|NCT02571855|Experimental|Part B: ACT-541468 single ascending doses|Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg
2548991|NCT02571855|Placebo Comparator|Part B: Placebo|For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)
2549180|NCT02570581|Active Comparator|Jelly with memantine|Jelly with memantine
3204154|NCT00931138|Active Comparator|Arm 3 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
2548395|NCT02575729|Active Comparator|Inject betamethasone directly|Use 5/8 in medical needles inject betamethasone 7mg (1ml) in distal wrist crease directly. Entering skin with 30 degrees from the ulnar side of palmaris longus tandon. Changing direction of injection to prevent median nerve injury if patients feel numbness or pain in hand.
2548426|NCT02575482|Experimental|Single and Multiple ascending dose|Single dose of SUVN-D4010 in healthy male subjects
2548427|NCT02575482|Placebo Comparator|Placebo|Placebo in healthy male subjects
2548540|NCT02574442||Initial Colposcopy Visit|Women with a scheduled colposcopy and biopsy appointment at the Women's Clinic at Vancouver General Hospital
2548610|NCT02574299|No Intervention|1: Normal hearing children without SLI, transversal group|Normal hearing children without Specific Language Impairment (SLI),Transversal group for test-retest measures
2548612|NCT02574299|No Intervention|2: Normal hearing children without SLI, longitudinal group|Normal hearing children without Specific Language Impairment (SLI), longitudinal group without training
2548613|NCT02574299|Other|3: Normal hearing children with SLI, longitudinal group|Normal hearing children with Specific Language Impairment (SLI), longitudinal group with training
2548614|NCT02574299|No Intervention|4: Normal hearing adults without SLI, transversal group|Normal hearing adults without Specific Language Impairment (SLI), transversal group for test-retest measures
2548615|NCT02574299|No Intervention|5: Normal hearing adults without SLI, longitudinal group|Normal hearing adults without Specific Language Impairment (SLI), longitudinal group without hearing aids (HA)
2548616|NCT02574299|Other|6: Hearing Impaired candidates for HA, longitudinal group|Hearing Impaired adult candidates for hearing aids (HA), longitudinal group with hearing aids (HA)
2548651|NCT02573896|Experimental|NK cells with Ch14.18 & Lenalidomide|Patients in this arm will receive a designated dose of NK cells on Day 5 and 17.5 mg/m2/dose of Ch14.18 on Day 1-4. Patients on Dose Level 4 will also receive 25mg/m2/dose of Lenalidomide during Day -6 through 14 of treatment.
2548905|NCT02572492|Experimental|Carfilzomib/dexamethasone maintenance|Carfilzomib/dexamethasone maintenance after salvage HDT
2548908|NCT02572492|Sham Comparator|Observation without maintenance|Observation without maintenance after salvage HDT
2548926|NCT02572154|Other|Cases|men from couples with RPL after natural pregnancies, had blood and sperm samples for sperm DNA fragmentation exploration
2548927|NCT02572154|Other|Controls|men from couples who have a child consequently to a natural pregnancy, had blood and sperm samples for sperm DNA fragmentation exploration
2548998|NCT02571946|Experimental|Proton beam therapy|
2549153|NCT02570659|No Intervention|Information Folder|A folder with advise and exercises used by physiotherapeutic clinic of Södersjukhuset Hospital (Treatment as usual)
2549162|NCT02570659|Experimental|Information Video|A multiprofessional information video
2549246|NCT02570269|Active Comparator|AuraGain|The patient will get a fiberoptic Intubation via the AuraGain larynxmask
2549250|NCT02570269|Placebo Comparator|Slotted Guedeltubus|The patient will get a fiberoptic intubation via the slotted Guedeltubus
2549304|NCT02569983||Observational cohort|Observational study - all suspected or confirmed ovarian cancer patients
2549346|NCT02569528||Patients|Patients of consenting providers will complete a short survey and interview.
2549349|NCT02569528||Providers|Physicians treating patients with atrial fibrillation will complete a short survey and interview.
2549393|NCT02569333|Experimental|Educational Video|Subjects to have access to educational video during hospital stay
2549394|NCT02569333|No Intervention|Usual Care|Patients to receive usual care and will not have access to educational video.
2549447|NCT02568904||Alcohol binge|Healthy volunteers receive 2ml vodka 40% per kg bodyweight as a binge
2549448|NCT02568904||Fructose|75 g Fructose orally
2549449|NCT02568904||Glucose|75 g Glucose orally
2549450|NCT02568904||Vehicle|2ml tap water per kg body weight
3169503|NCT00563264|Experimental|2|Mothers and preschoolers in the intervention group will receive monthly mailed family kits that encourage interactive mother/child exercises for healthy lifestyle change. Mailings are supported by counseling calls and two in-person motivational/informational group sessions. The content of the intervention addresses parenting skills, healthy eating, and physical activity. Families can earn $40 for returning postcards describing their activities in the past month.
3169504|NCT00563303|Experimental|H|Hydrocortisone
3169505|NCT00563303|Placebo Comparator|P|Treatment by NaCl (placebo)
3169506|NCT00563394|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
3169507|NCT00563394|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
3169508|NCT00563433|Active Comparator|ofloxacin|an oral antibiotic (ofloxacin 400 mg) twice a day and a placebo vehicle topical cream twice a day for 14 days, extended up to 28 days if clinically warranted
3169509|NCT00563433|Active Comparator|MSI-78|an oral placebo twice a day and MSI-78 1%/2% Topical Cream twice a day for 14 days, extended up to 28 days if clinically warranted.
3169510|NCT00563459|Experimental|001|carisbamate 400-1200 mg/day for 12 months
3169511|NCT00563459|Active Comparator|002|topiramate 200-400mg/day for 12 months
3169512|NCT00563459|Active Comparator|003|levetiracetam 1000-3000mg/day for 12 months
3169513|NCT00563472|Active Comparator|1|10 mg estetrol
3169514|NCT00563472|Active Comparator|2|20 mg estetrol
3169515|NCT00563472|Active Comparator|3|20 mg estetrol and 150 microg desogestrel
3169516|NCT00563472|Active Comparator|4|20 mg E4 and 200 mg progesterone
3169517|NCT00563524|Placebo Comparator|1|
3169518|NCT00563537|Experimental|1|18F-X PET Scan imaging
2548442|NCT02575261|Experimental|Experimental:CAR-T cell immunotherapy|Enrolled patients will receive CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen by infusion.
2548443|NCT02575261|No Intervention|No Intervention|
2548484|NCT02575053||Latex group|patients who report ( a high risk for) latex allergy and will be operated on
2548538|NCT02574741|Active Comparator|Aripiprazole|Aripiprazole oral solution (1mg/mL) for 12 weeks. dosages range from 2-10mg per day.
2548541|NCT02574741|Active Comparator|Placebo|50% will be randomized to placebo.
2548544|NCT02574741|Active Comparator|Behavioral Intervention|All subjects will receive behavioral therapy, in addition to either active study drug (aripiprazole) or placebo.
2548625|NCT02574156|Experimental|Conventional Group|Patients randomized for Conventional Group will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 140 mg/dl and 180 mg/dl.
2548628|NCT02574156|Experimental|Moderate Group|Patients randomized for ModerateGroup will receive insulin infusion of regular insulin (100 UI) in 100 mL of saline in continuous infusion pump for maintenance of blood glucose between 100 mg/dl and 130 mg/dl.
2548759|NCT02573805||erectile dysfunction group|International Index of Erectile Function (IIEF-5) questionnaire≥22 Rigiscan test are performed for two nights
2548764|NCT02573805||control group|International Index of Erectile Function (IIEF-5) questionnaire<22 Rigiscan test are performed for two nights
2548849|NCT02572934||Chemotherapy group (CT-group)|Patients treated with chemotherapy >20 years ago
2548852|NCT02572934||Radiotherapy group (RT-group)|Patients treated with radiotherapy >20 years ago
2548854|NCT02572934||Surgery-only group (SU-group)|Patients treated with only orchidectomy >20 years ago
2548856|NCT02572934||Control-group|Healthy controls
2548895|NCT02572622|Experimental|spinal decompression group|only 15 sessions of spinal decompression therapy were applied.
2548896|NCT02572622|Experimental|combine group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and traction and last two weeks electrotherapy and exercise totally 15 session of treatment were applied.
2548897|NCT02572622|Experimental|exercise group|10 patients participated in this group. for two weeks electrotherapy, deep friction massage and last two weeks electrotherapy and exercise totally 15 session of treatment were applied whi
3169519|NCT00563563|Experimental|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg daily subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
2549052|NCT02571478|Experimental|7-Month Wait List Group|Couples will be randomly assigned to a wait list group. This group will wait seven months before starting The Marriage Checkup.
2549055|NCT02571478|Experimental|MC Right Away|Couples will be randomly assigned to receive The Marriage Checkup right away.
2549155|NCT02570451||undergoing any elective SDA surgical procedure|500 patients Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
2549166|NCT02570451||scheduled for elective joint replacement surgery|Patient Survey Independent Activities of Daily Living Score Sheet Geriatric Depression Scale Short Form 211 patients Activities of Daily Living Score Sheet Grip Strength Mini Cog RAND 36-Item Short Form Health Survey Confusion Assessment Method (CAM)
3169520|NCT00563602|Active Comparator|2|Standard Therapy: Endoscopic ligation (LEV) + Nadolol + Isosorbide mononitrate (MNI)(drugs carefully titrated until achieve maximum tolerated dose)
2549277|NCT02569866|Active Comparator|Antibiotics Group|Capsules containing cephalexin/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
2549281|NCT02569866|Placebo Comparator|Placebo Group|Capsules containing placebo/500mg will be administrated to the subjects, 4 times daily, for seven days during the postoperative period of reduction mammaplasty.
2549336|NCT02569697|Other|HEC Placebo Gel|The placebo gel will come in pre-filled individual applicators (4mL). Placebo gel is clear in color and contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
2549337|NCT02569697|Other|Placebo Vaginal Insert|The placebo vaginal inserts will be supplied in white plastic bottles. The placebo inserts are white to off-white in color, uncoated and bullet-shaped. The inserts are composed of ingredients generally recognized as safe including isomalt, xylitol, polyvinylpyrrolidone K 30, hydroxypropyl methylcellulose, poloxamer, and sodium stearyl fumarate. The inserts are approximately ½ to 1 inch long and approximately ¼ to ½ inch thick, similar in size to vaginal tablets that are currently available.
2549340|NCT02569697|Other|Placebo Vaginal Film|The placebo vaginal films will be individually wrapped. The placebo vaginal film is a thin, clear to translucent sheet with dimensions of 2 in x 2 in. The ingredients include hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC, E5), sodium carboxymethyl cellulose (NaCMC), and glycerin.
2549344|NCT02569697|Other|Placebo Intravaginal ring (IVR)|The placebo IVRs will be supplied in individual foil pouches. Each ring has a longer white to off-white segment and a shorter transparent/translucent segment, and ingredients include polyurethane, glycerin, water and modified starch.
2549456|NCT02568787|Experimental|Rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
2549463|NCT02568787|Placebo Comparator|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
3169521|NCT00563602|Experimental|1|"Hemodynamic guided therapy:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
3169522|NCT00563641|Experimental|1|Early NCPAP plus very early surfactant
3169523|NCT00563641|Active Comparator|2|NCPAP alone
3169524|NCT00563680|Experimental|Exploratory Cohort|If a total of two or more responses (partial and complete) in EFTs/DSRCTs are documented in this or the ongoing phase 1 study (20050118), then the study will allow enrollment of up to 10 additional EFT/DSRCT subjects who have been exposed to prior anti-IGF-1R targeting therapy.
3169525|NCT00563680|Experimental|Main Cohort|Subjects with relapsed Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have not received prior anti-IGF-1R therapy will receive AMG 479 at 12mg/kg.
2548458|NCT02575586|Active Comparator|Dry Needling out of MTrPs.|Control-Dry Needling: Deep Dry Needling distal to Myofascial Trigger Point of the soleus muscle (in the same taut band).
2548512|NCT02574949|Active Comparator|Conventional rate fluoroscopy|Radiation: 15 FPS Cine 15 PPS
2548513|NCT02574949|Experimental|Intermediate frame rate 7.5 fps|Radiation: 7.5 low Frame rate
2548515|NCT02574949|Experimental|Low frame rate|Low Cine 10 PPS
3204155|NCT00931138|Active Comparator|Arm 2 = Aracytine And Idarubicin|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
2548949|NCT02572050|Experimental|Robotic Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy (RDG) with D2 LND for patient with stage II or III gastric cancer The primary efficacy endpoint of number of dissected lymph nodes in the N2 area (which is #7, #8a, #9, #11p and #12a according to the JRSSGC) after oncologic resection for clinical stage II or III gastric adenocarcinoma.assessment.
2549010|NCT02571803|Experimental|Dietary And Lifestyle Counseling|Patients receiving strict dietary counseling (implementation of the DASH diet) and lifestyle changes support atop of optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
2549013|NCT02571803|Active Comparator|Optimal Medical Treatment|Patients receiving optimal medical treatment as per 2013 ESC guidelines on the management of stable coronary artery disease.
2549033|NCT02571309|Other|Smartphone app - Asthmatuner|"The app Asthmatuner contains four different modes;~Lung function testing with Bluetooth connection of external spirometry~Symptom evaluation~Actual treatment plan, based om lung function and symptoms~Trend views of lung function, symptoms and asthma control"
2549035|NCT02571309|Other|Conventional|Conventional treatment and Asthmatuner will be stratified and harmonized into categories of asthma management and current state-of-art at each health care centre. Each group harmonized group will include 43 subjects.
2549119|NCT02571114|Active Comparator|Control 1|white bread - 25 g available carbohydrate
2549121|NCT02571114|Active Comparator|Control 2|white bread - 25 g available carbohydrate
2549123|NCT02571114|Sham Comparator|Frozen Yogurt|unflavoured frozen yogurt - 25 g available carbohydrate
2549126|NCT02571114|Experimental|Saskatoon Berry Frozen Yogurt|frozen yogurt containing powder prepared from Saskatoon berries - 25 g available carbohydrate
2549151|NCT02570516|Active Comparator|Indigo carmine colonoscopy|Colonoscopy using indigo carmine is performed in second place
2549158|NCT02570516|Experimental|NBI colonoscopy|Colonoscopy using NBI is performed in first place
2549361|NCT02569385||spontaneous breathing trials|spontaneous breathing trials in patients with prolonged weaning
2549402|NCT02569099|Experimental|Intervention using standardised care|"Caregiver training /standardised care: where the participants (caregivers)s are trained on caring for relative who has survived a stroke once only for one hour using a developed curriculum.~Plus Conventional care: where the participants continue to receive the usual care as offered in protocols for treatment of stroke in Zimbabwe."
2549405|NCT02569099|No Intervention|Control|No training offered to caregivers but conventional care only where the people who have survived a stroke receive the usual care as offered in protocols for treatment of stroke in Zimbabwe.
2549440|NCT02568878|Experimental|Creatine monohydrate|5 grams of daily creatine monohydrate by mouth for 8 weeks
2549468|NCT02568605|Experimental|Prebiotic Fibre|The intervention group will receive two 8g packets/day of prebiotic fibre to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
2549469|NCT02568605|Placebo Comparator|Placebo|The control group will receive two 3g packets/day of maltodextrin to add to 250 ml of water and consume 30 minutes prior to breakfast and dinner.
2549473|NCT02568605|Other|Weight Loss|All participants will be supported through Registered Dietitian visits to achieve approximately 10% weight loss.
3169526|NCT00563693|Experimental|A|The patients use ASV
3169527|NCT00563693|Active Comparator|B|Patients without ASV
3169528|NCT00563745|Experimental|Telemedicine|Patients were submitted to a Telemedicine program for 1 year
3169529|NCT00563745|No Intervention|Control group|Patients were submitted to usual care (i.e: educational plan and outpatient visits every 3 months)
3169530|NCT00563836|Experimental|1|
3169531|NCT00563888|Experimental|A|Narrative Exposure Therapy (NET)
3169532|NCT00563888|No Intervention|B|Waitinglist Control Group
3169533|NCT00563901||1|Adults with a high risk for high blood pressure from the ALLHAT study
3169534|NCT00563914|Experimental|1|
3169535|NCT00563914|Active Comparator|2|
3169536|NCT00563940||1|
3169537|NCT00563940||2|
3169538|NCT00563953|Experimental|1|Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
3169539|NCT00563979|Active Comparator|1|VitaluxPlus®
3169540|NCT00563979|Active Comparator|2|Omega 3
3169541|NCT00563992|Experimental|1|Participants will take lithium for 12 months
3169542|NCT00563992|Experimental|2|Participants will take valproate for 12 months
3169543|NCT00564005|Experimental|1|constraint-induced therapy
3169544|NCT00564005|Experimental|2|bilateral arm training
3169545|NCT00564005|Experimental|3|combined therapy
3169546|NCT00564005|Active Comparator|Control intervention|
3169547|NCT00564031|Placebo Comparator|1|
3169548|NCT00564031|Experimental|2|
3169549|NCT00564031|Experimental|3|
3169550|NCT00564031|Experimental|4|
3169551|NCT00564044|Active Comparator|2|
3169552|NCT00564057|Experimental|1|candesartan 8-16 mg once daily
3169553|NCT00564057|Active Comparator|2|lercanidipine 10-20 mg once daily
3169554|NCT00564096|Active Comparator|Real TMS|10 patients will be given 20 minutes stimulation with real deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 20 consecutive working days.
3169555|NCT00564096|Placebo Comparator|Sham & real TMS|10 patients will be given 20 minutes stimulation with sham deep H1-Coil TMS to the Left Temporo-parietal Cortex in frequency of 1 Hz with 120% motor threshold during 10 consecutive working days, and thereafter 20 sessions of real TMS with the same parameters (=Left Tempor-oparietal Cortex in frequency of 1 Hz with 120% motor threshold).
3169556|NCT00564122||All subjects|
2548461|NCT02575183|Placebo Comparator|Placebo|"76 participants will be assigned to 4 behavioral therapy cessation for smoking cessation and will be randomized to receive a Placebo for Varinecline with instructions for administration for 12 weeks starting 1 week before Smoking Quit Date as suggested by the manufacturer: Days 1 to 3: a placebo (matched to 0.5 mg of Varenicline) orally once a day Days 4 to 7: a placebo (matched to 0.5 mg of Varenicline) orally twice a day Days 8 to end of treatment: a placebo (matched to 1 mg of Varenicline) orally twice a day.~Intervention 'Placebo (for Varenicline)' and Intervention 'Behavioral Therapy'"
2548627|NCT02574130|Experimental|Nebulized amikacin|Amikacin 400 mg nebulized every 12 hours plus intravenous antibiotic(s) for 10 days
2548629|NCT02574130|Placebo Comparator|placebo|nebulized placebo every 12 hours plus intravenous antibiotic(s)for 10 days.
2548720|NCT02573597|Active Comparator|Part A Group 1|CEI bupivacaine and CEI sufentanil
2548723|NCT02573597|Active Comparator|Part A Group 2|PIEB bupivacaine and PIEB sufentanil
2548726|NCT02573597|Active Comparator|Part B Group 3|CEI bupivacaine and PIEB sufentanil
2548727|NCT02573597|Active Comparator|Part B Group 4|PIEB bupivacaine and CEI sufentanil
2548770|NCT02573194|Experimental|Animal source of proteins|Breakfast based on animal proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2548779|NCT02573194|Experimental|Plant source of proteins|Breakfast based on plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2548782|NCT02573194|Experimental|Animal and plant source of proteins|Breakfast based on both animal and plant proteins: 1700 kJ, 25 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2548785|NCT02573194|Experimental|Low protein|Breakfast very low in protein: 1700 kJ, 5 E% Protein Acute effect of breakfasts varying in protein source content on appetite and energy intake
2548829|NCT02572856|Experimental|CGM patients|Apply continuous glucose monitor, calibrate and make glucose measurements. Measurements are blinded to the care provider
2548901|NCT02572700||Patients with psoriatic arthritis|PsA patients initiating anti-rheumatic treatment in routine care will be included as one group in the observational study. Analyses will be carried out for the overall study population as well as for subgroups (e.g., stratified according to treatment intervention) in an exploratory manner.
2548906|NCT02572700||Patients with skin psoriasis without arthrits|20 patients with skin psoriasis without arthrits will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
2548907|NCT02572700||Healthy controls|20 healthy controls will be included as one group at baseline only. Baseline characteristics including status of pain, fatigue, work, comorbidity and lifestyle factors will be recorded.
2548921|NCT02572219|Active Comparator|Nutraceutical|Treated with nutraceutical compound
2548922|NCT02572219|Placebo Comparator|Placebo|Treated with placebo
2548968|NCT02572011|No Intervention|Control|Participants in the control (CON) group will not complete any formalised balance training as part of the current study.
2548970|NCT02572011|Experimental|Experimental|Participants in the experimental group will complete the Home-based Games Console Balance Training intervention.
2549002|NCT02571725|Experimental|Olaparib and Tremelimumab|"Each cycle is 28 days:~Olaparib at 300 mg, orally, twice daily + Tremelimumab at 10 mg/kg, intravenously, every 4 weeks for the first 6 doses, then every 12 weeks until disease progression or unacceptable toxicity.~If 1 of the first 3 patients experiences a regimen-limiting toxicity (RLT), 3 more patients will be treated with 10 mg/kg Tremelimumab in Phase 1. If 2 or more of 6 patients experience RLT, then 6 mg/kg Tremelimumab will be tested~If at 6 mg/kg, 1 or more of 3 patients experience RLT, 3 patients will be treated at 3 mg/kg Tremelimumab~If at 3 mg/kg, 1 or more patients experience RLT, the study will be discontinued for safety purposes~In Phase 2, patients will receive doses of Olaparib and Tremelimumab determined in the Phase 1 portion as described above, based on tolerability."
2549069|NCT02571322|Experimental|Whole Body Vibration training|Use of the HyperVibe Whole Body Vibration training device for 12 weeks 3 times per week crossover to aerobic exercise
2549072|NCT02571322|Placebo Comparator|Aerobic Exercise|Aerobic exercise training for 12 weeks 3 times per week crossover to use of the HyperVibe Whole Body Vibration training device
2549214|NCT02570958|Experimental|Indocyanine green|
2549429|NCT02568982||patient with Cushing's disease|
3169557|NCT00564135|Experimental|A B C|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
3169558|NCT00564148|Experimental|A,1, II|
3169559|NCT00564161||1|
3169560|NCT00564161||2|
3169561|NCT00564174|Experimental|a|
3169562|NCT00564174|Active Comparator|b|Low dose aspirin only
3169563|NCT00564187|Active Comparator|1|"Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
3169564|NCT00564187|Active Comparator|2|• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B
3169565|NCT00564213|Experimental|1|A single intraoperative topical application of mitomycin C 0.02% for 15 seconds
3169566|NCT00564213|Experimental|2|A single intraoperative topical application of mitomycin C 0.02% for 30 seconds
3169567|NCT00564226|Experimental|SSR240600C Dose Level 1|
3169568|NCT00564226|Experimental|SSR240600C Dose Level 2|
3169569|NCT00564226|Experimental|SSR240600C Dose Level 3|dose level 3
3169570|NCT00564226|Active Comparator|Tolterodine|
3169571|NCT00564226|Placebo Comparator|Placebo|
3169572|NCT00564239|Experimental|A|
3169573|NCT00564239|Active Comparator|B|
3169574|NCT00564239|No Intervention|C|
3169575|NCT00564291||1|Healthy volunteers
3169576|NCT00564291||2|CSME secondary to diabetic retinopathy
3169577|NCT00564291||3|ARMD with CNV before and after therapy
3169578|NCT00564291||4|ARMD atrophic
3169579|NCT00564291||5|Retinal vein occlusion
3169580|NCT00564291||6|retinitis pigmentosa
2548845|NCT02572960|Placebo Comparator|Cholecalciferol|Cholecalciferol 70 mcg/day for 12 weeks Placebo Valsartan daily for 2 weeks
2548851|NCT02572960|Active Comparator|Valsartan|Placebo cholecalciferol/day for 12 weeks Valsartan 80 mg/day for 2 weeks
2548853|NCT02572960|Placebo Comparator|Placebo|Placebo cholecalciferol/day for 12 weeks Placebo Valsartan daily for 2 weeks
2548855|NCT02572960|Active Comparator|Cholecalciferol and Valsartan|Cholecalciferol 70 mcg/day for 12 weeks Valsartan 80 mg/day for 2 weeks
2548887|NCT02572518||2 doses of yellow fever vaccine|30 days,1-5 years and 6 years or more after last dose
2548916|NCT02572323|Active Comparator|Immediate group|1.4mg of tesamorelin is injected once a day for 6 months, then no treatment is given for 6 months
2548918|NCT02572323|Placebo Comparator|Deferred group|No treatment is given for 6 months, then 1.4mg of tesamorelin is injected once a day for 6 months
2548967|NCT02572024|Active Comparator|Baroreflex activation therapy|BAT ON
2548969|NCT02572024|Placebo Comparator|Placebo|BAT OFF
2549006|NCT02571673||Survivors of head and neck cancer|Data collection will take place in two parts. Aim 1: Part 1 will enroll 10 patients at MSK to participate in component pilot testing and usability testing of HN-STAR and the associated surveys. We will also elicit feedback from the NP. After incorporating any changes to HN-STAR or the surveys based on findings from Aim 1: Part 1, Aim 1: Part 2 will enroll 30 additional patients from MSK and 15 from HH to provide feedback on usability. We will also survey each patient's PCP in Aim 1: Part 2.
2549043|NCT02571426|Active Comparator|Propofol|Continuous infusion during surgery. Individual dosage.
2549044|NCT02571426|Active Comparator|sevoflurane|Inhalational anesthetic during surgery. Individual dosage
2549117|NCT02571088|Experimental|Training Program|The treatment will consist in an endurance training program. Only patients of the trained group will be subjected to this training program which will typically consist in 3 training sessions per week during 8 weeks i.e., 24 training sessions. Each training session will last 45 min. All training sessions will take place at the hospital and will be under medical supervision.
2549118|NCT02571088|No Intervention|No Training Program|It will be asked to the control patients to not change their habitual physical activity during the entire period of observation
2549168|NCT02570529|Experimental|Albis®|The intervention group
2549175|NCT02570529|Placebo Comparator|Placebo|The placebo comparator group
2549226|NCT02570243|Active Comparator|Standard dose of Heparin|50IU/Kg heparin intravenously
2549232|NCT02570243|Experimental|High dose of Heparin|100IU/Kg heparin intravenously
2549350|NCT02569502|Experimental|Enfuvirtide|Participants will receive 180 milligrams (mg) of enfuvirtide adminstered twice daily as subcutaneous injections
2549421|NCT02569294|Experimental|Choice 1: Yoga intervention|See intervention description
2549422|NCT02569294|Experimental|Choice 2: Hypnosis intervention|See intervention description
2549423|NCT02569294|Experimental|Choice 3: CBT intervention|See intervention description
2549426|NCT02569294|No Intervention|Control group|Participants who agreed not to participate in any of the interventions proposed.
2549451|NCT02568657|Active Comparator|Celox group|Celox placement is very simpe . During cesarean section celox is loaded in the lower uterine segment and part of it is passed through the cervix to the vagina. If PPH occurs after vaginal delivery the celox is inserted through the cervix to pack the lower uterine segment. Removal of Celox after 24 hours.
2549452|NCT02568657|Active Comparator|Bakri balloon group|Before insertion the balloon, ensure that the bladder is empty by placing a Foley catheter. Grasp the cervix with ring forceps. Insert the balloon into the cavity of the uterus under ultrasound guidance; making sure that the entire portion of the balloon passes the cervical canal above the internal cervical os. Once the correct placement is confirmed, inflate the balloon with sterile saline using the enclosed syringe.
3169581|NCT00564291||7|vitreoretinal proliferation
3169582|NCT00564317|Experimental|1 KIDNET|Narrative Exposure Therapy for Children
3169583|NCT00564317|Experimental|2 Meditation/Relaxation|mixed Meditation/Relaxation Protocol
3169584|NCT00564317|Experimental|3 KIDNET + Meditation/Relaxation|KIDNET according to protocol, waiting time of 5 months, then Meditation/Relaxation according to protocol
3169585|NCT00564317|Experimental|4 Meditation/Relaxation + KIDNET|Med/Relax according to protocol, 5 months waiting time, KIDNET according to protocol
3169586|NCT00564330|Active Comparator|esomeprazole|Esomeprazole 20mg twice daily
3169587|NCT00564330|Placebo Comparator|placebo|Placebo tablet twice daily
3169588|NCT00564343||ChSt, water training, Observation|Subjects suffer from chronic hemiplegia (a year or more post stroke) that upon questioning was judged to meet the following inclusion criteria: (a) able to stand independently 90 seconds; (b) able to walk 10 meters (with cane if necessary); (c) able to understand verbal instructions. The exclusion criteria will be: (a) Serious visual impairment; (b) Inability to ambulate independently (cane acceptable, walker not). (c) Severely impaired cognitive status (score less then 24 in Mini Mental State Examination). (d) Persons with impaired communication capabilities.
3169589|NCT00564356|Other|A|patients under coumadin and antiaggregants operated by phacoemulsification
3169590|NCT00564369|Experimental|1|2006 CDC recommendations
3169591|NCT00564369|Active Comparator|2|Prior CDC recommendations
3169592|NCT00564382|Other|1|Patients with ACS in the emergency department and primary tests (ECG, TNT) negative for myocardial ischemia
3169593|NCT00564408|Experimental|I|
3169594|NCT00564421|Experimental|Epinastine low concentration:low dose volume|
3169595|NCT00564421|Experimental|Epinastine low concentration:high dose volume|
3169596|NCT00564421|Experimental|Epinastine high concentration:low dose volume|
3169597|NCT00564421|Experimental|Epinastine high concentration:high dose volume|
3169598|NCT00564421|Placebo Comparator|Placebo nasal spray|
3169599|NCT00564460|Active Comparator|1|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
3169600|NCT00564460|Placebo Comparator|2|Placebo
3169601|NCT00564473||A|patients hospitalized in the Department of Internal Medicine of the Shaare Zedek Medical Center, Jerusalem, Israel.
3169602|NCT00564512|Experimental|FCCAM|Fludarabine-Cyclophosphamide-Campath (FCCam) Oral Fludarabine: 40 mg/m2 per os, D1 to D3 Oral Cyclophosphamide: 250 mg/m2/day as one dose at noon, D1 to D3 Campath®: 30 mg sc, D1 to D3 without dose escalation
3204156|NCT00931151|Experimental|Casein|Protein source in the high fat meal is casein
3204157|NCT00931151|Experimental|Milk soluble protein|Protein source in the high fat meal are milk soluble protein
3204158|NCT00931151|Experimental|Alpha lactalbumin|Protein source in the high fat meal is alpha-lactalbumin
3204159|NCT00931177||Dehydrated children|children with dehydration
3204160|NCT00931216|Experimental|Integrated ANC, PMTCT and HIV Services|HIV care and treatment services are integrated into antenatal care (ANC) services for women testing positive within the ANC at this facility.
3204161|NCT00931216|No Intervention|Non-Integrated Services|Women testing positive in the ANC department are referred for care at the HIV clinic. HIV care and treatment services are not provided within the ANC at facilities randomized to this arm.
3204162|NCT00931229|Experimental|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines.
2548911|NCT02572414|Experimental|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention consisted of three, 3-hour weekly small-group intervention sessions led by a trained facilitator using a detailed, scripted manual designed to increase adherence to guidelines for physical activity, 5-a-Day diet, and colon cancer screening.
2548912|NCT02572414|Active Comparator|Health Awareness Control|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
2548934|NCT02572115|Active Comparator|Intervention arm - jumped the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who choose to use the intervention."
2548936|NCT02572115|Active Comparator|Intervention arm - did not jump the line|"This arm is presented with the possibility to use the emergency access button that enables the patient to bypass the telephone waiting line. This arm represents the patients who got the option to use the intervention but DID NOT."
2548938|NCT02572115|No Intervention|Control|This arm does not get the intervention.
2549007|NCT02571881|Active Comparator|Oxycodone|Oxycodone 10 mg prolonged release tablet twice a day after caesarean section
2549009|NCT02571881|Experimental|Oxycodone-naloxone|Oxycodone-naloxone 10/5 mg prolonged release tablet twice a day after caesarean section
2549034|NCT02571348|Active Comparator|4 weeks and 8 weeks|Micro-osteoperforation will be done on either side of the maxilla at 4 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 8 weeks and the contralateral site will serve as the control
2549036|NCT02571348|Active Comparator|8 weeks and 12 weeks|Micro-osteoperforation will be done on either side of the maxilla at 8 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 12 weeks and the contralateral site will serve as the control
2549039|NCT02571348|Active Comparator|12 weeks and 4 weeks|Micro-osteoperforation will be done on either side of the maxilla at 12 weeks interval and the contralateral site will be the control. In mandible, micro-osteoperforation will be done every 4 weeks and the contralateral site will serve as the control
2549114|NCT02571127|Experimental|Only treatment|two weekly applications (monday and thursday or tuesday and friday) for 12 weeks
2549140|NCT02570646|Experimental|QA-DDS|Patients will receive exposure to the QA-DDS tool from their dental care practitioner.
2549265|NCT02570087|Active Comparator|Successful CTO PCI|Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
2549266|NCT02570087|No Intervention|Unsuccessful CTO PCI|Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)
2549279|NCT02569827|Placebo Comparator|Cohort 1|"Placebo Q6H for 5 days~A total of 72 participants (18 participants per group assuming up to two drop-outs per group) will be assigned in a randomised double-blind fashion."
2549282|NCT02569827|Active Comparator|Cohort 2|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg)
3204163|NCT00931281|Active Comparator|1|ABT-450/ritonavir
3204164|NCT00931281|Placebo Comparator|2|Placebo for ABT-450/placebo for ritonavir
3204165|NCT00931320||3000 patients|Who have at least made 1 visit to the outpatient clinic within previous 6 months .
3204166|NCT00931333|Experimental|1|
3204167|NCT00931346|Experimental|FTC/TDF Daily|Daily dosing
3204168|NCT00931346|Experimental|FTC/TDF Intermittent|Dosed intermittently
3204169|NCT00931346|Placebo Comparator|Placebo Daily|Placebo dosed daily
3204170|NCT00931346|Placebo Comparator|Placebo Intermittent|Placebo dosed intermittently, orally.
3204171|NCT00931372|Experimental|Sequence 1: AVE0010/Placebo|"Period 1: lixisenatide 20 µg in 200 µL, one single dose~Period 2: placebo 200 µL, one single dose"
3204172|NCT00931372|Experimental|Sequence 2: Placebo/AVE0010|"Period 1: placebo 200 µL, one single dose~Period 2: lixisenatide 20 µg in 200 µL, one single dose"
3204173|NCT00931398|Experimental|Methylphenidate HCl (Concerta)|
3204174|NCT00931398|Placebo Comparator|Placebo|
3204175|NCT00931424|Experimental|reconstruction|patients in this group will have both valve reconstruction and superficial vein surgery
3204176|NCT00931424|No Intervention|unreconstruction|patients in this group will only have superficial vein surgery
3204177|NCT00931437|Experimental|vitamin K-rich dairy product|one single intake of a dairy product containing several K-vitamins: phylloquinone, menaquinone-7,8,9-and 10.
3204178|NCT00931450|Active Comparator|Group 1|Patients receive oral exemestane and oral placebo once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3204179|NCT00931450|Experimental|Group 2|Patients receive oral exemestane once daily and oral sunitinib malate once daily on days 1-28. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3204180|NCT00931541|Experimental|A|AZD6088 oral solution
3204181|NCT00931541|Experimental|B|Placebo oral solution
3204182|NCT00931554|Active Comparator|Early drain removal|Drain removal in postoperative day 3
3204183|NCT00931554|Active Comparator|Standard drain removal|Drain removal on postoperative day 5
3204184|NCT00931567|Active Comparator|Vaselitulle|after surgery, the loss of substance is treated using vaseline dressing
2548619|NCT02574351||obese control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
2548620|NCT02574351||normal control|Participants from this group will be included in this study. A blood draw, breathing test will be performed to see if there is a difference in the t-regulatory cells amongst this group.
2548735|NCT02573454|Experimental|Prosocial Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Prosocial Exercise group use a GPS exercise app named Charity Miles, in which users can earn donations for charities based on the miles they walk or run (approximately 25 cents for every mile).
2548737|NCT02573454|Active Comparator|Personal Exercise|Participants are provided with the intervention (App Assignment). In this arm, the participants are randomly assigned to the Personal Exercise group use a traditional GPS exercise app named Nike + Running, in which users can track the mileage that they walk or run (i.e., there is no opportunity to earn donations for charity through exercise behaviour).
2548771|NCT02573220|Experimental|Treatment (FOLFIRI and cetuximab)|Patients receive irinotecan hydrochloride IV over 1-2 hours, fluorouracil IV continuously over 46 hours, and leucovorin calcium IV on days 1 and 15. Patients also receive cetuximab IV over 2 hours on days 3 and 15 of course 1 and days 1 and 15 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2548824|NCT02572765||Normotensive|Normotensive subjects
2548826|NCT02572765||Hypertensive|Hypertensive subjects
2548870|NCT02572739||haemodynamics measuring|those with already implemented PICCO device get impedance device (NICCOMO) attached
2549084|NCT02571582||Patients died|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
2549085|NCT02571582||living patients|"All patients underwent extensive evaluation:~- Body composition, Diabetes; dyslipidemia, hemoconcentration, hypertension, exercise capacity: 6-Minute Walk test procedure, renal function, inflammatory markers, cause and place of death, time tracking concentrator, quality of life and pulmonary Function."
2549129|NCT02570919|Active Comparator|IGRT 45 Gy in 5 fractions of 9 Gy|Arm A: Hypofractionated IGRT at a prescription dose of 45 Gy in 5 fractions of 9 Gy delivered in five consecutive days
2549131|NCT02570919|Experimental|IGRT 24 Gy single dose|Arm B: single fraction IGRT at a prescription dose of 24 Gy
2549171|NCT02570490|Experimental|CEM-102 (Sodium fusidate)|1500 mg by mouth every 12 hours for 2 doses, then 600 mg by mouth every 12 hours thereafter, until end of therapy (10 days total)
2549176|NCT02570490|Active Comparator|Linezolid|600 mg by mouth every 12 hours for 10 days
2549428|NCT02568969|Experimental|Lactate monitoring|The patients in the group will be subjected to the continuous perioperative monitoring of the venous blood lactate
3169603|NCT00564512|Active Comparator|FCR|"Fludarabine-Cyclophosphamide-Rituximab (FCR)~First course:~Rituximab 375 mg/m2 on D1.~D2 to D4:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon~Subsequent courses (2 to 6)~Rituximab 500 mg/m2 on D1~D1 to D3:~oral Fludarabine: 40 mg/m2/day as a single morning dose oral Cyclophosphamide: 250 mg/m2/day as a single dose at noon"
3169604|NCT00564525|Placebo Comparator|1|
3169605|NCT00564525|Experimental|2|Amitriptyline given
3169606|NCT00564538|Experimental|1|Patients in arm 1 will receive induction with thymoglobulin at time of transplant with delayed initiation of tacrolimus
3169607|NCT00564538|Active Comparator|2|patients in arm 2 will not receive thymo induction at time of transplant and will have immediate initiation of tacrolimus
3169608|NCT00564551|Active Comparator|2|High dairy intake and calcium supplement. High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
3169609|NCT00564551|Placebo Comparator|1|Usual diet of low dairy and calcium intake. Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet.
3169610|NCT00564564|Experimental|Quetiapine augmentation|Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage
3169611|NCT00564564|Active Comparator|Clomipramine augmentation|Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage
3169612|NCT00564577|Other|CFA/I and CS17 challenge strain|Colonization factor antigen (CFA/I) and CS17 challenge strainAscending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
3169613|NCT00564590|Experimental|A|Melatonin treatment group
3169614|NCT00564590|Active Comparator|B|Omeprazole 20 mg once a day for 3 months
3169615|NCT00564590|Experimental|C|Placebo once a day for 3 months
3169616|NCT00564603|Placebo Comparator|1|Saline with same volume added to tramadol infusion combined with morphine PCA.
3169617|NCT00564603|Active Comparator|2|Dexamethasone 10mg in 2mL added to tramadol infusion adjunct to morphine PCA.
3169618|NCT00564616|Placebo Comparator|voice group|"the voice group received voice CPR instruction via a voice-only cell phone"
3169619|NCT00564616|Experimental|video group|"the video group received interactive voice and video instruction via a video cell phone"
3169620|NCT00564655|Active Comparator|1|Patients in the control group will receive localized infiltration of local anesthesia at the beginning of the procedure as is current standard practice.
3169621|NCT00564655|Experimental|2|Patients in the experimental group will receive a regional anesthetic blockade of the anterior abdominal wall via the transversus abdominis plane.
3169622|NCT00564707|Active Comparator|1|Standard biofeedback therapy will be given for painful levator ani syndrome over a course of eight weeks.
3169623|NCT00564707|Active Comparator|2|Botulinum toxin type A will be injected under EMG guidance into spastic and painful levator ani muscles. This may be repeated only twice on separate visits.
3169624|NCT00564720|Experimental|1|GEM/TAR
3169625|NCT00564720|Experimental|2|GEM/OX/TAR
3169626|NCT00564746|Experimental|6 subjects in a single cohort|Each subject will be administered a single 10 milligrams (50 microcurie) oral dose of [14C]SB-681323.
3169627|NCT00564772|Experimental|single arm|all subjects dosed the same
2548632|NCT02574091|Placebo Comparator|Cohort 3-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2548635|NCT02574091|Experimental|Cohort 4-Experimental|"6 patients with mild to moderate psoriasis will be randomized to receive 2% icotinib hydrochloride cream, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2548640|NCT02574091|Placebo Comparator|Cohort 4-Placebo|"2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 13 consecutive days (final dose on the morning of Day 14).~The drug will be applied topically to the psoriasis site (excluding face, scalp, genital and groin) on the arms and/or legs and/or trunk only."
2548719|NCT02573610|Experimental|DE-108|High concentration / Antibacterial Ophthalmic Solution
2548721|NCT02573610|Active Comparator|Levofloxacin 0.5%|Low concentration / Antibacterial Ophthalmic Solution
2548773|NCT02573324|Experimental|ABT-414, Radiation and Radiation/Temozolomide (TMZ)|ABT-414 is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. ABT-414 is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
2548780|NCT02573324|Placebo Comparator|Placebo, Radiation and TMZ|Placebo is given on Day 1 of Week 1, 3 and 5 along with the standard therapy of TMZ and radiation during the chemoradiation phase. Placebo is given on Day 1 & 15 of each cycle along with TMZ (Days 1-5 of each cycle) per standard of care during the adjuvant phase.
2549037|NCT02571517|Experimental|Glucocorticoids|"methylprednisolone intravenous administration of 2mg/kg/day (divided in two doses) and/or oral prednisolone 2,5 mg/kg/day (in two divided doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis"
2549040|NCT02571517|Placebo Comparator|Placebo|"will receive iv/oral glucose 5% solution as placebo of 2mg/kg/day and/or 2,5 mg/kg/day (divided in two doses) during 7 days.~Patients younger than 2 year, who required hospitalization, affected by moderate or severe bronchiolitis."
2549106|NCT02571062|Experimental|experimental formulation|crossover design
2549109|NCT02571062|Experimental|final formulation|crossover design
3169628|NCT00564785|Placebo Comparator|Placebo|
3169629|NCT00564785|Experimental|Synera(TM)|
2549216|NCT02570217|Experimental|HHHFNC|The patients receive respiratory support by mean of Heated Humidified High Flow Nasal cannula
2549219|NCT02570217|Active Comparator|NCPAP|Patients receive respiratory support by Nasal Continuous Positive Airways Pressure(NCPAP)
2549411|NCT02569268||exposure population|No special intervention(s) .
2549436|NCT02568839|Active Comparator|A standard treatment|"docetaxel + trastuzumab sc + pertuzumab. Treatment with all three drugs is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm B.~Postoperatively, patients receive 2 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
2549439|NCT02568839|Experimental|B experimental treatment|"trastuzumab emtansine. Treatment is given on day 1, repeated every three weeks. Six courses of preoperative treatment. Response evaluations after every 2nd course. In case of no change (NC), treatment is switched to arm A.~Postoperatively, patients receive 4 courses of treatment with the combination epirubicin + cyclophosphamide (EC), followed by adjuvant trastuzumab, radiotherapy, eventually endocrine treatment."
3169630|NCT00564798||1|Study Group
3169631|NCT00564798||2|Control Group
3169632|NCT00564811|No Intervention|G1|
3169633|NCT00564811|Experimental|G2|
3169634|NCT00564824|Experimental|CAD patients|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
3169635|NCT00564824|Experimental|Placebo|Patients with prior history of coronary artery disease (CAD) (myocardial infarction, cerebrovascular accident, coronary angioplasty, S/p CABG operation) who will be given on the first day either caffeine of placebo tablet and 1-2 hours thereafter a brachial artery endothelial function testing (BRT) will be assessed for measuring the FMD. After 1 week the patients will come for a second BRT on placebo/caffeine tablets. If the patient received caffeine tablet the first BRT, he will be receiving placebo tablet the second week, however, if the patient received placebo the first BRT, a caffeine tablet will be given prior to the second BRT.
3169636|NCT00564837|Experimental|Home-based|Home-based post-operative rehabilitation program with 4 scheduled physiotherapy sessions over the first 3 post-op months
3169637|NCT00564837|Active Comparator|Physiotherapy supervised|Physiotherapy-supervised rehabilitation program including 17 scheduled physiotherapy sessions in the first 3 post-op months
3169638|NCT00564863|Other|CS19 expressing ETEC strain|Ascending dose finding study in 5-10 subjects per dose; to identify the dose able to give a diarrheal attack rate greater than or equal to 80%.
3169639|NCT00564928|Experimental|IPI-504: Group A|No Prior treatment for prostate cancer with cytotoxic chemotherapy (adjuvant or neoadjuvant chemotherapy is acceptable if completed >2 years prior to study)
3169640|NCT00564928|Experimental|IPI-504: Group B|"Must have evidence of radiographic metastatic disease~Must have been treated with a docetaxel-based chemotherapy regimen for HRPC with a minimum of 2 cycles with either PSA or RECIST defined radiographic progression during or witin 60 days of completeing docetaxel based chemotheraph or be intolerant of docetaxel-based chemotherapy~No more than three prior chemotherapies regimens for HRPC"
3169641|NCT00564941|Experimental|Deferasirox|
3169642|NCT00564967|Experimental|1|CBT via the Internet
3169643|NCT00564967|Experimental|2|15 weeks, CBT group therapy, 1 session/week (2.5 hours).
3169644|NCT00564980|Active Comparator|1|Wafer Procedure
2548652|NCT02574000||Single group baseline and follow-up|"Single group of adult stroke patients assessed using ShoulderQ shoulder pain questionnaire and Clinical shoulder examination at two time-points:~Baseline: within 72 hours post-stroke Follow-up: at 8-10 weeks post-stroke"
2548711|NCT02573740|Experimental|ABT-957|ABT-957 given twice a day for 84 days
2548717|NCT02573740|Placebo Comparator|Placebo|Placebo given twice a day for 84 days
2548751|NCT02573298|Active Comparator|Ice|patients randomized to receive local ice on inflamed joint
2548753|NCT02573298|Active Comparator|Cold gas|patients randomized to receive cold gas on inflamed joint
2548790|NCT02573038|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
3169645|NCT00564980|Active Comparator|2|Ulnar shortening osteotomy
2548868|NCT02572505|Experimental|HIV-Discordant Couple|A couple in which the man is HIV-seropositive and the woman is HIV-seronegative who wish to have a biologically related child. Couple will use condoms for all sexual acts except one act of unprotected intercourse during the fertile period when the woman will be taking the drug Truvada.
2548923|NCT02572375|Experimental|Codeine Phosphate/Guaifenesin ER Tablet|Patients receiving an extended release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin twice a day for 6 and a half days total. Total dosage [2 tablets] is 60 mg Codeine Phosphate and 1200 mg Guaifenesin twice a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
2548924|NCT02572375|Active Comparator|Codeine Phosphate/Guaifenesin IR Tablet|Patients receiving an immediate release tablet dosage form of a combination drug of Codeine Phosphate and Guaifenesin six times a day for 6 and a half days total. Dosage is 20 mg Codeine Phosphate and 400 mg Guaifenesin six times a day for a daily total of 120 mg Codeine Phosphate and 2400 mg Guaifenesin.
2549067|NCT02571257|Placebo Comparator|Placebo|Placebo treatment on stable background statin therapy
2549071|NCT02571257|Experimental|Gemcabene 300 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
2549074|NCT02571257|Experimental|Gemcabene 900 mg QD|Gemcabene (also known as CI-1027) treatment on stable background statin therapy
2549130|NCT02570945|Experimental|Intervention|Pharmacist-physician medication review
2549132|NCT02570945|No Intervention|Control|
2549165|NCT02570568|Active Comparator|Conventional Venepuncture|Veins will be identified by a combination of visualization and palpation. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2549172|NCT02570568|Experimental|Veinlite|Placing Veinlite onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2549177|NCT02570568|Experimental|Pen-torch Transillumination|The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up. Once a suitable vein is localized, a tourniquet is applied (Braun® International, USA). The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized 23G IV cannula is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a 23G needle (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture.
2549245|NCT02570178|No Intervention|standard practice advice|standard practice advice
2549247|NCT02570178|Other|balance training|balance training using the Nintendo™ Wii console and its balance board.
2549276|NCT02569918|Experimental|Surface electrical stimulation|Operation of hand prosthesis with surface electrical sensory feedback
2549325|NCT02569736||Tocilizumab|Patients with active moderate to severe RA fulfilling ACR criteria and requiring TCZ treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
2549327|NCT02569736||Methotrexate|Patients with active moderate to severe RA fulfilling ACR criteria and requiring MTX treatment, according to the EU label and French authority recommendations, who accept to enter the study and to sign the informed consent.
2549345|NCT02569450||Intervention arm|Hospitals randomly assigned to the intervention arm with surgical outcomes monitoring
3169646|NCT00564993|Active Comparator|A|"necessary re-intervention (pulmonary valve replacement) after repair of Fallot:~2 Visits with cardiac imaging under rest and stress (Dobutamin) before and after pulmonary valve replacement"
3169647|NCT00564993|Active Comparator|B|"comparison group: with a good result of repair of tetralogy of fallot and good ventricular function:~1 Visit with cardiac imaging under rest and stress (Dobutamin)"
3169648|NCT00565019|No Intervention|Control|
3169649|NCT00565019|Experimental|Steroid|
3169650|NCT00565071|Other|Field microscopy|Field microscopy is the main method of malaria diagnosis
3169651|NCT00565071|Other|Paracheck Pf® device|Paracheck Pf® device (Rapid Diagnostic Test) is the main method for malaria diagnosis
3169652|NCT00565071|No Intervention|Presumptive diagnostic method|
3169653|NCT00565097|Placebo Comparator|2|Placebo
3169654|NCT00565097|Experimental|1|Lanreotide
3169655|NCT00565123|Experimental|Group A|Experimental dosage
3169656|NCT00565123|Active Comparator|Group B|Classical dosage
3169657|NCT00565149|Experimental|1|Normal Protein (15%) diet
3169658|NCT00565149|Experimental|2|Low Protein (5%) diet
2548664|NCT02574104||Institution 11|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2548665|NCT02574104||Institution 12|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2548666|NCT02574104||Institution 13|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2548667|NCT02574104||Institution 14|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2548668|NCT02574104||Institution 15|"recruiting~Simulate a functional NICU prior to moving patients to preserve safety at transition"
2548733|NCT02573558||DEX|patients who received dexmedetomidine during the operation
2548734|NCT02573558||PPF|patients who received propofol during the operation
2548961|NCT02572297||video-EEG|Patients suffering from drug-resistant partial epilepsy for whom a video-EEG monitoring of their seizures was scheduled as part of pre-surgical assessment
2548989|NCT02571842|Experimental|Rituximab|"Drug: Rituximab~•Rituximab 375 mg/m2 on treatment month 1, 2, 3, 4~Other Name: Mabthera"
2548990|NCT02571842|Active Comparator|ACEI/ARB plus corticosteroids|"Drug: ACEI/ARB~An ACEI and /or ARBs will be used to achieve proteinuria reduction and a blood pressure goal of <130/80 mmHg. Patients not attaining the target blood pressure with an ACEI or ARB alone should be treated with the combination of ACEI + ARB~Corticosteroids will be used as prednisolone 0.5 mg/kg/day with gradually taper off in 6-8 weeks to 5mg/day daily~Other Name: Enalapril, Lorsartan, Prednisolone"
2549079|NCT02571491|Experimental|Ketamine Hydrochloride|"Received a combination of ketamine, remifentanil and morphine hydrochloride established by the following dosage regimen:~KETAMINE HYDROCHLORIDE 0,5mg/Kg Intravenous bolus administered during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0,3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
2549082|NCT02571491|Placebo Comparator|Placebo|"Received a combination of physiological serum, remifentanil and morphine hydrochloride established by the following dosage regimen:~0,9 % physiological serum 0,5mg/Kg administered by an intravenous (IV) line during the anesthetic induction, followed by 2 mcg / Kg / min of intravenous infusion during and after surgery until 72 hours postoperation~during surgery remifentanil 0.3 mcg / kg / min.~at the end of the operation morphine hydrochloride150 mcg / kg, PCA infusion postoperatively."
2549128|NCT02570802|Other|ultrasound of peripheral nerves|Ultrasonographic examination
2549312|NCT02569762|Experimental|Sucralose-Aspartame|Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.
2549318|NCT02569762|Experimental|Aspartame-Sucralose|Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.
2549338|NCT02569489|Experimental|HBI-8000, Paclitaxel, Trastuzumab|HBI-8000 at the assigned dose twice weekly while receiving weekly paclitaxel and trastuzumab for a minimum of 8 weeks (2 treatment cycles)
2549380|NCT02569229||Patients with Cystic Fibrosis|Patients between 10-20 years of age with genetically determined cystic fibrosis followed at the university children's hospital Basel and university children's hospital Kinderklinik Bern, Switzerland. All patients will get the diagnostics for glucose tolerance with 3 different methods (CGMS, OGTT and optionally IVGTT).
2549424|NCT02569060|Experimental|Immediate Intervention|"Participants randomized to the Intervention Arm will immediately begin a four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Diabetes self-management education and support"
2549425|NCT02569060|Active Comparator|Waitlist Control|"Participants randomized to the Waitlist Control arm will receive no intervention for six months, after which time they will begin a modified, four-component intervention.~Testing and monitoring of blood glucose levels~Referral to and/or coordination with primary care provider~Diabetes-appropriate food packages~Limited diabetes self-management education and support"
2549476|NCT02568631|Experimental|serious game JeStiMulE|"Evaluation of the social cognition for adults with autism.~The objective of the players of JeStiMulE (Educational Game for Multisensory Stimulation of Children with developmental disorders) will be to end the game after a period of learning and two periods of game (with emotional words and with idiomatic expressions understanding each three modules). The session ends when the module is carried out, what corresponds approximately at 1 am by module, that is 6 sessions of game.~Evaluation of the social cognition for adults with autism."
2549478|NCT02568631|Placebo Comparator|control video game|"Evaluation of the social cognition for adults with autism.~The objective of the players of the control video game will be to play 6 sessions of one hour.~Evaluation of the social cognition for adults with autism."
3169659|NCT00565149|Experimental|3|High Protein (25%) diet
3169660|NCT00565175|Experimental|famotidine|
3169661|NCT00565175|Placebo Comparator|Placebo|
3169662|NCT00565188|Experimental|I|
3169663|NCT00565188|No Intervention|C|
3169664|NCT00565201|Experimental|Botox and Rehab|"Patients will receive BOTOX® (100 to 360 U) injected into the any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site).~Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs."
3169665|NCT00565201|Placebo Comparator|Placebo and Rehab|Patients will placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
3169666|NCT00565214|Active Comparator|Group 1|On Day 1, Group 1 will initiate in a double-blinded fashion, a once daily vitamin combination of selenomethionine(400 μg), vitamin E(400 IU), and vitamin C (1000 mg) orally for 30 days at home. After 30 days of treatment with Vitamin supplements, the gene expression of the airway epithelium will be compared to that of the Placebo group.
3169667|NCT00565214|Placebo Comparator|Group 2|On Day 1, Group 2 will initiate the placebo in a double-blinded fashion.
2548675|NCT02573987|Active Comparator|Oxygen/nitrous oxide equimolar mix|96 participants undergoing chorionic villi sampling. self administered inhalation of equimolar mixture of oxygen and nitrous oxide (MEOPA)
2548681|NCT02573987|Active Comparator|Lidocaine|96 participants undergoing chorionic villi sampling infiltrative local anaesthesia of 1% lidocaine
2548729|NCT02573519|Active Comparator|Diabetic patient|"The study consists of four different parts:~11C Donepezil PET/CT scan~3D-Transit~3D-Transit during treatment with pyridostigmine~3D-Transit after Malone appendicostomy (only diabetic patients who had a Malone-surgery for severe obstipation ordered during standard clinical practice)"
2548732|NCT02573519|Active Comparator|Healthy subjects|"The study consists of two different parts:~11C Donepezil PET/CT scan~3D-Transit"
2548769|NCT02573129|Experimental|Red Meat Restricted|Following a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is restricted in lean, minimally processed red meat for 5 weeks.
2548777|NCT02573129|Experimental|Red Meat Rich|Following a 4-wk wash out period and a 2-wk baseline testing period to assess cardiometabolic and emotional well-being and habitual diet, subjects will consume a Mediterranean-style, weight-maintenance diet that is rich in lean, minimally processed red meat for 5 weeks.
2548836|NCT02572830|Experimental|Delayed Bilateral Eye Movements|Delayed Bilateral Eye Movements after reactivation of fear-memory.
2548844|NCT02572830|Active Comparator|Undelayed Bilateral Eye Movements|Undelayed Bilateral Eye Movements after reactivation of fear-memory.
2548881|NCT02572687|Experimental|Ramucirumab + MEDI4736 (NSCLC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given intravenously (IV) every 3 weeks (q3w) of a 21 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q3w. Participants may continue to receive study treatment until discontinuation criteria are met."
2548884|NCT02572687|Experimental|Ramucirumab + MEDI4736 (Gastric/GEJ)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV every 2 weeks (q2w) of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
2548888|NCT02572687|Experimental|Ramucirumab + MEDI4736 (HCC)|"In phase 1a (DLT phase), ramucirumab plus MEDI4736 given IV q2w of a 28 day treatment cycle. Participants may continue to receive study treatment until discontinuation criteria are met.~In phase 1b (expansion phase), ramucirumab plus MEDI4736 given IV q2w. Participants may continue to receive study treatment until discontinuation criteria are met."
2548980|NCT02571907|Experimental|Zenith® Branch Endovascular Graft-Iliac Bifurcation|Zenith® Branch Endovascular Graft-Iliac Bifurcation in combination with the Atrium iCAST™ and the Zenith® Flex AAA Endovascular Graft
2549030|NCT02571283|Experimental|Randomized Group A [Cocktail Injection]|"COCKTAIL INJECTION:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1 mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose"
2549031|NCT02571283|Experimental|Randomized Group B [Cocktail Injection Plus Exparel]|"COCKTAIL INJECTION PLUS EXPAREL:~Cocktail Injection Consists of:~Ropivacaine (Brand Name: Naropin) 5 mg/ml (49.25 ml) Ketorolac (Brand Names: Toradol, Sprix, Acuvail, Acular) 30 mg/ml (1 ml) Epinephrine (Brand Names: EpiPen, Adrenaclick, Medihaler-Epi, Twinject) 1 mg/ml (0.5 ml) Clonidine (Brand Names: Kapvay, Catapres, Duraclon, Nexiclon) 0.1mg/ml (0.08 mg = 0.8 ml) Normal Saline added to total of 100 cc Dosage Form: Injection Dosage: See above Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
2549032|NCT02571283|Experimental|Randomized Group C [Marcaine Plus Exparel]|"MARCAINE PLUS EXPAREL:~Bupivacaine Hydrochloride (Brand Name: Marcaine, Sensorcaine) Dosage Form: Injection Dosage: 3 ml vial, 0.5% solution Frequency: Single dose~Bupivacaine Liposome (Brand Name: Exparel) Dosage Form: Injection Dosage: 20 ml Single use vial, 1.3% (13.3 mg/ml) Frequency: Single dose"
3169668|NCT00565227|Experimental|docetaxel plus vorinostat|
3169669|NCT00565240|Experimental|Oral Contraceptive|
2549142|NCT02570438||Older surgical patients|older patients (≥ 65 years of age) presenting to Massachusetts General Hospital (MGH) or Newton-Wellesley Hospital (NWH) for elective noncardiac, non-neurological surgery requiring hospital admission
2549206|NCT02570386|Active Comparator|Control arm|Women allocated to the control arm will either undergo fresh embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
2549208|NCT02570386|Active Comparator|Intervention arm|Fresh embryo transfer will not be undertaken in this group. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
2549259|NCT02570113|Experimental|Renal Denervation by Neurolysis|Infusion of 0.6 ml of dehydrated alcohol (not less than 95% by volume) into the peri-adventitial space of the renal artery, to achieve renal denervation by neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
2549280|NCT02569879||Infants Group|"All infants ≤12 months of age in Bogota, reported with pertussis disease in the national databases of Bogota, between January 2005 and December 2014.~All infants ≤12 months of age in Bogota, deceased between January 2005 and December 2014 due to pertussis disease (primary diagnosis), based on death certificate information.~All infants ≤12 months of age in Bogota, with ALRTI, between January 2005 and December 2014.~All infants ≤12 months who have received primary pertussis vaccination in Bogota, between January 2005 and December 2014."
2549284|NCT02569879||Pregnant women Group|• Pregnant women will be included in the study to assess the vaccination coverage of Boostrix from March 2013 to December 2014
2549322|NCT02569684|Active Comparator|Arm A|Prebiotic fibers: Oligofructose and inulin
2549324|NCT02569684|Placebo Comparator|Arm B|Maltodextrin
2549474|NCT02568527|Experimental|PLGA Scaffold|Poly Lactide-co-Glycolic Acid (PLGA) 50:50
2548688|NCT02573714|Experimental|Intranasal Ketamine|Patients allocated to receive intranasal ketamine (intervention) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
2548689|NCT02573714|Placebo Comparator|Normal Saline|Patients allocated to receive intranasal normal saline (placebo) in addition to standard pain therapy. Patients enrolled in this arm will utilize the FPS-R and follow-up PedsQL-SCD.
2548750|NCT02573285|Active Comparator|Simple Aspiration|Subjects in this arm will undergo initial management of their pneumothorax with a simple aspiration procedure. The procedure will involve placement of a small catheter into the chest cavity and applying negative pressure to manually aspirate the air out of the chest cavity, which will allow the lung to re-expand.
2548752|NCT02573285|Active Comparator|Surgeon Preference|Subjects that choose the surgeon preference arm of the study are enrolling for prospective data collection only. These subjects will not have any portion their care directed by the study protocol. The decision to proceed with any treatment or intervention will be made jointly by the surgeon and the patient and his or her legal guardian. Any standard treatment option may be utilized, including simple aspiration, chest tube placement, or an operation (VATS).
2548789|NCT02573051|Active Comparator|Misoprostol plus isosorbide mononitrate|this group will receive 800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries) plus 40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company) will be inserted into the posterior vaginal fornix
2548793|NCT02573051|Active Comparator|Misoprostol plus placebo|This group will receive misoprostol 800 µg plus placebo in the same site.
2548883|NCT02572713||Early PD|20 early PD not requiring dopamine replacement therapy have been enrolled.
2548885|NCT02572713||Moderate PD|20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.
2548890|NCT02572713||Advanced PD|21 advanced PD with motor fluctuations have been enrolled.
2548892|NCT02572713||Healthy Controls|21 healthy controls have been enrolled.
2548950|NCT02572141|Experimental|Perioperative chemotherapy|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens
2548955|NCT02572141|Active Comparator|Postoperative chemotherapy|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens
2549003|NCT02571712|Other|GANFORT®|One drop of GANFORT® (bimatoprost 0.03% plus timolol 0.5%) instilled in each affected eye once daily in the evening for 24 weeks.
2549075|NCT02571270|Active Comparator|Active lifestyle|Active lifestyle involves nutritional education, physical activity and active recreation.
2549077|NCT02571270|Active Comparator|Lifestyle counseling|Lifestyle counseling helps patients to have better self-care.
2549078|NCT02571270|Active Comparator|secondary prevention|Secondary prevention it is essential to prevent a new unfavorable event.
2549080|NCT02571270|Active Comparator|survival|The survival of patients with heart failure may increase with exercise training.
2549103|NCT02570880|Experimental|Bread sample vs. glucose solution|glycemic index
2549141|NCT02570685|Experimental|Reflective Interpersonal Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful.
2549143|NCT02570685|Experimental|Reflective-Behavioral Gratitude|An interpersonal gratitude journal, designed to foster gratitude for one's existing social relationships, by writing and reflecting on people and positive daily encounters for which one is grateful. In addition participants are asked to choose a friend express this gratitude to them at the end of each week.
2549146|NCT02570685|Active Comparator|Neutral Control Journal|Write about and reflect on things that occurred over the course of the day.
2549260|NCT02570347|Active Comparator|Routine use arm|"All participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Antibiotic (Co-amoxiclav) will be given to all patients for a minimum duration of 5 days.~Daily clinical assessment would be done. Change of antibiotics is allowed if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
2549261|NCT02570347|Experimental|Clinically-directed use arm|"Participants allocated to this arm will be given~Injection Tetanus toxoid 0.5 ml intramuscularly Stat~Daily clinical assessment would be done. Antibiotic (Co-amoxiclav) will be started only if clinical failure occurs.~Use of antibiotics for emergent indications unrelated to the bitten limb such as nosocomial infections would be allowed at the treating physician's discretion."
2549371|NCT02569359|Experimental|Shea nut oil|100% shea nut oil extract with 75% triterpene esters. Daily dosage is three 750 mg soft gel capsules (2250 mg/per day) taken in the morning for 3 months
2549374|NCT02569359|Placebo Comparator|Placebo|placebo which comprised 100% canola oil or starch mixed soybean oil
2549458|NCT02568722|Active Comparator|Standard RRT initiation|RRT initiation will be guided by the presence of one or more clinical indications. Even in the absence of one of these indications, RRT may be commenced at the discretion of the treating physician.
2549462|NCT02568722|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of the patient meeting the eligibility criteria.
3169670|NCT00565240|Experimental|Contraceptive Ring|
3169671|NCT00565240|Experimental|Aromatase Inhibitors|
3169672|NCT00565240|No Intervention|Control|
3169673|NCT00565279|Experimental|ASF1057|
3169674|NCT00565279|Placebo Comparator|ASF1057 placebo|
3169675|NCT00565279|Placebo Comparator|ASF1057 Vehicle|
3169676|NCT00565305|Experimental|Healing Touch|Healing Touch + Standard Treatment Healing Touch treatments daily following standard Radiation Therapy. Standard radiation therapy is part of their medical care and is not administered as part of this study. Protocol of 4 HT techniques will be used including Pain Drain, Chakra connection, Magnetic Unruffling, and Mind Clearing. Treatments will be approximately 20-30 minutes.
3169677|NCT00565305|Active Comparator|Usual Care|Standard Treatment. These patients receive usual medical care but no additional intervention. Standard treatment is not administered as part of this study but as part of their medical treatment.
3169678|NCT00565318|Active Comparator|A|
3169679|NCT00565318|Placebo Comparator|B|
3169680|NCT00565331|Active Comparator|1|Rituximab
3169681|NCT00565331|Placebo Comparator|2|Placebo
3169682|NCT00565357|Experimental|E|
3169683|NCT00565357|No Intervention|C|
2548690|NCT02573701|Experimental|1 Guideline treatment|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
2548692|NCT02573701|Active Comparator|2 Treatment as Usual|Participants will receive the Treatment as Usual (atypical antipsychotic) plus psychosocial treatment decided by clinician
2548754|NCT02573363|Experimental|selinexor, cytarabine, and mitoxantrone|"INDUCTION CHEMOTHERAPY: Patients receive high-dose cytarabine and mitoxantrone hydrochloride per standard of care on days 1 and 5, and selinexor PO on days 2, 4, 9, and 11.~CONSOLIDATION CHEMOTHERAPY: Patients receive high-dose cytarabine per standard of care on days 1, 3, and 5, and selinexor PO on days 2, 4, 9, and 11. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE CHEMOTHERAPY: Patients achieving at least stable disease after consolidation chemotherapy may receive selinexor PO on days 1, 8, 15, and 22 at the discretion of principal investigator."
2548795|NCT02573025|Experimental|Test Followed by Reference|Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
2548798|NCT02573025|Experimental|Reference Followed by Test|Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.
3204185|NCT00931567|Experimental|Autologous platelets gel|after surgery, the loss of substance is treated with Autologous platelets gel
3204186|NCT00931580|Placebo Comparator|Placebo|placebo tablet
3204187|NCT00931580|Experimental|400 IU|Vitamin D3 tablet, 400 IU
2548902|NCT02572453|Experimental|Treatment (onalespib)|Patients receive onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2548960|NCT02572102|Experimental|Energy Drink|Two 16 ounce containers of an Energy Drink
2548963|NCT02572102|Active Comparator|Panax Ginseng|800 mg of Panax Ginseng in 70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
2548966|NCT02572102|Placebo Comparator|Placebo|70 mL of cherry syrup, 20 mL of lime juice, 410 mL of carbonated water
2548982|NCT02571764|Experimental|Nutritional Oats Cookie|
2549061|NCT02571335|Experimental|Intensive Training|Treatment consists of endurance training in both groups of physiologically defined heart rate controlled cycling at 50-60 rounds per minutes (rpm) and progressive resistance training. Training groups differ in the applied intensities and frequencies.The IT will train less frequent but training sessions will be more intensive in its effects. Training will be performed daily in six sessions (three morning and three afternoon sessions), synchronized and individually matched to a ratio of active versus passive sessions of 2:1.
2549064|NCT02571335|Active Comparator|Normal Training|The NT is the normal training performed out of the daily routine and outlines the usual care of the Valens clinic. Training will be performed in up to eight training sessions that will not be synchronized and not individually matched to a ratio of active versus passive sessions.
2549136|NCT02570932|Experimental|Autologous Mesenchymal Bone Marrow Cell|"All patients will be treated with the same treatment: Adult Autologous Mesenchymal Bone Marrow expanded Stem Cell (CME)~Pharmaceutical form: Suspension in autologous plasma cell Route of administration: Intrathecal in subarachnoid space by lumbar puncture. Dose: Total dose of 300 x 106 CME, given in 3 injections of 100 x 106 CME, at intervals of 3 months between each administration."
2549161|NCT02570477|Active Comparator|Fecal Microbiota Transplantatio|Fecal Microbiota Transplantation of stool from healthy donor to recipient.
2549170|NCT02570477|Active Comparator|Standard Therapy|125mg Vancomycin four times per day
2549212|NCT02570191|Experimental|Peginterferon alfa-2a|Participants received 180 micrograms (uG) of Pegasys (0.5 milliliter [mL] solution) once a week subcutaneously for 48 weeks.
2549293|NCT02569931|Experimental|study group|"36 participants recruited aged between 18 to 50 years of age~Participants will be considered eligible for the study group if they have had two or more episodes of patellar dislocation or multiple episodes of subluxation with at least one of the following:~i. Positive patellar apprehension test ii. Tenderness along the medial retinaculum iii. Abnormal patellar tracking or position.~The study group will undergo gait analysis and electromyography before surgery and 6 months after surgery.~During surgery the study group will undergo intra-operative tracking and pressure measurements."
2549297|NCT02569931|Other|control group|"36 participants recruited aged between 18 to 50 years of age, matched for age and gender with the study group. Control participants should be healthy subjects with no history of knee injury or surgery.~The control group will undergo gait analysis and electromyography."
2549420|NCT02569320|Experimental|Treatment (pomalidomide, dexamethasone, HDAC inhibitor AR-42)|Patients receive pomalidomide PO daily on days 1-21, dexamethasone PO BIW or TIW weeks 1-3, and HDAC inhibitor AR-42 PO BIW or TIW for weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3169684|NCT00565383|Active Comparator|Intravenous fentanyl analgesia|Intravenous fentanyl (50 mcg) analgesia
3169685|NCT00565383|Experimental|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia (intrathecal fentanyl 2.5 mg plus bupivacaine 2.5 mg) single administration
3169686|NCT00565396|Active Comparator|1|Fosinopril 10mg/day(oral)
3169687|NCT00565396|Active Comparator|2|Fosinopril 20mg/day(oral)
3169688|NCT00565396|Active Comparator|3|Losartan 50mg/day(oral)
3169689|NCT00565396|Active Comparator|4|Losartan 100mg/day(oral)
3169690|NCT00565422|Experimental|Single Arm|Escitalopram
3169691|NCT00565461|Experimental|Group 1|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT patch on the left deltoid by a Clinician on Day 0. Two weeks later will have the same treatment repeated on the right deltoid by the clinician
3169692|NCT00565461|Experimental|Group 2|40 subjects will be pretreated with SPS:Buffer and a patch containing 37.5ug will be applied on the left deltoid by the Clinician. Fourteen days later, the same procedure will occur on the left thigh by the clinician.
3169693|NCT00565461|Experimental|Group 3|40 subjects will have skin prepared using SPS:Buffer and will receive 37.5ug LT on the left deltoid by the clinician. Two weeks later subject will have the same treatment repeated by self-application in the clinic on the left thigh.
3204188|NCT00931580|Experimental|1,000 IU|Vitamin D3 tablet, 1,000 IU
2548718|NCT02573623||HIV-uninfected children aged<5 years with confirmed TB|Hospitalized children aged<5 years with TB confirmed by culture or GeneXpert
2548722|NCT02573623||HIV-uninfected children aged>4 years with confirmed TB|Hospitalized children aged>4 years with TB confirmed by culture or GeneXpert
2548724|NCT02573623||HIV-infected control children|Children hospitalized in the surgery ward without any evidence of tuberculosis infection
2548725|NCT02573623||HIV-uninfected controls aged <5 years|Children <5 years hospitalized in the surgery ward without any evidence of tuberculosis infection
2548728|NCT02573623||HIV-uninfected controls aged >4 years|Children >4 years hospitalized in the surgery ward without any evidence of tuberculosis infection
3169694|NCT00565461|Experimental|Group 4|40 subjects will have skin prepared using SPS:Buffer and will have 37.5ug LT patch on the left deltoid by a clinician. Two weeks later subjects will have the same treatment repeated by self-application at home on the left thigh.
2548830|NCT02572791|Experimental|Periodic personal decolonization|All household participants will perform chlorhexidine body washes twice weekly for 3 months and apply mupirocin ointment to the anterior nares twice daily for five consecutive days each month for 3 months.
2548834|NCT02572791|Experimental|Household environmental hygiene|In addition to their usual cleaning, households will be asked to perform targeted household hygiene focusing on sources known to harbor S. aureus and serve as reservoirs for transmission.
2548841|NCT02572791|Experimental|Integrated personal/household hygiene|Participants in households randomized to this arm will perform the Periodic Personal Decolonization plus the Household Environmental Hygiene, described above in arms 1 and 2.
2548879|NCT02572544|Experimental|Participants|All participants perform all exams under 3 conditions, that is baseline, single pinhole glasses, and multiple pinhole glasses
2549014|NCT02571660|Active Comparator|conventional treatment|GINA treatment fot asthma +vit.D low supplementation dose
2549015|NCT02571660|Experimental|conventional treatment + vitamin D3|GINA treatment fot asthma +vit.D high supplementation dose
2549062|NCT02571296|Active Comparator|group A|"subjects will recieve twice daily tablets of 100 mg of oral Micronized Progesterone from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: Oral micron ized progesterone Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
2549068|NCT02571296|Placebo Comparator|Group B|"subjects will receive placebo twice daily from (14-18 weeks) until 36 weeks or delivery.~Subjects: 106 cases Name: placebo Form: oral tablets Dosage: one tablet Frequency: every 12 hours Duration: 14-36 weeks gestational age."
2549104|NCT02570893|Experimental|adjuvant chemoradiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
2549108|NCT02570893|Experimental|adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
2549154|NCT02570633|Experimental|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
2549163|NCT02570633|Placebo Comparator|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
2549218|NCT02570204|Experimental|Self-assessment of abortion outcome|Patients enrolled in the study will self-assess the outcomes of their medical abortion with the aid of a multi-level pregnancy test (MLPT) which they will perform at home.
2549289|NCT02570061|Experimental|telephone|Information about the Calmette study was given by telephone
2549291|NCT02570061|Active Comparator|face-to-face|Information about the Calmette study was given face-to-face at a consultation at the hospital
3169695|NCT00565474|Active Comparator|1|fluvastatin 40mg b.i.d.
3169696|NCT00565474|Placebo Comparator|2|Placebo b.i.d.
2549410|NCT02569008|Experimental|1 ml / Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 1 ml/Kg IV over 5 minutes
2549412|NCT02569008|Experimental|2 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 2 ml/Kg IV over 5 minutes
2549415|NCT02569008|Experimental|3 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 3 ml/Kg IV over 5 minutes
2549419|NCT02569008|Experimental|4 ml/Kg|Patients receive a Fluid challenge with Compound Sodium Lactate 4 ml/Kg IV over 5 minutes
2549480|NCT02568774|Experimental|Traditional Acupuncture|Acupoints which are empirical for treating OAB in terms of Traditional Chinese medicine theory are used (in the sequence of scalp reproduction area and motor area of the unaffected side, RN3, bilateral BL32, BL33, BL28, BL39). And Ear point urinary bladder, and Ear point uterus will be treated after removal of needles. Needles will be left for 30 minutes and then removed. Subjects will be treated with acupuncture 2 times per week for the first 2 weeks and 1 per week for the 3rd and 4th week.
3169697|NCT00565487|Experimental|Single arm|This is a single arm dose escalation study with a cohort expansion.
3169698|NCT00565500|Experimental|1|
3169699|NCT00565500|Experimental|2|
3169700|NCT00565500|Placebo Comparator|3|
3169701|NCT00565513|Other|A|cord blood and maternal milk tests
3169702|NCT00565552|Active Comparator|1|Each patient uses the silicone gel on one half of the scar, leaving the other one blank as an internal control.
3169703|NCT00565565|Experimental|BAY60-4552, 1 mg|Subjects were planned to receive 1 mg of BAY60-4552 as solution
3169704|NCT00565565|Experimental|BAY60-4552, 2.5 mg|Subjects were planned to receive 2.5 mg of BAY60-4552 as tablet
3169705|NCT00565565|Experimental|BAY60-4552, 5 mg|Subjects were planned to receive 5.0 mg of BAY60-4552 as tablet
3169706|NCT00565565|Experimental|BAY60-4552, 7.5 mg|Subjects were planned to receive 7.5 mg of BAY60-4552 as tablet
3169707|NCT00565565|Experimental|BAY60-4552, 10 mg|Subjects were planned to receive 10 mg of BAY60-4552 as tablet
3169708|NCT00565591|Placebo Comparator|Dose escalation|
3169709|NCT00565630|Experimental|1|Vigamox via the experiemntal device
3169710|NCT00565630|Active Comparator|2|Vigamox drops from the commercially available bottles
3169711|NCT00565656|Experimental|A|Bevacizumab
3169712|NCT00565682|Experimental|A|Etoricoxib 120 mg
3169713|NCT00565708|Experimental|acetylsalicylic acid|200mg OD for 3 years
3169714|NCT00565708|Placebo Comparator|Placebo|200mg OD for 3 years
3169715|NCT00565734||Posterior surgical approaches|Posterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM)
2548757|NCT02573389|No Intervention|"Retrospective and prospective non-stented"|Non-stented patients undergoing distal pancreatectomy retrospectively (2008-2015) and prospectively from 2015 to 2017.
2548761|NCT02573389|Experimental|"Prospective stented"|Patients who undergo prophylactic pancreatic duct stenting prior to a distal pancreatectomy starting approximately September 2015.
2548837|NCT02572973|Active Comparator|Active Treatment|The Acoustic Neuromodulation (ANM) active treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The level of sound during Sound Stimuli (SS) presentation is relatively low (20-40 decibels), and the volume level can be adjusted downward if the subject requests it. The active intervention sounds used in the trial couple sequential frequencies to the base frequency in a nonlinear (exponential) manner following a special algorithm developed by Dr. Izvarina. This algorithm varies both the rate of change and duration of the overlaying modulation that is presented to the brain.
2548847|NCT02572973|Placebo Comparator|Non-Active Placebo|The Acoustic Neuromodulation (ANM) treatment intervention is a non-invasive form of therapy in which certain sounds at certain intervals are delivered to a subject through headphones five times over the course of two weeks. The sounds are delivered for 12 minutes at each session. The placebo sounds used in this trial mimic the active sounds, but instead of using nonlinear modulation, they are coupled to the base frequency in a linear manner. Both the sequence used as well as the rate of change and duration of this overlaying modulation are the same as that used for the active sounds. The only difference is use of a linear algorithm for the placebo sounds and a nonlinear (exponential) algorithm for the active sounds.
2548871|NCT02572635|Experimental|Cohort 1|50 µg of PnuBioVax
2548873|NCT02572635|Experimental|Cohort 2|200 µg of PnuBioVax
2548874|NCT02572635|Experimental|Cohort 3|500 µg of PnuBioVax
2548877|NCT02572635|Placebo Comparator|Placebo|Placebo
3169716|NCT00565734||Anterior surgical approaches|Anterior surgical approaches for symptomatic cervical spondylotic myelopathy (CSM).
2548975|NCT02571998|Experimental|Treatment|Omiganan (CLS001) Topical Gel applied once daily
2548977|NCT02571998|Placebo Comparator|Vehicle Gel|Vehicle Topical Gel applied once daily
2549046|NCT02571543|Experimental|Intervention|"2 Stage study design. Stage 1: 8 patients will be treated with the lower dose of 400mg of Ibuprofen. Should the efficacy be insufficient (3 or less patients) then the study will stop and stage 1 will recommence with 800mg.~Stage 2: 17 patients will be treated either with the lower dose of 400mg or the higher dose of 800mg of Ibuprofen should the respective stage 1 have been successful (4 or more patients showing an effect)."
2549049|NCT02571543|No Intervention|Control|The control group will consist of a no-treatment group of patients undergoing Intrauterine Insemination (IUI) or Timed Sexual intercourse (TSI), to verify the delay between LH-Peak onset and ovulation. 42h after Beta-HCG injection inducing LH-Peak, ovulation will be determined by ultrasound examination.
2549303|NCT02569840|Other|Amino Acid Feed|An amino acid based multi-nutrient powdered feed
3169717|NCT00565760|Experimental|1|
3169718|NCT00565760|Placebo Comparator|2|
3169719|NCT00565786||ArCom® Polyethylene|ArCom® Polyethylene
3169720|NCT00565786||ArComXL® Polyethylene|ArComXL® Polyethylene
3169721|NCT00565799|Active Comparator|1. Omentectomy|LAGB & Omentectomy
3169722|NCT00565799|Placebo Comparator|2 No Omentectomy|LAGB Only
3169723|NCT00565838||2|G1 - Autologous Fascial Sling G2 - TVT
3169724|NCT00565877|Experimental|1 - Neck Ultrasound|post-PICC insertion ultrasound inspection of the ipsilateral neck
3169725|NCT00565877|No Intervention|2 - Control|No post-PICC insertion ultrasound inspection of the ipsilateral neck
3169726|NCT00565890|No Intervention|2|No replacement therapy
3169727|NCT00565929|Experimental|Group A: MVA-BN 1 X 10^7 TCID 50|10 participants to receive vaccine dose 1X10^7 TCID 50; 2 participants to receive placebo.
3169728|NCT00565929|Experimental|Group B: MVA-BN 1 X 10^8 TCID 50|10 participants to receive vaccine dose 1X10^8 TCID 50; 2 participants to receive placebo.
3169729|NCT00565942|Active Comparator|Usual care|Treatment as usual coordinated by general practitioners in primary care.
3169730|NCT00565942|Active Comparator|Integrative care|Selected complementary therapies (Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong) added to usual care.
3169731|NCT00565955|Active Comparator|A1|Children Between 5-15 Years of Age Receiving Montelukast
3169732|NCT00565955|Placebo Comparator|A2|Children Between 5-15 Years of Age Receiving Placebo
3169733|NCT00565968|Experimental|Sorafenib dose escalation|
3169734|NCT00565981|Experimental|Overall study|The FLUSALEM protocol combines 4 cycles of oral fludarabine phosphate (40mg/m² d1-3; q 29d) and an intensive dose schedule of alemtuzumab (30mg sc.3 times weekly for 16 weeks) in an outpatient setting
3169735|NCT00565994||Hemodialysis patients|Male and female patients undergoing hemodialysis therapy as outpatients
3169736|NCT00565994||Control|Male and female healthy volunteers
3169737|NCT00565994||Pre-dialysis patients|Male and female patients with Stage 3, 4, or 5 chronic kidney disease, but not yet on dialysis
3169738|NCT00566007|Active Comparator|1|Discectomy/micro discectomy
3169739|NCT00566007|Active Comparator|2|Intradiscal ozone infiltration
3169740|NCT00566007|Active Comparator|3|Intradiscal oxygen infiltration (control arm)
3169741|NCT00566033|Experimental|1|
3169742|NCT00566033|No Intervention|2|Patients in this arm (arm 2) will undergo to standard care.
3169743|NCT00566046|Experimental|Levetiracetam|
3169744|NCT00566046|Placebo Comparator|Placebo|
3169745|NCT00566072|Experimental|1|instructions and coaching on the use and intake of ganciclovir
3169746|NCT00566072|No Intervention|2|
3169747|NCT00566085|Other|Molecular Breast Imaging|
3169748|NCT00566124|Active Comparator|1|Insulin detemir
3169749|NCT00566124|Active Comparator|2|Insulin glargine
3169750|NCT00566124|Active Comparator|3|NPH insulin
3169751|NCT00566189|Experimental|1|Roux-en-Y bypass gastroplasty
3169752|NCT00566202|Experimental|JNJ-18038683|
3169753|NCT00566202|Placebo Comparator|Placebo|
3169754|NCT00566202|Active Comparator|Escitalopram|
2548774|NCT02573168|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
2548783|NCT02573168|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
2549022|NCT02571595|Experimental|Immediate dCBT-I group|Digital cognitive behavioural therapy for insomnia (dCBT-I) is a 6 session training program (spanning 6 to 12 weeks) designed to improve sleep. Participants in the immediate dCBT-I group will receive the Sleepio intervention shortly after enrollment.
2549023|NCT02571595|Experimental|Waitlist control group|Participants in the waitlist control group will receive sleep hygiene recommendations from validated online resources for HIV patients (http://www.catie.ca/en/positiveside/winter-2013/sleep-tight) around the time of enrollment. They will start the digital cognitive behavioural therapy for insomnia (dCBT-I) intervention 12-14 weeks after the initial enrollment.
2549120|NCT02571101|Experimental|Test 1|Test 1 subjects will take one tablet of CDFR0812-15/25mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
2549122|NCT02571101|Experimental|Test 2|Test 2 subjects will take one tablet of CDFR0812-15/50mg and another tablet of Condencia-Placebo before sexual intercourse in on-demand for 8 weeks.
2549124|NCT02571101|Placebo Comparator|Comparator|Comparator subjects will take one tablet of Condencia and another tablet of CDFR0812-Placebo before sexual intercourse in on-demand for 8 weeks.
2549147|NCT02570464|Experimental|Patients undergoing aortic aneurysm surgery with RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery with Remote ischemic preconditioning (RIPC)
2549149|NCT02570464|Sham Comparator|Patients undergoing aortic aneurysm surgery without RIPC|Blood drawn is done for patient undergoing elective open infrarenal abdominal aortic aneurysm repair surgery without Remote ischemic preconditioning (RIPC)
2549210|NCT02570360|Active Comparator|exercise|Participants will engage in their outpatient treatment program as-usual, but additionally complete 30mins of moderately intense aerobic exercise 3 times per week for 6 weeks. They will complete 6 weeks of treatment, totaling 18 sessions with exercise.
2549211|NCT02570360|Placebo Comparator|treatment-as-usual|Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
2549285|NCT02570048||Experimental: Mutebutton intervention|This one armed trail will recruit participants who have been diagnosed with Tinnitus for a minimum of 6 months. Participants will use the Mutebutton device in their own home for 30 minutes every day for 12 weeks. The intervention requires sitting in a quiet space with the earphones on and the tongue tip placed on their tongue.
2549407|NCT02569138|Experimental|Insole (Experimental)|specially designed insole, featuring hard and thin design, modified insole
2549409|NCT02569138|Experimental|Insole (Control)|usual insole found in footwear, non-modified insole
2549435|NCT02568800|Experimental|Prolonged Cefepime Infusion|Cefepime infusions should last 4 hours at least
2549438|NCT02568800|Active Comparator|Usual Cefepime Infusion|Cefepime infusion should last no more than 30 minutes
2549475|NCT02568579||Breastfed|collection of blood/stool/breast milk samples and information about feeding changes and introduction of solid foods. - Cord Blood sample, stool samples monthly and blood sample at 6 month and 12 months of age
2549477|NCT02568579||Bottlefed|collection of blood/stool samples and information about feeding changes and introduction of solid foods. Coord blood sample, stool samples monthly and blood sample at 6 month and 12 month of age.
3169755|NCT00566215|Experimental|1|Duodenal exclusion plus total omentectomy
3169756|NCT00566215|Active Comparator|2|Duodenal exclusion without omentectomy
3169757|NCT00566241|Experimental|IGF-1|Recombinant human IGF-1
3169758|NCT00566241|Placebo Comparator|Placebo|Placebo
3169759|NCT00566267|Experimental|2|Low carb diet plus simvastatin 20 mg/ezetimibe 10 mg
3169760|NCT00566280|Other|Molecular Breast Imaging|
3169761|NCT00566306|Experimental|A|PHMG will be introduced in three wards for hand hygiene and environmental disinfection in CDAD patients' rooms. The rooms for showers and toilets will be coated with biocide coating (PHMG) as well as bed frames in investigational wards.
3169762|NCT00566306|No Intervention|B|Three wards will be control wards and continue using alcohol based hand disinfectants and routine environmental cleaning and disinfection with quats/chloramines.
3169763|NCT00566319|Experimental|1|
3169764|NCT00566319|Active Comparator|2|
3169765|NCT00566332|Active Comparator|1|Chlorambucil 8mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months
3169766|NCT00566332|Active Comparator|2|Fludarabine
3169767|NCT00566345|Experimental|1|Vero-cell derived influenza vaccine
3169768|NCT00566345|Placebo Comparator|2|Phosphate buffered saline (packaged in syringes identical to those used for the investigational vaccine)
3169769|NCT00566358|Experimental|1|Duodenal exclusion
3169770|NCT00566371|Experimental|1|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
3169771|NCT00566371|Placebo Comparator|2|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
2548985|NCT02571751|Experimental|Breast Augmentation|
2549025|NCT02571608|Active Comparator|Metformin|Metformin, dosage same as the patient's regular dosage
2549026|NCT02571608|Placebo Comparator|Placebo|Placebo
2549066|NCT02571192|Experimental|Experimental Drug|single oral dose radiolabelled 50mg of SHP626
2549105|NCT02570971|No Intervention|Control|Patients will receive supportive care measures.
2549107|NCT02570971|Experimental|Investigational|Patients will receive 500mL of 20% mannitol
2549196|NCT02570399|Experimental|Lymph nodal metastatic lesions|Oligometastatic patients with abdominal-pelvic lymph nodes
2549311|NCT02569775|Experimental|Stem cell transplantation|2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward
2549352|NCT02569567||US elastography|"Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic.~Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis."
2549445|NCT02568917|Active Comparator|Conventional Restoration|Conventional Restoration - Composite Resin (Bulk Fill)
2549446|NCT02568917|Experimental|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment - Ketac Molar Easy Mix
3169772|NCT00566384|Active Comparator|Arm 1|
3169773|NCT00566384|Placebo Comparator|Arm 2|
3169774|NCT00566397|Experimental|1|
3169775|NCT00566397|Experimental|2|
3169776|NCT00566397|Placebo Comparator|3|
3169777|NCT00566423|Experimental|1|Patients with Pulmonary Arterial Hypertension
3169778|NCT00566436|Active Comparator|REA|Patients presenting with a long occlusion of the superficial femoral artery enrolled in REA arm will undergo remote endarterectomy of the occluded superficial femoral artery
3169779|NCT00566436|Active Comparator|Bypass|Patients presenting with a long occlusion of the superficial femoral artery enrolled in Bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery
3169780|NCT00566449|Experimental|001|JNJ-31001074 10 mg daily for 4 weeks
3169781|NCT00566449|Placebo Comparator|003|Placebo one dose daily for 4 weeks
3169782|NCT00566449|Experimental|002|JNJ-31001074 30 mg daily for 4 weeks
3169783|NCT00566475|No Intervention|1|Usual care of type 1 diabetes at the diabetes center
3169784|NCT00566475|Experimental|2|Usual care at the diabetes center supplemented by a telemedicine intervention in the school involving school personnel, the child with diabetes and at least 1 parent of the child. The diabetes center NP conducts videovisits with the school nurse, patient (child) +/- parent monthly.
3169785|NCT00566488|Experimental|Thymus and Parathyroid transplantation|Thymus/Parathyroid Transplantation in Complete DiGeorge Syndrome Infants
3169786|NCT00566514|Active Comparator|1|D-ribose 5 grams TID orally
3169787|NCT00566514|Placebo Comparator|2|Dextrose 5 grams TID
3169788|NCT00566553|Active Comparator|Grape Seed Extract # 1|200 mg [1 pill]
3169789|NCT00566553|Active Comparator|Grape Seed Extract # 2|200 mg [2 pills]
3169790|NCT00566553|Active Comparator|Grape Seed Extract # 3|200 mg [3 pills]
3169791|NCT00566553|Active Comparator|Grape Seed Extract # 4|200 mg [4 pills]
3169792|NCT00566566||1|ALL survivors 5 years after completion of treatment, during routine medical follow up
3169793|NCT00566592|Experimental|1|Oral ethanol, overnight
3169794|NCT00566592|Experimental|2|IV ethanol, overnight
3169795|NCT00566592|Placebo Comparator|3|Placebo, overnight
3169796|NCT00566592|Placebo Comparator|4|Placebo, daytime
3169797|NCT00566605|Active Comparator|Group 1|
3169798|NCT00566605|Active Comparator|Group 2|
3169799|NCT00566618|Experimental|Dasatinib + Zoledronic Acid|"Dasatinib Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Zoledronic Acid Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort. Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
3169800|NCT00566657|Experimental|Riferminogene pecaplasmid|4 administrations of riferminogene pecaplasmid 4 mg at 2-week intervals
3169801|NCT00566657|Placebo Comparator|Placebo|4 administrations of placebo (for riferminogene pecaplasmid) at 2-week intervals
3169802|NCT00566670||Observation (all participants)|Stage 5 Chronic Kidney Disease and hemodialysis patients
3169803|NCT00566683|Active Comparator|1|Diazemuls-Pethidine
3169804|NCT00566683|Active Comparator|2|Propofol- Alfentanil
3169805|NCT00566774|Experimental|1|
3169806|NCT00566774|Active Comparator|2|
3169807|NCT00566826|Experimental|1|Patient support treatment sessions
3169808|NCT00566826|Active Comparator|2|Treatment as usual
3169809|NCT00566839|Experimental|1|
3169810|NCT00566839|Active Comparator|2|
3169811|NCT00566865|Experimental|2|mitiglinide + gemfibrozil
3169812|NCT00566865|Placebo Comparator|1|mitiglinide + placebo for gemfibrozil
3169813|NCT00566891|Active Comparator|A|Tirofiban
3169814|NCT00566891|Placebo Comparator|B|Clopidogrel
3169815|NCT00566904|Experimental|1|Participants will receive one of three different topical treatments on Days 8, 15, or 22.
3169816|NCT00566917|Active Comparator|1|Anterior colporrhaphy (standardised)
3169817|NCT00566917|Experimental|2|Anterior PROLIFT
3169818|NCT00566956|Experimental|1|For those assigned to Group 1, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
3169819|NCT00566956|No Intervention|2|Patients assigned to group 2 will not have the hydrosalpinx aspirated
3169820|NCT00566995|Experimental|Vandetanib in Participants with Kidney Cancer|300 mg/day (starting dose) oral dose of vandetanib once a day for 28 days
3169821|NCT00567021||1|patients with GERD or NSAID-related ulcers
3169822|NCT00567034|Active Comparator|1|taking naltrexone
3169823|NCT00567034|Placebo Comparator|2|taking placebo
2548889|NCT02572583|Active Comparator|Oseltamivir Phosphate Capsule Group|Oseltamivir Phosphate Capsule, take orally, 2 times a day, 75 mg each time, for a course of five days.
2548945|NCT02572271|Active Comparator|Rubins Mastopexy|Patients are allocated to a mastopexy using Rubins technique
2548954|NCT02572271|Active Comparator|LOPOSAM|Patients are allocated to a mastopexy using the LOPOSAM technique
2549004|NCT02571829|Experimental|ribociclib|single arm ribociclib Oral 600 mg x 1 a day duration according to response.
2549065|NCT02571413|Other|oral presentation|"Scoring the correct use of INC before, immediate after and 3 months after oral presentation without demonstration how to use INCS"
2549073|NCT02571413|Other|animated cartoon-aided VDO|"Scoring the correct use of INC before, immediate after and 3 months after animated cartoon-aided teaching how to use INCS"
2549102|NCT02570828|Experimental|Thermal imaging|All subjects in the study will have thermal images of the chest taken using the FLIR ONE attachment to an iPhone.
2549356|NCT02569424|Experimental|ventilated patients|Patient's position (Supine or Trendelenburg strict -20°)
3169824|NCT00567047|Experimental|1|Vildagliptin
3169825|NCT00567073||Pregnant women with confirmed diagnosis of pompe Disease|No experimental intervention is given. Pregnant women with confirmed diagnosis of Pompe disease that are participating in the Pompe Registry (NCT00231400) and consented to participate in the Pompe Pregnancy Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with alglusidase alfa) and irrespective of the commercial product with which she may be treated.
3169826|NCT00567073||Pregnant women receiving no treatment for pompe disease|Pregnant women with pompe disease enrolled in the pompe disease registry (NCT00231400) who are not receiving treatment
3169827|NCT00567073||Infants born to mothers receiving treatment for pompe disease|The infants of mothers with pompe disease enrolled in the pompe disease registry (NCT00231400) where the mothers are receiving treatment of alglucosidase alpha (Myozyme)
3169828|NCT00567073||Infants born to mothers receiving no treatment for pompe disease|The infants of mothers with pompe disease enrolled in the Pompe Disease Registry (NCT00231400) where the mothers are not receiving Treatment
3169829|NCT00567086|Placebo Comparator|A|
3169830|NCT00567086|Experimental|B|
3169831|NCT00567086|Experimental|C|
3169832|NCT00567086|Experimental|D|
3169833|NCT00567125||I|Patients with cholelithiasis operated on using standard laparoscopy method
3169834|NCT00567125||II|Patients with cholelithiasis operated on using low-pressure CO2 pneumoperitoneum laparoscopy
3169835|NCT00567177|Active Comparator|1|
3169836|NCT00567177|Placebo Comparator|2|
3169837|NCT00567203|Experimental|1|
3169838|NCT00567203|Experimental|2|
3169839|NCT00567203|Placebo Comparator|3|
3169840|NCT00567216|No Intervention|G|Endoscopic injection of cyanoacrylate alone
3169841|NCT00567216|Active Comparator|C|Combination of GVO and nadolol
3169842|NCT00567281|Experimental|1|Active bilateral rTMS to left/right Wernicke's area and opposite side middle temporal gyrus
3169843|NCT00567281|Active Comparator|2|Active rTMS to left/right Wernicke's region plus sham rTMS to opposite hemisphere middle temporal cortex
3169844|NCT00567294|Active Comparator|A|Participants will receive mailed education materials on osteoporosis and medication use.
3169845|NCT00567294|Experimental|B|Participants will receive a telephone coaching program.
3169846|NCT00567294|Experimental|C|Participants will receive a telephone coaching program, and doctors of these participants will receive medication adherence alert notifications.
3169847|NCT00567333|Other|1|
3169848|NCT00567333|Other|2|
3169849|NCT00567346|Active Comparator|grass pollen extract twice weekly|Current standard dose regimen of grass pollen immunotherapy (9,500 BU), given twice weekly. Note: patients in twice weekly dosing regimen will also receive placebo on days no active treatment is given.
3169850|NCT00567346|Active Comparator|Grass pollen extract, daily|Grass pollen immunotherapy, 9,500 BU, given daily
3169851|NCT00567346|Active Comparator|Increased dose of grass pollen extract|Increased dose of grass pollen immunotherapy, 19,000 BU, given daily
3169852|NCT00567346|Placebo Comparator|Placebo control|Patients randomized to placebo will receive placebo daily.
3169853|NCT00567411|Active Comparator|I|Eyes receiving Apraclonidine 0.5% (Iopidine) prior to SLT
3169854|NCT00567411|Active Comparator|A|Eyes receiving Brimonidine 0.1% (Alphagan) prior to SLT
3169855|NCT00567437|Other|A|10 patients with no aortic stenosis
3169856|NCT00567437|Other|B|100 patients with asymptomatic AS
3169857|NCT00567450|Active Comparator|B|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
3169858|NCT00567450|Experimental|A|30 ml of ropivacaine 0.75%
3169859|NCT00567463|Placebo Comparator|Placebo|Placebo inhalator will be used by subjects in the placebo group(same course as patients in the treated group)
3169860|NCT00567515|Experimental|LAA Clip|AtriCure LAA Exclusion System
3169861|NCT00567528|Other|1|Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
3169862|NCT00567528|Other|2|Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules
3169863|NCT00567554|Experimental|1|EC-T
3169864|NCT00567554|Experimental|2|EC-T +/- B
3169865|NCT00567554|Experimental|3|Pw
3169866|NCT00567554|Experimental|4|Pw + RAD001
3169867|NCT00567554|Experimental|5|EC-T + H
3169868|NCT00567554|Experimental|6|EC-T + L
3169869|NCT00567606|Experimental|1|Subjects in the G1 group receive 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine.
3169870|NCT00567606|Experimental|2|Subjects in the G2 group receive the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
3169871|NCT00567658|Placebo Comparator|A 1|Arm I: placebo group receives BID placebo
3169872|NCT00567658|Experimental|A2|subjects receive active drug, esomeprazole 40 mg BID
3169873|NCT00567671|Experimental|Treatment|Corneal collagen cross-linking
3169874|NCT00567671|Sham Comparator|Control|Sham Treatment
3169875|NCT00567684|Experimental|CTU + IVU|CTU = Computed Tomography Urography + IVU = Intravenous Urography
3204189|NCT00931580|Experimental|2,000 IU|Vitamin D3 tablet, 2,000 IU
2548948|NCT02572128|Experimental|Study 1|Iron fortified rice hot or cold extruded.
2548956|NCT02572128|Experimental|Study 2|Iron and zinc fortified rice hot extruded or coated.
2548996|NCT02571816|Experimental|ASP2215: Subjects with mild hepatic impairment|Subjects with Child Pugh classification score of 5-6 (mild)
2548999|NCT02571816|Experimental|ASP2215: Subjects with moderate hepatic impairment|Subjects with Child Pugh classification score of 7-9 (moderate)
2549001|NCT02571816|Experimental|ASP2215: Subjects with normal hepatic function|Healthy subjects that match with respect to age, sex and body mass index (BMI)
2549042|NCT02571361|Active Comparator|Treatment A:|Paracetamol 1g + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2549045|NCT02571361|Active Comparator|Treatment B:|Paracetamol 1g + placebo orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2549047|NCT02571361|Active Comparator|Treatment C:|Placebo + ibuprofen 400 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2549050|NCT02571361|Active Comparator|Treatment D:|Paracetamol 0,5 g + ibuprofen 200 mg orally starting 1 hour before surgery and given with 6-hour intervals (+/- 1 hour) i.e. a total of 4 times the first 24 hours postoperative.
2549098|NCT02570854|Experimental|CSJ137|In Part 1 up to 48 subjects will receive a single dose of CSJ137. In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
2549099|NCT02570854|Placebo Comparator|Placebo|In Part 2, up to 40 patients will be randomized to one of 2 arms with equal allocation: one CSJ137 dose arm from Part 1 and a placebo arm. Each patient in Part 2 will receive up to 2 doses (repeat dose).
2549139|NCT02570594|Other|healthy volunteers|
2549315|NCT02569788|Experimental|CIRT Arm|Patients included in this arm were treated with carbon ion radiotherapy (CIRT).
3169876|NCT00567697|Active Comparator|A|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection
3169877|NCT00567697|Sham Comparator|B|
3169878|NCT00567710|Experimental|I|BL - 1020 lowdose
3169879|NCT00567710|Experimental|II|BL 1020 high dose
3169880|NCT00567710|Placebo Comparator|III|
3169881|NCT00567710|Active Comparator|IV|Risperidone
3169882|NCT00567723||1|Test group: Patients who have received a minimum of 12 consecutive weeks of treatment with Fosrenol
3169883|NCT00567723||2|Historical control group: Patients with no lanthanum exposure
3169884|NCT00567723||3|Concomitant therapy group: Patients being treated for hyperphosphatemia with any marketed product
3169885|NCT00567736|Active Comparator|1|Disci/Rhus toxicodendron comp.®
3169886|NCT00567736|Placebo Comparator|2|placebo solution
3169887|NCT00567736|No Intervention|3|waiting list group
3169888|NCT00567749||A, Observational|
3169889|NCT00567762|Experimental|1|FK506 ophthalmic suspension
3169890|NCT00567762|Placebo Comparator|2|Base of eye drops
3169891|NCT00567788|Active Comparator|1|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
3169892|NCT00567788|Active Comparator|2|Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.
3169893|NCT00567801|Active Comparator|1|conventional embolectomy/thrombectomy
3169894|NCT00567801|Experimental|2|embolectomy/thrombectomy with controlled reperfusion
3169895|NCT00567814|Active Comparator|1|Lower dose combination of metyrapone with oxazepam
3169896|NCT00567814|Active Comparator|2|Higher dose combination of metyrapone with oxazepam
3169897|NCT00567814|Placebo Comparator|3|
3169898|NCT00567853|Other|MEMO 3D ring|All patients in the study will be implanted with the MEMO 3D ring
3169899|NCT00567866|Experimental|1|placebo -50 mg quetiapine- 100 mg quetiapine
3169900|NCT00567866|Experimental|2|50 mg quetiapine -100 mg quetiapine- placebo
3169901|NCT00567866|Experimental|3|50 mg quetiapine -placebo- 100 mg quetiapine
3169902|NCT00567905|Experimental|A|Green tea extract
3169903|NCT00567905|Placebo Comparator|B|
3169904|NCT00567918|Experimental|1|FK506 ophthalmic suspension
3169905|NCT00567931|Experimental|Treatment (Immunomodulating therapy)|Patients receive oral 1-methyl-d-tryptophan (1-MT) once or twice daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3169906|NCT00567957|Placebo Comparator|C|Saline starting before induction till entry to abdominal cavity
3169907|NCT00567957|Active Comparator|R|Remifentanil starting before induction till entry to abdominal cavity
3169908|NCT00567983|Active Comparator|1.|
3169909|NCT00567983|Placebo Comparator|2.|
3169910|NCT00568035|Active Comparator|QR-333|
3169911|NCT00568035|Placebo Comparator|Placebo|
3169912|NCT00568048|Experimental|Combination Therapy Temozolomide & Bevacizumab|"Combination therapy~Temozolomide 150 mg/m2 p.o., days 1-7, repeated every 14 days~Bevacizumab 10 mg/kg i.v., day 1, repeated every 14 days"
3169913|NCT00568100|Experimental|1|COPD patients
3169914|NCT00568113|Experimental|NAC group|NAC given plus 17Oh progesterone caproate
3169915|NCT00568113|Active Comparator|Progesterone group|17 OH progesterone caproate
3169916|NCT00568139||Mitotane|Patients with adrenocortical carcinoma treated with mitotane
3169917|NCT00568139||Control|Patients with adrenocortical carcinoma not treated with mitotane
3169918|NCT00568152|Experimental|Low PA apple puree|230grams of low PA apple puree (Golden Delicious) consumed daily for 14 days.
3169919|NCT00568152|Experimental|High PA apple puree|High PA apple puree (Mitchalin) 230grams consumed daily for 14 days
2549063|NCT02571231|Experimental|HFV+vg|volume guarantee given
2549070|NCT02571231|Experimental|HFV-VG|Volume guarantee not given
2549110|NCT02570997|Active Comparator|CT1812|"In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive CT1812. Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.~Should an MTD not be identified, additional cohorts at higher doses may be enrolled. The maximum dose administered will not exceed 1350mg."
2549112|NCT02570997|Placebo Comparator|Matching Placebo|In cohorts 1-6, 8 subjects will be enrolled. 6 subjects will receive matching placebo.
3169920|NCT00568152|Placebo Comparator|Aspirin|75mg dispersable aspirin taken daily for 14 days
3169921|NCT00568165|Experimental|1|Mobile Team
2549367|NCT02569346|Active Comparator|Triumeq whole|Single-dose Triumeq as a whole tablet in a fasted state
2549369|NCT02569346|Experimental|Triumeq crushed + breakfast|Single-dose crushed and suspended Triumeq in a fasted state
2549372|NCT02569346|Experimental|Triumeq crushed + drip feed|250 ml drip feed (Nutrison) followed by a single-dose crushed and suspended Triumeq
2549396|NCT02569047|Active Comparator|Atraumatic Restorative Treatment|The cavity will be prepared according to the ART (Atraumatic Restorative Treatments) steps and filled with the dental material Glass Ionomer Cement without local anesthesia.
2549397|NCT02569047|Experimental|Hall Technique|The cavity will not receive any preparation. A stainless crown will be placed and cemented with the dental material Glass Ionomer Cement without local anesthesia.
3169922|NCT00568165|Active Comparator|2|Standard care
3169923|NCT00568191||1|retinal thickness program Stratus OCT software 4.0
3169924|NCT00568191||2|retinal cube 200x200 program of Cirrus OCT
3169925|NCT00568204|Experimental|1|Mexyn-A
3169926|NCT00568217|Active Comparator|1 drug|diclofenac 15 mg/kg suppository once
3169927|NCT00568217|Placebo Comparator|2 drug|Placebo suppository once
3169928|NCT00568217|Active Comparator|3 drug|acetaminophen mixture 15 mg/kg up to four times a day
3169929|NCT00568217|Active Comparator|4 drug|ibuprofen mixture 10 mg/kg up to four times a day
3169930|NCT00568217|Placebo Comparator|5 drug|oral placebo mixture up to four times a day
3169931|NCT00568230|Experimental|1|Patient is screened for study, and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3169933|NCT00568256|Experimental|Experimental|Mind/Body Course
3169934|NCT00568256|Other|Other|Mind/Body Course
3169935|NCT00568269|Active Comparator|Lichtenstein|
3169936|NCT00568269|Experimental|TEP|
3169937|NCT00568295|Experimental|Acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP
3169938|NCT00568295|Active Comparator|Refecoxib 12.5 mg|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A
3169939|NCT00568295|Active Comparator|Rofecoxib 12.5 x 2|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A
3169940|NCT00568308|Placebo Comparator|1|
3169941|NCT00568308|Experimental|2|
3169942|NCT00568347||long acting bronchodilator|salmeterol 50mcg bid by DPI, no fluticasone in patients with COPD/emphysema to evaluate effect on bronchodilation and exhaled nitric oxide
3169943|NCT00568347||bronchodilator/ inhaled corticosteroid|fluticasone 250mcg/salmeterol 50 mcg bid X 3momths to evaluate effect on lung function and exhaled nitric oxide
3169944|NCT00568347||C|Fluticasone 100mcg/salmeterol 50mcg
3169945|NCT00568373|Experimental|Treatement|All subjects that meet the requirement for gastric stimulator placement
3169946|NCT00568412|Active Comparator|1|Zarzenda applied topically twice daily for three weeks
3169947|NCT00568412|Active Comparator|2|Elidel 1% cream, applied topically twice daily for three weeks
3169948|NCT00568464|Experimental|A|
3169949|NCT00568477|Experimental|Arm 1|Treatment with rituximab
3169950|NCT00568477|No Intervention|Arm 2|Treatment without rituximab
3169951|NCT00568503|Active Comparator|1|QAX028 high dose
3169952|NCT00568503|Placebo Comparator|2|Placebo
3169953|NCT00568503|Active Comparator|3|Tiotropium bromide
3169954|NCT00568503|Active Comparator|4|QAX028 medium dose
3169955|NCT00568503|Active Comparator|5|QAX028 low dose
3169956|NCT00568516|Experimental|1.Low dose group|
3169957|NCT00568516|Experimental|2.High dose group|
3169958|NCT00568529|Experimental|Combine Chemotherapy|XELOX(Xeloda and oxaliplatin combination)
3169959|NCT00568542|Active Comparator|1|35 I.E. erythropoetin beta given by subcutaneous injection once per week for 6 months. The drug is self-administered.
3169960|NCT00568542|Placebo Comparator|2|Placebo to erythropoetin beta.
3169961|NCT00568568|Experimental|Growth hormone|
3169962|NCT00568594|Experimental|1|
3169963|NCT00568594|Placebo Comparator|2|
3169964|NCT00568607|Experimental|IFO, VP-16, DDP, DXM|
3169965|NCT00568620|Experimental|1: Nasogastric feeding tube|
3169966|NCT00568620|Experimental|2: Placement of nasojejunal feeding tube|
3169967|NCT00568646|Experimental|1|
3169968|NCT00568659|Experimental|1|
3169969|NCT00568672|Active Comparator|1|Olanzapine 5 mg / day
3169970|NCT00568672|Placebo Comparator|2|Placebo
3169971|NCT00568711|Active Comparator|1|a 5-day course of daily 200-mg doses of doxycycline
3169972|NCT00568711|Active Comparator|2|a 5-day course of daily 600-mg doses of rifampin
3169973|NCT00568724||1|Children referred to surgical treatment of congenital hydronephrosis
3169974|NCT00568724||2|15 age- and sex-matched controls
3169975|NCT00568724||Children with healthy pelvic tissue|Children referred to nephrectomy due to nephrotic syndrome
3169976|NCT00568724||Adults with healthy pelvic tissue|Adults referred to nephrectomy due to another cause than hydronephrosis
3169977|NCT00568737|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3169978|NCT00568737|Placebo Comparator|2|0.9% sodium chloride
3169979|NCT00568750|Experimental|Dasatinib|
3169980|NCT00568789|Experimental|Ramelteon 8 mg, zolpidem 10 mg and placebo|
3169981|NCT00568815|Experimental|Chemo|
3169982|NCT00568841|Experimental|1|
2548992|NCT02571855|Experimental|Part C: repeated dose of ACT-541468|Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).
2548993|NCT02571855|Placebo Comparator|Part C: Placebo|Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C
2549027|NCT02571387|Experimental|Mindfulness|Computerized mindfulness-based intervention. 10 minutes per day, every day for 12 months of MP3 listening. Guidelines are in line with main mindfulness-based interventions (MBSR, MBCT, ACT). Participants can choose between 4 audio recordings (sessions): awareness of the breathing, awareness of postures and bodily sensations, acceptance of thoughts and emotions, and awareness of bodily sensations and related thoughts and emotions while executing 5 squats.
2549028|NCT02571387|Sham Comparator|Sham meditation|"Computerized sham meditation intervention. 10 minutes per day, every day for 12 months of MP3 listening. The unique guideline is to meditate at the beginning of each session. Participants can choose between 4 audio backgrounds: forest, night, beach, and river."
2549029|NCT02571387|No Intervention|Treatment as usual|Usual care in a nutrition pole in France: nutrition, diet, exercise.
2549083|NCT02571179|Experimental|Intranasal fentanyl 50 microg/dose|patient was given intranasal fentanyl 50 microg/dose up to 250 microg
2549100|NCT02570867||normal control group|Normal control group: healthy volunteers will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
2549101|NCT02570867||POAG group|POAG: The primary open angle glaucoma cases were will be received Functional magnetic resonance imaging（fMRI) and eye examination including visual acuity, visual field, intraocular pressure, anterior chamber angle, corneal thickness and optic nerve fiber thickness one time.
2549305|NCT02569814|Other|Group 1|Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.
2549306|NCT02569814|Other|Group 2|Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.
2549353|NCT02569554|Experimental|PF-06463922|each subject will receive four single doses of PF-06463922 without food, with food, with rabeprazole (without food), and one of the two new formulations without food.
2549406|NCT02569190|Experimental|Walkbot|Receive conventional physical therapy (session I for 30 min/day) with Walkbot training 3 days a week for 8 weeks, 20 session in all.
2549479|NCT02568891|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
3169983|NCT00568880|Experimental|Hydroxychloroquine Added to Bortezomib|Dose escalated by cohorts Hydroxychloroquine 200-600 mg pill every other day. Bortezomib 1.0-1.3mg/m2 IV, days 1, 4, 8, and 11 of each 21 day cycle.
3169984|NCT00568893|Experimental|1|24 microgram/kg/hr for 96 hours (+ or - 1 hour)
3169985|NCT00568945|Experimental|Arm 1|
3169986|NCT00568971|Experimental|weekly chemo|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
3169988|NCT00569023|Experimental|A,1,I|
3169989|NCT00569036|Experimental|BMS-754807|Single arm, multiple-ascending dose escalation study
3169990|NCT00569062|Experimental|Arm 1|GW856553X 7.5mg BID for 6 weeks
3169991|NCT00569062|Placebo Comparator|Placebo|Placebo to match, BID, 6 weeks
3169992|NCT00569075||High Risk|High risk disease prone population
3169993|NCT00569075||Low Risk|Low risk disease population
3169994|NCT00569088|Experimental|B|A combined treatment would be used in the arm.That means Chinese herb formula would be used with the current Modern Medicine therapy for stroke in this arm.
3169995|NCT00569088|Active Comparator|A|just the current Modern Medicine therapy for stroke would be available in the arm.
3169996|NCT00569101|Experimental|single|single arm study (tacrolimus trial group)
3169997|NCT00569114|Other|1|
3169998|NCT00569140|No Intervention|1|E10030
3169999|NCT00569153|Experimental|Arm 1 (TAK-700)|
3170000|NCT00569153|Experimental|Arm 2 (TAK-700 at 400 mg & 5 mg prednisone)|
3170001|NCT00569153|Experimental|Arm 3 (TAK-700 at 600 mg & 5 mg prednisone)|
3170002|NCT00569153|Experimental|Arm 4 (TAK-700 at 600 mg)|
3170003|NCT00569179|Experimental|Alloreactive NK cell infusion|Escalating doses of alloreactive NK cells.
3170004|NCT00569244|Experimental|Arm 1|
3170005|NCT00569244|Active Comparator|Arm 2|
3170006|NCT00569296|Experimental|T-cells|EGFRBi-armed autologous activated T cells
3170007|NCT00569335|Experimental|1|S-1, Irinotecan, Bevacizumab
3170008|NCT00569361|Other|A|Collection of nasal epithelial cells by brushing
3170009|NCT00569387|Experimental|Vaccine group|
3170010|NCT00569413||1|Healthy control subjects (n=20) age 21-65 who do not suffer from a psychiatric diagnosis or neurological damage, are under age, or are pregnant women
3170011|NCT00569413||2|20 patients who suffer from sexual disorder (reduced sexual desire or sexual function) from a sexual disorder clinic, age 21-65, without any other psychiatric disorder, neurological damage, are not under age or pregnant women.
3170012|NCT00569439|Experimental|D5|5% Dextrose Solution in Normal Saline
3170013|NCT00569439|Experimental|D10|
3170014|NCT00569439|Placebo Comparator|NS|
3170015|NCT00569452|Experimental|A|
3170016|NCT00569452|Experimental|B|
3170017|NCT00569465|Placebo Comparator|A|
3170018|NCT00569465|Experimental|B|
3170019|NCT00569478|Active Comparator|1|rehabilitation
3170020|NCT00569478|No Intervention|2|controls
3170021|NCT00569504||A, observatoin|inpatients and outpatients in Seoul National Hospital
2549048|NCT02571569|Experimental|Without inhibitors|Dose escalation steps for participants without inhibitors - intravenous infusion and subcutaneous injection
2549051|NCT02571569|Experimental|With inhibitors|Dose escalation steps for participants with inhibitors - intravenous infusion and subcutaneous injection
2549054|NCT02571569|Experimental|Without inhibitors_multiple dose|Multiple dose cohort for participants without inhibitors - a single subcutaneous injection once a week for 6 weeks
2549092|NCT02571010|Experimental|Vibrotactile stimulation|"Patients in this arm will have~treatment by medications and rehabilitation~treatment by vibrotactile at medical center~stimulation at home by soft tissue~non stimulation on allodynia area"
2549093|NCT02571010|Sham Comparator|Sham Stimulation with Vibradol device switched off|"Patients in this arm will have~treatment by medications and rehabilitation~Sham vibrotactile treatment at medical center but with Vibradol device switched off~abdominal breath exercises at home~non stimulation on allodynia area"
2549094|NCT02571010|Other|Standard Medical treatment|Observational group, treated as usually by medications and rehabilitation.
2549173|NCT02570763|Experimental|Active Stimulation|Active tDCS administration during the first 20 minutes of each of the six therapy sessions.
2549179|NCT02570763|Sham Comparator|Sham Stimulation|Sham tDCS administration during the first 20 minutes of each of six therapy sessions.
2549224|NCT02570256|Experimental|Deficit-fields to reduce error|We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
2549229|NCT02570256|Experimental|Deficit-fields to expand range of motion|Amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
2549235|NCT02570256|Experimental|Deficit-fields to improve function|Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
2549292|NCT02569944|Active Comparator|perineal bag|Perineal bag was placed in infants to collect an urine sample.
2549295|NCT02569944|Experimental|Bladder stimulation|Bladder stimulation technique was used in infants of this arm to obtain an urine sample
2549347|NCT02569645|Experimental|Single Arm - Rosuvastatin|This is a single arm, of Rosuvastatin (Crestor®) 40 mg orally daily starting 2 weeks prior to the initiation of radiation at week 1 and stopped 4 weeks after the completion of radiation at the start of week 12 or 13, depending on whether 25 or 30 fractions of radiotherapy are given.
2549408|NCT02569216|Experimental|Electrical Inhibition (EI) intervention|Electrical Inhibition (EI) uterine pacemaker is activated only when there is a preterm uterine contraction. The EI uterine pacemaker delivers a 1-15mA (20mA maximum) constant direct current for only 2 seconds only while there is a preterm uterine contraction.
2549444|NCT02568826|Experimental|IDN 5243|IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities for intramuscular administration in 4 mg/mL vials. It will be administered twice daily for 5 consecutive days with the first administration in the morning (8.00-10.00 AM) and the second in the evening (6.00-8.00 PM).
3170022|NCT00569517|Experimental|1|6-CBT-sessions for weight loss
3170023|NCT00569517|Experimental|2|Single educational intervention for weight
3170024|NCT00569556|No Intervention|Usual Care|Patients receive care through primary care provider
3170025|NCT00569556|Experimental|Case Management|Specially trained nurse case managers contact patients by telephone; monitor blood pressure, LDL, and HgbA1C;, and recommend lifestyle and medication changes as needed
3170026|NCT00569569|Experimental|1|Patients treated with Retaane
3170027|NCT00569595|Experimental|1|Multi-Level, Patient-Directed, Lifestyle Change, Health Promotion Program
3170028|NCT00569595|Sham Comparator|2|"Patient health counseling program by lay health educators Entitled Fighting Cancer with Advice."
3170029|NCT00569608|Experimental|EDA|Neonates submitted to the protocol of early discharge.
3170030|NCT00569608|No Intervention|SDP|Discharge following the standard protocol of the neonatal intensive care unit.
3170031|NCT00569621|Experimental|1|
3170032|NCT00569621|Placebo Comparator|2|
3170033|NCT00569634|Other|1|
3170034|NCT00569647|Experimental|v|Use of VRH headset
3170035|NCT00569647|Placebo Comparator|c|
3170036|NCT00569686|Active Comparator|1|treatment with lovaza
3170037|NCT00569686|Placebo Comparator|2|
3170038|NCT00569699|Experimental|1|S-1, Bevacizumab
3170039|NCT00569738||A|patients with neuroendocrine tumors
3170040|NCT00569764||observational|patients with schizophrenia who want to change an antipsychotics due to metabolic side effect
3170041|NCT00569790|Experimental|1|S-1, Irinotecan, Bevacizumab
3170042|NCT00569816|Active Comparator|Group 1|Propofol as the primary anesthetic
3170043|NCT00569816|Experimental|Group 2|Sevoflurane administered continuously after induction of anesthesia until initiation of cardiopulmonary bypass.
3170044|NCT00569816|Experimental|Group 3|Sevoflurane administered repetitive up to 1 MAC from induction of anesthesia until initiation of cardiopulmonary bypass. Wash in and wash out performed twice.
3170045|NCT00569829|Experimental|1|Cognitive behavioral therapy
3170046|NCT00569829|No Intervention|2|Waitlist
3170047|NCT00569842||observational|
3170048|NCT00569881||1|Corneal epithelial wound healing with moxifloxacin
3170049|NCT00569881||2|Corneal epithelial wound healing with gatifloxacin
3170050|NCT00569894||2|TIV
3170051|NCT00569894||1|FluMist
3170052|NCT00569894||3|Unvaccinated
3170053|NCT00569920|Placebo Comparator|1|Placebo
3170054|NCT00569920|Active Comparator|2|"dexamethasone low-dose"
3170055|NCT00569920|Active Comparator|3|"Dexamethasone high-dose"
3170056|NCT00569933|Other|A/B/C|Patients are randomized to voice/music/ or no CD
2549060|NCT02571504|Experimental|Waitlist control group|Participants in the waitlist control group will receive a brochure with 8 simple tips for better brain health around the time of enrollment. They will begin the Plasticity-based Adaptive Cognitive Remediation (PACR) intervention within 8 weeks of the initial enrollment.
2549215|NCT02570815|Experimental|indocyanine green|Non-toxic, fluorescent dye
2549287|NCT02570035||Mirabegron group|Subjects with overactive bladder and cardiovascular disease prescribed mirabegron
3170057|NCT00569959|Other|Fasting|
2549427|NCT02569125|Experimental|Everolimus (RAD001) 4.5 mg/m² daily over|Everolimus (RAD001) 4.5 mg/m² daily over 12 months. Patients will be on Everolimus (RAD001) therapy for 12 months; discontinuation can be necessary due to intolerable toxicity, withdrawal of consent, death or termination of the trial. After 12 months treatment is stopped. If there is progress of disease (see below) after end of therapy, re-start with Everolimus (RAD001) on a compassionate use is possible.
2549453|NCT02568670|Experimental|according to clinical signs|removal the peripheral catheter according to clinical signs
2549460|NCT02568670|No Intervention|sistematically every 96 hours|removal the peripheral catheter every 96 hours
3170058|NCT00569959|Other|Non-fasting|
3170059|NCT00569972|Experimental|15 mg PD 0200390|
3170060|NCT00569972|Experimental|30 mg PD 0200390|
3170061|NCT00569972|Experimental|45 mg PD 0200390|
3170062|NCT00569972|Experimental|60 mg PD 0200390|
3170063|NCT00569972|Experimental|Placebo PD 0200390|
3170064|NCT00569985|Experimental|Treatment (autologous HCT)|CONDITIONING: Patients receive carmustine IV over 1-2 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. TRANSPLANTATION: Patients undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells IV on day 0.
3170065|NCT00570011|Experimental|1|
3170066|NCT00570011|Experimental|2|
3170067|NCT00570024|Active Comparator|TA|Active TA
3170068|NCT00570024|Other|AA|
3170069|NCT00570024|No Intervention|Waiting Group|
3170070|NCT00570050|Experimental|Intranasal Insulin nasal spray|
3170071|NCT00570050|Experimental|Placebo nasal spray (i.e., no active treatment)|
3170072|NCT00570102|Active Comparator|A highly hydrolyzed casein formula|
3170073|NCT00570102|Placebo Comparator|A conventiona cow's milk based formula|
3170074|NCT00570115||A|The subjects for this group are matched for age, gender, body mass index. The presence of obstructive sleep apnea will divide the cohort in 02 subgroups: non-Obstructive Sleep Apnea and Obstructive Sleep Apnea
3170075|NCT00570167|Active Comparator|2|Total cementless hip arthroplasty with metal-on-metal bearings
3170076|NCT00570167|Active Comparator|1|Hip resurfacing
3170077|NCT00570180|Experimental|Single Arm|Please see intervention description for Bortezomib (Velcade)
3170078|NCT00570193|Experimental|I|Combined treatment with verteporfin (Visudyne) and ranibizumab (Lucentis)
3170079|NCT00570193|Experimental|II|Treatment with ranibizumab (Lucentis)
3170080|NCT00570206|Experimental|1|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
3170081|NCT00570206|No Intervention|2|Probation officers who are interested in Motivational Interviewing, but have not yet been trained to use it while conducting meetings with probationers.
3170082|NCT00570206|No Intervention|3|Treatment as usual. Regular probation officers conduct standard meetings with probationers.
3170083|NCT00570219|Experimental|B|Gradual benzodiazepine discontinuation and valproate treatment
3170084|NCT00570219|No Intervention|A|Gradual benzodiazepine discontinuation
3170085|NCT00570245|No Intervention|A|Neither donors or recipients will receive NO
3170086|NCT00570245|Active Comparator|B|Donor will not receive NO, recipient will receive up to 48 hours of NO
3170087|NCT00570245|Active Comparator|C|The donor will receive NO for 3 hours and the recipient will receive NO for up to 48 hours
3170088|NCT00570271|Experimental|1|
3170089|NCT00570271|Experimental|2|
3170090|NCT00570271|Experimental|3|
3170091|NCT00570271|Experimental|4|
3170092|NCT00570271|No Intervention|5|
3170093|NCT00570271|No Intervention|6|
3170094|NCT00570284|Experimental|LBH589|
3170095|NCT00570336|Experimental|2.5 milligram (mg) CTS-1027|2.5 mg CTS-1027
3170096|NCT00570336|Experimental|5 mg CTS-1027|5 mg CTS-1027
3170097|NCT00570336|Experimental|10 mg CTS-1027|10 mg CTS-1027
3170098|NCT00570336|Experimental|30 mg CTS-1027|30 mg CTS-1027
3170099|NCT00570336|Placebo Comparator|Placebo|Placebo
3170100|NCT00570375|Experimental|Single Arm|All patients will receive 150 mg of Erlotinib
3170101|NCT00570388|Active Comparator|2|Subjects in the active Prometa group will receive flumazenil, gabapentin, and hydroxyzine per the Prometa Protocol.
3170102|NCT00570388|Placebo Comparator|1|"Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine"
3170103|NCT00570414|Active Comparator|1|Laryngeal mask airway (LMA)
3170104|NCT00570414|Active Comparator|2|Endotracheal tube (ETT)
3170105|NCT00570427|Experimental|1.|All participants
3170106|NCT00570440|Experimental|A|
3170107|NCT00570440|Active Comparator|B|
3170108|NCT00570466|Experimental|Video games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit, vegetable and water intake, physical activity and decrease TV viewing.
3170109|NCT00570466|Placebo Comparator|Web and DVD knowledge|Parallel web and DVD based knowledge games on fruit, vegetable, water, physical activity and physical inactivity.
3170110|NCT00570479|Active Comparator|1|50 mgs of anecortave acetate (0.5 ml of a 10% suspension)
3170111|NCT00570479|Active Comparator|2|Patients will receive 30 mgs of anecortave acetate (0.5 ml of a 6% suspension)
3170112|NCT00570479|Active Comparator|3|Patients will receive 24 mgs of anecortave acetate (0.4 ml of a 6% suspension)
3170113|NCT00570479|Active Comparator|4|Patients will receive 12 mgs of anecortave acetate (0.2 ml of a 6% suspension)
3170114|NCT00570518||1|randomly stopped drivers of motorised vehicles and bicycles
3204190|NCT00931580|Experimental|4,000 IU|Vitamin D3 tablet, 4,000 IU
2549152|NCT02570620|Experimental|Observational cohort of patients|Patients will benefit from an ultrasonography of the cervix through endovaginal before induction of prostaglandins
2549223|NCT02570282|Experimental|Sildenafil|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
2549231|NCT02570282|Placebo Comparator|Placebo|Placebo IP will be the same as SST-6007 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6007
2549294|NCT02569970|Active Comparator|FLUOXETINE|4 weeks of treatment before video-EEG monitoring
2549298|NCT02569970|Placebo Comparator|PLACEBO|1 month of treatment before EEG video.
2549331|NCT02569606||Timeframe 2005 - 2007|Data of timeframe 2005 up to 2007 will be included
2549332|NCT02569606||Timeframe 2012 - 2014|Data of timeframe 2012 up to 2014 will be included
3170115|NCT00570518||2|drivers of motorised vehicles and bicycles injured or killed in road traffic accidents
3170116|NCT00570544||1|patients with moderate to severe copd with varying extent of emphysema
3170117|NCT00570557|No Intervention|Group A Nurses|Participants receive neither web-based refresher courses nor periodic feedback by SLP
3170118|NCT00570557|Experimental|Group B Nurses|Participants receive web-based skill refresher courses but no periodic feedback by SLP
3170119|NCT00570570|Other|group 1|Muscular Strengthening for paretic knee flexor and extensor
3170120|NCT00570570|Active Comparator|group 2|conventional physiotherapy
3170121|NCT00570583||Depressed|Older individuals with major depression
3170122|NCT00570583||Non-depressed|Older individuals without psychiatric disorder
3170123|NCT00570609|Experimental|CPR Anytime|Participants will be asked to complete the program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
3170124|NCT00570622|Active Comparator|1|Patients receive 60mg of pioglitazone once a day orally for 9 days
3170125|NCT00570622|Placebo Comparator|2|Patients receive Placebo orally once a day for 9 days
3170126|NCT00570635|Experimental|A|
3170127|NCT00570635|Experimental|B|
3170128|NCT00570648|Experimental|1|1% sodium hyaluronate (Healoon) applied at the end of surgery to the surface of the corneal transplant
3170129|NCT00570648|No Intervention|2|Nothing applied at the end of surgery
3170130|NCT00570752|Active Comparator|Placebo + background low to moderate dose statin|Placebo + background low to moderate dose statin Tablets, Oral, 0 mg, once daily, for 12 weeks
3170131|NCT00570752|Experimental|BMS-582949 + Background low to moderate dose statin|BMS-582949 + Background low to moderate dose statin Tablets, Oral, 100 mg, once daily for 12 weeks
3170132|NCT00570752|Active Comparator|Atorvastatin|Atorvastatin Tablets, oral, 80 mg once daily for 12 weeks
3170133|NCT00570791||Effect of age on intraocular pressure|Correlation between age and IOP with GAT compared to other tonometers.
3170134|NCT00570791||Effect of CCT and IOP|Correlation between CCT and IOP among all tonometers
3170135|NCT00570804|Other|MAPS+|"MAPS+ (Motivation and Problem-Solving Plus):~Counseling using specific treatment approach that focuses on combined smoking cessation and the reduction of at-risk alcohol use."
3170136|NCT00570804|Other|MAPS|"MAPS (Motivation and Problem-Solving):~Counseling treatment approach with a focus on smoking cessation."
3170137|NCT00570817|Other|1|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 4 hours prehydration. At the 2nd methotrexate infusion the child will receive 12 hours prehydration. At the 3rd methotrexate infusion the child will receive 4 hours prehydration. At the 4th methotrexate infusion the child will receive 12 hours prehydration. At the 5th methotrexate infusion the child will receive 4 hours prehydration. At the 6th methotrexate infusion the child will receive 12 hours prehydration. At the 7th methotrexate infusion the child will receive 4 hours prehydration. At the 8th methotrexate infusion the child will receive 12 hours prehydration."
3170138|NCT00570817|Other|2|"The child will receive prehydration at the methotrexate infusions in the following order:~At the 1st methotrexate infusion the child will receive 12 hours prehydration. At the 2nd methotrexate infusion the child will receive 4 hours prehydration. At the 3rd methotrexate infusion the child will receive 12 hours prehydration. At the 4th methotrexate infusion the child will receive 4 hours prehydration. At the 5th methotrexate infusion the child will receive 12 hours prehydration. At the 6th methotrexate infusion the child will receive 4 hours prehydration. At the 7th methotrexate infusion the child will receive 12 hours prehydration. At the 8th methotrexate infusion the child will receive 4 hours prehydration."
3170139|NCT00570830|Other|1|single armed case series in which all patients underwent the same treatment.
3170140|NCT00570843|Active Comparator|1.|
3170141|NCT00570843|Placebo Comparator|2.|
3170142|NCT00570856|Experimental|1|Folic acid supplementation
3170143|NCT00570856|Placebo Comparator|2|
3170144|NCT00570869|Active Comparator|CPR Class|mothers who are currently certified in CPR (i.e., have taken the traditional CPR class, or have been recertified in CPR by classroom instruction, within the past two years).
3170145|NCT00570882|Active Comparator|Sunitinib 4/2|Sunitinib 50 mg PO 4-week on and 2-week off
3170146|NCT00570882|Experimental|Sunitinib 2/1|Sunitinib 50 mg PO 2-week on 1-week off
3170147|NCT00570895|Active Comparator|A|Subjects in Arm A will receive the juice without ascorbic acid in addition to the muffin with ferrous fumarate.
3170148|NCT00570895|Active Comparator|B|Subjects in Arm A will receive the juice with 25mg ascorbic acid in addition to the muffin with ferrous fumarate
3170149|NCT00570934|Experimental|Placebo|order of interventions placebo,calcium, cholecalciferol, calcium plus cholecalciferol
3170150|NCT00570934|Experimental|Calcium|order of treatment calcium, placebo, calcium plus cholecalciferol, cholecalciferol
3170151|NCT00570934|Experimental|Cholecalciferol|order of treatments cholecalciferol, calcium and Cholecalciferol, placebo, and calcium
3170152|NCT00570934|Experimental|Calcium and cholecalciferol|order of treatment calcium and cholecalciferol, cholecalciferol, calcium, placebo
3170153|NCT00570947|Active Comparator|Class|The control group will be advised to take a traditional CPR class and be offered a list of local classes.
3170154|NCT00570973|Active Comparator|1|Endoscopic Band ligation combined with medical therapy (orally, daily administered propranolol and mononitrate)
2549187|NCT02570581|Active Comparator|jelly with ramipril|jelly with ramipril
2549188|NCT02570581|Active Comparator|jelly with Paracetamol + Furosemide + Levothyroxine sodium sa|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam
2549190|NCT02570581|Placebo Comparator|Plain apple compote control|Plain apple compote control
2549192|NCT02570581|Active Comparator|Apple compote Paracetamol|Apple compote Paracetamol
2549194|NCT02570581|Active Comparator|Apple compote Furosemide|Apple compote Furosemide
2549195|NCT02570581|Active Comparator|Apple compote Levothyroxine sodium salt|Apple compote Levothyroxine sodium salt
2549197|NCT02570581|Active Comparator|Apple compote Memantine|Apple compote Memantine
2549198|NCT02570581|Active Comparator|Apple compote Zopiclone|Apple compote Zopiclone
2549199|NCT02570581|Active Comparator|Apple compote Alprazolam|Apple compote Alprazolam
2549201|NCT02570581|Active Comparator|Apple compote Oxazepam|Apple compote Oxazepam
2549203|NCT02570581|Active Comparator|Apple compote Donepezil|Apple compote Donepezil
2549205|NCT02570581|Active Comparator|Apple compote Clopidogrel|Apple compote Clopidogrel
2549207|NCT02570581|Active Comparator|Apple compote Ramipril|Apple compote Ramipril
2549209|NCT02570581|Active Comparator|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopi|Apple Paracetamol Furosemide Levothyroxine NACL Memantine Zopiclone Alprazolam
3170155|NCT00570973|Active Comparator|2|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent
3170156|NCT00570986|Placebo Comparator|1|Arm #1 is used for entire study. At week 12, arm is rerandomized.
3170157|NCT00570986|Active Comparator|2|Arm #2 is used for entire study. At week 12, arm is rerandomized.
3170158|NCT00570986|Active Comparator|3|Arm #3 is not used for weeks 0-11. At week 12, arm is rerandomized.
3170159|NCT00570999|Experimental|Arm A|Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
3170160|NCT00570999|Placebo Comparator|Arm B|Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
3170161|NCT00571012||Only one group- A|Healthy young subjects aged 18-45.
3170162|NCT00571025|Experimental|1|AD risk assessment based on family history and APOE genotype
3170163|NCT00571025|Active Comparator|2|AD risk assessment based on family history alone
3170164|NCT00571051|Experimental|1|MBSR 8 week course
3170165|NCT00571051|No Intervention|2|8 weeks of natural history
3170166|NCT00571077||A|"This is a a single arm study evaluating the efficacy and accuracy of EIS in detecting malignant thyroid nodules.~PAtients with thyroid nodules scheduled for surgery will undergo EIS examination."
3170167|NCT00571090||Thyroid nodule|Subjects who present with thyroid nodules will be enrolled into the study. Euthyroid and hypothyroid subjects with a solitary thyroid nodule or multinodular goiter will be enrolled. For subjects with a suppressed TSH, a thyroid scan will be performed. Subjects with a hypoactive nodule in the thyroid scan and a low TSH will be enrolled.
3170168|NCT00571116|Experimental|Disulfiram and arsenic trioxide|"Patients receive disulfiram 250 mg PO twice daily and arsenic trioxide IV over 1-2 hours on Monday through Friday, alternating two weeks on treatment followed by two weeks off treatment. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~The Arsenic trioxide dose will be escalated or reduced until a tolerable dose is reached. Arsenic trioxide will be administered at a starting dose of 0.05 mg/kg. If the initial dose is tolerated, the patient will be dose escalated to 0.10 mg/kg/day. If the first dose escalation is tolerated, then a second dose escalation will be attempted to 0.15 mg/kg/day, the current dose recommended for leukemia. Dosing will be continued for two weeks on alternating with two weeks off as long as tolerated to a maximum of 60 doses."
3170169|NCT00571129|Active Comparator|with tubes or mitomycin|After DCR bicanalicular tubes were inserted After re-DCR mitomycin in cottonpads were placed into rhinostoma for 5 minutes
3170170|NCT00571129|Active Comparator|without tubes or mitomycin|After DCR no tubes were inserted After re-DCR no mitomycin was used
3170171|NCT00571142|Active Comparator|1|Renal disease
3170172|NCT00571142|Active Comparator|2|Without renal disease
3170173|NCT00571155|Other|1|
3170174|NCT00571168|Experimental|A|Aprepitant plus standard therapy (Kevatril + Dexamethason) on day 1-4
3170175|NCT00571168|Placebo Comparator|B|Placebo plus standard therapy (Kevatril + Dexamethason) on day 1-4
3170176|NCT00571181|Experimental|1|
3170177|NCT00571181|Active Comparator|2|
3170178|NCT00571207||I|Drivers suspected of driving under the influence of drugs
3170179|NCT00571207||II|Drivers not suspected of driving under the influence of drugs
3170180|NCT00571220||Gastric bypass surgery|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
3170181|NCT00571220||Diet induced weight loss|Diet group of obese patient with type 2 diabetes, matched with the surgical group for diabetes duration, diabetes control (HbA1C), BMI, age.
3170182|NCT00571233||1|Group one consists of children 1 month - 6 years old who have structurally normal hearts, no heart failure, and a patent ductus arteriosus (PDA).
3170183|NCT00571233||2|Group two consists of children 1 month - 6 years old who have single ventricle physiology. Children with and without heart failure may participate.
3170184|NCT00571246|Experimental|Topiramate|Participants will be randomized to topiramate (250mg)
3170185|NCT00571246|Experimental|Lamotrigine|Participants will be randomized to lamotrigine (250mg)
3170186|NCT00571246|Placebo Comparator|Placebo|Participants will be randomized placebo
3170187|NCT00571272||1|Infants less than 6 months old with a cholestatic liver disease who were initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
3170188|NCT00571272||2|Participants with a cholestatic liver disease who are between birth and 25 years old who were NOT initially enrolled into the Childhood Liver Disease Research and Education Network (ChiLDREN) Prospective Biliary Atresia Epidemiology study (PROBE study; P003)
2549227|NCT02571036|Experimental|Expansion Cohort 4|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with systemic mastocytosis and other hematologic malignancies.[Closed for Enrollment]
2549233|NCT02571036|Experimental|Expansion Cohort 5|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with malignant gliomas.[Closed for Enrollment]
2549236|NCT02571036|Experimental|Expansion Cohort 6|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with other solid tumors. [Closed for Enrollment]
2549239|NCT02571036|Experimental|Expansion Cohort 7|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with melanomas. [Closed for Enrollment]
2549242|NCT02571036|Experimental|Expansion Cohort 8|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with soft tissue sarcomas.[Closed for Enrollment]
2549248|NCT02571036|Experimental|Expansion Cohort 9|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with germ cell, penile cancer and non-small cell lung carcinoma (NSCLC). [Closed for Enrollment]
2549251|NCT02571036|Experimental|Expansion Cohort 10|150 mg DCC-2618 given once daily in repeated 28-day cycles in patients with GIST and other solid tumors with renal impairment. [Closed for Enrollment]
2549253|NCT02571036|Experimental|Extension Cohort|150 mg DCC-2618 given once daily in repeated 28-day cycles for active patients from the Escalation and Extension Phases.
2549334|NCT02569671|Other|Immediate Placement - Test|Straumann Bone Level Tapered Implant - Immediate Placement - Implant is placed at the time of tooth extraction to replace a single tooth.
2549335|NCT02569671|Other|Delayed Placement - Control|Straumann Bone Level Tapered Implant - Delayed Placement - Implant is placed after 16-18 weeks of healing to replace a single tooth.
2549437|NCT02568865||Major Depressive Disorder|
2549441|NCT02568865||Healthy Volunteers|
2549467|NCT02568566|Experimental|Prevention (Gardasil 9)|Patients receive recombinant human papillomavirus nonavalent vaccine IM at baseline (priming injection) and at 24 and 30 months (booster injections).
3170189|NCT00571272||3|Post-liver transplant participants with a cholestatic liver disease who are between 1 day and 25 years old. Affected parents of patients enrolled in the study are eligible for enrollment if they are 25 years old or less
3170190|NCT00571272||4|A screening group of participants, birth through 25 years old, suspected of having ALGS, PFIC (or BRIC) or BAD, who do not meet complete enrollment criteria for Group 1, 2, or 3.BRIC)
3170191|NCT00571272||5|Affected siblings (without evidence of liver disease) of Alpha-1 Antitrypsin Deficiency participants who are enrolled in LOGIC.
3170192|NCT00571285|Placebo Comparator|Placebo|Placebo capsule once a week and 600 IU vitamin D daily for 26 weeks
3170193|NCT00571285|Experimental|Vitamin D|50K IU vitamin D3 (high dose) weekly plus 600 IU Vitamin D3 capsule daily for 26 weeks
3170194|NCT00571298|Experimental|Extrapleural pneumonectomy (EPP)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3170195|NCT00571298|Experimental|Pleurectomy/Decortication (P/DC)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3170196|NCT00571298|Experimental|Tumor Debulking (TD)|This is dose escalation 3+3 study design. All the patients meet the eligibility criteria and then sign the informed consent. Then after they have completed their standard pre-operative evalutions were each brought to the operating room for this surgical resection. Regardless of the arm the subject is assigned to they all recieve surgical intervention (Extrapleural Pneumonectomy, Pleurectomy/Decortication, or Tumor Debulking), Amifostine, Cisplatin, Gemcitabine, and Sodium Thiosulfate
3170197|NCT00571350|Active Comparator|A|women with vaginal prolapse who underwent TVT O
3170198|NCT00571363|Active Comparator|standard surgery|basal cell carcinomas were excised with 4 mm margins
3170199|NCT00571363|Active Comparator|Mohs|Basal cell carcinoma were removed via Mohs Micrographic surgery
3170200|NCT00571376||1|Those exposed to health information technology or health information exchange
3170201|NCT00571376||2|Those not exposed to health information technology or health information exchange
3170202|NCT00571402|Experimental|FFT|Family-focused therapy (FFT) and pharmacotherapy for adolescents, a 21 session family psychoeducational interventio0n administered with best practice medication treatment
3170203|NCT00571402|Active Comparator|Echanced Care|Enhanced care (EC) and pharmacotherapy for adolescents
3170204|NCT00571415||cervix cancer patients|
3170205|NCT00571441||Primary|All subjects are included in this group, non-randomized observational study.
3170206|NCT00571454|Experimental|1|Telephone depression care management + treatment as usual
3170207|NCT00571454|No Intervention|2|Treatment as usual
3170208|NCT00571467|Experimental|PRTX-100 (Staphylococcal protein A)|"Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
3170209|NCT00571480|Experimental|1 true acupuncture|acupuncture needles are inserted into three preselected ear acupuncture points which are thought to be specific for low back pain
3170210|NCT00571480|Sham Comparator|2|three acupuncture needles are inserted to three ear acupuncture points which are not specific for low back pain during pregnancy
3170211|NCT00571480|Other|3|standard of care
3170212|NCT00571506|Experimental|1|Rosiglitazone 4 mg by mouth daily
3170213|NCT00571506|Active Comparator|2|Pioglitazone 30 mg by mouth daily
3170214|NCT00571545|Experimental|1|Subjects recruited from the community with a history of traumatic brain injury were enrolled into a 10 week supervised exercise program and encouraged to exercise at home as well.
3170215|NCT00571545|Other|2|Controls were wait-listed for the supervised exercise program but were not treated during the 10 week wait period.
2549286|NCT02569827|Active Comparator|Cohort 3|Modipafant 100 mg Q12H alternating with placebo Q12H 5 days (total of 10 modipafant doses = 1000 mg)
2549288|NCT02569827|Active Comparator|Cohort 4|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg total).
2549343|NCT02569619|Experimental|Activity Intervention|The activity intervention is MoVo-LISA (Göhner & Fuchs, 2007). A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through physical activity and make detailed plans, how to implement activity in their everyday routine. Difficulties and barriers are discussed.
2549348|NCT02569619|Active Comparator|Healthy Diet Intervention|The healthy diet intervention is a modification of MoVo-LISA. A psychological program with two group sessions of 90 minutes and one one-on-one session of about 15 minutes. The patients develop aims for their health, ideas, how to reach these aims through a healthy diet and make detailed plans, how to implement a healthy diet in their everyday routine. Difficulties and barriers are discussed.
2549413|NCT02569203|Placebo Comparator|control group|standard enteral nutrition
2549416|NCT02569203|Experimental|test group I|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
2549418|NCT02569203|Experimental|test group II|high-protein enteral nutrition of immune modulating nutrients without β-glucan
2549454|NCT02568709|Active Comparator|Interventional|40 IU Oxytocin
2549457|NCT02568709|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
3170216|NCT00571558|Experimental|Treatment (aminolevulinin acid and photodynamic therapy)|Patients receive aminolevulinic acid PO 3-4 hours before undergoing photodynamic therapy using pulsed dye laser on day 1.
3170217|NCT00571571|Experimental|TFP-A|Specific aspects of TFP-A involve the setting up of a treatment contract/collaboration between patient and therapist to deal with the likely threats both to the treatment and to the patient's well being that may occur in the course of the treatment. After the behavioral symptoms of identity pathology are contained through structure and limit setting, the psychological structure that is believed to be the core of identity pathology are analyzed. In particular, treatment would involve the family in setting up the contract parameters, provide a psychoeducational component to the family and patient, inclusion of school personnel as appropriate to reinforce contract parameters, place an emphasis on the technique of clarification to understand specific emotional states.
3170218|NCT00571571|Active Comparator|Control|The Control Group is treatment as usual in the outpatient clinic. Treatment in this arm will be carried out by therapists in the Outpatient Department. Treatment will be determined by the therapist(s) and carried out according to their particular orientation and their assessment of patient's needs. It is expected based on clinic data that the majority of patients will be seen at least one time per week.
3170219|NCT00571610|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3170220|NCT00571623||1|All subjects act as their own contral
3170221|NCT00571636|Active Comparator|fentanyl|Patients assigned to this arm will receive continuous infusion of fentanyl + open label boluses of Fentanyl if necessary.
3170222|NCT00571636|Placebo Comparator|placebo|Patients assigned to this arm will receive continuous infusion of placebo+ open label boluses of Fentanyl if necessary.
3170223|NCT00571675|Experimental|1|AT-101, prednisone and docetaxel
3170224|NCT00571675|Placebo Comparator|2|Placebo, prednisone and docetaxel
3170225|NCT00571714|Active Comparator|1|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day)in 2 divided daily doses
3170226|NCT00571714|Active Comparator|2|Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses plus betaine (20gm/day) in 2 divided doses for 12 weeks followed by Peginterferon alpha-2a q week plus weight based ribavirin (800-1400mg/day) in 2 divided daily doses for 36 weeks
3170227|NCT00571727|Experimental|mecasermin, injections BID of rhIGF-1|
3170228|NCT00571740|Active Comparator|Arm I (second-line therapy)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 46 hours beginning on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3170229|NCT00571740|Experimental|Arm II (second-line therapy)|Patients receive bevacizumab and modified FOLFOX7 as in arm I. Patients also receive cetuximab IV over 2 hours on day 1. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.
3170230|NCT00571753|Experimental|Test|Isoniazid dose adapted according to NAT2 status i.e. appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively
3170231|NCT00571753|Active Comparator|Control|Treatment with standard isoniazid dose (appr. 5 mg/kg b.w.)
3170232|NCT00571766|Experimental|1|Oral L-Arginine 2 g twice a day for 14 weeks
3170233|NCT00571766|Placebo Comparator|2|Placebo 2 g, twice a day for 14 weeks
3170234|NCT00571792||1|Individuals with normal lung function who do not smoke
3170235|NCT00571792||2|Individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
3170236|NCT00571792||3|Individuals who smoke that demonstrate symptoms of COPD
3170237|NCT00571805|Active Comparator|1|Varenicline
3170238|NCT00571805|Placebo Comparator|2|placebo
3170239|NCT00571818|Active Comparator|EP|
3170240|NCT00571818|Active Comparator|HP|
3170241|NCT00571818|Active Comparator|EK|
3170242|NCT00571818|Active Comparator|HC|
3170243|NCT00571831|No Intervention|letter|a blue-filtering IOL an UV-filtering IOL
3170244|NCT00571844|Experimental|DASH diet|
3170245|NCT00571844|Experimental|DASH diet plus Weight loss|
3170246|NCT00571844|No Intervention|Usual Care|Usual Care Control Group: Patients in the Usual Care control group will be asked to maintain their usual dietary and exercise habits for 4 months until they are re-evaluated. At biweekly intervals we will ask patients to describe any spontaneous changes in their eating habits or food preferences. To ensure patient safety, BPs will also be monitored biweekly by our staff.
3170247|NCT00571870|Active Comparator|A|Stimulated as conventional protocol
3170248|NCT00571870|Experimental|B|GnRH antagonist stopped one day earlier than conventional protocol
3170249|NCT00571896|Experimental|SennaS|This group of participants will receive SennaS to use after surgery.
2549300|NCT02569905|Active Comparator|Groups Flurbiprofen|Fifty-two, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2549302|NCT02569905|Placebo Comparator|Group Saline|Fifty-one, American Society of Anesthesiologists' (ASA) physical status1or2, patients, undergoing colorectal operation were selected in the clinical study.
2549330|NCT02569593|Other|RYGB-patient|Patients with a planned RYGB at UZ Leuven will be recruited. Iron supplements, more specific Ferrodyn and Vista Ferrum will be administrated in these patients before and 1, 3, 6 and 12 months post-RYGB with at least 7 days between the administration of the different supplements.
2549399|NCT02569073|Experimental|Dronabinol|Patients who receive Dronabinol 5 mg, every other night, orally.
2549400|NCT02569073|Placebo Comparator|Placebo|Patients who receive Placebo every other night, orally
2549434|NCT02568813|Experimental|Scales passation|
2549470|NCT02568618|Other|Immediate|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 1.
2549472|NCT02568618|Other|Delayed|Subjects will receive the results of the Pain Medication DNA Insight (TM) test at Visit 4. After 3 months of standard treatment.
3170250|NCT00571896|Placebo Comparator|Placebo|This group of participants will receive placebo pills to use after surgery.
3170251|NCT00571909|Experimental|video thoracoscopic splanchnicectomy (VSPL)|
3170252|NCT00572013|Experimental|Arm I|
3170253|NCT00572026|Experimental|1|Daytrana
3170254|NCT00572026|No Intervention|2|No treatment for ADHD
3170255|NCT00572065|Experimental|All Patients|Arsenic trioxide [TrisenoxTM Injection], will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12.
3170256|NCT00572078|Experimental|Sorafenib, Bevacizumab & Paclitaxel|Paclitaxel is given as i.v infusion over 60 min on days 1, 8, 15 every 28 days. Sorafenib is given orally starting with cycle 1 day 2. Bevacizumab is given as i.v infusion on days 1 and 15 every 28 days.
3170257|NCT00572091|Experimental|1|Patient is screened for study and given baseline assessments. Patient receives a diagnostic PTMA assessment and if responsive, receives a PTMA implant.
3170258|NCT00572104|Experimental|resistance exercise|12 month resistance exercise training
3170259|NCT00572104|Experimental|plyometric exercise|12 month plyometric exercise training
3170260|NCT00572130|Experimental|Rexin-G Dose 1|
3170261|NCT00572130|Experimental|Rexin-G Dose 2|
3170262|NCT00572143|Active Comparator|1|Postoperative follow-up of ca coli patients at the surgical outpatient dpt
3170263|NCT00572143|Active Comparator|2|Postoperative follow-up of ca coli patients by GP's
3170264|NCT00572169|Experimental|VDTPACE|Velcade, Dexamethasone, Thalidomide, Cisplatinin, Adriamycin, Cyclophosphamide and Etoposide
3170265|NCT00572208|Active Comparator|1|Gabapentin group
3170266|NCT00572208|No Intervention|2|placebo
3170267|NCT00572221|Other|CQI Program Only|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. (The SAVE+ intervention, the CQI system with facility responsible for identifying or designing care protocols for the identified problem condition.)
3170268|NCT00572221|Other|CQI Program and Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions. (The SAVE+ intervention, a CQI system plus best-practice protocols designed by study team to address identified problem condition.)
3170269|NCT00572247|Experimental|1|Behavioral
3170270|NCT00572247|No Intervention|2|
3170271|NCT00572286||1|heart transplant patient ( pre or post)
3170272|NCT00572299||glucocorticoids|patients receiving glucocorticoid treatment
3170273|NCT00572299||glucocorticoids and bisphosphonates|patients receiving both glucocorticoids and bisphosphonates
3170274|NCT00572325||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
3170275|NCT00572338||patients with myeloma/related diseases|
3170276|NCT00572351|Active Comparator|Red Wine|
3170277|NCT00572351|Active Comparator|White Wine|
3170278|NCT00572377|Active Comparator|FemLife Gel|
3170279|NCT00572377|Placebo Comparator|Placebo|
3170280|NCT00572390|Placebo Comparator|1|No oestrogen treatment
3170281|NCT00572390|Experimental|2|Oestrogen treatment
3170282|NCT00572416|Experimental|1|Four component behavioral sleep intervention comprised of activity-rest, sleep-wake, phychological distress and symptom management. Four components of the Individual Sleep Promotion Plan are: stimulus control, sleep restruction, relaxation, and sleep hygiene.
3170283|NCT00572416|Placebo Comparator|2|Equal time and attention, information about healthy eating and general conversation
3170284|NCT00572429|Placebo Comparator|A|
3170285|NCT00572442||1|"Subjects without any cardiovascular risk factors:~Age ≥ 45 in men; Age ≥ 55 in women.~Hypertension: BP > 140/90 mmHg or on BP meds.~Diabetes Mellitus: Known fasting blood sugar >126 mg/dl or on DM meds.~Dyslipidemia: On lipid lowering medication or LDL ≥ 160 mg/dl in absence of other risk factors; ≥ 130 mg/dl if other non-diabetic risk factors; ≥ 100 mg/dl if diabetic. Known HDL < 40 mg/dl.~Cigarette smoking (past or present).~Family history of premature CAD in first degree relatives: Age < 55 in men; Age < 65 in women."
3170286|NCT00572442||2|Subjects with 1 cardiovascular risk factor (listed above)
3170287|NCT00572442||3|Subjects with 2 cardiovascular risk factors (listed above)
3170288|NCT00572442||4|Subjects with more than 2 cardiovascular risk factors (listed above)
3170291|NCT00572494|Experimental|1|Stenting with AMS
3170292|NCT00572494|Active Comparator|2|PTA alone
3170293|NCT00572507|Experimental|MonoMax|MonoMax is used for abdominal wall closure
3170294|NCT00572520|Active Comparator|1|Evidence-based behavioral weight loss treatment with health education counseling
2549321|NCT02569749||Group 3|Patients with heart failure an preserved LVEF (40-50%)
2549323|NCT02569749||Group 4|Patients with heart failure and reduced LVEF (<40%)
2549363|NCT02569372|Experimental|GC1102 80,000 IU(Single does)|GC1102 80,000 IU(Single does) I.V.
2549364|NCT02569372|Experimental|GC1102 120,000 IU(Single does)|GC1102 120,000 IU(Single does) I.V.
2549366|NCT02569372|Experimental|GC1102 180,000 IU(Single does)|GC1102 180,000 IU(Single does) I.V.
2549368|NCT02569372|Experimental|GC1102 240,000 IU(Single does)|GC1102 240,000 IU(Single does) I.V.
2549370|NCT02569372|Experimental|GC1102 80,000 IU(Multiple does)|GC1102 80,000 IU(Multiple does) I.V.
2549373|NCT02569372|Experimental|GC1102 120,000 IU(Multiple does)|GC1102 120,000 IU(Multiple does) I.V.
2549375|NCT02569372|Experimental|GC1102 180,000 IU(Multiple does)|GC1102 180,000 IU(Multiple does) I.V.
2549376|NCT02569372|Experimental|GC1102 240,000 IU(Multiple does)|GC1102 240,000 IU(Multiple does) I.V.
2549404|NCT02569021||Biphasic DBS stimulations|Subjects in this group will have Biphasic DBS stimulation setting performed, Unified Parkinson's Disease Rating Scale (UPDRS), Tremor Rating Scale (TRS), kinesia accelerometer assessment, Trigno wireless system (EMG) assessment and GaitRite walking assessment performed.
3170295|NCT00572520|Experimental|2|Evidence-based behavioral weight loss treatment with brief behavior therapy for depression
3170296|NCT00572559|Experimental|1|
3170297|NCT00572559|Experimental|2|
3170298|NCT00572585|Experimental|AEB071|
3170299|NCT00572585|Placebo Comparator|Placebo|
3170300|NCT00572611|Experimental|I|Single oral dose of 20 mg [14C]-bilastine
3170301|NCT00572650|Active Comparator|1|
3170302|NCT00572689|Experimental|A|Subject receives injection of 10 micrograms of Exenatide sub-cutaneously the given mixed meal test and blood samples will be drawn for laboratory testing.
3170303|NCT00572689|No Intervention|B|Patients given mixed meal test and blood samples drawn for laboratory testing
3170304|NCT00572702|Active Comparator|A|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with Amreich-Richter procedure; it will be set randomly
3170305|NCT00572702|Active Comparator|B|Patients with 3 compartment pelvic organ prolapse after hysterectomy, treated with total Prolift procedure; it will be set randomly
3170306|NCT00572715||Observation|"Inclusion criteria - Families of infants (birthweight >1500g) be asked to participate in the study.~Exclusion criteria - Infants with prenatal renal ultrasound diagnosis of severe hydronephrosis or other known renal abnormalities will be excluded"
3170307|NCT00572741|Experimental|1|Nutritional supplementation
3170308|NCT00572741|Placebo Comparator|2|Placebo
3170309|NCT00572767|Experimental|1|
3170310|NCT00572767|Placebo Comparator|2|
3170311|NCT00572780||CTE with CD|Crohn's disease patients who underwent a CT enteroclysis as part of their clinical evaluation for symptomatic Crohn's disease.
3170312|NCT00572819|Active Comparator|Misoprostol|
3170313|NCT00572819|Placebo Comparator|Placebo|
3170314|NCT00572845|Experimental|1|Weaning of Spasticity Medication over a three day period while measuring Modified Ashworth Scale and Penn Spasm Frequency Score. Then titration of medication back to previous dose over a three day period.
3170315|NCT00572858||Premenopausal women|Female patients who have undergone coronary angiography and are under the age of 55
3170316|NCT00572871||Exercise after fasting|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions after a 10-hour fast
3170317|NCT00572871||No exercise|Will complete a ten-hour fast but do no exercise
3170318|NCT00572871||Exercise after snack|Will complete 2 resistance exercise sessions and 2 plyometric exercise sessions 2 hours following a 500 calorie nutritional supplement
3170319|NCT00572923||1|"Inclusion criteria~Histological or cytological proven SCLC~UICC stage I-III, limited disease~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma)~stage IV~performance status 3 or more~FeV 1 or DLCO< 30% of the age-predicted value"
3170320|NCT00572949||1|Patients with chest pain syndrome
3170321|NCT00572962|Experimental|1|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
3170322|NCT00572975|Experimental|1|
3170323|NCT00573001|Experimental|1|
3170324|NCT00573001|Experimental|2|
3170325|NCT00573001|Experimental|3|
3170326|NCT00573001|Active Comparator|4|
3170327|NCT00573014||OBTP|Obtunded blunt trauma patients with normal CT C-spine
3170328|NCT00573027|Other|Single Arm|"fill out baseline demographic and health/medical history questionnaires, CV risk factors, reasons of diagnosis of ischemia, information of coronary artery, and medication use~undergo clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory (Appendix);~undergo noninvasive Peripheral Artery Tonometry (PAT) testing (Appendix);~undergo clinically indicated Cardiac Magnetic Resonance (CMR) imaging (Appendix) to detect subendocardial ischemia (if indicated and referred by the treating physician). The three tests (heart catheterization with adenosine coronary flow reserve testing, acetylcholine provocative vasomotor testing during heart catheterization, cardiac MRI) are performed for standard care.~have blood and urine testing.~fill out health questionnaires~be followed prospectively 6-week, 6-month, and annually for clinical status"
3170329|NCT00573040||1|"Inclusion criteria~Histological or cytological proven NSCLC~UICC stage I-III~Performance status 0-2~FeV1 and DLCO at least 30% of age-predicted value~Exclusion criteria:~Not NSCLC or mixed NSCLC and other histologies (e.g. small cell carcinoma)~Stage IV~Performance status 3 or more~FeV 1 or DLCO < 30% of the age-predicted value"
3170330|NCT00573053|Active Comparator|High|Arterial oxygen saturations in the range of 91-95%
3170331|NCT00573053|Experimental|Low|Arterial oxygen saturations in the range of 85-89%
3170332|NCT00573079||Observation|Premature infants in the NICU; 500-1500g birthweight, >=25 weeks gestation
3170333|NCT00573092||1|Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs
3170334|NCT00573105|Experimental|1|Laparoscopic Ventral hernia repair by heavy weight mesh
3170335|NCT00573105|Experimental|2|Laparoscopic Ventral hernia repair by lighter weight mesh
2549329|NCT02569736||Healthy Controls|Healthy controls will be defined as people non-affected by an inflammatory disease (such as RA, ankylosing spondylitis, lupus…). This group will be constituted with patients affected by sciatica, osteoarthritis, osteoporosis…
2549342|NCT02569463|Experimental|Low-does rhIL-2 therapy|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks
2549395|NCT02569307|Active Comparator|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
2549398|NCT02569307|Active Comparator|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2mg once daily dose
2549401|NCT02569307|Active Comparator|Placebo|Placebo added to TAU
2549403|NCT02569307|Active Comparator|Minocycline Plus Omega-3 fatty acids|Minocycline+Omega-3 fatty acids added to TAU ,Minocyline will be administered in 200mg once daily dose and Omega-3 fatty acids 1.2 g taken as once daily dose
2549455|NCT02568735|Experimental|Etoricoxib|Etoricoxib 60mg if body weight≤ 60kg, 90mg if body weight 61-90kg and 120mg if body weight> 90kg by mouth
2549459|NCT02568735|Active Comparator|Dexketoprofen|Dexketoprofen 0,5 mg/kg up to 50 mg intravenously
3170336|NCT00573118||1|The study group included 49 patients with a previous history of one or more of the following pregnancy complications: preeclampsia (n = 17), severe IUGR (n = 13), IUFD (n = 14) or placental abruption (n = 5).
3170337|NCT00573118||2|The control group included 49 healthy women who delivered during the study period, who did not smoke during pregnancy and in whom pregnancy and delivery were uneventful
3170338|NCT00573196|Experimental|1|
3170339|NCT00573209|Other|1|
3170340|NCT00573274||1|Elective cesarean section patients
3170341|NCT00573300||Schizophrenia|Schizophrenia Patients
3170342|NCT00573300||Healthy Controls|Healthy Controls
3170343|NCT00573326|Experimental|1|Imatinib 200 mg p.o. once a day for 6 months
3170344|NCT00573339||Normal Controls|
3170345|NCT00573352|Other|1|Far infrared radiation
3170346|NCT00573365|Experimental|Treatment|LED treatment with Gentlewaves Select™ handheld high energy LED array 5 to 10 minutes before each radiation treatment and again 5-10 minutes after each radiation treatment
3170347|NCT00573365|Other|Control|Radiation only
3170348|NCT00573378|Experimental|1|
3170349|NCT00573404|Experimental|Therapeutic Intervention|
3170350|NCT00573417|Experimental|modafinil|modafinil 100mg, 200mg, or 300mg (dose escalation)
3170351|NCT00573417|Placebo Comparator|placebo|placebo
3170352|NCT00573456|Other|1|
3170353|NCT00573482|Active Comparator|control group|Control (only exposure to the food labels and the new lower ED foods).
3170354|NCT00573482|Experimental|intervention group|Education in REDE techniques plus exposure to the food labels and the new lower ED foods.
3170355|NCT00573495|Experimental|hTERT/Survivin Multi-Peptide Vaccine|
3170356|NCT00573573|Other|1|
3170357|NCT00573586|Other|HIFU|"Completely destroy prostate cancer tissue, without causing damage to the intervening tissue, with a drop in PSA levels to <0.5ng/ml.~Result in negative biopsies for evidence of viable malignant cells after the treatment (12 months if Nadir is not reached or PSA rises from Nadir)~Safely treat localized prostate cancer patients, with minimal and acceptable adverse effects"
3170358|NCT00573599|Experimental|1|prochlorperazine and benadryl IV, saline subQ
3170359|NCT00573599|Active Comparator|2|imitrex SubQ, saline IV
3170360|NCT00573612|Placebo Comparator|1|Telephone Call for the Attention Control Group Each AC call will follow the same format as the MI call. During the AC call, study subjects will receive health information on important topics relevant to their illness. Specifically, there will be one topic during each phone call that includes the following: (a) overview of FMS, (b) pain, (c) fatigue (d) sleep, (e) stress, and (f) living well with FMS. The AC calls will be an avenue to transfer relevant health information from the RA to the study subject. The scheduled topics during each contact will give the call face validity (i.e., establish a credible pretense for the contact) while being neutral with respect to encouragement of exercise.
3170361|NCT00573612|Active Comparator|2|Telephone-delivered Motivational Interviewing Participants will receive 6 telephone calls throughout the study. Harland et al reported that the most effective intervention for promoting exercise in the primary care setting was the most intensive treatment arm that included six MI sessions (208). Importantly, in our pilot study, participants who completed 5 to 6 phone calls achieved greater symptomatic benefits than participants who had ≤ 4 phone calls. The phone calls will be scheduled at week 3, 4, 6, 8, 10 and 12 of the study. Telephone sessions may run for 30 minutes on the average
3170362|NCT00573651|Other|Group A pauciarticular JIA|Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.
3170363|NCT00573651|Other|Group B polyarticular JIA|Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.
3170364|NCT00573651|Other|Group C seronegative arthritis|Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.
3170365|NCT00573664|Active Comparator|1|Gabapentin
3170366|NCT00573664|Placebo Comparator|2|Placebo
3170367|NCT00573690|Experimental|Group 1|Patients receive cisplatin IV over 1 hour on day 2 of courses 1 and 2 and on day 1 of all subsequent courses; etoposide IV over 30 minutes on days 1-3; and oral sorafenib tosylate once or twice daily on days 1-21. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
3170368|NCT00573690|Experimental|Group 2|Patients receive carboplatin IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Patients also receive sorafenib tosylate as in group 1. Treatment repeats every 21 days in the absence of unacceptable toxicity or disease progression.
3170369|NCT00573703|Active Comparator|Group A|
3170370|NCT00573703|Experimental|Group B|
2549351|NCT02569450||Hospitals in control arm|Hospitals randomly assigned to the control arm without surgical outcome monitoring
2549381|NCT02569281|Experimental|US-guided percutaneous electrolysis|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, they will receive one session of US-guided percutaneous electrolysis. This intervention consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
2549382|NCT02569281|Active Comparator|Eccentric exercise|Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
2549414|NCT02569034|Active Comparator|Young Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
2549417|NCT02569034|Experimental|Older Adults|These participants will perform the Effort-Expenditure for Rewards Task (EEfRT) while an functional magnetic resonance imaging (fMRI) is performed. They will also complete a battery of both cognitive and anhedonia questionnaires.
2549465|NCT02568761|Active Comparator|Injection snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate. 0.5 ml of the solution will be implemented in three different regions of the submucosal layer of the soft palate, one median and two paramedians.
2549466|NCT02568761|Active Comparator|Oropharyngeal Exercises|Weekly sessions of myofunctional exercises under the supervision of a qualified professional, lasting about 30 minutes each, combined with daily exercises without supervision for a period of three months.
3170371|NCT00573716||1|15 subjects who are taking aripiprazole monotherapy
3170372|NCT00573716||2|15 subjects who are taking Risperidone therapy
3170373|NCT00573716||3|30 healthy volunteers with an ethnicity, sex, and pubertal stage match of subjects taking aripiprazole monotherapy and Risperidone therapy
3170374|NCT00573729|Experimental|Pulsed Dye Laser 577 nm|Pulsed Dye Laser Treatment 577 nm treatment of Port Wine Stain Birthmarks
3170375|NCT00573729|Experimental|Pulsed Dye Laser 595 nm|Pulsed Dye Laser Treatment 595 nm treatment of Port Wine Stain Birthmarks
3170376|NCT00573781|Experimental|A|Diet with increased intake of rye bread, berries and fish
3170377|NCT00573781|Experimental|B|Increased intake of whole grain and rye bread
3170378|NCT00573781|Active Comparator|C|Control diet with decreased intake of rye bread, berries and fish
3170379|NCT00573807|Other|1|
3170380|NCT00573820|Other|1|
3170381|NCT00573885|Experimental|Arm I|Patients receive oral defined green tea catechin extract twice daily for 6 months.
3170382|NCT00573885|Placebo Comparator|Arm II|Patients receive oral placebo twice daily for 6 months.
3170383|NCT00573924|Active Comparator|1|Oral PPI
3170384|NCT00573924|Active Comparator|2|Intravenous PPI
3170385|NCT00573950|Experimental|Cilostazol|cilostazol group
3170386|NCT00573950|Placebo Comparator|Placebo|placebo group
3170387|NCT00573963|Active Comparator|1|Ropivacaine
3170388|NCT00573963|Placebo Comparator|2|Placebo
3170389|NCT00574002||Group A|Patients that have their chest tube removed when drainage is 400mL or less in 24 hours.
3170390|NCT00574002||Group B.|Patients that have their chest tube removed when drainage is 200mL or less in 24 hours.
3170391|NCT00574015|Active Comparator|oral|administration of oral analgesia
3170392|NCT00574015|Experimental|Dental Block|Administration of supraperiosteal nerve block to effected tooth
3170393|NCT00574041|Experimental|1|titrated dose of Avonex
3170394|NCT00574041|Active Comparator|2|full dose Avonex
3170395|NCT00574054|Other|1|
3170396|NCT00574093|Experimental|A|A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
3170397|NCT00574106|Other|1|Infrared Radiation
3170398|NCT00574132|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
3170399|NCT00574132|Placebo Comparator|Placebo Control|infusion every 13 weeks for a total of 6 infusions.
3170400|NCT00574132|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
3170401|NCT00574210|Experimental|1|Bilastine oral 20 mg once per day (1 x 20 mg bilastine tablet plus 1 placebo tablet)
3170402|NCT00574210|Experimental|2|Bilastine oral 20 mg twice per day (2 x 20 mg bilastine tablets)
3170403|NCT00574210|Experimental|3|Bilastine oral 10 mg once per day (1 x 10 mg bilastine tablet plus 1 placebo tablet)
3170404|NCT00574210|Experimental|4|Bilastine oral 10 mg twice per day (2 x 10 mg bilastine tablets)
3170405|NCT00574210|Placebo Comparator|5|Placebo oral twice per day (2 placebo tablets)
3170406|NCT00574223|Experimental|Arm 1|
3170407|NCT00574223|Placebo Comparator|Arm 2|
3170408|NCT00574301|Experimental|1|
3170409|NCT00574314||Women|Women with varying backgrounds
3170410|NCT00574327||A- Barrett's Esophagus subjects|Patients with documented Barrett's Esophagus with or without dysplasia (LGD or HGD) that will undergo surveillance endoscopies dictated by the grade of dysplasia.
3170411|NCT00574327||B- gastroesophageal reflux subjects|Patients undergoing endoscopy for evaluation of GERD symptoms.
3170412|NCT00574327||C-subjects without BE or GERD|The control group would include patients undergoing upper endoscopy for reasons other than stated above, such as evaluation of iron deficiency anemia, weight loss, positive fecal occult blood, etc.
3170413|NCT00574353|Experimental|1|FMISO PET study.
3170414|NCT00574366|Experimental|Erlotinib/RAD001 Ph I|"Tarceva (OSI-774; erlotinib) Everolimus (RAD001)~Study did not progress to Phase II:~Experimental: Erlotinib/RAD001 Phase II Maximum tolerated dose of erlotinib (Tarceva,OSI-774) and RAD001 (Everolimus)"
3204191|NCT00931593|Experimental|volunteers|"This is a descriptive study to compare two techniques (manometry with perfused dentsleeve probe vs high resolution manometry for the identification of tLESr). Each subject is his own control.~The date of perfused manometry is randomized to avoid bias due to examinations' order."
3204192|NCT00931606|Experimental|1|ACE-011 Treatment Group (Dose Level 1)
3204193|NCT00931606|Experimental|2|ACE-011 Treatment Group (Dose Level 2)
3204194|NCT00931606|Experimental|3|ACE-011 Treatment Group (Dose Level 3)
3204195|NCT00931606|Placebo Comparator|4|Placebo
3204196|NCT00931645|No Intervention|Complete responders|watch and wait policy
3204197|NCT00931645|Experimental|arm 2: complete responders patients|ABMT : TBI, 10 grays d-3-1 & cyclophosphamide 60 mg/sqm d-5-4
3204198|NCT00931645|Experimental|Non CR patients arm 3|Rescue chemotherapy and ABMT (see arm 2)
2549481|NCT02568891|Placebo Comparator|Placebo|similar looking and tasting placebo without bacteria
2549482|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
2549483|NCT02568501|Experimental|Daily feedback|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence.
3204199|NCT00931645|Active Comparator|Non CR patients at random : arm 4|Rescue DHAP, F+C
2549485|NCT02568501|Experimental|Daily Feedback, incentives|Participants receive daily feedback from wireless glucometers that transmit data on glucose monitoring adherence. Participants are eligible for a financial incentive if adherent.
3204200|NCT00931671|Other|Exercise|Exercise
2549487|NCT02568748|Experimental|CIK with TACE for HCC stage B|HCC patients stage B treated with TACE and CIK as adjuvant therapy.
3204201|NCT00931697|Experimental|AD 452 (+) mefloquine|
2549490|NCT02568748|Experimental|TACE only for HCC stage B|HCC patients stage B treated with TACE without receiving CIK cells infusion
2549489|NCT02568514|No Intervention|Usual care|Patients admitted to hospital floors without any other intervention.
2549491|NCT02568748|Experimental|CIK in HCC stage C or D|HCC stage C or D will receive supportive treatment in addition to CIK cells infusion
2549492|NCT02568514|Experimental|Secure text messaging|Patients admitted to hospital floors on which physicians and other staff are able to communicate with each other (not to the patient) using mobile secure text messaging.
2549494|NCT02568748|No Intervention|Supportive treatment in HCC stage C or D|HCC stage C or D will receive supportive treatment only .
2549493|NCT02568488|Experimental|metformin|PCOS women receiving metformin 850 mg orally twice daily over a period of 6 months
2549495|NCT02568592|Experimental|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
2549496|NCT02568592|Experimental|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
2549497|NCT02568592|Experimental|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORM (Normal), with an additional 30% extra energy coming from fat.
3204202|NCT00931697|Active Comparator|Racemic mefloquine|
3204203|NCT00931697|Placebo Comparator|Placebo|
2549500|NCT02568462|Experimental|Coronary Scaffold Implantation|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
3204204|NCT00931736|Active Comparator|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
3204205|NCT00931736|Active Comparator|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
2549503|NCT02568241|Experimental|interferon Alfa-2b|High-risk acute leukemia patients after hematopoietic stem cell transplantation receive interferon Alfa-2b after prophylactic DLI
2549504|NCT02568332|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 20 HIV seropositive individuals"
2549505|NCT02568410||CABG on CPB|Patients undergoing elective coronary artery bypass grafting using cardiopulmonary bypass. No study interventions beyond the standard clinical practice for these surgeries at Duke University Medical Center. No study drug administration.
2549506|NCT02568436|No Intervention|Conventional Decrowding|Crowded upper incisors will be treated in the conventional manner with a fake irradiation without using low level laser therapy.
2549509|NCT02568436|Experimental|Low Level Laser Therapy|Each maxillary incisor will be subjected to low level laser therapy at specific times in order to accelerate tooth movement
3204206|NCT00931749|Experimental|Low intensity Ultrasound group|
3204207|NCT00931749|Sham Comparator|Sham ultrasound group|
3204208|NCT00931775|Placebo Comparator|Citalopram + placebo|Citalopram 20 mg/day t.i.d
3204209|NCT00931775|Experimental|Citalopram + pindolol|Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.
3204210|NCT00931788|Experimental|Intensive pharmacist case management|
3204211|NCT00931788|Active Comparator|Usual care|
3204212|NCT00931814|Other|exercise|
3204213|NCT00931827||Group 1|
3204214|NCT00931827||Group 2|
3204215|NCT00931840|Experimental|EZN-2208|"EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.~PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL."
3204216|NCT00931840|Experimental|Cetuximab + EZN-2208|Cetuximab will be administered as an i.v. infusion on weekly basis. EZN-2208 administered as i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
3204217|NCT00931840|Active Comparator|Irinotecan + cetuximab|Cetuximab will be administered weekly as an i.v. infusion. Irinotecan will be administered as an i.v. infusion on Weeks 1 and 2 and repeated every 3 weeks.
3204218|NCT00931853|Experimental|SENNA + CASSIA (Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
3204219|NCT00931866|Experimental|Diclofenac Sodium Patch|
3204220|NCT00931866|Placebo Comparator|Topical Placebo Patch|
2549508|NCT02568215|Experimental|Group 1: Low-Dose VRC01|Participants will receive an IV infusion of 10 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2549507|NCT02568293|Experimental|SBCV|SBCV is administered to the site immediately post balloon dilation.
2549510|NCT02568215|Experimental|Group 2: High-Dose VRC01|Participants will receive an IV infusion of 30 mg/kg of VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
2549511|NCT02568293|Placebo Comparator|Control|Saline is used as a control and is delivered immediately post balloon dilation.
2549512|NCT02568215|Placebo Comparator|Group 3: Placebo for VRC01|Participants will receive an IV infusion of placebo for VRC01 over about 30 to 60 minutes at Weeks 0, 8, 16, 24, 32, 40, 48, 56, 64, and 72.
3170415|NCT00574379|Experimental|1|Bilastine 20mg once per day
3170416|NCT00574379|Experimental|2|Bilastine 20mg twice per day
3170417|NCT00574379|Experimental|3|Bilastine 10mg once per day
3170418|NCT00574379|Experimental|4|Bilastine 10mg twice per day
3170419|NCT00574379|Placebo Comparator|5|
3170420|NCT00574392||1|Multiwavelength and coherence confocal reflectance microscopy of pigmented and nonpigmented lesions on skin in vivo
3170421|NCT00574418|Other|1|
3170422|NCT00574431|Other|Observation|Observation
3170423|NCT00574431|Active Comparator|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
2549574|NCT02567994|Experimental|Teneligliptin|20mg qd
2549576|NCT02567877||levothyroxine in thyroidectomy patients|patients undergoing thyroidectomy for nodular thyroid disease
2549577|NCT02567994|Active Comparator|Sitagliptin|100mg qd
2549606|NCT02567604||Focus groups|AMD patients' caregivers defined as people actively taking part in providing support for AMD patients (e.g. family members, unpaid friends, volunteers)
2549625|NCT02567487|Active Comparator|Group Levobupivacaine high volume|TAP block with levobupivacaine 0.25% of 0.5 ml/kg under general anesthesia
2549626|NCT02567487|Active Comparator|Group Levobupivacaine low volume|TAP block with levobupivacaine 0.25% of 0.25 ml/kg under general anesthesia
2549632|NCT02567721||Study Cohort|Subjects who will receive influenza vaccination between 1 September 2015 and 30 November 2015 in the 9 GP practices from who clinical data routinely collected as part of clinical consultations in primary care will be extracted.
2549666|NCT02567305||Actual Sepsis|"For infants below 44 weeks inclusive of corrected age clinical sepsis is defined, according to the Expert Meeting on Neonatal and Pediatric Sepsis (Report on the Expert Meeting on Neonatal and Pediatric Sepsis - 8 June 2010, EMA London). Confirmed sepsis is defined as positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)~For children above 44 weeks corrected age clinical sepsis is defined according to the Goldstein criteria (Goldstein et al, 2005). Confirmed sepsis: positive culture for pathogens in a sample from a normally sterile site and at least one laboratory sign or clinical sign (not shown)"
2549667|NCT02567305||Suspected Sepsis|None of the above.
2549673|NCT02567006|Active Comparator|Short Message Service (SMS) group|Receiving SMS message reminders 1 week before scheduled vaccination
2549675|NCT02567006|Placebo Comparator|Usual care|Not receiving SMS messages
3170424|NCT00574444|Experimental|Procedure|Procedure/Surgery: transvaginal diagnostic peritoneoscopy For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
2549693|NCT02567240|Experimental|Carbon monoxide-bubbled mediums|Islets will be harvested with Carbon monoxide-saturated mediums
3170425|NCT00574457|Other|All subjects that meet the inclusion criteria invited|
2549707|NCT02567240|No Intervention|Normal mediums|Islets will be harvested with regular mediums
3170426|NCT00574470|Experimental|1|Treatment with daclizumab/infliximab
2549722|NCT02566772|Experimental|TAS3681|All participants will receive TAS3681 in 28-day cycles. The Escalation phase includes participants who have progressed after abiraterone, enzalutamide and chemotherapy. Eleven dose escalation cohorts are planned, one of which includes a preliminary assessment of food effect. The MTD/recommended dose for further development will be used for participants in the Expansion Phase. The Expansion Phase will enroll participants who have progressed after abiraterone or enzalutamide with chemotherapy consisting of no more than 2 prior taxane-based therapies (Group A) or without any chemotherapy (Group B). Participants receive TAS3681 until discontinuation criteria are met.
2549786|NCT02566278|Experimental|Obstructive Sleep Apnea|Upper airway collapsibility (passive Pcrit) will be measured using both clinically available equipment and research equipment in patients with obstructive sleep apnea (OSA) and stable on treatment of continuous positive airway pressure (CPAP) > 3 months to verify the Pcrit measurement obtained by the clinical equipment.
2549826|NCT02566057|Experimental|PGx testing guided treatment (PGT)|Results of the GeneceptTM Assay will be provided to their prescribers who may use the knowledge to guide medication management.
2549827|NCT02566057|No Intervention|Treatment as usual condition (TAU)|Patients will also utilize the GeneceptTM Assay but the results will not be provided back to their prescribers, who will treat the patients without the knowledge of pharmacogenetic testing results.
2549845|NCT02565927|Experimental|Radioactive stent|Patients diagnosed as MAO treated with radioactive airway stent loaded with Iodine-125 seeds
2549848|NCT02565927|Active Comparator|Traditional airway stent|Patients diagnosed as MAO treated with traditional airway stent
3170427|NCT00574483|Experimental|1|Unblinded treatment arm
3170428|NCT00574509|Experimental|131I-Anti-B1|BEAM + 131Iodine-Anti-B1 radioimmunotherapy and autologous HSCT
3170429|NCT00574522|Other|1|Infrared Radiation, wavelength between 5 and 20 microns
3170430|NCT00574574|Experimental|1|500mg/d of anthocyanin, contained in 4 X 250mg capsules (125mg anthocyanin/ capsule). 2 capsules to be taken with food, twice per day (n=4 in total).
3170431|NCT00574574|Placebo Comparator|2|500mg/d of placebo control containing no anthocyanin, 2 X 250mg capsules to be taken with food, twice per day (n=4, 250mg capsules in total / d).
3170432|NCT00574600|Experimental|Vaccine|SAAVI DNA-C2 administered as 1 ml intramuscularly in either deltoid at study entry and Months 1 and 2; SAAVI MVA-C administered as 0.5 ml intramuscularly in either deltoid at Months 4 and 5
2549524|NCT02568228|Experimental|Krill group|Krill oil capsules. 4 g/day encapsulated krill oil (Rimfrost Sublime) corresponding to ~900 mg/day EPA + DHA + DPA for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
2549523|NCT02568176|Experimental|Cohort 1|Participants will receive single oral dose of midazolam 6 milligram (mg) on Day 1 and 17. Participants will self-administer esketamine intranasally thrice per day on morning of Day 2, 5, 9, 12 and 16 (84 mg).
2549526|NCT02568228|Experimental|Fish group|Lean and fatty fish. Three weekly test-meals, containing two meals of fatty fish and one meal of lean fish for 8 weeks corresponding to ~900 mg/day EPA + DHA + DPA.
2549528|NCT02568176|Experimental|Cohort 2|Participants will receive single oral dose of bupropion 150 mg on Day 1 and 19. Participants will self-administer esketamine intranasally thrice per day on morning of Day 4, 7, 11, 14 and 18 (84 mg).
2549529|NCT02568228|Placebo Comparator|Control group|Placebo capsules. 4 g/day encapsulated high oleic sunflower oil (HOSO) for 8 weeks. The participants will be instructed to take the capsules with the breakfast and dinner meals.
2549552|NCT02567942|Other|propofol group|The patient who anesthetized by using propofol.
2549553|NCT02567942|Other|sevoflurane group|The patient who anesthetized by using propofol.
2549592|NCT02567929|Active Comparator|propofol group|The patient who anesthetized by using propofol.
2549593|NCT02567929|Active Comparator|sevoflurane group|The patient who anesthetized by using propofol
2549630|NCT02567812||In-patient with PID|In-patient with PID who diagnosed at Kangbuk Samsung Hospital
2549644|NCT02567565||cataract patients|cataract patients undergoing phacoemulsification
3170433|NCT00574600|Placebo Comparator|Placebo|Placebo administered at Months 0, 1, 2, 4 and 5
2549688|NCT02567279|Active Comparator|Denosumab subcutaneous injections|The treated group (n = 42) will receive Denosumab (60 mg, two subcutaneous injections at M0 and M6) associated with a daily treatment of vitamin D (800 IU) + calcium (1000 mg).
2549699|NCT02567279|Placebo Comparator|Placebo subcutaneous injections|The control group (n = 42) will received a placebo injection (two subcutaneous injections at M0 and M6) with daily treatment of vitamin D (800 IU) +calcium (1000 mg).
2549733|NCT02566837|Active Comparator|ELEC|electrical stimulation guidance
2549736|NCT02566837|Experimental|ECHO|ultrasound guidance
2549744|NCT02566694||Failed implants|All patients undergoing revision of an orthopaedic implant (previously this was limited to metal hips but this has now expanded to other orthopaedic implants)
2549750|NCT02566694||Controls with different failure modes|We will compare findings with different types of orthopaedic implants and categories of failure mode.
2549754|NCT02566707|Experimental|PRADAII regimen|Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.
2549766|NCT02566304|Experimental|RIC HSCT, GVHD prophylaxis|"RIC: Patients receive fludarabine phosphate IV on days -10 to -8 and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI followed by a DLI on day -7.~TRANSPLANT: Patients undergo CD34+ peripheral blood stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus PO beginning day -1 with a taper initiated on day 42 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
2549771|NCT02566330||EndoBarrier|Participants who were previously enrolled in the randomized clinical EndoBarrier procedure trial at the MUMC and the Atrium Medical Centre Heerlen.
2549777|NCT02566486|Other|Reciprocating system|Waveone root canal instrumentation file
2549780|NCT02566486|Other|Rotational system|ProTaper Next root canal instrumentation file
2549829|NCT02565940||diabetic patient with foot infection|
2549839|NCT02566200||IM group|Patients admitted in intensive care for a myocardial infarction
2549841|NCT02566096|Placebo Comparator|TAP with bupivicaine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
2549846|NCT02566096|Active Comparator|TAP with bupivicaine with morphine|30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
2549886|NCT02565771||Young adult survivors of childhood cancer|Adults treated for childhood cancer in Rhône-Alpes region in France between 1987 and 1992 with deregulation ANS or autonomic imbalance.
2549890|NCT02565836||fixed-dose aPCC|Patients receiving fixed-dose activated prothrombin complex concentrate (FEIBA VH) for reversal of warfarin-associated major hemorrhage.
2549893|NCT02565836||variable-dose PCC|Patients receiving vairable-dose inactivated prothrombin complex concentrate (Kcentra) for reversal of warfarin-associated major hemorrhage.
2549894|NCT02565667|Experimental|KOL group|KOL stapler was used for rectal anastomosis
2549899|NCT02565667|Active Comparator|traditional stapler group|traditional stapler was used for rectal anastomosis
2549918|NCT02565589||ICU patient|Critically ill patients who were enrolled less than 24 hours after ICU admission.
2549919|NCT02565589||Control|Age-, sex-, and BMI-matched healthy subjects.
2549921|NCT02565459|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party (from healthy donors) MSCs will be performed in patients randomized to the MSC procedure in addition to the kidney transplantation.
2549922|NCT02565433|Experimental|questionnaire administration|Quality of life questionnaires administration (EORTC QLQ C30 and BN20 / IADL / HADS / MoCa Edmonton Symptom Assessment Scale)
3170434|NCT00574613|Experimental|1|
3170435|NCT00574613|Placebo Comparator|2|
3170436|NCT00574626|Experimental|PBSCT|Peripheral Blood Stem Cell Transplant
3170437|NCT00574626|Active Comparator|BMT|Bone Marrow Transplantation
3170438|NCT00574639|Experimental|Arm 1|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
2549534|NCT02568189|Experimental|Sepsis 1|Sepsis patients receiving SonoSite Maxx Series Ultrasound System ultrasound prior to clinical orders including medication and fluid orders being placed by the treating physician
2549536|NCT02568189|Active Comparator|Sepsis 2|Sepsis patients having SonoSite Maxx Series Ultrasound System ultrasound performed after clinical orders have been placed by the treating physician
2549537|NCT02568189|Experimental|Gastroenteritis 1|Patients with gastroenteritis receiving SonoSite Maxx Series Ultrasound System ultrasound prior to having orders placed by treating physician
2549538|NCT02568189|Active Comparator|Gastroenteritis 2|Patients with gastroenteritis having SonoSite Maxx Series Ultrasound System ultrasound after initial clinical orders are placed by treating physician
2549559|NCT02567890|Experimental|Internet-based DBI|Internet-based DBI, which consists of four interactive occasions, some homework assignments, and monitoring
2549562|NCT02567890|Placebo Comparator|Expressive writing|Expressive Writing (placebo/attention control) where participants write texts. This is the active control condition.
2549564|NCT02567890|No Intervention|Waiting list|A wait-list control condition.Those in the wait-list condition will not receive any treatment until they have done the 6-month follow-up assessment.
2549587|NCT02567864|Experimental|Healthy Beat Accupunch|The HBA exercise program includes: 1) warm-up: 5 slow and gentle exercises to regulate qi, loosen up the body, and elevate the energy for a safe transition to the next phase, 2) accupunch: 14 low-to-medium speed exercises to punch the 14 meridians to enhance the cardiovascular-respiratory workout, and 3) relaxation: 5 low-speed, muscle relaxing exercises with deep breaths to sooth the body and mind. It is conducted 3 times per week and 40 minutes per practice.
2549589|NCT02567864|Active Comparator|control|The control group maintains daily activities.
2549591|NCT02567851|Experimental|Brentuximab Vedotin|brentuximab vedotin will be administered at an initial dose of 1.8 mg/kg every 3 weeks as a 30-minute outpatient i.v. infusion. A maximum of 16 cycles
2549607|NCT02567526|No Intervention|Usual Care Control Group|Eligible, consented residents continued to receive usual care from nursing home staff and were monitored by trained research staff.
2549608|NCT02567526|Experimental|Between-meal Intervention Group|Non-nursing staff trained as Feeding Assistants were utilized to deliver supplements and snacks twice per day, between meals for 24 study weeks.
3170439|NCT00574639|Experimental|Arm 2|Day 1 study two hyperinsulinemic (high Insulin dose) euglycemic (normal glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3170440|NCT00574639|Experimental|Arm 3|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
3170441|NCT00574639|Experimental|Arm 4|Day 1 study two hyperinsulinemic (high Insulin dose) hypoglycemic (low glucose level) clamps x 2. Day 2 exercise for 90 minutes on recumbent bike. Patient randomized to placebo or Xanax (Alprazolam) drug on Day 1 to receive 1 mg orally prior to each clamp.
2549658|NCT02567409|Experimental|Arm A (berzosertib, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 60 minutes on day 1. Patients also receive berzosertib IV over 60 minutes on days 2 and 9. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
2549661|NCT02567409|Experimental|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride and cisplatin as in Arm A.
2549761|NCT02566616|Experimental|Intervention|"Cubital Tunnel Release with stimulator for nerve location~1 hour of Ulnar nerve stimulation"
2549762|NCT02566616|Active Comparator|Non-Intervention|Cubital Tunnel Release with stimulator for nerve location NO prolonged ulnar nerve stimulation
2549775|NCT02566382|Experimental|shoulder arthroscopy arthrodesis|The shoulder surgery will be realized under arthroscopy only.
2549779|NCT02566564|Experimental|open label, single arm|Open label, single arm, dose escalating
2549840|NCT02566213|Other|Motor skills measurements|
3170442|NCT00574652|Other|1|it is a single arm study
3170443|NCT00574665|Experimental|1|
3170444|NCT00574678|No Intervention|1|
3170445|NCT00574691|Other|1|Vascular Closure Device
3170446|NCT00574717|Experimental|A|Infants will receive spectacle under-correction of their hyperopia.
3170447|NCT00574730|Experimental|Arm 1|
3170448|NCT00574743|No Intervention|2|
3170449|NCT00574743|Active Comparator|1|
3170450|NCT00574756|Other|1|Active drug for 2 weeks, then washout period for 2 weeks, then placebo for 2 weeks
3170451|NCT00574756|Other|2|Placebo for 2 weeks, then washout for 2 weeks, then ranolazine for 2 weeks
3170452|NCT00574769|Experimental|1|
3170453|NCT00574808|Experimental|intervention|Outreach Facilitation implementing elements of the Chronic Care Model. The facilitators will provide hands on support to practices and help to implement tools and processes designed to incorporate evidence-based practice into the routine delivery of cardiovascular care. Specifically, they will a) assist with practice performance assessment, feedback, and consensus building towards goal setting, b) offer clinical, technical, organizational resources and practical advice, and c) provide encouragement to face and overcome the challenges of implementing system change.
3170454|NCT00574808|No Intervention|control|Baseline data before implementation of the program will serve as the control. Comparisons will be made between baseline and post-intervention within each divisions of primary care practices as well as between divisions (ie. baseline information from one division will serve as the control for another).
3170455|NCT00574860|Experimental|EN3285 (NAC ProGelz)|The EN3285 arm is the product under development
3170456|NCT00574860|Placebo Comparator|No active ingredients (placebo)|This will be an oral product that contains no active ingredient
3170457|NCT00574860|Other|Standard of Care|This arm will reflect the typical standard of care for the patient
3170458|NCT00574886|Experimental|1|
3170459|NCT00574899||1|patients scheduled to receive standard of care with a Radical prostatectomy
3170460|NCT00574899||2|patients scheduled to receive standard of care with radiation therapy
3170461|NCT00574964|Experimental|1|
2549542|NCT02568150|Other|Intervention|Onset time of improvement effect of glabellar lines at maximum frown of botulinum toxin treatment
2549560|NCT02567903|Active Comparator|No Tourniquet|Knee arthroscopy without the use of a thigh tourniquet.
2549566|NCT02567903|Experimental|Tourniquet|Knee arthroscopy with the use of a thigh tourniquet.
2549616|NCT02567734|Experimental|Irreversible electroporation|In this group，eligible patients were selected to receive the CT-guided percutaneous irreversible electroporation ablation.
2549648|NCT02567799|Experimental|Single-arm|Ascending dose evaluation of BIO 300 Oral Suspension (3 dose levels) given in combination with paclitaxel/carboplatin and radiotherapy.
2549655|NCT02567370|Placebo Comparator|Placebo|
2549659|NCT02567370|Active Comparator|AMG 581|
2549683|NCT02567084|Other|"CERAMENT™ |BONE VOID FILLER"|"Intraoperativ application of medical device: CERAMENT™ |BONE VOID FILLER 5cc/10cc/18cc"
2549689|NCT02566980||Pre-partum|130 pregnant women will be enrolled in first trimester. Healthy women or those with any degree of depressive symptoms are eligible. Blood samples and psychiatric assessments will take place once every trimester and once in the post-partum. At delivery placenta will be collected. Enrollment takes place at Spectrum Health Ob/gyn out-patient clinics in Grand Rapids, Michigan.
2549705|NCT02566980||Post-partum|50-100 women experiencing perinatal depression with and without suicidality will be enrolled from a partial hospitalization program, the Mother and Baby unit as well as outpatient clinics at Pine Rest Christian Mental Health Services, Grand Rapids, Michigan.
3170462|NCT00574977|Experimental|A|Subjects who have been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection
2549749|NCT02566746|Experimental|Chait Trapdoor caecostomie catheter|Patients randomized in this arm will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter
2549755|NCT02566746|Active Comparator|Continuation of optimal medical therapy|"Patients randomized in this arm will continue this medical treatment of constipation with laxative and / or suppositories and / or enemas retrograde during 12 months.~At 12 months : patients will undergo percutaneous endoscopic caecostomy with Chait Trapdoor caecostomie catheter during 12 months."
2549763|NCT02566603|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between three and six patients will be enrolled per intervention level. Intervention levels range from 3 to 24 micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after initiation of PRTX-100 dosing for safety management.
2549776|NCT02566343||COPD cohort|confirmed COPD: 240 patients with COPD confirmed by spirometry undergoing high-risk noncardiac major surgery in the University Medical Center Hamburg-Eppendorf will be included in this group.
2549781|NCT02566343||Control cohort|disproved COPD: 80 patients without COPD (clinical risk factors but negative spirometry) undergoing high-risk noncardiac major surgery will be included as a control group.
2549947|NCT02565199|Experimental|Single motor training only|For a pilot experiment, healthy, right-handed subjects will complete one testing session. During the testing session, subjects will complete motor training. The results of this experiment will determine the motor training protocol used in the main experiment.
2549948|NCT02565199|Experimental|Repetitive TMS during motor training|Healthy, right-handed subjects will complete five testing sessions. During each testing session, subjects will complete motor training while receiving one of five repetitive transcranial magnetic stimulation (rTMS) protocols. Subjects will receive a different rTMS protocol at each testing session. By the end of the study, each subject will have received all rTMS protocols.
2549979|NCT02565082|Experimental|Sickle cell disease|This arm will include an approximate number of 50 sickle cell disease patients, homozygous and heterozygous.
2549986|NCT02565082|Other|Control|This arm will include an approximate number of 30 healthy volunteers.
3170463|NCT00574977|Experimental|B|Subjects will include those who have not been vaccinated with vaccinia virus (small pox)and will receive vvDD-CDSR by intratumoral injection.
3170464|NCT00574977|Experimental|C|Subjects will be those who have been vaccinated with vaccinia virus (small pox)and will be receiving the vvCD-CDSR via intravenous infusion
2550029|NCT02564770||Rheumatoid arthritis (RA) participants|Participants who had been treated with rituximab for RA are reviewed retrospectively using chart review from Baseline until and their most recent visit to the rheumatologist prior to the conduct of the chart review.
2550069|NCT02564523|Experimental|Group 1|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
2550078|NCT02564588|Experimental|Dasotraline|Dasotraline 4, 6, 8 mg
2550080|NCT02564588|Placebo Comparator|Placebo|Placebo Comparator
3170465|NCT00575003|Experimental|1|
3170466|NCT00575003|Placebo Comparator|2|
3170467|NCT00575055|Experimental|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
3170468|NCT00575055|Placebo Comparator|Placebo Dose|infusion every 13 weeks for a total of 6 infusions.
3170469|NCT00575055|Experimental|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions.
3170470|NCT00575068|Experimental|1|
3170471|NCT00575081||Stereotactic Brain Procedures|Patients who have consented to undergo or have undergone a stereotactic brain procedure for any reason including those who need Deep Brain Stimulation, SEEG or other brain neurmodulation device implant.
3170472|NCT00575107|Experimental|VSC-VLC|velocity-controlled variable resistance, lengthening contraction
3170473|NCT00575107|Active Comparator|SC|Constant weight shortening contraction
3170474|NCT00575120|No Intervention|A|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
3170475|NCT00575120|Active Comparator|B|Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
3170476|NCT00575172||U|Intensified insulin therapy with ultrarapid insulin-analogue (Insulin-Aspart)
3170477|NCT00575172||R|Intensified insulin therapy with human regular insulin
3170478|NCT00575198|Experimental|1|No drainage threshold
3204221|NCT00931905|Experimental|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used, and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.
3204222|NCT00931905|Placebo Comparator|hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol.
3204223|NCT00931931|Experimental|HSV1716 - Intratumoral route|Research participants with localized disease receiving HSV1716 as an intratumoral injection
3204224|NCT00931931|Experimental|HSV1716 - intravenous|Research participants with metastatic disease receiving HSV1716 intravenously
3204225|NCT00931957|Active Comparator|Etanercept-MTX-Prednisolone|Methotrexate + Prednisolone + Etanercept
3204226|NCT00931957|Other|B, MTX-Prednisolone|Methotrexate + Prednisolone
2549628|NCT02567591|Experimental|A: physical activity program|at home physical activity program (during 12 weeks)
2549629|NCT02567591|No Intervention|B: conventional management|conventional management
2549686|NCT02567253|Experimental|low dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
2549698|NCT02567253|Experimental|high dose, normothermic|CRS + normothermic (37°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
2549708|NCT02567253|Experimental|low dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 75mg/m² Cisplatin during 90min + adjuvant chemotherapy
2549713|NCT02567253|Experimental|high dose, hyperthermic|CRS + hyperthermic (41°C) intraoperative intraperitoneal chemoperfusion, with 100mg/m² Cisplatin during 90min + adjuvant chemotherapy
2549729|NCT02566629||IBS patients in episodes phase|collect faeces from IBS patients in episodes remission phase
2549730|NCT02566629||IBS patients in remission phase|collect faeces from IBS patients in remission phase
2549732|NCT02566629||healthy controls|collect faeces from healthy controls
3204227|NCT00931970||Dialysis modality|
3204228|NCT00932009||Human papillomavirus|Tanzanian men with HPV and Tanzanian men without
2549861|NCT02565888|Active Comparator|Treatment A|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + ritonavir 100mg QD from film-coated tablet for 10 days.
2549862|NCT02565888|Experimental|Treatment B|Daclatasvir 30 mg QD film-coated tablet + atazanavir 300mg QD hard capsule + cobicistat 150mg QD from film-coated tablet for 10 days.
2549911|NCT02565602|Other|Ca-41 & Sr-84 (isotope tracers) & vit D|Dosages: 3.7 kBq (100 nCi) Ca-41, 5 mg of Sr-84 and 400IU of vitamin D (daily)
2549975|NCT02565264|Experimental|plasma-derived exosomes|plasma-derived exosomes
2550033|NCT02564835|Experimental|Yoga|The Yoga Program includes two 90-minute classes every week tor a total of 12 weeks.
2550036|NCT02564835|Active Comparator|Physical Activity|The Physical Activity Program includes two 90-minutes classes every week for a total of 12 weeks.The intervention is based on the Exercise for People Living with Cancer program and will include nine resistance exercises (e.g. standing push up, squats, standing leg curl) and 8 flexibility exercises (e.g. shoulder stretch, quadriceps stretch, hamstrings and lower back stretch) targeted for the whole body as well as a brief warm up and cool down (walking).
2550038|NCT02564835|No Intervention|Usual Care|Participants randomized to this arm will receive standard care only.
3204229|NCT00932048|No Intervention|Control|
2550129|NCT02564081|Experimental|Static Stretching lower limb|Three 30 s bouts of static stretching for the gastrocnemius and the hamstrings respectively
2550134|NCT02564081|Active Comparator|Static stretching Cervical|Six 30 s bouts of static stretching of the cervical spine in the sagittal plane (flexion only)
2550135|NCT02564081|No Intervention|Ctrl|No intervention
2550158|NCT02563873|No Intervention|Standard pacemaker settings|Standard pacemaker settings will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange
2550165|NCT02563873|Experimental|Tailored pacemaker settings|The pacemaker settings will be altered to match optimal heart rate range with respect to cardiac contractility, as determined by echocardiography. This will be programmed and the patient will complete a symptom limited exercise tolerance test with metabolic gas exchange.
2550230|NCT02563613|Experimental|Physical Exercise (PE)|Physical exercise will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will comprise of a core intervention session on physical exercise, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on healthy diet. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
2550234|NCT02563613|Experimental|Healthy Diet (HD)|Healthy diet will be promoted through the use of one of three positive psychology themes: joy, gratitude and savoring. It will include a core intervention session on healthy diet, a booster session at 1 month to consolidate the knowledge and skills that they have gained, followed by a follow-up session at 3 months on physical exercise. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
2550242|NCT02563613|Placebo Comparator|Wait-list Control (C)|The control group will consist of a tea gathering session at the beginning and 1 month later, followed by a follow-up session at 3 months on physical exercise or healthy diet. The tea gathering sessions will cover topics unrelated to the intervention, such as arts and crafts workshops. Trained facilitators will have the relevant knowledge and skills to carry out the intervention effectively.
3204230|NCT00932048|Experimental|Atorvastatin|
3204231|NCT00932061|Active Comparator|Traditional Acupuncture|Acupuncture sites will be used for active intervention.
3204232|NCT00932061|Sham Comparator|Sham Treatment|Sham acupuncture is used.
3204233|NCT00932074|Experimental|3% KP-413 Ointment|
3204234|NCT00932074|Experimental|1% KP-413 Ointment|
3204235|NCT00932074|Placebo Comparator|Placebo|
3204236|NCT00932087||type 2 diabetics with metabolic syndrome|
3204237|NCT00932087||metabolic syndrome without diabetes|
3204238|NCT00932087||type 1 diabetes|
3204239|NCT00932087||control|
2549550|NCT02567955|Active Comparator|Immunogenicity two doses of Gardasil-9|Subjects will receive two doses of Gardasil-9
2549551|NCT02567955|Experimental|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a dose Cervarix and a dose Gardasil-9
2549554|NCT02568423|Experimental|Mirikizumab IV|Mirikizumab given by intravenous (IV) infusion once.
2549555|NCT02568423|Experimental|Mirikizumab SC|Mirikizumab given by subcutaneous (SC) injection once.
2549556|NCT02568423|Placebo Comparator|Placebo IV|Placebo given by IV infusion once.
2549557|NCT02568423|Placebo Comparator|Placebo SC|Placebo given by SC injection once.
2549642|NCT02567461|Experimental|DAPT plus high-dose edoxaban|High-dose edoxaban will be represented by edoxaban 60mg od, which will be reduced to 30mg od in patients with ClCr ≤50mL/min.
2549643|NCT02567461|Experimental|DAPT plus low-dose edoxaban|Low-dose edoxaban will be defined as edoxaban 30mg od, which will be reduced to 15mg od in patients with ClCr ≤50mL/min.
2549645|NCT02567695|Experimental|Treatment Sequence 1|Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 1 followed by Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 2.
2549646|NCT02567461|Active Comparator|DAPT|Aspirin 81 mg od plus clopidogrel 75 mg od
2549647|NCT02567695|Experimental|Treatment Sequence 2|Treatment B with 300 mg (3 × 100 mg) capsules (low-strength) of GBT440 administered in a fasted state (reference) in dosing Period 1 followed by Treatment A with one 300 mg capsule (high-strength) of GBT440 administered in a fasted state (test) in dosing Period 2.
2549674|NCT02567019|Experimental|periodontal diseases|blood samples will be done for patients suffering of periodontal diseases
2549676|NCT02567019|Active Comparator|healthy volunteers|blood samples will be done for healthy volunteers
2549695|NCT02567136||Amyotrophic Lateral Sclerosis|Patients with ALS
2549704|NCT02567136||Healthy Controls|Healthy control volunteers
2549737|NCT02566928|Experimental|Decolonization and Decontamination|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, oral antibiotics, and antibiogram-based antibiotic prescribing, and 2) a home-based intervention implemented by Community Health Workers/Promotoras that includes index patient and household member education and instructions to complete a decolonization and decontamination regimen, along with printed materials describing a standard hygiene protocol for reducing household contamination. Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of 2% mupirocin ointment to the anterior nares with a clean cotton applicator for five days, as well as daily bathing with chlorhexidine wash for five days. The household decontamination hygiene protocol includes the use of hand-washing, surface disinfection, and laundering.
2549740|NCT02566928|No Intervention|Usual Care|Index Patients will receive: 1) guidelines-directed care, which may consist of incision, drainage, and oral antibiotics, as well as antibiogram-based antibiotic prescribing, and 2) printed materials describing a standard hygiene protocol for reducing household contamination.
2549844|NCT02566161||Trio Cohort|families were from each of 5 exposure categories: A-father exposed, mother unexposed; B-mother exposed, father unexposed; C-both parents exposed; D-neither exposed; E-high dose emergency workers).
2549873|NCT02565745|Experimental|Skin Dressing|Hydrocolloid dressings applied during hospitalization
2549876|NCT02565745|Active Comparator|Moisturizing cream|Use of moisturizing cream, as part of conventional skin care
3170479|NCT00575198|Active Comparator|2|Drainage <2 mL/kg
3170480|NCT00575211||Cardiomyopathy|
2549967|NCT02565316|Active Comparator|Nepeta menthoides Boiss & Bohse freeze dried extract capsule|
3170481|NCT00575224|Other|A|Pegylated interferon and ribavirin for 24 weeks
3170482|NCT00575224|Other|B|Pegylated interferon and ribavirin for 48 weeks
3170483|NCT00575237|No Intervention|Control|In the control group, CO2 was removed by passive deflation of the abdominal cavity through the holes of the trocar.
3170484|NCT00575237|Experimental|Intervention|
3170485|NCT00575250|Active Comparator|1|Osteoporosis Prevention and Self-Management Course (4 x 2 1/2 hours)
3170486|NCT00575250|Active Comparator|2|"One introductory osteoporosis education session (1 x 2 1/2 hours)"
3170487|NCT00575263||Normal Teeth|Normal molar teeth
3170488|NCT00575263||painful teeth|Painful molar teeth
3170489|NCT00575276||1|Females with acute cholecystitis
3170490|NCT00575276||2|Females with Chronic Cholecystitis
3170491|NCT00575276||3|Males with acute cholecystitis
3170492|NCT00575276||4|Males with Chronic Cholecystitis
3170493|NCT00575302|Active Comparator|300|administration of 300 IU Gonal-f® in a short agonist protocol.
3170494|NCT00575302|Experimental|450|administration of 450 IU Gonal-f® in a short agonist protocol.
3170495|NCT00575341|Active Comparator|1|substitution of DHEA-hormone, oral, once daily
3170496|NCT00575341|Placebo Comparator|2|substitution of placebo, oral, once daily
3170497|NCT00575354|Active Comparator|1|Sevoflurane: induction 3-6%, maintenance 2-3%
3170498|NCT00575354|Active Comparator|2|Isoflurane: induction 3-6%, maintenance 2-3%
3170499|NCT00575406|Active Comparator|R-CHOP|Treatment with Rituximab, Cyclophosphamide, Doxorubicin, Vincristin and Prednisolone
3170500|NCT00575406|Experimental|R-COMP|Treatment with Rituximab, Cyclophosphamide, liposomal Doxorubicin, Vincristin and Prednisolone
3170501|NCT00575419|Experimental|1, IV NAC|N-acetylcysteine administered intravenously
3170502|NCT00575419|Experimental|2, IA NAC|N-acetylcysteine administered intra-arterial
3170503|NCT00575432||1|
3170504|NCT00575445||1|Pediatric patients with previously diagnosed asthma
3170505|NCT00575458||1|Static Splint
3170506|NCT00575458||2|Dynamic Splint
3170507|NCT00575471|Experimental|1|rivoglitazone HCl 0.5 mg tablets once daily for 12 weeks
3170508|NCT00575471|Experimental|2|rivoglitazone HCl 1 mg tablets once daily for 12 weeks
3170509|NCT00575471|Experimental|3|rivoglitazone HCl 1.5 mg tablets once daily for 12 weeks
3170510|NCT00575471|Placebo Comparator|4|Matching placebo tablets once daily for 12 weeks
2549788|NCT02566291||Supreme Group|Measuring Success rate and Insertion Time
2549790|NCT02566291||Gain Group|Measuring Success rate and Insertion Time
2549908|NCT02565498|Other|Preoperative Radiation Therapy (Arm A)|Preoperative intensity modulated radiation therapy followed by surgery
2549909|NCT02565498|Experimental|Postoperative Radiation Therapy (Arm B)|Surgery followed by postoperative intensity modulated radiation therapy
2549956|NCT02565134|Experimental|PAC-14028 cream 0.1%|PAC-14028 cream 0.1%, Twice daily for 4 weeks
2549959|NCT02565134|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, Twice daily for 4 weeks
2549961|NCT02565134|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, Twice daily for 4 weeks
2549962|NCT02565134|Placebo Comparator|PAC-14028 cream vehicle|PAC-14028 cream vehicle, Twice daily for 4 weeks
2550164|NCT02563756|Experimental|UKA, unicompartmental knee replacement|Procedure: Participants are operated with a mobile bearing medial unicompartmental knee arthroplasty (Oxford). They are followed with CT, functional tests and PROM, compared with those operated with TKA.
2550168|NCT02563756|Experimental|TKA, total knee replacement|Procedure: Participants are operated with a cruciate retaining conventional tricompartmental prosthesis (PFC). They are followed with CT, functional tests and PROM, compared with those operated with UKA.
2550219|NCT02563587|Experimental|Group LT-CT|Laughter therapy with conventional treatment
2550222|NCT02563587|Placebo Comparator|Group AW-CT|Accompaniment without causing the laughter of children more conventional treatment
2550224|NCT02563587|Sham Comparator|Group CT|Conventional treatment only
2550286|NCT02563236|Experimental|Parabolic flight and Augmented Reality interface alignments|
2550443|NCT02562313|Experimental|BioChaperone insulin lispro|
2550451|NCT02562313|Active Comparator|Humalog®|Insulin lispro
2550489|NCT02561845||rosuvastatin group|patients who received rosuvastatin
2550529|NCT02561650|Experimental|COV155|
2550651|NCT02560818|Active Comparator|Control population : Healthy Volunteers|"20 Healthy Volunteers will be recruited:~10 women to recover breast tissue (from surgical waste) : populations A and C~10 women to recover ovarian tissue (from surgical waste) : population B"
3170511|NCT00575484|Placebo Comparator|1|
3170512|NCT00575484|Active Comparator|2|
3170513|NCT00575497|Experimental|A|Six Day per week short daily hemodialysis
3170514|NCT00575497|Experimental|B|Six nights per week nocturnal hemodialysis
3170515|NCT00575497|Experimental|C|Every other day short daily hemodialysis
3170516|NCT00575497|Experimental|D|Every other night hemodialysis
3170517|NCT00575497|Experimental|E|5 days per week short daily hemodialysis
3170518|NCT00575497|Experimental|F|5 nights per week hemodialysis
3170519|NCT00575497|Active Comparator|G|Conventional three time per week short daily hemodialysis
3170520|NCT00575523|Active Comparator|1: Atropine|Atropine 0,5mg is administered intravenously immediately before starting percutaneous ethanol instillation.
3170521|NCT00575523|Placebo Comparator|2: Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
3170522|NCT00575536||Rhizotomy for children with spasticity|Children with spasticity needing Rhizotomy surgery
3170523|NCT00575575|Experimental|A,2|
3170524|NCT00575601|Active Comparator|A|
3170525|NCT00575601|Placebo Comparator|B|
3170526|NCT00575614|Active Comparator|1|
3170527|NCT00575614|Placebo Comparator|2|
3170528|NCT00575627|No Intervention|2|
3170529|NCT00575627|Experimental|1|Drug: peginterferon α-2a (40 kDa) plus ribavirin for 24-48 weeks
3170530|NCT00575640|Active Comparator|1|"The objective of this study is to determine the MTD for Hydralazine added to standard neoadjuvant chemotherapy for operable recta cancer. Four dose levels of hydralazine are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
3170531|NCT00575653||11-18 (Primary)|Enrolled members of one of the participating health plans who are ages 11-18 at any time during the study period, March 1, 2005 through August 31, 2008.
3170532|NCT00575653||19-21 (Secondary)|Enrolled members of one of the participating health plans who are ages 19-21 at any time during the study period, March 1, 2005 through August 31, 2008.
3170533|NCT00575679|Experimental|1|Brief motivational interview
3170534|NCT00575679|No Intervention|2|No discussion
3170535|NCT00575692||PulmoHypertension|Patients with suspected, latent or manifest pulmonary hypertension
3170536|NCT00575692||Controls|Controls without history of cardiac or pulmonary diseases
3170537|NCT00575718|Active Comparator|1|Hospital Counseling + Nicotine Replacement Therapy (HC+NRT)
3170538|NCT00575718|Experimental|2|Hospital Counseling + Nicotine Replacement Therapy + Pre-surgical Schedule Reduced Smoking (HC+NRT+PS/SRS)
3170539|NCT00575731|Experimental|Fine-Tuning|2-month intervention (8 lifestyle counseling classes)
3170540|NCT00575731|Active Comparator|Record-Keeping|2-month intervention (8 lifestyle counseling classes)
3170541|NCT00575744|No Intervention|1|
3170542|NCT00575757||Primary|HIV infected with abnormal liver enzymes in the absence of HCV or HBV coinfections.
3170543|NCT00575783||1A, 1B|"Type 1 diabetic subjects with a history of severe hypoglycemia and hypoglycemia unawareness who:~1A) meet criteria for islet cell transplantation and are referred by a participating islet cell transplantation center~1B) meet similar criteria but are not currently planning islet cell transplantation"
3170544|NCT00575783||2|Type 1 diabetics who are not optimally controlled (>8% HbA1c) and rarely experience hypoglycemia
3170545|NCT00575783||3|Healthy non-diabetics
3170546|NCT00575796|Experimental|1|"Children will be treated with Vinblastine Sulphate chemotherapy via intravenous administration once a week over a period of 26 weeks. MRI disease evaluation should be performed at weeks 12 and 26 (+/- 1 week). If response on MRI at week 26 > stable (i.e. stable disease, objective or partial or complete response compared to the baseline MRI exam), continue weekly Vinblastine to the total duration of treatment (i.e. 70 weeks).~All children will be followed until they demonstrate clear signs tumour progression."
2549569|NCT02568111|Experimental|brimonidine tartrate|Participants will apply gel to injection site erythema area after IRE development post peginterferon beta-1a injection
2549571|NCT02568111|Placebo Comparator|Vehicle Gel|Participants will apply vehicle gel placebo to injection site erythema area after IRE development post peginterferon beta-1a injection
2549636|NCT02567617|Active Comparator|Intervention group|Group receiving capsules with polyphenols.
2549639|NCT02567617|Placebo Comparator|Placebo controlled group|Group receiving capsules with starch.
2549682|NCT02567201|Experimental|Electrophysiological assessment of Healthy subjects|Experiences 1, 2 and 3 with healthy subjects
2549690|NCT02567201|Experimental|Electrophysiological assessment of patients|Experiences 1, 2 and 3 with patients
3204240|NCT00932100|Experimental|REG1-a|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3204241|NCT00932100|Experimental|REG1-b|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3204242|NCT00932100|Experimental|REG1-c|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3204243|NCT00932100|Experimental|REG1-d|Fixed dose of RB006 (anticoagulant) Variable blinded dose of RB007 (control agent)
3204244|NCT00932100|Active Comparator|Heparin|Heparin per standard of care at the local institution
3204245|NCT00932139|Experimental|Electro-acupuncture control|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the Electro-acupuncture control treatment."
3204246|NCT00932139|Experimental|Electro-acupuncture test|"Blood pressure will be recorded before and after each EA treatment for 8 weeks. The course is a once a week 8-week treatment.~Intervention is the active Electro-acupuncture treatment."
3204247|NCT00932178|Experimental|Calmer Life|Skills-based intervention to reduce anxiety and worry in adults age 50+.
3204248|NCT00932191|Active Comparator|Ultrasound phacoemulsification|Cataract nucleus is removed using standard amounts of ultrasound energy.
3204249|NCT00932191|Active Comparator|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
3204250|NCT00932204|Experimental|Active stimulation|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d)."
3204251|NCT00932204|Sham Comparator|Sham stimulation|For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area.
3204252|NCT00932217|Active Comparator|filgrastim|patients mobilized with filgrastim
3204253|NCT00932217|Active Comparator|lenograstim|patients mobilized with lenograstim
3204254|NCT00932230|Experimental|Group 1|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
3204255|NCT00932256|Experimental|STAHIST for seasonal allergic rhinitis|STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
3204256|NCT00932269||Seroimmunity 2007|Cord blood from 400 newborns, 1800 children (2 - 18 years) and 2400 adults (above 18 years), randomly selected and stratified in age groups, from which blood samples are taken.
2550231|NCT02563431|Active Comparator|SP-ED|Classic use
2550232|NCT02563431|Experimental|4P-ED|Literature update
2550292|NCT02563158|No Intervention|Hx with hepatic inflow occlusion|Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
2550294|NCT02563158|Experimental|Hx with non-occlusion technique|Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
3204257|NCT00932269||Sub Study|800 immigrated children (14 - 16 years) from which blood samples are taken.
3204258|NCT00932295|Active Comparator|Own brand cigarette|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
3204259|NCT00932295|Sham Comparator|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
3204260|NCT00932295|Experimental|Electronic cigarette Version One C7|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
3204261|NCT00932295|Experimental|Electronic cigarette version 2: NJ|"10 puffs from a so-called electronic cigarette named NJOY (16 mg cartridge; 30 second inter puff interval)"
3204262|NCT00932308|Active Comparator|1|Western-style, high-fat, low-calcium diet (WD)
3204263|NCT00932308|Active Comparator|2|Prudent, low-fat, calcium sufficient diet (PD)
3204264|NCT00932334|Experimental|TALK Plus|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
3204265|NCT00932334|Experimental|TALK Standard|Participants receive and educational video and booklet about living kidney donation
3204266|NCT00932334|Other|Usual Care|Participants receive their usual medical care
3204267|NCT00932347|Experimental|Mouthwash A|Mouthwash A: Camellia sinensis mouthwash
3204268|NCT00932347|Placebo Comparator|Mouthwash B|Mouthwash B: Placebo mouthwash
3204269|NCT00932386|Experimental|dexmedetomidine Hcl infusion|Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist, which possesses hypnotic, sedative, anxiolytic, sympatholytic and analgesic properties.
3204270|NCT00932386|Placebo Comparator|normal saline|
3204271|NCT00932412|Experimental|CLARA|Clofarabine / Intermediate-Dose Cytarabine (CLARA) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
2549570|NCT02568137|Experimental|Behavioral|Nurse-directed mobile health technology using smart phones to promote adherence to antihypertensive medication.
2549572|NCT02568137|No Intervention|Usual background care|Standard care
2549573|NCT02568059|Experimental|100 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 100 mg.
2549579|NCT02568059|Experimental|200 mg SHT extract|The Sahastara remedy alcoholic extract capsule dose 200 mg.
2549609|NCT02567747||Study cohort|The Total population will include all subjects included in the study. Only aggregated information will be collected for these subjects.
2549631|NCT02567682|Experimental|Fixed sequence, 2-periods|An open-label, fixed sequence, 2-period drug interaction study Period 1 Treatment A: Single dose of drug cocktail on Day 1 Period 2 Treatment B: GBT440 on Days 1 through 3 and Treatment C: Single dose of drug cocktail on Day 4 and GBT440 on Days 4 through 7
2549652|NCT02567396|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2549681|NCT02567045|Experimental|Fecal occult blood testing|"Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.~Colonoscopy will be performed in case of a positive FIT."
2549687|NCT02567045|Active Comparator|one-time Colonoscopy|One-time Colonoscopy with sedation
2549747|NCT02566668||Asthmatic|1 year observational follow-up
2549751|NCT02566668||Non-Asthmatic|1 year observational follow-up
2549770|NCT02566460|Experimental|lactate clearance group|Refer to lactate clearance rate to perform resuscitation therapy
2549774|NCT02566460|Sham Comparator|SCVO2 group|Refer to SCVO2 to perform resuscitation therapy
2549778|NCT02566356|Experimental|Oxytocin|40 IU Oxytocin
2549782|NCT02566356|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2549923|NCT02565446|Other|MRE|Clinical Cohort: NAFLD COHORT RECRUITED FROM THE LIVER CLINIC: 120 adult subjects evaluated at Mayo Clinic with a diagnosis of NAFLD who are at risk to have NASH will be recruited from our outpatient Liver Disease Clinic. Metabolic syndrome is a strong predictor of NASH and will be used to best identify subjects with a clinical indication for liver biopsy according to AASLD guidelines. The proposed sample size for this experiment will be calculated based on sensitivity and specificity of MRE for differentiating various stages of fibrosis.
2549999|NCT02565069|Experimental|Treatment group|Use of CartoFinder™ device with CARTO® 3 System V5 Navigation to treat complex arrhythmias
2550075|NCT02564549|Active Comparator|Group 1 (TRUS-guided biopsy)|"Baseline and annual systematic TRUS-guided biopsy performed as per standard of care by urologists for a total of one baseline diagnostic biopsy and two active surveillance systematic biopsies.~mpMRI at the end of the 2nd year with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
3170547|NCT00575809||Obsevational|
2550145|NCT02563938|Experimental|AK001|Up to six single ascending doses of AK001.
3170548|NCT00575822|Active Comparator|1|NDO Endoscopic Full-thickness Plicator procedure
3170549|NCT00575822|Sham Comparator|2|Sham control procedure
3170550|NCT00575835|Active Comparator|1|
3170551|NCT00575835|Experimental|2|
3170552|NCT00575848|Active Comparator|1|
3170553|NCT00575848|Placebo Comparator|2|
3170554|NCT00575861|Active Comparator|1|Advair 250/50 (baseline) fluticasone/salmeterol 250/50
3170555|NCT00575874|Experimental|1|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
3170556|NCT00575874|Experimental|2|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
3170557|NCT00575874|Experimental|3|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
3170558|NCT00575874|Active Comparator|4|30 mg pioglitazone HCl capsules once daily for 12 weeks
3170559|NCT00575874|Placebo Comparator|5|Matching rivoglitazone HCL placebo tablets and/or matching pioglitazone HCL placebo capsules
3170560|NCT00575900|Experimental|1|Low carbohydrate and low fat.
3170561|NCT00575900|Experimental|2|Low carbohydrate fat rich diet
3170562|NCT00575900|Active Comparator|3|A balanced low fat diet
3170563|NCT00575926|Active Comparator|A: Lingzhi extract|Oral 300mg capsules containing Lingzhi extract (4 to 6 capsules per day as dosed by patients' age)
3170564|NCT00575926|Placebo Comparator|B: Placebo|Starch with same appearance and taste as LingZhi
3170565|NCT00575939||HIV positive|HIV infected treatment naive with CD4 cell count of at least 400
3170566|NCT00575939||Healthy controls|Healthy controls
3170567|NCT00575952|Experimental|Treatment (doxorubicin hydrochloride, cisplatin, paclitaxel)|"Patients receive doxorubicin hydrochloride IV over 30 minutes followed by cisplatin IV over 1 hour on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive doxorubicin hydrochloride IV and cisplatin IV or IP on day 1, and paclitaxel IP on days 1 or 8. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3170568|NCT00575978|Experimental|Hydralazine|"The objective of this study is to determine the MTD for hydrazaline added to standard neoadjuvant chemotherapy for operable breast cancer. Four dose levels of hydrazalline are planned:~Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID"
3170569|NCT00575991|Experimental|A|
3170570|NCT00575991|Placebo Comparator|B|
3170571|NCT00576004|Active Comparator|group A|Pelvic organ prolapse repair plus concomitant Burch Colposuspension
3170572|NCT00576004|Active Comparator|group B|Pelvic organ prolapse without Burch colposuspension
3170573|NCT00576030|Other|H|habitual coffee drinkers
3170574|NCT00576030|Other|N|non-habitual coffee drinkers
2549578|NCT02567981|Experimental|21 micronutrient fortified supplement|21 micronutrient-fortified supplement
2549581|NCT02567981|Active Comparator|Current Standard of Nutritional Care|Cereal Fortificado (Fortified Cereal) Ferrous sulphate Vitamin A
2549617|NCT02567578|Experimental|YH12852 0.1 mg|twice daily for 4 weeks
2549618|NCT02567578|Experimental|YH12852 0.25 mg|twice daily for 4 weeks
2549620|NCT02567578|Experimental|YH12852 0.5 mg|twice daily for 4 weeks
2549623|NCT02567578|Placebo Comparator|Placebo|twice daily for 4 weeks
2549657|NCT02567318|Experimental|MRI-scan|All study participants will complete a MRI-scan of the brain
2549679|NCT02567110||Participants with Major Depression|Participants with major depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
2549680|NCT02567110||Participants without Depression|Participants without depression will complete neurocognitive and psychiatric assessments, complete self-report forms and undergo Magnetic Resonance Imaging scans. Blood and spinal fluid specimens will also be collected for estimation of inflammatory markers.
2549731|NCT02566941|Experimental|Stimulated|Patients included in the 'stimulated' group will be stimulated at the level of the quadriceps twice a day, bilaterally and simultaneously, five days per week from Monday to Friday (Stimulator: Gymna Belgium, DUO 400). The stimulation protocol (rectified alternating current; frequency, 75 Hz; intensity, 0-80 mA; pulse duration, 350 microseconds) is the one proposed by the manufacturer for atrophy prevention. The intensity of the electrical current will be gradually increased, without exceeding 80mA or the pain threshold of the patient.
2549734|NCT02566941|No Intervention|Control|
2549785|NCT02566551|Experimental|Prostate artery embolization|Prostatic artery embolization (PAE) To perform embolization, gelatin microspheres (300-500 microns) will be used in this arm
2549787|NCT02566551|Active Comparator|Transurethral resection of the prostate|Transurethral resection of the prostate (TURP) A bipolar electrosurgery generator will be used to perform TURP
2549820|NCT02565979|Active Comparator|Resveratrol|resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
2549821|NCT02565979|Placebo Comparator|Placebo|placebo will be given for 6 months, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
2549867|NCT02565875|Experimental|SLL Presentation|"Intervention: Standardized Language of Laparoscopy (SLL) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation on the use of a SLL for communication between the primary and assistant surgeons during laparoscopy as previously determined by a national survey of Canadian experts and a modified delphi technique."
2549870|NCT02565875|Placebo Comparator|Control Presentation|"Intervention: Surgical Anatomy (SA) Presentation and simulated laparoscopic task performed on a low-fidelity pelvis simulator~Will witness a presentation of similar duration as the intervention group on laparoscopy but not related to communication (laparoscopic anatomy). The simulated laparoscopic task will be identical to the SLL group."
3204272|NCT00932412|Active Comparator|HDAC|High-Dose Cytarabine (HDAC) with G-CSF given during each sequence of chemotherapy in order to increase the blast priming.
2550124|NCT02564172|Experimental|CMS group|Conus medullaris stimulation with pentapolar surgical lead plus optimal medical management.
2550127|NCT02564172|Active Comparator|OMM group|Optimal medical management alone.
2550187|NCT02563717|Active Comparator|Reference Device: T-piece System|
2550189|NCT02563717|Active Comparator|Investigational Device: The New System|
2550236|NCT02563444|Experimental|Ultrasound fusion guiding system|
2550295|NCT02563262|Other|body angles measurements during weightlessness|body angles : ankle, knee, hip, shoulder, elbow, wrist, and neck.
2550339|NCT02562885|Experimental|Acoustic pulses|"During NREM sleep:~15 minutes without acoustic pulses~15 minutes with acoustic pulses~15 minutes without acoustic pulses~Two different protocols are applied:~(A) tone application at the Down-phase of sleep slow wave (SSW) (B) tone application at the Up-phase of SSW.~Participants with Rolandic epilepsy/BECTS or generalized spike waves: Protocol A and B alternatingly.~Participants with ESES/CSWS: only Protocol A."
2550381|NCT02562586|Active Comparator|Closed Suction Drainage System|Group 1: patients undergoing total hip replacement received a Closed Suction Drainage System for 24 hours after the surgical procedure
2550388|NCT02562586|No Intervention|No Closed Suction Drainage System|Group 2: patients undergoing total hip replacement have not received a Closed Suction Drainage System after the surgical procedure
2550417|NCT02562222|Experimental|anodal tDCS on M1|anodal tDCS on left primary motor cortex
2550418|NCT02562222|Experimental|cathodal tDCS on M1|cathodal tDCS on left primary motor cortex
2550419|NCT02562222|Experimental|anodal tDCS on V1|anodal tDCS on visual cortex
2550420|NCT02562222|Experimental|cathodal tDCS on V1|cathodal tDCS on visual cortex
2550421|NCT02562222|Experimental|anodal tDCS on M1 and cathodal on V1|dual tDCS - anodal tDCS on left primary motor cortex and cathodal on visual cortex
2550422|NCT02562222|Experimental|cathodal tDCS on M1 and anodal on V1|dual tDCS - cathodal tDCS on left primary motor cortex and anodal on visual cortex
2550423|NCT02562222|Sham Comparator|sham tDCS|sham tDCS
2550467|NCT02562001|Experimental|Outpatient active group|This group will receive active tDCS, combined with Lokomat gait training
2550470|NCT02562001|Experimental|Inpatient active group|This group will receive active tDCS, combined with Lokomat gait training
2550472|NCT02562001|Experimental|Outpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
2550473|NCT02562001|Experimental|Inpatient placebo group|This group will receive placebo tDCS, combined with Lokomat gait training
2550549|NCT02561611|No Intervention|Control Group|"Usual Working Condition Group (UWC)~The no-intervention control condition will be asked to maintain their usual work and lifestyle throughout the study. Participants may be contacted by Pennington Biomedical staff during the intervention."
2550652|NCT02560818|Experimental|Patients|blood samples of 50 patients will be used (use of blood collection in study EXSAL N°ID-RCB 2009-A00833-54)
3204273|NCT00932464|Experimental|1|Neratinib Fasted
3204274|NCT00932464|Experimental|2|Neratinib Fed
2549580|NCT02568033|Experimental|A|"Chemotherapy:~for Non-Squamous Cell: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of 21 day cycle or Carboplatin AUC6 and Paclitaxel 75 mg/m2 on day 1 of 21 day cycle~for Squamous Cell: Cisplatin 75 mg/m2 and docetaxel 75mg m2 day 1 of 21 day cycle or Carboplatin AUC6 and paclitaxel 200 mg/m2 day 1 of 21 day cycle~Radiation- Stereotactic radiosurgery Peripheral Lung lesion: 60 Gy over 3 fractions Central Lung lesion: 50 Gy over 5 fractions Hilar and Mediastinal LNs 40-50Gy over 5 fractions~Schedule is:~2 cycles of chemotherapy, followed by SRS, followed by 2 additional cycles of chemotherapy."
2549627|NCT02567539|Experimental|Recurrent high grade glioma|IMRT with or without radiosensitive therapy
3204275|NCT00932490|Experimental|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and an advanced practice nurse will suggest individualized strategies to overcome barriers to adherence
3204276|NCT00932490|No Intervention|Control|
2549799|NCT02566252|Experimental|PUL-042|PUL-042 Inhalation Solution
2549800|NCT02566252|Experimental|Cromolyn sodium|Pre-Treatment with cromolyn sodium followed by PUL-042 Inhalation Solution Administration
2549802|NCT02566252|Experimental|Albuterol sulfate|Pre-Treatment with albuterol sulfate followed by PUL-042 Inhalation Solution Administration
2549824|NCT02565953|Experimental|Paclitaxel-releasing PTA balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with paclitaxel-releasing percutaneous transluminal angioplastic (PTA) balloon catheter.
2549825|NCT02565953|Active Comparator|PTA Balloon catheter|Treatment of renal dialysis arteriovenous fistula stenosis with percutaneous transluminal angioplastic (PTA) balloon catheter.
3204277|NCT00932503|No Intervention|PDS II|PDS II® loop suture was used for abdominal wall closure
3204278|NCT00932503|Active Comparator|Vicryl plus|"antiseptic coated Vicryl plus was used for abdominal wall closure"
3204279|NCT00932516|Active Comparator|South Beach Diet™ with SBD™ Products|
3204280|NCT00932516|Active Comparator|South Beach Diet™ alone|
2550067|NCT02564393||T|Control
2550071|NCT02564393||A|Adult with cystic fibrosis
2550116|NCT02564289||Healthy Chronic snus users|Healthy subjects that used snus for more than 15 years.
2550119|NCT02564289||Healthy Controls|Healthy subjects that are never-users of snus.
2550148|NCT02563925|Experimental|Radiation and Tremelimumab|Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab & durvalumab (75 mg & 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior & 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number & size of their brain metastases. Following the 1st dose, tremelimumab & duvralumab will be administered q28 days from the date of 1st tremelimumab & durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
2550209|NCT02563678|Active Comparator|Diabetics with active, chronic infection|Adult patients with diabetes mellitus and current antibiotic use for active infection will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2550210|NCT02563678|Active Comparator|No diabetes or infection|Adult patients without diabetes and not using antibiotics will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2550211|NCT02563678|Active Comparator|Critically ill patients with infection|Adult patients with acute, life-threatening infection for which hyperbaric oxygen is clinically indicated will have blood drawn before and after their first and fourth clinical hyperbaric oxygen treatments.
2550212|NCT02563678|Active Comparator|Carbon monoxide patients|Adult patients with acute carbon monoxide poisoning will have blood drawn before and after their first clinical hyperbaric oxygen treatment.
2550213|NCT02563678|Active Comparator|Glucose tolerance test|Diabetic patients co-enrolled in a hyperbaric oxygen and glucose control study will have blood drawn before and after their glucose tolerance test and their first clinical hyperbaric oxygen treatment.
2550215|NCT02563678|Experimental|Brain injury research subjects|Research subjects co-enrolled in a study examining hyperbaric oxygen for post-concussive symptoms will have blood drawn before and after their first and fourth hyperbaric chamber sessions.
2550217|NCT02563678|Experimental|Hyperbaric chamber inside attendants|Hyperbaric chamber inside attendants will have their blood drawn before, mid-session, and after their chamber exposure during their regular duty day. The hyperbaric chamber exposure will include hyperbaric air and hyperbaric oxygen components (hyperbaric air/oxygen).
2550218|NCT02563678|Active Comparator|Volunteers, hyperbaric oxygen|Healthy adult volunteers will have blood drawn before and after a single hyperbaric chamber session.
2550221|NCT02563678|Experimental|Volunteers, normobaric pressure|Healthy volunteers will have their blood drawn before and after breathing 100% oxygen at atmospheric pressure (normobaric oxygen) for 120 minutes.
2550276|NCT02563171|Placebo Comparator|Healthy periodontium without obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
2550285|NCT02563171|Active Comparator|Chronic periodontitis without obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
2550288|NCT02563171|Placebo Comparator|Healthy periodontium with obesity|GCF samples were taken at baseline Intervention: Gingival crevicular fluid collection
2550290|NCT02563171|Active Comparator|Chronic periodontitis with obesity|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
2550338|NCT02562872|Experimental|Cohort 1 Active DSM265|
2550346|NCT02562872|Placebo Comparator|Cohort 1 Placebo|
2550352|NCT02562872|Experimental|Cohort 2a Active DSM265|
2550355|NCT02562872|Placebo Comparator|Cohort 2a Placebo|
2550356|NCT02562872|Experimental|Cohort 2b Active DSM265|
2550357|NCT02562872|Placebo Comparator|Cohort 2b Placebo|
2550711|NCT02560571|Experimental|all patients|all study patients will undergo ultrasound and blood test
3204281|NCT00932516|Active Comparator|Calorie restricted diet w/ SBD™ Products|
2549582|NCT02567916|Experimental|FRESOFOL MCT|To compare the incidence and intensity of pain on injection that is caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol) .
2549584|NCT02567916|Active Comparator|Propofol|The purpose of this study is to compare the incidence and intensity of possible pain on injection as well as patient satisfaction caused by propofol (LCT propofol) versus fresofol (MCT/LCT propofol).
3204282|NCT00932516|Active Comparator|Calorie Restricted Diet alone|
2549717|NCT02566954|Experimental|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
2549739|NCT02566655|Experimental|Fucosylated MSC for Osteoporosis|Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.
3204283|NCT00932529|Active Comparator|Olanzapine|
3204284|NCT00932529|Active Comparator|Quetiapine|
2549842|NCT02565966|Experimental|Modified Atkins Diet (MAD)|
2549847|NCT02565966|No Intervention|Normal Diet|Those patients in the normal diet (no intervention) group will also meet with the epilepsy center nutritionist to review the food diary and completion of this document, similar to those in the intervention (MAD) group. No dietary restrictions will be made in this group.
2549898|NCT02565732|Experimental|Dose A|Botulinum toxin type A
2549900|NCT02565732|Experimental|Dose B|Botulinum toxin type A
2549901|NCT02565732|Placebo Comparator|Dose C|Placebo comparator
2549931|NCT02565420|Active Comparator|Lactated Ringer's solution|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of Lactated Ringer's solution fluids.
2549933|NCT02565420|Placebo Comparator|normal saline|During the perioperative period of the colorectal, orthopedic or similar surgery the patient will receive an intervention of normal saline solution.
3204285|NCT00932529|Active Comparator|Risperidone|
3204286|NCT00932529|Active Comparator|Ziprasidone|
2550072|NCT02564562|Experimental|Treatment|Radiolabeled PF-06463922 in healthy volunteers
2550137|NCT02564003||Oxycodone|Oxycodone 0,1 mg/kg iv
2550166|NCT02563769|Experimental|Treatment Arm 1|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Clavulanic Acid 500 mg; Day #4: Placebo
2550171|NCT02563769|Experimental|Treatment Arm 2|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Clavulanic Acid 250 mg (low dose); Day #3: Placebo; Day #4: Clavulanic Acid 500 mg
2550176|NCT02563769|Experimental|Treatment Arm 3|Clavulanic acid OR Placebo to be given in combination with intravenous cocaine; Day #2: Placebo; Day #3: Clavulanic Acid 250 mg (low dose); Day #4: Clavulanic Acid 500 mg
2550237|NCT02563483|Experimental|Yoga and compassion meditation program|"The duration of this group was 8 weeks. The program included sessions 3 times per week, with each session lasting 1 hour and 15 minutes. The volunteers performed yoga classes composed of asana (poses), pranayama (breathing exercise) and meditation."
2550244|NCT02563483|No Intervention|control|this group was a non treatment group.
2550277|NCT02563197|Experimental|T-326|Non Cystic fibrosis bronchiectasis patients will be enrolled for determination of peak inspiratory flow.
2550332|NCT02562781|Active Comparator|Supplemental Oxygen|Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
2550343|NCT02562781|Experimental|Air or supplemental oxygen|Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
2550400|NCT02562443|Experimental|rigosertib + best supportive care (BSC)|
2550407|NCT02562443|Active Comparator|Physician's Choice (PC) + best supportive care (BSC)|
2550605|NCT02561065|Experimental|Lifestyle intervention high risk group.|Participants in the intervention group will receive the intervention on top of standard care.
2550608|NCT02561065|No Intervention|Standard care high risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
2550610|NCT02561065|Experimental|Lifestyle intervention low risk group.|Participants in the intervention group will receive the intervention on top of standard care.
2550613|NCT02561065|No Intervention|Standard care low risk group.|Each participant in the standard care group will receive care as usual, provided by his own occupational physician (OP) and other possible care providers.
2550653|NCT02560831|Experimental|Therapeutic exercise and Pompage|strengthening exercises, balance training and knee's pompage
2550655|NCT02560831|Active Comparator|Control|Educational lectures.
3204287|NCT00932542|Experimental|Eutectic mixture|
2550777|NCT02559921|Experimental|rhRIG（20 IU/kg）only|Subjects received rhRIG（20 IU/kg） on day 0
2550780|NCT02559921|Experimental|rhRIG（40 IU/kg）only|Subjects received rhRIG（40 IU/kg） on day 0
2550783|NCT02559921|Active Comparator|HRIG（20 IU/kg）only|Subjects received HRIG（20 IU/kg）on day 0
2550786|NCT02559921|Experimental|rhRIG（20 IU/kg）+ vaccine|Subjects received rhRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
2550789|NCT02559921|Experimental|rhRIG（40 IU/kg）+ vaccine|Subjects received rhRIG（40 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3204288|NCT00932542|Placebo Comparator|placebo|
3204289|NCT00932542|Active Comparator|Medicaina|
3204290|NCT00932555||Group 1|
3204291|NCT00932581||Full Exam|The first group will receive the full motor examination section in its original order.
3204292|NCT00932581||Subscale|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
3204293|NCT00932594|Active Comparator|1.Arthrocentesis only|Patients only have Arthrocentesis, but without adjusting the pressure of the TMJ
3204294|NCT00932594|Active Comparator|3.Arthroscopic Treatment|Patient receives Arthroscopic treatments without adjusting the TMJ pressure
3204295|NCT00932594|Active Comparator|4.Arthroscopic with Adjust Pressure|Arthroscopic Treatment with Adjust TMJ Pressure Treatment, during the Arthroscopic treatment adjust the pressure of TMJ to normal value
2549585|NCT02568098|Experimental|TMEC 12-004 (OxTREC 58-11)|Subjects had previously taken drug PQ and DHA-PQP
2549586|NCT02568098|Experimental|New subject|"Subjects who not previously participated in study TMEC 12-004 (OxTREC ref. 58-11) and study TMEC 14-022 (OxTREC ref. 39-14)."
3204296|NCT00932594|Active Comparator|5.The TMJ Orperation Treatment|The TMJ Operation Treatment without adjusting the pressure of TMJ
3204297|NCT00932594|Active Comparator|6.The TMJ Operation with Adjust Pressure|The TMJ Operation with Adjust TMJ Pressure Treatment, during the treatments to adjust the TMJ pressure to normal value
2549746|NCT02566876|Active Comparator|Mixture of three Bifidobacteria|Patients were administered 1 sachet per day of a mixture of three Bifidobacteria (namely, 3 billions of Bifidobacterium longum BB536®, 1 billion of Bifidobacterium infantis M-63®, and 1 billion of Bifidobacterium breve M-16V®) for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
2549752|NCT02566876|Placebo Comparator|Placebo|Patients were administered 1 sachet per day of placebo for six weeks. Subsequently, no preparation was administered for a 2-week-''washout'' period. At each follow-up visit subjects underwent a complete physical examination, data recorded on the daily diaries were collected and compliance to treatment was verified.
3204298|NCT00932594|Active Comparator|7.Bite Plate Treatment|Bite Plate Treatment for Temporomandibular Disorders without adjusting the pressure of TMJ
3204299|NCT00932594|Active Comparator|8.Bite Plate with Adjust pressure|Bite Plate and Adjust Pressure Treatment for Temporomandibular Disorders, during the treatments adjust the pressure of TMJ to normal value
3204300|NCT00932594|Active Comparator|2.Arthrocentesis with adjust pressure|Arthrocentesis with adjust pressure according to the pressure of TMJ
3204301|NCT00932607|Active Comparator|Staloral Birch|"Start with 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
2550012|NCT02564939|Active Comparator|ramelteon|receive ramelteon
2550014|NCT02564939|Placebo Comparator|placebo|receive placebo
2550045|NCT02564627|Experimental|Self-applied patch|The patients will use a self-applied patch weekly for PENS of dermatome T6. A 1200 Kcal/day diet will be also prescribed.
2550049|NCT02564627|Active Comparator|Conventional procedure|The patient will attend weekly the Outpatient Clinic for receiving the PENS of dermatome T6. The procedure will be performed by the Medicine Doctor. A 1200 Kcal/day diet will be also prescribed.
2550052|NCT02564627|Other|1200 Kcal/day diet|A 1200 Kcal/day diet will be also prescribed.
2550083|NCT02564341|Experimental|TEACH Collaborative Care Intervention|Physicians randomized to the intervention will receive: 1) collaboration with an IT enabled nurse care manager; 2) physician education and academic detailing; and 3) facilitated access to a specialist in addictions to help manage the most challenging HIV-infected patients on COT.
2550085|NCT02564341|No Intervention|Standard of Care Control|Physicians in the control group will receive information summarizing guidelines for COT but will not have access to the support of the TEACH intervention.
2550125|NCT02564068|Experimental|Oxytocin Only|Subjects will come in for one visit, and will receive only oxytocin
2550128|NCT02564068|Experimental|Oxytocin & Placebo Crossover|Subjects will come in for two visit: They will receive either placebo or oxytocin on visit 1 and the other intervention of visit 2. Subjects will be blinded as to which drug they are receiving on which visit.
2550157|NCT02563795||Group I|Pregnant with BMI<30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
2550161|NCT02563795||Group II|Pregnant with BMI<30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
2550169|NCT02563795||Group III|Pregnant with BMI>30 and having spinal anesthesia with 10 mg hyperbaric bupivacaine
2550173|NCT02563795||Group IV|Pregnant with BMI>30 and having spinal anesthesia with 7,5 mg hyperbaric bupivacaine+25 mcg fentanyl
2550246|NCT02563522|Active Comparator|Active|VM202 + standard of care
2550247|NCT02563522|Placebo Comparator|Control|Placebo (VM202 Vehicle) + standard of care
3321425|NCT02018770|Experimental|Phototherapy|Three groups will receive different fototerapia of light sources, and group 1 will not receive dose: Group A (0, 65Joules), Group B (1.30 Joules) and Group C (1.95 Joules) .
2550340|NCT02562703|Active Comparator|ACTIVE tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
2550347|NCT02562703|Sham Comparator|SHAM tVNS|tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.
2550386|NCT02562612|Experimental|SM-88|SM-88 multiple ascending doses
2550440|NCT02562274|Placebo Comparator|Placebo group|Subjects are received the placebo product which has same color and smell look like the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) treatments once daily for 8 weeks
2550446|NCT02562274|Active Comparator|MP 50 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 50 mg/day treatments once daily for 8 weeks
2550453|NCT02562274|Active Comparator|MP 1500 mg/day|Subjects are received the herbal porridge containing the combined extract of mulberry and Vietnamese coriander (MP) 1500 mg/day treatments once daily for 8 weeks
2550498|NCT02561780|Active Comparator|Curriculum|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course."
2549588|NCT02568020|No Intervention|low-protein diet(LPD)|All patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
2549590|NCT02568020|Experimental|LPD+KA|LPD+KA group will be supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
2549633|NCT02567643|Experimental|Stereotactic Radiosurgery|
2549709|NCT02567214|Experimental|Ultibro® versus sham Spiriva®|"Indacaterol 110 µg/Glycopyrronium 50 µg Inhaled~1 time per day 21 days"
2549714|NCT02567214|Experimental|Sham Ultibro® versus Spiriva®|"Tiotropium 18 µg Inhaled~1 time per day 21 days"
2549758|NCT02566681|Experimental|MSC construct for Osteonecrosis|Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).
2549768|NCT02566447||Symptomatic|Subjects will be categorized by the clinician as symptomatic for Trichomonas vaginalis infection.
2549828|NCT02566148||HIV group|group living with HIV
2549830|NCT02566148||Hepatitis B group|group living with chronic hepatitis B
2549834|NCT02566148||Reference group|group who has neither HIV nor hepatitis B
2549880|NCT02565797|Experimental|DabirAIR overlay-ORICU|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room and in the post-op ICU.
2549884|NCT02565797|Experimental|DabirAIR overlay-OR|Patients scheduled for neurosurgical procedures will be placed over DabirAIR alternating pressure overlay (placed on top of standard of care support surface) in the operating room alone and on standard of care support surface in the post-op ICU.
2549885|NCT02565797|No Intervention|Control-SOC|Patients scheduled for neurosurgical procedures will be placed on standard of care support surface in the operating room and post-op ICU. Data will be abstracted through retrospective chart review.
3204302|NCT00932607|Experimental|SUBLIVAC Birch|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
2550018|NCT02564913||control group|
2550025|NCT02564913||pre-DM group|
2550027|NCT02564913||DM group|
2550082|NCT02564601|Experimental|A1 Piano Training|16 weekly classes will be provided to the piano training group. Each piano class session will focus upon review of materials (15-20 min), and the remaining portion of the class will focus upon learning new skills and concepts. This course includes finger dexterity exercises, basic piano technique, and basic piano repertoire.
2550084|NCT02564601|Experimental|A2 Computer Cognitive Training|16 weekly classes will be provided to the computerized cognitive training group. Computerized cognitive training involves process-based computerized practice of adaptive perceptual exercises. Each computer cognitive training class session will focus upon practice of cognitive exercises that vary in difficulty ranging from basic auditory processing speed to application through memory and working memory exercises. Within each exercise, the stimuli (i.e., tones, speech sounds, words, sentences) become less discriminable and speed of presentation increases (making the exercises more difficult) as performance improves.
2550086|NCT02564601|No Intervention|A 3 No Treatment Controls|No classes will be provided to our control group. This is a no-treatment control group.
2550115|NCT02564094|Experimental|Epoetin beta|Participants with hematologic or solid malignancies will receive epoetin beta for a treatment period of approximately 20 weeks.
2550349|NCT02562963|Experimental|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment. Intervention: Biological: NKT cell
2550379|NCT02562469|Experimental|ACTIVATE|ACTIVATE is a computerized neurocognitive training program (ACTIVATE; see: www.c8sciences.com) that simultaneously targets eight core neurocognitive factors (i.e., sustained attention, working memory (WM), response inhibition, speed of information processing, cognitive flexibility and control, multiple simultaneous attention, category formation, and pattern recognition and inductive thinking). ACTIVATE Is completed at home via computer with parent support. ACTIVATE intervention is conducted 3-5 times per week for between 20-30 minutes over the course or 3-4 months.
2550445|NCT02562287|Experimental|Clozapine|Clozapine, P.O., flexible dose, for up to 6 months
2550455|NCT02562287|Active Comparator|Risperidone, olanzapine or quetiapine|Risperidone, olanzapine or quetiapine, according to clinical indication, flexible dose, for up to 6 months
2550506|NCT02561741|Experimental|COV155|
2550531|NCT02561533|Experimental|BRAF immunohistochemistry (IHC)|
2550578|NCT02561286|Experimental|HIV risk reduction|BRO HIV Risk Reduction Intervention
2550581|NCT02561286|Active Comparator|Health promotion control|Health Promotion Intervention
2550712|NCT02560597|Experimental|repetitive transcranial magnetic stimulation|rTMS delivered over the epileptogenic focus
2550749|NCT02560220|Experimental|Intervention arm|Patients receive MIC cell therapy together with standard immunosuppressive therapy
2550770|NCT02559934|Experimental|SR-T100 gel|A single dose of 0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract) in 25 cm2 skin area covered by an occlusive dressing at least 20 hours a day and will be given once daily for sixteen consecutive weeks.
2550826|NCT02559531|Experimental|Intervention group|EMS providers will evaluate computerized clinical scenarios using a mobile triage device
2550916|NCT02559141|Other|Study group (SG)|"Before induction of anaesthesia:~Arterial line~Nexfin Monitoring System~Measurement of cardiac index (CI), pulse pressure variation (PPV) and mean arterial pressure (MAP)~Baseline blood samples. Induction of anaesthesia~Study Group:~PPV ≤10%, 500 ml of crystalloids/colloids as long as CI was ≥2.5 l/min/m²~Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min)."
2550918|NCT02559141|No Intervention|Control group (CG)|"MAP ≥65 mmHg~CVP ≤12 mmHg~Haemoglobin level ≥8 g/dl.~Maintenance of MAP ≥65 mmHg by using crystalloids/colloids, bolus injection of theodrenaline/cafedrine or continuous infusion of norepinephrine (0.03 µg/kg/min) according to clinical evaluation."
3204303|NCT00932672|Experimental|Atkins group|Men assigned to the Atkins diet will be asked to restrict carbohydrate intake to <20 grams/day. We will use an established clinical program directed by Dr. Eric Westman which implements this diet using a trained clinical nutritionist. No other dietary restrictions will be placed on the subjects. They will measure their urinary ketones at home weekly using urinary ketone strips. Subjects will meet with the nutritionist monthly during the 6 months of the study. Subjects in the Atkins arm will also be asked to walk at a brisk pace for 30 minutes a day, 5 days a week and will be provided a pedometer to measure the number of steps taken per day.
3204304|NCT00932672|No Intervention|Control group|Subjects assigned to the control group will be asked to make no changes in their dietary habits. At the completion of the study subjects will meet with the nutritionist and receive standard nutrition AHA recommendations.
3204305|NCT00932685|Active Comparator|2. Video Game|
3204306|NCT00932685|Active Comparator|1. Midazolam 0.5mg/kg|
3204307|NCT00932711|Experimental|Educational intervention|Subjects in this group will receive educational brochures about management of COPD
3204308|NCT00932724|Experimental|CY-503|
2549602|NCT02567838|Experimental|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
2549605|NCT02567838|Placebo Comparator|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
2549622|NCT02567474|No Intervention|control|no intervention
2549624|NCT02567474|Experimental|intervention|self management intervention based on 5A model
2549650|NCT02567448|Active Comparator|COPD Group|Patients who were previously diagnosed of moderate to severe COPD as determined by spirometry. All patients will have sleep and pulmonary physiologic measurements.
2549654|NCT02567448|Active Comparator|Normal Control Group|Patients who are healthy, without major medical or sleep problems, and have normal spirometry. All patients will have sleep and pulmonary physiologic measurements.
2549656|NCT02567500|Experimental|Patients with auditory hallucination|"Patients with auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NeuroPsychologic assessment (NEPSY) II) : theory of mind and affect recognition~The emotional marker:~Differential Emotion Scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS"
2549660|NCT02567500|Placebo Comparator|Patients without auditory hallucination|"Patients without auditory hallucination:~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with Diagnostic and Statistical Manual of Mental Disorders (DSM) -IV criteria:~Mini International Neuropsychiatric Interview (MINI) -Kids~Psychosis section of Kiddie-SADS (Schedule for Affective Disorders and Schizophrenia )"
2549662|NCT02567344|Experimental|Active rTMS|Active rTMS will be delivered to the Left DLPFC at 10Hz. A total of 4000 pulses will be delivered.
2549663|NCT02567344|Sham Comparator|Sham rTMS|Sham rTMS will be delivered to the Left DLPFC at 10 Hz using an electronic sham system used in multiple other investigations. A total of 4000 pulses of sham rTMS will be delivered.
2549692|NCT02567123|Experimental|Experimental|Runners are switched from a rearfoot strike running pattern to a forefoot strike running pattern.
2549694|NCT02567058|Experimental|3 groups of subjects|"3 groups:~group I : healthy volunters~group II : patient with an immobilisation (between 1 and 2 months)~group III : patient with an antecedent of Achilles tendon breakage during the 10 past years~Each group have the same interventions : ultrasound exam, IPAQ questionnaire"
2549697|NCT02567097|Active Comparator|Control|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form their plan to quit smoking.
2549701|NCT02567123|No Intervention|Control|Runners continue to use their normal rearfoot strike running pattern with no intervention in place.
2549703|NCT02567097|Active Comparator|Implementation Intention|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to form a specific 'if-then' plan using an implementation intention basis.
2549710|NCT02567097|Experimental|Weekly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each week which they have been successful in not smoking.
2549715|NCT02567097|Experimental|Monthly Self-Incentivising|Participants read a brief statement designed to encourage them to quit smoking (we would like you to plan to quit smoking). Participants are then asked to specify a self-incentive on which they could implement at the end of each month which they have been successful in not smoking.
2549724|NCT02566824|Experimental|Cognitive Behavioural & Skills Training|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of group cognitive behavioral and skills training therapy.
2549725|NCT02566824|Active Comparator|Supportive Group Therapy|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they undergo the 12 weeks of supportive group therapy.
2549726|NCT02566824|Active Comparator|Treatment as Usual - community resources|Participants can choose to be on medication or not. If they decide to take medication, they will be titrated to an optimal dose of stimulant medication. Then they are referred to their treating physicians and are free to use any resources that are available to them in their communities.
2549759|NCT02566733|Experimental|Remiva|This experimental group will use a generic drug of remifentanil, Remiva™ from Hana Pharmaceutical company.
2549760|NCT02566733|Active Comparator|Ultiva|This arm group will use a brand-named drug of remifentanil, Ultiva™ from GlaxoSmithKline company.
3204309|NCT00932724|Placebo Comparator|Placebo|
2549610|NCT02567760|Active Comparator|MP1 group|Subjects receive the MP1 product at the dose of 400 mg/day for 8 weeks.
2549611|NCT02567760|Placebo Comparator|Placebo group|Subject receive the Placebo product for 8 weeks.
2549635|NCT02567383|Experimental|Hyperthermia|Hyperthermia; Thermotron RF-8, radiation, Cisplatin and Taxotere
2549684|NCT02567149|Experimental|Cidofovir|Cidofovir clinical resolution of treated warts as evaluated by the investigators
2549742|NCT02566850|Experimental|Ekso Users|SCI subjects using Ekso
2549875|NCT02565862|Active Comparator|Treatment A|"Day 1-2: 500mg twice daily (BID) metformin film-coated tablets~Day 3-8: 1000mg BID metformin film-coated tablets"
2549881|NCT02565862|Experimental|Treatment B|"Day 15-16: 500mg BID metformin film-coated tablets + 60mg once daily (QD) daclatasvir film-coated tablets~Day 17-22: 1000mg BID metformin film-coated tablets~+ 60mg QD daclatasvir film-coated tablets"
2549913|NCT02565524|Experimental|genetic and phenotypic profile|blood sample, clinical and neurocognitive assessment
2549958|NCT02565290|Active Comparator|Omega-3|2 capsules of omega 3 - 2 times a day
2549960|NCT02565290|Placebo Comparator|Soy oil|2 capsules of soy oil - 2 times a day
3170575|NCT00576043|Active Comparator|1: Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator
2550107|NCT02564237|Experimental|Group 1: StreptAnova™|Three (3) 0.6 mL doses (600 µg protein) of StreptAnova™ (Group A streptococcal (GAS) vaccine) will be will be administered on days 0, 30 and 180.
2550109|NCT02564237|Active Comparator|Group 2: Comparator|Three (3) 0.5 mL doses of comparator (Hepatitis B vaccine, Hepatitis A vaccine, OR Human Papillomavirus vaccine) will be administered on days 0, 30 and 180.
2550138|NCT02563951|Experimental|GNS Spray 0.5mg|One spray of GNS 0.5mg/spray into right nostril.
2550139|NCT02563951|Experimental|GNS Spray 1.0mg|One spray of GNS 0.5mg/spray into both left and right nostril.
2550140|NCT02563951|Experimental|GNS Spray 2.0mg|One spray of GNS 1.0mg/spray into both left and right nostril.
2550141|NCT02563951|Active Comparator|Kytril 1mg (IV injection)|A dose of 1mg of Granisetron IV injection (kytril 1mL, 3mg/mL/vial) will be administered as a slow IV injection (over 30 seconds)
2550142|NCT02563951|Active Comparator|Kytril 1mg (Tablet)|a single dose (kytril 1mg, one tablet) orally administered with 240mL of water
2550240|NCT02563665||advanced chronic kidney disease|Subjects on dialysis with GFR (Glomerular Filtration Rate) > 30
2550243|NCT02563665||Renal replacement therapy.|Subjects who are not on dialysis with GFR (Glomerular Filtration Rate) < 15
2550299|NCT02563223|Other|electromyographic (EMG) measurements|Interaction between gravity (weightlessness, hypergravity, and normal gravity) and pull-down force ont EMG amplitude and EMG timing.
2550325|NCT02562820|Experimental|Ketamine|Subjects will receive intravenous infusion of a 0.1, 0.5, 1.0, 2.0 or 4.5 mg/kg dose over the course of 40 minutes
2550327|NCT02562820|Placebo Comparator|Placebo|Subjects will receive an intravenous infusion of normal saline over the course of 40 minutes
2550396|NCT02562547||All Vaginal Births|The application of the Hem-Avert Perianal Stabilizer
2550448|NCT02562196|Experimental|optimized protocol chosen|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
2550456|NCT02562196|Sham Comparator|sham tDCS|a randomized, sham-controlled, double-blinded and parallel group trial (12 therapeutic sessions) with optimal protocol (defined in phase 1) and sham tDCS will be conducted to evaluated electrical cortical activity and pain control, number of migraine attacks and quality of life of migraine patients. An interval of 48hs between sessions will be taken.
2550526|NCT02561637|Experimental|Case management|Before admission the spouse-patient dyads will take part in an interview with the case manager assessing the spouses' needs during admission through an individual care plan. During admission the case manager will follow-up and assess the goals and actions of the individual care plan and coordinate with other health professionals. During the discharge meeting the case manager will provide additional information to the spouse according to needs assessed in the care plan. After discharge the case manager will conduct a follow-up telephone call for the spouse 3-4 days and 10 days after the patient's discharge consisting of information similar to that provided at the discharge meeting.
2550527|NCT02561637|Other|Control group|Spouses and patients in the control group will receive usual care and written and oral information about the fast-track program and principles in general from the nursing staff. The usual care and information is provided before admission in the out-patient facilities and during admission
2550567|NCT02561325|Experimental|NaCI group|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
2550568|NCT02561325|Placebo Comparator|placebo NaCI|a clinical trial protocol intended to highlight a possible differential effect in the biological effects of the same sodium intake (2.56 g / day) orally, depending on the nature salt.
2550598|NCT02561091|Placebo Comparator|Placebo|Placebo gel for intratympanic use
2550601|NCT02561091|Experimental|AM-111 0.4 mg/ml|AM-111 gel for intratympanic use (0.4 mg/ml AM-111)
2550602|NCT02561091|Experimental|AM-111 0.8 mg/ml|AM-111 gel for intratympanic use (0.8 mg/ml AM-111)
2550844|NCT02559648|Placebo Comparator|Placebo|In Group B placebo will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
3170576|NCT00576043|No Intervention|2: No Training|No simulator training before starting endoscopy training on real patients
3170577|NCT00576069||asthma, quality of life, lung function|All Asthmatics will be treated with 1 of 3 long acting beta 2 agonist + corticosteroid using low or medium dose of inhaled (Advair) fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or (Symbicort) budesonide 320-640 mcg +formoterol 18 mcg/day or (Dulera) mometasone 400-800mcg + formoterol 20 mcg/day. In addition tiotropium 18ucg/day will be used. Additionally, albuterol 0.083%/ipratropium 0.02% solution or MDI HFA for acute exacerbation.Will measure lung function and asthma quality of life questionaire
3170578|NCT00576095||PMD|Patients diagnosed with major depression with psychotic features
2549612|NCT02567773|Experimental|Part A: GSK2881078|The first cohort subjects will receive GSK2881078 1.5 mg (for males) or 0.75 mg (for females) twice daily for 3 days followed by once daily for 25 days. The subsequent cohort subjects will receive GSK2881078 doses selected after reviewing the unblinded data from at least 2 weeks of dosing of at least 6 subjects in the first cohort. Each cohort subjects will receive GSK2881078 dose twice daily for the first 3 days followed by 25 days of once daily.
2549613|NCT02567773|Placebo Comparator|Part A: Placebo|Subjects will receive placebo twice daily for 3 days followed by once daily for 25 days.
2549614|NCT02567773|Experimental|Part B: GSK2881078-Itraconazole|Subjects will receive GSK2881078 (dose level will be determined based on the results from Part A) on Day 1 of Period-1 and Day 6 of Period-2. Subjects will also receive itraconazole 200 mg twice daily on Day1 of Period-2 and 200 mg once daily on Days 2-34 of Period-2.
2549649|NCT02567357|Active Comparator|Visual Scheduling|A caregiver training package on the use of a pictorial (visual) schedule to illustrate each day's expected activities to a child. Caregivers will be trained to ensure that activities occur as described in the schedule as far as possible, thus the expected mechanism of action is the reduction of (unexpected change) antecedents of children's temper outbursts.
2549653|NCT02567357|Experimental|Signalling change|A caregiver training package where parents are taught to present a distinctive visual-verbal cue to a child whenever they become aware that a change will take place in the child's usual/expected activities. Caregivers will be trained to only ever present to cue if they can be sure that a change to the child's routine or plan will occur, thus the expected mechanism of action is the child's learned association between the presentation of the cue and the subsequent occurrence of a change to their expectations. Signalled changes will therefore be more predictable for the child, and should therefore be easier for them to deal with.
2549696|NCT02567071|Experimental|Intervention Group|75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
2549702|NCT02567071|Placebo Comparator|Placebo Group|75 children born by planned C-section will be exposed to clean swab.
2549711|NCT02567071|No Intervention|Control Group|75 children born vaginally.
2549753|NCT02566798|Experimental|Oleogrape|Patients are taking capsules of OleograpeSEED (Extract of grape and olive) 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days
2549756|NCT02566798|Placebo Comparator|Placebo|Patients are taking capsules of placebo (lactose) 3 times a day in the morning, at noon and in the evening during 7 days
2549773|NCT02566499|Experimental|Abnormal x-ray Mammography group|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
2549833|NCT02566187|Other|Group 1|Subjects of Group 1 take Fimasartan and Atorvastatin Individual Tablets at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 1 take a Fimasartan/Atorvastatin Combination Tablet at 8th day.
2549835|NCT02566187|Other|Group 2|Subjects of Group 2 take a Fimasartan/Atorvastatin Combination Tablet at 1st day as period I. And then, after wash out for 7 days, as period II, subjects of Group 2 take Fimasartan and Atorvastatin Individual Tablets at 8th day.
2549872|NCT02565680|Placebo Comparator|placebo|tablets of Xyzall 5mg/ day during 5 days + placebo 40mg/ day during 4 days
2549877|NCT02565680|Experimental|prednisone|tablets of Xyzall 5 mg/j during 5 days + prednisone 40 mg/ day during 4 days
2549916|NCT02565563|Active Comparator|Eye Movements|Eye Movement Desensitisation Reprocessing with eye movements (measuring Heart Rate Variability using HeartMath)
2549917|NCT02565563|Active Comparator|No Eye Movements|Eye Movement Desensitisation Reprocessing without eye movements (measuring Heart Rate Variability using HeartMath)
2549977|NCT02565251|Experimental|Sepsis grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2549982|NCT02565251|Experimental|Sepsis grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2549989|NCT02565251|Experimental|Soc septic grup 1|Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours
2549992|NCT02565251|Experimental|Soc septic grup 2|Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours
2550050|NCT02564666|Active Comparator|Telephone counseling|regular telephone counseling per week
2550053|NCT02564666|No Intervention|No telephone counseling|no regular telephone counseling
3204310|NCT00932737|Active Comparator|HBB 20mg 1-5 tablets per episode|patient to receive 1-5 tablets containing 20mg HBB per APC episode
3204311|NCT00932737|Placebo Comparator|Placebo|patient to receive a tablet identical to those containing HBB and take 1-5 tablets per episode
2550175|NCT02563743|Experimental|Problem-solving based intervention|Problem-solving based intervention with a participative approach. During the intervention a systematic assessment of the match between the employee and the work environment is considered. The intervention applies a participatory approach where the supervisor and the employee are guided by the OHS consultant and encouraged to actively take part in problem solving concerning the work situation. The intervention consists of three meetings, one between the OHS consultant and a representative for the employer (usually the nearest supervisor), one between the consultant and the employee and then a third meeting where all three parties participate.
2550180|NCT02563743|Active Comparator|Treatment as usual|The control intervention consists of the usual interventions given at the participating OHS. These interventions are also work-directed and usually also include participation of both the employee and the supervisor. However, structured problem solving methods and the systematic consideration of the match between the employee and the job situation are not applied. The content of the control condition will vary between different occupational health service units.
2550274|NCT02563132|Experimental|Carbon dioxide insufflation colonoscopy (CO2)|Carbon dioxide during both insertion and withdrawal phase of the colonoscopy.
2550282|NCT02563132|No Intervention|Air insufflation colonoscopy (AI)|Air insufflation during both insertion and withdrawal phase of the colonoscopy.
2550328|NCT02562807|Placebo Comparator|Treatment B|Placebo single-dose and then TAS-303 18mg single-dose.
2550330|NCT02562937|Experimental|Intervention|text messages related to sedentary behaviour
2550331|NCT02562807|Active Comparator|Treatment C|TAS-303 9mg single-dose and then Placebo single-dose.
2549615|NCT02567513|No Intervention|Usual Care control group|Eligible, consented residents continue to receive usual care from nursing home staff and are independently monitored by trained research staff.
2549619|NCT02567513|Experimental|Supplement Intervention|Residents are offered a variety of supplement types and flavors consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
2549621|NCT02567513|Experimental|Snack Intervention|Residents are offered a variety of snack options (foods and fluids, including supplement) consistent with prescribed orders twice per day (morning and afternoon), five days per week, for 24 consecutive weeks by trained research personnel. Research staff also provide the appropriate level and amount of assistance to encourage consumption.
2549634|NCT02567786|Active Comparator|Fresh Frozen Plasma|The priming of the CPB oxygenator will be done with 15 ml/kg of FFP in addition to packed red blood cells.
2549638|NCT02567786|Active Comparator|Plasmalyte|The priming of the CPB oxygenator will be done with 15 ml/kg of Plasmalyte in addition to packed red blood cells.
2549664|NCT02567331|Experimental|Capecitabine|Participants will receive oral capecitabine 1250 milligrams per square meter (mg/m^2) twice daily for 14 days followed by 7 day rest period for 6 cycles.
3170579|NCT00576095||NPMD|Patients diagnosed with major depression without psychotic features
3170580|NCT00576095||Controls|Participants with no psychiatric or depression history
2549677|NCT02567032|Experimental|Oxytocin|40 IU Oxytocin
2549678|NCT02567032|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
2549706|NCT02566967|Other|open label|open label use of tofacitinib at either 5 mg bid or 10 mg bid delending on treat to target goal
3204312|NCT00932750|Placebo Comparator|MOS Weight maintenance|
3204313|NCT00932750|Placebo Comparator|MOS weight loss|
2549741|NCT02566811|Experimental|Abdominal surgery with lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)* with lymph node dissection to determine whether lymph nodes are positive or negative:~Positive: patients will receive systemic adjuvant treatment to include chemotherapy Negative: patients will receive vaginal brachytherapy only~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, the lymph node dissection will be performed as a separate procedure."
2549743|NCT02566915|No Intervention|CPET submaximal without EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). During the visit without EPAP will be maintained using the facial mask applied without resistance.
2549745|NCT02566811|Active Comparator|Abdominal surgery, no lymphadenectomy|"Patients will receive a hysterectomy and bilateral salpingo-oophorectomy (BSO)*. Patients will receive systemic adjuvant treatment to include chemotherapy.~Patients will then be followed up, to include assessment of adverse events and quality of life.~*There is an option for patients to be randomised following a pre-trial hysterectomy and BSO. If randomised to this arm, no further surgery will be given and the patient will proceed to receive systemic adjuvant treatment to include chemotherapy."
2549748|NCT02566915|Experimental|CPET submaximal with EPAP|Will be collected clinical and anthropometric data of the participants and they are packaged in self-evaluation form. Evaluation of pulmonary function at rest will be rescued from patient charts. When carried out for over six months, will be repeated by the researchers. Patients will conduct incremental CPET of 5-10W/min limited by symptoms (FEV1 <1L-5W or FEV1> 1L-10W) (Visit 1). After a period of 2-7 days the CPET will be performed submaximal with 75% of the peak load reached in the incremental CPET (visits 2-3). The application of EPAP (10cmH2O) via face mask (Vital RHDSON Signs®, New Jersey, USA) will be randomized with the help of opaque envelopes to be given in one visit. IC serial measurements will be carried out before, during and immediately after the exercise.
2549767|NCT02566421|Experimental|Treatment (precision medicine)|Patients receive treatment based on the results of their genomic sequencing analyses.
2549783|NCT02566512|Other|Tracheostomy cuff inflated|The tracheostomy cuff will be inflated.
2549784|NCT02566512|Other|Tracheostomy cuff deflated|The tracheostomy cuff will be deflated.
2549789|NCT02566434|Experimental|Methionine|All participants will consume free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day for the duration of a 4-week intervention period. Participants will cease intake when signs of toxicity are measured in blood work.
2549831|NCT02566070|Active Comparator|Continuous Gastric Feeding (CGF)|CGF group will have total daily enteral nutrition requirement delivered at a constant rate via infusion over the entire 24 hour period.
2549836|NCT02566070|Experimental|Bolus Gastric Feeding (BGF)|BGF group will have total daily enteral nutrition requirement delivered in interval, finite volumes over the course of the 24 hour period.
3204314|NCT00932776|Experimental|TBA|
3170581|NCT00576108|Experimental|KD7040 topical gel|
3170582|NCT00576108|Placebo Comparator|Placebo gel|
3170583|NCT00576121||1|Left ventricular ejection fraction (LVEF) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3170584|NCT00576121||2|End-diastolic volume (LVEDV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3170585|NCT00576121||3|End-systolic volume (LVESV) patients will be compared at two time-points, 2-5 days and 4 weeks after acute MI.
3204315|NCT00932776|Active Comparator|Control|
3204316|NCT00932802||Group 1|
3204317|NCT00932841|Placebo Comparator|Placebo|
3204318|NCT00932841|Active Comparator|VSL#3 90 billion bacteria|
3204319|NCT00932841|Active Comparator|VSL#3 900 billion bacteria|
3204320|NCT00932854|Experimental|EBUS|All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
3204321|NCT00932867||Group 1|
2549757|NCT02566720|Other|Treatment and MRI scanning|After informed consent has been obtained, the subjects will be examined by a physician and assigned a Disability Ratings Scale (DRS) score. Subjects will undergo MRI tractography study, which does not require the administration of contrast. All participants will receive oral amantadine at escalating doses to ensure tolerance (50mg twice daily for 7 days, then 100mg twice daily for 1 week, then 150mg twice daily, then 200mg twice daily). The usual length of stay on the inpatient brain injury program is ninety days. The MRI tractography study and DRS score will be repeated near the time of discharge or ninety days from enrollment.
2549769|NCT02566395|Experimental|Haploidentical Stem Cell Transplantation|Subjects will receive pretransplantation conditioning of total-body irradiation (1,200 cGy delivered in 8 fractions over 4 days [Days -9 through -6] and cyclophosphamide (60 mg/kg IV daily x 2 on Days -3 and -2). Donor lymphocyte infusion will occur on day -6; donor CD34+ cells will be infused on Day 0.
2549822|NCT02566018||experimental intervention|A greater degree of initial displacement is tolerated to allow for conservative, non-operative treatment in more simple fracture patterns. Two-part fractures with marked displacement including two part patterns with a non-displaced greater or minor tuberosity fracture (formally three part fractures) are treated with a proximal humerus nail; and displaced three and four part fractures are primarily managed with a reverse total shoulder arthroplasty. Proximal Humeral Internal Locking System (PHILOS)-plates are only used exceptionally in this group of patients.
2549823|NCT02566018||control intervention|"Since May 2013 we have changed our treatment algorithm for the treatment of fractures of the humeral head in the elderly. Before this change in algorithm we used PHILOS plates extensively and rarely Inverse Shoulder prostheses.~In general all proximal humerus fractures were operated except minimally or undisplaced."
2549887|NCT02565849||Control group|Recruited volunteers aged above 18 years with no history of smoking or hospitalization in the last three months without cardiac dysfunction, orthopedic or lung.
2549888|NCT02565849||Sickle Cell Anemia normal spirometry|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with normal medical report.
2549889|NCT02565849||Sickle Cell Anemia spirometry abnormal|Recruited patients aged above 18 years with no history of smoking or hospitalization in the last three months, ability to independent ambulation and spirometry tests and plethysmography with altered medical report.
2549912|NCT02565550|Experimental|IBS patients|eat the low FODMAPs diet for one week
2549915|NCT02565550|Active Comparator|healthy controls|eat the low FODMAPs diet for one week
2549952|NCT02565277|Active Comparator|Influenza Vaccine|Fluzone injection once IM
2549954|NCT02565277|Placebo Comparator|Placebo|Saline Injection once IM
3321426|NCT02018770|Placebo Comparator|Placebo phototherapy|The volunteers will be subjected to the same Groups intervention Phototherapy . The but researcher will receive placebo pen. It is the caveat that, after completed the voluntary participation, will be held with the active pen treatment.
2550065|NCT02564614|Experimental|RO7070179|Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT.
2550117|NCT02564159|Experimental|High-risk patient for malnutrition acquired in ICU|Patients admitted in ICU and treated with mechanical ventilation with expected duration of 48 hours or more
2550118|NCT02564159|Other|Controls patients: Elective surgery|"Controls patients: Elective surgery (neurosurgery, thoracic surgery, vascular surgery)~- Patients admitted in a post-operative care unit of the university hospital of Nantes after elective surgery with expected duration ICU length of stay < 48 hours"
2550156|NCT02563912|Experimental|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
2550160|NCT02563912|Active Comparator|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
2550261|NCT02563340|Experimental|MSCs group|cAMR patients in this group receive additional intravenous allogeneic BM-MSCs (1*10^6/kg) every two weeks for four consecutive doses, besides current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
2550264|NCT02563340|Active Comparator|Control group|cAMR patients in this group receive current desensitization therapy including at least one of the following treatments: plasmapheresis (PP), intravenous immunoglobulin (IVIG), rituximab or Bortezomib.
2550312|NCT02563041|Experimental|30%TSC|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of 30%TSC solution exactly equivalent to the catheter internal lumen.
2550315|NCT02563041|Active Comparator|Heparin 5000 U/mL|After each hemodialysis (HD) session, the catheter lumens were flushed with 0.9% sodium chloride and locked with a volume of unfractionated sodium heparin 5000 U/mL solution exactly equivalent to the catheter internal lumen.
2550351|NCT02562742||SOF+REB|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+REB as part of routine clinical care at a participating clinical site.
2550412|NCT02562352|Experimental|TAPER program|"The intervention arm is comprised of:~Identification of medications that are appropriate for discontinuation/dose reduction.~Linked pharmacist/family physician consultations with patient to discuss medication discontinuation/dose reduction."
2550414|NCT02562352|No Intervention|Control|Standard of Care as wait list control
2550500|NCT02561780|Active Comparator|Curriculum +eLearning Follow-up|"The curriculum is a mental health literacy resource designed to inform high school curricula and contains six distinct modules: 1) stigma of mental illness; 2) understanding mental health and mental illness; 3) information on specific mental illnesses; 4) experiences of mental illness; 5) seeking help and finding support; and 6) the importance of positive mental health.~A research assistant trained teachers on The Curriculum Guide content in a half-day session. Teachers implemented The Curriculum Guide, which requires approximately 6 hours of classroom time, during regular instruction of the Healthy Living course. Students are asked to complete follow-up modules online. These modules are only accessible after completion of the Healthy Living course."
2549772|NCT02566408|Experimental|Supportive Care (interview about KAPs towards PA)|"Participants undergo a 2-hour one-on-one interview and answer survey questions about their beliefs, attitudes, and preferences (KAPs) towards physical activity (PA). Ten topics will be used to explore older women's attitudes toward PA. Six topics will also be used to explore ethnic-specific and culture-specific contexts that surround older women's participation in PA.~REFINEMENT OF THE PA INTERVENTION: Approximately 1-2 months after the conclusion of interviews, participants are invited to a joint session and presented with results of analyzed data. Participants are asked to review results and themes identified from interviews, and to concur whether conclusions capture their KAPs. Through this process a set of preferences that is agreed upon by all as most critical for enhancing PA participation, adherence, and retention will be identified."
2549832|NCT02565992|Experimental|CAVATAK and pembrolizumab|Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
2549843|NCT02566122||muscle strength ,muscle mass|
2549879|NCT02565758|Experimental|Arm A4 (ABBV-085)|ABBV-085 administered on at 28 day cycle and enrolling at MD Anderson
2549883|NCT02565758|Experimental|Arm A3 (ABBV-085)|ABBV-085 will be administered at every cycle (28-day cycles).
3321427|NCT02018783|Experimental|Sensodyne|Digital application for 60 seconds.
2549932|NCT02565407|Experimental|Proprioceptive training|This arm will receive specialized robot-aided proprioceptive training of the wrist next to usual care.
2549935|NCT02565407|Active Comparator|Usual care|This arm will receive what participants have been receiving from their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy at home, day rehabilitation, or outpatient visits.
2549978|NCT02565121|Experimental|Olfactory disorder after brain trauma|Recruited from 250 patients with moderate to severe traumatic brain injury in the Hodeskadeprosjektet (TBI) cohort. Treatment with (first) corticosteroids and (second) olfactory stimulation.
2549997|NCT02564965|Other|Greater than 50% Necrosis|Subjects who have greater than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
2550002|NCT02564965|Other|Less than 50% Necrosis|Subjects who have less than 50% necrosis as determined by MRI, Endoscopic Ultrasound (EUS), or direct transluminal endoscopic imaging of the collection. This stratification group will be randomized to either the double pigtail plastic stent or the AXIOS metal stent.
3170586|NCT00576160|No Intervention|A|"Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin.~Usual Care: Participants assigned to UCC will only receive the pre- and post-assessment session, and any adherence education or encouragement that is regularly provided by their treating physicians."
3170587|NCT00576160|Experimental|B|Participants will complete Baseline and 30-day assessment visit. At both visits BDI II, Self-Efficacy Questions, AEs Assessment, and Treatment Satisfaction will be assessed. A MEMS cap will be used during the 30-day period to asses medication adherence to their prescribed aspirin. After Baseline, there is an initial session telephone session with PST therapist. Subsequent treatment sessions provide a context for the patient to discuss the problems and difficulties they face and that give rise to medication non-adherence.
2550044|NCT02564705||anterior cohort|Anterior Lumbar Interbody Fusion (ALIF)
2550046|NCT02564705||posterior cohort|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
2550057|NCT02564484||Neuropathy|Adult survivors who developed persistent treatment-related neuropathy.
2550062|NCT02564484||Control|Adult survivors who did not develop persistent treatment-related neuropathy.
2550089|NCT02564328|Active Comparator|Intravenous stem cell transplantation|Intravenous transplantation of autologous bone marrow mesenchymal stem cell plus conventional treatment include rehabilitation
2550090|NCT02564328|No Intervention|Conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
2550112|NCT02564302|No Intervention|Control|These patients will not receive a device, but have to fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
2550113|NCT02564302|Experimental|Treatment Group|These patients will receive the device. they are expected to use it for at least 5 minutes per day. Patients in this arm will fill out a quality of life questionnaire at the time of enrollment and 3 months after their procedure.
2550136|NCT02563977||DIEP flap breast reconstruction|14 patients who have had DIEP flap breast reconstruction and preoperative CT scan of the abdomen
2550154|NCT02563730|Experimental|Lung biopsy|assess the additional diagnostic value of cryobiopsy in patients with suspected Idiopathic Interstitial Pneumonia (IIP). Cryoprobe vs VATS
2550326|NCT02562807|Active Comparator|Treatment A|TAS-303 18mg single-dose and then Placebo single-dose.
3170588|NCT00576186||1|Patients being referred for the routine Equilibrium Radionuclide Angiocardiography (ERNA) for assessment of their left ventricular function will be asked to participate in the study. All patients will be asked to sign the consent form. Patients will be given a choice to participate in either or both studies (i.e. ERNA plus ACGBS or ERNA plus ACGBS and 3 DE).
3170589|NCT00576212|Experimental|A|Subjects in the intervention group will receive supportive telephone calls biweekly for 6 months.
3170590|NCT00576212|No Intervention|B|Subjects in the control group will receive no intervention.
3170591|NCT00576225|Experimental|Experimental|
3170592|NCT00576225|Active Comparator|Control|
3170593|NCT00576238|Experimental|1:1|Part 1 - eczema treatment
3170594|NCT00576238|Active Comparator|1:2|Part 1 - eczema treatment
3170595|NCT00576238|Experimental|2:1|Part 2 - maintenance treatment
3170596|NCT00576238|No Intervention|2:2|Part 2 - maintenance treatment
3170597|NCT00576329|Placebo Comparator|A|
3170598|NCT00576329|Experimental|B|
3170599|NCT00576342|Other|AL-3862+timolol, then COSOPT|AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
3204322|NCT00932906|Placebo Comparator|Instructor based training; <21 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
3204323|NCT00932906|Placebo Comparator|Instructor based training; 21-50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
2549944|NCT02565355|Other|Lifestyle Modification/Dietary Exclusion|In the lifestyle modification group, where specific IgG antibodies to foods are identified, the intervention is appropriate dietary elimination. The IgG antibody results will be disclosed and specific dietary elimination advice will be provided by an experienced dietician; provide diet alternatives to prevent nutritional deficiencies and improve adherence to diet. To improve compliance, a maximum of 2 high IgG positive foods will be eliminated at any one time in each 4 week period. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
2549946|NCT02565355|Other|The Standard Treatment Group|The standard therapy group will not receive results of IgG antibody testing. The patients will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relief as appropriate. Children will be followed-up in PG clinic at 4-weekly intervals for 16 weeks. Response is defined as more than 50% improvement in frequency and severity of abdominal pain. They will be assessed at visits 2, 3, 4 and 5 for follow-up, and non-responders, will cross over to the other arm of the study.
2550004|NCT02565043|Experimental|RENASYS TOUCH Negative Pressure Wound Therapy Device|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the intermittent/variable therapy mode, for up to 28 days of therapy."
2550007|NCT02565043|Active Comparator|RENASYS TOUCH Negative Pressure Wound Therapy System|"Active Device: RENASYS TOUCH NPWT device administered to all patients using the continuous therapy mode for up to 28 days of therapy."
2550047|NCT02564679|Experimental|Sleeve gastrectomy|These patients are surgically treated with laparoscopic sleeve gastrectomy in association to lifestyle intervention (hypocaloric diet and physical activity)
2550048|NCT02564679|Experimental|Lifestyle Intervention|These patients are treated with lifestyle intervention (hypocaloric diet and physical activity)
2550068|NCT02564367|Experimental|Treatment|"First Cohort 1:~(n = 30 patients) 18 cycles S-1"
3204324|NCT00932906|Placebo Comparator|Instructor based training; >50 years|The instructor based training is a 1.25 hour training as described by the ERC in their standard training program [ref; navragen bij Koen] and using the ERC PowerPoint presentation. There is one manikin and one AED trainer per six students. The group consists out of 12 students maximal, with one instructor per six students.
2550167|NCT02563847|Active Comparator|0.52 g L-Tryptophan|0.52 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550172|NCT02563847|Active Comparator|1.56 g L-Tryptophan|1.56 g L-Tryptophan in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550178|NCT02563847|Active Comparator|1.56 g L-Leucine|1.56 g L-Leucine in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550181|NCT02563847|Active Comparator|50 g Xylitol|50 g Xylitol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550183|NCT02563847|Active Comparator|75 g Erythritol|75 g Erythritol in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550186|NCT02563847|Placebo Comparator|75 g Glucose|75 g Glucose in 300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550188|NCT02563847|Placebo Comparator|Tap water|300 mL tap water (plus 50 mg 13C-sodium acetate) given via nasogastric tube
2550249|NCT02563405|Active Comparator|doxazosin|To observe the effects of doxazosin (4 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
2550252|NCT02563405|Active Comparator|nifedipine|To observe the effects of nifedipine (30 mg) on uric acid in plasma and blood pressure variability after 12 weeks of treatment
3204325|NCT00932906|Experimental|Video Skill Training; <21 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
3321428|NCT02018783|Experimental|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
3321429|NCT02018783|Experimental|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
2550384|NCT02562651|Experimental|Doxycycline|100 mg of Doxycycline bid for seven days in pts with STEMI underwent PCI (percutaneous coronary intervention) and with current medical therapy
2550389|NCT02562651|Active Comparator|Active comparator|Standard care for STEMI
2550511|NCT02561988|Experimental|Avapritinib (also known as BLU-285)|Avapritinib tablets for oral administration. Avapritinib will be dosed daily for 28 day cycles.
2550558|NCT02561390|Experimental|Skin prick test with aeroallergens|Mean wheal diameters of SPT with commercial and local American coakroach, house dust mite, cat, dog and mold
2550561|NCT02561390|Experimental|specific IgE measurement|specific IgE levels of commercial and local American coakroach, house dust mite, cat, dog and mold
2550729|NCT02560545|Active Comparator|Cannabis oil|Cannabis oil, 20% THC 0.2 mg/kg
2550733|NCT02560545|Placebo Comparator|Placebo|Oil
2550762|NCT02560155|No Intervention|Nose-SA-carriers control|Control Group, no intervention
2550769|NCT02560155|Active Comparator|Nose-SA-carriers decolonized|"Chlorhexidine sol 4%; Mupirocin 2% nasal ointement~1 shower/day for 5 days and Nasal ointement 2x/d in each nostril for 5 days preoperatively"
2550775|NCT02560155|No Intervention|Non-nose-SA-carriers control|Control Group, no intervention
2550779|NCT02560155|Active Comparator|Non-nose-carriers decolonized|Chlorhexidine sol 4% shower, daily for 5 days preoperatively
2550839|NCT02559648|Active Comparator|Denosumab|In Group A, 60 mg Denosumab will be administered sc, every 6 months for 12 months for a total of 2 doses (day 0 and day 180)
3204326|NCT00932906|Experimental|Video Skill Training; 21-50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
2549974|NCT02565342|Experimental|Interscalene brachial plexus block|
2550030|NCT02564861|Experimental|DS-1971a (Low Dose)|Participants in Cohort 1 who receive a low dose of DS 1971a in an oral suspension
2550031|NCT02564861|Experimental|DS-1971a (Mid dose)|Participants in Cohort 2 who receive a mid dose of DS 1971a in an oral suspension
2550035|NCT02564861|Experimental|DS-1971a (High dose)|Participants in Cohort 3 who receive a high dose of DS 1971a in an oral suspension
2550039|NCT02564861|Experimental|Pooled placebo|Participants in Cohort 1, 2 or 3 who receive matching DS-1971a Placebo
2550066|NCT02564419|Experimental|Medtronic Activa PC+S|"Objective of this pilot phase early feasibility study is to assess the safety and feasibility of Medtronic Activa PC+S implant (device) by;~Evaluating the ability of the Activa PC+S system to sense ECoG signals in subjects living with quadriplegia (C5 or C6 level).~Assessing the feasibility of activating fundamental upper extremity muscles to reproduce hand grasp.~These are important first steps towards creating and designing a device that can enhance or assist in performing activities of daily living (ADL) in the life of these subjects. Attachment 15.3"
3204327|NCT00932906|Experimental|Video Skill Training; >50 years|Participants practise AED skills, watching a 4.5-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock.
3204328|NCT00932906|Experimental|Video scenario training; <21 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
2550278|NCT02563288|Active Comparator|Esmolol|Esmolol 500mcg/kg before induction in anesthesia following by 300mcg/Kg/min until extubation.
2550284|NCT02563288|Active Comparator|Dexmedetomidine|Dexmedetomidine 1mcg/Kg following by 0.7mcg/Kg/h until end of surgery.
2550336|NCT02562833|Experimental|Self-Management and exercise|
2550345|NCT02562833|Active Comparator|Educational|
3321430|NCT02018783|Placebo Comparator|Cocorico|Digital application for 60 seconds
2550468|NCT02562014|Other|Lean|Participants with body mass index <=25
2550469|NCT02562014|Other|Overweight|Participants with body mass index >25
2550545|NCT02561676|Experimental|Web-Based Education Program Type 1|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
2550550|NCT02561676|Experimental|Web-Based Education Program Type 2|The education program involves ten weeks of web-based classes (1.5 hours per class) given once per week with daily homework assignments of approximately 30 minutes per day.
2550575|NCT02561182||Patients aged 5 years old and with a known diagnosis of a OGS|
2550631|NCT02560948|Placebo Comparator|Placebo|
2550634|NCT02560948|Experimental|gpASIT+TM|
2550666|NCT02560727||colonoscope via of FMT|FMT pathway is colonoscope
2550669|NCT02560727||Transendoscopic enteral tubing|FMT was performed via TET tube
2550730|NCT02560415|Experimental|1: Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
2550732|NCT02560415|Active Comparator|2: Comparator|Treatment as usual
2550807|NCT02559752||Arm 1: NIH Toolbox Cognitive Battery testing|"This study will use the NIH Toolbox Cognitive Battery computer testing software to investigate the cognitive outcomes in children with CNS tumors receiving PBRT.~Participants recruited for the study will complete one 45-minute testing session prior to the completion of the first week of radiation therapy.~They will then complete serial tests 6-12 months after the completion of PBRT and then yearly thereafter."
2550845|NCT02559492|Experimental|Group A: Itacitinib + epacadostat|Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
2550850|NCT02559492|Experimental|Group B: Itacitinib + INCB050465|Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
2550897|NCT02559154|Experimental|modified BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received regimen with bortezomib (1.6mg/㎡) as an intravenous bolus once weekly on day 1, 8 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
2550899|NCT02559154|Active Comparator|conventional BZ group|Patients with newly diagnosed or pre-treated MM(prior therapy not including bortezomib) received bortezomib (1.3mg/㎡) administration twice weekly on day 1,4, 8,11 in a 3 weeks cycle, in combination with dexamethasone,with or without doxorubicin/ cyclophosphamide/mitoxsnteone/thalidomide
2550963|NCT02558738||Ectoin Ear Spray|treatment according to instruction for use
2550965|NCT02558738||Normison ear spray|treatment according to instruction for use
2551014|NCT02558504|Active Comparator|Oesophagectomy|While surgical reference technique for invasive cancer of the lower esophagus is the technique according to Lewis Santy, there is no consensus on the technique and surgical approaches lack of specific work in the particular case of superficial lesions . The centers will have the choice of using the technique according to Lewis Santy with gastric plasty or technique of esophagectomy without thoracotomy with lower mediastinal dissection. In the absence of consensus to date available, abdominal surgery time will be by laparotomy or laparoscopy (laparoscopic assisted technique called). In both cases, an exploratory laparoscopy for diagnostic purposes is realized to remove an extension of the disease that would indicate against-resection with curative intent. For surgery, patients will be put under antisecretory therapy proton-pump inhibitor; this at least throughout the duration of the study.
2551050|NCT02558153|Experimental|DEB - drug eluting balloon (APERTO)|Percutaneous balloon angioplasty performed with the investigational device, the paclitaxel eluting APERTO balloon
2551054|NCT02558153|Active Comparator|standard PTA|Percutaneous balloon angioplasty performed with the clinical standard, that is, a non-drug-eluting balloon (POBA, plain old balloon angioplasty).
2549871|NCT02565719|Experimental|REP 2139-Mg with Viread and Pegasys|REP 2139-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
2549874|NCT02565719|Experimental|REP 2165-Mg with Viread and Pegasys|REP 2165-Mg in combination with tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys).
2549878|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2139-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2139-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
2549882|NCT02565719|Active Comparator|Viread and Pegasys with crossover to REP 2165-Mg and Pegasys|Tenofovir disoproxil fumarate (Viread) and pegylated interferon alpha-2a (Pegasys) - crossover into add-on REP 2165-Mg therapy (triple combination) in patients with < 3 log reduction in serum HBsAg from baseline after 24 weeks of Pegasys exposure.
2549941|NCT02565368|Experimental|RT group|R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T T: Test drug(CKD-395 0.5/1000mg) 1T
2549942|NCT02565368|Experimental|TR group|T: Test drug(CKD-395 0.5/1000mg) 1T R: Reference drug(Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg) 1T
2549973|NCT02565056|Active Comparator|Self-help|Self-help book completed over 6 weeks with up to 30 minutes of telephone support per week.
2549976|NCT02565056|No Intervention|Treatment as usual|Treatment as usual.
2550020|NCT02564822||Migraneurs - Visual stimulation|Patients will be recruited via advertisements on the university. Patients should have migraine diagnosis according to the International Classification of Headache Disorders (ICHD-III) criteria and clinical diagnosis by a neurologist.
2550023|NCT02564822||Control - Visual stimulation|Healthy volunteers will be recruited via advertisements on the university. For control subjects the individuals should not have migraine diagnosis assessed according to IHCD-III criteria.
2550070|NCT02564536|Experimental|Arm 1: Pacritinib and Decitabine|"Patients will receive one cycle of single agent pacritinib.~Patients who tolerate single agent pacritinib will then receive up to 11 cycles of pacritinib and decitabine combination therapy.~Patients who do not tolerate single agent pacritinib (require dose interruption for more than 7 days before Cycle 2 Day 1) will be considered non-evaluable and replaced.~Pacritinib will be administered orally at a dose of 200 mg twice daily continuously for Days 1 through 28 of a 28-day cycle.~Decitabine will be administered as a subcutaneous injection in clinic on Days 1, 5, 8, 12, 15, 19, 22, and 26 of a 28-day cycle.~Patients may continue treatment for up to 12 cycles."
2550130|NCT02564185|Active Comparator|Control|"The control group will follow usual practice."
2550133|NCT02564185|Experimental|Education program|"The Education program group benefit in addition of a therapeutic education program including nursing follow-up at 1, 3 and 6 months."
2550196|NCT02563821|Active Comparator|PCEA-DC|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loading dose (8mL).~In this group the pump is programmed to deliver a continuous infusion at 10 mL /h consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/ mL. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10."
2550198|NCT02563821|Active Comparator|PCEA-BIP|"Injection of a 2 mL initial epidural loading dose consisting of a blend (10 mL) of levobupivacaine 20 mg, sufentanil 10 µg to assure the absence of motor block and so exclude intrathecal placement of the epidural catheter.~Injection of the rest of the loadind dose (8 mL)~In this group the pump is programmed to deliver automated mandatory boluses of 5 mL consisting of levobupivacaine 0,573 mg/mL, sufentanil 0,37 µg/mL, clonidine 1,38 µg/mL every 30 minutes. Additional 5 mL patient-activated boluses will be allowed with a lockout interval of 10 minutes.~If the parturient feels she has inadequate analgesia after having activated the PCEA bolus twice in a thirty minutes period, an additional manual bolus of 6 mL of levobupivacaine 2,5 mg/mL will be administered until the Pain Visual Analog Scale (PVAS) is < 3/10 (0 = no pain and 10 = insufferable pain)."
2550250|NCT02563392|Experimental|Uterine arteries occlusion|Laparoscopic myomectomy with preventive uterine arteries occlusion
2550251|NCT02563392|Active Comparator|No uterine arteries occlusion|Laparoscopic myomectomy without preventive uterine arteries occlusion
2550275|NCT02563119|Active Comparator|Gastric Bypass Group|Twenty morbidly obese patients undergoing gastric bypass surgery
2550281|NCT02563119|Active Comparator|Sleeve Group|Twenty morbidly obese patients undergoing sleeve gastrectomy
2550287|NCT02563119|No Intervention|Healthy controls|Thirty healthy, lean controls
3204329|NCT00932906|Experimental|Video scenario training; 21-50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
3204330|NCT00932906|Experimental|Video scenario training; >50 years|Participants practises AED skills, watching a 9-min video in a single uninterrupted session. There is no instructor available. The video demonstrates the use of an AED; when to use it, how to turn it on, how to attach the electrodes, keeping distance and delivering a shock, and additional two scenarios, in each of which they practice the BLS/AED procedure.
3204331|NCT00932906|Experimental|Video demonstration training; <21 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3204332|NCT00932906|Experimental|Video demonstration training; 21-50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3204333|NCT00932906|Experimental|Video demonstration training; >50 years|Participants watch a 2.5 minutes video demonstration of the use of an AED, in a single uninterrupted session, without hands-on practice.
3204334|NCT00932919|Experimental|Thought field therapy|24 randomly selected patients will be treated with 5 sessions of standard Thought field therapy.
3204335|NCT00932919|Active Comparator|Cognitive therapy|Treatment with Cognitive therapy, 12 sessions with manualized therapy according to David Clark's model.
2549892|NCT02565823|Experimental|Exercise intervention|Subjects will undergo an acute bout of exercise for 45 mins at 75% of peak aerobic capacity
2549969|NCT02565030||CTEPH surgical disease, operated|Patients with proximal CTEPH who have undergone Pulmonary Endarterectomy (PEA) surgery
2549970|NCT02565030||CTEPH surgical disease, not operated|"Patients with proximal CTEPH with operable distribution of disease& have not undergone PEA surgery due to the following reasons:~Multiple co-morbidities~Patients choice~Mild disease /symptoms~Awaiting Surgery"
2549971|NCT02565030||CTEPH non surgical|Patients with distal CTEPH with inoperable distribution of disease inaccessable to surgery.
2549972|NCT02565030||IPAH|Patients with IPAH as per European Society of Cardiology(ESC) criteria
2550097|NCT02564315|Active Comparator|Reduction/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550099|NCT02564315|Active Comparator|Reduction/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550100|NCT02564315|Active Comparator|Reduction/Skill Counseling+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550102|NCT02564315|Active Comparator|Reduction/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Reduction Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Nicotine Mini-Lozenge for 11 Months; Preparation Phase Behavioral Reduction Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550103|NCT02564315|Active Comparator|Recycling/Supportive+Skill Counseling|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Skill Training Counseling. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Skill Training Counseling; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550104|NCT02564315|Active Comparator|Recycling/Supportive Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Supportive Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Supportive Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550105|NCT02564315|Active Comparator|Recycling/Skill Counsel+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Skill Training Counseling and Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Skill Training Counseling; Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550106|NCT02564315|Active Comparator|Recycling/Brief Info+Brief Info|"This arm includes Phase 2 (Preparation) Recycling Treatment and Phase 3 (Cessation) Brief Information. More specifically, treatments include the following:~Phase 2: Preparation Phase Recycling Counseling;~Phase 3: Cessation Phase Brief Information; Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge"
2550108|NCT02564315|Placebo Comparator|Preparation Phase Control/No Phase 3|"This arm includes Phase 2 (Preparation) Control Treatment and No Phase 3 (Cessation) Treatment. More specifically, treatments include the following:~Phase 2: Preparation Phase Control Treatment~Phase 3: No Treatment"
2550214|NCT02563574|Experimental|Motivational Interviewing Group|This group of participants will receive the motivational interviewing. In addition to blood specimen collection, a questionnaire assessment and neurocognitive assessments will also be performed.
2550216|NCT02563574|Active Comparator|Control Group|This group of participants will not receive motivational interviewing. They will have blood specimen collection, questionnaire assessment, and neurocognitive assessments performed.
2550307|NCT02563249|Other|Dexterity, Coordination,Perception measurements|Dexterity, Hand-eye Coordination and Perception of Orientation and Distances
2550322|NCT02562768|Experimental|LY3154207|LY3154207 administered orally once daily in multiple-ascending dose cohorts for 14 days.
2550323|NCT02562768|Placebo Comparator|Placebo|Placebo matching LY3154207 administered once daily for 14 days.
2550373|NCT02562534|Other|Patients with conductive troubles|Patients with conductive troubles
2550377|NCT02562534|Other|Patients with rhythm troubles|Patients with rhythm troubles
2550380|NCT02562534|Other|Volunteers|Volunteers with normal ECG
3170600|NCT00576342|Other|COSOPT, then AL-3862+timolol|Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
2550657|NCT02560766|Experimental|HORIZANT 300 mg|HORIZANT 300 mg once daily
2550658|NCT02560766|Experimental|HORIZANT 600 mg|HORIZANT 600 mg once daily
2550659|NCT02560766|Placebo Comparator|Placebo|Placebo once daily
3170601|NCT00576355|Active Comparator|2|Participants will receive treatment as usual
3170602|NCT00576355|Experimental|1|Participants will receive interpersonal and social rhythm therapy for adolescents
3170603|NCT00576368|Experimental|1|
3170604|NCT00576394|Active Comparator|1Moderate Glycemic Control|Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl
3170605|NCT00576394|Active Comparator|2Aggressive Glycemic Control|Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl
3170606|NCT00576433|Experimental|1|
3170607|NCT00576446|Experimental|1|
3170608|NCT00576459|Experimental|Fluocinolone acetonide 0.59 mg|0.59 mg fluocinolone acetonide intravitreal implant
2549895|NCT02565654||Rifaximin group|Patients are treated with rifaximin (Alfa Wassermann Pharmaceutical Co., Ltd. Italy) for 14 days at a daily dosage of 1200 mg (400 mg, three times daily)
2549920|NCT02565472|Experimental|Apple Juice|12 oz apple juice
2549924|NCT02565472|Experimental|Grape Juice|12 oz grape juice
2550019|NCT02564874|Experimental|Savory snack|1-2 assigned snacks to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (chips, pretzels, etc.)
2550022|NCT02564874|Experimental|Sugary beverage|1-2 soda-based drinks/juice to be taken in determined portions equivalent to 15% of dietary energy intake, chosen from 9-point hedonic preferences questionnaire completed by participant (coke, sprite, etc.)
2550079|NCT02564575|Experimental|Cohort 1|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^6 PFU/mL of the HPIV3-EbovZ GP vaccine.
2550081|NCT02564575|Experimental|Cohort 2|Participants will receive two doses, separated by 4-8 weeks, of approximately 10^7 PFU/mL of the HPIV3-EbovZ GP vaccine.
2550228|NCT02563652||Major abdominal surgery|Patients undergoing major abdominal surgery (laparotomy). Surgical procedures considered for inclusion include, but are not restricted to, procedures such as gastrectomy, pancreatic surgery, liver resection, open prostatectomy, colonic surgery, radical cystectomy with ileal conduit, open nephrectomy and vascular abdominal aortic surgery.
2550301|NCT02563275|Other|Human fine motor skills measurements during weightlessness|
2550324|NCT02562794|Experimental|Intervention|Family Strengthening Intervention-Refugees. A total of 20 Somali Bantu and 20 Bhutanese refugee families will participate in a Family Strengthening Intervention adapted for use with refugees.
2550329|NCT02562794|No Intervention|Control|A total of 20 Somali Bantu and 20 Bhutanese refugee families will receive services as usual.
2550385|NCT02562599|Experimental|drug:raltitrexed safety and efficacy|"To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin~Interventions:~Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).~Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .~Radiation: Intensity-modulated radiotherapy (IMRT)"
2550427|NCT02562157|Experimental|Patients with antro duodenal obstructions|NOTES gastroenteric anastomosis
2550485|NCT02561975|Experimental|Patient suffering from complex congenital heart disease|
2550515|NCT02561663|Experimental|NWT-03, followed by placebo|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
2550516|NCT02561663|Experimental|Placebo, followed by NWT-03|Dietary Supplement: NWT-03, an egg-white protein hydrolysate For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given Dietary Supplement: Placebo A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
2550564|NCT02561403|Experimental|EVO multitask video game|
2550565|NCT02561403|Experimental|EVO words video game|
2550566|NCT02561403|No Intervention|Assessment Only|
2550579|NCT02561104|Experimental|LenSx|Laser-assisted cataract surgery performed using the LenSx femtosecond laser.
2550583|NCT02561104|Experimental|Phaco|Traditional manual phacoemulsification cataract surgery
2550635|NCT02560909|Experimental|Experimental|The experimental group will receive one dose MF59 adjuvanted intramuscular vaccine.
2550638|NCT02560909|Active Comparator|Control|The control group will receive one dose of the standard 2015-2016 nonadjuvanted vaccine.
3204336|NCT00932919|Other|Wait list|24 patients will be randomly selected to 3 months on a wait list, thereafter randomly selected to either Cognitive therapy or Thought field therapy.
3204337|NCT00932932||PWS not receiving Growth Hormone|
2550828|NCT02559583||Participants with Chronic Lymphocytic Leukemia (CLL)|This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor.
2550831|NCT02559583||Participants with Multiple Myeloma (MM)|This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor.
2550833|NCT02559583||Participants with Non-Hodgkin's lymphoma (NHL)|This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor.
2550925|NCT02559037|Experimental|Acupuncture-moxibustion group|Receiving acupuncture and moxibustion treatment.
2550931|NCT02559037|Sham Comparator|Sham acupuncture-moxibustion group|Receiving sham acupuncture and sham moxibustion.
2550969|NCT02558764|No Intervention|Control|No intervention; basic wound contact absorbent dressings will be used as per current standard of care.
2550972|NCT02558764|Other|PICO|PICO device will be used for prevention of wound complications. This is a portable negative pressure wound treatment device. Patients will have the device for 7 days after undergoing kidney transplant surgery.
2551157|NCT02557724||liver transplant patients|5 blood samples at time points as described in protocol
3204338|NCT00932932||Control subjects healthy or obese|
3204339|NCT00932932||PWS subjects starting Growth Hormone|
3204340|NCT00932945|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Treatment duration: 21 consecutive days
3204341|NCT00932958||All comers >18 yrs old|This study is observational, studying patients who are already scheduled to undergo CCTA. Minors and those unable to consent to the study are excluded.
3204342|NCT00932971|Placebo Comparator|PEG-IFN alfa-2a plus placebo|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
3204343|NCT00932971|Active Comparator|PEG-IFN alfa-2a plus Tenofovir|Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
2549896|NCT02565641|Experimental|Capecitabine + Gemcitabine|Participants will receive oral capecitabine (830 milligrams per meter-squared [mg/m^2]) twice daily (BID) as intermittent treatment (Days 1 to 21 every 4 weeks [q4w]) along with IV infusion of gemcitabine (1000 mg/m^2) once weekly as intermittent treatment (4-week cycles of 3-week treatment period and 1-week rest period).
2549930|NCT02565394|Experimental|Micro-Break with Dynamic Activity|Micro Break with web based application of a video to lead surgeons through dynamic exercise activities
2549934|NCT02565394|No Intervention|Comparator|A baseline survey will be completed following a surgical day with no dynamic activities
2549983|NCT02565160||Septic Arthritis|Patients suspected of having septic arthritis
2549988|NCT02565160||Osteoarthritis|Patients suffering with osteoarthritis undergoing an intervention
2549991|NCT02565160||Joint Revision|Patients who has a prosthetic joint in situ
2550032|NCT02564653|Other|Technical Assistance, training,clinical reminders|provider adherence to tobacco use treatment guidelines
2550037|NCT02564653|Other|TTC + help of community health workers|We will assess this secondary aim by comparing smoking cessation outcomes among smokers who receive brief provider counseling alone only vs. smokers who receive provider counseling + community health worker counseling. The purpose of this assessment is to specifically analyze the impact of the community health worker counseling component of the intervention using a quasiexperimental design that leverages the larger RCT.
2550058|NCT02564458|Experimental|Interval Exercise Training/Motivational Accelerometry (IET/MA)|All patients on the experimental arm receive the intervention of 5-12 weeks of pre-transplant IET, motivational accelerometry via the FitBit Surge, pre- and post-fitness assessments, and periodic quality of life and symptom surveys.
2550063|NCT02564458|No Intervention|Normal Standard of Care (control)|All patients on the control arm participate in the pre- and post-fitness assessment, are given the FitBit Surge without the motivational component, and are also given periodic quality of life and symptom surveys.
3204344|NCT00932984|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3204345|NCT00933023|Experimental|Mild steroid|1%hydrocortisone for 8 weeks
2550248|NCT02563418|Experimental|Patient with Huntington's disease|
2550280|NCT02563145|Experimental|Real-time fMRI feedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 10 sessions of real-time fMRI feedback of insula- or amygdala activation (dependent on activation patterns during pre-testing), 1 session/week. Each session will last about 1 1/2 hours.~After training completion (10 weeks after the beginning of the treatment phase), subjects will undergo post-treatment assessment and follow up (6 months after the end of the training phase)."
2550283|NCT02563145|Active Comparator|Treatment as usual|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator TAU arm will receive several sessions of psychoeducation and counseling with their parents/caregivers or group training over 10 weeks.~Within the sessions, investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, subjects will undergo post-treatment assessment and follow up (6 months after the end of the treatment phase)."
2550289|NCT02563145|No Intervention|Typically developing (TD) control group|Healthy typically developing subjects will only participate in pre-training assessment to allow for comparison.
3204346|NCT00933023|Experimental|Potent Steroid|
3204347|NCT00933036|Experimental|Treatment arm|Crosstrees Pod System for PVA.
2550411|NCT02562339|Experimental|SMART-3RP for Parents or Caregivers|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
2550415|NCT02562339|Experimental|SMART-3RP for Adolescent Patients|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
2550458|NCT02562040|Active Comparator|Watchful Waiting with Supportive Care|All Watchful Waiting with Supportive Care (WWSC) participants will receive information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
2550460|NCT02562040|Experimental|Early Adenotonsillectomy|All Early Adenotonsillectomy (eAT) participants will receive information about healthy sleep habits for children, undergo adenotonsillectomy within 4 weeks of randomization and receive appropriate clinical referrals for management of co-morbidities
2550508|NCT02561728|Experimental|Plagiocephaly|Children with a misshaped head due to positioning. This is also known as flat head. Children with plagiocephaly will be treated with either the Hangar Helmet or the P-Pod helmet.
2550509|NCT02561728|Experimental|Craniosynostosis|Craniosynostosis occurs when one or multiple sutures fuse too early. Several sutures may be fused alone or in combination. An open or endoscopic surgical procedure to open the suture(s) is necessary to allow for normal brain growth and development. After surgery a cranial remolding helmet is used to direct skull growth. Children with craniosynostosis will be treated with either the Hangar Helmet or the P-Pod helmet
3204348|NCT00933049|Active Comparator|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole) + Amoxicillin placebo
2550766|NCT02559973|Experimental|RBP-6000 - Light MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a light molecular weight (MW) polymer.
3204349|NCT00933049|Active Comparator|Amoxicillin|Amoxicillin (25 mg/kg/dose) + Cotrimoxazole placebo
3204350|NCT00933062|Active Comparator|SRT2104|Subjects will receive a dose of 2.0 g SRT2104 (administered as eight 250 mg capsules) on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
3204351|NCT00933062|Placebo Comparator|Placebo|Subjects will receive placebo on eight occasions during the study; once as a single dose (study day 1) during Treatment Period 1, and once per day for seven consecutive days (study days 15 to 21) during Treatment Period 2.
3204352|NCT00933075|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also usedas a control sample.
3204353|NCT00933101||HgbA1c <8|Adolescents with HgbA1c < or equal to 8% for the previous 12 months
3204354|NCT00933101||HgbA1c >10|Adolescents with HgbA1c > or equal to 10% for previous 12 months
2549902|NCT02565693|Experimental|Apixaban|"Apixaban: oral, 5 mg twice daily. If two of the three following criteria are met, the dose will be reduced to 2.5 mg twice daily:~Age ≥ 80 years~Body weight ≤ 60 kg~Serum creatinine ≥ 133 μmol. Additionally, if the creatinin clearance is below 30 ml per minute, the dose will be reduced to 2.5 mg twice daily."
2549903|NCT02565693|Other|Avoiding oral anticoagulants|"The following treatment regimens are allowed in the comparator arm:~- No antithrombotic treatment~or:~Acetylsalicylic acid 80 mg once daily~Carbasalate calcium 100 mg once daily~Clopidogrel 75 mg once daily~Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily~Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily"
2549981|NCT02565173|Experimental|trabodenoson 4.5% BID|trabodenoson 4.5% Ophthalmic Formulation
2549985|NCT02565173|Experimental|trabodenoson 6.0% QD|trabodenoson 6.0% Ophthalmic Formulation
2549990|NCT02565173|Experimental|trabodenoson 3.0% QD|trabodenoson 3.0% Ophthalmic Formulation
2549993|NCT02565173|Active Comparator|timolol 0.5% BID|timolol 0.5% Ophthalmic Formulation
2549994|NCT02565173|Placebo Comparator|placebo BID|placebo Ophthalmic Formulation
2550041|NCT02564640|Active Comparator|videolaryngoscope|patients intubated by using the videolaryngoscopy
2550042|NCT02564640|Active Comparator|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
2550059|NCT02564406|Experimental|hypercapnic patients|patients with acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease, refused endotracheal intubation after failing NIV and were treated withLow flow etracorporeal CO2 removal
2550110|NCT02564276|Experimental|Indocyanine Green on the right side|Indocyanine Green will be injected on the right side of the cervix and Methylene blue on the left side of the cervix.
2550111|NCT02564276|Experimental|Methylene Blue on the right side|Methylene blue will be injected on the right side of the cervix and Indocyanine Green on the left side of the cervix.
3204355|NCT00933114||Functional Imaging|Functional imaging with MRI and PET
3204356|NCT00933140||HIV infected women|HIV infected women between ages 18 - 64 years of age due for cervical cancer screening were enrolled.
2550233|NCT02563457|Experimental|case|diabetic patients who will receive periodontal treatment blood sampling
2550239|NCT02563457|Experimental|control|diabetic patients without periodontal treatment (no periodontal treatment) blood sampling
2550291|NCT02563184|Active Comparator|COPD|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
2550293|NCT02563184|Active Comparator|Control|Group will receive either the Fluzone Trivalent or Fluzone Quadrivalent.
2550333|NCT02562859|Experimental|GLPG1837 as oral suspension fasted|Single dose of 500 mg GLPG1837 as oral suspension after an overnight fast
2550348|NCT02562859|Experimental|GLPG1837 as oral tablet fasted|Single dose of 500 mg GLPG1837 as oral tablet after an overnight fast
2550353|NCT02562859|Experimental|GLPG1837 as oral tablet fed|Single dose of 500 mg GLPG1837 as oral tablet after a high-fat high-calorie breakfast
2550399|NCT02562508|Experimental|9-17y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
2550404|NCT02562508|Experimental|9-14y (0,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 2 doses of HPV 16/18 bivalent vaccine
2550408|NCT02562508|Experimental|18-26y (0,1,6m)|Participants in this arm would receive 60μg of HPV 16/18 bivalent vaccine according to 3 doses of HPV 16/18 bivalent vaccine
3204357|NCT00933153|Active Comparator|Meals on Wheels|Participants will receive two meals daily from Meals on Wheels.
3204358|NCT00933153|Experimental|Meals on Wheels + Ensure Plus supplement|Participants will receive two meals from Meals on Wheels daily plus Ensure Plus supplements with meals.
2550552|NCT02561468|Experimental|Nefopam|20 mg nefopam in 100 ml normal saline is infused before starting operation.
2550554|NCT02561468|Placebo Comparator|Control|100 ml normal saline is infused before starting operation.
3204359|NCT00933179|Experimental|Arm 1|
3204360|NCT00933179|Active Comparator|Arm 2|
3204361|NCT00933192||Group 1: young healthy patients|
3204362|NCT00933192||Group 2: old healthy patients|
3204363|NCT00933218|Active Comparator|polyphenols (non-alcoholic beer)|
2550721|NCT02560363|Experimental|Treatment sequence 1|Period 1:Fast ER formulation of AZD9977 Period 2:Intermediate ER formulation of AZD9977 Period 3:Slow ER formulation of AZD9977 Period 4:IR formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
3204364|NCT00933218|Placebo Comparator|beverage without polyphenols|
3204365|NCT00933231|Active Comparator|Tacrolimus Standard Dose with ACEi/ARB|Participants receive a standard dose of tacrolimus with ACEi/ARB.
3204366|NCT00933231|Active Comparator|Tacrolimus Standard Dose without ACEi/ARB|Participants receive a standard dose of tacrolimus without ACEi/ARB.
3204367|NCT00933231|Experimental|Tacrolimus Low Dose with ACEi/ARB|Participants receive a low dose of tacrolimus with ACEi/ARB.
3204368|NCT00933231|Experimental|Tacrolimus Low Dose without ACEi/ARB|Participants receive a low dose of tacrolimus without ACEi/ARB.
3204369|NCT00933257|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3204370|NCT00933283|Experimental|Telaprevir + Methadone|Patients will receive telaprevir 750 mg orally, every 8 hours from Day 1 to Day 7, along with methadone 30 to 130 mg, once daily.
3204371|NCT00933296||A Patients with the Schnitzler syndrome|Patients with the Schnitzler syndrome
3204372|NCT00933296||B Control subjects:|B1 healthy B2 other diseases
3204373|NCT00933309|Experimental|Group 1|Exemestane alone
3204374|NCT00933309|Experimental|Group 2|Exemestane plus Avandamet
3204375|NCT00933322|Active Comparator|ruminant TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing ruminant TFA and with 15-20g rape oil for balancing the essential fatty acids.
3204376|NCT00933322|Active Comparator|industrial TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter containing TFA from PHVO and with 15-20g rape oil for balancing the essential fatty acids.
3204377|NCT00933322|Placebo Comparator|without TFA|In addition to the basic diet, volunteers enrich their diet with an individually calculated amount of butter without TFA and with 15-20g rape oil for balancing the essential fatty acids.
3204378|NCT00933348|Active Comparator|OPAL A plus standard wound care|
3204379|NCT00933348|Placebo Comparator|Placebo plus standard wound care|
2550193|NCT02563704|Active Comparator|ARTES|"Injectable Artesunate.Each vial contained 60 mg anhydrous artesunic acid, which was dissolved in 1 ml of 5% sodium bicarbonate (provided with the drug) and then mixed with 5 ml saline solution (provided with the drug) before injecting into an indwelling intravenous catheter.~Patients received 2.4 mg/kg bw of parenteral artesunate at H0, H12, H24 and thereafter once daily, for a minimum of 24 hours.~Patients exited from the protocol if they had clinically recovered and parasitaemia was negative."
2550194|NCT02563704|Active Comparator|QLD|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received a loading dose of 16.6 mg/kg bw of QB by intravenous (IV) infusion over 4 hours followed 8 hours after the start of the loading dose, with a maintenance dose of QB at 8.3 mg/kg bw over 4 hours every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
2550195|NCT02563704|Active Comparator|QNLD3|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 8.3 mg/kg bw of QB over 4 hours by IV infusion every 8 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
2550197|NCT02563704|Active Comparator|QNLD2|"Injectable quinine. Each vial contained 250 mg or 500 mg QB.~Patients received 12.5 mg/kg bw of QB over 4 hours by IV infusion every 12 hours diluted in 10 ml/kg bw of 10% dextrose solution.~Patients received a minimum of 24 hours of parenteral treatment and exited from the protocol if they had clinically recovered and parasitaemia was negative."
2550256|NCT02563301|Active Comparator|McGrath Series 5|Videolaryngoscope used to perform indirect (video) laryngoscopy and tracheal intubation
2550258|NCT02563301|Active Comparator|Macintosh|Laryngoscope used to perform direct laryngoscopy and tracheal intubation
2550300|NCT02563080||First attack of acute pancreatitis|50 patients with first attack of moderately severe or severe acute pancreatitis treated in Helsinki University Hospital.
2550335|NCT02562846||ECT patients|Depressive patients receiving electroconvulsive therapy.
2550372|NCT02562573|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once a day.
2550433|NCT02562300|Active Comparator|Sublingual misoprostol|The patients in this arm received 400 micrograms of sublingual misoprostol, immediately after delivery of the neonate.
2550437|NCT02562300|Active Comparator|oxytocin|The patients in this arm received 20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h , immediately after delivery of the neonate.
2550475|NCT02561936|Experimental|Panel 1: Group 1|Participants will receive Treatment A (25 milligram [mg] rilpivirine [RPV] formulated as the oral tablet under fed condition [standardized breakfast]) followed by Treatment D (25 mg RPV formulated as granules formulation G002 [10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast]) followed by Treatment B (25 mg RPV formulated as dispersible tablet formulation G007 [10*2.5 mg tablets, dispersed in water] under fed condition) followed by Treatment C (25 mg RPV formulated as dispersible tablet formulation G009-01 [10*2.5 mg tablets, dispersed in water] under fed condition).
2550477|NCT02561936|Experimental|Panel 1: Group 2|Participants will receive treatment B followed by treatment A then treatment C followed by treatment D.
2550479|NCT02561936|Experimental|Panel 1: Group 3|Participants will receive treatment C followed by treatment B then treatment D followed by treatment A.
2550481|NCT02561936|Experimental|Panel 1: Group 4|Participants will receive treatment D followed by treatment C then treatment A followed by treatment B.
2550482|NCT02561936|Experimental|Panel 2: Group 1|Participants will receive Treatment E (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition) followed by Treatment H (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [yoghurt] condition) followed by Treatment F (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fasted condition) followed by Treatment G (25 mg RPV formulated as dispersible tablet formulation G007 or G009-01 or as granules formulation G002 [10*2.5 mg tablets or 10 g of 2.5 mg/g granules, dispersed in water] under fed [standardized breakfast] condition).
2550483|NCT02561936|Experimental|Panel 2: Group 2|Participants will receive Treatment F followed by Treatment E then Treatment G followed by Treatment H.
2550484|NCT02561936|Experimental|Panel 2: Group 3|Participants will receive Treatment G followed by Treatment F then Treatment H followed by Treatment E.
2550486|NCT02561936|Experimental|Panel 2: Group 4|Participants will receive Treatment H followed by Treatment G then Treatment E followed by Treatment F.
3204380|NCT00933361|Experimental|ghrelin|Ghrelin, a 28 amino acid peptide discovered in 1999, is predominantly secreted by gastric endocrine cells and is an endogenous ligand for the growth hormone secretagogue (GHS) receptor. When administered peripherally it stimulates growth hormone secretion, food intake, triggers a positive energy balance, produces weight gain through a central mechanism involving hypothalamic neuropeptides and has anti-inflammatory effects
3204381|NCT00933374|Experimental|Paclitaxel and RAD001|175 mg /m3 paclitaxel every 3 weeks and 10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
2550739|NCT02560376|Experimental|68Ga-NOTA-exendin-4 PET/CT|The patients were injected with 55.5-111 MBq of 68Ga-NOTA-exendin-4 PET/CT in one dose intravenously and underwent PET/CT scan 30-60 min later.
2550793|NCT02559921|Experimental|HRIG（20 IU/kg）+ vaccine|Subjects received HRIG（20 IU/kg）in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
3204382|NCT00933387|Experimental|open label|an open-labelled, single-arm
3321431|NCT02018796||Women seeking medical abortion|Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.
2549963|NCT02565303|Experimental|L2-3 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.
2549964|NCT02565303|Experimental|L3-4 intervertebral group|The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.
3204383|NCT00933400|Active Comparator|Traditional Strategy (Group A)|In the traditional-care arm (Group A), all management and disposition decisions will be made by the healthcare providers caring for the participant. Participants will receive disposition (admit to hospital, admit to cardiac diagnostic unit, or discharge to home), diagnostic testing (none, stress testing, or cardiac catheterization), and treatment according to the team caring for the participant.
3204384|NCT00933400|Experimental|CT Coronary Angiography (Group B)|"In the study CT coronary angiography-based rapid rule out arm (Group B), participants will receive initial cardiac troponin and creatinine tests. Upon return of normal laboratory values (including a calculated creatinine clearance), the participants will receive a CT coronary angiography an estimated 90 minutes or as soon as the CT scanner is available following the initial values assessment. Participants with negative test results will be discharged unless other indications for admission per standard of care and follow up will comprise telephone interviews 30 days and 1 year after triage/presentation. Participants with positive test results will be admitted to the hospital for further management as dictated by the admitting team."
3204385|NCT00933413|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Application of Lactic acid during 21 consecutive days
3204386|NCT00933426|Experimental|Lenalidomide and Paclitaxel|"Phase I: Up to 5 differing doses of Lenalidomide tested plus fixed dose of Paclitaxel.~Phase II: Lenalidomide at highest tolerated dose from Phase I plus Paclitaxel."
3204387|NCT00933439|Experimental|Duloxetine|
3204388|NCT00933452|Experimental|low dose group|single oral administer 15mg duloxetine
2550310|NCT02563002|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 treatments (approximately 2 years). Participants that have stopped the initial course of pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
2550311|NCT02563002|Active Comparator|Standard of Care|Participants receive 1 of 6 possible standard chemotherapy regimens: mFOLFOX6, or mFOLFOX6+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or mFOLFOX6+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle, or FOLFIRI, or FOLFIRI+bevacizumab 5 mg/kg IV on Day 1 of each 2-week cycle, or FOLFIRI+cetuximab 400 mg/m^2 IV over 2 hours then 250 mg/m^2 over 1 hour weekly in each 2-week cycle. Participants with documented disease progression following chemotherapy can crossover to receive pembrolizumab for up to 35 cycles (approximately 2 years). Participants that have stopped pembrolizumab and have stable disease but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 year additional).
2550337|NCT02562729|Experimental|Nerve-Sparing Radical Hysterectomy (NSRH)|Type C1 Hysterectomy
2550382|NCT02562495|Experimental|CT scan and Ultrasonography|Up to three measurements (CT scan and Ultrasonography), will be made concurrently between the day of admission (D1) in intensive care unit and the tenth day ( D10 ) .
2550450|NCT02562248|Active Comparator|Intervention|Randomization is at the clinic level. Two clinics will be randomized to receive the revised module to screen for anxiety and ADHD among children who present with parental concern of disruptive behaviors. Parents who have concerns of disruptive behaviors will trigger the module and be administered both the Vanderbilt for ADHD and Screen for Childhood Anxiety Related Emotional Disorders (SCARED) screening tools.
2550459|NCT02562248|Active Comparator|Control|Randomization is at the clinic level. Two clinics will be randomized as the control clinics meaning that they will continue to provide care as usual for families who present to the clinic with concerns of disruptive behaviors. Currently, CHICA administers the Vanderbilt for ADHD screening tool.
3204389|NCT00933452|Experimental|moderate dose group/multiple dose group|single oral duloxetine 30mg, after that repeat 7 oral duloxetine 30mg/d
3204390|NCT00933452|Experimental|high dose group/crossover group|single oral duloxetine 60mg, after that single oral innovator duloxetine 60mg
2550700|NCT02560532|Experimental|Clazosentan|Diluted solution administered as a continuous intravenous infusion at a rate of 15 mg/h for up to a cumulative maximum of 10 days
2550738|NCT02560311||HER2+ metastatic breast cancer|
2550761|NCT02560090|Placebo Comparator|Control Group|Survey assessments as well as collection of medical records and billing information.
2550765|NCT02560090|Active Comparator|Telephonic Nurse Intervention|Survey assessments as well as collection of medical records and billing information. A nurse will communicate with participants via telephone to support diabetes self-management practices.
2550767|NCT02560090|Active Comparator|In-person Community Health Worker Intervention|Survey assessments as well as collection of medical records and billing information. A community health worker will work with participants in person to support diabetes self-management practices.
2550934|NCT02559011||All study participants|Patients who need a TAVI with symptomatic severe aortic valve stenosis
2550993|NCT02558751|Active Comparator|HIV positive PPV23|HIV-positive individuals 50-65 years of age immunized with one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23
2550997|NCT02558751|Active Comparator|HIV positive PCV13/PPV23|HIV-positive individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
2550998|NCT02558751|Active Comparator|HIV negative PCV13/PPV23|HIV-negative individual 50-65 years of age, Intervention: one dose of 13-valent pneumococcal conjugate vaccine,PCV13, followed 8 weeks later with one dose of 23-valent pneumococcal polysaccharide vaccine, PPV23
2551243|NCT02556957|Experimental|HealthScouts Intervention|HealthScouts (CHWs) regularly visit residents and counsel them using a motivational interviewing approach, supported by a smartphone application.
2551245|NCT02556957|Active Comparator|Standard of Care|Referral by RCCS to HIV services. Free HIV clinic available in the community.
2551330|NCT02556164|Experimental|Real EA|"Real EA as intervention is performed at the selected standard acupuncture points and De-qi is achieved with needle manipulation before electric stimulation is delivered."
2552448|NCT02549521|Active Comparator|Oral magnesium substitution|Daily 240 mg Magnesium Nycomed Pharma. Intervention day 0 - day 28.
2549984|NCT02565225||RheumaLive App use|RheumaLive App use and evaluation of feasibility
2549987|NCT02565225||RheumaLive App use & threshold values|RheumaLive App use and evaluation of feasibility
2550021|NCT02564809|Experimental|Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a cognitive training program (Fit Brains training) 6 hours a week for 8 weeks.
2550026|NCT02564809|Experimental|Exercise + Fit Brains training|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will be performing a combination of aerobic exercise and a cognitive training program (Fit Brains training) for 6 hours a week over 8 weeks.
2550028|NCT02564809|Sham Comparator|Balanced And Tone|Both healthy participants and participants with Mild Cognitive Impairment (MCI) will complete 3 weekly training sessions of 1 hour for 8 weeks.
2550055|NCT02564445|Experimental|Control|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~They will be given information on the federal and CDC guidelines for physical activity and will also be told that they should strive to achieve 10,000 steps per day to help promote weight loss."
2550056|NCT02564445|Experimental|Gamification|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
2550061|NCT02564445|Experimental|Gamification + Share Data with PCP|"Participants choose a weight loss goal of 6-8% of baseline weight and given access to a wireless weight scale and smartphone application activity tracker to receive feedback on weight and feedback on step counts.~Participants will be asked to allow the study team to share their weight and step data with their primary care physician (PCP).~All participants play a game with their teammate that includes points, levels and the opportunity to win a trophy, plaque or medal. They will advance or not advance based on their progress with weight loss and physical activity through 24 weeks. During the 12-week follow-up they'll be asked to maintain or make progress toward their weight loss goal."
2550132|NCT02564133|Experimental|detection of a patent foramen ovale|
2550155|NCT02563886|Experimental|EAMT, then standard care|Electrically Assisted Movement Therapy precedes usual and customary care.
2550162|NCT02563886|Active Comparator|Standard care, then EAMT|Usual and customary care precedes Electrically Assisted Movement Therapy.
3170609|NCT00576459|Experimental|Fluocinolone acetonide 2.1 mg|2.1 mg fluocinolone acetonide intravitreal implant
3170610|NCT00576459|Active Comparator|Laser photocoagulation|standard of care laser photocoagulation
3170611|NCT00576485|Experimental|1|Cataract surgery and implantation of a spherical intraocular lens
2550546|NCT02561520|Experimental|PRP and PPP|PRP eye drops and PPP eye drops will be prepared from patient's own blood by Magellan technology. Patients will receive eye drops in sterile amber glass droppers. Patients will be instructed to keep refrigerated each bottle after opening for 7 days and keep frozen the unopened bottles up to 30 days.
2550582|NCT02561169|Experimental|Oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
2550586|NCT02561169|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
2550654|NCT02560870|Active Comparator|Aloe Vera mouthwash|mouthwash (Aleo Vera)10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2550656|NCT02560870|Active Comparator|Chlorhexidine mouthwash|mouthwash (Chlorhexidine )10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
2550838|NCT02559479|Active Comparator|18%-Protein diet|Energy-restricted diet wit the following composition: 18% protein, 30% fat and 52% carbohydrates
2550840|NCT02559479|Active Comparator|35%-Protein diet|Energy-restricted diet wit the following composition: 35% protein, 30% fat and 35% carbohydrates
2550947|NCT02558855|Active Comparator|Thrust Joint Manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying.
2550949|NCT02558855|Sham Comparator|Non-thrust Joint Manipulation|Patients will receive non-thrust joint manipulation, oscillations into slight rotation, without cavitation, to their lumbar spine in side lying.
2551015|NCT02558491|Experimental|Decision Support System|Blinded CGM data will be collected prior to the Experimental Admission and analyzed by the study team to determine the optimal insulin therapy parameters that will be used during the Experimental Admission.
2551017|NCT02558491|No Intervention|Usual Care|Subjects will use their own insulin parameters, including basal rate, correction factor and carbohydrate-insulin ratio, and determine their own insulin usage during the Control Admission.
2551158|NCT02557724||Liver resection patients|3 blood samples at time points described in protocol
3170612|NCT00576485|Experimental|2|Cataract surgery and implantation of a spherical intraocular lens
3170613|NCT00576498|Experimental|1- Narrow Band Imaging|"NBI-AFI imaging - Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.~Autofluorescence Imaging (AFI)- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm)"
3170614|NCT00576498|Other|2-Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars
3170615|NCT00576511|Active Comparator|1|Prucalopride
3170616|NCT00576511|Placebo Comparator|2|
3170617|NCT00576537|Experimental|Dendritic Cell Immunotherapy|Patients who consent to participate in the study and receive the Dendritic Cell vaccine manufactured from their own tumor cells.
3170618|NCT00576550|Experimental|1:1|Part 1 of the study (maintenance part)
3170619|NCT00576550|No Intervention|1:2|Part 1 of the study (maintenance part)
3170620|NCT00576550|Experimental|2:1|Part 2 of the study (eczema part)
2549996|NCT02565017||Breast Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
2550001|NCT02565017||Lung Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
2550006|NCT02565017||Colorectal Cancer|and treatment type (chemotherapeutic adjuvant (i.e., chemotherapy delivered after primary therapy/surgery) or neoadjuvant (i.e., chemotherapy delivered prior to primary therapy/surgery) treatment, chemotherapeutic treatment for metastatic disease, or chemotherapeutic treatment through a clinical trial).
3204391|NCT00933465|Experimental|tablets first followed by syrup|first 6 weeks of study using tablets, then followed by assessment, and then the next 6 weeks using syrup, followed by assessment
2550120|NCT02564107|Experimental|Ibandronate|Female participants with metastatic bone disease secondary to breast cancer will receive ibandronate for a period of 25 weeks.
3204392|NCT00933465|Experimental|Syrup first followed by tablets|first 6 weeks of study using syrup, then followed by assessment, and then the next 6 weeks using tablets, followed by assessment
3204393|NCT00933478||Patients with Patulous Eustachian Tube Dysfunction|
2550266|NCT02563353|Active Comparator|controlgroup|Teriparatide, 20 microgram/day. 24 months of treatment
2550267|NCT02563353|Experimental|studygroup 1|"Teriparatide, 20 microgram/day. 24 months of treatment.~12 months of Whole-body vibration on vibration platforms."
2550269|NCT02563353|Experimental|studygroup 2|"Teriparatide, 20 microgram/day. 24 months of treatment.~24 months of Whole-body vibration on vibration platforms"
2550334|NCT02562976||early gastric cancer group|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia in patients with early gastric cancer or high-grade neoplasia(HGN)
2550350|NCT02562976||non-early gastric cancer group|patients diagnosed as non- gastritis, gastritis or low-grade neoplasia (LGN) by pathology were defined as non-EGC group
2550397|NCT02562560|Experimental|TGA|
2550405|NCT02562560|Experimental|Controls|
2550424|NCT02562092|No Intervention|Focus Group|Participants will complete a questionnaire and will be involved in a group discussion regarding good sites within the community to perform HIV testing.
2550425|NCT02562092|Other|Venue Testing Group- Negative Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. No followup is needed for a negative HIV test.
2550426|NCT02562092|Other|Venue Testing Group- Positive Test|Participants will perform a rapid HIV test and will be asked to answer questions about their sexual life and living situation. Participants with a positive HIV test will receive care from a psychologist and case manager for one year.
2550474|NCT02561923|Experimental|Rivaroxaban|Participants will be administered a single 20 milligram (mg) dose of rivaroxaban orally on Day 1 in Part 1.
2550476|NCT02561923|Experimental|Rivaroxaban plus tranexamic acid (TXA)|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, tranexamic acid (TXA) 1.0 gram (g) - (over 10 mins) intravenously administered on Day 4 in Part 2.
2550478|NCT02561923|Experimental|Rivaroxaban plus Kcentra|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, participants will be randomized to receive a single dose of Kcentra (a 4-factor PCC), 50 international units per kilogram (IU/kg), intravenously administered (maximum rate of 210 [international units per minute] IU/min) on Day 4 in Part 2.
2550480|NCT02561923|Experimental|Rivaroxaban plus Saline|Participants will be administered rivaroxaban (20 mg every 12 hrs) on Days 1 through 3 and a single 20 mg dose will be given on the morning of Day 4, all doses given orally. Following rivaroxaban adminsitration on Day 4, saline [Kcentra saline control or TXA saline control] on Day 4 in Part 2.
3204394|NCT00933504|Experimental|Dermacyd Silver Floral (Lactic Acid)|Lactic Acid sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
3321432|NCT02018835|Other|patients of an insufficiency organic severe surgical mitrale|
2550576|NCT02561117|Active Comparator|q8h|Metronidazole given every 8 hours
2550577|NCT02561117|Experimental|q24h|Metronidazole given once daily
2550625|NCT02561026|Experimental|FP Transfusion|patients randomized to receive frozen plasma transfusions
2550626|NCT02561026|No Intervention|no FP Transfusion|patients not receiving frozen plasma transfusions
3321433|NCT02018835|Other|insufficiency organic mitrale moderated in severe asymptomatic|
2550741|NCT02560246||Preterm Labor|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
2550742|NCT02560246||Term Labor|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
2550794|NCT02559999|Other|EEG responses|The study compares electroencephalographical responses (EEG) to painful stimuli tonic to those evoked by non-painful stimuli and with or without virtual reality
2550836|NCT02559674|Experimental|Phase Ib/II ALT-803 w/ gemcitabine and nab-paclitaxel|
2550892|NCT02559245|Experimental|Ficus carica|45 grams Ficus carica before breakfast and lunch with 1 glass of water every day respectively (total consumption: Ficus carica 90g/d)
2550894|NCT02559245|Experimental|Descurainia Sophia|30 grams Descurainia Sophia before breakfast and lunch with 1 glass of water every day respectively (total consumption: Descurainia Sophia 60g/d)
2550895|NCT02559245|No Intervention|controled|participants will follow their usual diet
2550943|NCT02558959|Experimental|Irinotecan and Capecitabine|irinotecan 180mg/m2 d1, capecitabine 1000mg/m2 bid d1-10, q2w
2550946|NCT02558959|Active Comparator|Irinotecan|irinotecan 180mg/m2 d1, q2w
2551000|NCT02558621|Experimental|Device: AQrate Robotic Assistance System|Precise positioning of surgical instruments and spinal implants during general spinal surgery.
3204395|NCT00933530|Experimental|Cohort 1 - Dose Level A (0.03g/day)|"0.03g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.03g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.03g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3321434|NCT02018835|Other|patients of an aortic bicuspidie|
3321435|NCT02018835|Other|patients of a syndrome of Marfan|
3321436|NCT02018835|Other|Healthy volunteers|
3321437|NCT02018848|Placebo Comparator|Attention Training Placebo|"Same procedure, stimulus material, frequency and duration as in experimental group.~The only difference: In the placebo group the probe randomly appears at one of the two locations on the screen so as not to train attention in any direction.~Thus, the placebo training sessions are identical to the bias assessment sessions."
2550253|NCT02563379||Dippers|"Dipping pattern is defined as daytime-nighttime BP/daytime BP reduction - based on either ABP monitoring- greater than 10% for systolic and/or diastolic BP.~Extreme dipping is marked nocturnal systolic and/or diastolic BP fall>20% of daytime systolic and/or diastolic values or night/day systolic and/or diastolic BP ratio <0.8.~Patients in this group will be dippers or extreme dippers. We aim to examine the association of this BP pattern with the development of asymptomatic episodes of paroxysmal atrial fibrillation, in hypertensive subjects."
2550254|NCT02563379||Non-dippers|"Non-dipping and rising: no reduction or increase in nocturnal systolic and/or diastolic BP or night/day systolic and/or diastolic BP ratio ≥1.~In this group we aim to examine whether an association exists between the non-dipping pattern and the development of asymptomatic episodes of paroxysmal atrial fibrillation in hypertensive subjects."
2550255|NCT02563379||Morning Hypertensives|"It is known that morning surge is the excessive systolic and/or diastolic BP elevation rising in the morning.~Patients in this group will have morning hypertension that is classified into two types:~the morning-surge type, characterized by a marked increase in blood pressure in the early morning, and the nocturnal-hypertension type, characterized by high blood pressure that persists from nighttime until early morning.~In our study we will examine whether an association between morning hypertension and asymptomatic episodes of paroxysmal atrial fibrillation exists in hypertensive subjects."
2550392|NCT02562664|Active Comparator|CC with placebo|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with placebo tablets taken twice daily continuously for three cycles.
2550393|NCT02562664|Active Comparator|CC plus Metformin|received t100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle with plus Metformin 500 mg twice daily continuously for three cycles.
2550430|NCT02562144|Experimental|Xylocaine spray|
2550435|NCT02562144|Placebo Comparator|Placebo|
2550491|NCT02561871|Experimental|Group 1|Two subsequent Intramuscular injections of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1 and Day 85, and one intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 169.
2550495|NCT02561871|Experimental|Group 2|Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 1, an intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 85 and and an intramuscular injection of placebo control consisting of the vaccine formulation buffer on Day 169.
2550497|NCT02561871|Experimental|Group 3|Three intramuscular injections of placebo control on Day 1, Day 85 and Day 169.
2550542|NCT02561494|Placebo Comparator|Control|Intravenous normal saline 2 ml is given slowly as a placebo before the anesthesia induction and after finishing anesthesia.
2550547|NCT02561494|Experimental|Nefopam|Intravenous nefopam 20 mg is given slowly before the anesthesia induction and after finishing anesthesia.
2550587|NCT02561208|Active Comparator|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps and SMS text messages.
2550589|NCT02561208|No Intervention|Usual Care Group|Women with HPV self-collected tests receive usual care.
2550629|NCT02560935|Active Comparator|Moderate Dose Hydroxyurea|Hydroxyurea at 20 mg/kg/day (range 17.5 to 26 mg/kg/day) for primary stroke prevention.
2550632|NCT02560935|Active Comparator|Low Dose Hydroxyurea|Hydroxyurea at 10 mg/kg/day (range 7 to 15 mg/kg/day) for primary stroke prevention.
2550670|NCT02560662|Experimental|Physical activity|Individual consultation with a physiotherapist in order to increase the participants existing level of physical activity by adding 30minutes of physical activity daily, preoperatively and 4 weeks postoperatively.
2550671|NCT02560662|No Intervention|Control|Participants randomized to the control group will not be advised to change their current level of physical activity.
2550722|NCT02560441|Other|chemotherapy followed by radiotherapy|Patients receive 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy followed by radiotherapy.
2550725|NCT02560441|Other|radiotherapy followed by chemotherapy|Patients receive radiotherapy followed by 3 cycles of IPGDP (ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6) chemotherapy.
2550727|NCT02560441|Other|IPGDP regimen chemotherapy|Patients receive 6 cycles of ifosfamide 1.2g/m2 iv on days 3-5; pegaspargase 2000U/m2 im on day 1; gemcitabine 800mg/m2 iv on days 3,8; cisplatin 25 mg/m2 iv on days 3-5; dexamethasone 20mg/m2 iv on days 3-6. 6 cycles, every 3 weeks one cycle.
2550795|NCT02559921|Placebo Comparator|placebo + vaccine|Subjects received placebo in combination with rabies vaccine for human use on day 0 and received vaccine only on days 3,7,14,28
2551224|NCT02557191||Group 1|Preterm infants <32 weeks gestational age
2550073|NCT02564523|Experimental|Group 2|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 57) or placebo (Day 1/Day 57) followed by a subset of participants who received Ad26.ZEBOV and MVA-BN-Filo (at selected sites) will receive Ad26.ZEBOV as third vaccination and who received placebo will receive placebo as third vaccination (at least 1 year post prime vaccination).
2550074|NCT02564523|Experimental|Group 3|Participants will receive Ad26.ZEBOV, MVA-BN-Filo (Day 1/Day 85) or placebo (Day 1/Day 85)
3204396|NCT00933530|Experimental|Cohort 2 - Dose Level B (0.1g/day)|"0.1g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.1g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.1g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3204397|NCT00933530|Experimental|Cohort 3 - Dose Level C (0.25g/day)|"0.25g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.25g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.25g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
2550501|NCT02561754|Active Comparator|Face-To-Face/CD|Delivery: Face-to-face Diet: Conventional diet
2550504|NCT02561754|Experimental|Technology delivery/CD|Delivery: Technology Diet: Conventional diet
2550505|NCT02561754|Experimental|Technology delivery/eSLD|Delivery: Technology Diet: enhanced Stop Light Diet
2550541|NCT02561429|Experimental|SPT of histamine|SPT of histamine concentration 1, 5 and 10 mg/ml
2550672|NCT02560688|Experimental|Period 1 - DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
2550674|NCT02560688|Other|Period 2 - Clopidogrel|Clopidogrel (Plavix) administered orally over 5 days (300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5)
2550675|NCT02560688|Experimental|Period 2 - DS-1040b and Clopidogrel|Concomitant administration of DS-1040b (20 mg single 12-hour intravenous infusion) and clopidogrel (single 75 mg oral dose)
2550851|NCT02559518|Experimental|anodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550854|NCT02559518|Experimental|cathodal ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550860|NCT02559518|Sham Comparator|sham ctDCS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550863|NCT02559518|Experimental|high frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550864|NCT02559518|Experimental|low frequency c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550865|NCT02559518|Sham Comparator|sham c-rTMS|Volunteers will be submitted to non-invasive cerebellar stimulation during serial reaction time task (SRTT).
2550923|NCT02559063|Experimental|Vision-based speed of processing|Vision-based speed of processing training will use the INSIGHT online program (Posit Science), which includes five games (i.e., Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All games share visual components, and the tasks become increasingly more difficult and require faster reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
2550928|NCT02559063|Active Comparator|Mental leisure activities|Mental leisure activities control activities were chosen to: 1) control for computer, online experience [and amount of time]; 2) not induce acute stress (i.e., without time management, speed component, or novel cognitive stimuli); 3) simulate participants' everyday mental activities; and 4) entertain participants to keep them from dropping out. Cross-word, Sudoku, and solitaire games will be used, which were also used in previous VSOP training study as control exercises. Participants can choose to practice any combination of games. At the end of their participation, the MLA control group will be provided with free 6-week access to the VSOP training program.
2550981|NCT02558777|Experimental|Intervention Group|Multicomponent nurse-led intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain)
2550984|NCT02558777|No Intervention|Control Group|Usual care
2551024|NCT02558439|Placebo Comparator|Placebo|Subjects will receive a single injection of placebo into the index knee following local anesthesia and adjunct joint cooling.
2551026|NCT02558439|Experimental|0.5 mg CNTX-4975|Subjects will receive a single injection of 0.5 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
2551027|NCT02558439|Experimental|1.0 mg CNTX-4975|Subjects will receive a single injection of 1.0 mg CNTX-4975 into the index knee following local anesthesia and adjunct joint cooling.
2551185|NCT02557360|Experimental|S-adenosyl-L-methionine|Patients with primary biliary cirrhosis will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
2551254|NCT02556710|Experimental|4 mL AMPION™|AMPION™, 4 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
2550077|NCT02564549|Experimental|Group 2 (mpMRI with targeted biopsy)|"Baseline systematic transrectal ultrasound-guided biopsy performed as per standard of care by urologists.~Baseline and annual mpMRI with targeted biopsy of any Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion. Patients needing image- guided targeted biopsies will undergo this procedure by interventional radiology, which is a common standard of care at HHM VAMC.~Optional transperineal template biopsy of the prostate performed at end of 2nd year (month 25-30).~Patients will be followed, as per standard of care, for any potential infections from biopsies.~Annual PSA tests performed as per routine standard of care."
2550121|NCT02564146|Active Comparator|nab-paclitaxel and gemcitabine (A)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: Continuing application of nab-paclitaxel and gemcitabine treatment cycles"
2550122|NCT02564146|Experimental|gemcitabine monotherapy and nab-paclitaxel and gemcitabine (B)|"Induction treatment: 3 cycles nab-paclitaxel and gemcitabine~Continuous treatment after randomization: alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles"
3204398|NCT00933530|Experimental|Cohort 4 - Dose Level D (0.5g/day)|"0.5g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 0.5g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 0.5g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
2550358|NCT02562690||Acute Coronary Syndrome|"Patients with acute chest pain and persistent ST-segment elevation or new left bundle branch block on the 12 lead ECG. This is termed ST-segment Elevation Myocardial Infarction (STEMI).~Patients with acute chest pain but without persistent ST-segment elevation. These patients, based on the measurement of cardiac biomarker values (troponin), will be further classified as Non-ST-segment Elevation Myocardial Infarction (NSTEMI) or unstable angina.~Where possible, all patients will have tests of thrombotic status including thrombin generation assays, TEG and GTT."
2550394|NCT02562430|Experimental|Active Treatment|12.5 % will be randomized to Welbutrin XL in phase 1 of the study.
2550395|NCT02562430|Active Comparator|Placebo Group|87.5% will be randomized to receive placebo in phase 1 of the study.
2550441|NCT02562079|Experimental|subjects SSc diagnosed|
2550447|NCT02562079|Experimental|subjects Localised sclerosis diagnosed|
2550454|NCT02562079|Experimental|subjects Sc|
2550510|NCT02561767|Experimental|MSCs group|"Allogeneic bone marrow-derived mesenchymal stem cells (10^6/kg) from third party donors is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21.Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.~The third-party MSCs have no similar HLA alleles of kidney donors, and have no HLA alleles specific to preformed anti-HLA antibodies in recipients prior to KTx."
2550512|NCT02561767|Placebo Comparator|Control group|Placebo (saline) is intravenously given at day 0 (after renal artery reperfusion), day 7, day 14 and day 21. Induction therapy: ATG or Basiliximab; Maintenance therapy: low-dose Tacrolimus + mycophenolic acid + prednisone.
2550731|NCT02560272|Experimental|Minhai-HIB|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
2550734|NCT02560272|Active Comparator|Act-HIB®|Participants at age 1 to 5 years of enrollment will receive one dose on Hib vaccine. Participants at age 6 to 11 months of enrollment will receive 2 doses on Hib vaccine at one months apart. Participants at age 2 to 5 months of enrollment will receive 3 doses on Hib vaccine at one months apart.
2550763|NCT02560064||laparotomy and small bowel length|measurement of small bowel length in laparotomies
2550804|NCT02559804||patients NB with SCI|Survival and late effects. Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression).
2550821|NCT02559557|Experimental|Supportive care (Spanish-adapted skills training)|"PHASE I (FOCUS GROUPS): Parents undergo a semi-structured interview with bilingual research assistants over 120 minutes. The content and purpose of the intervention is explained, and the focus group discussions elicit feedback on the intervention components and content of the sessions, and whether the material is culturally and linguistically appropriate. Following the focus group discussion, parents receive a copy of the educational handouts that they may choose to use with their child if they like.~PHASE II (PILOT TESTING): Parents of children age 5 to 17 years, 11 months old undergo adapted skills training in Spanish over 60 minutes (8 training sessions total) or 80 minutes (6 training sessions total). The adapted skills training sessions focus on parenting strategies and learning techniques. Sessions include homework assignments and techniques for parents to apply with their child for at least 30 minutes, 3 times a week at home."
2550885|NCT02559297|Active Comparator|Sevoflurane|In sevoflurane arm (n=20) at the beginning after successful intubation, 2 L/min nitric oxide (N2O), 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O.
2550893|NCT02559232||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fibrillation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
3170621|NCT00576550|Active Comparator|2:2|Part 2 of the study (eczema part)
2550259|NCT02563366|Experimental|MSCs group|Patients with early poor graft function receive allogeneic BM-MSCs at the dose of 1*10^6/kg every week for four consecutive doses.
2550262|NCT02563366|Placebo Comparator|Control group|Patients with early poor graft function receive placebo of MSCs, i.e. saline every week for four consecutive doses.
2550308|NCT02563054|Active Comparator|5-Fluorouracil + Cisplatin|Participants will receive 5-FU in combination with cisplatin upto disease progression.
2550309|NCT02563054|Experimental|Capecitabine + Cisplatin|Participants will receive capecitabine in combination with cisplatin upto disease progression.
2550371|NCT02562677|Experimental|ACTIVE tNS|TNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally. The study protocol will follow the rational of our previous trials with TNS.
2550401|NCT02562378|Experimental|Trastuzumab + doxorubicin|Trastuzumab and non-pegylated liposomal doxorubicin: Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
2550444|NCT02562053|Active Comparator|Fluoxetine|Women will receive daily oral fluoxetine 20 mg in addition to an oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation.
2550452|NCT02562053|Active Comparator|Combined oral contraceptives and fluoxetine|Women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily.
2550457|NCT02562053|Placebo Comparator|Placebo|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
3204399|NCT00933530|Experimental|Cohort 5 - Dose Level E (1.0g/day)|"1.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 1.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 1.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
2550660|NCT02560792|Experimental|Positive Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to positive affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to positive feelings.
2550662|NCT02560792|Experimental|Negative Affect Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise, and then read that most people indicated this level of intensity leads to negative affect. To further encourage participants to think about how the supposed typical affective response might apply to them personally, they were also asked to describe how they thought the exercise might lead to negative feelings.
2550665|NCT02560792|Experimental|Control Condition|Participants read that their exercise prescription was a healthy level of intensity for exercise - affect was not mentioned.
2550752|NCT02560454|Experimental|Cogmed®|"Cogmed® : working memory training (unifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
2550755|NCT02560454|Experimental|Presco®|"Presco® : different cognitive function are trained (multifactorial) Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling."
2550756|NCT02560454|No Intervention|Control|Control ( waiting list)
2550936|NCT02558972|Placebo Comparator|Northera-single dose|Study #1 -Does single large dose (600mg) of Northera improve upright hemodynamics and orthostatic intolerance in POTS and VVS
3170622|NCT00576563|Other|FDG PET CT|To investigate the evolution of the 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with rectal cancer during and after radiotherapy or combined radiotherapy and chemotherapy.
3170623|NCT00576589|Experimental|CE-326,597|
3170624|NCT00576589|Placebo Comparator|Placebo|
3170625|NCT00576602|Experimental|1|
3170626|NCT00576602|Active Comparator|2|
3170627|NCT00576615||1: placebo|placebo solution
3170628|NCT00576615||2: propofol|propofol
3170629|NCT00576641|Experimental|Vaccine|
3170630|NCT00576654|Experimental|Dose escalation (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days -1 to 14 (days 3-14 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3170631|NCT00576654|Experimental|Expansion portion (irinotecan hydrochloride and veliparib)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and veliparib PO BID on days 1-15 (days 2-15 of course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2550146|NCT02563938|Placebo Comparator|Saline Solution|Saline solution will be administered as a single infusion.
2550192|NCT02563691|Experimental|Stereotactic radiotherapy|Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
2550238|NCT02563509|Experimental|HIV-specific CD8 cells|Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
2550245|NCT02563509|No Intervention|Regualar therapy|Only receiving Highly active anti-retroviral therapy(HAART).
2550279|NCT02563210|Experimental|airway resistance measurement|interruption and plethysmography techniques airway resistance measurement at each routine visit
2550342|NCT02562950|Experimental|Midazolam and 500 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (250 mg b.i.d daily for 10 days) from Days 2 to 11.
2550354|NCT02562950|Experimental|Midazolam and 1000 mg GLPG1837|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12) and multiple oral doses of GLPG1837 (500 mg b.i.d daily for 11 days) from Days 2 to 12.
2550383|NCT02562456|Active Comparator|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars (rubber dam isolation + Adhesive system + composite resin Filtek z350)
2550387|NCT02562456|Experimental|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars with GIC Fuji IX
2550442|NCT02562183|Experimental|kallikrein group|Subjects receive kallikrein treatment according to real clinical practice (suggest above 14days treatment),0.15 peptide nucleic acids(PNA), once a day.
2550487|NCT02561793|Active Comparator|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
2550492|NCT02561793|Placebo Comparator|Placebo|Women will receive a placebo 12 weeks before starting IVF/ICSI
2550636|NCT02560961|Experimental|Kinesio Taping protocol - Group A|Kinesio Taping (Kinesio Tex Gold®; color: black) will be applied by an experienced, duly trained researcher. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
2550639|NCT02560961|Placebo Comparator|Placebo Taping - Group B|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The technique described by Kase [1] for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) and ending near the posterior surface of the heel.
2550663|NCT02560740|Experimental|PerOx Arm|PerOx Quench arm 4g/sachet each time by water, q6h
2550667|NCT02560740|Placebo Comparator|Comparative Arm|PerOx Quench placebo 4g/sachet each time by water, q6h
2550717|NCT02560480||groin injury (group A)|magnetic resonance imaging performed in all athletes with acute or subacute groin injury
2550720|NCT02560480||control (group B)|magnetic resonance imaging performed in selected asymptomatic control athletes
2550776|NCT02560181|Other|HDR whole gland salvage treatment|Locally recurrent prostate cancer Whole gland HDR brachytherapy administered Whole gland dose=10.5Gy x 2 fractions delivered one week apart GTV dose=13.5Gy x 2 fractions delivered one week apart
2550814|NCT02559739||Sleep deficiency/fragmentation|Patients with sleep deficiency/fragmentation
2550815|NCT02559739||No sleep deficiency/fragmentation|Patients without sleep deficiency/fragmentation
2550830|NCT02559427|Active Comparator|Immediate SPA treatment|3-week immediate SPA treatment (soon after randomization)
2550832|NCT02559427|Sham Comparator|Late SPA treatment|3-week late SPA treatment (soon after primary endpoint at 4 1/2 months visit)
2550912|NCT02559193||No treatment.|Data collection only trial design.
2550941|NCT02558946|Active Comparator|Physical Therapy Treatment Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit. The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 7-10 days postoperative, and 4-8 weeks postoperative .
2550942|NCT02558946|Active Comparator|Control Group|Written and verbal information on performing Kegel exercises (exercises that aim to strengthen pelvic floor muscles) will be provided at the pre-op clinic visit.
2550964|NCT02558660|Experimental|Double Up Food Bucks|Clinic-based educational intervention about an existing SNAP healthy food incentive program, as well as a $10 voucher to spend on produce at farmers markets
2551008|NCT02558517|No Intervention|Prednisone maintenance|Patients will be kept under Prednisone 5 milligrams/day. Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
2551009|NCT02558517|Experimental|Prednisone discontinuation|Prednisone will be stopped and remplaced by HYDROCORTISONE for one month (20 mg/day). Other treatments will be maintained (in particular HYDROXYCHLOROQUINE, METHOTEXATE etc..)
2551025|NCT02558205||CT Perfusion and PET/CT|Patients undergo both a CT liver perfusion study pre Y-90 treatment and a PET/CT of liver following Y-90 treatment. For the PET/CT no additional radioactivity is required.
2551084|NCT02557971||BOTOX®|Patients with idiopathic overactive bladder (OAB) treated with onabotulinumtoxinA (BOTOX®) injections into the bladder as standard of care in clinical practice. No intervention was administered in this study.
2551120|NCT02557568|Experimental|Hemodialysis patients (HPs)|staphylococcus aureus carriage is measured in nose
2551121|NCT02557568|Experimental|Healthcare Workers (HCWs)|staphylococcus aureus carriage is measured in nose
2551142|NCT02557412|Placebo Comparator|Conventional treatment|Hygiene and diet recommendations on sleep.
2551226|NCT02556996|Placebo Comparator|Placebo|Three doses administered orally at 2-week intervals
2550159|NCT02563782|Sham Comparator|Control group|Sham surgery and placebo immunosuppressive therapy (IMT)
2550163|NCT02563782|Active Comparator|Active Group|Sub-retinal transplantation of MA09-hRPE cells and IMT
2550220|NCT02563535|Experimental|Drug-eluting balloon|angioplasty with Litos drug-eluting balloon
2550225|NCT02563535|Active Comparator|conventional PTA|angioplasty with conventional balloon
2550296|NCT02563327|Active Comparator|Standard Therapy|"Eight weeks of daily treatment with rifampin, isoniazid, pyrazinamide, and ethambutol, followed by Eighteen weeks of daily treatment with rifampin and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifampin, 600 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
2550298|NCT02563327|Experimental|Rifapentine-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and ethambutol, followed by Nine weeks of daily treatment with rifapentine and isoniazid. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; ethambutol, < 55kg 800 mg, >= 55-75 kg 1200 mg, >75 kg 1600 mg."
2550303|NCT02563327|Experimental|Rifapentine- and Moxifloxacin-containing Regimen|"Eight weeks of daily treatment with rifapentine, isoniazid, pyrazinamide, and moxifloxacin, followed by Nine weeks of daily treatment with rifapentine, isoniazid, and moxifloxacin. All drugs are administered orally, seven days/week, directly observed by a health care worker at least five of the seven days each week. Pyridoxine (vitamin B6), 25 or 50 mg, is administered with each study dose.~Study drug doses: rifapentine 1200 mg; isoniazid, 300 mg; pyrazinamide, < 55kg 1000 mg, >= 55-75 kg 1500 mg, >75 kg 2000 mg; moxifloxacin, 400 mg."
3170632|NCT00576654|Experimental|Intermittent dose escalation (irinotecan, ABT-888)|Patients receive irinotecan hydrochloride IV over 90 minutes on days 3 and 10 and veliparib PO BID on days 1 to 4 and 8-11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3170633|NCT00576667|Experimental|Rimonabant|Rimonabant 20 mg once daily.
2551290|NCT02556580|Active Comparator|Conscious healthy volunteers|Intervention: intravenious infusion Drug: albumin 20%
2551292|NCT02556580|Experimental|Surgery under general anesthesia|Intervention: intravenious infusion Drug: albumin 20%
2551293|NCT02556580|Experimental|Post-surgical inflammation|Intervention: intravenious infusion Drug: albumin 20%
2551327|NCT02556268|Experimental|Riociguat and ATRIPLA|
2551338|NCT02556268|Experimental|Riociguat and COMPLERA|
2551340|NCT02556268|Experimental|Riociguat and STRIBILD|
2551341|NCT02556268|Experimental|Riociguat and TRIUMEQ|
2551342|NCT02556268|Experimental|Riociguat and antiretroviral protease inhibitor with TRIUMEQ|
2551398|NCT02555774|Experimental|cognitive training|Cognitive training programs 2 times a week for 3 months (totally 24 sessions) for 90 minutes per session. Lifestyle modification is educated first, then weekly phone call for lifestyle modification is done by investigators.
2551402|NCT02555774|Active Comparator|lifestyle modification|This group receives only lifestyle modification for 3 months. Lifestyle modification is educated at the first, then weekly phone call for lifestyle modification is done by investigators. The method of lifestyle modification is same with the first arm.
2551404|NCT02555774|No Intervention|No intervention|This group receives no intervention.
2551460|NCT02555384|Active Comparator|crowded drawing task|children will be asked to draw on a pattern presented under crowded viewing conditions.
2551463|NCT02555384|Placebo Comparator|uncrowded drawing task|children will be asked to draw on a pattern presented under uncrowded viewing conditions
2551506|NCT02555020|Experimental|Allocated to MN NPO group,|"Patients was administered in hospital~Randomization~Patient was allocated to MN group~Patients were NPO from mid night (MN) to Surgery"
2551511|NCT02555020|Placebo Comparator|Allocated to Placebo group|"Patients was administered in hospital~Randomization~Patient was allocated to Placebo group~Patients received 400 mL of water 12 hours before anesthesia and 400 mL 2 hours before anesthesia."
2551515|NCT02555020|Active Comparator|Allocated to Carbohydrated group|"Patients was administered in hospital~Randomization~Patient was allocated to Carbohydrated group~Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal."
2551615|NCT02554461||female players|national team players
2551618|NCT02554461||male players|national team players
2551654|NCT02554175|Experimental|the target propofol concentration|patients were allocated to 1 of 6 groups of predefined propofol target Ce for induction, namely, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5 µg.mL-1.Propofol was administered to achieve target propofol Ce.
2551687|NCT02554006|Other|good clinical practice|all patients will receive education from physician regarding management of dual antiplatelet therapy as part of the routine discharge process
2551690|NCT02554006|Experimental|bundle group|patients assigned to the bundle group will receive visits and materials as described by the protocol (counseling)
2551891|NCT02552940||Rheumatoid Arthritis participants treated with Tocilizumab SC|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
3170634|NCT00576667|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3170635|NCT00576706|Experimental|1|
3170636|NCT00576706|Active Comparator|2|
3170637|NCT00576719|Experimental|1|Participants will receive intensive cognitive behavioral therapy treatment without parent involvement
3170638|NCT00576719|Experimental|2|Participants will receive intensive cognitive behavioral therapy treatment with parent involvement
3170639|NCT00576719|Placebo Comparator|3|Waitlist control group
3170640|NCT00576745|Active Comparator|1 Vicryl Suture|Patients will have their incision closed with vicryl suture
3170641|NCT00576745|Experimental|2 Steri-Strips|Patients will have their incisions closed with 3M Surgical-Strips
3170642|NCT00576771|Experimental|1|"ALI/ARDS patients~evaluated the effect of PSV, NAVA and assisted controlled mechanical ventilation by patient through a button"
2550682|NCT02560610|Active Comparator|OC000459|Once daily dose of 50mg OC000459 tablets orally for 12/24 weeks
2550685|NCT02560610|Placebo Comparator|Placebo|Once daily dose of placebo tablets orally for 12/24 weeks
2550842|NCT02559596||Cases|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction occurring after their participation in the HSE.
2550849|NCT02559596||Controls|Adults (aged 16+) with stored serum samples collected for the Health Survey for England (HSE) between 2009 and 2013, who do not have a record of hospitalisation for stroke, transient ischaemic attack or myocardial infarction and are matched to cases on age, gender and year of participation in the HSE.
2551103|NCT02557867|Experimental|Obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
2551104|NCT02557867|Experimental|Non-obese|Body composition measurement before surgery using Dual energy X-ray absorptiometry. Dexmedetomidine infusion during surgery. Venous blood sampling for dexmedetomidine plasmatic levels during and after surgery. Liver blood flow indirect non-invasive assessment after surgery using indocyanine. Liver biopsy during surgery.
2551160|NCT02557490|Experimental|Oxaliplatin by TACE|Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
2551163|NCT02557490|No Intervention|Raltitrexed by TACE|Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
2551202|NCT02557152||Patients that were treated with the GentleWave System|
2551232|NCT02556944|Experimental|Mix and matched patients|Mix and matched patients will get phacoemulsification with multifocal intraocular lens implantation with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally.
2551261|NCT02556697|Experimental|patients with a suspicion of emphysema|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of emphysema
2551265|NCT02556697|Experimental|patients with a suspicion of scleroderma|A bronchoscopy with in vivo confocal endomicroscopy is assessed for patient with a suspicion of sclerodermia
2551336|NCT02556476||ICU patients|The actual cohort of 148 critically ill medical patients that received the treatment in the intensive care unit (ICU). The interventions include interventions that are usually performed within the ICU such as mechanical ventilation, non-invasive ventilation, neuromuscular blockade, renal replacement therapy.
2551417|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551419|NCT02555540|Active Comparator|Boostrix, Male, >/= 5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551420|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551421|NCT02555540|Active Comparator|Boostrix, Female, >/= 5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551422|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551423|NCT02555540|Placebo Comparator|Placebo, Male, >/= 5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551425|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551427|NCT02555540|Placebo Comparator|Placebo, Female, >/= 5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine at least 5 years ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551429|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D2 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551432|NCT02555540|Active Comparator|Boostrix, Male, <5 years, D3 visit|"25 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2552454|NCT02549521|Placebo Comparator|Magnesium + or Magnesium -|Placebo tablets without magnesium.
2550223|NCT02563600|Experimental|Pre-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
2550226|NCT02563600|Experimental|Post-letter telephone call|A brief 10 min telephone call to patients on waiting list prior to receipt of appointment invitation letter.
2550227|NCT02563600|No Intervention|No telephone call|No telephone call made to patient.
2550263|NCT02563314|Experimental|intervention|
2550265|NCT02563314|Other|control|
3170643|NCT00576784|Active Comparator|A|pioglitazone/glimepiride
3170644|NCT00576849|Experimental|A|Total balanced volume replacement regimen consisting of a balanced HES 130/0.42 plus a balanced crystalloid
3170645|NCT00576849|Active Comparator|B|Conventional volume replacement strategy consisting of 6% HES 130/0.4 prepared in saline solution plus Ringer's lactate
2550521|NCT02561546|Experimental|TAE plus p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
2550522|NCT02561546|Active Comparator|Trans-catheter embolization|Trans-catheter embolization (TAE) will be given once per month
2550679|NCT02560636|Experimental|Dose level 1a|Radiotherapy: 24Gy in 6f Pembrolizumab: 100mg
2550681|NCT02560636|Experimental|Dose level 1b|Radiotherapy: 24Gy in 6f Pembrolizumab: 200mg
2550684|NCT02560636|Experimental|Dose level 2a|Radiotherapy: 24Gy in 4f Pembrolizumab: 100mg
2550687|NCT02560636|Experimental|Dose level 2b|Radiotherapy: 24Gy in 4f Pembrolizumab: 200mg
2550691|NCT02560636|Experimental|Dose level 3a|Radiotherapy: 30Gy in 5f Pembrolizumab: 200mg
2551057|NCT02558088|Experimental|salmeterol|
2551115|NCT02557906|Experimental|Implant and Surgimend|Breast reconstruction surgery with an implant and an ADM (Surgimend)
2551117|NCT02557906|Active Comparator|Autologous tissue|Breast reconstruction surgery with autologous tissue
2551119|NCT02557906|Active Comparator|Implant + dermal sling/LD flap|Breast reconstruction surgery using a dermal sling or a latissimus dorsi (LD)flap
2551329|NCT02556151|Active Comparator|1 Hz|Six sessions of weekly therapy with 1 Hz magnetic stimulations of the lumbar and sacral regions.
2551333|NCT02556151|Active Comparator|5 Hz|Six sessions of weekly therapy with 5 Hz magnetic stimulations of the lumbar and sacral regions.
2551339|NCT02556151|Active Comparator|15 Hz|Six sessions of weekly therapy with 15 Hz magnetic stimulations of the lumbar and sacral regions.
3170646|NCT00576862|Experimental|1|
3170647|NCT00576875||Depressed|Older individuals with major depression
3170648|NCT00576875||Non-depressed|Older individuals without major depression
3170649|NCT00576888||Vascular Anomaly with Coagulopathy|All patients diagnosed with Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) or with a vascular anomaly with coagulopathy
3170650|NCT00576914|Active Comparator|A|vinorelbine plus cisplatin plus recombinant human endostatin
3170651|NCT00576914|No Intervention|B|vinorelbine plus cisplatin
3170652|NCT00576940|Experimental|IMEN: 1|Enteral nutrition with immunostimulating diet (IMEN group: formula supplemented with arginine, glutamine, omega-3 fatty acids)
3170653|NCT00576940|Active Comparator|SEN|postoperative enteral nutrition - standard oligopeptic diet
3170654|NCT00576979|Experimental|Treatment (radiation therapy, chemotherapy, transplant)|PREPARATIVE REGIMEN: Patients undergo IMRT using helical tomotherapy once or twice daily on days -10 to -6 or -10 to -7. Patients also receive etoposide IV on day -6 or -5 and cyclophosphamide IV on day -4 or -3. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplantation on day -1 or day 0.
3170655|NCT00576992||GI observation|Patients presenting for an upper endoscopy procedure with gastrointestinal symptoms or complaints.
3170656|NCT00577018|Active Comparator|1|
3170657|NCT00577018|Active Comparator|2|
3170658|NCT00577018|Placebo Comparator|3|
3170659|NCT00577070|Active Comparator|H1|"Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS,20 minutes each session, to the left prefrontal cortex using H1 coil, in frequency of 20 HZ, with intensity of 120 % of motor threshold. H1-coil is an extracorporeal device positioned on the patient's scalp, designed to stimulate deep prefrontal brain regions, preferentially in the left hemisphere. The effective part of the coil, which has contact with the patient's scalp, includes 14 strips of 7-12 cm length. These strips are oriented in an anterior-posterior axis.This coil stimulates neuronal fibers in anterior-posterior orientation.~During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas."
3170660|NCT00577070|Experimental|H2|Includs 20 patients.These patients will be given 4 weeks (5 days a week) of deep TMS, 20 minutes each session, to the prefrontal cortex bilateraly using H2 coil, in frequency of 0.1 HZ, with intensity of 120 % of motor threshold. H2-coil is designed to stimulate deep prefrontal brain regions bilaterally (without any preferencefor either hemisphere). The effective part of the coil, which has contact with the patient's scalp, includes 10 strips of 14-22 cm length.These strips are oriented in a right-left direction (lateral-medial axis).This coil is destined to stimulate lateral-medial neuronal fibers. During deep TMS exposure patients will listen to a clinical interview in which they describe the different expressions of their depression including their ruminations and depressive schemas.
3170661|NCT00577109|Experimental|1|
3170662|NCT00577148|Experimental|Rimonabant|Rimonabant 20 mg once daily.
3170663|NCT00577148|Placebo Comparator|Placebo|Placebo (for Rimonabant) once daily.
3170664|NCT00577161|Active Comparator|Comparator|fludarabine and rituximab
3170665|NCT00577161|Experimental|Experimental|fludarabine, rituximab, pixantrone
3204400|NCT00933530|Experimental|Cohort 6 - Dose Level F (2.0g/day)|"2.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 2.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 2.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period. A comprehensive safety assessment will be conducted one week prior to the initiation of an escalated dose in the subsequent cohort."
3204401|NCT00933530|Experimental|Cohort 7 - Dose Level G (3.0g/day)|"3.0g SRT2104 dosing will take place at approximately the same time every morning after fasting for at least 10 hours. Subjects will be required to stay overnight at the study center for all dosing days. Six subjects are assigned to this cohort. On Day1 of the single dosing period, one subject will be dosed with 3.0g SRT2014 while one is dosed with placebo on Day1. If no safety issues arise from this dosing, then on Day2, three subjects will be dosed with 3.0g SRT2104 while one is dosed with placebo. Subjects within the cohort will remain on a fixed dose for all dosing days.~This cohort of subjects will be dosed sequentially approximately two weeks apart from the single dose period, and return to the clinic approximately one week after their single dose administration to receive 7 consecutive days of daily dosing for the multiple dose period."
2550402|NCT02562638|No Intervention|Group 1 Fasting|Group 1(control group) Fasting for both solids and fluids for up to 4 hours pre-procedure
2550406|NCT02562638|Experimental|Group 2 Non-fasting|Group 2 (intervention arm) Clear fluids up to 1 hour before the procedure and fasting for solids up to 4 hours pre-procedure
2550439|NCT02562118|Experimental|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by Letrozole 2.5mg daily + lenvatinib x 12 weeks (for Part A) or continuous till progression or intolerability (Part B)
2550494|NCT02561858|Experimental|acid load test|
2550524|NCT02561624|Experimental|Intervention|Use of behaviour change communication via text messages to pregnant women receiving an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
2550525|NCT02561624|No Intervention|Control|Control group receives no behaviour change communication via text message, but receives an electronic voucher for long lasting insecticide treated nets redemption through antenatal clinics.
2550590|NCT02561377|Experimental|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
2550592|NCT02561377|Experimental|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
2550595|NCT02561377|No Intervention|standard care|standard care complied with the daily lifestyle.
2550678|NCT02560623|Active Comparator|Cases - Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic brushings of the esophagus.
2550680|NCT02560623|Active Comparator|Controls - No Barrett's Esophagus|Subjects will have sponge capsule procedure, blood draw, and clinically indicated endoscopy with endoscopic biopsies of the esophagus.
2550740|NCT02560337|Experimental|Cabazitaxel|"25 mg/m2 administered as a one hour intravenous infusion on day 1 of a 3-week cycle.~Treatment continues until progression or unacceptable toxicity."
3204402|NCT00933556|Experimental|probiotic|subjects will be given a powder formulation of a probiotic VSL#3 to be taken once a day, at a dose of 6 gms
3204403|NCT00933556|Placebo Comparator|sugar pill|placebo identical to the active product will be given
3204404|NCT00933569|Experimental|Dermacyd Silver Floral (Lactic Acid)|Aplication of Dermacyd Silver Floral (Lactic Acid) during 21 consecutive days
2550907|NCT02559167|Active Comparator|Cannabidiol|Participants will receive CBD 800 mg for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
2550909|NCT02559167|Placebo Comparator|Placebo|Participants will receive placebo for 92 consecutive days starting on Day 2 of a 10-day inpatient detoxification period followed by 12 weeks of outpatient follow-up
2551002|NCT02558634|Experimental|DBS-on|"Ventral intermediate Nucleus (VIM) Thalamic DBS on~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
2551004|NCT02558634|Sham Comparator|DBS-off (sham-stimulation)|"Ventral intermediate Nucleus (VIM) Thalamic DBS off~DBS system includes:~Implantable Pulse Generator (IPG)~DBS Lead~DBS Lead Extension Kit"
2551129|NCT02557997||ART-naive (primary infection)|ART-naive (primary infection) HIV infected adults
2551132|NCT02557997||ART-naïve (chronic infection)|ART-naïve (chronic infection) HIV infected adults
2551135|NCT02557997||ART-controlled|ART-controlled HIV infected adults
2551138|NCT02557997||ART-failing|ART-failing HIV infected adults
2551186|NCT02557269|Active Comparator|Group HPMC|Hydroxyl-propyl-methyl-cellulose (HPMC) powder added immediately after other intranasal treatment options
2551188|NCT02557269|Placebo Comparator|Group Placebo|Lactose powder (placebo) added immediately after other intranasal treatment options
2551192|NCT02557269|Other|Group Immunotherapy|Immunotherapy group with grass allergens sublingually (Staloral #688) and rescue medication
2551260|NCT02556827||H, Rosacea patients|"Rosacea patients who were between the ages of 18-70, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
2551268|NCT02556814|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
2550341|NCT02562807|Placebo Comparator|Treatment D|TAS-303 Placebo single-dose and then TAS-303 9mg single-dose.
2550429|NCT02562326|Experimental|BioChaperone insulin lispro|
2550432|NCT02562326|Active Comparator|Humalog®|
3204405|NCT00933595|Experimental|Smoking Cessation|The overall smoking cessation rate for the intervention is 18.8 at 3 months, 13.1 at 6 months and 10.0 at 12 months.
2550556|NCT02561442|Active Comparator|IV ceftriaxone (0.5hr) 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered IV over 30 minutes via infusion pump (Open Label)
2550559|NCT02561442|Experimental|subcutaneous ceftriaxone, (2hr), 1 gm|ceftriaxone for injection, (total dose = 1.0 g) administered subcutaneous over 2 hours (Blinded).
2550563|NCT02561442|Experimental|subcutaneous ceftriaxone, (2 hr), 2 gm|ceftriaxone for injection, (total dose = 2.0 g) administered subcutaneous over 2 hours (Blinded).
2550580|NCT02561143|Experimental|Intervention group|Patients in the intervention group will be given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
2550584|NCT02561143|Placebo Comparator|Control group|Patients in the control group will be given whole wheat flour (100 g) daily along with nutritional counseling and physical activity counseling for six months.
2550648|NCT02560805|Experimental|Veterans|Subjects with post-traumatic stress disorder (PTSD) will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine. For the second phase, they will be randomized to either losartan or atenolol.
2550650|NCT02560805|Experimental|Control|Healthy controls will be evaluated using microneurography, static handgrip exercise, cold pressor test, combat virtual reality video clip, and baroreflex sensitivity using sodium nitroprusside and phenylephrine.
2550736|NCT02560402||Patients with sepsis or trauma|Adult patients, admitted to the intensive or medium care unit with sepsis or trauma
2550764|NCT02560103||Single group|No treatment
2550805|NCT02559791|Experimental|Study participants|All study participants will receive 2 monthly doses of placebo followed by 4 monthly doses of IV reslizumab 3mg/kg
2550855|NCT02559466|Experimental|Patients stimulated with a H-TMS (deep)|20 sessions navigated with Deep Transcranial Magnetic Stimulation
2550859|NCT02559466|Other|Patients stimulated with a conventional TMS|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
2550915|NCT02559180|Experimental|Single Arm|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
2550944|NCT02558881||Virtual colonoscopy|"With virtual colonoscopy, the patient does not need to be hospitalized for examination, which is usually done without hospitalization. A bowel preparation is necessary. It may vary from site to site, but it generally comprises polyethylene glycol or sodium phosphate. The residual stools are marked by ingestion of a radiopaque product to differentiate colic lesions. But no contrast agent is injected intravenously. The patient should be supine and a rectal probe is set up to inject either air or CO2. The vesting period does not exceed thirty seconds apnea, and overall completion time of the examination (patient table) is about 10 minutes."
2550945|NCT02558881||Colon capsule|The colon capsule comprises two cameras located at both ends. Image acquisition is set between four to thirty-five images per second. It begins immediately after ingestion of the capsule which allows recording of esophageal and gastric images. She paused for 2 hours (to save batteries) while crossing the small intestine. It is reactivated in the terminal ileum. The films analysis time is approximately 1 hour, and the capsule remains on average 3 hours in the colon.
2550991|NCT02558608|Experimental|WR AND DIPL|patients undergo wedge resection and dissection the inferior pulmonary ligament by thoracoscopic surgery or video assisted thoracoscopic surgery
2550994|NCT02558608|Active Comparator|WR|patients undergo wedge resection by thoracoscopic surgery or video assisted thoracoscopic surgery without dissection the inferior pulmonary ligament
2551028|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Right Side|JUVÉDERM® VOLIFT® with lidocaine injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
2551032|NCT02558283|Active Comparator|Restylane® - Right Side|Restylane® injected into the right nasolabial fold on Day 1, with optional touch-up injections into the right nasolabial fold on Month 1.
2551042|NCT02558283|Experimental|JUVÉDERM® VOLIFT® with Lidocaine - Left Side|JUVÉDERM® VOLIFT® with lidocaine injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
2551043|NCT02558283|Active Comparator|Restylane® - Left Side|Restylane® injected into the left nasolabial fold on Day 1, with optional touch-up injections into the left nasolabial fold on Month 1.
2551101|NCT02557802|Experimental|Group A|Nasal spray at day 0, intramuscular injection at day 28
2551102|NCT02557802|Experimental|Group B|Intramuscular injection at day 0, nasal spray at day 28
2551165|NCT02557503|Experimental|Oxaliplatin by HAIC after TACE|To investigate the therapy effect and security of oxaliplatin on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
2551170|NCT02557503|No Intervention|Fluorouracil by HAIC after TACE|To investigate the therapy effect and security of fluorouracil on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer
2551216|NCT02557165||COPD patients|Patients with mild to moderate COPD having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery
2551219|NCT02557165||Patients with normal lung function|Patients with normal lung function having a scheduled lung surgery. Vastus lateralis and diaphragm muscle biopsies performed during surgery.
2551252|NCT02556853|Experimental|Ultrasound|Determination of correct placement of the double lumen tube by lung ultrasound.
2551257|NCT02556853|Active Comparator|Clinical|Determination of correct placement of the double lumen tube by clinical examination.
2551295|NCT02556528|Experimental|Health Coaching|
2551317|NCT02556294|Experimental|Self-acceptance behavioral intervention|The intervention will consist of individual and 4 group counseling sessions and 6 individual counseling sessions. The individual sessions are focused on specific individualized risk reduction plans, whereas the group sessions are focused on increasing self-acceptance and reducing HIV risk. Additionally, participants in this arm will receive HIV and STI counseling and testing.
2550344|NCT02562937|No Intervention|Control|text messages unrelated to sedentary behaviour.
2550390|NCT02562625|Experimental|Pembrolizumab Alone|If the patient is randomised to the Pembrolizumab Arm Only then they will receive 200mg of pembrolizumab every 3 weeks.
2550391|NCT02562625|Experimental|Pembrolizumab plus Radiotherapy|If The patient is randomised to this arm they will receive 200mg of pembrolizumab every 3 weeks in combination with a radiotherapy dosage of 24Gy in 3 fractions to be given over 3 consecutive days (only).
2550431|NCT02562170|Active Comparator|TiLoop Bra|immediate breast reconstruction with an implant and TiLoop Bra
2550436|NCT02562170|Active Comparator|Protexa|immediate breast reconstruction with an implant and Protexa
3170666|NCT00577174||1. Controls|Healthy children ages 8 to 18 years
3170667|NCT00577174||2. Obese childrens|Obese children, ages 8 to 18 years
3170668|NCT00577200|No Intervention|Control|Control group subjects are not undergoing any surgical procedures and will not be randomized to any anesthetic drug group.
3170669|NCT00577200|Experimental|Midazolam + Sufentanil + Propofol|"Midazolam 0.03 mg/kg + Sufentanil 0.1 µg/kg + Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.~For subjects who are chronic pain patients undergoing minor surgical procedures."
3170670|NCT00577200|Experimental|Midazolam and Sufenatnil|"Midazolam 1-5 mg in holding area + Sufentanil 5-10 mcg.~For subjects who are chronic pain patients undergoing minor surgical procedures."
3170671|NCT00577226||1 Shilla Technique|The patients whose data is observed are those who have undergone the shilla surgical technique.
3170672|NCT00577252||1|Adolescents with CF.
3170673|NCT00577278|Experimental|Treatment (chemo, monoclonal antibody therapy, transplant)|REDUCED-INTENSITY CONDITIONING: Patients receive rituximab IV followed by indium In-111 ibritumomab tiuxetan IV over 10 minutes on day -21 and rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day -14. Patients also receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. STEM CELL TRANSPLANTATION: Patients undergo APBSCT on day 0. GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO and sirolimus PO beginning on day -3 and continuing for up to 6 months with taper.
3170674|NCT00577304|Other|2|Placebo - Topical AmphiMatrix
3170675|NCT00577304|Active Comparator|1|Topical AmphiMatrix with Nitroglycerin
2550664|NCT02560675||120 healthy subjects|"One hundred and twenty healthy subjects (range 20-79; 20 subjects per age decade, 10 M and 10 F) will participate in the first phase of the study aimed to collect normative data from healthy population.~Study design Phase I - Normative data collection for the inhibitory and excitatory pain modulation responses, a study on healthy subjects (no blood tests)"
2550668|NCT02560675||750 subjects wuith acute whiplash-injury|"Seven hundred and fifty acute whiplash-injury based mild TBI will participate in this study.~Phase II - Multi-modal assessment of acute mild TBI whiplash patients and follow-up"
2550737|NCT02560506|Experimental|Elastic assisted treadmill walking|Participants will participate in treadmill training with a low cost pulley system device made of rubber bands (Theraband(R)), which will assist therapists in advancing limbs while gait training.
2550757|NCT02560077|Placebo Comparator|placebo|The placebo and cashew apple fruit juice had the same color and smell
2550758|NCT02560077|Active Comparator|cashew apple juice 120 mg/day|The subjects who were assigned as the low dose treatment group received cashew apple fruit juice extract at dose of 120 mg/day
2550759|NCT02560077|Active Comparator|cashew apple juice 240 mg/day|The subjects who were assigned as the high dose treatment group received cashew apple fruit juice extract at dose of 240 mg/day
2550810|NCT02559778|Active Comparator|Standard Immunotherapy without DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin. At the end of immunotherapy, DFMO will be given to all subjects BID for 730 days.
2550812|NCT02559778|Active Comparator|Standard Immunotherapy with DFMO|One of the following drugs will be chosen for each subject based on molecular guided results: ceritinib, dasatinib, sorafenib or vorinostat. This will be followed standard immunotherapy with Dinutuximab/GM-CSF/IL-2 and isotretinoin PLUS 1000mg/m2 BID of DFMO. At the end of immunotherapy, all subjects will go on to receive DFMO BID for 730 days.
2550919|NCT02559128||HF+T2D+|40 patients with chronic HF and type 2 diabetes or prediabetes without previous pharmacological treatment
2550920|NCT02559128||HF+T2D-|20 subjects with HF without T2D or prediabetes
2550926|NCT02559128||HF-T2D+|20 subjects with T2D or prediabetes alone
2550932|NCT02559128||HF-T2D-|20 healthy control volunteers
2551356|NCT02556034||Disease evaluation|Rheumatoid arthritis evaluations.
2551408|NCT02555748|Active Comparator|Pazopanib|"The daily dose of pazopanib will be the standard dose i.e. 800 mg once a day (2 tablets of 400 mg in one oral administration per day) administered each day, continuously, during the treatment phase (complete cycle will be defined as a 6-week period).~During the first stage of the study (Part I), adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage of the study (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
2551895|NCT02552849||Overall study|Specific treatment, dose, and treatment duration will be decided by the investigator independently of the participation of a patient in the study.
3170676|NCT00577330|Experimental|Myalgesin|Subjects receive Myalgesin twice daily
3170677|NCT00577330|Active Comparator|Acetaminophen|Subjects receive acetaminophen 1000 mg three times a day
3170678|NCT00577369|Active Comparator|1|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
3170679|NCT00577421|Experimental|1|5 mg/day risedronate
3170680|NCT00577447|Active Comparator|1|DHA supplemented group
3170681|NCT00577447|Placebo Comparator|2|Placebo group
3170682|NCT00577499||Only group|adult cystic fibrosis patients who are not at goal body mass index and have started lubiprostone therapy within one month of study enrollment
3170683|NCT00577525||1|Case : Patients with steroid sensitive nephrotic syndrome
3170684|NCT00577525||2|Controls (matched for age and sexe with the first group)
3204406|NCT00933621|Experimental|Autologous Bone Marrow infusion|Percutaneous intracoronary autologous bone marrow infusion
3204407|NCT00933634|Experimental|electrical cardioversion|Patients were sedated with propofol and external cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula). Patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
3204408|NCT00933634|Active Comparator|propafenone|Propafenone (2 mg/kg bolus) was administered iv to obtain pharmacologic sinus rhythm conversion.
2550398|NCT02562365|Experimental|A: three steps chemotherapy|Cyclophosphamide 400mg（250mg/m2）+Etoposide 100mg (70mg/m2)d1-d3 iv 4w/6cycles , followed by Carboplatin (AUC=5)+Cyclophosphamide 600mg(400mg/m2)d1-d2 iv 8w/6cycles.
2550403|NCT02562365|No Intervention|B: Follow-up|No interevention
2550428|NCT02562105||Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
2550490|NCT02561949|Experimental|YRI + Employment Program|Immediately following enrollment participants will complete the YRI intervention, followed by an income generating activity program.
2550493|NCT02561949|Experimental|Employment Program|Immediately following enrollment participants will complete an income generating activity program.
2550523|NCT02561559||Lung metastasis from soft-tissue sarcoma|Lung metastases from soft-tissue sarcoma
3204409|NCT00933647|Experimental|Yerba Mate Tea|Subjects will drink 1000ml/day of yerba mate tea for 8 weeks.
3204410|NCT00933647|Active Comparator|Green Tea|Subjects will drink 1000ml/day of green tea for 8 weeks.
3204411|NCT00933647|Placebo Comparator|Apple Tea|Subjects will drink 1000ml/day of apple tea for 8 weeks.
3204412|NCT00933660|Active Comparator|Control-1|ERC-training by instructor
3204413|NCT00933660|No Intervention|Control-2|No intervention
2550735|NCT02560467|Experimental|Patients with HCM|This is a prospective, non-blinded single center study. Subjects with known HCM with variant will be recruited. MCE at rest and during vasodilator stress will be performed. Full echocardiography including for diastolic function and regional strain imaging will also be performed. Patient history and questionnaires will be used for evaluation of symptoms and arrhythmias.
2550818|NCT02559830|Experimental|transduced CD34+ hematopoietic stem cell|Transplantation of autologous CD34+ hematopoietic stem cells transduced with ARSA/ABCD1 encoding lentiviral vector. Dosage: 2x10^6/Kg （Minimum）to 20x10^6/Kg （Maximum） transduced CD34+ cells at bedside for infusion
2550970|NCT02558712|Other|Face to face exam|Standard of clinical care, 8 point eye exam
2551035|NCT02558270|Active Comparator|patients dapa|Patients will be administered Dapagliflozin 10mg
2551041|NCT02558270|Placebo Comparator|patients placebo|Patients will be administered a placebo
2551044|NCT02558270|Active Comparator|controls dapa|controls will be administered Dapagliflozin 10mg
2551049|NCT02558270|Placebo Comparator|controls placebo|controls will be administered a placebo
2551092|NCT02557828|Active Comparator|palpation|participants who are randomized to have radial arterial cannulation via palpation technique
2551097|NCT02557828|Active Comparator|ultrasound|participants who are randomized to have radial arterial cannulation via a new ultrasound technique
2551148|NCT02557620|Experimental|semaglutide OD + placebo semaglutide OW|
2551150|NCT02557620|Placebo Comparator|placebo semaglutide OW + placebo semaglutide OD|
2551151|NCT02557620|Experimental|semaglutide OW + placebo semaglutide OD|
2551247|NCT02556879|Other|Liver retransplantation|"Donor specific antibodies :Additional samples for Donor specific at each visit~Serum bank : Additional samples for serum bank at each visit if possible~DNA banq : Additional sample for DNA banq at inclusion visit if possible~Liver biopsy :Liver biopsy at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)~Liver ultrasounds and Fibroscan : Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (dependind the centers : procedure performed in routine or interventional procedure)"
3204414|NCT00933660|Experimental|Experimental-1|Web-based training only
3204415|NCT00933660|Experimental|Experimental-2|Web-based training with a personal training manikin
3204416|NCT00933673|Experimental|L-DICE|
3204417|NCT00933699|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Treatment duration: 21 consecutive days
3204418|NCT00933712|Experimental|Dermacyd Silver Floral (Lactic Acid)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
2551546|NCT02554747|Experimental|Navigated laser|Aflibercept, Navilas®
2551550|NCT02554747|Active Comparator|Conventional laser|Aflibercept, Pascal
2551597|NCT02554552|Experimental|YY1201 2ml|YY1201 2ml
2551598|NCT02554552|Experimental|YY1201 3ml|YY1201 3ml
2551599|NCT02554552|Placebo Comparator|Placebo 2ml|Phosphate buffered saline 2ml
2551601|NCT02554552|Placebo Comparator|Placebo 3ml|Phosphate buffered saline 3ml
2551644|NCT02554240|Experimental|DA-5202 High dose|- DA-5202 20mg
2551645|NCT02554240|Experimental|DA-5202 Low dose|- DA-5202 10mg
2551650|NCT02554240|Active Comparator|Na Hyaluronate 20mg|Na Hyaluronate 20mg
3204419|NCT00933725|Experimental|TCM intervention|Particle of compound Chinese herbs and TCM emotion treatment and tablet placebo of Tibolone
3204420|NCT00933725|Active Comparator|Western intervention|Tibolone and supportive psychotherapy and Particle placebo of compound Chinese herbs
3204421|NCT00933751||Patients before emergent major abdominal surgery|
3204422|NCT00933777|Experimental|Therapy with everolimus and sorafenib|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
3204423|NCT00933790|Active Comparator|2EHRZ3/4HR3|Regimen 3. Intermittent - 2EHRZ3/4HR3 (E 1200mg, H 600 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg given thrice weekly)
2551905|NCT02553044|Experimental|500 000IU Vitamin D3|500 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
3204424|NCT00933790|Experimental|2EHRZ7/4HR7|Regimen 1. Daily - 2EHRZ7/4HR7 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily)
2550374|NCT02562417|Placebo Comparator|No IV dexamethasone|Patients will receive an equivalent volume of normal saline.
2550376|NCT02562417|Experimental|IV dexamethasone|Patients will receive 0.1 mg/kg of dexamethasone.
2550461|NCT02562261||Healthy|
2550462|NCT02562261||Uncomplicated Infection|Showing signs of infection as defined by International Sepsis Definitions Conference 2003
2550463|NCT02562261||Sepsis|"Sepsis is defined as systemic inflammatory response syndrome (i.e. presence of two or more of the following~Temperature of <36 °C (96.8 °F) or >38 °C (100.4 °F)~Heart rate >90bpm~Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)~WBC <4x109/L (<4000/mm³), >12x109/L (>12,000/mm³), or 10% bands in response to an infectious process.."
2550464|NCT02562261||Severe Sepsis/Septic Shock|Severe sepsis is defined as sepsis with sepsis-induced organ dysfunction or tissue hypoperfusion [manifesting as hypotension, elevated lactate (serum lactate 2 times the upper limit of normal), or decreased urine output (urine output < 0.5 ml/kg/hr)] Septic shock is defined as severe sepsis plus persistently low blood pressure (< 5th percentile for age or systolic blood pressure < 2 standard deviations below normal for age) following the administration of intravenous fluids.
3204425|NCT00933790|Experimental|2EHRZ7/4HR3|Regimen 2. Part Daily - 2EHRZ7/4HR3 (E 800 mg ,H 300 mg, R 450/600 mg depending on Weight <60, 600 mg for 60 kg or more, Z 1500 mg daily in the intensive phase followed by H-600 mg ,R-450/600 mg in the continuation phase thrice weekly)
2550627|NCT02561013|Experimental|3M™ Coban™ Custom Fit Compression System|3M™ Coban™ Custom Fit Compression System will be custom-fitted at first subject visit and will thereafter be applied and removed daily by the study subject. It will be worn throughout the day by the study subject and removed before bedtime. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers.
2550628|NCT02561013|Active Comparator|Profore|Profore multi-layer compression bandaging system will be applied at the first subject visit and will be worn by the study subject continuously for 7 days, at which time it will be replaced with a new system, or, in the case of a product or non-product reason, replaced before 7 days. It will provide therapeutic compression for edema control to help in the healing of venous leg ulcers
2550716|NCT02560519|Active Comparator|Ringers acetate solution|Ringer-Acetat Baxter Viaflo® (Baxter Finland, Finland): Ringer-Acetat is iso-oncotic solution.Pharmacodynamic and pharmacokinetic properties: The osmotic effect is approximately the same as that of blood plasma. Electrolytes are given to receive or to keep normal osmotic conditions in the extracellular as well as the intracellular compartment. Acetate is oxidized into bicarbonate, mainly in the muscles and peripheral tissues and gives a weak alkalizing effect. Qualitative and quantitative list of composition: 1000 ml of Ringer-Acetat Baxter Viaflo contains 5.86 g sodium chloride, 0.30 g potassium chloride dihydrate, 0.29 g, 0.20 g magnesium chloride hexahydrate, 4.08 g sodium acetate trihydrate. List of excipients: Water for injections, Hydrochloric acid.
2550718|NCT02560519|Experimental|Albumin solution|Albuman® 200g/L (Sanquin, the Netherlands) is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.The solution contains 100 mmol/l of sodium (2.3 g/L). Pharmacodynamic properties: Albumin stabilises circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Pharmacokinetic properties. Under normal conditions, the average half-life of albumin is about 19 days. Albuman® 40g/L is a solution containing 40 g/l (4%) of total protein of which at least 95% is human albumin. The solution contains 140 mmol/l of sodium (3.2 g/L).
2550760|NCT02560142||All Participants|Healthy participants will undergo behavioral assessment and fMRI.
2550816|NCT02559869||Amyotrophic Lateral Sclerosis (ALS)|Subjects will be diagnosed with possible, probable, probable-lab supported, or definite ALS.
2550817|NCT02559869||Healthy Controls|Subjects with no known neurological disorder.
2550857|NCT02559388|Active Comparator|montelukast|montelukast 10 milligram, daily for 30 days
2550861|NCT02559388|Placebo Comparator|placebo|Placebo one tablet for 30 days
3204426|NCT00933816|Experimental|Sorafenib with Low-dose FP|
3204427|NCT00933829|Placebo Comparator|Non-absorbable arm|uses non-absorbable suture such as Prolene to repair lacerations
3204428|NCT00933829|Active Comparator|Absorbable Suture Arm|uses absorbable sutures to repair lacerations
3204429|NCT00933842|Experimental|Dermacyd PH_DESILSTY_FL (Lactic Acid)|Dermacyd PH_DESILSTY_FL (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample
3204430|NCT00933855||communication training workshop|"The patient intervention is a 1 hour communication workshop entitled: Getting the Most out of your Doctor's Visit. The workshops will be offered to both patients and family members, but data will be collected only for patients. The workshops will be held on location at Queens Cancer Center."
2551168|NCT02557386|Experimental|A Levobupivacaine 5 mL|Adductor canal nerve block with levobupivacaine 0.25% 5 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551173|NCT02557386|Experimental|B Levobupivacaine 10 mL|Adductor canal nerve block with levobupivacaine 0.25% 10 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551176|NCT02557386|Experimental|C Levobupivacaine 15 mL|Adductor canal nerve block with levobupivacaine 0.25% 15 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551177|NCT02557386|Experimental|D Levobupivacaine 20 mL|Adductor canal nerve block with levobupivacaine 0.25% 20 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551178|NCT02557386|Experimental|E Levobupivacaine 25 mL|Adductor canal nerve block with levobupivacaine 0.25% 25 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551179|NCT02557386|Experimental|F Levobupivacaine 30 mL|Adductor canal nerve block with levobupivacaine 0.25% 30 mL and perineural catheter placement, an elastomeric pump with bupivacaine 0.1% at a rate of 5 ml/hr will be placed after surgery for continuous nerve block.
2551225|NCT02556996|Experimental|Killed ETEC/rCTB vaccine|Three doses administered orally at 2-week intervals
2550375|NCT02562391|Active Comparator|PVI+Box lesions|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.
2550378|NCT02562391|Experimental|PVI+Box lesions+LAA cutting|Patients were treated with video-assisted thoracoscopy under general anesthesia, according to a previously described protocol. In brief, PVI was performed from the epicardial side with a bipolar radiofrequency ablation clamp. At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. In addition to PVI, the bilateral epicardial ganglia were found by high-frequency stimulation and ablated, as confirmed by the absence of a vagal response after ablation. Finally additional lines were made to create a posterior box lesion. Sensing and pacing maneuvers verified isolation of the posterior box.The left atrial appendage was removed by stapling and then cutting.
2550434|NCT02562209|Experimental|PACER diet|High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER Diet) to be followed for 8 weeks.
2550438|NCT02562209|Active Comparator|Standard weight reducing diet|This group was prescribed Standard weight reducing diet to be followed for 8 weeks.
2550488|NCT02561884|Experimental|AB|Olostar Tab. followed by Olmetec and Crestor
2550496|NCT02561884|Experimental|BA|Olmetec and Crestor followed by Olostar Tab.
2550537|NCT02561598||Malignant Hyperthermia|Samples from persons who have a malignant hyperthermia diagnosis.
2550544|NCT02561598||Controls|Children who participated in pharmacogenetic research and had exposure to malignant hyperthermia triggering agents.
3204431|NCT00933868|Experimental|Magnesium infusion in patients breathing 100% oxygen|Patients will be given six infusions over three weeks. Each infusion will last between 4 and 10 minutes. They will then return to clinic in 1,2 and 3 months for the same tests (but no infusions will be given).
2550834|NCT02559661||Medical students|Students with limited knowledge of the anatomy and pathology of the eye.
2550835|NCT02559661||Ophthalmological trainees|The trainees have never done eye surgery but have a better understanding of the eyes pathology and anatomy than the medical students.
2550837|NCT02559661||Vitreoretinal surgeons|The vitreoretinal surgeons knows the eyes anatomy and pathology well and have training and skills in vitreoretinal surgery.
2551010|NCT02558647|Experimental|CBT for insomnia (CBT-I)|Internet-based cognitive-behavioral therapy for insomnia (CBT-I) comprises a fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention
2551012|NCT02558647|Active Comparator|Psychoeducation about Sleep (PE)|The PE intervention gives participants access to a website with information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
2551046|NCT02558166||Patients with shock|"Critically ill patients admitted to the intensive care unit (ICU)~with shock due sepsis/SIRS, cardiac failure or hemorrhage~age > 18 years,~noradrenalin support~< 24 hours of ICU admission~Signed informed consent"
2551047|NCT02558166||Patients without shock|"Critically ill patients admitted to the intensive care unit (ICU)~without shock, without vasopressor support and without fluid dependent circulation~age > 18 years~< 24 hours of ICU admission~Signed informed consent"
2551083|NCT02557984|Placebo Comparator|Placebo|Placebo Pill
2551087|NCT02557984|Experimental|Amisulpride|400 mg Amisulpride (Solian®)
2551090|NCT02557984|Experimental|Naltrexone|50 mg Naltrexone (Naltrexin®)
2551144|NCT02557529|Experimental|Progressive Resistance Training|12 weeks progressive resistance training (PRT) during and after concomitant chemoradiotherapy. Also optional/voluntary physical activity performed on their own is registered, as well as diet diary.
2551147|NCT02557529|Active Comparator|Control|Control arm. Optional/voluntary physical activity performed on their own is registered, as well as diet diary.
2551214|NCT02557204|Active Comparator|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
2551215|NCT02557204|Experimental|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
2551217|NCT02557204|Experimental|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
2551220|NCT02557204|Experimental|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
2551313|NCT02556463|Experimental|Escalation MEDI9197|MEDI9197
2551316|NCT02556463|Experimental|Escalation MEDI9197 with durvalumab|MEDI9197 in combination with durvalumab
2551318|NCT02556463|Experimental|Escalation MEDI9197 durvalumab radiation|MEDI9197 in combination with durvalumab and palliative radiation
2551323|NCT02556463|Experimental|MEDI9197 with palliative radiation|MEDI9197 in combination with palliative radiation
2551906|NCT02553044|No Intervention|Concurrent Control|Control group to receive no intervention.
3170685|NCT00577538||1|
3204432|NCT00933868|Placebo Comparator|Placebo infusion|The patients will receive six placebo infusions after which they will return to clinic at one, two and three months. At the conclusion of the trial those patients who received placebo may elect to receive the active treatment in another (open label) trial that will begin shortly after this one concludes.
3204433|NCT00933881||Gestational Diabetes Mellitus (GDM)|
2550449|NCT02562027|Experimental|High-risk NSCLC participants|"Baseline assessment of demographics and comorbidities~Comorbidity scoring by interview and chart review: the Adult Comorbidity Evaluation 27, Charlson Comorbidity Index, Global Initiative for Chronic Obstructive Lung Disease, Cumulative Illness Rating Scale, and COMorbidities in Chronic Obstructive Lung Disease.~Katz Activities of Daily Living: assessment of grip strength, walk speed, and activities of daily living~HRQOL questionnaires will also be administered prior to treatment and then repeated throughout follow-up: the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, EORTC QLQ-LC13, Modified Medical Research Council, EQ-5D, CES-D, and Medical Outcomes Study Social Support Survey.~All questionnaire responses will be obtained with the use of a computer assisted interview system which can be used to collect data in person or through telephone interviews"
2550513|NCT02561689|Experimental|Fissure sealant material 1|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
2550514|NCT02561689|Experimental|Fissure sealant material 2|Fissure sealing with Delton FS+ Fissure sealing withClinpro Sealant Fissure sealing withGrandio Seal Fissure sealing withControl Seal Fissure sealing withUltraSeal XT+ UltraSeal XT hydro
2550557|NCT02561416|Experimental|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) The MBSR consists in eight 2-h group sessions and an all-day mindfulness retreat, and offers intensive and structured training in mindfulness meditation to help patients to relate to their physical and psychological conditions in more accepting and nonjudgmental ways. Participants will be encouraged to engage in home mindfulness practices. Sessions will be lead by 4 MBSR accredited instructors.
2550560|NCT02561416|Active Comparator|Psycho-educational Program|Psycho-educational Program (FibroQol) It consists of eight 2-h group sessions including information about FMS (4 sessions) based on a consensus document of the Health Department of Catalonia + autogenic relaxation (4 sessions).
2550562|NCT02561416|Other|Treatment As Usual|Treatment As Usual.
2550798|NCT02560168|Experimental|Coronary artery disease|Patients scheduled for computed tomographic coronary angiography (CTA)
2550846|NCT02559635|No Intervention|No bowel stimulation|Patients undergoing loop ileostomy closures without having had bowel stimulation beforehand
2550852|NCT02559635|Experimental|Bowel stimulation|Patients undergoing loop ileostomy closures having undergone bowel stimulation beforehand
2550896|NCT02559258|Experimental|Cohort 1|
2550900|NCT02559258|Experimental|Cohort 2|
2550901|NCT02559258|Experimental|Cohort 3|
2550903|NCT02559258|Experimental|Cohort 4|
2550908|NCT02559258|Experimental|Cohort 5|
2551066|NCT02558049|Experimental|Decision aid|Patients will receive the patient decision aid during a 15 minute consultation with a clinical pharmacist.
2551098|NCT02557763|Experimental|Severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
2551099|NCT02557763|Experimental|non severe PF arthritis|Oxford unicompartmental knee arthroplasty is partial knee replacement. Oxford unicompartmental knee arthroplasty is applied for medial compartmental of knee.
2551233|NCT02556983||Suspected appendicitis|Patients who are suspected as having acute appendicitis
2551258|NCT02556671||Moderate CKD Patients Undergoing PCI|
2551259|NCT02556671||Normal renal function Patients Undergoing PCI|
2551310|NCT02556502|Experimental|FDG PET positive or negative|
2551368|NCT02556060|Experimental|lamotrigine|lamotrigine extended release up to 200 mg/day,
2551369|NCT02556060|Placebo Comparator|Placebo|Identical Placebo
2551456|NCT02555397|Experimental|Single|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 adenovirus at a dose of 1 x 10e10 to 1 x 10e12 viral particles.
2551504|NCT02555124|Experimental|Cohort A|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 or Placebo on Day 1, fasted condition.
2551508|NCT02555124|Experimental|Cohort B|Participants will receive single oral dose of 20 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
2551512|NCT02555124|Experimental|Cohort C|Participants will receive single oral dose of 40 mg of JNJ-42847922 or Placebo on Day 1, fasted condition.
2551571|NCT02554669|No Intervention|Control|No physical activity
2551576|NCT02554669|Experimental|Postabsorptive physical activity|Physical activity performed before breakfast
2551578|NCT02554669|Experimental|Postprandial physical activity|Physical activity performed in the postprandial period after breakfast
2551634|NCT02554448|Experimental|Circulating Tumor Cells|Use ISET system to test the number of CTCs from patients before and during treatment.
2551665|NCT02554058|Experimental|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
2551669|NCT02553850||Ibandronate|Patients receiving ibandronate will be evaluated for bone turnover markers for 12 months. Ibandronate is not an investigational medicinal product (IMP) in this study.
3170686|NCT00577538||2|
3170687|NCT00577603|Active Comparator|2|mesh reinforcement at stoma
3170688|NCT00577603|Active Comparator|Arm 1|standard stoma
3170689|NCT00577616|Other|1|Endovascular repair
3170690|NCT00577616|Other|2|conventional surgery repair
3170691|NCT00577668|Experimental|VDT and Melphalan|To find out if three drugs, bortezomib, thalidomide, and dexamethasone in addition to high doses of melphalan (M-VTD) and autologous transplant can be given safely and effectively to subjects who have failed previous regimens with transplant(s).
3170692|NCT00577681||1|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who have no history of CVD
3170693|NCT00577681||2|Participants from the SMART study who were randomly assigned to episodic or continuous ART and who experienced a major CVD event during the study, analyzed along with 2 matched controls
3170694|NCT00577681||3|Participants from the SMART study who have no previous use of ART or have taken ART but not done so within 6 months prior to study entry; allows for a comparison of immediate ART versus deferred ART
3170695|NCT00577694|Other|single arm study|1
3170696|NCT00577733||obese|obese
3170697|NCT00577733||healthy volunteers|healthy volunteers
3170698|NCT00577746||surgery|Those subjects who went to surgery for treatment for their lung cancer.
2550503|NCT02561780|No Intervention|Teaching As Usual (Control)|Schools randomized to this arm of the study received the unadulterated Healthy Living course, taught as usual.
2550540|NCT02561507||American College of Surgeons members|Survey participants
2550594|NCT02561260||autoimmune encephalitis|
2550596|NCT02561260||unknowm encephalitis|
2550599|NCT02561260||other encephalopathy|
3204434|NCT00933907|Experimental|Dermacyd PH_DESILSTY_FR (Lactic Acid)|Dermacyd PH_DESILSTY_FR (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
3204435|NCT00933920|Active Comparator|Fed Group|
2550751|NCT02560207|Active Comparator|Intermittent cefotaxime|Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days
2550754|NCT02560207|Experimental|Continuous cefotaxime|After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .
3170699|NCT00577746||no surgery|The subjects who did not go to surgery for treatment of their lung cancer.
3170700|NCT00577759|Experimental|Active Intervention|Direct referral to community organizations, with support for practices to do so. These include the North Carolina Tobacco Quitline, public health department dietitians, and the YMCA.
2550906|NCT02559284|Experimental|A - Experimental|Treatment Arm: 100 patients using Respimer® NetiFlow® solution as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
2550910|NCT02559284|Active Comparator|B - Comparator|Control Arm: 100 patients using saline solution (0.9% NaCl) as standard treatment for healing of nasal surgery wounds following an endoscopic ethmoidectomy as a postoperative care after ethmoid sinus surgery
2551105|NCT02557737|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
2551107|NCT02557737|Experimental|Electric stimulation|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Electric stimulation
2551109|NCT02557737|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
2551128|NCT02557464|Experimental|Alzheimer's disease group|24 patients with an Alzheimer's disease or related disorders
2551130|NCT02557464|Active Comparator|control group|24 age matched controls participants
2551198|NCT02557295||Remsima™|Patients who are taking Remsima™ for the treatment
2551199|NCT02557295||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
2551201|NCT02557295||Biologic naive patients|Biologic naive patients (in Korea only)
2551311|NCT02556281|Experimental|Patient with colorectal cancer|Blood sampling is done for patient with colorectal cancer
2551371|NCT02556073|Active Comparator|Usual care|"Usual care means that intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed acts as asthma controller and patients will be scheduled to revisit clinics."
2551372|NCT02556073|Experimental|Usual care+Smartphone action|Intervention by fluticasone/salmeterol 125/25 2 puffs bid plus salbutamol as needed and Smartphone action, which provides the real-time health information of surroudings and actively remind the patients to use controller.
2551624|NCT02554253|Active Comparator|ketamine|Ketamine induction
2551627|NCT02554253|Active Comparator|Propofol|Propofol induction
2551668|NCT02554071|Experimental|Pharmacist - Smoking Cessation Support'|Active Comparator Arm Receive smoking assessment Initial Smoking Cessation Counselling Smoking Cessation Prescription/Non-Prescription Product as required Follow-up Counselling
2551723|NCT02553824|Experimental|Phentermine/Topiramate-First + Placebo|Patients randomly assigned to this condition will receive the study medication first, have a 2 week washout, and then crossover to receive the control medication/placebo
2551726|NCT02553824|Placebo Comparator|Placebo-First + Phentermine/Topiramate|Patients randomly assigned to this condition will receive the control medication (placebo) first followed by a 2 week washout, and then receive the study medication.
3170701|NCT00577759|Experimental|Passive Intervention|Provision of information about community organizations to patients as above.
3170702|NCT00577759|Placebo Comparator|Usual Care|Usual care
3170703|NCT00577785||cystectomy group|Subjects undergoing planned cystectomy who agree to provide bladder tissue from removed bladder post cystectomy and/or cystoscopic biopsy tissue prior to cystectomy
2551992|NCT02552069||Tritanium® cup|
2552062|NCT02551783|Experimental|Urethroplasty with buccal mucosa graft|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the dorsal wall of the urethra.
2552234|NCT02550483|Placebo Comparator|Placebo Beverage|Participants will receive placebo beverage daily as part of controlled diet (base diet + placebo beverage).
3170704|NCT00577798|No Intervention|Observational|Only had observational arm
3170705|NCT00577811||1|Patients from 6 different Special Need Plans
3170706|NCT00577811||2|
3170707|NCT00577837|Active Comparator|1|5 mg risedronate, once daily for 6 months
3170708|NCT00577837|Experimental|2|100 mg risedronate, once a month for 6 months
3170709|NCT00577837|Experimental|3|150 mg risedronate, once a month for 6 months
3170710|NCT00577837|Experimental|4|200 mg risedronate, once a month for 6 months
3170711|NCT00577850|Experimental|1|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks
3170712|NCT00577850|Active Comparator|2|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 70 mg of alendronate once a week for 52 weeks
3170713|NCT00577876|Experimental|1|Day of Surgery:Patient is admitted through the Preoperative Surgical Center (PSC). If a large APA is identified, then subject will continue on study Dissect APA (without any changes from what is routinely done) with a penile injection of Trimix. Once the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
3170714|NCT00577902||Observational|This is an observational study
3204436|NCT00933920|Active Comparator|Fasted group|
3204437|NCT00933946|Experimental|Dermacyd Silver Frutal (Lactic Acid)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative. Physiologic solution and mineral oil will be also used as a control sample.
2550623|NCT02561039|Experimental|Ibandronate IV Infusion|Participants will receive ibandronate, 6 mg via IV infusion, every 3 to 4 weeks for 4 months.
2550624|NCT02561039|Experimental|Ibandronate PO Tablet|Participants will receive ibandronate, 50 mg PO daily, for 4 months.
3204438|NCT00933959|Experimental|Mind-Body Bridging Program|"Subjects will undergo two approximately 1.5 hr training sessions using MBBP spaced one week apart at the VASLCHCS. Each training session will comprise a number of objectives:~Session 1:~The patient will discover the underlying cause of the insomnia.~The patient will learn how to use easy to apply tools to quieten the mind to sleep soundly.~Session 2:~The patient will learn how to reduce daytime stress.~The patient will experience a greater sense of self.~To be maximally effective, the participant should master these objectives and practice MBBP on a daily basis. Bridging and all the other MBBP techniques can be implemented at any time throughout the day and right up to the onset of sleep."
2550746|NCT02560259|Active Comparator|Physiotherapy Group|Physiotherapy
2550748|NCT02560259|Placebo Comparator|Conservative group|Conservative treatment
2550797|NCT02559960||Breviscapine Powder-Injection|Breviscapine Powder-Injection will be given to the patients, and the investigators will record all the information including ADR, application of Breviscapine Powder-Injection and the combined medications, etc.
2550822|NCT02559609|Active Comparator|job activity contracting|Standard services plus job activity contracting and alcohol monitoring
2550823|NCT02559609|Experimental|reinforcement for negative alcohol samples|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings
2550824|NCT02559609|Experimental|reinforcement for completing activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for completing job-related activities
2550825|NCT02559609|Experimental|reinforcement for negative alcohol samples & activities|Standard services plus job activity contracting and alcohol monitoring plus reinforcement for negative breath alcohol recordings and for completing job-related activities
2550872|NCT02559336|No Intervention|Control|Usual care: Oncology team refers patients to palliative care team if deemed appropriate
2550874|NCT02559336|Experimental|Intervention|Integrated oncology care and palliative care
2550921|NCT02559102|Experimental|Dex Group|Intravenous dexmedetomidine sedation prior to single shot caudal anaesthesia and maintenance infusion of dexmedetomidine during bilateral inguinal hernia surgery.
2550929|NCT02559102|Active Comparator|GA Group|General sevoflurane anaesthesia with endotracheal intubation and single shot caudal anaesthesia for inguinal hernia surgery. This is currently the standard anaesthetic technique for bilateral inguinal hernia surgery in neonates and infants in KKH.
2550979|NCT02558699|Active Comparator|conventional group|Group operating the atrial fibrillation by physician's personal experience, not by virtual simulation.
2550980|NCT02558699|Experimental|3D atrial computer model|Group choosing choose the best effective rotor mapping by simulating 3D atrial computer model which consider patinet's heart size and shape.
2551060|NCT02558101|Active Comparator|Control invitation materials|Invitation materials and strategy mimicking those of existing UK screening programmes for other cancer types
2551065|NCT02558101|Experimental|Intervention invitation materials|A targeted, stepped and low information burden invitation strategy and materials, specifically designed to improve uptake by reducing barriers to participation among smokers from socioeconomically deprived backgrounds.
2551187|NCT02557334|Experimental|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
2551189|NCT02557334|Experimental|High Dose Strawberry Powder|40 g freeze dried strawberry powder
2551193|NCT02557334|Placebo Comparator|Placebo Powder|40 g color and taste matched placebo powder
2551244|NCT02556970|Experimental|Single-port surgery|"After induction of anaesthesia and lung isolation, a single intercostal incision will be placed laterally. This will usually be anterior to the border of the latissimus dorsi muscle, and in the 4th-7th space as appropriate to the planned surgery.~A soft tissue wound protector can be used to protect the wound edges, but rigid intercostal retraction is not permitted. All instruments will be placed via this incision."
2551246|NCT02556970|Active Comparator|Multiple port surgery|Patients in this arm will have 3 separate incisions placed to site the camera and other instruments. This will involve three separate incisions.
2551308|NCT02556450|Experimental|Spironolacton Group|Spironolacton Sandoz given 25mg daily oral use
2551309|NCT02556450|No Intervention|Control group|Only background treatment
2551352|NCT02556099|Experimental|Hydroxyurea Treatment|Hydroxyurea will be administered once daily by mouth. Participants will be monitored monthly to maximum tolerated dose and quarterly thereafter with periodic clinical evaluations, laboratory tests, and transcranial doppler examinations every 6 months.
2551378|NCT02555800|Experimental|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
2551379|NCT02555800|Experimental|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
2551381|NCT02555800|Placebo Comparator|Saline|Patients will receive 3 intralesional injections of 3.5 mL of saline solution every 3 to 6 weeks in a submucosal plane after surgical debulking.
2551510|NCT02555046|No Intervention|General Anaesthesia|EVAR-treatment is preformed with the patient in General Anaesthesia
2551513|NCT02555046|Experimental|Local Anaesthesia|EVAR-treatment is preformed with the patient in Local Anesthesia
2550551|NCT02561611|Experimental|Intervention Group|"Combined Intervention (Walk More and Pedal Desk; WMPD)~Participants in the WMPD condition will engage in both step-counting (Walk More, WM) and pedal desk (PD) intervention components."
3204439|NCT00933959|Active Comparator|Sleep Hygiene|Participants in the sleep hygiene arm will receive a 1 hr class directing them to the importance of following a list of up to 15 points (tips) for getting to sleep. These points include: limiting alcohol and caffeine intake before bed, using the bed only for sleeping, and having regular bedtimes. Once the instructor has gone over this list and has described in detail each of the 15 points, the class will have an opportunity to ask questions. The participant will be encouraged to learn and practice the objectives of the sleep hygiene class on a daily basis.
3204440|NCT00933972|Experimental|1 (normal)|
3204441|NCT00933972|Experimental|2 (mild)|
3204442|NCT00933972|Experimental|3 (moderate)|
3204443|NCT00933972|Experimental|4 (severe)|
3204444|NCT00933985|Experimental|Treatment (obatoclax, vincristine, doxorubicin, dexrazoxane)|"STRATUM 1 (dose-escalation): Patients receive obatoclax mesylate IV over 3 hours on days 1 and 8 and vincristine sulfate IV, doxorubicin hydrochloride IV, and dexrazoxane hydrochloride IV on day 8 of course 1 (28 days). Drugs are administered on day 1 of subsequent courses and repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity.~STRATUM 2: Patients receive obatoclax mesylate (at starting dose in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1.~STRATUM 3: Patients receive obatoclax mesylate (at the MTD determined in stratum 1), vincristine sulfate, doxorubicin hydrochloride, and dexrazoxane hydrochloride as in stratum 1."
3204445|NCT00933998|Experimental|Metanx|Metanx bid for 2 weeks then daily. Compare to non treated patient population
3204446|NCT00934011|Experimental|Group 1 - C-reactive protein (CRP) guided ab therapy|Intervention on antibiotic therapy will be based on circulating CRP levels
3204447|NCT00934011|Active Comparator|Group 2 - procalcitonin (PCT) guided ab therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
3204448|NCT00934037|Other|Combined CT Angiography and Myocardial Perfusion|Single Arm study. All patients underwent combined CT Angiography and Myocardial Perfusion.
3204449|NCT00934063||A|
3204450|NCT00934063||B|
3204451|NCT00934076|Experimental|AT-101 plus Erlotinib|"Subjects will begin study treatment at 150 mg of erlotinib taken once daily in a continuous regimen expressed in 3 week cycles.~Subjects will begin treatment with oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
3204452|NCT00934154|Experimental|Thalidomide|MPT
3204453|NCT00934154|Active Comparator|Control|MP
3204454|NCT00934167|Experimental|Test|Hipolabor
3204455|NCT00934167|Active Comparator|Comparator|5.000 USP/mL - APP
2551396|NCT02555735||Metastatic Pancreatic Cancer|Participants with metastatic pancreatic cancer treated with physician-choice standard of care chemotherapy.
3204456|NCT00934193|Active Comparator|Gabapentin|
2551500|NCT02554968||Study participants|Study participants will complete study related documents including a demographics questionnaire and the shoulder-related patient reported outcome measures.
3204457|NCT00934193|Placebo Comparator|Placebo|
3204458|NCT00934206|Experimental|Training|One month of endurance training (running / walking at 60 % heart rate reserve for 45 min 4 times per week)
3204459|NCT00934219|Active Comparator|High dose Lovaza|Lovaza 4 g twice a day, if not effective then 4 g 3 times a day
3204460|NCT00934219|Active Comparator|Standard Dose|2 g twice a day
3204461|NCT00934232|Experimental|Busulfan|Busulfex given to patients who are either ≥65 years or have renal insufficiency
2551739|NCT02553694|Experimental|Enhanced education and Enhanced follow up|Subjects will watch a short video and will be contacted by an MD by phone
2551741|NCT02553694|Active Comparator|Usual education and Usual follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and will be contacted by a sleep center staff member by phone
2551742|NCT02553694|Experimental|Enhanced education and Usual follow up|Subjects will watch a short video immediately prior to the initiation of the in-laboratory polysomnogram and will be contacted by sleep center non-MD staff member by phone
2551743|NCT02553694|Experimental|Usual education with Enhanced follow up|Standard education by American Academy of Sleep Medicine (AASM)- created educational pamphlets and contacted by an MD by phone
2551766|NCT02553226|Active Comparator|Continued group|Recieve routine treatment with oxytocin according to the danish national guidelines.
2551770|NCT02553226|Placebo Comparator|discontinued group (placebo)|The routine treatment with oxytocin will be discontinued and replaced with isotonic saline, when the active phase of labour is established.
2551880|NCT02552875|Active Comparator|Tetanic Stimulation|50 Hz tetanic stimulation for 5 seconds before TOF-twitch stabilization at the one arm
2551883|NCT02552875|Active Comparator|Staircase Stimulation|TOF-twitch stabilisation without 50 Hz tetanic stimulation at the contralateral arm
2551941|NCT02552537|Active Comparator|Omeprazole|patients will take Omeprazole 40mg, in capsules, once a day, during five days before walnut challenge
2551944|NCT02552537|Sham Comparator|Placebo|patients will take Mannitol, in capsules, once a day, during five days before walnut challenge
2551998|NCT02552017|Active Comparator|Endocuff Vision-assisted Colonoscopy|Participants in this arm undergo Endocuff Vision-assisted colonoscopy
2552005|NCT02552017|No Intervention|Standard Colonoscopy|Participants in this arm undergo standard colonoscopy
2552075|NCT02551601||Healthy volunteers|to measure the subfoveal choroidal thickness in healthy volunteers
2552123|NCT02551380|Experimental|Treated|treatment with Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
2552126|NCT02551380|Placebo Comparator|control|treatment with one capsule of placebo twice a day during 12 weeks
2552179|NCT02550964||HCQ/CQ|Patients who treated with HCQ(Hydroxychloroquine) or CQ(Chloroquine) for autoimmune diseases such as Rheumatoid arthritis(RA), systemic lupus erythematosus(SLE) will be recruited, and get the composite examination for toxic maculopathy.
2552217|NCT02550574|Experimental|Wound closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
3204462|NCT00934245|Active Comparator|Inactivated Polio Vaccine (IPV)|Inactivated trivalent poliovirus vaccine (IPV) age Dose # doses/year 1 # doses year 2 and 3 6 mo -8y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
3204463|NCT00934245|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated split virion trivalent influenza vaccine (TIV) age Dose # doses year 1 # doses year 2 and 3 6-35 mo 0.25 ml 2 1 3-8 y 0.5 ml 2 1 9-10 y 0.5 ml 1 1
3204464|NCT00934245|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
2550630|NCT02560974|Experimental|Capecitabine + Oxaliplatin|Patients will receive oral capecitabine (1000 mg/m^2 BID on Days 1 to 15 ) plus IV oxaliplatin (130 mg/m^2 on Day 1) during each 3-week cycle for up to 8 cycles (6 months).
2550633|NCT02560974|No Intervention|Observation|Participants will not receive any treatment but will be seen regularly by a physician.
3204465|NCT00934271||Fractionated stereotactic radiotherapy|patients with active acromegaly
3204466|NCT00934284|Active Comparator|Injection only|Participants receive a therapeutic selective nerve root block and advice to return to normal activity as tolerated.
2550799|NCT02559908|Experimental|Treatment Group_VYC-25L|VYC-25L injection into the chin and/or jaw areas on Day 1, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable
2550800|NCT02559908|Other|Control Group_No treatment then VYC-25L|No treatment for 3 months followed by VYC-25L injection into the chin and/or jaw areas, volume determined by the investigator (up to 4.0 mLs) and repeat treatment if applicable.
3204467|NCT00934284|Experimental|Injection plus physical therapy|Participants are referred to physical therapy within one week of receiving a therapeutic selective nerve root block. Physical therapy consists of end-range movements in a directional preference and/or mechanical traction to reduce radicular symptoms.
3204468|NCT00934297||Pilot group|Real-time US imaging with simultaneous display of dynamically corresponding MR images (from a previous MRI screening) will be used to re-locate the lesion previously reported as occult under a second-look ultrasound screening.
3204469|NCT00934310||Ambulatory Surgical Patients 1|"The nature of the operating room time out for ambulatory surgical patients will be examined before implementation of the World Health Organization's Surgical Safety Checklist."
3204470|NCT00934310||Ambulatory Surgical Patients 2|"The nature of the operating room time out for ambulatory surgical patients will be examined after implementation of the World Health Organization's Surgical Safety Checklist.Ambulatory surgical patients"
2551023|NCT02558387|Experimental|Nintedanib arm|Nintedanib has never been applied to salivary gland cancer. Nintedanib was given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
2551073|NCT02558036|Active Comparator|C-Mac D-Blade Neutral Position|C-Mac D-Blade videolaryngoscope with patients head and neck in neutral position.
2551074|NCT02558036|Active Comparator|C-Mac D-Blade Sniffing Position|C-Mac D-Blade videolaryngoscope with patients head and neck in sniffing position.
2551075|NCT02558036|Active Comparator|King Vision Neutral Position|King Vision videolaryngoscope with patients head and neck in neutral position.
2551076|NCT02558036|Active Comparator|King Vision Sniffing Position|King Vision videolaryngoscope with patients head and neck in sniffing position.
3204471|NCT00934323|Experimental|TR sequential group|Amaryl M SR 1/500 mg in period 1 and Amaryl M SR 2/500 mg in period 2
2551278|NCT02556619|No Intervention|Standard Therapy|Patients will undergo standard medical care for Hepatocellular Carcinoma diagnosis.Patients however will not be denied early palliative care if requested.
2551281|NCT02556619|Experimental|Early Palliative Care/Symptom Control|"Patients will undergo palliative care services at time of Hepatocellular Carcinoma diagnosis.~Palliative care and symptom control services are adapted from the National Consensus Project for Quality Palliative Care.~Early referral, patients meeting inclusion criteria will be enrolled and referred to palliative care within 3 weeks of the index consultation with Medical-Oncology, Surgical-Oncology or Gastroenterology.~Intervention will be:~Establish palliative care goals~Symptom Assessment and Control~End-of-Life Care"
2551302|NCT02556346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2551303|NCT02556346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2551305|NCT02556346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2551306|NCT02556346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days (M-W-F X 2 weeks), followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2551307|NCT02556346|Experimental|MT-3724 Phase 1b|MT-3724 IV for 6 doses over 12 days for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
3204472|NCT00934323|Active Comparator|RT sequential group|Amaryl M SR 2/500 mg in period 1 and Amaryl M SR 1/500 mg in period 2
2551384|NCT02555839||Pomalidomide and Dexamethasone|Pomalidomide 4mg capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (>75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity
3204473|NCT00934336|Experimental|preprandial injection|pre-prandial injection of an ultra-fast-acting analog during 3 months, then post-prandial injection of an ultra-fast-acting analog during 3 other months.
3204474|NCT00934336|Experimental|post-prandial injection|post-prandial injection of an ultra-fast-acting analog during 3 months then pre-prandial injection of an ultra-fast-acting analog during 3 other months.
3204475|NCT00934349||Patient|Native to the Comoro Archipelago (Grande Comore, Mayotte, Anjouan, Mohéli) fulfilling the clinical definition of the dry beriberi.
3204476|NCT00934349||Control|Native to the Comoro Archipelago, living in the same household as the patient, sharing the same meals. Free from beriberi and with normal neurological examination.
3204477|NCT00934388|Experimental|Mesh placed in pre peritoneal plane|
3204478|NCT00934388|Active Comparator|No mesh placed|
3204479|NCT00934414|Experimental|Smokers|
2550585|NCT02561312||RMPET|For rapid manual partial exchange transfusion, participants with a weight >50kg, 500 ml of whole blood is removed from the participant via a single lumen central venous line, followed by infusion of 500 ml of saline. A 30 second wait time is utilized for equilibration to occur. A second 500 ml aliquot is removed, and then two units of packed red blood cells (PRBC) are infused. (This is customized for a patient with large red blood cell mass). For participants <50 kg, the individual exchange aliquots are adjusted to 10 ml/kg or normal saline and PRBC.
2550588|NCT02561312||Simple Transfusion|For simple transfusion, the volume of packed red blood cells (PRBC) to be transfused in the participant is 10-15 cc/kg. No normal saline exchange is required. All blood is transfused through a single lumen central venous line.
2550673|NCT02560649|Experimental|A:PEG+NUC (HBsAg<200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus nucleoside analogue(NUC):~HBsAg<200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
2550676|NCT02560649|Active Comparator|B:PEG+NUC(HBsAg>200IU/ml at week 24)|"Peginterferon alfa-2a 180μg /wk plus+nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
2550677|NCT02560649|Active Comparator|C:NUC(HBsAg>200IU/ml at week 24)|"nucleoside analogue(NUC):~HBsAg>200IU/ml at week 24 (Following treatment with Peginterferon alfa-2a plus nucleoside analogue(NUC) for 24 weeks)"
2550713|NCT02560285||Development / 2000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
2550714|NCT02560285||Validation / 1000 participants|"Age >18 years;~Patients undergoing cardiac surgery procedures (elective, urgent or emergency) for CABG; heart valve surgery; CABG + heart valve surgery; ascending aorta surgery + heart valve surgery or CABG, who have mortality risk with STS score>5 or EuroSCORE II>5."
2550750|NCT02560194|Active Comparator|Flexible Sigmoidoscopy|People randomized to this arm are offered flexible sigmoidoscopy in addition to FOBT at the age of 60.
2550753|NCT02560194|Placebo Comparator|FOBT only|People in this are offered fecal occult blood testing only.
2550871|NCT02559843|Experimental|pomegranate juice|200 ml pomegranate juice + lifestyle modification
2550873|NCT02559843|Active Comparator|control|lifestyle modification including dietary recommendations
2550924|NCT02559089||anti-NMDA receptor encephalitis|
2550930|NCT02559089||other autoimmune encephlitis|
2550933|NCT02559089||other encephalopathy|
2550950|NCT02558842|Experimental|Education Strategy|Educational Strategy and Oversight Distance
2550952|NCT02558842|No Intervention|Routine|Routine hospital assistance
2550975|NCT02558582|Experimental|Immediate Rehabilitation|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
2550976|NCT02558582|Experimental|Immediate Rehabilitation with oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
2550977|NCT02558582|Experimental|Delayed Rehabilitation|Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
2550982|NCT02558582|Experimental|Delayed Rehabilitation with oxygen|"Waiting group that participates in the rehabilitation program after 3 months. The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
2551020|NCT02558413|Active Comparator|BTA-C585 oral capsules|25 or 100 mg oral capsules; Single ascending doses (SAD) from 50 mg to 800 mg
2551021|NCT02558413|Placebo Comparator|BTA-C585 matching placebo|BTA-C585 Matching placebo capsules; single doses
2551058|NCT02558062|Experimental|BAC ONE administration|All participants in this clinical study will be dosed on one occasion with BAC ONE. The final dosage will be 80 µg (± 25%).
2551134|NCT02557854|Experimental|Doxil + MR-HIFU Hyperthermia|Liposomal doxorubicin (Doxil) 50mg IV every 4 weeks followed by Magnetic Resonance High Intensity Focused Ultrasound hyperthermia (MR-HIFU) with Philips Sonalleve System to 42C for 30 minutes every 4 weeks
2551191|NCT02557282||Predicate software|Olea Sphere PACS with CT Perfusion Module
2551195|NCT02557282||Investigational software|Vue PACS 12.1.5 Computed Tomography (CT) Perfusion
3204480|NCT00934414|Experimental|Non-Smokers|
3204481|NCT00934427|Active Comparator|Vascana|
2551347|NCT02556125||Cervical SCI|Participants with acute, traumatic cervical spinal cord injuries (C-SCIs), classified according to the American Spinal Injury Association (ASIA) Impairment Scale (AIS) as A-C (complete SCI (A); motor complete SCI (B); motor incomplete with minimal motor function (C)), affecting C1-C6 spinal cord segments, and who have been scheduled to undergo implantation of a diaphragm pacer, or who have recently received (in past 5-days) implantation of intramuscular diaphragm pacing electrodes due to severe respiratory impairments and dependence on mechanical ventilation.
3204482|NCT00934427|Placebo Comparator|Vehicle|
3204483|NCT00934453|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) capsules containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
3204484|NCT00934453|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis.
3204485|NCT00934466|Experimental|1|MK2637 120 mg
2551786|NCT02553382|Experimental|Dietary, Herbal|
2551793|NCT02553382|Placebo Comparator|Positive Control|
3204486|NCT00934466|Experimental|2|MK2637 50 mg
3204487|NCT00934466|Placebo Comparator|3|Placebo
3204488|NCT00934466|Active Comparator|4|Dextromethorphan 220 mg
3204489|NCT00934466|Active Comparator|5|Dextromethorphan 110 mg
3204490|NCT00934479|No Intervention|Healthy Subjects|Healthy subjects completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing. Otherwise, the healthy subjects received no intervention.
3204491|NCT00934479|Experimental|Constipated Subjects|"Subjects with constipation included those with chronic constipation (CC) and those with constipation predominant irritable bowel syndrome (C-IBS). They completed a baseline 1-week diary of stool and defecatory characteristics, fasting breath for hydrogen and methane and a stool sample for pyrosequencing.~Following baseline test and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.~Following the 4-weeks treatment with lubiprostone, they completed another stool diary, fasting breath test, and stool sample for pyrosequencing."
3204492|NCT00934492|Active Comparator|Cotrimoxazole dispersible tablet|Children between 2-6 months will receive single dispersible tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible tablet daily for six months.
3204493|NCT00934492|Placebo Comparator|Placebo dispersible tablet|Children between 2-6 months will receive single dispersible Placebo tablet of 120mg,daily while children over 6 months to 5 years will receive 240 mg dispersible Placebo tablet daily for six months.
3204494|NCT00934518|Experimental|Radiation and Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
3204495|NCT00934531|Experimental|Donepezil|participants with MCI receiving donepezil
3204496|NCT00934531|Placebo Comparator|Placebo|Participants with MCI receiving placebo
3204497|NCT00934557|Experimental|Good prognosis/mismatched donor/BM|
3204498|NCT00934557|Experimental|Good prognosis/mismatched donor/PB|
3204499|NCT00934557|Experimental|Poor prognosis/matched donor/BM|
3204500|NCT00934557|Experimental|Poor prognosis/matched donor/PB|
3204501|NCT00934557|Experimental|Poor prognosis/mismatched donor/BM|
2551045|NCT02558361|Other|Open label, single arm|"Baseline visit:assess disease activity,synovial tissue biopsy of the knee with active synovitis [target joint] and punch skin biopsy of a target psoriatic plaque. Perform a similar punch skin biopsy on adjacent normal skin. Start apremilast (standard dosing). Perform venipuncture: blood samples will be obtained for routine studies, quantitative RT-PCR & ex vivo cytokine production assays. UA/pregnancy test.~Month 1: assess disease active , monitor for AE's; repeat punch skin biopsy of target psoriatic plaque. Blood samples will be obtained for RT-PCR and ex vivo cytokine production assays.~Month 3: same as month 1; repeat synovial tissue biopsy from target knee joint and punch skin biopsy on target psoriatic plaque. Blood samples for RT-PCR ex vivo cytokine production assays and routine studies."
2551080|NCT02557919|Experimental|Motivational Interviewing Training|Staff at the intervention sites were trained in basic tobacco control and motivational interviewing. Two booster trainings were held over 6 months.
2551085|NCT02557919|Other|Usual Best Practice|Staff at the usual best practice sites received basic tobacco control training.
2551152|NCT02557672|Active Comparator|Fresh frozen plasma|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
2551154|NCT02557672|Experimental|Prothrombin complex concentrate|After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target ACT within 10% of baseline value. After protamine administration the ACT, CBC, PT/ INR, APTT, and fibrinogen, will be collected via preexisting arterial access. If ACT >10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT >16.6 sec/ INR >1.6 sec will receive Prothrombin complex concentrate (Human) 15 units/kg.
3204502|NCT00934557|Experimental|Poor prognosis/mismatched donor/PB|
3204503|NCT00934557|Experimental|Good prognosis/matched donor/BM|
2551248|NCT02556866|Experimental|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
2551249|NCT02556866|Placebo Comparator|placebo|Prednisone treatment plus placebo administered by slow intravenous infusion at day 1 (D1), D8, D15 and D22.
2551370|NCT02556086|Experimental|Daclatasvir + Sofosbuvir|Daclatasvir 30, 60, 90 mg tablet (dose is dependent on cART regimen) + Sofosbuvir 400 mg tablet oral dosing once daily for 8 weeks
2551424|NCT02555514||Knee Osteoarthritis|The study population consists of 100 enrolled patients with different stages of knee OA and varus malalignment >4° with respect to the mechanical loading axis of the lower extremity. A minimum of 40 patients are to be included per year, so that the study period will be planned from January 1st, 2015 to June 30th, 2017. Preliminary results will be reviewed by the end of every year and intermediate reports will be generated by the sub-study-groups
2552475|NCT02548871|Experimental|Teen Outreach Program|Teen Outreach Program
3204504|NCT00934557|Experimental|Good prognosis/matched donor/PB|
3204505|NCT00934570|Active Comparator|Metformin, Standard exercise|Lifestyle intervention with metformin and standard exercise program.
3204506|NCT00934570|Placebo Comparator|Placebo, Standard exercise|Lifestyle intervention with placebo and standard exercise program
3204507|NCT00934570|Active Comparator|Metformin, Intensive exercise|Lifestyle intervention with metformin and intensive exercise
3204508|NCT00934570|Placebo Comparator|Placebo, Intensive exercise|Lifestyle intervention with placebo and intensive exercise program.
2550723|NCT02560363|Experimental|Treatment sequence 2|Period 1:Intermediate ER formulation of AZD9977 Period 2:IR formulation of AZD9977 Period 3:Fast ER formulation of AZD9977 Period 4:Slow ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
2550726|NCT02560363|Experimental|Treatment sequence 3|Period 1:Slow ER formulation of AZD9977 Period 2:Fast ER formulation of AZD9977 Period 3:IR formulation of AZD9977 Period 4:Intermediate ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
2550728|NCT02560363|Experimental|Treatment sequence 4|Period 1:IR formulation of AZD9977 Period 2:Slow ER formulation of AZD9977 Period 3:Intermediate ER formulation of AZD9977 Period 4:Fast ER formulation of AZD9977 Period 5:Fast, intermediate or slow ER formulation with food
2550808|NCT02559726|Experimental|O-HCM|20 patients with Hypertrophic Cardiomyopathy with outflow-tract obstruction
2550809|NCT02559726|Experimental|NO-HCM|20 patients with Hypertrophic Cardiomyopathy without outflow-tract obstruction
2550811|NCT02559726|Other|healthy volunteers|20 healthy volunteers
3204509|NCT00934583|Experimental|Image and Mood (IaM) program|Participants will participate in the IaM program.
3204510|NCT00934583|No Intervention|Wait-list control|Participants will be placed on a wait list until after participants in the IaM group have completed all assessments. After that, these participants will be offered the option to complete the IaM program.
3204511|NCT00934609|Experimental|Training|12 weeks of endurance training on the cycle ergometer under supervision on a physician
2550940|NCT02558933|Experimental|Epigallocatechin gallate (EGCG) treated|Intervention: Epigallocatechin gallate (EGCG) administered FAS children: An oral dose of 9 mg/Kg/day of EGCG will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment
2550992|NCT02558686|Experimental|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
2550995|NCT02558686|Sham Comparator|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
2550996|NCT02558686|Placebo Comparator|Placebo|Individuals will not perform any action after the application of trigger point dry needling
2551077|NCT02558023|Experimental|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
2551078|NCT02558023|Active Comparator|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
2551234|NCT02557061|Experimental|Patient with colorectal cancer|Colorectal surgery (resection) and blood sampling are done for patient with colorectal cancer
2551294|NCT02556567|Other|Intervention|Participants will wear the Fitbit® Charge Heart Rate (HR) wristband for eight weeks.
3204512|NCT00934609|No Intervention|Control|Control condition
3204513|NCT00934674|Experimental|1|Commercial Tablet manufactured by Excella
3204514|NCT00934674|Experimental|2|Clinical Tablet manufactured by Wyeth Montreal
3204515|NCT00934687|Experimental|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
3204516|NCT00934687|Placebo Comparator|0.9% sodium chloride NaCl solution|0.9% NaCl solution will be injected like the experimental compound
2551675|NCT02554136|Experimental|Sequence 1|HGP0918 -> HGP0816 -> HGP0918 + HGP0816
2551679|NCT02554136|Experimental|Sequence 2|HGP0816 -> HGP0918 + HGP0816 -> HGP0918
2551681|NCT02554136|Experimental|Sequence 3|HGP0918 + HGP0816 -> HGP0918 -> HGP0816
2551686|NCT02554136|Experimental|Sequence 4|HGP0918 -> HGP0918 + HGP0816 -> HGP0816
2551689|NCT02554136|Experimental|Sequence 5|HGP0816 -> HGP0918 -> HGP0918 + HGP0816
2551693|NCT02554136|Experimental|Sequence 6|HGP0918 + HGP0816 -> HGP0816 -> HGP0918
2551774|NCT02553473|Active Comparator|Doxycycline for 6 weeks|Doxycycline 200 mg once daily for six weeks
2551778|NCT02553473|Placebo Comparator|Doxycycline for 2 weeks + placebo|Doxycycline 200 mg once daily for two weeks + placebo for four weeks.
2551917|NCT02552524|Experimental|rTMS active then rTMS placebo|"A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo (rTMS active then rTMS placebo).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit."
2551918|NCT02552524|Experimental|rTMS placebo then rTMS active|"A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS active at the frequency of 10 Hz (rTMS placebo then rTMS active).~Patient will also have cognitive tests before and after rTMS session and HRV recording during visit"
3204517|NCT00934700|Experimental|Combination of hypothermia and xenon|Combination of hypothermia and inhaled xenon
2552049|NCT02551549|Experimental|CD101 IV|multiple ascending dose intravenous infusion
2552052|NCT02551549|Placebo Comparator|Placebo|normal saline
2552113|NCT02551419|Experimental|ketogenic drink|MCT ketogenic drink: ketogenic drink providing 30 g/d of MCT oil in 250 ml of lactose-free skim milk for 6 months supplementation
2552115|NCT02551419|Placebo Comparator|Placebo|Lactose-free skim milk-based placebo drink containing high-oleic sunflower oil of equivalent energy value to the active arm for a 6 months supplementation
2552172|NCT02551081||Birth Defects|Neonates were diagnosed as birth defects who were recieving genomic sequencing and personalized treatment in NICU.
2552294|NCT02550301||Mean Platelet Volume|4 blood samples (1 pre procedure before clopidogrel loading) and 3 after Percutaneous Coronary Intervention will be drawn to assess the MPV
2552303|NCT02550392|No Intervention|Control group|Participants in the usual care control group will continue to receive all other services routinely available to them as is usual practice.
3204518|NCT00934700|No Intervention|Hypothermia and standard intensive care|Hypothermia and standard intensive care
3204519|NCT00934713|Active Comparator|montelukast|montelukast 4 mg once per day for 8 weeks
2550771|NCT02559973|Experimental|RBP-6000 - Heavy MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with a heavy molecular weight (MW) polymer.
2550773|NCT02559973|Active Comparator|RBP-6000 - Intermediate MW|Single subcutaneous injection of RBP-6000 (buprenorphine) 300 mg, formulated with an intermediate molecular weight (MW) polymer (reference).
3204520|NCT00934726||1 group, schizophrenia patients|Patients with schizophrenia according to ICD-10(diagnostic and statistical manual of mental disorders)
2550922|NCT02559076|Experimental|Ten Steps Leaflet|Ten steps leaflet advice for healthy lifestyle
2550927|NCT02559076|No Intervention|Usual care|Usual care given
2550968|NCT02558816|Experimental|Ibrutinib - GA101 - GDC_0199|STEP A:C1:Ibrutinib 560mg D2-28;GA101 1000mg day 1/2,8,15;C2-6:Ibrutinib 560mg D 1-28;GA101 1000mg D1 / C7 (Maintenance phase)-C24:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2cycles (from C8) STEP B:C1:Ibrutinib 560mg D2-28;GA101 1000mg D1/2,8,15 / C1bis : Ibrutinib 560mg day 1-28 ; GA101 1000mg D 1 ; GDC-0199 20mg/d at W1, 50mg/d at W2, 100mg at W3, 200 mg/d at W4 / C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC-0199:400mg/d W1 and 400, 600 or 800mg/d W2-3-4 + 400, 600 or 800 mg/d C3-C6 (patients 1-12).Patients 13-24:GDC-199 400mg/d / C7(Maintenance phase)-C23:Ibrutinib 560mg D1-28 (until progression);GA101 1000mg D1 every 2 cycles (from C8);GDC:400, 600 or 800 mg D1-28 (patient 1-12).Patients 13-24 : 400mg/d STEP C:C1-C1bis=Step B; C2-6:Ibrutinib 560mg D1-28;GA101 1000mg D1;GDC:400mg/d C7 (Maintenance phase)-C23 : Ibrutinib 560mg D1-28 (-->progression);GA101 1000mg D1/2 cycles (from C8);GDC-0199 400mg/d
2551018|NCT02558426||CVD patients|Patients with CVD at various stages (C2-C6 of CEAP classification of CVD) with varicose veins and eligible to receive Open Venous Surgery.
2551029|NCT02558127||50 asthma patients|50 asthma patients with bronchial mucus hypersecretion
2551036|NCT02558127||asthma patients|50 asthma patients without bronchial mucus hypersecretion
2551079|NCT02557932|Active Comparator|Standard triple therapy|7 day-PPI based standard triple therapy
2551081|NCT02557932|Active Comparator|Bismuth quadruple therapy|10 day-bismuth quadruple therapy
2551141|NCT02557607|Other|Monitoring a subarachnoid hemorrhage|Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic). An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
2551197|NCT02557308||Remsima™|Patients who are taking Remsima™ for the treatment
2551200|NCT02557308||Other anti-TNF drugs|Patients who are taking other anti-TNF drugs such as infliximab (Remicade®), etanercept, adalimumab, etc.
3204521|NCT00934739|No Intervention|Control|Standard postoperative concurrent chemoradiotherapy
3204522|NCT00934739|Experimental|Thalidomide, Celebrex|Adjuvant anti-angiogenesis therapy
3204523|NCT00934739|Active Comparator|Cyclophosphamide, Dexamethasone|Adjuvant anti-angiogenesis therapy
3204524|NCT00934752|Experimental|Lutonix Catheter|
3204525|NCT00934778|Experimental|Bronchoscopy|
2551426|NCT02555501|Experimental|PDT + Low level laser|"PDT (photosensitizer and low level laser) and low level laser~Photosensitizer: aqueous solution of 0.005% methylene blue; Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)"
2551428|NCT02555501|Active Comparator|Low level laser|Low level laser: infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium) and red emitter with active medium InGaAlP (phosphide and Indium, Gallium and Potassium)
3204526|NCT00934804|Experimental|Comparative Diagnostic system|Galilei dual Scheimpflug analyzer
3204527|NCT00934817|Experimental|TR sequential group|Amaryl-M 1/500 mg in period 1, Amaryl-M 2/500 mg in period 2
2551523|NCT02554916||Dual-belt Exercise|The participants assigned to this group will use the dual-belt treadmill 3 times a week for 16 weeks.
2551524|NCT02554916||Treadmill Exercise|The participants assigned to this group will use the treadmill 3 times a week for 16 weeks.
2551525|NCT02554916||Usual Care|The participants assigned to this group will not use the treadmills.
2551629|NCT02554396|Experimental|PRX-100|PRX-100 ophthalmic solution
2551631|NCT02554396|Placebo Comparator|Placebo|saline solution
2551666|NCT02554110|Experimental|Stimulator Active Device|Intervention: This intervention arm will use a Stimulator Active Device peripheral nerve stimulation. Participants will receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
2551667|NCT02554110|Sham Comparator|Stimulator Sham Device|No intervention: This arm will use a Stimulator Sham Device peripheral nerve stimulation.Participants will not receive a cutaneous stimuli in response to oxygen desaturations in postoperative surgical patients.
2551708|NCT02553837|Experimental|Treatment only|Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
2551760|NCT02553603|Placebo Comparator|Mild Cognitive Impairment, Placebo|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
2551762|NCT02553603|Placebo Comparator|Non-cognitively impaired, Placebo|Subjects aged 55- 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving placebo Growth Hormone Releasing Hormone (GHRH).
2551764|NCT02553603|Experimental|Mild Cognitive Impairment, GHRH|Subjects aged 55 - 85 years, scored between 23- 26 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
2551765|NCT02553603|Experimental|Non-cognitively impaired, GHRH|Subjects aged 55 - 85 years, scored between 27-30 on screening Mini Mental Status Exam, receiving active Growth Hormone Releasing Hormone (GHRH).
2551888|NCT02553044|Experimental|50 000IU Vitamin D3|50 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
2551902|NCT02553044|Experimental|150 000IU Vitamin D3|150 000IU oral vitamin D3 (cholecalciferol) administered at baseline only.
2552479|NCT02548871|No Intervention|Comparison|Business as usual
3204528|NCT00934817|Active Comparator|RT sequential group|Amaryl-M 2/500 mg in period 1, Amaryl-M 1/500 mg in period 2
3204529|NCT00934830|Active Comparator|Antibiotic|
3204530|NCT00934830|Experimental|Therapeutic ultrasound|
3204531|NCT00934869||Metacarpal Shaft Fractures|
3204532|NCT00934882|Experimental|Arm 1|
3204533|NCT00934895|Experimental|Phase I / Phase II|"Phase I:~Abraxane will be given by IV for 30 minutes on the first day of the first three weeks of each 28 day cycle.~RAD001 will be given by tablet. The first group of patients will receive RAD001 once daily depending on side effects seen drug could be increased later to twice a day for a 28 day cycle.~Once a safe and effective drug range is established, the study moves into Phase II.~Phase II:~The maximum tolerated dose (established in Phase I) will be given as scheduled below and we will measure the effectiveness of the study drug combination.~Abraxane will be given by IV (intravenous infusion) for 30 minutes on the first day of the first three weeks of each 28 day cycle (Day 1, Day 8, and Day 15 of each cycle).~RAD001 will be given by tablet based on the dose established in the Phase I part of the study."
3204534|NCT00934908|Placebo Comparator|1|"Non-active sugar pill"
3204535|NCT00934908|Active Comparator|2|Green Tea Capsules
3204536|NCT00934973|Active Comparator|mebeverine + no website|Mebeverine 135mg tds for 6 weeks
3204537|NCT00934973|Active Comparator|methylcellulose + no website|methylcellulose 3 tablets twice a day for 6 weeks
3204538|NCT00934973|Placebo Comparator|placebo + no website|placebo tablets
3204539|NCT00934973|Active Comparator|mebeverine + CBT website minimal support|mebeverine 135mg tds and access to website
3204540|NCT00934973|Active Comparator|methylcellulose + CBT website|methylellulose 3 tablets twice a day and access to website
3204541|NCT00934973|Placebo Comparator|placebo + CBT website minimal support|placebo tablets and access to website
2551011|NCT02558543|Active Comparator|Stromal Vascular Fraction|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo (ringer lactate) ( placebo group)
2551013|NCT02558543|Placebo Comparator|Placebo|The injection is made for the patients of the both groups in the sub-dermic plan on the side faces of fingers distal and proximal or 4 times 0,25ml by finger, all in all every finger will be injected of 1ml of diluted Stromal Vascular Fraction ( experimental group) , or placebo ( placebo group)
2551059|NCT02558179||Nugent Score >/= 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Diagnosis of bacterial vaginosis (study group) according to Nugent score and/or diagnosis of vulvovaginal candidiasis; and/or diagnosis of Trichomonas vaginalis.
2551061|NCT02558179||Nugent Score< 7|Signs and symptoms of vaginitis/vaginosis, including vaginal discharge, pruritis, irritation, and/or dyspareunia. Bacterial vaginosis not diagnosed according to Nugent score (<7).
2551113|NCT02557789|Experimental|Treatment A|Lefamulin as a 600 mg IR tablet in the fasted state
2551114|NCT02557789|Experimental|Treatment B|Lefamulin as 600 mg API in capsule (three 200 mg capsules) in the fasted state
2551116|NCT02557789|Experimental|Treatment C|Lefamulin as 150 mg i.v. in 250 mL citrate buffered saline infused over 1 h
2551118|NCT02557789|Experimental|Treatment D|Lefamulin as a 600 mg IR tablet one hour after breakfast
2551159|NCT02557425||Maternal SP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of sulfadoxine-pyrimethamine (SP), and children receive every 3 month dihydroartemisinin-piperaquine (DP). No intervention is given in the observational PROTECT study.
2551161|NCT02557425||Maternal 3 dose DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive every 3 month DP.No intervention is given in the observational PROTECT study.
2551164|NCT02557425||Maternal 3 dose DP/Child monthly DP|In this group in the PROMOTE-II study, mothers receive 3 doses of DP, and children receive monthly DP. No intervention is given in the observational PROTECT study.
2551169|NCT02557425||Maternal monthly DP/Child 3mo DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every 3 month DP. No intervention is given in the observational PROTECT study.
2551171|NCT02557425||Maternal monthly DP/child monthly DP|In this group in the PROMOTE-II study, mothers receive monthly DP, and children receive every monthly DP. No intervention is given in the observational PROTECT study.
2551205|NCT02557126|Experimental|URC102|URC102
2551207|NCT02557126|Placebo Comparator|Placebo|Placebo
3204542|NCT00934973|Active Comparator|mebeverine + CBT website with support|mebeverine 135mg tds and access to website with nurse support session
3204543|NCT00934973|Active Comparator|methylcellulose + CBT website support|methylcellulose 3 tablets twice a day and access to website with nurse support
2551361|NCT02556047|Other|Injections|"Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.2mm needle length~Two injections of 0.1 ml sterile saline per injection using Star intradermal safety device 1.5mm needle length~Two injections of 0.1 ml saline per subject using Mantoux technique by N&S"
2551388|NCT02555696||nab-paclitaxel|nab-paclitaxel 260mg/m^2 in intravenous (IV) infusion every 3 weeks until progression or toxicity
2551482|NCT02555033|Experimental|M-RT|Machine-based resistance training. Exercising 'traditional' machine-based resistance training.
3204544|NCT00934973|Placebo Comparator|placebo + CBT website with support|placebo tablets and access to website with nurse support
3204545|NCT00934999|Active Comparator|Burch|Patients will receive a Burch urethropexy at the time of an abdominal sacral colpopexy.
3204546|NCT00934999|Experimental|Mid-urethral sling|Patients will receive a mid-urethral sling at the time of an abdominal sacral colpopexy.
3204547|NCT00935025|Experimental|1, AZD1305|
3204548|NCT00935025|Placebo Comparator|2, Placebo|
3204549|NCT00935051|Experimental|Arm 1|There is only one group of patients. Thus there is only one arm. Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. A numeric photograph of the wound will be taken at week 0, week 4 and week 12.
3204550|NCT00935077|Experimental|24 Month PPCM BP|A 24 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
3204551|NCT00935077|Experimental|9 Month PPCM BP|A 9 month long physician/pharmacist collaborative intervention is implemented to manage hypertension
3204552|NCT00935077|Sham Comparator|PPCM Asthma|A 9 month long physician/pharmacist collaborative intervention is implemented to manage asthma
3204553|NCT00935077|No Intervention|BP Control Arm|No PPCM intervention
3204554|NCT00935090|Experimental|3'-deoxy-3'-[18F]fluorothymidine|The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body.
2550827|NCT02559453|Active Comparator|2 operations|Subjects in this arm will receive a maximum of two surgical debridements of their wound.
2550829|NCT02559453|Active Comparator|3 or more operations|Subjects in this arm will receive three or more surgical debridements of their wound.
2550935|NCT02559024|Experimental|21 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 21 days prior to surgery
2550937|NCT02559024|Experimental|14 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 14 days prior to surgery
2550939|NCT02559024|Experimental|7 Days|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days starting 7 days prior to surgery
2550978|NCT02558673|Experimental|Egg|Study meals were administered in commonly consumed serving sizes (3 hard-boiled eggs) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
2550983|NCT02558673|Experimental|Beef|Study meals were administered in commonly consumed serving sizes (6 oz beef [Philly-Gourmet Beef Patties]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
2550985|NCT02558673|Experimental|Fish|Study meals were administered in commonly consumed serving sizes (6 oz fish [cod fillet]) and provided comparable amounts of TMAO dietary precursors. Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period.
2550986|NCT02558673|Active Comparator|Fruit|Study meals were administered in commonly consumed serving sizes (2 single-serve packages of Mott's natural applesauce) and provided comparable amounts of control (or active comparator). Each meal was served with one cup of water, administered in a single day and separated by a 1-week washout period. For the fruit control, 50 mg deuterium-labeled methyl-d9-TMAO (d9-TMAO; Cambridge Isotopes) was added to one cup of water for oral consumption to enable the tracing of the metabolic fate of TMAO, and to assess its bioavailability and clearance.
3204555|NCT00935103|Active Comparator|Psychoeducation|Psycheducation
3204556|NCT00935103|No Intervention|Control|The control group will not take any intervention
2551155|NCT02557685|No Intervention|Fecal Microbiota Translantation|After completing at least 10 days course of antibiotic treatment for C. difficile infection, subjects will receive Fecal Microbiota transplantation with a 300 mL fecal suspension delivered via sigmoidoscopy.
2551218|NCT02557217|Experimental|NP202|1000mg oral NP202 daily for 90 days
2551222|NCT02557217|Placebo Comparator|Placebo|Oral placebo daily for 90 days
3204557|NCT00935116|Active Comparator|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
3204558|NCT00935129|Experimental|OmniPod system|At this arm patients will be treated with the OmniPod system for 12 weeks
2551364|NCT02555904||Heart failure syndrome & pulmonary congestion|Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.
3204559|NCT00935129|Active Comparator|patient's conventional pump|At this arm patients will be treated with their conventional pump for 12 weeks
3204560|NCT00935155|Experimental|Acupuncture|Acupuncture in combination with exercise therapy
3204561|NCT00935155|Active Comparator|exercises|Coordination, mobilizing, endurance, strength
2551784|NCT02553213|Experimental|LSG group|Laparoscopic sleeve gastrectomy
2551791|NCT02553213|Experimental|LRYGB group|Laparoscopic Roux-en-Y gastric bypass
2551796|NCT02553213|Other|Control group|Caloric restriction
2551896|NCT02552927|Experimental|CALF|Chest shield with aluminum foil
2551899|NCT02552927|Sham Comparator|SHIELD|Chest shield without aluminum foil
3204562|NCT00935168|Experimental|Hydroxy-ethyl starch|Intravenous fluid resuscitation with 6% Hydroxy-ethyl starch (130/0.4)
3204563|NCT00935168|Active Comparator|Saline|Intravenous fluid resuscitation with saline (0.9% sodium chloride)
3204564|NCT00935181|Experimental|exercise training program|The exercise training program consisted of three 90-minute sessions per week for eight weeks. Each session consisted of a stretching exercise, resistance that patients started at 70% of the initial one-repetition maximum (1RM: the maximum load which can be moved only once over the full range of motion without compensatory movements) in the first week (3x8 repetitions). Every week the load was increased by 5% of the 1RM, and endurance training (treadmill walking speed was set at 60% of the average speed obtained from the 6MWT (6MWTpeak) for 10 mins in the first week and was increased to 20 mins in week 8
3204565|NCT00935194|Experimental|blank|do not take antiviral therapy
2552140|NCT02551185|Experimental|ACY-241 in combination with Paclitaxel|
2552182|NCT02550899|Active Comparator|Bulkamid injection treatment group 1|Injection at four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
2552187|NCT02550899|Active Comparator|Bulkamid injection treatment group 2|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
2552189|NCT02550899|Active Comparator|Bulkamid injection treatment group 3|injection at three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
2552257|NCT02550509|Experimental|patients with hemiplegia after stroke|ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural
2552299|NCT02550249|Experimental|Nivolumab|Nivolumab 3 mg every 2 weeks
2552353|NCT02549885|Experimental|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
2552355|NCT02549885|Experimental|Static stretching|Static stretching of neck muscles.
2552418|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 20% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve (Naproxen sodium) 220 mg tablet
2552480|NCT02548975||No delirium|Patients not diagnosed with delirium postoperatively.
3204566|NCT00935194|Experimental|Oseltamivir|antiviral therapy
2550813|NCT02559700|Experimental|Brain training programme|Participants will complete a package of online brain training games focusing on reasoning and problem solving. The intervention will be accessed via a computer. There is no minimum or maximum dosage but participants will be recommended to complete the intervention five times a week. The package takes approximately 10 minutes to complete, depending on individual performance.
2550841|NCT02559440|Active Comparator|mometasone furoate|In the first treatment stage, 120 children were assigned to mometasone furoate (50μg, 1 puff in each nostril every evening) after two week's run-in period.
2550843|NCT02559440|Placebo Comparator|Placebo|In the first treatment stage, 120 children were assigned to control group (normal saline) after two week's run-in period.
2550847|NCT02559440|Active Comparator|Oxymetazoline + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving Oxymetazoline and placebo.
2550853|NCT02559440|Placebo Comparator|Placebo + placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving placebo and placebo.
2550858|NCT02559440|Active Comparator|mometasone furoate + Placebo|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and placebo.
2550862|NCT02559440|Active Comparator|mometasone furoate + Oxymetazoline|Stage two is a parallel, randomized, double-blind, double-dummy study. Non-responders underwent 2-week washout period and were randomly assigned to groups receiving mometasone furoate and Oxymetazoline.
3204567|NCT00935194|Experimental|chinese medicinary herbs|antiviral therapy
2550966|NCT02558803|No Intervention|Usual Care|The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms
2550967|NCT02558803|Experimental|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
2551007|NCT02558465||Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxavban administration group
2551037|NCT02558257||Palliative Care Survey|Initial consultation visit followed by phone survey within 1 week +/- 4 days of initial consultation.
2551131|NCT02557958|Experimental|Azithromycin|Azithromycin 250mg daily, single daily use for 8 weeks
2551133|NCT02557958|Placebo Comparator|Placebo|Placebo daily for 8 weeks
2551190|NCT02557321|Experimental|Phase 1b|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
2551194|NCT02557321|Experimental|Phase 2 (Arm 1)|PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)
2551196|NCT02557321|Active Comparator|Phase 2 (Arm 2)|Pembrolizumab (2 mg/kg every 3 weeks)
2551231|NCT02556892|Experimental|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
2551266|NCT02556658|Experimental|Smartpilot View group|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
2551271|NCT02556658|Active Comparator|Control group|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
2551312|NCT02556411|Active Comparator|LNG-IUS|LNG-IUS 13,5 mg di Levonorgestrel
2551314|NCT02556411|Experimental|combined oral contraceptive plus LNG-IUS|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg+ LNG-IUS 13,5 mg di Levonorgestrel
2551355|NCT02556021|Experimental|CJ-12420 50mg|CJ-12420 50 mg, tablet, once daily, oral administration for up to 4 weeks
2551357|NCT02556021|Experimental|CJ-12420 100mg|CJ-12420 100 mg, tablet, once daily, oral administration for up to 4 weeks
2551358|NCT02556021|Placebo Comparator|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
2551389|NCT02555670||BIA and CT|Patients who had a CT-scan made for diagnostic reasons.
2551454|NCT02555462|Experimental|Real-Ear Measurement|The study arm goes through a comparative test run followed by a comparative hearing aid fitting.
2551489|NCT02555176|Experimental|Low Carbohydrate Diet|Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).
2551531|NCT02554851|Placebo Comparator|placebo|This group will receive the standard medication and the placebo drug
2551536|NCT02554851|Experimental|recombinant human Epidermal Growth Fact|This group will receive the standard medication and the recombinant human Epidermal Growth Factor (HEBERPROT)
3204568|NCT00935194|Experimental|oseltalmivir and chinese medicinal herbs|combination antiviral therapy
3204569|NCT00935207||Pediatric Pain Diary|Patients will be give a pain diary to complete.
3204570|NCT00935246|Experimental|Antidepressant treated group|Antidepressant treated group: depressed patients treated with Escitalopram
2551783|NCT02553265|Active Comparator|Placebo, Low Dose Carbidopa, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
2551790|NCT02553265|Active Comparator|High Dose Carbidopa, Placebo, High Dose Carbidopa|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
3204571|NCT00935246|No Intervention|other antidepressant treated group|other Antidepressant treated group: depressed patients treated with other antidepressant without escitalopram
3204572|NCT00935298|Experimental|T|"The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation.After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*3 and *1/*1 ,expressors; CYP3A5*3/*3 nonexpressor）.~The objective is to determine the initial dosage Range of tacrolimus in Chinese renal transplantation patients by genotyping of the cytochrome P450 3A5"
3204573|NCT00935324||Group A: patients following allo-SCT|Patients scheduled for allo-SCT fulfilling all inclusion criteria
2550886|NCT02559297|Experimental|Desflurane|In desflurane arm (n=20) at the beginning after successful intubation, 2 L/min N2O, 2 L/min O2, and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 MAC of desflurane in 50% O2 and 50% N2O.
2550961|NCT02558725|No Intervention|one capsule of iron supplement|instructed to take one capsule at least 2 hours after consumption of dairy products
2550962|NCT02558725|Active Comparator|two capsules of iron supplement|instructed to take two capsules of Aktiferrin F at least 2 hours after consumption of dairy products
2550999|NCT02558530|Other|Low carbohydrate diet|Isocaloric diet, <20 g carbohydrates per day
3204574|NCT00935324||Group B - healthy controls|healthy voluntary blood donors
3204575|NCT00935337|Experimental|Mind-Body Bridging Program|Mind Body Bridging subjects will be accessed with questionnaires and medical history evaluations for the impact of MBBP over the past 6 months since undertaking the program.
3204576|NCT00935337|Active Comparator|Sleep Hygiene|Sleep Hygiene subjects will be accessed with questionnaires and medical history evaluations for the impact of SH over the past 6 months since undertaking the program.
2551380|NCT02555709|Placebo Comparator|Placebo 1|healthy volunteers
2551382|NCT02555709|Experimental|VTP-43742 Dose 1|healthy volunteers
2551383|NCT02555709|Experimental|VTP-43742 Dose 2|healthy volunteers
2551387|NCT02555709|Experimental|VTP-43742 Dose 3|healthy volunteers
2551393|NCT02555709|Experimental|VTP-43742 Dose 4|healthy volunteers
2551395|NCT02555709|Experimental|VTP-43742 Dose 5|healthy volunteers
2551397|NCT02555709|Experimental|VTP-43742 Dose 6|healthy volunteers
2551401|NCT02555709|Experimental|VTP-43742 Dose 7|healthy volunteers
2551403|NCT02555709|Placebo Comparator|Placebo 2|psoriatic patients
2551405|NCT02555709|Experimental|VTP-43742 Dose 8|psoriatic patients
2551406|NCT02555709|Experimental|VTP-43742 Dose 9|psoriatic patients
2551407|NCT02555709|Experimental|VTP-43742 Dose 10|psoriatic patients
2551409|NCT02555709|Experimental|VTP-43742 Dose 11|psoriatic patients
3204577|NCT00935350|Placebo Comparator|1|Control White bread containing 50g available carbohydrate
2551617|NCT02554305|Active Comparator|Fusion oxygenation system|Fusion oxygenation machine will be used during the operation.
2551619|NCT02554305|Active Comparator|Affinity oxygenation system|Affinity oxygenation machine will be used during the operation.
2551620|NCT02554305|No Intervention|Peripheral vascular procedure|No oxygenation machine will be used in this group
2551621|NCT02554305|No Intervention|percutaneous coronary intervention|No oxygenation machine will be used in this group
2551656|NCT02554162|Active Comparator|Extruded wholegrain rye flakes|Rye products with varying structures
2551657|NCT02554162|Active Comparator|Extruded wholegrain rye puffs|Rye products with varying structures
2551659|NCT02554162|Active Comparator|Fresh wholegrain rye bread|Rye products with varying structures
2551661|NCT02554162|Active Comparator|Wholegrain rye beverage|Rye products with varying structures
2551662|NCT02554162|Active Comparator|Fresh wheat bread|Rye products with varying structures
2551682|NCT02553902|Active Comparator|Combination therapy|"Sleep Position Trainer + Mandibular Advancement device combination The SPT is a sensor that measures the sleeping position, and gives the user feedback about wrong positions with a soft vibration. A user is then able to react to the signal and turn into a non-supine position. To stimulate compliance, information is provided about nightly behaviour, implicating a learning pattern by viewing the data on a home computer.~MRA or oral appliances (OA) works by advancing the mandible and its attached soft tissue structures forward they aim to increase upper airway size."
2551684|NCT02553902|Active Comparator|CPAPContinuous positive airway pressure|Continuous positive airway pressure (CPAP) functions as a pneumatic splint to maintain upper airway patency. Possible side effect can be related to the interface, pressure and negative social factors.
2551775|NCT02553564|Experimental|Intervention group|"Checklist driven clinical encounter after hospital discharge~- Participant will receive standard medical care with the addition of a checklist driven clinical encounter upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
2551779|NCT02553564|No Intervention|Usual care group|"Participant will receive standard medical care upon return to the dialysis unit after hospital discharge.~* participants in both group will be receiving standard post discharge care which includes nursing assessment, social work intervention as needed and new dialysis orders."
2551859|NCT02553070||Pharmacy Students|Participants will be asked to indicate their perception of poisoning severity by answering a short survey.
2551914|NCT02552654|Experimental|Hydrocortisone and Stress Film|Administration of 10mg hydrocortisone before the trauma film.
2551915|NCT02552654|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
3204578|NCT00935350|Placebo Comparator|2|White bread and milk control
3204579|NCT00935350|Placebo Comparator|3|Granola control
3204580|NCT00935350|Placebo Comparator|4|Cornflakes and milk control
3204581|NCT00935350|Placebo Comparator|5|White rice control
2552035|NCT02551835||Tromso Impaired Glucose Tolerance (IGT) study|RCT on 20000 IU vitamin D3/week versus placebo for 1 year among persons with impaired glucose tolerance and/or impaired fasting glucose.
2552036|NCT02551835||Tromso OBESITY study|RCT on 20000 or 40000 IU vitamin D3/week plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 1 year among persons with a high body mass index.
2552037|NCT02551835||Tromso Bone Mineral Density (BMD) study|RCT on 40000 IU vitamin D3/week plus 800 IU/day and 1000 mg calcium/day versus placebo plus 800 IU/day and 1000 mg calcium/day for 1 year among women with a low bone mineral density.
2552038|NCT02551835||Tromso CLAMP study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <42 nmol/L.
2552039|NCT02551835||Tromso DEPRESSION study|RCT on 40000 IU vitamin D3/week versus placebo for 6 months among persons with 25(OH)D values <55 nmol/L.
2552343|NCT02549924|Experimental|Resveratrol|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
3204582|NCT00935350|Placebo Comparator|6|Fruit yogurt control
2551051|NCT02558322||Primary medical care in rural areas|People living in districts, where less than 50% of the population live in cities with more than 20,000 residents and the population density outside of the cities is below 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
2551053|NCT02558322||Primary medical care in region environs|People living in districts, where 50% or more of the population live in cities with more than 20,000 residents and/or population density outside of the cities is above 100 people per km². Excluding people living in cities with a population of at least 100,000 residents.
2551055|NCT02558322||Primary medical care in in urban areas|People living in cities with a population of at least 100,000 residents.
2551088|NCT02557841|Experimental|anodal ctDCS|Volunteers will be submitted to anodal ctDCS + motor learning assessments (SRTT and Handwriting test).
2551089|NCT02557841|Experimental|cathodal ctDCS|Volunteers will be submitted to cathodal ctDCS + motor learning assessments (SRTT and Handwriting test).
2551094|NCT02557841|Sham Comparator|sham ctDCS|Volunteers will be submitted to sham ctDCS + motor learning assessments (SRTT and Handwriting test)
2551123|NCT02557581|Experimental|Terbutaline|Beta2-adrenergic stimulation with terbutaline
2551125|NCT02557581|Placebo Comparator|Placebo|Placebo
2551127|NCT02557581|Experimental|Clenbuterol|Beta2-adrenergic stimulation with clenbuterol
2551183|NCT02557347|Experimental|Intervention|Aggressive fluid management
2551221|NCT02557087|Experimental|Hyoscine|Intravenous administration of Hyoscine N-butylbromide diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2551223|NCT02557087|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2551270|NCT02556840|Active Comparator|Insulin therapy from the beginning of pregnancy|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) administered from the beginning of pregnancy according to maternal blood glucose (if fasting blood glucose > 0.95g/l or post-prandial blood glucose > 1.20g/l) as recommended by the national guidelines for gestational diabetes mellitus.~Insulin administered to patients either by subcutaneous injections or by pump."
2551274|NCT02556840|Experimental|Insulin therapy initiated according to fetal growth|"Insulin therapy (Glargine/Lantus®, Détémir/Levemir® , Insulatard® , Umuline NPH® , Lispro/Humalog® , Asparte/Novorapid® or Actrapid ®) initiated according to fetal growth evaluated by ultrasonography measurements. MODY2 women will not be treated with insulin until delivery, except when the fetal abdominal circumference exceeds ≥ the 75 percentile on one US or maternal fasting capillary blood glucose is ≥ 1,20 g/L or maternal post-prandial capillary blood glucose is ≥ 2,00 g/L.~Insulin administered to patients either by subcutaneous injections or by pump."
2551321|NCT02556424|Active Comparator|Reference Drug|Intravitreal implant of 700μg of dexamethasone (Ozurdex®)
2551324|NCT02556424|Experimental|Tested Drug|Subconjunctival injection of 16 mg triamcinolone (Kénacort Retard®)
3170715|NCT00577915|Experimental|Breast MR Spectroscopy|Conventional images will be taken with standard pulse sequences. These images will be used for the diagnostic examination for which the patient will have been scheduled. Following the diagnostic study, a pulse sequence designed to obtain spectroscopy data will be used.This will be used on the existing magnets 1.5T and 3T. Memorial Sloan-Kettering Cancer Center has 1.5T and 3T magnets. The patient will have only one injection of contrast (gadolinium-DTPA) for the initial diagnostic study. No additional contrast will be administered. The additional sequence should take about 10 minutes, depending on breast size.
2552315|NCT02550041|Other|Cystic fibrosis|
3170716|NCT00577928||1|
3170717|NCT00577928||2|
2552551|NCT02548663|Experimental|active; sport therapy|active exercise carefully calibrated on residual capacities.
3170718|NCT00577954||1|Patients in a coma condition after a traumatic brain injury (250), stroke, cerebral anoxia or subarachnoid hemorrhage (150), for at least 7 days.
3170719|NCT00577980|Experimental|Testosterone|Testosterone 200 mg administered parenterally by intramuscular (IM) injection every 2 weeks
3170720|NCT00578006|Experimental|A|If you are in group A, the investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
3170721|NCT00578006|Experimental|B|If you are in group B, the investigators will provide you with access to the STAR website using a computer in the waiting area, into which you can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy. The investigators may also provide you with a website address so that you can access STAR from home (or any other location) to report your symptoms at any time.
3170722|NCT00578019|Active Comparator|1, A|
3170723|NCT00578019|Experimental|2, B|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
3170724|NCT00578032||1|Patients with head and neck malignancies that require simultaneous surgical resection and reconstruction of the ablative defect will be eligible to participate.
3170725|NCT00578045|Experimental|1|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
3170726|NCT00578058|Other|1|Counseling plus everyday noise type 1
3170727|NCT00578058|Other|2|Counseling plus static noise type 2
3170728|NCT00578058|Other|3|Counseling plus static noise type 3
3170729|NCT00578058|Other|4|Hearing aid and counseling plus everyday noise type 1
3170730|NCT00578058|Other|5|Hearing aid and counseling plus static noise type 2
3170731|NCT00578058|Other|6|Hearing aid and counseling plus static noise type 3
3170732|NCT00578084||surgery|those subjects who went to surgery to treat their lung cancer
3170733|NCT00578084||no surgery|those subjects who did not go to surgery for their lung cancer
3170734|NCT00578084||NSCLC|subjects with NSCLC
3170735|NCT00578084||Small cell lung cancer|those with small cell lung cancer
3170736|NCT00578097|Experimental|A - 125 units|
3170737|NCT00578097|Experimental|B - 250 units|
3170738|NCT00578097|Experimental|C - 500 units|
3170739|NCT00578097|Placebo Comparator|D|
3170740|NCT00578110|Experimental|Group 1|Glaucoma Patients
3170741|NCT00578110|Experimental|Group 2|Glaucoma suspects
2550938|NCT02558972|Placebo Comparator|Northera- chronic administration|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day.
2551001|NCT02558595|Experimental|Niacinamide|Participants will be asked to take niacinamide at a dose of 30 mg/kg/d orally.
2551003|NCT02558595|Placebo Comparator|Placebo|Participants will be asked to take a placebo pill at a dose of 30 mg/kg/d orally.
2551034|NCT02558218|Active Comparator|Systane ultra group|Participants in this group were administered systane ultra quid (Alcon, Fort Worth) for two months postoperatively), additionally to tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.
2551040|NCT02558218|Active Comparator|Control group|Participants in this group were administered the standard postoperative medication [tobradex quid (Alcon, Fort Worth) for 20 days postoperatively.]
2551106|NCT02557880|Experimental|Sleep Application Diary|A sleep application diary which will automatically report results back to sleep doctor is used in addition to standard sleep hygiene counseling.
2551108|NCT02557880|Active Comparator|Treatment as Usual|Sleep hygiene counseling
2551136|NCT02557451|Experimental|surgery + antiangiogenic|surgery (vitrectomy - air - TPA) with injections of an antiangiogenic
2551140|NCT02557451|Experimental|intravitreal injection of gas/TPA + antiangiogenic|intravitreal injection of gas - TPA with injections of an antiangiogenic
2551607|NCT02554565|Other|Tumor biopsies and blood sampling|
2551674|NCT02554201|Experimental|Electrical pudendal nerve stimulation|Electrical pudendal nerve stimulation At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of four weeks
2551677|NCT02554201|Active Comparator|Transvaginal electrical stimulation|At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 30 min three times a week for a total of four weeks.
2551750|NCT02553707|Experimental|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
2551811|NCT02553148||Argentina|One of the 23 countries studied
2551813|NCT02553148||Armenia|One of the 23 countries studied
2551816|NCT02553148||Australia|One of the 23 countries studied
2551818|NCT02553148||Brazil|One of the 23 countries studied
2551819|NCT02553148||China|One of the 23 countries studied
2551820|NCT02553148||Egypt|One of the 23 countries studied
2551822|NCT02553148||Ethiopia|One of the 23 countries studied
2551824|NCT02553148||Germany|One of the 23 countries studied
2551825|NCT02553148||India|One of the 23 countries studied
2551827|NCT02553148||Indonesia|One of the 23 countries studied
2551829|NCT02553148||Jordan|One of the 23 countries studied
2551830|NCT02553148||Kenya|One of the 23 countries studied
2551832|NCT02553148||Kyrgyzstan|One of the 23 countries studied
2551833|NCT02553148||Malaysia|One of the 23 countries studied
2551834|NCT02553148||Malawi|One of the 23 countries studied
2551837|NCT02553148||Mexico|One of the 23 countries studied
2551840|NCT02553148||Russia|One of the 23 countries studied
2551843|NCT02553148||Serbia|One of the 23 countries studied
2551847|NCT02553148||South Africa|One of the 23 countries studied
2551848|NCT02553148||Tajikistan|One of the 23 countries studied
2551850|NCT02553148||United Kingdom|One of the 23 countries studied
2551852|NCT02553148||United States|One of the 23 countries studied
2551853|NCT02553148||Zimbabwe|One of the 23 countries studied
2551959|NCT02552498|Experimental|vertical|Strangulation is applied on the the buccal side of the attached gingiva, parallel to the long axis of tooth 12, at the distal third of the tooth.
2551962|NCT02552498|Experimental|horizontal|Strangulation is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the tooth 12, 2 mm far from the gingival margin.
2551964|NCT02552498|Experimental|papilla base|Strangulation is applied on the the buccal side of the attached gingiva, on the base of the mesial papilla of tooth 12, in straight line going from one side of papilla to the other.
2551993|NCT02551965|Experimental|Caregiver of cancer patient followed in geriatric oncology|caregiver of cancer patient with 70 years old or more, for which a treatment is planned, along with their long term evolution
3170742|NCT00578110|Active Comparator|Group 3|Controls
3170743|NCT00578123|Other|1 Questionnaire|Quality of Life Questionnaires
2552597|NCT02548026|Experimental|Low Eating Frequency (High EF)|3 Eating Occasions
3170744|NCT00578162||1|Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory.
3170745|NCT00578188||RP100-400|Subjects with Chlamydia. The control group will also be identified with these numbers.
3170746|NCT00578201|Experimental|1|radiochemotherapy,combination Cetuximab-FOLFOX
3170747|NCT00578266|Other|No Arms|
3170748|NCT00578357|Experimental|1|immediate intervention
3170749|NCT00578357|No Intervention|2|note: participants in this arm will receive the intervention after the 6-month follow-up (serving as control during the trial)
3170750|NCT00578370|Experimental|1|
3170751|NCT00578370|Experimental|2|
3170752|NCT00578370|Active Comparator|3|
3170753|NCT00578370|Active Comparator|4|
3170754|NCT00578370|Placebo Comparator|5|
3170755|NCT00578396|Active Comparator|Dose Level 1|1 lb/day fresh red grapes
3170756|NCT00578396|Active Comparator|Dose Level 2|2/3 lb/day fresh red grapes
3170757|NCT00578396|Active Comparator|Dose Level 3|1/3 lb/day fresh red grapes
3170758|NCT00578422||Arm I: In Vitro IVUS Plaque studies|IVUS of Amputation Specimens
3170759|NCT00578422||Arm 2: Obserational Study|IVUS for patients undergoing standard lower extremity angiography for PAD.
3170760|NCT00578474|Experimental|Moxidex|Moxidex otic solution
3170761|NCT00578474|Active Comparator|FLOXIN|Ofloxacin otic solution
2550948|NCT02558868|Experimental|Oxaliplatin + Irinotecan|Irinotecan：160 mg/m2，iv 120 min，d1 q2w oxaliplatin: 85 mg/m2，iv 120 min，d1 q2w
2550951|NCT02558868|Active Comparator|Irinotecan|Irinotecan：180 mg/m2，iv 120 min，d1 q2w
2550988|NCT02558556|Experimental|NIRF-LC|"This group of patients will undergo near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy by use of a Laparoscopic Fluorescence Imaging System (Karl Storz), in combination with one intravenous injection of contrast agent ICG. The ICG is given directly after induction of anesthesia in a dose of 1 ml of 2,5 mg/ml solution.~Intraoperatively every 2-5 minutes (more often if desired by surgeon) camera is switched to ICG mode for fluorescence cholangiography, until CVS is established.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video."
2550990|NCT02558556|No Intervention|CLC|"This group will undergo conventional laparoscopic cholecystectomy as in standard practice with no other intervention.~Registration of time until establishment of CVS, visualization of the individual structures as described as secondary endpoints, and total operation time will be done.~The complete procedure will be recorded on video.~Postoperatively, as in the NIRF-LC arm, the videos will be analysed to determine whether CVS is actually established, is the transition of the cystic duct into the gallbladder visualized? Is transition of the cystic artery into the gallbladder visualized? Furthermore, cost-minimalisation will be calculated."
2551019|NCT02558348|Experimental|AL3818|"Part 1 (Phase 1b): Cohort 1 will initiate at a dose of 12 mg/day of AL3818, for 21-Day cycles (14 days of AL3818 treatment followed by 7 days of rest). After three subjects have completed the first cycle of therapy without a DLT, additional cohorts may be enrolled sequentially. After the first cohort has completed one full cycle of therapy without a DLT, two additional cohorts will be sequentially enrolled at 16 mg/day and 20 mg/day doses of AL3818 for the same 21-day cycles.~Part 2 (Phase 2a): Each subject will receive a dose of up to 20 mg AL3818 or a maximum of the MTD from Part 1 (Phase 1b) of this study for continuous 21-Day cycles of therapy (14 days of AL3818 treatment followed by 7 days of rest)."
2551062|NCT02558075|Experimental|MoodLifters Program|A program to provide evidence-based education and skills to reduce psychological distress and enrich people's lives.
2551093|NCT02557815|Experimental|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive Transcranial Magnetic Stimulation: Active 10hz stimulation over the right dorsolateral Prefrontal Cortex (dlPFC)
2551096|NCT02557815|Sham Comparator|Sham stimulation|Repetitive Transcranial Magnetic Stimulation: sham stimulation over the right dlPFC
2551122|NCT02557633|Placebo Comparator|Placebo|2% w/v L-Tyrosine
2551124|NCT02557633|Experimental|Grass MATA MPL 10200 SU|Grass MATA MPL cumulative dose 10200 SU given as six injections of placebo, placebo, 600SU, 1600SU, 4000SU and 4000SU.
2551126|NCT02557633|Experimental|Grass MATA MPL 18200 SU|Grass MATA MPL cumulative dose 18200 SU given as six injections of 600SU, 1600SU, 4000SU, 4000SU, 4000SU and 4000SU.
2551180|NCT02557373|Placebo Comparator|Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial.
2551181|NCT02557373|Experimental|Rice Bran + Vitamin A|Randomized participants will receive a one-dose of vitamin A supplementation (100,000 IU) at the beginning of the trial plus consume a measured dose of rice bran daily.
2551235|NCT02557074|Experimental|IL2 - Group A|"Patient will received IL2 low doses (1.5 to 3MUI/d) -~IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment~IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses"
2551236|NCT02557074|Placebo Comparator|Placebo - Group B|NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
2551262|NCT02556645|Experimental|Web-PE|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
2551264|NCT02556645|Active Comparator|PCT|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies.
2551299|NCT02556385|Experimental|High frequency rTMS|Most activated area from fNIRS with language task: Perileisional Broca's area
2551301|NCT02556385|Active Comparator|Low Frequency rTMS|Most activated area from fNIRS with language task: Contralesional homologs of Broca's area
2551328|NCT02556242|Experimental|Targeted indoor residual spraying|The intervention arm of the trial will receive Indoor Residual Spraying delivery through targeted spraying in the neighbourhood of recent local cases only.
2551335|NCT02556242|Active Comparator|Generalised Indoor residual spraying|The reference (control) arm of the trial will receive Indoor Residual Spraying through generalised annual spraying of all structures, as is the current standard practice.
2551446|NCT02555358|Experimental|A（DOX）|Interventions：This arm wil receive four cycles of DOX (docetaxel 60mg/m2 on day 1,oxaliplatin 130mg/m2 on day 1 and capecitabine 1,000 mg/m2 per day on days 1 to 14, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy
2551448|NCT02555358|Active Comparator|B（Xelox）|Interventions：This arm wil receive four cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as neoadjuvant therapy and four cycles of Xelox as adjuvant therapy
2551449|NCT02555358|Active Comparator|C（Xelox）|Interventions：This arm wil receive eight cycles of Xelox (capecitabine 1,000 mg/m2 per day on days 1 to 14 and oxaliplatin 130mg/m2 on day 1, repeated every 3 weeks) as adjuvant therapy.
3204583|NCT00935350|Placebo Comparator|7|Turkey dinner control
3204584|NCT00935350|Experimental|8|Granola
2551622|NCT02554500|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2552040|NCT02551835||Styrian Vitamin D Hypertension Trial|RCT on 2800 IU vitamin D3/day versus placebo for 8 weeks among persons a history of arterial hypertension and 25(OH)D values <75 nmol/L.
3204585|NCT00935350|Experimental|9|Cornflakes and milk
3204586|NCT00935350|Experimental|10|White Rice
3204587|NCT00935350|Experimental|11|Fruit yogurt
3204588|NCT00935350|Experimental|12|Turkey dinner
2551005|NCT02558569|Experimental|Levobupivacaine|Scalp nerve block with 0.5% Levobupivacaine adds up to intravenous fentanyl for intraoperative pain control during supratentorial craniotomy with brain tumor removal. The scalp block includes 4-6 nerves which give sensory supply to related location with the use of total 10-15 ml of 0.5% Levobupivacaine. Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given. is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
2551006|NCT02558569|Sham Comparator|NSS|Scalp nerve block with 10-15 ml of 0.9% sodium chloride(NaCl), or normal saline (NSS) includes 4-6 nerves which give sensory supply to related location (sham block). Intravenous fentanyl is used for intraoperative analgesia in both groups with continuous infusion (1 mcg/kg/hr until opening of dura and then 0.5 mcg/kg/hr until finishing of dural closure) and increment doses (0.5 mcg/kg) also given.
2551031|NCT02558192|Experimental|Probiotics|Vials containing 3 x 10^9 Colony Forming Units of LGG, vitamins ( B and C) and zinc
2551038|NCT02558192|Placebo Comparator|Placebo|Vials containing water, maltodextrin, magnesium stearate, potassium sorbate, sodium benzoate, citric acid, fructose, flavor.
2551091|NCT02557945|Experimental|Gabapentin|Gabapentin 3600mg PO daily
2551095|NCT02557945|Placebo Comparator|Placebo|Matching placebo PO daily
2551139|NCT02557594|Experimental|Viread → DA-2802|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
2551145|NCT02557594|Experimental|DA-2802 → Viread|"Viread 300mg(Tenofovir disoproxil fumarate)~DA-2802 319mg(Tenofovir disoproxil orotate)"
2551263|NCT02556723|Experimental|Ziv-aflibercept IV|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks.
2551315|NCT02556437|Experimental|Group A|24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia) followed by 24 weeks of treatment with HyQvia
2551320|NCT02556437|Experimental|Group B|24 weeks of treatment with HyQvia followed by 24 weeks of treatment with conventional subcutaneous immunoglobulin (Subcuvia)
2551375|NCT02555943|Active Comparator|Prophylactic/Early anti-HBV treatment|"HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection before or at the commencement of direct anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).~."
2551376|NCT02555943|Experimental|Deferred anti-HBV treatment|HCV/HBV co-infection patients in this arm will receive nucleos(t)ides analog (Entecavir or Tenofovir disoproxil fumarate) for the treatment of hepatitis B infection when HBV viral breakthrough occurred during anti-HCV treatment using DAAs (Ledipasvir/Sofosbuvir; or Sofosbuvir and Daclatasvir, or Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir; or Sofosbuvir+Ribavirin).
2551451|NCT02555410||Brain Sentinel Seizure Detection and Warning System|To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
2551502|NCT02555150|Active Comparator|PRC-063|Titration during which subjects will be titrated from a starting dose of 45 mg/day (dosed once daily) of PRC-063 oral capsules up to his/her final dose (45, 70 or 100 mg/day of PRC-063). This phase will be 10 to 21 days long.
2551505|NCT02555150|Active Comparator|lisdexamfetamine dimesylate|Titration during which subjects will be titrated from a starting dose of 30 mg/day of lisdexamfetamine up to his/her final dose (30, 50 or 70 mg/day of LDX). This phase will be 10 to 21 days long.
2551509|NCT02555150|Placebo Comparator|Placebo|Subjects will be dosed once daily with a placebo oral capsule for 10 to 21 days.
2551637|NCT02554357|Experimental|Exparel block in arthroscopic surgery|Evaluation of Exparel block in arthroscopic shoulder surgery.
2551641|NCT02554357|Experimental|Bupivacaine block in shoulder surgery|Evaluation of Bupivacaine block in shoulder surgery.
2551691|NCT02554045|Active Comparator|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
2551697|NCT02554045|Placebo Comparator|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
2551733|NCT02553616|Experimental|Behavioral intervention|Intervention to promote healthy behaviors.
3204589|NCT00935350|Placebo Comparator|13|White Bread
3204590|NCT00935350|Placebo Comparator|14|White bread
2551890|NCT02552706|Experimental|probiotics group|Administration of probiotics 500mg begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is continuous until preterm infants grow up to 36 weeks post menstrual age.
2551897|NCT02552706|Placebo Comparator|control group|control group received 1 mL of a 5% glucose solution. Administration of control group begins by mouth within 4 hours of life with 1-3 consecutive doses; the frequency depends on the feeding times. Study is also continuous until preterm infants grow up to 36 weeks post menstrual age.
2551939|NCT02552394|Experimental|HuJ591 Administration|6 subjects will be treated at 300 mg dose. The decision about treating subjects at the lower dose will depend upon their response. If ≥4 of 6 subjects respond at the 300 mg level, then 6 more subjects will be recruited at the 200 mg level. If ≥4 of 6 subjects respond at the 200 mg level than 6 more subjects will be recruited at the next dose level of 100 mg. If ≥ 4/6 subjects respond at this level, then 6 subjects will be recruited at the last dose level of 50 mg. At any level, if the first four consecutive subjects respond, the next two subjects will be enrolled in the same dose-level cohort and further subjects will be recruited at the next dose level. Response at every dose level is defined by conversion from an unfavorable CTC count at baseline to a favorable CTC count.
2551977|NCT02552095|Other|Triathlon PKR|Patient who receives the Triathlon.
3204591|NCT00935350|Experimental|15|Granola
3204592|NCT00935363|Experimental|glyburide + fluconazole|
2552232|NCT02550483|Active Comparator|Lycopene Tomato Juice|Participants will receive high lycopene tomato juice daily as part of controlled diet (base diet + high lycopene tomato juice).
3204593|NCT00935363|Experimental|glyburide + rifampin|
3204594|NCT00935363|Active Comparator|glyburide|
3204595|NCT00935363|Experimental|glyburide + fluconazole + rifampin|
2551016|NCT02558504|Experimental|Radiofrequency ablation|"The equipment processing is:~The radiofrequency generator,~The radiofrequency balloon 360,~the radiofrequency probe 90.~The radiofrequency treatment should be carried out according to the following protocol:~The radiofrequency treatment is done within 2 months following the last endoscopic assessment.~The maximum number of sessions is 4, including 2 maximum with 360 Halo probe.~Endoscopy is performed under general anesthesia.~The removal must begin at the top 1cm above the upper pole of the lesion and must end 1cm below the lower pole of the lesion.~The patient is left fasting until morning. In case of chest pain, the patient may receive analgesics.~During the time of treatment, the patient must follow an antisecretory therapy pump inhibitor with dual proton dose orally. The patient should avoid taking aspirin or nonsteroidal anti-inflammatory drugs during the 10 days following each session."
2551030|NCT02558140|Experimental|Part 1: Dose Escalation|All participants will be given RO6874813 as a single low dose of 0.5 milligrams per kilogram (mg/kg) via intravenous (IV) infusion in a 7-day pharmacokinetic (PK) run-in period (Cycle 0). This is followed by dose escalation (Cycle 1) for which participants will receive escalating doses of RO6874813 (starting dose = 1 mg/kg) via IV infusion every week (qw) or every 2 weeks (Q2W) for 28 to 42 days to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D).
2551033|NCT02558140|Experimental|Part 2: Tumor Biopsy and Imaging|The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.
2551039|NCT02558140|Experimental|Part 3: Preliminary Efficacy Assessment|Participants with locally advanced or metastatic non-resectable FAP+ sarcoma will be treated with RO6874813 at the RP2D and as per schedule determined upon completion of Part 1. Participants continuing treatment with RO6874813 beyond 36 weeks will enter the extension phase of Part 3 and will be monitored for disease status and clinical safety per routine standard of care.
2551110|NCT02557893|Experimental|Resistance exercise|Resistance exercise involved 12 weeks of weight lifting exercise
2551111|NCT02557893|Sham Comparator|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
2551112|NCT02557893|Placebo Comparator|Pregnancy education|Maternity nurses taught six bimonthly pregnancy education classes (~20 per class) which covered several topics including information about what to expect during normal labor and delivery, common interventions during delivery (medications, induction, Cesarean delivery), parenting skills needed for baby care, breastfeeding, baby and child cardiopulmonary resuscitation, typical child development and communicating with infants. No physical activity education was included in the curriculum. The pregnancy education participants formed an attention control group.
3170762|NCT00578500|Active Comparator|OCCT|Patients referred to ovarian cryopreservation.
3170763|NCT00578526|Active Comparator|Arm 1|SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks
3170764|NCT00578526|Placebo Comparator|Arm 2|1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.
3170765|NCT00578578|Active Comparator|1|"Active Arm:~1000 mg Lemon flavored Capsules. Three capsules every morning."
3170766|NCT00578578|Placebo Comparator|2|"Placebo Arm:~Cornstarch Capsules provided by Clinical Encapsulation services. Three capsules every morning."
3170767|NCT00578591|Experimental|Patient|Four Rituximab doses administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT)
2551240|NCT02556905||Korean patients|All Korean patients intended to be treated with REVLIMID® according to the approved package insert
2551374|NCT02555995|Experimental|All study participants|Patient's eyes are OCT-scanned with standard device and investigational device.
2551414|NCT02555553|No Intervention|Treatment as Usual|"The control group for the RCT will be a usual care condition in which participants are free to seek any assistance for their ED during the study period."
2551418|NCT02555553|Experimental|CBT-GSH with Noom Monitor|Participation will include 12 weeks of guided cognitive-behavioral therapy- guided self help (CBT-GSH) with an MA-level health coach or nutritionist from the KPNW health plan. Patients will use a self-help book, Overcoming Binge Eating (2013) by Christopher Fairburn. The first session will last 60 minutes, and each subsequent session lasts 20-25 minutes. The first four sessions are weekly, with the subsequent four twice monthly. Self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session.
2551530|NCT02554864|Active Comparator|Adductor Canal Block- Injection -Site A|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site A - after the sartorius muscle crosses over the femoral artery
2551537|NCT02554864|Active Comparator|Adductor Canal Block - Injection -Site B|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site B - before the sartorius muscle crosses over the femoral artery
2551538|NCT02554864|Active Comparator|Adductor Canal Block -Injection -Site C|AC Block-Injection (lidocaine 2% and ropivacaine 1%) Site C - as the sartorius muscle crosses over the femoral artery
2551610|NCT02554539|Experimental|Obese|Women, aged 21-45 with BMI >30
2551613|NCT02554539|Experimental|Normal weight|Women, aged 21-45 with BMI < 25
2551655|NCT02554214|Experimental|Glafkos device|
2551719|NCT02553980|Experimental|Physical activity promotion I|"Participants in this group attended the VT3 program (with Automatic HR detection)"
2551722|NCT02553980|Experimental|Physical activity promotion II|"Participants in this group attended the VT2 program (self PA report)"
2551724|NCT02553980|Placebo Comparator|Control|Participants in this group did not receive any VT treatment, and live as usual.
2552041|NCT02551835||Paravit study|RCT on 7000 IU vitamin D3/day versus placebo for 6 months among persons with a high body mass index and 25(OH)D values <50 nmol/L.
3170768|NCT00578604||Patients with a diabetic wound|Patients with a diabetic wound
3170769|NCT00578604||Control|Patients without a diabetic wound
2551022|NCT02558309||Intracranial Pressure Reduction|"Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.~The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant.~A slit lamp examination and indirect ophthalmoscopy will be performed.~Experimental:~The subject's eye will be held open with an eye speculum during the exam.~Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed.~Intraocular Pressure will be measured.~An Optic Coherence Tomography (OCT) will be performed.~At each step along the process of ICP reduction, the eye exam, IOP & OCT will be performed.~Optional:~The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained.~OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure."
2551063|NCT02558114|Other|Group A|Patients will receive ribavirin during 12 weeks
2551064|NCT02558114|Other|Group B|"Patients will receive:~ribavirin during 12 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is undetectable at week 4 after treatment start (adjust to renal function)~- ribavirin during 24 weeks if RNA (Ribonucleic acid) Hepatitis E virus (HEV) is detectable at week 4 after treatment start (adjust to renal function)"
2551100|NCT02557776|Experimental|Genetic testing of BRCA1 and BRCA2|"For detailes, please see Study procedure. Women with newely diagnosed breast cancer are offered written genetic counseling and screening of mutations in BRCA1 and BRCA2."
2551153|NCT02557542|Experimental|One Stop Vein Clinic|Patients randomised to this group will be invited to the One Stop Vein Clinic, offering same day diagnosis and treatment
2551156|NCT02557542|Active Comparator|Normal Care Pathway|Patients randomised to this group will be invited to the Normal Care Pathway
2551229|NCT02557113|Active Comparator|Vertebroplasty|This Group Underwent the Vertebroplasty Procedure (Injection of Bone Cement into the Fractured Osteoporotic Vertebral Body)
2551230|NCT02557113|Experimental|Cavuplasty|This Group Underwent the Cavuplasty Procedure (Small Cavity was Created in the Vertebral Body Prior to Injection of Bone Cement)
2551269|NCT02556749|Experimental|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
2551273|NCT02556749|Placebo Comparator|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
2551304|NCT02556398|Experimental|Intervention - Educ Module and App|"Participants in this arm to be given smartphone app (Sugar Sleuth) and educational module."
2551332|NCT02556229|Experimental|Aflibercept|Intravitreal injection of aflibercept (EYLEA) / 2mg
2551359|NCT02555982|Experimental|EXPERIMENTAL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
2551360|NCT02555982|Other|CONTROL GROUP|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
2551444|NCT02555475|No Intervention|Group 1, tertiary hospital based care|Group 1: (n=190) Following their initial screen, these participants will be referred to a tertiary hospital for hepatitis C care, transient elastography and DAA treatment (traditional / standard model of care).
2551445|NCT02555475|Experimental|Group 2, community based care|Group 2: (n=190) Following their initial screen, these participants will be offered community based hepatitis C care and treatment. Hepatitis C care, transient elastography and DAA treatment will be delivered at the primary healthcare centre only.
2551503|NCT02555111|Experimental|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
2551507|NCT02555111|No Intervention|untreated|the patient won't receive any treatment during his study participation.
3204596|NCT00935376|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
2551636|NCT02554318|Experimental|Intervention|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets~and 166.5 grams cooked fermented soybean (tempeh) daily for two months"
2551638|NCT02554318|Active Comparator|Control|"TB standard therapy with fixed dose combination :~once per day by mouth for 2 months Fixed dose combination = RHZE (150mg/75mg/400mg/275mg) R=rifampicin, H=isoniazid, Z=pyrazinamide, E=ethambutol,~Patients with body weight: 30 - 37 kg = 2 tablets, 38 - 54 kg = 3 tablets, 55 - 70 kg = 4 tablets, and ≥71 kg = 5 tablets"
2551717|NCT02553889|Experimental|PK Cohort|A 4-week screening period followed by a 4-week treatment period followed by a 6-week post-treatment evaluation period. Treatment period includes 1 dose of 300 mg ISIS 416858 on Day 1 and again on Day 29. Both doses of Study Drug will be administered subcutaneously (SC).
2551721|NCT02553889|Placebo Comparator|Cohort A|"Patients in Cohort A will be randomized to receive either 200 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort A, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort A will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
2551795|NCT02553265|Active Comparator|Low Dose Carbidopa, High Dose Carbidopa, Placebo|This is a 14-week study. Patients will receive, in random order, high dose carbidopa (600mg/day), low dose carbidopa (300 mg/day) or placebo. Between each crossover, there will be a titration down over 2-days followed by a 2-day washout.
2551146|NCT02557412|Active Comparator|Intensive lifestyle intervention|Lifestyle intervention will consist of a structured intervention in a specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%), which will be repeated in each review. Also, be recommended to increase daily physical activity, setting a target walking 10,000 steps a day. To do this, to patients assigned to this treatment arm, will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
2551149|NCT02557412|Active Comparator|Continuous positive airway pressure|Treatment with nasal continuous positive airway pressure (CPAP). Treatment begins with an empirical pressure of 8 centimetres of water (cmH2O) and in a period of three weeks, the pressure is adjusted by titration with an automatic positive airway pressure device (AutoSet II, ResMed).
2551227|NCT02556931|Experimental|PBSCT D90|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 90 or Day 180 depending on GVHD status.
2551228|NCT02556931|Experimental|PBSCT D60|Non-myeloablative peripheral blood stem cell transplant (PBSCT) with a fludarabine (Flu), cyclophosphamide (Cy), total body irradiation (TBI) preparative regimen and post-transplant Cy, mycophenolate mofetil (MMF), and tacrolimus as GVHD prophylaxis. Tacrolimus will be stopped at either Day 60 or Day 180 depending on GVHD status.
2551280|NCT02556593|Experimental|IMRT & erlotinib|Patients in experimental group receive IMRT and erlotinib: Daily IMRT(45Gy in 15 fractions) to the brain metastases with daily erlotinib(150mg.po) for three weeks
2551284|NCT02556593|Active Comparator|whole-brain radiotherapy|Patients in this group receive WBRT at 30Gy in 10 fractions
2551319|NCT02556320|Experimental|Epileptic patient|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
2551399|NCT02555761||Lastacaft®|One drop of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) in each eye daily as prescribed as standard of care in clinical practice.
2551630|NCT02554370|Experimental|Psychoeducational programme|Psychoeducational programme
2551632|NCT02554370|No Intervention|Usual care|No psychoeducational programme
2551670|NCT02554123|Experimental|Vitamin E ointment|Vitamin E ointment application. Every 12 hours during 7 days.
2551671|NCT02554123|Placebo Comparator|Vaseline ointment|Vaseline ointment application. Every 12 hours during 7 days.
2551709|NCT02553759|Experimental|Effective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement to each side, first 10 times towards the right and then 10 times towards the left. The movement will be performed effectively over the entire course of the cervical path, approximately 80º
2551711|NCT02553759|Active Comparator|Ineffective movement|This group will see a 1-minute video showing an individual performing a cervical rotation movement ineffectively, without achieving the maximum cervical travel, performing approximately 40º. First, 10 movements towards the right will be performed and then 10 towards the left
2551757|NCT02553291|Experimental|SystemCHANGE|Subjects will participate in SystemCHANGE behavioral intervention focusing on diet and exercise. This six-session intervention focuses on system redesign of an individual's interpersonal environment and daily routines using small self-designed experiments to increase healthy behavior.
2551759|NCT02553291|Active Comparator|Control|Subjects randomized to the control group will receive an usual care condition and pamphlets on diet and exercise from the U.S. Department of Agriculture and the American Heart Association (AHA)
2551836|NCT02553122|Other|Control Group|This group of patients will receive standard protocol to control intra-operative blood loss.
2551838|NCT02553122|Active Comparator|Treatment Group|This group of patients will receive TXA, Evicel and standard protocol to control intra-operative blood loss.
2551863|NCT02552797|Experimental|Using Power Up|Participants will use 'Power Up' to help them make shared decisions about their treatment or care
2551866|NCT02552797|No Intervention|Not using Power Up|Participants will continue treatment as usual
2551932|NCT02552628|Experimental|"Stimulation on"|"The deep brain stimulation is on"
2551934|NCT02552628|Sham Comparator|"Stimulation off"|"The deep brain stimulation is off"
2551980|NCT02552082||Scorpio NRG|
2552023|NCT02551900|Experimental|Warm water exercise & Cold water exercise|
2552024|NCT02551900|Active Comparator|Warm water exercise & Land cycling exercise|
2552079|NCT02551614|Experimental|Group 1: healthy subjects|Subjects will undergo inhaled challenge, either with lipopolysaccharide or saline in a 2:1 ratio, prior to imaging assessments. Assessments will be performed during one study day on an outpatient basis.
2552083|NCT02551614|Experimental|Group 2: COPD patients|Subjects will undergo imaging assessments during one study day on an outpatient basis. Approximately 10 of these COPD patients will repeat this study day 7-10 days after completion of the first study day to assess the reproducibility of the technique.
2552139|NCT02551341|No Intervention|control|normal ventilation
2552142|NCT02551341|Experimental|intervention|higher PEEP ventilation
2552176|NCT02550912|Active Comparator|Vitamin D group|Patients will receive vitamin D drug with generic name: V drops manufactured by Medical Union Pharmaceuticals, Egypt Dosage form: liquid drops Dosage, frequency, and Duration:1000 international units per day for 3 months then 1000 international units per 25 pounds per day for another 3 months.
2552178|NCT02550912|Placebo Comparator|Placebo group|Patients will receive glucose syrup same taste and color as vitamin D3 drops with same dosage regimen to vitamin D group.
2552245|NCT02550496|Experimental|tinea capitis|
2551256|NCT02556710|Placebo Comparator|4 mL Saline Placebo|Saline placebo, 4 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride.
2551326|NCT02556515|Active Comparator|Trapeziektomi and ligament interposition|Interpositional arthroplasty Interpositional arthroplasty (Burton-Pellegrini procedure)
2551337|NCT02556515|Experimental|Total joint replacement|Elektra CMC1 uncemented prosthesis Elektra prosthesis
2551363|NCT02555917|Experimental|Remnant preserving|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be preserved in the operation"
2551366|NCT02555917|Active Comparator|Remnant resecting|"Anterior cruciate ligament reconstruction:~anterior cruciate ligament remnant will be removed in the operation"
2551386|NCT02555644|Experimental|Prexasertib + Cisplatin + Radiation Therapy (Part A)|"Prexasertib administered intravenously (IV) every 14 days over an approximately 49-day treatment period.~Cisplatin administered IV every 7 days over an approximately 49-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 49-day treatment period.~Participants may remain on treatment until completion of the treatment period."
2551392|NCT02555644|Experimental|Prexasertib + Cetuximab + Radiation Therapy (Part B)|"Prexasertib administered IV every 14 days over an approximately 56-day treatment period.~Cetuximab administered IV every 7 days over an approximately 56-day treatment period.~Intensity modulated radiation therapy administered 5 days per week over an approximately 56-day treatment period (starting at Week 2).~Participants may remain on treatment until completion of the treatment period."
2551467|NCT02555280|Experimental|The coflex® Interlaminar Technology|The coflex device was designed to address the clinical needs of spinal stenosis patients by providing stabilization of the affected level without fusion. The coflex is an interspinous process functional dynamic implant designed to impart a stabilizing effect at the treated level(s). The coflex device was approved by FDA in 2012.
2551470|NCT02555280|Active Comparator|Decompression|Lumbar decompression back surgery is when a small portion of the bone over the nerve root and/or disc material from under the nerve root is removed to give the nerve root more space and provide a better healing environment.
2551516|NCT02554942|Experimental|Epoetin beta|Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram [IU/kg]) for 16 weeks.
2551584|NCT02554643|Experimental|Diet & Soccer|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Soccer training, 3 times a week, during 12 weeks"
2551586|NCT02554643|Experimental|Diet & Running|"Nutritional Intervention (Diet) once a week, during 12 weeks~+ Running training, 3 times a week, during 12 weeks"
2551588|NCT02554643|Active Comparator|Diet|Nutritional Intervention (Diet) once a week, during 12 weeks
2551664|NCT02554344|Experimental|All Patients|Fourteen subjects with histologically confirmed squamous CIN3 will be enrolled in a single arm study. All patients will receive 500 mg of curcumin administered orally, twice a day for 12 weeks upon enrollment on trial.
2551683|NCT02553863|Experimental|Intervention group|Acupuncture for 30min [twice weekly for 8 weeks]
2551685|NCT02553863|Other|Control group|Standard care
2551740|NCT02553668|Experimental|Hyperoxia|Participants receive 100% oxygen
2551839|NCT02553083|Active Comparator|Group 1|Nexium 40 mg and amoxicillin 1.5 gr twice daily for 14 days
2551841|NCT02553083|Active Comparator|Group 2|Nexium 40 mg and doxycycline 200 mg twice daily for 14 days
2551844|NCT02553083|Active Comparator|Group 3|Nexium 20 mg, clarythromicin 500 mg, and amoxicillin 1 gr twice daily for 14 days
2551995|NCT02552199||with hyperhidrosis|Patients with primary hyperhidrosis
2552001|NCT02552199||healthy|Healthy adult patients
2552078|NCT02551705|Experimental|functional Imaging mutation carrier|Premanifest mutation carrier, behavioral and neural emotional memory processing
2552081|NCT02551705|Active Comparator|functional Imaging non-carrier|non-carrier family member, behavioral and neural emotional memory processing
2552137|NCT02551367|Experimental|letrozole|patients receive letrozole 2.5 mg twice daily from day 2 to day 6 of the cycle , for 3 consecutive cycles, hcg hormone10.000 iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound.
2552138|NCT02551367|Active Comparator|clomiphene citrate|patients will receive clomiphene citrate 50 mg twice daily from day 2 to day 6 of the cycle for 3 consecutive cycles , hcg 10.000 hormone iu im injection is given when mature follicle diameter reach 18 mm by trans vaginal ultrasound .
2552346|NCT02549742|Experimental|Electrochemotherapy|25 patients treated with electrochemotherapy
2552403|NCT02549495||Patients with Diabetes or Hypertension|All patients in the seven study communities will receive the community health worker intervention provided by CES, as it is incorporated into the standard of care. However, they will receive the intervention at different points in time depending on which community they lived in, as community health worker programs can only be started at every-three-month intervals
2552429|NCT02549170|Experimental|Epoch 1: HYQVIA/HyQvia|Participants will receive HYQVIA/HyQvia at a dose of 80 Unit per gram (U/g) SC immunoglobulin (IgG) which will be same as the participants pre-randomization monthly equivalent IgG dose (or at matching infusion volume for participants in the placebo group) when administered at a dosing frequency of every 2, 3, or 4 weeks for 6 months or until relapse.
2552432|NCT02549170|Placebo Comparator|Epoch 1: Placebo with rHuPH20|Participants will receive sequential 0.25% albumin placebo with rHuPH20 at a dose of 80U/g IgG SC for 6 months or until relapse. Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
2552437|NCT02549170|Experimental|Epoch 2: IGIV|Participants will receive an induction dose of 2 gram per kilogram (g/kg) Intravenous immunoglobulin G (IGIV), followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks for 6 months or until relapse.
2552568|NCT02548416|Active Comparator|PEEP group|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using positive end-expiratory pressure.
2552629|NCT02548260|Experimental|Syndactyly without compression|Relative immobilization with a syndactyly (CE conformity), no compression is worn.
2551267|NCT02556827||K, Healthy volunteers|"Healthy volunteers who were compatible in terms of age, sex and skin phenotype, having no systemic illness and who were not smoking.~Obtaining a blood sample; TOC, TAC, OSI, PON-1, ARES, MPO, TNF-α, IL-1β, MMP-1 and MMP-9 levels in venous blood were measured Reflectance confocal microscopy; 1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM. Sebum rate at forehead and right cheek were evaluated with sebumeter. Dermoscopic photoaging scale were assessed by using video dermoscopy."
3204597|NCT00935376|Experimental|Mindfulness Meditation Program|Mindfulness Meditation Program (MMP) is based on Mindfulness-Based Stress Reduction (MBSR), which teaches participants mindfulness skills such as meditation and yoga. Mindfulness may be defined as paying attention in a particular way, on purpose, in the present moment, and nonjudgmentally. The goal of MBSR is to provide participants with experiential tools and mindfulness practices to assist them to become more mindful of themselves, others and their external environment. The techniques are easy to learn and teach individuals to be aware of the present moment, with an open mind in which they can perceive their thoughts, physical sensations, and emotions nonjudgmentally.
2551385|NCT02555852||Users of PPIs|Exposure to proton pump inhibitors (PPIs) will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole, and combinations) on the same day as the cohort entry defining prescription for an NSAID.
2551391|NCT02555852||Users of H2RAs|Exposure to histamine-2 receptor antagonists (H2RAs) will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as the cohort entry defining prescription for an NSAID.
2551394|NCT02555852||Unexposed group (Reference)|Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as the cohort entry defining prescription for an NSAID.
2551486|NCT02555059||BAYQ3939|Pediatrics patients treated with Ciproxan injection in daily clinical practice.
3204598|NCT00935376|Active Comparator|Sleep Education Program|The Sleep Education Program (SEP) will serve as the control intervention in which participants will receive classes informing them how to change their habits to improve their sleep, and what to do if they have concerns about their sleep quality.
3204599|NCT00935389|Experimental|immunosuppressor|TW 30mg,q.d.*3 months and reduced into 20mg b.i.d
3204600|NCT00935402|Experimental|Short Sleep|Subjects are permitted to spend 4 hours in bed per night for 5 consecutive nights. Subjects are inpatients for a period of 6 days.
3204601|NCT00935402|Active Comparator|Regular Sleep|Subjects are permitted to spend 9 hours in bed per night for 5 nights. Subjects are inpatients for a period of 6 days.
2551761|NCT02553252|Experimental|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants will receive training in SKY soon after completing baseline assessments.
2551763|NCT02553252|No Intervention|wait list control (WLC)|Participants will receive training in SKY after 12 weeks have passed since the baseline assessment.
2551835|NCT02553109||small unruptured paraclinoid aneurysm|Patients with newly diagnosed, small (less than 5mm) unruptured paraclinoid aneurysms who will visit one of the study centers during the period from January 2015 to February 2017. Patients would be eligible for enrollment if they were 20 years of age or older and had an unruptured paraclinoid aneurysm that is less than 5 mm in the largest dimension. All patients who would visit a study center during the enrollment period and meet these criteria will be asked to join the study. The cohort will consists of patients who agree to participate. Target population of this study is 645 aneurysms.
2551862|NCT02552771|Active Comparator|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
2551869|NCT02552771|Active Comparator|Mitral repair with leaflet resection|Removal of one or both of the mitral leaflets that flop or bulge back.
2551929|NCT02552446||All patients|All ICU patients mechanically ventilated staying more than 72 hours were included and indirect calorimetry was performed and compared to predictive energy expenditure formulas using different body weights.
2551985|NCT02552173||stem anteversion|intraoperative surgeon's estimation and postopertive CT sacn were taken to measure stem anteversion
3204602|NCT00935415|Active Comparator|Montelukast|capsules prepared in blindness
3204603|NCT00935415|Placebo Comparator|Placebo|matched placebo
2552132|NCT02551302|Other|PLIF|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF).
2552134|NCT02551302|Other|Hybrid system (PLIF + flexible pedicle screw system above the|The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion.
3204604|NCT00935441|Experimental|Telemonitoring|Case management with home telemonitoring for blood sugar and blood pressure plus home HbA1c measurement
3204605|NCT00935441|Active Comparator|Usual case management|Case management
3204606|NCT00935467|Other|Saxagliptin|
3204607|NCT00935480|Experimental|HAART+Raltegravir 12 months (+/-) Maraviroc|
2552275|NCT02550093|Active Comparator|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Oxytocin prior to Thermal Evaluation System Testing.
2552281|NCT02550093|Placebo Comparator|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of Normal Saline prior to Thermal Evaluation System Testing.
2552347|NCT02549963|Experimental|WATCHMAN LAA Occlusion Device|Subjects assigned to receive the WATCHMAN Left Atrial Appendage Occlusion Device.
3204608|NCT00935480|No Intervention|HAART|
3204609|NCT00935506|Experimental|Clopidogrel + Aspirin|
3204610|NCT00935519|Other|ceramic bearing|Survival rate of THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
3204611|NCT00935545|Experimental|Open Label|
3204612|NCT00935558|Experimental|Aromatase inhibitor and DC vaccination|the HLA-A2 positive patients will be treated with AI, DC vaccines, Zadaxin and IL-2
3204613|NCT00935558|Active Comparator|Aromatase inhibitor|the HLA-A2 negative patients will receive AI only
2551272|NCT02556814|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablets 0.3g three times per day for 3 months. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
2551331|NCT02556372|Experimental|JKB-122|AIH-positive subjects (n=20) who are intolerant, refractory, ineligible or unwilling to take current therapies, and have liver enzymes that are 2 to 10 times the upper limit of normal
2551377|NCT02555813||Abraxane + Gemcitabine|Abraxane 125mg by intravenous( IV) infusion + Gemcitabine 1000mg by intravenous on Days 1, 8, 15 of every 21 day cycle until progression
2551466|NCT02555254|Experimental|Low speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. Then, intervention will be proceeded after randomization: slowly rewarmed (0.25°C/h) to targeted temperature controlled at 37°C for 24 hours.
2551468|NCT02555254|Experimental|Fast speed of rewarming|Patients will be placed in targeted temperature controlled at 33°C for 24 hours. hen, intervention will be proceeded after randomization: fastly rewarmed (0.50°C/h) for targeted temperature controlled at 37°C for 24 hours.
2551485|NCT02554994|Active Comparator|Intervention|"ASPRA (Aging Study of PyeongChang Rural Area) cohort is a population-based, prospective cohort study of older adults living in PyeongChang County of South Korea. This cohort study is supported by public health center, named PyeongChang Health Center and Country Hospital managed by government, to improve the quality of aged public health services.~All participants will be recruited from ASPRA cohort. After 6 months of usual care period, eligible participants are screened by characteristics of ASPRA database, and are assigned to a multifactorial intervention arm."
2551487|NCT02554994|Active Comparator|usual care|The other participants enrolled to ASPRA cohort are acted as a control arm. The usual care according to ASPRA protocol will be maintained.
2551528|NCT02554838|Active Comparator|Rehabilitation|"Rehabilitation :~Physical activity~Home assessment and modification"
2551535|NCT02554838|Experimental|Rehabilitation and CBT|"Rehabilitation associated with cognitive behavioral therapy (CBT) :~Physical activity~Home assessment and modification~Cognitive behavioral therapy"
3170770|NCT00578630||1|All Pediatric Oncology and Bone Marrow Transplantation Service patients with a histologically proven tumor for whom there is an intent to treat with chemotherapy
3170771|NCT00578656|Experimental|1|Baked milk and at least 4 oral food challenges as clinically indicated
2551663|NCT02554149||stem anteversion|a hip lateral radiograph and CT scan were taken to measure stem anteversion
2551734|NCT02553551|Experimental|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
2551735|NCT02553551|Placebo Comparator|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
2551787|NCT02553343|Experimental|QIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 1)
2551794|NCT02553343|Experimental|QIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of High-Dose quadrivalent influenza vaccine (formulation 2)
2551798|NCT02553343|Active Comparator|TIV HD1 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of licensed High Dose trivalent influenza vaccine
2551800|NCT02553343|Active Comparator|TIV HD2 Group|Adults ≥ 65 years of age randomly assigned to receive an intramuscular injection of one dose of investigational High-Dose trivalent influenza vaccine
3204614|NCT00935571||Group I, Group II|"Group I: anesthetized with TIVA (Propofol + Remifentanil)~Group II: anesthetized with inhalation (sevoflurane)"
2552010|NCT02551939|Experimental|fat graft|Autologous Fat Grafting
2552295|NCT02550353|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery
2552307|NCT02550353|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the femtosecond laser-assisted laser in situ keratomileusis surgery.
2552337|NCT02549846|Active Comparator|Acute Group|Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission
2552339|NCT02549846|Other|Stable Group|Not start or withdraw Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment for a weak after admission.
2552433|NCT02549560|Active Comparator|tDCS GROUP|These patients will be submitted to 2 daily sessions of cerebral stimulation, starting from the first day after the surgery, for 4 consecutive days, with each session having 20 minutes, and a minimum break of 8 hours between them. Will be applied a direct current stimulus of 2 milliampere (mA) in the right anode and in the left cathode on the prefrontal right region.
3170772|NCT00578682|Experimental|1|Single IV dose of 0.3 mg/kg MEDI-557
3170773|NCT00578682|Experimental|2|Single IV dose of 3 mg/kg MEDI-557
3170774|NCT00578682|Experimental|3|Single IV dose of 15 mg/kg MEDI-557
3170775|NCT00578682|Experimental|4|Single IV dose of 30 mg/kg MEDI-557
3170776|NCT00578695|Experimental|Active|Lixivaptan
3170777|NCT00578695|Placebo Comparator|Placebo|Placebo
3170778|NCT00578708|Experimental|1|
3170779|NCT00578721|Experimental|325 mg Aspirin|325 mg aspirin po qd with arginine-restricted diet
3170780|NCT00578760|Placebo Comparator|2|placebo OD during course of chemotherapy
3170781|NCT00578760|Experimental|1|325mg ASA OD during course of chemotherapy
3170782|NCT00578773|Experimental|Moxidex|Moxidex otic solution
3170783|NCT00578773|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3170784|NCT00578773|Other|TT only|Tympanostomy tubes only
3170785|NCT00578799|Active Comparator|Kyo-Dophilus|Kyo-Dophilus (5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening)
3170786|NCT00578799|Placebo Comparator|Placebo|placebo capsules (potato starch)
2551447|NCT02555345||classic asthma/No intervention|Patients with classic asthma were stable.Chest X-ray or CT scan was normal.Fenofibrate(FeNO) was performed.Spirometry was needed. The leicester cough questionnaire (LCQ) was offered to physicians.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
2551450|NCT02555345||CVA/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered to physicians. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
2551452|NCT02555345||EB/No intervention|Chest X-ray or CT scan was normal.FeNO was performed. Spirometry was needed. The LCQ was offered.Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
2551453|NCT02555345||Healthy/No intervention|Chest X-ray or CT scan was normal.FeNO was performed.Spirometry was needed. Sputum,blood and urine samples were collected to study genetic, inflammation and other aspects of these diseases.
2551499|NCT02555137||outcome cohort study|'prediction score' and 'rule-out criteria'
3170787|NCT00578838||1|25 patients with metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
3170788|NCT00578838||2|25 patients with non-metastatic colorectal cancer. Each patient will have 4 MR exams: prior to or within one week of the start of the chemotherapy regimen, one after 6 weeks of chemotherapy, a third after completion of chemotherapy (between 12 and 24 weeks post-initiation of chemotherapy) and a long term followup study at least 4 months after the completion of chemotherapy.
3170789|NCT00578838||3|11 healthy volunteers, who will also undergo two scans 2-3 weeks apart.
3170790|NCT00578851||C2a Taper recipients|Patients who receive a THA with the C2a - Taper™ Acetabular System
2551646|NCT02554409||Pregnancy Cases|No Intervention as part of this protocol
3170791|NCT00578890|Experimental|1|
2551810|NCT02553161|Experimental|MED - Escitalopram with psychotherapy|Youth will also be assigned a board certified child psychiatrist (Drs. Singh or Chang at Stanford; Drs. DelBello or Patino at UC), who will be blind to treatment condition and see youth weekly for the first 4 weeks, then biweekly until 16 weeks. Youth in the MED condition will be given the USFDA (US Food & Drug Administration) approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks.
2551812|NCT02553161|Placebo Comparator|No MED -Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
2551815|NCT02553161|No Intervention|Healthy Control|60 (30 at Stanford, 30 at University of Cincinnati) 12- to 17-year old male and female typically developing healthy controls. Healthy controls will receive behavioral, neural, and physiological assessments at baseline only. healthy controls will be scanned at baseline only and serve as a reference group to determine whether MRI changes observed in the high-risk group from baseline to week 4 are toward or away from normal.
2551885|NCT02552836|Experimental|Interpersonal Psychotherapy (IPT)|Patients assigned to IPT will receive 12 sessions of individual therapy of approximately 50 minutes duration. Therapy will be manualized and slightly adapted to meet the needs of patients with Parkinson's Disease. Therapy focuses on one of four interpersonal events that are linked with onset or maintenance of depression (role transition, role disputes, unresolved grief, and interpersonal deficits).
2551887|NCT02552836|Active Comparator|Supportive Psychotherapy (SP)|Patients assigned to SP will receive 12 sessions of individual therapy of approximately 50 minutes duration. SP strives to create a supportive therapeutic relationship by emphasizing non-specific therapeutic interactions and techniques. Therapy will be manualized,
2552246|NCT02550717||Acetylsalicylic Acid|New users of low-dose Acetylsalicylic Acid (ASA)
3170792|NCT00578916|Experimental|1|
3170793|NCT00578981|Experimental|Arm 1|
3170794|NCT00578981|No Intervention|Arm 2|
3170795|NCT00578994||Oxford® Meniscal Unicompartmental Knee|Patients with PKA using the Oxford® Meniscal Unicompartmental Knee System
3170796|NCT00579007||1|Women with a strong family history of breast cancer.
3170797|NCT00579020|Experimental|Moxidex|Moxifloxacin/dexamethasone phosphate ophthalmic solution, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3170798|NCT00579020|Active Comparator|Moxifloxacin|Moxifloxacin ophthalmic solution 0.5%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3170799|NCT00579020|Active Comparator|Dexamethasone|Dexamethasone phosphate solution, 0.1%, one drop in cul-de-sac and 4 drops on closed lids of study eye(s), four times a day, for seven days
3170800|NCT00579033|Sham Comparator|1|
3170801|NCT00579033|Active Comparator|2|
3170802|NCT00579046|Experimental|1|
3170803|NCT00579072||Longitudinal Study|Take part in this study because subject has prostate cancer and are over 64 years old. To run this study,need men from two groups. First, we need men who are about to start hormone treatment. Second, we need men who do not plan to use this treatment in the future. We will use this second group as a control group and compare this group to the men who are using this treatment.
3170804|NCT00579072||Group Comparison|Take part in this study because subject has prostate cancer and are over 64 years old. Also, because subject has been on hormone therapy for about two to three years.
3170805|NCT00579085|Placebo Comparator|1|
3170806|NCT00579085|Experimental|2|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline with or without ketamine for four hours (25 ml/hr) daily for 10 days. The maximum intravenous ketamine infusion dose for this study will be 0.35 mg/kg/hr, not to exceed 25 mg/hr (100 mg of ketamine over a 4 hour period). On the first day, the intravenous ketamine infusion will be set to 50% of the maximum rate. On the second day, the intravenous ketamine infusion will be increased to 75% of the maximum rate. On the third day, the intravenous ketamine infusion will be increased to the maximum rate. The daily ketamine infusion rate is maintained at this level for the duration of the ten day study."
2551322|NCT02556294|Other|Comparison/Control|The comparison group will receive HIV and STI counseling and testing.
2551442|NCT02555488|Experimental|2|in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals.
2551443|NCT02555488|Experimental|1|In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done
2551491|NCT02555189|Experimental|Enzalutamide|Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2551493|NCT02555189|Experimental|Enzalutamide + Ribociclib|Patients receive enzalutamide PO QD on days 1-28 and ribociclib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2551567|NCT02554695|Placebo Comparator|placebo|single subcutaneous injection of placebo (normal saline)
2551569|NCT02554695|Active Comparator|Denosumab|single subcutaneous injection of denosumab 60 mg
2551572|NCT02554695|No Intervention|young normal premenopausal women|no intervention
2551596|NCT02554422|Experimental|PalpEar|Intraoperative palpation of the ossicles using the PalpEar device, to measure mobility of the ossicle chain.
2551692|NCT02554032|Active Comparator|Axillary artery cannulation|Axillary artery cannulation for antegrade cerebral perfusion
2551696|NCT02554032|Active Comparator|Innominate artery cannulation|Innominate artery cannulation for antegrade cerebral perfusion
2551752|NCT02553577||Conventional cigarettes -only|Women who are pregnant and use conventional tobacco products -only
2551754|NCT02553577||Electronic Cigarette (ecig) (ENDS) -ONLY|Women who are pregnant and use electronic cigarettes (ecigs) -only
2551755|NCT02553577||Conventional + ecig use (DUAL)|Women who are pregnant and use conventional + ecigs (dual)
2551805|NCT02553187|Experimental|Treatment group|Kanglaite Injection plus standard therapy.
2551809|NCT02553187|No Intervention|Control group|Blank control and standard therapy.
2551919|NCT02552550||Ability to swallow, speak and quality of life|This will just be an evaluation, before any treatment, his ability to swallow, speak and quality of life then, as in normal practice, after 3, 6 and 12 months after treatment.
2551972|NCT02552264|Active Comparator|Immediate intervention|Acceptance and Commitment Therapy
2551975|NCT02552264|Placebo Comparator|Waitlist control|Acceptance and Commitment Therapy
2552016|NCT02551913|Active Comparator|control|The adolescents will not receive any specific information
2552020|NCT02551913|Experimental|Intervention|The adolescents will receive relevant information on the importance of adequate sleep, the consequences of sleep deprivation, Provide information about others' approval,Provide normative information about others' behaviour,Goal setting ,action planning, coping planning, Set graded tasks,Prompt self-monitoring of sleep behaviour
3204615|NCT00935597|Experimental|Group 1|Patients with Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion
3204616|NCT00935597|Experimental|Group 2|Patients with greater than Minimal Residual Disease or Minimal Volume Relapse post allogeneic stem cell transplant will receive MSSM/BIIR HDC Vax-001 (Host Dendritic Cells) by infusion in conjunction with donor lymphocyte infusion (DLI)
3204617|NCT00935610|Active Comparator|Immunocal|20g of Immunocal
3204618|NCT00935610|Placebo Comparator|Casein|20g of Casein
2552341|NCT02549794|Active Comparator|High concentration (370)|CT angiography with hign concentration iodine contrast agent of 370 mg iodine/ml
2552342|NCT02549794|Experimental|Low concentration (320)|CT angiography with low concentration iodine contrast agent of 320 mg iodine/ml
2552344|NCT02549794|Experimental|Low concentration (270)|CT angiography with low concentration iodine contrast agent of 270 mg iodine/ml
2552407|NCT02549534||Women with Breast Cancer (WBC)|"Defined as women who:~Are 18 to 85 years old at the time of enrollment;~Have histologically-confirmed, first-time, non-metastatic breast cancer (Stage I-IIIB);~Have no history of neurotoxic chemotherapy or radiation treatment at the time of enrollment;~Will be receiving weekly paclitaxel (Taxol® or generic paclitaxel), 80-100mg/m2, or bi-weekly (i.e., dose-dense) Taxol, 175 mg/m2, as a part of their treatment regimen OR~Will be receiving an anthracycline and cyclophosphamide (AC) therapy followed by weekly or bi-weekly (i.e., dose-dense; 175 mg/m2) paclitaxel (Taxol® or generic paclitaxel, 80-100mg/m2);~Are willing to participate in up to four study sessions."
2552408|NCT02549534||Healthy Female Controls (HCs)|"Defined as women who:~Are 18 to 85 years old at the time of study enrollment;~Can read, write, and understand English,~Are willing to participate in three planned study sessions."
3204619|NCT00935623|Experimental|Cohort 1|The first cohort will be challenged with 5 bites from P. vivax-infected mosquitoes each carrying at least a grade 2 sporozoite infection (>10 sporozoites in salivary gland).
3204620|NCT00935623|Experimental|Cohort 2|If the first cohort has less than 100% infectivity rate, the second cohort will be challenged with up to 10 grade 2 infective bites to ensure 100% infectivity rate.
2552569|NCT02548377|Experimental|Remote ischemic preconditioning|Four 5-minute cycles of upper extremity ischemia, each separated by five minutes of reperfusion. The treatment will be carried out with a tourniquet inflated to 200 mmHg during general anaesthesia prior to flap ischemia and transfer.
2552573|NCT02548377|Sham Comparator|Sham|The tourniquet will be attached to the patient's upper extremity but never inflated.
3204621|NCT00935662|Experimental|AZD8329|AZD8329 oral solution
2552662|NCT02547597|Experimental|Carvedilol|Carvedilol 25 mg twice a day
2552665|NCT02547597|Active Comparator|Atenolol|Atenolol 50 mg twice a day
2552725|NCT02547506||Parkinson Disease (Boxing)|Individuals with Parkinson Disease who participate in boxing on a regular basis
2552726|NCT02547506||Parkinson Disease (Group Exercise)|Individuals with Parkinson Disease who participate in group exercise other than boxing on a regular basis
2552727|NCT02547506||Healthy Controls|Individuals without disability who participate in group exercise other than boxing on a regular basis
3204622|NCT00935662|Placebo Comparator|Placebo|Placebo for AZD8329 oral solution
3204623|NCT00935675|Active Comparator|Antidepressant treatment|
3204624|NCT00935675|Placebo Comparator|Placebo|
3204625|NCT00935688|Experimental|Rapid diagnostic tests|malaria diagnosis by rapid diagnostic test
3204626|NCT00935688|No Intervention|Clinic Microscopy|malaria diagnosed with field light-microscopy
2551334|NCT02556164|Sham Comparator|Sham EA|Sham EA as intervention is performed for the control group at non-acupuncture points without needle manipulation. The electric stimulation in sham acupuncture was performed in a similar fashion to the real EA.
2551416|NCT02555566|Experimental|Kidney transplant recipients|"blood sampling is done for determination of EPHX Lys55Arg and other polymorphisms status in Kidney transplant recipients.~flow-mediated distal stimulation of the forearm radial artery by cutaneous heating is assessed for evaluation of EEts level in Kidney transplant recipients."
2551455|NCT02555332||Women underwent screening for thyroid function|All these women underwent screening for thyroid function (TSH,FT4,TPOAb) at the first antenatal visit and the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation. The correlation between the combination of TSH level and TPOAb status and the risk of Gestational Diabetes Mellitus was analyzed.
2551514|NCT02555163|Experimental|HoLERBT|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor
2551517|NCT02555163|Active Comparator|cTURBT|Conventional Transurethral Resection Of Bladder Tumors
3204627|NCT00935688|No Intervention|Clinical Diagnosis|Malaria diagnosed on the basis of clinical symptoms alone (i.e. not laboratory diagnosis)
3204628|NCT00935714|Active Comparator|Muscle Group|Exercise
3204629|NCT00935714|Active Comparator|Sequence|Exercise
3204630|NCT00935727|Other|1|normally functioning transplanted kidneys
3204631|NCT00935727|Other|2|transplanted kidney undergoing known rejection or other known abnormality
2551688|NCT02553811|Experimental|intervention|accuracy diagnostic in carpal tunnel syndrome = evaluation and comparison ultrasonography X electromyography
2551747|NCT02553655|Active Comparator|4x 5min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 5 minutes following by 5 minutes of rest. This will be repeated for 4 times.
2551748|NCT02553655|Active Comparator|3x 10min Limb Preconditioning|Either the right or left leg of the participant(s) will be made transiently ischemic for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
2551749|NCT02553655|Sham Comparator|3x 10min Sham Preconditioning|Either the right or left leg of the participant(s) will be squeezed without causing ischemia for 10 minutes following by 5 minutes of rest. This will be repeated for 3 times.
2551808|NCT02553239|Experimental|Cryoablation|Cryoablation with the CoolLoop® catheter
2551892|NCT02552862|Active Comparator|Vivomixx®|"Vivomixx® is a probiotic mixture of 8 proprietary strains. Thirty consecutive patients with cirrhosis and SBP will be randomized to receive Vivomixx® , sachets containing 450 x 109 bacteria, 2 every 12 hours during all the hospitalization until a maximum of 30 days (n=15), or placebo (n=15).~All patients will receive endovenous antibiotics and also intravenous albumin 1.5 g/kg weight the first day and 1 g/kg weight the third day of treatment. The management of patients will follow current guidelines."
2551901|NCT02552862|Placebo Comparator|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
2551931|NCT02552459|Active Comparator|sufentanil|sufentanil 150μg，intravenous administration during the following 72 hours after operation.
2551933|NCT02552459|Experimental|sufentanil&dexmedetomidine 1|sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.
2551935|NCT02552459|Experimental|sufentani&dexmedetomidine 2|sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.
2551936|NCT02552459|Experimental|sufentanil&dexmedetomidine 3|sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.
2552086|NCT02551536|Active Comparator|Group A|FDC tablet of montelukast 10 mg and levocetrizine 5 mg was given once daily for 4 weeks
2552088|NCT02551536|Experimental|Group B|FDC tablet of montelukast 10 mg and fexofenadine 120 mg was given once daily for 4 weeks
2552119|NCT02551328||Sevofluorane|Patients preconditioned with Sevo
2552125|NCT02551328||Propofol|Patients with no preconditioning
2552160|NCT02551029|Experimental|Duodenal capsaicin infusion|Through a naso-duodenal tube, a capsaicin solution will be infused into the duodenum.
2552163|NCT02551029|Placebo Comparator|Placebo (saline)|Through a naso-duodenal tube, a saline solution will be infused into the duodenum.
2552255|NCT02550691|Experimental|Subject carrying 3 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
3204632|NCT00935727|Other|3|transplanted kidney with unknown diagnosis
3204633|NCT00935740||Age-Matched Healthy Controls|Age-Matched Healthy Controls
3204634|NCT00935740||Heart Failure|Subjects with LVEF < 40%
3204635|NCT00935753|Experimental|Kuvan|10mg/kg Kuvan for 5 days followed by 20mg/kg Kuvan for a total of 60 days
3204636|NCT00935779||Gastric cancer|patients with operable local gastric adenocarcinoma were studied
3204637|NCT00935779||Control group|patients operated on for benign diseases served as controls, randomly selected among patients with chronic gastro-esophageal reflux disease who were considered good candidates for antireflux surgery and properly matched in sex and age to study group
3204638|NCT00935805||Treatment|124 patients attending the primary care unit included after formal consent.
3204639|NCT00935831|Experimental|Subjects with renal impairment, non-dialysis|Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
3204640|NCT00935831|Experimental|Healthy volunteers|Healthy subjects will be matched to the moderate and severe renally impaired subjects for gender, age, and BMI. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
3204641|NCT00935831|Experimental|Hemodialysis dependent subjects|The arm will consist of subjects with severe renal impairment (end-stage renal failure) who have been on stable hemodialysis treatment scheduled three times per week. Subjects will receive single oral doses of 150 mg GSK1278863A in each of 2 dosing periods in an open-label, fixed sequence. GSK1278863A will be administered just prior to receiving scheduled hemodialysis in Dosing Period 1. In Dosing Period 2, subjects will receive a single oral dose of GSK1278863 the morning after completion of a scheduled hemodialysis session.
2551600|NCT02554526||Combination therapy|Effects of aPCC reaction in the presence of FVIII
3204642|NCT00935844|Experimental|TAK-901 Arm|
3204643|NCT00935870||A|DEPRESSED LATERAL CONDYLE FRACTURE
3204644|NCT00935870||B|BENIGN BONE TUMOR
3204645|NCT00935870||C|SPINAL FUSION
3204646|NCT00935896|No Intervention|high VT group|
3204647|NCT00935896|Experimental|Low tidal volume|
2551894|NCT02552693|Experimental|Experimental Facility|"Enhanced training, supervision and support for MOHCC Standard Operating Procedure (SOP) implementation of identifying, tracing and returning to care (tracking and tracing) defaulting mother/infant pairs.~Facilities in the experimental group will receive additional training, supervision and support in identifying, tracing and returning to care defaulting mother/infant pairs."
2551900|NCT02552693|No Intervention|Control Facility|Facilities in the control group will be operating as described in the MOHCC SOP. (Standard practice in tracking and tracing of defaulting mother/infant pairs)
2551930|NCT02552511||Exposure|Perinatal factors exposure
2551978|NCT02552186|Active Comparator|Pectus Excavatum Group|The first group (PE Group) will consist of patients presenting to the All Children's Hospital Johns Hopkins Medicine (ACH JHM) Pediatric Surgery or Cardiac Surgery Clinics and the outpatient clinic system at Johns Hopkins Hospital for evaluation of pectus excavatum. Clinical measurements will be obtained using calipers.
2551979|NCT02552186|No Intervention|Control Group|The second group (Control Group) will be age and gender matched patients presenting to the Radiology department of ACH JHM undergoing CT chest for indications other than chest wall deformity.
3204648|NCT00935922|Placebo Comparator|Soybean oil bar|A nutrition bar enriched with soybean oil
3204649|NCT00935922|Experimental|Flaxseed bar with low lignans|A nutrition bar enriched with flaxseed oil
3204650|NCT00935922|Experimental|Flaxseed bars with high lignans|A nutrition bar enriched with flaxseed oil and high lignans
2552060|NCT02551523|Experimental|Dolutegravir monotherapy|92 patients will be simplified to once daily dolutegravir monotherapy.
2552063|NCT02551523|Active Comparator|Standard of care combination antiretroviral therapy|46 patients will go on with standard of care combination antiretroviral therapy consisting of either a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or a integrase inhibitor in combination with two nucleoside reverse transcriptase inhibitors.
2552120|NCT02551393|Experimental|Intervention Group|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home Blood pressure monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
2552127|NCT02551393|No Intervention|Control Group|Usual Care of hypertension in primary care clinic
2552166|NCT02551003|Experimental|Cord blood with hypothermia|Autologous cord blood will be collected after birth and stored in Cord Blood Bank of hospital. All cord blood samples are routinely performed by dedicated, trained UCB collection staff and is restricted to deliveries of mothers who have given prior written informed consent for collection. If the mother delivered a baby with signs of HIE or cerebral infarction, Bank staff collected UCB utilizing standard procedures. Collected UCB was transported at roomtemperature in validated shippers to the NICU. Infusions were started when cells and study staff were available for administration and monitoring. Infants received up to 3 infusions, with the first dose as soon as possible after birth, and at, 48, and 72 postnatal hours. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
2552168|NCT02551003|Active Comparator|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
2552228|NCT02550600|Experimental|Intervention group|Intervention: iLA activve treatment. iLA activve treatment also requires anticoagulation with un-fractionized heparin and pre-defined PTT-goals (45s-60s depending on blood flow).
2552237|NCT02550600|Active Comparator|Control group|"Controls: standard care according to good clinical practice and recent guidelines; no extracorporeal lung assist.~For ethical reasons patients of the control group can be treated with iLA activve after fulfilling the primary endpoint criterium of an increase in SOFA ≥3 points. These cross-over patients will be analyzed as controls (intention to treat)."
3204651|NCT00935935||HIV older than 50 years|
3204652|NCT00935948|Active Comparator|Imescard ointment|
3204653|NCT00935948|Placebo Comparator|Placebo|
3204654|NCT00935961|Experimental|RAD001 + docetaxel + cisplatin|In this phase I trial, the primary endpoint will be considered to be reached when we have described a phase II recommended dose of RAD001 given with docetaxel + cisplatin as induction chemotherapy for head and neck cancer. Up to 3 dose levels of daily RAD001 will be studied. A standard 3 + 3 phase I dose escalation design will be used. The phase II recommended dose will be determined according to the dose escalation plan.
3204655|NCT00935987|Experimental|CYT387|
3204656|NCT00936000|Active Comparator|protandim therapy for 7 days|
3204657|NCT00936000|Placebo Comparator|placebo arm|Individuals will receive a placebo equivalent in two equally divided doses for seven days
3204658|NCT00936013|Experimental|oseltamivir|single antiviral treatment
3204659|NCT00936013|Experimental|oseltimivir and chinese medicinal herbs|combination treatment
3204660|NCT00936039|Experimental|unloading|2 weeks of unloading
3204661|NCT00936078||Non-donors/controls|People who have not donated a kidney.
3204662|NCT00936078||Living Kidney Donors|
2551390|NCT02555839||Pomalidomide, Bortezomib and Dexamethasone|Cycle 1-8: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1, 4, 8, 11 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle until progression or unacceptable toxicity; from cycle 9 onwards: Pomalidomide 4mg capsules by mouth (PO) on days 1 through 14 of a 21 day cycle, Bortezomib (1,3mg/m2) s.c. on day 1 and 8 of a 21 day cycle, and Dexamethasone 20mg PO (≤75 years) or 10mg (>75years) on Days 1, 2, 8, 9 of a 21 day cycle until progression or unacceptable toxicity
2551526|NCT02554825|Experimental|Healthy Futures|
2551529|NCT02554825|Other|Control|
2551590|NCT02554604||Pregnant woman|Pregnant woman with identified risk factors for the development of preeclampsia
3170807|NCT00579124|Other|1. CliniMACS CD3+/CD19+ depletion|"6/6 or 8/8 matched (fully matched)~1 antigen or allele mismatched (mismatch at A or B or DRB1)~2 antigen or allele mismatched (mismatch ONLY at A and B but NOT at DRB1 plus either A or B).~Patients will receive grafts that have undergone CD3+ and CD19+ depletion. The CD3(-) fraction will be infused."
3170808|NCT00579124|Other|2. CliniMACS CD3+/CD19+ depletion|"Stratum 2. CliniMACS CD3+/CD19+ depletion:~Haploidentical match~2 antigen and/or allele mismatched where one of the mismatches includes DRB1~For patients in Stratum 2 we will perform CD3+ (T cell) and CD19+ (B cell) depletion. There will be no T cell add back in this stratum."
3170809|NCT00579150||Exenatide|Exposure to any form of exenatide during pregnancy for treatment of type 2 diabetes. Patients also taking Insulin may be included, though only as part of a combination treatment.
3170810|NCT00579150||Non-exenatide group|Exposure to non-insulin antidiabetic medication not including exenatide for treatment of pre-existing type 2 diabetes during pregnancy. Patients also taking Insulin may be included, though only as part of a combination treatment.
2551797|NCT02553200|Active Comparator|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
2551799|NCT02553200|Experimental|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
2551801|NCT02553200|Sham Comparator|BreatheMAX (unload and non-oscillated)|inspiratory and expiratory breathing exercise for 10 breathes/set, 10 sets/day and rest 1 minute between set
2551860|NCT02552901|Experimental|LFT Dye Detection Monitor|
2551868|NCT02552901|Active Comparator|Serial Blood Draws|
2551973|NCT02552602|Active Comparator|Group A|Study participants in this arm will be given Multivitamin A
2551974|NCT02552602|Active Comparator|Group B|Study participants in this arm will be given Multivitamin B
2551976|NCT02552602|Active Comparator|Group C|Study participants in this arm will be given Multivitamin C
2552017|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir|Daclatasvir 60mg tablet and Sofosbuvir 400mg tablet oral dosing once daily for 8 weeks
2552022|NCT02551861|Active Comparator|Daclatasvir + Sofosbuvir + Ribavirin|Daclatasvir 60mg tablet + Sofosbuvir 400mg tablet+ Ribavirin 1000-1200mg tablet(weight based dosing) oral dosing split into am and pm once daily for 8 weeks
2552084|NCT02551575|Active Comparator|Treatment of MTX and HCQ|Patients were treated with methotrexate (MTX), hydroxychloroquine (HCQ), oral Qingre Huoxue granule placebo and Qingre Huoxue external preparation placebo.
2552087|NCT02551575|Experimental|Treatment of TCM|Patients were treated with oral Qingre Huoxue granule, Qingre Huoxue external preparation, methotrexate placebo and hydroxychloroquine placebo.
2552089|NCT02551575|Experimental|Integrative Medicine|The patients were treated with methotrexate, hydroxychloroquine, oral Qingre Huoxue granule and Qingre Huoxue external preparation.
2552101|NCT02551315||Type 2 diabetics, no fractures|Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
2552104|NCT02551315||Type 2 diabetics, prevalent fractures|Postmenopausal women and men with T2DM, with prevalent fragility fractures
2552107|NCT02551315||Controls, no fractures|Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
2552111|NCT02551315||Controls, prevalent fractures|Age and sex-matched non-diabetic controls
2552173|NCT02551068|Experimental|60% Oxgyen|While participants are exercising, they will be breathing 60% oxygen through a mask.
2552174|NCT02551068|Placebo Comparator|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
2552261|NCT02550444|Placebo Comparator|Control|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
2552263|NCT02550444|Experimental|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
2552265|NCT02550444|Experimental|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
2552270|NCT02550119|Experimental|Arm I (aprepitant, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate PO or IV, dexamethasone PO or IV, and aprepitant PO 1 day before chemotherapy and dexamethasone PO and aprepitant PO on days 2 and 3 after chemotherapy begins during course 2-3.
2552271|NCT02550119|Placebo Comparator|Arm II (placebo, dolasetron mesylate, dexamethasone)|Patients receive dolasetron mesylate and dexamethasone as in Arm I and placebo PO 1 day before chemotherapy and dexamethasone PO and placebo PO on days 2 and 3 after chemotherapy begins during courses 2-3.
2552388|NCT02549651|Experimental|MEDI4736|
2552390|NCT02549651|Experimental|MEDI4736 and tremelimumab|
2552393|NCT02549651|Experimental|MEDI4736 and AZD9150|
3170811|NCT00579189|Experimental|Moxidex|Moxidex otic solution
3170812|NCT00579189|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3174257|NCT00621478|Active Comparator|Cohort 1|"Cohort 1 (preconsented) patients will involve obtaining informed consent from the legally authorized representative of a potential study subject before they present to the ED in SE. Patient assent will be obtained for patients as per local IRB rules. The consent document (enclosed in this application) will inform parents that if their child comes to the ED and qualifies for the study based on study inclusion/exclusion criteria, they will be enrolled.~Patients who cannot be contacted to confirm consent will be enrolled in Cohort 2 (EFIC) as detailed below.~Patients in Cohort 1 will be randomized in a blinded fashion to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
2551410|NCT02555748|Active Comparator|Sunitinib|"Sunitinib will be administered at the standard dose of 50 mg, once daily during 4 consecutive weeks, followed by a wash-out period of 2 weeks (corresponding to a complete cycle of 6 weeks).~During the first stage of the study (Part I), dose adjustment of drug dose will be made according to individual patient tolerance to treatment evaluated by clinical and biological monitoring; During the second stage (Part II), dose modification should also be performed according to individual patient tolerance to treatment evaluated by clinical and biological monitoring ans also by using the new Pharmacokinetic-Pharmacodynamic (PK-PD) Algorithm elaborated during the first part."
2551461|NCT02555267||Elderly patients with DLBCL|Elderly patients (age>=65 years) with DLBCL treated with R-CHOP chemotherapy
2551488|NCT02555072|Other|naive children and adults for yellow fever vaccine|both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old
2551533|NCT02554812|Experimental|Cohort A1|NSCLC patients treated with avelumab + utomilumab (Dose level 1)
2551534|NCT02554812|Experimental|Cohort A2|NSCLC patients treated with avelumab + utomilumab (Dose level 2)
2551539|NCT02554812|Experimental|Cohort A3|NSCLC patients treated with avelumab + utomilumab (Dose level 3)
2551540|NCT02554812|Experimental|Cohort A4|Melanoma patients treated with avelumab +utomilumab
2551541|NCT02554812|Experimental|Cohort A5|SCCHN patients treated with avelumab + utomilumab
2551542|NCT02554812|Experimental|Cohort A6|TNBC patients treated with avelumab + utomilumab
2551543|NCT02554812|Experimental|Cohort A7|SCLC that has progressed after at least 1 line of platinum-containing therapy treated with avelumab +utomilumab
2551544|NCT02554812|Experimental|Cohort A8|NSCLC first-line Stage IV treated with avelumab +PF-05082566
2551549|NCT02554812|Experimental|Combination B Dose Escalation|PF-04518600 + avelumab in selected tumor types
2551551|NCT02554812|Experimental|Combination B Expansion Cohorts|PF-04518600 + avelumab in selected tumor types
2551554|NCT02554812|Experimental|Combination C Dose escalation cohorts|PD 0360324 + avelumab in selected tumor types
2551556|NCT02554812|Experimental|Combination C Dose expansion cohorts|PD 0360324 + aveluamb in selected tumor types
2551559|NCT02554812|Experimental|Combination D Dose escalation cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
2551562|NCT02554812|Experimental|Combination D Dose expansion cohorts|PF-05082566 + PF-04518600 + avelumab in selected tumor types
2551564|NCT02554812|Experimental|Cohort A9|NSCLC first-line Stage IV treated with avelumab +utomilumab (sequential starting with utomilumab monotherapy followed by combination)
2551566|NCT02554812|Experimental|Cohort A10|NSCLC first-line Stage IV treated with avelumab + utomilumab (sequential starting with avelumab monotherapy followed by combination)
2551568|NCT02554812|Experimental|Cohort F1|CMP-001 +avelumab in SCCHN
2551570|NCT02554812|Experimental|Cohort F2|CMP-001+avelumab+utomilumab in SCCHN
2551573|NCT02554812|Experimental|Cohort F3|CMP-001 +avelumab+PF-04518600 in SCCHN
3204663|NCT00936091|Placebo Comparator|placebo|125 schoolchildren were allocated randomly to receive placebo
3204664|NCT00936091|Active Comparator|vitamin A supplement|125 children received vitamin A supplements capsules (200 000 IU)
2551785|NCT02553356|Experimental|Fasted|PT2385 taken after fasting.
2551792|NCT02553356|Experimental|Non-Fasting|PT2385 taken after eating a high calorie meal.
2551909|NCT02552667|Experimental|HCP1102+HGP0711Placebo|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102+HGP0711Placebo(4weeks) Each 1 capsule, once daily
2551911|NCT02552667|Active Comparator|HCP1102Placebo+HGP0711|HCP1102Placebo+HGP0711Placebo(1week) -> HCP1102Placebo+HGP0711(4weeks) Each 1 capsule, once daily
3204665|NCT00936104||SP in PDAC|Side population cells isolated from resection specimens obtained from patients with pancreatic cancer
3204666|NCT00936130||Lifestyle counseling|This group will be comprised of participants on a low calorie diet program.
3204667|NCT00936130||Weight Loss Surgery|This group will be comprised of participants having weight loss surgery: Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy.
3204668|NCT00936143|Experimental|infliximab|200mg infliximab inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
2552055|NCT02551562|Placebo Comparator|Group A: Basic Skin Care|Subjects will use a basic skin care regime following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
2552059|NCT02551562|Experimental|Group B: NuDerm® System|Subjects will use the Nu-Derm® system following a full facial rejuvenation with hyaluronic acid soft-tissue filler and botulinum neurotoxin.
3204669|NCT00936156|Experimental|Chemotherapy|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
2552154|NCT02550834|Experimental|Experimental : Curling group|
2552156|NCT02550834|No Intervention|Control : Usual care group|
2552297|NCT02550392|Experimental|Group psychoeducation|The intervention group will receive a group psychoeducational intervention (designed in Phase 1: Qualitative study) and usual care.
3204670|NCT00936169|Experimental|IVUS optimised stent implantation|
3204671|NCT00936169|Active Comparator|angiographically guided DES implantation|
3204672|NCT00936182|Experimental|Fluconazole|
3204673|NCT00936182|Placebo Comparator|Placebo|Placebo capsule daily for 30 days
3204674|NCT00936195|Active Comparator|Atripla (R)|
3204675|NCT00936195|Active Comparator|Combivir (R) + Kaletra (R) or Aluvia (R)|
3204676|NCT00936234|Active Comparator|Vildagliptin|starting with vildagliptin for 30 days followed by placebo for 30 days
3204677|NCT00936234|Placebo Comparator|Placebo|starting with placebo for 30 days followed by vildagliptin for 30 days
2551433|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D2 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551434|NCT02555540|Active Comparator|Boostrix, Female, <5 years, D3 visit|"25 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551435|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D2 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551437|NCT02555540|Placebo Comparator|Placebo, Male, <5 years, D3 visit|"5 male subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551438|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D2 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 2'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 2 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551440|NCT02555540|Placebo Comparator|Placebo, Female, <5 years, D3 visit|"5 female subjects who have received their last dT(Pa) vaccine between 5 years and 6 months ago, and who have the Visit 2 on 'Day 3'.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 28 (blood sampling)"
2551490|NCT02555085|Experimental|IV Dose 1|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551492|NCT02555085|Experimental|IV Dose 2|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551494|NCT02555085|Experimental|IV Dose 3|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551495|NCT02555085|Experimental|IV Dose 4|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551496|NCT02555085|Experimental|IV Dose 5|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551497|NCT02555085|Experimental|IV Dose 6|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551498|NCT02555085|Experimental|IV Dose 7|Single ascending IV dose or matching placebo based on body weight recorded on Day 1
2551501|NCT02555085|Experimental|SC Dose|Single SC dose or matching placebo
3170813|NCT00579215|Experimental|1|Enhance Care (EC) will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits.
3170814|NCT00579215|Other|2|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
3170815|NCT00579228||1|Normal controls both men and women
2551647|NCT02554188|Placebo Comparator|Control|Participants will receive Seasonal influenza (flu) vaccine.
2551651|NCT02554188|Experimental|Diet|Participants will consume 2 cycles of a 5-day low calorie fasting-mimicking diet with approximately 3 weeks of gap period prior to receiving standard Seasonal influenza (flu) vaccine.
2551699|NCT02553941|Experimental|azacitidine, ibrutinib|Patients receive azacitidine intravenous infusion over 10-40 minutes or subcutaneous on days 1-7 or 1-5 and 8-9, and ibrutinib by mouth one daily on days 1-28. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2551963|NCT02552615|Experimental|body awareness therapy (BAT)|Each session started with short warm-up, continued with specific exercises. Following each session, verbal reflexions was taken for 10 minutes. Exercises fulfilled in lying, sitting, standing and walking positions. Additionally program included vocal-breathing exercises and massage. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
2551966|NCT02552615|Active Comparator|Traditional exercises|Program included traditional exercises intended for strengthening back, abdominal, pelvis and shoulder girdle muscles and muscles in convex side of the curve, stretching exercises especially for the concave side of the curve, flexibility exercises for spine, postural training and breathing exercises. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
2552345|NCT02549924|Placebo Comparator|Placebo|Individuals with T2DM inadequately controlled with metformin 2000 mg/day and A1C ≥7%.
3170816|NCT00579228||2|Individuals with type 2 Diabetes with good control
3170817|NCT00579228||3|Individuals with type 1 diabetes with good control
3170818|NCT00579241|Experimental|1|Transcranial imaging using Doppler ultrasound
3170819|NCT00579306||SPS3 patient cohort|All SPS3 patients who participate in Baseline and 1-Year F/U blood draw
3170820|NCT00579332|Placebo Comparator|1|one a day placebo
3170821|NCT00579332|Experimental|2|Brassica intake
3170822|NCT00579332|Experimental|3|indole-3-carbinol supplement
3170823|NCT00579371|Experimental|1|
3170824|NCT00579384|Experimental|001|
3170825|NCT00579397||1|"For Objective #1:~Healthy adult volunteers"
3170826|NCT00579397||2|"For Objectives #2 & #3:~Recipients undergoing an allogeneic stem cell transplant"
2551519|NCT02555007|Experimental|Oral Vinorelbine|
2551552|NCT02554734|Experimental|Levodopa standard carbidopa|Levodopa, carbidopa, ODM-104
2551553|NCT02554734|Experimental|Levodopa modified carbidopa|Levodopa, carbidopa, ODM-104
2551557|NCT02554734|Active Comparator|Stalevo|Levodopa, carbidopa, entacapone
2551635|NCT02554487|Experimental|sSDB ASV+|sSDB ASV+: Patients with an AHI > 20/h assessed during the first night of stroke that are randomized to ASV treatment (AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)).
2551640|NCT02554487|No Intervention|sSDB ASV-|sSDB ASV-: Patients with an AHI > 20 no ASV treatment.
2551642|NCT02554487|No Intervention|no SDB|no SDB: Stroke patients without SDB (AHI < 5 / h) serve as a control group to observe the evolution of the lesion volume and stroke outcome without the additional burden of SDB.
2551672|NCT02553993|Experimental|Wii Fit|The Wii Fit training was conducted using the Wii Fit bundle from Nintendo, which consists of the Wii console, a Wii Balance Board, and the Wii Fit Plus balance game disc. The Wii balance board has 4 transducers, which could assess the player's force distribution and resultant movements in the center of pressure (COP). The participants stood on the board and used the change of COP to play the games. Five games (Tilt, Soccer Heading, Balance Bubble, Penguin Slide, and Perfect 10) were selected from the Wii Fit Plus package based on the motor demand of these games. The major movement patterns to play the games included right-left weight shifting and front-back weight shifting.
2551673|NCT02553993|Experimental|Tetrax biofeedback|"The Tetrax biofeedback games aimed at postural rehabilitation to help patients or athletes improve their balance abilities. There were 11 games in Tetrax system; 8 games (Speedtrack, Catch, Skyball, Gotcha, Speedball, Tag, Freeze, Immobilizer) were chosen based on the same principle as those used for choosing Wii Fit games. The parameters of games' difficulties included target size and/or speed of target movement, which could be adjusted according to the patients' ability.~For the Wii Fit or Tetrax group, at each session, the supervising therapist chose 3 to 5 games for participants according to their ability, needs, and favorites."
2551676|NCT02553993|Placebo Comparator|Conventional weight-shifting|The conventional weight-shifting exercise group performed balance exercises with the similar movements and time required by the 2 exergame systems but without video games. By using occupational activities, participants did weight shifting in the sagittal and frontal planes. The investigators also used a balance board (Reebok Core board) for multi-directional weight shifting training
2551751|NCT02553681|Experimental|HPT treated|Hydra-PEG Treatment (HPT) treated RGP contact lenses made from roflufocon D
2551753|NCT02553681|Active Comparator|untreated|untreated RGP contact lenses made from roflufocon D
2551802|NCT02553174||Ketorolac|Patients who receive ketorolac perioperatively
2551803|NCT02553174||Caldolor|Patients who receive Caldolor perioperatively
2551806|NCT02553174||No NSAIDS|Patients who do not receive NSAIDS perioperatively
2551889|NCT02552953|Experimental|CYC065 - 4 hour infusion (Part 1 completed)|CYC065 will be administered by 4 -hour infusion every 3 weeks.
2551903|NCT02552953|Experimental|CYC065 - 1 hour infusion (Part 2 - ongoing)|CYC065 will be administered by 1 - hour infusion on Days 1, 2, 8, and 9 every 3 weeks
2551904|NCT02552953|Experimental|CYC065 - Oral (Part 3 - ongoing)|CYC065 will be administered orally on Days 1, 2, 8 and 9 every 3 weeks
2551916|NCT02552433||Body Contouring Surgery|All patients who undergo BCS after bariatric surgery.
2551942|NCT02552277|Experimental|PDA-002 Dose Level 1: 3 x 10^6 cells|3 x 10^6 PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
2551948|NCT02552277|Experimental|PDA-002 Dose Level 2: 30 x 10^6 cells|30 x 10^6 PDA-002 cells administered IM on study Days 1, 29, and 57.
2551950|NCT02552277|Placebo Comparator|Placebo|Subjects will receive placebo administered IM on study days 1, 29, and 57.
2551996|NCT02551978|Experimental|Intervention|Children in a primary school, aged between 9 and 12 years, play the serious game (two sessions, duration of each session 35 minutes, within two weeks). The game equips the children with knowledge about the core areas nutrition, physical activity, and psychosocial factors.
2552000|NCT02551978|No Intervention|Control|Children in the same primary school, aged between 9 and 12 years do receive basic information during the study phase.
3204678|NCT00936247|Experimental|1|HES 130/0.42 + Sterofundin ISO
3204679|NCT00936247|Active Comparator|2|Albumin + NaCl 0.9%
2552102|NCT02551289||Patients|Patients newly diagnosed with Coeliac disease before starting treatment with a gluten free diet
2552106|NCT02551289||Healthy volunteers|Participants who do not meet criteria for a clinical diagnosis of Coeliac disease as determined by screening blood sample.
2552147|NCT02551146|Experimental|A Locator with retention elements|"GC Pilier Locator abutment with retention elements:~For patients in the experimental group (arm A) the connection of the full dentures to the implants will be achieved by fitting the dentures with GC Pilier Locator abutments with retention elements."
2552148|NCT02551146|Active Comparator|B Locator without retention elements|"GC Pilier Locator abutment without retention elements:~For patients with the active comparator (arm B) the full dentures will get Pilier Locator abutments without retention elements and thus no connection to the implants."
2552184|NCT02550782|Active Comparator|perineural bupivacaine|"patient-controlled infraclavicular perineural bupivacaine~(1% bupivacaine (marcaine), 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
2552188|NCT02550782|Experimental|perineural dexmedetomidine|"patient-controlled infraclavicular perineural dexmedetomidine~(1% bupivacaine + 200 mic / 100cc dexmedetomidine, 5 ml bolus dose, infusion rate of 5 ml / h, lockout time 1 hour)"
2552225|NCT02550483|Active Comparator|Beta-Carotene Tomato Juice|Participants will receive high beta-carotene tomato juice daily as part of controlled diet (base diet + high beta-carotene tomato juice).
3170827|NCT00579410||A|Patients with Barrett's Esophagus
3170828|NCT00579410||B|Patients with reflux symptoms but no Barrett's Esophagus
3170829|NCT00579410||C|Patients without reflux symptoms and a normal endoscopy
3170830|NCT00579423|Experimental|vaccine|Patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administrated at the standard dose of 100ug.
3204680|NCT00936260|Experimental|alendronate 6 years|
2551472|NCT02555241|Experimental|One Baseline Session|Designated for participants #1 and #2. Participants complete 1 Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
2551473|NCT02555241|Experimental|Two Baseline Sessions|Designated for participants #3 and #4. Participants complete a Baseline Session followed by a 12 week wait period before repeating a Baseline Session followed immediately by 12 weeks of standard treatment. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
2551474|NCT02555241|Experimental|Three Baseline Sessions|Designated for participants #5 and #6. Participants complete a Baseline Session followed by two repetitions of the Baseline Session (each 12 weeks apart) and 12 weeks of standard treatment immediately following the third session. Standard treatment will require the participant to attend clinic-based treatment sessions for 1 hour per day, 3 days per week, for 12 weeks. Standard treatment will consist of 3 components: mand training, matrix training, and stimulus equivalence training.
2551521|NCT02554955|Experimental|Daclizumab + Mycophenolate mofetil|Participants will receive intravenous (IV) daclizumab (2 milligrams per kilogram [mg/kg] within 6 hours after transplantation and 1 mg/kg every 2 weeks for a total of five doses), along with mycophenolate mofetil (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg twice daily [BID] within first week and 1 grams per day [g/day] BID from second week onwards) and sirolimus (3 mg/day) for 6 months.
2551608|NCT02554578|Experimental|Pharmaceutical care programme supported by mHealth|
2551611|NCT02554578|No Intervention|Routine healthcare by the transplant team|
2551633|NCT02554227||Spondylodiscitis|vertebral osteomyelitis, erosive osteochondrose
2551678|NCT02554084|Experimental|Dry Eye Disease|Optical Coherence Tomography
2551680|NCT02554084|Active Comparator|Normals|Optical Coherence Tomography
2551731|NCT02553720|Experimental|Aquatic Group|Conventional management plus aquatic exercise At least 15 minutes of walking 3 times/week for 3 months
2551732|NCT02553720|Other|Control Group|Conventional management without aquatic exercise
2551788|NCT02553369||Enrolled patients|Patient randomly enrolled in the study within a cohort of patient followed for HIV infection.
2551858|NCT02552992|Experimental|Yoga Classes|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
2551861|NCT02552992|Active Comparator|Self-Directed Mind-Body Program|Study Participants will receive: The Back Pain Helpbook, a mind-body self-care program for better living.
2551920|NCT02552641|Experimental|Test 1|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, in fasting conditions, twice daily
2551922|NCT02552641|Experimental|Test 2|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, after meals, twice daily
2551924|NCT02552641|Experimental|Test 3|Esomeprazole, Amoxicillin, Clarythromycin - Administration of 20 mg esomeprazole, 1 g amoxicillin, and 500 mg clarithromycin together, twice daily in schedules variables with an interval of at least 8 hours between the doses
2552004|NCT02552056|Experimental|CAMH training|"Intervention clinics will receive a CAMH integration package comprising of:~Training PHC workers (midwives, nurses and/or clinical officers) on how to screen and refer for CAMH, based on WHO mhGAP implementation guide.~Support supervision in the clinics to reinforce training and provide on-job support to PHC staff.~Provision of job aids and training materials"
2552007|NCT02552056|No Intervention|No CAMH training|Clinics will continue to provide the standard of care.
2552103|NCT02551276|Experimental|Experimental|Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks
2552105|NCT02551276|Placebo Comparator|Control|Placebo and resistance training for 10 weeks
2552181|NCT02551120||Patients|Patients with idiopathic hypoparathyroidism, autosomal dominant hypocalcaemia and pseudohypoparathyroidism.
2552289|NCT02550418|Experimental|Budesonide|
3174854|NCT00627783|Experimental|Intervention|Patients are referred to a cardiologist for a systematic detection of silent ischemia by a bicycle exercise test performed according to the French Society of Cardiology protocol after washout of cardiovascular medications likely to interfere with the test. Dipyridamole Single Photon Emission Computed Tomography (SPECT) is used in patients unable to perform the exercise test, with a sub-maximal negative exercise test result or with electrocardiographic abnormalities impairing the interpretation of the exercise test. Subsequent investigations (such as coronary angiography) and treatments (such as revascularization procedures) are left at the cardiologist's decision.
3174855|NCT00627783|No Intervention|Control|Patients are treated according current guidelines but are not referred to a cardiologist
3174856|NCT00627796|Experimental|A|Newly diagnosed patients with acromegaly
3174857|NCT00627809|Experimental|1|Following standard primary percutaneous coronary intervention for ST elevation acute myocardial infarction 250.000 U intracoronary Streptokinase will be given
3174858|NCT00627809|Active Comparator|2|Standard percutaneous coronary intervention for ST elevation myocardial infarction will be performed
3174859|NCT00627822||Ward|Patients in the hospital ward
2552485|NCT02548884|Active Comparator|Pancreatic sphincterotomy|Pancreatic sphincterotomy technique used in difficult biliary cannulation
2552486|NCT02548884|Active Comparator|Double guide wire|Double guide wire technique used in difficult biliary cannulation
2552596|NCT02548039||Asian Normogonadotrophic Anovulatory Women|Asian women with normal gonadotropin levels but do not ovulate.
2552683|NCT02547909|Experimental|Study group|a probe-based Confocal Laser Endomicroscopy examination will be done using a standard recto-sigmoidoscopy, in women suffering from endometriosis who are referred for a TRUS examination as part of a suspected deep endometriosis diagnostic workup. pCLE images will be compared to normal bowel mucosa.
2552745|NCT02547376||Eligible patients with Soft Tissue Sarcoma|Primary Soft Tissue Sarcoma group
2552991|NCT02545894|No Intervention|BASELINE TESTING|Language and cognitive assessments conducted
3174860|NCT00627822||Emergency room|Patients in the emergency waiting room
3174861|NCT00627822||Intensive care unit|Family members of patients admitted to the intensive care unit
2551483|NCT02555033|Experimental|M-IRT|Machine-based instability resistance training; a similar training program with exercise-machines, but with additional unstable devices placed between participant and exercise-machine or floor respectively.
2551484|NCT02555033|Experimental|F-IRT|Free weight instability resistance training; conducted free-weight resistance training on unstable devices using dumbbells instead of exercise-machines.
3204681|NCT00936260|Experimental|alendronate 5 years|No treatment during year 6th
3204682|NCT00936260|Experimental|alendronate 5 years, not continued|No treatment during year 5th
3204683|NCT00936260|Experimental|alendronate 4 years|No treatment during year 5th and 6th
3204684|NCT00936260|Experimental|alendronate 5 years, uncontinued|No treatment during year 4th
3204685|NCT00936260|Experimental|alendronate 4 years, not continued|No treatment during year 4th and 6th
2551856|NCT02552745||study group|parecoxib sodium was administered postoperatively
2551857|NCT02552745||control group|parecoxib sodium was not administered postoperatively
2551908|NCT02552680|Experimental|Exercise + guideline|Participants will participate in eight meetings consisting of exercise and guidelines on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
2551910|NCT02552680|Active Comparator|brochure|Participants will receive a manual-brochure - containing information about general health.
2551940|NCT02552342|Active Comparator|methylprednisolone|This group was entitled to receive methylprednisolone 80mg/day for 3 days，then 40mg/day for 3 days
2551945|NCT02552342|Placebo Comparator|Placebo|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug
2551997|NCT02552030|Experimental|Blood pressure-measurement|Seven repetitive blood pressure measurements will be performed the left or right arm of all participants with an iPhone 4s and a conventional oscillometric device 'cuff device (Omron HBP-1300-E Pro)'
3204686|NCT00936260|Experimental|alendronate 4 years, uncontinued|No treatment during year 4th and 5th
3204687|NCT00936260|Experimental|Alendronato 3 years|No treatment during the last 3 years
3204688|NCT00936273||Suspected sleep apnea syndrome|Outpatients with suspected sleep apnea syndrome, age > 18 year
3204689|NCT00936286|Experimental|Respiratory Muscle Training|
3204690|NCT00936312||Females with Hemophilia|Females with severe or moderate Hemophilia A or B
2552274|NCT02550145|Experimental|Exendin(9-39)|IV infusion of Exendin (9-39).
2552282|NCT02550145|Placebo Comparator|Placebo|IV infusion of normal saline
2552357|NCT02549950|Active Comparator|Conventional OrthodonticTreatment|Conventional orthodontic mechanics: canine and incisor retraction
2552359|NCT02549950|Experimental|Accelerated Tooth Movement|Accelerated orthodontics: Peizo-Corticision Accelerated canine and Incisor retraction
2552404|NCT02549378|Experimental|patients with a hypercapnia test|confocal microscopy patients with a hypercapnia test
2552445|NCT02549144|Experimental|Low versus high fat/cholesterol diet|The first day of the study protocol a low-fat/low-cholesterol (LFLC) normocaloric diet for 14 days was prescribed to the participants followed by a high-fat/high-cholesterol (HFHC) normocaloric diet for further 14 days.
2552471|NCT02548923|Active Comparator|dexmedetomidine group|Patients who received dexmedetomidine for sedation
2552473|NCT02548923|No Intervention|propofol group|Patients who received propofol for sedation
3204691|NCT00936312||Control group|Male subjects with severe Hemophilia A or B and female subjects with mild (20-60%) Hemophilia A or B.
3204692|NCT00936338|Active Comparator|splint|
2552603|NCT02547961|Experimental|HER2-CAR-T|In interventional studies, participants are assigned to accept HER-2-targeting CAR T Cells infusion so that researchers can evaluate the effects and safety of the CAR-T cell.
2552614|NCT02547961|No Intervention|No Intervention|
2552674|NCT02547870|Experimental|Rilpivirine Long-Acting Parenteral Formulation (RPV-LA)|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
2552682|NCT02547870|Experimental|Aged RPV-LA|Participants will receive oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1 and IM injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
2552733|NCT02547350|No Intervention|Blank control|do not use prophylactic intravesical chemotherapy
2552735|NCT02547350|Experimental|single intravesical instillation|intravesical instillation within 24 hours postoperatively
2552738|NCT02547350|Experimental|multiple intravesical instillation|intravesical instillation every 1 week for the first 2 months, then once a month for the rest 10 months
2552794|NCT02547142|Experimental|Early Palliative Care Group|This is the intervention group and will consist of patients that have been randomized into the early palliative group, with a consultation expected to take place within one week of randomization. Patients in this group will still receive appropriate guideline based oncologic care including any surgical, brachytherapy, chemotherapy or radiotherapy services, along with palliative services.
2552869|NCT02546713|Other|Group 1|Abutments with a concave configuration of the subcritical contour (emergence shape).
2552871|NCT02546713|Other|Group 2|Abutments with convex configuration of the subcritical contour (emergence shape)
3204693|NCT00936338|Active Comparator|joint mobilization self exercise|
2552995|NCT02545894|Experimental|Treatment|"Intervention given:~visual tracking pressing a button every time a picture is seen on the screen~playing dominoes and snap~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
2552997|NCT02545894|No Intervention|Post intervention|Repeated testing
3204694|NCT00936364|Experimental|Group I (Stage I of study)|Patients fast for 24 hours on day -1
3204695|NCT00936364|Experimental|Group II (Stage I of study)|Patients fast for 48 hours on days -2 and -1
3204696|NCT00936364|Experimental|Group III (Stage I of study)|Patients fast for 72 hours on days -3, -2, and -1
3204697|NCT00936364|Experimental|Group IV (Stage I of study)|Patients undergo a modified 48-hour fast with minimal caloric intake on day -2 and -1
2551623|NCT02554500|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2551625|NCT02554500|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2551626|NCT02554500|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2551628|NCT02554500|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2551705|NCT02554097||EST+LC group|Patients accept the management of endoscopic sphincterotomy and laparoscopic cholecystectomy.
2551707|NCT02554097||LCBDE+LC group|Patients accept the management of laparoscopic common bile duct exploration and laparoscopic cholecystectomy.
2551712|NCT02554097||LTCBDE+LC group|Patients accept the management of laparoscopic transcystic common bile duct exploration and laparoscopic cholecystectomy.
2551782|NCT02553486||Internationally adopted children|All internationally adopted children, who arrived in France between 2008 and 2013, living in four French districts
2551886|NCT02553057|Active Comparator|Group 1|mechanical ventilation with Tidal volume 4 ml/kg and PEEP 8-10 cm H2o
2551893|NCT02553057|Active Comparator|Group2|mechanical ventilation with Tidal volume 6 ml/kg and PEEP 8-10 cm H2o
2551898|NCT02553057|Active Comparator|Group 3|mechanical ventilation with Tidal volume 8 ml/kg and PEEP 8-10 cm H2o
2552006|NCT02552160||Patients on Duaklir® Genuair®|Patients on fixed-dose combination Duaklir® Genuair® (Aclidinium/Formoterol)
2552009|NCT02552160||Patients on Ultibro® Breezhaler®|Patients on fixed-dose combination Ultibro® Breezhaler® (Glycopyrronium/Indacaterol)
2552011|NCT02552160||Patients on Anoro®|Patients on fixed-dose combination Anoro® (Umeclidinium/Vilanterol)
3204698|NCT00936390|Active Comparator|Arm I|Patients undergo external-beam radiation therapy (EBRT) once daily on days 1-5. Some patients instead receive EBRT with high-dose rate or low-dose rate brachytherapy implant.
2552286|NCT02550262|Experimental|60 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 60-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2552287|NCT02550262|Experimental|50 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 50-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2552288|NCT02550262|Experimental|40 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 40-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2552291|NCT02550262|Experimental|30 minutes|The infusion pump will deliver programmed intermittent epidural boluses at a 30-minute interval. The bolus will consist of 10mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml. A PCEA bolus of 5mL of 0.0625% Bupivacaine plus fentanyl 2mcg/ml will also be available.
2552329|NCT02549729|No Intervention|Control|Control group not using hormonal replacement therapy will not receive supervised pelvic floor muscle training. This group will be assessed at baseline and up to 12 weeks. For ethics reason at the end of the study women of the control group will be invited to receive the pelvic floor muscle training program. However, this will not be part of the study.
2552330|NCT02549729|Experimental|Exercise|Experimental group not using hormonal replacement therapy will receive supervised pelvic floor muscle training.
2552331|NCT02549729|No Intervention|Hormone Therapy|Experimental group using hormonal replacement therapy will not receive supervised pelvic floor muscle training.
2552332|NCT02549729|Experimental|Exercise and Hormone Therapy|Experimental group using hormonal replacement therapy will receive supervised pelvic floor muscle training.
2552384|NCT02549612|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. On the first day, a low pressure balloon is used, then it is changed with a higher pressure balloon. If no effect is noticed, (the child should experience clicking sound in one or both ears) after day 3, the balloon is replaced with a new balloon with additionally higher pressure. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one week.
2552386|NCT02549612|No Intervention|Control|No intervention is used in this group.
2552532|NCT02548780|Experimental|Chemoembolization + Pharmacokinetics|"First cohort: Chemoembolization with Doxorubicin-loaded LifePearl™ microspheres (TACE): Escalation of dose loaded in microspheres from 75 mg to 150 mg. Pharmacokinetic testing in all patients.~Second cohort: Chemoembolization with doxorubicin-loaded LifePearl™microspheres: microspheres loaded with maximum tolerated dose as established with dose escalation arm. Pharmacokinetic testing in all patients."
2552923|NCT02546258|Other|A Funagl Nail Treatment|Marketed treatment of Fungal Nail Follow instructions on pack
2553024|NCT02545530|Active Comparator|transdermal clonidine+|apply one transdermal clonidine(2.5mg) each week for 4 weeks besides regular antihypertensive agents, reduce oral antihypertensive agents' dosage or type if blood pressure decreased.
2551713|NCT02553785|Experimental|Revivent TC|Surgical treatment of left ventricle using the Revivent TC System
2551756|NCT02553525|Experimental|Therapeutic Stimulation Patterns|This group will receive temporal patterns of stimulation that are designed to suppress oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to alleviate motor symptoms.
2551758|NCT02553525|Experimental|Symptogenic Stimulation Patterns|This group will receive symptogenic patterns of stimulation that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies. These patterns are hypothesized to exacerbate motor symptoms.
2551826|NCT02553096|Experimental|ACCESS|ACCESS is used when participants experience more COPD symptoms.
2551828|NCT02553096|No Intervention|paper plan|Paper exacerbation action plan is used when participants experience more COPD symptoms.
3170831|NCT00579449|Active Comparator|HF 36|For those randomly assigned to the 3-year HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, when possible, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. The 3-year HFD group will receive services to the child's third birthday.
3170832|NCT00579449|Active Comparator|HF 18|For those randomly assigned to the 18-month HFD group, services begin during the third trimester of pregnancy. These families are assigned a Family Support Worker, who begins to initiate contact with the family at approximately 6 months gestation, so that the family can be engaged and services begun at seven months gestation. The Family Support Worker will provide home visiting services according the existing HFD model, which combines the empirically supported Parents as Teachers Curriculum (see attached description of the Parents as Teachers curriculum) provided in accordance with Healthy Families America standards of service delivery. Services for this group are terminated when the child is 18 months old, with clinically necessary referrals made for ongoing psychosocial and health needs.
3174862|NCT00627835|Experimental|Treatment Group 1: Cohort 1|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
3174863|NCT00627835|Experimental|Treatment Group 1: sorafenib and radiation: Cohort 2|Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
3174864|NCT00627835|Experimental|Treatment Group 2: Cohort 3|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
3174865|NCT00627835|Experimental|Treatment Group 2: Cohort 4|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
3174866|NCT00627835|Experimental|Treatment Group 2:Cohort 5|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
3174867|NCT00627874|Experimental|1|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
2551960|NCT02552329|No Intervention|Control group|Since no medication or other treatments are currently approved by Food and Drug Administration (FDA) for treatment of MCI, participants in the usual care group will not receive any form of treatment. They will receive an educational material about cognitive impairment. They will also be asked to maintain their daily routine.
2551965|NCT02552329|Experimental|Tai Chi exercise group|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down.
2552002|NCT02551952|Experimental|MentalPlus® PILOT-I|This preliminary group will be submitted to the digital game MentalPlus®, also be the submitted to fMRI before and after surgery. The results of standardized tests and the data of the MentalPlus® of patients undergoing surgery will be compared with the results of the same tests and the data of the MentalPlus® of healthy volunteers with similar characteristics regarding the variables age and education.
2552008|NCT02551952|Experimental|MentalPlus® PILOT-II|This preliminary group will be of healthy volunteers submitted to the digital game MentalPlus®. The results of standardized tests and the data of the MentalPlus® of volunteers will be compared with the results of tests of patients undergoing surgery and the data of the MentalPlus®.
2552012|NCT02551952|Active Comparator|Group I: MentalPlus®|Evaluated with neuropsychological tests and MentalPlus® before surgery. After surgery, from the 3rd postoperative day a tablet will be use with MentalPlus® in 7 versions for cognitive training during 7 days (7 versions with interfaces adapted for ages up to 20 years and 7 versions for ages over it).
2552013|NCT02551952|Sham Comparator|Group II: MentalPlus®|Ratings with neuropsychological testing and evaluation with MentalPlus® before surgery will be realized. After surgery, from the 3rd postoperative day a tablet will be use for entertainment with short films (20 minutes) for use in the placebo effect of digital game MentalPlus® this group also will be submitted to fMRI before and after surgery. (With the intention to respond to the specificity of findings in relation to the control for active placebo effect)
2552053|NCT02551627|Experimental|Test Product|MMN fortified beverage powder [27 gram (g)] made up in 150 milliliter (mL) of water, will be administered orally as a single serve, twice daily for 18 weeks.
2552057|NCT02551627|Active Comparator|Control|Isocaloric beverage powder without micronutrient fortification (27 g), made up in 150 mL of water will be administered orally as a single serve, twice daily for 18 weeks.
2552099|NCT02551471||French patients|
2552100|NCT02551471||Australians patients|
2552185|NCT02550990|Active Comparator|Cognitive training group|One 60-min session of cognitive training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
2552190|NCT02550990|Active Comparator|Aerobic exercise training group|One 60-min session of aerobic exercise training. Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment.
2552221|NCT02550574|Active Comparator|Wound closure with 5-0 vicryl sutures|One side of the patient's wound defect will be assigned to wound closure with 5-0 vicryl sutures.
2552349|NCT02549963|Active Comparator|Rivaroxaban|Subjects assigned to receive the Rivaroxaban therapy.
2551725|NCT02553889|Placebo Comparator|Cohort B|"Patients in Cohort B will be randomized to receive either 300 mg ISIS 416858 or placebo. A 2:1 ratio will be used.~For Cohort B, the study will include a 4-week screening period and a 12-week treatment period followed by a 12-week post-treatment evaluation period.~Cohort B will receive Study Drug (ISIS 416858 or placebo) twice a week during the first 2 weeks, followed by once weekly for the remaining 10 weeks of the treatment period. All doses of Study Drug will be administered subcutaneously (SC) 10 minutes after completion of the hemodialysis treatment."
2551746|NCT02553408|Other|Neo meter|This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
2551768|NCT02553278|Experimental|Treatment with VelaShape device|"One treatment will be performed by the VelaShape device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery, The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 5 days after treatment Sub-group 3: Surgery 10 days after treatment Sub-group 4: Surgery 20 days after treatment Sub-group 5: Surgery 30 days after treatment Sub-group 6: Surgery 60 days after treatment Sub-group 7: Surgery 90 days after treatment"
2551773|NCT02553278|Experimental|Treatment with Contour I V3 device|"One treatment will be performed by Contour I V3 device on one randomized abdominal subarea, while the other abdominal subarea will not be treated and will serve as a control. Biopsies from treated and untreated subareas will be harvested during abdominoplasty and cultured. Two histology samples, for each subject, will be obtained during the abdominoplasty surgery. The arm is divided to 6 sub-groups, where each Sub-group contains up to 2 subjects as follows:~Sub-group 1: Surgery immediately after treatment Sub-group 2: Surgery 10 days after treatment Sub-group 3: Surgery 20 days after treatment Sub-group 4: Surgery 30 days after treatment Sub-group 5: Surgery 60 days after treatment Sub-group 6: Surgery 90 days after treatment"
2551845|NCT02553005|Sham Comparator|sham acupuncture|False acupuncture treatment using not acupuncture points
2551849|NCT02553005|Experimental|verum acupuncture|Real acupuncture treatment
2551851|NCT02553005|No Intervention|Control|
2551864|NCT02552758|Experimental|Omega-3 fatty acid|omega-3 fatty acid
2551867|NCT02552758|Placebo Comparator|placebo|placebo
2551943|NCT02552589|Experimental|Test group|Amine fluoride toothpaste
2551947|NCT02552589|Placebo Comparator|Control group|Placebo Sodium monofluorophosphate toothpaste
2551983|NCT02552043|Experimental|Nintendo Wii exercise program group|The EG will perform a domiciliary Pulmonary Rehabilitation program of 30-60 min exercise, 5 days/week during 6 weeks using a Nintendo Wii platform with the game EA SPORTS ACTIVE 2. The exercise activities were loaded into each participant´s console during the clinical interview and adjusting the exercises according to their age in 2 groups (>12 years and <13 years). The program consisted of 6 different workouts (1st and 2nd weeks: legs exercises; 3rd week: upper limb exercises; 4th week: thorax exercises; 5th and 6th weeks: cardio exercises), so the patients had a gradual increase reaching the maximum load at the end of training.
2551984|NCT02552043|No Intervention|Control group|The CG carried out their routine patient management
2552116|NCT02551250||Study|Surveillance of HCC by biannual ultrasonography AND annual noncontrast MRI
2552162|NCT02550977|Experimental|Gestodene/EE Patch|
2552227|NCT02550665|Experimental|donepezil 15mg titration|donepezil 15mg during the first 4 weeks before escalation to 23mg
2552230|NCT02550665|Experimental|donepezil 10mg & 23 mg alternating|alternating donepezil 10mg and 23mg during the first 4 weeks before escalation to 23mg
2552236|NCT02550665|Active Comparator|no titration of donepezil|no titration and direct escalation to 23mg donepezil
2552268|NCT02550314|Experimental|NPC-18,FBG-18|"Intervention drug:~NPC-18;trafermin(recombination) and gelatin spnge, combination drug FBG-18;fibrin glue~Usage:NPC-18 and FBG-18 is administered at the same time for regenerative treatment of tympanic membrane"
2552276|NCT02550067|Active Comparator|Depot medroxyprogesterone acetate (DMPA)|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
2552280|NCT02550067|Active Comparator|Levonorgestrel implant (LNG)|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
2552283|NCT02550067|Active Comparator|Copper T380a IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
2552391|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered.
2552394|NCT02549599|Experimental|Chat/Text Program|Participants will receive real-time answers to questions they have about sexual and reproductive health topics from trained chat agents via the digital intervention program.
2552395|NCT02549599|Other|Website Content|Participants will be routed to the Planned Parenthood website to information and content about issues regarding sexual and reproductive health.
2552430|NCT02549274|Experimental|self-rehabilitation + physiotherapy|Patients will have, in addition to conventional physiotherapy, to visit two training sessions in self-rehabilitation at the hospital. They will then perform a self-rehabilitation / day session.
2552434|NCT02549274|Active Comparator|physiotherapy|Patients will have only conventional physiotherapy
2552476|NCT02548975||Delirium|Patients diagnosed with delirium at any time postoperatively with the CAM-ICU.
3174868|NCT00627874|No Intervention|2|
3174869|NCT00627887|Experimental|ECT+pharmacotherapy|Unilateral brief pulse ECT weekly for 6 weeks thereafter every 2 weeks; Venlafaxine target dose 300mg/day; Lithium target dose 0,5-0,8 mmol/L.
3174870|NCT00627887|Active Comparator|pharmacotherapy|Venlafaxine target dose 300mg/day; Lithium 0,5-0,8 mmol/L.
3174871|NCT00627900|Other|BMS|Implantation of a bare metal stent
3174872|NCT00627900|Other|SES|Implantation of a sirolimus-eluting stent
3174873|NCT00627913|Active Comparator|1|Healon 5
3174874|NCT00627913|Experimental|2|Retrobulbar Anesthetic Injection
3174875|NCT00627952|Active Comparator|amlodipine 10 mg|
3170833|NCT00579449|Active Comparator|YC|For those assigned to the Yearly Checkup group, a clinically-trained member of the HFD team will make yearly home visits to conduct the evaluation assessment. Information about community services and assistance with referrals are provided based on needs identified.
2551781|NCT02553434|Experimental|Pigtail catheter (case)|Inserting 14 French pigtail catheter
2551789|NCT02553434|No Intervention|Chest tube|inserting 32-36 French chest tube
2551842|NCT02553018|Experimental|Auto-injector of methotrexate|"The Auto-injector is a disposable, fixed, single dose, auto-injector to be used for Methotrexate (25mg/ml) therapy.~Dosage form: solution for injection Dosage: 0.3ml contains 7.5mg of Methotrexate, 0.4ml contains the 10.0mg of Methotrexate, 0.6ml contains 15.0 mg of Methotrexate, 0.8ml contains 20.0 mg of Methotrexate, 1.0ml contains 25.0 mg of Methotrexate.~Frequency: one injection per week Duration: until the end of the study"
2551846|NCT02553018|Active Comparator|Pre-filled syringe of methotrexate|"Pre-filled syringes contains a volume of 1 ml with attached injection needle. Dosage form: solution for injection. Dosage: 0.15 ml contains 7.5 mg of methotrexate, 20 ml contains 10 mg of methotrexate, 0.30 ml contains 15 mg of methotrexate, 0.40 ml contains 20 mg of methotrexate, 0.50 ml contains 25 mg of methotrexate disodium.~Frequency: one injection per week Duration: until the end of the study"
2551882|NCT02552784|Experimental|patients and their parents with inherited metabolic diseases|The population is a dynamic/open cohort consists of all patients MHMRS diagnosed and supported in one of the six Centers of Reference for Metabolical disease or one of the three Centers of Competence for Hereditary Metabolic Diseases or in the Center of Réference for Hereditary liver Metabolism Diseases since 2000. For each patient, the date of entry into the cohort is the diagnostic date of MHMRS. The study includes all prevalent and incident cases .
2551925|NCT02552563|No Intervention|Usual Care|Standard care received by veterans in the Corporal Michael J. Crescenz VA Medical Center
2551927|NCT02552563|Active Comparator|Dementia Care Management|CG education, continuous support, communication and coping skills training, and veteran monitoring, via CG report, of medication, symptoms, and service needs.
2552247|NCT02550457|No Intervention|Control group|It will not apply any tape.
2552254|NCT02550457|Experimental|Experimental group 1|Apply the KT with tension in the erector spine muscles.
2552256|NCT02550457|Experimental|Experimental group 2|Apply the KT without tension in the erector spine muscles.
2552259|NCT02550457|Placebo Comparator|Placebo group|Apply Micropore tape in the erector spine muscles.
2552306|NCT02550184|Experimental|Ultrasonography findings unblinded|"Intervention group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Intervention: The treating physician receives the results from the ultrasonographic examination (=unblinding of ultrasonography examination results)."
2552310|NCT02550184|Active Comparator|Ultrasonography findings blinded|"Control group: Patients in this group will receive a focused ultrasonography examination of the heart and the lungs which will be performed by the investigator.~Active Comparator: The ultrasonographic examination results will remain blinded for the treating physician."
2552591|NCT02548013|Experimental|Home management|outpatient management patients if stable will be discharged to continue treatment at home
2552595|NCT02548013|Active Comparator|hospital management|Inpatient management patients will continue there treatment in hospital till delivery
3170834|NCT00579449|No Intervention|MCC|Women placed in the community services as usual (Maternity Care Coordination only) group will receive no additional services or assessments as a part of this study.
3170835|NCT00579462||1|Patients with advanced lung cancer.
3170836|NCT00579475|Placebo Comparator|Placebo|
3170837|NCT00579475|Active Comparator|I|Mifepristone (Mifegyne) 50 mg every other day for 3 months
3170838|NCT00579514|Active Comparator|1|"All incident second primary cancers of colon, breast, bladder, kidney, prostate, ovarian cancer lung cancer and lymphoid cancer diagnosed between 1999 and present will be included in the secondary design to compare second primary cancer cases and first primary controls."
3170839|NCT00579514|Placebo Comparator|2|Controls will be volunteer blood donors from the New York Blood Center as well as normal volunteers from other AMDeC sites.
3170840|NCT00579540|Active Comparator|1|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3170841|NCT00579540|Active Comparator|2|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3170842|NCT00579540|Active Comparator|3|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks.
3170843|NCT00579566||1|Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum
3170844|NCT00579592|Experimental|1|Campath, Rituximab, Myfortic, and 10-20 days of cyclosporine
3170845|NCT00579605|Experimental|1|1 intervention group 1 attention intervention group Behavioral: Motivational Interviewing Client-centered strategy that may decrease ambivalence in behavior performance
3170846|NCT00579631||1|Questionnaire or Interview
3170847|NCT00579644|Active Comparator|1 Methotrexate* & minocycline|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
3174876|NCT00627952|Active Comparator|manidipine 20 mg|
3174877|NCT00627965|Experimental|1|Sildenafil citrate
3174878|NCT00627965|Placebo Comparator|2|Placebo
3174879|NCT00628004|Experimental|1|
3174880|NCT00628004|Active Comparator|2|
3174881|NCT00628004|No Intervention|No treatment|No treatment as wound was healed
2551736|NCT02553642|Experimental|melanoma and bladder cancer patients|All eligible patients with melanoma will receive ipilimumab at a dose of 3 mg/kg combined with nivolumab at a dose of 1 mg/kg. The ipilimumab and nivolumab will be dosed every 3 weeks for 4 doses. Thereafter, patients may be eligible to continue to receive nivolumab monotherapy at a dose of 240 mg administered every 2 weeks OR nivolumab at dose of 480mg every 4 weeks for up to 2 years All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years. All eligible patients with bladder cancer will receive nivolumab at a dose of 240 mg administered every 2 weeks for up to 2 years, if the patient is clinically benefitting, the PI and treating investigator may elect to continue treatment beyond 2 years.
2551957|NCT02552251|Experimental|A: hydrocortisone|hydrocortisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
2551958|NCT02552251|Experimental|B :dexamethasone (DECTANCYL)|dexamethasone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
2551961|NCT02552251|Experimental|C : prednisone (CORTANCYL)|prednisone equivalent to physiological doses for each patient Strategy: administration of glucocorticoids during sequences of eight weeks
2552090|NCT02551796|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
2552091|NCT02551796|Experimental|laser in situ keratomileusis|The patients in this group chose to receive the laser in situ keratomileusis surgery.
2552092|NCT02551796|Experimental|FS assisted laser in situ keratomileusis|The patients in this group chose to receive the FS assisted laser in situ keratomileusis surgery.
2552122|NCT02551237|Active Comparator|Radiochemotherapy|"Patients who will be treated with~radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks associated with~oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
2552124|NCT02551237|Experimental|Radiotherapy|"Patients who will be treated with radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm) without chemotherapy.~The surgery will be planned 7 weeks (±1 week) after the end of preoperative treatment"
2552153|NCT02550808||Heart failure|
2552157|NCT02550808||Chronic obstructive pulmonary disease|
2552159|NCT02550808||Chronic kidney disease|
2552161|NCT02550808||Malignancy|
2552164|NCT02550808||Controls|
2552216|NCT02550730|Experimental|Birth Sisters|Half of the women who agree to participate in the evaluation will be randomized to the Birth Sisters Best beginnings for Babies Program, which includes community doula support and consultation with Medical Legal Partnership when indicated.
2552222|NCT02550730|Active Comparator|Routine care|Half of the women who agree to participate in the evaluation will be randomized to the usual maternity care group
2552279|NCT02550379|Placebo Comparator|Placebo|The placebo protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point at baseline. A test phase is then administered which is identical to the baseline phase to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
2552284|NCT02550379|Experimental|Intervention|The ER training protocol consists of 3 phases, baseline, training, and test. The baseline phase consists of 45 trials which calculates the balance point at which the participant rates a face as 'happy' rather than 'disgusted' over a continuum of 15 faces ranging from happy through ambiguous to disgust. 3 training blocks are then administered with 30 trials per block. Behavioural feedback is given during training (correct/incorrect) based on the participant's balance point however this balance point is adjusted by 2 points on the 15 face continuum to train the participant to rate more faces as 'happy'. A test phase, identical to the baseline phase, is then administered to reassess the participant's balance point. The task takes approximately 15 minutes to complete all 3 phases.
2552382|NCT02549976|Experimental|Evaluation group|"Digestive damage will be assessed on patients by using the methods described in the Lemann index protocol, dependant of Crohn's disease locations.~All patients will have clinical examination and abdominal magnetic resonance imaging analyses. Upper endoscopy, colonoscopy, and pelvic magnetic resonance imaging analyses will be performed according to disease locations :~Upper tract location : upper endoscopy~Colorectal location : colonoscopy~Perianal location : pelvic MRI~All patients : abdominal MRI"
2552410|NCT02549261|Experimental|the tolerance trial of treatment|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
2552411|NCT02549261|Experimental|A|nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
2552413|NCT02549261|Placebo Comparator|B|chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
2552628|NCT02548273||Diabetics|diabetics with cataract who opted for phacoemulsification surgery
2552632|NCT02548273||controls|non-diabetics with cataract who opted for phacoemulsification surgery (subjects without corneal opacity, PXF ,high myopia, uveitis)
3174882|NCT00628017|Experimental|1|omega-3 PUFAs(180mg eicosapentaenoic acid[EPA] + 120mg docosahexaenoic acid[DHA]/capsule), 3 capsules twice daily, total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA
2552814|NCT02546687||Canidate for elective esophagectomy|Venous blood sampling from gastric tube during elective esophagectomy
2552854|NCT02546531|Experimental|Dose expansion (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
2551921|NCT02552576|Experimental|Voncento|The frequency and dose of Voncento administration will be determined by the investigator using the information included in the Voncento Summary of product characteristics (SmPC)
2551986|NCT02552134|Experimental|frequent participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence.
2551988|NCT02552134|Experimental|medium participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
2551989|NCT02552134|Experimental|low participation|After termination of a stationary stay in a health resort, participants will visit an initial standardised regional sport club based exercise programme for 12 sessions at the place of the residence
2551991|NCT02552134|Active Comparator|recommendation to be active|"During the stay in the health care resort participants are introduced to be active in the future. They will receive a brochure Physical Activity: Health for all."
3204699|NCT00936390|Experimental|Arm II|Patients receive androgen-deprivation therapy comprising luteinizing-hormone releasing-hormone (LHRH) agonist (leuprolide, goserelin, buserelin, or triptorelin) subcutaneously or as an injection every 1 to 3 months AND an oral antiandrogen therapy (flutamide 3 times daily or bicalutamide once daily) for 6 months. Beginning 8 weeks after the first LHRH injection, patients undergo radiotherapy as in arm I.
2552141|NCT02551172|Experimental|experimental sequence|Run-in period → Treatment period HGP0816 20mg 1tab HCP1105 4capsues +Placebo of HGP0816
2552143|NCT02551172|Placebo Comparator|comparative sequence|Run-in period → Treatment period HGP0816 20mg 1tab Placebo of HCP1105 4capsues +HGP0816 20mg
2552180|NCT02550860|Active Comparator|soybean oil (SO)-based IVFE (Medialipide)|
2552186|NCT02550860|Active Comparator|fish oil (FO)-containing IVFE (Lipidem)|fish oil (FO)-containing IVFE (Lipidem)
2552267|NCT02550535|Experimental|Gene-modified WT1 TCR-transduced T cells|A single dose of bulk WT1 TCR-transduced T cells (≤ 2 x 107/kg) will be intravenously (i.v.) administered following protocol-specified lymphodepletive conditioning regimen. Additionally, daily IL-2 subcutaneous injections (1x106 units/m2 subcutaneously (s.c.)) will be administered for 5 days concomitantly to each subject, following infusion of the ATIMP.
3204700|NCT00936403|Experimental|NNC126-0083|
2552409|NCT02549547|Experimental|Lifestyle Intervention|Physical Activity focused, interdisciplinary, Group Medical Visits (GMVs)
3204701|NCT00936403|Active Comparator|Norditropin NordiFlex®|
3204702|NCT00936416|Experimental|GFR and RBF followed by MRI|Subjects will undergo GFR and renal blood flow estimation by Inulin and PAH clearance method, followed by a MRI test. The MRI examination will be performed on the same day as the inulin/PAH procedure.
2552658|NCT02547688|Other|Nasal High Flow|All subjects are in this group
2552695|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
2552698|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue|
2552701|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
2552702|NCT02547571|Active Comparator|1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue|
2552703|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid|
2552705|NCT02547571|Active Comparator|1) Early colonoscopy; 2) High-dose, day before; 3)Low residue|
2552709|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid|
2552712|NCT02547571|Active Comparator|1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue|
2552713|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid|
2552714|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue|
2552715|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid|
2552716|NCT02547571|Active Comparator|1) Later colonoscopy; 2) Low volume day before; 3)Low residue|
2552864|NCT02546596|Experimental|Electro-hyperthermia plus radiation|External beam radiation 40 Gy with 20 fractions (4 weeks) Electro-hyperthermia twice a week, one hour for each session
2552943|NCT02546271|Experimental|Treatment Group|GPS program - an 8-week, peer-led group counselling program using motivational interviewing techniques.
2552967|NCT02545790||Persistent hypertrophy|Elevated cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
2552970|NCT02545790||Normal geometry|Normal cardiac mass at follow-up time point as measured by Echocardiographic and Serologic evaluations.
2553021|NCT02545426|Active Comparator|Calcium dialysate 2.5mEq/L|Dialysis with low calcium concentration
2553026|NCT02545426|Active Comparator|Calcium dialysate 3.5mEq/L|Dialysis with high calcium concentration
2553090|NCT02545049|Experimental|BAY94-8862|Finerenone tablet
2553098|NCT02545049|Placebo Comparator|Placebo|Matching placebo
3204703|NCT00936429|Experimental|10 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 10 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
3204704|NCT00936429|Experimental|50 µg DEN1-80E + 3.5 mg Alhydrogel|Administration of 50 µg DEN1-80E vaccine at Weeks 0, 4, and 8.
3204705|NCT00936429|Placebo Comparator|Placebo|Administration of placebo vaccine at Weeks 0, 4, and 8.
3204706|NCT00936442||Group A|Standard treatment: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
3204707|NCT00936442||Group B|Standard treatment + educational material: 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice plus reception of educational material on regular basis.
3204708|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (3.75ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 3.75ug given by IM injection to the upper deltoid.
3204709|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (7.5ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 7.5ug given by IM injection to the upper deltoid.
3204710|NCT00936468|Experimental|Fluzone® vaccine with JVRS-100 (25ug)|One vaccination on Day 0 with Fluzone® vaccine at 45 ug mixed with JVRS-100 adjuvant at 25ug given by IM injection to the upper deltoid.
3204711|NCT00936468|Experimental|Fluzone® vaccine alone|One vaccination on Day 0 with Fluzone vaccine at 45 ug given by IM injection in the upper deltoid.
2551923|NCT02552381||Group I|"Patients without LMWH treatment.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays~Other markers activity : sFVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
2551926|NCT02552381||Group II|"Patients with LMWH treatment at prophylactic dose at enrollment only.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
2551928|NCT02552381||Group III|"Patients with LMWH treatment at therapeutic dose.~A thromboembolic event has to be diagnosed according to standard imaging criteria (spiral computed tomography CT, proximal lower limb venous compression ultrasonography US) by clinicians who will not have knowledge of the result of the fibrin structure marker.~The following assays will be performed for these patients :~Fibrin Structure measured at baseline and every month using prototype assays,~Anti-FXa activity measured at baseline and every month,~Other markers activity : FVIII:C and TFPI for coagulation activation, DDimers and PAI-1 for fibrinolysis resistance and fibrin assay, all measured at baseline and every 3 months."
3204712|NCT00936494|No Intervention|Control|No inferior turbinate surgery.
3204713|NCT00936494|Other|Intervention|Intervention group: Cold ablation inferior turbinate reduction utilizing radiofrequency ablation surgery (CITR).
2552094|NCT02551484|Experimental|Procedure 1|Measures with 60 minutes interval during the consultation of equipment, functional testing, receuil pain.
2552095|NCT02551484|Experimental|Procedure 2|Measuring J15, J30 J 45 and after the different settings functional amputation, pain and tissue oxygenation.
2552129|NCT02551263||Observational group|All patients will receive adequate treatment for breast cancer which selected by the primary physician after enrollment using the Japanese Breast Cancer Society Clinical Practice Guideline of Breast Cancer and the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Investigators at the investigational sites will enter patient data into an electronic data capture (EDC) system up to the third chemotherapy in the study.
2552167|NCT02551016||Primary care only|Patients with heart failure recorded in primary care and never hospitalized for heart failure
2552169|NCT02551016||Primary care and secondary care|Patients with heart failure recorded in primary care with at least one record of a heart failure related hospitalization.
2552171|NCT02551016||Secondary care only|Patients with heart failure recorded in at least one heart failure related hospitalization without a concurrent primary care record.
2552209|NCT02550678|Experimental|Cohort 1|Study Participants will receive ASN-002 at a dose 5X 10(10) vp, weekly injection in tumor nodules for 3 weeks.
2552210|NCT02550678|Experimental|Cohort 2|Study Participants will receive ASN-002 at a dose of 1.5X 10(11) vp weekly injection in tumor nodules for 3 weeks
2552212|NCT02550678|Experimental|Cohort 4|Study Participants will receive ASN- 002 at a dose of 3.0X 10(11) vp weekly injections in tumor nodules for 3 weeks.
2552214|NCT02550678|Experimental|Cohort 5|Study Participants will receive ASN- 002 at a dose of 2.25X 10(11) vp weekly injections in tumor nodules for 3 weeks.
2552215|NCT02550678|Experimental|Combination Cohorts|Study Participants will receive ASN- 002 at either dose of Cohorts II, IV or V in combination with a low dose 5-FU (1mg/2.5 mg/5mg/10mg or 25mg) weekly injections in tumor nodules for 3 weeks.
2552290|NCT02550275|Other|presymptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) < 5
2552292|NCT02550275|Other|symptomatic patient|patient with Unified Huntington's Disease Rating Scale (UHDRS) > 5
2552293|NCT02550275|Other|controls|unaffected patient with Huntington's disease
2552326|NCT02549820|Experimental|FETO in CDH|Fetoscopic Endoluminal Tracheal Occlusion (FETO) will be performed by placing a detachable balloon inside the fetal airway and removing the balloon after several weeks. Devices: GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
2552360|NCT02549690|Active Comparator|Testosterone gel|Testosterone gel 10mg, used transdermally, once a day. Treatment duration: 6-8 weeks
2552365|NCT02549690|Active Comparator|DHEA|DHEA 25mg tablet, orally, three times per day. Treatment duration: 6-8 weeks
3204714|NCT00936507|Experimental|Low-ED, small portion|
3204715|NCT00936507|Experimental|Low-ED, large portion|
2552474|NCT02549118|Experimental|Tenoxicam|Intravenous administration of tenoxicam, a lyophilisate with 20 mg to be dissolved and diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2552478|NCT02549118|Active Comparator|Pethidine|Slow intravenous administration of pethidine, 50 mg to be diluted in 10 mL of sterile water (single dose), as an analgesic during the first stage of labor, given by a member of the study team.
2552504|NCT02548715|Placebo Comparator|Control|Daily placebo
2552508|NCT02548715|Experimental|Treatment|Participants administered daily levothyroxine at 1.6mcg/kg to a target normal TSH, measured at 6 weeks after the initiation of therapy
2552549|NCT02548533|Active Comparator|Region 1|Standard topical anesthesia using eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) applied two hours before treatment.
2552555|NCT02548533|Experimental|Region 2|Anesthesia using articaine hydrochloride 40 mg/ml and epinephrine 10 µg/ml solution (AHES) applied on ablative fractional laser (AFXL) pretreated skin 15 minutes prior to the treatment.
2552593|NCT02548026|Experimental|High Eating Frequency (High EF)|8 Eating Occasions
3204716|NCT00936507|Experimental|High-ED, small portion|
3204717|NCT00936507|Experimental|High-ED, large portion|
3204718|NCT00936520|Experimental|Dose 1|SAR 1118 dose 0.1%
3204719|NCT00936520|Experimental|Dose 2|SAR 1118 dose 1.0%
3204720|NCT00936520|Experimental|Dose 3|SAR 1118 dose 5.0%
3204721|NCT00936546|Experimental|Rituximab|
3204722|NCT00936559|Experimental|1|Arm A
2551937|NCT02552407||Manual Aspiration Thrombectomy with PCI|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to Manual Aspiration Thrombectomy followed by percutaneous coronary intervention (PCI).
2551938|NCT02552407||PCI Alone|Subjects from the randomized controlled trials to be included in this meta-analysis will have been randomly allocated to percutaneous coronary intervention (PCI) alone without manual aspiration thrombectomy.
2551981|NCT02552108|Experimental|Behavioural experiments (CBT)|"Behavioural experiments involve selecting a specific thought to be tested (e.g., uncertainty makes me unable to act) and designing a detailed experiment to test out the thought."
2551982|NCT02552108|No Intervention|Waiting list|12 week wait (with assessments) before being transferred to the experimental condition.
2552019|NCT02551848|Experimental|Essential tremor treatment|"A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction.~Participants will be treated by BoNT-A injections every 12 weeks over 72 weeks. BoNT-A parameters will be determined solely by biomechanical analysis of tremulous movements in both upper extremity BoNT-A dose will range from 50-300 U per arm"
2552048|NCT02551640|Experimental|Group A|"Receive a Samsung smartphone~Receive the FeatForward app~Receive a Samsung smartwatch~Continue to receive medical care as usual"
2552050|NCT02551640|No Intervention|Group B|"Receive a Samsung smartphone~Receive a Samsung smartwatch~Continue to receive medical care as usual"
2552109|NCT02551458|Experimental|Arm A: Systematic surgery|
2552110|NCT02551458|Experimental|Arm B: Surveillance and rescue surgery in cases of resectable|
2552183|NCT02550886||Patient/Caregiver Dyad|
2552266|NCT02550561|Experimental|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots. If benefits are obtained, 12 weeks of treatment is followed by spaced maintenance sessions at timing of provider and patient discretion.
2552338|NCT02550015|Experimental|Training|Supervised high intensity interval training (uphill treadmill walking 4 x 4 min at 90-95% of peak heart rate) 3 times weekly for 8 weeks
2552340|NCT02550015|Other|standard care|Standard clinical follow-up care, including general information about importance of physical activity as part of a healthy lifestyle
3204723|NCT00936559|Experimental|2|Arm B
2552681|NCT02547844|Active Comparator|efavirenz + emtricitabina + tenofovir|Patients assigned to the control group will continue receiving the same medication than before to be included in the study: Atripla (efavirenz + emtricitabina + tenofovir)
2552689|NCT02547844|Experimental|rilpivirina + emtricitabina + tenofovir|Patients assigned to the experimental group will change the medication that are taking before to enter in the study ( atripla) for eviplera (rilpivirina + emtricitabina + tenofovir)
2552741|NCT02547402|Experimental|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
3174883|NCT00628017|Placebo Comparator|2|three identical placebo capsules twice daily which contained olive oil esters.
2552797|NCT02546830|Experimental|FreeO2 v2.2 active|Automatic Oxygen Administration
2552798|NCT02546830|Active Comparator|FreeO2 v2.2 with manual oxygenation|Manual Oxygen Administration
2552926|NCT02546076|Active Comparator|Laser coagulation|Er:YAG laser treatment with coagulation modality
2552932|NCT02546076|Active Comparator|Laser w/o coagulation|Er:YAG laser treatment without coagulation modality
2552981|NCT02545855|Experimental|Arm A (myAIRVO2® + HOT, HOT)|Subjects will receive the myAIRVO2® therapy plus HOT for week 1-6 and HOT only for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
2552984|NCT02545855|Experimental|Arm B (HOT, myAIRVO2® + HOT)|Subjects will receive HOT only for week 1-6 and the myAIRVO2® therapy plus HOT for week 7-12. After treatment period (week 1-12), willing subjects can continue the myAIRVO2® therapy plus HOT for week 13-52 regardless of treatment arm assignment.
2553015|NCT02545374|Experimental|Telemedicine|"In the telemedicine arm, all patients will be supported by Telemedicine protocol according to the development of telemedicine in the region.~The use of teleconsultation allows the couple expert doctor / nurse expert to perform a complex of wound assessment consultation and / or chronic. The use of telemedicine allows for acts of telecare, when the nurse applicant sought a remote support of an expert nurse (under the responsibility of a doctor) for the realization of an act. The use of tele-expertise enables physicians to remotely bring special expertise to improve patient care."
2553029|NCT02545530|No Intervention|transdermal clonidine-|regular antihypertensive treatment
3174884|NCT00628043|Experimental|EPOCH|
3174885|NCT00628043|Placebo Comparator|placebo|
3174886|NCT00628056|Active Comparator|1|
3174887|NCT00628056|Placebo Comparator|2|
3174888|NCT00628069||Group 1|performers who will participate in the training sessions.
3174889|NCT00628069||Assistants|Assisants-paired with the performers and will be allowed to assists only, without the opportunity to practice the technical skills related to the task.
3174890|NCT00628082||HfpEF|Patients with Heart Failure with preserved ejection fraction
3174891|NCT00628082||Control|Healthy Volunteers
3174892|NCT00628095|Experimental|Active|
3174893|NCT00628095|Placebo Comparator|Placebo|
3174894|NCT00628121|Experimental|Cetrorelix 1 mg|
3174895|NCT00628121|Experimental|Cetrorelix 2 mg|
3174896|NCT00628121|Experimental|Cetrorelix 3 mg|
2551946|NCT02552290|Active Comparator|Cervicothoracic manipulation|Description of a Right C7/T1 manipulation. The subject will lie prone. The therapist will stand on the L side of the subject facing in a cephalic direction (towards the patient's head). The therapist's right hand makes contact with the thumb on the right side of the spinous process of the first thoracic vertebra. The therapist left hand supports the head making contact on the temporal bone. The hand/neck is gently laterally flexed to the right, until slight tension is palpated in the tissues. A high-velocity low-amplitude thrust will be applied towards the subjects left side. If cavitation does not occur (an audible pop) the subject will be repositioned and the manipulation attempted a second time. A maximum of 2 attempts will be performed for each side of the neck.
2551949|NCT02552290|Active Comparator|Upper trapezius stretch|"The subjects will be in a supine position. A researcher will passively place the subject's head into flexion, side-bending away and rotation towards the side to be stretched until the muscle barrier is met. The researcher will depress the subject's shoulder with 100 Newtons of force measured with a Micro FET pressure dynamometer (Hoggan Health Industries, Salt Lake City, UT).) Once this pressure amount is achieved the stretch will be held for 30 seconds. This will be repeated two times on each side.~The subject will be asked to provide continuous feedback about the stretch felt and the degree of discomfort (if any) felt during the 30 second stretches."
2551951|NCT02552290|Other|Control group|Subjects assigned to the control group will receive no intervention. They will stay behind the curtained research area for approximately 3 minutes in a seated position.
2552003|NCT02552004|Experimental|pCLE|Patients subject to endocrine or digestive surgery will have intraoperative pCLE examination. The installation and surgical opening will be performed according to standard protocols. The contrast agent, fluorescein, will be injected intravenously to allow tissue visualization with pCLE. During the surgery, the surgeon will perform the pCLE examination, to obtain and record video sequences of in situ structures. Frozen sections will be obtained on the same samples and will further guide the surgical decision-making.
2552051|NCT02551679|Active Comparator|ACP-01|Injection into lower extremity
2552056|NCT02551679|Placebo Comparator|Placebo|Injection into lower extremity
2552136|NCT02551211|Experimental|Patients with resectable non-small cell lung cancer|
2552151|NCT02550925|Experimental|Acceptance and Commitment Therapy Group|
2552152|NCT02550925|Active Comparator|Usual Care|
2552298|NCT02550080|Experimental|The prospective genetic screening arm|Prospective HLA-B*1301 screen before administrated treatment included dapsone
2552302|NCT02550080|Active Comparator|The control arm|No HLA-B*1301 screen before administrated treatment included dapsone
3170848|NCT00579644|Active Comparator|2|"Methotrexate Dosing:~Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month~12 month evaluation: End of the blinded portion of the study."
3170849|NCT00579657|Placebo Comparator|1|"Intervention: 'control diet, supported by dietary supplement twice daily'~control diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement daily)]"
2552392|NCT02549625|Experimental|Single-arm|Intracoronary delivery of autologous bone marrow-derived mononuclear cells using catheterization procedure
2552443|NCT02549300|No Intervention|Control Group|15 patients will be included in control group. Control group will just receive advices about life style modifications, such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.
2552447|NCT02549300|Experimental|Study Group|15 patients will be included in study group. Study group will be treated with connective tissue massage in addition to life style modifications (such as teaching good postural habits, using right glasses, not smoking, regular and quality sleep habits.). Connective tissue massage will be applied 5 times a week, totally 20 sessions in a month. Each session lasts approximately 20-30 minutes. Connective tissue massage will be applied on basic part, lower thoracic, scapular, inter scapular and neck regions.
2552488|NCT02548858|Active Comparator|Perineorrhaphy|Patients who are randomized to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
2552490|NCT02548858|Active Comparator|No Perineorrhaphy|Patients who are randomized not to receive a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure
2552677|NCT02547805|Placebo Comparator|Placebo|Five (5) capsules of placebo by mouth (PO) three times per day (TID) with meals
3170850|NCT00579657|Experimental|2|"Intervention: 'high cereal fiber diet, supported by dietary supplement twice daily'.~high cereal fiber diet [carbohydrates 55(50 - 60)% , protein 15(10 - 20)% protein; fat ca. 30% of energy content; dietary fiber > 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber daily)]"
3170851|NCT00579657|Experimental|3|"Intervention: 'high protein diet, supported by dietary supplement twice daily'~high protein diet [carbohydrates 40 - 45% , protein > 25 - 30%; fat ca. 30% of energy content; dietary fiber < 15 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 25 g whey and plant protein daily)]"
3170852|NCT00579657|Experimental|4|"Intervention: diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily.~high cereal fiber/high protein (MIX) moderately high cereal fiber/high protein diet (carbohydrates 45- 50)% , protein 20 - 25%; fat ca. 30% of energy content; dietary fiber 15 - 20 g/1000 kcal and day; intensive dietary advice plus supplement (2 x basic supplement including 2 x 15 g cereal fiber and 2 x 25 g whey and plant protein daily)"
3170853|NCT00579683||1|This is a protocol to study tissue specimens to identify changes in tumor DNA in NSCLC patients who have previously responded to therapy and who have subsequently experienced disease progression.
3170854|NCT00579709|Experimental|1|Thymus Tissue for Transplantation
3170855|NCT00579748||1|
3170856|NCT00579774|Experimental|1 - Low AGE Diet|Low Age Diet
3170857|NCT00579774|Active Comparator|2 - Regular Diet|Regular Diet
3170858|NCT00579787||1|Women with early stage cervical cancer undergoing radical trachelectomy
2551967|NCT02552615|Experimental|core stabilization exercises|Exercises started to progress from static to dynamic positions in which muscle activation incorporate into functional tasks including trunk and extremity movements. Local, global muscle stability training, global muscle mobility training and strengthening training of these core structure was carried out progressively advancing more difficult. Patients received 20 sessions for one hour at clinic for ten-week treatment period.
2552018|NCT02551926|Experimental|mobile text messaging|Patients will receive some SMS in a regular interval.
2552021|NCT02551926|Experimental|virtual communities|Patients will receive some messages by a virtual community in a regular interval.
2552025|NCT02551926|Experimental|brochures|Patients will receive some messages by as a printed media
2552026|NCT02551926|Active Comparator|Control|control group will be included without any intervention
2552054|NCT02551588||Valvular aortic stenosis surgery|"Patients with symptomatic AVS had indication for surgery. They were proposed to have per procedure cardiac biopsy.~They were followed when possible one year after surgery."
2552058|NCT02551588||Valvular aortic stenosis without surgery|These patients with asymptomatic AVS had no indication for surgery. They were followed when possible one year after inclusion.
2552061|NCT02551588||Control subject|Patients without history of cardiac infarction, primary or secondary myocardiopathy or of radiotherapy or chemotherapy.
2552114|NCT02551445|Experimental|Gradual exposure to food stimuli|The intervention entails 2 sessions of psychoeducation and a clinical assessment including a discussion on learned food-related fears, role of food-related fears in the maintenance of anorexia nervosa, anxiety and its time course, avoidance, exposure and habituation, irrational fears and safety behaviors; and 8 sessions of in vivo exposure to foods, starting from the least scary food of a hierarchy of threatening foods created by each patient. Each session will involve exposure to a new food item and patients will be encouraged to confront their fear by looking at and touching the chosen food item. They will also be encouraged to eat the food and reflect on the consequences of eating and assessing those relative to their fears (e.g. checking whether they have lost control or changed shape after eating).
2552175|NCT02551133|Active Comparator|0.1 mg/kg dexamethasone|0.1 mg/kg dexamethasone intravenous will be given 1 h before surgery.
2552177|NCT02551133|Active Comparator|0.2 mg/kg dexamethasone|0.2 mg/kg dexamethasone intravenous will be given 1 h before surgery.
2552241|NCT02550548|Experimental|GIP infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
2552244|NCT02550548|Experimental|GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GLP-1 infused at 4 incremental dosages, (initial dose will be 1.0 ng/kg/min, followed by 2.0, 3.0, and 4.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
2552249|NCT02550548|Experimental|GIP + GLP-1 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP + GLP-1 infused simultaneously at 4 incremental dosages (doses will be half the amounts described above). These doses will be infused continuously for 30 minutes, followed immediately by the next higher doses. The total time of this procedure is 240 minutes.
2552252|NCT02550548|Experimental|GIP + Ex-9 infusion|During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages (as described above) with Ex-9 infused at a steady dose of 2.5 mcg/kg/min starting 90 minutes before the GIP infusion and maintained throughout the clamp experiment. The total time of this procedure is 240 minutes.
3204724|NCT00936559|Experimental|3|Arm C
2552381|NCT02549677|Experimental|EC regimen|Epirubicin, cyclophosphamide
2552383|NCT02549677|Active Comparator|TC regimen|docetaxel, cyclophosphamide
2552451|NCT02549313||position changes of head with brain lesion|patient with position changes of the head: registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 °.
3204725|NCT00936572|Experimental|high dose|high dose of probiotics (109 cfu)
3204726|NCT00936572|Experimental|low dose|low dose of probiotics (107 cfu)
2552547|NCT02548481||BESTA scale|BESTA scale is administered at T0, T1 (3 months) and T2 (1 year)
2552617|NCT02548247|Experimental|Orafti® Inulin|Daily consumption of 12g Orafti® Inulin (3x 4g/d) over a period of 4 weeks
2552622|NCT02548247|Placebo Comparator|Placebo|Daily consumption of 12g/ Maltodextrin (3x 4g/d) over a period of 4 weeks
2552668|NCT02547792|Experimental|VXA-BYW.10 (Low Dose) Oral Vaccine|Single administration of Influenza B (Low Dose) oral vaccine tablets
2552669|NCT02547792|Experimental|VXA-BYW.10 (High Dose) Oral Vaccine|Single administration of Influenza B (High Dose) oral vaccine tablets
2552670|NCT02547792|Placebo Comparator|Placebo Tablets|Matching placebo dose (size and number of tablets) to low dose vaccine (part 1) and high dose (part 2)
2552740|NCT02547415||patients with questionnaires and psychological testing|children and adolescents with chronic pain without proven medical cause, type painful somatic complaints
3204727|NCT00936572|Placebo Comparator|probiotics|Maltodoxtrin
3204728|NCT00936624|Experimental|SOTB07 100mg|
2552897|NCT02546141|Active Comparator|skimmed milk (UHT)|portion size that contains 25 g of protein, oral, single administration
2552904|NCT02546141|Active Comparator|skimmed milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
3204729|NCT00936624|Experimental|SOTB07 200mg|
3204730|NCT00936624|Placebo Comparator|Placebo|
3204731|NCT00936624|Active Comparator|Montelukast 10mg|
3204732|NCT00936637|Experimental|Extensively hydrolyzed infant formula|
3204733|NCT00936650|Experimental|cinacalcet|
3204734|NCT00936650|Placebo Comparator|placebo|
3204735|NCT00936676||Rasagiline mesylate|Enrollment by invitation to participates from the ADAGIO trial
3204736|NCT00936689|Sham Comparator|Traditional TACE|Chemoembolization by standard technique: epirubicin (maximum dose of 75 mg) conjugated with an oil-based contrast medium (Lipiodol) at the maximum dose of 15 ml + gelatin sponge particles(particles of transient embolization material, required to obstruct the treated vessel).
3204737|NCT00936689|Active Comparator|TACE with microsphere|
3204738|NCT00936728|Experimental|Arm A (white wine)|Patients consume white wine twice daily for 3-4 weeks.
2552108|NCT02551510|Active Comparator|Suture|Skin incision closure with standard subcuticular technique
2552112|NCT02551510|Active Comparator|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl®
2552165|NCT02551107|Experimental|Congenital heart disease|"Inclusion criteria: All participants, less than one year of age, with CHD will be eligible for this study with the exception of those patients with only patent foramen ovale (PFO) and patent ductus arteriosus (PDA). The diagnosis of CHD will be confirmed by echocardiography.~Exclusion criteria: Participants with only PDA or PFO, without written informed consent, patients older than one year of age or any subject on oxygen at the time of nNO assessment."
2552170|NCT02551107|Active Comparator|Controls|The control group will consist of age matched infants, less than one year of age, without CHD or acute respiratory illness. The participants will also require written informed consent and will have to be breathing room air at the time of the nNO test.
2552219|NCT02550626||Delirium|occurrence of post-operative delirium
2552223|NCT02550626||No delirium|no presence of post-operative delirium
2552272|NCT02550405|Experimental|Craving behavioral intervention|The craving behavioral intervention (CBI) was developed based on the framework of craving, combining with behavior intervention (Dong and Potenza, 2014), and conducted among individuals with IGD.
2552273|NCT02550405|No Intervention|Control|The control group were individuals with Internet gaming disorder who did not receive any intervention but were scanned twice with the similar interval period as experimental group.
2552348|NCT02550002||Strict treatment regimen with aflibercept|Treatment intervals with aflibercept in the strict retinal fluid treatment regimen will be extended by two weeks only if no SRF in the central subfoveal field and no IRF can be detected SD-OCT examination.
2552351|NCT02550002||Relaxed treatment regimen with aflibercept|Treatment intervals with aflibercept in the relaxed retinal fluid treatment regimen will be extended by two weeks only if SRF in the central subfoveal field is ≤100 μm in a vertical extent and no IRF is detected on SD-OCT examination.
2552506|NCT02548689||Non-scarring hair loss|Patients seen at Northwestern Memorial Hospital or Northwestern Medical Faculty Foundation physician offices that have undergone evaluation for hair loss and have a diagnosis of androgenetic alopecia, telogen effluvium or alopecia areata.
2552510|NCT02548689||Control|Age-matched controls who do not have a history of hair loss and have normal scalp skin without evidence of hair loss.
2552554|NCT02548546|Active Comparator|Surveillance|No Surgery with ECHO and ECG-gated MRA imaging.
2552557|NCT02548546|Active Comparator|Surgery-Open|Open Surgery with ECHO and ECG-gated MRA imaging.
2552560|NCT02548546|Active Comparator|Surgery-EVAR|EVAR with ECHO and ECG-gated MRA imaging.
3204739|NCT00936728|Active Comparator|Arm B (non-wine nutritional supplement)|Patients receive an oral non-wine nutritional supplement (e.g., Boost or Ensure) twice daily for 3-4 weeks.
3204740|NCT00936754|Experimental|Treatment|Single administration of 500 mg of encapsulated brown seaweed powder, taken 30 minutes before test meal
3204741|NCT00936754|Placebo Comparator|Placebo|Single administration of encapsulated placebo, taken 30 minutes before test meal
3204742|NCT00936767|Experimental|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
2552867|NCT02546414||Esophageal varices haemorrhage group|HBV hepatic cirrhosis with first esophageal varices haemorrhage were included and stratified using their Child-Pugh score. The platelet count were evaluated, and ultrasound was used to measure the longest diameter of the spleen. The platelet count(PC)/spleen diameter (SD)ratio was calculated and analyzed to determine whether it can predict the variceal haemorrhage. Upper gastrointestinal endoscopy was used as the gold standard.
2552868|NCT02546414||no haemorrhage but esophageal varice presence|HBV hepatic cirrhosis with no esophageal varices haemorrhage were included and upper gastrointestinal endoscopy were validate.They also stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated, The PC/SD ratio was calculated and analyzed to determine whether it can predict the variceal presence.
2552870|NCT02546414||no esophageal varice but cirrhotic|HBV hepatic cirrhosis with no esophageal varices were included and also validated by upper gastrointestinal endoscopy.They stratified using their Child-Pugh score. The platelet count and longest diameter of the spleen were evaluated,The PC/SD was calculated and analyzed to determine whether it can predict the variceal absence .
2552917|NCT02546219||Adults with EoE|Adult patients with active eosinophilic esophagitis will under blood collection and esophagus biopsies in order to perform eosinophil isolation and characterization.
3204743|NCT00936767|Active Comparator|Artesunate/Mefloquine (MAS3)|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
3204744|NCT00936780|Experimental|Infinnium-Core™ Paclitaxel eluting Coronary Stent|
3204745|NCT00936806||Unilateral intracranial tumor|Subjects with unilateral intracranial tumor
3204746|NCT00936806||Control group|Subjects without intracranial pathology
3204747|NCT00936819|Placebo Comparator|Plasma-Lyte A and 25% autologous plasma|
2553218|NCT02544204|Active Comparator|8 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
2553220|NCT02544204|Placebo Comparator|8 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
2553221|NCT02544204|Active Comparator|16 mg JVS-100|Biological/Vaccine: JVS-100 Injection Intramuscular Injection
2553222|NCT02544204|Placebo Comparator|16 mg placebo|Biological/Vaccine: Placebo Injection Intramuscular Injection
2553295|NCT02543632||Treated group|Subjects who meet the inclusion/exclusion criteria listed and also are approved via anatomical inclusion criteria for treatment with the Parachute Implant System.
3204748|NCT00936819|Experimental|Autologous EPCs|
3204749|NCT00936819|Experimental|Autologous EPCs Transfected with human eNOS|
3204750|NCT00936845||Females with Hemophilia|Females with severe or moderate Hemophilia A or B.
3204751|NCT00936871|Experimental|Part A|Lersivirine Tolerability
3204752|NCT00936871|Experimental|Part B|Thorough QTc
3204753|NCT00936923|Active Comparator|furosemide1|Patients will take furosemide 60mg per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
2552042|NCT02551835||Oosterwerff study|RCT on 1200 IU vitamin D3/day plus 500 mg calcium/day versus placebo plus 500 mg calcium/day for 16 weeks among non-western immigrants with pre-diabetes and 25(OH)D values <50 nmol/L.
2552043|NCT02551835||Chel study|RCT on 600 IU vitamin D3/day (or daily equivalent) versus placebo for 4 months among nursing home residents >70 years of age.
2552044|NCT02551835||Wicherts study|RCT on 800 IU vitamin D3/day versus 100,000 IU/3 months versus sunlight advice for 6 months among non-western immigrants with 25(OH)D values <25 nmol/L.
2552045|NCT02551835||University College Cork (UCC) 1 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons > 63 years of age.
2552046|NCT02551835||UCC 2 study|RCT on 200, 400, or 600 IU vitamin D3/day versus placebo for 22 weeks among persons 20-40 years of age.
2552077|NCT02551497|Experimental|Other drug|Other drug BID
2552082|NCT02551497|Experimental|placebo|Placebo to match BID
2552121|NCT02551354|Experimental|Patients|"Pain assess by :~Visual Analogic Scale (VAS).~Portable video pupillometer"
2552155|NCT02551042|Experimental|Active treatment arm|Fibrogammin®P, coagulation factor XIII concentrate (Human) IV infusion
2552158|NCT02551042|Placebo Comparator|Placebo arm|Placebo will be 0.9 % Sodium chloride solution IV infusion
2552202|NCT02550639|Active Comparator|A1-prophylaxis group,positive elispot test|POSITIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
2552204|NCT02550639|Experimental|A2- preemptive group,positive elispot test|POSITIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
2552207|NCT02550639|Active Comparator|B1- prophylaxis group,negative elispot test|NEGATIVE ELISPOT TEST, PROPHYLAXIS GROUP (CMV PROPHYLAXIS)
2552208|NCT02550639|Experimental|B2- preemptive group,negative elispot test|NEGATIVE ELISPOT TEST, PREEMPTIVE GROUP (NO CMV PROPHYLAXIS)
2552285|NCT02550366||CMR|Subjects with no contraindication to magnetic resonance imaging, who will undergo cardiac MRI scanning.
2552350|NCT02549989|Experimental|LY3023414|This is an MSKCC investigator-initiated, single-center, non-randomized, open-label, phase II study to evaluate the activity of LY3023414 dosed at the RP2D of 200 mg orally twice daily in patients with recurrent or persistent endometrial cancer.
2552398|NCT02549456|Experimental|Natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer with natural orifice specimen extraction
2552400|NCT02549456|Experimental|Laparoendoscopic resection|Laparoscopic assisted transanal endoscopic resection of rectal cancer
3170859|NCT00579787||2|Women with early stage cervical cancer undergoing radical hysterectomy
2552563|NCT02548494|Placebo Comparator|Control Group|The control group will receive all traditional methods of treatment for DKA including iv insulin, correction of fluid loss, and electrolyte correction, including a placebo subcutaneous injection.
2552565|NCT02548494|Experimental|Treatment Group|The study group will receive the same treatment including iv insulin, correction of fluid loss, and electrolyte correction, but will be supplemented with a subcutaneous glargine injection.
2552585|NCT02548000|Experimental|Resistance training|Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
2552588|NCT02548000|Active Comparator|Stretching control|The control group will perform one stretching session a week.
2552680|NCT02547896|Experimental|Pain control using codeine + diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of codeine + 50mg of diclofenac
2552688|NCT02547896|Experimental|Pain control using diclofenac|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, receiving for pain relief after the procedure 50mg of diclofenac
2552973|NCT02545816|Other|study group|Patients (age ≥ 18 years) admitted to the ICU with an acute neurological insult which will be sedated/ventilated (Glasgow Coma Scale (GCS) ≤ 8).
2553013|NCT02545491|Experimental|Care for Child Development group|Training of caregivers on the Care for Child Development (CCD) program, in addition to the training on Infant and Young Child feeding program by World Vision.
2553016|NCT02545491|Active Comparator|World Vision Lebanon training group|caregivers will receive training in Infant and Young Child Feeding (WV-IYCF) offered by World Vision.
2553191|NCT02544399||Subject practicing golf and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
2553193|NCT02544399||Subject practicing foot walk and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
2553194|NCT02544399||Subject sedentary and accept bone measure|Each patient will have 1 blood sample and 1 measure of bone by 3D micro-tomography
3170860|NCT00579800|Experimental|women undergoing routine breast MRI|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
3170861|NCT00579839|Experimental|A|Delayed Cord Clamping
3170862|NCT00579839|Active Comparator|B|Immediate cord clamping
3170863|NCT00579852||1|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day.
3170864|NCT00579865||Group A|Patients scheduled for percutaneous drainage
2553281|NCT02543749|Experimental|DC vaccine|"Autologous DC pulsed with leukemia-associated peptides+adjuvant.~Ten vaccinations over 26 weeks with 10 x 106 freshly thawed DC Intradermal injections (1-2 ml volume)"
2553469|NCT02542748|Experimental|norepinephrine|norepinephrine is injected after spinal anesthesia
2553475|NCT02542748|Other|ephedrine|ephedrine is injected after spinal anesthesia
3170865|NCT00579865||Group B|Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
3170866|NCT00579904|Active Comparator|walnuts|Patients will be randomized to receive walnuts
3170867|NCT00579904|Active Comparator|almonds|Patients will be randomized to receive almonds
3170868|NCT00579917||1 Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT) involves one-on-one counseling
3170869|NCT00579917||2 Usual Care|Usual Care
3170870|NCT00579943||premature infants|Inpatient very low birth weight infants who are ventilated and have an umbilical arterial catheter in place
2552064|NCT02551783|Active Comparator|Ventral Buccal|Intervention: Procedure/Surgery: Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
3204754|NCT00936923|Active Comparator|furosemide 2|Patients will take 120mg furosemide per day for 1 years and undergo a study assessment at 3, 6, 12, 18, 24 months .
3204755|NCT00936923|No Intervention|control|Patients in control group will not take furosemide
3204756|NCT00936936|Experimental|Cycle # 1|"First Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #1: Gemcitabine/Docetaxel/Melphalan/Carboplatin + PBPC"
3204757|NCT00936936|Experimental|Cycle #2|"Second Cycle High-dose (HD) chemotherapy followed by stem-cell infusion (PBPC)~HD Cycle #2: Ifosfamide/Carboplatin/Etoposide + PBPC"
3204758|NCT00936949|Active Comparator|posterolateral approach|The posterolateral approach was described by many authors, but all share a common muscular interval in reference to the gluteus medius tendon. Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
3204759|NCT00936949|Active Comparator|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
3204760|NCT00936962|Experimental|Group 1 NeisVac C vaccine - 0 doses|NeisVac C (Meningococcal C) vaccine - 0 doses
2552317|NCT02550028|Experimental|Oral levetiracetam|Oral levetiracetam 50 mg/kg loading dose. 10 mg/kg 8 hourly maintenance
2552318|NCT02550028|Active Comparator|Intravenous phenobarbital|Intravenous phenobarbital 20 loading dose (add to 40 mg/kg if seizure discontrol). 5 mg/kg 24 hourly maintenance
3204761|NCT00936962|Experimental|Group 2 NeiscVac C - 2 doses|2 priming doses of NeisVac C vaccine at 2 and 4 mths of age
3204762|NCT00936962|Experimental|Group 3 NeiscVac C - 1 dose|1 priming dose of NeisVac C vaccine at 2 mths of age
2552424|NCT02549131|Active Comparator|Suture|Randomizing to Suture closure of Cesarean Section wound. In woman meeting inclusion criteria and not meeting exclusion criteria.
2552427|NCT02549131|Active Comparator|Staples|"Women in this Arm will be assigned to Standard Surgical Staples closure of Cesarean section.~Women will have met inclusion criteria and not meet exclusion criteria and willing to consent to study. Intervention is the randomization to either Arm. Both are standard of care at this facility."
2552468|NCT02549001|Experimental|P-3058 10%|P-3058 10%
2552470|NCT02549001|Placebo Comparator|vehicle of P-3058 10%|vehicle of P-3058 10%
2552472|NCT02549001|Active Comparator|amorolfine 5%|Loceryl®
2552522|NCT02548598||AIMS-Full Characterization|Participants in this group undergo characterization at the UCSF Airway Clinical Research Center 6 weeks following their scheduled sinus surgery.
2552524|NCT02548598||AIMS-OR|Participants in this group complete limited questionnaires and provide biological samples that are collected during their scheduled sinus surgery. No further characterization in done in this group.
2552527|NCT02548598||AIMS-M|Participants returning to UCSF Sinus Center clinic following sinus surgery who have nasal secretions that are removed by a study clinician will provide samples at these clinic visits.
3204763|NCT00936988|Experimental|cinacalcet|
2552649|NCT02547948|Experimental|CAR T cells|In interventional studies, participants are assigned to accept CD19-targeting CAR T Cells infusion so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. Arm refers to each group or subgroup of participants in a clinical trial that receives specfic interventions (or no intervention) according to the study protocol. This is decided before the trial begins.
2552650|NCT02547948|No Intervention|No Intervention|
3204764|NCT00937001|Experimental|Biopsy/Ultrasound|
3204765|NCT00937014|Active Comparator|Standard infant formula|
2552784|NCT02547051|Experimental|Food allergy and vocal cord tension|To determine if dietary allergen responses and frequency and severity of vocal cord tension.
2552802|NCT02546804|Experimental|HOT SALT WATER|3% HOT SALT WATER , 25ml used for rinsing for 60 sec, twice daily for 60 days.
2552803|NCT02546804|Experimental|POTASSIUM PERMANGANATE|0.01% POTASSIUM PERMANGANATE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
2552807|NCT02546804|Active Comparator|CHLORHEXIDINE|0.2% CHLORHEXIDINE, 10ml used for rinsing for 60 sec, twice daily for 60 days.
2552849|NCT02546557||OPTICABG|Patients undergoing a coronary artery bypass graft surgery for the repair of a multi-vessel disease or left main-coronary disease.
2552924|NCT02546284|Experimental|Single Agent lenzilumab|Dose levels: lenzilumab IV infusion once monthly for a 28 day dosing cycle (with extra dose on Day 15 during cycle). Three (3) to Six (6) subjects will be enrolled into planned escalating cohorts of 200 mg, 400 mg or 600 mg lenzilumab.
2553052|NCT02545361|Experimental|KAHR002|premedication (20mg Dexamethasone (IV), 10mg Loratadine (P.O), and 1gr Paracetamol (P.O), 1 hour before treatment) with 2µg/kg KAHR-102 subcutaneous (SC) injection
2553082|NCT02544945|Active Comparator|Standard Bolus|The radiotherapy treatment days when the standard bolus is used
3204766|NCT00937014|Experimental|Test formula|
3204767|NCT00937027|Active Comparator|Aminopterin one 1.0 mg tablet|
3204768|NCT00937027|Active Comparator|Aminopterin 1 four 0.25 mg tablets|
3204769|NCT00937053|Experimental|Hemoglobin below 120 g/dL|
3204770|NCT00937053|Active Comparator|Hemoglobin below 70 g/dL|
3204771|NCT00937066||1|Adult patients 18-65 years with moderate to severe uncontrolled asthma
3204772|NCT00937092|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
3204773|NCT00937092|Active Comparator|low-dose dopamine + low-dose furosemide|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
3204774|NCT00937144|Experimental|viagra|viagra versus placebo will be given to patients with sickle cell anemia
3204775|NCT00937144|Placebo Comparator|placebo|viagra versus placebo will be given to patients with sickle cell anemia
3204776|NCT00937170|Experimental|Gender Specific LPS flex|Participants in this arm will receive the Zimmer LPS flex Gender Specific Implant design
2552128|NCT02551198|Active Comparator|HAPREP® (PEG-Asc)|"subjects randomized to 2L polyethylene glycol with ascorbic acid (PEG-Asc) were instructed to use PEG-Asc for bowel preparation~: PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
2552130|NCT02551198|Experimental|SUCLEAR® (OSS)|"subjects randomized to oral sulfate solution were instructed to use oral sulfate solution (OSS) for bowel preparation~: OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]"
2552149|NCT02550951|Experimental|pre-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
2552150|NCT02550951|Experimental|post-operation Lymphedema|before magnetic resonance imaging(MRI), GADOVIST PFS [Bayer Korea] 7.5mL and local anesthetics 0.5m L mixed. and then 24 gauge needle using about 1 mL by the first , and second , the third the space between the toes intradermal injection , and then about 1-2 minutes , and massage the injection site, and Acquiring an image(coronal T1-weighted three-dimensional gradient-echo sequence) of the foot from a range including up to the pelvis from the comparison with lymphoscintigraphy
2552194|NCT02550756|Experimental|0.2 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.1 to 0.2 mg/ml
2552195|NCT02550756|Experimental|0.6 mg of CNTX-4975|CNTX-4975 will be provided at a capsaicin concentration of 2.0 mg/ml and will be diluted to final concentration using sterile water and 30% PEG 300. Dose volume 1.0 mL-2.0 mL will be used at the discretion of the investigator. Capsaicin concentration will be 0.3 to 0.6 mg/ml
3170871|NCT00579956|Experimental|Meropenem|Meropenem
2552453|NCT02549222||Control Cohort|During the Control cohort period patients will have study data collected following transfusion with only conventional PCs for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
2552456|NCT02549222||INTERCEPT Cohort|During the INTERCEPT phase, patients will receive only INTERCEPT PCs and will have study data collected following transfusion for up to 21 days of transfusion support, as clinically indicated in a manner that is consistent with the local standard of care.
2552521|NCT02548806|Experimental|Clonidine MBT 50µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50µg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
2552523|NCT02548806|Experimental|Clonidine MBT 100µg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100µg single dose ,a single-dose of reference catapres 100μg tablets..
2552526|NCT02548806|Active Comparator|Catapres 100μg|Each subject will receive the following treatments in random order over 3 Treatment Periods (1 treatment/period): Clonidine MBT 50μg single dose, Clonidine MBT 100μg single dose ,a single-dose of reference catapres 100μg tablets.
2552552|NCT02548390|Experimental|RXDX-107|
2552615|NCT02548234|Experimental|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
2552626|NCT02548234|Experimental|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
2552730|NCT02547259|Experimental|schizophrenic pain words test|schizophrenic will have memory test with pain words on computer
2552734|NCT02547259|Experimental|schizophrenic negative words test|schizophrenic will have memory test with negative words on computer
2552736|NCT02547259|Other|Healthy volunteer pain words test|Healthy volunteer will have memory test with pain words on computer
2552737|NCT02547259|Other|Healthy volunteer negative words test|Healthy volunteer will have memory test with negative words on computer
2552790|NCT02547103|Experimental|Chlorhexidine gluconate|Chlorhexidine gluconate-soaked cloths, clean topical area around catheter exit site with CHG 2% soaked cloths
2552792|NCT02547103|Active Comparator|Normal saline (usual care)|Normal saline, clean topical area around catheter exit site
2552793|NCT02547103|Active Comparator|Mupirocin ointment|Mupirocin ointment 2%, clean topical area around catheter exit site with Mupirocin ointment
2552824|NCT02546648|Experimental|Tranexamic Acid vs. matching placebo|Tranexamic Acid 1g bolus with anesthesia induction followed by 1g bolus at the start of surgical closure.
2552826|NCT02546648|Experimental|Rosuvastatin vs. matching placebo|Rosuvastatin 20 mg orally or matching placebo once per day until 30 days after surgery
2552876|NCT02546479||Patientis|patients diagnosed with scoliosis and other spinal deformities
3170872|NCT00579956|Active Comparator|Ceftazidime|Ceftazidime
3170873|NCT00579969|Experimental|1|prostaglandin analogue
3170874|NCT00579969|Experimental|2|prostaglandin analogue
3170875|NCT00579995|No Intervention|1, oral N-Acetylcysteine|
3170876|NCT00579995|No Intervention|2, Intravenous Sodium Bicarbonate|
3170877|NCT00580021||1|Patients with breast and pancreas cancer.
3170878|NCT00580086||1|
3170879|NCT00580099|Experimental|1|4 weeks of assisted exercise using passive range of motion on all major joints
3170880|NCT00580099|Active Comparator|2|cuddle for 20 minutes
3174258|NCT00621478|Active Comparator|Cohort 2|"Cohort 2 (EFIC) will include patients who appear in the ED with SE and qualify for the study but have not given prior consent. These patients will be enrolled under the EFIC regulations. The parent/guardian will be given the opportunity to object to participation or ask additional questions.~The child will be enrolled (dosed) with study medication under an EFIC. Once the child is stabilized, a research staff member will approach the parent or LAR to obtain informed consent to continue the child's participation in the study. If a parent or LAR refuses continued participation, then no further study procedures will be performed. Safety and data will be collected in accordance with federal regulations.~Cohort 2 will be randomized, like Cohort 1, to either lorazepam 0.1 mg/kg or diazepam 0.2 mg/kg"
2552192|NCT02550990|Experimental|Sequential training group|"One 30-min session of aerobic exercise training + one 30-min session of cognitive training.~Before and after the treatment, a total of 2 evaluations were conducted, including clinical assessments and blood test (each 18c.c.). A saliva sample (2 mL) will only be collected once from each subject. A follow-up assessment of clinical outcomes will be conducted at six month after the end of the course of treatment."
3204777|NCT00937170|Active Comparator|LPS flex|Participants in this arm will receive the Zimmer High Flex LPS implant
3204778|NCT00937170|Active Comparator|Triathlon|Participants in this arm will receive the Stryker Triathlon Implant design
2552385|NCT02549664||LQT/HCM sedentary patients|LQT/HCM sedentary lifestyle
2552387|NCT02549664||LQT/HCM moderate/vigorous exercise|LQT/HCM participate in moderate or vigorous exercise
2552529|NCT02548741|Active Comparator|Treatment (Metformin)|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the active comparator (metformin).
2552530|NCT02548741|Placebo Comparator|Placebo|Forty patients with elevated glycosylated hemoglobin A1c (HbA1c) > 6.0% (patients with type 2 diabetes mellitus or prediabetes) but HbA1C < 9.0%. They will receive the placebo comparator.
2552531|NCT02548741|Other|Non-diabetic|Forty matched non-diabetic patients with HbA1C ≤ 5.6%. They will not receive either treatment (metformin) or placebo.
2552608|NCT02548104|Active Comparator|Adductor canal block (ACB)|Group I Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
2552618|NCT02548104|Experimental|Adductor canal ACB + genicular (IPACK)|Group II Adductor canal block (ACB): 0.25% bupivacaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
3204779|NCT00937196|Active Comparator|Histaminum hydrochloricum globuli|To allow double-blind administration of the placebo pills going along with verbal suggestions of a blood-pressure-lowering effect
2552739|NCT02547324|Experimental|Slump sitting|Slump sitting flexion of lumbar spine
2552743|NCT02547324|Active Comparator|Forward bending|Forward erect bending of lumbar spine
2552785|NCT02547077|Experimental|Wound Closure with 2-octylcyanoacrylate|One side of the patient's wound defect will be assigned to wound closure with 2-octylcyanoacrylate liquid bonding agent).
2552786|NCT02547077|Active Comparator|Wound Closure with 5-0 Fast Absorbing Gut|One side of the patient's wound defect will be assigned to wound closure with 5-0 fast absorbing gut sutures.
2552861|NCT02546752|Experimental|THEO Video Arm|"THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). Two programs have been developed. Parents/guardians of children who have not received the first HPV vaccine, will first assess whether the family has already decided in favor of the HPV vaccine or if they would like more information. The parent/guardian will be shown a video specific to where they are in the decision-making process. After completion, the THEO system will then ask the parent/guardian a series of Post Video questions. Parents/guardians of children who have received the first or second vaccine in the series, will emphasize the need to make the first vaccine count. Pre and post video questions have been developed."
2552865|NCT02546752|No Intervention|Usual Care Arm|This arm will receive usual care.
2552911|NCT02546180|Experimental|YouTube Video Viewers|Subjects in this arm were randomized to viewing YouTube videos.
2552920|NCT02546180|Active Comparator|Standard Education|Subjects in this arm were randomized to standard preoperative education.
3204780|NCT00937196|Experimental|Placebo globuli|
2553042|NCT02545218|Active Comparator|Perineorraphy.|Secondary surgical repair of the perineal body. Operation is performed by a urogynecologist in an operation theater in local anesthesia. The operation aims to re-create the anatomy in the injured perineum using 2-4 sutures.
2553046|NCT02545218|Active Comparator|Pelvic floor exercise.|Tutored pelvic floor exercise. A trained physio therapist evaluate the pelvic floor musculature and helps the patient to perform proper pelvic floor exercises using biofeedback. The patient receives a training scheme and meets the therapist regularly every second week during 4 months.
2553097|NCT02544932|Experimental|dabigatran 110mg or 150mg|After once enrolled, subjects will be randomized to dabigatran group. (110mg or 150mg twice a day)
2553101|NCT02544932|Experimental|ribaroxaban 20mg|After once enrolled, subjects will be randomized to ribaroxaban group. (20mg once daily)
2553103|NCT02544932|Active Comparator|warfarin|After once enrolled, subjects will be randomized to warfarin group. (controlled by INR 2-3)
2553137|NCT02544620||Total Hip arthroplasty|"Unselected primary THA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
2553139|NCT02544620||Total Knee arthroplasty|"Unselected primary TKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
2553143|NCT02544620||unicompartmental knee arthroplasty|"Unselected primary UKA~American Society of Anesthesiologists (ASA) score I/II~Can be operated as #1 or #2~No sleep apnea treated with Continuous positive airway pressure (CPAP)"
2553178|NCT02544282|Active Comparator|Pecs II|General anesthesia followed by a Pecs II block and opioids if required
2553180|NCT02544282|Placebo Comparator|Placebo|General anesthesia followed by a placebo Pecs II block and opioids if required
2553352|NCT02543606|Experimental|Esomelone|powder for injection/ infusion Esomeprazole 40mg
2553353|NCT02543606|Active Comparator|Nexium|powder for injection/ infusion Esomeprazole 40mg
3204781|NCT00937196|No Intervention|No treatment|
3204782|NCT00937248|Experimental|Interventional|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device with a CVID.
3204783|NCT00937248|Active Comparator|Standard Arm|Patient randomized to be immobilized using a prone pillow and simple ankle fixation device without a CVID
3204784|NCT00937261|Experimental|Risperdal|Risperdal 2-8mg per day
3204785|NCT00937261|Experimental|Invega|Invega 6-12mg per day
3204786|NCT00937274|Experimental|Test product|
3204787|NCT00937274|Active Comparator|Commercial product|
3204788|NCT00937274|Placebo Comparator|Standard care|
3204789|NCT00937287||youth and caregivers|
3204790|NCT00937313||Champagne wine|
2552233|NCT02550704|Experimental|Irritable Bowel Syndrome with diarrhea|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability. Intestinal permeability is not routinely performed and is assessed in colonic biopsies (occludin, claudin and ZO-1 by western blot, qPCR and immunofluorescence)
2552269|NCT02550340||Acute alcohol intake|Visitors of the Munich Octoberfest or similar events who fulfil in- and exclusion criteria
2552300|NCT02550054|Experimental|Erythropoietin|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
2552305|NCT02550054|Placebo Comparator|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
2552334|NCT02549807||Children muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
2552335|NCT02549807||Adolescent muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured ((muscle elasticity measure)
2552336|NCT02549807||Adult muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured (muscle elasticity measure)
2552389|NCT02549586|Experimental|Autologous HSCT|Eligible participants will undergo an Autologous Hematopoietic Stem Cell Transplant (HSCT) as a two-step intervention.
3204791|NCT00937313||Placebo|alcohol with sparkling mineral water
3204792|NCT00937339|Active Comparator|Control|The control group will perform the same exercises on the vibration platform, as in the experimental group. However, the vibration device will be turned off during the exercises.
2552544|NCT02548468|Experimental|Reduced Intensity Conditioning, DLI, PBSCT|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -11 to -8 and undergo total body irradiation BID on day -7. Patients also receive donor CD3+ enriched T lymphocyte infusion on day -6 and high-dose cyclophosphamide IV over 2 hours on days -3 to -2.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV with taper (drug wean) by day 60 and mycophenolate mofetil IV BID on days -1 to 28 in the absence of GVHD."
3204793|NCT00937339|Experimental|Whole body vibration|Subjects in the experimental group will undergo whole body vibration (1 session per day, 3 sessions per week) for 8 weeks. The vibration loading will be carried out using the Jet-Vibe System (Danil SMC Co., Ltd., Seoul, Korea). The vibration protocol used in this study will be 30Hz. While standing on the vibration platform, patients will be instructed to repeat the following set of light exercises: (1) light squatting,(2)deep squatting , (3) side-to-side weight-shift, (4) Forward and backward weight-shift, (5) forward lunge, (6) marching on the spot. The total duration of exposure of whole body vibration per session will be about 10 minutes.
3204794|NCT00937352|Active Comparator|Bapineuzumab 0.5 mg/kg|0.5 mg/kg
3204795|NCT00937352|Active Comparator|Bapineuzumab 1.0 mg/kg|1.0 mg/kg
3204796|NCT00937365|Active Comparator|Exercise|Specific strengthening exercises demonstrated to improve pregnancy-related low back pain are taught to participants of this arm. Additionally, each participant will be evaluated and additional exercises will be prescribed relevant to her particular needs. Study participants of this arm are asked to perform the exercises at home at least once a day. Exercise is recorded in a diary. Participants follow the same study visit schedule as the two other arms.
3204797|NCT00937365|Experimental|Spinal Manipulation|Women randomized to this arm will be evaluated for spinal subluxations and, if appropriate, treated with chiropractic manipulation. Type of manipulation is determined by presentation. Woman may be manipulated with high velocity low amplitude thrust, blocking, activator, or other appropriate means of manipulating.
3204798|NCT00937365|Experimental|Neuroemotional technique (NET)|"Neuroemotional technique (NET) is a mind-body technique which combines elements of chiropractic medicine, Chinese medicine, and behavioral psychology. Muscle response testing, a form of functional neurology, and visceral somatic reflexes are used to ascertain whether the pain or dysfunction experienced by the participant has an emotional component. If an emotional component is present, it is identified and the original triggering occurrence is identified. The participant creates a snapshot of that original occurrence and while she holds that image in her mind spinal levels which innervate the associated organ are adjusted."
3204799|NCT00937417|Experimental|Arm 1|vandetanib and docetaxel
3204800|NCT00937430|Experimental|Bowel preparation group|Patients randomized to this arm will perform a bowel preparation prior to their pelvic organ prolapse surgery.
2552942|NCT02546050|Experimental|Metformin|18 weeks study with intervention during week 6 to 12: the intervention consist of 500 mg of metformin once daily for week 7, then 500 mg twice daily week 8, 1000 mg + 500 mg daily week 9 and 1000 mg + 1000 mg daily for weeks 10-12.
2552956|NCT02545751|Experimental|SBRT and Thymalfasin arm|SBRT is given during combined therapy to one of the lesions, 25Gy in 5 fractions over one week, conformally to maximally spare normal tissue or organ. Thymalfasin treatment is given twice a week with an interval of 3-4 days until tumor progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
2553001|NCT02545582||Therapy|Heart failure patients implanted with the VITARIA system
3204801|NCT00937430|No Intervention|No Bowel preparation group|Patients randomized to this group will not be performing a bowel preparation prior to their pelvic organ prolapse surgery.
3204802|NCT00937443||Walking Exercise Group|Walking Exercise Group versus Control Group
2553085|NCT02544945|Experimental|3D printed bolus|the radiotherapy treatment days when the 3D bolus is used
3204803|NCT00937456|Experimental|Laparoscopically-assisted esophagectomy|Laparoscopically-assisted esophagectomy: standard abdominal procedure of gastric mobilisation but through laparoscopic route. Right thoracotomy as usual.
2552243|NCT02550470|Active Comparator|Randomized to Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
2552248|NCT02550470|Active Comparator|Randomized to Drager 800 Absorbent|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
2552251|NCT02550470|Active Comparator|Randomized to Drager Free|Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.
2552277|NCT02550158|Experimental|Educated Group|"Training of patients by the educational program EDU-MICI"
2552278|NCT02550158|Other|Control group|"During the first 6 months : no training of patients by the educational program EDU-MICI. Then, a crossover allowed uneducated patients to benefit from the educational program the next 6 months."
2552374|NCT02549768|Active Comparator|Dexmedetomidine|Use of dexmedetomidine during surgery (1 mcg/kg in 10 minutes, then infusion at 0.7 mcg/kg/h)
2552378|NCT02549768|Placebo Comparator|Placebo|"Use of crystalloid solution (sodium chloride 0.9%), injection pump programmed with drug Dexmedetomidine with 1 mcg/kg in 10 minutes, infusion 0.7 mcg/kg/h."
2552412|NCT02549326|Placebo Comparator|Obese, placebo|Placebo daily for 12 weeks
2552414|NCT02549326|Active Comparator|Obese, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
2552415|NCT02549326|Placebo Comparator|Control, placebo|Placebo daily for 12 weeks
2552416|NCT02549326|Active Comparator|Control, vitamin D|Vitamin D3 50 µg / daily for 12 weeks
3204804|NCT00937456|Active Comparator|Open esophagectomy|Conventional open esophagectomy: Esophagectomy with extended 2-field lymphadenectomy through laparotomy and right thoracotomy (Ivor-Lewis standard procedure)
2552610|NCT02548195|Experimental|GEMOX|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2; every three weeks for 6-8 cycles in total.
2552631|NCT02548195|Active Comparator|Capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
2552655|NCT02547701|Experimental|P-3058|
2552699|NCT02547558|Experimental|Indacaterol|"Drug:~-Indacaterol, inhaled, single dose, 300 mcg~Diagnostic Interventions:~Arterial blood gases~Cardiac output~Vital signs~Exhaled breath~Spirometry"
3204805|NCT00937469|Experimental|Social sk. tr., parent tr.,standard tr.|
3204806|NCT00937469|Active Comparator|Standard treatment|
2552850|NCT02546505|No Intervention|Control|The current situation with current way brands show or not nutritional information on Front of Pack (FoP) - without consumer information
2552853|NCT02546505|Experimental|Intervention n°1|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. No additional consumer information
2552856|NCT02546505|Experimental|Intervention n°2|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods. Additional consumer information specifically targeting nutritional information and explaining the 5-CNL will be performed (this information will consist in a concept shown to respondents before the shopping session).
2552899|NCT02546336|Experimental|Ultrasound-Guided Hip Denervation|This is a pilot study. 15 Hip Osteoarthritis patients with chronic pain will be recruited in this pilot arm. These will undergo Ultrasound-Guided Cooled Radiofrequency Hip Denervation as intervention.
2552966|NCT02545972|Experimental|Once a day tacrolimus|Tacrolimus extended release will be given at an initial once daily dose equivalent to the total daily dose of the twice a day Tacrolimus formulation.
2553116|NCT02544854|Experimental|Ages 1 year - 3 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
2553118|NCT02544854|Experimental|Ages 4 years - 8 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
2553119|NCT02544854|Experimental|Ages 9 years - 11 years 11 months|Propofol infusion, measuring of plasmatic levels of propofol through venous sampling
2553154|NCT02544516|Experimental|Patients|patients suffering schizophrenic disorders and who will perform cognitive tasks + PANSS+ IQ
3204807|NCT00937482|Experimental|Treatment (cediranib maleate and WBRT)|Patients receive oral cediranib maleate on day 1. Patients undergo whole-brain radiotherapy 5 days a week for 3 weeks beginning on day 3. Treatment continues treatment in the absence of disease progression or unacceptable toxicity.
3204808|NCT00937508|Placebo Comparator|Smoking counseling, Placebo|
3204809|NCT00937508|Experimental|Smoking counseling, Varenicline|
3204810|NCT00937534|Active Comparator|Part A|Young male healthy volunteer
3204811|NCT00937534|Active Comparator|Part B|Elderly male healthy volunteer
3204812|NCT00937573||Xience V|Percutaneous coronary intervention with Xience V stent placement
2552250|NCT02550717||Other medications|Users of other medications such as clopidogrel, oral anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs)
2552296|NCT02550236||LIFE Child Health|The LIFE Child HEALTH cohort is a sample of 5.000 children and adolescents. A basic program that will be carried out annually at each study centre visit. This program includes clinical history (perinatal and past medical history, medications, allergies, immunizations, developmental history and family history) clinical examination, collection of blood, hair, stool and urine samples, anthropometry and different age-dependent questionnaires. Questionnaires are completed by the parents and starting at the age of nine years also by the child itself.
2552304|NCT02550236||LIFE Child Obesity|The LIFE Child OBESITY cohort is a sample of 500 obese children and adolescents that will be assessed and compared to a lean control group (N=500) with equally detailed phenotyping including metabolic and cardiovascular evaluation. The LIFE Child OBESITY cohort (including the control group) performs the basic program of the LIFE Child HEALTH cohort plus additional parameters such as electrical bioimpedance, assessment of basal metabolic rate, oral glucose tolerance test, liver elastography, spirometry and actigraphy.
2552309|NCT02550236||LIFE Child Health: Pregnancy/Birth|The LIFE child Pregnancy/Birth cohort is a sample of 1,000 pregnant women and their offspring. Prenatal examinations are conducted during the 24th to 26th and 34th to 36th week of gestation. During the first year of life, data is collected from children at 3, 6 and 12 month of age.
2552361|NCT02549898|Experimental|Vascular inflammation|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan, undergo pharmacological induction of a migraine attack, and subsequently are MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI ).
2552364|NCT02549898|Experimental|Effect of sumatriptan|Subjects with habitual unilateral migraine without aura, undergo a baseline MRI scan and then undergo pharmacological induction of a migraine attack. Sumatriptan is given and subjects subsequently undergo MRI scans prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
2552368|NCT02549898|Experimental|Pilot w/o cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan. Subjects are then MRI scanned prior to (BBI-MRI) and after Feraheme infusion (USPIO-MRI).
2552372|NCT02549898|Experimental|Pilot w/ cilostazol|Subjects without habitual unilateral migraine without aura undergo a baseline MRI scan and then receive cilostazol. Subjects are then MRI scanned prior (BBI-MRI) to and after Feraheme infusion (USPIO-MRI).
2552420|NCT02549248||Idiopathic interstitial diseases|" Test group : patients suffering from idiopathic interstitial lung diseases including sarcoidosis and idiopathic pulmonary fibrosis.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
2552423|NCT02549248||Non idiopathic intertitial diseases|" Control group : patients suffering from interstitial lung diseases of known aetiologies, such as hypersensibility pneumonitis, infectious or cancerous interstitial diseases and interstitial diseases caused by drug reactions.~Nanoparticles (NP) loads will be measured on Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood specimen and urine specimen."
2552482|NCT02548897|Experimental|Freezing of gait in PD|All participants will undergo an deep brain stimulation (DBS) for the FOG, and an electroencephalography (EEG) to better understand the neurophysiological underpinnings of the symptom. In addition, review changes in scalp recorded EEG and gait parameters during natural FoG episodes while participants are ambulatory in an advanced gait laboratory setting using a wireless EEG amplifier with active electrodes.
2552533|NCT02548637|Experimental|Acupuncture Therapy|Based on the Traditional Chinese Medicine theory, investigators will use the systemic treatment methods (full body treatment with the joint specifications). Every patient will receive the standard protocols of these points uniformly regardless of their symptoms. The only variable will be the location of placement of the four electrodes (two positive charges and two negative charges) to the needle points at the most painful joints bilaterally. Needles will be in place a total of 45 minutes per session. The Thermal Design Power (TDP) infrared heat lamp will be applied concurrently to the most painful joint(s) for the entire 45 minutes. Acupuncture will be administered twice a week for 6 weeks, then once a week for an additional 4 weeks.
2552606|NCT02548299|Experimental|Cooking Lecture|Participants in this arm will receive cooking education through lecture/PowerPoint presentation led by our executive chef. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
2552620|NCT02548299|Experimental|Cooking Demo|Participants in this arm will receive cooking education through observation of our executive chef who will explain cooking techniques and healthy food preparation practices as he cooks a healthy recipe(s) for participants to sample. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
2552627|NCT02548299|Experimental|Hands-on Cooking|Participants in this arm will receive cooking education through hands on practical experience with our executive chef in a teaching kitchen. Participants will be able to sample what they prepare. Participants will also attend nutrition education classes led by our registered dietician. Lastly, e-coaching with a certified health coach will be offered to participants with access to a personal email account.
3204813|NCT00937573||Historical BMS|Percutaneous coronary intervention with bare metal stent placement prior to availability of Cypher, Taxus, or Xience V drug eluting stents at WFUBMC
3204814|NCT00937573||Historical DES|Percutaneous coronary intervention with drug eluting stent placement prior to availability of Xience V drug eluting stents at WFUBMC
2552766|NCT02547194||No touch vein grafts|The grafts were harvested with there surrounding tissues.
2552768|NCT02547194||Conventional vein grafts.|The grafts were stripped from surrounding tissue.
2552804|NCT02546908||High-risk localized Prostate Cancer (PC)|No intervention will be administered in this study. Participants with High-risk localized PC will be enrolled. High-risk localized PC involves clinical T stage greater than or equal to (>=) cT3a and one of the following high risk features: Gleason score 8-10 or prostate specific antigen (PSA) level above 20 nanogram per milliliter (ng/mL).
2552906|NCT02546141|Active Comparator|skimmed yoghurt|portion size that contains 25 g of protein, oral, single administration
2552258|NCT02550691|Other|Subject carrying 2 copies of the SMN1 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
2552260|NCT02550691|Other|Subject carrying 3 copies of the SMN2 gene|Using blood sampling, use of molecular combing to identify a genomic morse code (GMC) composed of a combination of probes specific of a structural motif on the cis-duplication chromosome.
2552301|NCT02550223|Experimental|Oblique|Ultrasound guided radial artery catheterization using oblique view obtained by tilting the US probe 30-45 degrees over the course of the artery
2552308|NCT02550223|Active Comparator|Transverse group|Ultrasound guided radial artery catheterization using transverse view
2552311|NCT02550223|Active Comparator|Longitudinal group|Ultrasound guided radial artery catheterization using longitudinal view
2552373|NCT02549872||Dementia|Patients with a recorded diagnosis of dementia in primary or secondary care
2552377|NCT02549872||Non-dementia|Patients without a recorded diagnosis of dementia in primary or secondary care
2552417|NCT02549404|Experimental|KHK7580|
2552460|NCT02549105|Active Comparator|EMLA CREAM|EMLA CREAM 5 mg TOPICAL APPLICATION FOR CS WOUND AND ASSESSMENT FOR POST OPERATIVE PAIN IN FIRST 6 HOURS
2552462|NCT02549105|Active Comparator|LIDOCAINE INFILTERATION|LIDOCAINE 1 % 20 ml INFILTERATION FOR WOUND AND ASSESSMENT OF POST OPERATIVE PAIN IN FIRST 6 HOURS
2552514|NCT02548832|Active Comparator|Berberine more Placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
2552516|NCT02548832|Active Comparator|Bezafibrate more placebo|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
2552518|NCT02548832|Experimental|Berberine more Bezafibrate|Men and women aged 30 to 60 years with an established diagnosis of mixed dyslipidemia: total cholesterol> 200 mg / dL, triglycerides> 150 mg / dL
2552559|NCT02548442||Autism Spectrum Disorder|Subjects identified as having Autism Spectrum Disorder using behavioral based methods.
2552562|NCT02548442||Developmental Delay|Subjects identified as having a developmental delay that is not Autism Spectrum Disorder using behavioral methods.
2552566|NCT02548442||Typically Developing Children|Subjects identified as not having a developmental delay or autism spectrum disorder using behavioral methods as well as not having another serious medical or psychological condition.
2552599|NCT02548117|Active Comparator|Finasteride|ARM 1 subjects will receive finasteride 5 mg orally daily.
2552605|NCT02548117|No Intervention|No Treatment|The ARM 2 (control group) will not receive any study treatment.
2552671|NCT02547831||Observational approach|Patients will be placed on wait and see approach and then shifted to specific treatment in case of progression
2552746|NCT02547480|Experimental|TACE with irinotecan loaded LifePearl|10 patients receiving unilobar treatment: day 1=chemoembolization of first lobe of liver, day 14=chemoembolization of second lobe of liver, day 30=chemoembolization of first lobe of liver, day 44= chemoembolization of second lobe of liver; AND 10 patient receiving bilobar treatment: day 1=chemoembolization of both lobes of the liver, day 30=chemoembolization of both lobes of the liver
3204815|NCT00937573||Contemporary BMS|Percutaneous coronary intervention with bare metal stent placement after Xience V drug eluting stents were available for use at WFUBMC
3204816|NCT00937573||Contemporary DES|Percutaneous coronary intervention with Cypher or Taxus drug eluting stent placement after Xience V drug eluting stents were available for use at WFUBMC
2552950|NCT02546024||Treatment responder|Participants who receive standard care and achieve HAM-D score reduction of 50% or more, or score below 8 at Week 12.
2552951|NCT02546024||Treatment non-responder|Participants who receive standard care but have HAM-D score reduction less than 50% at Week 12.
2552957|NCT02545660|Experimental|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the QLF group will be shown the QLFD images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
2552958|NCT02545660|Experimental|White light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown the White light images.Standardized oral hygiene reinforcement shall be given based on the White light images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
2553007|NCT02545569|Active Comparator|Hearing Device Type A|In the ear (ITE) hearing aid, 1-3 weeks wearing
2553008|NCT02545569|Experimental|Hearing Device Type B|In the ear (ITE) hearing aid, 1-3 weeks wearing
2553041|NCT02545244|Experimental|Black Tea|0.5% Black Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
2553047|NCT02545244|Active Comparator|Green Tea|0.5% Green Tea as Mouthwash, 5mL to be used twice daily for 30 seconds undiluted.
2553050|NCT02545244|Active Comparator|Chlorhexidine|0.12% Chlorhexidine Mouthwash 5mL to be used twice daily.
2553081|NCT02544893|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block
2553084|NCT02544893|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block
2553092|NCT02544893|Active Comparator|serum phsyologic|0,9% 21 ml serum physiologic
2553126|NCT02544659|Experimental|pamidronate disodium|the patients will be administered intravenous pamidronate disodium
2553168|NCT02544425|Experimental|VIDL+ASCT|"VIDL Induction (repeated 28 days) : VP-16, Ifosfamide, Dexamethasone, L-asparaginase~Peripheral blood stem cell mobilization:Etoposide~Conditioning regimen for autologous stem cell transplantation:Busulfan,Melphalan,Etoposide"
2553228|NCT02544087|No Intervention|The basic treatment|Comply to the Chinese guidlines of acute ischemic stroke in 2014
2553232|NCT02544087|Other|Clearing heat|Treat with KDZ injection on the basis of basic treatment
2553236|NCT02544087|Other|Promoting blood circulaton|Treat with Xueshuantong injection on the basis of basic treatment
3204817|NCT00937586||Newly diagnosed patients|Patients with newly diagnosed prostate cancer.
3170881|NCT00580112|Experimental|Group A|Participants with triple negative phenotype: estrogen receptor, progesterone receptor and human estrogen receptor-2 (HER-2) negative status for breast cancer (abnormal tissue that grows and spreads in the body until it kills) will receive trabectedin 1.3 milligram per meter square (mg/m^2) intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over 3-hours (hrs) every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72hrs after the start of study drug infusion from Day 1 to 3.
3174259|NCT00621491|Placebo Comparator|1|Single daily dose of Placebo during six months
2552370|NCT02549638||Tissue Collection|We plan to prospectively collect 5 bronchoscopic biopsies, 3ml blood and one tumor and adjacent normal samples from 200 qualified patients who meet the study criteria. If a patient has already had a bronchoscopy and has samples available that were previously collected and stored for research at the Mayo Clinic we will use those samples.
2552428|NCT02549417|Experimental|KHK7580|
2552477|NCT02549053|Experimental|Barrett esophagus patients|esophagus biopsies (pathologic and healthy zones)
2552481|NCT02549053|Sham Comparator|control patients|esophagus biopsies (healthy zones)
2552540|NCT02548676||Glaucoma Patients|Patients with primary open angle glaucoma
2552542|NCT02548676||Healthy controls|age- and sex matched controls
2552724|NCT02547545||All|The side effects after chemotherapy were observed for all patients. Potential risk factors would be explored for the side effects such as chemotherapy realted vomit.
2552751|NCT02547298|Experimental|All patients|All patients in this study receive hydrodistension
2552811|NCT02546999|Experimental|botox|Botox® (onabotulinumtoxin A),injections in the calf muscles. The total maximum body dose of Botox® in this study will be 420 Units. Maximum dose per injection site will be 50 Units. The gastrocnemius muscle will receive 5-6 Units Botox® per kg, but maximum 180 Units in each leg. The soleus muscle will receive 2 Units Botox® per kg with maximum dose 60 Units in each leg. Dilution: 100 Units Botox® in 1 ml 0.9% sodium chloride, and the maximum volume per injection site will be 0,5 ml in both study groups. The route of administration is intramuscular injection.
2552812|NCT02546999|Placebo Comparator|placebo|Sterile 0,9% Sodium Chloride injection The placebo dose will be the same dose in ml as the reconstituted Botox
2552847|NCT02546492|Experimental|Acthar|The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.
2553037|NCT02545231|Active Comparator|Low dose 1mg pitavastatin|pitavastatin 1mg which is considered low dose statin will be administered for 36 months
2553038|NCT02545231|Active Comparator|High dose 4mg pitavastatin|pitavastatin 4mg which is considered high dose statin will be administered for 36 months
2553079|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase I)|The first 6 participants will be enrolled in the open label Phase I portion of the study and will receive Tadalafil, Anti-mucin 1 (MUC1) Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
2553083|NCT02544880|Experimental|Tadalafil plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
2553089|NCT02544880|Experimental|Tadalafil plus Vaccine Placebo Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive Tadalafil, placebo for the Anti-MUC1 Vaccine and placebo for the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
2553128|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 18 years and older|One dose of PCV13a vaccine will be given in aged 18 years and older
2553132|NCT02544698|Experimental|One dose of PCV13a vaccine in aged 2-5 years old|One dose of PCV13a vaccine will be given in aged 2-5 years old
3174260|NCT00621556|Experimental|1|Drug + MR with MRCP
3174261|NCT00621569|Active Comparator|1|Group intervention with no dietary focus
3174262|NCT00621569|Experimental|2|DASH diet intervention
3174263|NCT00621595|Active Comparator|1|Fasting
3174264|NCT00621608|Experimental|1|Hyperbaric Oxygen Therapy
3174265|NCT00621608|Sham Comparator|2|Placebo Hyperbaric Oxygen Chamber
3174266|NCT00621634|Experimental|1|Active treatment with omega-3 fish oil capsules (1 g each capsule, 50% DHA), 6 capsules each day for 12 weeks
3174267|NCT00621634|Placebo Comparator|2|Matching placebo treatment
3174268|NCT00621647|Experimental|1|1st fixed dose
3174269|NCT00621647|Experimental|2|2nd fixed dose
3174270|NCT00621647|Sham Comparator|3|Placebo
3174271|NCT00621660|Experimental|Acupuncture|
3174272|NCT00621660|Placebo Comparator|Sham|
3174273|NCT00621673|Other|Arm 1|
3174274|NCT00621699|Experimental|C|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg tacrolimus)
3174275|NCT00621699|Active Comparator|A|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe)
3174276|NCT00621699|Active Comparator|B|administration of 1 capsule Prograf(R) (5 mg tacrolimus)
3174277|NCT00621712|Active Comparator|A|Patients in group A will be provided with a commercially available and CE certified standard double lumen catheter without surface coating (GamCath® catheter, No. CE 76891).
3174278|NCT00621712|Experimental|B|Patients in group B will be treated with a CE certified double lumen catheter with a new antibacterial bismuth-containing surface coating (GamCath Dolphin® Protect, No. CE 90671).
3174279|NCT00621725|Experimental|1|
3174280|NCT00621790|Experimental|Fenoldopam|Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
2552319|NCT02550327|Experimental|All Patients|"All patients will receive Nab-paclitaxel, Gemcitabine, Cisplatin, and Anakinra given on Day 1 and 8 of a 21 day cycle (two weeks on with one week rest). Anakinra will be self-administered subcutaneously corresponding with chemotherapy.~The patient will complete a total of 6 cycles of chemotherapy."
2552376|NCT02549703||Relapsing Remitting Multiple Sclerosis|Patients with Relapsing Remitting Multiple Sclerosis/Clinically Isolated Syndrome
2552379|NCT02549703||Secondary Progressive Multiple Sclerosis|
2552380|NCT02549703||Primary Progressive Multiple Sclerosis|
2552449|NCT02549430|Experimental|Arm A|Palbociclib monoterapy
2552455|NCT02549430|Experimental|Arm B|Palbociclib + HT (Anastrozole, Letrozole, Exemestane, Fulvestrant)
2552525|NCT02548793|Active Comparator|VSI Kit|Education: CPR Training using the CPR Anytime VSI Kit Individuals will learn chest-compression only CPR (no rescue breaths) using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
2552528|NCT02548793|Experimental|Mobile Application|Education: CPR Training via Mobile App Individuals will learn chest-compression only CPR (no rescue breaths) using a newly developed mobile training application.
2552580|NCT02548338|Other|electric scalpel (ES)|Breast surgery is performed using regular electric scalpel
2552581|NCT02548338|Other|argon plasma coagulation (APC)|Breast surgery is performed using argon plasma coagulation scalpel
2552582|NCT02548065|Active Comparator|Balneotherapy|"Daily thermal-mineral bath with mineral water named Debole of Vetriolo for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)"
2552583|NCT02548065|Placebo Comparator|Placebo|daily thermal bath with tap water bath for a total of 12 applications carried out over a period of two weeks at Levico Terme Spa Center (Levico Terme, Italy)
3204818|NCT00937599|Experimental|Brazil Nuts|The first group consumed the brazil nuts and the other group placebo (lactose pills)
3204819|NCT00937612|Experimental|concurrent chemoradiation|patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.
3204820|NCT00937638|Experimental|Modified-DASH Diet|
2552884|NCT02546401|Experimental|Group 1|"Patients will perform their bolus for 2 weeks before meals (BE) and for 2 weeks after meals (AF).~Intervention: drug (insulin Aspart)"
2552886|NCT02546401|Experimental|Group 2|"Patients will perform their bolus for 2 weeks after meals (AF) and for 2 weeks before meals (BE).~Intervention: drug (insulin Aspart)"
2552895|NCT02546115|Active Comparator|Intervention|standard practice (structured rehabilitation programme) + TNS
2552901|NCT02546115|Active Comparator|control|standard practice (structured rehabilitation programme)
2552982|NCT02545946|Active Comparator|Traditional|cutaneous abscess with be opened in the traditional incision and drainage technique with large incision, breaking up of pockets of pus, washing out the pocket and with or without packing gauze placed into residual cavity
2552985|NCT02545946|Active Comparator|Minimally Invasive|Cutaneous abscess will be opened with two small incisions just large enough to pass a vessel loop through both to keep them open. Pockets of pus will be broken up and the cavity washed out before placing the loop through both incisions and loosely tieing it over the skin
2553022|NCT02545439|Experimental|ALKS 5461|Sublingual tablet
2553091|NCT02545088|Experimental|Study group Hybrid Assistive Limb (HAL)|
2553099|NCT02545088|Active Comparator|1st control group|
2553102|NCT02545088|Active Comparator|2nd control group|
3204821|NCT00937638|Experimental|BOLD diet|
3204822|NCT00937638|Experimental|BOLD-X|
3204823|NCT00937651|Placebo Comparator|Placebo|Placebo, 3 tablets
3204824|NCT00937651|Active Comparator|BR-A-657•K 20 mg group|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
2553437|NCT02542956|Active Comparator|Exparel|Injection of Exparel
2553439|NCT02542956|Active Comparator|Marcaine|Receive Marcaine in a pain pump or by injection
3204825|NCT00937651|Active Comparator|BR-A-657•K 60 mg group|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
3204826|NCT00937651|Active Comparator|BR-A-657•K 180 mg group|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
3204827|NCT00937664|Other|AZD7762 + gemcitabine|AZD7762 administered alone and in combination with gemcitabine
3204828|NCT00937677||1|63 patients with relapsing-remitting Multiple Sclerosis who are enrolled in the TOUCH program and have been taking Tysabri monotherapy for 2 years.
3204829|NCT00937677||2|22 age- and sex-matched normal controls who completed 1 year follow-up.
2553700|NCT02541136|Experimental|Exercise|Participants in this arm took part in the aerobic exercise component of the study and attended St. James's Hospital in Dublin twice a week for 16 weeks. Furthermore, exercising participants were asked to engage in recorded aerobic activity outside of the class, which followed a standardised progression from 1-3 additional sessions, at the same intensity as the week's class.
2553704|NCT02541136|No Intervention|Control|Participants in the control group didn't change their sedentary habits.
2553752|NCT02540720|Experimental|group 1|Dexamethasone 0.5mg/kg.d i.v.
2553753|NCT02540720|Experimental|group 2|Dexamethasone & gamma globulin Dexamethasone 0.5mg/kg.d i.v. & gamma globulin i.v. qd*3d, and the total dose is 2g/kg
2553755|NCT02540720|Experimental|group 3|Dexamethasone & hemoperfusion Dexamethasone 0.5mg/kg.d i.v & hemoperfusion should be given at least three times in five days
3204830|NCT00937690||infrared imaging of cutaneous lesions|patients and volunteers with cutaneous lesions, with and without clinically detectable melanoma, and with one or more palpable cutaneous lesions
3204831|NCT00937703|Placebo Comparator|Group1: Control group|face to face visit à T4mounths
3204832|NCT00937703|Active Comparator|Group2: IVS Group|face to face visit at T4mounths plus telephone visits each 2 weeks
3204833|NCT00937703|Active Comparator|Group3: PDAphone group|PDA system face to face visit at T4mounths plus telephone visits each 2 weeks
3204834|NCT00937716||Diagnosis of Schizophrenia|Patients with a diagnosis of schizophrenia that have been off antipsychotic medicine and would like to resume treatment will be enrolled in the study.
2552354|NCT02549911|Experimental|HIPEC,Chemotherapy AND surgery|"surgical exploration,if PCI<20,then we perform this study~HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
2552399|NCT02549443|Active Comparator|Insulin|hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.
2552401|NCT02549443|Active Comparator|Insulin and amino acids|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~Amino Acids (AA) in amounts to preserve normal AA"
2552402|NCT02549443|Active Comparator|Insulin and hyperaminoacidemia|"hyperinsulinemic-normoglycemic clamp: an insulin infusion of 5 mU.kg-1.min-1 and a variable continuous infusion of glucose (dextrose 20%) to maintain the blood glucose between 4.0 and 6.0 mmol/L.~AA in amounts to increase AA plasma concentrations to supra-normal levels (hyperaminoacidemia)"
2552431|NCT02549183|Active Comparator|Arm 1|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to A KHz
2552435|NCT02549183|Active Comparator|Arm 2|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to B KHz
2552438|NCT02549183|Active Comparator|Arm 3|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to C KHz
2552439|NCT02549183|Active Comparator|Arm 4|Boston Scientific PRECISION Spinal Cord Stimulator System with MultiWave Technology programmed to D KHz
2552487|NCT02548936|Experimental|Lipid-lowering treatment|The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration. The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
2552489|NCT02548936|No Intervention|No lipid-lowering treatment|Without any Lipid-lowering treatment for 12 month.
2552545|NCT02548611|Experimental|Prasugrel|single-dose loading with 60 mg of prasugrel pre PCI
2552546|NCT02548611|Active Comparator|Clopidogrel|loading with 600 mg of clopidogrel pre PCI
2552673|NCT02547584|Active Comparator|Group 1: with baseline anxiety+catheter ablation|Baseline anxiety will be defined as; Cardiac Anxiety Questionnaire (CAQ) score >2.14 Hospital Anxiety and Depression Questionnaire (HAD) >7 State-Trait Anxiety Inventory (STAI): State-anxiety score >40
2552678|NCT02547584|Active Comparator|Group 2: Without baseline anxiety + catheter ablation|Cardiac Anxiety Questionnaire (CAQ) score <2.14 Hospital Anxiety and Depression Questionnaire (HAD) <7 State-Trait Anxiety Inventory (STAI): State-anxiety score <40
2552834|NCT02546583|Experimental|Increased Intravenous Loop Diuretic (Bumetanide or Furosemide)|2.5x Visit 1 dose
2552836|NCT02546583|Experimental|Loop Diuretic (Bumetanide or Furosemide) + IV Chlorothiazide|Loop diuretic (Bumetanide or Furosemide) dose remains the same as visit 1 dose but now with the addition of 500-1000 mg IV chlorothiazide
2552837|NCT02546583|No Intervention|Observational Arm|Subjects taking an IV loop diuretic (Bumetanide or Furosemide) that have sodium output greater than 100 mmol. These subjects will continue to be followed and have data collected on them.
2552881|NCT02546440|Experimental|treatment arm|patients are treated with dimethylfumarate over 24 weeks. Dosage will be escalated weekly from 30 mg/d to 720 mg/d over 9 weeks. The dose escalation scheme is the same as approved for psoriasis treatment in Germany
2552908|NCT02546154||CKD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
2552918|NCT02546154||IBD, iron deficiency anaemia|10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
2553000|NCT02545803|Other|study group|Adult patients (age ≥ 18 years) at the Intensive Care Unit (ICU) who become refractory to conventional mechanical ventilation and are switched to HFPV.
2553014|NCT02545296|Other|In-vitro Diagnostics|All infants are recruited into the same arm.
3174281|NCT00621790|Placebo Comparator|Placebo|Placebo (normosaline), continuous perfusion
3174282|NCT00621816|Active Comparator|1|Blinded nitroprusside infusion
2553157|NCT02544568|Experimental|High-Carb Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
2553161|NCT02544568|Experimental|High-Protein Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
2553163|NCT02544568|Experimental|High-Fat Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr) .
2553164|NCT02544568|Experimental|High-Fibre Meal|The 3 Groups (Control, T1DM, T2DM) will receive 4 meals with different compositions at 4 occasions (High-Carb, High-Fat, High-Protein, High-Fibr).
2553203|NCT02544165|Experimental|Caffeine intake|100mg of Caffeine intake
2553205|NCT02544165|Experimental|Cigarette smoking|smoking of one cigarette
2553206|NCT02544165|Experimental|Caffeine intake and Cigarette smoking|100mg of Caffeine intake and smoking of one cigarette
2553209|NCT02544165|No Intervention|Control group|no intervention group
2553381|NCT02543138|Experimental|Closed thoracostomy|Closed thoracostomy using the new trocar by novice
3174283|NCT00621816|Placebo Comparator|2|Blinded placebo infusion
3174284|NCT00621829|Active Comparator|1|"High susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
3174285|NCT00621829|Active Comparator|2|"Low susceptibility ALOX5 gene polymorphisms. Low susceptibility ALOX5 gene polymorphisms. Patients will be classified as having high susceptibility ALOX5 gene polymorphisms based on the number of repeats of the SP1 promoter."
3174286|NCT00621868|Experimental|1|Lowest dose
3170882|NCT00580112|Experimental|Group B|Participants with overexpressing HER-2 breast cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 milligram (mg) orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
2552422|NCT02549391|Experimental|KHK7580|
2552426|NCT02549391|Active Comparator|KRN1493|
3204835|NCT00937716||Healthy Volunteers|Healthy Volunteers without a psychiatric diagnosis, central nervous system condition, serious head injury, or current drug use will be matched on an individual basis to schizophrenic participants and used as a control population.
3204836|NCT00937729||enfuvirtide|all patients would received enfuvirtide and and optimised background
3204837|NCT00937742|Experimental|Non-tomato products|Non-tomato products (i.e. teriyaki marinade, sprite, applesauce) to be consumed daily in replace of tomato products
3204838|NCT00937755||olanzapine|olanzapine 10-20 mg/day
3204839|NCT00937755||quetiapine|quetiapine 300-600 mg/day
3204840|NCT00937755||risperidone|risperidone monotherapy, 2-4 mg/day
3204841|NCT00937807|Active Comparator|sévoflurane|hypnotic use in standard general anesthesia
3204842|NCT00937807|Experimental|LENOXe™ (xénon 100 % v/v)|Safety of use in terms of hemodynamic stability to the LENOXe™ (xénon 100 % v/v) within the framework of the carotid surgery on the old person
3204843|NCT00937820|Experimental|YM150 group|
3204844|NCT00937846|Experimental|GSK1034702|Single oral 5 mg dose in liquid formulation
3204845|NCT00937872|Experimental|SRT2104|Single arm with crossover from single dose of oral suspension formulation to single dose intravenous formulation.
2552609|NCT02548286|Active Comparator|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1day or 22day
2552621|NCT02548286|Experimental|CKD-330|CKD-330 8/5mg, PO, 1day or 22day
2552660|NCT02547727|Experimental|Four-site intradermal vaccination|0.1 ml of rabies vaccine is distributed to 4 sites over both arms and thigh intradermally on day 0. Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
2552664|NCT02547727|Active Comparator|Intramuscular vaccination|0.5 ml of rabies vaccine is injected to one arm on day 0 and 3.Blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
2552729|NCT02547519|Experimental|oral insulin capsule (dose escalation using 3 dose strengths)|Dose 1 is 7.5 mg rH-insulin crystals; dose 2 is 22.5 mg rH-insulin crystals; dose 3 is 67.5 mg rH-insulin crystals. The insulin crystals are formulated together with filling substance (microcrystalline cellulose to a total weight of 200 mg) and contained in hard gelatine capsules. The study treatment will be given orally.
2552731|NCT02547519|Placebo Comparator|Placebo capsule|Daily treatment with placebo capsules containing filling substance (microcrystalline cellulose).
2552789|NCT02547090||CP who underwent PSF by two attendings in 2012|
2552791|NCT02547090||CP who underwent PSF by a single surgeon from 2008-2010|
2552838|NCT02546739|Experimental|Experimental: 1|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
2552839|NCT02546739|Experimental|Experimental: 2|Chronic lymphoblastic leukemia with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
2552841|NCT02546739|Experimental|Experimental: 3|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells(Anti-CD19-CAR) targeting CD19.
3204846|NCT00937885|Experimental|Implementation of reminiscence|Individual and group reminiscence sessions held with residents, supplemented by reminiscence boxes, posters and exhibitions.
3204847|NCT00937885|No Intervention|Usual nursing care|
3204848|NCT00937898|Experimental|DASH Diet|High fruit and vegetable, low sodium diet
2553039|NCT02545192|Experimental|Active LFMS treatment|20 minutes of active Low Field Magnetic Stimulation using the LFMS device.
2553045|NCT02545192|Sham Comparator|Sham LFMS treatment|20 minutes of sham Low Field Magnetic Stimulation using the LFMS device.
2553074|NCT02544919|No Intervention|Control group|No Intervention group: Patients do not receive any lipid emulsion of any type during the study period
2553076|NCT02544919|Active Comparator|SMOF Group|Intervention Group: Patients receive 1 gm.kg.day-1 SMOFlipid for 48 hours before the operation and 5 days post-operatively.
2553136|NCT02544737|Experimental|Apatinib arm|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
2553177|NCT02544347|Other|diabetes mellitus group|gingival crevicular fluid was collected
3204849|NCT00937898|Active Comparator|Average American Diet|Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
3204850|NCT00937911|Experimental|YM150 group|
3204851|NCT00937924|Placebo Comparator|1|Control. Normal Saline Injections.
3204852|NCT00937924|Experimental|2|Diphenhydramine injections given as adjunct sedative.
3204853|NCT00937924|Experimental|3|Promethazine given as an adjunct sedative.
3204854|NCT00937963|Experimental|Palm Oil|Traditional palm oil normally used in foods
3204855|NCT00937976|Other|Control-delayed periodontal therapy|
3204856|NCT00937976|Other|Intensive Periodontal Therapy|
3204857|NCT00938028||Microbiome, Metabolome, Stool, Toddler|healthy infant stool samples
3204858|NCT00938067|Experimental|Staying Connected: Care Management|The intervention combines case management, psychopharmacological and culturally appropriate and individually tailored trauma support activities with evidence-based treatments.A key feature is the provision of a continuous healing relationship by a care management treatment team.The care manager, informed by the Native healer interviews, will provide a culturally appropriate and ongoing helping relationship to each intervention patient in the weeks and months post-injury and will remain in close contact with the trauma survivor subject for 6 months.Together, the care manager and trauma survivor subject will work on a plan to readjust to daily activities. The care management team will also coordinate psychopharmacological interventions for PTSD and related co-morbidities with primary care and or other community providers.
2552419|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 30% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
2552421|NCT02549469|Experimental|Naproxen sodium extended release 660 mg, 40% HPMC|Bioequivalence in healthy adult subjects in a fasted state relative to the established commercial Aleve 220 mg tablet
2552425|NCT02549469|Active Comparator|Naproxen sodium 220 mg|Bioequivalence in healthy adult subjects in a fasted state
2552467|NCT02548988|Experimental|Healthy|Healthy women are submitted to selective neuromuscular electrical stimulation on VMO.
2552469|NCT02548988|Experimental|Patellofemoral pain syndrome|Women with patellofemoral pain syndrome are submitted to selective neuromuscular electrical stimulation on VMO.
2552536|NCT02548767|Experimental|HFCS-EB|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
2552537|NCT02548767|Placebo Comparator|Asp-EB|Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement. All and only the provided beverage and diet will be consumed for eight weeks.
2552538|NCT02548767|Experimental|HFCS-AL|Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet. The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
2552539|NCT02548767|Placebo Comparator|Asp-AL|Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet. The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement. All the provided beverage will be consumed for eight weeks. Only the provided beverage and diet will be consumed for eight weeks. The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
2552624|NCT02548208|Active Comparator|Verum focused extracorporeal shockwave therapy|Verum focused extracorporeal shockwave therapy is applied at 7 equidistant points, perpendicular to the belly of the biceps brachii muscle on a thought line between the radial tuberosity and the coracoid process (Dermagold120, Tissue Regeneration Technologies, Woodstock, Georgia, U.S.). Shock waves are generated by electrohydraulic mechanisms.
2552633|NCT02548208|Sham Comparator|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy. The study personal is blinded to the applicators. All handling, adjustments and noises are thus same in this group.
2552637|NCT02548208|No Intervention|Control|Control procedure stipulates participants to lay down on the same therapy table for 5 minutes receiving no intervention.
2552717|NCT02547532||usual COPD|Patients meeting the diagnostic criteria for COPD and without AATD
2552718|NCT02547532||normal smokers|subjects with a history of smoking, without symptoms, without AATD and with normal lung function
2552719|NCT02547532||normal non smokers|subjects without a history of smoking, without symptoms, without AATD and with normal lung function
2552720|NCT02547532||AATD not treated|patients with COPD, with AATD and not on augmentation therapy for AATD
2552721|NCT02547532||AATD treated|patients with COPD, with AATD on augmentation therapy for AATD
2552728|NCT02547272||Nasal and rectal samples|ICU patients with nasal and rectal bacterial samples for the presence of S Aureus
2552769|NCT02547168|Experimental|iRhythm ZIO XT patch group|This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure
2552799|NCT02546843|Experimental|Group A|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with rocuronium 0.6 mg/kg (1 mg/kg only in a case of a rapid sequence induction).~maintaining the depth of neuromuscular blockade - rocuronium: the appropriate depth of the block will be maintained with repeated boluses of rocuronium 0.3 mg/kg according to TOF 0, PTC 0-1.~Specific Neuromuscular Blockade reversal will be performed with Sugammadex intravenously. The proper dosage of sugammadex will depend on the depth of the blockade:at TOF -1-2 (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered"
2552800|NCT02546843|Active Comparator|Group B|"After anesthesia induction: intravenous cannulation, preoxygenation, sufentanil 0.2 μg/kg intravenously, propofol 2.0mg/kg the neuromuscular blockade will be induced with cisatracurium 0.15mg/kg intravenously.~Maintaining the depth of neuromuscular blockade - cisatracurium:the appropriate depth of the block will be maintained with repeated boluses of cisatracurium 0.03 mg/kg - according to TOF maintaining of muscular relaxation TOF 1.~Nonspecific Neuromuscular Blockade reversal will be performed with neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously, the reversal will be applicated in case of TOF 1 or higher."
2552852|NCT02546531|Experimental|Dose escalation (defactinib, pembrolizumab, gemcitabine)|"Defactinib is an oral drug which will be administered on an outpatient basis at the prescribed dose twice a day daily during each 21-day cycle.~Pembrolizumab is an intravenous (IV) drug which will be administered on an outpatient basis over 30 minutes (-5/+10) at a dose of 200 mg on Day 1 of each 21-day cycle.~Gemcitabine is an IV drug which will be administered on an outpatient basis over 30 minutes at the prescribed dose on Days 1 and 8 of each 21-day cycle.~Participants enrolled in Dose Level 1 and 2 will not receive gemcitabine."
2552907|NCT02546206|Experimental|Probiotic Yoghurt|Probiotic yoghurt consumption
2552910|NCT02546206|Placebo Comparator|Natural Yoghurt|Natural yoghurt consumption
2552925|NCT02546141|Active Comparator|non-homogenized full-fat milk (pasteurized)|portion size that contains 25 g of protein, oral, single administration
2552436|NCT02549560|Sham Comparator|CONTROL GROUP|In these patients will be applied, with the same equipment used in tDCS, a simulated stimulus similar to the active one. They will also be submitted to some psychological test to evaluate theirs mnemonics, attentional, executive and global functions.
3204859|NCT00938080|Experimental|AG013: one mouth rinse/day|
3204860|NCT00938080|Experimental|AG013: three mouth rinses/day|
3204861|NCT00938080|Experimental|AG013: six mouth rinses/day|
2552570|NCT02548364|Experimental|Calcifediol|One capsule with 15,690 IU p.o. every two weeks
2552574|NCT02548364|Placebo Comparator|Placebo|One capsule with placebo p.o. every two weeks
3204862|NCT00938080|Placebo Comparator|one mouth rinse/day|
2552675|NCT02547636||Subjects/specimens that meet the inclusion criteria|Subjects/specimens that meet the inclusion criteria
2552742|NCT02547441|Experimental|Treatment|CLS001 (Omiganan) gel applied once daily
2552747|NCT02547441|Placebo Comparator|Vehicle Gel|Vehicle gel applied once daily
2552801|NCT02546791||Chronic myeloid leukemia patients treated with Dasatinib|patients with a diagnosis of chronic myeloid leukemia treated with Dasatinib for at least 45 days
2552833|NCT02546635|Experimental|Potential food effect|
2552835|NCT02546635|Experimental|Multi-dosing|
2552877|NCT02546453|Other|Tumoral specific genetic alterations|NGS techniques (next generation sequencing) will be used to identify specific genetic alterations of tumoral cells of a patient. If specific genetic alterations is detected, they will be used to detect circulating tumor DNA and/or circulating/disseminated tumoral cells (CTC/DTC) in peripheral samples (blood, bone marrow, cerebral spinal fluid) collected before, during and after treatment.
2552916|NCT02546167|Experimental|Cohort 1|will receive 1-5x10^7 CART-BCMA cells given as a split dose infusion over 3 days.
2552929|NCT02546167|Experimental|Cohort 2|Cyclophosphamide infusion prior to 1-5x10^7 CART BCMA cells given as a split dose infusion over 3 days.
2552933|NCT02546167|Experimental|Cohort 3|Cyclophosphamide infusion prior to 1-5x10^8 CART BCMA cells given as a split dose infusion over 3 days.
2552986|NCT02545764|Experimental|Intervention|Strength and neuromuscular exercise programme
2552987|NCT02545764|No Intervention|Control|Control group will receive opportunity for the training programme after data capturing is finished
2553057|NCT02545166||Carotid endarterectomy patients|40 male and female patients, aged 18 years and over, scheduled for carotid endarterectomy. Fasted pre-operative (arterial and capillary), peri-operative (arterial) and 1-hour and 24-hour post-operative (arterial) blood samples will be collected and analysed for serum purine concentration.
2553062|NCT02545166||Control patients|80 age and sex-matched control patients scheduled for non-vascular, non-oncological day surgery. A single pre-operative fasted capillary (finger-prick) blood sample will be collected and analysed for serum purine concentration.
2553065|NCT02545166||Dynamic controls|10 aortic aneurysm repair patients, 10 critical leg ischaemia patients, 10 endovascular aneurysm repair patients, 10 kidney transplant patients, and 10 free flap surgery patients.
2553066|NCT02545166||Local sampling patients|10 Patients undergoing revascularisation, 10 patients undergoing lower limb surgery with a tourniquet and 5 patients diagnosed with acute compartment syndrome.
2553088|NCT02544815|Active Comparator|Digoxin|Oral digoxin 0.25 mg: one pill per day for three consecutive days.
2553095|NCT02544815|Placebo Comparator|Placebo|Oral placebo for three days.
2553130|NCT02544672|Experimental|Myoelectric Elbow-Wrist-Hand Orthosis|
2553172|NCT02544412|Experimental|Intervention Group|"A novel mindfulness-based well-being training for preservice teachers will be employed. The intervention will be held once a week for 8-10 weeks. Two 4-hour days of mindfulness will also be implemented during the intervention period. The intervention will involve training in a range of attentional and constructive (Dahl, Lutz, & Davidson) contemplative practices. During the follow-up period participants will receive weekly 15 minute booster trainings."
2553174|NCT02544412|No Intervention|Control Group|Teacher education as usual. These participants will continue with the prescribed teacher training regime established by the Early Education Certification Program at the university.
3204863|NCT00938080|Placebo Comparator|three mouth rinses/day|
3204864|NCT00938080|Placebo Comparator|six mouth rinses/day|
2553274|NCT02543775|Experimental|Sentinel lymph node mapping|Patients who consent to the study will have preoperative and intraoperative SLN mapping performed. This will include injection of a radioisotope (Technetium 99) into the cervix and imaging (SPECT/CT) at Nuclear Medicine in the morning prior to surgery in an effort to identify the lymph node basin containing the sentinel nodes. Intraoperatively, blue dye will also be injected into the cervix to aid in location of the sentinel nodes.
3204865|NCT00938093|Active Comparator|Cognitive-behavioral therapy|cognitive-behavioral therapy
3204866|NCT00938093|Placebo Comparator|Enhanced usual care|enhanced usual care
2553399|NCT02543021|Active Comparator|Conventional chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
2553402|NCT02543021|Experimental|Virtual chromoendoscopy|Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy
3204867|NCT00938106|Experimental|(MR BT) in Cervix Cancer|
2553531|NCT02542293|Experimental|Combination Therapy|Durvalumab (PD-L1 monoclonal antibody) + Tremelimumab (monoclonal antibody directed against CTLA-4)
3204868|NCT00938119||Diabetes patients with PCI|this is single group
3204869|NCT00938132|Experimental|Fimasartan|
3204870|NCT00938145|Experimental|MRI+surgery|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI
3204871|NCT00938145|Experimental|MRI+surgery+chemotherapy|3 Tesla MRI/Cystectomy and Lymphadenectomy/Urinary Diversion/Specimen Ultra-High field MRI/chemotherapy
3204872|NCT00938158|Experimental|Stage 1 normal renal function|Subject with estimated glomerular filtration rate (GFR) greater than 80 milliliter per minute (mL/min)
3204873|NCT00938158|Experimental|Stage 1 moderate/severe renal function|Subject with estimated GFR >= 20 mL/min and less than 50 mL/min
3204874|NCT00938158|Experimental|Stage 2 normal renal function|Subject with GFR greater than 80 mL/min
3204875|NCT00938158|Experimental|Stage 2 moderate renal impairment|Subject with estimated GFR >= 30 mL/min and less than 50 mL/min
3204876|NCT00938158|Experimental|Stage 2 subjects requiring hemodialysis|Subjects who require hemodialysis
2552534|NCT02548702|Experimental|Community-based sport|Patients with type 2 diabetes will receive motivational counselling and will be allocated to a low intensity community-based sporting activity (Fit4Life programme) depending on their interests and perceived barriers to taking part.
2552535|NCT02548702|No Intervention|Control|One in 10 participants will be allocated to a control group who do not receive the intervention
2552564|NCT02548403|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
2552567|NCT02548403|Active Comparator|PEG-Asc with simethicone|group 2 (PEG-Asc with simethicone, N=130) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure.Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
2552613|NCT02548052|Experimental|GSK2981278, Vehicle, Betamethasone valerate|All subjects will receive all six treatments (GSK2981278 ointment 0.03%, 0.1%, 0.8%, 4%, vehicle to match GSK2981278 ointment and betamethasone valerate 0.1% cream); with random assignment of the treatments to 6 test fields on identified stable plaque(s) on the upper extremities, thighs and/or trunk. Subjects will be treated once-daily (except Days 7 and 14) over 19 days (a total of 16 applications) under semi-occlusive conditions (covered by an adhesive non-woven fabric).
2552659|NCT02547662|Experimental|Treatment (ixazomib citrate, pomalidomide, dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2552765|NCT02547181|Experimental|Splint|Patients will be provided instructed to use a tensor bandage as well as specific behaviours to prevent movement of the injured part of the hand.
2552767|NCT02547181|Experimental|Behavioral Modification|Patients are given a removable plaster/fiberglass splint with a tensor bandage underneath
2552787|NCT02546882|Experimental|stromal vascular fraction|The adipose tissue in abdomen or thigh will be harvested and digested at 37 °C for 60 min with 0.2% collagenase I/Ⅲ. After filtration and centrifugation, mature adipocytes are separated from the cell pellet. The pellet then is treated with erythrocyte lysis buffer twice to remove red cell fragment. The harvested pellet is stromal vascular fraction (SVF).
2552788|NCT02546882|Placebo Comparator|saline|1 ml saline without cells will be used as placebo.
2552857|NCT02546726|Experimental|Heat & Aerobic Training (HEAT) Condition|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the HEAT condition will be asked to sit quietly on the bench in the steam-room within their same-sex locker room for no more than 20 minutes. They will start at 11 minutes to get acclimated to the mild heat stress, and gradually work up to 20 minutes. A trained research staff member will be stationed outside the room.
2552862|NCT02546726|Active Comparator|Exercise Only|Participants will receive supervised, moderate intensity (50-75% maximum heart rate) aerobic exercise sessions, 3 times per week for 50 minutes in duration. After the exercise portion of each session, participants assigned to the Exercise Only condition will be asked to sit quietly on the bench in the lobby of the fitness facility, initially for 11 minutes and then gradually working up to 20 minutes.
2552914|NCT02546232|Active Comparator|Control|Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks
2552921|NCT02546232|Experimental|Additional therapy|"Carboplatin AUC 6 (area under curve; mg/ml/min) once every 3 weeks, for 12 weeks.~Paclitaxel 80 mg/m2 weekly for 12 weeks, thereafter current standard chemotherapy for 12 weeks"
2552960|NCT02545777|Active Comparator|treatment group|Take oral medicine of tonifying spleen and descending turbid, one bag each time, two times a day, continuous treatment for 10 days.The onset of the joints afford steeping washing and wet wrapping medicine of descending turbid and clearing heat, once per day, continuous treatment for 10 days.
2552963|NCT02545777|Active Comparator|Control group|Take diclofenac sodium enteric-coated, 50 mg, three times a day, continuous treatment for 10 days.
2553020|NCT02545465||BAY63-2521|Patients who have been switched from a Pulmonary Hypertension treatment to Adempas
2553068|NCT02545010|Experimental|LDWART + paclitaxel|All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices. Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
2553135|NCT02544789|Experimental|clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
2553183|NCT02544373|Active Comparator|Immediate PAP therapy (Group 1)|Subjects will receive PAP treatment for OSA as soon as possible after baseline PSG and repeat baseline cognitive testing 3 months after initiation of PAP therapy. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
2553186|NCT02544373|Other|Standard Care PAP therapy (Group 2)|Subjects will delay PAP treatment for 3 months following their baseline sleep study, and repeat their baseline cognitive testing prior to PAP treatment for sleep apnea. PAP therapy is considered standard clinical care for OSA. It involves wearing an apparatus that includes a hose and a mask (that covers the nose, or nose and mouth), connected to a small machine that blows air into the airway during sleep. The degree of air pressure given depends on your apnea severity, and the supplied air pressure can be continuous or change with your breathing pattern (bilevel).
2553258|NCT02543879|Experimental|Dose Escalation FT-1101|Following a 3+3 dose escalation strategy, the first cohort of patients will be administered FT-1101 at 10 mg, oral capsules, once weekly on a continuous basis. Subsequent cohorts dose and frequency will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will continue until the MTD is determined.
2552548|NCT02548572|Experimental|Treatment group|Subjects in the treatment group will undergo bilateral transcorneal electrical stimulation using OkuStim device once a week for fifty-two weeks
2552550|NCT02548572|Placebo Comparator|Sham group|Subjects in the Sham group will wear the OkuSpex and OkuEl (applied to cornea upon the lower lid) and be attached to the OkuStim device in the same manner as the treatment group, but will receive no electrical stimulation for the 30 minutes that the TES fiber is applied to the cornea (even though the device has been turned on) once a week for fifty-two weeks
2552611|NCT02548182|No Intervention|control|A standardized education material on diet, exercise, and behavior modification were provided to all participants, and each participant received a one-to-one education on diet and exercise from a trained nurse for 5 minutes each session.
2552630|NCT02548182|Active Comparator|smartcare|Participants allocated to a smartcare arms received the Fit.life™ wireless physical activity tracker (Fit.life™, Suwon, Korea) that measures daily and weekly physical activity. It is convenient for data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer, and has been validated for measurement of free-living physical activity in adults [REF]. Participants allocated to a smartcare arms were also provided a standardized education material on diet, exercise, and behavior modification.
2552636|NCT02548182|Active Comparator|smartcare plus financial incentives|Participants in the 'smartcare plus financial incentive' arms were told that they are entitled to receive financial incentives depending on their achievement of the physical activity and weight target, and the amount they ca expect .The investigators provide financial incentives classified as process-based incentive and outcome-based incentive in addition to smartcare group intervention. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group.
2552672|NCT02547753||Transplanted group|patients who are kidney receptors for at least 6 months and need tooth extraction
2552679|NCT02547753||Control group|healthy patients who need tooth extraction
2552805|NCT02546869|Experimental|Lebrikizumab|Participants will receive lebrikizumab SC using prefilled syringes (PFS), q4w up to Week 12.
2553018|NCT02545257|Active Comparator|Active comparator|In addition to normal, standard care, participants allocated to intervention group will receive a coordinated medication management model containing prescription review, drug-related problems (DRP) risk assessment and required action based on the DRP risk assessment.
2553019|NCT02545257|No Intervention|Control group (standard care)|Normal, standard care (control group)
2553086|NCT02545062|Experimental|group of type 1 and 2 diabetics|"A group of type 1 and 2 diabetes patients who meets the inclusion criteria will be done the MoCa test. A fingertip blood glucose will be made previous to the begin with the test in order to avoid doing it on a hypoglycemia event. The participants are instructed to do or respond the items in a organized manner. For each items there's a score. If the participant has 12 years of education or fewer, a point is added to his total score. At the end of the test the investigator will sum all sub items scores listed on the right side of the test paper. The maximum score is 30.~The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria."
2553093|NCT02545062|Experimental|control group|The MoCa test will be done in a control group, no diabetics, that meets the inclusion criteria.
2553129|NCT02544685|Active Comparator|Synbiotics group|"Interventions: administration of Probio-Fix Inum + Beneo Synergy 1~Start of prophylaxis: 5 days before or 2 days after starting chemotherapy~Prophylaxis duration: 3 months"
2553131|NCT02544685|Placebo Comparator|Placebo group|"Interventions: administration of placebo~Start: 5 days before or 2 days after starting chemotherapy~Duration: 3 months"
2553196|NCT02544386||Patients|Patients who have experienced a vascular hemiplegia and accept bone measure by MRI and 3D CT scan
3170883|NCT00580112|Experimental|Group C|Participants with familial breast cancer gene 1 (BRCA1) or breast cancer gene 2 (BRCA2) mutation carriers cancer will receive trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks on Day 1 of each cycle. Each cycle length will be 3 weeks. Treatment will be continued until disease progression, unmanageable toxicity, participant refusal or treatment delay no longer than 3 weeks due to toxicity. Along with study drug participants will be given dexamethasone 4 mg orally 24 hrs and 12hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion from Day 1 to 3.
3170884|NCT00580125|Experimental|A2|
3170885|NCT00580125|Placebo Comparator|A5|
3170886|NCT00580125|Active Comparator|A4|
3170887|NCT00580125|Experimental|A3|
3170888|NCT00580125|Experimental|A1|
3170889|NCT00580164||1|Splint
3170890|NCT00580164||2|No Splint
3170891|NCT00580177|Active Comparator|L|The Lichtenstein procedure for repair of inguinal hernia (Single On-lay patch)
3170892|NCT00580177|Active Comparator|P|The well-konown PerFixPlug technique for inguinal hernia repair.
3170893|NCT00580177|Active Comparator|PHS|The well-known Prolene Hernia System method for inguinal hernia repair.
3170894|NCT00580190|Active Comparator|1|
2553291|NCT02543645|Experimental|Varlilumab and Atezolizumab|
2553433|NCT02542995|No Intervention|Non-intervention|Usual clinical conditions
2553534|NCT02542293|Active Comparator|Standard of Care|Standard of Care chemotherapy treatment
3170895|NCT00580190|Placebo Comparator|2|
3170896|NCT00580190|Experimental|3|
2552553|NCT02548559|Experimental|Full-Spectrum Cannabidiol|1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
2552558|NCT02548559|Experimental|Single-Compound Cannabidiol|1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
2552561|NCT02548559|Placebo Comparator|Placebo|1 ml of placebo solution administered three times per day (TID) for four weeks.
2552616|NCT02548091|Active Comparator|Preventive non invasive ventilation|Patients will receive the non invasive ventilation (NIV) systematically during the whole procedure of pulmonary angioplasty, and then systematically in post procedure period, 1 hour every 4 hours, during the whole hospitalization in post anesthesia care unit (PACU).
2552625|NCT02548091|Other|Non invasive ventilation on demand|Patients will not receive the NIV during the procedure of pulmonary angioplasty; in case of respiratory decompensation in post procedure period they will receive NIV during the whole hospitalization in PACU according to the following criteria: paradoxical breathing, respiratory rate above 25/minutes, a ratio of arterial oxygen pressure to fraction of inspired oxygen values (PaO2/FiO2) below 200.
2552722|NCT02547389|Active Comparator|Intervention Group (IG)|IG additionally received community health programs with health workers(intensive education, consultation services, maintenance of anepilepsy tracking card, and repeated reminders).
2552723|NCT02547389|Other|Control Group (CG)|Patients in the CG were supplied with only printed epilepsy educational module
2552732|NCT02547285||Shoes characteristics in elderly people|The subjects will test different characteristics on the same shoe. A single parameter vary for each test (Different insole, heel height, stem length ...)
2552780|NCT02547155|Experimental|Spinal anesthesia|Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
2552783|NCT02547155|Active Comparator|General anesthesia|Subjects randomized to general anesthesia will receive propofol induction, in combination with a muscle relaxant and inhalational gas per anesthesia standard of care at our institution
2552858|NCT02546778|Experimental|Dermosux RF|The group received the radio frequency for 20 minutes with the frequency of 1 MHz with 40 W.
2552900|NCT02546349|Experimental|high eNO: ICS/LABA|patients with eNO >=23.5 ppb, receive inhaled corticosteroid (ICS)/long-acting beta2 agonist (ICS/LABA) of fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid.
2552902|NCT02546349|Active Comparator|high eNO: LAMA|patients with eNO >=23.5 ppb, receive long acting muscarinic antagonist (LAMA) of tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
2552905|NCT02546349|Experimental|Low eNO: ICS/LABA|patients with eNO < 23.5 ppb, receive fluticasone/salmeterol 250/25 mcg/puff, 2 puffs bid
2552915|NCT02546349|Active Comparator|Low eNO: LAMA|patients with eNO < 23.5 ppb, receive tiotropium 2 inhalations 2.5 mcg/inhalation, once daily
2552979|NCT02545738|Experimental|Liraglutide|Liraglutide s.c. up-escalated to 1.8 mg/day for 12 weeks.
2552980|NCT02545738|Placebo Comparator|Placebo|Placebo s.c. for 12 weeks.
2553044|NCT02545413|Experimental|Probiotic|Probiotic VSL#3 will be given at a dose of one capsule thrice daily for 8 weeks, amounting to a total of 337.5 billion CFU/day. Each capsule contains 112.5 billion viable lyophilized bacteria of four strains of Lactobacillus (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734), three strains of Bifidobacterium (B. longum DSM 24736, B. breve DSM 24732, B. infantis DSM 24737) and one strain of Streptococcus (S. thermophilus DSM 24731) and excipients.
2553049|NCT02545413|Placebo Comparator|Placebo|Placebo capsules will be given at a dose of one capsule thrice daily for 8 weeks; Placebo capsules contain all excipients as present in capsules (without the 8 strains of bacteria as mentioned above).
2553071|NCT02544971|Experimental|NF-N group|Neurofeedback in a neutral context
2553073|NCT02544971|Active Comparator|NF-T group|Neurofeedback in a trauma-related context
2553075|NCT02544971|Active Comparator|Control group|Treatment as usual
2553138|NCT02544711|Experimental|Prospective group :Innovation|Surgical treatment using a patient specific instrument (PSI)
2553140|NCT02544711|Other|Retrospective group: Reference|Conventional surgical treatment without PSI, using 2D imaging planification
2553215|NCT02544269|Experimental|Lumbosacral plexus blockade|Peripheral nerve blockade of lumbar and sacral plexus with ropivacaine max 225 mg perineural
2553219|NCT02544269|Active Comparator|Continuous spinal anesthesia|Continuous spinal anesthesia with plain bupivacaine max 15 mg intrathecal
2553266|NCT02543905||Family History Cohort|"Caucasian men with a family history of prostate cancer defined as:~Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years~Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years~Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age"
2553268|NCT02543905||Black African / Black Caribbean Cohort|"Men of black African or black Caribbean ancestry defined as:~Both parents and all 4 grandparents from that origin."
2553272|NCT02543905||High-risk gene mutation cohort|Men of any ethnicity who have been found to have inherited a gene mutation that increases risk of prostate cancer (gene mutation including BRCA1, BRCA2, ATM, PALB2, MLH1, MSH2, MSH6, CHEK2 and other DNA repair gene mutations as listed in the study protocol).
2553341|NCT02543489|Other|Flex IM Rod|
3170897|NCT00580216|Experimental|Idrabiotaparinux|"Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months.~Avidin, 100 mg, at the discretion of the investigator whenever deemed appropriate and possible (ie, life-threatening bleeding, emergency invasive procedure with the potential of uncontrolled bleeding, or overdosage)."
3170898|NCT00580216|Active Comparator|Warfarin|Warfarin, INR-adjusted dose, for a minimum total treatment duration of 6 months.
3174287|NCT00621868|Experimental|2|Low-middle dose
3174288|NCT00621868|Experimental|3|High-middle dose
3174289|NCT00621868|Experimental|4|Highest dose
3174290|NCT00621868|Placebo Comparator|5|placebo
3174291|NCT00621881|Experimental|1|750 mg naproxcinod
2552556|NCT02548663|Experimental|passive; osteopathic treatment|manipulative treatment according to osteopathic principles.
2552604|NCT02548169|Active Comparator|Group 1|Group 1 will consist of patients with resectable, borderline resectable or locally advanced pancreatic cancer. Group 1 will receive DC Vaccine + Standard of Care Chemotherapy.
2552612|NCT02548169|Active Comparator|Group 2|Group 2 will consist of patients with metastatic pancreatic cancer, newly diagnosed/untreated metastatic pancreatic cancer, or metastatic pancreatic cancer who have undergone prior neo-adjuvant therapy. Group 2 will receive DC Vaccine + Standard of Care Chemotherapy.
3170899|NCT00580242|Experimental|1|This is a Phase I dose escalation trial with three cohorts of 3-6 patients each plus 10 additional patients (up to a maximum total of 28 patients) treated at the candidate maximum tolerated dose.Cohorts will receive increasing doses of bortezomib at 0.7, 1, and 1.3 mg/m2 on days 1, 4, 8, and 11 in combination with lenalidomide at 10 mg a day for Days 1-21. Each cycle will be 28 days. Patients will receive up to 9 cycles of treatment, with efficacy assessed after 3, 6, and 9 cycles.
3170900|NCT00580268||H|Pregnant women with bipolar disorder
3170901|NCT00580281|Experimental|blood, urine, and dexa scan|This study will involve venipuncture for obtaining blood samples; a spot second void (whenever possible) urine sample will be obtained at the same time. A Dexa scan to evaluate bone density will be obtained at the beginning, middle and end of the study.
3170902|NCT00580307|Placebo Comparator|Septoplasty|Septoplasty only
2552952|NCT02545998|No Intervention|Standard care|Patients will receive a face-to-face asthma review
2552953|NCT02545998|Active Comparator|Telehealthcare|Patients will receive a telephone consultation and e-mail with attached PAAP and video link
2552977|NCT02545634|Placebo Comparator|Placebo powder|Placebo powder contains the same ingredients as the probiotic powder except the L. helveticus R0052 and B. longum R0175. All participants will consume the placebo for 28 days during one of two dosing phases.
2552983|NCT02545634|Experimental|Probiotic powder|The Investigational Product is formulated with a combination of two active ingredients: L. helveticus R0052 and B. longum R0175 and the percentage of each strain is 90% and 10% respectively. The minimum total count of L. helveticus R0052 and B. longum R0175 is 3 x 109 colony forming units (CFU) per stick during the shelf-life. The IP also contains the following excipients: xylitol (sweetener), maltodextrin (coating agent), fruit flavor and malic acid (acidity regulator). The total weight is 1.5 g per stick. All participants will consume the placebo for 28 days during one of two dosing phases.
2553110|NCT02544828|Experimental|Experimental group|Iron Sucrose 200mg
2553112|NCT02544828|Placebo Comparator|Control Group|placebo
2553147|NCT02544542|Experimental|Rectum cooling system|Insert the self-made device into the patient's rectum, pump ice-cold saline in to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by controlling the pumping speed of saline.
2553152|NCT02544542|Active Comparator|Hyper-hypothermia blanket|Let the patient sleep on the hyper-hypothermia blanket, set the target temperature to induce mild hypothermia, sustain the desired temperature for 12 hours,then let the body rewarm slowly. Body temperature changes are achieved by adjusting the target temperature of the device accordingly.
2553198|NCT02544295|Experimental|Clinical interview-Virtual reality task:1|Healthy controls will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
2553201|NCT02544295|Experimental|Clinical interview-Virtual reality task:2|Patients will be assessed by a clinical interview by a psychiatrist, once, 1 day-duration and Virtual reality task, once, 1 day-duration
3170903|NCT00580307|Experimental|Septoplasty and correction|Septoplasty and endoscopic contact point correction
2553277|NCT02543762||Inflammatory Bowel Disease|"Inflammatory bowel disease (IBD) is comprised of two major disorders: ulcerative colitis and Crohn disease.~Ulcerative colitis is a chronic inflammatory condition characterized by relapsing and remitting episodes of inflammation limited to the mucosal layer of the colon. It almost invariably involves the rectum and typically extends in a proximal and continuous fashion to involve other portions of the colon.~Crohn disease is characterized by transmural inflammation and by skip lesions. The transmural inflammatory nature of Crohn disease may lead to fibrosis and strictures, and to obstructive clinical presentations that are not typically seen in ulcerative colitis. More commonly, the transmural inflammation results in sinus tracts, giving rise to microperforations and fistulae.~Crohn disease may involve the entire gastrointestinal tract from mouth to perianal área patients with long-standing inflammatory bowel disease are prone to the development of colorectal cancer"
2553335|NCT02543424|Experimental|Patient group|Brain damaged adults with either hemiparesis and/or hemineglect. Brain damaged children with developmental and/or acquired disease inducing hemiparesis and/or hemineglect.
2553336|NCT02543424|Sham Comparator|Control group|Healthy adults and children.
2553425|NCT02543281|Active Comparator|aCRT Off|The adaptive CRT algorithm will be turned off for the CRT device implanted in the patients in this arm.
2553428|NCT02543281|Experimental|aCRT On|The adaptive CRT algorithm will be turned on for the CRT device implanted in the patients in this arm.
2553486|NCT02542683||physical activity program|enrollment for 12 months in a structured physical activity program
2553492|NCT02542683||delayed physical activity program|No intervention for 12 months, then enrollment in structured physical activity program
3170904|NCT00580320|Experimental|A|dacarbazine + bortezomib
3170905|NCT00580346|Experimental|2|
3170906|NCT00580359|Active Comparator|A|S-1 40mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
3170907|NCT00580359|Active Comparator|B|Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)
3170908|NCT00580385|Experimental|1|
3170909|NCT00580411||Alcohol Problem First|Alcohol Problem precedes Insomnia
3170910|NCT00580411||Insomnia First|Insomnia Precedes Alcohol Problem
3170911|NCT00580437|Experimental|Arm 1|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
3170912|NCT00580450|No Intervention|2|
3170913|NCT00580450|Experimental|1|
3170914|NCT00580476||1|150 patients will be women with breast cancer (75 early stage and 75 late stage)
3170915|NCT00580476||2|150 will be men with prostate cancer (75 early stage and 75 late stage)
3170916|NCT00580489|Active Comparator|C|either fentanyl or morphine
2552572|NCT02548416|Active Comparator|Control group zero PEEP|Induction and maintenance of anaesthesia in a conventional manner. Peroperative ventilatory settings using zero end-expiratory pressure.
2552598|NCT02548130||Patients before MELD score|Recipients before the MELD score
2552602|NCT02548130||Patients after the MELD score|Recipients after the MELD score
2552686|NCT02547857||Cohort 1|All women who undergo pelvic US in the ED, assuming they meet inclusion/exclusion criteria
2552795|NCT02547116|No Intervention|Standard anti-staphylococcal antibiotic|
2552796|NCT02547116|Experimental|Standard anti-staphylococcal antibiotic + Rifampin|Individuals with known, persistent small-colony variant MRSA, who are treated with standard anti-staphylococcal antibiotics, will be treated with their standard therapy in addition to Rifampin.
2552832|NCT02546674|Experimental|Nilotinib|Patients with newly diagnosed CML in chronic phase will be enrolled.
2552944|NCT02546063|Other|GoCARB app|Smartphone app
2552945|NCT02546063|No Intervention|Conventional carbohydrate estimating methods|Individual usual carbohydrate estimation methods (weighing, experience, carbohydrate exchange tables etc.).
2552961|NCT02545712||Neonatal patients|Receiving 2 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
2552964|NCT02545712||Pediatric patients (28 days ≤ 5 years)|Receiving 3 or more drugs at one day during their hospitalisation. For each drug, it is listed whether it is an extemporaneous, registered, the preparation, dosis, amount, interval, formulation and route of administration. It is noted if the drug contains ethanol, propylene glycol, benzyl alcohol, methyl-p-hydroxybenzoate, propanyl-p-hydroxybenzoate, acesulfam potassium, aspartame, glycerin and/or sorbitol.
2553051|NCT02545205|Experimental|Hybrid Assistive Limb (HAL)|
2553053|NCT02545205|Active Comparator|Conventional gait training|
2553111|NCT02544867|Experimental|Reduction in sitting time|Those randomized to this condition focused on reducing their overall sitting time by two hours per day (a goal achieved in similar studies [17,18] that represented approximately a 25% reduction in daily sitting time). Participants were encouraged to reach this goal by standing in bouts of roughly 10 minutes per hour. The purpose of this arm was to investigate whether we could replicate improvements in sitting time achieved in other worksite studies in our cohort of older adults, which included both workers and non-workers.
2553115|NCT02544867|Experimental|Increase in sit-to-stand transitions|Those randomized to the sit-to-stand condition focused on increasing the number of sit-to-stand transitions they performed throughout the day with a goal of adding 30 additional transitions per day. Previous studies have not succeeded in increasing the number of sit-to-stand transitions in older adults, possibly because they focused on reducing overall sitting time, encouraged longer standing breaks and did not provide a specific goal for sit-to-stand transitions [26-28]. An increase in sit-to-stand transitions would not be expected with an increase standing intervention alone, as prolonged standing reduces the opportunity for sit-to-stand transitions.
2553142|NCT02544555|Experimental|Intentional intraluminal approach|Intentional intraluminal approach is the way that the passage of guidewire in chronic total occlusive femoro-popliteal arterial lesion is performed via intraluminal route using various intraluminal devices. in an intraluminal approach, the response to the balloon is more favorable, but the outcome depends on the experience of the surgeon, and the approach requires more time and is more costly.
2553144|NCT02544555|Active Comparator|Intentional subintimal approach|Intentional subintimal approach is the method that recanalization is performed via subintimal route with a 0.035-inch looped guidewire and a supporting catheter at the occlusion site. Due to its simplicity and low cost, this approach has been used for many patients with femoropopliteal occlusion.
2553197|NCT02544256|Experimental|Mild hypothermia|After induction to general anaesthesia the patients will be cooled to 33° C. Targeted body temperature 33,8° C - 34,8° will be maintained up to the end of microcirculation measurement after aneurysm clipping.
2553199|NCT02544256|No Intervention|Normothermia|The body temperature will be maintained in the range 35,8° C - 36,8° C.
3170917|NCT00580489|Active Comparator|D|either fentanyl or morphine
2553265|NCT02543697|Experimental|Adrenal venous sampling|Patients going trough an adrenal venous sampling to find out if hypercortisolism is uni or bilaterally produced.
2553338|NCT02543567|Experimental|Group 1|Ad26.ZEBOV 5*10^10 viral particles (vp) single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] single dose IM injection on Day 57
2553343|NCT02543567|Experimental|Group 2|Ad26.ZEBOV 2*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U single dose IM injection on Day 57
2553348|NCT02543567|Experimental|Group 3|Ad26.ZEBOV 0.8*10^10 vp single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo 5*10^7 Inf. U. single dose IM injection on Day 57
2553350|NCT02543567|Experimental|Group 4|Participants will receive intramuscular (IM) injection of Placebo (0.9% saline) once on Day 1 and Day 57
2553384|NCT02543034|Experimental|Betafoam Wound Dressing|This contains 3% povidone iodine. Dressing will be routinely changed on day 3 and day 7, and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
2553389|NCT02543034|Active Comparator|Petrolatum Gauze|Dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
2553392|NCT02543034|Active Comparator|Allevyn Wound Dressing|Allevyn adhesive wound dressing will be routinely changed on day 3 and day 7 and can be replaced anytime due to various factors such as exudate control, dislodgement, or by investigators' clinical decision.
2553449|NCT02542891|Experimental|Blended CBT|"Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with smart phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 16 sessions (8 online and 8 face-to-face), once a week. The online platform is called Moodbuster.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
2552635|NCT02548260|Experimental|Syndactyly with compression|Relative immobilization with a syndactyly (CE conformity), compression (CE conformity) is worn over the finger
2552640|NCT02548260|Experimental|Rigid splint without compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), no compression is worn
2552641|NCT02548260|Experimental|Rigid splint with compression|Rigid immobilization with a custom made thermoplastic splint (CE conformity), compression (CE conformity) is worn over the finger
3204877|NCT00938158|Experimental|Stage 2 severe renal impairment not requiring hemodialysis|Subjects with GFR less than 30 mL/min
2552752|NCT02547246|Experimental|rTMS session|Patients will have a 20 minute session of rTMS at a frequency of 10 Hz.
2552754|NCT02547246|Placebo Comparator|rTMS placebo (SHAM) session|Patients will have a 20 minute session of placebo rTMS
2552774|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 4)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V (4:4:4:4) or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
2552775|NCT02546960|Experimental|ExPEC4V (4 : 4 : 4 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
2552776|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 8)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses (4 : 4 : 4 : 8/8 : 8 : 8 : 8) of ExPEC4V or placebo and in step 3, either of 2 highest doses of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
2552777|NCT02546960|Experimental|ExPEC4V (8 : 8 : 8 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
2552779|NCT02546960|Experimental|ExPEC4V (16 : 16 : 16 : 16)|Participants will be stratified according to their age in 2 groups >=18 to <50 years and >=50 years. Part 1: In age group >= 18 to <50 years, participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle. The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B. Participants in >=50 years group will be enrolled in stepwise,dose-escalating procedure. In step 1, lowest dose of ExPEC4V or Placebo will be given, in step 2 either of 2 medium doses of ExPEC4V or placebo and in step 3, either of 2 highest doses (8 : 8 : 8 : 16/16 : 16 : 16 : 16) of ExPEC4V or placebo. Participants will be enrolled into subsequent steps only if vaccination in previous steps is deemed safe based on review of safety data by the IDMC. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe based on the review of safety data through Day 8 by the IDMC.
2552781|NCT02546960|Placebo Comparator|Placebo|Participants will be stratified according to their age in 2 groups >= 18 to <50 years and >=50 years. Part 1: Participants will receive matching placebo to ExPEC4V as an intramuscular injection into the deltoid muscle. Participants will be enrolled into Part 2 only if vaccination in Part 1 is deemed safe and well tolerated based on the review of safety data through Day 8 by the IDMC.
3204878|NCT00938158|Experimental|Stage 2 mild renal impairment|Subjects with GFR >= 50 mL/min and <= 80 mL/min
3204879|NCT00938171|Active Comparator|local anesthesia|local anesthesia with propofol sedation Target-controlled infusion (TCI) system will be used to maintain proper sedation level)
2552909|NCT02546141|Active Comparator|full-fat milk (UHT)|portion size that contains 25 g of protein, oral, single administration
3204880|NCT00938171|Active Comparator|General anesthesia|Patients receiving general anesthesia
3204881|NCT00938184|Experimental|Treatment sequence A/B/C|Eligible subjects will be randomized in sequence A/B/C and will receive A: single tablet of paroxetine 12.5 milligrams, B: single tablet of paroxetine 25 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3204882|NCT00938184|Experimental|Treatment sequence A/C/B|Eligible subjects will be randomized in sequence A/C/B and will receive A: single tablet of paroxetine 12.5 milligrams, C: two tablets of paroxetine 25 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3204883|NCT00938184|Experimental|Treatment sequence B/A/C|Eligible subjects will be randomized in sequence B/A/C and will receive B: single tablet of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and C: two tablets of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
2552806|NCT02546934|Experimental|ABX, cisplatin|AP (ABX and cisplatin combination)
2552809|NCT02546934|Active Comparator|Gemcitabine, Cisplatin|GP (Gemcitabine and Cisplatin combination)
3204884|NCT00938184|Experimental|Treatment sequence B/C/A|Eligible subjects will be randomized in sequence B/C/A and will receive B: single tablet of paroxetine 25 milligrams, C: two tablets of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
2552912|NCT02546128|Experimental|intervention|"rehabilitation + active-dose ESWT (extra-corporeal shockwave therapy)"
2552919|NCT02546128|Placebo Comparator|control|"rehabilitation + placebo-dose ESWT (extra-corporeal shockwave therapy)"
2552988|NCT02545829|Experimental|Sequence 1|HGP1406 → HIP1302
2552992|NCT02545829|Experimental|Sequence 2|HIP1302 → HGP1406
3204885|NCT00938184|Experimental|Treatment sequence C/A/B|Eligible subjects will be randomized in sequence C/A/B and will receive C: two tablets of paroxetine 25 milligrams, A: single tablet of paroxetine 12.5 milligrams and B: single tablet of paroxetine 25 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
2553072|NCT02544958|Experimental|Er:YAG laser|4 treatments of 1 month interval
2553124|NCT02544750|Experimental|GWP42003-P|100 mg/mL GWP42003-P oral solution taken twice daily (morning and evening). Participants will be dosed up to a maximum of 50 mg/kg/day. Dose may be lower if Investigator judges benefit and/or tolerability issues.
2553166|NCT02544464|Experimental|Experimental group|ferric carboxymaltose 1000 mg
2553167|NCT02544464|Placebo Comparator|Control group|placebo
3204886|NCT00938184|Experimental|Treatment sequence C/B/A|Eligible subjects will be randomized in sequence C/B/A and will receive C: two tablets of paroxetine 25 milligrams, B: single tablet of paroxetine 25 milligrams and A: single tablet of paroxetine 12.5 milligrams administered orally in the morning. Subjects will be fasting since 10 hours before dosing in each period.
3204887|NCT00938197|Active Comparator|Part A|
2553339|NCT02543411|Experimental|Lidocaine group|Administration of lidocaine 1%
2553344|NCT02543411|Placebo Comparator|Control group|Administration of normal saline
2553405|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 1|Dose Level 1 of OPT-302 in combination with Lucentis™
2553409|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 2|Dose Level 2 of OPT-302 in combination with Lucentis™
2553411|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 3|Dose Level 3 of OPT-302 in combination with Lucentis™
2553412|NCT02543229|Experimental|Part 1 Dose escalation - Cohort 4|Dose Level 3 of OPT-302 monotherapy
2553417|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 5|OPT-302 (at Maximum Tolerated Dose [MTD] or highest dose tested in Part 1) in combination with Lucentis™
2553421|NCT02543229|Experimental|Part 2 Dose expansion - Cohort 6|OPT-302 (at MTD or highest dose tested in Part 1) monotherapy
2553490|NCT02542527|Experimental|Pumping with a fluid filled breast pump|Participants pump (each breast 25 min) with the new fluid filled breast pump
3204888|NCT00938197|Active Comparator|Part B|
3204889|NCT00938210|No Intervention|Laparoscopic surgery|Patients undergoing laparoscopic colonic surgery are compared with a historical cohort of patients undergoing similar open colonic surgery (right hemicolectomy and sigmoid resections).
2553573|NCT02541890|Experimental|Work place intervention|Work place intervention in addition to rehabilitation program.
2553576|NCT02541890|No Intervention|Rehabilitation program only|Rehabilitation program without intervention at the work place.
2553594|NCT02541591|Experimental|Neuroprotect|MAP between 85-100mmHg SVO2 between 65-75%
2553596|NCT02541591|Active Comparator|Control|MAP>65mmHg
2553641|NCT02541344|Active Comparator|Dose 1 of IQP-VV-102|Total 4 tablets (2 tablets with active ingredients and 2 placebo tablets) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
2553648|NCT02541344|Active Comparator|Dose 2 of IQP-VV-102|Total 4 tablets (4 tablets with active ingredients) to be taken, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
2553654|NCT02541344|Placebo Comparator|Placebo|Total 4 placebo tablets, 15 minutes before test meals (on 3 treatment days at the study site) with 200mL of water.
2553673|NCT02541071|Experimental|Yohimbine and Stress Film|Administration of 10mg yohimbine before the trauma film.
2553676|NCT02541071|Experimental|Placebo and Stress Film|Administration of placebo before the trauma film.
2553678|NCT02541071|Experimental|Clonidine and Stress Film|Administration of 0.15mg clonidine before the trauma film.
2553739|NCT02540837|Experimental|Bupivacaine|Obturator nerve block
2553741|NCT02540837|Placebo Comparator|Saline|Saline is injected as a placebo
2553781|NCT02540473|Experimental|Group therapy|12 week manualized group therapy (one hour per week)
2553784|NCT02540473|Other|Control Group|Participants get one hour of time away from patient care/duties to do as they wish.
2553818|NCT02540148|Experimental|Active Treatment|Patients will be fully consented before the start of the study. In the treatment group, subjects will undergo a treatment session to the enrolled eyes for three days during Week 1, followed by a single treatment session during Weeks 2, 14 and 26 with the Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.e.
2554078|NCT02538549|Active Comparator|ACE4 and TAU|This group will receive ACE4 as an intervention and treatment as usual.
2552685|NCT02547805|Experimental|ALLN-177|Five (5) capsules of ALLN-177 (1,500 units per capsule) PO TID with meals
2552744|NCT02547311|Experimental|Team Clinic Intervention|Middle School and High School Team Clinic Intervention
2552749|NCT02547311|No Intervention|Standard Clinical Care - Control|Standard Clinical Care - Control
2552770|NCT02547025|Experimental|rabeprazole+3 antibiotics|patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days
2552771|NCT02547025|Experimental|rabeprazole+bismuth+2 antibiotics|patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days
2552773|NCT02547025|Active Comparator|rabeprazole+amox+tetr+levo|patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days
2552872|NCT02546700|Experimental|Lebrikizumab: Biomarker-high|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
2552873|NCT02546700|Experimental|Lebrikizumab: Biomarker-low|Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
2552874|NCT02546700|Placebo Comparator|Placebo: Biomarker-high|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.
2552875|NCT02546700|Placebo Comparator|Placebo: Biomarker-low|Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.
2552955|NCT02545985|Experimental|Prolim stent implantation|In patients with symptomatic coronary artery disease Prolim stent was implanted in coronary arteries
2552993|NCT02545621||ARDS Group (acute respiratory distress syndrome)|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
2552996|NCT02545621||control group|The purpose of this monocentric observational prospective pathophysiology study is to compare alveolar monocyte/macrophage activation profiles between patients with or without ARDS
2553109|NCT02545140||UK (Lead Site)|"Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries:~UK (Lead Site) Germany Portugal Greece Spain (Basque Country)"
2553148|NCT02544581||Mandated impaired professionals|Physicians and other licensed healthcare professionals in mandated monitoring programs by State licensing boards due to Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
2553151|NCT02544581||Non-mandated adults|A general population of adults in aftercare following residential treatment for Alcohol Use Disorder who are treated with Soberlink combined with aftercare services following residential treatment.
2553187|NCT02544334||RA - naïve to biologics|This group will consist of 25 Rheumatoid Arthritis (RA) adult subjects who have not been treated with biologics (naïve to biologics). During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
2553188|NCT02544334||Healthy Controls|This group will consist of 25 adult subjects which will be healthy controls from members of the same household as the 25 naive to biologics, and be of the same age. During the exam the following will take place: dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
2553189|NCT02544334||RA responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who have been responsive to first line anti-TNF-alpha therapy. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
2553190|NCT02544334||RA non responsive to anti-TNF|This group will consist of 25 adult subjects with Rheumatoid Arthritis (RA) who are resistant to two or more anti-TNF-alpha therapies, and be of the same age as the RA responsive to anti-TNF group. During the exam the following will take place: the multidimensional health assessment questionnaire (MDHAQ), dental exam, saliva collection, and dental plaque will be removed from different tooth surfaces for supragingival.
2553279|NCT02543736|Other|Instrumented Treadmill System|The Instrumented Treadmill System records vertical ground reaction force and pressures.
3204890|NCT00938223|Active Comparator|4-peptide vaccine|Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A 2) and a tetanus helper peptide.
3204891|NCT00938223|Active Comparator|12-peptide vaccine|Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
3204892|NCT00938236|Other|Inhaled cyclosporine|Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001
3204893|NCT00938249|Experimental|Monascus Garlic Fermented Extract|
3204894|NCT00938249|Placebo Comparator|Placebo|
2553572|NCT02541825|Experimental|the stent of diameter of 7mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,7mm balloon,Pigtail catheter,the stent of diameter of 7mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
2553578|NCT02541825|Other|the stent of diameter of 8mm|Procedure/Surgery:Jugular vein puncture and catheterization. Device:RUPS-100(COOK Company)sheath ,8mm balloon,Pigtail catheter,the stent of diameter of 8mm (Bard,Fluency) Drug(including placebo):No Biological/Vaccine:No
2554080|NCT02538549|No Intervention|TAU Only|This group will receive only the treatment as usual.
3204895|NCT00938262|Experimental|Fimasartan, Ketoconazole, Rifampicin|
2552863|NCT02546947|No Intervention|Appropriate clinical group|group of patients with clinical dose adjustment
2552866|NCT02546947|Active Comparator|TOF adapted group|group with an objective of less than 2 responses to TOF stimulation monitored
2552913|NCT02546310|Experimental|HTL0009936 high dose|high dose infusion
2552922|NCT02546310|Experimental|HTL0009936 low dose|low dose infusion
2552928|NCT02546310|Placebo Comparator|HTL0009936 matching placebo|matching infusion
2552959|NCT02545842|Experimental|Group 1|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
2552962|NCT02545842|Experimental|Group 2|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
2552965|NCT02545842|Experimental|Group 3|Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L
2553087|NCT02545153|Active Comparator|Fibrin sealant|Tisseel, Baxter (Aprotinin and Fibrinogen)
2553094|NCT02545153|Placebo Comparator|Control|Suturing the incision without fibrin glue
2553127|NCT02544646|Other|trabeculectomy|
2553165|NCT02544438|Experimental|Astarabine|Astarabine
3170921|NCT00580528|Experimental|1|
2553740|NCT02540824|Experimental|Apatinib single agent arm|Apatinib, single agent, 750mg once daily p.o until disease progression
2553778|NCT02540499|Experimental|DIBH VMAT|"Volumetric modulated arc radiotherapy in visually guided voluntary -deep inspiration breath-hold for patients with locally advanced NSCLC referred for concomitant radiotherapy 2 Gy x 33, 5 F/W and 3 courses of platinum based combination chemotherapy.~Will be compared to a historic cohort of patients treated with VMAT in free breathing"
2553968|NCT02539095|Experimental|Cartizol, collagen injection|Their eligibility to participate in the study is checked, and they are randomized either into the intra-articular collagen injection group based on a randomization table.
2553974|NCT02539095|Placebo Comparator|Normal Saline injection|Their eligibility to participate in the study is checked, and they are randomized either into the (placebo) injection group based on a randomization table.
2554008|NCT02538731|Other|Dilation-assisted group|Dilation-assisted group:Dilation-assisted stone extraction
2554009|NCT02538731|Other|laser lithotripsy group|laser lithotripsy group:laser lithotripsy
2554070|NCT02538588|Experimental|Nebulizer 1|Nebulization with akita nebulizer
2554072|NCT02538588|Active Comparator|Nebulizer 2|Nebulization with eFlow nebulizer
2554090|NCT02538289|Other|Patients admitted before talks|Patients admitted to Cardiology or Respiratory Medicine Departments before the interventional teaching talks.
2554093|NCT02538289|Other|Patients admitted after talks|Patients admitted to Cardiology or Respiratory Medicine Departments after the interventional teaching talks.
2554157|NCT02538133|Experimental|99mTc-Exametazime (HMPAO)-labeled leucocytes|
2554213|NCT02537782|Other|Cardiac resynchronisation therapy implantation|Patients with current guideline-based indication for CRT implantation.
2554260|NCT02537366|Placebo Comparator|Placebo|Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.07 ml/kg/h Adaptation to sedation status by changing infusion speed of 0.02 ml/kg/h every 30 minutes up to 0.14 ml/kg/h Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
2554261|NCT02537366|Experimental|DEX|Dexmedetomidine diluted to 10 µg/ml in Sodium Chloride 0,9 % Continuous IV infusion begun one hour before NIV session at 0.7 µg/kg/h (= 0.07 ml/kg/h) Adaptation to sedation status by changing infusion speed of 0.2 µg/kg/h (= 0.02 ml/kg/h) every 30 minutes up to 1.4 µg/kg/h (= 0.14 ml/kg/h) Sedation objective Richmond Agitation Sedation Scale -3 (moderate sedation) to 0 (alert and calm)
2554308|NCT02537119|Experimental|Dynamic massage therapy|Rubbing on hamstrings combined with articular movement
2554313|NCT02537119|Active Comparator|Massage therapy|Rubbing on hamstrings
2554362|NCT02536742|Experimental|Experimental|Palbociclib plus Fulvestrant
3170922|NCT00580528|Experimental|2|
3170923|NCT00580528|No Intervention|3|
3170924|NCT00580567||1|Pathological Gamblers
3170925|NCT00580567||2|Non-Pathological Gamblers
3170926|NCT00580580|Active Comparator|1|"Administration of Optison (0.1-0.4 mL) intravenously followed by Contrast Pulse Sequencing to image both the coronary and carotid arteries.~Use will depend on availability of the contrast for the given study Optison will not be used on patients with blood allergies or Jehovah Witnesses"
3170927|NCT00580580|Active Comparator|2|Intravenous injection of Definity (0.05-0.20 mL) followed by Contrast Pulse Sequencing to image both coronary and carotid arteries
3170928|NCT00580580|Active Comparator|3|intravenous Injection of PESDA at a rate of 0.05-0.20 mL followed by image of coronary and carotid arteries PESDA will be used exclusively in patients who are eligible for other IRB studies
3170929|NCT00580593|Active Comparator|1|
3170930|NCT00580593|Sham Comparator|2|
3170931|NCT00580619|Experimental|1 (markers of sympathetic activity)|To evaluate if the various indices of sympathetic activity (Autonomic Function Testing) differ between patients with chronic fatigue syndrome and postural tachycardia syndrome (CFS-P), and CFS without POTS.
3170932|NCT00580619|Experimental|2 (saline)|To test the null hypothesis that there is no difference between two saline therapies (pulse saline vs. sham saline) in improving both the fatigue score and postural tachycardia syndrome.Saline infusions
3170933|NCT00580619|Experimental|3 (NO inhibition/ autonomic blockade)|Response to nitric oxide inhibition in the presence and absence of an intact autonomic nervous system will be evaluated. L-NMMA trimethaphan will be used for NO inhibition and autonomic blockade, respectively.
3170934|NCT00580619|Active Comparator|4 (methyldopa)|The effects of chronic autonomic withdrawal on improving symptoms of chronic fatigue and postural tachycardia syndrome will be evaluated
3208764|NCT00977847|Experimental|Internet Portal Practice|Patients in this practice will receive the informational letter either by email or mail one month before their scheduled visit. It will have directions to access the MFHP website and how to transfer data through the hospitals secure internet portal (Patient Gateway). About 1/3 of patients are signed up to use this service. Those who do not have a Patient Gateway account will be provided with directions on how to establish this service. Patients will be required to have a Gateway account to ensure that the MFHP data file is sent securely to the correct EHR record. Patients in this arm will receive an initial email or letter with a single follow-up reminder sent 2 weeks later. For patients who participate, the completed family history data will be transmitted to the patient's EHR.
2552972|NCT02545686|Experimental|one|"this is a single arm study. All subjects treated the same way, and undergo four interventions:~Chest wall movement assessment without CPAP~Breath hold assessment without CPAP~Chest wall movement assessment with CPAP~Breath hold assessment with CPAP"
2553067|NCT02545023||Observational (Supportive care, health-related QOL)|Participants complete the demographic questionnaire, SCNS-34, SF-36, and the Lifestyle Needs Survey. Within 1 year of completing questionnaires, some participants may complete a one-hour in-person one-on-one interview comprising questions about the challenges and experiences of cancer survivorship, their health and well-being, and supportive care needs.
2553121|NCT02544802|Experimental|ADMSCs|Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection
2553159|NCT02544503|Experimental|Stroke Patients|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months post stroke.
2553162|NCT02544503|Active Comparator|Healthy Controls|Subjects will undergo single pulse transcranial magnetic stimulation (TMS), paired pulse transcranial stimulation (ppTMS), and low frequency repetitive transcranial magnetic stimulation (rTMS) at one month and six months.
2553225|NCT02544126|Experimental|eSMART-MH|HIV+ young adults will be randomized to receive Electronic Self-Management Resource Training for Mental Health (eSMART-MH)
2553227|NCT02544126|Active Comparator|Attention Control|HIV+ young adults will be randomized to receive screen-based health education
2553254|NCT02543827|Experimental|MV140 I|The subjects will receive daily dose of MV140 during 6 months
2553255|NCT02543827|Experimental|MV140 II|The subjects will receive daily dose of MV140 during 3 months and placebo during 3 months
2553256|NCT02543827|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 6 month
2553354|NCT02543580|Experimental|single acupoint|transcutaneous electric acupoint stimulation is given at bilateral neiguan or 30min before anesthesia induction
2553357|NCT02543580|Experimental|double acupoints|transcutaneous electric acupoint stimulation is given at Danzhong and bilateral neiguan or 30min before anesthesia induction
2553359|NCT02543580|Experimental|sham electroacupuncture|electrode attached but no stimulation
2553398|NCT02543151|Experimental|SpyGlass Choledochoscopy procedure|Any patient referred to endoscopic management for biliary post liver transplant complication without previous treatment will be submitted to SpyGlass (direct visualization system) choledochoscopy procedure.
2553483|NCT02542826|Experimental|Pulmonary Rehabilitation|
2553520|NCT02542254|Active Comparator|Salbutamol alone|200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
2553523|NCT02542254|Experimental|Salbutamol and RPL554|200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
2553528|NCT02542254|Active Comparator|Ipratropium|Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
2553532|NCT02542254|Experimental|Ipratropium and RPL554|Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
2553535|NCT02542254|Experimental|RPL554|Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
2553537|NCT02542254|Placebo Comparator|Placebo|Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
2553602|NCT02541799|Experimental|Telemedicine|Participants allocated to this arm will be approached the using a telemedicine medium to discuss study participation. The consent form will be administered while the investigator is on a telemedicine link.
2553604|NCT02541799|Active Comparator|Standard Care|Participants allocated to this arm will be approached in standard fashion where the investigator approaches the patient face to face. The consent form will be administered while the investigator is in the participant's room.
2553644|NCT02541331|Experimental|ISMIGEN|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
2553650|NCT02541331|Placebo Comparator|PLACEBO|Treatment over 3 successive months with one daily tablet over 10 days followed by 20 days of rest
2553696|NCT02541032|Active Comparator|Intensive Dental Treatment|Patients will undergo up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm. All patients will be reexamined at 3, 6 and 9 months for safety checks. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention.
2553703|NCT02541032|Active Comparator|Standard Dental Treatment|Patients will undergo supragingival mechanical scaling and polishing. They will be informed of the presence and severity of their periodontal disease and will be advised to be seen by their dentist if their condition requires immediate attention. If they have no dental provider they will be referred for care. All patients will be reexamined at 3, 6 and 9 months for safety checks. Among the group the periodontal condition will be monitored to assure there is no progression of disease. If any site demonstrates an increase in periodontal pockets >3mm, they will receive site-directed scaling and root planing. Patients will be given instructions in basic oral hygiene and treated for stroke risk factors in accordance to the current guidelines for secondary stroke prevention. At the completion of the study, the control treatment patients will be offered to receive the same dental care as provided to the intensive treatment group as needed.
2554134|NCT02538276||Group carotid endarterectomy (CEA)|Patients submitted to carotid endarterectomy
2552808|NCT02546908||Non-metastatic Biochemically Recurrent PC|No intervention will be administered in this study. Participants with Non-metastatic biochemically recurrent PC will be enrolled. A non-metastatic biochemically recurrent PC involves a confirmed PSA value of >0.2 ng/mL following prostatectomy (European Association of Urology (EAU) guidelines), a PSA value of 2 ng/mL or more above the nadir following radiation therapy (American Society for Radiation Oncology (ASTRO) guidelines).
2552810|NCT02546908||Metastatic PC|No intervention will be administered in this study. Participants with Metastatic PC will be enrolled.
2552860|NCT02546427|Experimental|Treatment|"Step 1: Pelvic Lymph Node Irradiation~Helical TomoTherapy (HT): 41.25 Gy in 15 fractions of 2.75 Gy each~Step 2: Treat boost volume to prostate and seminal vesicles~Acceptable treatment modalities:~CyberKnife SBRT: 19 Gy in 2 fractions of 9.5 Gy each with SBRT~Permanent prostate implant (PPI):~108 Gy for low dose rate PPI with I-125 90 Gy for low dose rate PPI with Pd-103 HDR brachytherapy: 15 Gy in one fraction for HDR"
2552898|NCT02546245|Experimental|Heroes of Knowledge Game|
2552903|NCT02546245|Active Comparator|Attention/Time Control Games|
2552969|NCT02545959|Active Comparator|Control group|receive a single pulse of methylprednisolone IV (120mg)
2552974|NCT02545959|Experimental|Rituximab IT group|receive a single intrathecal infusion of rituximab (with IV methylprednisolone 120mg to avoid side effect)
2552976|NCT02545959|Experimental|Rituximab IT + IV group|receive Rituximab IT as previous and Rituximab IV (375mg/m2) the same day
3170935|NCT00580684|Active Comparator|G1|G1: prevenar
3170936|NCT00580684|Active Comparator|G2|G2: pneumo 23
2553447|NCT02542878|Experimental|FOAM ROLLER|"Treatment with foam roller will be applied for 60 seconds to this group. Subjetc lye in supine position over the foam roller placed on back muscle extensors. Then, they must slide the body on the device, from postero-superior iliac spine to the dorsal zone.~A brief explanation of this self-application will be showed prior the intervention."
2553448|NCT02542878|Placebo Comparator|PLACEBO|An intervention similar (position and time) to the experimental group will be done, but the used device will be a very soft roller not compressing the contact zone.
2553472|NCT02542566|Active Comparator|early weight bearing|early weight bearing and accelerated physiotherapy rehabilitation
2553477|NCT02542566|Active Comparator|protected weight bearing|protected weight bearing and conservative physiotherapy rehabilitation.
2553505|NCT02542371||HIV infected with known subclinical atherosclerosis|
2553508|NCT02542371||HIV infected without known subclinical atherosclerosis|
2553509|NCT02542371||Non-HIV infected with known subclinical atherosclerosis|
2553511|NCT02542371||Non-HIV infected without known subclinical atherosclerosis|
2553548|NCT02541929|Experimental|DHA|DHA (2grams/day) for 26 weeks
2553549|NCT02541929|Placebo Comparator|placebo|placebo (4 capsules per day) for 26 weeks
2553592|NCT02541760|Experimental|Montelukast|4 ml monteleukast daily for one month
2553593|NCT02541760|Active Comparator|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
2553595|NCT02541760|No Intervention|Control|No intervention
2553635|NCT02541370|Experimental|anti-CD133 CAR T cells|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Patients receive anti-CD133-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity."
2553748|NCT02540746|Experimental|ERG Skills Training|ERG Skills Training for 12 weeks
2553750|NCT02540746|Experimental|ERG Skills Training + ME|ERG Skills Training for 12 weeks preceded by Motivational Enhancement for 4 weeks
2553754|NCT02540746|Experimental|ERG Skills Training + FAM|ERG Skills Training with concurrent 12-week Family Skills Training
2553756|NCT02540746|Experimental|ERG Skills Training + ME + FAM|ERG Skills Training with concurrent 12-week Family Skills Training preceded by Motivational Enhancement for 4 weeks
2553823|NCT02540174|Experimental|Arm A|integrated addiction treatment program
2553827|NCT02540174|Other|Arm B|standard of care
2553868|NCT02539849|Other|adalimumab + FOS|Adalimumab will be administered during 12 weeks in combination with daily FOS 6g. (FOS administration will start 2 weeks before Adalimumab)
2553976|NCT02539030|Active Comparator|microfracture|simple microfracture for cartilage defect of knee
2553979|NCT02539030|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of knee
2554135|NCT02538276||Group carotid stenting (CAS)|Patients submitted to carotid artery stenting
3170937|NCT00580710||conventionally treated|conventionally treated, relatively poorly controlled patients with type 1 diabetes
3170938|NCT00580710||intensively treated|intensively treated, well controlled patients with type 1 diabetes
3170939|NCT00580710||lean healthy|age- and sex- matched non-diabetic, normal weight (BMI > or = 18.5 but < or = 25 kg/m2) control subjects
3170940|NCT00580710||obese subjects|obese individuals defined as BMI > or = 30kg/m2
3170941|NCT00580710||type 2 diabetics|Type 2 diabetics on diet only or diet and Metformin
3170942|NCT00580710||type 1 diabetes unaware|Type 1 diabetics unaware of hypoglycemic symptoms
3170943|NCT00580710||type 1 diabetes aware|Type 1 diabetics aware of hypoglycemic symptoms
3170944|NCT00580736|Experimental|Optical Clearing|Optical Clearing
3170945|NCT00580749|Active Comparator|DJ|Naso disal jejunal(DJ) feedings randomized to 50% of subjects meeting criteria.
3170946|NCT00580749|Active Comparator|NG|Placement of naso gastric feeding tube through nare into stomach for enteral feeding.
3170947|NCT00580762|Experimental|ESRD|End-Stage Renal Disease (ESRD) patients on dialysis who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
3170948|NCT00580762|Active Comparator|Non-ESRD|Non-ESRD patients who meet the NIH guidelines and preoperative requirements for RYGB will undergo laparoscopic RYGB
3170949|NCT00580775||Placebo|Observing heart rate variability in placebo and active estrogen preparations
3170950|NCT00580775||Active estogen|Observing heart rate variability in placebo and active estrogen preparations
3170951|NCT00580827|Placebo Comparator|placebo disulfiram|placebo disulfiram (0 mg/day)
3170952|NCT00580827|Experimental|disulfiram 62.5|disulfiram at 62.5 mg/day
3204896|NCT00938275|Experimental|0.5g SRT2104|"Cohort 1 (10 males) & Cohort 2 (10 females) must attend the clinic on 4 separate treatment visits during the study; each treatment visit will be one week apart. At each treatment visit, subjects will receive one of the following 4 treatments:~A) 0.5g SRT2104 administered as an oral suspension in the fasted state B) 0.5g SRT2104 administered as an oral suspension following consumption of a standard meal C) 0.5g SRT2104 administered as two 0.25g capsules in the fasted state D) 0.5g SRT2104 administered as two 0.25g capsules following consumption of a standard meal.~For treatments A and C, subjects will have fasted for at least 10 hours overnight. Water will be restricted from 1h prior to dosing until 1h post dose. A light lunch will be provided 4h post dose. For treatments B and D, subjects will receive SRT2104 within 30 min following the start of consumption of a standardized non high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat)."
3204897|NCT00938288|Other|1|Single group
2552878|NCT02546466|Experimental|Functional Star-shape taping (FST)|For the Functional Star-shape taping (FST) procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
2552879|NCT02546466|Sham Comparator|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
2552880|NCT02546466|Active Comparator|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
2552930|NCT02546102|Experimental|1|Arm 1 will receive ICT-107 in combination with the standard of care, temozolomide (TMZ). ICT-107 will be given once a week for 4 weeks in the induction phase. During the maintenance phase, ICT-107 will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
2552937|NCT02546102|Placebo Comparator|2|Arm 2 will receive TMZ with a blinded control. Control will be given once a week for 4 weeks in the induction phase. During the maintenance phase, Control will be given monthly for the 11 months after induction and once every 6 months thereafter until depletion of supply or confirmation of progressive disease (PD). Administration is intradermal in axilla.
2553009|NCT02545556|Experimental|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
2553010|NCT02545556|Placebo Comparator|control|liver cancer patients received traditional therapy
2553036|NCT02545179|Experimental|intervention|web-based daily care training 12 week interactive web based caring training education
2553040|NCT02545179|No Intervention|control|Previous therapy
2553108|NCT02544997|Experimental|Poziotinib|12mg P.O. for 2wks q21days
3204898|NCT00938301|Active Comparator|Treatment|2 cohorts will recieve single rising doses of PF-04455242 or placebo in a cross-over fashion.
3204899|NCT00938301|Placebo Comparator|Placebo|2 cohorts will receive single rising doses of PF-04455242 or placebo in a cross-over fashion.
3204900|NCT00938353|Experimental|BDP UDV|
3204901|NCT00938353|Placebo Comparator|Placebo|
3204902|NCT00938379|Experimental|20% deet insect repellent|experimental intervention
3204903|NCT00938379|Placebo Comparator|lotion without repellent active|
3204904|NCT00938405|Experimental|Colesevelam HCl|Beginning at Visit 1, two weeks after screening, subjects in the active treatment group will take 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
3204905|NCT00938405|Placebo Comparator|Comparison group|Beginning at Visit 1, two weeks after screening, subjects in the comparison group will be administered placebo, taking 3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
3204906|NCT00938444||Patients with moderate to severe RA|Patients with moderate to severe RA treated with Tocilizumab
3204907|NCT00938483|Experimental|Extensively hydrolyzed infant formula|New extensively hydrolyzed formula, NPS-202
3204908|NCT00938483|Active Comparator|Infant formula - Extensively hydrolyzed Nutramigen Lipil|Currently marketed extensively hydrolyzed formula (Nutramigen Lipil)
3204909|NCT00938522|Experimental|Cilostazol loading|
3204910|NCT00938522|Placebo Comparator|Placebo|
3204911|NCT00938535|Experimental|Obesity Prevention|
3204912|NCT00938535|No Intervention|Usual Care|This arm includes usual care.
3204913|NCT00938561||With and without Chronic Kidney Disease|A cohort of 10 patients subjects with and without kidney disease exhibiting a broad range of age and kidney function
3204914|NCT00938574|Experimental|Drug Atu027|
3204915|NCT00938587|Experimental|PF-04171327 10 mg|
3204916|NCT00938587|Experimental|PF-04171327 25 mg|
3204917|NCT00938587|Active Comparator|Prednisone|
3204918|NCT00938587|Placebo Comparator|Placebo|
3204919|NCT00938600|Experimental|A1 - non-pregnant single-dose|
2553438|NCT02542917||All patients|IBDoc home test for faecal calprotectin
3204920|NCT00938600|Experimental|A2 - non-pregnant; weekly dose|
3204921|NCT00938600|Experimental|B1 - pregnant; single-dose|
3204922|NCT00938600|Experimental|B2 - pregnant; weekly dose|
2552822|NCT02546661|Experimental|Module A: AZD4547 Monotherapy|"AZD4547 will be given orally twice daily until disease progression.~Patients who receive AZD4547 as monotherapy will have the option to cross over to durvalumab as monotherapy at the point of objective progression, as long as the following criteria are met:~The investigator believes it is in the patient's interest to receive durvalumab;~The patient consents to the continued treatment;~It is clinically appropriate for the patient to continue on durvalumab treatment;~The patient satisfies the key eligibility criteria for receiving durvalumab treatment."
2552823|NCT02546661|Experimental|Module A: MEDI4736 (durvalumab) + AZD4547|AZD4547 will be given orally twice daily until disease progression. Patients will also receive MEDI 4736 (durvalumab) by IV infusion once every 4 weeks.
2552825|NCT02546661|Experimental|Module B: MEDI4736 (durvalumab) + Olaparib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Olaparib will be given orally twice daily.
2552827|NCT02546661|Experimental|Module C: MEDI4736 (durvaluamb) + AZD1775|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. AZD1775 will be given orally in approximate 12 hour intervals over 3 days (6 doses) on Days 1-3, 8-10, and 15-17 of 28 day cycles.
2552828|NCT02546661|Experimental|Module D: MEDI4736 (durvalumab) monotherapy|MEDI 4736 (durvalumab) will be given by IV infusion once every 4 weeks.
2552829|NCT02546661|Experimental|Module E: MEDI4736 (durvalumab) + Vistusertib|MEDI4736 (durvalumab) will be given by IV infusion once every 4 weeks. Vistusertib will be given orally twice per day on an intermittent schedule (2 days on, 5 days off).
2552830|NCT02546661|Experimental|Module F: MEDI4736 (durvaluamb) + AZD9150|AZD9150 will be given as monotherapy on Days -7, -5, and -3 of a one week lead-in period. Combination dosing with IV AZD9150 followed by IV MEDI4736 (durvalumab) begins on Day 1 of each 28 day cycle. Thereafter AZD9150 is given weekly and MEDI4736 is given once every 4 weeks.
2552831|NCT02546661|Experimental|Module G: MEDI4736 + Selumetinib|
2552894|NCT02546089|Active Comparator|intervention group|"local anaesthetic - lidocaine 1%, dry needling, autologous blood injection,~+ structured rehab programme"
2552896|NCT02546089|Placebo Comparator|control group|"local anaesthetic - lidocaine 1%, dry needling,~+ structured rehab programme"
3204923|NCT00938600|Active Comparator|C1 - active control; pregnant women|
3204924|NCT00938613|Experimental|Captisol-Enabled Budesonide|32 ug/spray
2553204|NCT02544191|Experimental|GnRHa/ hCG/ hMG|3.6mg GnRHa (Goserelin, AstraZeneca UK Limited) every 28days for 5 months. After 2 months from the first Goserelin injection, all subjects were treated with hCG (Pregnyl, N.V. Organon Oss,Holland ) at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG (Urofollitropin for Injection, Livzon Pharm Group Inc., China) at a dose of 150 IU every 3 days for 2 months.
3204925|NCT00938613|Active Comparator|Rhinocort Aqua|32 ug/spray
3204926|NCT00938613|Placebo Comparator|Placebo|posphate buffered saline
3204927|NCT00938626|Experimental|Armed-activated T cells/Immunotherapy|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
3204928|NCT00938652|Active Comparator|Arm G/C|gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
2553432|NCT02543073|Experimental|MSCs|MSCs will be given the patients in MSCs group. Besides, azithromycin (AZM) and glucocorticoid will also be administered.
2553435|NCT02543073|Active Comparator|Non-MSCs|AZM and glucocorticoid will be given for the patients in Non-MSCs group.
2553468|NCT02542579||Subjects for pyrosequencing analysis|Dyspeptic subjects who visited for evaluation and agreed on 16S rRNA pyrosequencing analysis
2553504|NCT02542332|Active Comparator|With Data|Participants received statistical data about lung cancer screening
2553507|NCT02542332|No Intervention|Without Data|Participants had no statistical data on lung cancer screening
2553570|NCT02542059||Responders|Patients with resolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
2553571|NCT02542059||Non-responders|Patients with unresolved type 2 diabetes after bariatric surgery, will undergo 68Ga-exendin PET/CT
2553616|NCT02541552|Experimental|Knee arthroscopic patient|"1) Male and females 2) Age 16-60 years 3) Scheduled surgery 4) Knee arthroscopy 5) ASA Class I - III~Volume finding study to follow up-and-down design using a single cohort of patients. Intervention of patient will be dependent on effect of previous patients dose of and response to Ropivacaine 0.5% injectate."
2553695|NCT02541227||Cerebrolysin group|Patients who are treated with Cerebrolysin; dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
2553701|NCT02541227||Control group|Patients who are not treated with Cerebrolysin; treatment follows local clinical practice
2553744|NCT02540733||Diabetic stroke|
2553746|NCT02540733||Non-diabetic storke|
2553808|NCT02540382|Experimental|covered stent|"Procedure/Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm covered stents (Bard, Fluency).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
2553813|NCT02540382|Other|bare stent|"Surgery: Jugular vein puncture and catheterization. Device: RUPS-100 (COOK Company) sheath, 8 mm balloon, Pigtail catheter, 8 mm bare stents (EV3, protégé; Cordis, Smart).~Drug (including placebo): No Biological/Vaccine: No Radiation: No Behavioral (e.g., Psychotherapy, Lifestyle Counseling): No Genetic (including gene transfer, stem cell and recombinant DNA): No Dietary Supplement (e.g., vitamins, minerals): No."
2553893|NCT02539719|Experimental|SC-003|Phase 1a (Escalation) - IV infusion Phase 1b (Expansion) - IV infusion
2553895|NCT02539719|Experimental|SC-003 in combination with ABBV-181|Phase 1a (Escalation) - IV infusion of SC-003 followed by IV infusion of ABBV-181 Phase 1b (Expansion) - IV Infusion of SC-003 followed by IV infusion of ABBV-181
2553983|NCT02538991|Experimental|Bulkamid|
2553986|NCT02538991|Active Comparator|Tension-free Vaginal Tape|
3204929|NCT00938652|Experimental|Arm G/C/I|gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
3204930|NCT00938665||Control Group|
3204931|NCT00938665||AD Group|
3204932|NCT00938678|Experimental|Treatment Group 1|
3204933|NCT00938678|Active Comparator|Treatment Group 2|
2552846|NCT02546518|Experimental|Moniri Otovent|A face mask is connected to a tube to which a coloured balloon is attached. The tube is also connected to ambu bag balloon. A safety valve is used to prevent too high air pressure. The ambu bag balloon is hidden in a green soft toy in the form of frog. The parent and the child hold the face mask against the mouth and the child blows the balloon. On need, mainly in the beginning of treatment course, the parent presses the frog's abdomen in order to fill the balloon with air. During the first week day, a low pressure balloon is used, then it is changed with a higher pressure balloon. Full compliance for the treatment is defined as 20 blows (5 minutes) in the morning and evening for one month.
2552848|NCT02546518|Active Comparator|Tympanostomy tube in the ear drum|Operation for insertion of tympanostomy tube under general anesthesia.
2552931|NCT02546297|Active Comparator|ICS/LABA Group|Symbicort，Inhalation，Individualized medication，12 months.
2552935|NCT02546297|Active Comparator|LAMA Group|Tiotropium Bromide，Inhalation,Individualized medication，12 months.
2552939|NCT02546297|Active Comparator|LAMA+LABA Group|Tiotropium Bromide, Symbicort, Inhalation, Individualized medication, 12 months.
2552968|NCT02545699|Experimental|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
2552971|NCT02545699|Active Comparator|Standard Colonoscopy|Standard Colonoscopy
2553027|NCT02545452|Experimental|BAY98-7196|Investigate the pharmacokinetics effect of a vaginally administered antimycotic (miconazole) during the use of an intra-vaginal ring (IVR) releasing anastrozole (ATZ) and levonorgestrel (LNG)
2553031|NCT02545452|Experimental|Administered Antibiotic|Investigate the pharmacokinetics effect of a vaginally administered antibiotic (clindamycin) during the use of an IVR releasing ATZ and LNG
2553034|NCT02545452|Experimental|Administered Spermicide|Investigate the pharmacokinetics effect of a vaginally administered spermicide (nonoxynol-9) during the use of an IVR releasing ATZ and LNG
2553035|NCT02545452|Experimental|Tampons|Investigate the pharmacokinetics effect of the concomitant use of tampons during the use of an IVR releasing ATZ and LNG; investigate the pharmacokinetics over an extended IVR wearing period of 35 days
2553107|NCT02544841|Experimental|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is the treatment condition. SSI is an in-person, individual-level, clinic-based intervention that aims to reduce risky sexual behaviors among sexually active adolescent females.
2553113|NCT02544841|Active Comparator|Female Sexual Health|Female Sexual Health is the control counterfactual condition. It is an individual-level, information-only sex education program that aims to increase participants' knowledge on various topics related to STIs.
2553150|NCT02544594|Active Comparator|Extra-Corporal Life Support (ECLS)|Standard treatment plus Extra-Corporal Life Support (ECLS) (from Sorin) in patients with cardiogenic shock due to myocardial infarction.
2553153|NCT02544594|No Intervention|Standard treatment|Standard treatment alone without Extra-Corporal Life Support (ECLS) in patients with cardiogenic shock due to myocardial infarction.
2553200|NCT02544308|Active Comparator|No further treatment|No further treatment
2553202|NCT02544308|Experimental|Lenalidomide + Dexamethasone|Lenalidomide 25mg orally daily on days 1-21 Dexamethasone 20mg orally on days 1, 8, 15 & 22 Up to 9 cycles
2553259|NCT02543853|Active Comparator|veres needle entry arm|Vere needle will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
2553260|NCT02543853|Active Comparator|direct trocar entry arm|Direct trocar entry will be used to provide penumoperiteum than postoperative gastrointestinal functions will be compared
2553355|NCT02543593|Experimental|Intervention|Participants will receive active transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
2553356|NCT02543593|Sham Comparator|Placebo|Participants will receive sham transcranial direct-current stimulation (tDCS) for ten 20 minute sessions of 2 mA stimulation over a 2-week period.
2553382|NCT02543164|Other|REFERENCE: white bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
2553383|NCT02543164|Other|TEST: b-glucan enriched bread|Participants will consume a meal standardised to contain 50 g of available carbohydrates. Sample Will be consumed together with 250 mL of water, within 10-15 minutes.
2553429|NCT02542969|Other|Treatment|Simvastatin followed by Rosuvastatin then MGL-3196 daily followed by separate co-administration of Simvastatin and Rosuvastatin
2553462|NCT02542644|Other|Patients with Fuchs endothelial dystrophy scheduled for DMEK|
2553530|NCT02542423|Other|patients undergoing cardiac surgery|
2553557|NCT02541994|Other|Ultrasound Testing|Single arm with all patients getting measurements of axial length and central corneal thickness.
2553619|NCT02541682|Other|Control|Participants who have PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 3 and showing no symptom of nausea and/or vomiting during the three control visits. Control visits are performed a month apart.
2553621|NCT02541682|Other|Mild nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 4-6 during the three control visits. Control visits are performed a month apart.
2553623|NCT02541682|Other|Moderate nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 7-12 during the three control visits. Control visits are performed a month apart.
2553626|NCT02541682|Other|Severe nausea and vomiting of pregnancy|Participants who have maximum PUQE ( Pregnancy Unique Quantification of Emesis scoring index) score equal to 13-15 during the three control visits. Control visits are performed a month apart.
2553702|NCT02541149||Group 1:|Fifty patients with early stage hepatocellular carcinoma(BCLC stage A)
2553707|NCT02541149||Group 2|Twenty five patients with chronic liver disease diagnosed based on clinical, laboratory, and ultrasonographic investigations;
2553708|NCT02541149||Group 3|Control Group: Fifteen healthy, age and sex-matched subjects with seronegative hepatitis viral markers
2553764|NCT02540707|Placebo Comparator|Solifenacin|Women with overactive bladder syndrome will be treated by solifenacin 5 mg qd * 12 weeks
2553767|NCT02540707|Experimental|Mirabegron|Women with overactive bladder syndrome will be treated by mirabegron 25 mg qd * 12 weeks
3204934|NCT00938691|Experimental|Tepha|
3204935|NCT00938691|Active Comparator|Vicryl|
3204936|NCT00938730|Experimental|1. YM150, Dose W, twice daily|
2552938|NCT02546037||SOLACEA 21H|single haemodiafiltration treatment using a SOLACEA 21H dialyzer (Nipro Corp, Osaka, Japan)
2552941|NCT02546037||FX100|single haemodiafiltration treatment using a FX100 dialyzer (Fresenius MC, Bad Homburg, Germany)
3204937|NCT00938730|Experimental|2. YM150, Dose X, once daily|
3204938|NCT00938730|Experimental|3. YM150, Dose X, twice daily|
3204939|NCT00938730|Experimental|4. YM150, Dose Y once daily|
3204940|NCT00938730|Experimental|5. YM150, Dose Y twice daily|
2553400|NCT02543216|Experimental|CC genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
2553403|NCT02543216|Experimental|TT genotype|4-week study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. The same diets were instructed for both genotypes.
2553465|NCT02542800|Experimental|Healthy participants|
3204941|NCT00938730|Experimental|6. YM150, Dose Z, once daily|
3204942|NCT00938730|Active Comparator|7. Warfarin|
3204943|NCT00938743|Active Comparator|Atomoxetine|Treatment with a final dosis of 40-80mg atomoxetine daily
3204944|NCT00938743|No Intervention|Waiting list|
2553591|NCT02541656|Experimental|preloaddependence indice after volume expansion in laparoscopy|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
3204945|NCT00938769|Other|Self-Efficacy Training for Caregivers|The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
3204946|NCT00938769|Other|Comparison Conditions for Caregivers|Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for support.
3204947|NCT00938795|Other|Uncertainty Management Intervention|The Uncertainty Management Intervention will consist of six 30-minute phone calls with a study educator to discuss issues of psychological distress, uncertainty management, symptom control, self efficacy for symptom management, and quality of life.
3204948|NCT00938795|Other|Comparison Conditions for Liver Disease|Six 30-minute telephone calls that provide structured education about liver disease.
2553785|NCT02540460|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
2553788|NCT02540460|Experimental|LCB01-0371 800mg BID|LCB01-0371 800mg BID
2553789|NCT02540460|Experimental|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
2553791|NCT02540460|Placebo Comparator|Placebo|LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID
2553836|NCT02540096|Experimental|Intervention (Mental Practice)|Participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups). They will also participate in a structured mental practice session (lasting 30 minutes and three times a week), totaling 12 sessions at the end of this intervention.
2553838|NCT02540096|Placebo Comparator|Control group|Participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes. They will also participate in a cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions.
2553887|NCT02539823|Placebo Comparator|Control|Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
2553889|NCT02539823|Experimental|CBD 400mg|Subjects will receive 400mg of cannabidiol
2553892|NCT02539823|Experimental|CBD 800mg|Subjects will receive 800 mg of cannabidiol
2553985|NCT02539394|Experimental|Treatment|Procedure: Anterior Cervical Discectomy and Fusion. The treatment arm will receive 40 mg of Methylprednisolone Acetate delivered with a Hemostatic Matrix Kit prior to closure.
2553987|NCT02539394|Placebo Comparator|Control|Procedure: Anterior Cervical Discectomy and Fusion. The control group will receive only a Hemostatic Matrix Kit prior to closure.
2554044|NCT02538744|Placebo Comparator|placebo|placebo po 1x/day from day -12 through 4
2554047|NCT02538744|Active Comparator|doxazosin 8 mg|day -12 through -9: Doxazosin 1 mg po 1x/day day -8 through -5: Doxazosin 2 mg po 1x/day day -4 through -1: Doxazosin 4 mg po 1x/day day 1 through 4: Doxazosin 8 mg po 1x/day
2554112|NCT02538328|Active Comparator|harmonic scapel|Obesity surgery cases where hamonic scalpel is used for the comparison of different surgical devices
2554116|NCT02538328|Placebo Comparator|Ligasure sealing device|Ligasure used in obesity surgery for the comparison of different surgical devices Randomly chosen cases where ligasure is used instead of hamonic scalpel in surgical procedures comparison of multiple dissectors
2554163|NCT02538068|Experimental|Daily Surveys|Participants complete a daily survey regarding their daily life meaning, mood, physical activity, and other activities for 4 weeks.
2554166|NCT02538068|Active Comparator|Random Surveys (8)|Participants complete 8 random surveys over the first 4 weeks.
3204949|NCT00938808|Active Comparator|One per day, Formula diet|The Cambridge Programme. Formula diet One-daily
3204950|NCT00938808|Experimental|Repeated formula diet|Dietary instruction (low-energy diet) 3x5 weeks per year
3204951|NCT00938821||Caudal Block|Review of charts of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B).
3208765|NCT00977847|Active Comparator|Usual Care Physician Assesment Practice|Usual standard family history assessments will be conducted by physicians during the patient visit. This arm will allow us to account for any temporal trends in family history assessment.
3208766|NCT00977860|Other|SBRT|
3208767|NCT00977873|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
3208768|NCT00977873|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
2552927|NCT02546141|Active Comparator|full-fat cheese (semi-matured)|portion size that contains 25 g of protein, oral, single administration
2552934|NCT02546141|Active Comparator|whey protein|portion size that contains 25 g of protein, oral, single administration
2552940|NCT02546141|Active Comparator|micellar casein|portion size that contains 25 g of protein, oral, single administration
2552975|NCT02545647|No Intervention|Standard RYGB|65 patients undergo a standard Roux-en-Y gastric bypass
2552978|NCT02545647|Active Comparator|Banded RYGB|65 patients undergo a banded RYGB (BRYGB)
2553025|NCT02545478||Infected Group|subjects with suspected infection
2553030|NCT02545478||Non-infected group|subjects without any infection
2553077|NCT02544906|No Intervention|Control|No drugs will be given. the emergence agitation will be monitored and recorded
2553078|NCT02544906|Experimental|Propofol group|Propofol at dose of 1 mg/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
2553080|NCT02544906|Experimental|dexmedetomedine group|dexmedetomedine at dose of .5 mic/kg over 5 minutes will be started before extubation. the emergence agitation will be monitored and recorded
2553146|NCT02544724|Experimental|NM-IL-12|NM-IL-12 will be administered subcutaneously
3208769|NCT00977886|Placebo Comparator|Placebo|
3208770|NCT00977886|Experimental|ELB353|
2553278|NCT02543710|Experimental|phase 4 implementation study|The historical MoMaTEC1 outcome data, collected from 2001-2015 serve as control arm. These data have been rigorously collected and quality controlled with extensive clinical annotation and follow-up data, and reflect the outcome in (for a larger part) the same population as expected for MoMaTEC2 as there have not been major changes in surgical or medical treatment for endometrial cancer in this time period that could cause confounding. Internal validity, and to a degree also external validity, covering practice in multiple countries, should in this way be assured.
2553284|NCT02543710|Experimental|phase 2b biomarker study|For the current study, stathmin is used as an integrated marker and does not dictate treatment modality, therefore there is no requirement for a control arm.
2553358|NCT02543385|Active Comparator|SKET|Intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol infusion according to Schnider model through target control infusion pump.
2553361|NCT02543385|Placebo Comparator|PLACEBO|Intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model through target control infusion pump.
2553385|NCT02543177|Experimental|group A|direct coronary angiography
2553388|NCT02543177|Experimental|group B|direct coronary angiography plus ischemic precondition
2553391|NCT02543177|Experimental|group C|delayed coronary angiography; the kidneys will be irrigated prior to coronary angiography
2553394|NCT02543177|Experimental|group D|delayed coronary angiography plus ischemic precondition; the kidneys will be irrigated prior to coronary angiography
2553471|NCT02542839|Experimental|Real rTMS Stimulation|Repetitive TMS will be delivered over each cerebellar hemisphere, using a NeuroStar TMS therapy system. The coil will be positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. The coil position will be marked on the skin. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. Constant coil position will be continuously monitored during the experiment. A similar protocol will be observed for the contralateral cerebellum. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
2553478|NCT02542839|Sham Comparator|Sham rTMS Stimulation|Patients will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham NeuroStar TMS therapy system coil which produces discharge noise and vibration without stimulating the cerebral cortex. This technique has been suggested to provide more effective blinding compared to other methods use in previous controlled studies. In addition, this group will have the following performed: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) test, Cerebellar-brain Inhibition (CBI) measurement, and Craniocervical Dystonia Questionnaire (CDQ-24) questionnaire to fill out.
2553499|NCT02542202|Experimental|Stereotactic body radiation therapy|Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.
2553569|NCT02542098|Experimental|HYD 20 - 120 mg|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets administered orally every 24 hours
2553620|NCT02541617|Active Comparator|Movement Disorder Center|Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
2553622|NCT02541617|Experimental|Programming by community Neurologist|Device programming, Deep Brain Stimulator will be programmed by community Neurologist
2553689|NCT02541175||All study participants|In order to cover a wide variety of common arrhythmias but keeping the number of subjects needed low (pilot study), the subjects are pre-selected according to following 4 categories: 1) 4 patients with intermitting or persisting atrial fibrillation. 2) 4 patients with atrial flutter 3) 6 patients with frequent atrial or ventricular extra-systoles. 4) 6 cardiac healthy subjects.
2553738|NCT02540811|Experimental|dCELL® ACL Scaffold|
2553786|NCT02540512|Placebo Comparator|Standard Drug Group|"Participants randomized into this group will be receiving the standard medical care and placebo acupuncture. For the placebo acupuncture procedure, the ASP® needles will be double taped onto the ear in the same anatomical position as the acupuncture groups. The needles will be taped so that the needles will never puncture the skin. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed."
2553904|NCT02539615|Experimental|ForeCYTE Breast Aspirator - Nipple Aspirate Fluid Collection|Nipple Aspirate is collected using the ForeCYTE Breast Aspirator
3208771|NCT00977912|Experimental|"Milk containing B. Lactis"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
3204952|NCT00938834|Active Comparator|CFQ Qigong training group|"Qigong training con- sisted of an initial workshop conducted over three con- secutive half-days by a qualified CFQ instructor. Participants received training in level 1 CFQ; this con- sisted of instruction in seven key movements known as the hexagram and ancillary exercises. Hexagram move- ments consist of choreographed movements that emphasize softness, relaxation, downward releases and full body distribution of qi. Once initial training was complete, participants were asked to practice CFQ at home for 45 to 60 minutes per day for eight weeks; time could be broken up into shorter sessions during the day. Participants returned for a 60 minute weekly review/group practice sessions for these eight weeks."
2552989|NCT02545595|Experimental|Sugammadex 1mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
2552990|NCT02545595|Experimental|Sugammadex 2mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
2552994|NCT02545595|Experimental|Sugammadex 4mg/kg|for profound rocuronium-induced neuromuscular blockade reversal in morbidly obese patients
3204953|NCT00938873||Mindfulness Based Cognitive Therapy|The present study will use participants who have experienced more than three episodes of depression as judged by South London and Maudsley NHS Trust. No restrictions are placed in terms of participants' use of antidepressant medication. Participants will be 18 to 65 years old and would have participated in an MBCT course run by South London and Maudsley NHS Trust.
3204954|NCT00938912|Experimental|Lacosamide|Subjects and their caregivers may chose to receive Lacosamide oral solution (syrup) or Lacosamide tablets. The maximum duration of LCM administration will be approximately 2 years.
2553283|NCT02543671|Active Comparator|vitamin D3 enriched cheese|vitamin D3 enriched, reduced-fat yellow cheese
2553286|NCT02543671|Placebo Comparator|plain cheese|plain (non-fortified) reduced-fat yellow cheese
2553346|NCT02543476||patients' group with tumor sample|SCCHN patients having available archived tumor sample(s).
2553406|NCT02543060|Experimental|stannous fluoride toothpaste|brush twice a day for 8 weeks
2553408|NCT02543060|Sham Comparator|cavity protection toothpaste|brush twice a day for 8 weeks
2553470|NCT02542787|Experimental|Active|VSN16R (Canbex name for molecule) oral capsules, 50mg-400mg daily or twice daily, total exposure 26 days
2553476|NCT02542787|Placebo Comparator|Placebo|Placebo capsules, 50mg-400mg daily or twice daily, total exposure 26 days
3204955|NCT00938925|Experimental|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
2553581|NCT02541747|Active Comparator|massage|massage for 30 min, once a week for 4 weeks
2553583|NCT02541747|No Intervention|control|Rest as control
3204956|NCT00938925|Experimental|nail lacqer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
2553800|NCT02540395|Active Comparator|Group A: Standard of care|"Standard of care immunosuppressive regimen based on TAC (Prograf) (achieving 4-8ng/ml trough levels), MMF (Cellcept, Myfortic, Myfenax)(1gr bid) and steroids (6-methyl prednisolone, Urbason, Methypred) (according to KDIGO guidelines).~All patients in group A recieve the tripple-drug IS as suggested by guidelines. In case of rejection the patients are treated with high dosage of Methypred and/or Thymoglobuline"
2553803|NCT02540395|Experimental|"Group B: Low Immunosuppression regimen"|"(based on TAC monotherapy (Prograf) to achieve 8-10 ng/ml trough levels during the first 4 weeks after transplantation and 6-8 ng/ml thereafter, MMF (Cellcept, Myfortic, Myfenax) (1g bid) during the first 7 days post-transplant and stopped thereafter) and steroids (6-methyl prednisolone; Urbason, Methypred) (tapering until discontinuation on month 2 post-transplant).~In contrast to Group A the patients are treated with a two drug IS combination consisting of Prograf and Methypred. In case of rejection the patients are treated with hifg dosage of Methypred and/or Thymoglobuline."
2553876|NCT02539784|Experimental|Spinal Cord Stimulation|
2553947|NCT02539524|Active Comparator|Pulmonary Rehabilitation Group|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
2553948|NCT02539524|Experimental|Yoga Group|Yoga Bhastrika Pranayama breathing exercises consisted of: 12-week pulmonary rehabilitation (two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs). After each pulmonary rehabilitation session, participants of this group performed 10 bhastrika pranayama breathing exercises (1 bhastrika is formed by 20 kapalabhati followed by 1 surya bedhana - described earlier).
2553981|NCT02539056|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect
2554066|NCT02538874|Experimental|Part A: Single Ascending Dose (SAD)|BMS-986171 or Placebo on specified days
2554068|NCT02538874|Experimental|Part B: Multiple Ascending Dose (MAD)|BMS-986171 or Placebo on specified days
2554069|NCT02538874|Experimental|Part C: Multiple Ascending Dose in Japanese subjects (J-MAD)|BMS-986171 or Placebo on specified days
2554130|NCT02538302|Experimental|Minirin|120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months
2554133|NCT02538302|Active Comparator|Oxybutynin|5 mg Oxybutynin twice a daily for 6 months
2554158|NCT02538003|Experimental|Group 1(RT):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Reference: Taken drug before meal)~Period: LCB01-0371 Tablet 800 mg(Test: Taken drug after meal)"
2554159|NCT02538003|Experimental|Group 2(TR):LCB01-0371 Tablet 800mg|"Period:LCB01-0371 Tablet 800mg(Test:taken drug after meal)~Period: LCB01-0371 Tablet 800 mg(Reference:taken drug before meal)"
2554240|NCT02537457|Experimental|BAY59-7939 Rivaroxaban granule|
2554242|NCT02537457|Active Comparator|BAY59-7939 Rivaroxaban tablet|
3204957|NCT00938938|Experimental|Press guide plus press release|Participants in the intervention group will receive a press guide (a one-page summary of study findings written by the investigators) in addition to the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
3204958|NCT00938938|No Intervention|Press release only|Participants in the control group will receive the journal's full narrative press release for the selected article, a copy of the article's abstract, and a link to the full text of the journal article.
3170953|NCT00580827|Experimental|disulfiram 125|disulfiram at 125 mg/day
3170954|NCT00580827|Experimental|disulfiram 250|disulfiram at 250 mg/day
2553397|NCT02543320|Experimental|Supportive care (neurofeedback)|Beginning at weeks 4 and 5 or 5 and 6 of radiotherapy, patients undergo neurofeedback training QID TIW for up to 6 treatments. Patients also complete questionnaires over 10 minutes at baseline and after neurofeedback training.
2553458|NCT02542709|Active Comparator|Active transcranial magnetic stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
2553460|NCT02542709|Sham Comparator|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
2553647|NCT02541383|Other|Arm A Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)
2553656|NCT02541383|Experimental|Arm B Part 1|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab
2553658|NCT02541383|No Intervention|Arm A Part 2|Observation
2553659|NCT02541383|Experimental|Arm B Part 2|daratumumab
2553787|NCT02540408||presence of COPD|COPD patients are defined according to the results of a spirometry
2553815|NCT02540187||haemophilia A|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
2553820|NCT02540187||Haemophilia B|"Blood specimen for measuring :~Free TFPI and TFPI activity levels~Thrombin generation in platelet rich plasma (PRP) and platelet poor plasma (PPP)~Thrombin generation assay (TGA) in fresh PRP and frozen PPP~Hemorrhage score for each patient"
2553872|NCT02539862|Experimental|cognitive behavioral therapy online|patients receive cognitive behavioral therapy via an online program
2553875|NCT02539862|Other|no cognitive behavioral therapy online|patients receive psychoeducation by a doctor
2553934|NCT02539550|Placebo Comparator|Placebo|Placebo
2553935|NCT02539550|Experimental|PF-06266047|PF-06266047
2553966|NCT02539082|Placebo Comparator|placebo injection|placebo, normal saline, injection in the plantar facia through randomization
2553970|NCT02539082|Experimental|Regenseal injection|Regenseal, collagen, injection in the plantar facia through randomization
2554065|NCT02538822|Experimental|thoracic ascending aorta (ATA)|the risk of rupture of thoracic ascending aorta (ATA) is assessed fom the dynamic imaging and mechanical testing
2554190|NCT02537925|Active Comparator|concurrent_radiochemotherapy|Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
2554191|NCT02537925|Experimental|celecoxib_radiochemotherapy|Celecoxib 200mg bid po; Concurrent radiotherapy with Nedaplatin 40mg/m2/week through intravenous infusion.
2554244|NCT02537470|Other|Arm 1|Placebo
2554246|NCT02537470|Experimental|Arm 2|Biphasic remogliflozin etabonate
2554321|NCT02537106|Experimental|1.5% NaCl|After standardized induction to general anesthesia group A patients will be given the infusion of hyperosmotic 1.5% NaCl 5 ml/kg/BW during 15 min.
2554323|NCT02537106|Experimental|3% NaCl|After standardized induction to general anesthesia group B patients will be given the infusion of hyperosmotic 3% NaCl 5 ml/kg/BW during 15 min.
2554426|NCT02536365|Experimental|Sensory Integration Therapy|Children receive manualized SIT intervention that follows principles of sensory integration. SIT directly addresses the specific sensory factors hypothesized to underlie the child's functional skills difficulties and follows the Data Driven Decision Making Process, to tailor the intervention to the child's specific sensory issues.
2554430|NCT02536365|Active Comparator|Applied Behavioral Analysis|This involves examination of environmental variables that influence behavior and altering those variables to improve the child's skills. Intervention is individualized based on identified needs of the child, assessment of environmental variables impacting their performance of specific functional skills, and their abilities.
2554434|NCT02536365|No Intervention|No Treatment|Treatment as usual will occur through the treatment period. As with the other treatment conditions, the participant agrees to refrain from beginning new treatments during participation in this study.
3170955|NCT00580892||Airway and Pleural Disorders|Optical Coherence Tomography imaging
2554704|NCT02534610|Placebo Comparator|Group PLACEBO|1 placebo pill PO 1 h preoperative and 1 placebo pill PO postoperative at the end of surgery.
3170956|NCT00580905|Active Comparator|1|To compare the effects of adenosine at a dose of 80 mcg/kg/min for 30 minutes, Sodium nitroprusside will be used at a dose that produce similar systemic effects (5 mcg/kg/.min)
3170957|NCT00580905|Active Comparator|2|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
3170958|NCT00580918||1|Mild Traumatic Brain Injury group
3170959|NCT00580918||2|Normal healthy control group
3170960|NCT00580931|Experimental|1|Subjects will receive experimental drug in a blinded fashion.
3170961|NCT00580931|Placebo Comparator|2|Identical in size, shape and color to experimental drug.
3170962|NCT00580944|Experimental|Port Wien Stain Birthmark|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
3170963|NCT00580996|Experimental|1|16 oz water in AM
3170964|NCT00580996|Active Comparator|2|water 1 oz in AM
3170965|NCT00581009|Experimental|1|chronobiological augmentation group
3170966|NCT00581009|Experimental|2|medication only group
3170967|NCT00581009|Experimental|MDD Mechanism|
3170968|NCT00581022||1|Patients with Chronic Orthostatic Intolerance
3170969|NCT00581035|Experimental|1|Prevenar and Meningitec
3170970|NCT00581035|Experimental|2|Prevenar
3170971|NCT00581035|Experimental|3|Meningitec
3170972|NCT00581074|Active Comparator|G|grapefruit
2553017|NCT02545374|Active Comparator|Control|"In the control arm, patient care depend on his home, as is currently the case:~If it is in the action zone of Cicat-LR network, then it will be supported by an expert nurse of the network that are physically visit the patient's home-lon is the protocols established by the network.~If not, then it will be supported by the customs of the attending physician and nursing teams who follow him."
2553117|NCT02545114|Other|Tolvaptan|Intervention arm. Open label, no control group
2553156|NCT02544529|Experimental|Echothiophate Iodide|Echothiophate Iodide 0.03% one drop to each eye three times per week for 18 weeks
2553160|NCT02544529|Placebo Comparator|Carboxymethylcellulose Sodium (0.5%)|Carboxymethylcellulose Sodium (0.5%) one drop to each eye three times per week for 18 weeks
2553207|NCT02544178||diagnostic procedure|neurocognitive tests before and after radiotherapy
2553271|NCT02543944|Active Comparator|Gabapentin|"Gabapentin started on day 3 of week 1, increased up to a maximum dose of 800 mg BID by day 3 of week 2 and maintained for 2 weeks followed by 5-day taper.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
2553275|NCT02543944|Placebo Comparator|Placebo|"Participants in this arm begin receiving placebo (microcrystalline cellulose) in twice daily capsules on day 3 of week 1 and continue to do so through the beginning of week 5.~Buprenorphine (BUP) stabilization up to 12 mg (day 2 of week 1) then a 10-day BUP taper by the end of week 3.~During week 4, detoxed subjects get 0.1 mg of clonidine followed by oral naltrexone (NTX) at 6.25 mg and another 6.25 mg (day 1), 25 mg (day 2) and 50 mg (day 3) then depot NTX injection (later on day 3 or day 4)."
3204959|NCT00938951|Experimental|Systane® Ultra|Systane® Ultra
3204960|NCT00938977|Active Comparator|CPAP|Response to treatment before/after treatment in patients with OSAS and SOH
2553401|NCT02543047|Active Comparator|Right Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the right region of the heart
2553407|NCT02543047|Active Comparator|Left Region|Angioshield will be applied to provide Mechanical Support for Vein Grafts Used in CABG in the left region of the heart
2553488|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50, 200, 400, 600)|Subjects will receive IM oxytocin, IH placebo/IH oxytocin at doses of 50, 200, 400, 600 mcg.
2553494|NCT02542813|Experimental|IM oxytocin - IH placebo/IH oxytocin (50)|Subjects will receive IM oxytocin and IH placebo and/or IH oxytocin at 50 mcg.
2553512|NCT02542176|Experimental|Freeze-dried Whole Grape Powder|
2553516|NCT02542176|Placebo Comparator|Grape Powder Placebo|
2553553|NCT02541968|Active Comparator|Face-to-face CBT|16 sessions of individual CBT delivered in 14 weeks.
2553555|NCT02541968|Experimental|Internet-based CBT|Internet-based CBT (ICBT) with therapist support (14 weeks).
2553558|NCT02541968|Experimental|ICBT without therapist support|Internet-based CBT without therapist support (14 weeks).
3204961|NCT00938977|Active Comparator|Bilevel support ventilation|Before and after effect of Bilevel support ventilation in patients with SOH without OSA
3204962|NCT00938990|Active Comparator|Midazolam|
3204963|NCT00938990|Experimental|Etomidate|
3204964|NCT00939016|Active Comparator|High SD/ Low DR|This group contains females that exhibit characteristics of high social desirability and low dietary restraint.
3204965|NCT00939016|Active Comparator|High SD/ High Dr|This group contains females that exhibit characteristics of high social desirability and high dietary restraint.
2553715|NCT02540915||All patients 17 years or younger|Standard of Care - Registry. Must have been 11 yrs or under at initial treatment/evaluation.
2553799|NCT02540330|Active Comparator|Intramuscular Fulvestrant|500mg fulvestrant administered intramuscularly
2553805|NCT02540330|Experimental|Intraductal Fulvestrant|up to 500mg fulvestrant administered intraductally
2553858|NCT02540018|Active Comparator|Paclitaxel-coated Luminor® Balloon Catheter|The balloon dilatation procedure, including deployment to the target lesion and balloon inflation, deflation and retrieval, is performed under fluoroscopic observation. An endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion is mandatory. After pre-dilatation of the target lesion an angiographic assessment will be performed (DSA or XA). Randomization will be performed by envelope pull. The treatment group represents the Luminor® DEB PTA. After dilation of the target lesion, the PTA catheter is withdrawn through the introducer sheath, and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
2553861|NCT02540018|Active Comparator|Uncoated Balloon Catheter|Identical procedure also for control arm with PTA balloon (see below): After pre-dilatation, randomization will be performed by envelope pull. The control group requires an uncoated balloon catheter. After dilation of the target lesion, the PTA catheter is withdrawn and a post-PTA angiography is performed (DSA or XA) to evaluate the technical result and possible procedural complications. A final run-off angiography (DSA or XA) of the BTK arteries is required.
2553915|NCT02539628|Experimental|Intermittent bolus|ropivacaine 0.2%, 21 ml every 3 hours
2553916|NCT02539628|Active Comparator|Continuous infusion|ropivacaine 0.2%, 7ml/h
2553988|NCT02539277|Experimental|Treatment group|Jinyebaidu granule, blunt, 10g / time, three times a day; Fufangshuanghua granule placebo, blunt, 6g / time, 4 times a day.
2553989|NCT02539277|Active Comparator|Control group|Fufangshuanghua granule, blunt, 6g / time, 4 times a day; Jinyebaidu granule placebo, blunt, 10g / times, three times a day.
2554021|NCT02538705|Experimental|Neovasculgen|
3204966|NCT00939016|Active Comparator|Low SD/ High DR|This group contains females that exhibit characteristics of low social desirability and high dietary restraint.
3204967|NCT00939016|Active Comparator|Low SD/ Low DR|This group contains females that exhibit characteristics of low social desirability and low dietary restraint.
3204968|NCT00939042|Active Comparator|1|PCI plus BNNC Therapy after acute myocardial infarction
3204969|NCT00939042|Active Comparator|2|Percutaneous Coronary Intervention after acute myocardial infarction
3208772|NCT00977912|Placebo Comparator|"Milk containing placebo"|"Milk = Breast-milk from the mother, pasteurized breast-milk from a donor, or preterm formula."
3208773|NCT00977925|Experimental|Fibrin Pad|
3208774|NCT00977925|Active Comparator|Standard of Care|
2553069|NCT02545036|Experimental|TCM daycare model|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The intervention is Traditional Chinese Medicine (TCM) daycare model, which provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage on meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total). And the model will be provided by a team work clinical care system organized by doctors, nurses, pharmacists and case managers, also provide a comprehensive TCM care system for every visit.
2553070|NCT02545036|No Intervention|Control group|30 patients will be assigned to this arm. The assignment depends on the patients' own will. After diagnosis by nephrology physician, these patients will be distributed to control group by their wills. The control group will only receive assessment and follow-up without intervention.
2553120|NCT02544776|Experimental|Clomifene citrate and Amlodipine|Amlodipine 5mg tablet and Clomifene citrate 50 mg tablet once by mouth daily at morning starting from day number 5 of menstrual cycle till day number 9.
2553123|NCT02544776|Active Comparator|Clomifene citrate|Clomifene citrate 50mg and once daily at morning starting from day number 5 of menstrual cycle till day number 9
2553434|NCT02542982|Experimental|Active treatment|Group of patients on active treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by 20 minutes of 2 mA anodal tDCS over the ipsilesional motor cortex.
2553441|NCT02542982|Sham Comparator|Sham comparator|Group of patients on sham treatment will receive intensive motor training for 45 min/day, 5 days/week, for 2 weeks, which would be preceded by sham tDCS over the ipsilesional motor cortex.
3170973|NCT00581074|Active Comparator|J|Juice
2553514|NCT02542384|Active Comparator|CR845 IV 1 mcg/kg|CR845 IV solution will be supplied in 2 mL glass vials.Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
2553521|NCT02542384|Active Comparator|CR845 IV 0.5 mcg/kg|CR845 solution will be supplied in 2 mL glass vials. Study drug will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
2553527|NCT02542384|Placebo Comparator|Placebo IV|Placebo will be supplied in matched vials containing the same volume of buffer but with no active drug. It will be administered as an IV bolus into an infusion line, the volume is dependent upon the patient's body weight.
2553575|NCT02541838|Experimental|Muscle, Balance, and aerobic exercise|This trial will have a single experimental arm that will include the following interventions: Leg muscle strengthening, balance training using balance perturbations, and aerobic exercise. All individuals in this trial will receive all interventions listed.
2553597|NCT02541539|Active Comparator|Lactobacillus casei Zhang|Intervention consists of daily administration of 2g probiotic Lactobacillus casei Zhang, administered daily at a fixed dosage of 9 log CFU/sachet/day and continue for 12 months.
2553598|NCT02541539|Placebo Comparator|Placebo|Intervention consists of daily administration of 2g placebo (no probiotic bacteria), administered daily and continue for 12 months.
2553643|NCT02541318|Experimental|Practice-from Beginning Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
2553649|NCT02541318|Other|Practice-2 month Later Group|"The Practice-from Beginning Group will practice Duo-in exercise 20 minutes every day for 2 months; while there is no intervention in the Practice-2 month Later Group. Then, after 2 weeks, the participants of Practice-from Beginning Group and Practice-2 month Later Group will crossover. The Practice-from Beginning Group has no intervention, but the Practice-2 month Later Group will practice Duo-in exercise for 2 months."
2553677|NCT02541045|Placebo Comparator|Group 1: Placebo|Placebo
2553683|NCT02541045|Experimental|Group 2: Metadoxine|therapy with metadoxine
2553719|NCT02540863|Experimental|myofascial release protocol and Rocabado exercise therapy|"Myofascial Release Protocol:~Suboccipital release.~Compression - decompression of temporomandibular joint.~Horizontal release of temporomandibular joint.~Deep fascia release in temporal region.~Masseter deep fascia release.~Pterygoiddeep fascia release.~Intraoral pterygoid deep fascia release."
2553723|NCT02540863|Active Comparator|exercise therapy|Rocabado´s 6 x 6 exercises program utilizes six exercises six times by day. The patient is in supine position with a loop of 6 cm in the cervical area, and the therapist sits at the head of the bed.
2553742|NCT02540590||Mucograft|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and xenograft collagen matrix (Mucograft).
2553743|NCT02540590||CTG|Laser speckle contrast imaging of the oral mucosa and wound fluid measurement before and after root coverage surgery. In this group the roots are covered by a combination of modified coronally advanced flap and subepithelial connective tissue graft (CTG), which was harvested from the patient's palate.
2553814|NCT02540369||BAY86-5321- with wAMD|Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
2553817|NCT02540369||BAY86-5321 - with DME|Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients
2553900|NCT02539927||Controlled|
2553901|NCT02539927||Not controlled|
2553902|NCT02539927||Control status yet to be clarified|
3170974|NCT00581074|Placebo Comparator|W|placebo
3170975|NCT00581087|Experimental|1|DHEA
3170976|NCT00581087|Placebo Comparator|2|Placebo
3170977|NCT00581126|Experimental|1|Patients will receive Benefix IV according to blood amount
3170978|NCT00581139|Active Comparator|1|
3170979|NCT00581139|Active Comparator|2|
3170980|NCT00581139|Active Comparator|3|
3170981|NCT00581139|Active Comparator|4|
3170982|NCT00581191|Experimental|1|0.5 mg SLV-351 (fasted)
3170983|NCT00581191|Experimental|2|1 mg SLV-351 (fasted)
3170984|NCT00581191|Experimental|3|2.5 mg SLV-351 (fasted)
3170985|NCT00581191|Experimental|4|5 mg SLV-351 (fasted)
3170986|NCT00581191|Experimental|5|10 mg SLV-351 (fasted)
2553096|NCT02544880|Experimental|Tadalafil Placebo plus Vaccine Group (Phase II)|After completion of the Phase I portion of the study, new participants will be enrolled for the randomized, placebo-controlled Phase II. Participants randomized in this group will receive placebo for Tadalafil, the Anti-MUC1 Vaccine and the Anti-Influenza Vaccine for 5 courses. A standard of care (SOC) tumor removal surgery will be completed after the completion of Course 1. Course 2 will resume 5-8 weeks after completion of SOC tumor removal surgery.
2553100|NCT02544880|Other|Control Group|For eligible participants who opt out of receiving study intervention. Participants in this group will receive SOC treatment only.
2553169|NCT02544477|Experimental|High-flow nasal cannula oxygen (HFNCO)|Patients will receive HFNCO treatment with a gas flow level = 50 L/min and a FiO2 set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
2553170|NCT02544477|Active Comparator|standard oxygen therapy|Patients will receive oxygen treatment by means of a conventional face mask, with a level of fraction of inspired oxygen (FiO2) set to maintain peripheral oxygen saturation (SpO2) of 92% - 98%.
2553264|NCT02543931|Placebo Comparator|Placebo|Participants will take 4 placebo capsules twice a day for one month
2553267|NCT02543931|Experimental|Meriva, low dose|Participants will take 4 Meriva-250mg capsules twice a day for one month
2553270|NCT02543931|Experimental|Meriva, high dose|Participants will take 4 Meriva-500mg capsules twice a day for one month
2553345|NCT02543502|Experimental|periodontal treatment|Group will receive treatment: periodontal treatment
2553349|NCT02543502|No Intervention|Control Group.|Group will not receive treatment: periodontal treatment
2553415|NCT02543242|Experimental|Intervention|Participants will undergo the InTone TM (InControl Medical, LLC) medical device treatment for Urinary Incontinence. The frequency of treatment is once/day (12 minutes), 5-6 days/week. The route of administration is vaginal.
2553459|NCT02542722|Active Comparator|Control|General dietary and physical exercise recommendations
2553463|NCT02542722|Experimental|Intervention|Intensive intervention on dietary and physical exercise habits.
2553517|NCT02542436||Cohort 1: bevacizumab|Participants with metastatic colorectal cancer between 2010-2013, who received bevacizumab (25 mg/ml concentrate for solution for infusion) with first-line chemotherapy.
2553522|NCT02542436||Cohort 2: no bevacizumab|Participants with metastatic colorectal cancer between 2005-2008, who did not receive bevacizumab with first-line chemotherapy.
2553552|NCT02542033|Active Comparator|verum|500mL treated apple juice with low sugar content given on one experimental day
2553556|NCT02542033|Placebo Comparator|control|500mL un-treated apple juice with normal sugar content given on one experimental day
2553601|NCT02541708|Experimental|IV ferric carboxymaltose|IV Ferric carboxymaltose is given at a dose calculated according to the severity of anemia and patients weight. The maximal weekly dose is 1000mg. If total dose exceeds 1000mg the dose is split in 1-3 infusions with one infusion per week.
2553603|NCT02541708|Active Comparator|Ferrous sulphate 60mg+Folic acid 0.25mg|Three dried ferrous sulphate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia.
2553662|NCT02541292||Patient group|Patients over 18 years old with confirmed FSHD (facioscapulohumeral muscular dystrophy).
2553672|NCT02541084||PRN group|wAMD-patients treated with anti-VEGF therapy ´pro re nata´ (PRN)
2553674|NCT02541084||TAE group|wAMD-patients treated with anti-VEGF therapy ´treat-and-extend´ (TAE)
2553680|NCT02541084||PRN-to-TAE switcher group|wAMD patients treated with anti-VEGF therapy and switching from PRN to TAE regimens
2553721|NCT02540889|Experimental|trial arm|100 hours of therapy.
2553722|NCT02540889|No Intervention|Normal therapy arm|12 weeks of normal therapy.
2553774|NCT02540603|Experimental|Full Face Mask|F&P Jupiter Full Face Mask with Headgear
2553840|NCT02540057|Active Comparator|Flexor carpi radialis|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the flexor carpi radialis tendon.
2553842|NCT02540057|Active Comparator|Abductor pollicis longus|These patients will have their trapeziectomy with ligament reconstruction and tendon interposition using the abductor pollicis longus tendon.
2553871|NCT02539836|Experimental|Obesity with dietary nutrition|Obese children will be intervented by dietary nutrition based on plant fermentation extract for 2 months.
2553873|NCT02539836|Active Comparator|Liver fat of obese children|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
2553994|NCT02539498|Active Comparator|Control|Control post menopausal women without PHPT
2553995|NCT02539498|Experimental|Experimental|Post menopausal women with PHPT followed for one year
3204970|NCT00939068|Experimental|Telbivudine|Drug administration and follow up: the subjects in Telbivudine group start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continue to one month after delivery.And their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
3208775|NCT00977951|Experimental|Intradermal avotermin|
2554142|NCT02538237|Experimental|ibuprofen mouthwash|Subgingival Irrigation of ibuprofen 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
2554145|NCT02538237|Sham Comparator|placebo mouthwash|Subgingival Irrigation of placebo 2% mouthwash (made from the Faculty of Pharmaceutical Sciences, Islamic Azad University, Tehran) with an insulin syringe 0.5 ml were rinsed
2554170|NCT02537964|Experimental|Chlorhexidine bath|Intervention: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
2554172|NCT02537964|No Intervention|Standard bathing|Standard bathing with water +/- mild soap according to age and gestational week
2554235|NCT02537691|Other|Inhaled Corticosteroids (ICS) + Controller Medications|Participants with severe asthma Global Initiative for Asthma (GINA) step 4/5 as indicated by current treatment with daily ICS consisting of >/=500 mcg FP administered by DPI (or equivalent), and at least one of the following controller medications: LABAs, LTRAs, LAMAs, theophylline or oral corticosteroids.
2554354|NCT02536573|No Intervention|Control|Intraoperative fluoroscopy of the hip is used to visually estimate the acetabular cup angle and make any necessary adjustments.
2553133|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 2, 4, 6 months|One dose of PCV13 vaccine will be given at 2, 4, 6 months respectively in aged 2 months old
2553134|NCT02544698|Experimental|One dose of PCV13 vaccine will be given at 3、4、5 months|One dose of PCV13 vaccine will be given at 3、4、5 months respectively in aged 3 months old
2553182|NCT02544360|Experimental|Intervention|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
2553185|NCT02544360|No Intervention|Control|The control group consists of schools participating in the survey but not receiving the intervention.
2553224|NCT02544100||Database Entry / Biospecimen Collection|Systematic Medical information of infants born with severe encephalopathy entered into database. In addition, Blood, urine, CFS samples will be collected.
2553423|NCT02543190|Experimental|compliance surveillance|"Prospective audits by study personnel~Call from the clinic nurse practitioner or physician's assistant within 7 days of discharge to administer a screening questionnaire to identify patients at risk of dehydration. Study personnel will ensure this phone call is made."
2553426|NCT02543190|No Intervention|Usual Care|educational session at the start of the study
3170987|NCT00581191|Experimental|6|15 mg SLV-351 (fasted)
2553554|NCT02541916|Experimental|Controlled weaning of immunosuppression|Participants who are found to have the tolerance gene expression profile during phase 1 of the study will undergo closely monitored immunosuppression weaning during phase 2.
2553588|NCT02541773||Chronic Heart Failure Patients|Undergoing CRT implantation, all will be observed for 6 months and will be defined at the end of the observation period as responder or non-responder
3170988|NCT00581191|Experimental|7|20 mg SLV-351 (fasted)
3170989|NCT00581191|Experimental|8|30 mg SLV-351 (fasted)
3170990|NCT00581191|Experimental|9|xx mg SLV-351 (fasted and fed)
2553691|NCT02541123||Cohort A|CT negative for acute intracranial lesion with initial blood draw within 4 hours of head injury
2553692|NCT02541123||Cohort B|CT negative for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
2553693|NCT02541123||Cohort C|CT positive for acute intracranial lesion with initial blood draw within 4 hours of head injury
2553694|NCT02541123||Cohort D|CT positive for acute intracranial lesion with initial blood draw within 4-6 hours of head injury
2553698|NCT02541123||Cohort E|Uninjured control group
2553779|NCT02540421||Case|Recurrent lesions
2553782|NCT02540421||Control|Absence of lesions
2553824|NCT02540200|Active Comparator|Standard treatment|The patients undergo standard bone marrow stimulation technique (i.e. microfracture) for the treatment of their chondral lesions of the hip. This is currently the standard treatment for this condition.
2553829|NCT02540200|Experimental|BST-CarGel|In addition to undergoing the standard intervention with microfracture, BST-CarGel (the device of interest for the study) is applied during the intervention.
2553890|NCT02539914|Experimental|VR motor-cognitive task|The VR motor-cognitive task group will perform a virtual reality motor and cognitive attention/memory task customized to each user in terms of the positive content.
2553894|NCT02539914|Active Comparator|Standard rehabilitation|The standard rehabilitation group will perform conventional motor and cognitive rehabilitation tasks.
2553928|NCT02539420|No Intervention|Control|"Patients assigned to the control group will receive any treatment for status asthmaticus that does not entail use of positive pressure ventilation."
2553930|NCT02539420|Experimental|Late BiPAP treatment|"Patients assigned to the late treatment group will be started on BiPAP greater than 6 hours after randomization."
2553931|NCT02539420|Experimental|Early BiPAP treatment|"Patients assigned to the early treatment group will be started on BiPAP as soon as possible after randomization."
2554091|NCT02538263|Experimental|Volume-targeted noninvasive ventilation|For Volume-targeted noninvasive ventilation, the target VT was set at 10 ml/kg of ideal body weight, with inspiratory positive airway pressure (IPAP) ranging from 10 cmH2O up to 25 cmH2O.
3170991|NCT00581204||Diagnostic Tool|Near-Infrared Diffuse Optical Spectroscopy Imaging
3170992|NCT00581217||Single arm study|Burn patients or patients with skin loss requiring split-thickness skin graft
3170993|NCT00581243|Experimental|1|2 mg SLV-313 SR (fixed dose)
3170994|NCT00581243|Experimental|2|5 mg SLV-313 SR (fixed dose)
3170995|NCT00581243|Experimental|3|10 mg SLV-313 SR (fixed dose)
3170996|NCT00581243|Experimental|4|xx mg SLV-313 SR (titration)
3170997|NCT00581269|Active Comparator|1|low-impact aerobic exercise group
3170998|NCT00581269|Active Comparator|2|dietary restriction group
3170999|NCT00581269|No Intervention|3|control group
3171000|NCT00581282||1|Cocaine abstinent group
3171001|NCT00581282||2|Normal healthy control group
3171002|NCT00581295||trauma|Diffuse optical spectroscopy measurment
3171003|NCT00581321|Experimental|1|water ingestion
3171004|NCT00581373|Experimental|1|water 16 oz
3171005|NCT00581425|Experimental|Treated|
3171006|NCT00581438||1|
3171007|NCT00581451|Experimental|A|bifeprunox 25 day
3171008|NCT00581451|Experimental|B|bifeprunox 14 day
3171009|NCT00581451|Experimental|C|bifeprunox 14 day
3171010|NCT00581451|Experimental|D|bifeprunox 9 day
3171011|NCT00581464|Active Comparator|1|
3171012|NCT00581464|Active Comparator|2|
3171013|NCT00581477|Placebo Comparator|2|
3171014|NCT00581477|Experimental|1|
3171015|NCT00581490||Idiopathic premature pubarche|Children with premature pubarche without precious puberty, adrenal hyperplasia or androgen secreting tumors
3171016|NCT00581503||diagnostic|oct imaging
3171017|NCT00581568|Experimental|Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
3171018|NCT00581594|Other|1|Posterior repair with graft augmentation.
3171019|NCT00581594|Other|2|Posterior repair without graft augmentation.
3171020|NCT00581607|Active Comparator|Bosentan for 16 weeks|Active drug
3171021|NCT00581607|Placebo Comparator|Placebo|Placebo for 16 weeks
3171022|NCT00581620|Active Comparator|G1|G1: HIV+
3171023|NCT00581620|Active Comparator|G2|G2: Sicle Cell disease
2553370|NCT02543359|Experimental|Clinicians and Supervisors|After randomization clinicians and supervisors from community behavioral health agencies receive training in one of three PCIT training models: Train the Trainer (TTT), Learning Collaborative (LC) or Web-Supported Self Study (SS).
2553371|NCT02543359|Experimental|Administrators|After randomization administrators from participating community behavioral health agencies receive one of three treatments for PCIT (1/3 Learning Collaborative, 1/3 other treatment - none, and 1/3 other treatment - none).
2553374|NCT02543359|Experimental|Parent-Child Dyads|Parent-child dyads receive Parent-Child Interaction Therapy (PCIT) treatment from trained clinicians/supervisors.
2553427|NCT02543008|Experimental|Physical activity plus thoracic mobilization|Subjects randomly allocated to this arm will be submitted to a 10 minutes anaerobic exercise (2 minutes warming up, 5 minutes of 75% to 85% maximal heat rate, 3 minutes slowdown), followed by 5 minutes of passive intervertebral thoracic mobilization (3 sets of 1 minute, grade III, and 1 minute rest between each set).
2553430|NCT02543008|Active Comparator|Physical activity|Subjects allocated to this arm will be submitted to the same anaerobic exercise protocol, without the thoracic mobilization.
2553431|NCT02543008|Placebo Comparator|Placebo|Subjects in this group will be conducted to a placebo thoracic mobilization, without anaerobic exercise protocol. The investigator will apply only a manual contact, to mimic the genuine thoracic mobilization. The same 5 minutes period will be respected, and the same position of therapist and subject.
2553457|NCT02542670||Cancer colon with no distant metastasis|Genetic: Whole genome Sequencing
2553461|NCT02542670||Cancer colon with distant metastases|Genetic: Whole genome Sequencing
2553464|NCT02542670||control group|Genetic: Whole genome Sequencing
2553502|NCT02542345|Experimental|magnetic resonance imaging|
2553563|NCT02542085|Active Comparator|laparoscopic repair|patients who are randomized to have a laparoscopic mesh repair
2553565|NCT02542085|Active Comparator|hybrid repair|patients who are randomized to have a laparoscopic mesh repair and fascial closure
2553745|NCT02540785|Experimental|lenticule extraction|The patients in this group chose to receive the lenticule extraction surgery.
2553747|NCT02540785|Experimental|small-incision lenticule extraction|The patients in this group chose to receive the small-incision lenticule extraction surgery.
2553809|NCT02540278|Experimental|Treatment|Received the 11 lesson Positive Prevention Curriculum
2553811|NCT02540278|No Intervention|Control|Did not receive any sex-related instruction
2553847|NCT02540031|Experimental|Additional oral preparation|"The investigational or experimental arm will receive standard oral preparation plus additional oral preparation (1l of polyethylene glycol (PEG)+ascorbic acid (Asc)) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
2553854|NCT02540031|Active Comparator|Standard oral preparation|"The control arm will receive currently used oral preparation (2L of polyethylene glycol+ascorbic acid) for colonoscopy.~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
2553937|NCT02539446|Other|stable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
2553940|NCT02539446|Other|unstable condition & attentional focus|for measure the relationships between task difficulty and attentional focus on supraposture
2553967|NCT02539069|Experimental|Chondron Implantation|Chondron Implantation for the suject with cartilage defect through arthroscopy
3171024|NCT00581620|Active Comparator|G3|G3: neprotic symdrome
3171025|NCT00581620|Active Comparator|G4|G4: Chronic pulmonary disease
3171026|NCT00581633|Experimental|1|saline infusion for sodium loading
3171027|NCT00581646||1|gynecologic cancer survivors
3171028|NCT00581646||2|survivors of any type of malignancy with history of BMT/SCT
2554236|NCT02537899|Other|Treatment|NeuroAiD
2554258|NCT02537275|Experimental|wearing contact lense group|normal subjects after wearing tinted/normal contact lenses
2554281|NCT02537158|Experimental|sorafenib group|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
2554283|NCT02537158|Experimental|TACE group|TACE group patients will accept TACE therapy once at a month after resection.
2554288|NCT02537158|No Intervention|control group|Control group patients will not accept any intervention,except necessary supportive treatment.
3171029|NCT00581646||3|non-cancer infertile women awaiting third party reproduction
3171030|NCT00581659||Lens A, Lens B|The first independent variable is the contact lens. Each subject will wear both PureVision (TM0 aspheric contact lenses and conventional spherical contact lenses on separate visits. The second independent variable is visibility condition. Subjects will complete the study drive both in clear nighttime conditions and at night under glare conditions. In both cases, the driver will experience oncoming traffic; however, in the glare condition, the simulator will be equipped with a point light source sufficient to provide glare similar to that provided by oncoming traffic in the real world.
3171031|NCT00581672||questionnaires|Black men with prostate cancer
3171032|NCT00581685|Placebo Comparator|2|Prospective, single center, randomized, double-blinded, placebo controlled study
3171033|NCT00581698||Surgical|Patients with primary melanomas Clark III and Breslow thickness > 1 mm, or Clark IV-V and any Breslow thickness, and clinically negative regional nodes
3171034|NCT00581711|No Intervention|Control|Usual Care
3171035|NCT00581711|Experimental|HIT Intervention without feedback|3-Part Intervention: Training, Otitis Media Episode Grouper, Clinical Decision Support
3171036|NCT00581711|Experimental|HIT Intervention with feedback|4-Part Intervention: Training, Episode Grouper, Clinical Decision Support, and Physician Feedback.
3171037|NCT00581711|Experimental|Feedback only|1 part intervention: Physician Feedback
3174292|NCT00621894|Experimental|LGD4665|LGD-4665: Experimental Thrombopoietin mimetic
3174293|NCT00621894|Placebo Comparator|Placebo|Placebo
3174294|NCT00621907|Experimental|1|patient who received levobupivacaïne
2553155|NCT02544516|Active Comparator|control group|healthy patients who will perform cognitive tasks
2553214|NCT02544243|Experimental|A|Vinorelbine 25 mg/m2 d1, 8; Gemcitabine 1000 mg/m2 d1, 8 q 3 weeks
2553216|NCT02544243|Experimental|B|Vinorelbine 25 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1,2,3 q 3 weeks
2553257|NCT02543866|Experimental|Fecal Microbiota Transplantation|Subjects will receive 50mL of prepared stool fecal via nasogastric tube
2553309|NCT02543619|Active Comparator|Gow-Gates injection|An injection technique for infra alveolar nerve anesthesia
2553311|NCT02543619|Active Comparator|Infra alveolar nerve block injection|An injection technique for infra alveolar nerve anesthesia
3204971|NCT00939068|Other|Control|The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
3204972|NCT00939081|Active Comparator|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
3204973|NCT00939081|Experimental|Adaptive recommendation|The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
3204974|NCT00939133|Active Comparator|Tretinoin microsphere 0.04% gel|
3204975|NCT00939133|Placebo Comparator|Vehicle gel|
3204976|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
3204977|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
2553713|NCT02541006|Experimental|Tiotropium 18 mcg dry powder for inhalation|Tiotropium 18 mcg dry powder for inhalation, one inhalation, once daily with the DISCAIR
2553717|NCT02541006|Active Comparator|SPIRIVA 18 mcg HANDIHALER|Tiotropium 18 mcg dry powder capsul for inhalation one capsule once daily with the HandiHaler
2553766|NCT02540694|Active Comparator|EBUS-TBNA using 22G needle|EBUS-TBNA using 22G needle (transbronchial route)
2553768|NCT02540694|Active Comparator|EBUS-TBNA using 25G ProCore needle|EBUS-TBNA using 25G ProCore needle (transbronchial route)
2553769|NCT02540694|Active Comparator|EUS-B-FNA using 22G needle|EUS-B-FNA using 22G needle (transoesophageal route)
2553771|NCT02540694|Active Comparator|EUS-B-FNA using 25G ProCOre needle|EUS-B-FNA using 25G ProCOre needle (transoesophageal route)
3204978|NCT00939172|Experimental|TTP607|
2553933|NCT02539485|Other|heating precondition|The mean maximum sealing pressure, gas leakage, gastric distension, postoperative sore throat and other complication were compared between heating precondition group and control group.
3204979|NCT00939224||Cohort Phase 1|Cardiac Catheterization
3204980|NCT00939237|Experimental|Active Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
3204981|NCT00939237|Placebo Comparator|Placebo|placebo dietary supplement supplied as one capsule taken daily
3204982|NCT00939250|Experimental|Diabetes and depression intervention|Measurement based care for diabetes and depression, disease self management for diabetes and depression
2554121|NCT02538224|Active Comparator|experimental(case): group A|Group A: 2.5%ketoprofen gel + 3 % doxycycline gel which(0.05cc,mixed gel) be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
2554127|NCT02538224|Sham Comparator|control: group B|Group B: 2.5%ketoprofen gel which (0.05cc,gel)be put into the periodontal pocket using an insulin syringe;For every 15 days within 3 months .
3204983|NCT00939250|Active Comparator|Diabetes intervention|Measurement based care for diabetes, disease self management for diabetes
3204984|NCT00939263||1|cohorts 1 (item weighting phase): 100 children with Eosinophilic Esophagitis, 150 adults with Eosinophilic Esophagitis
2554245|NCT02537561|Experimental|Arm 1: Cisplatin, Gemcitabine, Talazoparib Solid Tumors|"Dose levels of the drugs will be dependent on which dose level the participants is enrolled.~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
2554247|NCT02537561|Experimental|Arm 2: Cisplatin, Gemcitabine, Talazoparib NSCLC|"Dose levels of the drugs will depend on what the MTD is in the dose escalation portion of the study~Cisplatin will be infused as a 30 minute intravenous piggyback (IVPB) on Day 1 of each 21 day cycle.~Gemcitabine will be infused as a 30 minute IVPB on Days 1 and 8 of each 21 day cycle. On day 1, gemcitabine will be given before cisplatin.~Talazoparib will be started with cycle 2. It is an oral drug which will be administered on an outpatient basis daily.~Cisplatin and gemcitabine will be given for a total of 6 cycles.~Talazoparib may be continued as a single agent maintenance therapy."
2554307|NCT02537145||Obese pregnant women|20 obese pregnant women (BMI ≥ 30)
2554310|NCT02537145||Lean pregnant women|20 lean pregnant women (BMI 18,5 - 25)
3204985|NCT00939263||2|cohorts 2 (evaluation phase): 200 children with Eosinophilic Esophagitis, 200 adults with Eosinophilic Esophagitis
3204986|NCT00939276|Experimental|NEVANAC|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
3204987|NCT00939276|Placebo Comparator|Nepafenac Vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
3204988|NCT00939289||Adults with T1DM|Adults (18+ years-old) diagnosed with type 1 diabetes mellitus; treated with multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy
3208776|NCT00977951|Placebo Comparator|Placebo (vehicle)|
2553179|NCT02544347|Other|Control group|gingival crevicular fluid was collected
2553181|NCT02544347|Other|diabetics with chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
2553184|NCT02544347|Other|chronic periodontitis group|non-surgical periodontal treatment was completed and gingival crevicular fluid was collected
2553223|NCT02544061|Experimental|NM-IL-12 plus Standard of Care (SOC)|"Single 12 µg unit subcutaneous dose of NM-IL-12 plus SOC.~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
2553226|NCT02544061|Placebo Comparator|Placebo plus SOC|"Single subcutaneous dose of placebo plus SOC~Standard wound management: wet to dry dressing care and perioperative antimicrobial therapy"
2553280|NCT02543788|Other|patients|patients with chronic optic neuropathy in multiple sclerosis
2553285|NCT02543788|Other|Controls|healthy volunteers
2553342|NCT02543541|Active Comparator|Standard Supportive Care|
2553347|NCT02543541|Experimental|Structured Supportive Care|
3204989|NCT00939380|Experimental|P-SCIP|Arm I (Parent Social-Cognitive Intervention Program [P-SCIP]): Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns. Participants receive a laptop computer and a CD-ROM after the first session.
3204990|NCT00939380|Experimental|BPC|"Arm II (Best-recommended Psychosocial Care [BPC]): Participants undergo usual care and receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD, and 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks."
2553498|NCT02542488||Pregnant women with BMI >39 at booking|All women will receive routine care and in addition will complete the 8 question STOPBANG screening tool, an Epworth sleepiness scale and have overnight oximetry recorded.
2553562|NCT02542111|Experimental|V-GDP|Bortezomib 1.6 mg/m2/d iv d1 and d8 Gemcitabine 1000mg/m2/d iv d1 and d8 Dexamethasone 40mg/d iv d1-4 cisplatin 25 mg/m2 iv d2-4 Frequency every 28 days Total cycles 4
3204991|NCT00939406|No Intervention|Control|Control group consists of subjects randomized to the control arm who will receive lumbar decompression surgery (laminotomy or laminectomy) alone
2553897|NCT02539706|Experimental|Follıcular group|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
2553898|NCT02539706|Active Comparator|Luteal group|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied.
2553929|NCT02539355|Active Comparator|Diet A|Standard Healthy Diet (Diet A)
2553932|NCT02539355|Experimental|Diet B|Alternative Test Diet (Diet B)
2553971|NCT02539121|Experimental|Acupuncture|In the intervention group with real acupuncture, after the umbilical cord is clamped, the acupuncturist disinfects the abdominal area with antiseptic and pricks the needle in the point Ren Mai 6. This point is located on the anterior midline, between the umbilicus and the upper part of the pubic symphysis, at a distance of 0.3d from the umbilicus, being d the distance from the umbilicus to the upper part of the pubic symphysis. A sterilized steel needle of 0.25x40 mm is inserted in this point at 15-30 mm, depending on the adipose tissue of the woman. After that, the needle is covered with a opaque plastic cup and the cup is fixed with the adhesive tape.
2553972|NCT02539121|Placebo Comparator|Control|In the control group the puncture of the Ren Mai 6 is not performed, the acupuncturist disinfects the abdominal area with antiseptic and put the needle in the area of Ren Mai 6 without puncturing, after that, the needle is fixed but not punctured, and it is covered with a opaque plastic cup fixed with adhesive tape, guaranteeing that neither the mother nor the midwife responsible of measuring the variables can identify the assigned group.
2554007|NCT02538861|Active Comparator|ARM-A|Arm-A patients will receive the standard of care diagnostic test at Baptist Hospital, which includes SPECT imaging
2554010|NCT02538861|Active Comparator|ARM-B (Group-1)|Group-1 will receive CT Angiography and CT myocardial perfusion with new Revolution CT scanner.
2554012|NCT02538861|Active Comparator|ARM-B (Group-2)|The Group-2 of arm B will receive SPECT imaging test.
3204992|NCT00939406|Experimental|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
2554194|NCT02537834|Experimental|Tofogliflozin ＋GLP-1 analogue|Tofogliflozin administered once daily for 52 weeks. GLP-1 analogue administered as base treatment.
3204993|NCT00939419|Other|Health worker TB care group|
3204994|NCT00939419|Other|Community health worker TB care group|
3204995|NCT00939419|Other|Self-administered treatment group|
3204996|NCT00939432||Gender|male/female
2554350|NCT02536521||Hemodynamically stable|
2554352|NCT02536521||Hemodynamically unstable|Hemodynamically unstable patients are defined as those with a 20% decrease in systolic blood pressure according to the change of intraabdominal pressure.
2554476|NCT02535845|Experimental|Self-persuasion group|HPV information plus self-persuasion intervention in a tablet-based application (Project Voice)
2554481|NCT02535845|Active Comparator|Information only group|HPV information only in a tablet-based application (HPV Informational Video)
3204997|NCT00939432||Age|18-100 years
3204998|NCT00939432||Educational level|primary school, secondary school, university
3204999|NCT00939445|Active Comparator|Online HDF|Online HDF
3205000|NCT00939445|Active Comparator|Short Daily Hemodialysis|Short Daily Hemodialysis
2553238|NCT02544087|Experimental|Clearing heat&Promoting blood circulaton|Treat with both KDZ injection and Xueshuantong injection on the basis of basic treatment
2553269|NCT02543684|Experimental|ready to eat mixed meal 1|
2553273|NCT02543684|Experimental|ready to eat mixed meal 2|
2553276|NCT02543684|Experimental|ready to eat mixed meal 3|
2553282|NCT02543684|Experimental|oral glucose load|
2553333|NCT02543450|Experimental|Cardiovascular/task-oriented training|8 cardiovascular exercises at moderate intensity, interrupted by 1-minute active breaks of task-oriented exercises.
2553334|NCT02543450|Active Comparator|Upper limb strength training program|Nine 5-minute station circuit session. Patients work 2+2 minutes in each exercise, with a 30-second rest between the 2-minute periods and between stations.
2553395|NCT02543307|Experimental|Nurse-led Patient Pathways|Patients were cared for under the three NPP developed for the orthopedic populations: NPP-1) patients with total hip arthroplasty; NPP-2) exploration and decompression of the spinal cord; and NPP-3) rotator cuff reconstruction. NPP are characterized by four principles: evidence-based nursing, patient and family centred care, comprehensive discharge planning beyond hospital discharge and nurses' responsibility for patients' processes. The principles support and strengthen patient and family preferences as well as formalize nursing activities, and therefore contribute to process transparency in relation to other health care professionals. Aims: to improve patients' and health care professionals' as well as institutional outcomes.
2553396|NCT02543307|No Intervention|Standard usual nursing care|Patients in the control group will receive usual nursing care, which is based on the institutional principles and standards of care for surgical patients. Based on the type of surgery and assessment of the nurse the nursing process is used to care for the patients. The nurses will be ending their activities with discharge of the patients.
3205001|NCT00939549|Experimental|High-dose cyclohosphamide|
3205002|NCT00939575||Preeclampsia|Women hospitalized for pre-eclampsia after 20 0/7 weeks of gestation. The diagnosis of preeclampsia include a combination of the following criteria: after 20 weeks of gestation in a previously normotensive woman, a diastolic blood pressure > 90 mmHg recorded twice at least four hours apart or > 110 mmHg, with proteinuria > 300 mg/24h or > 30 mg / mmol protein / urinary creatinine in a urine sample or factor (s) serious maternal / fetal (according to SOGC consensus ).
2553542|NCT02542137|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
3208777|NCT00977964|Experimental|Milk Based Protein Formula Process A|
2553664|NCT02541461|Other|Non-Obese|Patients who underwent laparoscopic gastrectomy and with BMI < 25 kg/m2
2553667|NCT02541461|Other|Obese|Patients who underwent laparoscopic gastrectomy and with BMI ≥ 25 kg/m2
3208778|NCT00977964|Experimental|Milk Based Protein Formula Process B|
3208779|NCT00977964|Experimental|Milk Based Protein Formula Process C|
2554650|NCT02534740|Experimental|4 soft gel capsules of 20 mg tafamidis meglumine|
2554651|NCT02534740|Experimental|48.8 mg tafamidis soft gel capsule formulation 1|
2554652|NCT02534740|Experimental|48.8 mg tafamidis soft get capsule formulation 2|
2554653|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 1|
2554655|NCT02534740|Experimental|61 mg tafamidis soft gel capsule formulation 2|
2554728|NCT02534402|Experimental|Prednisone Group|30mg of prednisone PO (orally) everyday for 5 days.
2554732|NCT02534402|No Intervention|Control Group|no treatment
2554792|NCT02533856|No Intervention|Usual Care|Discharge from emergency department by usual care
2554795|NCT02533856|Experimental|ETOC|Discharge from emergency department with increased support services provided by BoardRounds after ED discharge
2554821|NCT02533557|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
2554829|NCT02533557|Active Comparator|1P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced with a direction of upward at the same puncture site and penetrated the nerve sheath. If hand muscle twitching is observed at 0.3 mA, LA 15 mL is injected.
2554865|NCT02533102|Experimental|Part A: E7050 100 mg tablet under fasted conditions|Participants will receive a single tablet containing 100 mg E7050 following an overnight fast.
2554866|NCT02533102|Experimental|Part A: E7050 100 mg tablet with low-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard low-fat meal.
2554867|NCT02533102|Experimental|Part A: E7050 100 mg tablet with high-fat breakfast|Participants will receive a single tablet containing 100 mg E7050 with a standard high-fat meal.
2554868|NCT02533102|Experimental|Part B: E7050 200 mg tablet under fasted conditions|Participants will receive a single dose of 200 mg (two 100 mg tablets) of E7050 under fasted conditions.
2554869|NCT02533102|Experimental|Part B: E7050 400 mg tablet under fasted conditions|Participants will receive a single dose of 400 mg (four 100 mg tablets) of E7050 under fasted conditions.
2554924|NCT02532894|Experimental|Esmoke|Inhaling e-cigarette vapor
2554925|NCT02532894|No Intervention|Control|
2555002|NCT02532608|Experimental|Acute sleep deprivation|Registration of habitual sleep and sleep after sleep deprivation
2555062|NCT02532140|Experimental|WCK 5107|A single administration of the investigational product will be administered intravenously in 7 SAD cohorts at different dose level . The SAD cohorts will enroll 10 subjects ( 8 on active drug and 2 on placebo)
3208780|NCT00977964|Experimental|Milk Based Protein Formula Process D|
2553261|NCT02543879|Experimental|Dose Expansion FT-1101|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 3 Expansion cohorts of up to 20 patients each will be treated with the RP2D of FT-1101
2553262|NCT02543879|Experimental|Dose Escalation FT-1101 + azacitidine|Following a 3+3 dose escalation strategy, the first cohort of AML/MDS patients will be administered FT-1101 at approximately 50% or lower than the MTD identified for the single agent FT-1101. Subsequent cohorts dose will be determined by investigators and sponsor following observations of previous cohorts. Dose escalation will not exceed the dose determined to be the single agent MTD for that schedule.
2553263|NCT02543879|Experimental|Dose Expansion FT-1101 + azacitidine|Once the MTD is determined, the Recommended Phase 2 Dose (RP2D) will be identified. 1 Expansion cohorts of up to 20 AML/MDS patients each will be treated with the RP2D of FT-1101 in combination with azacitidine.
2553337|NCT02543463|Other|With Navigation system|Large diameter head with Trident X3 insert with Navigation system
2553340|NCT02543463|Other|Without Navigation system|Large diameter head with Trident X3 insert with conventional instrumentation
2553416|NCT02543268|Experimental|Group 1|Ad26.ZEBOV -Batch #1, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
2553419|NCT02543268|Experimental|Group 2|Ad26.ZEBOV -Batch #2, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
2553422|NCT02543268|Experimental|Group 3|Ad26.ZEBOV -Batch #3, single dose intramuscular (IM) injection on Day 1; MVA-BN-Filo, single dose IM injection on Day 57
2553424|NCT02543268|Experimental|Group 4|Placebo (0.9% saline)- single dose IM injection on Day 1 and Day 57
2553467|NCT02542553|Experimental|Bilateral BAL|Bronchoscopies are performed in strict accordance with consensus guidelines. The left or right lung is examined with a flexible fiberoptic bronchoscope. If localized infiltrates are present on the chest radiograph, the tip of the scope is wedged into a subsegment of the area displaying the most marked opacity. In the presence of diffuse opacity or when no clear roentgenographic abnormalities are observed, the tip is positioned in the lingula or right middle lobe. Five 20-ml aliquots of sterile normal saline are then injected and reaspirated with a syringe. Bronchoscopy is then repeated in the same manner in the contralateral lung with a second, sterile bronchoscope of the same brand and model.
3205003|NCT00939575||control|Women will be matched to women with pre-eclampsia according to gestational age at diagnosis of preeclampsia, maternal age (in stratum of 5 years), gender, ethnicity (4 categories: Caucasian, black, Asian and other) and body mass index (5 classes: <20, 20-25, 26-30, 31-35 and <35). Patients of this group should be at low risk of obstetric complications at recruitment and planning to deliver at the CHUS.
2553574|NCT02541877|Experimental|Down sizing valve in type-0 BAS|Down Sizing Transcatheter Self-expandable Valve in Type-0 BAS
2553577|NCT02541877|Active Comparator|Standard sizing valve in type-0 BAS|Standard Sizing Transcatheter Self-expandable Valve in Type-0 BAS
2553579|NCT02541877|Active Comparator|Standard sizing valve in TAS|Standard Sizing Transcatheter Self-expandable Valve in TAS
2553613|NCT02541526|Experimental|mirtazapine|30 mg mirtazepine will be given to patients on day 6 of their treatment for a period pf 3 days to observe for tolerability followed by 60 mg from day 9 of treatment until the end of the study (16 weeks).
2553614|NCT02541526|Placebo Comparator|Placebo|matched placebo mirtazapine capsules will be given to patients in this group
2553711|NCT02541201|Experimental|Plant sterols-enriched low-fat milk|Daily consumption of 1.5g of plant sterols as provided by two servings of 273 ml of plant sterols-enriched low-fat milk for consecutive 3 weeks, each serving taken right before breakfast and lunch.
2553714|NCT02541201|Placebo Comparator|Low-fat milk|Daily consumption of two servings of 273 ml of low-fat milk (without plant sterols) for consecutive 3 weeks, each serving taken right before breakfast and lunch.
2553770|NCT02540655|Experimental|Stemchymal®|Infusion of Stemchymal®
2553773|NCT02540655|Placebo Comparator|Vehicle|Infusion of excipients
3205004|NCT00939588|Experimental|Aliskiren and Valsartan|
3205005|NCT00939588|Active Comparator|Telmisartan and Ramipril|
2553919|NCT02539576|Experimental|ABC/DTG/3TC FDC|Each subject will receive treatment with a single oral dose of ABC 600 mg/DTG 50 mg/3TC 300 mg FDC tablet administered under the fasted state
2553957|NCT02539251||Validation of Arabic ASQ-3|This group of patients will serve as a reference for validation of the Arabic ASQ-3
2554020|NCT02538939|Experimental|Injection of sodium thiosulfate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sodium thiosulfate
2554076|NCT02538562||Study Population|Available tumor samples from patients with gastric or gastroesophageal junction cancer will be analyzed. No study visits or interventions are planned.
2554137|NCT02538250|Experimental|1 Nutricomp Drink Plus|Nutricomp Drink Plus
2554169|NCT02538081|Active Comparator|Risperidone plus placebo|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus placebo
2554173|NCT02538081|Active Comparator|Risperidone plus DMXB-A|Risperidone titrated to a dose equivalency of the patients' prior dose of olanzapine plus DMXB-A
2554197|NCT02537665|Other|incidence of bleeding|the effect of the epidural catheter filled with heated or normal saline before inserting into epidural on the incidence of bleeding.
2554199|NCT02537665|Placebo Comparator|inserting time of catheter|record the time from beginning of catheter inserting to completing the placement of the catheter.
2554269|NCT02537483|Experimental|IDP-120 Gel|IDP-120 Gel, applied topically to the face once daily for 12 weeks.
2554270|NCT02537483|Active Comparator|IDP-120 Component A|IDP-120 Component A, applied topically to the face once daily for 12 weeks
2554271|NCT02537483|Active Comparator|IDP-120 Component B|IDP-120 Component B, applied topically to the face once daily for 12 weeks
2554272|NCT02537483|Placebo Comparator|IDP-120 Vehicle Gel|IDP-120 Vehicle Gel, applied topically to the face once daily for 12 weeks
2554326|NCT02537028|Experimental|MSC2364447C 25 mg|
2554327|NCT02537028|Experimental|MSC2364447C 75 mg|
3205006|NCT00939601|Active Comparator|Motivational Enhancement Therapy|MET will involve counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
3205007|NCT00939601|Active Comparator|Educational Counseling|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
3205008|NCT00939601|No Intervention|Standard Care|
3205009|NCT00939666|Experimental|Wait&see or TEM with intensive follow-up|All patients will be included in this arm
2553362|NCT02543333||Asthma|Patients attending outpatient clinic as part of their clinical care who have FEV1 less than 80% of predicted and are referred by their clinician for a bronchodilator test
2553364|NCT02543333||Acute Asthma|Inpatients admitted for an acute asthma exacerbation
2553368|NCT02543333||Normal|Participants with no current or previous diagnosis of a respiratory condition
2553387|NCT02543125|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O,R:30 per minute .
2553393|NCT02543125|Active Comparator|NHFOV|NHFOV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,MAP：6-14 cm H2O,Hertz(HZ):5-10 to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP)<6cm H2O.
2553442|NCT02542904|Active Comparator|LME|the anastomosis was performed as stapled side-to-side with local excision of the mesenteric tissue adjacent to the diseased bowel
2553444|NCT02542904|Active Comparator|EME|the anastomosis was performed as a stapled side-to-side anastomosis with extensive excision of mesenteric tissue.
2553474|NCT02542592|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
2553480|NCT02542592|Placebo Comparator|Placebo|Preoperative single dose of isotonic Sodium Chloride
2553518|NCT02542306|Experimental|fibrinogen concentrate-treated group|The initial fibrinogen concentrate dose was 25 - 50 mg/kg, but additional fibrinogen concentrate was administered repeatedly if the first infusion of fibrinogen concentrate did not increase the fibrinogen level over 2.0 g/L.
2553526|NCT02542306|No Intervention|non-fibrinogen concentrate-treated group|The participants who did not received fibrinogen concentrate treatment were enrolled as the non-fibrinogen concentrate-treated group
2553550|NCT02541955|Active Comparator|40 Units|40 units of Acthar per week
2553551|NCT02541955|Active Comparator|80 Units|80 units of Acthar twice per week
2553600|NCT02541721|Experimental|LabiaStick#01|Each participant will have an at least 2-week baseline period followed by a 4-week treatment period with LabiaStick#01.
2553640|NCT02541305|Active Comparator|Cotrol|No propioceptive program.
2553651|NCT02541305|Experimental|Experimental|Propioceptive program
2553710|NCT02541097|Active Comparator|Language therapy-Individual treatment|Participants will receive intervention for naming impairment based on either phonological or semantic cues.
2553716|NCT02541097|Active Comparator|Language therapy-Group treatment|Following the individual therapy, participants will be randomly assigned to either verbal or non-verbal group
3205010|NCT00939679|Experimental|Earlier gastric bypass surgery (7 weeks)|These patients will undergo gastric bypass surgery 7 weeks after starting a low calorie diet, and will continue the low calorie diet for 3 weeks following surgery.
3205011|NCT00939679|Active Comparator|Later gastric bypass surgery (10 weeks)|These patients will undergo gastric bypass surgery 10 weeks after starting a low calorie diet.
3205012|NCT00939718|Active Comparator|Vitamin B12 with antidepressants|Subjects in this arm will receive vitamin B12 supplement (injectable)along with their routine antidepressant treatment as prescribed by their primary physicians. subjects will be blind to their arm allocation and will receive injections in a concealed manner with injection vials covered with foil.
2553907|NCT02539680|Experimental|normal renal function|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
2553909|NCT02539680|Experimental|CKD stage 3-5 (not on dialysis)|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
2553911|NCT02539680|Experimental|on dialysis|Evaluation of the expression level of phosphate transporters at the mRNA and, if possible, on the protein level.
2553965|NCT02539303|Experimental|Intervention|Infusion of Yamani-15/5 chemical solution.
2554014|NCT02538913|Experimental|Exercise training|Patients randomized to the exercise training group will be individually instructed in correct pelvic floor muscle contractions and intensive pelvic floor muscle training to perform daily. In addition they will be encouraged to exercise regularly ≥3 days/week. The exercise program will be individualized and consisting of both aerobic and strength exercise training.
2554022|NCT02538913|Active Comparator|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
3205013|NCT00939718|Placebo Comparator|Placebo injections dextrose water|Subjects in this arm will receive placebo injections which will contain only dextrose water. They will also receive 6 injections on a weekly basis and the injection vials will be covered with foil to ensure masking.
3205014|NCT00939744||EAU2|Women who will have a c-section at the CHUS
2554210|NCT02537795||Deep Brain Stimulation Patients|Patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
2554215|NCT02537795||Deep Brain Stimulation Family Members|Family members of patients who have previously been treated with a deep brain stimulation procedure for obsessive compulsive disorder will be included in this group
2554218|NCT02537795||Anterior Capsulotomy Patients|Patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
2554220|NCT02537795||Anterior Capsulotomy Family Members|Family members of patients who have previously been treated with an anterior capsulotomy procedure for obsessive compulsive disorder will be included in this group
2554259|NCT02537379||SOF+COPE|Adult patients with genotype 2 chronic HCV infection with or without compensated cirrhosis who take SOF+COPE as part of routine clinical care at a participating clinical site.
2554374|NCT02536716|Active Comparator|Platform-matched dental implant|Platform-matched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
2554380|NCT02536716|Experimental|Platform-switched dental implant|Platform-switched dental implant placement to measure marginal bone loss, gingival margin position, and papilla fill.
2554424|NCT02536235|Experimental|Intervention: intraoperative topical heat|
2553297|NCT02543632||Control group|Subjects who meet the inclusion/exclusion criteria listed and also are are excluded for treatment with the Parachute Implant System due to anatomical characteristics such as obstructing pseudochordae, calcification, or wall thickness.
2553360|NCT02543372|Experimental|Behavioral Couples Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. Both the gamblers and the CSOs receive 10 modules each.
2553363|NCT02543372|Active Comparator|Cognitive Behavioral Therapy|The participants receive 10 modules each containing treatment focusing on gambling and relationship functioning. The modules consist of text, videos, images and assignments. The participants receive support from an assigned therapist via email and telephone. The gamblers receive 10 modules, but the CSOs do not receive any modules.
2553386|NCT02543099|Experimental|policosanol|Patients will receive policosanol 20mg daily until the end of the trial.
2553390|NCT02543099|Placebo Comparator|placebo|Patients will receive placebo 20mg daily until the end of the trial;
2553446|NCT02542852|Experimental|Open label single arm|Introduction of treatment regimen with atazanavir 300mg qd + ritonavir 100mg qd + dolutegravir 50mg qd
2553491|NCT02542540|Experimental|OI Children training with Nintendo Wii console|Training for 3 months using the Nintendo Wii console on physical capacity in a group of children with Osteogenesis Imperfecta
2553496|NCT02542540|No Intervention|Children with OI without training|No training
2553503|NCT02542241|Experimental|Sodium Chloride [3%]|
2553506|NCT02542241|Active Comparator|Sodium Chloride [0.9%]|
2553585|NCT02541786|Active Comparator|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
2553587|NCT02541786|Experimental|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
2553609|NCT02541448|Active Comparator|AIS at 9±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 9±1mmHg
2553611|NCT02541448|Active Comparator|AIS at 15±1mmHg|Use of the SurgiQuest AIRSEAL® Insufflation System (AIS) at 15±1mmHg.
2553688|NCT02541240|Experimental|Resilience Curriculum|The intervention is exposure to an 8-hour Resilience Curriculum. It will provide education for participants about methods to increase protective factors against stress, the use of effective coping strategies, and the importance of accessing social support, with the goal of better managing stress and enhancing resilience. The curriculum will include a didactic component, skills-building training, and homework exercises to encourage the application of the skills.
2553690|NCT02541240|No Intervention|No Resilience Curriculum|The Waitlist Control group will receive no exposure to the Resilience Curriculum. After the final data is collected, this group will be offered the opportunity to attend a condensed 2-hour version of the curriculum.
2553729|NCT02540759|Placebo Comparator|High oleic sunflower oil (HOSO)|10 ml HOSO/day in a single dose, 28 days
2553730|NCT02540759|Experimental|High dose Buglossoides oil|10 ml Buglossoides oil/day in a single dose, 28 days
2553731|NCT02540759|Experimental|Medium dose Buglossoides oil|6 ml Buglossoides oil + 4 ml HOSO/day in a single dose, 28 days
2553732|NCT02540759|Experimental|Low dose Buglossoides oil|3 ml Buglossoides oil + 7 ml HOSO/day in a single dose, 28 days
2553780|NCT02540525|Experimental|Single incision mini-sling|Experimental group: surgery to treat stress urinary incontinence with the Ophira mini sling systemt®
2553783|NCT02540525|Active Comparator|Transobturator sling|Control group: surgery to treat stress urinary incontinence with the Unitape T Plus®.
2553819|NCT02540135|Experimental|Arm A|Flourescein plus intraoperative MRI
2553826|NCT02540135|Active Comparator|Arm B|intraoperative MRI alone
2553886|NCT02539875|Experimental|AWARD, Brief leaflet, Referral leaflet, active referral|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation. A 2-side color printed A4 referral leaflet will be used for motivate and assist the smokers to use the smoking cessation services. the smokers will be active refer to various smoking cessation services in Hong Kong (using the referral leaflet) and motivate the smokers to use the smoking cessation services.
2553888|NCT02539875|Experimental|AWARD, Brief leaflet|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit as soon as possible and not later than a quit date (which will qualify them for the QTW prizes), Refer smokers to smoking cessation services, and Do it again: to repeat the intervention. Brief innovative leaflet on health warning and smoking cessation. A 2-side color printed A4 leaflet will be designed to systematically cover the most important messages to motivate smoking cessation.
2553891|NCT02539875|Active Comparator|Smoking cessation booklet, general advices|"Participants will receive minimal intervention, including: (1) the 12-page smoking cessation booklet (provided by COSH); (2) very brief, minimal and general smoking cessation advice include: Please quit smoking for improving health and save money, Please refer to the booklet for the details about smoking cessation and Please call us if you have any enquiry."
2553925|NCT02539433|Experimental|F-18-F-DOPA i.v.|F-18-F-DOPA i.v. one injection of a dose of up to 8.5 mCi (millicurie). Standard PET scanning started 60-90 minutes post injection.
2553993|NCT02539147||patients with severe sepsis|blood samples from patients with severe sepsis
2554048|NCT02538718|Active Comparator|YTP(ritodrine) arm|who randomly assigned to have Yutopar(ritodrine) as tocolytics
2554052|NCT02538718|Experimental|MgSO4 arm|who were randomised to have MgSO4 as tocolytics
2554098|NCT02538458|Active Comparator|Test group|3 % hypertonic saline up to 72H.
2554102|NCT02538458|Placebo Comparator|Placebo control group|"3 % hypertonic saline up to 24H.~Followed by 48 hours of placebo (nebulized 0.9% normal saline)."
3205015|NCT00939757|Experimental|1. mirabegron, lower dose|
3205016|NCT00939757|Experimental|2. mirabegron, higher dose|
3208781|NCT00977964|Experimental|Milk Based Protein Formula Process E|
3208782|NCT00977964|Experimental|Milk Based Protein Formula Process F|
3205017|NCT00939848|Experimental|B|The experimental arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with cediranib 20mg oral daily (continuous dosing).
3205018|NCT00939848|Placebo Comparator|Arm A|The control arm will consist of cisplatin 25 mg/m2 plus gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle with a matching placebo 20mg oral daily (continuous dosing)
3205019|NCT00939861|Experimental|1|laparoscopy
2553440|NCT02542930|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin;
2553473|NCT02542618|Experimental|Inquiry Based stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie. It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
2553479|NCT02542618|Active Comparator|Cognitive Behavioral Therapy (CBT)|CBT is a psychological treatment method, focusing on a structured way to identify and modify unhelpful thinking patterns, underlying assumptions and idiosyncratic cognitive schemes about the self, the world (including other people) and the future.
2553500|NCT02542319|Experimental|Magnesium|Oral Magnesium Hydroxide (Mablet 360 mg) twice daily for 12 months.
2553501|NCT02542319|Placebo Comparator|Placebo|Matching placebo tablets twice daily for 12 months.
2553580|NCT02541734|Experimental|gelofusine and 111In-exendin 4 SPECT/CT|subjects will receive a gelofusine injection before the injection of the radiopharmaceutical (111In-exendin 4)
2553582|NCT02541734|Placebo Comparator|saline and 111In-exendin 4 SPECT/CT|As a control, subjects will receive an injection of saline before the injection of the radiopharmaceutical (111In-exendin 4)
2553599|NCT02541513|Experimental|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for 3 days followed by an injection of Paliperidone 150 mg injection on Day 8
2553636|NCT02541357|No Intervention|Usual care|Does not receive a specific study intervention
2553638|NCT02541357|Experimental|preoperative relaxation program|preoperative relaxation program
2553642|NCT02541357|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
2553652|NCT02541357|Experimental|preop relaxation and surgery education|preoperative relaxation program AND single education unit
2553675|NCT02541058||Confirmed 22q.11.2 deletion/duplication|
2553681|NCT02541058||Suspected 22q.11.2 deletion/duplication|
2553709|NCT02540928|Experimental|AMG 319 Hydrate|Up to 36 patients will be randomised into the Active Treatment arm to receive AMG 319 400 mg once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
2553712|NCT02540928|Placebo Comparator|Placebo|Up to 18 patients will be randomised into the Placebo arm to receive Placebo once daily administered orally for a minimum of 20 days and a maximum of 29 days prior to resection surgery
3205020|NCT00939861|Experimental|2|laparotomy
3205021|NCT00939887|Experimental|Treatment|
2553822|NCT02540122|Active Comparator|Subject A (Neophytes)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
2553828|NCT02540122|Active Comparator|Subject B (Habitual Lens Wearers)|Subjects will wear the Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, and Marketed Contact Lens 4 for a 6-hour period in a bilateral and random fashion, with a washout period of one week between lenses. Each subject will randomly be assigned to one of four unique sequences of a 4 x 4 crossover design. A block size of two sequences will be used.
3205022|NCT00939913|Placebo Comparator|intravenous N-acetlycysteine|"intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo~Acetadote provided by Cumberland Pharmaceuticals Inc."
3205023|NCT00939913|Placebo Comparator|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
3205024|NCT00939939|Experimental|sitagliptin|
2553969|NCT02539238|Active Comparator|control|Annual BLS training
2553973|NCT02539238|Experimental|intervention|Brief CPR training dispersed over a year period of time with real-time feedback during working hour
2554050|NCT02538835|Experimental|Metacognitive Therapy|
2554054|NCT02538835|Active Comparator|Mindfulness based cognitive therapy|
2554058|NCT02538835|Placebo Comparator|Support groups|
2554103|NCT02538380|Experimental|EUS-B-FNA for LAG analysis|All patients will undergo a mediastinal nodal staging procedure with the EBUS scope (EBUS + EUS-B) (routine clinical care) followed by an evaluation of the LAG including LAG sampling (experimental). Subsequently, all patients undergo a conventional EUS procedure with sampling of the LAG (current standard of care)
2554164|NCT02538120|Active Comparator|Diabetes type 1 patients|The intervention will be : Microvascular assessment with laser speckle contrast imaging
2554165|NCT02538120|Active Comparator|Matched control-subjects|The intervention will be : Microvascular assessment with laser speckle contrast imaging
3205025|NCT00939939|Active Comparator|glimepirid|
2554280|NCT02537210|Active Comparator|Mesalazine|mesalazine 2g od po for 12 months
3205026|NCT00939978|Active Comparator|Venoferrum|
3205027|NCT00939978|Placebo Comparator|saline|
3205028|NCT00940004|Active Comparator|cytokine matured DC|vaccination with autologous dendritic cells matured with standard cytokine cocktail and electroporated with mRNA encoding tumor associated antigens
3205029|NCT00940004|Experimental|TLR ligand matured DC|vaccination with autologous TLR-ligand matured dendritic cells electroporated with mRNA encoding tumor associated antigens
3205030|NCT00940030|Experimental|MBP+enema|mechanical bowel preparation and enema
3205031|NCT00940030|Active Comparator|enema|
3205032|NCT00940043||Rupture of fetal membranes|women with rupture of fetal membranes before onset of labor
3205033|NCT00940056|Experimental|Endoscopic ablation of atrial fibrillation|
3205034|NCT00940056|Active Comparator|Rate control|
2553404|NCT02543086|Experimental|Multiple Sequential Cohort|"This study is divided in 2 parts (Part A and part B). Each participant in each of the cohorts will be inoculated with viable parasites of Plasmodium falciparum-infected human erythrocytes administered intravenously. For Part A & Part B, commencement of treatment will be determined by Quantitative-Polymerase Chain Reaction results.~The First cohort of Part A (A1) will be dosed with a single dose of KAE609. During Part A, an additional second single-dose of KAE609 may be tested (~15 days after first dose of KAE609 but may vary) if sexual parasitemia is identified. Subsequent cohorts of part A (An) will be dosed based on the results of first cohort (A1).~Subjects enrolled in Cohort B will receive a pre-treatment with Piperaquine followed by KAE609 (~15 days)."
2553519|NCT02542449|Active Comparator|Globes®|Partecipants received twice a day for 3 months Globes® (Pharmextracta, Pontenure, Piacenza, Italy) formulated to be enteric-coated and containing 150 mg/dose of Greenselect Phytosome® and pure piperine (15 mg/dose) from Piper nigrum L.
2553525|NCT02542449|Placebo Comparator|Placebo|Partecipants received twice a day for 3 months placebo (undistinguishable from Globes in terms of size, shape, taste, odor, primary and secondary packaging).
2553625|NCT02541474|Other|Integrated care|All patients fitting inclusion criteria will receive care from The Patient -centered health care team ( PACT ) which is a service model for frail elderly patients with multiple long term conditions.
2553628|NCT02541474|No Intervention|Usual care|All patients in the Control hospitals (Bodø and Narvik) that match the index patient from the intervention group, and who consents to participate in the study. Eligible patients receive an invitation to participate from the local study nurse. Included controls receive usual care in control hospital and municipalities. Data collection in intervention and control groups are the same.
2553679|NCT02541162|Experimental|INFORMED|"Interventional Group (I): Couples enrolled during the diagnosis will receive written information as usual about the disease and in addition they benefit special oral interviews and written information about experiences of their sexuality during the illness.The document used for the interventional group is Sexuality and Cancer and will be given to couples. (intervention: Oral information and interviews about sexuality and self experience during the disease). Qualitative analysis will be provided by a psychologist"
2553682|NCT02541162|No Intervention|ORDINARY USE|"Non-interventional Group (NI): Couples enrolled during the diagnosis will only receive written information about their experience of disease . The document used fot the non interventional group is Live during and after cancerand will be given to couples. Qualitative analysis will be provided by a psychologist"
2553718|NCT02540902|Experimental|All-poly|Knee arthroplasty with all-polyethylene tibia
3171038|NCT00581724||1|"First 50 breast cancer survivors and then after demonstrating feasibility of the study design in the first 50 participants, recruitment will be opened to the other services Colorectal, Genitourinary, Head and Neck, and Thoracic.~Participants will be recruited in allotments of 50 patients from each service."
3171039|NCT00581750||LCIS diagnosis|Patient with LCIS diagnosis
2553802|NCT02540343||acute neck pain patients|Participant recently received the diagnosis of neck pain (< 30 days) >18 years old able to speak, read and write German, questionnaires
2553804|NCT02540343||chronic neck apin patients|Participant has neck pain for a longer period of time (> 90 days) > 18 years old able to speak, read and write German, questionnaires
2553812|NCT02540343||test persons|no neck pain > 18 years old able to speak, read and write German, questionnaires
2553848|NCT02539979|Active Comparator|IV Paracetamol|Patients will receive 1gram of IV paracetamol mixed in 100ml infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
2553855|NCT02539979|Placebo Comparator|IV Placebo (Normal Saline)|Patients will receive 100ml of normal saline infused over 15 minutes. The patients will undergo radiofrequency lesioning of two consecutive levels of lumbar facets under fluoroscopic guidance
2553896|NCT02539745||primary open-angle glaucoma patients|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in primary open-angle glaucoma patients.
2553899|NCT02539745||randomly age-matched people|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay and vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis in randomly age-matched people.
2554334|NCT02536937|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
2554335|NCT02536937|Experimental|GZ385660 (subjects with mild renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
2554337|NCT02536937|Experimental|GZ385660 (subjects with moderate renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
2554339|NCT02536937|Experimental|GZ385660 (subjects with severe renal impairment)|Single dose of eliglustat tartrate will be given under fed conditions
2554377|NCT02536495|Experimental|Treatment (docetaxel, selinexor)|Patients receive docetaxel IV on day 1 and selinexor PO BID on days 1, 3, 7, 9, 13, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2554447|NCT02536157|Active Comparator|Dorsal block splint|Thermoplastic splint in 20 degrees flexion applied to the dorsum of the PIPJ.
2554448|NCT02536157|Experimental|Volar gutter splint|Thermoplastic splint in 0 degrees flexion applied to the volar surface of the finger.
2554486|NCT02535897|Placebo Comparator|CON|500 ml of flavoured water
2554488|NCT02535897|Active Comparator|CHO|500 ml of flavoured water containing 80 g carbohydrate
2554492|NCT02535897|Active Comparator|CHO-PRO|500 ml of flavoured water containing 40 g carbohydrate and 40 g whey protein
2554527|NCT02535585|Active Comparator|knotted anchors|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
2554912|NCT02532920||Atopic dermatitis|Atopic dermatitis is diagnosis as Hanifin and Rajka from physician.
3171040|NCT00581763||Observation|Those with a condition
3171041|NCT00581789|Experimental|1|Erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
3174295|NCT00621907|Placebo Comparator|2|patient who received placebo
3174296|NCT00621972||Observation|Chronic kidney disease patients presenting for fisulta evaluation with documented GFR<30ml/min by abbreviated MDRD calculation.
2553436|NCT02542995|Other|Intevention|"QI interventions and got to see their own survey data - examples include:~Workflow redesign:~Medical Assistant (MA) data entry Improved clinic efficiency projects Assessed workflow with staff Provided time for MAs and RNs to perform tasks Paired MAs and providers Non-physician staff assist with forms~Communication improvement:~Improved teamwork Improved communication between provider groups Routine clinician meetings discussing meaningful topics Survey of providers for wish list of issues Routine emails from leaders Clinicians meeting with leaders~Chronic disease QI projects:~Establishing quality metrics with clinician input Automated Rx refill line Med reconciliation project Screening project for diabetics Screening for depression Improved patient portals"
2553466|NCT02542735||Spanish di@bet.es cohort|Representative of Spanish population
2553524|NCT02542475|Experimental|Mood Improvement|Mood change with daily Low Field Magnetic Stimulation in participants suffering from affective disorders and/or anxiety
2553566|NCT02542007|Experimental|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
2553567|NCT02542007|Active Comparator|Nano Polymer-free sirolimus-eluting stent system|The Nano polymer-free sirolimus-eluting stent produced by LePu medical.
2553618|NCT02541500|Experimental|Minocycline|Patients in this arm will receive oral minocycline
2553685|NCT02541214|Experimental|Trial Nasal Mask|The participant will use the Saturn nasal mask for 2 weeks in home
3205035|NCT00940069|Experimental|TS high expression genotype|TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
3205036|NCT00940069|Experimental|TS low expression genotype|TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.
3205037|NCT00940082||youth control group|healthy people which ages from 30 to 59
3205038|NCT00940082||youth diabetes group|type 1 and type 2 diabetes patients which ages from 30 to 59
3205039|NCT00940082||the elderly diabetes group|type 1 and type 2 diabetes patients which ages from 60 to 90
2553864|NCT02539940||Patients with critical limb ischemia|Patients undergoing endovascular intervention of below-the-knee arteries with ELUTAX SV DEB (drug-eluting balloon).
2553906|NCT02539641|Other|Good responder RYGB|Good responders after Roux-en-Y gastric bypass (RYGB). EWL > 50%. Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
2553910|NCT02539641|Other|Bad responder RYGB|Bad responders after Roux-en-Y gastric bypass (RYGB). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
2553912|NCT02539641|Other|Good responder SG|Good responders after sleeve gastrectomy (SG). EWL > 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
2553913|NCT02539641|Other|Bad responder SG|Bad responders after sleeve gastrectomy (SG). EWL < 50% Interventions: Gastric emptying scintigraphy and Determination of gut hormones.
2553914|NCT02539641|Other|Duodenal-jejunal bypass liner|Patients who will have a duodenal-jejunal bypass liner (DJBL) Intervention: Gastric emptying scintigraphy before and after implantation of DJBL
2553955|NCT02539212|Active Comparator|microwave ablation|microwave ablation
2553956|NCT02539212|Active Comparator|radiofrequency ablation|radiofrequency ablation
2554013|NCT02538952|Experimental|Xpert package|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the experimental phase therefore include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; (c) training health facility personnel in TB diagnostic algorithms; and (d) Xpert device activation. The combination of the ICF interventions and rollout of the Xpert device is referred to as the Xpert package in this protocol."
2554015|NCT02538952|Active Comparator|Active comparator|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. Interventions in the active comparator phase therefore include only: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only standard of care microscopy-based TB diagnostic algorithms are available during this phase."
2554024|NCT02538952|No Intervention|Standard of Care|"There are three phases to this stepped-wedge trial: (1) the retrospective cohort (standard of care) phase, (2) the active comparator phase, where intensified TB case finding (ICF) interventions are in place but no Xpert device, and (3) the experimental phase of full Xpert package implementation that includes both ICF interventions and Xpert device activation. There are no interventions in the standard of care arm (retrospective cohort). There are no ICF interventions and no Xpert device activations in this phase. Only the standard of care TB case finding procedures and microscopy-based TB diagnostic algorithm are available during this phase."
2554086|NCT02538497|Experimental|NBO plus routine care|The Newborn Behavioral Observation
2554088|NCT02538497|Other|Routine care|
2554147|NCT02538185|Placebo Comparator|Vaccine injected ID with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with vaccine (0.1mL);~Non-dominant deltoid, Intramuscular (IM) with classical syringe filled with placebo (0.5mL)."
2554212|NCT02537587|Active Comparator|Control 1|67g of Control energy bar containing 4g protein, 15g fat, 42g carbohydrate, 2g fiber, and 24g sugar.
3205040|NCT00940082||elderly control group|healthy people which ages from 60 to 90
3205041|NCT00940095|Experimental|Clazosentan 5 mg/h|Continuous intravenous infusion of clazosentan (5 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
2553450|NCT02542891|Active Comparator|Treament as Usual (TAU)|"In order to increase the comparability between the two arms, we defined TAU as a traditional face to face CBT of 16 sessions. These sessions will be administered over a course of 16 weeks.~The trial will not interfere with regular medication treatment, and patient's care will be monitored throughout the study."
2553487|NCT02542514|Experimental|Ibrutinib|ibrutinib in monotherapy 28 days/cycles
2553513|NCT02542215|Experimental|Cobiprostone 30 mcg four times daily|Cobiprostone oral spray, four times daily, in addition to standard care radiation and chemotherapy
2553515|NCT02542215|Placebo Comparator|Placebo 0 mcg four times daily|Matching placebo oral spray, four times daily, in addition to standard care radiation and chemotherapy
3205042|NCT00940095|Experimental|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan (15 mg/h) started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
3205043|NCT00940095|Placebo Comparator|Placebo|Continuous intravenous infusion of placebo matching clazosentan started within 56 hours post-aSAH and scheduled to continue until Day 14 post-aSAH, or at least until Day 10 post-aSAH, for patients discharged before Day 14
3205044|NCT00940121|Experimental|1. mirabegron, low dose|Oral mirabegron 25 mg
3205045|NCT00940121|Experimental|2. mirabegron, middle dose|Oral mirabegron 50 mg
2553878|NCT02539771|Other|Nocturnal VOC|
2553879|NCT02539771|Other|Diurnal VOC|
2553883|NCT02539771|Other|Slightly symptomatic|
3205046|NCT00940121|Experimental|3. mirabegron, higher dose|Oral mirabegron 100 mg
2554057|NCT02538627|Experimental|MM-151+MM-121 Dose Escalation|MM-151 and MM-121 dose escalation in lung, head and neck, and colorectal cancers
2554059|NCT02538627|Experimental|MM-151+ trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
2554061|NCT02538627|Experimental|MM-151+MM-141 Dose Escalation|MM-151 and MM-141 dose escalation in lung, head and neck, and colorectal cancers
2554063|NCT02538627|Experimental|MM-151+trametinib Dose Escalation|MM-151 and trametinib dose escalation in lung, head and neck, and colorectal cancers.
2554064|NCT02538627|Experimental|Colorectal cancer Expansion|Doses established in part 1 of the study
2554067|NCT02538627|Experimental|Head and neck Expansion|Doses established in part 1 of the study
2554120|NCT02538211|Placebo Comparator|Control|"Control group - subjects will receive no antibiotics~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
2554129|NCT02538211|Active Comparator|Broad-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~Ciprofloxacin 500mg 2dd1~Vancomycin 250mg 3dd2~Metronidazole 500mg 3dd1~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
2554132|NCT02538211|Active Comparator|Narrow-spectrum antibiotics|"Subjects will receive 7 days of pre-treatment (days -9 to -3) with:~• Vancomycine 250mg 3dd2~followed by Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine"
2554167|NCT02538055|Placebo Comparator|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
2554168|NCT02538055|Experimental|Living Healthy Program|Participants in this arm worked with a Community Health Worker (CHW) who provided the Living Healthy Program. The Living Healthy Program was a cognitive-behavioral therapy based lifestyle modification program. Participants and CHW interacted by telephone 8 times over 3 months.
2554230|NCT02537704|Experimental|Group Lifestyle Balance Program|"Participants will be assigned to an adaptation of the Group Lifestyle Balance Program, a behavioral curriculum implemented in the Diabetes Prevention Program Study. The Group Lifestyle Balance Program will be provided weekly for the first 3.5 months, bi-weekly from 3.5 to 6 months and then monthly until 12 months. Health care providers will be trained for the implementation of the intervention.~Additionally, participants will attend at least one monthly visit with a nutritionist (individually).~The lifestyle objectives for participants will be as follows:~To lose 5-10% of initial weight through healthy eating.~To do 150 minutes of physical activity each week."
2554274|NCT02537301||ERCP-chat group|All the doctors who finished their ERCP training in Xijing Hospital of Digestive Diseases and were invited to join in a chatting group in a mobile social app (Wechat).
2554312|NCT02537041|Other|healthy volunteers|to obtain normal values diastolic myocardial stiffness references. The objective will be to confirm the increase with age in myocardial stiffness assessed by elastography in healthy subjects.
2554315|NCT02537041|Other|diastolic Heart Failure|older patients with isolated diastolic HF (EF> 45%, 60-80 years, n = 20) and infiltrative cardiomyopathy restrictive-type amyloidosis (n = 20) . The objective will be to study the results of elastography on two separate clinical types of IC diastolic well identified.
2554318|NCT02537041|Other|systolic Heart Failure|"elderly patients with heart failure with impaired ejection (<45%) fraction, but no segmental dysfunction.~The evaluation of myocardial stiffness by elastography in all these patients will be compared to conventionally ultrasound and biological parameters currently used for diagnosis of elderly's diastolic HF"
3205047|NCT00940134|Placebo Comparator|placebo|Study participants will receive a 3 hour IV infusion of saline while fasting.
3205048|NCT00940134|Experimental|PYY3-36 + GLP-1|Study participants will receive a 3 hour IV infusion of (GLP-1 + PYY3-36) while fasting.
2554445|NCT02536092|Experimental|755nm and 1064nm Nd:YAG laser|755nm and 1064nm Nd:YAG laser
2554510|NCT02535923|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
3205049|NCT00940134|Active Comparator|GLP-1|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
3205050|NCT00940134|Active Comparator|PYY3-36|Study participants will receive a 3 hour IV infusion of PYY3-36 while fasting.
2553543|NCT02542124|Experimental|NM-IL-12 and TSEBT|TSEBT and subcutaneous doses of NM-IL-12
3205051|NCT00940147||1|patients with OAC, Score finding
3205052|NCT00940147||2|patients without OAC, Score finding
2553637|NCT02541396|Placebo Comparator|Group A|"Placebo wafers given every 2 hours Placebo capsule given every 4 hours Placebo wafers top-up dose given at hour 1"
2553639|NCT02541396|Active Comparator|Group B|"Placebo wafers given every 2 hours Oxycodone given every 4 hours Placebo wafers top-up dose given at hour 1"
2553645|NCT02541396|Experimental|Group C|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
2553646|NCT02541396|Experimental|Group D|"Wafermine™ 35 mg wafer + placebo wafer given every 2 hours Oxycodone 5 mg capsule every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
2553653|NCT02541396|Experimental|Group E|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Placebo capsule given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
2553655|NCT02541396|Experimental|Group F|"Wafermine™ 35 mg + placebo wafer given every 4 hours Placebo wafers given every 2 hours Oxycodone 5 mg given every 4 hours Wafermine™ 35 mg wafer + placebo wafer top-up dose at hour 1"
2553657|NCT02541396|Experimental|Group G|"Wafermine™ 70 mg given every 4 hours Placebo wafer given every 2 hours Placebo capsule given every 4 hours 2 Placebo wafers top-up dose at hour 1"
3205053|NCT00940160|Active Comparator|QAX576 1 mg/kg|
3205054|NCT00940160|Active Comparator|QAX576 3 mg/kg|
3205055|NCT00940160|Active Comparator|QAX576 10 mg/kg|
3205056|NCT00940160|Placebo Comparator|Placebo|
3205057|NCT00940173|Other|Group 1|Dose Group 1 (Receiving a dose of 10,000 IEQ/kg of DIABECELL(R))
2553939|NCT02539381|Other|Gold Standard Assessments|"Formal perimetry (Goldman or Octopus visual field)~Albert's visual inattention test~Star cancellation visual inattention test~line bisection test~These are performed as part of the routine assessment in the visual stroke orthoptic clinic and neuro-ophthalmology clinics.~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
2553941|NCT02539381|Other|Usual Clinical Screening Practice|"Visual field assessment to confrontation~Visual inattention assessment to bilateral stimuli~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
2553942|NCT02539381|Other|Stroke Vision App|"Digital tumbling E visual accuity assessment~Digital visual field assessment~Digital line crossing assessment~Digital shape cancellation assessment~The time to perform the assessments or if the participant is unable to complete the assessment will be recorded.~Researcher will record a score (0-10) to quantify the participant's compliance"
2553977|NCT02539043|Active Comparator|Focused ultrasound cavitation: Lipofocus|The first group will receive only the application of focused ultrasound cavitation.
2553980|NCT02539043|Active Comparator|Focused ultrasound and drainage: Lipofocus|The second group will receive focused ultrasound cavitation followed by stereodynamic drainage.
2554018|NCT02538848|Experimental|50mg in SAD|single dose of 50mg HTD4010 or placebo injectable in healthy volunteers
2554025|NCT02538848|Experimental|100mg in SAD|single dose of 100mg HTD4010 or placebo injectable in healthy volunteers
2554028|NCT02538848|Experimental|200mg in SAD|single dose of 200mg HTD4010 or placebo injectable in healthy volunteers
2554030|NCT02538848|Experimental|300mg in SAD|single dose of 300mg HTD4010 or placebo injectable in healthy volunteers
2554084|NCT02538484|Active Comparator|Letrozole|Letrozole 2.5 mg by mouth daily for 30 days.
2554085|NCT02538484|Active Comparator|Fish Oil|Fish oil 2700 mg by mouth daily for 30 days.
2554087|NCT02538484|Active Comparator|Letrozole and Fish Oil|Letrozole 2.5 mg and Fish oil 2700 mg by mouth daily for 30 days.
2554153|NCT02538172|Experimental|Intervention|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
2554154|NCT02538172|Other|Control|T-Track® CMV assay Quantiferon-CMV® assays Valganciclovir
3205058|NCT00940173|Other|Group 2|Dose Group 2 (Receiving a dose of 15,000 IEQ/kg of DIABECELL(R))
2554532|NCT02535663|Experimental|test group|Dietary Supplement: RG consumed one pack (150ml) of dairy yogurt containing RG (100mg Korean citrus Hallabong peel polysaccharide) per day for 8 weeks
2554533|NCT02535663|Placebo Comparator|placebo|Dietary Supplement: placebo consumed one pack (150ml) of dairy yogurt without RG per day for 8 weeks
2554574|NCT02535260||Fertility Monitor|Clearblue Fertility Monitor
3205059|NCT00940173|Other|Group 3|Dose Group 3 (Receiving a dose of 20,000 IEQ/kg of DIABECELL(R))
3205060|NCT00940173|Other|Group 4|Dose Group 4 (Receiving a dose of 5,000 IEQ/kg of DIABECELL(R))
3205061|NCT00940186||pikamilone|
3205062|NCT00940186||dosage|low dosage group: administrate pikamilone tablet 50 mg; middle dosage group: administrate pikamilone tablet 100 mg; hige dosage group: administrate pikamilone tablet 200 mg.
3205063|NCT00940186||tablet|
3205064|NCT00940199||Standard of Care|I:Application of L-M-X topical anesthetic cream 4% to the breast within one hour of sub-areaolar injection of 4 ml 99mTc-sulfur colloid (1 mCi in normal saline)
3205065|NCT00940199||1 mCi in sodium bicarbonate|II. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate)
3205066|NCT00940199||1 mCi in 1% Lidocaine|III. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in 1% Lidocaine)
3205067|NCT00940199||1 mCi in sodium bicarbonate + 1% Lidocaine|IV. Sub-areolar injection of 4 ml pH-adjusted 99mTc-sulfur colloid (1 mCi in sodium bicarbonate + 1% Lidocaine)
3205068|NCT00940212|Experimental|A|AZD2423
3205069|NCT00940212|Experimental|B|Placebo
3205070|NCT00940225|Experimental|Arm 1|RDT Open-Label
3205071|NCT00940225|Experimental|Arm 2|RDT Randomized Blinded-XL184
3205072|NCT00940225|Placebo Comparator|Arm 3|RDT Randomized Blinded
3205073|NCT00940225|Experimental|Non-Randomized Expansion (NRE) Cohorts|Drug: XL184
3205074|NCT00940251|Placebo Comparator|CORN STARCH|
3205075|NCT00940251|Active Comparator|Mersina, Diet and exercise|
2553606|NCT02541695|Active Comparator|1E10 CFU Escherichia coli (E. coli)|"1E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 1E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
2553607|NCT02541695|Experimental|5E10 CFU Escherichia coli (E. coli)|"5E10 Colony Forming Units (CFU) Diarrhoeagenic E. coli (strain E1392-75-2A; collection NIZO food research). Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain.~At day 14, after a standardized evening meal and overnight fast, subjects receive a single oral dose of 5E10 CFU of the attenuated diarrhoeagenic E. coli strain E1392-75-2A. At day 35, after a standardized evening meal and overnight fast, all subjects receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
2553697|NCT02541253|Experimental|GC3110A|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
2553706|NCT02541253|Active Comparator|GCFLU Pre-filled Syringe inj.|One injection : 0.5ml or 0.25ml, IM on day 0 Two injection : 0.5ml or 0.25ml, IM on day 0
2553765|NCT02540551|Experimental|Sentinel node procedure.|Intervention: injection of blue dye and radioactive tracer (99mTc-nanocolloid or Nanocoll) in remains of the ovarian ligaments.
2553797|NCT02540304|Experimental|TPP program|Reducing the Risk, Safer Sex Intervention, Cuidate!
2553798|NCT02540304|No Intervention|Business as Usual|Business as usual
2553844|NCT02540070|Active Comparator|Periarticular|Patients in group 1 will receive periarticular infiltration of LA mixture (100 ml) consisting of 0.3% ropivacaine, 2.5 µg/mL of epinephrine, 10 mg of morphine and 30 mg of ketorolac at the end of surgery and sham injections of saline into the motor sparing knee blocks preoperatively.
2553845|NCT02540070|Experimental|Motor free|Patients in group 2 will receive motor sparing knee blocks with 0.5% ropivacaine with 2.5 µg/mL of epinephrine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Sham injections of saline (100 ml) will be injected periarticularly at the end of surgery.
2553846|NCT02540070|Experimental|Motor free with Dex|Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
2553918|NCT02539602|Experimental|Need to Know (N2K)|The intended dosage for treatment participants is 16 lessons (25 minutes each) each year of the program (8 in the fall and 8 in the spring). The program consists of 3 years (48 lessons) of curriculum intended for 9th, 10th and 11th grade students to be delivered in a group or classroom setting of up to 32 students. There are 16 lessons in each year of the curriculum. Eight lessons are intended to be taught in the fall semester and eight in the spring. Each lesson is 25 minutes long, and can be taught in any class period that allows for 25 minutes of content instruction.
2553920|NCT02539602|No Intervention|Counterfactual|The counterfactual condition received no intervention.
2553962|NCT02539290|Experimental|Uterine flushing|Detection of ovulation, injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
2553964|NCT02539290|Sham Comparator|Vaginal flushing|Detection of ovulation, injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge, and sexual intercourse within 12 hours after intervention
2554017|NCT02538796|Experimental|Patients group 1|TEA + Grober Test + Task 1 + Grober Test
2554023|NCT02538796|Experimental|Patients group 2|TEA + Grober Test + Task 2 + Grober Test
2554027|NCT02538796|Experimental|Patients group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
2554029|NCT02538796|Experimental|Patients group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
2554031|NCT02538796|Active Comparator|Healthy volonteers group 1|TEA + Grober Test + Task 1 + Grober Test
2554032|NCT02538796|Active Comparator|Healthy volonteers group 2|TEA + Grober Test + Task 2 + Grober Test
2554033|NCT02538796|Active Comparator|Healthy volonteers group 3|TEA + Grober Test + Implicit Task 3 + Grober Test
2554034|NCT02538796|Active Comparator|Healthy volonteers group 4|TEA + Grober Test + Explicit Task 3 + Grober Test
2554113|NCT02538393|Experimental|Treatment A-C-B-D|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the first intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
2554117|NCT02538393|Experimental|Treatment B-A-D-C|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the first intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the second intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the third intervention period; and then a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
2554150|NCT02538185|Active Comparator|Vaccine injected ID with NanoJect device (DebioJect™)|"Right forearm, ID with NanoJect device (DebioJect™) filled with vaccine (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with placebo (0.5mL)."
2553608|NCT02541487||Nutritional/Physical Activity (NuPA) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
2553610|NCT02541487||Physical Activity only (PAo) Intervention|Obese participants in the FIT-PLESE clinical trial randomized to the exercise only arm that achieve pregnancy.
2553612|NCT02541487||Infertile, non-lifestyle intervention controls|Obese women (60) with unexplained infertility who meet the inclusion/exclusion criteria for FIT-PLESE but decline participation in the trial and who elect to undergo CC-IUI treatment and achieve pregnancy without prior diet and exercise interventions.
2553666|NCT02541266||Group 1|Patients currently recruited to studies with imaging at The Marsden
2553668|NCT02541266||Group 2|Patients who have previously participated in studies with imaging at The Marsden
2553669|NCT02541266||Group 3|Patients attending for scans as part of their clinical pathway
2553684|NCT02540967||BAY86-4875|Gadovist administration goup
2553720|NCT02540876|Experimental|Treatment (ilorasertib)|Patients receive ilorasertib PO BID on days 1, 8, 15, 29, and 36. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3205076|NCT00940264||Given indication for cholecystectomy|
3205077|NCT00940277|Experimental|Enhanced Couples Group|Enhanced Couples Group: consists of eight 90-minute sessions, conducted weekly. ECG has a didactic educational content presented by the group leader or practice of specific relationship communication, relationship support, and couple-focused stress management. ECG participants are also given instruction about what types of behaviors are unsupportive and training in how to not behave in an unsupportive manner.
2553921|NCT02539589|Experimental|Becoming a Responsible Teen (BART)|Becoming a Responsible Teen (BART) is the treatment condition. BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk.
2553922|NCT02539589|Active Comparator|Healthy Living|Healthy Living is the control counterfactual condition. It is a knowledge-based intervention that aims to impact nutrition, healthy eating, body image, and exercise.
3205078|NCT00940277|Experimental|Support Group|Support Group: 8 weekly 90-minute group counseling sessions. Using a standard approach to supportive therapy, the group interventionists will focus on encouraging participants to share their experiences with cancer, express their emotions related to the experience, voice problems they have in coping with the cancer, and offer support and advice to other members of the group. The co-facilitators will facilitate expression of affect and the sharing of the group's common issues related to cancer. Each session has a broad topic for discussion. Topics include communication with health care providers, issues related to occupational life, and coping with medical procedures and treatment. No formal or didactic information will be provided.
3205079|NCT00940303|Experimental|1|
3205080|NCT00940329|Active Comparator|Treatment A|
2554273|NCT02537249|Experimental|Dexmedetomidine|
2554276|NCT02537249|Sham Comparator|Saline 0.9%|
2554314|NCT02537002|Experimental|Cohort 1- PF-05230907 or Placebo|
2554317|NCT02537002|Experimental|Cohort 2- PF-05230907 or Placebo|
2554358|NCT02536690|Active Comparator|Group P|Induction with propofol bolus. Dose will be started at 1 mg/kg and will be adjusted as described in summary.
2554364|NCT02536690|Active Comparator|Group PR|Induction with propofol and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by propofol bolus Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary.
2554367|NCT02536690|Active Comparator|Group PMR|"Induction with propofol, midazolam and remifentanil. Remifentanil infusion 0.25 mcg/kg/min for 5 min followed by midazolam 0.03 mg/kg bolus 1 min after remifentanil infusion start and propofol bolus administration.~Propofol dose will be started at 1 mg/kg and will be adjusted as described in summary."
2554406|NCT02536222|Experimental|Reactive case investigation : FT/FDA with DHA-PQ|All consenting household members eligible to receive DHA-PQ and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHA-PQ. If no one in the household tests RDT positive then no one in the household will receive DHA-PQ.
2554407|NCT02536222|No Intervention|No Intervention: Standard of Care (Control)|The standard of care arm will have the standard of care offered by the Ministry of Health which applies to all arms. This includes available mosquito net coverage and passive case detection of individuals seeking treatment from a health provider at a health post or community.
2554451|NCT02536066|No Intervention|Control|maintain usual physical activity patterns
2554452|NCT02536066|Experimental|Intervention|Addition of daily postprandial physical activity in addition to usual activity patterns
2554493|NCT02535832|Placebo Comparator|Placebo|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the placebo arm. Participants will take matching placebo throughout the 15 weeks of treatment.
2554494|NCT02535832|Active Comparator|Pioglitazone|From the total participants enrolled into the cross-sectional study, the investigator will identify up to 18 participants who have insulin resistance and recruit them to participate in the pioglitazone arm. Participants will start by taking increasing doses for three weeks as follows: 1 capsule (15 mg) per day for 7 days, 1 capsule per day (30 mg) for 7 days, and 1 capsule (45mg), if tolerated. Participants will continue this dose (45 mg) throughout the 12 weeks of treatment.
2554547|NCT02535507|Experimental|Pyrotinib treatment arm|pyrotinib treatment arm
2554594|NCT02535052||Chronic Kidney Disease (CKD) patients|Any gender, aged 65 years and over. Chronic kidney disease with eGFR between 15 and 60 ml/min. No immunological cause of kidney disease. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
2554598|NCT02535052||Healthy Control subjects|Any gender, aged 65 years and over. No known renal disease and eGFR 60ml/min or greater. Not immunosuppressed. To receive both seasonal influenza and pneumococcal polysaccharide vaccines as part of recommended clinical care.
2554628|NCT02534818|Experimental|Group 1|lower fluorescein sodium dosage 0.02ml/kg for gastric intestinal metapalsia
2554629|NCT02534818|Active Comparator|Group 2|conventional fluorescein sodium dosage 0.1ml/kg for gastric intestinal metapalsia
3205081|NCT00940329|Active Comparator|Treatment B|
2553663|NCT02541279|Experimental|Intervention|The intervention group received 6 sessions of shoulder exercises controlled by a physiotherapist.
2553665|NCT02541279|Active Comparator|Control|The control group received a paper explaining the same exercises which were performed by the intervention group. This group made the exercises at home.
2553699|NCT02541019|Experimental|Palonosetron|Palonosetron (iv) one minute before anesthesic induction.
2553705|NCT02541019|Experimental|Ondansetron|ondansetron (iv) one minute before anesthesic induction and ondansetron regular three times a day for two days after the surgery.
2553758|NCT02540642|Active Comparator|Vitamin B12 and Antidiabetics|Tablet Methylcobalamin 500 ug once daily with other usual antidiabetic drugs
2553761|NCT02540642|No Intervention|antidiabetics|Only regular antidiabetic drugs will be given
2553807|NCT02540317|Experimental|Active treatment, Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy. Participants will be stratified based on diagnosis, i.e. adjustment disorder and burnout.
2553810|NCT02540317|No Intervention|Waiting list control|The control condition is a waiting list. Participants in this arm receive no active treatment. After 12 weeks on waiting list, participants are crossed over to treatment.
2553849|NCT02540044|Experimental|ANSWER-2 decision aid|The Intervention Group will receive simple instructions to access ANSWER-2 and complete the program on their own computers within two days. At the end of the session, ANSWER-2 will produce a one-page summary summarizing the participant's questions, concerns, and preferred medication option.
2553856|NCT02540044|Active Comparator|Control Group (TAS Consumer Guide)|The Control Group will receive the online Arthritis Medications: A Consumer's Guide, published by The Arthritis Society. It contains standard information about biologics, including an introduction of the different biologic options, dosages and side effects.
2553881|NCT02539693|Experimental|Clonidine 75|Patients will receive sacrococcygeal local anesthesia with 75µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 0.5 mL with 0.5 mL of saline (thus 75 µg/mL).
2553882|NCT02539693|Experimental|Clonidine 150|Patients will receive sacrococcygeal local anesthesia with 150µg/mL of clonidine. The anesthetic mixture will contain: lidocaine 2% 14 mL, bupivacaine 0.5% 5 mL, and clonidine 1 mL (thus 150 µg/mL).
2553923|NCT02539407||Anti-infectives|"Anti-infectives of the following : β-lactam antibiotics, Aminoglycosides, Glycopeptides, Fluoroquinolone, Daptomycin, Rifampin, Trimethoprim, Sulfamethoxazole, Clarithromycin, Fungal, Antiviral~Pharmacokinetics"
2553975|NCT02539199|Active Comparator|Misoprostol modified-release pessary|
2553978|NCT02539199|Active Comparator|Misoprostol, per-oral tablets|
2554042|NCT02538770|Experimental|Rapid Anyplex TMII RV16 Detection|Intervention is the rapid performance of Anyplex TMII RV16 detection
2554046|NCT02538770|Active Comparator|Delayed Anyplex TMII RV16 Detection|Comprative intervention is the delayed performance of Anyplex TMII RV16 detection
2554136|NCT02538445|Experimental|Patients group 1|Memorization of the verbs by miming the action
2554138|NCT02538445|Experimental|Patients group 2|Memorization of the verbs by imagining the action
2554139|NCT02538445|Experimental|Patients group 3|Memorization of the action verbs by means of another word
2554141|NCT02538445|Experimental|Patients group 4|Simple memorization of the verbs
2554144|NCT02538445|Active Comparator|Healthy volonteers group 1|Memorization of the verbs by miming the action
2554148|NCT02538445|Active Comparator|Healthy volonteers group 2|Memorization of the verbs by imagining the action
2554149|NCT02538445|Active Comparator|Healthy volonteers group 3|Memorization of the action verbs by means of another word
2554151|NCT02538445|Active Comparator|Healthy volonteers group 4|Simple memorization of the verbs
3205082|NCT00940355|Experimental|Intervention pulmonary nurse|group III: intervention conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, increasing motivation to engage in additional treatment, and improving health status.
3205083|NCT00940355|No Intervention|Usual care|group II: usual care as delivered by the outpatient clinic.
2554290|NCT02537236|Experimental|Group one|20 subjects received Therapeutic Lifestyle Changes diet more 1.05 grams of fish oil omega 3 fatty acids
2554293|NCT02537236|Active Comparator|Group two|20 subjects received conventional diet more 1.05 grams of fish oil omega 3 fatty acids
2554295|NCT02537236|Experimental|Group three|20 subjects received Therapeutic Lifestyle Changes diet more 2.10 grams of fish oil omega 3 fatty acids.
2554296|NCT02537236|Active Comparator|Group four|20 subjects received conventional diet more 2.10 grams of fish oil omega 3 fatty acids
2554297|NCT02537236|Placebo Comparator|Group five|20 subjects, control group received conventional diet.
3205084|NCT00940368|Experimental|Ginger arm|"The patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day"
3205085|NCT00940368|Placebo Comparator|Placebo arm|"Patients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B:~Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day"
3205086|NCT00940381|Experimental|Sirolimus + Cetuximab|Sirolimus beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle. Cetuximab Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
3205087|NCT00940394|Other|standard care|Families receive routine community and family mental health care services
2554528|NCT02535585|Active Comparator|knotless anchors|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
2553759|NCT02540486|Experimental|LTHome web tool|The long-acting insulin glargine titration web tool (LTHome) will provide insulin glargine titration suggestions based on user inputted blood glucose readings.
2553763|NCT02540486|Active Comparator|Enhanced Usual Therapy (EUT)|The Enhanced Usual Therapy arm will receive insulin glargine titration instructions that are the usual therapy provided by the physician/HCP, in addition to diabetes education.
2553801|NCT02540239|Placebo Comparator|2L PEG|only used 2L PEG
2553806|NCT02540239|Experimental|Simethione+2L PEG|used 2L PEG+Simethione
2553857|NCT02539966|Experimental|Cohort A|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group A (6-month angiographic follow-up)
2553859|NCT02539966|Experimental|Cohort B|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group B (9-month angiographic follow-up)
2553863|NCT02539966|Experimental|Cohort C|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold - Treatment Group C (6-month angiographic follow-up), Long Lesion/Multi-Vessel
2553936|NCT02539537|Active Comparator|Arm A: Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes on D1 of each week for the 4 weeks of the first cycle (1 cycle = 4 weeks). For the following five cycles, gemcitabine infusion on D1, D8, and D15 of each cycle, followed by 1 week without injection (i.e. in total 4 cycles over 24 weeks; with 19 administrations of Gemcitabine).
2553938|NCT02539537|Experimental|Arm B: Folfirinox|"Administered once every 14 days for 24 weeks (12 cycles). A cycle equals 14 days with injection on D1 of each cycle. Treatment starts with oxaliplatin (85 mg/m²) administration; IV infusion over 2 hours, followed by the simultaneous administration (using a Y-tubing) of folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours and irinotecan 180 mg/m² IV infusion over 90 minutes. The irinotecan will begin 30 minutes after the start of the folinic acid infusion.~5-Fluoro-uracil (5-FU) IV 2,400 mg/m²/h will be administered over 46 hours after the end of the folinic acid infusion, i.e. 1200 mg/m²/day for the duration of 2 days.~Treatment will be continued for 24 weeks (12 cycles)."
2554060|NCT02538653|Experimental|Sandwich biscuits high in SDS|50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.
2554062|NCT02538653|Active Comparator|Co-extruded cereals low in SDS|48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.
2554082|NCT02538406||non segmental withdrawal|A standard of care colonoscopy will be done on the patient without extra time on the right side of the colon.
2554083|NCT02538406||Segmental withdrawal|A standard of care colonoscopy will be done on the patient , however the time spent in the right side of the colon will be more than half of the normal colonoscopy procedure (i.e. more than 3 minutes)
2554146|NCT02538198|Experimental|Lenalidomide|Subjects will receive lenalidomide 10 mg by mouth daily on days 1-21 of a 28-day cycle. Subjects may continue lenalidomide until disease progression, diagnosis of new malignancy, unacceptable toxicity, investigator discretion, voluntary withdrawal, or the end of the study (5 years); whatever comes first. Patients who complete at least four cycles of treatment will be considered evaluable.
3205088|NCT00940394|Experimental|mutual support group|bi-weekly, 12-session, family-led mutual support group
3205089|NCT00940394|Active Comparator|psychoeducation group|bi-weekly, 12-session, family psychoeducation group program
3205090|NCT00940420|Experimental|A|
2554248|NCT02537626|Active Comparator|Erchonia ALS Laser|The Erchonia ALS Laser is a mains powered variable hertz laser device made up of five independent red laser diodes mounted in scanner devices and positioned equidistant from each other. Each scanner emits 7.5 milliwatts (mW) ± 1.0 mW 640 nanometers (nm) with a tolerance of ±10 nm of red laser light.
2554249|NCT02537626|Placebo Comparator|Placebo Laser|The Placebo Laser is identical in appearance and operation to the Erchonia ALS Laser but does not emit any therapeutic light.
2554279|NCT02537184|Other|Group 1 - Recall Interval of 4 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
2554284|NCT02537184|Other|Group 2 - Recall Interval of 8 months|"Oral clinical conditions:~Only at baseline all childrens will receive 5% sodium FV (Duraphat, Colgate Oral Pharmaceuticals). Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment Procedure/Surgery: Oral clinical conditions Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
2554361|NCT02536911|Experimental|GZ385660 (healthy subjects)|Single dose of eliglustat tartrate will be given under fed conditions
2554365|NCT02536911|Experimental|GZ385660 (subjects with mild hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
2554368|NCT02536911|Experimental|GZ385660 (subjects with moderate hepatic impairment)|Single dose of eliglustat tartrate will be given under fed conditions
2554427|NCT02536287|Experimental|total PTX without autotransplantation|all parathyroid glands were found and removed
2554432|NCT02536287|Active Comparator|total PTX with autotransplantation|all parathyroid glands were found and removed,and then a portion of it is sliced into 1*1*1 mm pieces for autotransplantation
2554475|NCT02535936|Other|3Tesla MRI with DTI-MRI and rsfcMRI|Patients will receive 2 post-operative MRI's with DTI and rsfcMRI at 2 months and 12 months.
2554543|NCT02535650|Experimental|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles.
2554579|NCT02535143|Experimental|Test Group|Group will prepare a test cavity in an acrylic block. They will receive 250 ml of a commercially available energy drink containing caffeine and taurine (Red Bull, Red Bull GmBh Austria) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
3205091|NCT00940420|Experimental|B|
2554861|NCT02533284|Experimental|Magnesium sulfate group|US guided TAP with magnesium sulfate
3205092|NCT00940433|Active Comparator|open properitoneal|patients undergoing open properitoneal hernia repair
3205093|NCT00940433|Active Comparator|Lechtenstien repair|Patients undergoing Lechtestien hernia repair
3205094|NCT00940433|Active Comparator|Laparoscopic transperitoneal repair|Patients undergoing TAPP repair
3205095|NCT00940433|Active Comparator|Lap totally extraperitoneal approach|Patients undergoing TEP approach
2553834|NCT02540109|Experimental|High-Definition tDCS (Active)|
2553835|NCT02540109|Experimental|High-Definition tDCS (Sham)|
2553870|NCT02539810|Experimental|Renal artery stenting|"Renal artery angioplasty plus stenting and standardized and optimized medication regimen.~Patients are treated with renal artery stenting plus a standardized optimal medical treatment, including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits."
2553874|NCT02539810|Active Comparator|standardized and optimized medication regimen|Patients are treated with a standardized optimal medical treatment including the antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
2553960|NCT02539329||patient|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
2553963|NCT02539329||control|Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies
2554049|NCT02538640|Experimental|High-SDS biscuit|50 g of moist biscuit with high-SDS content and low GI with a glass of water
2554056|NCT02538640|Active Comparator|Low-SDS breakfast cereals|42 g of extruded cereals with no SDS and medium to high GI with a glass of water
2554125|NCT02538432|Experimental|RQ-00000007 Alone|RQ-0000007 250 mg will be self-administered orally, with or without food, each morning and evening, approximately 12 hours apart.
2554131|NCT02538432|Active Comparator|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be given as an IV.
3205096|NCT00940459|Experimental|Acuvue Oasys|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3205097|NCT00940459|Experimental|Biofinity|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
2554239|NCT02537548|Experimental|Treatment (RPLND)|Patients undergo RPLND.
2554286|NCT02537171|Active Comparator|Apatinib 750mg group|Apatinib mesylate tablets(ATAN) is taken 750mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.The dose of the study drug may be modified following the occurence of a clinically significant adverse event(AE).
2554291|NCT02537171|Active Comparator|Apatinib 500mg group|Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
2554336|NCT02536885|Experimental|Liberal group|During the surgery, blood pressure of the patients will be maintained within ± 25% of the patient's normal blood pressure.
2554338|NCT02536885|Experimental|Restrictive group|During the surgery, blood pressure of the patients will be maintained within ± 10% of the patient's normal blood pressure.
2554360|NCT02536560||Antibiotics|150 infants, (because of hospital protocol) treated with antibiotics because of a perinatal infection during the first week of life
2554366|NCT02536560||Controls|The control group comprises 300 healthy newborns, born in the hospital and needing clinical observation for 24-48 hours for several reasons like maternal comorbidity, low probability of neonatal infection, blood sugar monitoring, meconium containing amniotic fluid, or delivery by caesarean section
2554419|NCT02536352|Experimental|Fluoride prenatal vitamin|Prenatal vitamin-mineral containing 3 mg fluoride
2554421|NCT02536352|Active Comparator|Standard prenatal vitamin|Prenatal vitamin-mineral containing 0 mg fluoride
2554509|NCT02535962|Experimental|Corticosteriod + Probiotic Treatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Investigational drug (Intervention is Lactobacillus acidophilus and Bifidobacterium lactis): Patients will be instructed to take one sachet of the study product mixed into a 60 ml of water that is not hot. Each sachet will contain Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 at a dose of 5*109 CFU of each strain. The investigational product will be taken daily for the duration of the study, which is a year."
2554513|NCT02535962|Placebo Comparator|Corticosteriod + PlaceboTreatment|"Corticosteroid dosing of 1 mg/kg of body weight given once at the onset of the febrile period, repeated once within 24 hours if necessary, but no more than two doses per cycle. The second dose of corticosteroid treatment is only to be given within one day following the initial dosage if the fever persists.~Placebo: will be taken daily and patients will be instructed to take one sachet of placebo mix into 60ml of water that is not to hot. The placebo will be taken daily for the duration of the study, which is one year. Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product."
2554545|NCT02535429|Experimental|massage|massage
2554556|NCT02535429|No Intervention|Control|
2554617|NCT02535117|Experimental|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
2554698|NCT02534610|Experimental|Group ETORICOXIB PREOP|Preoperative (1 h) per os (PO) 120 mg Etoricoxib (Arcoxia) and 1 placebo pill PO at the end of surgery.
2554789|NCT02534012|Experimental|PVB group|Patients will receive nerve stimulator guided paravertebral block
3205098|NCT00940459|Experimental|Air Optix|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
3205099|NCT00940459|Experimental|PureVision|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
2553790|NCT02540512|Experimental|Standard Drug Plus Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The patients will then be given hydrocodone / acetaminophen 5mg/325mg (generic) with a prescription to take home and use as needed (in the acupuncture groups, the physician administering the treatment will not know if the patient is receiving the standard drug or the placebo pill). The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1)."
2553792|NCT02540512|Experimental|Acupuncture Group|"The participants in this group will receive auricular acupuncture following the Battlefield Acupuncture Protocol. The physician can administer up to 10 needles (5 in each ear) until the patient has a significant drop in pain (pain level 0 or 1). The patient will then be given a placebo pill."
2553851|NCT02540005||Aneurysmatic subarachnoid haemorrhage|Acute subarachnoid haemorrhage (confirmed by computed tomography, CT, or cerebrospinal fluid erythrocyte count over 1000 x 106/l) AND confirmed origin either with computed angiography (CTA) or digital subtraction angiography (DSA)
2553852|NCT02540005||Control patients|Elective craniotomy due to non-ruptured intracranial aneurysm
2553869|NCT02539758|Experimental|ocular massage|over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.We observed changes of anterior chamber depth before and after ocular massage by LenstarLS900,and changes of intraocular pressure before and after ocular massage by Goldmann tonometer
2553924|NCT02539472|Experimental|investigation|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
2553958|NCT02539173|Experimental|Experimental|Ultrasound scan of diaphragm is made preoperatively during the pre-anesthetic visit, patients are informed of the purpose of the study. Written consent is collected after oral and written information.
3205100|NCT00940459|Active Comparator|Acuvue 2|One of five contact lens brands worn bilaterally on a daily wear basis in randomized order for 10 days each.
2554196|NCT02537938|Experimental|NGP 555|NGP 555 given once a day for 14 days as a capsule; 100 mg, 200 mg, or 400 mg
2554198|NCT02537938|No Intervention|Placebo|Placebo comparator given once a day for 14 days as a capsule.
2554229|NCT02537496|Experimental|Alzheimer's disease rTMS|The intervention procedure done in this group is repetitive Transcranial Magnetic Stimulation.
2554231|NCT02537496|Sham Comparator|Alzheimer's disease rTMS Sham|The intervention procedure done in this group is Repetitive Transcranial Magnetic Stimulation - Sham
2554232|NCT02537496|No Intervention|Healthy Control|Healthy control group will only participate in baseline assessments which include baseline neuropsychological testing and baseline measurement of neuroplasticity. This will be used to standardize neuropsychological test scores and to compare the baseline neuroplasticity between healthy participants and Alzheimer's disease (AD) participants. Healthy control group will not get rTMS intervention.
2554287|NCT02537288|Experimental|Placebo matched to fedovapagon|One dose of placebo (matched to fedovapagon)
2554289|NCT02537288|Experimental|Fedovapagon 2 mg|One dose of 2 mg fedovapagon
2554292|NCT02537288|Experimental|Fedovapagon 20 mg|One dose of 20 mg fedovapagon
2554294|NCT02537288|Experimental|Moxifloxacin 400 mg (open label)|One dose of moxifloxacin 400 mg (open label)
3171042|NCT00581802||1|Intensively studied participants initiating potentially suppressive drug therapy. Group 1 participants may undergo optional leukapheresis. Group 1 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 1 participants will default to either Group 3 or Group 4.
3171043|NCT00581802||2|Intensively studied, well-suppressed participants on HAART. Participants in Group 2 may undergo optional leukapheresis. Group 2 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 2 participants will default to either Group 3 or Group 4.
3205101|NCT00940472|Experimental|Experimental Drug|DMMET-01 + Diet
2554565|NCT02535312|Experimental|Arm A (methoxyamine, pemetrexed disodium, cisplatin)|Patients receive methoxyamine PO QD on days 1-4, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
2554567|NCT02535312|Experimental|Arm B (methoxyamine, pemetrexed disodium)|Patients receive methoxyamine PO QD on days 1-4 and pemetrexed disodium IV over 10 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue methoxyamine and pemetrexed disodium beyond cycle 6 if the patient continues to benefit from treatment at the discretion of the treating physician.
2554641|NCT02534766||Patients who attended the MISSION COPD clinics|COPD patients who attended the MISSION COPD clinics, identified as having uncontrolled or potentially severe COPD or unrecognised COPD from GP records by the MISSION clinical team
2554642|NCT02534766||Health Care Professionals|Health Care Professionals who attended the MISSION COPD clinics in a professional/ clinical capacity.
2554685|NCT02534480|Active Comparator|NGP 555 25 mg|NGP 555 25 mg capsule and placebo by mouth once per day
2554686|NCT02534480|Active Comparator|NGP 555 50 mg|NGP 555 50 mg capsule and placebo by mouth once per day
2554687|NCT02534480|Active Comparator|NGP 555 100 mg|NGP 555 100 mg capsule and placebo by mouth once per day
2554688|NCT02534480|Active Comparator|NGP 555 200 mg|NGP 555 200 mg capsule and placebo by mouth once per day
2554689|NCT02534480|Active Comparator|NGP 555 300 mg|NGP 555 300 mg capsule and placebo by mouth once per day
2554719|NCT02534246|Experimental|Pro Core EUS guided Fine Needle Biopsy|Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) with reverse bevel design for diagnosis of pancreatic lesions.
2554722|NCT02534246|Experimental|Shark Core EUS guided Fine Needle Biopsy|SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) with six cutting edge surfaces and an opposing bevel design for diagnosis of pancreatic lesions.
2554992|NCT02532686|Experimental|DAAOI-2|DAAOI-2: 500-2000mg/d
2553825|NCT02540148|Sham Comparator|Non-active treatment|A second group of subjects will act as the control group. This group will undergo sham treatment to the enrolled eyes at the same intervals as the treatment group (Weeks 2, 14 and 26), but with a nonfunctional Nova Oculus device. A treatment session is 15 minutes of treatment on each closed eye lid for a total of 30 minutes. ETDRS visual acuity will be performed on all subjects at enrollment (prior to the first treatment), prior to each treatment session, and at four weeks from enrollment. The effect of treatments with the Nova Oculus device compared to sham treatment on the visual acuity of subjects with dry AMD will be determined.
2553877|NCT02539901||12-30 months-old deaf children|Children with deafness of bilateral deep perception had : Evaluation of the detection of non-linguistic sounds, Early Social Communication Scale (ECSP) and psychomotor infancy development scale or Lézine Brunet-Revised scale
2553880|NCT02539901||6-9 years-old deaf children|"Free hearing test categorization and NEPSY (two domains: memory and learning and attention and executive functions) in 6-9 years-old deaf child cohort with deafness of bilateral deep perception and carrying a cochlear implant"
2553884|NCT02539901||12-30 months-old normal hearing children|Evaluation of the detection of non-linguistic sounds in 12-30 months-old normal hearing child cohort
2553885|NCT02539901||6-9 years-old normal hearing children|'Free hearing test categorization' in 6-9 years-old normal hearing child cohort
3205102|NCT00940472|Active Comparator|Metformin|Metformin + Diet
3205103|NCT00940498|Experimental|1|PF-05212384 (also known as PKI-587)
2553982|NCT02539017|Experimental|Combined|Combined Chemo Therapy and immunotherapy with double dendritic cell (DC) and cytokine-induced killer (CIK) cell
2553984|NCT02539017|Active Comparator|Chemo|Control group: Chemo Therapy group
2554051|NCT02538601|Experimental|CBT-A|An 8-session, CBT-based group smoking cessation program (CBT-A) enhanced with transdiagnostic skills for the management of anxiety and fear-based avoidance behaviors.
2554055|NCT02538601|Active Comparator|CBT-S|An 8-session, CBT-based, traditional group CBT based smoking cessation program.
3205104|NCT00940511|Experimental|Coordinated care|Individuals will be passively enrolled in Medicaid managed care. Those who do not opt out of managed care will be provided with care coordination.
3205105|NCT00940511|No Intervention|Usual care|The usual care group will remain in fee-for-service Medicaid and receive services normally available through that system.
2554177|NCT02537860|Experimental|Three PVB injections|Patients will receive three PVB injections from T12 to L2 and placebo at T11 and L3
2554183|NCT02537860|Experimental|Five PVB injections|Patients will receive five PVB injections between T11 and L3.
2554267|NCT02537340||EMVI-MR positive|Patients with primary rectal cancer and extramural vascular invasion detected by staging MR
2554268|NCT02537340||EMVI-MR negative|Patients with primary rectal cancer and without extramural vascular invasion detected by staging MR
2554298|NCT02537093|Active Comparator|Synchronous telepsychiatry (STP)|Control Arm/Synchronous telepsychiatry (STP): After baseline assessment, subjects will be assessed by a psychiatrist using live interactive videoconferencing every 6 months for a 1 year follow up (3 STP assessments: baseline plus 2 assessments). A report with treatment recommendations following American Psychiatric Association guidelines will be sent to the PCP who will be able to have adlib telephone or email consultations with the telepsychiatrist. The telepsychiatrist will have access to all previous clinical information about the patients.
2554299|NCT02537093|Experimental|Asynchronous telepsychiatry (ATP)|Intervention Arm (ATP): All ATP assessments at 6 monthly intervals post baseline will be conducted by an ATP trained clinician. This interview will be video recorded.The ATP clinicians will then fill out a standardized medical template that will be reviewed by a psychiatrist who will provide a written assessment and psychiatric treatment plan. He will have access to any previous assessments and the PCP will also have continuing access to this psychiatrist by phone or email between the 3 consultations.
2554332|NCT02536859|Experimental|IDeg|
2554333|NCT02536859|Active Comparator|IGlar U300|
2554379|NCT02536625||Everolimus|Immunomonitoring
2554409|NCT02536274|Experimental|Schwertbad Aachen|20 Patients with specific back pain will get Lumbo Sensa® bandage. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
2554701|NCT02534610|Experimental|Group ETORICOXIB POSTOP|Preoperative (1 h) 1 placebo pill PO and 120 mg Etoricoxib PO at the end of surgery (Arcoxia).
2554793|NCT02534012|Experimental|GA group|Patients will receive general anesthesia
3205106|NCT00940524|Experimental|Chemotherapy|A phase I study designed to determine the dose of dasatinib that can be safely administered with cytarabine and high-dose mitoxantrone in Ph+ ALL / lymphoid blast crisis of known chronic myelogenous leukemia patients.
3205107|NCT00940550|Experimental|Prolonged-release melatonin 2 mg|
3205108|NCT00940550|Active Comparator|Temazepam 20 mg|
3205109|NCT00940550|Active Comparator|Zolpidem 10 mg|
3205110|NCT00940550|Placebo Comparator|Placebo|
3205111|NCT00940563|Experimental|Imatinib|
3205112|NCT00940615|Experimental|1|participants in the aerobic exercise intervention
2553949|NCT02539160|Active Comparator|CKD - Ticagrelor 90|Patients with chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
2553950|NCT02539160|Experimental|CKD - Ticagrelor 60|Patients with chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
2553951|NCT02539160|Active Comparator|Non-CKD - Ticagrelor 90|Patients without chronic kidney disease will receive ticagrelor 90mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 60mg twice/daily for 7-10 days.
2553952|NCT02539160|Experimental|Non-CKD - Ticagrelor 60|Patients without chronic kidney disease will receive ticagrelor 60mg twice/daily for 7-10 days. Then patients will cross over to ticagrelor 90mg twice/daily for 7-10 days.
2554011|NCT02538887||Radio Frequency Surgical Detection|
2554071|NCT02538575|Experimental|6-minute walk test|
2554195|NCT02538315||Surgery plus PET/CT imaging|Dopaminergic stem cell transplant and [18F]FDOPA PET/CT
2554226|NCT02537509|Active Comparator|Cholecalciferol|Administration of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
2554227|NCT02537509|Placebo Comparator|Placebo of cholecalciferol|Administration of placebo of cholecalciferol every 3 months during 2 years combined with new phototherapy regimen during winter (phototherapy winter 1, observation winter 2 or the opposite)
2554278|NCT02537223|Experimental|BYL719, Cisplatin, and Radiation Therapy|BYL719, orally, at a starting dose of 200-350 mg, once daily, for 7 weeks. Cisplatin, intravenously, at 100 mg/m2 over 1 hour, every 3 weeks for 3 doses. Radiation therapy, Monday to Friday, for 7 weeks.
2554341|NCT02536950|No Intervention|Blinded Sensor|Subjects will wear a blinded Dexcom G4P (Generation 4 Platinum) AP (Artificial Pancreas) glucose sensor for a week
2554343|NCT02536950|Experimental|Fixed set point|Subjects will be in a hotel and use a fixed set point for glucose control for two days initialized at 130 mg/dl. The setpoint will be adjusted, if necessary, over the two days in the hotel before they are sent home for 5 days
2554346|NCT02536950|Experimental|Variable Set Point|"Subjects will begin using a variable setpoint which will make adjustments based on their past glucose control over the previous day"
2554351|NCT02536534||Patients with PAH and CTEPH|Patients diagnosed with symptomatic Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and stable on optimal medical therapy who meet the study's eligibility criteria
2554416|NCT02536131|Other|Study group|7-10 sessions gut-directed hypnotherapy within 12 weeks
3205113|NCT00940615|Active Comparator|2|participants in the stretching/toning control condition
3205114|NCT00940628|Experimental|1|
2554575|NCT02535156|Experimental|Schizotypal Personality Disorder|Schizotypal Personality Disorder (SPD) patients. They received two interventions: risperidone 1 mg and placebo (lactose).
2554576|NCT02535156|Experimental|Healthy controls|Control group consisting of healthy volunteers.They received two interventions: risperidone 1 mg and placebo (lactose).
2554632|NCT02534922|Experimental|Daily dosing|Daily subcutaneous dosing of Prolanta, a human prolactin receptor antagonist
2554718|NCT02534623|Active Comparator|Spinal anesthesia|Transurethral resection of the bladder performed under spinal anesthesia.
2554721|NCT02534623|Active Comparator|General anesthesia|Transurethral resection of the bladder performed under general anesthesia.
2554788|NCT02533843|Active Comparator|Arm I|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) Intervention: AF ablation
2554791|NCT02533843|Active Comparator|Arm II|ablation at sources guided by FIRMap (using RhythmView™ Workstation from TOPERA) + conventional pulmonary vein antrum isolation (PVAI) Intervention: AF ablation
2554794|NCT02533843|Active Comparator|Arm III|Extended PVAI plus ablation of non-PV triggers and complex fractionated atrial electrograms (CFAE) Intervention: AF ablation
2554825|NCT02533479|Experimental|Caloric restriction|three alternate days weekly along 4 weeks.
2554931|NCT02532673||Hyperbilirubinemia Cohort|Patients will be included who have evidence of hyperbilirubinemia (laboratory test of grade 2 or greater or > 2 medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification code of 782.4 or 277.4 in any position) in the first 90 days after initiating Atazanavir therapy.
2554932|NCT02532673||Non-hyperbilirubinemia cohort|Patients will be included who have no evidence of hyperbilirubinemia (no laboratory test of grade 2 or greater or any medical claims with an International Classification of Diseases, Ninth Revision, Clinical Modification of 782.4 or 277.4 in any position) in the 12-month follow-up period.
3205115|NCT00940628|Other|2|
3205116|NCT00940641|Experimental|1|IV dose of AZD7325
2555088|NCT02532023|Active Comparator|omega 3 fatty acid supplementation|patients with migraine receive 2 capsules 1000 mg omega3, 2 times a day, for 2 months.
2555090|NCT02532023|Active Comparator|curcumin supplementation|patients with migraine receive 2 capsules 1000 mg curcumin, 2 times a day, for 2 months.
2555092|NCT02532023|Placebo Comparator|omega 3 fatty acid Placebo|patients with migraine receive 2 capsules of omega 3 fatty acid placebo for 2 months.
2555093|NCT02532023|Placebo Comparator|curcumin placebo|patients with migraine receive 2 capsules of curcumin placebo for 2 months.
2555103|NCT02531542|Other|READ echography|
3205117|NCT00940641|Experimental|2|14C oral dose of AZD7325
3205118|NCT00940654||Patients with fever|
2555384|NCT02530203|Other|Conventional treatment|Non interventional group, patients that belong to this arm will receive the conventional treatment for CABG and they will wear the Holter for 5 days.
2555386|NCT02530203|Experimental|Spinal Cord Stimulation System|This group will receive the Spinal Cord Stimulation System and they will wear the Holter for 5 days.
3205119|NCT00940654||Patients without any fever|
3205120|NCT00940667|Experimental|amlodipine/losartan 5/50mg|
3205121|NCT00940667|Active Comparator|amlodipine 5mg|
3205122|NCT00940680|Experimental|amlodipine/losartan 5/100mg|
3205123|NCT00940680|Active Comparator|losartan 100mg|
3205124|NCT00940693|Active Comparator|duloxetine|
3205125|NCT00940693|Placebo Comparator|placebo|
3205126|NCT00940706|Experimental|Physical activity in groups|Exercises of physical activity
2553953|NCT02539186|Experimental|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve in intervention group.
2553954|NCT02539186|Active Comparator|splinting|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study in control group.
2553998|NCT02538978|Experimental|Device Arm|Device arm subjects will receive an intra-operative point of care aspiration, preparation and intramuscular injection of autologous bone marrow concentrate (aBMC) into the afflicted lower index limb.
2553999|NCT02538978|Placebo Comparator|Placebo Arm|Placebo arm subjects will undergo an intra-operative point of care aspiration and preparation of bone marrow via the investigational device exactly as the Treatment Arm. However, instead of receiving the dosing with the aBMC device output, they will receive an intramuscular injection of diluted autologous peripheral blood into the afflicted lower index limb.
3205127|NCT00940706|Experimental|Activity monitoring with accelerometers|Each subject will wear the accelerometer 24 hours a day for 4 days The activity will be recorded and analyzed
3205128|NCT00940706|Active Comparator|Treadmill|Treadmill with safety adaptations for handicapped persons
3205129|NCT00940719|Experimental|Vitamin D3|Patients receive 1dd 500ug vitamin D3 for 3 months
2554373|NCT02536638||Pyelonephritis Group|patients with pyelonephritis
2554382|NCT02536638||Without pyelonephritis Group|patients without pyelonephritis
3205130|NCT00940732|Experimental|Destigmatisation and Mental Health Literacy|
3205131|NCT00940732|Experimental|Help-seeking list|
2554468|NCT02535767|Experimental|A: 0.40 mg/kg PQ G6PDd|0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
2554471|NCT02535767|Experimental|B: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
2554472|NCT02535767|Experimental|C: PQ in G6PDd|A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
2554473|NCT02535767|Experimental|D: PQ G6PDn|A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.
3205132|NCT00940732|Experimental|Feedback|
3205133|NCT00940732|No Intervention|Control|
3205134|NCT00940745|Experimental|Stereotactic Aspiration and Thrombolysis|To position haematoma's location, drills several millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
3205135|NCT00940745|Active Comparator|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
2554678|NCT02534415|Active Comparator|Periodontal dressing material|Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
2554680|NCT02534415|Experimental|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
2554681|NCT02534415|Experimental|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
2554724|NCT02534272||Symptomatic subjects|Subjects with intestinal symptoms
2554726|NCT02534272||Asymptomatic subjects|Subjects without intestinal symptoms
3205136|NCT00940758|Experimental|PEP02|
2554843|NCT02533323|Experimental|P-Gemox|P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.
2554888|NCT02533011||24 Hours|HBP lab test performed 24 hours after meeting sepsis inclusion criteria.
2554894|NCT02533011||48 Hours|HBP lab test performed 48 hours after meeting sepsis inclusion criteria.
2554896|NCT02533011||72 Hours|HBP lab test performed 72 hours after meeting sepsis inclusion criteria.
3205137|NCT00940784|Experimental|Clopidogrel|Subjects will be randomized to clopidogrel (oral-75 mg per day) in addition to low dose aspirin and hydroxyurea
3205138|NCT00940784|Placebo Comparator|Placebo|Subjects will be randomized placebo in addition to low dose aspirin and hydroxyurea
2555152|NCT02531360|Experimental|[18F]MNI-815 (MNI-815)|At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815
2555188|NCT02531152|Experimental|SAR366234 (Dose 1)|A low dose of SAR366234 will be administered 2 drops per eye per day for 28 days
2555193|NCT02531152|Experimental|SAR366234 (Dose 2)|A medium dose of SAR366234 will be administered 1 drop per eye per day for 28 days
2555194|NCT02531152|Experimental|SAR366234 (Dose 3)|A medium dose of SAR366234 will be administered 2 drops per eye per day for 28 days
2555195|NCT02531152|Experimental|SAR366234 (Dose 4)|A high dose of SAR366234 will be administered 1 drop per eye per day for 28 days
2555198|NCT02531152|Experimental|SAR366234 (Dose 5)|A high dose of SAR366234 will be administered 2 drops per eye per day for 28 days
2555199|NCT02531152|Active Comparator|Latanoprost|A dose of Latanoprost will be administered 1 drop per eye per day for 28 days
2555271|NCT02530736||IPF_RESP|Pulmonary Rehabilitation: a 6 - 8 week exercise and education programme (this is part of usual care)
3205139|NCT00940797|Experimental|DMMET-01|
2555382|NCT02530190|Active Comparator|Intermittent pneumatic compression|20 minutes of intermittent pneumatic compression
3205140|NCT00940797|Placebo Comparator|Control|
3205141|NCT00940810|Experimental|PDD procedure|
3205142|NCT00940810|Active Comparator|Conservative Care|
2553959|NCT02539316|Active Comparator|Médialipides|parenteral nutrition by Médialipides (dosage form depending child's weight as recommended by the SPC)
2553961|NCT02539316|Experimental|SmofLIPID|parenteral nutrition by Smoflipid (dosage form depending child's weight as recommended by the SPC)
2554019|NCT02538926|Experimental|Treatment (DA-EPOCH-A)|Patients receive etoposide, doxorubicin hydrochloride, and vincristine sulfate IV continuously over days 1-4, cyclophosphamide IV over 1 hour on day 5, and prednisone PO BID on days 1-5. Patients also receive asparaginase IM or IV over 1-2 hours every 2-3 days, beginning day 7 of each course. Patients who are CD20 positive and Philadelphia chromosome negative also receive rituximab IV on day 1 or 5. Patients who are Philadelphia chromosome positive also receive imatinib mesylate PO on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3205143|NCT00940836|Active Comparator|Resfenol|"Patients in this arm will receive 15 capsules containing a combination described below. They are instructed to take one capsule at 7, 11, 15, 19 and 23h every day, starting after baseline evaluation. The duration of the treatment goes from 48 to 72 hours, depending on patient availability for the second evaluation.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
3205144|NCT00940836|Placebo Comparator|Placebo|"Patients in this arm will receive 15 capsules of placebo, that they are instructed to take in the same posology and in the same duration than the active comparator.~Patients also receive co interventional acetaminophen pills, that they are allowed to take in case of persisting pain or fever, up to 4 times a day."
3205145|NCT00940849|Experimental|Dietary Supplement: Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
2554347|NCT02536820|Other|Conventional treatment + PNIT|PNIT: Psychoneuroimmuno therapy Conventional treatment: Usual treatment that each diabetic patient recieved
2554348|NCT02536820|Active Comparator|Conventional treatment|Conventional treatment: Usual treatment that each diabetic patient recieved
3205146|NCT00940862|Experimental|adalimumab|A total of 20 patients will be randomized to adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
2554549|NCT02535377||High cryoresistance|High resistance to sperm cryopreservation (decreased sperm motility <20%)
2554553|NCT02535377||Low cryoresistance|Low resistance to sperm cryopreservation (decreased sperm motility >20%)
2554683|NCT02534558|Experimental|miR-29a precursor oligonucleotide|Effects of IL-1β, miR-29a precursor oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
2554684|NCT02534558|Experimental|miR-29a antisense oligonucleotide|Effects of IL-1β, miR-29a antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
2554764|NCT02533973|Active Comparator|Xamiol® gel|calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks
2554770|NCT02533973|Active Comparator|. Daivonex® scalp solution|calcipotriol 50mcg/g twice daily as required, for up to 28 weeks
2554826|NCT02533622||Standard of care|Patients admitted to the ICU will receive current standard of care related to mobility
2554835|NCT02533622||Progressive mobility|patients admitted to the ICU will receive mobility per Progressive Mobility protocol using TotalCare beds and lifts
2554897|NCT02533193|Active Comparator|enhanced recovery after surgery protocal|ERAS perioperative cares patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
2554900|NCT02533193|Active Comparator|Conventional perioperative cares|Conventional perioperative cares patents will be managed by our hospital's critical pathways.
2554958|NCT02532712|Experimental|Single dose group-Group 1-Experimental|Single dose, 500mg of Study drug(EC-18)
2554959|NCT02532712|Placebo Comparator|Single dose group-Group 1-Placebo|Single dose, 500mg of Placebo
2554963|NCT02532712|Experimental|Single dose group-Group 2-Experimental|Single dose, 1000mg of Study drug(EC-18)
2554966|NCT02532712|Placebo Comparator|Single dose group-Group 2-Placebo|Single dose, 1000mg of Placebo
2554970|NCT02532712|Experimental|Single dose group-Group 3-Experimental|Single dose, 2000mg of Study drug (EC-18)
2554978|NCT02532712|Placebo Comparator|Single dose group-Group 3-Placebo|Single dose, 2000mg of Placebo
2554985|NCT02532712|Experimental|Single dose group-Group 4-Experimental|Single dose, 4000mg of Study drug (EC-18)
2554987|NCT02532712|Placebo Comparator|Single dose group-Group 4-Placebo|Single dose, 4000mg of Placebo
2554989|NCT02532712|Experimental|Multiple dose group-Group 1-Experimental|Multiple dose, Study drug(EC-18) 500mg, Once daily, for 14 days
2554991|NCT02532712|Placebo Comparator|Multiple dose group-Group 1-Placebo|Multiple dose, Placebo 500mg, Once daily, for 14 days
2554994|NCT02532712|Experimental|Multiple dose group-Group 2-Experimental|Multiple dose, Study drug(EC-18) 1000mg, Once daily, for 14 days
2554997|NCT02532712|Placebo Comparator|Multiple dose group-Group 2-Placebo|Multiple dose, Placebo 1000mg, Once daily, for 14 days
2555005|NCT02532712|Experimental|Multiple dose group-Group 3-Experimental|Multiple dose, Study drug(EC-18) 2000mg, Once daily, for 14 days
2555009|NCT02532712|Placebo Comparator|Multiple dose group-Group 3-Placebo|Multiple dose, Placebo 2000mg, Once daily, for 14 days
2555011|NCT02532712|Experimental|Multiple dose group-Group 4-Experimental|Multiple dose, Study drug(EC-18) 4000mg, Once daily, for 14 days
2555012|NCT02532712|Placebo Comparator|Multiple dose group-Group 4-Placebo|Multiple dose, Placebo 4000mg, Once daily, for 14 days
2555069|NCT02532049|Active Comparator|Group 1|ChAd63 Pfs25-IMX313 (5x10^9 vp)
2555076|NCT02532049|Active Comparator|Group 2A|ChAd63 Pfs25-IMX313 (5x10^10 vp)
2555081|NCT02532049|Active Comparator|Group 2B|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (1x10^8 pfu) 8 weeks later
2555082|NCT02532049|Active Comparator|Group 2C|ChAd63 Pfs25-IMX313 (5x10^10) and MVA Pfs25-IMX313 (2x10^8 pfu) 8 weeks later
2555274|NCT02530710|Placebo Comparator|Placebo|Placebo tablets (same excipients used in Q203 drug products)
2554016|NCT02538692|Experimental|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
2554026|NCT02538692|Placebo Comparator|Placebo|It is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
2554089|NCT02538536|Experimental|PBI4050|Four 200 mg capsules (total 800 mg) administered orally, once daily.
2554161|NCT02538146|Experimental|Treatment|Acetyl-L-carnitine 1000mg 2X per day for 3 months
2554205|NCT02537756|Experimental|1- Verbalize, Choice|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics they choose
2554208|NCT02537756|Experimental|2- Listen, Choice|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics they choose
2554209|NCT02537756|Experimental|3- Verbalize, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to verbalize their own arguments based on topics assigned to them
2554214|NCT02537756|Experimental|4- Listen, Assigned|Parents will use a tablet-based application (Project Voice) that directs them to listen to peer-generated arguments based on topics assigned to them
2554263|NCT02537392|Experimental|Vitamin B Complex and Folic Acid|Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
2554265|NCT02537392|Experimental|Iron and Folic Acid|Daily supplements of iron (60 mg) and folic acid (0.4 mg).
2554266|NCT02537392|Active Comparator|Folic Acid|Daily supplement of 0.4 mg folic acid.
2554319|NCT02537067|Experimental|Autologous cultured Chondrocyte|Subjects who give consent will be screened and those who meet trial criteria will receive CHONDRON (Autologous cultured Chondrocyte) by transplant.
2554349|NCT02536703|Experimental|Lotus Valve System|Transcatheter Aortic Valve Implantation (TAVI) with Lotus Valve System
2554372|NCT02536469|Experimental|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
2554431|NCT02536261||Withdrawal group|Withdrawal observation after reaching the withdrawal standard
2554436|NCT02536261||Continue treatment group|Continue treatment obsevation after reaching the withdrawal standard
2554461|NCT02535910|Experimental|breakfast rich in vitamin D3|subjects are asked to consume a breakfast with (20µg) vitamin D3 fortified milk and butter
2554462|NCT02535910|Experimental|breakfast rich in 25(OH) D3|subjects are asked to consume a breakfast with (20µg) 25(OH) D3 fortified milk and butter
2554463|NCT02535910|Placebo Comparator|Control|subjects are asked to consume a normal milk and butter (no vitamin D is added) in the breakfast
2554523|NCT02535689|Active Comparator|1|ARM 1: 10 of SLE patients will be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
2554525|NCT02535689|Active Comparator|2|ARM 2: 10 of SLE patients will NOT be heterozygous or homozygous for the STAT 4 risk alleles, receive treatment with tofacitinib 5 mg twice daily.
2554526|NCT02535689|Placebo Comparator|3|ARM 3: 10 of SLE patients will be with variable genotypes will receive placebo twice daily.
2554548|NCT02535351|Active Comparator|A: TKIs|sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
2554554|NCT02535351|Experimental|B: TKIs + Cytoreductive Nephrectomy|Cytoreductive nephrectomy + sunitinib 50 mg orally 4 weeks on/ 2 weeks off or pazopanib 800 mg orally continuously
3205147|NCT00940862|Active Comparator|Non-systemic treatment.|A total of 10 patients will be randomized to non systemic therapy for psoriasis (topical treatments and/or UVB phototherapy).
2554735|NCT02534194||Newborn Infant|Newborn babies (within 7 days of birth) born between 23-42 weeks.
2554753|NCT02533960||NOAC|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs).~Hemorrhagic stroke substudy: inclusion of 334 patients under treatment with non-vitamin K antagonist oral anticoagulants (NOACs)."
2554757|NCT02533960||VKA|"Ischemic stroke substudy: inclusion of 1000 patients under treatment with vitamin K antagonists (VKA).~Hemorrhagic stroke substudy: inclusion of 333 patients under treatment with vitamin K antagonists (VKA)"
2554758|NCT02533960||Without OAC|"Ischemic stroke substudy: inclusion of 1000 patients without oral anticoagulation.~Hemorrhagic stroke substudy: inclusion of 333 patients without oral anticoagulation."
2554815|NCT02533648|Experimental|Allopurinol|Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month
2554816|NCT02533648|Placebo Comparator|Placebo|Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month
2554876|NCT02533245|Experimental|Tx exercise group|"Convenience sample of solid organ transplant recipients (heart, kidney, lung, liver, pancreas, small bowel) participating in the Transplantoux exercise training intervention.~Intervention:~Home-based individualized exercise training program~Supervised group training sessions~Climb of the Mont Ventoux"
2554879|NCT02533245|No Intervention|Tx matched control group|Controls are retrieved from the Leuven University Hospital heart, kidney, lung, liver, pancreas, small bowel transplant database and matched (1:4 matching) based on type of transplant, gender, age and time since transplant.
2554883|NCT02533245|Experimental|Healthy exercise group|"Convenience sample of health care providers (e.g. doctor, paramedic or medical companion involved in care programs for organ Tx) and patient's family members and friends participating in the Transplantoux exercise training intervention.~Intervention:~Supervised group training sessions~Climb of the mont ventoux"
3205148|NCT00940914|Other|pain disorders|patients with Parkinson's disease presenting pain disorders
2555121|NCT02531529|Experimental|D group|intraoperative dexmedetomedine infusion
2555125|NCT02531529|Sham Comparator|F group|Intraoperative fentanyl infusion
2555196|NCT02531256|Experimental|LMA Protector|Single Use Supraglottic Airway Device with 2 ports for gastric access (male and female port)
3205149|NCT00940914|Other|without pain disorders|patients with Parkinson's disease without pain disorders
3205150|NCT00940940|Experimental|Live attenuated herpes zoster vaccine|
3205151|NCT00940940|Placebo Comparator|Placebo|
3205152|NCT00940953|Experimental|Captisol-Enabled Budesonide + Azelastine|
3205153|NCT00940953|Active Comparator|Rhinocort Aqua+Astelin|
2554096|NCT02538367|Experimental|YH12852 IR 0.05mg|Once daily
2554100|NCT02538367|Experimental|YH12852 IR 0.1mg|Once daily
2554101|NCT02538367|Experimental|YH12852 IR 0.3mg|Once daily
2554104|NCT02538367|Experimental|YH12852 IR 0.5mg|Once daily
2554105|NCT02538367|Experimental|YH12852 IR 1mg|Once daily
2554106|NCT02538367|Experimental|YH12852 IR 2mg|Once daily
2554107|NCT02538367|Experimental|YH12852 IR 3mg|Once daily
2554108|NCT02538367|Experimental|YH12852 DR1 0.5mg|Once daily
2554109|NCT02538367|Experimental|YH12852 DR1 1mg|Once daily
2554110|NCT02538367|Experimental|YH12852 DR1 2mg|Once daily
2554111|NCT02538367|Experimental|YH12852 DR1 4mg|Once daily
2554115|NCT02538367|Experimental|YH12852 DR2 8mg|Once daily
2554118|NCT02538367|Active Comparator|Prucalopride 2mg|Once daily
2554123|NCT02538367|Placebo Comparator|Placebo|Once daily
2554188|NCT02537847|Experimental|Sitafloxacin group|The first third days of treatment was open label and all patients were given intravenous carbapenems. After day 3, the patients were randomized to either sitafloxacin group or ertapenem group by the use of a computer-generated random number allocation schedule and block size of four. The patients were allocated to the sitafloxacin group or ertapenem group using the sealed envelope method.
2554189|NCT02537847|Active Comparator|control group|Intervention was prescribed ertapenem for patients.
2554250|NCT02537600|Experimental|Cobimetinib + Vemurafenib combination|"Every patients will be treated with :~Vemurafenib 1920 mg / day from day 1 to day 28 continuously Cobimetinib 60 mg / day from day 1 to day 21 One cycle = 28 days Intervention = Cobimetinib + Vemurafenib combination treatment. Only one arm."
2554300|NCT02537080|Experimental|Nimodipine group|1 tbl of 30 mg nimodipine will be administered orally with premedication
2554302|NCT02537080|Experimental|Control group|1 tbl of placebo will be administered orally with premedication
3205154|NCT00940953|Placebo Comparator|Placebo|
2554487|NCT02535884|Experimental|Stimulation group|Patients in the stimulation group will be stimulated immediately after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
2554491|NCT02535884|Sham Comparator|Non-stimulation group|Patients in the non-stimulation group will not be stimulated for the first three months after implantation of the Stimulator (ACTIVA® PC neurostimulator (Model 37601))
2554546|NCT02535455|Experimental|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
2554634|NCT02535091|Experimental|YKP3089|Multiple dose
2554759|NCT02534025|Experimental|P group|Elevation of Cuff pressure to 200 mm Hg for 5 minutes four times 5 minutes apart
2554761|NCT02534025|No Intervention|C group|no intervention will be added to routine anesthetic mangement
2554804|NCT02533687|Active Comparator|Bipolar TURP-1|Transurethral resection of prostate (TURP) with bipolar resectoscope (Gyrus brand)
2554807|NCT02533687|Active Comparator|Bipolar TURP-2|TURP with bipolar resectoscope (Olympus brand)
2554810|NCT02533687|Active Comparator|Monopolar TURP|TURP with monopolar resectoscope (Karl Storz brand)
2554844|NCT02533362|Experimental|ANF-Rho|pegfilgrastim Anti-Neutropenic Factor (ANF)
3205155|NCT00940966|Experimental|energy restricted very-low carbohydrate|non-energy restricted ketogenic diet .
3205156|NCT00940966|Active Comparator|ADA diet|standard ADA diet
2554969|NCT02532777|Experimental|Prednisone & Cyclophosphamide|"Drug: prednisone & cyclophosphamide & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~cyclophosphamide: 0.1mg/kg. Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
2554971|NCT02532777|Experimental|Prednisone & Mycophenolate mofetil|"Drug: prednisone & mycophenolate mofetil & Angiotensin-converting enzyme inhibitor(ACEI).~Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~mycophenolate mofetil: 25mg/kg/d bid (the maximum dose is 1.5g/d). Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
2554996|NCT02532686|Placebo Comparator|placebo|
3205157|NCT00940966|Active Comparator|low glycemic index|restricted ketogenic diet
2555048|NCT02532218|Active Comparator|Active|ARI-3037MO (niacin analog) 3g bid for 24 wks
3205158|NCT00940979|No Intervention|No use of integuseal|
3205159|NCT00940979|Experimental|Use of Integuseal|Application of a layer of Integuseal (Cyanoacrylate) from a ready to use applicator preoperative before incision Polymerisation immobilise the bacteria that survived the conventional skin preparation This way there will be les contamination of the wound.
3205160|NCT00941018|Experimental|SAD cohort 1|Single ascending dose (SAD) cohort 1 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The starting dose will be 300 mg. Subsequent doses will be determined by the pk and safety data from previous cohorts.
3205161|NCT00941018|Experimental|SAD cohort 2|SAD cohort 2 will participate in three dosing periods separated by 2 weeks. Eight subjects will be enrolled, 6 will receive RX-10001 and 2 will receive vehicle control. The doses to be administered will be determined by the pk and safety data from previous cohorts.
3205162|NCT00941018|Experimental|MAD cohort 1|Multiple ascending dose (MAD) cohort 1 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous SAD cohorts.
3205163|NCT00941018|Experimental|MAD cohort 2|MAD cohort 2 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
3205164|NCT00941018|Experimental|MAD cohort 3|MAD cohort 3 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohorts.
2554095|NCT02538263|No Intervention|Pressure-limited noninvasive ventilation|For Pressure-limited noninvasive ventilation, IPAP was initially set at 10 cmH2O, and was adjusted by increments of 1-2 cmH2O according to patients' tolerance (up to 25 cmH2O) to obtain a VT of 8-10 ml/kg of ideal body weight and a respiratory rate (RR) less than 25 breaths/min.
2554155|NCT02538159|Experimental|Experimental CVC|CVC insertion Non-tunneled Central venous catheter insertion
2554156|NCT02538159|Experimental|Experimental PICC|PICC insertion Peripherally inserted catheter
2554187|NCT02537886||Evaluation Group|Researchers will conduct a focus group to evaluate VIC after it has been developed and used by patients. Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC. We will use this information to enhance the generalizability of the VIC approach.
2554211|NCT02537639||Control group|Control group. Standard teaching in transesophageal echocardiography.
2554216|NCT02537639||Intervention group|Intervention group. Additional teaching with a transesophageal echocardiography simulator.
2554304|NCT02537405|Experimental|BAY59-7939 granule|
2554306|NCT02537405|Active Comparator|BAY59-7939 tablet|
2554342|NCT02536807|Experimental|Hyaluronan|Hyaluronan gel injection
2554345|NCT02536807|Placebo Comparator|Control|Control placebo gel injection
2554353|NCT02536547||patients with suspected VAP|"All patients with suspected VAP will be included in the study (new or extension of a radiological image in a patient in mechanical ventilation for at least 48 hours associated with at least two of the following:criteria :~fever ≥38.5 ° C or <36, 5 ° C leukocytosis> 10 * 103 / ml or leukopenia <4 * 103 / ml secretions purulent tracheal reduction in PaO2 / FiO2 <300 or PaO 2 <60 mmHg"
2554398|NCT02536417|Active Comparator|Treatment arm: melatonin|melatonin 0.5 mg as treatment, to be given daily at bedtime
2554400|NCT02536417|Placebo Comparator|Placebo arm|Sugar pill identical in appearance to the melatonin 0.5 mg tablets used in treatment arm
2554474|NCT02535871|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
2554478|NCT02535871|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
2554542|NCT02535637||Mothers-Infant|Mothers who were planning to exclusively breastfeed for six months were enrolled into the study along with their infant.
2554596|NCT02535208|Experimental|Restrictive transfusion group|
2554599|NCT02535208|Active Comparator|Liberal transfusion group|
2554614|NCT02534805||Patient Buddy|Subjects and caregivers will be given iphones loaded with the App that will be used to enter medications, issues and orientation questions. They will be seen at day 15 and day 30 and will receive a phone call day 7 and day 21 inquiring about issues that would need medical attention
2554697|NCT02534363|Active Comparator|Aripiprazole & cognitive battery|Aripiprazole 5-30 mg/day. Cognitive battery at baseline and at 1 year.
2554699|NCT02534363|Active Comparator|Quetiapine & cognitive battery|Quetiapine 100-600 mg/day. Cognitive battery at baseline and at 1 year.
2554702|NCT02534363|Active Comparator|Ziprasidone & cognitive battery|Ziprasidone 40-160 mg/day. Cognitive battery at baseline and at 1 year.
3205165|NCT00941018|Experimental|MAD cohort 4|MAD cohort 4 will consist of 10 subjects, 8 will receive RX-10001 and 2 will receive vehicle control. The dose of RX-10001 to be administered will depend upon the pk and safety results of the previous cohort.
3205166|NCT00941044|Experimental|non-invasive NAVA|application of non-invasive neurally adjusted ventilatory assist in healthy volunteers
3205167|NCT00941057|Experimental|Estradiol + dienogest + levomefolate|Treatment A
2554999|NCT02532504|Experimental|CBT seven sheets|"8 sessions of CBT based intervention called change your life with seven sheets of paper"
2555007|NCT02532504|No Intervention|Treatment As Usual|Treatment As Usual
3205168|NCT00941057|Active Comparator|Estradiol + dienogest|Treatment B
3205169|NCT00941057|Active Comparator|Levomefolate|Treatment C
2555258|NCT02530827||LIPO-HIPO-|HIV-seropositive without lipodystrophy and no use of lipid-lowering drugs.
2555262|NCT02530827||LIPO+HIPO-|HIV-seropositive with lipodystrophy and no use of lipid-lowering drugs.
2555265|NCT02530827||LIPO+HIPO+|HIV-seropositive with lipodystrophy and use of lipid-lowering drugs.
2555330|NCT02530567|Experimental|Intervention|"The measurement of portosystemic pressure gradient will be performed before liver biopsy.~Then liver biopsy is performed. The MRI was performed on the day of biopsy or within one week around the completion of the biopsy.~The MRI machine used is the Siemens 3T."
2555364|NCT02530229||Periprosthetic joint infection|Patients with suspected periprosthetic joint infection of the hip, knee and shoulder
2555368|NCT02530229||Septic arthritis|Patients with suspected septic arthritis of a native joint of the hip, knee and shoulder
2555407|NCT02530021||Heart rate monitor|"Hospitalized patients with chest pain and suspected ischemic heart disease who are candidates for non invasive exercise stress test by their treating physician.~The patients will perform a one hour heart rate variability monitoring prior to the stress test."
3205170|NCT00941083|Experimental|RAL QD 800 mg/24 hs|
3205171|NCT00941083|Active Comparator|RAL BID 400 mg/12 hs|
3205172|NCT00941083|Experimental|RAL BID to QD|
3205173|NCT00941109|Experimental|1|
3205174|NCT00941109|Experimental|2|
3205175|NCT00941109|Experimental|3|
3205176|NCT00941109|Experimental|4|
3205177|NCT00941122||MRSA/VRE patients|patients known to be colonized with MRSA/VRE
3205178|NCT00941148|Active Comparator|Insulin glargine|Insulin glargine, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3205179|NCT00941148|Active Comparator|NPH Insulin|NPH Insulin, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3205180|NCT00941148|Active Comparator|Insulin detemir|Insulin detemir, dose individually adapted to reach treatment goal (FBG < 100 mg/dL)
3205181|NCT00941161|Experimental|combination|long acting Metformin/Glimepiride
3205182|NCT00941161|Active Comparator|metformin|metformin hydrocloride
3205183|NCT00941161|Active Comparator|glimepiride|glimepiride
2554122|NCT02538393|Experimental|Treatment C-D-A-B|Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the second intervention period; followed by a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the third intervention period; and then a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
2554126|NCT02538393|Experimental|Treatment D-B-C-A|Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) (Treatment D) in the first intervention period; followed by a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state (Treatment B) in the second intervention period; followed by a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state (Treatment C) in the third intervention period; and then a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state (Treatment A) in the fourth intervention period. A washout period of at least 10 days was maintained between sorafenib administrations.
2554160|NCT02537977|Experimental|CAR-T cells|Autologous 2nd generation CD19-directed CAR-T cells
2554192|NCT02537769|Experimental|LVAD+TVR|In addition to left ventricular assist device (LVAD) placement with the inflow cannula in the left ventricular apex and outflow cannula placed in the ascending aorta, a repair of the regurgitating tricuspid valve will be performed. A Patent Foramen Ovale, if present, will be closed primarily. Echocardiographic parameters relevant to study will be collected throughout the procedure.
2554193|NCT02537769|Active Comparator|LVAD only|LVAD placement will be performed without additional tricuspid valve repair (TVR). The inflow cannula will be sutured to the left ventricular apex followed by the outflow cannula placed in the ascending aorta. This will be performed under cardiopulmonary bypass. Echocardiographic parameters relevant to study will be collected throughout the procedure.
3205184|NCT00941174|Active Comparator|Capsule: 400 microg 13C5-Calcium-L-Leucovorin|
3205185|NCT00941174|Active Comparator|IV Injection: : 100 microg 13C5-Calcium-L-Leucovorin|
3205186|NCT00941187||patients after a first episode of pulmonary embolism|
3205187|NCT00941200||Blood collection|
3205188|NCT00941213|Active Comparator|Monopolar Electrosurgery|Preparation during the operation with Monopolar Electrosurgery
2554376|NCT02536612|Experimental|Lottery|"Conditional economic incentive (CEI) lotto arm participants will get a chance to win a type of lottery or lotto ticket with a 50% chance of winning each time: (a) if they come back to the clinic and are still using a modern contraception method after 3 months (including IUD, injectable contraceptive, or implant); (b) if they come back to the clinic and are still using modern contraception after 6 months; and (c) if they come back to the clinic at 6 months and they don't have a new curable STD (such as syphilis).~They will also will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months."
2554381|NCT02536612|Active Comparator|No Lottery|Participants in the Control (No CEI Lotto) group will receive reimbursement to cover their transport and time at baseline, at 3 months and at 6 months; they will NOT have a chance to win a lottery even if they are still using a modern contraception and are free of new curable STDs.
3205189|NCT00941213|Experimental|Ultrasound scissors|Preparation during the operation with ultrasound scissors
3205190|NCT00941226||Cerebral Palsy|Those kids who have cerebral palsy and are helped by carers
2554498|NCT02535754|Experimental|ALIVE|Email program N=170
2554500|NCT02535754|Experimental|CCS BCY|Comprehensive program N=285
2554502|NCT02535754|Experimental|ALIVE + CCS BCY|Email + comprehensive program N=225
2554552|NCT02535468||Prospective Arm|
2554559|NCT02535468||Contrived Arm|
2554610|NCT02535130|Experimental|Nebulization combined to positive expiratory pressure|Experimental arm
2554618|NCT02535130|Active Comparator|Nebulization|Control arm
2554706|NCT02534636|Experimental|Part A: Single ascending dose|BMS-986165 or Placebo specified dose on specified days
2554707|NCT02534636|Experimental|Part B: Multiple ascending dose|BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days
2554708|NCT02534636|Experimental|Part C: Multiple ascending dose|BMS-986165 or Placebo specified dose on specified days
2554709|NCT02534636|Experimental|Part D: Relative Bioavailability|BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days
2554748|NCT02533908|Active Comparator|Fentanyl intranasal|Fentanyl Sintetica 0.1mg/2ml: 1.5ug/kilogram intranasal= 0.03ml/kg once
2554749|NCT02533908|Placebo Comparator|NaCl 0.9% intranasal|NaCl 0.9% Sintetica 18mg/2ml: same dosage as fentanyl= 0.03ml/kg
3205191|NCT00941239|Experimental|metformin ER|Extended Release Metformin
3205192|NCT00941239|Active Comparator|metformin|Immediate release metformin
2554899|NCT02532959||Diagnostic Breath Analysis|Patients at risk of SIRS
2554967|NCT02532738|Experimental|MSC-1|Patients in this arms receive routine treatment with 3×10E6/kg of MSC
2554972|NCT02532738|Experimental|MSC-2|Patients in this arms receive routine treatment with 6×10E6/kg of MSC
2554979|NCT02532738|Placebo Comparator|Ctrl|Patients in this arms receive routine treatment with NS injection
3205193|NCT00941252|Active Comparator|Imiquimod|topical therapy for 16 weeks with imiquimod containing therapy
3205194|NCT00941252|Placebo Comparator|Placebo|topical therapy for 16 weeks with a placebo containing vaginal suppository
3205195|NCT00941265|Other|levodopa 100 mg and benserazide 25 mg|2 weeks with Daily CAT on list A+ levodopa and benserazide
3205196|NCT00941265|Other|placebo|2 weeks with Daily CAT on list B + placebo.
3205197|NCT00941278|Experimental|PH-10 Treatment|
3205198|NCT00941291||vitrectomy in pseudophakic eyes|
3205199|NCT00941291||vitrectomy and cataract:combined procedure|
3205200|NCT00941291||vitrectomy followed by cataract extraction|
3205201|NCT00941291||vitrectomy on phakic eyes|
3205202|NCT00941343|Experimental|1|XATRAL 10mg OD
3205203|NCT00941356|Experimental|1|Bio-K+ CL1285 contains 50 billion of live bacteria
3205204|NCT00941356|Placebo Comparator|2|placebo devoid of bacteria
2554152|NCT02538185|Placebo Comparator|Vaccine injected IM with classical syringe|"Right forearm, ID with NanoJect device (DebioJect™) filled with placebo (0.1mL);~Left forearm, ID with classical syringe filled with placebo (0.1mL);~Non-dominant deltoid, IM with classical syringe filled with vaccine (0.5mL)."
2554301|NCT02537418|Experimental|durvalumab ± tremelimumab|"durvalumab; Day 1 every 3 weeks or 4 weeks~tremelimumab; every 3-6 weeks for a total of 1-6 doses"
2554356|NCT02536768|Experimental|Intervention|Minimum package of interventions to improve ART adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
2554357|NCT02536768|No Intervention|Comparison|Standard of care HIV treatment
2554531|NCT02535533|Experimental|Study Treatment|"During the Dose-Escalation Part 1, patients will receive SLM twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Expansion Part 2, patients will be treated at the maximum tolerated dose (MTD) of SLM determined as 4000 mcg SLM. SLM will be given orally twice daily for 14 days followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert. Treatment will continue until disease progression or unacceptable toxicity.~During the Pilot Phase, dosing will begin at dose level 3 (4000, 5000, or 6000 mcg SLM calculated based on patients' BSA). SLM will be given orally twice daily for 14 days. Each cohort will enroll 2 evaluable patients."
2554588|NCT02535182||Control Arm|Patients who participate as controls on the main study will be controls on this ancillary study. The control arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
2554590|NCT02535182||Propranolol Arm|Patients who participate on the propranolol arm on the main study will be on the propranolol arm on this ancillary study. The propranolol arm will have blood drawn at baseline, day -2 and day -28 for the Rap1 testing.
2554621|NCT02534870|Experimental|ABT-450/r/ABT-267 + ABT-333|ABT-450/r/ABT-267 will be administered once daily in the morning and ABT-333 will be administered in the morning and evening for 14 days.
2554736|NCT02534220|Active Comparator|Manual Toothbrush|Patients were instructed in the Roll Brushing Technique, twice daily for 2 min.
2554737|NCT02534220|Experimental|Oscillating-rotating toothbrush|Patients received manufacturer's instructions for use, including brushing twice daily for 2 min.
2554796|NCT02533869|Experimental|Low-dose CT for acute appendicitis|Low-dose computed tomography for diagnosing acute uncomplicated appendicitis Laparoscopic appendectomy
2554827|NCT02533492|Active Comparator|Vicryl|Vicryl suture for wound closure after total knee replacement
2554833|NCT02533492|Experimental|vicryl plus|Vicryl plus suture for wound closure after total knee replacement
2554882|NCT02533128|Placebo Comparator|Liberal blood pressure management|
2554889|NCT02533128|Active Comparator|Tight blood pressure management|
2554935|NCT02532790|Experimental|group 1|Prednisone Drug : prednisone 1.5mg/kg/d for 4-6 weeks, then 1.5mg/kg/d qod for 4 weeks, reduce 5mg every 2-4 weeks If the proteinuria decreases by less than 50% after treating for two months, this candidate reaches the ending point.
2554936|NCT02532790|Experimental|group 2|Angiotension converting enzyme inhibitors(ACEI) Drug: lotensin 0.2-0.3mg/kg/d (the maximum dose is 20mg)
2554977|NCT02532413|Experimental|HBeAg(+):Poly IC+Entecavir|"45 subjects(HBeAg-positive chronic hepatitis B). Combination therapy will last 24 weeks from 0 week.~Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
2554983|NCT02532413|Active Comparator|HBeAg(+):Entecavir|45 subjects(HBeAg-positive chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
2554986|NCT02532413|Experimental|HBeAg(-):Poly IC+Entecavir|"45 subjects(HBeAg-negative chronic hepatitis B). Combination treatment will last 24 weeks from 0 week.~Drug: Enticavir 0.5mg, P.O.,qd, duration:48 weeks. Drug: PolyIC 2mg,im,qod,duration:from 0 week to 24th week"
2554988|NCT02532413|Active Comparator|HBeAg(-):Entecavir|45 subjects(HBeAg-negative chronic hepatitis B). Drug: Entecavir 0.5mg, P.O.,qd, duration:48 weeks.
3171044|NCT00581802||3|Nonintensively studied participants initiating potentially suppressive drug therapy
2555095|NCT02531906|Experimental|Arm I (gabapentin)|"Patients receive gabapentin PO TID for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
2555098|NCT02531906|Experimental|Arm II (gabapentin, methadone, oxycodone)|"Patients receive gabapentin PO TID, methadone hydrochloride PO BID, and oxycodone hydrochloride PO Q8H PRN for up to 7 weeks during radiotherapy.~All patients may continue to receive treatment for pain throughout their course of chemoradiation therapy (and up to 24 months following CRT if continuing on a pain regimen)."
2555132|NCT02531464|Experimental|Experimental: supportive care|Family caregivers (FC) in the experimental arm (supportive care) will be exposed to a multi-faceted intervention to help them cope with their caregiving role, support them and respond to their needs; the intervention includes 3 components: 1) systematic distress screening and problems assessment of FCs at 2-month interval during the study period; 2) privileged contact with an oncology nurse away from the patient to further identify and address FCs' problems; 3) liaison by the oncology nurse with the family physician of FCs fwho will have reported high distress or needing help
2555136|NCT02531464|No Intervention|Control: usual care|In the control arm (usual care), FCs will assist to their relative initial visit to the pivot nurse in oncology (PNO) . The PNO screens patients for distress and assesses their needs. She does a bio-psycho-social comprehensive evaluation and may provide help and information. She responds to questions and refers to appropriate resources, staying available for patients and their FCs throughout the cancer care trajectory. However, most PNO interventions target the patient, with no systematic distress screening and problems assessment for FCs, nor any service and resource specifically dedicated to them. If FCs clearly express distress or particular needs, the PNO will address them or refer to appropriate resources, but, in usual care, only few FCs receive support services
2555217|NCT02530983||Esophagectomy/Esophageal Reconstruction|Patients who have undergone esophagectomy or esophageal reconstruction
2555270|NCT02530710|Experimental|Q203|Q203 drug products (10mg and 100mg tablets)
2555387|NCT02530190|Active Comparator|Massage|20 minutes of massage therapy
3171045|NCT00581802||4|Nonintensively studied well-suppressed participants on HAART
3174297|NCT00621998|Experimental|1|Flexible dose of olanzapine
2554185|NCT02537912|Active Comparator|Sugarlock®|Subjects ingested 2 capsules Sugarlock® (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
2554186|NCT02537912|Placebo Comparator|Placebo|Subjects ingested 2 capsules placebo (Control group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks.
2554225|NCT02537652||Major Stroke|Patients diagnosed with major stroke who will undergo blood pressure assessment
2554228|NCT02537652||Minor stroke|Patients diagnosed with minor stroke who will undergo blood pressure assessment
2554320|NCT02537054|Experimental|Aflibercept|2 mg/ dose (pro re nata, maximum 1 dose/ month), intravitreal use
2554371|NCT02536729||Oral Sodium Phosphate - Normal preparation|Oral sodium phospate exposure with special diet (Liquid)
2554378|NCT02536729||Oral Sodium Phosphate - Modified preparation|Oral sodium phospate exposure with special diet (Liquid), but the participant can normally lunch the day before the test
2554383|NCT02536729||polyethylene glycol + Electrolytes|polyethylene glycol + Electrolytes exosure with special diet (Liquid)
2554399|NCT02536209|Experimental|Regimen 1|Period 1: MT-8554 low dose, Period 2: MT-8554 high dose, Period 3: Placebo and Period 4: Oxycodone hydrochloride, respectively single dosing
2554401|NCT02536209|Experimental|Regimen 2|Period 1: MT-8554 high dose, Period 2: Oxycodone hydrochloride, Period 3: MT-8554 low dose and Period 4: Placebo, respectively single dosing
2554403|NCT02536209|Experimental|Regimen 3|Period 1: Placebo, Period 2: MT-8554 low dose, Period 3: Oxycodone hydrochloride and Period 4: MT-8554 high dose, respectively single dosing
2554405|NCT02536209|Experimental|Regimen 4|Period 1: Oxycodone hydrochloride, Period 2: Placebo, Period 3: MT-8554 high dose and Period 4: MT-8554 low dose, respectively single dosing
2554466|NCT02536014|Experimental|Dexmedetomidine|
2554467|NCT02536014|Active Comparator|Saline|
2554516|NCT02535676|Active Comparator|Active tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 20 minutes.
2554517|NCT02535676|Sham Comparator|Sham tDCS|Sham Comparator: Sham Stimulation In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the temporo-parietal cortex with the Transcranial Direct Current Stimulation. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 19 minutes.
2554536|NCT02535403|Experimental|ICBT|14 weeks of internet-based cognitive behavioral therapy with therapist support
2554539|NCT02535403|No Intervention|Wait-list|14 weeks wait-list control
2554591|NCT02535234|Active Comparator|Arm 1|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Novel system followed by 7 nights with theTraditional system
2554593|NCT02535234|Active Comparator|Arm 2|Participants randomised to Arm 1 will receive an intervention of 7 nights with the Traditional system followed by 7 nights with the Novel system
2554624|NCT02534844|Experimental|Parts A/B: Sham Control|Participants receive no study drug
2554627|NCT02534844|Other|Parts A/B: Adrabetadex|Participants receive adrabetadex
2554705|NCT02534376|Experimental|Treatment|Vytorin (ezetimibe 10mg-simvastatin 40mg)
2554765|NCT02534116|Experimental|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will have incisional vacuum-assisted closure (VAC) therapy performed.
2554767|NCT02534116|Active Comparator|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision.
2554850|NCT02533349|Active Comparator|Proton pump inhibitor + prokinetics|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with prokinetics (Motilitone, 30mg, 1T, TID) for 3months.
2554852|NCT02533349|Placebo Comparator|Proton pump inhibitor + placebo|Patient will be prescribed proton pump inhibitor (pantoprazole, 40mg, 1T QD) with placebo (Motilitone, 30mg, 1T, TID) for 3months.
3205205|NCT00941369|Experimental|1|Insulin glargine: Lantus® (100 U/ml) in TactiPen® re-usable pen
3205206|NCT00941369|Active Comparator|2|Neutral Protamine Hagedorn basal insulin: Insuman® Basal (100 I.U./ml) in TactiPen® re-usable pen
3205207|NCT00941382|Experimental|Sibutramin-Metformin|Sibutramine-metformin therapy in a single tablet
3205208|NCT00941382|Active Comparator|Sibutramine|Sibutramine monotherapy
3205209|NCT00941382|Active Comparator|Metformin|Metformin monotherapy
3205210|NCT00941395|Experimental|Arm I (smoker, survey)|Participants who currently smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2. Participants also complete 3 internet surveys over 20 minutes.
3205211|NCT00941395|Experimental|Arm II (non-smoker, survey)|Participants who currently do not smoke complete a survey over 30 minutes and discuss the survey results with the counselor over 30 minutes at week 2.
3205212|NCT00941408||Diagnostic tumor core biopsy|
3205213|NCT00941421|Other|videocapsul and OGDFE|Each patient have a Fiberoptic endoscopy by videocapsul, followed by one traditional oeso-gastro-duodenal fiberoptic endoscopy
3205214|NCT00941434|Experimental|RUTF|Children with Severe malnutrition will be treated with Ready to use therapeutic food (RUTF) till their weight for age z scores are no longer in severe malnutrition group
3205215|NCT00941447|Experimental|Self-Regulation|Self Regulation Arm focuses on increasing participants self-monitoring blood glucose (SMBG) AND awareness of self-regulatory approaches to managing diabetes.
3205216|NCT00941447|Experimental|Self-Monitoring|Self-Monitoring Arm focuses on increasing participants self-monitoring blood glucose (SMBG) and providing nutrition education ONLY.
3205217|NCT00941460|Experimental|one week on one week off|One week on temozolomide is followed by a week without temozolomide.
3205218|NCT00941460|Experimental|three weeks on, one week off|Temozolomide is given over 3 weeks, followed by a week without temozolomide.
3205219|NCT00941473|Active Comparator|Epidural Steriod Injection|This study focuses on the changes in bone mineral density over time of the cohort previously described in the inclusion criteria (post-menopausal white women)
3205220|NCT00941486|Experimental|FST-100 Ophthalmic Suspension|FST-100 (PVP-I 0.4% and dexamethasone 0.1%)
3205221|NCT00941486|Placebo Comparator|Vehicle|
3205222|NCT00941499|Experimental|Group 1|HAI oxaliplatin in combination with HAI 5-fluorouracil and IV bevacizumab
3205223|NCT00941499|Experimental|Group 2|HAI oxaliplatin in combination with IV 5-fluorouracil, leucovorin, bevacizumab, and cetuximab
2554241|NCT02537353|Placebo Comparator|Group 1|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application of metal clips. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
2554243|NCT02537353|Active Comparator|Group 2|Patients with a clinical diagnosis of upper gastrointestinal bleeding and that during endoscopy revealed to non-varicose bleeding lesions in the endoscopic treatment being necessary. The group will be submitted to injection of adrenaline at a proportion of 1: 10,000 in the four quadrants of the lesion associated with application adsorption powder, marketed under the name Hemospray. The patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
2554282|NCT02537197|Experimental|Treatment Group|Regular Naltrexone dosing (approximately 12 weeks): Initially, participants will be given seven 25mg oral naltrexone (ReVia, Generic Health, or similar) half tablets at intake (days 1-7). The Full dosing regimen will begin if no toxicity issues are present and consists of fourteen 50mg tablets (two per day; 100mg). If required, dosages can be stepped up or down. If adverse symptoms persist (or if gambling symptoms escalates), the participant will be removed from the study and given alternative treatments. Participants will receive the following week's medication at each Calgary Opioid Dependence Program visit. Pill counts will be made at each visit. Physicians will monitor the progress of participants from intake and adjust dosages up or down to control gambling behaviour.
3205224|NCT00941499|Experimental|Group 3|HAI oxaliplatin in combination with IV bevacizumab.
2554359|NCT02536586|Experimental|LY3023414|LY3023414 administered orally, twice daily in 21-day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or other discontinuation criteria are met.
2554425|NCT02536391|Experimental|Sequence 1: Tablet/Capsule/Tablet with food|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
2554428|NCT02536391|Experimental|Sequence 2: Tablet/Tablet with food/Capsule|Day 1: ipatasertib tablet administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib capsule administered after fast.
2554433|NCT02536391|Experimental|Sequence 3: Capsule/Tablet/Tablet with food|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib tablet administered after high-fat meal.
2554439|NCT02536391|Experimental|Sequence 4: Capsule/Tablet with food/Tablet|Day 1: ipatasertib capsule administered after fast, Day 8: ipatasertib tablet administered after high-fat meal, Day 15: ipatasertib tablet administered after fast.
2554441|NCT02536391|Experimental|Sequence 5: Tablet with food/Tablet/Capsule|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib tablet administered after fast, Day 15: ipatasertib capsule administered after fast.
2554443|NCT02536391|Experimental|Sequence 6: Tablet with food/Capsule/Tablet|Day 1: ipatasertib tablet administered after high-fat meal, Day 8: ipatasertib capsule administered after fast, Day 15: ipatasertib tablet administered after fast.
3205225|NCT00941499|Experimental|Group 4|HAI oxaliplatin in combination with IV bevacizumab and cetuximab.
2554605|NCT02535247|Experimental|Treatment|MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles
2554606|NCT02535247|Active Comparator|Combination|MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study
2554636|NCT02534792||Revalvulation time early|Early revalvulation by homograft or percutaneous valve
2554638|NCT02534792||Revalvulation time late|Late revalvulation by homograft or percutaneous valve
2554657|NCT02534571|Experimental|TC-325|Endoscopic Application of a Hemostatic Powder TC-325, <=150gm , once
2554658|NCT02534571|Active Comparator|standard treatment|standard treatment of either hemo-clipping or thermo-coagulation with or without pre injection with diluted epinephrine <=20 clip or4 pulse , once only
2554717|NCT02534337|Experimental|GEMOX|gemcitabine 1000 mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2.
2554720|NCT02534337|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2.
3205226|NCT00941525|Other|Ocular hypertensives|"This study includes two groups.~Subjects with ocular hypertension and~Controls. Group 2 undergoes only 1 visit (visit 1) without any intervention. Group 1 undergoes visit 1 without intervention. Then they receive treatment (1 eyedrop of latanoprost (0.005%) dosed once a day in both eyes at 8:00pm for a 4-weeks period for 1 month) and undergo the visit 2 under the effect of treatment."
3205227|NCT00941538||Screening, Control|
2554858|NCT02533310|Experimental|OST treatment with in-vivo spiders|OST consists of increasingly intense interactions with an in-vivo phobic stimuli and human therapist non-phobic behavior modelling.
2554859|NCT02533310|Experimental|VR-OST treatment with virtual spiders|VR-OST consists of simulated OST treatment without the use of live spiders and with the support of a virtual therapist.
2554875|NCT02532985|Placebo Comparator|Negative control|No added fiber
2554878|NCT02532985|Active Comparator|Positive fiber control|90g positive control fiber
2554881|NCT02532985|Experimental|Novel fiber 30g|30g novel fiber
2554884|NCT02532985|Experimental|Novel fiber 60g|60g novel fiber
2554890|NCT02532985|Experimental|Novel fiber 90g|90g novel fiber
3205228|NCT00941551||Group A|receiving levothyroxine postoperatively
3205229|NCT00941551||Group B|not-receiving levothyroxine postoperatively
3205230|NCT00941564|Experimental|Commercially available infant formula A|Varying fat blend from comparator product
3205231|NCT00941564|Active Comparator|Commercially available infant formula B|
3205232|NCT00941577|Experimental|AIR645|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
3205233|NCT00941577|Placebo Comparator|Physiologic saline solution|Physiologic saline solution
2554217|NCT02537587|Active Comparator|Control 2|86g of Control energy bar containing 5g protein, 20g fat, 55g carbohydrate, 3g fiber and 30g sugar
2554219|NCT02537587|Experimental|15/0|Experimental bar with 15% added resistant starch and 0% added protein; 66g portion containing 3g protein, 7g fat, 50g carbohydrate, 10g fiber and 16g sugar
2554221|NCT02537587|Experimental|15/0-LS|Experimental bar with 15% added resistant starch and 0% added protein with reduced sugar; 84g portion containing 4g protein, 8g fat, 55g carbohydrate, 15g fiber and 15g sugar
2554222|NCT02537587|Experimental|15/5|Experimental bar with 15% added resistant starch and 5% added protein; 75g portion containing 9g protein, 7g fat, 52g carbohydrate, 12g fiber and 17g sugar
2554223|NCT02537587|Experimental|10/5|Experimental bar with 10% added resistant starch and 5% added protein; 72g portion containing 10g protein, 8g fat, 49g carbohydrate, 9g fiber and 19g sugar
2554224|NCT02537587|Experimental|10/10|Experimental bar with 10% added resistant starch and 10% added protein; 80g portion containing 17g protein, 7g fat, 49g carbohydrate, 9g fiber and 18g sugar
2554275|NCT02537314|Active Comparator|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
2554277|NCT02537314|Placebo Comparator|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
2554322|NCT02536989|Experimental|1|receive high dose PPI treament with intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
2554324|NCT02536989|Active Comparator|2|receive usual dose PPI treatment with ntravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
3174298|NCT00621998|Active Comparator|2|Flexible dose of risperidone
3174299|NCT00622011|Experimental|1|zotepine , start from 50mg/day then titrate according to individual case
2554535|NCT02535390|Experimental|Action based cognitive remediation|Participants in this condition will engage in simulated real world tasks in addition to standard cognitive remediation and group therapy sessions.
2554538|NCT02535390|Active Comparator|Standard cognitive remediation|Participants in this condition will engage in computerized cognitive training exercises in addition to standard cognitive remediation and group therapy sessions.
2554595|NCT02535195|Active Comparator|Ginger|Participants were randomly divided based on age, sex and severity of steatosis in two groups. Randomization lists were computer-generated by a statistician and participants, project managers and employees at the clinic were completely unaware (blind) about intervention and control groups. At the first visit, baseline data were gathered and patients advised to consume 2 capsules content 500 mg of ginger (made in Green Plants of Life Pharmaceutics Co., Iran) or placebo (starch) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
2554597|NCT02535195|Placebo Comparator|Placebo|2 capsules content 500 mg of placebo(starch) (made in Green Plants of Life Pharmaceutics Co., Iran) one hour after breakfast and two capsules after dinner for 3 weeks. Capsules was administrated for all patients in the first week for 3 weeks and in each visit new series of supplement was prescribed.
2554609|NCT02534831|Experimental|Soft Tissue Manual Therapy Protocol|Soft tissue manual therapy protocol. Seven techniques of manual therapy in 30 minutes.
2554679|NCT02534714||Retrospective (Part 1) Group|This is a retrospective pilot study in patients diagnosed with any form of spinal disease who underwent spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from November 1, 2012 to October 31, 2014. Only spinal fusion patients with a serum Vitamin D level prior to or at time of surgery and after surgery are included in this review. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The charts reviewed will belong to subjects who were closely followed at the OSF/INI clinic.
2554682|NCT02534714||Prospective (Part 2) Group|"This is a prospective pilot study in subjects diagnosed with any form of spinal disease that underwent cervical, thoracic, and/or lumbar spinal fusion at OSF/INI by Dr. Daniel Fassett, MD, MBA, Neurosurgeon from July 1, 2015 to June 30, 2016.~(Screening period July 1, 2015-June 30, 2016)~Only spinal fusion patients with a serum Vitamin D level, and Bone Marrow Density prior to or at time of surgery are included in this study. The following variables will be utilized to characterize the sample: age, sex, ethnicity, BMI, smoking history, pre-op Vitamin D level and supplement given. The subjects were closely followed at the OSF/INI clinic post-operatively at 3, 6, and 12 months. Pre-op Vitamin D level and Bone Marrow Density will be measured at the baseline, and again at 3, 6, and 12 months."
2554700|NCT02534298|Experimental|single sided deafness|single sided deafness and asymmetrical hearing loss patients functional magnetic resonance imaging
2554703|NCT02534298|Other|control group|Normal hearing subject functional magnetic resonance imaging
2554802|NCT02533752||Main Group|This an observational registry - there is only one group
2555059|NCT02531984|Experimental|Withdrawal of Azithromycin treatment|
3174300|NCT00622011|Active Comparator|2|Risperidone, start from 1mg/day
3174301|NCT00622037|Active Comparator|1|PEG-400 based artificial tear
3174302|NCT00622037|Active Comparator|2|Systane
3174303|NCT00622050|Experimental|1|This arm will be experiencing the same protocol as the control group, only their TV viewing time will be reduced. The TV viewing time reduction is the experimental intervention.
3174304|NCT00622050|Active Comparator|Control|The control group will be experiencing the exact protocol; only their TV viewing time will not be reduced.
3174305|NCT00622076|Active Comparator|1|postoperative catheterization after anterior colporrhaphy during five days.
3174306|NCT00622076|Active Comparator|2.|postoperative catheterization after anterior colporrhaphy during two days
3174307|NCT00622089|Experimental|1|150mg DIO-902 + 10mg Atorvastatin
3174308|NCT00622089|Experimental|2.|300mg DIO-902 + 10mg Atorvastatin
3174309|NCT00622089|Experimental|3|450mg DIO-902 + 10mg Atorvastatin
3174310|NCT00622102|Experimental|1|50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
3174311|NCT00622102|Other|2|50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
3174312|NCT00622115|Experimental|A|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 4 hours following the last injection of enoxaparin
2554233|NCT02537678|Experimental|Stepped Care TF-CBT|Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
2554234|NCT02537678|Active Comparator|Standard TF-CBT|Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.
2554303|NCT02537262|Experimental|carbohydrate group|
2554305|NCT02537262|Placebo Comparator|NPO(None Per Oral) group|
3205234|NCT00941590||Patients with tick borne encephalitis.|
2554485|NCT02535858|Experimental|Heart and respiratory rate and video|To determine the limits between normal and emotional anxious, thirty volunteers male's adults (GL) with age range between 20 and 50 years were recruited. None of them had any pathology associated with anxiety or psychiatric disorders, and none was drugs user or taking medication.
2554489|NCT02535858|Experimental|Heart and respiratory rate and VE|A second group has fifty adult volunteers (DG) ongoing outpatient chemical dependency clinic [treatment average's population: 5 months and 14 days]. The patients were abstained from drugs use for at least two months, and they were selected to test the VE. None of the DG's participants had any pathology associated with anxiety or psychiatric disorders, and none was taking medications. The DG volunteers were narcotic users of two or more illicit drugs, such as alcohol, marijuana, tobacco, cocaine and crack cocaine. Addiction for alcohol and tobacco were 72% and 56% respectively. The group's percentage for using psychoactive drugs were, 70% for cocaine and crack cocaine and 32% for marijuana.
3174313|NCT00622115|Experimental|B|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 6 hours following the last injection of enoxaparin
2554820|NCT02533700|Experimental|CEOP/IVE/GDP chemotherapy regimen|2 cycles of CEOP(cyclophosphamide,vincristine, epirubucin and prednisone),2 cycles of IVE(ifosfamide, epirubucin, etoposide)and 2 cycles of GDP(gemcitabine, cis-platinum, and dexamethasone)
2554830|NCT02533700|Active Comparator|CEOP chemotherapy regimen for 6 cycles|6 cycles of CEOP regimen(cyclophosphamide,vincristin,epirubucin and prednisone)
2554926|NCT02532868|Experimental|MK-0457|Participants received MK-0457 at assigned dose as a continuous intravenous infusion (CIV) over 24 hours; one group of participants also received MK-0457 100 mg capsules, orally, prior to the CIV.
2554927|NCT02532582||Living Liver Donor Transplant Donors|All adult living liver donors and liver surgery patients at Northwestern Memorial Hospital (same surgical setup is used for living liver donor surgery and liver surgery (e.g. retractors, arterial line for monitoring, surgeons). Living liver donors and liver surgery patients for enrollment to receive neuromuscular monitoring)
2555000|NCT02532491|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day during study duration.
2555006|NCT02532491|Active Comparator|Risperidone|Oral, dose range 1-6 mg/day, once or twice a day during study duration.
2555047|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and chromoendoscopy with Lugol for detection of esophageal lichen.
2555096|NCT02531854|Experimental|ADXS11-001 + Pemetrexed|
2555099|NCT02531854|Active Comparator|Pemetrexed Only|
2555109|NCT02531568|Experimental|Warfarin and MT-3995|Subjects will be administered a single dose of warfarin on day1. Subjects will be administered MT-3995 Days 8 to 20. Subjects will be administered MT-3995 and warfarin on Day21. Subjects will be administered MT-3995 from Day 22 to 27.
2555145|NCT02531425|Experimental|IT-pIL12-EP|intratumoral injection of plasmid-IL12 following immediately by electroporation
2555184|NCT02531178|Experimental|low dose ABBV-257|Low dose every other week (eow), Weeks 0-8
2555187|NCT02531178|Experimental|Medium dose of ABBV-257|Medium dose every other week (eow), Weeks 0-8
2555192|NCT02531178|Experimental|high dose of ABBV-257|high dose every other week (eow), Weeks 0-8
2555269|NCT02530866|Active Comparator|Standard care|Women in this arm will target fasting blood glucose values <95 mg/dL and 1 hour post-prandial values <140 mg/dL
2555277|NCT02530866|Experimental|Intensive therapy|Women in the arm will target fasting blood glucose values <90 mg/dL and 1 hour post-prandial values <120 mg/dL.
2555333|NCT02530463|Experimental|Cohort I (nivolumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive nivolumab and azacitidine at the discretion of the treating physician.
2555336|NCT02530463|Experimental|Cohort II (ipilimumab)|Patients receive ipilimumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab and azacitidine at the discretion of the treating physician.
2555338|NCT02530463|Experimental|Cohort III (nivolumab, ipilimumab)|Patients receive nivolumab IV over 30 minutes on days 1 and 15 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30 minutes every 2 weeks (or every 4 weeks if patients receive azacitidine) in the absence of disease progression or unacceptable toxicity. Patients with disease progression may receive ipilimumab, nivolumab, and azacitidine at the discretion of the treating physician.
2555341|NCT02530463|Experimental|Cohort IV (azacitidine, nivolumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes on days 6 and 20. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2555344|NCT02530463|Experimental|Cohort V (azacitidine, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and ipilimumab IV over 30 minutes on day 6. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2555346|NCT02530463|Experimental|Cohort VI (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine IV over 10-40 minutes on days 1-5 and nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 6. Treatment with ipilimumab repeats every 4 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. Cycles with nivolumab and azacitidine repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3174314|NCT00622115|Experimental|C|70 U/kg of UnFractionated Heparin (UFH) administered intravenously at 10 hours following the last injection of enoxaparin
3174315|NCT00622128|Experimental|1|Pilot study. Developing intervention
3174316|NCT00622141|Active Comparator|A|Day 1: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg 7-day washout period will follow. Day 8: take generic GPO squinavir/Norvir
2554285|NCT02537210|Placebo Comparator|Placebo oral capsule|placebo 5 capsules od po for 12 months
2554384|NCT02536924|Experimental|Waiting room intervention plus TAU|The treatment group will receive waiting room intervention plus treatment as usual.
2554386|NCT02536924|Experimental|Only TAU.|The control group will receive only treatment as usual.
2554442|NCT02536170|Experimental|L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
2554444|NCT02536170|Experimental|Loading Dose and L-Arginine|Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
2554446|NCT02536170|Placebo Comparator|Placebo|Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.
2554499|NCT02535819|Experimental|Subluxation|Nucleus is hydrodissected until it lilts above the capsular bag, rotated to face the incision then tumbled and emulsification continues from the opposite equator outside in until complete
2554501|NCT02535819|Other|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
2554550|NCT02535494|No Intervention|Standard Training|Participants receive our standard overdose training.
2554555|NCT02535494|Experimental|Extensive Training|Participant receives an more in-depth, extensive training concerning opioid overdose.
2554560|NCT02535494|Experimental|Extensive Training w/ Significant Other|Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.
2554616|NCT02535039|Placebo Comparator|Placebo|Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.The same volume of physiological saline will be given.
2554626|NCT02535039|Experimental|Methylprednisolne|in the anaesthesia to 1 mg/kg intravenous methylprednisolone, methylprednisolone continuous use 1 mg/kg * d until the third day after surgery.Before anesthesia induction, with electroacupuncture can cave, inside the closed cavity, foot three mile point, cupping model for continuous wave type, current pulse frequency of 2 hz, adjust the intensity of the electric acupuncture, with patients complained of needle feeling, can accept no pain and discomfort.Intraoperative sustained electroacupuncture.
2554663|NCT02534519||people negative in bg MNSs antigen U|"Blood group (bg) system MNSs. Individuals with phenotype U-. Homo- and heterozygous individuals may be considered."
2554666|NCT02534519||people positive in bg MNSs antigen St(a)|"Blood group (bg) system MNSs. Individuals with phenotype St(a)+. Homo- and heterozygous individuals may be considered."
3205235|NCT00941616|Experimental|PK|Includes subjects participating in the pharmacokinetic component of the study.
3205236|NCT00941616|Experimental|Prophylaxis|Includes subjects receiving 12 months of prophylactic therapy.
2554823|NCT02533518|Experimental|patients with lung cancer|
2554903|NCT02533206|Experimental|EPIC|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic. The participant will be discharged home from the clinic following their procedure.
2554904|NCT02533206|Active Comparator|FESS|The control intervention is functional endoscopic sinus surgery (FESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia
3205237|NCT00941616|Experimental|On-demand|Includes subjects receiving 12 months of on-demand treatment.
3205238|NCT00941616|Experimental|Cross-over to prophylaxis|"Includes subjects completing 12 months of on-demand treatment (the On-demand arm) who cross-over to prophylactic therapy for an additional 12-month period."
3205239|NCT00941629|Active Comparator|Cognitive Processing Therapy FTF|Cognitive Processing Therapy delivered in traditional face-to-face sessions (FTF)
3205240|NCT00941629|Experimental|Cognitive Processing Therapy TMH|Cognitive Processing Therapy delivered over videoconferencing equipment to a distant location (or telemental health; TMH)
3205241|NCT00941642|Active Comparator|Lovaza|Single blind, active treatment arm Lovaza, is the only fish oil supplement approved by the FDA. The Lovaza treatment group will take 4g of Lovaza daily for a minimum of 48 weeks.
2555112|NCT02531451|Experimental|Ibuprofen|Resistance exercise 20 sessions during 8 weeks Daily consumption of 1200 mg ibuprofen (400 mg x 3) during 8 weeks
2555114|NCT02531451|Active Comparator|Acetylsalicylic acid|Resistance exercise 20 sessions during 8 weeks Daily consumption of 75 mg acetylsalicylic acid (75 mg x 1) during 8 weeks
2555159|NCT02531334|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
2555164|NCT02531334|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
2555202|NCT02531100|Experimental|BonyPid-500TM implantation|Standard of care (SOC) treatment (Manual and ultrasonic debridement and surface decontamination) followed by BonyPid-500TM implantation.
2555205|NCT02531100|Other|SOC treatment|Standard of care treatment (Manual and ultrasonic debridement and surface decontamination) only
2555256|NCT02530853|Experimental|Group A|Laser acupuncture
2555261|NCT02530853|Sham Comparator|Group B|Simulation Laser acupuncture
2555332|NCT02530580|Experimental|20 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, 2 capsules as a single oral dose
3205242|NCT00941642|Placebo Comparator|Placebo|Single blind, Placebo arm study drug will contain 994.0 mg of corn oil and 6mg of alpha tocopherol as an excipient in a soft gelatin capsule shell. Subjects will take 4g daily for a minimum of 48 weeks.
3205243|NCT00941694|Experimental|Self-Management Intervention|Will receive 6 asthma self-management group or individual session over a 7 week period
3205244|NCT00941694|Placebo Comparator|Control|Group will receive 3 phone calls not related to asthma self management over a 7 week period
3205245|NCT00941707|Experimental|JNJ-38518168|
3205246|NCT00941707|Placebo Comparator|Placebo|
2554311|NCT02537132|Experimental|Home Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at home
2554316|NCT02537132|Active Comparator|Outpatient Group|Adaptation and training to Non Invasive Ventilation (NIV) (not less than five sessions), at the outpatient clinic
2554363|NCT02536755|Experimental|eliglustat|Cytochrome P450 (CYP) 2D6 Intermediate (IM), Extensive (EM) and Ultra-Rapid (URM) Metaboliser patients will be treated at 84 mg twice daily. CYP2D6 Poor Metabolisers (PM) will be treated at 84 mg once daily.
3171046|NCT00581802||5|Intensively studied participants who are currently participating in the Merck Expanded Access Program and receiving raltegravir. Participants in Group 5 may undergo optional leukapheresis. Group 5 participants may decline to be in the leukapheresis group at any time and will be given the option of continuing in the blood draw group or withdrawing from the study. If specimens are not obtained for any reason at any visit, Group 5 participants will default to either Group 3 or Group 4.
3171047|NCT00581815|Experimental|1|
2554664|NCT02534545|Experimental|Doctormate® (200mmHg)|Patients will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate®) (200mmHg) once daily for 12 months
2554669|NCT02534545|Sham Comparator|Doctormate® (60mmHg)|Patients will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate®) (60mmHg) once daily for 12 months
2554760|NCT02533817|Experimental|Dietary Sugar - Fructose|Each participant consumed 20% daily caloric requirement as fructose.
2554762|NCT02533817|Active Comparator|Dietary Sugar - Glucose|Each participant consumed 20% daily caloric requirement as glucose.
2554920|NCT02532907||Patients who will have their second Liver biopsy at week 4|The 4 week time point is performed in lieu of the 12 week and the purpose of this time point is to evaluate earlier responses and transcriptional changes that might predict viral clearance or treatment failure in a subset of patients.
2554921|NCT02532907||Patients who will have their second Liver biopsy at week 12|Liver biopsies will be obtained at week 12 when most DAA treatments end in order to compare the hepatic responses induced or reduced by clearance of HCV
2554973|NCT02532621|Experimental|Venous InterGraft Connector|Venous InterGraft Connector will be implanted and used with a sutured arterial anastomosis to create a AV shunt for dialysis access.
2555056|NCT02532244||sample collection|Each participant will have blood drawn for genetic analysis and for establishment of a lymphoblastoid cell line.
2555149|NCT02531399|Experimental|Healthy Subjects|20 healthy female and male volunteers, age 18-45 years, non-smokers. Measurements with FDOCT, DVA, LDV and LSFG will be done in all healthy subjects.
2555207|NCT02531048|Experimental|healthy volunteers|"Healthy volunteers are able to participate to this study. They must not have neurological troubles. They will have different stimulations :~laser stimulations on lower limbs~laser stimulations cervical~20 laser stimulations for each site on the upper limbs~laser stimulations on face and neck"
2555372|NCT02530307|Experimental|HT-3951 (15mg)|HT-3951 capsules administered once daily
2555373|NCT02530307|Placebo Comparator|Placebo|Placebo capsules administered once daily
2555434|NCT02529839|Experimental|Experimental|"Fludarabine 30mg/m2 for 4 days, Cyclophosphamide 50mg/kg for 2 days, Alemtuzumab administered subcutaneously 24mg total dose.~Autologous bone marrow transplantation"
2555600|NCT02528851|Experimental|Higher CPAP|Infants extubated to CPAP level 2cm H2O higher than extubation EAP
2555604|NCT02528851|Active Comparator|Equivalent CPAP|Infants extubated to CPAP equivalent to extubation EAP
2555624|NCT02528344|Experimental|HIIT - RA|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
2555662|NCT02528110|Sham Comparator|Radical gastrectomy without HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and postoperative chemotherapy (SOX or XELOX)
2555664|NCT02528110|Experimental|Radical gastrectomy with HIPEC|Patients will be treated with a D2 radical gastrectomy for locally advanced gastric cancer and HIPEC with paclitaxel and 5-Fu and postoperative chemotherapy (SOX or XELOX)
2555717|NCT02527824|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"intervention with triple combination chemotherapy with oxaliplatin, irinotecan, and S-1 Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
2555765|NCT02527525|Experimental|Stepped Care|150 subjects will be randomized to the stepped care intervention. All 150 participants will be assigned a parent coach after randomization to stepped care condition. At the child's next follow up clinic visit participants who have elevated depression scores OR who's child has not met A1c target will move on to Step 2 of the intervention- 5 sessions with a study interventionist. At the following child's clinic visit, participants can either remain in Step 1, move to Step 2, or if needed, move on to Step 3- using a continuous glucose monitor for 1 week followed by a meeting with a certified diabetes educator and a diabetes team clinical psychologist.
2555766|NCT02527525|No Intervention|Usual Care|Participants randomized to usual care will participate in regular diabetes clinic visits and diabetes education, as they would have done without participation in this study.
2555866|NCT02526784|Active Comparator|Injection A|Degarelix s.c. standard injections
2555867|NCT02526784|Experimental|Injection B|Degarelix s.c. optimised injections
2555868|NCT02526784|Experimental|Injection C|Degarelix i.m. injections
3171048|NCT00581841||1|Healthy adult participants with no history of knee injury or osteoarthritis.
3171049|NCT00581880||1|Terminally Ill patients
3171050|NCT00581906||pts undergoing surgery or chemo-radiation treatment|
3171051|NCT00581932||A|One group, all subjects with DSM-IV diagnosis of Schizophrenia, age 18-65 who are initiating clozapine therapy.
3171052|NCT00581958||Patients undergoing HSCT|Research subjects will have blood and/or urine sampled at three time points in the Department of Radiation Oncology. Participating patients will have at least a total two samples collected at each time point. The first sampling will occur before the first TBI treatment is given. The second sampling will occur before the second TBI treatment, usually 3 to 8 hours after the first treatment (in the case of multifraction TBI). If a patient is being treated with single fraction TBI, then the second sampling will occur approximately 3-8 hours after the first TBI treatment. The third and final sampling will occur at the next morning blood draw, prior to the fourth TBI treatment (in the case of multifraction TBI), 24 hours after the first TBI treatment.
2554340|NCT02536898|Experimental|Fracture liaison service|"Information, assessment & lifestyle advice~refer to DXA scan, except patients with dementia, difficulties laying on the back or short life exp.~Blood samples~Sufficient intake of Vitamin D & calcium, combined with physical activity will be recommended with lifestyle advice (smoking & alcohol intake)~Patients With Hip, Vertebral or two or more low-trauma fractures are recommended treated with anti-osteoporosis drug~Other fractures, treatment recommended if FRAX score≥20% for major fracture & T-score≤-1.5~Fracture patients with reduced kidney function will be treated with anti-RANKL~Anti-osteoporosis drug prescribed by hospital physician~Follow-up phone call after 3 months and visit to talk with coordinating nurse after 1 year~Patients with spine or femoral neck T-scores≤-3.5, >2 severe vertebral fractures & those who suffer a second fracture while using anti-osteoporosis drug, will be referred for further examination and teriparatide treatment will be considered"
2554344|NCT02536898|Other|Current treatment|Treatment as offered before intervention.
2554375|NCT02536482|Experimental|Amix|Dietary supplement. The formula is based in free amino-acid to treat children with cow's milk allergy. The children should have a minimum consumption of 400 mL, daily.
2554397|NCT02536326|Experimental|renal denervation|
2554437|NCT02536118||Patients implanted with Micra System|Patients implanted with a Micra Transcatheter Pacing System are eligible for enrollment into the Micra PA Registry.
2554635|NCT02534948|Experimental|Mindfulness and acceptance group therapy|The intervention group will consist of female participants who will be provided MABT in a group.The intervention will consist of 10 group therapy sessions. Each session will be conducted for 120 minutes.
2554637|NCT02534948|No Intervention|wait list control group|The control group will be the waiting list control group will receive no interventions in the first stage.
2554656|NCT02534506|Experimental|Urelumab (+ Nivolumab) intravenous (IV) infusion|
2554714|NCT02534389|Experimental|fish oil group|4 soft gel with omega-3 fish oil
2554716|NCT02534389|No Intervention|control group|without intervention
2554774|NCT02534077|Experimental|1|Drug: Omegaven
2554828|NCT02533609||Piperacillin/Tazobactam|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
2554836|NCT02533609||Imipenem/Cilastatin|Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics
2554886|NCT02533232|Placebo Comparator|placebo|Matching placebo for Minocycline
2554892|NCT02533232|Experimental|Minocycline|Minocycline 200mg once a day orally
2554960|NCT02532699|Active Comparator|AC mycelia|Subjects receive three capsules per day containing either 420 mg of AC mycelia.
2554964|NCT02532699|Placebo Comparator|Placebo|Subjects receive three capsules per day containing starch placebo of similar appearance.
2555065|NCT02532322|Experimental|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
2555074|NCT02532322|Placebo Comparator|normal saline|normal saline (placebo control) 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
2555175|NCT02531282|Experimental|Health promotion in patient education|The self-management patient education has been developed at the Healthy Life Centre in Trondheim municipality based on cognitive behavioural theory and psychomotor physiotherapy. The intervention is developed in a health promotion framework focusing on salutogenesis aiming to improve the participants ability to activate their own resources for health behaviour changes .
2555178|NCT02531282|Active Comparator|Physical activity in groups|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. .
2555331|NCT02530424|Experimental|Trast-pert-palbo-fulve|Patients will receive an association of drugs (trastuzumab, pertuzumab, palbociclib plus or minus fulvestrant) as neoadjuvant chemotherapy. Definitive surgery will be performed not earlier than 14 days and not later than 28 days after the last dose of any of the drugs in the combination. After completion of surgical treatment patients will receive irradiation as locally acceptable.
2555397|NCT02530138|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
2555398|NCT02530138|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
2555436|NCT02529800|Experimental|Sequence 1|High fat diet+HGP0412 → High fat diet+HIP1402 → fasted state+HIP1402
2555437|NCT02529800|Experimental|Sequence 2|High fat diet+HIP1402 → fasted state+HIP1402 → High fat diet+HGP0412
2555438|NCT02529800|Experimental|Sequence 3|fasted state+HIP1402 → High fat diet+HGP0412 → High fat diet+HIP1402
2555472|NCT02529475|Experimental|Gadoteric acid|Gadoteric acid 0.2 mmol/kg
2555525|NCT02529176|Experimental|Best-practice alert|Receive the best-practice alert (BPA) during the course of their clinical work in the electronic medical record.
2555533|NCT02529176|No Intervention|No alert|Physicians will receive no best-practice alert from the electronic medical record.
2555582|NCT02528773||HIV positive|Persons newly diagnosed with HIV.
2555621|NCT02528461||Sofosbuvir|"All patients receiving Sofosbuvir based treatment regimes during the study period will be included in the study.~All patients will receive all interventions (galactose elimination capacity test, gastroscopy, fibroscan), except liver biopsy which the patients may decline to participate in without affecting the participation in the rest of the study. If varices are found during the gastroscopy a liver vein catheterization will be performed."
2555692|NCT02527941|Experimental|metronidazole|50 women who test negative for HIV and classical sexually transmitted infections but test positive for Bacterial Vaginosis will be treated with metronidazole at a dosage of 400mg/dose, 3 doses per day, for 7 days (as per Kenyan National Guidelines).
3205247|NCT00941746|Experimental|Lowest dose of PG110|single, slow intravenous infusion
2555797|NCT02527187|Experimental|Betula verrucosa allergen extract|"The investigational product contained the allergen extract of the pollen of Betula verrucosa and will be tested by administration onto skin. The test will be carried out on the forearm following prick test technique.~The allergen extract of the pollen of Betula verrucosa will be tested in four concentrations (100, 50, 25 and 10 HEP/mL)."
3171053|NCT00581997|Experimental|1|QAX576
3205248|NCT00941746|Experimental|Second dose of PG110|single, slow intravenous infusion
3205249|NCT00941746|Experimental|Third dose of PG110|single, slow intravenous infusion
2554355|NCT02536573|Experimental|Radlink Surgical Positioning System|Fluoroscopic image of the hip joint is imported into the Radlink Surgical Positioning software. The software calculates a target cup position using bony landmarks, and the surgeon matches the cup to the target.
2554417|NCT02536430|Active Comparator|Buccal infiltration of Ketorolac|A buccal infiltration of 30 mg/mL of Ketorolac Tromethamine was applied for the patients in case group.
2554418|NCT02536430|Placebo Comparator|buccal infiltration of Normal Saline|A buccal infiltration of Normal Saline was applied for the patients in control group.
2554464|NCT02535975|Experimental|Metformin|Metformin 500mg PO three times a day for 24 weeks
2554465|NCT02535975|Placebo Comparator|Placebo|Placebo tab. PO three times a day for 24 weeks
3205250|NCT00941746|Experimental|Fourth dose of PG110|single, slow intravenous infusion
3205251|NCT00941746|Experimental|Fifth dose of PG110|single, slow intravenous infusion
3205252|NCT00941746|Experimental|Top dose of PG110|single, slow intravenous infusion
2554607|NCT02535104|Experimental|Treatment group|1 mg/ml solution of ranpirnase applied twice daily
2554608|NCT02535104|Placebo Comparator|Control|Vehicle - innert gel
2554729|NCT02534649|Other|Experimental|Newly obtained biopsy and Blood samples collection
2554776|NCT02533882|Experimental|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors.
2554782|NCT02533882|Active Comparator|Adapted Yoga|Yoga classes will consist of postures adapted by qualified yoga instructors who have extensive experience in disability.
2554784|NCT02533882|No Intervention|Waitlist Control|This group will receive biweekly newsletters on a variety of topics. At the end of this trial, they will receive a home based intervention.
2554811|NCT02533583||symptomatic newborn|the symptomatic newborn cohort( symptomatic definition see detail),all of babies will referred for chest X-ray,and within 2 hours performing echocardiography to exclude critical and serious heart disease.All clinical assessment will do by attending doctor.
2554812|NCT02533583||Asymptomatic newborn|the asymptomatic newborn cohort will gave pulse oximetry and clinical assessment every 8 hours within 3 days.everybody have positive results will been preformed chest X-ray and echocardiography.All clinical assessment will do by attending doctor.
2554860|NCT02533297|Experimental|clinical education|the researcher used the checklist to assess the student's mastery level skill l while changing a skill and recorded his score on the learning curve based on a 1 (no mastery) to 100 (complete mastery) scoring scale. This procedure continued until the learning curve reached to a plateau state, i.e. either reaching to the full mastery score (100) or revealing no significant change in three subsequent sessions. All the students achieved mastery (the plateau state) after performing the task for at most ten times.
2554870|NCT02533024|Experimental|Group Cohort|All subjects will have nerve conduction studies (Electromyography/EMG) pre-operatively, monitored intra-operatively and immediately post-operative.
2554933|NCT02532881|Experimental|Treatment as ususal (TAU) + Video Access|Patients in this arm receive access to various videos on the study website as well as treatment as usual (written information provided by the clinic).
2554934|NCT02532881|Placebo Comparator|Treatment as usual (TAU)|Patients in this arm receive treatment as usual (written information provided by the clinic).
2554974|NCT02532439|Experimental|Patient group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of patient group Patient group is patient with one of the following pathology : Osteoporosis, Bone Fragility, articular inflammatory disease or Endocrine diseases
2554984|NCT02532439|Experimental|control group|Measure bone quality and quantity with HR-pQCT, pQCT and DEXA of control group. Patient group is patient with episode of acute back pain or radicular pain
2555060|NCT02532192|Experimental|Belinostat + RDHAP Chemotherapy|Belinostat administered by vein on Days 1 - 2 of a 21-day cycle. Rituximab administered by vein on Day 2. Cisplatinum administered by vein on Day 2. Cytarabine administered by vein on Day 3 during the initial cohorts, and on Day 2 in the cohort of modified DHAP scheduling. Ciprofloxacin 500 mg twice daily for 10 days and Fluconazole 100 mg daily for 10 days may be utilized at the discretion of the treating physician.
2555104|NCT02531490|Active Comparator|randomized, interventiongroup|Women with a hyperdynamic vasodilated profile, characterized by a mean arterial pressure (MAP)/ Heart rate (Hr) ratio ≤ 1.1 are prescribed a beta-blocker. Women with a hypodynamic vasoconstrictive profile (MAP/Hr ratio ≥ 1.4) are prescribed nifedipine. Women with normodynamic profile (MAP/Hr ratio in between 1.1 and 1.4) are prescribed Methyldopa.
2555105|NCT02531490|No Intervention|randomized, control-group|Women who give informed consent for randomization, and are randomized to the control group will not be medicinally treated for mild to moderate gestational hypertension.
2555107|NCT02531490|No Intervention|not-randomized, control-group|Women who do not want to be randomized, but who give informed consent for follow-up on their data until discharge after delivery. They will receive standard care, i.e. no medication is prescribed for mild to moderate gestational hypertension.
2555185|NCT02531243|Experimental|CALMS|12 session family therapy using multi-user biofeedback games
2555218|NCT02530957|Experimental|Interventional|In the interventional group, a preoxygenation by NIV (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) combined to HNFC (Flow of 60L/min, FiO2 = 100%) is applied.
2555221|NCT02530957|Other|Reference|In the reference group, a preoxygenation by NIV only (PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100%) is applied.
2555279|NCT02530697|Active Comparator|Group 1 - Mucosal Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days. Pentoxifylline 400mg 3x/daily for 28 days.
2555281|NCT02530697|Experimental|Group 2 - Mucosal Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily. Oral Pentoxifylline 400mg 3x/daily for 28 days.
2555337|NCT02530580|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, 2 capsules as a single oral dose
3205253|NCT00941746|Experimental|Placebo|single, slow intravenous infusion that matches PG110 in appearance
3205254|NCT00941746|Experimental|Seventh Dose of PG110|single, slow intravenous infusion
3205255|NCT00941746|Experimental|Eight Dose of PG110|single, slow intravenous infusion
3171054|NCT00581997|Placebo Comparator|2|Placebo
2554643|NCT02534779|Experimental|Placebo Vaginal Insert|Placebo insert
2554710|NCT02534467|Experimental|Montelukast-Standard|8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy
2554712|NCT02534467|Active Comparator|Standard-Montelukast|8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy
2554773|NCT02534064|Experimental|Group A: 2 yogurts|consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
2554780|NCT02534064|Experimental|Group B: 1 yogurt|consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product during 8 weeks.
2554783|NCT02534064|No Intervention|Group C: No yogurt|no changes in dietary habits during 24 weeks.
3208784|NCT00978016|Experimental|arbaclofen placarbil-Cohort 1|"arbaclofen placarbil 20 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
2554961|NCT02532530|Other|Study group|Adult patients (age ≥ 70 years) undergoing elective on-pump cardiac surgery (i.e. valve replacement with or without 'Coronary Artery Bypass Graft' (CABG) surgery)
2555041|NCT02532361||Cohort 1 / Hysteroscopic device placement|Patients that had undergone sterilization through hysteroscopic device placement
2555042|NCT02532361||Cohort 2 / Tubal ligation|Patients that had undergone sterilization through tubal ligation
2555084|NCT02531919|Experimental|Sodium Bicarbonate|Dose concentration of 0.5 g/kg/day
2555163|NCT02531620|Experimental|Physiatry|Pre-operative Physiatry assessment and intervention
2555165|NCT02531620|Other|Routine Care|Patients will receive routine pre-operative care, this study arm does not have an intervention.
2555433|NCT02529826|Experimental|Testicular biopsy|Cancer affected prepubertal boys will undergo testicular biopsy for testicular fragments cryopreservation. The biopsy will be performed by an attending urologist, before any gonadotoxic therapy is initiated. Testicular biopsy specimens will be divided immediately on the operating table. Two thirds of the specimen will be cryopreserved for potential use by the patient at a later date and will have the patient's details and will stay at the sperm bank of Hadassah Medical Center. The other third of specimen will be used for research purposes in an effort to advance the science of isolating and culturing human SSC's for fertility research.
2555443|NCT02529527|Experimental|MyFamilyPlan|Web-based health education tool (interactive self-assessment) provided for participant completion 7-10 days prior to a scheduled primary care visit.
2555446|NCT02529527|No Intervention|Control|Standard preconception health education document provided for participant review 7-10 days prior to a scheduled primary care visit.
2555500|NCT02529371|Experimental|UriCap-RM|The device is comprised of a reusable part and a single use adhesive tape. The device is removed once daily and the reusable part is rinsed, dried and reapplied with a new adhesive tape.
2555557|NCT02528955|Active Comparator|A:De-Intensification Radiotherapy (RT) primary tumor region|"A:De-Intensification Radiotherapy (RT) primary tumor region~≤ pT2, R ≥ 5 mm, L0, Pn0~> 3 lymph node metastasis or patients with < 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection"
2555558|NCT02528955|Active Comparator|B:De-Intensification Radiotherapy contralateral lymph nodes|"> pT2 and/or R < 5mm and/or L1 and/or Pn1~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
2555559|NCT02528955|Active Comparator|C:De-Intensification RT primary tumor region /contralateral LN|"≤ pT2, R ≥ 5 mm, L0, Pn0~≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (>= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( >= 5 mm distance from midline) cancer of the oral cavity or oropharynx"
2555612|NCT02528552|Active Comparator|LH80 PRO|Low level laser therapy
2555615|NCT02528552|Sham Comparator|Sham device|No low level laser therapy
2555644|NCT02528227|Experimental|Language Curriculum|The Language Intervention group will receive some of the known methods for early language development. Six lessons will include: Knowing your Baby, Reading Aloud, Sing-A-Long, Mimicking First Sounds, Language Game and Narrating Your Day. Parents will receive feedback every 2 weeks from a Language Environment Analysis digital language processor (LENA).
2555648|NCT02528227|Placebo Comparator|Health and Safety Curriculum|Parents will receive six lessons on important infant safety topics including, feeding safety, care seat safety, bath safety, back to sleep/SIDS prevention, taking a temperature and signs of infection, infection control methods and vaccine information. Parents will receive LENA feedback at discharge from NICU.
2555742|NCT02527850|Experimental|treatment with real laser|10 min irradiation with B-cure soft laser on 3 points of quadriceps muscle.
2555743|NCT02527850|Sham Comparator|sham laser|10 min irradiation with sham B-cure soft laser on 3 points of quadriceps muscle.
3171055|NCT00582049||1|Cases: retinoblastoma patients
3171056|NCT00582049||2|Controls: first cousins or other blood relatives of the retinoblastoma patients (relative controls) or friends of the retinoblastoma patients or children of friends of the parents (friend controls).
2555848|NCT02526940||blood CD4 cells count < 200/mm3|"patients with blood CD4 cells count at the time of initiation of HAART< 200/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
2555921|NCT02526238|Experimental|TMS and trunk rotation|TMS and trunk rotation
3171057|NCT00582062||1|Positive controls will include patients who have positive cytology or positive biopsy of peritoneal metastases. Cell lines which over-express these tumor markers will also be used as positive controls. Sensitivity will be defined using serial dilutions of several established gastric and pancreatic tumor cell lines. The mRNA of the tumor markers will be normalized to glyceraldehyde-3-phosphate dehydrogenase mRNA expression.
2554411|NCT02536144|Experimental|MCCES|Magnetic -controlled capsule endoscopy system (MCCES) is a robot system that the capsule would be swallowed to observe the mucosa of the human alimentary canal especially the colon under the control of the magnetic-manipulator.
2554412|NCT02536144|Active Comparator|Colonoscopy|Colonoscopy has now been in use for many years to visualize and diagnose abnormalities of the colon and it is the gold standard for detecting colorectal lesions.In this study,the additional utility of the colonoscopy is to monitor the movement of the Magnetic -controlled capsule endoscopy.
2554460|NCT02536027|Experimental|septic AKI patients|septic AKI patients requiring CVVH
2554479|NCT02535780|Experimental|TMS Treatment Group|15 sessions active Transcranial magnetic stimulation (TMS) treatment
2554482|NCT02535780|Sham Comparator|TMS Sham Group|15 sessions sham Transcranial magnetic stimulation (TMS) treatment
2554484|NCT02535780|Experimental|tDCS Treatment Group|15 sessions active Transcranial direct current stimulation (tDCS) treatment
2554490|NCT02535780|Sham Comparator|tDCS Sham Group|15 sessions sham Transcranial direct current stimulation (tDCS) treatment
2554529|NCT02535559|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
2554530|NCT02535559|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
2554568|NCT02535299|Experimental|insulin|basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.
2554615|NCT02534987|Experimental|iCPR2 intervention|EMR integrated clinical prediction rule system guiding antibiotic prescription choices for strep and pneumonia
2554625|NCT02534987|No Intervention|iCPR2 control|Standard education/academic detailing on appropriate treatment of strep and pneumonia
2554741|NCT02534168|Experimental|skin conductance|The skin conductance monitor will be applied to all study patient. There is no second arm to the study
2554775|NCT02533830|Active Comparator|gum chewing group.|"Group A (81 Women) Who Received One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
2554778|NCT02533830|Placebo Comparator|Placebo group|Group B (81 Women) had Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
2554822|NCT02533544||tenofovir disoproxil fumarate monotherapy|a group which treated with tenofovir disoproxil fumarate
3171058|NCT00582062||2|Patients who are scheduled to undergo laparoscopy for benign disease (e.g., laparoscopic cholecystectomy, hernia repair, or prophylactic BSO) will be recruited as negative controls. A leukemia cell line which does not express epithelial cell markers will also be used as a negative control for the RT-PCR reactions.
3171059|NCT00582088|Experimental|Vaccine|VEE C-84 - Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Dried, C-84, TSI-GSD 205
3171060|NCT00582101|Experimental|Family-based HIV|
2555532|NCT02529358|Experimental|EG stand|Standardized text messages
2555540|NCT02529358|Experimental|EG ind|Personalized text messages
2555542|NCT02529358|Other|Control|Standardized text messages after 10 weeks
2555673|NCT02527928||desoxycholate|Amphotericin B desoxicholate
2555674|NCT02527928||Anfolipidcomplex|Amphotericin B complex lipid
2555675|NCT02527928||ABLiposomal|Amphotericin B liposomal
2555712|NCT02527746|Experimental|F-627 80 µg/kg|F-627 at the dose of 80 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
2555715|NCT02527746|Experimental|F-627 240 µg/kg|F-627 at the dose of 240 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
2555723|NCT02527746|Experimental|F-627 320 µg/kg|F-627 at the dose of 320 µg/kg administrated by s.c. injection on Day 3 of each cycle for 4 cycles.
2555785|NCT02527395|Other|Clinical pain models|Brief thermal sensitization. Heat pain detection threshold. Pain during 1 min. thermal stimulation
3171061|NCT00582101|Active Comparator|Family-based HP|
3171062|NCT00582127||1|Mild-moderate Alzheimer's Disease
3171063|NCT00582127||2|Age-matched Controls
3171064|NCT00582140|Experimental|Cohort Level 1|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3171065|NCT00582140|Experimental|Cohort Level 2|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3171066|NCT00582140|Experimental|Cohort Level 3|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
3171067|NCT00582179|Active Comparator|1, A|Group A patients will be treated with a pressure dressing and observation.
3171068|NCT00582179|Active Comparator|2, B|Group B patients will be treated with a Vacuum Assisted Closure device (VAC).
3171069|NCT00582192||1|Participants with certain types of cancers that are eligible for studies at Memorial Sloan-Kettering Cancer Center.
3171070|NCT00582244|Experimental|1|CBT and relaxation.
3171071|NCT00582244|Experimental|2|Physical activity
3171072|NCT00582244|Experimental|3|CBT and physical activity
3171073|NCT00582244|No Intervention|4|Control group
3171074|NCT00582257||High Genetic Risk:|"Early Onset Gastric Cancer - diagnosis of gastric cancer before the age of 50 without a family history of the disease.~Familial Gastric Cancer - having a family history of gastric cancer as defined as one first degree relative or 2 second degree relatives.~Relative - Relatives of participants eligible for the High Genetic Risk Cohort will be eligible for participation. These relatives may also be at high risk of developing gastric cancer. These individuals will fall under the Cancer Cohort. Eligible relatives will be defined as someone having a relative who meets criteria for either the Early Onset Cancer Cohort or the Familial Gastric Cancer Cohort, or having a family history of a genetic mutation known to be associated with gastric cancer."
3174317|NCT00622141|Active Comparator|B|Day 1: take generic GPO squinavir/Norvir 7-day washout period will follow. Day 8: receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg
3174318|NCT00622193|Experimental|1 Active 50 mg|
3174319|NCT00622193|Experimental|2 Active 100 mg|
3174320|NCT00622193|Placebo Comparator|3 Placebo|
2554413|NCT02536274|Experimental|Schön Klinik Fürth|20 Patients with specific back pain will get Dynaflex® flexion orthosis. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
2554414|NCT02536274|No Intervention|Schön Klinik Fürth & Schwertbad Aachen|20 Patients with specific back pain will get no intervention. Study related procedures include a course with 6 exercises which shall be performed at the beginning and completion of the intervention: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
2554415|NCT02536274|No Intervention|RPE|20 healthy Subjects of the same age without back pain participate in the course for one time to prove the significance of the procedures. (control group) Study related procedures include a course with 6 exercises: standing upright for 60s, keeping the upper body statically bent forward 40 degrees for 30s, carrying weight (1 kg) over a circular trajectory 3 times, stairs up and down for 60s, Chair rising test for 30s and 6 minutes walking test at the beginning and the end of the course. In addition, surface electromyogram (EMG) of the back muscles via surface electrodes during the course exercises will be recorded. Study procedures are the same for all study groups.
2554496|NCT02536001|Other|One mesh Endofast reliant system|Patients with anterior compartment stage III and uterus prolapse grade II will be treated with one mesh - Anterior Endofast reliant system (fixation of posterior arms to the sacrospinous ligament)
2554497|NCT02536001|Other|two meshes Endofast reliant system|intervention: Patients with anterior compartment stage III and uterus prolapse grade II will be treated with 2 meshes: anterior Endofast reliant system mesh to correct the anterior compartment and posterior Endofast reliant system mesh to correct the apical prolapse (fixation to the sacrospinous ligament)
2554647|NCT02534753|Experimental|Single Group|
2554725|NCT02534454|Experimental|Active TDCS + Active Retraining|2.0 milliamperes (mA) of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
2554727|NCT02534454|Experimental|Sham TDCS + Active Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during active nicotine avoidance retraining
2554730|NCT02534454|Experimental|Active TDCS + Sham retraining|2.0 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
2554731|NCT02534454|Experimental|Sham TDCS + Sham Retraining|0.1 mA of transcranial direct current stimulation (TDCS) applied during sham nicotine avoidance retraining
2555004|NCT02532569|Other|Japanese encephalitis vaccine|After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose,SC
2555033|NCT02532075|Experimental|Inspiratory Warm Up|(IWU). Two sets of 15 breaths
2555034|NCT02532075|Experimental|Expiratory Warm Up|(EWU). Two sets of 15 breaths
2555035|NCT02532075|Experimental|Combination Warm Up|(RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
2555037|NCT02532075|Other|Control Trial|No warm up
3174897|NCT00628160|Experimental|Terlipressin group|Terlipressin in continuous infusion plus alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
3174898|NCT00628160|Active Comparator|Control group|Alpha adrenergic drugs (noradrenaline and/or dopamine in continuous infusion)
2555113|NCT02531711|Experimental|Diet A|Dietary intervention: Dietary fats are adjusted. Key study foods and oils are provided for 12 weeks. Participants learn which foods to eat and which to avoid.
2555115|NCT02531711|Active Comparator|Diet B|Dietary intervention: This diet also adjusts dietary fats, and provides key study foods and oils for 12 weeks.
2555228|NCT02530931|Experimental|patients with Meniere's disease|
2555259|NCT02530684||Knee osteoarthritis|Patients with knee osteoarthritis
2555263|NCT02530684||Control participants|Individuals without signs of knee osteoarthritis
2555392|NCT02530099|No Intervention|Control group|Receive no training.
2555394|NCT02530099|Experimental|CN-group|Receive basic camera navigation training.
2555396|NCT02530099|Experimental|Procedure-group|Receive training on a laparoscopic procedure.
2555431|NCT02529891||COPD Patients|Patients with COPD, within 48h after hospital admission for exacerbation.
2555432|NCT02529891||non-COPD patients|Healthy person of the entourage of COPD patients.
2555452|NCT02529540|Other|Group 1|Self-refraction with adjustable glasses
2555456|NCT02529540|Other|Group 2|Subjective refraction by an expert refractionist after auto refraction and receiving custom standard glasses
2555464|NCT02529540|Other|Group 3|Subjective refraction by an expert refractionist after auto refraction and receiving ready-made glasses
2555538|NCT02529267||Experienced abuse|Experienced IPV in the past 12 months
2555541|NCT02529267||Did not experience abuse|Did not experience IPV in the past 12 months.
2555573|NCT02528669|Experimental|RX Navigait|Individuals in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals. In addition, they will be given additional education about the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
3174899|NCT00628173|Experimental|1|patients with refractory glaucoma who were candidate for AGV implantation allocated in superior site
3174900|NCT00628173|Experimental|2|patients with refractory glaucoma who were candidate for AGV implantation allocated in inferior site
3174901|NCT00628186|Experimental|1|Pancreaticojejunostomy has a risk factor of pancreatic fistula. Type of stent tube (external stent vs. short stent)across pancreaticojejunostomy was randomized for the patients with pancreaticoduodenectomy.
3174902|NCT00628225|No Intervention|1|Usual Care
2554819|NCT02533765|Experimental|Olaparib|Olaparib 300mg twice daily continuously
2554998|NCT02532400|Experimental|Neoadjuvant endocrine therapy|Six months of exemestane or anastrozole plus goserelin.
2555008|NCT02532400|Active Comparator|Neoadjuvant chemotherapy|Six cycles of docetaxel plus epirubicin and cyclophosphamide(TEC).
2555043|NCT02532114|Experimental|Treatment (niclosamide, enzalutamide)|Patients receive niclosamide PO TID and enzalutamide PO daily. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
2555144|NCT02531555|Active Comparator|Group M|Mechanical periodontal treatment (Group M): Scaling and root planing were performed with Gracey curettes until the operator feels that root surface is clean, hard and smooth.
2555150|NCT02531555|Experimental|Group L|Pocket disinfection with diode laser (Group L): Subgingival irradiation with a GaAlAs diode laser (CHEESE®, Gigaa Laser, China) was applied to residual pockets each for 20 sec in continious mode. The diode laser had a wavelenght of 810 nm and power output of 1 W for subgingival irradiation (Maximum output power of device was 7 W). Diode laser application was performed parallel to root surface by a 200 µm fiber tip inserted at the bottom of periodontal pocket and slowly moved from apical to coronal direction in a sweeping motion without local anesthesia.
2555154|NCT02531555|Experimental|Group M+L|Combined treatment (Group M+L): Following mechanical periodontal treatment, pocket irradiation with diode laser was performed as mentioned above.
2555203|NCT02531126|Experimental|RPC0163 (Ozanimod)|
2555617|NCT02528617|Other|Gaucher Type 1 or 3|Velaglucerase alfa IV 60 units/kg every other week for duration of the study.
2557049|NCT02518945|Placebo Comparator|Placebo|"12 weeks of treatment with Insulin, Liraglutide and Dapagliflozin Placebo"
2557054|NCT02518945|Active Comparator|Active drugs|"12 weeks of treatment with Insulin, Liraglutide and Active Dapagliflozin Drug"
2557206|NCT02517749|Active Comparator|Usual Care Group|Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc
2557210|NCT02517749|Active Comparator|Indwelling Pleural Catheter Group|Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc
2557320|NCT02517307|Experimental|glycerol/saline|Glycerol/Saline infusion
2557324|NCT02517307|Experimental|intralipid|Intralipid/Heparin infusion
2557416|NCT02516904|Experimental|CD101 IV|single intravenous infusion ascending dose
2557420|NCT02516904|Placebo Comparator|Placebo|normal saline
2557447|NCT02516293|Experimental|Intervention group|"Physical exercise intervention~Nutritional counseling~Pharmaceutical counseling"
2557490|NCT02516020|Active Comparator|Global|EmbryoSingle step culture medium Embryos are cultured in single step culture from day 1 to day 5 Other Name: Global medium (LifeGlobal)
2557496|NCT02516020|Active Comparator|Origio|Sequential media Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast) Other Name: Sequential Blast (Origio)
2557523|NCT02515812|Experimental|Adrenergic Function Explorations with CZT camera|I-123-MIBG and CZT Camera (D-SPECT)
2557525|NCT02515812|Active Comparator|Adrenergic Function Explorations with Anger camera|I-123-MIBG and Anger Camera
3174903|NCT00628225|Experimental|2|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement)
3174904|NCT00628225|Experimental|3|Multifacetted smoking cessation intervention (aimed at professional (training and education) and at patients (counseling + nicotine replacement + bupropion-SR)
3174905|NCT00628238|Active Comparator|A|Subjects younger than 65 years old.
3174906|NCT00628238|Active Comparator|B|Subjects aged 65 years and older
3174907|NCT00628264|Experimental|AP214|
3174908|NCT00628264|Placebo Comparator|Placebo|
3174909|NCT00628277|Experimental|1|Arm 1: high caloric expenditure exercise plus dietary counseling
3174910|NCT00628277|Active Comparator|2|Arm 2: low caloric expenditure exercise plus dietary counseling
3174911|NCT00628290|Experimental|1|
3174912|NCT00628290|Active Comparator|2|
3174913|NCT00628303|Experimental|1|Motavizumab
3174914|NCT00628303|Placebo Comparator|2|Placebo
3174915|NCT00628329||1|
3174916|NCT00628329||2|
3174917|NCT00628342|Experimental|1|
3174918|NCT00628342|Experimental|2|
3174919|NCT00628342|Placebo Comparator|3|
3174920|NCT00628381|Experimental|AA|24 ICU patients with severe sepsis will get a L-citrulline 8 h enteral supplementation.
3174921|NCT00628381|Active Comparator|AB|24 ICU patients with severe sepsis will get an alternative isocaloric amino acid supplementation (L-alanine) during 8 hours
3174922|NCT00628420|Other|1|Patients recieved single low dose of ACP-104
3174923|NCT00628420|Other|2|Patients recieved a high dose of ACP-104
3174924|NCT00628420|Other|3|Patients recieved a placebo
3174925|NCT00628433|Placebo Comparator|1|Placebo
3174926|NCT00628433|Experimental|2|HE3286 5 mg daily
3174927|NCT00628433|Experimental|3|HE3286 10 mg daily
3174928|NCT00628433|Experimental|4|HE3286 20 mg daily
3174929|NCT00628433|Experimental|5|HE3286 4 mg daily
3174930|NCT00628459|Active Comparator|1|
3174931|NCT00628459|Experimental|2|
3174932|NCT00628459|Experimental|3|
3174933|NCT00628485|Experimental|Low Stimulation|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation."
3174934|NCT00628485|Experimental|High Stimulation|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions."
3174935|NCT00628485|Placebo Comparator|Control Group|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises.
3174936|NCT00628511||observation|
3174937|NCT00628524||1|> 500 consecutive patients with coronary artery disease fulfilling eligibility criteria.
3174938|NCT00628537|Experimental|1|BION™ Experimental Group
3174939|NCT00628537|Active Comparator|2|Surface Stimulation Group
2554459|NCT02535988|Experimental|Radiotherapy and Thymalfasin arm|Patients with metastatic lesions of colorectal cancer receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy; Systemic agents are either capecitabine (Xeloda), paclitaxel or S-1;
2554495|NCT02535793|Other|laboratory workers with symptoms in presence of drosophila|
2554544|NCT02535598|Active Comparator|Normal presentation|Standard internet based CBT presentation.
2554551|NCT02535598|Experimental|Enhanced presentation|Enhanced internet CBT presentation.
2554558|NCT02535598|Active Comparator|Normal support|Standard internet based CBT support.
2554561|NCT02535598|Experimental|Enhanced support|Enhanced internet CBT support.
2554613|NCT02535013|Placebo Comparator|Control|No intervention during the perioperative period. Perform lung ultrasound twice only for the diagnostic purpose at the end of surgery and 6 to 12 hours after surgery in the intensive care unit.
2554619|NCT02535013|Active Comparator|Ultrasound|Perform lung ultrasound three times during the perioperative period; after the induction of general anesthesia, at the end of surgery, and 6 to 12 hours after surgery in the intensive care unit. According to the lung ultrasound finding, conduct appropriate interventions such as, alveolar recruitment maneuver for atelectasis, or chest tube insertion for pneumothorax.
2554723|NCT02534701||ERIC® and SOFIA™|ERIC® device in combination with SOFIA™ Distal Access Catheter
2554752|NCT02533947|Experimental|Exercise group|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
2554754|NCT02533947|Other|Control group|A waitlist control group will get the intervention after 7 month of treatment as usual.
2554800|NCT02533661|Experimental|Family-centered intervention program|"The FCIP group received:~In-hospital intervention: modulation of the NICU, teaching of child development skills, feeding support,massage,parent support and education,transition home preparation.~After-discharge: clinic (1, 2, 4, 9 months) and home visits (0, 6, 12 months) for teaching of child development skills, feeding support, dyadic interaction activities, modulations of home environment, parent support and education."
2554801|NCT02533661|No Intervention|Usual care program|"The UCP group received:~In-hospital intervention: environmental modulation and teaching of child development skills.~After-discharge:telephone calls (0, 1, 2, 4, 6, 9 and 12 months): consultation on general care concerns"
2554824|NCT02533414|Experimental|UAS (+)|RIRS with UAS: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
2554832|NCT02533414|Active Comparator|UAS (-)|RIRS without UAS: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
2554872|NCT02533141|Experimental|Intervention group|10 healthy subjects receiving at first simvastatin for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
2554874|NCT02533141|Placebo Comparator|Placebo group|10 healthy subjects receiving at first placebo for 4 weeks, then crossover. Measurements will be done with the Dynamic Vessel Analyzer (DVA) and Laser Doppler Velocimetry (LDV).
2554937|NCT02532816|Experimental|HND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 83.5 mg, zinc oxide 50.95 mg, Calcium carbonate 3104.05 mg, Thiamine Mononitrate1.85 mg, Nicotinic Acid 30.45 mg, Pyridoxine Hydrocloride 2.90 mg, Pteroyl monoglutamic acid 764.90 mcg, Cyanocobalamin 0.95 mcg, Retinol Palmitate (dry) 742.50 mcgRE)
2554939|NCT02532816|Active Comparator|SND-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + fortified biscuit (ferrous fumarate 32.6 mg, zinc oxide 3.78 mg, Calcium carbonate 874.12 mg, Thiamine Mononitrate1.25 mg, Nicotinic Acid 17.95 mg, Pyridoxine Hydrocloride 1.10 mg, Pteroyl monoglutamic acid 329.90 mcg, Cyanocobalamin 0.55 mcg)
2554941|NCT02532816|Placebo Comparator|NDN-CF|subjects will receive nutrient dense complementary foods in optimized CFRs + non fortified biscuit
2555003|NCT02532426||COPD patients with chronic hypoxemia|COPD patients with chronic and severe arterial hypoxemia at rest (paO2<55mmHg).
2555010|NCT02532426||COPD patients with normoxia|COPD patients with normoxia at rest (paO2>67mmHg), matched for age, sex, bronchial obstruction and lean mass.
2555052|NCT02532231|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 1 hour on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients may receive nivolumab on day 1 only. After cycle 12, patients may receive nivolumab on day 1 of every 3 cycles. Patients experiencing disease progression may go back to receiving treatment on days 1 and 15 of each cycle.
3205258|NCT00941785|Experimental|DHA-PQ|Three monthly administrations of dihydroartemisinin (DHA) plus piperaquine (PQ) in August, September and October.
3205259|NCT00941785|Active Comparator|SP-AQ|Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine
3205260|NCT00941837|Experimental|Olive Oil|
3205261|NCT00941837|Experimental|Coconut oil|
3205262|NCT00941837|Experimental|Palm Olein|
3205263|NCT00941850|Experimental|Triple site CRT|These patients will continue to receive CRT via existing device but will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced
3205264|NCT00941850|No Intervention|Optimised medical and device therapy|These patients will receive optimised medical and device therapy.
2555380|NCT02530190|No Intervention|Control|20 minutes of supine rest
2555421|NCT02529917|Experimental|Hemp powder|Hemp powder supplement
3205265|NCT00941876|Experimental|A. Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
3205266|NCT00941902||Patients scheduled to bariatric surgery|
3205267|NCT00941915|Experimental|Stereotactic Radiotherapy|Five fractions of 7.4 Gy each
3205268|NCT00941941|Experimental|Non-mesh Hernia Repair|Reinforcement with a strip of external oblique aponeurosis
3171075|NCT00582257||Low Genetic Risk: Closed to Accrual|"Sporadic Gastric Cancer - gastric cancer that appears to have occurred by random or sporadic mutation. Specifically, a patient with gastric cancer not eligible for either High Genetic Risk cohort.~Control (closed to accrual) - A participant that is not a blood relative of a patient or relative participant, without gastric cancer and without a family history of a CDH1 gene mutation. Select MSK participants with Hereditary Diffuse Gastric Cancer with identified CDH1 germline genetic mutation will be invited by MSKCC only to complete the onetime Pre-implantation Genetic Diagnosis (HDGC PGD) survey. These patients may be verbally consented over the telephone."
3171076|NCT00582270||1|Follicular Lymphoma
3171077|NCT00582270||2|Non-follicular Lymphoma
3171078|NCT00582283|Other|Diagnostic: iodine I-124 NM404 CT/PET scan|Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
3171079|NCT00582296||1|multi-organ follow-up
3171080|NCT00582296||2|control follow-up
3171081|NCT00582374||A|Pregnant Women
3171082|NCT00582387||nonmuscle invasive bladder cancer|This is a hospital-based cohort study in which subjects with non-muscle invasive bladder cancer diagnosed within the previous 12 months will be evaluated to determine whether candidate genetic variants in patients with superficial bladder cancer can predict the risk of disease recurrence and/or progression, with the goal of modifying surveillance schedules as a function of predicted risk of recurrence or progression. All patients will be treated according to the treatment plan as outlined by their attending physician. The study will not require any deviation from the planned usual treatment.
2554693|NCT02534428|Experimental|wool-first (wool-standard)|superfine merino wool clothing to be worn for 6 weeks followed by 6 weeks of standard clothing (cotton)
2554696|NCT02534428|Active Comparator|cotton-first (standard-wool)|standard (cotton) clothing to be work for 6 weeks followed by 6 weeks of superfine merino wool clothing
2554750|NCT02534142||Completed followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and had a colonoscopy following the result.
2554756|NCT02534142||Did not complete followup|All members aged 50-74 who completed a fecal occult blood test between 1/1/2014 and 1/1/2015, who had a positive result and did not have a colonoscopy following the result.
2554813|NCT02533739|Experimental|Patient group|This group will consist of vestibular patients and/or participants with vertigo.
2554814|NCT02533739|Sham Comparator|Control group|This group will consist of participants without vestibular/vertigo impairments.
2554851|NCT02533271|Experimental|TNT group|The intervention of TNT group is Short-course radiotherapy with neoadjuvant chemotherapy, which consists of a short-course radiotherapy (SCRT, 5 Gy x 5 alone), then after 7-10 days of radiotherapy completed, patients will receive neoadjuvant chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are prescribed preoperatively, then followed by a total mesorectal excision(TME) and postoperative adjuvant chemotherapy. If patients are eligible for postoperative chemotherapy this should consist of at least 2 cycles, which are the same as neoadjuvant chemotherapy.
2554856|NCT02533271|Other|CRT group|The intervention of CRT group is long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively, followed by a total mesorectal excision(TME) and then postoperative adjuvant chemotherapy. The radiotherapy is given in combination with capecitabine in a dose of 825 mg/m2 twice daily on days when radiotherapy, excluding weekends. If patients are eligible for postoperative chemotherapy this should consist of at least 6 cycles of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once every 3 weeks.
2554885|NCT02533037|Active Comparator|Traditional Instability Tools|Participants will use traditional instability tools during the impairment-based rehabilitation intervention.
2554891|NCT02533037|Experimental|Ankle destabilization shoes|Participants will use ankle destabilization shoes during the impairment-based rehabilitation intervention.
3171083|NCT00582413||1|Patients who have been diagnosed with Carcinoma of the oral cavity
3171084|NCT00582439|Other|1|Repair of Orthopaedic Trauma Fractures and Non-Unions
3171085|NCT00582452||2|Affected patients who are at high risk for metachronous colorectal tumors due to mutation status.
3171086|NCT00582452||1|Unaffected patients who are at high risk for developing colon cancer based on family history and/or mutation status.
3171087|NCT00582465||Observation|Lupus
3171088|NCT00582478||1|women with breast cancer
3171089|NCT00582504|Experimental|Vaccination|VEE TC-83
3171090|NCT00582530||1 men with prostate cancer|Patients who have opted for radical prostatectomy as treatment for prostate cancer.
3171091|NCT00582543|Experimental|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position.
3171092|NCT00582582|Experimental|A|Docetaxel plus doxercalciferol
3171093|NCT00582582|Placebo Comparator|B|Docetaxel plus placebo
3171094|NCT00582634|Experimental|Docetaxel followed by cisplatin|Docetaxel (75mg/m2) given IV followed by cisplatin (75mg/m2) given IV on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for 4 cycles.
3171095|NCT00582673|Experimental|1|
3171096|NCT00582673|Placebo Comparator|2|
3171097|NCT00582686|Active Comparator|ORIF with Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group A will be made up of patients that undergo ORIF and Tricortical iliac crest bone grafting.
3171098|NCT00582686|Active Comparator|ORIF without Bone Grafting|This study will be designed as a randomized, prospective, blinded evaluation of patients who have sustained an intra-articular calcaneous fracture that would require open reduction with internal fixation as the preferred method of treatment. Group B will consist of patients that undergo open reduction with internal fixation without bone grafting
3171099|NCT00582699||1|Patients with pancreatic cancer who meet DSMIV criteria for a current diagnosis of a Major Depressive Episode (N=25).
3171100|NCT00582699||2|Patients with pancreatic cancer who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25)
3171101|NCT00582699||3|Healthy controls who meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
2554512|NCT02535923|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
3205269|NCT00941941|Active Comparator|Mesh Hernia Repair|Polypropylene mesh placement
2554694|NCT02534441|Experimental|Skin patch testing to 6 known and 3 novel surfactants|
2554746|NCT02534181|Active Comparator|Intervention group|"Patients will undergo a caloric management protocol:~Days 1 and 2:~Reduction of caloric intake to 5kcal/kg/day;~Replacement of serum phosforus, potassium and magnesium;~Administration of 100mg intravenous thiamine, vitamins and microelements.~From day 3:~If serum phosphorus < 2.5mg/dL, protocol will be followed according to day 2;~If serum phosphorus > 2.5mg/dL, a gradual increase to target caloric intake will ensue."
2554747|NCT02534181|No Intervention|Control group|"Nutritional management will be followed according to institutional protocol.~Electrolyte replacement will be provided at the clinician's discretion."
2554803|NCT02533791|Experimental|low dose group|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
2554806|NCT02533791|Experimental|high dose group|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
2554809|NCT02533791|Placebo Comparator|placebo group|placebo
2555066|NCT02531945|Experimental|Intervention|"The device used in this research to the topography examination is three-dimensional morphometry device of AXS Medical society : the BIOMOD L.~'Use of Biomod device' for all the patient in addition to the conventional X-ray examination."
2555102|NCT02531789||Observation|45 patients receiving elective colorectal surgery
2555142|NCT02531503||Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of asthma medication during the past 12 months.
2555190|NCT02531217|Experimental|ATYR1940|ATYR1940 will be given intravenously at a dose of 3.0 mg/kg, weekly
2555233|NCT02530944||Lupus patients|People diagnosed with Systemic Lupus Erythematosus by a physician
2555323|NCT02530346|Active Comparator|Mechanical Bowel Preparation|"Patients will receive enteric polyethylene glycol at 100 ml/kg/dose during 4 hours, and up to 3 times, prior to surgery.~Enemas with normal saline 20 ml/kg/do will be administered through the stomas 3 times a day"
2555326|NCT02530346|Experimental|No Mechanical Bowel Preparation|Patients will not receive any preparation prior to surgery
3171102|NCT00582699||4|Healthy controls who do not meet DSMIV criteria for a current diagnosis of Major Depressive Episode (N=25).
2555444|NCT02529605|Active Comparator|Product B® IsaGenesis®, Then IsaGenesis®|Participants will come into the clinic in a fasting state to receive the Product B® IsaGenesis®, which will be a one time dose of the liquid-gel formulation contained in 2 capsules, 1280 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the IsaGenesis®. This will be given for a comparison in a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule.
2555449|NCT02529605|Active Comparator|IsaGenesis®, Then Product B® IsaGenesis®|Participants will come into the clinic in a fasting state to receive the IsaGenesis®, which will be a one time dose of the dried powder extract contained in 2 capsules; 1070 mg per capsule. After a washout period of 7 days, they will then come back to the clinic in a fasting state to receive the Product B® IsaGenesis®. This will be given for a comparison in a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
2555508|NCT02529189|Active Comparator|Nitrate-rich beetroot juice|70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
2555513|NCT02529189|Placebo Comparator|Nitrate-deplete beetroot juice|70 ml of a beetroot juice concentrate that is nitrate-depleted
2555594|NCT02528799|Experimental|Nexvax2 DQ2.5 Homozygotes (Cohort 1)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
2555596|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Homozygotes (Cohort 1)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
2555598|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 by ID injections for a total of 14 doses over 46 days.
3171103|NCT00582725|Experimental|R-CHOP + GM-CSF|R-CHOP therapy (6-8 cycles) with GM-CSF
3171104|NCT00582764||1|Any patient undergoing MRI guided preoperative needle localization or MRI guided biopsy of the breast.
3171105|NCT00582777|Active Comparator|USUAL|USUAL treatment - The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
3171106|NCT00582777|Experimental|HS Dosing|"HS DOSING - In this period, the patient's antihypertensive regimen at the baseline visit will be standardized for the once/day medications to be given at bedtime.~For those on monotherapy with a once/day antihypertensive regimen, the time of administration will be changed to bed time.~For those on multi-drug therapy, the time of administration of all once a day antihypertensive drugs will be changed to bed time."
3171107|NCT00582777|Experimental|ADD-ON DOSING|ADD-ON DOSING - This regimen will start with the USUAL regimen to which an additional agent will be added at bed time. An additional dose of ramipril, diltiazem, or hydralazine are three possible options for the add on medication. The intent of the ADD ON therapy is to lower nocturnal BP with minimal impact on daytime BP. Thus, agents with < 24 hr duration of action are preferred. The specific choice and dose of add-on therapy (of the three agents) will be up to the site investigator considering the clinical situation of each participant based on the guidelines below.
3171108|NCT00582829||1|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
3171109|NCT00582829||2|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
3174940|NCT00628537|Active Comparator|3|Control Group with conservative therapy (Range of motion exercises)
2554534|NCT02535624|Active Comparator|ANGIO|Patients with persistent hemodynamic instability (systolic blood pressure (SBP) <90 mmHg after the transfusion of 4 packed red blood cell (PRBC) units in the emergency department) were taken urgently to the angiography suite for pelvic angiography. These patients had to tolerate transfer to the suite. Patients receiving primarily angioembolization therapy were defined as the ANGIO group.
2554537|NCT02535624|Active Comparator|PACKING|Indication for pelvic packing was persistent SBP<90 mmHg during the initial resuscitation period with 3000 ml of intravenous (IV) crystalloids and transfusion of 4 PRBC units. These patients were treated primarly with retroperitoneal packing, while angioembolization OR staff was unavailable (5pm-7am), and were defined as the PACK group.
2554577|NCT02535169|Experimental|Health Education and Coaching|1. To evaluate whether a health education and coaching strategy in overweight and obese adolescents (≥85th percentile) with high risk for type 2 diabetes is superior to usual care (single nutrition consultation) for weight management, clinical health outcomes (measures of glucose tolerance), lifestyle behavior outcomes (diet and physical activity) and outcomes of importance to patients such as satisfaction with the health care team, treatment goals, and psychosocial functioning.
2554578|NCT02535169|Placebo Comparator|Usual Care|1. Dietary consult only
3171110|NCT00582829||3|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
3171111|NCT00582842||1|Men with prostate cancer
3171112|NCT00582842||2|Men with prostate cancer
2554763|NCT02534090||Feeding Intolerant Preterm Infants|32 weeks to 36 weeks 6 days old of post menstrual age infants, feeding intolerants monitored with INVOS device for rSO2
2554771|NCT02534090||Feeding Tolerant Preterm Infants (Controls)|32 weeks to 36 weeks 6 days old of post menstrual age infants without problems through the enteral feedings.
2554805|NCT02533635|Experimental|A-first intervention|Subjects in Arm A receive Ganoderma tea (30g) daily for 8 weeks initially, followed by 8 weeks no intervention.
2554808|NCT02533635|Experimental|B-second intervention|Subjects in Arm B receive no intervention for 8 weeks initially, followed by receiving Ganoderma tea (30g) daily for 8 weeks .
2554841|NCT02533388|Experimental|Electrical acupoint stimulation|Electrical acupoint stimulation at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints, Stimulus frequency was an alternate dense-disperse frequency of 2/10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, which was adjusted to maintain a slight twitching of the regional muscles according to individual maximum tolerance.
2554842|NCT02533388|Sham Comparator|Sham stimulation|Sham stimulation only connected to the apparatus, but electronic stimulation was not applied.
2554898|NCT02533076|Other|Cystinosis Patients|Cystinosis patients
2554901|NCT02533076|Other|Healthy volunteers|Healthy volunteers
2554976|NCT02532634|Experimental|ramosetron, aprepitant, dexamethasone|"Ramosetron 0.3mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
2554980|NCT02532634|Active Comparator|palonosetron, aprepitant, dexamethasone|"Palonosetron 0.25mg IV day1~Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3~Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4"
2555077|NCT02532101|Experimental|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 3 months
2555116|NCT02531750||Achilles tendon rupture|Patients with acute Achilles tendon rupture.
2555167|NCT02531295|Experimental|Kansui 1g per day x 1 day|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.
2555169|NCT02531295|Experimental|Kansui 1g per day x 2 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.
2555171|NCT02531295|Experimental|Kansui 1g per day x 3 days|Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.
3205270|NCT00941954|Experimental|Lifestyle counseling|A group-based structured educational programme.
2555327|NCT02530411|Experimental|Experimental|Fulvestrant 500mg Intra Muscular (IM) Day 1 (D1), D15, then D1 of every 28 day cycle Vandetanib 300 mg Per os (po) daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. Computerised Axial Tomography (CT) at week 8, 16, 24 then 12 weekly.
2555328|NCT02530411|Placebo Comparator|Control|Fulvestrant 500mg IM D1, D15, then D1 of every 28 day cycle Placebo po daily Clinician review D1, D15, weeks 4, 8, 12, 16, 20, 24 then 12 weekly. CT at week 8, 16, 24 then 12 weekly.
3171113|NCT00582855|Experimental|1|
3171114|NCT00582855|Placebo Comparator|2|
3171115|NCT00582868||Hemorrhage|Patients having experienced subarachnoid hemorrhage and have in place a ventriculostomy
2555439|NCT02529787|Experimental|A Test|Test drug (Doxirazole) 1 capsule contains 60 mg of Dexlansoprazole
2555440|NCT02529787|Active Comparator|B Reference|Reference drug (Dexilant) 1 capsule contains 60 mg of Dexlansoprazole
3171116|NCT00582959|Other|1|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
3171117|NCT00583024|Experimental|Arm A|
3171118|NCT00583037|Experimental|NAVA|Implementation of NAVA for 24 hours
3171119|NCT00583063|Experimental|A|Sunitinib taken by mouth every day. Rapamycin (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
3171120|NCT00583063|Experimental|B|Rapamycin taken by mouth every day. Sunitinib (taken by mouth) will be started on Day 15 and then taken every day. Drugs can be taken until disease progression.
3171121|NCT00583076|Experimental|1|AST-120, 2grams, three times daily
3171122|NCT00583089||1|Algorithm Test Set
3171123|NCT00583089||2|Algorithm Development Set
3171124|NCT00583128|Experimental|1|AST-120, 2 gram sachets
3171125|NCT00583128|Placebo Comparator|2|Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets
3171126|NCT00583154|Experimental|1|BLI-801 Dose 1
3171127|NCT00583154|Experimental|2|BLI-801 Dose 2
3171128|NCT00583154|Experimental|3|BLI-801 Dose 3
3171129|NCT00583154|Experimental|4|BLI-801 Dose 4
2554570|NCT02535273|Experimental|Low-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery"
2554571|NCT02535273|Experimental|Moderate-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery"
2554572|NCT02535273|Experimental|High-dose Dexmedetomidine|"load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.~Local anesthesia: lidocaine maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery"
2554573|NCT02535273|Placebo Comparator|normal saline Control group|Intravenous injection normal saline equal quantity，completed within 10 minutes. Local anesthesia: lidocaine Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
2554631|NCT02534909|Experimental|LFG316|During the treatment period, all patients will receive LFG316
2554690|NCT02534532||Cohort 1|Females and males ≥65 years old, attending to the primary care centers, located in three different major cities in Colombia, that are willing to participate in the study, and do not present any exclusion criteria
2554733|NCT02534207|Experimental|Basmisanil in Japanese Healthy Volunteers|Japanese healthy volunteers will receive a single oral dose of RO5186582 within 15 minutes after completing a standard meal.
2554779|NCT02533895|Experimental|Treatment with AV0113|"14 sarcoma and 7 non-sarcoma are treated with AV0113, an anti-tumour immune therapy with autologous DCs loaded with tumour cell lysates in order to establish the feasibility and safety of tumour vaccination.~Peripheral blood mononuclear cells (MNCs) are obtained from patients by leukocyte apheresis. Monocytes enriched by density gradient centrifugation from MNCs will be used to generate immature DCs. These immature DCs will be loaded with autologous tumour cell lysates obtained by needle biopsy or surgery prior to tumour vaccination. The antigen loaded immature DCs will then receive a final maturation stimulus transmitted by exposure to lipopolysaccharide and interferon-gamma. Maturation enables DCs to present antigen with high efficiency to T-lymphocytes."
2554781|NCT02533895|Other|Historic control|In order to be able to compare the survival data of 14 sarcoma patients treated with AV0113, 42 historic control sarcoma patients from the data base of the Department of Orthopaedics, Medical University Vienna, that will be matched for disease, recurrences, relapses etc. will be included into this study.
3205271|NCT00941954|Active Comparator|Control|Written Information (booklet).
3205272|NCT00941967|Experimental|Arm I|Patients receive oral sorafenib tosylate as in arm I. Patients also receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment with gemcitabine hydrochloride and oxaliplatin repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
2554962|NCT02532595|Active Comparator|Group 1 manual therapy and exercise|manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
2554965|NCT02532595|Experimental|Group 2 TDN, manual therapy and exercise|trigger point dry needling (TDN) to trigger points in the gastrocnemius, soleus and tibialis posterior; manual therapy with soft tissue mobilization to trigger points in the gastrocnemius, soleus, and tibialis posterior; exercise including stretching, concentric and eccentric exercises to the hip, triceps surae, tibialis posterior and foot intrinsics.
2555027|NCT02532309|Experimental|Rosuvastatin dose adjustment|
2555028|NCT02532309|Experimental|Rosuvastatin fixed dose|
3205273|NCT00941967|Experimental|Arm II|Patients receive oral sorafenib tosylate twice daily on days 1-14.
3205274|NCT00942006|Active Comparator|LNB-doxycycline|
3205275|NCT00942006|Active Comparator|LNB-ceftriaxone|
3205276|NCT00942019||obese smokers|BMI > 30 kg/m2 CO ≥ 15 ppm
3205277|NCT00942019||non-obese smokers|BMI < 25 kg/m2 CO ≥ 15 ppm
3205278|NCT00942019||obese non-smokers|BMI > 30 kg/m2 CO ≤ 6 ppm
3205279|NCT00942019||non-obese non-smokers|BMI < 25 kg/m2 CO ≤ 6 ppm
3205280|NCT00942058||CA9 level|Serum and urinary CA9 level
3205281|NCT00942071|Experimental|1. MVA-NP+M1 ID|12 volunteers to receive MVA-NP+M1 via ID route
3205282|NCT00942071|Experimental|2. MVA-NP+M1 IM|16 volunteers to receive MVA-NP+M1 via IM route
3205283|NCT00942071|Experimental|3. MVA-NP+M1 IM upper age group|30 volunteers to receive MVA-NP+M1 via IM route
2555404|NCT02530073|Experimental|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|An un-blinded non-randomized single arm pilot study of FETO in fetuses with congenital diaphragmatic hernia (CDH)
2555473|NCT02529501||SA|Patients undergoing spinal anesthesia
2555476|NCT02529501||GA|Patients undergoing short general anesthesia
2555530|NCT02529202|Experimental|Dexmedetomidine group|Neonates with hypoxic-ischemic encephalopathy will receive a dexmedetomidine maintenance infusion of 0.4 mcg/kg/hr during treatment with therapeutic hypothermia and during re-warming (78 hours total).
2555645|NCT02528474|Experimental|Pantera Lux|
2555646|NCT02528474|Active Comparator|SeQuent Please|
2555699|NCT02528006|Other|Titanium Bridges|Surgery
2555750|NCT02527603|Experimental|Spaso Method|Randomized for Sp method + 1 initial dose of 50mg dexketoprofen IM or 25mg Oral
2555754|NCT02527603|Experimental|Boss-Holzach-Matter Method|Randomized for BHM method +1 initial dose of 50mg dexketoprofen IM or 25mg Oral
3205284|NCT00942097|Placebo Comparator|Nutritional plus Placebo (homeopathy)|Nutritional oriented diet for pregnancy period add homeopathic preparation from inert substance.
3205285|NCT00942097|Active Comparator|Nutr and Homeop Sulph Puls Lyc Lackt Con Sep Nuxv Calcc Phos|Nutrition oriented diet for pregnancy period add active homeopathic medication (Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos)
3205286|NCT00942110|Experimental|CPAP|
3208785|NCT00978016|Experimental|arbaclofen placarbil-Cohort 2|"arbaclofen placarbil 40 mg QD with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
2554580|NCT02535143|Placebo Comparator|Control Group|Group will prepare a test cavity in an acrylic block. They will receive 250ml of a commercially available carbonated apple juice (Appy Fizz, Parle Agro, Mumbai, India) three hours after the last meal. The participants will then be required to perform a post intervention test cavity preparation 30 minutes after consuming the drink.
2554612|NCT02534857|Experimental|Intervention arm|Those allocated to the intervention arm, all the oocytes will be exposed to spermatozoa for 2 hours and gently wash through two organ dishes containing 1.5 ml of equilibrated medium, and then transferred to the corresponding microdroplet of equilibrated fresh medium. Surrounding cumulus cell will be retained, not removed from the ooctyes.
2554620|NCT02534857|Placebo Comparator|Control arm|Women who allocated to the control arm, all the oocytes will be exposed to spermatozoa for 20 hours, and checked for fertilization on day 1 (20 hours) after denuding
2554661|NCT02534597|Experimental|pctm|Receives the earliest Promotores training, followed by direct caregiver training, materials support, and technical assistance.
2554665|NCT02534597|Experimental|p_ctm|Receives the earliest Promotores training, followed by delayed caregiver training, delayed materials support, and delayed technical assistance.
2554668|NCT02534597|Experimental|_pmt|Receives the delayed Promotores training, followed by receipt of materials support and technical assistance.
2554670|NCT02534597|Experimental|_p_mt|Receives the delayed Promotores training, followed by delayed receipt of materials support and technical assistance.
2554671|NCT02534597|Experimental|_pct|Receives the delayed Promotores training, followed by caregiver training and technical assistance.
2554672|NCT02534597|Experimental|_p_ct|Receives the delayed Promotores training, followed by delayed caregiver training and technical assistance.
2554673|NCT02534597|Experimental|_pt|Receives the delayed Promotores training, followed by technical assistance.
2554674|NCT02534597|Experimental|_p_t|Receives the delayed Promotores training, followed by delayed technical assistance.
2554675|NCT02534597|Experimental|_pc|Receives the delayed Promotores training, followed by a full caregiver training only.
2554676|NCT02534597|Experimental|_p_c|Receives the delayed Promotores training, followed by delayed caregiver training.
2554734|NCT02534233|Experimental|CryoBalloon ablation|Patients having ablation of dysplastic tissue in esophagus.
3208786|NCT00978016|Experimental|arbaclofen placarbil-Cohort 3|"arbaclofen placarbil 20 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
2554849|NCT02533336|Experimental|DL+LLINs|DL treated with abamectin and fenpyroximate
2554854|NCT02533336|No Intervention|LLINs|LLINs only
2554887|NCT02533050|Experimental|Patients treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10. After randomization, they will be treated with CPAP treatment.
2554893|NCT02533050|No Intervention|Patients non-treated|Patients with CAD and SAS. This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10. After randomization, they will be not treated.
2554895|NCT02533050|No Intervention|Control group|Patients with CAD but without SAS (AHI<15).
2554938|NCT02532829||GROUP NS-A|Healthy Participants: No known disease, no previous surgery, HbA1c<5.7%, BMI<25 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554940|NCT02532829||GROUP NS-B|Obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554942|NCT02532829||GROUP NS-C|Non-obese, type 2 diabetic: Type 2 diabetes diagnosis longer than 3 years; BMI<30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554943|NCT02532829||GROUP NS-D|Obese non-diabetic: HbA1c<5.7%, No signs and history of T2D, and BMI>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554944|NCT02532829||Group SG|Type 2 Diabetic participants who underwent a sleeve gastrectomy, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554945|NCT02532829||Group MGB|Type 2 Diabetic participants who underwent a mini-gastric bypass, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554946|NCT02532829||Group IT|Type 2 Diabetic participants who underwent a sleeve gastrectomy with ileal transposition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2554947|NCT02532829||Group TB|Type 2 Diabetic participants who underwent a sleeve gastrectomy with transit bipartition, performed more than 6 months ago, but within the last 2 years, with steady weight profile. Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
2555013|NCT02532387||MGH ED/EDOU patients|"Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
2555014|NCT02532387||BWH ED/EDOU patients|"Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.~Intervention: Telephone follow-up at 7 and 30 days."
2555015|NCT02532387||Control subjects|"Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment~Historical controls:~Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.~Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol."
2554611|NCT02534961|Active Comparator|prophylactic antibiotics group|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy.
2554622|NCT02534961|No Intervention|on-demand antibiotics group|Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.
2554677|NCT02534662|Experimental|Treatment Arm|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
2554715|NCT02534311||Tocilizumab|Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks.
2554786|NCT02534051|Active Comparator|Clinical care pathway|The intervention is the clinical care pathway designed by investigators, informed by the national guideline co-authored by one of the team, and supplemented by the review of the literature
2554790|NCT02534051|No Intervention|Usual Care|The control group will receive the usual prenatal care.
3205287|NCT00942136|Experimental|Cohort 1, Sequence 1|Subjects in Cohort 1, Sequence 1 will receive a single dose of GSK134972 50 mg after a fast of 10 hours in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after a high fat meal in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
3205288|NCT00942136|Experimental|Cohort 2|Subjects will receive a single dose of either GSK1349572 250 mg or placebo as a suspension. Subjects will have a screening visit within 30 days prior to the dose of study medication and a follow up visit 7-14 days after the dose of study medication.
3205289|NCT00942136|Experimental|Cohort 1, Sequence 2|Subjects in Cohort 1, Sequence 2 will receive a single dose of GSK134972 50 mg after a a high fat meal in Period 1. Following a 7 day washout, they will receive a single dose of GSK134972 50 mg after fast of 10 hours in Period 2. After the last PK sample is collected in Period 2, they will receive a single daily dose of omeprazole 40 mg for 5 days. On Day 5 they will receive a single dose of GSK134972 50 mg 2 hours after the omeprazole dose. Subjects will have a screening visit 30 days prior to the first dose and a follow-up visit 7-14 days after the last dose of medication.
2554995|NCT02532478||Stoma reversed|Patients whose ileostomy have been closed after laparoscopic low anterior resection
2555001|NCT02532478||Stoma not-reversed|Patients whose ileostomy have not been closed due to some problems
2555025|NCT02532296|Active Comparator|Control|Receive usual hospital discharge, care transition and post-discharge care.
2555026|NCT02532296|Experimental|Transition Coach Intervention|In addition to usual care, the intervention group receives care from a trained Transition Coach to support patients for 30 days after discharge.
3205290|NCT00942201|Active Comparator|Single dose dexamethasone|Single dose dexamethasone 0.6 mg/kg, rounded to nearest 2 mg, max 16 mg administered in ED
3205291|NCT00942201|Active Comparator|Two dose dexamethasone|First dose in ED, a prescription for second dose to be administered on Day 3 after discharge
3205292|NCT00942227|Active Comparator|Extension oriented treatment approach|Extension exercises. Subjects are instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to further increase extension movement and/or reduction of symptoms.
2555148|NCT02531477|Experimental|experimental group|Intracarotid injection of propofol to detect efficacy and safety as a novel route for drug delivery
2555186|NCT02531204|Experimental|ASP1585 granules preceding group|
2555191|NCT02531204|Active Comparator|ASP1585 capsules preceding group|
3205293|NCT00942227|Experimental|Mechanical traction plus extension-oriented treatment|Mechanical lumbar traction will be utilized in addition to extension oriented exercises. Subjects are also instructed in a progression of extension oriented movements for the lumbar spine. Manual therapy may be added to increase extension movement and/or reduce radicular symptoms.
3205294|NCT00942240|Experimental|ACU-4429 tablet|
3205295|NCT00942240|Placebo Comparator|matching placebo tablet|
2555347|NCT02530320|Experimental|Palbociclib (PD0332991)|Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.
2555405|NCT02530112||Phase 1|First round of survey respondents.
2555408|NCT02530112||Phase 2|Second round of survey respondents.
2555409|NCT02530112||Phase 3|Third round of survey respondents.
2555477|NCT02529423|Placebo Comparator|Placebo|Placebo
2555481|NCT02529423|Experimental|Multi-nutrient supplement|Multi-nutrient supplement
2555483|NCT02529423|Experimental|Placebo + Behavioral Activation|Placebo + Behavioral Activation
2555486|NCT02529423|Experimental|Multi-nutrient + Behavioral Activation|Multi-nutrient + Behavioral Activation
3205296|NCT00942253|Experimental|Dopamine Agonist Group|"Dialysis patients will receive dopamine agonist for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist and aerobic intradialytic exercise.~Patients will be given evening doses of dopamine agonists, 2 hours before bedtime. The dopamine agonists' dose will be 0.25 mg/dose and remain constant until the end of the study."
3205297|NCT00942253|Placebo Comparator|Placebo Group|"Dialysis patients will receive placebo for 24 weeks following a 24 weeks period of combined treatment with placebo and aerobic intradialytic exercise.~Patients will be given evening doses of placebo, 2 hours before bedtime."
2555614|NCT02528539|Experimental|ITP (Integrative Thearpy Program)|"This ITP intervention consists of two distinct phases, Phase I, the active treatment phase and Phase II, the follow-up phase.~Phase I (Intervention phase) begins post-operatively in 4-6 weeks with a baseline visit that includes 30-minute acupuncture treatment, followed by the 30-minute self-management educational session, and the participants will return weekly for 10 weeks.~Phase II (Follow up phase) begins at month 6 and ends at month 18 from the surgery. The phase II consists of 1-hour quarterly ITP therapy at months 6, 9, 12, 15, and 18 and monthly telephone visits between ITP therapies at months 7, 8, 10, 11, 13, 14, 16, and 17. Self-management reinforcement and support will be implemented during telephone follow up visits"
2554623|NCT02535117|Active Comparator|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
2554692|NCT02534688|Experimental|LNG-IUS group|Single intervention LNG IUS
2554695|NCT02534688|Experimental|DMPA group|Three intervention DmPA 12 wk apart
2554743|NCT02534155|Active Comparator|MitraClip® Therapy|MitraClip® system is a CE marked medical device, which consists of two parts (Clip Delivery System and Steerable Guide Catheter). It is a single sized, percutaneously implanted mechanical Clip. The MitraClip® device grasps and coapts the mitral valve leaflets resulting in fixed approximation of the mitral leaflets throughout the cardiac cycle. The procedure is performed in the cardiac catheterisation laboratory with echocardiographic and fluoroscopic guidance while the patient is under general anaesthesia.
2554744|NCT02534155|Active Comparator|Surgery|Surgical therapy of degenerative mitral regurgitation: repair or replacement of mitral valve, clinical standard
2554797|NCT02533778|Experimental|Interventional mechanical thrombectomy|Mechanical thrombectomy with either Penumbra system, TREVO, or Solitaire device for acute stroke symptom onset between 8 - 24 hours
3205298|NCT00942292|Active Comparator|Lipidem (fish oil)|Lipidem (TPN containing fish oil)
2554905|NCT02532946|Experimental|Bedsider counseling group|Women exposed to: Bedsider.org counseling will be offered a computer or tablet at check-in to clinic. The outcome measure is measured at the patient's surgical abortion procedure appointment, or at medical abortion follow-up, which can range up to 10 days after enrollment
2554907|NCT02532946|No Intervention|Routine counseling group|Women were given counseling in the providers' usual practice style. They were given a card with Bedsider.org's web address along with the counseling.
2554975|NCT02532725||Lean|Men aged 35-55 years, having <20% body fat
2554981|NCT02532725||Obese|Men aged 35-55 years, having >29% body fat
2555057|NCT02532088|Active Comparator|Oil Palm Phenolics|500 mg gallic acid equivalent (GAE), twice daily, 12 months
2555064|NCT02532088|Placebo Comparator|Placebo|Placebo
2555158|NCT02531724|Active Comparator|Levosimendan|Levosimendan will be given as a loading dose of 12 ug/kg during 30 minutes, and then a continuous infusion of 0,1 ug/kg/min for 180 minutes.
2555162|NCT02531724|Placebo Comparator|Placebo|Sodium chloride will be given as a loading dose during 30 minutes and then a continuous infusion for 180 minutes at a rate mimicking the levosimendan group above.
2555201|NCT02531087||Individuals with OI|Individuals with OI with confirmed specific genetic mutations
2555204|NCT02531087||Controls/Unaffected|Individuals who do not have OI and who are not related to an individual with OI
2555254|NCT02530840|Experimental|medical team|personal meetings and follow-up of un-balanced diabetic patients by trained medical team (nurse and doctor), which designed to promote adherence to healthy life style and medical therapy.
2555257|NCT02530840|Experimental|peers group|group meetings and follow-up of un-balanced diabetic patients by trained peers (peers: balanced diabetic patients),which designed to promote adherence to healthy life style and medical therapy.
2555260|NCT02530840|Experimental|SMS notifications|un-balanced diabetic patients receiving daily SMS with content,which designed to promote adherence to healthy life style and medical therapy.
2555264|NCT02530840|No Intervention|control|un-balanced diabetic patients will get the basic and regular treatment for diabetic patients according to Clalit Health Services. In addition, the patients will have the same check-ups like all the patients in the experimental arms.
3205299|NCT00942292|Active Comparator|Lipofundin (TPN)|Control arm (no fish oil)
2555412|NCT02529969|Active Comparator|intervention|500 mg curcumin capsule
2555413|NCT02529969|Placebo Comparator|placebo|500 mg placebo
2555451|NCT02529709|Experimental|High-protein meal condition|
2555458|NCT02529709|Active Comparator|High-monounsaturated fat meal condition|
2555531|NCT02529319|Experimental|MRI-Guided Ablation|"Surgery~Patients will undergo catheter ablation using DE-MRI as a guide for fibrosis imaging."
2555539|NCT02529319|Active Comparator|Conventional Ablation|"Surgery~Patients will undergo conventional catheter ablation as described by the HRS guidelines."
2555572|NCT02528656|Experimental|Pectus Excavatum|Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.
2555579|NCT02528656|Experimental|Pectus Carinatum|Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.
2555631|NCT02528396|Experimental|BioChaperone insulin lispro|
2555636|NCT02528396|Active Comparator|Humalog®|
2555760|NCT02527564|Experimental|Suvorexant|"50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.~Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months."
2555764|NCT02527564|Placebo Comparator|Placebo|50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
3205300|NCT00942318|Experimental|PPE|PPE : CSII +/- Metformin.
3205301|NCT00942318|Active Comparator|injections|INJ: basal/bolus MDI +/- Metformin
2556008|NCT02525913|Other|Bi-lateral mastectomy|
3205302|NCT00942370||accelerometric device|
3205303|NCT00942383||IOUS-USEI|Receive intraoperative ultrasound (IOUS) using the Siemens Anteras to acquire ultrasound elasticity imaging (USEI) during standard of care surgical radiofrequency ablation and microwave ablation
3205304|NCT00942396|Experimental|mammography|Women must be at least 40 years of age, presenting for routine breast cancer screening or presenting with one or both breasts scored 4 or 5 on the BI-RADS scale as a result of SFM either for routine breast cancer screening or for follow-up or diagnostic mammography
3205305|NCT00942435|Experimental|YM150 group|
3205306|NCT00942435|Active Comparator|mechanical prophylaxis group|
2554751|NCT02533986|Placebo Comparator|Control drink|Dietary supplement: Control drink As control, subjects are asked to consume 150 ml control drink containing equal amount of insoluble fiber (cellulose) and sugar for 28 days. In addition, on days-1 and 28, subjects will receive an acute challenge of placebo drink at our clinical facility. After 30 min. control drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
2554755|NCT02533986|Experimental|Berry peel drink|Dietary supplement: Berry peel drink Subjects are asked to consume 150 ml experimental drink containing a berry peel fruit powder. In addition, on days-1 and 28, subjects will receive an acute challenge of test drink at our clinical facility. After 30 min. berry drink intake, subjects will be given standardized breakfast corresponding to 50 g available carbohydrates.
2554817|NCT02533440|Experimental|EXPAREL and Local Anesthetics|In the experimental group, patients will receive EXPAREL and local anesthetics, and will be prescribed opioid and non-opioid analgesics (for use only if in pain).
2554818|NCT02533440|Active Comparator|Oral Opioid and Local Anesthetics|In the control group, patients will receive local anesthetics at the time of surgery and oral opioid or non-opioid analgesics (for use only if in pain).
2554877|NCT02533154|Experimental|BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving BAC containing Prosicca eyedrops for 1 month
2554880|NCT02533154|Active Comparator|non-BAC treatment group|20 patients with mild or moderate dry eye syndrome receiving preservative-free Prosicca sine eyedrops for 1 month
2554993|NCT02532803|Experimental|Novel pelvic MRI scan assessment|All patients with rectal tumours of 20-50mm in size who consent to enter the trial will receive novel staging report for their pelvic MRI scan.
2555063|NCT02532153|Other|Open-Label Ketamine|
2555117|NCT02531763|No Intervention|Control|FHS participants who enrolled with family member will not receive the social incentive intervention and will participate individually but will set a daily step goal and receive daily feedback on whether he or she achieved the goal or not.
2555118|NCT02531763|Active Comparator|Intervention|FHS participants who enrolled with a family member will be placed on a team as connected individuals (both in the same family) who will set a daily step goal, receive daily feedback on whether they achieved their goal, and receive the social incentive intervention.
3205307|NCT00942461|Active Comparator|Laparoscopic Surgery group|Group of patients that are operated with laparoscopic approach
2555243|NCT02530762|Placebo Comparator|Negative control|No added fiber
2555245|NCT02530762|Active Comparator|Positive Fiber control|50g positive control fiber
2555247|NCT02530762|Experimental|Novel Fiber 10g|10g novel fiber
2555248|NCT02530762|Experimental|Novel Fiber 30g|30g novel fiber
2555250|NCT02530762|Experimental|Novel Fiber 50g|50g novel fiber
2555339|NCT02530593||Patients with colon cancer|All patients presenting with a newly diagnosed colon cancer regardless of tumour stage
2555367|NCT02530216|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
2555371|NCT02530216|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
2555467|NCT02529670|Experimental|Laser|15 patients will be positioned in a prone horizontal position under anesthetic monitoring. The intervertebral foramen between the second and third lumbar vertebrae will be accessed by percutaneous puncture guided by fluoroscopy. Laser Photon III® (DCM) will be applied through fiber optics crossing G18 cannulas, during 84 seconds.
2555469|NCT02529670|Active Comparator|Radiofrequency|15 patients will receive radiofrequency in the second dorsal root ganglion through tubes G20, 150 mm long and 5 mm active tip in contact with the target, neuromodulation will be held for 300 seconds at 42oC.
2555470|NCT02529670|Active Comparator|Drug: Lidocaine|In the local anesthetic group, 15 patients will receive the injection of 1 ml lidocaine without vasoconstrictor will be applied in the tubes G18, 150 mm long to block the second dorsal root ganglion.
2555497|NCT02529150|Experimental|exercise|
2555547|NCT02528994|Experimental|Serine 6g daily|Randomized participants will take 6g daily of dietary serine supplement
2555550|NCT02528994|Experimental|Serine 12g daily|Randomized participants will take 12g daily of dietary serine supplement
2555552|NCT02528994|Experimental|Serine 24g daily|Randomized participants will take 24g daily of dietary serine supplement
2555553|NCT02528994|Experimental|Serine 48g daily|Randomized participants will take 48g daily of dietary serine supplement
2555585|NCT02528604|Active Comparator|Catheter Ablation|Left atrial catheter ablation for persistent atrial fibrillation and implantable loop recorder.
2555590|NCT02528604|Active Comparator|Pacemaker and AV node ablation|Participants will have a permanent pacemaker implant followed by AV node ablation
2555591|NCT02528604|Active Comparator|DC cardioversion|Participants will have electrical cardioversion with concomitant anti-arrhythmic therapy and implantable loop recorder.
2555632|NCT02528266|Experimental|Nerve Capping Device|Implant with the experimental device
2555700|NCT02527993|Experimental|Glucobay|Tablet Glucobay (acarbose) 50 mg x 6 daily for 7 days.
2555701|NCT02527993|Experimental|Januvia|Tablet Januvia (sitagliptin) 100 mg orally O.D for 7 days.
2555703|NCT02527993|Experimental|Verapamil|Tablet Verapamil 120 mg orally O.D for 7 days.
3205308|NCT00942461|Active Comparator|Open surgery Group|Group of patients operated with open approach
3205309|NCT00942474|Experimental|Research Arm|Facilitate nerve stimulation lead placement with the nerve access tool
3205310|NCT00942487|Experimental|Nebivolol|
3205311|NCT00942487|Active Comparator|Metoprolol|
3205312|NCT00942500|Experimental|Post-conditioning|
3205313|NCT00942500|No Intervention|Conventional primary PCI|
3205314|NCT00942526|No Intervention|1|no intervention with perioperative oral anti-infective agent or water for gargling
2554957|NCT02532842||Participants with Schizophrenia|This is a retrospective, non-interventional, multicenter study to retrospectively evaluate hospitalization and medical resource use, patterns of paliperidone palmitate use, and clinical outcomes documented within the medical records of young, adult, newly diagnosed schizophrenia participants for the first 12 months of continuous treatment with paliperidone palmitate. Only retrospective data available from clinical routine practice and documented in a participant's medical record will be collected.
2555031|NCT02532348||HIV Patients with antiretroviral therapy|Blood samples in HIV patients under 2 NRTIs (Nucleosidic analogs of Transcriptase Reverse Inhibitors) and 1 PI or 2 NRTIs and 1 NNRTI, for at least one year with a plasmatic viral load under 40 cp/ml.
2555032|NCT02532348||HIV patients without antiretroviral therapy|Blood samples in HIV patients never treated by antiretroviral therapy
2555061|NCT02531958|Experimental|1 Egg|Consumption of 1 egg per day for 4 weeks
2555072|NCT02531958|Experimental|2 Eggs|Consumption of 2 eggs per day for 4 weeks
2555078|NCT02531958|Experimental|3 Eggs|Consumption of 3 eggs per day for 4 weeks
2555123|NCT02531685|Experimental|Cohort 1|13 subjects receive 0.1 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
2555130|NCT02531685|Experimental|Cohort 2|13 subjects receive 0.3 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
2555134|NCT02531685|Experimental|Cohort 3|13 subjects receive 1.0 mcg dmLT intradermally on days 1, 22 and 43. 3 subjects receive placebo.
2555137|NCT02531685|Experimental|Cohort 4|"A sentinel group of 5 subjects receive 2.0 mcg dmLT intradermally on days 1, 22, and 43. 1 subject receives placebo.~Safety data from days 1-14 in sentinel will be reviewed and upon approval to proceed, 8 additional subjects receive 2.0 mcg dmLT intradermally on days 1, 22 and 43. 2 subjects receive placebo."
2555141|NCT02531685|Experimental|Cohort 5|Up to 31 subjects receive TBD mcg dmLT intradermally on days 1, 22 and 43. 4 subjects receive placebo.
2555210|NCT02531074|Experimental|Mobile Application plus Usual Care|
2555211|NCT02531074|Active Comparator|Food Journal plus Usual Care|
2555251|NCT02530723|Experimental|Once a week|Group 1 will be invited to perform resistance training exercise 1 day/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
2555252|NCT02530723|Experimental|Twice a week|Group 2 will be invited to perform resistance training exercise 2 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
2555253|NCT02530723|Experimental|Thrice a week|Group 3 will be invited to perform resistance training exercise 3 days/week. After a 2-week familiarization phase, participants will engage in power training (40% of 1-repetition maximum) for 12 weeks. Instructions include telling participants to lift the weight concentrically 'as fast as possible', with a lowering phase (eccentric) of 2-3 seconds. Participants will perform 3 x 12-14 repetitions per exercise per session. Primarily lower body equipment will be used, including leg press, knee extension/flexion, hip extension/flexion, and calf-raises.
2555255|NCT02530723|No Intervention|wait-control|Participants in this group will serve as controls prior to participating in power training in 1 of the above treatment groups. The control period will last as long as the exercise period, or 3 months. Controls will participate in the same testing time points as the exercisers (baseline, midpoint, and post-intervention).
2555335|NCT02530502|Experimental|Treatment (RT, temozolomide, pembrolizumab)|"RT PORTION: Patients undergo focal RT over 42 days, and receive concurrent temozolomide PO QD on days 1-42 and pembrolizumab IV over 30 minutes on days 1, 22, and 43.~POST-RT: After completion of RT, patients receive temozolomide PO QD on days 1-5 and 29-34 of course 1 and days 1-5 and 29-33 of subsequent courses, and pembrolizumab IV over 30 minutes on days 1, 22, and 43. Treatment repeats every 9 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients deriving benefit may continue to receive pembrolizumab for an additional 12 months."
2555471|NCT02529696||Medical device, accelerometer|A wrist and chest accelerometer will be worn for the duration of stay in the ICU. Data will be generated from patient movement and recorded. Neither the generated data or the worn devices will influence care team's decisions during the patients' stay.
2555535|NCT02529254|Experimental|Video coaching|14 residents in general surgery from PGY-1(post graduate year-1) to PGY-4 Block randomized to the intervention group who will receive a 30 minute video coaching session as the intervention
2555537|NCT02529254|No Intervention|Control|14 residents in general surgery from PGY-1 to PGY-4 block randomized to the control group
2555575|NCT02528747||Study population|Breast cancer patients with metastatic bone disease
2555633|NCT02528201|Active Comparator|Celecoxib 200 milligrams mg QD|celecoxib 200 milligrams (mg) once a day (QD)
2555639|NCT02528201|Active Comparator|Celexocib 400 mg QD|celecoxib 400 milligrams (mg) once a day (QD)
2555641|NCT02528201|Active Comparator|Diclofenac 50 mg TID|diclofenac 50 milligrams (mg) three times a day (TID)
2555722|NCT02527811|Experimental|ulinastatin group|the ulinastatin group will be administered as follows:Ulinastatin 30,000 unit/kg will be diluted into saline solution and administered intravenously in the surgery; Postoperative administration will be 30,000unit/kg divided into 3 regimens until leave ICU.
2555923|NCT02526238|Sham Comparator|Sham TMS and trunk rotation|Sham TMS and trunk rotation
3205315|NCT00942526|Sham Comparator|2|perioperative gargling with water
3205316|NCT00942526|Experimental|3|perioperative oral gargling with oral anti-infective agent for seven days
3205317|NCT00942539|Experimental|Midazolam|Administration of Midazolam prior Lumbar Puncture
3205318|NCT00942565|Active Comparator|Tramadol/acetaminophen|The tramadol and acetaminophen combination was given to patients at the same day after surgery.
2555073|NCT02531997|Active Comparator|Hypnotic Relaxation Therapy|Hypnotic relaxation will be performed in three sessions, two weeks apart, over 6 weeks. The hypnosis sessions will build on each other in terms of content.
2555080|NCT02531997|Other|Progressive Muscle Relaxation (PMR)|The PMR will consist of progressive tensing and relaxing of the muscles from head to toe to a soothing sound of the participant's choosing.
3205319|NCT00942565|Active Comparator|acetaminophen|Acetaminophen was used as active control.
3205320|NCT00942591|Experimental|1|Interferon beta-1b AND atorvastatin
3205321|NCT00942591|Active Comparator|2|Interferon beta-1b
2555268|NCT02530814||Lake Apopka Farmworkers|This group will have a onetime blood collection and questionnaires regarding health status and health concerns.
2555276|NCT02530814||Existing Data Group|The investigators will collect existing data from the National Health and Nutrition Examination Survey (NHANES) for the range of concentrations of these chemicals in the blood of Americans.
3205322|NCT00942617|Experimental|40 mg non-enteric coated aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
3205323|NCT00942643|No Intervention|no treatment|being observed at 4 weeks and 12 weeks
2555406|NCT02530060|Experimental|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive single oral dose of fixed dose combination (FDC) tablet comprising of Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine on Day 1.
2555453|NCT02529748|Experimental|Participants for Surface Skin Sampling|Adult volunteers with healthy, intact skin will have surface skin wipe samples collected following contact with the approved test substances to measure the quantitative transfer of the test substances to and from the skin surface.
2555509|NCT02529215|Experimental|Just-in-time training (JITT) group|Receive a 20min just-in-time simulation-based teaching session targeting: (1) CPR quality and (2) medication administration within 3 hours of the scheduled in situ simulation.
2555512|NCT02529215|No Intervention|No additional training (control) group|Control group who receives no additional training.
2555616|NCT02528916||Primary Knee Arthroplasty Patients|Patients who consented, met inclusion and exclusion criteria, had plasma and synovial fluid samples drawn as described in the included protocol. No interventions were completed. No changes to standard of care treatment completed.
2555630|NCT02528240|Experimental|+ L-PRF|With leukocyte and platelet rich fibrin
2555635|NCT02528240|Active Comparator|- L-PRF|Without leukocyte and platelet rich fibrin
2555691|NCT02527980||dual users|Individuals who at the point of study enrollment are using both electronic cigarettes (ecig) and commercial cigarettes (CCs)
2555696|NCT02527980||commercial cigarette (CC) only users|Individuals who at the point of study enrollment are using exclusively commercial cigarettes
2555749|NCT02527642|Active Comparator|CRM sequential media (C1/C2)|CRM sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
2555751|NCT02527642|Active Comparator|CRM single step media (C3)|CRM single step media is used to culture the embryos from oocyte fertilization to blastocyst stage.
2555753|NCT02527642|Experimental|Vitrolife media G1/2 Sequential|Vitrolife sequential media, formulated according to the stages of embryo development, is used to culture the embryos from oocyte fertilization to blastocyst stage.
2555756|NCT02527642|Experimental|Vitrolife G-TL Time Lapse media Single Step|G-TL Time Lapse Single step (time lapse) media is formulated for continuous culture from oocyte fertilization to blastocyst stage.
2555780|NCT02527304|Experimental|Treatment (adaptive staged SBRT)|Patients undergo adaptive staged SBRT. Within 14-21 days, patients may undergo a second treatment of adaptive staged SBRT at the discretion of the treating physician based on clinical parameters, diagnostic interval imaging, and achievement of spinal cord dose constraints.
2555834|NCT02526927|Experimental|Patients 20 - 30 years-old|HR-pQCT and DEXA for measure bone quality and quantity
2555836|NCT02526927|Experimental|Patients 10 - 20 years-old|Blood samples, HR-pQCT and DEXA for measure bone quality and quantity
3205324|NCT00942643|Active Comparator|CPAP treatment|a machine delivers positive airway pressure into the upper airway via nasal mask
3205325|NCT00942669|Experimental|SleepStrip OTC(TM)|Participants will receive the SleepStrip OTC(TM) for a night (or two) test at home, before or after undergoing an independent PSG test at the Sleep lab. The reading of both methods will be analyzed.
3205326|NCT00942682|Experimental|Sorafenib and RAD001|"Since we are looking for the highest dose of the study drug that can be administered safely without severe or unmanageable side effects in participants that have neuroendocrine tumors, not everyone who participates in this research study will receive the same dose of the study drug. The dose the participant will be given will depend on the number of participants who have been enrolled in the study.~Each treatment cycle lasts 28 days. Participants will take RAD001 orally once a day in the morning. Participants will take sorafenib orally twice daily.~Participants will remain on this research study as long as they continue to benefit from the study medications."
2555965|NCT02526186|No Intervention|Standard of Care|Standard of Care only
2555966|NCT02526186|Experimental|Battlefield Auricular Acupuncture|Standard of Care plus Battlefield Auricular Acupuncture
2555999|NCT02525848|Active Comparator|dexamethasone|intravenous dexamethasone 8 mg 2 minutes before induction of anesthesia;
2556005|NCT02525848|Active Comparator|gapabentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
2556007|NCT02525848|Active Comparator|Aprepitant|aprepitan 80mg 1 hour before induction of anesthesia.
3205327|NCT00942695|Other|base|average American diet without pistachios
3205328|NCT00942695|Active Comparator|1.5PD|average American diet plus 1.5 oz per day pistachios
3205329|NCT00942695|Active Comparator|3.0PD|average American diet plus 3.0 oz per day pistachios
2556116|NCT02525237|Experimental|Apatinib plus S-1|Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
2556165|NCT02524899|Active Comparator|Cognitive Remediation Therapy and placebo|7.5 weeks of twice weekly cognitive remediation sessions
3205330|NCT00942721|Experimental|Web-based CBT for PPD|Participants will receive Web-based CBT for PPD.
3205331|NCT00942747|Experimental|Temsirolimus|Weekly IV temsirolimus
2554928|NCT02532660|Experimental|Escitalopram + LABCAT TCJUSS|Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
2554929|NCT02532660|Placebo Comparator|Escitalopram + LABCAT TCJUSS placebo|Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
2554930|NCT02532660|Experimental|Escitalopram Placebo + LABCAT TCJUSS|Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).
2554968|NCT02532452|Experimental|Viral Specific VST Infusion|3rd party VST infusion
2555036|NCT02532335|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
2555038|NCT02532335|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
2555039|NCT02532335|Active Comparator|Healthy Volunteers OCA|Obeticholic acid Obeticholic acid 25 mg/day in three weeks
2555040|NCT02532335|Placebo Comparator|Healthy volunteers Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3205332|NCT00942760||Research MRI|High Grade Glioma patients who show progression based on MRI
2555119|NCT02531776|Experimental|Subcutaneous insertions of needles|36 subcutaneous needle insertions per participant with 18 differently designed needles. 30test participants in total. No fluid will be injected. Pain perception will be rated by the subjects, penetration force and skin blood perfusion will be measured, and any skin reactions will be assessed.
2555176|NCT02531269||Patients treated with DCV (NPP)+Sofosbuvir +/- Ribavirin (RBV)|
2555177|NCT02531269||Patients treated with DCV (NPP) + Simeprevir +/- RBV|
2555179|NCT02531269||Patients treated with DCV(post-marketing) + Sofosbuvir +/- RBV|
2555180|NCT02531269||Patients treated with DCV(post-marketing) + Simeprevir +/- RBV|
2555216|NCT02531009||Healthy|Approximately 10 healthy adults will be enrolled into this study
2555219|NCT02531009||SSc|Participants with dcSSc and lcSSc
2555244|NCT02530788|Active Comparator|Selenium Supplement (sodium selenite)|Active arm receiving Selenium in form of sodium selenite
2555246|NCT02530788|Placebo Comparator|Placebo|Placebo arm receiving Sodium Chloride solution
2555325|NCT02530606|Experimental|Diagnostic (PAI)|Patients undergo PAI over 15-30 minutes prior to the ovarian excision.
2555374|NCT02530268||Ankylosing Spondylitis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
2555376|NCT02530268||Psoriatic Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible
2555401|NCT02529982|Active Comparator|intervention|500 mg curcumin capsule
2555403|NCT02529982|Placebo Comparator|control|placebo
2555441|NCT02529774|Experimental|Systemic Chemotherapy plus Hepatic Artery Infusion (HAI)|
2555442|NCT02529774|Active Comparator|Systemic Chemotherapy|
2555475|NCT02529449|Placebo Comparator|Placebo|once daily
2555478|NCT02529449|Experimental|ASP1941 Low dose group|once daily
2555480|NCT02529449|Experimental|ASP1941 Middle dose group|once daily
2555484|NCT02529449|Experimental|ASP1941 High dose group|once daily
2555520|NCT02529046|Active Comparator|Aerobic exercise associated with CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%).
2555526|NCT02529046|Placebo Comparator|Aerobic exercise|Placebo group received 4 g/day of olive oil.
2555584|NCT02528760|Experimental|Metaclopromide group|
2555587|NCT02528760|Experimental|Erythromycin group|
2555589|NCT02528760|Placebo Comparator|Placebo group|
3205333|NCT00942773|Active Comparator|CYP2C19 extensive metabolizer|
3205334|NCT00942773|Active Comparator|CYP2C19 heterozygous extensive metabolizer|
3205335|NCT00942773|Active Comparator|CYP2C19 poor metabolizer|
2556019|NCT02525835|Experimental|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
2556021|NCT02525835|Experimental|High Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) or a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
3205336|NCT00942799|Experimental|Study Drug: Genz-644282 (28-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
3205337|NCT00942799|Experimental|Study Drug: Genz-644282 (21-day dosing schedule)|Genz-644282 (Each cohort will be based on dose-escalation)
3205338|NCT00942812|Experimental|Intervention|A diarrhea Pack comprising of low osmolality ORS, Zinc, water purification sachets and pictorial chart.
2556195|NCT02524821|Active Comparator|drugs only, fasted|1 x 850 mg metformin tablet, under fasting conditions.
2556198|NCT02524821|Experimental|Gelesis100 plus drugs, fasted|3 x 0.75 g Gelesis100 capsules, followed 30 minutes later by the administration of 1 x 850 mg metformin tablet, under fasting conditions.
2556200|NCT02524821|Active Comparator|drugs only, fed|1 x 850 mg metformin tablet, followed by the ingestion of a high-fat, high-caloric meal.
2556260|NCT02524262|Experimental|Slow-release L-cysteine|Oral intake of slow-release L-cysteine 200 mg before challenge with ethanol.
3205339|NCT00942812|Other|Control|Standard Care through National LHW (Lady Health Workers)program
3205340|NCT00942916||Patients with confirmed diagnosis of NTM pulmonary disease|Those with sputum mycobacterial culture yielded the same NTM species for at least two sets within one year.
3205341|NCT00942916||Patients with not definite NTM pulmonary disease|Those who had sputum culture yielded NTM but did not satisfy the criteria for diagnosis with NTM pulmonary disease.
3205342|NCT00942929||Adolescents hospitalized for anorexia nervosa|Adolescent 12-18 years old, fulfilling the DSM IV criteria for anorexia nervosa, hospitalized for medical stabilization and/ or initiation of refeeding
3205343|NCT00942929||Controls|Adolescents 12-18 years old without anorexia nervosa hospitalized for reasons other than those involving the respiratory system and with no underlying lung disease
3205344|NCT00942955||CLT|The patients whose blood are analyzed by conventional central laboratory.
3205345|NCT00942955||POCT|the patients group whose lab analyze by POCT device.
2554982|NCT02532777|Experimental|Prednisone & Leflunomide|"Drug: prednisone & leflunomide & Angiotensin-converting enzyme inhibitor(ACEI). Prednisone: 2mg/kg/d (the maximum dose is 60mg) for 6-8 weeks, then two-thirds of the two day's dose qod.~Leflunomide: give patients the induction dose 1mg/kg/d for three days (the total dose is under 40mg/kg)，then give the maintaining dose 0.5mg/kg/d.~Angiotensin-converting enzyme inhibitor(ACEI): 0.2-0.3mg/kg/d. Methylprednisolone: the children with above 50% crescent in renal biopsy."
2555058|NCT02532062|Experimental|Supplementation|Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
2555067|NCT02532062|Active Comparator|Placebo|Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
3205348|NCT00943007|Active Comparator|Conventional Neuronavigation|Standard form of neuronavigation: based on preoperative MRI without intraoperative correction for brain shift
3205349|NCT00943007|Experimental|Intraoperative MRI|Standard neuronavigation plus intraoperative MRI to correct for brain shift
3205350|NCT00943020|Active Comparator|Nutricia PreOp + Lipid|Nutricia PreOp + Lipid
3205351|NCT00943020|Active Comparator|Nutrica PreOP + Glutamine|Nutrica PreOP + Glutamine
3205352|NCT00943020|Experimental|Nutricia PreOP|Nutricia PreOP: carbohydrate only drink
2555949|NCT02526537||Gefitinib|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Gefitinib for postoperative therapy (Gefitinib 250 mg daily for 2 years).
2555952|NCT02526537||Non-specific treatment|Stage IB NSCLC Patients with high risk factors and EGFR gene sensitive mutation who can not tolerate or decline chemotherapy and choose Non-specific treatment.(Chinese herbal medicine and nonspecific immunomodulators as adjuvant anti-cancer treatment for 2 years).
2555998|NCT02525939|Active Comparator|dalcetrapib|dalcetrapib 600 mg po QD
2556004|NCT02525939|Placebo Comparator|placebo|matching placebo tablet po QD
3205353|NCT00943033|Experimental|Mindfulness-Based Cognitive Therapy plus treatment as usual|
3205354|NCT00943033|No Intervention|MBCT Waitlist plus Treatment as Usual|
2556595|NCT02522013|Experimental|Aminophylline group|IV injection of aminophylline
2556600|NCT02522013|Placebo Comparator|isotonic saline group|IV injection of isotonic saline group
2556652|NCT02521675|Other|Diabrasport then Rest|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
2556655|NCT02521675|Other|Rest then Diabrasport|Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.
3171130|NCT00583167||A1|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count >200 cells/mm3. Group A1 will undergo continuous CSF ( cerebrospinal fluid) sampling via intrathecal catheter.
3171131|NCT00583167||A2|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. CD4+ T cell count <200 cells/mm3. Group A2 will undergo continuous CSF sampling via intrathecal catheter.
2556832|NCT02520947|Experimental|Bispectral index|The group that desflurane titrated according to bispectral index monitoring
2556833|NCT02520947|Other|Minimum alveolar concentration|The group that desflurane consumption titrated according to minimum alveolar concentration monitoring
2556886|NCT02520206||Arthritis|subjects with arthritis
2556887|NCT02520206||Health control subjects|Health control
2556909|NCT02520050|Active Comparator|Traditional MNT|Will be instructed to follow a MNT plan as recommended by the ADA through consultation with a RD.
2556912|NCT02520050|Active Comparator|Structured MNT|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day.
2556921|NCT02520050|Active Comparator|Structured MNT plus Weekly Support|Will be instructed to follow a MNT plan as applied in the Why WAIT™ program, which includes structured dietary plan, dietary modification and use of diabetes-specific meal-replacement (Ultra Glucose Control®; Metagenics Inc.) three times per day plus weekly coaching.
3205355|NCT00943046|Experimental|Siello pacemaker lead|Patients with Siello Pacemaker lead
3205356|NCT00943059|Experimental|Acipimox|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
3205357|NCT00943059|Placebo Comparator|Cellulosum mycrocryst capsula|Subjects will receive Acipimox or a placebo in random order. Acipimox is a commercially available and registrated drug, that lowers free fatty acids by inhibiting hormone sensitive lipase in the peripheral adipose tissue. No serious side-effects are known other than rare anaphylactic reactions.
2557035|NCT02519101|Experimental|Continunous blood pressure monitoring|Patients receive continuous noninvasive blood pressure monitoring in addition to intermittent monitoring
3171132|NCT00583167||B|HIV-infected subjects who are at least 18 years of age, with no ART in the previous 3 months, and with plasma HIV-1 RNA >20,000 copies/mL. Group B will not undergo continuous CSF sampling, but will undergo sparse CSF sampling by lumbar punctures.
3171133|NCT00583180||A|Capsaicin treated patients
3205358|NCT00943085|Experimental|Family-focused therapy|Participants will receive family-focused therapy.
3205359|NCT00943085|Active Comparator|Brief educational treatment|Participants will receive one session of diagnostic feedback, recommendations for continued treatment, and crisis intervention as needed.
3205360|NCT00943137|Experimental|5-FU dosage adjustments|The dose of continuous infusion 5-FU will be adjusted every cycle until patients reached the therapeutic plasma range (450 to 550 microgram/L).
2555120|NCT02531815|Experimental|Cohort 1 (subcutaneous [SC]) PF-06741086, Placebo|
2555124|NCT02531815|Experimental|Cohort 2 (SC) PF-06741086, Placebo|
2555127|NCT02531815|Experimental|Cohort 3 (SC) PF-06741086, Placebo|
2555131|NCT02531815|Experimental|Cohort 4 (Intravenous [IV]) PF-06741086, Placebo|
2555135|NCT02531815|Experimental|Cohort 5 (IV) PF-06741086, Placebo|
2555138|NCT02531815|Experimental|Cohort 6 (IV) PF-06741086, Placebo|
2555143|NCT02531815|Experimental|Cohort 7 (IV) PF-06741086, Placebo|
2555147|NCT02531815|Experimental|Cohort 8 (subcutaneous [SC]) PF-06741086|
3205361|NCT00943176|Placebo Comparator|Sugar Pill|
3205362|NCT00943176|Experimental|Modafinil|
2555293|NCT02530632|Active Comparator|Sevoflurane anesthesia|Anesthesia maintained with inhalational sevoflurane
2555295|NCT02530632|Experimental|Propofol anesthesia|Anesthesia maintained with intravenous propofol continuous infusion
2555340|NCT02530359|Active Comparator|Group 1|Pirfenidone extended release 600mg per mouth every 12 hours for 7 days.
2555342|NCT02530359|Active Comparator|Group 2|Pirfenidone extended release 600mg per mouth in the morning and placebo by night (each treatment every 12 hrs) for 7 days.
2555343|NCT02530359|Placebo Comparator|Group 3|Placebo equivalent per mouth every 12 hrs for 7 days.
2555381|NCT02530164|Active Comparator|real tDCS|
2555383|NCT02530164|Placebo Comparator|sham tDCS|
2555425|NCT02529943||Surgery Group|Consecutive patients from a two surgeon practice
2555459|NCT02529631|Active Comparator|Drug: orlistat 60mg capsules|"A tailored blister-strip for one day contains~three capsules with orlistat 60mg Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six placebo tablets Administration: 3 times daily 2 tablets with each main meal"
2555462|NCT02529631|Active Comparator|Medical device: polyglucosamine|"A tailored blister-strip for one day contains~three placebo capsules Administration: 3 times daily 1 capsule with each meal containing fat concomitant with~six tablets Administration: 3 times daily 2 tablets (whereas the 2 tablets in the mold breakfast are placebo tablets and the remaining 4 tablets for lunch and dinner contains poliglucosamine"
2555493|NCT02529228|Experimental|CON-2|Consuming 2 Low Protein, High Carbohydrate Meals i.e. changing Meal Frequency and Protein Composition.
2555494|NCT02529228|Experimental|CON-6|Dividing meal intake into 6 smaller Low Protein, High Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
2555495|NCT02529228|Experimental|PRO-2|Consuming 2 High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
2555496|NCT02529228|Experimental|PRO-6|Dividing meal intake into 6 smaller High Protein, Low Carbohydrate Meals. i.e. changing Meal Frequency and Protein Composition.
2555554|NCT02528968|Other|Educational Package|Patients will receive a standardised PK focused educational package in the form of a short video film.
2555561|NCT02528591|Experimental|renal transplant patient|
2555618|NCT02528526|Experimental|Treatment|Add-on application of Myo-inositol trispyrophosphate, total of 9 times, 3 applications per week, over 3 weeks.
2555650|NCT02528136|Experimental|Carbetocin|One minute injection of carbetocin 100 µg after the delivery of the baby
2555653|NCT02528136|Active Comparator|Oxytocin|One minute injection of oxytocin 2.5 U after the delivery of the baby
2555690|NCT02527915|Experimental|Mental Health eConsults|Primary care clinics that will receive the eConsults intervention at the start of the study.
2555697|NCT02527915|Active Comparator|Usual care|"Primary care clinics that will deliver care as usual for nine months, and will receive the eConsults intervention nine months subsequent to the eConsults intervention clinics."
2555739|NCT02527655|Experimental|Choice-Based Physical Activity and Active Transportation|Participants will meet one-on-one with an activity coach to develop a choice-based physical activity and active transportation plan based on their interest, abilities, and resources; attend group-based motivational meetings; and receive ongoing support and encouragement for physical activity and active transportation (e.g., telephone-assisted support, community centre and transit passes).
2555745|NCT02527655|No Intervention|Wait-List Control|Participants will be offered the Choice-Based Physical Activity and Active Transportation intervention after the experimental arm has completed the study.
2555820|NCT02527096|Experimental|dolutegravir(Tivicay®) and lamivudine(Epivir®)|
3205363|NCT00943228|Experimental|mycophenolate mofetil|mycophenolate mofetil 2000mg BID (4g/day) for 14 days, followed by mycophenolate 1000mg BID (2g/day) thereafter
3205364|NCT00943254|Experimental|Arm 1|"Patients randomized to this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based and DVD materials"
2555972|NCT02526199|Active Comparator|Group BA|Bupivacaine + Adrenaline Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml
2555974|NCT02526199|Experimental|Group BAD|Bupivacine + Adrenaline + Dexamethasone Sciatic nerve block with Bupivacaine 0.5% + Epinephrine 5 microg/ml PLUS Dexamethsone 8 mg
3205365|NCT00943254|Experimental|Arm 2|"Patients in this arm receive the diagnosis of metabolic syndrome and subsequent education using paper-based material"
2556263|NCT02524262|Placebo Comparator|Placebo|Oral intake of identically-looking placebo capsules
3205366|NCT00943254|No Intervention|Arm 3|Patients randomized to control receive the diagnosis of individual cardiovascular risk factors with paper-based educational material
3205367|NCT00943267|Experimental|Activated protein C|
3205368|NCT00943267|Placebo Comparator|Saline|
3205369|NCT00943280||1 EGD|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to EGD.
3205370|NCT00943280||2 Transnasal|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to Transnasal endoscopy.
3205371|NCT00943280||3 PillCam|Olmsted county residents with no history of Barrett's esophagus,who have previously completed GERQ questionnaire, randomized to PillCam.
3205372|NCT00943293|Experimental|Vaccine|
3205373|NCT00943332||spica casting|
3205374|NCT00943332||intramedullary nailing|
3205375|NCT00943332||submuscualr plating|
2555049|NCT02532218|Placebo Comparator|Placebo|Matching Placebo 3g bid for 24 wks
2555122|NCT02531841|Active Comparator|Arm A|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
2555126|NCT02531841|Active Comparator|Arm B|"Induction Treatment 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4)~Consolidation Treatment High-dose chemotherapy~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~*if not available at study site, Busulfan can be administered instead:~Busulfan 3,2 mg/kg/d i.v. (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
2555197|NCT02531139|Experimental|MAP maintained at 80 mmHg|During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
2555200|NCT02531139|Active Comparator|MAP maintained at 60 mmHg|During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
2555273|NCT02530879|Experimental|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
2555275|NCT02530879|Active Comparator|Antireflux medication|"Intervention includes treatment with one of the following:~Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Lansoprazole-Dose range 15mg per day- 30mg twice a day~Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day~Rantidine-Dose range: 150 mg twice a day or 300 mg once a day.~Rantidine may be used in combination with any of the above"
2555278|NCT02530879|Experimental|Voice therapy and Anti-reflux therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
2555304|NCT02530437|Experimental|Step I (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib PO for 7 days, followed by taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
2555306|NCT02530437|Experimental|Step II (taladegib, paclitaxel, carboplatin, and radiation)|Patients receive taladegib, paclitaxel, carboplatin, and external beam radiation therapy as in Phase IB.
3205376|NCT00943345|Active Comparator|GS dual sugar permeability test|"Golden standard GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3205377|NCT00943345|Other|Multi sugar test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
2555546|NCT02528981|Experimental|Probiotic|L. rhamnosus GR-1 and L. reuteri RC-14 will be supplied to 100 randomized pregnant people in gelatin capsules containing 2.5 billion viable cells of each strain (CFU). These organisms have been previously shown to colonize the vagina after being taken orally (11) and displace the pathogens causing bacterial vaginosis (12) and vaginal yeast infections (13), and have been shown to be an effective treatment, or accessory to treatment of these conditions. (7- 9, 13)
2555549|NCT02528981|Placebo Comparator|Placebo|Placebo capsules will be supplied to 100 randomized pregnant people in gelatin capsules that are identical to the probiotics that the experimental group will receive.
2555609|NCT02528630|Experimental|Exercise group|Performed a session regarding joint protection and energy conservation and a progressive resistance strength training program for intrinsic muscles of the hand for 12 weeks.
2555613|NCT02528630|Active Comparator|Control group|Performed a session regarding joint protection and energy conservation
3205378|NCT00943345|Other|Protein test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3205379|NCT00943345|Other|PEG test|"New GI permeability test - testing occurs for basal permeability (with placebo) and after ingestion of indometacin (for normal controls).~Coeliac patients will only have 1 test to assess basal GI permeability."
3205380|NCT00943358|Active Comparator|Vaccine|adjuvanted influenza vaccine
3205381|NCT00943358|Active Comparator|Vaccine 2|non-adjuvanted vaccine
3205382|NCT00943371|Experimental|1|MK6349
3205383|NCT00943371|Placebo Comparator|2|Placebo to MK6349
3205384|NCT00943410|Active Comparator|Surgical Candidate|After 5 consecutive weeks of treatment with Radiation and Herceptin, these subjects will receive mastectomy excision
2557273|NCT02517554||Remote cancer genetic services by videoconference|
2557274|NCT02517554||Remote cancer genetic services by telephone|
2557275|NCT02517554||Usual Care|
2557330|NCT02517177|Other|Cardiovascular parameters measurements|
2557379|NCT02516800||Aortic valve calcification|Patients with calcific aortic valve disease, age = 65 years or below
2557380|NCT02516800||Control group|Matched control group
2557543|NCT02515773|Experimental|MET and LIFE|Participants randomized to this group will receive both Metformin and lifestyle intervention.Participants randomized to treatment with MET will start at a dose of 500 mg orally at night and slowly titrated in 2-week intervals to ensure that each patient achieves maximum insulin-sensitizing effects of the drug while minimizing the chance of side effects. Investigators will also recommend that MET be taken with food to minimize side effects. If a participant's BMI percentile <5% (=underweight) his/her treatment with MET will be discontinued. Although the risk of low vitamin B12 while taking MET is associated with age > 50 years and having type II diabetes, Investigator will monitor B12 levels and a CBC throughout study participation.
2557563|NCT02515578|Active Comparator|Standard practice transformation support|Primary care practices will receive a cardiovascular care toolkit, practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions
2555054|NCT02532270|Experimental|Group C|Arterial pressure of the patients in Group C is measured by continuous non-invasive arterial pressure (CNAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
2555055|NCT02532270|Experimental|Group N|Arterial pressure of the patients in Group N is measured by intermittent oscillometric non-invasive arterial pressure (NIAP).When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug .If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
2555110|NCT02531828|Experimental|Biopolymer Film|Application of dressings for surgical correction.
2555111|NCT02531828|Active Comparator|Polyurethane Film, or the like|Application of dressings for surgical correction
2555151|NCT02531347|Experimental|Telemedical blood pressure monitoring|Telemedical home blood pressure measurements for three days every second week. The average of all measures excluding day one is electronically transmitted to the General Practitioners. Following communication primarily by email or telephone.
2555155|NCT02531347|Active Comparator|Conventional blood pressure monitoring|Conventional blood pressure monitoring
2555183|NCT02531191|Experimental|New Tablet Preceding Group|Each subject received an ASP015K small tablet in period 1 and an ASP015K current tablet in period 2 under fasted conditions with 200 mL of water.
2555189|NCT02531191|Experimental|Current Tablet Preceding Group|Each subject received an ASP015K current tablet in period 1 and an ASP015K small tablet in period 2 under fasted conditions with 200 mL of water.
2555234|NCT02530918|Experimental|Part 1 DS-7080a dose escalation|3 sequential ascending dose levels (1.0, 2.0, 4.0 mg), every 4 weeks for 12 weeks
2555236|NCT02530918|Experimental|Part 2 DS-7080a|Specific dose (either the maximum tolerated dose or 4.0 mg) of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
2555237|NCT02530918|Active Comparator|Part 2 ranibizumab|Ranibizumab 0.5 mg, every 4 weeks for 12 weeks
2555238|NCT02530918|Experimental|Part 2 DS-7080a and ranibizumab|Specific dose of DS-7080a determined in Part 1 and ranibizumab 0.5 mg, every 4 weeks for 12 weeks
2555239|NCT02530918|Experimental|Part 3 DS-7080a|Specific dose of DS-7080a determined in Part 1, every 4 weeks for 12 weeks
2555240|NCT02530918|Experimental|Part 3 ranibizumab|Ranibizumab 0.3 mg, every 4 weeks for 12 weeks
3205385|NCT00943410|Active Comparator|Non-Surgical Candidate|After 5 weeks of consecutive treatment with radiation and herceptin, these subjects will not be eligible for surgery. They will continue with radiation and herceptin for an additional 2 weeks.
3205386|NCT00943423|Active Comparator|Arm I|Within 6 weeks after completion of course 3 of chemotherapy, patients undergo involved field radiotherapy to disease areas.
3205387|NCT00943423|Experimental|Arm II|Patients receive no further treatment.
2555411|NCT02530047|Experimental|Mesenchymal Stem Cells + Interferon Beta (MSC-INFβ)|MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion. Starting dose: 10^5 MSC/kg once a week for 4 treatments. Up to 4 dose levels of MSC-INFβ tested. Symptom questionnaire completed once a week for 4 weeks.
2555466|NCT02529683|Experimental|Nuvaring (only arm)|Nuvaring use for six months, with monthly pickup of rings and returning of used rings, and other behavioral/clinical assessments conducted during the visit on day 21 of the menstrual cycle.
2555523|NCT02529332|Experimental|Omega-3 Supplementation Group|Omega-3 supplementation
2555529|NCT02529332|No Intervention|Control Group|
2555581|NCT02528825|Experimental|smooth emergence|ASA I-II, aged 19-65 years undergoing general anesthesia with DLT for lung wedge resection were enrolled in this study.After completing the surgery, the propofol infusion was stopped, and effect-site concentration of remifentanil was titrated to predetermined concentration ( initial concentration being 1.5ng/ml for the first patient).The predetermined concentration was maintained at least 10 min throughout emergence for the effect site concentration and plasma concentration can be expected stable. The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
2555619|NCT02528422|Active Comparator|50 µg Acyl-Ghrelin|Intravenous injection on examination day.
2555622|NCT02528422|Active Comparator|100 µg Acyl-Ghrelin|Intravenous injection on examination day.
2555626|NCT02528422|Placebo Comparator|Isotonic Sodium Chloride|Intravenous injection on examination day.
3205388|NCT00943449|Experimental|4SC-201|
3205389|NCT00943449|Experimental|4SC-201 + Sorafenib|
2555740|NCT02527629||Decellularized human valves|Aortic heart valve replacement
2555771|NCT02527330||Control group|Age- and gender-matched healthy volunteers recruited as normal control group.
2555774|NCT02527330||Stable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, LVEF>=55%
2555776|NCT02527330||Unstable HF group|Patients with acute HF episode with hospitalization treatment within 12 months, currently LVEF<55%.
2555812|NCT02527135|Experimental|Behavioural|Intervention arm receiving weekly HIV sensitization text messages
2555814|NCT02527135|No Intervention|Control|No weekly messages were sent to this group
2555852|NCT02526862|No Intervention|A-Mask or direct interface|Mask or direct interface
2555853|NCT02526862|Active Comparator|B-Autoadhesive polyurethane dressing|Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
2555980|NCT02526069|Other|SweetSpot users|Participants will interact with the smartphone application for as long or as little as they wish. They will be asked to complete questionnaires at baseline (pre), 4 weeks (post), and to attend an interview.
2555071|NCT02532140|Experimental|WCK 5107 1000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
2555079|NCT02532140|Experimental|WCK 5107 2000 mg and Cefepime 2000 mg|In the crossover cohorts (WCK 5107 and cefepime, both alone and in combination), 9 subjects will receive all 3 treatments.
2555139|NCT02531594|Experimental|SBIRT|"An assessment form, motivational interviewing, personalized educational materials, immediate access to cessation resources, a 12-week supply of nicotine replacement therapy and weekly booster materials for 12 weeks.~nicotine"
2555140|NCT02531594|Placebo Comparator|HHC|The Healthy Habits Control program has been previously developed and used in the out-patient setting, and will be used as an attention control in which caregivers will receive instruction on healthy lifestyle choices to improve their child's health. Cessation assistance will be offered at the study's conclusion.
2555181|NCT02531165|Experimental|Morphine|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Morphine, initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
2555182|NCT02531165|Experimental|Fentanyl|"Pre-hospital Ticagrelor 180 mg loading dose orally.~Fentanyl, initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required.~Aspirin 500 mg loading dose orally (or intravenously).~Unfractioned heparin 5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.~Primary PCI."
2555249|NCT02530801|Other|Avastin and 5 fluorouracil|Subconjunctival injection of bevacizumab combined with 5 fluorouracil
2555501|NCT02529384||malignant group|The lesion which is malignant tumors in breast
2555502|NCT02529384||begin group|The lesion which is begin lesion in breast
2555503|NCT02529384||The control group|Patient's ipsilateral or contralateral normal breast parenchyma were collected as a control group
2555562|NCT02528929|Active Comparator|At-risk serology|Gluten-free diet
2555563|NCT02528929|Active Comparator|Not at-risk serology|Gluten-free diet
2555623|NCT02528513|Experimental|midazolam|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam will continue to be used for sedation, with the dosage adjusted to achieve the desired level of sedation."
2555627|NCT02528513|Experimental|midazolam/propofol|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to achieve the desired level of sedation."
2555629|NCT02528513|Experimental|midazolam/dexmedetomidine|"Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to achieve the desired level of sedation.~After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5 μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to achieve the desired level of sedation."
2555716|NCT02527837|Active Comparator|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
2555721|NCT02527837|Placebo Comparator|Placebo|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
2555778|NCT02527499|Experimental|ROCBT group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Ride-On Cars with Bimanual Training Program (ROCBT) group.
2555782|NCT02527499|Active Comparator|Early Mobility Training group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Early Mobility Training Program group.
2555788|NCT02527499|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for Regular Therapy Program group.
2555844|NCT02527005|Active Comparator|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
2555845|NCT02527005|Active Comparator|Sulphadoxine-pyrimethamine|500mg of sulphadoxine and 25mg of pyrimethamine 3 tablets every 4 weeks for 3 doses
2555892|NCT02526576|Experimental|Stromal Vascular Fraction|Subjects will receive stromal vascular fraction assisted fat transfer.
2555894|NCT02526576|Active Comparator|Biopsy for Control -regular fat transfer|Subjects will receive regular fat transfer. A biopsy procedure will analyzes the different between experimental and control groups.
3171134|NCT00583180||P|Placebo treated patients
3171135|NCT00583193|Other|1|Open-label Study
2556121|NCT02525289|No Intervention|Control Group|six hours after extubation receiving breathing exercises. After 48 hour postoperative time, sitting on armchair and keeping the erect position and walking in the same place.
2556166|NCT02524899|Experimental|Guanfacine and CRT|7.5 weeks of twice weekly cognitive remediation sessions with 8 weeks of guanfacine
3171136|NCT00583232|Active Comparator|Corticosteroid|Subjects receiving corticosteroid therapy (1-2 mg/kg/day up to 60mg/day) with taper.
3171137|NCT00583232|Active Comparator|infliximab|Subjects receiving infliximab therapy (5 mg/kg at 0, 2 and 6 weeks, followed by every 8 week therapy)
3171138|NCT00583245|Experimental|1|Gait training
3171139|NCT00583258|Experimental|A|
3171140|NCT00583258|Placebo Comparator|B|
3171141|NCT00583271||1|subjects who are getting a celiac block for chronic pancreatitis
3171142|NCT00583271||2|subjects who are getting a celiac block for pancreatic cancer
3171143|NCT00583297||ABCD Subjects|The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study
3171144|NCT00583310|No Intervention|Control|Subjects receive standard written educational information at baseline, but do not receive the telephone-based intervention. Subjects may participate in the intervention following completion of the study.
2555106|NCT02531581|Experimental|Furosémide|"Furosemide: a dose of 40 mg IV bolus initially and live according to the diuretic response: possibility of 2nd Live IV bolus 40 mg if urine output <500 cc / 24 at the 4th hour.~Establishment of an infusion G5 500cc% in vein custody."
2555108|NCT02531581|Active Comparator|NaCl 9% isotonic|"Infusion of 500 cc of isotonic NaCl 9% in 4 hours and 1000 cc 24-hour peripheral vein. The filling is being used in an empirical in severe EP and this group is therefore the control group."
2555146|NCT02531412|Experimental|Spironolactone|Spironolactone 25 mg PO daily for three days. During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
2555153|NCT02531412|Placebo Comparator|Placebo|Placebo 25mg PO daily for three days During five days investigators will collect values of plasma creatinine, sodium, potassium, blood ureic nitrogen, vital signs and urinary output.
3205390|NCT00943462||Glioblastoma Multiforme (GBM)|We will conduct a prospective study on 20 consecutive patients who are seen at the Hôpital Notre-Dame neuro-oncology clinic for a diagnosis of GBM and who meet our inclusion criteria. We will meet with the eligible patients in order to provide them with a detailed description of the study procedures as well as to have them sign a consent form.
2555348|NCT02530333|No Intervention|Basketball Control|Control group of basketball players
2555349|NCT02530333|Experimental|Basketball intervention|Intervention group of basketball players
2555350|NCT02530333|No Intervention|Soccer Control|Control group of soccer players
2555351|NCT02530333|Experimental|Soccer Intervention|intervention group of soccer players
3205391|NCT00943475|Active Comparator|anaesthesia, circumcision|
3205392|NCT00943501|Experimental|I.a|
2555455|NCT02529644|Active Comparator|Comparison (Standard Information Arm)|The comparison/standard information churches will receive standard multilevel HIV education information that is similar in type to those provided to the intervention churches. These churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. These churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
2555461|NCT02529644|Experimental|Intervention|Taking It to the Pews (TIPS) will be delivered through church-based multilevel (community, church-wide, ministry group, interpersonal/individual) activities by trained church leaders using religiously/ culturally-tailored study materials packaged in a TIPS HIV Tool Kit and following a scripted, study implementation manual.
2555515|NCT02529280|Experimental|Intervention|The intervention group will receive three components: 1) a culturally sensitive, individually tailored, 30-minute computer-based BCCT video; 2) a bilingual, low-literacy booklet aimed at encouraging patients to communicate with family and friends and 3) assistance from a patient navigator.
2555517|NCT02529280|No Intervention|Usual Care|The usual care control group will receive the usual care breast cancer clinical trial information materials offered by the CTRC to their eligible patients.
2555611|NCT02528838||Patients receiving Revlimid according to clinical practice|
3205393|NCT00943501|Placebo Comparator|I.b|
2555693|NCT02527889|Experimental|Exercise Group|The exercise group will receive a supervised resistive exercise training. Subjects in the exercise group will attend small group-based exercise sessions twice a week for 8 weeks supervised by physiotherapists.
2555695|NCT02527889|No Intervention|Control Group|The control group will receive no exercise training and continue to receive standard medical care.
3205394|NCT00943501|Experimental|II.a|
3205395|NCT00943501|Placebo Comparator|II.b|
2555799|NCT02527200|Experimental|Liraglutide|
2555801|NCT02527200|Placebo Comparator|Placebo|
2555877|NCT02526745|Experimental|high doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
2555882|NCT02526745|Experimental|low doses of virus content between 4.7～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.7～5.0 lgPFU in 20 adults aged 50-80 years old on day 0
2555885|NCT02526745|Experimental|high doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with high doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
2555886|NCT02526745|Experimental|middle doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with middle doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
2555887|NCT02526745|Experimental|low doses of virus content between 4.3～5.0 lgPFU|live attenuated vaccine against herpes zoster with low doses of virus content between 4.3～5.0 lgPFU in 100 adults aged 50-80 years old on day 0
2555888|NCT02526745|Placebo Comparator|placebo|placebo in 100 adults aged 50-80 years old on day 0
3205396|NCT00943527||1|Premenopausal Women who are not taking hormones or birth control. Ages 35-45 who have had a negative mammograph performed at the Mayo Clinic in Rochester within the last year.
3205397|NCT00943527||2|Women Initiating Hormone Therapy and have had a negative mammogram preformed at the Mayo Clinic Rochester within the last year.
3205398|NCT00943527||3|Women Initiating Tamoxifen who have had a negative mammogram preformed at the Mayo Clinic Rochester.
3205399|NCT00943540|Experimental|Raltegravir BID-QD|"Week 1-4~600 mg of atazanavir to be taken once daily~400 mg of raltegravir to be taken twice daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily~Week 5-8~600 mg of atazanavir to be taken once daily~800 mg of raltegravir to be taken once daily~300 mg of lamivudine (or 200 mg of emtricitabine) to be taken once daily"
2556125|NCT02525276|Experimental|training - HT|training - HT
3205400|NCT00943553|Experimental|1|
3205401|NCT00943553|Experimental|2|
3205402|NCT00943566|Experimental|Sufentanil Transdermal Delivery System|Experimental drug
3205403|NCT00943566|Active Comparator|Control|Sustained release morphine sulfate
3205404|NCT00943709|Experimental|Arm I|Patients with goal blood glucose 80-14 mg/dL receive the Robert Wood Johnson Hospital IV insulin infusion protocol followed by insulin glargine and insulin glulisine (Apidra™) subcutaneously for 4 weeks.
2555129|NCT02531737|Experimental|traitment|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle including docetaxel 75 mg/m2 by intravenous infusion on day 1
2555208|NCT02531061|Experimental|active erosion|"HR-pQCT for measure bone parameters in active erosion group. The active erosion group will be defined by grades 2 and 3, ie by the presence of Doppler signals confluence in less than 50% of the synovial surface (grade 2) and in over 50% of the surface synovial for grade 3"
2555209|NCT02531061|Experimental|inactive erosion|"HR-pQCT for measure bone parameters in active erosion group. The inactive erosion group will be defined by grades 0 and 1, ie the absence of Doppler signal for grade 0 and the presence of some non confluence Doppler signals for the grade 1"
2555241|NCT02530775|Active Comparator|instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion with use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
2555242|NCT02530775|Active Comparator|non-instrumented arthrodesis|"Degenerative Spondylolisthesis and Spinal Stenosis patients having a surgical procedure. The surgical procedure is the intervention and is a spinal fusion without the use of instrumentation and lumbar laminectomy. No additional drug or device intervention."
2555285|NCT02530645|Experimental|OnTrack + BMI|Brief motivational interview plus the use of a smartphone application to monitor alcohol and marijuana use and sexual risk behaviors.
2555287|NCT02530645|Active Comparator|Treatment as Usual|Treatment as usual involves substance use/HIV referral and treatment as regularly offered to all participants who report substance use and sexual risk behaviors at Covenant House New York.
2555324|NCT02530398|Experimental|cinobufacini group|48 patients(half males and half females) will be in the group.Central venous catheters will be preserved for drainage of ascites, after the drainage of most of ascites, we will slowly inject a dilute concentration of cinobufacini injection with escalated dosage through the catheters. Then we will evaluate the observation indexes, including adverse events, vital signs, electrocardiogram, blood routine, urine routine, hepatic and renal function, etc.
3205405|NCT00943709|Active Comparator|Arm II|Patients with goal blood glucose < 250 mg/dL are started on subcutaneous insulin sliding scale at the discretion of the treating physician with blood glucose monitoring and adjustment according to the insulin sliding scale.
3205406|NCT00943748|Active Comparator|deferiprone|deferiprone 30 mg/kg/day
2555487|NCT02529410|Experimental|Triventricular pacing|2 Left ventricular leads and one right ventricular lead
2555488|NCT02529410|Active Comparator|Biventricular leads|1 left ventricular lead and one right ventricular lead
2555507|NCT02529111|Experimental|intervention|"The Echonavigator software will be used on all patients. It will be used after the introduction of the percutaneous closure of ASD prosthesis. The image fusion on fluoroscopy will then be applied."
2555566|NCT02528903|Experimental|Cohort A|
2555569|NCT02528903|Experimental|Cohort B|
2555571|NCT02528903|Experimental|Cohort C|
2555580|NCT02528903|Experimental|Cohort D|
2555586|NCT02528903|Experimental|Cohort E|
2555638|NCT02528279|Other|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
2555667|NCT02528019|Active Comparator|DPP-4 inhibitors|sitagliptin (25-100mg daily), vildagliptin (50-100mg daily), alogliptin (12.5-25mg daily), linagliptin (2.5-5mg daily), teneligliptin (20-40mg), anagliptin (100-200mg daily), saxagliptin (2.5-5mg daily) or trelagliptin (50-100mg weekly)
2555669|NCT02528019|Active Comparator|SGLT2 inhibitors|ipragliflozin (50-100mg daily), dapagliflozin (5-10mg daily), luseogliflozin (2.5-5mg), tofogliflozin (20mg daily), canagliflozin (100mg daily) or empagliflozin (10-25mg daily)
2555671|NCT02528019|Active Comparator|Glimepiride|glimepiride (0.5-8mg daily)
2555713|NCT02527785|Experimental|Oxaliplatin, Irinotecan, S-1(OIS)|"triple combination with oxaliplatin, irinotecan, and S-1.~Treatment will be delivered as a 2-week cycle.~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day 1-7"
2555762|NCT02527538||Pleth|The masimo probe is attached on the index fingertip and cover with black cover in all patients. Record the pleth variability index and blood pressure
2555770|NCT02527278||Laparoscopic tubal ligation (no pain)|Women who have laparoscopic tubal ligation, with no previous diagnosis of pain at baseline
2555773|NCT02527278||Laparoscopic tubal ligation (pain)|Women who have laparoscopic tubal ligation, with a previous diagnosis of pain at baseline
2555775|NCT02527278||Hysteroscopic sterilization (no pain)|Women who have hysteroscopic sterilization, with no previous diagnosis of pain at baseline
2555777|NCT02527278||Hysteroscopic sterilization (pain)|Women who have hysteroscopic sterilization, with a previous diagnosis of pain at baseline
2555816|NCT02527109|Placebo Comparator|Placebo|Intra-anal placebo administered BID.
2555817|NCT02527109|Experimental|Nifedipine 12 mg/day|Intra-anal Nifedipine 12 mg administered OD.
2555818|NCT02527109|Experimental|Nifedipine 24 mg/day|Intra-anal Nifedipine 12 mg administered BID.
2555870|NCT02526706|Experimental|Glaucoma Study Group|Glaucoma patients scheduled for trabeculectomy were recruited for this study and VisionBlue dye is injected prior to the surgery.
2555904|NCT02526472|Experimental|transabdominal US guidance (UGET)|ET under transabdominal US guidance (UGET)
2555905|NCT02526472|Experimental|TV-US ET guidance (mTVET)|ET after transvaginal US uterine measurement (mTVET)
3205407|NCT00943748|Placebo Comparator|placebo|placebo : 30 mg/kg/day, in 2 liquid doses
3205408|NCT00943774||All subjects|All subject participants
2556127|NCT02525276|Placebo Comparator|-training + HT|-training + HT
2556133|NCT02525276|No Intervention|- training - HT|- training - HT
3208787|NCT00978016|Experimental|arbaclofen placarbil-Cohort 4|"arbaclofen placarbil 30 mg BID with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3205409|NCT00943813||Patients in clinic waiting room|When patients are approached in the clinic, they will be given the permission form and asked to participate in the assessment through allowing video-recording and completing the survey. Procedures will be similar to our current operations, with the RSA starting the video-recording equipment before the fellow enters the room and stopping it when the fellow leaves the room. One additional step will be added: When the RSA goes into the room to turn off and remove the video-recording equipment, she will also give the patient the survey, to complete. We expect this survey to take no longer than 5 minutes. In our experience, it is usually at least 10 minutes from when the fellow leaves the room until the attending comes back into the room. Thus, we believe there will be sufficient time for the patient to complete the survey.
3205410|NCT00943839|Experimental|SUVEGIL|
3208788|NCT00978016|Placebo Comparator|Placebo-Cohort 5|"Placebo dose with PPI*~* Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD"
3208789|NCT00978055|Experimental|1|Liothyronine Sodium Tablets, 50 mcg
2555460|NCT02529657|Placebo Comparator|Placebo|23 patients were induced to think they will be getting the same treatment, although the LLLT is not operating.
2555463|NCT02529657|Experimental|Low level Laser Therapy|25 patients were submitted to spine surgery and have received low level laser therapy during surgery, 24 hours after surgery and 48 hours after surgery.
2555534|NCT02529293|Active Comparator|BioChaperone Lispro U-100|injection of 2 doses of 0.2 U/kg on separate visits
2555536|NCT02529293|Experimental|BioChaperone Lispro U-200|injection of 2 doses of 0.2 U/kg on separate visits
2555577|NCT02528708|Placebo Comparator|Placebo|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
2555588|NCT02528708|Experimental|Fibrinogen concentrate|At the same time of randomization code generation, blood samples for a baseline ROTEM® analysis will be drawn, and blood products will be ordered. Patients will be eligible to receive study drug (fibrinogen concentrate or 0.9% saline solution), according to the randomization code previously generated, only if FIBTEM® - A10 value is <18 mm (corresponding to a MCF value of <20 mm, that is a plasma fibrinogen level <3 g/L).
3208790|NCT00978055|Active Comparator|2|Cytomel® Tablets, 50 mcg
3208791|NCT00978081|Experimental|Arm I|Patients receive oral aminolevulinic acid and then undergo continuous photodynamic therapy 4-6 hours later.
2555718|NCT02527902|Experimental|IgAN with glomerular filtration rate (GFR) >90 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with glomerular filtration rate (GFR) >90 ml/min/1.73 m2
2555724|NCT02527902|Experimental|IgAN with GFR 60-89 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 60-89 ml/min/1.73 m2
2555728|NCT02527902|Experimental|IgAN with GFR 30-59 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 30-59 ml/min/1.73 m2
2555731|NCT02527902|Experimental|IgAN with GFR 15-29 ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR 15-29 ml/min/1.73 m2
2555736|NCT02527902|Experimental|IgAN with GFR < 15ml/min/1.73 m2|Measure of ANS by holter device in IgAN patients with GFR < 15ml/min/1.73 m2.
2555793|NCT02527473|No Intervention|Standard Education Group|Control group will receive standard basic life support training for one hour.
2555796|NCT02527473|Experimental|HEROS Group|HEROS group will receive the dispatcher-assisted basic life support training that includes standardized video-based CPR education, interactive role-playing with the dispatcher as well as group discussion for one hour.
2555837|NCT02527044|Experimental|Functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered functional for score of 3."
2555838|NCT02527044|Active Comparator|Non functional graft|"Follow-up angiography of all bypass grafts and anastomoses six months after surgery: anastomotic function was scored as 0 for an occluded graft, 1 when the flow from the native coronary artery was dominant, 2 when flow supply from the native coronary and from the graft was balanced, and 3 when the native coronary was fully opacified by the graft. An anastomosis was considered non functional for scores of 0 to 2."
2555878|NCT02526641||AbbVie|
2555936|NCT02526394|Active Comparator|1|Repevax + Meningitec
2555938|NCT02526394|Active Comparator|2|Repevax + Neis-VacC
2555940|NCT02526394|Active Comparator|3|Repevax + Menitorix
2555942|NCT02526394|Active Comparator|4|Boostrix + Meningitec
2555943|NCT02526394|Active Comparator|5|Boostrix + NeisVacC
2555944|NCT02526394|Active Comparator|6|Boostrix + Menitorix
2555945|NCT02526394|Active Comparator|7|Repevax + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
2555948|NCT02526394|Active Comparator|8|Boostrix + quadrivalent meningococcal conjugate )Nimenrix / Menveo)
2556023|NCT02525822|Experimental|IDP-123 Lotion|IDP-123 Lotion, applied topically to the face, once daily for 12 weeks.
2556025|NCT02525822|Active Comparator|Tazorac Cream, 0.1%|Tazorac Cream (tazarotene 0.1%), applied topically to the face, once daily for 12 weeks.
2556026|NCT02525822|Placebo Comparator|Vehicle Cream|Vehicle Cream, applied topically to the face, once daily for 12 weeks.
2556028|NCT02525822|Placebo Comparator|Vehicle Lotion|Vehicle Lotion, applied topically to the face, once daily for 12 weeks.
2556060|NCT02525484|Experimental|Pirfenidone ACBD treatment sequence|Participants will be given 801 milligrams (mg) single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 1 and in fasted state (treatment C) on Day 4, 801-mg tablet in fed state (treatment B) on Day 7 and in fasted state (treatment D) on Day 10.
2556067|NCT02525510|Active Comparator|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.
2555229|NCT02530892||Measurement Group|"This group contains oocytes and embryos which have their mechanical properties (elasticity and viscosity) measured prior to fertilization (oocytes) or within 24 hours after fertilization (embryos). The investigators are calling this mechanical measurement the EmbryoHug. All participants in the study will have half their embryos measured in this group. Outcomes will be evaluated after 6 days of embryo culture, at the time of pregnancy test, at 5-6 weeks, and at 8-10 weeks, and correlated with EmbryoHug parameters."
2555329|NCT02530372|Experimental|UriCap-F|"The UriCap-F is an FDA cleared Class I device intended for urinary management in women.~The device is comprised of a multiple use unit and a single use unit. The multiple use unit is intended to be reused by the same patient for up to 30 days. It is removed every 24 hours, rinsed under running water, dried and re-applied.~The UriCap is held in position by means of a single-use medically approved adhesive tape."
2555377|NCT02530255|Placebo Comparator|Placebo|Study subjects receiving placebo: Intervention - two capsules, one morning and one night for one year; placebo for cycloastragenol
2555379|NCT02530255|Active Comparator|cycloastragenol|Study subjects receiving cycloastragenol: Intervention - cycloastragenol; oral capsules 8mg. per day (two capsules) one in the morning and one at night for one year.
2555422|NCT02529930|Experimental|Cohort 1: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 3, Week 6, 3mgs per vaccination
2555427|NCT02529930|Experimental|Cohort 2: 3mg VB10.16 Vaccine|VB10.16 Immunotherapy (DNA vaccine): Biological/Vaccine Vaccination time points: Week 0, Week 4, Week 8, 3mgs per vaccination
2555490|NCT02529397|Experimental|Adaptive Working Memory Training|The experimental group will receive working memory training through a commercial computerized program: five weeks of adaptive working memory training concurrently with a behavioral weight loss program. Adaptive working memory training becomes progressively more challenging depending on an individual's performance on a given task. They will attend weekly classes of a behavioral weight loss program.
2555491|NCT02529397|Placebo Comparator|Non-adaptive Working Memory Training|The control group will receive five weeks of non-adaptive (placebo) cognitive training concurrent with the identical behavioral weight loss program as in the experimental group. Non-adaptive cognitive training remains at a constant level.
2555516|NCT02529020|Experimental|Mouthguard|All subjects perform all tests wearing mouthguard.
2555518|NCT02529020|Experimental|No mouthguard|All subjects perform all tests without mouthguard
2555592|NCT02528812|Experimental|Ipsi-R|Intervention group 1 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf that exhibited the higher tenderness (Ipsilateral Rolling: Ipsi-R)
2555595|NCT02528812|Experimental|Contra-R|Intervention group 2 included participants receiving heavy roller massage via the TheraBand Roller Massager on the calf of the contralateral limb (Contralateral Rolling: Contra-R)
2555597|NCT02528812|Sham Comparator|Sham group|The sham group received light stroking of the skin with TheraBand roller massager on the calf that exhibited the higher tenderness
2555599|NCT02528812|Experimental|Ipsi-M|Intervention group 3 included participants receiving manual massage on the calf that exhibited the higher tenderness (Ipsilateral Manual: Ipsi-M)
2555602|NCT02528812|No Intervention|control group|received no intervention
3208792|NCT00978081|Experimental|Arm II|Patients receive aminolevulinic acid as in arm I and then undergo fractionated photodynamic therapy 4-6 hours later.
2555752|NCT02527616|Experimental|IV followed by IC (investigation)|The patient undergoes the FFR measurement with the standard measurement first followed by FFR measurement using the FFR Infusion Microcatheter
2555755|NCT02527616|Experimental|IC (investigation) followed by IV|The patient undergoes the FFR measurement using the FFR Infusion Microcatheter measurement first followed by measurement via the standard measurement
2555803|NCT02527291||Study Group|"The Study group will comprise of seropositive CMV patients undergoing cardiothorathic surgery and having a complicated postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done three times: at enrollment, follow up 1 (7 days post operation) and follow up 2 (14 days post operation).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
2555805|NCT02527291||Control Group 1|"The first control group will be comprised of patients who are seropositive CMV undergoing cardiothorathic surgery and having a normal postoperative course.~In addition to the routine blood work which includes: CBC, chemistry and INR, blood work for CMV PCR will be done two times: at enrollment and follow up 1 (7 days after discharge).~Blood work for Interleukin28 (IL28) will be done at enrollment. All visits include data collection from computerized medical records."
2555806|NCT02527291||Control Group 2|"The second control group will include seronegative patients for CMV undergoing cardiothorathic surgery with complicated and uncomplicated post-operative course.~Blood work for CMV PCR and IL28 will be done at enrollment. All other visits include data collection from computerized medical records only."
2555831|NCT02526901||No treatment|
2555876|NCT02526732|Experimental|individual training program|Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.
2555920|NCT02526420|Experimental|Cohort A: Somavaratan in Older Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects >= 35 years of age
2555924|NCT02526420|Experimental|Cohort B: Somavaratan in Younger Adults|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects < 35 years of age
2555926|NCT02526420|Experimental|Cohort C: Somavaratan in Women on Estrogen|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)
2555988|NCT02525952|Experimental|Hepatectomy with NDR 0-2|Surgical removal of all lesions for patients with a NDR score 0-2 according to the NDR scoring system
2555990|NCT02525952|Active Comparator|TACE with NDR 0-2|Transarterial chemoembolization for patients with a NDR score 0-2 according to the NDR scoring system
2555282|NCT02530697|Experimental|Group 3 - Cutaneous Antimoniate and Pentoxifylline|20mgSb+5/kg/day meglumine antimoniate intravenous for 20 days Oral Pentoxifylline 400mg 3x/daily for 20 days.
2555283|NCT02530697|Experimental|Group 4 - Cutaneous Miltefosine and Pentoxifylline|Oral Miltefosine 2,5mg/kg/day up to 50mg 2x/daily Oral Pentoxifylline 400mg 3x/daily for 20 days.
3208793|NCT00978133|Active Comparator|Skin Staples|Skin closure with skin staples
3208794|NCT00978133|Experimental|Dermabond|Closure of abdominal wound with dermabond (2-octylcyanoacrylate)
2555416|NCT02529956|Experimental|UCB4940 8 mg|Single intravenous (iv) infusion of UCB4940 8 mg over at least 60 minutes.
2555419|NCT02529956|Experimental|UCB4940 40 mg|Single intravenous (iv) infusion of UCB4940 40 mg over at least 60 minutes.
2555426|NCT02529956|Experimental|UCB4940 160 mg|Single intravenous (iv) infusion of UCB4940 160 mg over at least 60 minutes.
2555428|NCT02529956|Experimental|UCB4940 480 mg|Single intravenous (iv) infusion of UCB4940 480 mg over at least 60 minutes.
2555429|NCT02529956|Experimental|UCB4940 640 mg|Single intravenous (iv) infusion of UCB4940 640 mg over at least 60 minutes.
2555430|NCT02529956|Placebo Comparator|Placebo|Single intravenous (iv) infusion of Placebo over at least 60 minutes.
2555445|NCT02529514|Active Comparator|Baclofen|Baclofen 25 mg per os for 7 days at 10 pm every day
2555448|NCT02529514|Placebo Comparator|Placebo|Placebo per os for 7 days at 10 pm every day
2555505|NCT02529345|Experimental|RoadSaver stent|patient treated with the RoadSaver stent of Terumo
2555574|NCT02528890||preganat women between 34 - 40 weeks|Eligible pregnant women, who meet the inclusion criteria, will have a vaginal/anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
2555642|NCT02528448|Active Comparator|plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
2555643|NCT02528448|Active Comparator|0,9% saline|Continuous 1 hour infusion of 0,9% saline15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
2555694|NCT02527954||Infertile with Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has a Y-chromosome microdeletion (detected in blood cells by Polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 1)"
2555698|NCT02527954||Infertile without Y-chromosome deletions|"No intervention will be performed.~Couples whose infertile men has not any Y-chromosome microdeletion (detected in blood cells by polymerase chain reaction multiplex) and fulfill the criteria will be included in this group (group 2)"
2555741|NCT02527668|Experimental|Calcifediol Hy.D (25-hydroxyvitamin D)|20 μg Calcifediol Hy.D (25-hydroxyvitamin D) (one capsule) per day for 6 months
2555746|NCT02527668|Active Comparator|Vitamin D3 (cholecalciferol)|3200 IU Vitamin D3 (cholecalciferol) (one capsule) per day for 6 months
2555747|NCT02527668|Placebo Comparator|Placebo|1 Placebo capsule per day for 6 months
2555781|NCT02527369|Experimental|XP1100RF group|Subjects in the XP1100RF group will be treated with the XP1100RF device.
2555824|NCT02527083|Active Comparator|BIA|Balanced Inhalational Anesthesia (consisting of a sevoflurane inhaled anesthestic only)
2555826|NCT02527083|Active Comparator|TIVA-K|Total intravenous anesthetic with ketamine
2555827|NCT02527083|Active Comparator|TIVA-R|Total intravenous anesthetic with remifentanil
2555871|NCT02526758|Experimental|beclomethasone / formoterol|beclomethasone 100ug and formoterol 6ug , 2 inhalations, twice daily ,for three months
2555873|NCT02526758|Active Comparator|budesonide / formoterol|budesonide 160ug and formoterol 4.5ug, 2 inhalations ,twice daily ,for three month
2555912|NCT02526368|Experimental|Pre-surgical Prostate Cancer patients|Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
2556010|NCT02526082||Total, observational|Various cardiovascular risk groups described below
2556011|NCT02526082||High-risk intervention|Healthy but at high risk in 1974
2556013|NCT02526082||High-risk control|Healthy but at high risk in 1974
2556015|NCT02526082||Low-risk conrtol|Healthy and at low risk in 1974
2556016|NCT02526082||Sick control|Medications or clinical disease in 1974
2556017|NCT02526082||Refused|Refused or no response in 1974
3208795|NCT00978146|Experimental|Desmoid tumor|Patients with desmoid tumors
3208796|NCT00978159|Active Comparator|esomeprazole|esomeprazole 20 mg
2556137|NCT02525068|Experimental|Phase ISafety Run-In|18 patients will receive the combination of enzalutamide and AZD5363 (on an intermittent schedule 4 days on 3 days off) to determine the AZD5363 dose to be used for the randomised phase II and single stage phase II expansion cohort. Approximately three dose-levels of AZD5363 in combination with enzalutamide are planned although other dose levels may be required.
2556141|NCT02525068|Placebo Comparator|Randomised phase II|100 patients will be randomised in a 1:1 ratio to receive 160mg enzalutamide od + AZD5363 bid 4 days on 3 days off (recommended dose from Phase I) vs 160mg enzalutamide od + matching placebo bid 4 days on 3 days off.
2556143|NCT02525068|Experimental|Single stage phase II expansion cohort|Following progression on enzalutamide alone, 18 patients will receive enzalutamide 160mg od and AZD5363 bid (recommended dose from phase I) 4 days on 3 days off
2556201|NCT02524704||Healthy controls|Subjects between the ages of 2 and 21 with healthy lungs. Electrical impedance tomography data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, and during FEV1 and FEF 25-75 spirometry maneuvers for subjects over age 8.
2556204|NCT02524704||CF patients scheduled for a CT scan|Subjects with CF between the ages of 2 and 21 who are either clinically indicated for a CT scan of the lungs or are scheduled for a pulmonary CT scan as part of their routine care. Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during forced expiratory volume in 1 second (FEV1) and forced expiratory flow (FEF) 25-75 spirometry maneuvers for subjects over age 8, and immediately before or after pulmonary CT scanning.
3208797|NCT00978159|Active Comparator|Famotidine|famotidine 40 mg
3208798|NCT00978198|Experimental|Part 1|single administration
3205411|NCT00943865|Active Comparator|hypocaloric diet + exercise advice|Group 1 (control: tailored hypocaloric diet and exercise advised): patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant. Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
3205412|NCT00943865|Experimental|pragmatic diet+ pedometer 10000 steps|Group 2 (pragmatic diet + step counter) - Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control. Subjects were provided with pedometers and were instructed to perform at least 10.000 steps daily, diary recorded.
3205413|NCT00943865|Experimental|pragmatic diet + fitness|Group 3 (pragmatic diet + fitness) - They received the same diet intervention (low carbohydrates, high protein and vegetables style diet and favoring daily brazilian cook habits colored handbook) and hand sized portion control instructions of group 2. They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions.
3205414|NCT00943891||Tumor biopsies|
3205415|NCT00943930||Marijuana-dependent volunteers|
3205416|NCT00943943|Experimental|G-CSF and Plerixafor with Sorafenib|G-CSF 10 mcg/kg adjusted body weight subcutaneous injection. Plerixafor fixed dose of 240 mcg/kg adjusted body weight subcutaneous injection in abdomen. Patients will receive the 1st doses of G-CSF and Plerixafor on day 1. G-CSF and Plerixafor every other day for 7 total doses, repeated every 28 days. Sorafenib starting dose 400 mg twice daily orally after G-CSF/Plerixafor injections.
3205417|NCT00943956|Experimental|Everolimus|Everolimus + radiation
3205418|NCT00943969|Other|obemo|
3205419|NCT00943995|Other|Treatment Arm|Getting Growth Hormone therapy TIW instead of nightly in the Pediatric Tanner 1 Hemodialysis population.
3205420|NCT00944008|Experimental|Depocyte|
3205421|NCT00944060|Experimental|lifestyle intervention|Control group: usual WIC care
3205422|NCT00944086||Recruitment Manoeuvre ,Laparoscopy|
3205423|NCT00944099|Experimental|Grazing|participants will be given an eating frequency prescription to eat every 2 to 3 hours
2555548|NCT02529007|Active Comparator|Standard|These patients have standard colonoscopy performed
2555551|NCT02529007|Experimental|Endocuff|These patients have colonoscopy performed with the endo-cuff attached to the end of the colonoscope
2555564|NCT02528578|Experimental|healthy volunteers|
3205424|NCT00944099|Experimental|Three Meals|participants will be given an eating frequency prescription of eating 3 meals per day
2555710|NCT02527876|Experimental|High Intensity Interval Training/FitBit Flex|Meet with personal trainer once per week for 20-minute exercise session
2555714|NCT02527876|Experimental|Moderate Intensity/FitBit Flex|Meet with personal trainer once per week for 30-minute exercise session and exercise two times a week outside of personal trainer
2555719|NCT02527876|Placebo Comparator|Delayed Control/FtBit Flex|No exercise offered
2555813|NCT02527122|Experimental|Allergen extracts|"Skin prick test of 4 concentrations of D. pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of one forearm. Assessment of the wheal size after 15 minutes.~Skin prick test of 4 concentrations of D. farinae allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the other forearm. Assessment of the wheal size after 15 minutes."
2555840|NCT02526849|Experimental|Fecal microbiota transplantation (FMT)|On day 1-6, patients received 100ml fresh FMT by nasointestinal tube, once per day. The nasointestinal tube was placed in the patient's proximal jejunum through endoscopy. Then, donor fecal microbiota was infused within 5 minutes through nasointestinal tube.
2555842|NCT02526849|Experimental|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
2555875|NCT02526615|Placebo Comparator|Placebo|placebo, 2 tablets per day
2555879|NCT02526615|Active Comparator|Metformin|500mg 1 tablet 2 times per day for the first 2 weeks, then after that 2 tables 2 times per day
2555883|NCT02526615|Active Comparator|Rosiglitazone|2 mg 1 tablets 2 times per day for the first 2 weeks, then after that 2 tablets 2 times per day
2555915|NCT02526316|Other|P16_37-63 Vaccination|Patients will receive P16_37-63 peptide (100 μg) combined with Montanide® ISA-51 VG subcutaneously once a week for four weeks, followed by a 4 week rest period (1 cycle). The vaccination is to be started one week before the initiation or continuation of the cisplatin-based chemotherapy.
2555983|NCT02526121|Experimental|Phlebotomy associated with dietary and lifestyle counseling|
2555987|NCT02526121|Active Comparator|Dietary and lifestyle counseling.|
3205425|NCT00944112|Experimental|Restrictive RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70g/L with a target Hb concentration of 71-90g/L during the intervention period.
3208799|NCT00978198|Experimental|Part 2|multiple administration
2555334|NCT02530489|Experimental|Treatment (atezolizumab, nab-paclitaxel)|"NEOADJUVANT: Patients receive atezolizumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo definitive breast surgery within 6 weeks of the completion of treatment.~ADJUVANT: Within 4 weeks after surgery, patients receive atezolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity."
2555390|NCT02530086|Active Comparator|Placement of a Nasogastric tube|Placement of a Nasogastric tube
2555391|NCT02530086|Experimental|No placement of a Nasogastric tube|No placement of a Nasogastric tube
2555423|NCT02529852|Experimental|Lenalidomide + Obinutuzumab + CHOP|"Phase I: Participants take Lenalidomide by mouth on Days 1 - 14 of each cycle. Participants receive Obinutuzumab by vein over 3 - 4 hours on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6. Participants receive Cyclophosphamide by vein over about 1 hour on Day 1 of all cycles. Participants receive Doxorubicin and Vincristine by vein over about 15 minutes each on Day 1 of all cycles.~Phase II: Participants treated at the recommended phase II dosing (RP2D) of Lenalidomide determined in the Phase Ib portion for 6 cycles of therapy. Dose of Obinutuzumab, Cyclophosphamide, Doxorubicin and Vincristine remain the same as in Phase I.~Each study cycle is 21 days."
2555524|NCT02529306||two parallel group|group with inflammatory markers high levels and control group with inflammatory normal levels markers.
2555555|NCT02528864||Normal endometrium|Control group (n=30) comprising surgical candidates with normal endometrial tissue will be collected for comparison.
2555556|NCT02528864||Endometrial/uterine cancer|"1st year: 50 eligible patients surgical candidates of endometrial cancer with pre-operative imaging and biological samples collected during operation.~2nd year: Enroll another 50 surgical candidates and complete the data regarding clinical MRS/diffusion-weighted imaging and tissue high resolution MRS. Together with the 50 cancer subjects in the first year there will be in total 100 cancer subjects for analysis.~3rd year: Collect enough positive events with any myometrial involvement (n=30), cervical stromal invasion (n=10) and nodal metastasis (n=10). Together with the 100 cancer subjects in the first and second years there will be in total 150 cancer subjects for analysis."
2555576|NCT02528565||Patients with failed RYGB (EWL <50%)|
2555735|NCT02528058||Myopic traction maculopathy|
3205426|NCT00944112|Experimental|Liberal RBC Transfusion Group|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90g/L with a target Hb concentration of 91-110g/L during the intervention period.
3205427|NCT00944138|Experimental|Mindful meditation|Participants assigned to the mindful meditation plus standard care arm will receive individualized instruction on mindful meditation at the time they are randomized to this arm. The participants will be led through a 20 minute relaxation exercise. They will then be led through a brief eating exercise where they will be instructed to eat the food very slowly and pay attention to how the food tastes and the sensations of swallowing the food. This is done to enhance the person's awareness of what and how they are eating and enhance their intuitive sense of satiety. Finally, they will receive an MP3-player with several relaxation instructional audios loaded on the MP3 player.
2555859|NCT02526823|Active Comparator|R-CHOP/CHOPE or ABVD chemotherapy regimen|R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses
2555861|NCT02526823|Experimental|R-CDOP/CDOPE or DBVD chemotherapy regimen|R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses
3208800|NCT00978211|Experimental|DOTA-TOC|Treatment arm
2556160|NCT02524925|Active Comparator|fast track protocol|Oral fluids intake (0.5 lt) 6 hours after operation Mobilization 4 hours after operation Check discharge criteria the 4th-6th postoperative day
2556163|NCT02524925|No Intervention|conventional protocol|Oral intake after bowel mobilization Mobilization after the 1st postoperative day Check discharge criteria the 7th-15th postoperative day
2556258|NCT02524327|Experimental|Toolbox: Automated group|"Toolbox: Automated administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index through a controller with a previously described algorithm.~Objective of depth anesthesia: 40-60"
2556261|NCT02524327|Active Comparator|Manual group|"Manual administration of intravenous anesthetic (propofol 1%) and analgesic (remifentanil, Ultiva(r)) guided by the Bispectral index as usually performed in the operative theater.~Objective of depth anesthesia: 40-60"
2556318|NCT02523976|Experimental|Arm A|Dasatinib 100 mg per day will be given orally along with combination chemotherapy starting day 8 of induction chemotherapy. Dasatinib will be given continuously (if it's tolerable) for 2 years since achievement of complete remission (CR) as part of consolidation chemotherapy and maintenance therapy.Patients can receive allogeneic hematopoietic stem cell transplantation (HSCT),or patients who keep BCR/ABL negative can receive autologous HSCT whenever possible during their first CR. Otherwise, they will finish the consolidation chemotherapy.
2556361|NCT02523404|Experimental|HepaSphere|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2556364|NCT02523404|Placebo Comparator|control|lung cancer patients received traditional therapy
2556389|NCT02523222|No Intervention|CONTROL|Infants at risk for transient neonatal hypoglycemia following standard-of-care.
2556390|NCT02523222|Active Comparator|Dextrose Gel|Infants given 40% Dextrose gel (0.5ml/kg) in the buccal mucosa after their first feed, within the first hour of life.
2556440|NCT02523053|Active Comparator|Hepatectomy|Surgical removal of all lesions
2556442|NCT02523053|Experimental|Hepatectomy plus 5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
2556467|NCT02522676|Active Comparator|Conventional PCNL|Endoscopic kidney stone surgery: Patients will undergo conventional percutaneous nephrolithotripsy.
2556470|NCT02522676|Active Comparator|Mini PCNL|Endoscopic kidney stone surgery: Patients will undergo mini percutaneous nephrolithotripsy.
2556471|NCT02522676|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
2556472|NCT02522676|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
2556473|NCT02522676|Active Comparator|Retrograde intrarenal surgery|Endoscopic kidney stone surgery: Patients will undergo retrograde intrarenal surgery.
3171145|NCT00583310|Experimental|Intervention|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
2555521|NCT02529085|Experimental|Infants with PWS|Blood samples for the bank in link with a multicenter database including clinical data on birth, auxology, endocrine functions and feeding behaviour
2555527|NCT02529085|Other|control group|Blood samples for the bank in children hospitalized for a planned surgery for malformation, orthopaedic or visceral surgery
2555583|NCT02528682|Experimental|Single arm|MiHA-loaded PD-L-silenced DC Vaccination
2555733|NCT02527772|Experimental|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8;Liposomal Doxorubicin 30mg/m2,d1.q4w
2555737|NCT02527772|Active Comparator|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks
2555779|NCT02527486||No predefined subgroups|
2555934|NCT02526303|Experimental|Anticoagulation|Drug: Nadroparin Calcium and Warfarin Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,along with Nadroparin Calcium 85IU／kg，subcutaneous, q12h,for the first 5 days at least.
2555935|NCT02526303|No Intervention|Non-anticoaglated|No anticoagulatoin or other treatment for PVT will be used in this group of patients.
2555994|NCT02526017|Experimental|Phase 1 a monotherapy dose escalation|FPA008: specified dose on specified days
2556000|NCT02526017|Experimental|Phase 1a combination therapy dose escalation|FPA008 + BMS-936558: specified dose on specified days
2556002|NCT02526017|Experimental|Phase 1b combination therapy dose expansion|FPA008 + BMS-936558: specified dose on specified days
2556099|NCT02525198|Placebo Comparator|Placebo|Placebo group: 12 month daily ingestion of placebo oil and flavonoid-poor matched extract
2556101|NCT02525198|Experimental|fatty acid/flavonoid blend|Experimental group: 12 month daily ingestion of 1.5 g EPA+DHA and 500 mg flavonoids
2556296|NCT02523911|Active Comparator|Simethicone Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL simethicone in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
2556307|NCT02523989||study group|children confirmed to have developmental delays
2556311|NCT02523989||control group|children with typical development
3171146|NCT00583323|Experimental|1|Lomotil given
3171147|NCT00583323|Placebo Comparator|2|Normal Saline given
3171148|NCT00583336|Experimental|Diagnostic|
3171149|NCT00583349|Experimental|Abraxane administration|Patients will restrict their fluid intakes the morning of treatments and will have emptied their bladders at each of their visits and have up to 100ml of Abraxane solution administered to their bladder via urinary catheter once weekly for six weeks.
3171150|NCT00583388||A|42 healthy subjects aged 18 to 60 will be be randomly assigned to 6 different treatment sequences.
3171151|NCT00583427|Experimental|Sulodexide|
3171152|NCT00583440|Experimental|1|
3171153|NCT00583440|Active Comparator|2|
3171154|NCT00583479|Other|A|subjects who get one medication injection into the celiac ganglion during the EUS
3171155|NCT00583479|Other|B|subjects who get divided dose of the medication injected into two locations within the celiac ganglion during the EUS
3171156|NCT00583531|Experimental|I|Active treatment with AST-120
3171157|NCT00583544|Placebo Comparator|1|
3171158|NCT00583544|Experimental|2|
3171159|NCT00583570|Experimental|A|
3171160|NCT00583609|Experimental|1|PEG3350
3171161|NCT00583635||1|Low Risk Pregnancy, Placebo
3171162|NCT00583635||2|Low Risk Pregnancy, Active Food Supplement
3171163|NCT00583635||3|High Risk Pregnancy, Placebo
3171164|NCT00583635||4|High Risk Pregnancy, Active Food Supplement
3171165|NCT00583648|Experimental|1|Recieves urinalysis by nurse per set protocol based off of inclusion criteria
3171166|NCT00583648|No Intervention|2|ordering of test will be up to the treating physician
3171167|NCT00583674|Experimental|B|
3171168|NCT00583674|Experimental|A|
3171169|NCT00583674|Active Comparator|C|
3171170|NCT00583726|Active Comparator|1|The control arm receives written information and pedometers
3171171|NCT00583726|Experimental|2|This arm also receives telephone counseling.
3171172|NCT00583739|Active Comparator|1|Yoga intervention
3171173|NCT00583739|No Intervention|2|Control. No Yoga for 8 weeks.
3171174|NCT00583752|Experimental|Arm B|On Arm B, subjects will be started on androgen deprivation therapy (ADT) 14 days prior to beginning the vaccinations.
3171175|NCT00583752|Experimental|Arm A|On Arm A, subjects can begin the three vaccinations immediately.
3171176|NCT00583765||A|Critically ill patients with acute renal failure requiring continuous renal replacement therapy
3171177|NCT00583778|Active Comparator|1|levalbuterol 1.25 mg every 20 minutes for 3 doses plus placebo (saline)
3171178|NCT00583778|Experimental|2|ipratropium 0.5 mg nebulized every 20 minutes for 3 doses added to levalbuterol 1.25 mg every 20 minutes for 3 doses
3171179|NCT00583817|Experimental|Ascending Aortic Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the ascending aorta.
2555417|NCT02529865|Experimental|ADRCs and Adipose tissue|Periurethral injection of autologous adipose derived regenerative cells and adipose tissue
2555450|NCT02529618||Football Athlete Group|"All football athlete participants in this arm will take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test. Participants who sustain a concussion during the football season will complete the iDETECT test and a standing balance test (BESS assessment) four times after injury. Participants in this arm are eligible to receive the Riddell High Impact Technology (HIT) System or the i1 Biometrics Vector Mouth Guard.~NOTE: Football athletes who sustain a concussion during the football season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
2555457|NCT02529618||Non-Collision Sport Athlete Group|"Non-collision sport athletes who are active in a school's Fall athletic program will be take the integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT) test, standing balance test (BESS assessment), and complete a questionnaire at the beginning of the sport season. Participants will be asked to take the iDETCT test up to 5 more times during the season. Participants who sustain a concussion during the athletic season will be asked to take additional iDETECT tests four times after the injury.~NOTE: Non-collision sport athletes who sustain a concussion during the season will be evaluated and managed according to standard concussion screening and return-to-play (RTP) protocols. Performance on iDETECT or other study related tasks will NOT be used to make diagnosis, management, or return to play decisions. Study staff will not assist with or influence diagnosis, management, or return-to-play decision making by teams' medical personnel."
2555498|NCT02529163|Active Comparator|Late-life Schizophrenia ICP|"The Late-Life Schizophrenia ICP arm will follow a medication algorithm composed of 3 trials and titration schedule with prompts.~First trial is Risperidone (2- 4mg daily).~Second trial: Quetiapine (100 - 400mg daily) OR Aripiprazole (100 - 200mg daily) OR OR Ziprasidone (80mg daily) OR Loxapine (100mg daily)~Third trial: Clozapine (450mg daily) or Olanzapine (20mg daily)~If non compliant depot preparation of: Paliperidone (50 - 150mg monthly), Risperidone (12.5 - 50mg q 2 weeks), Flupentixol (10 - 20mg q 2-3 weeks) or Aripiprazole ( up to 400mg monthly)~Prompts will be given to for non-pharmacological interventions such as:~metabolic monitoring~skin hygiene~pain management~nutritional counseling~counseling"
2555499|NCT02529163|Active Comparator|Treatment as Usual (TAU)|The TAU will not receive any prompts to follow a specific treatment. The TAU group will be treated according to the current standard of care by the treating physician. They will have an opportunity to be offered the same non-pharmacological interventions seen with the ICP group but at the discretion of the treating physician. Pharmacological interventions will include an anti-psychotic medication that is selected at the discretion of treating physician with no set titration schedule or timeline to meet a maximum dosage. Max dosage will be decided by the treating physician.
3208801|NCT00978224|Experimental|A|Viusid in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
2555634|NCT02528383|Experimental|Vagifem|Postmenopausal women diagnosed with breast cancer, are currently on an anti-estrogen called an aromatase inhibitor and you have agreed to undergo treatment with Vagifem based on your physician's recommendation.
2555683|NCT02528071||Patients|ALS patients performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity at the onset of the disease and repeated every 3 months up to respiratory failure or death
2555685|NCT02528071||Control|Healthy controls performing measurements of maximal respiratory forces, diaphragmatic endurance during a diaphragmatic endurance test and phrenic nerve activity. This arm will enable to establish reference values of IHT
2555748|NCT02527720|Experimental|Mindfulness Therapy|For the current study the investigators have developed a breathing-based, adapted for feasible application among SUD populations, and easy to carry out in clinical or non-clinical settings referred to as breathing-based mindfulness training (BBMT). BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention (more details below).
2555798|NCT02527356|Experimental|ROC-Stand group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-stand).
2555800|NCT02527356|Active Comparator|ROC-Sit group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for ride-on car with standing posture training (ROC-sit)
2555802|NCT02527356|Active Comparator|Regular Therapy group|The participant's performance is indicative of the extent to which early power mobility training is feasible for 1 to 3 years old and diagnosed as motor delay (>1.5 sd). Parents/caregivers and occupational therapists will be responsible for regular therapy.
2555830|NCT02526914|Experimental|Intranasal Oxytocin|Participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
2555832|NCT02526914|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
2555835|NCT02526914|Placebo Comparator|Intranasal placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient. Participants will self-administer 5 puffs per nostril.
3208802|NCT00978224|Placebo Comparator|B|Placebo in combination with standard treatment for Chronic Inflammatory Syndrome including hemodialysis and the administration of a hypercaloric and hyperproteic diet
2555913|NCT02526264|Experimental|Krankenhaus Nordwest Concept|specific preoperative education program realised by a specialized stoma-therapist containing individualized information on material maintenance, hygiene, nutrition, complications, activities of daily life and occupation
2555914|NCT02526264|Experimental|Standard concept|standard preoperative education program administered by a surgeon containing information on surgery, outcome, risks and alternatives
2555975|NCT02526134|Experimental|Laying of medical devices|radio opaque markers
3171180|NCT00583817|Experimental|Arch Branch Arm|Investigational endovascular stent-graft implantation to exclude aneurysm or repair dissection of the aortic arch.
2555418|NCT02529878|Experimental|conversion treatment|after 3 cycles S1/Paclitaxel chemotherapy plus Apatinib,subsequent surgery will be conducted with curative intent
2555482|NCT02529592|Experimental|Endotoxin|Endotoxin at 2ng/kg of body weight administered intravenously
2555485|NCT02529592|Placebo Comparator|Placebo|Placebo administered intravenously
2555510|NCT02529098|Sham Comparator|asymptomatic patients|fMRI Asymptomatic patients
2555514|NCT02529098|Experimental|symptomatic patients|fMRI patients with visual difficulties
2555568|NCT02528877|Experimental|Supportive care (ruxolitinib phosphate, tacrolimus, sirolimus)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV over 20 minutes on day -4. Beginning greater than 48 hours after completion of melphalan, patients undergo peripheral blood stem cell or bone marrow transplant according to standard guidelines on day 0.~GVHD PROPHYLAXIS: Patients receive ruxolitinib phosphate PO BID on days -3 to 30 tapered to day 60, tacrolimus IV continuously or PO BID on days -3 to 100 , and sirolimus PO QD on day -3 to 100. Treatment continues in the absence of disease progression or unacceptable toxicity."
2555652|NCT02528149||patients with renal aneurysm|Patient with one or more renal artery aneurysm (RAA) operated and with tissue; adjacent part and aneurysm; cryopreserved. Blood sample performed at day 1.
2555729|NCT02527863|Active Comparator|60 mg Tolvaptan|Oral administration of 60 mg tolvaptan on each examination day.
2555732|NCT02527863|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet.
2555821|NCT02527070|Experimental|Red LED|Light emitting diodes, 670 nm, 50 mW/cm2, Quantum Warp10 (Quantum Devices Inc, Barneveld, WI, USA); RESPeRATE; Heat/cold provocation
2555822|NCT02527070|Active Comparator|Near Infrared LED|Light emitting diodes, 830 nm, 55 mW/cm2, Omnilux new-U (Photomedex, Horsham, PA, USA); RESPeRATE; Heat/cold provocation
2555869|NCT02526771|Experimental|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
2555872|NCT02526771|Active Comparator|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
2555928|NCT02526433||Pregnancy women and new mothers|The study tracks what interventions women are already registered in and compares these with their mental wellbeing.
2556076|NCT02525497|Experimental|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h;
2556078|NCT02525497|Active Comparator|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h;
2556115|NCT02525250|Experimental|Acute myeloïd leukemia|Realization of 3 blood samples at day 0, day 15 and day 28.
2556207|NCT02524717|Experimental|JNJ-56021927|Participants with mild and moderate hepatic impairment and with normal hepatic function will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
2556251|NCT02524379|Experimental|Glyburide Treatment Arm|Enrolled patients will receive 12 doses of Glyburide starting within 8 hours of SCI. The dosing regimen involves an initial dose of 1.25 mg followed by eleven consecutive doses of 0.625 mg every 6 hours. The total daily dose of Glyburide on Day 1, Day 2 and Day 3 will be 3.125 mg, 2.5 mg, and 2.5 mg respectively.
2556283|NCT02524041|Experimental|secondary hyperparathyroidism|Blood specimen and HR-pQCT for measure bone quality and quantity
2556327|NCT02523794|Experimental|Electro-kinetically Modified Water|Subjects will drink 2 to 3 500 mL bottles of EMW daily for 3 months
2556330|NCT02523794|Placebo Comparator|Placebo|Subjects will drink 2 to 3 500 mL bottles of purified drinking water daily for 3 months
2556384|NCT02523521|No Intervention|Bronchopylmonary Dysplasia Control|Nothing
2556385|NCT02523521|Experimental|Bronchopylmonary Dysplasia Intervention|physical activity program.
2556387|NCT02523521|No Intervention|Healthy children|Nothing.
2556421|NCT02523079|Experimental|Cognitive Behavioral Group Therapy for Insomnia|Includes 6 group sessions (90 minutes each). The groups are led by trained psychologist or nurse of occupational health services. The manualized treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
2556422|NCT02523079|Experimental|Cognitive Behavioral Self-help Therapy for Insomnia|Mainly computerized self-help intervention. Includes an individual session before and after the intervention (30 minutes each) led by trained psychologist or nurse of occupational health services. The self-help treatment is based on the general CBT-I model and includes components such as sleep hygiene, relaxation, stimulus control, sleep restriction and cognitive restructuring. In addition, participants receive information on how to schedule sleep, wake and light based on circadian principles while working differently timed shifts.
2556423|NCT02523079|Experimental|Sleep Hygiene Guidance|Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
3205428|NCT00944138|Active Comparator|Music for relaxation|Participants assigned to the control arm will receive the dietary counseling and will be told that relaxation can help reduce appetite. However, techniques to relax will not be taught. Instead, participants will be encouraged to sit quietly listening to music (of their choice) every day for 20 minutes. Participants assigned to the standard care arm will receive an MP3-player and will be given a choice of selection of music that they can load on their MP3 player (classical music, country music, jazz, etc.).
3205429|NCT00944151|Placebo Comparator|Single injection with Saline infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given normal saline in infusion pump, attached to catheter.
2556710|NCT02521389|Experimental|Part 1|3 sequential groups (Groups A, B and C), comprising 3, 6 and 6 subjects, respectively, with 2 optional additional groups (Groups D and E), each comprising 6 subjects, to assess alternative dose levels or formulations (described below), if required.
2556711|NCT02521389|Experimental|Part 2|Single dose, 2-way crossover design to assess a selected formulation of PWT-143 in the fed and fasted states in 8 subjects.
2556763|NCT02521090|Experimental|Treatment (EGFRBi-armed autologous T cells)|"PHASE I: Patients receive EGFRBi-armed autologous T cells IT twice weekly for 4 weeks.~PHASE II: Patients receive EGFRBi-armed autologous T cells* IT twice weekly for 4 weeks and then IV over 15-30 minutes twice weekly for 2 weeks.~*NOTE: Six selected patients receive EGFRBi-armed autologous T cells IV on day -3, -2, or -1 prior to first IT infusion."
2555447|NCT02529579|Active Comparator|Gemcitabine|Standard Gemcitabine Therapy
2555454|NCT02529579|Experimental|cellular immunotherapy & Gemcitabine|iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy
2555522|NCT02529241|Experimental|Group 1: LCB01-0371|Period 1: LCB01-0371 Tablet 400 mg Period 2: LCB01-0371 Tablet 400 mg
2555528|NCT02529241|Experimental|Group 2: LCB01-0371|Period 1: LCB01-0371 Tablet 800 mg Period 2: LCB01-0371 Tablet 1200 mg
3205430|NCT00944151|Active Comparator|Single injection with Ropivicaine infused TAP catheter|Prior to surgery patient will receive single injection of 0.5% ropivacaine and a TAP catheter. Following surgery patient will be given 0.2% ropivicaine in infusion pump, attached to catheter
3205431|NCT00944164|Experimental|Healthy eating/physical activity|
2555676|NCT02528084|Experimental|yoga intervention|patients in the group are asked to follow an online video instructing them various yoga poses. Patients in this group are asked to do the yoga exercises 2-3 times a week, for a total of 6 weeks.
2555677|NCT02528084|Experimental|standard exercises intervention|patients in this group are asked to follow an online standard exercises video. Patients in this group are asked to follow specific exercises 2-3 times a day, for a total of 6 weeks.
2555679|NCT02528084|No Intervention|control|patients in this group carry forth with their daily activities. They are not asked to follow the online yoga video or the online standard exercise video.
2555709|NCT02527733|Active Comparator|Ranibizumab|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
2555711|NCT02527733|Active Comparator|Ranibizumab and laser|After initial single intravitreal injection of ranibizumab (0.5mg), participants receive monthly as-needed injection of ranibizumab (0.5mg) when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers. Macular laser photocoagulation will be performed when visual acuity is less than 1.0 and foveal thickness is more than 250 micrometers.
2555763|NCT02527551|Other|Haptic massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
3205432|NCT00944164|Active Comparator|Safety/Injury prevention|
2555967|NCT02526004|Active Comparator|Standard Empiric Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin
2555969|NCT02526004|Experimental|Microbiome Guided Treatment|Ceftazidime or Aztreonam (in case of Ceftazidime allergy) and Tobramycin and 3rd Antibiotic based on the Microbiome analysis
2556041|NCT02525770|Active Comparator|acetabular liner in X3 polyethylene|acetabular in X3 polyethylene
2556044|NCT02525770|Active Comparator|acetabular liner in N2VAC® conventional polyethylene|hip replacement with acetabular liner in N2VAC® conventional polyethylene
2556084|NCT02525445|Active Comparator|acupuncture positive communication|Genuine acupuncture needles combined with positive communication regarding the expected treatment effects
2556087|NCT02525445|Sham Comparator|sham acupuncture positive communication|Sham acupuncture needles combined with positive communication regarding the expected treatment effects
2556090|NCT02525445|Active Comparator|acupuncture neutral communication|Genuine acupuncture needles combined with neutral communication regarding the expected treatment effects
2556092|NCT02525445|Sham Comparator|sham acupuncture neutral communication|Sham acupuncture needles combined with neutral communication regarding the expected treatment effects
2556113|NCT02525120|Experimental|Triojection System for ozone injection|Triojection is a system including a single-use sterile syringe cartridge and an accessory console. The console is interfaced to a supply of medical oxygen and uses this supply to fill the syringe with oxygen. Ozone is produced by applying a high voltage to electrodes physically located within the syringe. When a concentration of 35µg/ml is reached, the cartridge is removed from the console. The sterile syringe, containing the gas, is extracted from the protective housing and the gas is administered directly to the center of the herniated disc through a spinal needle.
2556114|NCT02525120|Active Comparator|Surgical discectomy|The surgical group will be receive a standard surgical discectomy to remove the herniated disc material.
2556180|NCT02524860|Experimental|MRI-ultrasound fusion device|Using the Focal-Fusion Bx device, the urologist will fuse ('coregister') the MRI to the TRUS imaging
3205433|NCT00944190|Experimental|Self-management Intervention|Telephone based self management intervention targeted at pain, fatigue, depression, and cognitive difficulties.
3205434|NCT00944190|Active Comparator|Education|Education about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
3205435|NCT00944203|Experimental|Test Area|Test Area = Standard Treatment plus Ipomea pes-caprae oinment
2556299|NCT02523872||Acute respiratory failure|Patients with acute respiratory failure who might benefit from a strategy designed to limit fluid administration
2556354|NCT02523729|No Intervention|control|subjects drunk no Anke Malz product.
2556356|NCT02523729|Experimental|intervention one|subjects drunk one can Anke Malz product.
2556358|NCT02523729|Experimental|intervention two|subjects drunk two cans Anke Malz product.
2556408|NCT02523274|Placebo Comparator|Placebo + exercise|Placebo capsules will be taken orally daily in combination with exercise
2556413|NCT02523274|Experimental|Resveratrol 250 mg/day + exercise|250 mg/day resveratrol taken orally in combination with exercise
2556418|NCT02523274|Experimental|Resveratrol 1000 mg/day + exercise|1000 mg/day resveratrol taken orally in combination with exercise
2556460|NCT02522858|Placebo Comparator|Placebo|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, normal saline 0.5mL would be injected intravenously.
2556461|NCT02522858|Experimental|Atropine|After fixation of the block level of spinal anesthesia, and just before starting dexmedetomidine, ,atropine 0.03mg/kg would be injected intravenously.
2556536|NCT02522546||nasopharyngeal swab|Children ages 1-5 years and their household contacts
2556573|NCT02522117|Active Comparator|Atorvastatin|24 patients received oral atorvastatin 40 mg once a day, for 4 weeks.
2556574|NCT02522117|Placebo Comparator|Placebo|24 patients received oral placebo 40 mg once a day, for 4 weeks.
3205436|NCT00944203|No Intervention|Control Area|Control = Standard Treatment
3205437|NCT00944216|Experimental|Treatment|
3205438|NCT00944255||RA with drug|
3205439|NCT00944255||RA without drug|
3205440|NCT00944268|Experimental|Liquid and solid|
2555465|NCT02529761|Experimental|Sorafenib combined with TACE|220 subjects in this study group will receive the treatment of sorafenib combined with conventional TACE.
2555468|NCT02529761|Active Comparator|TACE monotherapy|110 subjects in this study group will receive the treatment of conventional TACE monotherapy.
2555504|NCT02529124|Placebo Comparator|CONTROL|a group of subjects receiving a placebo nutrient supplement (per kg of body mass: 0.25g maltodextrin; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
2555506|NCT02529124|Active Comparator|PROTEIN|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks
2555511|NCT02529124|Active Comparator|PROTEIN+PHYSICAL ACTIVITY|a group of subjects receiving a nutrient supplement (per kg of body mass: 0.33g milk protein + 0.25ug vitamin D + 10mg calcium; energy ~ 160 kcal per day) in two equal portions at the two low protein meals of the day, i.e. breakfast and lunch every day for a period of 24 weeks plus a prescribed regimen of physical activity
2555565|NCT02528695|Active Comparator|Healthy euglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
2555567|NCT02528695|Active Comparator|healthy hypoglycemic clamp|In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
2555570|NCT02528695|Experimental|Type 2 diabetes hypoglycemic clamp|In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
3205441|NCT00944281|Experimental|LNS-Zn5|Daily intake of 20 g LNS containing 5 mg of zinc and a daily placebo supplement
3205442|NCT00944281|Experimental|LNS-Zn10|Daily intake of 20 g LNS containing 10 mg of zinc and a daily placebo supplement
3205443|NCT00944281|Placebo Comparator|LNS-Zn0|Daily intake of 20 g LNS containing 0 mg of zinc and a daily placebo supplement
3205444|NCT00944281|Experimental|Suppl-Zn5|Daily intake of zinc supplement containing 5 mg of zinc and 20 g LNS containing 0 mg of zinc
3205445|NCT00944281|No Intervention|Delayed intervention group|Standard care from age 8 to 18 months. Daily consumption of LNS from age 18 to 28 months.
2555783|NCT02527577|Experimental|ropivacaïne chlorhydrate monohydrate|
2555789|NCT02527577|Placebo Comparator|placebo|
2555851|NCT02526992|Other|patients with anti-TNF therapy|patients with rheumatoid polyarthritis inadequately controlled by a conventional treatment, occurring during the first 12 months of initiation of an anti-TNF therapy
2555954|NCT02526381|Experimental|Danlou Tablets|Danlou prescription is a tablet, each piece weighs 0.3 g, taken orally, three times a day, five at a time, from jilin Cornell's pharmaceutical corporation, Limited Liability Company .
2555957|NCT02526381|Experimental|Tongmai Yangxin Pills|Tongmai Yangxin prescription is a pill,each pill weighs 0.1 g,taken orally, 2 times a day,40 pills at a time,produced by tianjin new pharmaceutical group corporation, Limited Liability Company . LeRenTang pharmaceutical.
2555961|NCT02526381|No Intervention|no drugs|
3205446|NCT00944294|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
2556111|NCT02525172|Experimental|ITT|immune modulation therapy
2556209|NCT02524886|Active Comparator|Immediate stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start immediately after surgery
2556210|NCT02524886|Sham Comparator|Delayed stimulation|Patients will be implanted with a Medtronic electorde and Active PC pulse generator for deep brain stimulation at baseline and GPi electric stimulation will start 3 months after surgery
2556244|NCT02524353|Experimental|cardiac surgery|cardiac surgery
2556306|NCT02524093|Experimental|Intervention|Participants in this arm will be given the Positive Mental Training programme. This consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly the participant needs to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
2556310|NCT02524093|Placebo Comparator|Control|Will receive treatment as usual for 12 weeks, when will be asked to complete rating scales again. They will then be given the Positive Mental Training programme.
2556360|NCT02523638|Other|Pegylated- Proline-Interferon alpha-2b|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen single arm
2556411|NCT02523040|Experimental|Lenalidomide|"After the screening procedures confirm participation in the research study.~- Lenalidomide Oral, Daily for 21 days of each cycle"
2556441|NCT02522897|Active Comparator|Ranibizumab|"Patients receive intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months."
2556443|NCT02522897|Experimental|Ranibizumab + Laser|"Apart from receiving intravitreal injections of 0,5 mg Ranibizumab (Lucentis®) / injection following the treat-and-extend scheme for 12 months, patients receive a panretinal photocoagulation on visit 3 and / or 4."
2556492|NCT02522663|No Intervention|Usual Care|Today, no post-discharge telephone support is offered as standard care from the hospital.
2556498|NCT02522663|Experimental|Intervention group|Experimental group is offered 24/7-telephone support during the first 1 month post-discharge, and patients are actively called at day 2 and day 9 day after discharge.
2556515|NCT02522468|Experimental|Radioactive Seed Localization|Radioactive Seeds
2556516|NCT02522468|Active Comparator|Wire Localization|Wire
2556566|NCT02522260|Active Comparator|Group 1|Intervention Strength/aerobic exercise, weights, bike or treadmill
2556567|NCT02522260|Active Comparator|Group 2|Intervention Aerobic exercise, bike or treadmill
2556570|NCT02522260|Active Comparator|Group 3|Standard supportive care
2556847|NCT02520232|Experimental|Physical activity program (B)|Physical exercises
2555474|NCT02529462|Experimental|NEUROPHARMAGEN-Guided Treatment|In the study patient group, the psychiatrist will have the results of the NEUROPHARMAGEN genetic test as supporting information to help him/her select the best treatment for the patient.
2555479|NCT02529462|Active Comparator|Treatment As Usual|"In the control patient group, treatment as usual will be selected and prescribed in accordance with routine clinical practice ."
2555519|NCT02529059|Experimental|Switch from Atripla to Eviplera|
3205447|NCT00944294|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
2555640|NCT02528292||Active Rheumatoid Arthritis|Patients with active Rheumatoid Arthritis with a DAS 28 score of greater than 5.1 and eligible for anti-TNF alpha therapy according to National Institute for Clinical Excellence guidelines will be recruited in this study
2555702|NCT02528032|Other|Echocardiographic evaluation|Echocardiographic evaluation of heart function with new processing tools
2555759|NCT02527590|Experimental|patient with neuropathic pain with allodynia|
2555761|NCT02527590|Experimental|healthy volunteers|
2555808|NCT02527226|No Intervention|No facial exercises|This group will not receive any training in facial exercises.
2555810|NCT02527226|Experimental|Facial exercises|This group will receive instruction to perform a series of self-administered exercises of facial expression and movements.
2555862|NCT02526875|Experimental|night|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 pm to 10 pm, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
2555863|NCT02526875|Active Comparator|morning|Telminuvo®Tab. 40/2.5mg ,Once daily, from 6 am to 10 am, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
2555910|NCT02526355|Experimental|Mobile based Intervention|Mobile based Intervention (Learning Through Play Plus) comprised of both LTP and CBT
2555911|NCT02526355|No Intervention|Waiting List Control|Waiting List Control group will receive no intervention, but intervention will be offered to interested participants at the end of the study
3205448|NCT00944307|Active Comparator|raltegravir alone|Subjects will receive a single dose of 400 mg raltegravir orally
3205449|NCT00944307|Experimental|raltegravir plus antacid|Subjects will receive a single dose of 400mg raltegravir orally simultaneously with an antacid
2556168|NCT02524834|Experimental|Endovascular Device Implantation|Endoluminal exclusion of thoracoabdominal lesion
2556226|NCT02524600|Experimental|"New Technology IQ-SPECT applied to myocardial imaging"|
2556305|NCT02524184|Experimental|Sildenafil|Eleven patients receive sildenafil 100mg/day (25 mg at 8 AM plus 25 mg at 4 PM plus 50 mg at 10 PM)for 7 days.
2556309|NCT02524184|Placebo Comparator|Placebo group|An identical placebo for 7 days in placebo group.
2556359|NCT02523612|Experimental|Patients with atypical lesions|
2556430|NCT02523261|Experimental|ADAPT|
2556433|NCT02523261|Active Comparator|Stent Retriever|
2556479|NCT02522741|Experimental|Parenting STAIR|
2556534|NCT02522520|Active Comparator|Pedometer intervention|"Individual progressive pedometer intervention of low to moderate intensity.~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
2556535|NCT02522520|Active Comparator|Pedometer + hospital based intervention|"Individual progressive pedometer intervention and 5 sessions supervised interval walking + followed by supervised hospital-based intervention of moderate to high-intensity~Furthermore, the patients receive individual health counseling and symptom management counseling to support behavioral change towards increased physical activity."
2556604|NCT02522091|Other|young healthy volunteers (18-44 years old)|young healthy volunteers (18-44 years old)
2556605|NCT02522091|Other|healthy volunteers (45-69 years old)|healthy volunteers (45-69 years old)
2556606|NCT02522091|Other|Mild Cognitive Impairment Patients|Mild Cognitive Impairment Patients
2556608|NCT02522091|Other|Alzheimer's Disease patient|Alzheimer's Disease patient
2556609|NCT02522091|Other|old healthy volunteers (70+ years old)|old healthy volunteers (70+ years old)
2556704|NCT02521636|Placebo Comparator|Anibiotic therapy guided with actual french recommandations|Guided by the antibiotic 2006 recommendations of the French consensus conference on anti-infective therapy of respiratory tract infections in low immuno-competent adult.
2556707|NCT02521636|Experimental|Anibiotic therapy guided with serum PCT value|"Guided antibiotic therapy serum PCT at admission, revalued at day 1, day 3 and day 6 as long as PCT is not less than 0.1 ng / mL:~PCT <0.1 ng / mL: no antibiotics~0.1 <PCT <0.25 ng / mL: antibiotic advised~PCT> 0.25 ng / mL: highly recommended antibiotics"
2556759|NCT02521116|Other|Healthy subjects|healthy study subjects, age 18-80 years
2556780|NCT02520778|Experimental|Treatment (navitoclax, osimertinib)|Patients receive navitoclax PO QD on days 1-28 and osimertinib PO QD on days 4-28 (days 1-28 during dose-expansion). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity
3205450|NCT00944333|Experimental|Clopidogrel 6|6 month dual antiplatelet therapies in patients after second generation DES implantation
3205451|NCT00944333|Experimental|Clopidogrel 12|12 month dual antiplatelet therapies in patients after second generation DES implantation
3205452|NCT00944359|Experimental|Daily preventive Zn; placebo treatment|7 mg zinc per day for 12 months and placebo supplement during diarrhea episode
3205453|NCT00944359|Experimental|Therapeutic Zn; daily placebo|20 mg of zinc for 10 days during episodes of diarrhea and daily placebo supplement
3205454|NCT00944359|Experimental|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, daily placebo during 80 days of 3 months period and placebo during diarrhea episode
3205455|NCT00944359|Active Comparator|Surveillance control group|Surveillance control group will be randomly assigned to intervention groups every 3 months
3205456|NCT00944359|No Intervention|Non-intervention|Standard care provided by health system
3205457|NCT00944372|Experimental|Group 1|Control, age greater than or equal to 18 with normal renal function
3205458|NCT00944372|Experimental|Group 2|Age 18 to less than 65 with mild renal impairment
3205459|NCT00944372|Experimental|Group 3|Age 18 to less than 65 with moderate to severe renal impairment
3205460|NCT00944372|Experimental|Group 4|Age 18 to less than 65 with end stage renal impairment
3205461|NCT00944372|Experimental|Group 5|Age 65 to less than 75 with mild renal impairment
2555578|NCT02528669|No Intervention|Control Group|Participants in this group will be given an activity tracking device that receives and displays walking reminders and daily walking goals but will not receive additional education regarding the benefits of walking. The device will track daily steps taken, minutes of walking, and frequency of walking bouts throughout the day.
2555620|NCT02528435||JIA patients|observationational study including children diagnosed with JIA. Patients aged 9 years and above, whom are treated with low-dose MTX may be included.
2555625|NCT02528435||ALL patients|observationational study including children diagnosed with ALL. Patients aged 9 years and above, whom are in maintenance treatment with low-dose MTX may be included.
2555665|NCT02528123|Experimental|Small incision lenticule extraction|Patients with high myopia will undergo a SMILE procedure to correct their refraction. Proxymetacaine 0.5% and Oxybuprocaine 0.4% will be used as anaesthetic during the procedure. Tobramycin and dexamethasone, and ofloxacin will be used four times a day for one week after the procedure.
2555787|NCT02527213|Experimental|Sodium Thiosulfate|Sodium Thiosulfate at 25g in 100 ml normal sterile saline (NSS)
2555792|NCT02527213|Placebo Comparator|Placebo|similarly-formulated placebo in 100 ml NSS
2555833|NCT02526966|Other|patient with primitive form of IgA nephropathy|
3205462|NCT00944372|Experimental|Group 6|Age 65 to less than 75 with moderate to severe renal impairment
3205463|NCT00944372|Experimental|Group 7|Age 65 to less than 75 with end stage renal impairment
2555973|NCT02526147|No Intervention|Control|Receives no intervention
2555976|NCT02526147|Experimental|Cash|Household receives cash transfer monthly for 6 months
2555977|NCT02526147|Experimental|Voucher|Household receives food voucher to use at local supermarket monthly for 6 months
2555981|NCT02526147|Experimental|Food|Household receives food transfer composed of rice, lentils, canned sardines, and vegetable oil, monthly for 6 months
3205464|NCT00944372|Experimental|Group 8|Age greater than or equal to 75 with mild renal impairment
3205465|NCT00944372|Experimental|Group 9|Age greater than or equal to 75 with moderate to severe renal impairment
2556105|NCT02525341|Experimental|Yoga Group|Participants in the yoga group received a total of eight weekly 45 minute yoga classes. A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session. Handouts were provided for participants to practice the yoga program for additional 30 minutes a day, 4 days a week at home.
2556107|NCT02525341|Active Comparator|Aerobic and Strengthening Exercise Group|Participants in the exercise group received a total of eight weekly 45 minute exercise classes. A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants. Handouts were provided for participants to practice the program at home for 30 minutes a day, 3 days a week (on non-consecutive days).
2556110|NCT02525341|Active Comparator|General education|Participants in this group received a one-time OA educational brochures from the Arthritis Foundation including topics focusing on the disease process, diet and exercise and OA management education. Participants were instructed not to begin any new exercise programs during the study period.
2556167|NCT02524938|Experimental|Treatment group|Chlorogenic Acid (CGA) 400mg/day (CGA-enriched coffee)
2556170|NCT02524938|Sham Comparator|Control group|Conventional coffee (habitual diet)
2556241|NCT02524587|Active Comparator|acetabular polyethylene vitamys®|acetabular polyethylene vitamys®
2556242|NCT02524587|Active Comparator|standard polyethylene acetabular irradiated at 3 Mrad|standard polyethylene acetabular irradiated at 3 Mrad
2556287|NCT02524080|Other|Emergency Department|Triage to optimal healthcare level
2556288|NCT02524080|Other|Healthcare Center|Triage to optimal healthcare level
2556331|NCT02523755|Active Comparator|Epidural analgesia Ropivacaine|Placement of an epidural catheter to achieve pain relief
2556334|NCT02523755|Sham Comparator|Absence of epidural analgesia|No placement of an epidural catheter either because of patient refusal or contraindication
2556412|NCT02523300|Experimental|TEVAR+GC|The patients underwent TEVAR. Then glucocorticoids will be intravenously given after TEVAR
3205466|NCT00944372|Experimental|Group 10|Age greater than or equal to 75 with end stage renal impairment
3205467|NCT00944385|Experimental|ulinastatin|Administer with 30,000U /ulinastatin
3205468|NCT00944385|Placebo Comparator|C group|administer normal saline
3205469|NCT00944398|Experimental|Zinc fortified group|Daily consumption of zinc-fortified complementary food
3205470|NCT00944398|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified complementary food and placebo supplement.
3205471|NCT00944398|Experimental|Zinc supplement group|Daily consumption of zinc supplement and non-fortified complementary food.
3205472|NCT00944424|Experimental|Arm A|Arm A = Docetaxel + High dose Vitamin D2
3205473|NCT00944424|Active Comparator|Arm B|Docetaxel + Standard dose Vitamin D2
3208803|NCT00978237|Active Comparator|EFV and Fixed combinations of analogues|EFV + Fixed combinations of analogue tenofovir + emtricitabine, or abacavir + lamivudine
2555603|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 2)|Nexvax2 Placebo by ID injections for a total of 14 doses over 46 days.
2555606|NCT02528799|Experimental|Nexvax2 DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
2555607|NCT02528799|Placebo Comparator|Nexvax2 Placebo DQ2.5 Non-homozygotes (Cohort 3)|Nexvax2 Placebo by ID injections for 18 doses (up to 27 doses) over 60 days (maximum of 91 days).
2555628|NCT02528175|Experimental|MRg-FU|Hyperthermia via magnetic resonance-guided focused ultrasound will be administered once per week for three weeks concurrent with standard radiation and chemotherapy.
2555688|NCT02527967||Group 1 (≤4 days)|Group 1 consisted of patients whose hospital stay was shorter or equal to the target LOS (≤ 4 days).
2555689|NCT02527967||Group 1 (>4 days)|In group 2 were patients whose hospital stay was longer than 4 days.
2555744|NCT02527707|Experimental|lonafarnib/ritonavir|Lonafarnib starting at 50 mg bid in combination with ritonavir 100 mg bid and escalating to lonafarnib 75 mg bid and then 100 mg bid as tolerated. The duration of the study for each patient is 6 months of treatment and 6 months follow-up.
2555809|NCT02527382|Experimental|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a distal clamp is placed on the rectal stump.
2555811|NCT02527382|No Intervention|Open stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while no distal clamp is placed on the rectal stump.
2555828|NCT02526888|Experimental|Sequence AB|During Period 1, subjects receive a single dose of ACT-541468 on Day 1. During Period 2, they receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4
2555829|NCT02526888|Experimental|Sequence BA|During Period 1, subjects receive Diltiazem from Day 1 to Day 7 and a single dose of ACT-541468 on Day 4. During Period 2, they receive a single dose of ACT-541468 on Day 1
2555857|NCT02526719|No Intervention|Standard Nipple-Sparing Mastectomy|Patients in the control group will receive usual care. The surgical oncologist will perform the NSM and sentinel lymph node biopsy if indicated (active breast cancer or DCIS). We will submit a nipple core biopsy and a 1cm thick biopsy of immediately retro-areolar ductal tissue for permanent section pathology for control patients, and all patients will have the mastectomy specimen submitted for permanent section pathology. Under the same general anaesthesia, the plastic surgeon will perform the IBR (2-stage tissue expander to implant or 1-stage direct to implant). Patients who later have a positive nipple core and retro-areolar biopsy will have a discussion with the surgical oncologist regarding the need for revision breast surgery to excise the NAC, as is current practice.
2555860|NCT02526719|Experimental|Nipple Delay Intervention|Patients in the experimental group will have a nipple-delay intervention in addition to usual care. The nipple delay procedure will be performed by the plastic surgeon in the minor clinic procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
2555893|NCT02526563||Iliac crest wound catheter group|These patients will receive an iliac crest wound catheter after an iliac crest bone harvest to repair a palatal defect. This catheter is part of standard of care. This study will collect blood to measure unbound ropivicaine levels.
2555956|NCT02526342|Active Comparator|Negative Pressure Wound Therapy|Patients receive a Negative Pressure Wound Therapy-Dressing (V.A.C. Ultra (KCI®,San Antonio, Texas, USA) with a subatmospheric pressure of 125mmHg to cover the muscle flap for five days following surgery.
2555959|NCT02526342|No Intervention|Conventional Dressing|Patients receive a conventional dressing for the muscle flap including fatty gauze and cotton gauze.
2556001|NCT02525900|Placebo Comparator|Wound Infiltration|0.5mg/kg of 0.25% bupivacaine will be injected around the incision for wound infiltration
2556006|NCT02525900|Experimental|TAP Blocks|20mL of 0.25% bupivacaine will be injected on each side of the abdomen for ssTAP procedures
2556009|NCT02525900|Experimental|TAP Catheters|20mL of 0.25% bupivacaine will be injection on each side of the abdomen and catheters placed for repeat bolus every 12 hours with 20mL of 0.25% Bupivacine until 48 hours post procedure or hospital discharge.
2556065|NCT02525601|Active Comparator|Triathlon CR cemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented Peri-Apatite (PA) knee fixation and migration properties versus the cemented version.
2556069|NCT02525601|Active Comparator|Triathlon CR uncemented|Triathlon Cruciate Retaining knee with cemented fixation randomised versus Triathlon Cruciated Retaining knee with uncemented fixation. The aim with this study is to evaluate the uncemented PA knee fixation and migration properties versus the cemented version.
2556106|NCT02525328||CT subjects|blood or saliva specimen
2556109|NCT02525328||subjects without CT|blood or saliva specimen
2556151|NCT02525016|Experimental|assessment of plasmatic lidocaine rate|Patients will receive intravenous administration of lidocaine based on a modified body weight ; blood sampling will be performed to assess plasmatic concentration of lidocaine
2556196|NCT02524743|Placebo Comparator|Placebo (Group I)|"For pretreatment the patients were administered IV 5ml normal saline.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
2556203|NCT02524821|Active Comparator|Gelesis100 plus drugs, fed|3 x 0.75 g Gelesis100 capsules, followed by the ingestion of a high-fat, high-caloric meal, followed by the administration of 1 x 850 mg metformin tablet (fed conditions).
2556417|NCT02523300|Placebo Comparator|TEVAR+Vehicle|The patients underwent TEVAR. Then saline will be given after TEVAR
2556450|NCT02522871|Experimental|OCS Liver System|OCS Liver System
3205474|NCT00944437|Active Comparator|Helmet|Patients in this group will receive continuous positive airway pressure delivered through a helmet connected to a high-flow reservoir system.
3205475|NCT00944437|Experimental|Mask|Patients in this group will receive continuous positive-airway pressure delivered through a novel full-face mask connected to a high-flow system. Expiratory pressure will be maintained using an expiratory valve connected to a T-tube.
2555807|NCT02527174|Experimental|Study treatment arm|"Will receive volasertib combined with idarubicin plus cytarabine in a 3+7 schedule as induction chemotherapy. Volasertib dose will be given on day 4 in a dose escalation schedule over 3 dose levels (140 mg/m2, 170 mg/m2, 200 mg/m2) in successive cohorts.~Non-hematologic toxicity will be determined using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 criteria for adverse events. Hematologic toxicity will be determined by days to absolute neutrophil count (ANC) and platelet recovery."
2555897|NCT02526836|Other|Comparison group|"including the number of cases with complete data who underwent surgery using the conventional method.~Conventional surgery"
2555898|NCT02526836|Active Comparator|Intervention group|"including a convenient sample of about 20 patients which is expected to be recruited, for whom Complete Mesocolic Excision (CME) and Central Vascular Ligation (CVL) will be done.~Complete mesocolic excision with central vascular ligation"
2555992|NCT02526030|Active Comparator|Aripiprazole|Oral, dose range 10-30 mg/day, once or twice a day, during study duration
2555996|NCT02526030|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
2556003|NCT02526030|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
2556103|NCT02525211|Experimental|Ropivacaine|Ropivacaine
2556104|NCT02525211|Placebo Comparator|placebo|physiological saline
2556152|NCT02525003|Placebo Comparator|Group 1: placebo|Group 1: daily dose of regular bread (87 g/d) and placebo pill (0 µg of vitamin D/d) for 8 weeks
2556153|NCT02525003|Experimental|Group 2: Vitamin D2 supplement|Group 2: daily dose of regular bread (87 g/d) and D2 supplement (25 µg of vitamin D2/d.) for 8 weeks
2556157|NCT02525003|Experimental|Group 3: Vitamin D3 supplement|Group 3: daily dose of regular bread (87 g/d) and D3 supplement (25 µg of vitamin D3/d.) for 8 weeks
2556162|NCT02525003|Experimental|Group 4: Vitamin D2-fortified bread|Group 4: D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
2556212|NCT02524652|Experimental|Local infiltration analgesia|Infiltration of the knee by the surgeon with local anaesthetics under general anaesthesia.
2556213|NCT02524652|Active Comparator|Adductor canal block|Injection of local anaesthetics under ultrasound guidance in the adductor canal by the anaesthesiologist after the surgery, before awaking the patient.
2556259|NCT02524301|Experimental|anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
2556262|NCT02524301|Experimental|Recovered anorexia nervosa patients|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
2556265|NCT02524301|Experimental|Healthy Volonteers|Cerebral [11C]diprenorphine Binding Potential measured by Positron emission Tomography (PET)
2556317|NCT02523963|Experimental|study group|"children with developmental delays participated 6 sessions of family work shop~The family work shop has 5 courses, with 6 families in one course.~Intervention of one course: 2-3 hours per session, one time per week, for a total of 6 weeks."
2556322|NCT02523963|No Intervention|control|children with normal development not participate the work shop followed up at before, and 6 weeks later
2556369|NCT02523664|Active Comparator|Hydrocortisone|10 mg hydrocortisone orally
2556372|NCT02523664|Placebo Comparator|Placebo|placebo orally
3205476|NCT00944463|Experimental|Gemcitabine+simvastatin|Gemcitabine and simvastatin
2556527|NCT02522559|Experimental|Spice Intervention|Spice intervention: Student-approved vegetable recipes will be served in the school cafeteria.
2556556|NCT02522182|Experimental|Intensive Secondary Prevention Programme|The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
2556557|NCT02522182|Active Comparator|Usual Treatment|The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
2556607|NCT02521922|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
2556656|NCT02521662|Active Comparator|Patch|21mg nicotine patch daily for 14 weeks (including a 2 week prequit period) plus behavioural support for six weeks post-quit
2556657|NCT02521662|Active Comparator|Patch and nicotine-free e-cigarette|21mg nicotine patch (daily) and nicotine-free e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
3205477|NCT00944463|Placebo Comparator|Gemcitabine+Placebo|Gemcitabine plus Placebo
3205478|NCT00944476||Pts/volunteers getting regular MRI exam|Fat-free MRI images utilizing standard magnetization transfer imaging will be acquired on 10 patients known or suspected sarcoma of the of the extremity or trunk, in addition to their traditional clinical MRI. In addition, we will perform the same scans on 4 volunteers who have no history of sarcoma.
3208804|NCT00978237|Experimental|LPV/r and combination of analogues.|
2555704|NCT02527993|Experimental|Victoza|Subcutaneous injection of Victoza (liraglutide) 0,6-1,2 mg O.D for three weeks.
2555706|NCT02527993|Experimental|Signifor|Subcutaneous injection of Signifor (pasireotide) 300 µg as a single dose prior to a meal tolerance test.
3171181|NCT00583817|Experimental|Thoracoabdominal Aortic Arm|Investigational endovascular stent-graft implantation to exclude thoracoabdominal aortic pathology including aortic aneurysms, renal artery aneurysms, and superior mesenteric artery aneurysms.
3171182|NCT00583830|Active Comparator|A|Paclitaxel and carboplatin
3171183|NCT00583830|Experimental|B|Paclitaxel, carboplatin and Mapatumumab 10 mg/kg
2555864|NCT02526810|Active Comparator|GROUP A|using continuous subcutaneous insulin injection with insulin lispro, Humalog, initiating with 0.5-0.8 IU/kg.
2555865|NCT02526810|Experimental|GROUP B|using glargine combined with oral drugs: insulin glargine, Lantus( initiating with 0.2 IU/kg) with metformin hydrochloride, Glucophage 500mg bid and gliclazide modified release tablets, Diamicron modified release(MR) tablets 60mg qd.
2555916|NCT02526446|Experimental|Self-administered acupressure|The intervention consists of a total of 28 hours over a period of 8 weeks. It comprises of individual learning and practice, self-practice at home, and home follow-up.
2555917|NCT02526446|Other|Wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
2555989|NCT02526108|Experimental|HIFT|High Intensity Functional Training group exercise session. Each session is 45 minutes. Participants will be asked to complete 3 sessions.
2556030|NCT02525731||Patient Cohort|The TEACH patient cohort component will establish an observational cohort of HIV-infected patients on chronic opioid therapy.
2556155|NCT02525458|Experimental|QAMS-containing PMMA|PMMA containing 5% QAMS
2556158|NCT02525458|Placebo Comparator|QAMS-free PMMA|PMMA containing 0% QAMS
2556222|NCT02524639|Experimental|Sirolimus|All enrolled subjects will receive Sirolimus 1 mg/m2/day twice a day for 6 weeks.
2556268|NCT02524249|Active Comparator|Early caffeine group|90 newborns will be randomized to receive caffeine within 24 hours of life. They will receive 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give PO caffeine if the newborn tolerates >75% of fluid goals by feeds.
2556271|NCT02524249|Placebo Comparator|Late caffeine group|90 newborns will be randomized to receive a placebo (dextrose) in the first 24 hours of life. They will receive a 20mg/kg IV bolus followed by IV or PO 5mg/kg daily for the next 14 days. The clinical team may decide to give the placebo orally is the newborn tolerates >75% of fluid goals by feeds.
2556391|NCT02523430|Experimental|HepaSphere|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2556392|NCT02523430|Placebo Comparator|control|nasopharyngeal carcinoma patients received traditional therapy
2556463|NCT02523014|Experimental|Arm A (vismodegib)|Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)
2556464|NCT02523014|Experimental|Arm B (FAK inhibitor GSK2256098)|Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)
2556465|NCT02523014|Experimental|Arm C (capivasertib)|Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.
2556468|NCT02523014|Experimental|Arm D (abemaciclib)|Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2557565|NCT02515747|No Intervention|conservative treatment|Men and women with stable CHD verified by angiography from one center and allocated to three treatment arms in real-world practice: 1. conservative treatment with statins, antiaggregants, antianginal drugs in standard dosage
2557567|NCT02515747|Active Comparator|percutaneous coronary intervention|2. elective balloon angioplasty alone or stent implanation on the basement of drugs treatment
2557570|NCT02515747|Active Comparator|coronary artery bypass grafting|elective surgery myocardial revascularisation on the basement of drugs treatment
2557614|NCT02515318|Experimental|Physiotherapy program|Patients with COPD are included in this group. They will receive a physiotherapy program during the hospitalization due to acute exacerbation of COPD, additionally to the standard medical treatment
2557616|NCT02515318|Active Comparator|Control group|Patients with COPD are included in this group. They will receive the medical standard treatment during the hospitalization due to acute exacerbation of COPD.
2557671|NCT02514954|Experimental|BioChaperone® Combo|1 single dose 400 U/mL
2557673|NCT02514954|Active Comparator|Humalog® Mix25|1 single dose 100 U/mL
2557721|NCT02514590|Experimental|Freedom SCS System - 1500 HZ|Epidural Space covering vertebrae level T8-T11 determined by paresthesia mapping for painful area.
2557730|NCT02514278|Experimental|Chemotherapy and Radiochemotherapy|"Neoadjuvant chemotherapy Folfirinox, 4 cycles:~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)~5FU: 2400 mg/m2~Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)"
2557731|NCT02514278|Active Comparator|Radiochemotherapy|Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)
2557817|NCT02513810|Experimental|Short-term DAPT after Biofreedom|
2557820|NCT02513810|Active Comparator|Long-term DAPT after BioMatrix or Ultimaster|
2557863|NCT02513511|Experimental|Hypnosis|the investigators will put the patient into a hypnotic state and analyze laryngoscopy under hypnosis, followed by intubation.
2557894|NCT02513290|Experimental|Bilastine group|Bilastine 20 mg administered once a day for ten days.
2557899|NCT02513290|Experimental|Loratadine group|Loratadine 10 mg administered once a day for ten days.
2557935|NCT02512978|Experimental|Levothyroxine group|The patients allocated to levothyroxine group receive levothyroxine with a starting dose of 12.5ug.
2557939|NCT02512978|No Intervention|Standard therapy group|The patients in this group receive standard therapy in consistent with the local clinical practice.
3171184|NCT00583830|Experimental|C|Paclitaxel, carboplatin and Mapatumumab 30 mg/kg
2555727|NCT02527811|No Intervention|control group|patients of control group received conventional therapy,eg,General anesthetic drug and monitoring during the whole process of surgery;Mechanical ventilation and close monitoring to prevent and manage respiratory acidosis and alkalosis and so on.
3171185|NCT00583843||Ultrasound|The group of women who are being followed by Ultrasound.
2555918|NCT02526511|Experimental|Diagnostic (pMRI)|Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.
2555982|NCT02525978|Experimental|Healthy Controls|Healthy controls will complete the video task and imaginal task in one session
2555986|NCT02525978|Experimental|Depressed + Ketamine|Subjects with major depressive disorder (MDD) who are scheduled to receive ketamine infusions will complete the video task and imaginal task twice. The first visit will be before any ketamine treatment. The second visit will be within 1 week after first ketamine infusion. This is NOT at treatment study. Study inclusion is open to participants with MDD who are already planning to receive ketamine treatment at Emory. No treatment is offered through this study.
2556049|NCT02525640|Experimental|Hearing Aid|CROS hearing aid
2556095|NCT02525393|Experimental|tDCS+rTMS|Stroke patients were treated with an initial two weeks of transcranial direct current stimulation and after six months with two weeks of repetitive transcranial magnetic stimulation.
2556096|NCT02525393|Experimental|rTMS+tDCS|Stroke patients were treated with an initial two weeks of repetitive transcranial magnetic stimulation and after six months with two weeks of transcranial direct current stimulation.
2556097|NCT02525393|Sham Comparator|Sham stimulation|Stroke patients were treated with two weeks of sham transcranial direct current stimulation.
2556156|NCT02525107|Experimental|SCD patients on Hydroxyurea|Omega-3 capsules [750 mg], 4 capsules a day for 52 weeks. [Each capsule will contain 417.9mg Docosahexaenoic acid [DHA], 50.8 mg Eicosapentaenoic acid [EPA] and 11.9mg Arachidonic acid [AA] and 1000 IU Vitamin E]
2556159|NCT02525107|Experimental|SCD patients not on Hydroxyurea|Dietary Supplement: Placebo [730 mg], 4 capsules a day for 52 weeks.[Each capsule will contain 538.2mg Oleic Acid [OA] and 1000 IU Vitamin E]
2556215|NCT02524626|Sham Comparator|Sham stimulation|no stimulation of vagus nerve
2556218|NCT02524626|Active Comparator|Vagus stimulation|Stimulation of the vagus nerve at the beginning and the end of the surgery
3171186|NCT00583869|Placebo Comparator|1|Patient to receive placebo beginning on the day of surgery until discharge.
2556316|NCT02523846|Active Comparator|Background morphine infusion to IV-PCA Morphine|Calculate based on patient's age, in mg/hour
2556321|NCT02523846|Experimental|Patient re-education to IV-PCA Morphine|Using patient information leaflet
2556381|NCT02523508|Experimental|Experimental group|Passive manual lumbar mobilization on L2-3 level
2556383|NCT02523508|Placebo Comparator|Control group|Passive limb mobilization which did not involve the spine
2556528|NCT02522572|Experimental|Group A|4 doses of plerixafor and plasmapheresis
2556529|NCT02522572|Experimental|Group B|4 doses of plerixafor, 1 dose of bortezomib, and plasmapheresis
2556533|NCT02522572|Experimental|Group C|6 doses of plerixafor, 2 doses of bortezomib, and plasmapheresis
2556579|NCT02522052|Experimental|Blue mussel diet|5 meals a week including blue mussels
2556581|NCT02522052|Active Comparator|Meat/control diet|5 meals a week including meat
2556775|NCT02521012|Active Comparator|Vitamin D 10 micrograms|"Vitamin D supplementation 10 micrograms/day given to depressed individuals, defined as reference"
2556776|NCT02521012|Experimental|Vitamin D 100 micrograms|Vitamin D supplementation 100 micrograms/day given to depressed individuals
2556821|NCT02520622|Experimental|Control|Patients use digital photographs loaded onto a mobile device
2556822|NCT02520622|Experimental|Reminders|Patients use digital photographs loaded onto a mobile device and receive skin exam reminders
2556824|NCT02520622|Experimental|Social Support|Patients use digital photographs loaded onto a mobile device and a social support network
2556827|NCT02520622|Experimental|Combined|Patients use digital photographs loaded onto a mobile device and a social support network and receive skin exam reminders
2556861|NCT02520258|Experimental|Aspartame Consumers - Cohort 1|"Experimental Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - (If OGTT results are abnormal, participants will be invited to participate in Phase II) Five (5) week study phase with Prudent Metabolic Diet and Intervention of diet soda containing aspartame only; Week 1: Prudent Metabolic Diet and 36oz diet soda po daily, Week 2-4: Prudent Metabolic Diet and no diet soda, Week 5: Prudent Metabolic Diet and 36 oz diet soda po daily."
2556866|NCT02520258|Active Comparator|Aspartame Naive Participants - Cohort 2|"Control Group/Arm~Phase I - Questionnaires and fasting oral glucose tolerance test (OGTT).~Phase II - Not applicable for this cohort."
3171187|NCT00583869|Experimental|2|Patient to receive 75mg PO BID pregabalin beginning on the day of surgery until discharge.
3171188|NCT00583869|Experimental|3|Patient to receive 150mg PO BID pregabalin beginning on the day of surgery until discharge.
3171189|NCT00583882|Other|1|Change every 6 days, rewire every 6 days
3171190|NCT00583882|Other|2|New site every 6 days
2556959|NCT02519517|Experimental|permissive hypercapnia|during one lung ventilation, right ventricular function was assessed by TEE and the effect of rising PCO2 appreciated
3171191|NCT00583882|Other|3|New site every 12 days
3171192|NCT00583895|Active Comparator|1|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
3171193|NCT00583895|Placebo Comparator|2|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
3171194|NCT00583934||A|Those six months post treatment for head and neck cancer.
3171195|NCT00583973||1|Chronic hemodialysis patients
3171196|NCT00583986|Experimental|1|Levalbuterol HFA MDI with top mounted actuation indicator
3171197|NCT00583999||A|bariatric surgery
3171198|NCT00584038|No Intervention|1 Standard Care (SC)|Participants receive usual contraceptive care administered by clinic provider.
2555791|NCT02527252|Experimental|Craniosacral therapy|"All treatments were applied by two experienced therapists with a 10-year certification in manipulative therapy after completion of their physical therapy degree and more than 20 years of clinical experience with patients. All patients received the intervention on the day of their initial examination. The techniques took 50 minutes and were conducted as follows:~Pelvic Diaphragm Release.~Respiratory Diaphragm Release.~Thoracic Inlet Release.~Hyoid release.~Sacral technique for stabilize L5/sacrum.~CV-4 Still Point Induction."
2555795|NCT02527252|Active Comparator|Classic Massage|Classics massage protocol was compounded by the following techniques of soft tissues massage: effleurage, petrissage, friction, and kneading. The techniques took thirty minutes.
2555846|NCT02526979|Experimental|mirabegron|single dose
2555889|NCT02526602|Experimental|Preservation (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are preserved.
2555890|NCT02526602|Active Comparator|Opening (endopelvic fascia)|During robotic assisted laparoscopic radical prostatectomy endopelvic fascia are opened.
2555933|NCT02526329|Experimental|Treatment (donor regulatory T lymphocytes)|Patients receive donor regulatory T lymphocytes intravenously (IV) over 5 minutes or less on day 0. Some patients receive a second infusion of frozen donor regulatory T lymphocytes 5-7 days after the initial infusion or 2 additional infusions separated by 5-7 days.
2555968|NCT02525991|Experimental|Staccato® Delivery System Loxapine|Staccato® Delivery System Loxapine, 9.1 mg one dose
2556024|NCT02525809|Other|mobility insert with tripod attachment (Novae E®)|mobility insert with tripod attachment (Novae E®)
2556027|NCT02525809|Other|mobility insert with press fit pure (Sunfit®)|mobility insert with press fit pure (Sunfit®)
2556029|NCT02525809|Other|fixed insert (Quartz®).|fixed insert (Quartz®).
3205479|NCT00944489||1|Patients with diagnosis of essential hypertension under the criteria established by the Joint National Committee VII (9) and those patients under pharmacological treatment with the same therapeutic regime during at least the last 6 months.
2556139|NCT02525081|Experimental|ACE-inhibitor|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
2556144|NCT02525081|Placebo Comparator|Placebo|"In both the placebo and Ramipril group medication will start with either 2,5 mg (Blood Pressure<130) or 5 mg (Blood Pressure>130) daily. After 2-3 weeks the dose is doubled to 5 mg or 10 mg unless blood pressure is below 115 mmHg. If blood pressure continues to be higher than 115 mmHg for patients up titrated to 5 mg treatment dose will be doubled to 10 mg at the third visit.~Patients taking a dose of~2,5 mg will take a half tablet a day~5 mg will take one whole tablet a day~10 mg will take two tablets a day"
2556208|NCT02524782|Experimental|MEDI-4166|MEDI-4166 administered subcutaneously
2556211|NCT02524782|Placebo Comparator|Placebo|Placebo administered subcutaneously
2556269|NCT02524223|Other|Population of couples candidate for MAP program|MAP = medically assisted procreation
2556298|NCT02523898|Experimental|metformine and clomiphene citrate|. metformin will be given at a dose of 500 mg three times a day for 8weeks. .In case of failure of ovulation after the end of this period, metformin was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene. When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose.
2556302|NCT02523898|Active Comparator|placebo and clomiphene citrate|"The patients in group two will be receiving placebo. In case of failure of ovulation after the end of this period, placebo was continued and patients were given 100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration .In cases of ovulation with CC without pregnancy, the patients were advised to participate in other two similar cycles of therapy with 100 mg clomiphene.When ovulation did not occur with 100 mg CC, its dose will be increased to 150 mg and the same treatment protocol will be used for this dose. .~10 days). ."
2556427|NCT02523157|Experimental|Intervention|Wellbeing Plan
2556428|NCT02523157|Active Comparator|Control|Control task. Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
2556517|NCT02522598|Experimental|VVZ-149 injection|VVZ-149 Injections will be mixed with saline,then intravenous infusion for 8hr. The drug product will be administered with a loading dose of 1.8 mg/kg for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h for 7.5 hours.
2556519|NCT02522598|Placebo Comparator|Placebo|placebo group will receive an water for injection the same volume and period of experimental group.
2556564|NCT02522208|Experimental|BiDil Extended Release (XR)|BiDil XR isosorbide dinitrate 40 mg and hydralazine hydrochloride 75 mg 2 capsules 9 hours apart for one day
2556565|NCT02522208|Active Comparator|BiDil Immediate Release (IR)|BiDil isosorbide dinitrate 20 mg and hydralazine hydrochloride 37.5 mg 3 tablets 6 hours apart for one day
2556629|NCT02521805|Sham Comparator|PA|Animal protein and no fiber (control)
2556633|NCT02521805|Experimental|PAF|Animal protein added fiber
2556639|NCT02521805|Experimental|PVF|Vegetable protein naturally containing dietary fiber
2556641|NCT02521805|Experimental|PAVM|Animal protein and dietary fiber in meal
2556715|NCT02521285|Experimental|Arm A (aspirin)|Patients receive aspirin PO QD for 12 months.
2556718|NCT02521285|Placebo Comparator|Arm B (placebo)|Patients receive placebo PO QD for 12 months.
2556803|NCT02520843|Experimental|Crohn's disease treated by SVF|Patients with Crohn's disease and fistula-in-ano refractory to conventional medical and surgical treatment, treated by Stromal Vascular Fraction ( SVF) reinjection
2556856|NCT02520453|Experimental|Durvalumab|Durvalumab 20 mg/Kg IV Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
2555839|NCT02527018||Healthy Subjects|Measurement of hemodynamic levels (BNP) of healthly term subjects using the Nexfin sphygmomanometer device.
2555841|NCT02527018||Preeclamptic Subjects|Measurement of hemodynamic levels (BNP) of preeclamptic subjects using Nexfin sphygmomanometer device.
2555874|NCT02526628||Testosterone naïve KS|Men with Klinefelter syndrome without testosterone treatment. After initial examination standard treatment with testosterone will be effectuated according to current guidelines.
2555880|NCT02526628||Testosterone treated KS|Men with Klinefelter syndrome receiving testosterone treatment
2555881|NCT02526628||Controls 1|Matched healthy male controls for testosterone naive KS
2555884|NCT02526628||Controls 2|Matched healthy male controls for testosterone treated KS
2555919|NCT02526407|No Intervention|Control|Participants continue with usual care. No planned intervention.
2555922|NCT02526407|Active Comparator|Group play|Participants take part in 10 weeks of group play activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
2555925|NCT02526407|Experimental|Singing|Participants take part in 10 weeks of group singing activities for one hour per week with their baby in a community setting alongside any usual care they may be receiving.
2555970|NCT02526056|Experimental|Physiotherapists|The physiotherapist have to play the exergame once.
2555971|NCT02526056|Experimental|elderly people|The elderly people have play the exergame twice.
3171199|NCT00584038|Other|2 Standard Care + Educational (SCE)|Participants receive standard contraceptive care from clinic provider, followed by 45-minute educational intervention.
3171200|NCT00584038|Other|3 Standard Care + Educational + Phone Calls (SCEP)|Participants receive standard contraceptive care from clinic provider, followed by phone calls weekly until onset of menses and monthly thereafter for six consecutive months.
3171201|NCT00584051||1|
2556093|NCT02525419|Experimental|Weight Loss Phase|12 week weight loss phase consisting of High Protein - Intermittent Fast-Low Calorie diet in 43 Obese Men and Women
2556094|NCT02525419|Experimental|Weight Loss Maintenance Phase|52 week weight loss maintenance phase consisting of either High Protein - Intermittent Fast (HP-IF) or Heart Healthy (HH) diet
2556233|NCT02524483|Experimental|Therapeutic Challenge Group|The Therapeutic Challenge Group will complete the Therapeutic Challenge Program twice a day, five days each week for 6 weeks.
2556236|NCT02524483|Active Comparator|Therapeutic Exercise Group|The Therapeutic Exercise Group will complete the Therapeutic Exercise Program twice a day, five days each week for 6 weeks.
2556393|NCT02523378|Experimental|ESAS Self-Administration - Group A|Participants complete the symptom questionnaire alone. It is then counterchecked by health care professional (HCP).
2556394|NCT02523378|Experimental|ESAS Assisted-Completion - Group B|Participants complete the symptom questionnaire with the help of the research nurse or assistant.
2556475|NCT02522962|Experimental|GroupCoreSIT|Before the group training starts, the physiotherapist in charge of the group does a clinical assessment of each participant in order to individualise the training. Each training group will consist of three participants. The training sessions will last for 60 minutes, performed three days per week, for six weeks, between 10 am and 5 pm.
2556478|NCT02522962|Active Comparator|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
2556675|NCT02521402|Other|Keloid Revision Surgery with Biovance|All enrolled patients will have Biovance applied during Keloid Revision Surgery
2556738|NCT02521233|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
2556741|NCT02521233|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
2556743|NCT02521233|Active Comparator|Comparator: losartan+hydrochlorothiazide (Hyzaar®)|he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
2556781|NCT02520882|Experimental|68Ga-NOTA-Aca-BBN(7-14) PET/CT|The patients were injected with 111-148 MBq of 68Ga-NOTA-Aca-BBN(7-14) in one dose intravenously and underwent PET/CT scan 30 min later.
2556825|NCT02520557||Case|Cases will be individuals with documented definite or probable Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), or drug reaction with eosinophilia and systemic symptoms (DRESS) or symptom onset consistent with one of these conditions within the first 4 months of using ESL (including up to 14 days after discontinuing ESL) will be considered a potential case. Blood draw or Saliva.
2556853|NCT02520232|No Intervention|Control|No physical exercices assigned by the protocol
3171202|NCT00584051||2|
3171203|NCT00584051||3|
3171204|NCT00584090|Experimental|1|
3171205|NCT00584090|Placebo Comparator|2|
3171206|NCT00584103|Experimental|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
3171207|NCT00584103|Other|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
3171208|NCT00584129|Experimental|1|Patients will receive pre-treatment swallowing exercises.
3171209|NCT00584129|Active Comparator|2|Post-treatment swallowing exercises.
3171210|NCT00584142|Experimental|1|
3171211|NCT00584142|No Intervention|2|
3171212|NCT00584155|Placebo Comparator|1|Each patient will receive a bottle containing normal saline and 0.03% ofloxacin.
3171213|NCT00584155|Experimental|2|Each patient will receive a bottle containing Lactated Ringer's solution and 0.03% ofloxacin.
3171214|NCT00584168|Placebo Comparator|2|Patient will receive a placebo.
3171215|NCT00584168|Experimental|1|Patient will receive dexamethasone.
3171216|NCT00584181||Lung transplant recipients|Lung transplant recpients enrolled as study subjects will undergo pulmonary function tests (spirometry and lung volume measurements) and initial HRCT of chest. These subjects will receive nebulized ipratropium followed by pulmonary function tests (spirometry and lung volume measurements) and repeat HRCT.
2555843|NCT02526953|Experimental|Paclitaxel|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of paclitaxel 45 mg/m2 on days 3,10,17,24,31, capecitabine 625 mg/m2 bid on treatment days and mitomycin C 10 g/m2 on day 1.
2555847|NCT02526953|Active Comparator|Standard|Patients will receive intensity-modulated radiotherapy with dose based on T stage. The planned doses to the primary tumor and pelvis are 52-58 Gy and 44 Gy, respectively.The concurrent chemotherapy regimen will consist of capecitabine 825 mg/m2 bid on treatment days and mitomycin C 12 g/m2 on day 1.
2555908|NCT02526485||Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture. Participants will be enrolled in equal numbers from three categories determined by their observed clinical course: (1) participants without HIT testing negative for heparin/PF4 antibodies (controls); (2) participants without HIT testing positive for heparin/PF4 antibodies (seroconversion cases); (3) participants with HIT testing positive for both heparin/PF4 antibodies (HIT cases).
2555946|NCT02526225|Active Comparator|ginkgo diterpene lactone meglumine injection|ginkgo diterpene lactone meglumine injection
2555950|NCT02526225|Placebo Comparator|Ginkgo diterpene lactone meglumine injection simulation|Ginkgo diterpene lactone meglumine injection simulation
2555993|NCT02525926|Experimental|denervation|
2555997|NCT02525926|Sham Comparator|control group|
2556066|NCT02525614|Active Comparator|Triathlon Standard Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
2556070|NCT02525614|Active Comparator|Triathlon Short Keel|Triathlon Cruciate Retaining knee (CR) with a tibial keel of standard length randomised against Triathlon Cruciate Retaining knee (CR) with a tibial part with a short keel, both system will be used with cemented fixation. The short tibial keel is thought to facilitate the surgery due to easier access and better positioning possibilities. This study is aimed to evaluate if the short tibial keel will have equal fixation and migration properties as the standard keel.
2556112|NCT02525380|Experimental|Doxorubicin loadeing-DC Bead(Device)|"DC Bead comprises hydrogel microspheres that are biocompatible, hydrophilic, non resorbable, precisely calibrated and capable of loading doxorubicin.~DC Bead is produced from polyvinyl alcohol."
2556186|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 20 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 20 mg/m2. Drug infusions will last approximately 2 hours.
2556187|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 26 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 26 mg/m2. Drug infusions will last approximately 2 hours.
2556188|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 34 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 34 mg/m2 . Drug infusions will last approximately 2 hours.
2556189|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 44 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 44 mg/m2 . Drug infusions will last approximately 2 hours.
2556190|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 57 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 57 mg/m2. Drug infusions will last approximately 2 hours.
2556191|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 74 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 74 mg/m2 . Drug infusions will last approximately 2 hours.
2556192|NCT02524951|Experimental|MSI-1436C (Trodusquemine) 96 mg/m2 IV|Open label, interventional, dose escalation of MSI-1436 (Trodusquemine), single intravenous infusion twice a week for 3 weeks on a 4-week cycle. Subjects will receive MSI-1436 at a dose of 96 mg/m2 . Drug infusions will last approximately 2 hours.
2556237|NCT02524444|Active Comparator|Mefloquine|Tabs Mefloquine 250mg 3 doses 4 weeks apart
2556239|NCT02524444|Active Comparator|Sulphadoxine-Pyrimethamine|500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets 4 weeks apart for 3 doses
2556286|NCT02524067|Experimental|Intervention|Intervention: Circadian lighting, systematic information, music, foreclosure of the individual patient
2556325|NCT02523781|No Intervention|Control group|The control group does not receive the information pamphlet
2556326|NCT02523781|Experimental|Intervention group|The intervention group receives the information pamphlet
2556341|NCT02523573||Study population|Adult ARF ICU patients needing BAL with HFNC
2556402|NCT02523391|Experimental|Treatment Period 1|Either 5mg TA-8995 Capsule or Tablet
2556405|NCT02523391|Experimental|Treatment Period 2|Either 5mg TA-8995 Capsule or Tablet
2556485|NCT02522936|Experimental|Biotene|Participants will be given Biotene oral spray to use as needed when taking oxybutynin.
2556491|NCT02522936|No Intervention|Routine care|Participants will be given routine care.
3205480|NCT00944502|Experimental|Dexamethasone and complex vitamins|"Group A: Vitatonus dexa injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablet:~1 tablet orally every 8 hours for 10 days."
3205481|NCT00944502|Active Comparator|Dexamethasone|"Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablet:~1 tablet orally every 8 hours for 10 days."
3205482|NCT00944515|Active Comparator|azithromycin|azithrimycin 3 days/week
2556663|NCT02521571|Experimental|Intervention Group|
2556664|NCT02521571|Placebo Comparator|Control Group|
2556721|NCT02521337||pregnant women not in active labor|
2556724|NCT02521337||pregnant women in preterm labor|
2555849|NCT02526940||blood CD4 cells count : 200 - 300/mm3|patients with blood CD4 cells count at the time of initiation of HAART between 200 and 300/mm3 Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years
2555850|NCT02526940||blood CD4 cells count >350/mm3|"patients with blood CD4 cells count at the time of initiation of HAART> 350/mm3.~Six rectal biopsies and blood samples collected for each patient treated by HAART more than 1 year and less than 4 years"
3205483|NCT00944515|Placebo Comparator|placebo|placebo 3 days/week
2555937|NCT02526173|Experimental|dHACM|This group will receive RALP using full nerve sparing technique plus dHACM application.
2555939|NCT02526173|Other|Control|This group will receive RALP using full nerve sparing technique only.
2555979|NCT02525965|Experimental|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
2555985|NCT02525965|Active Comparator|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of narrow resection margin <1cm
2556043|NCT02525679|Experimental|BI 655130|
2556048|NCT02525679|Placebo Comparator|Placebo|
2556119|NCT02525159|Active Comparator|DIM pills|75 mg of 3,3´-diindolylmethane (DIM) once a day for 30 days
2556124|NCT02525159|Placebo Comparator|Placebo pills|2 pills once a day for 30 days
2556217|NCT02524522|Active Comparator|INTELLiVENT-ASV mode|Active comparator: Discontinuation of mechanical ventilation in postoperative period will be provided using automatically driven mode - INTELLiVENT-ASV. In the INTELLiVENT-ASV mode target EtCO2 will be 30-35 mm Hg, target SpO2 - 94-98%, quick wean option - activated.
2556219|NCT02524522|Active Comparator|SIMV mode|Active comparator: Discontinuation from mechanical ventilation in postoperative period will be provided using physician driven protocol. The synchronized intermittent mandatory ventilation (SIMV) mode settings will be as follows: PEEP 5 cm of water, FiO2 to achieve SpO2 > 94 %. Inspiratory pressure will be adjusted to deliver a tidal volume (VT) of 8 mL/kg predicted body weight; pressure support will be 2 cm of water higher. Respiratory rate (RR) will be adjusted to provide EtCO2 of 30-35 mm Hg. Respiratory rate and inspiratory pressure will be decreased gradually every 30 minutes. After decrease of inspiratory pressure to 6 cm of water (8 cm of water in case of BMI > 30 kg/m2) and respiratory rate to 6/min, the spontaneous breathing trial (SBT) will be started.
3205484|NCT00944580|Experimental|Vaccine Intervention|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine: A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
2556366|NCT02523716|Experimental|Hypoxia|Mild hypoxia of 15% oxygen, equivalent altitude of 2440m over a period of 7 days
2556368|NCT02523716|Sham Comparator|Normoxia|Exposure to normal, sea-level air
3205485|NCT00944593|Experimental|300kcal liquid Nutrient|300kcal liquid nutrient delivered by NJ tube over 60 minutes before ingestion of a standard oral liquid nutrient test meal
3205486|NCT00944593|Placebo Comparator|Normal Saline|Normal Saline delivered via NJ tube over 60 minutes ahead of a standard liquid nutrient test meal
3205487|NCT00944606|Active Comparator|Vitamin D|
3205488|NCT00944606|Placebo Comparator|Placebo|
3205489|NCT00944619|Experimental|Closed loop (algorithm)|Subcutaneous delivery of Novorapid insulin, dose calculated by computer-driven control algorithm, based on continuous glucose sensor readings
3205490|NCT00944619|Placebo Comparator|Open loop|Subcutaneous delivery of Novorapid insulin according to usual pump regime
2556619|NCT02521818|Experimental|Modified Atkins Diet|modified Atkins diet; fewer than 20 mg. carbohydrates per day, supplemented by extra dietary fats
2556625|NCT02521818|Active Comparator|NIA Diet for Seniors|Diet recommended by NIA for seniors
2556685|NCT02521545|Experimental|BIIB061|Single oral dose of 30 mg BIIB061 of the new formulation
2556739|NCT02521246|Experimental|Test 1: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 12,5 mg) a day, in the morning.
2556740|NCT02521246|Experimental|Test 2: Candesartan + Chlorthalidone|The patients will take 1 tablet (Candesartan Cilexetil 16 mg + Chlorthalidone 25 mg) a day, in the morning.
2556742|NCT02521246|Active Comparator|Comparator: Losartan+hydrochlorothiazide (Hyzaar®)|The patients will take 1 tablet (Losartan 100 mg + Hydrochlorothiazide 25 mg) a day, in the morning.
3205491|NCT00944632|Active Comparator|Zk 245186 0.01% ointment|Active treatment, lowest dose
3205492|NCT00944632|Active Comparator|ZK 245186 0.03% ointment|Active comparator middle dose
3205493|NCT00944632|Active Comparator|ZK 245186 0.1% ointment|Active comparator highest dose
3205494|NCT00944632|Placebo Comparator|Vehicle ointment|Placebo comparator
3205495|NCT00944684|Experimental|A|PegIFN-alpha 2a + RBV (commenced according to kidney function) adjusted to plasma levels. Treatment with erythropoetin 3x3,000IU/week up to 3x10,000IU/week in case of hemolytic anemia
3205496|NCT00944684|Active Comparator|B|PegIFN-alpha 2a + RBV (weight based; 1,000 or 1,200 mg/day)
3205497|NCT00944723|Experimental|Zinc-fortified bread (10 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month
3205498|NCT00944723|Experimental|Zinc fortified bread (20 mg zinc/d)|Daily consumption of zinc fortified bread for 1 month.
3205499|NCT00944723|Experimental|Zinc supplemented group|Daily consumption of non-fortified bread and daily intake of zinc supplement (10 mg zinc/d)
3205500|NCT00944723|Placebo Comparator|Non-fortified group|Daily consumption of non-fortified bread and a placebo supplement for 1 month.
3205501|NCT00944736|Active Comparator|VSL#3|
3205502|NCT00944736|Placebo Comparator|Placebo|
3205503|NCT00944762|Experimental|Ecosystem Focused Therapy (EFT)|Participants will receive EFT.
3205504|NCT00944762|Active Comparator|Education in stroke and depression|Participants will receive education in stroke and depression.
2555854|NCT02526862|Active Comparator|C-Semi-permeable hydrogel-foam|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
2555856|NCT02526862|Active Comparator|D-Hyper hydrogenated fatty acids|Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
2555927|NCT02526498|Experimental|Treatment (APBI using HDR brachytherapy)|Within 1-5 days after balloon placement, patients undergo APBI using HDR brachytherapy over 15-60 minutes for 2-3 days.
2555978|NCT02526043|Experimental|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by laparoscopic surgery
2555984|NCT02526043|Experimental|Open hepatectomy|The HCC patients who meet the Louisville consensus will be underwent the liver resection by open surgery
2556052|NCT02525705|Experimental|Every EA patients|This is a one group interventional study. Every patient is included in the same arm.
2556120|NCT02525367|Experimental|PD-Experimental|PD patients using the online cognitive training for 8 weeks, 3 times a week
2556123|NCT02525367|Active Comparator|PD-Control|PD patients using the active control condition for 8 weeks, 3 times a week
2556130|NCT02525367|Experimental|MS-Experimental|MS patients using the online cognitive training for 8 weeks, 3 times a week
2556131|NCT02525367|Active Comparator|MS-Control|MS patients using the active control condition for 8 weeks, 3 times a week
2556134|NCT02525367|Experimental|postECT-Experimental|Depressed elderly treated with ECT patients using the online cognitive training for 8 weeks, 3 times a week
2556136|NCT02525367|Active Comparator|postECT-Control|Depressed elderly treated with ECT patients using the active control condition for 8 weeks, 3 times a week
3205505|NCT00944775|Experimental|exercise training|10-month exercise training program
3205506|NCT00944775|No Intervention|controls|usual care sedentary lifestyle
3205507|NCT00944788|Experimental|qi-gong|
2556401|NCT02523443|Active Comparator|IV PCA after surgery|general anesthesia with post-operative IV PCA with a standard demand pump
2556404|NCT02523443|Experimental|PCEA during and after surgery|general anesthesia with post-operative thoracic epidural analgesia with a standard demand pump
2556446|NCT02522923|Experimental|Physical Therapist|Participants randomized to this arm will receive care from a physical therapist first.
2556447|NCT02522923|Active Comparator|Primary Care Provider|Participants randomized to this arm will receive care from a primary care provider first.
2556474|NCT02522637|Active Comparator|Exercise training F1|Patients will be treated with a specific rehabilitation in-hospital program consisting of one daily sessions of 30 minutes of exercise (Frequency 1 : Program F1 )
2556477|NCT02522637|Experimental|Exercise training F2|Patients will be treated with a specific rehabilitation in-hospital program consisting of two daily sessions of 30 minutes of exercise (Frequency 2 : Program F2 )
2556511|NCT02522455|Other|Preterm infants with RDS|
3205508|NCT00944788|No Intervention|Usual care|
3205509|NCT00944801|Experimental|Pegylated Liposomal Doxorubicin|Radiotherapy is planned with dedicated computed tomography and three-dimensional planning systems and delivered to the gross tumor volume with a 2 to 3 cm margin for the clinical target volume. After a 4-week break, patients receive adjuvant TMZ 150 to 200 mg/m2 day 1 to 5 in 28 days until tumor progression or up to at least 12 cycles. In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
3205510|NCT00944814|Experimental|LNS with zinc|LNS containing 10 mg zinc per 20 g dose of LNS
3205511|NCT00944814|Placebo Comparator|LNS without zinc|LNS containing no zinc
2556632|NCT02521753|Active Comparator|Metformin|Metformin 850mg twice a day for six months
2556638|NCT02521753|Experimental|Magnesium|Magnesium chloride 250mg daily for six months
2556640|NCT02521753|Experimental|PUFA omega 3|Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) 1.1mg daily for six months
2556681|NCT02521441|Experimental|F-627, 10 mg/dose|F-627 at dose of 10 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
2556686|NCT02521441|Experimental|F-627, 20 mg/dose|F-627 at dose of 20 mg/dose administered by subcutaneous injection on Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
2556694|NCT02521441|Experimental|Filgrastim, 5 mcg/kg/dose|Filgrastim of 5 mcg/dose administered by subcutaneous injection for up to two weeks, start from Day 3 of each cycle for up to 4 cycles. EC regimen (Epirubicin and Cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for 4 cycles.
2556757|NCT02521103|Other|Triathlon Tritanium Cone Augments|Cases who receive the Triathlon TS Total Knee System with at least one Triathlon Tritanium Cone Augment
2556816|NCT02520700|Experimental|Study participants|This was split scalp design - so each patient had one half of scalp treated with daylight PDT and one side treated with the artificial white light PDT - a surgical light (Maquet Power 500 LED surgery light)
2556907|NCT02520115|Experimental|Arm I (induction)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum and tissue samples for analysis via PCR and IHC at baseline, time of surgery, and 7-14 days after surgery.
2556908|NCT02520115|Experimental|Arm II (surveillance and recurrence)|Patients receive valproic acid PO BID on days -7 to -3 and QD on day -2 and dexamethasone PO QD on days -5 and -2 and BID on days -4 and -3. Patients undergo collection of serum samples for analysis via PCR and IHC at the time of clinically suspected recurrence, 2 days after completion of induction, and 7-14 days after induction.
3205512|NCT00944827|Experimental|GTE|The experimental group will receive 20 mg atorvastatin (Lipitor) daily and 600 mg. of pure catechin in capsules
2555991|NCT02525952|Experimental|Hepatectomy with NDR >2|Surgical removal of all lesions for patients with a NDR score more than 2 according to the NDR scoring system
2555995|NCT02525952|Active Comparator|TACE with NDR >2|Transarterial chemoembolization for patients with a NDR score more than 2 according to the NDR scoring system
3205513|NCT00944827|Placebo Comparator|CON|The control group will receive 20 mg atorvastatin (Lipitor) and Placebo in identical capsules containing 600 mg placebo for 12 weeks
2556098|NCT02525146|Experimental|Intervention|Patients randomized to the intervention arm receive intensive social work case management based on the ARTAS (Antiretroviral Treatment and Access to Services) model. Patients may participate in 6-12 visits over a six-month period aimed at addressing barriers to re-engagement in HIV care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment.
2556102|NCT02525146|No Intervention|Usual Care|Patients randomized to the usual care arm are provide contact information for an HIV primary care clinic and for local AIDS service organizations. Patients are then encouraged to contact these organizations to re-establish care. Participants complete a battery of research questions at Baseline, 6-months, and 12-months and HIV-1 viral load and CD4 count labwork at Baseline and at 12-months post enrollment. Patients in the usual care arm are offered the intensive casework intervention after their 12-month followup is complete.
2556140|NCT02525042||Patients with ankylosing spondylitis|Patients with ankylosing spondylitis
2556142|NCT02525042||Comparator 1|family controls
2556145|NCT02525042||Comparator 2|population controls
2556216|NCT02524509||CHONDRON|Patients who already received autologous chondrocyte implantation using CHONDRON (Autologous Cultured Chondrocyte) for knee cartilage defects
2556220|NCT02524509||Microfracture|patients already underwent microfracture
2556257|NCT02524340||Juvenile Idiopathic Arthritis|Children diagnosed with Juvenile Idiopathic Arthritis
2556329|NCT02524028||Case Participant Cohort|Participants with atrial fibrillation
2556332|NCT02524028||Control Participant Cohort|Participants without atrial fibrillation or any other heart disease
2556343|NCT02523547|Experimental|Cavir|entecavir/0.5mg/day
2556345|NCT02523547|Active Comparator|Baraclude|entecavir/0.5mg/day
2556396|NCT02523352|Experimental|Treatment|Volunteers with a BMI > 35 Kg/m2 and central fat distribution, without any past medical history
2556457|NCT02522975|Active Comparator|Reference group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPREX® will be 60 IU/kg body weight."
2556459|NCT02522975|Experimental|Experimental group|"Generic name: recombinant human erythropoetin injection which is indicated for the treatment of anaemia caused by chronic renal disease.~Dosage form:Injection Strength:2000IU,3000IU,4000IU Frequency and Dosage:subcutaneously injection once a week for a period of 52 weeks. The initial dose of EPIAO® will be 60 IU/kg body weight."
2556530|NCT02522533|Experimental|Physical Therapy|Patients will be receiving 6 weeks of an exercise program.
2556575|NCT02522156|Experimental|Looming Vulnerability Induction|"Four audiotape-guided imagery exercises, each lasting about 3 minutes:~Conveyor Belt: Places the participants in a dimly-lit factory, in which they are being carried along faster and faster on a conveyor belt as they smoke. This conveyor belt is described as ultimately leading to the diagnosis of lung cancer.~Office Building: Places participants in an office all alone, watching calendar pages fly off the wall. As participants smoke and time progresses, participants are meant to feel their lungs withering away and their heart beat becoming weaker and weaker.~Train Tracks: Set in the open plains on top of a set of railroad tracks. As participants smoke, a train heading directly towards them gains speed.~Clock Ticking: In this timing exercise, participants are instructed to imagine terrible health consequences related to smoking coming closer and closer to them as they smoke. Participants are asked to keep track of time for a period of three minutes."
2556576|NCT02522156|Placebo Comparator|Control|"Four audiotape-guided imagery exercises, as follows:~Escalator (parallel to conveyor belt above): Takes place in an empty mall in the morning. The participants imagine they are slowly and steadily being carried by the escalator until they reach the top.~Metro (parallel to office building): Involves riding public transportation while reading a magazine, steadily flipping the pages.~Driving (parallel to Train Tracks): Involves driving a car. The car in this case moves steadily with no traffic hindrances that would cause a reduction of speed.~Human Clock (parallel to Clock Ticking): Another timing exercise. In this case, the participants receive instruction to pretend they are a human clock."
3205514|NCT00944840|Active Comparator|SP and amodiaquine|Study subjects received intermittent preventive treatment with SP plus amodiaquine.
3205515|NCT00944840|Placebo Comparator|SP placebo plus amodiaquine placebo|Intermittent preventive treatment with SP placebo and amodiaquine placebo
3205516|NCT00944853|Experimental|Zinc syrup|Liquid Zinc Syrup (ZnSO4) solution provided daily
3205517|NCT00944853|Experimental|Zinc tablet|Dispersible zinc tablets provided daily
3205518|NCT00944853|Placebo Comparator|Placebo|Liquid placebo supplement provided daily
3205519|NCT00944866||RA with drug|
2557032|NCT02519400|Experimental|Amitriptyline|Single oral dose of amitriptyline, 25 mg
3205520|NCT00944866||RA without drug|
3205521|NCT00944879||HPV vaccine|Those choosing to receive the HPV vaccine
3205522|NCT00944879||no HPV vaccine|Those choosing not to receive the HPV vaccine
3205523|NCT00944892|Experimental|Dose 1|
3205524|NCT00944892|Experimental|Dose 2|
3205525|NCT00944892|Experimental|Dose 3|
3205526|NCT00944892|Placebo Comparator|Placebo|
3205527|NCT00944905|Experimental|MDX-1203|Accelerated titration design (ATD)of 6 dose levels. Subjects will be assigned to a dose level in the order they enter the study
3205528|NCT00944918|Experimental|1|fulvestrant and anastrozole
3205529|NCT00944918|Experimental|2|fulvestrant and placebo
3205530|NCT00944918|Active Comparator|3|exemestane alone
3205531|NCT00944944||Gyn Pts with lymphedema|
3205532|NCT00944944||Gyn Pts without Lymphedema|
3205533|NCT00944957|Experimental|Raltegravir first|Patients treated with Raltegravir for first 2 weeks
3205534|NCT00944957|Experimental|Efavirenz first|Patients treated with Efavirenz for first 2 weeks
3205535|NCT00944970|Other|binodenoson then adenosine|binodenoson (experimental); adenosine (active comparator)
3205536|NCT00944970|Other|adenosine then binodenoson|adenosine (active comparator); binodenoson (experimental)
3205537|NCT00944970|Active Comparator|adenosine then adenosine|
3205538|NCT00944996|Active Comparator|antidepressant|
3205539|NCT00944996|No Intervention|Healthy volunteers|
3205540|NCT00945022|Experimental|Lipsus|
3205541|NCT00945074|Experimental|Condition 1|"Condition 1:~Subjects receive Standard Acu/Moxa (fixed protocol)"
3205542|NCT00945074|Experimental|Condition 2: Individualized Acupuncture/Moxibustion|"Condition 2:~Subjects receive Individualized Acupuncture/Moxibustion (patient-oriented, based on traditional Chinese medicine diagnosis)."
2556225|NCT02524470|Experimental|VSP Study Participants|Vital Signs Patch system study participants. Each study participant will receive the VSP System - NEHB Configuration and then the VSP System - PAL Configuration. Vital signs will be taken and adhesive will be assessed for each participant for each configuration.
2556277|NCT02524197|Active Comparator|CR845 0.25 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
2556278|NCT02524197|Active Comparator|CR845 0.50 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
2556279|NCT02524197|Active Comparator|CR845 1 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
2556280|NCT02524197|Active Comparator|CR845 5 mg|"Study medication will be taken b.i.d., in the morning (at least 2 hours before breakfast) and later in the afternoon (at least 2 hours before dinner), beginning on the morning of Day1 at the Baseline Visit.~Analgesic rescue medication (Acetaminophen) for the treatment of pain will be provided at the Screening Visit.~Patients will record their daily intake of study medication on the diary provided."
2556313|NCT02523807||Patients with Parkinson's Disease|Patients with tremor due to Parkinson Disease
2556315|NCT02523807||Patients with Essential tremor|Patients with tremor due to Essential tremor
3205543|NCT00945074|Sham Comparator|Condition 3: Control|"Condition 3:~Subjects receive Sham Acupuncture/Placebo Moxibustion (control group)"
3205544|NCT00945113|Experimental|Treatment group|attendance at one-week speech therapy group
2556448|NCT02523001||Naïve-S|Patients with hypercholesterolemia starting statin treatment for primary or secondary prevention of cardiovascular diseases.
2556449|NCT02523001||ONC-S|Patients with hypercholesterolemia who had been treated with statin for at least one year and continued their previous therapy during the study period
2556451|NCT02523001||Naïve-MC|Patients with mild hypercholesterolemia either refusing initial statin treatment or intolerant to standard statin treatment and starting with monacolin K
2556453|NCT02523001||Naïve-Diet|Patients refusing an initial pharmacologic treatments and choosing the hypolipidic diet
2556486|NCT02522650|Experimental|Amiloride Phase|Subject receives 5mg of Amiloride twice daily for 8 weeks.
2556495|NCT02522650|Active Comparator|Triamterene Phase|Subject receives 50mg of Triamterene twice daily for 8 weeks.
2556501|NCT02522650|No Intervention|Washout Phase|Subject does not take any study medication for 4 weeks
2556537|NCT02522351|Active Comparator|Thicken Up Clear concentration 1|Thicken Up Clear at concentration 1
2556538|NCT02522351|Active Comparator|Thicken Up Clear concentration 2|Thicken Up Clear at concentration 2
2556539|NCT02522351|Active Comparator|Thicken Up Clear concentration 3|Thicken Up Clear at concentration 3
2556540|NCT02522351|Experimental|Cereal extract concentration 1|Cereal extract at concentration 1
2556543|NCT02522351|Experimental|Cereal extract concentration 2|Cereal extract at concentration 2
2556544|NCT02522351|Experimental|Cereal extract concentration 3|Cereal extract at concentration 3
2556623|NCT02521857|Experimental|ALKS 5461|Sublingual tablet
2556690|NCT02521623|Experimental|Surgimend|Patients randomized to this arm will receive SurgiMend® Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
2556695|NCT02521623|Active Comparator|Strattice|Patients randomized to this arm will receive Strattice™ Acellular Dermal Matrix in their direct to implant primary breast reconstruction.
2556729|NCT02521194|Experimental|Caregiver Questionnaire|Questionnaire completion regarding opinion on the inpatient occupational therapy session person being cared for received.
2556734|NCT02521194|Experimental|Patient Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
2556788|NCT02520661|No Intervention|Usual Care|Older adults discharged from an ED to home who receive the usual processes and services.
2556790|NCT02520661|Active Comparator|Care Transitions Intervention|Older adults discharged from an ED to home who receive the Care Transitions Intervention.
3205545|NCT00945152|Experimental|Drug Vancogel,Treatment,Kill MRSA,Heal|Treatment of open wounds with Vancogel(R) 1.25-1.50% to eliminate MRSA. End point is: a negative culture report after 1-3 topical applications. The infected wounds with MRSA will be treated with the Vancomycin 1.25 to 1.50% complex gel formulation and will have conventional management in order to heal the wound. Vancogel is anticipated to accelerate wound healing by eliminating MRSA. A randomized, double blind study protocol approved by FDA.
2556840|NCT02520323||Blood only|20 sarcoidosis subjects and 20 healthy controls will complete lifestyle questionnaires and have blood drawn for microbiome analyses.
3171217|NCT00584233|Experimental|Breast CT and Breast MRI|Four hundred women who will be having breast biopsy as part of their standard care (BIRADS 4 and 5) will undergo pre- and post- contrast breast computed tomography and pre- and post- contrast magnetic resonance imaging.
3171218|NCT00584298|Experimental|1|
2556117|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 1|HT-100 multiple dose administration (dose 1).
2556122|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 2|HT-100 multiple dose administration (dose 1).
2556128|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 3|HT-100 multiple dose administration (dose 1).
2556132|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 4|HT-100 multiple dose administration (dose 1).
2556135|NCT02525302|Experimental|Cohort 1: HT-100 tablet, Dose 5|HT-100 multiple dose administration (dose 1).
2556284|NCT02524002|Placebo Comparator|Usual Clear Diet|This intervention consists of soup broth, variety of juices (apple, cranberry, grape), ginger ale, water, and ice.
2556285|NCT02524002|Experimental|Accel Gel|"This intervention is an enhanced clear liquid gel is Accel Gel, produced by PacificHealth Labs of Matawan, NJ. This gel has 4:1 carb to protein ratio formula, and ingredients that are not contraindicated in pregnancy (only the flavors with minimal caffeine are used).~http://www.pacifichealthlabs.com/accel-gel-all-natural-rapid-energy-gel-product.html"
2556301|NCT02523768|Experimental|ATG-F|The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
2556303|NCT02523768|Active Comparator|Simulect|The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).
2556432|NCT02523144|Active Comparator|Chloral Hydrate + placebo|Oral chloral hydrate sedation in flavored syrup plus nasal saline placebo
2556436|NCT02523144|Active Comparator|Dexmedetomidine 2mcg/kg + placebo|Nasal dexmedetomidine sedation 2 mcg/kg plus oral flavored syrup placebo
2556437|NCT02523144|Active Comparator|Dexmedetomidine 3mcg/kg + placebo|Nasal dexmedetomidine sedation 3 mcg/kg plus oral flavored syrup placebo
2556777|NCT02520856||Hypertrophic cardiomyopathy|"All patients with newly diagnosed unexplained HCM will be prospectively included.~All patients will undergo both classical genetic analysis and WES technology."
3171219|NCT00584298|Placebo Comparator|2|
3171220|NCT00584311|Experimental|1|All patients (with no structural damage on the plain x-ray) will receive a MRI and Ultrasound (US) of their most involved joint and an asymptomatic joint.
3171221|NCT00584324|Experimental|Bispectral Index (BIS) 40|Target BIS 40
2556934|NCT02519972|Experimental|Low dose computed tomography|All the Low dose computed tomography of lung was performed with 64 slices multidetectors CT in single hold breath covering entire lung. The protocol of scanning parameters (120KVp, 40-80 mA, 1.25 mm or less in thickness) was standardized. The raw data would be reconstructed to axial images (3 mm thickness and interval) and coronal images (3 mm thickness and interval). The scan should be finished in a single breath (15-20 second) from the thoracic inlet to adrenal glands.
2556966|NCT02519608|Active Comparator|Aspirin 100 mg + Clopidogrel 75 mg|dual antiplatelet therapy as suggested by guidelines with aspirin 100 mg and clopidogrel 75 mg daily
2556968|NCT02519608|Experimental|Aspirin 100 mg + Ticagrelor 90 mg x2|dual antiplatelet therapy with aspirin 100 mg and ticagrelor 90 mg x 2 daily
2557058|NCT02518763|Experimental|Vitamin D3, 100 000 IU weekly, 4 times|
2557103|NCT02518607|Experimental|Group 1, Session 1, Active|"Lowest dose of SAD:~MGB-BP-3, 250 mg liquid filled enterically coated capsule, single dose"
2557104|NCT02518607|Experimental|Group 1, Session 2, Active|"Dose Escalation SAD:~MGB-BP-3, 2X250 mg liquid filled enterically coated capsule, single dose"
2557106|NCT02518607|Experimental|Group 1, Session 3, Active|Dose Escalation SAD MGB-BP-3, 3X250 mg liquid filled enterically coated capsules, single dose
2557108|NCT02518607|Experimental|Group 2, Session 1, Active|Dose Escalation SAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules, single dose
2557111|NCT02518607|Experimental|Group 2, Session 2, Active|Dose Escalation SAD MGB-BP-3, 5X250 mg liquid filled enterically coated capsules, single dose
3171222|NCT00584324|Experimental|Bispectral Index (BIS) 60|Target BIS 60
3171223|NCT00584337||1|
3171224|NCT00584337||2|
3171225|NCT00584350|Experimental|A: Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
3171226|NCT00584350|Active Comparator|B: Standard hydratation|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
3171227|NCT00584350|Experimental|C: Hydratation with sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
3171228|NCT00584376|Active Comparator|1|Pregabalin
3171229|NCT00584376|Placebo Comparator|2|Placebo
3171230|NCT00584389|Experimental|1|Rimonabant treatment (20mg/d) for 12 weeks
3171231|NCT00584389|Other|2|Dietary intervention
3171232|NCT00584428|Experimental|1|
3171233|NCT00584441||1|Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
3171234|NCT00584441||2|Women without pre-menstrual asthma
3171235|NCT00584441||3|Women on oral contraceptives
3171236|NCT00584519||500 patients|Patients with diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (DSM-IV TR) with BMI (body mass index) more or equal to 25 Kg/m2
3171237|NCT00584532|Placebo Comparator|A|A=Placebo ARM of Study
3171238|NCT00584532|Active Comparator|B|B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.
3174941|NCT00628550|Experimental|1|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive vasopressin (0.8 units/kg) rescue as the second vasopressor medication.
3205546|NCT00945152|Placebo Comparator|Placebo|Half of the patients in the study will be given a placebo consisting of all ingredients in Vancogel except the active principal Vancomycin in order to compare their clinical efficacy in rate of wound healingafter 1-3 applications
2556100|NCT02525224|Other|Nutritional Supplement|Proprietary nutritional supplement
2556146|NCT02525029|Experimental|1: High-Risk aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has toxicity that meets the definition of dose limiting, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 7. Assess response at day 7:~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.~If no response, the patient will be taken off study treatment."
2556147|NCT02525029|Experimental|2a: Steroid-Dependent aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 5 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
2556148|NCT02525029|Experimental|2b: Steroid-Refractory aGVHD|"Standard of care immunosuppression, plus Pregnyl® (hCG supplementation) at assigned dose subcutaneously every other day for up to 7 doses.~Individual patient dose reductions: If a patient has a toxicity, the patient can drop down one dose level for the next injection and continue treatment. If the patient is enrolled in the phase I component, the event must be reported as a DLT per section section 11. If the same patient experiences a second DLT, the patient will discontinue treatment.~Continue protocol treatment through day 14. Assess response at day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment"
2556184|NCT02524678|Placebo Comparator|Placebo|Placebo
2556185|NCT02524678|Active Comparator|URC102|URC102
2556223|NCT02524535|Other|Therapetic alliance|
2556267|NCT02524236|Active Comparator|Botox 50 IU|"Intervention: Botox 50 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
2556270|NCT02524236|Active Comparator|Botox 100 IU|"Intervention: Botox 100 IU vial will be reconstituted with saline 0.9% to a total volume of 5 ml. All patients will receive five injections of 1 mL of the BoNT-A solution, including two injections in each lateral lobe (one proximal and one distal) and one injection in the median lobe. The injection depth will be 7-10 mm.~Botox injection in the prostate"
2556336|NCT02523950|Active Comparator|Staged group|Procedure/Surgery: Phacoemulsification + IOL implantation is performed in the first stage and DMEK is performed secondarily.
2556338|NCT02523950|Active Comparator|Combined group|Procedure/Surgery: Phacoemulsification + IOL implantation and DMEK are performed simultaneously.
2556362|NCT02523456|Experimental|Introduce EWS and Training on EWS|The group of patients who admitted to a ward where the staff has trained on EWS and EWS has been introduced.
2556363|NCT02523456|No Intervention|EWS not introduced|The group of patients who admitted to a ward where the staff has no special training on EWS and EWS has not been introduced.
2556454|NCT02523209||Bone quality and quantity|measure of bone quality and quantity parameters by HRpQCT and by DEXA
3205547|NCT00945165|Experimental|Exercise|
3205548|NCT00945165|Experimental|No exercise|
2556589|NCT02522039|Experimental|Latanoprost|solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs
2556592|NCT02522039|Experimental|Timolol|solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs
2556597|NCT02522039|Experimental|dorzolamide|solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs
2556602|NCT02522039|No Intervention|Other|no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements
2556650|NCT02521688||Group I (PTD + CP)|include ten mothers exhibiting spontaneous preterm delivery with moderate to severe chronic periodontitis +incisional biopsy from placenta and GCF sample
2556651|NCT02521688||Group II (TD + CP)|include ten mothers exhibiting spontaneous term delivery with moderate to severe chronic periodontitis+incisional biopsy from placenta and GCF sample
2556653|NCT02521688||Group III (PTD + HP)|include tenmothersexhibiting spontaneous preterm delivery with healthy periodontium +incisional biopsy from placenta and GCF sample
2556654|NCT02521688||Group IV (TD + HP)|ten mothersexhibiting spontaneous term delivery with healthy periodontium(Armitage GC. 1999)+ incisional biopsy from placenta and GCF sample
2556698|NCT02521415|Experimental|ketamine|ketamine (1mg/kg)
2556703|NCT02521415|Active Comparator|fentanyl|fentanyl (1.5 micrograms/kg)
2556752|NCT02521064||Exclusive Enteral Nutrition (EEN)|The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
3205549|NCT00945178|Experimental|Part A: A|AZD1386
3205550|NCT00945178|Experimental|Part A: B|Placebo for AZD1386
3205551|NCT00945178|Experimental|Part B: A|Naproxen
3205552|NCT00945178|Experimental|Part B: B|Placebo for Naproxen
2556062|NCT02525484|Experimental|Pirfenidone BADC treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fed state (treatment B) on Day 1, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 4, 801-mg tablet in fasted state (treatment D) on Day 7 and capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 10.
2556064|NCT02525484|Experimental|Pirfenidone CDAB treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 1, 801-mg tablet in fasted state (treatment D) on Day 4, capsules (3 x 267-mg capsule) in fed state (treatment A) on Day 7 and 801-mg tablet in fed state (treatment B) on Day 10.
2556068|NCT02525484|Experimental|Pirfenidone DBCA treatment sequence|Participants will be given 801 mg single oral doses of pirfenidone on Days 1, 4, 7 and 10 during the study. Participants will be administered, 801-mg tablet in fasted state (treatment D) on Day 1 and in fed state (treatment C) on Day 4, capsules (3 x 267-mg capsule) in fasted state (treatment C) on Day 7 and in fed state (treatment A) on Day 10.
2556108|NCT02525315|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
2556154|NCT02524990|Experimental|Home-based follow-up with SQPT|For the intervention, a semiquantitative pregnancy test (SQPT) will be performed at the health center before the participants take mifepristone, and again two weeks later by the participants, at home. Study staff will call the participants at two weeks to follow-up with the participants.
2556179|NCT02524756|Active Comparator|Group (A)|laparoscopic nerve sparing radical hysterectomy type III/C1
2556181|NCT02524756|Active Comparator|Group (B)|laparoscopic radical hysterectomy type III/C2
2556227|NCT02524548|Experimental|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor
2556230|NCT02524548|No Intervention|Standard care|Routine care
3205553|NCT00945204|Experimental|access to intermediate care clinics|
3205554|NCT00945204|No Intervention|usual care|
2556424|NCT02523105|Other|Participants diagnosed with depression.|EEG monitoring and evaluation
2556426|NCT02523105|Other|Healthy participants.|EEG monitoring and evaluation
2556480|NCT02522819|Experimental|obstructive sleep apnea in the acute phase of stroke|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke
3205555|NCT00945217||Postmenopausal women|women with natural menopause
3205556|NCT00945230|Experimental|Actigraphic Neurosurgical Outcomes|Actigraphic measurements that will be obtained by attaching the actigraphic watch device to the individual's non-dominant wrist and operationally defined repeated observational measurements. All measurements will continue through a baseline period and continue through the identified post surgical period. Actigraphic measurements will occur every 30 seconds with brief periods of non-measurement during the actual neurosurgical procedure and periods when the actigraphic device has reached storage capacity (approximately every 22 days) when data is retrieved and the device prepared resume measurements.
2556610|NCT02521961|Experimental|Arm I (support group sessions)|Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
2556611|NCT02521961|Active Comparator|Arm II (control)|Participants receive one phone call to arrange a follow-up with the promotora, a note acknowledging their participation in the study, and a community resource booklet. Participants are then yoked into one of the 3 intervention groups and asked to attend a 30 minute session similar to Arm I.
2556683|NCT02521597|Experimental|Cellscope|The intervention for this study will be the use of a smartphone otoscope attachment called CellScope Oto.
2556692|NCT02521597|Active Comparator|Traditional otoscope|The control group will be using a classic otoscope
2556719|NCT02521220|Experimental|L-citrulline|Oral food-supplemental amino-acid L-citrulline. 2 times 3g per day.
2556720|NCT02521220|Placebo Comparator|Maltodextrin|Maltodextrin as placebo. 2 times 3g per day
2556818|NCT02520739|Placebo Comparator|Virgin Olive Oil|Virgin olive oil obtained by traditional procedures (VOO);
2556820|NCT02520739|Experimental|Optimized High Phenolic Content Oil|Optimized virgin olive oil with a high phenolic content (OHPCO);
2556823|NCT02520739|Experimental|Functional Olive Oil|Functional olive oil (FOO) with both high phenolic compounds and triterpene content.
3205557|NCT00945269|Experimental|Treatment (cellular adoptive immunotherapy)|Patients receive autologous T-cell IV over 30-60 minutes on days 0 and 28 and low-dose aldesleukin SC twice daily on days 0 to 13 and 28 to 41. Beginning 4-6 days before second T-cell infusion, patients receive denileukin diftitox IV over 30 minutes on days 1-3.
2556914|NCT02519894|Experimental|Intervention group|Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
2556922|NCT02519894|Placebo Comparator|Controlled group|Standard education
3205558|NCT00945308|Active Comparator|Eptifibatide (intracoronary)|
2557006|NCT02519192|Experimental|VAC Arm, Vac sponge irrigations|For patients who fall under the VAC arm, a physician will do the initial placement of the wound VAC (V.A.C.Ulta™ Negative Pressure Wound Therapy System) at the patient's bedside. An information sheet will be provided to the patient, and the patient will be taught how to irrigate the sponge system independently. While inpatient, nursing will perform VAC sponge irrigation.
2557007|NCT02519192|Active Comparator|NonVac, ostomy bag, wet to dry dressings|For patients who fall under the non-VAC arm, a physician or wound care nurse will perform the initial application of the ostomy bag or wet to dry dressing change. An information sheet will be provided to the patient. While inpatient, members from the nursing or physician team will perform ostomy bag application and ostomy dressing changes.
3205559|NCT00945308|Active Comparator|Eptifibatide (intravenous)|
3205560|NCT00945347|No Intervention|Baseline|Visit 1
3205561|NCT00945347|Active Comparator|Miglustat|Nasal instillation of Miglustat (visit 2 or 3)
3205562|NCT00945347|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
2556071|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Right Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
2556072|NCT02525510|Active Comparator|Pump Eligible - Hypothermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
2556073|NCT02525510|Active Comparator|Not Pump Eligible - Normothermia|Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
2556074|NCT02525510|Active Comparator|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
2556171|NCT02524964|Experimental|sodium tanshinone IIA sulfonate|sodium tanshinone IIA sulfonate (80 mg q.d. for 7 days)
2556173|NCT02524964|Sham Comparator|control|same volume/day of normal saline.
2556224|NCT02524574|Experimental|cardiac Rehabilitation|
2556274|NCT02524210|Experimental|Arm A|"Period  Dabigatran~Washout period (at least 6 days)~Period  Rabeprazole + Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
2556275|NCT02524210|Experimental|Arm B|"Period Rabeprazole + Dabigatran ~Washout period (at least 6 days)~Period  Dabigatran~Washout period (at least 6 days)~Period  Omeprazole + Dabigatran"
2556276|NCT02524210|Experimental|Arm C|"Period  Rabeprazole + Dabigatran~Period  Omeprazole + Dabigatran~Period  Dabigatran"
2556304|NCT02523833|Other|Chronic HP patients|Chronic hypersensitivity pneumonitis patients - use of salbutamol
2556365|NCT02523625||Healthy volunteers|Age and gender matched to patient groups to undergo ultrasound of temporal and axillary arteries
2556367|NCT02523625||Patients with headache|Patients with new headache not due to GCA to undergo ultrasound of temporal and axillary arteries
2556371|NCT02523625||Patients with GCA (new)|Patients with new diagnosis of GCA to undergo ultrasound of temporal and axillary arteries
2556374|NCT02523625||Patients with GCA (flare)|Patients with apparent flare of GCA to undergo ultrasound of temporal and axillary arteries
2556395|NCT02523183||Subjects with medically refractory epilepsy|Pediatric epilepsy patients who are followed at Children's Hospital Colorado with medically refractory epilepsy, and whom the family has decided to treat with medical cannabis.
2556483|NCT02522988|Experimental|Group 1a|During the first 3-week period of the study, Group 1 will serve as the experimental arm and will receive the open-label placebo intervention. Group 1 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
2556489|NCT02522988|No Intervention|Group 2a|During the first 3-week period of the study, Group 2 will serve as the comparator arm.
2556493|NCT02522988|No Intervention|Group 1b|During the last 3-week period of the study, Group 1 will serve as the comparator arm.
2556499|NCT02522988|Experimental|Group 2b|During the last 3-week period of the study, Group 2 will serve as the experimental arm and will receive the open-label placebo intervention.Group 2 participants will take 2 placebos in the morning and 2 placebos in the evening for 21 days.
2556512|NCT02522390||Nutrition Researcher Cohort|This cohort study is an observational, one-group study. The intervention consists of research activities that participants are asked to perform throughout the cohort, including the use of do-it-yourself devices, filling out online-questionnaires and sample collection with supplied kits for the analysis of various health parameters. The frequency with which participants are asked to measure these health parameters varies, ranging from once to weekly.
3171239|NCT00584571|Active Comparator|Sensory Adaptation training|a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
3171240|NCT00584571|Experimental|Escitalopram Therapy|Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.
2557097|NCT02518412|Experimental|Active tDCS|Participants receive active tDCS stimulation. Half of the participants receive active tDCS stimulation, i.e 30 minutes active stimulation of the temporal cortex.
2557100|NCT02518412|Placebo Comparator|Placebo tDCS|Participants receive placebo tDCS stimulation. Half of the participants receive placebo tDCS stimulation, i.e 30 minutes inactive stimulation of the temporal cortex.
2557159|NCT02518243|Experimental|Alzheimer's Disease|
2557221|NCT02517983||Chronic respiratory disease|
2557258|NCT02517606|Experimental|Conventional physical therapy plus HPCS|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization) plus the addition of hip posterolateral complex strengthening (HPCS)
2557261|NCT02517606|Active Comparator|Conventional physical therapy|Conventional physical therapy (Combination of manual therapy techniques and exercises for spinal segmental stabilization)
2557448|NCT02516319|Active Comparator|Serial Blood Draws|Cohorts 3 and 4 - weight based doses of ICG dye followed by serial blood draws at 5, 10, 15 and 20 minutes post ICG injection.
3171241|NCT00584584|Experimental|1|
3171242|NCT00584584|Placebo Comparator|2|
3171243|NCT00584597|Placebo Comparator|1|Saline
3171244|NCT00584597|Experimental|2|Traumeel S 1 mL
3171245|NCT00584597|Experimental|3|Traumeel S 2 mL
3171246|NCT00584597|Experimental|4|Traumeel S 3 mL
3171247|NCT00584610|Experimental|1|Levonorgestrel-containing intrauterine device insertion
3171248|NCT00584610|Active Comparator|2|Copper containing intrauterine device
3171249|NCT00584636|Experimental|Pulmicort Respules|using pulmicort respules
3171250|NCT00584649|Other|Single Group Assignment|electrophysiology study and radiofrequency ablation
3171251|NCT00584662|Active Comparator|1|Oxymetazoline Hydrochloride
3171252|NCT00584753|Other|1|Normal volunteers
3171253|NCT00584753|Active Comparator|2|Breast PET/CT scan
3171254|NCT00584753|Active Comparator|3|Whole body and breast PET/CT
3171255|NCT00584766|Experimental|1|
3171256|NCT00584779|Experimental|1|
3171257|NCT00584779|Experimental|2|
2556308|NCT02523859|Active Comparator|Propofol|Propofol for induction will be given as a bolus administered manually at 2.0-2.5 mg/kg slowly over approximately 1 minute. Immediately after the propofol bolus for induction has been given, propofol maintenance will be started at a dose of 3.0-9.0 mg/kg/hr and adjusted as needed.
2556312|NCT02523859|Experimental|Remimazolam|Remimazolam for induction will be given at 6.0 mg/kg/hr, which can be increased to 12.0 mg/kg/hr for one minute if loss of consciousness is not reached after 3 minutes. Immediately after the remimazolam dose for induction has been given, remimazolam maintenance will be given at 1.0 mg/kg/hr and adjusted by down-titration or up-titration to a maximum of 3.0 mg/kg/hr.
2556370|NCT02523651|Experimental|DPSC injection|20 patients will receive DPSC injection（1000000 cells/ 0.5ml） at the local periodontal defects immediately after periodontal scaling and root planing.
2556373|NCT02523651|Placebo Comparator|Placebo control|20 patients will receive saline injection at the local periodontal defects immediately after periodontal scaling and root planing.
2556425|NCT02523170|Experimental|EUS guided nCLE|For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
3171258|NCT00584779|Experimental|3|
3171259|NCT00584779|Experimental|4|
2556798|NCT02520687|Experimental|Dietary nitrate, beetroot juice|Once daily 70mL dose of beetroot juice, containing 400mg inorganic nitrate, for 7 consecutive days.
2556800|NCT02520687|Placebo Comparator|Nitrate-depleted beetroot juice|Once daily 70mL dose of beetroot juice, depleted of nitrate, for 7 consecutive days.
2556849|NCT02520505|Other|Expectant Management: Timed Intercourse|Patients randomized to expectant management will be counseled on timed intercourse and the window in which intercourse should be performed during the randomization phone call. Patients will be encouraged to contact their fertility doctor and the primary investigator if they become pregnant and an estimated date of confinement will be calculated based upon the patient's last menstrual period. Patients will also be notified that they will be contacted at the end of the six month timeframe to inquire as to whether or not they became pregnant.
2556859|NCT02520505|Active Comparator|Supraovulation + IUI|Women randomized to super ovulation (SO) will be treated according to a standard protocol under the care of their staff physician and fertility nurses. The patient will be treated with 100mg/day of clomiphene citrate starting on day 3 of the menstrual cycle and ending on day 7. Intrauterine insemination will be performed 36 hours after the hCG surge (follicle rupture) by inserting a catheter through the cervix of the patient in dorsal lithotomy position.
2557057|NCT02518815|Experimental|Prewarming group|Prewarmed for 20 minutes prior to OR using 3M Bair Paws System, a forced air warming blanket. This warming blanket was then used intraoperatively throughout the case.
2557061|NCT02518815|No Intervention|Control group|Patients received standard care, which is no active prewarming prior to OR. A full body, forced air warming blanket (same as treatment group) was used intraoperatively throughout the case.
2557105|NCT02518568|Experimental|Drug|
2557155|NCT02518256|Other|(Suspected) Ovarian Epithelial Cancer|Lavage of the Cavum uteri and proximal fallopian tubes
2557246|NCT02517918|Experimental|Sirolimus combined with CP, MT and ZA|Drug : Metronomic Cyclophosphamide, Methotrexate, Sirolimus, Zoledronic acid Assessment of the maximum tolerated dose of sirolimus Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
2557417|NCT02516787|Other|EEG and NIRS measurements|
3171260|NCT00584792||1|Controls (No prostate cancer)
3171261|NCT00584792||2|Cases (Prostate Cancer Diagnosed)
3171262|NCT00584883|Experimental|ABT 510|The only arm will receive the ABT 510 following standard therapy with radiation and temozolomide chemotherapy concurrent.
3171263|NCT00584961||600 patients|Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
3171264|NCT00584974|Experimental|0.5 mg SEP-225289|0.5 mg SEP-225289
3171265|NCT00584974|Experimental|2.0 mg of SEP-225289|2.0 mg of SEP-225289
3171266|NCT00584974|Active Comparator|Venlafaxine|150 mg Venlafaxine
3171267|NCT00584974|Placebo Comparator|Placebo|placebo
3171268|NCT00585000|Experimental|1|
3171269|NCT00585065||1|
3171270|NCT00585091|Other|A|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
3171271|NCT00585117|Experimental|1 CNS|imaging with CuATSM
3171272|NCT00585117|Experimental|2. Head and Neck|Imaging with CuATSM
3171273|NCT00585117|Experimental|3. Lung|imaging with CuATSM
3171274|NCT00585117|Experimental|4. Prostate|PET imaging with CuATSM
3171275|NCT00585117|Experimental|5. Esophagus|PET imaging with CuATSM
3171276|NCT00585143|Experimental|1|
3171277|NCT00585156|Experimental|Arm #1|Celebrex treatment group
3171278|NCT00585208|Active Comparator|Active drug|Ramelteon - this group receives active drug at a fixed dose of 8mg daily throughout study
3171279|NCT00585208|Placebo Comparator|Placebo (sugar pill)|placebo (sugar pill) - this arm receive the fake pill, also know as placebo or the sugar pill
3171280|NCT00585234||1|We intend to photograph male and female subjects from age 1 through skeletal maturity. Healthy children will be photographed to determine the normative characteristics of thoracic function using this technique. We will also enroll patients with thoracic pathology to determine how digital imaging can document thoracic dysfunction. There are no specific disease related exclusion criteria. Participation is voluntary.
3171281|NCT00585260|Experimental|Exploratory Mannitol|This is an exploratory / ancillary study open to all participants in the BASALT trial [NCT00495157] who consented to undergo mannitol bronchoprovocation procedures during the 36 week treatment period
3171282|NCT00585273||1|Incident users of antipsychotics.
3171283|NCT00585273||2|Non-users of antipsychotics
3171284|NCT00585299|Experimental|Low-fat diet|20% kcals from fat diet followed for 8 weeks then 8 weeks of maintenance diet with visits to dietitian every other week
3171285|NCT00585299|Active Comparator|Traditional|Traditional low-fat diet given and dietitian follows up in 16 weeks
3171286|NCT00585338|Experimental|Tandem 532/1064 nm Laser|Treatment of Vascular LesionsWith a Tandem 532/1064 nm Laser
2556126|NCT02525289|Active Comparator|Bed Rotation Group|six hours after extubation receiving breathing exercises and submitted the continuous rotational bed therapy in the first postoperative day until 48 hours.
2556129|NCT02525289|Active Comparator|Orthostatic Group|six hours after extubation receiving breathing exercises and changing the body position following the sequence: sitting on the bed, sitting on the bed with the feet on the floor , standing and walking in the same place, in the first postoperative day until 48 hours.
3205563|NCT00945360|Experimental|aromatase inhibitors: Letrozole|All consenting patients will be started on Letrozole at a dose of 2.5 mg/day for 8 weeks.
2556253|NCT02524366|Experimental|Transcorporal AUS|The artificial urinary sphincter is placed through the tunica albuginea of the corpora cavernosa in order to theoretically provide a protective backing on the urethra.
2556255|NCT02524366|Active Comparator|Standard AUS|The artificial urinary sphincter is placed in the standard fashion.
2556281|NCT02524015|Other|Control|Standard Physical Therapy
2556282|NCT02524015|Experimental|Intervention|Novel Physical Therapy
2556295|NCT02523820|Experimental|fluticasone propionate|Fluticasone 1 mg + Normal saline (NSS) upto 4 ml nebulized after extubation
2556297|NCT02523820|Placebo Comparator|placebo|Normal saline (NSS) 4 ml nebulized after extubation
2556355|NCT02523703|Other|Healthy Volunteers|Healthy Volunteers
2556357|NCT02523703|Other|Multiple Sclerosis patient|Multiple Sclerosis patient
2556378|NCT02523287|Active Comparator|Fluad - 5 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
2556379|NCT02523287|Active Comparator|Fluad - 3 study visits (114 subjects)|"0,5 ml adjuvanted, subunit seasonal trivalent influenza vaccine (2014-2015). Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
2556380|NCT02523287|Placebo Comparator|Saline - 5 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~5 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 3 (blood sampling), Day 7 (blood sampling), Day 21 (blood sampling)."
2556382|NCT02523287|Placebo Comparator|Saline - 3 study visits (6 subjects)|"0,5 ml saline. Administration: Intramuscular, deltoid.~3 out-patient visits: Day 0 (blood sampling, vaccination), Day 1 (blood sampling), Day 7 (blood sampling). On day 21 there's a phone call for safety follow-up."
2556438|NCT02523092|Experimental|Acthar gel|After a 4-week period of baseline monitoring, Acthar gel will be administered by intramuscular or subcutaneous injection. Initial dosing will be 40 U every 72 hours (or twice per week) for 4 weeks. Dosage will then be increased to 80 U with similar frequency for 8 weeks and up to 16 weeks.
2556484|NCT02522754|Placebo Comparator|Placebo|Placebo
2556487|NCT02522754|Experimental|Protesomal Vaccine 1 x 30 µg|Protesomal Vaccine 1 x 30 µg
2556494|NCT02522754|Experimental|Protesomal Vaccine 2 x 30 µg|Protesomal Vaccine 2 x 30 µg
2556500|NCT02522754|Experimental|Protesomal Vaccine 2 x 15 µg|Protesomal Vaccine 2 x 15 µg
2556522|NCT02522364|Active Comparator|BioMonitor|Participants randomized for this arm will be implanted with a BioMonitor device an implantable loop recorder inserted under the skin in the region of the thorax. It continuously records heart rhythm for a period of up to 7 years. The device will be interrogated at 1 month intervals. All arrhythmic events and conductive disturbances will be noted. In addition will be followed as specified in the standard arm
2556525|NCT02522364|Active Comparator|Standard|Participants randomized for this arm will be followed by biannual office visits initialing clinical evaluation, review of clinical events, review and update of medical therapy. Participants will undergo ECG holter examination at 3 and 6 months after discharge
2556568|NCT02522143|Sham Comparator|Informational Sessions|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
2556571|NCT02522143|Experimental|Condensed-DBT treatment intervention|Condensed-DBT treatment intervention includes all DBT components, tailored to students.
2556622|NCT02521909||Tooth Extraction|Intervention is Tooth Extraction for Assessment of Different Apex Locators. All people in the study will contribute one or more teeth, which will be extracted for other clinical purposes, for device comparative testing
2556665|NCT02521558|Experimental|Intervention Group|In the Intervention Group, patients will receive an iPad with the Constant Therapy cognitive rehabilitation application. Patients in the Intervention Group will practice the memory tasks developed for the Constant Therapy application for a total of six months. On a weekly basis, a clinician and/or research assistant will check in with the patient to answer any questions or address any concerns the patient has with using the Constant Therapy application, or how to perform any of the memory tasks. At the end of six months, each individual in the Intervention Group is assessed with standard cognitive testing to determine if there was any change on overall cognition.
2556666|NCT02521558|Active Comparator|Control Group|The Control Group will not receive any intervention. The Control Group will be given simple sets of puzzle booklets to practice over the 6 month period (e.g., word search puzzles, number and/or math puzzles). The Control Group will also receive standardized cognitive testing at the end of 6 months. Weekly check-ins by a clinician and/or research assistant will also occur in the Control Group. Every 4th patient recruited for the study will be assigned to the Control Group.
2556714|NCT02521298|Active Comparator|Strength Training + Placebo|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Placebo: Ultrasound-guided subcutaneous injection of 2 ml isotonic saline over the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
2556764|NCT02520934|Experimental|Case_Miglustat|Besides regular ERT, patients in this group also need to take Miglustat for 24 months.
2556767|NCT02520934|No Intervention|Control|Patients will be tested for their pupil cycle time.
3205564|NCT00945373|Experimental|Erythematotelangiectatic Rosacea|2.5% gel calcium dobesilate and pulsed dye laser
3205565|NCT00945399|Experimental|Autologous Chondrocytes Implantation|
3205566|NCT00945399|Active Comparator|Microfracture|
3205567|NCT00945412|Experimental|Micropolysaccharide Hemospheres (MPH)|
2556410|NCT02523365|Experimental|HepaSphere|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2556415|NCT02523365|Placebo Comparator|control|cervical carcinoma patients received traditional therapy
3205568|NCT00945412|Active Comparator|Electrocautery|
2556552|NCT02522234|Experimental|F-627 240 µg/kg|"F-627 at the dose of 240 mcg/kg administered by s.c. injection on Day 2 of each cycle for up to 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
2556555|NCT02522234|Experimental|F-627 320 µg/kg|"F-627 at the dose of 320 mcg/kg administered by s.c. injection on Day 2 of each cycle for 6 cycles.~Chemotherapy (docetaxol, doxorubicin and cyclophosphamide) administered by intravenous injection on Day 1 of each cycle for up to 6 cycles."
2556586|NCT02521987|Active Comparator|8mm Port|Participates will be randomized to have an 8 mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
2556590|NCT02521987|Experimental|12mm Port|Participates will be randomized to have an 12mm assistant port used during their surgery. The participate will be asked to specify the point that represents their level of perceived pain intensity and mark it on the scale at four time points: baseline pain prior to the procedure in the pre-operatively holding area, 4 to 6 hours post operatively, on Post Operative Day 1 (POD1). The final pain assessment will be at the two weeks postoperative clinic visit.
2556624|NCT02521714|Experimental|Treatment A: 25mg capsule -under fasted condition|Single oral dose of 25mg lenalidomide (reference formulation, 1 x 25mg capsule) under fasted condition.
2556626|NCT02521714|Experimental|Treatment B: 25mg oral suspension - under fasted condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fasted condition.
2556631|NCT02521714|Experimental|Treatment C: 25mg oral suspension -under fed condition|Single oral dose of 25mg lenalidomide (test formulation, 2.5mL oral suspension) under fed condition.
2556678|NCT02521519|Other|One side of the patient's back|medial branch block (MBB): Using sterile conditions, 25 gauge needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
2556687|NCT02521519|Other|Other side of the patient's back|These injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
2556744|NCT02521207|Experimental|Part 1 OXP001|OXP001 formulation containing 800mg ibuprofen single dose
2556746|NCT02521207|Active Comparator|Part 1 Ibuprofen control|Ibuprofen control 800mg single dose
2556747|NCT02521207|Experimental|Part 2 OXP001|OXP001 formulation containing 800mg ibuprofen three times per day
2556748|NCT02521207|Experimental|Part 2 Ibuprofen control|Ibuprofen control 800mg three times per day
2556804|NCT02520869|Active Comparator|swim-up|swim-up technique for semen processing
2556807|NCT02520869|Active Comparator|zeta test|zeta test technique for semen processing
2556834|NCT02520375|Experimental|Prebiotic|This group will be administered a prebiotic mouthrinse and toothpaste
2556835|NCT02520375|Placebo Comparator|Control|This group will be administered a control mouthrinse and toothpaste
2556884|NCT02520193|No Intervention|Standard mobilization strategy|
2556888|NCT02520193|Experimental|protocolized early mobilization strategy|
2556915|NCT02519816|Experimental|Intervention|Open-label phase II study. After signing informed consent, patients will undergo 6 times an apheresis during the 6-month treatment period. These cells will be manufactured into the Rhitol and frozen in aliquots. Then re-infused.
2556956|NCT02519699|Experimental|Norepinephrine|Noradrenaline continuous infusion IV
3205569|NCT00945425|Experimental|1|Low dose or placebo, twice daily
3205570|NCT00945425|Experimental|2|Low dose or placebo, once daily
3205571|NCT00945425|Experimental|3|Middle dose or placebo, twice daily
3205572|NCT00945425|Experimental|4|High dose or placebo, once daily
3205573|NCT00945438|Experimental|Group 1|Participants aged 18 to 59 years at enrollment.
3205574|NCT00945438|Experimental|Group 2|Participants aged 60 years or older at enrollment.
3205575|NCT00945451|Experimental|CyberKnife irradiation|
3205576|NCT00945464||No treatment|Women over the age of 30 undergoing breast imaging at the Scripps Polster Breast Care Center.
3205577|NCT00945490|Experimental|NX-1207|
3205578|NCT00945490|Placebo Comparator|Placebo|
3205579|NCT00945503|Experimental|GSK1018921|All subjects will received a dose of GSK1018921 and will peforme three PET scans using the ligand [11C]GSK931145, but in order to obtain adequate sampling of the exposure-time-occupancy curves, a range of doses will be evaluated, and the timing of the post-dose scans will differ between subjects.
3205580|NCT00945516|Active Comparator|Flared end FCSEMS|Flared end FCSEMS will be inserted for the benign bile duct stricture.
3205581|NCT00945516|Active Comparator|Anchoring FCSEMS|Anchoring FCSEMS will be inserted for benign bile duct stricture
3208805|NCT00978263|Experimental|Glargine|Initial basal Insulin therapy was according to the dose administrated at bedtime in the last day hospitalization. basal Insulin doses were titrated every 3 days to achieve target FPG values between 80 and 130 mg/dl.
2556193|NCT02524795|Experimental|Hiomega-3 supplement|"Patients in the study group received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company). Participants were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
2556194|NCT02524795|No Intervention|Control group|"Patients in the control group did not receive the nutrient nor any kind of placebo. They were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment.~Variables measured at each visit included: disease activity index, using the Systemic Lupus Disease Activity Index (SLEDAI-2k)16; damage index (Systemic Lupus International Collaboration Clinics/American College of Rheumatology damage index - SLICC/ACR)17; fasting lipid and glucose proﬁle; standard laboratory tests to assess SLE ; cytokines (IL-6, IL-10), adipokines (leptin, adiponectin) C-reactive protein (CRP), nutritional assessment, and in use medications."
2556228|NCT02524457||Premenopausal|Premenopausal women going through gynecological surgery
2556231|NCT02524457||Postmenopausal|Postemnopausal women going through gynecological surgery
2556234|NCT02524457||Postmenopausal + HT|Postmenopausal women going through gynecological surgery who has been taking hormone treatment through the past year (as a minimum)
2556294|NCT02524132|Experimental|Physical Activity|5 minute movement breaks
2556339|NCT02523742|Other|Neuropsychiatric Disorders|Neuropsychiatric Disorders patients
2556340|NCT02523742|Other|Healthy volunteers|control subjects matched to patients by age, sex, socio-cultural level and laterality
2556429|NCT02523027|Experimental|Experimental Group 1:|Oral nutritional supplement (List No S691/Z0) and dietary counseling
2556431|NCT02523027|Experimental|Experimental Group 2|Oral nutritional supplement (List No- P968/Z0) and dietary counseling.
2556435|NCT02523027|No Intervention|Control Group|Dietary Counselling only.
3205582|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
2556637|NCT02521883|Active Comparator|Device: Sooma tDCS|The active group will receive active Sooma tDCS treatment for the first three weeks followed by maintenance treatments at weeks 5 and 6.
2556642|NCT02521883|Placebo Comparator|Device: Sham tDCS|The placebo group will receive sham tDCS treatment for the first three weeks followed by sham maintenance treatments at weeks 5 and 6.
2556702|NCT02521480|Active Comparator|Active Transcranial Magnetic Stimulation|During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression.
2556705|NCT02521480|Sham Comparator|Sham Transcranial Magnetic Stimulation|During sham TMS, a coil will be placed on the left prefrontal area of the head. Sham TMS will simulate active treatment as described in active arm.
2556750|NCT02521155|Experimental|Intervention group|Safeguard Your Smile an oral health literacy intervention.
2556751|NCT02521155|No Intervention|Control group|No intervention, only a conventional pamphlet will be given.
2556806|NCT02520830|Active Comparator|Blueberry Group|Dietary Supplement: 22 gram freeze-dried blueberry powder per day
2556809|NCT02520830|Placebo Comparator|Placebo Group|blueberry polyphenol deprived powder 22 gram per day
2556855|NCT02520362||Postmenopausal Women|Postmenopausal Women
2556864|NCT02520362||Women with post menopausal osteoporosis|Women with post menopausal osteoporosis
2556871|NCT02520362||Prolia for unapproved indications|Patients who receive Prolia for unapproved indications
2556878|NCT02520362||Men with osteoporosis|Men with osteoporosis treated with denosumab
2556903|NCT02519998||Concussed patients|The clinical focus of this study will be on concussed athletes, both children and adults, and we will also include non-sports patients who have mild traumatic brain injury due to other situations including slip and fall, occupational, motor vehicle accidents, assault, and blast exposure.
2556904|NCT02519998||Non-concussed patients|Cohort control. Primarily athletes who undergo routine pre-season baseline assessment
2556947|NCT02519725|Active Comparator|With diary|a ICU diary is open by staff for the patient and his relatives during the ICU stay
2556951|NCT02519725|No Intervention|Without diary|No diary is open during the ICU stay
2556981|NCT02519478|Experimental|Helmetless Tackling Training (HuTT)|The HuTT program is modeled after a tackling drill progression common to the sports of rugby and American football, but participants do not wear helmets or should pads as they normally would in football. Drills will be executed at 50%-75% effort. The goal of the contact is to execute proper technique. Drills will be supervised at all times and feedback will be provided to confirm proper technique and correct improper technique. The HuTT drill will be completed in two phases and takes approximately 6-10 minutes per session. A research assistant will ensure adherence and standardization of the treatment throughout the season. Subjects in the intervention group will participate in HuTT 4 times per week throughout the 2 weeks of pre-season and 2 times a week during in-season.
2556983|NCT02519478|No Intervention|Control|Control group subjects participate in normal football activities as they would normally have during a football season
3208806|NCT00978263|Experimental|metformin-based Oral Antidiabetic Drugs|Subject in metformin-based OAD group was visited every two weeks in the first month and the every four weeks for another five months. The subjects will start with Metformin 425mg bid, The dosage was titrated (up to 850mg bid) based on the fasting blood glucose every two weeks. If the patients fail to achieve the target, gliclazide-MR (Diamicron, Servier), or glimepiride (Amaryl, Sanofi-Aventis) would be added.
3208807|NCT00978302|Placebo Comparator|Placebo (vehicle)|
2556197|NCT02524743|Active Comparator|Group II|"For pretreatment the patients were administered IV acetaminophen 50 mg~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
2556199|NCT02524743|Active Comparator|Group III|"For pretreatment the patients were administered IV acetaminophen 25 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
2556202|NCT02524743|Active Comparator|Group IV|"For pretreatment the patients were administered IV lidocaine 20 mg~The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
2556205|NCT02524743|Active Comparator|Group V|"For pretreatment the patients were administered IV lidocaine 40 mg.~A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes, The infusion was stopped and the arm with the IV line was elevated for 15 seconds for gravity drainage of venous blood. The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm. During and after the injection of rocuromum, pain was graded with four point scale (TEST 1) and withdrawal movement was evaluated (TEST 2) by the study-blinded investigator"
2556246|NCT02524392|Experimental|Independent medical evaluation|Independent medical evaluation (IME) of another doctor than the treating general practitioner.
2556248|NCT02524392|No Intervention|Treatment as usual|Treatment as usual by the treating general practitioner. There will be one randomized control group in one county. Sick-listed in other counties serve as an extra control group.
3205583|NCT00945542|Experimental|Preemptive transfusion|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. This corresponds to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
3208808|NCT00978302|Experimental|Avotermin|
3208809|NCT00978315|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
2556348|NCT02523560|Experimental|telerehabilitation group|1 week hospital rehabilitation and 8 weeks home-based telerehabilitation and telemanagement (including HomeMonitoring)
2556350|NCT02523560|No Intervention|control group|Patients qualified to the control group will undergo a 9-week procedure appropriate to their clinical condition/status standardized for a particular center (usual care).
2556481|NCT02522702||Routine colonoscopy Cohort|
3208810|NCT00978315|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
2556614|NCT02521831|Active Comparator|General Anesthesia|"Inhalational anesthesia with Isoflurane 1-2% in 50%/50% oxygen/air mixture.~This arm will receive the General Anesthesia (isoflurane) intervention exclusively."
2556616|NCT02521831|Active Comparator|Spinal Anesthesia|"These infants will not receive any anesthetic gas prior to the spinal. These infants will be conscious for this procedure.~Spinal will be administered, containing 0.25% isobaric bupivacaine, 1 mg/kg (maximum 5mg), Clonidine, 1 µg/kg, and Epinephrine, 1:200,000.~This arm will receive the Spinal Anesthesia (bupivacaine) intervention exclusively."
2556679|NCT02521649|Experimental|10µg, Stage I-III|10µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
2556689|NCT02521649|Experimental|100µg, Stage I-III|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
2556693|NCT02521649|Experimental|250µg, Stage I-III|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
2556696|NCT02521649|Experimental|100µg, Stage IV|100µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
2556700|NCT02521649|Experimental|250µg, Stage IV|250µg/0.2 mL dose of G17DT administered at Weeks 0,2, and 6 with an option of a 125µg/0.1 mL dose of G17DT administered at Week 12 based on measured antibody titer.
2556760|NCT02521129|Experimental|Ablation|Intervention: ablation of biopsy needle track with a new device
2556830|NCT02520791|Experimental|Treatment (MEDI-570)|Patients receive anti-ICOS monoclonal antibody MEDI-570 IV over 1-4 hours on day 1. Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
2556206|NCT02524704||CF patients with pulmonary exacerbation|"Subjects with CF between the ages of 8 and 21 who are being started on intravenous (IV) antibiotics for a clinically diagnosed pulmonary exacerbation.~Electrical impedance tomography data data will be collected during tidal breathing, during 5 to 10 seconds of breath holding, during FEV1 and FEF 25-75 spirometry maneuvers upon admission for a pulmonary exacerbation and following 7 to 14 days hospitalized treatment including IV antibiotics. Further data will be collected at the same time with CT scanning if the scan is part of the patient's standard of care."
2556238|NCT02524431|Active Comparator|Glaucoma subjects|During glaucoma surgery, collection of trabecular meshwork tissue during surgery that is not needed is cut away from the surgical site. The physician will keep this tissue for analysis by the researchers at Wills Eye Hospital and Thomas Jefferson University Center for Translational Medicine.
2556240|NCT02524431|Active Comparator|Control cadaver eyes|control cadaver eye are ordered and the collection of trabecular meshwork tissue during surgery and is processed at Thomas Jefferson University
3205584|NCT00945568|Experimental|Aminolaban EN|Aminoleban EN™ was administered at a dose of 100 g per day commencing two weeks prior to surgery. A 100 g dose of Aminoleban EN™ contains 13.0 g of free amino acids, 13.0 g of gelatin hydrolysate, 1.0 g of casein, 62.1 g of carbohydrate, 7.0 g of lipid, glycyrrhizin, and other components, producing 420 kcal. The AEN group included 40 patients who were administered 100 g of Aminoleban EN™ as 50 g during the day and 50 g as a late evening snack.
2556386|NCT02523417|Experimental|HepaSphere|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2556388|NCT02523417|Placebo Comparator|control|breast cancer patients received traditional therapy
2556434|NCT02523066||Mitral Valve or Aortic Valve Replancement|One-arm group
2556482|NCT02522832|Experimental|Titre 1|Low infectious titre of innoculum
2556490|NCT02522832|Experimental|Titre 2|Medium infectious titre of innoculum
2556497|NCT02522832|Experimental|Titre 3|High infectious titre of innoculum
3205585|NCT00945568|No Intervention|Control|The patients were divided into two groups including one group administered Aminoleban (the AEN group) and a control group given no additional dietary supplementation. The total caloric energy intake per day during the study period was assumed to be equal to Aminolaban EN group.
3205586|NCT00945581|Experimental|AN777|Powder twice a day
2556569|NCT02522078|Active Comparator|Dry Misoprostol|400 µg of dry misoprostol
2556572|NCT02522078|Experimental|Wet misoprostol|400 µg of wet misoprostol
2556620|NCT02521896|Experimental|Steerable sheath for intracardiac access|Vado Steerable sheath system consisting of a dilator and steerable sheath for left atrial access, positioning of ablation catheters and placement of mapping and ablation catheters for circumferential ablation
2556745|NCT02521272|Experimental|air pocket|Breathing in the simulated avalanche snow.
2556778|NCT02520908||HSCT|Patients with an available sibling or 10/10 HLA-matched unrelated donor who undergo reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation (HSCT), will be included in the study. The reduced-intensity conditioning usually includes Fludarabine 90 mg/m2 IV and Melphalan 140 mg/m2 IV. As usual care, patients will receive peripheral blood stem cells from their sibling donor if available, otherwise from their 10/10 HLA-matched unrelated donor
2556779|NCT02520908||Standard care|Patients with no available sibling or 10/10 HLA-matched unrelated donor who therefore do not receive allogeneic HSCT but receive best standard of care treatment, will be included in the study, as the control group
2556836|NCT02520401|Experimental|Test|Probiotic tablet
2556837|NCT02520401|Placebo Comparator|Control|Control tablet
2556891|NCT02520180|Experimental|Firehawk™ stent system|MicroPort Firehawk™ stent system
2556894|NCT02520180|Active Comparator|Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
3205587|NCT00945581|Placebo Comparator|Placebo powder|Powder twice a day
3205588|NCT00945607|Experimental|Guided Relaxation Training|"Eligible subjects who have been randomized to the intervention arm will be scheduled for GRT introduction and training with a research staff member. The GRT sessions will consist of six weekly on-site sessions in which the subject is provided instructions and then allowed to listen to the GRT CD. Subjects will be instructed to conduct independent GRT sessions at home, twice daily, at least four hours apart, for the duration of the study. Subjects will also be instructed that on the days of one-on-one sessions with a research staff member at TCCC, that they will only be required to perform the independent session once at home.~Subjects will be provided with a diary to record the date and time of each independent GRT session performed at home. Subjects will be instructed to bring their completed diary with them at each subsequent visit."
3205589|NCT00945607|No Intervention|Standard of Care(SOC)|Eligible subjects who are randomized to the SOC arm will not receive the GRT sessions. During the six week treatment phase, these subjects will only receive SOC provided to all subjects newly diagnosed with breast cancer at TCCC. This consists of an education session with the nurse or nurse practitioner. In addition, they will also be provided with supportive care and symptom management as needed. This arm will also be provided with a diary to record their stress level at least twice daily.
2557030|NCT02519257|Experimental|CAD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
2557031|NCT02519257|Experimental|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
2557059|NCT02518880|Other|Plasma volume measurements|
2557112|NCT02518633||men with obstructive sleep apnoea|Continuous positive airway pressure devices
2557118|NCT02518633||control subjects|subjects with no obstructive sleep apnoea
2557172|NCT02518204|Experimental|BPT, NP|Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
2557178|NCT02518204|Experimental|NP, BPT|Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery
2557451|NCT02516319|Experimental|Liver Funtion Test Dye Detection Monitor|All cohorts receive continuous LFT monitoring post ICG injection.
2556247|NCT02524405||Normal Controls|Upto 85 normal elders, 50-90 years old who are within normal limits on the study neuropsychological battery will be enrolled. All patients involved in the study will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET.
2556249|NCT02524405||Alzheimer's Disease (AD)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
2556250|NCT02524405||Mild Cognitive Impairment (VCI)|Sixty-five subjects meeting the National Institute on Aging-Alzheimer's Association criteria for amnestic or multi-domain MCI with MoCA score ≥18 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
2556252|NCT02524405||Subcortical Vascular Impairment (VCI)|Sixty-five subjects meeting the American Heart Association-American Stroke Association (AHA-ASA) criteria for probable vascular dementia (VaD) or probable vascular mild cognitive impairment (VaMCI) due to subcortical ischemic vascular disease , and probable or possible Cerebral Amyloid Angiopathy using the Modified Boston Criteria116 will be enrolled. All patients will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
2556254|NCT02524405||LBD Spectrum|Sixty- five subjects with: Dementia with Lewy Bodies (DLB) meeting the criteria for probable Dementia with Lewy Bodies with MMSE score ≥20; or PD-MCI meeting the proposed Level I criteria for Mild Cognitive Impairment in Parkinson's Disease with MoCA score 18-24; or; PDD meeting the criteria for probable Parkinson's Disease - Dementia and MMSE score ≥20 will be enrolled. All patients involved will undergo SD-OCT, eye tracking, gait and balance assessments, blood draw for genomics and fluid biomarkers, neuropsychological assessment, brain MRI and brain amyloid PET. A subset will undergo SV-OCT.
2556320|NCT02523937||Group without PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for exclusion of PE or DVT are:~low or intermediate clinical probability and D-dimer <0,50 µg/mL~low and moderate clinical probability and negative spiral computed tomography CT and/or proximal lower limb venous compression ultrasonography (US)~high clinical probability and negative CT and US.~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
2556324|NCT02523937||Group with PE or DVT|"PE or DVT have to be confirmed or discarded by combining Wells score clinical probability, D-Dimer, and imaging tests.~The criteria for confirmation of PE or DVT are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasonography (US).~Soluble Fibrin assay will be performed in comparison with D-dimer assays."
3205590|NCT00945620|Placebo Comparator|right side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
2556416|NCT02523131|Experimental|24/7 closed loop insulin delivery|Unsupervised home use of day and night automated closed loop insulin delivery system (FlorenceM) combined with pump suspend feature over a 12-week period using 24/7 Medtronic insulin pump 640G and Android smartphone.
2556420|NCT02523131|Active Comparator|Sensor augmented pump therapy|Insulin pump therapy combined with unmasked real-time continuous glucose monitoring system for 12 weeks using Medtronic insulin pump 640G. Pump suspend features will be turned off.
2556488|NCT02522806|Experimental|Group A|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle.
2556496|NCT02522806|No Intervention|Group B|none endometrial biopsy
2556531|NCT02522429|Experimental|Low Intensity Focused Ultrasound Device|15 acute DOC patients, 15 chronic DOC patients
2556580|NCT02522130|Active Comparator|lidocaine group|Group A will receive 10 ml 1% lidocaine (Xylocaine 1%, Astra Zeneca, Egypt) Para cervical block prior to insertion of IUD (injection sites at cervix-vaginal junction typically at 4 ,8 O'clock), Then 3 minutes waiting period between the administration of the Para cervical block and IUD insertion,
2556582|NCT02522130|Active Comparator|misoprostol group|Group B will receive 400 mcg oral misoprostol (Sigma, Egypt) prior to IUD insertion
2556583|NCT02522130|Active Comparator|non steroid group|Group C will receive oral naproxen (Naprosyn, Syntax, Egypt) prior to IUD insertion
2556584|NCT02522130|Placebo Comparator|placebo group|group D will receive placebo tablets.
2556649|NCT02521701|Experimental|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
2556680|NCT02521454|Experimental|MBRT|Mindfulness-Based Resilience Training
2556688|NCT02521454|No Intervention|WL Control|waitlist control group
2556771|NCT02520921|Active Comparator|Arm 1 : Novel strategy|enteric coated aspirin 100 mg in the morning and 100 mg in the evening
2556773|NCT02520921|Active Comparator|Arm 2 : Conventional strategy|enteric coated aspirin 100 mg in the morning
2556801|NCT02520635||TEMODAL® standard therapy regimen|4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
2556815|NCT02520674|Other|Glaucoma and Ocular Hypertension|Patients to be examined with both smartphone ophthalmoscopy and slit-lamp biomicroscopy.
2556828|NCT02520557||Control|Controls will be individuals who have used ESL for at least 6 weeks and who have not developed SCAR. Blood draw or saliva.
2556844|NCT02520232|Experimental|Physical activity program (A)|Physical exercises
2556300|NCT02523911|Placebo Comparator|Placebo Group|Early in the evening prior to colonoscopy, patients will be instructed to consume one 6 ounce bottle of oral sodium sulfate/potassium sulfate/magnesium sulfate (Suprep) solution (containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams) diluted with 16 ounces of water over one hour. Over the next hour, the patient will be instructed to drink an additional 32 ounces of water. On the day of colonoscopy, the same procedure will be repeated. Patients will take 2.4 mL of placebo (identical in appearance to simethicone) in a half glass of water immediately after consuming each dose of the Suprep. All of the bowel preparation solution and required water should be consumed at least 2 hours prior to colonoscopy.
2556349|NCT02523534|Experimental|Recurrence Mapping|Participant undergoing their first ablation that fit our inclusion/exclusion criteria will undergo new atrial fibrillation mapping techniques to help identify the sources of atrial fibrillation. The participant will have an MRI and ECG prior to a clinically indicated ablation.
2556399|NCT02523326||Group A|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group A at 10 days
2556406|NCT02523326||Group B|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group B at 20 days
2556407|NCT02523326||Group C|Each patient was instructed how to prepare for saliva sampling. Patients were instructed to rinse their mouth vigorously with 10 ml of mouthwash during 30 s, then spit it into the tube and the extraction of DNA was performed at distinct times: group C at 30 days
2556458|NCT02522910|Experimental|Roniciclib with Docetaxel|
3171287|NCT00585364||CF (non-ABPA)|cystic fibrosis and culture positive for A. fumigatus in airway cultures.
2556550|NCT02522247|Active Comparator|Uvulopalatoplasty|Surgery with cold steel, single sutures of palate and tonsillar pillars including palatopharyngeal muscle
2556551|NCT02522247|No Intervention|Controls|Only waiting 6 months
2556587|NCT02522026||Healthy volunteers|
2556591|NCT02522026||Healthy smokers|
2556593|NCT02522026||COPD GOLD1|
2556596|NCT02522026||COPD GOLD2|
2556599|NCT02522026||COPD GOLD3/4|
2556628|NCT02521740||caregivers|someone who takes care and lives with a disabled elderly
2556634|NCT02521740||controls|someone who lives with an healthy elderly
2556708|NCT02521532|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
2556709|NCT02521532|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
2556756|NCT02521077|Experimental|Odd Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
2556758|NCT02521077|Experimental|Even Cycle Intravenous Ascorbic Acid|Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).
2556814|NCT02520752|Experimental|INC280|
3205591|NCT00945620|Placebo Comparator|Left side|The trans-abdominis block will be placed in every pat with one side being injected with ropivicaine, the other side placebo injection. Hence is subject can serve as their own control. Subjects will receive additional pain medications as needed
3205592|NCT00945646|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
3205593|NCT00945646|Placebo Comparator|vehicle|
2556997|NCT02519439|Experimental|ganaxolone|Up to a maximum of 1800 mg/day
2557010|NCT02519127|Experimental|Low glycaemic load diet|Subjects will be following a low glycaemic load diet, typically high in polyphenols, proteins, vegetables, pulses, fibres and nuts, and low in glycemic carbohydrates, for six continuous weeks.
2557015|NCT02519127|Experimental|Western diet|Subjects will be following a western diet, typically high in saturated fat, refined sugars and salt, and low in fruit and vegetables and fibers, for six continuous weeks.
2557075|NCT02518737||GIP-receptor deficient|Persons with a mutation (Glu354Gln) causing their GIP-receptor to loose function.
2557077|NCT02518737||Controls|Matched controls, with a normal functioning GIP-receptor.
2557099|NCT02518503||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (high doses of rosuvastatin, high doses of atorvastatin, and high doses of simvastatin) between 1 January 1997 and 31 March 2011, or 1 year after the beginning of data availability.
2557102|NCT02518503||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 31 of March 2011, or 1 year after the beginning of data availability.
2557161|NCT02518087|Experimental|CPB-oXiris®|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
2557163|NCT02518087|No Intervention|CPB-Standard|Non emergent cardiac surgery patients requiring expected CPB time > 90 minutes: double valve replacement or valve replacement plus coronary arterial bypass graft (CABG).
2557222|NCT02517853|Experimental|Tibial nerve stimulation|Tibial nerve stimulation during 16 sessions
2557226|NCT02517853|Sham Comparator|Sham comparator|Sham tibial nerve stimulation during 16 sessions
3171288|NCT00585364||CF and ABPA|cystic fibrosis and diagnosis of ABPA
3205594|NCT00945672|Experimental|PF-04360365 10 mg/kg|
3205595|NCT00945672|Experimental|PF-04360365 7.5 mg/kg|
3205596|NCT00945672|Placebo Comparator|placebo|
3205597|NCT00945685|Experimental|Endymion study group|
3205598|NCT00945698|Other|ST-DI (Delayed intervention)|"1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3208811|NCT00978328||001|oxycodone immediate release (OXYRX) Characteristics of pts. receiving prescription medications containing OXYRX
2556400|NCT02523248|Active Comparator|Tonsillectomy|Tonsillectomy with cold steel
2556403|NCT02523248|Active Comparator|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty; using cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
2556444|NCT02522949|Active Comparator|ColdZyme|ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
2556445|NCT02522949|Placebo Comparator|Placebo|Sugar based mouth spray manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
2556466|NCT02522689|Active Comparator|Ultra-mini PCNL|Endoscopic kidney stone surgery: Patients will undergo ultra-mini percutaneous nephrolithotripsy.
2556469|NCT02522689|Active Comparator|Micro PCNL|Endoscopic kidney stone surgery: Patients will undergo micro percutaneous nephrolithotripsy.
2556513|NCT02522507|Experimental|Empowering youth towards employment|This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
2556514|NCT02522507|No Intervention|Control group|The control group will have access to the employment activities during the 12-week employment readiness learning but will not have access to a mentor.
2556577|NCT02522065||Healthy controls|A sample of 30 healthy volunteers will be recruited to compare the typing signal with that of the cases.
2556578|NCT02522065||Early Parkinson's disease cases|A sample of 30 early PD cases (i.e. less than five years of disease and no axial signs or fluctuations) that are going to be prescribed de novo dopaminergic therapy will be recruited.
2556635|NCT02521779|Experimental|Test Meal Saturated Fat|Saturated-fat Treatment Meal
2556643|NCT02521779|Experimental|Test Meal N-6 Fat|N-6 fat Treatment Meal.
2556644|NCT02521779|Experimental|Test Meal N-3 Fat|N-3 fat Treatment Meal.
2556646|NCT02521779|Experimental|Test Meal Low-fat|Low-fat Treatment Meal.
2556697|NCT02521467|Active Comparator|PRF|Platelets Rich Fibrin
2556699|NCT02521467|Placebo Comparator|palatal stent|Palatal stent
2556754|NCT02521168|Experimental|Oral triiodothyronine|Oral T3 (triiodothyronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
2556755|NCT02521168|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anaesthesia for 60 hours
2556873|NCT02520817||Antioxidant supplementation and zinc plus Lactulose(Group A)|Patients With MHE were assigned to receive zinc and antioxidant plus lactulose (group A)
2556876|NCT02520817||Lactulose only (Group B)|Patients with MHE were assigned to receive lactulose oly (group B)
2556905|NCT02520024|Experimental|Self-directed Care|"Individuals in the experimental condition will work with a specially trained certified peer specialists (CPS) who will serve as recovery coaches to develop an individualized recovery plan that describes their goals and desires. They will then work with the team to select both the behavioral health treatment and rehabilitation services, and the non-behavioral health materials and resources they believe are necessary to achieve their goals."
2556906|NCT02520024|No Intervention|Treatment as usual|Participants in the control condition will receive services as usual.
2556949|NCT02519751|Experimental|D3 Creatine followed by creatine supplementation|Every participant will be orally administered with 60mg of D3 Creatine in a fasted state in a non-gelatin capsule. Creatine supplemented throughout the study will be administered in the following doses-0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
3205599|NCT00945698|Experimental|LNS-10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3208812|NCT00978354|Active Comparator|Furosemide|Furosemide intravenous continuous infusion
2556476|NCT02522676|Active Comparator|Extracorporeal shock wave lithotripsy|Non-invasive kidney stone treatment: Patients will undergo extracorporeal shock wave lithotripsy.
2556532|NCT02522338|Other|iohexol plasma clearance|patients had received iohexol for measuring GFR
2556562|NCT02522169|Active Comparator|Conventional treatment|"The patients of the control group undergo Infliximab-maintenance according to the approved dosing scheme, initially with 5 mg/kg body weight Infliximab. Before each administration laboratory parameters will be controlled (Albumin, CrP, Calprotectin) and disease activity scores will be obtained (PCDAI / PUCAI). Infliximab trough levels will be assessed but not have any implication. In the presence of clinical signs of a disease exacerbation and after exclusion of other causes an adjustment of the dosage will follow for the next Infliximab-infusion:~A) interval shortening, or B) Dose increase to 10 mg / kg body weight. With a clinical stable course of the disease without signs of deterioration, the dosage and the eight-week interval will be maintained."
2556563|NCT02522169|Experimental|Intervention Group|Aiming to maintain the therapeutic window of Infliximab a de- or increase of the dose or infusion interval will be carried out for the following administration, provided the patient shows no signs of a clinical worsening. With good trough levels and clinically stable conditions the therapy will be continued without modification until next check-up. In the case of an eminent disease exacerbation Infliximab trough levels and the search for anti - Infliximab antibodies should guide further treatment decisions. With trough levels below the target range antibody testing should be performed.
2556630|NCT02521935|Active Comparator|Complete traditional dentures|Complete maxillary/mandible dentures made in the traditional manner.
2556636|NCT02521935|Active Comparator|Complete CADCAM dentures|Complete maxillary/mandible dentures made with CADCAM (computer-aided design/computer-aided manufacturing) technology
2556682|NCT02521506|Experimental|Verio Pattern Alert® activated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer and they have activated the software Verio Pattern Alert® that could predict the glucose trends.
2556691|NCT02521506|Active Comparator|Verio Pattern Alert® deactivated|In this cohort, the patients will monitoring the glucose levels with capillar glucometer.
2556728|NCT02521142||AMD: treatment-naive|
2556732|NCT02521142||AMD: active neovascular AMD|
2556784|NCT02520895||large B lymphoma cells (group 1)|30 patients with large B lymphoma cells at diagnosis and who will receive an immunochemotherapy treatment patients will have blood samplings
2556785|NCT02520895||indolent B-cell lymphomas (group 2)|30 patients with indolent B-cell lymphomas without invasion excess blood lymphoma 1 giga / L at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
2556786|NCT02520895||indolent B-cell lymphomas (group 3)|20 Patients with indolent B-cell lymphomas with lymphocytosis (> 1 Giga / L) at diagnosis and who will receive an immunochemotherapy treatment- patients will have blood samplings
2556787|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 4)|20 patients with LLC never treated before and will receive an immunochemotherapy treatment (fludarabine +/- endoxan +/- rituximab or alemtuzumab)- patients will have blood samplings
2556789|NCT02520895||T-cell lymphoma (group 5)|10 Patients with T-cell lymphoma in 1st line therapy and will receive a combination of chemotherapy- patients will have blood samplings
2556791|NCT02520895||follicular lymphoma (group 6)|6 patients with follicular lymphoma in first line or relapsed and will receive a single immunotherapy treatment (rituximab)- patients will have blood samplings
2556792|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 7)|6 patients with LLC never treated and will receive a combination of rituximab, fludarabine, endoxan- patients will have blood samplings
2556794|NCT02520895||Lymphocytic Leukemia Chronic (LLC) (group 8)|6 patients with LLC stage A followed for a period of 18 months without treatment- patients will have blood samplings
2556848|NCT02520466|Active Comparator|flavanol-containing drink|flavanol-containing drink
2556857|NCT02520466|Placebo Comparator|flavanol-free drink|flavanol-free drink matched for taste and calories
2556900|NCT02520128|Other|Cohort 1 (closed to recruitment)|"Cohort 1: Patients with Limb/limb girdle soft tissue sarcoma (STS) receiving (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 1:~Pre-operative RT - 50 Gy in 25 daily fractions over 5 weeks~Post-operative RT - 60 Gy in 30 daily fractions to the high dose planning target volume (PTV) and 52.2 Gy in 30 daily fractions to the low dose PTV treated concurrently over 6 weeks~Post-operative RT (positive resection margins) - 66 Gy in 33 daily fractions to the high dose PTV, and 53.46Gy in 33 fractions to the low dose PTV treated concurrently over 6 ½ weeks."
2556901|NCT02520128|Other|Cohort 2|"Cohort 2: Patients with Ewing sarcoma of the spine/pelvis receiving definitive radical or (neo)-adjuvant radiotherapy (Intensity Modulated Radiotherapy)~Dose schedules for Cohort 2:~Pre-operative RT - 50.4 Gy in 28 daily fractions over 5½ weeks~Post-operative RT - 54 Gy in 30 daily fractions over 6 weeks~Primary RT - 54 Gy in 30 daily fractions over 6 weeks."
2556902|NCT02520128|Other|Cohort 3|"Cohort 3: Patients with non-Ewing primary bone sarcomas of the spine/pelvis receiving definitive radical or adjuvant Radiotherapy (Intensity Modulated Radiotherapy)~Dose schedule for Cohort 3:~Primary RT - 70 Gy in 35 daily fractions over 7 week~Post-operative RT (non-chordoma) - primary bone sarcoma 60 Gy in 30 daily fractions over 6 weeks~Post-operative RT (chordoma) - 70 Gy in 35 daily fractions over 7 weeks."
2556960|NCT02519530|Experimental|Intervention|Behavioral: Teen Outreach Program
2556961|NCT02519530|No Intervention|Comparison|This group did not receive TOP, they received business as usual health curriculum offered through the public school system
2557020|NCT02519322|Experimental|Arm A (nivolumab, surgery)|Patients receive nivolumab IV over 30 minutes on days 1, 15, 29, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
2557023|NCT02519322|Experimental|Arm B (nivolumab, ipilimumab, surgery)|Patients receive nivolumab IV over 1 hour and ipilimumab IV over 90 minutes on days 1, 22, and 43. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 30 minutes every 2 weeks for 13 doses in the absence of disease progression or unacceptable toxicity.
2557025|NCT02519322|Experimental|Arm C (nivolumab, relatlimab, surgery)|Patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour on days 1 and 29. Patients then undergo surgery on day 57. After surgery, patients receive nivolumab IV over 1 hour and relatlimab IV over 1 hour every 4 weeks for 10 doses in the absence of disease progression or unacceptable toxicity.
2556520|NCT02522585||Conservative management|Patients diagnosed of CIN-II by directed biopsy
2556553|NCT02522221|Experimental|Tecarfarin|Tecarfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
2556554|NCT02522221|Active Comparator|Warfarin|Warfarin will be administered and dose adjusted by the investigator. Dose adjustments will be made in accordance with a target INR range pre-specified by the investigator.
2556585|NCT02522000||Patients with functional dyspepsia|
2556588|NCT02522000||Healthy controls|
2556621|NCT02521727||exposed siblings/children|"Consecutive subjects with non-advanced adenomas will be identified from the colonoscopy database at Prince of Wales Hospital, Alice Ho Miu Ling Nethersole Hospital, Queen Elizabeth Hospital and the bowel cancer screening center at Siu Lek Yuen. Figure 1 illustrates subject recruitment flow chart. They will be consented to provide details on their number of FDR, their FDR contact details, and cause of death in FDR who are deceased. FDR aged 40 to 70 years of consecutive patients with newly diagnosed non-advanced adenomas confirmed from endoscopy and pathology reports will be contacted via phone and invited for an interview and a colonoscopy.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
2556627|NCT02521727||unexposed siblings/children|"Subjects (Control) FDR aged 40 to 70 years of asymptomatic average risk subjects who had undergone a colonoscopy in our bowel cancer screening programme between 2010 and 2014 and found to have a normal colonoscopy will be invited to participate by phone and invitation letters, to attend a health talk and to undergo a colonoscopy.~Confounding factors including use of drugs (aspirin and non-steroidal anti-inflammatory drugs), lifestyle factors (smoking, and diet questionnaire) and history of medical conditions (obesity with calculation of body mass index, diabetes, history of cardiovascular disease) between cases and controls will be recorded.~COLONOSCOPY With informed consents, experienced colonoscopists (GI physicians, colorectal surgeons) will perform colonoscopy under intravenous sedation, midazolam and pethidine after adequate bowel preparation."
2556701|NCT02521610|Placebo Comparator|Placebo|Healthy volunteers will receive the placebo equivalent to RG7625 as oral capsules once or twice daily for 8 days. Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin purified protein derivative [PPD], Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
2556706|NCT02521610|Experimental|RG7625|Participants will undergo a series of Screening visits prior to treatment and 7- to 14-day follow-up. Healthy volunteers will be enrolled in up to 4 cohorts and will receive RG7625 as oral capsules once or twice daily for 8 days. The first cohort is planned to receive 100 milligrams (mg) on Day 1, followed by 100 mg twice daily on Days 3 to 9. Subsequent dose and frequency decisions will be based upon observations in previous cohort(s). Each cohort will receive intradermal administration of 4 antigens (tetanus toxoid, tuberculin PPD, Candida albicans, and Trichophyton species) and a negative control at Screening and on Day 7 of treatment to assess for DTH.
3205600|NCT00945698|Experimental|LNS-20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3205601|NCT00945698|Experimental|LNS-20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3205602|NCT00945698|Experimental|LNS-40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
2556869|NCT02520544|Active Comparator|Accolade stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
2556875|NCT02520544|Active Comparator|Accolade II stem|All patients in a participating centre matching all of the inclusion criteria and none of the exclusion criteria and who receive the Accolade or Accolade II stem and Trident/Tritanium cup with X3 liner.
2556917|NCT02519946|Experimental|On-Line Diet and Exercise Intervention|
2556969|NCT02519686||Trendelenburg position maneuver|Trendelenburg (TD) positioning (supine with head tilt-down) is used in abdominal and gynecological surgery as well as during colonoscopy to allow better access to the pelvic organs, as gravity pulls the bowel out of the pelvic cavity and the rectosigmoid angle straightens.
2556970|NCT02519686||Left lateral position maneuver|Left Lateral (LL) position (patient laying on their side, traditionally used for colonoscopies)
2557021|NCT02519309|Experimental|onsite|Education (the virta program) for the onsite group will be delivered in person, with 26 classes over 12 months including group and individual sessions. Sessions will be scheduled weekly for the first 3 months, biweekly during months 4-6, and monthly thereafter. Each session will last approximately 90 minutes.
2557024|NCT02519309|Experimental|web-based|Education (the virta program) for the web-based educational group will be the same content as the onsite group, but delivered via the web and completed at the participant's own pace.
2557026|NCT02519309|No Intervention|Control (usual care)|The study will make no intervention to this group. Participants in this group will be recent referrals to a local diabetes education program and care for their condition will continue to be managed by their own medical providers.
2557047|NCT02518906|Experimental|Adolescent Identity Treatment|Psychotherapeutic treatment performed routinely at the centres in Basel and Santiago de Chile
2557051|NCT02518906|Experimental|DBT-A|Psychotherapeutic treatment performed routinely at the centre in Heidelberg
2557119|NCT02518594|Active Comparator|Progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
2557123|NCT02518594|Placebo Comparator|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
2557126|NCT02518594|Active Comparator|Arabin Pessary|placement management from randomization to < 35 wks
2557189|NCT02518035|Placebo Comparator|Control|No silicone gel treatment after remove of stitches
3205603|NCT00945698|Experimental|LNS-40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
3205604|NCT00945711||1|Eating Disorder Diabetes Mellitus T1 patients
2556722|NCT02521350||Control|- older than 40 years patients with no specific gender, who will stay at least one night in hospital will be included into our study. And cardiovascular, urological surgery patients and patients with known renal insufficiency will be excluded.
2556761|NCT02521025|Experimental|Intermittent feeding|Intermittent feeding pattern throughout the bedrest period, with 4 boluses per day
2556762|NCT02521025|Experimental|Continuous feeding|Continuous feeding pattern throughout the bedrest period, with 4 boluses per day, without breaks in food supply.
2556811|NCT02520713||Genetic testing and GAIN report|All enrolled patients will submit specimens for sequencing and analysis.
2556850|NCT02520271|Active Comparator|Depression|Behavioral activation only
2556860|NCT02520271|Active Comparator|Depression and SUD|Motivational interview and Behavioral activation
2556916|NCT02519985|Experimental|Repeatability and Reproducibility of ArcScan Insight 100|"For repeatability and reproducibility in normal eyes (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea and anterior segment will be performed by the second operator.~For repeatability and reproducibility in eyes after laser refractive surgery (n=20):~Firstly, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the first operator.~After a break of about 30 minutes, 5 consecutive repeated ArcScan Insight 100 scans of the cornea will be performed by the second operator."
2556964|NCT02519647|Active Comparator|tracheal intubation with Gliderite|Gliderite will be used for intubation
2556967|NCT02519647|Experimental|Tracheal intubation with S-Guide|S-Guide will be used for intubation
2557009|NCT02519283|Active Comparator|Standard of Care|In keeping with the strategy-based pragmatic nature of the trial, the discharge procedures will largely be kept as they are in common practice. Investigators will standardize usual care for ED discharge to include HF medication reconciliation as well as encourage 7-day follow-up.
2557016|NCT02519283|Active Comparator|GUIDED-HF|GWTG:HF has been successfully implemented across multiple inpatient populations and health systems over the last decade and has been shown to improve HF disparities.
2557160|NCT02518178|Active Comparator|NFC Sticker|Participants will receive an NFC (Near Field Communication) sticker, placed on their existing immunization (MAMTA) card. This will serve as a comparator to the NFC necklace while still allowing for patient data to be digitized and utilized by the health service provider, Seva Mandir.
2557162|NCT02518178|Experimental|NFC Necklace|Participants will receive a necklace with an NFC pendant, which interfaces with the Khushi Baby mobile application to digitize the data. This arm will allow for the assessment of peer influence effects of the necklace as a social symbol.
2557164|NCT02518178|Experimental|NFC Necklace + Voice Reminder|In addition to the NFC necklace, mothers of the participants in this arm will receive dialect-specific voice call reminders, informing them about the next camp and the importance of vaccinations.
2557207|NCT02517762|Experimental|Stay active|Receive the advice by the physician to stay as active as possible in spite of the pain experienced
2557211|NCT02517762|Experimental|Adjust activity|Receive the advice by the physician to adjust the activity according to the pain, i.e. to avoid activities, movements or positions that cause or worsen the pain
2557328|NCT02517112|Other|Cardiovascular parameters measurements|
2557391|NCT02516813|Experimental|Phase Ia Arm A: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 10 times, for two consecutive weeks in concomitance with fractionated radiotherapy (RT) (5 fractions /week).
2557394|NCT02516813|Experimental|Phase Ia Arm B: MSC2490484A +Fractionated RT|Subjects will receive MSC2490484A capsule once daily up to 35 times, for 7 consecutive weeks in concomitance with fractionated RT and Cisplatin (5 fractions/week).
2557398|NCT02516813|Experimental|Phase Ib Arm A Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week).
2557403|NCT02516813|Experimental|Phase Ib Arm B Expansion: MSC2490484A+Fractionated RT|Subjects will receive MSC2490484A tablet once daily up to 35 times in concomitance with fractionated RT (5 fractions /week) and cisplatin.
2557406|NCT02516813|Experimental|Ancillary cPoP: MSC2490484A+Fractionated RT|Ancillary Clinical proof-of-principle (cPOP) study, subjects will receive first dose of RT on Day 1, and will receive MSC2490484A capsule or Tablet formulation within 1.5 hour before the second dose of RT on Day 2.
3171289|NCT00585364||healthy control|healthy non-CF
3171290|NCT00585390|Experimental|Essential omega-3 fatty acid replacement|
3171291|NCT00585390|Placebo Comparator|Placebo|
3171292|NCT00585403||Children|Early and late pubertal girls and boys
3171293|NCT00585416|Experimental|1|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
3171294|NCT00585429||1|ESLD subjects on active liver transplant waiting list
3171295|NCT00585429||2|Subjects post-liver transplant with good liver function
3171296|NCT00585429||3|Subjects without liver disease undergoing kidney biopsy for diagnostic purposes
3171297|NCT00585442|Experimental|Calcitriol|
3171298|NCT00585442|Placebo Comparator|Placebo|
3171299|NCT00585455||A|Chronic heart failure patients with concomitant depression
3171300|NCT00585481||1|All subjects will perform samples collection for RSV analysis. Subject's enrolled in Porto Alegre's site will perform lung function tests.
3171301|NCT00585507|Experimental|single|fulvestrant 500mg
3171302|NCT00585520|Active Comparator|PG|
3171303|NCT00585520|Placebo Comparator|PLA|
3171304|NCT00585559|Placebo Comparator|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
3171305|NCT00585559|Active Comparator|Acetaminophen and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
3171306|NCT00585559|Active Comparator|N-acetylcysteine and acetaminophen|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
3171307|NCT00585559|Active Comparator|Acetaminophen 1 Gram and N-acetylcysteine|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
3171308|NCT00585559|Active Comparator|Acetaminophen 1.5 Gram and N-acetylcysteine|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
2556658|NCT02521662|Active Comparator|Patch and nicotine e-cigarette|21mg nicotine patch (daily) and nicotine e-cigarette (ad libitum) for 14 weeks (including a 2 week prequit period), plus behavioural support for six weeks post-quit
3171309|NCT00585598||1|all patients that are admitted to the trauma bay with a supralaryngeal airway
3171310|NCT00585624|Experimental|1|Supplement: 3 servings/day of Impact Advanced Recovery in addition to regular food or any other supplements recommended or desired by patient or primary care/surgical team.
2556782|NCT02520973|Experimental|Universal screening|All HIV + pregnant women will be asked to give a sputum sample for TB prior to TB symptom screen
2556783|NCT02520973|Active Comparator|Symptom- directed screening|Only symptomatic HIV+ pregnant women will be asked to give a sputum sample for TB
2556817|NCT02520570||general department|Patients using ulinastatin in department beyond ICU would be labelled as general department group.
2556819|NCT02520570||ICU|Patients using ulinastatin in ICU would be labelled as ICU group.
2557264|NCT02517476|Experimental|Nutritional support|For the purpose of this study, we have developed nutritional guidelines by consensus and adapted to current guidelines (e.g., ESPEN, ASPEN). These guidelines specify a reinforced nutritional therapy strategy to cover nutritional requirements, focusing on nutritional targets based on the specific nutritional diagnoses defined by the IDNT. The nutritional guidelines may vary according to important medical diagnoses (i.e. renal failure). They specify not only nutritional targets, but also escalation of the route (i.e. food fortification, oral, enteral, parenteral) if targets cannot be achieved (≤75%) every 5 hours. Nutritional goals are being assessed daily in patients in the intervention group.
2557265|NCT02517476|No Intervention|"Usual care (appetite-guided) controls"|"In control patients, we will use conventional nutrition according to the ability and desire of the patient to eat, using standard care food provided by the hospital kitchen (appetite-guided)."
2557282|NCT02517281|Experimental|Patients having received targeted therapies|Patients treated using targeted therapies
2557341|NCT02517151|Experimental|Ferric carboxymaltose|200 mg in normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
2557344|NCT02517151|Placebo Comparator|Placebo|normal saline (NS) 100 ml administered i.v. at day 0 and then every 4 weeks up to week 24.
2557389|NCT02516683||Shigella sonnei-exposed cohort|Shigella sonnei infection - A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
2557393|NCT02516683||control cohort|A control cohort of age and sex-matched, non-infected 105 contemporary hospital employees.
2557437|NCT02516384|Experimental|Fecal Microbiota Transplantation|Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.
2557474|NCT02516124||NISSC|Autologous HSCT
2557520|NCT02515903|Experimental|Intra-endoscopy|This intervention arm will receive intra-endoscopic evacuation surgery for ICH.
2557522|NCT02515903|Placebo Comparator|Stereotactic Aspiration|This arm will receive stereotactic aspiration surgery for ICH evacuation.
2557688|NCT02514837|Experimental|Temperature measured by RTM device|Both the internal temperature and skin temperature will be measured non-invasively through the skin.
2557725|NCT02514538|Experimental|Non-effervescent tablets|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
2557726|NCT02514538|Active Comparator|Effervescent Paracetamol|Comparing the effect of two different formulations of paracetamol (effervescent or non-effervescent tablets) in the blood pressure of hypertensive patients after 3 weeks treatment . The washing time between the two periods is approximately 1 week (minimum 3 days).
2557759|NCT02514213|Experimental|Arm A|2mg INO-5150 and electroporation device CELLECTRA®-5P
2557764|NCT02514213|Experimental|Arm B|8.5mg INO-5150 and electroporation device CELLECTRA®-5P
2557766|NCT02514213|Experimental|Arm C|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
2557767|NCT02514213|Experimental|Arm D|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
2558002|NCT02512484||high risk TB individuals attending A&E Departments|Assessment against inclusion/exclusion criteria in terms of risk of TB. If eligible, assessment and testing as appropriate for active or latent TB
2558123|NCT02511613|Placebo Comparator|Placebo|Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution
2558125|NCT02511613|Active Comparator|Active|Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%
2558175|NCT02511366|Experimental|ileal infusion of casein|Ileal infusion of casein
3171311|NCT00585624|Placebo Comparator|2|Standard Care: Food, beverages, or supplements as recommended or desired by patient or primary care/surgical team.
3171312|NCT00585676||Diabetic|Patients with Diabetes
3171313|NCT00585676||Abnormal glucose level|Patients who were screened and had abnormal blood glucose levels
3171314|NCT00585676||Control|Non-diabetic (normal glucose screening)
3171315|NCT00585702||1|Pregnant women with bipolar disorder
3171316|NCT00585702||2|Pregnant women without bipolar disorder
3171317|NCT00585728|Other|1|CT virtual proctoscopy
3171318|NCT00585741|Experimental|2. Head and neck|Imaging with 18F-FLT PET
3171319|NCT00585741|Experimental|3. Lung|Imaging with 18F-FLT PET
3171320|NCT00585741|Experimental|4. prostate|Imaging with 18F-FLT PET
3171321|NCT00585741|Experimental|5. esophagus|Imaging with 18F-FLT PET
3171322|NCT00585741|Experimental|1.CNS|Imaging with 18F-FLT PET
3205605|NCT00945711||2|Eating Disorder only patients
3205606|NCT00945724|Experimental|R-CHOP, Depocyte, Methotrexate|
3205607|NCT00945737|Active Comparator|Soy protein|
2556885|NCT02520245|Experimental|Open-Label|
2556897|NCT02519881|Experimental|modified microfracture using collagen|modified microfracture using collagen (CartiFill) for cartilage defect of ankle
2556899|NCT02519881|Active Comparator|microfracture|simple microfracture for cartilage defect of ankle
2556932|NCT02519764|Experimental|Hydration when thirsty|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
2556935|NCT02519764|Experimental|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
2556955|NCT02519556|Experimental|Probiatop|Probiotic comprising the mixture of strains: Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus paracasei and Bifidobacterium lactis, at a dose of 1 gram sachet, once a day for 6 months
2556958|NCT02519556|Placebo Comparator|Placebo|Placebo of Maltodextrin in sachet
2557018|NCT02519335|Other|Dexrazoxane|"Trial subjects will be assigned preoperatively to receive Dexrazoxane at one of three doses: low (200mg/m2/dose), medium (300mg/m2/dose), or high (400mg/m2/dose). Four patients will be assigned to each dosing regimen for a total of 12 patients.~The medication will be administered in the operating room 15-30 minutes prior to starting cardiopulmonary bypass (dose #1), after finishing cardiopulmonary bypass (dose #2), and on the morning after surgery in the cardiac intensive care unit (dose #3)."
2557071|NCT02518958|Experimental|RRx-001 + Nivolumab|Patients enrolled in this trial will receive study drug (RRx-001) on Day 1 as a single agent. Nivolumab (3 mg/kg) will be administered on Day 2 or Day 3 as a single agent.
2557147|NCT02518516||High potency statin users|Exposure will be defined as a new prescription for a high dose statin (rosuvastatin, high doses of atorvastatin, and high doses of simvastatin between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
2557148|NCT02518516||Low potency statin users|Exposure will be defined as a new prescription for a low dose statin (all doses of fluvastatin, all doses of pravastatin, all doses of lovastatin; low doses of atorvastatin and simvastatin) between 1 January 1997 and 30 of April 2008, or 1 year after the beginning of data availability.
3205608|NCT00945737|Placebo Comparator|Milk protein|
2557327|NCT02517216|Other|parabolic flight and MRI scans|
2557371|NCT02516969|Experimental|Stereotactic Body Radiotherapy|Subjects will receive Stereotactic Body Radiotherapy at the following levels: Treatment Volumes <25cc will receive 40Gy (5 fractions of 8Gy per fraction) or treatment Volumes ≥25cc will receive 44-50Gy (5 fractions of 8.8-10Gy per fraction). Ideally all tumors volumes ≥25cc will receive 50Gy over 5 fractions, however at the discretion of the treating radiation oncologist based on tumor bed volume, prior radiation dose, and proximity to critical organs the dose can be reduced to 44Gy over 5 fractions as outlined in prior SBRT protocols.
2557399|NCT02516540|No Intervention|Control|Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer
2557402|NCT02516540|Experimental|Intervention|Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet.
3205609|NCT00945763|Placebo Comparator|placebo|
3205610|NCT00945763|Experimental|N1539 15 mg|
2557551|NCT02515682|Active Comparator|High equol|High equol group will be given natural S-equol supplementation 20mg per day for 24 week.
2557552|NCT02515682|Active Comparator|Low equol|Low equol group will be given natural S-equol supplementation 10mg/d (+10mg starch) for 24 weeks
2557553|NCT02515682|Placebo Comparator|Placebo|Placebo group will be given placebo control (made from starch) 20 mg per day for 24 weeks.
2557578|NCT02515461|Experimental|Intervention: Low energy shockwave therapy|Low energy shockwave therapy performed on both kidneys applying 3000 shocks on each kidney.
3205611|NCT00945763|Experimental|N1539 30 mg|
2557693|NCT02514798|Experimental|High-flow humidified nasal oxygen delivery system|We will describe effects of varying settings of high-flow nasal oxygen (10-30-45-60 L/min) on respiratory rate, tidal volume, and diaphragmatic work of breathing in patients with severe COPD. We will also describe changes in gas exchange and effects on the subjects' comfort and dyspnea. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system.
2557694|NCT02514798|Active Comparator|CPAP (Positive Control)|"We want to describe the breathing responses to varying setting of CPAP in the subject population. We plan to use the CPAP response as a positive control, to determine if our population responds as described by CPAP studies in the literature. This will be measured using, esophageal and gastric balloons, respiratory inductance plethysmography (RIP) system, and Sentec transcutaneous monitoring system."
3205612|NCT00945763|Experimental|N1539 60 mg|
3205613|NCT00945763|Active Comparator|Motrin|
3205614|NCT00945776|Active Comparator|Weekly phone calls|Will be called weekly to answer questions regarding usage.
3205615|NCT00945776|Active Comparator|Frequently asked questions|Providing written general answers to commonly asked questions.
3205616|NCT00945776|Active Comparator|Usual care|
3205617|NCT00945789|Experimental|EPO HIE Group|Infants with hypoxic ischemic encephalopathy receive human recombinant erythropoietin
3205618|NCT00945789|No Intervention|Control HIE|Infants with hypoxic ischemic encephalopathy who do not receive treatment drug (EPO)
3205619|NCT00945789|Other|Healthy Controls|Healthy newborn without hypoxic ischemic encephalopathy
3205620|NCT00945802|Experimental|FST-201 (dexamethasone 0.1%) Otic Suspension|
3205621|NCT00945802|Active Comparator|ciprofloxacin 0.3%, dexamethasone 0.1%|
3205622|NCT00945828|Experimental|Annual Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
3208813|NCT00978354|Placebo Comparator|Normal Saline|Normal saline titrated continuous intravenous infusion
2556712|NCT02521363|Experimental|Upfront Breast Surgery|Patients will have the microdevice implanted prior to breast surgery, in the absence of neoadjuvant chemotherapy
2556713|NCT02521363|Experimental|Neoadjuvant Therapy|Patients will have the device placed and retrieved on a core biopsy the following day, then receive neoadjuvant chemotherapy prior to definitive breast surgery.
2556749|NCT02521051|Experimental|Alectinib and Bevacizumab.|"Phase 1~Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Alectinib, orally, twice a day, per cycle~Bevacizumab, iv, once per cycle~Phase II In the phase II portion of this study, the investigators will evaluate the combination of alectinib plus bevacizumab in ALK-positive patients with untreated or progressive, asymptomatic brain metastases. Eligible participants will receive alectinib plus bevacizumab at the recommended phase II doses determined in the phase I portion of the study."
2556854|NCT02520440||GIF and/or MOF patients|Development during the ICU stay of gastro-intestinal failure and/or multiple organ failure. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
2556863|NCT02520440||Controls|patients admitted to ICU without gastrointestinal failure and/or multiple organ failure during the intensive care unit stay. Investigators performed in each patient monitoring of plasmatic levels of Citrulline, monitoring of plasmatic levels of Arginine and Glutamine, and intra-abdominal pressure monitoring.
2556948|NCT02519738|Active Comparator|Silver Nitrate|Silver Nitrate is supplied in the form of pre-packaged applicator sticks to parents and patients. The concentration is 75% Silver Nitrate and 25% Potassium Nitrate. Application will be done 3 times a week for a period of 3 weeks.
2556950|NCT02519738|Active Comparator|Kenalog (Triamcinolone)|Kenalog is a topical corticosteroid that shares anti-inflammatory, anti-pruritic, and vasoconstrictive actions.The dosage of Kenalog used in the study is 0.5%. Application is topical, and the frequency is 3 times a day for the 3 week trial period. FDA approved use of Kenalog in the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It has not been studied whether Kenalog has any proven advantage over Silver nitrate in the treatment of granulation tissue, but it has been used for the treatment of granulation tissue at the gastrostomy site with good effect.
2556952|NCT02519738|Active Comparator|Washcloth Abrasion|Washcloth abrasion will be done with regular soap and water applied to a washcloth. The granulation tissue will be gently washed and abraded once daily for three weeks.
2556962|NCT02519465|Active Comparator|HEATED FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen heated .
2556965|NCT02519465|Active Comparator|COLD FLOW|The volunteers were randomly allocated into three groups - group 1 - 10l/min cold or heated, group 2 - 30l/min cold or heated, group 3 - 50 l /min - cold or heatedPhase 1 - 10l/min or 30l/min or 50l/min of the oxygen cold
3205623|NCT00945828|Experimental|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study.
2557149|NCT02518438|Active Comparator|the tramadol group|A preprepared 20 ml solution (tramadol 2 mgkg-1 within a 0.9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
2557151|NCT02518438|Placebo Comparator|the placebo group|A preprepared 20 ml solution (0,9% saline solution) was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
2557234|NCT02517970|Experimental|Classical Music versus Television show|This is within-subject study; all infants will be exposed to both conditions. Order of presentation will counterbalanced across infants.
3205624|NCT00945841|Other|1|
3205625|NCT00945880|Experimental|Experimental Group|clemizole hydrochloride, 100mg, BID
2557339|NCT02516826|Experimental|Rosuvastatin Arm|Rosuvastatin 10mg in combination with placebo of Olmesartan 20mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
2557343|NCT02516826|Experimental|Olmesartan Arm|Olmesartan 20mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan/Rosuvastatin(Combination) 20/10mg orally once daily
2557345|NCT02516826|Experimental|Combination Arm|Olmesartan/Rosuvastatin(Combination) 20/10mg in combination with placebo of Rosuvastatin 10mg plus placebo of Olmesartan 20mg
3205626|NCT00945932|Experimental|28 day repeat dose|
3205627|NCT00945971|Experimental|Physical activity|The intervention group will participate in an exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be performed at the start and in the end of this study.
3205628|NCT00945984||LESS|Patients who underwent LESS radical nephrectomy
3205629|NCT00945984||Conventional laparoscopy|Patients who underwent conventional laparoscopic radical nephrectomy
2557744|NCT02514460|Active Comparator|Intervention: Stents|Stents group
2557746|NCT02514460|Active Comparator|Intervention: Atherectomy|Direct Atherectomy group
3205630|NCT00945997|Active Comparator|A|
3205631|NCT00945997|Active Comparator|B|
3205632|NCT00946010||1|Click here for more information about this study: Investigation of Hepatitis B and Hepatitis C in Taiwan
3205633|NCT00946049|Experimental|Vicryl Plus|
3205634|NCT00946049|Active Comparator|Vicryl|
3205635|NCT00946062|Active Comparator|regular O&M-training|orientation and mobility training in use of the identification cane as provided by mobility trainers
2557990|NCT02512562|Active Comparator|Group 1: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
2557993|NCT02512562|Active Comparator|Group 2: AL-335, Simeprevir and ACH-3102|AL-335, ACH-3102, and Simeprevir dosed in healthy human volunteers once daily for 24 days.
2558103|NCT02511873|Experimental|Fycompa|Fycompa dose is chosen based on tolerability and efficacy. 2mg to 8mg daily for 6 weeks then washed out.
3205636|NCT00946062|Experimental|standardised O&M-training|standardised orientation and mobility training in use of the identification cane as provided by mobility trainers who received instruction in using the standardised protocol
3205637|NCT00946127||Shunt Arm|Ventriculoperitoneal Shunt
3205638|NCT00946127||ETV arm|Endoscopic Third Ventriculostomy
2556716|NCT02521298|Experimental|Strength Training + Cortico-Steroid Inj.|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Cortico-Steroid Injection: Ultrasound-guided injection of 1 ml depomedrol 40 mg/ml + 1 ml lidocaine 10 mg/ml deep to the proximal part of the common extensor tendon origin using a 0,8 mm needle. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
2556717|NCT02521298|Experimental|Strength Training + Dry Needling|"Strength Training: 2 weeks after the inclusion, the patients are instructed in heavy slow resistance exercise by a physiotherapist. Exercise is continued 3 times/week for the following 12 weeks, with supervised follow-up at week 4, 8 and 12. Exercise consists of wrist extension, flexion and supination/pronation. Starting at 3 x 15 repetition maximum, gradually increasing in weight to 3 x 6 repetition maximum from week 8.~Dry Needling: Ultrasound-guided penetration of the proximal part of the common extensor tendon origin is repeated 10 times using a 0,8 mm needle, followed by subcutaneous injection of 2 ml isotonic saline superficial to the tendon. No-touch technique is used, and the patient is blinded with regards to the content of the syringe and the ultrasound-image."
2556765|NCT02520999|Active Comparator|5days|5 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
2556769|NCT02520999|Active Comparator|35days|35 days after blood sampling, various external pressure test will be done. Blood wil be stored in refrigerator(Celsius 4 degree) until study day. External pressure 0, 100, 150, 200, 250, 300mmHg will be applied to each blood sample.
2556797|NCT02520583|Experimental|MICROBAC|Bacterial cultures
2556799|NCT02520583|Placebo Comparator|Placebo|Maltodextrin
2556872|NCT02520492|Experimental|noninvasive method of ICP measurements|"Patients will receive a noninvasive measurement of ICP variations during each of their follow up consultation. These measurements will last until 30 minutes for the first consultation (parameters to determine) and 10 minutes for the others. A postural test will be performed during the ICP measurements when the patient condition will make it possible to do.~Measurements will be performed by a device with noninvasive acoustic probes placed in the ear, and in case of electrophysiological test, regular electrodes on the brow."
3205639|NCT00946140||Patients with ovarian cancer currently undergoing treatment|All of the patients will be treated per their treatment protocols by their physicians and they will be referred to this study for the DCE-MRI scans at baseline, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
3205640|NCT00946166|Placebo Comparator|Placebo Control|Subjects receive standard treatment for pneumonia and a simvastatin-like placebo
3205641|NCT00946166|Experimental|Simvastatin|Subjects receive simvastatin in addition to standard pneumonia treatment
3205642|NCT00946179|Experimental|Group 1|Participants aged 18 to 60 years at enrollment
2557039|NCT02519153|Placebo Comparator|control|patient receive placebo for 4 weeks and followed for passage of stone distal ureter
2557040|NCT02519153|Active Comparator|sildenafil|patient receive sildenafil 50 mg for 4 weeks once per day and followed for passage of stone distal ureter
2557062|NCT02518854||study|children aged 6-18 years with pre-metabolic syndrome
2557065|NCT02518854||control|children aged 6-18 years without pre-metabolic syndrome
2557184|NCT02518334|Experimental|Alcohol consumption|Alcohol consumption and wine consumption
2557233|NCT02517840||Nonagenarian CLI|Patients suffering from Critical Limb Ischemia aged 90 year-old or above who undergo limb revascularization by means of open surgery or endovascular revascularization
3205643|NCT00946179|Experimental|Group 2|Participants aged 61 years or older at enrollment
3205644|NCT00946205|Experimental|Laparoscopic anterior mesh rectopexy|
2557367|NCT02516761|Experimental|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise.
2557370|NCT02516761|Experimental|Low-impact aerobic exercise|Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
2557373|NCT02516761|Active Comparator|Control group|With this group no intervention is done, but they are assessed like the other groups.
2557415|NCT02516514|Experimental|Multi-sampling strategy|2 or 3 blood cultures in 24 hours worked at ½ hour intervals with seeding at least a pair of flasks, aerobic and anaerobic, by blood culture.
2557419|NCT02516514|Active Comparator|Single-sampling strategy|1 single dose of venous blood 30ml ± 10ml with seeding 4 blood culture bottles (aerobic and anaerobic 2 2).
3205645|NCT00946205|Active Comparator|Laparoscopic posterior rectopexy|
2557511|NCT02515955|Experimental|Cohort 4|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
3205646|NCT00946218||Part A|Children with presumptive dengue infection enrolled for empiric cost modeling with retrospective clinical estimation and comparison of test performance to the standard of care.
3205647|NCT00946218||Part B|Children with definitive dengue infection enrolled for gene expression analysis.
3205648|NCT00946231||Heart Failure|Subjects admitted to the hospital with decompensated heart failure.
3205649|NCT00946244||Term infants|Healthy term infants
3205650|NCT00946244||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth
3205651|NCT00946244||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in previous study)
3205652|NCT00946244||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in previous study)
2556753|NCT02521064||Prednisone|Patients who receive the prednisone intervention will follow the Division of Pediatric Gastroenterology and Nutrition protocol for corticosteroid induction therapy, with 2 weeks of high dose IV/PO prednisone (maximum 40mg/day) followed by a 6 week wean (approximately decreasing 5mg/day per week). The patient will receive a phone call from the nurse practitioner at two weeks and will be seen in clinic at 4 weeks to assess progress and symptom improvement.
2556812|NCT02520804|Active Comparator|normal saline|normal saline for fluid resuscitation and maintenance for 72 hours
2556813|NCT02520804|Experimental|sterofundin|sterofundin for fluid resuscitation and maintenance for 72 hours
2556846|NCT02520336|Experimental|active management|Laboratoy test request given postpartum with phone reminder prior to test
2556852|NCT02520336|No Intervention|Routine care|
2556910|NCT02520154|Experimental|Treatment (carboplatin, paclitaxel, and pembrolizumab)|"NACT: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~ADJUVANT THERAPY: Beginning 3-6 weeks after surgery, paclitaxel IV over 1 hour on days 1, 8, and 15, patients receive carboplatin IV over 1 hour on day 1, and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 20 cycles in the absence of disease progression or unacceptable toxicity."
3171323|NCT00585754|Active Comparator|Guanfacine|
3171324|NCT00585754|Placebo Comparator|PLA|
3171325|NCT00585767||1|Patients with two kidneys
3171326|NCT00585767||2|Patients with solitary kidney
3171327|NCT00585793||PEPFAR 1|
2557037|NCT02519114|Experimental|Bone MarrowTransplantation|KIR-mismatched haploidentical bone marrow transplantation
2557056|NCT02518776|Other|Neuropsychological tests|
2557094|NCT02518672|Active Comparator|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
2557095|NCT02518672|Placebo Comparator|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
2557202|NCT02517879|Experimental|Group 1 - 1-3 days|Community health worker hang-up visit 1-3 days after the community point distribution
2557203|NCT02517879|Experimental|Group 2 - 5-7 days|Community health worker hang-up visit 5-7 days after the community point distribution
2557205|NCT02517879|Experimental|Group 3 - 10-12 days|Community health worker hang-up visit 10-12 days after the community point distribution
2557209|NCT02517879|Experimental|Group 4 - 15-17 days|Community health worker hang-up visit 15-17 days after the community point distribution
2557213|NCT02517879|Placebo Comparator|Group 5 - No hang-up visit|Did not receive any hang-up visit after the community point distribution
2557349|NCT02517060||Healthy participants|Male or female healthy participants
2557433|NCT02516657|Experimental|Liraglutide 0.6 mg|Liraglutide 0.6 mg daily injection x 7 days
2557454|NCT02516189|Experimental|Group A|group of elderly participants of strength training program
2557456|NCT02516189|No Intervention|Group B|group of seniors who did not practice strength training program
2557636|NCT02515370|Other|Friends for Life Circles|The intervention will include formation of peer support groups of eight to ten women in the community with incorporation of income generating activities to improve maternal adherence to clinic appointments and life long antiretroviral therapy
2557638|NCT02515370|No Intervention|Standard|Normal standard of care and follow up. The standard care provided in the clinic will be provided for the control arem
2557665|NCT02514902|Experimental|Lateral Flow Device|Determine the feasibility of testing whole blood samples from patients with acute stroke (both ischemic and hemorrhagic) and traumatic brain injury being evaluated in the Emergency Department and Inpatient Services at University of Kentucky. No diagnostic or treatment decisions will be based on the results for any patient and the patient will not be told of the results.
2557708|NCT02514668|Experimental|Isatuximab|Isatuximab (escalating dose) on Days 1, 8, 15, and 22, then Days 1 and 15 in 28-day cycles up to disease progression
2557773|NCT02514109||patient|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuronopathy.
2557775|NCT02514109||control|Male or female patient aged 18 years or more with a clinically pure sensory neuropathy, abnormal ENMG in sensory nerves in more than one limb and complete etiological assessment allowing a diagnosis of sensory neuropathy excluding a neuronopathy.
3171328|NCT00585806||1|Subjects with Heart Failure and ejection fraction greater than or equal to 45%
3171329|NCT00585806||2|Healthy Volunteers
3171330|NCT00585819|Experimental|2. Free breathing|Freebreathing in Body fix mold
3171331|NCT00585819|Experimental|1. breathing cycle|reproducing breathing cycles
3171332|NCT00585832|Experimental|A|DASH-4-Teens Intervention
3171333|NCT00585832|Other|B|Routine Care
3171334|NCT00585845|Experimental|CRS-207|
3171335|NCT00585858||1|Subjects on mimimal or no immunosuppression and no rejection history
3171336|NCT00585858||2|Subjects who have had rejection on conventional immunosuppression
3171337|NCT00585858||3|Subjects who have not had acute or chronic rejection who are on conventional immunosuppression
3171338|NCT00585871|Experimental|Clonidine therapy group|clonidine 0.1 TID
3171339|NCT00585871|Active Comparator|Metoprolol control group|metoprolol 25 TID
3171340|NCT00585897|Experimental|Behavioral counseling|Individual sessions which utilize motivational interviewing to assist participants to discontinue sugar sweetened beverages from their diet.
3171341|NCT00585936||1|Normal controls without evidence of diabetes or islet specific autoimmunity
3171342|NCT00585936||2|Individuals within 6 months of diagnosis with type 1 diabetes
3171343|NCT00585936||3|Individuals at high risk for the development of type 1 diabetes
3171344|NCT00585936||4|Individuals with longstanding autoimmune diabetes
3171345|NCT00585949||Angiography|Patients undergoing coronary angiography without percutaneous coronary angioplasty
3171346|NCT00585949||Percutaneous Coronary Angioplasty|Patients with stable coronary artery disease undergoing angioplasty
3171347|NCT00585988|Other|1|
2556772|NCT02520986|Experimental|Carbon dioxide Laser ablation|Excision of genital warts using a carbon dioxide laser, ie CO2 Laser
2556774|NCT02520986|Active Comparator|Electrocoagulation|Excision of genital warts using a superficial electrical coagulation mode, ie spray coagulation
2556793|NCT02520648|Active Comparator|Neuro-lymphatic treatment|Participants were positioned in prone, with the head in neutral position and the arms beside the body. They were asked to perform conscious breathing. The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement. Neuro-lymphatic reflexes as referred to applied kinesiology, are locations on the body that are believed to affect a specific muscle and organ. Duration of the treatment is 15 minutes.
2556795|NCT02520648|Experimental|Articulatory spinal manual therapy.|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached. Three repetitions are performed at each vertebral level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize possible slight dysfunctions of the spine, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
2556796|NCT02520648|Experimental|Articulatory costal Manual therapy.|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier. Three repetitions are performed at each costal level. It is done bilaterally, then longitudinal pressures are applied on dorsal vertebrae during expiratory time, 3 repetitions. It ends like treatment 1. This technique aims to normalize the mobility of the ribs, enhance the feeling of comfort and pain, and relax the spine. Duration of the treatment is 15 minutes.
2556831|NCT02520479|Experimental|sandwich protocols|"sandwich protocols: Patients with newly diagnosed ENKTL is given 2 cycles of P-CHOP[cyclophosphamide(CTX), 750 mg/m2 day 1; vincristine(VCR), 1.4 mg/m2 day 1 (maximal dose 2 mg),adriamycin(ADM) 50 mg/m2 day 1; dexamethasone(DXM) 10 mg days 1-8; Pegaspargase 2500 international unit day 1] before radiotherapy(RT) and then two consolidation cycles after RT."
2556881|NCT02520219|Experimental|GDP+Endostar|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum)chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma and Endostar."
2556883|NCT02520219|Active Comparator|GDP|"Patients in this group will be given conventional chemotherapy medicine:~GDP (gemcitabine+dexamethasone+cis-platinum) chemotherapy by treatment guidelines for Peripheral T-cell Lymphoma."
2556918|NCT02519933|Active Comparator|mNT-BBAVF|Patients in Chronic Kidney Disease (CKD) stage 4-5 without previous dysfunctional fistula access
2556925|NCT02519933|Active Comparator|BCAVF|Patients in CKD stage 4-5 without previous dysfunctional fistula access
2556975|NCT02519634|Other|Group 1|Patients in Group 1 undergo Super-Mini Percutaneous Nephrolithotomy
2556976|NCT02519634|Other|Group 2|Patients in Group 2 undergo Retrograde Intrarenal Surgery
2557012|NCT02519205||ED Nurses|ED triage nurses from Duke University Hospital (DUH) and Duke Regional Hospitals (DRH).
2557041|NCT02519010|Experimental|A Test|Test drug (Amlodipine/Valsartan) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
2557042|NCT02519010|Active Comparator|B Reference|Reference drug (Exforge) 1 tablet contains Amlodipine 10 mg & valsartan 160 mg
2557088|NCT02518711|Experimental|Behavioral teacher program|The behavioral teacher program was used by the participant's teacher in the classroom during 18 weeks.
2557089|NCT02518711|No Intervention|Control group|Children within the control group did not receive the behavioral teacher program but were allowed to receive regular care
2557165|NCT02518321|Experimental|Standard Toileting First|This group will complete the standard toileting trial before the TAT toileting trial.
2557168|NCT02518321|Experimental|TAT Toileting First|This group will complete the TAT toileting trial before the standard toileting trial.
2557231|NCT02517892|Experimental|Patients with metastatic oncogen-driven cancer|
2557299|NCT02517437|Active Comparator|Suprascapular & axillary blocks|Suprascapular and axillary blocks.
2557306|NCT02517437|Active Comparator|Interscalene block|Interscalene block.
2557385|NCT02517008|Experimental|Mama kits intervention|"Health facilities randomized to this arm provided mama kits - packages of childcare materials including a cloth (chitenge), baby blanket, and diaper - to all mothers who delivered at these facilities between June 1, 2013 - Aug 31, 2013."
2557386|NCT02517008|No Intervention|No intervention|Health facilities randomized to this arm provided obstetric services as normal.
3205653|NCT00946257|Experimental|Cohort 1|0.3 mg dose
2557596|NCT02515487|Experimental|Breast cancer patients receiving chemotherapy treatment|
2557655|NCT02515084|Experimental|18F-FDG-PET and dw-MRI|At the inclusion, both all patients, a 18F-FDG-PET/CT and a dw-MRI will be performed
2557700|NCT02514681|Active Comparator|Trastuzumab + chemotherapy|Trastuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel ,Vinorelbine, Eribulin, Capecitabine or Gemcitabine
2557702|NCT02514681|Experimental|Trastuzumab+ pertuzumab + chemotherapy|Trastuzumab+ pertuzumab + chemotherapy Chemotherapy regimen is chosen from the following; Docetaxel, Paclitaxel, nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine or Gemcitabine
3171348|NCT00585988|Other|2|
3171349|NCT00586014|Experimental|I|High-dose sequential cyclophosphamide and VP-16 followed by myeloablation with high-dose BCNU and melphalan with autologous stem cell transplant
3171350|NCT00586027||NT-proBNP|150 consecutive patients undergoing cardiac surgery with an intraoperative measured cardiac output <2L/min/m².
3171351|NCT00586040|Experimental|1|superficial closure with PTB
3171352|NCT00586040|Active Comparator|2|superficial sutures
3171353|NCT00586053||1|485 patients,who have an average risk (asymptomatic and without colon screening in the last 5 years) or those who have a high risk for colon cancer (strong family history of colon cancer or polyps and/or personal history of colon cancer or polyps).
3171354|NCT00586053||2|160 patients, with a known colorectal lesion at or greater than 1 cm.
2556802|NCT02520635||post-surgery supra-early TEMODAL® chemotherapy|Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.
3171355|NCT00586053||3|610 patients, who are of average risk for colon cancer (asymptomatic and no colon cancer screening in the last 5 years).
3171356|NCT00586079|Experimental|A|Ten patients who have had deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
3171357|NCT00586079|Experimental|B|Ten patients who are scheduled to have deep brain stimulation surgery for Parkinson's disease at Mayo Clinic Arizona.
3171358|NCT00586092|Other|1|This trial employs a phase I design with a dose escalation stage (stage I) and an expansion stage (stage 2) to better describe the tolerability of this combination and the effect of this combination on several biomarkers. In this second stage there will be two groups, each with ten patients, to better describe the tolerability of the bevacizumab/ABT-510 combination and the effect of this combination on several biomarkers. The primary objective of this study is to estimate the MTD/recommended phase II dose regimen. All other objectives are exploratory in nature.
3171359|NCT00586118||1-Sevo|Sevoflurane/ACD group (n=60)
2556898|NCT02519868|Experimental|Experimental arm|Patients will have both interventions: electrical stimulation followed by chemical stimulation
3171360|NCT00586118||2-Propofol|Propofol group (n=60)
3171361|NCT00586131|Active Comparator|Low normal pH (arterial pH 7.36-7.38)|Ammonium chloride or sodium citrate/citrate acid as needed to achieve the target pH
3171362|NCT00586131|Active Comparator|High Normal pH (arterial pH 7.44-7.46)|High Normal pH (7.44-7.46) with use of increasing doses of sodium bicarbonate up until the desired pH is achieved
2557008|NCT02519296|Active Comparator|Prolonged Exposure Therapy|"In total 30 Danish veterans will be recruited, who meet the ICD-10 diagnostic criteria for PTSD, and treated with PE.~Intervention with eight sessions of PE, psychometrics, blood analyses and fMRI."
2557013|NCT02519296|Active Comparator|30 Danish veterans without PTSD|"A group of controls will be recruited consisting of age-appropriate same sex veterans who have participated in international missions similar to the patient group.~Observation with psychometrics, blood analyses and fMRI."
2557070|NCT02518932|Experimental|Drug GLP-1 (32-36) Amide|To examine insulinomemtic of the last 5 amino acids of GLP-1 from 60-180 min during a 4 hour hyperglycemic clamp
2557073|NCT02518932|Placebo Comparator|Placebo|To examine the effect of saline on glucose uptake
3205654|NCT00946257|Experimental|Cohort 2|0.6 mg dose
3205655|NCT00946257|Experimental|Cohort 3|1.2 mg dose
2557185|NCT02518074|Other|HEARING AND VESTIBULAR INTERACTIONS|Hearing and Vestibular Interactions during two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
2557224|NCT02517827|Active Comparator|Endovascular procedure|Common femoral artery (target lesion) to be treated with directional atherectomy and paclitaxel-coated balloon angioplasty. Optional: stentimplantation.
2557227|NCT02517827|Active Comparator|Surgery|Common femoral artery (target lesion) to be treated with open, surgical endarterectomy
2557279|NCT02517450|Experimental|experimental group|The subjects had to participate an adventure-based training programme.
2557283|NCT02517450|Placebo Comparator|placebo control group|The subjects had to participate a placebo control programme
2557329|NCT02517125|Experimental|Patients with head and neck cancer|
2557340|NCT02516865|Experimental|Group 1|
2557342|NCT02516865|Experimental|Group 2|
2557346|NCT02516865|No Intervention|Group 3|
2557404|NCT02516696|Experimental|BiRD treatment regimen|Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.
2557407|NCT02516696|Active Comparator|Rd treatment regimen|Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.
2557446|NCT02516267|No Intervention|Control Group|Patients who will discontinue inhibitor-ADP for 5 days before surgery, and must be operated on the first working day after completing the 5 days without the drug. This group will have its aggregability evaluated by platelet function testing (Multiplate ADP®) immediately before the transport to the operating room.
2557452|NCT02516267|Active Comparator|Intervention Group|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG, to be held on the first working day after release.
3205656|NCT00946257|Experimental|Cohort 4|1.8 mg dose
3205657|NCT00946257|Experimental|Cohort 5|2.4 mg dose
2557580|NCT02515500|Active Comparator|Gradual Cessation|
2557585|NCT02515500|Experimental|Gradual Cessation w/ Quitbit|
2557691|NCT02514733||Young donor|Kidney transplant recipient > 60 years of age who received organ from donor <=40 years of age
2557692|NCT02514733||Old donor|Kidney transplant recipient >= 60 years of age who received organ from donor >=50 years of age
2557739|NCT02514525|Other|CryoBalloon Ablation System|Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.
2557844|NCT02513589|Experimental|Experimental arm|
2557876|NCT02513420|Experimental|Perineal muscle training|This group will recibe a training of a combination of perineal massage and pelvic floor muscle excersice that will start after 33 weeks of gestation. Every week until the childbith, They will be evaluated with a diary.
2557879|NCT02513420|No Intervention|Usual prental care|Usually pregnant women have not a training focused in pelvic floor muscle, so this group won't receive any indication of pelvic floor training except if They complains of urinary incontinence.
3171363|NCT00586183|Experimental|1|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
3171364|NCT00586222|Placebo Comparator|2|
3205658|NCT00946257|Experimental|Cohort 6|3.0 mg dose
2556911|NCT02519920|Experimental|group 1|This group patients were given dosages of fluorescein sodium 0.01ml/kg intravenous administration.
2556913|NCT02519920|Experimental|group 2|This group patients were given dosages of fluorescein sodium 0.02ml/kg intravenous administration.
2556923|NCT02519920|Experimental|group 3|This group patients were given dosages of fluorescein sodium 0.05ml/kg intravenous administration.
2556927|NCT02519920|Active Comparator|group 4|This group patients were given dosages of fluorescein sodium 0.1ml/kg intravenous administration.
3205659|NCT00946283|Experimental|Lactobacillus GG|Open label trial of Culturelle (Lactobacillus GG) administered to patients after engraftment, post allogeneic stem cell transplantation.
3205660|NCT00946335|Experimental|Treatment (veliparib, temozolomide)|"Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.~Blood samples are collected for pharmacokinetics and further laboratory analysis."
3205661|NCT00946361||Diagnostic|
2557064|NCT02518867|Experimental|high intensity iTBS|high intensity iTBS: 100% of active motor threshold for 3 days.
2557067|NCT02518867|Experimental|low intensity iTBS|low intensity iTBS: 80% of active motor threshold for 3 days.
2557068|NCT02518867|Sham Comparator|sham iTBS|sham iTBS for 3 days.
2557130|NCT02518477|Experimental|exercise group|"The first 20 weeks, twice-weekly 60 minute session of physical exercise supervised by the research assistant and once weekly home exercise programme is offered. The exercise intervention will consist of stretching, scar tissue mobilization and resistance exercises.~For the following 32 weeks a home-training manual specifying three times weekly training is provided. At week 26 an individual booster session will be offered. In the case of lymphedema, referral to trained lymphedema physiotherapist for evaluation of appropriate intervention is made."
2557133|NCT02518477|No Intervention|usual care control group|Receives all standard care offered from the operating hospital and rehabilitation in the municipality.
3205662|NCT00946387|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
3205663|NCT00946387|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
2557251|NCT02517671|Other|EECP Treatment|35 one hour (1hr) sessions of Enhanced External Counterpulsation (EECP).
2557295|NCT02517398|Experimental|MSB0011359C (M7824)|
2557438|NCT02516436|Experimental|BEMA Buprenorphine NX|Buprenorphine with naloxone in a buccal film
2557441|NCT02516436|Active Comparator|Buprenorphine|Buprenorphine in a buccal film
3205664|NCT00946400||Suspected HIT|Those who are clinically suspected of having HIT will be enrolled in this study.
3205665|NCT00946413|Experimental|CBT plus parent education|
3205666|NCT00946413|Experimental|CBT alone|
3205667|NCT00946426||Diagnostic|Hyperinsulinemic euglycemic clamp
2557722|NCT02514603|Experimental|Prexasertib|Prexasertib intravenously (IV) on day 1 of a 14 day cycle. Treatment with prexasertib may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met.
2557753|NCT02514265||UCPPS patients|"All participants in this study are men or women who have been diagnosed with Urologic Chronic Pelvic Pain Syndrome (UCPPS). Approximately one-half of the participants will be male, and one-half will be enriched to meet the body map pain location criteria of pelvic pain (PP) only. In addition, enrichment recruitment of 240 UCPPS patients (120 males; 120 females) will also be targeted for those who answer no to questionaire question about specific Bladder pain symptoms."
2557798|NCT02513979|Active Comparator|angiotensin type II receptor antagonists|Hypertensive patients treated with angiotensin type II receptor antagonists
2557799|NCT02513979|No Intervention|No treatment|Normotensive patients
2557875|NCT02513381|Active Comparator|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
2557878|NCT02513381|Placebo Comparator|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
2557915|NCT02513199|Experimental|TACE/SBRT combination|
2557916|NCT02513199|Active Comparator|TACE alone|
2557961|NCT02512887|Experimental|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
2557962|NCT02512887|Active Comparator|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
2558017|NCT02512523|Experimental|Teneligliptin|Film-coated tablet for oral administration Dosage: 20mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
2558020|NCT02512523|Active Comparator|Sitagliptin|Film-coated tablet for oral administration Dosage: 100mg/tablet Frequency and duration: 1 tablet/day for 4 weeks
2558071|NCT02512159|Experimental|drenovac handcrafted|Patients treatment with the handicraft topical device negative pressure therapy Economic craft
2558074|NCT02512159|Active Comparator|Healing|"Patients who were managed with traditional conservative treatment."
2558105|NCT02511756|Other|Perfusion-computed tomography (CTP)|Patients undergo a total of four perfusion-computed tomographies from baseline to progression of disease.
2558141|NCT02511548|Experimental|Intervention|Financial incentive
2558143|NCT02511548|No Intervention|Control|No financial incentive
2558222|NCT02511301|Experimental|Cyrcadia CBR™ Device|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.There are no interventions after the CBR™ is removed from the Study Subject
3205668|NCT00946465|Experimental|1|Ramipril 10 Capsule (Sandoz)
3205669|NCT00946465|Active Comparator|2|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)
2558391|NCT02509923|Experimental|2|3-way cross-over, Z-215 20 mg/day / Z-215 40 mg/day / Rabeprazole Sodium 20 mg/day
3205670|NCT00946491|Experimental|1|Haloperidol 10 mg Tablets (Cord Laboratories)
3205671|NCT00946491|Active Comparator|2|Haldol 10 mg Tablets (McNeil Pharmaceuticals)
3205672|NCT00946504|Experimental|1|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)
2556841|NCT02520323||Blood and BAL|10 sarcoidosis subjects, 10 healthy controls, and 10 subjects with non-sarcoid interstitial lung disease will complete lifestyle questionnaires and undergo blood sampling for microbiome analyses as well as bronchoscopy for bronchoalveolar lavage microbiome analyses.
2556919|NCT02520141|Experimental|Treatment (ramucirumab)|Patients receive ramucirumab IV over 60 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2556963|NCT02519569|Experimental|Intervention group|Internet-based cognitive-behavioral therapy for complicated grief
2557014|NCT02519166|Other|Patients with chronic wounds|
3205673|NCT00946504|Active Comparator|2|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)
2557107|NCT02518542|Active Comparator|Per oral endoscopic therapy A|Per oral endoscopic myotomy
2557110|NCT02518542|Active Comparator|Per oral endoscopic therapy B|Prolonged dilatation by implantation of large diameter stents.
2557115|NCT02518542|Active Comparator|Per oral endoscopic therapy C|Dilatation
2557122|NCT02518542|Active Comparator|Laparoscopic surgery|Laparoscopic Heller myotomy
3205674|NCT00946517||Parents|Parents or caregivers of type 1 diabetics
3205675|NCT00946517||Child|Type 1 diabetics
3208814|NCT00978367|Experimental|Drug, intradermal avotermin (Juvista)|
2557390|NCT02516852|Experimental|Intervention|
2557395|NCT02516852|No Intervention|Control|
2557492|NCT02516085|Experimental|L-arginine and metformin|7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g, respectively 3x 250 mg) for 16 weeks
2557594|NCT02515396|Experimental|Treatment Group A|MMI-0100 Inhaled, once daily x 5, followed by 3 week washout period, followed by Placebo Inhaled, once daily x 5
2557595|NCT02515396|Experimental|Treatment Group B|Placebo Inhaled, once daily x 5, followed by 3 week washout period, followed by MMI-0100 Inhaled, once daily x 5
2557791|NCT02514005|Active Comparator|Manual therapy|Overall bilateral manipulation (L5-S1-SI), Hip joint gapping, Stretching the hip rotators with hip and knee flexion, Femorotibial Gapping, Decompression of connective tissue of the patellofemoral region, Internal and external joint line opening in laterality, Mobilization of the base of the fibula, Tibiofibular-talus gapping, and Muscle strengthening.
2557796|NCT02514005|Experimental|Manual therapy and Dry needling|Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps.
2557887|NCT02513368|Experimental|Bio-Oss®, Bio-Gide®|augmentation procedure with Bio-Oss® and Bio-Gide®
2557888|NCT02513368|Active Comparator|connective tissue graft|augmentation procedure with connective tissue graft
3174942|NCT00628550|Active Comparator|2|Pediatric patients that experience in-hospital CPA who remain in cardiac arrest despite CPR and an initial, standard dose of epinephrine (0.01 mg/kg), will be randomly assigned to receive standard dose epinephrine (0.01 mg/kg)rescue as the second vasopressor medication.
3174943|NCT00628563||1|Asthma patients
3174944|NCT00628576|Active Comparator|1|UFH: patients treated with unfractionated heparin
3174945|NCT00628576|Experimental|2|FH: patients treated with low-molecular-weight (fractionated) heparin
3174946|NCT00628602|Experimental|Rx Group|BION Therapy Group
3174947|NCT00628602|Placebo Comparator|Control Group|control group
3174948|NCT00628615||2|male patients with lower urinary tract symptoms
3174949|NCT00628615||1|Female patients with overactive bladder syndrome
3174950|NCT00628654||Volunteers|Serum samples will be obtained from volunteers, but no tissue specimens. Volunteers will complete a questionnaire.
3174951|NCT00628654||Patients with cancer|Ascites from patients with ovarian, peritoneal, and fallopian tube cancers for basic science studies
3174952|NCT00628667|Experimental|1|
3174953|NCT00628667|Placebo Comparator|2|
3174954|NCT00628680|Experimental|AAT-023 (Zuragen Arm)|Active experimental consisting of AAT-023 (Zuragen)solution
3174955|NCT00628680|Active Comparator|Heparin|5000 units diluted with normal saline to the exact catheter lumen volume
3174956|NCT00628706|Experimental|A|Inhalation of THC, using a Volcano vaporizer
3174957|NCT00628706|Placebo Comparator|B|Inhalation of vehicle, using a Volcano vaporizer
3174958|NCT00628719|Experimental|1|a single dose of 10 mg/kg of liposomal amphotericin B
3174959|NCT00628719|Active Comparator|2|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
3174960|NCT00628732|Experimental|1|
3174961|NCT00628771|Active Comparator|Usual Care|Participants will receive usual care for their prenatal visits.
3174962|NCT00628771|Experimental|CenteringPregnancy Plus|Participants will receive the CenteringPregnancy Plus treatment program, which includes an HIV/STD prevention component.
3205676|NCT00946556|Placebo Comparator|Placebo|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
3205677|NCT00946556|Experimental|Valacyclovir|Participants will be assigned 2 months of placebo or active drug, with an intervening one month washout period.
2556930|NCT02519829|Active Comparator|Monocryl closure|"The skin incision is closed with monocryl dissolvable sutures and a topical adhesive (glue) called Dermabond and covered with a Tegaderm dressing.~Intervention: Monocryl closure, Tegaderm dressing"
2556931|NCT02519829|Active Comparator|Vicryl and staple closure|"The skin incision is closed with vicryl and staples and covered with a gauze dressing.~Intervention: Vicryl and Staple closure, Gauze dressing"
2556953|NCT02519543|Placebo Comparator|Placebo|Placebo comparator to be given twice daily, once with breakfast and once with supper
2556954|NCT02519543|Experimental|Metformin|Metformin 2000 mg daily to be given as follows: 1000 mg with breakfast and 1000 mg with supper
2557011|NCT02519426||Cumulative complexity score <9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score lower than 9.
2557017|NCT02519426||Cumulative complexity score y≥9|Mandibular third molar surgery patients with Juodzbalys and Daugela impacted mandibular third molars surgical extraction complexity index cumulative score higher than 9.
2557019|NCT02519426||Pell Gregory index <Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 1A, Class 1B, Class 1C, or Class 2A
2557022|NCT02519426||Pell Gregory index ≥Class 2B|Mandibular third molar surgery patients with Pell Gregory index Class 2B, Class 2C, Class 3A, Class 3B, or Class 3C
2557027|NCT02519426||Winter index <Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Mesio-Angular, Disto-Angular or Vertical impaction
2557028|NCT02519426||Winter index ≥Horizontal impaction|Mandibular third molar surgery patients with Winter predicted index of Horizontal, Buccal / Lingual Obliquity, Transverse, Inverse impaction
2557046|NCT02518841|Active Comparator|Achilles Tendon Stretching|This is the arm of participants who will first be assigned to perform 6 weeks of achilles tendon stretching as demonstrated in the protocol. As this is a crossover design study, this arm will then switch to 6 weeks of ThermaWedge TM stretching.
2557052|NCT02518841|Experimental|ThermaWedge TM|This is the arm of participants who will first be assigned to perform 6 weeks of ThermaWedge TM stretching as demonstrated in the protocol. As this is a crossover design study this arm will then switch to 6 weeks of Achilles Tendon Stretching
3205678|NCT00946569|Experimental|Treatment A (JNJ39758979)|Participants will receive JNJ39758979 300mg once daily for 12 weeks.
3205679|NCT00946569|Placebo Comparator|Treatment B (Placebo)|Participants will receive matching placebo once daily for 12 weeks.
3205680|NCT00946595|Active Comparator|efavirenz/emtricitabin/tenofovir|
2557333|NCT02516917|Experimental|Attention Training Technique (ATT)|Participants will receive 3-5 sessions of the ATT over a period of 3-5 weeks. A set of standardised instructions will be read to each participant and then they will engage in the procedure for a period of 12 minutes. Participants will listen to a set of auditory stimuli and follow the directions of the recording. This will ask them to focus their attention on selected sounds or spatial locations, switch attention between different sounds and locations, before allocating their attention to all sounds simultaneously. Participants will be given a recording of the ATT on a C.D and asked to practice this at least once before the second session.
2557411|NCT02516566|Experimental|PEEP group|Mechanical ventilation with PEEP 8 cmH2O
2557413|NCT02516566|No Intervention|No PEEP group|Mechanical ventilation with no PEEP
2557445|NCT02516345|Active Comparator|Child-based Incentive (CBI)|"Children earn rewards each week (with the week beginning on Monday and ending on Sunday) that they log 10,000 daily steps on the Fitbit according to the schedule below and their matched parent logs at least 2,000 steps on ≥4 of 7 days each week (regardless of which 4 of the 7 days they wear it). Incentives are tied, in addition to child's activity, to parent's Fitbit wear so that the investigators are better able to capture parent's activity in this arm.~Step Targets for Children in CBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
2557450|NCT02516345|Experimental|Family-based Incentive (FBI)|"Children earn rewards each week that they log daily steps on the Fitbit according to the schedule below but only if their matched parent also logs 10,000 steps according to the schedule below. Otherwise, children earn no incentive for that week.~Step targets for children and parents in FBI arm:~Months 1 - 3: ≥10,000 daily steps on ≥4 out of 7 days each week~Months 4 - 6: ≥10,000 daily steps on ≥5 out of 7 days each week~Months 7 - 12: ≥10,000 daily steps on ≥6 out of 7 days each week"
2557502|NCT02515955|Experimental|Cohort 1|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557506|NCT02515955|Experimental|Cohort 2|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557508|NCT02515955|Experimental|Cohort 3|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557518|NCT02515877|Experimental|Radiotherapy + Vistide + Chemoterapy|
3205681|NCT00946595|Experimental|lopinavir/ritonavir|
3205682|NCT00946608|Experimental|1|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)
3205683|NCT00946608|Experimental|2|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)
3205684|NCT00946608|Active Comparator|3|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)
3205685|NCT00946621|Experimental|1|Ramipril 10 mg Capsule (Sandoz)
3205686|NCT00946621|Active Comparator|2|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)
3205687|NCT00946634|Experimental|Ozone Gas|Endodontic protocol preconized by University of Sao Paulo associated to ozone gas 40 mg/L
2556865|NCT02520453|Placebo Comparator|Placebo|Placebo Q 4 weeks for 1 year, or until disease relapse or unacceptable toxicity
2556924|NCT02520102|Experimental|sargramostim|Sargramostim is administered daily until the absolute neutrophil count (ANC) equals or exceeds 1500/mm^3 for 3 consecutive measurements or up to 42 days post-induction chemotherapy.
2556977|NCT02519660|Experimental|Lidocaine/Tetracaine patch (Ralydan)|Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
2556978|NCT02519660|Active Comparator|Lidocaine/Prilocaine cream (EMLA)|EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
2557005|NCT02519179|Experimental|Conventional vs. Opaque, Weighted Bottle|This is a within-subject experiment; mothers will be asked to feed their infants from a clear, conventional bottle during one visit and an opaque, weighted bottle during the other visit. Order of conditions will be counterbalanced.
3205688|NCT00946634|Active Comparator|Control|Regular endodontic protocol preconized by University of Sao Paulo
3205689|NCT00946634|Experimental|Aqueous Ozone|Endodontic protocol preconized by University of Sao Paulo associated to Aqueous ozone 40mg/L
2557138|NCT02518347|Experimental|FDS-Strawberry|Freeze-dried strawberry powder (50g/d)
2557141|NCT02518347|Placebo Comparator|Placebo|Powder matched for carbohydrates and fiber in the strawberries
2557156|NCT02518100|Experimental|VSP 3-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 3-lead (NEHB) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
2557158|NCT02518100|Experimental|VSP 1-Lead Study Participants|"Intervention: Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration. The participants of this arm will have the following vital signs taken and recorded by the VSP System in the 1-lead (PAL) configuration:~Arterial blood oxygen Saturation (SpO2) ECG Heart Rate Surface Temperature Respiration"
2557214|NCT02517944||Familial hypercholesterolemia patients|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
2557215|NCT02517944||Control group|"clinical data~biological data~cardiac and aortic RMI with gadolinium"
2557266|NCT02517619|Experimental|Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate ophthalmic solution (40 mg/mL)
2557268|NCT02517619|Active Comparator|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate Ophthalmic (1%)
2557325|NCT02517229|Other|in balance control in response to microgravity|to evaluate changes in balance control in response to microgravity during reactive balance tasks compared to normal gravity.
2557336|NCT02516930|Other|Crowdsourced video|One-minute crowd-sourced video promoting condom use among men who have sex with men and transgender individuals.
2557338|NCT02516930|Other|Social marketing video|One-minute social marketing video promoting condom use among men who have sex with men and transgender individuals
2557436|NCT02516397|Experimental|Omnia group|After 2 weeks of run-in period, subjects take 2 Omnia pills per meal (3 meals a day) for 12 weeks.
2557439|NCT02516397|Placebo Comparator|Placebo group|After 2 weeks of run-in period, subjects take 2 Placebo pills per meal (3 meals a day) for 12 weeks.
2557470|NCT02516137|Experimental|Dry needling group|Subjects with tight hamstrings will receive dry needling to the hamstrings with the needle inserted into the muscle tissue in addition to a standard hamstring stretching exercise program.
2557477|NCT02516137|Sham Comparator|Sham dry needling group|Subjects with tight hamstrings will receive sham dry needling to the hamstrings with the needle inserted into the subcutaneous tissue in addition to a standard hamstring stretching exercise program.
2557481|NCT02516137|Placebo Comparator|No needling group|Subjects with tight hamstrings will receive no needling but have the tip of a blunt needle handle placed on the skin over the hamstrings in addition to a standard hamstring stretching exercise program.
2557534|NCT02515786|Experimental|oxygen humidification|Oxygen by nasal catheter delivery will be humidified by bubles.
2557535|NCT02515786|No Intervention|Dry oxygen|oxygen by nasal catheter delivery will be dry
2557599|NCT02515565|Experimental|Experimental group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will be included in a physiotherapy program added to the standard medical treatment.
2557603|NCT02515565|Other|Control group|Patients with a clinical diagnosis of pneumonia will be included in this group. They will receive only the standard medical treatment based on cephalosporin with or without erythromycin.
2557650|NCT02515006|Experimental|Homeopathy|Individualized homeopathy treatment as a supportive care
2557651|NCT02515006|No Intervention|Control|Usual Care
3205690|NCT00946673|Experimental|vorinostat & stereotactic radiosurgery|
2557760|NCT02514200|Experimental|Topography-based CXL (KXL2)|Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
2557763|NCT02514200|Active Comparator|Conventional pulsed CXL (pCXL)|Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.
2557824|NCT02513836|Experimental|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
3205691|NCT00946686|Experimental|1|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
3205692|NCT00946686|Active Comparator|2|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
3205693|NCT00946699|Experimental|1|MEDI-551
3205694|NCT00946699|Experimental|2|MEDI-551
3205695|NCT00946699|Experimental|3|MEWDI-551
3205696|NCT00946699|Experimental|4|MEDI-551
3205697|NCT00946699|Experimental|5|MEDI-551
3205698|NCT00946699|Placebo Comparator|6|Placebo
3205699|NCT00946725|Experimental|1|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)
3205700|NCT00946725|Active Comparator|2|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)
2556892|NCT02520167|Experimental|Dietary and Lifestyle Counseling|Women randomized to the intervention group will meet with a dietary counselor for 15 minutes at every prenatal appointment. They will receive a dietary and lifestyle curriculum based on the Diabetes Prevention Program curriculum (11 lessons) with one additional lesson providing prenatal breastfeeding education. They will also have access to a private online Facebook page for additional education and peer group support.
2556895|NCT02520167|No Intervention|Standard of Care|Usual prenatal care consists of regular clinical appointments, pregnancy ultrasounds, and recommendations to use prenatal multivitamins, eat a balanced diet, and remain physically active. Women with a pre-pregnant body mass index > 30 complete early glucose screening (as early as possible after presentation at the clinic) to detect pre-existing diabetes, and all women undergo routine gestational diabetes screening at 24-28 weeks. Women who test positive for pre-existing diabetes or gestational diabetes are referred to a registered dietitian.
3205701|NCT00946738|Active Comparator|physical therapy|
3205702|NCT00946738|No Intervention|control|
3205703|NCT00946751|Experimental|1|Levetiracetam Tablets, 750 mg (Sandoz Inc.)
2557259|NCT02517697|Experimental|Active drug|14 Nitrogen (N) Sodium Nitrite 40mg three times daily (TID)
2557263|NCT02517697|Placebo Comparator|Placebo|placebo capsules three time daily (TID)
2557292|NCT02517255|Experimental|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed within 7 days of rescue percutaneous coronary intervention (PCI) and after 3 and 6 months.
2557347|NCT02517086|Active Comparator|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
2557350|NCT02517086|Active Comparator|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
2557353|NCT02517086|Active Comparator|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
2557388|NCT02516618|Experimental|Cohort 1|Participants in this cohort will receive dose 1 of Fasinumab or placebo
2557392|NCT02516618|Experimental|Cohort 2|Participants in this cohort will receive dose 2 of Fasinumab or placebo
2557396|NCT02516618|Experimental|Cohort 3|Participants in this cohort will receive dose 3 of Fasinumab or placebo
2557397|NCT02516618|Experimental|Cohort 4|Participants in this cohort will receive dose 4 of Fasinumab or placebo
2557401|NCT02516618|Experimental|Cohort 5|Participants in this cohort will receive dose 5 of Fasinumab or placebo
2557449|NCT02516280|Experimental|Hyperbaric gaseous cryotherapy group|Conventional rehabilitation with Cryoton ™ hyperbaric cryotherapy
2557453|NCT02516280|Active Comparator|Control ice bag group|Conventional rehabilitation with ice bag cryotherapy. Application of a bag of crushed ice directly on the anterior aspect of the knee.
2557501|NCT02515968|Active Comparator|Desflurane|Anesthesia is maintained with desflurane during surgery.
2557503|NCT02515968|Experimental|Propofol|Anesthesia is maintained with propofol during surgery.
2557566|NCT02515734|Active Comparator|FOLFOXIRI+Bmab|Patients in the FOLFOXIRI + Bmab group receive until 12 cycles of FOLFOXIRI plus bevacizumab, consisting of a 30-minute infusion of bevacizumab at a dose of 5 mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and bevacizumab every 14 days until disease progression.
2557572|NCT02515734|Experimental|FOLFOXIRI+Cmab|Patients in the experimental group received until 12 cycles of FOLFOXIRI plus cetuximab, consisting of a 30-minute infusion of cetuximab first time at a dose of 400 mg per kilogram, after the second time at a dose of 250mg per kilogram, a 60-minute infusion of irinotecan at a dose of 150 mg per square meter, and a 120-minute infusion of oxaliplatin at a dose of 85 mg per square meter and a concomitant 120-minute infusion of leucovorin at a dose of 200 mg per square meter, followed by a 48-hour continuous infusion of fluorouracil to a total dose of 2400 mg per square meter. Cycles were repeated every 14 days. After 13 cycles, patients receive fluorouracil, leucovorin and cetuximab every 14 days until disease progression.
2557628|NCT02515162|Experimental|Fischer Cone Biopsy Excisor|Conization Methode using a triangular electrode , i.e. Fischer Cone Biopsy Excisor
2557633|NCT02515162|Active Comparator|Loop Excision Procedure|Conization Methode using a circular electrode , i.e. Loop excision Procedure
2557675|NCT02514928|Experimental|pancreatoduodenectomy & nerve resection|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
2557676|NCT02514928|Active Comparator|pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
2557727|NCT02514564||2x/wk|This group will be consisted of patients that will perform exercise two times a week.
2557728|NCT02514564||3x/wk|This group will be consisted of patients that will perform exercise three times a week.
2557729|NCT02514564||Control|This group will not perform exercise.
3205704|NCT00946751|Active Comparator|2|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)
2557827|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. They will repeat the questionnaire (POEM) after this education on opioid knowledge on the same day.
3205705|NCT00946764|Experimental|1|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)
2556896|NCT02520076|Experimental|AAT treated group|Study subjects will receive Alpha-1 Antitrypsin (AAT) study drug intravenously in 4 doses over 15 days around the time of their transplant. The islets will also be prepared in a solution of AAT.
2556991|NCT02519374|Placebo Comparator|Placebo|Placebo
2556992|NCT02519374|Active Comparator|PROMITOR® dose 1|Investigational product dose 1
2556995|NCT02519374|Active Comparator|PROMITOR® dose 2|Investigational product dose 2
2556996|NCT02519374|Active Comparator|PROMITOR® dose 3|Investigational product dose 3
2557038|NCT02519140|Experimental|Cook medical EMR Gel|"Prospective study involving excised human stomachs and colon harvested from sleeve gastrectomies and colectomies performed for benign or malignant disease.~Different Cook submucosal injections of varying viscosities will be injected into different areas of the excised stomachs or colons.~Data collected will involve lifting characteristics and dissection adequacy of the varying viscosities of gel."
2557060|NCT02518789|Experimental|Low-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 0.5 µg/kg，completed within 15 minutes.
2557063|NCT02518789|Experimental|High-dose Dexmedetomidine|-Pretreatment before anesthesia induction：Intravenous injection dexmedetomidine 1 µg/kg，completed within 15 minutes.
2557066|NCT02518789|Placebo Comparator|normal saline Control group|-Pretreatment before anesthesia induction：Intravenous injection normal saline equal quantity，completed within 15 minutes.
2557096|NCT02518399|Experimental|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
2557098|NCT02518399|Sham Comparator|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
2557166|NCT02518269|Active Comparator|G7 MoP (Arcom XL) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an Arcom Xl liner and a metal head
2557170|NCT02518269|Active Comparator|G7 MoP (E1) + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
2557177|NCT02518269|Active Comparator|G7 CoC + Echo BiMetric|Eligible patients will be enrolled and planned for Hip Arthroplasty and operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive a ceramic liner and a ceramic head
2557253|NCT02517723|Experimental|SIC + NET|Waiting List + Standard Inpatient Care + Narrative Exposure Therapy
2557254|NCT02517723|Active Comparator|SIC + DBT|Waiting List + Standard Inpatient Care + Dialectical Behavior Therapy
2557312|NCT02517320|Experimental|MT-3995 Low|
2557314|NCT02517320|Experimental|MT-3995 Middle|
2557316|NCT02517320|Experimental|MT-3995 High|
2557317|NCT02517320|Placebo Comparator|Placebo|
2557359|NCT02516956|Experimental|Breakfast meal 1|"Breakfast meal 1 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 2 and health-related cognitive perception as Breakfast meal 3.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
2557360|NCT02516956|Experimental|Breakfast meal 2|"Breakfast meal 2 is isocaloric (330 kcal) and balanced for protein and fiber contents with regard to the other two experimental breakfasts. It has the same sugar and lipid profiles as Breakfast meal 1 but a higher health-related cognitive perception than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
2557361|NCT02516956|Experimental|Breakfast meal 3|"Breakfast meal 3 is isocaloric (330 kcal) and similar for protein and fiber contents in relation to the other two experimental breakfasts. It has the same health-related cognitive perception as Breakfast meal 1 but lower lipid and higher sugar amounts than the other two experimental breakfasts.~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
2557362|NCT02516956|Placebo Comparator|Breakfast meal 4|"Breakfast meal 4 is a non-caloric meal representing fasting condition (control arm).~Breakfast consumption; Blood tests; Food choices and energy intakes assessments; Attention tests; fRMI tests."
2557440|NCT02516462|Experimental|IVM|Immature oocytes recovered from each subject will be placed into IVM media for maturation.
2557480|NCT02516111|Active Comparator|Open flap debridement group|SRP with Open flap debridement (OFD) alone for treating intrabony defect
2557483|NCT02516111|Active Comparator|PRF group|SRP with Open flap debridement (OFD) with autologous Platelet rich fibrin (PRF) placement into intrabony defect
2557484|NCT02516111|Active Comparator|Alendronate group|SRP with Open flap debridement (OFD) with 1% Alendronate (ALN) placement into intrabony defect
2557486|NCT02516111|Active Comparator|Atorvastatin group|SRP with Open flap debridement (OFD) with 1.2% Atorvastatin (ATV) placement into intrabony defect
3205706|NCT00946764|Active Comparator|2|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)
3205707|NCT00946777|Experimental|Systane® Ultra|
2557598|NCT02515435|Experimental|apatinib single agent|apatinib, single agent, 500mg or 750mg Qd po, continue until disease progression
3205708|NCT00946790|Experimental|1|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)
3205709|NCT00946790|Active Comparator|2|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)
3205710|NCT00946803|Experimental|PC-CB Intervention|Patient-Controlled Cognitive-Behavioral Intervention
3205711|NCT00946803|No Intervention|Wait list|Wait list control group. Offered PC-CB Intervention after the study.
3205712|NCT00946816|Active Comparator|Anorexia Nervosa|
3205713|NCT00946816|Active Comparator|Obesity|
3205714|NCT00946816|Active Comparator|Healthy volunteers|
3205715|NCT00946842|Experimental|Panel A: Treatment Sequence ABC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ABC with food and subsequent treatments will be separated by 4 weeks.
3208815|NCT00978367|Placebo Comparator|Placebo (vehicle)|
2556957|NCT02519582|Experimental|Niclosamid|Patients receive 2 g niclosamide orally per day until progression or toxicity
2557101|NCT02518529|Experimental|250µg dose treatment|Subjects were treated with a 250mcg/0.2ml G17DT injection at weeks 0, 2 and 6.
2557171|NCT02518295|Active Comparator|Positive control|Ultra high temperature (UHT) milk containing 18 g total lactose
2557176|NCT02518295|Active Comparator|Positive control with S. thermophilus|UHT milk containing 18 g total lactose+ S. thermophilus
2557181|NCT02518295|Active Comparator|Positive control with B. longum|UHT milk containing 18 g total lactose+ B. longum
2557182|NCT02518295|Placebo Comparator|Negative control|Lactose free milk
2557232|NCT02517775|Active Comparator|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
2557237|NCT02517775|Active Comparator|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
2557240|NCT02517775|Active Comparator|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
2557243|NCT02517775|Active Comparator|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
2557244|NCT02517775|Active Comparator|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
2557245|NCT02517775|Placebo Comparator|Cranberry deprived supplement|Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily)
2557280|NCT02517385|Experimental|Phosphatidylcholine paste|One dose of phosphatidylcholine paste 600 mg given orally 3 times a day at Days 0, 28, 56, and 84
2557387|NCT02517138|Other|Measurements of eye movements and perception|
2557444|NCT02516371|Other|lymphocytes|To evaluate the subpopulation of lymphocytes in cancer patients
2557497|NCT02516059|Active Comparator|Oxycodone and naloxone (Targin®)|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
2557498|NCT02516059|Active Comparator|Oxycodone (Oxycontin®)|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
2557499|NCT02516059|Placebo Comparator|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
2557538|NCT02515708|Experimental|Normothermic Liver perfusion|This group has the liver grafts preserved using the Normothermic Liver perfusion Device.
2557540|NCT02515708|Other|Normothermic Machine Perfusion (single pump)|This group has the liver grafts preserved using a single-pump variant of the Normothermic Liver perfusion Device.
2557577|NCT02515526|Active Comparator|Reference|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam
2557583|NCT02515526|Experimental|Test|A cocktail of six different test substances to be administered orally followed by an I.V. dose of midzolam. In addition, ethanol will be administered at six different time points with of reaching a blood alcohol concentration of 1 per mille to see its effect on the activity of major cytochrome P450 enzymes, NAT-2 and P-glycoprotein.
2557659|NCT02515071|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
2557662|NCT02515071|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
2557713|NCT02514629|Placebo Comparator|Placebo|Placebo for 52 weeks
2557715|NCT02514629|Experimental|Metformin|Metformin 850 mg tablets twice daily for 52 weeks
2557717|NCT02514629|Experimental|Testosterone|Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
2557718|NCT02514629|Experimental|Metformin + Testosterone|Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks
2557734|NCT02514343|Experimental|Magnesium sulfate|Will administrate 1 ml of magnesium sulfate 10% and 1.5 mL of sterile water
2557735|NCT02514343|Experimental|Bupivacaine|Will administrate 1 ml of magnesium sulfate 10% and 1.5 ml of bupivacaine (5mg/ml)
3205716|NCT00946842|Experimental|Panel A: Treatment Sequence ACB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence ACB with food and subsequent treatments will be separated by 4 weeks.
2557860|NCT02513563|Experimental|Carboplatin/Paclitaxel/AZD1775|Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
2557892|NCT02513238|Active Comparator|Stemcells injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the MSC-suspension , the surgeon will identify the submandibular glands and inject the suspension MSCs into the submandibular gland. Calculation of injected number of MSCs pr. participant rests on the following calculation: 2.8 x 10^6 MSC / Cm^3 X volume , where volume is the volume of the submandibular gland, and a gland-volume of app. 7-8cm3 is the norm. Therefore the amount of cells given to each participant will be app. 4.6 x 10^7 MSC in total. Afterwards the participant will be given a band-aid and over the counter analgesics.
2557893|NCT02513238|Placebo Comparator|Saltwater injected into submandibularis|The surgical procedure is done under local anaesthesia using ultrasonic guidance and sterile technique. After receiving the placebo-suspension , the surgeon will identify the submandibular glands and inject the suspension. Placebo will be 2ml of Isotonic NaCl (0,9mg/ml) and HA 1%.
2557955|NCT02512822|Experimental|Participants|Noninvasive Radiofrequency
3208816|NCT00978393|Experimental|A|
3208817|NCT00978393|Experimental|B|
3208818|NCT00978393|Experimental|C|
3205717|NCT00946842|Experimental|Panel A: Treatment Sequence BAC|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BAC with food and subsequent treatments will be separated by 4 weeks.
2557082|NCT02518724|Active Comparator|RIPC intervention group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after RIPC intervention exposure at the beginning of every meeting."
2557085|NCT02518724|Placebo Comparator|false exopsure group|"The experiment protocol consist 2 series (with a month between them), both series include the described 3 days:~Day 1 - anthropometry measurements and VO2max test (BRUCE protocol). Day 2 - steps test (heled protocol). Day 3 - anaerobic test (wingate protocol), 1 hour rest and time to exhaustion test (heled protocol).~the second series will be performed after placebo intervention exposure at the beginning of every meeting."
2557121|NCT02518451|Experimental|(Test) Group I|Valsartan 160 mg film-coated caplets of PT Dexa Medica
2557125|NCT02518451|Active Comparator|(Reference) Group II|Valsartan 160 mg film-coated caplets (Diovan® 160)
2557174|NCT02518152|Active Comparator|Group 1|Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
2557180|NCT02518152|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
2557183|NCT02518152|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
2557229|NCT02517788|Experimental|Part A: Interferon beta-1a in HSA-free solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a without albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
2557230|NCT02517788|Experimental|Part A: Interferon beta-1a combined with HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU biosimilar interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
2557235|NCT02517788|Active Comparator|Part A: Interferon beta-1a in marketed HSA+ solution|Twelve subjects will participate in 3 periods of part A, receiving 18 MIU original interferon beta-1a with albumin as i.v. bolus into a distal port under constant saline infusion as 3 treatments.
2557238|NCT02517788|Experimental|Part B: Interferon beta-1a in HSA-free solution|Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
2557241|NCT02517788|Active Comparator|Part B: Interferon beta-1a in marketed HSA+ solution|Part B: Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU original interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose [i.e. dose 1 and 3] and left side for even dose [i.e. dose 2 and 4]).
2557305|NCT02517411|Experimental|Experimental group|COPD patients with stable disease will be recruited and they will receive physiotherapy added to standard care.
2557308|NCT02517411|Other|Control group|COPD patients with stable disease will be recruited and they will receive standard care.
3205718|NCT00946842|Experimental|Panel A: Treatment Sequence BCA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence BCA with food and subsequent treatments will be separated by 4 weeks.
3205719|NCT00946842|Experimental|Panel A: Treatment Sequence CBA|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CBA with food and subsequent treatments will be separated by 4 weeks.
2557512|NCT02515929|Experimental|Oligomeric Proanthocyanidins|90 mg exocian cran 408 plus 120mg Vitamin C, 1 tablet by mouth, every 24 hours for 21 days
2557515|NCT02515929|Placebo Comparator|Placebo|Similar organoleptic experimental arm,1 tablet by mouth, every 24 hours for 21 days
3205720|NCT00946842|Experimental|Panel A: Treatment Sequence CAB|Participants will receive the 3 treatments (Treatment A,B and C) in sequence CAB with food and subsequent treatments will be separated by 4 weeks.
3205721|NCT00946842|Experimental|Panel B: Treatment Sequence DEF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DEF with food and subsequent treatments will be separated by 4 weeks.
2557604|NCT02515201|Active Comparator|Taurolidine|Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
2557608|NCT02515201|Active Comparator|Heparin|Heparin be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Heparin infusion will be used with heparin solution contain 50 International Unit (UI)/ml.
2557652|NCT02515032|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
2557653|NCT02515032|Placebo Comparator|Placebo|An isocaloric placebo comparator
2557710|NCT02514655|Experimental|1: Nosten® monitoring|One experimental group with the control of the cuff pressure by Nosten® device
2557712|NCT02514655|Active Comparator|2: Manual monitoring|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
2557752|NCT02514226|Placebo Comparator|G1-control group|"Arm description: G1 - control group - (n = 30) dental hygiene orientation (DHO) + supragingival treatment + simulation of using photodynamic therapy (PDT).~In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes and ultrasound. Supragingival treatment will be performed above the gingival margin. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed."
3205722|NCT00946842|Experimental|Panel B: Treatment Sequence DFE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence DFE with food and subsequent treatments will be separated by 4 weeks..
3208819|NCT00978393|Experimental|D|
2556999|NCT02519270|Experimental|Dose Escalation Stage/ Expansion Stage|"The Dose-Escalation Stage will employ a modified 3 + 3 cohort design, subjects will receive up to 26 doses of IGN002.~In the Expansion Stage, subjects will receive up to 24 doses of IGN002 at the maximum tolerated dose administered weekly in three 8-week cycles."
2557050|NCT02518828|Active Comparator|High SpO2|In the high SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range ≥96%
2557053|NCT02518828|Active Comparator|Low SpO2|In the low SpO2 set-point arm, patients will have a nasal cannula placed and will be manually titrated to SpO2 range 90-92%
2557140|NCT02518659|Other|Inulin|Intervention by inulin, max 20gr per day
2557143|NCT02518659|No Intervention|No Inulin|Same Patients of arm inulin. Here the phase without inulin supplementation (own controls)
3205723|NCT00946842|Experimental|Panel B: Treatment Sequence EDF|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EDF with food and subsequent treatments will be separated by 4 weeks.
3205724|NCT00946842|Experimental|Panel B: Treatment Sequence EFD|Participants will receive the 3 treatments (Treatment D,E and F) in sequence EFD with food and subsequent treatments will be separated by 4 weeks.
3205725|NCT00946842|Experimental|Panel B: Treatment Sequence FDE|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FDE with food and subsequent treatments will be separated by 4 weeks.
3205726|NCT00946842|Experimental|Panel B: Treatment Sequence FED|Participants will receive the 3 treatments (Treatment D,E and F) in sequence FED with food and subsequent treatments will be separated by 4 weeks.
2557331|NCT02517164||Fallers|patients aged 50 years and over who already fell
2557332|NCT02517164||At risk of falls|patients aged 50 years and over at risk of falls
2557355|NCT02516774|Experimental|Dose escalation|Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)
2557418|NCT02516631|Active Comparator|Oral (A)|One tablet of Angusta™ (25 µg) or 1/8 of a tablet of Cytotec® (25 µg).
2557421|NCT02516631|Active Comparator|Oral (B)|Two tablets of Angusta™ 25 µg or ¼ of a tablet of Cytotec®.
2557422|NCT02516631|Active Comparator|Sublingual (C)|Two tablets of Angusta™ (total dose of 50 µg) or ¼ of a tablet of Cytotec® (50 µg.
3205727|NCT00946855||soccer players|players of the first two German soccer leagues
2557536|NCT02515799|Active Comparator|Tacholiquine|Inhalation
2557537|NCT02515799|Placebo Comparator|Saline Solution 0,9%|Inhalation
2557562|NCT02515539|Experimental|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
2557622|NCT02515422|Active Comparator|Group 1, Ketamine|Ketamine, 1 mg/kg (Ketalar®, 10 mL inj., 50 mg ketamine hydrochloride/ml, Pfizer Drug Company, USA) was administered subcutaneously before the closure of pfannenstiel incision.
2557626|NCT02515422|Active Comparator|Group 2, Bupivacaine|Bupivacaine 0.5% 20 mL (100 mg) (Marcaine®, 20 mL inj. 5 mg bupivacaine hydrochloride/ml, AstraZeneca Drug Company, Turkey) was administered subcutaneously before the closure of pfannenstiel incision.
2557629|NCT02515422|Active Comparator|Group 3, Ketamine+Bupivacaine|Ketamine 1 mg/kg (Ketalar®) and bupivacaine 0.5% (100 mg) (Marcaine®) were administered subcutaneously before the closure of pfannenstiel incision.
2557632|NCT02515422|Placebo Comparator|Group 4, Placebo|Placebo (0.9% saline solution) was administered subcutaneously before the closure of pfannenstiel incision.
2557683|NCT02514850|Experimental|Biochaperone Combo|single subcutaneous injection of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
2557684|NCT02514850|Active Comparator|Humalog Mix25|single subcutaneous dose of 0.8 U/kg + injection of placebo (0.9% NaCl) to ensure the double dummy
2557685|NCT02514850|Active Comparator|Humalog and Lantus|simultaneous subcutaneous injections of 0.2 U/kg Humalog and 0.6 U/kg Lantus
2557768|NCT02514187|Other|Evaluation of hyperthyroidism|For the evaluation of hyperthyroidism each research subject will undergo imaging using both cyclotron-produced 99mTc and the current standard method used at the site for thyroid imaging (either 123I or generator-produced 99mTc). Each study will be performed on a separate day, with flexibility to schedule either study first.
2557769|NCT02514187|Other|Evaluation of altered osteogenesis by bone scintigraphy|For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
2557848|NCT02513888|Experimental|Vitamin D + diet and lifestyle|subjects will be given vitamin D supplement will be given along with diet nd lifestyle modification
2557852|NCT02513888|Placebo Comparator|placebo + diet and lifestyle|Subjects will be given placebo with diet and lifestyle
2557877|NCT02513394|Experimental|Arm A|Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.
2557884|NCT02513394|Other|Arm B|Standard adjuvant endocrine therapy for a duration of at least 5 years.
2558316|NCT02510482||Aortic valve stenosis|Individuals with clinically stable moderate aortic valve stenosis
3205728|NCT00946868||Intermittent claudication patients|Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
3205729|NCT00946894|Experimental|Total thyroidectomy|Patients who underwent total thyroidectomy
3205730|NCT00946894|Experimental|Dunhill operation|Patients who underwent unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
3205731|NCT00946894|Active Comparator|Bilateral subtotal thyroidectomy|Patients who underwent bilateral subtotal thyroidectomy
3205732|NCT00946907|Active Comparator|aspirin|
3205733|NCT00946907|Placebo Comparator|placebo|
3205734|NCT00946933|Placebo Comparator|Placebo|0.025 g/kg/day of NaCl (sodium chloride)
3205735|NCT00946933|Active Comparator|High salt diet|0.2 g/kg/day of NH4Cl (ammonium chloride)
3205736|NCT00946946|Experimental|Azathioprine|2.0-2.5 mg/kg/BW azathioprine tablets/day AND mesalazine placebo tablets
3205737|NCT00946946|Active Comparator|Mesalazine|4g mesalazine tablets/day AND azathioprine placebo tablets
3208820|NCT00978393|Experimental|E|
2557036|NCT02519101|No Intervention|Intermittent blood pressure monitoring|Control group with intermittent blood pressure monitoring
2557048|NCT02518802|Experimental|Synchronous therapy|'Gefitinib and Pemetrexed' Synchronous use of Gefitinib for 2 years during or after chemotherapy with Pemetrexed plus Cisplatin regimen. Gefitinb, 250mg per day,take orally for 2 years. Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
2557055|NCT02518802|Active Comparator|Chemotherapy|Pemetrexed: Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
2557113|NCT02518555|Experimental|Arm A (concurrent vaccines and ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Patients also receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 3 and 5 and trivalent influenza vaccine IM and DTaP vaccine IM on day 1 of course 4. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
2557116|NCT02518555|Experimental|Arm B (sequential vaccines and ibrutinib)|Patients receive pneumococcal 13-valent conjugate vaccine IM on day 1 of courses 1 and 3 and trivalent influenza IM and DTaP vaccine IM on day 1 of course 2. Beginning in course 4, patients receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 27 courses in the absence of disease progression or unacceptable toxicity.
2557218|NCT02518009||Men with gender dysphoria|Genetic men treated with estrogen
2557219|NCT02518009||Women with gender dysphoria|Genetic women treated with androgen
2557257|NCT02517593|Other|PRS|Providing polygenic risk score (PRS)
2557315|NCT02517294|Active Comparator|standard nasotracheal tube|Nasotracheal intubation using 'standard' side-beveled nasotracheal tubes
2557318|NCT02517294|Active Comparator|Parker flex-tip nasotracheal tube|Nasotracheal intubation using 'experimental' flex-tip midline-beveled nasotracheal tubes
3205738|NCT00946959|Experimental|cardiac surgery|This arm will include patients older than 18 years and candidate to cardiac surgery.
3205739|NCT00946959|No Intervention|cardiac angiography|Patients older than 18 years who undergo coronary angiogram. This arm will include patients with coronary revascularization and patients without coronary revascularization.
3205740|NCT00947024|Experimental|1|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.
3205741|NCT00947024|Active Comparator|3|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.
2557475|NCT02516176|Experimental|Treadmill Training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
3205742|NCT00947024|Experimental|2|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.
3205743|NCT00947037|Experimental|Extension|Open label extension, 1 arm
3205744|NCT00947050|Active Comparator|rest first|rest first, cfi, exercise, cfi
3205745|NCT00947050|Active Comparator|exercise first|ex first
3205746|NCT00947063|Experimental|1|Promethazine HCl 50 mg Tablets (Sandoz, Inc)
2557621|NCT02515344|Experimental|A: nominative list|"Providing a list of patients not compliant with CRC sreening~General Practitioners allocated to the intervention group (A) will receive:~a nominative list of their patients who were not compliant to colorectal cancer screening.~a document providing general information about colorectal cancer screening"
2557625|NCT02515344|Active Comparator|B: general information|"Providing general information about CRC screening~General Practitioners allocated to group (B) will receive:~- a document providing general information about colorectal cancer screening (but will not receive the nominative list of patients non compliant to colorectal cancer screening)"
2557630|NCT02515344|No Intervention|C: usual practice|General Practitioners allocated to group (C) will not receive any information (as in usual practice)
2557667|NCT02514980|Active Comparator|Bupivacaine group|Infraorbital nerve block using bupivacaine 0.25% on each side.
2557669|NCT02514980|Active Comparator|Bupivacaine-Ketamine group.|Infraorbital nerve block using bupivacaine 0.25% combined with 0.5mg/kg ketamine on each side.
3205747|NCT00947063|Active Comparator|2|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)
3205748|NCT00947076|Experimental|1|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)
3205749|NCT00947076|Active Comparator|2|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
3205750|NCT00947089|Experimental|group A-the treatment group|Group A-patients have their wound, the site of the previous stoma, wad with ORC
2558006|NCT02512601|Experimental|Sulodexide|Compression therapy + Sulodexide (two capsules of Sulodexide 15 mg twice daily).
3205751|NCT00947089|Active Comparator|group B-the control group|control group-patients have their wound wad with iodoform gauze
3205752|NCT00947102||Pancreatic tubular adenocarcinoma|Patients with pancreatic tubular adenocarcinoma
3205753|NCT00947128|Experimental|1|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)
3205754|NCT00947128|Active Comparator|2|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)
3205755|NCT00947141|Experimental|Group A|"Group A: (low level infection) has 2 arms:~Start treatment when 2 consecutive levels CMV PCR >200copies / ml~Monitor (Treatment starts when CMV PCR >3,000 copies / ml (current site clinical protocol))"
3205756|NCT00947141|Experimental|Group B|"Group B: (patients receiving pre-emptive therapy) has 2 arms:~Stop treatment when 2 levels CMV PCR <3,000 copies / ml~Monitor (Treatment stops when there are 2 consecutive levels of CMV PCR <200 copies / ml (current site clinical protocol))"
3205757|NCT00947180|Active Comparator|Electrogalvanic stimulation|High voltage electrical stimulation was delivered through an anal plug to induce relaxation of pelvic floor muscles.
3205758|NCT00947180|Active Comparator|Digital massage|The therapist massaged the levator ani muscles by applying firm pressure with a gloved finger and rotating from left to right.
3205759|NCT00947180|Experimental|Biofeedback|Electromyographic (EMG) activity was recorded from a probe in the anal canal, averaged and displayed to patients to help them learn to relax pelvic floor muscles during straining.
3205760|NCT00947206|Experimental|LHWO about CRC|The intervention group participants will be exposed to 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
3205761|NCT00947206|Active Comparator|Nutrition education + CRC brochure|The comparison group will receive a bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
3205762|NCT00947232|Experimental|Motivational interviewing|Motivational interviewing for people aging with multiple sclerosis or spinal cord injury to increase physical activity and decrease depression.
3205763|NCT00947232|Active Comparator|Education|Education about physical activity for people aging with multiple sclerosis or spinal cord injury to decrease depression.
3205764|NCT00947245|Experimental|BMS-791325 - Part A, Dose 1|
3205765|NCT00947245|Experimental|BMS-791325 - Part A, Dose 2|
3205766|NCT00947245|Experimental|BMS-791325 - Part A, Dose 3|
2557260|NCT02517684|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
2557262|NCT02517684|Active Comparator|Step-up|Step-up treatment will consist of standard induction treatment by either oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, followed by tapering in 6 weeks until stop, or EEN with polymeric feeding for 6-8 weeks after which normal foods are gradually reintroduced within 2-3 weeks. Either of these induction treatments will be combined with oral AZA 2-3 mg, once daily, as maintenance treatment.
2557400|NCT02516670|Experimental|Arm A (docetaxel, ascorbic acid)|Patients receive docetaxel IV on day 1 and ascorbic acid IV twice weekly. The first ascorbic acid treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2557405|NCT02516670|Placebo Comparator|Arm B (docetaxel, placebo)|Patients receive docetaxel IV on day 1 and placebo IV twice weekly.The first placebo treatment will be given on day 1 (same day as docetaxel). Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity.
2557500|NCT02515981|Experimental|Incentives|Participants randomly assigned to the incentive arm, will receive cash incentives for engaging in healthy lifestyle behaviors.
2557504|NCT02515981|Experimental|No Incentives|Participants randomly assigned to the no incentives arm, will not receive cash incentives for engaging in healthy lifestyle behaviors.
2557571|NCT02515604|Active Comparator|Single dose group|
2557574|NCT02515604|Active Comparator|Repeated dose group|
2557606|NCT02515292||IUGR: newborn with intrauterine growth restriction|"Inclusion criteria:~newborn infants with symmetrical (both weight and height lower than 10th percentile) or asymmetrical (birth weight is lower than 10th percentile but height and age-appropriated height) intrauterine growth restriction~agreement of the parents that their child to be included in the study"
2557611|NCT02515292||control: newborn without intrauterine growth restriction|"Inclusion criteria:~- matches newborn without intrauterine growth restriction in terms of gender and gestational age as IUGR group"
3205767|NCT00947245|Experimental|BMS-791325 - Part B, Dose 1|
3205768|NCT00947245|Experimental|BMS-791325 - Part B, Dose 2|
2557743|NCT02514408||Ancillary-Correlative (collection of blood samples)|Patients undergo placement of a central line via the right femoral vein and undergo ORC. Blood samples are collected and analyzed for CTCs pre-surgery, at 30 minutes and 1 hour once ORC begins, post-surgery, and 7 days after surgery.
2557787|NCT02514018|Other|Immediate Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 Plaque-forming unit - PFU) administered as a single-dose at day 0
2557788|NCT02514018|Other|Delayed Group|Live-attenuated varicella-zoster virus vaccine (≥ 19,400 PFU) administered as a single-dose at day 84 (+/- 3 days)
2557819|NCT02513784|Experimental|Antibacterial mouthwash|Subjects will be randomized to twice daily chlorhexidine gluconate mouthwash for 21 days.
2557821|NCT02513784|No Intervention|No intervention|Subjects will be randomized to no intervention for 21 days.
2557865|NCT02513485|Active Comparator|Sinemet/Placebo|Subjects with major depression will be given Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at one study visit and placebo at the other study visit. Sinemet will be given first followed by placebo at the subsequent visit.
2557867|NCT02513485|Active Comparator|Placebo/Sinemet|Subjects with major depression will be given placebo at one study visit and Sinemet (a combination of 250 mg of levodopa and 50 mg of carbidopa) at the other study visit. Placebo will be given first followed by Sinemet at the subsequent visit.
3205769|NCT00947245|Experimental|BMS-791325 - Part B, Dose 3|
3205770|NCT00947323|Placebo Comparator|placebo|
2557980|NCT02512744|No Intervention|Capping trial protocol|"Decannulation protocol based on tolerance to 24 hours capping trial to decide when to decannulate.~Decapping during the capping trial for aspiration of respiratory secretions is considered a failure criteria of the trial.~High flow conditioned oxygen therapy through tracheal cannula will be applied during periods out of capping trials."
2557981|NCT02512744|Experimental|Suctioning frequency protocol|"Decannulation protocol based on suctioning frequency to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).~Intervention: suctioning frequency of respiratory secretions will be recorded untill fulfill decannulation criteria. Capping trials will not be allowed in this group.~High flow conditioned oxygen therapy will be applied through tracheal cannula during all the study period."
2558001|NCT02512406||Patients with Tourette Syndrome|Questionnaires including the Sensory Profile or the Adult/Adolescent Sensory profile and Children's Yale-Brown Obsessive Compulsive Scale or Yale Global Tic Severity Scale will be administered. When time permits, the Children's Yale-Brown Obsessive Compulsive Scale or Yale-Brown Obsessive Compulsive Scale will also be administered. Demographic data will also be collected for each study patient.
3205771|NCT00947323|Experimental|Simvastatin|Treatment arm.
3205772|NCT00947336|Active Comparator|Norfloxacin + Synbiotic|
3205773|NCT00947336|Placebo Comparator|Norfloxacin + Placebo|
3205774|NCT00947362|Experimental|ETC + DAC N-055|
3205775|NCT00947362|Active Comparator|ETC + physiological saline|
3205776|NCT00947375|Experimental|Starch|In these study participants are randomly (by chance) assigned for two treatment arms of a clinical trial.
3205777|NCT00947375|No Intervention|Lifestyle councelling|May be required to comply with US Public Law 110-85, Section 801
3205778|NCT00947388|Experimental|Bendamustine plus Alemtuzumab|
3205779|NCT00947401||elective post surgery patients|
2557120|NCT02518373|Experimental|G17DT & Omeprazole|"A 14-day washout period~An Omeprazole Treatment Period 1 (Day -15 to Day -1)~A G17DT treatment period (Day 0 to Day 85)~An Omeprazole Treatment Period 2 (Day 86 to Day 100)"
2557167|NCT02518217|Active Comparator|Apps Only|
2557173|NCT02518217|Experimental|ShapeUp Empower|
2557179|NCT02518217|Experimental|ShapeUp Empower + Incentives|
2557225|NCT02517801|Experimental|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily)
2557228|NCT02517801|Placebo Comparator|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily)
2557300|NCT02517489|Experimental|Hydrocortisone|Patients in the treatment group will receive intra-venous hydrocortisone (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
2557303|NCT02517489|Placebo Comparator|Placebo|Patients of the control group will receive an intravenous placebo by intravenous route (in addition to the standard treatment of severe Community-Acquired Pneumonia (CAP)
2557381|NCT02516644|Experimental|Virtual reality|Xbox Kinect + treadmill training
2557382|NCT02516644|Active Comparator|Conventional Therapy|Specific conventional training for Parkinson's Disease
2557432|NCT02516449|Experimental|Patient decision aids|Participants read and fill a patient decision aid before being provided education on asthma.
2557435|NCT02516449|No Intervention|Usual care|Participants do not read and fill a patient decision aid before being provided education on asthma.
3205780|NCT00947414|Active Comparator|Shockwave plus strength training|6 sessions of extracorporeal shock wave plus daily gluteal strength exercises
3205781|NCT00947414|Sham Comparator|Sham extracorporeal shock wave plus gluteal strength exercise|SHAM extracorporeal shock wave plus gluteal strength exercise
3208821|NCT00978393|Experimental|F|
2557944|NCT02513147|Experimental|2 NRTI+ Dolutegravir|22 patients will be treated with 2 NRTI+Dolutegravir 50 mg during 24 weeks
2557945|NCT02513147|Active Comparator|2 NRTI + PI|22 patients will be treated with 2 NRTI + PI during 24 weeks
2557979|NCT02512666|Experimental|Non-Invasive Imaging|"Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients.~For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery"
2558013|NCT02512471|Experimental|middle aged group|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB
2558019|NCT02512471|Active Comparator|young group|brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB
2558039|NCT02512185||Chemotherapy|Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
2558045|NCT02512185||Abiraterone|Men with mCRPC starting Abiraterone
2558056|NCT02512185||Enzalutamide|Men with mCRPC starting Enzalutamide
2558089|NCT02511808|Active Comparator|Step-up Treatment: MI|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive two sessions of MI.
2558090|NCT02511808|Other|Control: BA|After receiving one session of Brief Advice (BA), participants will be assessed at week 4 for response to this treatment. Those who are deemed non-responders to the BA will be randomly assigned to receive either Motivational Interviewing (MI) or more BA. In this arm, participants will receive one additional session of BA.
2558094|NCT02511808|Active Comparator|Step-up Treatment: Specialist Care|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive four sessions of BSCT if they received MI at the previous randomization or five sessions of combined MI and BSCT if they received BA at the previous randomization.
2558099|NCT02511808|Other|Control: MI|After receiving one session of Brief Advice (BA) and two sessions of Motivational Interviewing (MI) or one session of BA over the first 8 weeks of the study, participants will be assessed at week 8 for response to this treatment. Those who are deemed non-responders will be randomly assigned to receive Behavioral Self-Control Training (BSCT) or more MI if they were randomized to MI at week 4 or five sessions of combined MI and BSCT or one more session of MI if they were randomized to BA at week 4. In this arm, participants will receive one session of MI if they received MI at the previous randomization or two sessions of MI if they received BA at the previous randomization.
2558156|NCT02511600|Experimental|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
2558158|NCT02511600|Active Comparator|Standard of Care|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest. Participants complete pain scale 3 times each day while in the hospital.
2558198|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia|minizone with Microneedles pretreatment and Metvixia cream application
2558201|NCT02511145|Active Comparator|Microneedles pretreatment and Metvixia under occlusion|minizone with Microneedles pretreatment and Metvixia cream application with occlusion
2558207|NCT02511145|Active Comparator|Laser pretreatment and Metvixia|minizone with laser pretreatment and Metvixia cream application
2558212|NCT02511145|Active Comparator|Laser pretreatment and Metvixia under occlusion|minizone with Laser pretreatment and Metvixia cream application with occlusion
2558215|NCT02511145|Active Comparator|Metvixia|minizone with Metvixia cream application, without pretreatment
2558218|NCT02511145|Active Comparator|Metvixia under occlusion|minizone with Metvixia cream application under occlusion, without pretreatment
2558221|NCT02511145|Experimental|Microneedles pretreatment only|minizone with Microneedles pretreatment only
2558224|NCT02511145|Experimental|Laser pretreatment only|minizone with Laser pretreatment only
3208822|NCT00978406||Healthy volunteers|Healthy volunteers
3205782|NCT00947440|Active Comparator|Tablet 1 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 1) vs. 100 mg ABT-072 (contents of capsules) suspended in liquid.
3205783|NCT00947440|Active Comparator|Tablet 2 vs. Capsule|Single dose of 2 x 50 mg tablets (Tablet 2) vs. 100 mg ABT-072 (contents from capsules) suspended in liquid.
2557169|NCT02518308|Experimental|Arm I (MBSR intervention)|Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
2557175|NCT02518308|No Intervention|Arm II (control)|Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.
3205784|NCT00947453|Experimental|montelukast group|Identified patients with asthma to recieve Montelukast 10 mg (Merck Sharp & Dohme Ltd, Herts, UK) at 0800 am once daily for 8 weeks.
3205785|NCT00947466|Experimental|Patch|
2557326|NCT02517190|Other|Stress response measurements|
2557375|NCT02516891|Experimental|hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.
2557377|NCT02516891|No Intervention|Non hydrophilic wire/Drug-Eluting Stents|Will include 100 patients with coronary bifurcation lesions in that they will be treated with stents and in which the technique is used jailed guide.non hydrophilic guide.
2557423|NCT02516527|Experimental|Induction Phase:Ipilimumab|Ipilimumab dose as specified
2557428|NCT02516527|Experimental|Maintenance Phase:Ipilimumab|Ipilimumab dose as specified
3205786|NCT00947479|Other|continuous positive airway pressure (CPAP)|CPAP will be applied in all patients
2557558|NCT02515760|Experimental|Lung cancer group|Bone marrow puncture in patients with non-small cell lung cancer
2557561|NCT02515760|Experimental|Control group (healthy donors)|Bone marrow puncture in healthy donors
2557592|NCT02515409||CPAP|CPAP, as a first line treatment to OSAS.
2557593|NCT02515409||HHHFNC|Treatment with HHHFNC after CPAP treatment fails.
2557609|NCT02515123|Experimental|E-Motion System|E-motion tube + E-motion EPG 1000
2557612|NCT02515123|Sham Comparator|E-Motion Sham Decive|E-motion tube + SHAM E-motion EPG 1000
2557657|NCT02514876|Experimental|Single arm- Foresight ICE System|This open label feasibility study will evaluate the Foresight ICE system for imaging chambers of the heart and guiding transseptal puncture during an atrial fibrillation (AF) ablation procedure.
2557745|NCT02514291|Experimental|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
2557749|NCT02514291|No Intervention|Standard care|Standard pediatric neurology care
3205787|NCT00947557|Active Comparator|Dutogliptin|Dutogliptin
3205788|NCT00947557|Placebo Comparator|Placebo|Placebo
2558134|NCT02511821|Experimental|Supportive Care (Vivofit watch, online surveys)|Patients complete online surveys comprising questions about quality of life, symptoms, and activity level, and wear a wristband device (Vivofit watch) 3-7 days prior to and after surgery. After going home, patients complete the symptom survey three times a week and quality of life survey once a week for 2 weeks post-surgery.
2558202|NCT02511314|Experimental|Intervention|"Tena Identifi is an integrated electronic monitoring system based upon a wearable continence pad which allows registration of resident's micturition patterns over a 72 hour period, allowing caregivers to construct an individualised continence care plan, including use of appropriate products.~To create a voiding report, a resident wears the Identifi Sensor Wear with an attached Identifi Logger for three consecutive days (72 hours). The logger continuously logs the moisture status of the brief. The resulting data is sent to a server via 3 G signal where it is mapped onto a graph indicating voiding times and volumes."
2558204|NCT02511314|No Intervention|Control Intervention|"The control portion of the study is usual care, defined as the routine practices and procedures, including continence assessment approach, prescribed in the nursing home unit or facility."
2558248|NCT02510885|Experimental|SD-OCT Angiography|Study participants will undergo imaging of both eyes with the AngioVue unit (approximately 60 seconds/eye), per standard operating protocol. Imaging is noncontact, and pharmacologic dilation will not be used for the purposes of this study. In most instances, study participants will undergo only a single imaging session on a single day. However, potential participants will be asked to consent for additional imaging sessions (up to 12) that may occur over the course of subsequent future visits to the clinic. Additionally, study participants will be asked to consent to prospective collection of clinical and demographic data, to correlate findings of OCT-A imaging to subsequent clinical course.
2558287|NCT02510560|Experimental|NTRA-2112 A|NTRA-2112 A - Dose 1 To be administered orally with daily feed for 28 days or until discharge from hospital.
2558289|NCT02510560|Experimental|NTRA-2112 B|NTRA-2112 B - Dose 2 To be administered orally with daily feed for 28 days or until discharge from hospital.
2558291|NCT02510560|Placebo Comparator|Placebo|Placebo To be administered orally with daily feed for 28 days or until discharge from hospital.
2558377|NCT02509871|Other|Body composition measurement|DXA, impedance
2558424|NCT02509637|Active Comparator|Flutter Intervention|After initial evaluation, the subjects will perform breathing exercises with quiet inspiration and prolonged expiration on the device for thirty minutes, with breaks of one minute every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
3205789|NCT00947570|Experimental|Cognitive behavioral therapy|Participants with panic disorder or generalized anxiety disorder (GAD) will receive a course of individual cognitive behavioral therapy targeted at their principal disorder.
3205790|NCT00947596|Experimental|Atropine Dry Powder Inhaler|
3205791|NCT00947596|Active Comparator|Atropen Autoinjector|
2557090|NCT02518698||Cohort 1 / Treatment patterns|Patients with castrated resistant prostate cancer and bone metastases
2557132|NCT02518360|Experimental|OSTEOPATHIC PROTOCOL|"Physiotherapist applies an osteopathic treatment in non-specific low back pain patients.~The experimental group is treated with osteopathy, three sessions (20 minutes/session) and a frequency one session/week. Osteopathic treatment osteopathic is a body adjustment protocol. This protocol adjusts the musculoskeletal disorders since neck to lower limbs in the experimental group. Before treatment, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry."
2557134|NCT02518360|Active Comparator|Auto Stretching|The patients realizes stretching protocol: two stretching global postures once a week (10 minutes for each posture) for three weeks: the first is for the anterior muscular chain and the second posture to stretch the posterior muscle chain. Before three stretching, immediately after the last session and a month later, are measured stabilometric parameters, height and Oswestry.
2557150|NCT02518126||control|Women with IUGR embryos so that their fetal weight estimate puts them in a percentile bellow 10th percentile
2557154|NCT02518126||IUGR|Women with AGA embryos so that their fetal weight estimate puts them in a percentile between 20th and 80th percentiles
2557236|NCT02517957|Experimental|Qinzhuliangxue Keli|Qinzhuliangxue Keli(common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets placebo (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.)
2557239|NCT02517957|Active Comparator|loratadine tablets|Qinzhuliangxue Keli placebo (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.),Loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
2557242|NCT02517957|Active Comparator|Qinzhuliangxue and loratadine|Qinzhuliangxue Keli (common name: QZLX particles, shenzhen China resources san-jiu pharmaceutical trading co., LTD.), loratadine tablets (common name: LLTD piece, Shanghai schering pharmaceutical co., LTD.).
2557278|NCT02517359|Experimental|Single dose, healthy volunteers|
2557281|NCT02517359|Experimental|14 day repeat dose, healthy volunteers|
2557285|NCT02517359|Experimental|28 day repeat dose, healthy volunteers|
2557287|NCT02517359|Experimental|14 day repeat dose, asthma patients|
2557289|NCT02517359|Experimental|14 day repeat dose, smokers|
2557334|NCT02516943|Active Comparator|Control|The patient were retrospectively included according to the last digit of their admission number (odd number). The had arterial blood gas analysis every 4 hour during the ICU stay.
2557335|NCT02516943|Active Comparator|Guideline|The patient were prospectively included and they had arterial blood gas analysis following the pathological- based guidelines for arterial blood gas analysis in patients aftercardiac surgery
2557383|NCT02516735|Experimental|Group 1|I-scan with magnification targeted biopsies for gastric intestinal metapalsia.
2557384|NCT02516735|Active Comparator|Group 2|Standard endoscopy with a standard biopsy protocol from the five standard biopsy sites following the updated Sydney System including two from the distal antrum (within 2-3cm from the pylorus, greater/lesser curvature), one from the incisura and two from the mid corpus (greater/lesser curvature).
2557425|NCT02516423|Experimental|ixazomib + lenalidomide + dexamethasone + zoledronic acid|Patients receive 4 mg ixazomib by mouth on days 1, 8 and 15. Patients also receive 15 mg lenalidomide by mouth on days 1-21, 12 mg dexamethasone by mouth on days 1, 8, 15, and 22 and zoledronic acid (dose based on creatinine clearance on day 1) IV infusion on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
2557430|NCT02516423|Active Comparator|zoledronic acid|Patients receive zoledronic acid (dose based on creatinine clearance on day 1) IV on day 1. Patients receive treatment every 28 days for a maximum of 6 cycles.
2557856|NCT02513901|Experimental|Chidamide|"Step 1 - Six participants will receive Chidamide 10 mg twice a week(BIW) for 4 consecutive weeks.~Step 2 - Another six participants will receive Chidamide 30 mg twice a week(BIW) for 4 consecutive weeks.~Participants will be enrolled into Step 1 first; if the dose given to Step 1 is well tolerated and no safety concerns are noted, Step 2 will be enrolled."
3205792|NCT00947609||HIV-infected and HIV-uninfected children|HIV-infected and HIV uninfected children with recent exposure to adults with active tuberculosis will be referred to the two study sites (HIV-NAT/Chulalongkorn and Queen Sirikit) for eligibility screening and enrollment in the study.
3205793|NCT00947622|Placebo Comparator|Placebo stimulation|Placebo stimulation at the occipital head area for 1800 seconds at 0 mA, three times a week, during one week (with seconds of stimulation to get onset tingling sensation)
3205794|NCT00947622|Experimental|Effective transcranial stimulation|Effective stimulation at the occipital head are for 1800 seconds at 2 mA, 3 times a week for 1 week
3205795|NCT00947635|Experimental|Islet transplant|People with Type 1 diabetes undergoing islet transplantation
3205796|NCT00947635|Experimental|Liver transplant|People with liver failure undergoing liver transplantation
3205797|NCT00947635|Experimental|Control|Healthy normal people which serve as control group
3205798|NCT00947648|Other|"Raw Group"|Participants will eat cooked food and the addition of raw fruits and vegetables.
3205799|NCT00947648|Other|"Cooked Group"|Participants will eat only cooked foods.
3205800|NCT00947674|Experimental|Cellsorba EX|
3205801|NCT00947674|Sham Comparator|Sham treatment|
2558281|NCT02510586|Experimental|Sevo_postconditioning|Patients receiving sevoflurane 1.0 minimum alveolar concentration (MAC) for 30 minutes after revascularization competed.
2558285|NCT02510586|No Intervention|Non_postconditioning|Patients not receiving sevoflurane postconditioning after revascularization completed
2558323|NCT02510313|No Intervention|Classic VUP (Control)|Families receive benefits (cash) in exchange for state-sanctioned labour intensive work.
2558330|NCT02510313|No Intervention|Expanded VUP|Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
3205802|NCT00947687|Experimental|PUR003|
3205803|NCT00947687|Placebo Comparator|Placebo|
2557153|NCT02518165|Active Comparator|Proprietary spearmint extract|Subjects randomized into the active treatment group will be asked to consume 900 mg/day of the proprietary spearmint extract.
2557157|NCT02518165|Placebo Comparator|Microcrystalline cellulose|Subjects randomized into the placebo group will be asked to consume 900 mg/day of the excipient, microcrystalline cellulose.
2557208|NCT02517931|Active Comparator|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
2557212|NCT02517931|Placebo Comparator|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
2557250|NCT02517632|Experimental|Exercise group|This arm will be submitted to a exercise session and counseling from pharmaceutical and nutritional professionals.
2557252|NCT02517632|Other|Control group|This arm will have only the counseling from pharmaceutical and nutritional professionals.
2557293|NCT02517372|Active Comparator|Cohorte 1|"Low dose pemirolast sodium (CRD007) given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
2557296|NCT02517372|Active Comparator|Cohorte 2|"Medium dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
2557301|NCT02517372|Active Comparator|Cohorte 3|"High dose CRD007 given as one single dose on day 1, and thereafter twice daily for 3 days, followed by one single dose on day 5 and last day"
3171365|NCT00586222|No Intervention|Healthy Comparsions|We will compare the BP group with 32 age-, gender-, and handedness-matched healthy adolescents. Subjects who have a first or second degree relative with a psychiatric history will be excluded from the healthy comparison group. Subjects must be safe to undergo MRI scanning as per Mayo MRI safety screening which is explained in detail elsewhere in this protocol. We will exclude the subjects with cardiac pacemakers, metallic clips, other bodily metallic implants and dental braces because of the MRS procedure. Subjects who cannot complete clinical assessments or the MRI scan and subjects who are not fluent in English will be excluded from the study.
3171366|NCT00586222|Experimental|1|
3171367|NCT00586235||1|patients with indeterminate kidney or liver lesions
2557489|NCT02516072|No Intervention|Control|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR.
2557493|NCT02516072|Experimental|Remote Ischaemic preconditioning (RIPC)|Patients will receive iv hydration prior to procedure dependent on classification of risk as per eGFR. Additionally, patients will receive RIPC; a blood pressure cuff will be placed around one arm of the patient, it will then be inflated to a pressure of 250mmHg for 5 minutes. The cuff will then be deflated and the arm allowed to reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles immediately prior to the procedure.
2557524|NCT02515864|Experimental|FYU-981 anticipated therapeutic dose|Drug: FYU-981, FYU-981 Placebo, Moxifloxacin Placebo (Oral)
2557526|NCT02515864|Experimental|FYU-981 supratherapeutic dose|Drug: FYU-981, Moxifloxacin Placebo (Oral)
2557527|NCT02515864|Placebo Comparator|Placebo|Drug: FYU-981 Placebo, Moxifloxacin Placebo (Oral)
2557528|NCT02515864|Active Comparator|Moxifloxacin|Drug: Moxifloxacin, FYU-981 Placebo (Oral)
2557568|NCT02515552|Other|All applicants|Study applicants who consented and completed the application to participate in the Fibromyalgia Wellness Project. From that point forward all subjects used the intervention program to at whatever frequency they chose voluntarily. It was recommended subjects complete a SMARTLog at least three times per week for at least three months.
3171368|NCT00586274|Experimental|CD34 selected haploidentical PBSCT|CD34 selected haploidentical PBSCT
3171369|NCT00586287|Experimental|A|Algorithm which uses serum albumin and weight to determine the loading dose of phenprocoumon within the first 5 days
2557672|NCT02514759|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions (one per week at 40-50 minutes each) and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
2557677|NCT02514759|No Intervention|Control group|The control group received business as usual.
2557719|NCT02514616|Active Comparator|Active Electric Stimulation Therapy|The subject receives Active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject continues on stimulation treatment after 14 weeks and an extended open-label follow-up phase includes annual visits through 5 years.
2557720|NCT02514616|Sham Comparator|Delayed Electric Stimulation Therapy|The subject receives no active Electric Stimulation Therapy for 12 weeks, 2 weeks after laparoscopic IPG and lead implant procedure. The subject and physician will be blinded to the randomization group assignment. The subject will receive Active Electric Stimulation Therapy at week 14 visit, and an extended open-label follow-up phase includes annual visits through 5 years.
2557117|NCT02518607|Experimental|Group 2, Session 3, Active|Dose Escalation SAD MGB-BP-3, 6X250 mg liquid filled enterically coated capsules, single dose
2557124|NCT02518607|Experimental|Group 3, Active|Lowest dose of MAD MGB-BP-3, 2X250 mg liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
2557127|NCT02518607|Experimental|Group 4, Active|Dose Escalation MAD MGB-BP-3, 4X250 mg liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
2557128|NCT02518607|Experimental|Group 5, Active|Dose Escalation MAD MGB-BP-3, 8X250 mg liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
2557129|NCT02518607|Placebo Comparator|Group 1, Session 1, Placebo|"Lowest dose of SAD:~Placebo, 1 liquid filled enterically coated capsule, single dose"
2557131|NCT02518607|Placebo Comparator|Group 1, Session 2, Placebo|Placebo, 2 liquid filled enterically coated capsules, single dose
2557135|NCT02518607|Placebo Comparator|Group 1, Session 3, Placebo|Placebo, 3 liquid filled enterically coated capsules, single dose
2557136|NCT02518607|Placebo Comparator|Group 2, Session 1, Placebo|Placebo, 4 liquid filled enterically coated capsules, single dose
2557137|NCT02518607|Placebo Comparator|Group 2, Session 2, Placebo|Placebo, 5 liquid filled enterically coated capsules, single dose
2557139|NCT02518607|Placebo Comparator|Group 2, Session 3, Placebo|Placebo, 6 liquid filled enterically coated capsules, single dose
2557142|NCT02518607|Placebo Comparator|Group 3, Placebo|Placebo 2 liquid filled enterically coated capsules (AM/PM), multiple dose for 9 days and 1 single dose on Day 10
2557144|NCT02518607|Placebo Comparator|Group 4, Placebo|Placebo 4 liquid filled enterically coated capsules (2XAM/2XPM), multiple dose for 9 days and 1 single dose on Day 10
2557145|NCT02518607|Placebo Comparator|Group 5, Placebo|Placebo 8 liquid filled enterically coated capsules (3XAM/3XPM), multiple dose for 9 days and 1 single dose on Day 10
2557194|NCT02518022|Experimental|Intervention|For carbohydrates in beer, subjects will get covering by Insulin (1/2 of calculated amount). As well Insulin basal rate will set to half for 12 hours
2557196|NCT02518022|No Intervention|Standard|No Insulin Treatment of carbohydrates in beer.
2557255|NCT02517710|Placebo Comparator|Control|Group of patients receiving standard hysterotomy closure with synthetic braided suture
2557256|NCT02517710|Experimental|Stratfix|group of patients having the hysterotomy incision closed with barbed synthetic suture. Time to closure, blood loss, and postoperative pain
2557309|NCT02517346|Active Comparator|Standard follow up-Sleep Unit|Patients diagnosed as OSA, treated with CPAP and followed up in sleep unit
2557311|NCT02517346|Experimental|Telemonitoring|Patients diagnosed as OSA and treated with CPAP in sleep unit, followed up by telemonitoring system
2557337|NCT02516995|Experimental|Patients with prostate cancer|
2557427|NCT02516722|Experimental|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
2557472|NCT02516254|Experimental|fortified bread|daily intake of fortified bread (1000IU vitamin D per 50 g) plus placebo
2557476|NCT02516254|Experimental|supplement|daily intake of plain bread (50 g) plus supplement (1000 IU per tablet)
2557482|NCT02516254|Placebo Comparator|placebo|daily intake of plain bread plus placebo
2557532|NCT02515838|Placebo Comparator|Placebo|Placebo infusion
2557533|NCT02515838|Experimental|Sevuparin|Sevuparin infusion
2557579|NCT02515474|Active Comparator|LCBDE group (single step)|Choledocholithiasis patient, after Laparoscopic Cholecystectomy (LC) to remove the gallbladder, Laparoscopic Common Bile Duct Exploration (LCBDE) was performed for removing the bile duct stone(s) in laparoscopy. Choledochoscope detection or cholangiograms should be chosen as a method of obtain stone clearance. T-tube was acceptable if needed.
2557582|NCT02515474|Active Comparator|ERCP group (sequential step)|Choledocholithiasis patient, Endoscopic Retrograde cholangiopancreatography (ERCP) was performed for removing the bile duct stone(s) in endoscopy prior to Laparoscopic Cholecystectomy (LC). Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be chosen accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
2557639|NCT02515136|Experimental|Parkinson's disease|Parkinson's disease patients
2557640|NCT02515136|Other|Controls|Healthy volunteers paired with Parkinson's disease patients on sex and age group, whose data will be extracted from a CNRS existing database
2557661|NCT02514915|Other|Stereotactic Radiosurgery|Subjects will receive stereotactic radiosurgery prior to resection
2557714|NCT02514694|Active Comparator|LEO 32731|Active
2557716|NCT02514694|Placebo Comparator|Placebo|Placebo
3171370|NCT00586287|Experimental|B|Algorithm which uses serum age and weight to determine the loading dose of phenprocoumon within the first 5 days
2557855|NCT02513602||TEST group (kidney transplanted)|"Kidney transplanted patients, passed through dialysis phase presenting a mandibular edentulism. It will be scheduled one or two dental implants to be inserted in mandible.~This group will be subjected to a dental implant insertion procedure."
2557859|NCT02513602||CONTROL group (healthy patients)|Healthy patients, with an inserted mandibular implant, retrospectively enrolled with a preoperative cbct scan.
2557895|NCT02513316||Study I (AF)|Prospective cohort study of patients anticoagulated after cardioembolic stroke started on best practice oral anticoagulant (without prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up for the occurrence of ICH, ischaemic stroke and cognitive function for an average of two years. Our main baseline exposures (risk factors of interest) are the presence of CMBs on MRI, and genetic polymorphisms in candidate genes with potential functional relevance to ICH risk.
2557900|NCT02513316||Study II (ICH)|Observational and genetics study of intracerebral haemorrhage Patients with ICH (non anticoagulant-related ICH cases and anticoagulant-related ICH cases).
2558061|NCT02512263|No Intervention|control group|They will have to do all the tests but not to follow the home-based training program.
3171371|NCT00586287|Active Comparator|C|The physician chooses the loading dose of phenprocoumon according to his/her experience
3171372|NCT00586300|Active Comparator|1|Physical training program
2557190|NCT02518035|Experimental|Experimental|Silicone gel applied for twice per day
2557247|NCT02517736|Experimental|sorafenib at a dose of 800 mg / day|
2557298|NCT02517424|Experimental|High THC/Low CBD Cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
2557304|NCT02517424|Experimental|High THC/High CBD cannabis|Investigational product will be administered via vaporization up to 2 grams per day as needed.
2557307|NCT02517424|Placebo Comparator|Low THC/Low CBD cannabis|Product will be administered via vaporization up to 2 grams per day as needed.
2557365|NCT02517034|Experimental|Arm I (geriatric assessment-driven treatment)|Patients follow an intervention plan created by the NP using the results of the geriatric assessment. The NP discusses the results of the assessment and treatment recommendations with the patient. They also share the treatment plan, proposed referrals, and specific vulnerabilities with the primary care physician and community oncologist. Some patients complete the intervention plan via Telehealth, which uses telecommunication technology to provide health services over a distance.
2557366|NCT02517034|Active Comparator|Arm II (standard of care)|Patients follow a standard of care treatment plan at the discretion of the primary oncologist. Beginning 6 months from the start of chemotherapy, patients undergo the geriatric assessment as in Arm I. Some patients complete the standard of care treatment plan via Telehealth.
2557424|NCT02516475|Active Comparator|zinc sulfate|1 zinc sulfate capsule for 15 weeks
2557431|NCT02516475|Placebo Comparator|starch|1 corn starch capsule for 15 weeks
2557455|NCT02516215||1_Hypertension|Patients with diagnosed hypertension, without other systemic diseases
2557458|NCT02516215||2_Diabetes mellitus|Patients with diagnosed diabetes mellitus, without other systemic diseases
2557460|NCT02516215||3_Hypertension and diabetes mellitus|Patients with both diagnosed hypertension and diabetes mellitus
2557461|NCT02516215||4_end stage renal disease with hemodialysis|Patients with end stage renal disease with hemodialysis
2557462|NCT02516215||5_Peripheral arterial occlusive disease|Patients with disgnosed peripheral arterial occlusive disease
2557463|NCT02516215||6_Coronary artery disease|Patients with diagnosed coronary artery disease
2557464|NCT02516215||7_liver cirrhosis|Patients with diagnosed liver cirrhosis
2557465|NCT02516215||8_Anemia|Patients with diagnosed anemia
2557581|NCT02515721|Experimental|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
2557584|NCT02515721|Experimental|Virtual Chromoendoscopy -SB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
2557620|NCT02515227|Experimental|6MHP + Pembrolizumab|6 MHP (200 mcg each peptide) will be administered intradermally and subcutaneously on days 1, 8, 15, 43, 64, and 85. Pembrolizumab (200 mg) will be administered intravenously every 3 weeks for up to 2 years, beginning on day 1.
2557666|NCT02514941|Experimental|pre OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed within three days before the scheduled proximal Roux-en-Y gastric bypass surgery. A gastroduodenoscopy with biopsy of the lower duodenum will be performed before the first pharmacokinetic study period.
2557668|NCT02514941|Experimental|post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period will be performed 5-7 days after the scheduled proximal Roux-en-Y gastric bypass surgery. A sampling of a tissue specimen from the jejunum will be collected during the operation.
2557670|NCT02514941|Experimental|one year post OP|The subjects will be administered 200 mg paracetamol, 250 mg amoxicillin and 50 mg talinolol dissolved in 40 ml water which must be drunken with additional 200 ml water on the first study day. This pharmacokinetic period and a gastrojejunoscopy with biopsy of the jejunum will be performed about one year after the scheduled proximal stomach bypass surgery.
2557742|NCT02514434|Experimental|Ultrasonography|Subjects will be regularly screened for HCC by ultrasonography with serum AFP(alpha fetoprotein).
2557747|NCT02514434|Experimental|Non-contrast MRI|Subjects will be regularly screened for HCC by non-contrast magnetic resonance imaging(MRI) with serum AFP(alpha fetoprotein).
2557806|NCT02514057||Healthy|Volunteers over 18 years
2557811|NCT02514057||Gastrointestinal disorders|Over 18 and with any gastrointestinal or liver disorder
2557814|NCT02514057||Non-gastrointestinal disorders|Over 18 and with any medical condition requiring hospital attention in which there is no primary gastrointestinal or liver disease
2557862|NCT02513524||Direct Observed Therapy test|Patients with resistant hypertension (as defined in the eligibility criteria) will be enrolled. They will all have undergone 24 hour ambulatory blood pressure monitoring (ABPM) before enrollment. As part of the study, the subjects will undergo direct observed therapy testing, followed by another 24 hour ABPM, which will be repeated at 1 month.
2557906|NCT02513303|Experimental|Treatment Group|AV fistula surgery Single administration of sirolimus-eluting Collagen implant
2557908|NCT02513303|Other|Control Group|AV fistula surgery
2557938|NCT02512913|Experimental|Adapted/enhanced MAPS|Counseling sessions delivered by phone to the pregnant/postpartum women and to the husbands/partners
2557942|NCT02512913|No Intervention|Usual Care|Couples in the control condition will receive usual care
2557982|NCT02512731|Active Comparator|Goal directed fluid therapy using esophageal doppler monitor|The esophageal doppler monitor directs the fluid therapy.
2557983|NCT02512731|No Intervention|Fluid therapy using standard management|The esophageal doppler monitor is in place however blinded to the healthcare providers, fluid management is as per standard clinical practice.
2557991|NCT02512458|Experimental|Cabazitaxel|Patient will be treated with iv cabazitaxel 25mg/m2 q 21days per standard clinical practice for up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision or patient's consent withdrawal (whichever occurs first).
2558054|NCT02512263|Experimental|Intervention group|They will have to do all the tests and to follow the home-based training program during 9 weeks.
2558387|NCT02510105|Experimental|ARDS patients|
2557223|NCT02517814|Experimental|Patients with cardiomyopathy|Patients with vitamin D deficiency and cardiomyopathy will receive supplementation with vitamin D 400 units per day for 6 months.
3205804|NCT00947700|No Intervention|Assessment & Monitoring|No Intervention. Parent-Child participants in assessment and monitoring visits but does not receive any study provided treatment.
2557352|NCT02516839|Experimental|Regulation of Cues (ROC)|The ROC program provides psychoeducation, coping skills, self-monitoring and experiential learning.
2557354|NCT02516839|Experimental|Behavioral Weight Loss (BWL)|The BWL program will include dietary recommendations, physical activity recommendations, and behavioral change recommendations.
2557356|NCT02516839|Experimental|BWL+ ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments.
2557357|NCT02516839|Active Comparator|Nutrition Education, Stress Management Social Support|Nutrition Education, Stress Management and Social Support will be covered. Mindfulness will be practiced in every session.
3205805|NCT00947700|Experimental|Assessment, Monitoring + Intervention|Parent-Child participants in assessment and monitoring visits but also the Promoting First Relationships PFR intervention (http://pfrprogram. Org). PFR is a 10 weekly 60-85 minute in-home visits by a masters level mental health provider trained in the PFR curriculum. The PFR curriculum focuses on increasing parenting sensitivity using attachment theory-informed, strength-based consultation strategies. The curriculum is fully manualized and fidelity was assessed according to the manual.
3205806|NCT00947713|Experimental|Low dose hCG group|
2557569|NCT02515643||Endothelial dysfunction in Cohort 1|Assessment of endothelial dysfunction in healthy subjects who will undergo a nephrectomy as part of the living donor program at each participating center.
2557573|NCT02515643||Endothelial dysfunction in Cohort 2|Assessment of endothelial dysfunction in renal transplant recipients from cohort 1
2557610|NCT02515240|Active Comparator|healthy controls|healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
2557613|NCT02515240|Active Comparator|newly diagnosed HIV >200|Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
2557615|NCT02515240|Active Comparator|newly diagnosed HIV <200|Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
2557617|NCT02515240|Active Comparator|newly diagnosed HIV <200 delayed|Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
2557618|NCT02515240|Active Comparator|HAART experienced HIV>200|HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
2557623|NCT02515240|Active Comparator|HAART experienced HIV<200|HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
2557732|NCT02514317|Experimental|percutaneous treatment|percutaneous treatment of carpal tunnel syndrome under ultrasound guidance in interventional radiology room.
2557779|NCT02514135||Elevated Intra-abdominal Pressure|Patients with intra-abdominal pressure > 12 mmHg at any time throughout admission
2557780|NCT02514135||Normal Intra-abdominal Pressure|Patients with intra-abdominal pressure < 12 mmHg throughout admission
2557803|NCT02513862|Experimental|APRP group|APRP group is performed autologous platelet-rich plasma harvest technique before administration of heparin to the patient,the red blood cell(RBC) component is retransfused to the patient when the RBC transfusion protocol is reached,and the autologous platelet-rich plasma is transfused to the patient immediately after heparin is neutralized with protamine.
2557805|NCT02513862|No Intervention|control group|APRP group receive no autologous platelet-rich plasma harvest technique.
2557861|NCT02513576|Experimental|Physiotherapy exercises|Two strategies of abdominal exercises with and without movement of the upper limbs applied in patients with sternal instability as randomization.
2557897|NCT02513342|Experimental|Endostar+Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma , and the Endostar-Recombinant human endostatin injection is injected by 30mg continuous intravenous injection pump,d1-d7.
2557901|NCT02513342|Active Comparator|Docetaxel+Cisplatin|Patients in this group will be given conventional chemotherapy medicine: Docetaxel+Cisplatin chemotherapy recommended by treatment guidelines for Advanced Non-small Cell Lung Squamous Carcinoma.
2557950|NCT02512939|Experimental|Contacts of TB cases|Blood test, not yet marketed, development phase
2558003|NCT02512627|Active Comparator|Cognitive training group (Cog)|The BrainHQ program will be used to train different cognitive functions of the participants. The participants will practice tasks that involve the abilities of visuospatial processing, attention, memory, language, and/or executive functions. The tasks will become more difficult as the participants progress in their abilities.
2558004|NCT02512627|Active Comparator|Physical exercise group (PE)|The participants in this group participate in multimodal exercise programs including aerobic exercise, balance, and strength training. The entire exercise program for the PE group will contain 10 minutes of warm-up, 70 minutes of physical exercise, and 10 minutes of cool-down. The 70 minutes of exercise session will be break up into 2 to 3 parts, and the participants can rest as needed during the exercise period.
2558005|NCT02512627|Experimental|Sequential training group (Seq)|The participants in this group will first perform 45 minutes of physical exercise followed by 45 minutes of cognitive training. The physical exercise training will be similar to the programs used in the PE group. The entire exercise program for the PE group will contain 5 minutes of warm-up, 35 minutes of physical exercise, and 5 minutes of cool-down. The cognitive training will be implemented with BrainHQ similar to what has been described in the COG group.
2558007|NCT02512627|Experimental|Dual-task training group (Dual)|In this group, the participants will be instructed to perform physical exercise and cognitive tasks simultaneously (e.g., math calculation while stepping). The difficulty of the cognitive tasks will increase as the participants improve in their performance.
2558117|NCT02511743||physicians|physicians taking care of patients with chronic Hepatitis B Virus infection
2558206|NCT02511275|Other|renal microdialysis|patient with renal microdialysis
2558257|NCT02510898|Experimental|Intervention Arm|All subjects enrolled in the study will receive the intervention. This is a one-arm study.
2557267|NCT02517502|Experimental|DHA|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of DHA daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
2557269|NCT02517502|Placebo Comparator|Placebo|Participants will be asked to take four 400 mg (1600 mg; 1.6 grams) capsules of a matched placebo daily. Participants will start taking capsules before the start of and for the duration of their neoadjuvant chemotherapy.
2557322|NCT02517242|Experimental|Pens Device|All patients will receive pens device, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
2557323|NCT02517242|Active Comparator|Syringe|All patients will receive syringe to insulin, insulin, blood glucose monitor, lancet tapes, capillary blood glucose tests (3 tests/day). All will be evaluated monthly for six months
2557376|NCT02516878|Experimental|Acupuncture group|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
2557378|NCT02516878|Sham Comparator|Control group|"For subjects assigned to control group, Streitberger's non-invasive acupuncture needles (Gauge 8 x 1.2 / 0.30 x 30 mm) will be applied to serve as sham control at the same acupoints with the same stimulation modality, except that the needles are only adhered to the skin instead of insertion.~The Semen Vaccariae embedded tape used in treatment group will be applied on 4 non-acupoints at the helix unilaterally, retained until the next visit and then the alternate ear will be used."
3171373|NCT00586300|Active Comparator|2|Self-management training program
3171374|NCT00586300|Active Comparator|3|Physical and self-management training programs
3171375|NCT00586352|Active Comparator|Normal|Subjects who have normal endoscopic findings
2557586|NCT02515513|Active Comparator|Pancreatic Cancer Patients|During the surgical resection for the pancreatic cancer a muscle tissue biopsy sample will be performed.
2557587|NCT02515513|Active Comparator|Surgical Patients with benign pathology|During surgical resection for patients with benign right upper quadrant pathology, a muscle tissue biopsy sample will be performed.
2557680|NCT02514967|Experimental|Blisibimod|
2557682|NCT02514967|Placebo Comparator|Placebo|
3171376|NCT00586352|Active Comparator|Newly diagnosed Crohn's disease|Subjects who are newly diagnosed with Crohn's disease after endoscopy.
3171377|NCT00586352|Active Comparator|Newly diagnosed Ulcerative Colitis|Subjects diagnosed with Ulcerative Colitis after endoscopy
3171378|NCT00586365|Experimental|1|Will receive 500 mg Naproxen twice a day for two weeks
3171379|NCT00586365|No Intervention|2|Will not receive naproxen
3171380|NCT00586391|Experimental|CD19CAR-28-zeta T cells|"Three dose levels of CTLs will be evaluated. Each patient will receive one injection according to their assigned dose over 1-10 minutes IV.~*At the discretion of the attending physician, if after a 4 to 6-week evaluation period the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies); repeat infusions separated by 4 to 6 weeks (up to a maximum of 3 extra doses) of modified T cells at the same dose level or below the patient's original dose can be administered."
3171381|NCT00586404||A|Patients with confirmed Barrett's Esophagus
3171382|NCT00586417|Experimental|1|This is a basic research study. There are no treatments with drugs or devices. Wound healing is being studied in healthy volunteers.
3171383|NCT00586430|Active Comparator|1|single 2 mg dose of lorazepam
3171384|NCT00586430|Placebo Comparator|2|single dose of placebo
3171385|NCT00586443|Other|I|This is a Phase I safety study. There is only one arm.
3171386|NCT00586534|Active Comparator|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
3171387|NCT00586534|Experimental|I/GDC + VR/CER|Second Arm:NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
3171388|NCT00586547|Experimental|Treatment|After patients have completed preparation to receive cells, they will be treated at one of five dose levels.
3171389|NCT00586560|Experimental|1|Stratum 1 (~ 25 patients) will include patients with known bone marrow metastases or those who have had prior intensive myelosuppression therapy (including autologous or allogeneic stem cell rescue [SCR], total body irradiation [TBI], craniospinal irradiation [CSI], or hemipelvic radiation).
3171390|NCT00586560|Experimental|2|Stratum 2 (~ 25 patients) will include patients without previous intensive myelosuppressive therapy and bone marrow metastases.
3171391|NCT00586586|Experimental|Group CBT|The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered in groups of 4 to 8. 10 weekly sessions plus 2 booster sessions.
3171392|NCT00586586|Experimental|Individual CBT|"The behavioral intervention FRIENDS (cognitive behavior therapy program developed by P. Barratt) delivered individually.~10 weekly sessions plus 2 booster sessions."
3171393|NCT00586586|No Intervention|Wait-list control|Wait-list control condition for 5 weeks after last child has been included.
3171394|NCT00586599|Other|Control|Subjects who have no inflammatory disease who will be age/gender matched controls for the 2 other arms.
3171395|NCT00586599|Other|IBD and infliximab|Subjects who have IBD and will be receiving infliximab for the first time.
3171396|NCT00586599|Other|Newly Diagnosed IBD|Subjects who are newly diagnosed with IBD and given corticosteroid therapy.
3171397|NCT00586638|Experimental|1|Video Game play with training strategy
3171398|NCT00586638|Active Comparator|2|Video game play without training strategy
3171399|NCT00586638|No Intervention|3|Minimal contact control
3171400|NCT00586651|Experimental|lestaurtinib|
3171401|NCT00586677|Active Comparator|RF|Relationship focused where the primary goals are to strengthen the relationship between the parent and the child and to give the parent additional skills that can be used to manage the behavior of the child.
2557277|NCT02517333|Other|Proof-of-principle (PoP)|"Proof-of-principle phase of the study. All participants undergo the exercise intervention as part of the feasibility.~Screen within Year 9 Class~Targeted recruitment for those scoring in bottom 5th percentile~Invite students to take part in 6-week intervention~Enroll students participating~Pre-intervention assessment~Start 6-week Epic Club gym intervention (1-2 times weekly for 45-60 mins) consisting of 30 min cardiovascular exercise and 25-30 min strength/resistance and weight training~Post-intervention assessment~Exit to longer-term sport/physical activity"
2557348|NCT02517099|Active Comparator|Pathological phenotype|Regular inhaled steroids- Beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co- amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
2557351|NCT02517099|Active Comparator|Clinical guidelines|The children will be treated as directed by their Consultant Paediatrician. The treatment may include- regular inhaled steroids- beclometasone dipropionate 200mcg bd for 4 months OR antibiotic therapy- Co-amoxiclav (0.3ml/kg bd) or Azithromycin (10mg/kg od) for 4 weeks
2557554|NCT02515695|Experimental|0.5 MIU i.v. and 1.5 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
2557555|NCT02515695|Experimental|1 MIU i.v. and 3 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
2557556|NCT02515695|Experimental|2 MIU i.v. and 6 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
2557557|NCT02515695|Experimental|4 MIU i.v. and 12 MIU s.c.|"All 12 subjects participated in 4 periods, receiving 4 different doses of interferon beta-1a from 2 of the 4 possible pairs of treatments.~The number of treatment sequences was limited to 6 and the subjects were randomized among the 6 sequences, as one male and one female per sequence. Thus 6 subjects received each dose. The washout period between two injections (Day 1 of subsequent periods) was of 7 days or more."
2557589|NCT02515448|Experimental|Gentamicine injectable(day 1+2)and then gentamicine inhalation|
2557634|NCT02515188|Experimental|propacetamol group|
2557637|NCT02515188|Placebo Comparator|placebo group|
2557660|NCT02514863||Patients undergoing CMR|"Assessment of hemodynamic function using:~CMR~EV with an inter-electrode gap (lower pair) of 5 cm~EV with an inter-electrode gap (lower pair) of 15 cm"
2557695|NCT02514720|Other|Fast Nicotine Metabolizers|Those in the upper tertile of NMR for cigarette/nicotine metabolism.
2557697|NCT02514720|Other|Slow Nicotine Metabolizers|Those in the lower tertile of NMR for cigarette/nicotine metabolism
2557737|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan|All patients in Part 1 will receive trilaciclib (G1T28) prior to standard chemotherapy, topotecan. Patients will have PK assessment completed on days 1 and 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
2557740|NCT02514447|Experimental|Trilaciclib (G1T28) + Topotecan -PART 2|All patients in Part 2 will be randomized 2:1 to receive trilaciclib (G1T28) to be administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
2557750|NCT02514447|Experimental|Placebo + Topotecan -PART 2|All patients in Part 2 will be randomized 1:2 to receive placebo administered prior to standard chemotherapy, topotecan. Patients will have limited PK assessments completed on day 4 in cycle 1 only. All patients will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
3205807|NCT00947713|Active Comparator|Clomiphen citrate plus HMG|
2557891|NCT02513251||Case group|Chronic pain patient
3205808|NCT00947739|Experimental|Cohort 1|80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY
3205809|NCT00947739|Experimental|Cohort 2|160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
2558008|NCT02512614|No Intervention|Comparison|Hand hygiene education.
2558010|NCT02512614|Experimental|Intervention|Hand hygiene education and 4 antimicrobial hand towels
2558055|NCT02512289|Active Comparator|Real stimulation|real tDCS associated with robot-assisted therapy (RAT)
2558062|NCT02512289|Sham Comparator|Sham stimulation|Sham tDCS associated with RAT
2558142|NCT02511886|Experimental|Arbaclofen Placarbil (AP)|Orally administered Arbaclofen Placarbil (AP) sustained release (SR) tablets
2558144|NCT02511886|Placebo Comparator|Placebo|Subjects remain on placebo for entire study
2558199|NCT02511249||cohort|"1 evaluation day : The evaluation team included a neuropsychologist, a speech therapist and either a pediatric neurologist or a pediatric physical and rehabilitation medicine practitioner.~tests carried out : Global intellectual functioning (WISC-IV), Oral language (N-EEL), Gross and fine motor abilities (clinical examination, Box & Block test, 9 Hole Peg test)"
2558262|NCT02510846|Experimental|Intensive educative program|5 hours a week
2558271|NCT02510846|Active Comparator|Usual practice of educative program|1 hour a week
2558334|NCT02510313|Experimental|Sugira Muryango & Classic VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned labour intensive work.
3205810|NCT00947739|Experimental|Cohort 3|320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3205811|NCT00947739|Experimental|Cohort 4|640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
2557575|NCT02515617|Active Comparator|Period with endotracheal tubes not allowing SSD|During this period, patients will be intubated with standard endotracheal tubes not allowing Subglottic Secretions Drainage
2557576|NCT02515617|Experimental|Period with endotracheal tubes allowing SSD|During this period, patients will be intubated with specific endotracheal tubes allowing Subglottic Secretions Drainage
2557627|NCT02515149|No Intervention|Standard of care|Referral laboratory based CD4 measurement after home-based HIV testing
2557631|NCT02515149|Experimental|Point of care|POC CD4 testing after home-based HIV testing
2557674|NCT02514993||Study group|Inclusion criteria for the study were (a) sternal fracture and concomitant thoracic spine fracture, (b) Injury Severity scale (ISS) ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
2557679|NCT02514993||Control group|The inclusion criteria for the control group included: (a) Thoracic spine fracture without concomitant sternal fracture, (b) ISS ≥ 16, (c) age under 50 years, (d) presence of a whole body computed-tomography (CT-scan) performed at admission of the patient to the hospital.
2557707|NCT02514642|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients withStable Coronary Artery Disease
2557709|NCT02514642|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
2557736|NCT02514356|Active Comparator|Own adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own Adherence'.
2557738|NCT02514356|Active Comparator|Own and group level adherence|Participants in this group receive a weekly message by SMS. They receive the intervention 'Behavioral: Own and Group Adherence'.
2558087|NCT02511977||overdenture with annual maintenance|Rehabilitation should be: overdenture with at least 2 implants placed in the mandible and 3 implants in the maxilla per person. They were divided into two groups: Group I: Annual maintenance for the past seven years
2558088|NCT02511977||overdenture whitout annual maintenance|Group II: individuals who have not returned for the last seven years. Individuals who said they went to the dentist at least once a year, for whatever treatment, were included in the maintenance group. Individuals who denied any visit to the dentist in the last seven years were included in the no maintenance group.
2558132|NCT02511652|Active Comparator|Ambu AuraGain|Insertion of the supraglottic device and evaluation of its clinical performance
2558133|NCT02511652|Active Comparator|LMA Supreme|Insertion of the supraglottic device and evaluation of its clinical performance
3171402|NCT00586677|Active Comparator|HS|The physical health and safety are the primary components of this parenting program where the parent is taught about basic healthcare and safety in the home.
2558266|NCT02510768|Experimental|ELAPR002f|ELAPR002f A tropoelastin polymer cross-linked with hyaluronic acid.
2558274|NCT02510768|Experimental|ELAPR002g|ELAPR002g A tropoelastin polymer cross-linked with hyaluronic acid.
2558279|NCT02510768|Placebo Comparator|Saline|Saline
2558337|NCT02510391|Experimental|PIPA|Modularized treatment for anxiety in children ages 3-7 years old
3171403|NCT00586742|Active Comparator|1|Labral repair with suture anchors
3171404|NCT00586742|Active Comparator|2|Biceps tenodesis with suture anchor
3171405|NCT00586742|Sham Comparator|3|only a diagnostic arthroscopy performed
3171406|NCT00586755|Experimental|Intensive Induction-BMT|Patients will undergo induction regimen and stem cell mobilization with cyclophosphamide for bone marrow transplant (BMT). This will be immediately followed by high dose therapy with stem cell support.
3171407|NCT00586781|Experimental|3|The S.T.A.R. ankle system is the study device. The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants. Both ankles of every subject will be treated with the STAR ankle.
3171408|NCT00586794|Active Comparator|A|
3171409|NCT00586794|Placebo Comparator|B|from the 26th weeks on open-label, all patients were treated with Sildenafil
3171410|NCT00586807|Other|Infliximab|Subjects on infliximab
3171411|NCT00586833||1|No CHF/HTN Never diagnosed with CHF and undergoing current treatment for HTN
3171412|NCT00586833||2|CHF with HFpEF HFpEF Cases will be recruited from the community. Subjects will be largely drawn from an existing Mayo database examining all incident cases of HF in Olmsted County.
3171413|NCT00586833||3 Healthy normal adults|No identifiable cardiac issues at time of exercise.
3171414|NCT00586859|Experimental|A|NDO Full-thickness Plicator Procedure
3171416|NCT00586885|Experimental|1|Single arm, active treatment
3171417|NCT00586911|Active Comparator|Cystadane|
3171418|NCT00586911|Placebo Comparator|Identical Placebo|
3171419|NCT00586924|Experimental|5 mcg/kg|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
3171420|NCT00586924|Experimental|10 mcg/kg|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
3171421|NCT00586924|Experimental|20 mcg/kg|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
3171422|NCT00586924|Experimental|30 mcg/kg|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
2557513|NCT02515955|Experimental|Cohort 5|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557514|NCT02515955|Experimental|Cohort 6|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or minocycline 100 mg capsule twice daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557516|NCT02515955|Experimental|Cohort 7|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557517|NCT02515955|Experimental|Cohort 8|Participants will be receiving either JNJ-54175446 at increasing dose levels using 2 oral formulation as suspension for oral dose once daily from Day 1 to Day 17 or placebo matching with JNJ 54175446 once daily from Day 1 to Day 17.
2557597|NCT02515357|Placebo Comparator|Control group|This arm will receive standard care, i.e. CPAP prescription and brief written healthy lifestyle advice.
2557600|NCT02515357|Experimental|Mediterranean lifestyle group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month lifestyle intervention based on the Mediterranean lifestyle on top of standard care.
2557601|NCT02515357|Experimental|Mediterranean diet group|This arm will receive a hypocaloric diet and attend a comprehensive 6-month dietary intervention based on the Mediterranean dietary pattern on top of standard care.
2557686|NCT02515019|No Intervention|Group Sevo1.8%|Anaesthesia was maintained with a constant inspired concentration of sevoflurane 1.8% (Sevorane; Abbvie, Wiesbaden, Germany) administered via the ventilator. From the beginning of CPB, a constant flow of sevoflurane 1.8% was administered with the oxygenator fresh-gas supply, using a common anaesthetic vaporiser (Draeger Vapor Version 2000; Draeger, Luebeck, Germany). Following successful weaning from CPB, sevoflurane was again administered at an inspired concentration of 1.8% using the ventilator.
2557689|NCT02515019|Experimental|Bispectral index Monitoring|The sevoflurane concentration via the ventilator and the oxygenator fresh gas supply was titrated to maintain a target BIS value between 40 and 60 (BIS-Monitor, Covidien, Boulder, Colorado, USA). However, the concentration of sevoflurane in the oxygenator fresh gas supply was not reduced below 0.3%.
2557758|NCT02514512|No Intervention|Standard SABR|Patients receive standard treatment
2557761|NCT02514512|Experimental|MLC Tracking SABR|Patients are treated with MLC tracking
2557800|NCT02513953|Experimental|Endometriosis|Four port laparoscopy by way of intervention was needed for convenience in aspirating the cystic fluid and reversal of the cyst wall taking care not to destroy the normal ovarian tissue to minimize loss of ovarian reserve
2557889|NCT02513355|Experimental|NP(Changchun marina+cisplatin)+Endostar|Patients in this group will be given conventional chemotherapy medicine,NP plan (Changchun marina+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer. Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles;Changchun marina;25mg/m2,d1 and d8,cisplatin 80mg/m2,d1, q21d×4
2557890|NCT02513355|Experimental|TP(Taxol+cisplatin or parapl) +Endostar|"Patients in this group will be given conventional chemotherapy medicine,TP(Taxol+cisplatin)recommended by treatment guidelines for Advanced non small cell lung cancer.~Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles; Taxol;135-175mg/m2,d1,cisplatin or parapl 75mg/m2,d1,q21d×4."
2557949|NCT02513069|Experimental|Mobile Contingency Management (mCM)|"The mCM arm represents a proactive tele-health intervention that combines guideline based cognitive-behavioral smoking cessation telephone counseling, a tele-medicine clinic for access to nicotine replacement therapy (NRT), and intensive behavioral therapy administered via a smart phone (with carbon monoxide monitor) based application. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
2557951|NCT02513069|Active Comparator|Tele-Health for Smoking Ccessation|"TELE-HEALTH FOR SMOKING CESSATION is a proactive tele-health intervention that will provide controls for therapist, medication, time and attention effects. The tele-health intervention provides the same guideline based cognitive-behavioral smoking cessation telephone counseling, and tele-medicine clinic for access to NRT as in the mCM intervention. NRT may include nicotine patches (21 mg, 14 mg, and or 7 mg) used daily for six weeks from the smoking quit date. Dosage will depend on participants' reported smoking patterns and carbon monoxide readings. NRT may also include a rescue method, i.e., either nicotine gum or nicotine lozenge. The participants' preferred NRT rescue method will be prescribed and used as needed to reduce smoking craving for six weeks from the smoking quit date."
2557997|NCT02512497|Experimental|Romidepsin + Busulfan + Fludarabine + Stem Cell Transplant|"Part 1:~Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies. Fludarabine 40 mg/m2 by vein on Days -6 to -3. Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the optimal dose. Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1. Stem cell infusion on Day 0.~Romidepsin Maintenance Therapy - Part 2:~Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
2558109|NCT02511951|Experimental|one-layer duct-to-mucosa anastomosis|one-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
2558111|NCT02511951|Active Comparator|two-layer duct-to-mucosa anastomosis|two-layer duct-to-mucosa anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3205812|NCT00947739|Experimental|Cohort 5a|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY
3205813|NCT00947739|Experimental|Cohort 6|2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205814|NCT00947739|Experimental|Cohort 7|18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
2558256|NCT02510924|Active Comparator|Tracheal intubation with Airtraq sp|Tracheal intubation with Airtraq sp.
2557546|NCT02515773|Experimental|Healthy lifestyle intervention (LIFE)|Participants randomized to this group will receive just lifestyle intervention alone.This healthy lifestyle intervention (LIFE) consists of counseling participants and families regarding a healthy eating plan, physical activity and sedentary activities. Prior to study initiation, clinical site staff will participate in a live (or taped) training session from a dietician to lean to administer LIFE. A trained site staff member (e.g. medical assistant or case manager) will meet with participants and their families for a 15-20 minute session at baseline that will focus on nutritional issues using the Traffic Light Plan (TLP).
2557602|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 50ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (50ug), administered as a 0.5mL intramuscular (IM) injection
2557605|NCT02515175|Experimental|GEN-003 60ug / Matrix-M2 75ug|GEN-003/M2 (60 ug of each antigen) with Matrix-M2 adjuvant (75ug), administered as a 0.5mL intramuscular (IM) injection
2557607|NCT02515175|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection
3205815|NCT00947739|Experimental|Cohort 8|36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205816|NCT00947739|Experimental|Cohort 9|72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205817|NCT00947739|Experimental|Cohort 10|144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205818|NCT00947739|Experimental|Cohort 11|288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
2557741|NCT02514330|Experimental|Interval Training at 1% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 1% incline, Final Drop Jump (20;30;40 cm)
2557748|NCT02514330|Experimental|Interval Training at 10% incline|Procedure: Initial Drop Jump (20;30;40 cm), Six Stimulus of High Intensity Interval Training at 10% incline, Final Drop Jump (20;30;40 cm)
2557751|NCT02514330|No Intervention|Control|Procedure: Initial Drop Jump (20;30;40 cm), 20 min Rest, Final Drop Jump (20;30;40 cm)
2557789|NCT02513992|Experimental|intra-arterial injection of tracer|The perfusion tracer 99m-Technetium Ethyl Cysteinate Dimer will be injected via an intra-arterial catheter by a pressure injector to obtain a subtracted ictal SPECT co-registered with MRI (SISCOM)
2557841|NCT02513680|Active Comparator|LASER and LED therapy application|The first group will use the two techniques under study combined: Infrared Laser + Amber LED (830 nm - 150mW + 590 nm - 1.500 mW)
2557846|NCT02513680|Active Comparator|LED Therapy application|The second group will use only Amber LED (590 nm - 1.500 mW)
2557871|NCT02513407|Experimental|Group I (EML)|Participants complete an assessment on knowledge, attitudes, and behaviors at baseline and attend 2 weekday sessions comprised of interactive education segment that is culturally responsive, and based on the community EML program, and topics including: nutrition guideline, nutrition label reading, comparison shopping/grocery store tour, recipe modification and healthy food preparation, eating healthy on a budget, and making healthy choices outside the home (e.g., restaurants) and physical activity over 1 hour led by CHE, a physical activity conducted by Duarte Fitness Centers instructors over 30 minutes, and cooking/taste test demonstration co-led by the CHE and local chef over 30 minutes over 12 weeks. Participants are also prescribed and encouraged to participate in 3 days a week exercise classes (for > 30 minutes) including salsa, Zumba and other aerobic exercises that are provided at Duarte Fitness Center.
2557872|NCT02513407|Active Comparator|Group II (control)|Participants receive a fitness tracker to track their physical activity and be wait listed to receive the intervention during month 10-12.
3205819|NCT00947739|Experimental|Cohort 12|576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205820|NCT00947739|Experimental|Cohort 13|750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
2558029|NCT02512354||Fetus|
2558093|NCT02512055|Experimental|Group 1|Pediatric patients undergoing repeat radiotherapy session under ketamine sedation
2558128|NCT02511665|Experimental|Metformin|Metformin given , 1g twice a day for 4 weeks until prostatectomy +/- one week
2558130|NCT02511665|Placebo Comparator|Placebo|placebo given , 1g twice a day for 4 weeks until prostatectomy +/- one week
2558131|NCT02511665|Experimental|PET-MRI|5 patients in this arm will all receive metformin and undergo two additional PET- MRI scans, one before and one after treatment
2558167|NCT02511392|Active Comparator|Group 1: Real rTMS-1 Hz|Included 15 patients, they received 1 Hz rTMS with intensity of 100% of the RMT continuous with total 2000 applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval
2558170|NCT02511392|Active Comparator|Group 2: Real rTMS-10 Hz|Included 15 patients, they received 10 Hz rTMS with intensity of 100% of the RMT applied in 10 trains, each of them 200 pulses, with 20 seconds intertrain interval
2558173|NCT02511392|Sham Comparator|Group 3: Sham rTMS|Included 15 patients; they received the same number of pulses 2000 pulse applied in 200 trains, each of 10 pulses, with 5 seconds intertrain interval, but coil was placed over the same area but perpendicular to the scalp.
2558267|NCT02510911|Experimental|Caffeine (100 mg)|Verum 1 with 100 mg caffeine
2558275|NCT02510911|Experimental|Caffeine (200 mg)|Verum 2 with 200 mg caffeine
2558278|NCT02510911|Placebo Comparator|corn starch (250 mg approx.)|approx. 250 mg corn starch as placebo
2558346|NCT02510209|Experimental|Teen Outreach Program|
2558350|NCT02510209|No Intervention|Control|Business as usual.
2558389|NCT02509923|Experimental|1|3-way cross-over, Z-215 10 mg/day / Z-215 20 mg/day / Rabeprazole Sodium 10 mg/day
3205821|NCT00947739|Experimental|Cohort 14|1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205822|NCT00947739|Experimental|Cohort 5b|1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID
3205823|NCT00947778|Active Comparator|session of training 1|Arm from which members will perform their training session after the first session of evaluation
3205824|NCT00947778|Active Comparator|Session of training 2|Arm from which members will perform their training session after the second session of evaluation
3205825|NCT00947804||1. Patients with symptoms of ACS|Patients whom present emergently to the Cardiac Catheterization Lab with current symptoms of Acute Coronary Syndrome (ACS), whom at the time of admission to the cardiac catheterization lab are believed to be suffering from STEMI, NSTEMI, or Unstable Angina, with the possible need for emergency Percutaneous Coronary Intervention (PCI), or Coronary Artery Bypass Grafting (CABG).
2557564|NCT02515578|Experimental|Enhanced practice transformation support|Primary care practices will receive practice facilitation, practice assessment with feedback, health information technology assistance, academic detailing, and periodic collaborative learning sessions PLUS patient advisory council support and a modified cardiovascular care toolkit based on combined practice and patient input regarding the local context.
3171423|NCT00586924|Experimental|40 mcg/kg|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
2557966|NCT02512770|Experimental|dilatation|esaphageal dilatation group
2557967|NCT02512770|No Intervention|control|control group ( only endoscopy for control)
2557995|NCT02512536|Experimental|Experimental|"Intervention:~Subjects receiving a single ultrasound scan guided injection of Botulinum Toxin type A into the supraspinatus muscle belly.~Drug: Dysport 300 units im. One single injection over course of study."
2558035|NCT02512328|No Intervention|Regular colonoscopy preparation|Comparison group. Regular colonoscopy preparation
2558036|NCT02512328|Experimental|APP supported colonoscopy preparation|APP as additional device for colonoscopy preparation
2558053|NCT02511990|Experimental|Group 1A|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~3 mg/kg, single dose IV administration of 10-1074"
2558060|NCT02511990|Experimental|Group 1B|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~10 mg/kg, single dose IV administration of 10-1074"
2558066|NCT02511990|Experimental|Group 1C|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml or On ART, HIV-1 viral load < 500 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
2558068|NCT02511990|Experimental|Group 1D|"HIV-infected individuals Off ART, HIV-1 viral load < 100,000 copies/ml~30 mg/kg, single dose IV administration of 10-1074"
2558070|NCT02511990|Experimental|Group 2A|"HIV-uninfected individuals~3 mg/kg, single dose IV administration of 10-1074"
2558072|NCT02511990|Experimental|Group 2B|"HIV-uninfected individuals~10 mg/kg, single dose IV administration of 10-1074"
2558073|NCT02511990|Experimental|Group 2C|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
2558075|NCT02511990|Experimental|Group 2D|"HIV-uninfected individuals~30 mg/kg, single dose IV administration of 10-1074"
2558154|NCT02511704|Experimental|Electronic cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) + Nicotine 0.8 mg, administrated by electronic cigarette (10 puffs) separated by 60 minutes"
2558155|NCT02511704|Active Comparator|Cigarette|"Multiple dose~Nicotine 0.8 mg, administrated by cigarette (10 puffs) + Nicotine 0.8 mg, administrated by cigarette (10 puffs) separated by 60 minutes"
2558209|NCT02511210|Active Comparator|regional anesthesia|spinal anesthesia or peripheral nerve block
2558213|NCT02511210|Active Comparator|general anesthesia|intubated patients
2558301|NCT02510807|Experimental|Pedometer group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided. The pedometer group will be instructed to carry the pedometer in their pocket during these exercise periods.
2558303|NCT02510807|No Intervention|Control group|Patients will be instructed to walk a minimum of three times per week up to one half hour total walking time. If they started to get pain in their legs, they will be instructed to stop and rest, and then to start again when the pain has subsided.
2558348|NCT02510235|Experimental|Lubricin|Lubricin 150 µg/ml eye drops solution
2558352|NCT02510235|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
2558366|NCT02509832|Other|Cooling + PCI|The subjects will be considered to be enrolled in the Test Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Test Arm of the trial to allow cooling with the Proteus IVTM System before and after PCI.
2558367|NCT02509832|Other|PCI only|The subjects will be considered to be enrolled in the Control Arm of the trial when all inclusion and exclusion criteria have been met, the informed consent form has been signed, and randomization to the Control Arm of the trial to allow PCI only.
2558446|NCT02509611|Experimental|Immediate treatment|Participants who are randomly assigned to the immediate treatment group will receive 60-minute biweekly Hatha yoga for 12 weeks.
2558447|NCT02509611|Active Comparator|Waitlist control|Participants who are randomly assigned to the wait-list group will receive no intervention during the first 12 weeks. Not only will they serve as the comparative group, they will also serve as their own control and receive the same yoga intervention at the end of 12 weeks when the immediate treatment group completed their program.
2558493|NCT02509208|Experimental|SurgiClot|All qualified subjects will be treated with the SurgiClot haemostatic dressing
2558523|NCT02508857|Active Comparator|ketorolac|intravenous ketorolac (30 mg) is injected in bolus, followed by continuous infusion of saline solution (Group K) during the surgical procedure
2558532|NCT02508857|Experimental|magnesium|intravenous magnesium sulfate (20 mg/kg) is injected in bolus, followed by continuous infusion of magnesium sulfate (2 mg/kg/h) (Group M) during the surgical procedure
2559076|NCT02505386|Experimental|Ertapenem SC|SC administration of ertapenem
3171424|NCT00586924|Experimental|50 mcg/kg|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
3171425|NCT00586937||1|Lung Cancer Survivors
3171426|NCT00586976|Experimental|1|Ropivicaine infusion into the sternal wound
3171427|NCT00586976|Placebo Comparator|2|Normal saline infusion into the sternal wound
3171428|NCT00586989||1|Patient with Barrett's Esophagus with a history of High grade dysplasia or early esophageal adenocarcinoma
3171429|NCT00587002|Active Comparator|1|Gender comparison
3171430|NCT00587015|Active Comparator|1|CAT-8015
3171431|NCT00587028||Oral Omnipaque MCA|Ten participant minimum: for stool tagging two days preceding the CT colonography, if applicable, with oral Omnipaque. This cohort at Scottsdale Mayo Clinic only.
3205826|NCT00947804||2. Patients without symptoms of ACS|Non-emergency patients presenting to the Cardiac Catheterization Lab for elective coronary angiography, and possible PCI. These are patients whom may have experienced typical or atypical ACS symptoms intermittently, and have elected to have cardiac catheterization to rule out obstructive CAD. Patients in this group will be selected randomly, with consent obtained, prior to cardiac catheterization.
2557757|NCT02514421|Experimental|Electrochemotherapy with gemcitabine/nab-paclitaxel|During the first cycle of chemotherapy, patients will receive electroporation of the primary pancreatic tumor prior to administration of chemotherapy with gemcitabine and abraxane. The schedule of administration of gemcitabine and nab-paclitaxel will be administered as per standard of care. The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15, followed by gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
2557807|NCT02513927|Active Comparator|A|To observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.Then to observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment.
2557810|NCT02513927|Active Comparator|B|To observe the effects of Nifedipine (30 mg) on blood pressure variation after 12 weeks of treatment. Then to observe the effects of metoprolol (95 mg) on blood pressure variation after 12 weeks of treatment.
3205827|NCT00947817|Experimental|patient|
2557954|NCT02512848||endometrial neoplasms|patients with risk of endometrial cancer in the postmenopausal period
2557992|NCT02512640|Active Comparator|Volume-controlled ventilation|Volume-controlled ventilation throughout the surgery
2557998|NCT02512640|Active Comparator|Pressure-controlled ventilation|Pressure-controlled ventilation throughout the surgery
2558037|NCT02512315|Active Comparator|CCRT group (Group A)|Patients who are allocated into in this group will be treated with concurrent chemoradiation (CCRT).
2558044|NCT02512315|Experimental|NACT-CCRT group (Group B)|Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CCRT.
3205828|NCT00947817|Other|control|
3205829|NCT00947843|Placebo Comparator|aspirin+placebo|aspirin protect (Bayer) 100mg + placebo clopidogrel 75mg for 1mo
2558172|NCT02511353|Placebo Comparator|placebo|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: placebo 600 mcg/kg/day.
2558176|NCT02511353|Experimental|ivermectin 300 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 300 mcg/kg/day and placebo 300 mcg/kg/day.
2558180|NCT02511353|Experimental|ivermectin 600 mcg/kg|Standard 3-day course of dihydroartemisinin-piperaquine, plus once a day for 3 days: ivermectin 600 mcg/kg/day.
2558220|NCT02511041|Experimental|1|This is a prospective exploratory study of nucleoside and monosaccharide supplement-ation and its effect on immunologic parameters in patients with evidence of altered glycosylation and immunologic abnormalities. Up to 50 subjects will receive escalating doses of oralmonosaccharide until a maximum tolerated dose is found and maintained for 6 weeks. Then nucleosidesupplementation will be added and the maximum tolerated dose will continue for 12 weeks. Parameters of interest will be assessed at NIH every 8 weeks. Themaximum participation time for each subject is 252 days. We will begin with PGM3 deficient patients, who will self-administer oral GlcNAc followed by dual supplementation with GlcNAc and Uridine. The remaining subjects will then receive these supplements following the same step-wise approach.
3205830|NCT00947843|Active Comparator|aspirin+pregrel|pregrel is a generic brand name of clopidogrel
3205831|NCT00947843|Active Comparator|Aspirin+Plavix|plavix is a original brand name of clopidogrel
3205832|NCT00947895|Active Comparator|Methylprednisolone|Intravenous (IV) methylprednisolone (Solumedrol) 1000 mg daily for 3 days.
3205833|NCT00947895|Active Comparator|ACTH|Intramuscular (IM) ACTH 80 mg/day for 5 days.
2558455|NCT02509390|Experimental|Severe trauma patients|All severe trauma patients (ISS>15) admitted in our trauma center Blood samples (additional blood tubing)
2558498|NCT02509130||Patients who attended RAAC/SAAC.|Patients who have previously attended the Rapid Access Asthma Clinic (RAAC) will be approached for the quantitative study. Patients who went onto the attend the Severe Asthma Assessment Clinics (SAAC) will also be approached for the quantitative and qualitive parts of the study.
2558499|NCT02509130||Patients eligible for RAAC, but DNA'd|Patients identified by the GP search, who did not attend the previous MISSION clinics will be approached to participate in the quantitative part of the study.
2559082|NCT02505620||Surgical|Surgical correction of OSAS disease
3205834|NCT00947908|Experimental|A|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
3205835|NCT00947921|Active Comparator|Plasty|Patients treated with restrictive Annuloplasty
3205836|NCT00947921|Active Comparator|Prosthesis|Patients treated with valve replacement
3205837|NCT00947934|Experimental|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation.
3205838|NCT00947947|Experimental|intervention media condition|Received a stage tailored DVD-based intervention
3205839|NCT00947947|Placebo Comparator|standard of care|received only clinical standard of care
2557696|NCT02514811|Experimental|The Teen Outreach Program|TOP is a youth development and service learning program for youth designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP program model consists of three components implemented in school, after school, or in community settings over nine months: (1) weekly curriculum sessions, (2) community service learning, and (3) positive adult guidance and support. The TOP Changing Scenes Curriculum is separated into four age-/stage-appropriate levels, Level 1 is typically for youth ages 12 or 13 and Level 4 is typically for youth age 17. The intended program dosage for each participant is a minimum of 25 weekly sessions and at least 20 hours of community service learning over nine months. One or two facilitators, who plan the order of sessions based on the needs and interest of youth, implemented TOP in a group of 10 to 25 youth.
2557699|NCT02514811|No Intervention|Control Group|Students in the control condition receive a benign intervention called the Community Voices (CV) program, which like TOP, meets in a group setting. The CV students are convened four times during the program year. Sessions are the same length as the TOP sessions. The first and last CV sessions are primarily focused on survey data gathering. At the two other sessions, CV students are convened to discuss current issues among young people in their community. The CV program specifically does not include any sexuality education or community service learning opportunities.
2557818|NCT02513758||HIV patients|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
2557924|NCT02513082|Experimental|Femoral nerve block|Femoral nerve block will be performed just one time after total knee arthroplasty in general anesthesia state
2557926|NCT02513082|Active Comparator|Adductor canal block|Adductor canal block will be performed just one time after total knee arthroplasty in general anesthesia state
2558024|NCT02512380|Experimental|SLOT group|4 cycles preoperative chemotherapy with Docetaxel+oxaliplatin+s1 . Gastric resection. 6 cycles adjuvant chemotherapy with sequential oxaliplatin+s1 or oxaliplatin+s1,then s1 for 6 months。
2558027|NCT02512380|Active Comparator|SOX group|3 cycles preoperative chemotherapy with oxaliplatin+s1. Gastric resection. 4 cycles adjuvant chemotherapy with sequential oxaliplatin+s1
2558038|NCT02512133|Experimental|MIGS Hydrus Ivantis|opening the anterior chamber (2mm.) injecting visco-material, injecting the Hydrus stent in the Schlemm's canal under gonioscopic control
2558048|NCT02512133|Experimental|SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
2558096|NCT02511834|Experimental|VEST supported|Vein graft supported by VEST
2558097|NCT02511834|Active Comparator|Control|Vein grafts unsupported by VEST
3171432|NCT00587028||IV Iodine MCR|Ten participant minimum: for intravenous iodine contrast dye. This cohort at Rochester Mayo Clinic only.
3171433|NCT00587028||NO oral and no IV MCR|Five participant minimum for no oral or IV contrast.
3171434|NCT00587028||Replacement Group|Five participant minimum for either cohorts 1, 2, or 3 as above should there be poor imaging results. A like prepped participant will replace that who had poor quality imaging to meet 25 imaging data sets.
2558308|NCT02510339||Observational|The Lysholm Knee score and the SF-36 questionnairs will be given to patients presenting to Orlando Regional Medical Center with open or closed fractures of the tibial shaft during their follow up visits post operativily.
2558361|NCT02510157|Active Comparator|dexamethasone|Dexamethasone is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
2558362|NCT02510157|Placebo Comparator|normal saline|Normal saline is administered intravenously before induction of anaesthesia. Deep neuromuscular blockade is induced with rocuronium and is assessed by acceleromyography (post-tetanic count stimulation) on the ulnar nerve of the patient's hand. At the end of surgery, sugammadex 4 mg/kg is administered to reverse neuromuscular blockade.
2558401|NCT02509715|No Intervention|Standard Conventional group|Standard conventional thyroid surgery
2558403|NCT02509715|Active Comparator|IONM group|Intraoperative nerve monitoring used thyroid surgery
2558457|NCT02509455||Normal 1|SwayStar device used 1st, Sensoro used 2nd
2558459|NCT02509455||Normal 2|Sensoro device used 1st, SwayStar used 2nd
2558513|NCT02509143|Experimental|High-dose acupuncture with intravenous infusion of ramosetron|Three sessions of acupuncture on the points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4), Pericardium 6 (PC6), Heart 8 (HT8), and Gall Bladder 41 (GB41) within 48 hours after surgery
2558518|NCT02509143|Active Comparator|P6 stimulation with intravenous infusion of ramosetron|P6 stimulation by wearing a study wristband within 48 hours after surgery
2558524|NCT02509143|Active Comparator|Intravenous infusion of ramosetron|A mixture of standard antiemetic medication (5-Hydroxytryptophan receptor antagonist; ramosetron hydrochloride 0.3 mg) and analgesics, including anon-steroidal anti-inflammatory drug (NSAID) (ketorolac tromethamine 120 mg), and a semi-synthesized opioid (oxycodone 20 mg), will be infused by intravenous patient-controlled analgesia (1ml bolus/20 min lockout, 1ml/hr continuous infusion).
3171435|NCT00587093|Other|1|CT scan and CA-125
3171436|NCT00587106||1|One cohort group of patient with PNDS or suspected PNDS
3171437|NCT00587119|Experimental|1|Single arm, active treatment
3171438|NCT00587184||1|patients who were seen clinically indicated endoscopic surveillance and biopsies of BE and confocal microscopy was performed.
3171439|NCT00587210||Suspected or known Crohn Disease|Suspected or known Crohn Disease
3171440|NCT00587236||1|Patients with chronic ulcerative colitis and concurrent primary sclerosing cholangitis.
3171441|NCT00587236||2|Patients with chronic ulcerative colitis and known dysplasia or cancer.
3171442|NCT00587249|Experimental|3|50 mcg of ICC-1132 with alhydrogel adjuvant.
3171443|NCT00587249|Experimental|2|20 mcg of ICC-1132 with alhydrogel adjuvant.
3171444|NCT00587249|Experimental|1|10 mcg of ICC-1132 with alhydrogel adjuvant.
2557754|NCT02514226|Active Comparator|G2- positive control group|"Arm description: G2 - positive control group (gold standard) - (n = 30) - DHO + periodontal treatment + simulation of using PDT.~All participants will receive periodontal treatment - scaling and root planning (SRP) by an experienced specialist with universal curetes and ultrasound in a full mouth manner. The simulation of using photodynamic therapy (PDT) will be performed with laser turned off. No antibiotics and oral antiseptics will be prescribed"
2557755|NCT02514226|Active Comparator|G3 -experimental active comparator group|"Arm description: G3 - experimental group - (n = 30) DHO +SRP + PDT with methylene blue~In G3, periodontal treatment and photodynamic therapy (PDT) will be performed. The scaling and root planing will be performed identical as G2. The PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the photosensitizer"
3205840|NCT00947960|Other|Active/Placebo|Subjects receive 1-2 grams/kilogram body weight triheptanoin divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive placebo vegetable oil at the same dose and frequency for the next 6 months during the randomization phase.
3205841|NCT00947960|Other|Placebo/Active|Subjects receive 1-2 grams/kilogram body weight placebo vegetable oil divided into 4 equal doses taken with meals and snack for 6 months crossing over to receive triheptanoin at the same dose and frequency for the next 6 months during the randomization phase.
3205842|NCT00947973|Experimental|Challenging Horizons Program after-school model|Participants will receive the CHP after-school model.
3205843|NCT00947973|Experimental|Challenging Horizons Program consultation model|Participants will receive the CHP consultation model.
3205844|NCT00947973|No Intervention|Community care|Participants will have access to standard community care.
3205845|NCT00947986|Experimental|Johnson's Baby Shampoo|1% diluted solution
2557946|NCT02513108|Active Comparator|same day discharge|patients discharged same day after uncomplicated PCI
2557947|NCT02513108|No Intervention|standard care|standard care where patients are discharged the day after procedure after adequate observation
3205846|NCT00947999||Healthy Control Group|Subjects in particular group will not have a diagnosis of SCI and do not experience chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
3205847|NCT00947999||Subjects with SCI and Chronic Pain|Individuals recruited into this particular group will have a diagnosis of a spinal cord injury and experience pain on a daily basis with an average intensity of 4 out of 10 on a 0-10 scale.
3205848|NCT00947999||Subjects with SCI and No Chronic Pain|Subjects in particular group will have a diagnosis of SCI and not have chronic pain. Subjects in this group will be matched roughly to subjects in the SCI chronic pain group based on age, gender and race/ethnicity.
3205849|NCT00948012||Patients without pulmonary hypertension|Patients with sickle cell with normal response of pulmonary artery pressure to exercise
3205850|NCT00948012||Exercise-induced pulmonary hypertension|Patients with sickle-cell anemia with exercise-induced pulmonary hypertension.
3205851|NCT00948038|Active Comparator|Soy|Soy-based supplement to normal diet
3205852|NCT00948038|Experimental|Milk|Milk-based supplement to normal diet
3205853|NCT00948051|Experimental|Fructo-oligosaccharides|
3205854|NCT00948051|Placebo Comparator|Placebo|
2558191|NCT02511171|No Intervention|No intervention|Subjects do not receive osteopathic care
2558192|NCT02511171|Experimental|Cranial osteopathic manipulative treatment|Subjects receive individualised osteopathic treatment
2558273|NCT02510950|Experimental|Arm 1: Peptide/poly-ICLC|"For all patients, concurrent chemoradiation with temozolomide will be given per standard of care and is outside the scope of this study as per standard of care.~The long peptide + poly-ICLC will be given on Cycle 1 Day 1 of maintenance temozolomide.~If the vaccine is not ready by this time, the first vaccination will begin on Day 1 of the next cycle of maintenance temozolomide.~The peptide + poly-ICLC vaccine will be given again on Days 8, 15, and 22 of the first cycle, as a priming strategy.~On all subsequent cycles, the peptide vaccine + poly-ICLC will be given on Day 22 (+/-3 days)."
3205855|NCT00948077|Active Comparator|Treatment A|"Study agents (Rifater+EMB) will be given approximately 45 minutes prior to the breakfast."
3205856|NCT00948077|Experimental|Treatment B|"Study agents (Rifater+EMB) will be given approximately 45 minutes after the breakfast is finished."
3205857|NCT00948103|Placebo Comparator|Oxygen|
3205858|NCT00948103|Active Comparator|Nitrous Oxide|
3205859|NCT00948116||Diabetes mellitus, renal impairment|Patients with both diabetes mellitus and eGFR <60 ml/min
3205860|NCT00948129|Active Comparator|Group I (standard care)|Participants undergo standard of care smoking cessation intervention consisting of brief advice to quit smoking, NRT, and self-help written materials.
3205861|NCT00948129|Experimental|Group II (enhanced care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number and supportive text messages daily for 12 weeks.
3205862|NCT00948129|Experimental|Group III (intensive care)|Participants undergo standard of care smoking cessation intervention as in Group I and attend a health feedback counseling session at baseline. Participants also receive access to a smoking cessation hotline telephone number, supportive text messages daily for 12 weeks, and a smoking cessation telephone call over 15 minutes weekly for 12 weeks.
3205863|NCT00948142|Active Comparator|Linezolid|600 mg BID
3205864|NCT00948142|Experimental|CEM-102 Regimen A|
3205865|NCT00948142|Experimental|CEM-102 Regimen B|
3205866|NCT00948181||Surgeon|To detect the degree of intraoperative stress, venous blod will be drawn from one surgeon during 8 pheochromocytoma resections.
3205867|NCT00948181||Anesthesiologist|To detect the degree of intraoperative stress, venous blood will be drawn from one anesthesiologist during 8 pheochromocytoma resections.
3205868|NCT00948181||Patients with pheochromocytoma|Venous blood will be drawn from 8 patients with pheochromocytoma during tumor resection.
3205869|NCT00948207|Experimental|My Living Story|"My Living Story elicits a dignity-enhancing life story via a telephone interview, and delivers the edited transcript on the patient's personal miLivingStory social network. miLivingStory also provides a direct link to miStory, a life review education website with links to high quality websites that provide cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks.~miLivingStory and miStory are both password protected."
2557790|NCT02513875|Experimental|vitamin D with diet and lifestyle|vitamin D supplementation along with diet and lifestyle modification was given
2557793|NCT02513875|Placebo Comparator|placebo with diet and lifestyle modification|placebo with diet and lifestyle modification was given
2557857|NCT02513693|Experimental|Standard Neuromuscular Blockade|"Drug: rocuronium + neostigmine~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Train-of-Four (TOF) count = 1-2, TOF-count measurement every 1 min. Neuromuscular blockade reversal at the end of anesthesia: neostigmine 0.03 mg/kg iv + atropine 0.5-1.0 mg iv Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1.5-2.5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv Extubation when patient is conscious and attained the recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
2557858|NCT02513693|Experimental|Deep Neuromuscular Blockade|"Drug: rocuronium + sugammadex~Administration of rocuronium 0,6 mg/kg iv, top-ups 5-10 mg iv to target value of Post-tetanic Count (PTC) = 1-2; PTC measurement every 4 min. Neuromuscular blockade reversal at the end of anesthesia: sugammadex 2 mg/kg iv (when PTC is 18-20 and TOF-count 0) or sugammadex 4 mg/kg iv (when PTC under 18).~Induction of anesthesia: midazolam 1-2 mg iv, sufentanil 10-30 mcg iv, propofol 1,5-2,5 mg/kg iv Anesthesia: sevoflurane in air to target 1.2-1.5 minimal alveolar concentration (MAC). Rescue medication: sevoflurane, propofol 20-40 mg iv.~Extubation when patient is conscious and attained recovery from neuromuscular blockade to a TOF-ratio of at least 0,9."
2557925|NCT02513004|Experimental|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose.Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
2557927|NCT02513004|Active Comparator|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
2557968|NCT02512757||Group 1|Patients with lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and diagnosed with primary lung cancer who have not yet initiated treatment of any kind for their lung cancer will contribute a fasting blood sample.
2557969|NCT02512757||Group 2|Patients whose most recent screening imaging is within 60 days who have lung nodule(s) ≥ 6 mm but ≤ 35 mm that have been biopsied and determined to not be cancerous OR that have demonstrated no nodule growth for >2 years by repeat CT imaging will contribute a fasting blood sample.
2557971|NCT02512757||Group 3|Patients who have undergone low-dose computed tomography (LDCT) or standard computed tomography (CT) or X-ray testing to screen for lung cancer with no nodules suspicious for lung cancer within 1 year prior to signing informed consent will contribute a fasting blood sample.
3205870|NCT00948207|Active Comparator|My Own Resources|"My Own Resources offers usual care access to high quality websites that provide cancer information, databases to do your own research, social support, and interactive planning tools. Participants will receive access to the website miOwnResources."
3205871|NCT00948220|Experimental|Treatment|Chronic hepatitis C patients on standard antiviral therapy with peginterferon alfa-2a and ribavirin
3205872|NCT00948220|No Intervention|Control|Chronic hepatitis C patients without standard antiviral therapy
2558043|NCT02512016|Other|Nulliparous Women in Third Trimester|Study Procedures
2558118|NCT02511938|Experimental|Menu Only intervention|Restaurants will receive a new healthy kids' menu
2558119|NCT02511938|Experimental|Menu Plus Intervention|Restaurants will receive a new healthy kids' menu, supporting marketing materials, and brief trainings for customer service staff and kitchen staff to support and promote the new menu items.
3205873|NCT00948233||Intervention|Educational video game
2558347|NCT02510196|Active Comparator|reminder|participants in this group will be reminded to use ultrasound for neuraxial anesthesia on a regular basis
2558351|NCT02510196|No Intervention|control|participants in this group will not be reminded to use ultrasound for neuraxial anesthesia
2558376|NCT02509962|Experimental|Slow sodium tablets|Increased dietary salt intake
3205874|NCT00948233||Standard Care|Pamphlets on stopping tobacco use
2558719|NCT02507843|Active Comparator|Vitamin D group|Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
2558720|NCT02507843|Placebo Comparator|Placebo group|Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.
2558745|NCT02507505|Active Comparator|Regional Anesthesia|Approximately half of the subjects will be randomized to the arm which receives Regional Anesthesia.
2558747|NCT02507505|Active Comparator|General Anesthesia|Approximately half of the subjects will be randomized to the arm which receives General Anesthesia.
2558842|NCT02506933|Experimental|Arm I (multi-peptide CMV-MVA vaccine)|Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.
2558847|NCT02506933|Placebo Comparator|Arm II (placebo)|Patients receive placebo IM on days 28 and 56 post-HCT.
2558893|NCT02506556|Experimental|experimental|BYL719 350 mg orally daily until progression, undue adverse events or withdrawal of consent.
2559083|NCT02505620||Conservative|Conservative treatment of OSAS disease
2559098|NCT02505009|Experimental|entecavir pretreated vaccine arm|Arm A,case group: 75 cases will be enrolled to receive Engerix-B injection and compared with histological non-vaccine treated controls
2557781|NCT02514161|Active Comparator|Inspiratory Muscle Training Group (IMT)|"The IMT program consisted of supervised and domiciliary exercises.~- The supervised exercises was performed in the presence of physiotherapist. This consisted of 30 min 2 days for 4 weeks using the threshold device (Powerbreathe classic level 1, Gaiam Ltd; Southam, Warwickshire, UK). This program involve 5 sets of 5 repetitions with 30 seconds rest between each one. The load of the training was distributed as follow:~First week: 30% Maximum Inspiratory Pressure (MIP)~Second week: 40% MIP~Third week: 50% MIP~Fourth week: 60% MIP~- The domiciliary exercises consisted of Yoga Breathing Exercises (Pranayama) that combines the inspiration and expiration through one or both nostrils, and requires the activation of chest and abdomen"
2557784|NCT02514161|Experimental|IMT + Manual Therapy and Motor Control Exercises|"The protocol for this group is identical to the previous group with the sole difference that is added a manual therapy (MT) and a motor control exercises (MCE). The MT protocol was performed for 15min, whereas the MCE was 10min. Below it described both protocols:~- MT:~Upper cervical region mobilization in flexion~Lower cervical postero-anterior mobilization + maintained traction~Costovertebral joint postero-anterior mobilization~Thoracic vertebral posteroanterior mobilization~Thrust dorsal~- MCE:~Isometric contraction of the deep neck flexors.~Isometric contraction of the neck extensors.~Neural self-mobilization.~Cervical retraction with theraband.~Sphinx.~Scapular adduction exercises in prone.~Scapular adduction exercises in sitting position with theraband."
2557795|NCT02513849|Experimental|Tamoxifen treatment|Patients will be administered tamoxifen, 80mg/ day orally for 4 days as a loading dose, followed by 20mg/ day thereafter until gastroscopy and biopsy 4 weeks later.
2557839|NCT02513654|Experimental|Lamotrigine dispersible tablets 25mg, 50mg, 100mg|Each subjects will start dosing with lamotrigine 25mg dispersible tablet once daily at Day 1 and remain at this dose level for 2 weeks (Days1-14), then will be titrated to 50 mg once daily at Day 15 and last for weeks 3-4 (Days 15-28), and then titrated to 100 mg once daily at Day 29 during weeks 5-6 (Days 29-42).
2557864|NCT02513433|Active Comparator|Bupivacaine & Levobupivacaine|Bupivacaine 15 ml 0.5% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
2557866|NCT02513433|Active Comparator|Bupivacaine & Ropivacaine|Bupivacaine 15 ml 0.5% and Ropivacaine 15 ml 0.75% in epidural route before surgery
2557870|NCT02513433|Active Comparator|Ropivacaine & Levobupivacaine|Ropivacaine 15 ml 0.75% and Levobupivacaine 15 ml 0.5% in epidural route before surgery
3171445|NCT00587262||1|Two pediatric participants with high frequency hearing loss post cochlear implant with either long or short electrode array.
3171446|NCT00587262||2|Eight participants with high frequency hearing loss post cochlear implant with either short or long electrode array.
2557934|NCT02512952|Active Comparator|Group 1|SRP with Open flap debridement (OFD) alone for treating periodontal pocket
2557937|NCT02512952|Active Comparator|Group 2|SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into bone defect
2557943|NCT02512952|Active Comparator|Group 3|SRP with Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into bone defect
2557996|NCT02512718|Experimental|Fish Oil Lipid Emulsion|1 g/kg intravenous fish oil lipid emulsion (Omegaven) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
2558000|NCT02512718|Active Comparator|Soybean Oil Lipid Emulsion|1 g/kg intravenous soybean oil lipid emulsion (SOLE) daily, provided starting day of transplant through day 30 or hospital discharge, whichever comes first.
2558152|NCT02511470|Other|CPR with metronome on|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome on. Data for compression rate and depth will be collected during this time interval.
2558153|NCT02511470|Other|CPR with metronome off|Participants will perform two minutes of uninterrupted chest compressions on a pediatric manikin with the metronome off. Data for compression rate and depth will be collected during this time interval.
3205875|NCT00948259|Experimental|NP031112|Patients will receive 400 mg of NP031112 for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this dose will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for dose escalation will remain on the tolerated dose for the remainder of the study.
2558282|NCT02510625|Active Comparator|Bankart repair|Arthroscopic bankart repair
2558286|NCT02510625|Experimental|Anatomic Glenoid Reconstruction|Arthroscopic distal tibia bone graft
2558396|NCT02509793|Experimental|Tetrabenazine|Xenazine (tetrabenazine), pill, dosage titrated to effect, three times a day, 12 weeks
3171447|NCT00587262||3|Fifteen participants from the existing Cochlear Implant data base.
2558582|NCT02508623|Experimental|Rifaximin|Rifaximin 550 mg 1 tablet BID for 60 days
2558583|NCT02508623|Placebo Comparator|Placebo|Placebo 1 tablet BID for +60 days
2558660|NCT02508246|Experimental|Treatment (WEE1 inhibitor MK-1, cisplatin, docetaxel, surgery)|Patients receive WEE1 inhibitor MK-1775 PO BID on days 2-4, 9-11, and 16-18, and day -7 prior to course 1, day 1 for PD assessment. Patients also receive cisplatin IV on days 1 (or up to two days after last dose of WEE1 inhibitor MK-1775 lead-in is completed), 8 (or 7 days after first chemotherapy dose), and 15, and docetaxel IV on days 1, 8, and 15. Patients experiencing progressive disease undergo surgical resection. Patients not deemed surgically resectable proceed to chemoradiation as clinically indicated. Patients experiencing stable disease or partial response may receive 2 additional courses of treatment every 28 days in the absence of disease progression or unacceptable toxicity.
2558755|NCT02507544|Experimental|TRX-818|
2558778|NCT02507245||GHD Children|Treatment with Growth Hormone-Releasing Hormone in children affected by idiopathic growth hormone deficiency (GHD)
2558825|NCT02507063||study subjects|Patients age 0-18 with intracranial monitoring devices in place or requiring a VP shunt revision who receive a ocular ultrasound evaluating ONSD
2558852|NCT02506803|Experimental|NAC-GEMABR|Neoadjuvant chemotherapy 2 courses of NAC-GEMABR for subsequent 10 patients.
2558925|NCT02506192|Experimental|Delayed-Release Prednisone|Take oral tablets as directed (2x5mg) with food each evening at bedtime- approximately 10:00 pm
2558928|NCT02506192|Placebo Comparator|Placebo|Take oral tablets as directed (2x5mg) with food each evening at bedtime-approximately 10:00 pm
2559006|NCT02505880|Active Comparator|1: General anesthesia|General anesthesia
2559011|NCT02505880|Experimental|2: Hypnosis|Hypnosis with local anesthesia
2557812|NCT02513914|Experimental|Dural Venous Sinus Stenting|Pt. will undergo pre-treatment with aspirin and clopidogrel. Transfemoral venous access will be obtained (pt. heparinized).Guide catheter will be placed in jugular bulb ipsilateral to dural venous sinus stenosis. Stent will be deployed across stenotic segment. Balloon angioplasty will not be performed unless initial stenosis is not easily traversed with stent. No pressure measurements will be taken during stent placement. Patients will undergo serial physical/neuro exams for 24 hours post-procedure. Daily dual anti-platelet treatment will continue for 6 months after initial procedure, after which clopidogrel will be discontinued and aspirin 81mg daily will be prescribed indefinitely. If significant bilateral venous sinus stenosis is present, stenosis with more severe pressure gradient will be stented. In pt. with bilateral venous sinus stenosis with equivalent pressure gradients, side will be at surgeon's discretion.
2557815|NCT02513914|Active Comparator|Cerebrospinal Fluid Shunting|Choice of shunt procedure (ventriculoperitoneal, ventriculoatrial, or lumboperitoneal), catheter laterality, brand and shunt equipment (including shunt catheters and valves), valve settings of programmable shunt valves (when applicable), intrathecal antibiotic administration and the use of stereotactic navigation will be at the discretion of neurosurgeon. Shunt procedures will be performed per the standard of care, under general anesthesia. An optional surgical procedure guidance document will be provided for other sites. Patients will undergo serial physical and neurological examinations for 24 hours post-procedure prior to discharge.
3205876|NCT00948259|Placebo Comparator|Placebo|Patients will receive 400 mg for 4 weeks, if tolerated, they will receive 600 mg for 4 additional weeks. Patients that tolerate this will receive 800 mg for 6 weeks and the patients that tolerate this will escalate to 1000 mg for an additional 6 weeks. Patients that are not eligible for escalation will remain on the tolerated dose for the remainder of the study.
3205877|NCT00948272|Experimental|VRVg Group|
3205878|NCT00948272|Active Comparator|Verorab Group|
3205879|NCT00948285|Experimental|MRI|Preoperative staging with mammogram, ultrasound, and MRI, followed by surgery (n=200)
3205880|NCT00948285|No Intervention|Non-MRI|Preoperative staging with mammogram and ultrasound alone, followed by surgery (n=200)
3205881|NCT00948324|Active Comparator|CSII|CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.
2558042|NCT02512029|Experimental|TBI Subjects|Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.
2558049|NCT02512029|Experimental|Control|Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.
2558102|NCT02511912|Experimental|V-Wave|"This is a single arm study, all eligible patients will receive the V-Wave implantable shunt.~The V-Wave device is implanted via standard femoral venous access and inter-atrial septal puncture intervention and is placed through the Fossa Ovalis."
2558136|NCT02511639|Experimental|Arm A: Everolimus & Aromatase inhibitors|Everolimus 10 mg po daily + Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
2558137|NCT02511639|Active Comparator|Arm B: Aromatase inhibitors|Aromatase inhibitors (Exemestane 25 mg po daily or Letrozole 2.5 mg po daily or Anastrozole 1 mg po daily)
2558203|NCT02511197|Experimental|68Ga-NOTA-PRGD2 injection & PET/CT scan|The patients were intravenously injected with 68Ga-NOTA-PRGD2 in one dose in nearly 111 MBq and then underwent PET/CT scan 0.5 h later.
2558260|NCT02510833|Experimental|Continuing Intervention Group|
2558270|NCT02510833|Active Comparator|Control Group|
2558324|NCT02510430|Experimental|Reducing Sitting Time Group|This group will be asked to reduce overall accumulated sitting time by 2 hours per day.
2558331|NCT02510430|Experimental|Re-Patterning Sitting Time Group|This group will be asked to use standing breaks to interrupt long bouts of sitting time.
2558335|NCT02510430|Placebo Comparator|Usual Care|This is an attention control group and is not asked to make changes to sitting time.
2558393|NCT02510027||Women aged 30-64 years old|Women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico
2558431|NCT02509520|No Intervention|Mobility-based Physical Rehab (MPR)|ICU control group receiving only mobility based rehabilitation (MPR).
2558433|NCT02509520|Active Comparator|MPR and Neuromuscular Stimulation and HPRO|ICU group receiving mobility based rehabilitation and NMES and High protein supplementation.
2558456|NCT02509273|Experimental|CLONIDINE HYDROCHLORIDE|solution for i.v. infusion (maximum 55 μg/kg per day; maximum 7 day treatment)
2558460|NCT02509273|Active Comparator|MIDAZOLAM|solution for i.v. infusion (maximum 5.5 mg/kg per day; maximum 7 day treatment)
2558598|NCT02508454||Greater Miami Area Community|Members of the Miami area who qualify for the study, are not an employee of BHSF, and enroll.
2558599|NCT02508454||Baptist Health South Florida Employees|Employees of BHSF who qualify for the study and enroll.
2558669|NCT02508220|Other|Oxy-Placebo|Syntocinon first, Placebo second 2 puffs in each nostril
2558670|NCT02508220|Other|Placebo-Oxy|Placebo first, Syntocinon second 2 puffs in each nostril
2558712|NCT02507882|Experimental|HCC|This group will include patients with chronic hepatitis C (no. =135)
2558713|NCT02507882|Experimental|HCC with Cirrhosis|This group will include patients with chronic hepatitis C (no. =135) with cirrhosis (F4).
2558715|NCT02507882|Experimental|HCV related HCC patients|This group will include patients with HCV related HCC (no. =135) This is confirmed by presence of focal lesion detected by Imaging (computed tomography (CT) and ultrasound), and elevated serum AFP.
3205882|NCT00948324|Active Comparator|ALA|ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.
3205883|NCT00948324|Active Comparator|RSG|RSG:CSII combined with three months rosiglitazoneor 4mg QD.
3205884|NCT00948324|Active Comparator|MET|MET:CSII combined with metformin 500mg BID-TID.
3205885|NCT00948337|Experimental|Photonovella of Secondary Cancer Screening|
3205886|NCT00948337|Active Comparator|Photonovella of Dietary Suppelment of Cancer survivor|
3205887|NCT00948350|Active Comparator|translaryngeal injection|translaryngeal injection of local anesthetics before the awake intubation
3205888|NCT00948350|Active Comparator|spray as you go|local anesthetics are given through the fiberoptic during awake intubation
2557828|NCT02513797|Experimental|LARIAT + PVI Treatment Group|Percutaneously isolate and ligate the Left Atrial Appendage (LAA) from the left atrium (LA) with the LARIAT System prior to planned pulmonary vein isolation (PVI) catheter ablation
2557831|NCT02513797|Active Comparator|PVI Catheter Ablation Group|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
2557922|NCT02512991||HEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Helicopter Emergency Medical Service (HEMS) in a 36-month period (May 1st 2010 - April 30th 2013).
2557923|NCT02512991||GEMS patients|Patients bound for Percutaneous Coronary Intervention (PCI) at the PCI centre at Copenhagen University Hospital, Rigshospitalet, and who were transported by Ground Emergency Medical Service in a 40-month period (January 1st 2010 - April 30th 2013).
2557952|NCT02512835||Clinic patients|Aims 1a and 1b: The participants include all unique patients seen at the 12 study practices (approximately 170,000 patients over the past two years).
2557953|NCT02512835||Clinicians|Aims 2 and 3: The clinicians in this analysis will include 15 participants recruited from the approximately 100 clinicians at the 12 practices
2558012|NCT02512653|Experimental|1|Cupressus arizonica allergen extract at 4 different concentrations. Positive control. Negative control
2558063|NCT02512211||Patients adults|Sample of patients with haemophilia over 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
2558067|NCT02512211||Children with haemophilia|Sign hemophilia patients under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
2558069|NCT02512211||Parents of children with haemophilia|Sample of parents of children with hemophilia under 18 years of age that will participate in piloting of reliability and validity of the Spanish version of the HAL and HEP questionnaires
2558115|NCT02511860|Placebo Comparator|Placebo|Patients will consume a placebo pill containing methylcellulose.
2558116|NCT02511860|Active Comparator|Active|Patients will consume 850 mg of burdock twice per day.
2558148|NCT02511483|Placebo Comparator|IV-PCA morphine + Placebo PO|"Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.~Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
2558150|NCT02511483|Experimental|IV-PCA morphine + Propranolol PO|"The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .~During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial."
2558226|NCT02511080|Active Comparator|Spot-on group|Use active measures against intraoperative hypothermia
2558231|NCT02511080|No Intervention|control|standard measures against intraoperative hipothermia
2558244|NCT02510755|Other|PTSD group|PTSD group
2558246|NCT02510755|Other|Healthy Volunteers|Healthy Volunteers, age-matched controls.
2558253|NCT02510599|Experimental|Solithromycin|Solithromycin 200 mg PO QD for 1 week, followed by 200 mg PO TIW for 12 weeks
2558339|NCT02510495|No Intervention|"0 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was deflated immediately. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
2558340|NCT02510495|Experimental|"30 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
2558341|NCT02510495|Experimental|"60 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
2558343|NCT02510495|Experimental|"180 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
2558345|NCT02510495|Experimental|"300 group"|After a small sphincterotomy was performed, a controlled radial expansion (CRE) balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
2558398|NCT02509806|Experimental|Apatinib Maintenance Therapy After First-line Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
2558400|NCT02509806|No Intervention|No Intervention After First-line Chemotherapy|No Intervention after DC First-line Chemotherapy (Docetaxel 60-85mg/m2 i.v. d1, Cisplatin 60-75mg/m2 i.v. d1, q21d）
2558458|NCT02509468|No Intervention|Observational|"Patients will first be included in an observational period, then, at a randomized time different from one to another, will all receive the experimental treatment (i.e. sirolimus).~This design has been defined a the randomized placebo-phase design (Feldman et al. J Clin Epidemiol. 2001 Jun;54(6):550-7)"
2557956|NCT02512796||Transplant patients, MRI with Gadolinium contrast dye|Patients with kidney, pancreas or liver transplant and exposed to gadolinium contrast agents.
2557957|NCT02512796||Non-transplant patients, MRI with Gadolinium contrast dye|Non-transplant patients exposed to gadolinium contrast.
2557959|NCT02512796||Healthy controls, no transplant no Gadolinium contrast dye|Age- and sex-matched healthy controls not exposed to gadolinium contrast.
2558138|NCT02511691|Other|18F-PSS232|Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
2558187|NCT02511327||Preterm born infants of vaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
2558188|NCT02511327||Term born infants vaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have received an acellular pertussis vaccine during pregnancy, within the national recommended vaccination programme. Infant vaccination against pertussis is performed according to the national recommended schedule.
2558189|NCT02511327||Term born infants unvaccinated women|Term born infants (>= 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy. Infant vaccination against pertussis is performed according to the national recommended schedule.
2558190|NCT02511327||Preterm born infants unvaccinated women|Preterm born infants (< 37 weeks of gestation) whose mothers have not received an acellular pertussis vaccine during pregnancy.Infant vaccination against pertussis is performed according to the national recommended schedule.
2558250|NCT02510716|Experimental|Scheduled Gradual Reduction (SGR)|Four week SGR program plus support text messages.
2558251|NCT02510716|Active Comparator|Support Message Only|Support text messages only.
2558288|NCT02510534|Active Comparator|Control|This arm receives Menopur 150 international units x 1 dose
2558290|NCT02510534|Active Comparator|Treatment|This arm receives Menopur 150 international units x 1 dose and Endometrin 100mg twice a day x 14 days
3171448|NCT00587275|Experimental|1|AST-120, 2 gram sachets
2558454|NCT02509299|Experimental|Experimental group 1|patients will be involved in the Physiotherapy program 1. The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises added to standard treatment.
2558462|NCT02509299|Experimental|Experimental group 2|patients will be involved in the physiotherapy program 2. The program was a combined intervention including the Control Group treatment plus neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises.
2558467|NCT02509299|Other|Control group|patients will receive standard medical treatment without physiotherapy intervention.
2558588|NCT02508662||Advanced Cancer (Refractory) with Genomic Mutation|Participants with advanced cancer who have exhausted standard treatment option and have no potential clinical trial available, and who have potentially actionable alterations on genomic profiling.
2558634|NCT02508311|Active Comparator|Active Oral Beta-2|Subjects will receive 16 weeks of active medication.
2558637|NCT02508311|Placebo Comparator|Placebo|Subjects will receive 16 weeks of placebo medication.
3171449|NCT00587275|Placebo Comparator|2|Celphere CP-305, stained to match appearance of AST-120 in 2g sachets.
3171450|NCT00587301|Experimental|Lap-Band|Lap-band surgery in treatment of morbidly obese adolescents
2558759|NCT02507479|Experimental|thiotepa|Thiotepa 5-10 mg/kg/d x 2 days
2558813|NCT02507167|Placebo Comparator|mixed meal|
3171451|NCT00587314||1|Patients with Barrett's Esophagus or early esophageal adenocarcinoma who will or have had ablation therapy will be enrolled in this long term follow up study
3171452|NCT00587327|Experimental|Barusiban|
3171453|NCT00587327|Experimental|Atosiban|
3171454|NCT00587327|Placebo Comparator|Placebo|
3171455|NCT00587340||1|15 subjects with subjective sleep disturbance based on the Pittsburgh Sleep Quality Index
3171456|NCT00587340||2|mild/moderate subjective sleep disturbance (insomnia) based on the Pittsburgh Sleep Quality Index
3171457|NCT00587340||3|severe subjective sleep disturbance (insomnia)based on the Pittsburgh Sleep Quality Index
3171458|NCT00587379|Active Comparator|1|Patients randomized to take 1 40mg Atorvastain pill per day for 6 week study period
3171459|NCT00587379|Placebo Comparator|2|Patients randomized to 1 40mg placebo pill per day for 6 week study
3171460|NCT00587392||A|Active NDO Endoscopic Full-thickness Plicator Procedure
3171461|NCT00587405|Active Comparator|1|Cryotherapy
3171462|NCT00587405|Active Comparator|2|Argon Plasma Coagulation
3171463|NCT00587418|Experimental|Arginine|
3171464|NCT00587418|Placebo Comparator|Placebo|
3171465|NCT00587444|Other|1|control standard dose heparin dose
3171466|NCT00587444|Active Comparator|2|high dose heparin dose
3171467|NCT00587444|Active Comparator|3|hepcon guided therapy
3171468|NCT00587470|Experimental|1|Atacand treatment.
3171469|NCT00587470|Placebo Comparator|2|Placebo
3171470|NCT00587496|Experimental|1|placebo, 6 capsules per day for 30 days
3171471|NCT00587496|Experimental|2|500 mg Valtrex one capsule per day plus 5 capsules of placebo per day for 30 days
3171472|NCT00587496|Experimental|3|500 mg Valtrex capsule one per day, Acetylsalicylic acid (aspirin) 325 mg capsules three per day, plus 2 placebo capsules per day for 30 days
3171473|NCT00587522|Experimental|A|NDO Full-thickness Plicator Procedure
3171474|NCT00587535||Hemochromatosis|Hemochromatosis
3171475|NCT00587535||Living-related liver donation|Living-related liver donation
3171476|NCT00587561|Experimental|1 Social Cognition Interaction Training|Will receive 20-26 sessions of a manualized group treatment called Social Cognition Interaction Training
3171477|NCT00587561|Other|2 Wait List Control|Wait list control; 6 months of treatment as usual followed by Social Cognition Interaction Training group
3171478|NCT00587574||I|Chronic graft-versus-host disease
3171479|NCT00587574||II|No chronic graft-versus-host disease
3171480|NCT00587600|Active Comparator|Photodynamic therapy|will have photodynamic therapy
3205889|NCT00948363|Active Comparator|Kiwi fruits|
2558104|NCT02511964|Experimental|Interval Training at 1% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 1% incline; Group metabolically balanced.
2558107|NCT02511964|Experimental|Interval Training at 10% incline|Six Sessions of High Intensity Interval Running (100% VO2Max) at 10% incline; Group metabolically balanced.
2558108|NCT02511964|No Intervention|Control|Only Dependent Variables Measures
3205890|NCT00948363|Placebo Comparator|Apple|
3205891|NCT00948376||Patients|All ages
2558225|NCT02511093|Experimental|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~BP measurements;~an educational and counselling intervention on patient adherence;~an educational and counselling intervention on lifestyle (physical activity and diet).~Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
2558229|NCT02511093|No Intervention|Usual care|
2558264|NCT02510781|Experimental|A group|docetaxel+carboplatin+trastuzumab
2558272|NCT02510781|Active Comparator|B group|Epirubicin+docetaxel+trastuzumab-docetaxel+trastuzumab
3205892|NCT00948376||Fetuses|
3205893|NCT00948402|Experimental|metformin|
2558406|NCT02509741|Experimental|Educational intervention|High-protein and low-GI diet education
2558408|NCT02509741|Experimental|Dietary intervention|High-protein and low-GI diet plus education
2558411|NCT02509741|Experimental|Internet-of-things (IOT) monitoring intervention|Dietary intervention plus IOT monitoring
2558416|NCT02509741|No Intervention|control|Routine diet recommendation
2558453|NCT02509364||AE-IPF|"Diagnosis criteria for AE-IPF:~Diagnosed IPF patient experiences unexplained dyspnea within 1 month~With objective evidence of hypoxia and new onset of pulmonary infiltration based on imaging examination~With other diagnosis like pulmonary embolism, pneumothorax or heart failure excluded."
2558461|NCT02509364||Stable-IPF|"Diagnosis criteria for Stable-IPF:~Exclusion of other known causes of ILDs~Presence of a usual interstitial pneumonitis (UIP) pattern on high-resolution computed tomography (HRCT)~Specific combinations of HRCT and surgical lung biopsy pattern in patients subjected to surgical lung biopsy."
2558466|NCT02509364||Health control|Healthy volunteer
2558521|NCT02509091|Experimental|The experimental group|fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)
2558531|NCT02509091|No Intervention|The controlled group|fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)
2558587|NCT02508558|Other|Measurements under different gravity states|motion perception and locomotor operation performance under different gravity states
2558653|NCT02508337|Experimental|XG-102|sterile ophthalmic solution for sub-conjunctival injection
2558655|NCT02508337|Placebo Comparator|placebo|sterile ophthalmic solution for sub-conjunctival injection
3205894|NCT00948402|Active Comparator|oral contraceptive|
3205895|NCT00948415|Experimental|SURI Enhanced|
2558764|NCT02507492|Experimental|RM-493 Once Daily|Dose once daily in the morning
2558836|NCT02507141||SCC of the oral cavity scheduled for surgery|The patients will be imaged for testing the feasibility of intra-oral imaging. Images will be compared to and evaluated against the corresponding pathology that is routinely prepared during surgery.
2558865|NCT02506621|Experimental|ELR monitoring|"Single arm study. All participants with existing permanent dual chamber pacemakers will be monitored with 5 different Loop recorder devices for a 2 week period to assess there sensitivity and specificity in detecting AF burden. The devices used will be~R test~Nuubo~TECHNOMED pocket ECG~ZIO xt patch~MoMe"
2558910|NCT02506348|Experimental|Diclofenac+Nepafenac|one drop Diclofenac in one eye one drop Nepafenac in other eye
2558977|NCT02506088|Experimental|Your Voice Your View|Participants in schools assigned to the treatment group will engage in a four session intervention aimed at prevention of sexual violence. Your Voice Your View is grounded in social norms theory and bystander intervention training. The intervention also includes a social norms marketing campaign.
2558979|NCT02506088|No Intervention|Wait List Control Group|Participants in schools assigned to the wait list control group will complete survey assessments at the same schedule as schools assigned to the treatment group. Schools will have the option to implement Your Voice Your View following completion of the 6-month survey.
2559048|NCT02505607|No Intervention|Standard Care Group|In this group, subjects will receive standard counseling regarding Overactive Bladder.
2559052|NCT02505607|Experimental|Care Plan Group|"In this group, subjects will receive counseling regarding Overactive Bladder using a printed Overactive Bladder Plan of Care information sheet."
2559108|NCT02505100|Experimental|Touching relaxant|session of massage
2559109|NCT02505100|Experimental|Hypnoses|session of hypnoses
2559110|NCT02505100|No Intervention|Standared care|standard care
3205896|NCT00948415|Active Comparator|SURI Standard|
3205897|NCT00948454||Light smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
3205898|NCT00948454||Heavy Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Subjects will bring their own cigarettes on that day and smoke their regular amount. Female subjects will also have a pregnancy test done on the test day.
3205899|NCT00948454||Non Smokers|2 blood draws, 3 urine collections and a test called an FMD which tests the circulation in your arm via ultrasound will be performed on the study day. Female subjects will also have a pregnancy test done on the test day.
3205900|NCT00948467|Experimental|TAK-733|
3205901|NCT00948519|Experimental|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
2557948|NCT02513030||Replacement of defibrillator|
2558016|NCT02512705|Other|Seclusion Room|The current practice is followed as a control group A.
2558021|NCT02512705|Experimental|Physical Restraint|Patient is placed in physical restraints to enable delivery of chemical restraints and medical monitoring and is monitored 1:1.
2558058|NCT02512198|Experimental|Bronchodilators|"Prescription Data Feedback to GP Practices - practices will be fed back data for people with presumed asthma who have either been dispensed more than 12 short-acting beta-agonist bronchodilators in the last 12 months who are not concurrently prescribed inhaled corticosteroids (poor asthma control with inadequate prevention) or been dispensed a long-acting beta-agonist bronchodilator as a single agent in the last 12 months who are not or are only infrequently concurrently prescribed inhaled corticosteroids (potentially harmful prescribing). To minimise inclusion of people with COPD, patient aged 35 years and older prescribed long-acting antimuscarinic bronchodilators will be excluded.~Practices in the bronchodilator arm are controls for the antibiotic experimental arm (below)."
2558065|NCT02512198|Experimental|Antibiotics|"Prescription Data Feedback to GP Practices - number of women in the GP practice aged 12 years and older dispensed more than 6 courses of urinary tract infection (UTI) antibiotics in the last year. UTI antibiotics are defined as trimethoprim, nitrofurantoin, co-trimoxazole, quinolones and cefalexin.~Practices in the antibiotic arm are controls for the bronchodilator experimental arm (above)."
2558113|NCT02511795|Experimental|AZD1775 (6 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 3 days (6 doses) on Days 1-3 of Week 1 and Days 8-10 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
2558114|NCT02511795|Experimental|AZD1775 (10 doses/week) + Olaparib|"In this Arm, AZD1775 will be given twice daily over 5 days (10 doses) on Days 1-5 of Week 1 and Days 8-12 of Week 2. Olaparib will be given orally BID on Days 1-14.~All patients will enter an olaparib sub-study in order to assess multiple dose pharmacokinetics of olaparib prior to entering the main study. In the olaparib PK sub-study patients will take olaparib for 3 consecutive days and venous blood samples will be collected on Day 3. The PK sub-study must be initiated 10 days prior to the Cycle 1 Day 1 administration of the AZD1775 and olaparib combination. The patient will experience a short gap in treatment (approximately 4-5 days) between Day 3 of the olaparib PK sub-study and Cycle 1 Day 1 AZD1775 and olaparib combined dosing."
2558145|NCT02511509|Experimental|Bifrontal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
2558147|NCT02511509|Active Comparator|Bitemporal electroconvulsive therapy|The ECT courses will be held twice or three times a week. There is no stated minimal nor maximal number of ECT courses. If there is no improvement after 12 courses, the ECT will be regarded as ineffective.
2558210|NCT02511262||Specimen Collection|Prospective patients with symptoms of upper respiratory infections which may be attributable to Mycoplasma pneumoniae, or from patients suspected of having Mycoplasma pneumoniae.
2558265|NCT02510872|Experimental|18F-FDG PET combined with CT with iodinated contrast injection|18F-FDG PET combined with CT with iodinated contrast injection
2558276|NCT02510872|Sham Comparator|18F-FDG PET combined with CT without injection|18F-FDG PET combined with CT without injection
2558314|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Neoadjuvant Chemo (NAC) Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 6 time points.
2558318|NCT02510456|Experimental|Diffuse Optical Spectroscopy Imaging - Non-NAC Cohort|Diffuse Optical Spectroscopy Imaging (DOSI) at 1 time point.
2558372|NCT02510066|Experimental|Acupuncture|Acupuncture participants would receive electroacupuncture on Jiaji (Ex-B2) points for 3 times in a week.
2558373|NCT02510066|Placebo Comparator|Placebo acupuncture|Placebo acupuncture participants would receive placebo acupuncture on non-point points for the same period.
2558472|NCT02509572|Experimental|Decision Support Arm|Patients randomized to the intervention will complete a sexual health screen (SHS). The results of the SHS will provide decision support for STI testing by risk stratifying patients with screening recommendations to the clinician based on risk.
2558474|NCT02509572|No Intervention|Usual Care Arm|Patients randomized to the usual care arm will complete the sexual health screen (SHS). However these results and the STI testing decision support will not be shared with the clinician.
3205902|NCT00948519|Active Comparator|Laser only|same as above, without ICG
3205903|NCT00948545||No treatment|Observing individuals pre and post bariatric surgery
3205904|NCT00948571||head down, laparoscopic|20 patients with laparoscopic surgery (radical robotic prostatectomy) in head down position
3205905|NCT00948571||head down, open|"20 patients undergoing opensurgery (open radical prostatectomy) in head down position."
3205906|NCT00948571||horizontal, open|"20 patients undergoing open surgery in horizontal position (open hemicolectomy)"
3205907|NCT00948584|Experimental|insulin titration by specialized system|Insulin dose titration system by using a SMS automatically produced by a knowledge matrix
2558673|NCT02508064|Experimental|Part 1|BMS-663068 1 × 600 mg extended-release (ER) tablet formulation
2559041|NCT02505516|Placebo Comparator|metformin|metformin 500mg
3205908|NCT00948623|Experimental|1|
3205909|NCT00948623|Sham Comparator|2|
3205910|NCT00948636||Related Donors|Related Hematopoietic Stem Cell Donors
2557910|NCT02513225|Experimental|Intervention|The adapted Project EMPWR will be comprised of 2 sessions delivered approximately 7-10 days apart by a trained Apache paraprofessional interventionist. In the first session, interventionists will use curriculum to help participants understand their personal risk factors for STDs including HIV/AIDS (i.e., substance use, mental and emotional health, sexual health, etc.) and develop an achievable personalized risk-reduction plan that emphasizes individual and community-based strengths and resources.The second counseling session will consist of the disclosure of results (if tested) and the provision of social support to help participants develop a longer-term risk-reduction plan. At visit two, participants in both groups will be offered a STD screening protocol test.
2557911|NCT02513225|Other|Control|The comparison condition will consist of Optimized Standard Care (OSC) alone. All participants will receive OSC at the first visit. OSC includes the distribution of educational pamphlets and provision of information on substance use, signs and symptoms of mental health problems, and information about STD screening resources. At visit two, participants in both groups will be offered a STD screening protocol test.
2557940|NCT02512926|Experimental|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide
2557994|NCT02512588|Experimental|BTD-001|
2557999|NCT02512588|Experimental|Placebo|
2558047|NCT02512107|Active Comparator|Juice Plus+|Subject will be taking supplement.
2558057|NCT02512107|Placebo Comparator|Placebo|Subjects will be taking the placebo.
3205911|NCT00948649|Active Comparator|Varenicline|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
3205912|NCT00948649|Placebo Comparator|Placebo|Participants will complete a 21-day study phase that will include a 10-day drug run-up and monitoring phase (days 1-10), a 3-day abstinence phase (days 11-13), and a programmed lapse (day 14) followed by a 7-day observation phase in which participants are asked to remain abstinent and will receive modest monetary reinforcement for doing so (days 15-21).
3205913|NCT00948662|Experimental|1|active arm/healthy young
2558227|NCT02511054|Experimental|1a|Arm 1a (n=2), the pilot phase, is designed to examinethat the dosing of PYR on 2, 3 days post DVI with Sanaria PfSPZ Challenge while under CQ prophylaxis does not result in subpatent parasitemia (positive qRT-PCR result defined as two consecutive samples > 20 parasites/uL or a single positive qRTPCR (Bullet) 100) or a single episode of patent parasitemia (positive blood smear defined as two unambiguous parasites in a thicksmear) in (Bullet)1/2 subjects. Subjects will considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
2558230|NCT02511054|Experimental|2|Arm 2 (n=12) will receive the selected regimen of pyrimethamine, on 2, 3 days (unless another Arm other than Arm 1a is determined from the pilot phase) post Sanaria PfSPZ Challenge via DVI while under CQprophylaxis. These subjects will be considered enrolledinto the study upon receipt of the loading dose of CQ(2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
2558233|NCT02511054|Experimental|3|Arm 3 (n=6) will receive Sanaria PfSPZ Challenge DVI while under CQ prophylaxis without PYR treatment. These subjects will be considered enrolled into the study upon receipt of the loading dose of CQ (2 days prior to administration of first dose of Sanaria PfSPZ Challenge).
2558235|NCT02511054|Experimental|4|Arm 4 (n=5) will only receive one dose of Sanaria PfSPZ Challenge at CHMI as a positive control for thestudy. Subjects in Arm 4 will be considered enrolledon the day of Sanaria PfSPZ Challenge via DVI.
2558310|NCT02510287|Active Comparator|Continuous Epidural Infusion|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A continuous infusion of 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour) will then be administered.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered."
2558313|NCT02510287|Experimental|Programmed Intermittent Epidural Bolus|"An initial dose of 10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution) will be given.~A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour.~Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.~If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered ."
2558386|NCT02509949|Experimental|Dexmedetomidine|Dexmedetomidine ivpump 0.2ug/kg/h during living donor renal transplantation.
2558390|NCT02509949|Placebo Comparator|Saline|Saline ivpump 0.2ug/kg/h during living donor renal transplantation.
2558469|NCT02509559|Active Comparator|Propanolol|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one Propranolol-CT 80 mg film-coated tablet.
2558470|NCT02509559|Placebo Comparator|Placebo|Memory performance for pictures, electrocortical activity, pharmacokinetics, skin-conductance, pulse waves, burdening heart frequency, pulmonary function, α-amylase in saliva, heart rate and blood pressure after administration of one placebo capsule.
2558512|NCT02508831|Experimental|Bilateral amputation of upper limb|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
3205914|NCT00948662|Placebo Comparator|2|placebo arm
2558821|NCT02507167|Active Comparator|mixed meal 2 h after single dose rifampin (600 mg)|
3205915|NCT00948662|Other|3|ketoconazole interaction evaluation
3205916|NCT00948701|Experimental|Phone-based PA program (RTR Plus)|"The PA intervention consists of PA counseling, matched to participants' motivational readiness, plus educational materials. RTR volunteers or coaches will be asked to contact participants by telephone once a week for 12 weeks. The purpose of these calls is to build a supportive relationship with the participant, monitor PA participation, identify any health concerns, assist the participant to identify relevant barriers to PA and help her to problem solve to overcome such barriers."
3208825|NCT00978471|Experimental|experimental arm thiotepa|4 courses of conventional chemotherapy followed by high-dose Thiotepa with peripheral stem cell rescue. Surgical resection of all tumor masses will be performed as soon as possible.
2557919|NCT02513017|Experimental|Stimulus Control Instructions (SCI)|"SCI is a behavioral treatment that aims to assist persons with insomnia to re-associate the bed and the bedroom with falling asleep or back to sleep, and to acquire a consistent sleep pattern. SCI entails specific instructions that focus on developing new sleep habits, such as avoiding activities other than sleep (e.g., reading, watching TV) in bed, and getting out of bed if unable to fall asleep and engaging in quiet activities until sleepy.~A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SCI. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt."
2557920|NCT02513017|Experimental|Sleep Restriction Therapy (SRT)|SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
2557921|NCT02513017|No Intervention|No therapy|No behavioral therapy for the management of insomnia is provided. However, a list of general recommendations and suggestions are provided to participants.
3208826|NCT00978471|Other|Reference arm|4 courses of conventional chemotherapy. Surgical resection of all tumor masses will be performed as soon as possible.
2558009|NCT02512367|Experimental|Intervention|
2558011|NCT02512367|Placebo Comparator|Surveillance|
2558041|NCT02512120|Experimental|volume controlled ventilation|Randomized 23 patients will be applied VCV during RALP.
2558050|NCT02512120|Active Comparator|autoflow-volume controlled ventilation|Randomized 23 patients will be applied autoflow-VCV during RALP.
2558146|NCT02511925||ICU Cluster 1|Adult Intensive Care Unit - Royal Brompton Hospital
2558149|NCT02511925||ICU Cluster 2|Paediatric ICU - Royal Brompton Hospital
2558151|NCT02511925||ICU Cluster 3|Adult Intensive Care Unit - Harefield Hospital
2558245|NCT02510976|Active Comparator|Prucalopride|Prucalopride tablet 2 mg
2558247|NCT02510976|Placebo Comparator|Placebo|matching placebo tablet
2558283|NCT02510573||sTBI group|The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
2558306|NCT02510352||Rotator cuff tear|patients with a symptomatic rotator cuff tear treated without surgical repair
2558394|NCT02510118|Experimental|conventional chemotherapy + placebo ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the placebo ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency.
2558397|NCT02510118|Experimental|conventional chemotherapy + ChangTai Keli|Patients in this group will be given conventional chemotherapy medicine: modified FOLFOX6 (mFOLFOX6) chemotherapy or XELOX recommended by treatment guidelines for colon cancer, and the ChangTai Keli corresponding to the traditional Chinese syndrome of dampness stasis type of spleen deficiency, a herbal extract twice daily for 26 weeks for lower dosage.
2558468|NCT02509403|Experimental|Intervention|Essential oils infused Perineal Hygiene wipe
2558538|NCT02509104|Experimental|Cohort 1 Fasted condition|Each subject will receive both treatments A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fasting conditions.
2558545|NCT02509104|Experimental|Cohort 2 Fed condition|Each subject will receive both treatment A and B in either of period 1 or 2 with a washout period of 28 days between treatment periods. Subjects will receive the study treatments under fed (high fat breakfast) conditions.
2558591|NCT02508519|Experimental|Zonal|The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
2558594|NCT02508519|Experimental|Balance|The balance acupuncture group will receive a treatment according to a balance method, and a pain level will be estimated according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
2558596|NCT02508519|No Intervention|Control|The control group will provide only the estimation of the the pain level according to a visual analog pain scale (VAS) but receive no acupuncture treatment. Then if possible the pain level will be measured again approximately 24 hours after the first measurement and the change of the pain level will be recorded.
2558621|NCT02508298|Active Comparator|Indocyanine green retention test|A baseline venous sample of 5 ml of venous will be drawn for pre-infusion measurement. Under sterile conditions 0.5 mg/kg body weight of ICG will be injected into vein. Further blood samples (5 ml each) will be collected at 5, 10, 15 and 20 minute intervals after the injection from a peripheral vein in the opposite arm using another intravenous catheter. After serum is separated by centrifugation, optical densities will be measured at 804 nm using a calibrated method for measurement of ICG level s. ICG retention at 15 minutes and elimination rate constant will be calculated by fitting the serum disappearance curve to a single exponential decay equation.This will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
2558622|NCT02508298|Active Comparator|Liver stiffness measurement|ARFI measurements of the liver will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
2558624|NCT02508298|Active Comparator|Spleen stiffness measurement|ARFI measurements of the spleen will be obtained using a standard ultrasound probe. The patient will be lying on his back and will be asked to hold his/her breath for 2-5 seconds during measurements.These will be compared to portal pressure measured by Hepatic Venous Portal Gradient (HVPG).
3171481|NCT00587600|Active Comparator|radiofrequency ablation of barretts esophagus|radiofrequency ablation of barretts esophagus
3171482|NCT00587626|Active Comparator|1|InterX treatment plus rehabilitation exercises
3171483|NCT00587626|Placebo Comparator|2|Inactive InterX treatment plus rehabilitation exercises
2558052|NCT02512003|Experimental|Fantom Treatment group|
2558139|NCT02511899|Active Comparator|Mango fruit powder 100mg|Mango fruit powder 100mg
2558140|NCT02511899|Active Comparator|Mango fruit powder 300mg|Mango fruit powder 300mg
2558208|NCT02511288||Cohort 1|Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
2558214|NCT02511288||Cohort 2|Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
2558217|NCT02511288||Cohort 3|Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
2558293|NCT02510742|Active Comparator|SPG neurostimulation|SPG neurostimulation of frequency 20 Hz
2558295|NCT02510742|Sham Comparator|Control|Sham neurostimulation of amplitude=0
2558321|NCT02510274|Experimental|Part1, ASP3325 Tablet A|ASP3325 tablets A will be orally administered with 150 mL of water in fasting condition on non-dialysis day in Day 1
2558328|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 1|ASP3325 tablets B will be orally administered t.i.d. 30 minutes before each meal for 2 weeks
2558336|NCT02510274|Experimental|Part2, ASP3325 Tablet B group 2|ASP3325 tablets B will be orally administered t.i.d. 30 minutes just after each meal for 2 weeks
2558475|NCT02509312|Experimental|Experimental|Patients in this arm will be given ketorolac at cord clamp with standard dose of 30 mg, then 3 additional 30 mg doses every 6 hours
2558478|NCT02509312|Placebo Comparator|Control|Patients in this arm will be given a placebo medication at cord clamp, and then 3 additional doses of placebo every 6 hours.
2558544|NCT02508883||Upper gastrointestinal bleeding|patients with cancer who presented or were admitted in the emergency room, wards or intensive care units of the Cancer Institute of São Paulo (ICESP), with a recent episode of upper gastrointestinal bleeding.
2558698|NCT02508012|Experimental|Immuno monitoring|in case of loss of response, the clinician uses immunomonitoring data to adapt the treatment following a treatment algorithm.
2558700|NCT02508012|No Intervention|No immuno monitoring|in case of loss of response, immunomonitoring data are not transmit to the clinician who adapts the treatment with classical biological informations.
2558730|NCT02507778|Other|biopsy|needle will be inserted before and after biopsy and will measure circulating tumor cells.
2558743|NCT02507466|Experimental|Variable high-intensity Training|high intensity variable stepping exercise on a treadmill and overground
2558750|NCT02507466|Active Comparator|Variable low-intensity training|low intensity variable stepping exercise on a treadmill and overground
2558752|NCT02507466|Active Comparator|Constant High Intensity Training|high intensity constant (forward) stepping exercise on a treadmill and overground
2558779|NCT02507323|Active Comparator|ticagrelor or matching placebo|ticagrelor (180 mg loading followed by 90 mg twice daily) or matching placebo
2558783|NCT02507323|Active Comparator|prasugrel or matching placebo|prasugrel (60 mg loading followed by 5-10 mg/d) or matching placebo
2558898|NCT02506504|Experimental|Inspiratory help then sham ventilation|The initial evaluation is performed using an Inspiratory Pressure Support. After the training, the final evaluation is performed using an Inspiratory help (sham ventilation).
2558899|NCT02506504|Experimental|Sham ventilation then Inspiratory help|"The initial evaluation is performed using an inspiratory help (sham ventilation).~After the training, the final evaluation is performed using an Inspiratory Pressure Support."
3171484|NCT00587652||1|Intermediate Segment Barrett's (2-4cm)
3171485|NCT00587652||2|Long segment Barrett's (>4 cm)
3171486|NCT00587665|Experimental|1|Low dose ketamine given
3171487|NCT00587665|Placebo Comparator|2|Saline given as control
3171488|NCT00587691|Experimental|Dose Level 1|6-9 million MRTC
3171489|NCT00587691|Experimental|Dose Level 2|30-45 million MRTC
3171490|NCT00587691|Experimental|Dose Level 3|60-90 million MRTC
3171491|NCT00587704|Other|Nerve Stimulation|Use of nerve stimulator for placement of PVB nerve block
3171492|NCT00587704|Other|Anatomic landmarks|Use of anatomic landmarks for placement of PVB block
3171493|NCT00587717|Active Comparator|1|Two 80 mg pills simvastatin taken 24 hours prior to surgery
3171494|NCT00587717|Placebo Comparator|2|Two 80 mg pills placebo are taken 24 hours prior to surgery
3171495|NCT00587730|Active Comparator|Clinical SPECT|GE Hawkeye Attenuation Correction Camera is being compared to the approved clinical use SPECT camera.
3171496|NCT00587756||1|Prospective cohort of consecutive patients who undergo surgery for colorectal cancer liver metastases
3171497|NCT00587808||HFpEF|Patients with a history of HFpEF
3171498|NCT00587808||control|Patients with a without a history of CHF
3171499|NCT00587821||1|The first 250 samples will be used as a training set and results of these breast biopsies (benign or malignant) will be used to determine the peptide profile characteristic of a diagnosis of breast cancer on biopsy.
3171500|NCT00587821||2|The predictive capacity of this profile will then be prospectively assessed using the next 250 samples, which will serve as a validation set. Subjects who are candidates for enrollment on cohort B of this study (metastatic disease)
3171501|NCT00587873|Experimental|1|MTX, 6-TG, and Leucovorin combination
3171502|NCT00587886||Cases|Cases will be women with newly diagnosed endometrial or ovarian cancer who are residents of six counties in New Jersey.
3171503|NCT00587886||Controls|Controls will be selected from the general population in those counties by use of random digit dialing for those under 65 years of age, from Centers for Medicare and Medicaid Services (CMS) lists for those aged 65 years and over, and from neighborhood sampling.
3171504|NCT00587899|Other|1|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation.
3171505|NCT00587899|No Intervention|2|The control group of patients will undergo operation for mitral valve disease without the additional Pulmonary Vein Isolation
3171506|NCT00587925|Experimental|1|Bone Mineral Density
3171507|NCT00587938||A|BNP level from protocol blood tests initiated in the ED, reported to ED physician prior to ED disposition.
3205917|NCT00948701|Active Comparator|Standard RTR services (RTR)|RTR volunteers will contact the participants in this group by telephone once a week, providing support and information integral to RTR. The volunteers will also review the educational materials sent to all participants receiving RTR services. This will allow the volunteers to build a relationship with the participants over 12 weeks and ensure that these participants receive a minimal intervention, reducing the risk of attrition at the 12-week assessment.
3205918|NCT00948714|Experimental|Case|
3205919|NCT00948714|Active Comparator|Control|
2558095|NCT02511769|Experimental|WEB-MAP CBT|Web-MAP Group. Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
2558100|NCT02511769|Active Comparator|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
2558126|NCT02511626||Case group|Women with a surgically confirmed diagnosis of endometriosis
2558127|NCT02511626||Control group 1|Women without any evidence of endometriosis (= no clinical symptom and/or no surgical evidence of endometriosis)
2558129|NCT02511626||Control group 2|Women without endometriosis (surgically confirmed) but chronic abdominal/pelvic pain due to other reasons (e.g. Crohn's disease, colitis etc)
2558166|NCT02511444|Other|single arm|All patients will have GBS culture and real time PCR performed.
2558234|NCT02511132|Experimental|Vigil + temozolomide + irinotecan|(i) oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle), (ii) irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle), intravenously (iii) peg-filgrastim 100μg/kg (Day 6) subcutaneously (optional and may be administered at home), and (iv) Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter. One cycle = 21 days.
2558252|NCT02510677|Other|myocardial perfusion scintigraphy|Low-dose dobutamine gated SPECT and CZT camera for the assessment of parameters of left ventricular dyssynchrony in heart failure patients eligible for the implantation of a cardiac resynchronization device.
2558312|NCT02510521|Placebo Comparator|in rest situation|No intervention during one week. Daily usual activities are allowed.
2558315|NCT02510521|Experimental|after acute muscle exercise by NMES|"A working session of 20 minutes with three sequences electrostimulation:~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
2558317|NCT02510521|Experimental|after a daily workout sequence with NMES in one week|"Working sessions of 20 minutes 7 days in a row, including :~warming-up sequence~work sequence (starting at 50% of the intensity achieved during warm-up)~relaxation sequence~Electrostimulation relates both quadriceps are stimulated simultaneously and jointly. During the sessions, the patient sits on a chair or on a chair, legs bent at 90 °. So that there is no extension of the legs when electrostimulation (which could be painful), a strap is placed behind the legs of the chair or armchair and holds the pegs."
2558383|NCT02509819|Experimental|Military Performance Lab testing|Subjects who use IDEOs will come to the Military Performance Lab for one test session during which they will walk in standardized shoes with six different foam heel wedges (Heel Cushion Material Bulk (foam) from Kingsley Manufacturing Company) in random order. Control data will also be collected on able-bodied individuals. Control subjects will also come to the MPL for one test session in which they will walk using the same standardized shoes. For all subjects, biomechanical gait data will be collected as the subjects walk along a walkway in the MPL. This data will be used to calculate roll-over shape, instantaneous radius of curvature, COP velocity, and ankle moment.
3205920|NCT00948727|Experimental|Dose adjustment according CN activity|
2558527|NCT02508987||Group 1|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as periodontally healthy.Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 18.50-24.99 kg/m2: Normal-weight"
2559043|NCT02505516|No Intervention|not on metformin|
3205921|NCT00948740|Experimental|ergocalciferol|After signing informed consent, all participants who meet the study criteria will receive ergocalciferol 50,000 IU weekly for 8 weeks. After completing the ergocalciferol course, participants will take a maintenance dose of cholecalciferol 1,000 IU daily.
3205922|NCT00948753|Experimental|Phase 1: 150mg Maraviroc|150mg twice daily
3205923|NCT00948753|Experimental|Phase 1: 300mg Maraviroc|300mg twice daily
3205924|NCT00948753|Experimental|Phase 2: 300mg Maraviroc|300mg twice daily
3205925|NCT00948779|Other|antibiotics|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the use of antibiotics at home.
3205926|NCT00948779|Experimental|the antipyretic therapy|antibiotic education for children in an emergency care unit: Patient and family's therapeutic education to improve the antipyretic therapy at home.
3208827|NCT00978484|Active Comparator|Static Virtual Reality|Exposure Therapy using a still computer image
3171508|NCT00587938||B|BNP level from protocol blood tests initiated in the ED, NOT reported to ED physician prior to ED disposition.
2558014|NCT02512445|Experimental|Trauma Informed Guilt Reduction Therapy|6-session psychotherapy intervention
2558018|NCT02512445|Active Comparator|Supportive Care Therapy|6-session psychotherapy intervention
2558040|NCT02512146||Irritable bowel syndrome|Patients meeting Rome III criteria of irritable bowel syndrome. Intervention: colonoscopy.
2558046|NCT02512146||Normal controls|"Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.~Intervention: colonoscopy."
2558135|NCT02511847|Other|single-arm|"Drug: Afatinib (single group assignment)~First phase: Afatinib montherapy~The following phases: combination with oral afatinib and weekly paclitaxel in a 3-weekly course for total of four courses."
2558186|NCT02511340|Experimental|Flumatinib mesylate tablet 600 mg qd|Flumatinib, 600mg, qd
2558232|NCT02511067|Active Comparator|Ranibizumab 0.3 mg|Mandatory monthly treatments with Intravitreal (IVT) ranibizumab (0.3 mg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis, based on retreatment criteria.
2558236|NCT02511067|Experimental|Tocilizumab (8.0 mg/kg)|Mandatory monthly Intravenous (IV) infusions with tocilizumab (8.0 mg/kg) starting at Baseline (BL) until Month 6. Starting at Month 6, treatments will be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on the retreatment criteria.
2558237|NCT02511067|Experimental|Tocilizumab (8.0 mg /kg) plus Ranibizumab 0.3 mg|Mandatory Intravitreal (IVT) ranibizumab 0.3 mg at Baseline (BL) followed with an IV infusion of tocilizumab (8.0 mg/kg) on same day starting at Baseline (BL) until Month 6. Combination treatments (IVT ranibizumab 0.3 mg followed by IV tocilizumab 8.0 mg/kg infusion administered at same visit) will be given every month until Month 6. Starting at Month 6, treatments will continue to be administered on as-needed basis with IVT ranibizumab (0.3 mg), based on retreatment criteria.
2558269|NCT02510729|Active Comparator|SPG neurostimulation|Sphenopalatine ganglion (SPG) neurostimulation of 20 Hz
2558277|NCT02510729|Placebo Comparator|Sham Stimulation|Sham stimulation with amplitude=0
2558307|NCT02510404|Experimental|mCTLs against three viruss|The investigator will use 3 different dose levels starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. They will give the option of administering 2 additional doses (at the same level) of the same or different cell lines, 28 days after the first dose, in subjects that have limited or no improvement in viral count after one dose in the absence of any toxicities attributable to the infusion,or who receive other therapy that may affect the persistence or function of the infused mCTLs.
2558363|NCT02509858|Active Comparator|thyroxine in eythyroid diabetics|50 μg of thyroxine once daily, for 2 months.
2558364|NCT02509858|Active Comparator|thyroxine in euthyroid healthy humans|50 μg of thyroxine once daily, for 2 months.
2558365|NCT02509858|Placebo Comparator|placebo in euthyroid diabetics|50 μg of placebo once daily, for 2 months.
2558425|NCT02509689|Experimental|Single Arm|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
2558476|NCT02509351|Experimental|misoprostol|women receiving pre-operative rectally administered 400 microgram misoprostol
2558481|NCT02509351|Active Comparator|placeboo|women receiving placebo
2558509|NCT02508896|Experimental|AFFITOPE® AT04A+adjuvant|3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
2558511|NCT02508896|Experimental|AFFITOPE® AT06A+adjuvant|3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
2558517|NCT02508896|Placebo Comparator|Adjuvant without active component|3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization
2558584|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
2558639|NCT02508272||Trauma patients|age ≥18 y ISS ≥ 17 points admission < 6 h.
2558686|NCT02508051|No Intervention|No daily emails|The usual care group will receive no intervention except for a reminder every six months to take a test of journal-based CME questions from 2 anesthesiology journals
2558690|NCT02508051|Placebo Comparator|Article email links|The email link group will get e-mailed web links to different specific articles, including articles on which the CME questions are based, published in 2 anesthesiology journals Monday through Friday with a reminder to take the same test every six months
2558695|NCT02508051|Experimental|Blog email links|The experimental group will get e-mailed web links to blogs Monday through Friday based on the same specific articles as in group 2; each daily blog will focus on a specific article, including articles on which CME questions are based, the blogs will have web links to the articles on which they are based and every six months group 3 will get a reminder to take the same test.
2558722|NCT02507817||31-32 with Mg for neuroprotection|"Women in 31-32 weeks gestation that where treated with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
2558860|NCT02506712|Experimental|spinal cord injury|use a wheelchair with and without a assisting device to power manuel wheelchair
3171509|NCT00587951||A|Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
3171510|NCT00587977||1|Aortic aneurysm repair
3171511|NCT00587977||2|Aortic aneurysm growth
3171512|NCT00587977||3|Aortic aneurysm growth stable.
2557984|NCT02512549|Active Comparator|Rehabilitation|Patients with diagnosed Chronic Obstructive Pulmonary Disease with severe airflow obstruction (spirometric forced expiratory volume in one second (FEV1) below 50% of the normal) and modified medical research council (mMRC) dyspnea grading 1 to 3 will undergo pulmonary rehabilitation program thrice a week for 2 months.
2557985|NCT02512549|No Intervention|Usual Care|Patients with COPD as described in rehabilitation arm, will be provided usual care from the hospital outpatient clinic.
3205927|NCT00948805|Experimental|GnRH agonist|3,6 mg of goserelin acetate (GnRH agonist) will be administered on the 21st day of the menstrual cycle previous to ovarian stimulation. 250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
2558091|NCT02512237|Experimental|Phase 1a: Dose-Escalation|Six cohorts with escalated dose levels of ARX788 at 0.33 mg/kg, 0.66 mg/kg, 1.3 mg/kg, 2.2 mg/kg, 2.9 mg/kg and 3.8 mg/kg will be administered every 3 weeks via intravenous infusion to determine the MTD.
2558092|NCT02512237|Experimental|Phase 1b: Dose-evaluation 1|Breast cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
2558098|NCT02512237|Experimental|Phase 1b: Dose-evaluation 2|Breast cancer subjects with mid/low HER2 expression, categorized as ISH negative AND IHC2+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
2558101|NCT02512237|Experimental|Phase 1b: Dose-evaluation 3|Gastric cancer subjects with high HER2 expression, categorized as ISH positive or IHC3+, will be administered with ARX788 at MTD every 3 weeks via intravenous infusion.
2558157|NCT02511574|Experimental|cervical pessary|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
2558159|NCT02511574|Active Comparator|natural progesterone|Patients with uterine cervical length ≤ 25 mm are randomized to use the cervical pessary or natural progesterone to compare their effectiveness in the reduction of preterm birth rates.
2558193|NCT02511223|Experimental|Single Arm|Only one Arm,All patients will receive Olaparib 300 mg (MILIGRAM)bid p.o till disease progression
2558302|NCT02510963|Experimental|Tenofovir 24 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 24 weeks of gestation to 1 month postpartum
2558304|NCT02510963|Experimental|Tenofovir 28 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 28 weeks of gestation to 1 month postpartum
2558305|NCT02510963|Active Comparator|Tenofovir 32 week|Pregnant women with high HBV DNA load in serum and normal liver function were treated with Tenofovir Disoproxil Fumarate 300 mg/day from 32 weeks of gestation to 1 month postpartum
2558354|NCT02510183|Active Comparator|Acupressure Wrist Band|Patient receive preoperative education a day before surgery, education for acupressure application on the day of surgery, an acupressure wrist band is applied on P6 acupoint in both wrist an hour before surgery
2558355|NCT02510183|Placebo Comparator|Placebo Wrist Band|Patient receive preoperative education a day before surgery, an placebo acupressure wrist band is applied in both wrist an hour before surgery
2558357|NCT02510183|No Intervention|Control Grup Without Band|Patient receive preoperative education a day before surgery, and patient are only visited an hour before surgery
2558368|NCT02509845|Experimental|Adolescent Safety Only Cohort|Prior to commencing enrollment of subjects 12-17 years of age in Study Arms 1 & 2, a safety only cohort of 4 to 8 adolescent subjects will receive 4 administrations of C16G2 on Day 0.
2558369|NCT02509845|Experimental|Study Arm 1|Subjects will receive 2 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 1 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
2558370|NCT02509845|Experimental|Study Arm 2|Subjects will receive 4 mL of study drug or placebo over two 7 day C16G2 administration periods, which will be separated by approximately 4 months. Subjects enrolled in Study Arm 2 will receive 4 study drug or placebo administrations on the first day of dosing followed by morning (AM) and evening (PM) dosing for 6 consecutive days. Study drug will be administered via manual toothbrush and custom dental trays.
2558448|NCT02509533|Experimental|V.A.C.® Therapy|In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.
2558449|NCT02509533|Active Comparator|usual dressing method (compresses)|In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.
3205928|NCT00948805|Active Comparator|Control|250 mg of hCG will be administered on the first day of menses and a starting dose of 150 IU of FSH will be started 2 days later as a part of a long ovarian stimulation protocol. Ovulation will be triggered with a 250 mg of hCG when at least 2 follicles attain 18mm and to accommodate oocyte retrieval within 36 hours.
3205929|NCT00948870|Experimental|Shugan Decoction|
2558734|NCT02507739|Other|possibility to walk during labor|possibility to walk during labor
2558735|NCT02507739|Other|no possibility to walk during labor|no possibility to walk during labor
2558758|NCT02507427|Experimental|Nerve monitoring arm|They will receive pelvic autonomic nerve monitoring and mapping using NIM-Eclipse (Medtronic) during robot-assisted laparoscopic prostatectomy.
2558824|NCT02507206|Experimental|DAR 0-100A then Placebo|15 mg is dissolved in 150 cc NS administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
2558828|NCT02507206|Placebo Comparator|Placebo then DAR 0-100A|15 mg dissolved in 150 cc NS saline is administered over 30 minutes x 3 consecutive days. Subjects will return a minimum of two weeks later for Visit 5 to receive drug (if randomized initially to placebo) or placebo (if randomized to drug).
2558832|NCT02507206|No Intervention|Healthy Control|patients without diagnosis of SPD
3205930|NCT00948870|Placebo Comparator|low does of Shugan decoction|
3205931|NCT00948883||Patient-Case|Transplanted patient with cancer
2559066|NCT02505243||HCV patients|HCV patients treated with direct acting antivirals and ribavirin
3205932|NCT00948883||Patient-Control|Transplanted patient without cancer
3205933|NCT00948909|Placebo Comparator|A. Sugar Pill|
2558168|NCT02511405|Experimental|Arm 1|VB-111 + Bevacizumab
2558169|NCT02511405|Active Comparator|Arm 2|Bevacizumab
3205934|NCT00948909|Experimental|B. ABT-126|
2558374|NCT02509910||Standard therapy|intraoperative standard fluid therapy for major abdominal surgery
2558381|NCT02509910||Goal directed therapy|intraoperative goal directed fluid therapy based on an angorithm lead by SVV/CI for major abdominal surgery patients
2558444|NCT02509663|Active Comparator|Sinuplasty balloon|Patients will receive the innovative health technology to treat frontal sinusitis : a balloon sinuplasty
2558445|NCT02509663|Active Comparator|Conventional surgical procedure|Patients will be treated with the conventional procedure : a sinus surgery with rigide instrumentation
2558502|NCT02509182|Active Comparator|100% FiO2|100% oxygen administered during pulmonary lobectomy surgery.
2558503|NCT02509182|Experimental|60% FiO2|60% oxygen administered during pulmonary lobectomy surgery.
2558530|NCT02508805|Experimental|Neuromultivit +Voltaren+Sirdalud|"Neuromultivit 2ml i.m. once a day for 7 days, then 2 ml i.m. one time every other day for 10 days.~Voltaren 100mg per os once a day for 20 days. Sirdalud 2 mg per os three times a day for 20 days."
2558537|NCT02508805|Active Comparator|Voltaren+Sirdalud alone|Voltaren 100mg per os once a day for 20 days Sirdalud 2 mg per os three times a day for 20 days
3205935|NCT00948909|Experimental|C. ABT-126|
3205936|NCT00948909|Active Comparator|D. donepezil|
2558714|NCT02507934|Experimental|Lubricin|Lubricin 150 μg/ml eye drops solution
2558716|NCT02507934|Active Comparator|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
2558744|NCT02507596|Experimental|Nano-crystalline hydroxyapatite silica gel|hydroxyapaptite bone graft with nano particle size in silica gel will be used to fill in the defect after opening a periodontal flap
2558749|NCT02507596|Sham Comparator|Open flap debridement|an open periodontal flap without adding bone graft.
2558795|NCT02507284|Experimental|SRX246 120mg BID|SRX246 capsules, administered orally, in divided doses twice daily
2558797|NCT02507284|Experimental|SRX246 160mg BID|SRX246 capsules, administered orally, in divided doses twice daily
2558801|NCT02507284|Placebo Comparator|Placebo|Placebo capsules, administered orally, in divided doses twice daily
2558882|NCT02506829|Active Comparator|Usual care|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.
2558885|NCT02506829|Experimental|Financial Incentives|Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital. Financial incentives for: a) speaking with a coach from the Smoker's Quitline ($50), b) completion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months after study enrollment ($250).
2558909|NCT02506270|Active Comparator|AirSeal Trocar valveless|patients are treated with the AirSeal-CO2-insufflator and trocar-system
2558911|NCT02506270|Sham Comparator|Conventional trocar|patients are treated with a conventional insufflation and trocar system
2558984|NCT02506075|Experimental|Pre-tDCS group|"In Pre-tDCS group, total sessions of the transcranical direct current stimulator stimulation(tDCS) was done for each three subgroups and visual inattention training was followed after that.~Patient had 2 times of tDCS for 13 minutes with 20minutes of resting interval. After that, additional 2 times of Visual inattention training was done with same protocol."
2558991|NCT02506075|Experimental|Simultaneous tDCS group|In Simultaneous transcranical direct current stimulator(tDCS) group, tDCS and visual inattention training was done simultaneously.
2558996|NCT02506075|No Intervention|Sham control group|without transcranical direct current stimulator(tDCS) or without visual training
2559067|NCT02505399|Experimental|ticagrelor|"In the intervention group, Ticagrelor will be administered orally, according to the following scheme:~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~90 mg the following morning (D Day before rotational atherectomy and angioplasty),~90 mg the following evening (D Day after rotational atherectomy and angioplasty),~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
2559077|NCT02505399|Active Comparator|clopidogrel|"In the control group, Clopidogrel will be administered orally, according to the following scheme:~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~75 mg the following morning (D Day before rotational atherectomy and angioplasty),~0 mg the following evening (D Day after rotational atherectomy and angioplasty),~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
2559137|NCT02504866|Experimental|AET|Aerobic exercise will be performed on an elliptical trainer at a vigorous intensity
2559139|NCT02504866|No Intervention|Control|Wait-list control that performs no exercise for first 12 weeks; randomized to an exercise intervention(either AET or RET) after 12 weeks
2559141|NCT02504866|No Intervention|Healthy Volunteer|Healthy volunteers will perform specific measures for asingle study visit
2559143|NCT02504866|Experimental|RET|Rapid reciprocal exercise will be performed on an elliptical trainer at light to moderate intensity
2559205|NCT02504437|Experimental|pre-conditioned BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) with hypoxia pre-condition and endothelial pre-induction.
2559210|NCT02504437|Active Comparator|BMMSCs|autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.
2559216|NCT02504437|Sham Comparator|Controls|standard therapy without autologous bone marrow mesenchymal stem cells (BMMSCs) infusion.
2559298|NCT02503839|No Intervention|Arm#3|arm#3 (n=10), the first group (n=5) serving as control to arm#1 and arm#2, the next group (n=5) serving as control to arm#4.
3205937|NCT00948987|Experimental|Aspirin|single dose of aspirin 325 mg p.o.
3205938|NCT00949000|Other|ICD Implant|Implantation of a commercially available AnalyST or AnalyST Accel ICD
3205939|NCT00949026|Experimental|A|
3205940|NCT00949039|Experimental|Chemotherapy|Isolated pelvis perfusion
3205941|NCT00949039|Active Comparator|Control|Standard treatment
3171513|NCT00588003|Experimental|1|This is an exploratory study utilizing micro-array technology and immunohistochemistry to test the hypothesis that changes in gene expression occur as an early event in response to endocrine therapy and that these changes can be correlated with changes in surrogate biological markers.
3171514|NCT00588003|Placebo Comparator|2|no medication before surgery
3171515|NCT00588016|Experimental|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
2558261|NCT02510859|Experimental|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
2558268|NCT02510859|No Intervention|Traditional nutritional follow up|Traditional nutritional follow up that is to say with a nutritional consultation before starting treatment and then when necessary on medical advice
2558319|NCT02510469|Experimental|Apatinib Maintenance Therapy After Adjuvant Chemotherapy|Apatinib Mesylate Tablets 500 mg qd p.o. after XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
2558327|NCT02510469|No Intervention|Only Adjuvant Chemotherapy|No Intervention After XELOX Adjuvant Chemotherapy (Capectabine 1000mg/m2 po bid d1-14, oxaliplatin 130mg/m2 iv d1, q21d)
2558371|NCT02510053|Other|Patients With IFI in ICU|40 patients receive Caspofungin for an Invasive Fungal Infection(IFI) in the Intensive Car will be recruited
2558427|NCT02509676|Experimental|dynamic stretching exercise|This group will perform dynamic stretching exercise to their left side gastrocnemius muscles for 5 weeks (5 days a week, 3 sets of exercise a day, each set including 5 repetitions of dynamic stretching lasting 45 seconds)
2558428|NCT02509676|No Intervention|control|this group will not perform any stretching exercises for 5 weeks
2558450|NCT02509338|Experimental|Electrode deep brain stimulation|Monocontact electrode deep brain stimulation
2558529|NCT02509169|Experimental|TAE plus p53 gene|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
2558535|NCT02509169|Active Comparator|TAE|Trans-catheter embolization (TAE) will be given once per month
2558589|NCT02508571|Sham Comparator|Control|Two 15-minute sessions of sham intervention/day, five days a week
2558592|NCT02508571|Experimental|DST group|One session of DST and the other of sham intervention/day, five days a week
2558595|NCT02508571|Experimental|DST+OSMS group|One session of DST and the other of OSMS/day, five days a week
2558659|NCT02508168|Experimental|Sequence I: AB|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by alogliptin 12.5 mg tablets and metformin 1000 mg tablets, orally, once, on Day 1 of Period 2.
2558662|NCT02508168|Experimental|Sequence II: BA|Alogliptin 12.5 mg tablets, orally and metformin 1000 mg tablets, orally, once, on Day 1 of Period 1, followed by a 7-day washout period, followed by SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets, orally, once, on Day 1 of Period 2.
2558703|NCT02507869|Experimental|Affect-Guided Prescription|Intervention: Participants in the affect-guided condition are instructed to exercise while monitoring how they feel, and to adjust the intensity of their exercise to maintain a pleasant affective response.
2558704|NCT02507869|Active Comparator|Heart Rate-Guided Prescription|Intervention: Participants in the heart rate-guided condition are instructed to exercise while monitoring their heart rate, and to adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
2558761|NCT02507661|Experimental|alveolar ridge preservation - 2 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months
2558766|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 2 months|no-preservation of alveolar ridge - 2 months
2558767|NCT02507661|Experimental|preservation of alveolar ridge - 4 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months
2558770|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 4 months|no-preservation of alveolar ridge - 4 months
2558772|NCT02507661|Experimental|preservation of alveolar ridge - 9 months|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months
2558773|NCT02507661|Active Comparator|no-preservation of alveolar ridge - 9 months|no-preservation of alveolar ridge - 9 months
2558835|NCT02507050|Experimental|Intervention|Patients randomised to stop beta blockers and start Ivabradine. Initial dose of 5mg BD, titrated to 7.5mg BD if possible.
2558837|NCT02507050|No Intervention|Standard therapy|Bisoprolol given as standard beta blocker treatment i.e. Bisoprolol (maximum dose 10mg OD).
3171516|NCT00588029||1|breast cancer patients
3171517|NCT00588029||2|control subjects without breast cancer
3171518|NCT00588042|Active Comparator|1|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
2558992|NCT02505776||GLASH VISTA™|Patients with eyelash hypotrichosis prescribed bimatoprost cutaneous solution 0.03% (GLASH VISTA™) as per local standard of care in clinical practice.
3171519|NCT00588042|Sham Comparator|2|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
3171520|NCT00588068||1|Tumor and Marrow Markers
3171521|NCT00588081|Other|1|Participants will receive a cover letter, questionnaire and invitation to participate in a post-operative interview.
3171522|NCT00588107|Experimental|Web site access|Web intervention- and access to pharmacotherapy
3171523|NCT00588107|Active Comparator|print materials|Receives tailored print materials and access to pharmacotherapy (Materials condition)
3171524|NCT00588120|Experimental|C-13 labeled oxalate|Hyperoxaluric patients
3171525|NCT00588133|Experimental|1|New drug dosing schedule
3171526|NCT00588133|Active Comparator|2|Standard drug dosing schedule
3171527|NCT00588172|Sham Comparator|1|Individuals with no nsSNPs or mutations known to alter oct1 function
3171528|NCT00588172|Active Comparator|2|Individuals with nsSNPs or mutations known to alter oct1 function
2558254|NCT02510703|Other|Type 2 diabetes group|Type 2 diabetes group
2558255|NCT02510703|Other|no diabetes|no diabetes
2558325|NCT02510508|Experimental|Group CRAFT|"All CSO's who are allocated to CRAFT group condition will be offered seven sessions of a CRAFT Group format. Each group will meet for 90 minutes weekly and will be completed within 2 months. The group content is based on the CRAFT techniques described by a training manual written by Roozen, Smith and Meyers (2015). Furthermore the CSOs in this condition will also receive a Dutch version of the CRAFT self-help book (Self Directed CRAFT Delivery), Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). Groups will engage in a combination of didactic teaching, role-play of new communication styles and discuss their experiences utilizing CRAFT skills."
2558329|NCT02510508|Active Comparator|Self-Directed CRAFT Delivery|"CSO's allocated to the Self- Directed CRAFT Delivery will receive the Dutch version of the CRAFT self-help book, Get your loved one sober: Alternatives to nagging, pleading and threatening (Meyers & Wolfe, 2012). The book helps CSO's how to utilize the CRAFT model in their daily lives. It includes guidelines for responding to IP behavior, improving positive communication skills, improving the CSO's own well-being and explains how to engage the IP into treatment."
2558333|NCT02510508|No Intervention|Non-intervention|Participants assigned to the non-intervention condition will be placed on a Group CRAFT waiting list.
2558395|NCT02509897|Active Comparator|Hypoxic training|Endurance training
2558399|NCT02509897|Placebo Comparator|Normoxic training|Endurance training
2558559|NCT02508766|Experimental|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
2558564|NCT02508766|No Intervention|Control group|Volunteers received no intervention. They just sat there for 20 minutes before being evaluated.
3171529|NCT00588185|Experimental|1|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
3171530|NCT00588198||1|Melanoma patients
2558661|NCT02508155|Experimental|MEDI7352 IV|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
2558665|NCT02508155|Placebo Comparator|IV Placebo|Up to 11 cohorts of subjects are planned to be dosed by IV infusion, with single and multiple ascending doses.
2558666|NCT02508155|Experimental|MEDI7352 Subcutaneous Injection|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
2558668|NCT02508155|Placebo Comparator|Subcutaneous Placebo|1 cohort of subjects is planned to be dosed by subcutaneous injection, one single ascending dose cohort.
2558721|NCT02507830||Glubran 2 fixation|Mesh fixation with Glubran 2 glue in primary inguinal hernia repair
2558756|NCT02507557||Before GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record prior to the start of the training curriculum.
2558757|NCT02507557||After GDFM Training|About 200 patients' medical record information will be extracted from the 1st Affiliated Hospital of Chongqing Medical University electronic medical record after the training program took place
2558788|NCT02507232|Active Comparator|Arm A|NovoTTF-200A
2558789|NCT02507232|Active Comparator|Arm B|NovoTTF-200A + Temozolomide 50 mg/m2 daily (oral)
3171531|NCT00588211||1|We will recruit fifteen New York University College of Dentistry (NYUCD) clinic patients who report current tobacco use.
2558912|NCT02506218|Experimental|10 + 20 g protein consumption|10 g breakfast followed by the consumption of a 20g whey protein shake
2558913|NCT02506218|Active Comparator|30 g protein breakfast|
2558914|NCT02506218|Active Comparator|10 g protein breakfast|
3171532|NCT00588211||2|Second, we will recruit thirty dental clinic smokers (10 per day for 3 days) from the NYUCD waiting room.
3171533|NCT00588211||3|Third, we will survey 200 student participants from Adelphi University.
3171534|NCT00588211||4|Queens Hospital Center with 800 patients.
3171535|NCT00588224||1|adults
3171536|NCT00588224||2|adolescents
3171537|NCT00588250|Experimental|A|
3171538|NCT00588250|No Intervention|B|
3171539|NCT00588276|Experimental|1|Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).
3171540|NCT00588302|Experimental|A, 1|All patients received an open-label moexipril during the study period.
3171541|NCT00588315||skin lesions|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
3171542|NCT00588315||normal skin|The integrated dermoscopic-and-confocal microscopic video-mosaics will be used to compare morphologic patterns and cellular patterns to each other and to the corresponding pathology
3171543|NCT00588328|Experimental|1|
3171544|NCT00588367||1|Suspected pancreatic ductal adenocarcinoma.
3171545|NCT00588367||2|Chronic pancreatitis and slated for decompression treatment.
3171546|NCT00588367||3|Autoimmune pancreatitis.
3171547|NCT00588419||1|Patients who have undergone mastectomy Patients who have undergone immediate, twostage expander/implant breast reconstruction; Patients who have undergone immediate, autogenous tissue flap reconstruction including: pedicled and/or free TRAM flap or DIEP flap reconstruction
3171548|NCT00588432||1|Hemiparesis as the result of an ischemic hemispheric stroke.
3171549|NCT00588432||2|Immobilization following severe Achilles tendon tear or rupture, ankle injury or plantar fascial pain.
3171550|NCT00588432||3|Myofascial trigger points in trapezius muscle.
3171551|NCT00588432||4|Hyperthyroid Myopathy
3171552|NCT00588458|Experimental|single arm|All patients with PSC in will have CT cholangiography.
3171553|NCT00588484||1|Men, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
3171554|NCT00588484||2|Women, age 35 to 65, being seen at the Mayo Clinic Department of Cardiovascular Health clinic, or has an appointment for a carotid duplex ultrasound exam.
2558106|NCT02511873|Placebo Comparator|Placebo|Inactive ingredient equal to 2mg tablets
3205942|NCT00949065|Active Comparator|Intravenous immunoglobulins (IvIg)|3 x 0.36-0.44g/Kg IvIg every 4 weeks, then 3 months washing out, then 3x NaCl 0.9% every 4 weeks
3205943|NCT00949065|Placebo Comparator|NaCl 0.9%|NaCl 0.9%, 3x, every 4 weeks, then 3 months washing out, then 0.36-0.44g/Kg IvIg, 3x, every 4 weeks
3205944|NCT00949091|Experimental|1|
2558259|NCT02510937|Experimental|Low dose CC-90001|Low dose (100 mg) CC-90001 administered orally once daily (QD) for 12 continuous weeks
2558263|NCT02510937|Experimental|High dose CC-90001|High-dose (200 mg) CC-90001 administered orally Once Daily (QD) for 12 continuous weeks
2558309|NCT02510365|Experimental|Functional collagen scaffold|Functional neural regeneration collagen scaffold transplantation.
3205945|NCT00949104|Active Comparator|Sucrose|1 ml of 24% sucrose was administered 2 minutes before the procedure
3205946|NCT00949104|Placebo Comparator|Placebo|Double distilled water
3205947|NCT00949130|Experimental|NXL103|BID for 7-14 days orally
2558480|NCT02509286|Experimental|Perioperative Chemotherapy (FLOT):|"The FLOT Arm consists of the FLOT protocol, which consists of 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel. Repetition every 2 weeks (d15, q2w). Four neoadjuvant cycles (8 weeks) prior to surgery and four adjuvant cycles (8 weeks) postoperatively are given.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
2558483|NCT02509286|Active Comparator|Neoadjuvant Chemoradiation (CROSS):|"The CROSS Arm consists of the CROSS protocol, which consists of neoadjuvant radiation therapy (41.4Gy / 23fractions) and concurrent chemotherapy with Carboplatin and Paclitaxel (5 weeks) prior to surgery.~Surgery is carried out by transthoracic subtotal esophagectomy or by transabdominal distal esophageal resection plus gastrectomy depending on tumor localization."
2558550|NCT02508779|Experimental|Bump2Be|Blood Glucose Awareness Training for pregnancy or preconception
2558555|NCT02508779|Active Comparator|Routine Care|Routine care provided by subject's medical team
2558605|NCT02508467|Experimental|Fisogatinib (BLU-554)|Fisogatinib (BLU-554) capsules for oral administration.
2558707|NCT02507960|Other|Pilot Study|The patient will undergo a conventional CT simulation in supine position without the breast immobilization cup. The purpose of the CT simulation is-two-fold: 1) the investigators will see if the TB volume can be accurately delineated and if the TB volume is too large for Gamma Pod boost; and 2) the CT images are used for planning the patient's whole breast irradiation. If, after viewing the CT images and the patient is deemed a study candidate and consents, the participants will receive a second CT-sim and the Gamma Pod TB boost treatment on the same day as described below.
2558736|NCT02507622|Other|gas concentration|Gaz concentration of C02, CO and NH4, 3 exhaled in weightlessness and normal gravity.
2558775|NCT02507401||Total laryngectomy patients|Users of voice prostheses
2558812|NCT02507115|Experimental|TMAP|Alcohol-related Text messages 4 days/week for 6 weeks
2558818|NCT02507115|Sham Comparator|Control|Motivational Text messages 4 days/week for 6 weeks
2558862|NCT02506777|Experimental|FDC x 6 cycles with metformin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID
2558875|NCT02506777|Experimental|FDC x 6 cycles with melatonin|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily
2558879|NCT02506777|Active Comparator|FDC x 6 cycles|32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days
2558947|NCT02506205|Experimental|LSVT LOUD|LSVT LOUD was developed based on concepts of neuroplasticity, motor learning, skill acquisition and motor speech. LSVT LOUD trains laryngeal and respiratory functions through loud and effortful phonatory tasks (Ramig, Sapir, Countryman, Pawlas, O'Brien, Hoehn, & Thomson, 2001). It targets vocal intensity via stimulation of effortful speech productions with multiple repetitions and through encouraging self-calibrations of loud voice by patients. LSVT LOUD cues patients to speak loud (e.g., Fox et al., 2002; Ramig et al., 2001; Sapir et al., 2007). Having a single cue may increase treatment effects, as it reduces cognitive load in adults with PD because some of them develop cognitive deficits when PD progresses (Fox et al., 2002). Treatment is intensive, consisting of 4 individual sessions a week for 4 weeks, with 16 sessions in one month.
2558993|NCT02505854|Active Comparator|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin
2558998|NCT02505854|Active Comparator|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide
2559003|NCT02505854|Placebo Comparator|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin
2559058|NCT02505321|Experimental|fATDIVA - OTTT (Cases)|"Individuals identified with the polygenic lipodystrophy genetic variants of interest will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
2559061|NCT02505321|Experimental|fATDIVA - OTTT (Controls)|"Control individuals carrying the average number of risk alleles and matched to individuals identified with the polygenic lipodystrophy genetic variants of interest for gender, age and BMI, will undergo the Oral Triglyceride Tolerance Test (OTTT) plus an abdominal fat biopsy (optional). Case/control status will be unblinded at analysis."
3205948|NCT00949130|Active Comparator|Linezolid|BID for 7-14 days orally
2559118|NCT02504814|Experimental|ventilatory effects|measuring mean airway pressure, breathing volumes and decrease in hypercapnia
3205949|NCT00949143|Experimental|forward position|
3205950|NCT00949143|Experimental|rear position|
3205951|NCT00949156||Retrospective cohort|The 198 cases of CP with primary surgery in our hospital (since July, 1997 until now) were divided into three topographical groups based on the pre-operative MRI, intraoperative findings and the tumor-membrane relationship. The presurgical manifestation, the different surgical approach, intraoperative techniques, and postoperative complication were described and analyzed to establish a normalized surgical treatment of individual CP patient, which has the highest rate of the totally tumoral resection and the lowest rate of the hypothalamic injury.
3208828|NCT00978484|Experimental|Dynamic Virtual Reality|Virtual Reality Exposure Therapy using full, immersive Virtual Reality
2558179|NCT02511366|Placebo Comparator|ileal infusion of tap water|ileal infusion of tap water
3171555|NCT00588497||Study Group|Twenty-five subjects for this study will be recruited from patients who have requested a form of permanent sterilization, and who, after considering all the options, choose the trans-cervical hysteroscopic sterilization for this end. Any subject who is deemed suitable for the micro-insert hysteroscopic sterilization system (Essure micro-insert system, Conceptus Incorporated, Mountain View, California) placement will be offered the opportunity to participate in the study.
3171556|NCT00588510||Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible.
2558489|NCT02509221||Less than 30 minutes|
2558491|NCT02509221||30-60 minutes|
2558492|NCT02509221||More than 60 minutes|
3208829|NCT00978497|Placebo Comparator|1|Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
2558551|NCT02508753|Experimental|CXA-101/tazobactam therapeutic dose|
2558554|NCT02508753|Experimental|CXA-101/tazobactam supra-therapeutic dose|
2558560|NCT02508753|Active Comparator|Moxifloxacin|
2558563|NCT02508753|Placebo Comparator|Placebo|
2558606|NCT02508415|Experimental|Non Surgical Periodontal Therapy|Will receive oral hygiene education, scaling and root planing. OHE includes brushing and flossing techniques, chlorhexidine mouth rinse twice a day
2558609|NCT02508415|No Intervention|No Non Surgical Periodontal Therapy|No treatment received
2558664|NCT02508142|Active Comparator|Hyoscine-N-Butylbromide|20 mg Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL)
2558667|NCT02508142|Placebo Comparator|Placebo|100 mL normal saline
2558710|NCT02507895|Experimental|MI-BCI training|subjects will undergo 12 sessions over 4 weeks of MI-BCI training
2558737|NCT02507648|Experimental|A Test|Test drug (Oseltamivir) 1 tablet contains 75 mg Oseltamivir
2558738|NCT02507648|Active Comparator|B Reference|Reference drug (Tamiflu®) 1 tablet contains 75 mg Oseltamivir
3208830|NCT00978497|Experimental|2|ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
2558894|NCT02506517|Experimental|Afatinib|Afatinib, orally, at a dose of 40 mg once a day, every day of each 28 day cycle.
2558930|NCT02506322|Experimental|SEKT Cognitive-Behavioral-Emotional|Specific psychotherapy (SEKT - 4 modules) for typical problems of Bipolar patients to maintain remission and to prevent relapse. Including classical elements of self observation, psychoeducation, cognitive and behavioral interventions, social rhythm but also emotion regulation and meta-cognitive techniques. Delivered in a group setting in 4 one day treatment workshops, each one month apart. Homework assignment and electronical monitoring during time between sessions.
2558937|NCT02506322|Active Comparator|FEST Clinical Supportive Educational|This supportive, active control psychotherapy (FEST) is using general principals and non-specific interventions such as positive attitude, optimism, support, empathy, focus on emotion, self-help, strengthening and eliciting own resources, time and room for discussion of personal experiences. Psychoeducation about illness and drug treatment (mood stabilizer) to facilitate compliance.
2558995|NCT02505893|Experimental|Treated|The investigational treatment will be islet transplant in the presence of induction with ATG/G-CSF and rapamycin treatment for one month. One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver. ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant. Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion. Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
2559289|NCT02503826|Experimental|1.5 SF|Sufentanil,1.5mcg/kg
2559290|NCT02503826|Experimental|2.0 SF|Sufentanil, 2.0mcg/kg
2559291|NCT02503826|Experimental|2.5 SF|Sufentanil, 2.5mcg/kg
2559379|NCT02503670|Other|HealthyDads.ca web-based program|An on-line self-help psychoeducational website tailored to new dads. Psychoeducational learning modules and tools, including a 6 week physical activity challenge..
2559385|NCT02503670|Other|Control group|No access to the intervention. Will complete the same questionnaires as the Healthydads.ca group over the study period.
2559416|NCT02503137|Experimental|Experimental Arm 1|Topical SM04554 0.15% solution, once daily for approximately 90 days
2559417|NCT02503137|Experimental|Experimental Arm 2|Topical SM04554 0.25% solution, once daily for approximately 90 days
2559419|NCT02503137|Placebo Comparator|Vehicle|Topical vehicle solution, once daily for approximately 90 days
3171557|NCT00588523|Experimental|1|temozolomide followed by high dose busulfan and thiotepa
2559533|NCT02502227|Active Comparator|Mindfulness Training|Mindfulness training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
2559537|NCT02502227|Active Comparator|Mindful Attention Only Training|Mindful attention only training intervention consisting of eight weekly 2.5 hour group sessions, a day-long retreat in the sixth week, and daily home mindfulness meditation
2559544|NCT02502227|No Intervention|No Treatment Control Condition|No treatment participants will be informed that their participation is important and that they are requested to not seek out similar treatments during this waiting period.
3171558|NCT00588562||Primary Hyperoxaluria patients|Registry will include data on patients with confirmed diagnosis of Primary Hyperoxaluria.
3171559|NCT00588562||Dent Disease Patients|Registry will include data on patients with confirmed diagnosis of Dent Disease.
3171560|NCT00588562||Cystinuria Patients|Registry will include data on patients with confirmed diagnosis of Cystinuria.
3171561|NCT00588562||APRT deficiency Patients|Registry will include data on patients with confirmed diagnosis of APRT deficiency.
3171562|NCT00588588|Active Comparator|1|Bronchoscopy
3171563|NCT00588588|Active Comparator|2|CPIS
3171564|NCT00588627||1|Post Nasal Drip and chronic cough
3171565|NCT00588627||2|Post nasal drip and no cough
3171566|NCT00588653|Active Comparator|1|All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.
2558228|NCT02511145|No Intervention|Normal skin|Normal skin control mini-zone
2558249|NCT02510651|Experimental|ORSHFS|Melanocyte-keratinocyte suspension.
2558280|NCT02510547|Active Comparator|CrossBoss Catheter|Crossing the CTO with upfront use of the CrossBoss catheter
2558284|NCT02510547|Active Comparator|Antegrade Wire Escalation Strategy|Crossing the CTO with upfront antegrade wire escalation strategy
2558349|NCT02510222|Experimental|Oral Magnesium sulfate|Magnesium sulphate 4% concentration orally ( 65 mg per day for children one to three years of age; 110 mg per day for children four to eight years of age; 350 mg per day for children older than eight years) for 1 month
2558353|NCT02510222|Placebo Comparator|Control|Fifty children with cerebral palsy will be treated with conventional therapy as physiotherapy. They will receive placebo.
2558402|NCT02509728|Active Comparator|standard nutrition|standard nutrition
2558404|NCT02509728|Experimental|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
2558405|NCT02509728|Experimental|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
2558409|NCT02509728|Experimental|choline and DHA supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days
2558463|NCT02509377|Experimental|BMI 35.0 to 40.0|"Mothers who meet all inclusion exclusion criteria for open fetal repair of myelomeningocele except BMI.~These mothers have a BMI between 35.0 and 40.0"
3205952|NCT00949156||Prospective cohort|The anticipated 40 cases of CP were surgical treated by our standard procedure, which is recruited in the prospective cohort. With the long-term follow up, QOL including the cognition, circadian rhythm, endocrine, Water-Electrolyte, and body weight et al were evaluated to assess the rationality of the treatment. Then according to the results, the surgical treatment was modified, and the endocrinic substitution therapy was also been developed.
3205953|NCT00949169||Carrotid IMT group according to maximal IMT|We defined increased IMT group as whom had maximal IMT ≥ 1.0 mm.
3205954|NCT00949182|Experimental|Sorafenib Tosylate, Doxorubicin, Mytomicin C|Micro and Macro arteriolar blockade of hepatocellular carcinoma (HCC): Treatment with Sorafenib 400mg two weeks prior to embolization HACE which includes the use of agents such as Doxorubicin Hydrochloride and Mytomicin C, continuing same Sorafenib dose after the procedure (dose adjustment according to tolerance).
3205955|NCT00949195||COPD patients|COPD patients with severe obstruction performed the tests.
3205956|NCT00949195||Healthy subjects|Age-matched healthy subjects performed the same test also.
2558853|NCT02507154|Experimental|Cetuximab + NK cells|During cycle 1, patient will receive intravenous cetuximab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, with subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo. Following NK cell infusion, cetuximab will be administered weekly for another 2 weeks. During cycle 2 and 3, one cycle of cetuximab monotherapy will be administered 3 weeks apart. Patients who demonstrate objective tumor response or stable disease after cycle 3 will receive a second infusion of NK cells along with cetuximab during cycle 4 therapy at the same dose and schedule as in cycle 1. This will be followed by 2 additional cycles of cetuximab monotherapy (3 weeks apart).
2558895|NCT02506530|Active Comparator|intensive decongestive treatment (IDT)|Patients will receive an intensive decongestive treatment for 5 days
2558896|NCT02506530|Experimental|IDT + Cellu M6|Patients will receive an intensive decongestive treatment + Cellu M6 for 5 days
2558897|NCT02506530|Active Comparator|Cellu M6 + bandages|Patients will receive an bandages + Cellu M6 for 5 days
2558908|NCT02506179||Open-label cohort|Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
3205957|NCT00949208||A|The study population will consist of healthy volunteers who fulfill all the inclusion criteria and do not meet any of the exclusion criteria.
3208831|NCT00978497|Experimental|3|ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks
2559059|NCT02505295|Active Comparator|selenium|vial selenium (selenase 500 microgr ) 2000 microgram stat and 1000 microgram daily for 5 days
2559062|NCT02505295|Placebo Comparator|normal saline|40 cc normal saline stat and 20 cc daily for 5 days( in vials like selenase vial)
2559243|NCT02504255||Patients with Crohn's Disease|patients will have biological samplings (blood, urine and faecal sampling) and will fill questionnaires to assess their stress and adaptation
2559318|NCT02504034|Experimental|Transhepatic portosystemic shunt|Patients with cavernous transformation of portal vein undergo transhepatic portalsystemic shunt and other interventional radiology treatment
2559362|NCT02503488|Experimental|Program Group|The treatment arm will consist of 20 randomly selected participants who will receive Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET) for their traumatic symptomology, aggression, and depression. FORNET consists of a guided exposure of the participant's traumatic experiences in chronological order and integrating them into a coherent biographical memory.The intervention addresses the participant's positive, negative, and violent memories of events that have taken place during their lifetime, and also provides participants an opportunity to asses their current situation and future plans. FORNET can be completed in six sessions and each session lasts 90 minutes on average.
2559367|NCT02503488|Active Comparator|Treatment As Usual (TAU)|Participants in the TAU group will receive group and individual psycho-social support from trained peer-support workers, with 10 sessions occurring throughout the course of the intervention for each participant. In addition, there will be sensitisation trainings as well as mentoring for establishing greater financial independence. Last, TAU will include one-day events promoting social cohesion and peace.
2559435|NCT02503163|Experimental|KCT-0809|
2559476|NCT02502760|Experimental|Prehabilitation|"Immediately after randomization and until surgery, patients in this arm will:~- Receive a personalized physical exercise program~- Receive nutritional counselling with Whey protein isolate powder~- Receive relaxation techniques"
2559480|NCT02502760|Active Comparator|Rehabilitation|Patients in this arm will receive the same personalized physical exercise program, nutritional intervention and relaxation techniques as patients in the other arm but to be started after surgery.
2559525|NCT02502331|Experimental|study group|Test Oral Cholera Vaccine
2558258|NCT02510924|Experimental|Tracheal intubation with Airtraq Mobile|Tracheal intubation with Airtraq Mobile
2558311|NCT02510443||BAY1454032|All subjects who give their consent and meet the eligibility criteria will be scheduled for an insert placement procedure
2558379|NCT02510131|Active Comparator|Pelvic floor exercise|"Participants randomized to Kegel's exercises will be asked to contract their pelvic floor muscle for 1-10 seconds, followed by 10 seconds' relaxation.~Length of duration of exercise is tailored to individual's ability in contracting her pelvic floor muscle.~Each cycle is equivalent to 1 contraction and 1 relaxation phase. Participants will be asked to perform 3 sessions per day, and to perform their Kegel exercises at home daily.~1 session of Kegel's exercise is consists of 20 cycles of slow twitch fibre contraction and 30 repetitions of fast twitch fibre for 1 minute."
2558384|NCT02510131|Experimental|Hyacinth exercise|"In this arm participants are also taught Kegel's exercises but will be additionally taught extra steps which mirrored Muslim's praying steps.~As well as their Kegel's exercises, participants will be asked to perform the extra steps at least 63 minutes per week.~Participants may choose to perform these at the same time or at a different time from their Kegel's exercises. Participants will be asked to perform 1 cycle (3 minutes and 1 second) for 3 sessions a day for daily.~Each cycle is consists of repetition of 4 positions: standing upright- 90 degree bow- prostration-sitting."
2558423|NCT02509598|Experimental|Tc99m tilmanocept and Vital Blue Dye (optional)|0.5 mCi, 50 ug of Tc99m tilmanocept single administration. Optionally, 1-3 mL of vital blue dye, single administration (per institution's standard of care).
2558525|NCT02509052|Experimental|Treatment (leflunomide)|Patients receive leflunomide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2558590|NCT02508506|Experimental|ALKS 5461|Sublingual tablet
3205958|NCT00949221|Other|Group 1|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months
3205959|NCT00949221|Other|Group 2|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intensive strategy using continuous glucose monitoring for 12 months
2558763|NCT02507609|Active Comparator|M group|moderate neuromuscular blockade group by intermittent injection of rocuronium bromide
2558768|NCT02507609|Active Comparator|D group|deep neuromuscular blockade group by continuous infusion of rocuronium bromide
2558819|NCT02507102|Experimental|Investigational Voyager Therapy|Investigational treatment with Voyager Therapy
2558934|NCT02506231|Experimental|Folinic acid|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
2558942|NCT02506231|Placebo Comparator|Placebo|Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.
2559025|NCT02505438|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
2559026|NCT02505438|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
2559027|NCT02505438|Experimental|Old Unilateral Exercise and HMB|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with HMB (beta-hydroxy-beta-methylbutyrate) supplementation
2559028|NCT02505438|Experimental|Old Unilateral Exercise and Omega 3|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training with Omega 3 supplementation
2559047|NCT02505204|Experimental|Clonidine|Will receive bilateral PVB with clonidine.
2559051|NCT02505204|Placebo Comparator|Placebo|Will receive bilateral PVB with placebo.
2559136|NCT02504970||Anesthesia Group Type|AQI collects data from anesthesia groups. The groups are classified according to practice type
2559190|NCT02504489|Active Comparator|Docetaxel (D)|A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
2559194|NCT02504489|Experimental|Docetaxel + Plinabulin (DP)|The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade >1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
2559317|NCT02503800||subjects undergoing venom immunotherapy|The study group will include all the subjects receiving routine venom immunotherapy at the Meir Medical Center Allergy Clinic.
2559345|NCT02503592|Active Comparator|Cochlear Implant group - Vestibular testing|Adult patients who have been implanted with a Med-El Cochlear implant device within the last 3 months who completed pre-op vestibular testing as standard of care. These subjects will undergo a series of post-op vestibular testing, at the 3 month and 12 month follow up visits
2559346|NCT02503592|No Intervention|Control Group - existing historical vestibular data|This group will consist of existing historical vestibular testing data only. No subjects will be enrolled on this arm.
2559387|NCT02503358|Experimental|Arm I (continuous selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-21 and paclitaxel IV over a fixed rate on days 1 and 8.
2559526|NCT02502331|Active Comparator|comparator group|Euvichol®
2558292|NCT02510612|Experimental|Dexmedetomidine|Patients in group D will be given dexmedetomidine during anesthesia induction and maintenance phase respectively.In induction phase infuse 1μg/Kg of dexmedetomidine in 10 minutes， the speed in maintenance phase is 0.4μg/Kg.h
2558294|NCT02510612|Placebo Comparator|placebo|Patients in group P will be given normal saline during anesthesia induction and maintenance phase
2558320|NCT02510248|Experimental|Study Drug|Study drug will be AL-704 once or twice daily for up to 7 days in dosages ranging from 100 mg to 1500 mg.
2558326|NCT02510248|Placebo Comparator|Placebo|Placebo to match study drug dosing.
3205960|NCT00949221|Other|Group 3|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE: Intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
3205961|NCT00949247|Experimental|Docetaxel,Carboplatin,Trastuzumab and Bevacizumab|
3205962|NCT00949260||Normal, Non-Pregnant|Normal, non-pregnant patients will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3205963|NCT00949260||Normal, Pregnant|Normal, pregnant patients in their 3rd trimester will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3205964|NCT00949260||Pregnant, PIH|Pregnant patients in their 3rd trimester with pregnancy-induced hypertension that has not been treated will have 15 minutes of monitoring at rest, followed by a passive leg raising test.
3205965|NCT00949273||cylindrical abdominoperineal resection|patients underwent cylindrical abdominoperineal resection for advanced very low rectal cancer
3205966|NCT00949273||abdominoperineal resection|patients underwent conventional abdominoperineal resection for advanced very low rectal cancer
3205967|NCT00949312||Stage II unresected Colon Cancer|
2558579|NCT02508714|Active Comparator|Orsiro DES (Biotronik)|The ORSIRO hybrid coating DES (Biotronik, Switzerland) is a device which includes a modern, highly flexible, thin-strut stent platform, eluting sirolimus from a thin biodegradable BIO-lute coating grom PLLA (poly(L-lactic acid)) which is located mainly on the abluminal side.
2558580|NCT02508714|Active Comparator|RESOLUTE ONYX DES (Medtronic)|The RESOLUTE ONYX is a permanent polymer DES that uses a novel highly flexible metallic stent backbone with increased radiographic visibility eluting the drug zotarolimus from the BioLinx durable polymer coating. The stent platform uses corewire technology that allows the stent to have a denser core metal surrounded by outer layer of cobalt-chromium.
3205968|NCT00949338|Active Comparator|Arm I|Patients empty their bladders and consume 6 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a bladder volume instrument (BVI) periodically during treatment.
3205969|NCT00949338|Experimental|Arm II|Patients empty their bladders and consume 3 cups of water 30 minutes before undergoing radiotherapy. Patients also undergo bladder volume measurements using a BVI periodically during treatment.
2558802|NCT02507180||Pregnant women with suspected DVT|Pregnant women presenting with suspected DVT will have the LEFt clinical decision rule applied by the attending physician and will have a clinical D-dimer test done.
2558887|NCT02506855|Experimental|Group A|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and anesthetic will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: Ropivacaine 75mg - 150 mg on each side (20mL ropivacaine 3.75mg/ml each side)~Weight greater than or equal to 70kg: Ropivacaine 100mg - 200mg on each side (20mL ropivacaine 5mg/ml each side"
2558891|NCT02506855|Placebo Comparator|Group B|"Study participants will undergo intraoperative transversus abdominis plane (TAP) block with the syringe of medication supplied by the pharmacy using a syringe with attached spinal needle between the transversus abdominis and internal oblique. The spinal needle will be threaded horizontally and as far laterally at the superior aspect of the vertical axis of the incision as possible within this space and the placebo solution will be injected after an initial pull back on the syringe to ensure there is no arterial exposure as per the following schedule:~Weight <70kg: 20mL each side~Weight greater than or equal to 70kg: 20mL each side"
3205970|NCT00949351|Placebo Comparator|Aliskiren|
3205971|NCT00949364|Experimental|Pomalidomide|Every patient will remain on treatment until disease progression for at least 12 cycles, withdrawal of patient's informed consent or the occurrence of unacceptable toxicity. If a patient may benefit from treatment with pomalidomide the investigator together with the principle investigator will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision. This additional treatment will be performed within the follow-up period of the study, data will be collected and duration will be maximally 12 cycles.
3205972|NCT00949377|Experimental|Methylnaltrexone Bromide|
3205973|NCT00949377|Placebo Comparator|Normal Saline|
2559012|NCT02505633|Experimental|2P2I group|subcutaneous injection is done widely. A nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach. After the needle is penetrated the nerve sheath with a direction of downward, the nerve stimulator is then turned on. If hand muscle twitching is observed even at 0.3 mA, LA 15 mL (lidocaine mixed with epinephrine) is injected. After that, the stimulating needle is re-advanced at the behind site of the initial puncture site. And the needle is penetrated the nerve sheath with a direction of upward, and then the same process is performed and LA 15 mL is injected.
2559015|NCT02505633|Active Comparator|1P1I group|After subcutaneous injection of 1 mL of 2% lidocaine, a nerve stimulating needle (Stimuplex insulated needle; D Plus B. Braun, Melsungen, Germany) attached to a nerve stimulator (Stimuplex HNS12; B. Braun, Melsungen, Germany) is advanced via an ultrasound in-plane approach from lateral to medial direction. After the needle is penetrated the nerve sheath, the nerve stimulator is then turned on, and the stimulation current starts at 0.5mA. If hand muscle twitching is observed even at 0.3 mA, local anesthetics 30 mL (lidocaine mixed with epinephrine) is injected.
2559072|NCT02505386|Active Comparator|Ertapenem IV|IV administration of ertapenem
2558378|NCT02510092|Active Comparator|Coronary artery diseae with revascularization indicated|Subjects with coronary artery disease, that require and are eligible for percutaneous revascularization.
2558385|NCT02510092|No Intervention|Coronary artery disease not requiring revascularization|Subjects with coronary artery disease that do not require revascularization.
3205974|NCT00949390||Phase I and CAM Survey|Complementary and alternative medicine (CAM) in patients with advanced malignancies currently treated on University of Texas MD Anderson Cancer Center Phase I clinical trials.
3205975|NCT00949442|Experimental|1|"Before randomization (common with arm 2):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: Insulin Glargine + OAD(s) at stable dose"
3205976|NCT00949442|Active Comparator|2|"Before randomization (common with arm 1):~2 weeks of Screening phase: Oral Anti Diabetics (OAD) 2 weeks of Run-In phase: switch of OAD (Sulfonylurea (except Glimepiride), glinides or alpha-glucosidase inhibitor) to Glimepiride~After randomization:~36 weeks of study treatment phase: NPH + OAD(s) at stable dose"
2558556|NCT02508727|Other|Healthy volunteers|Healthy volunteers
2558562|NCT02508727|Other|Subjects with an anterior myocardial infarction sequela|Subjects with an anterior myocardial infarction sequela
2558566|NCT02508727|Other|Subjects with lower myocardial infarction sequelae|Subjects with lower myocardial infarction sequelae
3205977|NCT00949455|Experimental|Arm I|Patients receive oral lapatinib ditosylate once daily in the absence of disease progression or unacceptable toxicity.
3205978|NCT00949455|Placebo Comparator|Arm II|Patients receive oral placebo once daily in the absence of disease progression or unacceptable toxicity.
3205979|NCT00949468||Keratitis group|37 patients with keratitis
2558769|NCT02507440|Active Comparator|Viscous Lidocaine|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of 2% lidocaine viscous solution and swallow.
2558771|NCT02507440|Placebo Comparator|Placebo|Five minutes prior to intravenous sedation the patients will be asked to gargle with 7.5 ml of placebo and then swallow. Placebo will be 3% methylcellulose which will be flavored and colored to match the characteristics of 2 % lidocaine.
2558810|NCT02507089|Experimental|Intervention|In this arm, the participants will receive access to a password protected website that features tailored information and educational materials on sleep health and the signs of sleep disorders such as obstructive sleep apnea (OSA). There will be both text-based information on sleep health and OSA, and also videos depicting narrative stories about patients who have been diagnosed with OSA and sought treatment.
2558811|NCT02507089|Active Comparator|Control|In this arm, participants will receive access to generic sleep educational materials that do not feature linguistic or cultural tailoring to the target population. This arm will include access to the same general information (materials on sleep health, sleep disorder signs and symptoms) but be intended for a general audience.
2558863|NCT02506738|Active Comparator|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
2558874|NCT02506738|No Intervention|Control|Patients in the control group received the usual care.
2558940|NCT02506452|Active Comparator|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading device
2558945|NCT02506452|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading device
2558975|NCT02505815||Regional Anesthesia|Patients with surgery in regional anesthesia.
2558976|NCT02505815||General Anesthesia|Patients with surgery in general anesthesia.
2559029|NCT02505490|Experimental|No Television|The purpose is to determine whether a change in liking of food will occur with a lack of television.
2559030|NCT02505490|Experimental|Television|The purpose is to determine whether a change in liking of food will occur while watching television.
2559159|NCT02504801|Active Comparator|nebulized Budesonide 2mg/4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
2559162|NCT02504801|Placebo Comparator|nebulized saline 4mL|+terbutaline 5mg/2mL,BID+ipratropium 2 puff(40ug)BID
2559231|NCT02504372|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg, intravenously (IV), every 3 weeks, for one year (expected maximum 18 doses).
2559232|NCT02504372|Placebo Comparator|Placebo|Participants receive placebo, IV, every 3 weeks, for one year (expected maximum 18 doses).
2559267|NCT02504125|Experimental|Receving TXA, Study group|Tranexamic acid, Study group tranexamic acid 1g, intravenous injection, pre-operationally
2559270|NCT02504125|Placebo Comparator|Normal saline, Control group|Not receiving tranexamic acid, Control group Normal saline 100mL, intravenous injection, pre-operationally
3205980|NCT00949468||Control Study Group|37 control volunteers
3205981|NCT00949481|Experimental|Supply|In each country, this arm will be comprised of women attending family planning clinics within the 5 facilities randomized to this group.
3205982|NCT00949481|Experimental|Demand|In each country, this arm will be comprised of women attending immunization clinics within the 5 facilities randomized to this group.
2559397|NCT02503280|Experimental|Group A - Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs. The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
2559399|NCT02503280|Experimental|Group B - Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
2558332|NCT02510378|Experimental|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
3205983|NCT00949481|No Intervention|Control|In each country, this arm will be comprised of women attending family planning and immunization clinics in 5 facilities randomized to this group.
3205984|NCT00949494|Active Comparator|Synvisc|
3205985|NCT00949494|Placebo Comparator|Placebo|
2559081|NCT02505152|Experimental|Shunt|Perform percutaneous transhepatic intrahepatic portosystemic shunt
2559248|NCT02504346|Experimental|Treatment|Non-randomized trial, all patients receive therapy - singel-arm
3205986|NCT00949507||anaesthesia using propofol|the children are anaesthetized using intravenous anaesthesia with propofol and remifentanil; a binasal catheter is used for administration of oxygen during the anaesthesia
2559401|NCT02503267||patients with congenital heart disease|patients with congenital heart disease
2559411|NCT02503033|Experimental|HMPL-523|"Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.~At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily."
2559477|NCT02502825|Experimental|asthma|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Wright nebulizer for 2 minutes with an output of 0.13ml/min.
2559479|NCT02502825|Experimental|normal controls|methacholine(0.031-16mg/ml) bronchial provocation tests. this is a crossover,normal-control study. nebulized with Devilbiss646 nebulizer for 2 minutes with an output of 0.13ml/min
2559540|NCT02502344|Experimental|medical intervention group|subjects in this group will accept healthy lifestyle changes such as food control and intensive exercise for 3 months first. Then their insulin resistance will be evaluated again . If their insulin resistance didn't improve, then they will take metformin 0.5g qd to reduce insulin resistance. If their insulin resistance improved, they will continued healthy lifestyle changes.
2559550|NCT02502344|No Intervention|clinical observeral group|subjects in this group will not accept medical interventions
3205987|NCT00949507||anaesthesia using sevoflurane|the patients are anaesthetized using sevoflurane 1 MAC; a laryngeal mask is used
2559815|NCT02500693|Experimental|Screening|
3205988|NCT00949546||placebo controlled|A randomized, double-blind trial of 3 months duration comparing etanercept 50 mg sc twice weekly to placebo in 20 patients with HS. Patients will be randomized with equal allocation to the two treatment groups.
3205989|NCT00949572|Experimental|Intramuscular administration|Intramuscular injection of HPV vaccine proteins
2559960|NCT02499822|Experimental|Nifedipine GITS 30 mg slow release|Nifedipine GITS 30 mg slow release in tablets.
2559962|NCT02499822|Experimental|Ramipril 10 mg|Ramipril 10 mg in tablets.
2559989|NCT02499523|Active Comparator|THR with conventional technique|Use of conventional technique in THR
2559996|NCT02499523|Experimental|THR with ACOG|THR with Acetabular Cup Orientation Guides (ACOG)
2560095|NCT02499055|Experimental|FearFighter|The experimental group will use the program FearFighter™.
2560096|NCT02499055|No Intervention|Control group|The control group receive no intervention for nine weeks.
2560127|NCT02498756|Experimental|IP plus CIK|Patients receive ipilimumab and CIK.
2560134|NCT02498756|Active Comparator|IP alone|Patients receive ipilimumab alone.
2560188|NCT02498561|Active Comparator|obese-chronic periodontitis patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
2560193|NCT02498561|Placebo Comparator|obese-periodontally healthy controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
2560196|NCT02498561|Active Comparator|normal weight-CP patients|GCF, plasma and GCF samples were taken before and after nonsurgical periodontal therapy
2560202|NCT02498561|Placebo Comparator|normal weight-PH controls|GCF, plasma and GCF samples were taken at baseline after oral hygiene instructions
3205990|NCT00949572|Experimental|Sublingual administration|Sublingual administration of HPV vaccine proteins
3205991|NCT00949585|Other|Dietary potassium intake: 100 mmol/day|Participants will be given one of two diets: one contains 100 mmol of potassium per day, and the other contains 40 mmol of potassium per day
2560306|NCT02497547|Experimental|Oxytocin 400 IU|Oxytocin 400 IU vaginal gel (1 x 1mL/400 IU oxytocin daily for 12 weeks)
2560309|NCT02497547|Experimental|Oxytocin 200 IU|Oxytocin 200 IU vaginal gel (1 x 1mL/200 IU oxytocin daily for 12 weeks)
2560314|NCT02497547|Placebo Comparator|Placebo|Placebo vaginal gel (1 x 1mL daily for 12 weeks)
2560356|NCT02497196|Experimental|Part 1:Active tPCS, Active tDCS|12 out of the 48 total health subjects will receive active tPCS and active tDCS. This will be done for 20 minutes simultaneously.
2560360|NCT02497196|Experimental|Part 1: Active tPCS, Sham tDCS|12 out of the 48 total health subjects will receive active tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
2560361|NCT02497196|Experimental|Part 1:Sham tPCS, Active tDCS|12 out of the 48 total health subjects will receive sham tPCS and active tDCS. This will be done for 20 minutes simultaneously.
2560362|NCT02497196|Sham Comparator|Part 1: Sham tDCS, Sham tDCS|12 out of the 48 total health subjects will receive sham tPCS and sham tDCS. This will be done for 20 minutes simultaneously.
2560390|NCT02497092|Active Comparator|Fast angled injection|fast and angled insertion of the needle through the sclera
3205992|NCT00949585|Other|Dietary potassium intake: 40 mmol/day|Diet containing 40 mmol/day of potassium
3205993|NCT00949598|Experimental|Arm I|Patients receive oral letrozole once daily for 16 weeks.
3205994|NCT00949598|Experimental|Arm II|Patients receive oral tamoxifen citrate once daily for 16 weeks.
3205995|NCT00949611|Experimental|FRAX + Decision Aid|
3205996|NCT00949611|No Intervention|Usual care|
3205997|NCT00949611|Experimental|FRAX estimated fracture risk|
2558338|NCT02510313|Experimental|Sugira Muryango & Expanded VUP|Families receive combination of Sugira Muryango and benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
2558375|NCT02509988|Experimental|Intervention (study nutritional drink)|"Study nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
2558380|NCT02509988|Active Comparator|Control (standard nutritional drink)|"Standard nutritional drink comes in the form of a sachet to mix with water & take twice a day (once in the morning and once in the evening).~The drink will be taken before the participant becomes pregnant (for up to 1 year) and throughout pregnancy."
2558477|NCT02509494|Experimental|Stage 1: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 milliliter (mL) intramuscular (IM) injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). The booster vaccination using Ad26.ZEBOV will be administered as a 0.5 mL IM injection (2 years post Dose 1).
2558482|NCT02509494|Experimental|Stage 2: Active vaccination|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2).
2558485|NCT02509494|Experimental|Stage 2: Active vaccination for children|Ad26.ZEBOV will be administered as a 0.5 mL IM injection (Dose 1); MVA-BN-Filo will be administered as a 0.5 mL IM injection (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of vaccination at 3 months post Dose 2 with Placebo.
2558486|NCT02509494|Active Comparator|Stage 2: Control vaccination|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2).
2558488|NCT02509494|Active Comparator|Stage 2: Control vaccination for children|MenACWY will be administered as a 0.5 mL IM injection on Day 1 (Dose 1) and placebo on Day 57 (Dose 2). Children aged less than 2 years at randomization will receive a booster dose of MenACWY vaccination at 3 months post Dose 2 with MenACWY.
2558508|NCT02508844|Experimental|Vivomixx®|Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus
2558510|NCT02508844|Placebo Comparator|Placebo|microcrytalline cellulose, magnesium stearate and silicon dioxide.
3205998|NCT00949624|Experimental|Cohort 1|60 mg BID/ 75 mg/m2
3205999|NCT00949624|Experimental|Cohort 2|100 mg BID/75 mg/m2
3206000|NCT00949624|Experimental|Cohort 3|100 mg BID/100 mg/m2
3206001|NCT00949624|Experimental|Cohort 4b|CP-868,596 + AG-013736 + TXT 75
3206002|NCT00949637|Experimental|Scouting curricular implementation|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
3206003|NCT00949637|Active Comparator|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
3206004|NCT00949663|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
2558867|NCT02506725|Experimental|Prenatal Care in groups|We will do prenatal care using centering care pregnancy methodology in 10 sessions
2558880|NCT02506725|No Intervention|Control Group|We will do in this arm conventional Prenatal care available in the family clinics
2558906|NCT02506387||Mitraclip patients|Patients with severe mitral regurgitation in whom decision for mitraclip implantation was made by the heart team.
2558949|NCT02506140|Experimental|Ticagrelor/ASA|Drugs: Ticagrelor and Acetylsalicylic acid.
2558951|NCT02506140|Active Comparator|Clopidogrel/ASA|Drugs: Clopidogrel and Acetylsalicylic acid.
2558981|NCT02505672||Study group|Patients older than 18 who are planned to undergo chemoradiotherapy for nasopharyngeal carcinoma.
2559070|NCT02505191|Experimental|Test|St. John's wort prolonged-release tablet 500 mg
2559075|NCT02505191|Active Comparator|Reference|St. John's wort film coated tablets 250 mg (Remotiv N)
2559184|NCT02504762|Experimental|Treatment: HCR|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
2559186|NCT02504762|Active Comparator|Control: Conventional CABG|Participants will be randomized into the treatment or control group. In the treatment group, participants will be treated with PCI and MICS CABG. In the control group, participants will be treated with conventional CABG for their multivessel CAD.
2559247|NCT02504229|Experimental|Chemotherapy+DC-CIK|Combined treatment group:mononuclear cells were obtained aseptically with blood cell separator composition spheresis 1 day before SOX program chemotherapy, cultured DC-CIK cells. SOX program was acted on Day 2. Cells were cultured 14d,2 times back to the patient.A 21d was a cycle, then evaluated the therapeutic effect after two cycles.
2559253|NCT02504229|Active Comparator|Chemotherapy alone|Chemotherapy: two groups were treated with SOX program,specific drugs:Venoclysis of oxaliplatin 130mg/㎡;Day 1; Tegafur,Gimeracil and Oteracil Porassium Capsules 80mg/㎡/d,two oral/d;Day 1 to 12; 21d as one cycle of treatment, evaluated the therapeutic effect after two cycles.
2559301|NCT02503904|Active Comparator|TAD+IVAD|
2559303|NCT02503904|Active Comparator|IVAD|
2559358|NCT02503566|Experimental|All patients|Optical coherence tomography will be performed in all patients
3206005|NCT00949663|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3206006|NCT00949663|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3206007|NCT00949676||Heart Failure|
2558360|NCT02509975|Experimental|Prostate Artery Embolization|Transarterial administration of OCL 503 to the arteries feeding the prostate.
2558413|NCT02509780|Experimental|Vichy|
2558497|NCT02509195|Experimental|Switch to Triumeq|HIV-1 infected subjects currently receiving stable antiretroviral therapy switch their treatment to abacavir/lamivudine/dolutegravir (Triumeq).
2558516|NCT02508870|Experimental|Cohort A: Atezolizumab - HMA R/R MDS|Participants with MDS who are HMA R/R will receive atezolizumab 1200 milligrams (mg) intravenous (IV) infusion every 3 weeks (Q3W) (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a partial response (PR) or hematological improvement (HI) after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
2558520|NCT02508870|Experimental|Cohort B: Atezolizumab+Azacitidine - HMA R/R MDS|Induction: Participants with MDS who are HMA R/R will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 milligrams per square meter (mg/m^2) subcutaneously (SC) on Days 1 to 7 of 28-day cycle, for 6 cycles. Maintenance: Participants who complete induction treatment will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
2558526|NCT02508870|Experimental|Cohort C1: Atezolizumab+Azacitidine - HMA-Naive MDS|Participants with MDS who are HMA-naive will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
2558533|NCT02508870|Experimental|Cohort C2: Atezolizumab+Azacitidine - HMA-Naive MDS|If the participants enrolled in Cohort C1 fulfil the dose limiting toxicity (DLT) criteria, then additional participants with MDS who are HMA-naïve will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first.
2558540|NCT02508870|Experimental|Cohort A2: Atezolizumab - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 1200 mg IV infusion Q3W (21-day cycle). Treatment will continue for up to 17 cycles or until loss of clinical benefit, evidence of unacceptable toxicity, non-compliance with the protocol, voluntary withdrawal from the study, or study termination, whichever occurs first. Participants who achieve/maintain a PR or HI after receiving 17 cycles of therapy may continue on study treatment beyond Cycle 17 until loss of clinical benefit.
2558548|NCT02508870|Experimental|Cohort B2: Atezolizumab+Azacitidine - HMA R/R MDS|If atezolizumab alone or in combination with azacitidine is found to be initially safe and tolerable in participants with HMA R/R MDS in both Cohorts A and B, then additional randomly assigned participants will receive atezolizumab 840 mg IV infusion on Days 8 and 22 of each 28-day cycle along with azacitidine 75 mg/m^2 SC on Days 1 to 7 of 28-day cycle, for 6 cycles during induction. Participants who complete induction treatment will receive maintenance atezolizumab 1200 mg IV infusion Q3W (21-day cycle) for up to 8 additional cycles. Participants who achieve/maintain a PR or HI after completing the 8 cycles of atezolizumab maintenance therapy, may continue on study treatment until loss of clinical benefit.
2558647|NCT02508181|Active Comparator|I-gel intra ocular pressure|supraglottic airway device
2558649|NCT02508181|Active Comparator|LMA Supreme intra ocular pressure|supraglottic airway device
2558709|NCT02507986|Active Comparator|7-Day Holter monitor|This arm will receive a 7-Day Holter monitor directly after randomization.
2558711|NCT02507986|Experimental|Single lead ECG device|This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.
2558733|NCT02507583|Experimental|Cohort 1|After protocol amendment dated 11 May 2017, all subjects enrolled into the trial will receive 20 chambers for 48 hours.
2558774|NCT02507414|Experimental|Group 1|"Patients under going Whipple's procedure, gastric resection and liver resection (n=75).~Interventions:~Blood samples obtained pre-, intra-, and one day postoperatively (n=15).~Measurements of microcirculation using LSCI from procedure start and up to 60 min during surgery.~Head down tilt of 20 degrees at three time points."
3206008|NCT00949689|Experimental|Cognitive Behavioral Therapy for insomnia and depression|cognitive behavioral therapy for insomnia followed by cognitive behavioral therapy for depression
3206009|NCT00949689|Active Comparator|contol|participants will receive sleep hygiene, time management techniques and cognitive therapy for depression
2558917|NCT02506283|Experimental|cooling intervention|subjects in this study receive a single pre-exercise (3x MVC) or post-exercise intervention (3x 30 counter movement jumps), consisting of an external cooling application (Zamar Therapy CT clinic) applied to both thighs. Both interventions have a duration of 20 minutes and a temperature of 8°C
2558921|NCT02506283|Sham Comparator|thermoneutral intervention|subjects in the control group receive a single pre-exercise (3x MVC) or post-exercise (3x 30 counter movement jumps) sham intervention, consisting of a 20 minute external thermoneutral application (Zamar Therapy CT clinic) applied to both thighs. Both sham interventions have a duration of 20 minutes and a temperature of 32°C.
2559034|NCT02505594||OSA Group|Apnea-hypopnea index (AHI) ≥ 15 events/h
2559035|NCT02505594||Control Group|Apnea-hypopnea index (AHI) < 5 events/h
2559065|NCT02505178|Experimental|Problem Solving Therapy|Study participation will involve 9 study visits over a total of 12 weeks. This includes 5 sessions of Case Manager implemented PST over a period of 8 weeks (week 1, 3, 5, 7, and 9) and 4 assessment visits (baseline, week 4, week 8, and week 12).
2559091|NCT02505022||Treatment seeking patients|Patients between 18 and 26 who arrive seeing treatment for new-onset mental health symptoms. They will receive treatment as usual, while being assessed overt he course of one year for changes in role functioning.
3206010|NCT00949728|Other|Fibrin glue|
3206011|NCT00949754|Active Comparator|histamine|histamine in saline administered ID as active control for Apitox
2559268|NCT02504112||X-Ray PSI Group|Male or female patients, over 18 years old and with indication of total knee arthroplasty
2558382|NCT02509754|Experimental|Atrial fibrillation catheter ablation|Atrial fibrillation (AF) catheter ablation is performed following each Center's common practice. Activated clotting time (ACT) is maintained above 350 seconds. The left atrium (LA) is accessed by transseptal puncture or through a patent foramen ovale. A multipolar catheter and an irrigated-tip ablation catheter are inserted into the LA and a 3-dimensional reconstruction of the LA and pulmonary veins (PVs) ostia is performed. The mainstay is to obtain a complete antral PVs isolation, defined by complete elimination of PVs potentials. PVs isolation may be accompanied by the creation of linear lesions (roof line, left isthmus) or ablation of complex fractioned atrial electrograms. Patients are discharged on oral anticoagulation and optimal medical therapy. Each center will evaluate patients for ICD implantation; a loop recorder may be implanted if within routine clinical practice.
2558388|NCT02509754|Experimental|Rate control arm|Patients randomized to rate control only arm will undergo ICD implantation and optimization of the rate control therapy. In case of uncontrolled ventricular rate at 24-h ECG Holter, defined as a mean resting heart rate higher than 90 bpm, patients will receive atrioventricular (AV) node ablation and resyncronization therapy (CRT-D) implantation, performed following common practice at each Center. In case of failure or technical difficulties of the transvenous approach, epicardial screw-in or steroid-eluting passive lead is implanted via a limited thoracotomy. Transcatheter AV node ablation is performed as follows: a non-irrigated tip ablation catheter is introduced on the right side of the interatrial septum and ablation performed on the fast pathway region or the smallest His bundle signal. The goal of the procedure is AV modulation below 30 bpm or complete AV block.
2558464|NCT02509546|Experimental|Treatment (8-chloro-adenosine)|Patients receive 8-chloro-adenosine IV over 4 hours on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
2558504|NCT02508961|Experimental|Web-based physio|Participants receive an online individualised exercise programme to complete over the internet twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. After this, every 2 weeks online exercise diaries are remotely monitored by a physiotherapist and exercise programmes progressed as appropriate.
2558505|NCT02508961|Active Comparator|Print-out exercise programme|Participants receive printed exercise programme to complete twice per week. Exercises can be a combination of aerobic, strengthening and balance exercises. Participants receive a weekly phone call from a physiotherapist for the first two weeks to check on progress. Participants complete a paper exercise diary and after the first 2 weeks if they require a progression to their exercise programme they contact their physiotherapist.
2558541|NCT02508792|Active Comparator|LASER|"Subject will receive application of LASER before muscle fatigue protocol.~Note: this is a crossover study."
2558546|NCT02508792|Placebo Comparator|LASER PLACEBO|"Subject will receive application of LASER (now deactivated) before muscle fatigue protocol.~Note: this is a crossover study."
2558585|NCT02508545|Other|perceived egocentric distance measurements - parabolic flight|perceived egocentric distance (PED) measurements during parabolic flight
2558623|NCT02508324|Other|Intervention|"All potential recipients will have complete (HLA) typing and determination of HLA antibodies. An appropriate umbilical cord blood unit (CBU) will be identified or in the absence of an appropriate CBU, a haplo-identical cells (donor) will be identified.~Within 72 hours after completion of the chemotherapy regimen, and no sooner than 24 hours after administration of the last dose of chemotherapy, umbilical cord graft or haplo-graft will be administered."
3206012|NCT00949754|Experimental|Apitox pure honeybee venom|ID study drug
3206013|NCT00949767|Experimental|BMS-866949 (Panel 1)|
2558740|NCT02507635|No Intervention|healthy volunteers|healthy volunteers
2558748|NCT02507635|Active Comparator|Desloratadine|patients with allergic rhinitis under treatment with Desloratadine 5 mg/day, 4 weeks
2558751|NCT02507635|Active Comparator|Levocetirizine|patients with allergic rhinitis under treatment with Levocetirizine 5 mg/day, 4 weeks
2558792|NCT02507271|Experimental|Experimental Group|
2558793|NCT02507271|Placebo Comparator|Control Group|
2558841|NCT02506946||PCOS subjects|Forty adolescents and young adults between the ages of 14 and 25 years with Polycystic Ovary Syndrome (PCOS) at least two years past menarche.
2558844|NCT02506946||Control subjects|Forty unaffected adolescents and young adults between the ages of 14 and 25 years at least two years past menarche.
2558859|NCT02506647|Experimental|Sequence 1|Gan & Lee insulin glargine followed by Lantus
2558872|NCT02506647|Active Comparator|Sequence 2|Lantus followed by Gan & Lee insulin glargine
2558943|NCT02506413|Other|MNCH Intervention Package|"The division assigned to this arm received a comprehensive Maternal and Newborn Health (MNH) intervention package using the 'MamaToto Process'. Key intervention activities included:~engaging district leaders in district health system strengthening;~strengthening health facility-based MNH services; and~establishing a Maternal, Newborn, and Child Health focused lay Community Health Worker program."
2559009|NCT02505958|Other|high caloric intake|Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories. Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
2559013|NCT02505958|Other|reduced caloric intake|On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
2559060|NCT02505360|Other|nasal and ear cartilage taken from the newborn|to compare biochemical and histological characteristics of both nasal and ear cartilage taken from the newborn at the time of surgical time cheilorhinoplasty
2559096|NCT02505074||Mitral Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the mitral valve with the Melody valve.
2559097|NCT02505074||Tricuspid Valve Replacement|Review of retrospective data of those patients who have had surgical replacement of the tricuspid valve with the Melody valve.
2559176|NCT02504749|Active Comparator|Group A: General anaesthesia group|-Standard rapid sequence induction with pre-oxygenation by 100 % OXYGEN FOR 3 MINUTES FOLLOWED BY 4-5 mg/kg thiopental and 100 mg succinylcholine,cricoid pressure was applied once necessary.After correct placement of tracheal tube was confirmed,anaesthesia was maintained with up to 1.5% isoflurane and oxygen,neuromuscular blockade was maintained with 0.4 mg/kg atracurium.
2559636|NCT02501824|Experimental|speech therapy first|11 sessions of speech therapy (anthroposophic therapeutic speech), then waiting phase
3206014|NCT00949767|Experimental|BMS-866949 (Panel 2)|
2558392|NCT02509923|Experimental|3|3-way cross-over, Z-215 20 mg/day (before breakfast) / Z-215 20 mg/day (after breakfast) / Rabeprazole Sodium 10 mg/day (after breakfast)
2558451|NCT02509429|Experimental|Control-to-Range algorithm and Threshold Low Glucose Suspend|"On this arm, patients will realize two investigational sessions:~the first with Control-to-Range algorithm (CTR),~the second with Threshold Low Glucose Suspend (TLGS)."
2558452|NCT02509429|Experimental|Threshold Low Glucose Suspend and Control-to-Range algorithm|"On this arm, patients will realize two investigational sessions:~the first with Threshold Low Glucose Suspend (TLGS),~the second with Control-to-Range algorithm (CTR)."
2558522|NCT02509039|Experimental|CC-122|CC-122 is administered orally, on a 5 continuous days out of 7 days per week intermittent dosing schedule.
2558586|NCT02508584|Experimental|Intervention|This is a single patient treatment IND
3206015|NCT00949767|Experimental|BMS-866949 (Panel 3)|
3206016|NCT00949767|Experimental|BMS-866949 (Panel 4)|
2558731|NCT02507791|Experimental|Early Fitbit|"Patients will receive Fitbit in the first phase of the study. In addition to attending weekly weight management classes, patients will wear Fitbit Charge HR devices to track heart rate, active minutes, steps taken, calories burned, and sleep patterns. Patients will receive weekly phone calls to review this data, and further recommendations will be given to encourage additional physical activity as clinically indicated based on time spent being physically active. The goal will be for individuals to reach 10,000 steps per day, though if subjects are significantly under that goal, realistic goal-setting (recommended increases of physical activity of 10% at a time). Patients will continue this intervention for 12 weeks. After 12 weeks, they will return for reassessment. This coincides with the completion of the weight loss program. Subjects will then be followed remotely for another 12 weeks and phone call interventions will continue before returning for a final study visit."
2558732|NCT02507791|Active Comparator|Late/Delayed Fitbit|These subjects will follow a similar pattern except they will not receive Fitbit Charge HR devices until the second phase of the study (specifically after completion of the 12 week weight loss program). In the first phase, these subjects will receive weekly phone calls to offer them the same attention as the experimental group, but instead of reviewing Fitbit data, these subjects will subjectively report their physical activity in minutes and by qualifying their physical activity as light, moderate, or vigorous. These individuals, after 12 weeks, will return for reassessment. At that time, these individuals will receive Fitbits and receive weekly telephone calls for an additional 12 weeks before returning for a final study visit.
2558760|NCT02507453|Other|Influence of Gravity on the Size-mass Illusion|to investigate the interaction between perceived size and perceived mass of objects in 0G and 1.8G compared to 1G using the size-mass illusion (SMI)
2558827|NCT02507128|Experimental|GLP-1 group|The treatment started 30 min before PCI with a dose of 1.8 mg liraglutide (the treatment was administered in the ambulance).
2558830|NCT02507128|Placebo Comparator|Control group|the treatment started 30 min before PCI with a dose of 1.8 mg placebo (the treatment was administered in the ambulance).
2558883|NCT02506686|Experimental|Meropenem|Meropenem i.v.
2558935|NCT02506335|Other|Hep quant cholate testing|diagnostic measure of liver function
2559004|NCT02505971|Active Comparator|Nadolol group|40 study participants will take Nadolol (oral liquid suspension)
2559005|NCT02505971|Active Comparator|Propranolol group|40 study paticipants will take Propranolol (oral liquid suspension)
2559053|NCT02505347|Experimental|No splint|will be able to move the arm as tolerated following surgery.
2559057|NCT02505347|Active Comparator|Splint|will receive a splint following surgery for 6 weeks.
2559122|NCT02505061|Experimental|Program|"The participants performance is indicative of the extent to which early power mobility training is feasible for both young infants and up to 3-year-old child with mobility Disabilities.Parents/caregivers and occupational therapists will be responsible for theHospital-based Program and Regular Therapy Program service respectively"
2559183|NCT02504593|Other|Community health volunteers|The study subjects are all community health volunteers in community units in Kenya (10 community units in Bungoma East and 6 community units in Kiminini) that have been trained to provide community-based malaria diagnosis through rapid diagnostic testing.
2559252|NCT02504333|Active Comparator|AG|nab-Paclitaxel followed by Gemcitabine
2559255|NCT02504333|Experimental|AG-mFOLFOX|nab-Paclitaxel followed by Gemcitabine and FOLFOXm at dose levels selected from the phase I trial
3206017|NCT00949767|Experimental|BMS-866949 (Panel 5)|
3206018|NCT00949767|Experimental|BMS-866949 (Panel 6)|
3206019|NCT00949767|Experimental|BMS-866949 (Panel 7)|
2559378|NCT02503345|Placebo Comparator|Placebo|Placebo capsules (1, 2 or 5) PO TID
2559384|NCT02503345|Experimental|ALLN-177 low dose|ALLN-177 1,500 units/meal PO TID
2559390|NCT02503345|Experimental|ALLN-177 mid dose|ALLN-177 3,000 units/meal PO TID
2559393|NCT02503345|Experimental|ALLN-177 high dose|ALLN-177 7,500 units/meal PO TID
2559438|NCT02502981|Experimental|CKD stage 2 & 3|"Patients with CKD stage 2 & 3 (eGFR 30-89ml/min/1.73m2) will be randomly assigned to receive either spironolactone or chlortalidone in a PROBE design.~Subjects will undergo cardiac MRI, carotid femoral pulse wave velocity, 24 hour ambulatory blood pressure monitoring, blood tests for renal function and spot urine analysis for proteinuria (albumin:creatinine ratio) at baseline and after 40 weeks of allocated treatment. Additional blood tests for renal function and potassium level will be assessed at week 1,2,4,8 and 20."
2559594|NCT02501980||Screening|All participants will be tested for HBsAg by using serum samples. Among those who are positive for HBsAg, further clinical work-ups including AFP test and ultrasonography for liver exam will be performed. Repeated check-ups will be performed in 6-months among HBsAg positive group and 3-years among HBsAg negative group.
2559595|NCT02501980||Non-screening|All subjects in this arm will be followed by linkage to Cancer Register and Population Register.
2559633|NCT02501681|Active Comparator|crystalloid|Group A (n=20); crystalloid as priming solution used in patients,
2559641|NCT02501681|Active Comparator|colloid|Group B (n=20); colloids as priming solution used in patients
2559686|NCT02501525|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
3206020|NCT00949780|Active Comparator|chloral hydrate , sedative|
3206021|NCT00949793|Experimental|All patients|
2558426|NCT02509637|Active Comparator|Chest Compression Intervention|After initial evaluation, the subjects will be instructed to perform deep breaths between three quiet inspiration brought, and expiration will be accompanied by bilateral compression with the therapist's hands on the lower ribs during thirty minutes with one minute intervals of rest every four minutes. Immediately after the exercise will be performed new assessment against Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied the acceptability and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for weight, adhesiveness and purulence.
2558429|NCT02509637|Active Comparator|Crontrol Intervention|After initial evaluation, patients will be remain seated quiet breathing without any guidance for thirty minutes. Immediately after this time will be held reassessment with Impulse Oscillometry. Then patients will be kept for 30 minutes at rest and at the end will be applied to acceptance and tolerance scale and a third evaluation with Impulse Oscillometry. The secretions expectorated during the protocol will be evaluated for wight, adhesiveness and purulence.
2558471|NCT02509247|Experimental|Telemonitoring group|Patients allocated to the telemonitoring group started with wireless telemonitoring after the titration period, i.e. in the beginning of habituation phase of CPAP treatment.
2558473|NCT02509247|No Intervention|Usual care group|Patients were followed-up during the habituation phase according to hospital's standard procedure.
2558515|NCT02509000|Active Comparator|Active-mode|Air purifier in active-mode
2558519|NCT02509000|Sham Comparator|Sham-mode|Air purifier in sham-mode
2558581|NCT02508688|Experimental|thoracoscopic mesh repair group|63 patients with refractory HH (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair were included in this study.
2558641|NCT02508350|Experimental|daptomycin|Daptomycin for injection 10-12mg/kg/day,determination of plasma concentration
2558701|NCT02507999|Experimental|Goal Directed Therapy - Flotrac Use Arm|This arm will employ the use of the Flotrac device to monitor cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure management.
2558702|NCT02507999|No Intervention|Non-Goal Directed Therapy|In this arm, patients will have the Flotrac machine attached to their arterial catheter but the screen that displays the monitor readings will be covered and machine alarms will be turned off. The anesthesiologist will not be aware of the Flotrac monitor readings.
3206022|NCT00949806|Experimental|Administrated|All patients included will receive an intradermal administration of BNT
2558866|NCT02506907||Atherosclerotic|Patients with atherosclerotic intracranial stenosis
2558915|NCT02506491|Experimental|Pilates exercise program|Incorporate Pilates principles to stimulate core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
2558916|NCT02506491|Experimental|Muscular exercise program|To train core muscles in a dynamic and static way, and exercising arms and legs complementarity with balance as an essential part of standing exercises.
2558919|NCT02506491|Active Comparator|Control group|Healthy active but nonexercising old women
2558960|NCT02505997|Experimental|Midazolam/Delafloxacin|Each subject will receive a single 5 mg oral dose of midazolam syrup on Day 1, oral 450 mg delafloxacin tablets twice daily (Q12h) for Days 3 to 8, and co-administered a single 5 mg oral dose of midazolam syrup in the AM on Day 8.
2559008|NCT02505763|Experimental|Strategy with thoracic ultrasound|"Use of thoracic ultrasound for the treatment of pleural effusion, treatment and monitoring.~Use of other examinations like chest CT if necessary"
2559014|NCT02505763|No Intervention|Strategy without thoracic ultrasound|"Usual care : without thoracic ultrasound~Use of chest radiography or chest CT scan if necessary, as for treatment and monitoring.~Usual care: without the use of ultrasound Using either chest radiography or TDM if necessary, as for treatment and monitoring."
2559049|NCT02505373|Experimental|Intervention Group ASSIP|Intervention Group ASSIP (Brief Therapy)
2559055|NCT02505373|Active Comparator|Control Group CG|Control Group CG (structured interview)
2559125|NCT02504996|Active Comparator|Paracetamol|1 g intravenous paracetamol (Perfalga, Bristol Myers) in 100 ml saline with a rapid infusion.
2559126|NCT02504996|Active Comparator|morphine|0.1 mg/kg morphine in 100 ml saline with a rapid infusion.
2559127|NCT02504996|Placebo Comparator|placebo|100 ml saline
2559188|NCT02504528|Experimental|allergic asthma|asthma patients that sensitive to house dust mites.
2559191|NCT02504528|Experimental|normal controls|normal controls with or without sensitive to house dust mites.
3206023|NCT00949819||no treatment|Men with previously untreated, early stage prostate cancer.
3206024|NCT00949832|Active Comparator|Vitamin D + Calcium|Vitamin D and calcium supplementation
2559821|NCT02500680|Experimental|Group 1 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 1µg (Standard Dose) Single Dose
2559823|NCT02500680|Experimental|Group 2 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 3µg (Standard Dose) Single Dose
2559827|NCT02500680|Experimental|Group 3 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 5µg (Standard Dose) Single Dose
2559828|NCT02500680|Experimental|Group 4 (Phase 1A)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg (Standard Dose) Single Dose
2559829|NCT02500680|Active Comparator|Group 5A (Phase 1A)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 15µg (Standard Dose) Single Dose
2559830|NCT02500680|Active Comparator|Group 5B (Phase 1B)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
2559831|NCT02500680|Experimental|Group 6 (Phase 1B)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) Optimal Vaccine Dose from Phase 1A (9µg) (Standard Dose) Single Dose
2559833|NCT02500680|Experimental|Group 7A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 9µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose
2559836|NCT02500680|Active Comparator|Group 7B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose
2560325|NCT02497560|Other|Treatment + Omega-3s|all natural dietary supplement + omega-3s
3206025|NCT00949832|Placebo Comparator|Calcium|Calcium supplementation
3206026|NCT00949832|Active Comparator|Vitamin D2|Vitamin D2 response
2558465|NCT02509468|Experimental|Experimental|At a randomized date, patients will start treatment with sirolimus (beginning dose: 0.08mg/kg/day)
2558514|NCT02508909|Experimental|Videoscopic ilioinguinal lymphadenectomy for melanoma|Melanoma groin lymph node metastasis.
2558625|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (10 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
2558626|NCT02508376|Experimental|ID93 (10 mcg) + AP10-602 (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
2558627|NCT02508376|Experimental|ID93 (10 mcg) + GLA-SE (5 mcg)|N=20 subjects will receive intervention on Days 1, 29, 57
2558628|NCT02508376|Experimental|ID93 (10 mcg) alone|N=10 subjects will receive intervention on Days 1, 29, 57
2558816|NCT02507076|Experimental|Treatment (ILP with melphalan)|Patients undergo ILP with melphalan IV over 60 minutes.
3171567|NCT00588679|Experimental|1|Patients taking part in this study will have one MRI and one MRSI scan acquired in succession during a single MR examination. For those patients who have undergone prostate biopsy it is recommended that this should be done at least eight weeks after the prostate biopsy and should take one hour to one hour and ten minutes total to complete.
3171568|NCT00588705||focus group & questionaire|The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
3171569|NCT00588718||Cases|Infants who meet the entry criteria
2558978|NCT02505802|Experimental|BoNT-A treatment group|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu). Both groups received comprehensive rehabilitation for 8 weeks.
2558980|NCT02505802|No Intervention|Control group|No special treatment was performed in the control group. Both groups received comprehensive rehabilitation for 8 weeks.
2559045|NCT02505529|Experimental|Resistance Exercise Training|12-weeks of high-intensity, progressive resistance exercise training (3x/wk).
2559050|NCT02505529|Experimental|Mental Imagery|6-weeks of mental imagery of strong muscle contractions and mobility tasks (5x/wk).
2559056|NCT02505529|No Intervention|Control Group|6-weeks of no change in lifestyle.
2559101|NCT02505035|Active Comparator|Default ordering of palliative consult|Hospitals randomized to the intervention arm will adopt a system whereby eligible patients are identified by the electronic health record, a consultation is ordered by default, and physicians may cancel the order after being alerted to it, and patients or family members may decline such services.
2559103|NCT02505035|No Intervention|Usual care|There will be no trial-driven approach to care. Inpatient palliative care consultative services will be actively requested by physicians as in usual care.
2559169|NCT02504684|Active Comparator|1470-nm|Endovenous 1470-nm diode laser
2559172|NCT02504684|Experimental|1920-nm Group|Endovenous 1920-nm diode laser
2559355|NCT02503683|Active Comparator|ALN-AAT|
2559357|NCT02503683|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
2559460|NCT02502682|No Intervention|Control|Receive the bathing standard of care.
2559461|NCT02502682|Experimental|Interventional|Receive daily bathing with 2% Chlorhexidine gluconate bathing wipes.
2559475|NCT02502565||Uric Acid Level|
3171570|NCT00588718||Controls|Banked blood samples from newborns who do not meet inclusion criteria for this study will be held at Stanford University Core Laboratory and will constitute controls. Proteomic and genomic profiles in blood samples of cases will be compared with blood samples of controls.
3171571|NCT00588757|Active Comparator|1|Optease filter
3171572|NCT00588757|Active Comparator|2|Tulip filter
3171573|NCT00588783||1|
3171574|NCT00588783||2|
3171575|NCT00588796||Healthy Volunteers|Healthy Volunteers
3171576|NCT00588796||Burn patients|Patients who have sustained burn injury greater than or equal to 20% of total body surface area
3171577|NCT00588796||Trauma patients|Patients who have undergone trauma
3171578|NCT00588835|Experimental|A|Aprepitant 125mg oral on day 1 and 80mg on day 2 and 3 during CE treatment.
3171579|NCT00588835|Active Comparator|B|CE cycle with standard anti-emetic regimen.
3171580|NCT00588861|Active Comparator|Answer® hip stem with Simplex Cement|Femoral stem replacement with Answer® hip stem & Simplex Bone Cement
3171581|NCT00588861|Active Comparator|Answer® hip stem with Palacos Cement|Femoral stem replacement with Answer® hip stem & Palacos Bone Cement
3171582|NCT00588874||1|men 50 yrs of age or older
3171583|NCT00588887||1|
3171584|NCT00588887||2|
3171585|NCT00588926|Experimental|A|The patients get a period of sedation with remifentanil, before, during and after which, the changes in the electrical activity of the Basal Ganglia is recorded.
3171586|NCT00588939||I|participants with symptoms of acid reflux disease (heartburn)
3171587|NCT00588978|Active Comparator|1|Diet alone
3171588|NCT00588978|Active Comparator|2|Exercise alone
3171589|NCT00588978|Active Comparator|3|Diet and exercise (combined)
3171590|NCT00589082|Active Comparator|1|standard 3+7
3171591|NCT00589082|Experimental|2|DNX 3+7
3171592|NCT00589095||1|
3171593|NCT00589134|Experimental|1|type of beverage
3171594|NCT00589147|Active Comparator|1|One study group will consist of patients treated with the modular cemented tibia.
3171595|NCT00589147|Active Comparator|2|Study arm will consist of patients that are treated with non-modular cemented tibia.
3171596|NCT00589147|Active Comparator|3|Study arm will consist of patients that are treated with non-modular uncemented tibia.
3171597|NCT00589173|Experimental|Intervention|Patients referred to the IPHR
3171598|NCT00589173|Active Comparator|Control|"Patients receiving standard preventive care"
3171599|NCT00589199|Experimental|1|Functional Electrical Stimulation for Production of Artificial Cough
3171600|NCT00589212|Experimental|1|Patients with 1-3 brain metastases
3171601|NCT00589225||1|Genetic Analysis
3171602|NCT00589238|Other|Arm 1 (Standard Arm)|Arm 1 (Standard Arm) Preoperative (primary/ neoadjuvant) intravenous weekly paclitaxel 80 mg/m2 for 12 weeks followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
2558479|NCT02509260|Experimental|Prevena™ incisional NPWT|Prevena wound management system: Post op application of the Prevena™ wound management system will be applied.
2558484|NCT02509260|Active Comparator|Standard Wound Dressings|Standard Wound Dressings: Control patients with standard wound dressings will have gauze and tape dressings applied.
2558528|NCT02508922|Experimental|Vitamin D3|2000iu vitamin D will be taken daily for 20 weeks.
2558536|NCT02508922|Placebo Comparator|Placebo|Matching placebo drops will be taken daily for 20 weeks
2558861|NCT02506699||analgesic effect of rTMS|Observe the analgesic effect of rTMS, reference method of noninvasive stimulation of the motor cortex validated by data from the literature and current practice, after 5 separate sessions a week apart, patients with neuropathic pain chronic, refractory to first and second-line treatments proposed in a multidisciplinary center specializing in chronic pain Lower Normandy.
2558923|NCT02506465|Experimental|iTind arm|iTind implant is implant during the study for 5-7 days.
2558927|NCT02506465|Sham Comparator|Sham arm|Foley catheter is used during the study
2558997|NCT02505828|Other|Septic arthritis|with bacteriological identification
2559001|NCT02505828|Other|Juvenile idiopathic arthritis|beyond the ILAR (International League of Associations for Rheumatology) definition
2559031|NCT02505451|Experimental|Type 2 diabetic patients|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with type II diabetes (according to the American Diabetes Association, 2012) free of coronary diseases.
2559032|NCT02505451|Experimental|Metabolic syndrom|Regional myocardial function will be assessed during dobutamine stress echocardiography in asymptomatic patients with the Metabolic syndrome (according to Alberti et al 2009) free of diabetes and coronary diseases.
2559033|NCT02505451|Experimental|controls|Regional myocardial function will be assessed during dobutamine stress echocardiography in healthy subjects.
2559068|NCT02505165|Experimental|Parent Uncertainty Intervention|A pediatric cancer-specific, clinic based, six-module interdisciplinary uncertainty intervention. Modules one through three target uncertainty prevention. Modules four through six target uncertainty responses for situations in which uncertainty cannot be prevented or avoided.
2559074|NCT02505165|Other|Education/Support Only|"Sessions in this condition aim to provide education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Information presented will be based upon, Young People with Cancer: A Handbook for Parents, a parent resource developed by the National Cancer Institute. Parents will also be provided with relevant educational brochures from COG. Each session will also include a structured set of questions that will facilitate discussion. All ESO interventionists will be trained in non-directive approaches including reflective listening. Content provided in the ESO sessions will offer valuable information to parents without providing the specific skills of the IMPACT."
3171603|NCT00589238|Experimental|Arm 2 (Experimental Arm)|Arm 2 (Experimental Arm) Preoperative intravenous weekly paclitaxel 80 mg/m2 in combination with carboplatin AUC 2 on D1, D8 and D15 every 28 days for 4 cycles followed by doxorubicin 60 mg/m2 in combination with cyclophosphamide 600 mg/m2 every 21 days for 4 cycles.
3171604|NCT00589251|Other|penicillin skin test|Patients will have the skin test placed
2559639|NCT02501655|Active Comparator|Phase 1|Jet Nebulizer - control group
3171605|NCT00589264|Experimental|1|iron + copper + zinc
3171606|NCT00589264|Active Comparator|2|iron + copper only
3171607|NCT00589316|Experimental|Treatment (chemo, TBI, transplant, immunosuppression)|"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 via central line on day -14.~NONMYELOABLATIVE CONDITIONING: Patients receive FLU IV over 30 minutes on days -6 to -2 and CY IV over 1 hour on days -6 and -5. Patients undergo TBI on day -1.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplantation on day 0.~POST-TRANSPLATATION IMMUNOSUPPRESSION: Patients receive CY IV over 1-2 hours on day 3, MMF IV or PO TID on days 4 to 35, and tacrolimus IV over 1-2 hours or PO on days 4 to 180 with taper on day 84."
3171608|NCT00589355||1|postmenopausal women with glucose intolerance (either pre-diabetes or diet-controlled diabetes)
3171609|NCT00589355||2|postmenopausal women with normal glucose tolerance
3171610|NCT00589368||1|stroke group
3171611|NCT00589368||2|control group
3171612|NCT00589394|Other|pneumococcal vaccination (Pneumovax)|"Intervention:~Patients receive one dose of the Pneumovax vaccine. The 23 pneumococcal serotypes are measured before and after vaccination in order to measure response in a healthy population."
3171613|NCT00589420|Experimental|Phase II|All patients received sorafenib 200 mg bid daily and docetaxel 75 mg/m2 every 3 weeks
3171614|NCT00589433||1|
3171615|NCT00589446|Experimental|1|Embryoscopy will be evaluated in women with at least two previous miscarriages, after confirmation of missed abortion by ultrasound. Embryoscopy will only be performed in patients in whom curettage is clinically indicated, and will only be added to the D&C if there is a possibility of visualizing embryonic tissue, i:e. from approximately 5½ weeks onwards when there is an embryonic pole detected on ultrasound.
3171616|NCT00589459||1|non-diabetic women with acute coronary syndrome (ACS)
3171617|NCT00589459||2|non-diabetic men with acute coronary syndrome (ACS)
3171618|NCT00589485||1|
3171619|NCT00589485||2|
3171620|NCT00589498|Experimental|1|Subjects who are randomized to overfeed will visit with the General Clinical Research Center dieticians as often as necessary to gain 2 kg of fat (about 4 kg overall) over a period of 8 weeks.
3171621|NCT00589498|No Intervention|2|Subjects who are randomized to non-overfeeding will continue with their normal diet and activity levels for a period of 8 weeks.
3171622|NCT00589589|Active Comparator|A|
3171623|NCT00589615|Active Comparator|1|The multidisciplinary osteoporosis prevention study started with a five-day program at a rehabilitation centre and will be followed by one-day group appointments twice.
3171624|NCT00589615|No Intervention|2|The control group will get information about osteoporosis through media and health care system.
3171625|NCT00589641|Experimental|CBT-RP + Enhanced TAU|CBT-RP augmenting relapse prevention intervention, in addition to enhanced treatment as usual, monthly check-ins, and monitoring
3171626|NCT00589641|Active Comparator|Enhanced TAU (Treatment as Usual)|Treatment as usual in the community, monthly monitoring regarding service use and needs, monitoring
2558500|NCT02509130||Asthma Outpatients|Patients who are attending outpatient clinics as new referrals will be approached to participate in the quantitative part of the study.
2558501|NCT02509130||Healthcare Professionals|Healthcare professionals who performed the MISSION RAAC or SAAC will be approached for qualitative interview part of the study only.
2558507|NCT02508818|Other|Cardiovascular measurements|
2558543|NCT02508740|Experimental|normal renal function|Healthy subjects with normal renal function (Stage 1, >90 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
2558549|NCT02508740|Experimental|mild renal impairment|Patients with mild renal impairment (Stage 2, 60-89 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
2558553|NCT02508740|Experimental|moderate renal impairment|Patients with moderate renal impairment (Stage 3, 30-59 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
2558557|NCT02508740|Experimental|severe renal impairment|Patients with severe renal impairment (Stage 4, <30 mL/min) will receive a single oral dose of 0.25 mg bevenopran.
2558561|NCT02508740|Experimental|End Stage Renal Disease (ESRD)|Patients with End Stage Renal Disease (ESRD) receiving dialysis for at least 3 months preceding the initial dose in this study (Stage 5) will participate in 2 treatment periods and will receive a single oral dose of 0.25 mg bevenopran at 3 hours after completion of the last hemodialysis session of the week in Period 1 and a single oral dose of 0.25 mg bevenopran at 3 hours before initiation of the last hemodialysis session of the week in Period 2
2558607|NCT02508402|Active Comparator|dexamethasone group|The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular After six hours of the initial dose, the labour induction will start via Oxytocin .III. The interval between the initiation of induction and the beginning of the active phase of labour is recorded (a cervical dilatation of 4 cm plus 3 forceful contractions over a 10-minute span each last from 40-60 Sec).
2558608|NCT02508402|Placebo Comparator|Placebo group|and the participants of placebo Group will not receive Dexamethasone or any other cervical ripening agent.II.two milliliters of normal saline given.
2558674|NCT02508129|Experimental|Brief Behavioral Treatment for Insomnia|Brief Behavioral Treatment for Insomnia (BBTI) employs behavioral strategies for managing insomnia and is administered in 4 brief weekly contacts with a therapist via online web conferencing.
2558676|NCT02508129|Experimental|Sleep Healthy Using the Internet (SHUTi)|SHUTi is an automated, interactive, personalized web-based program for improving insomnia through the use of Cognitive-Behavioral Therapy strategies for insomnia.
2558679|NCT02508129|Placebo Comparator|Enhanced Usual Care (EUC)|EUC involves the primary care physician's current treatment; feedback to patients and providers on assessment and treatment recommendations; an educational video from Emmi Solutions, Inc.
2558726|NCT02507804|Experimental|Arm A diary arm|Patients in Arm A are required to complete a patient diary. This will be reviewed by an Investigator at every visit in order to gain Adverse Event and Concomitant Medication information.
2558727|NCT02507804|Active Comparator|Arm B standard of care|Patients will be asked to recall Adverse Events and Concomitant Medication information as standard of care practice would dictate.
2558741|NCT02507518|Experimental|Experimental|Two Pet scan Imaging will be done : 14 days before and 16 days after the beginning of maintenance therapy
2558808|NCT02507258||PROFEMUR® Am Femoral Stem|Single study group previously implanted with a primary PROFEMUR® Am Femoral Stem and PROCOTYL® O HA Coated Acetabular Component
3206027|NCT00949832|Active Comparator|Vitamin D3|Vitamin D3 response
3206028|NCT00949897|Active Comparator|Biofoam|
3171628|NCT00589680||2|Patients treated for DKA under DKA protocol implemented by hospital
3171629|NCT00589680||1|To establish a baseline on how patients are being treating with DKA in general and without a standardized DKA protocol
2559063|NCT02505282||Orthostatic Hypotension|>20mmHg systolic BP drop or >10mmHg diastolic BP drop on standing, and syncopal symptoms on standing
2559064|NCT02505282||Control|No fall in BP or <20mmHg systolic BP drop and <10mmHg diastolic BP drop on standing, and no syncopal symptoms on standing
2559124|NCT02504957|Other|Photodynamic therapy|Patients who underwent photodynamic therapy for malignant biliary obstruction.
2559181|NCT02504567|Other|Laser ablation|Ablation with laser catheter
2559185|NCT02504567|Other|RF ablation|Ablation with RF catheter
2559339|NCT02503657|Placebo Comparator|Double-Blind Treatment|"Subjects who complete all of the screening assessments and meet all inclusion/exclusion criteria will be started on MN-001 (tipelukast) 750 mg or matching placebo bid. Subjects will return to the clinic on Treatment Day 1 to receive their first dose of study medication. Subsequently, subjects will return to the clinic on a regular basis for 26 weeks.~During the Treatment Phase, safety and efficacy parameters will be assessed and concomitant medications will be documented. The safety and tolerability of MN-001 will be evaluated by an Independent Safety Monitor during this phase."
2559644|NCT02501655|Experimental|Phase 2|Mesh nebulizers
3171630|NCT00589706|Experimental|A|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections. The purpose of this protocol is to allow you to receive course(s) of 1251-MAB 425 until your brain tumor begins to grow, you develop side effects to the treatment, or your medical condition changes (ie: become affected with human immunodeficiency virus (HIV) or develop another cancer).
3171631|NCT00589719||2000,3000,4000|Children at risk for asthma were identified using a cross-sectional asthma screening survey.
3171632|NCT00589732|Experimental|Valsartan treatment gorup|Valsartan 160mg per day group
3171633|NCT00589732|No Intervention|No Valsartan treatment group|No valsartan treatment
3171634|NCT00589745|Other|Subjects being evaluated for CF|Subjects will be referred from physicians who are clinically concerned about the possibility of Cystic Fibrosis. Nasal potential difference measurement will be obtained to potentially help aid in diagnosis.
3171635|NCT00589758||Acute Decompensated Heart Failure|"Admitted to Heart Failure ICU for acute decompensated heart failure. 2D and 3D echocardiography will be obtained at baseline, 24 -48 hours and 1-2 weeks post discharge.~Blood and urine will be collected for biomarker evaluation at each timepoint"
3171636|NCT00589771|Experimental|A|"Capsule Saccharomyces boulardii 250 mg TDS for six weeks.~Ispahgula husk 1 Tsf daily after dinner for six weeks."
3171637|NCT00589771|Placebo Comparator|B|"Capsule Placebo TDS for six weeks.~Ispaghula husk 1 Tsf daily after dinner for six weeks"
2558534|NCT02508987||Group 2|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as gingivitis. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.~18.50-24.99 kg/m2: Normal-weight"
2558542|NCT02508987||Group 3|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index.18.50-24.99 kg/m2: Normal-weight"
2558547|NCT02508987||Group 4|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as either 'periodontally healthy'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
2558552|NCT02508987||Group 5|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'gingivitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
2558558|NCT02508987||Group 6|"Periodontal status was assessed by clinical examination and classified according to criteria proposed by the 1999 International World Workshop for a Classification of Periodontal Disease and Conditions as 'generalized chronic periodontitis'. Periodontal status was determined by evaluating the following clinical parameters: Silness & Löe plaque index; Löe & Silness gingival index; probing pocket depth; clinical attachment level; bleeding on probing.~Obesity was diagnosed according to World Health Organization criteria using body mass index. 30.00-34.9 kg/m2: Obesity class I"
3171638|NCT00589810||Controls|Controls = Patients in Genebank that had BMS placed that did not go on to have ISR within 1 year of BMS placement and have not had prior ISR in any vessel ever. If testing is available, the Control status will be further verified by angiographic documentation of <50% luminal loss with the stent or negative stress test six or more months after stenting.
3171639|NCT00589810||Cases|Cases = Patients in Genebank that had BMS placed that went on to have ISR which is defined as PCI or CABG to the Target Vessel within 1 year of the BMS placement.
3171640|NCT00589823|Active Comparator|1|Immediate Release Morphine sulphate capsules taken at start of relevant BTCP episode. Each episode treated with either this medication OR the experimental comparator.
2558762|NCT02507700|Active Comparator|popliteal block|Popliteal block will be performed with a single dose of 0.3 ml·kg(-1) of 0.25% bupivacaine.
2558765|NCT02507700|Sham Comparator|Plaster cover|Only plaster cover will be applied without nerve block for sham procedure.
2558807|NCT02506998|Experimental|DLE plus standard medications|"DLE + Second generation anti histamines + Nasal corticosteroids DLE 2mg/5 milliliters (mL) P.O. every 24h per 5 days, followed by 2 mg/mL P.O. twice weekly for 5 weeks, follow by 2 mg/5mL per week for 5 weeks.~Second generation anti histamines at standard dosis every 24h, and Nasal corticosteroids two spray released per nostril every 24 h per 11 weeks"
3171641|NCT00589823|Experimental|2|Nasalfent spray taken at start of relevant BTCP episode. Each episode to be treated with either this medication OR the active comparator (IRMS)
3171642|NCT00589862|Experimental|1|
3171643|NCT00589875|Experimental|Single arm|This study is an extension of evaluation of the surgical resection arm, Arm B, from a phase Ib study in which dose escalation on arm B was completed.
3171644|NCT00589901|Experimental|A|phase II trial of capecitabine and cyclophosphamide in the management of metastatic breast cancer
3171645|NCT00589927|Experimental|cilostazol|Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
3171646|NCT00589927|Placebo Comparator|placebo|Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
3171647|NCT00589953|Placebo Comparator|EPO###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
3171648|NCT00589953|Experimental|EPO ###|"All subjects will be identified as a such by the study identifier EPO### where EPO designates enrollment in this study and ### is a numeric identifier (e.g. 103)."
3171649|NCT00589966|Experimental|Coping Skills Training|
3171650|NCT00589966|Active Comparator|Prostate Cancer Education|
3171651|NCT00590070|Active Comparator|1|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
3171652|NCT00590070|Active Comparator|2|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered.
3171653|NCT00590070|Placebo Comparator|3|Patients will receive intravenous administration of abciximab prior to PCI. After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary drugs will be selectively administered
3171654|NCT00590083|Experimental|Virus Specific Cytoxic T lymphocytes|Virus Specific Cytoxic T lymphocytes
3171656|NCT00590122|Experimental|b|Parcopa at equivalent dosage to subjects surrent stable dose
3171657|NCT00590122|Active Comparator|a|carbidopa-levodopa at subjects current stable dose
2558539|NCT02508857|Placebo Comparator|saline|intravenous saline solution (20 ml) is injected in bolus, followed by continuous infusion of saline infusion during the entire procedure (Group S).
2558597|NCT02508441|Experimental|Andes-1537 for Injection|Part 1 is an open-label, dose-escalation study. Part 2 is an open-label, dose-expansion study.
2558671|NCT02508233||Control|Healthy subjects (without ankle osteoarthritis) for validation of translation
2558672|NCT02508233||ankle OA|Ankle osteoarthritis patients to ensure validity of translated scale
2558776|NCT02507362|Experimental|experimental|Radiation: adjusted corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 7 minutes after 30 mitunes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
2558781|NCT02507362|Active Comparator|control|radiation: accelerated corneal collagen cross-linking (9mW/cm2 UV-A irradiation for 10 minutes after 30 minutes of riboflavin instillation) riboflavin 0.1%: after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation epithelial debridement: corneal epithelium will be removed by a cottons swab
2558814|NCT02506972|Other|30g oats|Classic Quick Quaker Oats
2558820|NCT02506972|Other|30g oats plus 9g sugar|Classic Quick Quaker Oats
2558823|NCT02506972|Other|40g oats|Classic Quick Quaker Oats
2558826|NCT02506972|Other|60g oats|Classic Quick Quaker Oats
2558829|NCT02506972|Other|22g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
2558831|NCT02506972|Other|29g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
2558833|NCT02506972|Other|33g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
2558834|NCT02506972|Other|44g cream of rice cereal|Cream of Rice Cereal, B&G Foods, Inc.
2558856|NCT02506608|Experimental|Operation of sensorized hand prosthesis|"A system composed by the integration of the following non-CE marked medical devices specifically designed for the study will be used in amputees:~STIMEP (multichannel electrical stimulator for the peripheral nervous system; AXONIC)~TIME 4H Intraneural Electrodes (ALBERT-LUDWIGS-UNIVERSITAET FREIBURG)~Sensorized hand Prosthetics for amputees IH2 Prosthetic Azurra Prensilia (Prensilia Ltd.)~Prosthetics sensorized hand for amputees DLR / HIT Hand II (Wessling Robotics)~ODROID software integration within the afferent and efferent bi-directional control of the robotic hand"
2558922|NCT02506478||ED patients|All ED patients who are able to drink water/juice, and be able to communicate juice preference.
2558972|NCT02506049|Other|S-LPC:Selective Laser Photocoagulation|S-LPC seals connecting vessels, normalizes flow between twins
2558987|NCT02505685||Lung cancer|People that were diagnosed with advanced lung cancer.
2559044|NCT02505568|Experimental|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 and will be evaluated for the induction phase at Week 8. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion at Week 14, Week 22, and Week 30 in the maintenance phase and will be evaluated at Week 32.
2559128|NCT02504983|Active Comparator|GALNT14 TT|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
2559129|NCT02504983|Active Comparator|GALNT14 non-TT TACE alone|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued.
2559130|NCT02504983|Experimental|GALNT14 non-TT TACE plus sorafenib|Patients will be treated by Transcatheter arterial chemoembolization every 12 ± 2 weeks dependent on CT evaluation, plus sorafenib adjuvant therapy. Before each TACE, dynamic CT will be performed for pre-treatment evaluation. When no viable tumor is seen on CT, TACE is to be discontinued. patients will receive sorafenib 400 mg/d between each TACE. Patient will start receiving Sorafenib on Day 4 (up to Day 7) after 1st TACE (Day 1) and will interrupt after evening dose 4 days before each next TACE and re-start Sorafenib on Day 4 (up to Day 7) after each TACE cycle.Additional sorafenib treatment is optional and will be judged by investigator in the subject's best medical interest.
2559198|NCT02504463|Experimental|Samidorphan IV|Samidorphan solution for IV administration
2559201|NCT02504463|Experimental|Samidorphan sublingual|[14c]-Samidorphan for sublingual administration
2559209|NCT02504463|Experimental|Samidorphan oral|[14c]-Samidorphan for oral administration
2559256|NCT02504190||lymphoma patients eligible for TEAM conditioning|Lymphoma Patients who are eligible will be included. Patients will undergo TEAM conditioning regimen followed by autologous haematopoietic stem cells transplantation according to standard practice of the centre and drugs label in France.
2559314|NCT02504060|Placebo Comparator|Starch capsule|During the 12- weeks treatment phase of the study, the daily dose of 3 tablets will be taken 30 minutes after breakfast, lunch and supper.
2559316|NCT02504060|Experimental|N-acetyl-D-glucosamine|During the 12- weeks treatment phase of the study, the daily dose of 100mg*3 (3 tablets) will be taken 30 minutes after breakfast, lunch and supper.
3206029|NCT00949897|Active Comparator|Iliac Crest Allograft with locked plate|
2559445|NCT02502942|Experimental|Untreated OSA Muscle Exercise Group|Patients who were previously diagnosed of obstructive sleep apnea (OSA) with apnea hypopnea index (AHI) > 10 events/hr and have previously failed or refused PAP therapy. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
2559448|NCT02502942|Experimental|PAP Therapy Muscle Exercise Group|OSA patients who are currently treated with PAP for their OSA (with AHI of previous sleep study > 10 events/hr). In this group, patients will learn and practice upper airway muscle exercise for six weeks.
2559451|NCT02502942|Experimental|Oral Appliance Muscle Exercise Group|OSA patients who are currently treated with an oral appliance with residual AHI > 10 events/hr. In this group, patients will learn and practice upper airway muscle exercise for six weeks.
2559453|NCT02502942|Active Comparator|Normal Control Sham Exercise Group|Patients of untreated OSA group, PAP therapy group, and oral appliance group are randomized to upper airway muscle exercise versus sham exercise.
2559497|NCT02502630|Experimental|Treated with microwave ablation|Patients undergoing MWA for pulmonary metastases from colorectal cancer.
3206030|NCT00949923|Active Comparator|tea capsules|3 tea capsules daily for 3 weeks
3206031|NCT00949923|No Intervention|Control|No tea capsules
3206032|NCT00949949|Experimental|Cohort I (everolimus and gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and everolimus PO once daily or 3 times weekly.
2558663|NCT02508090||Study Population|Participants who previously received 12 weeks of miravirsen monotherapy in Study SPC3649-207 will complete up to 36 months of safety and efficacy follow-up without investigational treatment.
2558739|NCT02507726|Experimental|Flexima Active Soft convexe|Flexima Active soft convexe (1 to 3 appliances per day)
3206033|NCT00949949|Experimental|Cohort II (everolimus, gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 1 hour on days 1 and 8 and everolimus PO once daily or 3 times weekly.
3206034|NCT00949949|Experimental|Cohort III (MTD)|Patients receive treatment as in cohort II.
2558857|NCT02506842|Experimental|nab-paclitaxel + gemcitabine (AG)|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
2558869|NCT02506842|Experimental|oxaliplatin + folinic acid + fluorouracil (OFF)|oxaliplatin at 85mg/m^2 on days 8 and 22, folinic acid at 200mg/m^2 on days 1,8,15 and 22, fluorouracil at 2000mg/m^2 on days 1,8,15 and 22.
2558920|NCT02506166|No Intervention|No or Mild Sleep Apnea Group (Group 1)|"ICM patients with no or mild sleep apnea enrolled in this arm will continue with standard therapy (ICD/CRT-D implant + maximal medical therapy), but will receive no active Positive Airway Pressure (PAP) therapy for sleep apnea treatment. See Part: Study Population for more details.~In all ICM patients enrolled into ESCAPE-SCD Study, the ICD/CRT-D devices will be implanted based on current ESC Guidelines for primary prevention of sudden cardiac death (see Section: References)"
2558926|NCT02506166|No Intervention|Obstructive Sleep Apnea - Control Group (Group 2)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), but no PAP therapy for sleep apnea treatment. See Part: Study Population for more details."
2558932|NCT02506166|Active Comparator|Obstructive Sleep Apnea - Active Group (Group 3)|"ICM patients with predominant obstructive sleep apnea randomised to this arm will receive standard therapy (ICD/CRT-D implant + maximal medical therapy), plus as intervention, all patinets in this group will receive sleep apnea treatment by using PAP device. See Part: Study Population for more details."
2558936|NCT02506166|No Intervention|Central Sleep Apnea Group (Group 4)|"ICM patients with predominant central sleep apnea enrolled in this group will receive standard therapy (ICD/CRT-D implant + maximal medical therapy). Because the SERVE-HF Trial demonstrated a negative effect of predominantly central sleep apnea treatment on cardiovascular mortality in patients with HFrEF by using adaptive servo-ventilation therapy, patients in Group 4 will not receive any PAP therapy for treatment of sleep disordered breathing. See Part: Study Population for more details."
2558962|NCT02505984|Active Comparator|Oxytocin|Sub-group of participants receiving oxytocin nasal spray (Syntocinon)
2558964|NCT02505984|Placebo Comparator|Placebo|Sub-group of participants receiving placebo nasal spray
2558983|NCT02505711|Experimental|Homestead Food Production|Enrolled in Homestead Food Production program from 2015 to 2019, 48 clusters, approx. 1350 women and 750 children
2558990|NCT02505711|No Intervention|Control|(Health system strengthening in the study area), 48 clusters, approx. 1350 women and 750 children
2559040|NCT02505503|Active Comparator|Unloading shoes|The unloading shoe will be a trainer-type shoe with a cosmetically-shaped rocker sole. The sole will have three circular curves whose arc centres are positioned at the anatomical ankle, hip and knee respectively; assuming a vertical lower limb. This is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
2559042|NCT02505503|Placebo Comparator|Unadapted control shoes|The control shoes will be similar in appearance to the unloading shoes, but they will not contain the altered sole.
2559107|NCT02505048|Experimental|rucaparib|"Tablets 200 mg and 300 mg per os : 600 mg / bid every day in continuous.~Patients will be treated with rucaparib Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks (RECIST 1.1) Safety will be assessed continuously"
2559156|NCT02504710|Active Comparator|Traditional Learning System|Traditional systems of manual therapy teaching
2559158|NCT02504710|Experimental|Kinematic Real-Time Feedback|Kinematic real time feedback to learn Manual therapy
2559233|NCT02504385|Experimental|Virtual Reality Timocco|The study group will integrate the use of Timocco in occupational therapy sessions. The session will begin with 15 minutes of spatial activity involving sensory-motor practice, 15 minutes of activity in a virtual environment, and 15 minutes of structured activity at a desk.
2559234|NCT02504385|Active Comparator|Conventional OT intervention|The control group will be given conventional occupational therapy without using Timocco. In order to ensure that the therapy sessions in this group have a structure similar to that one used in the study group, each session will include 25 to 30 minutes of spatial sensory-motor activity, followed by 15 to 20 minutes of structured practice at a desk.
2559265|NCT02504138|Experimental|Desflurane balanced anesthesia group|
2559266|NCT02504138|Active Comparator|Propofol total intravenous anesthesia group|
2559294|NCT02503839|Experimental|Arm#1|"arm#1 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days.~Step-wise inclusion starting with arm#1,arm#2 and arm#3 (first group) randomized (2:2:1) and if safety data are satisfactory proceeding with arm #4 and the rest of arm#3 randomized (2:2:1)."
2559297|NCT02503839|Experimental|Arm#2|arm#2 (n=10) receiving H56:IC31 vaccine at day 84 and 140 and no etoricoxib.
3206035|NCT00949962|Active Comparator|Arm I|Patients undergo post-operative conformal external beam irradiation for 6.5 weeks.
3206036|NCT00949962|Experimental|Arm II|Beginning on day -5 to -3, patients receive an antiandrogen for 2-4 weeks. Beginning on day 0, patients receive leuprolide acetate subcutaneously once (6-month depot) and undergo conformal external beam irradiation 5 times weekly for 6.5 weeks.
3206037|NCT00950001|Experimental|Arm I (SRS)|Patients undergo stereotactic radiosurgery to the surgical cavity within 30 days of the craniotomy.
3171658|NCT00590174|Experimental|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3171659|NCT00590174|Active Comparator|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
2558803|NCT02507193|Active Comparator|Open reduction internal fixation(ORIF)|This surgical intervention is performed using a plate and screws.Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
2558804|NCT02507193|Active Comparator|Intermedullary (IM) Nail|This surgical intervention is performed using an intermedullary nail. Under general anesthesia, an incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
2558840|NCT02506920|Active Comparator|Pack butter|Oral fat tolerance test contains: Cream, lactic acid culture, salt. Fat contents in grams: Saturated fat (SFA) 52, monounsaturated fat (MUFA) 19.1, polyunsaturated fat (PUFA) 1.6
2558843|NCT02506920|Active Comparator|Kjaergaarden blend butter|Oral fat tolerance test contains:Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 37.4, MUFA 27.3, PUFA 1.8
2558845|NCT02506920|Active Comparator|Blend butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, salt. Fat contents in grams: SFA 23.7, MUFA 23.2, PUFA 7.8
2558846|NCT02506920|Active Comparator|Fish oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, lactic acid culture, fish oil, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 0.7
2558848|NCT02506920|Active Comparator|Olive oil enriched butter|Oral fat tolerance test contains: Butter rapeseed oil, olive oil, lactic acid culture, salt. Fat contents in grams: SFA 22.6, MUFA 26.9, PUFA 5.7
2558849|NCT02506920|Active Comparator|Low saturated fat butter|Oral fat tolerance test contains: Butter, lactic acid culture, salt. Fat contents in grams: SFA14.9, MUFA16, PUFA 5.6
2558858|NCT02506582|Experimental|Test group|jerusalem artichoke and fermented soybeans powder mixture supplementation
2558873|NCT02506582|Placebo Comparator|Placebo group|placebo supplementation
2558929|NCT02506439|Experimental|10 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 10 mcg [400 IU] daily
2558939|NCT02506439|Experimental|20 mcg Vitamin D3|White-skinned women will receive Cholecalciferol (Vitamin D3) 20 mcg [800 IU] daily
2558944|NCT02506439|Placebo Comparator|Placebo|White-skinned women will receive a Placebo supplement, identical in appearance and taste to the active product
2558988|NCT02505841|Active Comparator|Group 1|Curare: Atracurium injection at 0.5 mg/kg
2558994|NCT02505841|Experimental|Group 2|TAP block and curare: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg then atracurium injection at 0.5 mg/kg
2558999|NCT02505841|Experimental|Group 3|TAP block: Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
2559102|NCT02505139||Study Group|
2559238|NCT02504242|Experimental|Inject BMP|ExcelOS Inject / rhBMP-2
2559239|NCT02504242|Active Comparator|Locally Harvested Bone|Locally Harvested Bone
2559328|NCT02503748|Experimental|Intervention|Online Tutorial
2559396|NCT02503293|Other|Chrono Super PID then Generic Syringe - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Chrono Super PID then Generic Syringe-Gammanorm"
2559398|NCT02503293|Other|Generic Syringe then Chrono Super PID - Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Generic Syringe then Chrono Super PID-Gammanorm"
2559423|NCT02503007|Placebo Comparator|Placebo|A placebo similar in composition and appearance to the experimental treatment.
2559426|NCT02503007|Experimental|HMB-FA|Active treatment consisting of 3 g of HMB-FA per day.
2559481|NCT02502799|Active Comparator|Continued Monitoring and Assessment|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. Participants randomized to the continued monitoring and assessment arm will receive no additional intervention. Primary and secondary outcomes will be monitored.
2559488|NCT02502799|Active Comparator|PT with ACBT|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (CBT).
2559528|NCT02502474|Experimental|Patients undergoing a colonoscopy|Staphylococcus aureus carriage is measured in nose, throat, colon, rectum and groin
3171660|NCT00590187|Experimental|A sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
3171661|NCT00590187|Experimental|B sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
3171662|NCT00590187|Experimental|C sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
3171663|NCT00590187|Experimental|D sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
3171664|NCT00590187|Experimental|E sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
3171665|NCT00590187|Experimental|F sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
3171666|NCT00590187|Experimental|G sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
3171667|NCT00590187|Experimental|H sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
3171668|NCT00590187|Experimental|I sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
3171669|NCT00590252||Scheduled for an MRI|Clinically Indicated Adults
3171670|NCT00590265|Experimental|1|
3171671|NCT00590265|Placebo Comparator|2|
3171672|NCT00590291||Cases|premature CAD and MI, AVM
3171673|NCT00590291||Controls|No CAD, MI, AVM
3171674|NCT00590304||EU, LV, MA, EL, DU|The population will consist of 120 English-speaking participants ages 4-17 years from four rural schools with physician-diagnosed asthma or symptoms of asthma in the previous 12 months. As of June 2008, an additional rural school has been added to the population criteria, making a total of five rural schools.
3206038|NCT00950001|No Intervention|Arm II (observation)|Patients undergo clinical observation after craniotomy.
3206039|NCT00950014|Experimental|Percentage format only|Numbers are presented in percentage format (e.g., 35%, 0.2%) only.
3206040|NCT00950014|Experimental|Fixed frequency format only|Numbers are presented in fixed frequency format only (5 out of 1000, 0.6 out of 1000). Denominators remains the same for each number.
2558742|NCT02507687|Experimental|Bimatoprost Sustained-Release (SR)|Assigned Primary Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
2558746|NCT02507687|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Assigned Primary Eye: SLT administered on Day 1 followed by up to two Sham Bimatoprost SR administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16). Contralateral Eye: Sham Selective Laser Trabeculoplasty (SLT) administered on Day 1 followed by up to two Bimatoprost SR Administrations (Cycle 1 at Day 4 and Cycle 2 at Week 16 or at the time of the second administration for patients who receive it later than Week 16).
2558855|NCT02506595|Experimental|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) -
2558870|NCT02506595|No Intervention|Waitlist control|Participants randomized to the Waitlist control condition will be contacted once weekly for 5 weeks to monitored status and then invited to participant in treatment.
2558918|NCT02506426|Active Comparator|Endoscopic Sinus Surgery + Septoplasty|A surgery that uses special telescopes through the nostrils to make the nasal septum straight and open the facial sinuses without any incisions. The sinuses are opened using special microscopic instruments and the procedure takes approximately 90 - 120 minutes.
2558924|NCT02506426|Experimental|Septoplasty alone|A surgery that is performed to straighten a bent nasal septum. It is shorter (take approximately 25 - 30 minutes) and less invasive (do not open the facial sinuses) that might provide the same benefits compared to the larger and longer endoscopic sinus surgery.
2558973|NCT02505932||Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
2558974|NCT02505932||Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
2559000|NCT02505659|Experimental|EXPERIMENTAL GROUP|Sessions are aiming to neuromuscular and functional training. Each session starts with trunk muscle activation. Patients will then have to realize a neuromuscular training on Huber Motion Lab® followed by multiple exercises targeting functional stability and neuromuscular control. From the 4th session, a jump sequence will be added to the previous exercices. Exercises used in this protocol are based upon successful exercises of protocols already performed on patients with anterior cruciate ligament rupture.
2559002|NCT02505659|No Intervention|CONTRL GROUP|a control group (without preoperative reeducation)
2559024|NCT02505464||Pregnant Women & their fetuses/infants|Information about pregnant women and their fetuses/infants, including the medical history, prenatal, perinatal, and postpartum periods (6 weeks after delivery) and throughout the treatment (e.g.surgery) for the child's medical condition (up to approx. child is @ 6 months of age), will be collected in this repository. The analysis of this information may help in understanding of the causes of fetal anomalies.
2559069|NCT02505256||case group|cases who presented as breast pain or breast lumps, and no intervention will be administered.
2559123|NCT02504944|Experimental|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%). The treatment will be started as soon as the diagnosis of stage 1 ROP is made and will be continue until the development of retinal vascularization is completed, but no more than 90 days. Cardiovascular and respiratory parameters will be continuously monitored. Blood samplings checking metabolic, renal and liver functions will be performed periodically, as well as cardiac function, in order to verify the treatment safety. Propranolol concentrations will be measured on dried blood spots at the steady state (10th day). Serial ophthalmological evaluations will be planned to monitor the efficacy of the treatment, the ROP progression and the possible complications.
3206041|NCT00950014|Experimental|Variable frequency format|Frequency denominators are adjusted to keep the numerator greater than 1, so they may change throughout the survey (e.g., 6 out of 1000, 42 out of 100)
3206042|NCT00950014|Active Comparator|Fixed combination format|Numbers are presented with both percentages and frequencies, and frequency denominators remain fixed (e.g., _ out of 1000).
3206043|NCT00950014|Experimental|Variable combination format|Numbers are presented with both percentages and frequencies, but frequency denominators may vary (e.g., _ out of 1000, _ out of 100).
2559467|NCT02502721|Experimental|Part A|To study effect of DWC20151 on DWC20152 PK
2559468|NCT02502721|Experimental|Part B|To study effect of DWC20152 on DWC20151 PK
2559511|NCT02502500|Active Comparator|Celecoxib|Celecoxib
2559512|NCT02502500|Experimental|AKB-6548 and Celecoxib|AKB-6548; celecoxib
2559585|NCT02502045|Experimental|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days. A flexible window of has been allowed to accommodate participants and care routines.
2559588|NCT02502045|Placebo Comparator|Non-Therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
2559621|NCT02501720|Active Comparator|Tourniquet Group|Post burn flexion contractures will be released under tourniquet control
2559627|NCT02501720|Experimental|Tumescent technique group|Post burn flexion contractures will be released using Tumescent solution
2559699|NCT02501499||Breastfeeding Buddies participants|Mothers that participated in Me Breastfeed workshops. Half will have been in the education-only group and half will have a buddy/peer support person in addition to the workshop.
3206044|NCT00950027|Experimental|povidone iodine|Povidone iodine
3206045|NCT00950027|Placebo Comparator|placebo|
3206046|NCT00950040|Experimental|Brief alcohol intervention|Brief alcohol intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
3206047|NCT00950040|Active Comparator|General Health Education|General health education intervention delivered in 2 15-minute in-person sessions and 2 5-minute telephone sessions.
2558675|NCT02508064|Experimental|Part 1: Prototype 1|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 1)
2558678|NCT02508064|Experimental|Part 1: Prototype 2|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 2)
2558680|NCT02508064|Experimental|Part 1: Prototype 3|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 3)
2558682|NCT02508064|Experimental|Part 1: Prototype 4|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 4)
2558683|NCT02508064|Experimental|Part 1: Prototype 5|BMS-663068 600 mg ER low-dose tablet formulation (Prototype 5)
2558684|NCT02508064|Experimental|Part 2|BMS-663068 1 × 600 mg ER tablet formulation
2558685|NCT02508064|Experimental|Part 2: Prototype 1|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 1)
2558687|NCT02508064|Experimental|Part 2: Prototype 2|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 2)
2558692|NCT02508064|Experimental|Part 2: Prototype 3|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 3)
2558696|NCT02508064|Experimental|Part 2: Prototype 4|BMS-663068 600 mg ER prototype multi-particulate formulation (Prototype 4)
2558777|NCT02507336|Experimental|Group A - CR+Thalidomide|Patients who achieved complete response (CR) in 20030165 and continue to receive maintenance Thalidomide. Patients in Group A will receive daily oral thalidomide (THALOMID®) as per standard of care and THALOMID® REMS™ guidelines. Patients will continue with thalidomide (THALOMID®) as per standard of care guidelines, until progression of disease, discontinuation due to toxicity, death or study withdrawal. Patients will receive annual clinical/laboratory evaluations.
2558784|NCT02507336|No Intervention|Group B - CR+No Thalidomide|Patients who achieved complete response (CR) in 20030165, but are not receiving maintenance Thalidomide. Patients will receive annual clinical/laboratory evaluations.
2558785|NCT02507336|No Intervention|Group C - PD or Expired|All other patients enrolled in 20030165 who expired or experienced disease progression (PD). Patients will be followed annually for survival.
2558817|NCT02507024||Intervention|The online questionnaire includes questions about how ANCA-associated vasculitis effects patients quality of life.
2558876|NCT02506751|Experimental|Liothyronine|"Subjects will take oral liothyronine for a total of 24 weeks following the below titration schedule:~0-6 weeks: liothyronine 10mcg po daily (5mcg po BID)~6-12 weeks: liothyronine 20mcg po daily (10mcg po BID)~12-18 weeks: liothyronine 50mcg po daily (25mcg po BID)~18-24 weeks: liothyronine 1mcg/kg/day (0.5mcg/kg po BID), not to exceed 75mcg po daily"
2559462|NCT02502903|Placebo Comparator|Part A|Single ascending dose (SAD) in NHVs, 7 cohorts, BIVV009 by IV infusion (0.3,1, 3, 10, 30, 60, or 100 mg/kg) or placebo.
2559463|NCT02502903|Placebo Comparator|Part B|Multiple ascending dose (MAD) in NHVs, 2 cohorts, 4 weekly IV doses of BIVV009 (30 or 60mg/kg) or placebo.
2559464|NCT02502903|Experimental|Part C|Multiple dose (MD) in a single cohort of patients with various complement-mediated disorders. All patients in Part C will receive a single IV test dose of BIVV009 of 10 mg/kg followed by 4 weekly doses of 60 mg/kg.
2559465|NCT02502903|Experimental|Part E|Multiple dose (MD) in a single cohort of patients with cold agglutinin disease previously treated with BIVV009. All patients in Part E will receive a single IV test dose at week 0, week 1, and every 2 weeks thereafter until EOT. Patients who weigh less than 75 kg will receive fixed doses of 6.5 grams of BIVV009; patients who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009. Dose will be increased from 6.5g to 7.5g dose level if patients current weight is >= 75 kg and there is evidence of hematologic breakthrough OR patients current weight is >= 75 kg and there has been at least a 10 percent increase from the patients last recorded weight. Dose will be decreased from 7.5g to 6.5g for patients whose last weight was >= 75 kg and current weight decreased to < 75 kg. Dose decrease will require Sponsor approval.
2559513|NCT02502513|Experimental|Intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department and completion of intrusive memory diary"
2559514|NCT02502513|No Intervention|Control|Usual care in the maternity department plus completion of intrusive memory diary
2559546|NCT02502201|Active Comparator|six-minute walk study indoors first|Participants randomized to indoor six-minute walk test first
2559551|NCT02502201|Experimental|six-minute walk study outdoors first|Participants randomized to outdoor six-minute walk test first
2559557|NCT02502201|Active Comparator|six-minute walk study indoors second|Participants randomized to indoor six-minute walk test second
2559561|NCT02502201|Experimental|six-minute walk study outdoors second|Participants randomized to outdoor six-minute walk test second
2559618|NCT02501863|Experimental|Ropivacaine+fentanyl|"Femoral nerve block with ropivacaine+fentanyl~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
2559625|NCT02501863|Experimental|Ropivacaine|"Femoral nerve block with ropivacaine~Interventions: Femoral nerve catheter insertion, spinal anesthesia, IV-PCA with hydromorphone."
2559691|NCT02501551|Experimental|Regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
2559714|NCT02501213|No Intervention|A : observation|Clinical monitoring and best supportive care.
2559716|NCT02501213|Active Comparator|B : diuretics|Diuretics (spironolactone +/- Furosemide) are administered the day after the paracentesis and until the next episode requiring paracentesis.
2559760|NCT02500992||Transrectal sigmoidectomy|Patients undergoing transrectal NOTES sigmoidectomy
2559761|NCT02500992||Laparoscopic-assisted sigmoidectomy|Patients undergoing laparoscopic-assisted sigmoidectomy
2558723|NCT02507817||33-34 without Mg for neuroprotection|"Women in 33-34 weeks gestation that per protocol are not entitled for treatment with Magnesium Sulphate for neuroprotection.~blood sample and tissue sample (placenta)."
2558724|NCT02507817||PET with Mg after 34 weeks|"Women that had severe preeclamsia and where treated with Magnesium Sulphate for seizure prophylaxis and delivere after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
2558725|NCT02507817||control|"Low risk pregnanacies in similar weeks to group 3 that did not require any special teatment and delivered after 34 weeks of gestation.~blood sample and tissue sample (placenta)."
2558754|NCT02507531|Experimental|Treatment|Placement of study device (currently called NeXsys) into target aneurysm via standard endovascular procedure.
2558780|NCT02507310|Active Comparator|Control|The room will be kept at 18-20 degrees Celsius. This is within the human thermoneutral zone. It will serve as the control condition.
2558782|NCT02507310|Experimental|Warm Environment|The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
2558815|NCT02507037|Experimental|gum+PEG|used 2L PEG+sugarless gum
2558822|NCT02507037|Placebo Comparator|PEG|only used 2L PEG
2558871|NCT02506790|Experimental|Toremifene and metformin|Toremifene 60 mg daily with metformin 850 mg BID
2558877|NCT02506790|Experimental|Toremifene and melatonin|Toremifene 60 mg daily with melatonin 3 mg before sleep daily
2558881|NCT02506790|Active Comparator|Toremifene|Toremifene 60 mg daily
2558931|NCT02506244|Experimental|Immediate Monitoring|"Individuals randomized to immediate monitoring will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of the 4 month monitoring period of time 0 to 4 months.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) continuously over the 4 month monitoring period."
2558938|NCT02506244|Active Comparator|Delayed Monitoring|"Individuals randomized to delayed monitoring will receive usual care for 4 months after which they will receive the ZIO XT patch sensor and wear it for the first and last 2 week period of study months 4 through 8.~Note: Approximately 250 consenting participants will also be invited to participate in a sub-study to wear an additional monitoring device (Amiigo wristband) daily for months 4 through 8."
3206048|NCT00950053|Active Comparator|Achilles decompression & debridement|
3206049|NCT00950053|Active Comparator|Achilles decompression,debride&FHLtransf|Achilles tendon decompression and debridement augmented with FHL transfer. The preferred skin incision will be followed by central-splitting Achilles debridement, resection of a Haglund's lesion if present and pathologic, followed by FHL harvest for patients in group 2. The fixation technique in group 2 will utilize an interference screw for the FHL. For all patients, the Achilles will be reattached with lateral and medial suture anchors (just distal to interference screw in FHL patients).
2559071|NCT02505230|Experimental|Meal Order 1|"[P,P+S,HVP,LVP]~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor)."
2559073|NCT02505230|Experimental|Meal Order 2|"[P+S,HVP,LVP,P]~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables."
2559078|NCT02505230|Experimental|Meal Order 3|"[HVP,LVP,P,P+S]~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices).~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices)."
2559079|NCT02505230|Experimental|Meal Order 4|"[LVP,P,P+S,HVP]~For the LOW-VOLUME PASTA (LVP) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with grated zucchini and squash (chopped in food processor).~For the PASTA (P) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) and no vegetables.~For the PASTA+SIDE (P+S) condition, participants will view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) with a side of mixed zucchini and squash (cut in 1/2 inch half-moon slices).~For the HIGH-VOLUME PASTA (HVP) condition, participants view, consume, and evaluate a main pasta entree (Fettuccini Alfredo) mixed with zucchini and squash (cut in 1/2 inch half-moon slices)."
2559174|NCT02504658|Experimental|Text Message Group|Subjects will set 2 lifestyle goals (exercise and nutrition) and receive health tips and goal status check in messages over 1 month.
2559177|NCT02504658|Active Comparator|Control Group|"The control subjects will set 2 lifestyle goals and receive a educational booklet to review.They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over. The approximate procedure time will be 20-25 minutes."
2560327|NCT02497560|Placebo Comparator|Placebo|vegetable oil
2558753|NCT02507570|Experimental|Open label|Single arm study to evaluate safety and tolerability of Enzalutamide with concurrent administration of Radium ra 223 dichloride in subjects with symptomatic metastatic prostate cancer.
3206050|NCT00950066|Placebo Comparator|Placebo|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with placebo once a day."
3206051|NCT00950066|Active Comparator|Irbesartan 150mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg once a day."
2558864|NCT02506894|Active Comparator|magnesium sulfate|this group will receive magnesium sulfate loading dose 6 g in 500 cc of ringer solution over 20 minutes then maintenance dose of 1 g/ hour for 24 hours.
2558878|NCT02506894|Placebo Comparator|placebo group|this group will receive sodium chloride 0.9% solution for 24 hours.
2558958|NCT02506023|Active Comparator|Hemophilia A carriers with mild mutation|Hemophilia A carriers with a mild type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
2558959|NCT02506023|Active Comparator|Hemophilia A Carriers with severe mutation|Hemophilia A carriers with a severe type mutation will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
2558961|NCT02506023|Active Comparator|Control|Subjects with a mild qualitative platelet dysfunction will be given a single intravenous dose of 0.3mcg/kg of DDAVP (Desmopressin).
2558982|NCT02505737|Experimental|TH-CBT|The treatment works by teaching people with PD (PWP) the coping skills needed to manage their emotional reactions to the numerous challenges posed by the disease. Specifically, the treatment targets maladaptive thought patterns (e.g., I have no control; I am helpless) and behaviors (e.g., social isolation, lack of exercise, poor sleep habits, excessive worry), and critically, provides caregivers with the tools needed to encourage the PWPs' practice of their newly acquired coping skills. Treatment is administered over the phone and no travel is required.
2558986|NCT02505737|Other|Enhanced Usual Care|All participants will continue to receive their routine medical treatment under the supervision of their personal doctors (e.g., neurologists, psychiatrists, primary care physicians, therapists) while participating in the study. This routine treatment (e.g., usual care) will be further enhanced with the provision of written educational materials for effective coping with PD, the close clinical monitoring of depressive symptoms by study staff, and the provision of counseling resources in the local community.
2559038|NCT02505477|Experimental|N-acetylcysteine|Patients in this group will receive N-acetylcysteine (NAC) 1200mg orally twice daily (total daily dose 2400mg), for eight weeks. Each individual tablet contains 300mg NAC, therefore patients will take two tablets by mouth each morning and two tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
2559039|NCT02505477|Placebo Comparator|Placebo|Patients in this group will receive placebo tablets indistinguishable from NAC tablets, with the same protocol as NAC: two placebo tablets by mouth each morning, and two placebo tablets by mouth each evening. Manufacturer: Jarrow Industries, Inc.; Brand name: N-A-C Sustain
2559131|NCT02505087|Active Comparator|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months, then N-Acetylcysteine (NAC) for 6 months.
2559133|NCT02505087|Experimental|N-Acetylcysteine followed by Placebo|Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
2559134|NCT02505087|No Intervention|Healthy volunteers|The purpose of this group is to collect reference values for biochemical markers.
2559193|NCT02504476|Active Comparator|AMG 581 - Dose 1|
2559199|NCT02504476|Active Comparator|AMG 581 - Dose 2|
2559208|NCT02504476|Active Comparator|AMG 581 - Dose 3|
2559213|NCT02504476|Active Comparator|AMG 581 - Dose 4|
2559219|NCT02504476|Placebo Comparator|Placebo - Dose 1|
2559222|NCT02504476|Placebo Comparator|Placebo - Dose 2|
2559225|NCT02504476|Placebo Comparator|Placebo - Dose 3|
2559226|NCT02504476|Placebo Comparator|Placebo - Dose 4|
2559227|NCT02504476|Other|AMG 581/Midazolam - Drug Interaction|
2559284|NCT02504086|Experimental|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
2559310|NCT02503774|Experimental|Monotherapy|MEDI9447 (oleclumab) only
2559313|NCT02503774|Experimental|Combination|MEDI9447 (oleclumab) and MEDI4736 (durvalumab)
2559373|NCT02503475|Other|Project 1- Real-Time fMRI|"This arm investigates Real-Time fMRI within 4 groups:~Attention Regulation (AR) Group- Experimental Cognitive Regulation (CR) Group- Experimental Sham Group- Sham Comparator Free Strategy Group- Active Comparator"
2559380|NCT02503475|Experimental|Project 2 - CBT/MBSR|"This arm investigates 2 experimental groups:~Cognitive Behavioral Therapy (CBT) Mindfulness Based Stress Reduction (MBSR)"
2559383|NCT02503475|Other|Project 3- Acupuncture|"This arm investigates Acupuncture within 2 groups:~Verum- Experimental Sham- Sham comparator"
2559412|NCT02503098|Experimental|Recovery Record adaptive smartphone application (RR-A)|Participants will have access to all Recovery Record standard functions and will additionally receive tailored, algorithm-generated content targeting cognitive distortions.
2559415|NCT02503098|Active Comparator|Recovery Record standard smartphone application (RR-S)|Participants will have access to all Recovery Record standard functions, including meal monitoring, motivational enhancement, social support, and coping skill strategies.
2559506|NCT02502877|Other|Midazolam Group|"In the midazolam group the investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after."
2559508|NCT02502877|Active Comparator|Propofol group|"In the propofol group the investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery."
2559573|NCT02502188|Experimental|Part 1 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
2559577|NCT02502188|Experimental|Part 2 - CC-90005 and Placebo|CC-90005 or Placebo will be administered orally from low to high dose
2558868|NCT02506712|Other|volunteer|push a wheelchair with and without a assisting device to power manuel wheelchair
2558970|NCT02506062|Experimental|Active Arm - 200 mmHg|Patients who start in the active arm of the study will receive ischemic preconditioning (IPC) treatment consisting of applying the blood pressure cuff to a pressure of 200 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week. Patients may choose to treat at home with a portable manual blood pressure machine or may be treated in clinic by research staff. Patients will receive treatment for two weeks followed by a wash-out period (no treatment) of two weeks. Patients will then receive the placebo treatment. This completes their participation in the study.
2558971|NCT02506062|Placebo Comparator|Placebo Arm - 60 mmHg|Patients who start in the placebo arm will receive placebo treatment, consisting of applying the blood pressure cuff to a pressure of 60 mmHg for 2 minutes and thirty seconds with a resting period of two minutes and thirty seconds between treatments. This procedure is performed four times, for a total of twenty minutes per treatment. This treatment will be done three times a week for two weeks followed by a two week wash-out and then two weeks in the active treatment phase, thus completing their participation in the study.
3206052|NCT00950066|Active Comparator|Irbesartan 150 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day."
3206053|NCT00950066|Active Comparator|Amlodipine|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Amlodipine 5 mg once a day."
3206054|NCT00950066|Active Comparator|Irbesartan 300 mg|"Active Comparator: Irbesartan~Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg once a day."
3206055|NCT00950066|Active Comparator|Irbesartan 300 mg / Amlodipine 5 mg|"Before randomization (common with other arms):~There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.~After randomization:~8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day."
3206056|NCT00950079|Experimental|Sodium bicarbonate|sodium bicarbonate
3206057|NCT00950079|Active Comparator|Saline|saline infusion
3206058|NCT00950092|Other|Treatment|
3206059|NCT00950105|Experimental|CPSI-2364 1 mg p.o.|Single dose
3206060|NCT00950105|Experimental|CPSI-2364 10 mg p.o.|single dose
2559437|NCT02503020|Active Comparator|Group A|Preterm infants formula A Pretarm infants were fed on formula with Arachidonic acid (0.6%) and Docosahexaenoic acid (0.3%)
2559440|NCT02503020|Active Comparator|Group B|Preterm infants formula B Pretarm infants were fed on formula with Arachidonic acid (0.3%) and Docosahexaenoic acid (0.3%)
2559605|NCT02502708|Experimental|Group 1 (CLOSED)|"Core Regimen: Dose-escalation of indoximod, in combination with temozolomide, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
2559606|NCT02502708|Experimental|Group 2 (CLOSED)|"Expansion cohorts: Indoximod therapy at the pediatric recommended phase 2 dose (RP2D) determined by Group 1, in combination with temozolomide.~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
2559608|NCT02502708|Experimental|Group 3 (CLOSED)|"Dose-escalation of indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with progressive brain tumors.~Indoximod will be administered in escalating doses. Initial dosing will be 12.8 mg/kg/dose BID with escalation planned to 22.4 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
2559610|NCT02502708|Experimental|Group 3b|"Indoximod, in combination with up-front conformal radiation therapy, for pediatric patients with newly diagnosed treatment-naive diffuse intrinsic pontine glioma (DIPG).~Indoximod will be administered at the RP2D of 19.2 mg/kg/dose BID.~Temozolomide to be given at 200 mg/m^2 x 5 days"
2559611|NCT02502708|Experimental|Group 4|"Continued access to indoximod in combination with low-dose oral cyclophosphamide and etoposide for patients with progressive disease after treatment with indoximod plus temozolomide.~Indoximod will be administered at 32 mg/kg/dose divided twice daily.~Cyclophosphamide to be given at 2.5 mg/kg/dose daily~Etoposide to be given at 50 mg/m2/dose daily"
2559673|NCT02501356|Active Comparator|ISOThrive supplement 1|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
2559674|NCT02501356|Active Comparator|ISOThrive supplement 2|Participants assigned to the ISOThrive supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
2559675|NCT02501356|Placebo Comparator|Placebo supplement|Participants assigned to the placebo supplement arm will be provided with daily servings of a supplement for 3 months. Participants will be instructed to take the supplement with water daily, once/day in the morning during the treatment period.
2559726|NCT02501278|Experimental|Arm A: Immunotherapy during and after CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy plus immunotherapy dosing after chemoradiotherapy in an adjuvant setting and vaccine boost one year after last vaccine dosing.
2559727|NCT02501278|Experimental|Arm B: Immunotherapy during CRT + vaccine boost|INO-3112 dosing during chemoradiotherapy, and vaccine boost one year after last vaccine dosing.
2559728|NCT02501278|Active Comparator|CRT without immunotherapy|Standard chemoradiotherapy without immunotherapy
3206061|NCT00950105|Experimental|CPSI-2364 30 mg p.o.|single dose
3206062|NCT00950105|Experimental|CPSI-2364 90 mg|single dose
3206063|NCT00950105|Experimental|CPSI-2364 270 mg p.o.|single dose
3206064|NCT00950118||Congenital Diaphragmatic Hernia (CDH)|Humans affected with congenital diaphragmatic hernia (CDH)
3206065|NCT00950118||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
2558890|NCT02506543|Experimental|COMPASS intervention|Subjects in this group will be pre-tested at the same time with the subjects in the Wait-list control group. Subjects in this group will receive the intervention immediately after the initial pre-test/baseline assessment, which includes life skills education, access to mentors in safe spaces, and a structured parenting intervention for girls' caregivers. Then, the subjects in this group have completed the intervention (at 12-months post-intervention initiation), the subjects in this group will take the post-test at the same time with the subjects in the Wait-list control group.
2558892|NCT02506543|Active Comparator|Wait-list control|No intervention
3206066|NCT00950131|Experimental|Directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009)and a directive warning (i.e., stating the issue and why it matters) for new drugs.~This directive warning mentions that serious drug side effects may emerge only after the drug is already on the market, and the reader should ask their doctor there is an available drug with a longer track record."
3206067|NCT00950131|Experimental|Non-directive new drug warning|"Survey contains information about when the drug was approved by the FDA (2009) and a non-directive warning (i.e., just stating the issue) for new drugs.~This non-directive warning mentions only that serious drug side effects may emerge only after the drug is already on the market."
2558985|NCT02505724|Active Comparator|Conventional training|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice
2558989|NCT02505724|Experimental|Intervention|Participants received access to a web-based tutorial for laparoscopic suturing and a box trainer for independent practice. In addition, they received two 1/2 hour peer-coaching sessions
2559046|NCT02505581|Experimental|Oral + Parenteral prophylaxis|
2559054|NCT02505581|Active Comparator|Only Parenteral prophylaxis|
3206068|NCT00950131|Experimental|No new drug warning|Survey contains information about when the drug was approved by the FDA (2009) only.
2559235|NCT02504359|Experimental|Treatment (BEAM allogeneic transplant, ixazomib)|"BEAM CONDITIONING REGIMEN: Patients receive carmustine on day -6, cytarabine and etoposide on days -5 to -2, and melphalan on day -1.~PERIPHERAL BLOOD STEM CELL TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO on days -2 to at least 6 months with a taper as early as 3 months post-transplant and methotrexate IV on days 1, 3, 6, and 11.~MAINTENANCE THERAPY: Beginning between days 100 and 180 post-transplant, patients receive ixazomib PO on days 1 and 14 or days 1, 8, and 15 if the principal investigator deems it medically important. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
3206069|NCT00950157|Experimental|"Directive open question statement"|"Survey describes the surrogate outcome of the drug along with a directive warning (i.e., stating the issue and why it matters) for drugs shown to improve surrogate outcomes.~This directive warning mentions that it is not known whether the drug will help patients feel better, and that readers should ask their doctor if there is an available drug shown to improve patient outcomes."
3206070|NCT00950157|Experimental|Non-directive open question statement|"Survey describes the surrogate outcome of the drug along with a non-directive warning (i.e., stating the issue only) for drugs shown to improve surrogate outcomes.~This non-directive warning mentions only that it is not known whether the drug will help patients feel better."
3206071|NCT00950157|Experimental|No open question statement|Survey only describes the surrogate outcome of the drug.
3206072|NCT00950196|Experimental|amantadine (PKMERZ)|
3206073|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l."
3206074|NCT00950209|Active Comparator|euglycaemic hyperinsulinic clamp with Endolipide and heparin|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l but will be also infused with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids."
3206075|NCT00950209|Active Comparator|hyperglycaemic hyperinsulinic clamp|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48. In the second step,the patients of this arm will perform a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose."
2559731|NCT02501031|Experimental|Flaxseed (ground)|
2559734|NCT02501031|No Intervention|Usual diet|
2559773|NCT02500888|Experimental|Treatment|Radiosurgery by linear accelerator.
2559895|NCT02500212|Experimental|ENVARSUS tablets|"Envarsus® (tacrolimus) prolonged-release tablets provided in 0.75 mg, 1.0 mg and 4.0 mg dose strengths.~Envarsus® tablets will be administered orally once daily in the morning"
2559900|NCT02500212|Active Comparator|ADVAGRAF capsules|"Advagraf® (tacrolimus) prolonged-release hard capsules provided in 0.5 mg, 1.0 mg, 3.0 mg and 5.0 mg dose strengths.~Advagraf® capsules will be administered orally once daily in the morning"
2559942|NCT02499848|Experimental|Intraprostatic administration|PRX302
2559981|NCT02499679||Patients diagnosed with CAD by cCTA|All clinically stable, symptomatic patients diagnosed with CAD by coronary computed tomography angiography (cCTA), that meet eligibility criteria, and are able and willing to participate are candidates for the ADVANCE Registry. Those patients that meet all inclusion/exclusion criteria and who sign the ethics committee (EC)/institutional review board (IRB) approved informed consent will be enrolled in the registry. FFRCT shall be used in accordance with the current Instructions for Use (IFU) document.
2560013|NCT02499432|Experimental|Motivational Enhancement|Motivational Interviewing/Enhancement is a form of collaborative discussion for strengthening motivation and commitment to change.
2560014|NCT02499432|No Intervention|Standard training|Training as usual
2560242|NCT02498106|Active Comparator|nutritional supplement|2 Orthica Soft Multi Mini capsules and 1 Orthica Fish EPA Mini capsule per day; duration: 6 months
2558946|NCT02506296|Other|Insulin treated T2D diagnosed >=35yrs|"split by presence or absence of severe endogenous insulin deficiency:~Severe deficiency = fasting blood C-peptide ≤0.08nmol/L or stimulated C-peptide ≤0.2nmol/L or post meal urine C-peptide creatinine ratio ≤0.2nmol/mmol~Retained endogenous insulin secretion = fasting blood C-peptide ≥0.25nmol/L or stimulated C-peptide ≥0.6nmol/L or post meal urine C-peptide creatinine ratio ≥0.6nmol/mmol~Groups will be compared for:~glucose variability (via Continuous Glucose Monitoring System (CGM)) and hypoglycaemia risk (via hypoglycaemia questionnaire)~glycaemic response to standard DPPIV inhibitor therapy"
3206076|NCT00950222|Experimental|1:Imipenem/Amikacin|"patients will receive as empirical therapy for VAP imipenem associated with amikacin.After primary outcome measure, antibiotic therapy will be left at the discretion of the physician in charge of the patient.~Imipenem: recommended usual dosage for VAP treatment, IV (in the vein), every 8 hours~Amikacin: recommended usual dosage for VAP treatment (20mg/kg), IV (in the vein), single dose (at H0) for the 48 first hours of treatment"
3206077|NCT00950261|Experimental|tri-weekly cisplatin|Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
2559195|NCT02504515|Active Comparator|Homeopathy|
2559200|NCT02504515|Active Comparator|Allopathy homeopathy control|
2559206|NCT02504515|Active Comparator|Acupuncture|
2559211|NCT02504515|Active Comparator|Allopathy acupuncture control|
2559218|NCT02504515|Active Comparator|Anthroposophic medicine|
2559221|NCT02504515|Active Comparator|Allopathy anthroposophy control|
2559259|NCT02504151|Experimental|Order 1|The subject will receive treatment with CBD for four weeks, followed by a two week washout period, followed by four weeks of placebo.
2559262|NCT02504151|Experimental|Order 2|The subject will receive placebo for four weeks, followed by a 2 week washout period, followed by four weeks of treatment with CBD.
2559287|NCT02503917||Healthy volunteers|Healthy female adult volunteers
2559288|NCT02503917||Cervical cancer patients|Patients receiving radiotherapy for cervical cancer at the Royal Marsden who will receive a planning CT scan and daily CBCT scanning as part of their treatment.
2559319|NCT02503761|Active Comparator|Infusion arm|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over four hours.
2559320|NCT02503761|Active Comparator|Bolus group|Infants will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection. Each dose will be infused over thirty minutes.
2559363|NCT02503527|Other|Diben 1.5 kcal HP|Diben 1.5 kcal HP, Food for Special Medical Purposes (diabetes-specific tube feed)
2559368|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Fresubin HP Energy Fibre (1.5 kcal), Food for Special Medical Purposes (standard tube feed)
2559434|NCT02503176|Experimental|KCT-0809|
2559482|NCT02502773|Experimental|crystalloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
2559487|NCT02502773|Experimental|colloid group|The proposed Flash multicenter study will be conducted to assess if the use of HES or crystalloid solutions during an individualized GDT contribute to outcome differences in patients at moderate-to-high risk of postoperative complications after abdominal surgery
2559532|NCT02502383|Experimental|ACTION PAC|
2559538|NCT02502383|Active Comparator|Comparison|
2559592|NCT02501993||Screening cohort|All participants will be tested for anti-EBV antibody by using serum samples. Participants are stratified into those having high, moderate and low antibody levels, those having moderate antibody levels are invited to retest annually in the following 3 years and those found to have high antibody levels on these occasions are referred to centers for diagnostic workup for NPC.
2559679|NCT02501564|Experimental|Naproxen Sodium Codeine|One tablet twice a day
2559684|NCT02501564|Placebo Comparator|Placebo|One tablet twice a day
2559719|NCT02501200|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
2559721|NCT02501200|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
3206078|NCT00950274|Active Comparator|CD133+ autologous bone marrow stem cells|
3206079|NCT00950274|Placebo Comparator|Placebo|
2559909|NCT02500121|Placebo Comparator|Control Arm A|Commercially available normal saline will be used as the placebo. No active placebo drug will be mixed with the normal saline. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
2559914|NCT02500121|Experimental|Experimental Arm B|Pembrolizumab, 200mg IV every 3 weeks. Treatment will continue, in the absence of prohibitive toxicities or disease progression, for up to 24 months.
2559982|NCT02499627|Experimental|Bendamustine + Brentuximab for 6 cycles|Bendamustine 90 mg/m2 d1-2. Brentuximab vedotin 1.8 mg/kg d1.Every 21 days for 6 cycles.
2560050|NCT02499354|Active Comparator|Oral Iron|Ferrous Sulfate 325mg (oral) tabs morning and evening
2560059|NCT02499354|Active Comparator|IV Iron|Ferumoxytol intravenous (IV) 1020 mg - 2 vials of 510 mg (IV push, 2-3 mins) each given 2-7 days apart
2560093|NCT02498899|Experimental|Video 1 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
2560094|NCT02498899|Experimental|Video 2 + Questionnaires|Participants complete 4 questionnaires at baseline. Participants then watch a short video. At end of video, 3 questionnaires completed. Participants then read a small story about the patient in the video. Afterwards, another set of questionnaires completed.
3206080|NCT00950287||cohort|One group of preterm infants
2560246|NCT02498106|Placebo Comparator|placebo|During 6 months one group receives 3 placebo supplements daily with identical look and feel to Orthica Soft Multi Mini and Orthica Fish EPA Mini
3206081|NCT00950313|Active Comparator|Self Assessment|Patients are approached and asked to complete a risk score that will determine their current risk of diabetes and the likelihood of requiring further testing.
2559036|NCT02505308|Experimental|DIVA-1 CCND2|Individuals carrying a genetic change in the CCND2 gene and controls matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
2559037|NCT02505308|Experimental|DIVA-2 Low Risk of Diabetes|Individuals carrying the fewest genetic risk alleles for diabetes and controls carrying the average number of genetic risk alleles, matched for gender, age and BMI. Participants will undergo the Glucose-Potentiated Arginine-Induced Insulin Secretion (GPAIS) test plus optional faecal elastase measurement. Case/control status will be unblinded at analysis.
2559117|NCT02505113||CTPV without Montelukast|Patients with CTPV do not receive the treatment of Montelukast.
2559119|NCT02505113||CTPV treated with Montelukast|Patients with CTPV treated with Montelukast (10mg, q.d., p.o.).
2559132|NCT02504606|Experimental|Besylsartan|amlodipine besylate 6.944mg+losartan K 100mg
2559135|NCT02504606|Active Comparator|Amosartan|amlodipine besylate 7.841mg+losartan K 100mg
2559377|NCT02503319|Experimental|arm A|2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
2559381|NCT02503319|Experimental|arm B|2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery(third stage after labor)
2559388|NCT02503319|Active Comparator|arm C|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
2559406|NCT02503072|Active Comparator|Prizes conditional on adherence|Participants in this group are eligible for a prize drawing if they come on their scheduled clinic day. They receive the intervention 'Behavioral: Small lottery prizes based on adherence'.
2559408|NCT02503072|Active Comparator|Prizes conditional on clinic visits|Participants in this group are eligible for a prize drawing if they show 95% adherence or higher based on their MEMS-cap measured adherence. They receive the intervention 'Behavioral: Small lottery prizes based on timely clinic visits'.
2559446|NCT02502929|Active Comparator|Social Services|Participants in this arm will receive referrals for social services as indicated.
2559447|NCT02502929|Experimental|Lifestyle|"Participants in this arm will receive lifestyle modification from community health workers using the manualized lifestyle intervention called Eat, Walk, Sleep. They will receive individual home visits, health activity group sessions, and supportive phone calls."
2559450|NCT02502929|Experimental|Lifestyle plus Medication Therapy Management|Participants in this arm will receive everything in the Lifestyle arm, plus Medication Therapy Management (MTM). Participants will receive MTM from a pharmacist via telemedicine with the assistance of a community health worker.
2559500|NCT02502617||Weight Improvement|Patients (n = 30) with severe AN, refered to the specialized medical nutrition section at Odense University Hospital are tested three times during nutritional rehabilitation: At admission, at discharge (or drop out) and two-four months after discharge. The first study is carried out not before the third day of hospitalization after acclimatization and water electrolyte correction.
2559503|NCT02502617||Weight-stable|To investigate the re-test effects of the the surveys, outpatients with a stable weight (less than 5%/3 months) with eating disorders (n = 15) are tested twice with 4-6 weeks interval.
3171675|NCT00590343|Experimental|1|Intervention=Patients will receive treatment with PTK787/ZK222584 daily. A treatment cycle will be defined as a 28-day period. Subjects will continue on their present treatment regimen of receiving Sandostatin LAR 30mg IM every 4 weeks.
3171676|NCT00590356|Active Comparator|A2|AngioSeal®
3171677|NCT00590356|Experimental|A1|StarClose®
3171678|NCT00590408|Active Comparator|1|
3171679|NCT00590408|Placebo Comparator|2|
3171680|NCT00590421||1|145 individuals treated by irradiation in their childhood
3171681|NCT00590421||2|150 matched control subjects with no history of irradiation
2560253|NCT02498132|Active Comparator|Treatment as Usual|TAU will be provided to individuals. These subject will be provided with therapy but will not utilize a mobile application.
3171682|NCT00590434||1|Patients older than 80 years presenting for average risk screening or surveillance colonoscopy
3171683|NCT00590434||2|Patients younger than 80 years presenting for average risk screening or surveillance colonoscopy
3171684|NCT00590447|Experimental|A|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients achieving a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 further courses of single agent rituximab on days 50, 72, 94 and 116.
3171685|NCT00590447|Experimental|B|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Patients who do not achieve a CR after the first 4 applications of single agent rituximab (evaluated between day 40 to 50) will go on with 4 courses of R-CHOP on days 50, 72, 94 and 116.
3171686|NCT00590473|Active Comparator|1|Unilateral Placement of Interstim IPG
3171687|NCT00590473|Active Comparator|2|Bilateral Placement of Interstim IPG
3171688|NCT00590499||agitation group|The Riker sedation-agitated scale (SAS) levels 5-7.
3171689|NCT00590499||non-agitation group|The Riker sedation-agitated scale (SAS) levels 1-4.
3171690|NCT00590512|Active Comparator|High Sodium|High sodium
3171691|NCT00590512|Active Comparator|Low sodium|Low sodium
3171692|NCT00590525||1|
3171693|NCT00590551|Experimental|1-6|
3171694|NCT00590603|Experimental|1|Dose escalation study with two cohorts. A standard dose of Arsenic Trioxide will be given with escalating dose of Bortezomib.
3171695|NCT00590616||1|
3171696|NCT00590642||1|
3171697|NCT00590655|Active Comparator|2|Treatment B includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). Treatment lasts 17 weeks and after that there will be one and two year control visits including weighing and questionnaires for eating behavior and quality of life.
3171698|NCT00590655|Experimental|1|Treatment includes a four month weight loss programme (10 weeks on a VLED and 17 weeks behavior modification visits). After that a maintenance programme starts with monthly sessions for one year. Weight loss, quality of life, and eating behavior will be assessed at the end of the maintenance program and one year later.
3171699|NCT00590694|Active Comparator|Group1|Will receive ranibizumab treatments until resolution of macular edema only and as macular edema recurs.
2559099|NCT02505009|Experimental|tenofovir pretreated vaccine arm|Arm B case group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
2559104|NCT02505009|Active Comparator|Entecavir pretreated control arm|Arm A control group: Age, gender and pretreatment DNA matched histological controls
2559106|NCT02505009|Active Comparator|tenofovir pretreated control arm|Arm B control group: A total of 50 patients will be randomized into case (vaccine) and control group according to age, gender, pretreatment HBV DNA level.
2559146|NCT02504697||Longitudinal Cohort|For this longitudinal screening cohort, we will enroll 800 participants who currently or historically smoked and who have a 10 year Bach risk model of lung cancer > 2.5% (5). We will include participants 50 to 79 years old, with ≥10 cigarettes/day for current smokers, or ≥20 pack years for former smoker who quit 20 years ago or less. In order to further enrich for lung cancer risk, participants also will have COPD/emphysema or at least one first-degree relative with a diagnosis of lung cancer. We will exclude patients previously diagnosed with lung cancer. These patients will be followed for a total of 4 years with annual follow-up visits. Biosamples from airway and blood and images will be collected.
2559244|NCT02504281||RM|Women 18-43 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (miscarriage occurred earlier than 22 weeks of gestation for equal or greater than 2 times) in our IVF institute.
2559249|NCT02504281||Control|Normal females who are visiting Shanghai JIAI genetics and IVF institute for IVF/ICSI because of only male factor.
2559296|NCT02504047|Experimental|T-Cell replete haplo-transplant|Infusion of peripheral blood stem cells from a haploidentical related donor following myeloablative conditioning. Cyclophosphamide, mycophenolate mofetil and tacrolimus will be given for GVHD prophylaxis.
2559347|NCT02503709|Experimental|Treatment (onalespib, CDKI AT7519)|Patients receive onalespib IV over 1 hour on days 1 and 4 (cycle 0 only). Patients then receive onalespib IV over 1 hour and CDKI AT7519 IV over 1 hour on days 1, 4, 8, and 11 (cycle 1 and subsequent cycles thereafter). Cycles repeat every 21 days (7 days for course 0 only) in the absence of disease progression or unacceptable toxicity.
2559425|NCT02503124|Experimental|Chronobiological intervention|Single night's wake therapy followed by bright light therapy for a week as add-on treatment to treatment as usual.
2559428|NCT02503124|Active Comparator|Control|Treatment as usual including a private educational meeting in sleep hygiene.
2559489|NCT02502695||Cohort 1-VATS-associated best practices|"Data to be collected will include demographic data and information about the pre-operative workup, surgical procedure, postoperative course and early discharge course for these patients.~After the last patient completes the 30-day post surgery follow-up, the investigators will determine a set of best practices to implement at each of the sites for the quality improvement initiative. During the assessment period, no patients will be enrolled into the study."
2559492|NCT02502695||Cohort 2-VATS-associated best practices|-Once the set of VATS-associated best practices, an additional cohort of approximately 200 patients will be enrolled and followed in a manner identical to the first cohort.
2559527|NCT02502292|Experimental|Intervention: Fotonovela|The Photo Novel Intervention is presented to users of four different facilities (sports clubs, senior homes) who are older than 50 years. The researchers welcome scheduled eligible participants, introduce the study and ask them for their consent. Afterwards, the participants are asked to fill in the questionnaire. Then, participants are randomized to one of the four groups and are presented with the photo novel or traditional brochure either as a hard copy brochure or as pdf on a tablet computer (2x2 group design). They are instructed to read the material in their own pace and answer the accompanying questions after each story / tip.and the accompanying questionnaire.
2559586|NCT02502084|Experimental|3NT flexible endoscope|Evaluation of 3NT flexible endoscope in terms of access and evaluation of the nasal anatomy
2559634|NCT02501772|Experimental|Sanyinjiao acupressor group|In addition to maintain current treatment included oral anti-hyperglycemia agent and ACEI(angiotensin-converting enzyme inhibitor ) or ARB, subjects should wear ankle band at Sanyinjiao point ( calf , ankle on the foot tip 3 inch ), with the thumb pressing daily five minutes later and carry more than four hours for 8 weeks
2559642|NCT02501772|Sham Comparator|Control Group|In the control group, ankle band was place as same as the those for the SA(Sanyinjiao acupressor) group, but was wearing at the acupoint of Sanyinjiao with anti- surface without pressure. It was applied four hours per day for 8 weeks
2559725|NCT02501291|Experimental|Thalidomide|Thalidomide was administered at a daily dose of 50 mg to the patients. Dosage adjustment of thalidomide from 25mg daily to 100mg daily was tailored individually according to patients' tolerance to thalidomide. To minimize the sedative effect of thalidomide, the investigators recommended patients take a single dose of the study drug in the evening before bedtime.
2559766|NCT02500953|Experimental|Japanese male single fasted ASP dose-1|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559774|NCT02500953|Experimental|Japanese male single fasted ASP dose-2|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559779|NCT02500953|Experimental|Japanese male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559781|NCT02500953|Experimental|Japanese male single fasted ASP dose-4|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559785|NCT02500953|Experimental|Japanese male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559787|NCT02500953|Experimental|Japanese male single fasted ASP dose-6|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559789|NCT02500953|Experimental|Japanese male single fasted ASP dose-7|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559791|NCT02500953|Experimental|Japanese female single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2560280|NCT02497651|Experimental|Healthy, non-smoking men|Twelve healthy, male subjects. Intervention: Will undergo a liquid mixed meal test and a skin biopsy.
2559112|NCT02505126|Placebo Comparator|Placebo tDCS group|Placebo tDCS : Inactive tDCS
2559304|NCT02503930|Experimental|Active tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
2559305|NCT02503930|Sham Comparator|Sham tDCS|The Sham tDCS - an inactive stimulation.
2559338|NCT02503618||HIV-negative YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-negative
2559344|NCT02503618||HIV-positive YBMSM|Subjects are young black men who have sex with men in Atlanta, Georgia and are HIV-positive
2559348|NCT02503423|Experimental|Phase 1 - Part 1 (completed)|Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.
2559349|NCT02503423|Experimental|Phase 1 - Part 2 (completed)|Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.
2559350|NCT02503423|Experimental|Phase 1 - Part 3 (optional)|The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.
2559354|NCT02503423|Experimental|Phase 2 - Cohort 1|Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.
2559359|NCT02503423|Experimental|Phase 2 - Cohort 2|Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
2559364|NCT02503423|Experimental|Phase 2 - Cohort 3|Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).
2559369|NCT02503423|Experimental|Phase 2 - Cohort 4|Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
2559370|NCT02503423|Experimental|Phase 2 - Cohort 5|Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.
2559371|NCT02503423|Experimental|Phase 2 - Cohort 6|Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.
2559501|NCT02502552||Inflammatory Bowel Disease|Inflammatory Bowel Disease patients followed in Saint-Etienne Hospital since 3 years or more. Blood specimen 3 years after a first blood specimen
2559542|NCT02502305|Experimental|Intervention group|intervention group receives liveonline course training, 3 questionnaires at an interval of 6 weeks
2559555|NCT02502305|No Intervention|Control group|control group receives 3 questionnaires at an interval of 6 weeks
3171700|NCT00590694|Active Comparator|Group 2|Will receive ranibizumab treatments until resolution of both macular edema and PED, and as macular edema or PED recur.
3171701|NCT00590785|Experimental|1|
2559676|NCT02501421|Active Comparator|TB/FLU-04L|Live recombinant influenza vectored tuberculosis vaccine
2559681|NCT02501421|Placebo Comparator|Placebo|Buffer
2559741|NCT02501252|Experimental|CORN Based at health post|Trained CORN based at health post will provide SBA and other RH services on demand at health post or household levels on an outreach bases.
2559745|NCT02501252|Active Comparator|CORN Based at health center|Trained CORN based at health center, but working in the community in an outreach basis will provide SBA and other RH services
2559746|NCT02501252|No Intervention|Control|will be composed of a randomly selected comparable controls clusters. Control clusters (arm) will be similar with the other two arms (groups) except for the intervention.
2559764|NCT02500823||CHD group|200 consecutive patients were recruited, who have diagnosed with coronary heart disease(CHD) by coronary angiography.
2559765|NCT02500823||Control group|The 200 healthy controls without previous CHD history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.
2559820|NCT02500667|Experimental|N91115 + Rifampin|N91115 200 mg twice daily (BID) from Study Day 1- 13, Rifampin 600 mg once daily (QD) from Study Day 8 - 12
2559854|NCT02500446|Active Comparator|Intensification|Oral dolutegravir 50 mg once daily for 8 weeks added to their current ART regimen.
2559858|NCT02500446|Placebo Comparator|Placebo|Oral placebo once daily for 8 weeks added to their current ART regimen.
2559892|NCT02500264|Active Comparator|Protocol #1|interventions: 1.6Hz, Rampdown 0.4S, electrodes position - both L.Rectus Abdominis, 5cmX5cm Size, on inspirium
2559896|NCT02500264|Active Comparator|Protocol #2|1Hz, Rampdown 0.6S, electrodes position - both Rectus Abdominis, 5cmX5cm Size, on inspirium
2559902|NCT02500264|Active Comparator|Protocol #3|1.6Hz, Rampdown 0.4S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium Oblique
2559905|NCT02500264|Active Comparator|Protocol #4|1Hz, Rampdown 0.6S, electrodes position - L.Rectus Abdominis and L.External Oblique, 5cmX5cm Size, on inspirium
3171702|NCT00590785|Experimental|2|
3171703|NCT00590798|Experimental|1|Patients are asked to walk within 30 minutes after implantation of the Star- Close vascular closure system.
3171704|NCT00590811||adolescents|3rd year high school girls (14-16 years old)
3171705|NCT00590811||young adults|1st year university young females (18 - 20 years old)
3171706|NCT00590837|Experimental|1|Patients will be treated by adding lomustine to chemotherapy
3171707|NCT00590837|No Intervention|2|Patients will be treated without adding lomustine to chemotherapy
3171708|NCT00590850|No Intervention|1|Closed Treatment
3171709|NCT00590850|Active Comparator|2|Open Reduction and Internal Fixation (ORIF) with Plate and Screws
3171710|NCT00590850|Active Comparator|3|Pin Fixation
3206082|NCT00950313|Active Comparator|Electronic risk score|Patients diabetes riks is determined based on their data held on practice systems. Patients are then invited for further testing based on this score.
2559155|NCT02504580|Experimental|Part A Cohort A|200 mg of HTX-011 by injection
2559157|NCT02504580|Experimental|Part A Cohort B|400 mg of HTX-011 by injection
2559160|NCT02504580|Experimental|Part A Cohort C|200 mg of HTX-011 by instillation
2559161|NCT02504580|Experimental|Part A Cohort D|400 mg of HTX-011 by instillation
2559163|NCT02504580|Experimental|Part A Cohort E|200 mg HTX-011 injection and 200 mg instillation
2559164|NCT02504580|Placebo Comparator|Part A Cohort F|Saline solution by injection
2559166|NCT02504580|Experimental|Part B Cohort A|200 mg HTX-011A by injection
2559168|NCT02504580|Experimental|Part B Cohort B|400 mg HTX-011A by injection
2559170|NCT02504580|Experimental|Part B Cohort C|200 mg HTX-011B by injection
2559173|NCT02504580|Experimental|Part B Cohort D|400 mg HTX-011B by injection
2559175|NCT02504580|Placebo Comparator|Part B Cohort E|Saline solution by injection
2559178|NCT02504580|Experimental|Part C Cohort A|200 mg HTX-002 by infiltration
2559179|NCT02504580|Experimental|Part B Cohort F|400 mg HTX-002 by infiltration
2559182|NCT02504580|Experimental|Part C Cohort B|200 mg HTX-011B by instillation
2559187|NCT02504580|Experimental|Part B Cohort G|400 mg HTX-011B by instillation
2559189|NCT02504580|Placebo Comparator|Part C Cohort C|Saline Solution by instillation
2559192|NCT02504580|Active Comparator|Part C Cohort D|0.25% bupivacaine hydrochloride injection
2559196|NCT02504580|Experimental|Part D Cohort A|400 mg HTX-011B via a combination of injection and instillation
2559203|NCT02504580|Experimental|Part E Cohort A|HTX-009 by injection
2559212|NCT02504580|Experimental|Part E Cohort B|HTX-009 by instillation
2559217|NCT02504580|Experimental|Part F Cohort A|300 mg of HTX-011B
2559220|NCT02504580|Experimental|Part F Cohort B|75 mg of 0.25% Marcaine
2559224|NCT02504580|Placebo Comparator|Part F Cohort C|10.26 mL of normal saline
2559311|NCT02503891|Experimental|Polymer on Ceramic|MP-1 Polymer on Ceramic articulation system
2559360|NCT02503579|Experimental|physical training|Participant receive a submaximal (60% -75% maximal oxygen uptake) physical activity training of 30 minutes during 8 weeks, 2 times a week. Individual heart rates will be monitored during the training.
2559365|NCT02503579|No Intervention|control|"1 training at the beginning of the study~1 training at the end of the study"
3171711|NCT00590876||1|T1DM patients with a history of severe hypoglycemia and/or hypoglycemia unawareness who have been selected based upon this history to undergo islet cell transplantation at the University of Minnesota.
3206083|NCT00950326|Active Comparator|B1-Physio|In Group B1, patients will be given physiotherapy of the hip or knee joint three times a week
3206084|NCT00950326|Experimental|A1 Hydro|In this group patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region.
3206085|NCT00950326|Active Comparator|C- Hydro & Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
3206086|NCT00950339|Experimental|4 weeks of omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
2559584|NCT02502032|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
2559587|NCT02502032|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg.
2559589|NCT02502032|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg.
3171712|NCT00590876||2|T1DM patients (C-peptide negative) who are matched for age, gender, and duration of diabetes, who also have a history of severe hypoglycemia and/or hypoglycemia unawareness meeting the criteria for islet cell transplantation. The hemoglobin A1c for each of these subjects will fall within 1% of the islet transplant recipient to whom they are matched.
2559678|NCT02501382||Patients with NSTI treated with HBOT|NSTI definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection causing necrosis in subcutis, muscle and/or fascia.
3206087|NCT00950339|Experimental|4 weeks of famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
3206088|NCT00950339|Experimental|4 weeks of pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
2559790|NCT02500745||Transesophageal echocardiography|Patients referred for transesophageal echocardiography for a clinical indication
2559792|NCT02500953|Experimental|Japanese female single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
3171713|NCT00590876||3|Nondiabetic subjects (fasting plasma glucose < 110 mg/dl) who are matched for age and gender to the islet transplant recipient to whom they are matched.
3206089|NCT00950378||CVI|Varicose veins, varicose veins with leg swelling, venous stasis skin color changes, no open ulcers
3206090|NCT00950378||No treatment|Subjects with no venous disease CEAP (clinical etiology antomy pathophysiology)Class 0
3206091|NCT00950391|Experimental|Tacrolimus|Treatment with tacrolimus following nerve repair/reconstruction
3206092|NCT00950404|Active Comparator|Viagra 50 mg tablet, administered with water.|
3206093|NCT00950404|Experimental|Formulation B ODT tablet 50 mg, administered without water.|
3206094|NCT00950404|Experimental|Formulation C ODT tablet 50 mg, administered without water.|
3206095|NCT00950404|Experimental|Formulation D ODT tablet 50 mg, administered without water.|
3206096|NCT00950417|Experimental|Esophageal Cancer|
2559329|NCT02503995|Active Comparator|No intervention|Participants not undertaking any additional exercise
2559332|NCT02503995|Experimental|Water-based exercise group|Participants assigned to a water-based exercise group
2559333|NCT02503995|Experimental|Land-based exercise group|Participants assigned to a land-based exercise group
2559374|NCT02503462|Experimental|darunavir/ritonavir vs cobicistat|All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.
3206097|NCT00950430|Experimental|PiB PET, FDG PET, Tau PET|
3206098|NCT00950443|Experimental|1|Children with upper airway obstruction
3206099|NCT00950443|Active Comparator|2|Children without upper airway obstruction
3206100|NCT00950456||H1N1 Pandemic Influenza Vaccine|Subjects will be enrolled and vaccinated according to national policy and standard practice.
2559478|NCT02502578|Experimental|CNT-01|Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
2559541|NCT02502448|No Intervention|Control group|patients undergoing cardiac surgery supposed not to get aucte normovolemic hemodilution (ANH) before CPB
2559549|NCT02502448|Active Comparator|Acute normovolemic hemodilution group|patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB
2559607|NCT02501941|Experimental|Ketamine first|"Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring."
2559609|NCT02501941|Experimental|Other sedation (typically propofol) first|Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
2559682|NCT02501616|Active Comparator|Metformin first|"Metformin first 8 wks --> Dapagliflozin 8wks.~Metformin for initial 8 weeks. During that period, metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' dapagliflozin is followed. During that period, dose of dapagliflozin is maintained 10mg/day."
2559688|NCT02501616|Active Comparator|Dapagliflozin first|"Dapagliflozin first 8 wks --> Metformin 8wks.~Dapagliflozin for initial 8 weeks. After 1 weeks of washout period, 8 weeks' metformin is followed."
2559736|NCT02501148||Carotid artery stenting|Symptomatic and asymptomatic subjects requiring carotid artery stenting, post-dilation performed using the Paladin System with integrated embolic protection
3206101|NCT00950469||patients with acute coronary syndrome|"94 consecutive patients without ST-segment elevation admitted to the Chest Pain Unit of the University of Heidelberg were enrolled with symptoms suggestive of ACS.~Unstable angina and non-ST-segment elevation myocardial infarction were diagnosed using the joint European Society of Cardiology/American College of Cardiology/American Heart Association/World Heart Federation Task Force redefinition of myocardial infarction guidelines. Patients with ST-segment elevation were excluded."
2559925|NCT02500004|Active Comparator|Cachectic pancreatic cancer|"Cachectic patients with pancreatic cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
2559927|NCT02500004|Active Comparator|Cachectic NSCLC|"Cachectic patients with non-small cell lung cancer~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
2559929|NCT02500004|Active Comparator|Cachectic COPD|"Cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
2559930|NCT02500004|Active Comparator|Non-cachectic COPD|"Non-cachectic COPD patients.~BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
2559931|NCT02500004|Other|Healthy individuals|"BAT activity: 18F-FDG PET-MRI-imaging. Body composition: DXA scanning, D2O and MRI. Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.~Systemic inflammatory profile: blood sampling. Resting metabolic rate: indirect calorimetry. Physical activity level: accelerometry. Total daily energy expenditure: double-labeled water."
2560019|NCT02499445|Active Comparator|Remifentanil and propofol|remifentanil (0.75 mcg/kg/min) propofol (TCI effect-site concentration 0.8-1.5 mcg/ml)
2560020|NCT02499445|Active Comparator|remifentanil and sevoflurane 1|remifentanil (0.75 mcg/kg/min) sevoflurane (end-tidal 0.8 vol%)
2560021|NCT02499445|Active Comparator|sevoflurane 2 and sufentanil|sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml)
3206102|NCT00950482|Active Comparator|TA|Active TA
3206103|NCT00950482|Active Comparator|AA|Alternative Acupuncture
3206104|NCT00950482|Active Comparator|WC|Waiting Group
3206105|NCT00950495|Active Comparator|Mandibular advancement device (MAD)|an MAD is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
3206106|NCT00950495|Active Comparator|nasal CPAP|The device is turned on, and the nasal mask is placed on the nose prior to sleep. After waking up in the morning, the device is turned off and the mask is removed
2559147|NCT02504632|Experimental|test group|Patient with severe, symptomatic AS (Aortic valve area < 0,6 cm2/m2 SC), deemed, after multidisciplinary heart team evaluation, contra-indicated or at high risk for surgery and suitable for TF TAVI with a MCV prosthesis.
2559149|NCT02504632|Other|control group|Patient with stable coronary artery disease, unscathed of AS Patient under aspirin treatment (75-160 mg/d for at least one week)
2559215|NCT02504411|Experimental|Device Assisted Colonoscopy|"Device assisted colonoscopy (DAC) is a technique of attaching disposable devices like Endocuff or Transparent cap at tip of colonoscope to improve mucosal visualization and stability."
2559223|NCT02504411|Active Comparator|Standard Colonoscopy|Standard colonoscopy is the endoscopic examination of the large bowel and the distal part of the small bowel with a camera on a flexible tube passed through the anus.
2559260|NCT02504177|Experimental|The group of keep medication NOAC|The randomization after scheduling of Ablation at clinic The explanation to stop taking medicine of NOAC 24 hours before the ablation
2559263|NCT02504177|Active Comparator|The group of stop medication NOAC 1 day|The randomization after scheduling of ablation at clinic. The explanation to stop taking medicine of NOAC day of ablation
2559306|NCT02503969||Screened|Those who received an adequate screen for colorectal cancer.
2559308|NCT02503969||Not Screened|Those who received an adequate screen for colorectal cancer.
2559337|NCT02503605|Active Comparator|Biosimilar recombinant FSH|Under current practice, 65 participants will be stimulated with 150 international units (IU)/day biosimilar recombinant FSH, .Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation. From this day may also vary the dose of recombinant FSH biosimilar according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
2559343|NCT02503605|Active Comparator|Urinary FSH|Under current practice, 65 participants will be stimulated with 150 IU/day of urinary FSH. Daily doses of 0.25 miligrams gonadotropin-releasing hormone (GnRH) antagonist will start on day 6 of stimulation From this day may also vary the dose of urinary FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.1 miligram GnRH agonist will be administered for triggering final oocyte maturation
2559351|NCT02503397||Latent iron deficiency|Infants with cord serum ferritin levels ≤ 75 ng/mL
2559356|NCT02503397||Normal iron status|Infants with cord serum ferritin levels > 75 ng/mL.
2559441|NCT02503241|Experimental|PEEP_Titration_INCREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP incremental value is based in transpulmonary pressure.~Intervention : PEEP INCREMENTAL"
2559444|NCT02503241|Experimental|PEEP_Titration_DECREMENTAL|"The investigators will compare 3 levels of PEEP (BASELINE versus PEEP INCREMENTAL versus PEEP DECREMENTAL). Baseline PEEP is based in the standard of care PEEP used in the participant units. PEEP decremental value is based in lung recruitment maneuver followed by a best compliance curve during PEEP decrements.~Intervention :PEEP DECREMENTAL"
2559471|NCT02502643|Experimental|OK-432 pleurodesis|Picibanil ( OK-432 ) ,OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci; UKIMA PLANT OF CHUGAI PHARMA MANUFACTURING CO, LTD; JAPAN).
2559472|NCT02502643|Active Comparator|normal saline pleurodesis|(Normal Saline),Isotonic Sodium Chloride Solution
2559518|NCT02502422|Other|Classic laryngeal mask airway|single arm
2559547|NCT02502162|Experimental|LDN|Naltrexone HCL, 4.5 mg, Once a day.
2559554|NCT02502162|Placebo Comparator|Placebo|Sugar pill
3206107|NCT00950495|Placebo Comparator|placebo|the placebo appliance is placed in the mouth prior to sleep. After waking up in the morning, the appliance is removed.
3206108|NCT00950508|Active Comparator|High volume plasma exchange|3 successive plasma exchanges over 3 days
3206109|NCT00950508|Placebo Comparator|Standard medical treatment|
3206110|NCT00950521|Active Comparator|PBSC Treatment|Patients in PBSC treatment will receive brain implant of autologous peripheral blood stem cell(CD34+) plus convention stroke treatment that include rehabilitation and antiplatelet medication
2559834|NCT02500615|Experimental|0 PG: 100 VG|
2559837|NCT02500615|Experimental|30 PG: 70 VG|
2559840|NCT02500615|Experimental|50 PG: 50 VG|
2559842|NCT02500615|Experimental|70 PG: 30 VG|
2559844|NCT02500615|Experimental|100 PG: 0 VG|
2559874|NCT02500381|Experimental|SRP-4045|Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
2559878|NCT02500381|Experimental|SRP-4053|Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
2559879|NCT02500381|Placebo Comparator|Placebo followed by SRP-4045 or SRP-4053|Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).
2560011|NCT02499484|Active Comparator|GTN and eccentric exercises|Participants will complete a 12 week eccentric exercise program and use 0.5cm of glyceryl trinitrate ointment daily for 24 weeks
2560012|NCT02499484|Placebo Comparator|Placebo and eccentric exercises|Participants will use a placebo ointment with no active ingredient for 24 weeks and complete an eccentric exercise program for 12 weeks
3206111|NCT00950521|Active Comparator|Control|Control group receive conventional stroke treatment that include rehabilitation and antiplatelet medication
3206112|NCT00950534|Experimental|General Practitioner initiation with insulin glargine|Patients will be prescribed insulin glargine by their Investigator and they will be taught how to administer insulin glargine according to Australian guidelines. Patients will be treated for 24 weeks.
3171714|NCT00590928|Active Comparator|1|patients with indication for stress ulcer prophylaxis and gastric pH < 4
3171715|NCT00590928|Active Comparator|2|patients with indication for stress ulcer prophylaxis and gastric pH < 4
2559300|NCT02504008|Experimental|AXS-02 (oral zoledronate)|Administered orally in the morning on Days 1, 8, 15, 22, 29, and 36
2559302|NCT02504008|Placebo Comparator|Placebo|Administered orally in the morning on Day 1, 8, 15, 22, 29, and 36
2559431|NCT02503150|Experimental|APDC + Chemotherapy|Patients in Arm APDC + Chemotherapy will receive APDC combined with chemotherapy.
2559433|NCT02503150|Active Comparator|Chemotherapy|Patients in Arm Chemotherapy will receive chemotherapy only.
2559535|NCT02502110|Experimental|rosuvastatin 20mg/day|To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.
2559539|NCT02502110|No Intervention|blank control|Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.
2559617|NCT02501954|Experimental|Regimen I|Cisplatin 50 mg/m2 IV Days 1 and 29 plus Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 4 cycles
2559620|NCT02501954|Active Comparator|Regimen II|Carboplatin AUC 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles followed by Volume-directed radiation therapy followed by Carboplatin AUC 5 or 6 plus Paclitaxel 175 mg/m2 q 21 days for 3 cycles
2559680|NCT02501343|Experimental|Sodium bicarbonate|High acid load meal (Western style meal) with Sodium bicarbonate (Sodibic 840mg*2)
2559683|NCT02501343|Placebo Comparator|Placebo|High acid load meal (Western style meal) with sodibic-matching placebo
2559867|NCT02500459|Experimental|intraparenchymally-administered topotecan|Patients will have topotecan administered directly into the tumor bed using convection-enhanced delivery (CED)
2559919|NCT02500160|Experimental|patient specific instrumentation (MRI)|MRI based patient-specific instrumentation
2559920|NCT02500160|Active Comparator|patient specific instrumentation (CT)|CT based patient-specific instrumentation
2559944|NCT02499835|Experimental|Arm I (pTVG-HP plasmid DNA vaccine, concurrent pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID every other week on days 1, 15, 29, 43, 57, and 71 and pembrolizumab IV over 30 minutes every 3 weeks on days 1, 22, 43, and 64.
2559947|NCT02499835|Experimental|Arm II (pTVG-HP plasmid DNA vaccine, sequential pembrolizumab)|Patients receive pTVG-HP plasmid DNA vaccine ID as in Arm I and pembrolizumab IV over 30 minutes every 3 weeks on days 85, 106, 127, and 148.
2559949|NCT02499835|Experimental|Extended Treatment Arm III|pTVG-HP (100 μg) with rhGM-CSF (208 μg) administered intradermally (i.d.) every 3 weeks, for a maximum of 16 doses. Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 3 weeks, for a maximum of 16 doses, beginning on day 1 after the first pTVG-HP vaccination.
2559950|NCT02499835|Experimental|Extended Treatment Arm IV|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) every 2 weeks, for a maximum of 24 doses Pembrolizumab 2 mg/kg, with a maximum dose of 200 mg, administered intravenously every 4 weeks, for a maximum of 12 doses, beginning on day 1 after the first pTVG-HP vaccination
2560147|NCT02498730|Active Comparator|Interval Training|6 stimulous (30 s) at 100% VO2Max/ 1 min 30 s to rest, 19 minutes (total exercise), 3 times/ week, 12 weeks
2560148|NCT02498730|Active Comparator|Continuous Training|Running at 60% VO2Max, 25 minutes (total exercise), 3 times/week, 12 weeks
2560149|NCT02498730|Sham Comparator|Control|Only Dependent Variables Measures
2560203|NCT02498379|Experimental|Cu[64]-25%CANF-Comb|Single IV injection of 4-8 mCi Cu[64]-25%CANF-Comb followed by PET-CT scan at 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours post injection.
2560270|NCT02497859|Active Comparator|Cereal Breakfast (CB)|"The CB will receive the following breakfast:~1.5 cups of Special K® Ready-to-Eat Original Cereal, 200 ml Silk® Original Soymilk, 1 slice of Nature's Own® Double Fiber Wheat Bread, 13 g of butter, and 10 g of Smuckers® Sugar-Free Strawberry Jam."
2560321|NCT02497560|Active Comparator|Treatment|all natural dietary supplement
3171716|NCT00590941|No Intervention|R-CHOP|Patients receiving R-CHOP via standard of care which consists of cyclophosphamide 750 mg/m2 IV day 1 of each 21 day cycle, doxorubicin 50 mg/m2 IV day 1 of each 21 day cycle, vincristine 1.4 mg/m2 IV day 1 of each 21 day cycle, prednisone 100 mg PO days 1-5 of each 21 day cycle, and rituximab 375 mg/m2 IV day 1 of each 21 day cycle.
3171717|NCT00590993||1 - MRSI / MRI|
3171718|NCT00591045|Experimental|1|The patients will undergo neoadjuvant chemotherapy with mFOLFOX and then an operation and then individualized adjuvant chemotherapy.
3171719|NCT00591045|No Intervention|2|No neoadjuvant chemotherapy and surgery and then adjuvant chemotherapy.
3171720|NCT00591058|Experimental|Cohort 1|0.04 mg/kg TM-601 dose per administration
3171721|NCT00591058|Experimental|Cohort 2|0.08 mg/kg TM-601 dose per administration
3171722|NCT00591058|Experimental|Cohort 3|0.16 mg/kg TM-601 dose per administration
3171723|NCT00591058|Experimental|Cohort 4|0.3 mg/kg TM-601 dose per administration
3171724|NCT00591058|Experimental|Cohort 5|0.6 mg/kg TM-601 dose per administration
3171725|NCT00591058|Experimental|Cohort 6|1.2 mg/kg TM-601 dose per administration
3171726|NCT00591071|Active Comparator|B|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
3171727|NCT00591071|Experimental|A|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
3171728|NCT00591084|Experimental|ginsenoside-Rd 10mg|both a ginsenoside-Rd injection (10mg/1ml/each) and a specific dilution (10%, 1ml trimethylene glycol) were respectively diluted by a specific dilution (10%, 9 ml trimethylene glycol) and then mixed.
3171729|NCT00591084|Placebo Comparator|placebo|2 specific dilutions (10%, 1ml trimethylene glycol) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed.
3171730|NCT00591084|Experimental|ginsenoside-Rd 20mg|2 ginsenoside-Rd injections (10mg/1ml/each) were respectively diluted by 2 specific dilutions (10%, 9 ml trimethylene glycol) and then mixed
3171731|NCT00591097||pediatric|
3171732|NCT00591110|Active Comparator|1|Educational intervention communicating practical information about vision, eye conditions and eye care.
3171733|NCT00591110|Sham Comparator|2|
3171734|NCT00591136|Experimental|Single Arm|
2559154|NCT02504788|Experimental|Hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of whole brain radiation (WBRT), the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc®.In terms of dose prescription, a dose of 30 Gy in 12 fractions was prescribed to whole-brain planning target volume (PTV) if the role of RT was considered either adjuvant following craniotomy with tumor removal or therapeutic for treating oligometastatic brain disease.
2559207|NCT02504398|Experimental|Fast injection|Vaccine injections will be given at a rate of approximately 2-4 ml/sec by the immunizer
2559214|NCT02504398|Active Comparator|Slow injection|Vaccine injections will be given at a rate of approximately 10 ml/sec by the immunizer
2559258|NCT02504164|Experimental|No premedication|No premedication before sedation
2559264|NCT02504164|Active Comparator|Midazolam|Premedication with midazolam before sedation
2559309|NCT02503943|Experimental|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide(50mg, 3/d)"
2559312|NCT02503943|Active Comparator|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
2559315|NCT02503943|Active Comparator|"Mitiglinide"|"Mitiglinide(50mg, 3/d)"
2559361|NCT02503553|Experimental|Decision aid|"Option grid for cerebral aneurysm treatment~Patients will receive an option grid during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded."
2559366|NCT02503553|Placebo Comparator|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
2559420|NCT02503189|Experimental|KCT-0809|
2559421|NCT02503189|Placebo Comparator|Placebo|
2559502|NCT02502838||Prolapse surgery without TVT|Patients who plan to undergo prolapse repair alone
2559504|NCT02502838||Prolapse surgery with TVT|Patients who plan to undergo prolapse repair with an additional TVT procedure
2559536|NCT02502318|Experimental|Lobectomy using video-thoracoscopy|
2559543|NCT02502318|Active Comparator|Lobectomy using thoracotomy|
3206113|NCT00950534|Active Comparator|Usual standard of care|Patients will be treated by their Investigator with the usual standard of care for 24 weeks (e.g., OAD dose titration, addition of a second or third OAD, or referral to an endocrinologist)
2559677|NCT02501330||Bosutinib|
3206114|NCT00950547|Active Comparator|Control|Traditional Chest drains
3206115|NCT00950547|Experimental|CARDIOPAT|CARDIOPAT Cell Saver after Surgery
2560531|NCT02496156|Active Comparator|Usual Clinical Practice (UCP)|UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study. The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population. Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
2560535|NCT02496156|Experimental|Shared Medical Decision Making (SMDM)|Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM). Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached. The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
2560598|NCT02495805|Active Comparator|adductor canal block (ACB)|Subjects randomized to this groups receive a continuous proximal adductor canal block (ACB) during surgery.
2560600|NCT02495805|Active Comparator|femoral nerve block (FNB)|Subjects randomized to this groups receive a continuous femoral nerve block (FNB) during surgery.
2560667|NCT02495441||Dribbling group|Any woman who presents with alleged leakage of amniotic fluid. They will under go rapid Immunoassay Tests for the Detection of PROM
2560715|NCT02494973|Active Comparator|Adjuvant systemic chemotherapy with mFOLFOX6|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:~Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,~Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours."
2560718|NCT02494973|Experimental|Adjuvant HAI oxaliplatin and systemic LV5FU2|"started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:~Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,~Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed."
3206116|NCT00950560||inpatient|
2560822|NCT02494232||minor blunt thoracic trauma patient|demographic data, physical examination findings
3206117|NCT00950560||outpatient|
3206118|NCT00950560||emergency patient|
3206119|NCT00950573||hemodialysis|patients treated with conventional hemodialysis
3206120|NCT00950573||peritoneal dialysis|patients treated with peritoneal dialysis
3206121|NCT00950573||nocturnal hemodialysis|patients treated with frequent nocturnal hemodialysis
3206122|NCT00950573||kidney transplantation|patients treated with renal transplantation
3206123|NCT00950586|Experimental|Cohort 1|14 days dosing
3206124|NCT00950586|Experimental|Cohort 2|Single dose followed by 14 days repeat dosing
3206125|NCT00950586|Experimental|Cohort 3|Up to 28 days repeat dosing with drug interaction
3206126|NCT00950625|Active Comparator|intraperitoneal lignocaine|Intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine for pain control after laparoscopic cholecystectomy
3206127|NCT00950625|Active Comparator|intraperitoneal bupevacaine|intraperitoneal lignocaine will be compared with intraperitoneal bupevacaine after laparoscopic cholecystectomy
2559180|NCT02504749|Active Comparator|Group B:Spinal anaesthesia group.|"Prehydration with 500 ml lactated ringer solution intravenous within 15 minutes in the sitting position.Low back was prepared and drapped in a sterile fashion with Betadine solution 10%.~Spinal anaesthesia performed at L 2-3 or L 3-4 intervertebral space using a fine needle size 22 G.Injection of local anaesthetics into the subarachnoid space,Bupivacaine(marcaine) 1.5 -3.5 ml used."
2559245|NCT02504307|Experimental|Inspiron|Sirolimus Eluting Stent Inspiron
2559250|NCT02504307|Active Comparator|Cronus|Bare Metal Stent
2559278|NCT02504021|Experimental|Family Consultation Condition|The family consultation will be one, 1-hour session conducted by trained, master's level therapists. The goals of the meetings are: a) Review patient and family understanding of events that caused the hospital admission; b) increase family awareness of the level of cognitive impairment that the patient is experiencing; c) discuss ways the family can get involved and help the patient with their medication and dialysis adherence; d) use motivational interviewing techniques as needed. This will be provided in addition to the usual care that inpatients receive in this unit.
2559279|NCT02504021|No Intervention|Treatment as Usual Control Condition|Standard of care for the nephrology unit.
2559295|NCT02503813|Experimental|Experimental|Venous blood gas will be obtained at the same time points as arterial blood gas in the apnea challenge test.
2559327|NCT02503722|Experimental|Treatment (sapanisertib, osimertinib)|Patients receive sapanisertib PO QD on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2559352|NCT02503371||Women under IVF stimulation at the begining and end|Coagulation parameters will be measured for all parturients at the beginning and conclusion of an IVF simulation cycle with the use of thromboelastogram
2559473|NCT02502591|Experimental|intervention|Additional pain relief (a Pudendal Nerve Block (PNB)) will be administered during surgery in addition to routine care.
2559474|NCT02502591|No Intervention|control|routine care only
2559614|NCT02501746|Active Comparator|Usual Clinical Care (UC)|This will be the current standard of care delivered by the AMPATH CDM Program, in accordance with the management protocol for diabetes and hypertension.
2559624|NCT02501746|Experimental|Usual clinical care plus microfinance groups only (MF)|Usual clinical care as described above. In addition, participants will be encouraged to create microfinance groups organized and supported by AMPATH's Safety Net Program.
2559626|NCT02501746|Experimental|Group medical visits only (GMV)|Participants randomized to this arm will be invited to create a group that will attend monthly group medical visits at the rural health facility. Each group medical visit will be staffed by both the rural clinician and the local CHW (educator). Groups will consist of the same patients at each of 12 monthly visits. Each visit will begin with the measurement of fasting blood glucose and resting electronic BP, as well as the ascertainment of medication regimens for BP and diabetes, and extent of adherence to the prescribed regimen.
2559628|NCT02501746|Experimental|GMV integrated into GMV-MF|Clinical care will be provided in the form of group medical visits, and the participants will be actively recruited to create microfinance groups. Thus, the monthly group medical visit will be integrated into the microfinance groups, wherein the visit will consist of an initial microfinance portion, followed by the group medical visit.
2559697|NCT02501369|Experimental|Self-directed Teen Triple P|"Self-directed Teen Triple P is a behaviourally based parenting intervention that parents follow at home using a workbook. It is based upon social learning theory principles and is used to help parents build upon their existing skills and information to practice positive parenting. Key skills promoted include: Increasing positive parent-teenager interactions, increase desirable behaviour, teach new behaviours and skills, and manage problem behaviour.~As this is a case series design participants will act as their own controls and so there are no other arms to the study."
2560129|NCT02498743|Experimental|Intervention group with television|Animated cartoons with sound were reproduced during the echocardiography
2560135|NCT02498743|No Intervention|control group with usual care|Echocardiography was performed by using the distractions available at the time of test.
3171735|NCT00591162|Active Comparator|1|Compare bone density of severly burned children to normal non-burned population
2560261|NCT02497898|No Intervention|regular chemotherapy|Patients after chemotherapy are just followed up.
2560263|NCT02497898|Experimental|CIK regimen|Patients after chemotherapy will receive at least 3 cycles of Cytokine-induced killer cells (CIK) treatment every 3 months.
2560288|NCT02497703|Experimental|Knee robot|This robotic system has been developed to facilitate functional motor recovery by practices walking with a one joint motor powered exoskeleton
2560357|NCT02497170|Other|Life style changes|Pre and post after education intervention Education program
3171736|NCT00591175||1|Standard Care
3171737|NCT00591175||2|Standard Care with Hygienist Counseling
3171738|NCT00591175||3|Standard Care with Hygienist Counseling & Personalized Risk Communication
3171739|NCT00591188|Experimental|1|All patients will receive capecitabine and interferon-alpha.
3171740|NCT00591201|Experimental|A|Infliximab
3171741|NCT00591201|Placebo Comparator|B|Placebo
3171742|NCT00591279||A|Barium enema and colonoscopy at one and three years after entry.
3171743|NCT00591279||B|Barium enema and colonoscopy at three years only after entry.
3171744|NCT00591292|Experimental|Single Arm|
3171745|NCT00591318|Experimental|A|IV Ceftriaxone 2 grams/day
3171746|NCT00591318|Placebo Comparator|B|IV Placebo (Normal Saline)
3171747|NCT00591331|Experimental|1|NatrOVA Creme Rinse - 1%
3171748|NCT00591331|Experimental|2|NatrOVA Creme Rinse Vehicle Only
3171749|NCT00591331|Placebo Comparator|3|Blank patch
3171750|NCT00591357|Active Comparator|A|Loperamide
3171751|NCT00591357|Placebo Comparator|B|Placebo
3171752|NCT00591383|Experimental|Single Arm|Once Maximum Tolerated Dose (MTD) is determined an expanded cohort will be enrolled to evaluate efficacy.
3171753|NCT00591396|Experimental|Single Arm|
3171754|NCT00591422|Experimental|Single Arm|
3171755|NCT00591435||1|200 laparoscopic cholecystectomies will be included, consultant cases will be compared to resident cases
3171756|NCT00591435||2|200 laparoscopic pelviscopies will be included, consultant cases will be compared to resident cases
3206128|NCT00950638|Active Comparator|dose comparison|
3206129|NCT00950638|Active Comparator|Dose comparison|
3206130|NCT00950677|Active Comparator|exenatide|exenatide one dose
3206131|NCT00950677|Active Comparator|pramlintide|pramlintide one dose
3206132|NCT00950716|Active Comparator|Usual care|The 'control arm' will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
3206133|NCT00950716|Active Comparator|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
2560941|NCT02493309|Experimental|Prolonged sitting|
2560945|NCT02493309|Active Comparator|Light activity breaks|
3206134|NCT00950768|Active Comparator|Mel100|
3206135|NCT00950768|Experimental|Mel200|
2561042|NCT02492399|Other|myectomy by Morrow|"Procedure: myectomy by Morrow.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. In the case of conservation SAM syndrome and mediated mitral insufficiency, the result will be read as unsatisfactory. Patients will perform advanced myoectomy. All patients who need to be supplemented by the operation extension myoectomy subsequently run out in the second group. When it is impossible to eliminate mediated mitral regurgitation without mitral valve replacement, patients performed myoectomy and mitral valve replacement. The result in this case is read as completely unsatisfactory. Upon reaching 15% replacement mitral valve study terminated.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
2561043|NCT02492399|Other|extended myectomy|"Procedure: extended myectomy.~Will be included in a group of 30 patients with obstructive hypertrophic cardiomyopathy and mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. The result in this case will become engrossed in reading as completely unsatisfactory. At achievement of 15% prosthetics of the mitralny valve research stops.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
2561089|NCT02492113|Experimental|Patients with BMI > 35|"ICU patients with a BMI > 35, on pressure support ventilation, scheduled for spontaneous breathing trial for evaluation of extubation~After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs) in randomized order. Either the patient will receive SBT at PEEP = 0-5 cmH2O, with PSV=0 and FiO2 unchanged; or the patient will perform an SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
2561131|NCT02491736|Experimental|ketoprofen|2.5% ketoprofen gel
2561134|NCT02491736|Placebo Comparator|Placebo|Placebo gel
3206136|NCT00950781||Group|Group
3206137|NCT00950794|Active Comparator|Hokunalin(tulobuterol) tape|Hokunalin(tulobuterol) tape: long-acting Beta2-agonist
2561395|NCT02490046|Experimental|MS and rec UTIs not using a catheter|people with multiple sclerosis and recurrent urinary tract infections with spontaneous voiding Intervention- will be given D-mannose
2561397|NCT02490046|Experimental|MS and rec UTIs using a catheter|people with multiple sclerosis and recurrent urinary tract infections using either urethral or suprapubic indwelling catheter or intermittent catheterisation Intervention- will be given D-mannose
3206138|NCT00950794|Experimental|Salmeterol(408DP-02)|Salmeterol(408DP-02)：long-acting Beta2-agonist
3206139|NCT00950820|Experimental|Panitumumab + XELOX|KRAS mutational status wild-type: Panitumumab plus Oxaliplatin and Capecitabine (XELOX)
2561490|NCT02489240|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
2561502|NCT02489240|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: study treatment was commenced 3 days before intervention and maintained for 3 days after the procedure.
2561545|NCT02489006|Experimental|Olaparib Prior to Surgery, Chemotherapy/Olaparib Post Surgery|"Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery.~Platinum-based chemotherapy chosen by the study doctor and per standard of care after surgery.~Olaparib, orally, at 300 mg twice per day, continuously, after chemotherapy."
2561549|NCT02489006|Experimental|Olaparib Prior to Surgery and Post Surgery|Olaparib, orally, at 300 mg twice per day, for 6 weeks (+/- 2 weeks) prior to surgery and after surgery.
2561627|NCT02488499|Active Comparator|Individualized Treatment|Individualized Treatment: 15 sessions of individualized treatment (i.e., parent-child) that target areas of presenting concern identified during assessment. These may include social problem-solving, emotion regulation, parent-child difficulties.
2561631|NCT02488499|Experimental|Coping Power|Coping Power: 15 sessions of concurrent parent and child group treatment. The child group focuses on developing problem-solving and emotion regulation skills. The parent group focuses on developing parenting skills and problem-solving strategies to manage and reduce their children's disruptive behaviour.
2561683|NCT02488148|Experimental|Hot yoga|3 hot yoga classes per week to be completed at local studios in Austin, TX.
2561686|NCT02488148|Experimental|Non-heated yoga|3 yoga classes to be completed at local studios in Austin, TX.
2561688|NCT02488148|No Intervention|Control|Maintain usual activities for the 12-week duration of the study.
2561718|NCT02487706|Experimental|Dolutegravir 50mg/day per 5 days|Dolutegravir 50mg/day per 5 days
2562117|NCT02485041|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3206140|NCT00950820|Other|XELOX (KRAS mutational status wt)|KRAS mutational status wild-type: Oxaliplatin and Capecitabine (XELOX)
3206141|NCT00950820|Other|XELOX (KRAS mutational status mutant)|KRAS mutational status mutant: Oxaliplatin and Capecitabine (XELOX)
2559257|NCT02504203|Active Comparator|Intervention: BCG and OPV at home visits|Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
2559261|NCT02504203|No Intervention|Control: No vaccines at home visits|For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.
2559292|NCT02503956|Experimental|Treated group|Patients treated with perforated punctal plugs
2559293|NCT02503956|Active Comparator|Comparison group|Comparison group treated with standard of care - Lacrimal intubation with Crawford lacrimal tube
2559353|NCT02503696||IBD|Subjects will be men and women, 18-84 years of age, inclusive, who have been diagnosed with IBD. Each with a screening colonoscopy resulting in normal findings.
2559407|NCT02503046||Arthritis with Periodontitis|"Patients aged between 30-65 years with 6 positive diagnostic criteria for Rhematoid Arthritis. Patients should have Clinical attachment loss >6mm, and Probing pocket depth>5mm in more than 6 teeth to satisfy criteria for periodontitis.~5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA) Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels."
2559409|NCT02503046||Periodontitis group|"Patients aged between 30-65 years with Periodontal findings being presence of atleast 20 teeth in the mouth .More than 6 teeth with Clinical attachment loss >6mm and Probing pocket depth>5mm to satisfy criteria for periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
2559410|NCT02503046||Healthy Subjects|"Subjects aged between 30-65 years with no systemic diseases and periodontitis. 5ml of blood to be collected from each patient, centrifuged and plasma extracted used for estimation of Pentraxin3(Quantikine ELISA).~Pooled plaque sample taken,DNA extracted by PCR for estimation of P.Gingivalis levels.."
2559548|NCT02502370|Active Comparator|Group1 Arm A Observation|
2559552|NCT02502370|Experimental|Group 1 Arm B LV5FU2|
2559558|NCT02502370|Active Comparator|Group 2 Arm C LV5FU2|
2559562|NCT02502370|Experimental|Group 2 ARM D FOLFOX|
2559629|NCT02501850|Experimental|Group A|Type 2 diabetic patients whom were prescribed GLP-1R agonists by the endocrinologist, according to usual clinical practice (liraglutide, exenatide, lixisenatide). The intervention is the prescription of an GLP-1R agonist (liraglutide, exenatide, lixisenatide)
2559630|NCT02501850|Active Comparator|Group B|Type 2 diabetic patients whom were prescribed metformin and/or sulphonilurea, according to usual clinical practice.
2559698|NCT02501395||Patients with Kennedy disease|Men over 18 years old with confirmed Kennedy disease.
2559703|NCT02501395||Healthy, voluntary controls|Gender and age matched healthy, voluntary controls.
2559772|NCT02500875|Experimental|PTNiA|"Topical negative pressure therapy with instillation of saline solution (6 times daily).~During the instillation of saline solution, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
2559775|NCT02500875|Experimental|PTNiB|"Topical negative pressure therapy with instillation of Amukine Med 0,05% (6 times daily).~During the instillation of Amukine Med 0,05%, aspiration is stopped for 10-15 minutes and subsequently the device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
2559780|NCT02500875|Active Comparator|PTN|"Topical negative pressure therapy (without instillation). The device is programmed to exert a sub atmospheric pressure in aspiration of at least 50 mmHg up to a maximum of 200 mmHg.~The change of dressing is carried out on the first day after the application of the device, and thereafter, as needed (approximately every 3 or 4 days)."
2559932|NCT02500030|Experimental|Air Stacking|Air Stacking was performed with the subject seated in his wheelchair using a manual resuscitation bag (LIFESAVER® model 5345, Hudson, Temecula, USA) connected to a corrugated tube with an internal diameter of 22 mm, a one-way valve and a pipette. The maximum capacity of the bag was 1600 mL. A chest physiotherapist insufflated the patient during the inspiratory phase, requesting that inspire as much air as possible
2559933|NCT02500030|Experimental|Glossopharyngeal Breathing|"Glossopharyngeal Breathing was also performed with the subject seated in his wheelchair and performing successive maneuvers of swallowing air until the maximum volume achieve was maintained. Then, the patient was instructed to breathe through ventilometer to register the MIC. Three measurements for each of the techniques were performed, and the highest reading was recorded. A difference of <10% between the measurements was used as the repeatability criterion"
3171757|NCT00591435||3|200 transurethral resection of urinary bladder or prostate gland will be included, consultant cases will be compared to resident cases
3171758|NCT00591448|Experimental|Virtual Reality|Patients with burns participate in VR during occupational therapy (OT) or physical therapy (PT) sessions ranging from 2 to 9 min in length
3171759|NCT00591461||1|Study participants must be older than 18 years of age who are having an endoscopy performed to evaluate symptoms of GERD such as heartburn, acid taste in the mouth, dysphagia, dyspepsia, or those who are having a screening/surveillance exam for BE.
3171760|NCT00591474|Experimental|1|VRE positive patients
3171761|NCT00591474|Placebo Comparator|2|VRE positive patients
3171762|NCT00591487|Active Comparator|I|Infiltration with 0.9% saline+1:1,000,000 epinephrine+0.06% Lidocaine
3171763|NCT00591487|Placebo Comparator|II|Infiltration with 0.9% saline+1:1,000,000 epinephrine
3171764|NCT00591500||Control|The control group comprises patients with a first primary melanoma diagnosed in a twelve-month period.
3171765|NCT00591500||Cases|Cases are patients diagnosed with a second or higher order primary in a six-year period.
2559299|NCT02503839|Experimental|Arm#4|arm#4 (n=10) receiving etoricoxib from inclusion day 0 and in 140 days and H56:IC31 vaccine at day 84 and 140.
2559335|NCT02503644|Active Comparator|IVA337 800mg|Patients receive twice daily 400mg IVA337.
2559340|NCT02503644|Active Comparator|IVA337 1200mg|Patients receive twice daily 600mg IVA337.
2559341|NCT02503644|Placebo Comparator|Placebo|Patients receive twice daily placebo.
2559457|NCT02502851|Active Comparator|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy followed by implantation of the ORSIRO sirolimus-eluting stent
2559458|NCT02502851|Active Comparator|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloon followed by implantation of the ORSIRO sirolimus-eluting stent
2559483|NCT02502604|Experimental|Goal Management Training|Participants in this arm of the study will attend GMT sessions, which will be administered weekly over a nine-week period following a script with accompanying slides and participant workbooks.
2559485|NCT02502604|No Intervention|Wait List Control|Participants in this category will be placed on a wait-list to receive goal management training following completion of their study participation.
2559534|NCT02502396||Chart Review - Patterns of Rivaroxaban Usage|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF).
2559632|NCT02501967|Experimental|COMET|The intervention consists of completion of the tool (COMET) by means of a 30 minute telephone interview prior to the primary care visit and provision of the tool's output to the patient and primary care physician. The COMET tool takes information about the patient's medications and chronic conditions from the electronic health record, and then supplements this with information obtained by a telephone interview assessing the patient's cognition, social supports, medication adherence, home medication regimen, medication side effects, and health status. In addition, there is a chart review screen to record renal function, blood pressure, and hemoglobin A1C. All of this information is run through a set of algorithms to identify medication reconciliation errors and potentially inappropriate medications.
2559635|NCT02501967|No Intervention|Usual Care|
3206142|NCT00950846|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
2559819|NCT02500654|Experimental|Surgery and Emdogain®|access peri-implant surgery with Emdogain® applied after cleaning of implant surface with saline
2559824|NCT02500654|Placebo Comparator|Surgery alone|access peri-implant surgery and cleaning of implant surface with saline
2559863|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
2559897|NCT02500290||Acute coronary syndrome|
3174963|NCT00628784|Experimental|Group 1|Specialized intestinal metaplasia (Barrett's esophagus) documented via endoscopic esophageal biopsy, with standard surveillance biopsies (four-quadrant biopsies obtained every 2-cm the entire length of the specialized intestinal metaplasia in the esophagus) performed within the past two years prior to study enrollment. Biopsies show either low grade dysplasia, indeterminate for dysplasia, or no dysplasia.
3206143|NCT00950885|Placebo Comparator|Placebo|placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
2560097|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 2 weeks|1800mg (High Dose) 2 weeks (HD - 2 weeks) Group: Fexinidazole, 1800 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 25,2 g)
2560098|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 4 weeks|1800mg (High Dose) 4 weeks (HD - 4 weeks) Group: Fexinidazole, 1800 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 50,4 g)
2560099|NCT02498782|Active Comparator|Fexinidazole, 1800 mg, 8 weeks|1800mg (High Dose) 8 weeks (HD - 8 weeks) Group: Fexinidazole, 1800 mg QD, for 8 weeks (total dose: 100,8 g)
2560100|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 2 weeks|1200mg (Dose 2 weeks) 2 weeks (LD - 2 weeks) Group: Fexinidazole, 1200 mg QD for 2 weeks, followed by placebo to complete 8 weeks (total dose: 16,8 g)
2560102|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 4 weeks|1200mg (Low Dose) 4 weeks (LD - 4 weeks) Group: Fexinidazole, 1200 mg QD for 4 weeks, followed by placebo to complete 8 weeks (total dose: 33,6 g)
2560105|NCT02498782|Active Comparator|Fexinidazole, 1200 mg, 8 weeks|1200mg (Low Dose) 8 weeks (LD - 8 weeks) Group: Fexinidazole, 1200 mg QD for 8 weeks (total dose: 67,2 g)
2560111|NCT02498782|Placebo Comparator|Placebo|Placebo (8 weeks) Group: Fexinidazole matched placebo tablets QD for 8 weeks.
2560178|NCT02498275||Healthy volunteers|Blood samples from healthy volunteers will be collected for ex vivo stimulation and for further sample preparation and analysis.
2560179|NCT02498275||Nucleoside/nucleotide analogue-treated CHB patients|Blood samples from nucleoside/nucleotide analogue-treated CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
2560181|NCT02498275||Treatment-naive CHB patients|Blood samples from treatment-naïve CHB patients will be collected for ex vivo stimulation and for further sample preparation and analysis.
2560213|NCT02498184|Experimental|real acupuncture|traditional chinese acupuncture
2560216|NCT02498184|Sham Comparator|sham acupuncture|non effective acupuncture
3206144|NCT00950885|Experimental|Low dose melatonin|0.5 mg melatonin
3206145|NCT00950885|Experimental|High dose melatonin|3.0 mg melatonin
2559336|NCT02503631||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or a pre-malignant colorectal lesion with large enough residual lesion to require subsequent surgical excision or complex colonoscopic polypectomy.
2559376|NCT02503306|Experimental|Avanafil dose 1|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
2559386|NCT02503306|Experimental|Avanafil dose 2|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
2559389|NCT02503306|Placebo Comparator|Placebo|Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
2559413|NCT02503111|Experimental|Ablative therapy|Ablative therapy involving electrocautery (EC) will occur for participants with AIN-2 and AIN-3. The Hyfrecator ® 2000 Electrosurgical System will be used for EC therapy.
2559414|NCT02503111|Active Comparator|Active Surveillance|The control arm includes active surveillance with observation alone; no treatment in AIN-2 and -3.
2559484|NCT02502812|Experimental|Treatment Sequence A (Innovator) - B (Clop F1) - C (Clop F2)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559486|NCT02502812|Experimental|Treatment Sequence A(Innovator) -C(Clop F2)-B (Clop F1)|Subjects will receive a single 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559490|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - A (Innovator) - C (Clop F2)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F2 (Treatment C) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559493|NCT02502812|Experimental|Treatment Sequence B (Clop F1) - C (Clop F2) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F1 (Treatment B) in treatment period 1, 75 mg tablet Clop F2 (Treatment C) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559494|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - A (Innovator) - B (Clop F1)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 2, and 75 mg tablet Clop F1 (Treatment B) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559495|NCT02502812|Experimental|Treatment Sequence C (Clop F2) - B (Clop F1) - A (Innovator)|Subjects will receive a single 75 mg tablet Clop F2 (Treatment C) in treatment period 1, 75 mg tablet Clop F1 (Treatment B) in treatment period 2, and 75 mg tablet of reference clopidogrel (Treatment A) in treatment period 3 under fasting conditions. Each treatment period will be separated by 7-14 days of washout Period.
2559545|NCT02502175|Experimental|Opium|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
2559553|NCT02502175|Active Comparator|methadone|patient-centered flexible dosing in line with the national protocol published by Iranian Ministry of Health for maintenance treatment of opioid dependent population
2559615|NCT02501837|Experimental|Oxytocin|24 IU Oxytocin (Syntocinon spray), intranasal application 30 min prior to the experiment
2559623|NCT02501837|Placebo Comparator|Placebo|Intranasal application, containing all ingredients except for the peptide, 3 puffs per nostril
2559696|NCT02501577|Experimental|SAD 1|FOI for placement
2559702|NCT02501577|Experimental|SAD 2|FOI für placement
2559735|NCT02501070||Pre-PROGALIAM|Patients treated for myocardial infarction before the implementation of the network for acute myocardial infarction care (2001 to 2005).
2559738|NCT02501070||PROGALIAM|Patients treated for myocardial infarction after the implementation of the network for acute myocardial infarction care (2005 to 2011).
3206146|NCT00950924|Experimental|Bifocal Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
2559852|NCT02500472|Experimental|Kava Supplement|See intervention description.
2559884|NCT02500329|Experimental|gemigliptin|gemigliptin for 4 weeks
2559886|NCT02500329|Active Comparator|acarbose|acarbose for 4 weeks
2559934|NCT02500095|No Intervention|Control|12 hours of fasting
2559936|NCT02500095|Experimental|Fasting and saline|72 hours of fasting and concomitant saline
2559938|NCT02500095|Experimental|Fasting and GHR blockade|72 hours of fasting and concomitant Growth hormone receptor (GHR) blockade with Pegvisomant (Somavert) for inhibition of the fasting-induced GH secretion
3206147|NCT00950924|Placebo Comparator|Single Vision Soft Contact Lenses|Subjects will be fitted with single vision soft contact lenses with goal of corrected emmetropia at a distance of 20 feet.
2560043|NCT02499276|Experimental|PSV, PAV, NAVA, Variable-PSV|This is a crossover study in which each patient will be ventilated in the following modes of mechanical ventilation: Pressure Support Ventilation (PSV), Neurally Adjusted Ventilator Assist (NAVA), Proportional assist ventilation (NAVA) and variable Pressure Support Ventilation (Variable-PSV), in a randomised order.
3206148|NCT00950976|Experimental|Citrulline|
2560279|NCT02497651|Experimental|Healthy, heavy smoking men|Twelve healthy, male subjects. Intervention: Will undergo two separate, identical test days. One absent smoking, and one with concomitant smoking.
3206149|NCT00950976|Placebo Comparator|lemonade|Equal volume and flavor to citrulline.
3206154|NCT00951002||acellualr dermal matrix|patients treated with acellular dermal matrix plug
2559342|NCT02503657|Other|Open-Label Extension|Upon completion of the Double-blind Treatment Phase, subjects who were taking placebo, will participate in the open-label extension (OLE) phase for an additional 6 months. Subjects randomized to the MN-001 (tipelukast) group will continue the study drug for additional 6 months.
3206155|NCT00951028|Active Comparator|Enhanced treatment as usual|Participants will receive the life-steps intervention and treatment as usual.
3206156|NCT00951028|Experimental|CBT for adherence and depression (CBT-AD)|Participants will receive the life-steps and CBT-AD interventions.
2559469|NCT02502747|Experimental|G-CSF and Myocardial Contrast Echocardiography (MCE)|subcutaneous Granulocyte - Colony Stimulating Factor ( on top of optimal standard of care) and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
2559470|NCT02502747|Active Comparator|Placebo and Myocardial Contrast Echocardiography (MCE)|Patients will be receive optimal standard of care and Myocardial Contrast Echocardiography with intravenous infusion of sulphur hexafluoride.
3206157|NCT00951028|Active Comparator|ISP for adherence and depression (ISP-AD)|Participants will receive the life-steps and ISP-AD interventions.
3206158|NCT00951067|Active Comparator|Group A|Exercise, Elevation, and Garment Compression
2559782|NCT02500849|Experimental|Cohort 1:|target busulfan AUC levels: 8,000 µM*min (+/- 1,000)
2559784|NCT02500849|Experimental|Cohort 2:|busulfan AUC levels: 12,000 µM*min (+/- 1,000)
2559860|NCT02500524|Experimental|10% Cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair on a single occasion and is washed off with shampoo after 60 minutes.
2559862|NCT02500524|Active Comparator|1% permethrin creme rinse|1% permethrin creme rinse is applied to shampooed and towel dried hair on a single occasion and left in situ for 10 minutes, then rinsed off with clean water.
2559908|NCT02500251|Experimental|Group A (5 subjects)|Subjects will receive bortezomib and plasmapheresis.
2559912|NCT02500251|Experimental|Group B (5 subjects)|Subjects will receive belimumab, bortezomib, and plasmapheresis.
2559916|NCT02500251|Experimental|Group C (5 subjects)|Subjects will receive belimumab, bortezomib, rituximab, and plasmapheresis.
2559964|NCT02499718|Experimental|Noninvasive ventilator|noninvasive positive pressure ventilation combined with long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
2559965|NCT02499718|No Intervention|LTOT|long-term oxygen therapy for severe stable chronic obstructive pulmonary disease
2559999|NCT02499549|Experimental|10% Cocamide diethanolamine 8 hours|Cocamide DEA topical lotion applied 8 hours/overnight with drying
2560004|NCT02499549|Experimental|10% Cocamide diethanolamine 2 hours|Cocamide DEA topical lotion applied 2 hours with drying, repeated after 7 days
2560049|NCT02499341|Active Comparator|Tramadol|Intraoperative administration of a bolus dose of tramadol and continuous intravenous infusion of tramadol for up to 48 h postoperatively.
2560058|NCT02499341|Active Comparator|Ketamine|Intraoperative administration of a bolus dose of ketamine and continuous intravenous infusion of ketamine for up to 48 h postoperatively.
2560115|NCT02498938||SERPINA1 gene in COPD and periodontitis|patients aged between 30-70 yrs with COPD (satisfying Gold's criteria) and chronic periodontitis (>4mm pocket probing depth)
2560150|NCT02498639|Active Comparator|BAV without pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) without previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done without rapid pacing.
2560151|NCT02498639|Active Comparator|BAV with pacing|Patients undergo percutaneous balloon aortic valvuloplasty (BAV) after previous insertion of a temporary pacemaker lead in the right ventricle. Stabilization of the balloon during inflation is done under rapid pacing.
2560252|NCT02498145|Experimental|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
2560255|NCT02498145|Active Comparator|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
2560301|NCT02497729|No Intervention|Sniffing Position, No Checklist|Patient in the sniffing position without the use of a written checklist
2560307|NCT02497729|Active Comparator|Sniffing Position, Checklist|Patient in the sniffing position with the use of a written checklist
2560312|NCT02497729|Active Comparator|Head of Bed Up, No Checklist|Patient with the head of bed up and without the use of a checklist
2560315|NCT02497729|Active Comparator|Head of Bed Up, Checklist|Patient with the head of bed up and with the use of a checklist
2560353|NCT02497144|Active Comparator|NMES Group|"Intervention: NMES group will receive neuromuscular electrical stimulation using high frequency galvanic stimulation and breathing exercises.~Neuromuscular electrical stimulation will be applied bilaterally to quadriceps femoris muscle for 3days/6 weeks by a physiotherapist.~NMES group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
2560354|NCT02497144|Sham Comparator|Control Group|"Sham: Control group will receive breathing exercises. Control group will perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
3206159|NCT00951067|Active Comparator|Group B|Pneumatic Compression Device (B)
3206160|NCT00951067|Active Comparator|Group C|Pneumatic Compression Device (C)
3206161|NCT00951067|Active Comparator|Group D|Pneumatic Compression Device (D)
3206162|NCT00951067|Active Comparator|Group E|Pneumatic Compression Device (E)
2560738|NCT02494908|Active Comparator|Healthy controls|Healthy controls with no known neurological disease matched for sex and age with the patients group
2560744|NCT02494908|Active Comparator|IPD patients|Men and women diagnosed with idiopathic parkinson's disease
2560763|NCT02494427|Experimental|1|CAD/CAM manufactured fixed unitary dental prostheses
3206163|NCT00951106|Experimental|Pyrimethamine/sulfdoxine (Fansidar)|Pyrimethamine/sulfdoxine (Fansidar)
3206164|NCT00951119|Experimental|resperate device|"Resperate© is a device that helps to slow down breathing. This device can measure the breathing patterns through a breathing sensor mounted on the upper abdomen or chest. Furthermore, music-like sound patterns can be composed similar to this breathing pattern, which the patient can hear through the headphones of the Resperate©. By prolonging the expiration, which can be voluntarily used by the user, the frequency of respiration can be slowed down and become more stable (aim<10 breathings per minute)."
3206165|NCT00951119|Sham Comparator|control device|Resperate device without slowing of breathing
2559391|NCT02503358|Experimental|Arm II (intermittent selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-5, 8-12, and 15-19 and paclitaxel as in Arm I.
2559392|NCT02503358|Experimental|Arm III (pulsatile selumetinib and paclitaxel)|Patients receive selumetinib PO BID on days 1-3, 8-10, and 15-17 and paclitaxel as in Arm I.
2559436|NCT02502968|Experimental|Cytarabine & BL8040|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and BL-8040 (1.25 mg/kg) subcutaneously on days 1 to 5 of each cycle"
2559439|NCT02502968|Active Comparator|Cytarabine & Placebo|"Subjects ≥60 years: cytarabine 1g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 2 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle~Subjects <60 years: cytarabine 3g/m2 intravenously twice a day over 3 hours on day 1, 3 and 5 on 3 cycles and Placebo (for BL-8040) subcutaneously on days 1 to 5 of each cycle"
2559496|NCT02502669|Active Comparator|Finasteride 23.5 mg tablets group|Finasteride 23.5mg tablets and large placebo tablets once per week
2559498|NCT02502669|Active Comparator|Finasteride 33.5 mg tablets group|Finasteride 33.5 mg tablets and small placebo tablets once per week
2559499|NCT02502669|Placebo Comparator|Placebo group|Large and small placebo tablets once per week
2559567|NCT02502136|Experimental|CO2 in sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with sedation
2559571|NCT02502136|Placebo Comparator|Air in sedated colonoscopy|Room air insufflation during colonoscopy with sedation
2559574|NCT02502136|Experimental|CO2 in mild sedated colonoscopy|Carbon dioxide insufflation during colonoscopy with mild sedation
2559578|NCT02502136|Placebo Comparator|Air in deep sedated colonoscopy|Room air insufflation during colonoscopy with deep sedation
2559580|NCT02502136|Experimental|CO2 in sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with sedation
2559581|NCT02502136|Placebo Comparator|Air in sedated panendoscopy|Room air insufflation during panendoscopy with sedation
2559582|NCT02502136|Experimental|CO2 in mild sedated panendoscopy|Carbon dioxide insufflation during panendoscopy with mild sedation
2559583|NCT02502136|Placebo Comparator|Air in deep sedated panendoscopy|Room air insufflation during panendoscopy with deep sedation
2559612|NCT02501785||patient and caregivers|This is a prospective cohort study. Four questionnaires will be used to collect data from caregivers: demographic and socioeconomic data will be collected from the caregiver before the patient's surgery, and caregiver burden information will be collected 15 (+/- 3) days after surgery.
2559694|NCT02501603|Experimental|afatinib plus paclitaxel|afatinib plus paclitaxel
2559747|NCT02501109|Experimental|Group A|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days with water.
2559749|NCT02501109|Experimental|Group B|Healthy volunteers will receive Aripiprazole Oral Soluble Film(OSF) 10mg orally a single of dose within 28 days without water.
2559751|NCT02501109|Experimental|Gruop C|Healthy volunteers will receive the reference drug Abilify tab. 10mg orally a single of dose within 28 days with water.
2559770|NCT02500784|Active Comparator|Formoterol A|12 months, formoterol, 20microgram/2ml, inhaler, BID
2559776|NCT02500784|Placebo Comparator|Formoterol B|12 months, normal saline, 2ml, inhaler, BID
2559861|NCT02500563|Active Comparator|Amino acid based infant formula|
2559864|NCT02500563|Experimental|Extensively hydrolyzed casein infant formula|
2559865|NCT02500563|Other|Mother's own breast milk|
2559911|NCT02500186|Experimental|High GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 55% carbohydrate group take 55% carbohydrate white rice diet.
2559915|NCT02500186|Experimental|Low GI meal containing 55% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in low GI meal containing 55% carbohydrate group take 55% carbohydrate brown rice diet
2559917|NCT02500186|Experimental|High GI meal containing 40% carbohydrate|The energy intake of study patients is 1800 kcal per day. Study patients in high GI meal containing 40% carbohydrate group take 40% carbohydrate white rice diet.
2559945|NCT02499809|Experimental|Passive|Passive recovery
2559948|NCT02499809|Experimental|Vibration|Vibration recovery
2559993|NCT02499666||Asymptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention wtih balloon angioplasty and coronary stent placement who are currently asymptomatic (without any chest pain or anginal equivalent) but have decreased exercise capacity or are easily fatigued. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
2559994|NCT02499666||Symptomatic|Patients with known chronic total occlusion who are undergoing percutaneous coronary intervention with balloon angioplasty and coronary stent placement who are currently symptomatic with chest pain or anginal equivalent.. Patients will also be on dual antiplatelet therapy with aspirin and a second agent such as clopidogrel.
3206166|NCT00951132|Experimental|2|Rosuvastatin
3206167|NCT00951132|Placebo Comparator|1|Placebo
3206168|NCT00951158|Experimental|CLA|Open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. oral dose 7.5 g/day 28 day cycle
2560414|NCT02496923|Experimental|High flow nasal oxygen therapy (Optiflow™)|In patients randomised to receive high flow nasal oxygen therapy (HFNO) the gas flow through the HFNO will be calculated for each patient, based on their body characteristics, and comfort level. The standard starting flow rate will be 30 L/min, and this will be adjusted up or down between a range of 20-50 L/min with the aim of achieving both patient comfort and a respiratory rate of less than 16 breaths per minute.
3206169|NCT00951197||elderly subjects retired from agriculture|
2560500|NCT02496494|Experimental|Tacrolimus conversion group|Cyclosprine was converted to tacrolimus in kidney transplant recipients.
2560849|NCT02493907||heart failure|heart failure patients with CRT
3206170|NCT00951210|Experimental|PLX-PAD low dose|IM injection Single treatment; multiple injections
3206171|NCT00951210|Experimental|PLX-PAD high dose|IM injection Double treatment; multiple injections
2559400|NCT02503280|Placebo Comparator|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).The Biosense Webster MyoStar NOGA Injection Catheter System will be used in the delivery of the study drug.
2559418|NCT02502994|Other|Intervention|Single arm of the castration resistant prostate cancer
2559466|NCT02502916||Preterm infant|Preterm infants born from October 2009 to June 2010 at a gestational age of less than 32 weeks or with birth weight of less than 1,200 g
2559507|NCT02502539|Experimental|autoimmune disease|to identify the mechanisms through which physical activity is liable to mediate inflammatory balance in autoimmune disease settings, and specifically in JIA patients.
2559529|NCT02502253|Experimental|Low dose|
2559530|NCT02502253|Experimental|moderate dose|
2559531|NCT02502253|Experimental|High dose|
3206172|NCT00951223||Patients with Chronic Hepatitis C|HCV positive patients who have failed previous HCV therapy This observational prospective registry is designed to evaluate the safety, adherence, and efficacy of prescribed, patientadministered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV. The primary endpoint for efficacy will be the SVR rate at 24 weeks after therapy ends. Safety will be assessed by monitoring AEs, reduction/discontinuation of therapy because of AEs, routine laboratory results and by other means determined by the Investigator
3206173|NCT00951236|Active Comparator|One injection|
3206174|NCT00951236|Active Comparator|Two Injections|
2559883|NCT02500316|Experimental|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
2559923|NCT02500069|Placebo Comparator|Placebo|Tap water infusion in all three locations (duodenum, jejunum and ileum)
2559924|NCT02500069|Experimental|Duodenum|Infusion of casein in duodenum
2559926|NCT02500069|Experimental|Jejunum|Infusion of casein in jejunum
2559928|NCT02500069|Experimental|Ileum|Infusion of casein in ileum
2559967|NCT02499744|Active Comparator|HHFNC|HHFNC is provided nasal cannula. Ventilator settings:fraction of inspired oxygen (FiO2):21-40%,flow:2-8(litre,L)/min,to maintain arterial blood hemoglobin oxygen saturation ( SaO2) at 90-95% The weaning process is left to the discretion of the attending physician.,when FiO2: 25%,flow:2(litre,L)/min.
2559969|NCT02499744|Active Comparator|NIPPV|NIPPV is provided via binasal prongs. Ventilator settings:FiO2:21-40%,peak inspiratory pressure( PIP)：12-22cm H2O,positive and expiratory pressure(PEEP):5-7cm H2O,Rate:30-60 per minute to maintain SaO2 at 90-95%,The weaning process is left to the discretion of the attending physician,when FiO2: 25%,mean airway pressure (MAP):6cm H2O,R:30 per minute .
2560010|NCT02499510|Experimental|GoldenFlow stent|Titanium nitrite coated woven nitinol stent
2560054|NCT02499250|Experimental|RIPC arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive daily remote ischemic conditioning plus optimal medical treatment over 30 days.
2560063|NCT02499250|Active Comparator|Control arm|The subjects will be interviewed and have their baseline frequency and severity of angina pectoris recorded, then they will receive optimal medical treatment over 30 days.
2560101|NCT02498886|Experimental|Iron deficient anaemic: IDA|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
2560106|NCT02498886|Experimental|Iron sufficient: non-IDA|"Women that are not anaemic or iron deficient.~Interventions: two iron supplements will be used:~IHAT- iron hydroxide adipate tartrate: an analogue of natural food iron. Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
2560110|NCT02498886|Experimental|Iron deficient anaemic (IDA): IHAT new manufacture|"Iron deficient anaemic women.~Interventions: two iron supplements will be used:~IHAT new manufacture- iron hydroxide adipate tartrate: an analogue of natural food iron.~Ferrous sulphate- the gold standard for iron supplementation. For both the iron single-dose will be 60mg elemental iron equivalent.~Each compound will be labelled with a stable isotope of iron:~IHAT with 2 mg 58Fe and ferrous sulphate with 10 mg 57Fe.~1 capsule of each compound will be ingested with a full glass of water in two separate occasions, 14 days apart."
2560239|NCT02498093|Experimental|Maximal strength training|Maximal strength training supervised by a physiotherapist
2560247|NCT02498093|Active Comparator|Control|Conventional rehabilitation supervised by a physiotherapist
2560300|NCT02497742|Active Comparator|Once daily BMP|Patient in this arm will receive once daily basic metabolic panel to monitor electrolytes
2560304|NCT02497742|Active Comparator|Twice daily BMP|Patient in this arm will receive twice daily basic metabolic panel to monitor electrolytes
2560341|NCT02497274|Experimental|Roux Y gastric bypass|candidates for bariatric surgery by Roux Y gastric bypass with taste assessment and epithelium gustatory smear and biopsy
2560342|NCT02497274|Experimental|Sleeve gastrectomy|candidates for bariatric surgery by sleeve gastrectomy with taste assessment and epithelium gustatory smear and biopsy
2560378|NCT02497079|Experimental|Nested PCR for formalin-fixed tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with formalin-fixed paraffin-embedded specimens obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
2560384|NCT02497079|Experimental|Nested PCR for fresh tissues|In all patients, nested polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
2560387|NCT02497079|Experimental|Real-time PCR for fresh tissues|In all patients, real-time polymerase chain reaction for Mycobacterium tuberculosis is performed with specimens in sterile saline obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
3206175|NCT00951249|Experimental|A|HIV-infected and uninfected black MSM
2559491|NCT02502799|Active Comparator|PT with ACBT and Methylphenidate|All participants will receive 5 sessions of BEI. Non-responders will then be randomized to one of three conditions. For participants randomized to the PT with ACBT and Methylphenidate arm, parents will participate in behavioral parent training (PT) and adolescents will participate in cognitive behavioral therapy to reduce substance use (ACBT). Adolescents will also receive methylphenidate.
2559522|NCT02502279|No Intervention|Control|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters with 0 PEEP/CPAP.
2559523|NCT02502279|Active Comparator|Lung Recruitment- PEEP group|Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.
2559524|NCT02502279|Active Comparator|Lung Recruitment- PEEP and CPAP group|"Engström Datex-Ohmeda ICU Ventilator: Pediatric patients under general anesthesia will be mechanically ventilated with the conventional ventilator parameters plus~lung recruitment manoeuvre with peak inflation pressure 35 cmH2O for 15 seconds followed by PEEP until extubation delivered by the ventilator.~Postoperative CPAP mask immediately after extubation"
3206176|NCT00951262|Experimental|life review|a life review program includes 3-session life review and formulation of a life review book as a gift for advanced cancer patients.
3206177|NCT00951262|No Intervention|controlled group|the subjects in the controlled group do not receive the life review program
3206178|NCT00951288|Active Comparator|Saffron|Crocus Sativus extract
3206179|NCT00951288|Placebo Comparator|Placebo|Placebo comparator
2559748|NCT02501005|Experimental|Treatment Group 1 (TG1)|Prophylactic VT ablation prior to ICD implantation
2559750|NCT02501005|Other|Treatment Group 2 (TG2)|ICD implantation and best medical care until the third appropriate ICD shock occurs and catheter ablation thereafter
2559794|NCT02500771|Experimental|children and tutors using V-Motive|"The following intervention will be administered:~ABA therapy enhanced with V-Motive software~Tutors treating children with Applied Behavioral Analysis therapy will use the V-Motive software to enhance therapy sessions. Children will receive therapy as usual, but half of their current behavioral programs (skills/goals) will have been selected for enhanced prompting through video modeling."
3206180|NCT00951301|Active Comparator|mangosteen juice|subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
3206181|NCT00951301|Placebo Comparator|placebo juice|subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient
3206182|NCT00951340|Active Comparator|CBT with listening therapy|Participants will receive CBT with listening therapy.
3206183|NCT00951340|Experimental|CBT with emotional processing and interpersonal therapy|Participants will receive CBT with emotional processing and interpersonal therapy.
3206184|NCT00951353||Pediatric Renal Transplant Recipients|
2560257|NCT02498197|Experimental|Participatory Intervention|Participatory intervention with workers and their leaders. Workshops with presentation of work tasks with excessive physical load and subsequently plans to reduce these loads
2560259|NCT02498197|Active Comparator|Control|Receive standard information about correct lifting technics, use of assistive technology, and ergonomics
2560299|NCT02497716|Experimental|Rivaroxaban|Single arm, open label study
2560382|NCT02497105|Experimental|Epilepsy/Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will receive the ketogenic diet intervention.
2560385|NCT02497105|No Intervention|Epilepsy/Non-Ketogenic Diet|Children (0-18 years of age) diagnosed with epilepsy will not receive the ketogenic diet intervention.
3206185|NCT00951366||Bronchopulmonary Dysplasia (BPD)|
3206186|NCT00951392|Experimental|Problematic aging|
3206187|NCT00951392|Experimental|successful aging|
3206188|NCT00951405|Experimental|A|
3206189|NCT00951405|Experimental|B|
3206190|NCT00951405|Experimental|C|
3206191|NCT00951431|Experimental|PPI|
2560633|NCT02495480|Experimental|sheathed group|The sterilized disposable sheath covered the outer surface of the colonoscope, then colonoscope will be performed in conventional way;a new sheath will be placed on the endoscope in sheathed group as a intervention
2560634|NCT02495480|No Intervention|conventional group|Colonoscopy will be performed with air insufflation during insertion
2560699|NCT02494999|Experimental|13-valent pneumococcal conjugate vaccine|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
3206192|NCT00951431|Placebo Comparator|Control|
3206193|NCT00951444|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, carboplatin IV over 30 minutes on day 1, and MK-0646 IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. After 4 courses, patients with stable disease or partial or complete response may then receive MK-0646 alone on days 1 and 15. Treatment with MK-0646 repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3206194|NCT00951444|Active Comparator|Arm II|Patients receive gemcitabine hydrochloride and carboplatin as in arm I. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients may crossover to arm upon disease progression.
3206195|NCT00951457|Experimental|Overall study|"Dose escalation phase:~Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.~Treatment phase:~Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles~Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
3206196|NCT00951470|Other|No CDT|CDT=complete decongestive therapy
3206197|NCT00951470|Other|Modified CDT Program|CDT=complete decongestive therapy
3206198|NCT00951470|Other|Full CDT Program|CDT=complete decongestive therapy
3206199|NCT00951522|Experimental|1|GS-9411 2.4 mg
3206200|NCT00951522|Experimental|2|GS-9411 4.8 mg
3206201|NCT00951522|Experimental|3|GS-9411 7.2 mg
3206202|NCT00951522|Experimental|4|GS-9411 9.6 mg
3206203|NCT00951522|Placebo Comparator|5|Placebo
3206204|NCT00951535|Other|Arm A|Treatment will be delivered in 1.8 Gy fractions; dose escalation will be in 1.8 Gy increments from 75.6 Gy to a maximum 81 Gy.
2559556|NCT02502357|Experimental|Healing Statements|Patients in the healing statements group will be read healing statements during anesthesia induction, prior to undergoing surgery.
2559559|NCT02502357|No Intervention|No Healing Statements|Patients in the no healing statements group will not be read healing statements during anesthesia induction prior to undergoing surgery. They will receive standard of care.
2559603|NCT02501915|Experimental|Kinesio Taping (GROUP A)|Received the application of KT from muscle Origin to Insertion
2559604|NCT02501915|Experimental|Kinesio Taping (GROUP B)|received the application of KT from muscle Insertion to Origen
3206205|NCT00951548|Experimental|VSL#3|Probiotic preparation VSL#3
3206206|NCT00951548|Placebo Comparator|placebo|Corn Starch
2559687|NCT02501434|No Intervention|Control|Standard of Care
2559690|NCT02501434|Experimental|LDIVH (Unfractionated Heparin)|Continuous Low-Dose IV Unfractionated Heparin Infusion
2559733|NCT02501044||Hemodialysis Patients|
2559767|NCT02500927|Experimental|ASP8273 group|Single oral administration of ASP8273 Capsule A for bioavailability evaluation, followed once daily multiple administration of ASP8273 Capsule
2559918|NCT02500199|Experimental|Pyrotinib|A two-part Phase I, open-label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy
3206207|NCT00951574|Placebo Comparator|saline solution|Pre-filled syringes of 0.4 ml, 1 subcutaneous injection/day (every 24 hours).
3206208|NCT00951574|Experimental|nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
2560131|NCT02498873|Active Comparator|Linear Periodization|Linear Periodization Running (Crossover Design)
2560136|NCT02498873|Active Comparator|Non Linear Periodization|Non Linear Periodization Running (Crossover Design)
3206209|NCT00951587|Experimental|1|Patients that are indicated for colonoscopy or who are suspected or known to suffer from colonic diseases.
3206210|NCT00951600|Experimental|1|Oxcarbazepine oral suspension 300 mg/5mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
2560233|NCT02498158||experimental protocol|Functional neural connectivity at rest of 3 groups (heat tolerant, heat intolerant and healthy subjects) will be assessed using the anatomical and functional MRI scans and compared.
2560305|NCT02497794|Active Comparator|postoperative chew gum|The patients in the study group will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours.
2560311|NCT02497794|Placebo Comparator|without postoperative chew gum|The control group will be followed without chew gum.
2560369|NCT02497261||Avoiding and possibly allergic to peanut|Challenge Group: Children with positive skin prick testing to peanut who are avoiding peanut will undergo a double-blind placebo-controlled peanut challenge (gold standard for peanut allergy diagnosis) if their allergy evaluation suggests that they have a good chance of not being allergic to peanut. Children who pass the challenge are not allergic to peanut. Children who react during the challenge are allergic to peanut and will continue to avoid peanut.
2560374|NCT02497261||Not allergic to peanut|Comparison Group: Children with positive skin prick testing to peanut who are eating and tolerating peanut are not clinically allergic to peanut and may continue eating peanut.
2560424|NCT02496897|Experimental|FP-02.2 Low Dose|A low dose of the FP-02.2 vaccine.
2560429|NCT02496897|Experimental|FP-02.2 High Dose|A high dose of the FP-02.2 vaccine.
2560432|NCT02496897|Experimental|FP-02.2 Low Dose with IC31® Adjuvant|A low dose of the FP-02.2 vaccine with IC31® Adjuvant.
2560435|NCT02496897|Experimental|FP-02.2 High Dose with IC31® Adjuvant|A high dose of the FP-02.2 vaccine with IC31® Adjuvant.
2560437|NCT02496897|Placebo Comparator|Placebo|Placebo component.
2560440|NCT02496897|Experimental|IC31® Adjuvant|IC31® Adjuvant alone.
2560510|NCT02496299|Active Comparator|dexametasone (BD),|BD ,a mixture of 0.2mg/kg dexamethasone in 1ml/kg bupivacaine
2560513|NCT02496299|Active Comparator|Bupivacaine,B|B ,1ml/kg bupivacaine:
2560550|NCT02495974||Patients with mCRPC prescribed enzalutamide|Oral
2560750|NCT02494700|Experimental|Treatment (low dose orbital EBRT)|Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
2560786|NCT02494310|Experimental|HRME - Prevention Mobile Unit|Procedures to be done in the mobile unit (van): Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
2560787|NCT02494310|Experimental|HRME - Barretos Cancer Hospital|Procedures to be done at Barretos Cancer Hospital: Visual inspection will be performed with 5% acetic acid (VIA) applied to the cervix followed by standard colposcopy. Proflavine (0.01%) will then be applied topically. Lugol's solution will then be applied and colposcopy performed and abnormal lesions noted. HRME images will be acquired from any areas that are abnormal by VIA and/or colposcopy. VIA, colposcopy and HRME observations will recorded by quadrant. Any abnormal areas by VIA and/or colposcopy will be biopsied. If no abnormal areas are noted, one cervical biopsy will be obtained from a normal appearing area with a HRME image of this area obtained.
2560823|NCT02494128|Active Comparator|Intervention group|Education in group leadership
2560824|NCT02494128|No Intervention|Control group|This group fills in the questionnaire. No intervention given.
2560861|NCT02493790||Volunteers|Cognitive and motor performances were measured in a single and dual task situations.
2560943|NCT02493192|Active Comparator|Meperidine|Use pethidine and haloperidol injection as a pain relief.
3206211|NCT00951600|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5mL of Novartis
3206212|NCT00951639|Experimental|5g Cassia cinnamon|Experimental treatment group
3206213|NCT00951639|Active Comparator|50 minutes endurnace exercise|Endurance exercise treatment known to influence blood glucose
2559569|NCT02502435||Patients with Night-Eating Syndrome|Individuals diagnosed with Night Eating Syndrome (NES); 18-65 years of age; eating 30% of their caloric intake after dinner with nocturnal awakenings to eat at a frequency of ≥ 5 times per week
2559575|NCT02502435||Matched Healthy Controls|Healthy volunteers; 18-65 years of age; eating <25% of their caloric intake after dinner; no nocturnal ingestions
2559631|NCT02501876||T2D-MCI|110 MCI subjects with type 2 diabetes. There is a retrospectiv observational study. No intervention will be performed.
2559640|NCT02501876||nonT2D-MCI|110 MCI subjects without diabetes. There is a retrospectiv observational study. No intervention will be performed.
2559685|NCT02501486|Other|ACTH stimulation test|this is a single arm study. An ACTH-stimulation test will be done
2559723|NCT02501239|Experimental|Accept Yourself! Intervention|Combined Health At Every Size and Acceptance and Commitment Therapy Psychotherapy Group
2559724|NCT02501239|Active Comparator|Behavioral Weight Loss|Weight Watchers groups
2559762|NCT02500966|Experimental|DUDA device|"The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).~Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)"
2559763|NCT02500966|Active Comparator|Control group|"The number of patients to be recruited in this arm will be 120.~Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device"
3206214|NCT00951639|Placebo Comparator|5g Cellulose|Placebo equivalent in weight and appearance to experimental treatment
3206215|NCT00951652|Experimental|CBT plus supportive listening|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be supportive listening
2559869|NCT02500394|Placebo Comparator|standard care|Patients in the standard care population receive - if biomarkers are elevated -treatment of AKI in accordance with KDIGO 2012 guidelines
2559872|NCT02500394|Active Comparator|interventional care|Patients in the interventional population receive - if biomarkers are elevated - individualized treatment/volume substitution (balanced electrolyte solution = Ionosteril; 1,25-5 ml/kg/bw/6 hours) ) on the basis of predefined criteria
2559894|NCT02500134||Normal|Healthy volunteer control without ocular surface disease or prior ophthalmic surgery history
2559955|NCT02499965|Active Comparator|Topical Ethyl Chloride (Product B)|Ethyl Chloride Topical Aerosol Anesthetic applied to arm
2559956|NCT02499965|Placebo Comparator|Topical Sterile Water (Product A)|Nature's Tears Sterile water in an aerosol can
3206216|NCT00951652|Active Comparator|CBT plus Interpersonal and emotional processing therapy|14 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques and the second hour will be Interpersonal and emotional processing therapy
3206217|NCT00951678||ER patients|"Subjects must be 18 yrs or older, male or female, and must have the anatomy that we will be examining. Patients will be given the option of enrolling in the study whilst being cared for in Tampa General Hospital Emergency Room.~We anticipate enrolling normal, healthy volunteers, elderly persons (>65) not cognitively impaired, persons with social, economic or educational disadvantages , and persons who do not understand English fluently."
3206218|NCT00951691|Experimental|Enhanced acute medical rehabilitation|Participants will receive enhanced acute medical rehabilitation.
2560173|NCT02498457|Active Comparator|low calcium dialysis|patients in this group will be dialyzed using a dialysate with a calcium concentration 1.25mmol/L.
2560175|NCT02498457|Other|Routine dialysis|Patients in this groups will be dialyzed using routine dialysate with a calcium concentration 1.5mmol/L.
2560212|NCT02498223|Experimental|research arm|50 subjects (healthy soldiers, male and female) from combat units will undergo the experiment protocol.
2560248|NCT02497950||HeartMate 3|This registry will include all patients that receive the HM3 LVAS in the post-market setting
2560292|NCT02497534||Affected with Friedreich's ataxia|Friedreich's ataxia patients aged 8 to 70 (inclusive). Assessments will include collection of genetic mutation reports, cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing with a recombinant bike and/or hand ergometer, pulmonary function testing, and gait analysis. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
2560293|NCT02497534||Healthy controls|Health controls aged 8 to 70 (inclusive). Assessments will include cardiac and exercise MRI, echocardiogram, the Friedreich's Ataxia Rating Scale (FARS), exercise testing, hand ergometer for exercise testing, pulmonary function testing, gait analysis, and an optional blood draw.
2560294|NCT02497534||Carriers of Friedreich's ataxia|An obligate carrier aged 18 to 70 (inclusive) of the abnormal Friedreich's ataxia gene by being a parent of a child with Friedreich's ataxia. No assessments are to be conducted. Optional labs include a blood draw, skin biopsy, and/or muscle biopsy.
2560345|NCT02497378|Experimental|JNJ-54767414 (Daratumumab) +Bortezomib+Dexamethasone|Participants will be administered JNJ-54767414 (daratumumab) intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, then on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks), First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles. Bortezomib at a dose of 1.3 milligram per meter square (mg/m^2) subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle for 8 treatment cycles and Dexamethasone orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles.
2560395|NCT02497027|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
2560397|NCT02497027|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
2560428|NCT02496741|Experimental|Metformin and chloroquine combination|"Metformin will be administered in a 3+3 dose-escalation schedule.~Chloroquine will be administered in a fixed dose."
2560826|NCT02494024|Experimental|Single dose C2N-8E12 level 1|Single IV infusion of C2N-8E12
3206219|NCT00951691|Active Comparator|Treatment as usual|Participants will receive treatment as usual.
3206220|NCT00951704||Cardiac arrest|
2559572|NCT02502123||OnabotulinumtoxinA (BOTOX®)|Patients diagnosed with chronic migraine headache treated with BOTOX® as standard of care in clinical practice. No intervention was administered in this study.
2559616|NCT02501798|Experimental|Drug: Methylphenidate|Drug: Methylphenidate 7 days dosage as (prior to study) clinically titrated long acting Equasym (brand)
2559622|NCT02501798|Active Comparator|Drug: Placebo|Drug: Placebo 7 days Empty green-yellow capsule
2559667|NCT02501447|Experimental|Guided audio-visual relaxation group|The guided relaxation (GR) intervention included a single 12-min GR video clip we administered to subjects at the baseline visit to determine the immediate effects of GR on stress and pain. The GR intervention also included six video clips, which ranged from 2 to 20 minutes in length to determine the short-term (2-week) effects of GR on stress and pain.
2559669|NCT02501447|No Intervention|Attention Control group|For the attention control group, subjects engaged in a 12-min computer-based discussion about their sickle cell disease (SCD) experience. The audio-taped questions and onscreen directions were programmed for self-administration. Subjects' responses were captured via the microphone so that Data Collectors were not involved in this discussion process, and it was equivalent to the guided relation activity.
2559701|NCT02501317|Experimental|Active Perineal Rehabilitation protocol|"study group that will be treated with Active Perineal Rehabilitation protocol"
2559705|NCT02501317|Active Comparator|Kari Bo protocol|control group will be treated with the protocol already widely used
2559873|NCT02500433|Experimental|Device: Kinect-Xbox360TM|"Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.~Participants were initially exposed to the games in an hour introductory session, 2 weeks before the study began. All the sessions were supervised by physiotherapist."
2559877|NCT02500433|Other|Conventional therapy|"Conventional therapy was based on neurodevelopment treatment, psychomotor activities and kinesiotherapy during one month, twice per week, with 30 minutes per session.~The treatment includes: active and passive kinesitherapy, muscle and tendons stretching, training of gait and deambulation, such as coordination and handling."
2559891|NCT02500147|Experimental|Metformin|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Metformin ER (extended release) will be administered as two pills of 500 mg each. For the first week subjects will take one pill orally on a daily basis and thereafter will take two pills orally on a daily basis. The intervention will last six months.
2559893|NCT02500147|Placebo Comparator|Placebo|Adolescents and young adults with PCOS and liver fat greater than or equal to 4.8% will be randomized to metformin or placebo. Subjects randomized to placebo will be instructed to take one pill daily by mouth for one week and then to take one pill daily by mouth for the remainder of six months.
2559941|NCT02499874|Experimental|Single treatment arm|All subjects will be administered oral Efavirenz 400mg together with the rest of the oral antiretroviral combination (tenofovir 245 mg/emtricitabine 200mg or tenofovir 245mg/lamivudine 300mg or lamivudine 300mg/zidovudine 600mg) throughout the study period
2559979|NCT02499601|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
2560022|NCT02499471|Other|Before levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure 6.8 ± 2.8 weeks after thyroidectomy, when plasma free T4-levels were at the minimum, before daily levothyroxine therapy 137.75 ± 25.75 μg.
2560023|NCT02499471|Other|After levothyroxine therapy 137.75 μg|18F-FDG PET CT scan after mild cold exposure four to six months after the initial measurements, after daily levothyroxine therapy 137.75 μg (fT4 levels 23.1 ± 3.9 pmol/L, TSH 0.5 ± 0.6 mU/L)
2560031|NCT02499133|Other|adult who suffered traumatic brain injury|
2560032|NCT02499133|Other|control group|
2560089|NCT02499068|Experimental|COPD, Telehealth|Patients randomized to this arm would be followed by home telehealth devices and monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.
2560091|NCT02499068|No Intervention|COPD, Normal clinical practice|Patients would do the usual clinical practice.
2560125|NCT02498808||Healthy controls|Staff or patients attending hospital or visitors attending with patients. They should not have vasculitis or inflammatory arthritis
2560128|NCT02498808||Early rheumatoid arthritis|Newly diagnosed patients with rheumatoid arthritis attending hospital, prior to use of biologic therapies
2560133|NCT02498808||New or relapsing ANCA vasculitis|Newly diagnosed or flaring patients with anti-neutrophil cytoplasm antibody associated systemic vasculitis attending hospital
2560137|NCT02498808||Newly diagnosed giant cell arteritis|Newly diagnosed patients with giant cell arteritis attending hospital
2560164|NCT02498574|Experimental|Group 1|Non-invasive brain stimulation protocol expected to improve performance, with cognitively challenging game
2560167|NCT02498574|Placebo Comparator|Group 2|Non-invasive brain stimulation protocol not expected to improve performance, with cognitively challenging game
3206221|NCT00951717|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
2560308|NCT02497495|No Intervention|GC|Control group - CG (n = 21), which suffered no recuperative technique
2560310|NCT02497495|Experimental|G1|G1 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
2560313|NCT02497495|Experimental|G2|G2 (n = 21) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
2559598|NCT02501889|Experimental|Walnut-rich weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. All participants will have contact with the project coordinator a minimum of every 1-2 weeks. Walnuts will be provided to participants in the walnut-rich study arm.
2559599|NCT02501889|Active Comparator|Standard weight loss diet arm|Participants will have an individualized reduced-calorie diet prescription and weight loss counseling session with the project coordinator, who is a registered dietitian. Composition of prescribed diets will be based on individual preferences. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Participants assigned to this arm will be instructed to abstain from the consumption of nuts during the study. All participants will have contact with the project coordinator a minimum of every 1-2 weeks.
2559645|NCT02501668||Lung cancer in population|Lung cancer cases in sample population (670,258 cases)
2559647|NCT02501668||COPD in population|COPD cases (670,258 cases)
2559649|NCT02501668||COPD with lung cancer|Lung cancer in COPD
2559650|NCT02501668||ILD without IPF|Interstitial lung disease (ILD) cases without idiopathic pulmonary fibrosis (IPF)
2559651|NCT02501668||ILD with lung cancer|Lung cancer cases in ILD
2559652|NCT02501668||Idiopathic pulmonary fibrosis|Idiopathic pulmonary fibrosis cases
2559653|NCT02501668||IPF with lung cancer|Lung cancer cases in IPF patients
2559654|NCT02501668||Connective tissue disorder with ILD|CTD with ILD cases
2559655|NCT02501668||CTD ILD with lung cancer|Lung cancer cases in CTD with ILD
2559656|NCT02501668||CTD without ILD|CTD with ILD cases in sample population
2559657|NCT02501668||CTD without ILD with lung cancer|Lung cancer in CTD without ILD
2559668|NCT02501408|Experimental|Propriofoot prosthesis|New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month
2559670|NCT02501408|No Intervention|Control|Usual prosthesis is worn for 1 month
2559706|NCT02501304|Experimental|ReVENT Sleep Apnea System|All patients will be implanted with the ReVENT Sleep Apnea System
2559737|NCT02501122||Adenotonsillectomy|Measuring quality of care in patients undergoing adenotonsillectomy.
2559771|NCT02500914|Experimental|SC-002|"Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability.~Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent."
3206222|NCT00951717|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
3206223|NCT00951730||Down syndrome|Adult and children with Down syndrome.
2559889|NCT02500225|Active Comparator|Etomidate|0.2 mg/kg etomidate during anesthesia induction
2559890|NCT02500225|Active Comparator|8% sevoflurane|Sevoflurane 8% concentration during anesthesia induction
3206224|NCT00951743|Experimental|Adaptavir Treatment|MDAPTA (Adaptavir) will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
3206225|NCT00951743|Placebo Comparator|Placebo|Placebo will be administered intranasally at 0.01 mg twice per day. Individuals with plasma viral load (PCR Roche Amplicor Ultrasensitive assay) less than 200 copies/mL, sustained for the previous 90 days, with CD4>350 cells/mm3 will be eligible to participate.
2559985|NCT02499705|Experimental|Sucralose|Flavored beverage with sucralose.
2559986|NCT02499705|Experimental|Sucrose|Flavored beverage with sucrose.
2559988|NCT02499705|Experimental|Sucralose + maltodextrin|Flavored beverage with Splenda + maltodextrin .
2560041|NCT02499302|Experimental|Mental training|"The intervention consists of one introductory session (patients and their parents/next-of-kin), followed by 9 individual therapy sessions (one each week) of 1.5 hours duration and related home-work, combining elements from cognitive behavioural therapy and music therapy: Important elements of the mental training program are:~Psychoeducation: Theories of CFS/ME pathophysiology and treatment rationale~Relaxation: Bodily stress reduction, mindfulness~Visualization: Contact with positive emotions, techniques of worrying reduction~Experiences: Behavioral 'experiments' (individually adjusted), 'trick into action'~Cognitive challenges: Challenging thoughts about disease process, stimulus and outcome expectancies, prognosis"
2560055|NCT02499302|No Intervention|Routine follow-up|Routine follow-up by the general practitioner, which is normal approach to chronic fatigue following acute EBV infection.
2560152|NCT02498704|Sham Comparator|Sham Needling intervention, Control|Sham dry needling, group does not receive true dry needling intervention.
2560153|NCT02498704|Experimental|Dry Needling Intervention, experimental|Group receives true dry needling intervention.
2560197|NCT02498392|Placebo Comparator|Responders-Placebo|Participants who responded in the placebo lead-in period will be administered with Matching Placebo orally.
2560200|NCT02498392|Experimental|Responders-JNJ-42165279|Participants who responded in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 milligrams (mg) tablets once daily for 6 weeks.
2560205|NCT02498392|Placebo Comparator|Non Responders-Placebo|Participants who did not respond in the placebo lead-in period will be administered with Matching Placebo orally.
2560206|NCT02498392|Experimental|Non Responders-JNJ-42165279|Participants who did not respond in the placebo lead-in period will be administered with JNJ-42165279 orally at a dose of 25 mg tablets once daily for 6 weeks.
2560264|NCT02497885||healthcare personnel group|healthcare worker who was exposed to confirmed MERS patients, irrespective of adequate personal protective equipment.
2559643|NCT02501824|Experimental|speech therapy second|10 weeks of waiting, then 11 sessions of speech therapy (anthroposophic therapeutic speech)
2559692|NCT02501460|Active Comparator|Supplement Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and dietary supplementation. Adherence will be assured as described below.
2559693|NCT02501460|Placebo Comparator|Placebo Group|Participants will receive educational handouts and complete research testing to evaluate their physical condition prior to beginning the resistance training and placebo. Adherence will be assured as described below.
2559732|NCT02501057|Active Comparator|Clinician's Guide|"The Baseline intervention includes a brief meeting (20 minutes or less) with a clinic staff member to discuss drinking and HIV medication adherence. The clinic staff member provides feedback on the participant's drinking, helps the participant set a drinking goal, and make suggestions to help the participant reduce their drinking. Participant receives a booklet called Rethinking Drinking that includes information about alcohol and tips for cutting down on alcohol use or quitting drinking. 30- and 60-day visits last about 10 minutes each, and include a meeting with the clinic staff member again to discuss drinking and HIV medication adherence, and to get additional feedback."
2559740|NCT02501057|Active Comparator|Enhanced Motivational Interviewing|Participants meet with a counselor to discuss their alcohol use, the impact it has on their health, and the possibility of reducing their drinking. The first counseling session is intended to help participants reduce their alcohol use. They are asked to describe the pros and cons of their alcohol use and whether it might be important to reduce or quit drinking. After, they are given a study smartphone and asked to use HealthCall-S daily to help keep track of their drinking. At 30 days, participants review a graph showing the results of HealthCall-S use and discuss it with the counselor. They also have a brief discussion about drinking patterns and goals for reduction. They are then asked to continue using HealthCall-S for the next 30 days, after which the counselor meets with the participant for another brief interview to go over the updated graph, and to discuss their experience with HealthCall-S. They will also have a brief discussion about drinking patterns and goals for reduction.
2559744|NCT02501057|Experimental|Enhanced Clinician's Guide|Participants in this group receive the Clinician's Guide intervention paired with daily use of HealthCall-S, which includes two cycles of daily use of HealthCall for 30 days, followed by personalized feedback in the form of a graph with a clinic staff member.
2559768|NCT02500810|Experimental|monosialoganglioside|patients receive monosialoganglioside.
2559778|NCT02500810|No Intervention|control|blank control
2559856|NCT02500576|Experimental|Arm I (pembrolizumab, high-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide IV over 2 hours on days -7 and -6 followed by fludarabine phosphate IVPB over 15-30 minutes on days -5 to -1. Patients also receive therapeutic tumor infiltrating lymphocytes IV over 15-60 minutes on day 0 followed by high-dose aldesleukin IV over 15 minutes every 8-16 hours for up to 15 doses on days 1-5. Beginning between 21-28 days after TIL infusion, patients receive maintenance therapy comprising pembrolizumab IV over 30 minutes every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2559859|NCT02500576|Experimental|Arm II (pembrolizumab, low-dose aldesleukin)|Patients receive standard lymphodepleting chemotherapy comprising cyclophosphamide and fludarabine phosphate and therapeutic tumor infiltrating lymphocytes as in Arm I, followed approximately 6 hours later by low-dose aldesleukin SC for 14 days. Patients also receive pembrolizumab as in Arm I.
2559951|NCT02499978|Experimental|DRV/COBI, DTG Immediate switch|DARUNAVIR/COBICISTAT (800mg/150MG), DOLUTEGRAVIR 50MG DAILY at randomization and follow through week 48.
2559953|NCT02499978|Active Comparator|DRV/COBI, DTG Delayed Switch|DARUNAVIR/COBICISTAT (800MG150MG), DOLUTEGRAVIR 50MG DAILY at week 24 and follow through week 48.
2559991|NCT02499562|Experimental|Hydronidone(180mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 2 capsules each time; with co-administration of placebo capsule, three times a day, 2 capsules each time, namely the daily dose of the investigational product is 180mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
2559997|NCT02499562|Experimental|Hydronidone(270mg) & Entecavir & Placebo|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 3 capsules each time; with co-administration of placebo capsule, three times a day, 1 capsules each time, namely the daily dose of the investigational product is 270mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
2560000|NCT02499562|Experimental|Hydronidone(360mg) & Entecavir|"hydronidone capsule 30mg/capsule hydronidone capsule, three times a day, 4 capsules each time; namely the daily dose of the investigational product is 360mg.~The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach."
2560003|NCT02499562|Experimental|Entecavir & Placebo(360mg)|placebo capsule 30mg/capsule placebo capsule, three times a day, 4 capsules each time. The test groups and the control group take the entecavir capsule which is orally taken for antiviral therapy, one time a day, 0.5mg each time, oral administration on an empty stomach.
2560039|NCT02499237|Active Comparator|Denosumab|Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year
2560045|NCT02499237|Experimental|Denosumab plus zoledronic acid|Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year
3206226|NCT00951756|Other|High Fat Low Fiber Diet|
2560198|NCT02498366|Experimental|experimental protocol|50 healthy, male, trained and aged 18-30 will be recruited and asked to undergo a series of physical tests.
3206227|NCT00951756|Other|Low Fat High Fiber Diet|
3206228|NCT00951769||Control,|Control
3206229|NCT00951769||DAS: Difficult Airway Society, UK|DAS difficult airway algorithm
3206230|NCT00951769||Australian|Australian difficult airway algorithm
3206231|NCT00951782|Active Comparator|High frequency TMS + smoking cue|
3206232|NCT00951782|Sham Comparator|Sham TMS + smoking cue|
3206233|NCT00951782|Active Comparator|Low frequency TMS +smoking cue|
3206234|NCT00951782|Sham Comparator|Sham TMS - no cue|
3206235|NCT00951782|Active Comparator|High frequency TMS - no cue|
3206236|NCT00951782|Active Comparator|Low frequency - no cue|
2559935|NCT02499991|Experimental|Treatment|"Treatment group will keep diary of social events according to training instructions.~Memory intervention will be used."
2559937|NCT02499991|No Intervention|Control|Control group will use own memory of social events without training instructions.
2559971|NCT02499731|Experimental|Strong Hearts, Healthy Communities|Full Intervention participants will meet twice per week for one hour each time, for approximately 6 months plus monthly community meetings and events. Participants will learn and practice good nutrition and physical activity for improved individual, family and community health.
2559974|NCT02499731|Experimental|Strong Hearts, Healthy Women|Strong Hearts, Healthy Women minimum intervention participants meet once per month for an hour each time for 6 months. Participants will learn and discuss techniques and strategies to improve personal health.
2560040|NCT02499393|Experimental|TH+MgSO4|Therapeutic hypothermia plus magnesium sulphate intravenous infusion Neonates who were randomized to the study group (TH+MgSO4) received three 250 mg/kg doses of magnesium sulfate given as one - hour continuous infusion spaced 24 hours apart on three consecutive days. 20% Magnesium Sulfuricum (Polpharma), 2 g /10 ml were used.
2560046|NCT02499393|No Intervention|TH- therapeutic hypothermia|therapeutic hypothermia without magnesium sulphate
3206237|NCT00951795||Adults|Adult men and women over age of 18
3206238|NCT00951795||Pediatrics|Pediatric boys and girls ages 12-18
2560159|NCT02498353|Experimental|study group|"Preoperative short-course radiotherapy with local boost ,the dose of radiotherapy is PTV-CTV 25Gy/5F with local boost of PTV-GTV 30Gy/5F.~TME surgery after radiotherapy."
2560161|NCT02498353|Active Comparator|control group|"Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F without local boost.~TME surgery after radiotherapy."
2560207|NCT02498249|Experimental|Experimental: low level laser therapy (LLLT)|"For the LLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the LLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 18 J"
2560208|NCT02498249|Placebo Comparator|Experimental: Placebo low level laser therapy (PLLLT)|"For the PLLLT irradiation, a paper template with 9 points (area of 1cm and a distance from center to center of 1 cm) will be used, distributed in three columns and three lines. The central point of the template will be positioned above the medium point of a line traced between the acromion and the spinous process of the seventh cervical vertebra, where the treatment should be close to the fixation point of the EMG electrode. The application point of the PLLLT was determined by the location of the innervation point of the upper trapezius muscle.~Individuals will be subject to application of low level laser with a total dose of 0 J"
2560273|NCT02498002|Active Comparator|Daily Calorie Restriction (DCR)|During the intervention phase, participants randomised to this treatment condition will be asked to reduce their normal energy intake by 25% on a daily basis.
2560274|NCT02498002|Experimental|Fasting with Weight Loss (IMF-WL)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 150% of normal energy intake) and fasting (no energy intake).
2560275|NCT02498002|Experimental|Fasting without Weight Loss (IMF-WS)|During the intervention phase, participants randomised to this treatment condition will be asked to alternate between 24 hour cycles of feeding (consume 200% of normal energy intake) and fasting (no energy intake).
3206239|NCT00951834|Experimental|Epigallocatechin-Gallate|"Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)~add-on to Donepezil."
2560580|NCT02495688|Experimental|Regional anesthesia|Patients are anesthezised with local aneshtetics administered with ultrasound guidance in the nerval plexus of the arm.
2560584|NCT02495688|Active Comparator|General anesthesia|Patients are anesthezised with general anesthesia and orotrachial airway. Local anesthetics (Chirocaine 5 mg/ml, 10 ml) is administered in the surgical wound during surgery.
2560627|NCT02495519|Experimental|imatinib|Imatinib 400 mg/day until disease progression
2560643|NCT02495246|Active Comparator|Group 1|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 28 days later.
2560651|NCT02495246|Active Comparator|Group 2|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 28 days later.
2560661|NCT02495246|Active Comparator|Group 3|ChAd3-EBO-Z (1x10^11 vp) and Ad26.ZEBOV (5x10^10 vp) 56 days later.
2560664|NCT02495246|Active Comparator|Group 4|Ad26.ZEBOV (5x10^10 vp) and ChAd3-EBO-Z (1x10^11 vp) 56 days later.
2560722|NCT02494895|Experimental|Ticagrelor monotherapy|Ticagrelor monotherapy at 3 months after PCI
2560724|NCT02494895|Active Comparator|Ticagrelor with Aspirin|Ticagrelor with Aspirin DAPT(Dual Anti-platelet Treatment)
2560775|NCT02494531|Other|Positon Emission Tomographic (PET)-scan|2 PET-scan: Fluorodeoxyglucose-PET and florbetapir F 18-PET
3206240|NCT00951834|Placebo Comparator|Placebo|add-on to Donepezil.
3206241|NCT00951847|Experimental|1|Oxcarbazepine oral suspension 300 mg/5 mL of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3206242|NCT00951847|Active Comparator|2|Trileptal® (oxcarbazepine) oral suspension 300 mg/5 mL of Novartis
3206243|NCT00951860||Newborn|Every child born in the CHU of Saint-Étienne (inborn), any term of its birth, in the hospital neonatal unit at the time of registration (after 37 weeks corrected for prematurity) or in the maternity
3206244|NCT00951873|Experimental|A|
3206245|NCT00951873|Placebo Comparator|B|
3206246|NCT00951873|Experimental|C|
3206247|NCT00951925||No Treatment|
3206248|NCT00951951|Active Comparator|Anterior Surgical Approach|(AMIS)
3206249|NCT00951951|Active Comparator|Posterior Approach Group|Posterior surgical approach for total hip replacement.
3206250|NCT00951964|Other|1|patients receive the treatment in first and placebo in second part of study
3206251|NCT00951964|Other|2|patients receive placebo in first and treatment in second part of study
2559689|NCT02501525|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
2559718|NCT02501187|Experimental|Patients operated for ptosis by levator advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- levator advancement.
2559720|NCT02501187|Experimental|Patients operated for ptosis by white line advancement|patients undergoing surgical repair for aponeurotic ptosis by the procedure- white line advancement
2559722|NCT02501187|Experimental|Patients operated for ptosis by Müller resection|patients undergoing surgical repair for aponeurotic ptosis by the procedure- Müller's muscle-conjunctival resection.
2559769|NCT02500940|Experimental|Control group|Neoadjuvant chemotherapy with tri-weekly cisplatin plus fluorouracil × 3 cycles (cisplatin 100 mg/m2, day 1, followed by fluorouracil 1000 mg/m2/d, days 1-4 continuous iv infusion, repeated every 3 weeks) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
2559777|NCT02500940|Active Comparator|Test group|Neoadjuvant chemotherapy with weekly cisplatin, fluorouracil and leucovorin × 10 weeks (cisplatin 60 mg/m2 at days 1, 15, 29, 43, 57; alternatively with fluorouracil 2500 mg/m2 + leucovorin 250 mg/m2 at days 8, 22, 36, 50, 64) + Intensity-Modulated Radiation Therapy ≧ 70 Gy/35 fractions
2559853|NCT02500485|Experimental|SHR3824 20mg/SP2086 100mg|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
2559898|NCT02500017|Experimental|Melatonin|A commercially available rapid-release formulation of melatonin (5 mg) capsules to be administered once a day for a total of 8 weeks
2559901|NCT02500017|Placebo Comparator|Placebo|Matching placebo capsules to be administered once a day for a total of 8 weeks
2559952|NCT02499926|Experimental|Dietary supplement: Arginine|Graded arginine excess intake
2559990|NCT02499640|No Intervention|GC|Control group - CG (n = 20), which suffered no recuperative technique
2559995|NCT02499640|Experimental|G1|G1 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 9±1 degrees Celsius
2559998|NCT02499640|Experimental|G2|G2 (n = 20) was subjected to a recovery procedure by immersion cold water for 5 minutes as from 14±1 degrees Celsius
2560002|NCT02499640|Experimental|G3|G3 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
2560005|NCT02499640|Experimental|G4|G4 (n = 20) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
2560029|NCT02499315|Experimental|AMG 357|
2560030|NCT02499315|Placebo Comparator|Placebo|
2560038|NCT02499094|Experimental|Intervention A- Heuristic based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as simple heuristic-based behavioral measures
2560048|NCT02499094|Experimental|Intervention B- Machine Learning Based|Behavioral-data driven support, both mobile phone application and phone-based, informed by their self-reported symptom assessment as well as machine learning model-based behavioral measures
2560057|NCT02499094|No Intervention|Control|No intervention
2560114|NCT02499042|Experimental|Oxygen reduction|post-ROSC oxygen reduced to 2L per minute then delivered to maintain oxygen saturation 90-94% to hospital
2560119|NCT02499042|Active Comparator|Standard Care|post-ROSC oxygen maintained ≥10L per minute to hospital
2560156|NCT02498626||venous saturations|venous saturations from the central venous line, venous side of the heart lung machine and from the pulmonary artery
2560184|NCT02498288|Experimental|Isotretinoin Arm|All subjects in this study will be randomized to receive all the 3 distinct medications of isotretinoin in a sequential manner. Subjects will receive a single dosage of two capsules x 20 mg (40 mg) orally, for three periods, six sequences, with a wash-out period of two weeks to eliminate the first dosage.
2560234|NCT02498080|Experimental|DEB PTA|Devices: paclitaxel drug eluting balloon PTA
2560236|NCT02498080|Active Comparator|standard PTA|devices: standard balloon PTA
3206252|NCT00951977||Subjects who have formerly donated a kidney|
2560391|NCT02497066|Placebo Comparator|Neuropathic Pain|Subjects with neuropathic pain will receive a neuropathic pain cream combined of Ketamine 10%/Gabapentin 6%/Clonidine 0.2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
2560393|NCT02497066|Placebo Comparator|Nociceptive pain|Subjects with nociceptive pain will receive a nociceptive pain cream combined of Ketoprofen 10%/Baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
2560394|NCT02497066|Placebo Comparator|Mixed pain|Subjects who have a mixed (nociceptive and neuropathic) pain conditions will receive a mixed pain cream combined of Ketamine 10%/Gabapentin 6%/Diclofenac 3%/baclofen 2%/Cyclobenzaprine 2% and Lidocaine 2% or placebo. They will be told to use the pain cream 3 times per day. Each will receive cream in identical dispensers. Cream is dispensed by rotating the base of the device and each rotation also produces a clicking sound. The number of clicks will be standardized so that all doctors utilize the same prescription depending on the size of the patient's pain location.
2560438|NCT02496780|Placebo Comparator|placebo|once or 3x daily injectable placebo (insulin diluent)
2560439|NCT02496780|Experimental|basal insulin levemir|once daily basal insulin therapy with insulin levemir
2560445|NCT02496780|Experimental|rapid-acting insulin Novolog|pre-meal rapid-acting insulin 3x/day with insulin novolog
2560503|NCT02496403|Experimental|Standard Medical Management|Standard Medical Management (SMM) is a relatively brief (1.5 hour per week for 9 weeks), medically-focused behavioral intervention for opioid dependence. The experimental arm does not involve an investigational drug, device, or biologic.
2560603|NCT02495584|Experimental|Treatment 3|500ml unfortified milk (placebo) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
3206253|NCT00951977||Matched community control Subjects|
2559704|NCT02501499||Volunteer Focus Group|Breastfeeding buddies volunteers that deliver education and support programs.
3206254|NCT00952003|Experimental|interventional arm|Oxaliplatin, Irinotecan and Bevacizumab for 3 cycles followed by Docetaxel and Bevacizumab for a further 3 cycles. Upon completion of the combination therapy cycles Bevacizumab will be continued until progression.
3206255|NCT00952029|Experimental|Maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab
3206256|NCT00952029|Active Comparator|No maintenance with bevacizumab|FOLFIRI + Avastin and during the chemotherapy-free interval NO maintenance
3206257|NCT00952042|Experimental|Heavy slow resistance training|12 wks of heavy slow resistance training. training three times per week. each session: 3 heel-raise exercises. 12-6RM. Slow contractions.
2560103|NCT02498795|Active Comparator|Group of Dry Needling|"They will receive a treatment of dry needling with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. The punction will be realized using the technique of entry - Hong's rapid exit. Three punction will realize in the disabled zone of 3 seconds of duration."
2560107|NCT02498795|Active Comparator|Group of electrolysis|"They will receive a treatment of Intratissue Percutaneous Electrolysis with ultrasound scan together with a treatment in which they will realize eccentric exercise's program that the patient will have to realize in his domicile.~The needle will get in the relevant zone of treatment. An intensity of 3 milliampere will be in use, during 3 seconds and one will repeat 3 times."
2560116|NCT02498795|Placebo Comparator|Control Group|They will receive a treatment of punction placebo with ultrasound scan together with a treatment in the one that will realize eccentric exercise's program that the patient will have to realize in his domicile.
3206258|NCT00952042|Active Comparator|Eccentric resistance training|12 wks of eccentric resistance training. 3 x 15 Eccentric heel-raises performed twice daily.
3206259|NCT00952055||Patients diagnosed with acute coronary syndrome (ACS)|
2560548|NCT02495961||Low risk population|Colombian children, between 6 and 12 years old, regular students of a Primary school.
2560549|NCT02495961||High risk population|Mexican children, between 6 and 12 years old, regular students of a Primary school.
2560588|NCT02495766|Experimental|Treatment A: XCEL-MC-ALPHA/Placebo|Single infusion of cryopreserved bone-marrow adult mesenchymal stromal cells followed by placebo infusion at month 6.
2560589|NCT02495766|Experimental|Treatment B: Placebo/XCEL-MC-ALPHA|Single infusion of placebo followed by cryopreserved bone-marrow adult mesenchymal stromal cells infusion at month 6.
2560630|NCT02495493|Experimental|Induction DCS chemotherapy|"Induction chemotherapy -- S-1 35mg/m2 bid day 1-14~Docetaxel 30 mg/m2 day1, 8~Cisplatin 30 mg/m2 day1, 8~Chemoradiotherapy : S-1 20 mg/m2 bid (Day 1-14, 21-28) cisplatin (30 mg/m2/day, Day 1,8, 21,28), Radiotherapy 45 Gy"
2560640|NCT02495207|No Intervention|Conventional Surgery|No intervention in this arm. The patients are going to undergo normal surgical intervention. Conventional surgery will be performed to extract the impacted third molars.
2560647|NCT02495207|Experimental|Piezosurgery|Patients here will undergo a piezosurgery to extract their third molars on both sides.
2560717|NCT02495077|Experimental|Experimental Arm|rATG is co-administered with anti-TNFa (infliximab/Remicade®) plus maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
2560721|NCT02495077|Active Comparator|Control group|Rabbit anti-thymocyte globulin (rATG/Thymoglobulin®) plus placebo (Sterile normal saline) induction followed by maintenance therapy with tacrolimus, a mycophenolic acid derivative (either MMF or enteric coated MPA) and prednisone.
2560830|NCT02494167|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for AML or MDS
2560836|NCT02494167|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for AML or MDS
2560882|NCT02493738|Experimental|Lozanoc 50mg|Lozanoc 50mg, oral administration
2560887|NCT02493738|Active Comparator|Sporanox 100mg|Sporanox 100mg, oral administration
2560927|NCT02493400||Exercise group|A follow up from 3 months detraining from the exercise group. Patients follows their earlier randomisation.
2560928|NCT02493400||Active Comparator: PAP group|A follow up from 3 months detraining from the active comparator group. Patients follows their earlier randomisation.
2560964|NCT02493075|Experimental|CF guided group|Ablation will be performed with smart-touch catheter.The operator will kown the real-time contact force (CF), ablation time, FTI, etc during the procedure.
2560966|NCT02493075|Active Comparator|Usual ablation group|Although we use the same catheter,operator will be blinded to CF data during the procedure.
2561017|NCT02492776|Experimental|Gefapixant + Omeprazole|Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days
2561037|NCT02492386|Experimental|Treatment|Bioabsorbable everolimus-eluting stent deployment
2561085|NCT02492230|Active Comparator|Control Group|After successful PCI the control group will take Triple therapy (warfarin + clopidogrel+aspirin) during 45 days and after combination of warfarin+clopidogrel to 6 months after procedure and then only warfarin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up.
2561208|NCT02491606|Experimental|High weekly dose|Loading with tafenoquine to 400 mg base for 3 days followed by tafenoquine 400 mg base weekly.
2561212|NCT02491606|Experimental|Placebo|Loading with placebo for 3 days followed by placebo once weekly.
3206260|NCT00952094|Active Comparator|KRN1493 50mg group|KRN1493 50mg single oral administration
3206261|NCT00952094|Active Comparator|KRN1493 75mg group|KRN1493 75mg single oral administration
3206262|NCT00952094|Active Comparator|KRN1493 100mg group|KRN1493 100mg single oral administration
3206263|NCT00952107|Experimental|Imaging system operation|
2559868|NCT02500355|Active Comparator|Group A|Carpal Tunnel Release via limited approaches with 2 years follow-up.
2559871|NCT02500355|Active Comparator|Group B|Carpal Tunnel Release via standard approach with 2 years follow-up.
2559875|NCT02500355|Placebo Comparator|Group C|Endoscopic Carpal Tunnel Release with 2 years follow-up.
2559899|NCT02500108||Treated with domperidone|Patients who received a new prescription for domperidone (ATC A03FA03) in the year prior to the index date.
2559903|NCT02500108||Unexposed (reference) group|Patients with no prescription for domperidone in the year prior to the index date.
2559959|NCT02499939|Active Comparator|Standard Care|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home.
2559961|NCT02499939|Experimental|Experimental: Ultrasound Therapy|Participants in this group will receive standard education about CIPN and therapeutic exercises to carry out at home. Participants in this group will also undergo 10 daily treatments of ultrasound therapy (e.g., Monday to Friday for two weeks) that is administered to their toes and fingers. The ultrasound therapy will be administered over the first two weeks of the intervention period.
2560001|NCT02499536|Experimental|Study participants|After general anesthesia development of the atelectasis will be investigated by the lung ultrasound
3171766|NCT00591526|No Intervention|A|"Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days AraC 200 mg/m2/d during 7 days~2) Consolidation treatment~First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection) 3) Maintenance treatment~Consists of the combination of continuous low dose chemotherapy and intermittent ATRA, during 2 years~Continuous low dose chemotherapy~Intermittent ATRA"
3171767|NCT00591526|Experimental|B|Patients aged ≤ 60 years and with initial WBC ≤ 10000/mm3 (Group B) Same treatment as Group A but without AraC.
3171768|NCT00591526|No Intervention|C|"First consolidation course (=2nd chemotherapy course) DNR 60 mg/m2/d d1-3 (intravenous bolus injection) AraC 200 mg/m2/d d1-7 (continuous infusion)~Second consolidation course AraC 1g/m2/12h d1-4 (1 hour infusion) Daunorubicin 45 mg/m2/d d1-3 (intravenous bolus injection)~CNS prophylaxis : consists of 5 intrathecal (IT) injections of MTX 15mg and AraC 50 mg (12 mg/m2 maximum 15 mg, and 30mg/m2, maximum 50 mg, respectively, in children) + depomedrol IT. I~3) Maintenance treatment"
3171769|NCT00591526|No Intervention|D|"Patients aged >60 years and initial WBC ≤ 10000/mm3 Induction treatment~a) ATRA and chemotherapy ATRA 45 mg/m2/d until hematological CR first intensive chemotherapy course : DNR 60 mg/m2/d during 3 days (intravenous bolus injection) NO ARA C DURING THIS FIRST COURSE~2) Consolidation treatment~First consolidation course DNR 60 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~Second consolidation course DNR45 mg/m2/d d1-3 AraC 100 mg/m2/d d1-5 G-CSF~3) maintenance treatment: similar to other groups"
3171770|NCT00591539||Carotid Ultrasound|Carotid Ultrasound: Irradiated and non-irradiated sides of the neck in long-term survivors of pediatric cancers who received unilateral radiation therapy involving the carotid artery as part of their treatment
3171771|NCT00591552|Active Comparator|Group A|Electrocautery used for dissection.
3171772|NCT00591552|Active Comparator|Group B|Harmonic Scalpel used for dissection
3171773|NCT00591604|Experimental|1|Vitamin D administration
3171774|NCT00591617|Active Comparator|1: MM|Medical Management: group receives medical management from study physician and Suboxone pharmacotherapy
3171775|NCT00591617|Active Comparator|2: CBT|Cognitive Behavioral Therapy (CBT) group receives CBT, medical management and Suboxone pharmacotherapy
3171776|NCT00591617|Active Comparator|3: CM|Contingency Management (CM) group receives CM, medical management, and Suboxone pharmacotherapy
3171777|NCT00591617|Active Comparator|4: CBT + CM|Cognitive Behavioral Therapy (CBT) and Contingency Management (CM) group receives CBT, CM, medical management, and Suboxone pharmacotherapy
3171778|NCT00591643|Experimental|Imaging, Adrenal acans & Radiation|
3171779|NCT00591669|Experimental|1|IBD patients
3171780|NCT00591669|Other|2|Control subjects
2560267|NCT02497859|Experimental|Egg Breakfast (EB)|"The EB will receive the following breakfast:~2 scrambled eggs, 120 mL skim milk, 2 slices of Mrs. Bairds® Extra Thin White Bread, 5 g of butter, and 18 g of Smuckers® Strawberry Jam."
3171781|NCT00591682|Experimental|1|MSX-122
3171782|NCT00591695|Active Comparator|A|positioning in emergency of a prosthetic metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
3171783|NCT00591695|Active Comparator|B|emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
3171784|NCT00591708|Experimental|B|Supplementation of a higher level of calcium (500-1300 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
3171785|NCT00591708|Experimental|A|Supplementation of a lower level of calcium (0-400 mg/d) via calcium fortified beverages (calcium citrate malate) to a basal diet of 600 mg/d for 21 consecutive days. All excreta will be collected.
3171786|NCT00591747|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3171787|NCT00591747|Active Comparator|2|Flexibility training 3 times a week for 12 months
3171788|NCT00591799|Experimental|Jarvik 2000 Ventricular Assist System|Jarvik 2000 Ventricular Assist System
3171789|NCT00591812|Experimental|1 - ComPreSs system|
3171790|NCT00591877|Active Comparator|AC|"Acupuncture:~The patients will receive acupuncture by a trained doctor with acupuncture expertise, at 3 points relevant to reflux symptoms. Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation."
3171791|NCT00591877|Sham Comparator|SAC|The patients randomized to this arm will receive acupuncture for a similar duration and number of sessions. The sham acupoints are at least 2 cm away from the actual acupoints to prevent acupressure effects
3206264|NCT00952146|Experimental|Transgastric peritoneoscopy|Only one arm, feasibility study
3206265|NCT00952159||Not Poor metabolizer|
3206266|NCT00952159||Poor metabolizer|
3206267|NCT00952198|Experimental|ARRY-403|
3206268|NCT00952198|Placebo Comparator|Placebo|
3206269|NCT00952224||Acute myocardial infarction patients|Patients undergoing primary percutaneous coronary intervention in ST-elevation myocardial infarction plus magnetic resonance imaging
2560145|NCT02498717|Active Comparator|RICE (control)|Standard of Care procedures including ice and elevation.
2560146|NCT02498717|Experimental|Cryocompression (experimental)|treatment using the GameReady cryotherapy system
2560189|NCT02498444|Experimental|Treprostinil|The subcutaneous continuous treprostinil infusion will start at a dose of 2 ng/kg/min. The dose will be increased over the first 24 hours to goal 10 ng/kg/min through day five. On postoperative day six, the dose will be decreased by 2 ng/kg/min every 8 hours with plans for discontinuation on postoperative day seven.
2560194|NCT02498444|Placebo Comparator|Saline|Saline administration via subcutaneous infusion
2560260|NCT02498041|Experimental|Transnasal Endoscopy|Unsedated transnasal endoscopy with biopsies
2560262|NCT02498041|Active Comparator|Standard Gastroscopy|Standard endoscopy with biopsies. Patients will decide whether they prefer to have endoscopy with intrevenous sedation or with local anaesthetic only
2560320|NCT02497599|Experimental|Intraoperative dual-modality imaging|Patients receive a single intravenous dose of Indium-111-DOTA-Girentuximab-IRDye800CW. At day 4 or 5 after antibody injection a whole body planar scan and SPECT/CT scan will be acquired. At day 7 standard of care (partial) nephrectomy will be performed. This will be extended with the use of dual-modality imaging.
2560443|NCT02496832|Experimental|FAZA PET-CT scan|"FAZA PET-CT imaging within 14 days of treatment from the EMR200592-001 study.~FAZA PET-CT imaging about 5 weeks after start of treatment from the EMR200592-001 study."
2560481|NCT02496507|Experimental|Intervention|Provision of a sit-stand workstation for use at work.
2560484|NCT02496507|No Intervention|Control|Participants were asked to maintain their normal work practices and received no intervention. Participants were offered the opportunity to have a sit-stand workstation installed for 8 weeks after all data collection.
2560517|NCT02496286|Experimental|Eligible patients requiring paracentesis for symptom control|
2560557|NCT02495922|Active Comparator|A1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone), 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
2560560|NCT02495922|Experimental|A2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
2560563|NCT02495922|Experimental|B1|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab , 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
3206270|NCT00952237|Experimental|IL-2 and GM-CSF for Mobilization|Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
3206271|NCT00952250|Active Comparator|Targeted Feedback Reports|Conventional feedback reports
3206272|NCT00952250|Experimental|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement.
3206273|NCT00952263|Experimental|MBL-HCV1|
3206274|NCT00952302|Placebo Comparator|CMS - placebo first|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
3206275|NCT00952302|Experimental|CMS - iron|Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
3206276|NCT00952302|Placebo Comparator|SLR - placebo|Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
3206277|NCT00952302|Experimental|SLR - iron|Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.
3206278|NCT00952328|Experimental|Limited Formula|Participants will supplement feedings with early limited formula following nursing
3206279|NCT00952328|No Intervention|Control|Participants are instructed to continue exclusively breastfeeding; no use of formula
3206280|NCT00952354||research group|60 children aged from 3 to 10 years, both genders, observed in a symbolic play situation with their language therapists
3206281|NCT00952406||Survey of Women PFDs|Women with PFDs
3206282|NCT00952432|Active Comparator|ACUPUNCTURE|ACUPUNCTURE
3206283|NCT00952432|Active Comparator|MEDICATION|Carbamazepine
3206284|NCT00952445|Experimental|T0903131 Besylate|1.0 mg
3206285|NCT00952445|Experimental|T0903131 Besylate|10.0 mg
3206286|NCT00952445|Placebo Comparator|Placebo|Once daily, oral
3206287|NCT00952458|Experimental|BIS monitoring|Dosing of sedatives with BIS monitoring
3206288|NCT00952458|No Intervention|Standard monitoring|Dosing of sedatives without BIS monitoring
3206289|NCT00952471|No Intervention|Baseline Period|Patients in the baseline period were cared for using the standard historical electronic order set.
3206290|NCT00952471|Active Comparator|Post Intervention Period|Patients in the Post intervention period were cared for with evidence-bsed modified order set changes
3206291|NCT00952497|Experimental|Cisplatin, Capecitabine, Telatinib|
3206292|NCT00952510||Whiplash patients|The cohort is based on 100 whiplash patients which underwent the measure procedure to obtain cervical range of motion.
2559793|NCT02500953|Experimental|Caucasian male single fasted ASP dose-3|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559796|NCT02500953|Experimental|Caucasian male single fasted ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559798|NCT02500953|Experimental|Japanese male single fed ASP dose-5|ASP3325 will be administered as a single oral dose with 240 mL of water to subjects after a meal.
2559799|NCT02500953|Experimental|Japanese male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559801|NCT02500953|Experimental|Japanese female single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559802|NCT02500953|Experimental|Caucasian male single fasted placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects who have been fasting from 22:00 on the day before administration.
2559804|NCT02500953|Experimental|Japanese male single fed placebo|Placebo will be administered as a single oral dose with 240 mL of water to subjects after a meal.
2559806|NCT02500953|Experimental|Japanese male multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559808|NCT02500953|Experimental|Japanese male multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559809|NCT02500953|Experimental|Japanese male multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559811|NCT02500953|Experimental|Japanese female multiple ASP dose-3|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559812|NCT02500953|Experimental|Japanese female multiple ASP dose-4|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559814|NCT02500953|Experimental|Japanese female multiple ASP dose-5|ASP3325 will be administered as multiple oral doses with 240 mL of water, three times a day, just after a meal.
2559817|NCT02500953|Experimental|Japanese male multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
2559818|NCT02500953|Experimental|Japanese female multiple Placebo|Placebo will be administered with 240 mL of water, three times a day, just after a meal.
2559822|NCT02500953|Experimental|Japanese male ASP dose-5 before a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
2559825|NCT02500953|Experimental|Japanese male ASP dose-5 during a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
2559826|NCT02500953|Experimental|Japanese male ASP dose-5 after a meal|ASP3325 will be administered with 240 mL of water, three times a day, for 2 days.
2559907|NCT02500238||Control|This group will provide 2 breath carbon monoxide (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings will be taken from this group.
2559910|NCT02500238||Smoking|This group will provide 1 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
2559913|NCT02500238||Vaping|This group will provide 2 breath carbon monoxide test (reading of ≤ 6 parts per million) and a saliva sample, urine sample, and toe nail clippings.
2559970|NCT02499757|Experimental|flavor and sweetener|E-cigarette with a novel flavor and sweetener added
2559973|NCT02499757|Experimental|flavor and nicotine|E-cigarette with a novel flavor and 12 mg nicotine added
2559975|NCT02499757|Experimental|flavor, nicotine and sweetener|E-cigarette with a novel flavor, sweetener, and 12 mg nicotine added
2559976|NCT02499757|Experimental|flavor|E-cigarette with a novel flavor: without a sweetener and 12 mg nicotine added
2560015|NCT02499419||Healthy|Individuals without any known heart/ respiratory/ metabolic problems that might limit their exercise capacity
2560016|NCT02499419||Mild MVP|0 or 1 of the following secondary risk factors: Mild MR Flail leaflet Left atrial diameter > 40 mm Atrial fibrillation Age ≥ 50
2560017|NCT02499419||Moderate MVP|2 or more of the above secondary risk factors.
2560018|NCT02499419||Severe MVP|1 or more of the following primary risk factors: EF < 50% MR ≥ moderate
2560051|NCT02499185|Experimental|Nephro Check Test|We take urine samples and analyse the level of [TIMP-2]●[IGFBP-7] using the NephroCheck Test to diagnose AKI
2560060|NCT02499185|Active Comparator|serum creatinine measurement|"This is the Golden standard to diagnose AKI"
3174321|NCT00622206|Active Comparator|1|Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
2560174|NCT02498509|Experimental|Treatment|CKD-342
2560176|NCT02498509|Active Comparator|Control 1|Mometasone furoate
2560177|NCT02498509|Active Comparator|Control 2|Levocabastine HCL
2560241|NCT02498132|Experimental|Behavioral Activation|Behavioral Activation will be administered via Moodivate will mirror the core BA components outlined above. Moodivate will also be modified for a mobile environment in key ways, with the most salient being: 1) Elimination of the need for a therapist: By eliminating the need for a therapist, we will be able to reach a broad patient/consumer base that may not utilize traditional therapy resources and will combat the primary barrier to PCPs recommending psychotherapy to their patients with elevated depressive symptoms and 2) Elimination of paper forms: By eliminating paper forms, we will increase the sensitivity of BA to motivational and organizational deficits frequently observed in patients with elevated depressive symptoms while also increasing treatment fidelity by prompting the patient to complete activities at scheduled times and giving the patient reinforcement for completing activities.
2560249|NCT02498132|Active Comparator|Cognitive Based Therapy|Moodkit will be used to administer cognitive based therapy which is commonly compared to behavioral activation.
3206293|NCT00952536|Active Comparator|Triple therapy|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule (test group 1)
3206294|NCT00952536|Active Comparator|Dual Therapy|Juice Plus+ with 2 vegetable & 2 fruit & 2 placebo capsule (test group 2)
3206295|NCT00952536|Placebo Comparator|Control|Daily Placebo in the form of 6 capsules (control group)
3174322|NCT00622219|Experimental|Drug Testing|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
3206296|NCT00952549|Experimental|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
2559957|NCT02499861|Experimental|Decitabine and Genistein|continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
2559983|NCT02499614|Experimental|Patients with MET amplification or MET exon 14 mutation|Pretreated NSCLC patients with MET amplification or MET exon 14 mutation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
2559984|NCT02499614|Experimental|Patients with ROS1 translocation|Pretreated NSCLC patients with ROS1 translocation with locally advanced or metastatic NSCLC and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o until disease progression, unacceptable toxicity or patient refusal.
2560033|NCT02499107|Experimental|Rice treatment|Dietary Intervention: Ad libitum intake of white rice
2560034|NCT02499107|Experimental|Pasta treatment|Dietary Intervention: Ad libitum intake of pasta
2560035|NCT02499107|Experimental|boiled and mashed potato treatment|Dietary Intervention: Ad libitum intake of boiled and mashed potato
2560036|NCT02499107|Experimental|Baked french fries treatment|Dietary Intervention: Ad libitum intake of baked french fries
2560037|NCT02499107|Experimental|Fried french fries treatment|Dietary Intervention: Ad libitum intake of fried french fries
2560109|NCT02499016|Experimental|suprapubic single-incision laparoscopic appendectomy|single incision laparoscopic surgery will be performed for patients in this group.
2560117|NCT02499016|Active Comparator|conventional multiport appendectomy|Conventional laparoscopic surgery will be performed for patients in this group.
2560185|NCT02498665|Experimental|Dosing Escalation Cohort|Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously. Dose-escalation will proceed according to the Criteria for Dose Escalation and Criteria for Determination of Dose-Limiting Toxicity (DLT) as indicated below. Dose Level I: 3.5 mg, Dose Level II: 10.5 mg, Dose Level III: 17.5 mg
2560187|NCT02498665|Experimental|MDS Cohort 1|Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
2560191|NCT02498665|Experimental|MDS Cohort 2|Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks.
2560222|NCT02497963|Experimental|Foreskin Graft-Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Foreskin Graft Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, graft inner foreskin, and create a new urethra on a urethral catheter.
2560223|NCT02497963|Active Comparator|Tubularized Incised Plate|Group of patients with primary hypospadias undergoing Tubularized Incised Plate Urethroplasty. The surgery involves making an incision on the midline of the urethral plate, and create a new urethra on a urethral catheter.
2560276|NCT02497846|Experimental|TEOSYAL® PureSense Redensity [I]/MicronJet®|"injection of the acid hyaluronic gel with lidocaine as an anesthetic and a dermo-restructuring complex (including 8 amino acids , 3 antioxidants Acid, vitamin B6 and 2 minerals).~Product will be injected in a unique device group:~in crow's feet in order to cover the zone to be treated. Quantity of product injected will be determined by the injector and noted (up to 1 ml by side). A subject can be injected in the left or/and right side.~using a MicronJet microneedle for the superficial wrinkles."
2560303|NCT02497521||ADPKD|Patients with diagnosis of ADPKD, who are either evaluated for tolvaptan treatment indication, planned for tolvaptan treatment, or are already treated with tolvaptan
2560388|NCT02497092|Active Comparator|Slow angled injection|Slow and angled insertion of the needle through the sclera
2560389|NCT02497092|Active Comparator|Slow straight injection|Slow and straight insertion of the needle through the sclera
3206297|NCT00952562|Active Comparator|cholecalciferol|3000 IU cholecalciferol per day for 16 weeks
3206298|NCT00952562|Placebo Comparator|placebo|
3206299|NCT00952575|Active Comparator|polyclonal anti-D immunoglobulin|
3206300|NCT00952575|Experimental|Monoclonal anti-D immunoglobulin|
3206301|NCT00952601|Experimental|Modified Atkins Diet|Patients are started on the modified Atkins diet at 15 grams per day.
3206302|NCT00952627|Experimental|Pycnogenol|200 mg/day
3206303|NCT00952627|Placebo Comparator|Control|placebo
3206304|NCT00952640|Active Comparator|vitamin A directly post-partum|200.000 IU of vitamin A within 3 days of delivery
3206305|NCT00952640|Experimental|vitamin A delayed|200.000 IU vitamin A 6 weeks post-partum
3206306|NCT00952666|Experimental|Device|Both the Robot-Assisted Laparoscopic Radical Prostatectomy (RALRP) and the Transrectal Ultrasound (TRUS) are common performed procedures, but are normally performed separately. In this proposed feasibility study, the procedures will be combined.
3206307|NCT00952679|Experimental|experimental arm|
3206308|NCT00952757||1.|Patients diagnosed of schizophrenia or bipolar disorder with APS-related hyperprolactinaemia who have been switched to quetiapine based on the clinician's judgement
3206309|NCT00952770|Experimental|Atorvastatin|Group receiving atorvastatin 20mg/day
3206310|NCT00952770|Active Comparator|Simvastatin/Ezetimibe|Group receiving simvastatin/ezetimibe 10/10mg
3206311|NCT00952783||1|
3206312|NCT00952796|Experimental|1|patients with intra-abdominal infection treated with moxifloxacin 400mg once daily
3206313|NCT00952796|Active Comparator|2|patients with intra-abdominal infection treated with ampicillin/sulbactam 1.5g 4 times daily
3206314|NCT00952835||asthma and rhinitis control|
2559838|NCT02500680|Experimental|Group 8A (Phase 1B extension)|MER4101 (MAS-1 Adjuvanted IIV [Fluzone quadrivalent influenza vaccine, Sanofi Pasteur]) 15µg/HA in 0.5 mL MAS-1 emulsion (Standard Dose) Single Dose (as 2 x 0.25 mL in each arm)
2559841|NCT02500680|Active Comparator|Group 8B (Phase 1B extension)|Fluzone quadrivalent influenza vaccine (Sanofi Pasteur) 60µg (High Dose) Single Dose (0.5 mL) in one arm and 0.5 mL of PBS in the other arm
2559887|NCT02500342|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2559888|NCT02500342|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
2559954|NCT02499796|Experimental|Single Arm|"Every patient receives 20 minutes of invasive mechanical ventilation with each of the three humidification systems in random sequence:~Heated and moisture exchanger (HME)~Heated humidifier (HH)~Hygrovent Gold"
2560042|NCT02499367|Active Comparator|Radiation therapy|Radiotherapy on metastatic lesion
2560052|NCT02499367|Active Comparator|Low dose doxorubicin|15mg flat dose, once weekly for 2 weeks
2560061|NCT02499367|Active Comparator|Cyclophosphamide|metronomic schedule, 50mg daily orally for 2 weeks
2560064|NCT02499367|Active Comparator|Cisplatin|40mg/m2, weekly for 2 weeks
2560069|NCT02499367|Active Comparator|No induction treatment|
3206315|NCT00952861|Active Comparator|Doxycycline|Doxycycline 200 mg QD in 5 days
3206316|NCT00952861|Placebo Comparator|Placebo|Matching placebo QD i 5 days
2560192|NCT02498314|Experimental|Grade I-II SZ mobilization|Grade I-IISZ hip traction in resting position
2560199|NCT02498314|Experimental|Grade II TZ mobilization|Grade IITZ hip traction in resting position
2560201|NCT02498314|Experimental|Grade III mobilization|Grade III hip traction in resting position
2560256|NCT02498015|Experimental|"3D regimen"|"The 3D regimen contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, and one dasabuvir tablet (250 mg) twice daily for genotype 1b without cirrhosis. Treatment will be 12 weeks."
2560258|NCT02498015|Experimental|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain two tablets of co-formulated paritepravir/ritonavir/ombitasvir (75/50/12.5 mg) once daily, one dasabuvir tablet (250 mg) twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a (with/without) and genotype 1b with cirrhosis. Treatment will be for 12 weeks."
2560289|NCT02497625|Experimental|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
2560290|NCT02497625|Active Comparator|Usual Care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
2560291|NCT02497625|Other|Control group|Patients will not receive intervention in the first mo nth of enrollment. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
3206317|NCT00952887|Experimental|ACE-031|8 dosing groups
2560426|NCT02496858||Early-onset CAD|The anticipated 2000 young CAD patients who aged ≤45years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
2560430|NCT02496858||Late-onset CAD|The anticipated 2000 old CAD patients aged≥65years undergoing coronary angiography will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
2560433|NCT02496858||Age-matched controls|The anticipated 2000 control subjects without obvious coronary stenosis aged≤45years or ≥65years will be recruited in the prospective cohort. Medical history and risk-factor information were obtained by interviewing patients and by abstracting information from medical records.
2560522|NCT02496208|Experimental|Part I (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 22 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
2560529|NCT02496078|Active Comparator|Active dual arm|"Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 24 week and follow up to week 48"
2560604|NCT02495584|Placebo Comparator|Treatment 4|500ml unfortified milk (placebo) +1 supplement capsule (placebo) daily for 24 weeks
3206318|NCT00952887|Placebo Comparator|Placebo|
3206319|NCT00952900|Experimental|Early Biobehavioral Intervention|This intervention involves the use of non-invasive treatment modalities such as relaxation/biofeedback, stress management, and cognitive coping skills. It is based upon previous clinical research studies demonstrating the efficacy of this intervention in allowing acute TMD patients to better cope with stress and lifestyle issues that produce the TMD pain/discomfort.
2559904|NCT02500277|Active Comparator|Cryobiopsy|Pleural biopsy with a flexible cryoprobe
2559906|NCT02500277|Active Comparator|Forceps biopsy|Pleural biopsy with a flexible forceps
2559943|NCT02499913|Active Comparator|breath alcohol monitoring|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use.
2559946|NCT02499913|Experimental|breath monitoring plus prize contingency management|Breath alcohol samples and self-reports of drinking will be collected once daily at lunch and will be used as objective indicators of recent alcohol use. Participants of this group earn opportunities to draw cards from a prize bowl for negative breath samples.
2559987|NCT02499653|Experimental|Psychological Intervention|In addition to the standard care, subjects are participating in a brief psychological support, which will include elements of psychological well-being's promotion and cognitive restructuring exercises (mindfulness).
2559992|NCT02499653|Active Comparator|Videos|The subjects assigned in the Control Group watch some videos relating to the management of their disease.
3206320|NCT00952900|Active Comparator|Attention Control Group|This intervention involves the presentation of helpful information to patients that explains etiology and potential treatment modalities used to modify/reduce TMD pain/discomfort.
2560130|NCT02498860|Experimental|Pemebit plus Cisplatin|Pemetrexed (Pemebit 500 mg/m2) plus cisplatin (75 mg/m2) every 3 weeks up to 4 cycles
2560154|NCT02498496|Experimental|Magnesium Sulfate|Administration of a bolus dose of 2 g of MgSO4 in 100 mL of Normal Saline IV, in 20 min.
2560155|NCT02498496|Placebo Comparator|Placebo|Administration of a bolus dose of 100 mL of Normal Saline, in 20 min.
2560180|NCT02498301|Experimental|Rifaximin 550 mg once/day|rifaximin, 550 mg, once daily, by mouth
2560182|NCT02498301|Experimental|Rifaximin 550 mg twice/day|rifaximin, 550 mg, twice daily, by mouth
2560183|NCT02498301|Placebo Comparator|Placebo|Placebo pills, twice daily, by mouth
2560232|NCT02497989|Experimental|Inter-personal Communication (IPC)|Interpersonal communication will entail delivery of intervention massages that are custom-made to address individual participants' specific barriers and facilitators of VMMC. RAs will discuss with uncircumcised men why they have not gone for VMMC using the 'VMMC Demand Creation Toolkit'. The aim will be to fully address their barriers and re-enforce their facilitators. RAS will be trained behavioral counselors, circumcised men, female partners, CHWs, or any other cadre of individuals identified during the formative phase.
2560235|NCT02497989|Experimental|Dedicated Service Outlets (DSO)|RAs shall visit all households with eligible men to inform them about the availability of, and give information on location of DSO sites in the Location. DSOs are sites: where services are offered exclusively to men aged ≥25 years by male service providers in the same age bracket; providing services in the evenings/weekends/designated days of the week, and through special mobile services for older men. DSO sites we will strive to shorten the waiting time to ≤ three hours. They will be informed that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do.
2560238|NCT02497989|Experimental|Combined IPC & DSO|Both Inter-personal Communication (IPC) and Dedicated Service Outlets (DSO) interventions (as described above) will be implemented concurrently. This will be done to determine the effect of both interventions delivered jointly compared to each delivered singly, and compared to no intervention.
2560245|NCT02497989|No Intervention|Control|In these Locations, participants will only be given the 'All You Need to Know About VMMC' booklet at the time of enrollment, which is the standard of care.
2560295|NCT02497690|Active Comparator|In-person ART|In-person approach to provide ART.
2560296|NCT02497690|Experimental|Telehealth ART|Telemedicine technology approach (e.g. interactive video) to provide ART.
2560349|NCT02497326|Active Comparator|Polyfax & Lignocain gel or silvazine cream|Polyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash
2560351|NCT02497326|Experimental|Topical heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval."
2560410|NCT02496962|Experimental|Statin group|drug: atorvastatin (Pfizer, U.S.); the frequency: 20mg atorvastatin was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
2560411|NCT02496962|Placebo Comparator|Control group|drug: placebo (Pfizer, U.S.); the frequency: Placebo was taken daily; duration: Study treatment was commenced 3 days before sleep deprivation and continued for 2 days during sleep deprivation.
2560518|NCT02496520|Experimental|Vaccines with autologous dendritic cells|Vaccines with autologous dendritic cells
3206321|NCT00952900|No Intervention|No Active Treatment Comparison Group|Unlike the other two treatment groups, that involve high-risk acute TMD patients, this group includes low-risk acute TMD patients. Past studies have shown that these low risk patients do not need any early intervention in order to prevent chronicity.
3206322|NCT00952913|Experimental|1|Bosutinib
2560601|NCT02495584|Experimental|Treatment 1|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (10µg vitamin D3) daily for 24 weeks
2560602|NCT02495584|Experimental|Treatment 2|500ml fortified milk (10µg vitamin D3) +1 supplement capsule (placebo) daily for 24 weeks
2560764|NCT02494427|Active Comparator|2|Conventionally manufactured unitary dental prostheses
3206323|NCT00952913|Experimental|2|bosutinib + lansoprazole
3206324|NCT00952965||blood pressure monitor|wrist circumference: 14cm-25cm
3206325|NCT00952965||stethoscopy|wrist circumference: 14cm-25cm
2560044|NCT02499211|Experimental|Intervention stores|Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) and Supplemental Nutrition Assistance Program (SNAP) funding. The intervention will last for 2 years, and will consist of in-store marketing of healthier (lower calorie) products through placement and promotion strategies in 6 food and beverage categories: milk; frozen meals; beverages in checkout coolers; bread; salty snacks; and cheese.
2560056|NCT02499211|No Intervention|Non-intervention stores|No intervention administered. Supermarkets will be the unit of randomization, intervention, and analysis. During randomization, stores are paired by size and percent sales of WIC and SNAP funding. The non-intervention stores will not receive an intervention.
2560120|NCT02498977|Active Comparator|Arm A (weaning)|All participants satisfying clinical criteria will be weaned off immunosuppression drugs irrespective of biomarker result.
2560122|NCT02498977|Active Comparator|Arm B+ (weaning- positive biomarker)|Participants with a positive biomarker will be weaned of immunosuppression drugs.
2560124|NCT02498977|Active Comparator|Arm B- (maintenance)|Participant with negative biomarker test result will be informed of the result and will remain on baseline maintenance immunosuppression drugs.
2560224|NCT02498548|No Intervention|Control|Individuals with no spinal cord injury or other neurological deficits.
2560227|NCT02498548|No Intervention|Unexercised SCI Knee or Hip|"Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. This group will serve as unexercised control for the Trained SCI Knee group or trained SCI Hip group"
2560228|NCT02498548|Experimental|Trained SCI Knee or Trained SCI Hip|Individuals with spinal cord injury who have been discharged from a locomotor training program at least 6 months prior to enrollment in this study. Training will specifically focus on rehabilitation of the knee joint or the hip joint.
2560339|NCT02497313|Placebo Comparator|Placebo+Placebo|Oral ingestion of metformin placebo combined with intravenous infusion of isotonic saline.
2560340|NCT02497313|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of metformin placebo combined with intravenous infusion of cholecystokinin.
2560343|NCT02497313|Active Comparator|Metformin+Placebo|Oral ingestion of metformin combined with intravenous infusion of isotonic saline.
2560344|NCT02497313|Active Comparator|Metformin+Cholecystokinin|Oral ingestion of metformin combined with intravenous infusion of cholecystokinin.
2560383|NCT02497053|Experimental|Arm A|Four cycles of pemetrexed/platinum
2560386|NCT02497053|Active Comparator|Arm B|Six cycles of pemetrexed/platinum
2560441|NCT02496806|Experimental|Treatment|400mg capsule containing seaweed extract (treatment) Intervention: Dietary Supplement: Treatment capsule containing seaweed extract (treatment)
2560492|NCT02496559|Active Comparator|Pre-consultation CRP|Every third child included get a CRP-test before the consultation and the doctor have the answer at start of consultation
2560494|NCT02496559|No Intervention|CRP requested|No intervention, the consultation with children as normal, the CRP is used at doctors request.
2560524|NCT02496182|Placebo Comparator|Placebo|Conventional treatment (Prednisone 0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Placebo tablet 2 times at day.
2560525|NCT02496182|Experimental|Pirfenidone 1800 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 900 mg 2 times at day, starting with 600 mg at day
2560527|NCT02496182|Experimental|Pirfenidone 1200 mg|Conventional treatment (0.5 mg/kg/day for 4 weeks, then 0.25 mg/Kg/day for 8 weeks and maintenance dosage of 0.125 mg/Kg/day plus Azathioprine 2-3 mg/kg/day with a maximal dosage of 150 mg/day starting with 25-50 mg/day increasing gradually until day 14 with maximal dosage) plus Pirfenidone long release tablet 600 mg 2 times at day starting with 600 mg at day
2560559|NCT02495870|Experimental|Pork, 58°C, 72 minutes|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 72 minutes
2560561|NCT02495870|Experimental|Pork, 58°C, 17 hours|Pork muscle (semitendinosus) sous-vide cooked at 58°C for 17 hours
2560564|NCT02495870|Experimental|Meat balls, 58°C, 17 hours|Meat balls made from pork Semitendinosus. Sous-vide cooked at 58°C for 17 hours
2560566|NCT02495870|Active Comparator|Pork, 160°C (until 58°C in core)|Pork muscle (semitendinosus) oven cooked at 160°C until 58° in core.
3206326|NCT00952978|Experimental|10 mg ilaprazole|
3206327|NCT00952978|Active Comparator|20 mg omeprazole|
3206328|NCT00953004|Experimental|fiber drink|
2560639|NCT02495324|Experimental|Fimasartan|Placebo daily for 2 weeks and Fimasartan 60mg daily for 2 weeks and 120mg daily for 4 weeks
2560648|NCT02495324|Active Comparator|Valsartan|Placebo daily for 2 weeks and Valsartan 80mg daily for 2 weeks and 160mg daily for 4 weeks
2560659|NCT02495324|Other|Olmesartan medoxomil|Reference group. Placebo daily for 2 weeks and Olmesartan 10mg daily for 2 weeks and 20mg daily for 4 weeks
3206329|NCT00953004|Experimental|fiber bread|
3206330|NCT00953004|Experimental|placebo|
3206331|NCT00953030|Experimental|COACH|"web-based risk assessments with an action plan that is negotiated with a Coach who provides personalized follow-up reinforcement"
3206332|NCT00953030|Experimental|RealAge|a web-based health risk assessment and risk profile with disease-specific follow-up reinforcement modules
3206333|NCT00953030|No Intervention|light health education control|
3208832|NCT00978523|Experimental|Treatment with AR-12|This is a single-agent, open-label, Phase 1, dose-escalation study in adult patients with advanced or recurrent solid tumors or lymphoma. Patients will receive orally administered AR-12 once daily for 28 consecutive days. The first dosing cycle will be followed by at least a 7 day off-treatment period; however, no off-treatment period will be scheduled between subsequent treatment cycles
3208833|NCT00978536|Other|group 1|MS with cortical cognitive troubles
3208834|NCT00978536|Other|group 2|MS with subcortical cognitive troubles
3206334|NCT00953095|Experimental|Caregiver Mediated Model (CMM)|focuses on joint attention/engagement intervention using an established evidence based treatment (Kasari et al., 2006). It involves meeting the parent and child in their home for one hour, twice a week for 12 weeks. In this intervention, the parent-child pair meet with the interventionist (as opposed to the group training in the CEM condition). Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input and coaching from the interventionist) as they implement these techniques with their child.
2560186|NCT02498340|Experimental|Diet challenge|The patients will have a single blood test after dietetic challenge, they will be subjected to eat non- fava beans diet at doses of 10 -30 gm of 3 different types of non- fava beans( each one will be given once daily for 3 days).
2560237|NCT02498119||Normal|Patient sample within the normal range of blood results.
2560243|NCT02498119||Abnormal|Patient sample from freshly diagnosed Type 2 Diabetes Mellitus.
2560298|NCT02497768|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (pistachios or Brazils) on two separate visit days.
2560350|NCT02497339|Experimental|Intervention group|Intervention group (Mindfulness Smoking cessation program): Women in intervention group will be provided 2 sessions mindfulness training within 2 weeks. Each session will last for 2 hours with 8-20 participants. For mindfulness training, it aims to understand women smokers' own life planning, stressors and their correlation with smoking; to help women smokers sit with negative affect and alleviate stress through mindfulness; to educate women smokers gain the self-control and replace the smoking habit; to teach women smokers how to prevent craving and relapse.
2560352|NCT02497339|Experimental|Control group|Control group (Self-help smoking cessation booklet): Only the self-help booklet related to quitting will be provided to the participants.
2560396|NCT02497014|Experimental|1 Stent|Patients who are going to receive 1 stent in the main vessel and the side vessel will be treated with kissing ballon inflation
2560398|NCT02497014|Experimental|2 Stents|Patients who are going to receive 2 stents in both vessels
2560476|NCT02496572||Short-course MDR-TB regimen patients|"Short course MDR-TB treatment regimen. New presumptively diagnosed MDR TB patients (adults and children) with Xpert® MTB/RIF or Hain MTBDR, or confirmed with Hain MTBDR plus on positive cultures if initial molecular tests negative or confirmed from MGIT culture/DST if initial molecular tests negative;~Children (<14 years old) suspected of MDR TB without bacteriological confirmation but documented as a close contact of a confirmed MDR TB patient"
2560508|NCT02496312|Experimental|ECOCAPTURE|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
2560533|NCT02496026|Experimental|tDCS plus wrist robot therapy|In addition to standard rehabilitation treatment Group A will perform daily sessions of wrist robot-assisted treatment in combination with tDCS (30 minutes). During first 20 min of each session the patient receives a direct current stimulation through surface sponge electrodes (35 cm2), 2 milliampere intensity: the anodal electrode is placed on presumed lesional area, the cathodal electrode is placed on the controlateral orbital bone.
2560537|NCT02496026|Sham Comparator|Sham tDCS plus wrist robot therapy|Group B is treated as Group A, but tDCS, even if the cap is applied on the patient head, is not activated and no current is delivered.
2560610|NCT02495818|Experimental|Lidocaine|Suprascapular nerve block with infusion of 5ml lidocaine at 2%, guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
2560613|NCT02495818|Sham Comparator|Saline solution|Intervention with suprascapular nerve block with 5ml saline solution guided by Ultrasound combined with homemade exercises (Codman and Hughston exercises).
2560650|NCT02495285||Gelofusine 4%|Children age ≤ 12 years
2560654|NCT02495285||Gelaspan 4%|Children age ≤ 12 years
2560727|NCT02494856|Experimental|Surgery with Naproxen|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg.
2560728|NCT02494856|Experimental|Surgery with Naproxen and Esomeprazole|Fifty healthy volunteers underwent removal of symmetrically positioned lower third molars, will be treated to control pain, swelling and trismus with naproxen 500mg and esomeprazole 20mg.
2560785|NCT02494492|Experimental|IVT of regulator T-cells|intravitreous administration of regulator T-cells
3208835|NCT00978536|Other|group 3|MS in the early stage of the disease when cognitive troubles are absent or inconspicuous
2560968|NCT02493114||Patients with lung cancer|No study intervention
2561024|NCT02492464|Active Comparator|Red yeast rice|Red yeast rice extract 200 mg, containing 10 mg monacolin K per daily dose, 1 capsule per day, per 6 months
2561025|NCT02492464|Placebo Comparator|Placebo|Placebo 200 mg (neutral fibre), 1 capsule per day, per 6 months
2561062|NCT02492347|Active Comparator|Neonates exposed to AN SSRI use|A group of newborn babies who have been exposed to SSRIs in pregnancy will receive an Electrocardiogram at 48-72 hours of age.
2561063|NCT02492347|Other|Neonates not exposed to AN SSRI use|A group of newborn babies, who require treatment with intravenous antibiotics for at least 36 hours, having been identified as being at risk of having an infection within 12 hours of being born. They are subsequently confirmed as clinically well and will receive an Electrocardiogram at 48-72 hours of age.
2561105|NCT02492035|Experimental|Physical activity|Tailoring intervention with kinesiologist
2561106|NCT02492035|Experimental|Diet|Tailoring intervention with nutritionist
2561108|NCT02492035|Experimental|Physical activity and diet|Tailoring intervention with kinesiologist and nutritionist
2561110|NCT02492035|No Intervention|Standard medical care|Follow with family doctor as usual care.
2561116|NCT02491697|Active Comparator|Capecitabine Monotherapy|"Patients with advanced breast cancer accept capecitabine monotherapy.~Drug: Capecitabine"
2561118|NCT02491697|Experimental|DC-CIK Immunotherapy+Capecitabine|"Biological/Vaccine: DC-CIK DC-CIK immunotherapy combined with capecitabine are used to treat advanced breast cancer.~Drug: Capecitabine"
2561196|NCT02491606|Experimental|Load only|Loading with tafenoquine 400 mg base for three days followed by placebo weekly.
2561204|NCT02491606|Experimental|Low weekly dose|Loading with tafenoquine 200 mg base for 3 days followed by tafenoquine 200 mg weekly.
2560047|NCT02499224|Experimental|YYB101|Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks
2560123|NCT02498990|Experimental|Weight reduction|
3206335|NCT00953095|Experimental|Caregiver Education Model (CEM)|focuses on teaching parents information about autism, behavior modification, and community services using a manualized approach (Brereton & Tonge, 2005). Parents will receive information on child development each week, and will be able to ask questions and discuss the information vis-à-vis their own child. This intervention is manualized (Brereton & Tonge 2005). In the CEM condition, parents meet in a group (without their children) in a community-based setting to receive the intervention. Intervention sessions occur once a week for 2 hours.
3206336|NCT00953108|Experimental|quetiapine|
2560251|NCT02497911|Experimental|Adductor Canal Catheter|Postoperatively, patients will be brought to the PACU. The needle insertion site, approximately 10cm proximal to their operative knee, will be exposed. A sterile field will be utilized and the femoral artery is identified with a high frequency linear transducer proximal to the operative knee. 18g insulated Tuohy needle will be inserted in an out-of-plane approach through the sartorius muscle to a final location in close proximity to the saphenous nerve. Once satisfied with needle placement and following negative aspiration, 15 cc's of 0.5% ropivicaine will be injected through the needle under visualization. A 20-g multi-orifice catheter will be inserted approximately 4 cm beyond the needle tip and secured.
2560254|NCT02497911|Experimental|Intraarticular Catheter|Intra-articular catheters will be placed by the surgeon at the end of the procedure, before wound closure. A bupivacaine 0.5% infusion will be admin through the On-Q system and continued for 48 hours postoperatively.
2560286|NCT02497638|Experimental|Metformin and Atorvastatin|Atorvastatin 20 mg once daily until progression with one month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
2560287|NCT02497638|Placebo Comparator|Placebo|One placebo tablet (corresponding to atorvastatin) once daily until progression, with one month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
3206337|NCT00953108|Active Comparator|escitalopram|
3206338|NCT00953134|Experimental|1|IFA - Iron and Folic Acid (60 mg of ferrous fumarate and 400 mcg folic acid)
3206339|NCT00953134|Active Comparator|2|FA - Folic Acid (400 mcg folic acid)
2560404|NCT02496988|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
2560406|NCT02496988|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
2560454|NCT02496715|Experimental|Treatment 1|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
2560455|NCT02496715|Experimental|Treatment 2|Advair 100/50 Diskus pMDI containing fluticasone propionate 100mcg / salmeterol 50 mcg. Single puff, twice daily (approximately every 12 hr) for 4 weeks
2560457|NCT02496715|Placebo Comparator|Treatment 3|Placebo inhalation. Single puff, twice daily (approximately every 12 hr) for 4 weeks
2560502|NCT02496364|Other|Observation|Clinical data analysis
2560558|NCT02496130||minilaparotomy|Subjects in this group will have tissue (uterus) extracted via mini-laparotomy incision with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
2560562|NCT02496130||vaginal extraction|Subjects in this group will have tissue (uterus) extracted via vaginal extraction with knife morcellation. Morcellation will be performed within a containment system. Method of extraction/group assignment will be determined clinically by the operating surgeon based on patient characteristics and patient preference.
2560578|NCT02495675|No Intervention|No flow|Subjects will be spontaneously breathing in room air with no flow.
2560582|NCT02495675|Experimental|Conventional flow via nasal prongs|Subjects will be breathing with nasal prongs delivering 5 L/min of air (inspired fraction of oxygen: 0.21)
2560585|NCT02495675|Experimental|High flow nasal cannulas 20 L/min|Subjects will be breathing with high flow nasal cannulas delivering 20 L/min with an inspired fraction of oxygen of 0.21.
2560586|NCT02495675|Experimental|High flow nasal cannulas 40 L/min|Subjects will be breathing with high flow nasal cannulas delivering 40 L/min with an inspired fraction of oxygen of 0.21.
2560587|NCT02495675|Experimental|High flow nasal cannulas 60 L/min|Subjects will be breathing with high flow nasal cannulas delivering 60 L/min with an inspired fraction of oxygen of 0.21.
2560626|NCT02495506|Experimental|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
2560628|NCT02495506|Active Comparator|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
2560635|NCT02495181|Sham Comparator|Aflibercept Monotherapy|IVT Aflibercept 2 mg + Sham PDT
2560636|NCT02495181|Active Comparator|Aflibercept + verteporfin PDT|IVT Aflibercept 2 mg + Verteporfin PDT
2560694|NCT02494882|Experimental|Adding Ruxolitinib to Combination of Dasatinib + Dexamethasone|"Steroid Pre-Phase (Days -6 to 0) Prednisone 10 mg/m2/day uptitrated to 60/mg/m2/day oral over seven days (capped at 120 mg/day).~Remission Induction (Days 1 to 84) Dasatinib 140 mg oral once daily. Days 1-84. Dexamethasone 10 mg/m2/day oral (capped at 20 mg/day). Days 1-24. Dexamethasone oral taper 10 mg/m2/day (capped at 20 mg/day) to off. Taper days 25-32. Off day 33.~Ruxolitinib phase I cohort dose oral. Days 1-84. Delivered BID. Delivered per the phase I dose cohort. Methotrexate (MTX) 12 mg Intrathecal (IT) for 4 doses on days 22, 43, 64, 85; +/- 3 days.~Post-Remission Induction Therapy (Starting Day 85) Allogeneic HSCT, at the discretion of the treating physician, at any point post-remission induction.~Or, post-remission induction (consolidation) therapy to be determined per the treating physician"
3206340|NCT00953186|Active Comparator|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
2560857|NCT02493816|Experimental|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
3206341|NCT00953186|Placebo Comparator|Placebo|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks
3206342|NCT00953251||patients with acute coronary syndrome|patients with acute coronary syndrome
3206343|NCT00953251||Non-STEMI and unstable angina|
3206344|NCT00953264|Experimental|life style intervention|
3206345|NCT00953277|Experimental|Avance Nerve Graft|Processed Human Nerve Tissue Scaffold
2560166|NCT02498431|Experimental|myocardial infraction|Patients with acute myocardial infraction who are admitted to the emergency department of 424 General Military Hospital before and after percutaneous coronary intervention and stent placement
2560169|NCT02498431|Active Comparator|coronary artery disease|Patients with coronary artery disease but not myocardial infraction who are being subjected to coronary angiography and percutaneous coronary intervention and stent placement
2560170|NCT02498431|Active Comparator|Control|Patients subjected to coronary angiography and found with no presence of coronary artery disease
2560215|NCT02498171|Experimental|Intrathecal morphine with fentanyl|Single shot of intrathecal morphine 100mcg mixed with 25mcg of fentanyl and filled up to make a 2ml solution. This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
2560218|NCT02498171|Active Comparator|Intrathecal morphine with bupivacaine|Single shot of intrathecal morphine 100mcg mixed with 2.5mg of spinal bupivacaine and filled up to make a 2ml solution.This would then be injected into the subarachnoid space through L2-3 or L3-4 following standard procedures.
2560240|NCT02497924|Experimental|GBT440|GBT440 / [C14] GBT440
3206346|NCT00953303|Experimental|glucocorticoid|
3206347|NCT00953303|Active Comparator|Standard care|
2560504|NCT02496351|Active Comparator|TENS INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours. The intensity of the impulse will be determined in a test carried out 3 days before surgery. The other parameters will be continuous, biphasic, compensated and symmetric impulse, frequency of 80 Hz, time impulse between 250 and 290 microseconds, modulation time 5´´
2560509|NCT02496351|Placebo Comparator|TENS NO INTERVENTION|In the immediately postoperative of limb amputation, TENS will be use in this patients during 24 hours, but in this case TENS just will be on. No intensity impulse should be programmed.
3206348|NCT00953316||at-risk infants|Includes all children born at less than 37 weeks gestation and other high risk newborns such as those with a history of breathing problems and/or low tone.
2560594|NCT02495753|Experimental|Abdominal and Vaginal Cleansing|In the treatment arm, the vagina will be cleansed prior to usual abdominal cleansing before cesarean section.
2560597|NCT02495753|Active Comparator|Abdominal Cleansing Alone|In the control arm, abdominal cleansing will be performed per routine with no vaginal cleansing.
2560670|NCT02495428|Experimental|Kinesio Tape Group|muscle Kinesio Taping in Triceps Surae, Tibialis anterior, and Quadriceps according Kenzo Kase Method
2560673|NCT02495428|No Intervention|Control group|They will do the same measurement of lactate and exercise protocol in treadmill, but always without kinesio tape intervention
2560705|NCT02494960|Placebo Comparator|Control Group|The doctor will offer a placebo intervention.
2560706|NCT02494960|Experimental|Intervention Group A|"The doctor will offer the brief smoking cessation AWARD model .~At 1-month follow-up survey, trained study personnel will repeat the brief smoking cessation AWARD model ."
2560709|NCT02494960|Experimental|Intervention Group B|The doctor will offer the brief smoking cessation AWARD model.
2560778|NCT02494570|Experimental|ABI-009|
2560844|NCT02494115|Experimental|subcutaneous drainage|This local treatment consists in inserting in lower limbs several catheters draining into enclosed bags in order to evacuate lymph fluid and to lower local pressure.
2560899|NCT02493634|Other|pressure gradient measurement|Diagnostic procedure to measure pressure gradient in series of patients. Focus is on safety and absence of adverse events
3206349|NCT00953342|Experimental|Aerobic exercise|12 weeks of supervised aerobic exercise and standard care
2560980|NCT02492893|Experimental|Hatha Yoga|A 12-session 90-minute weekly hatha yoga intervention, that includes asanas (physical postures), pranayama (breathing exercises) and dhyana (meditation.
2560987|NCT02492893|No Intervention|Treatment as Usual|
2561077|NCT02492646|Experimental|Saline group|In the saline group, disposable endotracheal tube was immersed in the 1 liter of sterile 0.9% sodium chloride irrigation solution before anesthetic induction.
2561079|NCT02492646|Experimental|Dry group|In the dry group, endotracheal tube was peeled off from sterile packing just before orotracheal intubation.
3206350|NCT00953342|Placebo Comparator|Usual care|12 weeks of standard care
2561223|NCT02491203|No Intervention|Usual care|All study participants in the control group will receive a 4-week written home exercise program (e.g. GRASP) , i.e. the usual care discharge home program.
2561248|NCT02490982||Teriflunomide|Patient-reported outcomes and clinical assessment
3206351|NCT00953355|Experimental|Folate|Folate plus metformin
3206352|NCT00953355|Placebo Comparator|Placebo|Placebo plus metformin
3206353|NCT00953368|Active Comparator|Remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
3206354|NCT00953368|Placebo Comparator|control|sham placement of a blood-pressure cuff around the upper limb without inflation
3206355|NCT00953381|Experimental|5 mg ilaprazole|
3206356|NCT00953381|Experimental|10 mg ilaprazole|
3206357|NCT00953381|Experimental|20 mg ilaprazole|
3206358|NCT00953381|Active Comparator|20 mg omeprazole|
3206359|NCT00953394|Experimental|treatment arm|continuous 5 fluouracil infusion plus long-acting octreotide
3208836|NCT00978575|Active Comparator|Intravenous iron|
3208837|NCT00978575|Active Comparator|Oral iron|
3206360|NCT00953420|Experimental|Chemotherapy and Immunotherapy|"Docetaxel 60 mg/m2 IV on Day 1~Carboplatin with target AUC of 5 (mg/ml x min) on Day 1~Dexamethasone 5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1~After cycle 1, subsequent cycles of chemotherapy may start once ANC > 1000 and platelets > 100,000 post nadir~Up to an additional 2 cycles of chemotherapy, given per the above schedule, may be given if the EBV-specific cytotoxic T lymphocytes product is not available after the initial 4 cycles"
3206361|NCT00953433|Experimental|Endoflex tube|Use of Endoflex tube for intubation.
2560204|NCT02498262|Experimental|Virtual Reality Training System|
2560219|NCT02498028||Cervical Fusion|patients with anterior cerivical decompression and fusion
2560220|NCT02498028||Cervical Disc Prostheses|patients with cervical total disc replacement
2560277|NCT02497833|Placebo Comparator|control|the participants in this arm are instruted to consume placebo capsules
2560278|NCT02497833|Experimental|treatment|the participants in this arm are instruted to consume retinoic acid capsules
2560316|NCT02497508|Experimental|Nivolumab|Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg
2560442|NCT02496845|Experimental|Group A|Topical treatment and PK. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
2560446|NCT02496845|Experimental|Groups B, C, D|Dual topical biweekly administration and intraurethral. Triple topical weekly administration. Multiple topical administration. Administration of VL#FIA3-30 (dual administration of MH30-01 & IS045-01)
2560482|NCT02496481|Experimental|Group1 Baseline+MI+tailored brochure|"Participants randomized to Group 1 will receive the motivational interviewing intervention in the ED and will be mailed a tailored educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
2560483|NCT02496481|Experimental|Group2 Baseline+MI+general info|"Participants randomized to Group 2 will receive the motivational interviewing intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
2560485|NCT02496481|Experimental|Group3 Baseline+tailored brochure|"Participants randomized to Group 3 will receive no intervention in the ED and will be mailed a tailored educational brochure about child passenger safety~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
2560486|NCT02496481|No Intervention|Group4 Baseline+general info|"Control Group. Participants randomized to this arm will receive no intervention in the ED and will be mailed a generic educational brochure about child passenger safety.~All participants will complete the baseline assessment survey, a 2 week follow-up phone call and a 6 month follow-up encounter."
2560556|NCT02496013|Experimental|68Ga-NEB injection and PET/CT scan|"Patients for blood pool imaging:~The patients were intravenously injected with 68Ga-NEB and underwent PET/CT scan 30~45min after the injection.~Patients for lymph node imaging:~The patients were locally injected 10~20MBq 68Ga-NEB and followed by dynamic regional PET acquisitions."
2560581|NCT02495649|Other|[18F]-DOPA|evaluate the added value of PET-CT with [18F]-DOPA tracer for Assessment of the Myocardial Sympathetic Denervation in patients with or suspected with Parkinson's disease.
2560622|NCT02495532|Active Comparator|Colon Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
2560624|NCT02495532|Active Comparator|Rectal Cancer|"The subjects in this group will undergo intervention by having surgery and lymph node clearing technique.~Intervention A: Carnoy solution Intervention B: GEWF solution"
2560642|NCT02495155|Active Comparator|Fatigue|Participants who have received treatment for early stage breast cancer and who experience fatigue, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
2560649|NCT02495155|Active Comparator|Treatment-related Pain|Participants who have received treatment for early stage breast cancer and who experience pain, rated at least a 4 on a scale of 0-10 during the previous week, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
2560658|NCT02495155|Active Comparator|Insomnia|Participants who have received treatment for early stage breast cancer and who experience insomnia, assessed as difficulty sleeping over the last week, yes or no, per patient report. Participants will complete baseline symptom questionnaires, then complete an internet-based cognitive behavioral therapy program (PROSPECT) for 8 weeks, then repeat questionnaires.
2560734|NCT02495064|Experimental|Mometasone Furoate Cream(MF)|"participants will be given conventional Chemoradiotherapy and MF.~MF Brief introduction:~Generic name :Mometasone Furoate Cream. Dosage form:Each gram of Mometasone Furoate Cream contains mometasone furoate, USP in a cream base of hexylene glycol, phosphoric acid, propylene glycol stearate, stearyl alcohol and ceteareth-20, titanium dioxide, aluminum starch octenylsuccinate, white wax, white petrolatum, and purified water.~Dosage:Apply a thin film of Mometasone Furoate Cream to the affected skin areas once daily during radiotherapy.~It is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses."
2560741|NCT02495064|No Intervention|Chemoradiotherapy|conventional Chemoradiotherapy only
2560788|NCT02494466|Active Comparator|Group E (n=10)|Patients with high Ig E levels
2560792|NCT02494466|Active Comparator|Group C (n=10)|Patients with normal Ig E levels
2560795|NCT02494466|Active Comparator|Group M (n=10)|Patients who would be administered with 4mg PO MS 10 days before surgery because of high IgE
2560104|NCT02498847|Experimental|ENGAGE intervention|8 in-person weekly treatment sessions with an occupational therapist of 30 minutes - 1 hour duration intervention content provided on website, homework assigned each week after intervention period, monthly calls conducted to check on health status
2560108|NCT02498847|No Intervention|Usual Care|participated in usual care and received monthly calls to check on health status
2560225|NCT02498691|Experimental|Type exposed|endometriosis
2560226|NCT02498691|Experimental|Type unexposed|Without endometriosis
2560281|NCT02497820|Active Comparator|100 mg daily aspirin|They will receive one small tablets each day for two years in a blinded fashion
2560282|NCT02497820|Active Comparator|300 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
2560283|NCT02497820|Active Comparator|600 mg daily aspirin|They will receive two large enteric coated tablets each day for two years in a blinded fashion
2560322|NCT02497456|Experimental|Follow-up counselling|Participants in the experimental arm will receive home-based HIV counselling and testing and referral for HIV care if found to have HIV infection. Additionally, participants will receive home-based follow-up counselling at 1 and 2 months after HIV diagnosis.
2560326|NCT02497456|No Intervention|Standard of care|Participants in this arm will receive only home-based HIV counselling and testing and referral for HIV care if found to have HIV infection.
2560355|NCT02497183|Experimental|first|a repeat abdominal ultrasound exam to patients following the filling of bowel with contrast material per os.
2560413|NCT02496975|Experimental|Cyclosporine A|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
2560415|NCT02496975|Active Comparator|Placebo|Participants assigned to this group will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
2560458|NCT02496676|Active Comparator|magnesium threonate|Participants will receive 12 weeks of magnesium threonate and 12 weeks of placebo. Will be dose escalated based on weight.
2560460|NCT02496676|Placebo Comparator|Placebo|Participants will receive 12 weeks of placebo and 12 weeks of magnesium threonate
2560499|NCT02496338|Experimental|Intervention group|Training program about menopausal health isues
2560501|NCT02496338|No Intervention|Control group|No training program about menopausal health isues
3206362|NCT00953433|Active Comparator|Endotracheal tube with stylet|Use of conventional endotracheal tube with a stylet for intubation.
2560606|NCT02495636|Experimental|Safety Run Up Group|The first 12 patients to be enrolled will initiate therapy with CDX-1401 alone, with the addition of MPDL3280A the day of their 4th CDX-1401 vaccination (week 7). These patients will undergo a tumor biopsy prior to initiation of trial therapy, after their 3rd CDX-1401 vaccination (during week 6) and after their 3rd MPDL3280A infusion (during week 14 or 15, if there are no dose delays). Although we don't expect significant synergistic toxicities of combination therapy based on mechanism of action/ formulation/ administration/ distribution of CDX-1401 and past vaccine/ immune checkpoint trials, these first 12 patients will constitute a safety run in group.
2560607|NCT02495636|Experimental|Expanded Trial Group|If there are no unexpected toxicities (no more than 3 of 12 patients with grade 3+ treatment related events as defined in 4.1.1), an additional 28 patients will be enrolled. Unlike the first 12 patients, these additional 28 patients will initiate both CDX-1401 and MPDL3280A on the same day, and will undergo tumor biopsies before starting trial therapy and after their 3rd CDX-1401 vaccination (during week 6).
2560657|NCT02495376|Active Comparator|Group A|Group A participates in the first available MBSR course.
2560663|NCT02495376|Active Comparator|Group B|Group B waits 16 weeks before participating in the MBSR course.
2560696|NCT02494934|Experimental|Cognitive-behavioural therapy|Eight sessions of psychotherapy incorporating cognitive-behavioural and sex therapy interventions.
2560697|NCT02494934|Experimental|physical therapy|Eight sessions of physical therapy targeting the pelvic floor muscles.
3206363|NCT00953446|Experimental|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|"ASL MRI~Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment"
3206364|NCT00953498|Active Comparator|pioglitazone|treatment with pioglitazone (dose from 30 mg:day to 45 mg/day)
3206365|NCT00953498|Active Comparator|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
2560919|NCT02493439|Experimental|Best Possible Self|Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health. The participants are instructed to practice the BPS intervention for a month, 5 minutes/day.
2560921|NCT02493439|Placebo Comparator|Daily Activities|Participants are asked to think and write about the activities carried out in the last 24 hours. The participants are instructed to practice the Daily Activities exercise for a month, 5 minutes/day.
3206366|NCT00953511|Other|genetic|
3206367|NCT00953537|Other|capecitabine|
2561018|NCT02492685|Experimental|Contrast enhanced EUS group|Contrast enhanced EUS with quantitative analysis
2561067|NCT02492321|Active Comparator|EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
2561073|NCT02492321|Placebo Comparator|Vehicle|Placebo Comparator: One of two study arms: placebo topical administered 3 times per day
2561216|NCT02491476|Experimental|micro-macroelectrodes|All patients will be implanted with usually 4 intracerebral micro-macroelectrodes(replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
2561246|NCT02490995|No Intervention|Group A|Information given by the anaesthetist during the consultation
2561251|NCT02490995|Experimental|Group B|Movie + Information given by the anaesthetist during the consultation
2561281|NCT02490722|Active Comparator|Intervention|Four times two hours interdisciplinary patient education and usual care
2561283|NCT02490722|No Intervention|Control|Usual care
3206368|NCT00953550|Experimental|Rocuronium-Sugammadex|
3206369|NCT00953550|Active Comparator|Succinylcholine|
3206370|NCT00953563|No Intervention|compression therapy|
3206371|NCT00953563|Active Comparator|Biologic with compression therapy|
3206372|NCT00953589|Experimental|Locteron ® PANEL A|PANEL A: Locteron™ 480 µg dosed every 2 weeks in two subcutaneous injections (160 µg and 320 µg)
2560112|NCT02498912|Experimental|Cyclophosphamide followed by Autologous T Cells|Cohorts of 3-6 pts will be infused with escalating doses of modified T cells to establish the MTD of modified T cells. There are 5 planned dose levels: 3 x 10^5, 1 x 10^6, 3 x 10^6, & 1 x 10^7 & 3 x 10^7 4H11-28z/fIL-12/EGFRt+ T cells/kg. Cohort I-IV & VI will be treated escalating dose levels. Once the MTD of T cells is established, the next cohort will receive lymphodepleting cyclophosphamide dose of 750 mg/m^2 or a regimen of cyclophosphamide dose 300 mg/m2 x 3 days concurrent with fludarabine dose 25-30 mg/m2 x 3 days 2-7 days prior to starting the T cell infusion at one dose level below the MTD. If MTD isn't established after Cohort IV, Cohort V will receive conditioning chemotherapy 2-7 days prior to starting the T cell infusion at the same dose as Cohort III. Pts in Cohort V received cyclophosphamide chemotherapy on Day 1 or cyclophosphamide concurrent with fludarabine on Day 1-3, followed 2 to 4 days later by T cell infusion. This cohort is closed to further accrual.
2560165|NCT02498535|Experimental|Nitric oxide gas at 160 ppm|Nitric oxide gas at 160 ppm inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days. Total dose of 2400 ppm hours.
2560171|NCT02498535|Placebo Comparator|Breathing 20.3% oxygen|Breathing 20.3% oxygen inhaled four times daily for 30 min delivered with air as the carrier via nasal inhalation for a total of 7.5 days.. 100% nitrogen will be injected into the breathing circuit (instead of 99.5% nitrogen and 0.5% NO).
2560268|NCT02498210|Experimental|IVF after IVM|"If the patients will not concive during the IVM cycle . results of this following IVF cycle will be compared to the initial IVF preformance~Intervention : In Vitro Maturation Procedure"
2560302|NCT02497586|Experimental|MRS|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. This is a prospective feasibility study, aiming to recruit 15 consecutive patients with lung cancer to undergo proton MRS. The feasibility and repeatability of the technique will be assessed by analysis of the MR spectra obtained.
2560358|NCT02497300|Experimental|Spironolactone|Participants will be randomized to spironolactone 25mg daily for the 1st or 2nd 6 week treatment period.
2560359|NCT02497300|Active Comparator|Amiloride|Participants will be randomized to amiloride 5mg daily for the 1st or 2nd 6 week treatment period.
2560402|NCT02496936|Experimental|Saturated Fat (SFA)|30 grams saturated fat in the form of heavy whipping cream will be provided to subject in a smoothie drink
2560405|NCT02496936|Experimental|Monounsaturated Fat (MUFA)|30 grams monounsaturated fat in the form of high oleic canola oil will be provided to subject in a smoothie drink
2560407|NCT02496936|Experimental|Polyunsaturated Fat Linoleic (PUFA-LA)|30 grams polyunsaturated fat in the form of high linoleic sunflower oil will be provided to subject in a smoothie drink
2560408|NCT02496936|Experimental|Polyunsaturated Fat Alpha-Linolenic (ALA)|30 grams polyunsaturated fat in the form of flaxseed oil will be provided to subject in a smoothie drink
2560409|NCT02496936|Experimental|Polyunsaturated Fat Long Chain Omega-3 (LCn3)|30 grams polyunsaturated fat in the form of fish oil (Coromega Omega3 Squeeze) will be provided to subject in a smoothie drink
2560468|NCT02496663|Experimental|Treatment (osimertinib, necitumumab)|Patients receive osimertinib PO QD on days 1-21 and necitumumab IV over 60 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2560521|NCT02496273|Experimental|CEA Specific CTL|Patients receiving CEA-specific CTLs as therapy for Gastric Cancer
2560577|NCT02495701||Patients|Patients having Hip arthroscopic surgery
2560614|NCT02495558|Experimental|Patients with Tracheostomy|Assessment of reflex cough Assessment of the deccanultation outcome (follow-up)
2560655|NCT02495363||PECS block in additions to general anesthesia|"As standard analgesic protocol participants undergoing mastectomy surgeries under general anesthesia will have an addition of Pectoral Block regional anesthesia.~Following obtaining written informed consent, ultrasound guided PECS Block will be performed by identifying the thoracic muscles, in addition to general anesthesia Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% ."
3206373|NCT00953589|Experimental|Locteron ® PANEL B|PANEL B: Locteron™ 480 µg dosed every two weeks in single subcutaneous injections
3206374|NCT00953589|Active Comparator|PEG-Intron® PANEL A|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
3206375|NCT00953589|Active Comparator|PEG-Intron® PANEL B|PEG-Intron® 1.5 µg/kg body weight weekly subcutaneous injection
3206376|NCT00953628|Active Comparator|o Group A=uHCG ovul trig|HCG for triggering
3206377|NCT00953628|Experimental|o Group B=recHCG ovul trig|recombinant HCG for triggering
2560946|NCT02493192|Experimental|birth ball|Use birth ball as a pain relief.
3206378|NCT00953641|Active Comparator|Pre-Menopausal 1|Pre-Menopausal group, receiving Misoprostol
3206379|NCT00953641|Placebo Comparator|Pre-Menopausal 2|Patients will insert a placebo vaginal suppository 12h or more prior to the endometrial biopsy
3206380|NCT00953641|Active Comparator|Post-Menopausal 1|Post-Menopausal patients will insert a Misoprostol vaginal suppository 12h or more prior to the endometrial biopsy
3206381|NCT00953641|Placebo Comparator|Post-Menopausal 2|Placebo vaginal suppository prior to the endometrial biopsy
3206382|NCT00953732||1|
3206383|NCT00953758|Experimental|1|
3206384|NCT00953771|Experimental|Danazol, Plex, Steroids|Everyone will receive Danazol with plasma exchange and corticosteroids
3206385|NCT00953784|No Intervention|1|Standard management
3206386|NCT00953784|Active Comparator|2|Extended management: with no bowel prep except enema,restricted fluids, increased O2,body warming and use of skin protectors during surgery as previously described
3206387|NCT00953810|No Intervention|control|General heart failure population staying under regular care of their primary care physician
3206388|NCT00953810|Active Comparator|Intervention|Like control plus one education training regarding heart failure aspects and management
3206389|NCT00953888|Experimental|Active|AZD5069 oral solution
3206390|NCT00953888|Placebo Comparator|Placebo|Placebo oral solution
3206391|NCT00953914|Experimental|Pyridostigmine|
3206392|NCT00953914|Placebo Comparator|Placebo|If a subject is randomized to placebo, he will receive placebo pills 3 times daily for 1 day.
3206393|NCT00953940|Experimental|Isotonic saline|Isotonic saline
3206394|NCT00953940|No Intervention|No treatment|Habitual therapy
3206395|NCT00953953||Acutely Decompensated Systolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
2560190|NCT02498327|Placebo Comparator|Gelatine Capsules|Gelatine capsules containing only inactive ingredients (starch amyral white, di-calcium phosphate DC and magnesium stearate fine), will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
2560195|NCT02498327|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butcher's Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate, will be taken once per day, in the morning after breakfast, for 30 days.
2560221|NCT02498054|Experimental|Education with new meter feature.|Subjects experience a computer stimulation of a new meter feature ( colour range indicator) to help subjects interpret whether blood glucose results are low, in-range or high based on accepted guidance.
2560265|NCT02497872|Experimental|Early Precut Sphincterectomy|Biliary stone removal using early precut: Patients enrolled in this arm received biliary drainage through a small incision on the papilla with an endoscopic needle-knife - a technique called precut sphincterotomy.
2560266|NCT02497872|Active Comparator|Pancreatic Duct Stent|Biliary stone removal using persistence of cannulation and a later pancreatic duct stent placement: Patients enrolled in this arm received conventional biliary drainage through persistent biliary cannulation. After completion of biliary drainage, a prophylactic pancreatic duct stent was placed.
3206396|NCT00953953||Chronic HF Patients on Dialysis|Patients who have heart failure (defined as NYHA class II, III, or IV) and are on dialysis.
3206397|NCT00953953||Ambulary Chronic HF|Patients with diagnosis of chronic heart failure (NYHA class II and III) who are on optimal medical therapy.
3206398|NCT00953953||Acutely Decompensated Diastolic HF|Patients with moderate or severe Heart Failure (defined ast NYHA class III or IV).
3206399|NCT00953966|Other|Starch 1|Starch 1
2560459|NCT02496598|Experimental|In Vitro Follicle Activation (IVA)|Ovarian tissue will be removed and cultured in vitro with compounds to activate dormant follicles. Following activation, ovarian tissue will be auto-grafted and the patient monitored for follicular growth.
2560496|NCT02496390|Placebo Comparator|Autologous|"Patients will be randomized to receive a fecal transplant using their own microbes/Feces (autologous - 9 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
2560497|NCT02496390|Active Comparator|Allogenic|"Patients will be randomized to receive a fecal transplant of feces/microbiome from the healthy donor (allogeneic - 12 patients).~Dosage - approx 100ml fecal sample, one time, procedure duration ~1hr"
2560615|NCT02496052|Experimental|dried biological amnion graft|patients, who are with IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2560618|NCT02496052|Sham Comparator|Foley catheter balloon only|patients, who are with IUA, treated by uterine application of Foley balloon only+ hormones (estradiol valerate tablets+dydrogesterone Tablets) following hysteroscopic adhesiolysis.
2560637|NCT02495194|Experimental|Active Horticultural Therapy|15 sessions of Horticultural Therapy program teaching the elderly about gardening techniques and for them to benefit from the therapeutic effects of the parks
2560641|NCT02495194|Other|Waitlist Control Group|Participants will receive the same horticultural therapy program at the end of the assessments
2560693|NCT02495012|Placebo Comparator|control|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
2560695|NCT02495012|Active Comparator|treatment|5IU/60 kg bolus and 0.002 IU/kg/h continuous infusion for 48 hours
2560716|NCT02494765|Active Comparator|I-gelTM|I-gel is a supraglottic device made of gel like material. It is used for administration of anesthesia in selected patients.
2560719|NCT02494765|Active Comparator|Ambu® AuraOnceTM|Ambu AuraOnce (AO) is a supraglottic device having different material and its shaft has greater curvature than I-gel. It is also used for administration of anesthesia in selected patients.
2560916|NCT02493543||Spinal cord injury|Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.
3206400|NCT00953966|Other|Starch 2|Starch 2
3206401|NCT00953966|Other|Starch 3|Starch 3
3206402|NCT00953966|Other|Starch 4|Starch 4
3206403|NCT00953966|Other|Starch 5|Starch 5
3206404|NCT00953966|Other|Starch 6|Starch 6
3206405|NCT00953966|Other|Starch 7|Starch 7
3206406|NCT00953979|Active Comparator|Sulfasalazine|Sulfasalazine is a drug in treatment RA, AS and ulcerative colonitis. In this study, Sulfasalazine is used to act as an active comparator to access the efficacy of kunxian capsule.
3206407|NCT00953979|Placebo Comparator|placebo|The placebo capsule was used to be a comparator of kunxian capsule
3206408|NCT00954005|Experimental|Rituximab, Gemcitabine and Oxaliplatin|Drug: Rituximab on day 0 or 1 of each 28-day cycle Drug: Gemcitabine on day 1 and 15 of each 28-day cycle Drug: Oxaliplatin on day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²) of each 28-day cycle
3206409|NCT00954018||Cystic Fibrosis patient during outpatient clinic visit|
3206410|NCT00954018||Cystic Fibrosis patients during hospitalization|
3206411|NCT00954018||CF patients about to have sinus surgery and bronchoscopy|
3206412|NCT00954031||case|hospitalized patients, adult or child, including the diagnosis of APA was made, after consulting their physician.
3206413|NCT00954031||The control group|"Two patients witnesses will be matched to each case:~Chronological criterion: consultation for a sore throat 10 days (± 3 days) before the date of hospitalization of cases, between 13 and J-J-7.~Age criteria: year of birth ± 5 years Geographical criteria: living in the same department, failing in an adjacent Department Social criteria: beneficiary or otherwise of the CMU, to avoid a selection bias leading social most frequently at the onset of the APA"
3206414|NCT00954044|Experimental|Exercising Together|Partnered progressive resistance exercise
3206415|NCT00954044|Placebo Comparator|Usual Care|Usual Care Control
3206416|NCT00954057|Experimental|LIPO-102|Intraorbital Injection
3206417|NCT00954057|Placebo Comparator|Placebo|Intraorbital Injection
3208838|NCT00978575|Placebo Comparator|Isotonic Sodium and placebo tablets|
3208839|NCT00978588|Experimental|HES 130/0.4|
3206418|NCT00954070||Case (subjects with NERD)|The investigators cases are subjects with confirmed NERD and include male or female patients aged between 21 and 65 years, who present with typical clinical manifestations of gastroesophageal reflux and have no esophageal mucosal breaks upon conventional white-light endoscopy examination but show evidence of pathologic gastroesophageal reflux on 24-hr pH monitoring.
2560376|NCT02497365|Experimental|Group A: Besifloxacin|Patients presenting with bacterial keratitis. These patients will be treated with besifloxacin ophthalmic suspesnion 0.6%, initially 6x a day and tapered down as the patient's condition improves based on the clinical judgement of the treating physician.
2560380|NCT02497365|Active Comparator|Group B: Fortified Antibiotics|Patients presenting with bacterial keratitis. These patients will be treated initially with fortified cefazolin and vancomycin drops every 1 hour around the clock (24hours) for a minimum of 48 hours, and will subsequently have their dosages tapered gradually by the treating physician as is the standard of care for bacterial keratitis.
2560462|NCT02496871|Active Comparator|KWMP-GP|Weekly group phone calls for 6 months. Group phone calls will last about 45 minutes each. Phone calls will include groups of 12-18 participants.
2560464|NCT02496871|Experimental|KWMP-SM|Participants interact through a private Facebook group. New activities for participants to complete each week for 6 months.
2560495|NCT02496325|Other|perineal technic|
2560541|NCT02496143|Experimental|Cohort 1|500 mg EC-18 dose or placebo
2560544|NCT02496143|Experimental|Cohort 2|1000 mg EC-18 dose orplacebo
2560546|NCT02496143|Experimental|Cohort 3|2000 mg EC-18 dose or placebo
2560547|NCT02496143|Experimental|Cohort 4|4000 mg EC-18 dose or placebo
2560591|NCT02495727|Experimental|Control Group|This group will undertake two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
2560593|NCT02495727|Experimental|Pre-Training Group|This group will undertake four weeks of strength training exercise (10 sessions) before two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
2560595|NCT02495727|Experimental|Exercise Snacking Group|This group will undertake home-based 'exercise snacks' of simple lower limb movement (5 minutes, 3 times a day) whilst undertaking two-weeks of step-reduction to <1,500 steps per day, followed by two-weeks of strength training exercise (6 sessions).
3206419|NCT00954070||Control|Healthy individuals aged between 21 and 65 years who are asymptomatic for GERD and other digestive diseases
2560710|NCT02494804|Other|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
2560712|NCT02494804|Other|Temozolomide+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after Temozolomide treat
3206420|NCT00954083|Experimental|DIR/Floortime intervention|1=DIR/Floortime intervention
3206421|NCT00954083|Active Comparator|routine care|2=routine care
3206422|NCT00954096|Experimental|Transdermal nicotine patch or placebo|A single blood specimen (85ml) will be drawn. They will be asked to empty their bladder. The patch will be applied. Following application of the patch, heart rate and blood pressure will be measured every 15 minutes for the 1st hour, every 30 minutes for the next 3 hours and hourly after that until the end of the study. Urine will be collected in two 4-hour aliquots. FMD will be measured after approximately 6 hours of nicotine exposure. After 8 hours exposure, following the end of the 2nd urine collection, the patch will be removed and the subject discharged. Following a minimum of 2 weeks (maximum 8 weeks) washout, the subject will repeat the study, receiving the other patch.
2560948|NCT02493166|Active Comparator|patients with Multiple sclerosis Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
2560949|NCT02493166|Active Comparator|Healthy volontiers Dual task cost|Dual task cost (cognitive-motor interference), comparing single versus dual task performance (on both motor and cognitive task)
3206423|NCT00954135|Active Comparator|letrozolo+cyclophosphamide|
2561078|NCT02492269|Experimental|Dexmedetomidine|Dexmedetomidine in addition to 15 µg/kg of fentanyl
2561082|NCT02492269|Placebo Comparator|Placebo|Normal saline as a placebo in addition to 15 µg/kg of fentanyl
2561144|NCT02491918|Active Comparator|In the bag IOL|Cataract surgery with IOL implantation in the capsular bag
2561151|NCT02491918|Active Comparator|Optic Capture of IOL|intraocular lens implantation in the capsular bag with posterior optic capture
3206424|NCT00954135|Experimental|letrozolo+sorafenib+cyclophosphamide|
2561355|NCT02490306|Experimental|Hemorrhagic stroke|"Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.~Interventions: Strokefinder MD100 measurement"
2561356|NCT02490306|Experimental|Ischemic stroke|"Patient group B is defined as patients that are diagnosed with ischemic stroke.~Interventions: Strokefinder MD100 measurement"
2561357|NCT02490306|Experimental|Stroke mimics|"Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.~Interventions: Strokefinder MD100 measurement"
3206425|NCT00954148|Active Comparator|PET/CT follow-up|PET/CT with history and physical exams at 3,9,18,36,60 months only
3206426|NCT00954148|Other|conventional follow-up|NCCN recommendations
3206427|NCT00954161|Experimental|first aid and helping behaviour|The helping behaviour training is given after 24 hours first aid training and aims to sensitise participants towards a helping reaction and teach participants how to deal with barriers to helping
3206428|NCT00954161|Active Comparator|first aid only|This group receives training in first aid only without training in helping behaviour.
2561557|NCT02488993||Prospective Phase Rifaximin-α 550mg|Prospective data collection of patients treated with Rifaximin-α 550mg from point of study entry.
3206429|NCT00954200|Placebo Comparator|Placebo|
3206430|NCT00954200|Active Comparator|ibuprofen|
3206431|NCT00954213|Experimental|DIR/Floortime parent intervention|
3206432|NCT00954226|Experimental|Arm I (standard-dose erlotinib hydrochloride)|Patients receive standard-dose erlotinib hydrochloride PO QD for 2-3 weeks (up to 8 weeks if surgery is delayed).
3206433|NCT00954226|Experimental|Arm II (high-dose erlotinib hydrochloride)|Patients receive high-dose erlotinib hydrochloride PO QD for 2-3 weeks (2-8 weeks for current smokers or up to 8 weeks if surgery is delayed).
3206434|NCT00954252|Experimental|Test Article|
3206435|NCT00954252|Placebo Comparator|Placebo|
3174323|NCT00622219|No Intervention|Control|Adolescents randomized to the control condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated) but will not be called for drug tests.
2560370|NCT02497222|Experimental|RNS60|RNS60 4 ml, inhaled twice daily by nebulization for 21 days.
2560372|NCT02497222|Placebo Comparator|Normal Saline|Normal Saline 4 ml, inhaled twice daily by nebulization for 21 days.
2560425|NCT02496910|Active Comparator|Group 1 - Period 1|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
2560431|NCT02496910|Experimental|Group 2 - Period 1|YH22162 FDC tablet of Yuhan Corporation
2560434|NCT02496910|Experimental|Group 1 - Period 2|YH22162 FDC tablet of Yuhan Corporation
2560436|NCT02496910|Active Comparator|Group 2 - Period 2|Telmisartan/Amlodipine 80/5 mg (FDC) and Chlorthalidone 25mg
2560487|NCT02496416|Experimental|Treatment|The treatment group will participate in an eight week aquatic exercise program during weeks 2-9 of the study. The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Randolph, NJ.. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
2560488|NCT02496416|Active Comparator|Control|The control group will participate in an eight week stretching program during weeks 2-9 of the study. The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
3208840|NCT00978588|Active Comparator|5% albumin|
2560609|NCT02495597||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
2560611|NCT02495597||Control Group|age- and sex matched to subject-group
2560638|NCT02495337||TIssue Collection|Only one arm will be used to collect tissue from Esophageal Adenocarcinoma
2560692|NCT02495090|Other|Hypospadias|Familial hypospadias trios (patients + parents)
2560732|NCT02494791|Other|Endometrial and Ovarian Cancer Participants|All study subjects will be offered the same options for screening and follow-up.
2560789|NCT02494505|Experimental|mycophenolate mofetil|
2560793|NCT02494505|Placebo Comparator|placebo|placebo pills
2560869|NCT02494050|Experimental|Behavioral Activation-Full|Twelve weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
2560871|NCT02494050|Experimental|Behavioral Activation-Short|Eight weekly sessions of phone therapy using Behavioral Activation Treatment for Anhedonia.
2560873|NCT02494050|Active Comparator|Bipolar Disorder Collaborative Care|Twelve weekly sessions of phone therapy using BDCC manual adapted for anhedonia.
2560920|NCT02493465|Experimental|LVH everolimus|Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.
2560959|NCT02493140|Active Comparator|Cashew apple extract (Cashewin)|
2560961|NCT02493140|Placebo Comparator|Placebo|
3174324|NCT00622245|Experimental|Lu AA34893: 4 mg|
3174325|NCT00622245|Experimental|Lu AA34893: 12 mg|
2561035|NCT02492568|Experimental|SBRT + Pembrolizumab|Stereotactic Body Radiation Therapy (SBRT) followed by pembrolizumab treatment within 7 days of completion. SBRT: 3 x 8 Gy, given 1-2 weeks prior to start of pembrolizumab. Dose of pembrolizumab is 200 mg, every 3 weeks. Patients can continue the pembrolizumab treatment for maximal 2 years.
2561039|NCT02492568|Active Comparator|Pembrolizumab alone|Dose of pembrolizumab is 200 mg, every 3 weeks.Patients can continue the pembrolizumab treatment for maximal 2 years.
2561092|NCT02492152|No Intervention|Control group|Women who will not be using this medicine that is checked.
2561098|NCT02492152|Experimental|Study group|Women who will use DIANATAL according to manufacturer's protocol from the stage of active labor.
2561135|NCT02491814|Experimental|1% M.F. Milk and Breakfast Cereal|Breakfast meal: 250 ml 1% M.F. Milk, 54 g Cheerios breakfast cereal, 100 mL water
2561136|NCT02491814|Experimental|Yogurt Beverage and Breakfast Cereal|Breakfast meal: 250 ml Yogurt Beverage, 54 g Cheerios breakfast cereal, 100 mL water
2561137|NCT02491814|Experimental|Soy Beverage and Breakfast Cereal|Breakfast meal: 250 ml Soy Beverage, 54 g Cheerios breakfast cereal, 100 mL water
2561138|NCT02491814|Experimental|Almond Beverage and Breakfast Cereal|Breakfast meal: 250 ml Almond Beverage, 54 g Cheerios breakfast cereal, 100 mL water
2561140|NCT02491814|Experimental|Water (control) and Breakfast Cereal|Breakfast meal: 250 ml Water, 54 g Cheerios breakfast cereal, 100 mL water
2561190|NCT02491268|Experimental|Cilostazol 50mg B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Investigational Treatment:~Cilostazol 50mg B.I.D. p.o. 96 Weeks"
2561198|NCT02491268|Placebo Comparator|Placebo B.I.D.|"After the registration, the Site Investigators should start protocol treatment within 28 days including the day of registration.~Protocol treatment defines as follows;~Comparative Treatment:~Placebo B.I.D. p.o. 96 Weeks"
2561232|NCT02491125|Placebo Comparator|Placebo|12 weeks placebo maltodextrin 15g/day ( 5 g in beverage, to be consumed three times a day)
2561238|NCT02491125|Experimental|soluble wheat bran fibre|12 weeks soluble wheat bran fibre 15g/day (5 g in beverage, to be consumed three times a day)
2561299|NCT02490774|Experimental|Arm 1: BAY1007626, low relase|Intrauterine device with a low in vitro release rate
2561303|NCT02490774|Experimental|Arm 2: BAY1007626, low to medium release|Intrauterine device with a low to medium in vitro release rate
2561308|NCT02490774|Experimental|Arm 3: BAY1007626, medium release|Intrauterine device with a medium in vitro release rate
3174326|NCT00622245|Experimental|Lu AA34893: 18 mg|
3174327|NCT00622245|Other|Quetiapine fumarate|Active reference 300 mg
3174328|NCT00622245|Placebo Comparator|Placebo|
3174329|NCT00622258|Experimental|Everolimus|
3174330|NCT00622271|Other|Wait List Control|Patients and their families will be enrolled into either a treatment group or a wait list control (WLC) group to receive the group therapy intervention.
2560297|NCT02497664|Other|Active Breathing Control|Planning-CT will be made of patients using the Active Breathing Control Technique (in expiration and inspiration phase)
2560336|NCT02497352|Experimental|Flaxseed|30 g milled brown flaxseed + lifestyle modification
2560337|NCT02497352|Active Comparator|control|lifestyle modification including dietary and physical activity recommendation
2560366|NCT02497118|Experimental|Endostatin plus NP|drug:Endostatins Intravenous drip， 7.5mg/m^2, d1-14 drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
2560368|NCT02497118|Active Comparator|NP neoadjuvant chemotherapy|drug:vinorelbine Intravenous drip 25mg/m^2,IV, d1, d8; drug:Cisplatin，75mg/m^2 Intravenous drip,divide into d1-3 for 2 cycles
2560448|NCT02496819|Experimental|Metacognitive self-regulated learning intervention|It involves training of daily tasks using a self-correct strategy. Participants' performance will be video-taped and they will then watch the video playback for reflection and self-correction under the guidance of the occupational therapist.
2560450|NCT02496819|Experimental|Sensory Integration intervention|It involves active, fun physical activity completing 8 stations of activities involving tactile, proprioceptive and vestibular tasks. Frequent breaks will be given to avoid exhaustion and fatigue throughout the activities.
2560452|NCT02496819|Active Comparator|Activity-Based Intervention|It provides constructional, drawing and crafts activity. Participants are guided to complete these tasks
2560498|NCT02496429|Other|BrownieForSymphony use|Each participant will use the BrownieForSymphony pumpset
2560534|NCT02496104||Preterm infants|Preterm infants born between 25 weeks and 32 weeks + 6 days of gestation
2560538|NCT02496104||Term newborns|Infant born at term
3206436|NCT00954265|Active Comparator|Urinary-HCG group|These patients received u-HCG for ovulation triggering during ovarian stimulation for IVF
3206437|NCT00954265|Experimental|Recombinant HCG group|These patients received rec-HCG for ovulation triggering during ovarian stimulation for IVF
3206438|NCT00954278|Experimental|sorafenib|
3206439|NCT00954291||Granisetron|14 mg Granisetron
2560781|NCT02494648|Experimental|Inspiratory muscles strengthening|"The device used is : POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK).~Class I, CE labelled. POWERbreathe fitness Plus uses the technique of training against resistance to increase the strength, the power and the endurance of the respiratory muscles (diaphragm and rib cage)."
2560783|NCT02494648|Placebo Comparator|Control|No intervention
3206440|NCT00954304|Experimental|1mg group|Administration of HM30181AK 1mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3206441|NCT00954304|Experimental|5mg group|Administration of HM30181AK 5mg on day 4 and Loperamide 16mg(Loperamide 2mg x 8cap) on day 1,4,8,11,15
3206442|NCT00954304|Experimental|10mg group|Administration of HM30181AK 10mg(HM30181AK 5mg x 2tab)on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
2560956|NCT02493270|Experimental|Adjunctive smoking cessation|non-surgical periodontal therapy and concurrent smoking cessation therapy
2560992|NCT02492906||Osteoarthrosis group|Patients with primary severe knee osteoarthrosis or with chronic knee pain.
2560996|NCT02492906||Healthy patients|Healthy patients
2561038|NCT02492542|Experimental|Electric Stimulation Treatment|Patients in the intervention group were treated with electric stimulation based on the routine clinical nursing.
2561040|NCT02492542|No Intervention|control group|patients in this group only received routine clinical nursing without electric stimulation
2561093|NCT02492217|Experimental|Adalimumab|Adalimumab will be provided to trial participants as 0.8 ml single dose pre-filled syringes containing 40mg adalimumab each. A kit will be dispensed to he subject every two weeks, each kit containing one syringe.
2561119|NCT02491801|Experimental|3.25% M.F. Milk|3.25% M.F. Milk
2561121|NCT02491801|Experimental|Greek Yogurt|Greek Yogurt (2% M.F.)
2561123|NCT02491801|Experimental|Cheddar Cheese|Regular Fat Cheddar Cheese
2561128|NCT02491801|Experimental|Control 1|Skim milk
2561133|NCT02491801|Experimental|Control 2|Filtered water, calorie-free control
2561201|NCT02491502|Experimental|Echopulse|Echopulse HIFU
2561229|NCT02491138|Placebo Comparator|Standard information|In this arm, participants will receive standard information pamphlets about the benefits of good sleeping habits.
2561234|NCT02491138|Experimental|Appearance-based information|In this arm, participants will receive information about how sleep modifies their physical appearance. This will involve a computer transformation that morphs their face according to hours of sleep obtained.
2561306|NCT02490787|Experimental|Concizumab|
2561310|NCT02490787|Placebo Comparator|Placebo|
2561400|NCT02490020|Experimental|iv of BMSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC iv(2*10^6cell/kg, 48h before op)
2561403|NCT02490020|No Intervention|routine treatment protocol to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
2561408|NCT02490020|Experimental|ia and iv of MSC to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)+BMSC (iv 2*10^6cell/kg + ia 5*10^6cell, 48h before op)
2561410|NCT02490020|No Intervention|routine treatment to prevent rejection|Routine treatment protocol(ATG 50mg*3;MP 2.0g to Pred 30mg,then maintaining 5mg qd;MMF 1.0 bid from the first day after op,then maintaining 1-1.5g/d;Plus CNI from the third day after op)
2561411|NCT02490020|Experimental|Routine CMR treatment plus MSC to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)+MSC( iv 2*10^6cell/kg at d1,d7)
3206443|NCT00954304|Experimental|15mg group|Administration of HM30181AK 15mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3206444|NCT00954304|Experimental|60mg group|Administration of HM30181AK 60mg on day 4 and Loperamide 16mg (Loperamide 2mg x 8cap) on day 1,4,8,11,15
3206445|NCT00954317|Active Comparator|Low epidural|epidural placed in the lower lumbar vertebral column
3206446|NCT00954317|Experimental|high epidural|high epidural
2560317|NCT02497495|Experimental|G3|G3 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 9±1 degrees Celsius
2560319|NCT02497495|Experimental|G4|G4 (n = 21) was subjected to a recovery procedure by immersion cold water for 15 minutes as from 14±1 degrees Celsius
3206447|NCT00954330|Experimental|surgery|All twenty-five patients underwent ligament repair, where the ruptured ends of the FTA (in 11 cases) or FTA and FC (in 14 cases) ligaments were rejoined by using absorbable sutures. A supine position and a tourniquet were used. A curvilinear skin incision of 5-10 cm was made; the retinacular structures were incised and the hematoma was removed.
2560449|NCT02496637|Experimental|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
2560451|NCT02496637|Active Comparator|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
2560453|NCT02496637|No Intervention|No Treatment Control|No intervention, assessment only
2560507|NCT02496468||new-onset wheeze/asthma|children with inhaled or systemic corticosteroid-/leukotriene receptor antagonist-naïve wheeze/asthma, will undergo follow-up after initial recruitment
2560514|NCT02496468||wheeze/asthma under controller therapy|children with wheeze/asthma, already under controller (inhaled or systemic corticosteroids or leukotriene receptor antagonist) therapy, will undergo follow-up after initial recruitment
2560516|NCT02496468||healthy controls|healthy age- and sex-matched controls, will not undergo follow-up after initial recruitment
2560540|NCT02495896|Experimental|Arm A (sEphB4-HSA, nab-paclitaxel, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, 15, and 22 (beginning course 2), paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2560542|NCT02495896|Experimental|Arm B (sEphB4-HSA, docetaxel)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2) and docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2560545|NCT02495896|Experimental|Arm C (sEphB4-HSA, cisplatin, gemcitabine hydrochloride)|Patients receive recombinant EphB4-HSA fusion protein IV over 1 hour on days 1, 8, and 15 (beginning course 2), cisplatin IV over 120 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2560644|NCT02495298|Experimental|Treatment Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
2560652|NCT02495298|Sham Comparator|Placebo Fascial Manipulation|Seven patients with diagnosis of CTS, received five sessions of Sham Fascial Manipulation performed by a physiotherapist. The sessions were performed once a week, and each session were 30 to 45 minutes long as to cover different painful spots.
2560698|NCT02495051||single group-study|
2560756|NCT02494674|Experimental|Bite Counter tracking|Study participants will be asked to track their energy intake via a wearable device called the Bite Counter. Participants will attend weekly meetings to provide feedback on the Bite Counter.
2560794|NCT02494375|Experimental|Sleep and glucose assessement.|
2560827|NCT02494154|Active Comparator|Conventional flow via nasal prongs|Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.
2560834|NCT02494154|Experimental|High flow nasal cannulas 20L/min|Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.
2560837|NCT02494154|Experimental|High flow nasal cannulas 40L/min|Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
2560839|NCT02494154|Experimental|High flow nasal cannulas 60L/min|Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.
2560884|NCT02493725|Active Comparator|Eculizumab|Eculizumab, 900 mg intravenously once a week
2560888|NCT02493725|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
2560973|NCT02493322|Experimental|Test 1: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 12,5 mg) a day, in the morning.
2560974|NCT02493322|Experimental|Test 2: Olmesartan + Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 20 mg + Chlorthalidone 25 mg) a day, in the morning.
2560975|NCT02493322|Experimental|Comparator: Benicar HCT®|The patients will take 1 tablet (Olmesartan 20 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
2561020|NCT02492503|Active Comparator|pacli carb 3|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
2561021|NCT02492503|Active Comparator|pacli carb 1|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
2561069|NCT02492360||Severe Toxicity Group|Diagnosis of testicular cancer; History of any grade 3 or higher peripheral neuropathy after receiving standard dose cisplatin completed more than 1 year but within the last 5 years; Long-term persistence (> 6 months) of grade 2 or higher peripheral neuropathy after completion of a cisplatin containing regimen. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
2561074|NCT02492360||Control Group|Diagnosis of testicular cancer; No history of neurotoxicity (grade 0-1) after completion of a standard cisplatin-containing chemotherapy regimen completed more than 1 year but within the last 5 years; Matched to a specified subject with neurotoxicity based on age (within 10 years), chemotherapy regimen or total cisplatin dosage. Interventions: blood sample collection and report of peripheral neuropathy after cisplatin therapy.
2561161|NCT02491879|Experimental|Ketoprofen|Ketoprofen gel
2561163|NCT02491879|Placebo Comparator|Placebo|Placebo form of ketoprofen gel
3208841|NCT00978601|Experimental|Multimodal analgesic protocol group|Women who received the multimodal analgesic protocol during minimally invasive myomectomy.
3206448|NCT00954330|Active Comparator|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle
3206449|NCT00954343|Experimental|Group I|
3206450|NCT00954343|Experimental|Group II|
3206451|NCT00954343|Experimental|Group III|
2560755|NCT02494635||Diagnostic (ultrasound, biomarker studies)|Previously collected tumor tissue samples, bladder washings, and urine cells are stained with calcium dye, washed and immersed in external buffer solution, and then transferred to the ultrasound imaging system. Tissue, bladder wash cells and urine cells samples are also analyzed for biomarkers of invasiveness derived from or related to REST gene via qRT-PCR, Western blot, and FISH.
2560797|NCT02494362|Experimental|Experimental Group|Computer gaming hand exercise regimen.
3206452|NCT00954343|Experimental|Group IV|
3206453|NCT00954343|No Intervention|Group V|
3206454|NCT00954369|Experimental|[F-18]W372|Approximately twenty (20) adult subjects including ten (10) healthy volunteers and ten (10) high probability AD subjects, as defined by protocol criteria
3206455|NCT00954382||IQ trend|all subjects
2560978|NCT02492789|Experimental|INCSHR01210|"3 dose levels are designed in this study.3 to 6 patients (traditional 3+3 design) will be enrolled in each dose cohort. INCSHR01210 injection at each dose level is administered every 2 weeks (q2w, except in the first cycle)."
2561028|NCT02492594||Pediatric patients with febrile neutropenia|Peripheral blood sampling - samples from 200 pediatric patients with severe immunosuppression and neutropenic fever will be analyzed
2561029|NCT02492594||Adult patients with febrile neutropenia|Peripheral blood sampling - samples from 200 adult patients with severe immunosuppression and neutropenic fever will be analyzed
2561071|NCT02492256|Active Comparator|PVI group|Conventional PVI by circumferential antral ablation according to standard procedures.
2561075|NCT02492256|Experimental|PVI+GP guided by SUMO technology group|Conventional PVI by circumferential antral ablation according to standard procedures and atrial ganglionated plexi ablation guided by the SUMO technology.
3206456|NCT00954395||1. anticoagulation suspension|eligible patients undergo measurement of residual venous obstruction (RVO) with compression ultrasound (CUS) in case of a previous deep vein thrombosis (DVT) and/or of pulmonary artery pressure (PAP) with echocardiography in case of previous pulmonary embolism (PE). In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is below age and gender cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If all the D-dimer measurements are below the cut-offs, anticoagulation is definitely interrupted and patients are followed-up for two years.
3208842|NCT00978601|No Intervention|No use of multimodal analgesic protocol group|Women who did not receive the multimodal analgesic protocol during minimally invasive myomectomy.
2561260|NCT02490917|Experimental|ACT™ device|Patients randomized to receive the Adjustable Continence Therapy device ACT™
2561262|NCT02490917|Other|AMS 800 ™ device|Patients randomized to receive the artificial urinary sphincter AMS 800 ™
2561288|NCT02490592|Experimental|G1|Thirty children aged seven to twelve years who had seventy one active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride foam, Flúor Care (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
2561292|NCT02490592|Experimental|G2|Twenty-eight children aged seven to twelve years who had seventy five active white spots lesions in permanent anterior teeth randomly assigned to four or eight weekly intervals applications of fluoride gel, Flugel FFA (NaF 1.23%), to verified the activity (visual scores) and the dimensional changes of whit spot lesions (with WHO probe and millimeter ruler), caries Management by Risk Assessment (CAMBRA) and OHI-S (Simplified Oral Hygiene Index) of children.
2561362|NCT02490358||1|Healthy smoking subjects
2561363|NCT02490358||2|COPD smoking subjects
2561364|NCT02490358||3|COPD ex-smoker subjects
2561453|NCT02489929|Experimental|patient suffering of MDS or Myeloid leukemia|The patients suffering of MDS or Acute myeloid leukemia will be the object of 8 sampling of blood (on tube EDTA) distributed as this: the first day of the usual treatment (azacytidine) at T0, T30 MIN, T60 MIN, T90 MIN, T120 MIN, then a second series of taking in the 5th day of treatment at T0, T30 MIN, T90 MIN to determine cytidine deaminase (CDA) activities by following its plasmatic dosage
2561485|NCT02489370|Experimental|Telemonitoring (intervention)|"an intervention arm testing the proposed telemonitoring service and a control arm with the current treatment.~Patients assigned to the intervention arm receive a home telemonitoring kit consisting of a tablet, a wireless weight scale and a portable blood pressure meter. The patient is asked to weigh him- or herself every day and the monitoring procedure happens as previously described. In addition a measurement of the blood pressure is also made."
2561486|NCT02489370|No Intervention|Usual care (control)|Patients assigned to the control arm receive treatment as usual, consisting of a recommendation to weigh themselves at home, using their own weight scale, and to report by phone to the polyclinic if there is a significant change in weight.
2561510|NCT02489162|Experimental|MyotonPRO|Experimental: Measurement of biomechanical properties of mimic muscles on the ipsilateral palsy side with the healthy contralateral side ( case - control design)
2561517|NCT02489162|Active Comparator|Non-invasive electromyography (EMG)|Comparing experimental intervention with gold standard
2561590|NCT02488694|Experimental|Arm A: Afatinib|105 patients to be treated with afatinib
2561591|NCT02488694|Active Comparator|Arm B: Pemetrexed|105 patients to be treated with pemetrexed
3208843|NCT00978614|Experimental|Neramexane, Placebo, Moxifloxacin|
3208844|NCT00978640|Experimental|fasting and exercise|36 h fast and 1 h ergometer cycling 50% VO2max
3208845|NCT00978640|Experimental|exercise|1 h ergometer cycling 50% VO2max
3208846|NCT00978653|Experimental|Allopurinol|Hyperuricemic (uric acid (UA)>7 mg/dL), nondiabetic CKD patients without any comorbidity, age<60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.
3208847|NCT00978666||Healthy controls|Healthy comparison adolescent females
2560331|NCT02497443|Experimental|study group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.anti-epileptic drugs [AEDs]) and receiving autologous mesenchymal stem cells
2560333|NCT02497443|No Intervention|control group|Pts undergoing carbamazepine, valproic acid, topiramate, lamotrigine, or phenobarbital (i.e.AEDs)
2560375|NCT02497157|Experimental|Treatment Arm|Patients receive FOLFOXIRI plus bevacizumab [oxaliplatin (L-OHP): 85 mg/sq.m., irinotecan hydrochloride hydrate (CPT-11): 165 mg/sq.m., continuous intravenous infusion of fluorouracil (CIV 5-FU): 3,200 mg/sq.m., Levofolinate calcium (l-LV): 200 mg/sq.m., bevacizumab: 5 mg/kg]. The treatment will be repeated every 2 weeks, for up to 12 cycles, unless the disease progression, unacceptable toxicity, tumor resection or consent withdrawal.
2560422|NCT02496754|Experimental|New protocol group|Use long term GnRH-a 3.75mg at day 2 of menstrual cycle. Around 30 days later, controlled ovarian hyperstimulation using gonadotropins is initiated.
2560427|NCT02496754|Active Comparator|Standard GnRH-a long protocol|Use short GnRH-a 0.1mg at luteal phase of last menstrual cycle for 10 days and 0.05mg for another 4 days. Once pituitary down regulation is achieved,controlled ovarian hyperstimulation using gonadotropins is initiated. During ovarian stimulation, short GnRH-a is used daily at the dose of 0.05mg until human chorionic gonadotrophin (HCG) trigger.
2560491|NCT02496546|Experimental|LEO 32731 cream|Topical application
2560493|NCT02496546|Placebo Comparator|LEO 32731 cream vehicle|Topical application
2560539|NCT02496169|Experimental|eucaLimus|Percutaneous Coronary Intervention (PCI)
3206457|NCT00954395||2. anticoagulation prolongation|If RVO is greater than 4 mm at CUS of the lower limbs and/or PAP is increased (> 35 mmHg, > 40 mmHg in the elderly or obese), anticoagulation is prolonged for additional 6 months and the measures of RVO and/oR PAP are repeated. In those in whom PAP is altered also after 6 months of additional therapy, anticoagulation is prolonged. In patients with RVO is less < 4 mm in case of a previous DVT and/or PAP is normal with echocardiography in case of previous PE and in those who have undergone additional 6 months of therapy for previously altered RVO, D-dimer is measured during anticoagulation. If D-dimer is above age and gender cut-offs , anticoagulation is prolonged. If D-dimer is below the cut-offs , anticoagulation is interrupted and D-dimer is then re-assessed after 15, 30, 60 and 90 days. If one of these D-dimer measurement is above the cut-off , anticoagulation is resumed for at least 6 months and patients are re-evaluated.
3206458|NCT00954408||Patients with dystonia|Patients with dystonia, 21-100 years of age.
2560733|NCT02494843|Active Comparator|Online haemodiafiltration|
2560739|NCT02494843|Active Comparator|Haemodialysis|
3206459|NCT00954434|Experimental|red wine|intervention: dietary supplement intake of red wine on a daily basis, 1 glass/day for women, 2 for men
2560881|NCT02493699|Experimental|Exercise|physical exercise- based intervention (Karate techniques training)
2560886|NCT02493699|No Intervention|Control|Not participating in physical exercise- based intervention (Karate techniques training)
3206460|NCT00954434|No Intervention|total abstention from alcohol|
3206461|NCT00954473||Ancillary-correlative (osteosarcoma genetic risk)|Blood samples undergo polymorphism analysis of common single-nucleotide polymorphisms and haplotypes to examine genetic variation, gene-gene interactions, and the population structure.
3206462|NCT00954486|Experimental|Epoetin alfa, 10,000 units/week|Epoetin alfa is a recombinant erythropoietin.
2561149|NCT02491645|Experimental|Intervention group|"Children would receive both standard therapy and home based sensory interventions as described below,~Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs .~Home based sensory interventions - children would receive home based sensory interventions targeting visual and auditory system, tactile abnormalities, proprioceptive and vestibular abnormalities.These interventions would be carried out daily , at least 5 days a week, for a minimum duration of 1hour/day."
2561157|NCT02491645|No Intervention|Control group|This group of children would receive only standard therapy as described below, Standard therapy - children would receive measures like speech and language services, behavioral interventions and educational program regularly as and when decided by the primary care physician. They would be individualized to child specific needs.
2561202|NCT02491372|Experimental|Intervention|Acceptance and commitment therapy group
2561209|NCT02491372|No Intervention|Comparison|Treatment as usual
2561243|NCT02491164|Experimental|BAC TWO administration|All participants in this clinical study will be dosed on one occasion with BAC TWO. The final dosage will be 80 µg (± 25%).
2561286|NCT02490748|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
2561291|NCT02490748|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
3206463|NCT00954499|Active Comparator|Standard care|
3206464|NCT00954499|Experimental|Tactile stimulation|
2561398|NCT02489955|Experimental|AUC group|
2561399|NCT02489955|Active Comparator|Trough dose monitoring|
2561511|NCT02489513|Other|Single group assignment|[14C]-AG-120
3206465|NCT00954525|Experimental|Intravenous Vitamin C|
2561603|NCT02488473|Experimental|Ropivacaine + Dexmedetomidine|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Dexmedetomidine 100ug/ml
2561604|NCT02488473|Placebo Comparator|Ropivacaine + Placebo|Adductor Canal Block 20 ml Ropivacaine 5mg/ml + 1 ml Saline
2561646|NCT02488252|Active Comparator|Standard medical care|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker and oral hypoglycemic agents or insulin at stable dose
2561701|NCT02487901|Active Comparator|Ultrasonic osteotome|making gutter on the hinge side of lamina with ultrasonic osteotome
2561707|NCT02487901|Sham Comparator|Drill|making gutter on the hinge side of lamina with conventional drill
2562118|NCT02485041|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
3206466|NCT00954551||All adult patients with SAH in ICU|All adult patients admitted for an expected ICU stay of more than 24 hrs over a 6-month period (tentative) between xx and xx 2009 with a diagnosis of SAH will be prospectively evaluated.
2560363|NCT02497196|Experimental|Part 2: Active tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and active tDCS (1/4 combinations all subjects will receive).
2560364|NCT02497196|Experimental|Part 2: Active tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving active tPCS and sham tDCS (1/4 combinations all subjects will receive).
2560365|NCT02497196|Experimental|Part 2: Sham tPCS/Active tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and active tDCS (1/4 combinations all subjects will receive).
2560367|NCT02497196|Sham Comparator|2: Sham tPCS/Sham tDCS|Part 2 will run as a four-period crossover design, where all chronic visceral pain subjects (18 total) will be receiving all (4) possible combinations of tDCS and tPCS interventions (active or sham) at the end of the experiment in a random, consecutive way. This represents the combination of receiving sham tPCS and sham tDCS (1/4 combinations all subjects will receive).
2560421|NCT02496728|Experimental|Cardiovascular Health|Participants will be given the results of their health assessment and feedback regarding their health behaviors and overall health. Recommendations for change will be given if warranted. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor health behaviors that are not already at ideal levels using the study application (environmental cues). Participants will be asked to join a secret Facebook group where informational materials will be posted, participants can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
2560423|NCT02496728|Active Comparator|Whole Health|Participants will be given the results of their health assessment. They will then receive educational materials about sunscreen use, safe sex, hydration and vehicular safety. Participants will download the study's mobile health application on their smartphone. They will then be asked to report once a week about their health behaviors on the application. Participants will also be asked to self-monitor how much water they drink using the study application. Participants will be asked to join a secret Facebook group where informational materials will be posted, they can post about study health behaviors and social interaction around health behaviors can occur (social support and environmental cues).
2560511|NCT02496442|Active Comparator|using Aqueduct|Patients passing procedures with Aqueduct
2560515|NCT02496442|No Intervention|Not using Aqueduct|Patients passing the standard procedures
3206467|NCT00954590|Experimental|Dimebon (latrepirdine)|Dimebon, 20 mg orally three times daily
3206468|NCT00954590|Placebo Comparator|Placebo|Placebo orally three times daily
3206469|NCT00954603|Experimental|quetiapine|atypical antipsychotic drug
3206470|NCT00954603|Active Comparator|haloperidol|typical antipsychotic drug
3206471|NCT00954629|Experimental|2PX|Pain medication
3206472|NCT00954629|Placebo Comparator|Placebo|
2560737|NCT02494739|Experimental|Yogurt enriched with polyphenols|Two yogurts (400g) enriched with polyphenols (10mg/100g yogurt) per day, for two weeks.
2560742|NCT02494739|Placebo Comparator|Yogurt not enriched with polyphenols|Two yogurts (400g) not enriched with polyphenols per day, for two weeks.
2560761|NCT02494453||Cardiac MRI|
2560828|NCT02493920|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room; the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
2560832|NCT02493920|No Intervention|Control|Preterm infants will be assisted in the delivery room with a continuous positive airway pressure (CPAP) of 5 cmH2O with mask and the parameters of respiratory mechanics will be monitored for 5 minutes by means of the forced oscillation technique.
3206473|NCT00954642|Experimental|A|
3206474|NCT00954642|Experimental|B|
2560951|NCT02493283|Active Comparator|Treatment A|single-dose administration of 100 mg dapsone; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
2561311|NCT02490774|Experimental|Arm 4: BAY 1007626, high release|Intrauterine device with a high in vitro release rate
3206475|NCT00954655||Group 1|Tumor samples are used for polymorphism and mutation analysis.
3206476|NCT00954668|Experimental|immediate angiography|Immediate invasive angiography < 2 h after randomization
3206477|NCT00954668|Active Comparator|early invasive angiography|early invasive angiography 12-72 h after randomization
3206478|NCT00954694|Experimental|introductory exercise regimen|sedentary adults will be introduced to an introductory fitness regimen using the NuStep
3206479|NCT00954720||Patient undergoing transplant|Patients with acute leukemia or MDS undergoing ablative stem cell transplantation. No intervention.
3206480|NCT00954746||Follow-up|Subjects Previously Treated with AA4500
3206481|NCT00954759|Experimental|Chiropractic treatment|Manipulation and/or mobilisation
3206482|NCT00954759|Placebo Comparator|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
3206483|NCT00954772||Staged Bilateral STN DBS|
3206484|NCT00954772||Simultaneous Bilateral STN DBS|
3206485|NCT00954785|Placebo Comparator|Placebo drug|
3206486|NCT00954785|Experimental|Etoricoxib|
3206487|NCT00954785|Active Comparator|Diclofenac|
3206488|NCT00954798|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
2560392|NCT02497092|Active Comparator|Fast straight injection|fast and straight insertion of the needle through the sclera
2560444|NCT02496793|Experimental|Peer Facilitator and Support Group|Peer-facilitated community support group is the experimental intervention. The intervention tested in this study involved using trained peer facilitators to create demand for and retention within the ANC/PMTCT program.The peer facilitators were volunteer women from the community, who had recently been through the ANC process themselves and could speak about their experience(s). the support group meetings was to develop skills and generate self-efficacy for the women to be able to take actions such as routine antenatal and postnatal clinic attendance using participatory learning techniques. The peer facilitators were provided with job aids which outlined key points for the various educational sessions.
2560447|NCT02496793|No Intervention|Standard Care|ANC/PMTCT activities as per standard of care in Zimbabwe
3206489|NCT00954798|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13.
3206490|NCT00954798|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 vaccine formulation 3
2560532|NCT02496117|Active Comparator|RNS-checked RDN|20 patients with hypertension will be enrolled undergoing RNS-checked RDN
2560536|NCT02496117|Experimental|RNS-guided RDN|20 patients with hypertension will be enrolled undergoing RNS-guided RDN
2560567|NCT02495792|No Intervention|Control group|Group does not receive the biofeedback sensor
2560568|NCT02495792|Experimental|Biofeedback group|Group does receive the biofeedback sensor
2560616|NCT02495662|Experimental|Liposomal prednisolone|Treatment with polyethylene glycol (PEG)-liposomal prednisolone sodium phosphate 150mg in 500ml saline intravenously at 1 and 15 days post surgery.
2560619|NCT02495662|Placebo Comparator|Placebo|Treatment with 500ml normal 0.9% saline intravenously at 1 and 15 days post surgery.
2560674|NCT02495311||Women with uterine myoma|Women with uterine myoma
2560679|NCT02495311||Women with adenomyosis|Women with adenomyosis
2560681|NCT02495311||Women without uterine myoma or adenomyosis|Control group
2560730|NCT02494869|Experimental|Nonlinear Aerobic Training (75 minutes/week) closed to accrual|The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
2560735|NCT02494869|Experimental|Nonlinear Aerobic Training (150 minutes/week)|The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
2560740|NCT02494869|Experimental|Nonlinear Aerobic Training (300 minutes/week)|The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
2560747|NCT02494869|Active Comparator|General Physical Activity|Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
3206491|NCT00954811|Active Comparator|HCG for ovulation triggering and luteal progesterone|conventional triggering with HCG and conventional luteal support with progesterone
2560863|NCT02493959|Experimental|PYY infusion|IV infusion on 4 separate days of PYY or saline in Healthy, normal-weight men, age 18-50 years
2560977|NCT02492828||Patients for filled prescriptions for apixaban|
2560979|NCT02492828||Patients for filled prescriptions for warfarin|
2561065|NCT02492204||Survivors|
2561068|NCT02492204||Non survivors|
3206492|NCT00954811|Experimental|Agonist triggering and rec-LH luteal support plus progesterone|new method of triggering with GnRH-agonist and proof of concept intervention with novel way of luteal support with rec-LH plus the usual co-treatment with progesterone
2561187|NCT02491307|Experimental|Ginger.io Application Users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have a diagnosis for anxiety, depression, and/or bipolar disorder; and 4) are active behavioral health patients at any of the four CHCI clinic sites (New London, New Britain, Middletown, or Meriden) where behavioral health providers are using the Ginger.io app with their patients. These patients receive the Ginger.io smartphone application for daily use.
3206493|NCT00954837|Other|Fine needle aspiration|Patient with solid nodules more than 10 mm in diameter will be biopsied by ultrasound-guided fine-needle aspiration(FNA)after consultation with an endocrinologist or ENT specialist.
3206494|NCT00954850||Severe asthmatics|Main study group
3206495|NCT00954850||Mild-moderate asthmatics|Control group
3206496|NCT00954889|Experimental|Tamsulosin|
3206497|NCT00954889|Placebo Comparator|placebo|
3206498|NCT00954902|Sham Comparator|No spice, no stress|Subject are given placebo capsules and told they contain an antioxidant concentrate
3206499|NCT00954902|Sham Comparator|No Spice, Stress|Subjects are given placebo capsules and told they are receiving an equivalent amount of an antioxidant concentrate.
3206500|NCT00954902|Experimental|Spice, no stress|
2560456|NCT02496624|Other|Lung cancer|
2560551|NCT02496065|Experimental|BLZ-100|
2560579|NCT02495740|Experimental|E-bike intervention|Intervention is active commuting to work by an electric assisted bike to work for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
2560583|NCT02495740|Active Comparator|Bike intervention|Intervention is active commuting to work by classic bike for a period of 4 weeks at least 3 times per week with a minimal distance of 6 km per way
2560625|NCT02495545|Experimental|CSFD with elevation of MAP|Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
2560629|NCT02495545|Active Comparator|Maintenance of MAP|Subjects will receive elevation of MAP (norepinephrine drip; goal 85-90 mm Hg). Target MAP will be sustained within 85-90 mmHg in the control group for 5 days. Duration of elevation of MAP treatment will be 120 hours (5 days) from time treatment is (time 0). Subjects will receive the same treatment as the subjects in investigational arm except for the initiation of the CSFD and less aggressive MAP elevation. They will have a drain placed the same way as the experimental subjects. While drain is in place, 10 mL of cerebrospinal fluid will be collected daily for laboratory testing. After that, ITP will be monitored but CSFD will not be initiated. Subjects will receive other treatment per standard of care at participating investigational sites.
3206501|NCT00954902|Experimental|Spice and Stress|
3206502|NCT00954928||Anticoagulated patients|Those patients taking Coumadin, Plavix, Aspirin, Lovenox.
3206503|NCT00954928||Control patients|Those patients having hand or wrist surgery who do not take any anticoagulant medication.
2560754|NCT02494609|Experimental|Treatment A|once daily dosing for 7 days, followed by 7-day washout
2560757|NCT02494609|Experimental|Treatment B|once daily dosing for 28 days
2560759|NCT02494609|Experimental|Treatment C|once daily dosing for 14 days of oral contraceptive, followed by coadministration with sotagliflozin once daily for 7 days
3206504|NCT00954954|Active Comparator|Standard|Knees that will be implanted with standard posterior stabilized RP-MB knee prostheses
2560847|NCT02493972|Experimental|manual exploration by GelPort|manual exploration in supplement of coelioscopy before laparotomy
2560894|NCT02493595||Cancer|Patients attending One-stop Symptomatic Breast Care clinics with suspicion of a breast lesion in one or both breasts.
2560969|NCT02493049|Experimental|Domperidone|Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks
2560970|NCT02493049|No Intervention|No add on treatment|No add on treatment. Control group
2560982|NCT02492737|Experimental|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression, development of other unacceptable toxicity or Investigator discretion
3206505|NCT00954954|Active Comparator|High-flexion|Knees that will be implanted with high-flexion posterior stabilized RP-MB knee prostheses
3206506|NCT00954967|No Intervention|Usual care|The subjects in the control group will receive the usual care for smoking cessation in diabetic smokers.
3206507|NCT00954967|Experimental|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
3206508|NCT00954980||Endovenous Sclerotherapy|For those who have been diagnosed with varicose veins of the leg and have been scheduled to undergo an endovenous sclerotherapy procedure
2561185|NCT02491632|Experimental|Arm I (high-dose dexamethasone, physical activity)|Patients receive high-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
2561191|NCT02491632|Experimental|Arm II (low dose dexamethasone, physical activity)|Patients receive low-dose dexamethasone PO BID for 7 days. Patients also follow a graded resistance exercise program 3 days a week and a walking regimen at least 5 days a week for 4 weeks. The frequency, duration, and intensity of the exercises will be evaluated and adjusted as necessary.
2561322|NCT02490501|Active Comparator|SC0806|Intervention with SC0806 (implantation of device with FGF1 and peripheral nerves) in addition to rehabilitation
2561326|NCT02490501|Other|Controls|Rehabilitation only
2561394|NCT02490254||1|Any child (aged 0-16 years) with a new diagnosis of uni or bilateral uveitis.
2561431|NCT02489812|Experimental|music|The Mozart Symphony No 40 in G minor K550 was played in headphones. While the child received restorative treatment in the teeth she heard music in a session and was subjected to other dental treatment session without listening to music. The cardiac and respiratory frequencies were measured with children's finger oximeter while the child listened to music and also in session in which she did not hear music. Changes in the measurements obtained by the oximeter showed levels of anxiety.
2561487|NCT02489526|Experimental|VVZ-149 Injections|
2561488|NCT02489526|Placebo Comparator|Placebo|
3206509|NCT00955006|Experimental|Group 1|Participants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
3206510|NCT00955045|Experimental|istradefylline|
2560412|NCT02496949|Experimental|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
3206511|NCT00955058|Active Comparator|cyproterone compound|Before and after treatment
3206512|NCT00955058|Experimental|oral contraceptive pill|Treatment
2560519|NCT02496247|Experimental|Immediate Herring|Participants in this arm will receive the Canned Herring intervention. Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child), which will be distributed weekly by community health workers. Families will be instructed to feed the study child half a can of herring per day (without reducing usual home food given to the child), and to not share the remaining herring with individuals who are in the Delayed Herring study arm. When families come to collect their weekly distribution they will be asked to bring in at least 7 empty herring cans in order to receive the next ration, and will answer a question about how often the child eats the herring.
2560520|NCT02496247|No Intervention|Delayed Herring (Control)|Families with children in this study arm will not receive any herring during the 8-10 week period when Immediate Herring families receive a weekly ration of herring. After the 8-10 week (end line) measurements, an equal amount of herring will be distributed to the family.
2560617|NCT02495935|Experimental|OkuStim®|The OkuStim® group will undergo 30-minute treatments once a week for 12 weeks at 200% threshold level according to their individual phosphene threshold (IPT) readings from the OkuStim® device at the pre-treatment visit (week 1). Rectangular biphasic current pulses (1-ms positive, directly followed by 1-ms negative) will be applied at a frequency of 20 Hz.
2560620|NCT02495935|Sham Comparator|Sham-OkuStim®|Subjects in the Sham-OkuStim® group will wear treatment glasses and corneal electrodes for 30 minutes weekly for 12 weeks, but corneal electrodes will not be activated.
3206513|NCT00955071|No Intervention|Control|
3206514|NCT00955071|Active Comparator|Exercise: LVLI|low volume, low intensity
2560816|NCT02494193|Active Comparator|Regular Treatment|Partial caries removal; Provisional restoration - control; Total caries removal; Definitive restoration.
2560818|NCT02494193|Experimental|Alternative Treatment|Partial caries removal; Provisional restoration - experimental; Total caries removal; Definitive restoration.
3206515|NCT00955071|Active Comparator|Exercise: HVLI|high volume, low intensity
3206516|NCT00955071|Active Comparator|Exercise: LVHI|low volume, high intensity
2561070|NCT02492191|Active Comparator|RAPP, e- assessed follow-up|"A mobile application (app) is installed on each patient's own smartphone. The app includes the Swedish web version of the QoR (SwQoR). After a patient is discharged from the day-surgery department, the patients in the intervention group will answer the RAPP daily for 14 days. His or her smartphone will initiate the postoperative recovery measurements daily through a push function. Each question will appear separately on the mobile phone screen and will disappear from the screen immediately after a response is given. The app also contains a question asking if the patient wants to be contacted by a nurse, which they will answer with a YES or NO. If YES, a nurse at the day surgery department will contact the patient and offer further information and assistance. The number of contacts and the reasons for contact requests will be documented."
2561076|NCT02492191|No Intervention|Control|The control group will receive standard care; i.e., no follow-up
2561130|NCT02491970|Experimental|Fluticasone/Formoterol|Brand name: Flutiform Dose: 250/10μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
2561132|NCT02491970|Active Comparator|Fluticasone/Salmeterol|Brand name: Seretide Dose: 250/50μg (2 puffs/once, BID) Duration of treatment: 12 weeks Mode of administration: oral inhalation
2561173|NCT02491554|Active Comparator|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based DBS implantation in the thalamic/subthalamic region (Vim-cZI) starting as awake surgery with a brief general anesthesia for stimulator implantation at the end of surgery.
2561175|NCT02491554|Experimental|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided DBS implantation in the dentato-rubro-thalamic bundle (DRT) in general anesthesia.
2561244|NCT02491177|Other|cMM and Text Messaging|Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention. The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
3206517|NCT00955097|Experimental|Definity Contrast Dye|During liver surgery Definity contrast dye will be administered follwed by an ultrasound to better detect liver tumors
3206518|NCT00955123||Active inflammatory bowel disease|Patients with moderate to severe active inflammatory bowel disease (ulcerative colitis and Crohn's disease)
3206519|NCT00955136|Experimental|High MI impulses, myocardial infarction, echocardiography|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
3206520|NCT00955149|Experimental|Arm A|Erlotinib (Tarceva) 25 mg by mouth once daily.
3206521|NCT00955149|Experimental|Arm B|Erlotinib (Tarceva) 50 mg by mouth once daily for 6 months
3206522|NCT00955162|Active Comparator|Subutex|
3206523|NCT00955162|Experimental|Suboxone|
3206524|NCT00955175|Experimental|Group 1|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 24 fractions (total of 72 Gy).
3206525|NCT00955175|Experimental|Group 2|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 22 fractions (total of 66 Gy).
3206526|NCT00955175|Experimental|Group 3|Patients undergo hypofractionated 3-dimensional conformal radiotherapy 5 days a week for 20 fractions (total of 60 Gy).
3206527|NCT00955214|Experimental|2.5mm Paclitaxel-eluting stent|
3206528|NCT00955227|No Intervention|Statins only|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. Patients in this arm will be excluded if they are on ezetimibe.
2560416|NCT02496923|Active Comparator|Standard oxygen therapy (Hudson face mask or nasal prongs)|Patients randomised to receive standard oxygen therapy will be fitted with a soft face mask or nasal prongs, and the oxygen flow titrated to provide pulse oxygen saturation of at least 95% (93% for those at risk of hypercapnic respiratory failure such as confirmed COPD patients and morbidly obese patients). The standard oxygen therapy group will have their oxygen gas flow reduced to the minimum level which provides saturations of at least 95% (93% for those at risk of hypercapnic respiratory failure such as patients with confirmed COPD and morbidly obese patients).
2560461|NCT02496650|Experimental|Group D|Dexmedetomidine (DEX) infusion was started in doses 0,2-1,4 μg/kg/hr and titrated to achieve target sedation level; symptom-triggered BZD administration (diazepam 10mg bolus) were used wherever DEX infusion was not enough. Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
2560466|NCT02496650|No Intervention|Group C|Benzodiasepine (BZD) boluses (diazepam 10mg) were used to achieve target sedation level and to control AWS symptoms (symptom-triggered administration). Antipsychotics (haloperidol 5mg boluses) were used as a rescue medication for severe agitation or hallucinations.
2560505|NCT02496377|Active Comparator|Group 1: Per Os Tardyferon|EPO associated with Iron per os tardyferon before surgery. The oral group received 160 mg ferrous glycine sulfate daily during the month prior surgery, associated with 3 epoetin alpha (EPO) injections (40 000 IU subcutaneous on day - 21, day - 14 and day-7).
2560512|NCT02496377|Experimental|Group 2: IV Ferinject|EPO associated with Iron per IV Ferinject before surgery. The IV group received ferric carboxymaltose 1000 mg IV in 15 minutes one month before surgery, associated with 3 EPO injections.
3206529|NCT00955227|Active Comparator|Statins and ezetimibe|In this arm- 15 Patients with heart disease and hypercholesterolemia will receive standard statin treatment as determined by the Cardiologist. In addition, these patients will be on ezetimibe.
3206530|NCT00955227|Experimental|Statins and flax oil only|In this arm- 15 Patients receiving standard statin treatment as determined by their cardiologist will also receive two flaxseed oil capsules/day each containing 500 mg of ALA.
2560621|NCT02495571|Experimental|ALS Patients|Study Group: Evaluation of the cough reflex and the voluntary cough by spirometer and nebulizer
2560623|NCT02495571|Other|Healthy Subjects|Control group matched by aged and sex with the study group
2560646|NCT02495220|Experimental|subtenon block Group (SB)|received SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
2560653|NCT02495220|Experimental|intravenous dexmedetomidine Group(IV)|received 1µ/kg IV dexmedetomidine after induction of anesthesia
3206531|NCT00955227|Experimental|Statins and ezetimibe and flax oil|In this arm- 15 Patients with heart disease and hypercholesterolemia that are on standard statin treatment as determined by their cardiologist, will also receive (as an intervention) ezetimibe and flaxseed oil capsules containing 500mg of ALA.
3206532|NCT00955292|Experimental|Quarfloxin|
3206533|NCT00955318|Experimental|KW-6500|
2560817|NCT02494245|Active Comparator|Intervention|128 participants will take part in the STARFISH intervention
2560819|NCT02494245|No Intervention|Control|Participants allocated to the control group will be given a booklet with general advice on physical activity.
2560848|NCT02493881|Active Comparator|Group 1|The RLNs having motor function on the anterior branch assessed by intraoperative neuromonitoring.
2560853|NCT02493881|Active Comparator|Group 2|RLNs having motor function on anterior and posterior branch assessed by intraoperative neuromonitoring.
2560898|NCT02493647|Experimental|Love, Sex, & Choices|Love, Sex, and Choices (LSC) is an engaging 12-episode video series to reduce HIV risk in young, adult predominately Black women. A peer video guide was added to the end of LSC episodes to provoke viewers to question their own sex scripts and consider their own need for change. Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods.
2560901|NCT02493647|No Intervention|Attention-Time Control|The Control is a 12-episode popular web miniseries with a storyline that promotes respectful relationships. time and frequency are matched to the active intervention.
2561060|NCT02492490|Experimental|SVF(Stromal Vascular Fraction) derived MSC transprlantation|"transplantation of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF~SVF will be cultured to abstain MSC~The abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD."
2561061|NCT02492490|Active Comparator|Basiliximab|induction with Basiliximab during kidney transplantation from DCD
2561153|NCT02491996|Experimental|DTIG|Outpatients who treated by DTIG at Outpatient Unit for Gambling Disorder of Kurihama Medical and Addiction Center
2561205|NCT02491398||First-line|Previously untreated CLL requiring therapy according to the NCI criteria and treated with at least one cycle of BR as first-line treatment.
2561211|NCT02491398||Second-line|CLL that received one previous line of treatment using alkylating agents and/or purine analogues with or without monoclonal antibodies, requiring second-line therapy according to the NCI criteria and treated with at least one cycle of BR.
2561285|NCT02490579||Facebook Survey Group|"During June, 2015, approximately 1200 women will be recruited through Facebook advertisements targeted at English-speaking women age 18-50 years living in the United States. Advertisements will contain 3 key features: an image, a caption, and ad copy followed by a link to the survey website. Individuals who click on the study link in the advertisement will be redirected to the study's Qualtrics web page where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics."
2562336|NCT02484001|Experimental|ESL 800 mg|ESL will be administered orally once daily (QD)
3206534|NCT00955344|Experimental|Web-based intervention (eToolbox)|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module that will embed a link to the web-based intervention (eToolbox).
2560656|NCT02495415|Experimental|Fenretinide emulsion|Patients enrolled will receive 600 mg fenretinide/m2/day on Day 1, followed by 1200 mg fenretinide/m2/day on Days 2 - 5 as a continuous intravenous infusion via central line over 5 days. Cycles are repeated every 3 weeks.
2560707|NCT02494830|Experimental|ketamine 5 mg intravenous|
2560708|NCT02494830|Experimental|ketamine 10 mg oral|
2560711|NCT02494830|Experimental|ketamine 20 mg oral|
2560713|NCT02494830|Experimental|ketamine 40 mg oral|
2560714|NCT02494830|Experimental|ketamine 80 mg oral|
2560774|NCT02494544|Active Comparator|ConforMIS iTotal Knee replacement|iTotal patient-specific knee replacement system
2560776|NCT02494544|Active Comparator|DePuy total knee replacement|Off the shelf knee replacement system
2560777|NCT02494544|Active Comparator|Zimmer total knee replacement|Off the shelf knee replacement system
2560779|NCT02494544|Active Comparator|Biomet total knee replacement|Off the shelf knee replacement system
2560780|NCT02494544|Active Comparator|Smith & Nephew total knee replacement|Off the shelf knee replacement system
2560782|NCT02494544|Active Comparator|Stryker total knee replacement|Off the shelf knee replacement system
3206535|NCT00955344|Active Comparator|Practice Improvement Module|This arm will allow diplomats of the American Board of Internal Medicine to complete the Practice Improvement Module without any link to the Web-based eToolbox.
3206536|NCT00955383|Active Comparator|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
2561006|NCT02492698|Experimental|Probiotic group|consumed 2 g of powder of a dual probiotic strains containing Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, twice a day after breakfast and dinner.
2561008|NCT02492698|Placebo Comparator|Placebo group|consumed 2g of powder that did not contain any probiotics, twice a day after breakfast and dinner.
2561022|NCT02492477|Experimental|6 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
2561023|NCT02492477|Experimental|12 months|evaluation of PORT-A-CATH®, blocking with Medunasal®-Heparinblock, restoration of PORT-A-CATH® with Alteplase
2561080|NCT02492282|Experimental|Closed-Loop|This group includes patients with randomization process be assigned to closed loop intravenous anesthesia; the system evaluates, feeds and acts according to the patient's bispectral index, excluding the anesthesiologist. This system use a variable control of specific therapeutic effect; a target value for this variable (set point); an actuator control (infusion pump), a system (patient) and a control algorithm.
2561081|NCT02492282|Active Comparator|Open-Loop|This group includes patients with the randomization process are assigned to open loop in which the application of anesthetics is exclusively with pharmacokinetic parameters using TCI and employs mathematical models drug. For propofol used Schneider model and Minto model for remifentanil based on effective site concentration. Changes will be made by the anesthesiologist according to his criteria, trying to keep the BIS range of 40 and 60.
2561141|NCT02491866|Other|psychiatric patients|patients with schizophrenia, bipolar disorder or depression according DSM V criteria
2561214|NCT02491528|Experimental|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
2561219|NCT02491528|Active Comparator|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
2561252|NCT02490943|Active Comparator|Warm Compress Pre-Injection|Group A, N = 10, will receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
2561257|NCT02490943|Active Comparator|Cold Compress Post-Injection|Group B, N= 10, will receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
2561258|NCT02490943|No Intervention|No Intervention Pre/Post-Injection|Group C, N= 8, will receive no treatment for six injections following screening.
2561268|NCT02490618|Experimental|Test|Probiotic tablet
2561270|NCT02490618|Placebo Comparator|Control|Control tablet
2561316|NCT02490527|Placebo Comparator|Statin only|The subject will consume simvastatin (40mg) and placebo once daily for 3 months.
2561320|NCT02490527|Experimental|Statin and epicatechin|The subject will consume simvastatin (40mg) and pure epicatechin capsules (50mg) once daily for 3 months.
2561406|NCT02490215||ARDS, non-ARDS|patients with ARDS and patients without ARDS
2561430|NCT02489591|No Intervention|Control|No oral appliance (control) first, oral appliance (BluePro oral appliance or other device) second
2561438|NCT02489591|Experimental|Oral appliance|oral appliance (BluePro oral appliance or other device) first, no oral appliance (control) second
2561499|NCT02489448|Experimental|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
2561625|NCT02488668|Experimental|Surface Electrical Stimulation|Please see information under 'Detailed description'
2561692|NCT02488174|Active Comparator|Standard Care|The pre-intervention control condition will be usual care: that is, clinicians practice as usual without clinician notification of risk and without prompting on care practices as recommended by PROOFcheck.
2561757|NCT02487589|No Intervention|Control group|"In Italy, medical risks and patients risk behaviour are not systematically registered and addressed by hospital physicians, specialists and general practitioners (GPs).~Patients allocated in control group will receive by the hospital staff tailored recommendations based on their own risk profile. The same information will be sent to their GPs. No restrictions on co-interventions will be placed."
3206537|NCT00955383|Placebo Comparator|Placebo|Matching placebo
3206538|NCT00955396|Other|Period 1|
3206539|NCT00955396|Other|Period 2|
3206540|NCT00955448|Experimental|SIS Mesh (Cook Medical)|Anterior prolapse repair will be reinforced using SIS mesh
2560506|NCT02496403|No Intervention|Intensive Outpatient Treatment|The Intensive Outpatient Treatment (IOT) arm is considered usual care and is a predominant model of care in specialty treatment. It incorporates psychosocial support, education, and relapse-prevention approaches and requires attendance at 12-step program. It is a group-based treatment, with individual counseling available as needed. During the initial, 3-week phase, treatment consists of 4-6 hours a day, 7 days a week. In weeks four through 9, treatment consists of 1.5 hours, four days each week. After 9 weeks, patients attend one-hour weekly group meetings for one year. Services include supportive therapy, psycho-education, relapse prevention, and family-oriented therapy. The program emphasis is on abstinence and is similar to many public and private intensive outpatient programs.
2560608|NCT02495714|Experimental|Intervention schools|Active Learning; One hour each schoolday of physical Activity as part of academic learning Dietary councelling; teaching children and parents about a healty diet
2560612|NCT02495714|No Intervention|Control schools|No intervention
2560662|NCT02495350||Initially didn't want an epidural and didn't receive one.|
2560665|NCT02495350||Initially didn't want an epidural and did receive one.|
2560666|NCT02495350||Initially wanted an epidural and didn't received one|
2560668|NCT02495350||Initially wanted an epidural and did receive one.|
3206541|NCT00955448|Active Comparator|No-mesh|Anterior prolapse repair with no mesh reinforcement
2560762|NCT02494414||French prospective cohort of cardiac arrest survivors|Outcome of cardiac arrest survivors: prospective cohort of Ile-de-France
2560811|NCT02494271||Total intravenous anesthesia|Total intravenous anesthesia using propofol and remifentanil
2560814|NCT02494271||Inhalation|Balanced inhalation anesthesia using volatile anesthetics and remifentanil
2560864|NCT02493985|Active Comparator|Atmosphere 1 - Ambient air|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and ambient air at sea level, followed by 2 hour exposure of 3% carbon dioxide inhalation.
2560865|NCT02493985|Experimental|Atmosphere 2 - 0.5% CO2|First, the subjects will have 1 baseline day in the upright body position. This will be followed by 28 hours of head down tilt body position and air with 0.5% carbon dioxide, followed by 2 hour exposure of 3% carbon dioxide inhalation.
2560908|NCT02493530|Experimental|Escalation and expansion|TGR1202 and Ruxolitinib combination
3206542|NCT00955461|Experimental|Laser treatment|Split-Face Comparison of an Electro-optic Q-Switched Nd: YAG Laser to a Fractionated Laser
3206543|NCT00955500|Active Comparator|Normal-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams).
2561146|NCT02491957|Experimental|LOFT Therapy|LOFT therapy twice weekly for 4 weeks
3206544|NCT00955500|Active Comparator|Low-protein diet|Daily diet containing 35 kcal/kg/day, 0.7 grams of proteins/kg/day + 30 grams of oral maltodextrine
3206545|NCT00955526|Experimental|Istradefylline 20mg|
2561336|NCT02490410|Experimental|whey protein|2 x 10g whey protein per day orally for 6 months
2561338|NCT02490410|Other|whey protein+soy protein|10g whey protein + 10g soy protein per day orally for 6 months
2561339|NCT02490410|Other|soy protein|2 x 10g soy protein per day orally for 6 months
2561378|NCT02490137|Experimental|Game Players|Participants that will play video game
2561386|NCT02490137|No Intervention|Control|No video game experience
2561459|NCT02489851|Active Comparator|Quadratus Lumborum block group|"Quadratus Lumborum block group (QL)~patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%"
2561465|NCT02489851|Active Comparator|Transversus abdominis plane block group|"Transversus abdominis plane block (TAP)~patients will receive a bilateral TAP block using Bupivicaine 0.125%"
2561496|NCT02489318|Experimental|Apalutamide plus ADT|Participants will receive apalutamide 240 milligram (mg) (4X 60 mg tablets) with ADT.
2561503|NCT02489318|Experimental|Placebo plus ADT|Participants will receive matching Placebo with ADT.
2561724|NCT02487602|Active Comparator|A|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
2561734|NCT02487602|Active Comparator|B|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a standard radiolabeled lunch.
2561741|NCT02487602|Placebo Comparator|C|Placebo capsules 30 minutes before a standard radiolabeled lunch.
2561747|NCT02487602|Experimental|D|Up to 5 Gelesis100 and/or placebo capsules 30 minutes before a radiolabeled water.
2561749|NCT02487602|Experimental|E|Up to 5 Gelesis100 and/or placebo capsules 10 minutes before a radiolabeled meal.
3206546|NCT00955526|Experimental|Istradefylline 40mg|
3206547|NCT00955526|Placebo Comparator|Placebo|
2561866|NCT02486861||culprit plaque|correlation of OCT characteristics of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
2561870|NCT02486861||non culprit plaque|correlation of OCT characteristics of non culprit plaque of culprit plaque with incidence of major adverse cardiovascular events (MACEs defined as the composite of death from cardiac causes, non- fatal MI, clinically driven target vessel revascularization (TVR), or re-hospitalization due to unstable or progressive angina according to Braunwald Unstable Angina Classification) and clinical baseline characteristics.
2561929|NCT02486575|Other|self-learning|Residents training alone with pre-recorded instructions. No tutor intervention, only self-learning training Intervention Type: Behavioral (video-based and instruction based learning)
2562119|NCT02485041|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
3206548|NCT00955539|Active Comparator|CRT group 1|
3206549|NCT00955539|Active Comparator|CRT group 2|
3206550|NCT00955552|Active Comparator|Condroflex|
3206551|NCT00955552|Experimental|Glucosamine/chondroitin sulphate|Glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association (Eurofarma) T.I.D. before each meal
3206552|NCT00955565|Experimental|Navigated|
3206553|NCT00955565|Active Comparator|Conventional|
3206554|NCT00955578||Segmental Dysplastic Nevi|One patient who has been diagnosed with SDN and has had previous biopsies in the past, comparing to current biopsies
2560523|NCT02496208|Experimental|Part II (cabozantinib s-malate, nivolumab, ipilimumab)|Patients receive cabozantinib s-malate PO QD on days 1-21, nivolumab IV over 30 minutes on day 1, and ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of 4 cycles with ipilimumab, patients continue receiving cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 21 cycles in the absence of disease progression or unacceptable toxicity. After 26 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity.
3206555|NCT00955591|Other|swab test|
3206556|NCT00955604||Group R+AD|Group R+AD Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) for at least 14 days
2560736|NCT02494726||Ischemic Stroke|Ischemic stroke patients who have had blood analyzed using thromboelastography (TEG)
2560743|NCT02494726||Healthy Controls|Healthy controls who have had their blood analyzed using thromboelastography (TEG)
2560746|NCT02494726||Hemorrhagic Stroke|Intracerebral hemorrhage patients who have had their blood analyzed by thromboelastography (TEG)
3206557|NCT00955604||Group R|At least 2 months of rasagiline
3206558|NCT00955604||Group AD|At least 2 months of Anti-PD and Rasagiline
2560960|NCT02493231|Active Comparator|Nefopam|The generic name is 'ACUPAN'. It is infused during operation. A induction dose is 0.3mg/Kg. A maintenance dose is 65 mcg/kg/hr
2560962|NCT02493231|Active Comparator|Ketamine|It is infused during operation. A induction dose is 0.3 mg/Kg. A maintenance dose is 3 mcg/kg/hr
2560963|NCT02493231|Placebo Comparator|Saline|It is infused during operation. A induction volume is 3mL A maintenance dose is 10mL/hr
3206559|NCT00955630|Active Comparator|Monthly injections|3 monthly injections of ranibizumab followed by prn injections
3206560|NCT00955630|Active Comparator|PRN injections|injections of ranibizumab on a prn basis from the start of the study
3206561|NCT00955643|Experimental|hyperbaric therapy|Hyperbaric therapy by oxygen
2561051|NCT02492373|Active Comparator|laser+steroid 2 days before and after laser|Before lentigines' treatment with Qs Nd:YAG 532 nm laser, topical 0.05% Clobetasol propionate ointment was applied 2 days on the lesion. Then applied 2 days after the treatment.
2561054|NCT02492373|Other|laser+steroid 2 days after laser|Controlled side. Applied topical 0.05% Clobetasol propionate ointment only 2 days after the laser treatment
2561100|NCT02492074|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
2561101|NCT02492074|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
2561102|NCT02492074|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each)
2561104|NCT02492074|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
3206562|NCT00955643|Experimental|dental scaling and root planing|dental scaling and cleaning
3206563|NCT00955656||primary care providers|"Primary care providers who receive the survey will be the primary care provider identified by study participants enrolled in our ongoing study entitled, Asthma in the Delta Region of Arkansas: Characterization of Disease and Impact of Environmental Factors (ARIA#53054)"
2561186|NCT02491229|Other|"Hepafast"|"This group consumes three portions of Hepafast and additionally 200 kcal of vegetables for two weeks. In the following ten weeks, they consume two portions of Hepafast and one meal which follows the instructions of the Low Glycemic and Insulinemic Diet (LOGI)."
2561194|NCT02491229|Other|Control|This group follows the instruction of the LOGI diet for the entire 12 weeks
2561230|NCT02491086|Experimental|Intervention|The intervention group will receive a free pack of one-week NRT. The nurse will help the subject to decide which NRT product (patch, gum and lozenge) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption, followed by the delivery of the sampling, instructions of using the NRT sampling, an education card about NRT and a 12-page smoking cessation booklet (Figure 1). Based on the experience in the previous trials, the choice of NRT (either patch, lozenge or gum) will be made according to subject's preference, and the counsellors will provide medication counselling [25-27]. If the subject is willing to continue the counselling at recruitment, the ambassador will further introduce the NRT's side effects, adherence and effectiveness (Table 1). Otherwise, the ambassador will contact the subject for providing these details and enquiring the usage through telephone within 2 days.
2561235|NCT02491086|Active Comparator|Control|The control group subjects will only be advised by the ambassador to purchase the NRT on their own, but will not be given the sampling. The same education card and the 12-page smoking cessation booklet will be provided.
2561295|NCT02490761||Study cohort|Patients aged 65 years or over admitted to a geriatric ward in 2 hospitals for more than 3 days
3206564|NCT00955669|Active Comparator|Symptoms and Objective Examination|
3206565|NCT00955734|Experimental|Early motion|This group of patients will begin wrist motion 1 week after surgery.
3206566|NCT00955734|Active Comparator|Immobilization|This group will be casted for 6 weeks after surgery
3206567|NCT00955773|Experimental|Group I|20 to 30 solid tumor subjects will be dosed with GSK1120212 in combination with everolimus to identify Maximum Tolerated Dose. Subjects will continue on study drug until disease progression or withdraw consent.
3206568|NCT00955773|Experimental|Group II|20 subjects with pancreatic cancer will receive the recommended dose identified in group I. Subjects will remain on study drug until disease progression or withdrawal from consent.
3206569|NCT00955773|Experimental|Group III|Approximately 40 lung cancer subjects will receive the recommended dose identified in group I. Subjects will remain on study until disease progression or withdrawal of consent.
3206570|NCT00955786|Experimental|CX-3543|
3206571|NCT00955799|Experimental|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
3206572|NCT00955799|Placebo Comparator|Placebo|Placebo: identical placebo tablets
2560530|NCT02496078|Placebo Comparator|Placebo arm|"Daclatasvir placebo in tablet form QD and Asunaprevir placebo in soft capsule form BID from day 1 to 12 week~Daclatasvir in tablet form at the dose of 60 mg QD and Asunaprevir in soft capsule form at the dose of 100 mg BID from 12 to 36 week and follow up to week 60"
2560605|NCT02495610|Other|Gait analysis and MRI|"Gait analysis: Intervention: Treadmill with pressure sensors (FDM-THM-M-System (Force distribution method-treadmill); 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Intervention: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
2560675|NCT02495402|No Intervention|No Intervention: Control|No Intervention
2560678|NCT02495402|Experimental|Motivational Interviewing|A brief interview intervention for substance abuse
2560745|NCT02494752|Experimental|Stem cell enriched|Fat graft will be enriched with ex vivo expanded stem cells
2560748|NCT02494752|Active Comparator|Non stem cell enriched|Fat graft will not be enriched with ex vivo expanded stem cells
2560766|NCT02494388||Serous cystadenoma|Serous cystadenoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
2560768|NCT02494388||Mucinous cystic neoplasms|Mucinous cystic neoplasms patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
2560769|NCT02494388||Intraductal papillary mucinous neoplasms (IPMN)|IPMN patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
2560772|NCT02494388||Mucinous cystdenocarcinoma|Mucinous cystadenocarcinoma patients. Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients.
2560773|NCT02494388||Other cystic lesions|Other cystic lesions patients (cystic neuroendocrine tumors, solid pseudopapillary neoplasms, cystic lymphangioma, etc.) Endoscopic ultrasound guided needle based confocal endomicroscopy will be applied in all patients..
3171792|NCT00591877|Active Comparator|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
3171793|NCT00591890|Experimental|Single Arm|
2561189|NCT02491424|Experimental|Fixation of ITAP to lower limb amputees.|"Direct skeletal fixation of ITAP to lower limb amputees. 20 patients in the study will be fitted with Intraosseous Transcutaneous Amputation Prosthesis.~The device has been designed to be surgically implanted in a one stage procedure."
2561376|NCT02490111|Experimental|DWJ1319 300 mg BID|DWJ1319 300 mg, orally, twice daily (BID) for up to 12 months
2561384|NCT02490111|Experimental|DWJ1319 300 mg QD|DWJ1319 300 mg, orally, once daily (QD), and DWJ1319 placebo-matching capsules, orally, once daily for up to 12 months
2561391|NCT02490111|Placebo Comparator|Placebo|Placebo, orally, twice daily (BID) for up to 12 months
2561435|NCT02489682|Experimental|Informed Consent Format - short written|"Intervention to be administered:~- Short-form written informed consent information, followed immediately by outcomes questionnaire"
2561440|NCT02489682|Experimental|Informed Consent Format - long written|"Intervention to be administered:~- Long-form written informed consent information, followed immediately by outcomes questionnaire"
2561443|NCT02489682|Experimental|Informed Consent Format - video|"Intervention to be administered:~- Video informed consent information, followed immediately by outcomes questionnaire"
2561621|NCT02488538|Active Comparator|Combined oral contraceptives and Fuoxetine|Group 1 will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® ScheringAG, Egypt) daily for 21 days starting from the 3rd day of menstruation in addition to oral fluoxetine 20 mg daily. .
2561624|NCT02488538|Active Comparator|Combined oral contraceptives|Group 2 will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine
2561629|NCT02488538|Placebo Comparator|Placebo|Group 3 will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation in addition to a daily oral placebo similar in size, color and structure to fluoxetine.
2561661|NCT02488031|Experimental|Error-reduction|The participants in the error-reduction group will participate in a 4-week home-based training intervention during the month between their pre- and post-test visits. During pre- and post- training visits, Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA), Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait analysis tests will be administered. Also biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted to evaluate the impact of the training on SCA individuals.
2561762|NCT02487589|Experimental|Treated group|Telephone support, telemonitoring and tele-exercise
2561803|NCT02487251|Experimental|Usual Exposure|Participants receive no additional information about healthy eating, family mealtimes, nutrition education or meal planning beyond any usual coverage of these areas.
3171794|NCT00591916|Experimental|1|Microbial Nanocellulose (NC), an inert material produced by Acetobacter xylinum is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3171795|NCT00591916|Experimental|2|fine mesh gauze impregnated with hyaluronan and thrombin (HT) is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3171796|NCT00591916|Active Comparator|3|Scarlet Red is one of three drug interventions the patient will be randomized to receive. One of the three drugs will be placed on a patient donor site immediately after harvesting skin while the patient is in surgery.
3171797|NCT00591929|No Intervention|1|No Continuous passive motion following ORIF of fractures around the knee
2560565|NCT02495922|Experimental|B2|Induction therapy with 4 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle, intensification (mobilization and autologous stem cell transplantation), consolidation therapy with 2 cycles VRD (Velcade, Revlimid, Dexamethasone) + elotuzumab, 21 days per cycle. Maintenance therapy: 26 cycles (28 days) with lenalidomide + elotuzumab (Dexamethasone on day 1 and 15 in cycles 1-6 and on day 1 in cycles 7 to 26).
2560677|NCT02495129|Experimental|VAY736 lower dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
2560680|NCT02495129|Experimental|VA736 higher dose|12 evaluable patients will be enrolled and randomized (at a ratio of 1:1) to receive either a lower dose or a higher dose of the study drug (VAY736)
3171798|NCT00591929|Active Comparator|2|Continuous Passive Motion following ORIF of fractures around the knee
3171799|NCT00591968|No Intervention|1|The control group will receive traditional ultrasound consults (i.e. travel to nearest tertiary center for intraabdominal sonographic evaluation and return with radiologist's report).
2560790|NCT02494349|Experimental|JLP-1207|JLP-1207 dosing in the fed state(high fat meal)
2560791|NCT02494349|Experimental|Solifenacin 5mg+Tamsulosin 0.2mg|Solifenacin 5mg+Tamsulosin 0.2mg in the fed state(high fat meal)
2560820|NCT02494063||Sentinel lymph node (SLN)|Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
2560821|NCT02494063||Control|Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
2560874|NCT02493894|Experimental|PEG & Cefazolin|patients firstly get liquid diet for 24 hours. After that they get PEG solution (80gr/1Litr) each 8 hours for 24 hours. After 48 hours, cefazolin 1gram, every 6hours for 2 days
2560876|NCT02493894|Sham Comparator|placebo & cefazolin|placebo for PEG and cefazolin 1gram, every 6hours for 2 days
2560933|NCT02493413||Group A|observational time of three months in the obese group with distressed (type D) personality (high DS 14 score) with moderate aerobic exercise
2560934|NCT02493413||Group B|observational time of three months in obese group without distressed personality (low DS 14 score) with moderate aerobic exercise
2561048|NCT02492438|Active Comparator|PPV23 naive, PPV23 vaccination|vaccination with PPV-23 in 40 PPV-23 naive patients
2561050|NCT02492438|Experimental|PPV23 naive, PCV13 vaccination|vaccination with PCV-13 in 40 PPV-23 naive patients
2561052|NCT02492438|Experimental|PPV23 > 4 years ago, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago
2561055|NCT02492438|Experimental|PPV23 < 4 years, PCV13 vaccination|vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago
2561087|NCT02492061|Active Comparator|Demand creation|In the intervention arm, demand creation for couples' HCT is done using small group (comprising about 20 people), couple-focused or men-only, interactive sessions. A senior counselor facilitates the sessions in which the advantages and fears associated with couples' HCT are discussed with invited couples or men. The sessions are reinforced by testimonies from couples or men who have ever tested as a couple. Attending couples or men receive couple invitation coupons inviting them to test for HIV together with their partners at a designated health facility in the community.
2561088|NCT02492061|No Intervention|Standard of care|In the standard of care arm, participants receive general adult health talks to educate them about the importance of HIV testing (including couples' HCT) but no invitations are issued to invite couples to test for HIV together with their partners at a designated health facility. However, couples can seek HCT out of their own volition. The sessions are not stratified by marital status, and attendants include all those who are willing and are able to attend.
2561145|NCT02491840|Experimental|Gastric and cardia adenocarcinomas|Biopsy of Gastric and cardia adenocarcinomas
2561213|NCT02491450|Experimental|A Test|Test drug (Heterosofir)1 tablet contains 400 mg Sofosbuvir
2561220|NCT02491450|Active Comparator|B Reference|Reference drug (Sovaldi)1 tablet contains 400 mg Sofosbuvir
2561259|NCT02490930|Experimental|Experimental|Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy. Fingolimod will be administered at 0.5 mg every day for the first two weeks. Beginning the third week, they will take fingolimod on Monday, Wednesday and Friday until the end of radiotherapy or until the 28th dose, whichever comes first.
2561367|NCT02490267||1|children with primary or secondary glaucoma
2561374|NCT02490267||2|children w/ cataract or previously treated for cataract
2561379|NCT02490267||3|children w/ microphthalmia, anophthalmia or coloboma
2561388|NCT02490267||control group|age matched children without eye and vision problems.
2561449|NCT02489786|Active Comparator|Regimen 1|patient takes 0.25mg of digoxin daily except friday
2561455|NCT02489786|Active Comparator|Regimen 2|patient takes 0.25mg of digoxin daily except Thursday and Friday
2561460|NCT02489786|Active Comparator|Regimen 3|patient takes 0.125mg of digoxin daily
2561464|NCT02489786|Active Comparator|Regimen 4|digoxin dose is calculated using Jusko-Koup method and given daily
2561495|NCT02489305||Participants With Major Depressive Disorder|Participants with major depressive disorder who have responded to oral antidepressant treatment will be observed over time.
2561585|NCT02488863||Older Adults with Musculoskeletal Pain|Older adults (60+ years old) experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
3171800|NCT00591968|Experimental|2|The experimental group will receive the teleultrasound service. Participants are randomly assigned to this group. All patients will receive a traditional clinical work-up. An ultrasound examination will be offered if, based on initial clinical evaluation by an attending physician, the patient is found to have symptoms consistent with any the following abnormalities: ascites, blunt abdominal trauma, cholelithiasis, cholecystitis, cholangitis, pancreatitis, hydronephrosis, abdominal aortic aneurysm, hepatitis, portal hypertension, urolithiasis, abnormal uterine bleeding, ovarian mass or torsion.
2560645|NCT02495272|Active Comparator|Control Group|Oxytocin 10IU im was administered after placental delivery
2560660|NCT02495272|Experimental|Study Group|Oxytocin 10IU im was administered after the anterior shoulder could be seen.
2560703|NCT02494947|Experimental|interval training|high intensity interval-based aerobic exercise
2560704|NCT02494947|Other|controls|usual care
2560758|NCT02494661|Experimental|Healthy Cart and Stress Mangement Videos|Healthy Cart and Stress Management Videos: Participants receive two nutritional intervention videos: active comparator and managing stress while food shopping.
2560760|NCT02494661|Active Comparator|Healthy Cart Video|Healthy Cart Video: Participants receive one nutritional video intervention on how to shop for healthy foods using My Plate Guidelines.
3206573|NCT00955812|Experimental|OPB-31121|OPB-31121 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
3206574|NCT00955838|Experimental|Manus|
2560825|NCT02493829|Experimental|AML Cell Vaccine|
2560856|NCT02493803|Experimental|Receive detailed dietary advice|Half of the participants will be randomly allocated to receive detailed dietary advice
2560859|NCT02493803|No Intervention|Receive standard of care dietary advice|These patients will receive dietary advice which is the current standard of care
2560891|NCT02493582|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.
2560896|NCT02493582|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
2560924|NCT02493348|Experimental|Continuous 40 Hz Rhythmic Sensory Stimulation|The intervention consists of Rhythmic Sensory Stimulation of a continuous sine wave single-frequency stimulation (40 Hz). The treatment prescription is 30 minutes daily 40 Hz Rhythmic Sensory Stimulation, 5 days per week, for five weeks of treatment, for a total of 25 sessions.
2560925|NCT02493348|Active Comparator|Intermittent Rhythmic Sensory Stimulation|The stimulation consists of random and intermittent complex wave gamma-range RSS with peaks at 45 Hz and 95 Hz, for 30 minutes daily stimulation, 5 days per week, for a total of five weeks of treatment.
2560965|NCT02493101||Chronic kidney disease|Patients with lupus nephritis and IgA nephropathy
2560967|NCT02493101||Control|Healthy controls
2560976|NCT02492815||Population with condition and without condition|Participating in EAP
2561056|NCT02492516|Experimental|Stem cell|The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.
3206575|NCT00955838|Experimental|BCI_Manus|
2561148|NCT02491658|Experimental|Treat Psoriasis Vulgaris with UC-MSCs|Subjects in this arm will receive 6 times UC-MSCs infusions (each time 1×10^6/kg) within 8 weeks.
2561181|NCT02491385|Experimental|TEA|thoracic epidural analgesia group
2561182|NCT02491385|Active Comparator|iv-PCA|intravenous patient controlled analgesia group
2561239|NCT02491190|Experimental|Treatment|Empower educational module: After the patient activation measure/s are collected, for parents or patients assigned to the intervention arm, they will be given an opportunity to launch the EMPOWER video and interactive powerpoint. They will be able to pause on reviewing the educational material and come back to it, as with other assigned education, and they will be able to review it again if they would like. Discharge surveys will be assigned 24 hours prior to the estimated discharge time in Apex. Oneview will display notifications that the surveys have been assigned.
2561242|NCT02491190|No Intervention|Control|Standard care: Those who opt to participate in the study will be randomly assigned to receive standard features of the media center (control group), or standard features plus the educational module intervention. They will complete online (1) a baseline patient activation survey (for patients old enough to complete and for caregivers) at the start of their participation, and (2) an end-of-study survey pre-discharge or at the end of the study period.
2561279|NCT02490826|Active Comparator|Table-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a table top material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
2561280|NCT02490826|Active Comparator|Tablet-based T2T intervention|"A combined phonological awareness therapy, listening and discrimination and auditory bombardment activities intervention will be applied. This will be based in a tablet (digital) material version.~The intervention will consist of 12 weekly sessions (individual) of 45 min in duration, divided into two blocks (6+6) without any breaks."
2561335|NCT02490423|Active Comparator|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
2561337|NCT02490423|No Intervention|Standard of Care|The standard of care arm will utilize Intermountain cardiovascular clinical program care processes as they are in place today for treatment of the study subjects.
2561368|NCT02490189|Experimental|Mindfulness-Based Intervention|Participants in the mindfulness-based intervention arm will receive 12 weekly sessions of 2 to 2.5 hours duration. The intervention will be delivered in a group format. Participants will be assigned weekly homework.
2561373|NCT02490189|Active Comparator|Cognitive Behavior Group Therapy|Participants in the cognitive behavior group therapy arm will receive 12 weekly sessions of 2 to 2.5 hours in duration. Participants will be assigned weekly homework.
2561451|NCT02489760|Experimental|Adalimumab switch to Etanercept|At week 8, the treatment arm will be switched to etanercept 25 mg subcutaneously biweekly for another 8 weeks.
2561458|NCT02489760|Experimental|Etanercept switch to Adalimumab|At week 8, the control arm will be switched to adalimumab 40 mg subcutaneously biweekly for another 8 weeks.
2561500|NCT02489266|Experimental|Arm 1|Patients will receive cyclophosphamide and fludarabine followed by infusion of the AKTi-treated TIL, followed by high dose aldesleukin.
2562337|NCT02484001|Experimental|ESL 1200 mg|ESL will be administered orally once daily (QD)
3206576|NCT00955851||Pneumonia patients|The study group will consist of individuals diagnosed with pneumonia and admitted to the Medicine ward under the Pneumonia Core Measure Protocol.
3206577|NCT00955890|No Intervention|control arm|anthracycline chemotherapy only
3206578|NCT00955890|Experimental|low dose dexrazoxane group|anthracycline chemotherapy plus low dose dexrazoxane(10:1)
2560700|NCT02494999|Active Comparator|Prevnar 13|Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10
2560765|NCT02494479|Active Comparator|50mg of Purisol daily|One (1) 50 mg tablet of Prurisol and one (1) matching placebo tablet given AM and two (2) matching placebo tablets given PM for 84 (± 3) days
2560767|NCT02494479|Active Comparator|100mg of Purisol daily|One (1) 50 mg tablets of Prurisol and one (1) matching placebo tablet given twice daily (AM and PM) for 84 (± 3) days
2560770|NCT02494479|Active Comparator|200mg of Purisol daily|Two (2) 50 mg tablets of Prurisol given twice daily (AM and PM) for 84 (± 3) days
2560771|NCT02494479|Placebo Comparator|Placebo daily|Two (2) placebo tablets given twice daily (AM and PM) for 84 (± 3) days
2560935|NCT02493335|Experimental|Budesonide 0.5mg orodispersible tablet twice daily|Budesonide 0.5mg orodispersible tablet twice daily
2560936|NCT02493335|Experimental|Budesonide 1mg orodispersible tablet twice daily|Budesonide 1mg orodispersible tablet twice daily
2560937|NCT02493335|Placebo Comparator|Placebo orodispersible tablet twice daily|Placebo orodispersible tablet twice daily
2561032|NCT02492659|Experimental|trial group|the trial group underwent femtosecond laser-assisted cataract surgery
2561033|NCT02492659|Other|control group|the control group underwent conventional phacoemulsification
2561064|NCT02492243|Experimental|Group 1|Patients with documented myocardial infarction in the 7days prior to enrolment and left ventricular ejection fraction >=40% as assessed by echocardiography within 7 days window after MI,who are not candidate to ICD/CRT/IPG implantation after PCI undergo ILR implantation
2561107|NCT02491983|Active Comparator|Arm A|Combination of Palbociclib and Letrozole
2561109|NCT02491983|Experimental|Arm B|Combination of Palbociclib and Fulvestrant
2561642|NCT02488369|Experimental|Patients with non-Hodgkin's lymphoma|
2561680|NCT02488044|Experimental|AEB1102|"AEB1102, modified human Arginase I administered IV Part 1 Each patient may receive up to 7 doses given up to every other week over a maximum of 14 weeks.~Part 2 Each patient will receive up to 8 weeks of repeat-dose therapy."
2561720|NCT02487693|No Intervention|RFA alone|Patients undergo radiofrequency ablation alone.
2561725|NCT02487693|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA Interventions
3171801|NCT00591981||Primary|All patients 70 years old and above scheduled for a thoracic oncologic surgery (typically esophageal or lung cancer) will be approached for entry into this study
3171802|NCT00592020|Active Comparator|1|Short Transverse Incision
2561843|NCT02487017|Sham Comparator|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization treatment according to NCCN guidelines，patients will receive 5-FU Hepatic arterial infusion,3 cycles at least.
2561844|NCT02487017|Experimental|DC-CIK|After accepting concurrent TACE according to NCCN guidelines,patients will receive 3 cycles of DC-CIK treatment at least.
2561895|NCT02486744|Active Comparator|80 Units of Acthar|Subjects assigned by random assignment to receive 80 Units of Acthar Gel 2x weekly for 6 months
2561896|NCT02486744|Active Comparator|40 Units of Acthar|Subjects assigned by random assignment to receive 40 Units of Acthar Gel 2x weekly for 6 months
2561986|NCT02486068|Active Comparator|Xience|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with Xience Prime.
3171803|NCT00592020|Active Comparator|2|Hockey Stick Incision
3171804|NCT00592033|No Intervention|2|Rehabilitation, no supplemental oxygen
3171805|NCT00592033|Experimental|1|Rehabilitation plus supplemental oxygen
3171806|NCT00592046|Experimental|Single Arm|
3171807|NCT00592085|Active Comparator|Relapse Prevention Counseling|Motivational Relapse Counseling: 6 counseling calls over two weeks accompanied by questionnaires
3171808|NCT00592085|Active Comparator|Relapse Prevention + Alcohol Counseling|Motivational Relapse Prevention Plus Alcohol Risk Reduction Counseling: 6 counseling calls over two weeks for both smoking cessation and at-risk alcohol use accompanied by questionnaires
3171809|NCT00592098|Experimental|1|2PX
3171810|NCT00592098|Placebo Comparator|2|Placebo
3171811|NCT00592111|Experimental|1|
3171812|NCT00592111|Experimental|2|
3171813|NCT00592111|Experimental|3|
3171814|NCT00592137|Placebo Comparator|C|During one three week session of a controlled diet subjects will receive a smoothie based on soy protein two times per day that does not contain any additional calcium
3171815|NCT00592137|Active Comparator|B|During one three week period half of the participants will receive two smoothies per day based on soy protein that contain 650 mg Ca as calcium carbonate
3171816|NCT00592137|Active Comparator|A|During one three week session subjects will receive two smoothies per day based on dairy protein containing 650 mg calcium
3171817|NCT00592150|Experimental|1|Fenoldopam infusion
3171818|NCT00592150|Placebo Comparator|2|Placebo infusion
3171819|NCT00592163|Experimental|Single Arm|
3171820|NCT00592189|Experimental|1|Amnion tissue and blood collection
3171821|NCT00592202|Experimental|1|Adolescents between the ages 14 through 17 with a BMI of 40 or more or with a BMI of 35 or more and with an obesity related comorbidity will undergo placement of an adjustable gastric band
3171822|NCT00592215|Experimental|A|Mifepristone followed by labor induction with misoprostol after 6-8 hours
3171823|NCT00592228|Other|1|Fractional flow guided drug-eluting stent implantation arm
3171824|NCT00592228|Other|2|Routine drug-eluting stent implantation
3171825|NCT00592241|No Intervention|A|Subject is diagnosed as a diabetic, or subject is parent/guardian of a diabetic child age under 18 years.
3171826|NCT00592254||A|
3171827|NCT00592267||1|
3171828|NCT00592280|Experimental|1|
3171829|NCT00592293|Experimental|Proton Beam Radiation|Proton Beam Radiation
3171830|NCT00592306|Active Comparator|thymoglobulin (intraoperative)|we plan to blindly randomize these 25 lung transplant patients to intraoperative dosing of thymoglobulin followed by 3 additional postoperative doses (the first of these 3 postoperative doses will be placebo)
3171831|NCT00592306|Placebo Comparator|thymoglobulin (postoperative dosing)|We plan to blindly randomize these 25 lung transplant patients to 3 postoperative doses of thymoglobulin (the intraoperative dose will be placebo)
3206579|NCT00955890|Experimental|middle dose dexrazoxane group|anthracycline chemotherapy plus middle dose dexrazoxane(15:1)
2560796|NCT02494284|Experimental|Short term dual therapy|
2560798|NCT02494284|Active Comparator|Long term dual therapy|
2560846|NCT02493933|Active Comparator|Phytoestrogen|Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
2560851|NCT02493933|Active Comparator|Isosorbid mononitrate|Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
2560855|NCT02493933|Active Comparator|N-Acetyl cysteine|Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.
2560892|NCT02493673|Active Comparator|CPAP therapy|Continuous positive airway pressure therapy
2560897|NCT02493673|Sham Comparator|Sham CPAP|Sham- Continuous positive airway pressure
2560931|NCT02493387|Experimental|Exercise group|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the RPE 6-20 scale
2560932|NCT02493387|Active Comparator|PAP group|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
3206580|NCT00955942|Experimental|Arm I|Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
2561066|NCT02492308|Experimental|SVF-MSC induction|"collection of autologous SVF~culture of SVF to abstain MSC~infusion of MSC during and after living-relative kidney transplantation"
2561072|NCT02492308|Active Comparator|Basiliximab induction|The control group will be inducted with Basiliximab
2561147|NCT02491931|Active Comparator|GLN group|All patients in the GLN group received an oral GLN supplement. The total GLN dose given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of GLN/maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
2561156|NCT02491931|Placebo Comparator|CONT group|All patients in the GLN group received an oral maltodextrin supplement, similar in shape and texture as GLN supplement. The total placebo given to patients was standardized to 0.5 g/kg/day during 3 days prior to CPB, and one final dose of 0.25 g/kg/day of maltodextrin in the morning of surgery 4 hours prior to initiation of anesthesia.
3206581|NCT00955942|Placebo Comparator|Arm II|Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.
2561312|NCT02490553||Dunkirk area|Representative sample of Dunkirk and the surrounding urban area (of ~200 000inhabitants).Dunkirk area is characterize by high emission of industrial air pollutant
2561315|NCT02490553||Lille area|Representative sample of Lille and the surrounding urban area (of ~1 million inhabitants, the fourth urban area in France)
3206582|NCT00955981|Experimental|RDEA594 200 mg qd for 28 days|
3206583|NCT00955981|Experimental|RDEA594 200 mg, 400 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 21 days
2561474|NCT02489617|Experimental|Pathologic evaluation of excised tissue|"Patient diagnosed with intraductal papilloma without atypia (IPWA) or flat epithelial atypia (FEA).~-- Pathologic evaluation of excised tissue"
2561494|NCT02489214|Experimental|donafenib tosilate tablets|200mg bid
2561555|NCT02489071|Experimental|Brain Training|8-session cognitive training program
2561560|NCT02489071|Experimental|Brain Health|8-session cognitive education program
2561564|NCT02489071|No Intervention|Control|Wait-list control group
3206584|NCT00955981|Experimental|RDEA594 200 mg, 400 mg and 600 mg|RDEA594 200 mg qd for 7 days followed by 400 mg qd for 7 days followed by 600 mg qd for 14 days
2561673|NCT02488213|Active Comparator|Usual Diet Guidance|The patients will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed in outpatient patients treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre.
2561675|NCT02488213|Experimental|Nutritional Counseling|The patients will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material.
3206585|NCT00955981|Placebo Comparator|Matching placebo|RDEA594 matching placebo qd for 28 days
3206586|NCT00956007|Active Comparator|Arm I: Intensity-Modulated Radiotherapy|Patients undergo intensity-modulated radiotherapy (IMRT) once daily 5 days a week for 6 weeks in the absence of disease progression or unacceptable toxicity.
2561834|NCT02487121|Experimental|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
3206587|NCT00956007|Experimental|Arm II: IMRT plus cetuximab|Patients undergo IMRT as in arm I. Patients also receive cetuximab IV over 1-2 hours once weekly beginning at least 5 days prior to the start of IMRT and continuing for 4 weeks after the completion of IMRT (for a total of 11 doses) in the absence of disease progression or unacceptable toxicity.
3206588|NCT00956033||Patients with multiple myeloma|
3206589|NCT00956046|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
3206590|NCT00956046|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; and a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
3206591|NCT00956046|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
3206592|NCT00956059|Experimental|prednisone, MMF and FK506|
3206593|NCT00956059|Active Comparator|prednisone|
3206594|NCT00956072|Experimental|Arm I|Patients undergo surgery of residual disease.
3206595|NCT00956072|Active Comparator|Arm II|Patients receive imatinib mesylate therapy according to standard of care.
3206596|NCT00956098|Placebo Comparator|placebo|
3206597|NCT00956098|Experimental|oltipraz|
3206598|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 7.5 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
2560850|NCT02493842|Experimental|Invasive nerve stimulation|"Invasive nerve stimulation using the following experimental devices~Transverse Intrafascicular Multichannel Electrode for human (TIME-4H)~The STIMEP stimulator~The EPIONE Psychophysical Testing Platform software for stimulator control~Nerve stimulation therapy is provided while providing visual guidance to the subject and without the use of hand prosthetic devices"
3206599|NCT00956111|Experimental|split-virion, adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
2560984|NCT02492945|Experimental|PDRN group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. PDRN group take ultrasonography-guided 3ml-Rejuvinex injection for the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks.
2560990|NCT02492945|Active Comparator|Dextrose group|They take the three times of the ultrasonography-guided injections for four weeks(0,2,4 weeks) under double-blind. Dextrose group as active control group takes the 3ml-15%-dextrose solution for same procedure: the lesion( tear or tendinosis about extensor carpi radialis brevis, extensor digitorum communis, radial collateral ligament ) of lateral epicondylitis for 4 weeks. This dextrose solution for common extensor tendons are used as prolotherapy.
2561034|NCT02492529|Other|Healthy volunteers|"60 old healthy volunteers (aged 25-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure"
2561036|NCT02492529|Experimental|Patients with early Alzheimer disease|"20 patients (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
2561041|NCT02492529|Experimental|Old healthy volunteers|"20 healthy volunteers (aged 60-75) will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Neuropsychological tests~Experimental procedure~A cranial MRI"
2561096|NCT02492087|Active Comparator|Tranexamic acid (TXA) Group|Subjects in the TXA group will receive the topical tranexamic acid solution which will be administered intra-operatively, during the caesarean section on the surgical wound and into the intrauterine cavity after the delivery of the baby and the placenta. 60mls of the solution will be applied topically to the placental bed as identified by the surgeon carrying out the surgery by spraying the study solution using a syringe into the uterine cavity. Another 30mls of the solution will be applied to the open incision wound. The surgeon will then proceed to close the first layer of the uterus in the usual manner. The remaining 30mls of the study drug solution is then applied topically on the closed incision wound
2561099|NCT02492087|Sham Comparator|Control Group|Subjects in the Control group will receive topical normal saline solution which will be administered intra-operatively in the same manner as described for the TXA group.
2561166|NCT02491723|Experimental|Azithromycin group|Patients with non-cystic bronchiectasis were treated with azithromycin. The intervention was 500mg daily for three to five days.
2561178|NCT02491333|Experimental|true acupuncture + placebo metformin|"True acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
2561179|NCT02491333|Sham Comparator|sham acupuncture + placebo metformin|"Sham acupuncture and placebo metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month. Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month."
2561180|NCT02491333|Active Comparator|sham acupuncture + metformin|"Sham acupuncture and metformin will be started 2 days after the baseline visit including OGTT. All subjects will be asked to use a barrier method for contraception.~Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.Placement of needles is unlikely to affect ovulation and IR in women with PCOS.~Metformin will be given at 0.5g/times, 3 times one day and for 4 month."
2561296|NCT02490813|Placebo Comparator|Control|This arm will receive the placebo.
2561297|NCT02490813|Experimental|Treatment - Chinese Herbal Formula - X|This arm will receive the Chinese Herbal Formula - CHFX as treatment to their existing fish, shrimp or crab allergy.
2561371|NCT02490332|Experimental|Ventilation tube treatment|Ventilation tube insertion in the tympanic membrane
2561380|NCT02490332|No Intervention|Conservative treatment|Conventional treatment
2561450|NCT02489747|Experimental|WBE group|wheat bran extract
2561457|NCT02489747|Placebo Comparator|Placebo group|placebo
2561498|NCT02489396||Grocery Customers|All customers who shop on the Rosie site during the intervention period.
2561544|NCT02489019|Placebo Comparator|Control|Individuals assigned to this condition will receive 0.9 mcg/kg sodium chloride (NaCL)
2561546|NCT02489019|Experimental|Low Dose|Individuals assigned to this condition will receive 1 mcg/kg fentanyl
2561550|NCT02489019|Experimental|High Dose|Individuals assigned to this condition will receive 2 mcg/kg fentanyl
2561615|NCT02488577|Active Comparator|TAMIS TME|T2 N0 Cases which undergo transanal minimally invasive total mesorectal excision.
2561618|NCT02488577|Active Comparator|TAMIS-Local|T2 N0 Cases which will undergo transanal minimally invasive locoregional resection.
2561669|NCT02488265|Experimental|Motor training|Balance training, Screening to prevent falls
2561672|NCT02488265|Experimental|Balance RhytmicalTraining|Balance training, Screening to prevent falls
2561777|NCT02487459|Experimental|BPX-501 and AP1903|"Three cohorts, 3 patients each, will receive two infusions (at the same dose) of BPX-501.~If needed to treat aGVHD, a single dose of AP1903 will be administered IV."
2560831|NCT02494024|Experimental|Single dose C2N-8E12 level 2|Single IV infusion of C2N-8E12
2560835|NCT02494024|Experimental|Single dose C2N-8E12 level 3|Single IV infusion of C2N-8E12
2560838|NCT02494024|Experimental|Single dose C2N-8E12 level 4|Single IV infusion of C2N-8E12
2560840|NCT02494024|Placebo Comparator|Single dose placebo|Single IV infusion of placebo
2561120|NCT02492022|Experimental|Probiotic L008-1|Encapsuled combinaison of 2 probiotics
2561122|NCT02492022|Experimental|Probiotic L008-2|Encapsuled combinaison of 2 probiotics
2561126|NCT02492022|Placebo Comparator|Placebo|Encapsuled non active ingredients
2561171|NCT02491567||Hashimoto Thyroiditis (HT)|Children and adolescents with Hashimoto thyroiditis either hypothyroidic or euthyroidic.
2561172|NCT02491567||Graves Disease (GD)|Children and adolescents with Graves Disease both those on remission and under antihyroid medication.
2561174|NCT02491567||Controls (C)|Healthy individuals matched for gender and age without 1) any autoimmune disease 2) family history of autoimmune disease in the first degree relatives
2561222|NCT02491255|Experimental|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3171832|NCT00592332|Experimental|2|Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.
3171833|NCT00592332|Experimental|1|Hyperinsulinemic glucose clamp in group with no drug.
3171834|NCT00592397|Experimental|1|All participants underwent the same dietary intervention
3171835|NCT00592410|Experimental|1|
3171836|NCT00592423|Other|1|"A convenience sample of children will be utilized for this study, which will include both genders and all ethnicities. There is no known predilection for any racial or gender inequalities with regard to subject recruitment or outcome variables related to this study."
2561668|NCT02488187|Other|ABUS vs MRI (ultrasound when indicated)|To compare the overall sensitivity and specificity of ABUS versus MRI (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients.
2561671|NCT02488187|Other|ABUS vs mammography (ultrasound when indicated)|To compare the sensitivity and specificity of ABUS versus mammography (and hand-held breast ultrasound when clinically indicated) for the ipsilateral and contralateral breast in newly diagnosed breast cancer patients when MRI is not performed.
2561713|NCT02487862|No Intervention|Screening|Participants were screened for the inclusion and exclusion criteria to select the study group. No intervention has been done.
2561714|NCT02487862|Placebo Comparator|catagerizing the study population|The selected participants where assigned into respective groups
2561715|NCT02487862|No Intervention|Stress Reduction Protocol|Participants were evaluated for the outcome of the intervention.
2561842|NCT02486874|Experimental|Treatment group|PoreSkin, a human acellular dermal matrix, were used for scar contracture treatment
2561930|NCT02486419||Summer|
2561941|NCT02486419||Winter|
2561965|NCT02486250||Main Study Recruits|Participants are recruited to come into a clinic and take supervised cognitive tests both online and paper/pencil as well as take unsupervised online cognitive tests at home. Participants will also be given a spit kit in clinic to determine ApOE Status.
2561967|NCT02486250||MRI & PET Substudy|A subset of 34 participants from the Main Study Recruits will be invited to have an MRI and PET scan. The purpose of the sub-study is to obtain feasibility data for collecting longitudinal neuroimaging studies for participants in this sample.
2562120|NCT02485041|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
3171837|NCT00592436||1|
3171838|NCT00592449|No Intervention|1|Participants with knee OA who meet research diagnostic criteria for insomnia will partake in Phase 1
3171839|NCT00592449|No Intervention|2|Participants with knee OA who meet research diagnostic criteria for normal sleep will partake in Phase 1
3171840|NCT00592449|No Intervention|3|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for primary insomnia will partake in Phase 1
3171841|NCT00592449|No Intervention|4|Participants without knee OA or a pain syndrome who meet research diagnostic criteria for normal sleep will enroll in Phase I
3171842|NCT00592449|Experimental|5|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive behavioral desensitization treatment for insomnia
3171843|NCT00592449|Experimental|6|Phase 1 participants with knee OA who meet research diagnostic criteria for insomnia will enroll in Phase 2 of the study and are assigned to receive cognitive behavior therapy for insomnia
3171844|NCT00592462||Whole Body MRI|
3171845|NCT00592540|Experimental|Unrelated Donor BMT|
3171846|NCT00592566|No Intervention|1|Standard supportive care
3171847|NCT00592566|Experimental|2|Dexamethasone treatment
3171848|NCT00592566|Experimental|3|Desmopressin treatment
3171849|NCT00592579|Experimental|1|Open label, oral administration of 2ME2
3171850|NCT00592592|Experimental|Proton Beam Radiation|Proton Beam Radiation
3171851|NCT00592644|Experimental|1|Pulse Dye Laser
3171852|NCT00592644|Active Comparator|2|Traditional surgeries
3171853|NCT00592657||1|Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
3171854|NCT00592657||2|Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion
3171855|NCT00592670|Experimental|1|Baseline measures followed by a randomized 6 weeks treatment of Prozac.
3171856|NCT00592670|Placebo Comparator|2|Baseline followed by a 6 week randomized treatment of placebo.
3171857|NCT00592696||Observation|
3171858|NCT00592735||1|
3171859|NCT00592748|Active Comparator|Group 1|40-44 Treatments
3171860|NCT00592748|Active Comparator|Group 2|37-40 Treatments
3171861|NCT00592800||1|children between 11 and 13 years of age
3171862|NCT00592800||2|children between 14 to 15 years of age
3171863|NCT00592800||3|children between 16 and 18 years of age
3171864|NCT00592813|Experimental|1|
3171865|NCT00592813|Placebo Comparator|cardiovascular education (attention control)|
3171866|NCT00592891|Experimental|Hyperbaric oxygen therapy|Patients undergoing low pressure HBOT for chronic brain injury
2560845|NCT02494011|Experimental|traditional exercise (group I)|"Mobilization:2 strokes per one second and repeated 6 times during session~stretching exercise: 15 to 20 minutes~passive range of motion: 5 minutes at beginning and at end~active range of motion: 20 repetition~oedema control: 15s active contraction of fingers of 15s relax for 3 times"
2560852|NCT02494011|Experimental|russian current stimulation (group II)|The frequency was 2.5 kHz for 15 minutes
2560854|NCT02494011|Experimental|CKC (group III)|"wall press exercise - plyometric exercise-Quadruped rhythmic stabilization- press up exercise~closed kinetic chain exercises performed 10 times and each week 2 more repetitions added as a progression"
2560909|NCT02493556|Experimental|LLLT before muscle damage|Low Level Laser Therapy (LLLT) will be applied before the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
2560910|NCT02493556|Placebo Comparator|Placebo LLLT before muscle damage|Placebo LLLT will be applied before the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
2560911|NCT02493556|Active Comparator|LLLT after muscle damage|Low Level Laser Therapy (LLLT) will be applied after the exercise protocol on one lower limb, while the other will receive placebo treatment. Phototherapy will be applied with an equipment of 810nm and a cluster with five diodes on eight different points of quadriceps muscle, totalizing a dosage of 240J.
2560912|NCT02493556|Placebo Comparator|Placebo LLLT after muscle damage|Placebo LLLT will be applied after the exercise protocol on one lower limb, while the other will receive real treatment. Placebo treatment will also be applied on eight different points of quadriceps muscle, but the equipment will be turned off.
2560950|NCT02493218|Experimental|Mindfulness Instruction|Instruction on mindfulness concepts and practices. Classes are 45-90 minutes each and held weekly for 12 weeks.
2560952|NCT02493218|Active Comparator|Health Education Instruction|Instruction on general health and wellness. Classes are 45-90 minutes each and held weekly for 12 weeks.
2560983|NCT02492919|Experimental|Medixair®|Cardiac reanimation unit bed with Medixair®
2560988|NCT02492919|No Intervention|NO Medixair®|Cardiac reanimation unit bed with NO Medixair®
2561049|NCT02492620|Active Comparator|Ferric Citrate|Ferric citrate (FC) will be supplied as tablets containing 210mg of ferric iron (as 1g ferric citrate) to those subjects randomized to FC. These participants will be initiated on study drug with a fixed dose of FC beginning with 2 tablet per meal.
2561053|NCT02492620|No Intervention|Standard of Care (SOC)|Participants may receive open-label, non-FC phosphate binders at the discretion of their treating physician. During the Dialysis Period, dose of phosphate binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.
2561083|NCT02492126||Chronic Cough|Subjects with chronic cough will undergo cough reflex sensitivity testing to citric acid. The dose, starting at 0.03 mol/L citric acid will be administered as single breath inhalations using flow-limited calibrated pots and a dosimeter with 3 placebo inhalations of normal saline randomly interspersed. Following each inhalation, the number of coughs in the subsequent 15 seconds will be counted and recorded. The challenge will be terminated once the citric acid has induced 5 or more coughs.
2561152|NCT02491905|Experimental|low dose HL tablet|HL tablet which contains 66.7mg of active compound by oral administration, twice daily in an hour after meal
2561154|NCT02491905|Experimental|high dose HL tablet|HL tablet which contains 200mg of active compound by oral administration, twice daily in an hour after meal
2561159|NCT02491905|Placebo Comparator|placebo group|Placebo by oral administration, twice daily in an hour after meal
2561183|NCT02491346|Active Comparator|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
2561184|NCT02491346|Experimental|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
2561237|NCT02491047|Experimental|BonyPid-1000|Implantation of BonyPid-1000 medical device, constructed of bone filler coated with controlled release antibiotic formulation, concomitantly with standard of care treatment (SOC)
2561241|NCT02491047|Other|Study control arm|Standard of care treatment (SOC) only
2561274|NCT02490657|Experimental|Iloprost group|
2561277|NCT02490657|Placebo Comparator|normal saline|
2561333|NCT02490449|Experimental|Exprerimental group|medication after diet
2561334|NCT02490449|Active Comparator|control group|medication before diet
2561401|NCT02490202|Experimental|SANGUINATE|Two (2) infusions of SANGUINATE
2561405|NCT02490202|Placebo Comparator|Normal Saline|Two (2) infusions of Normal Saline
2561429|NCT02489604|Experimental|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE 25.9 GBq activity. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
2561436|NCT02489604|Experimental|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE 18.5 GBq activity. Total activity of 18.5 GBq 100 mCi for 5 cycles, every 6 ± 2 weeks (500 mCi)
2561522|NCT02489435|Experimental|10 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
2561524|NCT02489435|Experimental|20 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
2561527|NCT02489435|Experimental|30 mg VM-1500 or Placebo|VM-1500 for 9 volunteers, Placebo for 3 volunteers.
2561598|NCT02488733|Experimental|Laparoscopic Sleeve Gastrectomy (LSG)|In addition to conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines.
2561600|NCT02488733|Other|Conventional medical therapy (CMT)|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss.
3171867|NCT00592917|Active Comparator|Ia|1718 subjects randomised for active calcium and vitamin-D -intervention, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except Ib (every four months)
2562338|NCT02484001|Experimental|ESL 1600 mg|ESL will be administered orally once daily (QD)
2560862|NCT02493790||COPD patients|Cognitive and motor performances were measured in a single and dual task situations, before rehabilitation, and compared to those of healthy subjects. Then, Chronic Obstructive Pulmonary Disease patients were re-evaluated after rehabilitation.
2560907|NCT02493569||Epidemiology breast cancer patients|Observe the features of clinical diagnosis and treatment for female breast cancer patients
2560939|NCT02493296||Observational|The cohort will have their central aortic pressure, and carotid-femoral and brachio-femoral pulse-wave velocities measured. These measurements will take place pre-operatively, within a week of surgery, 6-weeks and 1-year post-operatively also. The surgery will be abdominal aortic aneurysm repair.
2560989|NCT02493023|Experimental|navigated bronchoscopy|
2561030|NCT02492607|Active Comparator|Standard treatment|"Standard treatment according to local policy. This can be either wide local excision only, wide local excision and radiotherapy, or mastectomy. Hormonal therapy is also allowed.~Follow-up:by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years."
2561031|NCT02492607|Experimental|Active surveillance|Active surveillance : monitoring by annual digital mammography for a period of 5 years and a digital mammography at 7 and 10 years.
2561125|NCT02491749|Experimental|Ultra Fast-Track Anesthesia|Patients who fulfilled the extubation criteria were extubated at the end of surgery and transferred to the ICU for follow up.
2561129|NCT02491749|Experimental|Conventional|patients who did not fulfill extubation criteria were left intubated and sedated and transferred to the ICU for later management
2561167|NCT02491580||KTx Uppsala|Patients who have received a kidney transplant in Uppsala.
2561169|NCT02491580||KTx Europe|Patients who have received a kidney transplant in Uppsala.
2561188|NCT02491294|Experimental|School Only|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components
2561193|NCT02491294|Experimental|School + Family|Students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs)
2561200|NCT02491294|Experimental|School + About Eating|Students whose schools are randomized to this condition only receive the classroom, cafeteria and SPARK active recess components and their parents are invited to participate in the online 6 lesson About Eating program.
2561207|NCT02491294|Experimental|School + Family + About Eating|students whose schools are randomized to this condition receive the classroom, cafeteria and SPARK active recess components and the family component (family nights, parent blog and action packs) and their parents are invited to participate in the online 6 lesson About Eating program.
2561210|NCT02491294|No Intervention|Control|students and their parents in all schools during cohort 1 and 4 (and Ponderosa students in cohort 3) are tested but provided no intervention
2561261|NCT02490904|Experimental|Eplerenone group|Eplerenone administration within 2 hours prior to patient departure to the operating room and for 4 days after kidney transplantation.
2561263|NCT02490904|Placebo Comparator|Placebo group|Placebo administration within 2 hours prior to patient departure to the operatingroom and for 4 days after kidney transplantation
2561319|NCT02490566|Experimental|Technology Arm|Tablet computer with chronic disease apps will be given to patients. This tablet will also be used for follow-up visits done via video conferencing. Intervention: Telehealth.
2561346|NCT02490280|Experimental|Trier Social Stress Test|Participants will be administered the Trier Social Stress Test (TSST). The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
2561366|NCT02490033|Other|Contact force unblinded|
2561375|NCT02490033|Other|Contact force blinded|
2561382|NCT02490033|Other|ECI unblinded|
2561389|NCT02490033|Other|ECI blinded|
2561471|NCT02489825|Other|Augmentation vertebroplasty|Single level fracture fixation with vertebroplasty
2561472|NCT02489825|Other|Augmentation and prophylactic vertebroplasty|Triple level augmentation with VP fixation of the fracture and additional prophylactic vertebroplasty in both the adjacent levels
3206600|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
3208848|NCT00978666||Anorexia Nervosa|Adolescent females currently ill with Anorexia Nervosa, restricting type
2561571|NCT02488798||postmenopausal bleeding group|"100 women with postmenopausal bleeding undergoing 2D greyscale vaginal ultrasound and 3D Endometrial power Doppler and the features were classified using six different vascular patterns described by IETA group including the following patterns; single dominant vessel without branching, with branching, multiple vessels with focal origin, with multifocal origin at the myometrium-endometrium junction, scattered vessels or circular flow (Kucur et al., 2013 ).~All patients then had Office hysteroscopy carried out in the outpatient clinic using vaginoscopic approach (Cooper et al., 2010). With endometrial samples from lesions or from the cavity for histopathological analysis."
2561609|NCT02488590||CHRONIC OBSTRUCTIVE PULMONARY DISEASE|"Patients with an obstructive spirometry and characteristics of chronic obstructive pulmonary disease~Clinical intervention:~Long acting B agonist (LABA) + Long acting muscarinic receptor antagonist (LAMA) inhaled therapy"
2561611|NCT02488590||ASTHMA|"patients with asthma and a normal spirometry~Clinical intervention: Inhaled corticosteroids (ICS)"
2561612|NCT02488590||ASTHMA COPD OVERLAP SYNDROME|"patients with an obstructive spirometry and characteristics of both COPD and Asthma~Clinical Intervention: LABA + LAMA + ICS"
2561614|NCT02488590||OBSTRUCTIVE ASTHMA|"patients with an obstructive spirometry and characteristics of asthma~Clinical Intervention: LABA + ICS inhaled therapy"
2561617|NCT02488590||OTHER|"patients with another diagnosis or healthy persons~clinical Intervention: undefined - according to diagnosis"
2561700|NCT02488096|Active Comparator|TRUS-Guided Biopsy|Transrectal Ultrasound (TRUS)-guided biopsy systematic 12-core biopsy (standard care)
2561704|NCT02488096|Experimental|MRI + TRUS-Guided biopsy|Prostate MRI later followed by systematic 12-score TRUS-guided biopsy + targeted biopsy of additional MRI-detected scores.
2561823|NCT02487173|Experimental|Respirio Flu Test|"Upper respiratory tract samples from participants will be tested with:~Respirio Flu Test~Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)~Sofia® Influenza A+B Fluorescent Immunoassay (FIA)"
2560870|NCT02494219|Experimental|Rapid Immunochromatographic Streptococcal test|Throat swabbing by two port germ Amines agar (copan) swabs,the swabs were randomly labeled as swab A and swab B.Swab A was processed for rapid streptococcal test and swab B was processed for culture in Colombia blood agar.All patients were followed up after 48-72 hours with the final culture results that ultimately determined the need to continue or discontinue treatment.
2560914|NCT02493504|Experimental|Heparin|75 patients were randomly assigned to receive 100units/kg of heparin after dissection prior to anastomosis.
2560917|NCT02493504|No Intervention|Control|75 received no intraoperative heparin injection.
2560954|NCT02493244|Experimental|Treatment|Participants clean their eyelids with Cliradex wipes before going to bed at night.
2560957|NCT02493244|No Intervention|Control|No treatment
2560985|NCT02492932|Experimental|IJV_2nd|Ultrasonography examination of the patients who are assumed to take second attempt of internal jugular venous catheterization
2561045|NCT02492633|Active Comparator|Standard|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study.
2561047|NCT02492633|Experimental|Enhanced|At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing.
2561090|NCT02492178|Experimental|IR artesunate + IV artesunate|Patients receive 1 dose of intrarectal artesunate (10 mg/ kg b.w.) on admission and 1 dose of intravenous artesunate (2.4 mg/kg body weight) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
2561094|NCT02492178|Experimental|IV artesunate + IR artesunate|Patients receive 1 dose of intravenous artesunate (2.4 mg/kg b.w) on admission and 1 dose of intrarectal artesunate (10 mg/ kg b.w.) at 12 hours. All patients receive a loading dose of intravenous quinine (20 mg salt/kg b.w.) on admission followed by 10 mg/kg b.w. at 8 and 16 hrs.
2561124|NCT02491710|Experimental|Low-cost box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a low-cost tablet-based box trainer.
2561127|NCT02491710|Active Comparator|Standard box trainer|Trainees in this arm will perform their basic laparoscopic skills training on a standard box trainer
2561250|NCT02490956|Experimental|Rabies vaccination|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
2561289|NCT02490735|No Intervention|No-CIK|After accepting chemotherapy, patients will regularly follow up.
2561293|NCT02490735|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year
2561348|NCT02490384|Active Comparator|Physical exam indicated cerclage|Cerclage
2561349|NCT02490384|No Intervention|Expectant management|No cerclage
3206601|NCT00956111|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
3206602|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 5 μg|100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
2561637|NCT02488434|Active Comparator|fertile chip|sperm selection by using fertile chip and conventional methods
2561639|NCT02488434|No Intervention|classical ICSI procedure|unexplained infertile couples who will be undertaken intracytoplasmic sperm injection (ICSI) for fertilisation
2561662|NCT02488057|Active Comparator|Diet-induced weight loss|Investigators will randomize subjects to lifestyle change or lifestyle change plus GLP-1 receptor agonist. Lifestyle change will be developed around a meal replacement strategy. The intervention will be weight loss using Slim-Fast®. Participants will be provided Slim-Fast® meal replacement shakes to utilize for two meals daily plus one to two 100 calorie snacks, similar to the Look AHEAD protocol. The subjects will receive specific menus and training on food composition to prepare one healthy 500 calorie meal daily, for a net hypocaloric diet.
2561666|NCT02488057|Active Comparator|Weight loss plus liraglutide|Patients will be randomized to lifestyle change and the GLP-1 agonist, liraglutide. Subjects in this group will be administered 0.6mg liraglutide, sq injection daily for 1 week, increased to 1.2 mg for 1 week, and then 3.0 mg for the next 10 weeks of the acute phase. This gradual escalation of the dose is designed to minimize gastrointestinal side effects. Empty syringes will be monitored for compliance.
2561722|NCT02487784|Experimental|Particulate allograft + autogenous bone.|In the test arm of the study the treatment will include a mix of MinerOss CorticoCancellous Particulate allograft + autogenous bone chips.
2561728|NCT02487784|Active Comparator|Block allograft|The positive control treatment will include a block allograft plus Mineross corticocancellous particulate allograft.
2561783|NCT02487407|Experimental|ODM-109|ODM-109 capsules for oral administration
2561784|NCT02487407|Placebo Comparator|Placebo for ODM-109|Placebo ODM-109 capsules for oral administration
2561863|NCT02486978|Placebo Comparator|Control (no supplement)|Reference will be white bread to give 50 g available carbohydrates with placebo capsule
2561865|NCT02486978|Experimental|Dose 1|Test will comprise white bread to give 50 g available carbohydrates and one capsule of pomegranate/olive and one capsule placebo
2561868|NCT02486978|Experimental|Dose 2|Test will comprise white bread to give 50 g available carbohydrates and 2 capsules of pomegranate/olive.
2561942|NCT02486484|Experimental|intravitreal ziv-aflibercept|intravitreal ziv-aflibercept
2562019|NCT02485886|Experimental|68Ga-BMV101 injection and PET/CT scan|The patients were intravenously injected with 68Ga-BMV101 and underwent PET/CT scan 1 h and 2.5 h after that.
2562075|NCT02485587|Experimental|Individualized Arousal-Biofeedback|"After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the experimental condition will receive 20 sessions of arousal (electrodermal activity) feedback, 1 session/week. Each session will last about 1 hour. After the first 10 sessions (10 weeks after the beginning of the training phase), parents/caregivers will be asked to evaluate behavioral measures of aggression.~After training completion (approximately 20 weeks after the beginning of the training phase), subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the training phase)."
2562343|NCT02484001|Experimental|ESL 400 mg|ESL will be administered orally once daily (QD)
2560918|NCT02493543||Controls|Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.
2560938|NCT02493179|Active Comparator|Serodase 5 mg|Serodase ( Serratiopeptidase) 5 mg
2560940|NCT02493179|Placebo Comparator|Placebo|Placebo
2560995|NCT02493010|Experimental|Intervention|Participants will undergo a 4-week intervention (once per week, 1 hour each session). Each intervention session consists of approximately 30 minutes of computerized cognitive behavioral therapy, and 30 minutes of Virtual Reality Exposure Therapy with our novel arousal-based biofeedback system. For Virtual Reality Exposure Therapy, the physiological variables of participants will be continuously monitored and presented to them as feedback. Participants will have to deliver speeches to videotaped audiences while striving to regulate their physiological arousal.
2560998|NCT02493010|No Intervention|Waitlist Control|Participants in Waitlist Control will receive no intervention in the first 4 weeks of the study. After the Intervention group has completed treatment, participants in the Waitlist Control will then undergo the same intervention as the Intervention group.
2561044|NCT02492555|Experimental|Scheduled (SI)|"Scheduled means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment"
2561046|NCT02492555|Active Comparator|On Demand (OD)|"On Demand means screening of home FC and DA when the patients feel for it and upgrade of usual treatment"
2561097|NCT02492139|Other|Pumping|Each particpant will pump with the current pumpset one week and then two weeks with the pumpset
2561215|NCT02491489|Experimental|Painful shoulders|Subjects with shoulder pain undergoing glenohumeral mobilization
2561218|NCT02491489|Active Comparator|Normal shoulders|Subjects without shoulder pain undergoing glenohumeral mobilization
2561253|NCT02491008|Experimental|Drug: Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
2561256|NCT02491008|Placebo Comparator|Drug: Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
3206603|NCT00956111|Experimental|whole-virion, adjuvanted H1N1 vaccine of 10 μg|"200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21.~100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only."
3206604|NCT00956111|Placebo Comparator|Placebo control|100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
2561385|NCT02490085|Active Comparator|Multiple daily injections|Subjects will use multiple daily injections to regulate glucose levels. Subject's usual insulin analog will be used.
2561392|NCT02490085|Active Comparator|Closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
2561446|NCT02489695|Experimental|axitinib|axitinib 10mg twice a day
2561506|NCT02489292|Experimental|HepaStem|Target total dose 50x10E6 cells/kg
2561553|NCT02489032|Experimental|SBIRT Training & Support Tool|The SBIRT Training & Support Tool has two components, both of which will be evaluated: (1) online SBIRT Training for EAP and behavioral health practitioners conducting alcohol SBIRT with their adult clients and (2) mobile/web interactive alcohol screening tools and brief intervention protocols to facilitate use of SBIRT by practitioners.
2561556|NCT02489032|Other|Waitlist control|Subjects randomized to the control condition will be placed on a wait-list and given access to the SBIRT Training & Support Tool after 3 months and completion of the 3-month follow-up assessment.
2561732|NCT02487888|Experimental|Pain|Patients presenting to a clinic for pain, that will be either blinded to genetic testing results or unblinded to genetic testing results
2561743|NCT02487888|Experimental|Mental Health|Patients presenting to a clinic for mental health disorders, that will be either blinded to genetic testing results or unblinded to genetic testing results
2561746|NCT02487888|Experimental|Cardiovascular|Patients presenting to a clinic for cardiovascular complications, that will be either blinded to genetic testing results or unblinded to genetic testing results
2561750|NCT02487888|Experimental|Arthritis|Patients presenting to a clinic for osteoarthritis or rheumatoid arthritis, that will be either blinded to genetic testing results or unblinded to genetic testing results
2561751|NCT02487888|Experimental|Type 2 Diabetes Mellitus|Patients presenting to a clinic for T2DM, that will be either blinded to genetic testing results or unblinded to genetic testing results
2561833|NCT02487134|Placebo Comparator|Conventional abdominal wall closure|The aponeurosis is closed with continuous PDS 2/0 sutures, with self-locking anchor knots. The stitches are placed 5-8 mm from the wound edge, 4-5 mm apart.
2561835|NCT02487134|Active Comparator|Reinforcement with resorbable mesh|After closing the aponeurosis with PDS 2/0, a 7 cm wide TIGR Matrix Surgical Mesh is applied on the aponeurosis. The mesh is sutured to the aponeurosis with continuous PDS 2/0, with a wound to suture ratio of 1:4.
2561848|NCT02486822|Experimental|Labor scale|Observation Amniotomy Oxytocin Cesarean Section (CS)
2561851|NCT02486822|Active Comparator|WHO partograph|Observation Amniotomy Oxytocin Cesarean Section (CS)
2561922|NCT02486549|Experimental|Supraclavicular Block|Ultrasound guided supraclavicular block with 20 ml of 0.25% bupivacaine will be performed
2561936|NCT02486549|Active Comparator|Interscalene block|Ultrasound guided inter scalene block with 20ml of 0.25% bupivacaine will be performed.
2561983|NCT02486068|Experimental|ABSORB scaffold|Patient will undergoes elective or emergent percutaneous coronary intervention and will be treated with ABSORB scaffold.
3206605|NCT00956124||uveitic patients|
3206606|NCT00956124||patients with diabetes|
3206607|NCT00956137|Experimental|Ultrasound|Use of ultrasound to identify vertebral interspaces for needle insertion.
3206608|NCT00956137|Active Comparator|Palpation|Use of manual palpation to identify vertebral landmarks and vertebral interspaces for needle insertion.
3206609|NCT00956150|Active Comparator|60 GWS Rifaximin|
3206610|NCT00956150|Placebo Comparator|60 GWS Placebo|
2561139|NCT02491827||Cellvizio mini laser probe|Cellvizio mini laser probe will be administered via the endoscopic device used for the neurosurgical procedure to provide confocal laser endomicroscopy in patients requiring neurosurgery due to glioma multiforme or subcranial tumors
2561195|NCT02491541|Experimental|Changchun Werersai|A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
2561199|NCT02491541|Active Comparator|Jilin Maifeng|A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
2561236|NCT02491021|Active Comparator|Treatment Group|Treatment Group (TG) The TG underwent a 7-week outpatient rehabilitation programme comprising both exercise and education sessions under the direct supervision of the physiotherapy team. The exercise intervention was 20 minutes, 3x/week (1 supervised, 2 self directed) titrated to a specific intensity based on risk stratification - highvs low risk). The intervention also included 6 x 1 hour education sessions.
2561240|NCT02491021|No Intervention|Control Group|Control Group (CG) The CG received physiotherapy, exercises and education as per current standards of practice in our institution up until hospital discharge. Following discharge no further specific input or education was provided. Participants were contacted at least once during the study period to check on their general well being and to encourage attendance at the second assessment by the physiotherapy team. In line with the ethical requirements for the study, all control subjects were offered the chance to participate in the rehabilitation programme once their trial participation was completed following second assessment.
2561300|NCT02490852|Experimental|Investigational Infant formula|Healthy term infants fed exclusively the investigational Infant Formula
2561302|NCT02490852|Active Comparator|Commercially available Infant formula|Healthy term infants fed exclusively a commercially available Infant Formula
2561305|NCT02490852|Active Comparator|Human milk|Healthy term infants fed exclusively human milk
2561419|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
2561421|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
2561423|NCT02490098|Active Comparator|Single-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Glulisine) will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
2561426|NCT02490098|Active Comparator|Dual-hormone closed-loop strategy with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) and Glucagon (Eli Lilly) will be infused using two separate subcutaneous infusion pumps (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to the Smartphone platform, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pumps. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). For this strategy, meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO. The meal size assessment will be done by the patient.
2561427|NCT02490098|Active Comparator|Sensor-augmented pump therapy|Subjects will use sensor-augmented pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels. Patient's usual fast acting insulin analog will be infused using a subcutaneous insulin infusion pump. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
2561475|NCT02489565|No Intervention|Tertiary care|Outpatient from tertiary care with discharge criteria who remains in the tertiary care.
2562447|NCT02483091|No Intervention|Control|Printed copy of guideline recommendations
3206611|NCT00956150|Experimental|Healthy Control|Patient is a healthy control and will not be on study intervention. Asked to perform Lactulose Breath Test to compare results with GWS patients.
3206612|NCT00956163|Experimental|Diagnostic (fluorine F 18 sodium fluoride PET)|Patients undergo technetium Tc 99m methylene diphosphonate bone scan, fluorine F 18 sodium fluoride PET/CT scan, and whole-body MRI for the detection of bone metastases. Patients with discordant imaging results (negative bone scan and positive PET/CT scan and/or MRI) undergo additional imaging at 6, 12, 18, and 24 months.
3206613|NCT00956176|Experimental|Cidofovir|
2560953|NCT02493283|Active Comparator|Treatment B|multiple-dose administration of 100 mg dapsone s.i.d. for 7 days; sampling of blood, urine and feces; sampling for leucocytes collection and sampling for additional safety analyses (Met-Hb)
2561026|NCT02492412|Experimental|HE10|Drug: HE10 1~2 drops b.i.d at 12 hour interval for 12 weeks
2561027|NCT02492412|Active Comparator|Restasis|Drug: Restasis(Cyclosporine 0.05%) 1~2 drops b.i.d at 12 hour interval for 12 weeks
3206614|NCT00956189|Experimental|Amisulpride|A slow plateau cross-titration method was used to switch original antipsychotics to Amisulpride.
3206615|NCT00956189|Experimental|Aripiprazole|A slow plateau cross-titration method was used to switch original antipsychotics to Aripiprazole.
3206616|NCT00956202|Experimental|A/H1N1 Vaccine Group 1|All participants will receive A/H1N1 Influenza vaccine formulation 1 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
2561318|NCT02490540|Experimental|Anesthesiologist quided analgesia|Sufentanil anesthesiologist analgesia is based on anesthesiologist decision.
2561321|NCT02490540|Experimental|ANI guided analgesia|Sufentanil ANI analgesia based on ANI analgesia monitor figures.
2561324|NCT02490540|Experimental|SPI guided analgesia|Sufentanil SPI analgesia is based on the SPI analgesia monitor figures.
2561383|NCT02490150|Experimental|Day 5|Administration of corifollitropin alfa on Day 5 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
2561390|NCT02490150|Active Comparator|Day 7|Administration of corifollitropin alfa on Day 7 after last oral contraceptive pill in a GnRH antagonist protocol in donors.
2561493|NCT02489461|Experimental|VM-1500 20 mg + ART|VM-1500 - 20 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
2561504|NCT02489461|Experimental|VM-1500 40 mg + ART|VM-1500 - 40 mg (Stage I), then optimal dose (Stage II and Open-Label Stage), ART
2561507|NCT02489461|Active Comparator|Efavirenz 600 mg + ART|Efavirenz 600 mg (Stage I and Stage II), ART
2561543|NCT02488837||DBS subjects|deep brain stimulation (DBS) in patients with Parkinson's disease, tremor, dystonia, and Tourette's syndrome
2561592|NCT02488746||EFTR-GERDX|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
2561620|NCT02488460|No Intervention|Normal math|This arm serves as the control group receiving regular math lessons
2561622|NCT02488460|Experimental|Active math|This arm serves as the intervention group receiving physically active math lessons
2561645|NCT02488226|Experimental|Gaze Contingent|Participants will view social videos using Gaze-contingent eye-tracking technology . If the participants looking patterns deviate from a normative pattern, they will be redirected to the normative point of regard using gaze-contingent cues.
2561647|NCT02488226|No Intervention|Control Condition|Participants will view unaltered social videos which do not change based on where the participant is looking.
2561682|NCT02487992|Experimental|CIK plus S-1 and Bevacizumab|"Cytokine-Induced Killer Cells are used to treat advanced colorectal cancer patients with S-1 and Bevacizumab.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress.~Cytokine-induced killer cells 3 cycles,every 1 year. Continue until the disease progress."
2561684|NCT02487992|No Intervention|S-1 and Bevacizumab|"S-1 is an oral anticancer agent, is a derivative of fluorouracil. Bevacizumab (Avastin) is a recombinant human monoclonal IgG1 antibody, which plays a role in the biological activity of human vascular endothelial growth factor. Bevacizumab is mainly used in the treatment of advanced colorectal cancer.~S-1, 60mg,p.o.,Bid,d2-15. Bevacizumab (Avastin),7.5mg/kg,ivgtt,d1. 3 weeks is a cycle. Continue until the disease progress."
2561731|NCT02487745|Active Comparator|IPS Only|IPS Only participants will receive the Individual Placement and Support (IPS) supported employment.
2561740|NCT02487745|Experimental|IPS Plus Wage Supplement|IPS Plus Abstinence-Contingent Wage Supplement participants will receive the Individual Placement and Support (IPS) supported employment intervention and abstinence-contingent wage supplements.
2561778|NCT02487368|Experimental|Needle stimulation pad|a self-administered treatment with a mechanical needle stimulation pad, a mechanical device to be used for 30 minutes daily for 14 days.
3206617|NCT00956202|Experimental|A/H1N1 Vaccine Group 2|All participants will receive A/H1N1 Influenza vaccine formulation 2 at Visits 1 and 2; a subset will receive a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
3206618|NCT00956202|Experimental|A/H1N1 Vaccine Group 3|Participants will receive A/H1N1 Influenza vaccine formulation 3
2561885|NCT02486809|Experimental|Treatment 1: Needle and Syringe|Healthy volunteers will receive a single SC injection of lebrikizumab, withdrawn from a vial and administered by a needle and syringe.
2561888|NCT02486809|Experimental|Treatment 2: PFS-NSD|Healthy volunteers will receive a single SC injection of lebrikizumab, administered by PFS-NSD.
2561931|NCT02486458|No Intervention|Negative control|No treatment will be applied
2561940|NCT02486458|Experimental|Varnish 4 h|Fluoride varnish will be applied on teeth and removed after 4 hours
2561945|NCT02486458|Experimental|Varnish 24 h|Fluoride varnish will be applied on teeth and removed after 24 hours
2561947|NCT02486458|Experimental|Fluoride Gel|Fluoride gell will be applied on teeth and removed after 4 minutes
2561974|NCT02486133|Experimental|A|Prezista & Norvir & Tivicay
2561980|NCT02486133|Active Comparator|B|Prezista & Norvir & Truvada or Prezista & Norvir & Kivexa
2562021|NCT02485769|Experimental|PF-06650833|Active arm , PF-06650833 kinase.
2562024|NCT02485769|Placebo Comparator|Placebo|Placebo arm
2562050|NCT02485522||Fecal incontinence|Women age >18 years old with a diagnosis of fecal incontinence
2562051|NCT02485522||Controls|Women age >18 without a diangosis of fecal incontinence
2562096|NCT02485379|Other|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
2562113|NCT02485041|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
3206619|NCT00956215|Active Comparator|80mg of Aprepitant|Patients will be randomized to receive 80mg of Aprepitant with 50 ml of water no later than 30 minutes before induction of anesthesia.
3206620|NCT00956215|Placebo Comparator|80 mg of placebo|. Patients will be randomized to placebo with 50 ml of water no later than 30 minutes before induction of anesthesia.
2561091|NCT02492048|Active Comparator|Split Thickness Skin Graft Harvest|Retrospective review
2561095|NCT02492048|Experimental|Cellutome Epidermal Harvesting System|Prospective patients will receive a skin graft utilizing the Cellutome Epidermal Harvesting System
2561162|NCT02491762||bilateral|bilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
2561165|NCT02491762||unilateral|unilateral breast construction candidates will go through respiratory function tests a month prior to surgery, a month after surgery and three months after surgery
2561176|NCT02491320|Experimental|Pre-treatment acupuncture + letrozole|A 16 week acupuncture pretreatment followed by letrozole(LE). Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. All subjects will be requested to use contraception during the 16 week acupuncture pretreatment. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks. After 16 weeks of acupuncture treatment, LE will start on day 2-3 after a spontaneous period or after a withdrawal bleeding after progestin administration. The subjects will be instructed to have intercourse on a regular basis during the cycles.
2561177|NCT02491320|Active Comparator|Letrozole|LE alone. LE will be started on day 3-5 after a spontaneous period or a withdrawal bleeding following progestin. The subjects will be instructed to have intercourse on a regular basis during the cycles.
2561226|NCT02491216|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
2561228|NCT02491216|No Intervention|Control Group|No acupressure therapy will be provided during the study.
2561298|NCT02490865|Experimental|RNS60|Administration of nebulized RNS60 to test for systemic bioactivity
2561301|NCT02490865|Placebo Comparator|Normal Saline|Administration of normal saline used as control
2561347|NCT02490319||Group 1|Lung cancer patients treated with thoracic radiation therapy
2561402|NCT02490007||Allergy Cases|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999). Allergy case participants have all attended allergy clinics associated with tertiary teaching hospitals. They have confirmed IgE-mediated food allergy as defined by the case description and as ascertained by their medical records.
2561404|NCT02490007||Controls|All participants appear on the Australian Childhood Immunisation Register (ACIR) and have received their first pertussis vaccination before the age of 16 weeks. They will have been born during the period of change over from whole cell pertussis vaccine to acellular pertussis vaccine (1997-1999).
2561497|NCT02489474||Recipients undergoing liver transplantation|Patients undergoing liver transplantation will be included and followed up during the first 72 hours post-liver transplantation in order to confirm the development of acute kidney injury. The patients will be divided into two groups (AKI group vs. non-AKI group) according to the development of acute kidney injury.
3206621|NCT00956228|Experimental|Radioimmunoguided IMRT|All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
2561608|NCT02488564|Experimental|Liposomal doxorubicin +Docetaxel+Trastuzumab+Metformin|"Day 1: Liposome-encapsulated doxorubicin, 50 mg/m2 IV 1 hour infusion; Day 2 and 9: Docetaxel, 30 mg/m2 IV 1 hour infusion; Day 2, 9 and 16: Trastuzumab 4 mg/kg for the first infusion loading dose, then 2 mg/kg/week for subsequent injections.~Day -13 to 0: Metformin is administered as single agent. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10 Metformin 1000 mg will be administered twice a day continuously until end of the study treatment."
3206622|NCT00956241|Other|j-pouch coloanal anastomosis|although a j-pouch coloanal anastomosis is a common type of anastomosis, a comparison with the side-to-end has not been made.
3206623|NCT00956241|Other|side-to-end coloanal anastomosis|in the Netherlands, the side-to-end anastomosis is the standard procedure to perform an anastomosis in case of rectal resection. therefore, the side-to-end group was our control group
2561711|NCT02487680|Experimental|Breakfast meal|A breakfast like meal will be provided together with a drink to overnight fasted subjects
2561712|NCT02487680|Experimental|Lunch meal|A lunch like meal will be provided together with a drink to overnight fasted subjects
3206624|NCT00956267|Experimental|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
3208849|NCT00978679|Experimental|Orthokeratology|Myopic children wearing orthokeratology at night will be the study group
3171868|NCT00592917|Active Comparator|Ib|random sample of 292 of 1718 (Ia), data collection by questionnaires mentioned in Ia, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
3171869|NCT00592917|No Intervention|IIa|1714 subjects randomised to no intervention group, data collection with questionnaires at baseline and end of the study, data of falls and fractures in telephone-interviews annually except IIb (every four months)
2561995|NCT02486107||PECD|percutaneous endoscopic cervical foraminotomy
2561999|NCT02486107||MTPF|microscopic tubular retractor assisted foraminotomy
2562002|NCT02486107||ACDF|anterior cervical discectomy and fusion
2562048|NCT02485743|Active Comparator|Active Diet Products|A range of products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
2562068|NCT02485626||Anthracycline treated BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated with anthracyclines respectively 5-7 years ago and 10-12 years ago.
2561086|NCT02492230|Experimental|Study Group|Left Atrial Appendage Closure Device will be implanted immediately after successful PCI procedure. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The study group will take Triple therapy (warfarin+clopidogrel+aspirin) during 45 days following PCI and after control TEE, warfarin will be discontinued. Then patients from the study group will take DAPT combination (clopidogrel+aspirin) to 6 months after procedure and then only aspirin. Patients will be followed at 45 day, and every 3 months during 12 months of follow up
3206625|NCT00956267|Active Comparator|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
3206626|NCT00956306|Experimental|Child-Pugh A|
2561197|NCT02491281|Experimental|LNA043|LNA043 given intra-articularly
2561203|NCT02491281|Placebo Comparator|Placebo|Placebo given intra-articularly
2561231|NCT02491099|Experimental|Afatinib|Afatinib 40 mgs., Q 21 Day times 4 Cycles
2561273|NCT02490696|Experimental|Miso|In this arm two PET scans wiil be realized. The first one will be made with F-Miso tracer. 24 hours later the FAZA PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
2561275|NCT02490696|Experimental|FAZA|In this arm two PET scans wiil be realized. The first one will be made with FAZA tracer. 24 hours later the F-Miso PET scan will be performed. 24 hours after the last PET scan the surgery will be realized. During this surgery a piece of tumor will be collected and analyse by immunohistochemistry for markers of hypoxia
2561330|NCT02490462|Experimental|Education + Conventional PhysicalTherapy|Parents of children with cerebral palsy receive instructions for active inclusion of children in everyday activities. The education program for parents will take place once a week for twelve weeks. Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
2561332|NCT02490462|Active Comparator|Conventional Physical Therapy|Children with Cerebral Palsy make conventional physical therapy twice a week for a period of twelve weeks.
2561393|NCT02490163|Experimental|CMNC|the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow.
2561396|NCT02490163|Active Comparator|MNC|The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure.
3206627|NCT00956306|Experimental|Child-Pugh B|
3206628|NCT00956306|Experimental|Healthy Volunteers|
2561491|NCT02489201|Experimental|donafenib tosilate tablets|200mg bid
2561573|NCT02489097|Active Comparator|Nitrous Oxide|Receives a mixture of 70% Nitrous Oxide in 30% Oxygen
2561574|NCT02489097|Placebo Comparator|Air/Oxygen (placebo)|Receives a mixture of 70% Air in 30% Oxygen
2561634|NCT02488486|Experimental|Automated postoperative sedation|Postoperative sedation is provided automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 40 and 60.
2561679|NCT02488135|Experimental|Floseal Hemostatic Matrix|Patients will receive Floseal Hemostatic Matrix topically at the location of active bleeding. Floseal is a gel-like fibrin glue that is applied using a syringe and forms a hemostatic clot.
2561681|NCT02488135|Active Comparator|Traditional Nasal Packing|Patients will receive traditional nasal packing to try and abort bleeding. This includes either vaseline gauze or nasal merocels being inserted into the anterior nasal cavity using forceps. These expand upon contact with blood or liquid therefore creating a compression type hemostasis.
2561730|NCT02487732|Active Comparator|Ticagrelor|180mg loading dose, 90mg twice daily for 5 weeks, then crossover to prasugrel
2561739|NCT02487732|Active Comparator|Prasugrel|60mg loading dose, 10mg once daily for 5 weeks, then crossover to ticagrelor
2561773|NCT02487394|Active Comparator|Asthma, Smokers and Non-Smokers|In Phase I, One arm will contain subjects who are active smokers and the other arm will contain subjects with no active smoking. Active smoking will be defined as daily use of cigarettes, pipes, cigarillos or cigars at time of entry into the study and through duration of study. No active smoking defined as never smoking or having stopped smoking for 5 years or greater.
2561775|NCT02487394|Active Comparator|COPD, Smokers and Non-Smokers|For Phase II, Phase II will again be divided into two arms based on active smoking status as discussed previously.
2561819|NCT02487186|Active Comparator|Test group: DB+DOX|Test group: DB (full mouth debridment) +DOX (doxicicline) - 45 minutes of full-mouth debridement + subgingival application of PLGA microspheres loading doxycycline 10%.
2561820|NCT02487186|Active Comparator|Control group: DB alone|"Control group: DB alone (Full-mouth debridment)~Intervention: 45 minutes of full-mouth debridement + subgingival application of void PLGA microspheres."
3206629|NCT00956319|Experimental|Zolpidem group|
2561926|NCT02486445|Experimental|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours.
2561979|NCT02486159|Experimental|Herbal plaster and Acupuncture|"In the first year: Acupoint herbal plaster applications every one week over a 4-week period for a total of 4 applications.~In the second year: Acupoint herbal plaster used as the same method as first year, and combined with Acupuncture treatment in the same time."
3206630|NCT00956319|Active Comparator|Estazolam group|
3206631|NCT00956332|Experimental|MGA - Low therapeutic dose|
2562092|NCT02485392|Active Comparator|Single-Site robot-assisted cholecystectomy|Single-Site robot-assisted cholecystectomy
2562095|NCT02485392|Active Comparator|Single-incision laparoscopic cholecystectomy|Single-incision laparoscopic cholecystectomy
2562132|NCT02485093|Active Comparator|No pacing|Ventricular intrinsic conduction enhanced
2562137|NCT02485093|Experimental|Pacing|Septal ventricular pacing with optimized AV delay
3206632|NCT00956332|Experimental|MGA - Intermediate therapeutic dose|
3206633|NCT00956345|Experimental|25U/kg|
3206634|NCT00956345|Experimental|50U/kg|
3206635|NCT00956345|Experimental|100U/kg|
3206636|NCT00956358||Pre-HSCT|Haematological conditions requiring haemopoietic stem cell transplantation
3171870|NCT00592917|No Intervention|IIb|random sample of 314 of 1714 (IIa), data collection by questionnaires mentioned in IIa, data of falls an fractures by telephone interviews every four months, bone density measurements, clinical tests, laboratory sample collections at baseline and end of follow-up as described in study design
2561206|NCT02491619|Experimental|Orthodontic decompensation|Orthodontic decompensation in patients with class III dentofacial deformities
2561249|NCT02491060|Experimental|IDP-121 Lotion|IDP-121 Lotion, applied topically to the face, once daily for 12 weeks.
2561255|NCT02491060|Placebo Comparator|IDP-121 Lotion Vehicle|IDP-121 Vehicle Lotion, applied topically to the face, once daily for 12 weeks
2561276|NCT02490709|Experimental|Local excision|Local excision for rectal cancer with good response
2561329|NCT02490488|Experimental|Masitinib & gemcitabine|Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
2561331|NCT02490488|Placebo Comparator|Placebo & gemcitabine|Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.
2561365|NCT02490072|Experimental|Dexmedetomidine group|
2561370|NCT02490072|Placebo Comparator|normal saline|
2561456|NCT02489877||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis
2561462|NCT02489877||without Multiple Sclerosis|Healthy individuals without neurological disease associated
2561466|NCT02489877||with other neurological diseases|Patients diagnosed with the following diseases: Lateral Amniotrofic Sclerosis, Headache , Parkinson's disease, Dementia and Epilepsy.
2561513|NCT02489409|Experimental|Experimental group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14; EndostarTM Injection: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h).
2561518|NCT02489409|Active Comparator|Control group|Gemcitabine (Gem): 1.0 m/m2, iv 0.5h, d1, 8; Navelbine (NVB): 40 mg/d, iv, d1, 8; Platinum (DDP): 30 mg/m2, iv 3h, d1-3; Xeloda Tablets: 2 000 mg/m2, po, d1-14.
2561648|NCT02488356|Experimental|Litramine|Patented fibre complex from Opuntia ficus-indica (Litramine)
2561652|NCT02488356|Placebo Comparator|Placebo|Inert fillers that is manufactured to look and taste the same as verum
2561911|NCT02486705|Active Comparator|PTSD Family Coach Basic|PTSD Coach basic provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD and additional support resources.
2561912|NCT02486705|Experimental|PTSD Family Coach Full|PTSD Family Coach full provides an iOS mobile app with extensive information about caregiving for family members of those with PTSD, additional support resources, tools for coping with caregiving-related stress, and tools for self-monitoring stress symptoms.
2561978|NCT02486315||AXXESS stent|"all consecutive patients with de novo bifurcation lesions treated at the Clinica Mediterranea (Naples) and at the Sapienza University (Rome) were screened for potential inclusion in the present study. Inclusion angiographic criteria were: 1) significant (≥70% diameter stenosis) bifurcation lesion; 2) MV reference diameter between 2.75 and 4.75 mm by visually estimated, 3) SB reference diameter ≥2.25 mm by visual estimate; 4) bifurcation angle (between the distal MV and the SB) <70° by visual estimate. Both protected and unprotected left main bifurcation lesions were allowed to be included, provided that all previous angiographic criteria were satisfied. Patients deemed eligible underwent AXXESS stent implantation"
2562016|NCT02485951|Active Comparator|Central air injection|The needle was moved radially inside the trephination site and advanced to the central or paracentral cornea.
2562017|NCT02485951|Active Comparator|Peripheral air injection|The needle was inserted into the deep stroma from the trephination site and advanced into the peripheral cornea to approximately 1.5 mm anterior to the limbus.
2562067|NCT02485613||bortezominb and dexamethasone group|
2562174|NCT02484833|Active Comparator|FOLFIRI + Cetuximab until disease progression|FOLFIRI + Cetuximab until disease progression
2562176|NCT02484833|Experimental|FOLFIRI + Cetuximab followed by Cetuximab alone|FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression
2562231|NCT02484469|Experimental|Exposed|The Virtual Human Project videos and Team-Based learning session about leprosy
2562234|NCT02484469|Placebo Comparator|Unexposed|Standard Team-Based learning session about leprosy
2562339|NCT02483741|Experimental|Manuka Honey|Manuka Honey will be placed in the sockets of the extracted third molars in this group
2562341|NCT02483741|No Intervention|Traditional Extraction|No any special material will be placed in the sockets of the extracted third molars in this group
2562406|NCT02483364|Experimental|Experimental|HC-SVT-1001. Intraosseous use. 3x10(6) cells/cm3. (Initial protocol) HC-SVT-1002. Intraosseous use. 3x10(6) cells/cm3. (Protocol amendment)
3171871|NCT00592930|Experimental|1|olanzapine
3171872|NCT00592930|Placebo Comparator|2|matching placebo
3171873|NCT00592995|Placebo Comparator|1|
3171874|NCT00592995|Active Comparator|2|
3171875|NCT00593034||1|"Participants in this study will be 12-21 year old patients who have been referred to the Adolescent Substance Abuse Program for evaluation of drug or alcohol use and are participating in the parent study, Medical Office Intervention for Adolescent Drug Abuse."
3171876|NCT00593047|Placebo Comparator|1|Statin + placebo
3171877|NCT00593047|Experimental|2|Statin + KB2115 dose 1
3171878|NCT00593047|Experimental|3|Statin + KB2115 dose 2
3171879|NCT00593047|Experimental|4|Statin + KB2115 dose 3
3171880|NCT00593073|Experimental|1|Tailored Reminder Message
3171881|NCT00593073|Experimental|2|General Reminder Message
3171882|NCT00593086|Active Comparator|A|Standard of care pain management
3171883|NCT00593086|Experimental|B|SnoWorld Virtual Reality Game
3171884|NCT00593099|Experimental|1|Buproprion
3171885|NCT00593099|Placebo Comparator|2|Placebo
3171886|NCT00593125|Experimental|1|levetiracetam
3171887|NCT00593138|Experimental|1|
3171888|NCT00593151|Experimental|A, C, 320 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
3171889|NCT00593151|Experimental|B, C, 640 mcg|Bi-weekly subcutaneous doses of Locteron (controlled-release interferon alpha 2b) with oral ribavirin.
2561192|NCT02491307|No Intervention|Non-application users|This cohort is comprised of individuals that 1) are English-speaking; 2) possess an Android or iOS smartphone; 3) have anxiety, depression, and/or bipolar disorder; and 4) are patient of a behavioral health clinician that is providing paper surveys to patients in clinic. They do not receive the Ginger.io smartphone application.
2561233|NCT02491034|Other|Intervention|Depression Education Intervention
2561304|NCT02490839|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
2561309|NCT02490839|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
2561469|NCT02489890|No Intervention|Non-CIK|After accepting chemotherapy, patients will regularly follow up.
2561473|NCT02489890|Experimental|CIK|After accepting chemotherapy, patients will receive at least 3 cycles of Cytokine-induced Killer Cells treatment per year.
3171890|NCT00593151|Active Comparator|A, B, C PEG|Weekly subcutaneous injections of 1.5 ug/kg PegIntron (12 kDalton pegylated interferon alpha 2b) with oral ribavirin.
2561561|NCT02488785|No Intervention|Control|Patients in this group will attend regular clinical and education appointments as offered by the clinic for their diabetes care.
2561567|NCT02488785|Experimental|Intervention|Patients in this group will be part of a Virtual Diabetes Self-Care and Education Program. They will receive a phone to communicate with a diabetes educator for 6 months. They will connect with the diabetes educator for weekly video conferences of up to 30 minutes for twelve consecutive weeks, followed by 7 phone calls. Additionally, they will receive a weekly text message about diabetes for 6 months.
2561626|NCT02488642|Experimental|isosorbide dinitrate-oxytocin|"Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening."
2561630|NCT02488642|Placebo Comparator|misoprostol-oxytocin|"Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening."
2561660|NCT02488083|Experimental|all subjects treated by UltraShape|all the patients undergo fat reduction treatment by UltraShape
2561789|NCT02487849|Experimental|HIPEC|If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.
2561837|NCT02487069|Experimental|MSD group|The patients will received HSCT from MSD.
2561838|NCT02487069|Experimental|MUD group|The patients will received HSCT from MUD.
2561839|NCT02487069|Experimental|HRD group|The patients will received HSCT from HRD.
2562055|NCT02485652|Experimental|HM61713|HM61713 800 mg (2 x 400 mg tablets) once daily (QD)
2562250|NCT02484417|Experimental|Cohort 1: RSV A2 10^5 PFU/dose|Challenge 4 subjects with low dose and proceed to larger cohort after safety review.
2562251|NCT02484417|Experimental|Cohort 2: RSV A2 10^5 PFU/dose|Challenge 12 subjects with the low dose and proceed to high dose after safety review.
2562252|NCT02484417|Experimental|Cohort 3: RSV A2 10^6.3 PFU/dose|Challenge 12 subjects with the high dose
2562296|NCT02484066|Experimental|VBN-EBUS-GS group|Fluoroscopy are not used in this group. EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
2562297|NCT02484066|Active Comparator|VBN-EBUS-GS-X-ray group|EBUS and GS are inserted into bronchi in the assistance of VBN. The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained with fluoroscopic guidance.
2562400|NCT02483403|Other|Healthy Volunteers|Healthy elderly volunteers will undergo pulmonary function tests, hyperpolarized Helium-3 MRI at each visit.
2562463|NCT02483104|Experimental|veliparib (ABT-888)|
2562597|NCT02481960|Experimental|Treatment arm|Intraparenchymal administration of CM-BC2 irinotecan drug-eluting bead in recurrent high grade glioma.
3171891|NCT00593164|Experimental|1|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous magnesium sulfate (30 mg per kg IV over 15 min).
3171892|NCT00593164|Active Comparator|2|Comatose post-resuscitation patients cooled with ThermoSuit and treated with intravenous normal saline.
3171893|NCT00593177|Experimental|Treatment Group 1|0.05% PTH (1-34) Gel
3171894|NCT00593177|Experimental|Treatment Group 2|0.10% PTH (1-34) Gel
3171895|NCT00593177|Placebo Comparator|Treatment Group 3|Placebo (Vehicle) Gel
3171896|NCT00593190|Experimental|1|
3171897|NCT00593216||Healthy|Healthy volunteers devoid of any ear problems
3171898|NCT00593216||Vertigo|Patients with the symptoms of vertigo
3171899|NCT00593229||3|Familial atypical HUS
3171900|NCT00593229||4|Thrombotic thrombocytopenic purpura (TTP)
3171901|NCT00593229||1|Severe diarrhea-associated hemolytic uremic syndrome (D+HUS)
3171902|NCT00593229||2|Non-familial atypical HUS
3171903|NCT00593242|Experimental|infusions|infants who arrive at the study site within the first 14 postnatal days and had a history of moderate to severe hypoxic ischemic encephalopathy, and have cells available for infusion that pass Carolinas Cord Blood Bank Quality checks Outcomes will be measured at 22-26 months fby neurodevelopment assessment
3171904|NCT00593242|Other|historical control|Infants who had moderate to severe hypoxic ischemic encephalopathy in the neonatal period but did not receive autologous cord blood cells.
3171905|NCT00593281|No Intervention|1|IV Morphine
3171906|NCT00593281|Experimental|2|SC Morphine with Hylenex
3171907|NCT00593281|Active Comparator|3|SC Morphine with Saline
2561224|NCT02491203|Experimental|Telerehabilitation system|Participants in the experimental group will receive four weeks written home exercise program provided by a clinician, i.e. usual care discharge home program plus virtual reality (VR) and telerehabilitation system. The intensity and choice of game for the home program will be determined by the therapist based on the patient's abilities, interests, motivation and fatigue. The patient's performance for the VR home program will be monitored asynchronously and the program adapted to ensure it remains at an appropriate level for the patient.
2561264|NCT02490891|Experimental|PET scan with RGD K5 imaging|PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
2561350|NCT02490605|Experimental|occlusal plate group|"The sample group will receive an occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides). The occlusal plate will be made from Vacuum Form acetate with a thickness of 1.5 mm; the simultaneous, bilateral, occlusal contacts and the canine and anterior guides will be obtained by way of autopolymerizable, acrylic resin with the mandible in a centric relationship."
2561351|NCT02490605|Active Comparator|therapeutic exercises|The control group will only receive orientation to do physiotherapeutic exercises seeking to correctly position the mandible in the resting position (maxillar teeth should be approximately 2 mm away from the mandibular teeth) while the tip of the tongue is positioned and accommodated on the roof of the mouth over the incisive papilla on the hard palate (without touching the teeth). The exercise will consist of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth, 3 times per day, each period consisting of 3 sets with 15 repetitions.
2561424|NCT02489994|Experimental|all subjects|Treatment with the ePrime radiofrequency microneedling device in the upper thighs and buttocks
3206637|NCT00956358||Post-HSCT with BOS|Occurence of bronchiolitis obliterans syndrome after haemopoietic stem cell transplantation
3206638|NCT00956358||Control|Healthy HSCT donors
3206639|NCT00956371|Placebo Comparator|P|
3206640|NCT00956371|Experimental|E|
2561655|NCT02488343|Experimental|Behavioral Intervention|Participants in this group will receive tailored psychological intervention to promote adherence to their drug therapy.
2561656|NCT02488343|No Intervention|Non Intervention group|Participants in this group will be observed but will not receive any intervention.
2561699|NCT02487914|Active Comparator|lidocaine iontophoresis using interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the iontophoresis of Lidocaine using interferential current.
2561705|NCT02487914|Active Comparator|interferential current|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of interferential current.
2561709|NCT02487914|Active Comparator|lidocaine|the threshold of pressure, tactile,and pain thresholds were evaluated after the application of topical Lidocaine.
2561790|NCT02487576|Other|Carbohydrate-rich_Fat-rich (HC_HF)|Isocaloric carbohydrate-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric fat-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
2561793|NCT02487576|Other|Fat-rich_Carbohydrate-rich (HF_HC)|Isocaloric fat-rich meals in the morning (06.00 am - 01.30 pm) and isocaloric carbohydrate-rich meals in the evening (04.30 pm - 10.00 pm) for 4 weeks
2561946|NCT02486536|Active Comparator|Group A|Fast for 12h before the examination and take 8ml of Simethicone Emulsion (Berlin-Chemie, Germany, containing 40 mg simethicone in 1mL emulsion) with 250ml water 30min before capsule ingestion.CE are performed with the Pillcam SB2 capsule endoscopy system (Given Imaging Co. Ltd., Yoqnem, Israel).
2561948|NCT02486536|Active Comparator|Group B|the same as protocol A plus 1L Polyethylene glycol 11-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
2561949|NCT02486536|Active Comparator|Group C|the same as protocol A plus 2L Polyethylene glycol 10-12h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
2561950|NCT02486536|Active Comparator|Group D|Group D: the same as protocol A plus 1L Polyethylene glycol 3-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
2561951|NCT02486536|Active Comparator|Group E|Group E: the same as protocol A plus 2L Polyethylene glycol 2-4h before VCE. CE are performed with the Pillcam SB2 capsule endoscopy system.
2561985|NCT02486003||mTBI athletes|College athletes who undergo an mTBI during the season
2561990|NCT02486003||Control athletes|College athletes who do not undergo an mTBI during the season
2561994|NCT02486003||Control non-athletes|Control non-athletes with long term follow-up of approximately 4-6 weeks and 3-5 months
2562026|NCT02485899|Experimental|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
2562129|NCT02485067|Experimental|THVD-201|"1. Treatment period(12 weeks)~Double dummy(A+B) A. THVD-201: capsule B. Placebo(For Detrusitol 2mg tablet)~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm, all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
2562134|NCT02485067|Active Comparator|Tolterodine (Detrusitol)|"1. Treatment period(12 weeks)~Double dummy(A+B) A. Placebo(For THVD-201): capsule B. Detrusitol 2mg tablet~One capsule and One tablet bid on an empty stomach~2. Open-label extension period(An additional 12 weeks)~Regardless of the previous type of arm , all patients only take THVD-201 during this period.~One capsule bid on an empty stomach"
2562196|NCT02484560|Experimental|Ambulatory Patients|Ambulatory patients receiving stem cell therapy
2562197|NCT02484560|Experimental|Non-Ambulatory Patients|non-ambulatory patients receiving stem cell therapy
2562268|NCT02484352|Other|0 mg/kg of oxycodone|Intervention: patients receive 10 ml of normal saline without oxycodone through intravenous route before intubation.
2562279|NCT02484352|Other|0.05 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.05 mg/kg of oxycodone in normal saline through intravenous route before intubation.
3206641|NCT00956384|Experimental|One-stage dermal matrix/implant|One-stage breast reconstruction with dermal matrix and implant
3206642|NCT00956384|Active Comparator|Two-stage tissue expander/implant|Two-stage breast reconstruction with tissue expander and implant
3206643|NCT00956397|Active Comparator|Control Participants|
3206644|NCT00956397|Active Comparator|FD Participants|
3206645|NCT00956397|Placebo Comparator|FD (Placebo) Participants|
3206646|NCT00956410|Experimental|CAD106|
2561245|NCT02491177|Other|cMM Only|Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
2561247|NCT02491177|Other|Text Messaging Only|Participants randomized to this arm will receive the mobile phone text messaging intervention only. The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
2561254|NCT02491177|No Intervention|Neither cMM nor Text Messaging|Participants randomized to this arm will receive standard of care with no interventions.
2561272|NCT02490644||MGB1 in valvular heart surgery|Evaluation of the high mobility group box 1 as a prognostic biomarker in patients undergoing valvular heart surgery
2561317|NCT02490514||Mircera|Patients with stage III-IV CKD received open-label Mircera for 12 months at a dose to be determined by the investigator.
2561369|NCT02490228|Other|surgical group|transurethral resection of urethral caruncle
2561434|NCT02489916|Experimental|CM4307|CM4307 300mg bid，until disease progression,death, unacceptable toxic eff ects, withdrawal of consent by the patient, or decision by the treating physician that discontinuation would be in the patient's best interest
3206647|NCT00956423|Experimental|moderate-intensity exercise training|
3206648|NCT00956423|Active Comparator|low-intensity stretching|
2561572|NCT02488772|Experimental|Treatment Group|Patients allocated to treatment group will be supplied with sleep interventions (sleep mask and ear plugs), and standardized instructions of use.
2561575|NCT02488772|Active Comparator|Control Group|Patients allocated to control group will be assessed for sleep quality, but not offered sleep mask and ear plugs. They will receive standard of care as decided by treating emergency physician.
2561607|NCT02488512|Experimental|90Y-DOTATOC|90Y-DOTATOC
2561667|NCT02488291|Experimental|0.5 sufentanil|0.5µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
2561670|NCT02488291|Experimental|0.25 sufentanil|0.25µg/ml sufentanil, 0.1% ropivacaine for 6ml/h
3206649|NCT00956436|Experimental|Sorafenib Monotherapy|Sorafenib Monotherapy
3206650|NCT00956436|Experimental|Sorafenib with BIIB022|Sorafenib with BIIB022
2561958|NCT02486341|Experimental|Human Neutral Protamine Hagedorn (NPH)|The inclusion will be stratified into 2 groups according to the type of basal insulin being at baseline (ratio 1: 1): NPH human insulin / Long-acting basal insulin analogues. The type of insulin will not be changed by this protocol.
2561961|NCT02486341|Experimental|Long-acting basal insulin analogues|
3206651|NCT00956449|Experimental|1|
3206652|NCT00956462|Experimental|NSAID|
3206653|NCT00956462|Active Comparator|Steroids|
2562041|NCT02485639|Experimental|Arm 1|All study participants will receive licensed inactivated influenza vaccine intramuscularly on Day 1.
2562073|NCT02485470|Experimental|MPACT|A 7-week (7 weeks x 3 sessions per week), on site, functional resistance training (FRT) as well as a walking program concurrent with CCRT will be followed by a 7-week post-CCRT home program. The protocol follows American College of Sports Medicine (ACSM) prescription guidelines for cancer patients.
2562077|NCT02485470|No Intervention|Usual Care|
2562106|NCT02485236|Active Comparator|Low flow oxygen via nasal cannula|In the low flow oxygen via nasal cannula, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
2562107|NCT02485236|Active Comparator|Humidified Nasal High Flow Therapy|Adjustment of humidified high flow air therapy: To adjust oxygen 1-4 liters per minute to an arterial oxygen saturation of > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
2562128|NCT02484963|Experimental|zolpidem|Tablet zolpidem 5mg once daily will be given for 4 weeks
2562133|NCT02484963|Placebo Comparator|Placebo|One tablet of placebo will be given for 4 weeks
2562233|NCT02484703|Placebo Comparator|Placebo|Participants will receive matching placebo by mouth (PO) twice daily (BID) for up to 26 weeks.
2562235|NCT02484703|Experimental|RO5186582 120 mg BID|Participants will receive RO5186582 at a dosage of 120 milligrams (mg) PO BID for up to 26 weeks.
2562237|NCT02484703|Experimental|RO5186582 40 mg BID|Participants will receive RO5186582 at a dosage of 40 mg PO BID for up to 26 weeks.
2562239|NCT02484703|Experimental|RO5186582 60 mg BID|Participants will receive RO5186582 at a dosage of 60 mg PO BID for up to 26 weeks.
2562260|NCT02484131|Experimental|Educational materials/mail|Participants in this group will receive educational materials by mail on the first day of the follow-up period.
2562276|NCT02484131|Experimental|Educational materials/participant choice|Participants in this group will receive educational materials by participant choice on the first day of the follow-up period.
2562280|NCT02484131|No Intervention|Control|Participants in this group will not receive any educational materials during hte follow-up period. Educational materials will be sent by mail after the completion of this study.
2562340|NCT02483923|Experimental|Group S|
2562342|NCT02483923|Placebo Comparator|Group C|
2562357|NCT02483507|Active Comparator|Group T: transversal|Implementation of the vascular catheter with transversal approach under ultrasound guidance
2562359|NCT02483507|Active Comparator|Group L: longitudinal|Implementation of the vascular catheter with longitudinal approach under ultrasound guidance
2562364|NCT02483507|Active Comparator|Group O: oblique|Implementation of the vascular catheter with oblique approach under ultrasound guidance
3206654|NCT00956488|Experimental|supported treadmill ambulation training|
3206655|NCT00956514|Experimental|Transcranial Magenetic Stimulation|All subjects will be assigned to active, open-label treatment with the NeuroStar TMS System for 6 weeks (30 treatment sessions).
3208850|NCT00978679|Other|Others|Myopic children wearing single-vision spectacles in the daytime will serve as control group
3208851|NCT00978692|Experimental|Toric orthokeratology lenses|Children wearing toric ortho-k lenses at night for correcting astigmatism and myopia will be the study group
2561267|NCT02490683|Experimental|Luna Rich X|Luna Rich X©: 500 mg/ day in 4 pills of lunasin-enriched soy protein concentrate Reliv Now: 19 grams of powder/day, that subject will mix and consume daily with water or a beverage they commonly drink
2561269|NCT02490683|Experimental|Reliv Now|19 grams of power/day, that subjects will mix and consume daily with water or a beverage they commonly drink
2561271|NCT02490683|Placebo Comparator|Placebo|Placebo pills containing starch (provided by Reliv International, Inc.)
3171908|NCT00593294|Experimental|A,1,I|
3171909|NCT00593294|Active Comparator|B, 2, II|
3171910|NCT00593294|Placebo Comparator|C,3,III|
3171911|NCT00593307|Experimental|Low GI|low GI breakfast
3171912|NCT00593307|Experimental|Low GI -low carb|Low GI and Low carb breakfast
3171913|NCT00593307|Experimental|High GI|High GI breakfast
2561515|NCT02489175|Experimental|Stomaplasty KoringTM group|The KoringTM is a stomaplasty ring made of propylene, flexible and non-absorbable. It is fixed to the anterior sheath of the abdominal wall in order to prevent PSH.
2561520|NCT02489175|No Intervention|No preventive measure|In these patients, the stoma creation will be traditional, with no mesh implanted
2561752|NCT02487836|Other|First attempt stenting (T0 = date of the first act)|Efficacy of laying of a biliary stent for chemotherapy realization
2561805|NCT02487342|Experimental|milk|semi-skimmed milk (< 2% fat, Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
2561811|NCT02487342|Active Comparator|orange fruit-juice|orange fruit-juice (Tesco, UK). All items were isovolumetric (217 mL) and isoenergetic (427 kJ).
2561846|NCT02487043|Experimental|Dental health coaches|Telephone-based case-management intervention. Contact with families every 2 weeks during one year. Including motivational interviewing, support for dental preventive measures at home, answer questions, care coordination) + conventional protocol (Fluoride prevention program)
2561849|NCT02487043|No Intervention|Control group|Conventional protocol (Fluoride prevention program) and follow-up as usual
3171914|NCT00593307|Experimental|High GI Low Carb|high GI low carb breakfast
3171915|NCT00593359||A|Lactated Ringer's replacement for blood loss and placebo eye drops
2562281|NCT02484235|Experimental|Group HIIT|Only Aerobic Training with HIIT
2562287|NCT02484235|Experimental|Group Strength|Only Strength Training
2562290|NCT02484235|Experimental|HIIT and Strength|Both intervention HIIT and Strength training
2562321|NCT02483897|Experimental|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
2562324|NCT02483897|Placebo Comparator|placebo (Normal Saline placebo drops)|0.8 mls. drops provided to be used hourly p.r.n. for pain control
2562442|NCT02483091|Experimental|Multifaceted KT intervention|Webinars, online vignettes and e-module, copy of guideline recommendations
3171916|NCT00593359||B|Lactated Ringer's replacement for blood loss and brimonidine eye drops
3171917|NCT00593359||C|Albumin replacement for blood loss and placebo eye drops;
3171918|NCT00593359||D|Albumin replacement for blood loss and brimonidine eye drops
3171919|NCT00593424|Active Comparator|1|Low Fat/High Carbohydrate
3171920|NCT00593424|Active Comparator|2|High Monounsaturated Fat/Low Carbohydrate
3171921|NCT00593437||1|diagnosed with normal bone density by Norland Excel
3171922|NCT00593437||2|diagnosed with osteopenia by Norland Excel densitometer
3171923|NCT00593437||3|diagnosed with osteoporosis by Norland Excel densitometer
3171924|NCT00593463|Experimental|1|Receives 2-4 of the interventions listed
3171925|NCT00593476|Active Comparator|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
3171926|NCT00593476|Active Comparator|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
3171927|NCT00593502|Active Comparator|1|Oseltamivir
3171928|NCT00593502|Placebo Comparator|2|Placebo
3171929|NCT00593515|Experimental|1|Family CBT
3171930|NCT00593515|Active Comparator|2|Child-focused CBT
3171931|NCT00593528|Active Comparator|A|Naked Stents
3171932|NCT00593528|Experimental|B|PTFE Covered Stents
3171933|NCT00593567|Experimental|A|Daily topical gentamicin sponge and standard daily wound care
3171934|NCT00593567|Active Comparator|B|Daily oral levofloxacin 750 mg and standard daily wound care
3171935|NCT00593580|Active Comparator|1|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
3171936|NCT00593580|Placebo Comparator|2|
3171937|NCT00593619|Active Comparator|Iron Dextran|
3171938|NCT00593619|Active Comparator|Iron Sucrose|
3171939|NCT00593632|Experimental|High Fiber Intake|Two 3/4 Cup servings of high fiber Uncle Sam cereal daily
3171940|NCT00593658|Experimental|single|
3171941|NCT00593671|Active Comparator|PGS group|
3171942|NCT00593671|No Intervention|control group|
3171943|NCT00593697|Active Comparator|A|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 -> FE75C x3)
3171944|NCT00593697|Active Comparator|B|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
3171945|NCT00593710|Experimental|1|Losartan
3171946|NCT00593710|Active Comparator|2|Atenolol
3171947|NCT00593723|Experimental|IMRT + Concurrent chemotherapy|"180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks.~Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist."
3171948|NCT00593749|Active Comparator|HCS|Intervention group
3171949|NCT00593749|Placebo Comparator|Control|Control
3171950|NCT00593775|No Intervention|control|control group without intervention
3171951|NCT00593775|Active Comparator|AH group|assisted hatching performed on the embryo
3171952|NCT00593788||1|Normal-hearing adults between 18 and 31 years of age.
3171953|NCT00593801|Active Comparator|2: late rhEPO|late EPO treatment from the fourth week for 6 weeks
2561290|NCT02490579||Clinical Survey Group|During June-August, 2015, approximately 500 women will be recruited at routine obstetric visits to the University of Michigan's outpatient clinics. Women who check in for an Ob appointment will be offered the opportunity to participate in an anonymous online survey. Individuals who express interest in participating will be provided with a laptop and headphones and directed to the survey Qualtrics site where they will take a 15 web-page, multiple choice survey developed by the research team. The survey covers these domains: reaction to video, understanding of core message, self-efficacy around lifestyle behaviors, attitudes, beliefs and intentions regarding vaccination during pregnancy, key health information sources during pregnancy, and demographics.
2561294|NCT02490579||Social Network Group|Once a pregnant participant completes the survey, she will be asked to provide her email address. If she is willing to do so, Qualtrics will automatically send her an email containing a weblink to the survey for her social network. She can then provide this link to 1 or 2 social network members that she feels influence her health behaviors during pregnancy. These members are asked similar questions about their response to the video, as well as some additional questions about how they advise their pregnant person about different health topics. It is necessary to provide a unique weblink to her, so that the survey responses from the pregnant woman and her unique social network members can be linked.
2561360|NCT02490345|Active Comparator|Gabapentin Administration|gabapentin 600mg orally every 8 hours x 48 hours
2561361|NCT02490345|Placebo Comparator|Placebo|Placebo , 1 tablet, orally every 8 hours x 48 hours
2561415|NCT02489942||Jardiance|Patients with T2DM to receive Jardiance tablets 10 mg, 25 mg
2561463|NCT02489656|Experimental|Coloplast Hydrocoated silicone JJ stent|Double loop ureteral stent endoscopic placement
2561470|NCT02489656|Active Comparator|Boston Percuflex Plus JJ stent|Double loop ureteral stent endoscopic placement
2561547|NCT02488954|Experimental|Probiotics|Oral daily take of probiotics in the form of cheese portion (50g) during 8 weeks
2561594|NCT02488707|Active Comparator|LISR group|Cases which undergo rectal resection with laparoscopic intersphincteric resection.
2561596|NCT02488707|Active Comparator|TAMIS Group|Cases with rectal cancer which undergo Transanal minimally invasive Total mesorectal excision.
2561635|NCT02488421||Patient treated with Apixaban|
2561636|NCT02488421||Patient treated with Rivaroxaban|
2561638|NCT02488421||Patient treated with Dabigatran|
2561640|NCT02488421||Patient treated with vitamin K antagonists|
2561685|NCT02488122|Experimental|High Impact Exercise|weight bearing exercises, jumps, plyometric exercises
2561687|NCT02488122|Sham Comparator|Low Impact Exercise|Walking, Strength training, Cycling, Yoga.
2561723|NCT02487719|Active Comparator|Iron sulfate|"Iron sulfate (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron sulfate 1 tbl daily until birth"
2561733|NCT02487719|Active Comparator|Iron polymaltose|"Iron polymaltose (or) is given if randomly asigned in this group and Ferritin at inclusion < 50 mcg/L.~intervention: oral iron polymaltose 1 tbl daily until birth"
2561742|NCT02487719|No Intervention|Multimineral|"Routine supplementation of multivitamin. multimineral only. Ferritin level > 50 mcg/L at inclusion. No additional iron supplementation.~oral multivitamin- multimineral preparation 1 tbl daily until birth as done in daily clinic routine"
2561808|NCT02487355|Active Comparator|group (MG)|Magnesium sulfate 50 mg add to 1 ml/kg of 0.25%of bupivacaine
2561813|NCT02487355|Active Comparator|group (D)|Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
2561815|NCT02487355|Active Comparator|group (MD)|50 mg magnesium sulfate and Dexmedetomidine 1 μg/ kg to add to 1ml/kg of 0.25%of bupivacaine
2561816|NCT02487355|Active Comparator|group (C)|1ml/kg of 0.25%of bupivacaine + 1 ml of normal saline
3206656|NCT00956527|Experimental|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
2561916|NCT02486432|Experimental|Single arm Levodopa/Carbidopa|The intervention is dosing with Sinemet® which is an oral tablet containing Levodopa/Carbidopa. Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
2562005|NCT02486276|Active Comparator|Sumatriptan|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
2562007|NCT02486276|Placebo Comparator|Placebo|headache is induced with Cilostazol. This headache is treated double-blinded with 1 tablet of placebo
3206657|NCT00956553|Active Comparator|Cervarix|Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
2562146|NCT02485106|Active Comparator|Rifaximin group|Corticosteroid or Pentoxifylline for 28 days Rifaximin 400mg tid for 28 days
2562148|NCT02485106|Active Comparator|Control group|Corticosteroid or Pentoxifylline for 28 days
2562192|NCT02484599|Experimental|CAT active attention bias modification|Active computerized attention training (CAT). Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements intended to direct attention towards food stimuli using pictorial food and non-food stimuli (see Werthmann, Field, Roefs, Nederkoorn, & Jansen, 2014).
2562193|NCT02484599|Placebo Comparator|CAT sham bias modification|Sham computerized attention training. Attention training via repeated trials of a modified anti-saccade task with concurrent assessment of eye-movements not intended to change attention processing of food stimuli using pictures of two different non-food stimuli categories (e.g. household and musical instruments).
2562259|NCT02484313|Experimental|Greek yogurt|25 g available carbohydrates
2561313|NCT02490774|Active Comparator|Arm 5: Levonorgestrel, Jaydess|Intrauterine device releasing levonorgestrel (Jaydess)
2561314|NCT02490774|Active Comparator|Arm 6: Levonorgestrel, Mirena|Intrauterine device releasing levonorgestrel (Mirena)
2561377|NCT02490124||Type 1 Diabetic|Type 1 Diabetic
2561387|NCT02490124||Control|normal healthy control
2561454|NCT02489864|Active Comparator|Terlipressin and albumin|"Patients in this group received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.~albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day."
2561461|NCT02489864|Placebo Comparator|Albumin|Only albumin (Albumin 20 percent; Instituto Grífols, Barcelona, Spain) was given at a dose of 10 gram per day.
2561509|NCT02489383|Active Comparator|Continuous Exercise Training|The interventions of active comparator will be education program and exercise training.
2561512|NCT02489383|Active Comparator|Interval Exercise Training|The interventions of active comparator will be education program and exercise training.
2561551|NCT02488902|Placebo Comparator|Placebo|Placebo was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561554|NCT02488902|Experimental|Tafenoquine 25mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561559|NCT02488902|Experimental|Tafenoquine 50mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561563|NCT02488902|Experimental|Tafenoquine 100 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561568|NCT02488902|Experimental|Tafenoquine 200 mg|Tafenoquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561569|NCT02488902|Experimental|Mefloquine 250 mg|Mefloquine was administered initially as a loading course of one capsule daily for 3 days, followed by a weekly dosing regimen at the same dose.
2561605|NCT02488525|Experimental|Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
2561606|NCT02488525|No Intervention|Control|The control group will receive all treatments according to standard of care which does not include prophylactic administration of Wilfactin®
3206658|NCT00956553|Active Comparator|Gardasil|Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.
3206659|NCT00956566|Active Comparator|low fat hypocaloric diet|
2561726|NCT02487823|Experimental|BKM 120 (60 mg)|BKM120 (60 mg) in combination with LH-RH agonists and bicalutamide
2561736|NCT02487823|Experimental|BKM 120 (80 mg)|BKM120 (80 mg) in combination with LH-RH agonists and bicalutamide
2561744|NCT02487823|Experimental|BKM 120 (100 mg)|BKM120 (100 mg) in combination with LH-RH agonists and bicalutamide
2561785|NCT02487381|Experimental|THC|Subjects receive 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) and corresponding cannabidiol placebo capsules.
2561786|NCT02487381|Experimental|CBD|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and corresponding delta-9-tetrahydrocannabinol placebo capsules.
2561787|NCT02487381|Experimental|CBD+THC|Subjects receive 800 mg cannabidiol (4 capsules containing 200 mg each) and 20 mg delta-9-tetrahydrocannabinol (2 capsules containing 10 mg each) a
2561791|NCT02487381|Placebo Comparator|Placebo|Subjects receive corresponding delta-9-tetrahydrocannabinol and cannabidiol placebo capsules
2561864|NCT02486991|Active Comparator|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
2561867|NCT02486991|Experimental|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
2561927|NCT02486601|Experimental|nab-paclitaxel + FOLFOX|nab-paclitaxel + FOLFOX nab-paclitaxel: 150 mg/m2 D1 every 2 weeks Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks 5-FU infusion: 2400mg/m2 48h infusion every 2 weeks 6 pre-operative cycles 6 post-operative cycles (optional)
2562056|NCT02485808||Surgical|"Men and women presenting for clinical care for whom surgical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
2562057|NCT02485808||Medical|"Men and women presenting for clinical care for whom medical treatment of their lower urinary symptoms is planned.~There will be no interventions, as this is an observational cohort."
2562061|NCT02485808||Controls|"Men and women who are not experiencing lower urinary tract symptoms.~This group will undergo MRI, pain and auditory sensitivity testing."
2562063|NCT02485808||Neuroimaging & Sensory Testing|"Subjects from the Medical and Surgical Cohorts who agree to additional testing in the form of neuroimaging (via fMRI) and multimodal sensory testing.~This group will undergo MRI, pain and auditory sensitivity testing."
3206660|NCT00956566|Active Comparator|Low carbohydrate hypocaloric diet|
3206661|NCT00956579||Healthy individuals|"No intervention~Healthy participants ages 14-32 for a neuroimaging study"
3206662|NCT00956579||Individuals with Autism Spectrum Disorder|"No intervention~ASD participants ages 14-32 for a neuroimaging study."
3206663|NCT00956605|Experimental|EEG biofeedback intervention|
3206664|NCT00956605|Active Comparator|Non EEG biofeedback computerized attention training|
3206665|NCT00956605|No Intervention|waitlist control|
3206666|NCT00956644|Experimental|irbesartan/amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 150/10 mg fixed combination for 5 additional weeks
2561327|NCT02490436|Experimental|A: active drug first|Cetuximab in treatment period 1, placebo in treatment period 2, and open-label cetuximab in treatment period 3.
2561328|NCT02490436|Experimental|B: placebo first|Placebo in treatment period 1, cetuximab in treatment period 2, and open-label cetuximab in treatment period 3.
2561416|NCT02490176|Experimental|GLP-1 group|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
2561418|NCT02490176|Placebo Comparator|Control group|drug: placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.
2561432|NCT02489643|Experimental|Receiving training|Patients will be visited and receive information about the prescribed topical treatment according to the normal course and procedure of an outpatient visit at our institution. At the end of the visit, they will also receive practical instructions on dosages and application modalities of the topical therapy.
2561437|NCT02489643|No Intervention|No-receiving training|
2561483|NCT02489539|Experimental|Short Neck Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation ≤ 60˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
2561484|NCT02489539|Experimental|High Neck Angulation Substudy|Subjects with abdominal aortic aneurysms having infrarenal aortic neck angulation > 60˚ and ≤ 90˚ and infrarenal aortic neck length ≥10 mm treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis.
2561643|NCT02488395||de novo Parkinson's patients|"This group includes de novo Parkinson's patients who have just been diagnosed and not started their treatment at the inclusion.~This group will perform three fMRI sessions at different crucial steps of their normal follow up with a neurologist. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
2561644|NCT02488395||matching controls|"This group includes age-matching control participants to the first Parkinson group.~This group will perform one fMRI session. Their visual abilities will be tested with an ophthalmologic evaluation and their sensitivity to contrast with a visual psycho-physics test."
2561698|NCT02487953|Experimental|Nicotine ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
2561703|NCT02487953|Active Comparator|Nicotine ENDS + Placebo Patch|Participants will initially receive 1 week of placebo skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive nicotine-containing ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the placebo patch size will be gradually reduced to mirror standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
2561708|NCT02487953|Active Comparator|Placebo ENDS + Nicotine Patch|Participants will initially receive 1 week of 21 mg nicotine skin patches while continuing to smoke their usual cigarettes ad lib. Starting with week 2, they will receive placebo ENDS devices and will be instructed to substitute ENDS for as many cigarettes as possible in this week. The target quit-smoking date will occur at the beginning of week 3. Treatments will continue until week 8 post-quit, at which time participants will be instructed to reduce ENDS use over the next 4 weeks, at which time ENDS will no longer be dispensed. Subsequently, the nicotine patch dose will be gradually reduced according to standard weaning regimen from 21 mg/24 h to 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks. All nicotine-based treatments will end at week 16 after the quit date.
3171954|NCT00593801|No Intervention|3: no EPO|control group, no EPO treatment
3171955|NCT00593801|Active Comparator|1: early rhEPO|early rhEPO treatment from the first week until 9 weeks
3171956|NCT00593853|Active Comparator|1|
3171957|NCT00593853|Placebo Comparator|2|
2561955|NCT02486380|Experimental|Full face/Nasal masks|Simplus/Eson
2562116|NCT02485041|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
3171958|NCT00593879|Placebo Comparator|1|Placebo
3171959|NCT00593879|Experimental|2|
3171960|NCT00593892||Observation|All patients who are admitted to UAB for trauma, are 19 years of age and older, and whose Injury Severity Score (ISS) is greater than 9.
3174964|NCT00628784|Experimental|Group 2|Diagnosis of Barrett's esophagus and high grade dysplasia or intramucosal carcinoma. Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement). Endoscopic ultrasound* (EUS) demonstrating no evidence of metastatic lymph node involvement or extension of carcinoma beyond the mucosa (T1).
2561340|NCT02490397|Experimental|Exposed to Day light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI. A blood draw will be performed before any light therapy. The patients will then receive a light box (Square One Wake Up Light NatureBright 10,000 LUX) that they shall use every morning from 8.30-9.00 AM for the next 2 weeks. At the conclusion of the two weeks another blood sample will be drawn.
2561341|NCT02490397|Sham Comparator|Exposed to Room light|Patients with myocardial infarction (MI): This group will be enrolled on the day of their MI and will only be exposed to room light. They will have blood drawn on the day of enrollment and then at 2 weeks after the MI.
2561372|NCT02490059|Active Comparator|Standard size bronchoscopy|ll procedures were started using SB with an external diameter of 5.0-6.0 mm with a biopsy channel of 2.2-2.8 mm (models Olympus BF-30 and BF-1T160, Olympus, Tokyo, Japan). If during SB the lesion was endoscopically visible the bronchoscopy was continued as standard diagnostic procedure and the patients were excluded from the analysis. Only if no tumour was visible during complete inspection of the bronchial tree using the SB, a participant was randomised by opening a numbered sealed opaque envelope. Randomisation was performed using sequentially numbered (1-40) sealed opaque envelopes (block randomisation: block size 4). For subjects allocated to the SB group, the examination was immediately continued with the same SB bronchoscope.
2561381|NCT02490059|Experimental|Ultrahin bronchoscopy|For subjects randomised to UB, the instrument was changed immediately to an Olympus BF-XP 40 ultrathin bronchoscope with an outer diameter of 2.8 mm and a working channel 1.2 mm during the same bronchoscopy session.
3206667|NCT00956644|Active Comparator|amlodipine|Before randomisation : amlodipine 5 mg for 7 to 10 days (common to 2 arms) then After randomisation : amlodipine 5 mg for 5 weeks followed by amlodipine 10 mg for 5 additional weeks
3206668|NCT00956670|Experimental|Supportive care (lymphedema assessment)|"Patients with vulvar cancer undergo a radical vulvectomy or hemi-vulvectomy followed immediately by an ipsilateral or bilateral inguinal-femoral lymphadenectomy. (Closed to accrual as of June 9, 2014)~Patients with cervical cancer undergo a radical hysterectomy or trachelectomy and bilateral pelvic lymphadenectomy +/- para-aortic nodal sampling via vaginal, laparoscopic, or open route.~Patients with endometrial cancer undergo a laparoscopic-assisted vaginal hysterectomy, a total laparoscopic hysterectomy, or total abdominal hysterectomy with pelvic lymphadenectomy +/- para-aortic node sampling.~Patients undergo limb measurements at baseline, weeks 4-6, and at 3, 6, 9, 12, 18, and 24 months."
2561521|NCT02489188||ankle osteoarthritis|patients with ankle osteoarthritis scheduled for arthroplasty
2561523|NCT02489188||knee osteoarthritis|patients with knee osteoarthritis scheduled for arthroplasty
2561525|NCT02489188||hip osteoarthritis|patients with hip osteoarthritis scheduled for arthroplasty
2561531|NCT02489188||lumbar spinal stenosis|patients with lumbar spinal stenosis scheduled for lumbar spinal stenosis decompression
2561533|NCT02489188||muscle contracture|patients with functionally limited range of motion at the knee because of muscle contracture scheduled for manual therapy
2561536|NCT02489188||healthy subjects|healthy subjects
2561558|NCT02488850|Active Comparator|Surgery|An anatomical surgical resection of primary tumor
2561566|NCT02488850|Active Comparator|Radiotherapy|Stereotactic Ablative Radiotherapy (SABR), outpatient treatment that is typically delivered in between 3-8 fractions
2561623|NCT02488616|Active Comparator|Sensor-augmented pump therapy|Participants will use sensor-augmented pump therapy with low-glucose suspend to regulate glucose levels. The low-glucose suspend feature available in the MiniMed® Paradigm® Veo™, Medtronic combined with the Enlite sensor® will be used. This feature allows for suspension of insulin delivery at a pre-set sensor glucose value for up to 2 hours.
2561628|NCT02488616|Active Comparator|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion will be used to regulate glucose levels. Participant's usual fast-acting insulin analog will be infused using a subcutaneous infusion pump (MiniMed® Paradigm® Veo™, Medtronic). Every 10 minutes, the glucose levels as measured by the sensor (Enlite sensor®, Medtronic) will be transferred automatically to a smartphone, that harbors the algorithm, that will calculate the recommended doses and will send it wirelessly to the infusion pump.
3206669|NCT00956683|Experimental|Ultrasound|Ultrasound guided infraclavicular block
2561735|NCT02487524|Other|Nerve resection with pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
2561745|NCT02487524|Other|Nerve resection without pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
2561748|NCT02487524|Other|No nerve resection but pain|Questionnaires, cognitive tests, sensory examination, cold water test with autonomic nervous system monitoring. QST.
3206670|NCT00956683|Active Comparator|Dual Endpoint Nerve Stimulator|Nerve stimulator guided dual endpoint infraclavicular block
3206671|NCT00956696||Topiramte|single arm, flexible dosing
2561871|NCT02486848|Placebo Comparator|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
2561874|NCT02486848|Active Comparator|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
2561918|NCT02486562||People diagnosed with Multiple Sclerosis|
2562003|NCT02486289|Experimental|NBMI (Emeramide) 100mg|NBMI oral capsules 100mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg placebo capsule equals in total 3 capsules administered daily.
2562004|NCT02486289|Experimental|NBMI (Emeramide) 300mg|NBMI oral capsules 300mg administered once daily. Double dummy used for blinding i.e. 2 x 50mg NBMI + 1 x 200mg NBMI capsule equals in total 3 capsules administered daily.
2562006|NCT02486289|Placebo Comparator|Placebo|Placebo oral capsules administered once daily. Double dummy used for blinding i.e. 2 x 50mg size + 1 x 200mg size placebo capsules equal in total 3 capsules administered daily.
3206672|NCT00956722|Experimental|Treatment|Active treatment with Bovine colostrum
2562101|NCT02485340|Active Comparator|Sumatriptan|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg
2562102|NCT02485340|Placebo Comparator|Placebo|headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)
2562141|NCT02484989||Retinopathy of prematurity|Any baby with ROP who is treated or referred to another unit for treatment either in the form of laser therapy, cryotherapy, antiVEGF agent or vitrectomy/scleral buckling (or a combination of above treatments)
2561412|NCT02490020|No Intervention|Routine CMR treatment to prevent CMR|Routine CMR treatment protocol(MP as first line approach, ATG as second line approach,ATG be used to treat BPAR in 1 week after op)
2561413|NCT02490020|Experimental|Routine AMR treatment plus MSC to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)+MSC( iv 2*10^6cell/kg at d1,d7)
2561414|NCT02490020|No Intervention|Routine AMR treatment to prevent AMR|Routine AMR treatment protocol(plasma exchange and IVIG as first line approach, anti-CD20 monoclonal antibody as second line approach)
2561441|NCT02489669|No Intervention|LVEDP-guided group|Patients allocated to the LVEDP-guided group will continue to receive intravenous 0.9% sodium chloride, according to the protocol suggested in the POSEIDON trial (that is, 5 mL/kg/hr for LVEDP ≤12 mmHg; 3 mL/kg/hr for 13-18 mmHg; and 1.5 mL/kg/h for >18 mmHg). The fluid rate will be eventually modified at the start of the procedure in case of discordance between non-invasive and invasive LVEDP pressure estimate, being the invasive value considered as gold-standard. The fluid rate will continued during the procedure, and for 4 hours post-procedure.
2561444|NCT02489669|Experimental|Renalguard group|Patients enrolled in this group will be treated by hydration with 0.9% saline controlled by the RenalGuard system. On top of the 1.5-5.0 ml/kg/h that patients would have received over the previous hour (according to the non-invasive estimate LVEDP), an initial bolus of 250 ml will be administered. In case of LV ejection fraction ≤30% and/or LVEDP >18 mm Hg the bolus will 150 mL. Therefore, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow rate (≥300 mL/h). The controlled hydration by the RenalGuard system will be continued during the procedure and for 4 hours following the procedure. Urine flow rate is monitored and maintained at the target value through the procedure and during the following 4 hours. Additional furosemide doses are allowed in case of decrease of the urine flow rate below the target value.
2561492|NCT02489487|Experimental|VM-1500 + Raltegravir|VM-1500 40 mg in combination with 400 mg Raltegravir
2561505|NCT02489487|Experimental|VM-1500 +Darunavir|VM-1500 40 mg in combination with 600 mg Darunavir boosted with 100 mg Ritonavir
2561508|NCT02489487|Experimental|VM-1500|VM-1500 40 mg alone
3206673|NCT00956735|Experimental|Pistachio Diet|Incorporates 3.0 oz (2 servings) of pistachios into a daily diet
2561657|NCT02488304|Experimental|HRCT scans|High Resolution Computed Tomography scans will be taken
2561690|NCT02487927||Weaning success|patients pass SBT and weaning without any ventilation in 48 hours
2561694|NCT02487927||weaning failure|patients do not pass SBT or ventilation with any ventilation in 48 hours
2561716|NCT02487667|Active Comparator|Intervention Group|Therapeutic exercise
2561717|NCT02487667|No Intervention|Control Group|No treatment
3206674|NCT00956735|No Intervention|Non-Pistachio|Does not incorporate pistachios into a daily diet
3206675|NCT00956748|Active Comparator|Ciprodex otic solution|ciprofloxacin 0.3% / dexamethasone 0.1% otic solution
2561889|NCT02486926|Placebo Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane,and the incidence and severity of emergence agitation was investigated.
2561891|NCT02486926|Active Comparator|Remifentanil|Anesthesia was maintained with sevoflurane and remifentanil. The incidence and severity of emergence agitation was compared with sevoflurane group.
2561892|NCT02486926|Active Comparator|Alfentanil|"Anesthesia was maintained with sevoflurane and remifentanil, and alfentanil was administered 10 min before the end of surgery.~The incidence and severity of emergence agitation was compared with sevoflurane group."
2561893|NCT02486926|Other|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
2561894|NCT02486926|Other|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
2561962|NCT02486354|Experimental|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
2562008|NCT02485990|Experimental|Arm A: Tremelimumab Alone|25 patients will receive tremelimumab alone at 10 mg/kg IV every 4 weeks for 7 doses then every 12 weeks until disease progression.
2562010|NCT02485990|Experimental|Arm B1: DESE Tremelimumab and Olaparib|18 patients will receive tremelimumab (3 or 10 mg/kg IV) every 4 weeks for 7 doses then every 12 weeks and olaparib (150 or 300 mg orally twice a day) until disease progression.
2562013|NCT02485990|Experimental|Arm B2: Tremelimumab and Olaparib|25 patients will receive tremelimumab (every 4 weeks for 7 doses then every 12 weeks) and olaparib (daily) until disease progression. Dose of tremelimumab and olaparib will be determined during the DESE (Arm B1).
2562028|NCT02485691|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m^2 intravenously in 1 hour every 3 weeks + prednisone 10 mg orally given daily + Primary prophylactic G-CSF (the choice of the G-CSF product is left to the Investigator's decision). Treatment will continue until confirmed disease progression or unacceptable toxicity.
2562029|NCT02485691|Experimental|Abiraterone acetate or enzalutamide|Abiraterone acetate oral 1000 mg once daily continuously + prednisone 5 mg orally given twice daily OR enzalutamide oral 160 mg once daily continuously. Treatment will continue until confirmed disease progression or unacceptable toxicity.
2562151|NCT02484924||Clopidogrel Group|Those patients treated with clopidogrel for ACS (before new guideline implementation)
2562154|NCT02484924||Ticagrelor Group|Those patients treated with ticagrelor for ACS (after new guideline implementation)
2562199|NCT02484586|Other|Presbyope group|"40 years and over with a reading add.~Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
3206676|NCT00956748|Experimental|Ciprodex with 2% NAC|Ciprodex otic solution (ciprofloxacin 0.3% / dexamethasone 0.1%) augmented with 2% N-acetylcysteine
3206677|NCT00956774|Active Comparator|Balloon Catheter|
3206678|NCT00956774|Active Comparator|Cervical Vacuum Cup|
3206679|NCT00956774|Active Comparator|acorn-tipped cannula|
2561477|NCT02489565|Experimental|Primary care|Outpatient discharge from tertiary care to a primary care near the patient's home with the support of telemedicine.
2561489|NCT02489253||polygenic hypercholesterolemia|patients with high cholesterol level where no mutation was found in their FH-causing genes and had to gene score in their six LDL-C raising gene score undergo a carotid ultrasound, a CT coronary angiogram and a blood test
2561501|NCT02489253||monogenic FH|patients with a mutation in FH-causing gene undergo a carotid ultrasound, a CT coronary angiogram and a blood test
2561632|NCT02488551|Experimental|CALM Tools for Living - computer|This intervention includes the delivery of CALM via computer
2561633|NCT02488551|Active Comparator|CALM Tools for Living - manual|This intervention includes the delivery of CALM delivered manual
2561651|NCT02488161||Patients with colorectal cancer|One cohort of patients with colorectal cancer, studied before the intervention, and one month, one year, two years, three years and five years after.
3206680|NCT00956787|Experimental|Treatment with AR-67|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days.
3206681|NCT00956800|Experimental|telemedicine/study group|
3206682|NCT00956800|Active Comparator|control group|
3206683|NCT00956826|Experimental|Electrode added to device|With an electrode and a regular vacuum device
2561727|NCT02487511|Active Comparator|14 days|14 days treatment regimen
2561737|NCT02487511|No Intervention|7 days|7 days treatment regimen
2561781|NCT02487433|Experimental|Tofacitinib MR 22 mg Fed|Single dose of tofacitinib MR 22 mg administered under fed conditions
2561782|NCT02487433|Experimental|Tofacitinib MR 22 mg Fasted|Single dose of tofacitinib MR 22 mg administered under fasted conditions
2561883|NCT02487147|Active Comparator|N95 Respirator|Participants in this arm will wear an N95 respirator and safety goggles during Live Attenuated Influenza Vaccine exposure.
2561886|NCT02487147|Experimental|Free Air Portable Air Powered Respirator|Participants in this arm will wear a Free Air PAPR and safety goggles during Live Attenuated Influenza Vaccine exposure.
2561921|NCT02486471|Other|Observational approach|Wait and see
2561935|NCT02486471|Active Comparator|Use of Monsel´s Paste|cervical coagulation using a hemostatic agents, ie monsel´s paste
2561963|NCT02486172|Other|Peer supporter|Peer support program
2562027|NCT02485977||Pulmonary Hypertension|Adult patients with pulmonary hypertension referred for cardiac catheterization in the PI institution
2562053|NCT02485548|Experimental|Raltitrexed plus cisplatin|Raltitrexed plus cisplatin and IMRT
2562054|NCT02485548|Active Comparator|5-fluorouracil plus cisplatin|5-fluorouracil plus cisplatin and IMRT
3206684|NCT00956852||Lung cancer|Non-small cell lung cancer patients undergoing surgical lung resections
3206685|NCT00956865|Active Comparator|Voucher|Voucher for transportation reimbursement
2562241|NCT02484391|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|See Detailed Description
2562361|NCT02484014|Experimental|TSM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by teachers as SEHER Mitra)
2562366|NCT02484014|Experimental|SM Arm|Tarang Adolescence Education Programme + SEHER Intervention (delivered by SEHER Mitra)
2562372|NCT02484014|Other|Comparison Arm|Tarang Adolescence Education Programme
2562430|NCT02483221|Active Comparator|TCI-PCA|
2562439|NCT02483221|Active Comparator|PCA|
2562464|NCT02482883|Active Comparator|active Transcutaneous Electrical Nerve Stimulation|Arm A, treated by active stimulation of the trigeminovascular system after placement of the TENS device.
2562465|NCT02482883|Sham Comparator|sham Transcutaneous Electrical Nerve Stimulation|Arm B, treated by non-active (sham) stimulation after placement of the TENS device. This absence of stimulation corresponds to the standard of care currently received by patients hospitalized for SAH due to ruptured aneurysm.
2562521|NCT02482649|Experimental|EAA/T|EAA/TEquine-Assisted Activities and Therapy) bi-weekly for 12eeks
2562525|NCT02482649|Active Comparator|Drugs|Methylphenidate or Atomoxetine
2562578|NCT02482142|Placebo Comparator|phosphorus alone|Effect of phosphorus (500mg) ingestion alone. No meal. Needed to determine the impact of phosphorus alone on DIT
2562579|NCT02482142|Placebo Comparator|high CHO meal alone|Ingestion of placebo tablets with the high carbohydrate meal
2562580|NCT02482142|Active Comparator|High CHO meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high carbohydrate meal
2562581|NCT02482142|Active Comparator|High protein meal plus phosphorus|Effect of phosphorus (500mg) tablets ingestion of DIT of the high protein meal
2562582|NCT02482142|Placebo Comparator|High protein meal alone|Ingestion of placebo tablets with the high protein meal
2562614|NCT02481726|Experimental|68Ga|In patients in suspicion of lung cancer or lung tuberculosis; in patients with differential diagnosis difficulties; without treatment or surgery. They underwent a standard routine 18F-FDG PET/CT first, and were injected 10~20MBq 68Ga-Alfatide II in the next day, followed by whole body PET/CT acquisitions.
3206686|NCT00956865|Active Comparator|Voucher and call|Voucher for transportation and telephone calls
3206687|NCT00956865|Active Comparator|Voucher and call and contact|Voucher for transportation, telephone calls, and a contact at the senior center
2562705|NCT02481037|Experimental|Intervention group|Embedding a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate practitioners utilizing best-evidence; training these practices' chronic disease management (CDM) professionals to provide asthma education to children with asthma and their parents; and clinicians receiving an EMR embedded dashboard.
2562706|NCT02481037|No Intervention|Control group|Practice will continue with routine care. Control group will be offered the intervention at study completion, if successful.
2562871|NCT02480049|Active Comparator|B Reference|reference drug (Singulair) 1 tablet contains 10 mg Montelukast
2562948|NCT02479204|Experimental|Part B ACT-334441 + diltiazem|12 subjects will receive 240 mg of diltiazem (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
3206688|NCT00956878||Cancer Pain Patients|
3206689|NCT00956891||group A|autologous MSCs transplantation were performed plus medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin)
2561514|NCT02489149|Experimental|Multi-sector interventions|"Multi-sector interventions~Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
2561519|NCT02489149|Placebo Comparator|Control|Conventional approach of current public food and nutrition policies.
3171963|NCT00593931|Experimental|A|Normal Subjects
2563626|NCT02474927|Experimental|Carfilzomib Treatment Arm|Carfilzomib will be administered at a dose of 20 mg/m2 on two consecutive days, each week for three weeks (Days 1 2, 8, 9, 15, and 16) to constitute one therapeutic cycle. Carfilzomib may be administered for 1-2 complete cycles in the study.
2563673|NCT02474628|Placebo Comparator|Placebo|0.3 g∙kg-1body mass of calcium carbonate
2563678|NCT02474628|Experimental|Sodium bicarbonate|0.3 g∙kg-1body mass of sodium bicarbonate
2563755|NCT02474017|Experimental|MGR001|MGR001 (FP/Salmeterol) (250/50 µg) twice daily (BID)
2563819|NCT02473302|Placebo Comparator|ham|160g per day during 4 days
2563821|NCT02473302|Experimental|ham + pomegranate extract|160g per day during 4 days
2563825|NCT02473302|Experimental|ham + tocopherol|160g per day during 4 days
2563830|NCT02473302|Placebo Comparator|rare sirloin steak|110g per day during 4 days
2563836|NCT02473302|Experimental|marinated rare sirloin steak|110g per day during 4 days
2563838|NCT02473302|Experimental|marinated cooked sirloin steak|110g per day during 4 days
2563880|NCT02473003|Experimental|High intensity|high intensity exercise 80-90%
2563882|NCT02473003|Experimental|Low/Medium intensity|low/medium intensity exercise 40-50%
2563884|NCT02473003|Experimental|High Intensity with BM|high intensity exercise with Behavioral medicine strategies¨ 80-90%
2563885|NCT02473003|Experimental|Low/Medium intensity with BM|low/medium intensity exercise with Behavioral medicine strategies 40-50%
2563925|NCT02472717|Experimental|Interventional arm|liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
2563929|NCT02472717|Placebo Comparator|Placebo arm|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
2563950|NCT02472470|Experimental|Treatment|intermitten TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 2 weeks.
2564019|NCT02472275|Experimental|Treatment (PLX3397, radiation therapy, ADT)|Patients receive multitargeted tyrosine kinase inhibitor PLX3397 PO BID for 6 months, undergo radiation therapy for 2 months daily (Monday-Friday) beginning at month 3, and undergo ADT with leuprolide acetate, goserelin acetate, or degarelix injections in any month.
2564064|NCT02471625||Traumatic Brain Injury|Men and women ages 18-65 with suspected acute head trauma within 24-72hrs. of presentation, scoring a 3-15 on initial evaluation on GCS scale.
2564068|NCT02471625||Control|Men and women ages 18-65 with no history of head trauma and a score of 15 on the GCS scale.
2564194|NCT02471482|Experimental|Music First group|"Mozart music lullaby for 30 minutes with recording of cerebral oxygenation (by using Near infrared spectroscopy) and vital signs (respiratory rate, heart rate, oxygen saturations and frequency of apneic episodes continuously) followed by 10 minutes of washout period and then period of no music for next 30 minutes (with same variables recorded as outlined for music session).~This cycle is repeated every 6 hours for 24 hours. In addition, the behavioral response of baby is observed during the study period by video recording which will be in 'Mute' video mode and then reviewed by our developmental staff"
2564195|NCT02471482|Experimental|No Music First group|"No music in first 30 minutes of study followed by 10 minutes of washout period and then 30 minutes of Mozart music lullaby while recording same variables. This cycle was repeated every 6 hours for 24 hours."
2564535|NCT02468622||MO patients|Patients with migraine without aura. We will take blood samples during spontaneous migraine attacks
2564536|NCT02468622||MA patients|Patients with migraine with aura. We will take blood samples during spontaneous migraine attacks
2564571|NCT02468349|Experimental|Telemedicine|The telehealth group will be remotely monitored and managed on medication adherence, dosage titration, and management of drug side effects, through a combination of feed-forward blood pressure monitoring, app-based education and medication reminders, and remote consultations.
2564574|NCT02468349|No Intervention|Standard care|The standard care group will receive face-to-face consultations at one month, 6 months and 12 months.
3171964|NCT00593944|Experimental|1|Patients will receive active MDX-1342.
3171965|NCT00593970||1|All women presenting to our prenatal clinic and postpartum floor during the study period.
3171966|NCT00593983|Experimental|1|
3171967|NCT00593983|Placebo Comparator|2|Control
3171968|NCT00593996|Placebo Comparator|1|oral placebo 3 times weekly
3171969|NCT00594048|Experimental|1|15 hypertensive patients use the Resperate for 9 weeks and measure their blood pressure before and after using this device
3171970|NCT00594048|Active Comparator|2|15 patients use a discman with freely chosen music for 9 weeks and measure their blood pressure before and after use of this device
3171971|NCT00594074|Experimental|1|This group will receive 3.25 ounces of white wine with lunch and dinner
2561532|NCT02489136|Other|Spirit Pass|It is a transfusion of psychic energies. Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
2561535|NCT02489136|Placebo Comparator|laying of hands by workes|Laying of hand by workers and volunteers, not belonging to Spiritism.Laying of hands to be in front of the incubator or on bed, at a distance at around 10 to 15 cm, during 10 minutes. Evaluate the effects of spirit passe in newborn and adults before and after ten minutes for 3 days.
2561537|NCT02489136|No Intervention|No intervention|No intervention during, in adults before and after ten minutes for 3 days.
2561548|NCT02488889|Active Comparator|Varenicline vs placebo|Participants will be titrated on varenicline as follows: days 1-3, .5 mg per day; days 4-7, .5 mg twice per day, and days 7-12, 1 mg twice per day. Placebo and varenicline pills will be matched in number of pills and packaging of active medications.
2561552|NCT02488889|Active Comparator|Alcohol beverage vs. placebo beverage|During each experimental session, participants will ingest a beverage containing placebo (0.0 g/kg; 1% volume of ethanol as taste mask) or alcohol (0.8 g/kg). The beverage will be administered in clear plastic-lidded cups in 2 equal portions that will be consumed during a 5-minute interval and separated by a 5-minute interim rest. The beverages will contain 190-proof ethanol prepared with water, flavored drink mix, and a sucralose-based sugar substitute. Doses for women will be 85% of those of men to adjust for sex differences in total body water.
2561610|NCT02488629|Experimental|SCB01A|This study is a single arm, open-label, Phase II trial
2561795|NCT02487875|Experimental|COPD patients -study group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme. The study group performs in addition to the standard programme, also a peripheric muscle strength training
2561799|NCT02487875|Active Comparator|COPD patients -control group|COPD inpatients GOLD2-4, in stable conditions,hospitalized to follow a pulmonary rehabilitation programme
2561840|NCT02487095|Experimental|1/Phase I|VX-970 + (M6620) topotecan at escalating doses
2561841|NCT02487095|Experimental|2/Phase II|VX-970 (M6620) + topotecan at MTD/RP2D
2561880|NCT02486770|Experimental|Group 1|Aerucin 2.0mg/kg
2561881|NCT02486770|Experimental|Group 2|Aerucin 8.0mg/kg
2561882|NCT02486770|Experimental|Group 3|Aerucin 20.0mg/kg
2561920|NCT02486497|Active Comparator|5-FU group|Grades of hENT1 immunostaining are 0 or 1.
2561933|NCT02486497|Active Comparator|Gemcitabine group|Grade of hENT1 immunostaining is 2.
2562043|NCT02485665|No Intervention|Kegel exercise education|Prostate cancer patients of control group will received Kegel exercise education for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
2562045|NCT02485665|Experimental|Extracorporeal biofeedback device|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy.
2562072|NCT02485431|Experimental|Deflazacort, fasted|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water in Fasted state.
2562076|NCT02485431|Experimental|Deflazacort, high-fat meal|36mg of Deflazacort with 240 ml of room-temperature, non-carbonated water with high fat meal served 30 minutes prior to dosing.
2562080|NCT02485431|Experimental|Deflazacort, crushed, fasted|36mg of Deflazacort crushed and mixed with apple sauce.
2562083|NCT02485431|Experimental|Deflazacort alternate strength,fasted|Investigational Formulation Deflazacort tablet (6 X 6mg).
2562085|NCT02485431|Experimental|Deflazacort suspension with apple juice|Deflazacort oral suspension (36mg) mixed with 100ml apple juice in fasted state.
3171972|NCT00594074|No Intervention|2|This group receives the same amount of calories as the experimental group
3171973|NCT00594087|Active Comparator|1|Lunesta 2 or 3 mg
3171974|NCT00594087|Placebo Comparator|2|Placebo 2mg or 3 mg
3171975|NCT00594113|Experimental|1|Multimedia Colorectal Cancer Screening
3171976|NCT00594126|Other|1|3+3 cohort dose escalation
3171977|NCT00594139|Experimental|1|Receipt of autologous neo-bladder construct
2562258|NCT02484079|Active Comparator|Cold polypectomy|"Patients in this arm will have their polyps removed by cold polypectomy, i.e. a metal sling that is closed around the basis of the polyp, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
2562267|NCT02484079|Active Comparator|Hot polypectomy|"Patients in this arm will have their polyps removed by hot polypectomy, i.e. a metal sling taht is closed around the basis of the polyp, electrical currents is applied, and the polyp is cut off.~After removal there will be taken biopsies from the resection margins, and both the polyp and the biopsies will be examined by a histopathologist to see if the polyp is removed completely."
2562308|NCT02483988|Experimental|NUsurface Meniscus Implant|All eligible patients will receive the NUsurface® Meniscus Implant.
2562349|NCT02483702|Experimental|Patients under 4 months Receive Irradiated Blood|Patients under 4 months of age will receive irradiated blood products, as per hospital protocol. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
3171978|NCT00594152|No Intervention|1Control|Standard treatment of type 1 diabetes mellitus with 3-4 subcutaneous injections of insulin daily
3171979|NCT00594152|Experimental|Treatment|Intervention: three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to standard subcutaneous insulin.
3171980|NCT00594191|Placebo Comparator|A|Placebo treatment
3171981|NCT00594191|Experimental|B|
3171982|NCT00594217|Experimental|Progesterone|oral micronized progesterone suspension, single 100 mg oral dose
3171983|NCT00594217|Placebo Comparator|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
3171984|NCT00594243|Experimental|Intervention|8-week mindfulness based stress reduction program
3171985|NCT00594243|Active Comparator|Wait-list control|Wait-list received no intervention during the time the treatment group received the 8-week program
2561562|NCT02488993||Prospective Phase No Rifaximin-α 550mg|Prospective data collection of patients NOT treated with Rifaximin-α 550mg from point of study entry.
2561565|NCT02488993||Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received Rifaximin-α 550mg within the previous 12 months.
2561613|NCT02488603|Experimental|Decision aids|
2561616|NCT02488603|No Intervention|usual care|
2561649|NCT02488278|No Intervention|Self-Monitoring of Glucose Blood Measurements|Self-Monitoring of Glucose Blood Measurements using the GlucoMe Glucose Monitoring Device and App
3206690|NCT00956891||group B|only medical treatments (reducibility glutathione, glycyrrhizin, ademetionine, polyene phosphatidylcholine, alprostadil, and human serum albumin) were performed without autologous MSCs transplantation.
2561756|NCT02487537|Placebo Comparator|Non-sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day; soft drink does not contain glucose or any kind of sweet tasting substance
2561766|NCT02487537|Active Comparator|Sweetened soft drink|4-week-intervention with one liter of custom-made soft drink per day, soft drinks contains an amount of sweetener, which is isosweet compared to 100 g of sucrose in one liter of beverage
2561796|NCT02487238|Experimental|Fecal Microbiota Enema|Live, healthy, human donor stool prepared as fecal enemas. Fecal enemas are prepared and collected by Rebiotix(®) (RBX2660), using extensively screened donor stool. Enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
2561800|NCT02487238|Placebo Comparator|Normal Saline Enema|Normal saline enemas will be administered on site at one of the participating trial sites by trained study investigators. Enemas are given: 2x per week for 6 weeks (total = 12 enemas over 6 weeks). Patients will be masked to enema contents.
2561873|NCT02486965|Experimental|training group|"The training program consists of three sessions of 45 minutes of physical activity per week for 2 years. During the first 6-9 months, two individual workouts, supervised by a physiotherapist and a session in Living.~Depending on the capacity and exercise tolerance of the patient, patients realize the second phase of training until 2 years of the study: three exercise sessions from 45 to 60 minutes per week of which group session led by a professor of Adapted Physical Activity (APA) and 2 autonomous sessions.~Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms"
2561876|NCT02486965|Placebo Comparator|control group|A training program supervised by physical therapists and teachers in Adapted Physical Activity, identical to the active program in its follow-up, but the intensity of the sessions is lower than that of the training group
2561923|NCT02486510|No Intervention|Group 1 (Control)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy. Patients not receiving antiretroviral therapy will start it.~Patients randomized to this group will not receive clinical trial treatment (neither Maraviroc or Placebo)"
2561934|NCT02486510|Experimental|Group 2 (Treatment)|"Patients receiving intensive chemotherapy with/without stable antiretroviral therapy and Maraviroc.~Patients not receiving antiretroviral therapy will start this theraphy together with Maraviroc."
2561969|NCT02486185|Other|SARC-F|screening test for sarcopenia being studied, the SARC-F
2562086|NCT02485444|Active Comparator|Oxytocin|
2562087|NCT02485444|No Intervention|Observation|
2562135|NCT02485171|Experimental|Experimental|Introduction of a walking aid device SAFEWALKER for elderly patients during rehabilitation after a post-fall syndrome.
2562138|NCT02485171|No Intervention|No intervention|No introduction of a walking aid device for elderly patients during rehabilitation after a post-fall syndrome.
3171986|NCT00594269|Placebo Comparator|A|Discontinuation of antipsychotic or antidepressants
3171987|NCT00594282|Experimental|1|Enhanced Mammography (EM) - Women who are randomized to the Enhanced Mammography (EM) condition will receive a mammogram in which a MammoPad radiolucent breast plate cushion is used.
2562284|NCT02484209|Experimental|Glimepiride + metformin|Glimepiride (2-4mg twice daily) + metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
2562289|NCT02484209|Active Comparator|Metformin|Metformin (1500 mg daily) (n = 10 in total) Older subjects with moderate frailty will be assigned for 16 weeks to this arm. A subgroup (n=5) will undergo 3 x 72h periods of CBGM
2562356|NCT02483871|Experimental|Rosuvastatin|Two Cohorts, one at 20 mg and one at 40 mg will enroll in a dose escalation of rosuvastatin
2562404|NCT02483377||Observational (treatment summaries and plan report)|"Patients receive treatment summaries and plan report that captures patient data through the use of an intake checklist completed during the initial consultation with the breast oncology team and used to guide referrals to existing services and programmed with generic information related to disease and treatment management plan. Additional elements, such as psycho-social services, exercise, and/or nutrition, identified by the patient self-report, will be incorporated. Patients also complete 3 questionnaires at each clinic visit."
2562448|NCT02483026|Experimental|Intensive supplements care pre-surgery|Multi vitamins pills vitamin D
2562451|NCT02483026|Other|Standard supplements care pre-surgery|vitamin D (Vitamin D will be given in a reduced doses compared to the intervention group)
2562479|NCT02482753|Experimental|Chidamide + exemestane, open-label|Patients receive 30 mg Chidamide per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2562485|NCT02482753|Experimental|Chidamide + exemestane, double-blinded|Patients receive 30 mg Chidamide twice per week and 25 mg exemestane QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2562487|NCT02482753|Placebo Comparator|placebo + exemestane, double-blinded|Patients receive placebo twice per week and 25 mg exemestane PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
2562585|NCT02482103||Patients treated with renal denervation|Patients treated with RD in the Netherlands. The decision to perform RD was made by the treating physician in the participating hospitals.
2562654|NCT02481583|Experimental|part 1|12 subjects successively received a single dose of levosulpiride tablets 25, 50, or 100 mg via oral administration and 50-mg of levosulpiride tablets 3 times a day for 7 days.
2563000|NCT02479100|No Intervention|Follow Standard care|Patient will follow standard care pathway.
2561586|NCT02488863||Older Adults without Musculoskeletal Pain|Older adults (60+ years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
2561587|NCT02488863||Young Controls|Healthy young adults (18-25 years old) not experiencing musculoskeletal pain will undergo: MRI Neuroimaging, Quantitative Sensory Testing, Physical and Cognitive Function Testing, and questionnaire batteries.
2561641|NCT02488382|Experimental|Lonquek|treatment with Lonquek for autologous stem cell collection
2561753|NCT02487758|Experimental|Ridge preservation Flap|The flap procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal.
2561760|NCT02487758|Experimental|Ridge preservation Flapless|The test will be a flapless technique with tunneling and an intramucosal vertical incision on the buccal.
2561804|NCT02487316|Experimental|crizotinib combined with chemotherapy|crizotinib 250mg, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
2562306|NCT02484053|Experimental|Rheumatologic disease|Rituximab is administered over 120 minutes, 12.5% of the dose will be given over the first 30 minutes and the remaining 87.5% of the dose will be given over 90 minutes.
2562307|NCT02484053|Experimental|Cancer or blood disorder|Rituximab is administered over 90 minutes, 20% of the dose will be given over the first 30 minutes and the remaining 80% of the dose will be given over 60 minutes.
2562311|NCT02483767|Experimental|standard chemotherapy with goserelin|standard chemotherapy with the GnRH agonist goserelin
2562312|NCT02483767|Active Comparator|standard chemotherapy without goserelin|standard chemotherapy without goserelin
2562362|NCT02483598|Experimental|Buspirone|Buspirone alone
2562367|NCT02483598|Active Comparator|Buspirone plus grapefruit juice|Buspirone plus grapefruit juice
2562408|NCT02483338|Other|Children surgery|
2562458|NCT02483052|Experimental|RejuvenAir|RejuvenAir if the treatment areas are designated as Segmental, males will be dosed for 11 seconds and females for 10 seconds. If dosing is in the Lobar area males will be dosed for 12 seconds and females for 11 seconds.
2562488|NCT02482727|No Intervention|non-occlusion training group|The control (non-occlusion training) group will follow the standard post-operative distal radius fracture rehabilitation protocol. Treatment will include passive, active assistive,active range of motion (P/AA/AROM) to wrist, forearm and hand; desensitization as needed; edema control as needed; heat/cold modalities as needed; and strengthening exercises.
2562492|NCT02482727|Experimental|occlusion training with DELFI PTS ii tourniquet|The occlusion training group will follow the same protocol as described above but will utilize occlusion training with the strengthening exercises. Investigators will use an established occlusion training protocol already being. Intervention: occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)
2562534|NCT02482532|Experimental|tvs-CTL Vaccine|Infusion of activated T-cells generated from a patient's own peripheral blood mononuclear cells.
3171988|NCT00594282|No Intervention|2|Routine Mammography (RM) - Women who are randomized to the Routine Mammography (RM) condition will obtain a routine, un-altered mammogram during which typical exam protocol will be followed and no radiolucent cushion is used.
2562799|NCT02480491||Third day embryos|embryos culture media during third day after fertilization
2562803|NCT02480491||Fifth day embryos|embryos culture media during fifth day after fertilization
2562842|NCT02480192|Experimental|Experimental Group (CBT-Meno)|After an initial assessment, the experimental group received 12 weekly sessions (2 hours each) of group-based cognitive-behavioural therapy for menopausal symptoms (CBT-Meno) (up to n=8 per group). Symptoms that were targeted included vasomotor symptoms (hot flashes/night sweats), depressive symptoms, anxiety, poor sleep, and sexual concerns. Participants were re-assessed at 12-weeks post-baseline and at 3 months post-treatment.
2562845|NCT02480192|No Intervention|Waitlist|After an initial assessment, the waitlist comparison group did not receive any treatment for 12 weeks. They were then re-assessed at 12-weeks post-baseline and this data was used to compare this group to the experimental group to determine the effectiveness of the CBT-Meno treatment. After this re-assessment participants in the waitlist condition were offered the same CBT-Meno treatment as the experimental group: 12 weekly sessions (2 hours long) of cognitive-behavioural therapy for menopausal symptoms.
2562882|NCT02479906|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
2562884|NCT02479906|Experimental|Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The HAC Coil is designed to stimulate neuronal pathways in the medial prefrontal cortex or motor cortex, including the anterior cingulated cortex.
2562972|NCT02479425|Active Comparator|3 point turning|patients nursed by the traditional re-positioning (two hours on back, two hours on right and two hours on left).
2563157|NCT02478021|Experimental|Hydrocortisone|10 mg hydrocortisone
3171989|NCT00594321|Active Comparator|2|Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
3171990|NCT00594321|Experimental|1|Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
3171991|NCT00594334|Experimental|E, I|
3171992|NCT00594347|Experimental|Group A|Pneumo 23
3171993|NCT00594347|Active Comparator|Group B|Prevnar
3171994|NCT00594360|Active Comparator|1|
3171995|NCT00594373|Experimental|1|Application of 1% tenofovir gel for 14 consecutive days between menses
3171996|NCT00594373|Placebo Comparator|2|Application of 1% tenofovir placebo gel for 14 consecutive days between menses
3171997|NCT00594438|Experimental|1, A|Femoral reaming with the Synthes Reamer-Irrigator-Aspirator (RIA)
3171998|NCT00594438|Active Comparator|2 B|Femoral reaming with a Zimmer Sentinel Reamer.
3171999|NCT00594451||I|multicenter Veteran Affairs Rheumatoid Arthritis (VARA) registry
3172000|NCT00594451||II|NIH-funded Consortium for the Longitudinal Evaluation of African Americans with Early RA (CLEAR)
2561650|NCT02488252|Experimental|Chinese Medicine on top of standard medical care|"Semi-individualised Chinese Medicine treatment on top of standard medical care The treatment plan consists of 5 different formulas and will be prescribed to patients categorised to 5 subgroups according to clinical manifestation. Patients having multiple manifestations that fit more than 1 subgroup will not be included.~Minor adjustment of the medication will be allowed and determined by the Chinese Medicine practitioner to reflect actual clinical practice. Dosage will follow strictly the China Pharmacopeia.~A: spleen and kidney Qi deficiency, B: spleen and kidney Yang deficiency, C: spleen and kidney Qi and Ying deficiency, D: liver and kidney Ying deficiency, E: Ying and Yang deficiency~Rehmannia-6 decoction: Wolfiporia cocos, Rehmannia glutinosa, Common macrocarpium Fruit, Dioscorea opposita , Paeonia suffruticosa Andr., Oriental waterplantain rhizome~Rehmannia-8 decoction: Radix Aconiti Lateralis preparata, Cinnamomum cassia Presl, Rehmannia-6 decoction"
2561691|NCT02487940|Active Comparator|Intralipid|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
2561695|NCT02487940|Placebo Comparator|Placebo|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
2561719|NCT02487628|Experimental|HQ® Matrix Soft Tissue Mesh|HQ® Matrix Soft Tissue Mesh is a warp-knitted, multifilament, bioengineered scaffold which is comprised of the silk fibroin protein of the Bombyx mori (B. mori) silkworm. The porous network structure makes it soft and pliable and convenient to implant. The mesh is mechanically strong, biocompatible, and long-term bioresorbable. The pore size is suitable for macrophage migration and recruitment, which hinders bacteria growth. The mesh is provided in single sheets of varying widths and lengths and may be cut to the shape or size desired for a specific application. It is sterile and for single-patient use only.
2561721|NCT02487628|Active Comparator|ULTRAPRO® Partially Absorbable Lightweight Mesh|ULTRAPRO® Partially Absorbable Lightweight Mesh (Ethicon, Inc.) is manufactured from approximately equal parts of absorbable poliglecaprone-25 monofilament fiber and non-absorbable polypropylene monofilament fiber. Designed for open and laparoscopic hernia repairs, it allows surgeons the versatility to perform various hernia repairs with a single technology. It offers excellent strength with minimal foreign body mass, to allow patients to heal more naturally with increased comfort and mobility.
3206691|NCT00956904|Experimental|3-D TRUS navigation software during T-RALP|
3206692|NCT00956917|Active Comparator|Akern EFG|
3206693|NCT00956917|Active Comparator|RJL device|
2561869|NCT02486783||Baseline controls (no signs of infection)|Neonates admitted for serial blood draws for uncomplicated hyperbilirubinemia
2561872|NCT02486783||Signs of infection A|No infection: antibiotics stopped after 48 hours; negative cultures
2561875|NCT02486783||Signs of infection B|Clinical infection: 7 day antibiotics; negative cultures
2561878|NCT02486783||Signs of infection C|Sepsis: positive bacterial blood culture
2561879|NCT02486783||Signs of infection D|Meningitis: positive bacterial CSF culture
3206694|NCT00956956|Experimental|PF-04455242 treatment|
3206695|NCT00956956|Placebo Comparator|Placebo|
3206696|NCT00956969|Experimental|Anger awareness and expression|Training for anger awareness and expression
3206697|NCT00956969|Active Comparator|Relaxation Training|Teach patients relaxation training
3206698|NCT00956969|No Intervention|No-treatment control|Assessment only control condition
3206699|NCT00957060|Experimental|glimepiride|The initial dose is 2 mg once a day. At week 2, the dose can be increased to 4 mg once a day according to the titration. At week 4 and 12, the dose can be increased from 2 mg to 4 mg or from 4 mg to 6 mg according to the titration.
2562046|NCT02485938|Experimental|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|CAP-1002 is an investigational product consisting of allogeneic cardiosphere-derived cells (CDCs). All subjects assigned to the active treatment arm will receive an intended total dose of 75 million (M) CAP-1002 cells infused as 25M cells into each of the three left ventricle cardiac territories (anterior, lateral, inferior/posterior). If any of the three coronary arteries are deemed by the infusing Investigator to supply less than 30% of the left ventricular myocardium, the infusing Investigator may choose to infuse only 12.5M cells into that coronary artery or arteries. Therefore the full dose of CAP-1002 delivered may range from 50M cells to 75M cells provided that all three arteries are infused.
2562047|NCT02485938|No Intervention|Usual Care|Subjects randomized to receive usual care will continue to be cared for and treated in whatever manner the investigator deems most appropriate for the subject on an ongoing basis, and will receive no infusion.
2562071|NCT02485418|Experimental|Propofol infusion|"All subjects will be treated with an intravenous propofol infusion at the following escalating rate schedule:~20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes"
2562108|NCT02485249|Experimental|Dexamethasone Phosphate|Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 14.0 mA-min at 3.5 mA on Day 0, Day 4, and Day 14
2562111|NCT02484937|Active Comparator|Group 1 (PMS Treatment)|Subjects will be treated monthly for 6 months by Pain Medicine Specialist (PMS) per standard protocol. The PCP will not be involved in the treatment.
2562114|NCT02484937|Experimental|Group 2 (PCP Treatment)|Subjects will be treated monthly for 6 months by the Primary Care Provider (PCP).The PCP will be involved and a multimodal therapeutic strategy will be communicated to the PCP by the PMS. The PCP will make dosage based on an algorithm provided by the PMS on how to adjust drug doses over time. It is not intended that the PCP may have ongoing engagement with the PMS. A direct line of communication will be set up between the PCP and the data integration clinical coordinator to handle serious medical concerns.
3206700|NCT00957060|Active Comparator|sitagliptin|100 mg once a day. The dose will not be titrated.
3206701|NCT00957073|Experimental|Device|Rheos® system
3206702|NCT00957073|No Intervention|Medical Management|Medical Management Therapy
3206703|NCT00957086|Active Comparator|Nimotuzumab|Comprising Adjuvant Cisplatin, Concurrent RT and Nimotuzumab
3206704|NCT00957086|Placebo Comparator|Placebo|Comprising Adjuvant Cisplatin, Concurrent RT and Placebo
2561664|NCT02488031|Experimental|Best Medical Management|The participants in the best medical management group will undergo identical testing sessions (two visits one month apart) as those in the error-reducing group but will not receive the 4-week error reducing intervention. They will be administered the International Cooperative Ataxia Rating Scale (ICARS) and the Scale for the Assessment and Rating of Ataxia (SARA) assessments and the following tests: Purdue Pegboard, Brief Test of Attention, 6-minute Walk, Hand Grip Dynamometer, Physical Performance Function, Digit Span, SARA, Montreal Cognitive Assessment, Beck Depression Inventory 2nd Ed, Stroop and biomechanical gait. Biomechanical assessments of dysmetria and neurophysiological assessment of brain activity will be conducted at both visits.
2561755|NCT02487550|Experimental|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
2561761|NCT02487550|Other|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
2561850|NCT02487160|Experimental|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
2561854|NCT02487160|Active Comparator|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
2561924|NCT02486523|Active Comparator|Control group|"Outpatient management of children diagnosed with severe acute malnutrition.~Interventions allocated:~Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
2561937|NCT02486523|Experimental|Intervention group|"Outpatient management of children diagnosed with severe acute malnutrition + household WASH package~Interventions allocated:~Behavioral: Hygiene promotion sessions Device: Household WASH package The content of the kit: soap and aquatab for 3 months, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.~Behavioral: Household visits during the OTP phase Behavioral: Group discussions after successful discharge Procedure/Surgery: Outpatient Therapeutic Programme"
2561992|NCT02486081||children with intelligent disabilities|children with ID will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
2561997|NCT02486081||typical-developed children (TD)|TD children will be measured via a smart soccer ball. Performance will be measured as acceleration, total time for completion, total distance
2562020|NCT02485821|Experimental|Estradiol + Misoprostol|100 patient will receive single dose vaginal estradiol 50mcg tablet (Ethinyl Estradiol manufactured by KAHIRA Pharmaceutical company) and vaginal misoprostol 25mcg tablet (Vagiprost manufactured by ADWIA Pharmaceutical company), misoprostol alone will repeated every 6hours up to five doses.
2562023|NCT02485821|Placebo Comparator|Placebo + Misoprostol|100 patients will receive placebo vaginally and misoprostol 25 mcg which will be repeated every 6 hours up to five doses.
2562074|NCT02485509|Experimental|20 mg VM-1500/Placebo Healthy group|VM-1500 20 mg or placebo single dose.
2562078|NCT02485509|Experimental|40 mg VM-1500/Placebo Healthy group|VM-1500 40 mg or placebo single dose.
2562081|NCT02485509|Experimental|20 mg VM-1500/Placebo Patient group|VM-1500 20 mg or placebo once daily for 7 days.
2562084|NCT02485509|Experimental|40 mg VM-1500/Placebo Patient group|VM-1500 40 mg or placebo once daily for 7 days.
2562140|NCT02485184|Active Comparator|TIPS group|Transjugular intrahepatic portosystemic shunt
2562142|NCT02485184|Active Comparator|ET & drugs groups|"Endoscopic therapy.~Non-selective beta blockers.~Anticoagulation therapy."
2562207|NCT02484508|Experimental|Guli capsule|Guli capsule, the tested drug of this study
2562216|NCT02484508|Active Comparator|Kangguzengsheng capsule|Kangguzengsheng capsule, a CFDA approved drug for articular genu osteoarthritis,is adopted as active comparator in this study
2562263|NCT02484196||Couples|Women, with their partners, referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
2562269|NCT02484196||Women|Women referred to the Obstetrics and Gynecological Department of the University Hospital for surgical treatment of endometriosis.
2562313|NCT02484027|Experimental|statin-therapy|Rosuvastatin orally at a dose of 20mg daily is assigned to patients immediately for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
2562315|NCT02484027|Sham Comparator|non-statin-therapy|No statins is assigned to patients for the first 3 days of hospitalization. From the fourth day onward, rosuvastatin 10 mg daily will be administered for 1 year.
2562384|NCT02483624|Experimental|Low Dose|10 patients 225 mg of BR-DIM. 2 capsules AM and 1 PM. 52 weeks duration.
2562385|NCT02483624|Experimental|High Dose|10 patients 375 mg of BR-DIM. 3 capsules AM and 2 PM. 52 weeks duration.
2562386|NCT02483624|Placebo Comparator|Placebo|10 patients receiving weight matched placebo. 5 for high dose and 5 for low dose. 52 weeks of weight matched pills.
2562418|NCT02483182|Experimental|ZEP-3 ointment 1.0%|Topical administration
2562420|NCT02483182|Active Comparator|Acyclovir cream 5%|Topical administration
3206705|NCT00957099||Imaging|Women diagnosed with breast cancer having pre-treatment MRI for spread of disease
2562542|NCT02482389|Experimental|Single arm 7 Gray (Gy) fraction of radiotherapy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
2562633|NCT02481921|Experimental|MEDIC-HF|Multidisciplinary Education & Intervention Class in Heart Failure
2562635|NCT02481921|No Intervention|Usual Care|Usual heart failure care
2562686|NCT02481336||Cancer patients receiving chemotherapy|"Stage I-IV ovarian cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage II-IV endometrial cancer receiving chemotherapy Paclitaxel/Carboplatin~Stage III & high risk stage II colorectal cancer receiving chemotherapy with mFOLFOX~Questionnaires~Peripheral nervous system examination~Whole Genome Sequence"
2562744|NCT02480894|Experimental|Sequential Dosing|Treatment A: BMS-663068 orally twice daily (BID) on Days 1 through 4 Treatment B: Maraviroc BID on Days 7 through 11 Treatment C: BMS-663068 BID plus maraviroc BID on Days 12 through 18
2562771|NCT02480634|Active Comparator|High dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle , a total of six cycle，Radiotherapy dose: 30Gy/10f
2563164|NCT02478021|Placebo Comparator|Placebo|1 pill Placebo
3172001|NCT00594477|Experimental|IMRT|The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
2561759|NCT02487654|Active Comparator|Pulmonary vein isolation|Conventional endocardial radiofrequency catheter ablation for pulmonary vein isolation.
2561765|NCT02487654|Experimental|Ganglionated plexus ablation|Endocardial radiofrequency catheter ablation of ganglionated plexus in the left atrium
2561821|NCT02487212|Active Comparator|Laser+Topical corticosteroid|Hypertrophic scars were treated with fractional Erbium: Yttrium aluminium garnet (YAG) (2,940-nm) laser, then 0.05% Clobetasol propionate ointment was immediately applied on the perforated scar on one side
2561822|NCT02487212|Placebo Comparator|Laser+Petrolatum gel|Hypertrophic scars were treated with fractional Erbium: YAG (2,940-nm) laser, then topical petrolatum gel was immediately applied on the perforated scar on the other side
2561856|NCT02486913|No Intervention|Conventional Health Check|Patients undergoing conventional National Health Service Health Check
2561862|NCT02486913|Experimental|Enhanced Health Check|Patients undergoing National Health Service Health Check enhanced by risk report
2562022|NCT02485860|No Intervention|standard dressings|
2562025|NCT02485860|Experimental|standard dressings with sterile honey|Melectis G
3172002|NCT00594490||Silicone|patients undergoing placement of silicone breast prosthetics
2562149|NCT02485015|Other|Apatinib alone|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous.Patients undergo Apatinib.
2562153|NCT02485015|Experimental|Apatinib+CIK|Apatinib(YN968D1) ,850mg,p.o.,qd,continuous. plus autologous cytokine-induced killer cells 3 cycles,every 1 year,continuous.
2562195|NCT02484573|Experimental|Propanolol|Patients will take the non-selective beta blocker propranolol for approximately 4 weeks starting immediately after endoscopy for esophageal variceal ligation. Patients will be initiated on a dose of 20mg by mouth every 12 hrs before titration to maximum tolerated dose. Patients will undergo testing before and after treatment for the variables listed in the outcomes section below.
2562300|NCT02484339|Experimental|Treatment Group A|"Radium-223 dichloride (Xofigo®) 55 kilobecquerel (kBq)/kgbw (6 i.v. injections every 4 weeks)~External beam radiotherapy (EBRT)->conventional or high dose radiotherapy"
2562302|NCT02484339|Other|Treatment Group B|External beam radiotherapy (EBRT) ->conventional or high dose radiotherapy
2562355|NCT02483754||original MOCA|The Chinese retired military cadres were surveyed with the revised MOCA scale.
2562358|NCT02483754||revised MOCA|The random part of participants were surveyed with the revised MOCA scale.
2562552|NCT02482402|Experimental|Inhaled Iloprost|2 inhalations per day of 2.5 µg Iloprost [Ventavis®] per inhalation to a maximum of 6 inhalations per day of 5 µg Iloprost per inhalation (total daily dose 5 - 30 µg) will be performed according to each patient's health condition.
2562553|NCT02482402|Placebo Comparator|Placebo inhaled|2 to a maximum of 6 inhalations per day of placebo solution (PLA) will be performed. Study medication will be inhaled using the portable, hand-held I-Neb AAD vibrating mesh technology nebulizer system.
2562572|NCT02481999||Study group: Patients|"470 children for elective surgery 0,5 to 8 years~Analysis of EEG data will divided in four age-related groups because of the different baseline EEG activity:~0.5 - 12 month: 5-7 Hz activity / blocked by eye opening~12 - 36 month: 7-8 Hz activity / Variability 5 - 10 Hz~3 - 6 years: 8 Hz activity / amplitude 100µV~6 - 8 years 10Hz activity / amplitude 100 µV"
2562575|NCT02481999||Control group: Healthy children for POCD assessment|80 healthy children (siblings of study group children and children from Kindergarten) 0,5 to 8 years with no operation
2562616|NCT02481895|Experimental|Experimental|E-neurocognitive module training.
2562624|NCT02481895|No Intervention|Control|The group will note receive any sort of add-on training, just the recommendations from the therapists.
2562762|NCT02480660|Experimental|Video Intervention Group|Subjects will be randomized to intervention group where participants will be asked to watch a 7 minute educational video.
2562763|NCT02480660|No Intervention|Control Group|Subjects will be randomized to control group ( no intervention) and receive standard of educational care on adolescent to adult oriented health care transitions.
2562838|NCT02480387|Experimental|Treatment Arm|8 weeks treatment with Ledipasvir/Sofosbuvir FDC
2562889|NCT02480036|Experimental|Combined IORT and Kyphoplasty|IORT with Kyphoplasty IORT Device: Intrabeam®
2562934|NCT02479607|Experimental|Intervention group|Use of an application for a smartphone or tablet for daily reporting symptoms and access to self-care advice and health care professionals in real time in combination with standard care according to the clinic´s routines
2562935|NCT02479607|No Intervention|Control group|Standard care according to the clinic's routines.
2562967|NCT02479269|Experimental|intervention|Aerobic exercise+ blood sampling
2562982|NCT02479269|No Intervention|control|Blood sampling
2563685|NCT02474524|Active Comparator|Social intervention|+ treatment as usual
3172003|NCT00594503|Experimental|Hyperbaric oxygen therapy-TBI|Low pressure hyperbaric oxygen therapy
3172004|NCT00594529|Other|1|
3172005|NCT00594542|Experimental|0.5% lidocaine group|Group that receives 0.5% lidocaine with 1:200,000 epinephrine
3172006|NCT00594542|Experimental|1.0% lidocaine group|Group that receives 1.0% lidocaine with 1:100,000 epinephrine
3172007|NCT00594555|Experimental|Single Arm - treatment period|"Drug Name/Days Administered~Neupogen/Days 1-6~CLAG/Days 2-6~Gleevec/Days 2-15"
3172008|NCT00594581|Active Comparator|1|Juvista (avotermin) 50ng/100μl/linear cm wound margin
3172009|NCT00594581|Active Comparator|2|Juvista (avotermin) at 200ng/100μl/linear cm
3172010|NCT00594594|Experimental|1|Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
3172011|NCT00594607|Active Comparator|1: AN69ST|Hemodialysis sessions with use of the dialysis filter AN69ST.
3172012|NCT00594607|Active Comparator|2:Fx8|Hemodialysis sessions with use of the dialysis filter Fx8
3172013|NCT00594620|Experimental|1|Subjects receive supplement
3172014|NCT00594620|Placebo Comparator|2|Subjects will receive placebo
3172015|NCT00594633|Experimental|1|donepezil and questionaires
3172017|NCT00594711||1|Case-group
2561696|NCT02488174|Experimental|PROOFcheck|The intervention for this study will consist of 3 parts: 1) Education of clinicians on prevention of severe ARF and MOF in and out of the ICU, and best practice with regards to patients with severe ARF; 2) Clinicians will be notified that a patient they are taking care of has been identified as being at high risk for developing severe ARF requiring prolong MV; 3) Notified clinicians will be directed to PROOFcheck with a bundle of recommendations for best care for patients with ARF.
2561754|NCT02487641||Moderat Obesity|60 persons with BMI between 30-34.49 kg/m2
2561763|NCT02487641||Sever Obesity|60 persons with BMI above 34.49 kg/m2
2561767|NCT02487641||Normal weighted|60 persons with BMI between 18.5-24.49 kg/m2
2561788|NCT02487290|Experimental|Treatment|Aneufix ACP-T5
2561847|NCT02487082|Other|Group A|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
2561853|NCT02487082|Other|Group B|Melatonin and donepezil (melatonin 3mg and donepezil 1.25-5mg based on age/weight each night) or placebo for 15 weeks
3206706|NCT00957112|Experimental|Arm I|Patients undergo a 20-minute acupuncture session once a week for 6 weeks. Patients also receive written information about fatigue and its possible management.
3206707|NCT00957112|No Intervention|Arm II|Patients receive standard care. They also receive written information about fatigue as in arm I.
2562018|NCT02485795||Pain patients|Observational; Patients presenting to interventional pain management centers for therapy.
2562093|NCT02485405||stressed|stressed volunteers perform Trier social stress test
2562098|NCT02485405||non-stressed|non-stressed volunteers perform Trier social stress test
2562130|NCT02485080|Experimental|Simeprevir + sofosbuvir daily, 24 weeks|Eligible and consenting patients will be treated with sofosbuvir (SOF) 400 mg daily and simeprevir (SMV) 150 mg daily for 24 weeks. Both drugs will be administered orally, per manufacturers' instructions.
2562205|NCT02484625|Experimental|Potato chips|Commercial potato chips, 180 kcal
2562213|NCT02484625|Experimental|Greek yogurt|Greek yogurt, 180 kcal
2562219|NCT02484625|Experimental|Cookies|Sandwich-type cookies, 180 kcal
2562222|NCT02484625|Experimental|Cheese|Mozzarella cheese, 180 kcal
2562225|NCT02484625|Experimental|Milk (fluid)|Milk, 2% m.f., 180 kcal
2562305|NCT02484157|Experimental|Patient|Patients were checked activated coagulation time by both Hemochron Jr and ACT Plus during cardiac surgery with heparin administration.
2562318|NCT02483806|Experimental|PEEP 0 cmH2O|PEEP 0 cmH2O (zero end expiratory pressure, ZEEP)
2562320|NCT02483806|Experimental|PEEP 5 cmH2O|
2562322|NCT02483806|Experimental|EEP 10 cmH2O|
3206708|NCT00957112|Experimental|Arm A|Patients receive treatment as in arm I for 4 more weeks.
3206709|NCT00957112|No Intervention|Arm B|Patients receive standard care as in arm II for 4 more weeks.
2562562|NCT02482376|Other|Single arm 21Gy stereotactic radiotherapy|Subjects will receive a single fraction of 21Gy of stereotactic radiotherapy before proceeding to surgery.
3206710|NCT00957112|Experimental|Arm C|Patients learn to self-acupuncture and do so weekly for 4 more weeks.
3206711|NCT00957125|Experimental|Epirubicin Docetaxel Bevacizumab|"Epirubicin and docetaxel i.v. infusion q 3 weeks for 2 cycles.~If complete response this treatment continues for 4 cycles, totally 6 cycles.~If partial response or stable disease, epirubicin and docetaxel and bevacizumab i.v. infusion q 3 weeks for 4 cycles.~If progressive disease after the first 2 cycles individualized treatment."
2562714|NCT02481063|Active Comparator|Eccentric|6 Weeks Training with eccentric Overload (Squat with Yoyo Technology) 3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
2562715|NCT02481063|Active Comparator|Control|3 Consecutive Days Running 1 hour at 80% of Maximus Heart Rate
2562784|NCT02480738|Experimental|Mild cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
2562789|NCT02480738|Experimental|Subjective cognitive impairment|Intervention: Computerized Cognitive Training Apparatus
2562791|NCT02480738|Active Comparator|Normal controls|Intervention: Computerized Cognitive Training Apparatus
2562846|NCT02480231|Active Comparator|Babcock tensioning technique|Group for whom the retropubic mid-urethral sling was tensioned using a Babcock clamp.
2562849|NCT02480231|Active Comparator|Scissor spacer technique|Group for whom the retropubic mid-urethral sling was tensioned using a surgical scissor as a spacer.
2562900|NCT02479841|Experimental|self management program|Participation in an 11 week self-management program
2562905|NCT02479841|No Intervention|Control group|
2562991|NCT02479529|Experimental|administration of norepinephrine by dynamic elastance|The norepinephrine weaning strategy is based on an index that reflects the vasomotor tone: dynamic arterial elastance
2562994|NCT02479529|Other|control administration of norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
2563024|NCT02478918|Experimental|Receiving reminder phone call|Will receive phone call to remind colonoscopy date and bowel prep
2563029|NCT02478918|No Intervention|Not receiving reminder phone call|Will not receive phone call to remind colonoscopy date and bowel prep
2563060|NCT02478658|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
2563064|NCT02478658|No Intervention|Control|No intervention
2563213|NCT02477735||Study group|Infants with COME who will be referred for TTI will undergo actigraphy for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
3208852|NCT00978692|Other|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive error will be serve as control group
2561729|NCT02487797|Experimental|High dose oxytocin regimen|The oxytocin solution will be prepared using 90 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 6 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 6 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
2561738|NCT02487797|Active Comparator|Low dose oxytocin regimen|The oxytocin solution will be prepared using 30 units of oxytocin in 500 milliliters of normal saline (sodium chloride 0.9%). The oxytocin infusion will be initiated with a starting oxytocin concentration rate of 2 milliunits/minute (volume rate 2 milliliters/hour) that can be increased at increments of 2 milliunits/minute (volume rate 2 milliliters/hour) every 15-30 minutes until a labor pattern with uterine contractions every 2-3 minutes of moderate to strong intensity is established.
2561792|NCT02487329|Active Comparator|Calcium hydroxide|Direct pulp capping with a self-hardening calcium hydroxide paste
2561797|NCT02487329|Experimental|Er,Cr:YSGG laser + calcium hydroxide|Direct pulp capping using Er,Cr:YSGG laser combined with calcium hydroxide
2561801|NCT02487329|Experimental|TheraCal LC|Direct pulp capping with resin based tricalcium silicate material
2561802|NCT02487329|Experimental|Er,Cr:YSGG laser + TheraCal LC|Direct pulp capping using Er,Cr:YSGG laser combined with resin based tricalcium silicate material
2561845|NCT02487004||chronic hemodialysis patients|
2561904|NCT02486731||Noonan syndrome|Patients with Noonan syndrome
2561905|NCT02486731||LEOPARD syndrome|Patients with LEOPARD syndromes
2561906|NCT02486731||Controls|Healthy subjects
2561959|NCT02486393||type of surgery|patients undergoing parotid surgery
3206712|NCT00957164|Active Comparator|Pain Treatment Only|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
3206713|NCT00957164|Active Comparator|PTSD Treatment Only|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
3206714|NCT00957164|Active Comparator|Combined Pain and PTSD Treatment|This treatment arm will involve 5 sessions each of the Pain-Only and PTSD-Only treatments described above.
2562179|NCT02484820|Experimental|Pessary|Silicone pessary is associated with standard care Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
2562180|NCT02484820|No Intervention|Control|Standard care only, No silicone pessary will be placed in the vagina.
2562226|NCT02484430|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who are non-responders and in PR at the end of course 4 may receive sapanisertib PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3206715|NCT00957164|No Intervention|Treatment as Usual|The treatment as usual group will complete the assessments given in each of the other study arms, but will not participate in treatment through the study. Instead, participants randomized to this group will be encouraged to seek treatment for pain and/or PTSD through existing channels. Referrals for treatment will be made for those with clinically significant symptoms for pain and/or PTSD at intake.
3206716|NCT00957177|Placebo Comparator|Placebo|Placebo
3206717|NCT00957177|Active Comparator|Pregabalin group|Receiving 300mg pregabalin preoperative
2562427|NCT02483286|Experimental|ICG|Integrated Care Group
2562432|NCT02483286|Experimental|MTG|Muscle Training Group
2562438|NCT02483286|Experimental|XBG|X-box Group
2562532|NCT02482636|Other|Group 1|"Group 1 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 2, 4 and 12 months~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
2562533|NCT02482636|Other|Group 2|"Group 2 will receive the following interventions:~DTaP/IPV/Hib vaccine IM 0.5ml at 2, 3 and 4 months~13 valent pneumococcal conjugate vaccine (PCV13) IM 0.5ml at 3 and 12 months (instead of current routine schedule of 2,4 and 12 months)~Rotavirus vaccine oral 1.5ml at 2 and 3 months~4-component Meningococcal B (4CMenB) vaccine IM 0.5ml given at 2, 4 and 12 months~Meningococcal C/Hib vaccine IM 0.5ml at 12 months~Measles/Mumps/Rubella (MMR) vaccine IM 0.5ml at 13 months"
2562852|NCT02480374|Experimental|Single Arm|
2562897|NCT02479828|Active Comparator|Fascia iliaca compartment block (FICB)|Under ultrasound guidance performing fascia iliaca compartment block, in which 40 ml ropivacaine 0,5% are injected under the fascia iliaca.
2562903|NCT02479828|Placebo Comparator|Placebo (not FICB)|Half of the patients will not receive FICB
2563215|NCT02477735||Healthy infants|Healthy infants that were recruited from the community well-baby clinics.
2561810|NCT02487251|Experimental|Supports for Family Mealtimes|"In Phase 1 of the study, participants receive one or more interventions intended to promote the frequency of family meals as an obesity prevention strategy. Supports range from the least to the most comprehensive. The interventions include: Meal Delivery, Ingredient Delivery, Community Kitchen, Healthy Eating Classes, Cooking Demonstrations and Provision of Cookware. The goal of this phase was to identify intervention components most robustly related to primary outcomes.~The goal of Phase 2 is to test the finalized intervention in a randomized controlled trial. In Phase 2 of the study, participants are randomly assigned to a meal delivery/cookware provision intervention or to a usual exposure group. Participants in the intervention group receive two meals per week for 12 weeks and a set of cookware/dinnerware."
2561852|NCT02486887|Experimental|telemonitoring|telemonitoring of weight, arterial pressure and heart rate at home with connection to a medical platform to monitor the evolution.
2561857|NCT02486887|No Intervention|conventional follow-up|conventional follow-up
2561919|NCT02486679|Active Comparator|PGE2|Patients allocated to vaginal PGE2 (Prostin) for cervical ripening
2561932|NCT02486679|Active Comparator|Foley catheter|Patients allocated to foley catheter placement for cervical ripening
2562000|NCT02486237||Type 2 diabetes mellitus|Type 2 diabetes mellitus patients, no intervention is performed besides usual clinical practice
2562042|NCT02485756|Experimental|Educational handout|Participants in the intervention group will read an educational handout on hormonal contraceptives/antiepileptic interactions.
2562044|NCT02485756|No Intervention|Control (no educational handout)|Those in the standard care group will not receive the educational handout.
2562066|NCT02485457|Experimental|Low volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (250 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
2562069|NCT02485457|Experimental|High volume|"The protocol will follow the following steps :~basal measurements (heart rate, arterial pressure, stroke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by passive leg rising and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~second basal measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)~followed by low volume loading (500 ml of Ringer solution) and additional measurements (heart rate, arterial pressure, stoke volume estimated by esophageal Doppler, stoke volume estimated by Nicom)"
2562121|NCT02485002|Active Comparator|UAS (+)|RIRS with ureteral access sheath: A ureteral access sheath (UAS) will be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
2562122|NCT02485002|Experimental|UAS (-)|RIRS without ureteral access sheath: A ureteral access sheath (UAS) will not be positioned into the ureter of the patient prior to the insertion of the flexible ureterorenoscope (RIRS).
2562171|NCT02484781|Active Comparator|Total Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning total hip arthroplasty on a trendmill
2562172|NCT02484781|Active Comparator|Resurfacing Hip Arthroplasty|Gait analysis on a trendmill of patients with a well functioning resurfacing hip arthroplasty on a trendmill
2562198|NCT02484495|Experimental|Program evaluation in intervention areas|"A quasi-experimental matched-control cluster design will be used in which outcomes are compared in intervention and non-intervention areas. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Sixty intervention clusters have been purposively selected whereas the data will be collected from randomly selected subjects. The following interventions will be provided:~Processed complementary food rations will be distributed to all children 6-23 months of age, from a grain bank based on bartering of raw materials.~Monthly 15 sachets of MNP will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification."
2562203|NCT02484495|No Intervention|Non intervention areas|A quasi-experimental matched-control cluster design will be used in which outcomes will be compared in intervention and non-intervention clusters. The program evaluation will have three points of data collection to assess effect of the program on the nutritional status of children 6-29 months. Matching sixty non-intervention clusters have been purposively selected out of the predetermined non- intervention districts whereas study subjects will be randomly selected from the identified clusters on a population based sampling method both groups. These non-intervention areas do not get processed complementary food rations and do not receive MNPs.
2562274|NCT02484274|Other|infants followed by pediatrician|
3206718|NCT00957190|Experimental|Cosopt|Cosopt ('Dorzolamide 20 mg and Timolol 5 mg) bid And Xalatan hs Vs Xalatan hs Alone
3206719|NCT00957203|Experimental|Istradefylline|
2562449|NCT02483065||inpatients with dementia|
2562452|NCT02483065||inpatients without dementia|
3206720|NCT00957216|Placebo Comparator|sugar pill|
3206721|NCT00957216|Active Comparator|Coenzyme Q10|The CoQ10 arm will be compared with the placebo arm to determine if high-dose CoQ10 is safe and well tolerated in subjects with sporadic adult-onset spinocerebellar ataxias
3206722|NCT00957255|Active Comparator|RCR without augmentation|Rotator cuff repair without OrthoADAPT augmentation
3206723|NCT00957255|Experimental|RCR with augmentation|Rotator cuff repair with OrthoADAPT augmentation
3206724|NCT00957281||Asthma|Asthma patients on inhaled corticosteroids
3206725|NCT00957294||Schizophrenia|Patients with first-episode schizophrenia age 18-45 years
3206726|NCT00957294||Depression|First-time hospitalized patients with depression age 18-45 years
3206727|NCT00957294||healthy controls|Healthy controls matched on age and gender (18-45 years)
3206728|NCT00957320|Experimental|1|"Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL. The dose of sirolimus will be dose escalated following standard phase 1 statistical methods.~For patients with active CNS leukemia, intrathecal methotrexate, hydrocortisone and cytarabine (triple IT) will be administered weekly, with leucovorin rescue at the treating physician's discretion."
3206729|NCT00957346|Experimental|Mifepristone + Misoprostol|200 mg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
3206730|NCT00957346|Placebo Comparator|Misoprostol|Placebo resembling 200mcg mifepristone followed by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses
2561953|NCT02486367|Active Comparator|Standard care/clopidogrel|300mg load followed by 75mg daily.
2561956|NCT02486367|Experimental|Ticagrelor|180mg load followed by 90mg twice daily for 30 days.
2561988|NCT02486055|Active Comparator|Cohort 1|In Cohort 1, doses of BPM31510 Oral Nanosuspension 4% will be administered two times per day before the morning and evening meals with no less than 8 and no more than 10 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
2561993|NCT02486055|Active Comparator|Cohort 2|In Cohort 2 doses BPM31510 Oral Nanosuspension 4% will be administered three times per day before meals, with no less than 4 and no more than 6 hours between doses. Immediately after administration, subjects will ingest 6 ounces of tap or bottled water. Solid food and drinks, other than water should be restricted to 2 hours before and 1 hour after dosing.
2562015|NCT02485782||Hemodialysis patients|"midweek dialysis session~patients on maintenance hemodialysis at least 3 months~stable dry weight~single-pool Kt/V >1.4~no clinical cardiovascular disease during the 6 months preceding entry"
2562062|NCT02485600||DUODOPA patients.|Patients starting DUODOPA treatment at time of enrollment.
2562112|NCT02484950|Experimental|Rotator cuff repair with stem cells|Using clinically accepted methods, subjects will undergo bone marrow aspiration (from hip, proximal humerus or tibia) through a small incision prior to arthroscopy in the group undergoing MSC augmentation. They will then undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique with mesenchymal stem cell augmentation.
2562115|NCT02484950|Placebo Comparator|Rotator cuff repair without stem cells|Subjects will undergo arthroscopic full thickness rotator cuff repair using a double row, TOE anchor/suture technique, without augmentation of mesenchymal stem cells. To maintain patient blinding, all patients will receive a small incision around the site of expected bone marrow aspiration (hip, proximal humerus, or tibia), regardless of whether or not they receive bone marrow.
2562183|NCT02484794|Active Comparator|Treatment as Usual|Patients will receive standard outpatient treatment that consists of group psychotherapy, skills training, self-monitoring, nutritional counselling, and meal support.
2562185|NCT02484794|Experimental|Treatment with Smartphone App|Patients will receive the same standard outpatient treatment but will use the smartphone application instead of the paper food record. Patients in this group will receive daily feedback through the app, as opposed to weekly, but will still attend the weekly nutritional counselling group.
2562265|NCT02484378|Experimental|CER-001|CER-001 infusion
2562277|NCT02484378|Placebo Comparator|Placebo|Placebo infusion
2562369|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test +|These are patients with a history of metal allergy who are patch test positive to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
2562374|NCT02483728|Other|Metal Allergy Hx +, Metal Patch Test -|These are patients with a history of metal allergy who are patch test negative to metals (metal series, metal disc if available from manufacturer, bone cement components and topical antibiotics) prior to implantation of metal device.
2562410|NCT02483312|Experimental|IL-12|A single dose of IL-12, given intravenously.
2562443|NCT02483013|Active Comparator|Whitening dentifrices|Two groups used whitening dentifrices, three times per day during four weeks
2562446|NCT02483013|Placebo Comparator|Placebo|One group used conventional dentifrice, three times per day during four weeks
2562471|NCT02482740|Experimental|tamoxifen|tamoxifen 20 mg given everyday for 12 months
2562475|NCT02482740|Active Comparator|letrozole|letrozole 2.5 mg given everyday for 12 months
3206731|NCT00957385|Active Comparator|A|Arm A will receive Revlimid.
3206732|NCT00957385|No Intervention|B|Arm B will not receive Revlimid but an observational arm
3206733|NCT00957398||IBS-D|12 IBS-D patients who will all undergo MTS.
3206734|NCT00957398||IBS-C|12 IBS-C patients who will all undergo MTS.
3206735|NCT00957411|Active Comparator|Arm I|Patients receive cisplatin IV over 1 hour once weekly during weeks 1-6. Patients also undergo pelvic radiotherapy 5 days a week during weeks 2-5 or 2-6.
3206736|NCT00957411|Experimental|Arm II|Patients receive cisplatin and undergo radiotherapy as in arm I. Patients also receive cetuximab IV over 1 hour once weekly during weeks 1-6.
3206737|NCT00957437|Experimental|Part A: 3 way crossover|AZD1305: ER test formulation 1 (w/wo food) and reference formulation
3206738|NCT00957437|Experimental|Part B1: single arm|AZD1305: ER test formulation 1
2562746|NCT02480842|Experimental|Alloplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
2562748|NCT02480842|Experimental|Alloplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
2562749|NCT02480842|Experimental|Oncoplastic group A|"After randomization (15 days after surgery):~- Patients will start to perform exercises with free shoulder ROM. Patients will be told only to limit the movement if they feel pain."
2562985|NCT02479425|Experimental|2 points turning|patients nursed on the right and left side sonly in 30ْ avoiding the back
3206739|NCT00957437|Experimental|Part B2: 3 way crossover|AZD1305: ER test formulation 2 (w/wo food) and reference formulation
3206740|NCT00957450||1|"Impact of organ motion~Characterize the impact of normal organ motion in the pelvic on tumour movement, during treatment. This will be assessed in patients with pelvic cancer."
3206741|NCT00957463||smoker, with high apnea-hypopnea index|subjects who smoke either in the past or currently, with confirmed moderate-severe OSA
3206742|NCT00957463||smoker, mild OSA or without OSA|subjects who smoke either in the past or currently, with mild OSA or without OSA
3206743|NCT00957463||nonsmoker, with high apnea-hypopnea index|subjects who never smoke, with confirmed moderate-severe OSA
2561836|NCT02487121|Active Comparator|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
2561858|NCT02486835|Experimental|"Cough Syrup for adults and children"|Marked (authorized) medical device acting by protecting the oropharynx, in a non pharmacological way, to reduce cough. It contains honey, plantago lanceolata, thymus vulgaris.Dosage form: syrup Dosage: 5 ml three times a day. Frequency: the duration of the study for each patient is 4 nights, 3 days.
2561860|NCT02486835|Placebo Comparator|Placebo|The placebo intervention is a syrup of same taste and colour without the protective components. Dosage form: syrup. Dosage: 5 ml three times a day Frequency: the duration of the study for each patient is 4 nights, 3 days.
3206744|NCT00957463||nonsmoker, with mild OSA or without OSA|subjects who never smoke, with mild OSA or without OSA
3206745|NCT00957476|Active Comparator|Omega-3 Fish Oil|800mg DHA & 1200mg EPA
2562058|NCT02485678|Experimental|Proactive Telephone Toxicity Management|Proactive Telephone Toxicity Management
2562060|NCT02485678|Active Comparator|Control Arm|Control
2562109|NCT02485145|Experimental|A/B|In this crossover trial, the A/B group will receive the test product (A) and then the placebo (B). The topical product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the test product for 7 days, applying the topical product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the placebo cream, which will be used for 7 days, applying the topical placebo to the hands twice a day.
2562110|NCT02485145|Experimental|B/A|In this crossover trial, the B/A group will receive the placebo (B) and then the test product (A). The product contains the following: Diclofenac 3%, Baclofen 2%, Orphenadrine Citrate 5% and Bupivacaine 2% in a VersaPro cream, while the placebo is the VersaPro cream alone. Participants will use the placebo product for 7 days, applying the placebo product to the hands twice a day. There will be a 7 day washout period, and then participants will be given the test cream, which will be used for 7 days, applying the topical product to the hands twice a day.
2562143|NCT02484872||Lung neoplasms|Lung neoplasms irrespective of stage and histology
2562190|NCT02484664|Experimental|celecoxib|Celecoxib 200mg PO QD for 6 months
2562298|NCT02484365||single arm study|No treatment or intervention will given to the patients
2562325|NCT02483845|Experimental|Natalizumab|Natalizumab therapy will be given at 300mg intravenously every 4 weeks for 24 weeks
3206746|NCT00957476|Placebo Comparator|Placebo|Wheat germ oil
3206747|NCT00957489|Experimental|Functional appliance|
2562470|NCT02482987|Experimental|Cytoplast|Patients will receive ridge preservation procedure with a Cytoplast barrier membrane
2562474|NCT02482987|Experimental|BioXclude|Patients will receive ridge preservation procedure with a BioXclude barrier membrane
2562518|NCT02482454|Other|RFA alone|Patients undergo radiofrequency ablation alone.
2562522|NCT02482454|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA
2562583|NCT02482194|Experimental|Autologous mesenchymal stem cells|use of mesenchymal stem cells as therapeutic intervention for spinal cord injury patients by autologous transplantation
2562617|NCT02481752|Experimental|AAT Training Group|Individuals in this condition will receive four sessions of AAT training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the training may weaken automatic cigarette-approach and strengthen automatic cigarette-avoidance. Furthermore, they will be told that the opposite effect will be true for the stimuli not related to cigarettes (i.e., the positive stimuli).
2562623|NCT02481752|Sham Comparator|SHAM Training Group|Individuals in this condition will receive four sessions of SHAM training in which they are instructed to approach (pull the joystick) images tilted to the right and avoid (push the joystick) images tilted to the left. They will be told that the purpose of the training is to improve control over these automatic tendencies and that following the training sessions, they will easily be able to push or pull the stimuli regardless of content.
2562657|NCT02481531|Active Comparator|Previously marketed infant formula|Cow's milk-based infant formula
2562666|NCT02481531|Experimental|Previously marketed formula using a similar protein|Cow's milk-based infant formula
2562735|NCT02481011||users|patients on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
2562736|NCT02481011||non-users|patients not on antithrombotic drugs admitted to a Norwegian hospital for intracranial hemorrhage (ICH)
2562773|NCT02480673|Experimental|Free diet plus Chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days without changing their diet
2562779|NCT02480673|Experimental|Normocaloric diet plus chia|This subjects will consume 1 cookie oatmeal with chia before breakfast and dinner for 90 days along with a normocaloric diet
2562782|NCT02480673|Active Comparator|Normocaloric diet plus oatmeal|This subjects will consume 1 cookie oatmeal before breakfast and dinner for 90 days along with a normocaloric diet
2562786|NCT02480673|Active Comparator|Normocaloric diet|This subjects will only go under a normocaloric diet for 90 days
3206748|NCT00957502|Experimental|One year aged staples|Subjects implanted with sterile staples aged to approximately one year.
3206749|NCT00957502|Experimental|18 month aged staples|Subjects implanted with sterile staples aged to approximately 18 months.
3206750|NCT00957541|Experimental|CRT Therapy|All patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
3206751|NCT00957554|Experimental|irbesartan/amlodipine|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan/amlodipine 150/5 mg fixed combination for 5 weeks followed by irbesartan/amlodipine 300/5 mg fixed combination for additional 5 weeks
3206752|NCT00957554|Active Comparator|irbesartan|Before randomisation: irbesartan 150 mg for 7 to 10 days (common in the 2 arms) then After randomisation: irbesartan 150 mg for 5 weeks followed by irbesartan 300 mg for 5 additional weeks
3206753|NCT00957619|Active Comparator|pentoxyfilline group|pentoxyfilline group
3206754|NCT00957619|Placebo Comparator|placebo group|placebo group
3206755|NCT00957710|Other|langauge therapy|Naming therapy
3206756|NCT00957736||Allogeneic stem cell transplant|Stem cells from a genetically non-identical donor transplanted into a patient.
3206757|NCT00957749|Experimental|cPMP|
2561855|NCT02486900|Experimental|Neurofeedback training group|The neurofeedback group will perform 6 training sessions over a period of 4 months: 4 fortnightly sessions in the first two months will be followed by 2 monthly 'booster' sessions. Each session will include several behavioural assessments and fMRI-based neurofeedback training in an MRI scanner (1 h). The neurofeedback training phase will be be followed-up by two behavioural assessments 8 and 12 months after the first training.
2561859|NCT02486900|No Intervention|Treatment-as-usual control group|The control group will receive treatment as usual (e.g. medication, counselling) but no neurofeedback training during the study period. Patients in the control group will be invited for four behavioural assessment sessions (baseline assessment, follow-up assessments 4/8/12 months after baseline).
2561925|NCT02486640||Betaferon|
2561968|NCT02486198|Placebo Comparator|placebo+oxaliplatin-based chemotherapy|equal saline as placebo, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
2561973|NCT02486198|Experimental|GM+oxaliplatin-based chemotherapy|monosialotetrahexosylganglioside Sodium Injection, 40mg or 60mg, one hour before chemotherapy (if with chemotherapy) with oxaliplatin-based chemotherapy (every 2 or 3 weeks), or daily use until neurotoxicity progress.
2562030|NCT02485873||Rivaroxaban|Non-valvular Atrial Fibrillation (NVAF) patients who were initiated on rivaroxaban for stroke prevention
2562032|NCT02485873||Vitamin K antagonists (VKA)|NVAF patients who were initiated on VKA (predominately phenprocoumon in Germany) for stroke prevention
3206758|NCT00957762||Body Composition|120 subjects will help create the regression models. The remaining 50 subjects will be recruited to determine if the equations work for the population.
3206759|NCT00957775|Active Comparator|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, self-help groups) provided at the treatment site.
3206760|NCT00957775|Experimental|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
3206761|NCT00957788|Experimental|Cohort 0|
2562224|NCT02484456|Experimental|Test Session 1|2 weeks of 1,080 or 1,440 mg/day (single daily dose) of study drug
2562228|NCT02484456|Placebo Comparator|Test Session 2|2 weeks of single daily dose of placebo pill
2562282|NCT02484170|Active Comparator|mannitol in vehicle cream /vehicle cream|one week on the mannitol cream (mannitol 30% in vehicle cream), a 3 day washout period, and one week on the placebo cream (vehicle cream alone). To be applied over the painful area as needed for pain. Usual frequency is 2 to 3 times daily.
2562288|NCT02484170|Active Comparator|vehicle cream /mannitol in vehicle cream|one week on the placebo cream (vehicle cream alone), a 3 day washout period, and one week on the mannitol cream (mannitol 30% in vehicle cream).To be applied over the painful area as needed for pain. Usual frequency is unknown.
2562323|NCT02483858|Experimental|PQR309|Different dose Evaluation (continous and intermittent) 20-160mg daily
3206762|NCT00957788|Experimental|Cohort 1|
3206763|NCT00957788|Experimental|Cohort 2|
3206764|NCT00957788|Experimental|Cohort 3|
3206765|NCT00957814|Experimental|Control|Usual care with medical and nursing staff
2562718|NCT02480959|Other|Medial plication|Patient undergoing surgical treatment for recurrent patellar instability that includes medial retinacular plication
2562722|NCT02480959|Other|MPFL reconstruction|Patient undergoing surgical treatment for recurrent patellar instability that includes medial patellofemoral ligament reconstruction using a tendon graft
2562777|NCT02480725||CJD (Creutzfeldt-Jakob disease) patients|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
3206766|NCT00957814|Experimental|Intervention|Usual care with medical and nursing staff and additional nutritional guidance about diet and its relationship with disease, sources of nutrients, and reduction of dietary sodium and fats. Enforcement of the nutritional guidance was performed after 4 weeks.
3206767|NCT00957840|Other|Omaya reservoir group- observational|These infants have been identified with severe enough post hemorrhagic ventricular dilation (PHVD) that they require a reservoir placed for serial cerebro-spinal fluid (CSF) removal. There is no randomization, and infants are compared to a baseline. Observational data will be collected to include NIRS and aEEg which will be done twice weekly, and CSF will be analyzed with each reservoir tap for protein biomarkers.
3206768|NCT00957879|Active Comparator|ergocalciferol|Weekly ergocalciferol for 12 weeks
3206769|NCT00957879|Active Comparator|calcitriol|Daily calcitriol for 12 weeks
3206770|NCT00957918|Experimental|Nicotine|Active drug is nicotine dihydrate bitartrate, provided as an oral capsule at escalating doses, 1 mg to 6 mg, once every 6 hours
3206771|NCT00957918|Placebo Comparator|placebo|Subjects in this arm receive placebo capsules orally
3206772|NCT00957957||1|Participants having elective Roux-en-Y gastric bypass surgery (RYGBP)
3206773|NCT00957957||2|Participants having elective gastric banding surgery (GB)
3206774|NCT00957970|Active Comparator|Stemless femoral component|Stemless PROXIMA femoral component
3206775|NCT00957970|Active Comparator|Stemmed femoral component|IPS, proximal anatomical fit stemmed femoral component
3206776|NCT00957983|Active Comparator|BGC20-1531 200mg|
3206777|NCT00957983|Placebo Comparator|sugar pill|
3206778|NCT00957983|Active Comparator|BGC20-1531 400mg|
3206779|NCT00958022|Experimental|LBH589 and carboplatin with etoposide|"The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with carboplatin with etoposide in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how lung cancer responds to the LBH589 in combination with carboplatin and etoposide.~This study will also investigate how the body processes the combination of LBH589 and carboplatin with etoposide."
2561939|NCT02486575|Other|Mentoring|"Residents training with a mentor, giving tailored instruction to each of them and correction to wrong behaviours.~Intervention Type: Behavioral (tutored learning)"
3172018|NCT00594711||2|Control-group
3172019|NCT00594724|Experimental|1|
2562031|NCT02485730||Adult children of AD patient|Cognitively healthy adult children of AD patient: First-degree descendant of an AD patient (following diagnosis as define in protocol) from 45 to 64 years old.
2562059|NCT02485535|Experimental|Treatment (selinexor)|Beginning on day 60-100 after allo-SCT without evidence of GVHD above grade 1 and disease relapse with stable hematopoietic recovery, patients receive selinexor PO on day 1 of each week or on days 1 and 3 of weeks 1-3. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
2562103|NCT02485327|Experimental|Afrezza®|"Two-period, replicate single dose, euglycemic clamp study. There will be 2 treatment periods with a replicate administration of 1 dose of Afrezza TI (40U) in both periods.~Each patient will be given a replicate administration of 1 dose level of Afrezza TI with washout duration between treatment periods (5-19 days between periods, ie, 7 to 21 days between dosing occasions)."
2562145|NCT02485028|Experimental|M→D→D+M|Mirodenafil(M) in period 1, Dapoxetine(D) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
2562147|NCT02485028|Experimental|M→D+M→D|Mirodenafil(M) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Dapoxetine(D) in period 3
2562150|NCT02485028|Experimental|D→M→D+M|Dapoxetine(D) in period 1, Mirodenafil(M) in period 2, Dapoxetine+Mirodenafil(D+M) in period 3
2562152|NCT02485028|Experimental|D+M→M→D|Dapoxetine+Mirodenafil(D+M) in period 1, Mirodenafil(M) in period 2, Dapoxetine(D) in period 3
2562156|NCT02485028|Experimental|D+M→D→M|Dapoxetine+Mirodenafil(D+M) in period 1, Dapoxetine(D) in period 2, Mirodenafil(M) in period 3
2562158|NCT02485028|Experimental|D→D+M→M|Dapoxetine(D) in period 1, Dapoxetine+Mirodenafil(D+M) in period 2, Mirodenafil(M) in period 3
2562604|NCT02481856|Experimental|12 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
2562605|NCT02481856|Experimental|7 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
2562606|NCT02481856|Experimental|2 DU SQ tree SLIT-tablet|Betula verrucosa, allergen extract, Oral lyophilisate
2562607|NCT02481856|Placebo Comparator|Placebo|No active ingredient, Oral lyophilisate
2562675|NCT02481544|Experimental|Gratitude Journaling Plus Standard of Care|"The most often used gratitude intervention consists of journaling, writing lists of things for which the individual is grateful. This technique was first employed and found to be effectual for enhancing wellbeing by Emmons and McCullough and has been suggested to be as effective as methods frequently used in clinical therapy. We are proposing an 8-week intervention in which the participant records 3-5 things for which they are grateful most days of the week. A longer intervention was chosen because Emmons and McCullough (2003) suggest that healthy behavior changes only occurred in a prolonged multi-week intervention. To ensure some conformity in the intervention, instructions that will be used will be similar to Emmons and McCullough (2003): There are many things in our lives, both large and small, that we might be grateful about. Think back over your day (week) and write down on the lines below up to five things in your life that you are grateful or thankful for."
2562678|NCT02481544|Sham Comparator|Memorable Events Journaling Plus Standard of Care|"In the sham control condition, individuals will record memorable events with methods identical to the gratitude journaling condition: Patients will be asked to record 3-5 memorable events in a given day, on most days of the week. Patients will be contacted once per week to remind them to continue with the memorable events journal. Patients will be given 2 journals during their first testing session (one journal is for the first four weeks and the second is for the second four weeks of journaling). Patients will be contacted once per week to remind them to continue with gratitude journal writing. Patients will be instructed to record the date of each journal entry next to each new day of journaling Patients will be provided with materials to return their first journal by mail and will and return their second journal at the T2 laboratory testing session."
2562679|NCT02481544|No Intervention|Standard of Care|SOC consists of medical care that is included in post-MI treatment, such as physician visits and medication adjustments and cardiac rehabilitation. These patients will not have any active intervention, but will undergo the same testing routine as the gratitude intervention group. These patients will be given the opportunity to participate in the gratitude journaling intervention after they have completed the study. Patient records will be evaluated at each timepoint for changes in medications and medical treatment.
2562732|NCT02481128|No Intervention|A (access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy with preoperative access to lymphoscintigraphy findings
2562733|NCT02481128|Experimental|B (no access to lymphoscintigraphy)|Axillary sentinel lymph node biopsy without preoperative access to lymphoscintigraphy findings
2562798|NCT02480517|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
2562805|NCT02480517|Sham Comparator|Sham Control|Blinded Sham Control Arm
2562847|NCT02480179|Experimental|single arm pilot feasibility study|Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.
2562887|NCT02479932|Active Comparator|Extraperitoneal cesarean|
2562888|NCT02479932|Active Comparator|Transperitoneal cesarean|
3172021|NCT00594763||TS|Women with Turner syndrome
3172022|NCT00594776||1|Patients who have received a structrual allograft or vascularized fibular autograft surgery to reconstruct their tibia, femur, ulna/radius or humerus for treatment of a bone tumor.
3172023|NCT00594789|Experimental|1 (physician-only)|Physician(s) connected with a fracture that meets study inclusion criteria.
3172024|NCT00594789|Experimental|2 (physician/patient)|Physician(s) and patient connected with a fracture that meets study inclusion criteria.
3172025|NCT00594789|No Intervention|Control|Usual care.
3172026|NCT00594802||CHART REVIEW ONLY|CHART REVIEW OF PATIENTS WITH SYSTEMIC REACTIONS
3172027|NCT00594828|Experimental|1|6 months of supervised patient self testing using an expert system
3172028|NCT00594828|Active Comparator|2|6 months of routine medical care by the anticoagulation management service
3172029|NCT00594841|Active Comparator|1|Conservative (nonoperative) management of the AC joint dislocation.
2561971|NCT02486250||ReVeRe 1|A subset of 250 participants from the Main Study Recruits and all MRI & PET Substudy participants will be invited to participate in ReVeRe 1. The purpose of ReVeRe is to validate an additional unsupervised online cognitive measure, administered via an iPad application.
2561976|NCT02486250||ReVeRe 2|A subset of approximately 80 participants from the Main Study Recruits and MRI & PET Substudy participants will be invited to participate in ReVeRe 2. The purpose of ReVeRe 2 is to determine if performance on ReVeRe test battery is sensitive to amyloid positivity in cognitively intact older adults and also sensitive to longitudinal cognitive decline in this patient population.
3206780|NCT00958048|Experimental|2|ALS with non-invasive ventilation
2562100|NCT02485314||Participation|Parents will complete the PEM-CY (Participation and Environment Measure for Children and Youth).
2562139|NCT02485054||Eligible patients|Adults having had a transient visual disturbance during the last 8 days, except a diplopia
2562194|NCT02484677|Experimental|Head and neck cancer patient|Association of Docetaxel, Cisplatin, 5-Fluorouracile for pharmacokinetic evaluation
2562272|NCT02484300|Experimental|Melatonin 4hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
2562285|NCT02484300|Experimental|Melatonin 2hrs before bed|Time of dosage comparison on blood serum melatonin phase and subjective sleepiness
2562291|NCT02484300|Experimental|Melatonin|To determine effects of 10mg daily melatonin on chemoreflex control, oxidation status, loop gain and apnea hypopnea index in obstructive sleep apnea
2562293|NCT02484300|Placebo Comparator|Placebo|Placebo outcomes versus melatonin
2562344|NCT02483884|Experimental|Low risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with low risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
2562345|NCT02483884|Experimental|Intermediate risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with intermediate risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
2562346|NCT02483884|Experimental|High risk for recurrence|Diagnostic [68Ga]RM2 is administered to 10 primary prostate cancer patients with high risk of recurrence who undergo PET/CT 60 min post i.v. for at least 20 min.
2562376|NCT02483455|Experimental|ALC-919 Topical Solution|ALC-919 Topical Solution will be applied twice daily to study area for the treatment of Common Warts
2562380|NCT02483455|Placebo Comparator|Vehicle-Control Topical Solution|Vehicle-Control Topical Solution will be applied twice daily to study area for the treatment of Common Warts
2562440|NCT02483234|Experimental|Psoriasis/Psoriatic arthritis|Patients with Psoriasis and inflammatory and/or structural lesions and/or erosions in the MRI/HR-qCT scan will be treated with Secukinumab. Patients with psoriatic arthritis will be treated with Secukinumab. Bone changes will be evaluated influenced by IL-17 blockade
2562491|NCT02482922|Experimental|IET and Nutrition|3 times per week of interval exercise training Once daily meal replacement
2562512|NCT02482545|Experimental|Breakfast Meal Replacement|Once daily of a powdered meal replacement (high fat, high protein) will be consumed, mixed with water, at breakfast.
2562516|NCT02482545|No Intervention|Control|No placebo or intervention
2562590|NCT02482324|Other|Treatment A-B|12 subjects will receive a single oral inhaled dose of ALZT-OP1a, via dry powder inhaler, and a single oral tablet dose of ALZT-OP1b on Day 1, and two doses of ALZT-OP1a and ALZT-OP1b on Day 2, within two minutes of each other. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
2562594|NCT02482324|Other|Treatment B-A|12 subjects will receive two oral inhaled doses of ALZT-OP1a, via dry powder inhaler, and two oral tablet doses of ALZT-OPb, within two minutes of each other, on Day 1, and single doses of ALZT-OP1a and ALZT-OP1b on Day 2. All subjects will have plasma collected for PK analysis and 6 of 12 consented subjects from this group will provide CSF samples for analysis. CSF collected on Day 1 only.
2562638|NCT02481635|Experimental|Gemcitabine/Nab-paclitaxel, Radiation and Surgery|"Gemcitabine (neoadjuvant and adjuvant), intravenously, at a dose of 1000 mg/m2 given over 30-40 minutes, on Day 1 of every 28 day cycle for 2 cycles.~Nab-paclitaxel, intravenously, at a dose of 125 mg/m2 given over 30-40 minutes, on Days 1, 8, and 15 of every 28 day cycle for 2 cycles.~Radiation Therapy: 50.4 Gy in 28 fractions (1.8 Gy/fraction)~Surgery: Tumor resection and arterial resection/reconstruction"
2562655|NCT02481323|Active Comparator|Group 1|Isosorbide mononitrate 25mg bd
2562665|NCT02481323|Active Comparator|Group 2|Cilostazol 100mg bd
2562670|NCT02481323|Active Comparator|Group 3|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd start immediately
2562672|NCT02481323|Other|Group 4|Isosorbide mononitrate 25mg bd and cilostazol 100mg bd delayed start
2562775|NCT02480790||Patients with malignant disease|Patients with ovarian, tubar or primary peritoneal cancer
2562780|NCT02480790||Patients with benign disease|Patients with suspected ovarian cancer where the final pathologic diagnosis is benign
2562853|NCT02480361|Experimental|Acupuncture|The patients who were received acupuncture after gastric cancer surgery
2562854|NCT02480361|No Intervention|Non-acupuncture|The patients who were not received acupuncture after gastric cancer surgery
2562879|NCT02479867|Experimental|A Test|Test drug (Duricef) 1 tablet contains 1 gm Cefadroxil
2562881|NCT02479867|Experimental|B Reference|Reference drug (Biodroxil) 1 tablet contains 1 gm Cefadroxil
2562911|NCT02479646|Experimental|Treatment A|MYL-1401H: single subcutaneous injection (2mg)
2562915|NCT02479646|Active Comparator|Treatment B|EU-Neulasta: single subcutaneous injection (2mg)
2562916|NCT02479646|Active Comparator|Treatment C|US-Neulasta: single subcutaneous injection (2mg)
2563110|NCT02478710|Placebo Comparator|Aerosolized Placebo|Placebo tobramycin 0.5 mL 0.9% normal saline q.12h. Placebo vancomycin 0.5 mL 0.9% normal saline q.8h.
2563115|NCT02478710|Experimental|Aerosolized Tobramycin or Vancomycin|Aerosolized tobramycin 300 mg diluted in 5 mL 0.9% normal saline q.12h. Aerosolized vancomycin 125 mg diluted in 5 mL 0.9% normal saline q.8h.
2562160|NCT02484846|Experimental|60% TIB|Participants were to spend 60% of their normal time in bed on the night prior to the second visit.
2562161|NCT02484846|Experimental|70% TIB|Participants were to spend 70% of their normal time in bed on the night prior to the second visit.
2562162|NCT02484846|Experimental|80% TIB|Participants were to spend 80% of their normal time in bed on the night prior to the second visit.
2562163|NCT02484846|Experimental|90% TIB|Participants were to spend 90% of their normal time in bed on the night prior to the second visit.
2562164|NCT02484846|Active Comparator|100% TIB|Participants were to spend 100% of their normal time in bed (i.e., no change) on the night prior to the second visit.
2562166|NCT02484846|Experimental|115% TIB|Participants were to spend 115% of their normal time in bed on the night prior to the second visit.
2562169|NCT02484846|Experimental|130% TIB|Participants were to spend 130% of their normal time in bed on the night prior to the second visit.
2562177|NCT02484521|Active Comparator|Schizophrenia patients|Patients diagnosed with Schizophrenia. Will be assigned to PPI monitoring device protocol, according to unified protocol and have questionnaires to assess their status.
2562178|NCT02484521|Other|Healthy subject|This group would be assigned to PPI monitoring device protocol, according to a unified protocol similar to group of patients but not to questionnaires.
3172030|NCT00594841|Experimental|2|Operative fixation (i.e., ORIF) of the dislocation with a hook plate and screws.
2562399|NCT02483390|Experimental|Intervention group: All dyads are in the intervention arm.|
2562426|NCT02483156|Active Comparator|SOF + RBV|Sofosbuvir 400 mg once daily +RBV (1000 mg/day) for 12-24 weeks
2562433|NCT02483156|Experimental|sof + RBV + AH|Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg for 12-24 weeks
2562477|NCT02482857|Experimental|Acetylsalicylic acid 75 mg twice daily|Aspirin 75 mg BID is a new experimental dosing regimen which has shown improved efficiency regarding laboratory parameters in several studies, mainly in diabetic patients.
2562484|NCT02482857|Active Comparator|Acetylsalicylic acid 160 mg once daily|Aspirin 160 mg OD is an accepted and used dosage after CABG.
2562489|NCT02482857|Active Comparator|Acetylsalicylic acid 75 mg once daily|Aspirin 75 mg OD is an accepted and used dosage after CABG.
2562517|NCT02482558|Experimental|High GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day high glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
2562520|NCT02482558|Experimental|Low GI diet|8 Healthy subjects will be assessed at the start and end of a 7 day low glycaemic in diet following the appropriate High/Low Glycaemic index test breakfast.
2562609|NCT02481791|Experimental|Remifentanil|"Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.~Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.~Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min."
2562684|NCT02481414|Experimental|PepCan|Four injections (one every 3 weeks) of PepCan
2562687|NCT02481414|Active Comparator|Candin|Four injections (one every 3 weeks) of Candin
2562802|NCT02480452||CVI|All children consulting at the CVI clinic (with suspicion of CVI) receiving a diagnosis of CVI
2562807|NCT02480452||no CVI|All children consulting at the CVI clinic (with suspicion of CVI) not receiving a diagnosis of CVI
2562843|NCT02480205|Experimental|NeuroBox to deliver the NeuroPAP|
2562909|NCT02479919|Experimental|TBS-MPC|Intervention with Magstim® Active TBS aiming Medial Prefrontal Cortex in 18 patients with schizophrenia
2562912|NCT02479919|Active Comparator|TBS-CPDLF|Intervention with Magstim® Active TBS aiming Dorsolateral Prefrontal Cortex in 18 patients with schizophrenia
2562917|NCT02479919|Sham Comparator|TBS-Sham|Intervention with Magstim® Sham TBS in 25 patients with schizophrenia
2562954|NCT02479347|Experimental|Chloraprep|Preoperative skin preparation with chlorhexidine 2% in alcohol 70% solution
2562969|NCT02479347|Active Comparator|Povidone-iodine|Preoperative skin preparation with povidone-iodine 10% solution
2563013|NCT02478944|Experimental|Inflammatory bowel disease|Patients with Crohn's disease and ulcerative colitis undergoing manometry
2563141|NCT02478242|Active Comparator|Nafamostat mesilate group|Nafamostat mesilate was used for maintenance anticoagulation during continuous renal replacement therapy.
2563142|NCT02478242|Placebo Comparator|No anticoagulation group|Normal saline was used for maintenance anticoagulation during continuous renal replacement therapy.
2563163|NCT02477865|Experimental|PEX168(100µg)|PEX168(100µg),100µg,Subcutaneous injection,once a week,for 52 weeks.
2563167|NCT02477865|Experimental|PEX168(200µg)|PEX168(200µg),200µg,Subcutaneous injection,once a week,for 52 weeks.
2563176|NCT02477865|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week for 24 weeks,followed by PEX168(100µg or 200µg) qw sc for 28 weeks.
2563212|NCT02477631|Experimental|Deferiprone|patient treated with study drug
2563959|NCT02472587||Pap test|Women attending our institute in order to do Pap test
3172031|NCT00594867|Active Comparator|1|Acetaminophen - 4 grams per day + Placebo
3172032|NCT00594867|Active Comparator|2|Aspirin - 325 mg per day + Placebo
3172033|NCT00594867|Experimental|3|Acetaminophen 4 gram per day + Aspirin 325 mg per day
3172034|NCT00594893|Active Comparator|1|Mini Incision Approach
3172035|NCT00594893|Active Comparator|2|2 Incision Approach
3172036|NCT00594919||AKI group|Acute kidney injury group after cardiac surgery.
3172037|NCT00594919||NKF group|Normal kidney function group after cardiac surgery
3172038|NCT00594971|Other|B|90 terminally ill cancer patients will be referred to a specialist palliative care team at time of discharge.
3172039|NCT00594971|Other|C|90 terminally ill cancer patients will be discharged from hospital with extra effort put into improving the communication between the hospital and the primary sector.
3206781|NCT00958048|No Intervention|1|ALS without non-invasive ventilation
2562123|NCT02484885|Other|Healthy Volunteers|Healthy volunteers will undergo pulmonary function tests, hyperpolarized Xenon MRI at each visit.
2562211|NCT02484755|Experimental|gefitinib|gifitinib 250 mg oral administration once daily for a total of 4 weeks.
2562303|NCT02484261|No Intervention|Monitoring phase|Patients who have received a Stem cell transplant for Hematologic malignancies will be monitored for signs of relapse with blood tests for CD34+ chimerism. Patients with signs of relapse will have bone marrow aspirate and/or other appropriate tests to confirm presence of relapse. All patients who are confirmed to have relapsed and meet eligibility criteria to receive study drug will be eligible to receive treatment on the treatment arm.
2562304|NCT02484261|Experimental|Treatment phase|Patients with confirmed disease will initiate therapy with bortezomib and pravastatin, a regimen that has efficacy in treatment of leukemia and graft-versus-host disease, while sparing healthy donor hematopoietic stem cells may improve the dismal survival of relapse post allogeneic transplant. Depending on response, patients may receive up to 13 cycles of therapy
2562309|NCT02483780|Experimental|Storytelling intervention|"Two communes will be assigned to intervention group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with stories of patients who have successfully controlled their hypertension and Learn More section, which will be coordinated with specific patient stories and will fill in gaps not covered by the storytellers."
2562310|NCT02483780|No Intervention|Usual care|"Two communes will be assigned to usual care group. Within each commune, 25 adults with HTN will be enrolled.~Patients will receive 2 DVDs with only didactic material about common non-communicable diseases but without hypertension related stories."
2562347|NCT02483689|Placebo Comparator|Saline|Patient will be given saline with a maximum of 30 cc either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
2562348|NCT02483689|Experimental|Local|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
2562394|NCT02483429|Experimental|VRT Care|Patients randomized to VRT (VOG-guided Rapid Triage) care will have an algorithm-determined patient-specific diagnosis and treatment pathway in the emergency department. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
2562396|NCT02483429|No Intervention|Standard of Care (SOC)|Patients randomized to Standard of Care will undergo usual emergency department care without revealing results of VOG testing. Patients will complete a 1 week in-person follow up and a 1 and 6 month phone follow up.
2562398|NCT02483429|No Intervention|Observational|Patients who signed an informed consent but did not meet inclusion/exclusion criteria and don't randomize will enter a parallel track observational sub-study with limited 1 and 6 month phone follow-up.
2562444|NCT02483117||Eating disorder patients by type of compensating behavior.|Data collection started in 2010; one year follow-ups were conducted through 2011-2012. Psychiatrists collaborating in the study informed personally their patients about the objectives of the study, and recorded the sociodemographic information, including age, gender, marital status, level of education, employment status, and people with whom the patient lived. Those who agreed to take part were also sent the questionnaires and informed consent form by mail. They were asked to return these by mail using an enclosed, pre-stamped envelope. Two reminders also were sent at intervals of 15 days to those who did not respond to the first mailing.
2562466|NCT02482844|Other|Pacemaker|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
2562468|NCT02482844|Other|holter implantable|Every patient included with a de novo LBBB, persistent that is observed beyond 24 hours after the TAVI procedure, will benefit from an endocavitary electrophysiological exploration . According to the meditative delay of conduction, we shall hold the setting-up of a pacemaker in case of delay lengthened HV (> 70 ms) or of infrahissian block, in the opposite case the implantation of an holter with remote monitoring will be made
2562523|NCT02482597|Experimental|WBPA (Whole Body Accleration)|"Whole-body periodic acceleration (WBPA) is a new, non-invasive, and promising therapy for a diverse and growing list of disorders including cardiovascular disease 6. During WBPA, patients lie in the supine position on a bed that is capable of translating back and forth parallel to the ground, along the head-to-foot axis of the patient. Thus, this treatment is best described as a form of passive exercise. The frequency of the translation (up to 180 cycles/minute; cpm) as well as the distance traveled (2-24mm) by the bed can be adjusted by the patient or health care professional."
2562526|NCT02482597|Active Comparator|Active Recovery|Active recovery methods (e.g.walking, biking) have been shown to decrease blood lactate levels more than passive recovery 1,2. This arm requires subjects to walk at a low intensity as recovery.
3206782|NCT00958061||Vietnam-Era Women Veterans|For this study we will use a cohort of women who are on a roster of Vietnam Era women veterans (4,644 Vietnam, 1,213 near Vietnam, 5,465 non-Vietnam) previously identified and characterized by a review of their military personnel records and link it to a list of 8,061 women who presumably served in Southeast Asia. This final cohort could potentially contain approximately 14,000 women. After deceased individuals are removed from the active cohort and contact information is updated, we estimate that there could be approximately 10,000 women to whom the informed consent and mailed survey will be initially mailed.
2562639|NCT02481674|Experimental|VX15/2503|The study drug VX15/2503 will be administered via monthly intravenous infusions
2562640|NCT02481674|Placebo Comparator|Placebo|A placebo control will be administered via monthly intravenous infusions
2562870|NCT02480049|Experimental|A Test|test drug (Asmakast)1 tablet contains 10 mg Montelukast
3206783|NCT00958087||Sarcoidosis with cardiac involvement|
3206784|NCT00958087||Dilated cardiomyopathy|
3206785|NCT00958087||Sarcoidosis without cardiac involvement|
3206786|NCT00958087||Healthy controls|
3206787|NCT00958100|Experimental|Tenofovir Emtricitabine Raltegravir|Patients switching to raltegravir with tenofovir+emtricitabine as backbone
2562049|NCT02485743|Placebo Comparator|Placebo Diet Products|A range of products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
2562091|NCT02485366|Experimental|Rejuvenated PRBCs|The investigators will restore important energy molecules in stored red blood cells before they are transfused, with a rejuvenating solution (Rejuvesol).
2562144|NCT02485119|Experimental|BAY94-9343|"Cohort 1: Safety, tolerability and PK of 4.5 mg/kg dose given Q3W. Proceeding to Cohort 2 or not will be decided based on both safety variables during Cycle 1 (21 days) of 3 to 6 subjects in Cohort 1 and PK obtained from Cycle 1 (at least Day 1 to Day 5).~Cohort 2: Safety, tolerability and PK of 6.5 mg/kg dose given Q3W. Whether recruitment will be continued up to 9 subjects for Cohort 2 or not will be decided based on safety variables during Cycle 1 (21 days) of the first 3 subjects in Cohort 2. The safety and tolerability of 6.5 mg/kg will be assessed based on the data of 9 subjects during Cycle 1 in Cohort 2, and considering long term toxicity, the safety and tolerability of BAY94-9343 will be assessed all safety data by the end of 3 cycles in Cohort 2."
2562201|NCT02484612|Experimental|Lean adolescents|15 lean adolescents (BMI Under the national cut-offs for obesity), 12-15 years old, males, will be recruited
2562208|NCT02484612|Experimental|Obese adolescents|15 obese adolescents (BMI above the national cut-offs for obesity), 12-15 years old, males, will be recruited
2562327|NCT02483949|No Intervention|Control|
2562329|NCT02483949|Experimental|Intervention|Lifestyle intervention with peer-counseling follow-up
2562379|NCT02483559|Other|Amber Lenses|Participants will be randomized to participate in the amber lens condition first or second. Outcome measures to assess the effects of wearing amber lenses to block the blue light spectrum of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
2562383|NCT02483559|Other|Placebo Lenses|Participants will be randomized to participate in the placebo lens condition first or second. Outcome measures to assess the effects of wearing placebo lenses to allow all spectrums of light includes mood and sleep rating questionnaires (Positive and Negative Affect Scale, PANAS; Leeds Sleep Evaluation Questionnaire) as well as measuring the levels of melatonin the body is producing while wearing the glasses.
2562411|NCT02483299|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
2562413|NCT02483299|Active Comparator|combined|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
2562699|NCT02481284||Laser Doppler Perfusion Imaging|20 consequetive cases undergoing breast reconstruction with Deep inferior epigastric artery perforator flap who had evaluation of the microcirculation of the abdominal skin with laser Doppler perfusion imaging
2562716|NCT02480946|Experimental|Single Ascending Dose and Food Effect|Part A will be a single-dose, sequential-group, double-blind, placebo-controlled study of MBS2320.
2562719|NCT02480946|Experimental|Multiple Ascending Dose|Part B will be a multiple-dose, sequential-group, double-blind, placebo-controlled study to investigate 3 planned dose levels.
2562724|NCT02480946|Experimental|Relative Bioavailability|Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.
2562728|NCT02480946|Experimental|Drug-Drug Interaction with Methotrexate|Part D will be a multiple dose study incorporating an open-label, fixed-sequence drug-drug interaction between MBS2320 and methotrexate and biomarker evaluation.
3172040|NCT00594971|No Intervention|A|90 terminally ill cancer patients will be discharged from hospital, receiving usual care.
2562936|NCT02479542|Active Comparator|Standard Gauze Dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the Standard Gauze Dressing Arm, a saline moistened sterile gauze will be packed into the wound with dry gauze and either tape or other means will be used to secure the dressing. The dressing will be changed daily and measured and photodocumented every 72 hours with the Wound Zoom system.
3172041|NCT00594984|Active Comparator|Arm 1 - Phase 1|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
3172042|NCT00594984|Placebo Comparator|Arm 2 - Phase 2|"Cetuximab + Irinotecan + Brivanib~OR~Cetuximab + Irinotecan + Brivanib Placebo"
3172043|NCT00595010|Experimental|Managing Child Behavior|Families with a high risk for or a history of child abuse and are enrolled in Comprehensive Home-Based Services and receive services as usual, which includes SafeCare, plus Managing Child Behavior module if they report significant behavior problems with their child between the ages of 2-12.
3172044|NCT00595023||1|All eligible subjects
3172045|NCT00595049|Experimental|bosentan|
3172046|NCT00595062|Experimental|1|
3172047|NCT00595140|No Intervention|1|patients with acromegaly on stable pegvisomant therapy
3172048|NCT00595140|Active Comparator|2|Patients with acromegaly on stable pegvisomant therapy and additional application of octreotide 100µg
3172049|NCT00595140|Active Comparator|3|Patients with acromegaly on stable pegvisomant therapy and additional application of cabergoline 0.5mg orally
3172050|NCT00595166||B|Speculum Sheath group. Participants all received the speculum sheath.
3172051|NCT00595205||Group IS|Subjects <1 year of age with definite intussusception cases who had received Rotarix™.
3172052|NCT00595218|No Intervention|1|Patients whose radiation oncologist are blinded to their patient preference survey results
3172053|NCT00595218|Active Comparator|2|Patients whose radiation oncologist are not blinded to their patient preference survey results
3172054|NCT00595257|Experimental|1|injection of BMAC into ischemic limb
3172055|NCT00595257|Active Comparator|2|Injection and Infusion of BMAC into ischemic lower limb
3172056|NCT00595283|Experimental|1|Participants assigned to Parent-Child Interaction Therapy-Emotional Development
3172057|NCT00595283|Active Comparator|2|Participants assigned to Developmental Education Parenting Intervention
3172058|NCT00595296||1|All eligible patients.
3172059|NCT00595322|Experimental|1|bevacizumab and radiation (IMRT)
2562070|NCT02485626||Anthracycline naive BC patients|AVL or UMCG patients between the age of 40 - 50 at the time of BC diagnosis and treatment, treated without anthracyclines respectively 5-7 years ago and 10-12 years ago.
2562126|NCT02485132||T2DM at SU initiation|T2DM newly prescribed a SU
2562173|NCT02484768|Experimental|Group A|Infusion of 1000 mg iron isomaltoside 1000 at baseline. The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
2562175|NCT02484768|Placebo Comparator|Group B|Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
2562200|NCT02484482|Experimental|Group 1|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→Standard Meal→High Fat Meal"
2562209|NCT02484482|Experimental|Group 2|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→High Fat Meal→Fasting"
2562217|NCT02484482|Experimental|Group 3|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Fasting→Standard Meal"
2562220|NCT02484482|Experimental|Group 4|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Fasting→High Fat Meal→Standard Meal"
2562223|NCT02484482|Experimental|Group 5|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~Standard Meal→Fasting→High Fat Meal"
2562227|NCT02484482|Experimental|Group 6|"CKD-519 200mg administration, subjects have a Fasting, Standard Meal, High Fat Meal by randomized group.~High Fat Meal→Standard Meal→Fasting"
2562273|NCT02484183|No Intervention|Low-flow oxygen|Low-flow oxygen supplementation if respiratory danger signs are present or if their oxygen saturation is <90%. Respiratory danger signs include any of the following: grunting, severe chest indrawing, very fast breathing (>70 breaths/minute if 1-11 months; >60 breaths/minute if 12-59 months), nasal flaring, stridor in a calm child, or apnea. Low-flow oxygen given by an oxygen concentrator with a nasal cannula. Low-flow is 0.5 liters per minute (LPM) for patients 1-2 months, and 1-2 LPM for patients 2-59 months. For 2-59 month olds oxygen can be increased to a maximum of 2 LPM to maintain a 90% saturation or treat respiratory danger signs.
2562283|NCT02484183|Experimental|bubble CPAP|Bubble continuous positive airway pressure (bCPAP) patients are eligible if respiratory danger signs are present or if oxygen saturation is <90%. bCPAP will be initiated at 7 centimeters (cm) water (H20) if 1-2 months of age or 8cm H20 if 2-59 months of age using the minimum oxygen flow necessary to achieve these pressures. Gradual weaning can be attempted after 24-48 hours of treatment. All changes will be followed by 60 minutes of monitoring.
2562326|NCT02483936|Experimental|Test 1: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
2562330|NCT02483936|Experimental|Test 2: Olmesartan+Chlorthalidone|The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
2562334|NCT02483936|Active Comparator|Comparator 1: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
2562335|NCT02483936|Active Comparator|Comparator 2: Benicar HCT®|The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
2562434|NCT02483195|Active Comparator|Combination Group|This group will use a mixed combination of 5% Minoxidil and 200mg Spironolactone for 12 months to be used once daily.
2562436|NCT02483195|Active Comparator|Single Group|This group will use a mixed combination of 5mg Finasteride with placebo topical preparation for 12 months to be used once daily.
2562481|NCT02482792|Experimental|Norwegian Psychomotor Physiotherapy|NPMP is a body-mind awareness approach, often given in a combination of massage, exercises and conversations. The NPMP is individualized, with duration of 45-60 minutes in each session. As the NPMP is a longitudinal and normally slow process to obtain change, treatment can last up till one year, in the beginning once a week, and after some time once a month.
2562490|NCT02482792|Active Comparator|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.They will receive one session weekly with COPE, given by a physiotherapist, maximum 4 times, followed by active individual Physiotherapy (PT).
2562503|NCT02482506|Other|SG-WLP|Self-guided weight loss program
2562504|NCT02482506|Active Comparator|MF-WLP|Moving Forward Weight Loss Program
3206788|NCT00958100|Experimental|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
3206789|NCT00958100|Experimental|Abacavir free|Patients switched to raltegravir whose backbone therapy should not be randomized in order to avoid the use of abacavir (HLA-B*5701 positive patients,Framingham score 20% or higher)
3206790|NCT00958113||Autoimmune Thyroid Disease|Patients with Hashimoto's disease or Graves' disease
2562637|NCT02481609|Experimental|NAC arm|Topical intranasal N-acetyl cysteine (NAC 200 mg/2 ml vials) BID for one month
2562660|NCT02481349|Experimental|Arm I (couple-based Hatha yoga program)|Patients and their partners attend up to 15, 45-60 minute sessions of Hatha yoga over the course of radiation therapy 5 times a week for 5-6 weeks. The program comprises four main components: joint loosening with breath synchronization; postures with deep relaxation techniques; breath energization with sound resonance; and meditation. At the fifth session, patients and their partners receive a DVD and are encouraged to practice on their own (individually and/or together) on the days when they do not meet with the instructor.
2562669|NCT02481349|Active Comparator|Arm II (waitlist control)|Patients receive standard of care provided by the health care team and complete questionnaires before and after radiation therapy.
2562726|NCT02481076|Experimental|compression therapy|"Intervention arm: administration of~Flowtron Hydroven boot in the Emergency Department~Coban2 Lite after surgery~Flowtron Hydroven boot after surger, before discharge"
2562731|NCT02481076|Other|controle|"The leg is elevated on a Braun frame. This is the old fashioned conservative treatment to prevent swelling."
2562767|NCT02480686|Experimental|SOF+PEG+RBV|Participants with HCV genotype 1b infection will receive Sofosbuvir (SOF) 400 mg +PEG+RBV for 12 weeks.
3206791|NCT00958113||Unaffected Population|Population not known to be affected by Hashimoto's Disease or Graves' Disease
2562945|NCT02479204|Experimental|Part B ACT-334441 + atenolol|12 subjects will receive 50 mg of atenolol (once daily) from day 1 to day 15, placebo once on day 6, and ACT-334441 4 mg (once daily) from day 8 to day 15
2562079|NCT02485587|Active Comparator|Treatment as usual|After a pre-training assessment at baseline, subjects will be randomized to either treatment arm or treatment as usual. Subjects in the comparator condition will receive several appointments together with their parents/caregivers or group trainings over a timeframe of 20 weeks. Within the sessions, the investigators will focus on psychoeducational issues and provide general counseling for the families. After 10 weeks, parents/caregivers will be asked to evaluate behavioral measures of aggression. After 20 weeks, subjects will undergo post-treatment assessment (week 20/21) and follow up (6 months after the end of the treatment phase).
2562082|NCT02485587|No Intervention|Typically developing (TD) control group|Healthy, typically developing children will only undergo baseline assessment (observational) for comparison
2562104|NCT02485197|Other|Low 25(OH)D|We will recruit individuals with low 25(OH)D (<30ng/mL).
2562105|NCT02485197|Other|High 25(OH)D|"We will recruit individuals with higher 25(OH)D (at least 20ng/mL units higher then that of the low 25(OH)D group)."
2562125|NCT02484976|Experimental|Family Based Behavioral Treatment|Central satiety brain and hormonal responses will be compared pre-and post-Family Based Behavioral Treatment, as well, as to a non-obese sample.
2562210|NCT02484742|No Intervention|Sleep control condition|8 hours of sleep throughout the 18-day stay in the Clinical Research Center
2562218|NCT02484742|Experimental|Insomnia symptom induction condition|4 4-day cycles, each consisting of 3 nights with sleep disruption followed by one night of recovery sleep.
2562253|NCT02484248|Active Comparator|cross-over of Ketotifen|Patients will begin the active ketotifen treatment first and cross over to placebo.
2562254|NCT02484248|Placebo Comparator|cross-over of Placebo|Patients will begin the placebo treatment first and cross over to the active ketotifen.
2562368|NCT02484040|Experimental|Two-week course arm|"Experimental arm receive 33 Gy in 10 fractions of radiation for 2 weeks with oral capecitabine.~Two-week course of radiation, 33 Gy/10 fx and oral capecitabine, 825 mg/m2, bid"
2562373|NCT02484040|No Intervention|Conventional arm|conventionally fractionated radiation of 50.4 Gy/28 fx and 5-FU, 500 mg/m2 and leucovorin, 20 mg/m2 for 5 days, monthly or Capecitabine, 825 mg/m2, bid
2562441|NCT02483260|Other|10-day course of treatment|10-day course of treatment with follow-up 14 ± 2 days after first dose
2562483|NCT02482818|Placebo Comparator|Control-Placebo|"Administration of Placebo (Lactose instead of Pregabalin) pills in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of placebo (Lactose) will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial placebo administration, following an assessment by the Doctor of how well subjects are doing on their (drug or placebo), the study placebo will be increased to 100 mg twice a day.~Twenty eight days after initial placebo administration subjects will begin to receive the study placebo in a reducing dose regimen for 7 days then follow up at day 42."
2562486|NCT02482818|Experimental|Pregabalin|"Administration of Pregabalin in an increasing dose regimen followed by a decreasing dose regimen over 35 days during a 42 day trial.~Initially an increasing dosage of Pregabalin will be administered. On Visit 1 an increasing dose (25 mg twice a day for 3 days, then 50 mg twice a day for 2 days and then 75 mg twice a day for 2 days).~Eight days after initial medication administration, following an assessment by the Doctor of how well subjects are doing on the medication, the study medication will be increased to 100 mg twice a day.~Twenty eight days after initial drug administration subjects will begin to receive the study medication in a reducing dose regimen for 7 days.~Forty two days after initial drug administration the Doctor will meet with subjects to follow up."
2562513|NCT02482441|Experimental|OMP-131R10 intravenous (in the vein) infusions|OMP-131R10 will be administered IV on the first day of each 14-day cycle.
2562515|NCT02482441|Experimental|FOLFIRI (5-FU, irinotecan, leucovorin).|dosing continues up to the 20 mg/kg dose level
2562591|NCT02482168|Experimental|APX005M every 3 week|Subjects receive APX005M intravenously every 3 week until disease progression, unacceptable toxicity or death.
2562595|NCT02482168|Experimental|APX005M every 2 week|Subjects receive APX005M intravenously every 2 week until disease progression, unacceptable toxicity or death.
2562599|NCT02482168|Experimental|APX005M every 1 week|Subjects receive APX005M intravenously every 1 week until disease progression, unacceptable toxicity or death.
2562615|NCT02481661|Experimental|segmentectomy|Patients undergo anatomic segmentectomy by minimal incision thoracotomy or thoracoscopy/VATS.
2562621|NCT02481661|Active Comparator|lobectomy|Patients undergo lobectomy by minimal incision thoracotomy or thoracoscopy/VATS.
2562658|NCT02481518|Experimental|Magnesium|Magnesium preloading group : Magnesium preloading for Cisplatin treatment
2562667|NCT02481518|Active Comparator|Control|Control group : Normal saline preloading for cisplatin treatment
2562696|NCT02481167||group1|This study was consisted of patients with older than 40 years of age who complained with dry eye.
2562809|NCT02480699|Experimental|Hemodialysed patients|
3206792|NCT00958139|Experimental|Permethrin treatment of clothing|0.5% permethrin sprayed one time on uniform shorts, pants, and socks
3206793|NCT00958139|Sham Comparator|Placebo|Water sprayed on uniform shorts, pants, and socks
2562986|NCT02479360||Outcome measurement|Each participant will be asked to complete each standardised outcome measure (SOM) three times and each trial will be videotaped by the researcher. The selected SOM's are the 10 metre walk test, the timed up and go test, the functional reach test and the nine-hole peg test. A physiotherapist will watch the video on 2 separate occasions to evaluate intra-rater reliability. Inter-rater reliability will be assessed through asking three other neurofibromatosis specialist professionals (two NF1 consultants and one NF1 specialist nurse) to review the video and to score each measure completed. Once the filmed sessions have been analysed by the relevant clinician's the data will be destroyed in line with Trust policy.
2564727|NCT02467296|Active Comparator|B: 3 gr of Sodium|Meal Plans with 3 gr of Sodium
3206794|NCT00958152|Experimental|Cohort 1|
3206795|NCT00958152|Experimental|Cohort 2|
3206796|NCT00958152|Experimental|Cohort 3|
3208853|NCT00978718|Placebo Comparator|Arm I|Patients receive oral placebo daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
2562131|NCT02485210|Active Comparator|Covencional treatment|"Convencional endodontic treatment for deciduous teeth, with Surgical chemical preparation with series of Kerr files appropriate for each case, using initial file and an additional two files of larger size, with irrigation and aspiration with 1% sodium hypochlorite (Milton's solution) and endo PTC (Fórmula & Ação) with each change of file.~Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session."
2562136|NCT02485210|Experimental|Photodynamic therapy|Endodontic Treatment with photodynamic terapy Irrigation of the root canal system Insertion of sterile paper cone immersed in Chimiolux® methylene blue for three minutes; administration of wireless Therapy XT EC laser device (DMC - São Carlos, Brazil) after removal of cone; energy density: 4 J/cm², power: 100 mw; wavelength: 660 nm; exposure time: 40 seconds Filling of root canals with calcium hydroxide (Ultra-cal, Ultradent, Brazil); base of thin gutta-percha and filling with glass ionomer cement; restorative treatment performed in subsequent session
3206797|NCT00958178|Experimental|Rebreathing method of preoxygenation|Subjects will breathe Oxygen through a close fitting mask, but the flow will be low so that they rebreathe some of their expired air. After 30 seconds, the flow will be turned up so that they will breathe 100% Oxygen.
3206798|NCT00958178|Active Comparator|T method of preoxygenation|Tidal breathing of 100% oxygen through a well fitting facemask, for 4 minutes.
3206799|NCT00958204|Experimental|1|Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
3206800|NCT00958204|Experimental|2|Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
3206801|NCT00958204|Active Comparator|3|Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
2562478|NCT02482831||Diabetes|Diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
2562482|NCT02482831||non-Diabetes|Non-diabatic participants who experienced unilateral lower limb surgery and received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml in Peking Union Medical College Hospital were selected.
2562511|NCT02482519|Other|10 day overfeeding/fasting|10 day high calorie diet followed by a 10 day fast
2562543|NCT02482272|Active Comparator|Lamivudine plus Adefovir or Adefovir|Lamivudine+Adefovir or Adefovir for 48 weeks
2562546|NCT02482272|Experimental|Entecavir plus Adefovir|Entecavir+Adefovir for 48 weeks
2562586|NCT02482012||Staff|Staff nurses and physicians in the NICU
2562589|NCT02482012||Parents|Parents of infants in the NICU and a smaller group of parents of infants in the well baby nursery.
3206802|NCT00958204|Placebo Comparator|4|Negative ion generator (30 minutes daily) plus placebo pill every day
3206803|NCT00958230|Experimental|dCell Vascular Patch|This Xenograft device is manufactured from Porcine Pericardium Tissue which has been decellularised leaving a scaffold style structure for ingrowth of human endothelial cells after placement into the operative site.
3206804|NCT00958269|Experimental|dutogliptin (double-blind, placebo-controlled period)|weeks 1-26
3206805|NCT00958269|Experimental|dutogliptin (single-blind, active-controlled period)|weeks 27-52
2562738|NCT02480933|Experimental|female cadavers|female cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
2562741|NCT02480933|Experimental|Male cadavers|male cadavers above 40 years without known breast cancer Bilateral mastectomy Biopsy
3206806|NCT00958269|Placebo Comparator|placebo (double-blind, placebo-controlled period)|weeks 1-26
3206807|NCT00958269|Placebo Comparator|placebo (single-blind, active-controlled period)|weeks 27-52
2562840|NCT02480075||Chronic pain|Observational ; Adult patients seeking medical treatment that have been diagnosed with chronic pain.
2562883|NCT02479958|Experimental|Control|
2562885|NCT02479958|Experimental|APDT 1|
2562886|NCT02479958|Experimental|APDT 2|
2562947|NCT02479581|Experimental|ERAS group|Perioperative management follows the Enhanced Recovery after Surgery（ERAS） program
2562963|NCT02479581|Experimental|Conventional control group|Perioperative management follows the conventional program
2563034|NCT02478775|Experimental|Frequent Blood Sampling|Investigators will assess the change in inhibin B levels following repeated bolus dosing of recombinant FSH (rFHS) following Degarelix (GnRH antagonist) blockade over a 2-day period.
2563106|NCT02478515|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
2563139|NCT02478151|Experimental|OrganOx Metra|OrganOx Metra Device
2563182|NCT02477917|Experimental|Allergovac depot|Allergovac depot with Parietaria judaica pollen extract
2563217|NCT02477579|Experimental|NovaCross|NovaCross microcatheter will be used.
2563259|NCT02477293|Experimental|Hyeonggaeyeongyo-tang|
2563312|NCT02477124|Active Comparator|transvaginal digital colposcope (TVCD)|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
2563319|NCT02477124|Active Comparator|standard of care screening|Each enrolled patient will undergo the standard of care for cervical cancer screening at her institution, and then the trans-vaginal colposcope will be used to collect digital images of the cervix.
2563511|NCT02475512|Placebo Comparator|Standard care|Washing will be done using water and pH neutral soap. No other preventive barrier or hydration products will be allowed in the genital-anal region.
3206808|NCT00958269|Active Comparator|sitagliptin (single-blind, active-controlled period)|weeks 27-52
3206809|NCT00958321|Experimental|3-DCRT|Patients will receive a total dose of 60-66 Gy in 30-33 fractions with 3-DCRT
3206810|NCT00958386|Experimental|1|Panitumumab+irinotecan
3206811|NCT00958399|Placebo Comparator|No fiber|No fiber added to study products
3206812|NCT00958399|Experimental|Resistant Starch|Muffins, cereal, and bars made with a resistant starch
3206813|NCT00958399|Experimental|Resistant starch + soluble fiber|Muffins, cereal, and bars made with a mixture of resistant starch and a soluble fiber
3206814|NCT00958399|Experimental|Fiber made from corn starch|Muffins, cereal, and bars made with novel corn fiber
2562202|NCT02484638|Experimental|CSL689 low-dose|"Part 1: single injection of low-dose CSL689 for PK evaluation~Part 2: up to 2 injections of low-dose CSL689 per bleeding event (bleeding events 1 to 3*)~Part 3: up to 3 injections of low-dose CSL689 per bleeding event * Note: All subjects in the low-dose arm will be treated with high-dose CSL689 for bleeding events 4-6 in Part 2"
2562212|NCT02484638|Experimental|CSL689 high-dose|"Part 1: single injection of high-dose CSL689 for PK evaluation~Part 2: up to 2 injections of high-dose CSL689 per bleeding event (bleeding events 4 to 6*)~Part 3: up to 3 injections of high-dose CSL689 per bleeding event~Note: All subjects in the high-dose arm will be treated with low-dose CSL689 for bleeding events 1-3 in Part 2"
2562214|NCT02484638|Active Comparator|Eptacog alfa low-dose|Single injection of low-dose Eptacog alfa in Part 1 for PK evaluation
2562221|NCT02484638|Active Comparator|Eptacog alfa high-dose|Single injection of high-dose Eptacog alfa in Part 1 for PK evaluation
2562261|NCT02484144||patients receive usual information|Patients receive usual information before Scheduled Coronarography
2562275|NCT02484144||patients receive modern information|Patients receive usual information and a information by video before Scheduled Coronarography
2562314|NCT02483715|Experimental|High-dose dual therapy|group A-high-dose dual therapy ( rabeprazole 20 mg, tablet, qid + amoxicillin 750 mg, capsule, qid for 14 days)
2562316|NCT02483715|Active Comparator|Bismuth-containing quadruple therapy|group B-bismuth-containing quadruple therapy (rabeprazole 20 mg, tablet, bid + tripotassium dicitrate bismuthate 300 mg, tablet, qid + metronidazole 250 mg, tablet, qid + tetracycline 500 mg qid, capsule, for 10 days)
2562371|NCT02483546|Experimental|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
2562375|NCT02483546|Active Comparator|traditionally teaching|students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
2562455|NCT02483247|Experimental|Combo with Capecitabine|
2562456|NCT02483247|Experimental|Combo with Doxorubicin|
2562457|NCT02483247|Experimental|Combo with Nivolumab (US only)|
2562459|NCT02483247|Experimental|Combo with Pembrolizumab|
2562460|NCT02483247|Experimental|Combo with Paclitaxel|
2562461|NCT02483247|Experimental|Combo with Sunitinib|
2562530|NCT02482480|Experimental|Interventional group|"Participants followed a 8-week intervention program with a total of 24 sessions (12 of those were supervised). The aim of the supervision was to increase the adherence to the treatment and to control the compliance of patients. General physical activity consisted in walking along previously standardized urban parks designed for the urban EPOC training project (Arbillaga-Etxarri et al, 2016). The duration of walking were 30 minutes. The physiotherapist supervised the accomplishment of other activities such as oropharyngeal exercises and diet control.~Oropharyngeal exercises:~Expiratory muscle strength training (EMST):~Masako Manoeuvre~Shaker Head Lift:~Facial exercise"
2562531|NCT02482480|Sham Comparator|Control Group|Control group participants only received general recommendations regarding general physical activity, diet and sleep hygiene. After 8-weeks of control, they were re-evaluated with the same evaluation test used in the beginning of the study period. Recommendations for general physical activity were walking during 30 minutes at least 3 times a week maintaining the greatest possible pace. Also, control group patients received the same diet control document as intervention group and verbal advice for sleep hygiene. Approximately 1 month after enrolment, a follow-up phone call was completed were we also informed about the new re-evaluation data.
3206815|NCT00958399|Experimental|Fiber made from corn starch + soluble fiber|Muffins, cereal, and bars made with a mixture of novel corn fiber and a soluble fiber
3206816|NCT00958425|Experimental|Hyaluronic acid gel|
2562648|NCT02481401|No Intervention|Control Arm|Will not receive any structured program except for the health promotion education program that the children will receive for 4 months. Complementary to the Si! Program. This is essentially healthy habits related information and activities to be performed with their kids through family newsletters. All participants (including controls) have access to the study website for health related information.
2562653|NCT02481401|Experimental|Intensive Individual Intervention Program|A combination of one-on-one personalized lifestyle counseling (8 months with 4 complimentary sessions for a total of 12 months) and a wearable physical activity monitor such as the Garmin Vivofit.
2562664|NCT02481401|Active Comparator|Peer-To-Peer Program Intervention|Monthly meetings for 60-90 minutes in groups of about up to 20 supporting each other in self-control of CV risk factors, for a total of 12 months.
2562703|NCT02481089||training group|
2562737|NCT02480855|Other|Questionnaire and feedback|Patients that will see a doctor randomized to the intervention group will fill in the Work Stress Questionnaire prior to the visit. The doctor gets the results from the questionnaire and then gives consultation to the patient based on the results.
2562739|NCT02480855|No Intervention|Control group|Patients that will see a doctor randomized to the control group get the usual treatment/consultation and after the visit fill in the Work Stress Questionnaire.
2562760|NCT02480647|Experimental|levonorgestrel & etonogestrel|"Levonorgestrel releasing intrauterine system~Other names:~Mirena."
2562761|NCT02480647|Active Comparator|etonogestrel|"Etonogestrel implant:~Other name: Implanon Releasing 20μg/day."
2562830|NCT02480400|Experimental|Supported Escitalopram|Escitalopram, with assessment visits at baseline, and weeks 2, 4, 6 and 8
2562832|NCT02480400|Active Comparator|Escitalopram|Escitalopram, with assessment visits at baseline, week 4 and week 8, and a safety visit at week 2
3206817|NCT00958425|Active Comparator|Saline|
2562204|NCT02484586|Other|Non-Presbyope group|"18-39 years with no reading add.~Control lens: Etafilcon A, Nelfilcon A, Omafilcon A~Test lens: Etafilcon A~Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit."
2562262|NCT02484105|Experimental|Comforting Conversation|Conversation according to the initital qualitative study.
2562270|NCT02484105|Active Comparator|Standard Communication|Standard information prior to and during endoscopy.
2562332|NCT02483962|Placebo Comparator|Gelatine capsule|Gelatine capsules containing no active ingredients, will be taken once per day, in the morning after breakfast, for 30 days. These capsules will be of identical appearance to the experimental comparator.
2562333|NCT02483962|Experimental|Venavine Intensive®|Gelatine capsules containing the active ingredients of: 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butcher's broom extract and 3,2 mg of vitamin B6, will be taken once per day, in the morning after breakfast, for 30 days.
3206818|NCT00958451|Active Comparator|Paricalcitol|Arm 1: 40 patients will be assigned to paricalcitol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
3206819|NCT00958451|Active Comparator|Ergocalciferol|Arm 2: 40 patients will be assigned to the Ergocalciferol treatment group. Patients will be randomized once they meet inclusion and exclusion criteria. If patients are not on any vitamin D treatment when enrolled, they will have 2 screening visits before randomization. Screening visits will consist of a physical exam and lab tests to measure Vitamin D, calcium, iPTH, and safety profile. Patients on vitamin D treatment prior to study will have a minimum 4 week washout period before screening tests. Patients' Lean Body Mass and Aortic Blood Pressure and pulse wave velocity will be measured before dosing. Cardiovascular markers will be checked throughout the study. Patients will be monitored monthly after starting study treatment. Total treatment period: 4 months.
2562417|NCT02483130||NAC or Placebo|Participants will receive 2400mg capsules of N-Acetylcysteine or placebo
2562469|NCT02482948|Active Comparator|Collagenase|This is an enzymatic debridement agent to remove non-viable tissue from wounds to be applied daily
2562473|NCT02482948|Active Comparator|Active leptospermum honey|This is an active medicinal grade honey used to promote autolytic debridement and applied daily
2562519|NCT02482584|Active Comparator|CPAP treatment|Continuous Positive Airway Pressure (CPAP) treatment during three month.
2562524|NCT02482584|Other|Control group|Control group
2562570|NCT02482220|Experimental|High intensity|in this group, the participants will follow a high intensity physical activity program (High Intensity Interval exercise from 75 to 95% VO2max)
2562576|NCT02482220|Experimental|Moderate intensity|in this group, the participants will follow a moderate intensity physical activity program (Intensity from 50 to 65% VO2max)
2562610|NCT02481843||Hyperoxia|2-hours of hyperoxia (FiO2 = 1.0)
2562620|NCT02481843||Control|2-hours control without hyperoxia
2562685|NCT02481479|Other|Single group -Paired comparison|Saxagliptin 2.5mg or 5mg od
3206820|NCT00958464||1|MRI protocol on 2 separate occasions
3206821|NCT00958490|Active Comparator|First walking group|Group walking at 2 months postop
2562795|NCT02480478||intrahepatic cholestasis of pregnancy|5 ml whole blood sample is going to collect from intrahepatic cholestasis of pregnancy group for the assessment of serum autotaxin levels
2562796|NCT02480478||healthy control group|5 ml of whole blood is going to taken from healthy control group
2562861|NCT02480218||Tamoxifen|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed tamoxifen.
2562864|NCT02480218||Aromatase Inhibitors|Chemotherapy-naïve women 65 and older with a first diagnosis of early stage HR+ BC, post surgical resection prescribed aromatase inhibitors.
2562895|NCT02479750|Experimental|ColdZyme|ColdZyme® mouth spray liquid. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
2562901|NCT02479750|Placebo Comparator|Placebo|Sugar based mouth spray liquid manufactured to mimic ColdZyme® mouth spray. Treatment (6 doses per day) will be applied for 11 days from the day of inoculation.
2562973|NCT02479477|Experimental|kinesio therapy|"The intervention is one protocol of labour kinesiotherapy that will be realized tree times per week, eatch intervention with fiveteen minutes, during eitgh weeks.~To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase."
2562987|NCT02479477|No Intervention|control|the control group will continue their daily tasks uring eitgh weeks. To change to sf-36 questionary after intervention. the intervention is the use of labour kinesio terapy in the auxiliary nursing The chance is in the score of questionary, the investigators hope that after intervention the score will increase.
3206822|NCT00958490|Active Comparator|Second group walking|Group walking at 3 months postop
3206823|NCT00958503|Placebo Comparator|Placebo|Placebo
3206824|NCT00958503|Active Comparator|Thiamphenicol|Active comparator
3206825|NCT00958516|Experimental|LEO 29102 cream|
3206826|NCT00958529|Experimental|inulin|0, 5, 10 g inulin
2563143|NCT02478229|Experimental|SOF and LDV|Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.
2564831|NCT02466711|Placebo Comparator|Placebo|
2562378|NCT02483663||27 Monozygotic Pairs|
2562382|NCT02483663||27 Dizygotic Pairs|
2562453|NCT02483078|Active Comparator|PRO 140|PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
2562454|NCT02483078|Placebo Comparator|Placebo|Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
2562538|NCT02482337|Experimental|POEM procedure|Patients who underwent POEM
2562563|NCT02482077|Experimental|SOF+RBV 8 wk|Participants will receive SOF+RBV for 8 weeks.
2562564|NCT02482077|Experimental|SOF+RBV 12 wk|Participants will receive SOF+RBV for 12 weeks.
2562565|NCT02482077|Experimental|SOF+DCV 8 wk|Participants will receive SOF+DCV for 8 weeks.
2562566|NCT02482077|Experimental|SOF+DCV 12 wk|Participants will receive SOF+DCV for 12 weeks.
2562567|NCT02482077|Experimental|LDV/SOF 8 wk|Participants will receive LDV/SOF for 8 weeks.
2562568|NCT02482077|Experimental|LDV/SOF 12 wk|Participants will receive LDV/SOF for 12 weeks.
2562634|NCT02481648|Experimental|ARM1: Exercise Intervention|"The exercise program is a 4-12 weeks progressive combined resistance and aerobic exercise for participants from time of diagnosis to RP.~Participants will undergo twice weekly group-training (four-six participants/group) combined aerobic-resistance sessions (1hr per session), supervised by trained exercise therapists. In addition, participants will undergo home-based aerobic exercise independently three times a week with the goal to meet the current physical activity guidelines for cancer survivors (150min/week of moderate intensity aerobic activity and two resistance training sessions per week). Participants will also be supplied with the Canadian Physical Activity and Sedentary Behavior Guidelines Handbook and accompanying Log Sheets."
2562636|NCT02481648|No Intervention|ARM2: Control Group|Participants will be asked to exercise as they normally would and will be asked to record their exercise activity on provided activity logs.
2562644|NCT02481362|Active Comparator|Order 1|Order for sessions: Cake, apricots
2562645|NCT02481362|Active Comparator|Order 2|Order for sessions: apricots, Cake
3172060|NCT00595387|Active Comparator|1|Participants receiving supportive psychotherapy
2562783|NCT02480751|Experimental|1: Exprimental (TRK-100STP)|high dose
2562787|NCT02480751|Experimental|2: Exprimental (TRK-100STP)|low dose
2562790|NCT02480751|Placebo Comparator|3: Placebo Comparator|Placebo
2562855|NCT02480257|Experimental|TARA Intervention group|TARA is comprised of 12 weekly classes delivered in a group format by two trained facilitators with approximately 8-15 participants. The 90 minute sessions are designed to promote skills for autonomic regulation, attention modulation, emotion regulation and cognitive control.
2562978|NCT02479217||Adjuvant therapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
2562989|NCT02479217||Combination Therapy|Patients prescribed Xeloda with docetaxel for metastatic breast cancer after failure to anthacyclines were observed until disease progression
2562993|NCT02479217||Monotherapy|Patients prescribed Xeloda per registered indicatilons were observed until disease progression or 8 cycles for adjuvant colon cancer
2563086|NCT02478606|No Intervention|Control Group|Without intervention
2563087|NCT02478606|Experimental|Static Group|Will receive passive static stretching in hamstring muscle
2563092|NCT02478606|Experimental|PNF Group|Will receive passive proprioceptive neuromuscular facilitation stretching in hamstring muscle
2563147|NCT02478216|No Intervention|C group|Remote ischemic preconditioning will not be applied
2563150|NCT02478216|Experimental|R group|Remote ischemic preconditioning will be applied.
2563195|NCT02477787|Experimental|treatment|patients will receive donor-derived NK cell infusion after haploidentical HCT
2563199|NCT02477787|No Intervention|control|patients will undergo haploidentical HCT but not receive donor-derived NK cells after HCT
2563234|NCT02477488|Experimental|Allopurinol HS|Allopurinol at bedtime compared to AM administration
2563268|NCT02477254||SLE patients|SLE patients who received HPV vaccination
2563270|NCT02477254||Control subjects|Healthy subjects who received HPV vaccination
2563288|NCT02476955|Experimental|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 milligrams (mg) every day (QD), 5 days on/9 days off of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously. The combination treatment will continue until progression of disease (clinical or radiological), unacceptable toxicity, or another of the discontinuation criteria is documented.
2563313|NCT02476838|Other|traumatic amputation of the hand|may be male or female patients between the ages of 18 and 60 who are missing all or part of one or both hands and forearms
2563358|NCT02476734||Diffuse Large B-cell Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
2563364|NCT02476734||Follicular Lymphoma|There is no intervention. Will undergo baseline FDG-PET/CT to be performed within 6 weeks of infusion of CART-19 autologous T-cell therapy in a different study and then undergo repeat FDG-PET/CT at approximately 1 month after infusion. Infusion of CART-19 autologous T-cell therapy is not part of this study.
2563607|NCT02475317|Experimental|Maralixibat 100mg|Participants will receive maralixibat 100 mg liquid formulation orally QD for 7 days.
3172061|NCT00595387|Experimental|2|Participants receiving cognitive behavioral therapy
3172062|NCT00595426|Experimental|1. YM150 Dose X, twice daily|
3172063|NCT00595426|Experimental|2. YM150 Dose Y, once daily|
3172064|NCT00595426|Experimental|3. YM150 Dose Y, twice daily|
3172065|NCT00595426|Experimental|4. YM150 Dose Z, once daily|
3172066|NCT00595426|Active Comparator|5. Warfarin|various doses
2562264|NCT02484287|Active Comparator|Integra External Drainage Catheter|The Integra External Drainage Catheter non antibiotic-impregnated EVD catheter
2562271|NCT02484287|Active Comparator|Ventriclear EVD Antibiotic Catheter|The Ventriclear EVD Antibiotic Catheter antibiotic-impregnated EVD catheter
2562278|NCT02484287|Active Comparator|Codman Bactiseal EVD Catheter Set|The Codman Bactiseal EVD Catheter Set antibiotic-impregnated EVD catheter
2562328|NCT02483910|Experimental|DI-LL via telehealth|Subjects with autism spectrum disorder (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to receive Direct Instruction-Language for Learning (DI-LL) for 40-48 sessions (roughly twice a week for 24 weeks). Subjects in this arm will be allowed to continue ongoing treatment during the randomized phase of the study
2562331|NCT02483910|Active Comparator|Standard of care delivered via telehealth|"Subjects with (ASD) plus moderate language between 4 years and 7 years 11 months will be randomly assigned to continue treatment as usual (TAU) for 24 weeks.~NOTE: after the randomized trial, subjects who do not show a positive response at Week 24, will be offered Direct Instruction-Language for Learning (DI-LL) for 24 weeks."
2562360|NCT02483494|Experimental|APN-led Telemedicine|Participants will receive APN-led Telemedicine in addition to usual care.
2562365|NCT02483494|No Intervention|Usual care|Participants will receive the standard of care which includes education by cardiac care nurses and face-to-face consultations.
2562415|NCT02483351|Experimental|Liberal RBC Transfusion Strategy|
2562416|NCT02483351|Active Comparator|Restrictive RBC Transfusion Strategy|
2562502|NCT02482688|Experimental|Multisensory Acute|Multisensory intervention delivered within 2 months post-stroke.
2562505|NCT02482688|Experimental|Multisensory Chronic|Multisensory intervention delivered 6 months post-stroke.
2562510|NCT02482688|Active Comparator|Unisensory Acute|Unisensory intervention delivered within 2 months post-stroke.
2562514|NCT02482688|Active Comparator|Unisensory Chronic|Unisensory intervention delivered 6 months post-stroke.
3172067|NCT00595491|Experimental|allergic asthmatic, allergic nonasthmatic, healthy|Adults who are allergic asthmatics, allergic nonasthmatics, or healthy controls will receive segmental allergen challenge to the lung
3172068|NCT00595543|Active Comparator|1|
2562656|NCT02481453|Experimental|Rapamycin|rapamycin 1 mg/ml oral solution, 2 mg/day (2 ml/day), once a day, during one year
2562662|NCT02481453|Placebo Comparator|Placebo|Placebo oral solution, 2 ml/day, once a day, during one year
2562940|NCT02479568|Active Comparator|Control|Control drink (placebo)
2562941|NCT02479568|Experimental|Natural Florida orange juice|100% Florida orange juice (OJ) (natural content of hesperidin)
2562942|NCT02479568|Experimental|Enriched Florida orange juice|100% Florida orange juice (OJ) (enriched hesperidin content)
2562962|NCT02479191||Female (Treatment Group)|Device: Ovation Abdominal Stent Graft Platform
2562979|NCT02479191||Male (Control Group)|Device: Ovation Abdominal Stent Graft Platform
2563021|NCT02479035|Active Comparator|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
2563025|NCT02479035|Active Comparator|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
2563031|NCT02479035|Placebo Comparator|Control meal|0 g red raspberry
2563100|NCT02478502|Experimental|Cabazitaxel (single arm study)|Cabazitaxel 25 mg/m2 each 3. week (no other drugs will be administered)
2563155|NCT02478060|Experimental|Cohort 1|Birch-SPIRE or placebo, 2 weeks apart
2563159|NCT02478060|Experimental|Cohort 2|Birch-SPIRE or placebo, 2 weeks apart
2563165|NCT02478060|Experimental|Cohort 3|Birch-SPIRE or placebo, 2 weeks apart
2563170|NCT02478060|Experimental|Cohort 4|Birch-SPIRE or placebo, 2 weeks apart
2563175|NCT02478060|Experimental|Cohort 5|Birch-SPIRE or placebo, 2 weeks apart
2563201|NCT02477566|Experimental|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal
2563206|NCT02477566|Active Comparator|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
3172069|NCT00595543|Active Comparator|2|
3172070|NCT00595543|Active Comparator|3|
3172071|NCT00595569||Type 1 diabetes|
3172072|NCT00595608|Active Comparator|1|Nasal Sterimar spray
3172073|NCT00595608|Active Comparator|2|Nasal saline spray
3172074|NCT00595647|Active Comparator|1|Percutaneous coronary intervention
3172075|NCT00595647|Placebo Comparator|2|Percutaneous coronary intervention
3172076|NCT00595660|Active Comparator|1|Needle 21 for FNA
3172077|NCT00595660|Active Comparator|2|22 needle for FNA
3172078|NCT00595660|Active Comparator|3|23 needle for FNA
3172079|NCT00595660|Active Comparator|4|24 needle for FNA
3172080|NCT00595686|Experimental|Single Arm|
3172081|NCT00595699|Placebo Comparator|2|Double-blind
3172082|NCT00595699|Experimental|1|escitalopram group
3172083|NCT00595712|Active Comparator|A|Using Iliac crest allograft in high tibial osteotomy
3172084|NCT00595712|Active Comparator|B|Using iliac crest autograft in high tibial osteotomy
3172085|NCT00595725|Experimental|1|
3172086|NCT00595738||Heart Failure Patients|Patients admitted with advanced heart failure for tailoring of heart failure therapy via placement of a pulmonary artery (PA) catheter. In our study, the patients will already have a PA catheter placed for clinical/treatment reasons when we approach them for the study.
3172087|NCT00595777|No Intervention|1. Comparison|The centres allocated to the comparison group will continue to provide usual care only.
3172088|NCT00595777|Experimental|2. Experimental|The EPAT package consists of an educational programme, which deals with the common barriers to effective cancer pain control and the bedside pain tool.
3172089|NCT00595816|Experimental|1|Active treatment: physical training and counselling
3172090|NCT00595829|Experimental|1|
3172091|NCT00595842||Group one|Subjects are drawn from a search of all patients treated with MTA between ages 5-40
3172092|NCT00595855|Active Comparator|TE|trabeculectomy
3172093|NCT00595855|Experimental|DS|deep sclerectomy
3172094|NCT00595894||1|CLEAR enrollees include African American patients with early rheumatoid arthritis, as defined using ACR criteria
2562286|NCT02484352|Other|0.1 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.1 mg/kg of oxycodone in normal saline through intravenous route before intubation.
2562292|NCT02484352|Other|0.15 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.15 mg/kg of oxycodone in normal saline through intravenous route before intubation.
2562294|NCT02484352|Other|0.2 mg/kg of oxycodone|Intervention: patients receive 10 ml of fluid with 0.2 mg/kg of oxycodone in normal saline through intravenous route before intubation.
2562317|NCT02483793|Active Comparator|Oxybutynin group|This group will be prescribed oxybutynin as well as standard narcotic pain medications. Oxybutynin will be prescribed based off of standard dosing. Patients who are unable to swallow pills will be given oxybutynin elixir (0.5mg/kg/day, divided TID). Patients who are able to swallow pills will be given oxybutynin 5mg either BID or TID.
2562319|NCT02483793|Active Comparator|Tamsulosin group|This group will be prescribed tamsulosin and standard narcotic pain medication. Patients will be given tamsulosin 0.4mg at bedtime. This dosage has been used in other studies for children age ≥ 4.
2562425|NCT02483273||Brain dead patients|Brain dead patients certified by cerebral angiography.
2562428|NCT02483273||Healthy volunteers|Any person with no known cerebral pathology.
3206827|NCT00958542|Experimental|Surgical Arm|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
2562588|NCT02482090|Experimental|Patient group|"All patients receive the same treatment. Alle patients are hospitalized during treatment (approximately 3 weeks) and receive treatment only once.~Stem Cells are harvested a minimum of 3 weeks before treatment for potential later use if the patients are having difficulties recovering from the lymphodepleting chemotherapy.~The patients are admitted to hospital day -8 and receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine= on day -7 to day -1.~The TILs are infused on day 0 and Interleukin-2 therapy is administered on day 0 to day 5.~Interleukin-2 is administered in an i.v. continous decrescendo regimen starting approximately 6 hours after TIL infusion with a duration of approximately 5 days.~Stem Cells can be administered after treatment if needed."
2562698|NCT02481271|No Intervention|Usual care|Does not receive a specific study intervention
2562700|NCT02481271|Experimental|preoperative relaxation program|preoperative relaxation program
2562701|NCT02481271|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
2562702|NCT02481271|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
2562747|NCT02480868|Experimental|ARTEBONE|Bone Void Filler
2562766|NCT02480608|Experimental|combination Imatinib + Hydroxyurea|Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy.
2562770|NCT02480608|Active Comparator|monotherapy Imatinib|Imatinib monotherapy
2562833|NCT02480348|Experimental|Polymer-free DES (Drug Eluting Stent)|
2562926|NCT02479997|Active Comparator|Radioisotope (RI)|"Using RI only as SLNB mapping in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected only RI~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- ."
2562929|NCT02479997|Active Comparator|Indocyanine green (ICG) +RI|"Dual sentinel node staining method using mixture of indocyanine green (ICG) and radioisotope (RI) in breast cancer patients who receive neoadjuvant chemotherapy.~Interventions - patient assigend RI groups are injected RI +ICG~prepare fluorescence camera when the surgery begin~surgeon uses the camera to decect fluorescence flow on SLN~fill the Primay Case Report Form during surgery~PCRF including SLN detection time, duration of SLN approch time to 1st sentinel node dection time, incision length , depth, RI +/- , ICG+/-"
2562946|NCT02479282|Other|group A|natural cesarean section
2562958|NCT02479282|Other|group B|traditional cesarean section
2563019|NCT02479152|Active Comparator|LUCAS 2 AD|LUCAS 2 AD will be used for CPR
2563020|NCT02479152|Other|LUCAS2|LUCAS2 will be used for CPR
2563075|NCT02478619|Active Comparator|IMT group|The volunteers will do the respiratory muscle training through a linear inspiratory pressure resistance device (POWERbreathe®) at 50% of the maximal inspiratory pressure.
2563078|NCT02478619|Placebo Comparator|Control group|Patients will do a placebo respiratory muscle training through a load pressure resistance device (POWERbreathe®) with the minimum load available (10cmH20).
2563121|NCT02478294||the surgical intervention group|Thoracoscopic LAA Excision plus AF Ablation. Patients receiving thoracoscopic left atrial appendage excision plus atrial fibrillation alation
2563124|NCT02478294||oral anticoagulant treatment group|Warfarin or Novel Oral Anticoagulants. Patients receiving warfarin treatment (INR 2.0-3.0) or novel oral anticoagulants
2563179|NCT02477995|Experimental|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
2563181|NCT02477995|Active Comparator|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B (Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
2563203|NCT02477644|Experimental|Olaparib|Tablets per os 300 mg
2563208|NCT02477644|Placebo Comparator|Placebo|Tablets per os 300 mg
2563374|NCT02476630||Study subjects|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as blood gases(ScvO2) from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
2563465|NCT02475941|Active Comparator|Non Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Non weight bearing are those who are NOT permitted in the post operative instructions to be Weight Bear after fracture fixation.
2562299|NCT02484118|Experimental|Targeted blood flow rate 320 ml/min|Hemodialysis blood flow will be targeted at 320 ml/min during hemodialysis for two weeks
2562301|NCT02484118|Experimental|Targeted blood flow rate 380 ml/min|Hemodialysis blood flow will be targeted at 380 ml/min during hemodialysis for two weeks
2562377|NCT02483832|Active Comparator|Gain-frame|This group will receive messages about the benefits of colorectal cancer screening.
2562381|NCT02483832|Active Comparator|Loss-frame|This group will receive messages about the disadvantages of not getting colorectal cancer screening.
2562409|NCT02483325|Other|Busulfan with adapted doses|Conditioning regimen for allogeneic transplant (Busulfan, Thymoglobuline and Fludarabine)
2562445|NCT02483039|Experimental|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. The target appointment date is within 30 days of hospital discharge. Routine laboratory investigations will be performed at minimum every three months. Additional in-person visits with a nephrologist at the AKI Follow-up Clinic will be determined at the local sites based upon the participant's clinical status. If in-person visits at 12, 24, and/or 36 weeks are not necessary given the patient's clinical status, they may be replaced with a telephone visit
2562450|NCT02483039|No Intervention|Usual Care|Participants randomized to this arm will have a letter outlining their AKI diagnosis mailed to their family physician. Participants may still be referred to a nephrologist by their inpatient or outpatient healthcare provider, but these participants will not have access to the AKI Follow-up Clinic. Rather, they will proceed through the standard local nephrology referral pathway. In addition, all usual care participants will be contacted via telephone by study staff every three months to assess their clinical condition and ensure study engagement. All usual care participants will be offered a nephrologist assessment and/or bloodwork one year after randomization to determine if ongoing nephrology care is indicated based upon the same criteria applied to AKI Follow-up Clinic participants.
2562476|NCT02482766|Experimental|INRECSURE|Infants in the INRECSURE arm will undergo the following approach: as soon as possible after the recruitment manoeuver (at CDP-Optimal) a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. A temporary reduction of frequency may be necessary to increase the VT up to 2.5 ml/kg for improving the surfactant spreading.
2562480|NCT02482766|Active Comparator|INSURE|Infants in the INSURE arm will undergo the following approach: after intubation, a dose of poractant alfa (Curosurf [Chiesi Farmaceutici, Parma, Italy]) of 200 mg/kg will be administered via a closed administration system in one-two aliquots (1-2 minutes). The tube position will be confirmed by auscultation. During surfactant administration, infants will be manually ventilated to facilitate surfactant distribution.
2562571|NCT02482207|Experimental|Rosuvastatin|Rosuvastatin 10 mg qd for 1 year and life style modification
2562574|NCT02482207|Placebo Comparator|Placebo|Life style modification alone
2562618|NCT02481804|Experimental|Dietary intervention|There is one arm. Patients will first have an observation period, whre hey will get standard treatment during four weeks. Thereafter they will have the dietary intervention during 14 weeks.
2562671|NCT02481466|Experimental|Portfolio diet and structured exercise|Participants will receive advice on a therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and be instructed on a standardized physical activity/exercise component supervised by kinesiologists.
2562673|NCT02481466|Active Comparator|DASH-like diet and structured exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and a be instructed on the Laval exercise program-a standardized physical activity/exercise component supervised by trained kinesiologists (exercise physiologists).
2562674|NCT02481466|Experimental|Portfolio diet and routine exercise|Participants will receive advice that will conform to the current therapeutic diet appropriate for hypercholesterolemia (ie <7% of energy from saturated fat, <200mg/d cholesterol) PLUS the combination of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
2562676|NCT02481466|Active Comparator|DASH-like diet and routine exercise|Participants will receive advice to follow a DASH-like diet of whole grains, and low-fat dairy products with fruits and vegetables and will be provided with a copy of Health Canada Physical Activity Guidelines with advice to increase physical activity.
2562765|NCT02480530|No Intervention|Control|Patients will be given educational material on the importance of adherence to statin medications. The GlowCaps device will be set to only record adherence.
2562769|NCT02480530|Experimental|Individual Feedback|In addition to educational material on adherence to statin medications, the research coordinator will review set-up of personal reminders for the GlowCaps device which will be set to glow and buzz when the medication is missed. In addition, patients will receive information on the weekly adherence feedback report.
2562774|NCT02480530|Experimental|Feedback Friend|The patient will be given educational material on the importance of adhering to statin medications. The research coordinator will review set-up of alarm features of GlowCaps device. Similar to Arm 2, patients will be given information on interpretation of weekly adherence feedback report. If the patient chooses a family/friend, they will be called and provided information on the interpretation of weekly adherence feedback report. If the patient chooses a reciprocal partner, they will be assigned to another patient who has made a similar choice
2562866|NCT02480335|Experimental|Usual care and bosentan|Usual care and also treatment with bosentan.
2562867|NCT02480335|No Intervention|Usual care|Usual care only.
2562939|NCT02479490|Experimental|Prednisone + Everolimus|Prednisone + Everolimus
2562943|NCT02479204|Experimental|Part A ACT-334441 + atenolol|4 subjects will receive 50 mg of atenolol once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
2562944|NCT02479204|Experimental|Part A ACT-334441 + diltiazem|4 subjects will receive 240 mg of diltiazem once daily for 6 days, and a concomitant single administration of ACT-334441 2 mg on Day 6
2562999|NCT02479100|Other|Undergo a CESM|Patients will undergo an experimental Contrast Enhanced Spectral Mammogram (CESM) in addition to standard diagnostic procedures
2562350|NCT02483702|Experimental|Patients Over 4 Months Recieve Non-Irradiated Blood|Patients over 4 months of age will receive non-irradiated blood products. The patient's extracellular potassium levels will be recorded pre-transfusion, at 30 minute intervals during the transfusion, and post-transfusion. The collected data will be compared to test for correlation between extracellular potassium levels, the type of blood transfused, and the amount of calcium that is administered.
2562391|NCT02483442||No CT Pulmonary Angiography|Low Clinical Pretest Probability with D-dimer < 1000 ug/L and Moderate Clinical Pretest Probability with D-dimer < 500ug/L
2562393|NCT02483442||CT Pulmonary Angiography Required|Low Clinical Pretest Probability with D-dimer > or = 1000ug/L and Moderate Clinical Pretest Probability with D-dimer > or = 500 ug/L and High Clinical Pretest Probability
2562419|NCT02483143|Active Comparator|NAC plus normal saline group|1ml/3mgr NAC+NS preCTPA 3 ml/kg for 1 h, 1 ml/kg/h for post CTPA for 6 h
2562421|NCT02483143|Active Comparator|NaHCO3 plus normal saline group|132 mEq NaHCO3+NS preCTPA 3 ml/kg for 1h, post CTPA 1ml/kg/h for 6 h
2562423|NCT02483143|Placebo Comparator|Normal saline alone|preCTPA 3 ml/kg NS for 1h, postCTPA 1ml/kg/h SF for 6 h
3206828|NCT00958542|No Intervention|Non-Surgical Arm|Non-Surgical No intervention - Includes patients who have either refused to have surgery or have not been recommended to have surgery at this point. These patients will continue to be monitored closely, however, will not receive any other intervention.
3206829|NCT00958607|Active Comparator|Self-Directed Program|
2562649|NCT02481388||Weakness Group (WG)|Patients with heart failure and a maximum inspiratory pressure (MIP) <70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
2562652|NCT02481388||Control group (CG)|Patients with heart failure and do not have a maximum inspiratory pressure (MIP) > 70% of predicted MIP to age, considered as inspiratory muscle weakness. Following the recruitment process, these volunteers will be evaluated by spirometry and manovacuometry. Afterwards, volunteers will be also assessed in a maximal exercise ramp test. Before and after the ramp test, the optoelectronic pletysmography will be performed to analyse the chest wall tricompartmental distribution and the shortening velocities of rib cages muscles. Also a high-definition ultrasonography will be performed to measure the right diaphragmatic cupule thickness
2562709|NCT02481180|Experimental|T0001|
2562711|NCT02481180|Active Comparator|Enbrel|
2562800|NCT02480504|Experimental|intermittent energy restriction|dietary intervention, intermittent energy restriction. Participants in the experimental group will follow av 5:2 diet and consume a very low calorie diet providing 400 (females) to 600 (males) calories of energy to days a week and for an average male participant, this will reduce energy intake approximately 22%.
2562806|NCT02480504|Active Comparator|continuous energy restriction|dietary intervention, continuous energy restrictions.Participants in the active comparator group will be asked to reduce daily energy intake by 22-23%
3206830|NCT00958607|Active Comparator|Stroke Support Person|
3206831|NCT00958607|No Intervention|Standard Care|"Participants in this arm receive Standard Care which consists of being given a copy of the Heart& Stroke Foundation's stroke resource titled Let's Talk About Stroke"
2562920|NCT02479672|Active Comparator|VividTrac video laryngoscope|VividTrac® Videolaryngoscope, A device for endotracheal intubation
2562922|NCT02479672|Active Comparator|Direct laryngoscopy|Direct laryngoscopy, A device for endotracheal intubation
2562974|NCT02479334|Placebo Comparator|Fat challenge breakfast|200 ml control drink (non-energy flavored water) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2562988|NCT02479334|Experimental|Fat challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high fat breakfast (% Energy Carbohydrate:Fat:Prot / 20:60:20), acute study / one time administration
2562992|NCT02479334|Placebo Comparator|Carbohydrate challenge breakfast|200 ml control drink (non-energy flavored water) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
2562995|NCT02479334|Experimental|Carbohydrate challenge breakfast+spices|200 ml spices drink (non-energy flavored water + spices extract) and high carbohydrate breakfast (% Energy Carbohydrate:Fat:Prot / 60:20:20), acute study / one time administration
2563076|NCT02478879|Experimental|ZP-PTH Patch|Intradermal microneedle patch coated with 40 mcg of PTH, applied intracutaneously to the abdomen daily for 30 minutes, 14 days of treatment
2563079|NCT02478879|Active Comparator|FORTEO(R) Pen|Marketed FORTEO 20 mcg, administered daily as a subcutaneous injection to the abdomen or thigh for 14 days of treatment.
2563144|NCT02478255|Active Comparator|Patients scheduled to undergo Radiation Therapy (RT)|Patients scheduled to undergo Radiation Therapy (RT) for lung cancer, or other malignancies such as breast cancer or lymphoma that involve significant irradiation of the thoracic cavity.
2563145|NCT02478255|Active Comparator|Healthy volunteers|
2563189|NCT02477813|Experimental|Temozolomide|oral Temozolomide 200 mg/m2/die for 5 consecutive days, every 28 days.Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
3206832|NCT00958620|Active Comparator|Active ESWT|
3206833|NCT00958620|Sham Comparator|Sham ESWT|
3206834|NCT00958633|Active Comparator|8 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s)and will be randomized to one of two treatment arms for up to 52 weeks:~Group 1 patients randomized to the 8 week arm will discontinue antidepressant treatment after 8 weeks, as recommended in current clinical practice guidelines. The antidepressant will be tapered in a double-blind manner beginning at 6 weeks, and will be substituted with placebo by 8 weeks.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
2563474|NCT02476058|Placebo Comparator|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
2562363|NCT02483468|Experimental|tDCS|Active Transcranial Direct Current Stimulation - Stimulation of the left dorsolateral prefrontal cortex with 2mA of electrical current
2562370|NCT02483468|Sham Comparator|tDCS (sham)|Inactive (sham) Transcranial Direct Current Stimulation
2562431|NCT02483208|Experimental|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
2562437|NCT02483208|Other|Advate|Advate infusion to analyze pharmacokinetics.
2562467|NCT02482909|Experimental|Hepatic resection|Hepatic resection is performed as a primary treatment for hepatocellular carcinoma.
2562472|NCT02482909|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed as a primary treatment for hepatocellular carcinoma.
2562528|NCT02482623|Experimental|Intervention|Dyads in this arm will receive care provided by an interprofessional team trained through the DSM-H to provide patient/caregiver-centered dementia care through home healthcare.
2562529|NCT02482623|No Intervention|Control|Dyads in this arm will receive usual care provided in the home healthcare setting.
2562569|NCT02482155|Experimental|ibuprofen|ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
2562613|NCT02481882|Other|Healthy Volunteers|Healthy Volunteers will undergo an Magnetic Resonance Imaging scan.
2562622|NCT02481882|Other|MS Patients|Patients will undergo and Magnetic Resonance Imaging scan including the use of Prohance (Gadoteridol).
2562661|NCT02481427|Experimental|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
2562668|NCT02481427|Experimental|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
2562704|NCT02481115||Critically Ill Children|Children in the Pediatric Critical Care Unit regardless of admitting diagnosis aged at least 6 months of age up to 5 years of age.
2562750|NCT02480907|Active Comparator|Workshop Group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
2562753|NCT02480907|Active Comparator|Internet-based support group|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the Internet-based support group for parents, including material from the manual and the DVD and additional information available online within a structured program. Over the course of three months, parents will get access to the 8 support sessions online with the instruction to work out the program at home. Additionally email support is offered after completing each session.
2562755|NCT02480907|No Intervention|Control group - TAU|Parents of ~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will get treatment as usual and take part in conventional parental intervention groups.
2562797|NCT02480556|Experimental|Group A|manual seperation of the placenta
2562804|NCT02480556|Active Comparator|Group B|Conservative separation of placenta
2562835|NCT02480140|Experimental|Self-regulated constraint-induced movement therapy|Self-regulated constraint-induced movement therapy (SR-CIMT) - participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days) (CIMT) (the same CIMT protocol as in the CIMT group described under 'comparator/control treatment'); participants were taught using the self-regulation (SR) strategy to relearn the tasks; SR strategy involved participants self reflecting on their abilities and deficits in performing the tasks, identifying problems and solutions in achieving the most independence in the tasks, and then actually carrying out the tasks.
2562836|NCT02480140|Active Comparator|Constraint-induced movement therapy|In the constraint-induced movement therapy group (CIMT), participants' non-hemiplegic arm was restrained in a mitt for 4 hours every day, 2 weeks, 5 days a week (therapy days); therapist provided demonstration on the adapted task performance with one arm (the side of participants' hemiplegic arm), and participants to practice the tasks with the unrestrained hemiplegic arm under supervision.
2562837|NCT02480140|Active Comparator|Conventional occupational therapy|It involved therapist to demonstrate the adapted task performance followed by patient's practice under supervision.
2562873|NCT02479971|Active Comparator|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
2562874|NCT02479971|Experimental|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin and clyndamycin solution will be performed.
3172095|NCT00595894||2|VARA enrollees will include male veterans with established RA diagnosed using ACR criteria
2562951|NCT02479451|Experimental|Nasal theophylline|20 μg intranasal theophylline (theophylline methylpropyl paraben in a 0.4-mL saline solution) once daily (in the morning) into each naris for a total of 6 weeks
2563014|NCT02479022|Experimental|Level 1-7 escalating doses|
2563067|NCT02478684|Active Comparator|30 seconds of DCC|30 Seconds of placental blood transfusion
2563071|NCT02478684|Active Comparator|60 seconds DCC|60 Seconds of placental blood transfusion
2563113|NCT02478320|Experimental|Ilorasertib (ABT-348)|"Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.~Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle."
2563156|NCT02478099|Experimental|1 Treatment with MPDL3280A|Treatment with MPDL3280A
3172096|NCT00595933|Experimental|1|Each participant will receive an unidentified product to use for a one week period. This will continue until all 7 dry-mouth products have been evaluated.
3206835|NCT00958633|Active Comparator|52 week arm|"During the double-blind phase, all patients will continue treatment with their anti-manic medication(s) and will be randomized to one of two treatment arms for up to 52 weeks:~Group 2 patients randomized to the 52 week arm will continue treatment with their antidepressant medication for 52 weeks, or until withdrawal from the study.~Escitalopram 10 - 30 mg Wellbutrin XL 150 - 450 mg"
2562545|NCT02482363|Active Comparator|Active UVA radiation|This arm will receive 20 minutes of UVA to the skin while resting quietly.
2562548|NCT02482363|Sham Comparator|Sham control|This arm will receive 20 minutes of quiet rest and heat but with their skin protected from UVA
3206836|NCT00958646|Experimental|Osteopathic Manipulation|Standardized OMT procedure
3206837|NCT00958646|Placebo Comparator|Placebo|Light touch placebo procedure
3206838|NCT00958659||Ancillary-Correlative (gene expression profiling)|Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative PCR-based gene expression profiling.
3206839|NCT00958685|Experimental|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
3206840|NCT00958685|Experimental|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
2562717|NCT02480985|Other|Pituitary function evaluation|Exams performed according to a determined schedule following admission in the intensive care unit in order to determine the risk factors and the outcome associated with pituitary disorders.
3206841|NCT00958698|Experimental|Arm I (nurse-assisted intervention module)|Patients are given password-protected access to their own web-based message board to communicate with a research nurse. The nurse leads patients through WRITE Symptoms? intervention module, with personalized support and advice. The nurse will encourage the patient to try new selected strategies, continue with effective strategies, and work with local health care providers in an ongoing process to improve symptom management.
2562878|NCT02479854|Experimental|A Test|test drug (Asmakast)1 chewable tablet contains 5 mg Montelukast
2562880|NCT02479854|Active Comparator|B Reference|reference drug (Singulair) 1 chewable tablet contains 5 mg Montelukast
2562910|NCT02479659|No Intervention|Control|Facilities in this arm maintained status quo HIV testing and routine childhood immunization services
2562914|NCT02479659|Experimental|Simple Intervention|This included: 1) HIV testing commodity reinforcement and 2) a policy reinforcement meeting
2562918|NCT02479659|Experimental|Comprehensive Intervention|This arm included: 1) HIV testing commodity reinforcement, 2) a policy reinforcement meeting, 3) community sensitization, 4) Opt-out HIV testing for mothers and newborns, and 5) Operational support for service integration
2562966|NCT02479295|Active Comparator|Straight Tenckhoff catheter|Tenckhoff catheter with straight intra-abdominal part
2562981|NCT02479295|Active Comparator|Coiled Tenckhoff catheter|Tenckhoff catheter with coiled intra-abdominal part
2563012|NCT02478957|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 6 weeks
2563015|NCT02478957|Placebo Comparator|Placebo|Placebo, administered via inhalation three times daily for 6 weeks
2563059|NCT02478567|Experimental|Scapular Training|Initiated scapular training exercise for the first 4 weeks followed by addition of rotator cuff exercises the next four weeks
2563063|NCT02478567|Experimental|Rotator Cuff Training|initiated rotator cuff training exercise for the first 4 weeks followed by addition of scapular training exercises the next four weeks.
2563114|NCT02478346|Experimental|All Patients|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 500mg (100mg/ml) will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used).
2563132|NCT02478125|Active Comparator|burixafor hydrobromide|Four daily doses of burixafor hydrobromide alone
2563133|NCT02478125|Active Comparator|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
2563134|NCT02478125|Experimental|Docetaxel|"Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV.~The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2"
2563184|NCT02477943||Injured and Matched Control Subject Pool|Injured subjects consist of athletes who are head injured and meet the inclusion/exclusion criteria. Injured subjects will be tested within 72 hours (3 days) of injury and at specified time points post injury. Matched control subjects will be tested at the same time intervals as the injured subject. BrainScope Battery will be performed at each time point and consists of the following components: brain electrical activity (EEG), neurocognitive performance assessment, balance/sway measurement, and clinical symptoms/assessments. In addition, a subset of injured and matched control subjects will receive advanced MRI/DTI neuroimaging at time of injury and following RTP.
2563185|NCT02477943||Pre-Season and Post-Season Subject Pool|This subject pool will consist of uninjured (not head injured) contact and non-contact athletes and will be tested at two time points - pre-season and post-season. These subjects will perform the same BrainScope Battery as the injured and matched control subjects at each time points.
2563232|NCT02477449|Experimental|low dose group|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS; All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
2563233|NCT02477449|Experimental|mid dose group|12 subjects in 0.5ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
3208854|NCT00978718|Experimental|Arm II: 200 μg selenium (Se) as high-Se Baker's yeast daily|Patients receive 200 μg of oral selenium (Se) as high-Se Baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
2562392|NCT02483637|Experimental|RejuvenAir|RejuvenAir treatment of the right lower lobe and right main stem bronchus. Each MCS will be tailored to the bronchial area undergoing treatment and the amount of liquid nitrogen delivered will vary depending on the airway diameter.
2562422|NCT02483169|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
2562424|NCT02483169|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
2562429|NCT02483169|Experimental|Cilostazol|cilostazol plus placebo of aspirin
2562435|NCT02483169|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
2562493|NCT02482714|Experimental|Rehab Institute|This group will do some physical activity in a specialized institute
2562495|NCT02482714|Active Comparator|Club structure|This group will do some physical activity in a club.
2562507|NCT02482467|Other|Cases|Prenatal diagnosis of ovarian cyst
2562509|NCT02482467|Other|controls|No prenatal diagnosis of cyst
2562540|NCT02482311|Experimental|AZD1775|"Single-arm study. AZD1775 will be administered for 3 consecutive days at the start of week 1 and week 2 of each 21-day cycle.~This study will be conducted in two parts, designated Part A and Part B. Part A is a safety lead-in. Part B will commence after the safety lead-in and will investigate the safety and efficacy of AZD1775 monotherapy in expansion cohorts of specific tumour types."
2562598|NCT02481973|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy, prescribed according to their characteristic symptoms and confirmed my their miasmatic facial features. Although different individualised remedies may be dispensed, each remedy will be homoeopathic and prepared in accordance with the German Homoeopathic Pharmacopoeia. Each prescription will be in a potency of 30CH which will be taken once daily, according to the GBM. Sucrose pillules will used as the vehicle for each remedy.
2562646|NCT02481687||Ulcerative colitis|"Consecutively admitted patients with active ulcerative colitis, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
2562650|NCT02481687||Crohn's disease|"Consecutively admitted patients with active Crohn's disease, confirmed by histopathology.~I-SCAN and pCLE will be applied in all patients."
2562708|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 4μg|4μg group: vaccines serial number is A0001-A0100（18-55 years-old group A0001-A0020，7-17 years-old group A0021-A0040，1-6 years-old group A0041-A0060，7-10 months-old group A0061-A0080，2 months-old group A0081-A0100）
2562712|NCT02481232|Experimental|freeze-dried group ACYW135 MCV 8μg|8μg group: vaccines serial number is B0001-B0100（18-55 years-old group B0001-B0020，7-17 years-old group B0021-B0040，1-6 years-old group B0041-B0060，7-10 months-old group B0061-B0080，2 months-old group B0081-B0100）
2562758|NCT02480803|Active Comparator|continuous levodopa infusion|continuous intrajejunal infusion of levodopa-carbidopa
2562759|NCT02480803|Active Comparator|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
2562801|NCT02480465|Experimental|Lobelitazone 0.5mg|Lobelitazone 0.5mg
2562808|NCT02480465|Active Comparator|Sitagliptin 100mg|Sitagliptin 100mg
2562848|NCT02480127|Experimental|Endometrial injury|In the intervention group, endometrial sampling is obtained twice by Pipelle [one in the follicular phase (during 8-9 or 11- 13 day in the beginning of buserelin cycle) and the last in the luteal phase (during 19-21 or 20-23 day) preceding the embryo transfer cycle preceding the embryo transfer cycle]. Blood samples (5- 10 cc) are taken in the both groups twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
2562850|NCT02480127|No Intervention|Control|In the control group endometrial sampling will be done only in the luteal phase of the cycle preceding the embryo transfer cycle. Blood samples (5- 10 cc) are taken twice (one on the 9-8 or 11- 13 day and 19-21 or 20-23 day preceding the embryo transfer cycle).
2562902|NCT02479893||cold snare polypectomy|CSP: In this group polyps will be removed with the cold snare polypectomy technique, as a single piece. Additionally, a 1-2mm of normal tissue around the small polyp will also be ensnared in the CSP.
2562907|NCT02479893||hot snare polypectomy|HSP: In this group polyps will be removed with the hot snare polypectomy technique as a single piece with a electrosurgical snare and monopolar current with a setting of 30-35 W in the endocut function.
2562908|NCT02479893||APC polyp destruction-polypectomy|APC: In APC group polyps will be cauterized by application of high power argon plasma coagulation on small waves at 50-60W and flow at 2lt/min,as result the polyp destruction.
2562959|NCT02479386||Cohort Geographic Atrophy|Cohort of participants with GA secondary to AMD will be evaluated for changes in GA over time.
2563061|NCT02478749|Experimental|Infant|patients aged younger than 1year
2563062|NCT02478749|Experimental|Child|patients aged 1year to 5years
2563068|NCT02478749|Experimental|Adult|adult patients
3206842|NCT00958698|Experimental|Arm II (self-directed intervention module)|Patients are given password-protected access to an interactive web-based computer program that will lead them through a modified WRITE Symptoms? intervention module (comprising the same elements as in arm I) without guidance and individualized recommendations from a nurse. Patients work through 3 selected symptoms using the WRITE Symptoms? intervention module over approximately 4 weeks. The program will generate an encouragement for the patient to try new selected strategies, continue with effective strategies, and continue the new approach to symptom management with local health care providers in an ongoing process to improve symptom management.
2563318|NCT02476825|Active Comparator|Inhaled fluticasone|Inhaled fluticasone propionate (via dry powder inhaler [Accuhaler]), 500 micrograms b.i.d. for 4 weeks
2563326|NCT02476825|No Intervention|Observational|Observation
2563404|NCT02476305|Experimental|cryoablation|patients undergo cryoablation procedure for desmoid tumor
2563470|NCT02476058|Experimental|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
2563472|NCT02476058|Experimental|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
2563485|NCT02475759|Active Comparator|two weeks prehabilitation group|optimal caloric intake for two weeks in malnourished congenital heart disease children
2562541|NCT02482350|Experimental|Reading Training|A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
2562584|NCT02482064|No Intervention|Traditional Obturators|Patients will use traditional obturators which are going to be made from ordinary heat-activated acrylic resin.
2562587|NCT02482064|Experimental|Flexible Obturators|Patients will use the new obturators made from flexible resin.
2562659|NCT02481570|Experimental|Anesthesia optimization|Information from the pharmacokinetic simulation during an anesthetic regimen of a propofol based Total Intravenous Anesthetic (TIVA)
3206843|NCT00958698|Active Comparator|Arm III (standard care from local provider)|Patients are given password-protected access to online questionnaires. Patients are prompted monthly to complete online questionnaires. Patients receive standard symptom management from their local health care providers.
3208855|NCT00978718|Experimental|Arm III: 400 μg Se as high-Se baker's yeast daily|Patients receive 400 μg of oral Se as high-Se baker's yeast daily. Treatment continues for up to 57 months in the absence of unacceptable toxicity or diagnosis of prostate cancer.
2562817|NCT02480426|Experimental|CT-image guidance|Previously acquired portal venous phase of CT datasets and intra-operative CT datasets were registered on a dedicated workstation. The selected volume of interest of the CT-image showing portal vein vasculature was overlaid onto the fluoroscopic display as real-time 3D CT-image guidance during the procedure.
2562820|NCT02480426|Active Comparator|CO2 portography|two two-dimensional (2D) CO2 portograms
2562856|NCT02480101|Active Comparator|H7N9 LAIV|H7N9 live influenza vaccine
2562858|NCT02480101|Placebo Comparator|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
2562899|NCT02479776|Active Comparator|Stem cell injection|Stem cells are injected and patients crossed over to placebo at 6 months
2562904|NCT02479776|Placebo Comparator|saline injection|saline is injected and patients crossed over to active arm at 6 months
2562957|NCT02479516|Experimental|CHAPP intervention communities|"CHAPP intervention: The proposed CHAPP intervention will include:~Diabetes risk assessment (modified FINRISK and assessment of lifestyle risk behaviours) sessions be at least every 2 weeks in accessible community locations, manned by trained volunteers of LLO~Volunteers educate CHAPP participants regarding their diabetes risk factors and ways to practice healthy lifestyle (including referral to local resources/activities) using diabetes education materials adapted for local context~Use of an accepted process have participant data transmitted to a central web database system through a combination of cell-phone and computer-based technology~Have participant assessment result forwarded to the Municipal Health Officer (doctor) for follow-up and screening"
2562971|NCT02479516|No Intervention|Delayed Intervention communities|
2563047|NCT02479113||Lean with normal glucose tolerance|"Pregnant women who are lean with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
2563048|NCT02479113||Obese with Normal glucose tolerance|"Pregnant women who are obese with normal glucose tolerance~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
2563049|NCT02479113||Gestational diabetes mellitus|"Pregnant women who have Gestational Diabetes Mellitus~- Bloods will be taken at 12 - 32 weeks, at 36 weeks/ delivery"
2563112|NCT02478424|Experimental|Cannabidiol arm|Patients undergoing an allogeneic hematopoietic cell transplantation will be given standard GVHD prophylaxis comprising cyclosporine and a short course of methotrexate plus CBD 150 mg BID starting 7 days before transplantation until day 100.
2563135|NCT02478047|Active Comparator|only antiemetic|The participants in the control group received standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology cClinical pPractice gGuideline. The 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are administered before the chemotherapy treatment.
2563136|NCT02478047|Experimental|Matching points ST36+CV12|
2563137|NCT02478047|Experimental|Matching points PC6+CV12|
2563138|NCT02478047|Experimental|Matching points CV3+CV12|
2563207|NCT02477696|Experimental|ACP-196|acalabrutinib 100 mg BID (Arm A; N=250)
2563210|NCT02477696|Active Comparator|ibrutinib|ibrutinib 420 mg QD (Arm B; N=250)
2563298|NCT02476799|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
2563307|NCT02476799|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl and ketorolac for 48 hours postoperatively.
2563345|NCT02476591||Charge transparency|Providers with access to charge transparency as displayed via a dashboard with patient specific charge data for a given ICU stay
2563351|NCT02476591||Without charge transparency|Providers without access to patient specific charge data
2563409|NCT02476409|Experimental|Tolvaptan|Augmentation of current dose of loop diuretic + 30 mg of oral tolvaptan daily
2563412|NCT02476409|Placebo Comparator|Placebo|Augmentation of current dose of loop diuretic
2563487|NCT02475759|Active Comparator|one week prehabilitation group|optimal caloric intake for one week in malnourished congenital heart disease children
3208856|NCT00978783|Active Comparator|speaking valve|
3208857|NCT00978783|Active Comparator|Positive end expiratory pressure|
2562547|NCT02482415|Experimental|Intervention|Family caregivers were invited to meet in a group for 2 hours once a week for 3 weeks. Each meeting had a specific topic presented by a health care professional of the palliative care team (physician, nurse and social worker). The meetings addressed multi-dimensional issues in dialogue with the participants. A nurse acted as group leader and participated in all meetings. The intervention included both supportive and educational components. Each meeting began with a presentation based on a specific topic (palliative care, practical care and emotional reactions). This was followed by reflection and conversation, and finally a relaxation exercise
2562550|NCT02482415|No Intervention|Control|
2562593|NCT02482038|Experimental|geko device|
2562612|NCT02481765|Experimental|Direct current Stimulation|High definition transcranial direct current stimulation (HD-tDCS)
2562647|NCT02481492|Experimental|No flip technique|One group of boys will undergo a circumcision with no flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will detach spontaneously without intervention, and the participants are asked to have a visit soon after ring detached. The last scheduled follow-up visit is at 90 days.
2562651|NCT02481492|Experimental|Flip technique|One group of boys will undergo a circumcision with flip technique of Shang Ring Circumcision and receive regular follow-up to evaluate pain, operation associated adverse events, wound healing time. The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 90 days.
3172097|NCT00595972|Experimental|A|patients will be treated by ECF regimen (epirubicin, cisplatin plus 5-FU) combined with endostar
2562745|NCT02480881|Experimental|Single Sequence A, B, C, and D|Treatment A/Cycle 1: OC containing EE and progestin taken by mouth. Treatment B/Cycle 2: OC containing EE and progestin taken by mouth. Treatment C/Cycle 3: Loestrin 1.5/30 taken by mouth. Treatment D/Cycle 4: Loestrin 1.5/30 (alone) and Loestrin 1.5/30 with BMS-663068 taken by mouth.
2563011|NCT02478814|Experimental|Active, Young Adult Males|Subjects will receive different levels of amino acid intakes varying from 0.2 to 2.6 g/kg/day.
2563072|NCT02478736||delirium group|the patients with delirum after on-pump cardiac surgery
2563073|NCT02478736||no delirium group|the patients without delirum after on-pump cardiac surgery
2563098|NCT02478307|Active Comparator|Cognitive Therapy|Eight, 2-hours sessions of group delivered cognitive therapy.
2563103|NCT02478307|Active Comparator|Mindfulness Meditation|Eight, 2-hours sessions of group delivered mindfulness meditation.
2563109|NCT02478307|Active Comparator|Mindfulness-Based Cognitive Therapy|Eight, 2-hours sessions of group delivered mindfulness-based cognitive therapy
2563197|NCT02477774|Experimental|Arista|Arista to ALT donor site
2563200|NCT02477774|No Intervention|Control|No Arista to ALT donor site
2563231|NCT02477475||NEXIUM|Oral dose 20mg/day
2563350|NCT02476487|Experimental|FDG PET CT|FDG PET CT
2563430|NCT02476383|Active Comparator|augmented spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner interacting in a warm and friendly way who is free to respond to participant conversation. Participants in this group will receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
2563433|NCT02476383|Active Comparator|neutral spinal manipulative therapy|Participants in this group will receive spinal manipulative therapy provided by a practitioner engaging in minimal interaction. Participants in this group will not receive information about the effectiveness of spinal manipulative therapy for some individuals experiencing low back pain.
2563461|NCT02475941|Experimental|Early Weight Bearing|Surgeon based prospective cohort supported in the literature to answer research questions in which surgeons have a preferred treatment type. Early weight bearing are those who are permitted in the post operative instructions to be Weight Bear as tolerated after fracture fixation.
3172098|NCT00595985|Experimental|A|administer sorafenib 400mg bid until disease progression or intolerable toxicity or patients withdrawal of consent
3172099|NCT00595998||1|newly onset CNV secondary to AMD
3172100|NCT00595998||2|Intermediate AMD
3172101|NCT00596024|Experimental|1|Daily Lutein/zeaxanthin supplementation with a meal
3172102|NCT00596024|Placebo Comparator|2|
3172103|NCT00596037|Experimental|LB03002 throughout|administered LB03002 for preceding 26 weeks
3172104|NCT00596037|Experimental|Switched to LB03002|administered placebo for preceding 26 weeks
3172105|NCT00596050|Active Comparator|ketamine and midazolam|ketamine and midazolam
3172106|NCT00596050|Active Comparator|etomidate and fentanyl and lidocaine|etomidate and fentanyl and lidocaine
3172107|NCT00596063|Experimental|Wosulin R|Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
3172108|NCT00596063|Active Comparator|Novolin R|Regular insulin for injection (recombinant human insulin)
3172109|NCT00596076|Experimental|1|Workers with low back pain
3172110|NCT00596089||1|Men and women 60 years and older
3172111|NCT00596089||2|Men and women 20-30 years of age
3172112|NCT00596128|No Intervention|1|Blood sugar monitoring and intervention as clinical routine, no SOP defined and implemented
3172113|NCT00596128|Experimental|2|Blood sugar monitoring after implementation of SOP
3172114|NCT00596141|Experimental|1|Conventional postoperative care and instructions on dental hygiene will be provided along with the TOWE treatment which consists of the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site 3 times daily for a period of 7 days. At three (3) days and seven (7) days postoperatively, photographs will be taken of all vertical releasing incisions (before suture removal).
3172115|NCT00596141|No Intervention|2|Conventional postoperative care and instructions on dental hygiene.
3172116|NCT00596154|Experimental|1|Rituximab, methotrexate (MTX), procarbazine and vincristine (R-MPV). The peripheral blood stem cell (PBSC) harvest procedure will be performed at the discretion of the hematology attending (usually after the 1st or 2nd cycle of R-MPV)and high dose chemotherapy Busulfan, Thiotepa, and Cyclophosphamide. Patients will be off study at the time of death. All patients will be followed for survival every 6 months throughout their lifetime. Survival status may be obtained by phone call, clinical visit or medical records (e.g. physician notes/laboratory results of clinic or hospital visit.
2562663|NCT02481583|Experimental|part 2|30 subjects were randomly assigned to 1 of 3 treatment groups (25, 50, or 75 mg) via i.m. administration, the 50-mg group subjects also received levosulpiride by i.v. route and repeated administration by i.m. route (twice a day for 3 days).
2562707|NCT02481193|Experimental|Cisatracurium 0.005 mg/kg|The group received pretreatment of cisatracurium 0.005 mg/kg.
2562710|NCT02481193|Experimental|Cisatracurium 0.01 mg/kg|The group received pretreatment of cisatracurium 0.01 mg/kg
2562713|NCT02481193|Experimental|Cisatracurium 0.02 mg/kg|The group received pretreatment of cisatracurium 0.02 mg/kg
2562756|NCT02480816|Experimental|Bicarbonated mineral water (BW)|Bicarbonated mineral water
2562757|NCT02480816|Active Comparator|Control mineral water (CW)|Mineral water low in mineral content (control)
2562788|NCT02480569|Experimental|Side-Hole Catheter|2 FFR measurements from an engaged side-hole guide catheter and a disengaged side-hole guide catheter
2562792|NCT02480569|Experimental|Non-Side-Hole Catheter|2 FFR measurements from an engaged non-side-hole guide catheter and a disengaged non-side-hole guide catheter
2562826|NCT02480283||Control|Subjects aged 18 to 55 who have never used cannabis by self report (validated via urine drug screen), who have never used tobacco/cigarettes and have the capacity to give informed consent.
2562827|NCT02480283||Cannabis Smokers|The exposed cohort will have daily or near daily cannabis smoking histories equivalent to a minimum of 20 joint years (number of joints smoked per day multiplied by years of cannabis smoking), will not have a significant tobacco/cigarette smoking history and will be able to provide informed consent.
2562919|NCT02480023|Experimental|healthcare|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
2562956|NCT02479399||Suglat group|Tablets
2563111|NCT02478541|Active Comparator|Sugar Study_low fructose|Consumption of a single test meal that contains fat and a sugary drink made with a low amount of fructose and high amount of glucose
2563116|NCT02478541|Active Comparator|Sugar Study_high fructose|Consumption of a single test meal that contains fat and a sugary drink made with a high amount of fructose and low amount of glucose
2563154|NCT02478112|Experimental|Biodegradable Balloon Implant|Biodegradable balloon implanted before radiotherapy
2563226|NCT02477722|Experimental|EFP-NF|Subjects are asked to change their brain activity in response to feedback they receive from the brain itself, mediated via various visual or auditory stimuli.
2563229|NCT02477722|Sham Comparator|Sham-NF|Placebo
2563253|NCT02477267|Experimental|Test-Reference Sequence|SL spray, followed by SL film
2563255|NCT02477267|Experimental|Reference-Test Sequence|SL film followed by SL spray
2563308|NCT02477033|Active Comparator|Butyricicoccus pullicaecorum|Lyophilized Butyricicoccus pullicaecorum 25-3T bacteria, encapsulated with a pH-resistent coating.
2563316|NCT02477033|Placebo Comparator|Placebo (maltodextrin)|Lyophilized maltodextrin, encapsulated with a pH-resistent coating.
2563343|NCT02476474|Active Comparator|3 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 3 cm from pylorus (antrum).
2563348|NCT02476474|Active Comparator|6 cm start of resection|The line of resection for the Laparoscopic Sleeve gastrectomy will start at 6 cm from pylorus (antrum).
2563405|NCT02476344|Experimental|research arm|40 subjects will undergo the experiment protocol, total 3 days, each consisting different training exercises.
3208858|NCT00978796|Active Comparator|Sitagliptin|Patients will receive sitagliptin for 4 weeks and then cross over to sugar pill
2563686|NCT02474433|Active Comparator|PO Misoprostol|Patients assigned to PO Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
2563687|NCT02474433|Active Comparator|PV Misoprostol|Patients assigned to PV Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
2563688|NCT02474433|Active Comparator|Buccal Misoprostol|Patients assigned to buccal Misoprostol (Cytotec) 400 mg once, 2-4 hours prior to hysteroscopy
2563732|NCT02474134|Other|PF530/Betaferon|Single subcutaneous injection of two interferon beta-1b products (PF530 and Betaferon) 0.25 mg
2563735|NCT02474134|Other|Betaferon/PF530|Single subcutaneous injection of two interferon beta-1b products (Betaferon and PF530) 0.25 mg
2563765|NCT02473861|Experimental|Immediate exercise arm|The length of the intervention for the immediate exercise group will be determined by treatment protocol and could range from 8 to 13 weeks. The intervention can begin up to one week before the first treatment and will continue until 2 weeks after the final taxane-containing treatment. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
2563767|NCT02473861|Experimental|delayed exercise arm|The delayed exercise group will begin an exercise intervention two weeks after completion of their last taxane-containing chemotherapy treatment that will last the length of their taxane chemotherapy plus two weeks. If participants in the delayed exercise group have a surgery planned during the intervention time that will require >1 week off from exercise, the exercise intervention will be delayed until after the surgery. The intervention will consist of thrice weekly supervised aerobic and resistance exercise training.
2563791|NCT02473575|Experimental|Caffeine gum|caffeine (300 mg) in gum form x 1 ingestion
2563792|NCT02473575|Placebo Comparator|Placebo gum|placebo gum consumed x 1 ingestion
2563796|NCT02473575|No Intervention|Non-intervention group|A third group of runners will be used to adjust for changes in environmental conditions. They will complete 2 runs without consuming either placebo or experimental treatment
2563818|NCT02473328|Experimental|non comparative open study|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4), switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks."
2563875|NCT02473146|Experimental|Mylotarg Arm|"After randomization patients in the experimental arm are assigned to receive chemotherapy with:~Gemtuzumab Ozogamicin 3 mg/m2 (maximum dose: 5 mg) per IV, 60mn on Day 1 and 4 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7"
2563876|NCT02473146|No Intervention|Control Arm|After randomization patients in the control arm are assigned to receive chemotherapy with Idarubicin 12mg/m2 per IV, 30mn on Day 1,2,3 Cytarabine 200 mg/m2 per CIV over 24h on Day 1 to 7
3208859|NCT00978796|Placebo Comparator|Sugar pill|Subjects will receive sugar pill for 4 weeks and then cross over to active sitagliptin
2562955|NCT02479555|Active Comparator|Treatment Group: Dexamethasone Delivery|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy.~Treatment Group: Standard endovascular revascularization therapy consisting of angioplasty followed by Dexamethasondihydrogenphosphat-dinatrium (Ph.Eur.) 4 mg/mL Injektionslösung and with or without stent placement. The drug is diluted to 3.2 mg/mL and administered to the adventitia per Bullfrog Instructions for Use in a dose of 0.8 mg dexamethasone (0.25 mL) per cm of desired vessel treatment length, up to 30 cm."
2562970|NCT02479555|No Intervention|Control Group|"Up to 60 angioplasty procedures at up to 30 sites in Europe and in the United States.~Patients will be randomized 1:1 to receive either the active treatment or control therapy. Control Group: Standard endovascular revascularization therapy consisting of angioplasty with or without stent placement. No specific distribution of gender regarding enrollment or randomization is intended. There will also be a separate randomization of patients with Rutherford 6 score to a maximum of 20 enrolled patients."
2563018|NCT02478970|Experimental|Corneal endotheliopathy|Patients with primary corneal endotheliopathies, such as posterior polymorphous dystrophy, congenital hereditary endothelial dystrophy, Fuchs' dystrophy, iridocorneal endothelial syndrome will be evaluated with the NIDEK CEM-350 and Konan SP4000
2563023|NCT02478970|Placebo Comparator|Normal|Patients without corneal endotheliopathies will be evaluated with the NIDEK CEM-350 and Konan SP4000
2563066|NCT02478593|Experimental|Experimental group|Group to receive educational booklet regarding risk/benefits of Benzodiazepine.
2563070|NCT02478593|No Intervention|Control group|Group to receive educational booklet regarding risk/benefits of exercise.
3206844|NCT00958737|Experimental|Arm I|"Patients receive modified FOLFOX 6 comprising oxaliplatin IV 85 mg/m² over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46 hours on day 1. Treatment repeats every 14 days for 6 courses (3 months).~Patients receive XELOX comprising oxaliplatin IV 130 mg/m² over 2 hours (day 1 every 3 weeks) in combination with capecitabine, which will be administered orally at a dose of 1000 mg/m2 twice-daily (equivalent to a total daily dose of 2000 mg/m2), with first dose the evening of day 1 and last dose the morning of day 15, given as intermittent treatment (3-week cycles consisting of 2 weeks of treatment followed by 1 week without treatment)"
3206845|NCT00958737|Experimental|Arm II|Patients receive modified FOLFOX 6 or XELOX as in arm I. Treatment repeats every 14 days for 12 courses (6 months)or regarding XELOX every 21 days for 8 courses (6 month).
2563166|NCT02477904|Experimental|ASD/KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will receive the ketogenic diet (KD) intervention.
2563173|NCT02477904|Active Comparator|ASD/non-KD|Children (2-21 years of age) diagnosed with autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
2563177|NCT02477904|Active Comparator|non-ASD/non-KD|Typically developing children (2-21 years of age) diagnosed as not having autism spectrum disorder (ASD) will not receive the ketogenic diet (KD) intervention.
3206846|NCT00958750|Active Comparator|5% MTF|5% minoxidil topical foam used once daily
3206847|NCT00958750|Active Comparator|2% MTS|2% minoxidil topical solution twice daily use
2563266|NCT02477202|Experimental|Mirena® IUD|This is a non-randomized study of the effect of Mirena® IUD use of at least 10 days before an RRSO or RRS on cell proliferation within the FTF and when available within ovarian CICs in women aged 35 through 50. The study will compare the results from 14 women using Mirena® with the results from 28 normally cycling women identified under MSK IRB Protocol #14-165 described above; all patients will be aged 35-50 years, and will have undergone the RRSO at MSK. To date we have identified approximately 100 suitable controls and are continuing to identify further suitable controls among women who have recently undergone RRSOs at MSK. The balancing/matching factors will be BRCA status (BRCA1/BRCA2/BRCA-ve), age (35-39/40-44/45-50), parity (nulliparous/parous), and BMI (<30/30+ kg/m^2). As each Mirena® patient completes the study and is deemed evaluable, she will be matched on each of these factors with 2 controls.
2563304|NCT02476929|Active Comparator|Nasal nitrous oxide|Mesurement of Nasal nitrous oxide in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group
2563314|NCT02476929|Active Comparator|Electronic nose|Measurement with the Electronic nose in all groups: allergic rhinitis, non-allergic rhinitis, nasosinusal polyps and healthy group.
2563355|NCT02476695||S0/1|S0 = no fibrosis and S1 = portal fibrosis without septa
2563359|NCT02476695||S2|S2 = portal fibrosis with few septa
2563362|NCT02476695||S3|S3 = numerous septa without cirrhosis
2563369|NCT02476695||S4|S4 = liver cirrhosis (compensatory stage)
2563507|NCT02475512|Experimental|Wash wipes|Washing with water and soap (standard care) will be replaced with two wash wipes during 30 days: (1) daily total body wash (using 3M Cavilon Bathing and Cleansing wipes) and (2) Continence Care (using 3M Cavilon Continence Care Wipes). No other preventive barrier or hydration products will be allowed in the genital-anal region.
3206848|NCT00958763|Experimental|Motivational Interviewing, Single - MIS|
3206849|NCT00958763|Experimental|Motivational Interviewing, Group - MIG|
3206850|NCT00958763|Other|Usual Care Group - UCG|
3206851|NCT00958802|Placebo Comparator|Arm A|Chondrocyte culture with FBS medium
3206852|NCT00958802|Experimental|Arm B|Chondrocyte culture with PRP
3206853|NCT00958815||HIV-seronegative with no CVD risk factors|Healthy, 35-60 yr old HIV-seronegative men and women with no CVD risk factors (normal fasting glucose tolerance, normal fasting lipid/lipoprotein levels, normotensive, waist circumference <102cm (men) and <88cm (women).
2562839|NCT02480088|Experimental|ramosetron|patients receiving ramosetron for prophylaxis of postoperative nausea and vomiting
2562841|NCT02480088|Active Comparator|palonosetron|patients receiving palonosetron for prophylaxis of postoperative nausea and vomiting
2562875|NCT02479945|Other|Selective internal iliac vein sampling|
2562892|NCT02479685|Experimental|SORD-BILL|PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
2562893|NCT02479685|Active Comparator|STANDARD|Conventional monopolar hook and conventional mechanic morcellator for subtotal hysterectomy and uterine morcellation, respectivelly, during sacral colpopexy for Pelvic Organ Prolapse.
2562953|NCT02479594|Experimental|competence-feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
2562968|NCT02479594|Placebo Comparator|control|Therapists assigned to this group will receive no competence-feedback.
2563028|NCT02478996|Experimental|Internet-based exercise program|The intervention group is supervised by a sports scientist eight to twelve weeks before and after surgery. Patients receive an individually designed intensive exercise program based on the functional and Fitness measurements at first diagnosis.
2563035|NCT02478996|No Intervention|Basis therapy|Participants of the Treatment as usual (TAU) group receive written information material enlightening the importance of regular physical activities and general releases on preparation for esophagectomy.
2563065|NCT02478554|No Intervention|Population-based|Participants will be randomly assigned to population-based fetal growth curves
2563069|NCT02478554|Active Comparator|Customized-based|Participants will be randomly assigned to customized-based fetal growth curves (intervention)
3172117|NCT00596180||1|HBOT
3172118|NCT00596193||Group I|patients with normal or irreversible pulpitis teeth with capsaicin administered at increasing volumes.
2563459|NCT02475889||RFA group|patients who received hepatic RFA followed by primary tumor resection were assigned to the RFA group
2563464|NCT02475889||Non-RFA group|patients who received initial primary tumor resection without RFA
2563515|NCT02475707|Experimental|Group A|Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.
2563518|NCT02475707|Experimental|Group B|Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
2563570|NCT02475226||Patients with body and head trauma|type of the brain injury in patients with brain damage associated both general body and head trauma
2563572|NCT02475226||Patients with pure head trauma|type of the brain injury in patients with brain damage associated pure head trauma
2563578|NCT02475226||Patients with spontaneous hemorrhage|type of the brain injury in Patients with brain damage associated spontaneous hemorrhage
2563630|NCT02474680||Care Coordination Group|Patients participating in the Avera Care Coordination Program for Intervention 'Pharmacogenetic testing'
2563711|NCT02474446|Experimental|1|"Anthropometry measurement, Skin colour grading using Fitzpatrick scale, Dietary intake of calcium and vitamin D using food frequency questionnaire (FFQ), Baseline fasting blood samples for vitamin D, VDBP, VDBP genotype, Calcium, Phosphorus, Albumin, Parathyroid Hormone(PTH), Alkaline Phosphatase, Bone turnover markers(P1NP, CTX).~Fasting urine for Calcium Creatinine ratio. Saliva for bio-available Free Vitamin D measurement.~Vitamin D administration under direct supervision. Spot Urine sample for calcium : creatinine ratio after a week. Repeat all measurements done at baseline except VDBP genotype 4 weeks from baseline."
2563907|NCT02472912|Experimental|Treatment A|Single Injection of 40mg / 0.8 mL BMO-2
2563909|NCT02472912|Active Comparator|Treatment B|Single Injection of 40mg / 0.8 mL EU-Humira
2563911|NCT02472912|Active Comparator|Treatment C|Single Injection of 40mg / 0.8 mL US-Humira
2564105|NCT02471599|Experimental|tonsillectomy group|The case group will receive tonsillectomy.
3172119|NCT00596193||Group II|Patients with normal teeth only with capsaicin added at a specific volume only
3172120|NCT00596206|Experimental|1|100 mg of leflunomide
3172121|NCT00596206|Active Comparator|2|20 mg of leflunomide
3172122|NCT00596219|Experimental|1|
3172123|NCT00596232||Asthma|People who have been diagnosed with Asthma
3172124|NCT00596232||Cystic Fibrosis|People who have been diagnosed with Cystic Fibrosis
3172125|NCT00596232||Healthy|People who are non-asthmatic, non smokers with less than 10 pack years and who do not have cystic fibrosis
3172126|NCT00596245|Experimental|1|MT 400, naproxen sodium 550mg
3172127|NCT00596258|Experimental|A-007|Single arm open label
3172128|NCT00596284|Experimental|CBT-AD|Participants will receive Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)
3172129|NCT00596284|Active Comparator|EUC|EUC will consist of regular ongoing care from healthcare providers and phone assessments at 1-month and 2-month. Following the 6 month assessment, participants in EUC will be offered a half-day Cognitive Behavior Workshop.
3172130|NCT00596297|Experimental|A|Preoperative Intravitreal bevacizumab and pars plana vitrectomy
3172131|NCT00596297|Active Comparator|B|Pars plana vitrectomy only
3172132|NCT00596310|Experimental|1|Screening CT
3172133|NCT00596336|Active Comparator|Group A CLL patients|Vaccination with current trispecific influenza vaccine Day 1
3172134|NCT00596336|Experimental|Group B CLL patients|Vaccination with current trispecific influenza vaccine Day 1, together with the application of Imiquimod cream to the vaccination site on day 2 to 6.
3172135|NCT00596336|Active Comparator|Group C volunteers|Vaccination with current trispecific influenza vaccine Day 1
3172136|NCT00596349||A|epithelial ovarian cancer survivors (women disease-free at 5 to 10 years from diagnosis of ovarian cancer)
3172137|NCT00596349||B|women in second- or greater remission (women who have had one or more relapses from ovarian cancer but are considered to be currently clinically disease-free 5 to 10 years from original diagnosis of ovarian cancer).
3172138|NCT00596349||C|women surviving with epithelial ovarian cancer (women alive with disease 5 to 10 years from original diagnosis of ovarian cancer)
2562751|NCT02480842|Experimental|Oncoplastic group B|"After randomization (15 days after surgery):~- Patients will keep shoulder exercises limited to 90° up to 30 days after surgery. At that moment (one month after surgery), then patients will also be allowed to move the shoulder with no restriction"
2562768|NCT02480543|Active Comparator|PO Misoprostol|Cervical preparation with per-os (PO) Misoprostol 400 mcg 2-4 hours prior to curettage
2562772|NCT02480543|Active Comparator|PV Misoprostol|Cervical preparation with per-vagina (PV) Misoprostol 400 mcg 2-4 hours prior to curettage
2562778|NCT02480543|Active Comparator|Buccal Misoprostol|Cervical preparation with buccal Misoprostol 400 mcg 2-4 hours prior to curettage
2562825|NCT02480322||Sleeve group|Patients undergoing gastric sleeve resection.
2562828|NCT02480322||Proximal RYGB group|Patients undergoing proximal gastric bypass surgery.
2562829|NCT02480322||Distal RYGB group|Patients undergoing distal gastric bypass surgery.
2562831|NCT02480322||BMI-matched control group|
2562834|NCT02480322||Normal-weight control group|
2562857|NCT02480062|Experimental|mWELLCARE software arm|The doctor and nurse care coordinators (NCCs) in the mWELLCARE intervention arm will be trained on the use of mWELLCARE software loaded on a tablet computer. Patients diagnosed with hypertension and/or diabetes will be registered by the nurse using mWellcare application. The nurse will record patient parameters, medical history, medication etc and generate a management plan (including drug recommendation, lifestyle advise) using the mWellcare application based on standard treatment guidelines. The doctor will review the recommendation and agree or disagree giving reasons. Patient will be followed up using SMS.
2562860|NCT02480062|Active Comparator|Usual care arm|"In the control arm or the usual care arm CHCs, the doctor and Nurse will get refresher training in the detection, management and follow up of hypertension and diabetes patients based on standard guidelines. They will be provided with charts for quick reference to standard treatment guidelines. Patients diagnosed with hypertension and/or diabetes will be managed by the doctor at the CHC. The nurse will assist in recording blood pressure, height, weight etc, providing lifestyle advise and follow up advice to patients."
2562921|NCT02479633|Other|gingival recession type 1|recession defects without CAL intervention:Coronally advanced flap with connective tissue graft
2562924|NCT02479633|Other|gingival recession type 2|gingival recession with an amount of CAL equal or smaller to the buccal CAL. Intervention: Coronally advanced flap with connective tissue graft
2562965|NCT02479373|Experimental|Resistance Exercise (RE)|Those assigned to RE will complete baseline and post-testing assessments and participate in 12 weeks of individually-supervised resistance exercise, which will take place in the exercise facility on the Johns Hopkins Bayview Medical Center Campus. Exercises will be performed on Ren-Ex Machines. This equipment is suitable for the proposed study because it provides ultra-low friction movement which creates a personalized resistance profile, which minimizes force on joints and thereby reduces the risk of joint trauma and injury.
2562980|NCT02479373|Other|Control Group (CG)|Those assigned to the CG will complete baseline and post-testing assessments and will also be given JIA educational materials, including physical activity and exercise recommendations from the American Academy of Pediatrics (AAP) Council on Sports Medicine and Fitness (COSMF).
2563089|NCT02478697|Experimental|Tobacco Treatment|The tobacco treatment includes: (a) the ProChange ExpertSystem, a Transtheoretical-model (TTM) tailored, computer-assisted web-delivered program focused on increasing intrinsic motivation, (b) a stage-tailored treatment manual with goal setting for quitting tobacco, and (c) education on proper use of nicotine replacement therapy (NRT, patch plus gum or lozenge) with guidance on obtaining low-cost or free NRT through MediCal, private insurance plans, and community programs.
2563093|NCT02478697|No Intervention|Usual Care|"Usual care includes: completing the study assessments at baseline, 3- and 6-months and receiving referrals to tobacco treatment in the community, including the state quitline, in line with the public health Ask, Advise, Refer model of tobacco cessation intervention."
2563140|NCT02478138|Other|Surgical - therapeutic|patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system
2563286|NCT02477176||Small annular defect group|Patients with lumbar defect less than 6mm wide after lumbar discectomy
2563287|NCT02477176||Large annular defect group|Patients with lumbar defect greater than 6mm wide after lumbar discectomy
2563289|NCT02476877||Prescribed-drug treatment group|Eight hundred (800) subjects of which 200 subjects in each of the four mental illnesses will continue to receive prescription drug therapy (as prescribed by their physician/psychiatrist) and counseling to treat their mental illness.
2563290|NCT02476877||Naïve drug group|Two hundred (200) subjects of which about 50 subjects in each of the four mental illnesses will be initially drug naïve (i.e. currently not taking psychotropic drugs) at the beginning of the study and continue to be drug naïve until the end of the study (6 months) as they receive counseling for their mental illness.
2563357|NCT02476643||Integrative Therapy|"This group receives and integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.~Patients are admitted to the hospital ward for 14 days."
2563400|NCT02476279|Experimental|Indomethacin alone|Indomethacin 100 mg rectally immediately after ERCP
2563401|NCT02476279|Active Comparator|Indomethacin+pancreatic stent|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
2563618|NCT02475057|Experimental|Degarelix (LHRH antagonist)|Degarelix (LHRH antagonist) EndoPAT2000
2562776|NCT02480634|Experimental|Low dose group|Zoledronic acid 4 mg + 0.9% sodium chloride injection 100 ml intravenous drip more than 15 min, 28 days for a transfusion cycle, a total of six cycle，Radiotherapy dose: 15Gy/5f
2562844|NCT02480244|Experimental|Behavioral intervention|Behavioral intervention consisting of 12 educational sessions promoting healthy diet and increased physical activity
2562851|NCT02480244|Active Comparator|Control|Control arm receives no health-related behavioral intervention
2562896|NCT02479815|Other|1gm MNP, 15 sachets per month|Quasi experimental matched control cluster design where for every child 1gm Micronutrient Powder (MNP) for two days, is given which totlas to 15 sachets per month
2562938|NCT02479503||French Adult Heart Transplantation Center|All center performing adult heart transplantation in France in 2015.
2562977|NCT02479243||Collateral Circulation|Symptomatic patients with unilateral MCA severe stenosis confirmed ≥ 90% by magnetic resonance angiography or 70-99% by conventional angiography were performed 3D pseudo-Continuous Arterial Spin Labeling MRI.
3206854|NCT00958815||HIV+ with CVD risk factors|35-60 yr old HIV-infected men and women with insulin resistance, dyslipidemia, hypertension, and central adiposity.
3206855|NCT00958867|Experimental|1|Six-month, twice-weekly aerobic training (AT) program
2563183|NCT02478008|Experimental|CardiAQ TMVI System (Transapical DS)|
2563216|NCT02477540|Experimental|2-time injection group : Cellgram-CLI|Within 30 days after extracting bone marrow, autologous bone marrow-derived mesenchymal stem cells is directly injected into the lesion. Then the second cell is injected within 30 days after the first cell injection.
2563252|NCT02477371|Experimental|Fractional flow reserve-guided CABG|Patients are randomized to an FFR-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan form the heart team meeting are changed by the study investigator according to the FFR-measurements and randomization, so that coronary arteries with FFR ≤ 0,8 receive grafting and coronary arteries with FFR > 0,8 are deferred.
2563254|NCT02477371|Active Comparator|Angiography-guided CABG|Patients are randomized to an angiography-guided CABG. FFR-measurements are made on coronary arteries with intermediate stenoses, that are planned for grafting. The FFR-values are blinded for both the operator, the patient and the heart team meeting. The graft plan are based on the coronary angiography.
2563305|NCT02477072|Active Comparator|Fixed heparin dose (general anesthesia)|Study subjects will be randomized to receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
2563317|NCT02477072|Experimental|Weight-adjusted doses of heparin|Study subjects will be randomized to receive 100 units of heparin per kilogram administered intravenously 2 minutes before vascular clamping and blood flow interruption. Subsequent doses of heparin will be administered to maintain the ACT between 300 and 350 seconds at all times during vascular clamping. Anticoagulation will be monitored at different time points during surgery using ACT and TEG. Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial index and toe-brachial index.
2563328|NCT02477072|Active Comparator|Fixed heparin dose (regional anesthesia)|For safety reasons, study subjects under regional anesthesia will automatically be assigned to this group and will receive a fixed dose of 5000 units of heparin administered intravenously 2 minutes prior to vascular clamping and blood flow interruption. A subsequent dose of heparin will be administered if requested by the surgeon following a visual assessment of the anticoagulation in the surgical field. Anticoagulation will be monitored at different time points during surgery using ACT and TEG.
3206856|NCT00958867|Experimental|2|Six-month, twice-weekly resistance training (RT) program
3206857|NCT00958867|Active Comparator|3|Six-month, twice-weekly stretch & relax (S & R; control) program
2563440|NCT02476123|Experimental|Mogamulizumab+Nivolumab|"During parts 1 and 2, Mogamulizumab and Nivolumab are administered at appropriate intervals.~Part 1 (Dose Escalation Part) During Cohort 1 to 2, Mogamulizumab and Nivolumab are administered in combination.~Part 2 (Expansion Part) Patients will be treated with maximum tolerated dose established in the dose escalation part for each combination."
2563500|NCT02475590|Experimental|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
2563502|NCT02475590|Experimental|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
2563593|NCT02475317|Placebo Comparator|Placebo|Participants will receive placebo matched to maralixibat 10 milligram (mg), 20 mg, 50 mg once daily (QD), 50 mg twice daily (BID), 100 mg liquid formulation and volixibat 10 mg, 20 mg capsule orally for 7 days.
2563596|NCT02475317|Experimental|Maralixibat 10mg|Participants will receive maralixibat 10 mg liquid formulation orally QD for 7 days.
2563598|NCT02475317|Experimental|Volixibat 10mg|Participants will receive volixibat 10 mg capsule orally QD for 7 days.
2563599|NCT02475317|Experimental|Maralixibat 20mg|Participants will receive maralixibat 20 mg liquid formulation orally QD for 7 days.
2563601|NCT02475317|Experimental|Volixibat 20mg|Participants will receive volixibat 20 mg capsule orally QD for 7 days.
2563603|NCT02475317|Experimental|Maralixibat 50mg|Participants will receive maralixibat 50 mg liquid formulation orally QD for 7 days.
2563604|NCT02475317|Experimental|Maralixibat 50mg BID|Participants will receive maralixibat 50 mg liquid formulation orally BID for 7 days.
2564834|NCT02466724|Experimental|Web Group|Patients given web site (aiddly) instructions for colonoscopy
3206858|NCT00958906|Experimental|Intravitreal infliximab|
3206859|NCT00958932|Experimental|Speech recognition (TEAM intervention)|
3206860|NCT00958932|Active Comparator|Speech recognition (Usual care)|
3206861|NCT00958945||FloSeal - Knee - control|100 Historical Control Patients, knees - no FloSeal (retrospective)
3206862|NCT00958945||FloSeal - Knee - 5ml|100 Patients, knees - 5mL FloSeal (retrospective)
3206863|NCT00958945||FloSeal - Knee - 10ml|100 Patients, knees- 10mL FloSeal (prospective)
3206864|NCT00958945||FloSeal - Hip - Control|100 Historical Control patients, hips-no FloSeal (retrospective)
3206865|NCT00958945||FloSeal - Hip - 5ml|100 retrospective patients, hips-5mL of FloSeal (retrospective)
2562781|NCT02480725||non-CJD patients with a type of dementia|"Prior to inclusion in the study a senior neurologist will interview the patient and will verify that he fully understands the objectives of the study and he is mentally qualified to sign the informed consent form (severely demented patients who will not be able to adequately consider the participation in the study will be excluded).~Cognitive performance will be evaluated using the Mini-mental Status Examination and Frontal Assessment Battery scales.~No clinical data other than the cognitive assessment and those needed for the clinical work up will be especially collected for this study.~We plan to collect CSF samples for thrombin activity assay."
2562785|NCT02480725||CSF samples of non-CJD patient used as control|CSF samples : Thrombin activity will be assayed.
2562859|NCT02480296|Experimental|MYK-461|Oral Tablet x 28 days
2562863|NCT02480296|Placebo Comparator|Placebo|Oral Tablet x 28 days
2562898|NCT02479789|Experimental|Lidocaine|Subjects in the Lidocaine arm of the randomized trial will receive a bolus of 1 mg /Kg of IV lidocaine followed by 1.5 mg/KG/h of IV lidocaine infusion during the surgery which will be stopped at extubation.
2562906|NCT02479789|Placebo Comparator|Placebo|Subjects in the Placebo arm of the randomized trial will receive a bolus of 1mg/kg Placebo ( 0.9% saline) followed by 1.5 mg/KG/h Placebo ( 0.9% saline) infusion during the surgery which will be stopped at extubation.
2562976|NCT02479438||Diagnosed with GERD|Collect data on GERD patients
2563022|NCT02479048|Active Comparator|Test meal 1 (TM1)|High fat meal (HF) with ½ avocado (~68g)
2563027|NCT02479048|Active Comparator|Test meal 2 (TM2)|High fat meal (HF) with 1 avocado (~136g)
2563032|NCT02479048|Placebo Comparator|Control meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
2563085|NCT02478528|Experimental|Experimental|
2563148|NCT02478203|Placebo Comparator|normal|intubation of a normal airway pediatric manikin with direct laryngoscopy, airtraq , glidescope
2563151|NCT02478203|Active Comparator|tongue edema|intubation of a tongue edema simulated pediatric manikin with diract laryngoscopy, glidescope and airtraq
2563153|NCT02478203|Active Comparator|face-to-face intubation|intubation of an entrapped pediatric manikin with diract laryngoscopy, glidescope and airtraq
2563240|NCT02477436|Experimental|Avanafil 50mg group|Avanafil 50mg tablet + Placebo 100mg tablet
2563241|NCT02477436|Experimental|Avanafil 100mg group|Avanafil 100mg tablet + Placebo 100mg tablet
2563242|NCT02477436|Experimental|Avanafil 200mg group|Avanafil 100mg 2 tablets
2563243|NCT02477436|Placebo Comparator|Placebo group|Placebo 100mg 2tablets
2563273|NCT02477189||Study Group|This was the group that received the penis implant, consented for participation and completed the follow-up questionnaire.
2563320|NCT02476981|Experimental|Remifentanil|Remifentanil is commonly used in monitored anesthesia care because of its rapid onset and short duration of action.
2563325|NCT02476981|Experimental|Dexmedetomidine|Dexmedetomidine is a highly selective α 2 adrenergic agonist and has both sedative and analgesic properties, and rarely causes respiratory depression.
2563329|NCT02476981|Other|midazolam|Midazolam is commonly used before induction for its anxiolytic effect.
2563330|NCT02476981|Other|propofol|Propofol is the most commonly used in sedative analgesia for its rapid onset and recovery time.
2563332|NCT02476981|Other|ephedrine|Adrenergic agonist to treat hypotension
2563376|NCT02476552|Experimental|Niraparib Oral and IV|Single Oral dose of Niraparib capsules (unlabeled active pharmaceutical ingredient) orally and a 15-minute IV infusion of Niraparib (labeled active pharmaceutical ingredient)
2563382|NCT02476552|Experimental|Niraparib Oral|Single Oral dose of Niraparib capsules (labeled active pharmaceutical ingredient)
2563398|NCT02476227|Experimental|Visitag group|Ablation using CARTO system. Visitag module: automated algorithm to collect RF ablation points using Visitag module. Criteria of ablation point: catheter stability range of motion ≤2.5mm, catheter stability time >15sec, contact force >5g over >50% of time. Optimal contact force suggested: 10-40g.
2563399|NCT02476227|Active Comparator|Control group|Ablation using CARTO system. Manual collection of RF ablation points by operator or by assistant. Optimal contact force suggested: 10-40g.
2563524|NCT02475473|Experimental|Intervention|"The acute intervention will consist of 1 session of training following the program:~Resistance Training Exercises. Each participant in the intervention group will perform resistance-training exercises in the form of a circuit. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Initial intensity 6-7 of RPE and ending the set at 9-10. Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round."
2563530|NCT02475473|No Intervention|Control|Control
2563576|NCT02475213|Experimental|Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
2563583|NCT02475213|Experimental|Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
2563585|NCT02475213|Experimental|Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg|enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks
2563591|NCT02475213|Experimental|Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg|enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg
2563680|NCT02474576|Experimental|Percutaneous aponeurotomy|Treatment of Dupuytrens-induced finger flessum using percutaneous aponeurotomy
2563713|NCT02474264|Other|male BRCA mutations carriers|Endothelial function assessment and Cardiovascular biomarkers
2563715|NCT02474264|Other|healthy males - control group|Endothelial function assessment and Cardiovascular biomarkers
2563800|NCT02473744|Experimental|Oedematous lower limb subcutaneous drainage|In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
2563851|NCT02473237|Active Comparator|Tiotropium|Tiotropium 18 mcgr, 1 inhaled capsule, dose once time a Day, with dry powder inhaler device.
3206866|NCT00958958|Other|Quality improvement program|"There are multifaceted Interventions for the clinic hospital team Including~Distribution of educational materials~Case manager~Reminders~Practical training"
3206867|NCT00958958|No Intervention|Hospital standard treatment|Hospital standard treatment
2562975|NCT02479464|No Intervention|Part 1|This is the treatment as usual arm to monitor the current standard clinical practice
2562990|NCT02479464|Other|Part 2|This group will be provided with genotyping results after baseline visit to guide clinical medication management
2563033|NCT02479074|Active Comparator|Montelukast (high FeNO)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
2563036|NCT02479074|Active Comparator|Prednisolone, Montelukast (high FeNO)|Prednisolone 5 mg and montelukast 10 mg. Patients to take Prednisolone 5 mg, 4 tablets per day for 14 days patients to take Montelukast 10 mg film-coated tablet per day for another 14 days Prednisolone is a Class A medicine Montelukast is a Class B medicine
2563038|NCT02479074|Active Comparator|Montelukast|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days Montelukast is a Class B medicine
2563088|NCT02478450|Experimental|Cohort 1|Unilateral lumbar surgical transplantation of Q-Cells dose level 1
2563091|NCT02478450|Experimental|Cohort 2|Unilateral cervical surgical transplantation of Q-Cells dose level 1
2563095|NCT02478450|Experimental|Cohort 3|Unilateral cervical surgical transplantation of Q-Cells dose level 2
2563096|NCT02478450|Experimental|Cohort 4|Unilateral cervical surgical transplantation of Q-Cells dose level 3
2563099|NCT02478450|Experimental|Cohort 5|Unilateral cervical surgical transplantation of Q-Cells dose level 4
2563104|NCT02478450|Experimental|Cohort 6|Unilateral cervical surgical transplantation of Q-Cells dose level 5
2563161|NCT02478086|Experimental|use amine acids parenteral 3.5g|"Amino acids parenteral (Levamin Nomo 10% ®) Group A with an initial doses of amino acids until reaching 3.5 g/kg/day during 28 days.For the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
2563168|NCT02478086|Experimental|use amine acids parenteral 4g|"Group B with an initial doses of 2.5 g/kg/day with daily increments of 0.5 g/kg/day until reaching 4 g/kg/day during 34 days.Weight, urea, creatinine and blood urea nitrogen (BUN) were measured weeklyFor the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
3206868|NCT00958971|Experimental|TKI258 - Positive|These are the participants who had a positive T(4;14) status
3206869|NCT00958971|Experimental|TKI258 - Negative|These are the participants who had a negative T(4;14) status
2563346|NCT02476500|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 30 LLETZ procedures will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
2563352|NCT02476500|Experimental|Novices|Medical students with no previous experience in gynecological surgery will undergo a Video Training and subsequently will perform LLETZ on a Training model. Their performance will be scored by using a 23-item OSATS scheme. The exact time Frame for the OSATS-assessment is within 1 hour after the Video Training.
3206870|NCT00958971|Experimental|TKI258 Non-interpretable|These are the participants who had a non-interpretable T(4;14) status
3206871|NCT00958997||Type 1 diabetic subjects|Patients with Type 1 diabetes who have a diagnosis of Type 1 diabetes mellitus defined by ADA criteria or judgment of physician
3206872|NCT00958997||Healthy control subjects|Age-weight-BMI matched to the subjects with type-1 diabetes
3206873|NCT00959010|Experimental|Omega 3 Premium|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA
2563662|NCT02474550||CISL 14-03|"Patients who were newly diagnosed with Diffuse Large B cell Lymphoma (DLBCL).~Aged 19 or more~Treated with R-CHOP therapy"
3206874|NCT00959010|Placebo Comparator|Placebo|capsules containing middle chain triglycerides
2563850|NCT02473211|Experimental|SOF+DCV|Participants will receive Sofosbuvir (SOF) 400 mg and Daclatasvir (DCV) 60 mg daily for 12 weeks.
2563886|NCT02473029||Cases|Patients admitted to a tertiary hospital, with a clinical suspicion of Horton disease
2563947|NCT02472678|Other|Standard care|The control group will receive standard care.
2563948|NCT02472678|Experimental|Experimental group|In addition to standard care, the experimental group will be given access to the web-based tailored information and support system (with a username/password)
2564051|NCT02471976|Other|Group B|strategy promoting early consideration and collegiate vulnerability of patients
3206875|NCT00959036|Experimental|Treatment Group 1|ATN-103 10 mg every 4 weeks until week 12
3206876|NCT00959036|Experimental|Treatment Group 2|ATN-103 10 mg every 8 weeks until week 12
3206877|NCT00959036|Experimental|Treatment Group 3|ATN-103 30 mg every 4 weeks until week 12
3206878|NCT00959036|Experimental|Treatment Group 4|ATN-103 80 mg every 4 weeks until week 12
3206879|NCT00959036|Experimental|Treatment Group 5|ATN-103 80 mg every 8 weeks until week 12
3206880|NCT00959036|Placebo Comparator|Treatment Group 6|Placebo every 4 weeks
3206881|NCT00959062|Experimental|clonidine|
3206882|NCT00959062|Placebo Comparator|placebo|
3206883|NCT00959075|Experimental|Oral thiamin supplementation|Vitamin B1 (Oral thiamin) 100mg BID for 6 months
3206884|NCT00959075|Placebo Comparator|Sugar pill|oral placebo 1 tablet BID for 6 months
2562872|NCT02479984|Experimental|Staging laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
2562925|NCT02479711|Experimental|composite restoration|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with Tetric EvoCeram Bulk Fill composite
2562927|NCT02479711|Active Comparator|glass ionomer cement|lower permanent molar with an approximal and /or occlusal carious lesion will be restored with the glass ionomer restoration, Equia
2562952|NCT02479308|Active Comparator|Moxifloxacin|Oral tablet
2562964|NCT02479308|Experimental|ALKS 5461|Sublingual tablet
2562983|NCT02479308|Placebo Comparator|Placebo|
2563026|NCT02478983|Experimental|LMA Supreme|1 arm will receive LMA supreme for airway management
2563030|NCT02478983|Active Comparator|LMA Proseal|1 arm will receive LMA Proseal for airway management
3206885|NCT00959088||1|HIV-infected individuals with suspected TB co-infection.
3206886|NCT00959101|Experimental|A|
2563162|NCT02477956|Experimental|vitamin D3|subjects taking the standard vitamin D protocol with added monthly high dose cholecalciferol of 100,000 IU cholecalciferol
2563171|NCT02477956|Active Comparator|Control|group of subjects taking the standard vitamin D
3206887|NCT00959101|Experimental|B|
3206888|NCT00959101|Active Comparator|C|
2563392|NCT02476461|Active Comparator|xiapex|1: xiapex: 0,58 mg clostridium histolyticum administered in the dupuytrens cord as discribed in producers manual
2563393|NCT02476461|Experimental|PNF|percutaneous needle fasciotomi is performed at affected cords
2563407|NCT02476188|Experimental|Patients|Samples of blood at H0, H+6, H+24 and H+72
2563410|NCT02476188|Experimental|Patients control|Samples of blood at H0
2563414|NCT02476188|Active Comparator|Control (healthy person)|Samples of blood at H0
3206889|NCT00959114|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
3206890|NCT00959114|Placebo Comparator|Placebo comparator|Excipients for ALV003 absent the experimental compounds
3206891|NCT00959127|Experimental|ARRY-438162 (MEK 162)|
3206892|NCT00959140|Experimental|CD3+ T-cell depletion|CD3+ T-cell depletion
3206893|NCT00959153|Experimental|Kidney stones|Kidney stones
2563710|NCT02474459|Active Comparator|iPad-based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be performed using an iPad-based decision support system. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
2563714|NCT02474459|Active Comparator|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care. Outcomes will be measured using the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-39) and the Multi-Dimensional Caregiver Strain Index (MCSI).
2563749|NCT02473887|Experimental|gastroenteritis with persistent vomiting.|patients with gastroenteritis with persistent vomiting received single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
2563801|NCT02473705|Active Comparator|Fish Oil and Bicarbonate placebo|1280mg of fish oil per day and bicarbonate placebo
2563803|NCT02473705|Active Comparator|Fish Oil Placebo and Bicarbonate|fish oil placebo and 1mg of bicarbonate per Kg of body weight per day
2563805|NCT02473705|Experimental|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
2563806|NCT02473705|Placebo Comparator|Fish Oil placebo and Bicarbonate placebo|Fish oil placebo and Bicarbonate placebo
3206894|NCT00959179||Device therapy patients for CHF.|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
2563924|NCT02472899||Alzheimer's Disease|Blood sample from subjects older than 60 years with a clinical diagnosis of Alzheimer's Disease
2563928|NCT02472899||Older controls|Blood sample from subjects older than 60 years who are cognitively normal
2563930|NCT02472899||Younger controls|Blood sample from healthy subjects aged 20 to 30 years who are cognitively normal
3206895|NCT00959179||ICD and CRT-D patients|enroll all consecutive patients undergoing implantable cardioverter defibrillator (ICD) and ICD with biventricular pacemaker (CRT-D) implantation for heart failure from in-patient and out-patient referral setting
3206896|NCT00959205|Active Comparator|Angiography|Conventional fluoroscopically guided activation mapping
2564004|NCT02472054|Experimental|hemophagocytic lymphohistiocytosis (HLH)|"Alemtuzumab (CAMPATH®)~Initial Treatment (D1 to D3) D1: 0.5 mg / kg / day Alemtuzumab combined with 2 mg /kg/d of IV Methylprednisolone (MP) or PO Prednisolone, and IVC or PO cyclosporine (CSA) (target rate from 150 to 200 ng / ml in the absence of renal failure) D2 and D3: 1 mg / kg / day Alemtuzumab combined with 2 mg / kg / d of IV MP or PO Prednisolone and IVC or PO CSA (target rate 150-200 ng / ml)~The maximum dose of Alemtuzumab is limited to 30 mg per day (1 vial).~Maintenance treatment (D4 to D14)~MP/Prednisolone progressive tapering starting at D4 (2 mg / kg / day) to reach the dose 0.5 mg / kg / day at D14~CSA IVC or PO at a target rate of 150-200 ng / ml"
2564094|NCT02471859|Placebo Comparator|Part B: Placebo|Participants in different cohorts will receive placebo in multiple ascending doses under fed/fasting conditions.\n
2564836|NCT02466724|No Intervention|Paper Group|Patients given paper instructions for colonoscopy
3206897|NCT00959205|Experimental|CARTO 3D|CARTO (3D Electroanatomic imaging)
3206898|NCT00959218|Experimental|Dronabinol|
3206899|NCT00959218|Placebo Comparator|Placebo|
2562930|NCT02479620|Active Comparator|Dexamethasone Delivery|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution."
2562931|NCT02479620|No Intervention|Control|"Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe.~Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control."
2562950|NCT02479256|Experimental|Clomiphene citrate + placebo|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily), and one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
2562960|NCT02479256|Experimental|Tamoxifen + placebo|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily), and one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
2563017|NCT02478905||surveillance cohort|Flocked mid-turbinate nasal swabs for influenza PCR will be collected from study participants daily
2563080|NCT02478645|Experimental|ramosetron 0.3|
2563081|NCT02478645|Active Comparator|ramosetron 0.45|
2563082|NCT02478645|Active Comparator|ramosetron 0.6|
2563130|NCT02478268|Active Comparator|Patients with idiopathic pulmonary fibrosis|
2563131|NCT02478268|Active Comparator|Healthy volunteers|
2563174|NCT02477969|Experimental|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
2563178|NCT02477969|Experimental|PEX168(200µg)|PEX168,200µg,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
2563180|NCT02477969|Placebo Comparator|Placebo|Placebo,0.5ml,Subcutaneous injection,once a week. Metformin,0.5mg, tid,oral.
3206900|NCT00959257||Asthma|Asthma patients on inhaled corticosteroids
3206901|NCT00959257||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
3206902|NCT00959283||Ancillary-correlative|Patients undergo peripheral blood collection periodically for biomarker analysis. Samples are analyzed for GATA1 mutations by real-time PCR, polymorphisms, cytogenetics, and K-RAS mutations, gene expression, drug sensitivity patterns, and minimal residual disease by flow cytometry.
3206903|NCT00959296||Patients with a device implant|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
3206904|NCT00959309|Experimental|Intervention|
3206905|NCT00959309|Active Comparator|Control|
3206906|NCT00959335|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
2563495|NCT02475746|Experimental|PF-06372865 treatment arm|treatment arm includes two treatment periods, a single dose of PF-06372865 (period 1) followed by 8-days itraconazole with a single dose of PF-06372865 co-administered on Day 4
3172139|NCT00596375|No Intervention|Routine Care Group|The routine care group will help us to quantify the routine amount of distress associated with catheterization.
3206907|NCT00959335|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
2563557|NCT02475135|Experimental|Panel 1: Group 1|Subject will receive a single oral tablet of fixed dose combination (FDC) containing darunavir (DRV)/ cobicistat (COBI)/emtricitabine (FTC) /tenofovir alafenamide (TAF) (D/C/F/TAF) under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 1 and by FDC of elvitegravir (EVG)/cobicistat (COBI)/emtricitabine (FTC)/ tenofovir alafenamide (TAF) (E/C/F/TAF) under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 2.
2563558|NCT02475135|Experimental|Panel 1: Group 2|Subject will receive a single oral tablet of FDC containing E/C/F/TAF under fed conditions (standardized regular breakfast, reference Panel 1) on Day 1 of treatment period 1 and a single oral tablet of FDC containing D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 1) on Day 1 of treatment period 2.
2563625|NCT02475057|Active Comparator|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist EndoPAT2000
3206908|NCT00959348||Asthma|Asthma patients on inhaled corticosteroids
3206909|NCT00959348||Control|Select matched controls from the general population database of Cardiovascular Risk Factor Prevalence Study 2 (CRISPS2)
3206910|NCT00959361|Experimental|pharmaceutical care|consultation with the pharmacists
3206911|NCT00959361|No Intervention|control|usual care without consultation with the pharmacists
3206912|NCT00959387|Experimental|Induction TP chemotherapy followed by CRT|paclitaxel 175mg/m2 as a 3-h infusion on Day 1, and cisplatin 80mg/m2 as a 2-h infusion on Day 1 three weekly followed by concurrent chemoradiotherapy based on cisplatin. All patient were given adequate hydration and antiemetics. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
3206913|NCT00959400|Experimental|Fentanyl Transdermal|
3206914|NCT00959413||A|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load greater than 1,000 copies/ml
3206915|NCT00959413||B|Participants who have a CD4 count of 200 cells/mm3 or less and a viral load of 1,000 copies/ml or less
3206916|NCT00959413||C|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is greater than 1,000 copies/ml
3206917|NCT00959413||D|Participants will have a CD4 count that is greater than 200 cells/mm3 and a viral load that is 1,000 copies/ml or less
3206918|NCT00959426|Experimental|PF-04620110|
3206919|NCT00959426|Placebo Comparator|Placebo Comparator|
3206920|NCT00959439|Experimental|1|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)
3206921|NCT00959439|Active Comparator|2|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)
3206922|NCT00959452|Experimental|Psychotherapy|
2562996|NCT02479165|Active Comparator|Opioid group|"If randomized to the opiod group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Oxycodone (slow-release) 10mg, Twice daily for 1 week Tbl. Paracetamol 1000mg, Four times daily for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed, until discharge. Inj, oxycodone 2.5 mg, Max 4 times daily, as needed, until discharge Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml 10 drops daily, for 1 week"
2562997|NCT02479165|Active Comparator|Ibuprofene group|"If randomized to the ibuprofen group, the patient was given the following regimen for 1 week, upon return from the intensive care unit, after surgery.~Tbl. Ibuprofen (slow-release) 800mg, Twice daily, for 1 week Tbl. Paracetamol 1000mg, Four times daily, for 1 week Tbl.oxycodone 5mg Max 4 times daily, as needed. Until discharge. Inj, oxycodone 2.5 mg Max 4 times daily, as needed. Until discharge. Tbl. Lanzoprazole 40 mg, Once daily, for 1 week Tbl. Magnesia 1g, Twice daily, for 1 week Sol. Sodiumpicosulfate 7.5mg/ml, 10 drops daily, for 1 week"
2563016|NCT02478840|Experimental|Lamazym|1 mg Lamazym/kg Body weight
3206923|NCT00959465|Experimental|Cohort 1/Dose Level A|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
2563097|NCT02478333|Experimental|ALS-008176 (250 mg) or Placebo|Participants will receive ALS-008176, 250 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
2563102|NCT02478333|Experimental|ALS-008176 (500 mg) or Placebo|Participants will receive ALS-008176, 500 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
2563107|NCT02478333|Experimental|ALS-008176 (750 mg) or Placebo|Participants will receive ALS-008176, 750 milligram (mg) or placebo oral suspension once on Day 1 under fasted conditions.
2563160|NCT02478034|Experimental|fludrocortisone|effects of fludrocortisone on cognition compared to placebo
2563169|NCT02478034|Placebo Comparator|Placebo|effects of fludrocortisone on cognition compared to placebo
3206924|NCT00959465|Experimental|Cohort 1/Dose B|Subjects in Cohort 1 will be randomized 1:1 to receive two vaccinations of Dose A or Dose B of H1N1 pandemic influenza vaccine at a 21-day interval.
2563262|NCT02477306|Experimental|Study group|60 subjects will receive a single oral dose of idiazole 20mg DR tabs under fasting condition in one period. And the subjects will receive a single dose of PARIET 20 mg DR tabs under fasting condition in the second period. A 7 days washout interval is in between the 2 periods
2563309|NCT02477046|Experimental|tOPV + IPV|tOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive tOPV plus IPV boost
2563321|NCT02477046|Experimental|bOPV + IPV|bOPV (6, 10, and 14 weeks) + IPV (14 weeks) Randomized to receive bOPV plus 1 IPV boost
2563327|NCT02477046|Experimental|bOPV + 2 IPV|bOPV (6, 10, and 14 weeks) + IPV (14 and 18 weeks) Randomized to receive bOPV plus 2 IPV boost
3206925|NCT00959465|Experimental|Cohort 2/Dose C|A second cohort may be enrolled with all subjects in this cohort receiving two vaccinations of Dose C of H1N1 pandemic influenza vaccine at a 21-day interval.
3208860|NCT00978809|Active Comparator|Semont|BPPV patients treated by Semont maneuver by a physical therapist.
2563456|NCT02476045|Active Comparator|ARM A|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with 5-FU/LV (De Gramont regimen) plus panitumumab given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
2563457|NCT02476045|Experimental|ARM B|"Induction phase with panitumumab as 1 hour intravenous infusion at the dosage of 6 mg/kg, given every two weeks, plus FOLFOX-4 chemotherapy as standard guidelines.~Maintenance therapy with panitumumab alone given at 6 mg/Kg every two weeks until progressive disease, unacceptable toxicity or informed consent withdrawal"
2563513|NCT02475603|Experimental|tourniquet|Total knee arthroplasty will be performed with tourniquet
2563514|NCT02475603|Experimental|non-tourniquet|Total knee arthroplasty will be performed without tourniquet
2563552|NCT02475291||Significant coronary lesions|Significant lesions with more than 70% diameter stenosis at proximal major coronary arteri(es).
2563605|NCT02475044|No Intervention|Treatment as usual (TAU)|Participants recive Psycho-education and neuro-psycological diagnosis.
2563608|NCT02475044|Experimental|Cognitive-Behavioral Therapy (CBT)|Participants recive 16 sessions of CBT in addition to arm TAU treatment.
2563637|NCT02474745|Experimental|INTERVENTION GROUP|"Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible"
2563640|NCT02474745|Other|CONTROL GROUP|"Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
2563718|NCT02474420|Active Comparator|Deferasirox|deferasirox iron chelation therapy and standard of care by the treating physician
2563719|NCT02474420|Experimental|Deferasirox plus amlodipine|deferasirox iron chelation therapy with amlodipine
2563746|NCT02473900|Experimental|Sequence 1|HIP1403→HGP0919
2563750|NCT02473900|Experimental|Sequence 2|HGP0919→HIP1403
2563793|NCT02473627|Experimental|Period 1|Period 1 Day 1: single oral dose of 2.5 mg midazolam hydrochloride Day 2: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion
2563795|NCT02473627|Experimental|Period 2|"Period 2 Days 1 through 12 repeated doses of 400 mg DS-1971a administered orally bid .~On the days listed below, each probe substrate(s) will be coadministered with the morning dose of DS 1971a:~Day 8: single oral dose of 2.5 mg midazolam hydrochloride Day 9: single oral cocktail dose of 20 mg omeprazole, 15 mg pioglitazone hydrochloride, 500 mg tolbutamide and 150 mg bupropion"
2563847|NCT02473237|Experimental|indacaterol|Indacaterol 150 mcgr, one inhaled capsule, dose once time on visit one, with dry powder inhaler device.
3208861|NCT00978809|No Intervention|control|healthy volunteers.
3208862|NCT00978809|Active Comparator|Epley maneuver|BPPV patients treated with Epley maneuver by a physical therapist.
3208863|NCT00978822|Experimental|Clevidipine butyrate injectable emulsion|
2562937|NCT02479542|Experimental|WiCare NPWT dressing|Patients with wounds that meet eligibility criteria will be randomized, if randomized to the WiCare NPWT Dressing Arm, a saline moistened sterile gauze will be packed into the wound and then the WiCare dressing and wound pump will be placed on the wound. The dressing will be changed, measured and photodocumented every 72 hours with the Wound Zoom system.
2562984|NCT02479230|Experimental|vaccine: gemcitabine hydrochloride|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning 3, 7, or 10 days later, patients receive tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine ID followed by a second vaccination 7 days later. Courses may repeat after at least 4 weeks in the absence of disease progression or unacceptable toxicity.
2563042|NCT02478827|Experimental|Working Memory group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games are adaptive. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
2563045|NCT02478827|Experimental|Processing Speed group|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. One experimental group will complete the processing speed training, which involves three games: Line It Up, Sliding Search, and Bubble Math. These games are designed to engage processes involving thinking speed. Participants randomized to this cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks
2563046|NCT02478827|No Intervention|Control group|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, a post-assessment will be completed.
2563300|NCT02476864|Experimental|Sequence AB|Subjects receive treatment A in Period 1 followed by treatment B in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
2563324|NCT02476864|Experimental|Sequence BA|Subjects receive treatment B in Period 1 followed by treatment A in Period 2 with a washout phase of 10 to 14 days between the two treatment periods
2563415|NCT02476136||Placebo group|Patients participating in one of the included randomized controlled trials, assigned to the placebo group
2563416|NCT02476136||Intervention group|Patients participating in one of the included randomized controlled trials, assigned to the investigational antidepressant (paroxetine, duloxetine or fluoxetine) or active comparator (venlafaxine) group.
2563458|NCT02475902|Experimental|Computer guided home exercise program|"A laptop computer & MS Kinect camera will be connected to a 40 TV to deliver guided fall prevention exercises. Research staff will train the participants in the use of the computerized program and be supervised performing the exercises during the instruction period. Then participants will be instructed to exercise 3 times per week for 4 weeks. Half of the participants will begin the study with the computerized version of the home exercise program while the other half begins with the paper booklet version of the home exercise program. After one month the arms will cross over."
2563462|NCT02475902|Active Comparator|Paper guided home exercise program|A paper booklet with pictures and written instructions, and an exercise log for the home exercise program will be given to half of the participants. Participants will be carefully instructed in performing the exercises correctly and then asked to perform the exercises 3 times per week for one month. Participants who began the study with the paper exercise program will switch to the computerized version of the exercise program for the second month.
2563610|NCT02474979|Experimental|CBPM-system|CBPM-system (Continuous Bedside Pressure Mapping System): the bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure. The CBPM-system will be used in addition to standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
2563612|NCT02474979|Experimental|Control|Standard pressure ulcer prevention (PU reducing mattress, floating heels, repositioning).
2563631|NCT02474706|Experimental|cefoxitin|Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
2563635|NCT02474706|Active Comparator|imipenem|Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
2563822|NCT02473406|Experimental|Thymosin|Thymosin alpha 1 has been shown to have immunomodulatory properties
2563826|NCT02473406|Placebo Comparator|Placebo|normal saline;
3172140|NCT00596375|Experimental|Lidocaine Group|A experimental group will include patients who will have 2% Lidocaine instilled into the urethra prior to catheterization. This group of subjects receiving routine care plus Lidocaine, will be evaluated during each of the four phases of the intervention.
3172141|NCT00596375|Experimental|Instillation|This group will undergo catheterization utilizing routine care plus lubricant jelly instilled into the urethra. This placebo group will aid in discerning the effects of instillation into the urethra on pain and associated distress.
3172142|NCT00596388||1|Subjects diagnosed as intermediate AMD
3172143|NCT00596401||1|HP eradication group
3172144|NCT00596401||2|No eradication group
3172145|NCT00596401||3|No Hp group
3172146|NCT00596414|Placebo Comparator|1|
3172147|NCT00596414|Experimental|2|midazolam
3172148|NCT00596414|Experimental|3|midazolam + pethidine
3172149|NCT00596492|Active Comparator|High Dose|
3172150|NCT00596492|Active Comparator|Low Dose|
3172151|NCT00596505||1|Group 1 will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
3172152|NCT00596505||2|Group 2 will not receive bevacizumab pretreatment
3172153|NCT00596518|Experimental|PF-00734200|
2562998|NCT02479087|Experimental|Plasma-derived FVIII/VWF concentrate|"The drug will be delivered through intravenous slow infusion/injection. The starting dosage can vary between the minimum dosage of 50 IU/Kg 3 times a week up to a maximum of 200 IU/kg per day.~This starting dosage will be decided by the Principal Investigator according to patient's condition and other variables.~The initial dosage can be then adjusted on the base of response."
2563039|NCT02478788|Experimental|LR-MAS - Low-risk ADHD adolescents|ADHD adolescents without any first or second degree-relatives with bipolar disorder. Low-risk ADHD adolescents (n=60) will receive treatment with open-label mixed amphetamine salts-extended release (MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD.
2563040|NCT02478788|Experimental|HR-MAS - High-risk ADHD adolescents|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). The subjects in this group will receive mixed amphetamine salts-extended release( MAS-XR), which is approved by the United States Food and Drug Administration (USFDA) for the treatment of ADHD and is a commonly prescribed psychostimulant medication for adolescents with ADHD."
2563041|NCT02478788|Placebo Comparator|HR-P - High-risk ADHD on Placebo|"ADHD adolescents with a parent with bipolar disorder (high-risk). High-risk ADHD adolescents will be randomized to double-blind treatment with MAS-XR (n=60) or placebo (n=60). Following initiation of treatment, the ADHD adolescents will have regularly scheduled visits during which symptom and tolerability ratings will be performed."
2563044|NCT02478788|No Intervention|HC (Healthy Controls)|Healthy subjects (n=60) will be recruited from the community and will not receive medication but will undergo MR scans at the same intervals to assess normal variability in imaging parameters between time points as well as to adjust and interpret comparisons within patients (i.e., whether patient values are changing toward or away from those of healthy adolescents). Neuroimaging evaluations will be performed at baseline and Week 12 (or termination).
2563090|NCT02478437|Active Comparator|Group 1|Conventional radiofrequency ablation (RFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
2563094|NCT02478437|Active Comparator|Group 2|Cooled radiofrequency ablation (CRFA) Following ablation, 0.5 cc of 0.5% bupivacaine will be injected to provide post procedure analgesia.
2563149|NCT02478190|Experimental|Tight control|Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
2563152|NCT02478190|Experimental|Loose control|Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
2563204|NCT02477761|No Intervention|Water preload|"During the Water preload study, each subject consume 500 ml of water 30 minutes before a 75 g glucose ingestion"
2563209|NCT02477761|Experimental|Nutrient preload|"During the Nutrient preload study, each subject consume a small mixed meal 30 minutes before a 75 g glucose ingestion. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
2563247|NCT02477410|Experimental|Hydrolysed porcine protein from blood|Dietary intervention with hydrolysed porcine protein from blood
2563249|NCT02477410|Experimental|Hydrolysed porcine protein from muscle|Dietary intervention with hydrolysed porcine protein from muscle
2563250|NCT02477410|Experimental|Hydrolysed whey protein|Dietary intervention with hydrolysed whey protein
2563276|NCT02477137|Experimental|Intervention group|In combination with usual care according to the routines at the clinic, patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
2563277|NCT02477137|No Intervention|Control group|Usual care according to the routines at the clinic.
3206926|NCT00959478|Experimental|Educational tool & Carbon Monoxide Alarm|"Parents will be randomly assigned into a control and intervention group. Both groups will complete a computer based survey at enrollment and at their home visits occuring two weeks and approximately six months following enrollment. Participants will be given the following materials at enrollment.~Intervention:~Fast Facts about Carbon Monoxide Educational Tool~Kidde Nighthawk Carbon Monoxide Alarm~Control:~- Central Ohio Poison Control Center Flyer"
3206927|NCT00959491||Colonoscopy indication|All outpatients referred to colonoscopy according to inclusion criteria in the specified period time of one year .
2563420|NCT02476318|Experimental|ArterX Vascular Sealant|
3206928|NCT00959517|Experimental|CQ|
3206929|NCT00959517|Experimental|CQ+PQ|
2563527|NCT02475421|Experimental|Healthy, lean subjects|Healthy subjects with BMI < 27 kg/m^2
2563531|NCT02475421|Experimental|Healthy, obese subjects|Healthy subjects with BMI > 33 kg/m^2
2563533|NCT02475421|Experimental|Diabetic, lean subjects|Diabetic subjects with BMI < 27 kg/m^2
2563535|NCT02475421|Experimental|Diabetic, obese subjects|Diabetic subjects with BMI > 33 kg/m^2
2563559|NCT02475161|Experimental|JNJ-42847922 Plus Rabeprazole|Participants will receive JNJ-42847922, 20 milligram (mg) on Day 1 and Day 6. Participants will receive rabeprazole 20 mg once daily from Day 2 to Day 6.
2563616|NCT02474914|Active Comparator|Octreotide|Enrolled patients will be randomized to either the octreotide (sandostatin ) or the placebo group. The randomization process will be done using closed envelop method and will be withdrawn by a nurse after pancreaticoduodenectomy . Patients in the octreotide group will receive sandostatin 100ug SC every 8 hours daily staring from the day of operation to the postoperative day 7. Patients in the placebo group will receive saline administered in a similar manner.
2563620|NCT02474914|Placebo Comparator|Placebo|pancreaticoduodenectomy without octreotide postoperative
3206930|NCT00959517|Experimental|CQ + AS|
3206931|NCT00959517|Experimental|SP|
2563740|NCT02474095|Experimental|Arm I (ALTENS QIW)|Patients undergo ALTENS delivered via the Codetron machine QIW for 6 weeks in the absence of disease progression or unacceptable toxicity.
2563741|NCT02474095|Active Comparator|Arm II (ALTENS BIW)|Patients undergo ALTENS delivered via the Codetron machine BIW for 12 weeks in the absence of disease progression or unacceptable toxicity.
2566609|NCT02455414||Healthy Control (HC) Group|• Age within the 0-28 yrs age range of WFS participants
3206932|NCT00959517|Experimental|SP + PQ|
3206933|NCT00959517|Experimental|SP + AS|
3206934|NCT00959530|Experimental|lingualized|complete denture fabricated by lingualized occlusion scheme
3206935|NCT00959530|Placebo Comparator|Full Bilaterally Balanced Articulation|complete denture fabricated by Full Bilaterally Balanced Articulation scheme
3206936|NCT00959543|Other|waterpolo players|30 throwing shoulders of waterpolo players
3206937|NCT00959543|Other|controle group|15 healthy patients (non waterpolo players); 30 shoulders
3206938|NCT00959569|Experimental|esmolol|the study group will receive esmolol (1-3 mg/kg)
3206939|NCT00959569|Placebo Comparator|normosaline|normosaline (same ml of the study drug)
2563190|NCT02477852|Experimental|anti-tuberculosis treatment two weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for two weeks.
2563192|NCT02477852|Experimental|anti-tuberculosis treatment four weeks|anti-tuberculosis drugs All the patients in the groups receive anti-tuberculosis treatment with Isoniazid 0.3g po qd, Rifampicin 0.45g po qd, Ethambutol 0.75 g po qd,Pyrazinamide 0.5g po tid. for four weeks.
2563238|NCT02477462||Primary Biliary Cirrhosis|Subjects meeting internationally accepted criteria for the diagnosis of primary biliary cirrhosis
2563239|NCT02477462||Control|Subjects without evidence of primary biliary cirrhosis, liver disease, or inflammatory condition who are of similar age and sex distribution to the Primary Biliary Cirrhosis group
2563265|NCT02477241|Other|Healthy female subjects|Healthy female subjects with or without overactive bladder undergoing functional MRI brain and urodynamic study.
3206940|NCT00959582|Experimental|1|18-F-FDG PET/CT imaging
3206941|NCT00959595|Experimental|EMLA cream|
2563354|NCT02476526|Experimental|Low Volume Contrast|Subjects in this arm will receive a single intravenous injection of low volume iso-osmolar non-ionic radio contrast medium, prior to undergoing 64-MDCT scanning. The use of low volume radio contrast medium constitutes the intervention. Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
2563356|NCT02476526|Sham Comparator|Control|Subjects in this arm will undergo 64-MDCT scanning without Radio Contrast Medium (RCM). Both experimental and control groups receive a) acetylcysteine inhalation (Mucomyst) 1200 mg po BID x 48 hours starting the day prior to the CT scan; and b) isotonic Sodium Bicarbonate Solution 3ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan
3206942|NCT00959595|Placebo Comparator|Placebo cream|A placebo cream identical in appearance and consistency to the experimental cream
3206943|NCT00959608|Active Comparator|Basic|Basic program participants receive 10-15 minute PCP weight management counseling at approximately four month intervals for up to 24 months and weight management materials.
2563670|NCT02474537|Experimental|Normal hepatic function|Subjects with normal hepatic function
2563676|NCT02474537|Experimental|Mild hepatic impairment|Subjects with mild hepatic impairment
2563682|NCT02474537|Experimental|Moderate hepatic impairment|Subjects with moderate hepatic impairment
2563684|NCT02474537|Experimental|Severe hepatic impairment|Subjects with severe hepatic impairment
2563734|NCT02474186|Experimental|Radiation therapy|"Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy~Systemic agents are either capecitabine (Xeloda), paclitaxel, docitaxel or taxol"
2563763|NCT02473809|Experimental|Liraglutide|"Liraglutide (Victoza), subcutaneous 1,8 mg once daily for 180 days"
2563769|NCT02473809|Placebo Comparator|Placebo|Saline, subcutaneous once daily for 180 days
3206944|NCT00959608|Experimental|Basic Plus|Half of study participants are randomly assigned to Basic Plus program, where in addition to receiving the same intervention as the Basic program participants, the Basic Plus participants also receive counseling from a lifestyle coach at the primary care provider's office (monthly in year 1 and bimonthly in year 2).
2563843|NCT02473263|No Intervention|Conventional|No antibiotic administration and no hemodynamic target are required
2563845|NCT02473263|Active Comparator|Aggressive|Antibiotics (Ceftriaxone or piperacillin tazobactam) administration, hemodynamic optimization and opotherapy (norepinephrine, hydrocortisone) when required should be performed in the first 60 minutes after contact with the patient
3206945|NCT00959621|Active Comparator|ASA|The patients received either Enoxaparine+placebo, Enoxaparine+ASA (Aspirin 100 mg) or ASA alone.ASA or placebo were blinded in the two first groups.
3206946|NCT00959621|Active Comparator|Klexane|Clexane (enoxaparine) 40 mg sc
2564029|NCT02472171|Experimental|Group 1|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
2564033|NCT02472171|Experimental|Group 2|"Order of treatments:~A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil"
2564037|NCT02472171|Experimental|Group 3|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil C. High saturated fat meal, placebo powder and DHA"
2564043|NCT02472171|Experimental|Group 4|"Order of treatments:~B. High saturated fat meal, blueberry powder and sunflower oil C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil"
2564044|NCT02472171|Experimental|Group 5|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA B. High saturated fat meal, blueberry powder and sunflower oil A. High saturated fat meal, placebo powder and sunflower oil"
2564046|NCT02472171|Experimental|Group 6|"Order of treatments:~C. High saturated fat meal, placebo powder and DHA A. High saturated fat meal, placebo powder and sunflower oil B. High saturated fat meal, blueberry powder and sunflower oil"
2564126|NCT02471417|Placebo Comparator|Nitrate depleted placebo beetroot juice|Placebo beetroot juice is identical to active beetroot juice in every way except nitrate content.
3206947|NCT00959621|Active Comparator|Aspirin and Enoxaparine|
3206948|NCT00959634|Experimental|1|Dose 1 BID
3206949|NCT00959634|Experimental|2|Dose 2 BID
3206950|NCT00959634|Placebo Comparator|3|Placebo BID
3206951|NCT00959686|Experimental|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
2563010|NCT02478801|Experimental|Endurance trained|subjects will receive different levels of amino acids intakes varying from 0.2 to 2.8 g/kg/day.
2563050|NCT02478762|Active Comparator|Normal glycemic control|GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
2563051|NCT02478762|Experimental|Low glycemic control|GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
2563074|NCT02478411|Experimental|Cycle ergometer physiotherapy|15 minutes of cycle ergometer physiotherapy plus 15 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
2563077|NCT02478411|Active Comparator|Conventional physiotherapy|30 minutes of conventional physiotherapy, once daily, five days a week, as long as patients remain in the intensive care unit
2563128|NCT02478281|Experimental|Methylene Blue Injection, USP|Single dose of Methylene Blue Injection, USP at a dose of 1 mg/kg solution per kg given intravenously over a period of approximately 5 minutes.
2563186|NCT02477982||control group|BMI ≤ 25 kgm-2
2563187|NCT02477982||obese group|BMI ≥ 30 kgm-2
3206952|NCT00959712|No Intervention|Control|Subjects are given a pedometer and step count log in which to record their daily step counts for 1 year.
3206953|NCT00959712|Active Comparator|ECA Interaction|"Subjects are given pedometers and step count logs in which to record their daily steps for 1 year. Subjects are also given a tablet computer and instructed to interact with the ECA (Embodied Conversational Agent) Tanya every day for 2 months."
3206954|NCT00959725|Experimental|Intravitreal infliximab.|
2563437|NCT02476084||Conventional synthetic DMARD naïve|"Naive RA patients commencing Methotrexate and Hydroxychloroquine.~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
2563441|NCT02476084||DMARD-IR: anti-TNF|"Conventional synthetic DMARD inadequate responders commencing Anti-TNF~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
2563443|NCT02476084||DMARD-IR: anti-IL6|"Conventional synthetic DMARD inadequate responders commencing anti-IL6~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
2563446|NCT02476084||DMARD-IR: anti-CTLA-4|"Conventional synthetic DMARD inadequate responders commencing anti-CTLA-4~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
2563447|NCT02476084||DMARD-IR: anti-CD20|"Conventional synthetic DMARD inadequate responders commencing anti-CD20~Musculoskeletal Ultrasound imaging, synovial biopsy, biological samples collection, questionnaires."
2563505|NCT02475642|Active Comparator|PVI-ADT|discontinue antiarrhythmic drugs at 3 months post PVI
2563509|NCT02475642|Active Comparator|PVI+ADT|discontinue antiarrhythmic drugs at 12 months post PVI
2563547|NCT02475304|Experimental|Experimental FP187|Treatment with a daily dose of 500mg FP187 (twice daily). Other names: Dimethyl fumarate
2563548|NCT02475304|Placebo Comparator|Placebo Comparator|Patients will receive the same number of tablets as patients randomized to FP187 arm in order to maintain the blind. The colour and shape of the FP187 and placebo tablets will be the same so that no visible difference is detectable
2563581|NCT02475096|Experimental|Internet-delivered CBT|Children and parents will receive 10 weekly modules of internet-delivered CBT (Cognitive Behavior Therapy). Parents will also receive 10 weekly specific modules for parents. Main components in the modules directed at children and parents are exposure for symptoms, feared stimuli and situations. The parents modules contain information on how they can support their children in the treatment and is based on social learning theory. Therapist support is provided through written messages within the secure platform. Therapists are trained CBT-psychologists.
2563622|NCT02474888||Rituximab|a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/m² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.
2563671|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY - PBEA|Endodontic surgery 15 teeth - PBEA
2563675|NCT02474615|Experimental|TOOTH ENDODONTIC SURGERY -MTA|Endodontic surgery 15 teeth - MTA
2563706|NCT02474238|Experimental|The sequential technique|By using the double frequency YAG laser to make the initial bore and the Nd:YAG laser to complete the perforation on iris.
2563708|NCT02474238|Active Comparator|The pure Nd:YAG laser technique|By using the pure Nd:YAG to make a complete perforation on iris.
2563756|NCT02473978||Participants undergoing cesarean sections|The participants preoperative data will be compared to intraoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
2563759|NCT02473978||Participants throughout cesarean sections|The participants intraoperative data will be compared to preoperative data and analyzed in order to evaluate the dynamic cerebral oxygen and blood perfusion changes in participants undergoing cesarean sections.
3206955|NCT00959738|Other|A|diverting loop ileostomy with rod
2563869|NCT02473159|Experimental|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
3206956|NCT00959738|Other|B|diverting loop ileostomy without rod
3206957|NCT00959777|Experimental|DA-3031|
3206958|NCT00959777|Active Comparator|filgrastim|
3206959|NCT00959790|Experimental|High vegetable dose|Consumption of 200 grams of vegetables daily, for four weeks.
3206960|NCT00959790|Experimental|Low vegetable dose|Consumption of 50 grams of vegetables daily, for four weeks.
3206961|NCT00959790|Active Comparator|Weight loss interventio|Consumption of - 1000 kcal daily, for four weeks to be used as a positive control for the vegetables interventions.
3206962|NCT00959803|Experimental|Single dose|3 way crossover with randomized placebo substitution to evaluate single escalating oral doses of PF 04447943 in 9 healthy young adult subjects.
3206963|NCT00959803|Experimental|Multiple dose|3:1 active PF 04447943 to placebo randomization in 8 healthy elderly subjects.
3206964|NCT00959816|Experimental|Single Dose (Part 1)|
3206965|NCT00959816|Experimental|Multiple Dose (Part 2)|
3206966|NCT00959829|Placebo Comparator|silence|"The control group listened silence and was evaluated the same things."
2563037|NCT02479126||Interstitial Lung Disease|Patients will be identified from a specified 5 year period based on an International Classification of Diseases-9 (ICD-9) code diagnosis of Interstitial Lung disease (515) or Idiopathic Pulmonary Fibrosis (516.3). The patients will be obtained from the records of the Veterans Integrated Service Network (VISN) 6: VA Mid-Atlantic Health Care Network.
3206967|NCT00959855|Experimental|Pulmonary Rehabilitation|Pulmonary rehabilitation classes based on the British Thoracic Society guidelines will be undertaken for two hours for 16 sessions within an eight week period.
3206968|NCT00959855|No Intervention|Pulmonary Rehabiliation|The control group will be assessed in the same time frame without participating in the rehabilitation class. They will avail of the next available class after the 12 month assessment.
2563214|NCT02477514|Experimental|Experimental Arm|Day 1: participants will receive midazolam (2 mg); Day 3: participants will receive rosuvastatin (10 mg); Days 5-13: participants will receive tedizolid phosphate (200 mg); Day 14: participants will receive tedizolid phosphate (200 mg) plus midazolam (2 mg); Day 15: participants will receive tedizolid phosphate (200 mg); Day 16: participants will receive tedizolid phosphate (200 mg) plus rosuvastatin (10 mg); Day 17: participants will receive tedizolid phosphate (200 mg)
3206969|NCT00959881|Experimental|Donepezil plus placebo|
3206970|NCT00959881|Experimental|Donepezil plus begacestat|
3206971|NCT00959933|Experimental|1|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
3206972|NCT00959933|Active Comparator|2|Rebetol 200 Capsules (Schering Corporation, U.S.A.)
3206973|NCT00959959|Experimental|650 mg TOK-001|
3206974|NCT00959959|Experimental|1300 mg TOK-001|
3206975|NCT00959959|Experimental|1950 mg TOK-001|
3206976|NCT00959959|Experimental|975 mg TOK-001|
2563516|NCT02475486|Other|high fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is > 5
2563519|NCT02475486|Other|low fatigue|Measure of ANS by VistaO2 device in Rheumatoid arthritis (RA) patients with low disease activity according to DAS28 <3.2 with visual analog scale of fatigue is < or equal to 5
3206977|NCT00959959|Experimental|975 mg TOK-001, supplement|
2563592|NCT02474966|Experimental|Real-Sham dTMS|This arm will be treated before with real deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with sham dTMS (the second day)
2563595|NCT02474966|Experimental|Sham-Real dTMS|This arm will be treated before with sham deep Transcranial Magnetic Stimulation (dTMS) (the first day) and after with real dTMS (the second day)
2563645|NCT02474797|Experimental|Diaphragmatic ultrasonography in septic patient|Diaphragmatic Thickening Fraction
2563705|NCT02474394|Active Comparator|Mcgrath|The endotracheal intubation will be provided using Mcgrath series 5 video laryngoscope
2563709|NCT02474394|Active Comparator|Macintosh|The endotracheal incubation will be provided using macintosh laryngoscope
3206978|NCT00959959|Experimental|1950 mg TOK-001, split dose|
3206979|NCT00959959|Experimental|2600 mg TOK-001|
2563857|NCT02473198|Active Comparator|Femoral Nerve Block (Group 1)|"In group1 (standard group) all patients receive the standard current perioperative pain management protocol for TKR.~The patient will then undergo an ultrasound guided femoral nerve block with bupivacaine 0.25% 20 cc. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint. Postoperatively patients will receive narcotic pain medication on a PRN basis."
2563858|NCT02473198|Experimental|Exparel (Group 2)|Group 2 will receive standard perioperative pain management for TKR; will undergo placebo femoral nerve block under ultrasound guidance with normal saline (NS) 20 cc. Following femoral bone cuts they will receive local anesthetic injection mixture of 30cc 0.25% bupivicaine with epinephrine 20 cc of preservative free normal saline, 30mg of toradol and 10 mg of morphine sulfate into the periarticular tissues including periosteum, joint capsule and posterior capsule of the knee joint and collateral ligaments and subcutaneous tissues. Prior to cementing prosthesis, a second injection with mixture of 20mL 1.3% Exparel and 40mL normal saline solution will be injected into the same tissues, joint capsules and collateral ligaments.
2563887|NCT02472873|Experimental|study group - sclerotherapy|Aspiration and Sclerotherapy of endometriomas.
2563889|NCT02472873|Other|control group - cystectomy|cystectomy of endometriomas.
3206980|NCT00959959|Experimental|2600 mg TOK-001, split dose|
2564024|NCT02472093|Active Comparator|Physical exercises treatment|The types of exercises included: low-impact to moderate aerobic training (gradually starting from 50% of the Fc max to 70%-80% of Fc max); walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing.
3206981|NCT00959972|Experimental|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
2566618|NCT02455258|Active Comparator|Aerobics Exercise (AE)|
3206982|NCT00959972|Experimental|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
3206983|NCT00959998|Active Comparator|Relaxation acupressure|
3206984|NCT00959998|Experimental|High Intensity Stimulating Acupressure|
3206985|NCT00959998|Experimental|Low Intensity Stimulating Acupressure|
3206986|NCT00960024|Experimental|Individual Placement and Support-vocational rehabilitation|
3206987|NCT00960024|Active Comparator|Vocational rehabilitation available at study site|
3206988|NCT00960037|Experimental|Vitamin D|Vitamin D3 supplementation based on baseline 25(OH)D level
3206989|NCT00960037|Placebo Comparator|Placebo|
3206990|NCT00960089|Experimental|LIQUICURE|Medical Device
3206991|NCT00960102|Active Comparator|bilateral cochlear implant|
3206992|NCT00960102|Active Comparator|cochlear implant and hearing aid|
3206993|NCT00960102|Active Comparator|bilateral hearing aid|
3206994|NCT00960128||A|Adult cohort
3206995|NCT00960128||B|Paediatric cohort
2563043|NCT02478866|Experimental|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg, 600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
2563146|NCT02478177||Stroke|Patients who had an acute ischemic stroke while taking one of the novel oral anticoagulants or patients who had an intracerebral hemorrhage while taking warfarin or one of the novel oral anticoagulants
2563188|NCT02477826|Experimental|Arm A: Nivolumab|Nivolumab intravenously (IV) as specified
2563191|NCT02477826|Experimental|Arm B: Nivolumab + Ipilimumab|Nivolumab + Ipilimumab IV as specified
2563193|NCT02477826|Experimental|Arm C: Nivolumab + Platinum doublet chemotherapy|Nivolumab + Platinum doublet chemotherapy (IV) dose as specified
2563194|NCT02477826|Experimental|Arm D: Platinum doublet chemotherapy|Chemotherapy administered on specified days of IV chemotherapy
3206996|NCT00960167|Experimental|Dose Level I|42 Gy in 12 fractions.
3206997|NCT00960167|Experimental|Dose Level II|49 Gy in 14 fractions.
2563551|NCT02475343|Experimental|Control|People without keratoconus, history of ocular surgery, and other diseases mentioned in exclusion criteria. Normal people will receive treatment or measurement including: Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking, Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination.
2563553|NCT02475343|Experimental|Keratoconic patients|Patients with keratoconus.Keratoconic patients will receive treatment or measurement including:Schiotz tonometer measurement, UVA/riboflavin corneal crosslinking,Ocular morphology measurement,and routine ophthalmic examination.
2563555|NCT02475343|Experimental|Patients received keratoplasty|Patients received keratoplasty. Patients received keratoplasty will receive treatment or measurement including:Schiotz tonometer measurement,Keratoplasty, Ocular morphology measurement,and routine ophthalmic examination..
2563614|NCT02474940|Experimental|Intervention #1|NF-HYP
2563617|NCT02474940|Experimental|Intervention #2|MM-HYP
2563621|NCT02474940|Experimental|Intervention #3|HYP-ONLY
2563656|NCT02474602|Experimental|Group A - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group A, received program 1 before strength training, and the same program 1 after training."
2563661|NCT02474602|Experimental|Group B - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 1 before strength training, and program 2 after training."
2563666|NCT02474602|Experimental|Group C - Active or Placebo Phototherapy|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group C, received program 2 before strength training, and program 1 after training."
2563668|NCT02474602|Experimental|Group D - Active or Placebo Phototherapy'|"The phototherapy was divided in program 1 and program 2. One of these programs consisted in active phototherapy and the other placebo.~The subjects allocated in group B, received program 2 before strength training, and the same program 2 after training."
2563691|NCT02474290|Experimental|Sorafenib group|Sorafenib will be used from day 30 to 180 post-transplantation.
2563695|NCT02474290|No Intervention|non-Sorafenib group|
2563752|NCT02474056||trauma patients|patients with decreased blood volume
2563754|NCT02474056||surgical patients|patients with decreased blood volume
2563758|NCT02474056||non surgical patients|patients with decreased blood voloume
2563794|NCT02473731|Experimental|A|Treatment with KTN3379 in HPV positive head and neck cancer patients
2563798|NCT02473731|Experimental|B|Treatment with KTN3379 in HPV negative head and neck cancer patients
2563932|NCT02472990|Other|Duchenne muscular dystrophy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
2563934|NCT02472990|Other|Healthy children|"No drug and no placebo were used in this study. For 2h30 (time)~Measurement of leg strength using a dynamometer~Measurement of Motor Function~Walk test 6 minutes~Walk test 10 meters~Walk analysis: 3D recording of walking~Muscle MRI"
3206998|NCT00960167|Experimental|Dose Level III|56 Gy in 16 fractions.
3206999|NCT00960167|Experimental|Dose Level IV|63 Gy in 18 fractions.
3207000|NCT00960180|Experimental|1|
3207001|NCT00960180|Placebo Comparator|2|
2564076|NCT02471742||NAC-PC|patients treated with neoadjuvant chemotherapy and NAC-sparing mastectomy
2564082|NCT02471742||NAC|patients treated NAC-sparing mastectomy and adjuvant therapy
2564090|NCT02471742||PC|patients treated with neoadjuvant chemotherapy and conventional mastectomy
2564124|NCT02471417|Experimental|Nitrate rich beetroot juice|Concentrated, beetroot juice is a rich source of dietary nitrate.
3207002|NCT00960219|Experimental|DAAOI-1|
3207003|NCT00960219|Placebo Comparator|placebo|
3207004|NCT00960232|Experimental|Vitamin D|vitamin D 40.000 IU per weel
3207005|NCT00960232|Placebo Comparator|Placebo|Placebo
3207006|NCT00960245|Experimental|1|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)
3207007|NCT00960245|Active Comparator|2|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
3207008|NCT00960258|Experimental|Arm 1|
3207009|NCT00960271||NON SMALL CELL LUNG CANCER|Non small cell lung cancer, with clinical N2 disease, otherwise operable.
3207010|NCT00960284|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
2563105|NCT02478385|Active Comparator|Birth environment labour room|Supportive care of labour room designed with special attention on sound and light effects, covering medical devices and insulation from outside noise
2563108|NCT02478385|Placebo Comparator|Labour in a standard labour room|The woman gives labour in a standard labour room
3207011|NCT00960284|Experimental|Arm II|Patients receive cisplatin IV over 1 hour and epirubicin hydrochloride IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Patients also receive fluorouracil IV continuously beginning on day 1 or oral capecitabine. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
2563220|NCT02477501|Active Comparator|Ephedrine|A continuous Ephedrine infusion at 10 mcg/kg/min
2563224|NCT02477501|Active Comparator|Norepinephrine|A continuous Norepinephrine infusion at 0.1 mcg/kg/min
2563258|NCT02477280|Experimental|Methylphenidate|Methylphenidate 20 mg Tablet single-dose per os
2563263|NCT02477280|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
2563291|NCT02477007|Experimental|Ibuprofen+placebo of paracetamol|Patients will receive in addition to morphine (usual care) ibuprofen and placebo of paracetamol
2563292|NCT02477007|Experimental|Paracetamol + placebo of ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and placebo of ibuprofen
2563294|NCT02477007|Experimental|Paracetamol + ibuprofen|Patients will receive in addition to morphine (usual care) paracetamol and ibuprofen
2563302|NCT02477007|Placebo Comparator|Placebo of paracetamol + placebo of ibuprofen|Patients will receive morphine alone(usual care).
2563344|NCT02476604|Experimental|Electronic Messaging|Subjects randomized to the intervention arm will receive health coaching and electronic messages at the rate of up to six times per week over an 8 week period.
2563347|NCT02476604|No Intervention|Control|Subjects randomized to the control arm will undergo all of the same measurements for baseline and follow up data but will not receive the intervention of health coaching and electronic messaging.
2563419|NCT02476370|No Intervention|Usual care|Does not receive a specific study intervention
2563425|NCT02476370|Experimental|preoperative relaxation program|preoperative relaxation program
2563428|NCT02476370|Experimental|preoperative surgery education|single education unit to understand the complete surgical procedures
2563431|NCT02476370|Experimental|preoperative relaxation program+preoperative surgery education|preoperative relaxation program AND single education unit
2563567|NCT02475148|Experimental|Part 1: Cohort 1|Participants will receive either JNJ-54175446 0.5 milligram (mg) or placebo on Day 1.
2563568|NCT02475148|Experimental|Part 1: Cohort 2|Participants will receive either JNJ-54175446 2.5 mg or placebo on Day 1.
2563569|NCT02475148|Experimental|Part 1: Cohort 3|Participants will receive either JNJ-54175446 10 mg or placebo on Day 1.
2563573|NCT02475148|Experimental|Part 1: Cohort 4|Participants will receive either JNJ-54175446 30 mg or placebo on Day 1.
2563577|NCT02475148|Experimental|Part 1: Cohort 5|Participants will receive either JNJ-54175446 100 mg or placebo on Day 1.
2563580|NCT02475148|Experimental|Part 1: Cohort 6|Participants will receive either JNJ-54175446 200 mg or placebo on Day 1.
2563587|NCT02475148|Experimental|Part 2: Cohort 7|Participants will receive JNJ-54175446 on Day 1. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
2563590|NCT02475148|Experimental|Part 3: Cohort 8|Participants will receive JNJ-54175446 on Day 1 along with high fat/high calorie breakfast. The dose of JNJ-54175446 will be determined in part 1 as suitable dose.
2563702|NCT02474485|Active Comparator|BVS - Absorb|"BVS - Absorb scaffold group will be treated by implantation of drug eluting bioresorbable vascular scaffold (Absorb®). In this arm following interventions will be performed:~BVS Absorb implantation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
2563703|NCT02474485|Active Comparator|DEB - Sequent Please|"In DEB - Sequent Please Group, dilatation of drug eluting balloon Sequent Please ® will be used for treatment of the narrowed part of the artery. In this arm following interventions will be performed:~DEB Sequent Please inflation. For in stent restenosis treatment during index procedure.~OCT visualization.During index procedure and at 9 month follow-up.~Control coronary angiography. Control angiography will be performed at 9 month follow-up.~Clinical observation. Clinical observation will be performed at 9, 12 and 60 month follow-up."
3207012|NCT00960310|Experimental|1|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
3207013|NCT00960310|Active Comparator|2|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
2563813|NCT02473432|Experimental|RMT + usual care|Device: Orygen-Dual® valve trainer Intensity: 30% of maximal respiratory pressures (increasing intervals: 10 cmH2O per week) Training schedule: 5 sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, two sessions per day, 5 days per week, for 3 weeks.
2563814|NCT02473432|Experimental|NMES + usual care|Device: Vital Stim (Chattanooga Group, Hixson, TN, USA) Administration of 80 Hz transcutaneous electrical biphasic stimulus Schedule: 40 minutes per day, 5 sessions per week during hospitalization in the Neurorehabilitation ward (3 weeks approx).
2563815|NCT02473432|Active Comparator|Usual care|Usual care (standard multidisciplinary inpatient rehabilitation program) consisting of physical, occupational and speech therapy sessions to improve activities of daily life, mobility and communication skills (minimum 3 hours per day, 5 days a week, during 3 weeks), Standard swallow therapy (usual care of dysphagia in stroke patients) consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
2563867|NCT02473172|Experimental|Pressure Support Ventilation|Assisted mechanical ventilation
2563868|NCT02473172|Experimental|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
3207014|NCT00960336|Experimental|single arm|
3207015|NCT00960349|Other|Treatment A|Cediranib 20mg + Cisplatin + S-1
3207016|NCT00960349|Other|Treatment B|Cediranib 20mg + Cisplatin + Capecitabine
2564048|NCT02471976|No Intervention|Group A|the centres applies their usual practices
3207017|NCT00960362|Placebo Comparator|A|
3207018|NCT00960362|Experimental|B|Intravenous cohort 1; 0.01 mg/kg
2563172|NCT02477878|Experimental|BPX-501 and Rimiducid|"All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).~Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion."
2563202|NCT02477592|Experimental|Individualized substrate modification|Circumferential pulmonary vein isolation(CPVI) ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by Individualized substrate modification.
2563205|NCT02477592|Active Comparator|Stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
2563251|NCT02477397|Experimental|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
2563256|NCT02477397|Active Comparator|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
2563301|NCT02477059|Experimental|tocilizumab|2 infusions four weeks apart
2563322|NCT02477059|Placebo Comparator|saline solution|2 infusions four weeks apart
2563380|NCT02476682||Normal subjects|blood or stool samples will be collected from people referred for screening colonoscopy
2563383|NCT02476682||Colorectal cancer|blood or stool samples will be collected from people with colorectal cancer detected at colonoscopy or resection
2563384|NCT02476682||Polyps <10mm and no high risk features|blood or stool samples will be collected from people with no polyps or low risk polyps (<10mm, no villous component or dysplasia) detected at colonoscopy
2563385|NCT02476682||Advanced Mucosal Neoplasia|blood or stool samples will be collected from people with AMN detected at resection
2563387|NCT02476682||Sessile Serrated Adenoma|blood or stool samples will be collected from people with SSP detected at resection
2563388|NCT02476682||non-colorectal neoplastic disease|Participants with disease that is not colorectal neoplasia. Analysis of this cohort is not a primary endpoint but the investigators will report assay positivity in this group on an opportunistic basis. This cohort will include patients diagnosed with, for example, inflammatory bowel disease or extracolonic cancer.
2563429|NCT02476214|Experimental|Intervention group|Group prenatal care- receiving prenatal care through a group
2563432|NCT02476214|No Intervention|Control group|Individual prenatal care - receiving regular individual prenatal care
2563482|NCT02475967|Experimental|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.
2563484|NCT02475967|Active Comparator|Control group|The control group patients receive conventional cardiac care alone.
2563523|NCT02475551|Experimental|Treatment|IdeS as a single infusion
2563575|NCT02475239|Experimental|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
2563579|NCT02475239|Active Comparator|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
2563639|NCT02474849|Active Comparator|Conventional cigarette|
2563643|NCT02474849|Experimental|First-generation e-cigarette|
2563647|NCT02474849|Experimental|Rechargeable cig-like e-cigarette|
2563649|NCT02474849|Experimental|Closed modular system e-cigarette A|
2563651|NCT02474849|Experimental|Closed modular system e-cigarette B|
3207019|NCT00960362|Experimental|C|Intravenous cohort 2; 0.1 mg/kg
2563952|NCT02472561|Experimental|Mobile Health Application Group 1|"Participants will wear a Fitbit Physical Activity Monitor to objectively quantify physical activity patterns. Once a week (± 3 days) during the 12 week mHealth intervention patients will measure and download their blood pressure and blood glucose (if diabetic) by means of a mHealth blood pressure cuff and mHealth glucometer. Medication adherence will be measured at baseline and 12-weeks by the Morisky Medication Adherence Scale-8 (MMAS-8) questionnaire. Each participant will be provided with a electronic version of the book titled, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease; patients will be asked to read approximately one chapter per week for educational purposes."
2563954|NCT02472561|No Intervention|Usual Care Group 2|"Participants will follow standard care as ordered by their individual, treating physician. Each participant will be given a paperback copy of the book, Your COMPLETE and EASY GUIDE to Understanding Peripheral Artery Disease. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments."
2564015|NCT02472236|Experimental|Digoxin and PEX168(200µg)|Digoxin: 0.5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
2564110|NCT02471547|No Intervention|TURBT ONLY|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
2564111|NCT02471547|Experimental|BWT with Mitomycin-C prior TURBT|"A total of 150 patients in this arm will be divided into five follow-up sub groups according to pathology reports.~Group 1 - Primary Low risk patients Group 2 - Primary Intermediate risk patients Group 3 - Primary High risk patients Group 4 - Recurrent Intermediate risk patients Group 5 - Recurrent Intermediate risk patients"
2564152|NCT02471209||Biliary Atresia Infants|Twenty-five infants diagnosed with Biliary Atresia and undergoing surgery were included in the study (age range 1-3 months). Inclusion criteria were persistent yellow skin or sclera, pale stool (in severe cases, clay-like), and hepatomegaly; increased serum bilirubin (progressively or no decline after increase), increased total bilirubin (TBil) dominated by increased direct bilirubin (DBil) (>60%); elevated liver enzymes; ultrasound confirmation of poor gallbladder filling and signs of liver fibrosis; with radionuclide imaging confirmation of obstructed biliary excretion. Infants were excluded if they had concomitant cardiovascular or abdominal organ malformations.
2564176|NCT02470858|Experimental|LDV/SOF+ASV|Participants with genotype 1b HCV infection will receive LDV/SOF FDC + ASV 3 weeks.
3207020|NCT00960362|Experimental|D|Intravenous cohort 3; 0.6 mg/kg
2563218|NCT02477748|Active Comparator|MDX|Metadoxine Immediate-release/slow-release, bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.; alternative name: MG01CI.
2563221|NCT02477748|Placebo Comparator|Placebo|Inert tablets
2563274|NCT02477150|Active Comparator|SLE (vaccine)|Zostavax SC injection (0.65ml)
2563275|NCT02477150|Placebo Comparator|SLE (placebo)|Placebo SC injection (normal saline 0.65ml)
2563360|NCT02476773|Experimental|Group 1|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563361|NCT02476773|Experimental|Group 2|"5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 10µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563367|NCT02476773|Experimental|Group 3|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563372|NCT02476773|Experimental|Group 4|"5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 30µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563375|NCT02476773|Experimental|Group 5|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563378|NCT02476773|Experimental|Group 6|"5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with Sterile Saline Placebo administered to the alternate arm.~5 subjects will receive 100µg Na-APR-1 (M74)/Alhydrogel plus GLA-AF, with 100µg Na-GST-1/Alhydrogel plus GLA-AF administered to the alternate arm."
2563438|NCT02476162||Group 1: Daily for 3 Months|Participants randomly assigned to this group will be instructed to measure their blood pressure (BP) every day during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
2563439|NCT02476162||Group 2: Daily for 1 Week/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
2563444|NCT02476162||Group 3: 3 Consecutive Days Once/Month|Participants randomly assigned to this group will be instructed to measure their BP for seven consecutive days once each month during the 3-month study period. BP reading will be taken using an iHealth Wireless Blood Pressure Monitor.
2563486|NCT02475785|Experimental|FFRD and mini plates group|"Upper will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~2 Y shaped mini plates will be inserted in the mandibular symphysis Insertion of the FFRD with Direct application over the mandibular mini plates"
2563488|NCT02475785|Active Comparator|conventional FFRD|"Upper and lower arches will be bonded, levelled and aligned until reaching 0.019 x 0.025 ss archwires.~Insertion of FFRD with application over the lower archwire"
2563490|NCT02475785|No Intervention|untreated control group|Patients will be observed for an average duration of 6-8 months
2563544|NCT02475460|Experimental|HM 3 LIS|All patients implanted with the HM 3 LVAD via less invasive surgical technique
2563594|NCT02475122|Other|open-label study|open-label study
2563650|NCT02474810|Experimental|Intensive|In the Intensive Protocol, alteplase intervention is administered to all catheters based on blood flow and/or line reversal
2563654|NCT02474810|Experimental|Standard|In the Standard Protocol, alteplase intervention is administered to all catheters based only on blood flow.
2563712|NCT02474316|Experimental|PegINF plus nucleos(i)de analgoue|Peginterferon alfa-2a 180μg /wk plus nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
2563716|NCT02474316|Active Comparator|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece qd for 48 weeks
2563745|NCT02473874||Skin Spect dermoscope|Skin mole
2563748|NCT02473874||Spatially modulated quantitative|Skin mole
3207021|NCT00960362|Experimental|E|Intravenous cohort 4; 3.0 mg/kg
3207022|NCT00960362|Experimental|F|Intravenous cohort 5; 10 mg/kg
2563891|NCT02473094|Experimental|Neoadjuvant capecitabine and metformin|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Metformin 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
2563893|NCT02473094|Placebo Comparator|Neoadjuvant capecitabine and placebo|"Capecitabine 825 mg/m2 bid D1-5, q7d, for five weeks;~Placebo 2500mg/d for five weeks;~3D radiotherapy 50,4Gy divided in 25 fractions"
2563962|NCT02472548|Experimental|Group A, DPX-RSV(A) low dose (Step 1)|
2563965|NCT02472548|Experimental|Group B, RSV(A)-Alum low dose (Step 1)|
2563969|NCT02472548|Experimental|Group D, DPX-RSV(A) high dose (Step 2)|
2563972|NCT02472548|Experimental|Group E, RSV(A)-Alum high dose (Step 2)|
2563973|NCT02472548|Placebo Comparator|Group C & F, Placebo control (Step 1 and 2)|
3207023|NCT00960362|Experimental|G|Intravenous cohort 6; 30 mg/kg
3207024|NCT00960401||cardiac counseling|10 left sided breast cancer patients 10 right sided breast cancer patients
3207025|NCT00960401||coronary artery evaluation|10 left sided breast cancer 10 right sided breast cancer
3207026|NCT00960414|Experimental|SHINE A|
3207027|NCT00960414|Active Comparator|SHINE B|
3207028|NCT00960453|Other|Sitagliptin 25mg|Repeated administrations for 4 days
3207029|NCT00960453|Other|Sitagliptin 50mg|Repeated administrations for 4 days
3207030|NCT00960453|Other|Sitagliptin 100mg|Repeated administrations for 4 days
3207031|NCT00960466|Active Comparator|Usual Care Arm|The usual care group will receive their Chemotherapy or Radiotherapy as normal.
3208864|NCT00978835|Experimental|Nurse case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
3208865|NCT00978835|Active Comparator|Nurse Education|Didactic, non-interactive education by a nurse on general health topics.
2563235|NCT02477449|Experimental|high dose group|12 subjects in 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects). All the subjects were given infusion of study drugs for 24 hours, and then were observed for 48 hours in the clinic.
2563267|NCT02477228|Active Comparator|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
2563269|NCT02477228|Active Comparator|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
2563295|NCT02476942||Cohort A: Adults and Adolescents with FVIII Inhibitors|Adults and adolescents with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
2563303|NCT02476942||Cohort B: Children with FVIII Inhibitors|Children with hemophilia A of any severity with the presence of FVIII inhibitors will be observed.
2563323|NCT02476942||Cohort C: Adults and Adolescents without FVIII Inhibitors|Adults and adolescents with severe hemophilia A without the presence of FVIII inhibitors will be observed.
3207032|NCT00960466|Experimental|DT&PL arm|"During the second week of radiotherapy/second cycle of chemotherapy, patients in the Distress Thermometer and Problem List (DT&PL) arm of the study will complete the DT&PL (estimated 15 minutes to complete) with the trained radiographer/nurse.~The DT&PL assessment will be repeated at the end of therapy fractions/cycles. This will elicit concerns about post-therapy issues and facilitate continuity of care between the cancer team and primary care. Depending on the duration of therapy, therapists may choose to use the DT&PL at other points during patient care. A copy of the DT&PL will be stored in the medical record to track the frequency of use and to check that those assigned to usual care were not monitored with the DT&PL."
3207033|NCT00960479|Experimental|1|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
3207034|NCT00960479|Active Comparator|2|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
3207035|NCT00960492|Experimental|Arm 1|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent during the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase.
3207036|NCT00960492|Experimental|Arm 2|XL184 will be initiated during the maintenance phase with TMZ
3207037|NCT00960492|Experimental|MTD Expansion|XL184 will be initiated at the start of the 6-7 week concurrent phase of RT (+TMZ; some subjects found to have specific gene activity in their tumor tissue may not receive TMZ), given as a single agent in the rest phase (4 weeks), if applicable, and continued subsequently in the maintenance phase. Subjects in this group will receive XL184 and TMZ at the maximally tolerated dose levels determined in Arms 1 and 2.
3207038|NCT00960518|Placebo Comparator|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
2563536|NCT02475447|Placebo Comparator|Placebo|Placebo-matched tablets twice daily for 4 weeks.
2563537|NCT02475447|Experimental|Asimadoline|Asimadoline tablets twice daily (5 mg total daily dose) for 8 weeks.
3207039|NCT00960518|Experimental|TACE+adefovir|patients received adefovir, at a dose of 10 mg daily after TACE treatment, for 48 weeks
3207040|NCT00960544|Experimental|Capecitabine|Capecitabine - Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
2563628|NCT02474732|Other|Usability|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
3207041|NCT00960557|Experimental|Combretastatin A1 Diphosphate|
3207042|NCT00960583|Experimental|Exercise program|"Exercise program comprising muscle strengthening, cardiovascular training and stretching exercises.~Program duration : 12 weeks Sessions frequency : twice per week Session duration : 1h30"
3207043|NCT00960583|Active Comparator|Routine follow-up|Routine follow-up after functional multidisciplinary rehabilitation by attending physician (Advice to stay active)
2563802|NCT02473692||Online MigraineTreatment Optimization|After providing informed consent, participants will complete a series of questionnaires related to their headaches and medication beliefs. After completion, they will have full access to an informational website including access to text-based supplemental materials pertaining to headache and headache treatment, and a series of videos designed specifically for this trial. Participants will be asked to watch seven videos of approximately four-minute length each and to complete a post-assessment question following the completion of each of the first 6 videos. The total time required to complete all study activities will be approximately one hour.
3207044|NCT00960609||caval confluence HV involvement|Patients carriers of primary or metastatic tumour with direct contact or invasion of one HV at the caval confluence.
3207045|NCT00960635|Active Comparator|calcitriol|
3207046|NCT00960635|Placebo Comparator|pill without agent|
3207047|NCT00960648||Xience/Promus|Active prospective registration of patients receiving everolimus eluting stent
3207048|NCT00960648||Cypher|Retrospective historical controls that received sirolimus-eluting stent
3207049|NCT00960674|Experimental|Tactile massage|A gentle form of massage given once a week for three weeks
3207050|NCT00960674|Experimental|Relaxation|Relaxation (by the use of a CD with relaxation exercises used at least once a week for 10 weeks)
3207051|NCT00960713||The RITAI cohort|Every patient treated by rituximab off-label for auto-immune diseases in the public hospitals of the Midi-Pyrénées County (South of France) is eligible for the study, whatever the dose and planned infusions number. The enrolment is definitive when the first rituximab infusion begins. Follow-up visits are planned at months 1, 3, 6, 12 and 18 after the first infusion. At each visit, the investigators will record the adverse events that have occurred since the last visit. Serious or unexpected adverse events will be systematically monitored and declared to the Department of Pharmacology Pharmacovigilance unit and to Health Authorities (AFSSAPS). Imputability will be quoted according to the French method. A biological collection will be constituted to allow pharmaco-immunological studies.
3207052|NCT00960726|Experimental|NOV-002|
3208866|NCT00978848||Women seeking emergency contraception|Women seeking emergency contraception
3172154|NCT00596531|Active Comparator|A|"Subjects will take acamprosate (Campral) at a dose of 666 mg. three times daily (morning, lunch time, bed time) for 28 days. Only responders will be included in the subsequent double-blind cross over arms after a minimum washout period of 4 weeks.~Subjects will randomly be assigned to Group 1 (A/B) or Group 2 (B/A) after completion of Phase I and its subsequent washout period (Figure 1, periods 1 and 2). Group 1 will receive acamprosate (Campral) at a dose of 666 mg. three times daily for 24 weeks followed by a 4-week washout period"
2563296|NCT02477085||all women with an induced labor|prospective population-based cohort of all women who have an induced labor during one month in seven perinatal networks
2563366|NCT02476760||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
2563371|NCT02476760||Treated with insulin|Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
2563373|NCT02476760||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
2563377|NCT02476760||Treated with a single oral agent|Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
2563381|NCT02476760||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.
2563460|NCT02475876|Other|clindamycin|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
2563463|NCT02475876|Other|trimethoprim-sulfamethoxazole|Each subject will be assigned to study drug (clindamycin or TMP-SMX) at the discretion of the treating clinician. The dose and dosing interval of study drug are dictated by this protocol (see interventions).
2563501|NCT02475577|Experimental|Control|Control: Peripherals with HealthInterlink technology will record and transmit data, without intervention. Subject is able to view graphed data, bring the HealthInterlink tablet/smartphone to the physician's office and share data with family/other caregiver.
2563503|NCT02475577|Experimental|Intervention 1|Intervention 1: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver.
2563506|NCT02475577|Experimental|Intervention 2|Intervention 2: Peripherals with HealthInterlink technology will record and transmit data and send out-of-range data (Red) alerts to subject via HealthInterlink tablet/smartphone and also text/email to family/other caregiver, and nonconformity (Blue) alerts to subject's personal text/email and also text/email to family/other caregiver, and a call will be placed by the nurse research assistant to study subject (on Blue alerts) or study subject's healthcare professional (on Red alerts). The physicians will have access to the subject's data on a web-based program.
2563582|NCT02475252|Active Comparator|Experts|Surgically experienced gynecologists with a personal history of at least 50 hysteroscopy procedures will perform a hysteroscopy on a training model.
2563586|NCT02475252|Experimental|Novices|Medical students will perform a hysteroscopy on a training model.
2563655|NCT02474862|Experimental|Prenatal Walking Program|The Prenatal Walking Program (PWP) is a gentle walking intervention tailored for pregnant women. The PWP intervention consists of 3 components: 1) biweekly session with a study interventionist; 2) the use of activity monitors to increase motivation and self-monitoring; 3) incentives to promote intervention adherence.
2563660|NCT02474862|Active Comparator|Postpartum Prep Program|In the Postpartum Prep Program control condition (PPP) participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn wellbeing.
2563297|NCT02477098|Experimental|Pre RSB|patients who receive preoperative rectus sheath block of ropivacaine hydrochloride and receive postoperative rectus sheath block of saline
2563306|NCT02477098|Experimental|Post RSB|patients who receive preoperative rectus sheath block of saline and receive postoperative rectus sheath block of Ropivacaine hydrochloride
2563363|NCT02476656||GPNC|CenteringPregnancy group prenatal care
2563368|NCT02476656||IPNC|Individual prenatal care
2563408|NCT02476331|Experimental|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
2563413|NCT02476331|No Intervention|Control|The control group will wait 10-weeks, during which they will receive treatment-as-usual (TAU), which might involve pharmacotherapy, psychotherapy, or both. After the 10-week waiting period, participants will complete post-testing assessments.
2563466|NCT02475993|Experimental|SMART app|SMART, a mobile phone-based self-monitoring service to enhance outpatient treatment in chronic illness will be tested for its utility to help reduce acute care utilization rates for patients given SMART following acute care visits at the Sickle Cell Day Hospital. SMART will enable symptom monitoring with a particular emphasis on pain measures, co-symptoms, and related interventions aided by provider daily monitoring and support guided by patient report via SMART to provide a Sickle Cell Disease Information interchange (SCDi) service. Instead of using their current routine of triaging phone messages daily, assessing patients' need for intervention, providers will instead monitor patients' entries via SMART daily.
2563468|NCT02475993|No Intervention|Standard of care control group|The control group will get standard of care, including a printed plan for medications to be taken, phone number to call for questions or issues, and the return date for visit
2563538|NCT02475681|Active Comparator|Obinutuzumab in Combination with Chlorambucil|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. Chlorambucil will be orally administered on Days 1 and 15 of Cycles 1 through 6.
2563539|NCT02475681|Experimental|Acalabrutinib in Combination with Obinutuzumab|Obinutuzumab IV infusions will be administered over a total of 6 treatment cycles. ACP-196 will be orally administered starting on Cycle 1 Day 1. Daily administration of ACP-196 will continue until disease progression or unacceptable toxicity.
2563540|NCT02475681|Experimental|Acalabrutinib Monotherapy|Acalabrutinib will be orally administered on Cycle 1 Day 1 until disease progression or unacceptable toxicity.
2563697|NCT02474212|Active Comparator|Enoxaparin 40 mg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
2563698|NCT02474212|Active Comparator|Enoxaparin 40 mg i.v.|Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
2563699|NCT02474212|Active Comparator|Enoxaparin 0.5 mg/kg s.c.|Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
2563700|NCT02474212|Active Comparator|Enoxaparin 1 mg/kg i.v.|Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)
2563753|NCT02474004|Experimental|medial meniscus repair|patients receiving medial meniscus repair
2563757|NCT02474004|Active Comparator|medial partial meniscectomy|patients having medial partial meniscectomy
2563824|NCT02473419||Vayarin|Vayarin x 16 weeks
2563829|NCT02473419||Placebo|Placebo x 16 weeks
2563835|NCT02473419||Vayarin and Placebo|Placebo x 8 weeks and then Vayarin x 8 weeks
2563874|NCT02473081|Experimental|Minimal Psychological Intervention|Participants allocated to this group not only received the usual care as given by their family physicians, but also accepted biweekly minimal psychological intervention via telephone during six weeks.
2563877|NCT02473081|Other|Usual care|Participants in this group received usual care only.
2563897|NCT02472808|Other|cTBNA without ROSE|Patients who will undergo conventional TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
2563900|NCT02472808|Other|cTBNA with ROSE|Patients who will undergo conventional TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
2563901|NCT02472808|Other|EBUS-TBNA without ROSE|Patients who will undergo EBUS-TBNA without ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
2563903|NCT02472808|Other|EBUS-TBNA with ROSE|Patients who will undergo EBUS-TBNA with ROSE + Endobronchial biopsy + Transbronchial Lung Biopsy
3207053|NCT00960739|Experimental|Topotecan / 131-iodine MIBG association|"The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle). *~Iobenguane I 131: 444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity up to 11,100 MBq per injection. *~A dosimetry is performed during hospitalization.~A second dose of 131-iodine MIBG (maximum 11 100 MBq) is administered to D21 so as to obtain a total body irradiation of 4 Gy. *~Autologous hematopoietic stem cell transplantation : Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG.~If the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled."
3207054|NCT00960765||Roux-En-Y Gastric Bypass|
2564071|NCT02471950||Elective Cardiac surgery|Those patients scheduled for elective heart surgery requiring cardiopulmonary bypass who will be given 2.5% isoflurane while on bypass.
3207055|NCT00960765||Gastric Banding|
2564200|NCT02470767||DOAC treated patients|Patients diagnosed with Non-Valvular Atrial Fribilation at risk of stroke or systemic embolism treated in primary care centres with DOAC.
2564237|NCT02470533|Active Comparator|Transarterial chemoembolization|Chemoembolization will be performed through a transarterial route delivering drug eluting beads, i.e. hydrogel-based microspheres (Biocompatibles UK, Ltd, HepaSphere Biosphere Medical) loaded with the chemotherapeutic agent doxorubicin.
2564240|NCT02470533|Experimental|Stereotactic body radiation therapy|Risk-adapted dose prescription for delivering the highest possible tumor dose not exceeding the maximum dose in 6 fractions of 8-9 Gy, while hepatic normal tissue complication probability (NTCP) < of 5%
3207056|NCT00960765||Sucessful Response to RYGB|
2563310|NCT02476851|Experimental|Supernatant Hemoglobin|"Ensure that whole blood passed through the POLFA needle assembly (the investigational needle assembly or INA) has a supernatant hemoglobin within the acceptable range of < 100mg/dL. In instances where resulting supernatant hemoglobin levels are > 100 mg/dL for the INA, if supernatant hemoglobin levels are > 100 mg/dL for the Kawasumi needle assembly (the control needle assembly or CNA), then there would be justification for removing these data from analyses."
2563365|NCT02476708|Experimental|Curcumin 1800mg|curcumin capsule 600mg taken 3 times per day for 8 weeks
2563370|NCT02476708|Placebo Comparator|Placebo|placebo capsule taken 3 times per day for 8 weeks
2563402|NCT02476253|Experimental|Intervention|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
2563403|NCT02476253|No Intervention|Control|No intervention
2563467|NCT02476019|Experimental|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
2563469|NCT02476019|Placebo Comparator|Placebo|Placebo administered subcutaneously
3207057|NCT00960765||Failed Response to RYGB|
2563674|NCT02474511||general anesthesia|In this group，the patient is received radiofrequency ablation under general anesthesia.
2563677|NCT02474511||local anesthesia|In this group，the patient is received radiofrequency ablation under local anesthesia.
2563704|NCT02474251|Active Comparator|Group A|25 cognitively normal elderly subjects (age 55-75), newly enrolled or currently participating in R01HL118624-01 (IRB S12-03068), a 2-year longitudinal on-going study that is aimed at examining the longitudinal associations between SDB and cognitive decline in the elderly.
2563707|NCT02474251|Active Comparator|Group B|20 cognitively normal adults (age 30-75) with severe SDB (Apnea Hypopnea index [AHI]-all >30/hour) and good CPAP compliance from Mt. Sinai School of Medicnie (MSSM)
3207058|NCT00960791|Experimental|1|14C-labelled AZD1656
3207059|NCT00960817|Active Comparator|1. Routine treatment|Control group
2563855|NCT02473185|Experimental|Methylphenidate|Methylfenidate 20 mg Tablet single-dose per os
2563856|NCT02473185|Placebo Comparator|Placebo|Placebo 20 mg Tablet single-dose per os
2563896|NCT02472938|Experimental|BG00012|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
2563898|NCT02472938|Placebo Comparator|Placebo|Placebo capsules orally twice a day.
2563951|NCT02472613|Experimental|traditional acupuncture & placebo|Apply traditional acupuncture to treat the ischemic post-stroke depression according to TCM theory.
2563955|NCT02472613|Active Comparator|sham-acupoint acupuncture & fluoxetine|Fluoxetine was given at a dose of 20 mg/day. sham-acupoint will be penetrated for treat the ischemic post-stroke depression.
2564017|NCT02472197|Experimental|morcellation|
2564021|NCT02472197|Active Comparator|standard resection|
2564065|NCT02471820|Experimental|Lenalidomide, adriamycin & dexamethasone|Lenalidomide 25 mg administered orally for the first 21 days of each 28-day-cycle, plus Adriamycin i.v. on days 1,2,3 & 4 of every cycle, plus Dexamethasone 40 mg orally on days 1, 8, 15 & 22 of every cycle for 4 cycles
2564116|NCT02471248|Experimental|Ankle Robot with Power Assistance|In this experimental group, the Ankle Robot assists the ankle dorsiflexion when the stroke patients voluntarily perform the swing phase gait movement.
2564117|NCT02471248|Placebo Comparator|Sham group|In this sham group, the Ankle Robot provides very low assistance to generate tactile feedback to the stroke patients indicating they are performing the swing phase gait movement, but no assistance will be given to support their ankle dorsiflexion.
3207060|NCT00960817|Experimental|2. Dipyridamole treatment|Group that receives Dipyridamole treatment
3207061|NCT00960830|Placebo Comparator|mirtazapine|
3207062|NCT00960830|Placebo Comparator|mirtazapine, sugar pill|
3207063|NCT00960882|Experimental|DMMET-01|
3207064|NCT00960908||Resolute|Prospective recruitment of Resolute arm will start in March 2009
3207065|NCT00960908||Endeavor|The retrospective recruiting period of Endeavor arm comprises a fixed 2-year time between January 2006 and December 2008. The patients, who were treated with Endeavor in that period, will be enrolled if they agree to participate in this study.
3207066|NCT00960921|Experimental|Iron group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of iron sucrose, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
2564622|NCT02467894|Experimental|Group-based Care|Participants who are randomized to group-based care will attend monthly outpatient clinic visits as part of a group of 8-10 patients with CKD and hypertension.
2564623|NCT02467894|No Intervention|Usual Care|Participants who are randomized to usual care will see their provider on clinic days when there is no group meeting.
2564647|NCT02467725|Experimental|Dynamic Culture Platform|Embryos randomized to the dynamic arm will be placed on the NSSB-300 microvibration platform within the designated incubator. The platform will vibrate at a strength setting of 4 for 5 seconds every 60 minutes. The embryos will be placed on the platform at the two pronucleur stage of development and remain on the platform until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
2564651|NCT02467660|Experimental|Online Mindfulness Meditation Training|Weekly 1-hr online training and daily meditation for 30-45 min for 6 wks
2564652|NCT02467660|Experimental|Online Health & Wellness Education|6-week training entails completing weekly 1-hour online training and listening to educational podcasts for 30-45 minutes per day
3207067|NCT00960921|Placebo Comparator|Saline group|Patients with high altitude pulmonary hypertension receive six intravenous infusions of normal saline, administered on days 0, 4, 8, 12, 16 and 20 of the study. The total study period is 28 days. Pulmonary artery systolic pressure is measured before each infusion, and again on day 28.
3207068|NCT00960960|Experimental|Part 1 (Cohort 1-2): Pictilisib 60 mg +Paclitaxel +Bevacizumab|Pictilisib 60 mg will be administered orally (PO) once daily (QD) for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 milligrams per meter square (mg/m^2) intravenously (IV) on Days 1, 8, and 15 and bevacizumab 10 milligrams per kilogram (mg/kg) IV on Days 1 and 15 of each 28-day cycle. In Cohort 1 (Part 1), pictilisib will be evaluated with paclitaxel only; participants in Cohort 1 (Part 1) will be eligible to receive bevacizumab starting at Cycle 2. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
2563349|NCT02476747|Experimental|Cold snare polypectomy|CSP will be performed by closing the snare loop after positioning the open snare at the point of lesion.
2563353|NCT02476747|Active Comparator|Endoscopic mucosal resection|EMR will be performed in the way of drawing the lesion into the loop of the snare and resecting followed by saline injection to the its margin.
2563442|NCT02476071|Experimental|Mass Media and Stylish Events|Mass Media (radio messages/posters promoting HIV prevention) plus one annual Stylish Man Event (SMEvent), a multimedia/community mobilization event promoting VMC.
2563445|NCT02476071|Active Comparator|Control arm: mass media only|Mass media (radio messages and posters which promote VMC for HIV prevention). .
2563483|NCT02475772|Experimental|Cisplatin and doxorubicin|Cisplatin and doxorubicin will be applied under pressure into the abdomen via laparoscopic trocars. The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
2563510|NCT02475525|Experimental|Arginine enriched oral nutritional supplement group|Patients randomised to the oral nutritional supplement group will continue their normal diet. In addition, this group will commence taking oral nutritional supplement twice daily 5 days prior to surgery and continued for 4 weeks post surgery. Intake of nutritional drink will be suspended during their fasting period prior to surgery and will commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment. Patient adherence to the study protocol with the nutritional supplement regimen will be recorded daily by the patient for four the four weeks the supplement is provided.
2563512|NCT02475525|No Intervention|Control|This group will continue on their normal diet before and after surgery. Normal diet will be suspended during their fasting period prior to surgery and will re commence once surgery is completed and group are able to tolerate food post surgery. Wound examination will take place at 1 and at 4 weeks post surgery by the tissue viability nurse specialist who will be blinded to the treatment.
2563560|NCT02475330|Experimental|Dietary Supplement: Flaxseed|
2563609|NCT02474953|Experimental|Dosing Sequence 1|Proprietary Curcumin Formulation administered first, Unformulated Comparator Curcumin Product administered second
2563611|NCT02474953|Experimental|Dosing Sequence 2|Unformulated Comparator Curcumin Product administered first, Proprietary Curcumin Formulation administered second
2563629|NCT02474667|Active Comparator|BB3|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
2563633|NCT02474667|Placebo Comparator|Normal Saline|Administered IV for 30 min within 24 hours after transplantation and around 24 hours after previous dosing 3 days in a row
2563701|NCT02474173|Experimental|Treatment (onalespib, paclitaxel)|"SAFETY RUN-IN: Patients receive onalespib IV over approximately 1 hour on day -7.~TREATMENT: Patients receive paclitaxel IV over 60 minutes on day 1, 8, and 15. Patients also receive onalespib IV over 1 hour beginning on days 8 and 15 of cycle 1 and on days 1, 8, and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
2563764|NCT02473835|Experimental|Calorie Restriction|Participants reduced calorie intake by 50 % for a period of 3 consecutive days - the target calorie intake for each participant will be determined by a period of energy balance (diet and activity) monitoring.
2563788|NCT02473562|Experimental|Varenicline|Varenicline capsule 1 mg BID
2563789|NCT02473562|Placebo Comparator|Placebo|Placebo capsule
2563828|NCT02473354|Other|Resp Depression Sequence 1 - 3|"Sequence #1: breathe 21% through the facemask and increase ventilation to achieve a target hypocapnic ET CO2 of 25 - 30 mmHg. Subject will then breathe a gas mixture containing 6% CO2 / 30% O2 to achieve a target hypercapnic ET CO2 up to 60 mmHg or HCVR is terminated at the discretion of the PI.~Sequence #2: breathe 21% O2 (normoxia) before remifentanil administration Sequence #3: breathe 50% O2 (hyperoxia) before remifentanil administration"
2563870|NCT02473055|Experimental|Kangaroo care|kangaroo Care was skin-to-skin, chest-to-chest placement of preterm infant wearing only a diaper placed up against mother's chest and covered in one receiving blanket folded into fourth
2563872|NCT02473055|No Intervention|control|control infants remained prone in an incubator wearing only diaper
2563899|NCT02472821|Active Comparator|Interactive Lesson|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health
2563902|NCT02472821|Active Comparator|Interactive lesson + Web-based booster|Subjects will receive a community-based face-to-face interactive youth educational program on hearing health followed by an Internet-based educational booster
2563904|NCT02472821|No Intervention|No-intervention control|No interventions; pre- and post- measures only.
2563960|NCT02472574|Experimental|0.3 mg|Subjects randomized to the 0.3 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle, followed by up to 4 doses of 0.3 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
2563966|NCT02472574|Experimental|0.5 mg|Subjects randomized to the 0.5 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 0.5 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
2564655|NCT02467660|No Intervention|Wait List Control|No training
2563331|NCT02476786|Experimental|Endocrine therapy alone|"Neoadjuvant endocrine therapy will be given at the discretion of the treating physician as directed by the package insert and could include the following: goserelin, anastrozole, letrozole, exemestane, fulvestrant, or tamoxifen~Frequency of office visits will be decided by the treating physician but must occur no less frequently than every 3 to 6 months for tumor assessment~After 6 months and after 12 months, patients will be assessed; patients who progress will have standard care recommended , and at any point a patient can opt to receive standard care even if she has not progressed on neoadjuvant endocrine therapy~Information on quality of life will be collected at baseline, Year 1, and Year 2 by the FACT-B questionnaire~Archival tissue will be collected and sent to Genomic Health for analysis using the Oncotype DX assay. The Recurrence Score predicts chemotherapy benefit and indicates the 10-year risk of recurrence (will not be used to determine treatment)"
2563342|NCT02476539|Experimental|Hemay022|"Part one: Dose Escalation Group Hemay022 tablets will be taken orally once daily in doses of 50mg, 100mg, 200mg, 300mg,400mg or 500mg daily for 28 days.~Part two: Extension Group Hemay022 tablets will be taken in three dose groups that had been assessed by Part one for 28 days."
2563406|NCT02476435|Active Comparator|Experimental = Active rTMS|Daily rTMS with Active coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
2563411|NCT02476435|Placebo Comparator|Sham Comparator = Sham rTMS|Daily rTMS with Sham coil 30 minutes of 1Hz rTMS, 5 days per week, for 3 weeks
2563454|NCT02475928|Placebo Comparator|100 mg placebo|100 mg Placebo plus nutritional education
2563455|NCT02475928|Experimental|100 mg zinc supplement|Nutritional education plus 100 mg of zinc gluconate
3172155|NCT00596531|Placebo Comparator|B|Group 2 will be assigned to the placebo group and take matched placebos for next 24 weeks followed by a 4-week washout period. After the washout period each group will be assigned to the other intervention (acamprosate or placebo) and complete another trial for 24 weeks.
3172156|NCT00596544||1|FSFI score <= 26
3208867|NCT00978848||Women seeking urine pregnancy testing|Women seeking urine pregnancy testing
3208868|NCT00978861|Experimental|whitening|30% Hydrogen peroxide
2564261|NCT02470325|Active Comparator|1 Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Avidekel oil (6-to-1 ratio of CBD to THC)
2564267|NCT02470325|Active Comparator|2 Enriched Avidekel|Patients with spasticity and dystonia related to genetic neurodegenerative disease will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
2564270|NCT02470325|Active Comparator|3 Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Avidekel oil (6-to-1 ratio of CBD to THC)
2564275|NCT02470325|Active Comparator|4 Enriched Avidekel|Patients with spasticity and dystonia due to cerebral palsy will consume Enriched Avidekel oil (20-to-1 ratio of CBD to THC)
2564349|NCT02469974|Experimental|Ruxolitinib / INC 424|Ruxolitinib, Jakafi ®, will be given orally at standard dose daily for 16 weeks pre ASCT and up to 3 months post-ASCT for 10 patients (allowing for 2 additional screen failures). Patients will restart ruxolitinib at 100 days after the ASCT as long as their platelet count is at least 50 x103. For patients whose platelet count is below 50 x103 at day 100, ruxolitinib should be restarted once platelet count reaches 50 x103. The dose of ruxolitinib can be titrated up as per clinical guidelines. PBSC mobilization will include G-CSF 10 mcg/kg/day. HDC for ASCT will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2.
2564426|NCT02469428|Sham Comparator|Clean air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2564431|NCT02469428|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
2564484|NCT02468960|Other|OPN strategy (study group)|"Interventions planned in this arm are as follows:~Predilatation with OPN NC balloon catheter.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
2564487|NCT02468960|Other|Standard strategy (control group)|"Interventions planned in this arm are as follows:~Predilatation with standard compliant balloon.~Absorb BVS implantation.~Treated segment visualization by OCT.~Clinical FU at 12 months."
3172157|NCT00596544||2|FSFI score >26
3172158|NCT00596557|Experimental|Everolimus, Immunosupression|everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
3172159|NCT00596570||1|Patient with atrial fibrillation who underwent PCI
3172160|NCT00596583|Active Comparator|High Dose|
3172161|NCT00596583|Active Comparator|Low Dose|
3172162|NCT00596596|Active Comparator|1|0,5 mg prucalopride
3172163|NCT00596596|Active Comparator|2|1 mg prucalopride
3172164|NCT00596596|Active Comparator|3|2 mg prucalopride
3172165|NCT00596596|Placebo Comparator|5|Placebo arm
3172166|NCT00596596|Active Comparator|4|4 mg prucalopride
3172167|NCT00596609||1|Group 1 will be subjects who receive Intrathecal Morphine.
3172168|NCT00596609||2|Group 2 will be subjects who do not receive Intrathecal Morphine.
3172169|NCT00596648|Experimental|Phase 1 Arm|Escalating doses of XL184 + erlotinib
3172170|NCT00596648|Experimental|Phase 2 Arm 1|XL184 + erlotinib (dose determined from Phase 1 portion of study)
3172171|NCT00596648|Experimental|Phase 2 Arm 2|XL184 administered as a single agent
3172172|NCT00596661|Experimental|TRIMAXX|TRIMAXX Coronary Stent
3172173|NCT00596674|Experimental|Lifestyle Counts Intervention|A wellness intervention that includes 8 weeks of behavior change classes focused on acquiring the skills and knowledge to improve health behaviors (e.g., exercise, stress management), followed by 3 months of phone support.
3172174|NCT00596674|Placebo Comparator|Attention Countrol|8 weeks of general health classes followed by phone calls for 3 months
3172175|NCT00596700|Experimental|Device|"Patient preparation procedure will be done according to chapter 4 in the Given Diagnostic System user manual. In brief: to drink only clear liquids beginning 12:00 noon the day before.at least 8 hours (since 12:00 PM) fast prior to the procedure. Patient will undergo a standard capsule endoscopy. Patients will be allowed to drink clear liquids 2 hours post ingestion, and eat 4 hours post ingestion.~Eight hours post ingestion, data recorder will be removed and the patient will be dismissed.~A local experienced reader will review the RAPID video to determine the diagnosis blinded to the results of the standard workup procedures, and to each other results. Results will be recorded in the case report forms. A decoded video will be transferred to the principal investigator for reevaluation"
2563417|NCT02476240|Active Comparator|Internally Focused PD-SAFEx|While performing the exercises in PD-SAFEx™, participants will be instructed to focus their attention on sensory feedback. This will include focusing participants' attention on the stretch in their limbs while walking, on the straightness of their backs while sitting, on limb and body orientation in space while coordinating their movements, and on chest movements during breathing exercises. Throughout each exercise session, the instructor and volunteers will constantly provide attention-directing instructions.
2563422|NCT02476240|Experimental|Externally Focused PD-SAFEx|While performing the exercises from the PD-SAFEx™ program, participants will be instructed to focus their attention externally on the movement of coloured labels attached to their feet, knees, elbows and hands. Participants will be reminded and encouraged by the exercise instructor and volunteers to perform all exercises while focusing attention on the labels.
2563426|NCT02476240|No Intervention|Control Group|This group will be asked to refrain from changing activities of their daily lives throughout the 20-week duration of the experiment (from pre-assessment to washout).
3207069|NCT00960960|Experimental|Part 1 (Cohort 3): Pictilisib 100 mg+ Paclitaxel + Bevacizumab|Pictilisib 100 mg will be administered PO QD for 21 consecutive days of each 28-day cycle (21+7 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3207070|NCT00960960|Experimental|Part 2 (Arm A: Cohort 1a): Pictilisib 165 mg + Paclitaxel|Pictilisib 165 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity
2563589|NCT02475109|Experimental|PAN-90806 Ophthalmic Solution|PAN-90806 Ophthalmic Solution taken daily for 8 weeks.
2563648|NCT02474823|Other|Sleep Apnea assessment|all participants are in the same arm & undergo the same assessments: PSG, HST, ESAP
2563693|NCT02474303|Other|HIV Pre-exposure Prophylaxis (PrEP)|Truvada
2563738|NCT02474043|Active Comparator|Usual care|Standard health education and prevention counseling by trained staff
2563739|NCT02474043|Experimental|Hep-Net Intervention|Computerized tailored behavioral intervention
3207071|NCT00960960|Experimental|Part 2 (Arm A: Cohort 2a): Pictilisib 250 mg + Paclitaxel|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
2563831|NCT02473458|Placebo Comparator|Control|patients with acute ischemic stroke who received standard care plus placebo filled capsules,
2563834|NCT02473458|Experimental|450 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 450 mg of whole extract of licorice.
2563837|NCT02473458|Experimental|900 mg licorice|patients with acute ischemic stroke who received standard care plus capsules filled with 900 mg of whole extract of licorice.
2563915|NCT02473107|Other|Control Caries Detection Strategy|Detection and treatment based on more advanced lesions, despite activity status - Advanced caries lesions detection (no activity assessment)
2563920|NCT02473107|Other|Test Caries Detection Strategy|Detection and treatment based on all detected caries lesions, considering their activity status as a differential in clinical decision-making - All caries lesions detection (+activity assessment)
2563958|NCT02472418|Experimental|DFN-15 120 mg (treatment A)|DFN-15 120 mg (treatment A)
2563964|NCT02472418|Experimental|DFN-15 240 mg (treatment B)|DFN-15 240 mg (treatment B)
2563968|NCT02472418|Placebo Comparator|Placebo (treatment C)|Placebo (treatment C)
2564010|NCT02472119|Experimental|rusks made with treated flour|Gluten-free diet adding rusks (100g / day) produced with commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester.
2564014|NCT02472119|Active Comparator|rusks made with not-treated flour|Gluten-free diet adding rusks (100g / day) produced with untreated wheat flour.
2564133|NCT02471300||1|stable mild-moderate asthmatic subjects
2564214|NCT02470559|Experimental|Treatment (aldesleukin, sargramostim, HER2Bi-aACT)|Patients receive HER2Bi-aATC IV over 5-15 minutes and IP within 3-4 days of IV dose weekly for 4 weeks. Patients also receive low-dose aldesleukin SC daily and sargramostim SC twice weekly beginning 3 days before the first HER2Bi-aATC infusions infusion and ending 7 days after the last HER2Bi-aATC infusion. Treatment continues in the absence of disease progression or unacceptable toxicity.
3208869|NCT00978887|Experimental|A|Retorna (facial cream)
3208870|NCT00978887|Placebo Comparator|B|Placebo (facial cream)
2564335|NCT02469753|Experimental|Patients treated with anti-TNF and continuous daily NSAIDs|
2564338|NCT02469753|Active Comparator|Patients treated with anti-TNF and NSAIDs on demand|
2564445|NCT02469233|Experimental|TranS-C|The Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C) is comprised of cross-cutting interventions, 'core modules' and 'optional modules'. TranS-C is derived and adapted from our previous disorder-focused research, firmly grounded in basic science and treatment literature.
2564454|NCT02469233|Active Comparator|UC-DT|Usual Care, Delayed Treatment (DT) is comprised of a case manager who co-ordinates care and refers each client for a medication review and to rehabilitation programs. At the end of 6-months in UC-DT, the participants will receive TranS-C.
2564501|NCT02468856|Active Comparator|Armodafinil|Armodafinil 250 mg tablets, one time administration per study session in the morning of day 2
2564503|NCT02468856|Placebo Comparator|Placebo|one time administration per study session in the morning of day 2
2564543|NCT02468466|Experimental|Multi-level suicide prevention programs|The study team, including staff members from the intervention municipalities, provided each municipality with a standardized form of the work plan used in our study. The intervention municipality autonomously conducted the intervention program during the implementation period.
2564545|NCT02468466|Active Comparator|Community intervention as usual|Suicide prevention program as usual
3208871|NCT00978900|Active Comparator|Acesulfame K|
2564768|NCT02466932||Birth Weight|
2564826|NCT02466711|Active Comparator|Relamorelin|
3208872|NCT00978900|Active Comparator|Sucralose|
2563421|NCT02476266|No Intervention|Control|Participants randomized to this group will come in for testing at pre-intervention, post-intervention, three month wash out and six month wash out. Participants will be asked to continue their activities of daily living. To account for any physical activity changes over the length of the study the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire will be administered to all individuals. A control group is necessary to compare to show normal disease progression over the length of the study as well as to demonstrate that improvements in outcome measures are due to the interventions and not practice effects.
2563423|NCT02476266|Active Comparator|Strength Training|Individuals randomized to this program will complete three sets of eight to ten repetitions at 70% of their predicted 1-RM for each of the exercises mentioned above. The speed of the movements in this program will be two to three seconds each for the concentric and eccentric components. When participants are able to complete ten repetitions in their third set for two consecutive days, weight will be increased for the following session by 5% of the current weight that they are at in accordance with Canadian Society for Exercise Physiology (CSEP) and American College of Sports Medicine (ACSM) guidelines. Participants will complete a total of 24 sessions over the course of 12 weeks, two times per week for an hour each session.
2563427|NCT02476266|Experimental|Power Training|Participants randomized to this program will complete three sets of 12 to 15 repetitions completed at 40% of predicted 1-RM for each exercises. The concentric part of the movement will be completed as fast as possible, whereas the eccentric component will be accomplished in two to three seconds. The load in this group is lower as it has been shown that by performing power training at lighter loads, the muscles are able to be activated, throughout the entire concentric component, while maintaining a consistent level of force. The progression will be determined through the same means as the conventional strength training group. Participants will complete a total of 24 sessions over 12 weeks, twice per week for an hour each session
2563471|NCT02475863|Experimental|Warfarin dosing aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin.
2563473|NCT02475863|Active Comparator|Standard practice|Dosing adjustments according to the normal unit protocol
2563498|NCT02475616|Experimental|PCO371|Single oral dose of PCO371
2563499|NCT02475616|Placebo Comparator|Placebo Comparator|Single oral dose of placebo
2563554|NCT02475356||Mirena|Mirena treatment group
2563597|NCT02475018|Experimental|Milk fortified with plant sterol esters|250mL of Shuhua Milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
2563600|NCT02475018|Placebo Comparator|Plain milk|250mL of placebo milk(plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
2563602|NCT02475018|No Intervention|No dairy product consumption|Participants have not consumed any dairy product during the 60-days of study period.
2563669|NCT02474641|Active Comparator|Standard radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
2563672|NCT02474641|Experimental|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
2563797|NCT02473588|Other|LTIA Group|Patients in the LTIA Group (all patients) will have blood pressure recorded continuously. LTIA will be used to measure stroke volume and cardiac output after the completion of data collection
2563832|NCT02473380|Experimental|Intraoperative fluorescence spectroscopy|The experimental device will be assessed during an open surgical approach for surgical removal of the tumors
2563881|NCT02473133|Experimental|Personalized dose redistribution|Patients in the will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy (about two thirds of patients are expected as positive). An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week using a twice-a-day fractionated radiotherapy.
2563883|NCT02473133|Sham Comparator|No dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET result).
2563905|NCT02472743|Experimental|Custom-built phototherapy lamp|"Custom-built phototherapy lamp:~All participants will receive light treatment twice weekly for three weeks (or until ulcer/s healing) to one or both hands (both hands if ulcer/s present bilaterally).~The participant will place their hand within the treatment area of the light-based device (total treatment area approximately 15cm2), aiming to centralise the digital ulcer/s to the centre of the treatment region.~At each treatment study visit (visits 1-6 inclusive), the device will undergo a period of (automatic) calibration before use. All three wavelengths (red, infrared and blue) will be delivered simultaneously in combination, with the fluence of the device set at [3J/cm2] (treatment duration approximately 10 to 15 minutes)."
2563967|NCT02472626|Experimental|Treatment (CPI-613, cytarabine, daunorubicin hydrochloride)|"INDUCTION: Patients receive cytarabine IV continuously on days 1-7, daunorubicin hydrochloride IV on days 1-3, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 3-7. Patients then undergo biopsy on day 14. Patients experiencing significant residual disease receive cytarabine IV continuously on days 1-5, daunorubicin hydrochloride IV on days 1-2, and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5.~CONSOLIDATION: Beginning 42 days later, patients receive cytarabine IV continuously on days 1-16 and 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 2-6. Treatment repeats every 14 days for 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients not undergoing transplant after consolidation receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5. Treatment repeats every 4 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity."
2564073|NCT02471859|Experimental|Part A: GDC-3280|Participants in multiple cohorts and treatment periods will receive single doses of GDC-3280 under fed/fasting conditions.
2564081|NCT02471859|Placebo Comparator|Part A: Placebo|Participants in multiple cohorts and treatment periods will receive single doses of placebo under fed/fasting conditions.
2564088|NCT02471859|Experimental|Part B: GCD-3280|Participants in different cohorts will receive GDC-3280 in multiple ascending doses under fed/fasting conditions.\n
2564671|NCT02467426||Chemotherapy|intraarterial chemotherapy with cisplatin and mitoxantrone
2563477|NCT02475915|Experimental|ART + VHM|"Group 1: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.~Plus: 3 X 14-day cycles of vorinostat administered at weeks 0, 4 and 8; hydroxychloroquine and maraviroc prescribed at week 0 for a period of 10 weeks."
2563480|NCT02475915|Active Comparator|ART alone|Group 2: Combination Antiretroviral Therapy prescribed at week 0 for a period of 10 weeks. Likely consisting of two NRTI such as tenofovir and emtricitabine and either an NNRTI, such as efavirenz. For subjects on NNRTI therapy, a protease inhibitor, such as darunavir will be substituted for the NNRTI 2 weeks prior to treatment interruption.
3207072|NCT00960960|Experimental|Part 2 (Arm A: Cohort 3a): Pictilisib 330 mg + Paclitaxel|Pictilisib 330 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3207073|NCT00960960|Experimental|Part2(Arm B:Cohort 1b):Pictilisib 200mg+Paclitaxel+Bevacizumab|Pictilisib 200 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
2563658|NCT02474992|Experimental|Intervention|This arm is eligible for participation in the Microclinic intervention, a social network-based educational program.
2563664|NCT02474992|No Intervention|Comparison|This arm is not eligible for participation in the intervention during the first twelve months of the study. Following collection of the primary study endpoints, this arm will also be invited to participate in a Microclinic group. Participants in this arm will still have access to standard HIV care at the facility of their choice. At time of recruitment into the study, prior to randomization, all eligible participants will be counseled on the importance of returning to their clinic for ongoing HIV care.
2563690|NCT02474342|Experimental|Autologous Adipose Tissue derived MSCs|
3207074|NCT00960960|Experimental|Part2(Arm B:Cohort 2b):Pictilisib 250mg+Paclitaxel+Bevacizumab|Pictilisib 250 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
2563938|NCT02472691|Experimental|Lenalidomide + Aza + DLI|Patients will be included at the time of relapse after first allo-SCT. As standard of care all patients will receive Azacitidine 75 mg/m2/d for 7 days every 28 days for up to 8 cycles and DLIs given after cycle 4, 6 and 8 at a dose of 0.5-1x106CD3/kg (1st DLI), 1-5x106CD3/kg (2nd DLI) and 5-15x106CD3/kg (3rd DLI). As intervention (investigational drug), Lenalidomide will be also started on day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
2564084|NCT02471885|Experimental|Remote ischaemic conditioning|Remote ischaemic conditioning in the form of a blood pressure cuff on upper arm inflated upto 200 mm Hg (or systolic BP + 20 mm Hg if low platelets e.g. 50-150 x10^9/L, skip remote ischaemic conditioning (RIC) if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire pre-conditioning phase will last 40 minutes.
2564091|NCT02471885|Placebo Comparator|Control|Blood pressure cuff on upper arm inflated to 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes, for 4 cycles before beginning of chemotherapy infusion. The entire control comparator will last 40 minutes
2564118|NCT02471274|Experimental|Group 1|healthy control subjects with normal hepatic function
2564119|NCT02471274|Experimental|Group 2|subjects with mild hepatic impairment
2564121|NCT02471274|Experimental|Group 3|subjects with moderate hepatic impairment
2564123|NCT02471274|Experimental|Group 4|subjects with severe hepatic impairment
2564178|NCT02470962||Patients with muscular dystrophy|Boys aged 8 to 18 years with muscular dystrophy of the Duchenne / Becker type
2564188|NCT02470962||Children without heart disease|Children without heart disease, aged 8-18 years, as CMR comparison group
2564216|NCT02470650|Experimental|elvitegravir/cobicistat/emtricitabine/tenofovir|EVG / COBI / FTC / TDF (Stribild®) 150 elvitegravir, 150 cobicistat, 200 emtricitabine, 245 tenofovir disoproxil. 1 recovered tablet once a day (on a day)
2564217|NCT02470650|Active Comparator|darunavir+ritonavir+lamivudine|Darunavir 800 mg (Prezista®) 1 recovered tablet once a day Ritonavir 100 mg(Norvir® ) 1recovered tablet once a day lamivudine300 mg (Epivir®) 1 recovered tablet once a day
2564218|NCT02470650|Active Comparator|abacavir/lamivudine+rilpivirine|Abacavir 600 mg +lamivudine 300mg (Kivexa®) 1tablet once a day rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
2564266|NCT02470299|Experimental|Ketorolac|Once deemed stable in the first 1-3 post-operative days, patients will be receive age-based ketorolac (30 mg <65, 15mg > 65) daily for three days
2564273|NCT02470299|Placebo Comparator|Placebo|Once deemed stable in the first 1-3 post-operative days, patients will be receive placebo daily for three days
2564344|NCT02470026|Experimental|Yohimbine-Placebo|single low dose treatment with yohimbine on test day 1, placebo on test day 2
2564350|NCT02470026|Experimental|Placebo-Yohimbin|placebo on test day 1, single low dose treatment with yohimbine on test day 2
2564401|NCT02469480|Experimental|FERRIC CARBOXYMALTOSE|max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
2564402|NCT02469480|Active Comparator|ferro sanol(R) duodenal 100 mg|200 mg ferro sanol per day over 12 weeks
2564424|NCT02469142|Experimental|ADM tension-free hernia reparation|Use ADM to repair incarcerated inguinal hernia by tension-free
2564430|NCT02469142|Placebo Comparator|traditional tension hernia reparation|Just repair incarcerated inguinal hernia by nothing in tension condition
2564498|NCT02468687|Other|N-methyl-pyrrolidone|NMP dose escalation in accelerated phase and standard phase
2563489|NCT02475824|Experimental|MMD arm|Both midazolam® (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea) are given intravenously at the initiation of sedation. In addition, a continuous IV infusion of dexmedetomidine (1ug/kg/h, Precedex; Hospira, Seoul, Republic of Korea) is administered 15 min before the ERCP till complete procedure
2563491|NCT02475824|Active Comparator|BPS arm|IV bolus dose of midazolam® (0.06mg/kg, 50% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea) and meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea). Repeated doses of 10-20 mg propofol® are titrated to achieve the target level of sedation. 0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
2563528|NCT02475408|Experimental|Interventional Study Arm|In the presence of a significant right coronary artery stenosis, catheter-based occlusion of the right IMA distal to the take-off of the pericardio-phrenic branch is performed at baseline using a dedicated occlusion device (Amplatzer vascular plug).
2563636|NCT02474836|Active Comparator|Atopic subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
2563641|NCT02474836|Active Comparator|Non atopic subjects|Healthy volunteers
2563644|NCT02474836|Other|Allergic Subjects|
2563689|NCT02474277|Other|30 sec chair stand test|all patients in this Group receives a diagnostic test for functional impairment
2563731|NCT02474108|Placebo Comparator|without prevention|isolated mitral valve replacement or reconstruction, implantation of cardiac monitor
2563736|NCT02474108|Active Comparator|group of prevention|"mitral valve replacement or reconstruction with surgical prevention of AF (concomitant ablation of the left atrium) and implantation of cardiac monitor.~Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe."
2563768|NCT02473848|Experimental|Ingenol mebutate 500 ucg|active arm
2563799|NCT02473601|Experimental|Mivacurium Chloride by liver dysfunction|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
2563804|NCT02473601|Other|Mivacurium Chloride by normal liver function|Mivacurium Chloride 0.2mg/kg,during anesthesia induction. Mivacurium Chloride 6mg/kg/h,during anesthesia maintenance
3208873|NCT00978900|Active Comparator|Aspartame|
3208874|NCT00978900|Active Comparator|Glucose|
2563978|NCT02472483|Experimental|bipolar disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
2563979|NCT02472483|Experimental|anxious disorders|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
2563983|NCT02472483|Experimental|alcohol disorder|"Cognitive and Behavior Therapy (CBT) : 20-weeks CBT~+ Mindfulness Based Cognitive Therapy (MBCT) : 8-weeks MBCT"
2564060|NCT02471937|Experimental|Pregnant women negative for GBS colonization|Only women negative for GBS during all the study will be included.
2564130|NCT02471508|Experimental|Tank top with biofeedback system|"The design of biofeedback tank-top will incorporate sensors to record and monitor the posture of the wearer in real time basis. Alerts will be emitted to the wearer once poor posture is detected. The tank-top will be designed to fit the wearer's body and allow the sensor to be placed securely at the targeted position along the spine to minimize the noise from other factors than the wearers' posture and yet comfortable for long-term wearing."
2564230|NCT02471092|Placebo Comparator|Water Control|Skim milk products. Water and permeate control; 250mL serving.
2564231|NCT02471092|Active Comparator|Skim Milk|Skim milk products. Skim milk (regular 80:20 protein ratio); 250mL serving.
2564232|NCT02471092|Experimental|High Protein Milk|Skim milk products. High protein milk (regular 80:20 protein ratio); 250mL serving.
2564234|NCT02471092|Experimental|High Protein Milk (Modified Ratio)|Skim milk products. High protein milk with modified protein ratio (40:60 ratio); 250 mL serving.
2564238|NCT02471092|Experimental|Skim Milk (Modified Ratio)|Skim milk products. Skim milk with modified protein ratio (40:60 ratio); 250 mL serving.
2564315|NCT02470156|Experimental|High Intensity Arm (Intervention)|"Women in the High Intensity (intervention) arm are counseled by a wellness coach and have a group meeting each month. They are also interviewed four times (at baseline, 4 months, 8 months, and 12 months). Women in the high intensity group must have monthly contact with coaches during at least 9 of 12 months via participation in a group activity and/or monthly coaching to receive a full dose of the intervention."
2564316|NCT02470156|Active Comparator|Low Intensity Arm (Comparison)|Women in the Low Intensity (comparison) arm are interviewed and coached four times during the study (at baseline, 4 months, 8 months, and 12 months).
2564330|NCT02469779|Experimental|ASPIRE Group|Participants complete baseline survey. Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
2564331|NCT02469779|Active Comparator|Control Group|Participants complete baseline survey. Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living. This viewing will be videotaped and audio recorded. 3 to 4 sessions will be completed. After each website session, survey will be completed.
2564388|NCT02469584|Experimental|1|symptomatic cystocele described as Points Aa or Ba >= 0 according to the International Continence Society pelvic organ prolapse quantification system (POP-Q). The changes in POPQ score preoperatively and three months after the anterior colporrhaphy with the new small stitch technic will be analyzed.
2564413|NCT02469363|Active Comparator|Macintosh laryngoscope|Endotracheal intubation with classic (Macintosh) laryngoscope
2564414|NCT02469363|Active Comparator|Mc-Coy laryngoscope|Endotracheal intubation with Mc-Coy laryngoscope
2564415|NCT02469363|Active Comparator|C-Mac videolaryngoscope|Endotracheal intubation with C-Mac videolaryngoscope
2564416|NCT02469363|Active Comparator|McGrath videolaryngoscope|Endotracheal intubation with McGrath videolaryngoscope
2564629|NCT02467959||Ultrasound|Ultrasound evaluation
3208875|NCT00978900|Active Comparator|Fructose|
3208876|NCT00978900|Placebo Comparator|Water|
2563517|NCT02475499||Treated with incretins|Ever-use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) between (and including) base cohort entry and the index day - 365 days.
2563520|NCT02475499||Treated with sulfonylureas|Ever-use of sulfonylureas between (and including) base cohort entry and the index day - 365 days, and never-use of incretin-based drugs.
2563521|NCT02475499||Treated with other antidiabetic agents|Ever-use of other antidiabetic agents (biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) between (and including) base cohort entry and the index day - 365 days, with never-use of incretin-based drugs and never use of sulfonylureas.
2563653|NCT02475005|Experimental|Mobile self management app on smartphone|Mobile self management app on smartphone
2563657|NCT02475005|No Intervention|Treatment as usual|Treatment as usual (control group)
2563692|NCT02474381|Experimental|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
2563694|NCT02474381|Active Comparator|Single PTA|Angioplasty of arteries below tibial plateau level only
3207075|NCT00960960|Experimental|Part2(Arm B:Cohort 3b):Pictilisib 260mg+Paclitaxel+Bevacizumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and bevacizumab 10 mg/kg IV on Days 1 and 15 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3207076|NCT00960960|Experimental|Part2(Arm C:Cohort 1c):Pictilisib 180mg+Paclitaxel+Trastuzumab|Pictilisib 180 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
3208877|NCT00978913|Experimental|DC vaccination and Cyclophosphamide|
2563913|NCT02472704|Active Comparator|Gluten challenge|Gluten powder (10 g every 12 hours), 24 weeks
2563918|NCT02472704|Placebo Comparator|Placebo challenge|Placebo (maltodextrin; 10 g every 12 hours), 24 weeks
2563953|NCT02472509|Experimental|Open Label|32 patients with hemolytic disorders meeting the inclusion and exclusion criteria will be commenced on Ursodeoxycholic acid (UDCA).
2564067|NCT02471638|Experimental|Single arm study|PQ Bypass System for Femoropopliteal Bypass to complete percutaneous fem-pop bypass
3172176|NCT00596713||1|Both genders aged 20 to 80 years and living in private households in the city of São Paulo. Pregnant or lactating women, people with physical or mental impairment and workers in night shifts are not part of the population of interest.
3172177|NCT00596765|Experimental|1|Neuropsychological cognitive behavioral psychotherapy for patients with acquired brain injury consists of 25 weekly 1-hr sessions of individualized outpatient treatment. The therapeutical intervention is modularised, patients are assigned to specific interventional modules according to the results of cognitive testing and interviews. Modules concern on the one hand the treatment of deficits in attention, memory, and executive functions. On the other hand psychosocial adjustment to chronic illness is addressed through modules that concern the development of a positive self-concept, the adjustment of life-goals and coping with negative affect (e.g. depressive symptoms, irritability, guilt).
2564170|NCT02470988|Active Comparator|CBASP|Cognitive Behavioural Analysis System of Psychotherapy (CBASP) is a form of therapy specifically designed to treat individuals with chronic depression. CBASP combines a number of elements, with a focus on teaching the client to become aware of their interpersonal behaviour and its consequences.
2564173|NCT02470988|Experimental|CBASP Without DPI|In this arm CBASP will be delivered without Disciplined Personal Involvement (DPI) by the therapist.
2564211|NCT02470624||treatment following current guideline|
2564269|NCT02470416|Active Comparator|Case|Patients who have had a previous diagnosis and/or treatment of a duodenal/ampullary polyp at Westmead hospital
2564271|NCT02470416|Active Comparator|Control|Age matched controls having VCE for OGIB/IDA at Westmead hospital.
2564314|NCT02470052|Experimental|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
2564336|NCT02469727|Experimental|Fitbit + Facebook|Participants will use the Fitbit device and join the Facebook group.
2564337|NCT02469727|No Intervention|Usual care control|No intervention provided.
2564389|NCT02469558|Active Comparator|probiotic|Winclove 851 and 110 consist of 6g of a probiotic mixture containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g and 10g of a prebiotic mixture of galacto-oligosaccharides P11 (GOS), Fructo-oligosaccharides P6 (FOS), Konjac glucomannan P13 (E425), Maltodextrin, Calcium carbonate (E170), Natural Elderflower flavouring, Gum Arabic (E414), Zinc citrate 3-hydrate, Vitamin D3 (Cholecalciferol) and Vitamin B2 (Riboflavin) (E101) daily for 6 months
2564390|NCT02469558|Placebo Comparator|placebo|a similar looking and tasting placebo without bacteria
2564444|NCT02469337|Active Comparator|Preoperative carbohydrate drinks|Patients who were randomised to carbohydrate group ingested 800ml PreOp (Nutricia Clinical Care, 12.5g CHO/100 ml) the night before and 400ml in the morning of surgery, about 2-3 hours before the induction of anaesthesia.
2564451|NCT02469337|Active Comparator|Dichloroacetate infusion|The patients in the dichloroacetate group received the CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 min, one- two hours before the induction of anaesthesia.
2564457|NCT02469337|Active Comparator|Moderate intensity exercise|Patients randomised to exercise group, will perform a 30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate(determined by the formula: (220-Age)*0.7 under close supervision and monitoring of their vital parameters.
2564459|NCT02469337|No Intervention|Control|Patients in this group will have surgery as standard practice with none of the above interventions
2563525|NCT02475538|Experimental|Electroacupuncture|"Subjects in this group will be treated with electroacupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~Subjects will receive electroacupuncture 2 times per week for 4 consecutive weeks. Electroacupuncture involves acupuncture needling at traditionally used acupoints according to Chinese medicine theory."
2563529|NCT02475538|Placebo Comparator|Placebo acupuncture|"Subjects in this group will be treated with placebo acupuncture along with a gradual tapering schedule.~Benzodiazepines will be tapered off over four weeks. The expected reduction rate of benzodiazepines should be 25% in the first two weeks and 12.5% in 3-4 days in week 3 and week 4. If the participants cannot tolerate the effects after tapering according to our suggested plan, the dose can be kept unchanged or they can reduce the dose at a slower pace.~The subjects will be receive placebo acupuncture 2 times per week for 4 consecutive weeks. Placebo acupuncture is a treatment that simulates the procedure of acupuncture treatment but may not have the effects of acupuncture."
2563565|NCT02475174|Experimental|Without upper limb elevation|Manual lymphatic drainage will be held with the voluntary supine without upper limb elevation.
2563566|NCT02475174|Experimental|Upper limb elevation to 30º|Manual lymphatic drainage will be held with the voluntary supine with the upper limb elevation to 30º.
3208878|NCT00978939|Experimental|Aggressive Drainage Arm|Patients will drain up to 1 liter of pleural fluid everyday
3208879|NCT00978939|Active Comparator|Standard Drainage Arm|Patients will drain up to 1 liter of pleural fluid every other day
2563726|NCT02474147|Experimental|Type 2 diabetics|Patients with type 2 diabetes Interventions: processed meat hamburger and vegan sandwich
2563729|NCT02474147|Active Comparator|Obese subjects|Obese subjects without diabetes Interventions: processed meat hamburger and vegan sandwich
2563737|NCT02474147|Active Comparator|Healthy lean controls|Healthy lean controls Interventions: processed meat hamburger and vegan sandwich
2563771|NCT02473796|Experimental|Home based child care|The home based child care included treatment of various various childhood illnessed by locally avialable trained village health workers, improving hygiene and nutrition among children and women throgh health education. This care was in adiition to the local health care provided by the Government's primary health care services.
2563773|NCT02473796|No Intervention|control|The control arm included population where the home based neonatal care was not implimented. The health services were provided by the Government run primary health care services. Vital statistics data was collected by VHWs.
2563810|NCT02473549|Experimental|Brain Stimulation|Patients will receive, Sham TDCS, Anodal TDCS, Cathodal TDCS, and Magnetic Resonance Imaging (MRI).
2563859|NCT02473224|Experimental|Cohort 1|9 secretor-positive subjects will receive 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1; and 2 secretor-positive subjects will receive the placebo, n=11
2563860|NCT02473224|Experimental|Cohort 2|9 secretor-positive subjects will receive either 1.2 x 10^2GEC, or 1.2 x10^6 GEC oral dose on Day 1, depending on the percentage of subjects with illness from Cohort 1; 2 secretor-positive subjects will receive the placebo, n=11
2563861|NCT02473224|Experimental|Cohort 3|9 secretor-positive subjects will receive either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, 1.2 x 10^6 GEC, or 1.2 x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2; 2 secretor-positive subjects will receive the placebo, n=11
2563863|NCT02473224|Experimental|Cohort 4|8 secretor-negative and 3 secretor-positive subjects will receive 1.2 x 10^7 GEC oral dose on Day 1, n=11
2563917|NCT02472860|Experimental|Cognitive Training|Targeted Cognitive Training (TCT)
2563923|NCT02472860|Placebo Comparator|Control Condition|Youth appropriate online games
2563949|NCT02472535|Experimental|placebo, MBX-8025 50 mg, 100 mg or 200 mg capsules|
2564018|NCT02472210|Placebo Comparator|Placebo|Saline IM Injection
2564022|NCT02472210|Active Comparator|Onabotulinum Toxin A|IM Injection
2564055|NCT02471872|Experimental|Air Pollution Education|Students are presented with a one-hour interactive information session about air pollution and the environment.
2564057|NCT02471872|Placebo Comparator|Non-Air Pollution Education|Students are presented with a one-hour interactive information session about vaccines.
2564103|NCT02471534|Experimental|Pediatric patients with hypovolemia|Right upper abdominal compression is performed in patients with hypovolemic signs including hypotension, decreased urine output and central venous pressure less than 5 mmHg. Changes of blood pressure during abdominal compression is continuously recorded.
3208880|NCT00978952|Experimental|Investigational Group|Use of Large Diameter Advanta™ V12 Covered Stent.
3208881|NCT00978965||All patients|
2564161|NCT02471040|Experimental|Type 1 diabetic subjects|Subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
2564162|NCT02471040|Active Comparator|Healthy Subjects|Healthy control subjects will undergo a hyperinsulinemic-hypoglycemic clamp with a target glucose level of 55mg/dl. Once a stable glycemic state is reached, subjects will receive a bolus-continuous infusion beta-hydroxybutyrate (BHB) or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study. Throughout the BHB or saline infusion cognitive function will be tested via a standardized testing battery.
2564220|NCT02470689|Active Comparator|Diacerin cream 1%|
2564222|NCT02470689|Placebo Comparator|ultraphil cream|
2564342|NCT02470013|Experimental|Intervention Group|Nutrition counselling and balanced, energy dense, moderate protein sip feed ('Fortimel Compact, Nutricia GmbH) for 3 months
2564343|NCT02470013|No Intervention|Control Group|Nutrition counselling upon hospital discharge (usual care)
2564419|NCT02469545|Active Comparator|SSRI and probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and probiotic (Lactobacillus Plantarum 299v) to a group of patients diagnosed with depression (n=30).
3207077|NCT00960960|Experimental|Part2(Arm C:Cohort 2c):Pictilisib 260mg+Paclitaxel+Trastuzumab|Pictilisib 260 mg will be administered PO QD for repeated rounds of 5 consecutive days followed by 2 consecutive drug-free days in each 28-day cycle (5+2 schedule) with paclitaxel 90 mg/m^2 IV on Days 1, 8, and 15 and trastuzumab 2-4 mg/kg IV on Days 1, 8, 15, and 22 of each 28-day cycle. Cycle 1 will be 29 days and subsequent cycles will be 28 days. Study treatment will continue until disease progression or unacceptable toxicity.
2563571|NCT02475083|Experimental|Virtual Reality Group|Rehabilitation with virtual reality using games with balance training goal.
2563574|NCT02475083|Active Comparator|Conventional Group|Conventional physiotherapy with exercises for balance training.
2563613|NCT02474875|Active Comparator|Educational program Control Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: talk about medical issues (drugs, nutrition, importance of sleep...)
2563615|NCT02474875|Experimental|Educational program High Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
2563619|NCT02474875|Experimental|Educational program Diluted Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 6 sessions: 45 minutes of educational sessions about the neurophysiology of pain + 15 minutes of relaxation exercises
2563623|NCT02474875|Experimental|Educational program Concentrated Low Dose Group|6 group sessions: 1h/session - 1 session/week - 6 weeks 4 first sessions: relaxation exercises 2 last sessions: educational sessions about the neurophysiology of pain
2563665|NCT02474563||Bortezomib, Melphalan, Prednisone (VMP) Group|Participants will not receive any intervention in this study. Participants receiving VMP therapy for MM that was not eligible for autologous stem cell transplantation will be enrolled in the study.
2563776|NCT02473939|Experimental|VR942 Dose 1|VR942 Dose 1
2563780|NCT02473939|Experimental|VR942 Dose 2|VR942 Dose 2
2563781|NCT02473939|Experimental|VR942 Dose 3|VR942 Dose 3
2563783|NCT02473939|Experimental|VR942 Dose 4|VR942 Dose 4
2563784|NCT02473939|Experimental|VR942 Dose 5|VR942 Dose 5
3207078|NCT00960960|Experimental|Part 3: Pictilisib 260 mg + Letrozole|Pictilisib 260 mg will be administered PO QD continuously with letrozole 2.5 mg PO QD for each 28-day cycle. Study treatment will continue until disease progression or unacceptable toxicity.
2563892|NCT02472925|Other|Arm 1: Control|"MedSignals pill box will be set into quiet mode to track patient compliance. This mode sends daily adherence data to the Way to Health platform each time the participant opens the pill box, however, does not remind the participant to take the medication."
2563894|NCT02472925|Experimental|Arm 2: Reminders/Feedback|MedSignals pill box will track patient compliance and the Way to Health platform will allow participants to receive tailored text message reminders to take the medication if in case the interval from last cap opening is >30 hours (greater than 6 hours overdue).
2563895|NCT02472925|Experimental|Arm 3: Reminders/Feedback/Incentives|MedSignals pill box will track patient compliance and in addition to reminders with missed doses and weekly adherence feedback, patients in this arm will be eligible to receive a small financial incentive each week they demonstrate perfect >85% adherence. The weekly adherence feedback message will also alert patients whether they earned the incentive for the past week.
2563971|NCT02472665|Experimental|plasma-derived FVIII/VWF concentrate|Pharmacokinetic single dose study with Fanhdi (high-purity Von Willebrand containing FVIII concentrate)
2564025|NCT02472184|Active Comparator|Office Hysteroscopy|Group of patients in which office hysteroscopy will be performed prior to endometrial biopsy
2564027|NCT02472184|Active Comparator|Endometrial biopsy|Group of patients in which endometrial biopsy will be performed prior to office hysteroscopy
2564070|NCT02471729|Experimental|Renal Denervation|patients with chronique heart failure will undergo EnligHTN™ Renal Denervation System as a complementary treatment of their therapy
2564127|NCT02471391|Experimental|Ibrutinib + ABT-199|
3207079|NCT00960973|Experimental|Vitamin K|Vitamin K supplementation (menatetrenone 30 mg, 3 times a day for 4 weeks)
2564438|NCT02469220|Experimental|Low FODMAP diet|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement low in FODMAPS are administered in a blinded fashion.
2564442|NCT02469220|Active Comparator|Standardized FODMAP|Diet with a low content of fermentable oligo-, di-, monosaccharides and polyols (low FODMAP diet). The patients will receive dietary instructions from registered clinical dieticians. A food supplement with FODMAPS are administered in a blinded fashion.
2564452|NCT02469220|No Intervention|Control|Watchful waiting. No diets or food supplements are administered
2564496|NCT02468869|Experimental|Information structuring skills training|Physicians received a communication skills training focusing on information structuring with the so-called book metaphor for a structured discharge communication with the patient.
2564499|NCT02468869|Active Comparator|Empathy skills training|Physicians received a communication skills training focusing on empathy skills with the acronym NURSE for an empathetic discharge communication with the patient.
2564579|NCT02468544|Experimental|Single Arm Intervention Study|All participants will receive individualized text messages based on a schedule determined during the development and refinement of the mHealth text messaging intervention (i.e., once or twice a week). All participants will receive text messages for: 1) medication reminders, 2) appointment reminders, and 3) text messages addressing barriers (educational information to improve HIV knowledge) or promoting facilitators (e.g., routinizing taking of HIV antiretroviral medication) of care engagement. Each participant will complete baseline assessments, and will select their preferences for personalized messages on the day of baseline assessments. Text messages will be deployed for the duration of the 30-day trial. Participants will be followed-up at the completion of the 30-day intervention. Each participant will be asked to complete a follow-up survey, including questions on the acceptability of the mHealth intervention.
2564634|NCT02467998||NPWT treated wounds|NPWT from any FDA cleared NPWT device including
2564687|NCT02467530|Experimental|AGE diet|Dietary intervention consistent of consuming low amounts of (AGEs).
2564693|NCT02467530|No Intervention|Original diet|Patients will continue their original diet.
2564755|NCT02467231||Exposed|Females ages 11-35 to be exposed to alkylating agent chemotherapy
2563561|NCT02475135|Experimental|Panel 2: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 1 and a single oral tablet of DRV, a tablet of emtricitabine/ tenofovir alafenamide (FTC/TAF) and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2.
2563562|NCT02475135|Experimental|Panel 2: Group 2|Subject will receive a single oral tablet of DRV, a tablet of FTC/TAF and a tablet of COBI under fed conditions (standardized regular breakfast, reference Panel 2) on Day 1 of treatment period 2 and a single oral tablet of D/C/F/TAF under fed conditions (standardized regular breakfast, test Panel 2) on Day 1 of treatment period 2.
2563563|NCT02475135|Experimental|Panel 3: Group 1|Subject will receive a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 1 and a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 2.
2563564|NCT02475135|Experimental|Panel 3: Group 2|Subject will receive a single oral tablet of D/C/F/TAF with a standardized high-fat breakfast (reference Panel 3) on Day 1 of treatment period 1 followed by a single oral tablet of D/C/F/TAF under fasted conditions (test Panel 3) on Day 1 of treatment period 2.
2563652|NCT02474719|Experimental|conventional scheme followed by alternate schem|"The first day of the study, patients receive an adapted conventional peritoneal dialysis scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²).~The second day, patients receive an adapted and alternate scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once."
2563659|NCT02474719|Experimental|alternate scheme followed by conventional scheme|"The first day of the study, patients receive an adapted and alternate peritoneal dialysis scheme: 1 cycle of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 1 cycle of purification (stasis: 110 mn ; volume 1200cc/m²), the two cycles being repeated once.~The second day, patients receive an adapted conventional scheme: 2 cycles of ultrafiltration (stasis: 35 mn ; volume: 650cc/m²) and 2 cycles of purification (stasis: 110 mn ; volume 1200cc/m²)."
2563720|NCT02474368|Experimental|Cohort 1|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 1 (patients who have received prior radiation in the head and neck with gross unresectable disease)~Intensity Modulated Radiation Therapy (IMRT) : daily for 6 weeks~Cisplatin will be administered intravenously on predetermined days~Stereotactic Body Radiotherapy (SBRT)"
2563722|NCT02474368|Experimental|Cohort 2|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Cohort 2 (patients with metastatic solid tumors of any histology who have targetable lesions within the head and neck) -- Stereotactic Body Radiotherapy (SBRT)"
3207080|NCT00960973|Placebo Comparator|Placebo control|Placebo control
3208882|NCT00978978|Active Comparator|Propofol, endoscopies, liver diseases|Propofol, endoscopies, liver diseases
2563842|NCT02473315|Experimental|cryotherapy|
2563844|NCT02473315|Placebo Comparator|light cryotherapy|
2563871|NCT02473068|Active Comparator|Group 1|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 31°C.
2563873|NCT02473068|Experimental|Group 2|In random order, CPAP via a standard humidifier with chamber output temperature of 31°C, or CPAP with a prototype humidifier with chamber output temperature of 27°C.
2563906|NCT02472834|Experimental|Amino acid supplementation NephrAmine®|250 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 8 weeks plus 4 weeks of follow-up.
2563908|NCT02472834|No Intervention|Standard-of-care|Standard-of-care does not include amino acid supplementation, but this control arm will be evaluated for the same outcomes as the experimental arm for 8 weeks plus 4 weeks of follow-up
2563956|NCT02472600|Active Comparator|colistin + neomycin followed by FMT|"CAPSULE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days) Treatment day 6: no treatment~Treatment days 7 and 8:~-15 capsules of capsulized Fecal microbiota transplantation (FMT) per os per day~NASOGASTRIC TUBE APPROACH:~Treatment days 1-5~Colistin sulphate 2 million IU per os 4x/day (for 5 days)~Neomycin sulphate 500 mg (salt) per os 4x/day (for 5 days)~Treatment day 6 and 7:~- Omeprazole 20 mg per os 1 dose on the evening of day 6 and on the morning of day 7~Treatment day 7:~- Infusion of 80 ml of a standardized stool suspension through a nasogastric tube - Fecal microbiota transplantation (FMT)"
2563957|NCT02472600|No Intervention|No intervention|Control arm without any intervention
2564009|NCT02472080|Experimental|gemcitabine -oxaliplatine combination|
2564093|NCT02471911|Experimental|All subjects|"All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.~RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone."
2564120|NCT02471222|Experimental|ADS-5102 (amantadine HCl extended release)|
2564122|NCT02471222|Placebo Comparator|Placebo|
2564174|NCT02470845|Experimental|Tian Jiu group|The TJ group will undergo a 4-week treatment with herbal patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in the TJ group will be treated with herbal patches of Tian Jiu group on five acupoints on the back.
2564187|NCT02470845|Sham Comparator|Placebo-control group|The placebo-control group will undergo a 4-week treatment with placebo patches one session per week and a 4-week post-treatment follow-up, of one assessment session per week. Participants in this group will be treated with placebo patches of placebo-control group on the same acupionts as the TJ group.
2564726|NCT02467296|Active Comparator|A: 1.5 gr of Sodium|Meal Plans with 1.5 gr of Sodium
3208883|NCT00978978|Active Comparator|midazolam and fentanyl, endoscopies, liver diseases|Control: midazolam and fentanyl, endoscopies, liver diseases
3208884|NCT00979004|Experimental|ICA-105665|
3208885|NCT00979043|Active Comparator|Dietary weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
2563632|NCT02474654|Experimental|Arm 1: PI+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
2563634|NCT02474654|Experimental|Arm 2:NS+FNB+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, 0.5% Ropivicaine with1:400,000 Epinephrine 30ml, Normal Saline 100ml
2563638|NCT02474654|Experimental|Arm 3: PI+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
2563642|NCT02474654|Experimental|Arm 4: PI+FNB+NS|Bupivicaine 15mg, Fentanyl 15mcg, Normal Saline 0.3ml, 0.5% Ropivicaine with 1:400,000 Epinephrine 30ml, Ropivicaine 100ml, Epinephrine 600mcg, Ketorolac 30mg
2563646|NCT02474654|Active Comparator|Arm 5:NS+NS+IO|Bupivicaine 15mg, Fentanyl 15mcg, Epimorphine 150mcg, Normal Saline 30ml, Normal Saline 100ml
2563879|NCT02473120|Experimental|Determination of ESR1 mutations|Blood sample will be collected every 3 months during two years to determine ESR1 mutations
2564036|NCT02472015|No Intervention|normal care|patients who will have normal care
2564041|NCT02472015|Experimental|telemedicine|patients who will have telemedicine
3172178|NCT00596765|Other|2|"Waiting list: Patients are randomly assigned to one of two existing groups after completion of the first session of various neuropsychological tests and interviews.~Patients assigned to the experimental group receive therapy immediately after completing the first session of various neuropsychological tests and interviews. Patients randomized to the waiting list receive the treatment as specified above after waiting for 5 month."
3172179|NCT00596778|Other|C, CP|Thirty-one adults were randomly assigned to control (C) and chest physiotherapy (CP) groups. Chest physiotherapy group received treatment at the post-anesthesia unit care and control group did not.
2564339|NCT02469766|Active Comparator|Extracorporeal Shockwaves|Patients in this arm will undergo SWL
2564340|NCT02469766|Active Comparator|Semirigid URS|Patients in this arm will undergo Semirigid Ureteroscopy
2564341|NCT02469766|Active Comparator|Flexible URS|Patients in this arm will undergo Flexible Ureteroscopy
2564406|NCT02469532||Atherectomy|"Up to 20 atherectomy procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-atherectomy revascularization procedures."
2564407|NCT02469532||Angioplasty|"Up to 20 angioplasty procedures at up to 5 sites in the United States. Change in inflammatory biomarkers (hs-CRP, MCP-1 and MMP-9) from baseline to 24 hours post-procedure and 30-days post-revascularization procedure.~This registry will also observe outcomes (target lesion revascularization rates, 6 and 12 month duplex ultrasound-detected binary restenosis with PSVR>2.4) post-angioplasty revascularization procedures."
2564461|NCT02469103|Experimental|C2 & colonoscopy|C2 and colonoscopy
2564510|NCT02468843||Biphasic DBS stimulations|Subjects in this group with have Biphasic DBS stimulation setting performed, Unified Dystonia Rating Scale (UDRS), and Burke-Fahn- Marsden scale (BFMDRS), tremor accelerometer, kinesia accelerometer, and GaitRite walking assessments performed.
2564559|NCT02468388|Experimental|maltitol|
2564564|NCT02468388|Active Comparator|xylitol|
2564568|NCT02468388|Placebo Comparator|gum base|
2564572|NCT02468388|No Intervention|no gum|
2564610|NCT02468063|Experimental|Noradrenaline + low dose terlipressin|
2564618|NCT02468063|Active Comparator|Noradrenaline|
2564646|NCT02467738|Experimental|Cesium-131 Brachytherapy|Patients undergo brachytherapy using Cesium-131 during surgical resection
2564779|NCT02466841||Patients undergoing cubital tunnel release surgery|Patients undergoing cubital tunnel release surgery will be enrolled. All enrolled subjects will be followed regardless of the technique used by surgeon.
2564802|NCT02466542|Placebo Comparator|Placebo group|Patients in placebo group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a saline 0,9% infusion pump.
2564811|NCT02466542|Active Comparator|Esmolol group|Patients in esmolol group will receive general balanced inhaled anesthesia with sevoflurane and remifentanil and a bolus infection of esmolol 500 mgc/kg followed by a continuous infusion of esmolol 100 mcg/kg/min
2564883|NCT02466308|Experimental|SAM Ultrasound Diathermy Device|SAM (sam Professional System) 3 MHz ultrasound diathermy device: 4 hours/day, at least 5 days per week, for 6 weeks
2564929|NCT02465840|Placebo Comparator|Immobilization programs|custom-made protective hand splint physical therapy and occupational therapy
3172180|NCT00596791|Other|1 arm|Open-lable study with one arm.
3172181|NCT00596843|Experimental|1|Motivational intervention
3172182|NCT00596843|Active Comparator|2|Educational intervention
3172183|NCT00596856|Active Comparator|1|25 randomly selected pediatric practices that have never participated in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to non-participating practices)
3172184|NCT00596856|Experimental|2|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through the mail with instructions on how to implement them in the practice. (Passive dissemination to participating practices)
3172185|NCT00596856|Experimental|3|25 randomly selected pediatric practices currently participating in IMB will receive the newly developed risk assessment forms and guidelines through an intense in-office intervention. (Intense intervention with participating practices)
3172186|NCT00596882|Other|1|Threat only message. Participants hear information about the negative health consequences of smoking
3172187|NCT00596882|Other|2|Genetic threat + threat. Participants will bear infomration about genetic influences of smoking in additon to the negative health consequences of smoking.
3172188|NCT00596895|Experimental|1|Isoflavone treatment
3172189|NCT00596908||1|Subjects with Parkinsonian Tremor (PT)
3172190|NCT00596908||2|Subjects with non Parkinsonian Tremor (nPT)
3172191|NCT00596973|Experimental|Ileal transposition with SG|Procedure: Surgical Treatment
3172192|NCT00596986|Active Comparator|AD|Antidepressant Duloxetine
3172193|NCT00596986|Active Comparator|PT|Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
2563779|NCT02473770||Disaster responders|Conducting emergency disaster relief.
3207081|NCT00961012|Experimental|Intervention|"Experimenter A places the subject in the High Fowler's position by raising the foot of the bed to its highest position, 50 degrees, and the head of the bed to its highest position, 60 degrees. Experimenter A sets the timer for 8 minutes as per pressure mapping protocol. For more stable values, a settling time of 8 minutes is required to factor in creep of the pressure mapping sensors and mattress. Experimenter A aims the laser beam to the top of the scapulae where the subject's shoulder meets the mattress surface. Experimenter B initiates a FSA file with the subject's number, takes a pressure reading once 8 minutes is up, measures the trunk displacement, obtains spirometry readings as per protocol, and takes a measure of discomfort. Experimenter B leaves the room, Experimenter A sets the timer for 5 minutes and opens the randomization/ allocation envelope."
2563914|NCT02472951|Active Comparator|Type 2 diabetic subjects|
2563922|NCT02472951|Active Comparator|Prediabetic subjects|
2563927|NCT02472951|Active Comparator|Healthy subjects|
2563975|NCT02472431|Experimental|ADRC injection|
2564005|NCT02472158|Experimental|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
2564007|NCT02472158|Active Comparator|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
2564063|NCT02471807|Experimental|Edwards FORMA Tricuspid Transcatheter Repair System|Edwards FORMA Tricuspid Transcatheter Repair System
2564138|NCT02471443||Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
2564219|NCT02470702|Experimental|Oritavancin|Subjects randomized to oritavancin will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1200 mg oritavancin, infused intravenously over 3 hours
2564221|NCT02470702|Placebo Comparator|Placebo|Subjects randomized to placebo will receive four doses (Cohort 1) or eight doses (Cohort 2) of 1000 mL D5W, infused intravenously over 3 hours
2564276|NCT02470338|Active Comparator|MBP plus ankle arthroscopy (Group A)|Group A will receive a diagnostic ankle arthroscopy followed by the Modified Brostrӧm Procedure (MBP). In the ankle arthroscopy, multiple pictures are taken inside of the joint to note possible pathologic processes (for example - osteochondral lesions of the talus). Ankle arthroscopy involves one incision in the middle of the ankle anteriomedial (middle) incision and one incision on the outside of the ankle. Each incision (a small cut in the skin) is roughly 5mm in length (which is about 0.2 inches). After the incision is made, the participant will receive a diagnostic ankle arthroscopy.If the surgeon detects an abnormality inside the joint, he will operate on the abnormality with the arthroscope according to the generally accepted principles for treating the abnormality.
2564277|NCT02470338|Sham Comparator|MBP alone (Group B)|Group B will receive sham skin incisions on the ankle a Modified Brostrӧm Procedure (MBP) alone (that is, there will be no diagnostic ankle arthroscopy) followed by the Modified Brostrӧm Procedure (MBP). If a participant is assigned to Group B, the participant will receive two small superficial skin incisions at the sites where the investigators would normally insert instruments for the ankle arthroscopy. As with Group A, there will be one anteriomedial (middle) incision on the middle of the ankle and one anteriolateral (side) incision to on the outside of the ankle. Each incision will be roughly 5mm in length and 5 mm in depth, but will not violate subcutaneous tissue. The width of these incisions will be the width of the blade, at 1mm. However, unlike Group A, the participants in Group B will not have any instruments inserted into their ankle and will not have any operation to repair or remove damaged tissue.
2564304|NCT02470000|Experimental|Experimental Group|Intravascular laser irradiation of blood (ILIB, output power 0.3mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
2564309|NCT02470000|Sham Comparator|Control Group|Intravascular laser irradiation of blood (ILIB, output power 0mW), Transcutaneous electrical nerve stimulation (TENS), stretching exercise.
2564435|NCT02469155|Experimental|20 mg ITI-007|20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
2564439|NCT02469155|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks
2564443|NCT02469155|Placebo Comparator|Placebo|Placebo administered orally as visually-matched capsules once daily for 6 weeks
2564448|NCT02469155|Active Comparator|Risperidone|Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks
2564556|NCT02468323|Placebo Comparator|Placebo group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of saline 0,9%.
2564563|NCT02468323|Experimental|Ondansetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of ondansetron after cord clamping.
3172194|NCT00596999||1|all subjects will be treated with UCB and HPDSC
2563995|NCT02472340||Sedentary, Pre-frail|10 sedentary, pre-frail elderly, >61 year of age
2563996|NCT02472340||Active, Healthy|10 Active, healthy elderly, >61 years of age
2564045|NCT02472002|Experimental|Mesenchymal cell therapy|
2564056|NCT02471703||SMF mini-stem hip replacement recipient|Received the device via total hip arthroplasty
2564158|NCT02471131|Experimental|WATCHMAN Implantation|
2564197|NCT02470780|Experimental|Three-month follow-up|
2564201|NCT02470780|Experimental|Six-month follow-up|
2564228|NCT02470520||AKI without CRRT|Patients with AKI who are not treated with continuous renal replacement therapy
2564229|NCT02470520||AKI with CRRT|Patients with AKI who are treated with continuous renal replacement therapy
2564288|NCT02470221||Goal-directed fluid therapy|The fluid in group Goal-directed fluid therapy will be administered based upon real-time monitoring stroke volume variation and cardiac output achieved by the Flo-Trac monitoring system.
2564290|NCT02470221||Conventional fluid therapy|The fluid in group Conventional fluid therapy will be administered based on the principle crystalloid solution: colloid solution =2-3:1. The total volume of fluid will be adjusted in accordance with blood pressure, heart rate and urine output of each patient.
2564345|NCT02469922|Experimental|Positron emission tomography|Two additional PET Scan will be performed at 2 and 4 weeks for the first 30 patients. Then for the other patients only one additional PET-Scan will be performed
2564397|NCT02469493|Experimental|Acupuncture 1|In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
2564398|NCT02469493|Experimental|Acupuncture 2|In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
2564399|NCT02469493|Sham Comparator|Sham acupuncture|In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist. S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
2564400|NCT02469493|No Intervention|Waitinglist control|In this group, patients received no electroacupuncture
2564417|NCT02469207||Deceased organ donors|Patients with consent for organ donation towards transplantation and research. Organs not used for transplantation will be used for this study if determined appropriate and necessary.
2564785|NCT02466919|Experimental|Levofloxacin-based concomitant|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day10 Metronidazole 500 mg BID day1~day10 Levofloxacin 500 mg QD day1~day10
2564789|NCT02466919|Active Comparator|Sequential|Pantoprazole 40 mg BID day1~day10 Amoxicillin 1000 mg BID day1~day5 Metronidazole 500 mg BID day6~day10 Clarithromycin 500 mg BID day6~day10
3172195|NCT00597025|Active Comparator|Group A|Center Hemodialysis patients
3172196|NCT00597025|Active Comparator|Group B|Center hemodialysis patients
3172197|NCT00597025|No Intervention|Group C|Center Hemodialysis Patients
3172198|NCT00597025|Active Comparator|Group D|Peritoneal dialysis patients
3172199|NCT00597025|No Intervention|Group E|Peritoneal dialysis patients
3172200|NCT00597077|Active Comparator|Rate control|
3172201|NCT00597077|Active Comparator|Rhythm control|
3172202|NCT00597090||1|
3172203|NCT00597103||1|Prevalent patients who have been receiving more frequent dialysis.
3172204|NCT00597103||2|Incident patients new to more frequent dialysis
3172205|NCT00597103||3|Patients who switch from one more frequent hemodialysis treatment regimen to another more frequent dialysis regimen.
3172206|NCT00597129|Experimental|Multi Dose levels|different doses of 90YhPAM4 will be given only once.
3172207|NCT00597142|Experimental|1|
3172208|NCT00597181|Active Comparator|1|Trabeculectomy with Mitomycin C 0.2 mg/cc for 2 minutes
3172209|NCT00597181|Active Comparator|2|Ex-Press mini shunt; Model R50 with mitomycin C 0.2 mg/cc for 2 minutes
3172210|NCT00597194|Active Comparator|OH|Inguinal hernia operated using a classic open herniotomy(OH)
3172211|NCT00597194|Active Comparator|LH|Laparoscopic herniorraphy (LH) for inguinal hernia
3172212|NCT00597220|Experimental|1|Omega 3
3172213|NCT00597220|Placebo Comparator|2|
3172214|NCT00597259|Experimental|A|
3172215|NCT00597259|Active Comparator|B|Entecavir Alone
3172216|NCT00597298|Active Comparator|1|inspiratory muscle training program using a pressure threshold device
3172217|NCT00597298|Sham Comparator|2|
3172218|NCT00597311|Experimental|1|preoperative short term radiation group 5x5 Gy and surgery after 6 weeks
3172219|NCT00597311|Experimental|2|preoperative chemoradiotherapy group 50Gy + 5FU/Lv and surgery after 6 weeks.
3172220|NCT00597324|Active Comparator|1|Patients with normal Allen's test
3172221|NCT00597324|Experimental|2|Patients with intermediate Allen's test
3172222|NCT00597324|Experimental|3|Patients with abnormal Allen's test
3172223|NCT00597337|Experimental|1|Receiving FearNot
3172224|NCT00597337|No Intervention|2|Control: Treatment as usual (normal curriculum)
3172225|NCT00597350||1|Group with diabetes mellitus
3172226|NCT00597363|Experimental|1|Neptune PAD utilization to accelerate closure of the vascular access site
3172227|NCT00597363|Active Comparator|2|manual compression for closure of the vascular access site
3172228|NCT00597389|Active Comparator|1|oral solution of propranolol (propranolol HCL 20 mg/5 ml solution) or a liquid placebo twice daily for 10 days (and taper for 5 days; based on Pitman et al, 2002). Dose was calculated as determined by Famularo et al. (1988) to be 2.5 mg/kg/d with a maximum dose of 40 mg bid (Green, 2001).
3172229|NCT00597389|Placebo Comparator|2|A 25/5ml solution of placebo (a sugar solution that looks and tastes like the propranolol solution)
3172230|NCT00597415|Placebo Comparator|A 1|A 1=placebo
3172231|NCT00597415|Active Comparator|A 2|A 2=celecoxib
3172232|NCT00597441|Experimental|I|Thymic tissue from third party donor
3172233|NCT00597454|Experimental|1|
3172234|NCT00597467|Experimental|Test Contact Lenses|VISA (comfilcon A) Silicone Hydrogel Soft contact lens
2563747|NCT02473926|Experimental|Physical Activity Program Intervention|"The intervention seeks to increase physical activity and improve strength by addressing individual , behavioral, and social/environmental factors. Health promotion clinic staff will deliver counseling by phone on a bi-weekly basis - a clinic physician assistant will coordinate with the counselor during in-person clinic visits, teach participants to perform strengthening exercise, and assess for safety concerns associated with type 2 diabetes.~In addition to behavioral counseling targeting social cognitive theory constructs, counselors will assist participants in the intervention group to set specific goals for physical activity in a paper log and on an electronic FitBit activity tracking device.Health promotion clinic staff will encourage participants to advance goals towards meeting U.S. physical activity guidelines of 150 minutes/week of moderate intensity activity and 2-3 days/week of strength activities."
2563751|NCT02473926|Other|Usual Care Group|Participants in the usual care arm will receive three mailings (Intervention Questionnaires) during the intervention phase. Health promotion clinic staff will mail materials from the Center for Disease Control and Prevention website that address general health aging topics.
2563785|NCT02473666||All Health Conditions.|All Health Conditions. Area of Focus: Transfusions of blood products.
2564047|NCT02472067|No Intervention|Physical Therapy|Usual care of physical therapy and rehabilitation for a musculoskeletal injury. Patients complete self-rated standardized surveys before and following treatment.
2564050|NCT02472067|Experimental|Psychologically-Based Physical Therapy|Psychologically-Based Physical Therapy includes the early identification and management of psychological obstacles to recovery in order to modify maladaptive responses previously found to be associated with chronicity and disability. This is accomplished through patient education, an emphasis on functional goals and encouraging self-care techniques. Patients complete self-rated standardized surveys before and following treatment.
2564079|NCT02471690|Active Comparator|Oritavancin|IV -Single Dose - 1200 mg Oritavancin
2564087|NCT02471690|Placebo Comparator|Placebo|250 mL Dextrose 5% in Water
2564163|NCT02471066|Experimental|active rTMS|12 patients will be enrolled in this arm.
2564164|NCT02471066|Sham Comparator|sham rTMS|12 patients will be enrolled in this arm.
2564227|NCT02470715||Molecular profile|Molecular profiled group receiving treatment based on genetics
3172235|NCT00597467|Active Comparator|Control Contact Lenses|Acuvue 2 Soft Contact Lens
2564403|NCT02469376|Experimental|Diagnosis with GP1|Injection and scanning of [18F]-GP1
2564449|NCT02469181||FD(Fabry disease) group|28 patients with newly diagnosed genetically confirmed Anderson-Fabry's disease will undergo diastolic stress echocardiography, LV vortex flow analysis, and cardiac MRI before enzyme replacement therapy(ERT) (baseline study) and after 1 year of treatment with agalsidese beta at the dose of 1mg/kg (follow-up study).
2564538|NCT02468596|Experimental|Patients|Patients suffering from anti-MAG neuropathy
2564580|NCT02468258|Active Comparator|endometrial flushing (A)|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected in a sterile container and was centrifuged at 600 rpm for 10 min at room temperature and a 5-ml sample of the supernatant was obtained for laboratory workup, while the remaining amount of supernatant was used to flush the endometrium through an applied uterine catheter in FF group and was discarded in the other group.
2564585|NCT02468258|No Intervention|B|no intervention Control group included 40 women would not have FF endometrial flushing.
2564624|NCT02467907|Experimental|Bevacizumab in Combination with Carboplatin and Paclitaxel|Administration of bevacizumab, carboplatin and paclitaxel once every 3 weeks, for at least 6 cycles, until disease progression (as assessed by the investigator), unacceptable toxicity, physician or participant decision or withdrawal of consent. If either chemotherapy or bevacizumab is discontinued, the participant may continue to receive the other ongoing therapy.
2564672|NCT02467374|Active Comparator|Immediate Behavior Therapy|If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
2564674|NCT02467374|Active Comparator|Waitlist Behavior Therapy|Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
3172236|NCT00597480|Active Comparator|1|the recommended dose in the EU of rhGH (Norditropine SimpleXx®)
3172237|NCT00597480|Active Comparator|2|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
3172238|NCT00597532|Experimental|1|soy (soy protein supplementation 50 grams/day)
3172239|NCT00597532|Placebo Comparator|2|milk protein supplementation 50 grams/day
3172240|NCT00597597|Experimental|A|Open label; all subjects receive active drug, Erlotinib
3172241|NCT00597610|Experimental|1|
3172242|NCT00597623|Experimental|1|2 injections of Adalimumab (Humira®)
3172243|NCT00597623|Placebo Comparator|2|2 injection of Placebo
3172244|NCT00597636||1|NEVER SMOKERS WITH LUNG CANCER
3172245|NCT00597636||2|NEVER SMOKERS WITHOUT ANY CANCER
3172246|NCT00597649|Experimental|1|Bicifadine 800 mg/day for a year
3172247|NCT00597649|Experimental|2|Bicifadine 1200 mg/day for a year
3172248|NCT00597662|Experimental|1|
3172249|NCT00597662|Active Comparator|2|
3172250|NCT00597688|Active Comparator|1|Chlorhexidine gel
3172251|NCT00597688|Placebo Comparator|2|Placebo gel
3172252|NCT00597779|Active Comparator|EM device|Extramedullary Device (EM)
3172253|NCT00597779|Active Comparator|IM device|Intramedullary Device (IM)
3172254|NCT00597792|Active Comparator|A|Active Plicator Treatment
3172255|NCT00597805||1|Patients scheduled for a total, anterior or posterior pelvic exenteration
2563820|NCT02473276|Active Comparator|EPID PFM|"The group EPID PFM will receive 3 mg (6 ml) of preservative-free morphine, followed by 3 ml of sterile normal saline, to be administered through the epidural catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
2563823|NCT02473276|Sham Comparator|EPID SAL|"The placebo group, EPID NS, will receive 6 ml of sterile normal saline via the epidural catheter followed by another 3 ml NS. Sixteen to 24 hours after receiving the first study drug,the patient will then receive the identical study drug (for a total of two doses)."
2563827|NCT02473276|Active Comparator|IT PFM|"The group, IT PFM will receive 200 micrograms (mcg) (0.4 ml) of preservative-free morphine via the intrathecal catheter, followed by a flush of the catheter with 2 ml of sterile saline.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses)."
2563833|NCT02473276|Sham Comparator|IT SAL|The placebo group IT SAL will receive 0.4 ml and then 2 ml of sterile normal saline through the intrathecal catheter.Sixteen to 24 hours after receiving the first study drug, the patient will then receive the identical study drug (for a total of two doses).
2563878|NCT02473016|Experimental|Treatment|All subjects will receive both Active (Carbon Dioxide Drug Delivery System) and Placebo. This is a single-blind study so subjects will not know the order. Subjects will receive 3 doses of active and 3 doses of placebo. One dose is a 60 second delivery of CO2 or placebo. At the discretion of the investigator, subjects may receive up to 3 additional doses of CO2.
2563916|NCT02472769|Active Comparator|IBP-9414|IBP-9414 Oral Daily
2563921|NCT02472769|Placebo Comparator|Placebo|Sterile water
2563961|NCT02472379|Experimental|Writing: Group 1|Subjects will be asked to write about experiences with familiar individuals in their lives.
2563963|NCT02472379|Placebo Comparator|Writing: Group 2|Subjects will be asked to write about experiences with familiar places in their lives.
2564012|NCT02472249|Experimental|Norepinephrine intra-arteriel/hepatic|This is the only arm of this study. These patients will receive 24 micrograms of norepinephrine in the hepatic artery with subsequent CT perfusion imaging to evaluate liver blood flow.
2564062|NCT02471833|Experimental|Telmisartan 20mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 20mg once a day orally.
2564069|NCT02471833|Experimental|Telmisartan 40mg|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive Telmisartan 40mg once a day orally.
2564074|NCT02471833|Placebo Comparator|Placebo|African American subjects with hypertension and at high risk for Alzheimer's disease will be randomly assigned to receive placebo once a day orally.
2564157|NCT02470819|Experimental|Targeted Therapy|Those who will receive targeted therapy based on their genetic profiling
2564199|NCT02470793|Active Comparator|DSAEK group|Subjects operated of Descemet Stripping Automated Endothelial Keratoplasty.
2564203|NCT02470793|Experimental|DMEK group|Subjects operated of Descemet Membrane Endothelial Keratoplasty.
2564248|NCT02470468|Experimental|DCVAC add on to SOC|Combination therapy with DCVAC and Standard of Care (Carboplatin, Paclitaxel)
2564249|NCT02470468|Experimental|DCVAC and immune enhancers add on to SOC|Combination therapy with DCVAC, immune enhancers (Interferon-α, Hydroxychloroquine) and Standard of Care (Carboplatin, Paclitaxel)
2564253|NCT02470468|Other|Standard of Care Chemotherapy|Standard of Care chemotherapy (Carboplatin, Paclitaxel)
2564347|NCT02469948|Experimental|Ultrasonography direct-guidance|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance.
2564348|NCT02469948|Active Comparator|Surface anatomy landmark|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Surface anatomy landmark.
2564395|NCT02469454|Experimental|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
2564396|NCT02469454|Active Comparator|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted after 6 week of the delivery. The ENG implant will be inserted subdermally in the non-dominant arm of volunteers upon local anesthesia with 2% lidocaine with vasoconstrictor, according to the manufacturer's instructions.
2564436|NCT02469259|Experimental|Treatment|Subjects will receive either 20IU or 40IU intranasal oxytocin
2564440|NCT02469259|Placebo Comparator|Placebo|Subjects will receive intranasal saline spray
2564504|NCT02468908|Experimental|Molgramostim nebuliser solution, inhaled|Single dose 150, 300 and 600 ug, multiple dose 300 and 600 ug for 6 days
2564507|NCT02468908|Placebo Comparator|Nebuliser solution, inhaled|Inhaled nebuliser solution
2564581|NCT02468453|Experimental|Cohort 1 -facial skin disorders|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of facial skin disorders including photo-damage, age spots, lentigos, solar telangiectasia and general facial telangiectasia
2564583|NCT02468453|Experimental|Cohort 2 - leg veins|Pulsed dye laser/bipolar radiofrequency (Velos) treatment of leg veins of diameter of at least 1mm, i.e., venulectasia and reticular leg veins.
2564586|NCT02468453|Experimental|Cohort 3-general skin rejuvenation|Pulsed dye laser/bipolar radiofrequency (Velos) treatment treatment of general skin rejuvenation including Rosacea, erythematous scars (including acne), and erythematous striae (subjects enrolled in this group must have at least two of the above mentioned treatment indications.
2564587|NCT02468453|Experimental|Cohort 4-improving skin laxity|Velos (Bipolar radiofrequency only) treatment for improving skin laxity or skin tightness/firmness
2564658|NCT02467855||Cross-Sectional Cohort|Participants receiving standard of care for hypertension with well-controlled hypertension will participate in 1 visit.
2564660|NCT02467855||Longitudinal Cohort|Participants receiving standard of care for hypertension with history of hypertension who are uncontrolled on the current antihypertensive medications or participants with newly diagnosed hypertension (diagnosed within the past 4 weeks and uncontrolled on antihypertensive therapy) will be observed over the course of 12-16 weeks.
3172256|NCT00597831||A|All patients in the Rijnstate Hospital with an indication for unilateral ECT treatment and a major depression or psychotic depression according to DSM IV-TR criteria.
2563981|NCT02472392|Active Comparator|Treatment Plan A|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Busulfan (BU) will be given at a dose of 0.8 mg/kg IV q 6 hrs. BU doses will be modified based upon pharmacokinetics data to maintain steady state levels of 600-900 ng/dl. Seizure prophylaxis with levetiracetam should begin prior to the 1st dose of BU and stoped 24 hrs after the last dose of BU. Melphalan will be given at a dose of 60 mg/m2 I.V. over 15-20 min per Pediatric SCT Standards of Practice Manual.
2563984|NCT02472392|Active Comparator|Treatment Plan B|Rabbit anti-thymocyte globulin (ATG) will be given only to unrelated donor transplant recipients at a dose of 3 mg/kg/day I.V. Equine ATG at a dose of 30mg/kg/day may be substituted in the event of severe allergic reaction to the rabbit ATG. Rabbit ATG is only used with recipients of unrelated donor marrow or peripheral blood transplants. Fludarabine will be given at a dose of 30 mg/m2/day IV over 30 mins for 5 doses. Cyclophosphamide will be given at a dose of 50 mg/kg/day IV over 2 hrs for 4 doses.
2564049|NCT02471989|Experimental|Low-FODMAP diet|FOS in diet
2564052|NCT02471989|Active Comparator|Classical GERD diet|avoid fatty meals, head of bed elevation...
2564151|NCT02471157||Eugonadal|Eugonadal men
2564153|NCT02471157||Hypogonadal|Hypogonadal men
2564171|NCT02470871|Experimental|Low-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the low dose
2564184|NCT02470871|Experimental|High-dose CSL689|Single dose of subject's routine FVII replacement therapy (either eptacog alfa [activated] [ie, comparator drug 1] or pdFVII [ie, comparator drug 2]), followed by a single dose of CSL689 at the high dose.
2564212|NCT02470611|Experimental|Sodium Alendronate|Adjunctive use of 1% sodium alendronate gel as part of periodontitis treatment
2564213|NCT02470611|Placebo Comparator|Placebo|Adjunctive use of placebo gel as part of periodontitis treatment
2564462|NCT02469051|Other|Breathhold SPECT-MPI vs. standard freebreathing SPECT-MPI|
2564508|NCT02468817|Active Comparator|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions, one at 16 degrees C and one at 26 degrees C.
2564513|NCT02468817|Experimental|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise.
2564553|NCT02468284|Experimental|Degarelix|
3172257|NCT00597844|Experimental|1|voice evaluation and fMRI prior to surgical rehabilitation of UVCP
3172258|NCT00597844|Other|2|Healthy volunteers-voice evaluation and fMRI
2564696|NCT02467361|Experimental|Combo with Ipilimumab|
2564704|NCT02467361|Experimental|Combo with Nivolumab|
2564708|NCT02467361|Experimental|Combo with Pembrolizumab|
2564775|NCT02467010|Experimental|Bortezomib, cyclophosphamide, dexamethason|"To assess the efficacy of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy.~To assess the safety of bortezomib, cyclophosphamide and dexamethasone during re-induction and in maintenance therapy in patients with refractory or relapsed multiple myeloma."
2564833|NCT02466529||type 1 spinal muscular atrophy|The age of onset of patients with type 1 SMA is below 6 months of age.
2564862|NCT02466321|Experimental|Inverse / Reverse Shoulder|Patient treated with a inverse / reverse shoulder device.
2564896|NCT02466035|Experimental|Lactobacillus GG|Treatment with Lactobacillus rhamnosus GG
2564897|NCT02466035|No Intervention|Other formula|Children assuming other hypoallergenic formulas
2564977|NCT02465801|Experimental|Group 1|"Intervention: HSA-GCSF 1.2 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.2mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration."
2564979|NCT02465801|Experimental|Group 2|"Intervention:HSA-GCSF 1.5 mg~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein（1.5mg）will be injected subcutaneously at night o'clock a.m. in the 3rd and 7th day of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. If not up to standard, investigator should decide whether or not the third administration.~Intervention: Drug: TE or TEC"
3172259|NCT00597857|Placebo Comparator|1|receipt of a placebo pill for 16 days
3172260|NCT00597857|Active Comparator|2|oral pill of hydrocortisone (ranging from 20mg - 2.5mg) taken for 10 days with a taper for 6 days (based on Pitman et al, 2002).
3172261|NCT00597870|Experimental|Treatment of Thoracic Lesions|Endoluminal treatment of thoracic lesions
3172262|NCT00597922||1|2,000 women between the ages of 18 and 55 years who are hospitalized with a heart attack
3172263|NCT00597922||2|1,000 men between the ages of 18 and 55 years who are hospitalized with a heart attack
3172264|NCT00597948|Experimental|1|Workshop Group: Receives Healthy Lifestyles curriculum and subsequent support.
3172265|NCT00597948|No Intervention|2|Comparison Group: Does not receive Healthy Lifestyles curriculum and subsequent support.
3172266|NCT00597974||Patients having angioplasty (case)|Patients undergoing carotid artery angioplasty and/or stent-supported angioplasty for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
3207082|NCT00961012|No Intervention|Control group|"Experimenter A reminds the subject to remain immobile.~For both intervention and control group. After the five-minute period, experimenter A calls experimenter B to return. Experimenter B takes a pressure reading, measures the trunk displacement, obtains spirometry readings, and takes a measure of discomfort."
2564008|NCT02472327|No Intervention|Typical Care|These patients will receive normal peripartum care and support.
2564016|NCT02472327|Experimental|Pre-operative support|These patients will receive additional emotional support prior to undergoing an unplanned cesarean section during labor.
2564080|NCT02471898|Experimental|HTX-011|Evaluate the analgesic efficacy of HTX-011
2564089|NCT02471898|Placebo Comparator|Placebo|Saline
2564605|NCT02468011|Experimental|Vibration|Whole body vibration with 35 Hz
2564717|NCT02467829|No Intervention|10° of elbow flexion|This handle height is the nearest position the walker can be set to to achieve 10° of elbow flexion. Elbow flexion is measured with the child standing in their walker using an electronic goniometer.
2564718|NCT02467829|Experimental|30° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 30° of elbow flexion.
2564721|NCT02467829|Experimental|50° of elbow flexion|Increase in handle height. This handle height is the nearest position the walker can be set to to achieve 50° of elbow flexion.
2564758|NCT02467062|Active Comparator|4Dflow MRI parallel imaging|4D flow MRI with conventional parallel imaging
2564762|NCT02467062|Other|4D flow ktARC parallel imaging|4D flow MRI kt ARC spatiotemporal parallel imaging
2564996|NCT02465580|Active Comparator|hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
2564999|NCT02465580|Placebo Comparator|hrIL-2 placebo|1 million U doses of placebo s.c. injection
2565060|NCT02465125|Active Comparator|Low transfusion trigger|Intervention group. Low or restrictive transfusion trigger: hemoglobin < 5 mmol/L (approx. 8 g/dl or a hematocrit of 25%) This trigger is what is recommended by the Danish Health and Medicines Authority for stable patients with chronic heart disease.
2565075|NCT02465125|Active Comparator|High transfusion trigger|Control group. High or liberal transfusion trigger: hemoglobin < 6 mmol/L (approx. 10 g/dl or a hematocrit of 30%) This trigger reflects the practice among Danish vascular anesthesiologists and correspond to the transfusion trigger recommended by the European society for vascular surgery
2565131|NCT02464722|Experimental|Dexmedetomidine|"Before induction of Anesthesia, 1 mcg/kg iv loading dose of dexmedetomidine over 10 minutes.~Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~After Mask ventilation with 6 vol% desflurane in 100% oxygen for 3 minutes, tracheal intubation was done~Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and dexmedetomidine, sending recovery room."
2565133|NCT02464722|Active Comparator|Remifentanil|"Anesthesia was induced with propofol 2 mg kg-1 , rocuronium 0.6 mg kg-1~Mask ventilation with 6 vol% desflurane in 100% oxygen for 2 minutes.~After 1 mcg/kg iv loading dose of remifentanil over a period of 1 minutes. tracheal intubation was done.~Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min. The infusion rate was adjusted according to the patient's response, to achieve a mean arterial pressure between 60 and 80 mmHg.~Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.~At the end of surgery, discontinuation of desflurane and remifentanil, sending recovery room."
2565192|NCT02464488||Main cohort (only cohort of the study)|Patients aged 80 years or older under treatment with dabigatran, rivaroxaban or apixaban because atrial fibrillation. All patients will have plasma drug concentrations measured and will be followed afterwards similarly
3172267|NCT00597974||Patients having angiography (control)|Patients undergoing coronary angiography for the treatment of carotid artery stenosis will receive neurological and neuropsychological evaluations
3172268|NCT00597987||1|RNA samples
3172269|NCT00598000||1|Determine the impact, in terms of quality of life (QOL), of minimally invasive, video-assisted thoracic surgery (VATS)
3172270|NCT00598000||2|Determine the impact, in terms of quality of life (QOL), in traditional thoracotomy and anatomic lung resection in early stage lung cancer.
3172271|NCT00598013|Experimental|1|
3172272|NCT00598013|No Intervention|2|
3172273|NCT00598026|Experimental|1|Tele- follow-up: remote transmission to the implantation centre every 3 months
3172274|NCT00598026|Active Comparator|2|Conventional follow-up: visits at the implantation centre every 3 months
3172275|NCT00598052|Active Comparator|A|Escitalopram + cognitive-behavior treatment
3172276|NCT00598052|Placebo Comparator|B|Placebo + cognitive-behavior therapy
3172277|NCT00598091|Active Comparator|A|
3172278|NCT00598091|Active Comparator|B|
3172279|NCT00598104|Experimental|1|
3172280|NCT00598104|Placebo Comparator|2|
3172281|NCT00598117||1|Group 1 (newly diagnosed patients) Initial assessment → first post op visit → 6 and 12 months post surgery
3172282|NCT00598117||2|Group 2 (post-treatment patients) A one-time assessment will be conducted at least 18 months following treatment
3172283|NCT00598130|Experimental|I|patients who will be treated in accordance with standard of care
3172284|NCT00598130|Active Comparator|II|patients for which the Fibrin Fleece will be applied directly on the active bleeding site.
3172285|NCT00598143||Group A|Ten healthy smokers will provide a saliva sample used to genotype UGT1A7 and complete a questionnaire to assess understanding of and willingness to participate in molecular risk assessments.
3172286|NCT00598143||Group B|Thirty smokers will receive standard smoking cessation therapy and provide urine specimens for PGE-M analysis at approximate 3-monthly intervals over one year. Self-reported smoking status and expired-air carbon monoxide (CO) will also be recorded at 3-monthly clinic visits.
3172287|NCT00598156|Experimental|1|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab and erlotinib as maintenance treatment until progression
3172288|NCT00598156|Experimental|2|bevacizumab and chemotherapy (according to investigators choice) during 18 weeks, followed by bevacizumab every third week until progression
3207083|NCT00961025|Placebo Comparator|Placebo|
3207084|NCT00961025|Experimental|DA-1229|DA-1229
2564098|NCT02471573|Active Comparator|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
2564099|NCT02471573|Active Comparator|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
3207085|NCT00961038|Experimental|Arm 1|
3207086|NCT00961038|Experimental|Arm 2|
3207087|NCT00961038|Placebo Comparator|Arm 3|
2564258|NCT02470286|Experimental|SA001|Dose escalation
2564263|NCT02470286|Placebo Comparator|Placebo|Dose escalation
2564301|NCT02470104|Experimental|Enteral Donor Breastmilk|"Donor milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
2564302|NCT02470104|No Intervention|Control|• Children randomized to the control arm will receive standard enteral or parenteral nutrition per standard clinical practice, supervised by a registered dietician.
3207088|NCT00961090|Other|Single-Arm|Single-Arm All subjects received 20mg/kg of Aminolevulinic Acid diluted in 50cc of water, orally, approximately 3 hours prior to surgery.
3207089|NCT00961103||SMA II and SMA III|patients with SMA II and SMA III
2564523|NCT02468661|Experimental|INC280 200mg BID + ERL 150mg QD|Subjects who took INC280 200mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
2564525|NCT02468661|Experimental|INC280 400mg BID + ERL 150mg QD|Subjects who took INC280 400mg twice a day (BID) in combination with erlotinib (ERL) 150mg one a day (QD)
2564592|NCT02468206|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
2564594|NCT02468206|Active Comparator|NBCA|Endoscopic Cyanoacrylate injection in the gastric varix
2564649|NCT02467803|Active Comparator|Intervention|We applied scapula mobilization with shoulder ROM exercises
2564650|NCT02467803|Other|Control|We applied only shoulder ROM exercises
3207090|NCT00961129||patients with colorectal cancer|patients with colorectal cancer in any stage or survivors
3207091|NCT00961155|Active Comparator|cyklezonid|children will receive 160 mcg once daily cyklezonid for 3 months
2564765|NCT02467205|Other|Intervention|pedometer supported walking and education A ;pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period Educational component; participants will attend six weekly sessions in small groups of up to six people; the content of the sessions will be based on educational cognitive behavioural programme development, In addition, participants will receive education material in the first education session. The intervention group will receive two booster sessions, after 3 and 6 months.
2564770|NCT02467205|No Intervention|Control|participants randomly allocated to the comparison group will receive one education session (visit 2) regarding the importance of exercise and healthy diet and will be given education material similar to intervention group and encouraged to read it.
3207092|NCT00961155|Active Comparator|montelukast sodium|children will receive 5 or 10 mg montelukast sodium for 3 months
3207093|NCT00961155|Placebo Comparator|placebo|children will receive placebo for 8 weeks out of allergy season to house dust mite
3207094|NCT00961155|Active Comparator|formoterol|children will receive formoterol aerolzol 12mcg twice daily for 3 months
2564923|NCT02465892|No Intervention|Standard Care|Subjects in this group will continue receiving standard care from their provider team.
2564924|NCT02465892|Experimental|Pillars4Life|Subjects in this group will complete the Pillars4Life online coping skills curriculum.
3207095|NCT00961168|Experimental|Lung-Protective Ventilation|Lung-Protective Ventilation comparing volume vs. pressure control
3207096|NCT00961194|Placebo Comparator|placebo|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3207097|NCT00961194|Experimental|dose of ketamine tested = 0.35 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3207098|NCT00961194|Active Comparator|dose of ketamine tested = 0.7 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
2565081|NCT02464930||No-GERD Controls|"NERD controls will be enrolled from subjects presenting to the endoscopy unit who are being evaluated for reasons other than GERD or BE surveillance. These are patients who are referred to the endoscopy unit for: evaluation of anemia, dysphagia, occult blood positivity, gastrointestinal blood loss etc.~No history of GERD~Response no to presence of symptoms on a standardized GERD questionnaire~No prescriptions for acid suppressive medication over the past 2 years as documented in electronic pharmacy records.~Normal endoscopy that does not find Barrett's esophagus, hiatus hernia or erosive esophagitis."
2565083|NCT02464930||GERD Controls|"Respond yes to the presence of symptoms on a standardized GERD questionnaire~Prescriptions for acid suppressive medication as documented in electronic pharmacy records."
2565084|NCT02464930||BE Cases|• Patients who present for evaluation of reflux symptoms and are found to have at least 1 cm of columnar lined esophagus on endoscopy with intestinal metaplasia on biopsies. This will include patients with esophageal adenocarcinoma
3207099|NCT00961194|Active Comparator|dose of ketamine tested = 1.4 mg/kg|"The study will be conducted using 4 parallel groups (three doses of ketamine versus placebo).Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
3207100|NCT00961207|Active Comparator|Aliskiren in Macroalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300 mg daily for 4 weeks.
3207101|NCT00961207|Active Comparator|Aliskiren Microalbuminuria|Aliskiren 150 mg daily for 2 weeks and then increased to 300mg daily for 4 weeks
2564053|NCT02471963|Active Comparator|Empagliflozin|Empagliflozin, 25 mg/day, oral administration, 6 weeks
2564054|NCT02471963|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
2564102|NCT02471560|Experimental|dimethyl fumarate|As prescribed by the Investigator according to the local Summary of Product Characteristics.
2564104|NCT02471560|Active Comparator|injectable MS DMT|As prescribed by the Investigator according to the local Summary of Product Characteristics.
2564125|NCT02471196|Experimental|ORM-12741 low dose|ORM-12741 low dose twice a day for 12 weeks.
2564134|NCT02471196|Experimental|ORM-12741 high dose|ORM-12741 high dose twice a day for 12 weeks.
2564141|NCT02471196|Placebo Comparator|Placebo|Placebo twice a day for 12 weeks.
2564168|NCT02470897|Experimental|Arm A (moderate dose SBRT with SIB)|"Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 8.0Gy escalated dose"
2564182|NCT02470897|Active Comparator|Arm B (uniform dose SBRT)|"Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.~SBRT: 7.5Gy conventional dose"
2564233|NCT02470481||Cohort 1|Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.
2564306|NCT02470182||At-Home|Overnight sleep at home (30 subjects)
2564308|NCT02470182||Sleep Lab|Overnight sleep at the OHSU sleep lab during routine polysomnography (30 subjects)
2564310|NCT02470182||Sleep Lab + At-Home|Overnight sleep at the OHSU sleep lab during routine polysomnography, followed by overnight sleep at home (30 subjects)
2564351|NCT02469831|Active Comparator|group D|deep neuromuscular block by rocuronium defined :post tetanic (PTC) >1 but no response to a train of four (TOF) stimulation.
2564352|NCT02469831|Active Comparator|group I|intermediate neuromuscular block by rocuronium defined as TOF count of 1-3.
2564404|NCT02469519|Experimental|Betamethasone - ACTIVE|Booster Course of Antenatal Steroids consists of Betamethasone [12 mg intramuscular injection, 24 hours apart X 2 doses] or if unavailable may give Dexamethasone [6 mg intramuscularly 12 hours apart x 4 doses]
2564405|NCT02469519|Placebo Comparator|normal saline - PLACEBO|Normal saline of equivalent volume given intramuscularly at the equivalent dosing regimes listed in experimental arm.
3207102|NCT00961246|Active Comparator|general health information group|participants received general health information
3207103|NCT00961246|Experimental|individually-tailored intervention|participants received individually-tailored intervention
2564540|NCT02468505|Experimental|STEPS|structured psychosocial transition support that includes individual counseling, and education/training for parent and school personnel
2564542|NCT02468505|No Intervention|TAU|typical transition services and supports
2564611|NCT02468102||Rivaroxaban / Cohort 1|Patients who have filled a prescription for rivaroxaban in any pharmacy in Sweden during the study period.
2564616|NCT02468102||Standard of care drugs / Cohort 2|Patients who have filled a prescription for standard of care drugs (warfarin, aspirin, clopidogrel, ticlopidine, prasugrel or ticagrelor) in any pharmacy in Sweden during the study period.
2564670|NCT02467478|Placebo Comparator|Placebo|Matching placebo 1 pill daily for 12 weeks
2564673|NCT02467478|Active Comparator|Linagliptin|Linagliptin 5mg once daily for 12 weeks
3207104|NCT00961272||HIV-infected, pre-menopausal women|
3207105|NCT00961324|Experimental|IDeg|
3207106|NCT00961324|Experimental|IGlar|
2564944|NCT02465723|Experimental|MRI with IVIM DW-MRI|Upon enrollment in the study, each patient will undergo a standard pre-treatment evaluation in the Radiation Oncology Clinic. Imaging will include MRI with IVIM DW-MRI (as a research exam). MR imaging will begin within 30 minutes (+/- 15 mins) of the completion of single-dose radiation or the first dose for patients treated with a multifractioned regime. Patients will have corresponding serum samples collected at approximately 1 hour before and 18-24 hours after the first radiation treatment. If radiation therapy occurs on a Friday, the collection of the serum 18-24 hours post-treatment may still be feasible. Patients will be treated with radiation therapy according to our standard clinical guidelines using one of several Varian megavoltage linear accelerators with on-board kilovoltage image-guidance capabilities, using established immobilization devices that are specific to the anatomical site treated at MD's discretion.
3207107|NCT00961337|Experimental|Vaccination township|Shinwu township was randomly designated as intervention township which freely vaccinated on grade 1-4 and 5-9 students.
3207108|NCT00961337|No Intervention|Control townships|Guanyin township was designated as control township which only provide free vaccination on grade 1-4 students.
2565061|NCT02465047|Experimental|Self-help booklet|The intervention consists of a brief A5 self-help stress management booklet with an audio Compact Disk.
2565066|NCT02465047|No Intervention|Delayed Intervention|Participants do not receive the intervention until one month after the initial assessment.
2565157|NCT02464787|Experimental|Medical Students|Medical students willing to maintain the increased consumption of LifePak Nano dietary supplements, two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period, to maintain the logs and to report at each of the times that measurements will be made.
2565226|NCT02464371||ICU acquired muscle weakness (IAMW) group +|"The Medical Research Council score (MRC score) is lower than 48, defining an ICU acquired muscle weakness (IAMW).~Kinetic of microRNAs is measured"
2565230|NCT02464371||ICU acquired muscle weakness (IAMW) group -|The Medical Research Council score (MRC score) is higher than 48. Kinetic of microRNAs is measured
2565319|NCT02463864|Experimental|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercise sessions
3207109|NCT00961363|Experimental|Sitagliptin|Sitagliptin
3207110|NCT00961363|Placebo Comparator|Placebo|Placebo
3207111|NCT00961376|Active Comparator|Cohort A|PBMC re-infusion
3207112|NCT00961376|Experimental|Cohort B|CD25 depletion
3207113|NCT00961389||delirious patients|minimal any positive CAM-ICU score during ICU admission
3207114|NCT00961389||non-delirious patients|without any positive CAM-ICU score during ICU admission
2563970|NCT02472574|Experimental|1.0 mg|Subjects randomized to the 1.0 mg arm will undergo minimally invasive surgery with YL-1 type of intracranial hematoma puncture needle,followed by up to 4 doses of 1.0 mg of rt-PA (Activase/Alteplase/CathFlo) for intracerebral hemorrhage clot resolution.
2564011|NCT02472132|Experimental|Intervention|Prospective implantation of POC US for CVC tip placement.
2564013|NCT02472132|No Intervention|Control|Retrospective data collection for CVC placement in the medical and surgical ICUs, before the initiation of the study and without the use of POCUS for CVC tip placement.
2564061|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Trans thoraciq cardiac ultrasonography wil be perforfomed for pregnant women having a spinal or spinal-epidural anesthesia for elective caesarean section. All patients are more 18 years old and more 37 weeks pregnancy
2564132|NCT02471495|Experimental|Synergo® RITE + MMC|"Induction~Patients will receive 8 weekly treatments of Synergo® RITE + MMC, using the Synergo® System. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. These 8 treatments will be followed by a pause (see Table 1), after which a follow-up cystoscopy (first follow-up control) will be conducted during Weeks 12-13 (from the first treatment).~Maintenance~Patients will receive one Synergo® RITE + MMC treatment every 6 weeks. Each treatment lasts about 60 minutes and consists of two 30-minute cycles with 40 mg MMC/50 ml sterile water for injection each cycle. Maintenance treatments will be given until the end of 12 months after the patient's first induction treatment."
2564183|NCT02471027||Experimental group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is neoadjuvant chemotherapy combined with cervical cancer radical surgery .
2564191|NCT02471027||control group|2009 FIGO staging ⅠB2 or ⅡA2，the treatment is cervical cancer radical surgery.
2564215|NCT02470637|Experimental|SAR439065 + insulin lispro|1 of 6 sequences with single administration of 3 dose levels of SAR439065 (Afrezza Technosphere insulin) and 3 dose levels of insulin lispro with a washout duration between dosing days (7 to 28 days)
2564260|NCT02470377|Experimental|Transcranial Magnetic Stimulation|After determination of the motor threshold, the TMS coil will be positioned at predetermined locations over the brain using MRI guidance and a frameless stereotaxy system. A train of stimulation pulses (repetitive TMS) at 1Hz up to 10Hz or in theta burst mode will be delivered at one or more locations over the head, depending on the brain location under study (brain locations determined by MRI data). Real or active sham conditions will be used in the study but all participants will receive real treatment at some point during their enrollment. Real rTMS over one area may also be compared to real rTMS over another area.
2564303|NCT02470117|Active Comparator|Alginate-based reflux suppressant|Alginate-based reflux suppressant 15 ml oral every 6 hours for 2 weeks
2564305|NCT02470117|Sham Comparator|magnesium-aluminium antacid gel|magnesium-aluminium antacid gel 15 ml oral every 6 hours for 2 weeks
2564427|NCT02469467|Experimental|VS-505|750 mg capsule
2564520|NCT02468973|Other|Life style counseling|Students will meet chronic patients and will counsel for life style
2564582|NCT02468440|Experimental|ESPAIR|Patients with an educational therapy's program since registration in transplant list.
2564584|NCT02468440|No Intervention|normal care|Patients without educational therapy
2564632|NCT02467920|Experimental|glargine + exenatide|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily).
2564636|NCT02467920|Active Comparator|aspart 30|Type 2 diabetic patients with inadequate glycaemic control on premixed human insulin and metformin previously. After a 12-week run-in period , switching premix human insulin to aspart 30 ( subcutaneous injection, twice daily).
2564720|NCT02467608|Experimental|Isoniazid with HUEXC030 and RZE|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid with HUEXC030 [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid with Isoniazid(H):300mg/600mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
2564723|NCT02467608|Other|Isoniazid|"Subjects who are genotyped as high risk group will be receiving 2 months of intensive treatment comprised of 4 drugs (Isoniazid [H], rifampin [R], pyrazinamide [Z] and ethambutol [E]), followed by 4 months of continual chemotherapy consist of Isoniazid, Rifampin (2HRZE/4HR regimen). Subjects who are of low risk genotype will be removed from study after 8 weeks of study treatment, then return to conventional TB medication at least one follow-up visit at 4 weeks after the end of study treatment visit.~Dosage is as below:~Isoniazid (H):300mg daily, rifampin [R]: 450~600mg daily, pyrazinamide [Z]; 1000~2000mg daily and ethambutol [E]: 800-1600mg daily)"
2564734|NCT02466945|Other|V063B-DP3003|all patients will received the study product (V063B-DP3003)
2564810|NCT02466737|Experimental|no axillary surgery|
2564817|NCT02466737|Active Comparator|sentinel lymph node biopsy|standard arm in first randomization
2564821|NCT02466737|Experimental|sentinel lymph node biopsy alone|
2564823|NCT02466737|Active Comparator|completion axillary lymph node dissection|standard arm in second randomization
2564980|NCT02465385|Experimental|Intervention|Linaclotide 290mcg
2565045|NCT02465268|Experimental|pp65-shLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
2565047|NCT02465268|Experimental|pp65-flLAMP DC with GM-CSF and Td|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
2565049|NCT02465268|Placebo Comparator|unpulsed PBMC and Saline|Given under the skin at day 22-24 after the first temozolomide cycle then at 2 week intervals. Doses 4-10 will be given on day 22-24 of each temozolomide cycle. Doses will continue until a total of 10 or until progression or unacceptable toxicity.
2565222|NCT02464397|Active Comparator|SYNERGY-EES 6|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 6 months after the index procedure.
2563990|NCT02472288|Experimental|Electroacupuncture (EA) group|"Electroacupuncture therapy (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints, bilateral)~20 minutes duration, middle frequency (30 Hz) of electrical stimulation~conventional treatments permitted"
2563992|NCT02472288|Sham Comparator|Sham group|"Non-penetrating Park sham electroacupuncture treatment (10 sessions in total, 5 per a week, 2 weeks)~BL31, BL32, BL33, and BL34 (total 8 acupoints on the right and left sides)~20 minutes duration, undelivered electrostimulation of middle frequency (30 Hz)~conventional treatments permitted"
2564003|NCT02472041|Experimental|Reanimator Group|Reanimator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®), which was connected in a circuit extending along the Muller Resuscitator equipment applied continuously for four series 10 of the patient breaths active and with an interval of two minutes between them in Fowler 45 position
2564006|NCT02472041|Experimental|Control Group|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
2564072|NCT02471794|No Intervention|Standard Shared Medical Appointment|The SMA group will be a standard shared diabetes medical appointment group consisting of up to 10 patients that utilizes the design and curriculum of the SMAs that are currently being held at the Duke Family Medicine Center.
2564075|NCT02471794|Experimental|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum.
2564083|NCT02471794|No Intervention|Retrospective|A retrospective chart review will be conducted once all participants (both SMA group and PHP SMA group) complete the intervention. The retrospective chart review will collect healthcare utilization data six months prior, during, and after each subject's participation in the SMA.
2564129|NCT02471456||EVH|Patients that have undergone Endoscopic Vein Harvesting (EVH)
2564135|NCT02471456||OVH|Patients that have undergone open vein harvest (OVH)
2564167|NCT02470936|Experimental|Group 1- Lifestyle Intervention|Men will receive a web-based, personalized lifestyle program. They will receive personalized prostate cancer-specific lifestyle recommendations on specific habits based on their eligibility survey responses. They will have access to the website composed of four topic areas (get active, eat well, stop smoking, and find support), receive a Fitbit and access to a Fitbit account and community group, and receive text messages and refrigerator magnet to reinforce behaviors. The website will be updated frequently with new tips and material and two weekly blogs will be maintained. Final content is reviewed by study investigators and patient advocates. Men will complete an intervention acceptability survey (acceptability of the website and intervention components) at 3 months.
2564175|NCT02470936|No Intervention|Group 2 - Control|Men randomized to the control group will receive standard of care. They will receive access to the website and personalized lifestyle recommendations on the 8 healthy habits targeted in the study after the 3 month trial.
2564259|NCT02470663|Experimental|Study group|Children recieving DENSITYTM caplets (marketed as Amorphical) 200 mg BID for 12 months
2564265|NCT02470663|Active Comparator|Control group|Children recieving Calcium carbonate 600 mg once daily for 12 months
2564322|NCT02470065|Experimental|Neo adjuvant afatinib|once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection).
2564324|NCT02470065|Active Comparator|Immediate surgery|immediate surgery with curative intent (anatomical resection and systematic lymph node dissection).
2564358|NCT02469688|Experimental|Part1 ASP4070 intramuscular vaccination group|ASP4070 high dose x 4 times
2564361|NCT02469688|Experimental|Part1 ASP4070 intradermal vaccination group|ASP4070 high dose x 4 times
2564363|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 1|ASP4070 high dose x 4 times
2564364|NCT02469688|Experimental|Part2 ASP4070 intramuscular vaccination group 2|ASP4070 high dose x 1 time, Placebo x 3 times
2564365|NCT02469688|Placebo Comparator|Part2 Placebo intramuscular vaccination group|Placebo x 4 times
2564367|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 1|ASP4070 high dose x 4 times
2564369|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 2|ASP4070 low dose x 4 times
2564371|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 3|ASP4070 high dose x 1 time, Placebo x 3 times
2564373|NCT02469688|Experimental|Part2 ASP4070 intradermal vaccination group 4|ASP4070 low dose x 1 time, Placebo x 3 times
2564376|NCT02469688|Placebo Comparator|Part2 Placebo intradermal vaccination group|Placebo x 4 times
2564409|NCT02469272|Experimental|Fecal Microbiota Transplantation|Intervention: standardized preparation of frozen fecal material from lean healthy donors Route: infused into the duodenum through the working channel of the instrument at upper endoscopy Dosing: 1 dose
3207115|NCT00961467|Experimental|RMPT (Arm A -thalidomide 50 mg/day)|
2564522|NCT02468713|Experimental|Group 1|Combiflex® lipid peri as a reference product (Period 1) -> Winuf® peri as a test product (Period 2)
2564524|NCT02468713|Experimental|Group 2|Winuf® peri as a test product (Period 1) -> Combiflex® lipid peri as a reference product (Period 2)
2564576|NCT02468362|Active Comparator|Laparoscopic group|
2564578|NCT02468362|Active Comparator|Open group|
3207116|NCT00961467|Experimental|RMPT (Arm B - thalidomide 100 mg/day)|
3207117|NCT00961480|Active Comparator|Treatment A|50 mg sitagliptin and 500 mg metformin as individual tablets
2563991|NCT02472301|Experimental|Cowpeas|Cowpea supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
2563993|NCT02472301|Experimental|Common bean|Common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
2563994|NCT02472301|Active Comparator|Corn Soy Flour|Corn flour with 10% soy supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
2564035|NCT02472028|Experimental|blood pressure lowering algorithm|enhanced strategy aiming to reduce systolic blood pressure to <135 mmHg
2564038|NCT02472028|Active Comparator|usual strategy|usual strategy based on the usual care of routine care
2564078|NCT02471677|Active Comparator|Puregon|Patients will undergo ovarian stimulation using daily injections of recombinant FSH (Puregon), as performed traditionally in IVF cycles
2564085|NCT02471677|Experimental|Elonva|Patients will undergo ovarian stimulation using a single injection of corifollitropin alfa (Elonva)
3207118|NCT00961480|Experimental|Treatment B|sitagliptin/metformin 50 mg/500 mg tablet
2564236|NCT02470455||Normoglycemic group|25 patients were recruited who were on Atorvastatin and with normal blood glucose and Hb1Ac level.
2564241|NCT02470455||Prediabetic with normal GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with normal GTT.
2564244|NCT02470455||Prediabetic with impaired GTT|25 patients were recruited who were on Atorvastatin and with fasting blood sugar level 100-125 mg/dl with impaired GTT.
2564320|NCT02470169|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
2564321|NCT02470169|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
2564323|NCT02470169|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
3207119|NCT00961480|Active Comparator|Treatment C|50 mg sitagliptin and 1000 mg metformin as individual tablets
3207120|NCT00961480|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
3207121|NCT00961480|Active Comparator|Treatment E|50 mg sitagliptin and 850 mg metformin as individual tablets
3207122|NCT00961480|Experimental|Treatment F|sitagliptin/metformin 50 mg/850 mg tablet
3207123|NCT00961493|Experimental|1|
2564630|NCT02467972|Experimental|UBF group|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
2564635|NCT02467972|Placebo Comparator|Control|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
2564638|NCT02467972|Experimental|Inulin group|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
2564639|NCT02467972|Experimental|Nisin group|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
2564712|NCT02467569|Experimental|Hemay020|"Part one: Dose Escalation Group Hemay020 capsules will be taken orally in doses of 25mg, 50mg, 100mg, 200mg or 300mg once daily for 28 days.~Part two: Extension Group Hemay020 capsules will be taken in two dose groups that assessed by Part one for 28 days."
3207124|NCT00961493|Active Comparator|2|
2564791|NCT02466594|Other|Hilotherm Clinic®|Intervention: Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
3207125|NCT00961506|Experimental|LESS cholecystectomy|LESS cholecystectomy
3207126|NCT00961506|Active Comparator|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
3207127|NCT00961558|No Intervention|Observation arm|Patient will not to undergo any form of Assisted Reproductive Technologies for a period of 6 months
3207128|NCT00961558|Other|Surgery Arm|Patients will have varicocelectomy within 1 month of assessment and will not undergo any form of Assisted Reproductive Technologies for a period of 6 months after surgery
2565623|NCT02461420||Phelan-McDermid Syndrome|Phelan-McDermid Syndrome
2565702|NCT02461082|Other|EMST and sham-TMS|Active expiratory muscle strength training in combination with sham transcranial magnetic stimulation
2565710|NCT02461082|Other|sham-EMST and TMS|Sham expiratory muscle strength training in combination with active transcranial magnetic stimulation
2565715|NCT02461082|Other|EMST and TMS|Active expiratory muscle strength training in combination with active transcranial magnetic stimulation
2565719|NCT02461082|Other|sham-EMST and sham-TMS|Sham expiratory muscle strength training in combination with sham transcranial magnetic stimulation
2566668|NCT02454881|Active Comparator|Dexmedetomidine 10|Oxycodone 1 mg / mL + Dexmedetomidine 10 μg / mL
3207129|NCT00961597|Experimental|Meniscus repair with PRP|Meniscus repair for tears extending into the red/white region with PRP
3207130|NCT00961597|Active Comparator|Meniscus repair without PRP|
3207131|NCT00961610||Internet support group Intervention|
3207132|NCT00961610||Control group|
3207133|NCT00961675|Active Comparator|FST201|
3207134|NCT00961675|Active Comparator|Ciprodex|
3207135|NCT00961714|Experimental|OsseoFix|
3207136|NCT00961727||PEWS System of Care|
2564026|NCT02472093|Experimental|Perceptive Rehabilitation Treatment|Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
2564028|NCT02472093|Active Comparator|Control group|The control group did brief educational sessions.
3207137|NCT00961740|Other|Cognitive Behavioral Therapy|Design: 49 children (aged 8-12)with obesity was recruited, the children were randomly assigned to a group that started a cognitive behavioural intervention immediately after recruitment, and another group that received the same treatment after a 12-week wait list condition. For further description of the treatment, see summary. Arm 1 (this arm) started receiving a cognitive behavioural intervention immediately after randomization.
3207138|NCT00961740|Other|12-weeks waitlist condition|After an initial pre-assessment no contact were made before assessment after 12-weeks and start of intervention after this assessment. After the 12-week waitlist condition the families were offered the same familibased cognitive behavioral intervention as in arm one.
2564165|NCT02471105|Experimental|Lumigan 0.01% + Saflutan 15 µg/ml|Bimatoprost 0.01 % Eye drops solution Topical use Once in the evening 3 months
2564166|NCT02471105|Experimental|Saflutan 15 µg/ml + Lumigan 0.01%|Tafluprost Unit Dose Preservative Free 15microgram/ml Eye drops solution Topical use Once in the evening 3 months
3207139|NCT00961753|Experimental|Optimized Ibuprofen|
2564346|NCT02469675|Experimental|All subjects|"All subjects undergo same full protocol, including different combinations of stimulation on different days:~Transcranial Magnetic Stimulation Cervical Transcutaneous Stimulation Median Nerve Stimulation"
2564423|NCT02469441||Arm A|Arm A (treatment arm: coffee): patients after colorectal surgery receive coffee in addition to the regular infusion therapy and/or alimentation
2564429|NCT02469441||Arm B|Arm B (control arm: water / tea): patients after colorectal surgery receive water or tea (excluding black tea) and no coffee until the first bowel movement in addition to the regular infusion therapy and/or alimentation
2564493|NCT02469012|Experimental|IFN-free antiviral treatment|Combination #1 or Combination #2 or Combination #3 or Combination #4 or Combination #5
2564551|NCT02468492|Experimental|Platelet Rich Plasma|Approximately 5mL of intraarticular PRP once at baseline
2564552|NCT02468492|Other|Normal Saline|Approximately 5mL of intraarticular normal saline once at baseline
3207140|NCT00961753|Active Comparator|Standard Ibuprofen|
3207141|NCT00961766|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010 or matching placebo
2564663|NCT02467582|Experimental|Aspirin 100 mg|Asprin 100 mg daily for 3 years standard chemo if indicated
2564664|NCT02467582|Active Comparator|Placebo|Placebo daily for 3 years standard chemo if indicated
3207142|NCT00961766|Placebo Comparator|Placebo|Participants may be randomized to escalating doses of BG00010 or matching placebo
3207143|NCT00961779|Placebo Comparator|Placebo (Normal saline infusion)|
2564801|NCT02466490|Experimental|Fimasartan 60 mg Tablets|FMS 60 mg tablets once a day during the initial 8 treatment weeks of the study
2564805|NCT02466490|Active Comparator|Fimasartan 120 mg Tablets|FMS 120 mg tablets once a day during 4 weeks (treatment weeks 8 to 12)
2564812|NCT02466490|Active Comparator|Fimasartan; Hydrochlorothiazide 60/12.5|FMS 60 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 4 weeks (treatment weeks 8 to 12)
2564818|NCT02466490|Experimental|Fimasartan; Hydrochlorothiazide 120/12.5|FMS 120 mg + HCTZ 12.5 mg tablets (fixed dose combination) once a day during 12 weeks (treatment weeks 12 to 24)
2564873|NCT02466152|Experimental|GSK2894512 2.0% Cohort|Subjects will apply a thin layer of GSK2894512 2.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
2564875|NCT02466152|Experimental|GSK2894512 1.0% Cohort|Subjects will apply a thin layer of GSK2894512 1.0% topical cream twice daily (morning and evening) for 20 days and only in morning on day 21, to all affected skin areas (15-35% BSA) identified at baseline, excluding the scalp and around the eyes
2564968|NCT02465905|Active Comparator|Raw milk|For raw milk immunotherapy (RMI), fixed dose of raw milk was daily administered at home, determined using tolerated threshold dose during the DBPCFC. Augmentation was made every 5 weeks in the allergy clinic.
2564971|NCT02465905|Active Comparator|Heated milk|For heated milk immunotherapy (HMI), families were asked to weekly increase the daily dose of milk at home using industrial preparations. Milk included in the preparation was less and less heated among time. Passage from heated-milk to half-heated milk and then raw milk was performed in the allergy clinic.
2565000|NCT02465320|Active Comparator|COL-1077|lidocaine bioadhesive gel, 10%
2565001|NCT02465320|Placebo Comparator|Placebo|placebo bioadhesive gel
2565035|NCT02465008|Experimental|levobupivaciane group|Levobupivacaine group (L- bupivacaine 0,25% -2,5 mg/ml-) 60 ml. Total dosis in topical use 150 mg (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
2565037|NCT02465008|Placebo Comparator|Placebo Comparator (saline solution)|Placebo group (saline solution) 60 ml (administered irrigation 30 ml into the surgical pocket bilaterally intraoperatively).
2565141|NCT02464748|Experimental|Intervention|Patients and their primary carer will use a weekly telehealth system. This involves a series of questions on a tablet computer that is transmitted to their regional MND care centre for review and action.
2565142|NCT02464748|No Intervention|Control|Usual care
2565229|NCT02464475|Experimental|OMT|
2565233|NCT02464475|Sham Comparator|Sham|
2565288|NCT02463890|Experimental|Training|"In this group, patients will perform 3 sessions of one hour per week of the NeuroGyV training program. It is a physical activity program with one session of Nordic walking, one session of aquagym and one session of gymnastic. Program lasts 9 months."
2565289|NCT02463890|Other|Control|In this group, patients will receive only diets and physical activity counselling
2565404|NCT02462811|Active Comparator|Active Comparator: Norco|Commercial product containing hydrocodone 7.5 mg, acetaminophen 325 mg
2564066|NCT02471664|Experimental|Single|Intervention: Device: Mitral Loop Cerclage Annuloplasty with CSTV Protective Device
2564144|NCT02471430|Experimental|Arm A|Participants in Arm A will receive panobinostat as an oral tablet on days 0, 2, and 4 of the treatment week. The dose of panobinostat will be a 15 mg tablet.
2564146|NCT02471430|Experimental|Arm B|Participants in Arm B will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0. The dose of pegylated IFN-alpha2a will be 180 mcg. Simultaneously with interferon-alpha2a, a 15 mg tablet of panobinostat will be administered on day 0. Participants will also receive panobinostat as an oral tablet on days 2 and 4 of the treatment week.
2564148|NCT02471430|Experimental|Arm C|Participants in Arm C will receive one subcutaneous injection of pegylated interferon-alpha2a on day 0.The dose of pegylated IFN-alpha2a will be 180 mcg.
2564169|NCT02470832|Experimental|Combination therapy RG1662 + itraconazole|Days 20-29: Oral administration RG1662 twice daily within 30 minutes of a meal + 2 x 100 mg itraconazole once daily with food
2564177|NCT02470832|Experimental|RG1662 Monotherapy|Days 1-10: RG1662 120 mg twice daily (b.i.d.) within 30 minutes of a meal for 10 days (Days 1 to 9, Day 10 only a.m. dose). (Cohort A subjects will receive 1 x 120 mg RG1662 tablets twice daily. In Cohorts B and C the dose of RG1662 will be decided upon following review of the interim safety and pharmacokinetic data of the 4 subjects in Cohort A.)
2564185|NCT02470832|Experimental|itraconazole Monotherapy|Days 15-19: 200 mg of itraconazole twice daily for 5 days (Days 15 to 18, Day 19 only a.m. dose)
2564278|NCT02470273||Dermatology patients|Patients with a suspicious skin lesion indicated for biopsy
2564332|NCT02469987|Experimental|MYL-1402O|MYL-1402O (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
2564333|NCT02469987|Active Comparator|US Marketed Avastin (R)|US Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
2564334|NCT02469987|Active Comparator|EU Marketed Avastin(R)|EU Marketed Avastin(R) (bevacizumab), single 1mg/kg i.v. infusion over 90 minutes.
2564391|NCT02469571|Active Comparator|Probiotic|5 g of Winclove-607 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Enterococcus faecium W54, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W1, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24 at a concentration of 1.1 x 109 cfu/g twice daily for the 4 weeks
2564392|NCT02469571|Placebo Comparator|Placebo|a similar looking and tasting placebo without bacteria once daily for 4 weeks
2564437|NCT02469311|Sham Comparator|Primary Control TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
2564441|NCT02469311|Active Comparator|Primary Treatment TKA|Patients undergoing a first or primary total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
2564446|NCT02469311|Active Comparator|Revision Treatment TKA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of a chlorhexidine impregnated cloths.
2564455|NCT02469311|Sham Comparator|Revision Control TKA|Patients undergoing a second or revision total knee arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
2564458|NCT02469311|Sham Comparator|Primary Control THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
2564460|NCT02469311|Active Comparator|Primary Treatment THA|Patients undergoing a first or primary total hip arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
2564463|NCT02469311|Sham Comparator|Revision Control THA|Patients undergoing a second or revision total hip arthroplasty will be randomized to the intervention of Standard of care bathing with antibacterial soap and water.
2564464|NCT02469311|Active Comparator|Revision Treatment THA|Patients undergoing a second or subsequent or a revision total knee arthroplasty will be randomized to the intervention of chlorhexidine impregnated cloths.
2564512|NCT02468791|Experimental|MabionCD20®|A course of MabionCD20® in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
2564515|NCT02468791|Active Comparator|MabThera®|A course of MabThera® (Rituximab, Roche) in rheumatoid arthritis patients consists of two 1000 mg intravenous infusions with two weeks interval.
2564627|NCT02468167|Active Comparator|BRTO|Balloon-occluded retrograde transvenous obliteration
2564633|NCT02468167|Active Comparator|NBCA|Endoscopic cyanoacrylate injection
2564677|NCT02467556|Other|intervention|Open label study with psychological intervention and physiotherapy intervention with medication of morphine, memantine for ten weeks (morphine 30mg tbl per day and memantine up to 40mg tbl per day if tolerated).
2564763|NCT02467244||Euthyroid group|Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
2564769|NCT02467244||Hypothyroid group|Fifty (50) hypothyroid patients attending the outpatient department of General Medicine, AIIMS, Bhubaneswar, will be recruited for the present study following inclusion and exclusion criteria.
2564794|NCT02466633|Experimental|Change in in-hospital cardiac monitoring method|Pre- and post-intervention, where the intervention is a change in in-hospital cardiac monitoring method
2564866|NCT02466451||Children operated at birth on CDH and EA|Standardized Questionnaires:For not collaborative patients,< 4 years:Standardized questionnaire collecting anamnestic-clinical data;Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents) For collaborative patients, >4 years:Standardized questionnaire collecting anamnestic-clinical data;Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar);Spirometry;6-minutes walk test (WT 6'); Prick tests;Children Quality of life questionnaire (KINDL questionnaire);Psychological test (Raven Matrices);Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents).
2564892|NCT02465996|Other|postprandial distress syndrome (PDS)|"FD patients fulfilled Rome III criteria were subclassified into postprandial distress syndrome (PDS) or epigastric pain syndrome (EPS).~pCLE examination was performed in PDS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination."
2564934|NCT02465840|Experimental|Kleinert programs|custom-made dynamic hand splint physical therapy and occupational therapy
2564077|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort I|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade and achieved best response of confirmed complete or partial response, or stable disease will receive GDC-0919, at the MTD or maximum administered dose (MAD) determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
2564086|NCT02471846|Experimental|Anti-PD-1/PD-L1 Relapsed Cohort II|Approximately 20 participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade and achieved unconfirmed partial response or stable disease will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
2564092|NCT02471846|Experimental|Biopsy Cohort A|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive GDC-0919 during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
2564095|NCT02471846|Experimental|Biopsy Cohort B|Approximately 20 participants with melanoma, HNSCC, gastric, ovarian, Merkel cell, cervical, or endometrial cancer will receive atezolizumab during Cycle 1, followed by combination treatment with GDC-0919 and atezolizumab from Cycle 2 onwards. Serial biopsies of extrahepatic lesions will be performed. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
2564096|NCT02471846|Experimental|Dose-Escalation Cohort(s)|Approximately 6 to 65 participants will be enrolled and treated at escalating doses of GDC-0919 in combination with fixed-dose atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio. Successive groups of at least 3 participants will be evaluated during a 21-day window for DLTs, which will determine the enrollment and dosing for subsequent cohorts in the dose-escalation stage. The MTD or MAD, whichever is reached first, will be considered for the expansion stage.
2564097|NCT02471846|Experimental|Expansion Cohorts|Approximately 160 participants (40 per diagnosis) with NSCLC, RCC, TNBC, and UBC will receive GDC-0919, at the MTD or MAD determined during the dose-escalation stage, in combination with Atezolizumab. Treatment may continue until unacceptable toxicity or disease progression with an unfavorable risk-benefit ratio.
2564172|NCT02470923|Other|Group 1|Usual care including medical advice to quit and confrontation with abnormal spirometry results if relevant.
2564181|NCT02470923|Other|Group 2|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, and follow up for at least 5 weeks after discharge (will be done weekly by phone for five consecutive weeks).
2564190|NCT02470923|Other|Group 3|Intensive counseling (15 minutes) by a smoking cessation counselor including confrontation with abnormal spirometry results if relevant, offering and providing nicotine replacement therapy (NRT) and follow up (will be done weekly by phone for five consecutive weeks).
2564243|NCT02470546|Active Comparator|Metformin|Patients receiving metformin
2564251|NCT02470546|Placebo Comparator|Placebo|Patients receiving placebo
2564325|NCT02470130|Active Comparator|relax actor|actor during simulation and relaxation before debriefing
2564326|NCT02470130|No Intervention|no relax actor|actor during simulation and no relaxation before debriefing
2564327|NCT02470130|Active Comparator|relax observer|observer during simulation and relaxation before debriefing
2564328|NCT02470130|No Intervention|no relax observer|observer during simulation and no relaxation before debriefing
3207144|NCT00961779|Experimental|NNZ-2566|NNZ-2566 reconstituted in bicarbonate buffer and normal saline. 6/8 subjects in each cohort (5 cohort in total) to receive NNZ-2566 experimental treatment.
3207145|NCT00961792|Experimental|Beverage with Heavy Alcohol Dose|Beverage containing 0.8 g/kg alcohol
2564450|NCT02469324|Active Comparator|Cognitive-Behavioral Therapy|see intervention explanation
2564456|NCT02469324|Experimental|Compassionate Mind Training|
2564509|NCT02468895||Idiopathic Inflammatory Myopathy|PM, DM, sIBM, necrotizing myopathy, anti-synthetase syndrome, suspected myopathy
3207146|NCT00961792|Experimental|Beverage with Low Alcohol Dose|Beverage containing 0.4 g/kg alcohol
3207147|NCT00961792|Placebo Comparator|Beverage with No alcohol (Placebo)|Beverage containing 0.0 g/kg alcohol to act as placebo
2564688|NCT02467335|Active Comparator|Healthy Subjects|Healthy subjects will receive a single, oral dose of BMS-663068 on Day 1.
2564695|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Mild Rating|Mildly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
2564706|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Moderate Rating|Moderately impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
2564709|NCT02467335|Active Comparator|Hepatic Impaired Subjects - Severe Rating|Severly impaired subjects will receive a single, oral dose of BMS-663068 on Day 1.
2564743|NCT02467127|No Intervention|control group|Patients without headache. No drugs will be administered
2564747|NCT02467127|Experimental|Chronic Headache|Patients with headache > 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
2564748|NCT02467127|Experimental|Chronic headache with drug overuse|Patients with headache > 6 months related to drug treatment, i.e. non steroidal antinflammatory drugs. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
2564749|NCT02467127|Experimental|Acute Headache|Patients without chronic headache but with an history of headache < 6 months. Vitamin D supplementation (from 400 iU/day up to 1600 IU/day) will be administered.
2564808|NCT02466763|Active Comparator|round window|Half of the participants will be randomized to the round window technique of cochlear implant device electrode insertion. Intervention for participants randomized to the round window arm include having the round window technique used for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
2565312|NCT02463812|Experimental|Intralipid|Patients will receive Intralipid infusion in the recovery room.
3207148|NCT00961792|Experimental|Beverage with Diphenhydramine|Beverage containing 1.5 standard dose of Diphenhydramine (Benadryl)
2564106|NCT02471599|Active Comparator|non-tonsillectomy group|The controlled group will not receive tonsillectomy.
2564136|NCT02471235|Experimental|Intervention group|The physiotherapist will provide every patient an individualized physical training programme that fits their cardiopulmonary status. Patients will have the training as out-patient in the physiotherapy department for 4-8 sessions, 2 hours each time, 1-2 times weekly. Home exercise will be taught. Our case manager will give phone calls to the subject every 2 weeks to provide support and reinforcement for having continuous exercise at home for one year. Patients will be invited to attend reinforcement out-patient physiotherapy training once very month or every 2 months if they are willing to attend.
2564143|NCT02471235|No Intervention|Control group|The control group will receive no physiotherapy training by physiotherapist and no phone calls from case manager for reinforcement of home exercise. .
2564180|NCT02471001||Heart Surgery Using Heart-lung Machine|All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. The medical and surgical care plans for participants remain as usual in this study with an exception being two additional blood samples of about two-teaspoonful in volume will be collected from an in-placed catheters in vein and aorta.
2564223|NCT02470676|Active Comparator|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
2564224|NCT02470676|Experimental|Progesterone plus Experimental device|Experimental device + 200 mg daily progesterone vaginal suppositories (Utrogestan)
2564268|NCT02470260||Diabetes|Defined by clinical history or HbA1c criteria (HbA1c greater of equal to 6.5%)
2564272|NCT02470260||Pre-diabetes|Defined by HbA1c criteria (5.7 to 6.4%)
2564274|NCT02470260||Normal glucose tolerance|Defined by HbA1c criteria (< 5.7%)
2564307|NCT02470078|Experimental|Pharyngeal electrical stimulation|Pharyngeal electrical stimulation once daily for 10 minutes on three consecutive days.
2564311|NCT02470078|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days.
2564381|NCT02469805|Active Comparator|stimulated intrauterine insemination (IUI)|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3rd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
2564383|NCT02469805|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
2564384|NCT02469805|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
2564410|NCT02469285|Experimental|Modified pork|Pork with modified fatty acid composition, more unsaturated fat. 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
2564411|NCT02469285|Active Comparator|Normal pork|Normal pork 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
2564412|NCT02469285|Experimental|Normal pork and berries|Normal pork and berries (strawberry, raspberry, wild blueberry, lingonberry, cloudberry, blackcurrant) 160 g pork or pork products daily for 4 weeks, consumption of other red meat is prohibited
3207149|NCT00961792|Experimental|Beverage with Caffeine|Beverage containing the equivalent of 1.5 times participant's average caffeine consumption
3207150|NCT00961831|Experimental|Arm 1|
2564516|NCT02468726|Experimental|NER1008|Use of NER1008 enema for bowel cleansing
2564518|NCT02468726|Active Comparator|Fleet|Use of Fleet enema for bowel cleansing
2564557|NCT02468427|Experimental|hands-on Teaching|Medical students receive a 30 minutes hands-on training session. All study probands perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
2564562|NCT02468427|Active Comparator|Frontal teaching|Medical students receive a 30 minutes frontal teaching session using a training video demonstrating how to perform assisted delivery (operative vaginal delivery) by vacuum extraction on a pelvic model immediately after the training.
2564598|NCT02468128|Experimental|SDE 150mg|Single dose, intramuscular, Sebacoyl Dinalbuphine Ester injection 150 mg (2 ml)
2564602|NCT02468128|Placebo Comparator|placebo|Single dose, intramuscular , Sebacoyl Dinalbuphine Ester placebo injection (2mL)
3207151|NCT00961831|Experimental|Arm 2|
3207152|NCT00961844|Experimental|DC vaccine + Temozolomide|Dendritic cell loaded with h-TERT mRNA, survivin mRNA and autologous tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion.
2564756|NCT02466880|Experimental|Telemedicine|Diabetes education and support via telemedicine
2564761|NCT02466880|Active Comparator|Usual care|Diabetes education and support in person
3207153|NCT00961857|Active Comparator|Treatment A|Individual Tablets of 50 mg sitagliptin and 500 mg metformin
3207154|NCT00961857|Experimental|Treatment B|Sitagliptin/metformin 50 mg/500 mg tablet
2564919|NCT02465918|Active Comparator|Original Setting- MCS 30 min off/0 min off|Patients at baseline with their original MCS settings: on 30 minutes, off 0 minutes in any single half-hour.
2564920|NCT02465918|Experimental|MCS 25 min on/5 min off|Patient MCS settings programmed to: on 25 minutes, off 5 minutes in any single half-hour.
2564921|NCT02465918|Experimental|MCS 20 min on/10 min off|Patient MCS settings programmed to: on 20 minutes, off 10 minutes in any single half-hour.
2564922|NCT02465918|Experimental|MCS 15 min on/15 min off|Patient MCS settings programmed to: on 15 minutes, off 15 minutes in any single hour.
2564994|NCT02465554||No atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have no plaque and an Agatston score of 0. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into No atherosclerosis/endothelial function normal and No atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
3207155|NCT00961857|Active Comparator|Treatment C|Individual Tablets of 50 mg sitagliptin and 1000 mg metformin
3207156|NCT00961857|Experimental|Treatment D|sitagliptin/metformin 50 mg/1000 mg tablet
3207157|NCT00961870|Experimental|Healthy postmenopausal women|Forearm vibration will be applied in women without postmenopausal osteoporosis
3207158|NCT00961870|Experimental|Osteoporotic postmenopausal women|Forearm vibration will be applied in women with postmenopausal osteoporosis
3207159|NCT00961870|Experimental|Healthy young adult women|Forearm vibration will be applied in healthy young adult women
3207160|NCT00961870|Experimental|Healthy young adult men|Forearm vibration will be applied in healthy young adult men
3207161|NCT00961883|Experimental|1|Thirty participants will receive injections in the following order: NYVAC-B for injections one and two, placebo for injection three, and rAd5 for the fourth and final injection. Two participants in this group will receive placebo vaccines only.
3207162|NCT00961883|Experimental|2|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3207163|NCT00961883|Experimental|3|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3207164|NCT00961883|Experimental|4|Fifteen participants will receive injections in the following order: rAd5 for injection one, placebo for injection two, and NYVAC-B for injections three and four. One participant in this group will receive placebo vaccines only.
3207165|NCT00961909|Experimental|1active|
3207166|NCT00961909|Placebo Comparator|1placebo|
3207167|NCT00961909|Experimental|2active|
3207168|NCT00961909|Placebo Comparator|2placebo|
2564497|NCT02468765||Depressive MS patients|Neuropsychological and emotional evaluation with monitoring
2564502|NCT02468765||Non depressive MS patients|Neuropsychological and emotional evaluation with monitoring
2564506|NCT02468765||Control|Neuropsychological and emotional evaluation with monitoring
2564558|NCT02468531|Other|Oxygen group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50% oxygen during CPB.
2564560|NCT02468531|Experimental|Xenon group|50% oxygen inhalation one hour before and after CPB,and Pulmonary Static Inflation with 50%,75% and 100% Xenon during CPB respectively.
2564614|NCT02468076|Experimental|Radiofrequency ablation (StarMed)|Radiofrequency ablation catheter
3207169|NCT00961922|Experimental|Neurofeedback|Children in this group receive 30 sessions of neurofeedback
3207170|NCT00961922|Sham Comparator|Placebo feedback|The children in this group receive 30 sessions of placebo feedback, based on muscular tension.
2564691|NCT02467348|Experimental|Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres with intravenous albumin at a dose 8 gms/l of ascitic fluid.
2564698|NCT02467348|Active Comparator|No Albumin|MVP (Modest Volume Paracentesis) of less than 5 litres without albumin.
3207171|NCT00961922|No Intervention|Siblings|The siblings will be tested 1 time, they will function as a healthy control group.
2564793|NCT02466581|Active Comparator|Arm 1|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting at randomization."
2564798|NCT02466581|Active Comparator|Arm 2|"Patients keep the intervention they had in the NORD-STAR-study (NCT01491815), i.e. one of the four below:~Sulphasalazine + Hydroxychloroquine OR Prednisolone plus Methotrexate and steroids~Cimzia plus Methotrexate and steroids~Orencia plus Methotrexate and steroids~RoActemra plus Methotrexate and steroids~This intervention is de-escalated starting 24 weeks after randomization."
3207172|NCT00961974|No Intervention|Standard Care|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
3207173|NCT00961974|Experimental|Care Plus|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
2564966|NCT02465749|Experimental|Continuous Oxygen|Continuous oxygen intake and routine drug treatment .
2564967|NCT02465749|Experimental|Blue Light Deprivation|Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
2564970|NCT02465749|Experimental|Continuous Oxygen Therapy Combined With Blue Light Deprivation|Continuous oxygen intake , Wearing blue light-absorbing sunglasses at daily time and routine drug treatment
2564973|NCT02465749|Other|control|Routine drug treatment
3207174|NCT00961974|Experimental|Care Ultra|"Routine diabetes support and education from diabetes health care team~Assistance from a non-medical case manager (Care Ambassador) to schedule appointments, provide reminders about appointments, and help families contact health care providers about questions or concerns"
3207175|NCT00961987|Experimental|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
3207176|NCT00961987|Active Comparator|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
3207177|NCT00962026|Experimental|Rilonacept|
3207178|NCT00962117||Obese/Non-obese|
3207179|NCT00962130|Experimental|Blood Glucose Measurement|Subjects have sensors placed on skin before surgery and these sensors will measure the subject's glucose until the third day after surgery when they are removed.
3207180|NCT00962143|Active Comparator|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
3207181|NCT00962143|Experimental|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
3207182|NCT00962156|Experimental|HES 130/0.4|Volume expansion
3207183|NCT00962156|Active Comparator|Ringer acetate|Volume expansion
3207184|NCT00962169|Experimental|Quality improvement program|
3172289|NCT00598169|Experimental|CD20+ Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, rituximab 375mg/m2 on Day 1 of a 21-day cycle."
2564160|NCT02471053|Experimental|Moderate Intensity Exercise|All consenting patients will participate in an aerobic training program, twice-weekly over a 12-week period. Assessments will be performed at baseline (pre-training) and post-program (12-weeks). All participants will continue to receive standard care for their cancer diagnosis.
3207185|NCT00962169|Experimental|Electronic patient device (EPD)|
3207186|NCT00962182|Experimental|Enzyme treatment|Enzyme for 12 weeks
2564312|NCT02470039|Experimental|Oral insulin 338 and subcutaneous placebo|
2564313|NCT02470039|Active Comparator|Subcutaneous insulin glargine and oral placebo|
2564356|NCT02469740|Experimental|Ticagrelor|Patients in this group will be prescribed ticagrelor 90 mg BD for 4 weeks.
2564362|NCT02469740|Active Comparator|Clopidogrel|Patients in this group will be prescribed clopidogrel 75 mg OD for 4 weeks
3207187|NCT00962182|Placebo Comparator|Placebo control|Placebo enzyme for 12 weeks
3207188|NCT00962182|Experimental|Enzyme + gluten|Enzyme and 500 mg gluten b.i.d. for 12 weeks
3207189|NCT00962195|Experimental|purple sweet potato juice|Daily oral intake of 3x 125 ml of PSP-juice for a period of 8 weeks
2564606|NCT02468089|Experimental|Carbepenem+albumin+GMCSF.|
2564613|NCT02468089|Active Comparator|Carbepenem+albumin|
2564702|NCT02467517|Experimental|INTRAVENOUS KETAMINE|
2564729|NCT02467101|Experimental|Corticosteroid/Saline|"Corticosteroid/Saline~Patients with diagnosis of frontal fibrosing alopecia are included in the study. The diagnosis is based on the clinical findings of frontal and temporoparietal hairline recession with loss of follicular ostia.~In the same patient, intralesional triamcinolone acetone will be injected to half-head (in the active border of hairline) and in the other half-head the patient will be injected with saline solution (placebo).~The intralesional triamcinolone acetone (40 mg/ml)l) of 0,1 mL/1cm, is given along the frontal and frontoparietal hairline every 4 weeks (3 sessions).~This study includes 4 visits: 3 visits of treatment (with 1-month interval) and 1 visit of follow-up (month 6)."
2564741|NCT02466906|Experimental|rhGM-CSF group|rhGM-CSF was injected subcutaneously perioperation.
2564746|NCT02466906|Placebo Comparator|placebo group|Placebo was injected subcutaneously perioperation.
2564822|NCT02466776|Active Comparator|Stainless steel staples|Patients in this arm will receive stainless steel staples for skin closure at time of cesarean section.
2564825|NCT02466776|Active Comparator|Absorbable subcuticular Suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
2564901|NCT02466048|Experimental|SurgiFill™ on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
2564904|NCT02466048|Active Comparator|Autograft on Spinal Fusion|In one side of one patient, autogenous bones and SurgiFill™ will be grafted; and in the other side, only the autogenous bones will be grafted.
2564969|NCT02465736|Experimental|A (DP-RT)|"• Arm A consists of the concurrent chemoradiotherapy prior to surgery. The patient will receive 4 weeks of radiation therapy and 4 weekly cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Chemotherapy is given by intravenous infusion on days 1, 8, 15, and 22.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Docetaxel~Drug: Cisplatin"
2564972|NCT02465736|Experimental|B (NP-RT)|"• Arm B consists of the concurrent chemoradiotherapy followed by surgery. The patient will receive 4 weeks of radiation therapy and 2 cycles of chemotherapy. The radiation will generally commence on the 1st day of treatment and will run for 4 weeks. Each cycle of chemotherapy lasts 21 days/3 weeks. The drugs include Vinorelbine and Cisplatin.~Interventions:~Radiation: (44 Gy/20 fractions)~Drug: Vinorelbine~Drug: Cisplatin"
3207190|NCT00962195|Placebo Comparator|Control juice|Daily oral intake of 3x 125 ml of control juice for a period of 8 weeks
3207191|NCT00962221||subclinical hypothyroidism|Patients with subclinical hypothyroidism
2565198|NCT02464215|Active Comparator|open surgery|Conventional procedure,Open surgery
2565199|NCT02464215|Experimental|laparoscopic surgery|Minimum invasive procedure，Laparoscopic surgery
2565236|NCT02464137|Experimental|Radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
2565314|NCT02463812|Placebo Comparator|Control|Patients will receive infusion of normal saline in the recovery room.
2565326|NCT02463214|No Intervention|Standard Room|Standard bone marrow transplant recovery, single occupancy, room
3207192|NCT00962234||Metabolism|Lung cancer patients who exhibit abnormalities in lipid measures.
3207193|NCT00962273|Experimental|Pandemic Stress Vaccine - Interactive|
3207194|NCT00962273|Active Comparator|Pandemic Stress Vaccine - Didactic|
3207195|NCT00962273|No Intervention|Wait list|Some participants are assigned to an eight week waiting condition prior to the course commencing.
3207196|NCT00962286|Experimental|Furosemide, obesity, glomerular hyperfiltration|
3207197|NCT00962299|Active Comparator|Beclomethasone|Inhaled corticosteroids
3207198|NCT00962299|Placebo Comparator|Placebo|Placebo Comparator
3207199|NCT00962312|Experimental|Capecitabine and Lapatinib|
3207200|NCT00962325|Experimental|Activity behaviors counseling|
3207201|NCT00962325|No Intervention|Standard care control|6 weeks of standard preoperative care
3172290|NCT00598169|Experimental|CD20- Non-Hodgkin Lymphoma|"Part A: Velcade Day 1 and Day 8, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2. Dexamethasone 20 mg IV and etoposide 100 mg/m2 IV Days 8-10, carboplatin dosed to AUC=5 (maximum 750 mg) IV and ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna on Day 9 of a 28-day cycle.~Part B: Velcade on Days 1 and 8, dexamethasone 20 mg IV Days 1-3 and Day 8; etoposide 100 mg/m2 IV on Days 1-3; carboplatin dosed to AUC=5 (maximum 750 mg) IV on Day 2; ifosfamide 5000 mg/m2 mixed with an equal amount of Mesna and administered as a continuous IV infusion over 24 hours on Day 2, 21-day cycle."
3172291|NCT00598195|No Intervention|Ketamine Pharmacokinetics|The pharmacokinetic action of Ketamine used in Children having heart surgery.
2564235|NCT02470507||AKI with SIRS|Patients with AKI stage II or III and systemic inflammation without sepsis
2564239|NCT02470507||AKI without SIRS|Patients with AKI stage II or III and no systemic inflammation
2564247|NCT02470507||SIRS without AKI|Patients with systemic inflammation and normal renal function
2564252|NCT02470507||No SIRS and no AKI|Patients after major surgery who do not have an infection, SIRS or AKI
2564317|NCT02470143||Bike application arm|The bike application arm contains cardiac patients that will be instructed to use the cycling application during a one month period.
2564353|NCT02469792|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into anterior cruciated ligament.
2564418|NCT02469402|Active Comparator|Standard infant formula|Standard infant formula
2564420|NCT02469402|Experimental|Protein reduced formula|Protein reduced alpha-lactalbumin formula
2564422|NCT02469402|No Intervention|Breast-feeding|Exclusive breast-feeding
2564488|NCT02469025|Experimental|Resting position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in a resting position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
2564490|NCT02469025|Experimental|End range position mobilization group|"This group receive six manual therapy interventions based on manual traction mobilization in an end range position of the hip joint.~In addition the physical therapist teach the patients six exercises to do at home between manual mobilization sessions."
2564526|NCT02468635|Other|without training for upper limb|Receive treatment from traditional pulmonary rehabilitation and without resistive training for upper limb (UL)
2564528|NCT02468635|Other|upper limb exercises|Receive the same treatment control with additional upper limb resistance training.
2564577|NCT02468375|Experimental|mirabegron 50mg|about 434 OAB patients intake mirabegrone 50mg/day for 12 weeks.
2564625|NCT02467985|No Intervention|Control|
2564628|NCT02467985|Experimental|intervention|Flow of insufflation will be set to 2-3L / min. After the intervention, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. Suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who applies 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 sec. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures.
2564710|NCT02467673|Active Comparator|NANOPARTICULATE estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal nanostructured estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
2564714|NCT02467673|Active Comparator|MICRONIZED estradiol+ progesterone|"The Blood samples are collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal micronized estradiol and progesterone is prescribed.~The patients are evaluated 3 months after THRT treatment protocol. All the patients were instructed about how to use the pump for transdermal application, the first application is performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
2564777|NCT02466828|Experimental|Single patient group receiving Feraheme®|Newly diagnosed GBM patients with no prior treatment will receive Feraheme® as MRI contrast agent
2564787|NCT02466503|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
2564792|NCT02466503|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
2564851|NCT02466256|Placebo Comparator|Autosert Group|Procedure / Surgery : Intraocular lens implantation with Autosert injector
2564854|NCT02466256|Placebo Comparator|Royale Group|Procedure / Surgery : Intraocular lens implantation with Royale Injector
2565408|NCT02462811|Placebo Comparator|Placebo|CL-108 formulation without API
3172292|NCT00598208|Experimental|1|60 µg Org 36286 (corifollitropin alfa)
3172293|NCT00598208|Experimental|2|120 µg Org 36286 (corifollitropin alfa)
3172294|NCT00598208|Experimental|3|180 µg Org 36286 (corifollitropin alfa)
3172295|NCT00598208|Active Comparator|4|Follitropin beta injection
3172296|NCT00598234|Active Comparator|1|Celecoxib (Celebrex)
3172297|NCT00598234|Placebo Comparator|2|Placebo
3172298|NCT00598247|Experimental|A|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks. A
3172299|NCT00598260|Experimental|1- study group|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
3172300|NCT00598260|No Intervention|2 - control group|control group
3172301|NCT00598299||A|Healthy adult serum
3172302|NCT00598299||B|cord blood serum
2564186|NCT02470858|Experimental|SOF+DCV+SMV|Participants with genotype 1b HCV infection will receive SOF + DCV + SMV for 3 weeks.
2564192|NCT02470858|Experimental|SOF+DCV+ASV|Participants with genotype 1b HCV infection will receive SOF + DCV + ASV for 3 weeks
2564225|NCT02470442|Experimental|Sevoflurane/Desflurane|After induction of general anesthesia with sevoflurane, anesthesia was maintained with desflurane.
2564226|NCT02470442|Experimental|Sevoflurane|the anesthetic induction and maintenance with sevoflurane.
2564299|NCT02470247|Experimental|Remote ischemic preconditioning|"Remote Ischemic Preconditioning (RIPC) is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
2564300|NCT02470247|Sham Comparator|SHAM remote ischemic preconditioning|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
2564329|NCT02469883|Experimental|Sinotecean|
2564408|NCT02469350|Experimental|Rehabilitation with serious game|18 rehabilitation sessions with serious game during a 6-8 weeks period
2564447|NCT02469129|Experimental|Dosimetry Studies Arm|Twelve participants with cancer and eight healthy volunteers will be recruited first to undergo whole-body PET/CT imaging to determine the whole body dosimetry of [18F]FluorThanatrace.
2564453|NCT02469129|Experimental|Kinetic Studies Arm|An additional 30 participants with cancer will undergo a 1-hour dynamic scan upon injection of [18F]FluorThanatrace to determine the kinetics of the tracer in tumors to correlate with tissue-based markers of PARP activity and to obtain metabolite information to help determine the best quantification approach for the PET images. When possible these subjects will also undergo 18F-FDG imaging for comparison to tumor metabolism
2564500|NCT02468882|Experimental|Intervention group|"Watercress will be tested in its natural form as a food item that will supplement the usual diet, via the prescription of watercress as whole food added daily to the usual diet. The intervention group will be asked to consume 100 grams of watercress per day, in addition to their usual diet for the total time of RT treatment. These 100 grams of watercress per day will allow the achievement of the daily therapeutic dose."
2564505|NCT02468882|No Intervention|Control group|The control group will receive the standard of care, thus will maintain their ad libitum diet.
2564544|NCT02468518|Experimental|Patients|Vitamin E capsule 200 IU bd x 12 weeks
2564546|NCT02468518|Active Comparator|Arsenic exposed controls|Vitamin E capsule 200 IU bd x 12 weeks
2564547|NCT02468518|Active Comparator|Healthy volunteers|Vitamin E capsule 200 IU bd x 12 weeks
2564591|NCT02468232|Experimental|LCZ696|Before randomization, all patients receive 2 week LCZ696 50 mg twice daily (b.i.d) as single blind run-in active treatment epoch. In double blind epoch, randomized patients in this arm will start with 100 mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 200 mg b.i.d. at week 4 if they are tolerant to 100 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
2564593|NCT02468232|Active Comparator|Enalapril|In double blind period, all randomized patients in this arm will receive enalapril 5mg twice daily (b.i.d.) for 4 weeks. Patients will then be up-titrated to 10 mg b.i.d. at week 4 if they are tolerant to 5 mg b.i.d. Total duration of treatment will be up to approximately 40 months.
2564711|NCT02467439|Active Comparator|Notification Cards|Includes two groups of newly diagnosed HIV-infected participants (ppt): Seropositive and Acutely Infected. After consent and a full survey, blood and urine sample are collected for viral genetic testing and future STI testing. Ppts will be given notification cards for their sexual partners, social contacts. Ppts will receive contract partner notification: if the named sexual partners do not present for testing within 7-14 days, community outreach workers will contact and counsel the partners to visit the clinic. Any returning sexual partner or social contact presenting to the clinic with the notification card linking to the original index ppt will be consented (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If HIV-infected, they will be in the active arm, and will receive partner notification and social contact referral cards. If they are HIV-seronegative they will be screened for acute HIV infection.
2564716|NCT02467439|No Intervention|Base Case Arm|consist of HIV seropositive and seronegative STI clinic patrons . After a brief survey to obtain demographics and sexual behavior, seronegative ppts will have blood collected for screening for acute HIV infection. If a person has acute HIV infection, they will be contacted by a community outreach worker and brought back in for counseling, and, if consenting, enrolled in the active arm. STI clinic patrons who are seropositive at screening will be given cards and asked to refer their sexual partners for evaluation using passive referral. Sexual partners presenting to the clinic with the notification card linking to the original index ppt in the base case arm will be consented to be in study (HIV testing, blood and urine specimen collected for viral genetic testing and future STI testing if HIV positive). If they are seropositive, these participants will be in the base case arm, and will receive partner notification cards for passive referral.
2564784|NCT02467153|Experimental|RET + vitamin D3|Resistance Exercise Training (RET) + vitamin D3 given orally as tablets at a dosage of 800 International Units (IU)/day for 6 months.
2564788|NCT02467153|Placebo Comparator|RET + placebo|Resistance Exercise Training (RET) + placebo given orally as tablets; 1 tablet per day for 6 months.
2564858|NCT02466347|Experimental|Synflutide HFA MDI, 250/25 mcg/dose|Synflutide HFA MDI(Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
2564861|NCT02466347|Active Comparator|SeretideTM EvohalerTM, 250/25 mcg/dose|SeretideTM EvohalerTM (Fluticasone propionate/ Salmeterol, 250/25mcg), Single dose, 4 puffs
2564891|NCT02466022|Experimental|Dexmedetomidine|Patients will receive one 0.5ug/kg bolus of Dexmedetomidine over 10 minutes for sedation prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
2565483|NCT02462629|Experimental|BLZ-100|
3172303|NCT00598325|Experimental|NicVAX|
2564193|NCT02470845|No Intervention|Waitlist-control group|The waitlist-control group will receive no treatment during the first 4 weeks but, beginning with the 5th week this group will receive TJ treatment for four weeks as compensatory.
2564246|NCT02470572|Active Comparator|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
2564250|NCT02470572|Placebo Comparator|Conventional light microscope|conventional light microscope
2564297|NCT02470195|Experimental|workshop|workshop of procedural simulation
2564298|NCT02470195|No Intervention|control|no specific workshop of procedural simulation
2564357|NCT02469909|Other|immediate decannulation|In the immediate decannulation group - the tracheostomy tube is removed and the patient would be monitored overnight in an intermediate monitored unit. On the next day a clinical evaluation would be held, and the patient would be discharge or transferred to his department according to the clinical course of the patient
2564360|NCT02469909|Other|Gradual tracheostomy tube decrease|In the gradual decannulation group The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
3207202|NCT00962338||lap. inguinal herniorrhaphy|Patients undergoing planned lap. inguinal herniorrhaphy
3207203|NCT00962351|Other|Metal-on-Polyethylene|
3207204|NCT00962351|Other|Metal-on-Metal, 28mm femoral head|
3207205|NCT00962351|Other|Metal-on-Metal, 36mm femoral head|
2564740|NCT02467088|Experimental|Individualised Homoeopathic Remedy|Each participant will receive an individualised homoeopathic remedy, in a vehicle of sucrose pillules, according to the symptoms of their PMS. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing as outlined by De Schepper.
2564807|NCT02466815|Experimental|Treatment A, then Treatment B and then Treatment C|Participants will receive treatment A (JNJ-42756493 10 milligram [mg] tablet, current clinical formulation [G-018] which uses milled active pharmaceutical ingredient [API]) in period 1, treatment B (JNJ-42756493 10 mg tablet, Prototype Formulation I [G-025] which uses coarser API) in period 2 and then treatment C (JNJ-42756493 10 mg tablet, Prototype Formulation II [G-025] which uses coarser API) in period 3.
2564815|NCT02466815|Experimental|Treatment B, then Treatment C and then Treatment A|Participants will receive treatment B in period 1, treatment C in period 2 and then treatment A in period 3.
2564819|NCT02466815|Experimental|Treatment C, then Treatment A and then Treatment B|Participants will receive treatment C in period 1, treatment A in period 2 and then treatment B in period 3.
2564824|NCT02466815|Experimental|Treatment A, then Treatment C and then Treatment B|Participants will receive treatment A in period 1, treatment C in period 2 and then treatment B in period 3.
2564828|NCT02466815|Experimental|Treatment B, then Treatment A and then Treatment C|Participants will receive treatment B in period 1, treatment A in period 2 and then treatment C in period 3.
2564832|NCT02466815|Experimental|Treatment C, then Treatment B and then Treatment A|Participants will receive treatment C in period 1, treatment B in period 2 and then treatment A in period 3.
2564871|NCT02466113|Experimental|An experimental group|A 6 microRNA stratified tool is applied in this group.Investigators defined high risk patient and low risk patient according to the microRNA stratified tool.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
2564872|NCT02466113|Other|A control group|A classic stratified tool is applied in this group. Investigators defined high risk and low risk patient according to classical pathological features.The high risk group should receive adjuvant chemotherapy while the low risk group observation.
3207206|NCT00962364||AMI|Patients with acute myocardial infarction treated with intracoronary administration of bone marrow derived cells
3207207|NCT00962364||ICM|Patients with ischemic cardiomyopathy treated with intracoronary administration of bone marrow derived cells
2564985|NCT02465593|Experimental|PEP503+5-FU/capecitabine+Radiotherapy|Patients will receive PEP503 given as intratumor injection on Day 1, followed by preoperative radiation therapy.
3207208|NCT00962364||DCM|Patients with dilated cardiomyopathy treated with intracoronary administration of bone marrow derived cells
3207209|NCT00962377|Other|AlloMap Molecular testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
2565145|NCT02464592|Active Comparator|Biopsy with Cryoprobes|Transbronchial lung biopsy with a cryoprobe.
2565149|NCT02464592|Active Comparator|Biopsy with Conventional Forceps|Transbronchial lung biopsy with conventional forceps.
2565214|NCT02464397|Experimental|OPTIMAX-BAS 1|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 1 month after the index procedure.
2565216|NCT02464397|Active Comparator|SYNERGY-EES 1|SYNERGY™ everolimus eluting stent (EES). Patients will have OCT follow-up 1 month after the index procedure.
2565219|NCT02464397|Experimental|OPTIMAX-OCT 6|Titanium-nitride-oxide coated cobalt-chromium OPTIMAX™ bio-active stent (BAS). Patients will have OCT follow-up 6 months after the index procedure.
3207210|NCT00962377|Active Comparator|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in the monitoring of asymptomatic heart transplant patients for acute cellular rejection
3207211|NCT00962403|Experimental|Yoga treatment|
3207212|NCT00962403|No Intervention|Waitlist|Waitlist control, no active treatment, treatment as usual, active treatment offered after waitlist control period. This study began as a single arm treatment trial and then transitioned to a randomized controlled trial.
3207213|NCT00962416|Active Comparator|1|Biolimus eluting Stent (Biomatrix)
3207214|NCT00962416|Active Comparator|2|Bare metal stent (Gazelle)
3207215|NCT00962442|Active Comparator|nutritional support + N-Acétylcysteine|N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
3207216|NCT00962442|Placebo Comparator|nutritional support + placebo|placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days
3207217|NCT00962455|Experimental|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
3207218|NCT00962455|Active Comparator|Usual practice|Usual practice regarding spirometry execution in family practice
3207219|NCT00962468|Experimental|Pathway|A care pathway will be implemented in this experimental group.
3207220|NCT00962468|No Intervention|Usual care|Usual care will be provided.
3207221|NCT00962481|Active Comparator|Bimosiamose|
2564355|NCT02469844||Patients with epilepsy having seizures in sleep|
2564425|NCT02469506|Experimental|NMES group|Patients will receive twice daily sessions of neuromuscular electrical stimulation (NMES).
2564428|NCT02469506|No Intervention|Control group|Patients will receive daily visits by the investigator to check progress.
2564489|NCT02468999|Active Comparator|insulin nasal spray|160 Units of human insulin as nasal spray
2564491|NCT02468999|Placebo Comparator|placebo nasal spray|Nasal spray containing placebo solution
3207222|NCT00962481|Placebo Comparator|Placebo|
2564589|NCT02468245|Active Comparator|Control Arm|"This is a usual care group. Patients in this arm will receive the standard pre-drug initiation training and 4 week clinic follow up visit."
2564590|NCT02468245|Experimental|Intervention arm|Patients in this arm will also receive the standard pre-drug initiation training followed by telephone follow up by an oncology certified chemotherapy nurse (OCN) at week one, two, and three. Patients will then have the standard 4 week follow up clinic visit.
2564640|NCT02467881|Active Comparator|Physical Activity Increase (GLB-MOD)|Participants randomized to this arm will follow the traditional GLB program with an activity goal of 150 minutes per week of moderately intense physical activity similar to a brisk walk. Progression of the activity goal each week is slow and safe with increases of no more than 30 minutes per week. Participants are requested to try and achieve 20-30 minutes per day of moderate activity but, to allow for flexibility, that amount can be split into 10 minute increments. Self-reported monitoring for this group includes keeping track of weight, daily food intake as well the number of minutes each day spent being active as part of their planned activity goal. This is all recorded in the self-monitoring keeping track book.
2564641|NCT02467881|Active Comparator|Sedentary Time Decrease (GLB-SED)|"The GLB curriculum will be adapted to direct participants to decrease the time they spend sitting in a day rather than to increase moderate+ physical activity as is the case in the current GLB program. In order for the participant to become aware of how much time they spend sitting and where most of their sitting time occurs, they will fill out a 7 Day Sedentary Diary that consists of daily entry of time spent sitting over the course of one week. Participants will be asked to eliminate a 45 minute sitting bout in a day with non-sitting activity. They will initially be asked to eliminate 45 minutes of sitting for two days in that week. This will increase one day a week until 7 days in a week are met."
2564642|NCT02467881|Other|6-month delayed (DELAYED)|Those assigned to the DELAYED group at baseline will wait for 6 months to begin intervention. During the delayed time period, these participants will receive periodic health information newsletters. At the end of 6 months, the DELAYED participants will be randomly assigned to GLB-MOD or GLB-SED intervention, and will begin their intervention program at that time.
2564682|NCT02467543|Placebo Comparator|20% Ethanol|20% ethanol containing no active ingredients. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
2564685|NCT02467543|Experimental|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol. Ten drops will be taken three times daily when the pain and cramping of dysmenorrhea start, and should be stopped when the pain and cramping have ceased.
2564774|NCT02467218|Experimental|Immediate Hyperbaric Oxygen Treatment|If a participant is randomized to the group receiving the intervention, the participant will be receiving a baseline assessment functional magnetic resonance imaging (fMRI) and subsequently receiving hyperbaric oxygen treatment for 90 minutes, once daily, five times a week for 8 consecutive weeks (40 treatments with 100% oxygen at 2.0 ATA). A follow-up fMRI will be performed after the last day of treatment.
2564776|NCT02467218|Experimental|Delayed Hyperbaric Oxygen Treatment|If the participant is assigned to the cross group, the participant will also receive a baseline assessment functional magnetic resonance imaging (fMRI). However, it will be followed-up in a controlled manner for 3 months. After 3 months, the participant will be receiving hyperbaric oxygen treatment identical to Group A and a follow-up fMRI will be performed after the last treatment.
2564795|NCT02466568|Experimental|Phase I and Phase II Treatment Arm|Participants will receive nivolumab and GM.CD40L. Treatment will be administered on an outpatient basis. The nivolumab will be given first followed by the GM.CD40L vaccine for those enrolled on this arm.
2564800|NCT02466568|Active Comparator|Phase II Control Arm|Nivolumab treatment without GM.CD40L. Nivolumab will be given every 2 weeks at a dose of 3mg/kg.
2564846|NCT02466295|Experimental|Volume-controlled ventilation|The patient's lungs will be mechanically ventilated using the volume-controlled ventilation with tidal volume 8 ml/kg.
2564847|NCT02466295|Experimental|Pressure-controlled ventilation|The patient's lungs will be mechanically ventilated using the pressure-controlled ventilation with tidal volume 8 ml/kg.
2564879|NCT02466100|Experimental|Goc Intervention|Patient education materials, study nurse phone call, tip sheet, provider tip sheet
2564882|NCT02466100|No Intervention|usual care|care as usual in the community
2564930|NCT02465879|Experimental|Therapist Triage|All subjects in this group will be triaged by an extended role occupational or physical therapist prior to their visit with the rheumatologist.
2564987|NCT02465502|Experimental|Regorafenib (BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
2565046|NCT02465281||Stroke patients|20 patients who are at least 6 months post stroke. Device: 3T scanner with MRI-compatible robot
2565048|NCT02465281||Healthy volunteers|80 age-matched healthy volunteers
3207223|NCT00962494|Experimental|online workshop|
3207224|NCT00962533|Experimental|ROADMAP Group (Group I)|"Patients were to take telbivudine 600 mg orally daily from Baseline.At Week 24, patients in Group I were split into Group I-A or Group I-B based on their virologic load:~Group I-A: This group of patients was those with HBV DNA ≥300 copies/mL at Week 24 and adefovir was to be added at Week 28;~Group I-B: This group of patients was those with HBV DNA <300 copies/mL at Week 24. Telbivudine monotherapy was to be continued until there was a viral breakthrough (confirmed by two examinations with at least 1 month interval with compliance factor excluded) and then adefovir was to be added;~The total treatment duration was 104 weeks."
3172304|NCT00598325|Experimental|NicVAX Lot 2|2nd cohort receives a different lot of vaccine from the 1st cohort
3172305|NCT00598338|Active Comparator|1|Prucalopride
2564537|NCT02468609|Other|Ultralow-Dose-CT|Additional Ultralow-Dose-CT of the chest
2564561|NCT02468336|Experimental|AngioDefender|The AngioDefender device uses a novel, proprietary software algorithm to analyze pulse wave amplitude data collected before and after BA occlusion by a standard upper arm sphygmomanometric blood pressure (BP) cuff. The procedure is non-invasive and employs neither ultrasound nor Doppler flow analysis.
2564567|NCT02468336|Active Comparator|Brachial Artery Ultrasound Imaging|A non-invasive procedure for detecting endothelial dysfunction by measuring the flow-mediated dilation of the brachial artery (BA) using high resolution continuous ECG-gated B-mode (2D) ultrasound imaging during reactive hyperemia, a state of transient increase in tissue blood flow that occurs following a brief period of ischemia, e.g., BA occlusion. BA diameter is measured at end-diastole, coincident with the R wave of a simultaneously recorded ECG.
2564604|NCT02468037|Experimental|Phlebotomy|All subjects receive counseling to follow a healthy diet and regular exercise. Phlebotomy occurs at the rate of 500 ml (one Unit) of blood per month over the period of 3-6 months. At two-month intervals, serum ferritin and complete blood counts are determined. When serum ferritin reaches the lowest quartile of normal (<50 ng/mL for females and <70 ng/mL for males, but no sooner than 3 months or later than 6 months after beginning phlebotomy, subjects will be retested for glucose tolerance as described
2564615|NCT02468037|No Intervention|Control|Subjects receive counseling to follow a healthy diet and regular exercise.
2564654|NCT02467790|Experimental|Mild renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
2564657|NCT02467790|Experimental|Moderate renal insufficiency|PEX 168: 200µg,Subcutaneous,one time.
2564659|NCT02467790|Experimental|Normal renal function|PEX 168: 200µg,Subcutaneous,one time.
2564757|NCT02466984|Experimental|metoclopramide subcutaneous|every two days, first from 10 to 20 and then from 20 to 30 mg/d
2564764|NCT02466984|Active Comparator|metoclopramide intravenous|first from 10 to 20 and then from 20 to 30 mg/d
2564797|NCT02466607|Other|RETeval color flicker ERG|Compare implicit times and amplitudes of electroretinograms obtained from series of color flashes to those obtained from white flashes.
2564804|NCT02466607|Other|RETeval dilated versus un-dilated flicker ERG|Compare implicit times and amplitudes of ERGs obtained from cd/m2/sec stimulation (used with dilated pupils) to those obtained from troland stimulation (used with un-dilated pupils).
2564852|NCT02466334|Active Comparator|Active|1.5µg/min IV calcitonin-gene related peptide for 20 minutes
2564855|NCT02466334|Placebo Comparator|Placebo|IV placebo for 20 minutes
2564899|NCT02466074|Experimental|Acetazolamide|Acetazolamide in oral daily divided dose administered for 6 consecutive months
2564900|NCT02466074|Placebo Comparator|Placebo|Placebo in oral daily divided dose administered for 6 consecutive months
2564933|NCT02465775|Experimental|UltraShape treatment in all subjects|UltraShape treatment for fat reduction to unilateral flank for all subjects with untreated flank as control.
2565093|NCT02464891|Experimental|CCX168|Study medication will be administered as hard gelatin capsules containing 10 mg CCX168. Patients will take 30 mg CCX168, given as 3 x 10 mg capsule, twice daily for 15 days.
2565169|NCT02464631|Active Comparator|Sofosbuvir + Ribavirin 1|Sofosbuvir + Ribavirin x 24 weeks
2565172|NCT02464631|Experimental|Sofosbuvir + Ribavirin 2|Sofosbuvir + Ribavirin x 36 weeks
2565176|NCT02464631|Experimental|Sofosbuvir + Ribavirin 3|Sofosbuvir + Ribavirin x 48 weeks
2565234|NCT02464280||Patients scheduled for lung imaging|"Patients with lung changes and scheduled for lung imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
2565320|NCT02463864|Sham Comparator|Sham exercise|Twice daily, individual, stretching and relaxation exercise sessions
3172306|NCT00598338|Placebo Comparator|2|Placebo
3172308|NCT00598364||Thyroidectomy or neck dissection|Patients with thyroid cancer or benign thyroid disease (nodules or goiter) who underwent thyroidectomy and/or neck dissection as standard of care.
3172309|NCT00598377|Active Comparator|1|Patients with autosomal dominant polycystic kidney disease
3172310|NCT00598377|Active Comparator|2|Healthy subjects
3172311|NCT00598403|Experimental|1|Cefditoren pivoxil
3172312|NCT00598403|Active Comparator|2|Ciprofloxacin
3172313|NCT00598416|Experimental|Psychoeducation|
3172314|NCT00598429|Active Comparator|High dose|PGE1 300 ng/kg/min via nebulizer over a 72-hour period
3172315|NCT00598429|Active Comparator|Low dose|PGE1 150 ng/kg/min via nebulizer over a 72-hour period
3172316|NCT00598429|Placebo Comparator|Placebo|Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
3172317|NCT00598533|Experimental|Dual-DES|Rapamycin + Probucol-eluting stent
3172318|NCT00598533|Active Comparator|ZES|Polymer based Zotarolimus-eluting stent
3172319|NCT00598546||1|
3172320|NCT00598572|Experimental|1|All participants will receive various dose-regimens of the study drug (deferoxamine mesylate). Each dose cohort will consist of at least 3 subjects.
3172321|NCT00598611|Active Comparator|1|desloratadine 20 mg
3172322|NCT00598611|Active Comparator|2|desloratadine 20 mg
3172323|NCT00598624|Experimental|A|
3172324|NCT00598637|Active Comparator|EES|Everolimus-eluting stent (Xience)
3172325|NCT00598637|Experimental|ZES|Zotarolimus-eluting stent (Endeavor Resolute)
3172326|NCT00598676|Experimental|BPRES|biodegradable polymer rapamycin-eluting stent
3172327|NCT00598676|Active Comparator|PPRES|permanent polymer rapamycin-eluting stent
3172328|NCT00598676|Active Comparator|PPEES|permanent polymer everolimus-eluting stent
3172329|NCT00598715|Experimental|Same drug|sirolimus-eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
3172330|NCT00598715|Active Comparator|Different drug|paclitaxel eluting stent will be implanted for restenosis after previous the implantation of a sirolimus-eluting stent
3172331|NCT00598728||1|Hodgkin lymphoma Survivors
3172332|NCT00598741|Experimental|1|
2564421|NCT02469545|Placebo Comparator|SSRI and placebo of probiotic|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor: Escitalopram or Sertraline) and placebo of probiotic (crystalline cellulose powder) to a group of patients diagnosed with depression (n=30).
2564595|NCT02468219|Active Comparator|aortic valve replacement|patients with aortic stenosis submitted to aortic valve replacement procedure
2564596|NCT02468219|Experimental|transcatheter aortic valve implantation|patients with aortic stenosis who underwent to transcatheter aortic valve implantation
2564665|NCT02467816|Experimental|School lunch intervention|Intervention schools (6 middle and 6 high) will receive the complete school lunch intervention for two school years.
2564666|NCT02467816|No Intervention|School lunch control|Control schools (6 middle and 6 high) will not receive the school lunch intervention for two school years. Lunch delivery will proceed as normal.
2564751|NCT02467140|Active Comparator|Self-fixating mesh|During surgery, the Parietex ProGrib mesh will be used.
2564752|NCT02467140|Active Comparator|Tack fixation|During surgery, the mesh will be fixated with tacks.
3172333|NCT00598780||1|Patients with newly diagnosed persistent allergic rhinitis, within the approved age limits.
3172334|NCT00598845||Consecutive numbers|Patients with endometrial cancer
2564856|NCT02466373|No Intervention|No clonidine|No clonidine is administered. The outcome measures are recorded, to compare them with the outcome measures of the other clonidine arms
2564860|NCT02466373|Experimental|Clonidine 600mcg|4 patients receive 600 µg/day of clonidine without loading schedule. 4 patients receive 600 µg/day of clonidine with a loading schedule of 300 µg in 4 h.
2564863|NCT02466373|Experimental|Clonidine 1200mcg|"4 patients receive 1200 µg/day of clonidine without loading schedule.~4 patients receive 1200 µg/day of clonidine with a loading schedule of 600 µg in 4 h."
2564864|NCT02466373|Experimental|Clonidine 1800mcg|"4 patients receive 1800 µg/day of clonidine without loading schedule.~4 patients receive 1800 µg/day of clonidine with a loading schedule of 900 µg in 4 h."
3172335|NCT00598858|Experimental|Treatment (docetaxel and prednisone)|Patients receive docetaxel IV over 60 minutes on days 1 and 2 and prednisone PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2564947|NCT02465606|Experimental|Group 1: Lebrikizumab Dose Level 1 Monotherapy|During the 2-week run-in period, participants will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 12-week treatment period, lebrikizumab monotherapy will be administered by subcutaneous (SC) injection, but participants assigned to this group will not receive topical corticosteroids. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
2564953|NCT02465606|Active Comparator|Group 2: Topical Corticosteroid Creams Only|During the 2-week run-in period and during the 12-week treatment period, participants assigned to this group will receive topical corticosteroid creams to be self-applied two times per day to active skin lesions only. During the 8-week safety follow-up period, all participants will receive topical corticosteroids to be self-applied to active skin lesions as decided by the participant and study investigator.
2565007|NCT02465307||Delirium group|ICU patients with a positive Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
2565010|NCT02465307||Control group|ICU patients with a negative Confusion Assessment Method (CAM) score; observational using accelerometers, commercially available camera, and Internet Pod (iPod).
2565019|NCT02465307||Healthy control group|Healthy subjects that sleep in their home environment; observational using accelerometers, cortisol swabs, and Internet Pod (iPod)
2565054|NCT02464995|Experimental|Thermoplasty group|Procedure: Bronchial thermoplasty with the Alair System and conventional therapy
2565062|NCT02464995|No Intervention|Control group|Conventional therapy
2565129|NCT02464852|Other|Snood|All recruited participants will try out the snood
2565220|NCT02464189||Children with asthma|
2565335|NCT02463461|Experimental|ActiSleep Activity Monitor|Subjects placed in this group will given an ActiSleep Activity Monitor for the one night of the study.
2565341|NCT02463461|Experimental|Jawbone Activity Monitor|Subjects placed in this group will given a Jawbone Activity Monitor for the one night of the study.
2565343|NCT02463461|Experimental|Actiwatch 2 Activity Monitor|Subjects placed in this group will given an Actiwatch 2 Activity Monitor for the one night of the study.
2565344|NCT02463461|Experimental|FitBit Activity Monitor|Subjects placed in this group will given a FitBit Activity Monitor for the one night of the study.
2565346|NCT02463461|Experimental|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects placed in this group will given an Actigraph by Ambulatory Monitoring Activity Monitor for the one night of the study.
2565396|NCT02462863|Experimental|Immunonutrient treatment|Administration of arginine and fish oil.
2565466|NCT02462681|Active Comparator|bupivacaine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% paravertebrally, divided into 3-4 ml in each level
2565471|NCT02462681|Active Comparator|bupivacaine + 0.5 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 0.5 mg/kg ketamine paravertebrally divide into 3-4 ml in each level
3172336|NCT00598884|Experimental|6-week delay start|This group begins treatment 6 weeks after recruitment and baseline.
3172337|NCT00598884|Experimental|No delay start|This group begins treatment after enrollment and assessment with no wait period.
3172338|NCT00598897|Experimental|clarithromycin and rifabutin/rifampin|Clarithromycin and rifabutin/rifampin with ethambutol given three times weekly.
3172339|NCT00598910|Experimental|A|
3172340|NCT00598910|Placebo Comparator|B|
3172341|NCT00598923|Experimental|1|Phenytoin 20mg/kg load, then Topiramate, 100 mg twice daily, starting at 24 hours post-TBI for 6 days.
3172342|NCT00598923|Experimental|2|topiramate for 3 months after loading dose of phenytoin
2564478|NCT02468986||Uncontrolled Rheumatoid Arthritis|"18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Uncontrolled: Patients will be labeled as uncontrolled RA if Disease Activity Score (DAS) score is >3.2 and C-reactive protein (mg/dL) elevated above normal range.~Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing."
2564482|NCT02468986||Controlled Rheumatoid Arthritis|18-75 years old; Rheumatoid arthritis, defined by 1987 American College Rheumatology criteria; Attending clinic at Aston Center for Rheumatology or Parkland Rheumatology Clinic; Controlled: Disease activity score (DAS) <3.2, normal C-reactive protein. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
2564485|NCT02468986||Healthy Controls|18-75 years old. Excluding: Insulin dependent diabetes; Cardiovascular or Cerebrovascular disease (history of myocardial infarction, stroke, peripheral vascular disease); Tobacco use in the past 24 months; Uncontrolled hypertension (BP > 150/90) in the past 3 months; Uncontrolled hyperlipidemia (LDL>160) in the past 6 months; Pregnant or nursing.
2564517|NCT02468752|Sham Comparator|Air|Normobaric air breathing
2564521|NCT02468752|Experimental|Oxygen|Normobaric oxygen breathing
2564573|NCT02468401|Experimental|Coronary angiography|Patients undergoing coronary angio with or without percutaneous coronary intervention using a new protocol designed to minimize the exposure to contrast medium
2564603|NCT02468141|Experimental|SJDBT group|Herbal medicine
2564612|NCT02468141|Placebo Comparator|Placebo|Placebo control
3207225|NCT00962533|Active Comparator|SOC (Standard of Care) Group (Group II)|patients were to take telbivudine 600 mg monotherapy from Baseline until Week 104. If viral breakthrough (defined as HBV DNA 1 log10 above nadir) was confirmed (by two examinations with at least a 1 month interval with compliance factor excluded), adefovir 10 mg daily was to be added.
3207226|NCT00962546||CTA/CTP|Patients undergo CTA/CTP imaging prior to cerebral angiography
2564806|NCT02466698|Experimental|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
2564813|NCT02466698|Active Comparator|Usual Care|Patients will receive usual care for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The usual care group will receive the same antibiotic doses as the experimental arm of the study. For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
2564869|NCT02466191|Experimental|memantine first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
2564870|NCT02466191|Experimental|gabapentin first|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
2564916|NCT02465944|Experimental|FFP104 - 2.5 mg/kg|FFP104
2564917|NCT02465944|Experimental|FFP104 - 5.0 mg/kg|FFP104
2564918|NCT02465944|Placebo Comparator|Placebo|Placebo
3207227|NCT00962611|Experimental|Copanlisib|
3207228|NCT00962637|Experimental|1|Androxal™ 12.5 mg
3207229|NCT00962637|Experimental|2|Androxal™ 25 mg
3207230|NCT00962637|Active Comparator|3|AndroGel®
2565684|NCT02461238|Active Comparator|Vouchers|Families included in the Voucher arm will receive vouchers for fruits and vegetables by mail every month for a period of 1 year coupled to nutritional education from a dietician
2565690|NCT02461238|Other|Control|Families included in the control arm will only receive nutritional education
2565741|NCT02460796||hippotherapy group or study group|8 weeks of hippotherapy therapy: Familiarization sessions were initially 15 minutes and gradually evolved to 30 minutes in order to allow all participants to adapt to the horse's rhythmic movements and to the act of mounting the horse. Each session had warm up before the training and exercises for relaxation in the end of each session.
2565743|NCT02460796||control group|8 weeks of Parkinson's disease lectures: this group did not hippotherapy classes in the same period.
2565768|NCT02460510|Experimental|Mannitol|Treatment with mannitol intravenous (IV) bolus over 20 to 30 minutes. The dose is 0.25 g/kg IV as a 20% solution repeated every 4th hourly.(8) Mannitol infusion to be stopped if s osmolarity >320mm
2565772|NCT02460510|Active Comparator|3% hypertonic saline|Treatment with 3% hypertonic saline as continuous infusion. Continuous 3% NaCl infusion to be started at a rate of 25ml /hr and titrated q4hrs per sliding scale to achieve a target serum sodium level of <160 mmol/L.
2565905|NCT02459691|Active Comparator|Usual Care Only|Patients assigned to this group will continue medical care as usual.
3207231|NCT00962637|Placebo Comparator|4|Placebo
3207232|NCT00962663|Experimental|ICA-105665|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
3207233|NCT00962663|Active Comparator|Ibuprofen|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
3207234|NCT00962663|Placebo Comparator|Placebo|Three study drug treatments will be used: ICA-105665, ibuprofen, and placebo (for both ICA-105665 and Ibuprofen). The order of study drug treatment given to each subject during each specified treatment period is determined at randomization.
2564570|NCT02468310|Experimental|Intervention districts|Access to protocols for management of obstetric and neonatal emergencies via text messaging on request in Intervention districts. Maternal and Neonatal emergency protocols
2564575|NCT02468310|No Intervention|Control districts|No access to protocols for management of obstetric and neonatal emergencies via text messaging in control district
2564609|NCT02468050|Experimental|Self Management|In addition to the weekly supervised exercise session, participants in this arm will view an instructional video. The video will deliver theory driven training of cognitive behavioural strategies for self management of exercise. It is expected that this will improve adherence to the exercise program.
2564617|NCT02468050|Experimental|Exercise|Personalized 6 week moderate intensity (50 - 75% of heart rate reserve) facility and home based exercise program including cardiovascular and muscular conditioning.
2564619|NCT02468050|No Intervention|Prospective Cohort Control|Eligible, consented participants who are unable to attend the weekly exercise sessions will serve as a cohort control group. Participants will be asked to complete patient reported measures of anxiety, depression, and exercise behaviour within 3 days of biopsy, and 6 weeks post biopsy.
2564653|NCT02467647|Experimental|A|Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
2564656|NCT02467647|Active Comparator|B|Arm B: Thalidomide 100mg oral once per day for 6 months
2564690|NCT02467400|Placebo Comparator|placebo|Sugar pill 2/day for 20 weeks; The once daily groups will receive a placebo as the second dose
2564701|NCT02467400|Active Comparator|Atenolol|Atenolol 50 mg 1/day for 20 weeks
2564707|NCT02467400|Active Comparator|Nebivolol|Nebivolol 5 mg/day for 20 weeks
2564713|NCT02467400|Active Comparator|Propranolol 40 mg|Propranolol 20 mg bid for 20 weeks
2564715|NCT02467400|Active Comparator|Propranolol 80 mg|Propranolol 40 mg bid for 20 weeks
2564728|NCT02467049|Active Comparator|ECG-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ECG-guided insertion.
2564730|NCT02467049|Experimental|ULTRASOUND-guided insertion of PICC|Placement of the PICC (Peripherally Inserted Central Catheter ) ULTRASOUND-guided.
2564745|NCT02466893|Other|ADAPT Technique/Standard SR Group|
2564867|NCT02466438|Experimental|Piperacillin-tazobactam|"Piperacillin-tazobactam administration (fixed combination, ratio piperacillin:tazobactam = 8:1).~Recruitment stratified by age group and pediatric populations to ensure good representation of those subgroups. Maximum dose: 16g/day. Treatment duration: up to 14 days depending to the treating physician.~Patients with Normal Renal function:~Pediatric and surgery units: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Pediatric intensive care unit (PICU): 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Haematology-oncology unit: 2-5 months (7); 6-11 months (7); 12-23 months (7); 2-6 years (16)~Patients with Acute Kidney injury:~Pediatric and surgery units: 2 months-6 years (10)~PICU: 2 months-6 years (10)~Haematology-oncology unit: 2 months-6 years (10)"
2564911|NCT02465957|Experimental|aNK (NK-92)|aNK (activated NK-92, formerly Neukoplast)
2564992|NCT02465424||questionnaire order|the order of presentation of the 4 quality of life questionnaires to the patients will be randomised to reduce the impact of boredom and habituation on responses
2565064|NCT02465151|Experimental|No Protein|
2565070|NCT02465151|Experimental|Low Protein|
2565074|NCT02465151|Experimental|Medium Protein|
2565077|NCT02465151|Experimental|High Protein|
2565161|NCT02464670|Experimental|Group 1|INO-4201 IM + EP, 2 mg, 3 doses
2565165|NCT02464670|Experimental|Group 2|INO-4202 IM + EP, 2 mg, 3 doses
2565166|NCT02464670|Experimental|Group 3|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
2565167|NCT02464670|Experimental|Group 4|INO-4212 IM + EP, 4 mg, 3 doses
2565168|NCT02464670|Experimental|Group 5|INO-4212 + INO-9012 IM + EP, 4+1 mg, 3 doses
2565170|NCT02464670|Experimental|Group 6|INO-4201 ID + EP 0.2A, 1 mg, 3 doses
2565175|NCT02464670|Experimental|Group 7|INO-4201 ID + EP 0.2A, 2 mg, 2 doses
2565180|NCT02464670|Experimental|Group 8|INO-4201 ID + EP 0.2A, 1 mg, 2 doses
2565183|NCT02464670|Experimental|Group 9|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 3 doses
2565187|NCT02464670|Experimental|Group 10|INO-4201 + INO-9012 ID + EP 0.2A, 1.6 + 0.4 mg, 2 doses
2565189|NCT02464670|Experimental|Group 11|INO-4201 + INO-9012 ID + EP 0.2A, 0.8 + 0.2 mg, 3 doses
2565190|NCT02464670|Experimental|Part II: Group 3A|INO-4201 ID + EP 0.2A, 2 mg, 3 doses
2565191|NCT02464670|Experimental|Part II: Group 3B|INO-4201 ID + EP 0.1A, 2 mg, 3 doses
3207235|NCT00962676||immunocompromised group|
3207236|NCT00962676||non-immunocompromised group|
3207237|NCT00962689||Chronic Rhinosinusitis|Patients with chronic rhinosinusitis as defined by American Academy of Otolaryngology-Head and Neck Surgery and American Rhinologic Society guidelines
3207238|NCT00962689||Control Group|Patients undergoing endoscopic sinus surgery for diseases other than chronic rhinosinusitis (i.e., access to pituitary gland, etc)
2565293|NCT02463604|Experimental|Remote Ischemic Preconditioning|"A blood pressure cuff is placed on upper arm and inflated to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
2565322|NCT02463188|Experimental|Sleep Fitness Intervention|The intervention consists of 5-7 sessions on sleep science, the connection between sleep and substance use, behavior change strategies, and motivation to change behavior.
3207239|NCT00962702|Experimental|Exclusion of Left Atrial Appendage|Exclusion of Left Atrial Appendage
3207240|NCT00962715|Experimental|TIV|TIV (Influenza Vaccine Trivalent Inactivated) alone
3207241|NCT00962715|Experimental|TIV + PEGrIFN-α|TIV + Pegylated Interferon
3207242|NCT00962715|Experimental|TIV + IFNα|TIV + Interferon
3207243|NCT00962767|Experimental|a|2 doses of gemtuzumab ozogamicn administered at monthly intervals
3207244|NCT00962767|Active Comparator|b|2 years maintenance therapy with intermittent ATRA plus 6-Mercaptopurine (6-MP) and methotrexate (MTX)
3207245|NCT00962806|Active Comparator|Exercise|8 week intensive exercise group
2564643|NCT02467868|Experimental|MYL-1401H|MYL-1401H
2564645|NCT02467868|Active Comparator|Neulasta|Neulasta
2564697|NCT02467322|Experimental|Albumin|MVP (Moderate Volume Paracentesis) of less than 5 liters with iv albumin at a dose 8 gms/l of ascitic fluid.
2564705|NCT02467322|Active Comparator|No Albumin|MVP(Moderate Volume Paracentesis) of less than 5 liters without albumin.
3207246|NCT00962806|Other|Control Lifestyle counseling|Lifestyle counseling without intensive exercise
3207247|NCT00962819||cross-sectional|College-aged students who were immunized with MMR.
2564827|NCT02466464|Active Comparator|Microporous Polysaccharide Hemospheres (MPH)|Subjects with acute epistaxis will receive microporous polysaccharide hemospheres (Arista) powder. In the event that Arista fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the control group and will receive Merocel.
2564829|NCT02466464|Active Comparator|Merocel (Control)|Subjects with acute epistaxis will receive standard-of-care treatment, nasal tampon (Merocel). In the event that Merocel fails to assist in resolving nosebleed in 15 minutes, subjects will be promptly escalated to the MPH group and will receive Arista powder.
2564874|NCT02466204|Active Comparator|corifollitropin alfa (long action FSH)|corifollitropin alfa 150 mcg subcutaneous injection. Seven days after, combines with recombinant FSH 300 IU daily subcutaneous injection
2564876|NCT02466204|Active Comparator|Follitropin Beta (recombinant FSH)|300 IU of recombinant FSH, daily subcutaneous injection
2564927|NCT02465827|Active Comparator|Saphenous and obturator nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of ropivacaine 0,75% for the obturator nerve block.~Ropivacaine 0.75% for nerve blockades for both nerves mentioned."
2564932|NCT02465827|Active Comparator|Saphenous nerve block|"5 ml of ropivacaine 0.75% for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Ropivacaine 0.75% for the saphenous nerve block and saline for the obturator nerve block"
2564935|NCT02465827|Placebo Comparator|Placebo nerve block|"5 ml of isotonic saline for the saphenous nerve and 10 ml of isotonic saline for the obturator nerve block.~Saline for nerve blockades for both nerves mentioned."
3207248|NCT00962832|Placebo Comparator|Part 1 - Placebo intravenously|Participants received placebo intravenously every 4 weeks for 24 weeks.
3207249|NCT00962832|Experimental|Part 1 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 24 weeks.
2565056|NCT02464982||Women with 1 year non-invasive technology areola tattoo|Women with 1 year non-invasive technology areola tattoo realized in standard care as part of 1 breast mammary reconstruction following an operated breast cancer
2565159|NCT02464813|Active Comparator|Pregabalin|Pregabalin in hard capsule 2mg/kg rounded up to next 25mg twice daily, max 150mg x 2, for 5 days.
2565163|NCT02464813|Placebo Comparator|Sugar pill|Same hard capsule and same amount of tablets twice daily for 5 days.
2565212|NCT02464293|Experimental|mindfulness-based cognitive therapy|
2565258|NCT02463994|Experimental|MPDL3280A + HIGRT|
2565283|NCT02463747|Experimental|Prolonged Infusion of antibiotics|"Prolonged (4 hours) Infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician."
2565286|NCT02463747|Active Comparator|Fixed time infusion of antibiotics|"Fixed time (half and hour) infusion of antibiotics.~Intervention:~Primary care would be one of three options:~Piperacillin/tazobactam : 4.5gr, TID, I.V.~Or~Fortum (Ceftazidim): 2.0gr, TID, I.V. - for penicillin-sensitive patients.~Or~Meropenem: 1.0gr, TID, I.V.~Supplementation of Vancomycin will be at the discretion of the treating physician/"
2565349|NCT02463344||MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
2565414|NCT02462915|Experimental|i-gel, an brand of supraglottic airway device|a supraglottic airway devices with a gastric suction channel
2565419|NCT02462915|Experimental|endotracheal tube|traditional use for protect airway during the surgery
2565468|NCT02462447||Prostate Cancer|Subjects will receive two PET/CT examinations, one with 11C-sarcosine and one with 11C-choline. These scans will take 30-45 minutes each.
2565470|NCT02462447||Healthy Volunteer|Subjects will receive one PET/CT examination, with 11C-sarcosine. This scan will take approximately 90 minutes.
2565514|NCT02462200|Active Comparator|BCS Arm (breast-conserving surgery - standard of care)|"Defined as partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (except for those patients with iodine or seafood allergies or in cases where the goggles are unavailable for use).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of and CSM that are taken."
2565522|NCT02462252|Experimental|BL-8040 plus hATG, methylprednisolone, cyclosporine|"BL-8040 0.75mg/kg will be administered Subcutaneously (SC ) on Days 1-10, then on first 5 days of months 2-6.~Standard therapy: hATG: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: methylprednisolone: Days 11-14: 40mg/kg/day IV over 6-8 hours, in all AA subjects, or in MDS subjects less than 55 years old. 35mg/kg/day IV over 6-8 hours in MDS subjects 55 years and older.~Standard therapy: cyclosporine: 5mg/kg/day orally, given in 2 divided doses, starting on day 11 and continuing through Month 6 Day 30 (end of treatment)"
2565555|NCT02461823|Experimental|Z Crown|A Zirconia crown will be provided to patients.
3207250|NCT00962832|Placebo Comparator|Part 2 - Placebo subcutaneously|Participants received placebo subcutaneously every 2 weeks for 24 weeks.
3207251|NCT00962832|Experimental|Part 2 - Rontalizumab 300 mg subcutaneously|Participants received rontalizumab 300 mg subcutaneously every 2 weeks for 24 weeks.
2564565|NCT02468297|Experimental|Electronic Acupuncture Shoe|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoe three times a week. 6 weeks of treatment was given. Subjects took placebo only in the first week. No placebo or medicine was prescribed to the subjects since the second week."
2564569|NCT02468297|Placebo Comparator|Control group|Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy. Subjects took ibuprofen(400mg, TID) only in the first week. No placebo or medicine was prescribed to the subjects since the second week.
2564620|NCT02468115|Experimental|VIS410|Single intravenous fixed dose of VIS410
2564621|NCT02468115|Placebo Comparator|Placebo|Single intravenous infusion of placebo
2564684|NCT02467686|Active Comparator|Cimicifuga racemosa|"The other group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal and will start with 2 tablets per day of dry extract of Cimicifuga racemosa.~Each tablet contains 20 mg of dry extract of Cimicifuga racemosa standardized between 1 mg and 1.25 mg of triterpene glycosides expressed in 26-deoxyactein. Will be guided 1 tablet 12/12 hours for 6 months.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
2564686|NCT02467686|Placebo Comparator|Control|"Control group will have 30 patients receiving tamoxifen 20 mg orally daily or exemestane (aromatase inhibitor) 25 mg orally once daily after a meal . They will be followed for 6 months and answer Kupperman scale, WHOQOL questionnaire and FSFI questionnaire at the first visit, 3-month and 6-month follow-up.~WHOQOL questionnaire (The World Health Organization Quality of life)application for evaluation at the first visit, 3-month and 6-month follow-up.~FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up."
2564753|NCT02466997|Experimental|Tacrolimus group|Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
2564760|NCT02466997|Placebo Comparator|Control group|"In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given."
3207252|NCT00962832|Experimental|Part 3 - Rontalizumab 750 mg intravenously|Participants received rontalizumab 750 mg intravenously every 4 weeks for 120 weeks.
3207253|NCT00962845|Experimental|Hydroxychloroquine|Patients must have tumor accessible for pre-treatment biopsy (see 5.1.2). Patients will be enrolled on the trial, undergo biopsy of their tumors if no banked tumor is available, and then begin an oral dose of HCQ at the dose of 200 mg twice daily. At the end of two weeks the patients will undergo resection of their tumors. HCQ will be given to the patients up to the day of the operation but not resumed postoperatively.
3207254|NCT00962897||Surgical Bypass Group|Those patients that underwent bypass of blockage in the thigh with surgery.
3207255|NCT00962897||Stent-graft group|Patients that underwent treatment of blockage in the thigh with balloon angioplasty and stent placement.
3207256|NCT00962910|Experimental|Pathway|A care pathway will be implemented in this experimental group.
2564946|NCT02465710||pelvic organ prolapse|All women who underwent surgical treatment of pelvic organ prolapse in this study.
2564993|NCT02465359|Experimental|Immune globulin subcutaneous (Human)|lmmune Globulin Subcutaneous(Human) 20% Liquid (Hizentra) will be given weekly
3207257|NCT00962910|No Intervention|Usual Care|Usual Care will be provided.
3207258|NCT00962936|Experimental|CT-011|
3207259|NCT00962962|Other|Low-Amount/Moderate Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
2565182|NCT02464527|Experimental|Stimulus-stimulus pairing (SSP)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
2565185|NCT02464527|Active Comparator|Waitlist Control (Delayed Treatment)|Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations will be randomly assigned to the Waitlist Control group. During the waitlist control subject's assigned session block of six weeks, s/he will not receive any treatment. The subjects will receive the stimulus-stimulus pairing procedure (delayed procedure) after the completion of the assigned 6-week block as a waitlist control participant. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
2565225|NCT02464254|Experimental|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and the positive affect component
2565232|NCT02464254|Active Comparator|Physical activity plus education|Subjects will be randomized to a physical activity goal and education
2565264|NCT02463838|Experimental|Care Support Intervention|Eligible members are assigned a CareSupport Coordinator who carries a caseload of 25-35 members. A team of 5 Coordinators is supervised by a master's level Social Worker. Community Coordinators work with members to conduct standardized assessments to develop a Care Plan shared with other providers within and outside of SFHP. Coordinators provide members advocacy and navigation across systems of care, to improve coordination focus on treatment goals. Coordinator focus on prevention and early intervention around disease management, advocacy, appointment reminders and accompaniment, home visits, and regular communication with primary care and other providers. Coordinators are encouraged to be accountable for coordinating and following through on all aspects of a member's needs.
2565267|NCT02463838|No Intervention|Usual Care|All eligible SFHP members randomized to usual care will receive medical and health plan by virtue of enrollment in the SFHP and Medi-Cal. Services include assignment to a primary care physician and access to all services available through Medi-Cal in the county of San Francisco.
2565368|NCT02463162|No Intervention|Control|"This group will receive usual care which is to receive no intervention."
2565370|NCT02463162|Experimental|Intervention|This group will receive the intervention which is two Conversations Matter videos about Advance Care Planning and Goals of Care Designations respectively
2564566|NCT02468323|Experimental|Palonosetron group|Patients in placebo group will receive spinal anesthesia with bupivacaine and morphine and a slow intravenous injection of palonosetron after cord clamping.
2564626|NCT02467933|Placebo Comparator|Placebo|The placebo arm receives a placebo letter unrelated to Seroquel
2564631|NCT02467933|Experimental|Informative Letter|The interventional arm prescribers receive an initial informative letter (called a comparative billing report or peer activity report) followed by 2 followup informative letters at approximately 3 month intervals.
2564683|NCT02467634|Experimental|HuCNS-SC|HuCNS-SC sub-retinal transplantation
2564744|NCT02467114|Experimental|All study participants|Stimulation with TMS, a sham coil & no intervention
2564799|NCT02466750|Experimental|Primary vaccine|Subjects receive 3 doses off WEE vaccine on Day 0, Day 7 ± 2 days, and Day 28-35 days. A booster will be administered on Day 180 ± 14 days and a sample collected for PRNT80 28-35 days later.
2564803|NCT02466750|Experimental|Booster series|Subjects who previously received the WEE vaccine under another protocol and have a PRNT80 < 1:40. Boosters (and follow-up titers 28-35 days later) may continue while the subject has titers of < 1:40 for a maximum of 4 booster doses in a year. If the titer remains < 1:40 after 4 booster doses in 1 year, the subject will not be given WEE vaccine for 1 year. If the titer is < 1:40 after that interval, one booster dose will be given and the titer will be assayed. If the immune response to the last booster dose is < 1:40, the subject will be considered to have completed the study as a nonresponder.
3207260|NCT00962962|Other|High-Amount/Moderate-Intensity Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
3207261|NCT00962962|Other|High-Amount/Vigorous-Intensity Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
2564945|NCT02465684|Experimental|tourniquet|UKA surgery with tourniquet
2564950|NCT02465684|Experimental|no tourniquet|UKA without tourniquet
2564988|NCT02465411|Experimental|Long-term CGM|Continuous glucose monitoring with DexCom G4 platina or later generations during 12 months following participation in the CGMMDI trial
2565069|NCT02465086|Experimental|Training|This arm, which is a half of the sample size, will be receiving training of linguistic recursion
2565073|NCT02465086|No Intervention|No training|The no intervention group, which is a half of the sample size, will not be recieving training in linguistic recursion.
2565143|NCT02464761|Experimental|Dose escalating PDT|
3207262|NCT00962962|Other|Low-Amount/Moderate-Intensity Exercise + Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The CLI sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
3207263|NCT00962975|Experimental|Single Arm|
2565355|NCT02463149|Experimental|Youth Chef Academy|Receives intervention
2565358|NCT02463149|No Intervention|Control|Usual classroom curriculum
2565412|NCT02463006|Experimental|porous bone graft group|Intervention: Flap surgery procedure with porous bone grafting (Periooglass)
2565417|NCT02463006|Active Comparator|Non-porous bone gaft group|Intervention: Flap surgery procedure with non-porous bone grafting (Novabone morsels)
2565458|NCT02462525|Experimental|ABBV-838 dose escalation|Varying doses of ABBV-838
2565461|NCT02462525|Experimental|ABBV-838 plus pomalidomide/dexamethasone|ABBV-838 to be evaluated with pomalidomide/dexamethasone.
2565539|NCT02462044|Experimental|240|Group 240 will receive CM with 240 mg Iodine/ml IDR 2.0 gI/s
2565541|NCT02462044|Experimental|300|Group 300 will receive CM with 300 mg Iodine/ml IDR 2.0 gI/s
2565542|NCT02462044|Experimental|370|Group 370 will receive CM with 370 mg Iodine/ml IDR 2.0 gI/s
2565672|NCT02461186|Experimental|Arterolane maleate-piperaquine phosphate (Synriam)|
2565674|NCT02461186|Experimental|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
2565720|NCT02460913|Experimental|Acupuncture|patients received a 20 to 30 minutes session of acupuncture
2565725|NCT02460913|Active Comparator|IV Morphine|patients received an intravenous titration of morphine every 5 minutes.
2565797|NCT02460653|No Intervention|Current|Current level of HFNC support
2565800|NCT02460653|Experimental|Low|Low flow range per kg.
2565802|NCT02460653|Experimental|Medium|Medium flow range per kg.
2565804|NCT02460653|Experimental|High|High flow range per kg
2565841|NCT02460146|Active Comparator|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
2565846|NCT02460146|Placebo Comparator|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
2565915|NCT02459860|Experimental|Problem Solving Treatment|Problem Solving Treatment Individual, face-to-face PST sessions over a span of 8 weeks and 3 monthly booster sessions. The PST protocol is highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies.
2565916|NCT02459860|Active Comparator|Enhanced Usual Care|Enhanced Usual Care EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
2566032|NCT02459145|Active Comparator|Graduated Exercise Protocol|Intervention involves exercise starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation. The exercise protocol includes treadmill speed and track minutes per lap conversion, rate of perceived exertion and talk test for each stage of exercise plus total time to execute for 5 days each week.
2566034|NCT02459145|Other|Rest followed by Protocol|No activity in weeks 1 - 8. In week 9 we will begin their intervention phase as described in graduated exercise protocol
2566078|NCT02458586|Placebo Comparator|MUFA|daily intake of 50 g of olive oil over a period of 8 weeks
2566080|NCT02458586|Active Comparator|PUFA|daily intake of 50 g of canola oil (rapeseed oil) over a period of 8 weeks
2564637|NCT02467946|Experimental|Adcetris-Levact (BV-Be) Association|Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles
2564678|NCT02467595|Experimental|R 0.15 group|"Rocuronium bromide 0.15 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.15 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy."
2564679|NCT02467595|Active Comparator|R 0.3 group|"Rocuronium bromide 0.3 mg kg-1 group~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and rocuronium bromide 0.3 mg kg-1~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide 0.3 mg kg-1 .~Drug: Rocuronium bromide Rocuronium bromide 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy."
2564681|NCT02467595|Placebo Comparator|S group|"saline~Anesthesia was induced with propofol 2.5 mg kg-1 , fentanyl 2 mcg kg-1, and saline.~After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.~At the end of surgery, discontinuation of sevoflurane and extubation, sending recovery room.~When poor intubating condition., added rocuronium bromide0.3 mg kg-1 ."
2564735|NCT02467023|Experimental|effective muscle stimulation group|Subjects in this arm will be in the study for up to 28 days or until discharge from the ICU. They will receive lower extremity muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength, muscle biopsy with muscle biopsy medication fentanyl, muscle biopsy medication versed, muscle biopsy medication lidocaine, and blood and urine sampling.
2564736|NCT02467023|Active Comparator|ineffective muscle stimulation group|Subjects assigned to this arm will be studied for up to 28 days or until discharge and will receive a sham muscle stimulation with Niveus medical stimulator, multiple measurement of maximal isometric twitch strength blood and urine samples, and a muscle biopsy sample with muscle biopsy medication fentanyl, muscle biopsy medication versed, and muscle biopsy medication lidocaine.
2564809|NCT02466477|Experimental|GeneSight Psychotropic (GEN)|The GeneSight Psychotropic (GEN) product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection. More specifically, patients are tested for clinically important genetic variants of multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to metabolize, tolerate or respond to medications.
2564814|NCT02466477|Experimental|Enhanced-GeneSight Psychotropic (E-GEN)|The current GEN test lacks predictive genes for antipsychotic-induced weight gain (AIWG), a major complication of antipsychotic drug use. Therefore, the Enhanced-GeneSight Psychotropic (E-GEN), which is an enhanced version of the GEN test, was developed by incorporating 6 new genes (represented by 7 SNPs) that are predictive for AIWG, to those used in the GEN algorithm. An increasing risk level associated with AIWG is estimated by an increasing number of risk genotypes that a given patient possesses among the 7 SNPs.
2564820|NCT02466477|Active Comparator|Treatment as Usual (TAU)|"The comparator chosen for this study provides a real world comparison of standard of care for patients who receive no pharmacogenomics guidance.~Patients randomized to the TAU arm will also have their DNA collected and a pharmacogenomic-based interpretive report will be generated using GEN testing. However, this report will not be shared with the treating clinicians until completion at 12 months of the study. Therefore, patients in this arm will receive clinical treatment as usual, without the use or knowledge of genotyping results by their treating clinicians."
2564877|NCT02466165|Experimental|MS patients intervention group|the feasibilty and influence of high intense interval exercise on the cardiometabolic risk state in MS patients will be investigated in a pilot trial.
2564881|NCT02466165|No Intervention|healthy controls|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
2564886|NCT02466165|No Intervention|larger group of MS patients|To identify whether MS patients have a higher cardiometabolic risk state than healthy controls, this project discovers the prevalence of cardiometabolic risk factors (dyslipidemia, hypertension, body fat, glucose tolerance/IR, inflammation and heart function), in MS and referent subjects.
2564981|NCT02465853|Placebo Comparator|Placebo group|Injection 0.9% Physiological saline solution<2.5 ml and physical therapy and occupational therapy
2564984|NCT02465853|Experimental|Hyaluronic Acid|injection Hyaluronic Acid 2.5ml and physical therapy and occupational therapy
2565053|NCT02465164|Other|Cook catheter|Control
2565059|NCT02465164|Active Comparator|Cook catheter plus low dose oxytocin|Test group
2565156|NCT02464826|Experimental|Edit arms|Nailprotex apply to the abnormal nail twice daily
2565202|NCT02464358|Experimental|IMB Intervention Group|"The IMB group received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, they received the following:~Additional educational content related to HPV, Cervical Cancer, and HPV vaccination,~Motivational content to help identify and problem-solve benefits and barriers to vaccination,~Skills-building content, including brief communication skills training and ways to access the vaccine."
2565203|NCT02464358|Active Comparator|Attention Control Group|The attention control group also received an HPV Vaccination Information Statement (VIS) often given to individuals prior to vaccination. In addition, to maintain consistency with the treatment's presentation format, participants watched a set of short video clips encompassing aspects of women's general and sexual health.
3207264|NCT00962988|Experimental|Cost-Free Group|
2565292|NCT02463552|Placebo Comparator|Placebo|
2565294|NCT02463552|Experimental|Naproxen|
3207265|NCT00962988|Other|Prescription Only Group|
2565394|NCT02462811|Experimental|CL-108|CL-108 hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
3207266|NCT00963040|Experimental|Syntocinon®|
3207267|NCT00963040|Placebo Comparator|Sterile water|
3207268|NCT00963053|Experimental|VA111913 100mg twice daily|
3207269|NCT00963053|Placebo Comparator|Starch pill|
2564648|NCT02467725|No Intervention|Static Culture|The embryos randomized to the static or control arm of the study will be placed directly into the incubator and will not have any additional vibration, per routine care. The embryos will be placed in the incubator at the two pronucleur stage of development and remain in the incubator until the blastocyst stage of development at which time the embryos will be biopsied for preimplantation genetic screening and frozen.
3207270|NCT00963066|Active Comparator|Pressure Support ventilation|
2564754|NCT02467036|Experimental|Family Based Behavioral Treatment Egg|The FBT+Egg group will participate in group-based FBT and will be assigned to eat eggs a minimum of 5 days a week for breakfast. Families are provided eggs each week to facilitate compliance, along with recipes
2564759|NCT02467036|Active Comparator|Family Based Behavioral Treatment Cereal|The FBT+Cereal group will participate in group-based FBT and will be assigned to eat cereal a minimum of 5 days a week for breakfast. Families are provided cereal each week to facilitate compliance.
3207271|NCT00963066|Experimental|NAVA flow triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with flow triggering
3207272|NCT00963066|Experimental|NAVA EMG triggering|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram
2564978|NCT02465645|Experimental|Carvedilol + Simvastatin|"Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.~Simvastatin will be administered orally at a start dose of 20 mg for 15 days followed by 40 mg OD for the next 3 months. Along with Simvastatin, Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min."
2564982|NCT02465645|Active Comparator|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55-60/min.
2565063|NCT02465242||NPi greather than 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi greater than 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
2565071|NCT02465242||NPi less than or equal to 3|All patients will undergo initial pupillometry evaluation with recording of the NPi in the initial evaluation in the emergency department as per standard evaluation of all trauma patients. If pupils are unequal, group assignment will be determined by lowest pupil reading. Patients with an NPi less than or equal to 3 will be assigned to this group. Pupillometry readings will be gathered for the first 7 days of hospital admission or until discharge. 30, 60, and 90 day post-injury outcomes will be collected.
2565158|NCT02464800||Higher cutting rate group|Vitrectomy with higher cutting rate instruments (5000 cut per minute) were performed in 174 eyes for proliferative diabetic retinopathy
2565162|NCT02464800||Conventional cutting rate group|Vitrectomy with conventional instruments (2500 cut per minute) were performed in 219 eyes for proliferative diabetic retinopathy
2565256|NCT02463877|Other|Minimally-Invasive Procedure|single-arm study of laparoscopic cytoreduction and HIPEC
2565301|NCT02463773|Experimental|Ultrasound|Adults older than 18 years old who develop ARDS, as defined by the Berlin criteria, within 72 hours of ICU admission.
3207273|NCT00963079|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
2565398|NCT02462798|Placebo Comparator|Whole grain rye bread|Whole grain rye bread, 200 g/d. Control intervention.
2565403|NCT02462798|Experimental|Whole grain sourdough rye bread|Whole grain rye bread, 200 g/d. Experimental intervention.
2565435|NCT02462694|Active Comparator|Treatment as Usual|Treatment as usual (TAU): Standard psychological, psychopharmacology and case management services
2565437|NCT02462694|Experimental|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy (DBT): weekly individual sessions, skills training group and telephone coaching as needed
2565450|NCT02462408|Experimental|Posterior approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
2565453|NCT02462408|Active Comparator|Conventional approach|The main difference between this block approach and the conventional infraclavicular approach is the site and angle of needle insertion. Otherwise, the end point of local anaesthetic injection remained the same for both approaches.
2565497|NCT02462343|Other|2 minute walk test|
2565499|NCT02462343|Other|6 minute walk test|
3207274|NCT00963079|Active Comparator|Fresh blastocyst transfer|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
3207275|NCT00963118|Placebo Comparator|placebo|Rice powder based nutrition bar
2565557|NCT02461823|Active Comparator|PFM Crown|A Porcelain metal crown will provided to patients.
2565614|NCT02461615||Registry Participants|All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.
2566269|NCT02457338|No Intervention|Control Group|This group will receive standard care plus lactation consultation only.
3207276|NCT00963118|Experimental|Angelica keiskei|Angelica keiskei (green leafy vegetable) based nutrition bar
3207277|NCT00963118|Experimental|Glycine max|Glycine max (black soybeans) based nutrition bar
3207278|NCT00963118|Experimental|Angelica keiskei + Glycine max|Angelica keiskei (green leafy vegetable) and glycine max (black soybeans) based nutrition bar
3207279|NCT00963131|Experimental|antioxidant tablets|the study arm received antioxidant tablets (Icaps) for 3 months or until the resolution of the disease
2564675|NCT02467413|Active Comparator|BAC treatment group|BAC, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
2564676|NCT02467413|Placebo Comparator|BAC Matched vehicle|BAC Matched vehicle, topical application on external nasal skin, scalp, and neck, 30g/day, 2 times daily, for 12 weeks
2564733|NCT02467257|Experimental|Intrevention arm|Patients received Gum Arabic as intervention
2564766|NCT02466867|Experimental|Naftin® Cream, 2% (younger pediatric cohort)|Subject aged 2 years to 5 years, 11 months with tinea corporis
2564771|NCT02466867|Experimental|Naftin® Cream, 2% (older pediatric cohort)|Subject aged 6 years to 11 years, 11 months with tinea corporis
3207280|NCT00963131|Placebo Comparator|placebo tablets|the control arm received placebo tablets for 3 months or until the resolution of the disease
2564878|NCT02466178||Serene RF System|Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.
3207281|NCT00963183|Experimental|A|Drug: AZD5423
3172343|NCT00598923|Placebo Comparator|3|Phenytoin 20 mg/kg as loading dose than 300 mg/day for total of 7 days
3172344|NCT00598936||Cardiac Surgery or Hospitalization|"Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure.~The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours."
2565144|NCT02464566|Experimental|L Group|"Weekly individual session in obesity clinic (15 to 20 min.) for the first 4 weeks then one individual session in obesity clinic (10 to 20 min.) every two weeks (week 5 to week 12).~Total sessions in 12 weeks: 8 (including the final data collection visit). The components of the program:~1) Low carbohydrate (aim to achieve spontaneous reduction in calorie intake) 2) increased physical activity; 3) behavioural strategies to facilitate adherence to diet and activity prescriptions."
2565146|NCT02464566|Active Comparator|C Group|One session regarding diet restriction and physical activity with printed health education papers.
2565208|NCT02464410|Experimental|Motivational Intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT) and uses the structure of ME brief interventions. The motivational session is overlaid on the VA long-term opioid therapy informed consent process.
2565211|NCT02464410|Active Comparator|Enhanced Usual Care|In addition to covering the VHA's long-term OA informed consent process, the enhanced usual care (EUC) condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic. This EUC condition will include some information related to risks of opioid use as part of the informed consent and will consequently have sufficient face validity as an intervention on opioid safety to effectively blind participant to randomization. However, the EUC therapist will not use the motivational enhancement approach of discussing strategies for avoiding these risks. It is designed to be equal in length to the motivational intervention.
2565313|NCT02463942|Active Comparator|Doxycycline, Doxy®|Beside symptomatic therapy, patients will receive oral doxycycline 100 mg (Doxy®) twice daily. Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
2565316|NCT02463942|Other|No antibiotics|Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients will answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
2565318|NCT02463942|Other|Healthy controls|"Patients will be asked to refer a spouse to serve as a control. If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.~Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia."
2565329|NCT02463175|Experimental|Intervention group|Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
2565339|NCT02463175|Experimental|Control group|Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment
2565422|NCT02462954|Experimental|ContraGel|ContraGel, a personal lubricant has a Conformite Europeenne (CE) mark and has been used with barrier devices in Europe and other countries outside the US, but it is not currently approved by the US FDA.
2565424|NCT02462954|Placebo Comparator|HEC Placebo|The placebo gel is supplied by CONRAD in pre-filled individual applicators, each applicator containing 4.0 mL of HEC gel. Placebo gel contains HEC as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide.
2565481|NCT02462499|Experimental|Treatment|Treatment: Eplerenone (Inspra) All patients will receive 25mg eplerenone once a day for a week, followed by 50mg once a day, for a total of 4-12 weeks.
3172345|NCT00598962|Experimental|azithromycin and rifabutin/rifampin|Azithromycin and rifabutin/rifampin administered three times weekly.
3172346|NCT00598988|Experimental|A|Traditional Chinese acupuncture in conjunction with standard medical care
3172347|NCT00598988|Active Comparator|B|standard medical care
3172348|NCT00599001|Experimental|Escalating Dose of SD-101|
3172349|NCT00599001|Placebo Comparator|Placebo|
3172350|NCT00599040|Active Comparator|Weight loss|Weight loss diet focused on the DASH diet
3172351|NCT00599040|Active Comparator|DASH diet|The DASH diet without weight loss
3172352|NCT00599040|Active Comparator|Diary|Dairy Intervention
3172353|NCT00599066||Study cases|Application of a second M-Entropy probe on the forehead of the patient; at the end the patient will have 2 probes on the forehead, one in the right and one in the left.
3172354|NCT00599079|Experimental|Azithromycin|Azithromycin combined with 2 other drugs given 3 times weekly for MAc lung disease
3172355|NCT00599118||atrial fibrillation|Atrial fibrillation
3172356|NCT00599118||Control|Control subjects with no atrial fibrillation
3172357|NCT00599144|Experimental|1|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
3172358|NCT00599144|Experimental|2|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
3172359|NCT00599144|No Intervention|3|Group3: control group without any local anesthetic use.
2564739|NCT02467283||Patients with Chronic Periodontitis|"All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age.~Chronic periodontitis was diagnosed according to American Academy of Periodontology 1999 Consensus Report."
2564742|NCT02467283||Control Patients|"Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.~All subjects were free of systemic diseases and to be included, individuals had to be older than 18 years of age."
2564786|NCT02466802|Experimental|A: regorafenib and sildenafil citrate|Patients receive regorafenib and sildenafil citrate by mouth every day (PO QD) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2564868|NCT02466269||the preauricular approach|A classic preauricular incision was used to treat diacapitular condylar fractures
2564912|NCT02465970|Experimental|TDCS session|Intervention : Stimulation is applied during a 60 min session with STARSTIM
2564913|NCT02465970|Placebo Comparator|TDCS Placebo|Intervention : Stimulation is not applied during a 60 min session with STARSTIM
2564943|NCT02465619||Severe acute hepatitis|Severe acute hepatitis without ascites.
2564951|NCT02465619||Non-cirrhotic|
2564957|NCT02465619||Cirrhotic patients with ascites|
2564959|NCT02465619||decompensated cirrhosis|
2564976|NCT02465398|Other|Fracture device|Patient were treated with an Anatomical Shoulder Fracture device.
2565052|NCT02465255|Experimental|Ketorolac|Ketorolac 0.5 mg/kg administrated by sublingual route
2565057|NCT02465255|Active Comparator|Tramadol|Tramadol 2.0 mg/kg administrated by sublingual route
2565065|NCT02465255|Active Comparator|Acetaminophen (paracetamol)|Acetaminophen (paracetamol) 20.0 mg/kg administrated by sublingual route
2565127|NCT02464709|Experimental|Actinic keratosis patients|Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.
2565184|NCT02464514|Other|Healthy obese children|High carbohydrate meal High fat meal
2565188|NCT02464514|Other|Children with Prader Willi Syndrome|High carbohydrate meal High fat meal
2565200|NCT02464228|Experimental|Tipifarnib|tipifarnib, oral
2565284|NCT02464085||Longitudinal evaluation of recovery|Stroke survivors with subacute and severe upper limb disability
2565350|NCT02463513|Placebo Comparator|Treatment 1|
2565357|NCT02463513|Active Comparator|Treatment 2|
2565363|NCT02463513|Active Comparator|Treatment 3|
2565416|NCT02462850|Experimental|CL-108|CL-108 Hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg
2565457|NCT02462590|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in tap water, administered through a nasogastric (or orogastric) or nasoduodenal (or oroduodenal) tube twice daily while patients are in the ICU. The first dose will be within 72 hours of intubation. Patients in the ICU who await discharge and can swallow pills will take the capsules orally.
2565463|NCT02462590|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in tap water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population [Morrow 2010]. This has also been used successfully in the PROSPECT Pilot Trial.
3207282|NCT00963183|Placebo Comparator|B|Drug: Placebo
3207283|NCT00963196|Active Comparator|One unsuccessful trial|Patients with one unsuccessful previous antidepressant trial
2565686|NCT02460926|Experimental|Scaling & Root Planing - Quadrant|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. Q-SRP patients received four quadrants sessions of PT with an interval of 1 week between sessions
2565693|NCT02460926|Experimental|Scaling & Root Planing - Full Mouth|Periodontal treatment (PT), consisting in both supra- and sub-gingival mechanical instrumentation of the root surface (scaling and root planing), was performed by a single periodontist . Treatment was provided using both hand and ultrasonic instrumentation with fine tips. Local anaesthesia was used when needed and no time constraints were enforced. FM-SRP patients received treatment within 24 hrs in two separate sessions, one side of the mouth for each session: two quadrants were instrumented in an afternoon session, whereas the other two were instrumented the following morning
2565774|NCT02460731|Experimental|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors]
2565822|NCT02460354|Experimental|Metformin|Subjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
3207284|NCT00963196|Active Comparator|One successful trial|Patients with one previous successful antidepressant trial
2565967|NCT02459340|Experimental|patient group|Inpatient setting (cPTSD, DDNOS, DIS): Trauma-adapted psychotherapy (individual and group setting), body-related, cognitive stabilization groups, pharmacotherapy, and other non-verbal treatment modalities (e.g. music, art, and occupational therapy)
2565972|NCT02459340|No Intervention|healthy control group|passive control group
2566025|NCT02459054|Experimental|Primary Pediatric Arm|Cardiac transplant-eligible pediatric patients at imminent risk of death from biventricular failure who are 10 - 18 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
3207285|NCT00963196|Active Comparator|No previous trial|Patients with no prior antidepressant therapy
3207286|NCT00963209|Experimental|Tamoxifen|
3172360|NCT00599183|Other|1|Participants will receive baseline conventional MRI of the cervical spine as part of their clinical care with an additional diffusion tensor imaging (DTI)sequence as part of the research; they will complete an anonymized questionnaire about their condition. Participants will receive an MRI with DTI and tractography as part of the research and will complete an anonymized questionnaire about their condition. The baseline and follow up data will be compared.
3172361|NCT00599209|Experimental|A - coded unit ID|Nursing home units provided the CDS intervention
2565270|NCT02464072|Experimental|Subtotal Parathyroidectomy|Patients will be submitted to subtotal parathyroidectomy. The intention is to leave a parathyroid remanent equivalent to two normal parathyroid glands in situ. The type of the operation is the intervention. No drugs or devices are tested.
2565272|NCT02464072|Active Comparator|Total Parathyroidectomy + 45 autografts|Patients will be submitted to a total parathyroidectomy and 45 fragments of parathyroid tissue are grafted in the forearm. This is the current standard treatment at the institution for severe secondary hyperparathyroidism.The type of operation is the intervention itself. No new device or drug is involved.
2565273|NCT02464072|Experimental|Total Parathyroidectomy + 90 autografts|Patients will be submitted to a total parathyroidectomy and 90 fragments of parathyroid tissue are grafted in the forearm. The type of operation is the intervention. No new device or drug is involved. .
2565299|NCT02463617|Other|PD patients|
2565354|NCT02463435|Active Comparator|Nutritional intervention|Patients under only nutritional intervention for weight loss
2565362|NCT02463435|Experimental|Nutritional intervention plus olive oil|Patients under conventional treatment (nutritional intervention) plus extra virgin olive oil supplementation
2565364|NCT02463435|Experimental|Olive oil|Patient under habitual food consumption plus extra virgin olive oil supplementation
2565426|NCT02462837|Experimental|Treatment Arm|after stent placement, patient will be given Mirabegron 50 mg, PO, once daily, for 2 weeks
2565430|NCT02462837|Placebo Comparator|Placebo Arm|after stent placement, patient will be given placebo PO, once daily, for 2 weeks
2565452|NCT02462434|Experimental|Early palliative care team consultation|Early pediatric palliative care team consultation for single ventricle patients will occur in this group following birth but prior to the first stage palliative surgery.
2565455|NCT02462434|No Intervention|Usual care|Usual care for single ventricle patients will be provided with palliative care team consultation occurring at any point (if it is determined the child and family would benefit from palliative care consultation) during the child's neonatal hospital stay.
3172362|NCT00599209|No Intervention|B - coded unit ID|Nursing home units not provided the CDS intervention
3172363|NCT00599222|Active Comparator|TTT|TTT is given every three months
2565543|NCT02462018|Experimental|WalkAide|
2565561|NCT02461797|Other|healthy controls|biopsy of nasal mucosa healthy controls
2565563|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa allergic rhinitis to house dust mite with nasal corticosteroid spray
2565566|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa allergic rhinitis to house dust mite without any use of medication for symptom control
2565852|NCT02460068|Active Comparator|fotemustine|fotemustine alone
2565854|NCT02460068|Experimental|fotemustine and ipilimumab|fotemustine in combination with ipilimumab
2565856|NCT02460068|Experimental|ipilimumab and nivolumab|ipilimumab in combination with nivolumab
2565897|NCT02459704|Experimental|SCPF + EMD (TEST)|Semilunar coronally positioned flap with Enamel matrix derivative (Emdogain)
2565909|NCT02459704|Active Comparator|SCPF (CONTROL)|Semilunar coronally positioned flap alone
2565974|NCT02459444|Experimental|IMT group and physiotherapy|Inspiratory muscle training with POWERBREATHE an approximate load of 50 % of MIP , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
2565977|NCT02459444|Placebo Comparator|Sham IMT group|Inspiratory muscle training with the same device in the experimental group , however without charge , for 1 set of 30 breaths twice a day, 7 days a week for 4 weeks ( total 56 sessions). Associated with physiotherapy program.
2566022|NCT02458963|Active Comparator|IVF group|Women will undergo one full IVF cycle
2566024|NCT02458963|Active Comparator|Gonadotropin group|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.
2566096|NCT02458625|Active Comparator|Iron sucrose 500 mg|One treatment arm will receive a single dose of I.V iron sucrose 500 mg.
2566101|NCT02458625|Active Comparator|Iron sucrose 500 mg+60 mg Iron bisglycinate|Second treatment arm will receive a single dose of I.V iron sucrose 500 mg and oral treatment with 60 mg Iron bisglycinate for 6 weeks after giving birth.
2566144|NCT02458144|Other|"MIS anterior group"|"Total Hip Arthroplasty anterior surgical approach"
2566156|NCT02458144|Other|"MIS anterolateral group"|"Total Hip Arthroplasty anterolateral surgical approach"
2566278|NCT02457299|Active Comparator|Two Stage Esophagectomy|Ischemic gastric preconditioning performed 7-10 prior to esophagectomy
3172364|NCT00599222|Sham Comparator|Sham TTT|Sham TTT is given every three months
3172365|NCT00599235|Experimental|1|
3172366|NCT00599235|Active Comparator|2|
3172367|NCT00599261|Experimental|1|Removal of the fibrotic pocket surrounding the generator and leads
3172368|NCT00599261|Experimental|2|Tissue is not removed
3172369|NCT00599274||A|This group was treated with Avonex once a week
3172370|NCT00599274||B|This group was treated with Rebif three times a week
3172371|NCT00599287|No Intervention|1|No intervention
3172372|NCT00599287|Experimental|2|Methylphenidate
3172373|NCT00599287|Experimental|3|Rivastigmine
3172374|NCT00599287|Experimental|4|Haloperidol
3172375|NCT00599352|Experimental|1|Magnesium infusion
3174965|NCT00628784|Experimental|Group 3|Diagnosis of esophageal carcinoma (T1smN0 or T2N0 via EUS). Deemed inoperable based on the following criteria: co-morbid conditions such as severe heart, lung, kidney, or liver disease; or refusal of surgical intervention. CT scan demonstrating no evidence of advanced esophageal cancer (extension into or through the wall or lymph node involvement).
2564816|NCT02466763|Active Comparator|cochleostomy|Half of the participants will be randomized to the cochleostomy technique of cochlear implant device electrode insertion. For the participants randomized to the cochleostomy arm, the surgeon will use a cochleostomy technique for the electrode insertion during the participant's cochlear implant surgery. Participants in this arm of the study will also have a post operative CT scan at about three months after surgery.
2564884|NCT02466360||chronic lower back pain|
2564925|NCT02465788|Experimental|755nm alexandrite laser with bipolar RF|GentleTouch (Helos) combines 755nm alexandrite laser energy with bipolar RF energy.
3172376|NCT00599365|Experimental|Pharmacy Care arm|"The pharmacist:~will take all the patient's medication bottles, and give medication boxes filled with medications in the order the patient should take them in.~will need to obtain a complete list of medications.~will teach the patient about the medications.~will provide a medication schedule, and other papers about the medications.~will count the pills in the medication boxes.~will review all the medications with the patient and answer any question.~will check to see if the medication is working for the patient.~will work with the patient's kidney doctor to adjust medications if needed.~will give the medication boxes filled with medications to take home."
3172377|NCT00599365|No Intervention|Control|"The pharmacist:~will obtain a complete list of medications.~will count the pills in the patients' medication bottles.~will inform patients to take their medications from these bottles."
3172378|NCT00599378|Experimental|1|Implementation Intentions-based telephone counseling. Partnership intervention between rural Primary Care Physicians, their patients, and CRC Information Specialists using an implementation intentions based approach.
3172379|NCT00599378|No Intervention|2|Healthy Living information on Physical Activity and Nutrition
2565305|NCT02463630|Experimental|Compression distraction reduction|All the participants in this group will be performed Posterior Compression Distraction Reduction Technique for reduction of basilar invagination and atlantoaxial dislocation
2565400|NCT02462772|Experimental|Cabotegravir|Women randomised to the cabotegravir arm will receive daily oral cabotegravir (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of cabotegravir LA (800 mg, administered as two 400 mg injections) every 12 weeks
2565406|NCT02462772|Placebo Comparator|Placebo|Women randomised to the placebo arm will receive daily oral tablets (30 mg tablets) for approximately 30 days and thereafter will receive intra-muscular gluteal injections of Intralipid® 20% every 12 weeks
2565467|NCT02462616||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
2565511|NCT02462278|Experimental|TempuRing|Women will wear the continuous temperature sensor, TempuRing, for 3 menstrual cycles.
2565833|NCT02460185|No Intervention|Control|Without maternal physical exercise practice
2565835|NCT02460185|Active Comparator|Study Group|Behavioral: 30 minutes of walking, 3 times a week at 4 Km/h. Induction of labor was performed at 41 weeks.
2565870|NCT02459912|Other|Unilateral Nerve-Sparing Cryoablation|Unilateral Nerve-Sparing Cryoablation of the Prostate using Galil Medical Precise Cryoablation System with IceRod Needles.
2566027|NCT02459054|Experimental|Primary Adult Arm|Cardiac transplant-eligible adult patients at imminent risk of death from biventricular failure who are 19 - 75 years old at time of TAH-t implant. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
3172380|NCT00599391|Other|1|Far Infrared Radiation
3172381|NCT00599417|Experimental|1|
3172382|NCT00599417|Placebo Comparator|2|
3172383|NCT00599430|Placebo Comparator|1|Placebo
3172384|NCT00599430|Active Comparator|Active 1|One probiotic strain
3172385|NCT00599430|Active Comparator|Active 2|Blend of two strains
3172386|NCT00599443|Experimental|1|
3172387|NCT00599443|Placebo Comparator|2|
3172388|NCT00599456|Experimental|1|Omega 3 vitamin supplements
3172389|NCT00599456|Placebo Comparator|2|Placebo capsule
3172390|NCT00599469|Other|1|Far Infrared Radiation
3172391|NCT00599482|Other|1|Far Infrared Radiation
3172392|NCT00599508|Active Comparator|grape juice active intervention|Concord grape juice administered daily for 12 or 16 weeks
3172393|NCT00599508|Placebo Comparator|juice placebo|berry placebo juice administered daily for 12 or 16 weeks
3172394|NCT00599508|Active Comparator|blueberry juice active intervention|wild blueberry juice administered daily for 12 weeks
3172395|NCT00599508|Active Comparator|blueberry powder intervention|whole fruit blueberry powder administered daily for 16 weeks
3172396|NCT00599508|Placebo Comparator|powder placebo|placebo powder administered daily for 16 weeks
3172397|NCT00599534|Active Comparator|1|4 mg tablet for 16 weeks
3172398|NCT00599534|Placebo Comparator|2|5 mg for 16 weeks
3174331|NCT00622310|Experimental|1 Exercise|Subjects in the EX group will perform supervised exercise 5 d/wk. Exercise will consist primarily of walking on an inclined motor-driven treadmill, but alternate activities will be permitted for 20% of the total exercise sessions (1 of 5 days). Exercise sessions will be preceded by a 5 min warm-up performed at a HR corresponding to 40% of VO2max. The initial exercise duration and intensity at baseline will be 20 minutes at an intensity that elicits a heart rate (HR) corresponding to 60% of VO2max. The target EE will be achieved by a gradual progression of exercise duration and intensity over the first 8 weeks of the exercise program. The target exercise intensity will be the workload corresponding to 75% of VO2max.
3174332|NCT00622310|Experimental|2 Walk|Subjects in the WALK group will also perform exercise 5 d/wk. Exercise will consist exclusively of walking on level grades, and will be prescribed in two equal duration bouts each day. Subjects in the WALK group will be individually prescribed a walking program based on the EE during moderate intensity walking. The target exercise intensity will be walking speeds corresponding 45% of VO2max.
3174333|NCT00622349|Experimental|A|
3174334|NCT00622349|Active Comparator|B|
3174335|NCT00622349|Experimental|C|
3174336|NCT00622362|Active Comparator|A|Subcutaneous administration
3174337|NCT00622362|Experimental|B|Sublingual administration
3174338|NCT00622362|Placebo Comparator|C|Sublingual administration
3174339|NCT00622375|Experimental|1|
2564848|NCT02466282|Active Comparator|Angiography-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
2564850|NCT02466282|Experimental|OCT-guidance|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
3207287|NCT00963222|Active Comparator|with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
3207288|NCT00963222|Placebo Comparator|with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
3207289|NCT00963222|Active Comparator|without atherosclerosis/ vitamin A|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
2565067|NCT02465112|Experimental|metabolic radiotherapy|In111-Pentetréotide at 12, 18 and 24 weeks after surgery,
2565072|NCT02465112|Active Comparator|No metabolic radiotherapy - simple monitoring|No metabolic radiotherapy - simple monitoring without theraoy
2565173|NCT02464683|Placebo Comparator|Placebo|The patient will take a single tablet of placebo daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
2565179|NCT02464683|Experimental|VitaminD|The patient will take a single tablet of Vitamin D (200 International Units) daily for 60 days. Each patient will go to the hospital in order to take the blood sample.
2565259|NCT02463968||CHRONIC CHIKUNGUNYA|Twenty participants with chronic chikungunya defined as continued knee joint effusion at least three months after diagnosis of chikungunya will be enrolled in the study.
2565261|NCT02463968||ACUTE CHIKUNGUNYA|Ten participants with acute chikungunya defined as clinical symptoms of chikungunya with acute fever and joint pain within 10 days the onset of symptoms.
2565262|NCT02463968||HEALTHY CONTROLS|Five healthy controls will have only blood drawn once.
2565307|NCT02463721|Other|SBP patients|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
2565356|NCT02463318|Experimental|Multiple slerosis|Melatonin,,one millimolar,one micromolar,one nanomolar, 12 hr treatment.
2565359|NCT02463318|Experimental|Healthy subjects|Melatonin,one millimolar,one micromolar,one nanomolar, 12 hr treatment. hydrogen peroxide, 250 micromollar,2 hr treatment
2565401|NCT02462889|Experimental|Intravitreal aflibercept injection|Subjects will be randomized to receive intravitreal aflibercept injection every three months for 24 months.
2565407|NCT02462889|Placebo Comparator|Placebo|Subjects will be randomized to receive sham injection every three months for 24 months.
2565465|NCT02462577|Active Comparator|local instillation of morphine 5 mg|5 ml plain bupivacaine 0.5% and 5 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
2565472|NCT02462577|Active Comparator|local instillation of morphine 10 mg|5 ml plain bupivacaine 0.5% and 10 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
2565476|NCT02462577|Active Comparator|local instillation of morphine 15 mg|5 ml plain bupivacaine 0.5% and 15 mg morphine .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
2565478|NCT02462577|Placebo Comparator|local instillation of local anesthetics|5 ml plain bupivacaine 0.5% .Study drugs will be diluted by saline 0.9% to 20 ml volume and irrigated onto the surgical field before skin closure and suction drain will be closed for 30 min after skin closure.
2565576|NCT02461719|Experimental|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|CYPORIN N EYE DROPS 0.05%(TJCS eye drop) 1 drop twice/day for 12 weeks to both eyes
2565585|NCT02461719|Active Comparator|Restasis eye drop|Restasis eye drop(Cyclosporine ophthalmic solution 0.05%) 1 drop twice/day for 12 weeks to both eyes
2565701|NCT02461199||Fecal microbiota transplantation|Patients with proven gut colonization status with following bacteria: Klebsiella pneumoniae resistant to carbapenems, Pseudomonas aeruginosa resistant to carbapenems, Enterococcus faecalis VRE (vancomycin-resistant enterococcus), Enterococcus faecium VRE, Enterobacter cloacae resistant to carbapenems or other MDR species. Gut colonization proven by conventional microbiological culture and/or molecular methods.
2565770|NCT02460757||Patients with COPD|
2565773|NCT02460757||Patients with interstitial lung disease|
2565776|NCT02460757||Healthy subjects|
2565838|NCT02460341|Experimental|ondansetron-8|Single dose of 8 mg ondansetron (crossover with single dose of placebo)
2565844|NCT02460341|Experimental|ondansetron-16|Single dose of 16 mg ondansetron (crossover with single dose of placebo)
2565849|NCT02460341|Experimental|ondansetron-24|Single dose of 24 mg ondansetron (crossover with single dose of placebo)
2565910|NCT02459808||GBS Patients|Patients with Guillain-Barré syndrome
2565944|NCT02459535|Active Comparator|Glucose only|oral ingestion of 54 g Glucose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2565951|NCT02459535|Active Comparator|Glucose + Saccharin|oral ingestion of 54 g Glucose + 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2565953|NCT02459535|Active Comparator|Saccharin only|oral ingestion of 0,112 g Saccharin in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2565955|NCT02459535|Active Comparator|Glucose + Aspartame|oral ingestion of 54 g Glucose 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2565958|NCT02459535|Active Comparator|Aspartame only|oral ingestion of 0,197 g Aspartame in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2564857|NCT02466256|Placebo Comparator|Monarch III Injector|Procedure / Surgery : Intraocular lens implantation with Monarch III group
2564902|NCT02466061|Experimental|Arm A: Telemedicine Group|"Telemedicine Weight Management plus Wi-Fi Scale (Arm A) Participants in the Telemedicine Group will receive a Wi-Fi Scale that measures weight, lean mass, and fat mass. Participants will receive 15-20 minute telephone counseling sessions by phone. Sessions will occur at routine intervals during the six month intervention period.~All Aim 1 participants, including those randomized to Arm A, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 followup weight data also will be collected through medical record abstraction."
2564906|NCT02466061|Experimental|Arm B: Text for Diet (Text4Diet) Group|"Text for Diet (Text4Diet) Group (Arm B) The intervention in this Arm involves delivery of Short Message Service (SMS) text messages to participants each day over the course of a 6 month intervention period. Participants will also receive a digital scale to track weight on a weekly basis. SMS text messages will be sent 2-3 times per day and will provide feedback, support, prompting, and strategies to adhere to behaviors associated with long-term weight management.~All Aim 1 participants, including those randomized to Arm B, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
2564908|NCT02466061|Active Comparator|Arm C: Enhanced Usual Care Group|"Enhanced Usual Care Group (Arm C) Participants will be provided with handouts based on American Cancer Society guidelines on healthy eating and exercise.~All Aim 1 participants, including those randomized to Arm C, will complete a packet of psychosocial measures at baseline and 6 months (final assessment).~Month 12 follow up weight data also will be collected through medical record abstraction."
2564942|NCT02465697|Experimental|BPD Emotion Regulation Training|Guided practice in reappraisal
2564949|NCT02465697|No Intervention|BPD Control|no training in reappraisal
2564954|NCT02465697|Experimental|APD Emotion Regulation Training|Guided practice in reappraisal
2564956|NCT02465697|No Intervention|APD Controls|no training in reappraisal
2564960|NCT02465697|Experimental|Healthy Controls Emotion Regulation Training|Guided practice in reappraisal
2564961|NCT02465697|No Intervention|Healthy Controls|no training in reappraisal
2564986|NCT02465346|Experimental|MSU-based stroke management|The Mobile Stroke Unit (MSU) and the conventional emergency medical Service (EMS) will meet at the emergency site. The patient's medical history, the physical examination will directly be performed by a physician. Laboratory tests will be analyzed by a point of care laboratory. CT will be performed. After performance of the acute stroke diagnostic work-up the patients and, if indicated thrombolysis, the patient will be transported according to the diagnostic results: Stroke due to large vessel occlusion or to intracranial hemorrhage-> Neurovascular centre; Stroke without large vessel occlusion or without hemorrhage-> primary hospital with regional stroke unit.
2564989|NCT02465346|Active Comparator|Control stroke management|After performing patient's medical history, physical examination (reassessment of the extended Face Arm Speech Time score) and glucose testing by the (stroke trained) emergency personnel, the patient will be transported according to current best clinical practice and relevant guidelines to the next stroke unit or neurovascular centre. The hospital stroke team will be prenotified by the EMS. According to the patients needs the patient might be further transferred.
2565055|NCT02465229|Experimental|Diagnostic methods of indeterminate biliary stricture|
2565154|NCT02464865|Experimental|Thiamine 1|presence of severe symptoms and signs of thiamine deficiency: heart failure, convulsion, coma, loss of ankle and knee jerks with muscular wasting and paralysis (typically symmetrical foot- and wrist-drop)
2565160|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
2565164|NCT02464865|Experimental|Thiamine 2|presence of mild symptoms and signs of thiamine deficiency; peripheral neuropathy alone (paraesthesia of hands and feet)
2565227|NCT02464306|Experimental|SOT Recipients|SOT recipients (heart, lung, kidney, liver, kidney-pancreas, and pancreas) with a first-episode of CDI. Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days. The rate of sustained clinical response (SCR; cure without recurrence at 30 days) will be assessed.
2565231|NCT02464306|No Intervention|Historical Cohort|Historical cohort of SOT recipients who received standard of care therapy for CDI at our institution.
2565303|NCT02463903|Experimental|Coping effectiveness Training (CET)|The intervention consists of Coping Effectiveness Training (CET), a manual-based group intervention based on a cognitive transactional theory of stress and coping. The purpose of CET is to improve skills to appraise stress, teach a number of techniques to cope with stress, and to give an opportunity to interact with other people with similar experiences of living with CHF. The CET program will, in this study, be modified for patients with CHF. The intervention consists of seven, 90-minute weekly sessions led by a nurse with a Masters degree in nursing science and extensive experience in heart failure care in collaboration with a professional psychologist. Each group consisted of 8 to 12 patients.
2565304|NCT02463903|No Intervention|Control|The control group will receive standard health care and will not take part of the intervention.
3207290|NCT00963222|Placebo Comparator|without athrosclerosis/ placebo|patients in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive placebo
3207291|NCT00963261|Experimental|psycho-oncological intervention|stepped care psycho-oncological intervention
3207292|NCT00963261|No Intervention|control group|
2565432|NCT02462733|Active Comparator|Tools of the Mind (TOM)|These 10 classrooms will be exposed to the TOM program.
2565433|NCT02462733|Active Comparator|Playing to Learn (PTL)|These 10 classrooms will be exposed to the PTL program.
2564889|NCT02466243|Experimental|JBT-101|"Part A: JBT-101 20 mg capsule once a day on Days 1-28, then 20 mg capsule twice a day on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
2564890|NCT02466243|Placebo Comparator|Placebo|"Part A: Placebo capsule once a day on Days 1-28, then placebo capsule twice a day on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
2564926|NCT02465814|Experimental|Arm 1 - BAY1002670 + BAY1002670|Vilaprisan (BAY1002670) 2 mg once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
2564931|NCT02465814|Experimental|Arm 2 - Placebo + BAY1002670|Placebo once daily (12 weeks), Vilaprisan 2 mg once daily (12 weeks)
2564936|NCT02465814|Experimental|Arm 3 - BAY1002670 + BAY1002670|Vilaprisan 2 mg once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily (12 weeks)
2564937|NCT02465814|Experimental|Arm 4 - Placebo+BAY1002670|Placebo once daily (12 weeks), treatment break, Vilaprisan 2 mg once daily(12 weeks)
2564938|NCT02465814|Active Comparator|Arm 5 - Ulipristal + Ulipristal|Ulipristal 5 mg once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
2564940|NCT02465814|Active Comparator|Arm 6- Placebo + Ulipristal|Placebo once daily (12 weeks), treatment break, Ulipristal 5 mg once daily (12 weeks)
2564941|NCT02465814|Active Comparator|Arm 7- Ulipristal + Placebo|Ulipristal 5 mg once daily (12 weeks), treatment break, Placebo once daily (12 weeks)
2565036|NCT02465021|Experimental|Snack bar 1|Dietary intervention: 190 Kcal, 12g fat, 14g carbohydrate, 5g fibre, 6g sugar, 10g protein
2565038|NCT02465021|Experimental|Snack bar 2|Dietary intervention: 200 Kcal, 15g fat, 12g carbohydrate, 5g fibre, 4g sugar, 8g protein
2565039|NCT02465021|Experimental|Snack bar 3|Dietary intervention: 210 Kcal, 16g fat, 12g carbohydrate, 2g fibre, 6g sugar, 6g protein
2565040|NCT02465021|Experimental|Control 1|Dietary intervention: Water (500 g)
2565041|NCT02465021|Experimental|Control 2|Dietary intervention: White bread (190 Kcal, 2g fat, 37g carbohydrate, 2g fibre, 3g sugar, 6g protein)
2565042|NCT02465021|Experimental|Control 3|Dietary intervention: Soft baked pretzel (190 Kcal, 2g fat, 38g carbohydrate, 2g fibre, 6g sugar, 4g protein)
2565096|NCT02464904|Experimental|Cryotherapy|Cryospray and biopsies
2565100|NCT02464904|Other|Control|Biopsies
2565178|NCT02464605|Experimental|SEL-037 (pegsiticase)|Pegylated uricase
2565213|NCT02464319|Active Comparator|Experimental: hrIL-2 active|Intervention：Add hrIL-2 according to the protocol to original treatment. HrIL-2 active: 1 million U doses of human recombinant interleukin-2 s.c. injection
2565215|NCT02464319|Placebo Comparator|Placebo Comparator: hrIL-2 placebo|1 million U doses of placebo s.c. injection
2565252|NCT02463916|Active Comparator|Immediate exercise|This group will immediately commence an 8 week exercise programme.
2565253|NCT02463916|Active Comparator|Delayed exercise|This group will continue regular activities for 8 weeks and then commence 8 week exercise programme.
2565353|NCT02463422||San Diego, CA|Toddlers detected with ASD and other disorders based on the Get SET Early Model in San Diego.
2565361|NCT02463422||Phoenix, AZ|Toddlers detected with ASD and other disorders based on the Get SET Early Model in Phoenix.
3207293|NCT00963274|Experimental|bortezomib + romidepsin|Bortezomib via a short intravenous infusion (3-5 seconds) followed by romidepsin via a 4 hour intravenous infusion weekly x 3 every 4 weeks. In order to identify appropriate doses, different subjects will be treated with different drug doses and observed for the effects, especially the side effects associated with higher doses.
3207294|NCT00963287|Experimental|bascial prescription|Decoction ,two times a day,one bag of decoction one time
3207295|NCT00963287|Placebo Comparator|low does of bascial decoction|Decoction ,two times a day, one bag decoction of one time
2565647|NCT02461264|Active Comparator|ARM A|Two packed red blood cells will be transfused in patient with anemia defined as a hemoglobin level below 8 g / dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, two new packed red blood cells are transfused and so on.
2565649|NCT02461264|Experimental|ARM B|Single red blood packed cells Transfusion will be administered in patient with anemia defined as a hemoglobin level below 8 g/dL. Clinical and biological monitoring will be carried out later each day. If the hemoglobin is <8 g / dL, a single unit is transfused and so on.
2565687|NCT02461017||Endotracheal Leak|Assess for Audible Endotracheal Leak; Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
2565762|NCT02460770|Experimental|autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, Mesenchymal Stem Cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of Mesenchymal Stem Cells during Left Ventricular Assist Device surgery
2565824|NCT02460393|Placebo Comparator|Placebo group|The arm is as a control group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
2565826|NCT02460393|Experimental|experimental group|The arm is as an experimental group to study the tolerance, safety and pharmacokinetic characteristics of Subcutaneous injection of different doses of humanized TNFα monoclonal antibody.
2565960|NCT02459574|Active Comparator|Group 3-Conventional AF Ablation|This will involve an ablation procedure carried out in the usual manner. The patient will have three sheaths placed in the leg veins. Catheters will be passed up to the patient's heart from these veins. Two crossing are required into the left atrium. The ablation will involve freeze technology using the Advance Cryoballoon. It will include measuring the electrical signals and may also involve radiofrequency or 'burning' technology in addition.
2565964|NCT02459574|Active Comparator|Group 2-Anti-arrhythmic therapy|Anti-arrhythmic drugs: On the treatment start date the patient will have a new tablet prescribed or a change in the dosage of the medication. The patient will be reviewed at 8wks (visit 1) later to see if the medication is working. If the tablets are working, the patients medication will be left unchanged. If not, an alternative tablet or a higher dose will be used.
2566070|NCT02458651||Tier 2 and Middle|Site as described by tier level of the city where the site is located and by geographical location: Tier city in middle region of China
2566282|NCT02457299|Active Comparator|One Stage Esophagectomy|Esophagectomy alone
3207296|NCT00963313||Adalimumab, injection|Adalimumab, one injection every fourteen days during 24 weeks.
3207297|NCT00963339||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
3207298|NCT00963352||Patients operated for colon cancer|
2564893|NCT02466022|Placebo Comparator|Normal Saline|Patients will receive 0.1cc/kg Normal Saline bolus delivered over 10 minutes for control arm prior to spinal anesthetic (12.75mg of heavy Bupivicaine and 10ug of Fentanyl) and 0-4mg of Midazolam for rescue sedation
2564928|NCT02465671||Patients group|All patients with acute spontaneous basal ganglia hemorrhage admitted to the Jinhua People's Hospital within the first 24 h from stroke during the same period were enrolled.
2564991|NCT02465541|Experimental|Arm I (gentle yoga and dietary counseling)|Participants undergo onsite gentle yoga once weekly over 45-60 minutes for 8 weeks and home-based gentle yoga for 6 weeks. Participants also undergo dietary counseling over 8 weeks.
2564997|NCT02465541|Active Comparator|Arm II (enhanced usual care)|Participants undergo enhanced usual care designed to educate on best practices for exercise, diet and lifestyle change once weekly for 14 weeks.
3172399|NCT00599547|Experimental|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
3172400|NCT00599560|Experimental|1. Meniere's disease|Patients were eligible for enrollment if they had received a clinical diagnosis of Meniere's disease according to the 1995 AAO-HNS criteria (Committee, 1995). These criteria can be briefly described as follows: 1) Repeated attacks of vertigo: A definitive spell is spontaneous vertigo lasting at least 20 minutes. A mixed type of spontaneous nystagmus is observed during attacks. 2) Fluctuating cochlear symptoms: The hearing test usually reveals a marked fluctuation of the threshold in the low and middle tone range.
3172401|NCT00599560|No Intervention|2. Acoustic neurinoma|Diagnosed by CT and/or MRI
3172402|NCT00599573|Experimental|1|Ondansetron
3172403|NCT00599586|Experimental|group 1|specific acupoints of Shaoyang meridians
3172404|NCT00599586|Experimental|Group 2|Non-specific acupoints of Shaoyang meridians
3172405|NCT00599586|Experimental|group 3|Acupoints of other meridians
3172406|NCT00599586|Sham Comparator|group 4|Non-acupoints
3172407|NCT00599599|Experimental|1|Prolonged Exposure Therapy.
3172408|NCT00599599|No Intervention|2|Weekly monitoring/Waitlist Control Group.
3172409|NCT00599612|Experimental|Healthy male volunteers|Six healthy male volunteers aged between 30-60 years old will be recruited for this study,
3172410|NCT00599625|Experimental|1|Patients with active Crohn's Disease
3172411|NCT00599651|Experimental|1|Surfactant by LMA
3172412|NCT00599651|Other|2|Standard of care
3172413|NCT00599664|Experimental|1|Drug
3172414|NCT00599664|Placebo Comparator|2|Vehicle
3172415|NCT00599677|Experimental|group 1|specific acupoints of Stomach meridians
3172416|NCT00599677|Experimental|group 2|Non-specific acupoints of Stomach meridians
3172417|NCT00599677|Experimental|group 3|alarm and transport points
3172418|NCT00599677|Experimental|group 4|acupoints of the other meridian
3172419|NCT00599677|Sham Comparator|group 5|non-acupoints
3172420|NCT00599677|Active Comparator|group 6|Itopride
3172421|NCT00599690|Experimental|A|Epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
3172422|NCT00599703||1|neurosurgical patients
3207299|NCT00963365|Experimental|AZD6765 oral solution|Active
3172423|NCT00599716|Experimental|1|study drug
3172424|NCT00599716|Placebo Comparator|2|vehicle control
3172425|NCT00599729||1|patient demonstrating degenerative changes in the knee joint (osteoarthritis)
3172426|NCT00599742|Active Comparator|A|Balance training group
3172427|NCT00599742|Active Comparator|B|Motor Training
3172428|NCT00599781|Experimental|PBL/HSC|
3172429|NCT00599794||1|Healty volunteers who are euvolemic.
3172430|NCT00599794||2|Critically ill patients who will be having a central venous catheter with a monitor to measure central venous pressure placed as part of their planned care independent of this study.
3172431|NCT00599807|Active Comparator|1: 2000 IU D3/day|2000 IU vitamin D3 taken orally each day for 2 years
3172432|NCT00599807|Active Comparator|2: 800 IU D3 / day|800 IU vitamin D3 taken orally each day for 2 years
3172433|NCT00599859|Active Comparator|1|Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
3172434|NCT00599859|Active Comparator|2|Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
3172435|NCT00599885|Active Comparator|1|
3172436|NCT00599885|Active Comparator|2|
3172437|NCT00599898|Experimental|1|
3172438|NCT00599898|Experimental|2|
3172439|NCT00599911|Experimental|Lu AA24530: 5 mg|
3172440|NCT00599911|Experimental|Lu AA24530: 10 mg|
3172441|NCT00599911|Experimental|Lu AA24530: 20 mg|
3172442|NCT00599911|Active Comparator|Duloxetine: 60 mg|
3172443|NCT00599911|Placebo Comparator|Placebo|
3172444|NCT00599937|No Intervention|ATRA ->Chemo|Patients 65 years of age with a WBC count less than 5,000 were randomized to receive the reference ATRA treatment of our previous trial (APL91 trial), ie, 45 mg/m2/d ATRA followed by CT or ATRA plus CT (ATRA+CT). In the ATRA followed byCT group, patients received 45 mg/m2/d ATRA orally until CR, with a maximum of 90 days. After CR achievement, they received a course of 60 mg/m2/d daunorubicin (DNR) for 3 days and 200 mg/m2/d AraC for 7 days (course I). However, course I was added to ATRA if the WBC count was increased to greater than 6,000, 10,000, or 15,000 by day 5, 10, and 15 of ATRA treatment, respectively, because, from our experience, patients were at risk of ATRA syndrome above those thresholds.
3172445|NCT00599937|Experimental|ATRA+CT|Patients randomized to the ATRA+CT group received the same combination of ATRA and CT, with course I of CT starting on day 3 of ATRA treatment. This 48-hour interval before onset of CT was based on our previous report, because it allowed correction of coagulopathy.
3207300|NCT00963365|Experimental|AZD6765 IV infusion|Active
3207301|NCT00963365|Placebo Comparator|Placebo to AZD6765 oral solution|Placebo
3207302|NCT00963365|Placebo Comparator|Placebo to AZD6765 IV infusion|Placebo
2564894|NCT02465996|Other|epigastric pain syndrome (EPS)|pCLE examination was performed in EPS patients, and then those who were willing to receive Puyuanhewei to treat FD were given 4 pills three times a day for 4 weeks after pCLE examination.
2564939|NCT02465762|Experimental|ultrashape fat reduction treatment|all patient undergo non-invasive fat and circumference reduction at the flanks area
2564974|NCT02465476|No Intervention|normal care|patient who will have normal treatment pathway
2564975|NCT02465476|Experimental|telemedicine|patient who will have telemedicine
2565058|NCT02465294|Placebo Comparator|Potato starch and magnesium stearate|This arm will be used as a control to asses the efficacy of the other probiotic arms. The placebo will contain encapsulated potato starch and magnesium stearate which is used the matrix in the probiotic supplements. The placebo refers only to the intervention supplement, not the behavioral lifestyle intervention. All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
2565068|NCT02465294|Experimental|Lactobacillus|Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
2565076|NCT02465294|Experimental|Mix of Bifidobacterium and Lactobacillus|A blend of Bifidobacterium and Lactobacillus will be taken as a capsule once daily for 12 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). All subjects will participate in the same behavioral lifestyle intervention. In addition, blood tests will be performed.
2565147|NCT02464618|No Intervention|Usual care|The social contact of patients in this arm will not be contacted
2565150|NCT02464618|Active Comparator|Social contact intervention|The social contact of patients in this arm will be contacted and asked to facilitate the endoscopy care plan of the patient
2565209|NCT02464384|Other|cohort study|Collection of blood samples and ultrasound / MRI and x-ray examination.
2565268|NCT02464020|Experimental|primary sclerosing cholangitis|Two week course of oral vancomycin 500mg twice a day.
2565271|NCT02464020|No Intervention|Control group|A control group of participants without Primary Sclerosing Cholangitis. Control group will consist of both healthy subjects and subjects with Inflammatory Bowel Disease.
2565306|NCT02463682|Active Comparator|Sensor-Augmented Pump Open-Loop Care (Week 1)|The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
2565308|NCT02463682|Experimental|Closed-Loop Control System with Zone MPC and HMS|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels. The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device.
2565351|NCT02463279|Experimental|SinuSys Dilation System|Opening of previously constrained frontal recess and/or sphenoid sinus ostia via dilation procedure (sinuplasty)
3207303|NCT00963391|Experimental|ABHS use|Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). Proper safety measures were followed. Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
2565554|NCT02462005||ALL COMERS|Patients implanted or scheduled for an implant with a Ranger Drug coated balloon.
2565608|NCT02461641|Other|Standard of Care|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe.
2565611|NCT02461641|Experimental|NuShield|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a dehydrated amnion-chorion membrane, NuShield, for up to 4 weeks.
2565613|NCT02461641|Experimental|Affinity|Wounds will be treated with Standard of Care treatment which for the purpose of this study is defined as, extensive debridement of nonviable tissue, saline-moistened non-occlusive dressing and off-loading to decrease press on the extremity using a DARCO shoe. In addition, wounds will be treated with a fresh hypothermically stored amniotic membrane, Affinity, for up to 4 weeks.
2565696|NCT02461121|Experimental|MST（microtransplantation）|The microtransplantation conditioning regimen included high-dose Ara-C chemotherapy (2.0 to 2.5 g/m2 per 12 hours intravenously on days -4 to -2) followed by an infusion of HLA mismatched stem cell 24 hours (day 0) after the completion of cytarabine.
2565706|NCT02461121|Active Comparator|NST（nonmyeloablative transplantation）|The NST（nonmyeloablative transplantation）conditioning regimen consisted of 30 mg/m2/d fludarabine for days -6 to -2, 1.5-2 mg/kg/d anti-lymphocyte globulin for days -5 to -2, 40 mg/kg/d cyclophosphamide for days -4 and -2 and 2.0-3.0 g/m2/d cytarabine for days -6 to -4，followed by an infusion of HLA matched stem cell after the completion of regimen. The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
2565765|NCT02460497|Experimental|Treatment|
2565812|NCT02460419|Experimental|maintenance capecitabine|maintenance capecitabine plus best supportive care(BSC)
2565814|NCT02460419|Other|best supportive care|Best supportive care and following-up every 6-8 weeks
2565913|NCT02460016|Experimental|AK0529|AK0529 pellets
2565933|NCT02459431|Active Comparator|21G needle group|21 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
2565937|NCT02459431|Active Comparator|22G needle group|22 gauge endobronchial ultrasound guided transbronchial aspiration needle ( Vizishot, Olympus ) would be used to perform endobronchial ultrasound guided Transbronchial needle aspiration
2566072|NCT02458651||Tier 2 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in northern region of China
2564962|NCT02465983|Experimental|CART-meso-19 T cells|A single dose of CART-meso-19 T cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting.
2564990|NCT02465333|Other|Pathway A|"Screening visit followed by heel fat grafting procedure with local anesthetic and visits at:~1 week Post op study visit 2 (1 month) Post op study visit 3 (2 month) Post op study visit 4 (6 month) Post op study visit 5 (12 month) Crossover to standard podiatry visits Study visit 6 (18 months) Study visit 7 (24 months)"
2564995|NCT02465333|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6 months) Study Visit 2 (12 months) Crossover to Pathway A~Heel fat grafting procedure and local anesthetic and visits at:~1 week Post op study visit 2 (1 month post procedure) Post op study visit 3 (2 month post procedure) Post op study visit 4 (6 month post procedure) Post op study visit 5 (12 month post procedure)"
2565050|NCT02465138|Placebo Comparator|Placebo|Normal Saline will be administered prior to procedure.
2565051|NCT02465138|Active Comparator|Toradol|Intravenous ketorolac prior to ERCP
2565152|NCT02464696|Experimental|Arm A (NIPPV therapy)|Patients undergo intermittent NIPPV, with the recommended schedule comprising 2 hours on NIPPV followed by =< 2 hours off NIPPV and continuous NIPPV at night or while sleeping for 8 hours per day, for 28 days or until discharged from the hospital.
2565155|NCT02464696|Active Comparator|Arm B (high flow oxygen therapy)|Patients continue to receive high flow nasal cannula oxygen therapy using current protocol for titration of high flow oxygen therapy for 28 days or until discharged from the hospital. Patients may receive NIPPV if they develop evidence of accessory muscle use with breathing or at the discretion of the treating physician.
2565207|NCT02464150|Experimental|Participants|Participants are subjected to gluten intervention in an unblinded fashion.
2565269|NCT02464007|Experimental|sSIFN-co|Dose escalation of rSIFN-co
2565296|NCT02463643|Experimental|Z-215 10 mg/day|Drug: Z-215 10mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
2565297|NCT02463643|Experimental|Z-215 20 mg/day|Drug: Z-215 20mg Drug: Z-215 Placebo Drug: Rabeprazole Sodium Placebo
2565298|NCT02463643|Experimental|Z-215 40 mg/day|Drug: Z-215 20mg Drug: Z-215 20mg Drug: Rabeprazole Sodium Placebo
2565300|NCT02463643|Active Comparator|Rabeprazole Sodium 10 mg/day|Drug: Z-215 Placebo Drug: Z-215 Placebo Drug: Rabeprazole Sodium
2565330|NCT02463292||patient group|The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
2565337|NCT02463292||peer control group|The control group will be recruited as good friends (same gender, approx. same age of the patients, in command of the German language). The patients will be given a study information for controls to hand this to their good friend and ask the friend to contact the study nurse for participation in the study. No intervention.
3207304|NCT00963391|No Intervention|No treatment|Centers assigned to the control group received no hand hygiene recommendations other than to continue with current hand hygiene practices and no further information on hand hygiene other than the general information received before trial initiation was provided.
3207305|NCT00963404|Experimental|Tumor-boost|Image-guided tumorboost of the bladder cancer.
2565434|NCT02462707|Experimental|PF-03084014|
2565451|NCT02462460||Patients with BRCA mutation|The purpose of this study is to optimize rapid pancreatic and ovarian MR screening protocols using T1, T2 and DW imaging sequences in BRCA mutation carriers. Each screening MR protocol is considered optimized if we reach 5 consecutive patients with technically adequate image quality. We will enroll up to 60 patients to perform the MR screening protocol, if the initial MR sequence parameters do not yield technically adequate MR images in a single patient, we will stop and modify our imaging protocol. We will continue to modify the technique until we reach 5 consecutive patients with technically adequate MR images for both on all imaging sequences. Thus, it is possible we will optimize different imaging sequences at different time points in our study. We plan to enroll at least 5 patients, and up to 60 patients with BRCA mutation who undergo breast MRI for this study. Participants will receive a copy of the questionnaire on the day of their Breast MRI.
2565498|NCT02462317|Active Comparator|botulinum A toxin|Patients are injected with botulinum toxin in a standardized protocol and received placebo baclofen tablets (120 patients)
2565501|NCT02462317|Active Comparator|Baclofen|Patients are injected with placebo in a standardized protocol and received baclofen tablets (120 patients)
2565504|NCT02462317|Placebo Comparator|double Placebo|Patients are injected with placebo in a standardized protocol and received placebo baclofen tablets (60 patients)
2565560|NCT02461953|Experimental|low flux hemodialysis|low flux hemodialysis alone, 3 times a week, 4 hours per session
2565562|NCT02461953|Experimental|high flux hemodialysis|high flux hemodialysis alone, 3 times a week, 4 hours per session
2565567|NCT02461953|Experimental|low flux hemodialysis + hemoperfusion|low flux hemodialysis 2times a week and the HD+HP once a week
2565568|NCT02461953|Experimental|high flux hemodialysis + hemoperfusion|high flux hemodialysis 2times a week and the HD+HP once a week
3207306|NCT00963417|Active Comparator|Triptorelin plus tamoxifen|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus tamoxifen for 5 years.
2565733|NCT02460861|Active Comparator|PCA Magdeburg|Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg
2565736|NCT02460861|Active Comparator|Non-prostate cancer Magdeburg/Gronau|Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau
2565738|NCT02460861|Active Comparator|PCA Gronau|Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa
2565766|NCT02460471|Experimental|palliative radiation therapy|25 Gy in 5 daily fractions
2564983|NCT02465801|Active Comparator|Group 3|"Intervention: GCSF~Drug: TE or TEC TE: Taxotere+Epirubicin Taxotere (75mg/m2) and Epirubicin (75mg/m2), IV on day 1 of each 21 chemotherapy cycle.~TEC:Taxotere+Epirubicin+Cyclophosphamide Taxotere (75mg/m2),Epirubicin (75mg/m2) and Cyclophosphamide (500mg/m2), IV on day 1 of each 21 chemotherapy cycle.~Recombinant Human Granulocyte Colony-Stimulating Factor Injection (5μg/kg/day) will be injected subcutaneously at night o'clock a.m. from the 3rd of per chemotherapy cycle. After the injection, stop administrating if Absolute Neutrophil Count (ANC) in peripheral blood exceeded 1.5×109/L at two contiguous times at least. The maximum of usage was continuous 14 days.~Intervention: Drug: TE or TEC"
2565148|NCT02464774|Experimental|Breast-Conserving Therapy|"Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles.~Within 4-8 weeks after completion of chemotherapy, patients undergo radiation therapy as follows:~N0: Radiation therapy to whole breast (+boost to tumor bed). N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes."
2565151|NCT02464774|Active Comparator|Mastectomy|"Patients undergo mastectomy (MT) with surgical axillary staging.~Within 4-8 weeks after surgery, patients receive adjuvant chemotherapy as follows:~TC for stage I: Docetaxel 75 mg/m + Cyclophosphamide 600 mg/m, cycled every 21 days for 4 cycles.~TAC for stage II: Docetaxel 75 mg/m + Doxorubicin 50 mg/m + Cyclophosphamide 500 mg/m, cycled every 21 days for 6 cycles."
2565201|NCT02464332|Experimental|BLZ-100|"All participants in the study will receive the investigational drug product BLZ-100.~In part 1 of the study, two dose levels of BLZ-100 will be evaluated (3 mg and 12 mg) in 6 subjects, with a 2-3 post-dose imaging window.~In part 2 of the study up to 15 additional subjects will be randomized to one of three imaging interval groups (up to 6 subjects/interval): Early Imaging (within 1 day post-BLZ-100 dose), Intermediate Imaging (2 - 3 days post- BLZ-100 dose), and Late Imaging (4 - 7 days post- BLZ-100 dose)."
2565285|NCT02464124|Experimental|lactulose plus nitazoxanide|"Nitazoxanide dosing: 500 mg tablets twice daily~Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day"
2565287|NCT02464124|Active Comparator|Lactulose alone|Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
2565342|NCT02463474|Experimental|mHealth Intervention|Each week for 10 weeks, participants will receive two text messages on their cell phone. The first text message will contain a link to a culturally tailored, informational video clip about living with breast cancer. The second text message that provides a supportive message about the video content.
2565411|NCT02463019|Other|Tenofovir|Tenofovir Disoproxil Fumarate 300mg daily for 3 years
2565489|NCT02462564||postoperative cognitive dysfunction|Z score>1.96
2565490|NCT02462564||non-postoperative cognitive dysfunction|Z score<1.96
2565515|NCT02462213||Amyloidosis|Patients being managed for amyloidosis without prior history of cardiac involvement
2565518|NCT02462213||Cardiac amyloidosis|Patients being managed for cardiac amyloidosis
2565587|NCT02461901||Fidaxomicin treatment|Patients being treat with fidaxomicin (on the decision of their treating physician)
2565592|NCT02461901||Metronidazole or vancomycin treatment|Patients being treated with metronidazole or vancomycin (on the decision of their treating physician)
2565639|NCT02461446||PTEN ASD|PTEN participants with Autism Spectrum Disorder group
2565640|NCT02461446||PTEN no ASD|PTEN participants without Autism Spectrum Disorder group
2565642|NCT02461446||Controls|Healthy control group
2565685|NCT02461004|Experimental|TR group|CKD-391 and combination dose of Atrovastatin and Ezetimibe in order
2565692|NCT02461004|Experimental|RT group|combination dose of Atrovastatin and Ezetimibe and CKD-391 in order
2565798|NCT02460705|Experimental|IBD patients receiving FMT|IBD patients receiving biologically active human fecal material sourced from OpenBiome. The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL, through the endoscope. The material will be delivered to the most proximal point of insertion.
2565810|NCT02460250|Experimental|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked. Liver recipients will be followed up during one year. Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
3207307|NCT00963417|Experimental|Triptorelin plus exemestane|Determination of bone mineral density in patients randomized in TEXT-1 or TEXT-2 trials to receive triptorelin (GnRH analogue) for 5 years plus exemestane for 5 years.
3207308|NCT00963443|Experimental|Arm 1|
3207309|NCT00963443|Active Comparator|Arm 2|
3207310|NCT00963443|Active Comparator|Arm 3|
3207311|NCT00963443|Placebo Comparator|Arm 4|
3207312|NCT00963495|Experimental|Clioquinol|Patients will take Clioquniol at various doses depending on which dose level they come into the study at. Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
3207313|NCT00963534|Experimental|lenalidomide, bendamustine, rituximab|
3207314|NCT00963573|Experimental|loratadine/betamethasone oral solution|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
3207315|NCT00963586||HNC Maastricht|Patients treated for HNC in the University Hospital Maastricht/MAASTRO clinic, the Netherlands
3207316|NCT00963586||HNC Groningen|Patients treated for HNC in the University Medical Center Groningen, the Netherlands
2566289|NCT02457143|Experimental|Letter|Patients will receive a reminder letter signed by their family physician which indicates which cancer screening tests they are overdue for and encourages them to book an appointment for screening.
3207317|NCT00963612|Other|Single Arm|"In this project, there is only one study group which comprises of patients with Hepatocellular Carcinoma (HCC) who will undergo Liver BOLD-MRI before hepatic resection."
3207318|NCT00963625|Experimental|Blastocyst transfer in PTEC cycle|Transfer of two blastocysts derived from thawed bipronuclear oocytes that were subject to post-thaw extended culture (PTEC).
3207319|NCT00963625|Active Comparator|Fresh blastocyst transfer.|Transfer of two fresh autologous blastocysts following controlled ovarian stimulation.
2564998|NCT02465554||Atherosclerosis cohort|"This group will have patients who have undergone clinically-indicated CT coronary angiography (CT-A) and who have non-critical plaque (<50% diameter) and at least 1 high risk feature according to the ROMICAT indices. They will then undergo a myocardial contrast echocardiography study during vasodilator stress to subdivide risk further into atherosclerosis/endothelial function normal and atherosclerosis/endothelial function abnormal. Blood will then be collected for metabolomics, lipidomic and whole genome sequencing."
2565218|NCT02464436|Experimental|human retinal progenitor cells (hRPC)|Single subretinal administration of human retinal progenitor cells (hRPC)
2565263|NCT02463851|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
2565266|NCT02463851|Active Comparator|AF-Ablation with Contact Force single-tip electrode|Regular AF-ablation with a regular Contact Force single-tip ablation catheter
2565309|NCT02463695|Experimental|vestibular deficit|"Initial clinical assessment including otoneurological examination, pure tone audiometry, tympanometry vestibular screening tests and Magnetic Resonance Imaging as clinically indicated.~The cortical vestibular evoked potentials will add approximately add an extra 30 minutes to the test sequence but is minimally invasive and will not cause any pain or discomfort. It will be conducted on both the affected and non-affected ears."
2565310|NCT02463695|Active Comparator|otologically normal controll|Normative data will be collected from 36 normal ears from subjects that have no history of audiovestibular symptoms and are not being investigated for any balance disorders. The cortical vestibular evoked potentials will be recorded from both ears
3172446|NCT00599937|No Intervention|High WBC|Patients with a WBC count greater than 5,000 at presentation (irrespective of their age) and patients 66 to 75 years of age with a WBC count 5,000 were not randomized but received ATRA plus CT course I from day 1 (high WBC group) and the same schedule as in the ATRA->CT group (elderly group), respectively.
2565393|NCT02462785|Active Comparator|In-Class Instruction|This group of adolescents will receive carbohydrate counting instruction through an in-person, in class session led by a registered dietician. This represents the usual standard of care at the Diabetes Clinic at The Hospital for Sick Children (SickKids).
2565399|NCT02462785|Experimental|Internet-Based Teaching|This group of adolescents will receive carbohydrate counting instruction through an online teaching tutorial.
2565448|NCT02462668|Placebo Comparator|Control|"Preoxygenation with Bag-mask ventilation before fibreoptic bronchoscopy assisted intubation.~Intervention: Bag-mask ventilation."
2565449|NCT02462668|Experimental|NIPPV|"The NIPPV group preoxygenation with noninvasive positive pressure ventilation(NIPPV), And then receives fibreoptic bronchoscopy intubation through a face mask (there is a small hole allow to insert the tracheal tube through the mask into trachea) during NIPPV.~Intervention: noninvasive positive pressure ventilation(NIPPV)"
2565488|NCT02462369|Experimental|Saxagliptin|Saxagliptin 5mg/d, 52 weeks
2565491|NCT02462369|Active Comparator|glimepiride|glimepiride 1~4mg/d,52 weeks
2565525|NCT02462096|Experimental|Treatment|Subject to undergo the ReLeaf study procedure.
2565577|NCT02461927|Experimental|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular naltrexone once a month (a total of 2 injections).
2565583|NCT02461927|Experimental|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine treatment once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
2565589|NCT02461927|Placebo Comparator|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous placebo treatment (psychoactive placebo midazolam) once a week for 4 weeks (a total of 4 infusions) with a follow-up of 4 weeks and (2) intramuscular placebo once a month (a total of 2 injections).
2565644|NCT02461459||Tuberous Sclerosis Complex|Tuberous Sclerosis Complex
3172447|NCT00599937|No Intervention|no maintenance|No maintenance
3172448|NCT00599937|Experimental|maintenance ATRA|Intermitent ATRA as maintenance
2565815|NCT02460276|Experimental|Lenalidomide, ibrutinib and rituximab.|
2565885|NCT02459938|Experimental|ZP-Glucagon 0.5 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 0.5 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
2565888|NCT02459938|Experimental|ZP-Glucagon 1.0 mg|glucagon applied to the ZP transdermal microneedle patch system at a dose of 1.0 mg applied by means of a purpose built reusable applicator and worn for 30 minutes
2565889|NCT02459938|Active Comparator|Glucagon by injection, 0.5 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
2565891|NCT02459938|Active Comparator|Glucagon by injection, 1.0 mg|glucagon applied as GlucaGen (NovoNordisk) injector system at a dose of 0.5 mg
2565948|NCT02459548|Experimental|Primary Care Group|This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
2565952|NCT02459548|Other|Sleep Unit Group|This group will be follow up in Sleep unit at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
2566058|NCT02458703|Experimental|Patients with pulmonary AVMs and no airflow obstruction|30 patients with pulmonary AVMs and no airflow obstruction will undergo cardiopulmonary exercise testing
2566059|NCT02458703|Experimental|Patients with pulmonary AVMs and airflow obstruction|30 patients with pulmonary AVMs and airflow obstruction will undergo cardiopulmonary exercise testing
3172449|NCT00599937|Experimental|maintenance Cxt|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) as maintenance
3172450|NCT00599937|Experimental|maintenance both|continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally) AND ATRA as maintenance
3172451|NCT00599950|Experimental|1|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
3172452|NCT00599950|Placebo Comparator|2|Photorefractive keratectomy (PRK)without mitomycin C.
3172453|NCT00599963|Experimental|1|paricalcitol 1 mg/day for 12 weeks, followed by a washout period of 4 weeks, then crossed over to no treatment for another 12 weeks
3207320|NCT00963651||Suspicion of pulmonary nodules|Eligible participants will include those referred for x-ray computed tomography (CT) of the chest for suspicion of a pulmonary nodule or other unrelated reasons.
2565204|NCT02464462|Experimental|CaD Group|This arm received total of 1800 IU of vitamin D3 and 720 mg of calcium
2565205|NCT02464462|Placebo Comparator|Placebo Group|This arm received rice powder pills
2565277|NCT02464046|Experimental|JNJ-42847922 then Placebo|Participants receive 2*20 milligram (mg) tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive matching placebo from Day 1 to Day 5 of period 2.
2565278|NCT02464046|Experimental|Placebo then JNJ-42847922|Participants will receive matching placebo from Day 1 to Day 5 of period 1. After a washout period of 5 to 9 days participants will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 of period 2.
2565282|NCT02463565||hospitalized patients|
2565345|NCT02463526|Experimental|Group 1 - MWM condition/Sham condition|Subjects will receive treatment for 4 times with Mulligan's Mobilization with Movement (MWM) condition, and after 72 hrs, will be treated 4 times with the sham condition.
2565348|NCT02463526|Experimental|Group 2 - Sham condition/MWM condition|Subjects will receive treatment for 4 times with sham condition, and after 72 hrs, will be treated 4 times with the Mulligan's Mobilization with Movement (MWM) condition.
2565415|NCT02462941|Experimental|Adenosine|After cardiac catheterization, the study protocol will begin with 12.5µg/kg of adenosine (one eighth the recommended starting clinical dose), and will double to 25µg/kg, 50µg/kg, 100µg/kg and finally 200µg/kg (not to surpass the total maximum dose of 12mg). A pacing catheter will be placed within the right ventricle prior to medication administration. Escalating doses will stop if ventricular pacing is required due to a ventricular pause greater than 12 seconds or if atrioventricular block is demonstrated with a ventricular pause less than 12 seconds. If there is no prolonged pause requiring pacing and no demonstration of medication effect the subsequent dose will be given.
3207321|NCT00963664|Experimental|Interferon and lovastatin treatment|Patients receive outpatient treatment with lovastatin (oral) and interferon alfa-2b (subcutaneous injection) as per protocol parameters.
3207322|NCT00963690|Experimental|CloSys HD with standard compression|CloSys Arm
3207323|NCT00963690|Active Comparator|Standard compression alone|Manual compression arm
2565571|NCT02461862||Intra Uternine Device|Women who came to the medical service, to insert an intra uterine Device (IUD) of Cu or a Levonorgestrel Intra Uterine System( Lng- IUS) after have been attended in the Family Planning Service of Federal University of São Paulo . All patient have had the pain evaluated by Application of the Visual Analog Scale of Pain (VAS), and also their vital signs ( Evaluation of blood pressure,Evaluation of radial pulse) evaluated pre and five minutes after the IUD/ IUS insertion.
2565633|NCT02461485|Experimental|1=BOW_01|1= Fermented Milk Product containing Probiotics
2565635|NCT02461485|Experimental|2=BOW_01 + fiber C|2= Fermented Milk Product containing Probiotics + Fibers C
2565638|NCT02461485|Experimental|3 =BOW_01 + fiber W|3= Fermented Milk Product containing Probiotics + Fibers W
2565641|NCT02461485|Placebo Comparator|4 = Control|4= Non fermented Milk Product with same color, texture and organoleptic properties as investigational products 1 to 3.
2565688|NCT02461056|Active Comparator|Ibuprofen|Ibuprofen: Patients receive ibuprofen 50 mg, 100 mg, 200 mg, 400mg or 800 mg intravenously once at post-anesthesia care unit.
2565698|NCT02461056|Active Comparator|hydromorphone|Hydromorphone: Patients receive hydromorphone 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, or 2 mg intravenously once at post-anesthesia care unit.
2565707|NCT02461056|Active Comparator|ibuprofen+hydromorphone|Ibuprofen+Hydromorphone: Patients receive ibuprofen 25 mg + hydromorphone 0.125 mg, ibuprofen 50 mg + hydromorphone 0.25 mg, ibuprofen 100 mg + hydromorphone 0.5 mg, ibuprofen 200 mg + hydromorphone 0.75 mg, or ibuprofen 400 mg + hydromorphone 1 mg intravenously once at post-anesthesia care unit.
2565792|NCT02460640|Active Comparator|Tap Block|the intervention will be tap block after induction of anesthesia with ropivacaine 0,5% 15ml and continuous patient-controlled analgesia with morphine
2565794|NCT02460640|Active Comparator|No Tap Block|the patients who not receive tap block but they will be as intervention intravenous Patient controlled analgesia
3207324|NCT00963703|Experimental|Rituximab|
3207325|NCT00963716|Experimental|Hot biopsy|Hot biopsy i.e. Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
2565884|NCT02459717|Experimental|Probiotics and prebiotic|fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
2565886|NCT02459717|Placebo Comparator|Placebo|pasteurized fermented milk (125 grams) without prebiotics
2565932|NCT02459561|Experimental|EndoBarrier Arm|The EndoBarrier Gastrointestinal Liner device received CE Mark for 12 months implant duration on 11 December 2009 and is a single use, minimally invasive device, used to achieve weight loss and improve Type 2 Diabetes status in subjects who are obese. The intent of the EndoBarrier Gastrointestinal Liner is to mimic portions of the standard Roux-en-Y bypass procedure. The device consists of 3 components: the implant, the delivery system, and the removal system. At study visit 4, after eight hours fasting, 80 subjects will arrive to the pre- assessment unit as part of the theatres at St. Mary's Hospital or Southampton Hospital and receive the EndoBarrier TM Gastrointestinal Liner as part of the EndoBarrier Arm Intervention.
3207326|NCT00963716|Active Comparator|Cold biopsy|Cold biopsy i.e. Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
3207327|NCT00963729|Experimental|Arm I|Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3207328|NCT00963729|Experimental|Arm II|Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
3207329|NCT00963742|Experimental|Lenstec Softec HD IOL implantation|390 eyes of 390 study subjects all receiving the investigational IOL; IOL implanted after surgical removal of cataract
3207330|NCT00963755||Primary prostate cancer|Patients referred with a suspicion of prostate cancer based on elevated PSA and rectal examination in whom a prostate biopsy is planned and radical prostatectomy is envisioned in the event of a positive biopsy finding
3172454|NCT00599963|Active Comparator|2|no treatment for 12 weeks, followed by a washout period of 4 weeks, then crossed over to paricalcitol for another 12 weeks
3172455|NCT00599989|Experimental|APBI|
3172456|NCT00600002|Experimental|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
3172457|NCT00600041|Experimental|A|Pantoprazole IV
3172458|NCT00600041|Placebo Comparator|B|NaCl 0.9% IV
3172459|NCT00600054|Experimental|Single arm|
3172460|NCT00600093|Experimental|A|
3172461|NCT00600145|Experimental|1|Mirtazapine
3172462|NCT00600145|Placebo Comparator|2|Placebo
3172463|NCT00600158|Experimental|2|lidocaine intravenously
3172464|NCT00600158|Active Comparator|1|epidural local anesthetic
3172465|NCT00600197|Experimental|Back school|a kind of educational program for low back pain
3172466|NCT00600197|Experimental|back school|
3172467|NCT00600210|Experimental|I|
2567483|NCT02449551|Experimental|Volitinib|Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
2567546|NCT02449343|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2567553|NCT02449343|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2567627|NCT02448732|Experimental|ACM-1 team|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
3172468|NCT00600223||1|Patients undergoing laryngectomy and pharyngeal reconstruction
3172469|NCT00600275|Experimental|BGT226|
2567757|NCT02448212|Experimental|PART 1 (Test/Retest)|Dosing with [11C]TASP0410699 for PET imaging without dosing of TS-121
2567760|NCT02448212|Experimental|PART 2 (PET Receptor Occupancy Study)|Dosing with [11C]TASP0410699 for PET imaging with dosing of TS-121
2567881|NCT02447159|Experimental|Intervention|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
2567882|NCT02447159|No Intervention|Control|Antenatal care utilization data will be extracted from the administrative records. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
2567919|NCT02446860|Experimental|Nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit
2567962|NCT02446665|Experimental|PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
2567963|NCT02446665|Active Comparator|Non-PSC Patients|MR Elastography, Fibroscan and standard of care biopsy
3172470|NCT00600288|Experimental|1|
2568051|NCT02446067|No Intervention|Healthy control|No Repetitive Transcranial Magnetic Stimulation (rTMS)
2568055|NCT02446067|Active Comparator|Active rTMS group|Active Repetitive Transcranial Magnetic Stimulation (rTMS)
2568062|NCT02446067|Sham Comparator|Sham rTMS group|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
2568245|NCT02445079||HIV uninfected|HIV uninfected sub-group, age and gender matched to the HIV-infected group
3172471|NCT00600288|Placebo Comparator|2|
3172472|NCT00600314||High risk|Patients who are at high risk of developing acute or chronic GVHD
3172473|NCT00600314||GVHD|Patients who currently have either grade II or greater acute GVHD, or clinically extensive chronic GVHD
3172474|NCT00600327|Experimental|1|
3172475|NCT00600379|Experimental|A,|Virtual Reality training for an overall of 18 sessions 2/week + usual care.
3172476|NCT00600379|No Intervention|B,|Usual care
3172477|NCT00600392||1|patients who meet criteria for CRT-D implantation
3172478|NCT00600405|Experimental|I|Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
3172479|NCT00600405|Other|II|Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
3172480|NCT00600431||1|Study group: 16 children under 18 years undergoing systemic chemotherapy
3172481|NCT00600431||2|Control group: 16 age and sex matched healthy children under 18 years
3172482|NCT00600444|Active Comparator|A|Venae Sectio technique will be used to insert totally implantable access port (TIAP) by a surgeon
3172483|NCT00600444|Experimental|B|Punction of Vena Subclavia will be used to insert totally implantable access port (TIAP) by a radiologist.
3172484|NCT00600457||A,1|
3172485|NCT00600470|Experimental|1|Doctor-office collaborative care management
3172486|NCT00600470|Active Comparator|2|"Treatment as usual: psychoeducation and outside referral to treatment (PORT). In papers, this arm is referred to as Enhanced Usual Care (EUC)."
3172487|NCT00600483|Experimental|1|Insertion of 2 gentamicin-collagen sponges between the sternal halves before closure of the sternotomy
3172488|NCT00600483|No Intervention|2|Standard of care, ie, insertion of no gentamicin-collagen sponge.
3172493|NCT00600522||1|Patients selected for hepatectomy because carriers of hepatocellular carcinoma or colorectal cancer liver metastases invading the middle hepatic vein at caval confluence (last 4 cm).
3172494|NCT00600535|Experimental|Abiraterone acetate (non-fasting)|
3172495|NCT00600535|Experimental|Abiraterone acetate (fasting)|
3172496|NCT00600548|Experimental|1.1|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Miltefosine.
3172497|NCT00600548|Active Comparator|1.2|Cutaneous leishmaniasis patients in Manaus-Amazonas randomized to receive Meglumine antimoniate (standard treatment).
2565153|NCT02464839||Hallux valgus patients|All of participants will perform a potassium hydroxide (KOH) examination and fungal culture to prove a fungal nail and feet fungal infection
2565217|NCT02464423|No Intervention|Control|"Usual care: WE-ACTx For Hope and CHUK offer a host of services for HIV+ young people, and these will represent the usual care condition for the study. Both clinics provide adolescent-friendly environments with multidisciplinary teams that offer weekly or monthly support groups, peer education, medical services, mental health screenings, sports activities, HIV and health education sessions, and outreach to parents and guardians. The services youth in the usual care condition receive will be carefully tracked."
2565221|NCT02464423|Active Comparator|Treatment|Culturally-adapted, trauma-informed cognitive behavioral therapy (TI-CBT) intervention: The components of the TI-CBT include a) psychosocial health education b) relaxation training c) cognitive restructuring d) adherence barriers e) caregiver psycho-education. The TI-CBTe will be administered in groups of 8-10 weekly for 2 hours for 3 Sundays each month over 2 months. Two IYL will co-lead each intervention, and two IYL will rate fidelity.
2565311|NCT02463955|Experimental|Thoracoscopy|"experimental intervention (flexible video endoscope)~reference procedure (video-rigid thoracoscope)"
2565328|NCT02463253||Phase 1|"A. OBJECTIVE: The objective of this phase of the study is to allow the clinical site to gain familiarity with patient recruitment, sample and data collection, and interpretation of the proteogenomic biomarker report provided, through retrospective analysis. This phase of the study will provide a platform for the transplant physicians to gain confidence with the format, logistics, and potential use of the biomarker tests on blood and tissue.~B. STUDY DESIGN: Enroll 20 subjects who are post-transplant and are undergoing kidney transplant biopsies at the UC Davis transplant center. Ten subjects will be enrolled who are receiving surveillance protocol biopsies and 10 subjects."
2565477|NCT02462642|Experimental|Brahmi - 36 subjects|36 subjects both male and female will consume 2 capsules of Brahmi for 84 days.
2565479|NCT02462642|Placebo Comparator|Placebo- 36 subjects|36 subjects male and female who will take 2 capsules of placebo every day
2565480|NCT02462642|Experimental|Brahmi - 8 Subjects|For PK part of the study 8 male subjects will be taken for treatment arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
2565482|NCT02462642|Placebo Comparator|Placebo- 4 subjects|4 male subjects in PK part will be in the placebo arm. Each volunteer will consume 2 capsules of Brahmi each day for 84 days.
3207331|NCT00963755||Prostate cancer relapse|Patients previously treated for prostate cancer and being investigated for biochemical relapse, (mostly in the Urology and Radiation Therapy Department, but not exclusively), for whom surgical or radiation therapy is envisioned in the event of a positive FCH-PET finding
3207332|NCT00963768|Experimental|Cohort 1|JNJ-28431754 30 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3207333|NCT00963768|Experimental|Cohort 2|JNJ-28431754 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
3207334|NCT00963768|Experimental|Cohort 3|JNJ-28431754 300 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2565620|NCT02461342||Dr.Tang's research group|Dr.Tang's research group for genetic, environment and its interaction analysis of human complex disease
3207335|NCT00963768|Experimental|Cohort 4|JNJ-28431754 600 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2565764|NCT02460484|Experimental|Cord Blood Infusion|Autologous cord blood infusion
2565811|NCT02460406|Other|control group|traditional physiotherapy (stretching, normal range of movement, walking)
2565813|NCT02460406|Active Comparator|intervention group|progressive functional strength training protocol on lower extremities consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises.
2565942|NCT02459483|Experimental|Nurse phone call|a nurse will interview patients by phone every 14 +/- 2 days for 6 months
2565943|NCT02459483|No Intervention|Control Group|Common practice
3207336|NCT00963768|Experimental|Cohort 5|JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
2566109|NCT02458612|Other|control group|We will apply only upper limbs exercises with traditional therapy.
2566113|NCT02458612|Active Comparator|intervention group|We will apply mirror therapy and progressive strength training for upper extremities.
2566174|NCT02458079|Experimental|Pentoxiphylline|
2566181|NCT02458079|Active Comparator|Stool Microbiota Transplantation|
2566221|NCT02457676|Experimental|Alert Program for Self-Regulation|Participants with FASD who received the Alert Program for Self-Regulation therapy between the two testing periods.
2566231|NCT02457676|No Intervention|FASD Alert Waitlist|Participants with FASD who did not receive therapy between the two testing periods but were provided intervention on study completion.
2566234|NCT02457676|No Intervention|Typically Developing Control|Normally developing controls not exposed to alcohol in utero who were not treated between the two testing periods.
3207337|NCT00963781|Experimental|Six months DAPT|All patients will be assigned to 6 months of DAPT
3207338|NCT00963794|Other|Electromagnetic measurement|Electromagnetic measurement to detect rectal cancer.
3207339|NCT00963833||Group 1|
3207340|NCT00963846|Placebo Comparator|placebo|
2566380|NCT02456480|Experimental|CLS001 topical gel, 2.5%|
2566388|NCT02456480|Experimental|CLS001 topical gel 1%|
2566392|NCT02456480|Placebo Comparator|Vehicle gel|
2566455|NCT02456246|Experimental|FLT-PET|"Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy.~Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT~Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence."
3207341|NCT00963846|Experimental|huperzine 0.2 mg BID|
2565177|NCT02464644|Experimental|People with HHT|"People with HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
2565181|NCT02464644|Other|Controls without HHT|"People without HHT will identify themselves within the questionnaire, first by statement of what they think is their diagnosis, and second by provision of the HHT diagnostic criteria within specific questions.~They will be directed to appropriate questions, according to answers to the previous questions."
2565206|NCT02464241||normal control|normal control
2565210|NCT02464241||patients|patients with optic or macular pathology or amblyopia
3207342|NCT00963846|Experimental|huperzine 0.4 mg BID|
2565321|NCT02463201||Obese children and adolescents|Attending a weightloss programme, that consist of lifestyle counseling, dietary restriction and exercise. The prevalence of obstructive sleep apnea (OSA) will be investigated in group. Children diagnosed with OSA will be followed to investigate if weight loss changes the condition.
2565371|NCT02463136|Experimental|Behaviour and brain training|fMRI-based neurofeedback
2565395|NCT02462824|Experimental|Home-based exercise intervention|PAD Participants randomized to the home-based exercise intervention will be asked to take part in walking exercise to determine whether a patient-centered home-based exercise program improves walking ability, mobility, pain, and social functioning.
2565402|NCT02462824|No Intervention|Usual care group|PAD participants randomized to usual care will not receive any study interventions. Rather, they will receive usual care from their own physicians.
2565459|NCT02462655|Experimental|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
2565462|NCT02462655|Experimental|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
3207343|NCT00963846|Experimental|huperzine 0.8 mg BID|
3207344|NCT00963885|Placebo Comparator|Part 1: Placebo|Placebo in combination with standard doses of Pegasys and Copegus.
2565634|NCT02461316||Combination Treatment in Chronic Lymphocytic Leukemia (CLL)|All participants receiving combination treatment in Chronic Lymphocytic Leukemia (CLL)
2565683|NCT02461108|Experimental|Price difference|Introduce a 10% price difference between foods labeled as nutritious and foods labeled as less nutritious and frame the price difference as either a Subsidy, Tax, or combination of a Tax and Subsidy.
2565695|NCT02461108|No Intervention|No price difference|No price difference between nutritious and less nutritious foods.
2565744|NCT02460718|No Intervention|control group|Participants received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight.
2565745|NCT02460718|Experimental|Encourage study|"Participants in the intervention arm were paired with a peer coach, interacting by telephone weekly for the first 8 weeks and then monthly for a total of 10 months.~Participants also received 1-hour group diabetes education class covering diabetes basics, healthy eating, stress reduction, physical activity, social support, and how to get the most out of their doctors visit. Participants also received a diabetes report card showing their Hba1c, blood pressure, ldl cholesterol, and body weight."
3207345|NCT00963885|Experimental|Part 1: RO5190591 300mg po|RO5190591 300mg po every 8 hours in combination with standard doses of Pegasys and Copegus.
2565863|NCT02460081|Experimental|PDA-002 -3x10^6 cells|Subjects will be treated with Investigational Product (IP) administered intramuscular (IM) on Study Days 1, 29 and 57.
2565864|NCT02460081|Experimental|PDA-002 - 30X10^6 cells|Subjects will be treated with IP administered IM on Study Days 1, 29 and 57.
2565865|NCT02460081|Placebo Comparator|Placebo|Subjects will be treated with Placebo administered IM on Study Days 1, 29 and 57.
2565934|NCT02459756|Active Comparator|Intervention|Spray dried blackcurrant powder dissolved in water
2565938|NCT02459756|Placebo Comparator|Placebo|(sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
2566010|NCT02459210|Experimental|CLUES|active treatment
2566012|NCT02459210|Active Comparator|therapy and computer games|supportive therapy + computer games
2566061|NCT02458781|Placebo Comparator|Placebo|"Placebo capsule:~To be provided by BAMC Pharmacy. It will be made and stored by BAMC pharmacy. The matching placebo will be a gelatin capsule filled with methylcellulose powder only. Patient will take 2 capsules two times a day for 14 days."
2566063|NCT02458781|Active Comparator|Ciprofloxacin|"Ciprofloxacin 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Ciprofloxacin 250mg tablet will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of Ciprofloxacin 250mg two times a day for 14 days."
2566064|NCT02458781|Active Comparator|Metronidazole|"Metronidazole 250mg capsule:~To be provided by BAMC pharmacy. It will be made and stored by BAMC Pharmacy. Metronidazole 250mg will be encapsulated with a gelatin capsule filled with methylcellulose. Patient will take 2 capsules of metronidazole 250mg two times a day for 14 days."
3207346|NCT00963885|Experimental|Part 1: RO5190591 600mg po|RO5190591 600mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
2566167|NCT02457975|Active Comparator|Intravitreous VEGF-inhibitors|Three intravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
3207347|NCT00963885|Experimental|Part 1: RO5190591 900mg po|RO5190591 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
3207348|NCT00963885|Placebo Comparator|Part 2: Placebo|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive placebo in combination with standard doses of Pegasys and Copegus.
2565186|NCT02464501|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrainguinal de novo and restenotic femoropopliteal lesions. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 4mm to 7mm in diameter. Following the achievement of optimal interventional results (less than thirty (30) percent residual stenosis without stenting) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment. Data will be collected to assess acute safety, long-term safety and durability to demonstrate the safety and efficacy of paclitaxel delivered with the ACT, Inc. OPC device.
3207349|NCT00963885|Experimental|Part 2: RO5190591 300mg po|If the safety and virological response data from Part 1 of the study are supportive, in Part 2 patients will be randomized to receive RO5190591 300mg po every 8 hours or 600mg po every 12 hours or 900mg po every 12 hours in combination with standard doses of Pegasys and Copegus.
3207350|NCT00963898|Experimental|Mental Retardation|
3207351|NCT00963950|Experimental|Intervention group|transvaginal cholecystectomy
2565290|NCT02463591|Experimental|Beriplex 50 IU/Kg|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Placebo).
2565291|NCT02463591|Placebo Comparator|Placebo|Cross over design: After therapy with Dabigatran Etexilate 300mg BID for 2.5 days, subjects will receive a single dose of Placebo identically in appearance to Beriplex 50 IU/Kg. After a 10 day minimum wash-out period subjects will receive the alternative treatment (Beriplex).
2565332|NCT02463370|Experimental|Group II|Group II patients will receive local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas and the remaining injections are placebo (saline).
2565336|NCT02463370|Experimental|Group V|Group V patients will receive local anesthesia in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum. The remaining maxillary injection is placebo.
2565379|NCT02462993|Experimental|Aloe vera group|Group recieving scaling and root planing and aloe vera gel local drug delivery
2565380|NCT02462993|No Intervention|SRP group|Group recieving only scaling and root planing
3207352|NCT00963950|Active Comparator|laparoscopic cholecystectomy|Laparoscopic cholecystectomy (4 port)
3207353|NCT00963963|Active Comparator|health promotion materials|Parents receive health promotion booklets
2565524|NCT02462187|Experimental|NVN1000 8% Gel twice daily|NVN1000 8% Gel twice daily
2565532|NCT02462187|Experimental|NVN1000 8% Gel once daily|NVN1000 8% Gel once daily
2565535|NCT02462187|Experimental|NVN1000 16% Once daily|NVN1000 16% Gel once daily
2565536|NCT02462187|Placebo Comparator|Vehicle Gel|Vehicle Gel at frequency to match active
2565537|NCT02462187|Experimental|NVN1000 24% once daily|NVN1000 24% once daily
2565556|NCT02461732|Active Comparator|CBT for Substance Dependence|Standard CBT for substance use disorders
2565559|NCT02461732|Experimental|Integrated CBT for PTSD and Substance Dependence|Integrated CBT for PTSD and substance use disorders, combining elements of cognitive processing therapy for PTSD with coping skills and relapse prevention for substance use disorders
2565645|NCT02461277|Active Comparator|Fast-track protocol|Before surgery, patients are informed about the surgical procedure, anesthesia and rehabilitation protocol. The surgery occurs in accordance with the principles of the Fast-track: minimal invasive surgery, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization.
2565648|NCT02461277|No Intervention|Conventional care|Usual care routine postoperative
2565703|NCT02461069|Active Comparator|Dimethyl fumarate treatment arm (A)|All patients will receive dimethyl fumarate (Tecfidera®) according to national recommendations (Krankheitsbezogenes Kompetenznetz Multiple Sklerose, KKNMS) from week 0 to week 24 (EOS-1) in the core study.
2565712|NCT02461069|No Intervention|Healthy subject arm (B)|Healthy subjects will not receive any treatment for RRMS during the study.
2565784|NCT02460627|Experimental|Lidocaine adhesive tape|
2565788|NCT02460627|Placebo Comparator|Adhesive tape|
3207354|NCT00963963|Active Comparator|attention-controlled parent print materials|Booklets on adolescent sexuality and health
3207355|NCT00963963|Experimental|audio-CD parent education|audio-CDs on parenting practices
2565907|NCT02459782|Other|US Guided Dual Quadrant Peribulbar block|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia
2565945|NCT02459496|Active Comparator|low-carb diet, followed by conventional DGE diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory low-carb ketogenic diet (VLCKD, below 40 g carbs per day), followed by an isocaloric or moderate hypocaloric low-carb diet (below 40 kcal% carbs per day)
2565949|NCT02459496|Active Comparator|very-low calory diet, followed by conventional diet|subjects receive dietary consulting for a first phase of 3 weeks, being represented by a very-low calory diet (VLCD; MODIFAST substitute, approx. 1200 kcal/day), followed by a conventional isocaloric or moderate hypocaloric diet under DGE guidelines
2566014|NCT02459067|Experimental|ImmuniCell®|Subjects will receive 6 cycles of ImmuniCell®, one infusion over an hour, at two-week intervals. During Stage 1, intra-patient dose escalation to achieve a total dose of 30 x 109 γδ T cells.
2566037|NCT02458742|Experimental|Morphine|0.5%Bupivacaine 2 ml with morphine 50 mcg for spinal anesthesia
2566040|NCT02458742|Placebo Comparator|Placebo|0.5%Bupivacaine 2 ml for spinal anesthesia
3207356|NCT00963976|Experimental|Target systolic BP < 150 mmHg|Systolic blood pressure will be reduced to <150 mmHg within 1 hour of randomization.
2566163|NCT02457936|Experimental|Mindfulness Based Cognitive Therapy (MBCT)|This group will receive 8 weeks of Mindfulness Based Cognitive Therapy
2566171|NCT02457936|Active Comparator|Waiting list|This group will be tested twice 8-10 weeks apart and then receive 8 weeks of Mindfulness Based Cognitive Therapy
2566276|NCT02457442|Active Comparator|PR1|Propofol-Remifentanil: Prop high, Remi low. Changing Remi (up-and-down)
3207357|NCT00963976|Active Comparator|Target systolic BP < 180 mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
3207358|NCT00964015|Active Comparator|Starch group|Patients randomized to the Starch group will receive Voluven (6% Hydroxyethyl Starch 130/0.4) for their intravenous bolus and fluid resuscitation requirements.
3207359|NCT00964015|Active Comparator|Saline group|Patients randomized to the Saline group will receive 0.9% Normal Saline for their intravenous fluid bolus and resuscitation requirements
3207360|NCT00964041|Experimental|D-cycloserine|Participants will receive D-cycloserine weekly, one hour before any assessments, for eight weeks.
2565238|NCT02464111|Experimental|Group 1|Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses
2565242|NCT02464111|Experimental|Group 2|Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose
2565244|NCT02464111|Experimental|Group 3|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given Treatment 3: Divided Dose - LNS supplement provided in 3 doses
2565246|NCT02464111|Experimental|Group 4|Treatment 2: Bolus - LNS supplement provided in one dose Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given
2565248|NCT02464111|Experimental|Group 5|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 2: Bolus - LNS supplement provided in one dose Treatment 1: Control - no supplement given
2565250|NCT02464111|Experimental|Group 6|Treatment 3: Divided Dose - LNS supplement provided in 3 doses Treatment 1: Control - no supplement given Treatment 2: Bolus - LNS supplement provided in one dose
2565302|NCT02463708||BHL COTP Caregivers|Caregivers participate in the BHL COTP, which provides support, education, and care management services from a Behavioral Health Provider (BHP) in addition to the Telehealth Education Program (TEP), a manualized program that consists of various modules that seek to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
2565334|NCT02463383|Experimental|Sequence 1|"Ibuprofen Tab 400MG~Placebo Tab"
2565340|NCT02463383|Experimental|Sequence 2|"Placebo tab~Ibuprofen Tab 400MG"
2565413|NCT02462902|Experimental|5% albumin Infusion|(250 ml over 15 to 30 minutes)
2565418|NCT02462902|Active Comparator|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minute)
2565486|NCT02462538|Experimental|Brentuximab vedotin and Imatinib|Brentuximab vedotin (every 3 weeks i.v., 1.8 mg/kg) and imatinib (200mg daily orally, escalated from 100mg daily) for up to 48 weeks
3207361|NCT00964041|Placebo Comparator|Placebo|Participants will receive placebo weekly, one hour before any assessments, for eight weeks.
2565584|NCT02461680|Experimental|Tangential resection|the tendon's injury is treated with a tangential resection
2565590|NCT02461680|Active Comparator|Suture|The tendon's injury is sutured
2565621|NCT02461511||Therapeutic Education + Documentation|diabetic patient hospitalized patient particpating in therapeutic education program
2565627|NCT02461511||No Therapeutic Education No Documents|diabetic patient hospitalized patient without therapeutic education program no documentation submitted
2565629|NCT02461511||Documentation, No Therapeutic Education|diabetic patient hospitalized patient without therapeutic education program documentation submitted
2565682|NCT02461147||Validation cohort|All patients of the study (single group, single arm) will undergo initial cholecystectomy with intraoperative cholangiogram, followed if required by ERCP, according to the standard protocol of treatment previously implemented at the investigators institution.
2565799|NCT02460783|Experimental|5-2 CR|Healthy living diet for 5 days/week; Calorie Restriction(530 Kcal in the form of a shake) for 2 days/week
2565801|NCT02460783|Active Comparator|Healthy Living|Healthy living diet for 7 days/week
2565819|NCT02460211|Active Comparator|Treatment|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation.
2565829|NCT02460211|Placebo Comparator|Placebo/Control Arm|Those randomized to the control arm will receive three oral placebo doses.
2565868|NCT02459977|Experimental|No basiliximab group|The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants.
2565869|NCT02459977|Active Comparator|Basilixiab group|Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group)
2565936|NCT02459678|Other|Standard of Care|The MOH-recommended approach is opt out HIV testing in pregnancy followed by immediate initiation of ART for HIV-infected pregnant women. ART initiation is accompanied with counseling geared to educate and prepare women to take up and be retained on ART lifelong. Women who do not return for clinical or drug refill visits are traced by phone or in person.
2565941|NCT02459678|Experimental|Enhanced adherence package|The enhanced adherence package will be designed on the basis of the results of formative research. The intervention will support women who are eligible for ART under Option B+.
2565996|NCT02459171||Participants|"Subjects who meet eligibility requirements and consent to participate.~Interventions: Blood sample, nasal wash, throat swab, questionnaire"
2566071|NCT02458729|Placebo Comparator|Placebo Group|Primary total knee replacement with 0.9% normal saline 20ml administration intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
2566074|NCT02458651||Tier 2 and South Eastern|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south eastern region of China
3207362|NCT00964054|Experimental|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
3207363|NCT00964054|Active Comparator|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
3207364|NCT00964067|Active Comparator|Treadmill group|Interval exercise performed on treadmills, supervised
3207365|NCT00964067|Active Comparator|Exercise groups|Supervised and organised in groups of ten
3207366|NCT00964067|Active Comparator|home-based exercise|Interval training at home, free choice of modality
3207367|NCT00964080|Experimental|Study of MBP-426/leucovorin/5-FU|Study of MBP-426/leucovorin/5-FU. MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered ata dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
2565235|NCT02464280||Patients scheduled for wrist imaging|"Patients with wrist fracture or with osteoprotetic material in the wrist and scheduled for wrist imaging will undergo:~the scheduled conventional X-ray examination~the scheduled CT scan~the tomosynthesis scan"
3207368|NCT00964093|No Intervention|No intervention|
3207369|NCT00964106|Experimental|Probe drugs|"Caffeine 100 mg CYP1A2 Pioglitazone 15 mg CYP2C8 Flurbiprofen 40 mg CYP2C9 Omeprazole 20 mg CYP2C19 Dextromethorphan 45 mg CYP2D6 Midazolam 3 mg (Part 1, Part 2 Cohorts B and C)~1 mg (Part 2 Cohort A) CYP3A4/5 Rosuvastatin 10 mg OATP1B1"
2565325|NCT02463266||SUSTAIN Monitoring and Care Management|SUSTAIN program participants who complete an initial clinical assessment and, if indicated, agree to follow-up services including Monitoring and/or Care Management.
3207370|NCT00964106|Experimental|Default Inhibitors|A Ketoconazole 400 mg once-daily Day 1 through Day 9 CYP3A4 B Fluconazole 400 mg x1 dose on Day 1 200 mg once-daily Day 2 through Day 9 CYP2C9 C Rifampin 600 mg x1 dose on Day 1 and Day 8 OATP1B1
2565454|NCT02462395|Experimental|Cefaly tDCS|Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
2565495|NCT02462304|Experimental|Combination Anti-VEGF and EPM laser|Subjects will receive both anti-VEGF injections and EPM laser.
2565496|NCT02462304|Active Comparator|Anti-VEGF monotherapy|Subjects will receive anti-VEGF injections monotherapy.
2565512|NCT02462031|Experimental|KD101|
2565513|NCT02462031|Placebo Comparator|KD101 placebo|
2565586|NCT02461914|Experimental|Warfaring and PEX168(200µg)|Warfarin: 5mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
2565632|NCT02461524|Other|Endovasculair repair|Endurant Evo AAA Stent graft system
2565691|NCT02461030|Experimental|CSPR + NS treatment|"In-office and at home Colgate sensitive pro-relief - CSPR~Intervention: Non-surgical periodontal treatment (full-mouth debridement, scaling and root planing with ultrasonic/hand instruments) associated with In-office application of Colgate Sensitive Pro-Relief (CSPR) + tooth brushing with at home CSPR toothpaste during 8 weeks."
2565704|NCT02461030|Placebo Comparator|Villevie® + NS treatment|"In-office Villevie® prophy paste + Colgate Toothpaste~Treatment: In-office application of a Villevie® (fluoride-free) prophy paste + tooth brushing with a Colgate Cavity Protection Toothpaste during 8 weeks, after non-surgical periodontal treatment. (Full-mouth debridment/ Scaling and root planing with ultrasonic/hand instruments)"
2565786|NCT02460614|Experimental|Rhinopharyngeal clearance + 0.9% saline|The retrograde rhinopharyngeal clearance (RRC) is based on the inspiratory reflex that follows a slow and prolonged expiration (passive exhalation technique performed using a slow thoracic-abdominal compression that begins at the end of a spontaneous exhalation and continues until the expiratory reserve volume). At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver. The instillation of saline (0.9%) preceded this step, resulting in the inhalation of the substance during the forced inspiration, contributing to the nasopharyngeal clearance.
2565793|NCT02460614|Active Comparator|Aspiration + 0.9% saline|Nasopharyngeal aspiration consisted in the introduction of a catheter that, by using negative pressure (vacuum), promotes the suction of secretion from the airways. In order to do that, a sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient. The saline instillation of 0.9% was used for humidification before the procedure.
2565825|NCT02460224|Experimental|Arm A|Single agent treatment arm with LAG525
2565830|NCT02460224|Experimental|Arm B: combination of LAG525 and PDR001|Combination treatment arm with LAG525 and PDR001
2565831|NCT02460224|Experimental|Arm C|Single agent treatment arm with LAG525 in Japanese pts
2565872|NCT02459769|Active Comparator|Dyadic Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed to both cancer survivors and their caregivers (daily walking and 3 times/week resistance prescription for 6 weeks). Cancer survivor and caregiver are also asked to discuss ways they can support one another in a) remaining adherent to exercise, and b) dealing with stress, including LGBT-specific minority stress.
2565874|NCT02459769|Other|Individual Exercise Intervention|Progressive walking and resistance exercise treatment, prescribed solely to cancer survivors (daily walking and 3 times/week resistance prescription for 6 weeks). The caregiver is told not to change his/her exercise behavior in any way.
2565924|NCT02459600|Experimental|All participants|"The measurement will be done at all the participants. the results will the divides in the following way:~Refraction measurements under general anesthesia without cycloplegic eye drops.~Refraction measurements under general anesthesia with cycloplegic eye drops."
3207371|NCT00964132|Experimental|NRX194204|
3207372|NCT00964145||Nulliparous female patients|Nulliparous female patients ages 21-70 years old.
2566029|NCT02458820|No Intervention|Usual Care|Patients will be recorded and interpreted as per standard of care. If a seizure is noted by the neurology service, the standard seizure treatment protocol will be used by the clinical team.
2566031|NCT02458820|Experimental|DSA EEG + Usual Care|Patients will undergo at least hourly interpretation of DSA by the ICU bedside care provider. If the bedside care provider is concerned that there is a seizure on DSA they will contact the EEG tech on call for confirmation. If a seizure is confirmed by neurology, the standard seizure treatment protocol will be used by the clinical team.
2566067|NCT02458651||Tier 1 and North|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in northern region of China
2566068|NCT02458651||Tier 1 and South|Site as described by tier level of the city where the site is located and by geographical location: Tier 1 city in southern region of China
3207373|NCT00964184|Experimental|Drug|1 gm metformin per day
3207374|NCT00964184|Other|control|lifestyle intervention
3207375|NCT00964197|Experimental|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
2565254|NCT02463929|Experimental|diphenhydramine|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5mg/kg diphenhydramine intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
2565255|NCT02463929|Placebo Comparator|control|Subject sedated with sevoflurane, and given bilateral extraoral infraorbital block with 0,125% bupivacaine. Subject injected 0,5cc/kg normal saline intravenously, 15 minutes prior to discontinuation of sevoflurane. If subject develop agitation, 0,1 mg/kg ketamine is administered
2565352|NCT02463305|Experimental|Treatment arm|6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.
2565360|NCT02463305|Placebo Comparator|Placebo arm|6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.
2565365|NCT02463305|Experimental|Optional Open-Label Treatment arm|Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.
3207376|NCT00964236||Sapropterin|Individuals with phenylketonuria (PKU) who are beginning treatment with Kuvan (sapropterin).
3207377|NCT00964236||Control|Healthy individuals without phenylketonuria (PKU).
2565569|NCT02461979|Other|Hepatocellular carcinoma (HCC)|The VDR genotype in 20 HCV cirrhotic patient with HCC
2565574|NCT02461979|Other|Liver cirrhosis|The VDR genotype in 20 HCV cirrhotic patient without HCC
2565580|NCT02461979|Other|Control group|The The VDR genotype in 10 healthy individuals as control
2565628|NCT02461537|Active Comparator|RIST(remission induction)|high-dose cytarabine 3 g/m2 (days 1-3)/mitoxantrone 10mg/m2 (days 3-5)
2565630|NCT02461537|Experimental|DISC (disease control)|low-dose cytarabine 20 mg/ m2 and /or mitoxantrone 10mg/m2
2565759|NCT02460809|Active Comparator|In-lab tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in a controlled laboratory environment with an investigator.
2565760|NCT02460809|Experimental|In-home tDCS|Three people with chronic stroke will participate in finger tracking training while receiving transcranial direct current stimulation (tDCS) in their own home. Patients will be taught how to use a blue-tooth enabled telerehabilitation module that is being controlled by an investigator in the lab on the University campus. For safety, an investigator will be in the home with each patient during tDCS use and finger tracking training but will only be supervising procedures.
2565816|NCT02460432|Experimental|Paclitaxel-eluting metal Stent|Niti-S Mira-Cover III Biliary Stent (TaeWoong Medical Co., Ltd. Korea)
2565818|NCT02460432|Active Comparator|Covered Metal Stent|ComVi Biliary Covered Stent (TaeWoong Medical Co., Ltd. Korea)
2565875|NCT02459886|Experimental|Cohort 1|Single intravenous (IV) low dose infusion with staggered participant dosing
2565878|NCT02459886|Experimental|Cohort 2|Single IV ascending dose infusion with staggered participant dosing
2565879|NCT02459886|Experimental|Cohort 3|Single IV ascending dose infusion with staggered participant dosing
2565880|NCT02459886|Experimental|Cohort 4|Single IV ascending dose infusion with staggered participant dosing
2565881|NCT02459886|Experimental|Cohort 5|Single IV ascending dose infusion with staggered participant dosing
2565882|NCT02459886|Experimental|Cohort 6|Single IV ascending dose infusion with staggered participant dosing
2565883|NCT02459886|Experimental|Cohort 7|Single IV ascending dose infusion with staggered participant dosing
2565976|NCT02459327|Experimental|VIP/FCU|VIP (Video Interaction Project) will be offered to all families assigned to the treatment group. FCU (Family Check Up) will be offered to families identified as high risk within the treatment group. Both treatments are parenting interventions.
2565979|NCT02459327|No Intervention|Control|
2566035|NCT02459015|Experimental|Reaxon® Nerve Guide|Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
2566039|NCT02459015|Active Comparator|Autologous Nerve Graft|Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.
2566095|NCT02458547|Experimental|Group D|General anesthesia with desflurane
2566102|NCT02458547|Active Comparator|Group P|General anesthesia with propofol total intravenous anesthesia
2566111|NCT02458547|Active Comparator|Group S|Spinal anesthesia with 0.5% bupivacaine
2566168|NCT02458131|Experimental|TEEN HEED|Adolescent pre-diabetics will receive 8-12 weekly peer-led diabetes prevention educational workshops in community sites. The in-person group workshops will be supplemented by support through mobile health technologies such as text messaging and social media.
2566176|NCT02458131|No Intervention|Wait List Control|Adolescent pre-diabetics in this group will not receive any intervention until collection of all follow up data and will then be offered the same intervention as the participants in the experimental arm.
3207378|NCT00964249|Experimental|LABA|After randomization subject will inhale either 12.5 microgram or 25 microgram GW642444M once daily for 7 days.
3207379|NCT00964249|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
2566313|NCT02456974||amoxicillin-clavulanate|Patients receiving amoxicillin-clavulanate as part of routine clinical care.
3207380|NCT00964262|Experimental|SR Exenatide (PT302)|Intervention: Drug: SR Exenatide (PT302)
3207381|NCT00964275|Experimental|Arm I|Patients undergo diagnostic fludeoxyglucose F 18 PET in addition to standard methods.
3207382|NCT00964275|Active Comparator|Arm II|Patients only undergo standard diagnostic methods.
3207383|NCT00964288|Other|Period 1|
3207384|NCT00964288|Other|Period 2|
3207385|NCT00964288|Other|Period 3|
3207386|NCT00964288|Other|Period 4|
3207387|NCT00964301|Experimental|Intervention Group|Participants, caregivers and school nurse will attend telemedicine education sessions at school.
3207388|NCT00964301|Active Comparator|Usual care|Usual care participant will receive routine care from their primary care provider.
2565257|NCT02463825|Experimental|Group 1 Pimozide (2mg per day)|Pimozide will be initiated at 1 mg twice daily and maintained on 2mg/day for 50 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will then be stopped.
2565260|NCT02463825|Experimental|Group 2 Pimozide (4mg per day)|Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
2565265|NCT02463825|Placebo Comparator|Group 3 Placebo (Lactose tablet)|Placebo tablets will be utilized and administered in an identical manner for subjects in Group 3
2565327|NCT02463396|Experimental|Mindfulness Based Cognitive Therapy (MBCT) for ADHD|Adapted MBCT for ADHD
2565338|NCT02463396|No Intervention|Treatment as usual (TAU)|Usually medication & psycho-education
2565383|NCT02463045|Experimental|TOP1288 1mg (or placebo)|TOP1288 1mg single dose or placebo
2565384|NCT02463045|Experimental|TOP1288 10mg (or placebo)|TOP1288 10mg single dose or placebo
2565385|NCT02463045|Experimental|TOP1288 100mg (or placebo)|TOP1288 100mg single dose or placebo
2565386|NCT02463045|Experimental|TOP1288 200mg single dose or placebo|TOP1288 200mg single dose or placebo
2565387|NCT02463045|Experimental|TOP1288 400mg dose or placebo|TOP1288 400mg (200mg bid) dose or placebo
2565388|NCT02463045|Experimental|TOP1288 A mg or placebo|TOP1288 A mg daily for 4 days
2565389|NCT02463045|Experimental|TOP1288 B mg or placebo|TOP1288 B mg daily for 4 days
2565390|NCT02463045|Experimental|TOP1288 C mg or placebo|TOP1288 C mg daily for 4 days
2565391|NCT02463045|Experimental|TOP1288 D mg or placebo|TOP1288 D mg bid for 4 days
2565392|NCT02463045|Experimental|TOP1288 Xmg or placebo|TOP1288 X mg od or bid for 4 days
3207389|NCT00964314|Experimental|five elements music|Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
3207390|NCT00964314|Active Comparator|western music|Listening western music based on conventional therapy in China.
2565484|NCT02462356|Active Comparator|Conventional VATS|Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
2565487|NCT02462356|Experimental|Uniportal VATS|Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
2565516|NCT02462109|Experimental|Lorazepam|"Children with confirmed Nodding syndrome that had 2 or more of the symptoms on the 10-item Kampala Catatonia Panel (KCP) scale were recruited to undergo the catatonia test using oral Lorazepam EG® (n.v. Eurogenerics s.a. Brussels, Belgium) using the 1 mg formulation tablets. The amount of Lorazepam (LZP) drug given orally was based on the weight of the child. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.~A positive response to a catatonia test consisted of a reduction in catatonic symptoms, 60 minutes later, by at least 50% assessed by the KCP (using all 10 items). If no response to the initial dose of LZP, was observed after one hour, a second administration of the same medication at double the dose was given. Catatonia was again assessed at 60 minutes thereafter. If no response was observed, the test was considered negative."
2565575|NCT02461940|No Intervention|Standard care|The control group will receive the standard care provided by the STI clinic.
2565582|NCT02461940|Active Comparator|Adolescent Behavioral intervention|Participants allocated to the intervention arm receive 4 on-site personalised counselling and 2 phone/online sessions over a 12-month period, targeting individual, relational, sociocultural and environmental factors pertaining to the acquisition of STI/HIV.
3207391|NCT00964314|No Intervention|Without music|no music therapy will be done in the arm.
3207392|NCT00964340|Placebo Comparator|Placebo|The Placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3207393|NCT00964340|Active Comparator|0.5g SRT2104|The 0.5g SRT2104 treatment group will be administered 2 SRT2104 capsules with 6 matching placebo capsules, for a total of 8 capsules per day. 0.5g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3208886|NCT00979043|Active Comparator|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
2565729|NCT02460887|Experimental|Experimental|Induction chemotherapy+IMRT gemcitabine and cisplatin regimen Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT).
2565730|NCT02460887|Active Comparator|Active Comparator|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with weekly cisplatin 40 mg/m² up to 7cycles.
2565780|NCT02460536|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
2565781|NCT02460536|Active Comparator|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
2565783|NCT02460536|Active Comparator|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
2565785|NCT02460536|Placebo Comparator|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
2565817|NCT02460237|Experimental|Arm I (intervention)|Participants receive a study kit that includes culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing. Participants are asked to complete the HPV self-test and return the test for HPV testing.
2565295|NCT02463604|Sham Comparator|Control|"A blood pressure cuff is placed on upper arm and inflated to 10 mmHg for 5 minutes and then deflated for 5 minutes. This cycle is repeated 3 times in total.~The procedure has to be completed between 5 and 60 minutes prior coronary angiography."
2565324|NCT02463448|Experimental|Autologous Muscle Derived Cells|Autologous Muscle Derived Cells are obtained by needle biopsy from the subject's own thigh muscle. These cells are sent to a special lab for growth and processing. When ready the cells are sent to the treatment location for injection into the bladder wall.
2565397|NCT02463110|Experimental|1: Sertraline|ACS, depression
2565405|NCT02463110|Placebo Comparator|2: Placebo|ACS, depression
2565409|NCT02463110|Other|3: Control|ACS, no depression, no treatment
2565474|NCT02462603|Experimental|EPI-589 500 milligrams (mg) twice daily (bid)|All enrolled participants will receive treatment with EPI-589
2565521|NCT02462161|Experimental|Insulin Aspart|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of insulin aspart (20 IU) for 12 weeks.
2565529|NCT02462161|Placebo Comparator|Placebo|Fifteen randomly assigned participants with Alzheimer's disease or mild cognitive impairment will receive twice daily intranasal administrations of placebo (saline) for 12 weeks.
2565564|NCT02461836|Experimental|Chemo|adjuvant chemotherapy using Gemcitabine for 6 rounds
2565565|NCT02461836|Experimental|Chemo+SBRT|SBRT is delivered prior to adjuvant chemotherapy with Gemcitabine for 6 rounds
2565619|NCT02461576||HIV-1 infected|this is a study comparing Xpert HIV-1 VL assay quantitation to an already FDA approved HIV-1 quantitative HIV-1 RNA assay in known HIV-1 infected individuals
2565676|NCT02461212|Experimental|Liver MRI|Liver MRI imaging will be performed on subjects undergoing a liver biopsy
2565677|NCT02461212|Experimental|Liver MRI repositioned|Liver MRI imaging will be performed on subjects undergoing a liver biopsy and then they will be repositioned and will repeat the MRI
2565742|NCT02460835|Experimental|Adaptive Radiation Therapy|
2565775|NCT02460523|Active Comparator|conservative|"1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen ) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.~Improvement: If the stone spontaneously passes to the duodenum and CBD is clear completely from the stones proved by US, the patient will undergo laparoscopic cholecystectomy (LC) within 3 days.~No improvement: the patient will undergo ERCP and then LC."
2565777|NCT02460523|Active Comparator|ERCP (endoscopic)|"2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.cholecystectomy (LC) within 3 days.~b- No improvement: the patient will undergo ERCP and then LC."
2565823|NCT02460315|Active Comparator|early cholecystectomy|group (A) will be managed by early laparoscopic cholecystectomy after clearness ERCP
2565828|NCT02460315|Active Comparator|late cholecystectomy|group (B) will be managed by late LC one month after ERCP.
2565866|NCT02460003|Experimental|Physiotherapy program|Physiotherapy program and usual drugs
2565867|NCT02460003|Active Comparator|Home exercise program|Home exercise program and usual drugs
2565871|NCT02459730|Experimental|ART with GIC containing 1.25% CHX|The cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
2565873|NCT02459730|Active Comparator|ART with GIC|The cavities were filled with the press finger technique using KetacMolar Easymix® (control group).
2565929|NCT02459613|Experimental|Imaging|99mTc Annexin V-128 SPECT
2565997|NCT02459236|Experimental|CERC-301 12mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
2565998|NCT02459236|Experimental|CERC-301 20mg|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
2565999|NCT02459236|Placebo Comparator|Placebo|The study includes two dose administrations 7 days apart (Day 0 and Day 7) followed by 14 days of observation for a total of 21 days.
2566052|NCT02458833|Experimental|Intervention|Behavioral: Home Plate intervention
2566056|NCT02458833|Experimental|Delayed Entry Control|This Arm will receive the Home Plate intervention 3 months after the Intervention Arm completes the intervention.
3207394|NCT00964340|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered 8 SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. Dosing will take place at approximately the same time every day, approximately 15 minutes following the consumption of a standardized meal, and subjects must wait at least 1-2hrs after dosing before consuming additional calories. Water is permitted ad libitum.
3207395|NCT00964379|Active Comparator|intraperitoneal colostomy|
3207396|NCT00964379|Active Comparator|extraperitoneal colostomy|
2566142|NCT02457923|Experimental|Mobile phone counselling|"The intervention will include:~An App for real time data collection of mothers by ASHAs, data transfer, and, display of counselling messages and health video during ASHAs monthly home visit.~Weekly voice and text messages from server at a prescribed time to provide targeted information on infant feeding counselling.~Server generated reminders and alerts, delivered to the mother, ASHA and ANM.~An App for field supervisor to monitor ASHAs~Women will receive fortnightly mobile phone counselling calls by an ANM at times they recommend. Need based counselling will also be provided"
2566150|NCT02457923|No Intervention|Usual health care services|The control clusters to receive usual health care services at PHC. The existing data collection methods will be continued in these clusters. Routine IYCF counseling is provided in existing level of care and its frequency is consistent with the visit schedule described in the intervention group: at antenatal clinics; at delivery; and at immunization clinics postnatal.
3207397|NCT00964405|Experimental|LAMA|After randomization subject will inhale either GSK233705 50, 100 or 200 microgram once daily for 7 days.
3207398|NCT00964405|Placebo Comparator|Placebo|After randomization subjects will inhale placebo once daily for 7 days.
3207399|NCT00964418|Experimental|IDeg|
2566374|NCT02456441|Experimental|Intervention group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after TENS application, through Heart Hate Variability analysis.
2565323|NCT02463500||DFU with/without osteomyelitis|Patients of the investigators. Male and female, age 18 and older (up to age 89), of any race or ethnicities, who have diabetes (Type I or II) and a foot ulceration.
2565420|NCT02463058|Experimental|Research arm|"10 young and healthy civilian volunteers will participate in this study. The subjects will undergo 5 experiment days:~Recruitment , medical examination and VO2max test.~Acclimatization day by performing moderate exercise protocol under hot and humid climate.~3 days of performing moderate exercise under hot and humid conditions protocol, each day dressed with different protective garment:~Protective garment in current use + NBC mask.~The new BC protective undergarment + standard combat uniforms~The new BC protective undergarment + standard combat uniforms + NBC mask"
2565473|NCT02462551|Experimental|FEAST|Patients with treatment-resistant depression will undergo 3 sessions of focal electrically administered seizure therapy for two to six weeks. The complete parameter range of the stimulus delivered (Freq: 20-120 Hz; PW: 0.2-2 ms; Duration: 0.1 to 8 s; Current: 0.5-0.8A; charge: 1-576 mC) is determined by an initial titration session and the PI (as an expert in neuromodulation treatments).
3172498|NCT00600548|Experimental|2.1|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Miltefosine.
3172499|NCT00600548|Active Comparator|2.2|Cutaneous leishmaniasis patients in Corte de Pedra-Bahia randomized to receive Meglumine antimoniate (standard treatment).
2565605|NCT02461784||Case|Male subjects with IBD diagnosis currently taking methotrexate (MTX) as treatment for their disease.
2565607|NCT02461784||Control|Male subjects with IBD diagnosis not exposed to methotrexate (MTX) as treatment for their disease.
2565624|NCT02461407|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2565626|NCT02461407|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2565726|NCT02460874|Experimental|Pilot Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS. Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Take Glyburide 1.25mg (twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education- begin glucose monitoring (4 times a day).~Step 3: 1 week after SRS, return to clinic to review glucose logs- continue glyburide and blood glucose monitoring.~Step 4: 1 month after SRS, discontinue both glyburide and blood glucose monitoring, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
2565727|NCT02460874|Placebo Comparator|Randomized Portion|"Step 1: Patients with brain metastases requiring SRS and not taking corticosteroids 5 days prior to SRS.Treatment planning MRI may be done within 21 days prior to SRS treatment.~Step 2: Randomization (1:1)~Group 1: take Glyburide (1.25mg, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Group 2: Take Placebo (1 pill, twice a day by mouth) beginning 5 days prior to SRS. Receive glucose monitoring materials and blood glucose education. Begin glucose monitoring (once a day) {This portion will be double blinded}.~Step 3: 1 week after SRS, return to clinic to review glucose logs, continue investigation medication, but discontinue glucose monitoring.~Step 4: 1 month after SRS, discontinue investigation medication, undergo MRI.~Step 5: 3 months after SRS, undergo MRI."
2565790|NCT02460601|Experimental|Qizhiweitong granule|2.5g/time,tid,oral administration,6 weeks
2565795|NCT02460601|Placebo Comparator|Placebo|2.5g/time,tid,oral administration,6 weeks
2565836|NCT02460302|Experimental|Vaginal Progesterone|"In the experimental arm, the participants will be randomized (1:1 allocation) to receive a vaginal progesterone suppository (100mg) as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the drug three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
2565843|NCT02460302|Placebo Comparator|Placebo Comparator|"In the placebo arm, the participants will be randomized (1:1 allocation) to receive a vaginal suppository (100mg) containing hard fat without any active hormonal ingredient as the intervention.~Participants will be instructed to insert the vaginal suppository into the vagina, as high as is comfortable for the patient. They are to insert the placebo three days per week, on Monday, Wednesday and Fridays, preferably at bedtime. Patients will record the use of their medications. This will be done for the study period of 12 weeks."
3172500|NCT00600561|Active Comparator|1-Day MBSR|One-day condensed MBSR class
3172501|NCT00600561|Experimental|8-week MBSR|8-week Mindfulness-Based Stress Reduction Intervention
2565956|NCT02459366||control|establish the reliability of measurement of lumbopelvic asymmetry, mechanical and physical properties of thoracolumbar fascia, and the norm of different age
2565962|NCT02459366||low back pain|compare the differences among asymptomatic subjects and patients with and without lumbopelvic asymmetry, and investigate whether lumbopelvic symmetry, core muscle contractility, proprioception and standing balance change after manipulating thoracolumbar fascia tissue by physical therapy
2566060|NCT02459106||Healthy lean insulin-sensitive individuals|This group will be studied by measuring the adipose tissue miRNA release, adipose tissue-released miRNA will be profiled, and these effects will be examined.
2566062|NCT02459106||Obese insulin-resistant individuals|This group will be studied by measuring the effect of adipose tissue-release miRNA on skeletal muscle biology and insulin sensitivity, adipose tissue-released miRNA will be profiled, and these effects will be examined on obese insulin-resistant individuals on skeletal muscle biology and insulin sensitivity.
2566092|NCT02458443|Sham Comparator|IHG 5% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip (IHG) exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
2566140|NCT02457988|Experimental|Vivify Kit|Patients with cirrhosis will undergo home monitoring for 30 days post-discharge through the use of the Vivify kit which contains a wireless tablet with daily medication/diet/symptom questionnaires and vital sign monitoring.
3172502|NCT00600574|Active Comparator|S|physiotherapy in warm pool by means of stretching
3172503|NCT00600574|Experimental|AI|physiotherapy in warm pool by means of Ai Chi
3172504|NCT00600587|Experimental|A|Erlotinib targeted NSCLC population based on EGFR gene analysis(EGFR gene status: activating mutation)
2565331|NCT02463188|No Intervention|Psychoeducation (PE)|The control classes will receive an 1-session psycho-educational (PE) intervention that provides information on sleep but does not provide guidance for implementing behavior change and does not explicitly teach about sleep's relationship to substance use.
2565423|NCT02463084|Experimental|Low Diet|Diet intervention consisting of foods with low saturated fats, low glycemic index and low salt
2565427|NCT02463084|Experimental|High Diet|Diet intervention consisting of foods with high saturated fats, high glycemic index and high salt
2565485|NCT02462512||FNAB of Thyroid nodule|The Patients with thyroid nodule who are scheduled for FNAB
2565520|NCT02462174|Active Comparator|Topical ketamine and topical bupivacaine|0.5 mg/ kg ketamine in 0.3 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered directly around the spermatic cord in the wound after end of surgery and before closure of the wound.
2565527|NCT02462174|Active Comparator|Caudal ketamine and caudal bupivacaine|0.5 mg/ kg ketamine in 1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) administered by caudal epidural route after anesthesia and before the start of surgery.
2565579|NCT02461810|Experimental|SpineJack® system|VCF treatment system Vertebral fracture surgery
2565588|NCT02461810|Active Comparator|Balloon Kyphoplasty|VCF treatment system Vertebral fracture surgery
3207400|NCT00964418|Active Comparator|IGlar|
3207401|NCT00964457|Active Comparator|Capecitabine, oxaliplatin|
2565713|NCT02460900|Active Comparator|Varenicline and Standard of Care|Participants will receive varenicline and standard of care
2565717|NCT02460900|Placebo Comparator|Placebo and Standard of Care|Participants will receive placebo and standard of care
2565721|NCT02460900|Active Comparator|Positively Smoke Free and Placebo|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Placebo
2565723|NCT02460900|Active Comparator|Positively Smoke Free and Varenicline|Participant will receive Positively Smoke Free (a tailored behavioral intervention) and Varenicline
3207402|NCT00964457|Active Comparator|capecitabine, oxaliplatin and cetuximab|capecitabine, oxaliplatin ane cetuximab
3207403|NCT00964483|Experimental|DASH materials|Participant randomized to a 12-week, group-based lifestyle intervention using modified DASH materials and intervention delivery approaches to help them adopt the DASH diet. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium.
2565832|NCT02460120|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System
2565900|NCT02459925|Active Comparator|CBT- Mental Health Program|Cognitive Behavioral Therapy. Manualized Stress Management class; brief individual behavioral counseling.
2565906|NCT02459925|Active Comparator|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
2565981|NCT02459353|Experimental|dapagliflozin 10mg|a group which treated with dapagliflozin 10mg plus basal insulin therapy
2565983|NCT02459353|Placebo Comparator|placebo 10mg|a group which treated with dapagliflozin placebo plus basal insulin therapy
2566006|NCT02458989|Active Comparator|Scalpel|Use of a scalpel as a first incision during thyroid operation.
2566008|NCT02458989|Experimental|Electrocautery|Use of an electrocautery as a first incision during thyroid operation.
2566046|NCT02458794|Active Comparator|LMA SupremeTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2566049|NCT02458794|Active Comparator|Ambu-Aura GainTM|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
2566143|NCT02458196|Experimental|Prednisone|Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
2566153|NCT02458196|Experimental|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
2566189|NCT02457780|Experimental|Relaxation Response Resiliency Program|The Relaxation Response Resiliency Program (3RP) is an 8-session (90min/session) group based intervention which includes a variety of skills and techniques designed to address chronic stress. Techniques used include psychoeducation on healthy lifestyle behaviors, goal-setting, CBT skills, relaxation training and self-monitoring.
2566190|NCT02457780|Active Comparator|Health Enhancement Program|The Health Enhancement Program (HEP) is an 8-session (90min/session) group based intervention which includes psychoeducation and self-monitoring of health behaviors (e.g., sleep hygiene, nutrition, exercise, substance use etc).
3207404|NCT00964483|Active Comparator|Delayed intervention|"The intervention participants will receive an NHLBI brochure entitled Your Guide to Lowering Blood Pressure. They will then receive the modified DASH materials and the intervention at the end of the study, following the intervention group's completion of the study."
3207405|NCT00964522|No Intervention|Standard care|The arm A is the one of standard education and care.
2566403|NCT02456688|Experimental|Patients with im paired hepatic function|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
2566417|NCT02456688|Experimental|Healthy Volunteers|One dose of Imrecoxib followed by 5 days' pharmacokinetic sample collection.
2566461|NCT02456194|Experimental|Calcium Sulfate + Antibiotics + Internal Fixation|
2566519|NCT02455856|Experimental|JNJ-42847922 plus Itraconazole|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6 and itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
2566617|NCT02455258|Experimental|Dance/Movement Therapy (DMT)|
2565333|NCT02463214|Experimental|Engineered Room|Single occupancy bone marrow transplant recovery room, engineered with touchless devices, and surfaces coated with either copper or titanium dioxide.
3207406|NCT00964522|Active Comparator|Nurse education and care program|The arm B will receive programmed education and care about the chemotherapy by a nurse of the Medical Oncology service before the beginning of the treatment and in each cycle, in a specific nurse consultation.
3207407|NCT00964535|Experimental|Budesonide/formoterol Easyhaler|
3207408|NCT00964535|Experimental|Charcoal and Budesonide/formoterol EH|
3207409|NCT00964535|Active Comparator|Symbicort Turbohaler|
3207410|NCT00964535|Active Comparator|Charcoal and Symbicort Turbohaler|
3207411|NCT00964561|Experimental|Ciprofloxacin and Valortim|First two subjects to receive treatment arm of Ciprofloxacin and Valortim. Total of sixteen volunteers to be randomized to receive Ciprofloxacin and Valortim.
2565596|NCT02461667|Placebo Comparator|placebo|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
2565597|NCT02461667|Active Comparator|Metformin|SRP plus Metformin SRP was done for all the subjects. metformin was delivered in the pocket subgingivally
2565599|NCT02461667|Active Comparator|Alendronate|SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
2565678|NCT02461225|Active Comparator|Erchonia® FX-635™|The Erchonia® FX-635™ is made up of 3 independent 17 milliWatts (mW), 635 nanometers (nm) red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
2565679|NCT02461225|Placebo Comparator|Placebo Laser|The Placebo Laser has the same appearance as the Erchonia® FX-635™ but does not emit any therapeutic light.
2565680|NCT02461225|Active Comparator|Erchonia® FX-635™ Placebo Cross-over|The Erchonia® FX-635™ is made up of 3 independent 17 mW, 635 nm red laser diodes mounted in scanner devices with flexible arms positioned equidistant from each other.
2565778|NCT02460744|Experimental|Single arm treatment with radiation|Patients with breast cancer will be given adjuvant hypofractionated radiotherapy
3207412|NCT00964561|Experimental|Placebo Antibiotic and Valortim|Randomized such that four subjects to receive Placebo Antibiotic and Valortim.
3207413|NCT00964561|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that 4 subjects to receive Placebo Antibiotic and Placebo Valortim.
2565961|NCT02459314|Placebo Comparator|soymilk|Soymilk (SM) contained 5 gm soy protein and 6.5 gm sugar per 180 mL package.
2565965|NCT02459314|Active Comparator|sterol/fiber-enriched soymilk|PLant sterol and soluble fiber-enriched soymilk (SFSM) contained 1 gm free plant sterol, 5 gm inulin (soluble fiber), 5 gm soy protein and 6.5 gm sugar per 180 mL package
2566036|NCT02459041||Pancreatic cancer|"Consecutively admitted patients with pancreatic cancer confirmed by EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
2566038|NCT02459041||Benign pancreatic masses|"Consecutively admitted patients with benign pancreatic masses with negative EUS-guided FNA.~EG-EUS and CE-EUS will be applied in all patients."
2566041|NCT02459041||Malignant lymph nodes|"Consecutively admitted patients with malignant lymphnodes confirmed by EUS-guided FNA.~EG-EUS will be applied in all patients."
2566042|NCT02459041||Benign lymph nodes|"Consecutively admitted patients with benign lymphnodes with negative EUS-guided FNA.~EG-EUS will be applied in all patients."
2566097|NCT02458495|No Intervention|Standard of Care Control Group|"Participants will be granted access to a generic Diabetes website. Participants will complete the same eligibility and baseline self-report as the intervention group. The 1 month and 3 month self-report survey will omit mention of the Diabetes MAP website and will reference the generic diabetes website.~Participants will be provided with access to a generic Diabetes website. Participants will complete the same eligibility, baseline and self-report surveys as the intervention group."
2566106|NCT02458495|Experimental|Diabetes MAP Intervention Group|Participants will be granted access to the Diabetes MAP website. Participants will complete the same eligibility and baseline self-report as the control group. The 1 month and 3 month self-report will refer to the Diabetes MAP website specifically.
3207414|NCT00964574|Experimental|APIDRA + LANTUS basal|The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12
3207415|NCT00964587|Active Comparator|Usual Care|Packet of standard print patient education materials on CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA).
3207416|NCT00964587|Experimental|Self Study|One 90-minute educational session. Print materials and DVDs for self-study
3207417|NCT00964587|Experimental|Group Problem-Solving Training|One 90-minute education session. Group problem-solving training (eight, 90-minute sessions)
3207418|NCT00964587|Experimental|Individual Problem-Solving Training|One 90-minute education session. Individual problem-solving training (eight, 60-minute sessions)
3207419|NCT00964600|Experimental|TAP blockade|bilateral TAP blockade at the end of cesarean delivery
3207420|NCT00964600|No Intervention|No TAP|These patients would have usual analgesic drugs after cesarean
3207421|NCT00964639|Placebo Comparator|Saline|
3207422|NCT00964639|Active Comparator|Naropin|
3207423|NCT00964652|Experimental|PD Group|Nine subjects with idiopathic PD, previously diagnosed by one specialist physician participated in this study.
3207424|NCT00964665|Experimental|Group 1 ABF656 900ug Q2w|
3207425|NCT00964665|Experimental|Group 2 ABF656 900ug Q4w|
3207426|NCT00964665|Experimental|Group 3 AB656 1200ug Q4w|
3207427|NCT00964665|Experimental|Group 4 ABF656 1500ug Q4w|
3207428|NCT00964665|Active Comparator|Group 5 Pegasys® 180µg qw|
3207429|NCT00964691|Active Comparator|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
3207430|NCT00964691|Active Comparator|IPTp with Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
3207431|NCT00964704|Experimental|Single Arm|
3207432|NCT00964717|Active Comparator|Chiropractic|Real Chiropractic treatment
3207433|NCT00964717|Sham Comparator|Sham Chiropractic|stimulation utilizing 'activator' thumper
3207434|NCT00964717|No Intervention|No treatment|No add on therapy - patients lay down for a period of 15 minutes without any treatment or intervention
2565421|NCT02462746|No Intervention|No supplement|This group subjects will not receive the supplement
2565425|NCT02462746|Active Comparator|1.5 gram of l-cysteine|Intervention: single dose of 1.5 g L-Cysteine.
2565428|NCT02462746|Active Comparator|3 grams of l-cysteine|Intervention: single dose of 3.0 g L-Cysteine.
3207435|NCT00964730|Experimental|Talampanel|
3207436|NCT00964730|Placebo Comparator|Placebo|
3207437|NCT00964730|Other|Moxifloxacin|
2565739|NCT02460848|Experimental|Outpatient therapeutic program, counseling and cash transfer|Ten outpatient therapeutic program sites (OTP) will be randomly allocated to unconditional cash transfer for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
2565740|NCT02460848|Active Comparator|Outpatient therapeutic program and counseling|Ten outpatient therapeutic program sites (OTP) will be randomly allocated for children admitted for treatment of SAM according to the integrated management of acute malnutrition national protocol which will be associated with counseling on infant and young child feeding (IYCF).
2565789|NCT02460549|Experimental|therapeutic education program|patients attend three sessions of therapeutic education
2565821|NCT02460289|Experimental|Treatment|
2565925|NCT02459509|Active Comparator|Dexmedetomidine 2 mcg/kg|2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
2565926|NCT02459509|Active Comparator|Dexmedetomidine 4 mcg/kg|4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction
3207438|NCT00964756|Experimental|Gene therapy|
3207439|NCT00964769|Experimental|Pneumococcal polysaccharide vaccine|The immunogenic response to the pneumococcal polysaccharide vaccine was compared between children, adults and elderly.
3207440|NCT00964808|Experimental|Buprenorphine|Double dummy; Group A: Active Buprenorphine and placebo oxycodone
2566239|NCT02457572||Valsalva maneuver|This is an observational study and as a diagnostic intervention, subjects in the study would receive valsalva maneuver. Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration. The investigators perform this procedure to every patients and do not assign this intervention to the subjects of the study.
2566260|NCT02457286|Experimental|Metformin|Metformin is being compared to exercise and diet modifications. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
2566262|NCT02457286|Experimental|Lifestyle modification|The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating participants condition or disorder. The study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe
2566311|NCT02456987|Experimental|Intervention|Patients that qualify for the intervention will receive the Samsung Gear virtual reality experiences and will participate in a brief survey about their opinions and preferences once the experiences are completed.
2566315|NCT02456987|No Intervention|Control|Age and sex matched control participants will be asked to answer a series of satisfaction questions after the study recruitment period is over. These individuals will have been inpatients during the same time as the intervention participants.
2566369|NCT02456779||Erosive Esophagitis|"Patients diagnosed with GERD with erosive esophagitis present on routine endoscopy during the previous 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
2566370|NCT02456779||non erosive reflux disease|"Patients diagnosed with GERD with erosive esophagitis not present on routine endoscopy during the last 6 months.~RDQ greater or equal to 12~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire"
2566371|NCT02456779||healthy controls|"No GERD symptoms RDQ = 0 RSI = 0-9~Saliva samples to be obtained intervention: in vitro diagnostic test Peptest intervention: questionnaire intervention: questionnaire"
2566454|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
2566457|NCT02456363|Experimental|NSAIDs(+) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of NSAIDs and no sulfasalazine
2566460|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(+)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) combine with use of sulfasalazine and no NSAIDs
2566464|NCT02456363|Experimental|NSAIDs(-) and sulfasalazine(-)|use TNF alpha: Adalimumab (Humira)、Etanercept (Enbrel) or Golimumab (Simponi) neither NSAIDs nor sulfasalazine
2566551|NCT02455674||Age under 6 years|"All children 1 to 6 years~Used formula for weight calculation:~Children 1-5 years: Weight (kg) = (2 × age in years) + 8"
2566552|NCT02455674||Age over 6 years|"All children 6 to 12 years~Used formula for weight calculation:~Children 6-12 years: Weight (kg) = (3 × age in years) + 7"
2566599|NCT02455401|Experimental|high dose remifentanil group|Intervention: high dose remifentanil will be administrated.
2566605|NCT02455401|Experimental|low dose remifentanil group|Intervention: low dose remifentanil will be administrated
3207441|NCT00964808|Experimental|Oxycodone|"Double Dummy:~Group B: Placebo Buprenorphine and Active Oxycodone"
3207442|NCT00964821||Flu vaccine|Patients and normal volunteers who have received a flu vaccine
3207443|NCT00964821||Non-vaccine|Patients and normal volunteers who have not received the flu vaccine
3207444|NCT00964834|Experimental|Doxycycline and Valortim|Randomized such that sixteen volunteer subjects to be renadomized to receive Doxycycline and Valortim
3207445|NCT00964834|Experimental|Placebo Antibiotic and Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Valortim.
3207446|NCT00964834|Experimental|Placebo Antibiotic and Placebo Valortim|Randomized such that four volunteer subjects to receive Placebo Antibiotic and Placebo Valortim.
3207447|NCT00964847|Active Comparator|Blood pressure education/walking program|
2565530|NCT02462265|Experimental|'Oshadi D & Oshadi R; salvage therapy'|Oshadi D (180mg/tid) & Oshadi R (180mg/tid) will be administrated orally; Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days) will be administrated
2565573|NCT02461875|Active Comparator|Cabergoline group|Cabergoline is administered starting on the day of HCG administration.
2565581|NCT02461875|Experimental|GnRH antagonist rescue & cabergoline group|Converting a long GnRH agonist cycle to an GnRH antagonist cycle (GnRH antagonist rescue) and Cabergoline is administered starting on the day of HCG administration.
2565631|NCT02461472||Dr.Tang's research group|Dr.Tang's research group for clinical risk analysis of human complex disease
2565689|NCT02461095|Active Comparator|Impairment based approach|The intervention will address the patients impairments found during evaluation. Treatment will based on the Physical therapist evaluation and will be individualized to each patient.
2565700|NCT02461095|Experimental|PFPS algorithm|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
3207448|NCT00964847|Active Comparator|Combined intervention|
3207449|NCT00964847|Experimental|Yoga Exercise Program|
2565837|NCT02460107|Placebo Comparator|Normal saline|Normal saline
2565845|NCT02460107|Active Comparator|Botulinum toxin type A 50U|Botulinum toxin 50U
2565848|NCT02460107|Active Comparator|Botulinum toxin type A 100U|Botulinum toxin 100U
2565931|NCT02459834|Experimental|Allulose + 75g OGTT|Allulose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
2565935|NCT02459834|Experimental|Fructose + 75g OGTT|Fructose added to a 75 g OGTT of 500 mL at 2 doses (5g and 10g). The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
2565940|NCT02459834|Active Comparator|75g OGTT (Control)|A 75 g OGTT (alone) of 500 mL will be given to each participant. The drinks will be matched as much as possible in appearance, taste (sweetness), texture, and packaging.
3207450|NCT00964873|Experimental|1 Part 1|
3207451|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 1)|
3207452|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 2)|
2566045|NCT02458755|Experimental|High-dose statin treatment|Atorvastatin (40mg) or Rosuvastatin (20mg)
2566099|NCT02458508||GBM patients|patients with diagnosis of glioblastoma treated with concomitant radio-chemotherapy with temozolomide as Stupp protocol will be evaluated for pharmacogenetic evaluation
2566179|NCT02458248|Experimental|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day).
2566180|NCT02458248|No Intervention|Usual care|For all participants, standard care will be provided at the nephrology clinic at GUH or by local general practitioners, and includes treatment of hypertension, underlying comorbidities and optimizing the metabolic profile. Participants randomized to usual care will also attend a dietitian-developed healthy eating guidance session but will not receive specific recommendations targeting sodium intake.
2566203|NCT02457689|Placebo Comparator|Group 1 (Transcutaneous and Placebo)|Group 1 (Transcutaneous and Placebo) Participants will receive 1.0ml intramuscular injections of the vaccine Sodium Chloride BP into the upper thigh. Participants will also have a further 0.2ml of Sodium Chloride BP delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
2566211|NCT02457689|Active Comparator|Group 2 (Transcutaneous and Active)|Group 2 (Transcutaneous and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2 mg/ml) into the upper thigh. Participants will also have a further 0.2ml of the vaccine (2mg/ml) delivered transcutaneously. An area of skin of approximately 4 x 4cm will be photographed and prepared first. During this preparation, the area is shaved to remove the hair, and then superglue is applied to remove the top layer of skin (like waxing). The vaccine is spread onto the skin surface. Once applied, the area is covered with a comfeel bandage, the investigator will ask volunteers to not engage in strenuous exercise, shower, or bathe for 24 hours afterwards.
2566214|NCT02457689|Placebo Comparator|Group 3 (Electroporation and Placebo)|Group 3 (Electroporation and Placebo) Participants will receive 1.0ml intramuscular injections of Sodium Chloride BP into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
2566226|NCT02458027|Placebo Comparator|Control Shake|Non-protein control shake, given once, at beginning of acute trial.
2566265|NCT02457338|Experimental|Supplement Group|This group will receive probiotic B. infantis supplementation, plus standard care and lactation consultation.
3207453|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 3)|
3207454|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 4)|
2565475|NCT02462681|Active Comparator|bupivacaine + 1 mg/kg ketamine group in paravertebral block|patients will be received 20 ml of bupivacaine 0.25% + 1mg/kg ketamine paravertebrally divide into 3-4 ml in each level
2565526|NCT02462226|Active Comparator|Arm Precaution|"Patients assigned to Education #1 will receive arm precaution self-care strategies. The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb. Exercises to promote limb mobility will also provided. Only the patients in the control group will be given access to Arm Precautions section.~Patients will be given access to the website to learn about the arm precaution program."
2565534|NCT02462226|Experimental|The-Optimal-Lymph-Flow|"The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.~Patients will be given the access to the website to learn about the The-optimal-Lymph-Flow program"
2565572|NCT02461888|Experimental|Ixazomib, CD|"Ixazomib, cyclophosphamide and dexamethasone (ICD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Ixazomib 4mg orally on days 1, 8 and 15~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
2565578|NCT02461888|Active Comparator|CD|"Cyclophosphamide and dexamethasone (CD) will be administered as part of a 28 days cycle until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Cyclophosphamide 500mg orally on days 1, 8 and 15~Dexamethasone 40mg orally on days 1-4 and 12-15"
2565622|NCT02461368|Experimental|anterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
2565625|NCT02461368|Active Comparator|posterior approach|Ultrasound-guided anterior approach of glenohumeral joint injection for primary adhesive capsulitis of shoulder. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
3207455|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 5)|
3207456|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 6)|
3207457|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 7)|
2565887|NCT02460055|Active Comparator|Endotracheal tube|Following routine inhalation induction with 8% sevoflurane in oxygen and nitrous oxide, 100% oxygen will be administered and intravenous access will be secured. Intravenous administration of Propofol 3mg/kg and Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation with an age appropriate endotracheal tube. Presence of an audible air leak around the endotracheal tube will be addressed by inflating the cuff with air until the audible leak is no longer appreciated. The endotracheal tube will not be lubricated prior to intubation. Other medications that will be administered during the procedure include Dexamethasone at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg.
2565890|NCT02460055|Active Comparator|No Endotracheal tube|Those not receiving endotracheal intubation will undergo an inhalation induction, have intravenous access secured and intravenous propofol 3mg/kg with Fentanyl 1mcg/kg will be administered prior to placement of the nasal trumpet and connection to the anesthesia circuit.patients will receive a general anesthetic consisting of sevoflurane in oxygen and air at routine concentrations for maintenance of anesthesiaOther medications that will be administered during the procedure to both arms of patients include Dexamethasone which will be administered at a dose of 0.15mg/kg up to 20 mg and Ondansetron 0.15mg/kg up to 4mg for post operative nausea and vomiting prophylaxis.
2565947|NCT02459470|Experimental|SVV and PPV|"SVV(stroke volume variation): recorded using the Flotrac/Vigileo system (Edwards Lifesciences)~PPV(pulse pressure variation): recorded using philips Intelivue MP70 monitors (Philips Medical System)~Intervention: Other: Fluid loading using HES 130/0.4; voluven; Fresenius Kabi; Stans, Switzerland"
2566015|NCT02459132|Experimental|Exercise Group|Subjects in the exercise group will attend supervised exercise sessions three times a week, for 12 weeks. The exercise intervention will consist of uphill walking or jogging on a treadmill between 50% and 95% of VO2peak for 35 minutes (including a 5-minute warm up and cool down). The participants will complete four, 4-minute, high-intensity intervals at 85-95% of VO2peak. The work period intervals will be interspersed with three, 3-minute periods of active recovery at an intensity below that of their ventilatory threshold.
2566016|NCT02459132|No Intervention|Usual Care|The usual care group will not receive an intervention, and they will be asked to maintain baseline physical activity levels throughout the observation period.
2566054|NCT02458716|Experimental|Surgery followed by hormone therapy (ADT)|Patients undergo Robotic Assisted Radical Prostatectomy (RARP) or conventional open retropubic radical prostectomy (RRP). Immediately following surgery, patients receive the standard systemic androgen deprivation therapy.
3207458|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 8)|
3207459|NCT00964912|Active Comparator|BMS-820836 (Part 1, Panel 9)|
2566191|NCT02457845|Experimental|HSV G207|"Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI. If G207 is safe in the first two cohorts of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor defined by MRI followed by a 5 Gy dose of radiation to the tumor given with 24 hours of virus inoculation.~Intervention: Biological: G207"
2566277|NCT02457481|Experimental|Embryo Culture medium|Embryos from each patient are randomly allocated to culture in the commercial or experimental embryo culture medium (half of the embryos in commercial and half in experimental medium).
2566387|NCT02456441|Placebo Comparator|Placebo group|Will be obtained the evolution parasympathetic and sympathetic system 10 minutes after placebo current application, through Heart Hate Variability analysis. p. The placebo group will receive transcutaneous electric stimulation, for 30 seconds and then will gradually decrease by 15 seconds to not pass any current. This approach will aim to masking of the subject.
3207460|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel A)|
3207461|NCT00964912|Active Comparator|BMS-820836 (Part 2, Panel B)|
2565517|NCT02462200|Experimental|CSM Arm (breast-conserving surgery with cavity shave margins)|"Partial mastectomy, lumpectomy, or local excisional biopsy with or without needle/wire localization with the addition of additional tissue specimens from all 6 margins (anterior, posterior, superior, inferior, medial, lateral) of the wound cavity if possible. In cases where an additional margin would involve the skin at the anterior margin and/or the pectoral muscle at the posterior margin, only the 4 (or 5) remaining margins should be obtained~A margin thickness of 1 cm will be the defined goal to establish uniformity among different surgeons and allow for appropriate pathological evaluation~The ICG will be prepared per manufacturer instructions and diluted to allow for intravenous dosing up to 0.5 mg/kg (no iodine or seafood allergies).~Following the BCS procedures, the surgeon or a study team member will don the goggles and state the NIR fluorescence margin information of the excised primary tumor specimen and of any CSM that are taken."
3207462|NCT00964951|Experimental|Group 3: 15 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3207463|NCT00964951|Experimental|Group 1: 3.75 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 3.75 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
3207464|NCT00964951|Experimental|Group 4: 7.5 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3207465|NCT00964951|Experimental|Group 2: 7.5 mcg H1N1 vaccine + AS03 adjuvant|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 7.5 mcg H1N1 vaccine plus AS03 adjuvant on Day 0 and Day 21.
2565652|NCT02461251|Experimental|Rotational thromboelastometry (ROTEM)|"Rotational thromboelastometry results are used to guide the treatment of major obstetric hemorrhage, eg. administration of prothrombin complex concentrate, fresh-frozen plasma, fibrinogen concentrate or platelets. In case of massive hemorrhage, shock packs of blood products in 1:1:1 ratio are administered."
2565655|NCT02461251|No Intervention|Standard care|"Patients are treated according to clinical decision making and conventional coagulation tests, and in case of massive hemorrhage, shock packs are administered."
2565681|NCT02460965||Patients with schizophrenia|
2565694|NCT02460965||Patients with borderline personality disorder|
2565705|NCT02460965||Patients with hearing impairment|
2565711|NCT02460965||Patients with visual loss|
2565716|NCT02460965||Patients with Parkinson's Disease|
2565718|NCT02460965||Patients with Alzheimer's Disease|
2565724|NCT02460965||Patients with dementia with Lewy Bodies|
2565728|NCT02460965||Healthy participants|
2565787|NCT02460692|Placebo Comparator|Placebos|The present study is designed to evaluate whether or not a medium dose of cannabis (3.7% delta-9-THC/5.6% CBD) can maintain an analgesic response over an eight week period compared to placebo.
2565791|NCT02460692|Active Comparator|Dronabinol|A direct comparison of cannabis and dronabinol has not been performed in a clinical population. The present study will fill this void by performing a randomized, controlled 8 week trial comparing the effectiveness of oral versus vaporized cannabis in patients with neuropathic low back pain.
2565796|NCT02460692|Experimental|Vaporized Cannabis 3.7% THC/5.6% CBD|The eight week outpatient study will compare the efficacy and side effect profile of cannabis (3.7%THC/5.6%CBD) and dronabinol. We will also perform a human laboratory experiment evaluating driving using the same study medications that subjects received during their 8 week outpatient treatment.
3207466|NCT00964951|Experimental|Group 5: 15 mcg H1N1 vaccine unadjuvanted|150 subjects (100 aged 18-64 and 50 aged greater than or equal to 65) to receive 15 mcg H1N1 vaccine unadjuvanted on Day 0 and Day 21.
3207467|NCT00964964|Experimental|SIBA 3W|
2565914|NCT02459652|Experimental|Neoadjuvant S-1/RT|This is a single arm prospective study. All eligible subjects will receive neoadjuvant S-1 and concurrent radiation followed by surgical resection. Subjects may receive adjuvant chemotherapy after surgical resection at the clinical discretion of the medical oncologists.
2565959|NCT02459301|Experimental|IPH2201|"Part 1: 1, 4 or 10mg/kg, IV, 1 hour duration on Day 1 every 2 weeks.~Part 2: Patients will receive single agent IPH2201 as above with the actual dose dependent on the outcome of Part 1"
2566021|NCT02459028|Experimental|T3P Intervention group|"Intervention group: Participants are instructed to practice 4 out of 10 different Positive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
2566023|NCT02459028|Active Comparator|Control group|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
2566098|NCT02458677|Experimental|PRX003|
2566107|NCT02458677|Placebo Comparator|Placebo|
2566154|NCT02458222|Experimental|game therapy then standard therapy|participants will take part in language game therapy followed by standard aphasia therapy
2566159|NCT02458222|Experimental|standard therapy then game therapy|participants will have standard aphasia therapy first then will take part in language game therapy
3207468|NCT00964964|Experimental|SIBA OD|
3207469|NCT00964977|No Intervention|no irradiation|Patients within this arm only receive curative intended radical surgery
3207470|NCT00964977|Active Comparator|Radiation|Patients receive radiation within 6 weeks after curative intended radical surgery.
2566446|NCT02456220|Experimental|Herbst Group|Patients treated with Herbst appliance.
3207471|NCT00964990|Experimental|001|JNJ-42160443 SC injection (1 3 or 10 milligrams) once every 28 days
3207472|NCT00964990|Placebo Comparator|002|Placebo SC injection once every 28 days
3207473|NCT00965003|Experimental|MRI scan with surface coil|Patients with known laryngeal cancer, with suspected cartilage involvement by conventional computed tomography scanning, who undergo high resolution magnetic resonance imaging enhanced with a surface coil placed over the larynx.
3207474|NCT00965016|Sham Comparator|No Hypothermia, No intervention, ECMO|No hypothermia used during ECPR
3207475|NCT00965016|Active Comparator|Hypothermia, intervention, ECMO|Hypothermia + intervention
2565523|NCT02462135|Experimental|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each).
2565531|NCT02462135|Active Comparator|Passive information activities|The training of active control group is the same as VIMT group (45 min/day, 3 days/week, for 12 weeks, for a total of 36 sessions). The active control group receives only the initial training.
2565558|NCT02461849|Experimental|Imatinib|Imatinib 400mg qd daily Until disease progression, patient's refusal
3207476|NCT00965016|Active Comparator|Hypothermia, no intervention, ECMO|Hypothermia without intervention after ECMO
3207477|NCT00965042|Experimental|Ceftobiprole|Ceftobiprole 500 mg by 2 hour intravenous infusion every 8 hours for 7 days
2565697|NCT02461173|Active Comparator|Stimulated IUI|On the 3rd day of menstruation women in group 1 will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins starting from the 3nd day of menstruation. On day 8 the ultrasound will be repeated and serum E2 will be measured, hMG dose will be adjusted and continued and the frequency of ultrasound scans will be individualized. HMG will be stopped when at least 2 follicles measuring 18 mm are associated with serum E2 of 500-3000 Pg/mL, this was followed by the administration of 10000 IU of human chorionic gonadotropin
2565709|NCT02461173|Active Comparator|Unstimulated IUI|Women in group 2 will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit. IUI will be performed on the day after the surge in urinary excretion of luteinizing hormone.
2565714|NCT02461173|Active Comparator|Control group|Women will be asked to test their urine for luteinizing hormone by the same method as group 2. They will be asked to have an intercourse on the day after the surge in urinary excretion of luteinizing hormone and this will be repeated for 12 months.
3207478|NCT00965107|Experimental|Thiopental|Thiopental for induction of anaesthesia.
3207479|NCT00965107|Active Comparator|Propofol|Propofol for induction of anaesthesia.
2565839|NCT02460133|Other|HCV Genotype 1, with and without cirrhosis|
2565898|NCT02459821|Experimental|Robot-assisted gait training group|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
2565908|NCT02459821|Active Comparator|Conventional training group|The group will be subjected to conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
2566048|NCT02458937||Osteonecrosis|"Observational measures of functional outcomes will be obtained from all participants who consent to and complete the study.~Interventions: Functional Mobility Assessment (FMA), GAITRite® System, and Range of Motion."
2566118|NCT02458391|Experimental|Treatment 2x/wk|Participants will receive standard of care complete decongestive therapy 2x/wk for 4 weeks.
2566122|NCT02458391|Experimental|Treatment 4x/wk|Participants will receive standard of care complete decongestive therapy 4x/wk for 4 weeks.
2566175|NCT02458040||Biomarker-positive patients|
2566182|NCT02458040||Biomarker-negative patients|
2566183|NCT02458040||All patients|
3207480|NCT00965120|Placebo Comparator|1|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of placebo (saline).
2566379|NCT02456402|Experimental|Drug Coated Balloon|PCB (SeQuent Please®, paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany)
2566384|NCT02456402|Active Comparator|Bare Metal Stent|BMS (Vision®)
2566444|NCT02456233|Active Comparator|Conventional AF Ablation with PVI|These patients will be treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
2566451|NCT02456233|Experimental|FIRM-guided ablation plus PVI|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM). Conventional ablation (PVI) will then be performed as part of the standard of care procedure.
2566501|NCT02455830||Cell-treated|Infants with encephalopathy who receive autologous umbilical cord blood cell therapy along with therapeutic hypothermia.
2566509|NCT02455830||Cooled only|Infants with encephalopathy who receive therapeutic hypothermia only.
2566613|NCT02455440|Active Comparator|Esmolol|500 mcg/kg of esmolol bolus 10 min before induction of anesthesia, followed by additional 200 mcg/kg/min of esmolol until 30 minutes after extubation.
2566619|NCT02455440|Placebo Comparator|control|Control group did not receive esmolol or other b-blocker in the perioperative period.
2566646|NCT02454881|Active Comparator|Placebo|Oxycodone 1 mg / ml alone
2566655|NCT02454881|Active Comparator|Dexmedetomidine 2.5|Oxycodone 1 mg / mL + Dexmedetomidine 2,5 μg / mL
2566664|NCT02454881|Active Comparator|Dexmedetomidine 5|Oxycodone 1 mg / mL + Dexmedetomidine 5 μg / mL
3207481|NCT00965120|Active Comparator|2|Ischaemia 20 minutes. Blood pressure cuff will be inflated to 200mmHg around the upper arm for 20 minutes to induce ischaemia. Systemic infusion of bradykinin receptor antagonist (HOE-140).
3207482|NCT00965133|No Intervention|Normal daily activity|
3207483|NCT00965172|Experimental|Caphosol|Caphosol (calcium phosphate)
3207484|NCT00965172|Active Comparator|Baking Soda|Control Group (standard of care)
3207485|NCT00965198||Clearlink Arm, EUH|Standard catheter access device at Emory University Hospital
3207486|NCT00965198||VLINK Arm, EUHM|Novel, silver-coated catheter access device at Emory University Hospital Midtown
3207487|NCT00965198||Clearlink, EUM|Standard catheter access device at at Emory University Hospital Midtown
2565643|NCT02461381||Dr.Tang's research group|This group included diabetic participants with completed both the short-term HRV test and Ewing's test.
2565699|NCT02461043|Experimental|Arm A|chemotherapy and radiotherapy
2565708|NCT02461043|Active Comparator|Arm B|radiotherapy
3207488|NCT00965198||VLINK Arm, EUH|Novel, silver-coated catheter access device at Emory University Hospital
2565840|NCT02460094|Experimental|Panel 1: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
2565847|NCT02460094|Experimental|Panel 2: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
2565850|NCT02460094|Experimental|Panel 3: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
2565851|NCT02460094|Experimental|Panel 4: BIIB092/ Placebo|BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks.
2565894|NCT02459743||Patients with hematological malignancies|Patients with a conclusive diagnosis of haematological malignancies according to WHO criteria referred to the Rete Ematologica Lombarda (REL) clinical network will be enrolled. The investigators will analyse genomic DNA extracted from hematopoietic cells at different time points of patient disease. The study contemplates the use of two optimized molecular platforms aimed at the identification of recurrent mutations in myeloid and lymphoid neoplasms, respectively. Screening of gene mutations by NGS will be prospectively implemented in the context of REL clinical network. Patient samples will be analyzed at diagnosis and sequentially during the course of the disease at specific timepoints.
2565923|NCT02459522||Dr.Tang's research group|This group included participants with completed both the short-term HRV test and Ewing's test.
2565980|NCT02459288|Experimental|Clopidogrel first|Clopidogrel (Plavix) 75 mg qd, 2 weeks; followed with Ticagrelor (Brilinta) 90 mg bd, 2 weeks
2565982|NCT02459288|Experimental|Ticagrelor first|Ticagrelor (Brilinta) 90 mg bd, 2 weeks; followed with Clopidogrel (Plavix) 75 mg qd, 2 weeks
2566033|NCT02458976|Experimental|PDL|Pre-treatment of surgical area with PDL
2566081|NCT02458599|Experimental|Test product|One ready-to-drink beverage of 500 milliliter (mL) volume, containing 20 gram (g) protein will be administered orally, twice daily for four days.
2566082|NCT02458599|Active Comparator|Reference product 1|One ready-to-drink beverage of 500 mL volume, containing 20 g carbohydrate will be administered orally, twice daily for four days.
2566084|NCT02458599|Placebo Comparator|Reference product 2|One ready-to-drink beverage of 500 mL volume, containing 0 g carbohydrate will be administered orally, twice daily for four days.
2566135|NCT02458300|Placebo Comparator|Control Arm|Nebulized hypertonic saline. Aspiration of secretions
2566136|NCT02458300|Active Comparator|Intervention Arm.|Nebulization of hypertonic saline. Application of Prolonged slow expiration technique (PSE) expiratory volume. Patient coughing Provocation (TP) Inspiratory maneuver to rhinopharyngeal cleaning DRR Aspiration of secretions
2566141|NCT02457949|No Intervention|Treatment As Usual (TAU)|Receipt of social assistance on government cheque issue days for 6 income assistance cycles (approx 26 weeks).
2566147|NCT02457949|Experimental|Staggered Arm|Receipt of social assistance once monthly on a randomly assigned day that does not fall during the week of government cheque issue (Non-synchronized social assistance receipt), for 6 income assistance cycles (approx 26 weeks).
2566155|NCT02457949|Experimental|Staggered and Split Arm|Receipt of social assistance twice monthly on equally spaced randomly assigned days that do not fall during the week of government cheque issue (Non-synchronized social assistance receipt, cheque divided into two equal disbursements), for 6 income assistance cycles (approx 26 weeks).
2566224|NCT02457806|Experimental|Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in each nostril (bilateral dosing) administered 4 minutes apart
2566232|NCT02457806|Active Comparator|Kovacaine Mist and Placebo|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the right nostril and three sprays of placebo in the left nostril (right-sided unilateral dosing) administered 4 minutes apart
2566233|NCT02457806|Active Comparator|Placebo and Kovacaine Mist|3 sprays of Kovacaine Mist (Tetracaine HCl 3% and Oxymetazoline HCl 0.05%) in the left nostril and 3 sprays of placebo in the right nostril (left-sided dosing) administered 4 minutes apart
2566235|NCT02457806|Placebo Comparator|Placebo spray|3 sprays of placebo in each nostril administered 4 minutes apart
2566526|NCT02455921|Active Comparator|sugammadex|iv sugammadex 2 mg/Kg
3207489|NCT00965224|Experimental|standard therapy + vaccination|
3207490|NCT00965224|No Intervention|standard therapy|
3207491|NCT00965289|Experimental|HDT combined with rituximab before ASCT|The study treatment consisted on 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose methotrexate with cytarabin. For patients who achieved at least a PR, ASCT started with a BEAM regimen.
3207492|NCT00965302|Active Comparator|Intensive medical management of Type 2 DM|Intensive medical management of Type II diabetes will include visits every three months for a year with an endocrinologist, with lifestyle counseling, weight management, regular exercise, and glucose control forming the core of the medical therapy.
3207493|NCT00965302|Experimental|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy is performed as part of a bariatric surgical program emphasizing healthy dietary choices, regular exercise, and glucose control.
3207494|NCT00965328|Active Comparator|hemofiltration at 4L/h|Hemofiltration was started at 4L/h and crossed over to 2L/h after 60 minutes of hemofiltration
3207495|NCT00965328|Active Comparator|hemofiltration at 2L/h|hemofiltration was started at 2L/h and crossed over to 4L/h after 60 min
3207496|NCT00965354||Influenza diagnosis|Patients admitted to hospital with a suspected or confirmed influenza diagnosis on admission
3207497|NCT00965367|Experimental|Acustimulation|
2565617|NCT02461329|Experimental|Gelatine solution|"Gelofusine will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
2565618|NCT02461329|Experimental|Balanced Crystaloid solution|"Ringerfundin will be administrated like fluid challenge - 250ml of solution will be infused within 5 minutes in case of hypotension ( mean arterial pressure - MAP below 65 mmHg or below 70mmHg in patient with chronic hypertension disease).~The blood pressure and heart rate before and after fluid challenge will be recorded."
3207498|NCT00965367|No Intervention|Standard treatment group|
3207499|NCT00965393|Placebo Comparator|1|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of placebo (saline).
3207500|NCT00965393|Active Comparator|2|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, remote ischaemic preconditioning will be induced by inflating a cuff around the dominant arm to 200 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times. Systemic infusion of bradykinin receptor antagonist (HOE-140).
3207501|NCT00965406|Placebo Comparator|glucose insulin potassium (GIK)|Glucose + insulin +6 potassium (GIK) infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours.
3207502|NCT00965406|Experimental|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
3207503|NCT00965406|No Intervention|Control group|No intervention and patients were treated with updated international recommendations of acute coronary syndrome.
3207504|NCT00965432|Placebo Comparator|Placebo|
3207505|NCT00965432|Active Comparator|STX107|
3207506|NCT00965445||cardiac surgery with CPB|
3207507|NCT00965471|Experimental|managed group|
3207508|NCT00965471|Placebo Comparator|control group|
3207509|NCT00965510|Experimental|Care Coordination|Patients receive care coordination to improve their diabetes.
3207510|NCT00965510|No Intervention|control|patients with type II diabetes receive usual health care
2565899|NCT02459639||Anthroposophic integrative care|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
2565903|NCT02459639||Multimodal pain rehabilitation|"Inclusion criteria are: Pain patients with a primary diagnosis corresponding to ICD-10 M79, or long-term pain for a period of over 3 months in neck/shoulders and/or low back, or generalised pain, fluency in Swedish and allowing for co-morbidity/ multiple secondary diagnoses.~The exclusion criteria are: psychotic illness, schizophrenia, bipolar disorder, substance dependency problems, and cancer."
2565946|NCT02459457|Active Comparator|Paclitaxel and Cisplatin (TP)|Patients receive TP concurrent with radiotherapy (1.8Gy/d, d1-5/week, 34Fx) Paclitaxel: 175mg/m2/d, ivgtt over 3 hours, d1; Cisplatin: 25mg/m2/d, ivgtt, d1-3, q4w*4
2565950|NCT02459457|Active Comparator|Paclitaxel and Fluorouracil (TF)|Patients receive TF concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; 5-FU 300mg/m2, civ 96h, d1-4, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; 5-FU 1800mg/m2, civ 72h, d1-3, q4w*2
2565954|NCT02459457|Active Comparator|Paclitaxel and Carboplatin（TC）|Patients receive TC concurrent with radiotherapy(1.8Gy/d, d1-5/week, 34Fx) Concurrent: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=2, ivgtt, d1, qw*6; Adjuvant: paclitaxel 175 mg/m2/d, ivgtt over 3 hours, d1; carboplatin AUC=5, ivgtt, d1, q4w*2
2566065|NCT02459002||NSCLC - Current Palliative Care Referral Practices|Early palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
2566066|NCT02459002||Primary Caregiver|Caregiver satisfaction with quality of care and early palliative consultation impact assessed via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
2566069|NCT02459002||NSCLC - After Early Palliative Care Consult System|Palliative consultation impact assessment via questionnaires during a regularly scheduled clinic visit or during inpatient stay.
2566115|NCT02458339|Experimental|Experimental|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle will be of 4 weeks duration. During the first 3 weeks, methotrexate will be infused twice weekly on days 1 and 4 (+/- 2 days). The 4th week is a rest week.
2566193|NCT02458027|Experimental|20g Hemp Protein Shake|Hemp protein shake, 20 grams, given once at beginning of acute trial.
2566201|NCT02458027|Experimental|40 g Hemp Protein Shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial.
2566208|NCT02458027|Active Comparator|20 g Soybean Protein Shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial.
2566215|NCT02458027|Experimental|40 g Soybean Protein Shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial.
3207511|NCT00965536||1|Seroquel
3207512|NCT00965536||2|Seroquel Prolong
3207513|NCT00965549|Experimental|Lantus + Apidra basal plus one|"Before randomization (common with arm 2):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day"
3208887|NCT00979043|Active Comparator|Dietary weight-loss & exercise|Participants received both the dietary weight-loss and exercise interventions for 18-months
2565779|NCT02460588|Placebo Comparator|Corticosteroid with placebo|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid."
2565782|NCT02460588|Experimental|Corticosteroid associated with Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~All patients will receive non experimental medication with high dose of corticosteroid.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
3207514|NCT00965549|Active Comparator|NovoMix 30 Biphasic|"Before randomization (common with arm 1):~A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy.~8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued.~After randomization:~24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)"
3207515|NCT00965588|Experimental|Vaccine (UB 311)|
2565901|NCT02459626||HFpEF and servere diastolic dysfuntion|Left ventricular ejection fraction (LV-EF) > 50%, echocardiographic criteria for diastolic dysfunction, New York Heart Association classification (NYHA)=>2, Diagnostic P-V-loops and MRI
2565904|NCT02459626||HFpEF no servere diastolic dysfuntion|LV-EF > 50%, no echocardiographic criteria for diastolic dysfunction, NYHA=>2, Diagnostic P-V-loops and MRI
2565912|NCT02459626||No HF or diastolic dysfunction|LV-EF > 50%, no diastolic dysfunction, no heart failure, Diagnostic P-V-loops and MRI
2565930|NCT02459405|Experimental|NIR anastomotic perfusion assessment|"Patient will have their anastomosis assessed after they receive 7.5 to 9 mg of Indocyanine green intravenously (at a concentration of 2.5mg/ml).~The microvascularisation assessment will be performed using a near infrared device(Pinpoint device), allowing to increase reality.~This procedure will be repeated twice during the surgery, the first time before and the second time after the anastomosis has been done."
2566053|NCT02459158|Experimental|Low dose of ME1100|
2566057|NCT02459158|Experimental|High dose of ME1100|
2566125|NCT02458326|Experimental|Aerobic Training|The experimental group will follow the protocol: performing heating for 5 minutes at low speed on a treadmill; after heating, the speed is increased gradually until the patient reaches the proper heart rate for aerobic training obtained during cardiopulmonary exercise testing, maintaining the same for 20 minutes to perform the aerobic workout; completed, the velocity will be decreased to regain speed heating maintained for 5 minutes and finishing training. It is envisaged that in practice using the FC to ensure proper aerobic exercise for 20-60 minutes at a frequency of 3-5 times per week are effective in increasing the functional capacity of individuals with low fitness
2566126|NCT02458326|Other|Control Training|In the control group, these women will be guided to perform 10 minutes of heating on the treadmill with a low speed that does not cause patient effort (monitored by the Borg scale and FC close to the basement).
2566149|NCT02458014|Experimental|Treatment (blinatumomab)|Patients receive blinatumomab IV continuously on days 1-28. Treatment repeats every 6 weeks for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients who do not proceed with stem cell transplantation may receive blinatumomab IV maintenance therapy with one cycle every 3 months for up to 4 cycles. Patients who remain in MRD remission for 3 months and then become MRD positive again can be retreated following the same treatment plan previously received.
2566256|NCT02457559|Experimental|Tirabrutinib|Participant will receive tirabrutinib once or twice daily for up to 5 years.
2566288|NCT02457169|Experimental|Parent Engagement Intervention group|This group of parents will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool.
2566294|NCT02457169|Other|Attention Control|Waitlist Control Group: This group will receive the brief, 2-4 hour intervention which will utilize motivational interviewing principles to enhance parents' preschool engagement as their children transition from Early Intervention to preschool after a 3 month delay.
2566325|NCT02457013|Experimental|HFNC treatment|HFNC : High flow nasal canula 24hours Patients will be treated by a High flow nasal canula (HFNC: 2l/kg/min) for the initial management of their bronchiolitis (24 hours)
2566328|NCT02457013|Active Comparator|nCPAP treatment|nCPAP : nasal NCPAP Patients will be treated by a nasal CPAP (n-CPAP: 7 cmH2O) for the initial management of their bronchiolitis (24 hours)
2566397|NCT02456714|Experimental|Progressive cholangiocarcinoma, second line treatment|FOLFIRINOX
2566468|NCT02456207|Experimental|Experimental|SCT400:375 mg/m2, iv, one infusion
2566473|NCT02456207|Active Comparator|Active Comparator|Rituximab: 375 mg/m2, iv, one infusion
2566531|NCT02455804|Other|Single Arm|This is a prospective, post-marketing, non-randomized, multi-center, single-arm clinical study that will be conducted at up to 15 sites in the United States (US). All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
2566615|NCT02455531||Transplant-free survivors|Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
2566666|NCT02455115|Experimental|60 mmHg|Alternating mean arterial pressure by lowering of the infusion rate of norepinephrine
2566669|NCT02455115|Experimental|75 mmHg|Alternating mean arterial pressure by adjust of the infusion rate of norepinephrine
2566671|NCT02455115|Experimental|90 mmHg|Alternating mean arterial pressure by augmentation of the infusion rate of norepinephrine
2566739|NCT02454465|Experimental|Intervention group|The first group at the top of the waiting list will receive the Acceptance and Commitment Therapy group intervention, which is 1 hour per week for six weeks.
2566742|NCT02454465|No Intervention|Waiting list group|The outcomes of those on the waiting list will be compared with those in the intervention group. Once the intervention group completes, those on the waiting list will be invited to attend the Acceptance and Commitment Therapy group intervention.
3207516|NCT00965601|Active Comparator|CTB Group|Subjects will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
3207517|NCT00965601|No Intervention|Usual Care|Subjects will not receive any type of intervention
3207518|NCT00965653|Experimental|1|
3207519|NCT00965653|Active Comparator|2|
2565820|NCT02460367|Experimental|Phase 1: Dose Escalation|Up to 18 participants will be enrolled and treated at escalating doses of Indoximod with a fixed dose of tergenpumatucel-L and docetaxel. Treatment may continue until definitive disease progression or significant toxicology.
2565876|NCT02459873|Experimental|Computer games to assess change in executive function skills|Children in Intervention group get to train using executive function games at more difficult levels.
2565877|NCT02459873|Active Comparator|Easy games as active comparators for executive function skills|Children in Non-intervention group get to play executive function games at an easy level.
3207520|NCT00965666|Experimental|Open Label|
3207521|NCT00965705|Active Comparator|Guided Self Help|
2565991|NCT02459223|Active Comparator|Test Group|Treated with nutritional biscuits and khichadi. Nutritional biscuits providing 2.5 to 3 gm Protein and 90-100kcal/kg body Weight/day, as well as local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
2565993|NCT02459223|Active Comparator|Control Group|Treated with only local food Khichadi (Rice and hulled split green gram cooked together with spices) for the three months period.
2566017|NCT02458859|Active Comparator|PICO|PICO Negative Pressure Wound Therapy (NPWT) system
2566018|NCT02458859|No Intervention|Standard care|Standard care
2566094|NCT02458573|Experimental|continuous epidural analgesia group|
2566104|NCT02458573|Active Comparator|continuous intravenous analgesia group|
2566148|NCT02458209|Active Comparator|Treatment A|150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Pfizer Andover
2566158|NCT02458209|Experimental|Treatment B|• Treatment B: 150 mg SC dose administered in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma
2566161|NCT02458209|Experimental|Treatment C|150 mg SC dose administered in a prefilled pen using drug substance manufactured at Pfizer Andover.
3207522|NCT00965705|Active Comparator|Cognitive Behavioral Therapy|
3207523|NCT00965705|Active Comparator|Dialectical Behavioral Therapy|
2566358|NCT02456831|Active Comparator|Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
2566360|NCT02456831|Experimental|Experimental Infant Formula 1|Experimental Ready-to-Feed Soy Formula
2566363|NCT02456831|Experimental|Experimental Infant Formula 2|Experimental Ready-to-Feed Soy Formula
2566364|NCT02456831|Experimental|Experimental Infant Formula 3|Experimental Ready-to-Feed Soy Formula
2566402|NCT02456454|Experimental|Risperidone|Risperidone, PO 0.25-2 mg/day
2566410|NCT02456454|Experimental|Valproic|Valproic Acid PO to achieve plasma levels of 85-100
2566416|NCT02456454|Placebo Comparator|Placebo|Liquid placebo PO matched for color and taste.
2566482|NCT02456116|Experimental|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
2566483|NCT02456116|Sham Comparator|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear sham-acupuncture needles bitten once (day 0-5)~Body sham-acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
2566485|NCT02456116|Other|PCA/NSAID|minimal intervention (included in every arm) standard boli of morphine by pressing a button of PCA availability in the postoperative period (day 0-4) readout once a day NSAID (non-steroid antiinflammatory drug) 2x i.v. (75mg diclofenac-sodium, 30 mg orphenadrine citrate) (day 0-4)
2566491|NCT02455700|Active Comparator|Hand driven enamel reduction|This group will have enamel reduction in the lower incisor region carried out using hand held devices
2566492|NCT02455700|Active Comparator|Rotary ( motor driven) device|This group will ahve enamel reduction in the lower incisor region carried out using a rotary (motor driven) device
2566604|NCT02455596|Experimental|Experimental|Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week.
2566686|NCT02454764|Experimental|Tenofovir + Interferon alpha 2 b|
2566687|NCT02454764|Active Comparator|Tenofovir|
2566714|NCT02454504|Active Comparator|sugammadex|this arm will receive sugammadex at the end of the surgery
2566720|NCT02454504|Active Comparator|neostigmine|this arm will receive neostigmine at the end of the surgery
3207524|NCT00965744|Experimental|Vessel sealing system LigaSure (VS group)|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
3207525|NCT00965744|No Intervention|Conventional hand-tied method (CH group)|Patients in CH group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the conventional hand-tied method.
2566883|NCT02453594|Experimental|Cohort 1|Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle for up to 24 months.
2566884|NCT02453594|Experimental|Cohort 2|Participants with RRcHL who were unable to achieve CR or PR to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months.
2566886|NCT02453594|Experimental|Cohort 3|Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.
2566920|NCT02453217|Experimental|Chinese CHIP|Chinese Health Improvement Profile (CHIP) screening and intervention
2566932|NCT02453217|No Intervention|Treatment as usual|Routine community mental health care and medical outpatient appointments
2566978|NCT02452918|Experimental|oritavancin|oritavancin, a single 1200mg IV dose, over 3 hours
2567087|NCT02452307|Experimental|Peptide vaccine|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51
2567089|NCT02452307|Experimental|Peptide vaccine + GM-CSF|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Granulocyte macrophage colony stimulating factor (GM-CSF)
2567168|NCT02451891|Active Comparator|Group 2|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 14 days
2565827|NCT02460237|Active Comparator|Arm II (control)|Participants receive a study kit that includes standard instructions for using and returning the HPV self-test device and a standard information sheet about HPV and cervical cancer. Participants are asked to complete the HPV self-test and return the test for HPV testing.
3172505|NCT00600587|Active Comparator|B|Non-erlotinib targeted NSCLC population based on EGFR gene analysis
3172506|NCT00600600|Experimental|Tigecycline|tigecycline titrated dose according to patient age and clinical status
3172507|NCT00600639|Experimental|1|non-invasive ventilation with BiPAP Vision or another ICU ventilator with NIV option
2566044|NCT02458924|Active Comparator|Schizophrenia|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
2566047|NCT02458924|Active Comparator|Bipolar disorder|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
2566051|NCT02458924|Active Comparator|First degree relatives|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
2566055|NCT02458924|Active Comparator|Health controls|Skin niacin test was performed by two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate. The two solutions were applied for one minute to the inside of the different forearms of each individual.
2566108|NCT02458482|Active Comparator|Standard Nebulizer Mask Group|"Patients randomized to this Control or standard therapy group are to receive current institutional standard therapy for moderate asthma exacerbation which includes 10 mg Albuterol combined with 1.5mg Ipratropium nebulized therapy over one hour."
2566112|NCT02458482|Experimental|AccuPAP Group|"Patients randomized to this group must also have moderate asthma exacerbation and will use an investigational device called AccuPAP to receive three allotments of Albuterol and Ipratropium in nebulized form."
2566312|NCT02456883|Experimental|gilteritinib and 14C-labeled gilteritinib|Gilteritinib will be taken once daily on study days 1 through 14 and days 16 through 47. On day 15, each participant will be given a single dose of 14C-labeled gilteritinib.
3172508|NCT00600639|Active Comparator|2|standard therapy + oxygen
2566722|NCT02454426|Experimental|Open-Label Treatment|Patients will be initiated on vortioxetine 5 mg/day for 4 days, then increased to 10 mg/day. After the week 2 visit, patients will then be increased to 20 mg/day for the remainder of the study
2566786|NCT02454205|Active Comparator|Conventional treatment 21-24 months|"Participants will receive a 6-8 month intensive phase of: Kanamycin IM 500-750mg (40-50kg) or 1000mg (51-90kg) daily, Moxifloxacin 400mg od, Pyrazinamide 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily,Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~The continuation phase will start after 2 consecutive negative sputum cultures and continue for 18 months with Moxifloxacin, PZA, Ethionamide and Terizidone.~In 2016 the WHO revised the treatment guidelines for MDR-TB. The South African National Tuberculosis Program adopted these recommendations and it was integrated into the study in September 2016: SA NTP recommended shorter regimen(9-12 months):Intensive phase (4-6 months): kanamycin, levofloxacin, clofazimine, pyrazinamide, high-dose isoniazid/ethionamide, ethambutol. Continuation phase (5 months): levofloxacin, clofazimine, pyrazinamide, ethambutol."
2566794|NCT02454205|Experimental|Interventional treatment 6-9 months|"Participants will receive six to nine months of oral:~Linezolid 600mg daily (reduce to 300mg if toxicity occurs), Bedaquiline 400mg for 2 weeks, followed by 200mg three times per week, Levofloxacin 750mg (<50kg) or 1000mg (>50kg) daily, PZA 1000-1750mg (40-50kg) or 1750-2000mg (51-70kg) or 2000-2500mg (71-90kg) daily, Ethionamide 15mg/kg (max 900mg) daily, or high-dose Isoniazid 500mg (40-50kg) or 750mg (51-70kg) or 750-1000mg (71-90kg) daily, or Terizidone 750mg (40-70kg) or 750-1000mg (71-90kg) daily.~A gene-directed diagnostic approach will be used in the interventional arm to individualise therapy and to inform on the use of high dose INH versus ethionamide. Treatment will stop after 3 consecutive negative sputum cultures."
2566876|NCT02453633|Experimental|Emotional SMS text|Patients in this arm will receive an emotion-based SMS reminder of their scheduled outpatient clinic appointment.
2566880|NCT02453633|Active Comparator|Standard SMS text|Patients in this arm will receive the standard SMS reminder of their scheduled outpatient clinic appointment.
2566934|NCT02453308|Active Comparator|ACT-arms|"1.1 Artemether-lumefantrine for 3 days.~1.2 Dihydroartemisinin-piperaquine for 3 days~1.3 Artesunate-Mefloquine for 3 days"
2566937|NCT02453308|Active Comparator|TACT-arms|"2.1: Artemether-lumefantrine for 3 days.plus: Amodiaquine for 3 days.~2.2: Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days.~2.3 Dihydroartemisinin-piperaquine for 3 days. plus: Mefloquine hydrochloride for 3 days."
2566985|NCT02452827||Primary Chronic Neck Pain|Patients suffering for at least 3 years from neck pain without any underlying pathology who have undergone MRI. Biomechanical parameters of neck movements will be investigated.
2566993|NCT02452827||Control|Patients without neck pain who have undergone MRI for any reason. Biomechanical parameters of neck movements will be investigated.
3172509|NCT00600652||1|glucocorticoid-resistant patients
3172510|NCT00600652||2|glucocorticoid-sensitive patients
3172511|NCT00600652||3|normal controls
3172512|NCT00600665|Active Comparator|Usual Care|In Part 1 of the study, participants will access PAINReportIt and computer games. PAINReportIt helps the patient describe the pain experienced. In Part 2 of the study, participants will continue to access PAINReportIt when they are seen in the clinic, emergency department (ED), acute care center (ACCA), and hospital. They will gain access to the PAINUCope computer-based programs, which provides multimedia education tailored to the patient's misconceptions about pain management. They will receive medial usual care at the outpatient clinic, ED, ACC, and hospital.
2565911|NCT02459691|Experimental|Vida Sana|Patients assigned to this group will continue medical care as usual and in addition will receive the culturally adapted intervention.
3207526|NCT00965770||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
3207527|NCT00965783|Experimental|1|Sleep time restriction
2566100|NCT02458521|Experimental|Transcranial Magnetic Stimulation|TMS sessions will consist of both 10Hz left pre-frontal stimulation for 3,500 pulses followed by 1Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session.
2566105|NCT02458521|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7.
2566164|NCT02458053|Experimental|TEAM Enhanced|The enhanced intervention will include group sessions where the participant attends with partner ( including a couples skill training session), weekly tailored feedback, and weekly lessons.
2566172|NCT02458053|Active Comparator|TEAM Traditional|The intervention will include group sessions where the male attends alone, weekly tailored feedback, and weekly lessons.
2566261|NCT02457234|Experimental|Cultural Immersion Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons within a cultural immersion context as part of the camp program.
2566263|NCT02457234|Active Comparator|University Children's Day Camp|Participants in this group received four culturally adapted nutrition lessons in addition to camp activities that did not include cultural immersion.
2566266|NCT02457234|No Intervention|Recreational Children's Sports Day Camp|Participants in this group participated in existing camp activities that were exclusively physical activity.
2566340|NCT02457091|Active Comparator|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
2566344|NCT02457091|Experimental|Resistance exercise|The resistance condition will consist of 1-3 sets, 10-15 repetitions of 12 exercises targeting lower body, upper body, and core muscle groups performed 2 days per week.
2566395|NCT02456649|Experimental|MarginProbe|Single arm study - MarginProbe in addition to standard procedure
2566441|NCT02456272|Experimental|External hearing aid & Otosclerosis surgery|Trying an hearing aid for at least two months and then undergo otosclerosis surgery
2566497|NCT02455999|Experimental|SYL1001 eye drops dose C|SYL1001 eye drops dose C administration via the ophthalmic route
2566499|NCT02455999|Experimental|SYL1001 eye drops dose D|SYL1001 eye drops dose D administration via the ophthalmic route
2566504|NCT02455999|Placebo Comparator|Placebo|Placebo eye drops administration via the ophthalmic route
2566592|NCT02455414||Wolfram Syndrome Group|"Participant has confirmation of a WFS1 mutation OR~Both of the following conditions: diabetes mellitus requiring insulin and optic nerve atrophy diagnosed by a physician. Both conditions diabetes mellitus and optic nerve atrophy had to be diagnosed at age younger than 18 years old"
2566596|NCT02455414||WFS Pre-symptomatic Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Participant has confirmation of WFS1 (+/+) mutation but is asymptomatic."
2566598|NCT02455414||WFS Control Sibling Group|"Has had genotyping~Willingness to share result of genotyping~Patient has confirmation of NO WFS1 mutation (-/-) or confirmation as a carrier (+/- or -/+)."
2566602|NCT02455414||T1DM Group|"Age within the 0-28 yrs age range of WS participant~Dx of T1 diabetes mellitus"
3207528|NCT00965783|Experimental|2|Sleep time extension
3207529|NCT00965796|Experimental|Lidocaine, pain intensity and Saline|(2 mg/kg/h) and patients of group 2 (n = 20) received 0.9% saline infusion throughout the surgical procedure
3207530|NCT00965809|Experimental|ACTIVE THC|Subjects will take 5MG of THC in 6 drops of olive oil orally.
3207531|NCT00965809|Placebo Comparator|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
2565939|NCT02459561|Other|Medical Therapy Arm|"The standard medical therapy arm will be carried out in accordance with the guidelines of the American Diabetes Association. These guidelines have been chosen as they are applicable to an International audience and thus would adhere to the current best worldwide practice that would still be likely to be relevant when the results are published following study completion.~Diabetes reviews appointments with a Diabetologist/Endocrinologist will be performed with the control arm patients at visits 2, 4, 6, 7, 9, 11, 12, 13 and 15.~At study visit 4, 80 subjects will arrive at Mary's Hospital or Southampton Hospital and receive the best Medical Care and dietary advice as part of the Medical Therapy Arm Interventions."
2565990|NCT02459184|Experimental|Early intervention|Participants will meet with the Income Security Health Promoter immediately.
2565995|NCT02459184|Active Comparator|Late intervention|Participants will meet with the Income Security Health Promoter at 6 months.
2566019|NCT02458898|Experimental|Text Message Intervention|A series of 45 unique educational text messages sent over a period of 3 months in the evenings. Text messages include humorous reminders, links to online celiac disease resources, and bidirectional questions.
2566020|NCT02458898|No Intervention|Control (No Text Messages)|Routine care by primary gastroenterologist with no text messages.
3207532|NCT00965822|Active Comparator|1|
3207533|NCT00965822|Placebo Comparator|2|
2566151|NCT02458001|Experimental|SAFFRON stepped care|3 level intervention: level 1:Self help booklet level 2: CNS delivered intervention level 3: psychologist delivered intervention
2566160|NCT02458001|No Intervention|enhanced treatment as usual (ETU)|level 1 intervention: self help booklet Non study trained CNS will offer assessment, advice, vaginal dilator training where appropriate, arrange topical oestrogens or other creams
2566198|NCT02457858|Experimental|BMX-010 treated islets|Islet isolation using BMX-010
2566281|NCT02457468||Stenosis patients treated with coflex|Patients with a primary diagnosis of lumbar spinal stenosis treated with coflex after decompression
2566323|NCT02456857|Experimental|Treatment (DAE)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over about 3 hours on day 1, bevacizumab IV over 90 minutes on day 1, and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients will not receive bevacizumab during cycle 4 of therapy. Patients then undergo surgery.
2566415|NCT02456389|Active Comparator|Standard perioperative management|Standard postoperative care
2566423|NCT02456389|Experimental|Risk-based, perioperative management|Preoperative risk stratification Postoperative risk stratification Risk-based, escalating levels of care Risk-based, escalating levels of monitoring Risk-based, escalating levels of co-management
2566459|NCT02456077|Experimental|Intervention Practices|Intervention offices will adopt a multi-modal vaccine program to increase their patients' vaccine rates.
2566463|NCT02456077|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
2566513|NCT02455934|Placebo Comparator|Sucrose|Sucrose 50 g
2566520|NCT02455934|Active Comparator|SAlloulose2.5|Sucrose 50 g + D-allulose (psicose) 2.5 g
2566527|NCT02455934|Active Comparator|SAllulose5|Sucrose 50 g + D-allulose (psicose) 5 g
2566535|NCT02455934|Active Comparator|SAllulose7.5|Sucrose 50 g + D-allulose (psicose) 7.5 g
2566541|NCT02455934|Active Comparator|SAllulose10|Sucrose 50 g + D-allulose (psicose) 10 g
3207534|NCT00965835||DS|Those with Down syndrome
3207535|NCT00965835||Non-DS|Healthy controls
3207536|NCT00965861||1|The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.
2566631|NCT02454829||Adults, gonadotoxic treatment|Women 18 years of age or older who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
2566633|NCT02454829||Girls, gonadotoxic treatment|Girls under 18 years of age who underwent ovarian cortex cryopreservation before gonadotoxic treatment (chemotherapy, radiotherapy)
2566636|NCT02454829||Adults, ovarian pathology|Women 18 years of age or older who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
2566642|NCT02454829||Girls, ovarian pathology|Girls under 18 years of age who underwent ovarian cortex cryopreservation for an ovarian pathology not requiring gonadotoxic treatment but surgery
2566650|NCT02454829||Adults, genetic disorders|Women 18 years of age or older who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
2566662|NCT02454829||Girls, genetic disorders|Girls under 18 years of age who underwent ovarian cortex cryopreservation in the context of a genetic risk of premature ovarian failure
2566721|NCT02454634|Experimental|IDH1 peptide vaccine|The IDH1 peptide vaccine is a 20mer peptide encompassing the IDH1R132H-mutated region emulsified in Montanide®. It is injected subcutaneously and administered in combination with topical imiquimod. The vaccine is administered 8 times every 2 or 4 weeks.
3207537|NCT00965874|Experimental|Magnesium Sulfate high dose infusion|9 g Magnesium sulfate infusion over 30 minutes
3207538|NCT00965874|Active Comparator|Magnesium Sulfate low dose infusion|4.5 magnesium sulfate infusion over 30 minutes
3207539|NCT00965874|Placebo Comparator|placebo|serum salin
3207540|NCT00965887|Active Comparator|1|MK0974 Ethanolate
3207541|NCT00965887|Active Comparator|2|MK0974 Hydrate
3207542|NCT00965900|Active Comparator|Endoscopic band ligation|Endoscopic band ligation until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment
3207543|NCT00965900|Active Comparator|Propranolol|start with 20 mg b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)
3207544|NCT00965900|Active Comparator|EBL+Propranolol|"EBL until eradication of esophageal varices with 4 weeks interval, and then follow-up endoscopy with 3-6 months interval until 36 months after enrollment~start with 20 mg of propranolol b.i.d, and adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min. After reaching target HR, then follow-up according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
2565963|NCT02459535|Active Comparator|Glucose + Sucralose|oral ingestion of 54 g Glucose + 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2565969|NCT02459535|Active Comparator|Sucralose only|oral ingestion of 0,088 g Sucralose in 300 ml water at t=0 in fasted state; blood samples over 120 mins
2566086|NCT02458456|Sham Comparator|IHG 5% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566087|NCT02458456|Experimental|IHG 30% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566088|NCT02458456|Experimental|IHG 30% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 30% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566089|NCT02458456|Sham Comparator|IHG 5% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 5% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566090|NCT02458456|Experimental|IHG 10% Hypertensive|Participants who are either un-medicated pre-hypertensive or medicated for blood pressure management conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566091|NCT02458456|Experimental|IHG 10% Normotensive|Participants who are normotensive conducting isometric resistance training using a hand dynamometer at 10% of their maximum voluntary contraction. Participants with perform 4 x 2 minutes isometric handgrip exercises 3 times per week under supervision for 8 weeks.
2566146|NCT02458183|Experimental|DTaP-IPV combination vaccine|Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of right thigh at the age of 2, 4, and 6 months
2566157|NCT02458183|Active Comparator|DTaP vaccine and IPV vaccine|"Product name: : Boryung DTaP Vaccine Inj. (Prefilled syringe) (Absorbed diphtheria, tetanus toxoid, and purified pertussis combination vaccine) Dosage and administration: A 0.5-mL dose is administered 3 times intramuscularly in the anterolateral aspect of right thigh at the age of 2, 4, and 6 months.~Product name: IPVAX INJ. PREFILLED SYRINGE INJ. Dosage and administration: A 0.5-mL dose is administered intramuscularly in the anterol-ateral aspect of left thigh at the age of 2, 4, and 6 months."
2566197|NCT02457624||Experienced endoscopists|All the experienced endoscopists will receive education and feedback on the diagnosis for premalignant lesion of chronic atrophic gastritis and intestinal metaplasia
2566279|NCT02457455||Sick passangers|Passengers or cabincreew whom needed urgent medical supports during flights with completed medical records. (Aforementioned Flight Company records complaints, symptoms and diagnoses, demographic data, the mortality of those who request medical aid, whether medical treatment is performed by the cabin crew or by a medical professional on the plane, as well as those conditions which resulted in an emergency landing and dead). All ages are included.
2566332|NCT02457078|Experimental|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
2566336|NCT02457078|Placebo Comparator|Control Supplement|Control Supplement: Capsule containing soybean oil and α-tocopheryl (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
2566405|NCT02456701|Experimental|Combination of Vemurafenib and KTN3379|Vemurafenib 960 mg po bid KTN3379 1000 mg IV q2weeks
2566456|NCT02456142|Experimental|caudal bupivacaine|1ml/kg of 0.125% caudal bupivacaine given over 2 minutes will be given at the end of surgery
2566458|NCT02456142|Active Comparator|intravenous morphine|0.05mg/kg intravenous morphine given over 5 minutes
2566505|NCT02455869|Placebo Comparator|Placebo group|SRP plus placebo SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
2566518|NCT02455869|Active Comparator|Atorvastatin group|SRP plus Atorvastatin SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
2566523|NCT02455869|Active Comparator|Alendronate Group|Alendronate SRP plus Alendronate SRP was done for all the subjects. Alendronate was delivered in the pocket subgingivally
2566640|NCT02455180|Experimental|4x 1 gram bolus (q12H) dosage regimen|1 gram of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 4 grams).
2566648|NCT02455180|Experimental|4x 5 grams bolus (q12H) dosage regimen|5 grams of intravenous Vitamin C (ascorbic acid) is given 4 times at 12 hour intervals (total dose 20 grams).
2566657|NCT02455180|Experimental|4 gram continuous dosage regimen|1 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
2566663|NCT02455180|Experimental|20 gram continuous dosage regimen|5 gram per 12 hours of intravenous Vitamin C (ascorbic acid) is given continuously for 48 hours
3207545|NCT00965913|Experimental|Three Interventions on Lower Back|Three treatments were applied on the lower back, according to treatment sequence, daily for 21 days
3207546|NCT00965926|Experimental|Low dose group|3 way cross-over. Fasting, normal diet and high-fat diet
3207547|NCT00965926|Experimental|High dose group|3 way cross-over. Fasting, normal diet and high-fat diet
2566783|NCT02453971|Experimental|eCHUG-D|The eCHUG group is requested to conduct the German Version of eCHECKUP TO GO and to fill in their code on the last page of the program.
2566790|NCT02453971|No Intervention|control|It is an assessment only condition.
2566862|NCT02453854|Active Comparator|Treatment as Usual|A Treatment as Usual (TAU) group received a psycho-educational programme for weight management over one year
2566866|NCT02453854|Experimental|Group Motivational Intervieiwng|A Motivational interviewing group received one year of programme using motivational interviewing as the approach for treatment.
3207548|NCT00965965|Experimental|Experimental patient education document|
3207549|NCT00965965|Active Comparator|Traditional patient education document|
2565971|NCT02459574|Experimental|Group 1-AVATAR-AF Ablation Protocol|AF ablation with pulmonary vein isolation. The patient will have two sheaths in their leg veins instead of the usual three sheaths. Catheters will be passed up to the heart from these leg veins. The single crossing into the left atrium will be by the usual method. Veins will be ablated using freeze technology known as the Advance Cryoballoon. After the ablation is completed the patient will have scans on their heart and checks of the leg veins. If all the checks are satisfactory at six hours after the procedure the patient will be allowed to go home on the same day. The patient will be reviewed in clinic in 8 weeks (visit 1) after the procedure and if it has been successful, will be reviewed again a month later (visit 2) and if all is well, the patient will be discharged from clinic.
2566119|NCT02458534|Experimental|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
2566123|NCT02458534|Experimental|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
2566124|NCT02458534|Active Comparator|Macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway setting. Then the participants perform three intubation attempts using the manikin with difficult airway setting.
2566166|NCT02458066|Active Comparator|Bendiocarb|IRS: bendiocarb
2566178|NCT02458066|Active Comparator|Deltamethrin|IRS: deltamethrin
2566200|NCT02457702|Experimental|Orally administered Labeled Glycerol|Patients will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water.
2566280|NCT02457429|Other|Routine oesophageal pH monitoring|Routine oesophageal pH investigation involves the trans-nasal placement of a microelectrode into the distal oesophagus as per hospital protocol. Examining the oropharynx and confirming visualisation of the red LED at the catheter tip in the correct position just below the soft palate will confirm its position in the oropharynx. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
2566350|NCT02456948|Experimental|Minocycline|Minocycline and standard antidepressant treatment
2566353|NCT02456948|Placebo Comparator|Placebo|Placebo and standard antidepressant treatment
2566404|NCT02456493||increased carotid IMT group|Patients who have increased carotid IMT (intima media thickness)
2566411|NCT02456493||normal carotid IMT group|Patients who have normal carotid IMT
2566443|NCT02456350|Experimental|Anti-CD19-CAR transduced T cells|Patients will receive a lymphodepleting preconditioning regimen followed by anti-CD19- CAR-transduced T cells.
2566500|NCT02455882||Neoadjuvant|Patients initiating standard of care treatment with primary systemic therapy for breast cancer
2566510|NCT02455882||Adjuvant|Patients initiating standard of care treatment with surgery followed by adjuvant chemotherapy for breast cancer
2566517|NCT02455882||Recurrence|Patients with a history of breast cancer who are diagnosed with disease recurrence
2566576|NCT02455635|Active Comparator|women with pain|women who felt pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
2566578|NCT02455635|Active Comparator|women without pain|women who didn't feel pain at time of office hystroscopy at time of saline infusion and for 15 minutes after end of procedure
3207550|NCT00965978|Experimental|Low dose group|Receives low dose of ONO-5920/YM529 with and without food
2566715|NCT02454439|Experimental|CRT-D or CRT-P ON|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
2566724|NCT02454439|Other|CRT-D or CRT-P OFF|This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
3207551|NCT00965978|Experimental|High dose group|Receives high dose of ONO-5920/YM529 with and without food
3207552|NCT00965991|Active Comparator|Metformin|
3207553|NCT00965991|Active Comparator|Glyburide|
2566943|NCT02453087|Experimental|DCDS0780A Monotherapy|Participants will receive escalating doses of DCDS0780A as intravenous infusion as monotherapy on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
2566945|NCT02453087|Experimental|DCDS0780A + Rituximab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with rituximab at a dose of 375 milligrams per square meter (mg/m^2) of body surface area as intravenous infusion on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
2566948|NCT02453087|Experimental|DCDS0780A + Obinutuzumab|Participants will receive escalating doses of DCDS0780A on Day 2 of Cycles 1 and 2, and from Cycle 3 onwards on Day 1 of each 21-day cycle in combination with obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion on Days 1, 8, and 15 of Cycle 1, and from Cycle 2 onwards on Day 1 of each 21-day cycle up to approximately 1 year or until disease progression or unacceptable toxicity (whichever comes first).
2567015|NCT02452814||Cohort|
3207554|NCT00966004|Experimental|YM178 group|oral
3207555|NCT00966004|Placebo Comparator|Placebo group|oral
2567213|NCT02451436|Active Comparator|Sleep and Media Use Intervention|The sleep intervention group will receive four sessions including cognitive behavioral training aimed at increasing sleep duration, education on the effects of media use on sleep and problem solving with the participant and parent about increasing sleep duration and decreasing nighttime media use.
3207556|NCT00966004|Active Comparator|tolterodine group|oral
3207557|NCT00966017||DS|Those with Down syndrome
3207558|NCT00966017||Non-DS|Healthy controls
3207559|NCT00966030|Experimental|1|MK0974 Tablet
3207560|NCT00966030|Active Comparator|2|MK0974 Liquid filled capsule
2565992|NCT02459249|Experimental|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
2565994|NCT02459249|Placebo Comparator|Treatment of Mexican Health Minister|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
2566026|NCT02458872|Experimental|Intervention Arm|Safety huddle alarm intervention.
2566028|NCT02458872|No Intervention|Control Arm|Usual care.
2566121|NCT02458664||Colo-rectal cancer|All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
2566165|NCT02458105|Experimental|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
2566170|NCT02458105|Active Comparator|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
2566196|NCT02457715||Prostate Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
2566205|NCT02457715||Renal Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
2566207|NCT02457715||Brain Cancer|Subjects will use a Jawbone Up24 for 14 weeks.
2566220|NCT02457715||Amyotrophic Lateral Sclerosis (ALS)|Subjects will use a Jawbone Up24 for 14 weeks.
2566240|NCT02457507|Experimental|Vitamin B12|Vitamin B12, 1mg, daily, 27 months
2566242|NCT02457507|Placebo Comparator|Placebo|Placebo comparator
3207561|NCT00966056|Active Comparator|Mitomycin C|Cases recruited into this arm receive topical application of mitomycin c (1mg/ml)following surgical synechiolysis
3207562|NCT00966056|Active Comparator|Teflon septal splint|Cases recruited into this arm receive insertion of teflon internal nasal septal splint following surgical synechiolysis
3207563|NCT00966069|Active Comparator|Healthcare worker visit|"Healthcare worker performs home visit when study child has acute respiratory illness to collect a respiratory swab (nasopharyngeal swab).~At the healthcare worker home visit, the HCW will collect the nasopharyngeal swab, and a parent will collect an anterior nasal swab. The HCW swab is to be returned immediately to the laboratory, and the parent collected swab was placed in a post box for return to the laboratory by surface mail."
3207564|NCT00966069|Experimental|Parent collection|Home collection of respiratory swab (anterior nose) and mailed return when study subject has an acute respiratory illness.
2566372|NCT02456519||PaedQoR-15 Questionnaire|Questionnaire to be completed by all participants
2566476|NCT02456376|Experimental|Children with Cerebral palsy|"Sensory integration testing~SR stimulation and Sensory integration testing"
2566479|NCT02456376|Active Comparator|Children with Typical Development|"Sensory integration testing~SR stimulation and Sensory integration testing"
2566506|NCT02455713||Intervention|Alter PEEP and PIP and measure hemodynamic outcomes.
3207565|NCT00966082|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval
2566680|NCT02454777|Experimental|ARM I (HIT group)|Participants undergo HIT exercises over 30 minutes, thrice weekly for 8 weeks.
2566682|NCT02454777|Active Comparator|Arm II (Delayed group)|Participants maintain their current sedentary activity level (< 60 minutes of total exercise per week) for 8 weeks. Participants document their weekly activity in an exercise log. Following completion of all study visits, participants are given the option to complete the HIT program as in Arm I.
3207566|NCT00966082|Active Comparator|endoscopic band ligation+Propranolol|Perform endoscopic band ligation (EBL) until eradication of esophageal varices, and then follow-up endoscopy with 3-6 months interval, with propranolol
2566869|NCT02453646|Experimental|NexSite HD Patients|NexSite HD patient catheter device placement
3207567|NCT00966095||men scheduled for prostate biopsy|
3207568|NCT00966108||Healthy subjects|
3207569|NCT00966108||Glaucoma patients|
2567435|NCT02450019|Other|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP. Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to protective.
2567436|NCT02450019|Other|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2). Arterial CO2 partial pressure will be maintained between 30 and 35 mmHg. After intracranial pressure measurement ventilation will be switched to traditional.
2567512|NCT02449681|Experimental|TH-4000 (Tarloxotinib)|
2567586|NCT02449031||TOBI Podhaler cohort|
2567588|NCT02449031||non-TOBI Podhaler cohort|Approximately 250 patients treated with other FDA-approved inhaled antipseudomonal antibacterial drugs at enrollment
2567661|NCT02448407|Experimental|Platelet rich plasma|Three intraarticular injection, one each fifteen days
2567665|NCT02448407|Active Comparator|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1 % solution, administered by intraarticular injection (3 doses, one each fifteen days)
2567718|NCT02448186|Experimental|ESTEEM|cognitive behavioral treatment adapted to improve depression, anxiety, and co-occurring health risks (i.e., alcohol use, sexual compulsivity, condomless sex) among young adult gay and bisexual men by reducing minority stress processes that underlie sexual orientation-related mental health disparities
2567719|NCT02448186|No Intervention|Waitlist|3-month waitlist control
3207570|NCT00966121|Active Comparator|Endoscopic band ligation|Perform endoscopic band ligation (EBL) until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
3207571|NCT00966121|Active Comparator|EBL+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
3207572|NCT00966134||probands|
3207573|NCT00966147|Experimental|Lidco group|All patients monitored by the lidco system and treated to optimize oxygen delivery
2566030|NCT02459054|Experimental|Secondary Arm|Cardiac transplant-eligible pediatric and adult patients at imminent risk of death from biventricular failure who do not meet enrollment criteria for a Primary Arm, but meet less restrictive enrollment criteria for the Secondary Arm. The intervention is implantation with the 50cc temporary Total Artificial Heart as a bridge to transplantation.
2566255|NCT02457533|No Intervention|Control|Only SF-36 and CAT
2566257|NCT02457533|Active Comparator|Active|Lifestyle behavioral. Health plan, telephone support
2566357|NCT02456818||Centers using contact isolation|"Isolation triggered by the detection of ESBL-EC at hospital admission in surveillance screening or during the hospitalization by weekly screening or clinical cultures~Contact isolation terminated, after at least two negative consecutive fecal screening cultures~Contact isolation resumed, if subsequent ESBL-EC positive cultures are identified for the same patient including readmissions~Contact isolation must include:~Patient placement in single rooms~Cohorting only possible, when no single rooms available and corresponding ESBL-EC strains are phenotypically identical~Staff and visitors wearing gloves and gowns as contact precautions when entering the room, patient when leaving the room"
2566361|NCT02456818||Centers using no contact isolation|"not regularly isolating for ESBL-EC~ESBL-EC colonized or infected patients with urinary or fecal incontinence or diarrhea (>3 loose bowel movements/day) isolated in single rooms with above described contact precautions"
2566375|NCT02456597|Active Comparator|lidocainhydrochlorid|Lidocaine 20mg/ml, 15 ml injected perineural at the sciatic nerve
2566383|NCT02456597|Placebo Comparator|Isotonic saline|0.9% Saline Solution, 15ml injected perineural at the contralateral sciatic nerve
2566448|NCT02456259||Neck cannula group|Patients in this group are indicated for neck cannula insertion due to tzpu of cardiac surgery (MICS)
2566453|NCT02456259||Central venous catheter only group|Patients in this group are indicated for central venous catheter insertion only.
2566524|NCT02455960|Experimental|Arginine|Participants need to take arginine 3 g/day orally for 3 days before CT with contrast media injection
2566529|NCT02455960|Placebo Comparator|Placebo|Participants need to take placebo (corn powder) 3 g/day orally for 3 days before CT with contrast media injection
2566658|NCT02454842|Experimental|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib), 150 mg/m2 will be administered by IV infusion on Days 1, 8, 15, and 22 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity
2566716|NCT02454556|Experimental|FOLITIME®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
2566725|NCT02454556|Active Comparator|Gonal-F®|Therapy will be initiated in the early follicular phase (cycle day 2 or 3) subcutaneously at a dose of 225 IU per day, until sufficient follicular development is attained.
2566770|NCT02454140|Experimental|Cohort 1|SBRT 40 Gy in 5 fractions
2566771|NCT02454140|Experimental|Cohort 2|SBRT 45 Gy in 5 fractions (starting dose level)
2566774|NCT02454140|Experimental|Cohort 3|SBRT 50 Gy in 5 fractions
2566776|NCT02454140|Experimental|Cohort 4|SBRT 55 Gy in 5 fractions
2566777|NCT02454140|Experimental|Cohort 5|SBRT 60 Gy in 5 fractions
2566830|NCT02453958|Experimental|mTBI-diagnosed group|Subjects diagnosed with mTBI were assessed with a multi-modal assessment system.
2566832|NCT02453958|Experimental|non mTBI-diagnosed group|Non-concussed subjects were assessed with a multi-modal assessment system.
2566983|NCT02452801|Experimental|ALKS 5461|Sublingual tablet
2567036|NCT02452697|Active Comparator|Cohort A - NK cell enriched-DLI only|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
2567047|NCT02452697|Experimental|Cohort A - NK-DLI + DUK-CPG-001|Patients with a 7-8/8 human leukocyte antigen (HLA)-matched related or unrelated donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
2567057|NCT02452697|Active Comparator|Cohort B - NK cell enriched-DLI only|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) only
2567059|NCT02452697|Experimental|Cohort B - NK-DLI + DUK-CPG-001|Patients with a 4-6/8 human leukocyte antigen (HLA)-matched related donor receiving natural killer (NK) cell enriched donor lymphocyte infusion (DLI) and investigational DUK-CPG-001
2567086|NCT02452151|Experimental|Infliximab-biosimilar|Infliximab-Biosimilar (Inflectra) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
2567088|NCT02452151|Active Comparator|Infliximab-Innovator|Infliximab-Innovator (Remicade) (5mg/kg or 10mg/kg) by intravenous (IV) infusion administered as a 2-hour infusion per dose as treatment. In total 4 to 6 doses of the study drug will be administered while continuing patient's dosing intervals, ranging between 6 to 10 weeks.
3172513|NCT00600665|Experimental|PAINUCope/PAINConsultN|In Part 1 of the study, participants will access PAINReportIt and PAINUCope computer-based programs. PAINReportIt helps the patients describe the pain experiences and PAINUCope provides multimedia education tailored to the patient's misconceptions about pain management. In Part 2 of the study, participants will continue to access PAINReportIt and PAINUCope programs when they are seen in the clinic, emergency department (ED), acute care center (ACC), and hospital. Their doctors will have access to PAINConsultN when seen at the ED, ACC, and hospital. PAINConsultN is just-in-time decision support for the physicians with the pain data summarized and suggestions for analgesics that may be useful to help manage the patient's pain.
3172514|NCT00600678|Experimental|1|
3172515|NCT00600691|Experimental|1|5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.
3172516|NCT00600717||Pediatric Patients and Healthy Children|Healthy children without dental works. Pediatric patients with epilepsy and migraine (headache).
3172517|NCT00600730|Experimental|1|Hyperinsulinemic euglycemic clamp with fMRi
3172518|NCT00600730|Experimental|2|Hyperinsulinemic hypoglycemic clamp with fMRI
3172519|NCT00600769|Other|treatment of MAC and other NTM|Clarithromycin drug given twice daily.
3172520|NCT00600782|Experimental|Group A|These subjects were further stratified into 3 groups according to the size of their PPD skin test reactions
2566043|NCT02458846|Experimental|Screened Schools|25 schools. Screening involved: crowded HOTV acuity test, Preschool Randot Stereoacuity Test, and Plusoptix autorefractor. Referral criteria followed AAPOS guidelines for screening for amblyopia and amblyopia risk factors. Children who fail any one of the three tests (including uncooperative/unable children) will be given a referral letter, which includes an assigned appointment time for a comprehensive eye exam at school with a licensed optometrist. Any needed glasses will be dispensed at no cost to the parents. 6 months after the eye exam, we will follow up with a phone call to parents to offer any additional support (such as replacing broken/lost glasses)
2566050|NCT02458846|No Intervention|Care As Usual Schools|"25 schools were randomly allocated to the care as usual schools. No intervention was provided by the research team, however, children may have received optometry/ophthalmology care via regular referral channels (e.g., family physicians, teachers)"
2566127|NCT02458417|Active Comparator|Full surface CO2 laser 200mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 209 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
2566128|NCT02458417|Experimental|Full surface CO2 laser 150mJ + ReCell|This test region will receive full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
2566132|NCT02458417|Experimental|Fractional CO2 laser 7.5mJ 20% + ReCell|This test region will receive pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density. After pretreatment ReCell autologous epidermal cell suspension will be applied on this test region.
2566133|NCT02458417|No Intervention|Control|No intervention
3207574|NCT00966160|Active Comparator|PI|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
2566287|NCT02457273|Experimental|Assigned Interventions|TLC 388
3207575|NCT00966160|Active Comparator|NNRTI|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over a 56-week run-in and a 420-week follow-up
3207576|NCT00966199|Experimental|Hypertensive elderly|community dwelling hypertensive elderly from general practices
2566406|NCT02456428||Treated with incretins|Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
2566419|NCT02456428||Treated with insulin|Current use of insulins between base cohort entry and the index or event day (alone or in combination with other anti-diabetic drugs) and no current use of incretin-based drugs.
2566424|NCT02456428||Treated with ≥2 oral hypoglycemic agents|Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
2566427|NCT02456428||Treated with single oral agent|Current use of any single non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins.
2566429|NCT02456428||Not currently exposed group|All patients not currently exposed to: incretin-based drugs, insulins, ≥2 OHAs, or a single OHA.
2566486|NCT02456025|Active Comparator|Topical tacrolimus|20 eyes with active Vernal Keratoconjunctivitis
2566487|NCT02456025|Placebo Comparator|Placebo|20 eyes with active Vernal Keratoconjunctivitis
2566549|NCT02455687|Active Comparator|Hi-Mg + Bud|Group one will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized budesonide.
2566554|NCT02455687|Placebo Comparator|Hi-Mg + P|Group two will receive a high,then standard dose of intravenous magnesium sulfate with blinded nebulized normal saline.
2566555|NCT02455687|Active Comparator|Std-Mg + Bud|Group three will receive a single standard dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized budesonide.
2566556|NCT02455687|Placebo Comparator|St-Mg + P|Group four will receive a single dose of intravenous magnesium sulfate plus one dose of intravenous normal saline with blinded nebulized normal saline
2566593|NCT02455284|Experimental|Healthy subjects|MRI and neuropsychological evaluation
2566639|NCT02454907|Active Comparator|Control|One kind of communication with the clinic will be used.
2566649|NCT02454907|Experimental|Experimental|A different kind of communication with the clinic will be used.
2566700|NCT02454673||Group A|"3-4 cycles of preoperative chemotherapy~Surgery"
2566701|NCT02454673||Group B|"3-4 cycles of induction chemotherapy~Radiotherapy with concurrent chemotherapy for 5 weeks~Surgery"
2566758|NCT02454348|Active Comparator|Norepinephrine and vasopressin|Norepinephrine (0.05 to 0.5 mcg/kg/min) and vasopressin (0.04 units/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
2566760|NCT02454348|Active Comparator|Norepinephrine|Norepinephrine (0.05 to 0.5 mcg/kg/min) will be given by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg).
2566800|NCT02454036|Experimental|BBI Intervention|Biobehavioral Intervention
2566853|NCT02453880|Experimental|Web-based Cognitive Behavioral Therapy|"Participants will be directed to a web-based CBT self-help program with weekly modules."
2566903|NCT02453477|Experimental|Adults|"≥18 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
3207577|NCT00966212|No Intervention|health promotion materials|
3207578|NCT00966212|Active Comparator|print parent education|
2566073|NCT02458729|Active Comparator|One-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously five minutes before deflation of the tourniquet. and then 0.9% normal saline 20ml administration intravenously 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
2566075|NCT02458729|Active Comparator|Two-dose TXA Group|Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously twice, five minutes before deflation of the tourniquet and 3 hours after operation Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis
3207579|NCT00966225|Experimental|One gram LIP-01 per day|One gram LIP-01 per day for 12 weeks
2566236|NCT02457585|Experimental|experimental group|"anti Tumor necrosis factor treatment group : treatment with remicade 5mg/kg as scheduled (0, 2, 6, 14, 22, 30, 38, 46, 54weeks).~evaluation of response at 30weeks by PET CT, acute phase reactants, symptom~No placebo group"
2566290|NCT02457312|Active Comparator|Letrozole group|Letrozole 10 mg daily for 7 days before suction evacuation
2566295|NCT02457312|Placebo Comparator|Placebo group|Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation
2566326|NCT02456935|Experimental|CJ-12420 100 mg QD|CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks
2566331|NCT02456935|Active Comparator|Esomeprazole 40 mg QD|Esomeprazole 40 mg, tablet, once daily, oral administration for up to 8 weeks
3207580|NCT00966225|Experimental|Two grams LIP-01 per day|Two grams LIP-01 per day for 12 weeks
3207581|NCT00966225|Experimental|0.333 grams LIP-01 per day|0.333 grams LIP-01 per day for 12 weeks
2566445|NCT02456038|Experimental|Asfotase Alfa (ALXN1215)|Asfotase Alfa (ALXN1215) is administered 6mg/kg in total per week, divided into 3 times.
2566495|NCT02455778|Experimental|Cinnamon|3 grams of oral cinnamon per day in form of capsules (6) along with standard diet and exercise protocol
2566498|NCT02455778|Placebo Comparator|Placebo|2.5 grams of wheat flour per day in form of capsules ( 6) along with standard diet and exercise protocol
2566580|NCT02455583|No Intervention|Standard of Care|All Form 1 learners at 25 of the 50 schools will receive HIV prevention sessions from the Botswana life skills education program for junior secondary school students called LIVING.
2566582|NCT02455583|Experimental|Intervention|Form 1 learners at the 25 intervention schools will receive the Project AIM intervention and LIVING (standard of care).
2566643|NCT02455154|Placebo Comparator|Letrozole|"Early Breast Cancer patients receiving adjuvant endocrine therapy~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po."
2566651|NCT02455154|Active Comparator|Letrozole + Xinglinggubao|"Early Breast Cancer patients receiving adjuvant endocrine therapy plus Xianlinggubao~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Xinglinggubao: 0.5g bid po"
2566661|NCT02455154|Active Comparator|Letrozole + Zhongyaofufang|"Early Breast Cancer patients receiving adjuvant endocrine therapyplus Zhongyaofufang (Traditional Chinses Medicine)~Adjuvant Endocrine Therapy: letrozole 2.5 mg qd po.~Zhongyaofufang: qow po"
2566788|NCT02454322||Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Treated with Magnesium Sulfate
2566796|NCT02454322||No Magnesium|Hypertensive Disorder of Pregnancy (gestational hypertension or preeclampsia) Not Treated with Magnesium Sulfate
2566838|NCT02453867|Active Comparator|Standard immunosuppression|starting immunosuppression: tacrolimus (Advagraf) (target trough levels >5 ng/ml), mycophenolate mofetil >1g/d in MMF or >720 mg/d in mycophenolic acid, steroids from month 1-3 dosing according to local practice; 200 pts are planned to carry on with standard immunosuppression (tacrolimus (Advagraf), Mycophenolate, steroids) as stated above according to international guidelines for kidney transplant recipients from month 3 posttransplant to month 12 posttransplant
2566839|NCT02453867|Experimental|Reduced immunosuppression|"The Intervention is stopping medication:~200 pts are planned to receive a reduced immunosuppression after month 3: carry on with tacrolimus (Advagraf; trough levels >5 ng/ml) steroids stop at month 3 mycophenolate stop at month 6"
3207582|NCT00966251|Experimental|CT-011|
3207583|NCT00966290|Experimental|ACC group|Anticoagulant clinic-based shared-care group
3207584|NCT00966290|Active Comparator|UC group|Usual care group
2566924|NCT02453139|Experimental|Exercise group|6 month supervised and home based moderate intensity aerobic exercise programme
2566931|NCT02453139|No Intervention|Control|Non-exercising control group receiving usual care
3207585|NCT00966303|Experimental|Cardiac Rehabilitation|9 patients with cardiomyopathy in functional class III or IV, submitted to an 8-week program with exercises and respiratory muscle training.
3207586|NCT00966316|Experimental|pathway|aspirin，Chinese herbs；acupuncture；rehabilitation；health education；
3207587|NCT00966329|Experimental|to switch from the NNRTI/PI to maraviroc|to switch from the NNRTI/PI to maraviroc
3207588|NCT00966329|Active Comparator|to continue with the same approach|to continue with the same approach
2567091|NCT02452138||Low EAA|Endotoxin Activity Assay [EAA] level < 0.40 EAA units
2567094|NCT02452138||Intermediate EAA|Endotoxin Activity Assay [EAA] level between 0.40-0.59 EAA units
2567096|NCT02452138||High EAA|Endotoxin Activity Assay [EAA] level >= 0.60 EAA units
3207589|NCT00966342|Other|Vaccine|Everyone gets licensed Influenza vaccine
3207590|NCT00966368|Experimental|IDeg E|
3207591|NCT00966368|Experimental|IDeg M|
3207592|NCT00966381|No Intervention|Control|The minimal care group will receive standard public health information on nutrition from the American Heart Association twice during the 16-week intervention. Upon completion of the endpoint measurement (20 wks postpartum), they will be given all intervention materials.
3207593|NCT00966381|Experimental|Exercise Group|The intervention group will participate in a 16-week exercise and diet intervention from 4 to 20 wks postpartum. The PI will travel to the participant's homes three times per week during the 16-week intervention to guide mothers with the exercise program, ensure dietary compliance, and provide social support. The 16-wk exercise protocol consists of strength training three times per week and walking 10,000 steps per day at least five days per week.
3207594|NCT00966394||ADHD medication|Children with ADHD and pharmacologic treatment
3207595|NCT00966394||ADHD without medication|Children with ADHD without pharmacologic treatment
3207596|NCT00966394||healthy|Healthy children ASA1
2566076|NCT02458651||Tier 2 and South Western|Site as described by tier level of the city where the site is located and by geographical location: Tier 2 city in south western region of China
2566139|NCT02458274||Patient without bronchiolitis obliterans syndrome|Lung transplanted patient without bronchiolitis obliterans syndrome
2566145|NCT02458274||Patient with bronchiolitis obliterans syndrome|Patient with bronchiolitis obliterans syndrome three years after lung transplantation.
2566206|NCT02457871|Experimental|Ecological Nurse Case Managemnt|Ecological Nurse Case Management (ENCM) group receives 6 months of ENCM services in addition to their usual primary care services at the study site.
2566219|NCT02457871|No Intervention|Comparison|Usual Clinical Care - is the usual primary care services delivered at the site of the study, a free clinic.
2566264|NCT02457416|Active Comparator|Peanut oral immunotherapy|Oral immunotherapy with peanut
2566268|NCT02457416|No Intervention|Controls|Avoid peanut exposure
2566330|NCT02457104||normal weight individuals not taking PPI|
2566337|NCT02457104||normal weight individuals taking PPI|
2566339|NCT02457104||obese individuals not taking PPI|
2566341|NCT02457104||obese individuals taking PPI|
2566412|NCT02456545||help-seekers at-risk|"persons consulting collaborating Early Recognition Centers presenting with hints for ≥ 1 potential risk factor for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse, ADHD)~anticipated n = 500"
2566420|NCT02456545||patients with depressive syndrome|"in- and outpatients with depressive syndrome (SCID)~anticipated n = 500"
2566425|NCT02456545||patients with ADHD|"in- and outpatients with Attention-Deficit/Hyperactivity-Disorder (ADHD)~anticipated n = 150"
2566428|NCT02456545||representative population cohort|"representative population cohort from the IMAGEN study~anticipated n = 500"
2566440|NCT02456064|Experimental|Lifestyle counseling|"In this group we will make an intensive program based on: workshops, educational talks, group medical practices and expert patient among others conduct auditions."
2566442|NCT02456064|No Intervention|Normal group|In this group will be controlled as usual in the consultations.
2566488|NCT02456012|Experimental|The D group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg twice daily for 36 weeks.
2566489|NCT02456012|Experimental|The S group|After 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment, patients receive oral esomeprazole 20 mg once daily for 36 weeks.
2566490|NCT02456012|No Intervention|The C group|The cohort control group includes patients from a previous study who had peptic ulcer bleeding and Rockall scores ≥ 6 but who did not receive esomeprazole or other proton pump inhibitors after 3-day intravenous 8 mg/h and 16-week oral 40 mg/day esomeprazole treatment.
2566548|NCT02455661|Experimental|Radial PCI with TR Band (TM)|Patients with a PCI using the radial approach and the above radial compression device.
2566550|NCT02455661|Active Comparator|Femoral PCI with AngioSeal device|Patients with a PCI using the femoral approach and the above femoral vascular closure device.
2566553|NCT02455661|Active Comparator|Femoral PCI with StarClose device|
2566589|NCT02455323|Experimental|Suboccipital inhibitory|Suboccipital inhibitory pressure technique. According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues.
2566590|NCT02455323|Experimental|Spinal Manipulative|Suboccipital inhibitory pressure technique. This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility.
2566594|NCT02455323|Experimental|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
2566597|NCT02455323|Placebo Comparator|Control group|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
2566645|NCT02454998|Experimental|Orthodontic treatment arm|Previous to the surgical alveolar bone grafting, orthodontic treatment is performed several months before surgery
2566653|NCT02454998|No Intervention|No orthodontic treatment arm|No orthodontic treatment previous to surgical alveolar bone grafting
2566705|NCT02454725|Experimental|Social Network|Leaders of social networks will communicate messages endorsing regular HIV testing to network members.
2566707|NCT02454725|Active Comparator|Comparison|HIV counseling and testing
2566804|NCT02454257||Admission to ICU|Patients admitted to an adult critical care unit or cardiothoracic critical care unit
2566810|NCT02454257||In-hospital cardiac arrest|Patients experiencing an in-hospital cardiac arrest
2566865|NCT02453919||RECOVIH|"Complete cardiac examination including echocardiography, ischemia tests, and ambulatory blood pressure monitoring.~Collection of clinical information and biochemical laboratory results."
3207597|NCT00966407||Healthy Young Adults|College-age (18-35 years) participants recruited from Howard University, East Carolina University, and University of Massachusetts, Amherst, University of Calgary, Winston-Salem University
2567002|NCT02452788|Other|Intervention|Pharmaceutical care with educational intervention provided by a pharmacist to ambulatory hemodialysis patients
2567004|NCT02452788|No Intervention|Usual Care|Usual Care
2567025|NCT02452632|Experimental|ASP1941 group|once daily over a 24 week treatment
2567026|NCT02452632|Placebo Comparator|Placebo group|once daily over a 24 week treatment
2567063|NCT02452450|Active Comparator|Paracetamol|
2567083|NCT02452125|Experimental|Nicotine Gum|Nicotine chewing gum administered for 30 minutes
2567121|NCT02452008|Experimental|Arm 1: Enzalutamide with LY2157299|
2567122|NCT02452008|Experimental|Arm 2: Enzalutamide alone|
2566093|NCT02458443|Sham Comparator|IHG 5% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 5% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
2566103|NCT02458443|Experimental|IHG 30% Un-medicated|Participants with high blood pressure (greater than 120/80) who are not medicated for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
2566110|NCT02458443|Experimental|IHG 30% BB|Participants with high blood pressure (greater than 120/80) who are currently taking beta blockers for blood pressure control will conduct isometric handgrip exercise at 30% of their maximum voluntary contraction (MVC). Isometric resistance training will be conducted three times a week for 12 weeks, with participants conducting 4 x 2min IHG exercises at each session.
2566173|NCT02458118|Experimental|Secretin|Secretin 1 IU/kg over 3 min
2566192|NCT02457650|Experimental|Anti-NY ESO-1 TCR-transduced T cells|Patients will receive a lymphodepleting conditioning regimen followed by an infusion of anti-NY-ESO-1 TCR-transduced T cells.
2566274|NCT02457390|Experimental|CE-LUS|"Laparoscopic ultrasound examination (LUS) of the liver during robot assisted CRC surgery. The liver is systematically scanned for unrecognized liver metastases.~After the laparoscopic LUS procedure, the liver is then systematically scanned with contrast enhancement with SonoVue® containing Sulphurhexafluoride. A bolus of 2.5 ml is injected into a peripheral vein followed by 10 ml of isotonic saline. The liver is then systematically scanned in 3 phases (arterial, venous and parenchymatous phase) searching for unrecognized liver metastases. The procedure is repeated after 5 minutes.~The time it takes to do the scan is measured and any technical challenges are reported. Time, challenges and findings of liver metastases (number, segment and size) are entered on a registration form."
2566322|NCT02457052|Experimental|DATP +|Introduction of a device allowing a custom sitting to help patients with swallowing disorders .
2566329|NCT02457052|No Intervention|DATP -|No introduction of a device allowing a custom sitting to help patients with swallowing disorders .
3207598|NCT00966420|Experimental|mucosa resection|
3207599|NCT00966459|Other|1|
3207600|NCT00966472|Experimental|Erlotinib + Rosuvastatin|To determine the recommended phase II dose (RP2D) of rosuvastatin that can be given in combination with standard erlotinib treatment in patients with advanced incurable squamous cell cancer and NSCLC.
2566659|NCT02455128|Experimental|Experimental Group|This group will receive the therapeutic listening.
2566667|NCT02455128|No Intervention|Control Group|This group will receive usual care offered by the hospital where the study will be conducted.
2566727|NCT02454699|Experimental|1000mg MBX400|6 subjects receive 1000 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
2566732|NCT02454699|Experimental|100mg MBX400|6 subjects receive 100 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
2566736|NCT02454699|Experimental|350mg MBX400|6 subjects receive 350 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
2566740|NCT02454699|Experimental|750mg MBX400|6 subjects receive 750 mg MBX400 orally once per day for 7 days, 2 subjects receive Placebo orally once per day for 7 days
3207601|NCT00966485|Active Comparator|80 mg ASA dose|6 months post stent on 80 mg ASA
2566871|NCT02453607||CD Monotherapy|Crohn's disease treated with infliximab (monotherapy)
2566874|NCT02453607||CD Combo therapy|Crohn's disease treated with infliximab in combination with thiopurine (a 6MP metabolite) (combo therapy)
2566915|NCT02453269|Experimental|Transdisciplinary program|"Children in G1 were submitted to a transdisciplinary intervention once a week. Each child received a nutritional education kit including four games (Cool Diet, a board game, a memory game and a word search puzzle) and an interactive booklet containing)."
2566916|NCT02453269|No Intervention|Control group|The children in the control group (G2) were not exposed to interventions.
2566995|NCT02453061|Placebo Comparator|Placebo group|Subjects will receive safflower oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
2567000|NCT02453061|Active Comparator|Triheptanoin group|Subjects will receive triheptanoin oil at 1g/kg/day for 6 months (months 0 - 6) and triheptanoin oil at 1g/kg/day for 6 months (months 7 - 12)
2567031|NCT02452580||Family Centered Care Unit|Cohort of premature infants and their families receiving Family Centered Care hospitalized at VVHF
2567035|NCT02452580||Open-bay Care Unit|Cohort of premature infants and their families receiving and traditional open-bay care hospitalized at HUH
2567082|NCT02452281|Experimental|ipilimumab + HSPPC-96|"Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.~HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab.~Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses.~Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine."
2567172|NCT02451891|Active Comparator|Group 3|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1 x 10^8 pfu) after 28 days
2567174|NCT02451891|Active Comparator|Group 4|ChAd3-EBO Z (2.5 +/- 1.2 x 10^10 vp) and MVA-EBO Z (1.5 x 10^8 pfu) after 28 days
3207602|NCT00966485|Active Comparator|500 mg ASA dose|6 months posr stent on ASA alone
3207603|NCT00966498|Experimental|1|This study is a single-arm, non-randomized trial. Peripheral blood stem cells will be harvested by mobilization with chemotherapy followed by G-CSF. Following adequate peripheral blood stem cell collection, the patients would be transplanted using the conditioning regimen consisting of thiotepa and cyclophosphamide (tandem one) and busulfan and melphalan (tandem two). They will receive G-CSF post transplant. There will be 6-8 weeks interval between tandem transplants. All patients would be carefully observed for any toxicity, transplant-related complications, relapse and disease-free survival.
3207604|NCT00966511||Lung resection candidates|Study participants will be patients who are candidates for lung resection (lobectomy or greater)
2566152|NCT02457988|No Intervention|Standard of Care|Patients with cirrhosis will undergo standard of care, which includes a post-discharge lab check and follow-up clinic appointment. Otherwise, no day-to-day monitoring of these patients will occur.
2566194|NCT02457884|Active Comparator|Temporal Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
2566202|NCT02457884|Active Comparator|Spatial Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
2566210|NCT02457884|Active Comparator|Combined Group|Receive 6 weekly 1-hour training sessions by Trigrams (A tailor made reading-task training programme).
2566218|NCT02457884|Placebo Comparator|Control Group|Receive 6 weekly 1-hour training sessions of leisure reading activities
2566275|NCT02457351|Experimental|Roniciclib + Itraconazole|Pharmacokinetics and safety in patients with advanced solid tumor
2566376|NCT02456675|Experimental|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
2566381|NCT02456675|Experimental|INCB040093 and itacitinib (INCB039110) Combination Therapy|Subjects allocated to Group B will be given INCB040093 BID in combination with itacitinib SR tablets. The dose of itacitinib will be orally given once daily (QD). Doses should be taken in the morning on an empty stomach if possible.
2566494|NCT02455752|Active Comparator|Reroperitoneal Group|LE-TME
2566587|NCT02455622|Experimental|Enrolled Patients|Patients who are receiving treatment with Elaprase in this study (SHP-ELA-401), who are <6 years of age, and were previously treatment-naïve. Patients who are not enrolled in this study (SHP-ELA-401) but are enrolled in the Hunter Outcome Survey (HOS) patient registry and were < 6 years of age at start of Elaprase treatment. While not enrolled in the present Study SHP-ELA-401, their height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
2566778|NCT02454738|Experimental|Chest CT scan|Two follow-up ultralow dose chest CT scans will be taken 3 months and 1 year after the initial ultralow dose chest CT scan in close contact at high risk for developing multidrug- or extensively drug-resistant tuberculosis.
2566831|NCT02453945|Experimental|Medical Support Bra|ClearPoint Medical Support Bra worn by patients during their post-cardiac surgery hospital stay (approximately 5-7days).
2566833|NCT02453945|No Intervention|Control|Usual Care
2566846|NCT02453659|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
2566851|NCT02453659|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
2567065|NCT02452372|Active Comparator|givosiran (ALN-AS1)|
2567067|NCT02452372|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
2567109|NCT02452099|Other|5% DMSO|
2567114|NCT02452099|Other|7.5% DMSO|
2567116|NCT02452099|Other|10% DMSO|
2567153|NCT02451865|Experimental|Treatment (binimetinib and docetaxel)|Patients receive binimetinib PO BID on days 1-21 and docetaxel IV on day 21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who have stable disease or better after completing 6 courses of binimetinib and docetaxel may continue receiving binimetinib PO BID in the absence of disease progression or unacceptable toxicity.
2567200|NCT02451527|Experimental|Digoxin and PEX168|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of a single dose of 200ug PEX168, followed by a further single dose of 0.5mg digoxin on Day 38.
2567237|NCT02451293|Active Comparator|Melatonin (N-acetyl-5-methoxytryptamine)|Melatonin (N-acetyl-5-methoxytryptamine) 25 mg oral administration 1 hour before bedtime for 12 weeks.
2567238|NCT02451293|Placebo Comparator|Placebo|Comparable placebo pill, oral administration 1 hour before bedtime for 12 weeks.
2567280|NCT02450981|Experimental|BCD-021 group|BCD-021 (bevacizumab) at a dose of 1.25 mg, administered as single intravitreal injection every 28 days up to 12 months.
3172521|NCT00600795||A|Patients diagnosed with Normal Pressure Hydrocephalus
2567491|NCT02449694|Experimental|OCS Liver|OCS Liver will be used to preserve the donor liver
2567571|NCT02449382|Active Comparator|continuous venovenous hemofiltration|CVVH was mainly determined by the differences of sodium concentration between serum and replacement fluid. The rate of decline serum sodium could be real-time adjusted using different-sodium-concentration replacement fluid according to the updated serum sodium concentration.
2567581|NCT02449382|Active Comparator|Control group|Treatment of hypernatremia is correction of water deficit.
3172522|NCT00600834||1|patients with moderate CKD (stage 3, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
3172523|NCT00600834||2|patients with severe CKD or kidney failure (stages 4 and 5, according to the classification of CKD by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2).
3172524|NCT00600847|Active Comparator|1|desloratadine 20 mg
3172525|NCT00600847|Active Comparator|2|desloratadine 5 mg
3172526|NCT00600847|Placebo Comparator|3|
3172527|NCT00600860||MDS patients|Patients with MDS according to current WHO criteria and International Prognostic Scoring System (IPSS) classification
3172528|NCT00600873|Experimental|1|patients with early ALS
3172529|NCT00600899|Experimental|A|Group A patients will receive perisciatic continuous infusion of ropivacaine 2 mg/ml through an elastomeric pump (Baxter, Deerfield, IL, USA)) 8 ml/h (reservoir of 500 ml)as postoperative analgesia.
2566162|NCT02458157|Experimental|Forced Fluid Removal|"The experimental intervention is guided by a therapeutic goal of average negative fluid balance ≥ 1 ml/kg/h and safety variables indicating inadequate circulation (lactate ≥ 4, MAP < 50 or mottling beyond the edge of kneecaps).~The effect of fluid removal is evaluated three times daily (06:00. 14:00 and 22:00), while the safety variables are evaluated continuously. Resuscitation is started if one or more signs of inadequate circulation is present.~The first choice for fluid removal is diuretic therapy with furosemide, which is continued for a minimum of 8 hours. If the therapeutic goal (negative fluid balance ≥ 1 ml/kg/h) is not achieved and/or maintained by furosemide alone, then fluid removal with continuous renal replacement therapy (CRRT) is initiated."
2566169|NCT02458157|Active Comparator|Usual Care|Usual Care at the discretion of the treating clinicians, except for the initiation of renal replacement therapy (RRT).
2566270|NCT02457221|Experimental|Tacrolimus group|Tacrolimus capsules + steroid
2566273|NCT02457221|Active Comparator|Cyclophosphamide group|Cyclophosphamide injections + steroid
2566367|NCT02456792|Active Comparator|IVF group|Women will undergo one full IVF cycle
2566368|NCT02456792|Active Comparator|LOD group|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
2566400|NCT02456415|Experimental|K-MET™ Bioresorbable Bone screw|The K-MET™ Bioresorbable Bone Screw, intended to be used for trauma therapy, consists of Cortex screws, Cannulated headless screws. For Headless screw and Cannulated headless screws, the design is similar to normal headless compression screws but the compression function was achieved by using different lengths for the front and rear pitches. These screws are dynamic and allow therewith the fracture at the Carpal, metacarpal, and small hand bone.
2566472|NCT02456324|Experimental|Treatment Group|Patients Treated with PICS-AF device
2566475|NCT02456324|Other|Historical Controls|Patients Treated with Commercially Available Fistula Plug Devices at Same Sites
2566507|NCT02455765|Experimental|White rice control|Subjects will consume white rice as control (50g carbohydrate)
2566514|NCT02455765|Experimental|co-ingest low dose of amino acid|Subjects will receive 68 ml of amino acid mixture together with white rice
2566521|NCT02455765|Experimental|co-ingest high dose of amino acid|Subjects will receive 136 ml of amino acid mixture together with white rice
2566528|NCT02455765|Experimental|pre-load low dose15 min|Subjects will receive 68 ml of amino acid mixture 15 min before consumption of white rice
2566536|NCT02455765|Experimental|pre-load low dose 30 min|Subjects will receive 68 ml of amino acid mixture 30 min before consumption of white rice
2566540|NCT02455765|Experimental|pre-load high dose 15 min|Subjects will receive 136 ml of amino acid mixture 15 min before consumption of white rice
2566545|NCT02455765|Experimental|pre-load high dose 30 min|Subjects will receive 136 ml of amino acid mixture 30 min before consumption of white rice
2566564|NCT02455375||Cases|"Case group = group of patients positive with reference tests including serological (ELISA, IF neutralization) and/or molecular assays:~detection of PUUV RNA in plasma collected at admission.~or/and detection of IgM and IgG against PUUV in serum collected at admission,~or/and detection of a seroconversion in IgG against PUUV from admission and late sera"
2566566|NCT02455375||Controls|Control group = group of patients who do not have the criteria listed above
2566632|NCT02455141|Active Comparator|Taxanes|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel
2566635|NCT02455141|Experimental|Taxanes plus carboplatin|Epirubicin plus Cyclophosphamide followed by Paclitaxel or Docetaxel + Carboplatin
2566738|NCT02454387|Experimental|Experimental: ONO-4474 Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566741|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A1|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566744|NCT02454387|Experimental|Experimental: ONO-4474 Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566745|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part A2|Single doses (2 periods) of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566746|NCT02454387|Experimental|Experimental: ONO-4474 Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566747|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part B|Multiple ascending doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566748|NCT02454387|Experimental|Experimental: ONO-4474 Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
2566749|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part C|NGF hyperalgesia and single or multiple doses of ONO-4474, randomized 1 active: 1 placebo in cross over design
2566750|NCT02454387|Experimental|Experimental: ONO-4474 Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566753|NCT02454387|Placebo Comparator|Experimental: ONO-4474 Placebo Part D|Single doses of ONO-4474 or placebo, randomized 3 active: 1 placebo
2566847|NCT02453906|Experimental|healthy subjects|they receive XNKQ acupuncture, as well as control 1, control 2, and control 3 in a randomized order.
2566911|NCT02453412|No Intervention|Control|Standard care in operative planning in AVF creation, that is physical examination and extensive duplex examination of the arm vasculature carried out by an experience vascular technician.
2566913|NCT02453412|Experimental|Simulation|Standard care with the intervention of advisement of the preferred AVF-configuration, based on computational model simulation for predicting postoperative flow (AVF-simulation).
2566987|NCT02453035||PTCA - Desolve Scaffold|Patients with coronary artery stenosis who have been treated with a DESolve bioresorbable coronary scaffold
2567044|NCT02452593|Active Comparator|"Tibial Nerve Stimulation"|"This group will do transcutaneous electrical stimulation of the tibial nerve at home.~Development of an innovative portable equipment, with domestic technology for home application of the posterior tibial nerve stimulation technique using the type SSP surface electrodes (Silver Spike Point). Frequency: 20 Hz, Pulse width: 200 us; duration: 15min daily"
2567054|NCT02452593|Active Comparator|"Pelvic Floor Exercises"|This group will make pelvic muscle training 3 times a day . In decubit dorsal posture, legs flexed and abductee. Perform pelvic floor contractions keeping 2 seconds and relaxing 4 seconds for 10 times, and contractions keeping 4 seconds and relaxing 8 seconds for 10 times.
2567104|NCT02452242|Experimental|ABX464|
2566177|NCT02457975|Experimental|670nm PBM plus VEGF-inhibitors|Subjects in the 670 nm Photobiomodulation (PBM) intervention arm will be treated (in addition to Anti-VEGF treatment) with 670nm light (WARP10, Quantum, Devices, Inc, Barneveld, WI). The portable, battery-operated 670 nm LED array specifically designed not to generate heat will be held 1 inch from the closed treatment eye. A 90-sec light treatment will be delivered. After 90 sec a timer turns off the light. The dose of light delivered at the surface of the cornea is calculated to be 4.5 J/cm2 (90 sec x 0.05 W/cm2 = 4.5 J/cm2). PBM treatment will be applied for 90 sec once per day, three consecutive days per week for 8 weeks. Previous clinical studies, have shown this treatment regimen and dose to be safe and effective in the treatment of dry AMD and non-center involving DME
3207605|NCT00966524|Experimental|Video|Teaching tracheal intubation to medical students using video-guided feedback during the procedure.
2566291|NCT02457208|Experimental|2HRZE/4HR|"2HRZE/4HR~Intensive phase: 2 months HRZE - once daily~Continuation phase: 4 months HR - once daily~Adults will be treated with fixed dose combination (FDC) tablets containing:~Intensive phase (content per tablet)~Isoniazid -75 mg,~Rifampicin - 150 mg,~Pyrazinamide - 400 mg,~Ethambutol - 275 mg~Continuation phase (content per tablet)~Isoniazid 150 mg~Rifampicin 300 mg~*Drug dosing will be adjusted by patient body weight."
2566324|NCT02456922|Other|Group A|Subjects wearing Harmony 1 Sensor for up to 10 days.
2566373|NCT02456766||F0|Liver Steatosis Grade: <5%
2566386|NCT02456766||F1|Liver Steatosis Grade: 5-33%
2566391|NCT02456766||F2|Liver Steatosis Grade: 34-66%
2566394|NCT02456766||F3|Liver Steatosis Grade: > 66%
2566447|NCT02456051||High AM|Newly diagnosed diabetic patients with high Adrenomedullin serum levels
2566450|NCT02456051||Low AM|Newly diagnosed diabetic patients with low Adrenomedullin serum levels
2566542|NCT02455986|Experimental|Intervention|"The intervention group includes 150 participants aged 12-14 across three schools. Each participant has been given a Fitbit Zip pedometer to wear for a six month period and enrolled on the StepSmart challenge. Participants within the intervention group will take part in two competitions during this period.~School and team based competition. 27/05/15 - 22/06/15 (8 weeks)~Individually focused competition. 22/06/15 - 26/10/15 (18 weeks)~Prizes of low monetary value will be given to participants based on competition performance"
2566544|NCT02455986|No Intervention|Control|The control group for the study involves approximately 90 participants aged 12 - 14. across two schools. Participants within the control group will complete the same measures as the intervention group including wearing an actigraph GT3X accelerometer for a seven day period and completing all questionnaires at the same time points as the intervention group.
2566730|NCT02454621|Active Comparator|Control|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation and are asked to tick critical situations/appropriate responses that might be useful to them."
2566735|NCT02454621|Experimental|Volitional help sheet|"Participants read a brief statement designed to encourage them to quit smoking (We want you to plan to quit smoking). Participants are presented with a table with two columns and twenty rows. Twenty critical situations (temptations) are presented in the left hand column and 20 appropriate responses (processes of change) are presented in the right hand column (see Armitage, 2008). Participants are told that identifying situations in which they were tempted to smoke and identifying ways to overcome those temptations had been shown to promote smoking cessation. Implementation intentions are formed by linking critical situations with appropriate responses by drawing lines between critical situations and appropriate responses."
2566825|NCT02454192|Other|CHAMPS Intervention|Tailored asthma education and counseling for children with moderate to severe asthma who have confirmed allergies to environmental triggers present in their homes provided through a combination of clinic and home visits
2566828|NCT02454192|No Intervention|Usual Care|Usual asthma care and management
2566899|NCT02453503|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
2566902|NCT02453503|Experimental|Licorice|Licorice mucoadhesive films 1 mg every 6 hours for two weeks.
3207606|NCT00966524|Active Comparator|Standard|Teaching tracheal intubation to medical students using direct visualization feedback during the procedure.
3207607|NCT00966563|Active Comparator|Mangafodipir treatment|Treatment will be undertaken with a ready-to use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI. Formulation content: MnDPDP 10 mmol/ml.
3207608|NCT00966563|Placebo Comparator|NaCl 0.9%|
3207609|NCT00966576|Experimental|Brinzolamide/Timolol Maleate Fixed Combination|
2567052|NCT02452385|Experimental|CM082 tablet|Escalating dose of CM082 tablet starting at 25mg once a day
2567100|NCT02452177|Experimental|Vitamin D|Patients in this group were treated with oral vitamin D at a dose of 1200 IU per day for 2 months.
2567103|NCT02452177|Placebo Comparator|Placebo|
3207610|NCT00966589|Sham Comparator|conservative treatment|physiotherapy
2567214|NCT02451475|Other|Amitriptyline|Amitriptyline 25 mg/day
2567217|NCT02451475|Active Comparator|Venlafaxine|Venlafaxine 75 mg/day
3207611|NCT00966589|Active Comparator|surgery|laparoscopic hernioplasty (TEP)
3207612|NCT00966602|Experimental|Treatment Period 1|
3207613|NCT00966602|Experimental|Treatment Period 2|
3207614|NCT00966602|Experimental|Treatment Period 3|
3207615|NCT00966615|Experimental|Balance group|peritoneal dialysis with neutral peritoneal dialysis solution with minimal glucose-degradation-product
3207616|NCT00966615|Active Comparator|Control group|conventional PD solution
3207617|NCT00966628|Active Comparator|Ringer's lactate|
3207618|NCT00966628|Experimental|Hypertonic sodium lactate|
3207619|NCT00966667||cancer survivor|cancer survivor
3207620|NCT00966680||1|Observational study comparing the speed of general versus spinal anesthesia during emergency cesarean
2566195|NCT02457832|Experimental|Internal guidance training (IG)|Adapted tango dancing is a sophisticated, yet accessible system of tactile communication that conveys motor intentions and goals between a leader and follower. Those in IG training will choose direction, timing and amplitude of each successive step, and will communicate this information to their partner through moving their frame and center of mass.
2566204|NCT02457832|Experimental|Externally guided training (EG)|Those in EG will learn to attend to sensory cues for movement direction, timing and amplitude of steps, communicated from their partner to them via the frame and center of mass. The 'follower' will wait to receive the movement cue before moving.
2566212|NCT02457832|Active Comparator|Behavioral Control (BC)|BC participants will attend group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety. Participants in this training will be instructed not to change their habitual exercise routines. After completing health education, participants will be assigned to an IG or EG training class but will not undergo evaluations.
2566223|NCT02457832|No Intervention|Normal Control (NC)|Age-matched controls without Parkinson's disease will come in for a single assessment including MRI.
2566318|NCT02457130|Experimental|Group A|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week; washout period of 2-4 weeks; crossover to clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week."
2566320|NCT02457130|Experimental|Group B|"After providing written informed consent, eligible subjects will be randomized in a 1:1 fashion to group A or B.~Clopidogrel (600-mg loading dose the first day followed by 75-mg daily maintenance dose) for one-week; washout period of 2-4 weeks; crossover to ticagrelor (180-mg loading dose the first day followed by 90-mg b.i.d. maintenance dose) for one week."
2566398|NCT02456584|Experimental|DMPA 150|single subcutaneous injection of 150mg/mL of DMPA in the abdomen
2566413|NCT02456584|Experimental|DMPA 300|single subcutaneous injection of 300mg/2mL of DMPA in the abdomen
2566421|NCT02456584|Active Comparator|DMPA 104|two injections, given at three months intervals, of 104mg/0.65mL of DMPA in the abdomen
2566539|NCT02455843|Experimental|Microwave plus chemotherapy|In combination group, patients will be treated with microwave ablation in primary tumor sites followed by chemotherapy （For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip, or docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip,or novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
2566543|NCT02455843|Placebo Comparator|chemotherapy|In chemotherapy group,patients will be treated with chemotherapy alone（For non-squamous cell lung cancer，patients will be treated with pemetrexed，500mg/m2, d1, ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with a area uder the curve of 5 d1 ivdrip. For squamous cell lung cancer，patients will be treated with docetaxel,75mg/m2, d1, ivdrip or gemcitabine 1250mg/m2, d1 d8, novelbine 25mg/m2 d1 d8, ivdrip, paclitaxel 175mg/m2 d1 ivdrip plus cisplatin 75mg/m2, d1 d2, ivdrip or carboplatin with an area under the curve of 5 d1 ivdrip；repeated every 3 weeks and up to 6 cycles are administrated ）
2566611|NCT02455271||Participants with insomnia|Participants with insomnia who will receive eszopiclone per approved label.
2566670|NCT02455011|Experimental|REMD-477 Treatment A|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
2566673|NCT02455011|Placebo Comparator|Matching placebo|Placebo administered as single and repeated SC doses in subjects with Type 2 Diabetes
2566674|NCT02455011|Experimental|REMD-477 Treatment B|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
2566675|NCT02455011|Experimental|REMD-477 Treatment C|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
2566676|NCT02455011|Experimental|REMD-477 Treatment D|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
2566677|NCT02455011|Experimental|REMD-477 Treatment E|Administered as a single and repeated SC doses in subjects with Type 2 Diabetes
3172530|NCT00600899|Active Comparator|B|Group B patients will receive standard treatment: continuous perisciatic infusion of 2 mg/ml ropivacaine 5 ml/t (Baxter infusor with 275 ml reservoir)
3172531|NCT00600912|Experimental|1-SMOFlipid®|lipid emulsion based on soybean oil, medium-chain triglycerides, olive oil and fish oil SMOFlipid®-Group (n = 21)
2566784|NCT02454062|Experimental|Dose Escalation TAS-114 (PART 1)|Each cycle will be 21 days: 14 days of treatment and 7 days recovery. TAS-114 and S-1 will be escalated according to a defined dosing table and specific DLT criteria.
2566799|NCT02454062|Experimental|Expansion phase TAS-114 (PART 2)|"The TAS-114 and S-1 MTD established in the Dose Escalation Phase will be administered BID for 14 days followed by a 7 day recovery period.~This regimen is repeated every 21 days thereafter. Approximately 40 to 60 evaluable patients will be enrolled in the Expansion Phase. PGx, PD and PK analysis will be performed based on specific criteria."
2566922|NCT02453230|Active Comparator|light on|BPP done with lights on
2566930|NCT02453230|No Intervention|light off|Biophysical profile examinations done with the light off
2566990|NCT02453009|Experimental|Arm A|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks
2566997|NCT02453009|Active Comparator|Arm B|Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks
2567090|NCT02452307|Experimental|Peptide vaccine + local hyperthermia|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with local hyperthermia
3172532|NCT00600912|Active Comparator|2-ClinOleic 20%®|olive and soybean oil-group (n=21)
3172533|NCT00600951||1|Patients with moderate chronic kidney disease (stage 3, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR comprised between 30 and 59 mL/min/1.73m2)
2566222|NCT02457689|Active Comparator|Group 4 (Electroporation and Active)|Group 4 (Electroporation and Active) Participants will receive 1.0ml intramuscular injections of the GTU®-MultiHIV B Clade Vaccine (2mg/ml) into the upper thigh using the ICHOR TriGridTM delivery system for intramuscular (TDS-IM) delivery with electroporation. Electroporation (EP) improves the delivery of the product into muscle cells, by delivering an electrical pulse with the injection using a hand held device that is pressed against your thigh. This will cause a muscle twitch with a sharp cramp-like feeling in the thigh lasting a few seconds. Once the procedure is carried out, the muscle will feel sore for up to 72 hours. The investigator will ask volunteers not to engage in any strenuous exercise for at least 24 hours after the procedure.
2566267|NCT02457377|Experimental|Laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
2566408|NCT02456753||trans-perineal ultrasonography|"Patients included are women about to give birth, they undergo a clinical examination done by midwives. Followed by a trans-perineal ultrasonography examination done by a technical operator in order to measure the perineal-cephalic distance.~These examination are done the day of enrollment, they last for a few minutes and no further tests will be done afterwards."
2566452|NCT02456311|Other|Harmonic Ace+7|Pulmonary ARtery sealing with Harmonic Ace+7 in open lobectomy
2566546|NCT02455973|Experimental|Transtheoretical model of change|In this type of intervention, the focus will be the development of skills through educational activities on health based on interdisciplinary motivational strategies.
2566547|NCT02455973|Placebo Comparator|Health information|In this type of intervention, the focus will be the development of skills through educational activities on health using the pedagogy of transmission.
3207621|NCT00966706|Experimental|Arm I|Patients receive cisplatin, gemcitabine hydrochloride, and docetaxel on days 1 and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3207622|NCT00966706|Experimental|Arm II|Patients receive cisplatin, gemcitabine hydrochloride, and epirubicin hydrochloride on days 1and 15, and capecitabine on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2566684|NCT02454816|Experimental|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
2566685|NCT02454816|Active Comparator|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
3207623|NCT00966732|Experimental|yoga condition|assigned to start the yoga program right away
2566870|NCT02453529|Experimental|WCK 4873|Oral tablets
3207624|NCT00966732|No Intervention|wait-list control condition|This condition will control for any effects of symptom measurement reactivity in patients receiving routine fibromyalgia medical care. After the 3-month assessment, the yoga intervention program will be provided to these patients.
2566996|NCT02452775|Experimental|Arm 1|Subjects in ARM 1 will receive the vaccination with OC-L alone
2566999|NCT02452775|Experimental|Arm 2|subjects in ARM 2 will receive vaccination with OC-L admixed with Montanide,
2567003|NCT02452775|Experimental|Arm 3|subjects in ARM3 will receive vaccination with OC-L admixed with 1 mg poly-ICLC (Hiltonol)
2567005|NCT02452775|Experimental|Arm 4|subjects in ARM 4 will receive vaccination with OC-L admixed with both Montanide and 1 mg poly-ICLC.
2567029|NCT02452515|Experimental|BAY1142524 (5 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
2567033|NCT02452515|Experimental|BAY1142524 (10 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
2567043|NCT02452515|Experimental|BAY1142524 (25 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
2567055|NCT02452515|Experimental|BAY1142524 (50 mg)|12 patients with left-ventricular dysfunction after myocardial infarction, 9 patients allocated to verum treatment, 3 patients allocated to placebo treatment
2567102|NCT02452073||CRE group|patients with chronic radiation enteritis
2567105|NCT02452073||malignancy group|patients with some kinds of malignant tumors but had not previously received radiotherapy
2567111|NCT02452073||control group|age-matched healthy volunteers
2567133|NCT02451904||Severe/Cerebral Malaria|Intensive monitoring
2567135|NCT02451904||Uncomplicated Malaria|Intensive monitoring
2567138|NCT02451904||Sepsis|Intensive monitoring
2567140|NCT02451904||Acidosis|Intensive monitoring
2567141|NCT02451904||Encephalitis|Intensive monitoring
2567142|NCT02451904||Healthy Individuals|Monitoring
3207625|NCT00966745|Active Comparator|milrinone|milrinone infusion
3207626|NCT00966745|Placebo Comparator|placebo|
2567230|NCT02451319|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w holmium laser device who have 1-2 cm diameter kidney stones
2567232|NCT02451319|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser device (working over 20w power) who have 1-2 cm diameter kidney stones
2567292|NCT02451098|Experimental|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe10mg will be administered (Duration 8 weeks)
3207627|NCT00966758|Other|1|
2566365|NCT02456805|Active Comparator|Infant Formula 1|A standard commercial milk-based infant formula
2566366|NCT02456805|Experimental|Infant Formula 2|A standard commercial soy-based infant formula.
2566396|NCT02456467||Cardiac Surgery Patients|Intervention: Procedure: Blood specimen collection
2566470|NCT02456337|Experimental|CAF+MC+EMD|Coronally Advanced Flap with Mucograft and Emdogain
2566474|NCT02456337|Active Comparator|CAF+MC|Coronally Advanced Flap with Mucograft
2566477|NCT02456337|Active Comparator|CAF+EMD|Coronally Advanced Flap with Emdogain
2566481|NCT02456337|Active Comparator|CAF|Coronally Advanced Flap alone
2566493|NCT02455726|Experimental|Mg-group|"Standard therapy plus magnesium oxide.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
2566496|NCT02455726|Placebo Comparator|C-group|"Standard therapy plus fructose.~Standard therapy: oxycodone 5 mg and pregabalin 25 mg per day for two weeks. Starting by day 2, the opioid dose will be titrated every 48 hours in order to reach the maximum therapeutic goal and to minimize side effects.~A rescue dose: paracetamol 1g (maximum dose 3 g per day)."
2566562|NCT02455310||Outpatients with dementia|Medication use will be evaluated among outpatients with dementia in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
2566563|NCT02455310||Nursing home residents|Medication use and behavioral outcomes will be evaluated among nursing home residents in intervention and control counties, as well as statewide to evaluate the long-term effectiveness of the statewide intervention.
2566621|NCT02455232|Experimental|hemiplegic patient|muscle participation in upper limb spasticity
2566713|NCT02454660|Experimental|SMS (Text messaging)|This group will receive text messages during their entire enrollment period in the study.
2566718|NCT02454660|No Intervention|No SMS (No text messages)|This group will not receive text messages during their entire enrollment period in the study.
2566801|NCT02454244|Experimental|Amygdala Retraining Technique (ART) with Mindfulness|Consists of 10 weekly sessions, followed by 3 monthly sessions
2566805|NCT02454244|Experimental|Mindfulness Compassion|Includes the attentional training aspect of mindfulness and meditation practices, proved to bring benefits in relation to fibromyalgia and CFS symptoms, as fatigue and pain. Compassion training focuses on the ability to be kind to participants and their own experience, specifically to their experience of suffering. The protocol consists of 10 weekly sessions, followed by 3 following monthly sessions
2566809|NCT02454244|Active Comparator|Relaxation|Consists of 10 weekly sessions, followed by 3 monthly sessions
2566856|NCT02453763||Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation and an magnetic resonance imaging (MRI).
3207628|NCT00966771||IUD|Women presenting for emergency contraception who select the copper IUD
3207629|NCT00966771||Oral levonorgestrel|Women presenting for emergency contraception who select oral levonorgestrel
3207630|NCT00966810|Experimental|CML allogeneic stem cell transplantation|Patients with chronic myeloid leukemia suitable for allogeneic stem cell transplantation with a matched related donor.
3207631|NCT00966836|Experimental|Pre-emptive everolimus|
3207632|NCT00966836|Experimental|Prophylaxis mycophenolate|
2567032|NCT02452437|Experimental|control|Oxycodone will be administered and subjects will undergo hemodialysis
2567042|NCT02452437|Experimental|hemodialysis|Oxycodone will be administered and subjects will undergo hemodialysis
2567128|NCT02452229||Burn patients|The included patient are burn victims who sustained a burn of at least 1 % total body surface are (TBSA); with no restriction on age.
2567170|NCT02451800|Experimental|in-class yoga|"The intervention is a in-class yoga course taught by yoga instructors for 3 times per week for 3 months. This class is based on Peggy Cappy's Program: More Yoga for Every Body. Class is taught at Sanford Wellness Centers in Sioux Falls, South Dakota and Fargo, North Dakota. Each class in 1 hour in length."
2567173|NCT02451800|Active Comparator|yoga by DVD|"For the intervention participants are asked to do yoga at home following the Peggy Cappy's Program: More Yoga for Every Body DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
2567175|NCT02451800|Active Comparator|stretching by DVD|"For the intervention participants are asked to do stretching exercises at home following Bob Anderson's DVD-Stretching: the DVD. They are asked to complete these exercises 3 times per week for 3 months. The DVD is 1 hour in length."
2567208|NCT02451540|Active Comparator|Roflumilast|Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
2567210|NCT02451540|Placebo Comparator|Placebo|Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.
2567293|NCT02451098|Active Comparator|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, placebo will be administered (Duration 8 weeks)
2567295|NCT02451098|Experimental|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe10mg will be administered (Duration 8 weeks)
2567297|NCT02451098|Active Comparator|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, placebo will be administered (Duration 8 weeks)
3207633|NCT00966836|Experimental|Prophylaxis Everolimus|
3207634|NCT00966836|Active Comparator|Pre-emptive mycophenolate|
3207635|NCT00966888|Experimental|Arm I|Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
3207636|NCT00966888|Active Comparator|Arm II|Patients receive standard of care and observation only.
3207637|NCT00966901|Experimental|Three Treatment Sites UV Exposed|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
3207638|NCT00966914|Placebo Comparator|Placebo|Placebo in combination with cisplatin and either paclitaxel or docetaxel
3207639|NCT00966914|Active Comparator|Tavocept (BNP7787)|Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
3207640|NCT00966927||subjects with spina bifid|subjects with spina bifid between 14 and 21 years old referred to Unit for Care of Spina Bifid Hospital of Parma
2566351|NCT02456844|Experimental|Group 1|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142
2566354|NCT02456844|Experimental|Group 2|Methotrexate,Leucovorin and BMS-986142
2566407|NCT02456610|Experimental|Infusion of CMV/EBV specific CTLs|Repetitive CTLs infusion to treat CMV/EBV activation and infection
2566478|NCT02456298|Active Comparator|Standard FA+FCT|Parents are coached via weekly telehealth visits to use Functional Analysis (FA) to assess problem behavior and Functional Communication Training (FCT) to treat the problem behavior identified.
2566480|NCT02456298|Experimental|Pragmatic FA+FCT|Parents are coached via weekly telehealth visits to use a brief, streamlined version of Functional Analysis (FA) to assess problem behavior and to follow that assessment with Functional Communication Training (FCT) to treat the problem behavior identified. The version of FCT used in the Pragmatic arm involves significantly less data scoring and graphing than the version used in the Standard arm.
2566525|NCT02455739|Experimental|chewing gum positive|chewing gum group will chew gum
2566532|NCT02455739|No Intervention|chewing gum negative|chewing gum group will not chew gum
3207641|NCT00966966|Experimental|1|SAM-531_gemfibrozil
3207642|NCT00966979|Other|Triathlon PKR|All subjects enrolled will receive the Triathlon PKR device.
3207643|NCT00967031|Experimental|Lapatinib + capecitabine|lapatinib 1250mg/day + capecitabine 2000mg/m2/day
3207644|NCT00967057|Experimental|Arm I (induction therapy)|Patients receive idarubicin IV over 1 hour on days 1 and 2; oral dexamethasone twice daily on days 1-5 and 15-19; intrathecal (IT) methotrexate on days 1 and 8; vincristine sulfate IV on days 3, 10, 17, and 24; and pegaspargase intramuscularly (IM) on days 3 and 17 or asparaginase IM on days 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, and 25.
2566679|NCT02454868|Experimental|Study arm|There is a single study arm. Remifentanil will be infused before intubation. The first patient will receive remifentanil 2mg/kg. If a success occurs the next patient's dose will be decreased by 0.25mg/kg and else it will be increased by 0.25mg/kg. This rule will apply recursively as Dixon's Up-And-Down Method.
2566765|NCT02454335|Active Comparator|Anterior Approach|For the anterior approach, an incision will be made in the 1 to 2 o'clock position of the esophageal wall.
2566766|NCT02454335|Active Comparator|Posterior Approach|For the posterior approach, a mucosal incision will be made at the 5 to 6 o'clock position
2566789|NCT02454023|Active Comparator|Standard of care|Patients receive usual standard of care for investigating obstructive sleep apnea after stroke/transient ischemic attack, which is in-laboratory polysomnography.
2566797|NCT02454023|Experimental|Portable sleep monitor (ApneaLink Air)|Patients will undergo screening for obstructive sleep apnea using the ApneaLink Air portable sleep monitor.
3207645|NCT00967057|Experimental|Arm II (induction therapy)|Patients receive mitoxantrone IV over 1 hour on days 1 and 2. Patients also receive dexamethasone, methotrexate, vincristine sulfate, and pegaspargase or asparaginase as in arm I.
2566917|NCT02453204|Experimental|Sitting|Participants will remain sitting throughout the test period whilst undertaking typical sedentary behaviours such as watching TV, using a computer, reading and writing. Walking and standing will be restricted.
2566925|NCT02453204|Experimental|Standing|Participants will be asked to break their sitting time by standing for five minutes every 30 minutes. Participants will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
2566935|NCT02453204|Experimental|Walking|The walking condition will be identical to standing, but the breaks in sitting time will be punctuated with five minute bouts of self-paced walking rather than standing.
2566977|NCT02452905|Active Comparator|Nitazoxanide|Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
2566991|NCT02452905|Placebo Comparator|Placebo|The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide. It is reconstitutes, administered and dosed as per the active study drug.
2567038|NCT02452541|Other|Prognostic evaluation|Prognostic tests/exams performed according to a determined schedule during the acute phase of care following admission in the intensive care unit.
2567107|NCT02452112|Active Comparator|Lidocaine|Active arm with administration of active 5% Lidocaine patch
2567113|NCT02452112|Placebo Comparator|Placebo|Placebo arm with administration of placebo patch
2567157|NCT02451761||Sequencing|Blood sampling will be carried out in all patients ; molecular analysis and sequencing will be performed on these samples
2567199|NCT02451618||Epidermal Electronic System|EES, wireless tattoo electrode
2567202|NCT02451618||Hydrogel electrode|EKG electrode, looking at hairline placement of electrodes.
2567228|NCT02451332|Experimental|vaccinated|These women will have received the seasonal influenza vaccine.
2567261|NCT02451111|Active Comparator|Rituximab/Ibrutinib|Ibrutinib capsules for 24 months (104 weeks) daily (always at the same time) in a dose of 560 mg (4 x 140 mg capsules)
2567272|NCT02451111|Placebo Comparator|Rituximab/Placebo|Placebo as comparator for 24 months (4 capsules daily always at the same time)
2567352|NCT02450500|Experimental|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging.
2567404|NCT02450253|Active Comparator|Active Treatment|Tadalafil 20mg Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
2567408|NCT02450253|Placebo Comparator|Control|Matched placebo Capsule Stat single dose 2 x MRI scans (pre and post dose) Neuropsychological tests pre and post IMP dose Cognitive functioning prior to 1st MRI scan of that visit
2567458|NCT02449850|No Intervention|Observation only|Observation only
2567461|NCT02449850|Experimental|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
2567467|NCT02449850|Experimental|Skin care|Intervention: regular baths with bath-oil 0.5-9 months of age
2567468|NCT02449850|Experimental|Food intervention and skin care|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age Intervention: regular baths with bath-oil 0.5-9 months of age
2566283|NCT02457442|Active Comparator|PR2|Propofol-Remifentanil: Prop low, Remi high. Changing Prop (up-and-down)
2566284|NCT02457442|Active Comparator|SR1|Sevoflurane-Remifentanil: Sevo high, Remi low. Changing Remi (up-and-down)
2566286|NCT02457442|Active Comparator|SR2|Sevoflurane-Remifentanil: Sevo low, Remi high. Changing Sevo (up-and-down)
2566292|NCT02457442|Active Comparator|SPR1|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Propofol.
2566296|NCT02457442|Active Comparator|SPR2|Sevoflurane-Propofol-Remifentanil: Sevo plus Remi intermediate, Remi intermediate; changing Sevoflurane.
2566347|NCT02456870|Other|MA|Middle-aged overweight and obese men (age 25-40yr)
2566348|NCT02456870|Other|OA|Older overweight and obese men (age 55-75yr)
3207646|NCT00967070|Experimental|Both Treatments Applied on Lower Back|Treatments were applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
3207647|NCT00967083||family caregivers of lung cancer patients|In this 2-year pilot study, we plan to screen family caregivers of lung cancer patients within 4 to 6 weeks after the a new visit to the thoracic clinic. We will screen spouses, adult children, and other family members using the HAD-18 to determine their level of anxiety and depressive symptoms at enrollment.
3207648|NCT00967096|Experimental|1|The primary clinical endpoint to be assessed in this study will be the proportion of Rifaximin doses successfully administered. Because of mucositis, compliance with oral agents, even those that are well tolerated in other settings, may be limited in the early post-transplant period. Thus, it will be important to demonstrate the feasibility of administering Rifaximin to BMT patients before embarking on larger scale studies. Secondary outcomes will include AGVHD, event-free survival, overall survival, non-relapse mortality, neutrophil and platelet engraftment.
2566557|NCT02455648|Experimental|ESD/EMR plus Cell Sheet|Patients receive both mucosal buccal biopsy and insertion of cell sheets during/after ESD/EMR
2566558|NCT02455648|Sham Comparator|ESD/EMR|patients receive both mucosal biopsy but no placement of cell sheets during/after ESD
2566608|NCT02455297|Experimental|Copanlisib|Copanlisib (BAY80-6946) solution for IV infusion
3207649|NCT00967109|Active Comparator|Allowed drop in hemoglobin to 4,5-5,5 mmol/L|Transfusion with red blood cells to level between 4.5-5.5 mmol/L
3207650|NCT00967109|Experimental|Allowed drop in hemoglobin to 5,5-6,5 mmol/L|Transfusion with red blood cells to level between 5.5-6.5 mmol/L
3207651|NCT00967122|No Intervention|No Arm|
3207652|NCT00967135|Experimental|Pregabalin|Study subjects will be randomized to receive on the morning of surgery, at least 30 minutes before induction, a 150 mg oral dose of pregabalin. Patients will then receive a 150 mg oral dose of pregabalin on the evening of the surgery. Subsequently, patients will receive a 150 mg oral dose of pregabalin twice daily on the following four postoperative days.
2566807|NCT02454088|Active Comparator|Triamcinolone acetate|Injection of Calcium hydroxylapatite with Triamcinolone acetate
2566811|NCT02454088|Placebo Comparator|Placebo|Injection of Calcium hydroxylapatite with a placebo
2566864|NCT02453776|Experimental|PRECISION dosing|Infliximab may vary between 1-10 mg/kg and the interval between 4 and 12 weeks.
2566867|NCT02453776|No Intervention|Conventional dosing of Infliximab|Infliximab 5 mg/kg every 8 or 6 weeks
3207653|NCT00967135|Placebo Comparator|Placebo|Study subjects will be randomized to receive a matching placebo on the morning of surgery, at least 30 minutes before induction. Patients will then receive a placebo on the evening of the surgery. Subsequently, patients will receive a placebo twice daily on the following four postoperative days.
3207654|NCT00967148|Experimental|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
3207655|NCT00967148|Active Comparator|Standard of care|The control arm will receive a subcutaneous injection of 4,500 U of tinzaparin daily beginning with the first postoperative dose and continued for the duration of hospitalization.
2567012|NCT02452736|Experimental|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|This is a Single arm, Non-randomized Study. All patients meet the eligibility criteria and sign the informed consent form will participate in this study.
2567041|NCT02452489|Other|Single point group (Zhongwan)|Patients will be acupuncture with Zhongwan(RN12).
2567048|NCT02452489|Other|Combination of He-Mu points group|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).
2567058|NCT02452489|Other|Control group|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.
2567084|NCT02452164|Active Comparator|Teaching group|Parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals at the first study visit.
2567085|NCT02452164|Other|Control group|Families receive the cellphone otoscope as if they had bought it themselves from the internet. After the first study week, parents are taught to conduct cellphone otoscopy and if necessary study physician removes cerumen from childrens´ ear canals.
2567124|NCT02451969|Experimental|Experimental Group|"Single intramuscular injection of the investigational vaccine (0.5 ml) on Day 0~Intervention: investigational 23-valent PPV"
2567127|NCT02451969|Active Comparator|Control Group|"Single intramuscular injection of the control vaccine (0.5 ml) on Day 0~Intervention: control 23-valent PPV"
2567158|NCT02451774|Experimental|Pentoxifylline Plus Chemotherapy|"Pentoxifylline: 10-20 milligrams per kilogram, doses daily by oral, for 30 days.~Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine"
2567163|NCT02451774|Placebo Comparator|Placebo Plus Chemotherapy|Placebo: double blind period, one doses daily for 30 days. Chemotherapy: Prednisone, Vincristine, Daunorubicin, L-asparaginase, Cyclophosphamide, Cytarabine, 6-Mercaptopurine, Methotrexate, Hydrocortisone and Cytarabine
2567286|NCT02450968|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
2567288|NCT02450968|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
2566293|NCT02457143|Experimental|Phone call|Patients will receive a phone call from a member of the practice staff. The call will inform them about which cancer screening tests they are overdue for and will encourage them to book an appointment for screening.
2566314|NCT02456961|Active Comparator|Standard epithelium-off CXL|Removing the central 8-10mm of the epithelium and applying a riboflavin solution (0.1% riboflavin-5-phosphate and 20% dextran T-500) to the corneal surface 30 minutes before irradiation and at 5 minutes intervals during the course of a 30 minute exposure to 370 nm UVA with an irradiance of 3 mWcm-2 (UFalink, Russian Federation)
2566316|NCT02456961|Experimental|Transepithelial CXL via iontophoresis of riboflavin|"impregnation of the cornea with a riboflavin 0.1% hypotonic solution is performed by using an iontophoresis device (galvanizator; Potok-1, Russian Federation). The passive electrode (anode) was applied to the inferior part of the cervical vertebrae. The active electrode (cathode), a bath tube (glass or plastic - 10-12 ml) is applied to the open eye,then r the tube is taped to the skin of the orbital margins and filled with riboflavin 0.1%. The current intensity is initially 0.2 mA and then gradually increased to 1.0 mA at 0.2 mA for 1 minute at 10-second intervals increments to determine individual tolerance. The total time that the riboflavin administration is 10 minutes.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) using UFalink device, (Russian Federation) is then applied at a 5-cm distance for 30 minutes with continuing hypotonic riboflavin drops every 2 minutes"
2566377|NCT02456571||Group A|men with mCRPC starting sipuleucel-T (Provenge) with or without abiraterone acetate or enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, 4-12 weeks after completion of sipuleucel-T, and at progression.
2566382|NCT02456571||Group B|men with mCRPC with visceral or high risk disease pre-abiraterone/enzalutamide will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
2566389|NCT02456571||Group C|men with high volume metastatic castration sensitive prostate cancer (mCSPC) starting hormonal therapy and docetaxel chemotherapy or who decline docetaxel chemotherapy will have CTC enumeration and immune checkpoint characterization at baseline, 3 months, and progression.
2566393|NCT02456571||Group D|men with enzalutamide or abiraterone acetate resistant mCRPC will have CTC enumeration and immune checkpoint characterization at baseline (i.e. progression on enzalutamide or abiraterone acetate) and 4-12 weeks after completion of next therapy (ex. radium-223 or chemotherapy)
2566471|NCT02456181|Experimental|JumpMath|"The JUMP method focuses more on the mental activity involved in constructing mathematical knowledge. There is a strong emphasis on symbolic math (numbers, letters, mathematical symbols). Manipulatives are used prescriptively, in lessons carefully scaffolded to help students connect the objects (e.g., three buttons) to what they are intended to stand for (the magnitude 3)."
2566512|NCT02455908|Experimental|Proleukin®|"Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:~cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.~cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.~Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle."
2566603|NCT02455544||Pregnant Women|Any pregnant women that is referred to or presents to our tertiary care facility with concern for preeclampsia, will have a Congo Red Dot test preformed by research nurses. The research nurses are not involved in patient management and the results are blinded to the clinical providers and have no impact on clinical diagnosis or patient management.
2566683|NCT02455089|Experimental|Test group|"250 SLE patients : All SLE patients included in the study. Intervention : Blood analysis including GADD34 RNA level measurement every 3 months up to 1 year.~They will provided a blood sample every 3 months during a year. The result of GADD34 RNA level in mononuclear blood cells will be correlated to the clinical assessment of a SLE flare during the next 3 months.~A flare occurence will the group"
2566711|NCT02454491|Active Comparator|standard of care|intraradial heparin (5000 UI) immediately after a 6 F sheath insertion
2566719|NCT02454491|Experimental|experimental therapy|intraradial verapamil (5 mg) immediately after a 6 F sheath insertion
2566792|NCT02454231|Experimental|peripheral blood EPC injection|
2566802|NCT02454231|Active Comparator|bone marrow MNC injection|
2566848|NCT02453789|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and placebo in the second period
2566850|NCT02453789|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
2566910|NCT02453425|Active Comparator|60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
2566912|NCT02453425|Active Comparator|75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
2566914|NCT02453425|Active Comparator|90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
2566989|NCT02452983|Experimental|Sertraline|Sertraline tablets 100mg daily for 4 (28-day) cycles
3207656|NCT00967161|Experimental|Evolution Medial Pivot Knee|20 Patients will receive the EMP Knee Implant
2567222|NCT02451384|Experimental|routine surgery|In this arm the patients will be performed routine surgery to remove the tumors. And then we compare their circulating tumor cell countings in the pre and post-operation.
2567227|NCT02451384|Experimental|no-touch surgery|In this arm the patients will be performed no-touch surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
2567233|NCT02451384|Experimental|laparoscopy surgery|In this arm the patients will be performed laparoscopy surgery to remove the tumors. And then we compare their circulating tumor cells countings in the pre and post-operation.
2567269|NCT02451033|Active Comparator|standard medical therapy|Standard medical therapy
2567276|NCT02451033|Active Comparator|G-CSF|Standard medical therapy plus G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year.
2567277|NCT02451033|Active Comparator|G-CSF plus growth hormone|Standard medical therapy plus G-CSF plus Growth Hormone therapy. Growth Hormone will be given in low dose of 1unit sc daily for 1 year.
3207657|NCT00967161|Active Comparator|Triathlon PS Knee|20 Patients will receive the Triathlon PS Knee
2567833|NCT02447549|Experimental|DART|Dose escalated Adaptive tumour boost radiotherapy (DART)
3207658|NCT00967174|Experimental|Three Treatments Applied to Lower Back|Treatments were applied on the lower back, according to treatment sequence, daily for 21 days.
3207659|NCT00967187|Experimental|MPC-4326 200 mg BID X 14 Days|
2566399|NCT02456623|Experimental|Intervention|Behavioral intervention that targets the parent of a preschool age child who is overweight. The intervention is 8 sessions in length. Each session is expected to last 1-1.5 hours and will be carried out in the participant's home over 4 months. The sessions will target the nutrition and physical activity knowledge of parents and their motivation for changing parenting related to these factors. Intervention content for the parent will be based on Motivational Interviewing principles.
2566418|NCT02456623|Active Comparator|Attention Control|The attention control condition includes 1 initial Motivational Interviewing (MI) session conducted in the home. The content of the MI session will be the same as for the intervention participants. Following this session, parents will receive bi-monthly newsletters that will include content similar to what intervention participants receive. AC participants will receive a total of 7 newsletters; 2 on nutrition, 2 on physical activity, 2 on parenting behavior and 1 on community resources. AC participants will also receive a monthly 20-min phone call designed to review newsletter content and answer parent questions.
2566462|NCT02456129|Experimental|Vilaprisan + Itraconazole|Vilaprisan (BAY1002670)
2566502|NCT02455817||Cypher|Access rate of angina including degree, post PCI up to 1 year for the Cypher stent.
2566508|NCT02455817||Taxus Express|Access rate of angina including degree, post PCI up to 1 year for the Taxus Express stent.
2566515|NCT02455817||Xience V|Access rate of angina including degree, post PCI up to 1 year for the Xience V stent.
2566522|NCT02455817||Promus Element|Access rate of angina including degree, post PCI up to 1 year for the Promus stent.
2566530|NCT02455817||Resolute|Access rate of angina including degree, post PCI up to 1 year for the Resolute stent.
2566537|NCT02455817||Bare metal stents|Access rate of angina including degree, post PCI up to 1 year for bare metal stents.
2566588|NCT02455609|Active Comparator|dexmedetomidine (I)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine in 1 ml volume.
2566591|NCT02455609|Active Comparator|ketamine (II)|intrathecal drug administartion of 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg ketamine in 1ml volume.
2566595|NCT02455609|Active Comparator|Dexmedetomidine + Ketamine group (III)|intrathecal drug administartion of patients in this arm received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 5µg of dexmedetomidine plus 0.1 mg/kg of Ketamine in 1 ml volume.
2566638|NCT02454894|Experimental|Group 1|no anesthesia; postoperative management
2566641|NCT02454894|No Intervention|Group 2|no anesthesia; lying without the pillow and fasting water and food for four hours after lumbar puncture
2566652|NCT02454894|Experimental|Group 3|surface anesthesia with lidocaine; postoperative management
2566660|NCT02454894|Experimental|Group 4|surface anesthesia with lidocaine; lying without the pillow and fasting water and food for four hours after lumbar puncture
2566767|NCT02454270|Experimental|Dose Escalation: Participants With Certain B-Cell Malignancies|During accelerated dose titration in Group 1, participant will receive duvortuxizumab starting at 0.5 nanogram per kilogram (ng/kg) for biweekly dosing. Dose will be increased by half logarithmic steps in subsequent Dose Level (DL). After safety stopping criteria are met, Dose Escalation (DE) in Group 1 will transition to 3+3 design, and will continue until the Maximum tolerated Dose (MTD) is defined. DE in Groups 2 and 3 will follow 3+3 design, begin after initial dose level in Group 1 is deemed safe and recommended phase 2 doses (RP2D) for Part 1 of study can be decided. Duvortuxizumab at a starting dose of 50 ng/kg weekly will also be investigated in Group 1 and will follow 3+3 study design continue until the MTD or Maximum administered dose (MAD) is reached. Disease-specific dose escalation in Group 2 and 3 will not be initiated until dose in Group 1 is determined safe.
2566768|NCT02454270|Experimental|Dose Expansion: Diffuse-Large B-Cell Lymphoma Participants|Participants with Diffuse-Large B-Cell Lymphoma (DLBCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
2566769|NCT02454270|Experimental|Dose Expansion: Follicular Cell Lymphoma Participants|Participants with Follicular Cell Lymphoma (FL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
2566772|NCT02454270|Experimental|Dose Expansion: Mantle Cell Lymphoma Participants|Participants with Mantle Cell Lymphoma (MCL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
2566773|NCT02454270|Experimental|Dose Expansion: Chronic Lymphocytic Leukemia Participants|Participants with Chronic Lymphocytic Leukemia (CLL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
2566775|NCT02454270|Experimental|Dose Expansion: Acute Lymphoblastic Leukemia Participants|Participants with Acute Lymphoblastic Leukemia (ALL) will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) either with or without a priming dose.
2566855|NCT02453828|Experimental|Checklist|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care with an additional, electronically pre-populated checklist displayed on the anesthesia record keeping system
2566857|NCT02453828|Active Comparator|Standard of Care|after non-cardiac surgery, patients will have current standard-of-care anesthesia handover during anesthesia transitions in care
2566905|NCT02453451|Experimental|2D-/3D-TTE; 3D-TEE, Walking Test|6 months after the MitraClip procedure
2566940|NCT02453100|Experimental|Exercise|"Women will be included in group mobility and pelvic floor exercise classes for one and a half hours twice weekly for 12 weeks and encouraged to carry out independent exercises each day when there is no group session.~A research paramedics will meet with the woman each month for six months from the initial training session to encourage her continued participation and adherence to the individual exercise program. At this meeting the research paramedic will also provide and reinforce simple education about how to manage urinary incontinence."
2566942|NCT02453100|Placebo Comparator|Education|On recruitment and each month for six months a research paramedic will meet with each woman to provide and reinforce simple education about how to manage urinary incontinence.
2567108|NCT02452242|Placebo Comparator|Placebo|
3207660|NCT00967187|Experimental|MPC-4326 300 mg BID X 14 Days.|
2566317|NCT02456974||piperacilline-tazobactam|Patients receiving piperacilline-tazobactam as part of routine clinical care.
2566319|NCT02456974||vancomycin|Patients receiving vancomycin as part of routine clinical care.
2566321|NCT02456974||teicoplanin|Patients receiving teicoplanin as part of routine clinical care.
2566327|NCT02456974||meropenem|Patients receiving meropenem as part of routine clinical care.
2566333|NCT02456974||ciprofloxacin|Patients receiving ciprofloxacin as part of routine clinical care.
2566338|NCT02456974||amikacin|Patients receiving amikcain as part of routine clinical care.
2566378|NCT02456532|Placebo Comparator|Placebo|Intervention: Six months of nightly placebo
2566385|NCT02456532|Active Comparator|Zolpidem CR|Intervention: Six months of zolpidem cr 12.5 mg nightly use
2566390|NCT02456532|Active Comparator|Eszopiclone|Intervention: Six months of eszopiclone 3 mg nightly use
2566466|NCT02456155|Experimental|ultrasound group|using B ultrasound as a instruction technique to place Nasal Jejunal Tube
2566467|NCT02456155|Placebo Comparator|endoscope group|Conventional methods for placing Nasal Jejunal Tube
2566503|NCT02455791|Experimental|Ultrasound-Guided Biopsy of Tumor Site|Ultrasound-guided biopsy of the tumor site performed before scheduled surgery.
2566627|NCT02455206|Active Comparator|Usual Care|outpatient pulmonary Rehabilitation program
2566628|NCT02455206|Experimental|Counseling|outpatient pulmonary Rehabilitation program plus physical activity counseling
2566634|NCT02454855|Experimental|"Group Melatonin"|standard anticancer treatment + 3-month of melatonin supplementation
2566637|NCT02454855|Placebo Comparator|"Group Placebo"|standard anticancer treatment + placebo (3 months)
2566708|NCT02454582|Other|Group 1|15min without CPAP, then 15min with CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
2566709|NCT02454582|Other|Group 2|15min with CPAP, then 15min without CPAP NIRS measurement, Somanetics INVOS Cerebral Oxymeter 5100C
3207661|NCT00967213|Experimental|Ranibizumab|three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
3207662|NCT00967252||atorvastatin 10 mg or equivalent dose|Patients already taking atorvastatin 10 mg or equivalent dose in another statin who is undergoing high risk surgery
3207663|NCT00967252||atorvastatin 20 mg or equivalent dose|Patients already taking atorvastatin 20 mg or equivalent dose in another statin who is undergoing high risk surgery
3207664|NCT00967252||atorvastatin 40 mg or equivalent dose|Patients already taking atorvastatin 40 mg or equivalent dose in another statin who is undergoing high risk surgery
3207665|NCT00967252||atorvastatin 80 mg or equivalent dose|Patients already taking atorvastatin 80 mg or equivalent dose in another statin who is undergoing high risk surgery
2566919|NCT02453243|No Intervention|Baseline|Retrospective Chart Reviews will be conducted for the period between the original ED-SAFE and the new study to test the long-term sustainability of nurse administered universal screening implemented in the original study.
2566929|NCT02453243|Other|Intervention|"Safety Plan Intervention: Clinician training in safety planning, and~A Lean Implementation Strategy: The Implementation of the safety planning guided by Lean~Combine, this is expected to increase safety planning by clinicians."
2566936|NCT02453243|No Intervention|Maintenance|Test sustainability of safety planning during the Maintenance phase.
3207666|NCT00967252||non-statin group|Patients who are not taking or cannot take a statin drug who is undergoing high risk surgery
3207667|NCT00967265|Experimental|Introduction seminar|Psychoeducation for patients on waiting list
3207668|NCT00967265|Active Comparator|Usual care|Usual care
2567245|NCT02451254|Experimental|Atrial Fibrillation|Atrial Fibrillation patients electively admitted for circumferential ablation of the pulmonary veins.
2567249|NCT02451254|Active Comparator|control|patients electively admitted for SVT ablation
2567285|NCT02450955|Active Comparator|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading.
2567287|NCT02450955|Experimental|Occiput-Atlas-Axis Technique|The technique is applied in two stages: in the first stage, a light core decompression is performed and then small circumductions are made with the aim of increasing viscoelasticity of tissues. Subsequently the appropriate joint barrier is sought by selective tension and high-velocity rotation manipulation is performed in a cranial helical motion without raising the subjects head.
2567673|NCT02448615||Birth Cohort|The cohort will comprise approximately 1500 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02208960).
2567736|NCT02448199|Experimental|Kit 1 ( ML + CG ) + P|One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet
2567740|NCT02448199|Active Comparator|Kit 2 ( ML + P)|One tablet of meloxicam and one sachet of placebo once per day for 12 weeks
2567746|NCT02448199|Active Comparator|Kit 3 ( P+ GC)|One sachet of glucosamine and one tablet placebo once a day for 12 weeks
2567775|NCT02447731||Sonic Gas Exchange|"Gas exchange rates in the lungs of subjects breathing through a mouthpiece will be compared with their gas exchange rates after addition of sound pressure vibrations into the supplied gas. 'Induction of sound waves in lungs by sonic oscillator' can be as loud as a human screaming or singing very loudly (about 95 dB). The effects of these pressure oscillations on gas exchange will be assessed using 3 tests as explained in the section under detailed description."
2567826|NCT02447549|Active Comparator|WBRT|Standard dose whole bladder radiotherapy
2567829|NCT02447549|Experimental|SART|Standard dose Adaptive tumour focused radiotherapy (SART)
2566334|NCT02457039|Active Comparator|Comprehensive acupuncture (CAI)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Dense cranial electroacupuncture stimulation (DCEAS) and Body acupuncture (BA).
2566335|NCT02457039|Sham Comparator|Least acupuncture stimulation (LAS)|Breast cancer patients receiving Cytoxan-containing chemotherapy regimens (Chemo) will receive Least acupuncture stimulation (LAS)
2566401|NCT02456506|Experimental|Hyperfractionated IMRT Group|IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)
2566409|NCT02456506|Active Comparator|Conventional Fraction IMRT Group|IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)
2566465|NCT02456168||SLE|
2566469|NCT02456168||Healthy control|
2566511|NCT02455895|Active Comparator|iLid Cleanser (Avenova)|iLid Cleanser - applied 2 times per day for 10 days
2566516|NCT02455895|Placebo Comparator|iLid Cleanser Vehicle|iLid Cleanser Vehicle - applied 2 times per day for 10 days
2566565|NCT02455362|Placebo Comparator|Placebo|Double-blind placebo capsule, looking identical to capsules with active treatment, during all three treatment weeks.
2566567|NCT02455362|Experimental|Morphine sulfate (0, 0, 8 mg)|Placebo during treatment week one and two and morphine 8 mg per day week three.
2566568|NCT02455362|Experimental|Morphine sulfate (0, 8, 8 mg)|Placebo during treatment week one and morphine 8 mg per day week two and three.
2566569|NCT02455362|Experimental|Morphine sulfate (0, 8, 16 mg)|Placebo week one, morphine 8 mg per day week two, and morphine 16 mg per day week three.
2566570|NCT02455362|Experimental|Morphine sulfate (8, 8, 8 mg)|Morphine 8 mg per day during all three treatment weeks.
2566571|NCT02455362|Experimental|Morphine sulfate (8, 8, 16 mg)|Morphine 8 mg per day week one and two and morphine 16 mg per day week three.
2566572|NCT02455362|Experimental|Morphine sulfate (8, 16, 16 mg)|Morphine 8 mg per day week one and morphine 16 mg per day week two and three.
2566573|NCT02455362|Experimental|Morphine sulfate (8, 16, 24 mg)|Morphine 8 mg per day week one, morphine 16 mg per day week two, and morphine 24 mg per day week three.
2566574|NCT02455362|Experimental|Morphine sulfate (16, 16, 16 mg)|Morphine 16 mg per day during all three treatment weeks.
2566575|NCT02455362|Experimental|Morphine sulfate (16, 16, 24 mg)|Morphine 16 mg per day week one and two, and morphine 24 mg per day week three.
2566577|NCT02455362|Experimental|Morphine sulfate (16, 24, 24 mg)|Morphine 16 mg per day week one and morphine 24 mg per day during week two and three.
2566579|NCT02455362|Experimental|Morphine sulfate (16, 24, 32 mg)|Morphine 16 mg per day week one, morphine 24 mg per day week two, and morphine 32 mg per day week three.
3207669|NCT00967278||Off-Pump|Patients with coronary artery disease undergoing elective off-pump CABG
3207670|NCT00967304|Experimental|1 Discontinue OAT or AAA|"Patients classified as being at low risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at low recurrence risk (<3% per year); anticoagulant therapy will be withdrawn and the participant will then be followed for 1 year for any VTE recurrence and/or bleeding."
2566702|NCT02454400|Other|Pre-surgery physiotherapy|Twice a week, in 9 weeks
2566703|NCT02454400|Other|Waiting-list|Standard information by the orthopedic surgeon
2566785|NCT02454309|Experimental|Cranberry concentrate|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate)
2566795|NCT02454309|Placebo Comparator|Placebo|A capsule containing control formulation
2566872|NCT02453802|Active Comparator|Topic TXA group|"Primary total knee replacement with intravenous 0.9% normal saline (20 ml) administration before deflation of the tourniquet and intraarticular application of Tranexamic Acid 5%,5ml/amp 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
2566877|NCT02453802|Active Comparator|IV TXA group|"Primary total knee replacement with 1 g Tranexamic Acid 5%,5ml/amp administrated intravenously before deflection of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
2566879|NCT02453802|Placebo Comparator|Control group|"Primary total knee replacement with 0.9% normal saline administration intravenously before deflation of the tourniquet and topical 160 ml 0.9% normal saline application after closure of joint capsule.~Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14 for VTE prophylaxis"
2566918|NCT02453165|Experimental|TRANSVAGINAL SUTURE|INTERVENTION: Transvaginal suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using vaginal valves and needleholders.
2566927|NCT02453165|Active Comparator|LAPAROSCOPIC SUTURE|INTERVENTION: Laparoscopic suturE of the vaginal vault at the end of a total laparoscopic hysterectomy using with laparoscopic needleholders.
3207671|NCT00967304|No Intervention|2 Observation arm|"Men and patients classified as being at high risk of recurrent VTE by the HER DOO2rule.~If the clinical decision rule indicates that a patient is at high recurrence risk then the decision to continue or discontinue anticoagulant therapy will be left to the discretion of physicians and patients as per current standard of care and this decision recorded. High risk patients (females classified as being at high risk of recurrent VTE by the CDR, and all males) will then be followed as an observational cohort for 1 year for any VTE recurrence and/or bleeding."
3207672|NCT00967317|Experimental|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
2567016|NCT02452723|Experimental|ISC-hpNSC|
2567056|NCT02452450|Experimental|Ibuprofen lysine|
2567060|NCT02452450|Experimental|Ibuprofen sodium|
2567061|NCT02452450|Experimental|Ibuprofen liquid capsules|
2567062|NCT02452450|Active Comparator|Ibuprofen acid|
3207673|NCT00967317|Active Comparator|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
3207674|NCT00967356|Experimental|A|AZD5985
3207675|NCT00967356|Placebo Comparator|B|Placebo
2566343|NCT02457026|Experimental|Adjunctive PDT + Aflibercept|Participants will receive adjunctive verteporfin PDT at Study Visit 1 as well as intravitreal aflibercept at Study Visits 1, 2, 3. At Study Visit 4, participants will have repeat assessment of disease activity. If disease activity is resolved or trivial, the individual will be maintained on aflibercept injections. If PDA remains unresolved, the individual will undergo repeat verteporfin PDT at Study Visit 4, as well as intravitreal aflibercept at Study Visits 4, 5, and 6. Disease activity will be reassessed at Study Visit 7. If disease activity is resolved or trivial, the individual will be switched to aflibercept injections once every three months. If PDA remains unresolved, then the individual will default to a standard-of-care treatment strategy with aflibercept (monthly injections).
2566346|NCT02457026|Active Comparator|Aflibercept Alone|"Participants in this group will receive intravitreal aflibercept at Study Visits 1, 2, and 3. At Study Visit 4, participants will have repeat assessment of disease activity. From Study Visit 4 onwards, aflibercept will be administered according to a treat-and-extend strategy. If disease activity is considered to be resolved or trivial, then the interval between treatments can be initially extended from every 28 days to every 42 days. If disease activity remains stable, treatments can be extended in 14-day increments, up to 10 weeks between treatments. For individuals who have PDA that remains unresolved, aflibercept will continue to be administered every days, but if disease quiescence is achieve at a later time point, the treatment period can be extended at that time."
2566414|NCT02456558|Experimental|Intravenous deferiprone, 1.5 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 1.5 g, twice-daily
2566422|NCT02456558|Experimental|Intravenous deferiprone, 2 g|Subjects in this arm will receive an infusion of intravenous deferiprone at a dose of 2 g, twice-daily
2566426|NCT02456558|Placebo Comparator|Placebo|Subjects in this arm will receive an infusion of placebo twice-daily for 10 days, at a volume equivalent to that of the active product in the respective cohort
3207676|NCT00967382|No Intervention|Control|"Subjects randomized to control will receive identical obstetrical care and follow-up, but not antenatal dalteparin.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
2566623|NCT02455245|Active Comparator|Carboplatine and Vincristine|"Induction: 10 weeks of Carboplatin and Vincristine therapy. Carboplatin 175 mg/m2 give an an IV infusion weeks 1, 2, 3, 4, 7, 8, 9, 10. Vincristine 1.5mg/m2 (0.05 mg/kg if child less than 12 kg) (maximum dose 2.0 mg) give as an IV bolus infusion on weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.~Maintenance: Maintenance consists of 8, 6-week cycles of chemotherapy. It begins week 12 of Induction or when peripheral counts recover with ANC >1,000/µL and platelet count >100,000/µL. Each cycle will consist of 4 weekly doses of carboplatin, three weekly doses of vincristine (given concomitantly with the first 3 weeks of carboplatin), followed by two weeks of rest for a total of 6 weeks. Maintenance will continue for a total of 8 cycles.~Carboplatin 175 mg/m2 as an IV continuous infusion over 60 minutes on Week 1, 2, 3, 4 of each cycle. Vincristine 1.5 mg/m2 (0.05 mg/ kg for children <12 kg) (maximum dose 2.0 mg) IV bolus infusion on Week 1, 2, 3 of each cycle."
2566626|NCT02455245|Experimental|Carboplatin alone|"Carboplatin is given once every four weeks, Each 4-week period is considered a cycle. Regimen B will last for 13 cycles which is equivalent to one year (52 weeks).~Carboplatin 560 mg/m2 (or 19 mg/kg for children weighing less than 12 kg) IV over 1 hour every 4 weeks"
2566757|NCT02454361|Experimental|KBP-7072 cohort 1|KBP-7072 by mouth once
2566759|NCT02454361|Experimental|KBP-7072 cohort 2|KBP-7072 by mouth once
2566761|NCT02454361|Experimental|KBP-7072 cohort 3|KBP-7072 by mouth once
2566762|NCT02454361|Experimental|KBP-7072 cohort 4|KBP-7072 by mouth once
2566763|NCT02454361|Experimental|KBP-7072 cohort 5|KBP-7072 by mouth once
2566764|NCT02454361|Experimental|KBP-7072 Fed Group|KBP-7072 by mouth once to the fed group
2566782|NCT02454010|Experimental|Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101
2566793|NCT02454010|Experimental|2X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 2X the lowest dose
2566803|NCT02454010|Experimental|3X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 3X the lowest dose
2566806|NCT02454010|Experimental|4X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 4X the lowest dose
2566808|NCT02454010|Experimental|5X Lowest dose of FF-21101(90Y)|In the therapeutic phase subjects in this cohort will receive one dose of radiolabeled FF21101 that is 5X the lowest dose
2566812|NCT02454010|Experimental|Expansion Phase (Cohort 6), Ovarian|In the expansion phase, subjects in this cohort will be diagnosed with epithelial ovarian, peritoneal or fallopian tube carcinoma and will receive a dose of 25 mCi/m2 FF-21101(90Y)
2566813|NCT02454010|Experimental|Expansion Phase (Cohort 7), Adv Tumors|In the expansion phase, subjects in this cohort will be diagnosed with triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), biliary cancer (cholangiocarcinoma or gall bladder carcinoma), pancreatic carcinoma, colorectal cancer and will receive a dose of 25 mCi/m2 FF-21101(90Y)
3207677|NCT00967382|Active Comparator|dalteparin sodium|"Subjects randomized to the treatment group will receive daily injections of dalteparin during the antenatal period. They will be taught how to self-administer sub-cutaneous injections of dalteparin 5000 IU once daily (o.d.) until gestational age 20, then twice daily (bid) until 37 weeks gestation or onset of labour.~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
3207678|NCT00967395|Experimental|Healing|patients receive healing while blindfolded and with hearing protector. The healer is behind a screen and not allowed to speak with the subject.
3207679|NCT00967395|Sham Comparator|Sham healing|Same design of room as with the healing, while in this case a student is behind the screen
3207680|NCT00967395|No Intervention|Control|Business as usual in the third arm
3207681|NCT00967408|Experimental|Rehabilitation + Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
3207682|NCT00967408|Placebo Comparator|Rehabilitation + Placebo|Rehabilitative treatment + Non active Placebo tablets for 6 months
2567164|NCT02451891|Active Comparator|Group 1a|MVA-EBO Z (1 x 10^8 pfu)
2566449|NCT02456220|No Intervention|Comparison Group|Patients that received only teeth movement (alignment and leveling before Herbst insertion), without any orthopedic intervention.
2566533|NCT02455947|Experimental|Inquiry Based Stress Reduction (IBSR)|"IBSR intervention is the clinical implementation of a mindful-process, named The Work developed by Byron Katie.It teaches the individual to identify and question the thoughts that causes stress and suffering through four questions and turnarounds."
2566538|NCT02455947|No Intervention|Control group|A non interventional group/ The participants completed questionnaires before and after the intervention.
2566585|NCT02455505||Risk Screening tool & Cognitive Interview|
2566654|NCT02455102|Active Comparator|Electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive an electronic warning alert.
2566665|NCT02455102|No Intervention|No electronic alert|Physicians, whose patients with atrial fibrillation do not receive stroke preventive measures, will receive no electronic warning alert.
2566728|NCT02454413|Sham Comparator|brush + water|denture brushing with water and soap + overnight storage in water
2566731|NCT02454413|Active Comparator|brush + cleansing tablet|denture brushing with water and soap + overnight storage in water with a cleansing tablet
2566734|NCT02454413|Sham Comparator|ultrasonic cleaning + water|ultrasonic denture cleaning + overnight storage in water
2566737|NCT02454413|Active Comparator|ultrasonic cleaning + cleansing tablet|ultrasonic denture cleaning + overnight storage in water with a cleansing tablet
3207683|NCT00967421|Experimental|BAC 0.5|BAC level 0.5 g/dL (drink + placebo pill)
3207684|NCT00967421|Experimental|BAC 1.0|BAC level 1.0 g/dL (drink + placebo pill)
2566904|NCT02453490|Experimental|Raltitrexed-based chemotherapy|Raltitrexed plus Oxaliplatin/Raltitrexed plus Irinotecan
2566906|NCT02453490|Active Comparator|5-fluorouracil-based chemotherapy|5-fluorouracil plus Oxaliplatin/5-fluorouracil plus Irinotecan
2566979|NCT02453022|Experimental|Danirixin HBr + Danirixin FB + Omeprazole|Subjects will receive danirixin FB 50 milligram (mg) immediate release (IR) tablet, single dose, in the fed state (treatment A), danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment B), danirixin HBr 50 mg IR tablet, single dose, in the fasted state (treatment C), or danirixin HBr 50 mg IR tablet, single dose, in the fed state (treatment D) as per randomization in period 1 to 4. In treatment Period 5, subjects will receive danirixin HBr 50 mg IR table, single dose, in the fed state with concomitant, steady state OMP (40 mg once daily for 5 days) (treatment E). Subject will receive treatment with washout period of 5 days in one of the four sequence DCABE, ADBCE, BACDE, CBDAE.
2567046|NCT02452567|Experimental|Metabolically abnormal lean|Moderate (8-10%) diet-induced weight loss.
2567076|NCT02452333|Experimental|Evidence-based Oncoplastic Algorithm|Oncoplastic Approach Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
2567077|NCT02452333|Experimental|Control|- Conventional Excisional Breast Biopsy, Tezel Method of Breast Volume Measurement and Cosmetic Assessment
3207685|NCT00967421|Placebo Comparator|placebo|BAC level 0,0 g/dL (placebo drink+ placebo pill)
3207686|NCT00967434|Active Comparator|Group A- atorvastatin in pre and postop|Atorvastatin 80 mg administered daily for at least 7 preoperative days, 80 mg on day of surgery and 80 mg daily for up to 7 postoperative days.
3207687|NCT00967434|Active Comparator|Group B- Atorvastatin postop|Placebo administered for up to 7 preoperative days, atorvastatin 80 mg administered on day of surgery and daily for up to 7 postoperative days.
2567262|NCT02451020|Experimental|Altitude exposure|Stay at 3200 m for 3 weeks
2567316|NCT02450877|Experimental|Azacitidine Treatment|: Subjects randomized to the experimental arm will receive up to 3 cycles of IV azacitidine on Days 1 through 7 at the dose selected from the safety run-in part.
2567320|NCT02450877|Other|Control Arm: 'Watch and Wait'|Subjects randomized to the control arm will undergo 'watch and wait' until clinical relapse (defined as at least 5% blasts in PB (peripheral blood) and/or BM (bone marrow) and/or proven histological extramedullary relapse).
2567356|NCT02450422||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2567360|NCT02450422||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2567365|NCT02450422||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2567368|NCT02450422||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2567428|NCT02450123|Experimental|sunitinib|sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.
2567451|NCT02449811||Perindopril|Treatment period 1: Perindopril 5mg, oral, once daily, for 4 weeks Treatment period 2: Perindopril 10mg, oral, once daily, for 4 weeks
2567453|NCT02449811||Olmesartan|Treatment period 1: Olmesartan 20mg, oral, once daily, for 4 weeks Treatment period 2: Olmesartan 40mg, oral, once daily, for 4 weeks
2567456|NCT02449811||Amlodipine|Treatment period 1: Amlodipine 5mg, oral, once daily, for 4 weeks Treatment period 2: Amlodipine 10mg, oral, once daily, for 4 weeks
2567460|NCT02449811||Hydrochlorothiazide|Treatment period 1: Hydrochlorothiazide 25mg, oral, once daily, for 4 weeks Treatment period 2: Hydrochlorothiazide 50mg, oral, once daily, for 4 weeks
2567482|NCT02449525|Experimental|perfusion of flaps by a bypass system|Support of perfusion of microvascular free flaps until ingrowth of vessels from the wound bed has taken place. The System works with a pressure controlled bypass to ensure low grade perfusion.
3207688|NCT00967434|Placebo Comparator|Group C- Placebo|Patients receive placebo daily for up 7 preoperative days, placebo on day of surgery and placebo daily for up to 7 postoperative days.
3207689|NCT00967460|No Intervention|Control group: No intervention|No intervention, regular childcare program
3207690|NCT00967460|Experimental|Intervention group|Promoting unstructured spontaneous PA through an adaptation of the built environment and the provision of a supportive social environment
3207691|NCT00967512|Experimental|cenersen, idarubicin, cytarabine|cenersen, idarubicin, cytarabine
2566534|NCT02455921|Active Comparator|neostigmine - atropine|"iv neostigmine 0,05 mg/Kg - atropine 0,02 mg/kg~Efficacy, safety and effect on cognitive and behavioural function"
2566607|NCT02455427|Active Comparator|Active tDCS+ Physical Therapy|Active tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After active session of tDCS, the patient will receive physical therapy for 60 minutes. Number of treatment sessions: 6 (3 times a week, for 2 weeks)
2566616|NCT02455427|Sham Comparator|Sham tDCS+Physical Therapy|"Sham tDCS (transcranial direct current stimulation) will be applied for 20 minutes. After sham session of tDCS, the patient will receive physical therapy for 60 minutes.~Number of treatment sessions: 6 (3 times a week, for 2 weeks)"
2566688|NCT02454751|Experimental|Pre-fentanyl dose/fentanyl dose|Crossover: 6-six minute walk test, subjective rating of dyspnea, heart rate, respiratory rate, oxygen saturation and participants' general appearance measured before and after a dose of fentanyl.
2566726|NCT02454452|Active Comparator|Saphenous vein stripping|Saphenous venous stripping surgical technique
2566729|NCT02454452|Active Comparator|CHIVA|conservative hemodynamic treatment venous insufficiency (CHIVA)
2566733|NCT02454452|Experimental|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
2566826|NCT02454114|Active Comparator|Standard Hospital Care (SHC)|All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. Patients receiving SHC will be discussed at weekly case note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.
2566829|NCT02454114|Active Comparator|HOMEFIRST|"Patients randomised to HOMEFIRST care will initially receive up to twice daily visits for the first 48 hours. After this, the frequency and duration of visits will depend on clinical need but not exceed 5 days. The study nurse will establish the need for the involvement of other MDT members. Laboratory tests will be performed as clinically indicated. Venepuncture will be performed for clinical purposes as needed.~Patients will be discussed at a weekly case-note MDT meeting and followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.~Patients are either discharged from HOMEFIRST, readmitted or handed over to their community care team at the end of the intervention."
3207692|NCT00967512|Placebo Comparator|placebo, idarubicin, cytarabine|placebo, idarubicin, cytarabine
3207693|NCT00967525|Experimental|1|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
3207694|NCT00967538|Experimental|Etanercept|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
3207695|NCT00967564||001|epidemiologic study QoL assessment
3207696|NCT00967577|Experimental|J591|
2567178|NCT02451722|Active Comparator|Healthy subjects|"Kyboot shoes will be administered to the healthy subjects.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
2567182|NCT02451722|Active Comparator|Diabetic patients|"Kyboot shoes will be administered to the diabetic patients.~Pressure distribution and gait parameters will be recorded in comparison with their normal footwear."
2567216|NCT02451501|Experimental|Lying|Nebulization in lying position
2567220|NCT02451501|Active Comparator|Sitting|Nebulization in sitting position
2567265|NCT02451163|Active Comparator|polysaccharides from wheat|12.0 g powder containing 10.0 g active ingredient (wheat polysaccharides) as well as 2.0 g filling substance (maltodextrin) stirred in milk or filtered apple juice (200 ml each).
2567273|NCT02451163|Placebo Comparator|control product|12.0 g maltodextrin stirred in milk or filtered apple juice (200 ml each).
2567311|NCT02450838|Experimental|Adjuvanted V180 vaccine|Participants will receive one intramuscular (IM) injection of adjuvanted (with Alhydrogel™) V180 at study entry.
2567312|NCT02450838|Experimental|Nonadjuvanted V180 vaccine|Participants will receive one IM injection of nonadjuvanted V180 at study entry.
2567314|NCT02450838|Placebo Comparator|Placebo|Participants will receive one IM injection of placebo at study entry.
2567347|NCT02450513||Single-group study|Subjects with active refractory Crohn's disease naïve to TNF antagonists starting adalimumab therapy.
2567397|NCT02450201|Experimental|Part 1: Reproducibility|Pyruvate injection followed by an MRI scan. 2-3 weeks after imaging #1: a second pyruvate injection followed by an MRI scan.
2567401|NCT02450201|Experimental|Part 2: Treatment Response|Pyruvate injection followed by an MRI scan. 2 months after imaging #1: a second pyruvate injection followed by an MRI scan.
2567437|NCT02449980|Active Comparator|Primary Surgery Group|Patients randomized to the primary surgical intervention group will undergo VATS (video-assisted thoracoscopic surgery), apical blebectomy and mechanical pleurodesis during the initial hospital admission by the admitting staff surgeon. The general principles of the surgical technique consist of a 3-port thoracoscopic approach, stapled blebectomy, apical mechanical pleurodesis, and placement of chest tube . Variations of this technique will be at the discretion of the surgeon.
2567438|NCT02449980|Active Comparator|Initial Non-operative management|Those randomized to the control group will be admitted and their chest tube or percutaneous drainage catheter managed according to standard protocol. This consists of a minimum of 48 hours of Pleur-Evac suction and daily chest radiographs. The drainage tube is then placed to water seal when resolution of the pneumothorax is documented by x-ray, as well as absence of an air leak. If there are no clinical or radiographic changes after a water seal period, the chest tube is then removed. A post-removal chest radiograph is obtained and the patient is discharged if clinical and radiographic criteria are met.
2567493|NCT02449642||group 1|group 1 include 10 women in which blood tests will be taken on the day of oocyte pick up
2567498|NCT02449642||group 2|group 2 include 10 women in which blood tests will be taken on the day of embryo transfer
2567561|NCT02449369|Active Comparator|Control|Preop acetaminophen IV 1000 mg, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, and Postop hydromorphone IV 0.5 mg every 4 hours PRN
2567861|NCT02447562|Experimental|G_NOMHAD|Intervention group with a health platform NOMHADchronic
3207697|NCT00967590|Experimental|1|
2566610|NCT02455401|Placebo Comparator|No remifentanil group|Intervention: no remifenatnil will be administrated
3207698|NCT00967590|Placebo Comparator|2|
3207699|NCT00967603|No Intervention|observation|no therapy until progression
2566755|NCT02454374|Experimental|Knee Loading|Progressive joint loading intervention will be taught by a program of exercises by the treating physiotherapist. The intervention consists of knee flexion (bending) and knee extension (straightening). Participants will be assessed for their immediate response to treatment during each assessment or treatment session and advised on the appropriate level of self-directed exercises to be performed twice daily. The clinician will review the patient at follow up appointments during the treatment period, progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate. The physiotherapist will encourage compliance during the treatment period and beyond
2566756|NCT02454374|Active Comparator|Routine physiotherapy care|Normal care delivered to the control group will be based on current NICE guidelines (2014) for non-pharmacological management of OA which includes verbal and written advice/education; education regarding weight loss; exercise to include local muscle strengthening and general aerobic fitness; with or without manual therapy. Clinicians will be asked to refrain from using the progression of techniques specifically documented in the progressive loading protocol (not currently considered to constitute 'normal care'). Treating clinicians will be asked to record specific exercises and manual therapy techniques employed in the patient's records. Participants will be asked to complete a home treatment record sheet.
2566820|NCT02454049|Active Comparator|beetroot juice|beetroot juice containing 6mmol nitrate, ingested 3hours before the exercise test
2566822|NCT02454049|Active Comparator|sodium nitrate|6mmol sodium nitrate dissolved in plain water, ingested 3hours before the exercise test
2566827|NCT02454049|Placebo Comparator|water|85ml of plain water, ingested 3 hours before the exercise test
2566849|NCT02453698|Experimental|Methylphenidate|
2566852|NCT02453698|Placebo Comparator|Control Group|
2566921|NCT02453178|Experimental|Steady state moderate intensity cycling|Moderate intensity exercise training will be a 12-week supervised cycling program, with supervision directly from our research team. All participants will first receive a one-on-one orientation with an exercise training specialist that has been trained by Dr. Gary Pierce in monitoring an exercise program for healthy older adults. Training will start with a 5 minute-warm-up, 20 minutes moderate intensity cycling and 30 minutes passive cycling, and 5 minute cool-down per session, for 3 sessions/week. In each additional week, we will add 6 minutes of moderate intensity cycling per session, until the total time for moderate intensity is 50 minutes per session by the start of week 5 (with additional 5 minute warm-up and 5 minute cool-down).
2566933|NCT02453178|Active Comparator|Intermittent cycling|The intermittent cycling group will come to the exercise lab for the same duration and frequency each week and complete primarily passive cycling such that a motor in the stationary bicycle moves the pedals for them. To maintain interest in this intervention, we will include short bouts of moderate intensity activity. The short bouts of moderate intensity cycling will be designed to be ineffective for substantially increasing cardiorespiratory fitness over the course of the intervention.
3207700|NCT00967603|Experimental|sunitinib|sunitinib until progression or for a maximum of 6 months
3207701|NCT00967629|Other|Sevelamer Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
3207702|NCT00967629|Other|Calcium Carbonate crossover|Participants will be patients with stage II-IV CKD due to diabetic nephropathy randomized to start either with sevelamer carbonate or calcium carbonate
3207703|NCT00967642|No Intervention|standard treatment|glycemia before meals and subcutaneous regular insulin if higher than 200 mg/dl
3207704|NCT00967642|Other|Intravenous Insulin|intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
3207705|NCT00967681|Experimental|A|Oncoxin, a nutritional supplement
3207706|NCT00967681|Placebo Comparator|B|
2567353|NCT02450604|Other|Patients with chronic pains of unknown aetiology|
2567504|NCT02450058|Active Comparator|FEC|5-Fluorouracil 600 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, intravenously on day 1, every 21 days
2567511|NCT02450058|Active Comparator|EP|Epirubicin 90 mg/m2 and paclitaxel 175 mg/m2, 3-hour infusion on day 1, every 21 days
2567574|NCT02449109|No Intervention|Control|Liver cancer patients never received any interventional therapy.
3207707|NCT00967707|Active Comparator|Gabapentin + venlafaxine|
3207708|NCT00967707|Active Comparator|Gabapentin + donepezil|
3207709|NCT00967720||Barriers, Adherence, Asthma|
3207710|NCT00967733|Active Comparator|High ALA-Low Linoleic|
3207711|NCT00967733|Placebo Comparator|Low ALA-Low Linoleic|
3207712|NCT00967733|Active Comparator|High ALA-High Linoleic|
3207713|NCT00967733|Placebo Comparator|Low ALA-High Linoleic|
3207714|NCT00967746|Experimental|ENG-MIUS low|Low dose: ENG-MIUS containing 38 mg ENG with a skin thickness of approximately 350 μm
3207715|NCT00967746|Experimental|ENG-MIUS intermediate|Intermediate dose: ENG-MIUS containing 61 mg ENG with a skin thickness of approximately 140 μm
3207716|NCT00967746|Experimental|ENG-MIUS high|High dose: ENG-MIUS containing 72 mg ENG with a skin thickness of approximately 50 μm
3207717|NCT00967746|Active Comparator|Multiload|Multiload-cu 375®
3207718|NCT00967759|Experimental|Decongex Plus|
3207719|NCT00967759|Active Comparator|Bronpheniramine isolated|
3207720|NCT00967759|Active Comparator|Fenilefrine isolated|
3207721|NCT00967772|Experimental|Naftopidil|
3207722|NCT00967785|Active Comparator|Treatment Arm|Neutropenia and infections
3207723|NCT00967811|Experimental|1. Formulation E1|Formulation E1 of Latanoprost-PPDS
3207724|NCT00967811|Experimental|2. Formulation E2|Formulation E2 of Latanoprost-PPDS
3207725|NCT00967837|Experimental|Diabetes with non healing wounds|To determine and monitor progress of diabetic patients with non healing wounds that have failed conventional 60 day treatment respond to pulsatile intravenous insulin therapy in improving and completing healing in non healing wounds
3207726|NCT00967850|Experimental|Intravitreal Bevacizumab|Intravitreal injections of bevacizumab
2566612|NCT02455414||Proxy Group|Adult Biological parent(s), biological caregiver or non-biological caregiver of adult and minor participants in the any of the groups.
3207727|NCT00967850|Active Comparator|Visudyne|Photodynamic Therapy with Visudyne
3207728|NCT00967902|Experimental|Combo|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
3207729|NCT00967902|Active Comparator|Taxus® Liberté® Stent|Commercially available product
3207730|NCT00967915|Experimental|Frenotomy|Group of neonates that will receive frenotomy for tongue-tie
3207731|NCT00967915|Sham Comparator|No frenotomy|Group of infants that will undergo sham procedure (no frenotomy performed)
2566791|NCT02453984|Experimental|1|89Zr-MPDL3280A-PET scan
2566854|NCT02453893|Experimental|oral iloperidone|2~12mg/day for 2 weeks,12~24mg/day for 6 weeks.
2566858|NCT02453893|Active Comparator|oral risperidone|1~3mg/day for 2 weeks,3~6mg/day for 6 weeks.
2566900|NCT02453373|Experimental|ThermoSuit Cooling Induction|Induction of therapeutic hypothermia (32-34 degrees C) using the LRS ThermoSuit System. Prior to initiating hypothermia, Magnesium Sulfate will be administered intravenously to control shivering and tPA administered intravenously (if indicated). Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort. Neurothrombectomy will be performed if indicated.
2566901|NCT02453373|No Intervention|Historical Control|Historical patients treated for ischemic stroke using conventional medical treatments, but without induced hypothermia.
2566980|NCT02452970|Experimental|RRx-001 the cisplatin and gemcitabine|Patients with advanced and metastatic biliary tract adenocarcinoma (cholangiocarcinoma) who had been treated with and failed first-line chemotherapy will be treated with RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
2567045|NCT02452645|Experimental|Intervention|The intervention will integrate: a) support from peer counselors with child care experience who will serve as team leaders for groups of FCCPs; b) tailored print and video materials; and c) a set of portable active toys to elicit changes to the nutrition and physical activity environments of family child care homes.
2567053|NCT02452645|Active Comparator|Comparison|The comparison intervention will provide print materials and videos on literacy and school readiness to children and books in both English and Spanish. Participants will also receive support from peer counselors with child care experience.
3207732|NCT00967928|Experimental|Single arm|All subjects receive RAD001 in combination with standard field whole pelvic radiation and cisplatin.
3207733|NCT00967967|Other|Mometasone furoate and desloratadine|Mometasone and desloratadine treatment
3207734|NCT00967980|Active Comparator|1. Femoral Nerve Block|Patients will be randomized with a computer program to receive a femoral catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
3207735|NCT00967980|Active Comparator|2. Psoas Compartment Catheter|Patients will be randomized with a computer program to receive a psoas compartment catheter. The catheter will be placed using standard technique. The time of catheter placement will be recorded as well as the pain/discomfort of catheter placement as reported by the patient on a 0-10 scale where 0=no pain/discomfort and 10=worst imaginable pain/discomfort.
2567548|NCT02449122|Experimental|Nano drug|Lung cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
2567556|NCT02449122|Active Comparator|Drug MicroSpheres|Lung cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
2567559|NCT02449122|No Intervention|Control|Liver cancer patients never received any interventional therapy.
3207736|NCT00968006|Experimental|Treatment|Sitagliptin 100 mg once daily for 4 weeks
3207737|NCT00968006|No Intervention|Control|No change in anti-diabetic treatment regimen for at least 4 weeks.
3207738|NCT00968045|Placebo Comparator|Placebo|100 ml infusion of saline is given during 15 minutes after anesthesia induction before start of surgery.
2567690|NCT02448277|Experimental|Macintosh Laryngoscope|experimental Macintosh Laryngoscope group: laryngoscope is used to assist for nasotracheal intubation.
2567693|NCT02448277|Experimental|Pentax Airway scope|experimental Pentax Airway scope group:Pentax Airway scope is used to assist for nasotracheal intubation.
2567696|NCT02448277|Experimental|Glidescope|experimental Glidescope group:Glidescope is used to assist nasotracheal tube into trachea
3207739|NCT00968045|Experimental|Study drug|Fibrinogen 2g in 100 ml sterile water given during 15 minutes after anestesiainduction before surgery start
3207740|NCT00968110|Experimental|Xolair|All patients will receive Xolair treatment for 16 weeks.
2567850|NCT02447315|Experimental|Treatment Sequence ABCDD|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence ABCDD. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
2567857|NCT02447315|Experimental|Treatment Sequence BDACC|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence BDACC. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3207741|NCT00968136||a short-term trial of the ketogenic diet|
3207742|NCT00968136||long-term trial of the ketogenic diet.|
3207743|NCT00968162|Experimental|Dose de-escalation|
3207744|NCT00968175|Active Comparator|Group 1: CPN + analgesic therapy|Receives ultrasound guided celiac plexus neurolysis (CPN) in addition to standard analgesic therapy
3207745|NCT00968175|No Intervention|Analgesic therapy alone|Will not receive ultrasound guided celiac plexus neurolysis (CPN); only standard analgesic therapy for pain management
3207746|NCT00968188|Experimental|Active intervention|Highly interactive, motivational, culturally tailored, online HIV prevention.
3207747|NCT00968188|Active Comparator|Information only|Medically fact based online intervention.
2566620|NCT02455258|No Intervention|Waiting List|This group is placed on a waiting list and asked to refrain from making any changes to their current lifestyle.
2566647|NCT02455037|No Intervention|Body Strengthening (Only)|All participants will complete a general resistance exercise training program.
2566656|NCT02455037|Experimental|Body Strengthening + Neck Strengthening|Participants assigned to the neck strengthening group will complete additional supervised exercises specifically designed to strengthen the neck.
2566704|NCT02454712|Experimental|PF614|PF614 is the drug under evaluation. Doses may range from 15 mg to 640 mg. N=6 subjects per cohort. For Cohort 7, N=16 subjects in crossover study ± naltrexone.
2566706|NCT02454712|Active Comparator|Oxycodone extended-release (OxyContin)|Initial dose (Cohort 1) will be 10 mg. Subsequent doses will be 10, 20, 40, or 80 mg. N=2 subjects per cohort. Active comparator will not be used in Cohort 7.
2566840|NCT02453932|Experimental|Tianzhi granule|Tianzhi granule and placebo identified to donepezil
2566841|NCT02453932|Active Comparator|Donepezil|Donepezil and placebo identified to Tianzhi granule
2566844|NCT02453932|Placebo Comparator|Placebo|Placebo identified toTianzhi granule and placebo identified to donepezil
2566908|NCT02453464|Experimental|Sevacizumab+FOLFIRI|Two weeks as one cycle. Cycle 1: FOLFIRI on day1-2, Sevacizumab on day3; Cycle 2 and after: Sevacizumab on day 1, and then FOLFIRI on day1-2
2566988|NCT02452957||Device: Simpliciti™ System|"The Simpliciti™ nucleus is a humeral prosthesis intended for total and hemi shoulder arthroplasty in patients with a severely painful and/or disabled joint resulting from osteoarthritis or traumatic arthritis.~The implant is sized to match and replicate the anatomy of the proximal humerus, while maintaining a bone conserving approach. It does not extend beyond the metaphysis, leaving the humeral canal untouched. Fixation is enhanced through a porous coating with a high coefficient of friction; resulting in a solid initial fit and long term fixation.~The Simpliciti™ nucleus is designed to receive a humeral head. The Simpliciti™ system is authorized to bear the CE mark and will be investigated within this clinical study in accordance with its intended use."
2567027|NCT02452710|Experimental|Open-Label Placebo|- Placebo Tablets-Twice a day for 3-4 weeks
2567028|NCT02452710|No Intervention|NT-Control|- No Placebo Tablets
3207748|NCT00968214||Single group|DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.
2567193|NCT02451631|Active Comparator|Traditional care|Traditional care with paper(SMBG) and healthcare staff advice in office
2567195|NCT02451631|Experimental|Health-On G App.+ Physician web portal|Patient self-mgmt using Health-On G Application on smartphone; Healthcare staffs monitoring through physician web to review data
2567212|NCT02451371|Experimental|tDCS|Patients with schizophrenia to receive tDCS treatment
2567264|NCT02451189|Experimental|Inulin acetate ester|Inulin acetate ester, 10g/day for 30 days
2567270|NCT02451189|Experimental|Inulin propionate ester|Inulin propionate ester, 10g/day for 30 days
2567274|NCT02451189|Experimental|Inulin butyrate ester|Inulin butyrate ester, 10g/day for 30 days
2567315|NCT02450773|Experimental|Furosemide/Potassium chloride|40 mg furosemide; 20 meq potassium chloride
2567318|NCT02450773|Placebo Comparator|Placebo|Placebo #1, Placebo #2
2567362|NCT02450461||Asthma|20 patients with asthma
2567367|NCT02450461||Controls|20 control subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
2567410|NCT02450214|Sham Comparator|Control group (C)|50 mL syringe with saline, plus 1 flask of 100 mL saline (Saline)
2567412|NCT02450214|Experimental|Ketamine group (K)|50 mL syringe with ketamine (50mg / 50ml), plus 1 flask of 100 mL saline (Ketamine)
2567418|NCT02450214|Experimental|Magnesium + ketamine group (MGK)|50mL syringe with ketamine (50mg / 50ml), plus a flask of 100ml of saline with 5 g of magnesium sulfate (Ketamine + magnesium)
3207749|NCT00968266|Experimental|Group intervention|"In short, the intervention consists of two group sessions moderated by a pharmacist. During these sessions, patients' self-perceived needs to take medication ('necessity beliefs'), concerns about taking medication ('concern beliefs'), and practical barriers are discussed. To explore a patient's individual ambivalence regarding his/her beliefs and barriers, the pharmacist uses Motivational Interviewing techniques. In between the sessions, participants make a homework assignment about their own beliefs and barriers, and eight weeks after the second session, a follow-up call to the individual patients is made by the pharmacist.~Patients in the experimental arm also receive a brochure about the DMARDs they currently use (see: control arm)"
3207750|NCT00968266|Active Comparator|Control arm: usual care|In the control arm, patients receive a brochure about the DMARDs they are currently using.
3207751|NCT00968279||Atrial Fibrillation|
3207752|NCT00968292|Experimental|Congenital/Traumatic|Individuals who were born with a limb deficiency or who have had a traumatic amputation.
3207753|NCT00968292|Experimental|Dysvascular/Diabetic|Individuals who have had an amputation as a result of vascular disease.
3207754|NCT00968305||Children with asthma|African American children with clinically diagnosed stable asthma
3207755|NCT00968318|Other|Rate of seroma formation|Excision of strip of deep fascia was assessed regarding the rate of seroma formation with tissue expander insertion
3207756|NCT00968331|Experimental|REVLIMID plus RITUXIMAB|"Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles."
3207757|NCT00968357|Experimental|SCV-07|Cohort 1: SCV-07 0.1 mg/kg. Cohort 2: 1.0 mg/kg per day administered SC
3207758|NCT00968370|Active Comparator|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
2567851|NCT02447237|Experimental|liquid food|dietary counselling in fulfilling need of protein and energy through liquid food
2567858|NCT02447237|Other|solid food|dietary counselling in fulfilling need of protein and energy through solid food
2567972|NCT02446548|Experimental|aliskiren - placebo - losartan|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
2567976|NCT02446548|Experimental|losartan - placebo - aliskiren|aliskiren (Rasilez) 150 mg; losartan (Xartan) 50 mg
2566710|NCT02454543|Other|Radical prostatectomy and BST|BST plus radical prostatectomy with ext. lymphadenectomy
2566712|NCT02454543|Other|Best Systemic Therapy (BST)|e.g. Androgen deprivation therapy, chemotherapy, others
2566787|NCT02454218|Active Comparator|Transcranial Direct Current Stimulation|The intensity of the asset is little perceived and painless.
2566798|NCT02454218|Placebo Comparator|Simulation Transcranial Current|Will receive only simulation.
2566868|NCT02453815|Experimental|arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to receive an arterial catheter at surgery, then the subject will be placed in the experimental arm of the study.
2566873|NCT02453815|Placebo Comparator|no arterial catheter|If a patient is randomized by the web-based system before non-cardiac surgery to not receive an arterial catheter at the time of surgery, then the subject will be placed in the placebo comparator arm of the study.
2566923|NCT02453295|Experimental|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. All workshops will be recorded and transcribed, then analyzed qualitatively. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will take place over the phone. The questionnaires will be administered 3 days prior to workshop 1 (T0), between workshop 4 and 5 (T1), and 3 days following the completion of the intervention (T2). The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2.
2566928|NCT02453295|No Intervention|Comparison Group|The CG will receive LE treatment as usual, without the hope intervention. They will be administered the same questionnaires (by phone) as the IG at the same timepoints. Potential participants (n=46) will be screened based MIQ. The individuals scoring in the top ~30% (n=16) will be excluded from the study. The remaining 30 individuals scoring the lowest level of hope will be admitted into the study.
2566984|NCT02452996|Active Comparator|6 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
2566994|NCT02452996|Active Comparator|18 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
2567001|NCT02452996|Active Comparator|36 mg/kg GNbAC1|7 subjects randomized 5:2 active treatment:placebo
2567037|NCT02452619||Brain trauma|Patients with chronic brain injury that have been treated with Hyperbaric oxygen therapy and underwent MRI imaging and cognitive tests before and after the treatment
2567080|NCT02452294|Experimental|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events.
3207759|NCT00968370|Other|Hospital management|Hospital management: all children admitted at the hospital will be managed with injection Ceftriaxone and other micronutrients for the total duration of hospitalization as per approved protocol.
3207760|NCT00968383|Active Comparator|Optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification
2567207|NCT02451566||Fast-Track Group|Includes subject who complete the Fast-Track EVAR protocol.
2567209|NCT02451566||Standard P-EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access.
2567211|NCT02451566||Standard EVAR Group|Includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair).
2567396|NCT02450318|Experimental|Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
2567433|NCT02449993||MammaTyper™|MammaTyper™ will be used to assess tumor material of patients treated with neo-adjuvant therapy.
2567507|NCT02449759|Experimental|ACT Intervention Group|This group will receive an ACT self-help manual to be completed over the course of 6 weeks. They will also receive two brief telephone calls during the reading of the manual by a member of the research team.
2567513|NCT02449759|No Intervention|Control Group|This group will receive no intervention
2567688|NCT02448329|Experimental|AZD1775 in Combination With Paclitaxel|AZD1775 225 mg BID q 12 hours (x 5 doses, 2.5 days) administered days 1~3 Weekly paclitaxel 80 mg/m2 IV on 1, 8 and 15 of a four week l cycle is an widely used dose of paclitaxel given on this schedule in gastric adenocarcinoma patients as second-line therapy.
2567738|NCT02448056||Pre-treatment|All enrolled HCC patients.
2567747|NCT02448056||Post-treatment one week|All enrolled HCC patients.
2567752|NCT02448056||Post-treatment one month|All enrolled HCC patients.
2567777|NCT02447874|Experimental|Standard dose|Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
2567788|NCT02447874|Experimental|Loading dose + standard dose|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first
2567795|NCT02447874|Experimental|Loading dose + continuous infusion|Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first
2567864|NCT02447341||In patients|
2567868|NCT02447341||Out patients|
2567894|NCT02447016|Experimental|eviplera (complera)|Tab eviplera QD
2567897|NCT02447016|Active Comparator|atripla|Tab Atripla QD
2567943|NCT02446795|Experimental|Experimental Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).
3207761|NCT00968383|Experimental|PCI with optimal medical therapy|Conventional medical management, including aspirin, clopidogrel, statins, beta blockers, angiotensin converting enzyme (ACE) inhibitors and/or angiotensin receptor blocker (ARB) and/or aldosterone antagonist and risk factor modification plus percutaneous coronary intervention and coronary stenting
3207762|NCT00968396|Experimental|Stem Cell Collection + Transplantation|Apheresis: On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation. Co-culture Stem Cell Infusion on Day 0. Melphalan 100 mg/m^2 IV over 30 minutes daily on Days -2 and -1.
3207763|NCT00968409|Other|FFNP-PET/CT Imaging|All subjects will receive an injection of F-18-FFNP followed by PET/CT imaging, laboratory testing and safety testing.
3207764|NCT00968422|Experimental|Low dose ABT-384|
3207765|NCT00968422|Experimental|Mid dose ABT-384|
3207766|NCT00968422|Experimental|High dose ABT-384|
3207767|NCT00968422|Placebo Comparator|Placebo|
2567014|NCT02452749|Experimental|Cardiovascular Health Dietary Supplement|The cardiovascular health dietary supplement will be administered at a dosage of 1 caplet po per day for a period of 6 months
3207768|NCT00968435|Experimental|(IMRT) + cisplatin + bevacizumab + cetuximab|This is a single-institution, non-randomized, phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab + cetuximab.
3207769|NCT00968448|Active Comparator|Training|respiratory muscle training (pressure threshold loading)
3207770|NCT00968448|Sham Comparator|sham training|training with low resistance
2567179|NCT02451735|No Intervention|Intervention Development|Psychoeducational Intervention (PEI) development. PEIs include printed and DVD materials, and represent a commonly used and effective approach to implement theoretically based individual-level interventions. These materials serve as important sources of information for the general public, cancer patients, and survivors from a variety of backgrounds, including populations with limited health literacy. An interview and feedback collection process will take place to provide data to improve current PEI materials.
2567183|NCT02451735|Experimental|Intervention Pilot - Intervention Group|The intervention group will receive the PEI materials: video and booklet. Self-reported feedback will be collected and reviewed to compare response with the control group.
2567184|NCT02451735|Active Comparator|Intervention Pilot - Control Group|The control group will receive a patient factsheet about Genetic Counseling (GC). Self-reported feedback will be collected and reviewed to compare response with the intervention group.
3207771|NCT00968461|Experimental|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
3207772|NCT00968487|Experimental|Lyophilized Plasma|
3207773|NCT00968487|Active Comparator|Fresh Frozen Plasma|
2567527|NCT02449499||therapy|patients who meet inclusion criteria, continue to work with individual therapist, and participate in adjunct weekly group therapy
2567528|NCT02449499||control|patients who meet inclusion criteria, continue to work with individual therapist, and are eligible for group therapy participation but cannot participate in group due to schedule constraints
2567596|NCT02448979|Active Comparator|Left thoracotomy|Esophagectomy through left side transthoracic approach, with esophagogastric anastomosis above aortic arch and two-field lymphadenectomy (thoracic and abdominal lymph node)
2567597|NCT02448979|Active Comparator|Right thoracotomy|Esophagectomy through right side transthoracic approach, with esophagogastric anastomosis above azygos vain arch or on the top of chest cavity and two-field lymphadenectomy (thoracic and abdominal lymph node)
3207774|NCT00968500||Parents Who Have Lost a Child to Cancer|The overall goal of the proposed cross-sectional study is to obtain information necessary to the development of an effective Meaning-Centered Grief Intervention for parents who lost a child to cancer. In order to identify a subset of parents with whom we will conduct qualitative interviews with a subset of participants to address Aims 1 and 2, we will first screen participants to determine their levels of Prolonged Grief Disorder symptoms using a quantitative assessment (PG-13). The screening measure (PG-13) and the additional questionnaires included in the quantitative battery of measures will be analyzed to achieve Aim 3.
3207775|NCT00968513|Active Comparator|Usual Care|(N=150) brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
3207776|NCT00968513|Experimental|Brief Treatment|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization.
3207777|NCT00968513|Experimental|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
3207778|NCT00968552||Patients undergoing stent placement|Patients who are scheduled to undergo stent placement via endoscopy as part of their routine medical care.
3207779|NCT00968565|Experimental|Citrate|Sodium citrate will be infused as the blood enters the ECMO circuit and calcium chloride will be infused as the blood leaves the ECMO circuit and enters the patient
3207780|NCT00968578|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
3207781|NCT00968578|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
3207782|NCT00968591|Experimental|RAD001|
3207783|NCT00968604|Experimental|BikDD Nanoparticle|BikDD Nanoparticle starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
2567849|NCT02447224|Experimental|Antibiotics|Once-a-day dose of IV/IM ertapenem for at least two days and cefdinir and metronidazole, to complete 10 days total antibiotic therapy.
2567856|NCT02447224|Active Comparator|Appendectomy|Patients in the surgery therapy arm will only receive one dose of IV ertapenem prior to surgery.
2567944|NCT02446834|Experimental|intensive lifestyle intervention|3 months intensive lifestyle intervention, including low GI diet and exercise.
2567946|NCT02446834|Experimental|GLP-1 Receptor Agonists|3 months GLP-1 Receptor Agonists treatment
2567947|NCT02446834|Experimental|metformin|3 months metformin treatment
2567950|NCT02446834|Experimental|acarbose|3 months acarbose treatment
2566889|NCT02453516|Experimental|Serratus Block Group|Patients will receive a preoperative ultrasound-guided serratus block with 0.4ml/kg (max.30ml) of ropivacaine 0.5% with 1:4000,000 epinephrine injected between the serratus anterior (superficial) and external intercostal (deep) muscles followed by subsequent general anesthesia
2566893|NCT02453516|Placebo Comparator|Placebo Block - Control Group|Patients will receive a preoperative placebo injection with a subcutaneous injection of 1ml normal sterile saline solution in the midaxillary line and the ultrasound probe will be used to simulate the pressure and block duration associated with the serratus block. These patients will then receive general anesthesia.
2566926|NCT02453152||Males with X-linked myotubular myopathy|History and physical, Tidal breathing, Maximal respiratory pressures, Peak cough flow, Pediatric Evaluation of Disability Inventory, PedsQL Multidimensional Fatigue Scale, Review of ventilation requirements
2566982|NCT02452853|Experimental|HR combined with FOLFOX4|"HR ;~FOLFOX4 4 weeks after HR"
2567030|NCT02452684||Participants with insomnia|Participants with insomnia who will receive eszopiclone, per approved label.
2567101|NCT02452255|Active Comparator|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
2567106|NCT02452255|Active Comparator|Fenofibrate and Propranolol|Fenofibrate and Propranolol by mouth given throughout hospitalization for up to 12 months
2567112|NCT02452255|Placebo Comparator|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
2567115|NCT02452255|Active Comparator|Propranolol|Propranolol by mouth given throughout hospitalization for up to 12 months
2567154|NCT02451826|Active Comparator|1.5 mg tablet LNG after 12 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and a single dose of levonorgestrel delivered in a 1.5 mg tablet after 12 weeks of CVR use
2567160|NCT02451826|Active Comparator|1.5 mg tablet LNG every 4 weeks|CVR delivering 2,500 µg of Ulipristal acetate per day and one 1.5 mg tablet levonorgestrel every 4 weeks of CVR use (three times).
2567281|NCT02451215|Experimental|Laser interstitial thermotherapy (LITT) treated patients|All patients enrolled on the trial will undergo LITT therapy per protocol. Side-effects and outcomes will be monitored and compared with disease matched historical controls.
2567303|NCT02450760|Other|Control|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. If subjects miss blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. Subjects will also receive weekly emails with their blood pressure data for the week.
2567305|NCT02450760|Other|Social Incentive|Subjects will take their blood pressure twice daily using the provided Withings blood pressure cuff. Subjects in this arm will also identify a social supporter who may help subjects adhere to daily blood pressure readings. If the subject misses blood pressure readings, they will receive automated alerts reminding them to take their blood pressure. The identified social supporter will also receive these alerts, with the expectation that the social supporter will remind the subject to take their blood pressure. Both the subject and the social supporter will also receive weekly emails with their blood pressure data for the week.
2567341|NCT02450630|Experimental|training on diagnosis, treatment and referral of children|Intervention Arm : training in diagnosis, treatment and referral of sick children
2567342|NCT02450630|No Intervention|Presumptive treament of sick children|Control Arm - Training of private providers in completing study tools i.e. filling in register and referral forms. No training in diagnosis, treatment and referral and no community awareness on referral
2567372|NCT02450370|Active Comparator|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
2567373|NCT02450370|Experimental|Low FODMAP diet group|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
2567426|NCT02450110|Experimental|Intervention|Spinal cord stimulation on top of standard treatment
2567427|NCT02450110|No Intervention|Control|Standard treatment
3172534|NCT00600951||2|Patients with severe chronic kidney disease or kidney failure (stages 4 and 5, according to the classification of chronic kidney disease by the National Kidney Foundation, i.e., with eGFR stably below 30 mL/min/1.73m2)
3172535|NCT00600964|Experimental|GX15-070MS|GX15-070MS at various doses and schedules
3172536|NCT00600977|Active Comparator|doxorubicine|VAD
3172537|NCT00600977|Experimental|Doxorubicine pegylated|Doxorubicine pegylated 40 MG/M² J1
3172538|NCT00601003|Experimental|Nifurtimox|
3172539|NCT00601029||1|Winter Phase - Observational
3172540|NCT00601029||2|Summer Phase - Observational
2567506|NCT02449512||complete|individuals with somato-sensory complete spinal cord injury
3172541|NCT00601042|Experimental|1|Swedish snus ad libitum as a substitute for cigarettes
3172542|NCT00601042|Placebo Comparator|2|Tobacco-free, nicotine-free placebo snus ad libitum as a substitute for cigarettes
3172543|NCT00601055|Experimental|Problem Solving-Rx Adherence (PSA)|Participants will receive problem-solving therapy integrated with adherence-enhanced procedures (PSA).
3172544|NCT00601055|Active Comparator|PID-C|Participants will receive adherence-enhanced (PID-C) procedures, a treatment mobilizing patients to participate in their care.
3172545|NCT00601068||Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
3172546|NCT00601081||1|Very low birth weight and preterm infants who will likely receive fortification of breast milk with HMF
3172547|NCT00601094|Experimental|experimental arm|
3172548|NCT00601133||Patient Postural Instability|Participants having difficulty walking and with balance after cancer treatment that are leaving the M.D. Anderson rehabilitation hospital or after treatment through the rehabilitation mobile team.
3172549|NCT00601159|Experimental|gemcitabine and cisplatin|cisplatin and gemcitabine in the management of triple negative metastatic breast cancer
3172550|NCT00601185||1|Patients undergoing a shave biopsy and confocal microscopy.
2566907|NCT02453477|Experimental|Elderly children|"8-17 years (3 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
2566909|NCT02453477|Experimental|Younger children|"3-7 years (4 subjects) The ATIMP consists of autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the beta-globin gene re-suspended in their final formulation medium.~Dosage indications The target dose in the transduced product is 5x10(6) cells/Kg CD34+cells, with a minimum dose of 2x10(6)/Kg and a maximum dose of 20x10(6)/Kg, depending on the yield of cells.~The product will be injected intraosseously."
3207784|NCT00968630|Experimental|Treatment (HIV-specific immune reconstitution after HCT)|Patients undergo leukapheresis for analysis of HIV-1 latent reservoir at baseline and at days +90, +180, +365, and +730, and then annually thereafter as feasible.
3207785|NCT00968643|Active Comparator|Arm I (control)|Patients undergo radiotherapy to the area of spinal cord compression once daily for 5 days (total of 20 Gy).
2567051|NCT02452658|Experimental|Changed menu|All participants will be exposed to the same changed menu after making their hypothetical choice. Changes will include reduced calorie labels, reduced prices, and changes to item descriptions.
3207786|NCT00968643|Experimental|Arm II|Patients undergo a single fraction of radiotherapy to the area of spinal cord compression (total of 10 Gy).
3207787|NCT00968695|Experimental|Albumin|The subjects will be receiving albumin 20% infusions
2567176|NCT02451709|Experimental|Feedback and alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device ( activated smartinhaler or smartturbo - Nexus 6) with twice daily alarm reminders activated. Patient decides times, different times on weekdays and weekends if required. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device and data shared with patient and family (feedback of adherence data). Discussion about adherence rates, and action planning for the next 3 months to improve adherence if necessary."
2567180|NCT02451709|Active Comparator|No feedback or alarms|"Standard education about importance of inhaled steroids and regular adherence to inhaled steroids after recruitment to study.~Randomized to receive an electronic adherence device. Deactivated Smartinhaler or Smartturbo.~Device not activated to play reminder alarms. This device fitted to their regular preventer inhaler, patient aware of its presence and its purpose in the context of the study.~Reviewed in standard asthma clinic every 3 months for 12 months. At each clinic visit, adherence information downloaded from device but data not shared with patient, and no adherence discussion."
3207788|NCT00968721||IBD patients|
3207789|NCT00968734|Experimental|Low fat meal|
2567278|NCT02450929||Standard Barrel-Cuff ETT|Standard Barrel-Cuff ETT use in surgical patients
2567282|NCT02450929||Taperguard ETT|Taperguard ETT use in surgical patients
3207790|NCT00968734|Experimental|Hight fat meal|
2567403|NCT02450227|Active Comparator|Spinach - Whole leaf (10 mg lutein)|"1-2: Group given whole leaf as first intervention Whole leaf spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Minced spinach (10 mg lutein) given every second day for a 15 days period."
2567406|NCT02450227|Experimental|Spinach - Minced (10 mg lutein)|"2-1: Group given minced spinach as first intervention Minced spinach (10 mg lutein) given every second day for a 15 days period.~Followed by:~Whole leaf spinach (10 mg lutein) given every second day for a 15 days period."
2567447|NCT02449941||Helicobacter pylori(HP) positive|Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
2567496|NCT02449577|Experimental|Beverage sequence ABCD|Each participant randomized to this arm is exposed to 4 test meals in the order ABCD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567503|NCT02449577|Experimental|Beverage sequence CADB|Each participant randomized to this arm is exposed to 4 test meals in the order CADB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567509|NCT02449577|Experimental|Beverage sequence DACB|Each participant randomized to this arm is exposed to 4 test meals in the order DACB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
3207791|NCT00968747|Experimental|Fasting (Healthy).|Participants will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily and two fat samples will be obtained by a trained surgeon. (We are no longer recruiting for Study Arm A).
2567893|NCT02446977|Experimental|Vitamin B2 Streuli®|20mg IV
3207792|NCT00968747|Experimental|Fasting (NAFLD)|Participants with liver-biopsy diagnosed non-alcoholic fatty liver disease (NAFLD) will fast for 72 hours during an inpatient stay at the Beth Israel Deaconess Medical Center in Boston, MA. Blood samples will be collected daily, and participants will have an MRI before and after the fast.
3207793|NCT00968747|Experimental|Hypocaloric diet (NAFLD)|Participants will follow a low-calorie diet until they lose 3-5% of their body weight. Participants will have weekly outpatient visits at Beth Israel Deaconess Medical Center in Boston, MA for weight measurements. Participants will have blood drawn before and after the diet. Participants will also have an MRI before and after the diet.
3207794|NCT00968747|Experimental|Oral carbohydrate challenge|Participants will fast for 16 hours overnight then ingest drinks containing fructose, glucose or a mixture of fructose and glucose. Blood will be drawn postprandially at specified timepoints for up to 5 hours
3207795|NCT00968760|Experimental|CD19-specific T cell Infusion without IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 1 - low dose of T cells without IL-2.~Group 3 - higher dose of T cells without IL-2."
2567093|NCT02452086|Active Comparator|Low Level Laser Therapy|"In laser therapy group, group who received interventions was the patients received laser with 2 Joule/centimeters2, 90 milliwatt~, 3 days/week, for 4 weeks (12 sessions)"
2567097|NCT02452086|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the LLLT group, but the laser light was off and Guiding light was laser was on
3207796|NCT00968760|Experimental|CD19-specific T cell Infusion with IL-2|"Conditioning Regimen of Chemotherapy (Carmustine, Cytarabine, Etoposide, and Melphalan), Stem Cell Transplant, and Gene Transfer~Group 2 - higher dose of T cells with IL-2.~Group 4 - higher dose of T cells with IL-2."
2567229|NCT02451306|Experimental|Quetiapine|"18 patients of the risk-group will receive quetiapine (Seroquel Prolong (c)) for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~Dosages: 50mg (day 1-3), 100mg (day 4-6) and 150mg (from day 7 onwards). Administration: Quetiapine will be given once daily before bedtime, not together with a meal and swallowed as a whole."
2567231|NCT02451306|Placebo Comparator|Placebo|"18 patients of the risk-group will receive placebo for 8 weeks in adjunction to their antidepressant standard therapy. Group allocation is randomised and double-blind.~The placebo does not contain any psychoactive substance."
2567234|NCT02451306|No Intervention|Control-group|18 depressive patients without a heightened risk for BPD will not receive any medication apart from their standard antidepressant therapy (control-group).
2567266|NCT02451059|Experimental|Intervention-WE CARE|"The WE CARE survey is used to identify unmet material needs; it will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age.~Providers will be trained to review the WE CARE survey at health supervision visits and generate our WE CARE community resource handouts (referrals) through the EMR.~A peer patient navigator will offer personalized guidance to families with accessing community resources. The patient navigator will be available for at least a 1/2 day per week at each intervention health center to meet with families and offer guidance. Providers can communicate the patient navigator to refer families via the electronic medical record and families will also have the opportunity to contact the peer navigator at any time via the hotline number listed on the referral information sheets."
2567275|NCT02451059|No Intervention|Control-Standard of Care|Participants in the delayed-intervention control group will receive standard pediatric care. However, since the health centers share a common EMR, and for ethical reasons, investigators will also embed the health IT referral mechanism into the EMR at the control sites. Control providers will be made aware of this prior to the start of the study. Although this may potentially reduce the effect size, the investigator's prior study found that the impact on referral rates of provider access to resource information was minimal. Families at control health centers will not receive the WE CARE surveys at health supervision visits and will not have access to the peer patient navigators
2567328|NCT02450721||Acute stroke|"Patients in the acute phase of atherothrombotic stroke or TIAs with 50-99% ACAS within the first 3 days af vascular event.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE, National Institutes of Health Stroke Scale (NIHSS)"
2567330|NCT02450721||Stable carotid artery stenosis|"Patients with 50-99% ACAS without history of vascular events during one month before enrollment.~Interventions to be administered: Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE"
2567333|NCT02450721||Control group|Healthy volunteers without ACAS Interventions to be administered:Biomarkers serum level measurement, history taking, neurological examination, duplex ultrasound, MMSE
2567407|NCT02450240||Depression and Anxiety Disorders|"350 subjects who screen positive for anxiety or depressive symptoms on the Patient Health Questionnaire (PHQ-9) ≥ 10 and/or Overall Anxiety Severity and Impairment Scale (OASIS) ≥ 8.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
2567409|NCT02450240||Eating Disorders|"350 subjects who screen positive for problems related to eating behavior on the Eating Disorder Screen (SCOFF), score ≥ 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
2567411|NCT02450240||Substance Use Disorders|"350 subjects who screen positive for problems related to substance use on the Drug Abuse Screening Test (DAST-10), score > 2.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
2567415|NCT02450240||Healthy Controls|"150 subjects who do not screen positive for anxiety and depression symptoms or problems related to eating behavior and/or substance use.~Interventions: (1) standardized diagnostic assessment, (2) self-report questionnaires, (3) behavioral tasks, (4) physiological measurements, 5) structural and functional magnetic resonance imaging and EEG, (6) biomarker and microbiome assessments, (h) blood to derive induced pluripotent stem cells, (8) and genetic and epigenetic assessments."
2567514|NCT02449512||incomplete|individuals with somato-sensory incomplete spinal cord injury
3207797|NCT00968773|Experimental|The Rebound hernia repair device with no fixation|Competent adults who have a unilateral, bilateral inguinal hernia that is primary in nature.
3207798|NCT00968773|Active Comparator|Standard Hernia Mesh using fixation|Competent adults who have a unilateral or bilateral inguinal hernia that is primary in nature.
3207799|NCT00968786|No Intervention|no home monitoring|no automated measuring devices for patients use at home
2567191|NCT02451644|Experimental|high risk for PTD with pedometer|Patient with high risk for preterm delivery including short cervix or rapture of membranes
2567218|NCT02451462|Experimental|Zoledronic acid arm|Zoledronic acid
2567223|NCT02451462|No Intervention|placebo arm|placebo
2567263|NCT02451176|Active Comparator|Active Comparator: Davol Bard ®Soft Mesh|Device: Davol Bard ®Soft Mesh Synthetic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: synthetic mesh SoftMesh™ (CR Bard)
2567271|NCT02451176|Active Comparator|Active Comparator: LifeCell Strattice®|Device: LifeCell Strattice® Reconstructive Tissue Matrix Biologic mesh for open ventral hernia repair for clean-contaminated or contaminated abdominal wall hernias Other Name: Biologic mesh Strattice
2567310|NCT02450825|Other|Mechanically ventilated patients|Mechanically ventilated patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 and Day 2 to 4. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
2567313|NCT02450825|Other|Spontaneously breathing patients|Spontaneously breathing patients who underwent a computed tomographic scan for dyspnea or hypoxemia will undergo a standardized lung ultrasound examination on Day 1 only. The GE Vivid ultrasound system will be used to perform the lung ultrasound examination.
3207800|NCT00968825|Active Comparator|Dose D|RT001
3207801|NCT00968825|Placebo Comparator|Dose E|Placebo
2567529|NCT02449447|Experimental|Blended treatment|10 weeks of four face-to-face Cognitive behavioral therapy sessions and internet-based CBT as a complement and support to the four sessions.
2567530|NCT02449447|Active Comparator|Treatment as usual|Usual course of antidepressants and management in primary care (e.g medication and supportive counselling).
2567551|NCT02449083||Arm 1|Patients with indication for MRI and coronary angiography
2567558|NCT02449083||Arm 2|Patients with atrioseptal or ventriculoseptal Shunt with indication to coronary angiography
2567563|NCT02449083||Arm 3|Patients with chronic obstructive pulmonary disease with indication to coronary angiography
2567611|NCT02448849|Experimental|MSC recipients|The patients with nonunion fracture who underwent percutaneous implantation of bone marrow derived mesenchymal stem cells in combination with platelet lysate product.
2567618|NCT02448849|Placebo Comparator|Placebo|The patients with nonunion fracture who underwent percutaneous injection of placebo.
2567647|NCT02448524|Experimental|MiStentTM|MiStentTM coronary drug eluting stent (MiStent SES) consists of four parts: a bare-metal stent (BMS), a delivery system, resorbable polymer coating and anti-proliferative drug (sirolimus).
2567648|NCT02448524|Active Comparator|TIVOLI|TIVOLI stent is a mature and fully degradable coating on a cobalt-chromium alloy drug-eluting stent on the market, findings of four years fully demonstrated the efficacy and safety of sirolimus-coated TIVOLI stent.
2567694|NCT02448264|Experimental|BCX7353|BCX7353 capsules administered orally
2567697|NCT02448264|Placebo Comparator|Placebo|Placebo to Match BCX7353 capsules, administered orally
2567741|NCT02448030|Experimental|Functional electric stimulation|Other: The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively.
2567745|NCT02448030|Placebo Comparator|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test.
2567776|NCT02447770|Experimental|Cocoa Flavanol intake escalation|Ingestion of increasing number of capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process (500 mg of cocoa flavanols/capsule) during 6 weeks followed by a 2 week of washout (no capsule intake)
2567827|NCT02447536|Active Comparator|BCG-DENMARK|"Infants randomised to receive BCG-DENMARK at dismissal from the Maternity Ward will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine BCG-Denmark 1331 (Statens Serum Institute) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.~NOTE: By 1st of July 2016, infants in this arm has received BCG-Japan due to a worldwide shortage of BCG-Denmark because of a halt in production of this vaccine at the Statens Serum Institut in Copenhagen."
2567830|NCT02447536|Active Comparator|BCG-RUSSIA|Infants randomised to receive BCG-RUSSIA at dismissal from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum Institute of India) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG-vaccination.
3207802|NCT00968851|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 84 days
2567966|NCT02446574|Experimental|Arm A|"During the Phase I it will administered weekly paclitaxel(dose escalation) and cisplatin with concurrent radiation therapy~During the Phase II it will administered weekly paclitaxel(dose according to phase I) and cisplatin with concurrent radiation therapy"
2568001|NCT02446275|Experimental|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression.
2568007|NCT02446275|Experimental|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid.
2568085|NCT02446106|Active Comparator|Soup with MSG|0.5% MSG incorporated into a soup preload
2568087|NCT02446106|Placebo Comparator|Control Soup|Negative control match for sodium (no MSG + 0.635% salt)
3207803|NCT00968851|Active Comparator|EVP-6124 1.0 mg|one 1.0 mg capsule every day for 84 days.
3207804|NCT00968851|Placebo Comparator|Placebo|Placebo every day for 84 days
2568165|NCT02445313||Control|Normal, healthy participants
3207805|NCT00968877|Active Comparator|Cholecalciferol|
3207806|NCT00968877|Placebo Comparator|Placebo|
3207807|NCT00968903|Active Comparator|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
3207808|NCT00968903|Placebo Comparator|Saline|Saline iv pre-operatively in equivalent volume (placebo)
2566986|NCT02452879|Experimental|Electroacupuncture group|Needle on bilateral BL33 acupoint 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day. The treatment period lasts eight weeks. totally 24 times.30min/time.
2566992|NCT02452879|Placebo Comparator|Placebo group|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
2566998|NCT02452879|Active Comparator|Solifenacin Succinate group|Solifenacin Succinate Tablets (made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg, 1 tablets each time, 1 times / day, oral administration of 30min before meal, even for 8 weeks.
3207809|NCT00968916|Experimental|1|"Level 1:~15.5 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 2:~25 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 3:~35 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal~Level 4:~50 mg/m2 of AVE8062 will be administered once in every 3 weeks, with 30-minute intravenous infusion and continued until unacceptable toxicity or disease progression or patient refusal"
3207810|NCT00968929|Experimental|r-SK group|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
2567146|NCT02451878|Experimental|Intervention|The E-Couch self-help social anxiety module which is based on cognitive behavioural therapy principles. This module contains a literacy section and 5 toolkits comprising exposure practice, cognitive restructuring (modifying your thinking), attention practice, social skills training and relaxation. E-Couch is designed to be completed at the participant's own pace. It is free to use, browser-based and widely accessible on a range of connected devices.
2567149|NCT02451878|No Intervention|Control|Wait list control (WLC)
2567188|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Assessment of electrophysiology in the time domain to examin temporal organization of corticospinal function
2567189|NCT02451683|Experimental|Electrophysiology Assessment of Location|Assessment of electrophysiology to examine spatial organization of corticospinal function
2567190|NCT02451683|Active Comparator|Training with some stimulation|Training with non-invasive stimulation and training with sham stimulation
2567267|NCT02451228||Single-group|Observational opportunistic pharmacokinetic study of 300 pregnant women receiving Indomethacin therapy as standard of care for risk of preterm birth. Receive serial blood collection from IV.
2567304|NCT02450786|Experimental|Donepezil group|Donepezil is started in 5mg for 8 weeks followed by dose escalation to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
2567306|NCT02450786|No Intervention|control group|No administration of any therapeutic medications for dementia including cholinesterase inhibitor or NMDA receptor blocking agents. Standard treatment protocol of Parkinson's disease with mild cognitive impairment would be fulfilled including dopaminergic or nondopaminergic medications as well as nootropic drugs.
2567339|NCT02450643|Active Comparator|Test then Control|Subjects will perform a DBPCFC with the Test formula followed by the Control formula
2567340|NCT02450643|Active Comparator|Control then Test|Subjects will perform a DBPCFC with the Control formula followed by the Test formula
2567419|NCT02450279|Active Comparator|Nebulization with a vibrating-mesh nebulizer|Nebulization performed with a vibrating-mesh nebulizer
2567420|NCT02450279|Active Comparator|Nebulization with a jet nebulizer|Nebulization performed with a jet nebulizer
2567464|NCT02449824||magnetic resonance imaging|Participants will undergo MRI at baseline, after 1 cycle, 3 cycles and at completion of neoadjuvant chemotherapy.
2567481|NCT02449538|Experimental|everolimus|everolimus 10 mg qd daily
2567538|NCT02449421|Experimental|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
2567539|NCT02449421|Experimental|Quality Improvement Learning Community|The Quality Improvement Learning Community arm will include clinicians who set goals related to CPT delivery, execute a plan, study results, refine plan, and continue each cycle until goals are met.
2567587|NCT02449005|Experimental|Group A|Group A (BM-MSCs/fibrin glue/collagen fleece) will receive regenerative treatment using autologous bone marrow mesenchymal stem cells free of animal derived reagents, produced in clean room facilities and seeded into collagen scaffolds enriched with autologous fibrin glue
2567591|NCT02449005|Experimental|Group B|in Group B (Fibrin glue/collagen fleece), a collagen fleece enriched with autologous fibrin glue devoid of stem cells will fill the osseous defect
2567594|NCT02449005|Active Comparator|Group C|Group C will receive open flap debridement retaining the soft tissue wall of the pocket
2567686|NCT02448355|Experimental|Patient undergoing carotid endarterectomy|"All patients undergoing carotid endarterectomy in Shaare Zedek Medical Center Visual acuity measurement (Snellen) SS-OCT (DRI-Atlantis, Topcon) 3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.~On pre-op visit (Monday)~Day 1 post-surgery~Discharge day~Week 1 post-surgery~Month 1 post-surgery"
2567737|NCT02448121|Experimental|Autologous bone marrow stem cell graft|Autologous bone marrow stem cell implantation
2567773|NCT02447900|Other|Treatment|
2567847|NCT02447562|Active Comparator|G_AH|Usual care group
2567855|NCT02447562|Other|G_SP|Phone-based care
2567034|NCT02452606|Experimental|Stalevo®|Participants who are assigned to Stalevo Arm will take Stalevo® at bedtime for 3 month.
3172551|NCT00601198|Experimental|Treatment Period|The chemotherapy regimen will be given for 2 consecutive days. On day #1, pt. will be premedicated with drugs to prevent nausea and vomiting in addition to intravenous fluids. Then they will receive amifostine intravenously followed by oxaliplatin, 5FU and leucovorin. This will be followed by an infusion of 5FU given in a pump over 22 hours. If the doctor decides on giving the pt. Avastin, this will be given on day #1. On day #2, they will receive the same treatment except for oxaliplatin.
3172552|NCT00601224|Experimental|1|Participants will receive social cognition and interaction training plus treatment as usual
2567236|NCT02451345|Experimental|Intervention|Personalized risk model+website+phone coaching
2567260|NCT02451072|Experimental|Placebo, LSD, Ketanserin/LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject
2567399|NCT02450305||Treated with HBO|QOL questionnaires at 5 time points for those having HBO therapy at least one year post radiation therapy for head and neck cancer, daily x6 weeks
2567405|NCT02450305||Not treated with HBO|QOL questionnaires for those at least one year post radiation therapy for head and neck cancer at 5 times points.
2567518|NCT02449785|Experimental|Cystic fibrosis adults|
2567590|NCT02448992|Experimental|PCI via hippocampal-sparing WBRT|All studied patients should undergo a computed tomography (CT) simulation scan encompassing the entire head region with 1.25-mm slice thickness using a thermoplastic mask for immobilization. To achieve conformal hippocampal sparing during the delivery of WBRT, the technique of volumetric modulated arc therapy (VMAT) via Linac-based RapidArc® or TrueBeamTM is employed in our treatment planning. All treatment plans are delivered by using the Linac Varian-iX or TrueBeamTM. In terms of dose prescription, a dose of 30 Gy in 15 fractions is prescribed to whole-brain planning target volume (PTV) under the setting of prophylactic cranial irradiation for NSCLC patients.
2567593|NCT02448992|No Intervention|observation without PCI|
2567667|NCT02448602|Other|Single point group (Shenmen)|Patients will be acupuncture with Shenmen(HT7).
2567674|NCT02448602|Other|Sancai coordinated points group|Patients in Sancai coordinated points group, will be acupuncture with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6).
2567679|NCT02448602|Other|Control group|Patients in Control group, will be acupuncture with at the junction of deltoid and biceps.
2567721|NCT02448134|Experimental|Youth Access|"Youth Engagement in Prosocial Alcohol-Free Activities Participate in the Reward and Reminder program in their community"
2567723|NCT02448134|No Intervention|Control|Student will receive regular information and programs.
2567762|NCT02447978||PCR-positive pertussis cases|Cases will be all individuals who tested PCR-positive for pertussis and negative for parapertussis during the study period and who received 5 doses of DTaP vaccines (either manufactured by GSK or any brand, depending on study objective) through 84 months of age before testing PCR-positive.
2567763|NCT02447978||PCR-negative pertussis controls|Controls will consist of persons who tested PCR-negative for both pertussis and parapertussis and who received 5 DTaP doses (either manufactured by GSK or any brand, depending on study objective) before testing PCR negative.
2567764|NCT02447978||KPNC-matched controls|Controls will consist of all KPNC members of the same sex, age (year and quarter of birth), race or ethnic group (7 groups; 6 for reported, 1 for imputed), and medical centre as each pertussis case and who were members on the date the case tested PCR-positive (anchor date).
2567804|NCT02447653|Experimental|Hydroxyapatite Coating|G7 HA Acetabular component will be implanted
2567806|NCT02447653|Active Comparator|Plasma Porous Spray|G7 PPS Acetabular component will be implanted
2567821|NCT02447406|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Phase Ib:Volitinib should be administered at least 200mg orally once a day in 21 days for achieving appropriate antitumor activity.~Phase II: Subjects will receive Volitinib once daily ( at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
2567904|NCT02447146|Experimental|Training group|9-week resistance training program
2567907|NCT02447146|Other|Control group|'Lectures on the disease'
3172553|NCT00601224|Active Comparator|2|Participants will receive treatment as usual
3172554|NCT00601237|Experimental|A|Participants will receive HIV-related text messages
3172555|NCT00601237|Active Comparator|B|Participants will receive nutrition-related text messages
3172556|NCT00601237|No Intervention|C|Participants will attend a 90-minute focus group to develop messages for the cell-phone program
3172557|NCT00601263|Active Comparator|1a|Low dose ASHMI (2 caps bid).
3172558|NCT00601263|Placebo Comparator|1b|Placebo 2 caps bid.
3172559|NCT00601263|Active Comparator|2a|Medium dose ASHMI (4 caps bid).
3172560|NCT00601263|Placebo Comparator|2b|Placebo 4 caps bid.
3172561|NCT00601263|Active Comparator|3a|High dose ASHMI (6 caps bid).
3172562|NCT00601263|Placebo Comparator|3b|Placebo 6 caps bid.
3172563|NCT00601276|Experimental|1|
3172564|NCT00601276|Active Comparator|2|
3172565|NCT00601341|Experimental|1|lumbosacral joint manipulation
3172566|NCT00601341|Experimental|2|lumbar passive range of motion
3172567|NCT00601341|Other|3|lie on exam table for 3 minutes
3172568|NCT00601393|Active Comparator|1|Participants will receive treatment as usual followed by 8 weeks of Internet-based cognitive behavioral therapy treatment
3172569|NCT00601393|Experimental|2|Participants will receive 8 weeks of Internet-based cognitive behavioral therapy treatment
3172570|NCT00601471|Experimental|1|proximal tibiofibular manipulation
3172571|NCT00601471|Experimental|2|distal tibiofibular manipulation
3172572|NCT00601471|No Intervention|3|no treatment
3172573|NCT00601497|Experimental|1|
3172574|NCT00601497|Placebo Comparator|2|
3172575|NCT00601510|Experimental|Imatinib mesylate|Imatinib mesylate 300mg/day(maximum dose will be 800 mg) on day -4, -3, -2, -1, 1, 2, 3 through d21 in combination with capecitabine 1250 mg/m2 twice daily (d1-d14) and iv cisplatin 60mg/m2
3172576|NCT00601549|Experimental|1|Patients with low rectal cancer after CCRT undergoing laparoscopic surgery
2567039|NCT02452502|Active Comparator|moderate dose|Drug: Atorvastatin Atorvastatin 20 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
2567050|NCT02452502|Experimental|high dose|Drug: Atorvastatin Atorvastatin 80 mg daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months Other Name: Lipitor
2567110|NCT02452216|Experimental|Ferumoxytol group|All subjects in the experimental arm will have a single intravenous dose of ferumoxytol (5 mg Fe/kg), to be administered 24 hours before the subject undergoes ferumoxytol-enhanced magnetic resonance imaging (MRI). These subjects will subsequently undergo surgery, and tissue analysis of surgically resected samples (specifically the number of iron-containing and non-iron-containing macrophages) will be correlated with imaging features on ferumoxytol-enhanced MRI.
2567226|NCT02451423|Experimental|MPDL3280A|MPDL3280A: Intravenously; Day 1 of each 21-day Cycle
2567279|NCT02450994|Active Comparator|Dexamethasone|Dexamethasone 4 mg capsules, twice per day, orally
2567284|NCT02450994|Placebo Comparator|Placebo|Placebo capsules twice per day, orally
2567308|NCT02450734||Carotid endarterectomy|Realisation of an ultrasound-guided intermediate cervical plexus block for anesthesia of carotid endarterectomy
3207811|NCT00968929|Active Comparator|UK group|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
2567424|NCT02450097|Other|Lifestyle counseling|"Intermittent Caloric restriction in 3 Groups:~I- 40 patients with diabetes type 2 BMI 25.1-37 II- 40 non diabetic over weight subjects with BMI 25.1-37 III- 20 non diabetic subject with BMI 23.1 - 25 and visceral fat"
2567442|NCT02449863||Low risk ultrasound|Patients with a low risk ultrasound
2567445|NCT02449863||High risk ultrasound|Patients with a high risk ultrasound
2567490|NCT02449616|Experimental|Study Drug|MST-188
2567566|NCT02449252|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
2567568|NCT02449252|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maxomal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or partial response beginning 1 month after the last cycle of chemotherapy."
2567607|NCT02448745|No Intervention|Control|21 clusters composed of one or more villages with a total number of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is the only malaria control intervention.
2567616|NCT02448745|Experimental|Intervention|21 clusters composed of one or more villages with a total of 30 to 70 children under 5 years old. Routine distribution of long-lasting insecticidal nets is available and in addition insecticide treated wall lining is installed in all sleeping areas with homeowner consent. All 4 walls and the ceiling are covered with lining.
2567670|NCT02448589|Experimental|TAS-119 Monotherapy|"Dose Escalation:~A Monotherapy Dose-Escalation Phase Performed in Approximately 5 Dose Levels (3 to 12 Patients Per Dose Level) to Determine the MTD for TAS-119 Given Orally (PO), Twice-Daily (BID) in a 28-Day Treatment Cycle; and:~Dose Expansion:~A Monotherapy Expansion Phase in Which Approximately 40 Additional Patients will be Enrolled to Further Evaluate the Recommended Phase II Dose (RP2D)"
2567743|NCT02448147|Active Comparator|Interval training|
2567751|NCT02448147|Active Comparator|Continuous training|
2567754|NCT02448147|No Intervention|Control|
2567781|NCT02447705|No Intervention|Lamivudine group|continue Lamivudine
2567787|NCT02447705|Experimental|Telbivudine group|Telbivudine replaces Lamivudine
2567846|NCT02447484|Experimental|Mujer Segura Siempre|Twice-daily safer-sex and safer-drug-use text messages, 5 days per week, for 24 months. Text message content based on 8 different constructs of behavior-maintenance theory and tailored to specific preferences and motivators provided by participant.
2567854|NCT02447484|Active Comparator|General Health Message Texts|Twice-daily text messages, 5 days per week, for 24 months. Text message content centered on general health promotion, including getting regular medical checkups and maintaining good dietary and exercise habits.
3207812|NCT00968942|Active Comparator|Dose A|RT001
3207813|NCT00968942|Placebo Comparator|Dose B|Placebo
2568094|NCT02445846||Pregnant women|Pregnant women, regardless of HIV status, seeking antenatal care at clinics in Lusaka, Zambia
2568112|NCT02445599|Experimental|Diclofenac group|"Diclofenac 100 mg tablet were administered orally and Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication, 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
2568113|NCT02445599|Experimental|Control group|"Midazolam 5 mg + Atropine 0.5 mg were administered intramuscularly as premedication 60 minutes before surgical interventions.~Every patient recieved additional thoracic epidural analgesia during and after the surgery.~As rescue medication patients get nalbuphine 10-20mg, diclofenac 75 mg + orphenadrine 30 mg (NEODOLPASSE infusion), metamizole-sodium 2g, tramadol 50-100mg as needed postoperatively."
2568199|NCT02445144||SCA Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
2568200|NCT02445144||Control Patients|Asymptomatic sickle cell anemia patients will undergo imaging/neurocognitive testing and be compared to controls
2568234|NCT02444897|Experimental|Epidural PCA group|Epidural patient-controlled analgesia group
2568236|NCT02444897|Active Comparator|IV PCA group|Intravenous patient-controlled analgesia
3207814|NCT00968955|Active Comparator|Local infiltration with ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
3207815|NCT00968955|Placebo Comparator|Local infiltration with saline|Local infiltration with saline (150 ML) (placebo)
2567040|NCT02452411|Experimental|Homework assignments using TEO system|Experimental: Homework assignments using TEO system. It is an internet-based system which allows the therapist to create homework sessions using multimedia materials (videos, images, texts, and narratives) and to offer and present this material to the patients through the Internet. Participants receive a CBT treatment for adjustment disorder supported by virtual reality and they do the homework assignments component using TEO at home over the Internet.
2567049|NCT02452411|Experimental|Homework assignments using Traditional method|The traditional way of applying homework assignments consists of reading and writing materials and audio session records. Participants receive a CBT treatment supported by virtual reality for adjustment disorder and they do the homework assignments component at home using traditional materials.
2567098|NCT02452203|Experimental|Floating|The participant will float supine in water with a high concentration of Epsom salt for 90 minutes.
2567099|NCT02452203|Placebo Comparator|Chair|The participant will lay in the supine position while reclined in a zero-gravity chair for 90 minutes.
3172577|NCT00601549|Active Comparator|2|Patients with low rectal cancer after CCRT undergoing traditional open surgery
3172578|NCT00601653|Active Comparator|1|Cognitive behavioral therapy plus general nutrition counseling
2567350|NCT02450474|Other|A: baseline - IPC|"A: baseline - IPC - washout - NMES - washout - follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. IPC phase will consist of normal care plus IPC of the lower limbs for the duration of each dialysis session."
2567355|NCT02450474|Other|B: baseline - NMES|"B: baseline - NMES - washout - IPC - washout follow up~The baseline phase, washout phase and follow up phase will consist of treatment as normal. NMES phase will consist of normal care plus stimulation of the foot and calf muscles for a period of one hour during dialysis."
2567398|NCT02450188|Active Comparator|vardenafil|The study includes a total period of 10 week with a total of 3 visits for vardenafil Group (at the beginning, at 5th week and at the end). In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.
2567400|NCT02450188|Active Comparator|vardenafil+cbst|"The study includes a total period of 10 week with a total of 10 visits for vardenafil+cbst Group (one weekly visit).~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks.CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings."
2567439|NCT02449954|Active Comparator|morphine group|intravenous 0.1mg/kg morphine
2567443|NCT02449954|Active Comparator|tramadol group|intravenous 2 mg/kg tramadol
2567446|NCT02449954|Active Comparator|ketorolac group|intravenous30 mg ketorolac
2567486|NCT02449564|Experimental|sirolimus|sirolimus 1mg daily
2567626|NCT02448953|Active Comparator|negative lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
2567629|NCT02448953|Active Comparator|positive lymph node|lymph node along the right recurrent laryngeal nerve should be confirmed negative by intraoperative frozen pathology examination
2567657|NCT02448420|Experimental|Arm A: HER2-positive/Hormone receptor-negative|"Patients with hormone receptor-negative, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
2567659|NCT02448420|Experimental|Arm B1: HER2+/Hormone receptor-positive|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib.~Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks."
2567663|NCT02448420|Experimental|Arm B2:HER+/HR+: trastuzumab + palbociclib +letrozole|"Patients with hormone receptor-positive, HER2 positive breast cancer, who received trastuzumab + palbociclib + letrozole Palbociclib: oral, 200 mg/day for 2 weeks, followed by 1 week off. Trastuzumab: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Letrozole: daily oral dose of 2.5 mg."
2567668|NCT02448420|Experimental|Arm C1: Palbociclib, trastuzumab and endocrine therapy|"HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive trastuzumab + palbociclib + endocrine therapy~Trastuzumab or biosimilar: intravenous trastuzumab loading dose of 8mg/kg followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.~Palbociclib: oral, 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.~Endocrine therapy: either an Aromatase Inhibitor, Fulvestrant, or Tamoxifen."
2567676|NCT02448420|Active Comparator|Arm C2: Treatment based of physician's choice|HR-positive, HER2 positive, Luminal intrinsic subtype determined by PAM50 who will receive treatment based on physician's choice from the following options: TDM1 or chemotherapy (gemcitabine, vinorelbine, capecitabine, eribulin or a taxane) in combination with trastuzumab.
2568076|NCT02445950|Experimental|Technology-aided counseling|Customers receive intervention via technology-aided phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. The customers are able to view their change change needs and choose tasks/goals for the coaching. The independent phase lasts 13 weeks and coaching is done via a digital tool.
3172579|NCT00601653|Experimental|2|Cognitive behavioral therapy plus low energy density diet counseling
3172580|NCT00601679|Experimental|NT-proBNP|Surveillance NT-proBNP levels disclosed to physicians. Intervention (e.g. Diuretic management) based on NT-proBNP results.
3172581|NCT00601679|No Intervention|Usual Care|Surveillance NT-proBNP levels blinded. Intervention (e.g. Diuretic management) based on clinical judgments.
3172582|NCT00601692|Experimental|Regimen 1|Patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Beginning in week 8, patients receive docetaxel IV over 15 minutes and irinotecan hydrochloride IV over 30 minutes on days 1 (week 8) and 8 (week 9). Patients also undergo radiotherapy once daily, 5 days a week, in weeks 8-10. Treatment with chemoradiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
2567092|NCT02452307|Experimental|Peptide vaccine + Imiquimod|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with Imiquimod
2567095|NCT02452307|Experimental|Peptide vaccine + mRNA/Protamin|Subcutaneous application of Prostate-specific peptide vaccine compound emulsified in Montanide ISA-51 in combination with mRNA/Protamin
2567155|NCT02451813|Experimental|Intervention|"A 22 GA 5 cm nerve block needle will be advanced to the following conditions:~Needle tip slightly indenting the fascia iliaca~Needle tip advanced through fascia iliaca~Needle tip slightly indenting the anterior surface of the femoral nerve~Needle tip withdrawn 1 mm from nerve.~At each of these conditions, 1 ml of dextrose solution will be injected and spread of injectate observed sonographically. A blinded observer will measure injection pressure. If opening pressure reaches 15 psi, this investigator will halt the injection. In addition, minimum threshold current required to elicit a motor response will be recorded for conditions 3 and 4."
2567201|NCT02451605|Active Comparator|Femoral nerve blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade with continuous catheter infusion as (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
2567203|NCT02451605|Active Comparator|Adductor canal blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for for total knee replacement surgery.
2567204|NCT02451605|Active Comparator|Subgluteal sciatic nerve blockade|In this group, patient will benefit of an ultrasound guided subgluteal sciatic nerve blockade with continuous catheter infusion (initial bolus of 20ml of ropivacaine 0.75% follow with 7ml/hour of ropivacaine 0.2%) as analgesic nerve blockade for total knee replacement surgery.
2567241|NCT02451280|Experimental|Unilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and UAT training in each session.
2567242|NCT02451280|Experimental|Bilateral Hybrid Intervention Group|Participants will receive 6 weeks of bilateral RT training using the BMT and BAT training in each session.
2567243|NCT02451280|Experimental|Robot-Assisted Training Group|Participants will receive 6 weeks of RT training using the BMT in each session.
2567283|NCT02450942|Experimental|18F-FDS injection and PET/CT scan|The patients were intravenously injected with 18F-FDS and underwent PET/CT scan 1 h after the injection.
3207816|NCT00968994|Experimental|exSALT SD7™ Wound Dressing|The exSALT™ SD7 Wound Dressing provides an antimicrobial barrier that inhibits microbial growth in the dressing. The exSALT™ SD7 Wound Dressing consists of 3 layers: two non-adherent polyethylene mesh wound contact layers and one absorbent core made of polyester. All three layers are silver coated. The concentration of silver on the exSALT™ SD7 Wound Dressing is approximately 0.4 mg/cm2 (2.5% w/w).
3207817|NCT00968994|Active Comparator|Xeroform® Petrolatum Dressing|Xeroform® Petrolatum Dressing (Xeroform® / Control Dressing) is fine mesh gauze impregnated with 3% Bismuth Tribromophenate in a special petrolatum blend. The dressing is a non adherent dressing that clings and conforms to all body parts.
3207818|NCT00969007|Experimental|Lifestyle counseling|
2567431|NCT02450032|Experimental|G17DT|Treatment with 500µg/ 0.4mL dose of G17DT administered by intramuscular injection at 0, 2, and 6 weeks.
2567477|NCT02449733|Experimental|HIV+ subjects|Men who test positive for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, risk-reduction counseling, couples HIV counseling and testing, and linkage to care
2567478|NCT02449733|Experimental|HIV- subjects|"Men who test negative for HIV will receive a comprehensive package of HIV prevention services, including condom choices, condom-compatible lubricant choices, enhanced HIV testing options, risk-reduction counseling, couples HIV counseling and testing, linkage to care, and screening for and offering of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP).~If men test positive for HIV during the study, they will be transitioned into the HIV+ subjects arm."
2567536|NCT02449265|Experimental|ISRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-site radiotherapy (ISRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
2567537|NCT02449265|Active Comparator|IFRT group|"Six cycles chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) +prednisone 60mg/square meter on day 1 through 5,repeated at 21-day intervals ).~Consolidation involved-field radiotherapy (IFRT) following in patients with complete or paratial response beginning 1 month after the last cycle of chemotherapy."
2567598|NCT02448966||Traditional open esophagectomy|Treated by traditional three-incision esophagectomy in the centers with enough experience in esophagectomy via right thoracotomy and the volume ≧50 cases each year.
2567599|NCT02448966||Minimally invasive eophagectomy|treated by minimally invasive thorascopic/laparoscopic esophagectomy in the centers with enough experience in VATS esophagectomy and the volume≧50 cases each year.
3207819|NCT00969020|Active Comparator|Telemedicine|RRS via telemedicine. By developing the concept of Remote Rehabilitation Support (RRS) the investigators will try to bring preoperative education of the patient, dissemination of information and postoperative support to a new level.
2567695|NCT02448290|Experimental|docetaxel+selumetinib|Selumetinib 75 mg will be administered orally twice a day with continuous dosing schedule Docetaxel 60 mg/m2 will be administered via intravenous access every 3 weeks.
2567750|NCT02448069|Experimental|Argatroban treatment|Intravenous Argatroban delivered at 100mcg/kg bolus, then 12-hour infusion initiated at 3mcg/kg/min.
2567779|NCT02447861||3q29 deletion|Individuals with 3q29 deletion
2567786|NCT02447861||3q29 duplication|Individuals with 3q29 duplication
2567792|NCT02447861||Unaffected siblings|Unaffected siblings of 3q29 deletion or duplication individuals
2567797|NCT02447861||Healthy Controls|Unrelated age-matched controls without 3q29 deletion or duplication
2567825|NCT02447523||Patients with metabolic syndrome|Patients fulfilling criteria to establish the diagnosis of metabolic syndrome
2567831|NCT02447523||Patients without metabolic syndrome|Patients not fulfilling criteria of the metabolic syndrome
2567125|NCT02451956|Experimental|AZD5363 in combination with paclitaxel|AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.If paclitaxel therapy is stopped then AZD5363 can be given on a 4on/3off continuous schedule.
2567156|NCT02451787|Experimental|Active|vitamin D supplementation group (2500 IU day for 3 months)
2567161|NCT02451787|Placebo Comparator|Control|no vitamin D supplementation
2567205|NCT02451579|Active Comparator|Cetirizine Hydrochloride|Prophylactic use of cetirizine hydrochloride prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
2567206|NCT02451579|Placebo Comparator|Placebo|Prophylactic use of placebo prior to and after Topical 5-aminolevulinic Acid Photodynamic Therapy
2567244|NCT02451267|Experimental|positive CPR: research group|physical therapy treatment with aerobic exercise
2567246|NCT02451267|Experimental|negative CPR: research group|physical therapy treatment with aerobic exercise
2567247|NCT02451267|Active Comparator|positive CPR: control group|physical therapy treatment
2567251|NCT02451267|Active Comparator|negative CPR: control group|physical therapy treatment
2567326|NCT02450695|Experimental|Active rTMS|"In rTMS, a device called a stimulator provides energy to a magnetic coil. The coil is a handheld unit that delivers magnetic pulses. The coil is placed against the scalp on the top of your head. Sessions will occur once a day, 5 days/week, for 3 weeks."
2567331|NCT02450695|Sham Comparator|Sham rTMS|The coil in the sham rTMS phase will be positioned 90 degrees off the scalp, with one wind of the coil touching the scalp. This will ensure that the participant will not be affected by the machine during this time. All other factors will be similar to the active rTMS phase.
2567351|NCT02450435||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2567358|NCT02450435||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2567361|NCT02450435||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2567366|NCT02450435||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2567422|NCT02450149|Experimental|Sorafenib|Sorafenib 400 mg will be administered orally twice a day for 28 days.
2567440|NCT02449876|Experimental|Neuroscience Education|"Subjects will have 2 sessions of education 2 weeks apart. After the first session subjects will be given a 50 page book Why Do I Hurt by Adriaan Louw. Session 1 will last approximately 60 minutes and session approximately 30 minutes."
2567501|NCT02449655|Experimental|AZD5363 plus paclitaxel|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
2567510|NCT02449655|Active Comparator|AZD2014 plus paclitaxel|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
2567569|NCT02449200|Experimental|Multimodal physiotherapy group|4 week multimodal physiotherapy treatment programme provided by an experienced musculoskeletal physiotherapist
2567579|NCT02449200|No Intervention|Advice to stay active group|Advice to stay active and continue use of prescribed medication as appropriate, via weekly phone calls from a physiotherapist over a 4 week period.
2567609|NCT02448797|Experimental|icotinib|125 mg three times daily (375 mg per day) orally for two years.
2567617|NCT02448797|Active Comparator|standard chemotherapy|"Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.~cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles.~For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles."
2567658|NCT02448433|Other|Phototherapy|
2567735|NCT02448225|Experimental|Diagnostic (18F-FDG PET/CT, 18F-FSPG PET/CT)|Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes.
2567839|NCT02447367|Experimental|JLP-1207, Fasted followed by fed|JLP-1207 dosing in the fasted state followed by fed dosing
2567842|NCT02447367|Experimental|JLP-1207, Fed followed by fasted|JLP-1207 dosing in the fed state followed by fasted dosing
2567900|NCT02447068|No Intervention|Non-treatment Control|Control arm will not have any intervention
2567901|NCT02447068|Active Comparator|Occlusive Dressing|An off-the-shelf dressing occlusive dressing will be used as an active comparator.
2567903|NCT02447068|Active Comparator|Luma Light|A NBUVB light will be used as an active comparator.
2567908|NCT02447068|Experimental|Luma Light System|The experimental arm will be a combination of an occlusive dressing and NBUVB light.
3207820|NCT00969020|No Intervention|Standard|The standard procedure for THA used under The Lundbeck Center for fast track hip and knee surgery
3207821|NCT00969033|Experimental|CS-1008 with irinotecan|CS-1008 and irinotecan
3207822|NCT00969033|Active Comparator|irintoecan|irinotecan alone
3207823|NCT00969046|Experimental|Bolus|20 min bolus infusion
3207824|NCT00969046|Experimental|CIV-1d|1 day continuous infusion
2568022|NCT02446197|Experimental|Patient Directed Exercise Group|Participants will complete a combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
2568024|NCT02446197|No Intervention|Standard of care|Standard of care comprehensive inpatient rehabilitation program.
2568050|NCT02446041||ICS/LABA Patients|ICS/LABA Patients following standard of care
3207825|NCT00969046|Experimental|CIV-5d|5 day continuous infusion
3207826|NCT00969059|Placebo Comparator|PLACEBO|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive placebo for 28 days.
3207827|NCT00969059|Experimental|Active|Eligible participant with at least moderate intensity of pain (an average daily pain score of ≥ 4 on the 11 point PI-NRS at baseline) will receive 7.5 mg twice daily (bid) GW856553 for 28 days.
3172583|NCT00601692|Experimental|Regimen 2|Patients receive docetaxel IV and irinotecan hydrochloride as in regimen 1 induction chemotherapy. They also receive cisplatin IV over 20-30 minutes on days 1 and 8. Treatment with irinotecan hydrochloride, docetaxel, and cisplatin repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients receive docetaxel IV, irinotecan hydrochloride IV, and undergo radiotherapy as in regimen 1 chemoradiotherapy. Patients also receive cisplatin IV over 20-30 minutes on days 1 (week 8) and 8 (week 9). Treatment with irinotecan hydrochloride, docetaxel, cisplatin, and radiotherapy repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3172584|NCT00601744||Patient|Diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
2567192|NCT02451657||Cohort|
2567221|NCT02451397||Dr.Tang's research group|Chinese lifestyle associated with osteoporosis
2567479|NCT02449746|Active Comparator|Intravenous Immunoglobulin (IVIG)|"Intravenous Immunoglobulin IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
2567480|NCT02449746|Active Comparator|Plasma Pheresis / Plasma Exchange (PLEX)|Plasma Exchange (PLEX) is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and its use was first reported in myasthenia gravis in 1976, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects . PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice
2567550|NCT02449330|Experimental|Teneligliptin in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as Teneligliptin treatment by randomization
2567555|NCT02449330|No Intervention|Other agents in the inhibition test|Patients showing E/e' by echocardiography less than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
2567560|NCT02449330|Experimental|Teneligliptin in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as Teneligliptin treatment by randomization
2567564|NCT02449330|No Intervention|Other agents in the improvement test|Patients showing E/e' by echocardiography more than 8 at base line and assigned as anti-diabetic agents except for DPP-4 inhibitors treatment by randomization
2567689|NCT02448342|Experimental|ReDS Guided Treatment|After discharge from hospital, patient will perform daily ReDS measurement. Data is automatically transmitted to the secured web portal. Treating physician will follow up on patients' measurements through a secured dedicated web site. Notification messages will be automatically sent by the system to the physician if certain thresholds are crossed (thresholds are physician adjustable). Medications will be adjusted according to defined guidelines. During the study a service center will monitor and support patient adherence and investigators attending to patients' notifications.
2567692|NCT02448342|Active Comparator|Standard of Care- Control arm|After discharge from hospital, patient will be followed up and medically managed according to standard of care guidelines.
2567774|NCT02447822|Active Comparator|6.0ATG|Recipients who have 6.0 mg/kg Thymoglobulin as induction therapy
2567780|NCT02447822|Active Comparator|4.5ATG|Recipients who have 4.5 mg/kg Thymoglobulin as induction therapy
3172585|NCT00601744||Family Member/Friend|Family member or close friend of a patient with a diagnosis of orbital or head and neck cancer and a history of orbital exenteration.
3172586|NCT00601757|Other|1|Participants assigned to the Postpartum Prevention Program
3172587|NCT00601757|Other|2|Participants assigned to enhanced care as usual
3172588|NCT00601770|Experimental|IC41|8 injections of 4 x 0.125mL
3172589|NCT00601809|Experimental|GG|
3172590|NCT00601809|Other|TT|
3172591|NCT00601822|Experimental|1|Group receiving cognitive behavioral therapy for anorexia nervosa (CBT-AN)
3172592|NCT00601822|Experimental|2|Group receiving cognitive behavioral therapy for anorexia nervosa, plus cognitive remediation therapy (CBT-AN+CRT)
3172593|NCT00601861|Experimental|A|
3172594|NCT00601913|Experimental|Erlotinib|Erlotinib
3172595|NCT00601939|Experimental|Psychoeducational intervention (PEI)|Culturally competent group empowerment psychoeducational treatment (group intervention that is culturally informed and educational in nature)
3172596|NCT00601939|Active Comparator|Enhanced Treatment as Usual|Enhanced treatment as usual that includes an adherence protocol (regular care at the hospital plus an adherence protocol)
3172597|NCT00601978|Active Comparator|1|Immediate-Release Carbidopa/Levodopa
3172598|NCT00601978|Active Comparator|2|Carbidopa/Levodopa/Entacapone
3172599|NCT00602030|Experimental|1|Lead in Open Label Phase 1 dose-finding study to identify a safe dose of entinostat in combination with erlotinib for further evaluation
3172600|NCT00602030|Experimental|2|erlotinib (Tarceva) and entinostat
3172601|NCT00602030|Placebo Comparator|3|"erlotinib (Tarceva) and matched Placebo~patients in this arm who progress will be offered the opportunity to receive SNDX-275 with erlotinib for up to 6 28-day treatment cycles"
3172602|NCT00602056|Experimental|1|Redesigned immunization card
3172603|NCT00602056|Experimental|2|Center based education to mothers/caregivers
3172604|NCT00602056|Experimental|3|Redesigned immunization card with center based education to mothers/caregivers
3172605|NCT00602056|No Intervention|4|Standard care only
3172606|NCT00602069|Experimental|1|Participants will receive cognitive behavioral therapy through the Helping to Overcome PTSD through Empowerment program
3172607|NCT00602069|Active Comparator|2|Participants will receive standard shelter services
3172608|NCT00602095|Experimental|1|Labour induction with misoprostol
3172609|NCT00602095|Active Comparator|2|Labour induction with dinoprostone
3172610|NCT00602095|Experimental|3|Labour induction with bard
3172611|NCT00602147||Retrospective sample|People who have been diagnosed with multiple myeloma and have received high-dose melphalan.
2567224|NCT02451410|Experimental|Nutrition and physical activity|This arm includes all preschool classes receiving the educational and behavioral intervention to improve nutrition and physical activity
2567348|NCT02450565||Neuropathic pain subjects|The diagnosis of neuropathic pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
2567354|NCT02450565||Nociceptive pain subjects|The diagnosis of nociceptive pain will be made by pain specialists based on a detailed history, physical examination, investigation results and medical records.
2567423|NCT02450266|Active Comparator|A: Transrectal ultrasound-guided biopsy|Patients of arm A receive a systematic transrectal ultrasound-guided prostate biopsy (12-18 biopsy cores depending on individual prostate volume)
2567425|NCT02450266|Experimental|B: MRI/ultrasound fusion-guided biopsy|Patients of arm B receive a targeted MRI/ultrasound fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
2567542|NCT02449408||Overweight or Obese|Children being seen in consultation or follow-up within the Duke Division of Pediatric Endocrinology and Diabetes who are overweight or obese.
2567544|NCT02449408||Premature or Small for Gestational Age|Infants hospitalized in the Duke Transitional Care Nursery who were born prematurely or small for gestational age.
2567610|NCT02448927|Other|TAVI patients without balloon aortic valvuloplasty|Patients that will not undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
2567619|NCT02448927|Active Comparator|TAVI patients with balloon aortic valvuloplasty|Patients that will undergo balloon aortic valvuloplasty (BAV) before transcatheter aortic valve intervention (TAVI) with the Medtronic Evolut R (or CoreValve).
2567666|NCT02448498|Experimental|Strength Training Only|Participants in the strength-training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in strength training 3 days per week for approximately 60 minutes each exercise session.
2567669|NCT02448498|Experimental|Aerobic Training Only|Participants in the aerobic training only group will take part in a 9-month exercise intervention at a local exercise facility. They will engage in aerobic training over 3 -5 days per week to achieve the targeted dose of 12 kcal/kg per week at a training intensity between 50-80% VO2 max.
2567675|NCT02448498|Experimental|Combination (Strength and Aerobic) Training|Participants in the combination (strength and aerobic training) group will take part in a 9-month exercise intervention at a local exercise facility. They will engage aerobic training that will expend 10 kcal/kg/week in combination with strength-training, 3 days per week.
2567717|NCT02448173|Experimental|OncoVAX and Surgery|Autologous Specific Immunotherapy given intradermally following surgical resection of Stage II colon cancer
2567720|NCT02448173|Active Comparator|Surgery|Surgical resection of Stage II colon cancer
3172612|NCT00602147||Prospective sample|People who have been diagnosed with multiple myeloma and will be receiving high-dose melphalan.
3172613|NCT00602160|Active Comparator|1|2 different dosages
3172614|NCT00602160|Placebo Comparator|2|
3172615|NCT00602186|Experimental|1|taking Tamsulosin
3172616|NCT00602186|Active Comparator|2|taking prasosin
2568178|NCT02445378|Experimental|Group I (aromatherapy and essential oils week 1)|Patients select between 3 scented essential oils: peppermint, lavender, or chamomile which is diffused in the hospital room from approximately 9 PM in the evening until morning during week 1 and placebo intervention using rose water during week 2.
2568180|NCT02445378|Experimental|Group II (aromatherapy and essential oils week 3)|Patients undergo placebo intervention using rose water during week 1 and aromatherapy and essential oils as in Group I during week 2.
2568230|NCT02444910|Experimental|KDT501|Experimental drug, KDT501, is administered at 600mg for 10 consecutive days. On days 11 and 21 (+/- 1 day), based on the KDT501 drug exposure level, the subject will be provided instructions on dose adjustment of KDT501. Dose adjustments will be administered at 800mg for 10 consecutive days, determined at day 11; followed by 1,000mg for 8 consecutive days if determined at day 21.
3172617|NCT00602212|Active Comparator|VR + Mobile Phone without Biofeedback|In this experimental condition patients received an eight-session VR-based treatment including relaxation and exposure
3172618|NCT00602212|Experimental|VR + Mobile Phone with biofeedback|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
3172619|NCT00602264||1|Treatment-naïve patients with a recent diagnosis of anorexia nervosa
3172620|NCT00602264||2|The weight recovered subgroup of group 1
3172621|NCT00602264||3|Recovered patients with a previous history of anorexia nervosa but normal menstrual cycles and body weight at the present time
3172622|NCT00602264||4|Control group
3172623|NCT00602277|Experimental|Treatment (viral therapy)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5 in course 1, followed by insertion of an IP access port. Beginning in course 2, patients receive wild-type reovirus IV over 60 minutes on days 1-5 and wild-type reovirus IP over 10 minutes on days 1 and 2*. Treatment with IV and IP wild-type reovirus repeats every 28 days in the absence of disease progression or unacceptable toxicity. (phase II closed as of 1/7/2011). NOTE: *Patients receive IP wild-type reovirus on days 2 and 3 in course 3.
3172624|NCT00602329|Experimental|Arm I|Patients receive leucovorin calcium IV over 2 hours and oxaliplatin IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours (FOLFOX) beginning on day 1. Patients also receive bevacizumab at 5 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
3172625|NCT00602329|Experimental|Arm II|Patients receive FOLFOX as in arm I and bevacizumab at 10 mg/kg IV over 90 minutes on day 1. Treatment repeats every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.
3172626|NCT00602329|Active Comparator|FOLFOX alone (control)|Patients receive FOLFOX as in arm I.
3172627|NCT00602433||questionnaire and laboratory biomarker analysis|Subjects with advanced non-small cell lung cancer and take erlotinib as part of their anticancer therapy for at least 3 months. Subjects have had some changes in hair growth, acne or menses (periods) that might be a side effect of erlotinib. Subjects will complete a questionnaire and blood collected for biomarker analysis.
2567257|NCT02451241|Sham Comparator|sham acupuncture|group will be submitted to placebo electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
2567258|NCT02451241|Experimental|acupuncture|group will be submitted to electroacupuncture for 20 minutes, two times a week for 5 weeks. Each session lasts about 40 min.
2567381|NCT02450357||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2567383|NCT02450357||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2567386|NCT02450357||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2567389|NCT02450357||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2567432|NCT02450045|Active Comparator|Femoral nerve block|Patients will receive a pre-operative continuous femoral nerve block.
2567434|NCT02450045|No Intervention|Control|Patients will receive standard care without a continuous femoral nerve block.
2567494|NCT02449720|Active Comparator|Laparoscopic Bowel Surgery: IPLA|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
2567500|NCT02449720|Placebo Comparator|Laparoscopic Bowel Surgery: Control|Participants will undergo laparoscopic bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
2567508|NCT02449720|Active Comparator|Open Bowel Surgery: IPLA|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of IPLA (0.2% Ropivacaine) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of IPLA (0.2% Ropivacaine, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
2567516|NCT02449720|Placebo Comparator|Open Bowel Surgery: Control|Participants will undergo open bowel surgery. Both on entry into the abdominal cavity and prior to dissection and post-operation but prior to closure of abdominal wall a 50 ml loading dose of Control (0.9% Saline, 20mg/hr) solution will be distributed throughout the abdomen. Following these bolus doses an ON-Q Painbuster continuous infusion pump will be placed in close proximity to the operative region of greatest dissection and a 10ml/hr intraperitoneal infusion of Control (0.9% Saline, 20mg/hr) solution commenced immediately post-operation and continued for 48 hrs without disruption.
2567687|NCT02448316|Active Comparator|endoscopic surgery|Endoscopic operation through 2 portals profound for the fascia plantaris
3172628|NCT00602511|Active Comparator|1|Bortezomib - dexamethasone
2567896|NCT02446977|Placebo Comparator|Solution for injection|4ml IV
3172629|NCT00602511|Experimental|2|Thalidomide - dexamethasone
3172630|NCT00602563|Experimental|1 Attention Modification Program (AMP)|The AMP is a computer-delivered attention modification
3172631|NCT00602563|Active Comparator|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
3172632|NCT00602563|Placebo Comparator|Clinical monitoring control|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions ; however, they will not be randomized to treatment until after the 3-month follow-up assessment. To control for the effects of psychoeducation, symptom monitoring, contact by project staff, and maturation effects, participants will be asked to complete pre-, mid- and post-assessments, and will be informed that they will receive treatment.
3172633|NCT00602563|Experimental|Combining the AMP and AR|Both AMP and AR
3172634|NCT00602576|Experimental|Arm A|Patients who were temozolomide naive and had no brain metastases received oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
3172635|NCT00602576|Experimental|Arm B|Patients who were temozolomide naive and had no brain metastases received sorafenib tosylate as in arm A and oral TMZ once daily on days 1-5 and 29-33.
3172636|NCT00602576|Experimental|Arm C|Patient with or without treated brain metastases who were treated with prior temozolomide and progressed were treated with oral sorafenib tosylate twice daily on days -7 to 56 of course 1 and on days 1-56 of all subsequent courses. Patients also receive oral TMZ once daily on days 1-42.
3172637|NCT00602576|Experimental|Arm D|Patients with treated brain metastases were treated with sorafenib tosylate as in arm B and oral TMZ once daily on days 1-5 and 29-33.
3172638|NCT00602602|Experimental|GemOx and Bev, then chemoradiation, then surgery|"Gemcitabine 1000 mg/m2 over 100 min on day 1 every 2 weeks~Oxaliplatin 85 mg/m2 over 2 hours on day 2 every 2 weeks~Bevacizumab 10 mg/kg over 90 minutes on day 1 every 2 weeks. Infusion duration may be shortened in subsequent courses if tolerated.~One cycle is 2 weeks. Chemoradiation to begin prior to 4 weeks from last dose of Gem. Between 4 and 6 weeks following chemoradiotherapy, patients will undergo re-staging with CT or MRI and CA 19-9. If there is no evidence of disease progression, the patient will be referred to the surgeon for re-evaluation and consideration of surgical intervention"
3172639|NCT00602680|Experimental|1|dose 1
3172640|NCT00602680|Experimental|2|dose 2
3172641|NCT00602680|Experimental|3|dose 3
3172642|NCT00602680|Placebo Comparator|4|
3172643|NCT00602680|Active Comparator|5|
2567177|NCT02451748|Other|DMARD's Responder and Non-Responder|In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28<2.6). The subjects that achieve remission (DAS28<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
2567181|NCT02451748|Other|DMARD's plus Cimzia (Certolizumab pegol)|"The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists."
3207828|NCT00969072|Experimental|GI198745|
3207829|NCT00969085|Experimental|Curcumin|
3207830|NCT00969111|Experimental|Postop Non-High Risk|Proton to 66.6 CGE
3207831|NCT00969111|Experimental|Postop High Risk|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE
2567335|NCT02450656|Experimental|Afatinib plus selumetinib|Combination of afatinib and selumetinib at the optimal dose and regimen as determined in the phase I part of this study
2567337|NCT02450656|Active Comparator|Control|Standard-of-care second line treatment for non small cell lung cancer (docetaxel)
2567384|NCT02450344|Experimental|Internet intervention|Interactive health promotion
2567388|NCT02450344|Active Comparator|Conventional intervention|Passive health promotion
2567497|NCT02449668|Sham Comparator|Acupuncture on sham points (SA)|The control group received treatment with acupuncture needles on sham points (SA).
2567502|NCT02449668|Experimental|True acupuncture (TA)|The intervention group received treatment with true acupuncture techniques (TA) on a selection of points described as effective in the literature.
2567533|NCT02449304|Experimental|Endometrial Ablation (4th gen)|A single-centre uncontrolled observational study is proposed. All women presenting to the gynaecology outpatient clinic with heavy menstrual bleeding (HMB) in the absence of recognizable pelvic pathology, as determined by one or all of a normal pelvic ultrasound, hysteroscopy and / or endometrial biopsy, refractory to medical therapy that persists despite treatment with recommended pharmacological agents, who have no desire to preserve their fertility and are willing to have an endometrial ablation will be invited to participate. Eligible women with HMB will undergo RFA G4 endometrial ablation in either an inpatient or outpatient setting according to their preference.
2567570|NCT02449070|Experimental|Nicorandil|Receive nicorandil before primary PCI and thereafter for 6 months along with the standard therapy.
2567576|NCT02449070|No Intervention|Control|Receive primary PCI and the standard therapy.
3207832|NCT00969111|Experimental|Salvage Non-High Risk|Proton to 70.2 CGE
3207833|NCT00969111|Experimental|Salvage High Risk|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE
3207834|NCT00969137|Active Comparator|Nicotine|Intravenous Nicotine
3207835|NCT00969137|Placebo Comparator|Saline|Saline infusion
3207836|NCT00969163|Experimental|1|2.5 mg testosterone gel
3207837|NCT00969163|Experimental|2|300 ug testosterone gel
2567811|NCT02447627||Part A|Cohort 1- Participants with severe SCD (4-10 VOC/year) Cohort 2- Participants with milder SCD (<4-10 VOC/year) Cohort 3- Healthy volunteers Part A and B can occur in parallel
2567813|NCT02447627||Part B|Adults with SCD receiving chronic red blood cell exchange transfusion Part A and B can occur in parallel
2567820|NCT02447393|Other|levocetirizine|Study Drug
2567822|NCT02447393|Other|cetirizine|Study Drug
2567824|NCT02447393|Other|placebo|Study Drug
3207838|NCT00969163|Placebo Comparator|3|placebo gel
3207839|NCT00969176|No Intervention|paracetamol|not applicable, since all included cases will receive intravenous paracetamol
3207840|NCT00969189||Children|between 10 and 30 kgs
3207841|NCT00969189||Infants|between 5 - 10 kg
3207842|NCT00969202|Experimental|Stereotactic Radiosurgery using NovalisTx|Single arm study using the Novalis Tx to perform radiosurgery to treat low grade prostate cancer.
3207843|NCT00969215|Experimental|Laser treatment|Half of each subject's scar will be treated with a fractional CO2 laser.
2568642|NCT02442245|Placebo Comparator|Placebo|Placebo group will receive microcrystalline cellulose
2568648|NCT02442245|Active Comparator|Treatment|Treatment group will get 2 g daily of XSurge in microcrystalline cellulose
3207844|NCT00969215|No Intervention|No treatment|Half of each subject's scar will not be treated.
3207845|NCT00969254|Experimental|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
3207846|NCT00969254|Active Comparator|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
3207847|NCT00969267|Experimental|Stimulation A|with needle A stimulation
3207848|NCT00969267|Active Comparator|Stimulation B|with stimulation
3207849|NCT00969267|Sham Comparator|Stimulation C|without needle
3207850|NCT00969306|Active Comparator|Chloroquine|Patients receive Chloroquine
3207851|NCT00969319||Group 1|
3207852|NCT00969345|Sham Comparator|Control Group|Stretching exercises performed twice a day for 10 minutes (4 months)
3207853|NCT00969345|Active Comparator|Respiration Group|Respiratory Yoga exercises performed twice a day for 10 minutes (4 months)
3207854|NCT00969371|Experimental|Lenstec Tetraflex IOL implantation|patients in Study arm received TetraFlex Lens
3207855|NCT00969371|Active Comparator|Control IOL|commercially approved PCIOL implanted
3207856|NCT00969384|Experimental|waist circumferences|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
3208888|NCT00979043|No Intervention|Health lifestyle control|The healthy-lifestyle control served as the usual care comparison group. For 3 months, participants met monthly with a health educator to discuss topics such as osteoarthritis, obesity, and exercise. Regular phone contact was maintained during months 4-18.
2567215|NCT02451436|Active Comparator|Study Skills Control Group|The control group will receive four sessions of study skills training.
3207857|NCT00969384|Experimental|Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
3207858|NCT00969397|Experimental|Topical Antiangiogenic|Topical Antiangiogenic Agents
2567819|NCT02447601|Experimental|Simvastatin and PEX168(200µg)|Simvastatin: 40mg, oral Administration. PEX 168: 200µg,injected subcutaneously,once a week.
2567873|NCT02447211|Active Comparator|doxepin cream|Patients use doxepin cream 5% twice daily for two weeks
2567874|NCT02447211|Placebo Comparator|Placebo|Patients use cream without doxepin ingredient twice daily for two weeks
3207859|NCT00969397|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
3207860|NCT00969410|Experimental|AV-299 administered IV (monotherapy)|Subjects will be enrolled sequentially and treated with AV-299 (formerly SCH 900105) in dose escalating cohorts. Accrual to the next cohort will occur only if <= 1 out of 6 subjects experiences a dose-limiting toxicity (DLT) during the first 2 cycles. If >= 2 subjects in the same dose cohort experience a DLT during the first 2 cycles, dose-escalation will be terminated.
2568102|NCT02445820||HES|Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.
2568103|NCT02445820||Crystalloid|Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.
2568151|NCT02445469|Other|Parkinson's disease|MRI exam of the brain
2568152|NCT02445469|Other|Multiple System Atrophy|MRI exam of the brain
2568153|NCT02445469|Other|Progressive Supranuclear Palsy|MRI exam of the brain
2568154|NCT02445469|Other|Vascular parkinsonism|MRI exam of the brain
2568155|NCT02445469|Other|Healthy volunteers|MRI exam of the brain
2568185|NCT02445157||IPF_Reliability|Patients diagnosed with IPF according to NICE guidelines.
2568221|NCT02444962|Experimental|HAVD implant|
2568240|NCT02444702||CLBP and degenerative lumbar spine|Participants with CLBP (>12 weeks) and degenerative changes of the lumbar spine confirmed by CT imaging who were recommended surgery and chose to undergo surgery will be recruited from the department of Orthopedic Surgery at the Meir Medical Center, Kfar-Saba, Israel. Included participants will be men or women, aged 40-80 years, of any race or ethnic background. Participants' diagnosis may include unstable degenerative spondylolisthesis, radicular pain, or documented stenosis with referred pain.
2568281|NCT02444468|Experimental|IPC and bandage|Pneumatic device and bandage
2568284|NCT02444468|Active Comparator|Bandage only|Bandage only
2568360|NCT02444026|Experimental|iCBT for Insomnia|The Internet intervention offered is the SHUT-i program (Sleep Healthy Using The Internet), which is based on the existing consensus concerning non-pharmacological treatment of insomnia and builds on previous validated CBT's for insomnia (CBT -I)
2568366|NCT02444026|No Intervention|Control|The control group will be offered the intervention AFTER the study
2568418|NCT02443428||Eribulin Mesilate|Participants will be treated in accordance with normal clinical practice. The recommend dose of eribulin is 1.23 mg/m2 administered intravenously on days 1 and 8 of every 21-day cycle. Treatment with eribulin is continued until disease progression, onset of unacceptable drug toxicities, or participant/physician's request to discontinue.
2568467|NCT02443051|Experimental|Attention Bias Modification|Training in bias modification for 80% of experimental trials
2568474|NCT02443051|Active Comparator|Control|Bias modification for 50% of trials
2568547|NCT02442817|Active Comparator|Linagliptin patients with schizophrenia|This group will be made up of 8 participants with schizophrenia and minimal thought disorder who have been stable and taking their prescribed antipsychotics; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day, while continuing their antipsychotic treatment.
2568554|NCT02442817|Active Comparator|Linagliptin control group|This group will be made up of 10 control participants with no diagnosis of mental disorder; they will have 12 weeks of treatment and week for assessment. They will receive linagliptin, 5 mg by mouth once per day.
2568604|NCT02442375|Active Comparator|standard dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
2568607|NCT02442375|Experimental|FDG-PET guided gradient dose prescription|"FDG-PET-scan in treatment mask for radiotherapy planning~Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)"
2568628|NCT02442024|Experimental|Modified diet|This group will follow a modified diet over a period of two months.
2568629|NCT02442024|Active Comparator|Standard diet|This group will follow a standardized diet over a period of two months.
2568673|NCT02441881|Active Comparator|Venefit|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
2568681|NCT02441881|Active Comparator|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
2568685|NCT02441881|Active Comparator|Endovenous Radiofrequency|Endovenous radiofrequency ablation device for truncal great saphenous vein ablation
2568711|NCT02441504|Active Comparator|Low intensity exercise|physical inactivity
2568761|NCT02441322|Experimental|Methods to identify treatment response|The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
2568831|NCT02440607|Experimental|Electronic aid|The dynamic aid will consist of a centralized electronic aid embedded within a simulated EMR.
2568832|NCT02440607|Active Comparator|Static Cognitive aid|The static aid represents the standard algorithm put forth by a leading clinical care organization.
3207861|NCT00969423|Experimental|5 mm equipment|5 mm videoscopic equipment
3207862|NCT00969423|Experimental|10 mm|Use of standard 10 mm VATS equipment
3207863|NCT00969449|Experimental|Arm 1|
3207864|NCT00969449|Active Comparator|Arm 2|
2567235|NCT02451319|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w holmium laser(working under 20w power) device who have 1-2 cm diameter kidney stones
3207865|NCT00969462|No Intervention|Doxorubicin|Single arm
2567429|NCT02450084|Experimental|Rectus sheath block|Patients of RSB group will be performed ultrasound-guided bilateral RSB after induction of general anesthesia. After draping the needle insertion site, a 22-gauge, 50-mm needle will be inserted medial to the probe by the in-plane technique and advanced in a lateral direction on just lateral to umbilicus. 15 ml of 0.25% ropivacaine will be injected on the posterior border of rectus muscle. This procedure will be performed bilaterally and total 30 ml of 0.25% ropivacaine will be injected. After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery. All patients will use total 100 ml of IV-PCA containing fentanyl 800 µg for 48 hours postoperatively.
2567430|NCT02450084|Sham Comparator|Control|Patients of Control group will be proceeded a surgery scheduled after induction of general anesthesia without any procedure such as placebo injection. After the surgery, a bandage will be attached on the incision site where is same as the block injection site of RSB group. All patients will use total 100 ml of IV-PCA containing fentanyl 800µg for 48 hours postoperatively.
2567492|NCT02449707|Active Comparator|Control|Lateral Window Technique Augmentation for Maxillary Sinus without the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of membrane. Placement of Purus® Cancellous Allograft, stabilized by Biomend ™ Collagen membrane. Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
2567495|NCT02449707|Experimental|Ultrasonic Pins|Lateral Window Technique Augmentation for Maxillary Sinus with the use of Ultrasound activated resorbable poly-D-L-lactide pins for the stabilization of the Purus® Cancellous Allograft, and Resorb X Membrane.Cone Beam CT image of the sinus will be taken to evaluate the bone formation. Trephine Biopsy will be performed after 1 year, at the time of placement of implant to check the quality of bone formed.
2567573|NCT02449096|Other|ORIF group|"No arthroscope ORIF = Open reduction and internal fixation~All Patients will be operated following a standardized protocol of our foot and ankle department:~Posterior malleolus: ORIF of the posterior malleolus fractures will be performed using a one-third tubular plate in an antiglide-technique.~Lateral malleolus: If the patients suffer a fracture of the posterior and lateral malleolus, a posterolateral approach will be performed. After posterior fracture fixation a lag screw and a one-third tubular plate will be used laterally. In special cases a locking plate will be used. If the patient only suffers a lateral malleolus fracture, we utilize the standard lateral incision.~Medial malleolus: We perform a curved incision and two cannulated leg screws/tension wiring or locking plate for fixation.~Syndesmotic complex: After all, the stability of the syndesmotic complex is tested and reduction will be performed if necessary."
2567577|NCT02449096|Active Comparator|AORIF group|Arthroscope AORIF = Arthroscopically assisted open reduction and internal fixation Our standard operative protocol is described above. Intervention: In case of randomization to the AORIF group, the arthroscopic procedure will be performed as the first step during the surgery before internal fixation. No distraction device will be used for the ankle. To avoid lesions of the cartilage and soft tissue, the joint will first be inflated with saline, and the portals will be created by blunt dissection. A 2.7mm, 30° arthroscope will be inserted into the ankle through a standard anteromedial portal. Fluid will be aspirated and the cavity filled with water. Afterwards the standard anterolateral portal will be performed in the same way. A standardized systematic examination as described by Ferkel and Fasulo will be performed to inspect the internal structures. At this stage loose bodies and disrupted ligaments extending into the joint will be removed.
2567622|NCT02448823|Experimental|Stylish Events and Mass Media|Mass Media (radio, posters) and annual Stylish Man/Stylish Living Event (SMLEvent), a multimedia event promoting CHP.
2567623|NCT02448823|Active Comparator|Control arm: mass media only|Mass media
3207866|NCT00969475|No Intervention|Control|Half of each subject's wound will not be treated.
3207867|NCT00969475|Experimental|Laser resurfacing|Half of each subject's wound will be treated with a fractional CO2 laser.
3207868|NCT00969488|Experimental|high protein diet group|"Women in high protein diet will be stimulate to consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group. The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats). The experimental groups will also receive six cans of sardine to increase the women's commitment to the study.~Both women group will receive a nutritional plan based on an 1800 kcal diet."
2567796|NCT02447913|Experimental|Voucher|
2567798|NCT02447913|No Intervention|Control|
3207869|NCT00969488|Active Comparator|normal protein diet group|The control group will receive a diet to lose weight with norma protein intake and will receive 2kg of pasta to increase the women's commitment to the study. The nutritional plan based on an 1800 kcal diet.
3207870|NCT00969514||Robotic cystectomy|Patients undergoing robotic laparoscopic cystectomy at Beaumont Hospital-RO
3207871|NCT00969527|Experimental|A|Oncoxin + Viusid
3207872|NCT00969527|Placebo Comparator|B|
3207873|NCT00969566|Experimental|Metformin+Sitagliptin|Initial combination of metformin and sitagliptin
3207874|NCT00969592|Active Comparator|insulin glulisine, insulin aspart|insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp
3207875|NCT00969592|Active Comparator|insulin aspart, insulin glulisine|insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp
2567991|NCT02446431|Experimental|Metronomic Therapy|"There is only one arm in this study. All subjects receive the same therapy for a period of 420 days (42 day cycles x 10 cycles).~Bevacizumab: IV, 10 mg/kg, Days 1, 8~Cyclophosphamide: PO, 25 mg/m2 Days 1-14 (max dose = 50mg/dose)~Valproic Acid: PO, 5 mg/kg, three times per day (TID), Days 22-35~Temsirolimus: IV, 25 mg/m2, Days 22, 29"
2567259|NCT02451085|Experimental|remote rehabilitation group|'training with video therapy' a domestic exercise plan through remote rehabilitation system based on short film. (http://videotherapy.co/vt/home.php), the plan will include installation of exercises adapted according to the physical condition of the patient. The content of each exercise is dynamic and variable. The difference between each exercise and the other depends on the feedback that the patient fills at the end of each exercise and sends to the therapist. Before each exercise, it is shown with explanations about the importance of performing it the way of performing. Furthermore, during the training, the patient listens to vocal explanation about the quality and importance of performing the exercise, and a vocal counting is heard and then a positive feedback is given.
2567268|NCT02451085|Other|conventional exercise group|will receive instruction for self-training as accepted today through exercise sheet. The exercises will be suited to the ones provided to the patients in the intervention group. Moreover, a follow-up sheet will be given to the patients to fill in order to receive a feedback at the end of experiment. The training duration will be identical in both groups and will last for 30-45 minutes, three times a week.
2567321|NCT02450864|Experimental|patient with ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
2567323|NCT02450864|Sham Comparator|patient without ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
2567349|NCT02450448||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2567357|NCT02450448||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2567359|NCT02450448||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2567364|NCT02450448||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2567421|NCT02450136|Experimental|pazopanib|pazopanib 800 mg will be administered orally once a day 28 days.Study treatment will be continued until objective disease progression.
3207876|NCT00969605|Active Comparator|Pressure support ventilation|
3207877|NCT00969605|Active Comparator|Adaptive support ventilation|
3207878|NCT00969631|Experimental|Metformin-CC|
2567552|NCT02449239|Experimental|Vicinium|"Induction - 30 mg of Vicinium in 50 mL of saline administered twice weekly (BIW) for 6 weeks followed by once weekly for 6 weeks, for a total of 12 weeks.~Maintenance - 30 mg of Vicinium in 50 mL of saline administered once weekly every other week for up to 104 weeks."
2567680|NCT02448394|Experimental|Intervention|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. Strong preference will be given to matching CSWs and clients from the same kebele (village or neighborhood of residence). CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
2567683|NCT02448394|No Intervention|Standard of Care|At control sites, patients will receive standard of care facility-based medical care and counseling, consistent with general standards of care offered to HIV patients throughout the country as determined by the Ethiopian Ministry of Health.
2567742|NCT02448082|Placebo Comparator|Shampoo (inactive)|Shampoo containing no active anti-dandruff ingredients will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the placebo group will wash their hair with 25ml of the placebo shampoo per hair washing session.
2567748|NCT02448082|Experimental|Sodium shale oil sulponate 1% shampoo|Shampoo containing sodium shale oil sulponate 1% will be used to wash the participants' hair every second day, starting from day 1 to day 15. Each participant in the experimental group will wash their hair with 25ml of the sodium shale oil sulponate 1% shampoo per hair washing session.
2567782|NCT02447783|Placebo Comparator|Control, Flavanol-free intervention|Intake of flavanol-free, macro- and micro-nutrient matched control capsules
2567790|NCT02447783|Active Comparator|CF intervention|Intake of capsules containing Mars Cocoa Extract Capsules manufactured by the Cocoapro® process and providing 500 mg of cocoa flavanols per capsule
2567843|NCT02447471||study group|all participants
2567915|NCT02447094||Exposed|AIS patients evaluated through RTP and who receive i.v. tPA
2567917|NCT02447094||Un-exposed|AIS patients evaluated through RTP and who do not receive i.v. tPA
2567932|NCT02446678|Active Comparator|Capsule group: PillCam ESO2|Perform capsule endoscopy and esophagogastroduodenoscopy will be preformed within 24 hours after capsule ingestion
2567934|NCT02446678|No Intervention|Standard group|Perform standard esophagogastroduodenoscopy
2567967|NCT02446561|Active Comparator|MRXXX|Active comparator
2567971|NCT02446561|Experimental|MR1XXX|MR1XXX
2567978|NCT02446561|Experimental|MR2XXX|MR2XXX
2567980|NCT02446561|Experimental|MR3XXX|MR3XXX
2568000|NCT02446262|Other|Substudy 1: Instructed subjects|Participants are instructed about outcomes
2568005|NCT02446262|Other|Substudy 1: Uninstructed subjects|Participants learn through experience
3207879|NCT00969631|Active Comparator|Laparoscopic ovarian diathermy (LOD)|
3207880|NCT00969644|Active Comparator|GH|
2567299|NCT02451098|Experimental|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe10mg will be administered (Duration 8 weeks)
2567300|NCT02451098|Active Comparator|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, placebo will be administered (Duration 8 weeks)
2567343|NCT02450617|Experimental|Stabilizing group treatment for PTSD|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
2567344|NCT02450617|Active Comparator|Conventional Individual treatment - PTSD|Conventional individual treatment.
2567345|NCT02450617|Experimental|Stabilizing group treatment for Dissociative disorders|Group treatment, 20 sessions psychoeducation and skills-training. In combination with conventional individual treatment.
2567346|NCT02450617|Active Comparator|Conventional Individual treatment - Dissociative disorders|Conventional individual treatment.
2567414|NCT02450175|No Intervention|Cases|Patients with cancer whose platelets are examined
2567416|NCT02450175|Placebo Comparator|Control|Patients without cancer whose platelets are examined for comparison
2567448|NCT02449928|Active Comparator|lactate group,|
2567450|NCT02449928|Active Comparator|control group|
2567484|NCT02449590|Active Comparator|Onion powder|Initial test meal contained 20g freeze dried onion powder in hot meals (1 potato soup and 1 meatball-meal daily). Subsequent daily meals contained 20g onion powder in the same meal formats.
2567487|NCT02449590|Placebo Comparator|Placebo|Hot meals (1 potato soup and 1 meatball-meal daily)containing 8.5 g sucrose and 2 g soy protein instead of onion powder
2567557|NCT02449317|Other|Control|standard hydration : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
2567562|NCT02449317|Experimental|Bioimpedance guided|"Bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~extracellular water/total body water < 0.36 : 4 ml/kg/hr~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
3207881|NCT00969644|Active Comparator|Pegvisomant|
3207882|NCT00969683|Active Comparator|Double lumen tube without a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
2567655|NCT02448381|Active Comparator|SGX301|"Three treatment cycles, each six (6) weeks followed by a two (2) week rest period. Treatment uses 0.25% SGX301 in USP Hydrophilic Ointment (or placebo) applied twice per week followed by fluorescent light therapy.~Cycle 1: Patients randomized 2:1 to active/placebo will have three (3) index lesions treated and evaluated.~Cycle 2: All patients will have three (3) index lesions treated and evaluated with active SGX301 ointment.~Cycle 3: All patients will be given the opportunity to enter an open-label cycle of active SGX301 ointment treatment for all lesions (index and non-index)."
2567656|NCT02448381|Placebo Comparator|Placebo|Placebo ointment is indistinguishable from ointment containing active SGX301 and is only used in Cycle 1. Treatment paradigm (ointment application and fluorescent light therapy) is identical.
2567756|NCT02448004|Experimental|JNJ-63623872|Participants will receive a single 600-milligram (mg) dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
2567785|NCT02447796|Active Comparator|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24)
2567793|NCT02447796|Active Comparator|Dexmedetomidine (DEX)|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24)
2567848|NCT02447419|Experimental|Gefitinib|Gefitinib 250 mg will be administered orally daily
3207883|NCT00969683|Experimental|Double lumen tube with a hook|Broncho-Cath™, Mallinckrodt France, Parc d'Affaires Technopolis, 3 avenue du Canada, Bât Sigma, Les Ulis, 91975 Courtaboeuf Cedex
3207884|NCT00969696|Active Comparator|Galatamine|Galantamine is used for the treatment of mild to moderate Alzheimer's disease and various other memory
3207885|NCT00969696|Placebo Comparator|Sugar Pill|Sugar Pill
3207886|NCT00969722|Experimental|ARM I|Intravenous MAb-3F8 plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
3208889|NCT00979056|Experimental|Rifaximin|
3208890|NCT00979056|Placebo Comparator|Lactose|
2568129|NCT02445508|Placebo Comparator|Placebo+Placebo|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.
2568134|NCT02445508|Active Comparator|Placebo+Cholecystokinin|Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.
2568139|NCT02445508|Active Comparator|Sevelamer+Placebo|Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.
2568144|NCT02445508|Active Comparator|Sevelamer+Cholecystokinin|Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.
2568163|NCT02445209|Active Comparator|EOX|"Epirubicin 50mg/m2 IV on day 1; Oxaliplatin 130mg/m2 IV on day 1; Capecitabine 625mg/m2/day PO BID days 1-21; Cycled every 21 days. Cycled every 3 weeks for a maximum of 8 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 8 cycles of EOX chemotherapy, could be rechallenged with the same regimen."
2568169|NCT02445209|Active Comparator|mDCF|"Docetaxel 40 mg/m2 IV od day 1; Leucovorin 400 mg/m2 IV on day 1; 5fluorouracyl 400 mg/m2 IV on day 1; 5fluorouracil 1000 mg/m2/d IV continuous infusion days 1-2; Cisplatin 40 mg/m2 IV on day 3; Cycled every 2 weeks for a maximum of 12 cycles initially (24 weeks of treatment).~Patients who experienced a long term response to the initial 12 cycles of mDCF chemotherapy, could be rechallenged with the same regimen"
2568217|NCT02445040|Experimental|Babylog VN500 in HFOV mode|Subjects will be treated with HFOV provided by the Babylog VN500 - the investigational device - for up to 14 days.
2568249|NCT02444637|Experimental|Rivastigmine (Exelon) Patch|For the first 4 weeks of the study, subjects will receive Rivastigmine patch 4.6mg/24 hours. Thereafter, subjects will receive Rivastigmine patch 9.5mg/24 hours.
2568299|NCT02444351|Active Comparator|control group|
2568303|NCT02444351|Experimental|botox group|
2568344|NCT02443948||adjuvant/follow up setting|
2568345|NCT02443948||neo-adjuvant setting|
2568346|NCT02443948||advanced disease|
2568400|NCT02443649|Experimental|Sleep hypnosis plus sleep hygiene|Those randomized into this group will receive the sleep hygiene program plus hypnosis.
2567325|NCT02450682|Active Comparator|Apixaban|30 participants prescribed Apixaban 3-14 days before and 28 days after CIED procedure.
2567327|NCT02450682|Other|Warfarin|30 participants will take stable dose of warfarin and go through the procedure without drug interrupt. The dose is adjusted by INR level. Length of treatment is 42 days, 14 days before and 28 days after the procedure.
2567363|NCT02450409|Active Comparator|gap technique (GT)|"The patients receive a total knee arthroplasty using the established gap technique (gold standard serving as control). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using the gap technique is the intervention. Intervention is not a drug but a specific operative technique."
2567370|NCT02450409|Experimental|anatomical alignment (AA)|"The patients receive a total knee arthroplasty using the new anatomical alignment technique (experimental). The intervention is the implantation of a total knee arthroplasty with this specific technique.~Implantation of TKA using anatomical alignment Intervention is not a drug but a specific operative technique."
2567413|NCT02450162||conventional lateral rectus recession|This is the standard technique for recession with two single-armed sutures.Exposure of the rectus muscle insertion includes freeing the insertion and proximal muscle borders sufficiently to place the sutures. And the needle is passed through the tendon avoiding the anterior ciliary arteries. If the sutures are passed as shown a true knot is formed, and the muscle is detached. Then a caliper measures from the limbus or the original insertion. A passage of the needle through sclera. The recessed muscle is ideally parallel to the old insertion (or nearly so). Conjunctival incision was finally sutured.
2567417|NCT02450162||hang-back lateral rectus recession|"The hang-back recession has been described as a simple, safe alternative to conventional recession. The procedure is said to be less likely to result in scleral perforation because needles are placed through relatively thicker sclera near the insertion site. It is the modified techique for recession with one double-armed sutures."
2567441|NCT02449967|Experimental|HepaSphere|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2567444|NCT02449967|No Intervention|control|pancreatic cancer patients did not receive any interventional therapy
2567485|NCT02449629||TGMY in HIV Care|TGMY (16-24 years of age) currently in HIV care at an Adolescent Medicine Trials Unit (AMTU) site or elsewhere.
2567488|NCT02449629||TGMY Not in HIV Care|TGMY (16-24 years of age) not currently in care who are living with HIV, not living with HIV, or those who are unaware of their HIV status.
2567489|NCT02449629||Health Care and Social Service Providers|Health care and social service providers who work with TGMY at AMTU sites or elsewhere that serve TGMY within the AMTU cities.
2567540|NCT02449187|Experimental|JLP-1310, Fasted followed by fed|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
2567541|NCT02449187|Experimental|JLP-1310, Fed followed by fasted|"JLP-1310 dosing in the fasted state followed by fed dosing~Interventions:~Drug: JLP-1310"
2567605|NCT02448940|Experimental|Species of Lactobacillus|2 capsule/day of Lactofem Containing Species of Lactobacillus
2567606|NCT02448940|Placebo Comparator|lactose|2 capsule/day Containing lactose
2567624|NCT02448667|Experimental|FAXE Kondi - a sugary soft-drink|100 ml FAXE Kondi (10 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
2567628|NCT02448667|Placebo Comparator|FAXE Kondi Free - a sugarfree soft-drink|100 ml FAXE Kondi Free (0 grams of carbohydrates per 100 ml) is ingested every ten minutes during exercise plus 400 ml before exercise start.
3207887|NCT00969722|Active Comparator|ARM II|Oral 13-cis-Retinoic Acid (RA) plus Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
3207888|NCT00969735|Active Comparator|Cryoablation|Deflectable over-the-wire cryoablation balloon catheter (Arctic Front®, Cryocath Technologies)
3207889|NCT00969735|Active Comparator|Radiofrequency ablation|Open irrigation ablation catheter (Navistar® Thermo-cool®, Biosense Webster Inc).
3207890|NCT00969787|Experimental|DWP05195|
3207891|NCT00969800|Experimental|Active Cleverin Gel|Active Cleverin Gel, which generates chlorine dioxide gas, is placed in a room of subject.
3207892|NCT00969800|Sham Comparator|Inactive Cleverin Gel|Inactive Cleverin Gel is placed in a room of subject. It does not generate chlorine dioxide gas.
3207893|NCT00969813|Experimental|Normal hepatic function|
2567961|NCT02446808|Experimental|Intraoperative nerve monitoring|Patients for which intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
2567999|NCT02446405|Experimental|Enzalutamide|"Enzalutamide is 160 mg daily, by mouth, until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
2568004|NCT02446405|Active Comparator|Conventional NSAA|"Conventional NSAA, by mouth until clinical disease progression or prohibitive toxicity.~All participants are to receive standard background therapy with a LHRHA or surgical castration, as per standard of care. The choice of the LHRHA or surgical castration is at the discretion of the treating clinician."
3207894|NCT00969813|Experimental|Mild hepatic impairment|
3207895|NCT00969813|Experimental|Moderate hepatic impairment|
2568225|NCT02444858|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous injection
2568226|NCT02444858|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
2568308|NCT02444429|Experimental|Sub-study A experimental arm|"This experimental arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to receive a treatment for rejection (intensification of the corticotherapy with corticosteroid boluses = Corticosteroid boluses Methylprednisolone )"
3207896|NCT00969826|Experimental|GCPGC 30 μg/kg|Ten volunteers were administered GCPGC 30 μg/kg or placebo (active:placebo=8:2)
3207897|NCT00969826|Experimental|GCPGC 100 μg/kg|Ten volunteers were administered GCPGC 100 μg/kg or placebo (active:placebo=8:2)
3207898|NCT00969826|Experimental|GCPGC 300 μg/kg|Ten volunteers would be administered GCPGC 300 μg/kg or placebo (active:placebo=8:2)
3207899|NCT00969826|Experimental|Neulasta 100 μg/kg|Eight volunteers were administered Neulasta 100 μg/kg
3207900|NCT00969839|Experimental|Intramedullary Fixation System|Humeral fractures to be treated with the Intramedullary Fixation System
3207901|NCT00969852|Experimental|Sertraline|Single Arm
3207902|NCT00969865||Individualized Managment Group|Participants receiving, in addition to standard of care, blood tests for markers of heart disease, DNA and RNA analysis, and coronary artery calcium scan.
2567543|NCT02449148|Experimental|Intermittent Calorie Restriction|2 days per week fasting with 25 % energy intake and 5 days per week at 100% energy intake
2567545|NCT02449148|Experimental|Continuous Calorie Restriction|daily energy intake of 80 %
2567547|NCT02449148|No Intervention|Healthy Nutrition|general advice on healthy nutrition
2567671|NCT02448511|Experimental|Ozone|this group received local application of ozone gas in addition to conventional treatment.
2567678|NCT02448511|Sham Comparator|Placebo|This group received sham treatment in addition to conventional treatment
2567739|NCT02448095||CML ph+ patients|Chronic myeloid leukemia patients who are philadelphia positive
2567814|NCT02447614|Experimental|Surgery|Adenotonsillectomy
2567815|NCT02447614|Experimental|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
2567816|NCT02447614|Experimental|no treatment|just regular follow-up
2567836|NCT02447289|Experimental|Experimental|Intranasal administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.2 mg/kg, max. 5 mg)
2567838|NCT02447289|Active Comparator|Comparator|Oral administration of ketamine (4.0 mg/kg, max. 100 mg) and midazolam (0.5 mg/kg, max. 20 mg)
2567841|NCT02447289|Active Comparator|Control|Oral administration of midazolam (1.0 mg/kg, max. 20 mg)
2567913|NCT02446925|Experimental|Surefire® Infusion System|Patients randomized to the Surefire® Infusion System treatment arm will undergo Y-90 glass microsphere embolization with a Surefire catheter.
2567916|NCT02446925|Active Comparator|Standard End-hole catheter|Patients randomized to the standard end-hole catheter treatment arm will undergo Y-90 glass microsphere embolization with a standard end-hole catheter.
2567968|NCT02446704|Experimental|Olaparib and Temozolomide|"- Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation. Once the MTD is determined, the study will move to the phase II portion.~Olaparib- Oral, on determined days per cycle~Temozolomide- Oral, on determined days per cycle"
2568041|NCT02446288|Active Comparator|TMJ Next Generation|The TMJ NextGeneration device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The proposed mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
2568042|NCT02446288|Active Comparator|DSG Relaxer|The occlusal splint to be used in this study will be the DSG Relaxer™. The DSG Relaxer™ is a device that has been FDA cleared for the treatment of medically diagnosed migraine pain as well as migraine associated tension-type headaches and relieving bruxism and TMJ syndrome through the reduction of trigeminally innervated muscular therapy.
2568083|NCT02445872|Experimental|Arm A|Aprepitant: 125mg PO on day1, 80mg PO on day2 and day3. Palonosetron (a 5-HT3 receptor antagonist): 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 3.75mg PO on days 4-5.
2568086|NCT02445872|Active Comparator|Arm B|Palonosetron: 0.25 mg IV push on day 1 only. Dexamethasone: 5mg IV push once daily from day 1 to day 3,and 7.5mg PO on days 4-5.
3207903|NCT00969865||Standard Management Group|Participants who receive standard of care.
2568283|NCT02444572|Experimental|ENOXA® group|"Patients under ENOXA® 4000 IU according to randomization:~Administer ENOXA® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer ENOXA® subcutaneously~The administration of ENOXA® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
2568286|NCT02444572|Active Comparator|LOVENOX® group|"Patients under LOVENOX® 4000 IU according to randomization:~Administer LOVENOX® 4000 IU (Enoxaparin 4000 IU) per day, regardless of the patient's weight at inclusion~Start injections 12 hours after the surgical procedure~Administer LOVENOX® subcutaneously~The administration of LOVENOX® should be at the same time on a daily basis for 30 successive days as per the american and french clinical guidelines"
3207904|NCT00969891||AML patients in induction treatment|
3207905|NCT00969904|Active Comparator|1|
3207906|NCT00969904|Placebo Comparator|2|
3207907|NCT00969917|Experimental|IPI-504|IPI 504 administered twice weekly for 2 weeks followed by 1 week off treatment
3207908|NCT00969930||healthy controls|
3207909|NCT00969930||BD type I patients|
3207910|NCT00969943||Cocaine-dependent Men|
3207911|NCT00969943||Cocaine-dependent Women|
3207912|NCT00969943||Control Men|
3207913|NCT00969943||Control Women|
3207914|NCT00969956||Group A|150 Type 1 Diabetes, duration of 15 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 2 years (+/- 2 years) (50% women / men)
3207915|NCT00969956||Group B|150 Type 1 Diabetes, duration of 20 years (+/- 2 years) and 150 Type 2 Diabetes, duration of 7 years (+/- 2 years) (50% women / men)
3207916|NCT00969956||Group C|150 Type 1 Diabetes, duration of 25 years (+/- 2 years) and 150 Type 2 Diabetes duration of 12 years (+/- 2 years) (50% women / men)
3207917|NCT00969956||Group D|50 LADA (Late Autoimmune Diabetes in Adults), debut after 35 years of age, duration of 5-10 years (50% women / men)
3207918|NCT00969969|Active Comparator|Arthrodesis|Fusion
3207919|NCT00969969|Experimental|Cartiva|Synthetic Cartilage Implant
3207920|NCT00969982|Experimental|mifepristone+misoprostol|200 mg mifepristone followed by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
3207921|NCT00969982|Active Comparator|misoprostol|Placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion up to a maximum of 10 doses within 48 hours (maximum 5 doses per 24 hours).
3207922|NCT00969995||migraine1|50 subjects with migraine without aura
2567522|NCT02449486|Active Comparator|Ropivacaine|Ropivacaine 4 ml/h (8 mg/h) continuous infusion for 48 hours
2567525|NCT02449486|Placebo Comparator|Placebo|Saline infusion 4 ml/h for 48 hours
2567549|NCT02449161|Experimental|MPA|medroxyprogesterone acetate, 10 mg/day, for 90 days, following endometrial ablation
2567554|NCT02449161|Placebo Comparator|placebo|1 placebo/day, for 90 days, following endometrial ablation
2567608|NCT02448888|Experimental|Adapted exercise|The experimental group is going to follow a home-exercise program designed specifically to compensate the overloads and strength necessities of the workplace, the patient enter the description of the workplace in a mobile application and the APP shows the specific exercise that the patient needs to practice and general exercise recommendations.
2567615|NCT02448888|Experimental|General exercise recommendations|The control group is going to receive general exercise recommendations (ACSM recommendations) with the same kind of APP to control the amount of exercise that each patient performs during the week.
2567681|NCT02448550|Experimental|bivalirudin|Bivalirudin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
2567682|NCT02448550|Active Comparator|unfractionated heparin|Unfractionated heparin will be used for PCI with bailout glycoprotein 2b3a inhibitor use permitted.
2567744|NCT02448108|Experimental|i-IPSRT|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer.
2567749|NCT02448108|Experimental|i-IPSRT + CH|Participants randomized to this arm will complete bi-weekly i-IPSRT modules over the course of 12 weeks and they will track their mood and SRM's via smartphones or computer. Additionally, i-IPSRT support will be delivered by Clinical Helpers, who will reach out to participants in this arm via 5-10 minute weekly phone calls.
2567753|NCT02448108|Other|CC (Controlled Condition)|Participants randomized to this arm will receive brief written psychoeducational material that includes information about social rhythm regularity. This information will be either mailed or e-mailed to them.
3207923|NCT00969995||migraine 2|50 subjects with migraine with aura
3207924|NCT00969995||tension|50 subjects with tension headache
2567840|NCT02447276|Experimental|Group A|Group A will receive REGN475 dosing regimen 1
2567845|NCT02447276|Experimental|Group B|Group B will receive REGN475 dosing regimen 2
2567853|NCT02447276|Experimental|Group C|Group C will receive REGN475 dosing regimen 3
2567860|NCT02447276|Experimental|Group D|Group D will receive REGN475 dosing regimen 4
2567866|NCT02447276|Experimental|Group E|Group E will receive matching placebo
2567969|NCT02446587||Stroke with Mechanical Thrombectomy|Eligible patients will be adults ≥18 with the final diagnosis of an acute ischemic infarction and large artery occlusion in anterior circulation strokes who undergo endovascular therapy with mechanical thrombectomy utilizing stent retrievers
2567974|NCT02446587||Stroke without Mechanical Thrombectomy|Patients who would have large artery occlusion treated with best medical management (IV-tPA if eligible) and not receiving endovascular therapy will be collected for a secondary analysis as a comparison group and to evaluate the selection methods in them as well
2567998|NCT02446249|Experimental|single arm dose escalation|single arm dose escalation
2568060|NCT02446119||Gastroparesis|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~patients with an established diagnosis of gastroparesis, either diabetic or idiopathic etiology. The gastroparesis subjects will have delayed gastric emptying on gastric scintigraphy defined as greater than 60% retention at 2 hours and/or greater than 10% retention at 4 hours. This gastric emptying test would have been done prior to the endoscopy and is not part of the research study. Patients will undergo EndoFlip during upper endoscopy."
2568064|NCT02446119||Normals|"Inclusion criteria:~1. Subjects will be of either sex, 18 to 70 years of age.~control subjects will be nondiabetic patients without gastroparesis or gastroesophageal reflux symptoms undergoing upper endoscopy. Patients will undergo EndoFlip during upper endoscopy."
2568128|NCT02445742|Experimental|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
2568321|NCT02444312|Experimental|Benefit-finding Writing Activity|For two weeks, on six days of their choice, caregivers will be instructed to write about their thoughts and feelings in a diary/ notebook about the benefits of caring.
2568324|NCT02444312|Active Comparator|Neutral Writing activity|For two weeks, on six days of their choice, caregivers will be instructed to write about a neutral topic.
2568363|NCT02443844|Active Comparator|First group|Patients taken tamsulosin for benign prostate hyperplasia who have non muscle invasive bladder cancer
2568370|NCT02443844|Active Comparator|Second Group|Patients taken transurethral resection prostatectomy for benign prostate hyperplasia who have non muscle invasive bladder cancer
2568413|NCT02443415||Healthy Controls|Non-diabetic subjects
2568423|NCT02443415||Diabetics without DKA|Diabetic subjects (recent(< 1 year) diagnosis of diabetes) without a history of diabetic ketoacidosis (DKA)
2568425|NCT02443415||First episode of DKA|Diabetic subjects that just had their primary event of diabetic ketoacidosis (DKA)
2568428|NCT02443415||Three or more DKA episodes|Diabetic subjects who have had three or more diabetic ketoacidosis (DKA) episodes
2568482|NCT02443129|Experimental|control group|"18-99 year old male + female~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
2568486|NCT02443129|Experimental|mydramide only|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
2568488|NCT02443129|Experimental|mydramide and ephrine 10%|"Patients in the clinics undergoing pupil dilation~Intervention:~Tropicamide and ephrine 10% instillation to both eyes DRI-1 Swept source OCT, Atlantis, Topcon"
2568798|NCT02440997|Experimental|foot bath and aromatherapy|10 minute foot bath with addition of jojoba with added Mentha piperita
3207925|NCT00969995||cluster|50 subjects with cluster headache
3207926|NCT00969995||Healthy|50 healthy subjects
2567499|NCT02449603|Experimental|Exenatide|Exenatide (Colorless transparent liquid, comes in a prefilled pen.5ug/10ug, AstraZeneca) should be initiated, 60 minutes pre-breakfast and pre-supper, at 5ug twice a day for 4 weeks and then titrated up at 10ug twice a day until the completion of the study.
2567505|NCT02449603|Active Comparator|Biphasic insulin Aspart 30|Biphasic insulin Aspart 30 (Colorless transparent liquid, 100u/mL, 3ml each, Novo Nordisk), subcutaneous injection, starting at a dose of 0.2-0.4 IU/kg, or 10～12 IU/d assigned in pre-breakfast and pre-supper in a 1:1 ratio. The adjustment of insulin dose is instructed to achieve an optimal balance between glycaemic control and risk of hypoglycaemia as dictated by best clinical practice, titrated to glucose targets of fasting plasma glucose (FPG) and pre-supper <7 mmol/L.
2567572|NCT02449278|Experimental|ISRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals) .~Consolidation involved-site radiotherapy (ISRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
2567578|NCT02449278|Active Comparator|IFRT group|"Six cycles Chemotherapy (cyclophosphamide 750mg/square meter on day 1 + doxorubicin 50mg/square meter on day 1 + vincristine 1.4mg/square meter on day 1 (up to a maximal dose of 2 mg) + prednisone 60mg/square meter on day 1 through 5, repeated at 21-day intervals).~Consolidation involved-field radiotherapy (IFRT) following in patient with complete or partial response beginning 1 month after last cycle of chemotherapy."
2567613|NCT02448693|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging. All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
2567620|NCT02448693|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, tandem colonoscopy. It consists of two revisions of the polypectomy scar using firstly Narrow Band Imaging and secondly High Definition White Light Endoscopy (WLE). All suspected neoplasia will be classified macroscopically and resected and differentiated from both techniques. The rest of the gut will be inspected following conventional standards.
2567660|NCT02448459|Experimental|COOL-COS|All women will receive Letrozole, Clomiphene, and Corifollitropin Alfa for controlled ovarian stimulation
2567734|NCT02448238|Experimental|probiotic|This is a single arm study all subjects will receive the study VSL#3 probiotic. Subjects will take 1 sachet of powder orally daily for 12 weeks
3207927|NCT00970008|Active Comparator|Massage 30 min - 2x wk for 4 wks & 1x wk for 4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
2567834|NCT02447263|Experimental|HepaSphere|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
2567835|NCT02447263|No Intervention|control|liver cancer patients did not receive any interventional therapy
2567909|NCT02447107||Outpatients|Outpatients enrolled in this study are required to complete study assessments on mobile applications and through questionnaires. A daily electronic diary will be completed through the Ohmage app. The Mobility app will be used to track the patients' movement and activity. Patients will be administered a questionnaire at the 1 and 2 week endpoints.
2567933|NCT02446730|Active Comparator|BES with Prasugel 5mg|Biolimus-eluting stent with Prasugrel 5mg once daily MD
2567936|NCT02446730|Active Comparator|BES with Clopidogrel 75mg|Biolimus-eluting stent with Clopidogrel 75mg once daily MD
3207928|NCT00970008|Active Comparator|Massage 60 min - 2x wk for 4 wks & 1x wkly for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
3207929|NCT00970008|Active Comparator|Massage 30 min sessions - 1x/wk for 8wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
2568054|NCT02445924||Control group 1|ten non smoker volunteers
2568061|NCT02445924||Control group 2|ten smoker volunteers
2568067|NCT02445924||NSCLC patients|twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy
2568118|NCT02445781|Experimental|90 mg/dl glucose clamp|Glucose clamp intervention of 90 mg/dl maintained for 90 minutes.
2568127|NCT02445781|Experimental|70 mg/dl glucose clamp|Glucose clamp intervention of 70 mg/dl maintained for 90 minutes.
2568136|NCT02445781|Experimental|60 mg/dl glucose clamp|Glucose clamp intervention of 60 mg/dl maintained for 90 minutes.
2568140|NCT02445781|Experimental|50 mg/dl glucose clamp|Glucose clamp intervention of 50 mg/dl maintained for 90 minutes.
3207930|NCT00970008|Active Comparator|Massage 60 min sessions - 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
3207931|NCT00970008|No Intervention|Usual Care Control|Continue on usual care for eight (8) week period.
3207932|NCT00970021|Placebo Comparator|Water with artificial colour|Placebo
3207933|NCT00970021|Active Comparator|Extract of agaricus blazei Murill|Agaricus blazei Murill
2568343|NCT02443935|Experimental|MGN1703|TLR-9 agonist MGN1703 administered to HIV-1 positive patients on cART
3207934|NCT00970034||AF|Patients with degenerative mitral valve regurgitation and permanent atrial fibrillation who require mitral valve repair or replacement.
3207935|NCT00970034||SR|Patients with degenerative mitral valve regurgitation and maintaining sinus rhythm who require mitral valve repair or replacement.
3207936|NCT00970047||Pregnant females|Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.
2568692|NCT02441790|Experimental|Early Active Range of Motion|Early Active Range of Motion (EAROM) 3-9 days following hand fracture
2568697|NCT02441790|Active Comparator|Standard Immoblization|Standard immobilization with plaster splint for 21-27 following hand fracture
3207937|NCT00970060|Experimental|Exercise program|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
3208891|NCT00979095||Multiple hernia|Patients with more than 3 primary hernias
2567515|NCT02449577|Experimental|Beverage sequence CBAD|Each participant randomized to this arm is exposed to 4 test meals in the order CBAD with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567517|NCT02449577|Experimental|Beverage sequence ABDC|Each participant randomized to this arm is exposed to 4 test meals in the order ABDC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567519|NCT02449577|Experimental|Beverage sequence DABC|Each participant randomized to this arm is exposed to 4 test meals in the order DABC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567520|NCT02449577|Experimental|Beverage sequence DCAB|Each participant randomized to this arm is exposed to 4 test meals in the order DCAB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567521|NCT02449577|Experimental|Beverage sequence DBCA|Each participant randomized to this arm is exposed to 4 test meals in the order DBCA with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567523|NCT02449577|Experimental|Beverage sequence ADCB|Each participant randomized to this arm is exposed to 4 test meals in the order ADCB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567524|NCT02449577|Experimental|Beverage sequence BADC|Each participant randomized to this arm is exposed to 4 test meals in the order BADC with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567526|NCT02449577|Experimental|Beverage sequence ACDB|Each participant randomized to this arm is exposed to 4 test meals in the order ACDB with a washout period of at least a week between each meal. Each meal consisted of a standardized lunch of Parisian toast (sandwichbread, ham, cheese) together with a beverage. Each beverage is assigned a letter, A, B, C, or D. The letter assignment is blinded. The following four drinks were used Placebo: 330 ml of a soft drink (Sports drink), Beer 1 - 330 ml of an alcohol-free beer (<0.1% alcohol), Beer 2 - 330 ml of a regular lager beer (4.6% alcohol), and Beer 3 - 330 ml of a strong beer (7.2% alcohol)
2567575|NCT02449057|Experimental|JUST|Juveniles Under Supervision and Treatment. This entails swift, certain, and modest sanctions for violations of terms of community supervision.
2567582|NCT02449057|No Intervention|Probation-as-Usual|Juvenile probation-as-usual.
2567614|NCT02448836|Experimental|Active dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of dTMS active treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
2567621|NCT02448836|Sham Comparator|Sham dTMS treatment|In each menstrual cycle, patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week) with dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil. The post ovulation phase is the luteal and symptomatic phase of PMDD patients.
2567672|NCT02448576|Experimental|PCI group|Receiving prophylactic cranial irradiation after response to first line chemotherapy.
2567677|NCT02448576|No Intervention|observation group|Patients in the observation group do not receive prophylactic cranial irradiation after response to first line chemotherapy.
2567733|NCT02448160|Experimental|alfapump with albumin treatment|patients implanted with an alfapump, receiving intermittent salt-poor Human Albumin solution treatment
2567783|NCT02447835|Active Comparator|Olanzapine|Olanzapine administration
2567789|NCT02447835|Placebo Comparator|Placebo|Placebo administration
2567865|NCT02447445||Older inpatient at MOP|The group includes older patients who are admitted to one of the Medicine for Older Patients (MOP) wards. Grip strength will be part of the routine assessment of older patient when admitted to MOP.
2567902|NCT02447042|Experimental|2 ml/Kg|Fluid challenge with crystalloids (2 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
2567905|NCT02447042|Experimental|3 ml/Kg|Fluid challenge with crystalloids (3 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
2567910|NCT02447042|Experimental|4 ml/kg|Fluid challenge with crystalloids (4 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
2567565|NCT02449369|Active Comparator|Standard|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop oral orphenadrine 100 mg every 12 hours for 3 doses, Postop oral oxycodone & acetaminophen (5/325 mg) 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
2567567|NCT02449369|Experimental|IVAM|Preop acetaminophen IV 1000 mg, Preop orphenadrine IV 60 mg, Postop acetaminophen IV 1000 mg every 6 hours for 7 doses, Postop orphenadrine IV 60 mg every 12 hours for 3 doses, Postop oral oxycodone 5 mg 1 to 2 tabs every 4 hours PRN, Postop hydromorphone IV 0.5 mg every 4 hours PRN
3208892|NCT00979095||Control group|Patients without hernias
2567770|NCT02447939|Experimental|Dabrafenib and Trametinib|Subject will be assigned in 2 cohorts, in cohort A, subjects will be administered dabrafenib (150 mg BID) monotherapy from Day1 to Day 21 (first part), followed by dabrafenib (150 mg BID) and trametinib (2mg QD) combination (second part, starting from day 22). After the last subject in cohort A has finished the last pharmacokinetic sampling(1st part ), another 10 subjects will be enrolled in cohort B with administration of dabrafenib (150 mg BID) in combination with oral trametinib (2mg QD).
2567817|NCT02447588|Other|Group 1|Intrauterine insemination with sperm donor (IAD) at 36 hours post-hCG. Cases where the IAD is scheduled at 36 hours post-administration of hCG.
2567818|NCT02447588|Experimental|Group 2|Intrauterine insemination with sperm donor (IAD) at 24 hours post-hCG. Cases where the IAD is scheduled at 24 hours post-administration of hCG.
3172644|NCT00602693|Experimental|UCB post-transplant Treg Cell Infusion|Includes patients with high risk malignancy receiving allopurinol, fludarabine phosphate, cyclophosphamide, sirolimus, total body irradiation, double umbilical cord blood transplantation and Treg infusion cells after transplant. Patients will receive differing dose levels as they are entered and assigned to determine the maximum tolerated dose.
3172645|NCT00602732|Experimental|1|Participants assigned to the ROSE program
3172646|NCT00602732|Active Comparator|2|Participants assigned to enhanced care as usual
2568300|NCT02444247|Other|High Dose Exercise vs Sedentary Option|Relative Reinforcing Value of high dose exercise (300 kcal expenditure per session) versus sedentary activity will be determined.
2568306|NCT02444247|Other|Low Dose Exercise vs Sedentary Option|Relative Reinforcing Value of low dose exercise (150 kcal expenditure per session) versus sedentary activity will be determined.
2568311|NCT02444247|Other|No Exercise vs Sedentary Option|Relative Reinforcing Value of no exercise (0 kcal expenditure per session) versus sedentary activity will be determined.
2568447|NCT02443311|Experimental|Group I|Pimecrolimus 1% cream (Elidel, Novartis Pharmaceuticals, East Hanover, NJ)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
2568449|NCT02443311|Active Comparator|Group II|Betamethasone 17-valerate 0.1% cream (Betnovate, GlaxoSmithKline, Cairo, Egypt)+ custom made hydrophilic Adhesive gel base (Department of Pharmaceutics and Industrial Pharmacy. Faculty of Pharmacy. Ain Shams University) 4 Times/day for 4 weeks
2568489|NCT02442934|Experimental|Multicomponent program|Multicomponent intervention to reduce perceived discomforts in critically ill patients : the IPREA3 program
2568491|NCT02442934|Active Comparator|Standard Care|Standard care
2568541|NCT02442557|Active Comparator|single dose 4 mg|a single intravenous injection of 4 mg DC-TAB
2568544|NCT02442557|Active Comparator|single dose 12.5 mg|a single intravenous injection of 12.5 mg DC-TAB
2568550|NCT02442557|Active Comparator|single dose 25 mg|a single intravenous injection of 25 mg DC-TAB
2568551|NCT02442557|Active Comparator|single dose 37.5 mg|a single intravenous injection of 4 mg DC-TAB
2568556|NCT02442557|Placebo Comparator|single dose placebo|a single intravenous injection of placebo
2568557|NCT02442557|Active Comparator|multiple dose 10 mg|three consecutive daily intravenous injections of 10 mg DC-TAB
2568564|NCT02442557|Active Comparator|multiple dose 25 mg|three consecutive daily intravenous injections of 25 mg DC-TAB
2568570|NCT02442557|Active Comparator|multiple dose 37.5 mg|three consecutive daily intravenous injections of 37.5 mg DC-TAB
2568574|NCT02442557|Placebo Comparator|multiple dose placebo|three consecutive daily intravenous injections of placebo
2568609|NCT02442297|Experimental|HER2-specific T cells - High Risk|Subjects with HER2 staining of Grade 3 (51-100% of cells staining for HER2) and intensity scores of 3+ will be assigned to the High Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
2568613|NCT02442297|Experimental|HER2-specific T cells - Standard Risk|All other patients not meeting the high risk description will be assigned to the Standard Risk arm. Three cell dosing schedules (1, 2, 3) consisting of combinations of three cell doses (A, B, C) will be evaluated.
2568705|NCT02441712|Experimental|Motor PENS|Motor PENS will be a strong tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors for strength training (50Hz impulses for 200ms every 1500 ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program.
2568793|NCT02441010|No Intervention|Group 1|Participants without suboptimal health status are randomly grouped into the group without monitor (Group 1) and the monitor group (Group 2 or Group 3). Thus, no monitoring or intervention technologies are used in Group 1.
3172647|NCT00602745|Active Comparator|5-Fluorouracil|
3172648|NCT00602745|Experimental|S-1|
3172649|NCT00602758|Experimental|Enhanced Counseling|Participants meet with a counselor trained in motivational interviewing and cognitive behavioral techniques
3172650|NCT00602758|No Intervention|Standard Care|Participants receive usual clinical care provided by health care providers and they participate only in evaluation components of the study
3172651|NCT00602758|Experimental|Enhanced Counseling/Modified Directly Observed Therapy|Participants receive their ART medications delivered to them by study staff and they receive the enhanced counseling
3172652|NCT00602784|Experimental|IC41-B-01/02|peptide dose 0.00 mg, polyarginine dose 2.00 mg
3172653|NCT00602784|Experimental|IC41-C-01/02|peptide dose: 5.00 mg, polyarginine dose: 0.00 mg
3172654|NCT00602784|Experimental|IC41-G-01/02|peptide dose: 2.50 mg, polyarginine dose: 1.25 mg
3172655|NCT00602784|Experimental|IC41-H-01/02|peptide dose: 2.50 mg, polyarginine dose: 2.00 mg
3172656|NCT00602784|Experimental|IC41-K-01/02|peptide dose: 5.00 mg, polyarginine dose: 2.00 mg
2567580|NCT02449109|Experimental|Nano drug|Liver cancer patients received nano drug interventional therapy using digital subtraction angiography（DSA）. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.
2567583|NCT02449109|Active Comparator|Drug microspheres|Liver cancer patients received drug microspheres (HepaSphere Microspheres) interventional therapy using digital subtraction angiography（DSA）.
2567612|NCT02448784||Participants with DLB|Participants with DLB who will receive donepezil hydrochloride per approved label.
3207938|NCT00970086|Experimental|transversus abdominal plane block|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures with ultrasound, insertion of the stimuplex needle G22, 50mm, in an in-plane approach and administration of 0.4ml/kg levobupivacaine 0.25%."
3207939|NCT00970099|Active Comparator|Exercise|12 week exercise regimen
2567765|NCT02447965|Active Comparator|Bupivacaine|Will have 20ml of bupivacaine injected into each rectus sheath.
2567766|NCT02447965|Placebo Comparator|Normal Saline|Will have 20ml of normal saline injected into each rectus sheath.
2567802|NCT02447679|Experimental|thalidomine|"Thalidomide 400mg/day for 1 year~tegafur-uracil 2 tables for 1 year."
2567844|NCT02447380|Experimental|AZD6094 (Volitinib) in combination with docetaxel|"Subjects will receive Volitinib once daily (at the MTD determined from Phase Ib) for 21 days as one cycle.~Docetaxel 60 mg/m2 will be administered via intravenous access once every 3 weeks."
3207940|NCT00970099|Placebo Comparator|non-exercise|Normal lifestyle routine with no exercise for 12 weeks.
3207941|NCT00970112|Placebo Comparator|Placebo|Placebo 1 hour before surgery
2567989|NCT02446444|Experimental|Enzalutamide|Enzalutamide 160 mg daily, by mouth, for 24 months from randomisation. All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)
2567990|NCT02446444|Active Comparator|Conventional Non-steroidal Anti-androgen (NSAA)|"Conventional Non-steroidal Anti-androgen (NSAA), by mouth, for 6 months from randomisation.~All participants are treated with a LHRHA for 24 months from randomisation and external beam radiation therapy started approximately 16 weeks after randomisation (+/- brachytherapy boost)"
3207942|NCT00970112|Experimental|Etoricoxib|Etoricoxib 1 hour before surgery
3207943|NCT00970112|Experimental|Dexamethaone|Dexamethasone 1 hour before surgery
2568184|NCT02445417||EES|Epidermal Electronic System
2568188|NCT02445417||Hydrogel Electrode|Hydrogel based EEG electrode
2568215|NCT02444975|Experimental|Increased water intake+coaching program|Women in the intervention group will be asked to increase their mineral water intake of 1.5L/day
2568219|NCT02444975|Other|No intervention|No intervention
2568298|NCT02444364|Experimental|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
2568374|NCT02443987|Experimental|Received intravenous fluids|The patient will receive 500ml of 0.9% NaCl fluid intravenously during the operation.
2568377|NCT02443987|No Intervention|Control Arm|The patient will receive no intravenous fluid as per current routine protocol
2568444|NCT02443467||HER2-positive early breast cancer|Human Epidermal Growth Factor Receptor 2 (HER2)-positive early breast cancer treated with loading dose of Herceptin (trastuzumab) administered as 6 mg/kg followed by once in 3 weeks administration at 4 mg/kg up to 12 months of treatment
2568484|NCT02443025|Experimental|Intervention|Classes receive anti-tobacco presentations from Teens Against Tobacco Use members
2568487|NCT02443025|No Intervention|Wait list control|Classes continue as usual without receiving anti-tobacco presentations from Teens Against Tobacco Use members until the end of the year, when data collection is complete.
3207944|NCT00970125|Experimental|Cancer subjects|
3207945|NCT00970138|Experimental|A 850|apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2568586|NCT02442479|Active Comparator|HHH3|High-resistance concentric-eccentric training (H) 3 d/wk (HHH3).
2568590|NCT02442479|Experimental|HLH3|3 d/wk mixed model consisting of high-resistance concentric-eccentric training 2 d/wk separated by 1 bout of low-resistance, high-velocity, concentric only training (L) (HLH3).
2568593|NCT02442479|Experimental|HH2|High-resistance concentric-eccentric training 2 d/wk (HH2).
2568594|NCT02442479|Experimental|HL2|2 d/wk mixed model consisting of high-resistance concentric-eccentric training 1 d/wk and low-resistance, high-velocity, concentric only training 1 d/wk (HL2).
2568657|NCT02442128|Active Comparator|Group1|comparison of different dosages of drugs ( Fentanyl / Propofol), fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
2568659|NCT02442128|Active Comparator|Group 2|comparison of different dosages of drug ( Fentanyl / Propofol) ,fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
2568690|NCT02441660|Experimental|experimental group|Qutenza, Capsaicin 8% Patch will be used
2568691|NCT02441660|Active Comparator|control group|Active control with low dose capsaicin
2568752|NCT02441452|Active Comparator|Early rehabilitation|one day before surgery, patients and their families were instructed by physiotherapists than explained the importance to perform physical exercises and breath exercises in postoperative. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation.
2568753|NCT02441452|No Intervention|Conventional care|Usual care routine postoperative.
2568756|NCT02441101|Experimental|RV DDD(R)-60 with AV optimization|RBBB pacing
2568757|NCT02441101|Placebo Comparator|RV DDD(R)-60|Standard demand pacing
2568795|NCT02440997|Placebo Comparator|foot bath only|10 minute foot bath with addition of jojoba only
3207946|NCT00970138|Experimental|B 425|apatinib 425 mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3207947|NCT00970138|Placebo Comparator|C pla|placebo bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3207948|NCT00970177|Experimental|low dose of antigen + low dose of adjuvant|
3207949|NCT00970177|Experimental|high dose of antigen + high dose of adjuvant|
2567631|NCT02448628|Experimental|CS-3150|CS-3150 1.25 to 5.0 mg , orally, once daily after breakfast for 12 weeks
2567731|NCT02448251|Experimental|single dose per day (QD)|Phase I Arm 1: AC0010MA orally taking once daily, starting from 100 mg per day.
2567732|NCT02448251|Experimental|two doses per day (BID)|Phase I Arm 2: AC0010MA orally taking twice daily, starting from 200 mg per day (100 mg BID). Arm 2 will be initiated once the drug plasma t1/2 is 10 hours or below in the first dose cohort (100 mg QD).
2567771|NCT02447809|Experimental|Regular DAPT(IPA≤60%)|ASA and Clopidogrel
2567772|NCT02447809|Active Comparator|Regular DAPT(IPA>60%)|ASA and Clopidogrel
3207950|NCT00970177|Experimental|high dose of antigen|
3207951|NCT00970229|Experimental|Assess [123I]MNI-420 and SPECT Imaging|To assess [123I]MNI-420 and SPECT Imaging in PD, HD subjects and similarly aged healthy subjects.
3207952|NCT00970255|Active Comparator|Frenotomy|
2568056|NCT02446028|Experimental|BIOD-531|BIOD-531 injected twice daily
2568063|NCT02446028|Active Comparator|Humalog® Mix 75/25|Humalog® Mix 75/25 injected twice daily
2568121|NCT02445716|Active Comparator|Testosterone 500 mcg / Biolipid B2|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment."
2568126|NCT02445716|Placebo Comparator|Placebo|"The arm, is part of a randomized, double-blind, placebo-controlled, parallel group trial.~The arm have 35 women. It consists of a 4-week screening period plus a 12-week treatment phase involving three study visits and one telephone contact at week 7 of the treatment.~Participants will be attended at the Federal University of São Paulo / Post Graduation Program in São Paulo, Brazil for their study visits."
2568229|NCT02444780||elective cardiac surgery patients|consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period
2568269|NCT02444585|Experimental|Denosumab|Drug for prevention of bone loss
2568270|NCT02444585|Placebo Comparator|Control|Hip Replacement Patient without Drug
2568393|NCT02443532|Experimental|Structured Group education|Six weekly interactive group sessions of 4 hours each, providing information and developing skills for diabetes self-management, including eating habits, food composition, calculation of bolus insulin, information on physical exercise, blood glucose self-monitoring, management of hypoglycemia.
2568399|NCT02443532|Other|Individual education|Usual care (individual consultations as routinely performed)
2568445|NCT02443272|Active Comparator|Control Arm|Receive standard incision and drainage
2568448|NCT02443272|Experimental|Intervention Arm|Receive minimal invasive loop drainage using the Vesi-loop device
2568468|NCT02442947|Experimental|Research arm|"1 day which will include: physician examination,ECG,anthropometric measurements and Vo2max test.~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% HR) and when dressed in shorts.At the sixth day, the subjects will be dressed in a standard work uniform as a baseline exposure. Core (rectal) and skin temperature and heart rate will be monitored continuously.~4 experiment days carried out by the following protocol: 2 hour walk on a treadmill (5 Km/h,2% incline) under heavy heat stress conditions (30 deg. centigrade,60% RH) and when dressed each time with different clothing out of 4 options:~NBC protective garment (charcoal base).~combat garment.~2 different types of work uniforms. physiological stress will be examined based on rectal temperature and heart rate measurements."
2568533|NCT02442843|Experimental|active tDCS|Investigators will use cathodal tDCS to inhibit the brain regions that may be associated with symptoms of PTSD (temporal cortex). Active tDCS will be provided at 2 miliamps (mA) for 20 minutes (with gradual increase and withdraw of stimulation during the first and last minute).
2568534|NCT02442843|Sham Comparator|sham tDCS|Participants randomized to the sham condition will receive stimulation during the first and final minutes of the 20 minute period (with gradual increase and removal of current during that time).
2568537|NCT02442843|No Intervention|Combat Controls|Participants without PTSD will undergo neuropsychological testing and a single fMRI scan.
2568631|NCT02442427|Active Comparator|Palivizumab|A single dose of IV palivizumab
2568633|NCT02442427|Placebo Comparator|Placebo|An equivalent volume of 0.9% normal saline.
2568672|NCT02441829|Experimental|Mild Renal Impairment (CLcr 60-89 mL/min)|Participants with mild renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
2568677|NCT02441829|Experimental|Moderate Renal Impairment (CLcr 30-59 mL/min)|Participants with moderate impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
2568682|NCT02441829|Experimental|Severe Renal Impairment (CLcr 15-29 mL/min)|Participants with severe renal impairment and matched control participants with normal renal function will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).
3207953|NCT00970255|Sham Comparator|Sham Frenotomy|
2568796|NCT02441010|Sham Comparator|Group 2|Group 2 are participants without metabolic abnormality in the monitor group. Group 2 use the monitoring device with three months.
2568799|NCT02441010|Sham Comparator|Group 3|Group 3 are participants with metabolic abnormality in the monitor group. Group 3 use the monitoring device and the health information push technology with three months.
3207954|NCT00970333|Experimental|assess [18F]-FEPPA PET imaging|
3207955|NCT00970346|Experimental|Inhaled OligoG CF-5/20|
3207956|NCT00970372||Involuntary patients|Compulsory treated patients according to the Norwegian Social and Welfare Act of 1992. Most patients have dualdiagnosis.
3207957|NCT00970372||Voluntary patients|Voluntary patients on the same wards. Most patients have dual-diagnosis.
3207958|NCT00970385|Active Comparator|CHOP 21|"Induction therapy CHOP every 21 days:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
3207959|NCT00970385|Experimental|VIP/ABVD arm|"VIP cycle:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatin 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD cycle:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D Each alternating cycle was repeated three times for a total of 6 cycles (3 VIP, 3 rABVD)."
2567805|NCT02447640|Experimental|Part 1|A receptor occupancy dose curve will be obtained by using an adaptive design in this arm.
2567809|NCT02447640|Experimental|Part 2|In this arm, the time course of the receptor occupancy will be studied for the dose which gives 70% receptor occupancy as determined in Part 1.
3207960|NCT00970398|No Intervention|Reference group|Human milk breastfeeding
3207961|NCT00970398|Active Comparator|Control formula|Standard infant formula, with no Osteopontin supplemented.
3207962|NCT00970398|Active Comparator|Formula with 50% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 50% level of that of breast milk.
2567965|NCT02446522|Active Comparator|Open vein harvesting|Patients with IHD, who were underwent open vein harvest method (OVH)
2567970|NCT02446522|Active Comparator|Endoscopic vein harvesting|Patients with IHD, who were underwent edoscopic vein harvestingopen vein harvest method (EVH).
2568002|NCT02446379||EnLightTM and LightPathTM Imaging Systems arm|"Patients will first be injected intravenously with 2-5 MBq/kg, up to a maximum 300 MBq of the marketed product 18F-fluorodeoxyglucose (FDG) and after this undergo tumour excision surgery according to standard of care.~The surgical cavity will be imaged by the EnLightTM system and the tumour excision specimen will be imaged by both the EnLightTM and LightPathTM Imaging Systems. The EnLightTM and LightPathTM Imaging Systems results will not influence any surgical or clinical decision-making. The tumour excision specimen will be analysed according to standard of care pathology. Patients will be followed-up (Visit 3) 2-14 days after the end of surgery for adverse events (AEs)."
2568088|NCT02446093|Experimental|Test Arm|GMCI + chemoradiation + surgery
2568089|NCT02446093|Active Comparator|Control Arm|Chemoradiation + surgery
2568119|NCT02445547|Experimental|UC-MSCs|UC-MSCs by peripheral intravenous infusion
2568124|NCT02445547|Active Comparator|control|received hormone maintenance therapy
2568204|NCT02445391|Active Comparator|Arm A (observation) (closed to accrual 05/16/2016)|Patients undergo observation.
2568206|NCT02445391|Experimental|Arm B (cisplatin or carboplatin)|Patients receive cisplatin IV or carboplatin IV on day 1. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
2568208|NCT02445391|Experimental|Arm C (capecitabine)|Patients receive capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
2569749|NCT02434367|Experimental|Arm A|Women randomized to the WWE program will receive a workbook, and a daily walking log, the latter to be completed during the study.
2569751|NCT02434367|No Intervention|Arm B|Patients randomized to the usual care arm will receive a document with information on exercise to improve fatigue during radiotherapy
3207963|NCT00970398|Active Comparator|Formula with 100% Osteopontin|Infant formula supplemented with bovine milk Osteopontin at 100% level of that of breast milk.
2569901|NCT02433730|Active Comparator|placebo|intramuscular injection
2569903|NCT02433730|Active Comparator|testosterone|intramuscular injection
2569948|NCT02433067|Experimental|Physical activity intervention|"- Arm A standard oncologic care coupled with physical activity intervention (3 times / week)  during 3 months"
2569950|NCT02433067|Active Comparator|Control group|"- Arm B (control group) standard oncologic care"
2570003|NCT02432755|Experimental|home-based MTOT|Home-based mirror therapy combined with task-oriented training (MTOT)
2570011|NCT02432755|Active Comparator|hospital-based therapy|hospital-based individualized occupational therapy
2570013|NCT02432755|Experimental|hospital-based MTOT|hospital-based mirror therapy combined with task-oriented training (MTOT)
2570060|NCT02432313|Experimental|Modified Release Formulation x (MRx)|Various formulations of Modified Release anatabine citrate tablets
2570130|NCT02431962|Experimental|Screening arm|Annual low dose screening chest CT scan x 3.
2570132|NCT02431962|Experimental|Smoking cessation counseling|Active smokers randomized to this arm will be contacted by a trained smoking cessation counselor and offered cessation support and advice.
2570133|NCT02431962|Active Comparator|Smoking cessation control|Active smokers randomized to this arm will receive general information on available smoking cessation resources.
3207964|NCT00970411|Experimental|KRN951|
3207965|NCT00970424|Placebo Comparator|1|placebo, oral tablet administered once daily on background of pioglitazone
3207966|NCT00970424|Experimental|2|dutogliptin, oral tablet administered once daily on background of pioglitazone
2570331|NCT02430701|Experimental|IRE Group|irreversible electroporation for Unresectable Esophageal Neoplasms
2570334|NCT02430701|No Intervention|Control|The patients without treatment
3207967|NCT00970437|Active Comparator|CBASP|CBASP as the experimental intervention will follow a manual (McCullough, 2000; German version: Schramm et al., 2006). The approach is specifically tailored for the treatment of chronic forms of depression, particularly with early-onset by focusing on the problems resulting from an inhibition of maturation in early childhood and by using the therapeutic relationship in a personal, disciplined way as well as other specific techniques (e.g. Interpersonal Discrimination Exercise, Situation Analysis). CBASP integrates behavioural, cognitive, and interpersonal strategies.
2570493|NCT02429752|Experimental|Inspiratory Muscle Training|Subjects will receive 8 weeks of IMT
2570527|NCT02429492|Experimental|ALS patients|Patients with amyotrophy lateral sclerosis (ALS)
2570530|NCT02429492|Experimental|Control subjetcs|Neurologically intact subjects sex and age-matched to ALS patients
2570725|NCT02428140|Experimental|Implanted Loop Recorder|long-term implantable ECG (Medtronic Reveal LINQ) coupled with remote monitoring (MyCareLink) for 12 months
3207968|NCT00970437|Placebo Comparator|SYSP|The comparator for CBASP is SYSP, a system of supportive psychotherapy, an active but less specific, manualized control treatment. SYSP - defined as non-interpersonal and non-cognitive-behavioral therapy - resembles supportive clinical management, client-centered therapy, counseling, and psychoeducation about depression. There is no specific explanatory mechanism for treatment effect offered to the patient and it does not focus on specific themes.
3207969|NCT00970450|Experimental|Paracetamol|
3207970|NCT00970450|Experimental|Paracetamol/Tropisetron|
3207971|NCT00970450|Placebo Comparator|Saline|Proband will receive Saline
3207972|NCT00970450|Active Comparator|Tropisetron|Proband will receive Tropisetron alone
2567801|NCT02447666|Experimental|Azacitidine Myelodysplastic Syndrome (MDS)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
2567803|NCT02447666|Experimental|Azacitidine Juvenile Myelomonocytic Leukemia (JMML)|Azacitidine 75 mg/m2 by Intravenous (IV) or Subcutaneous (SC) administration once daily (QD) on Days 1 to 7 of a 28-day cycle for a minimum of 3 cycles and a maximum of 6 cycles.
2567875|NCT02447185|Experimental|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
2567876|NCT02447185|Active Comparator|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetonide group will receive Triamcinolone Acetonide 4mg/0.1 ml intravitreal injection.~During operation all subjects in this group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in this group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
2567912|NCT02446873|No Intervention|Control|Control group
2567914|NCT02446873|Experimental|Treatment|Egg supplementation
3207973|NCT00970463||GH|Patients with GHD
2568023|NCT02446210|Active Comparator|Healthy Controls Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
2568025|NCT02446210|Active Comparator|Spinal Cord Injury Group|Magstim 200 magnetic stimulator for Transcranial Magnetic Stimulation and Peripheral Nerve Stimulation
2568049|NCT02446002|Experimental|Lofexidine + Naltrexone|
3207974|NCT00970463||Pegvisomant and Somatostatin analogues|Acromegaly
3207975|NCT00970515|Experimental|Laparoscopic approach|group A: Laparoscopic approach
2568231|NCT02444884|Experimental|Stratum A1|Establish MTD in patients with solid tumors MLN8237 orally, once daily on Days 1-7
2568235|NCT02444884|Experimental|Stratum A2|MTD determined in Stratum A1in patients with solid tumors MLN8237 orally, twice daily on Days 1-7
2568237|NCT02444884|Experimental|Stratum B|Expand MTD in patients with neuroblastoma MLN8237 orally, once daily on Days 1-7
2568274|NCT02444455|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by intravenous infusion
3207976|NCT00970515|Active Comparator|Open approach|group B: Open anterior approach
3207977|NCT00970528|Experimental|Arm 1|
2568365|NCT02443714|Experimental|Needle-free jet injection|Jet injectors deliver insulin at a high velocity (typically.100 m/s) across the skin in the subcutaneous tissue and may dispense the insulin over a larger area than insulin injected with a syringe.
2568373|NCT02443714|Experimental|Conventional pen|Conventional insulin administration with insulin pens.
2568405|NCT02443454||Patients after kidney transplantation|Short and Long-term results containing first 10 years after KTx.
2568406|NCT02443454||Healthy subjects|Medical staff: medical doctors, nurses
2568455|NCT02443181|Experimental|Activa PC+S|Patients will be implanted with standard DBS electrodes for treatment of essential tremor, at the Vim nucleus of the thalamus, and an additional subdural electrode array overlying hand motor cortex.. The patient will receive standard of care programming for thalamic stimulation for essential tremor. During research study visits, implementation and evaluation of closed-loop DBS using the PC+S system will be performed.
2568509|NCT02442921|Experimental|Colchicine|20 patients will receive up to 2 mg of colchicine for 18 months
2568510|NCT02442921|Placebo Comparator|Placebo|20 patients will receive placebo for 18 months
3207978|NCT00970528|Active Comparator|Arm 2|
3207979|NCT00970541|Active Comparator|Cinnamon Supplementation|A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
2568615|NCT02442323|Experimental|Walking Intervention|Intervention patients will receive a 12-week home-based walking program, which includes a personalized instruction booklet and pedometer. The walking program consists of 3 phases and will be individualized for each patient based on their physical condition and baseline assessment. Patients are instructed to walk 3 to 5 times each week at home or other safe environment. Patients will be instructed on a gradual increase in walking time over the course of the intervention.
2568616|NCT02442323|No Intervention|Usual Care|Usual care patients will receive standard of care. They will not receive any instruction on walking or other physical activity other than what is normally provided by their physician or clinical staff.
2568674|NCT02441842|Active Comparator|Group A : Atenolol|oral atenolol (50mg)
2568680|NCT02441842|Placebo Comparator|Group C: Placebo|glucose tablet (10mg)
2568684|NCT02441842|Active Comparator|Group L: Lisinopril|oral lisinopril (5mg)
3207980|NCT00970541|Placebo Comparator|Placebo|A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
3207981|NCT00970554|Active Comparator|Patching only|
3207982|NCT00970554|Experimental|Patching plus telescope group|
3207983|NCT00970567|Other|Arm 1|stop after positive ketone bodies in urine
3207984|NCT00970567|Other|Arm 2|stop after positive ketone bodies in blood, normal therapy
3207985|NCT00970567|Other|Arm 3|stop after positive ketone bodies in blood, additional therapy
3207986|NCT00970580|Experimental|BIIB022 in Combination with Paclitaxel and Carboplatin|BIIB022 in Combination with Paclitaxel and Carboplatin
3207987|NCT00970619|No Intervention|Conventional anticoagulation therapy|Conservative treatment consists of an initial treatment with therapeutic doses of low molecular weight heparin (LMWH) in combination with vitamin K-antagonists, followed by treatment with vitamin K-antagonist alone (after completing LMWH treatment of at least 5-7 days and after an international normalized ratio (INR) above 2 has been reached on two consecutive measurements). Or alternatively the new direct activated factor X inhibitors can be used as anticoagulation therapy. Anticoagulant treatment will be installed according to national and international guidelines (ACCP 2008 [23], CBO 2008 [24]) tailored based on the character of the event (6 months of therapy for idiopathic DVT and 3 months for provoked DVT).
2567691|NCT02448316|Active Comparator|conservative treatment|The standard treatment here acting as controle treatment . All patients are informed to decrease activity level, use shoes with good shock absorption and are recommended to use insoles (standard orthoses) for increased shock absorption. Training is supervised every third week by a physiotherapist (week 1,3,6,9), and daily training is carried out at home. Glucocorticoid injections of 1 ml Glucocorticosteroid (methylprednisolon 40 mg) and 1 ml of Lidokaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris are given every month until the fascia thickness is below 4 mm (max 3 injections).
2567755|NCT02448017|Active Comparator|The Herbst appliance|Orthodontic functional appliance
2567759|NCT02448017|Active Comparator|Twin block appliance|Orthodontic functional appliance
2567778|NCT02447757||Parturients with remifentanil analgesia|Parturients after induction of remifentanyl analgesia during the delivery
2567823|NCT02447510|Other|group 1|bone substitute grafting material applied to the defect site control (n=10)
2567828|NCT02447510|Other|group 2|experimental platelet rich growth factor PRGF applied to the defect site (n=10) G2
2567832|NCT02447510|Other|group 3|platelet rich fibrin PRF applied to the defect site (n=10) G3.
2567899|NCT02447055|Experimental|Arm 1 (Flu/Mel/PT-Cy & Tac/MMF for certain cases)|"Fludarabine 30 mg/m^2 intravenously (IV) on Days -5, -4, -3, and -2~Melphalan 140 mg/m^2 IV on Day -2~Tocilizumab 8 mg/m^2 (capped at 800 mg) IV on Day -1~Stem cell infusion on Day 0~Cyclophosphamide 50 mg/kg IV on Days +3 and +4~Tacrolimus 1 mg/day IV on Day +5 (for unrelated & haploidentical cases)~Mycophenolate mofetil 15 mg/kg orally three times per day on Day +5 (for unrelated & haploidentical cases)~Filgrastim 10 ug/kg/day subcutaneously until neutrophil recovery starting on Day +5"
3172657|NCT00602862|Experimental|1|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
3172658|NCT00602862|Experimental|2|10 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/10mg 111In-cG250. Patients are then treated with Sorafenib 200 mg 2dd2 po for 4 weeks. In the last week of treatment, the same injection is given to determine tumor accumulation of the radiolabeled mAb after Sorafenib treatment. Whole-body scintigraphic images are recorded 1 week after both injections to calculate tumor uptake. After Sorafenib treatment, patients will undergo surgery.
3207988|NCT00970619|Experimental|Ekos Endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
2568602|NCT02442414|Experimental|KBP-5209|Dose escalation for KBP-5209 will initially follow a modified accelerated titration design with a starting dose of 20 mg QD. Early dose escalation will proceed with one-patient cohorts and 100% dose increments (ie, dose doubling) until a patient experiences a DLT, at which point the cohorts will move to a 3+3 design. Treatment will continue until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. A cycle is defined as continuous treatment for 28 days.
2568664|NCT02442050|Experimental|del Nido solution|Administering of cardioplegia using del Nido solution in eligible patients.
2568666|NCT02442050|Active Comparator|Blood-based cardioplegia|Administering of cardioplegia using current standard of care blood-based cardioplegia protocol.
2568736|NCT02441530|Experimental|vitamin D|667 unit of vitamin D once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
2568739|NCT02441530|Experimental|vitamin E|200 unit of vitamin E once a day ,two days before the expected date of menstruation and continued through the first three days of bleeding.
2568744|NCT02441530|Experimental|ibuprofen|400 mg ibuprofen twice a day, two days before the expected date of menstruation and continued through the first three days of bleeding.
2568848|NCT02440672|Other|Device:JOURNEY™ II CR Total Knee System (J II CR TKS)|Subjects having TKA with JOURNEY™ II CR Total Knee System
2568895|NCT02440347|Experimental|Computer controlled anesthetic delivery by Anaeject|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by computer controlled anesthetic delivery system (C-CLADS) for AMSA nerve block
2568896|NCT02440347|Active Comparator|Conventional anesthetic delivery by carpule syringe|Patients received single dose of 0.6 ml of 4% articaine with epinephrine (1:100.000) by conventional anesthetic delivery for AMSA nerve block
2568967|NCT02440048|Experimental|HA ®Bond-apatite|10 extraction sockets will be preserved with Bond Apatite synthetic bone substitutes as test group
2568970|NCT02440048|Active Comparator|BioOss bovine bone substitute|10 extraction sockets will be preserved with BioOss particles bovine bone substitute as a positive control
2568972|NCT02440048|No Intervention|extraction|10 extraction sockets with no use of bone substitute as negative control.
2569008|NCT02439580|Experimental|Annona muricata extract|Annona muricata ethanol-soluble fraction of water extract capsule, 300 mg/day, for eight weeks
2569011|NCT02439580|Placebo Comparator|Placebo|Maltose capsule, 300 mg/day, for eight weeks
2569037|NCT02439346|Experimental|BAY1143269 5 mg|Subjects received BAY1143269 5 milligram (mg) tablet orally, once daily (QD) from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
2569040|NCT02439346|Experimental|BAY1143269 10 mg|Subjects received BAY1143269 10 mg (2*5 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
3172659|NCT00602862|Active Comparator|3|5 Patients planned to undergo (partial) nephrectomy or metastasectomy receive an iv injection of 100 MBq/1mg 111In-Bevacizumab. Whole-body scintigraphic images are recorded 1 week after the injection to calculate tumor uptake. Hereafter, patients will undergo surgery.
3172660|NCT00602901|Experimental|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
3172661|NCT00602901|Experimental|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
2567906|NCT02446964|Experimental|Treatment (TMLI, chemotherapy, transplant, GVHD prophylaxis)|"CONDITIONING: Patients undergo TMLI BID on days -7 to -4 or -3 (depending on the dose level). Patients also receive fludarabine phosphate IV on days -7 to -3 and cyclophosphamide IV on days -7, -6, 3, and 4.~TRANSPLANT: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.~GHVD PROPHYLAXIS: Patients receive tacrolimus* IV QD or PO BID on days 5-180. Patients also receive mycophenolate mofetil PO TID or IV on days 5-35. Treatment with tacrolimus and mycophenolate mofetil may continue in the presence of active GVHD.~*NOTE: Patients intolerant of tacrolimus may receive cyclosporine."
2568035|NCT02446340|Experimental|dalazatide 5ug|8 subjects, 6 given active agent and 2 given placebo
2568037|NCT02446340|Experimental|dalazatide 15ug|8 subjects, 6 given active agent and 2 given placebo
2568039|NCT02446340|Experimental|dalazatide 30ug|8 subjects, 6 given active agent and 2 given placebo
2568040|NCT02446340|Experimental|dalazatide 60ug|8 subjects, 6 given active agent and 2 given placebo
2568095|NCT02445833|Experimental|Lifestyle on-line intervention|"The self-applied on-line intervention will received acces to the web and the Vivir mejor modules."
2568122|NCT02445612||Experimental: MA09-hRPE|Sub-retinal transplantation of MA09-hRPE cells
2568192|NCT02445339|Active Comparator|Intervention Arm: XR-NTX+CM|XR-NTX+CM (Extended Release Naltrexone + Care Management)
2568195|NCT02445339|No Intervention|Standard Care Arm|Standard Care/Alcohol-Medical Management (MM) Only
2568220|NCT02444923|Experimental|Scleral rigid gas permeable contact lenses|The experimental intervention is the Scleral Rigid Gas Permeable contact lens (SRGPcl), Zenlens™. These lenses are designed to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with corneal contact.
2568223|NCT02444923|Placebo Comparator|Corneal rigid gas permeable contact lenses|The control intervention is the RoseK2™ Corneal Rigid Gas Permeable contact lens (CRGPcl). Corneal lenses are considered the gold standard in the management of the visual disability due to keratoconus and other related irregular cornea disorders.
2568250|NCT02444611|Active Comparator|Group 1|BCG vaccine, 0,05ml intradermally at birth
2568255|NCT02444611|Active Comparator|Group 2|BCG vaccine, 0,05ml intradermally at birth Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
2568257|NCT02444611|Active Comparator|Group 3|Hepatitis B vaccine, 5 micrograms, intramuscularly at birth
2568261|NCT02444611|No Intervention|Group 4|No birth vaccines
2568292|NCT02444286||standard care group|optimal standard of care therapy
2568293|NCT02444286||device group|Follow-up of MitraClip device implantation plus optimal standard of care therapy
2568334|NCT02444052|Experimental|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
2568335|NCT02444052|Experimental|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
2568436|NCT02443246|Experimental|Vitamin D deficiency|Group 1
2568441|NCT02443246|Experimental|Vitamin D deficiency (Low)|Group 2
2568471|NCT02442960|Active Comparator|Cohort 1|Herbal treatment (SA100) 500 mg/day (250 mg twice per day)
2568479|NCT02442960|Active Comparator|Cohort 2|Herbal treatment (SA100) 1.5 g/day (750 mg twice per day)
2568521|NCT02442778|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
2568522|NCT02442778|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
2568524|NCT02442778|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
2568623|NCT02442219||Coeliac|Persons with coeliac disease on a gluten free diet where diagnosis is confirmed by duodenal biopsy.
2568624|NCT02442219||Non coeliac gluten sensitive|Persons on a gluten free diet where coeliac disease is excluded by duodenal biopsy.
2568625|NCT02442219||Healthy control group|Persons on a gluten containing diet without known coeliac disease.
2568668|NCT02441933|Active Comparator|control group|
2568670|NCT02441933|Experimental|carboplatin group|
2568730|NCT02441478|Experimental|Patients|
2568733|NCT02441478|Active Comparator|Controls|
2568771|NCT02441140|Experimental|Culdocentesis|"Patients with known or highly likely ovarian cancer (i.e. highly elevated CA-125, ascites, pelvic mass) scheduled for cytoreductive surgery will be identified during preoperative consultation and offered participation in the study.~During Surgery:~Blood Collection~Vaginal Swab~Chromopertubation~Culdocentesis~Tissue Collection"
2568826|NCT02440750|Experimental|Dienogest|Women selected for operative hysteroscopy that received for 21 days dienogest 2 mg/die
2568827|NCT02440750|Experimental|Ulipristal acetate|Women selected for operative hysteroscopy that received for 21 days ulipristal acetate 5 mg/die
3172662|NCT00602901|Active Comparator|Usual Medical Care|Usual medical care - (Celebrex, Aleve, Bextra, Naproxen)
3172663|NCT00602914|Experimental|1|10 healthy volunteers will receive 0.1 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
3172664|NCT00602914|Experimental|2|10 Type II DM subject will receive 0.2 U/kg. Once administered with a conventional needle (SQ) and then with MicronJet needle (ID) in a randomized order
3172665|NCT00602940|Experimental|1|Active acupuncture treatment
3172666|NCT00602940|Sham Comparator|2|Sham acupuncture treatment
3172667|NCT00602966||Slow Freeze|
3172668|NCT00602966||Vitrification|
3172669|NCT00603005|Experimental|1|
3172670|NCT00603005|Experimental|2|
3172671|NCT00603005|Experimental|3|
3172672|NCT00603005|Experimental|4|
3172673|NCT00603031|Experimental|GLP-1|time -30-90 min: Continuous infusion with GLP-1 (1,2pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3207989|NCT00970645|Active Comparator|traditional mediastinoscopy/thoracoscopy|Traditional Mediastinoscopy used to detect or stage lung cancers.
2567895|NCT02446951||ED Jaundice Patients|Patients presenting to the ED in either the implementation period or pre-implementation period.
2567940|NCT02446821|Experimental|VeraCept IUD System|All women will receive VeraCept.
2567983|NCT02446470|Experimental|Sinus Tarsi approach|The Sinus Tarsi approach is the surgical approach for the incision.
2567985|NCT02446470|Active Comparator|Extensile Lateral approach|The Extensile Lateral approach is the surgical approach for the incision.
2568036|NCT02446301|Experimental|Period I (reference drug)|Before administration of investigational products, subjects should be fasted for 10 hours. On the dosing day, subjects will be confined after administration and won't be discharged until after completion of sample collections for 24 hours following dosing in Period I (Bain® IM injection).
2568038|NCT02446301|Experimental|Period II (Test drug)|Subjects will be back to the clinical site to join Period II (SDE IM injection) and will be discharged after completion for sample collections for 24 hours post drug administration.
2568082|NCT02445885|Experimental|Acute PCI|Acute re-opening of the occluded coronary artery including premedication as for primary PCI within 12 hours
2568084|NCT02445885|Active Comparator|Subacute PCI|Standard subacute re-opening of the occluded coronary artery including premedication as for subacute PCI within 72 hours
2568132|NCT02445664|Experimental|Video intervention|A tablet-administered educational video (10 minutes duration).
2568137|NCT02445664|No Intervention|Control|No intervention (no video)
3207990|NCT00970645|Active Comparator|EBUS/EUS|Minimal invasive technique for staging/detecting lung cancer.
2568238|NCT02444689|Experimental|Electronic Media Application|Participants will receive an age-appropriate behavioral intervention designed to promote weight loss, improved diet quality, and exercise.
2568241|NCT02444689|Active Comparator|Control|Participants will receive standard of care education and feedback on how to implement a heart healthy lifestyle to promote weight loss, improved diet quality and exercise.
2568275|NCT02444442|Active Comparator|Renal Denervation|participants randomised to undergo renal denervation
2568276|NCT02444442|Sham Comparator|Sham control|participants randomised to undergo sham procedure
2568296|NCT02444208|Experimental|Cocaine Inhibitory Control Training|This group will receive active inhibitory control training.
2568302|NCT02444208|Placebo Comparator|Neutral Inhibitory Control Training|This group will receive neutral inhibitory control training.
2568340|NCT02443974|Experimental|Knee brace group|Patients received knee brace with hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
2568341|NCT02443974|Experimental|Knee sleeve group|Patients received knee sleeve without hinges (Fisiotensor®) and were instructed to use it in daily activities, every day, during six months
2568342|NCT02443974|No Intervention|Control group|Keep medication usual
2568351|NCT02443727|Experimental|Intranasal oxytocin group|Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).
2568352|NCT02443727|Placebo Comparator|Placebo group|"The placebo is identical to the oxytocin formulation with the exception of the active compound.~Participants will self-administer three puffs per nostril of placebo (6 puffs total)."
2568495|NCT02443116|Placebo Comparator|Cohort 1 - Placebo|Cohort 1 - Placebo
2568497|NCT02443116|Experimental|Cohort 1 - NGM282 3mg|Cohort 1 - NGM282 3mg
2568499|NCT02443116|Experimental|Cohort 1 - NGM282 6mg|Cohort 1 - NGM282 6mg
2568501|NCT02443116|Experimental|Cohort 2 - NGM282 0.3mg|Cohort 2 - NGM282 0.3mg
2568502|NCT02443116|Placebo Comparator|Cohort 2 - NGM282 1mg|Cohort 2 - NGM282 1mg
2568503|NCT02443116|Experimental|Cohort 2 - NGM282 3mg|Cohort 2 - NGM282 3mg
2568504|NCT02443116|Experimental|Cohort 3 - NGM282 1mg|Cohort 3 - NGM282 1mg
2568505|NCT02443116|Placebo Comparator|Cohort 4 - Placebo|Cohort 4 - Placebo
2568506|NCT02443116|Experimental|Cohort 4 - NGM282 1mg|Cohort 4 - NGM282 1mg
2568567|NCT02442544|Placebo Comparator|Placebo|maltodextrin 3.3 g orally/ day for 12 weeks
2568571|NCT02442544|Experimental|Prebiotic|1:1 oligofructose: inulin 8 g orally /day for 12 weeks
3207991|NCT00970658|Experimental|Salonsip|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
2568698|NCT02441751||bleeding|intraoperative blood loss > 500 ml
2568700|NCT02441751||no bleeding|intraoperative blood loss < 500 ml
2568754|NCT02441387||Antidepressant treatment|"According to their previous treatment history and clinical presentation, patients may take:~Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year."
2568755|NCT02441387||Antidepressant treatment & Psychoeducation intervention|Antidepressant treatment and psych education program (10 weekly sessions).
3207992|NCT00970658|Active Comparator|Sabiá|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
2568868|NCT02440711|Experimental|mRSF-ESF|Study participants in Arm 1 will first receive the Modified running specific foot (mRSF) and then the Energy storing foot (ESF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
2568870|NCT02440711|Experimental|ESF-mRSF|Study participants in Arm 2 will first receive the Energy storing foot (ESF) and then the Modified running specific foot (mRSF). Outcomes will be assessed (in each condition) after 1 month of use. Order of interventions will be randomly assigned.
2568898|NCT02440230|Experimental|OFS + Anastrozole|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Anastrozole.
2568900|NCT02440230|Active Comparator|OFS + Exemestane|Patients who were anticipated to receive adjuvant OFS+AI endocrine therapy according to MDT discussion results were randomized to this arm,they will receive OFS+Exemestane.
3208893|NCT00979108|Active Comparator|Standard exercise|Subjects will be instructed in neck and postural exercises.
2567862|NCT02447315|Experimental|Treatment Sequence CADBB|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence CADBB. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
2567867|NCT02447315|Experimental|Treatment Sequence DCBAA|Subjects receive a single dose out of 4 oral doses of study drug (pilocarpine or matching placebo) per day for 5 subsequent days in the sequence DCBAA. Treatment A: pilocarpine low dose, Treatment B: pilocarpine medium dose, Treatment C: pilocarpine high dose, Treatment D: Placebo
3207993|NCT00970697|Experimental|becaplermin gel|application of a continuous thin layer of becaplermin gel (Regranex Gel®) during 8 weeks. The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment.
3207994|NCT00970697|Active Comparator|Duoderm Hydrogel™|application of a continuous thin layer of hydrogel dressing (Duoderm Hydrogel®), during 8 weeks. Duoderm Hydrogel™ is a sodium carboxymethylcellulose aqueous-based gel, similar in composition to becaplermin excipient.
3207995|NCT00970710|Experimental|Lifestyle counseling|VACOPP (Vaasa Childhood Obesity Primary Prevention Study): Intensified lifestyle counseling including physical activity and nutritional information beginning during maternity health care and continuing during child health care clinic visits.
2568166|NCT02445183||Lung Cancer|Confirmed diagnosis of lung cancer
2568172|NCT02445183||No Lung Cancer Controls|Unconfirmed lung cancer diagnosis, false positive
2568211|NCT02445066|Other|Open label|Vitamin D3 - 4,000 IU/day for 4 months
2568242|NCT02444806|Active Comparator|Full Polysomnography|Patients will have NIV settings established using overnight full polysomnography.
2568243|NCT02444806|Active Comparator|Oximetry-capnography|Patients will have NIV settings established using only Oximetry-capnography and subjective sleep comfort.
2568279|NCT02444403|Other|Police Education Program (PEP)|The entire police force mandated for periodic refresher training will be assigned to classes which receive one PEP course over 2 years.
3207996|NCT00970723|Experimental|intensive treatment|with a systematic screening for sleep apnea and/or uncontrolled high blood pressure, and intensified intervention on both anomalies if detected
3207997|NCT00970723|Active Comparator|conventional treatment|in accordance with national guidelines
3207998|NCT00970749||history of chlamydia infection|Women who self-reported a history of cervical infection with Chlamydia trachomatis
3207999|NCT00970749||no history of chlamydia infection|Women who self-reported no history of cervical infection with Chlamydia trachomatis
3208000|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.1 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
3208001|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.15 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
3208002|NCT00970762|Experimental|Rocuronium 0.6 INT, 0.2 MNT|Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
3208003|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.1 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium.
3208004|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.15 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium.
3208005|NCT00970762|Experimental|Rocuronium 0.9 INT, 0.2 MNT|Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium.
3208006|NCT00970762|Active Comparator|Vecuronium 0.1 INT, 0.025 MNT|Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium.
2568722|NCT02441569|Experimental|Common factors intervention|Children and parents in this arm will be cared for by a provider who has received brief training in common factors patient engagement skills (the intervention) for use in addition to standard anxiety-related advice. Thus this arm will receive common factors engagement training for provider.
2568724|NCT02441569|Active Comparator|Control|Children and parents in this arm will be cared for by a provider who is able to offer standard pediatric anxiety-related advice (the control intervention). Families will receive standard pediatric advice for childhood anxiety.
3208007|NCT00970775|Experimental|1. AZD2423|
3208008|NCT00970775|Placebo Comparator|2. Placebo|
2568859|NCT02440555||patients included|fulfill the self-administered questionnaire.
2569006|NCT02440035|Experimental|Group 1|Two subsequent Intramuscular injections of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
2569009|NCT02440035|Experimental|Group 2|Intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1, an intramuscular injection of placebo control on Day 85 and an injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 169.
2569012|NCT02440035|Experimental|Group 3|One intramuscular injection of Ad35.RSV.FA2 (1x10^11 vp) on Day 1 and an intramuscular injection of placebo control on Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 vp) on Day 169.
2569013|NCT02440035|Experimental|Group 4|Two subsequent intramuscular injections of placebo control on Day 1, Day 85 and an intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169.
3208009|NCT00970788|No Intervention|verbal group|Verbal description of goals of care.
3208010|NCT00970788|Experimental|Video group|Video decision aid.
3208011|NCT00970827|Active Comparator|1|Leg postconditioning
3208012|NCT00970827|Active Comparator|2|Arm postconditioning
3208013|NCT00970827|Placebo Comparator|3|Control group
3208014|NCT00970840|Experimental|LNS-20gM or LNS-P&L|
3208015|NCT00970866|Active Comparator|Iron and Folic Acid (IFA)|
3208016|NCT00970866|Active Comparator|Multiple Micronutrient (MMN)|
3208017|NCT00970866|Active Comparator|Lipid-based Nutrient Supplements (LNS)|
3208018|NCT00970879|Experimental|cotrimoxazole (high)|CD4 cell count≥350/mm3
3208019|NCT00970879|Active Comparator|mefloquine|CD4 cell count≥350/mm3
3208020|NCT00970879|Experimental|cotrimoxazole (low)|CD4 cell count<350/mm3
3208021|NCT00970879|Active Comparator|mefloquine & cotrimoxazole|CD4 cell count<350/mm3
2567911|NCT02447042|Experimental|5 ml/Kg|Fluid challenge with crystalloids (5 ml/Kg) infused in 5 minutes Measurment of Pmsf-arm before and after the fluid challenge
2567938|NCT02446652|Experimental|Hydralazine/Magnesium valproate + QT|This group will receive TRANSKRIP® (Hydralazine/Magnesium valproate) + Carboplatin plus Paclitaxel
2567939|NCT02446652|Placebo Comparator|placebo + QT|This group will receive placebo + Carboplatin plus Paclitaxel
2567986|NCT02446457|Experimental|Cohort I (rituximab, pembrolizumab)|Patients receive rituximab IV over 4-8 hours on days 1, 8, 15, and 22. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 16 cycles (1 year) in the absence of disease progression or unacceptable toxicity.
2567987|NCT02446457|Experimental|Cohort II (rituximab, pembrolizumab, lenalidomide)|Patients receive rituximab IV over 4-8 hours on days 1, 8 and 15 of cycle 1, and day 1 of cycle 2. Patients also receive pembrolizumab IV over 1 hour on day 2 every 3 weeks for up to 2 years, and lenalidomide PO on days 1-14 every 3 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3208022|NCT00970905|Experimental|Aprepitant & Ondansetron|
3208023|NCT00970918|Experimental|1|
2568107|NCT02445560|Experimental|Probiotic capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
2568109|NCT02445560|Experimental|Probiotic capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
2568110|NCT02445560|Experimental|Placebo capsule and Fiber sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
2568111|NCT02445560|Placebo Comparator|Placebo capsule and Placebo sachet|Participants will be randomly assigned to receive all of the following in random order: a probiotic capsule and fiber sachet daily for 2-weeks, a probiotic capsule and placebo sachet for 2-weeks, a fiber sachet and placebo capsule for 2-weeks, and placebo capsule and placebo sachet for 2-weeks. Each treatment period is separated by a 2-week washout. During each treatment period, in addition to consuming a probiotic capsule or placebo and/or a fiber sachet or placebo sachet participants will be on a controlled higher protein diet.
3208024|NCT00970931|Placebo Comparator|placebo|
3208025|NCT00970931|Experimental|chlortalidone-amiloride|
2568233|NCT02444767|Experimental|13mg Bimatoprost Insert|Subjects in this arm have 13mg Bimatoprost Ocular Inserts placed in both eyes for 7 days.
2568282|NCT02444520|Experimental|Integrated GP Care|"GP training in utilising cognitive behavioural skills during 10-minute consultations;~GP Supervision;~Audio-visual and written materials/guidelines for GP's;~Copies of self-help materials for patients;• Integrated case management discussion prior to secondary care referral. GPs will be encouraged to consult with a colleague before making a referral;~Booklets for patients once consent gained."
2568285|NCT02444520|No Intervention|Waiting List Control Group|Patients in the waiting list control group will continue to receive treatment as usual (TAU), and will be crossed over to receive 'Integrated GP Care' at 6 months post randomization.
2568330|NCT02444156|Experimental|Exercise training|All participants will receive usual care, including standard advice about diet and physical activity. In addition to usual care, participants will be asked to take part in a 12-week exercise programme. Participants will use an indoor rower (Concept 2, Model E) three times per week at Leicester Diabetes Centre. Each session will be supervised and the investigators will liaise with the participants to arrange convenient times to exercise, including mornings and evenings. The supervisors will teach the participants how to row correctly.
2568391|NCT02443545|Experimental|Group 1: Deferiprone 3 years|Patients in this group are those who were randomized to the deferiprone arm in study LA38-0411, and hence will receive deferiprone for a total of 3 years (1 year in the initial study plus 2 years in the extension study)..
2568396|NCT02443545|Experimental|Group 2: Deferiprone 2 years|Patients in this group are those who were randomized to the deferoxamine arm in study LA38-0411, and hence will receive deferiprone for 2 years (both of them in the extension study).
2568454|NCT02443168|Experimental|100-mg AG-221 oral solution + a microtracer of [14C]-AG- 221|Subjects will receive a 100 mg AG-221 to be swallowed with 240 mL of room-temperature, non-carbonated water.
2568456|NCT02443168|Experimental|100-mg AG-221 tablet + 100 micrograms [14C] AG-221|Formulated tablet containing 100 mg AG-221 + IV solution containing 100 micrograms [14C] AG-221
2568531|NCT02442583|No Intervention|Arm 1: Phase 1, Step 1|In this part, 15 early stage colorectal cancer survivors will fill out surveys and have a recorded phone interview regarding their physical activity and sedentary behaviors, to inform the creation of a brochure about sedentary behaviors.
3208026|NCT00970957|Experimental|Central RVO - Macular edema - Avastin|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
3208027|NCT00970957|Sham Comparator|Central RVO - Macular edema - Sham|Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
3208028|NCT00970957|Experimental|Branch RVO - Macular edema - Avastin|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.
2567935|NCT02446756|Experimental|acupuncture group|Acupuncture treatment was given once every other day and 20min each time for four weeks.
2567937|NCT02446756|Active Comparator|physiotherapy group|Physiotherapy treatment was given five times a week and 30min each time for four weeks.
2567964|NCT02446535|Experimental|BIA DW assessment|All patients have undergone a Clinical DW assessment. Then, they undergo HD sessions in which BIA DW is determined reducing body weight (kg): when flattening of the BIA resistance occurs, the BIA DW is achieved and compared with the Clinical DW
2568003|NCT02446353|Experimental|Megace : fed|Megace / Apetrol ES : comparator / test, fed
2568010|NCT02446353|Experimental|Apetrol ES : fed|Apetrol ES / Megace : test / comparator, fed, cross-over
2568011|NCT02446353|Experimental|Megace : fasting|Megace / Apetrol ES : comparator / test, fasting
2568015|NCT02446353|Experimental|Apetrol ES : fasting|Apetrol ES / Megace : test / comparator, fasting, cross-over
2568032|NCT02446054|Experimental|One Arm Study|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
3208029|NCT00970957|Sham Comparator|Branch RVO - Macular edema - Sham|Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.
3208030|NCT00970970||Von Hippel Lindau|Adult patients with Von Hippel-Lindau disease
3208031|NCT00970983|Active Comparator|QUART|Patients in this arm will receive quadrantectomy, axillary dissection and radiotherapy (the current standard therapy).
3208032|NCT00970983|Experimental|QURT (SN-)|Patients will receive quadrantectomy, sentinel node investigation and radiotherapy. Selective axillary dissection will be performed if sentinel node is positive.
2568193|NCT02445404|Active Comparator|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
2568197|NCT02445404|Experimental|Fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
2568357|NCT02443909|Active Comparator|first group|Patients undergoing Retrograde Intrarenal Surgery with 20w Holmium laser device who have 2-3 cm kidney stones
2568359|NCT02443909|Active Comparator|second group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power) who have 2-3 cm kidney stones
2568362|NCT02443909|Active Comparator|third group|Patients undergoing Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power) who have 2-3 cm kidney ston
2568440|NCT02443363||Patients After Kidney Transplantation|A total of 300 consecutive patients admitted to routine visit in Transplant Centre with functioning graft longer than 3 months to 10 years
2568463|NCT02443012|Experimental|Nevanac|Patients with CSME treated with argon laser photocoagulation (focal/grid laser) and Topical Gutt Nepafenac 0.1% given 8 hourly interval for 3 months
2568470|NCT02443012|Placebo Comparator|Laser|Patients with CSME treated with argon laser photocoagulation (focal/grid laser)
2568589|NCT02442739|Experimental|Ketamine|oral ketamine 0.5 mg/kg mixed with syrup
2568592|NCT02442739|Placebo Comparator|Placebo|oral placebo (syrup)
2568702|NCT02441764||Halaven|Participants who are prescribed with Halaven per approved prescribing information of Halaven.
2568767|NCT02441348||CTT group|CTT will be initiated in a prospective fashion to study population
2568834|NCT02440854||Afatinib|
2568917|NCT02440464|Experimental|Ixazomib Maintenance|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by Ixazomib maintenance
2568923|NCT02440464|Placebo Comparator|Placebo|Allogeneic HSCT and Fludarabine/Melphalan/Bortezomib conditioning followed by placebo maintenance.
2569005|NCT02439697|Experimental|Darbepoetin alfa (NESP®) same dose|Patients on stable low dose Aranesp® (darbepoetin alfa manufactured by Amgen®) (on 20mcg preparations or on 40mcg every 2 weeks or less) will be converted to the same dose of NESP® (darbepoetin alfa manufactured by Kirin®)
2569007|NCT02439697|Experimental|Extended dosing Darbepoetin alfa (NESP®)|Patients on stable dose of Aranesp® (darbepoetin alfa manufactured by Amgen®) will be converted to higher dose preparation of NESP® (darbepoetin alfa manufactured by Kirin®) 40 or 120 mcg preparations) with extended dosing intervals. The total dose of Darbepoetin alpha remains the same.
2569010|NCT02439697|Experimental|Darbepoetin alfa (NESP®) 120mcg|Patients on Aranesp® 100 mcg preparation (darbepoetin alfa manufactured by Amgen®) will be switched to the NESP® (darbepoetin alfa manufactured by Kirin®)120mcg preparation with slight increase in dosing interval according to the conversion
3208033|NCT00970996|Experimental|Biochemotherapy|Abraxane with Cisplatin, Temozolomide, interleukin-2 and interferon a2b
3208034|NCT00971009|Experimental|OPPC service|A practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
3208894|NCT00979108|Experimental|Over-door traction and exercise.|Subjects will receive traction utilizing an over-the-door traction unit in addition to neck and postural exercises.
2569267|NCT02437786|Experimental|GRAZAX|GRAZAX
2569310|NCT02437474||Omnivorous diet|Participants are consuming meat, fish, milk/milk products, eggs, plant products.
2569317|NCT02437474||Lacto-ovo-vegetarian diet|Participants are consuming milk/milk products, eggs, plant products but no meat, fish or by-products.
2569324|NCT02437474||Vegan diet|Participants are consuming plant products but no meat, fish, milk/milk products, eggs or by-products as well as honey.
2569367|NCT02437097|Experimental|Aerobic Exercise|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 - their age. The aerobic exercise will utilize a Monarch 818E Monarch Lower Body Ergometer (Monark Exercise, Stockholm, Sweden). Participant's heart rate will be monitored using Polar heart rate monitor.
2569375|NCT02437097|Experimental|Video Gaming|Participants will play Brain Age: Train Your Brain in Minutes a Day! on Nintendo 3DS for 30 minutes in a seated resting position.
2569379|NCT02437097|Experimental|Aerobic Exercise and Video Gaming|Participants will perform 30 minutes of cycling at an intensity of 60 to 70% of maximum heart rate based on 220 minus their age on a Monarch ergometer while playing Brain Age: Train Your Brain in Minutes a Day! on a Nintendo 3DS. Participant's heart rate will be monitored using Polar heart rate.
2569385|NCT02437097|Placebo Comparator|Control|Participants will sit quietly for 30 minutes
2567941|NCT02446782|Experimental|Cefazolin|A single dose of intravenous cefazolin 2 gms will be administered over 10 minutes, dissolved in 100 mL of normal saline between 15 and 30 minutes before the incision. This will be preceded by an intradermal test dose to check for hypersensitivity to the drug. If hypersensitivity is present, the patient will be administered a single dose of intravenous Clindamycin 900 mg.
2567942|NCT02446782|Placebo Comparator|saline|100 mL normal saline will be administered intravenously over a period of 10 minutes between 15 and 30 minutes before the incision. An intradermal test dose with normal saline will be administered to this group.
3208035|NCT00971009|Experimental|WebChoice IHCA|WebChoice is an interactive health communications application (IHCA) that in addition to offer a practice-integrated nurse administered online patient-provider communication (OPPC) service, allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
3208036|NCT00971009|No Intervention|Control group|The control group receives usual care
2568073|NCT02445937|No Intervention|Control|The control group will receive usual care, in which the frequency and content of physician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
2568075|NCT02445937|Experimental|Behavioral: The PARTNER II Intervention|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
2568115|NCT02445703|Experimental|Group 1 (HAV + HAV)|"Intervention: Inactivated Hepatitis A vaccine (HAV);~Subjects in this group each received 2 doses of inactivated HAV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
2568116|NCT02445703|Experimental|Group 2 (HAV + HABV)|"Intervention: Inactivated Hepatitis A vaccine (HAV) and Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 1 dose of inactivated HAV at day 0, and 1 dose of HABV at month 6.~Route of administration: intramuscular injection in deltoid region;"
2568125|NCT02445703|Experimental|Group 3 (HABV + HABV)|"Intervention: Combined hepatitis A and hepatitis B vaccine (HABV);~Subjects in this group each received 2 doses of HABV with a 6-month interval (day 0, month 6);~Route of administration: intramuscular injection in deltoid region;"
2568161|NCT02445261|Active Comparator|normal growth|120 woman with normal fetal growth will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations were assessed
2568162|NCT02445261|Active Comparator|growth restricted group|70 woman with l growth restricted fetus will be subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound will be done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone. UA resistance indices, number of fetal kicks, the loss of acceleration and variability, and the appearance of decelerations
2568213|NCT02445092|Experimental|Catheter prewashing|"Intervention: prewashing the catheter before IUI.~450 patients randomly included in this group will have their insemination catheter prewashed with the same media used to wash the sperm, prior to performing the insemination using the washed catheter."
2568214|NCT02445092|No Intervention|Control group|450 patients randomly assigned in this group will have their insemination performed routinely, without washing the insemination catheter..
2568248|NCT02444754||Health services research (surveys, questionnaires)|Patients complete survey items across a number of domains (patient characteristics, access to health care, perceived quality of care, clinical trial knowledge and attitudes, and cancer related health needs). Patients also complete questionnaires to obtain demographics information including age, education, race and ethnicity, marital status, employment status, insurance coverage, and income, as well as health status/indicators. Cancer-related characteristics, including diagnosis, stage, time since diagnosis, and treatments received are obtained self-report and patients' medical records.
2568316|NCT02444338|Active Comparator|Control Group|optimal standard of care therapy
2568317|NCT02444338|Experimental|Device Group|MitraClip device plus optimal standard of care therapy
3208037|NCT00971022||Low-income Populations|
3208038|NCT00971035|Experimental|A|
3208039|NCT00971035|Experimental|B|
3208040|NCT00971035|Experimental|C|
2568942|NCT02440100|Experimental|Multiple Doses PF-06648671 (Cohort1)|Healthy subjects receive 14-day repeated dose once a day at 4 mg of PF-06648671 or matching placebo
2568943|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 2)|Healthy subject receive 14-day repeated dose once a day at 12 mg of PF-06648671 or matching placebo
2568945|NCT02440100|Experimental|Multiple doses PF-06648671 (cohort 3)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo and CSF LP is collected at baseline and steady state predose on day 1 and 14
2568947|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 4)|Healthy subject receive 14-day repeated dose once a day at 40 mg of PF-06648671 or matching placebo
2568948|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 5)|Healthy subject receive 14-day repeated dose once a day at 100 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours after last dosing on day 14
2568949|NCT02440100|Experimental|Multiple Doses in Healthy Elderly (cohort 7)|Healthy Elderly subjects receive 14-day repeated dose once a day at MTD PF-06648671 defined in healthy adult subjects (part 1)
3208041|NCT00971035|Placebo Comparator|D|
3208042|NCT00971061|Experimental|MSPI|Molteno single-plate implant
2567945|NCT02446795|Placebo Comparator|Placebo Arm|Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).
3208043|NCT00971061|Active Comparator|AVI|Ahmed valve implant
3208044|NCT00971074|Experimental|Hylan G-F 20|Single injection of Hylan G-F 20 into the affected knee.
2568174|NCT02445300|Active Comparator|AQUACEL® Ag Surgical dressing|AQUACEL® Ag Surgical dressing is used to cover the surgical wound in the OR. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer.
2568176|NCT02445300|Active Comparator|Sofra-Tulla® dressing|The Sofra-Tulle® dressing was used in the OR and routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine.
3208045|NCT00971074|Sham Comparator|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
2568258|NCT02444728|Active Comparator|Group1:Hydroxychloroquine|Hydroxychloroquine: 100 mg tablets by mouth, 400mg everyday for 12 months Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months
2568260|NCT02444728|Active Comparator|Group 2:Cyclophosphamide|"Cyclophosphamide, Azathioprine & Methylprednisolone Cyclophosphamide: 200mg powder intravenous infusion, 1000mg every month for 6 month.~Azathioprine: 100 mg tablets by mouth, everyday for 6 months. Methylprednisolone: 4 mg tablets by mouth, 40-50mg everyday and tapering for 12 months"
2568358|NCT02444013|Active Comparator|Folic acid|Oral folic acid (5 mg, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
2568361|NCT02444013|Placebo Comparator|Placebo|Oral placebo (1 tablet, tid) were given at least two days before CTA/angiography/angioplasty and continued for two days after.
3208046|NCT00971087|Other|Biopsy|subjects presenting for a breast biopsy procedure, subject will be imaged before her biopsy procedure with the investigational 2D plus 3D mammography system
3208047|NCT00971087|Other|screening|subjects presenting for routine asymptomatic mammograms and will then have an investigational 2D plus 3D mammogram
2568584|NCT02442518||women with placenta praevia|women with placenta previa diagnosed at antenatal ultrasound in the third trimester of pregnancy (lower placental edge within 20 mm from the internal os above 26 week's gestation)
2568637|NCT02442193|Experimental|Individual Placement and Support|Individual Placement and Support
2568640|NCT02442193|No Intervention|Treatment as Usual|Treatment as Usual is comprised of routine clinical care.
2568715|NCT02441816|Other|Eylea Treatment|The intravitreal dose of Eylea will be 2mg (in 0.05ml) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks in the first year of treatment before applying a treat and extend paradigm to patient visits in year 2. This is an open-label study.
2568775|NCT02441231|Experimental|Probiotic Group|Visbiome probiotic group (900 billion bacteria daily; 2 sachets daily)
2568779|NCT02441231|Placebo Comparator|Placebo Group|Placebo comparator group
2568833|NCT02440815|Other|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
2568920|NCT02440256|Other|Cluster 1|Cluster 1 is the first OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the sixth month of the trial. Cluster 1 will be a 'no intervention' arm in the first 6 months of the study, and will cross-over to an experimental arm for months 6-24.
2568925|NCT02440256|Other|Cluster 2|Cluster 2 is the second OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the twelfth month of the trial. Cluster 2 will be a 'no intervention' arm in the first 12 months of the study, and will cross-over to a experimental arm for month 12-24.
2568926|NCT02440256|Other|Cluster 3|Cluster 3 is the final OST cluster (with an estimated 15-16 OST sites) to receive the 'Expanded HIV care in Opioid Substitution Treatment' intervention, to be administered during the 18th month of the trial. As such, Cluster 3 will be a 'no intervention' arm in the first 18 months of the study, and will cross-over to an experimental arm for months 18-24.
2568973|NCT02439931|Experimental|Remote psychosocial intervention|10 sessions of remotely delivered psychoeducation and support
2569020|NCT02439632|Experimental|prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet without active components."
2569021|NCT02439632|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.~Placebo of prulifloxacin film-coated tablet, without active components."
2569105|NCT02438956|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
2569106|NCT02438956|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
3208048|NCT00971100|Experimental|low dose of antigen + low dose of adjuvant|
3208049|NCT00971100|Experimental|high dose of antigen + high dose of adjuvant|
3208050|NCT00971100|Experimental|high dose of antigen|
3208051|NCT00971113|Experimental|sc-FOS+Sideritis euboea group|Jelly supplemented with short chain fructooligosaccharides and Sideritis euboea extract
3208052|NCT00971113|Placebo Comparator|placebo group|Jelly without short-chain fructooligosaccharides and Sideritis euboea
3208053|NCT00971126|Experimental|Single Group Assignment|
3208054|NCT00971139|Experimental|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
3208055|NCT00971139|No Intervention|Control group|Patients receiving usual care
3208056|NCT00971152|Active Comparator|450 IU daily dose of gonadotrophin|
3208057|NCT00971152|Experimental|600 IU daily dose of gonadotrophin|
3208058|NCT00971165|Active Comparator|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily for 18 months
3208059|NCT00971165|Experimental|losartan|Oral losartan up to 100 mg daily, once a day, for 18 month
2567975|NCT02446509|Experimental|Experimental Group|The experimental group will receive a 7-week group psychoeducation intervention. Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
2567977|NCT02446509|Active Comparator|Wait List Control Group|Subjects in the wait list control group will receive the same 7 psychoeducation sessions after the experimental group receives these sessions.
2568006|NCT02446327|Other|Diastolic heart failure cohort|This is a prospective cohort of patients with diastolic heart failure. Blood sampling for biomarker assessment
2568059|NCT02446145|Experimental|Experimental intervention arm|"Eltrombopag daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
2568068|NCT02446145|Placebo Comparator|Control intervention arm|"Placebo daily from day 1: 200 mg/day p.o. (100 mg for east asian patients) dose modification 100 mg up to 300 mg/d p.o. (50 - 150 mg for east asian patients)~concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes~one cycle lasts 28 days"
3208060|NCT00971191|Experimental|treatment|Patients treated with brief exposure to PF-00299804 prior to surgical resection
2568190|NCT02445170||Below-knee amputees|The present group consists of diabetic below-knee prosthetic user
2568196|NCT02445170||Transmetatarsal amputees|The present group consists of diabetic transmetatarsal amputees
3208895|NCT00979108|Experimental|Mechanical traction and exercise|Mechanical cervical traction will be utilized in addition to neck and postural exercises.
2568271|NCT02444598|Experimental|Negative-pressure wound therapy|Vaccum Assisted Closure device. Patients will receive negative-pressure wound therapy according to manufacturer treatment guidelines.
2568272|NCT02444598|Active Comparator|Standard|Patients will be treated with conventional wound dressings according to local treatment protocols.
2568309|NCT02444273|No Intervention|Control Group|Subjects will receive standard care both pre and post transplant.
2568312|NCT02444273|Experimental|Exercise Group|Subjects will receive a personalized home exercise program and regular phone calls from a therapist to monitor and promote activity.
2568353|NCT02443961|Experimental|Mesenchymal Stem Cell (MSC) therapy|There will only be one treatment arm to evaluate the security of the treatment with MSC.
2568388|NCT02443558|Experimental|Complete Injury|"Patients suffering from complete injury at the cervical spinal cord level (ASIA Impairment Scale A).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms."
2568392|NCT02443558|Experimental|Incomplete Injury|"Patients suffering from incomplete injury at the cervical spinal cord level (ASIA Impairment Scale B,C,D,E).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
2568398|NCT02443558|Active Comparator|Non-cervical injury|"Patients suffering from complete or incomplete injury of the spinal cord at a level other than the cervical (thoracic or lumbar).~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
2568401|NCT02443558|Active Comparator|Healthy participants|"Healthy participants, age and sex matched to those of the other Arms.~Brain-Computer Interface control of robotic arms. MERCURY v2.0 robotic arms"
2568451|NCT02443220|Experimental|distal-proximal group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu"
2568452|NCT02443220|Active Comparator|regional group|"TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Juque"
2568453|NCT02443220|Sham Comparator|control group|"no TEAS (transcutaneous electric acupoint stimulation) on Danzhong and Hegu ."
2568507|NCT02442908|Experimental|NF Cachexia|Nutrifriend Cachexia, an Omega-3 enriched fruit juice (non complete dietary formula).
2568508|NCT02442908|Placebo Comparator|Placebo|An isocaloric placebo comparator
2568530|NCT02442609||patient|patient schedulled for elective surgery, adult (> 18yrs), non emergency procedure, able to read questionaire
2568600|NCT02442466|Experimental|Endothelin receptor B inhibitor BQ-788|Intra-lesion administration of an Endothelin Receptor B inhibitor (BQ-788)
2568606|NCT02442466|Experimental|PBS|Intra-lesion administration of vehicle
2568634|NCT02442089|No Intervention|No Intervention|The intervention arm subjects will not receive the automated interactive voice reminder before their appointment.
2568639|NCT02442089|Experimental|Intervention|The intervention arm subjects will receive the automated interactive voice reminder before their appointment.
2568708|NCT02441803|Experimental|Matched Sibling Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Stem cell infusion performed on Day 0."
2568709|NCT02441803|Experimental|Haploidentical Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Total body irradiation (TBI) delivered at 2Gy on Day -2. Stem cell infusion performed on Day 0. Cyclophosphamide 50 mg/kg by vein on Days +3 and +4. Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5. Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100."
2568710|NCT02441803|Experimental|Matched Unrelated Donor Group|"Salvage Chemotherapy Before Transplant: Decitabine 20 mg/m2 by vein on Days 1 - 5. Cytarabine 1 g/m2 by vein on Days 6 - 10. Idarubicin 10 mg/m2 by vein on Days 6 - 8. Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3. Fludarabine 10 mg/m2 by vein on Days -6 to -3. Clofarabine 40 mg/m2 by vein on Days -6 to -3. Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2. Stem cell infusion performed on Day 0."
2567997|NCT02446236|Experimental|Dose Escalation Study|Ibrutinib 560 mg/daily rituximab 375mg/m2 IV Day 1 Lenalidomide 10-25 mg PO days 1-21
2568057|NCT02446080|Experimental|Probiotic Group|Milk drink with probiotic culture (150 mL/daily) for 60 days.
2568065|NCT02446080|Active Comparator|Control Group|Milk drink (150 mL/daily) for 60 days.
2568135|NCT02445768|Experimental|Cognitive multisensory rehabilitation|The treatment group will receive the cognitive multisensory rehabilitation that uses motor imagery and sensory discrimination exercises
2568168|NCT02445365|Experimental|Active RIC|Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
2568173|NCT02445365|Sham Comparator|Sham|As above with a cuff pressure of 20 mmHg
2568251|NCT02444624||not necrotizing enterocolitis group|not necrotizing enterocolitis preterm neonates matched with necrotizing enterocolitis preterm neonates
2568254|NCT02444624||necrotizing enterocolitis group|necrotizing enterocolitis preterm neonates of gestational age less than or equal to 31+6 weeks of amenorrhoea with confirmed NEC diagnosis (Bell stage II or III)
2568297|NCT02444377|Experimental|High-intensity interval -2min|5 bouts of 2 min cycling at varying intensities of VO2peak (80-100%) with 1 min recovery.
2568301|NCT02444377|Experimental|High-intensity interval -1min|10 bouts of 1 min cycling at 90% of VO2peak with 1 min rest periods
2568307|NCT02444377|No Intervention|Control|No exercise
2568347|NCT02444000|Experimental|experimental|Administration of 6 cycles of PCV chemotherapy PCV chemotherapy is given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
2568348|NCT02444000|Active Comparator|control|radiotherapy followed by 6 cycles of PCV chemotherapy given as: Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally
2568394|NCT02443584|Other|4-Week Group|Pharmacogenetic testing released to physician at 4 weeks following enrollment into study
2568397|NCT02443584|Other|12-Week Group|Pharmacogenetic testing released to physician at 12 weeks following enrollment into study
2568415|NCT02443259||late preterms from pre eclamptic mothers|late preterms born to pre eclamptic mothers
2568421|NCT02443259||late preterms|late preterm neonates
2568483|NCT02443142|Experimental|Ibuprofen|Ibuprofen is a nonselective NSAID that inhibits both COX-1 and COX-2 isoenzymes. COX-2 inhibition prevents arachidonic acid from converting to vasoactive prostaglandins and reactive oxygen species in brain cell. The analgesic, antipyretic, and antiinflammatory activity of ibuprofen operates mainly through inhibition of COX-2. The experimental treatment oral doses of either ibuprofen (800 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
2568485|NCT02443142|Active Comparator|Acetaminophen|Acetaminophen is a poor inhibitor of both COX isoenzymes in the CNS and has significantly weaker antiinflammatory effects than NSAIDs. Acetaminophen does not inhibit COX in peripheral tissues and is less effective in the presence of peroxides. The active comparator treatment is oral doses of acetaminophen (1000 mg three times per day). Subjects will receive the first medication dose in the emergency department and will be given the remaining 5 doses to take over 48 hours as outpatients.
2568543|NCT02442713|Experimental|fluvoxamine|fluvoxamine: 50-300mg/day
2568643|NCT02442388|Experimental|Hand file|Instrumentation technique
2568646|NCT02442388|Experimental|ProTaper file|Instrumentation technique
2568651|NCT02442388|Experimental|Wave-One file|Instrumentation technique
2568693|NCT02441725|Other|Pulmonary Rehabilitation Patients|"Validation of the 1-minute sit-to-stand test; for participants who consent including a extended daily assessment period of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients (≥40 years of age) from two pulmonary rehabilitation clinics (Klinik Barmelweid and Zürcher Höhenklinik Wald)"
2568696|NCT02441725|Other|Acute Care Hospital Patients|"Validation of the 1-minute sit-to-stand test, including daily assessment of physical activity and patient-reported symptoms of exacerbations:~Male and female COPD inpatients from two acute care hospitals (≥40 years of age; Stadtspital Waid and Spital Uster)"
2568740|NCT02441426||Bangladesh|"Birth cohort study community in Bangladesh is urban, and located in the Mirpur neighborhood of Dhaka.~Case control study is being conducted in the same catchment area. Cases defined as children 6-24 months of age with <-2WAZ (weight for age) score, controls are age and community matched with >-1WAZ."
2568743|NCT02441426||Brazil|"Birth cohort study community in Brazil is urban, and located within the Papoco area of Fortaleza.~Case control study is being conducted in the same area as the cohort study. Cases are children 6 - 24 months of age, with <-2 WAZ (weight for age) score, controls are age and community matched children with >-1 WAZ."
2568746|NCT02441426||India|Birth cohort study community in India is urban, and located in the southern state of Tamil Nadu, specifically in Vellore.
2568747|NCT02441426||Nepal|Birth cohort study community in Nepal is semi-urban, and located in Bhaktapur, approximately 25km from Kathmandu.
2568748|NCT02441426||Pakistan|Birth cohort study community in Pakistan is rural, and located in Naushero Feroze, Sindh.
2568749|NCT02441426||Peru|Birth cohort study community in Peru is rural, and located approximately 15km from Iquitos in Loreto.
2568750|NCT02441426||South Africa|Birth cohort study community in South Africa is rural/peri-urban, and comprised of nine settlements within Limpopo Province.
2568751|NCT02441426||Tanzania|Birth cohort study community in Tanzania is rural, and located within Haydom.
2568765|NCT02441088|Experimental|PRRT with 90Y--DOTA-tyr3-Octreotide|A radiopharmaceutical, 90Y--DOTA-tyr3-Octreotide, and a renal protectant, Aminosyn II, in a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Radiopharmaceutical will be administered IV in 3 doses, 6 weeks apart, with Aminosyn II administered concomittantly with each dose. Two followup visits are required at three and 6 months following third dose of 90Y-DOTA-tyr3-Octreotide.
2569050|NCT02439398|Experimental|Allogeneic human cardiac stem cells|After randomization, subjects will received a suspension of allogeneic human cardiac stem cells (35 millions of CSCs - cell medicine) infused into the coronary artery responsible for the ischemic event.
2568009|NCT02446262|Other|Substudy 2: heat group|Participants learn about heat outcomes through conditioning
2568012|NCT02446262|Other|Substudy 2: salt group|Participants learn about salt outcomes through conditioning
2568016|NCT02446262|Other|Substudy 2: sugar group|Participants learn about sugar outcomes through conditioning
2568019|NCT02446262|Other|Substudy 3: healthy volunteers|All participants experience all outcomes, within subjects designs
2568020|NCT02446262|Other|Substudy 4: healthy volunteers|Participants are instructed to attend toward or away from the stimulus
2568021|NCT02446262|Other|Substudy 5: healthy volunteers|Participants experience both placebo and cue-based expectations within subjects
2568046|NCT02445976|Experimental|Prior Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
2568052|NCT02445976|Experimental|Prior Abiraterone and Enzalutamide|Seviteronel: given orally once daily in 28-day cycles
2568114|NCT02445638|Active Comparator|Whole egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 whole eggs for 4 weeks.
2568117|NCT02445638|Placebo Comparator|Yolk-free egg|Subjects will be provided with a daily breakfast meal containing the equivalent of 2 yolk-free eggs for 4 weeks.
2568167|NCT02445352|Active Comparator|Rosuvastatin 5mg & Placebo & Placebo|Once a day, administration of rosuvastatin 5mg and two types of placebo for 20 weeks
2568171|NCT02445352|Experimental|DP-R207 5/10mg & Placebo & Placebo|Once a day, administration of DP-R207 5/10mg and two types of placebo for 20 weeks
2568175|NCT02445352|Active Comparator|Rosuvastatin 10mg & Placebo & Placebo|Once a day, administration of rosuvastatin 10mg and two types of placebo for 20 weeks
2568177|NCT02445352|Experimental|DP-R207 10/10mg & Placebo & Placebo|Once a day, administration of DP-R207 10/10mg and two types of placebo for 20 weeks
2568179|NCT02445352|Active Comparator|Rosuvastatin 20mg & Placebo & Placebo|Once a day, administration of rosuvastatin 20mg and two types of placebo for 20 weeks
2568181|NCT02445352|Experimental|DP-R207 20/10mg & Placebo & Placebo|Once a day, administration of DP-R207 20/10mg and two types of placebo for 20 weeks
2568256|NCT02444741|Experimental|Group I, Phase I (pembrolizumab + SBRT)|Patients who exhibit a lung lesion of size and location amenable to SBRT receive pembrolizumab IV over 30 minutes on day 1. Patients also receive SBRT in 4 fractions daily on days 2-5 or either IMRT, PBRT, or 3D-CRT in 15 fractions total concurrent with pembrolizumab administration on days 1-19. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
2568259|NCT02444741|Experimental|Group I, Phase II (pembrolizumab + SBRT)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV on day 1 and SBRT on days 44-47 or IMRT, PBT, or 3D-CRT on days 43-61. Treatment with pembrolizumab repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
2568262|NCT02444741|Experimental|Group II, Phase I (pembrolizumab + IMRT, PBRT or 3D-CRT)|Patients who exhibit a lung lesion of size or location not amenable to SBRT, but amenable to WFRT receive pembrolizumab as in Group I and either IMRT, PBRT, or 3D-CRT in 15 fractions total on days 1-19 concurrent with pembrolizumab administration.
2568263|NCT02444741|Experimental|Group II, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location amenable to SBRT receive pembrolizumab IV as in Group I without XRT. At the first planned efficacy evaluation (5 weeks), patients exhibiting PD are treated with SBRT concurrent with the remaining cycles of pembrolizumab. In the event that lesion size has progressed to the point where the attending physician no longer considers SBRT safe, then the patient will be salvaged with IMRT, PBRT, or 3D-CRT and analyzed as part of the fourth treatment group.
2568264|NCT02444741|Experimental|Group III, Phase II (pembrolizumab + IMRT, PBRT, or 3D-CRT)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I and IMRT, PBRT, or 3D-CRT on days 43-61.
2568265|NCT02444741|Experimental|Group IV, Phase II (pembrolizumab + XRT upon PD)|Patients who exhibit a lung lesion with size and location not amenable to SBRT, but amenable to WFRT receive pembrolizumab IV as in Group I without XRT. The decision on when to start XRT will be assessed first at week 5 (after the second dose of pembrolizumab). If a patient has PD based on irRC then XRT will be delivered after the third dose of pembrolizumab, while patients with SD or PR will not start XRT and will continue to be followed. These patients will then have follow up CT scans 5 weeks after course 3 and then approximately every 3 months for the remainder of the trial; any patient at this point with PD will then have XRT delivered with the sixth dose of pembrolizumab.
2568266|NCT02444741|Experimental|Group V, Phase II (low dose radiation therapy)|Patients with lesions amenable to SBRT or WFRT receive pembrolizumab IV as in Group I. Patients also receive either IMRT, PBRT, or 3D-CRT in 15 fractions to the primary lesions and low dose radiation therapy to other lesions on days 43-61 or SBRT in 4 fractions to primary lesions and low dose radiation therapy to other lesions on days 44-47.
2568403|NCT02443896|Experimental|Sealant applied to molars|"All 'sealable' permanent molars will be sealed: Occlusal fissures and where appropriate, buccal pits (on lower molars) and palatal pits (on upper molars) will be sealed.~If patient compliance is adequate, a resin based sealant will be used as the first choice material. The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard."
2568404|NCT02443896|Sham Comparator|No sealant applied to molars.|No molars will be sealed.
2568461|NCT02442986||Septic Shock or severe sepsis|Septic patients on ICU with severe sepsis or septic shock.
2568466|NCT02442986||Non-Septic, Surgical Patients|Non-septic patients after surgical treatment and anesthesia on ICU.
2568477|NCT02442986||Non-Septic, Non-Surgical Patients|Patients without sepsis criteria treated on ICU, non-surgical patients.
3208896|NCT00979160|Experimental|Dasatinib|Patient will be treat at a starting dose of 20mg once daily, that can be escalated up to 100mg once daily.
2568652|NCT02442245|Sham Comparator|Control Group|The control group will be included to quantify or describe the effects of the acute exercise training but will not receive any supplement
2568742|NCT02441400||EndoStim LES Stimulation System implant.|Registry subjects whom have been implanted commercially with the EndoStim LES Stimulation System device.
3208897|NCT00979173|Experimental|AC480|Patients who are not on enzyme inducing anti-epileptic drugs (EIAEDs) and are scheduled to undergo salvage surgical resection treated with preoperative AC480 at 300 mg BID followed by post-surgical AC480 at 300 mg BID.
2568029|NCT02446184|Experimental|Fetal cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
2568030|NCT02446184|Active Comparator|Vesicoamniotic shunt|The fetal vesicoamniotic shunt is considered the standard prenatal therapy for severe LUTO. Amnioinfusion and vesicoamniotic shunt placement will be performed under ultrasound guidance.
2568031|NCT02446184|No Intervention|No fetal intervention group|Those patients that refuse fetal intervention and do not elect to terminate the pregnancy will be followed as part of the no fetal intervention group.
2568048|NCT02445989|Active Comparator|Cyclic NuvaRing CVR Use|CVR use for 3 weeks, remove for 1 week, then replace
2568053|NCT02445989|Experimental|Continuous NuvaRing CVR Use|CVR use for 4 weeks, then replace
2568120|NCT02445729|Active Comparator|Dressing Removal at 24 Hours|These patients are randomly assigned to have their dressing removed 24 hours after cesarean section.
2568123|NCT02445729|Active Comparator|Dressing Removal at 48 Hours|These patients are randomly assigned to have their dressing removed 48 hours after cesarean section.
2568183|NCT02445274|Experimental|Capsule-reserved surgical procedure|"In this group, the anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.~Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group."
2568186|NCT02445274|No Intervention|Conventional surgical procedure|In this group, the anterior lens capsule was not reserved or attached onto the posterior lens capsule.
2568216|NCT02444949|Experimental|endostar+DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)+endostar (150mg/5d; civ; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
2568218|NCT02444949|Other|DF+IMRT|patient first receive one periodicity chemotherapy(DDP (25mg/m2/d; ivgtt; d1～3)+5-FU (600mg/m2/d; ivgtt; d1～5)), then given IMRT (5 times per week, 6 weeks). After rest 4 weeks, continue to give the chemotherapy (21 days for a periodicity, 3 periodicities).
3172674|NCT00603031|Placebo Comparator|NaCl|time -30-90 min: Continuous infusion with NaCl time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3172675|NCT00603031|Experimental|GIP|time -30-90 min: Continuous infusion with GIP-1 (3,6pmol/kg/min) time 0-90 min:hyperglycemic clamp(20mmol/L) time 45 min:infusion of L-Arginine (5g).
3172676|NCT00603057||Lung Cancer Imaging Patients|Adult patients (>18 years of age)with histologically confirmed or clinically diagnosed lung cancer who require radiation therapy, with or without surgery and with or without chemotherapy.
3172677|NCT00603070||1|All physicians and nurse practitioners at 1 ambulatory care clinics
2568304|NCT02444325|No Intervention|Routine Prenatal Care|Subjects randomized to routine care will receive their care in the usual diabetic clinic attended by residents and faculty. They will receive consultation with the diabetes educator at diagnosis and as needed. Patients are seen every 2 weeks (or more by provider discretion) until 37 weeks and weekly until delivery. Visits are 10-15 minutes and focus on routine screening tests and review of blood sugar logs/medication titration. Each subject's medical chart will be reviewed for demographics, antenatal management, maternal and neonatal outcomes.
2568310|NCT02444325|Experimental|Group prenatal care|Group visits will be held every 2 weeks in a continuous cycle through a four session curriculum. Women will have weekly visits beginning at 37 weeks with traditional prenatal visits on the weeks when the group does not meet. Groups of 4-12 women will meet for two hour visits and much of that time will be spent on pregnancy, behavioral health, diabetes and nutrition education. Groups will be co-facilitated by 2 CenteringPregnancy trained providers at each site and an obstetric provider. Women may be instructed to have additional visits in the traditional clinic at the discretion of the obstetric provider.
2568364|NCT02443922|Experimental|Glimepiride|Glimepiride 2mg qam
2568372|NCT02443922|Experimental|Sitagliptin|Sitagliptin 100mg qam
2568376|NCT02443922|Active Comparator|Metformin|Metformin as prescribed
2568603|NCT02442492|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
2568608|NCT02442492|Placebo Comparator|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
2568626|NCT02442037|Experimental|UCMSC group|Human umbilical cord MSCs are administrated to patients by three intravenous infusion
2568627|NCT02442037|Other|Control group(Normal saline)|Patients will receive normal saline at the same time points as that in experimental group.
2568671|NCT02441907|Other|aflibercept treatment|aflibercept, 40 mg/mL Solution for Intravitreal Injection
2568727|NCT02441595|Experimental|MBCP intervention|The intervention involves eight 2.5 h weekly group sessions in which exercises in mindfulness are practiced and associated theory is taught to increase metacognition, emotional regulation and body awareness.
2568731|NCT02441595|Active Comparator|Control condition|Participants in the control condition are being offered a standardized course in psychoprophylaxis.
2568774|NCT02441127|Experimental|Diode laser group|In the test sites, an aluminum, gallium, and arsenide diode laser (wavelength 810 nm and power of 1W) was applied in continuous mode.
2568780|NCT02441127|Active Comparator|Scalpel control group|The surgical technique used in the control group was a FGG harvested by two horizontal and two vertical incisions by scalpel defining the area to be harvested .
2568835|NCT02440841|Experimental|fedovapagon and itraconazole|Two daily doses of fedovapagon and once daily doses of itraconazole
2568838|NCT02440841|Experimental|fedovapagon and rifampicin|Two daily doses of fedovapagon and once daily doses of rifampicin
2568905|NCT02440438|Experimental|Clostridium difficile infection|
2568963|NCT02440074|Experimental|MSV autologous transplantation|
2568033|NCT02446158|Experimental|Chlorhexidine gluconate|PD (peritoneal dialysis) paitents with daily chlorhexidine exit site care
2568034|NCT02446158|No Intervention|Control group|PD (peritoneal dialysis) patients with usual (Normal saline) exit site care
2568077|NCT02445898|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
2568079|NCT02445898|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
2568106|NCT02445677|Experimental|Active TENS|Receiving active transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
2568108|NCT02445677|Placebo Comparator|Simulated TENS|Receiving simulated transcutaneous electrical nerve stimulation (TENS) treatments during the rehabilitation sessions (only the first half of the rehabilitation period, i.e. 4 to 6 weeks.
2568160|NCT02445443||LEGION Hinge Knee System|This group will be receiving the LEGION Hinge device.
2568210|NCT02445001|Experimental|ICG loaded erythrocytes|Ability to directly visualize erythrocyte dynamics within the retinal and choroidal microcirculations would facilitate focused investigations into the relationships between vasomotion (i.e., pulsatile erythrocyte movement through capillaries) and oxygen distribution to localized tissue regions.
2568232|NCT02444819|Experimental|HM61713|Subjects who entered the study will be administered HM61713 800 mg per day.
2568280|NCT02444481|Experimental|Polygynax, antibiotic, vaginal treatment|Polygynax combinaison of nystatine, polymyxin, neomycin, Local treatment of vaginal infection during 12 days. One vaginal capsule every evening.
2568327|NCT02444104||Patients with atrial fibrillation|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with atrial fibrillation.
2568328|NCT02444104||Patients with highly reduced LV function|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with a highly reduced left ventricular function (LV function)
2568329|NCT02444104||Patients with aortic stenosis|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with severe aortic stenosis
2568331|NCT02444104||Patients with LVAD|It is Primarily a comparison of methods , non-invasive measured blood pressure versus invasively measured blood pressure and non-invasively measurement of cardiac output versus invasive cardiac output measurement in patients with left ventricular assist-device (LVAD)
3208898|NCT00979225|Experimental|Medication report|Medication reports delivered to providers at the point of care
2568446|NCT02443389||Neonates admitted to NICU|Retrospective cohort of neonates admitted to NICU with stated inclusion and exclusion criteria
2568469|NCT02442973||Control group (CG):|Standard practice group
2568476|NCT02442973||Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
2568552|NCT02442726|Active Comparator|Thermal Injury|A first degree heat injury is induced by a contact thermode (12.5 cm2; 47C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC)
2568559|NCT02442726|Sham Comparator|Sham Injury|"A sham injury is induced by a contact thermode (12.5 cm2; 38C; 420 s) applied at the skin at the lower leg. CO2-Laser stimulation (Laser Stimulation Device, SIFEC) is used to assess"
2568585|NCT02442362|Active Comparator|TOF Group|"Patients in the TOF group received chemotherapy with paclitaxel+oxaliplatin+fluorouracil"
2568588|NCT02442362|Experimental|SOX Group|The patients in the SOX group received chemotherapy with 'oxaliplatin+S1'
2568636|NCT02442154|Experimental|Early tracheostomy|To do an early tracheostomy within 24hours of admission of the severely head injured patients
2568641|NCT02442154|No Intervention|standard of care|To use the standard of care of mulago hospital for the management of the severely head injured patients
2568707|NCT02441777|Experimental|Control: Healthy|Polarization Sensitive Optical Coherence Tomography (PS-OCT) Imaging will be used to look at the nerve fiber layer (NFL) in the healthy retina.
2568769|NCT02441335||Group 1 (Preterm labor, PPROM, cervical insufficiency)|Singleton pregnancy between 20 0/7 36 6/7 weeks gestational age who is admitted with PTL or cervical insufficiency (Equal or greater than 2 cm dilated) or PPROM
2568777|NCT02441335||Group 2 (Term labor)|Admitted to the hospital with spontaneous labor (regular contractions, cervical dilation) or spontaneous rupture of membranes
2568781|NCT02441335||Group 3 (PTB-medically indicated)|Singleton pregnancy between 20 0/7 34 5/6 weeks gestational age who is admitted with a medically indicated preterm birth (IOL for abruption, non reassuring fetal heart tones, intrauterine growth restriction, preeclampsia, trauma, etc.)
2568816|NCT02440880|Placebo Comparator|CONTROL|TAP block without Dexamethasone neither intravenous nor in combination with the block
2568817|NCT02440880|Experimental|Group 2 (TD8IS)|Dexamethasone in combination with TAP block in dose of 8 mg
2568819|NCT02440880|Experimental|Group 3(TD4IS)|Dexamethasone in addition to TAP block in dose of 4 mg
2568821|NCT02440880|Experimental|Group 4 (TSID8):|Dexamethasone intravenous in addition to TAP block in dose of 8 mg
2568823|NCT02440880|Experimental|Group5(TSID4)|Dexamethasone intravenous 4mg+ TAP block
2568857|NCT02440581|No Intervention|Control, low turnover|No intervention in low turnover osteoporosis control group.
2568860|NCT02440581|Experimental|Treatment, low turnover|Low turnover osteoporosis group treated with teriparatide and cinacalcet.
2568861|NCT02440581|No Intervention|Control, high turnover|No intervention in high turnover osteoporosis control group.
2568862|NCT02440581|Experimental|Treatment, high turnover|High turnover osteoporosis group treated with alendronate.
2568915|NCT02440295||Lower Extremity Amputations|"All patients >= 18 years of age requiring Below Knee Amputation (BKA) or Above Knee Amputation (AKA) cared for by the Spectrum Health vascular surgery service will be assessed for eligibility.~Subjects with a history of allergies to iodides or iodinated contrast agents, pregnant or nursing women, subjects who are unable to provide consent, and prisoners will be excluded. Eighteen subjects will be enrolled in the pilot study. No special population subjects will be enrolled."
2568130|NCT02445521||PKU (low phe-level)|A subject diagnosed with phenylketonuria (PKU) with low phenylalanine levels, defined as 1-5 mg/dL
2568131|NCT02445521||PKU (mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with middle phenylalanine levels, defined as 6-10 mg/dL
2568138|NCT02445521||PKU (high mid phe-level)|A subject diagnosed with phenylketonuria (PKU) with high middle phenylalanine levels, defined as 11-15 mg/dL
2568142|NCT02445521||PKU (high phe-level)|A subject diagnosed with phenylketonuria (PKU) with high phenylalanine levels, defined as 16-20+ mg/dL
2568146|NCT02445521||Control|A normal subject without phenylketonuria (PKU)
2568287|NCT02444546|Experimental|Treatment (sargramostim, wild-type reovirus)|Patients receive sargramostim SC daily on days 1 and 2 and wild-type reovirus IV over 60 minutes on days 3-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
2568322|NCT02444091|Experimental|Cyclophosphamide|Cyclophosphamide, intravenous infusions four weeks apart. Six infusions in total. First infusion: 600 mg/m2. Infusions 2 to 6: 700 mg/m2
2568367|NCT02443857|Experimental|ChARMin|Single-arm only
3172678|NCT00603070||2|All physicians and nurse practitioners at 1 ambulatory care clinics
3172679|NCT00603083|Active Comparator|A|This group receive local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg 10 and 22 hours after the operation. The medicine solution is given in a catheter, wich is placed in the hip at the end of the operation.
3172680|NCT00603083|Placebo Comparator|B|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, wich is placed in the hip at the end of the operation.
3172681|NCT00603096|Experimental|1|patients will benefit from a complete polysomnography under NIV
3172682|NCT00603096|Active Comparator|2|settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas
3172683|NCT00603109|Experimental|I|Subjects receive rimonabant 20 mg per day PO
3172684|NCT00603109|Placebo Comparator|II|Subjects take placebo capsule one a day PO
3172685|NCT00603122|Experimental|1|fast ascent
3172686|NCT00603122|Active Comparator|2|slow ascent
2568726|NCT02441413|Experimental|HRCT scans|HRCT scan will be taken
2568772|NCT02441166|Other|Mastocytosis diagnosis|For each enrolled subject, 5 mL sample of peripheral blood and 1 mL sample of BM aspirate will be collected the same day to do diagnosis mastocytosis tests (quantification of the kit mutations by qPCR, plasma tryptase level, immunophenotyping of BM mastocytes by flow cytometry, BM tryptase level, degree of dilution of the BM aspirate...) using the WHO criteria as the reference standard.
2568864|NCT02440516|Active Comparator|Neurorehabilitation program|Standardized comprehensive ambulatory neurorehabilitation program
2568866|NCT02440516|Placebo Comparator|Waiting list|Waiting list
2568889|NCT02440269||A：day|the patients who receive surgery and anesthesia during 8:00 am to 6:00 pm
2568891|NCT02440269||B：night|the patients who receive surgery and anesthesia during 10:00 pm to 5:00 am next day
2568936|NCT02440152|Experimental|Deep brain stimulation|
2568990|NCT02439840||Light sedation|Light sedation is defined as RASS of +1 to -2.
2568992|NCT02439840||Deep sedation|Deep sedation is defined as RASS of -3 to -5
2569033|NCT02439541|Experimental|UCMSC group|Patients in this arm received umbilical cord MSCs by intracoronary injection
2569034|NCT02439541|No Intervention|Control group|Patients in this arm did not receive any intervention.
2569098|NCT02439112|Active Comparator|Exercise|Supervised exercise combined with home based exercise and physical activity
2569101|NCT02439112|No Intervention|Control|Usual care consisting of advice regarding exercise, physical activity, person lifting and moving.
2569133|NCT02438735||Endometrioma|Reproductive aged women diagnosed with endometrioma. Conservative follow up for six months.
2569135|NCT02438735||Healthy Controls|"Women with regular menstrual cycles and without ovarian pathology will be recruited from physicians, nurses and other staff of the same hospital.~Controls will be matched for age with the women in the endometrioma group. They will be conservatively followed up for six months."
3172687|NCT00603135|Experimental|A|
3172688|NCT00603174|Experimental|A|Intubated and mechanically ventilated infants with respiratory failure (age < 1 year old). see inclusion-exclusion criteria.
3172689|NCT00603200||Group 1|Patients with cirrhosis, who have refractory ascites requiring large volume paracentesis
3172690|NCT00603226||1|Patients diagnosed with slow coronary artery flow during coronary angiography
3172691|NCT00603226||2|Patients with normal coronary artery flow observed during coronary angiography
3172692|NCT00603317|Experimental|1|Order 1 : Firstly Amoxicillin-Acid clavulanic, and Secondly Placebo
3172693|NCT00603317|Experimental|2|Order 2 : Firstly Placebo, and Secondly Amoxicillin-Acid clavulanic
3172694|NCT00603330|Experimental|1|MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3172695|NCT00603330|Experimental|2|MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3172696|NCT00603330|Experimental|3|MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.
3172697|NCT00603343|Active Comparator|1|
3172698|NCT00603343|Placebo Comparator|2|
3172699|NCT00603356|Experimental|1|Dose Escalation
3172700|NCT00603369|Experimental|1|13 session group intervention including sexual health information, affect management skills, cognitive monitoring, and communication skills training.
3172701|NCT00603369|Active Comparator|2|2 session group intervention including sexual health information training.
3172702|NCT00603395|Other|ReCap|ReCap Total Hip Resurfacing System
3172703|NCT00603421|Experimental|1|Patient benefits from treatment as usual plus access to a crisis 24 hour phone line.
3172704|NCT00603421|Active Comparator|2|Patient benefits from treatment as usual
3172705|NCT00603434|Experimental|1|Osmotic-Release Methylphenidate
3172706|NCT00603434|Experimental|2|Osmotic-Release Methylphenidate
3172707|NCT00603434|Experimental|3|Osmotic-Release Methylphenidate
3172708|NCT00603460|Active Comparator|A|
2568078|NCT02445950|Active Comparator|Traditional counseling|Customers receive intervention via traditional phone wellness counseling. The intensive phase lasts 13 weeks and includes 5 phone calls. Change needs and goals are set during the phone calls. The independent phase lasts 13 weeks and includes 3 phone calls.
2568104|NCT02445690||Clinical remission without inflammation|Patients with Crohn's disease in clinical remission and no inflammation in the colonoscopy
2568105|NCT02445690||Clinical remission with inflammation|Patients with Crohn's disease in clinical remission and active inflammation in the colonoscopy
2568158|NCT02445456|Experimental|Ex-vivo|Patients with relatively advanced rectal cancer who are scheduled to undergo radical surgery to excise rectal tumour and mesorectum. They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery. They will then undergo surgery to excise rectal cancer. The excised specimen will be examined using the Sentimag probe and by standard histology to assess for lymph nodes ex-vivo.
2568159|NCT02445456|Experimental|In-vivo|Patients with early rectal cancer scheduled to undergo local excision of a rectal tumour by transanal endoscopic microsurgery (TEM). They will receive endoscopic Sienna+ injection (magnetic tracer) 5 days before planned surgery, and have an MRI scan to assess tracer spread. They will then undergo TEM surgery to excise the rectal cancer. During surgery the Sentimag probe will be used to locate the sentinel lymph node so it can be surgically removed. The excised specimen will be examined by standard histology.
2568203|NCT02445118||Adipose Allograft Matrix Injection|AAM injected to create a 2 to 3mm raised wheal on the proximal dorsal wrist of the non-dominant hand
2568239|NCT02444845||Study Population|Hypertensive and diabetic patients who meet eligibility criteria will be enrolled and evaluated for the presence of anemia secondary to CKD. The first visit will capture medical history including risk factors for CKD; laboratory assessments will be performed at the second and third visits to evaluate glomerular filtration rate (eGFR) and anemia profile, respectively. Participants who are not diagnosted with CKD based upon the second visit will not return for the third visit.
2568277|NCT02444507|Active Comparator|Reference Drug: Nexium|Name: Nexium powder for injection and infusion 40 mg, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
2568278|NCT02444507|Active Comparator|Test Drug: Esomelone|Name: Esomelone Powder for Solution for Injection / Infusion 40 mg Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
2568290|NCT02444195|Experimental|Guided Imagery|Guided Imagery With Audio Media
2568291|NCT02444195|No Intervention|Routine Postoperative Care|Subjects will receive routine pre-operative, intra-operative, post-operative, chemotherapy, and radiation care as dictated by pathologic diagnosis.
2568336|NCT02444065|Experimental|Cognitive Behavior Therapy (CBT)|In this arm, participants receive the Cognitive behavior therapy (CBT) intervention as an augmentative treatment to standard day hospital treatment as usual.
2568338|NCT02444065|Active Comparator|Motivational Interviewing (MI)|In this arm, participants receive the Motivational Interviewing intervention as an augmentative treatment to standard day hospital treatment as usual.
2568355|NCT02443779||Early Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
2568356|NCT02443779||Advanced Parkinson's disease patients|All subjects will undergo a complete neuro-ophthalmological examination, including assessment of best-corrected visual acuity, ocular motility, pupillary reflexes, slit-lamp biomicroscopy, intraocular pressure (IOP) measurement, and dilated fundus examination, followed by an optical coherence tomography study. Subjects will also have a DaTscan for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging. A clinical examination will also be performed in order to document motor and cognitive functioning.
2568386|NCT02443597||obese pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
2568389|NCT02443597||lean pregnant women|"With the use of trans-abdominal ultrasound, the following measurements will be recorded:~Fetal nuchal translucency thickness.~Nasal bone.~Fetal facio-maxillary angle.~The flow across the tricuspid valve as normal or regurgitated.~A-wave in the ductus venosus as normal or reversed."
2568411|NCT02443285|Active Comparator|Cefotaxime|cefotaxime 2gm every 12 hours daily for 5 days
2568414|NCT02443285|Active Comparator|Ceftriaxone|ceftriaxone 2 gm every 24 hours for 5 days.
2568464|NCT02443090|Experimental|Fispemifene 450 mg|Fispemifene capsules will be taken orally each morning immediately after eating a meal
2568475|NCT02443090|Placebo Comparator|Placebo|Placebo capsules will be taken orally each morning immediately after eating a meal
2568553|NCT02442674|Active Comparator|Tolvaptan|Tolvaptan (3.75 mg, 7.5 mg, 15 mg, 30 mg, 60 mg dose daily depending on age and weight)
2568561|NCT02442674|Placebo Comparator|Placebo|Placebo tablet matching active drug
3172709|NCT00603460|Active Comparator|B|
3172710|NCT00603499|Active Comparator|1|Magnesium chloride
3172711|NCT00603499|Placebo Comparator|2|Placebo
3172712|NCT00603551||Chemotherapy|Postmenopausal women who have been diagnosed with a breast or gynecological cancer and who have undergone chemotherapy as a result of that diagnosis
3172713|NCT00603577|Placebo Comparator|Placebo|
3172714|NCT00603577|Experimental|Xaliproden|
3172715|NCT00603603|Experimental|80% inhaled oxygen-non-rebreather|10 liters of oxygen via non re-breather mask during cesarean section and up to two hours post-operatively
3172716|NCT00603603|Active Comparator|30% inhaled oxygen-nasal cannula|2 liters of oxygen via nasal cannula (standard of care) during cesarean section only
3172719|NCT00603629||I|People with acute asthma in the Emergency department or inpatient settings
3208061|NCT00971217|Experimental|Exercise|"Participants will engage in 2 exercise sessions each week for 10 weeks. Each session will last 50 minutes and will commence with a 5 minute warm up on the bike or treadmill and conclude with a 5 minute cool down. The participants will be required to exercise on their own without interference from others. Participants will wear heart rate monitors to ensure that they are exercising to moderate intensity (70-80% of age predicted maximum heart rate).~Exercise: Aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines."
3208062|NCT00971217|Experimental|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a web-site specifically aimed at young men once per week and complete the set cognitive-behavioural tasks.
3208063|NCT00971217|Experimental|Combined Exercise/Online CBT|Participants will simultaneously par-take in both the exercise and the online CBT conditions already outlined.
3208899|NCT00979225|Experimental|Med. report plus care manager notices|Medication reports delivered to providers at the point of care and notices sent electronically to care managers
3208900|NCT00979225|No Intervention|Control|
2568368|NCT02443701|Experimental|Exercise|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).
2568375|NCT02443701|Experimental|NEMES|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump).The healthy athletes electrical stimulation group will perform the same training program described above, but strength training is associated with electrical stimulation, medium frequency current (1kHz), modulated at 70Hz, cycle Work 10%, intensity used will vary according to the capacity and tolerable for each individua. The stimulated muscle group will be the quadriceps femoris
2568378|NCT02443701|Experimental|Phototherapy|All 12 volleyball athletes performed a strength training and jump, to be held in both legs at the same time. The training will be held in a six-week period, a total of 18 training. Athletes will hold a warmup in stationary bike for 6 minutes, maximum isometric strengthening in leg extension (knee positioned at 60 ° of flexion and hip in 75 ° of flexion), 10 repetitions of 10 seconds with 30 seconds interval. After strengthening conduct a complete rest 5 minutes and jump training countermovement in 5 sets of 10 jumps (1 minute interval between each jump). The 12 healthy athletes participating in the phototherapy group will undergo a phototherapy protocol before performing the strength and jump training. Phototherapy will be conducted through a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J. The application sites will be six points on the belly of the quadriceps femoris muscles bilaterally.
2568417|NCT02443376||Hemodialysis patients|Stable end-stage renal disease patients on maintenance conventional hemodialysis received 4-5 hours of treatment thrice weekly. Pulse wave velocity and central aortic pressure was measured before and after the midweek dialysis session.Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM) was measured before the midweek dialysis session just after Complior device
2568422|NCT02443376||Healthy subjects|Medical staff: medical doctors, nurses
2568542|NCT02442635|Experimental|Condition 1|Yoga Breathing
2568546|NCT02442635|Experimental|Condition 2|Static Yoga
2568548|NCT02442635|Experimental|Condition 3|Flowing Yoga
2568591|NCT02442401|Experimental|NPWT group|Negative pressure wound therapy was used to prevent donor site seroma formation
2568595|NCT02442401|No Intervention|Control group|Conventional method was used to the donor site
2568644|NCT02442180|Experimental|G-CSF + steroid in partial responder|Patients who are randomized to prednisolone plus G-CSF treatment group in patients with partial responder to prednisolone therapy.
2568647|NCT02442180|Placebo Comparator|Placebo + steroid in partial responder|Patients who are randomized to prednisolone plus placebo treatment group in patients with partial responder to prednisolone therapy.
2568649|NCT02442180|Experimental|G-CSF in null responder to steroid|Patients who are randomized to G-CSF treatment group in patients with null responder to prednisolone therapy.
2568653|NCT02442180|Placebo Comparator|Placebo in null responder to steroid|Patients who are randomized to placebo treatment group in patients with null responder to prednisolone therapy.
2568689|NCT02441647|Experimental|Experimental group|
2568713|NCT02441491|Experimental|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, will be given by vein once every day to try to help your blood cells grow faster."
2568760|NCT02441257|Experimental|control ventilation|patients are scheduled to receive control or spontaneous ventilation
2568830|NCT02440958|Experimental|modified FOLFIRINOX|
2568863|NCT02440529|Active Comparator|(Intervention Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management plus aid
2568865|NCT02440529|Active Comparator|(Control Group)|The discussion about how smoking cigarettes impacts patient orthopaedic management.
2568901|NCT02440282||Group A|patients undergo general anesthesia
2568902|NCT02440282||Group B|spinal anesthesia
2568907|NCT02440282||Group C|ultrasound-guided sciatic nerve block
2569026|NCT02439359|Placebo Comparator|Placebo|Placebo
2569028|NCT02439359|Experimental|CF-301|CF-301
2569078|NCT02439151|Experimental|New Strategy|New Strategy: use transpulmonary pressure guide new lung ventilation strategy in ECMO for severe ARDS patients
2569090|NCT02439151|Other|Conventional Strategy|Conventional Strategy: use conventional ventilation strategy (ELSO guide ventilation strategy) in ECMO for severe ARDS patients
2569322|NCT02437331||advanced heart failure|the patients was diagnostic on Chronic heart failure with NYHA class 3 and 4, AHA stage D, or LVEF<40%.
2568205|NCT02445105|Active Comparator|Autism Navigator Enhanced Practice|A 6-hour training will be provided to community service providers with the Autism Navigator for Primary Care professional development course and use of a web-based platform that includes an automated communication and autism screening and monthly electronic monitoring.
2568207|NCT02445105|Experimental|Family Engagement plus Autism Navigator|A 6-hour training will be provided to community service providers on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler, in addition to Autism Navigator Enhanced Practice.
2568371|NCT02443623|Experimental|Single Arm Vaccinated with ACAM2000|"To vaccinate plasma donors with the ACAM2000 smallpox vaccine thereby inducing an immune response resulting in high anti-vaccinia antibody titers. The collection of donor plasma will be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).~To ensure the safety of plasma donors vaccinated with ACAM2000 through the implementation of risk factor screening procedures and the collection of post-vaccination safety data."
2568416|NCT02443493|Experimental|Treatment group|Treatment group (receives low-level laser therapy (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
2568420|NCT02443493|Sham Comparator|Control group|Control group (receives sham laser (2x/week) in combination with standard skin care starting from day 1 of radiotherapy)
3172720|NCT00603655|Experimental|A|This group will receive a low glycemic load
3172721|NCT00603655|Active Comparator|B|This group will receive a high glycemic load
2569035|NCT02439437|Active Comparator|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
2569038|NCT02439437|No Intervention|Treatment as usual|Treatment as usual
2569058|NCT02439099||MDD|Currently unmedicated patients with a depressive episode in the context of unipolar major depression
2569060|NCT02439099||Control|Healthy Controls
2569068|NCT02439099||Alzheimer's Disease|Patients with Alzheimer's disease
2569072|NCT02439099||Alcoholism|Subjects with alcoholism
2569074|NCT02439099||Schizophrenia|Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole
2569128|NCT02438891|Experimental|CBT course|8-week internet-based cognitive behavioral therapy and sound therapy course
2569311|NCT02437721|Active Comparator|infant formula containing folic acid|Infant formula including folic acid within the range stipulated by European legislation on infant formula
2569318|NCT02437721|Experimental|infant formula containing MTHF|Infant formula including MTHF instead of folic acid
2569323|NCT02437721|No Intervention|Breast milk|non randomized reference group
3172722|NCT00603668|Experimental|milatuzumab|different doses of hLL1
2569357|NCT02436837|Active Comparator|young|20 to 30 years old individuals used as a comparator for elderly group
2569362|NCT02436837|Experimental|elderly|target of treatment to improve the balance.
3172723|NCT00603681|Experimental|T|Test product
3172724|NCT00603681|Active Comparator|C|Reference product
3172725|NCT00603694||1|(Experimental group): Receiving > 2 Gy SRS to left hippocampus (n=10)
3172726|NCT00603694||2|(Low-dose control group): Receiving < 0.5 Gy SRS to left hippocampus (n=10)
3172727|NCT00603694||3|(High-dose control group): Receiving whole brain PCI (n=10)
3172728|NCT00603707||Normal|healthy adult subjects with no history or current gastrointestinal disorders or conditions
3172729|NCT00603707||Constipated|Adult subjects with functional constipation as define by Rome II criteria
3172730|NCT00603759|Active Comparator|1|
3172731|NCT00603759|Placebo Comparator|2|
3172732|NCT00603772|Experimental|1|Safety when exposed to sunlight
3172733|NCT00603785|Placebo Comparator|A|Subjects to receive placebo treatment for 6 months
3172734|NCT00603785|Experimental|B|Subjects to receive Xolair treatment for 6 months
3172735|NCT00603811|Experimental|1|VAX102, a recombinant fusion protein that links the influenza A virus M2e antigen to S. typhimurium flagellin, a TLR5 ligand.
3172736|NCT00603811|Placebo Comparator|2|Vaccine buffer
3172737|NCT00603824|Experimental|A|Fondaparinux
3172738|NCT00603824|Active Comparator|B|Direct thrombin inhibitor
3172739|NCT00603850||1|Intermediate AMD Patients
3172740|NCT00603863|Experimental|multiple dose levels|1 of 3 different dose levels of 90Y-hPAM4 given once weekly for 3 weeks along with 4 weekly doses of gemcitabine.
3172741|NCT00603876|Experimental|2|Step 1 dietary counseling plus 100-110 grams of almonds daily
3172742|NCT00603876|No Intervention|1|Step 1 dietary counseling
3172743|NCT00603954|Active Comparator|1|Conditioning regimen consisting of fludarabine 30 mg/m2 on days -4, -3 and -2 (total dose 90 mg/m2), followed by a singe dose of 2 Gy TBI administered on day 0, at a low dose-rate (≈ 7 cGy/min), before infusion of cells.
3172744|NCT00603954|Active Comparator|2|Conditioning consisting of 8 Gy TLI and ATG. TLI will be administered by linear accelerator at a dose of 80 cGy daily, starting 11 days before transplantation, until a total of 10 doses (800 cGy) has been delivered. The irradiation will consist of a supradiaphragmatic mantle field, a subdiaphragmatic field including an inverted Y and splenic ports, encompassing all major lymphoid organs, including the thymus, spleen, and lymph nodes, as used in the treatment of Hodgkin's disease (Kaplan HS, Cancer Research 26:1268-1276, 1966). The Waldeyer ring is not included. ATG (Thymoglobulin®, Genzyme), at a dose of 1.5 mg/kg/d, will be given intravenously on days -11 through -7.
3172745|NCT00603967|Other|Aromatase inhibitor|
3172746|NCT00604006|Experimental|Group A|
3172747|NCT00604006|Placebo Comparator|Group B|
3172748|NCT00604032|Placebo Comparator|1|
3172749|NCT00604058|Experimental|Group A|
3172750|NCT00604058|Active Comparator|Group B|
3172751|NCT00604071||1|subjects with AMD related lesions: New onset (up to 60 days) non-treated CNV
3172752|NCT00604084|Experimental|Ivermectin|Non-pregnant, non-breastfeeding, taller than 90cm and 5 years or older
3172753|NCT00604084|Experimental|Permethrin|Pregnant, breastfeeding, children under 90cm or under 5 years old
3172754|NCT00604097|Experimental|1|Attachment-Based Family Therapy
2568288|NCT02444559|Experimental|Ropivacaine+Clonidine|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ Clonidine 150ug
2568289|NCT02444559|Placebo Comparator|Ropivacaine+Placebo|Adductor Canal Block Ropivacaine 20ml 5mg/ml+ saline
2568332|NCT02444078|Experimental|Exercise|Exercise sessions will be done in groups of three-to-eight persons; whilst being a group-based exercise program, participants will be guided and the exercises will be adapted in an individual basis, which may increase adherence and compliance rates.
2568333|NCT02444078|Active Comparator|Social activity|Participants in this group will participate in group-based activities such as music (percussion instruments), arts and board games; no intervention on physical activity will be provided to these participants.
3172755|NCT00604097|Active Comparator|2|Enhanced Usual Care
2568457|NCT02443194|Active Comparator|Group # 1- ACTIVE|"Patients who underwent resection or biopsy of glioblastoma (newly diagnosed glioblastoma), will randomization ratio of 1: 1 by the pharmacist (by age, KPS, the degree of tumor resection) two research groups:~Group # 1: consisting of 50 patients who will be treated immediately after diagnosis, 30 mg Cymbalta duloxetine -morning for a week and then a dose exceeding 60 mg for 3 months."
2568458|NCT02443194|Placebo Comparator|Group # 2-PLACEBO|Group # 2 will include 50 patients treated immediately after diagnosis with placebo for 3 months
2568514|NCT02442882||Boxers|Individuals who participate in a boxing tournament will be tested on balance, neuropsychological, and visual functions before and after the tournament.
2568540|NCT02442596||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
2568601|NCT02442440|Experimental|anisodamine group|administration of the drug
2568605|NCT02442440|No Intervention|control group|these arm do not use anisodamine, other resuscitation protocol is as usual.
2568703|NCT02441738|Active Comparator|Hybrid Ablation|Epicardial surgical ablation performed thoracoscopically with occlusion/removal of the LAA combined with percutaneous endocardial ablation (one-stage).
2568704|NCT02441738|Active Comparator|Catheter Ablation|Percutaneous endocardial catheter ablation, with optional repeated catheter ablation(s).
2568787|NCT02441374|Experimental|Forced Use Therapy|Constriction (through the tubular mesh) of non paretic upper limb for a period of 12 and 24 hours, 5 days per week for 4 weeks.
2568788|NCT02441374|Active Comparator|Classical Kinesiotherapy|Rehabilitation of classical kinesiotherapy,at least 2 times a week for 4 weeks.
2568829|NCT02440763||Spinocerebellar ataxia type 1,2,3 and 6|Spinocerebellar ataxias (SCA) are autosomal dominantly inherited progressive ataxia disorders. An epidemiological study performed in the Netherlands found a prevalence of 3.0 : 100,000 (van de Warrenburg et al. 2002). The SCA´s are genetically and clinically heterogeneous disorders with SCA1, SCA2, SCA3 and SCA6 being the most frequent genotypes worldwide. While SCA1, SCA2 and SCA3 have a complex phenotype, SCA6 patients usually present with pure cerebellar ataxia (Schols et al. 2004). Although precise knowledge of the rate of disease progression is a prerequisite for the biometrical design of future therapeutical trials, prospective studies of the natural history of SCA´s have not been performed. Similarly, the occurrence and evolution of accompanying non-ataxia symptoms have not been studied prospectively.
2568937|NCT02440126||Group A: Natalizumab Naïve|This group will consist of up to 10 people who are naïve to natalizumab (haven't received the drug before) and are just beginning therapy. These participants will meet with the study staff at Week 0 (Baseline) prior to their natalizumab infusion. They will then have a follow up appointment every 3 months for the first 12 months of their natalizumab infusions, for a total of 5 visits. Natalizumab concentration and other biomarkers will be measured at each visit.
2568939|NCT02440126||Group B: Intracycle Regular Dosing|This group will consist of at least 50 people who are on a regular infusing cycle of 28-31 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week during their regular cycle at Week 1, Week 2, and Week 3, for a total of 4 study visits. Natalizumab concentration and other biomarkers will be measured during their participation in the study.
2568940|NCT02440126||Group C: Intracycle Extended Dosing|This group will consist of up to 60 people who are on an extended infusing cycle of greater than 30 days. These participants will be consented at Week 0 (Baseline) and asked to come back each week for a blood draw to measure Natalizumab concentration and other biomarkers during their extended cycle at Week 2, and Week 4, for a total of 3 study visits.
2568941|NCT02440126||Group D: Transition Dosing|This group will consist of up to 10 people who are on a regular infusing cycle of 28-30 days who will be transitioning to an extended dosing cycle. The decision to transition will be made by their treating neurologist. These participants will be consented at Week 0 (Baseline) and will be followed for 8 cycles. Natalizumab concentration will be measured at each cycle. During certain cycles, other biomarkers will be measured.
2568984|NCT02439853|Experimental|Check-In group|Subjects in the Check-In group will undergo three check-in sessions with the speech therapist. These sessions will happen remotely, via video-chat, and will last less than an hour. They will occur at 3-, 4-, and 5-months from the subject's enrollment date.
2568988|NCT02439853|No Intervention|Control Arm|Subjects in the Control arm will not undergo three check-in sessions with the speech therapist.
2569045|NCT02439489|Experimental|BKM120-CIS|BKM120 (60, 80 100 mg po continuously) and Cisplatin (iv 75 mg/m2)
2569048|NCT02439489|Experimental|BKM120-CARBO|BKM120 and (60, 80 100 mg po continuously) and Carboplatin (iv AUC 5)
2569057|NCT02439073|Experimental|early initiated rehabilitation|A supervised 12-week rehabilitation program, initiated two weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
2569064|NCT02439073|Active Comparator|late initiated rehabilitation|A supervised 12-week rehabilitation program, initiated 14 weeks post surgery, containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
3172756|NCT00604123|Experimental|JNJ-17166864|
3172757|NCT00604123|Placebo Comparator|Placebo|
3172758|NCT00604149||1|case of out-of-hospital cardiac arrest
3172759|NCT00604149||2|cases of MI
3172760|NCT00604149||3|controls without coronary disease
3172761|NCT00604227|Experimental|1|high altitude exposure
2568379|NCT02443831|Experimental|CD19 CAR T-cells|Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19CAR T-cells. Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19CAR T-cells.
2568473|NCT02443038|Active Comparator|Home Exercise|Participants will practice 10 minutes of yoga in addition to 5 minutes of relaxation exercises at home each day when not in class.
2568480|NCT02443038|Placebo Comparator|Relaxation Exercise|Participants will practice 5 minutes of relaxation exercises at home each day when not in class.
2568562|NCT02442752|Experimental|Regimen A: Dexlansoprazole 10 mg|Dexlansoprazole 10 mg, delayed-release capsules, orally, once daily for 8 weeks.
2568565|NCT02442752|Experimental|Regimen B: Dexlansoprazole 15 mg|Dexlansoprazole 15 mg, delayed-release capsules, orally, once daily for 8 weeks.
2568572|NCT02442752|Experimental|Regimen C: Dexlansoprazole 20 mg|Dexlansoprazole 20 mg, delayed-release capsules, orally, once daily for 8 weeks.
2568575|NCT02442752|Experimental|Regimen D: Dexlansoprazole 30 mg|Dexlansoprazole 30 mg, delayed-release capsules, orally, once daily for 8 weeks.
3208901|NCT00979238|Other|Group 1|"All participants who meet the eligibility requirements.~Intervention: Gene Transfer and drug (scAAV2/8-LP1-hFIXco)."
2568758|NCT02441270|Experimental|Cyclophosphamide|
2568794|NCT02440984|Other|Enteric nervous system dysfunction|colonic biopsies and usual care
2568845|NCT02440724|Experimental|winged stent group|participants who are assigned to winged-stent group will be treated with deployment of a winged stent(partially covered or uncovered SEMS).
2568906|NCT02440412|Experimental|Massage Therapy|A 45 minutes massage therapy (manual) standardized session, based in Swedish techniques.
2568909|NCT02440412|Placebo Comparator|Rest condition|45 minutes of rest in supine position, listening music with headphones, and warm condition.
2568911|NCT02440412|No Intervention|Control|Normal working condition, as a office workers (secretaries and managements employees)
2568957|NCT02439983|Placebo Comparator|Placebo|
2568959|NCT02439983|Experimental|Proprietary Nutritional Supplement|
2568994|NCT02439671|Experimental|Immediate intervention|Participant assigned to McGill Transition Support Program in next available session
2568999|NCT02439671|No Intervention|Waiting List control|Participant assigned to waiting list for one session prior to receiving McGill Transition Support Program in following session
2569111|NCT02438917||Hepatitis C|Patients who are about to begin HCV treatment
2569153|NCT02438579|Experimental|Nasal Irrigation & Gargling|"Videos on how to collect nasal swabs, prepare and perform hypertonic saline nasal irrigation and gargling (HSNIG) are shown. A nasal swab is collected. Participant chooses the highest concentration of hypertonic saline he/she is comfortable with (from 1.5, 2.0, 2.5 and 3.0%) and performs HSNIG under observation. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
2569157|NCT02438579|No Intervention|Control|"The control group are advised to manage the URTI as they normally do. A video on how to collect nasal swabs is shown. A nasal swab is collected. Nasal swabs are to be collected first thing in the morning on 4 consecutive days and posted using the Royal Mail Safebox. Daily diaries are to be completed (online / paper form) until they document not unwell for two consecutive days; or a maximum of 14 days or if they need medical attention for the URTI. Swabs are tested in parallel to detect change in viral shedding."
2569217|NCT02438241|Active Comparator|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
2569218|NCT02438241|Placebo Comparator|Placebo TENS Group|Will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
2569219|NCT02438241|Experimental|TENS group|Patients randomized to this group will receive conventional physical therapy for the control group, and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
2569236|NCT02437851|Experimental|Treatment (surgery)|Participants undergo therapeutic conventional surgery to remove anal or perianal cancer (SISCCA). Any HSIL remaining is treated with the goal for complete eradication in accordance with clinician and participant preference.
2569281|NCT02437617||Control Group #1|Participants who have had tumor molecular analysis performed with the similar clinical characteristics and genomic aberrations but who receive therapy not matched to their aberrations, or who have received results from Foundation Medicine that fail to demonstrate any molecular alteration.
2569283|NCT02437617||Control Group #2|Participants from historical archives of MD Anderson, no older than two years, who received therapy not matched to their aberrations and are matched not only on the basis of the clinical characteristics, but also, as much as possible, on the basis of genomic aberrations.
2569285|NCT02437617||Matched Targeted Therapy Group|Participants with tumor aberrations who received matched targeted therapy.
3172762|NCT00604240||1|Parents / caregivers of any infant who has a length of stay of at least 1 week in the NICU at Christiana Hospital or Thomas Jefferson University Hospital.
3172763|NCT00604266||1|10-15 patients with potentially resectable hiilar cholangiocarcinoma
3172764|NCT00604292||A|Patients that are indicated for colonoscopy, who are suspected or known to suffer from colonic diseases
3172765|NCT00604305|Active Comparator|Acrysof|Routine monofocal IOL
3172766|NCT00604305|Active Comparator|Acuity's AIOL|Accomodaing IOL
2568313|NCT02444429|Active Comparator|Sub-study A control arm|"This control arm corresponds to patients with borderline infiltrates at 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)"
2568314|NCT02444429|Experimental|Sub-study B experimental arm|This experimental arm corresponds to patients without significant infiltrates 3 months, who will be randomized to stop maintenance corticotherapy (Stop maintenance corticotherapy )
2568315|NCT02444429|Active Comparator|Sub-study B control arm|This control arm corresponds to patients without significant infiltrates 3 months, who will be randomized to not change their immunosuppressive treatment (No therapeutic modification)
2568369|NCT02443753|Experimental|Device|Subjects who receive the device
2568437|NCT02443506|Experimental|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
2568443|NCT02443506|Placebo Comparator|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
2568462|NCT02442999|No Intervention|Usual care|
2568465|NCT02442999|Experimental|Screen for Sleep Apnea|Screen for sleep apnea, treat with continuous positive airway pressure (CPAP) if diagnosed with sleep apnea
2568536|NCT02442765|Placebo Comparator|Placebo|Placebo capsules administered twice a day over a 12-week period
2568538|NCT02442765|Experimental|AVP-786 (dose 1)|AVP-786 dose 1; capsules administered twice a day over a 12-week period
2568539|NCT02442765|Experimental|AVP-786 (dose 2)|AVP-786 dose 2; capsules administered twice a day over a 12-week period
2568660|NCT02441972|Experimental|18F-Al-NOTA-PRGD2 PET/CT|Imaging with 18F-Al-NOTA-PRGD2 PET/CT.
2568699|NCT02441673|Active Comparator|Nefopam|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~0.15mg/kg of Acupan(Nefopam) would be administered IV after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Acupan is not satisfactory."
2568701|NCT02441673|Active Comparator|Tramadol|"Premedication of IV (Intravenous)10mg Metoclopramide and 50mg Ranitidine would be given morning of surgery to all patients.~1mg/kg of tramadol would be administered after the initiation of the subarachnoid block (Time 0) and presence and severity of shivering (the primary outcome) would be looked out for.~IV Ephedrine in 3mg alliquots would be given if hypotension occurs; IV oxytocin 30-50mg would be given after delivery of the baby to all patients and IV Pethidine 25mg would be given to abate any residual shivering if a repeat dose of Tramadol is not satisfactory."
2568759|NCT02441244|Experimental|Probiotic Group|Visbiome experimental group (900 billion bacteria daily; 2 sachets daily)
2568762|NCT02441244|Placebo Comparator|Placebo Group|Placebo comparator group
2568842|NCT02440919|Other|Hyperoxygenation - 100% FiO2|Hyperoxygenation involved supplying 100% fraction of inspired oxygen (FIO2).
2568843|NCT02440919|Other|Hyperoxygenation - 20% FiO2|Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
2568846|NCT02440919|Other|Hyperinflation - Basal FiO2|Ventilator hyperinflation, with keeping the oxygen already offered to the patient.
2568850|NCT02440919|Other|Hyperinflation - 20% FiO2|Ventilator hyperinflation and hyperoxygenation involved supplying 20% oxygen.
2568916|NCT02440360|Active Comparator|Permanent Supportive Housing|Permanent Supportive Housing (PSH) is subsidized housing with closely linked or on-site supportive services that typically include case management, physical and mental health care, substance use treatment services and vocational support.
2568922|NCT02440360|Placebo Comparator|Usual Care|Usual Care consists of public benefits (e.g., General Assistance and CalFresh), integrated medical and behavioral health services provided by Valley Medical Center and the rest of the County Health & Hospital System including those offered by Valley Homeless Healthcare Program, specialty mental health and substance abuse treatment services and housing programs, and approximately 2,000 year-round beds of emergency shelter and transitional housing.
2568953|NCT02439944|Experimental|Experimental Arm|Escalating nicotine patch dose to satiety over 6 weeks with dosage depending on the number of cigarettes smoked per day and the occurrence of adverse effects
2568955|NCT02439944|Active Comparator|Positive Control Arm|Nicotine patch dose of 21mg coupled with nicotine mouthspray which is to be used as needed.
2569036|NCT02439333|Active Comparator|Nasal high flow therapy|AECOPD patients with no severe respiratory insufficiency are given NHF therapy for at least 15 hours per day.
2569039|NCT02439333|Active Comparator|Conventional oxygen therapy|AECOPD patients with no severe respiratory insufficiency are given conventional oxygen therapy such as nasal catheter or venturi mask for at least 15 hours per day.
2569085|NCT02439086|Experimental|Long Course Radiotherapy|all patients diagnosed with rectal cancer, amenable for neoadjuvant chemoradiotherapy, who agree to participate in this study will undergo 2 PET-CT scans: at baseline and 9 weeks after commencing therapy.
2569109|NCT02438800|No Intervention|Standard Counseling|Women in this arm will receive standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
2569110|NCT02438800|Experimental|Video Counseling|Women in this arm will receive LARC First video-based contraceptive counseling in addition to standard contraceptive counseling routinely provided during prenatal care. All participants will receive information regarding access to free LARC methods in the postpartum period.
2569193|NCT02438150|Experimental|Intervention|Will receive hospital fire video training
2569202|NCT02438150|Placebo Comparator|Control|Will receive non-fire video training
2569240|NCT02437994|Experimental|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include supervised exercise training (interval exercise and resistance exercises), breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability.
2569246|NCT02437994|No Intervention|Control|In addition, a control group (Group C) which will not participate in the rehabilitation program (usual care) will be include at the same time as patients in Group A and B so as to be able and independently address study objectives 2 and 3 and 4. Group C will also randomized to those into paper-pencil version and electronic version.
2570153|NCT02431949||Controls|Participants without a psychosis disorder diagnosis.
2568323|NCT02444260|Sham Comparator|Intravenous Normal Saline|Intravenous Normal Saline plus Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg ; Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus i
2568326|NCT02444260|Active Comparator|Midazolam|Lignocaine HCl (1%) - administered by wound infiltration to a maximum dose of 4.5mg/kg Bupivocaine HCl (0.25%) - administered by wound infiltration to a maximum dose of 2 mg/kg plus Midazolam - administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg.
3208902|NCT00979251|Experimental|ADS-8902|Amantadine and Ribavirin administered with Oseltamivir phosphate
3208903|NCT00979251|Active Comparator|Comparator|Oseltamivir Phosphate
2568599|NCT02442531|Experimental|CriPec® docetaxel|Docetaxel containing nanoparticle
2568678|NCT02441868|Experimental|Intervention|all participants will receive the training
2568721|NCT02441582|Experimental|Telemetry|In this group, participants will have a prehospital 12 lead ECG taken and sent through to the receiving facility.
2568723|NCT02441582|Other|Non-Telemetry|In this group, participants will have a prehospital 12 lead ECG taken which will not be sent through to the receiving facility.
2568773|NCT02441192|Experimental|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
2568778|NCT02441192|Experimental|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
2568782|NCT02441192|Experimental|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
2568836|NCT02440802||Gonadoliberin antagonist treatment|Single arm study, all patients are treated the same way. Saliva sample collection for genetic analyses.
2568914|NCT02440243|Active Comparator|Patients active|Purethal Grass
2568921|NCT02440243|Placebo Comparator|Patients placebo|Placebo
2569030|NCT02439476||Relapsed multiple myeloma patients who are considered eligible|Patients mobilized using G-CSF+Plerixafor according to Plerixafor label in France will be included. Apheresis will be performed according to standard practice and local guidelines. Once the autologous stem cell product becomes available, patients will undergo ASCT conditioned by high dose Melphalan according to standard practice in each centre
2569051|NCT02439177|Experimental|Omnitest 3|Blood glucose monitoring system
2569053|NCT02439177|Experimental|Omnitest 5|Blood glucose monitoring system
3172767|NCT00604318|Placebo Comparator|placebo|To receive the placebo treatment in connection with the primary RI therapy and the T3 tablets and rh-TSH injections prior to second RI uptake measurement
3172768|NCT00604318|Active Comparator|rh-TSH|To continue with L-T3 and to receive rh-TSH stimulation with 0,9 mg Thyrogen® (Genzyme) x 2 days minus 1 and 2 prior to RI therapy, and following this to have placebo tablets and placebo injections with isotone NaCl prior to the RI uptake measurement 4-6 months later
2569112|NCT02438774|Active Comparator|Routine agriculture extension services|Routine agriculture extension services alone
2569113|NCT02438774|Experimental|Post-harvest intervention package|Post-harvest intervention package and routine agriculture extension services
2569159|NCT02438553|Experimental|OSTNS Neurostimulator|Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
2569162|NCT02438553|Placebo Comparator|Placebo OSTNS Neurostimulator|Placebo Combined Occipital & Supraorbital Transcutaneous Neurostimulator.
2569189|NCT02438215|Experimental|IRX4204|IRX4204 20 mg QD for Days 1-30
2569242|NCT02438007|Experimental|Galeterone|
2569247|NCT02438007|Active Comparator|Enzalutamide|
2569361|NCT02436954|Placebo Comparator|CO2 insufflation at intra-abdominal pressure 8 mmHg|CO2 insufflation with intra-abdominal pressure 8 mmHg during deep-NMB
2569370|NCT02436954|Active Comparator|CO2 insufflation at intra-abdominal pressure 12 mmHg|CO2 insufflation with intra-abdominal pressure 12 mmHg during deep-NMB
2569423|NCT02436746||Neurofibromatosis type I (NF1)|Monozygotic twin pairs with genetically confirmed Neurofibromatosis type I
2569433|NCT02436746||Tuberous Sclerosis Complex (TSC)|Monozygotic twin pairs with genetically confirmed Tuberous Sclerosis Complex
2569481|NCT02436395|Experimental|Group A (povidone-iodine group)|"The surgical incision is washed by the mixed solution with 400ml 9% normal saline and 100ml 5% povidone-iodine solution.~We declare that we have no conflicts of interest."
2569487|NCT02436395|Experimental|Group B (normal saline group)|"The surgical incision is washed by the 500ml 0.9% normal saline.~We declare that we have no conflicts of interest."
2569614|NCT02435407|Experimental|SOS arm|The Sequential Oral Sensory (SOS) approach treatment protocol, involving systematic desensitization hierarchy of skills needed to build feeding skills.
2569725|NCT02434744|Experimental|Cohort 2 150 mg KD026 BID|150 mg KD026 BID in combination with Metformin for 12 weeks
3172769|NCT00604331|Active Comparator|A|Pyruvate
3172770|NCT00604357|Experimental|1|Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.
3172771|NCT00604370||1|Acutely ill medical and surgical patients who were hospitalized at BWH, and at-risk for VTE, but were not treated with prophylaxis at hospital discharge.
3172772|NCT00604370||2|Acutely ill medical and surgical patients who were at risk for VTE at time of hospital discharge and prescribed a prophylaxis strategy.
2568402|NCT02443649|Active Comparator|Sleep hygiene only|Those randomized into this group will receive the Optimizing Sleep Hygiene program during the intervention visit and hypnosis recording after the follow-up visit.
2568435|NCT02443233||Maternal hepatitis B carrier|
2568439|NCT02443233||Paternal hepatitis B carrier|
2568478|NCT02443064|Experimental|MRSA blood stream infection patient|"Intervention:Vancomycin~Dosing:~15-20mg/kg, IV,q 12~8h (or 1 g, IV, q12~8h) for adult patient with normal renal function; Dosage should be adjusted by blood creatinine clearance in patients with impaired renal function; Administration route： 1~2 h/ dosing, IV~Drug combination:~Drug combination is not recommended for patients with simple MRSA infection; Rifampicin can be combined in case of MRSA artificial valve endocarditis; Anti-G- antibacterial agents can be combined in case of concurrent G- bacterial infections.~Duration:~Septicemia: 2~4 weeks Endocarditis: 6~8 weeks"
2568517|NCT02442791|Experimental|GLP-1|"Half of the participants will receive the study drug, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin added 25 microg Byetta (Lilly, Exenatide).~The study drug infusion is initiated as soon as possible at rate of 72ml/hour (0.12 μg/min) for 15 min (set volume at 18 ml), followed by 26ml/hour (0.043 μg/min) to be continued for 6 hours (set volume at 156 ml). This concludes the pharmacological intervention."
2568519|NCT02442791|Placebo Comparator|Placebo|"Half of the participants will receive placebo, that will be given as follows:~250 mL isotonic sodium chloride added 1.5 mL of 20% Human Albumin. The placebo infusion is administered exactly the same way as the study drug infusion."
2568578|NCT02442570|Active Comparator|DC-TAB 7.5 mg|three intravenous injections of 7.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
2568580|NCT02442570|Active Comparator|DC-TAB 12.5 mg|three intravenous injections of 12.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
2568582|NCT02442570|Active Comparator|DC-TAB 17.5 mg|three intravenous injections of 17.5 mg DC-TAB (recombinant human alpha B-crystallin), 2 months apart
2568583|NCT02442570|Placebo Comparator|placebo|three intravenous injections of placebo, 2 months apart
2568611|NCT02442232||Normotensive|
2568612|NCT02442232||Hypertensive taking ACEi|
2568614|NCT02442232||Hypertensive not taking ACEi|
2568630|NCT02442063|Experimental|Radium Ra 223 dichloride|Radium Ra 223 dichloride (Xofigo, BAY88-8223)
2568676|NCT02441855||pneumonia|patients with community-acquired pneumonia
2568683|NCT02441855||control|patients admitted to emergency department with shortness of breath
2568712|NCT02441556|Active Comparator|standard medical therapy|Patients receive standard medical therapy alone.
2568714|NCT02441556|Experimental|endovascular + standard medical therapy|Patients receive endovascular treatment plus standard medical therapy.
2568763|NCT02441049|Experimental|Home-based promotora intervention|Study participants and their families received the home-based promotora family intervention
2568766|NCT02441049|No Intervention|Delayed treatment control|Study participants received intervention materials after the final study evaluation measures were taken, 10 months post-baseline.
2568811|NCT02440893||Corus CAD (ASGES) Post-metformin|Corus CAD (ASGES) second sample draw results to compare to Corus CAD (ASGES) first draw results (per patient).
2568849|NCT02440685|Experimental|ASN002 Dose Escalation|Multiple ascending doses of ASN002 will be administered to determine the maximum tolerated dose (MTD). Arm Closed
2568851|NCT02440685|Experimental|ASN002 Recommended dose (RD) - DLBCL|ASN002 administered at the recommended dose in subjects with DLBCL. Arm Closed
2568852|NCT02440685|Experimental|ASN002 RD - Mantle Cell Lymphoma|ASN002 administered at the recommended dose in subjects with MCL. Arm Closed
2568853|NCT02440685|Experimental|ASN002 RD - Follicular Lymphoma|ASN002 administered at the recommended dose in subjects with FL.
2568854|NCT02440685|Experimental|ASN002 RD - Peripheral T-cell Lymphoma|ASN002 administered at the recommended dose in subjects with PTCL.
2568855|NCT02440685|Experimental|ASN002 RD - Myelofibrosis|ASN002 administered at the recommended dose in subjects with MF.
2568856|NCT02440685|Experimental|ASN002 RD - Chronic Lymphocytic Leukemia|ASN002 administered at the recommended dose in subjects with CLL.
3208064|NCT00971217|No Intervention|Control|Individuals will be advised that the start of their intervention will be delayed by 10 weeks. After 10 weeks individuals in the control condition will be given the opportunity to avail of an induction session in the gym and subsequently use the gym facilities for three sessions if they so desire. Participants will be asked to refrain from exercise for the 10 week study period.
2568954|NCT02439905|Experimental|Dexmedetomidine group|
2568956|NCT02439905|Placebo Comparator|Normal saline group|
2569002|NCT02439762|Experimental|Cognitive Behavioral Therapy (CBT)|The CBT condition will cover topics such as orienting the patient to the cognitive model of suicidal thoughts, plans and behaviors and the role of substance use in increasing the likelihood of suicidal behaviors and presenting tools to help patients better manage responses to suicide-related triggers.
2569003|NCT02439762|Active Comparator|Supportive Psycho-education (SPC)|The SPC condition is designed to match the CBT condition in terms of level of attention and the non-specific aspects of receiving support for a suicidal crisis and substance misuse. Specific content related to suicide risk will consist of general information about suicide-related resources available, while content related to substance use is based on a modified psycho-educational attention control treatment for alcoholism. The sessions will help patients to better understand the resources available during a suicidal crisis and how substance use impacts in their life. However, topics related to identifying thoughts and behaviors associated with suicidal crises and possible coping mechanisms will not be a part of the formal content of these SPC sessions.
2569087|NCT02439385|Experimental|Avastin/FOLFIRI with curcumin|Patients will receive first line Avastin/FOLFIRI in combination with curcumin-containing supplement
2569118|NCT02438761|Experimental|PF-05212384|150 mg Intra-venous every week
2569165|NCT02438449||Abdominal-based Autogenous Tissue (AAT)|The AAT-based breast reconstruction surgery will include any of the following techniques: pedicled transverse rectus abdominis myocutaneous (TRAM) flap, Free TRAM, muscle-sparting TRAM flap, deep inferior epigastric perforator (DIEP) flap, superficial inferior epigastric artery (SIEA) flap, and Rubens flap.
3208065|NCT00971230|Experimental|FTC/TDF- Daily|FTC/TDF dosed daily
3208066|NCT00971230|Experimental|FTC/TDF-Intermittent|FTC/TDF dosed intermittently
2568490|NCT02443129|Experimental|All patients presenting with RD|"Patients with retinal detachment~Intervention:~RD surgery DRI-1 Swept source OCT, Atlantis, Topcon"
2568492|NCT02443129|Experimental|Impact of previous grid treatment|"Patients after grid laser~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
2568493|NCT02443129|Experimental|Effect of glaucoma medications|"Patients requiring new intraocular presssur (IOP)-lowering treatment Patients with long-term IOP-lowering treatment~Intervention:~If needed, start of new IOP-lowering treatment DRI-1 Swept source OCT, Atlantis, Topcon"
2568496|NCT02443129|Experimental|Effect of arteritic/non-arteritic AION|"About 180 living patients diagnosed at ShaareZedek with anterior ischemic optic neuropathy (AION).~Longitudinal arm with newly diagnosed patients for 2 years follow-up~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
2568498|NCT02443129|Experimental|NVAMD poorly responsive to Rx|"Patients with neovascular age-related macular degeneration and epiretinal membreane/vitreomacular traction who do not respond to first course of Avastin~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
2568500|NCT02443129|Experimental|Retrospective analysis|"All patients pictured with DRI-OCT~Intervention:~DRI-1 Swept source OCT, Atlantis, Topcon"
3208067|NCT00971230|Placebo Comparator|Placebo-Daily|Placebo dosed daily
3208068|NCT00971230|Placebo Comparator|Placebo-Intermittent|Placebo dosed intermittently
3208069|NCT00971256||Bladder cancer patients|Bladder cancer patients from one Beaumont Urologist.
2568675|NCT02441894|Experimental|Cabazitaxel|"25 mg/m^2 of cabazitaxel is given intravenously in combination with prednisolone 10 mg orally per day. PEG-G-CSF is administered subcutaneously 24 hours after the completion of cabazitaxel infusion once every 3 weeks.~Antihistamine (dexchlorpheniramine or diphenhydramine), corticosteroids (dexamethasone), and H2 antagonist (ranitidine) premedications will be administered by IV infusion at least 30 minutes prior to each dose of cabazitaxel. A prophylactic antiemetic treatment (metoclopramide, granisetron, or ondansetron) should be given to the patients in all cycles."
2568719|NCT02441439|Other|Iron sucrose 200 mg|first arm will be treated with iron sucrose 200 mg 2-3 times a week
2568720|NCT02441439|Active Comparator|Iron sucrose 500 mg|Second arm will be treated with iron sucrose 500 mg once a week
2568770|NCT02441205|Experimental|HIIT Aging|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
2568809|NCT02440906|Experimental|Intervention|A person-centered wellness intervention that includes a patient-directed wellness account. Enrollees meet with a patient Navigator to develop a wellness plan. The enrollee can then use the flexible wellness account to make purchases that are consistent with the goals of the wellness plan. Health Navigators have monthly phone contact with enrollees and meet quarterly with them to discuss goals and spending with the express goal of improving self-management, use of preventive services, satisfaction with care, healthcare utilization and expenditures and quality of care.
2568810|NCT02440906|No Intervention|Control|Control group participants receive a monthly mailing requesting updated contact information. They can send this card via mail, or by calling the toll free number.
2568815|NCT02440906|No Intervention|Comparison|These are STAR+PLUS enrollees who meet the same enrollment criteria as the intervention and control but reside outside of the Harris Service Area. The purpose of the comparison group is to follow them and their outcomes. This group will help us to better compare the outcomes we see with those enrolled in the WIN Project to a comparable group for whom we already house data.
3208070|NCT00971308|Experimental|BMS-824393 (Panel 1)|
3208071|NCT00971308|Experimental|BMS-824393 (Panel 2)|
2568912|NCT02440217||DCM-AGT|Subjects with both dilated cardiomyopathy (DCM) and abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
2568918|NCT02440217||DCM-NGT|Subjects with dilated cardiomyopathy (DCM) and normal glucose tolerance (NGT).
2568924|NCT02440217||N-AGT|Subjects without dilated cardiomyopathy (N) with abnormal glucose tolerance (AGT, either impaired glucose tolerance or type 2 diabetes).
2568975|NCT02439996|Experimental|IVIG(1g/kg,once)|The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.
2568977|NCT02439996|Experimental|IVIG(1g/kg,twice)|The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
2568979|NCT02439996|Active Comparator|IVIG(2g/kg.once)|The KD children will be randomly assigned to three groups. The patients in group A will receive IVIG 2g/kg once.
2569015|NCT02439528|Other|Combined pulmonary fibrosis and emphysema syndrome|Genetic analysis on patients with combined pulmonary fibrosis and emphysema syndrome.
2569017|NCT02439528|Other|Pulmonary fibrosis|Genetic analysis on patients with pulmonary fibrosis.
2569018|NCT02439528|Other|Emphysema|Genetic analysis on patients with emphysema.
2569019|NCT02439528|Other|Healthy subject|Genetic analysis on healthy subject.
2569054|NCT02439203|Experimental|JM-010|JM-010
2569055|NCT02439203|Placebo Comparator|Placebo|Placebo
2569114|NCT02438930|Experimental|Motivational interviewing counseling|"The brief intervention is adapted from the OPTIONS project, which is a brief client-centered risk reduction intervention for HIV-positive patients in clinical care. The OPTIONS intervention content is based upon the IMB model of health behavior change, and uses motivational interviewing techniques to create client-centered discussions in which HIV counselors and patients collaborate to identify patients' HIV transmission risk behaviors and to mutually identify strategies and goals for reducing the patient's risky behavior.~The brief intervention will be facilitated by health care providers (nurses, lab technicians) specifically trained in the intervention protocol and will consist of 2 brief counseling sessions occurring during the same-day rapid HIV-testing procedure"
2569121|NCT02438930|Active Comparator|Standard of care counseling|Participants in this study condition will receive standard-of-care counseling that is usually implemented during HIV testing.
2569163|NCT02438501|Experimental|LD-IFRT group|Chemotherapy / Low-dose involved-field radiotherapy
2569164|NCT02438501|Active Comparator|IFRT group|Chemotherapy / Involved-field radiotherapy
3208072|NCT00971308|Experimental|BMS-824393 (Panel 3)|
3208073|NCT00971308|Experimental|BMS-824393 (Panel 4)|
3208074|NCT00971308|Experimental|BMS-824393 (Panel 5)|
2568511|NCT02442895||Long luteal protocol|Subcutaneous administration of GnRH agonist (Triptorelina pamoato 0.1 mg/ml) in the medium-luteal phase (21th day) of the cycle before the stimulation. The next menstruation, in the presence of estradiol level (E2)<30pg/ml and in the absence of follicular cysts, the gonadotropin stimulation was begun. In the presence of at least three follicles of diameter ≥18mm was induced final oocyte maturation by administration of human chorionic gonadotropin (hCG).
2568512|NCT02442895||Daily antagonist protocol|GnRH antagonist (cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed protocol from the day +6 of stimulation or with a flexible protocol from the day in which at least one follicle reached a diameter of 14mm. In both protocols GnRH antagonist was administered until the day of the assumption of hCG. Recombinant Follicle Stimulating Hormone (rFSH) was administered from the 3rd day of menstruation at a dose of 150-300 IU/die according to the characteristics of women. The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle.
2568513|NCT02442895||Depot antagonist protocol|"GnRH antagonist (Cetrorelix acetate 0.25 mg) was administered subcutaneously with a fixed or flexible protocol until the day of the assumption of hCG. Corifollitropila alfa was used at dose of 100μg (in women with weight ≤60 kg and age ≤36 years) or 150μg (in women with weight> 60 kg of any age or weight ≥50 kg and age greater than 36 years). Corifollitropina alfa was administered subcutaneously in the day +3 and in the day +5 or +6 was supplemented with rFSH at doses 112-300 IU/day.~The hCG was administered when at least three follicles had reached 18 mm in diameter and estradiol levels were higher than 150 pg/mL/dominant follicle."
2568555|NCT02442648|Experimental|Group A (5-8 patients) - Carfilzomib|Two cycles of carfilzomib desensitization given.
2568560|NCT02442648|Experimental|Group B (5-8 patients) - Carfilzomib/plasmapheresis|Two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
2568563|NCT02442648|Experimental|Group C (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to two cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
2568568|NCT02442648|Experimental|Group D (5-8 patients) - Rituximab/Carfilzomib/plasmapheresis|1 dose of rituximab prior to three cycles of carfilzomib desensitization given with weekly plasmapheresis prior to carfilzomib therapy
3208075|NCT00971347|Active Comparator|Nutrition brochure|Control participants will receive only a nutrition brochure, Finding Your Way to a Healthier You, based on a USDHHS/USDA publication, Dietary Guidelines for Americans 2005.
2568665|NCT02441959|Active Comparator|Endoscopic Discectomy|Randomized to Endoscopic Discectomy Lumbar discectomy Endoscopic Intervention type is lumbar endoscopic surgery- no device or drug
2568667|NCT02441959|Active Comparator|Open Discectomy|Randomized to Open Discectomy Lumbar discectomy Open Intervention type is lumbar open surgery- no device or drug
2568669|NCT02441959|Other|Open Discectomy-Cross Over Arm|Randomized to Endoscopic Discectomy Cross over to lumbar discectomy open based on surgeons assessment pre or post incision Intervention type is lumbar open surgery- no device or drug
2568694|NCT02441608|Experimental|Experimental group|This study is designed as a single group assignment, because the 4 dressings (3 placebos and 1 containing the product) will be applied in all volunteers. This means that the region in which the tested product will be applied will be compared with the other placebo regions in the same volunteer.
2568718|NCT02441465|Experimental|Vemurafenib|Participants will receive oral vemurafenib BID from Day 1 to Day 28 and a single IV infusion of 14C-labeled vemurafenib on Day 21.
3208904|NCT00979264|No Intervention|Control|Standard quality improvement approaches available through participation in Get With the Guidelines - Heart Failure.
3172773|NCT00604409|Experimental|Treatment (SIRT and capecitabine)|Patients receive capecitabine PO twice daily on days 1-14. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo SIRT on day 2 and may undergo a second course of SIRT on day 58.
2569027|NCT02439736||CT positive for acute intracranial lesion|
2569132|NCT02438618|Experimental|Minimally invasive punch technique|New surgical technique for Ponto bone anchored hearing implants
2569134|NCT02438618|Other|Hultcrantz technique|Standard surgical technique for bone anchored hearing implants
2569191|NCT02438397|Active Comparator|metformin+premix insulin|metformin:500mg tid
2569195|NCT02438397|Experimental|acarbose+premix insulin|acarbose:100mg tid
3172774|NCT00604422||A|Subjects that are indicated for standard colonoscopy due to suspected or known Ulcerative colitis disease
3172775|NCT00604435|Active Comparator|chemotherapy|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin
3172776|NCT00604435|Experimental|chemotherapy plus endostatin|neoadjuvant therapy with 3 cycles of Docetaxel and Epirubicin plus endostatin
3172777|NCT00604448|Experimental|Pulse group|a group receiving a meal with pulses (5 cups/week) for 8 weeks
3172778|NCT00604448|Experimental|Energy-restricted group|a group with a diet restriction of 500 kcal/day for 8 weeks
3172779|NCT00604474|Active Comparator|1|
3172780|NCT00604487|Active Comparator|1|Insertion of the Atad double balloon ripener device (100 ml NS in each balloon).
3172781|NCT00604487|Active Comparator|2|Insertion of the double balloon instillation device (100 ml NS in each balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
3172782|NCT00604487|Active Comparator|3|Insertion of the folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
3172783|NCT00604513|Experimental|1|
3172784|NCT00604513|Sham Comparator|2|
3172785|NCT00604526|Experimental|1|Questionnaires, Iridium 192 radioactive seeds
3172786|NCT00604539|Experimental|1|Chondroitin sulphate
3172787|NCT00604539|Placebo Comparator|2|
3172788|NCT00604591|Placebo Comparator|Placebo then Tolcapone|"Participants take placebo during study week 1 and then tolcapone during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
2568532|NCT02442583|No Intervention|Arm 2: Phase 1, Step 2|5 early stage colorectal cancer survivors will have recorded telephone interviews to provide feedback about the brochure.
2568535|NCT02442583|Experimental|Arm 3: Phase 2|15 early stage colorectal cancer survivors will complete a baseline survey about sedentary behaviors, then wear an Actigraph device and self-report their sedentary activities for one week. They will receive feedback regarding their activity, and one month after receiving the feedback will participate in a phone survey regarding use of the brochure, physical activity and sedentary behaviors.
2568596|NCT02442453|Active Comparator|curcuma longa|"curenext gel containing curcuma longa i.e. turmeric has strong antioxidant and antiinflammatory properties.~Test group:Topical application twice daily for ten minutes after brushing for four weeks."
2568598|NCT02442453|Placebo Comparator|Placebo gel|Placebo gel consists of corbopol 934 polymer and triethonalamine. Control group:Topical application twice daily for ten minutes after brushing for four weeks.
2568656|NCT02442115||ASD with GID|Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
2568658|NCT02442115||ASD without GID|Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.
2568695|NCT02441686|Experimental|Bortezomib, Lenalidomide, Dexamethasone|"After the screening procedures confirm eligibility to participate in the research study: Each participant will be given a study drug-dosing diary for each treatment cycle. The diary will also include special instructions for taking the study drugs.~- Study Drugs:~Bortezomib- subcutaneous injection on predetermined days of each cycle~Lenalidomide oral daily on predetermined days of each cycle.~Dexamethasone oral on predetermined days of each cycle"
2568783|NCT02441296|Experimental|Formula with lactose|Carbohydrate-free formula with added lactose
2568784|NCT02441296|Experimental|Formula with maltodextrins|Carbohydrate-free formula with added maltodextrins
2568785|NCT02441296|No Intervention|Breastfeeding|Breastfed reference group
2568881|NCT02440828|Experimental|tobramycin inhalation|twice daily tobramycin inhalation (Bramitob) 300 mg and standard intravenous antibiotics treatment
2568882|NCT02440828|Placebo Comparator|Placebo|twice daily placebo inhalation and standard intravenous antibiotics treatment
2568938|NCT02440113||Nellix|Patients with endovascular Nellix repair
2568974|NCT02439866|Placebo Comparator|prescription placebo|control Group consisted of 30 patients who received gelatinous capsules filled with sugar as placebo
2568976|NCT02439866|Active Comparator|prescription Intravenous methylprednisolone|Group 2 or steroid consisted of 30 patients received methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day
2568978|NCT02439866|Active Comparator|prescription normobaric oxygen with face mask|Thirty patients in group 3 or oxygen received 100% normobaric oxygen with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
2569025|NCT02439567|Experimental|Patients|Treatment with new oral antiviral drugs for HCV infection, Fibroscan: Liver and Spleen elastography
3208076|NCT00971347|Experimental|Chewing gum + nutrition brochure|Participants in the experimental arm will be instructed to incorporate gum chewing in their diet with a goal of at least 90 minutes per day. The schedule is 20 minutes each after breakfast, lunch and dinner plus 10 minutes mid-morning, mid-afternoon and 1 to 2 hours after dinner. Experimental participants also will be told to chew gum instead of unplanned eating in response to hunger, cravings, preoccupation with eating, or negative feelings.
3208077|NCT00971360||Conversion disorder|
2569185|NCT02438111||age related macular degeneration|metagenome AMD
2569186|NCT02438111||controls|metagenome controls
2569237|NCT02438085||ACS patients|prospective collection of data and follow-up
2569304|NCT02437370|Experimental|Arm A (pembrolizumab, docetaxel)|pembrolizumab IV over 30 minutes on day 1 and docetaxel IV over 60 minutes on day 1.
2569309|NCT02437370|Experimental|Arm B (pembrolizumab, gemcitabine hydrochloride)|pembrolizumab IV as in Arm A and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8.
3208078|NCT00971360||Healthy control|
2569461|NCT02436434|Active Comparator|pulsed radiofrequency|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
2569464|NCT02436434|Sham Comparator|Sham pulsed radiofrequency|Sham intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in controlled joint
2569482|NCT02436174||study group|patients undergoing cesarean under epidural anesthesia
2569518|NCT02436018|No Intervention|Control group|Oxygen(2L/min) supplied with nasal catheter
2569520|NCT02436018|Experimental|Nasopharyngeal airway group|Oxygen(2L/min) supplied directly through WEI NASAL JET without jet ventilator
2569523|NCT02436018|Experimental|WEI NASAL JET group|Oxygen supplied through WEI NASAL JET with a manual jet ventilator
3208079|NCT00971373|Experimental|Exp Scrubs|antimicrobial impregnated scrubs
3208080|NCT00971373|No Intervention|Non-antimicrobial scrubs|Non-antimicrobial scrubs
2569648|NCT02435030||NP-C Patients|NPC type 1 or 2 patients aged 2-18 years
2569716|NCT02434744|Experimental|Cohort 1 100 mg KD026 BID|100 mg KD026 twice a day (BID) in combination with Metformin for 12 weeks
3208081|NCT00971386|Other|Normal Healthy Subjects|Normal healthy subjects without history, signs-symptoms or diagnosis of heart failure
2568617|NCT02442258|Experimental|Group 1 - Mild Renal Impairment|Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
2568618|NCT02442258|Experimental|Group 2 - Moderate Renal Impairment|Subjects with moderate renal impairment. eGFR (by MDRD equation) range 30 - 59 mL/min/1.73 m2 as determined at Screening.
2568619|NCT02442258|Experimental|Group 3 - Severe Renal Impairment|Subjects with severe renal impairment. eGFR (by MDRD equation) range 15 - 29 mL/min/1.73 m2 as determined at Screening.
2568620|NCT02442258|Experimental|Group 4 - End Stage Renal Disease, Not Yet on Dialysis|Subjects with end stage renal disease, not yet on dialysis. eGFR (by MDRD equation) range < 15 mL/min/1.73 m2 as determined at Screening.
2568621|NCT02442258|Experimental|Group 5 - Normal Renal Function|Subjects with normal renal function. eGFR (by MDRD equation) range ≥ 90 mL/min/1.73 m2 as determined at Screening.
2568622|NCT02442258|Experimental|Group 6 - End Stage Renal Disease, Requiring Dialysis.|Subjects with end stage renal disease, requiring dialysis. eGFR (by MDRD equation) < 15 mL/min/1.73 m2 as determined at Screening.
2568663|NCT02441920||Patients with rheumatoid arthritis|The inception cohort of 400 patients will be followed up for 20 years following recruitment.
2568716|NCT02441699||Intervention group|Rural villages in which Gram Vikas has fully implemented its water supply and sanitation (Mantra) intervention. Intervention villages must: 1) be within 3 hours travel to the study office in Brahmapur, 2) have started the intervention by January 2003, and 3) have completed the intervention by January 2013.
2568717|NCT02441699||Control group|Rural villages that have been matched with intervention villages on demographics and other criteria. The sampling frame for control villages is limited to those: 1) within 3 hours travel to the study office in Brahmapur, and 2) within Gram Panchayats which do not include an intervention village and are not adjacent to an intervention village, to minimize spillover effects. In addition, both intervention and control villages must appear in the Government of India Census in 2001.
3208082|NCT00971386|Other|Chronic Ambulatory Heart Failure|Diagnosis of Chronic Heart Failure and currently on optimal medical therapy
2568879|NCT02440477||partial rotator cuff tears|50 subjects with shoulder pain who are diagnosed with partial rotator cuff degenrative tears by ultrasound. All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
2568880|NCT02440477||control group|50 volunteering subjects without any pain in the upper quadrant.All patients will be measured for their body weight and height and their hand dominance will be notified. Following reliability trials on the first 10 subjects, all subjects will be tested for pain provocation and level of pain (VAS) in both shoulders with 3 commonly used clinical shoulder tests for the diagnosis of rotator cuff diseases Empty can ,Neer test and Hawkins-Kennedy test in 3 sitting postures; normal resting posture, slouched posture, and upright posture with scapular retraction. In addition, the rotator cuff muscle strength tests during shoulder abduction, internal rotation and external rotation will be measured for the 2 shoulders using a hand-held dynamometer.
2568930|NCT02440165|Experimental|Experimental|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
2568931|NCT02440165|No Intervention|Usual care|All participants, both in the intervention group and the control group, receive usual care containing a regular visit to a nurse who will perform a malnutrition screening with the MUST (Malnutrition Universal Screening Tool). If patients are 'malnourished', a visit to the dietician is suggested.
2568960|NCT02439892|Experimental|Early rehabilitation|Exercise and nutrition during radiotherapy: Physical exercise, nutritional advice and oral nutritional supplements.
2568962|NCT02439892|Active Comparator|Late rehabilitation|Multidimensional rehabilitation after radiotherapy: Physical exercise, nutritional advice, oral nutritional supplements and patient education
2569042|NCT02439658||Dofetilide patients|Patients admitted for dofetilide initiation
2569046|NCT02439658||Sotalol patients|Patients admitted for sotalol initiation
2569086|NCT02439034|Active Comparator|Arm A|Paracetamol
2569092|NCT02439034|Experimental|Arm B|Paracetamol + Ketoprofen
2569117|NCT02438709|Experimental|COX-2 Inhibitor|Patients who take COX-2 inhibitor
2569197|NCT02438319||patients with open angle glaucoma|patients with open angle glaucoma who had their optic discs routinely documented by fundus photography. Optic disc photographs will be analyzied by manual planimetry or automated planimetry.
2569352|NCT02437279|Active Comparator|Arm A|Post-surgery infusion for 12 weeks with the combination of ipilimumab+nivolumab
2569353|NCT02437279|Active Comparator|Arm B|A split design 6 weeks upfront surgery and 6 weeks post-surgery infusion with the combination of ipilimumab+nivolumab
3208083|NCT00971386|Other|Acute Heart Failure|Patients admitted to the hospital with acute congestive heart failure.
2569497|NCT02436109||study group|elective cesarean delivery patients
3208084|NCT00971399|Experimental|RMS|ramosetron 0.1mg q.d. SL on D1-5
3208085|NCT00971399|Active Comparator|ODS|ondansetron 8mg, b.i.d SL on D1-5
3208086|NCT00971438|Experimental|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of acute appendicitis are randomised to either diagnostic imaging (US or CT) or a repeat examination after 4-8 hours in-hospital observation.
2568635|NCT02441985|Experimental|Real rTMS Stimulation|rTMS will be delivered over each cerebellar hemisphere, using a 70mm figure-of-eight coil connected to a Magstim RapidStim2 machine while positioned 3 cm lateral to the inion on the line joining the inion and the external auditory meatus. 900 pulses will be delivered consecutively to each side with a frequency of 1 Hz and at an intensity of 90% of the resting motor threshold (RMT) for a total duration of 15 min for each cerebellar hemisphere. The RMT will be defined as the lowest stimulation intensity required to evoke a 50 μV potential in a target muscle. The inion will be taken as the boundary between the posterior cerebellum and the occipital cortex. Therefore the area stimulated will be caudal to the inion to stimulate the posterior cerebellum.
2568638|NCT02441985|Sham Comparator|Sham rTMS Stimulation|Patients randomized to receive sham treatment will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using sham Magstim RapidStim2 Placebo which produces discharge noise and vibration similar to the real coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. The investigator will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp. The investigator will use an electromyography to administer electrical shocks to the scalp simultaneous to each simulated rTMS train.
2568728|NCT02441621|Other|Passive leg raising|
2568732|NCT02441621|Other|premedication|
2568734|NCT02441621|Other|intubation and mechanical ventilation|
2568735|NCT02441621|Other|central venous catheter|
2568737|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
2568738|NCT02441621|Other|transesophageal echocardiography|
2568741|NCT02441621|Other|transpulmonary thermodilution catheter|
2568764|NCT02441075|Experimental|70% Ethanol|The study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
2568812|NCT02440932|Experimental|Phenylketonuria-type diet|"Breakfast: one pouch of amino acid supplement (174 mls supplemented drink PKU cooler 20, Vitaflo®; 20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich [low protein bread (Juvela, UK), no protein vegan cheese (Viotros, UK)], low protein crackers (Vitaflo, UK), and low protein cookies (Juvela, UK).~Dinner: ad libitum buffet meal"
2568814|NCT02440932|Other|Normal diet|Breakfast: 174 ml of milk (20 g protein, 9.4 g carbohydrates, 0.7 g Fat) Lunch: cheese sandwich, crackers, and cookies (regular foods) Dinner: ad libitum buffet meal
2568869|NCT02440646||CCTA group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) without further immediate quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) and/ or percutaneous intervention (PCI).
2568871|NCT02440646||CCTA + Invasive group|All stable chest pain comers admitted to the chest-pain outpatient or inpatient cardiac center with the chronic coronary syndrome who underwent functional tests (CMR, and/ or SPECT, and Echo are mandatory) and coronary computed tomography angiography (CCTA) with further quantitative coronary angiography (QCA), applicable intravascular imaging (FFR, QFR, OCT, IVUS, VH-IVUS) with or without implantation of a stent.
2568913|NCT02440191|Active Comparator|3DCRT|conventional 3-dimensional conformal radiotherapy on the breast, 50.4 Gy/28 fx and tumor bed boost, 9 Gy/5 fx will be irradiated for 6.5 weeks.
2568919|NCT02440191|Experimental|IMRT (Intensity modulated radiotherapy)|"Intensity-modulated radiotherapy (IMRT) with simultaneous integrated boost (SIB) on the whole breast, 50.4 Gy/28 fx and tumor bed, 57.4 Gy/28 fx will be irradiated for 5.5 weeks.~Unlike 3DCRT, concomittant boost technique is used in the IMRT arm."
3208087|NCT00971438|Active Comparator|Repeat examination after observation|Patients with a clinical scoring suggesting an equivocal diagnosis of appendicitis are randomised to either 4-8 hours of in-hospital observation or diagnostic imaging (US or CT)
3208088|NCT00971451|Experimental|knee joint cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
2569031|NCT02439502|Experimental|open label|Upper and Lower digestive tract diagnostic. The Fuse® system is intended for diagnostic visualization of the digestive tract. The system also provides access for therapeutic interventions using standard endoscopy tools. Fuse Colonoscopies are indicated for use within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) for adult subjects and for the upper digestive tract (including the esophagus, stomach, and duodenum).
3208089|NCT00971451|Experimental|TENS|continuous TENS for duration of the 1 hour exercise session
3208090|NCT00971451|No Intervention|No intervention|no modality intervention; just exercise
2569139|NCT02438657|Experimental|median nerve block|"An ultrasound-guided nerve block with dextrose 5% hydrodissection is performed in each case. The first patient will receive a 2 mL local anesthetic solution. For following patients, the volume of local anesthetic depends on the clinical result of the previous patient:~increase of the volume (0.5 mL) in case of failure,~no change or decrease (0.5 mol) in case of success; a randomization is made in this case (BCD method, Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics 2002;58:171-7)"
2569198|NCT02438358|Experimental|LUM Imaging System|No dose or a single dose of LUM015 (0.5 mg/kg or 1.0 mg/kg) will be administered by intravenous injection between 2 to 6 hours prior to surgery. The dose administered in Phase B will be determined based on results of Phase A. All subjects will have intraoperative imaging using the LUM 2.6 Imaging Device.
2569254|NCT02437968|Experimental|Wave 1|South New Jersey school service providers.
2569260|NCT02437968|Experimental|Wave 2|Philadelphia suburbs and surrounding community service providers
2569261|NCT02437968|Experimental|Wave 3|Mississauga, ON (Canada) school district service providers.
2569326|NCT02437539|Experimental|68Ga-NOTA-AE105 PET|One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection
3208905|NCT00979264|Active Comparator|Intervention|Enhanced and/or intensive quality improvement approaches, coupled with standard approaches available through participation in Get With the Guidelines - Heart Failure.
3208906|NCT00979290||Separate anti-TB drugs|
3208907|NCT00979290||Fix-dosed combination anti-TB drugs|
2568706|NCT02441712|Sham Comparator|Subsensory PENS|Subsensory PENS will be a sub sensory stimulus also administered by a tri-phasic stimulation pattern to the hip, quadriceps, hamstring, and adductors (50Hz impulses for 200ms every 1500ms). The stimulus will be administered for 15-minutes followed by the impairment rehabilitation program
2568725|NCT02441361|No Intervention|control|Subjects will undergo bariatric surgery and no exercise training will be prescribed.
2568729|NCT02441361|Experimental|exercise training|Subjects will undergo bariatric surgery and exercise training will be prescribed.
2568768|NCT02441153||Group 1(Extended Timing)|Surgery will be performed at 10-11 weeks after the completion of chemoradiotherapy.
2568776|NCT02441153||Group 2 (Non-extended timing)|Surgery will be performed at 6-7 weeks after completion of chemoradiotherapy.
2568837|NCT02440867|No Intervention|Healthy subjects|Multimodal imaging data acquisitions Clinical data acquisitions
2568839|NCT02440867|Experimental|TBS-MPC|"Intervention with active TBS aiming Medial Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
2568840|NCT02440867|Active Comparator|TBS-CPDLF|"Intervention with active TBS aiming Dorsolateral Prefrontal Cortex in 6 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
2568841|NCT02440867|Sham Comparator|TBS-Sham|"Intervention with Sham TBS in 8 patients with schizophrenia~Baseline: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Endpoint: Multimodal imaging data acquisitions; Clinical data acquisitions; P50 acquisition~Continuous actimetry acquisition"
2568903|NCT02440399|Experimental|Fix protocol - Oral treatment|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
2568910|NCT02440399|Experimental|Spinal morphine|The women will receive 150 mcg morphine with the spinal anesthesia given in the cesarean section
3208091|NCT00971464|Experimental|Eccentric viewing|"Eccentric viewing is the use of a retinal locus other than the anatomical fovea for fixation in cases when there is central vision loss. This other area (or areas) is called the preferred retinal locus (PRL). In eccentric viewing the patient is aware that they are looking to the side or using their side vision. Most patients with a dense central scotoma will develop eccentric viewing naturally over time. It is thought, however, that, in many cases the naturally developed PRL is not in the ideal position. The four components of eccentric viewing that will be taught are: 1) The optimal direction for eccentric viewing 2) Using large objects to teach eccentric viewing 3) Repetitive practicing of the technique and 4) Maintaining the eye in the eccentric viewing position."
3208908|NCT00979316|Experimental|BMS-708163 (800 mg)|
3208909|NCT00979316|Experimental|BMS-708163 (200 mg)|
3208910|NCT00979316|Placebo Comparator|Placebo|
2569740|NCT02434575||PAE|Men with LUTS BPE who have opted for PAE at a participating site, and have consented to take part in the UK ROPE Register Study.
2569742|NCT02434575||TURP|Men with LUTS BPE who have consented to TURP at a participating site, and have consented to the UK ROPE Register Study.
2569746|NCT02434575||Other|Men with LUTS BPE who have had an Open Prostatectomy or laser surgery at a participating site, and have consented to the UK ROPE Study.
2569800|NCT02434094||T1DM Clinicians|Clinicals currently teaching T1DM patients how to use insulin pumps and continuous glucose monitors will be asked to complete the eDAPT on-line training program.
2569802|NCT02434094||T1DM Subjects with DiAs experience|T1DM subjects will prior DiAs experience will be asked to complete the eDAPT on-line training program.
2569803|NCT02434094||T1DM Subjects with no prior DiAs experience|T1DM subjects will no prior DiAs experience will be asked to complete the eDAPT on-line training program.
2569829|NCT02433795|Experimental|Bendamustine plus rituximab(BR)|Intravenous bendamustine plus rituximab intravenously at 1st cycle and subcutaneously from 2nd cycle (to maximum 8th cycle).
2569868|NCT02433431|Active Comparator|Mindfulness Training|14-lesson audio-guided mindfulness training program instructing present-moment attention and an orientation of acceptance
2569869|NCT02433431|Active Comparator|Mindful Attention Only Training|14-lesson audio-guided mindfulness training program instructing present-moment attention only
2569871|NCT02433431|Active Comparator|Analytic Thinking Training|14-lesson audio-guided analytic thinking program encouraging reflection on one's thoughts, feelings, and behaviors, but not instructing mindfulness
2569934|NCT02433197|Experimental|Aerobic program|Individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants.
2569937|NCT02433197|No Intervention|Control group|They will be instructed to continue their current activities and not to increase objectively levels of physical activity performed during the 8-week intervention.
2569985|NCT02432872|Experimental|escalated daunorubicin|Daumorubicin 60mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
2569993|NCT02432872|Active Comparator|standard daunorubicin|Daunorubicin 45mg/m2 per day for 3 days combined with Cytaruabine 100mg/m2 per day for 7 days.
2569995|NCT02432872|Experimental|medium dosage cytarabine|1g/m2 q12h for 3 days as consolidation therapy.
2569996|NCT02432872|Active Comparator|standard dosage cytarabine|100mg/m2 cytarabine for 6 days combined with aclacinomycin 20mg per day for 6 days as consolidation therapy.
2570022|NCT02432469|Experimental|Intervention group|APP specific for this study, with reminder, education materials and feedback mechanism for improving secondary medications
2570025|NCT02432469|No Intervention|Control group|Usual Care
3208911|NCT00979316|Active Comparator|Moxifloxacin|
3208912|NCT00979329||mRCC or GIST treated with sunitinib/sorafenib|
2570157|NCT02431949||Patients|Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
2568789|NCT02441023|Experimental|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
2568790|NCT02441023|No Intervention|Nutritional Therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
2568847|NCT02440737|Experimental|NEST Intervention|Patients (PTs) and their caregivers (CGs) receive educational intervention, follow-up care, psychosocial assessment and care, and questionnaire administration interventions by completing psychosocial questionnaires and meeting with a nurse practitioner (NP) or nurse navigator (NN) for an initial survivorship care planning session to review the expected course of therapy and recovery, identify resources that may be needed and provide recommendations for follow-up. At the end of their treatment EOT), PTs and their CGs complete a 2nd set of questionnaires and meet with the NP/NN for a booster survivorship care planning session. They will receive an individualized final survivorship care plan and related materials. 2 months after EOT, PTs and their CGs complete a final set of questionnaires.
3208092|NCT00971464|Active Comparator|CCTV arm|A CCTV is an electro-optical device mainly used for reading, but which can also be used for writing or viewing pictures. It is comprised of a video camera which faces downwards towards the reading material and which inputs the image to a digital monitor. Magnification is variable over a large range. By means of a zoom lens and the brightness, contrast, and image polarity (black letters on white or white on black) can be controlled to provide the best combination of viewing conditions for an individual user. The significant advantages of CCTV over optical magnifiers are that it provides high levels of magnification with a greater field of view (compared to the equivalent optical device), allows reading at a more normal viewing distance of about 40 - 50 cms and allows binocular viewing.
2568989|NCT02439788|Experimental|GINAKIT Cells plus chemotherapy|Patients receive chemotherapy with Fludarabine and Cyclophosphamide and then an infusion of the GINAKIT cells (iC9-GD2.CD28.OX40.zeta Natural Killer T cells)
2569049|NCT02439424|Experimental|Reactive ATP|"all enrolled subjects will have the Reactive ATP feature in their ICD turned on"
2569080|NCT02439008|Experimental|Blood samples collection|"Nine blood samples will be collected in each patient before, during and after radiotherapy treatment.~Interventions :~Blood samples collection before radiotherapy (T0)~Blood samples collection during radiotherapy (T1-T3)~Blood samples collection after radiotherapy (T4-T8)"
2569140|NCT02438748||Patients|Individuals undergoing Repetitive Transcranial Magnetic Stimulation treatment for major depressive disorder.
2569145|NCT02438748||Controls|Healthy age-, and sex-matched control individuals.
2569190|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 1 breast implants
2569196|NCT02438332||NATRELLE® INSPIRA® TruForm® 1 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 1 breast implants
2569203|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Smooth)|Subjects receiving primary breast augmentation with smooth NATRELLE® INSPIRA® TruForm® 2 breast implants
2569212|NCT02438332||NATRELLE® INSPIRA® TruForm® 2 (Textured)|Subjects receiving primary breast augmentation with textured NATRELLE® INSPIRA® TruForm® 2 breast implants
2569232|NCT02437825|Experimental|octreotide treatment|The studied drug Octreotide 100 mcg will be administered I.V in the evening prior to surgery and for two weeks on a thrice daily basis.
2569234|NCT02437825|Placebo Comparator|placebo treatment|plasebo will be administrated I.V in the evening prior to surgery and two weeks on a thrice daily basis
2569289|NCT02437643|Placebo Comparator|WL-LoEX|10% Weight loss diet plus low intensity exercise (protein ~0.8g/kg). Participants will be provided one serving of dairy protein daily.
2569290|NCT02437643|Active Comparator|Pro-WL-LoEX|Protein-enhanced 10% Weight loss diet plus low intensity exercise (protein ~1.2 g/kg with > 30g per meal and >60% as dairy). Participants will be provided at least 8 servings of dairy protein daily.
3208093|NCT00971477|Experimental|Teledermatology|Online Telemedicine Group
2569456|NCT02436460|Experimental|AbGn-168H|AbGn-168H will be administered once weekly for four weeks via intravenous infusion.
2569608|NCT02435446|Experimental|Eligible patients for cone-beam|A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.
2569774|NCT02434614|Experimental|Induction CT+IMRT alone|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT )alone
2569779|NCT02434614|Active Comparator|Induction CT+IMRT Combined Concurrent CT|Induction Chemotherapy(CT) Followed by Intensity-modulated Radiation Therapy (IMRT ) Combined Concurrent Chemotherapy
2569897|NCT02433782|Experimental|Experimental group|Treatment through myofascial therapy for the treatment of pain and restricted mobility in patients with hemophilic arthropathy of the knee and ankle
2569898|NCT02433782|No Intervention|Control group|No myofascial intervention. Patients continue their treatment with FVIII or FIX concentrates, normally
2569935|NCT02433093|Experimental|Basimglurant: Healthy Cohort (1)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. Cohort 1 will receive a prespecified titration scheme; however, adaptive titration schemes may be applied in subsequent cohorts.
2569938|NCT02433093|Experimental|Basimglurant: Healthy Cohort (2)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 2 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in Cohort 1.
2569940|NCT02433093|Experimental|Basimglurant: Healthy Cohort (3)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 3 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1 and 2.
3208094|NCT00971477|Active Comparator|Usual Care|Conventional in-office care
3208095|NCT00971490|Experimental|Group 1|
3208096|NCT00971490|Placebo Comparator|Group 2|
3208097|NCT00971490|Sham Comparator|Group 3|
3208098|NCT00971503|Sham Comparator|saline injection|
3208099|NCT00971503|Experimental|Autologous bone marrow implantation|
3208100|NCT00971516|Active Comparator|Diabetes|compare cytokines between diabetes and non diabetes patients
3208101|NCT00971516|Active Comparator|Implants|Compare implant healing phases
2569061|NCT02439411||Dabrafenib|
2569067|NCT02439411||Dabrafenib plus Trametinib|Patients treated with Dabrafenib plus Trametinib
2569151|NCT02438644||Study Population|Patients who are prescribed vismodegib in Argentina, according to standard of care and in line with the current SPC and local labeling, are eligible for observation. Dosing and treatment duration of vismodegib are at the discretion of the physician in accordance with local clinical practice and local labeling. Only patients with laBCC or mBCC will be considered in the effectiveness analysis.
2569239|NCT02438072|Other|Overall population|
2569313|NCT02437526|Experimental|Treatment interruption|Antiretroviral therapy will be discontinued under close laboratory monitoring and clinical supervision.
2569338|NCT02437201|Experimental|Liberty Group|Weekly intensive support group for women with children who have suffered or are still suffering from domestic abuse (DA).
2569339|NCT02437201|No Intervention|Control group|
2569369|NCT02436980|Active Comparator|tramadol|1mg/kg of tramadol drop (Contramal® drop, Abdi Ibrahim Ilaç San.,istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, Group T who were separated randomly to two premedication groups.
2569374|NCT02436980|Active Comparator|midazolam|0.15 mg/kg of midazolam (Dormicum®, ampoule, Roche Products A.Ş., istanbul) was administered orally in 10 mL of cherry juice without particles in preparation room before intervention, to Group M who were separated randomly to two premedication groups.
2569427|NCT02436694|Active Comparator|Local Anesthetic ropivacaíne|Femoral nerve block with ropivacaine 0.375% and sciatic nerve block with ropivacaine 0.2%
2569434|NCT02436694|Experimental|Perineural Dexamethasone|Femoral nerve block with ropivacaine 0.375% and perineural dexamethasone and sciatic nerve block with ropivacaine 0.2% and perineural dexamethasone
3208102|NCT00971529||lifestyle|70 volunteers were double-blinded, placebo-controlled and randomized into 2 groups (smoking with tea filters or regular filters).
3208103|NCT00971529||tea filter|The investigators then recruited 59 volunteers with longer smoking history and stronger desire for quitting smoking for smoking cessation test using the tea filter.
3208104|NCT00971542|Experimental|low dose of antigen + low dose of adjuvant|
2569573|NCT02435654|Experimental|Treatment group|All EOS patients will receive olanzapine treatment with flexible dose(2.5 to 20 mg/day)according to standard body weight,olanzapine will be initiated at 2.5 or 5 mg/day and the dose could be increased by 2.5 or 5 mg/day dose increments at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,the investigator could decrease the dose at any time and in any number of dose decrements if patients experienced an adverse event.
3208105|NCT00971542|Experimental|high dose of antigen + high dose of adjuvant|
3208106|NCT00971542|Experimental|high dose of antigen|
3208107|NCT00971555||Late preterm|Late preterm infants admitted to the NICU
3208108|NCT00971568||Urine sample|To prepare for SELDI-TOF we will use 15 samples. Each sample (25ul) will be analyzed with the Luminex 100 IS (MiraiBio, South San Francisco, CA) using a LINCOplex cytokine/che-
3208109|NCT00971581|Experimental|FDC KETOPROFEN+OMEPRAZOLE|One capsule of Ketoprofen 200 mg + Omeprazole 20 mg FDC once daily Treatment duration: 4 weeks
3208110|NCT00971594|Experimental|WL+AEX|Weight loss plus aerobic exercise
3208111|NCT00971607|Active Comparator|1|Sevoflurane
3208112|NCT00971607|Placebo Comparator|2|Oxygen
3208113|NCT00971646||OAB|Patients with overactive bladder syndrome
3208114|NCT00971646||Osteoporosis|Patients with osteoporosis
3208115|NCT00971659|Experimental|insulin glargine + exenatide + metformin|
3208116|NCT00971659|Experimental|Insulin glargine + sitagliptin + metformin|
3208117|NCT00971659|Active Comparator|insulin glargine + metformin|
3208118|NCT00971672||Toddlers from Jewish origin|Toddlers from Jewish origin aged 18 to 36 months
3208119|NCT00971672||Toddlers from non Jewish origin|Toddlers aged 18 to 36 months belonging to non Jewish (Arab) population
3208120|NCT00971685|Experimental|Lenalidomide plus Dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
3208121|NCT00971698||Sickle Cell Patients|Patients with homozygous Sickle Cell Anemia
3208122|NCT00971698||Sickle Cell Thalassemia|Patients with Sickle Cell Thalassemia
3208123|NCT00971711|Experimental|Probiotic|To determine the safety and effectiveness of the probiotic VSL#3 in adults with irritable bowel syndrome (IBS).
3208124|NCT00971724|Placebo Comparator|Placebo|Treatment with placebo for 15 days
3208125|NCT00971724|Experimental|Prednisolone 7.5 mg daily|Treatment with prednisolone 7.5 mg daily for 15 days
3208126|NCT00971724|Experimental|Prednisolone 15 mg daily|Treatment with prednisolone 15 mg daily for 15 days
3208127|NCT00971724|Experimental|Prednisolone 30 mg daily|Treatment with prednisolone 30 mg daily for 15 days
3208128|NCT00971724|Experimental|Prednisolone 75 mg|Treatment with prednisolone 75 mg for a single day
3208129|NCT00971724|Experimental|Prednisolone 15 mg twice daily|Treatment with prednisolone 15 mg twice daily for a single day
3208130|NCT00971763|Experimental|R-GCVP|"Up to 6 x 21 day cycles of R-GCVP:~Gemcitabine 750mg/m^2 days 1 & 8 (increasing to 875mg/m^2 for cycle 2 & 1g/m^2 for subsequent cycles if tolerated satisfactorily)~Cyclophosphamide 750mg/m^2 day 1~Vincristine 1.4mg/m^2 day 1 (capped at 2mg)~Prednisolone 100mg/day days 1-5~Rituximab 375mg/m^2 day 1~Neulasta 6mg day 9"
3208131|NCT00971802|Experimental|Cohort 1|Healthy volunteers - PF-03882845 versus Placebo
3208132|NCT00971802|Experimental|Cohort 2|Healthy volunteers - PF-03882845 versus Placebo
3208133|NCT00971802|Experimental|Cohort 3|Healthy volunteers - PF-03882845 versus Placebo
3208134|NCT00971802|Experimental|Cohort 4|Healthy volunteers - PF-03882845 versus Placebo
2568803|NCT02441010|Active Comparator|Group 4|All of participants with suboptimal health status use the monitoring device with three months, and are randomly grouped into the non-intervention group (Group 4 or Group 5) and the intervention group using the meridian therapy instrument (Group 6 or Group 7). Group 4 are participants without metabolic abnormality in the non-intervention group. No intervention technologies are used in Group 4.
2568805|NCT02441010|Active Comparator|Group 5|Group 5 are participants with metabolic abnormality in the non-intervention group. Group 5 use the health information push technology with three months.
2568806|NCT02441010|Experimental|Group 6|Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
2568807|NCT02441010|Experimental|Group 7|Group 7 are participants with metabolic abnormality in the intervention group. Group 7 use the health information push technology with three months and the meridian therapy instrument with two weeks. Similar with Group 6, if the suboptimal health status is not improved after the treatment of the meridian therapy instrument, then the instrument will continue to be used with an interval of one week.
2568897|NCT02440321|Experimental|parent-child interactive program|The parent-child interactive program is designed by three phase: precontemplation/ contemplation stage, preparation stage, and action/maintenance stage. In phase 1, the main focus is to promote motivation through information providing and being aware of children's perception toward ETS and smoking. In phase 2, the main focus is strengthening parents/children's ability to plan and implement smoke-free home. In phase 3, intervention focus is on maintaining behavioral change and smoke-free home by continuously strengthening implementing ability, identifying and eliminating barriers, and reinforcing successful experience. Parent-child interaction is designed through three phases, and parents perceive children's feedback through all phases.
2568899|NCT02440321|Active Comparator|written materials|The mailed materials included information on ETS and its adverse effects, smoking behavior that causes ETS at home, and a workbook for smoking cessation.
2568964|NCT02440061|Active Comparator|Study Group: Type 2 Diabetes Mellitus (T2DM)|Subjects with Type 2 Diabetes Mellitus (T2DM). Subjects will receive AG and saline infusions, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
2568965|NCT02440061|Active Comparator|Control Group|Control group of healthy subjects. Subjects will receive AG and saline, but the order of which they receive will be random and they will not be told which one they are receiving on each given visit. Arginine will be used at both study visits.
2569014|NCT02439593|Active Comparator|Chemoradiotherapy (CTRT) (Control Group)|"Intervention type:~Drug and Radiation~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT)~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2"
2569016|NCT02439593|Experimental|Thermochemoradiotherapy (CTRTHT)|"Intervention type:~Drug, Radiation and Hyperthermia~Intervention name:~Drug (Gemcitabine) Radiation (Loco-regional radiotherapy by SIB-IMRT) Hyperthermia (Loco-regional hyperthermia),~Intervention description:~Radiotherapy: 5 days a week (Days 1 to 5) of each week for 5.5 weeks (28 fractions), Total dose: 50.4 Gy at 1.8 Gy /fr. over 5.5 weeks Chemotherapy: Gemcitabine (400 mg / sq. m) would be administered weekly 24 hours after hyperthermia on Day 2 and after radiotherapy every week on D2 Hyperthermia: Weekly Local hyperthermia before radiotherapy on D1 of every week, 41-43°C for 60 mins, once every week"
2569065|NCT02439307|Active Comparator|Rifaximin|Patients will receive per day 1200 mg of rifaximin
2569071|NCT02439307|Placebo Comparator|Placebo|Patients will receive a placebo of rifaximin
2569130|NCT02438852|Experimental|Arm I (ropivacaine hydrochloride)|Patients receive ropivacaine hydrochloride IV continuously over 72 hours after radical cystectomy.
2569131|NCT02438852|Placebo Comparator|Arm II (placebo)|Patients receive normal saline (placebo) IV continuously over 72 hours after radical cystectomy.
2569220|NCT02438228|Other|Cardiac output measurement|
3208135|NCT00971815|Active Comparator|escitalopram|A pill containing Escitalopram
2569292|NCT02437422|Experimental|SANGUINATE|Single infusion of SANGUINATE
3174340|NCT00622414|Experimental|Treatment (ziv-aflibercept)|"PART 1: Patients receive aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days for 2 years in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive aflibercept until the maximum tolerated dose (MTD) is determined.~PART 2: Patients receive aflibercept as in part 1 at 150% of the MTD determined in part 1. Treatment repeats every 21 days for 2 years in the absence of disease progression or unacceptable toxicity."
3174341|NCT00622453||Registry of Arrhythmias|Screening of individuals with myotonic muscular dystrophy to evaluate the utility of non-invasive electrocardiographic screening methods and history in predicting serious arrhythmic events.
2569500|NCT02436083|No Intervention|control|no antibiotics
2569501|NCT02436083|Active Comparator|experimental group|drug administration (antibiotic)
2569631|NCT02435329||Healthy volunteers|"10 healthy volunteers~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
3174342|NCT00622479|Experimental|Arm 1|
3174343|NCT00622492||VV-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
3174344|NCT00622492||VA-ECMO|newborn infants with reversible causes of PPHN eligible for ECMO treatment
3174345|NCT00622531||BNP Open|Subjects treated based on clinical assessment and knowledge of BNP values
3174346|NCT00622531||Control|Subjects treated based on clinical assessment alone
3174347|NCT00622557||Surgical|
3174348|NCT00622570|Experimental|1|Pentobarbital
3174349|NCT00622570|Active Comparator|2|thiopental
3208136|NCT00971815|Placebo Comparator|placebo|a placebo pill
3208137|NCT00971828||Idiopathic inflammatory myopathy|IIM patients will be recruited via the Adult Onset Myositis clinic, Salford Royal NHS Foundation Trust. Suitable patients will be asked if they are willing to partake in the study, via a letter, including a patient information leaflet. If willing, they will contact our study co-ordinator, who will facilitate the visit to the WTCRF. The patient will then sign a consent form and be able to enter the study.
3208138|NCT00971854|Experimental|60 Hz stimulation|Experimental reduced frequency pallidal stimulation
2568858|NCT02440542||Postoperative Popliteal nerve block|All patients in the cohort are receiving a postoperative popliteal nerve block as part of their surgical plan. Outcomes including length of stay, Visual Analog Scale Scores, narcotic intake, and patient satisfaction will be collected as the intervention.
2568904|NCT02440386|No Intervention|Control|The control arm receives standard of care. Standard of care involves referral for ART services and follow-up calls (maximum of 6) to assess whether linkage to care has occurred.
2568908|NCT02440386|Experimental|Incentive|The incentive arm receives standard of care plus a R300 voucher. The R300 voucher can be exchanged for cash if the participant starts ART at any clinic of their choice within three months from study enrollment.
3208139|NCT00971854|No Intervention|130 Hz stimulation|Current standard pallidal stimulation setting
3208140|NCT00971867|Experimental|Paclitaxel|
2569081|NCT02439047|Experimental|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~-Adipose tissue samples : will be collected during surgery for breast reconstruction"
3208141|NCT00971880||Patients receiving blood transfusions|All the patients with blood disorders that require blood transfusions
3208142|NCT00971893||Methylprednisolone Group|
2569282|NCT02437734|Other|Coronary angiography|Selected patients will be asked to undergo Coronary angiography with cardiac magnetic resonance imaging before and after Percutaneous Coronary Intervention. Clinical data collection will happen over a 30 month period.
2569299|NCT02437396||Treatment naive GD1|Type 1 Gaucher disease subjects who are naive to any treatment
2569301|NCT02437396||Treated GD1|Type 1 Gaucher disease who are stable on therapy (on the specific ERT and/or SRT and specific dose for at least 2 years)
2569305|NCT02437396||Healthy Volunteers (No longer recruiting)|Age matched healthy controls. No new participants will be enrolled to this arm.
3208143|NCT00971906|Experimental|low dose of antigen + low dose of adjuvant|
3208144|NCT00971906|Experimental|high dose of antigen + high dose of adjuvant|
2569415|NCT02436551||Pregnant women in Tajikistan|
2569462|NCT02436447|Experimental|Normal renal function|
2569463|NCT02436447|Experimental|Mild renal impairment|
2569465|NCT02436447|Experimental|Moderate renal impairment|
2569466|NCT02436447|Experimental|Severe renal impairment|
3208145|NCT00971906|Experimental|high dose of antigen|
3208146|NCT00971958|Active Comparator|Mogen Clamp|
2569674|NCT02434978|Active Comparator|Supplementary doppler-guided endoscopic therapy|
2569675|NCT02434978|Placebo Comparator|control group|
2569680|NCT02434627|Experimental|Sodium Nitrate (Beetroot Juice)|Sodium nitrate in the form of beetroot juice will be administered orally. Patients will be assessed with a number of functional muscle assessments.
2569699|NCT02434588|Experimental|Bhattacharjee ring|
2569713|NCT02434419|Experimental|PENS with training|Patients undergoing percutaneous electrostimulation (PENS) of the pectoral muscle combined with specific training during 12 weeks postoperatively
2569718|NCT02434419|Active Comparator|Specific training|Patients undergoing specific training during 12 weeks postoperatively
2569724|NCT02434419|No Intervention|No intervention|No specific treatment was assigned to these patients postoperatively
2569762|NCT02434315|Active Comparator|Group A - Control|FreeStyle Libre Pro 3 sensor wears
2569765|NCT02434315|Experimental|Group B - Intervention|FreeStyle Libre Pro 4 sensor wears, 2 with reviews
2569768|NCT02434315|Experimental|Group C - Intervention|FreeStyle Libre Pro 6 sensor wears, 4 with reviews
2569864|NCT02433470|Active Comparator|Active tDCS|Active transcranial direct current stimulation
2569867|NCT02433470|Sham Comparator|Sham tDCS|Sham transcranial direct current stimulation
2569941|NCT02433132|Other|Diagnostic test|Diagnostic test will be perform on cell from nasal brushing
2569980|NCT02432833|Experimental|Envarsus® (tacrolimus)|prolonged-release tablets once daily and orally
2569990|NCT02432833|Active Comparator|Prograf or Advagraf|Prograf® hard capsules, twice daily, oral formulation or Advagraf® prolonged-release hard capsules, once daily, oral formulation
2570002|NCT02432534|Experimental|UVB + treatement|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months.
2570008|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
2570051|NCT02432339|Experimental|mycophenolate mofetil (MMF)|Mycophenolate Mofetil (MMF) 500 mg tablet twice a day for 7 1/2 days.
2570052|NCT02432339|Placebo Comparator|Placebo|Placebo (sugar pill) in the same size capsule that the MMF is used in - twice a day for 7 1/2 days.
2570075|NCT02432027|Experimental|IMP 1|C-82 Topical Gel, 1%
3208147|NCT00971958|Active Comparator|Plastibell|
3208148|NCT00971958|Active Comparator|AccuCirc|AccuCirc is a device approved by the FDA for circumcision of male infants up to ten days of life.
3208149|NCT00971971|No Intervention|Control|Traditional SLED
3208150|NCT00971971|Experimental|Profiling|dialysate temperature reduction with Na and ultrafiltration (UF) profiling
3208151|NCT00971984||Alpha thalassemia patients|Patients diagnosed with alpha thalassemia mutations and anemia
3208152|NCT00972036|Experimental|Unresectable colon cancer patients with liver metastases|This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
3208153|NCT00972049|Experimental|1|Capsule administered once orally
3208154|NCT00972049|Placebo Comparator|2|Capsule administered once orally
3208155|NCT00972062|Placebo Comparator|Placebo cream|Cream base used in compounding medications into cream media
2568883|NCT02440490|Experimental|Computerised cognitive training|The cognitive training protocol will be run using pre-validated software, HappyNeuronPro, that delivers cognitive training games. The games are designed to be visually interesting and engaging, and are varied so that each session will comprise multiple different games, to avoid boredom. They begin with easy-to-follow instructions and demonstrations, then as the participant progresses, the difficulty is automatically increased in correspondence with their performance, to avoid ceiling or plateau effects. Participants will be assigned a program targeting multiple facets of cognition found to be compromised in chronic pain states, including divided attention, working memory, mentally planning a sequence of items to form a pattern or complete a puzzle, and response inhibition.
2568886|NCT02440490|Active Comparator|Video watching|This group will be provided with a variety of videos to watch, the content of which will be in the style of documentaries on general interest topics such as nature, travel, culture, and history. Each video is followed by multiple-choice questions that participants will answer, to ensure attention was engaged. The videos are visually stimulating and engaging, but involve no increment in difficulty or requirement to improve skills. They may provide some distraction from pain and may be relaxing, interesting and informative.
3172789|NCT00604591|Experimental|Tolcapone then Placebo|"Participants take tolcapone during study week 1 and then placebo during week 3.~On Day 1, 100 mg of tolcapone/placebo will be taken at three specific times: once in the morning, once in the afternoon, once at night. Then, from Days 2-6, 200 mg of tolcapone/placebo will be taken three times a day: once in the morning, once in the afternoon, once at night. On Day 7, 200 mg of tolcapone/placebo will be taken only in the morning and afternoon. On Day 8, 200 mg of tolcapone/placebo will be taken only in the morning. After the last dose on Day 8 is taken, the wash-out period begins and lasts through Day 14."
3172790|NCT00604604|No Intervention|1|Control group (usual postpartum care)
2568996|NCT02439723|Experimental|Regorafenib|All patients will be treated with 160 mg regorafenib taken orally once daily for the first 21 days of each 28-day cycle. Doses are to be taken immediately following a light breakfast. During the seven-day break period of cycle 1, patients will start pantoprazole 40 mg twice daily for 8 days
2569029|NCT02439450|Experimental|Arm 5: Viagenpumatucel-L + Nivolumab|Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/ 0.5 mL for 18 weeks and bi-weekly nivolumab infusions. After 18 weeks of treatment, patients will continue on monotherapy standard of care nivolumab until confirmed disease progression or unacceptable toxicity, whichever occurs first. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
2569032|NCT02439450|Experimental|Arm 6: Viagenpumatucel-L + pembrolizumab +/- pemetrexed|HS-110 dosing to be initiated at/before the start of the 3rd maintenance treatment cycle, or within 19 weeks of front-line pembrolizumab monotherapy. Patients will receive a combination of weekly HS-110 administered as 5 intradermal 0.1 mL injections at a dose of 1 × 107 viable cells/0.5 mL for 13 weeks in combination with SOC pembrolizumab ± pemetrexed every 3 weeks. Following the 13-week priming period, HS-110 injections will be administered for boosting every 3 weeks in combination with SOC pembrolizumab ± pemetrexed until confirmed disease progression or unacceptable toxicity, whichever occurs first.
2569124|NCT02438943|Active Comparator|Audit and Physician intervention|The intervention will comprise the feedback of the results of the baseline audit, training in motivational interviewing for clinic staff, use of a physician reminder stamp in the patients' charts and distribution of patient education cards
2569127|NCT02438943|Sham Comparator|Audit only|The intervention will comprise the feedback of the results of the baseline audit only
2569174|NCT02438436|Experimental|simo decoction|Patients will receive simo decoction (10 mL/piece,three times per day) and bilateral tsusanli acupoint injections with vitamin B1 two times per day, starting in the first day after resection until flatus.
2569176|NCT02438436|Active Comparator|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
2569177|NCT02438436|No Intervention|empty control|
2569256|NCT02437799||Caesarean section spinal anaesthesia|Dicrotic Wave analysis of pulse oximeter of Women undergoing planned caesarean section under spinal anaesthesia.
2569312|NCT02437565|Active Comparator|Control|Placement of stainless steel crown under general anesthesia without the use of an occlusal template
2569319|NCT02437565|Experimental|Impression|Placement of stainless steel crown under general anesthesia with the use of an occlusal template prepared after making an impression of the teeth using a fast setting polyvinyl siloxane material
2569376|NCT02437136|Experimental|Ph 2 NSCLC (squamous or adeno)|Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)
2569380|NCT02437136|Experimental|Ph 2 NSCLC pre-treated PD-1/LD-L1|Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
2569383|NCT02437136|Experimental|Ph 2 Melanoma pre-treated PD-1/PD-L1|Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)
2569387|NCT02437136|Experimental|Ph 2 Mismatch Repair-Proficient CRC|Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody
2570057|NCT02432222|Experimental|Music Training|Music training
3172791|NCT00604604|Experimental|2|Experimental group (usual postpartum care plus telephone-based support from an experienced mother who has participated in a 4-hour training session)
3172792|NCT00604630|Placebo Comparator|placebo|50ml 0.9% NaCL
3172793|NCT00604630|Active Comparator|verum|erythropoietin alfa 40,000 IU iv in 50ml 0.9% NaCl
3172794|NCT00604682|Experimental|Administration of CC10004|
3172795|NCT00604734|Other|ReCap|ReCap Total Hip Resurfacing System
3172796|NCT00604747|Other|1, 2|
3172797|NCT00604760|Experimental|A|
3172798|NCT00604760|Experimental|B|
3172799|NCT00604760|Experimental|C|
3172800|NCT00604760|Placebo Comparator|D|
3172801|NCT00604773||delirious patients|minimal one positive CAM-ICU score during ICU admission
3172802|NCT00604773||non-delirious patients|without any positive CAM-ICU scores during ICU admission
3208156|NCT00972062|Experimental|Herbal Cream|Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications
3208157|NCT00972075|Experimental|Circadin|Circadin is 2 mg of prolonged release melatonin
3208158|NCT00972075|Placebo Comparator|Placebo|
3208159|NCT00972101|Experimental|Regimen 1: No TBI|High Dose Chemotherapy without Total Body Irradiation (TBI)
3208160|NCT00972101|Experimental|Regimen 2: TBI|High Dose Chemotherapy with Total Body Irradiation (TBI)
3208161|NCT00972114|Experimental|CABG combined cardiomyoplasty|Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
3208162|NCT00972114|Active Comparator|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
2568983|NCT02439827|Experimental|"Fortaleça sua Saúde program"|The intervention program was structured into four main components: (i) training and activities in general curriculum; (ii) training and activities in Physical Education classes; (iii) active opportunities in the school environment; (iv) health education in school community.
2568986|NCT02439827|No Intervention|Control|Schools from the control group carried out one semester with the regular and conventional activities of a full-time school. In general, the control schools had two weekly Physical Education classes that include content and activities according to the perspective of their teachers. The conventional Programa Saúde na Escola were also performed in these schools.
2569041|NCT02439515|Experimental|Biofeedback training|"It consists of 15 daily sessions of voluntary cycling training augmented by functional electrical stimulation (FES) followed by 15 daily sessions of balance training (multimodal biofeedback training). Both cycling and balance training are supported by a visual biofeedback and last about 20 minutes.~In addition to cycling or balance training, subjects perform standard physical therapy in order to reach 90 minutes of training per day."
2569044|NCT02439515|Active Comparator|Usual Care|It consists of 30 daily sessions of standard physical therapy. Each session last about 90 minutes.
2569077|NCT02439021|Experimental|CobraPLA|Patients will randomly assign to either LMA or Cobra PLATM
2569089|NCT02439021|Experimental|LMA|Patients will randomly assign to either LMA or Cobra PLATM
3208163|NCT00972114|Active Comparator|CABG alone|Coronary artery bypass graft surgery alone
2569306|NCT02437591|Experimental|fidaxomicin|tablet twice daily
2569342|NCT02437045|Active Comparator|Meropenem|Meropenem 1g every 8 hrs IV to day 4
2569343|NCT02437045|Experimental|Piperacillin-tazobactam combination product|Piperacillin tazobactam 4.5g every 6 hrs IV to day 4
2569356|NCT02436863||Surgical perfomance (Laminoplasty)|After the lesions inside the spinal canal were surgical removed by laminectomy, the lamina and spinous process were replanted with titanium plates and screws.
3208164|NCT00972140|Experimental|Formoterol-HFA|Formoterol-HFA pMDI 12µg twice daily
3208165|NCT00972140|Active Comparator|Formoterol-DPI|Formoterol-DPI 12µg twice daily
3208166|NCT00972179|Active Comparator|AMG 157|Six subjects in each cohort (cohorts 1 to 6) will receive AMG 157 for a total of 36 subjects.
3208167|NCT00972179|Placebo Comparator|AMG 157 Placebo|Two subjects in each cohort (cohorts 1 to 6) will receive placebo, for a total of 12 subjects.
3208168|NCT00972192|Active Comparator|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and counseling immediately after the baseline interview. Patients underwent phlebotomy and serologic testing and results were disclosed the following day with post-test counseling (before they were discharged from the hospital).
3208169|NCT00972192|No Intervention|HIV testing post-discharge|Participants who were randomized to the control group were given a referral card and an appointment, by the interviewers, to return for free HIV testing and counseling at Mulago hospital one week after discharge. Participants who returned had their transport reimbursed.
3208170|NCT00972218|Experimental|Enteropathic spondyloarthritis|Patients have concomitant inflammatory spinal symptoms and inflammatory bowel disease.
3208171|NCT00972231||Thalassemia Group|Patients suffering from Thalassemia Major and patients with Thalassemia Intermedia
3208172|NCT00972231||Sickle Cell Group|Patients with Sickle Cell Anemia and Sickle Cell Thalassemia
3208173|NCT00972257|Active Comparator|Drug: Dorzolamide/Timolol|
3208174|NCT00972257|Active Comparator|Treatment with Brimonidine/Timolol|
3208175|NCT00972270|Experimental|IMPELLA LP 2.5|
3208176|NCT00972270|Active Comparator|Intra-Aortic Balloon Pump|
3208177|NCT00972296||Persons with hemophilia with ankle pain|
3208180|NCT00972348|Experimental|Access to Personal Health Record|Full access to the Personal Health Record including lists of diagnoses, medications and laboratory values.
3208181|NCT00972348|Active Comparator|No access to the PHR|No access to the PHR but patients will complete surveys.
3208182|NCT00972387|Active Comparator|Order 1|Supplement order for each time trial run, 1-4 respectively: CHO, CHO-P, CHO-CHO, PLA
3208183|NCT00972387|Active Comparator|Order 2|Supplement order for each time trial run, 1-4 respectively: CHO-P, CHO-CHO, PLA, CHO
3208184|NCT00972387|Active Comparator|Order 3|Supplement order for each time trial run, 1-4 respectively: CHO-CHO, PLA, CHO, CHO-P
3208185|NCT00972387|Active Comparator|Order 4|Supplement order for each time trial run, 1-4 respectively: PLA, CHO, CHO-P, CHO-CHO
3208186|NCT00972413|Experimental|Group I|
3208187|NCT00972413|Experimental|Group II|
3208188|NCT00972413|Experimental|Group III|
3208189|NCT00972426|Experimental|Treatment A Group|Mikelan LA + Xalatan
3208190|NCT00972426|Active Comparator|Treatment B Group|Timoptol XE + Xalatan
3208191|NCT00972452|Experimental|Exercise|5-10d exercise training
3208192|NCT00972491|Other|0 sec, 60 sec, 90 sec|LMA will be inserted at 0, 60, and 90 seconds after eyelash reflex disappears
3208193|NCT00972556|Experimental|GMTA|
3208194|NCT00972556|Active Comparator|20% FC|
3208195|NCT00972569|Active Comparator|BNP with PDE-V|BNP (Nesiritide) will be infused starting at 0.0025 g/Kg/min IV for 3 hours, if tolerated increased to 0.005 g/kg/min for 45 hours without bolus with PDEV inhibition, they will also receive Sildenafil 12.5 mg at timepoints 0,12, 24 and 36 hours
3174351|NCT00622596|Experimental|Mobile Access to Buprenorphine|High risk populations accessing a mobile health care system can obtain Buprenorphine for treatment.
3174352|NCT00622609|Experimental|Subjects receiving GSK249320A|Eligible subjects will receive escalating doses of GSK249320A in cohort 1 to 6 with a starting dose of 0.04 milligrams/kilograms up to the maximum dose of 25 milligrams/kilograms, administered as a slow intravenous infusion over 1 hour on Day 1.
2569155|NCT02438566|Active Comparator|Oral Tranexamic Acid (OTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
2569160|NCT02438566|Active Comparator|Intravenous Tranexamic Acid (IVTA)|Subjects will be randomized 1:1 to receive either IVTA or OTA with corresponding placebos. IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
2569194|NCT02438189|Active Comparator|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
2569204|NCT02438189|No Intervention|Predictive Low Glucose Suspend|The control algorithm will run passively and not dose additional insulin. If hypoglycemia is predicted, the system will suspend the pump.
2569275|NCT02437916|Experimental|AMG 228 monotherapy|Part 1 and Part 2 of the study will both be with single agent AMG 228 in different selected tumor types.
2569296|NCT02437435|Experimental|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
2569298|NCT02437435|Placebo Comparator|Placebo technique|The researcher puts his right hand on the right shoulder of the patient for 20 times Metronome.
2569390|NCT02437240|Experimental|Pilates-based CPT|incorporated the concept of pilates training into cardiopulmonary physical therapy after cardiac surgery
2569392|NCT02437240|Active Comparator|Traditional CPT|usual bed side cardiopulmonary physical therapy after cardiac surgery
2569450|NCT02436616||EEG monitoring|All subjects enrolled in this observational study will undergo EEG monitoring using the microEEG device.
2569478|NCT02436213|Experimental|Healthy control|A group of up to 30 healthy controls will be recruited to have a cardiopulmonary exercise test and a blood test.
2569485|NCT02436213|Experimental|Pulmonary AVM|A group of up to 30 pulmonary AVM patients will be recruited to have a cardiopulmonary exercise test, and a blood test.
2569490|NCT02436213|Experimental|HHT but no pulmonary AVM|Most patients with pulmonary AVMs have underlying hereditary hemorrhagic telangiectasia (HHT). If there is a difference between pulmonary AVM and control groups that does not correct following embolization of pulmonary AVMs, a group of up to 30 people with HHT but no evidence of pulmonary AVMs will be selected to have a cardiopulmonary exercise test and a blood test.
2569526|NCT02435888||Polycystic ovary syndrome|
2569572|NCT02435667|Experimental|Resistance Exercise Training|Entails 36 supervised resistance exercise training sessions (3 sessions per week for 12 weeks). Each exercise session will be supervised by a trained, certified Exercise Physiologist specializing in Cardiac Rehabilitation. The specific resistance exercise training will include Aerobic Exercise, Resistance Exercise, and Core Strengthening Exercises. Other baseline and follow-up tests include: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
2569574|NCT02435667|Placebo Comparator|Standard Care|No resistance exercise training. Patients will stay on their current healthcare regimen as previously assigned by their physician. Patients will still undergo baseline and follow-up tests similar to the Resistance Exercise Training group, including: DEXA bone scan, Blood Draw, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, and a Submaximal Exercise Test.
2569645|NCT02435043|Experimental|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management
2569646|NCT02435043|Active Comparator|Treatment as usual|standard management after stroke
2570035|NCT02432690|Experimental|Arm A|
2570070|NCT02432157|Experimental|Hypertonic saline (HTS)|A protocol of prophylactic 3% HTS as a volume expander with bolus (over 30 minutes) of 3% HTS at a dose of 250 ml every 6 hours for 7 days. This will be given through a central line as soon as possible and within 72 hours of onset of SAH symptoms.
3174353|NCT00622609|Placebo Comparator|Subjects receiving placebo|Eligible subjects will receive single dose of sodium chloride in cohort 1 to 6, administered as a slow intravenous infusion over 1 hour on Day 1.
3174354|NCT00622622|Experimental|Phase I study|
3174355|NCT00622648|Experimental|A|Enoxaparin: 40 mg once daily for 6 to 14 days (10 ± 4 days)
3174356|NCT00622648|Placebo Comparator|B|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
3174357|NCT00622661|Other|1|Normal weight
3174358|NCT00622661|Other|2|Overweight
3174359|NCT00622674|Experimental|Bortezomib and Cetuximab|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2. A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
3174360|NCT00622687|Active Comparator|A|low dose iloprost therapy 0.5 ng/kg x min
3174361|NCT00622687|Active Comparator|B|high-dose therapy
3174362|NCT00622752|Experimental|1|EVT 302, 10 mg
3174363|NCT00622752|Experimental|2|EVT 302, 10 mg + NRT patch, 21 mg
3174364|NCT00622752|Experimental|3|NRT patch, 21 mg
3174365|NCT00622752|Placebo Comparator|4|Placebo to match EVT 302 and placebo patch to match NRT patch
3174366|NCT00622765|Experimental|001|R256918 5 mg capsule twice daily
3174367|NCT00622765|Experimental|002|R256918 10 mg capsule twice daily
3174368|NCT00622765|Experimental|003|R256918 15 mg capsule twice daily
3174369|NCT00622765|Placebo Comparator|004|placebo Placebo capsule twice daily
3208196|NCT00972569|Active Comparator|BNP (Nesiritide) will be infused at 0.005 u/Kg/min IV for 48 h|BNP (Nesiritide) will be infused at 0.025 ug/Kg/min IV for 3 hours then 0.005ug/kg/min 45 hours without bolus. No PDE-V is given.
2568987|NCT02439801||Compliance|"Pulmonary compliance (or lung compliance) is a measure of the lung's ability to stretch and expand. In clinical practice it is separated into two different measurements, static compliance and dynamic compliance. Static lung compliance is the change in volume for any given applied pressure. Dynamic lung compliance is the compliance of the lung at any given time during actual movement of air.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on static and dynamic compliance levels will be investigate."
2568991|NCT02439801||Pulmonary Function tests|"Pulmonary function testing has diagnostic and therapeutic roles and helps clinicians answer some general questions about patients with lung disease.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on pulmonary function test values will be investigate."
2568993|NCT02439801||volatil agent elimination time|"Volatile anaesthetics are eliminated in the terminal phase via the lungs. A low blood:gas partition coefficient is therefore necessary for quick removal of the anaesthetic.~Effects of intra-operative PEEP 0, PEEP 5, PEEP 8 treatment on volatil agent elimination time will be investigate."
2569062|NCT02439190|Active Comparator|Treatment A: BMS-986120|BMS-986120 on specified days
2569070|NCT02439190|Active Comparator|Treatment B: Aspirin and Clopidogrel|Aspirin and Clopidogrel on specified days
2569141|NCT02438865|Active Comparator|Single instillation group|will receive single intravesical dose of epirubicin intravesical therapy (50 mg) within 48 hours of radical nephroureterectomy with open bladder cuff excision.
2569144|NCT02438865|Active Comparator|Maintainance therapy group|will receive a single intravesical dose of epirubicin and an additional 6 weekly doses of intravesical therapy (50 mg) after surgery then monthly maintenance therapy for 1 year.
2569199|NCT02438267||Non-NC group|Enrolled subjects who did not have evidence of NC on renal ultrasound
2569209|NCT02438267||NC group|Enrolled subjects who did have evidence of NC on renal ultrasound
2569250|NCT02438033|Experimental|Treatment Arm|All patients will be implanted with the investigational device in an open-label fashion
2569315|NCT02437656|Experimental|Metformin treatment|"J1 : dosimetric scan~J3 : initiation of the Metformin therapy (at a dosage of 1700 mg / day)~J10 : increasing the dose of Metformin (2550 mg / day) + initiation of the radiochemotherapy~J44 : end of the radiochemotherapy~Between J86 and J100 : surgery (discontinuation of the Metformin therapy 48 hours before surgery)"
2569405|NCT02436928|Experimental|AT-501 High Dose vaccine|Inactivated H7N9 High Dose Antigen
2569407|NCT02436928|Experimental|AT-501 High Dose vaccine with Adjuvant|Inactivated H7N9 High Dose Antigen with Adjuvant
2569408|NCT02436928|Experimental|AT-501 Low Dose vaccine|Inactivated H7N9 Low Dose Antigen
2569411|NCT02436928|Experimental|AT-501 Low Dose vaccine with Adjuvant|Inactivated H7N9 Low Dose Antigen with Adjuvant
2569448|NCT02436512|Experimental|Inhaled Nitric Oxide|Active Comparator: Nitric Oxide
3208197|NCT00972569|No Intervention|standard care|Patients randomized to this group will continue to receive therapy at the discretion of the heart failure specialist who is managing the patient (with the exception of BNP and low dose dopamine). Blood and Urine will be collected after the patient has been randomized for 48 hours
2569605|NCT02435394|Experimental|Remote Coach plus Asthma Module|The intervention is for practices to have remote coach support for patients with asthma in addition to doctors using CHADIS-Asthma module. Practices will start sequentially for a time series analysis.
2569609|NCT02435394|Experimental|Asthma Module- No Coach|The intervention is for practices to use CHADIS-Asthma module to improve patient care without a remote coach assisting patient adherence.
2569616|NCT02435394|Active Comparator|CHADIS- no Asthma module|Practices using CHADIS but no Asthma module as a control condition.
2569657|NCT02435121|Experimental|SAR125844|Given intravenously weekly at the dose of 570 mg/m^2 for at least 18 weeks
2569687|NCT02434809|Experimental|Patients with lung cancer|Physician evaluation of patient setup accuracy will be performed using all available images and adjustments will be made as per standard practice. In addition, a respiration motion-corrected CBCT (daily for SBRT, weekly for standard fractionation) will be used to confirm the accuracy of Calypso-based setup. Patients will return for follow up at 3,6, 9, 12, 15, 18, 21 and 24 months (+/- 4 weeks) following completion of radiation therapy. The following assessments will be performed at these visits: history and physical exam, diagnostic CT chest, and toxicity assessment.
3208198|NCT00972582|Experimental|Leucine|
2569758|NCT02434289|Experimental|Resistance exercise and protein products|Practice intervention trial including resistance exercise training and intake of dietary protein products in (frail) elderly, implemented by health care professionals.
2569816|NCT02433951||healthy individuals|Age, gender and BMI matched healthy subjects without any chronic disease or physical disability, and being sedentary.
2569822|NCT02433951||CABG patients|Age, gender and BMI matched CABG patients, without neurologic, nephrologic, respiratory disease.
2569825|NCT02433951||endo-ACAB patients|Age, gender and BMI matched endo-ACAB patients without neurologic, nephrologic, respiratory disease.
2569872|NCT02433574|Experimental|Neoadjuvant stereotactic body radiation|Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
2569908|NCT02433249|Active Comparator|1 Physical Activity|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. All participant receive Fitbit Ones and are asked to use them on a daily basis.
2569912|NCT02433249|Experimental|2 Interpersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
2570058|NCT02432222|Experimental|Visual Arts Training|Visual arts training
2568950|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 8)|Healthy subjects receive 14-day repeated dose once a day at 360 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 15, 24 hours post last dose
2568951|NCT02440100|Experimental|Midazolam DDI (optional cohort 9)|Healthy Subjects receive single dose of 2 mg midazolam in period 1 followed by 14 days PF-06648671 once a day and coadministration of PF-06648671 and midazolam 2 mg in period 2 (Optional cohort)
2568952|NCT02440100|Experimental|Multiple Doses PF-06648671 (cohort 6)|Healthy subject receive 14-day repeated dose once a day at 200 mg of PF-06648671 or matching placebo, CSF LP is collected at baseline 72 hours prior to day 1 dosing and at steady-state on Day 25, 24 hours after last dosing on day 14
2569023|NCT02439619|Experimental|Feasibility Trial|
2569084|NCT02439255|Experimental|Arm I (BRB nectar)|Participants receive BRB nectar PO QD for 12 weeks.
2569088|NCT02439255|Placebo Comparator|Arm II (placebo nectar)|Participants receive placebo nectar PO QD for 12 weeks.
2569138|NCT02438670|No Intervention|Open-Loop Care|The subjects Open-Loop Care for the 24-hour period prior to each study sessions assessed for time in the target range 70-180 mg/dL, and frequency of hypoglycemia and hyperglycemia as assessed by CGM.
2569143|NCT02438670|Experimental|PID algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a proportional-integral-derivative (PID) control algorithm, incorporating a personalized model of glucose-insulin dynamics.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
2569147|NCT02438670|Experimental|MPC algorithm with HMS|"Subjects will be treated with closed-loop care for 27.5h using a model predictive control (MPC) control algorithm with HMS, using the identical model as in the first experimental arm.~The health monitoring system (HMS) predicts impending hypoglycemia, and will be used in both experimental arms as an important safety feature of the device."
2569206|NCT02438254||FH+|Young adults with at least one parent with an alcohol or other drug use disorder history.
2569215|NCT02438254||FH-|Young adults with no histories of alcohol or other drug use disorders in any parents or grandparents.
2569255|NCT02438046|Experimental|Palatal wound bandage by PRF|Intervention: In the test group (n=20 patients) the palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
2569257|NCT02438046|Placebo Comparator|Palatal wound bandage by gelatin sponge|Intervention: The control group patients (n=20) will have their palatal wound medicated by absorbable gelatin sponge.
2569293|NCT02437552|Placebo Comparator|Control group: routine physiotherapy|Are patients who carry out the routine already established the Unit, consisting of the first post surgery, the patient lying down doing the breathing exercises, active exercises ends and active-assisted upper (UL) and lower limbs (LL),
2569294|NCT02437552|Active Comparator|Intervention group: ergometer cycle exercise|Are the patients who will carry out the exercises routine over the cycle ergometer twice daily from 3 PO for 5 minutes with its progressiveness at discharge for ward for 10 minutes
2569334|NCT02437292|Experimental|Ischemic compression with stretching|The participants will receive the ischemic compression with stretching onto the trapezius muscle
2569336|NCT02437292|No Intervention|Control|Rest on the bed
2569373|NCT02437032|Active Comparator|Group 1: recombinant FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of rFSH (Gonal-F®, Merck-Serono, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously
2569378|NCT02437032|Active Comparator|Group 2:urinary FSH|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of urinary FSH (uFSH) (Fostipur®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously.
2569384|NCT02437032|Active Comparator|Group 3: with hMG|An oral contraceptive pill (Microgynon30®, Bayer Hispania, Spain) was taken for a maximum of 21 days, starting on day 1-2 of the menses of the previous cycle. After a wash-period of five days after the last pill, donors started to receive daily doses of 150-300 UI of hMG (HMG-Lepori®, Angelini, Spain; n=30) depending on their age, body mass index (BMI) and ovarian response in previous cycles. Daily doses of 0.25 mg gonadotropin- releasing hormone antagonist cetrorelix (Cetrotide®, Merck-Serono, Spain) were started on day six of stimulation in each group. When at least three or more leading follicles reached a mean diameter of ≥18 mm, hCG (Ovitrelle®, 250 µg; Merck-Serono, Spain) was administered subcutaneously, and transvaginal oocyte retrieval was performed 36 h later.
2569471|NCT02436421|Other|Atrial Fibrillation BPA|The alert will notify providers when patients with atrial fibrillation are not on anticoagulation
2569472|NCT02436421|Other|Hypertension BPA|The alert will notify providers when patients have elevated blood pressure
2569473|NCT02436421|Other|Atrial Fibrillation and Hypertension BPA|Providers in this arm will receive both alerts
2569514|NCT02436057|No Intervention|Usual care|Individuals in this arm will undergo usual care with their physician.
2569515|NCT02436057|Experimental|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Individuals in the AEGIS arm will be invited to use AEGIS/My GI Health prior to their clinic visit. For those who complete AEGIS/My GI Health, their physician will have access to their AEGIS symptom report (includes a GI symptom heat map and GI history) and tailored education prescription.
2569538|NCT02435758|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
3208199|NCT00972647|No Intervention|Unguided|Fluoroscopy images taken without laser beam guidance
2569022|NCT02439606|Active Comparator|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
2569024|NCT02439606|Experimental|Parker-Flex-It Directional Stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It Directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
2569056|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
2569059|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
2569066|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|Subjects will be randomized after the results of the polysomnography (21st day ± 10) in one of this three groups
3174370|NCT00622778||1|Patients from daily practice
3174371|NCT00622791||CABG group|Patients undergoing coronary artery bypass graft with cardiopulmonary bypass
2569233|NCT02437877||Mouth Breather|Mouth Breathers Children from 7 to 13 years old
2569235|NCT02437877||Nasal Breather|Nasal breathers children from 7 to 13 years old
2569308|NCT02437708|Experimental|REP with L-PRF|The first REP session will be performed as described by Diogenes et al. (2013). For the second REP-session a venipunction will be performed before the endodontic treatment. 2 to 4 tubes of blood will be collected per tooth. These blood samples will be put into a centrifuge for 12 minutes at 2700 rpm. Fibrin clots will be collected after centrifugation and inserted in the root canal with endodontic pluggers. Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
2569320|NCT02437708|Active Comparator|REP|A REP will be performed on immature infected permanent teeth, as described in the protocol of Diogenes et al. (2013). Medcem Portlandcement (GmbH, Swiss) will be used instead of mineral trioxide aggregate in the second session, to prevent tooth discoloration.
2569360|NCT02437071|Experimental|Pembrolizumab Plus Radiotherapy|pembrolizumab plus RT in subjects with metastatic CRC who are undergoing RT as standard therapy
2569368|NCT02437071|Experimental|Pembrolizumab Plus Ablation|pembrolizumab plus ablation in subjects with metastatic CRC who are undergoing ablation as standard therapy
2569474|NCT02436161|Experimental|"Care management program PROMIC"|care management program provided by a multidisciplinary team that optimizes care with the main role of nurses acting as coaches of patients and carers, within the primary care teams
2569475|NCT02436161|No Intervention|Usual care|Patients in the control group belongs to different Primary health care centres from the intervention group and are treated as usual by their Primary Care team and by cardiologists different from the intervention group
2569704|NCT02434432|Experimental|condition 1|Infants in this arm will receive their mother's choice of music recorded on an Mp player and delivered via headphones.
2569705|NCT02434432|Active Comparator|condition 2|Infants in this arm wil receive a recorded Lullaby music delivered to the infant via headphones.
2569706|NCT02434432|No Intervention|Condition 3|Infants in this arm will have the headphones applied but no music played.
2569754|NCT02434341||septic patients|wake septic patients on mechanical ventilation
2569755|NCT02434341||COPD patients|wake COPD patients on mechanical ventilation
2569797|NCT02434107|Experimental|Completion Lymphadenectomy|Completion Lymphadenectomy and monitoring afterwards
2569799|NCT02434107|Experimental|Clinical Monitoring (Palpation and node ultrasound)|Monitoring only
2569861|NCT02433704|Active Comparator|Intraosseous Administration|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
2569865|NCT02433704|No Intervention|Systemic Intravenous Administration|Historical controls will be used and will have received systemic dosing of cefazolin within one hour of the incision.
2570059|NCT02432222|No Intervention|Control|Waitlist control
3174372|NCT00622791||OPCAB group|Patients undergoing off-pump coronary artery bypass graft
3174373|NCT00622804|Other|1|Billroth-II (B-II)reconstruction
3174374|NCT00622804|Other|2|Roux en Y gastrojejunostomy (RY-GJ)
3174375|NCT00622804|Other|3|uncut Roux en Y gastrojejunostomy (uncut RY-GJ)
3174376|NCT00622817|Active Comparator|1|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
3174377|NCT00622817|Experimental|2|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
3174378|NCT00622843|Experimental|Group 1|PCV, 210 patients
3174379|NCT00622843|Active Comparator|Group 2|PPV, 110 patients
3174380|NCT00622843|Active Comparator|Group 3|PPV, HIV-negative, 25 patients
3174381|NCT00622856|Experimental|1|Psychological intervention for strengthening parental authority
3174382|NCT00622856|Active Comparator|2|Diabetes education- 5 sessions with diabetes nurse, taking place once a week
3174383|NCT00622856|No Intervention|3|Control group- regular treatment without any intervention
3174384|NCT00622882|Active Comparator|ID|Patients receiving an early Infectious disease consultation ( within first 48 hours of a positive blood culture)
3174385|NCT00622882|No Intervention|NO ID|Includes those patients who do not receive an Infectious disease consultation in the first 48 hours
3174386|NCT00622921|Other|1|Couples-based behavioral psychotherapy
3174387|NCT00622934|Active Comparator|1|
3174388|NCT00622934|Placebo Comparator|2|
3174389|NCT00622947|Active Comparator|repetitive transcranial magnetic stimulation|Low frequency ( 1 HZ) rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
3174390|NCT00622947|Sham Comparator|Placebo stimulation|Sham- rTMS of the right prefrontal cortex. On each of 15 consecutive week days (apart from weekends), the patients received two 60-second1-Hz trains delivered at an intensity of 110% of motor thresholdand with a 180 seconds' intertrain interval.
2568980|NCT02440009|Active Comparator|Glucocorticoid group|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
2568981|NCT02440009|Experimental|Itraconazole plus glucocorticoid group|Oral itraconazole 200 mg BD for 6 months AND oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma.
2569079|NCT02439125|Experimental|Eltoprazine HCl 2.5 mg|Eltoprazine HCl 2.5 mg capsules to be taken orally b.i.d. (ie, 5 mg/day) for 3 weeks
2569093|NCT02439125|Experimental|Eltoprazine HCl 5.0 mg|Eltoprazine HCl 5.0 mg capsules to be taken orally b.i.d. (ie, 10 mg/day) for 3 weeks
2569097|NCT02439125|Experimental|Eltoprazine HCl 7.5 mg|Eltoprazine HCl 7.5 mg capsules to be taken orally b.i.d. (ie, 15 mg/day) for 3 weeks
2569099|NCT02439125|Placebo Comparator|Placebo|Placebo capsules to be taken orally b.i.d. for 3 weeks
2569137|NCT02438696|Experimental|3 BI 1060469 low dose|TF2 followed by iFF followed by TF1
2569142|NCT02438696|Experimental|1 BI 1060469 high dose|TF1 followed by TF2 followed by iFF
2569149|NCT02438696|Experimental|2 BI 1060469 high dose|iFF followed by TF1 followed by TF2
2569152|NCT02438696|Experimental|3 BI 1060469 high dose|TF2 followed by iFF followed by TF1
2569156|NCT02438696|Experimental|1 BI 1060469 low dose|TF1 followed by TF2 followed by iFF
2569161|NCT02438696|Experimental|2 BI 1060469 low dose|iFF followed by TF1 followed by TF2
2569207|NCT02438098|Other|Rivaroxaban arm|Pharmacokinetics / Pharmacodynamics
2569249|NCT02437955|Experimental|FESO4+T|Ferrous sulfate fortified bread with tea
2569252|NCT02437955|Experimental|FESO4+W|Ferrous sulfate fortified bread with water
2569253|NCT02437955|Experimental|FeFu+T|Ferrous fumarate fortified bread with tea
2569258|NCT02437955|Experimental|FeFu+W|Ferrous fumarate fortified bread with water
2569295|NCT02437448||Idiopathic lung fibrosis|20 IPF patients
2569297|NCT02437448||Controls|20 subjects with no apparent lung disease and normal lung function testing. Matched for gender, age and smoking history.
2569354|NCT02437266|Experimental|Scapular mobilization|The participants will receive a twenty minutes session of scapular mobilization onto the scapular
2569355|NCT02437266|No Intervention|Control|Rest on the bed for twenty minutes
2569421|NCT02436785|Active Comparator|Music Therapy|The music therapy group will run for approximately an hour (twice a week) and will involve in-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
2569422|NCT02436785|Active Comparator|Music Listening|The control group will also run for approximately an hour (twice a week) and will involve listening to relaxing music on a CD player.
3208200|NCT00972647|Experimental|Laser guided|Fluoroscopy images taken with laser beam guidance
3208201|NCT00972660|Active Comparator|Control group|"Patients with newly diagnosed extensive cGVHD receive prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive primary treatment (eg,prednisone and cyclosporine or tacrolimus, or plus mycophenolate mofetil, or methotrexate.)"
2569643|NCT02435004|Other|Spinal Modulation Axium™|Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:
2569741|NCT02434380|Active Comparator|Low dose vitamin D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
2569743|NCT02434380|Active Comparator|High dose vitamin D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
2569780|NCT02434159|Active Comparator|Scan|Heart scan prior to device insertion
2569787|NCT02434159|No Intervention|No scan|No heart scan prior to device insertion
2569838|NCT02433925|Active Comparator|Supplement B|Administration of 500mg of trans-resveratrol per day, for 4 weeks
2569840|NCT02433925|Placebo Comparator|Supplement A|Administration of 500mg of placebo per day, for 4 weeks
2569875|NCT02433444||Patients receiving ERCP|Patients receiving Endoscopic retrograde cholangiopancreatography (ERCP) at Cedars-Sinai Medical Center.
2569970|NCT02432989|No Intervention|Resting Control Group|Patients will receive standard concussion management, but will be asked not to exercise for the first 7 days after their concussion.
2569971|NCT02432989|Experimental|Exercise Group|Patients will receive standard concussion management, but will be asked to exercise on a stationary bike on two different occasions (once for 15 minutes and again for 30 minutes) in their first week of recovery. This group will also be asked to complete a 30 minute leisurely walk at their convenience on the two days they are not tested at UBC or Fortius.
2570068|NCT02432079||Heterotaxy and congenital heart defects|Patients and family members with heterotaxy and related congenital heart defects
2570147|NCT02431936|Experimental|Prazosin|Prescription for 1mg oral Prazosin twice per day will be administered for 71/2 days.
2570151|NCT02431936|Placebo Comparator|Placebo|Prescription for placebo identical to Prazosin dosage will be administered for twice daily for 71/2 days.
2570214|NCT02431403|Experimental|ESHAP-Imatinib 100mg|"Imatinib 100 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
2570218|NCT02431403|Experimental|ESHAP-Imatinib 200mg|"Imatinib 200 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
2569043|NCT02439346|Experimental|BAY1143269 25 mg|Subjects received BAY1143269 25 mg tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
2569047|NCT02439346|Experimental|BAY1143269 50 mg|Subjects received BAY1143269 50 mg (2*25 mg) tablet orally, QD from Day 1 to 21 in treatment cycle until evidence of tumor progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator. A treatment cycle consisted of 21 days.
2569063|NCT02439060|Experimental|Arm I (biologic mesh)|Patients undergo placement of biologic mesh during radical cystectomy and placement of the ileal conduit.
2569069|NCT02439060|No Intervention|Arm II (no intervention)|Patients undergo standard of care radical cystectomy and placement of the ileal conduit.
2569150|NCT02438878|Experimental|Baby Behavior|"The intervention is comprised of 2 components: HCP and medical staff training and participant education. The trainings will be video-based and aim to build providers' knowledge and skills to support parents' recognition and understanding of common healthy infant behaviors that may be misinterpreted by parents. The intervention does not include any specific recommendations for infant feeding, nor does it include any information related to the assessment, diagnosis or treatment for any medical condition.~After completion of the intervention trainings, health care providers and medical staff will be asked to use what they learned with the mothers of infants in their care. Short handouts for mothers will be provided as tools to reinforce the verbal education. All educational materials will be focused only on supporting parents' abilities to recognize and understand common, healthy infant behaviors."
2569154|NCT02438878|No Intervention|Control|The control arm will continue with standard well-baby visit practices during the intervention period and will be offered the option to complete the Baby Behavior online trainings for continuing education credits.
2569244|NCT02437812|Experimental|Paclitaxel, carboplatin and metformin|"Drug: Metformin (850 mg) Drug: Carboplatin (AUC 5 or 6) Drug: Paclitaxel (80 mg/m2)~The regimen will be administered as a dose dense schedule."
2569363|NCT02437006|No Intervention|rehabilitation|half an hour physical and half an hour occupational therapy in rehabilitation
2569371|NCT02437006|Experimental|Low-intensity exercise|Low-intensity exercise plus rehabilitation
2569377|NCT02437006|Experimental|High-intensity exercise|High-intensity exercise plus rehabilitation
3172803|NCT00604799|Active Comparator|Test (Enrollment Completed)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair whom are low to moderate risk (0, 1, & 2) per the modified SVS/AAVS criteria who meet inclusion/exclusion criteria. The aneurysm must be at least 20 mm distal to the left common carotid artery & 20 mm proximal to the origin of the celiac artery.
3172804|NCT00604799|Other|Registry (Enrollment Completed)|Surgical candidates of low to moderate risk (SVS 0, 1, 2) that meet the Registry Inclusion/Exclusion criteria.
3172805|NCT00604799|Other|High Risk (Enrollment Completed)|"Patients that meet one or more of the following:~High Risk (SVS 3)~Non-surgical candidates not associated with SVS scoring~Traumatic thoracic injuries"
3172806|NCT00604799|Other|Talent Captivia (Recruiting)|Patients diagnosed with a TAA of degenerative etiology that are considered candidates for open surgical repair who meet inclusion/exclusion criteria.
2569493|NCT02436096|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks
2569495|NCT02436096|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks
2569548|NCT02435771|Experimental|BMI <25|Normal BMI
2569552|NCT02435771|Experimental|BMI 25-35|Overweight and obese by BMI
2569553|NCT02435771|Experimental|BMI >35|Obese by BMI
2569576|NCT02435498|Experimental|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
2569577|NCT02435498|Active Comparator|Video|The online video will contain the same information within the website.
2569578|NCT02435498|Active Comparator|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
2569621|NCT02435342|Experimental|30ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
2569622|NCT02435342|Experimental|60ug dalazatide|12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks.
2569644|NCT02435017||Adults 20-85 years|Data from adults 20-85 years old will be evaluated for serum phosphorus concentration.
2569681|NCT02434952|Experimental|DHA PP plus primaquine, G6PD deficiency|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
2569682|NCT02434952|Active Comparator|DHA PP plus primaquine, G6PD normal|"Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.~Target dose of 0.25mg/kg primaquine given orally with first dose only of DHA PP, dosing by weight for children <18 years and standard 15mg primaquine dose for all adults ≥18 years. Small children (<25kg) will receive a primaquine suspension, adults receive 7.5mg or 15mg primaquine tablets."
2570073|NCT02432131||Divers with PFO|
2570082|NCT02432131||Divers without PFO|
3172807|NCT00604838|Experimental|I|
3172808|NCT00604864|Experimental|1|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
3172809|NCT00604864|Placebo Comparator|2|women with a deep endometriosis nodule of at least 1 cm in diameter; and severe pain (at least one severe pain score on Biberoglu Behrman scale)
3172810|NCT00604877|Experimental|1|
2569052|NCT02439398|Placebo Comparator|Placebo: Human Serum Albumin-HSA 5%|After randomization, subjects will received placebo (which is also the cell medicine diluent). The placebo consists of a final administered volume of human serum albumin 5% in saline solution equivalent to the reconstituted cell medicine (18 mL). The placebo to be used is a marketed product (HSA 5%).
2569107|NCT02438982|Active Comparator|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
2569108|NCT02438982|Experimental|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3 , it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
2569158|NCT02438605||Treatment group|Patients eligible for AAA repair using Nellix and willing to participate in this trial.
2569205|NCT02438293||children undergoing cardiac surgery|paediatric patients with a congenital heart disease undergoing elective cardiac surgery
2569243|NCT02437942|Experimental|Biomechanics led physical therapy rehabilitation|Physical therapy exercise rehabilitation
2569316|NCT02437578||Infertile couples|Infertile couples referred to Dansk fertilitetsklinik (Danish Fertility clinic) for IUI, IVF and ICSI treatment
2569349|NCT02437227|Experimental|Experimental: CCT3833|The starting dose of CCT3833 is 20 mg, taken as two 10 mg capsules. The starting schedule is a once daily continuous dosing schedule, but other dosing regimens may be considered depending on tolerability and exposures.The first dose of continuous dosing defines Cycle 1 Day 1. All treatment cycles have a duration of 28 days.
2569358|NCT02436824|Experimental|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days.
2569365|NCT02436824|Placebo Comparator|Placebo patch|Identical in size and shape to the AB001 patch. Two placebo patches will be applied to the low back once daily for 14 days.
2569416|NCT02436629|Active Comparator|Nitrate-rich concentrated beetroot juice|Dietary supplement: 800 mg of nitrate in 140 mL of concentrated beetroot juice (Beet-IT)
2569419|NCT02436629|Placebo Comparator|Nitrate-depleted conc. beetroot juice|Placebo: 140 mL of nitrate-depleted concentrated red beetroot juice
2569512|NCT02436369|Experimental|low fat yogurt enriched with flaxseed|200 gr low fat yogurt enriched with 30 gr flaxseed
2569513|NCT02436369|Placebo Comparator|low fat yogurt|200 gr low fat yogurt
2569542|NCT02435784|Active Comparator|2-COM group|Patients will use the Two-Way Communication Checklist (2-COM) once in a psychiatric consultation.
2569549|NCT02435784|Placebo Comparator|TAU group|Treatment as usual (TAU) group.
3208202|NCT00972660|Experimental|Mesenchymal stem cell (MSC)|"Patients with newly diagnosed extensive cGVHD receive MSC plus prednisone and cyclosporine or tacrolimus.~Patients with refractory extensive cGVHD receive MSC plus their primary immunosuppressive treatment (eg. prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate.)"
3208203|NCT00972673|Experimental|arm 1|In Arm 1 subjects will receive 200, 400 or 800 microgram of powdered inhalation of GW685698X once daily for 7 days from Day 5 to Day 11.
2569670|NCT02435108|Experimental|crizotinib arm|crizotinib medication
2569719|NCT02434757|Experimental|Acthar 40 U|Acthar 40 U (0.5mL)
2569760|NCT02434237||patients|
2569767|NCT02434237||healthy subjects|
2569831|NCT02434029|Experimental|Budesonide|Budesonide 1mg orodispersible tablet twice daily
2569835|NCT02434029|Placebo Comparator|Placebo|Placebo orodispersible tablet twice daily
2569878|NCT02433522|Experimental|Rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months
2569883|NCT02433522|Placebo Comparator|Placebo|Placebo infusion at the randomization visit and every 6 months for 18 months
2569917|NCT02433184|Experimental|Etanercept|Treatment Arm 1 will receive etanercept and methotrexate combination therapy administered for a total duration of 48 weeks.
2569920|NCT02433184|Active Comparator|Methotrexate-treat to target|Treatment Arm 2 will receive initial methotrexate monotherapy with adoption of a treat to target protocol (standard care involving monthly DAS28-ESR assessment with escalation to combination sDMARD therapy if not achieving LDA at, or after, 8 weeks) and step-up to etanercept and methotrexate at 24 weeks if failing to achieve clinical remission
3208204|NCT00972673|Placebo Comparator|arm 2|In Arm 2 subjects will receive Placebo powdered inhalation once daily for 7 days from Day 5 to Day 11.
3208205|NCT00972686|Experimental|GSK2126458|GSK2126458 will be dosed continuously (every day) for the duration a 28 day cycle. The 28 day cycles will continue until the subjects withdraw from the study.
2570064|NCT02432352|Experimental|Intervention|Families are randomly allocated to a behavioral intervention arm (called Our Family Our Future) focusing on reducing sexual risk behavior in adolescents and reducing or maintaining symptoms that fall below the clinically significant range for depression. Arms will be allocated using urn randomization.
2570072|NCT02432352|No Intervention|Control|Families are randomly allocated to the control arm (which receives standard usual care, and then offered the intervention after outcome assessments as a wait-list) using urn randomization.
2570108|NCT02431910|No Intervention|Control group|The control group remains at rest for 10 minutes, which is not applied KT in the RF, VL and VM muscles. The volunteers of this group perform all evaluation without the application of KT
2570109|NCT02431910|Placebo Comparator|Placebo group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 0%.
3208206|NCT00972699|Experimental|Mentor Mothers Intervention|In the intervention arm, participants will receive the Department of Health-delivered Prevention of Mother to Child Transmission (PMTCT) program plus the Project Masihambisane mentor mothers support program. HIV positive mentor mothers, who have been through the PMTCT program, will be recruited and trained to deliver the intervention to pregnant mothers living with HIV.
2569082|NCT02439216|Experimental|Dose 1|Edasalonexent 67 mg/kg/day. Capsules taken by mouth two times per day
2569094|NCT02439216|Experimental|Dose 2|Edasalonexent 100 mg/kg/day. Capsules taken by mouth three times per day
2569096|NCT02439216|Placebo Comparator|Placebo|Matching placebo
2569119|NCT02438683|Placebo Comparator|1 Placebo|2 x single doses (1x resting conditions, 1 x exercise conditions)
2569122|NCT02438683|Experimental|2 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
2569125|NCT02438683|Experimental|3 BI 409306|2 x single doses (1 x resting conditions, 1 x exercise conditions)
2569166|NCT02438462||Group with PE|"The criteria for confirmation of PE are:~PE on spiral computed tomography (CT)~proximal deep vein thrombosis on ultrasound (US)~thromboembolic events objectively confirmed during the follow up"
2569168|NCT02438462||Group without PE|"The criteria for exclusion of PE are:~low or moderate clinical probability and D-dimer ELISA <0.50 µg/mL or <10xage in patients older than 50 years and negative follow up~low and moderate clinical probability and negative CT and negative follow up~high clinical probability and negative CT, US and follow up."
2569208|NCT02438163|Experimental|Patients with MDD|the group of depressed patients undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
2569213|NCT02438163|Experimental|healthy Controls|the group of healthy controls undergo 2 Theta Burst Stimulations : iTBS and cTBS. There is one session per stimulation. Cerebral Plasticity is measured after each stimulation for each session
2569238|NCT02437929||Patients receiving standard procedures|
3208207|NCT00972699|No Intervention|Control|Mothers living with HIV in the standard of care control clinics will receive the Department of Health-delivered PMTCT program.
3208208|NCT00972712|Experimental|A|Bortezomib and Tipifarnib
3208209|NCT00972764||Control|
3208210|NCT00972764||Laryngomalacia Cases|
2569467|NCT02436473|Experimental|Test fluoride toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods
2569468|NCT02436473|Placebo Comparator|Fluoride free (0ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
2569469|NCT02436473|Active Comparator|Low dose fluoride (250ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
2569470|NCT02436473|Active Comparator|Fluoride (1150ppm F) reference control toothpaste|Participants will apply 1.5 weighed g (± 0.1 g) of the study toothpaste to a wet toothbrush and brush their natural teeth twice daily for one timed minute. Participants will wear their mandibular partial denture with test specimens while brushing and continuously for 24 hours a day during each of the 4-week treatment periods.
3208211|NCT00972790|Sham Comparator|Control Group|The patients in the control arm will receive sham nerve blocks with 20 ml of saline + epinephrine 1:200,000, in a manner identical to that described for the treatment group.
3208212|NCT00972790|Active Comparator|Intervention Group|The patients in the intervention group will receive bilateral scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000.
3208213|NCT00972803|Experimental|pistacia Mutica|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
3208214|NCT00972803|Placebo Comparator|placebo|The subjects were asked to use a mouthwash containing Placebo twice a day for 4 days.
2569669|NCT02435290||patients with malignant cancer receiving chemotherapy|five hundred patients suffering malignant cancer from eight wards ( breast , GIT ,gynecological , genitourinary , lung , head and neck, lymphoma and myeloma ,skin and melanoma) ,receiving various chemotherapy protocols .
3208215|NCT00972803|Active Comparator|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
3208216|NCT00972829|Experimental|Crestor|Crestor 10 or 20 milligrams
3208217|NCT00972829|Active Comparator|Ezetimibe|Ezetimibe 5 or 10 milligrams
2569891|NCT02433405||Group 1|Chronic Periodontitis-serum amyloid A, Fetuin-A
2569893|NCT02433405||Group 2|Plaque induced Gingivitis-serum amyloid A, Fetuin-A
2569894|NCT02433405||Group 3|Control Group-serum amyloid A, Fetuin-A
2569931|NCT02433119|Experimental|Amlodipine orotate & Valsartan|Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks
2569933|NCT02433119|Active Comparator|Valsartan & Hydrochlorothiazide|Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks
2569955|NCT02432885|Experimental|ACE inhibitor|ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
2569956|NCT02432885|No Intervention|Control|Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance
3208218|NCT00972855|Experimental|Bicalutamide|Bicalutamide 50 mg Tablet
2570079|NCT02432027|Placebo Comparator|IMP 2|C-82 Topical Gel, placebo
3208219|NCT00972855|Active Comparator|Casodex®|Casodex® 50 mg Tablet
3208220|NCT00972868|Experimental|COPD|Thirty adult (> 18 years of age) patients in acute hypercapnic respiratory failure resulting from COPD and requiring Noninvasive Positive Pressure Ventilation (NPPV)
3208221|NCT00972907|Experimental|Treatment|Nifedipine coated suppositories BID.
3208913|NCT00979342|Experimental|Cervical Block, 6 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 2cc at 12:00, 10cc at 3:00, 10 cc at 9:00, 5 cc at 4:00, 5 cc at 8:00, and 5 cc at 6:00.
2569136|NCT02438735||Historical controls who underwent surgical excision|20 women who underwent surgical excision of endometrioma in the same clinic had serum AMH levels measured preoperatively and on post operative sixth month. Their values will be compared with that of endometrioma group. These data were priorly published in detail (Uncu et al. 2013).
2569262|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adolescents|12 Cognitive-Behavioral Therapy sessions scheduled weekly over a 12-week period.
2569264|NCT02437773|Other|Stress Management Therapy - Adolescents|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
2569268|NCT02437773|Active Comparator|Cognitive Behavioral Therapy - Adults|12 CBT sessions scheduled weekly over a 12-week period.
2569270|NCT02437773|Other|Stress Management Therapy - Adults|"12 SMT sessions scheduled weekly over a 12-week period.~After study completion, the OCD subjects who received SMT may derive benefit for non-OCD anxiety symptoms. They will be offered a 12-week course of CBT with a study therapist to directly target OCD symptoms (i.e., a partial cross-over)."
2569271|NCT02437773|Other|Healthy Control - Adolescents|Healthy control adolescents matched to gender, race and socioeconomic status (SES) with adolescent patients with OCD will be enrolled. These healthy adolescents will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
2569272|NCT02437773|Other|Healthy Control - Adults|Healthy control adults matched to gender, race and socioeconomic status (SES) with adult patients with OCD will be enrolled. These healthy adults will be scanned with fMRI before and after 12 weeks, but without any intervention (i.e., no therapy).
2569273|NCT02437773|Other|Optional CBT - Adolescents|OCD adolescent participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
2569274|NCT02437773|Other|Optional CBT - Adults|OCD adult participants who were randomized to the SMT and have completed all study procedures will be offered an additional 12 weeks of Optional Cognitive-Behavioral Therapy.
2569300|NCT02437357|Experimental|Metacognitive Training|D-MCT is conceptualized as a variant of cognitive behavioral therapy (CBT) that uses a metacognitive perspective to focus on the modification of cognitive biases by using creative and engaging strategies (e.g., multimedial presentation). The training seeks to enable group members to recognize and correct the often automatic and unconscious depressive thought patterns, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). Besides dysfunctional assumptions about one's thought processes, more general cognitive biases, which have been identified by basic research are at the core of the D-MCT. Finally, dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are discussed and modified.
2569302|NCT02437357|Active Comparator|Positivity Training|"Positivity Training (PT) is a euthymic therapy group based on cognitive behavioral therapy (CBT) with a focus on the education and training of sensual enjoyment and pleasure. Aim of the training is to reduce depressive symptomatology by increasing the ability to enjoy and to (re-)install positive sensory experiences. Therefore, group members are informed about the impact of positive experiences on well-being and the awareness of the five senses is trained in different practical exercises (hearing, sight, smell, taste, and touch)."
2569345|NCT02437175|Placebo Comparator|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
2569346|NCT02437175|Experimental|Trace elements|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
2569402|NCT02436850|Experimental|Intervention group|The intervention group will receive large volume thoracentesis.
2569403|NCT02436850|No Intervention|Control group|The control group will be taped with an 18 gauge and 20 gauge venflons and drain will not be placed.
2569420|NCT02436538||Mullerian duct anomalies|Anti Mullerian hormone level; Mullerian duct anomaly type
2569484|NCT02436382|No Intervention|Ambient Temperature of 67F|These patients will have an operating room temperature of 67F for cesarean delivery, the standard of care at our institution.
2569489|NCT02436382|Active Comparator|Ambient Temperature of 73F|These patient will have an operating room temperature of 73F for cesarean delivery, a temperature more consistent with WHO recommendations.
2569848|NCT02433717|Experimental|Paliperidone ER|Six-week paliperidone ER
2569892|NCT02433392|Experimental|CM-BC2|Patients diagnosed with recurrent, surgically resectable glioblastoma multiforme will receive up to 75 mg irinotecan delivered by drug-eluting beads (CM-BC2).
2569923|NCT02433158|Experimental|Cohort 1|Includes one adult stratum (>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
2569925|NCT02433158|Experimental|Cohort 2|Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
2570030|NCT02432430|Experimental|quality improvement technical support|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and attend 6 virtual QI Learning Sessions and 12 monthly conference calls with a coach and other participant teams. On a monthly basis for 11 months, participants collect, submit and review immunization data of 10-20 of their patients ages 3 months to 18 months. After 12 months, participants attend a virtual QI Debriefing Session.
2570031|NCT02432430|Active Comparator|pay for performance|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage. Participants receive a Vaccinator Toolkit and are informed of a tiered incentives structure. Practices receive bonuses for both improvement in individual practice coverage as well as improvement in coverage for all practices allocated to this study arm.
3172811|NCT00604877|Active Comparator|2|
3172812|NCT00604903|Experimental|Patients implanted with Pressure Sensor|Implant of Pressure sensor. These are patients, who were implanted with the Remon CHF Implantable Pressure Sensor utilizing the corresponding delivering system.
2569146|NCT02438527|Experimental|Chest Compressions Only|"After recruitment and consenting, volunteers in the chest compressions only arm will receive a chart with a description of Basic Life Support without mouth to mouth ventilations. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
2569148|NCT02438527|Experimental|Standard CPR|"After recruitment and consenting, volunteers in the standard CPR arm will receive a chart with a description of Basic Life Support. The participants will be asked to perform Cardiopulmonary Resuscitation according to the chart (including the initial check, chest compressions and mouth to mouth ventilations) for a period of 5minutes on a manikin in a simulated cardiac arrest scenario."
2569183|NCT02438345|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg, weekly for 24 weeks
2569184|NCT02438345|Placebo Comparator|Treatment Arm 2|PRO 140: one SC dose, placebo, weekly for 24 weeks
2569201|NCT02438124|Experimental|Patient|Patient with Parkinson's Disease with walking test and neuropsychological evaluation
2569211|NCT02438124|Experimental|Contrôle|normal control with walking test and neuropsychological evaluation
3208222|NCT00972920|Active Comparator|Blind TAP block|"TAP block technique as first described by McDonnell. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Identification of triangle of Petit just above iliac crest and between external oblique and latissimus dorsi muscles. Insertion of regional anaesthesia needle perpendicular to skin, and its advancement until sensation of two 'pops' indicating advancement of needle through both external oblique and internal oblique muscle layers.~After confirmation of negative aspiration the local anaesthetic is injected slowly, (1mg/kg of levobupivacaine), concentration 2.5 mg/mL. Repeat procedure bilaterally (to a maximum dose of 2mg/kg of levobupivacaine)."
3208223|NCT00972920|Active Comparator|Ultrasound-guided TAP block|"Technique as described by Hebbard. Sterile field obtained with chlorhexidine wash and use of sterile gloves. Ultrasound probe covered with sterile sheath.~Identification of triangle of Petit with USS probe perpendicular to skin. Insertion of regional anaesthesia needle transversely to the probe, using in-plane (IP) technique, moving posteriorly. Advancement of the needle under ultrasound control until its tip is located between internal oblique and transversus abdominis muscle layers."
3208224|NCT00972933|Experimental|Ipilimumab|Induction ipilimumab 10 mg/kg IV day 0, 21 (baseline, week 3) Maintenance Ipilimumab 10 mg/kg IV days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
3208225|NCT00972946|Experimental|Administration of labelled cells|MRI scanning before and after administration of iron-labelled cells
3208226|NCT00972946|Experimental|Administration of Endorem|MRI scanning before and after intravenous administration of Endorem
2569570|NCT02435693|Experimental|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
2569571|NCT02435693|Other|control|without pharmaceutical care programe (control)
2569722|NCT02434653|Experimental|Postpartum anemia diagnosis following symptoms|Post partum anemia will be assessed by taking hemoglobin level following symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL in the first 5 days following delivery
2569727|NCT02434653|Experimental|Postpartum anemia diagnosis following patients screening|Post partum anemia will be assessed by taking hemoglobin level in patients at increased risk to develop post-partum anemia in the first 5 days following delivery, defined as patients with initial (before or immediately after delivery) hemoglobin level of 10.5 g/dl or less regardless of symptoms, or in cases of severe post partum hemorrhage.
2569761|NCT02434250|Experimental|SLT arm|Patient receiving 'Selective Laser Trabeculoplasty' (SLT) due to failed Phacoemulsification Cataract Extraction with Intraocular Lens Implantation combined with Eximer Laser Trabeculectomy (phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension to control intraocular pressure and/or glaucoma progression.
3208227|NCT00972972|Active Comparator|dietary supplement|Extracts of bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.)
3208228|NCT00972972|Placebo Comparator|placebo dietary supplement|Placebo juice extracts
3208229|NCT00972985|Experimental|modafinil|All healthy control subjects receive modafinil in this crossover design
3208230|NCT00972985|Experimental|methylphenidate|All healthy control subjects receive methylphenidate in this crossover design
3208231|NCT00972985|Experimental|lorazepam|All healthy control subjects receive lorazepam in this crossover design
3208232|NCT00972985|Placebo Comparator|placebo|All healthy control subjects receive placebo in this crossover design
3208233|NCT00972998|Experimental|Healthy individuals|
3208234|NCT00973011|Experimental|A|
3208235|NCT00973024|Experimental|JNJ-42160443 1 mg|
3208236|NCT00973024|Experimental|JNJ-42160443 3 mg|
3208237|NCT00973024|Experimental|JNJ-42160443 6 mg/3mg|
3208238|NCT00973024|Experimental|JNJ-42160443 10 mg|
3208239|NCT00973037||CYP2D6|CYP2D6 genotype
3208240|NCT00973050|Experimental|Bicalutamide (test)|Bicalutamide Tablet, 50 mg
3208241|NCT00973050|Active Comparator|Casodex® (reference)|Casodex® Tablet, 50 mg
3208242|NCT00973063|No Intervention|conventional gloving|
3208243|NCT00973063|Experimental|routine sterile gloving|
3208244|NCT00973076|Experimental|AZD8055|AZD8055 will be administered orally
3208245|NCT00973089|No Intervention|Complete caries removal|Control group
3208246|NCT00973089|Other|Incomplete caries removal|Test group
3208247|NCT00973115|Experimental|Simvastatin CR 20mg- morning administration|
3208248|NCT00973115|Active Comparator|Simvastatin CR 20mg- evening administration|
3208249|NCT00973128|Experimental|Group 1|Group 1: Cutaneous leishmaniasis patients randomized in Corte to receive antimony (20mg/daily for 10 days) plus GM-CSF Treatment: antimony (20mg/daily for 10 days) plus GM-CSF (400 µg, divided in two doses a week apart)
3208250|NCT00973128|Active Comparator|Group 2|Group 2: antimony in standard dose plus saline administered in an identical fashion to the GM-CSF.
3208251|NCT00973141|Experimental|JNJ-42160443 1mg every 4 weeks|
2569169|NCT02438449||Tissue Expander-Implants (TE/I)|The TE/I approach will include two-stage breast reconstruction surgery. In the initial stage, immediately after mastectomy and with or without sentinel node biopsy, an expander will be placed in the subpectoral plane and the defect closed. Two weeks after the surgery, the expansion of the TE will commence until the desired volume of the respective expander is achieved. The second stage will include removal of the TE and the placement of a permanent implant which may be either saline or gel. The delayed method will be similar to the immediate reconstruction with the exception of the incision, which will be relatively smaller as the mastectomy was performed previously with breast cavity being fully closed.
2569187|NCT02438176|Experimental|single puncture group|single trans-septal puncture
2569188|NCT02438176|Active Comparator|conventional group|conventional bilateral groin puncture
2569245|NCT02438059|Experimental|Intervention|Access to the SoSu-liv website and app for 38 weeks.
2569251|NCT02438059|No Intervention|Control|No treatment for 38 weeks.
3208252|NCT00973141|Experimental|JNJ-42160443 3mg every 4 weeks|
3208253|NCT00973141|Experimental|JNJ-42160443 3mg every 8 weeks|
3208254|NCT00973141|Experimental|JNJ-42160443 6mg every 8 weeks|
2569426|NCT02436798||Pediatric patients|"Children <6 months to 18 years of age receiving ondansetron for management of:~Post-operative nausea and vomiting~Chemotherapy-induced nausea and vomiting"
2569430|NCT02436798||Female patients|"Pregnant patients or women of a reproductive age (18-45 years) receiving ondansetron for management of:~Hyperemesis gravidarum~Post-operative nausea and vomiting"
2569480|NCT02436343||obese pregnant women|"pregnant women wit body mass index more than or equal to 30 kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
2569488|NCT02436343||lean pregnant women|"pregnant women wit body mass index less than or equal to 25kg/m2 will be subjected to four serial echocardiograms in the 3 trimesters of pregnancy and in the postpartum state.~Height, weight, systolic and diastolic blood pressures will be measured at each echocardiographic evaluation."
3208255|NCT00973141|Experimental|JNJ-42160443 10mg every 8 weeks|
3208256|NCT00973141|Placebo Comparator|Matching placebo every 4 or 8 weeks|
3208257|NCT00973154|Active Comparator|Prednisone|Drug
2569600|NCT02435420||EMPERION Modular Primary Stem subjects|All subjects have previously been implanted with the EMPERION Modular Primary Stem for primary total hip arthroplasty.
2569671|NCT02435160|Experimental|Ulcerative Colitis|
2569773|NCT02434796|Experimental|Arm 1 Male Peer Groups (MPG)|Women participate in savings groups and male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. This intervention aims to improve knowledge and attitudes about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals (e.g. caring for one's family) and to challenge gender stereotypes (e.g. women are not equal to men); and the ability to formulate positive outcome expectations regarding IPV (intolerance of violence perpetrated by themselves or others) and healthy relationships with their spouses and communities.
2569777|NCT02434796|Experimental|Arm 2 MPG & Community Dialogues|This arm will include women participants in savings groups, male peer groups and community dialogues. Village community leaders will engage in community dialogues on gender norms, IPV and HIV prevention.
2569902|NCT02433912|Experimental|Test - Laterally positioned flap|Incisions were made in mesial and distal aspects of the recession, in order to remove the epithelial attachment. The root surface was then instrumented. The flap design was outlined by two vertical incisions which extended from the horizontal incision which was performed either at the gingival, or 1 - 2mm apically, following the marginal gingival contour. The flap was rotated laterally in order to completely cover the recession defect and extend for approximatelly 1mm coronal to the CEJ. Careful flap suturing was performed in order to position and secure the soft tissues over the root surface by means of sling and simple sutures.
2569904|NCT02433912|Active Comparator|Control - Coronally advanced flap|The CAF was designed performing two vertical releasing incisions at both the mesial and distal aspects of the recession to be treated, in such a way that both the proximal papillae were not included as part of the flap. The vertical incisions were joined by an intrasulcular incision. A combined mucoperiosteal-mucosal flap was elevated. Thorough root planning was performed. A complementary horizontal incision was performed on the apical aspect of the flap, releasing it from the attached periosteum. This allowed the elongation and free coronal positioning of the flap. The flap was coronally positioned and maintained in place by means of individual 5.0 monofilament sutures.
2570034|NCT02432495||Anterior screw fixation|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
2570037|NCT02432495||Halo immobilization|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone of halo immobilization of type II odontoid fractures
3208258|NCT00973154|Placebo Comparator|Placebo|
3208259|NCT00973167|No Intervention|Control|Remains sedentary with normal lifestyle
3208260|NCT00973167|Experimental|Treatment|Receive LMHFV treatment for 18 months.
3208261|NCT00973180|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
2570734|NCT02428140|Experimental|External Loop Recorder|external event-triggered ECG loop recorder (Sorin Spiderflash-t) for 30 days
3208262|NCT00973180|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
3208263|NCT00973193|Experimental|panitumumab|
3208264|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Adefovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Adefovir for a period of 48 weeks.
3208265|NCT00973219|Active Comparator|Peg-Interferon alfa 2a + Tenofovir|50 HBeAg negative chronic hepatitis B patients with low viral load will receive Peg-Interferon alfa 2a + Tenofovir for a period of 48 weeks.
3208266|NCT00973219|No Intervention|no treatment|50 HBeAg negative chronic hepatitis B patients with low viral load will not receive treatment during a period of 48 weeks
3208267|NCT00973232|Experimental|Part A, Arm A|
3208268|NCT00973232|Experimental|Part A, Arm B|
3208269|NCT00973232|Active Comparator|Part A, Arm C|
3208270|NCT00973232|Active Comparator|Part A, Arm D|
3208271|NCT00973232|Experimental|Part B, Arm E|
3208272|NCT00973232|Active Comparator|Part B, Arm F|
3208273|NCT00973232|Active Comparator|Part B, Arm G|
3208274|NCT00973245|Experimental|Arm 1|
3208275|NCT00973245|Experimental|Arm 2|
3208276|NCT00973245|Active Comparator|Arm 4|
3208277|NCT00973245|Experimental|Arm 3|
3208278|NCT00973258|Experimental|Nutritional Intervention|Nutritional intervention
2569441|NCT02436486|Placebo Comparator|Placebo|
2569444|NCT02436486|Experimental|Idalopirdine 120 mg|Therapeutic dosages
2569445|NCT02436486|Experimental|Idalopirdine 360 mg|Supra-therapeutic dosages
2569447|NCT02436486|Active Comparator|Moxifloxacin 400 mg|Positive Control
2569477|NCT02436252|Experimental|DSP-7888|
2569530|NCT02435862|Experimental|1.0mg Luminate®|1.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
2569534|NCT02435862|Experimental|2.0mg Luminate®|2.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
2569535|NCT02435862|Experimental|3.0mg Luminate®|3.0mg Luminate® injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
2569537|NCT02435862|Placebo Comparator|Balanced Salt Solution 0.10cc|Balanced Salt Solution 0.10cc injections at day 0, 30, and 60 (day 30 and 60 if a stage 4 PVD is not present)
2569580|NCT02435485|Experimental|spondylolisthesis with balance training|Intervention: 1. Biodex balance training including weight shift training and random control training, 2. Regular rehabilitation including core spinal stabilization exercise.
2569587|NCT02435485|Active Comparator|spondylolisthesis, no balance training|Intervention: Regular rehabilitation including core spinal stabilization exercise
2569592|NCT02435485|Active Comparator|lumbar spondylitis|Intervention: Regular rehabilitation including core spinal stabilization exercise
2569659|NCT02435199|Experimental|EMA401 600mg|2 X 150mg BID
2569662|NCT02435199|Placebo Comparator|Placebo|Placebo to match, 2 capsules BID
2569781|NCT02434848|Active Comparator|Engerix B|15 subjects per group (n = 30 in total)
2569788|NCT02434848|Active Comparator|Fendrix|15 subjects per group (n = 30 in total)
3208279|NCT00973258|Experimental|Physical Exercise|Physical exercise training intervention
3208280|NCT00973258|Experimental|Cognitive Training|Cognitive training intervention
3208281|NCT00973258|Experimental|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
3208282|NCT00973258|Placebo Comparator|Control Group|Participants will receive their usual diet and placeboes.
3208283|NCT00973271|Experimental|290 mg DCCR|
3208284|NCT00973271|Experimental|435 mg DCCR|
3208285|NCT00973271|Active Comparator|135 mg fenobric acid|
2569961|NCT02432924|Experimental|Feedback Group|Participants randomised into the intervention group will be invited to return to the university for a one-off 60 minute set-up session once their physical activity monitor has been returned and processed. Within this session the participant will be given detailed instructions on how to use and wear the activity monitor and real time display and upload their data to and navigate the multidimensional feedback web platform (See materials section for details). They will also be introduced to the concept of goal setting and talked through the different aspects of the instantaneous feedback display and how that might benefit them. Following this visit the participant will be given licence to wear and use the physical activity monitoring devices for a 6-week period and encouraged to self-monitor their behaviour using the combined instantaneous and multidimensional feedback.
2570084|NCT02432027|Active Comparator|IMP 3|Daivonex cream
3208286|NCT00973271|Placebo Comparator|Placebo|
3208287|NCT00973284|Experimental|Norwalk VLP Vaccine 100 µg|Norwalk Virus-like Particle (VLP) Vaccine 100 µg, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 Reverse Transcription Polymerase Chain Reaction (RT-PCR) units, solution, orally, on Day 42 in the Challenge Stage.
3208288|NCT00973284|Placebo Comparator|Placebo|Norwalk VLP placebo-matching vaccine, dry powder, intranasally using a delivery device with a puff of air, 50 µg in each nostril, on Days 0 and 21 in the Vaccination Stage. Norwalk Virus, 48 RT-PCR units, solution, orally, on Day 42 in the Challenge Stage.
3208289|NCT00973297|Experimental|Falls prevention|
3208290|NCT00973297|No Intervention|Control group|Routine rehabilitation treatment
3208291|NCT00973310|Experimental|Combined Treatment arm|All the patients received oral erlotinib and concurrent radiation therapy
3208292|NCT00973323|Experimental|Arm 1|
3208293|NCT00973323|Experimental|Arm 2|
3208294|NCT00973323|Experimental|Arm 3|
3208295|NCT00973323|Active Comparator|Arm 4|
3208296|NCT00973336|Experimental|Calcium and vitamin D|Intervention
3208297|NCT00973336|No Intervention|No treatment (control)|
3208298|NCT00973375||Endeavor group and Excel group|Endeavor group: measurements from the vessels implanted Endeavor stent(s). Excel group: measurements from the vessels implanted Excel stent(s).
3208299|NCT00973401||Diabetic individuals|
3208300|NCT00973414|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before CSEA
3208301|NCT00973414|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after CSEA
3208302|NCT00973414|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before CSEA
3208303|NCT00973414|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after CSEA
3208304|NCT00973453|Other|Slow regimen|
3208305|NCT00973453|Other|Intermediate regimen|
3208306|NCT00973453|Other|Fast regimen|
3208307|NCT00973466||HIV-infection|All HIV-infected patients attending the Clinic for Infectious Diseases at Berne university hospital, having been sexually active during the past 12 months and having given written informed consent
3208308|NCT00973492||patients with functional insulinotherapy|There is only one group in this study. The participants will attend a functional insulinotherapy class.
3208309|NCT00973505||CYP19|CYP19 genetic polymorphism
3208310|NCT00973518||Alzheimer's Disease subjects|Subjects diagnosed with dementia of Alzheimer's type (DSM-IV-TR).
3208311|NCT00973518||Healthy Control subjects|Age & gender-matched subjects determined to be healthy.
3208312|NCT00973531|Other|Ambulatory APAP and SMT|Subjects placed on the APAP machine
2569192|NCT02438202|Experimental|Electroconvulsive Therapy (ECT)|A modified Electroconvulsive Therapy Series in Patients with Alzheimer's Disease. Device for the intervention ECT will be the Thymatron IV device (Somatics, LLC. Lake Bluff, Illinois, USA).
2569241|NCT02438020|Experimental|Metformin|500 mg metformin oral intake before main meal
2569248|NCT02438020|Placebo Comparator|Placebo|Placebo tablet before main meal.
3208313|NCT00973531|Other|Titration Polysomnogram with CPAP and SMT|Subjects placed on CPAP machine
2569359|NCT02436993|Experimental|Carboplatin+Paclitaxel+Bevacizumab (HER2-)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Bevacizumab every other week, 5 doses
2569366|NCT02436993|Experimental|Carboplatin+Paclitaxel+Trastuzumab+Pertuzumab (HER2+)|Carboplatin weekly 12 doses Paclitaxel weekly 12 doses Trastuzumab weekly 12 doses Pertuzumab every 3 weeks, 4 doses
2569425|NCT02436590|Active Comparator|Active PEMF|Subjects have a 2 out of 3 chance to get the active device which emits a Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315OA device. Double blind randomization
2569429|NCT02436590|Placebo Comparator|Control/no PEMF|Subjects have a 1 out of 3 chance of getting the control/placebo device which does not emit Pulsed Electromagnetic Field (PEMF) from the Physio-Stim Model 3315A device. Double blind randomization
2569483|NCT02436317|Experimental|Study group|"All patients included in intervention group will be examined with an ultrasound machine with cardiac probe and vascular probe [Saote/ Mylab 5/ Italy] using both 2 dimensional and color Doppler imaging modalities according to our local point of care ultrasonography protocol.~Including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator."
2569492|NCT02436317|No Intervention|Control group|All patients included in the control group won't be examined with an ultrasound machine. Participation including demographic and medical data collection. Also, a wellbeing questionnaire will be filled by the investigator.
2569528|NCT02435927|Experimental|ASLAN001 + CAPOX|ASLAN001 + CAPOX: ASLAN001 twice daily in combination with oxaliplatin 130 mg/m2 intravenously on day 1 and capecitabine 850 mg/m2 orally twice daily on days 1 to 14 every 3 weeks
2569532|NCT02435927|Experimental|ASLAN001 + mFolfox6|ASLAN001 + mFolfox6: ASLAN001 twice daily in combination with mFolfox6 (oxaliplatin 85 mg/m2 intravenously on day 1 and 5-FU bolus 400mg/m2 i.v on day 1 and as a continuous infusion 2400mg/ m2 over 46h and leucovorin 400mg/2 i.v on day 1) every 2 weeks
2569591|NCT02435628||Satisfaction Questionnaires|"After enrollment, subjects will be given baseline measures to assess demographics, psychosocial factors, and health literacy. This assessment will occur online via Computerized Assessment Center. Participants will complete the PROMIS battery of measures assessing: depression, anxiety, anger, fatigue, pain behavior and interference, physical function, satisfaction with discretionary social activities, satisfaction with social roles, and health literacy. Participants will also complete the FFFHL scale.~Upon completion of the baseline assessments, the participant will meet with their doctor at the NF clinic for a routine appointment. Post-treatment assessments will be administered immediately after completion of the medical visit. This assessment will evaluate the participant's satisfaction with the appointment in the NF clinic using the MISS and CAHPS surveys. This will be done online via REDCap."
2569647|NCT02435303|Experimental|Sildenafil|Sildenafil 20mg tid for six months (* consider open-label extension study for 1 year)
2569651|NCT02435303|Placebo Comparator|Placebo|Placebo tablets do not contain an active ingredient but are identical in shape with each active tablet of Sildenafil
2569679|NCT02434835|Experimental|[14C]KWA-0711|
2569690|NCT02434640|Experimental|BAY1128688 [Dose1]|BAY1128688 dose level 1
2569692|NCT02434640|Experimental|BAY1128688 [Dose2]|BAY1128688 dose level 2
2569693|NCT02434640|Experimental|BAY1128688 [Dose3]|BAY1128688 dose level 3
2569694|NCT02434640|Experimental|BAY1128688 [Dose4]|BAY1128688 dose level 4
2569695|NCT02434640|Placebo Comparator|Placebo|Placebo to match arm 1,2, 3 and 4
2569783|NCT02434458||Fibromyalgia case group|Patients diagnosed with fibromyalgia from the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
2569791|NCT02434458||Control|Healthy control subjects
2569793|NCT02434458||Rheumatoid arthritis group|Patients diagnosed with rheumatoid arthritis at the department of rheumatology will be subject to sudoscan evaluation and NCS studies.
2569820|NCT02433899|Experimental|Test - Microsurgical semilunar flap|"Semilunar coronally repositioned flap performed under magnification with a surgical microscope.~SLI was carried out following the outline of the gingival margin with a microsurgical blade under (8x) magnification. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap."
2569826|NCT02433899|Active Comparator|Control - Conventional Semilunar flap|Semilunar coronally repositioned flap performed without magnification. A semilunar incision (SLI) was carried out with a 15c surgical blade. An ISI was performed mid-facially. Then, a split-thickness dissection was performed from the initial incision coronally until connecting to the ISI. The mid-facial tissue was completely released, positioned coronally to the CEJ and held in place against the tooth. A cyanoacrilate adhesive (CAA) was applied over the post-surgical gingival margin and tooth enamel to stabilize the flap.
2569887|NCT02433418|Active Comparator|Tubal flushing with Urografin®|Women will have HSG using water soluble media
2569890|NCT02433418|No Intervention|Control group|Women will not receive any intervention
2570006|NCT02432950|Experimental|Supportive care (PNP)|Patients participate in the PNP intervention, which begins with a baseline meeting with a diet and lifestyle instructor to discuss baseline testing results, begin an educational plan, determine an individualized eating plan, and print out food choices. Patients also undergo automated glucometry every 15 minutes, review their individual food choices and blood glucose levels 90 minutes after eating, keep a daily nutrition and lifestyle journal log, fill out a daily meal discovery card log, and attend weekly meetings with a diet and lifestyle instructor for 12 weeks.
2570143|NCT02431780|No Intervention|non ANSeR Software System|Routine clinical EEG monitoring
3208314|NCT00973544||control|drains would be removed when daily discharge will be below 20 cc for 2 consecutive days
3208315|NCT00973544||study|drains will be removed on post operative day (POD) 10
2569263|NCT02437747|Experimental|SRP+ Aloe Group|Scaling and root planing was done along with application of aloe vera gel as an adjunct in selected sites.
2569265|NCT02437747|Sham Comparator|SRP Group|Only scaling and root planing was done on the opposite side.
2569303|NCT02437461|Active Comparator|single dose 20 mg|Intraarticular injection of triamcinolone hexacetonide
2569307|NCT02437461|Experimental|single dose 40 mg|Intraarticular injection of triamcinolone hexacetonide
2569372|NCT02437149|Experimental|Video and Brochure|Real stories video presentation and a brochure with information about distracted driving will be given to the participant.
2569381|NCT02437149|Experimental|Power Point and Brochure|Brief power point presentation and a brochure with information about distracted driving will be given to the participant.
2569386|NCT02437149|Experimental|Brochure Only|Only a brochure with information about distracting driving will be given to the participant.
2569417|NCT02436655|No Intervention|conventional drug treatment|conservative treatment and watchful waiting till symptom onset (then aortic valve replacement). Other indications for aortic valve replacement include reduced left ventricular systolic function
2569418|NCT02436655|Active Comparator|elective aortic valve replacement|elective aortic valve surgery (replacement) within 4 weeks after randomization
2569476|NCT02436291|Experimental|CURE-EX device|twice daily treatment with CURE-EX device for 24-30 weeks
2569529|NCT02435979|Experimental|Proximal strengthening + hand therapy|Patients in this group will perform traditional hand therapy for 30 minutes and proximal strengthening of the core, cervical spine, and shoulder complex for up to 30 minutes
2569533|NCT02435979|Active Comparator|Traditional hand therapy|This group will receive traditional hand therapy for 45-60 minutes each session.
2569581|NCT02435550|Experimental|Acute Myeloid Leukemia|Patients with acute myeloid leukemia will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
2569586|NCT02435550|Experimental|Acute Lymphoblastic Leukemia|Patients with acute lymphoblastic leukemia will have blood, bone marrow aspirate , and saliva collected from them as part of routine care.
2569593|NCT02435550|Experimental|Myelodysplastic Syndrome|Patients with myeloplastic syndrome will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
2569597|NCT02435550|Experimental|Myelofibrosis|Patients with myelofibrosis will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
2569599|NCT02435550|Experimental|Multiple Myeloma|Patients with multiple myeloma will have blood, bone marrow aspirate, and saliva collected from them as part of routine care.
2569649|NCT02435225|Experimental|Mindfulness group|Participation in a 12 week mindfulness therapy group.
2569696|NCT02434861|Experimental|Part A|Rolapitant IV and Digoxin
2569697|NCT02434861|Experimental|Part B|Rolapitant IV and Sulfasalazine
2569698|NCT02434861|Experimental|Part C|Rolapitant IV and Cooperstown Cocktail
2569734|NCT02434445||Hepatorenal syndrome group|Patients with advanced cirrhosis who develope hepatorenal syndrome
2569736|NCT02434445||Non-hepatorenal syndrome group|Patients with advanced cirrhosis who do not hepatorenal syndrome
3172813|NCT00604916|Experimental|E|received a 7 day standardized oral care protocol
2569818|NCT02433847|Experimental|mosapride|
2569881|NCT02433639|Experimental|treatment|single arm study: TH-302 monotherapy is given
2569921|NCT02433236|Experimental|Fostamatinib Disodium tablet 100 mg|Fostamatinib Disodium tablet 100 milligram (mg) by mouth twice a day for 15 months
2569924|NCT02433236|Experimental|Fostamatinib Disodium tablet 150 mg|Fostamatinib Disodium tablet 150 milligram (mg) by mouth twice a day for 15 months
2569958|NCT02432911|Experimental|CAG regimen|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
2569960|NCT02432911|Active Comparator|Low dose cytarabine|cytarabine 20mg bid for 10 days.
2570016|NCT02432651|Other|6 mg xanthohumol per day vs. placebo|All participants take 6 mg xanthohumol daily and placebo in a crossover design with a washout period.
2570018|NCT02432651|Other|12 mg xanthohumol per day vs. placebo|All participants take 12 mg xanthohumol daily and placebo in a crossover design with a washout period.
2570019|NCT02432651|Other|24 mg xanthohumol per day vs. placebo|All participants take 24 mg xanthohumol daily and placebo in a crossover design with a washout period.
2570158|NCT02431663|Experimental|ketamine up to 100 mcg/kg/min|Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
2570163|NCT02431663|Active Comparator|midazolam & thiopental & propofol|"Midazolam intravenous will be increased every 5 minutes, using 2 mcg/kg/min increments, up to 12 mcg/kg/min and Thiopental intravenous will be increased every 30 minutes or longer, using 1 mg/kg/h increments, up to 6 mg/kg/h and Propofol intravenous will be increased every 5 minutes or longer, using 1 mg/kg/h increments, up to 5 mg/kg/h.~Maximum duration of infusion for each drug will be 48 hours."
2570210|NCT02431416|Active Comparator|Gonadotropin releasing hormone (GnRH)|A single intravenous injection of gonadotropin releasing hormone GnRH (Relefact LHRH 0,1 mg/mL). Dose: 100 micrograms per square meter body surface. Maximal dose: 100 micrograms.
2570216|NCT02431416|Placebo Comparator|Sodium chloride|A single intravenous injection of sodium chlorid (9 mg/mL). Dose: the same volume as the volume given/to be given with GnRH, that is maximal dose = 1 mL = 9 mg sodium chlorid.
3172814|NCT00604916|Placebo Comparator|C|received a 7 day mimic protocol
3172815|NCT00604929|Experimental|1|
3172816|NCT00604942|Experimental|Achalasia|Long vs Short Myotomy repair of Achalasia
3172817|NCT00604942|Experimental|Dysphagia control|Conservative Management
3172818|NCT00604942|Experimental|GORD for surgery|Partial vs Full Fundoplication repair
3172819|NCT00604942|Experimental|GORD not for surgery|esomeprazole 40 mg vs no esomeprazole
3172820|NCT00604955|Experimental|A|Paromomycin IM Injection (approved product in India)
3172821|NCT00604981|Experimental|1|Multisystemic Therapy (MST)
3172822|NCT00604981|Active Comparator|2|Shapedown
3174391|NCT00622960|Experimental|High MUFA diet|Those subjects assigned to a high monounsaturated fat diet
2569314|NCT02437630||Patients with COPD|Patients with COPD aged >40 years with Gold stage II as measured by standard lung function testing or worse and at least 10 pack year history of smoking who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflow and volumes at the mouth. The facemask which will be used to deliver a positive airway pressure (continuous positive airways pressure(CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
2569321|NCT02437630||normal subjects without copd|Subjects without COPD and normal lung function as measured by standard lung function tests who will have insertion of an oesophageal balloon to measure intra-thoracic pressure, fibre-optic laryngoscopy to observe movement of the larynx during respiration and facemask pneumotachograph measurement of airflows and volumes at the mouth which will be used to deliver a positive airway pressure (continuous positive airways pressure CPAP) This will provide face mask CPAP with variation of mouth pressure with CPAP
2569404|NCT02436902|Experimental|TACE|Transarterial chemoembolization (TACE) is performed two to four weeks after hepatic resection.
2569406|NCT02436902|Active Comparator|sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection.
2569409|NCT02436902|Other|TACE plus sorafenib|Patients will receive sorafenib at a dose of 400 mg twice daily after 2 weeks of hepatic resection. At the same time, TACE is performed two to four weeks after hepatic resection.
2569410|NCT02436902|No Intervention|empty control|This group patients will receive best supportive care.
2569446|NCT02436499|Experimental|Treatment with Botox and fMRI screening|"Following baseline screening, participants will receive two subsequent treatments with botulinum-A toxin, each separated by 12 weeks. Participants will receive standardized botulinum-A toxin dosing for chronic migraine prophylaxis, comprised of 155 total units given at 31 specified sites across 7 head/neck muscles (protocol to be explicitly described in full protocol). Second dose of botulinum-A toxin will either be maintained at 155 total units as dosed initially, or be increased to 195 total units, depending on response to clinical questionnaires and examination to evaluate response and efficacy (to be described in full protocol, consistent with the Follow-the-Pain Injection Paradigm)."
2569494|NCT02436278||IPF_MORT|Patients diagnosed with Idiopathic Pulmonary Fibrosis according to NICE guidelines.
2569527|NCT02435953|Experimental|TACE-RFA|1-2 times of TACE treatment, then followed by RFA treatment.
2569531|NCT02435953|Active Comparator|TACE alone|TACE treatment several times till tumor progress to advance stage
2569575|NCT02435615|Experimental|Study group|There is one group of patients which are those presenting to the hospital with suspected clinical case of dengue fever for diagnosis. This group will have oral fluid collected via the SaniSal oral fluid collector and a pipette, and blood collected via venipuncture.
2569619|NCT02435355|No Intervention|standard support|All patients in this study underwent this procedure, which is the regular procedure in France.
2569620|NCT02435355|Experimental|coached group|In the coached group (CG), patients received standard support completed by 5 sessions (day 3, 10, 30, 60, 90 with equipment at home) of telephone-based counselling session by competent staff. Sessions were performed by a qualified person in education, qualifies by a university degree (Paul Sabatier University, Toulouse, France). The dates of phone calls were planned with the patient availabilities.
2569667|NCT02435186|Experimental|p53 gene plus chemotherapy|Intraperitoneal p53 gene plus cisplatin, and paclitaxel iv
2569668|NCT02435186|Active Comparator|chemotherapy|Intraperitoneal cisplatin, and paclitaxel iv
2569759|NCT02434276|Experimental|Vaccine Dose Group 8 mcg dose|VAX2012Q, 8 mcg dose
2569766|NCT02434276|Experimental|Vaccine Dose Group 12 mcg dose|VAX2012Q, 12 mcg dose
2569769|NCT02434276|Active Comparator|Control|Fluzone Quadrivalent vaccine
2569823|NCT02433808|Experimental|Neostigmine Group|Neostigmine will be administered at the conclusion of the surgical procedure
2569827|NCT02433808|Placebo Comparator|No Neostigmine group|Saline will be administered at the conclusion of the surgical procedure
2569851|NCT02433561|Active Comparator|Intraplexic catheter|Intraplexic approach (Patients will have the catheter placed within the plexus, classical approach)
2569856|NCT02433561|Experimental|Extraplexic catheter|Extraplexic approach (Patients will have the catheter placed out of the plexus.)
3208316|NCT00973557||Taking Bevacizumab|Patients who are currently being treated for cancer by the drug Bevacizumab.
2570090|NCT02432001||Image-Guided Biopsies|Image-guided biopsies will be performed at the Dream Team Site enrolling the patient. Lesions will be chosen based upon the strength of the evidence suggesting the presence of metastasis and with the goal of minimizing patient risk. Soft tissue lesions and lesions with documented radiologic progression should be prioritized for biopsy. If the Radiologist in charge of the procedure cannot identify a lesion amenable for biopsy, the patient will be considered a screening failure.
2570150|NCT02431832|Experimental|Augmentin tab|
2570208|NCT02431481|Experimental|Normal renal function|Normal renal function; matched demography to renal impariment cohorts
2570212|NCT02431481|Experimental|Severe renal impairment|Severe decrease in GFR (15-29 ml/min)
2570213|NCT02431481|Experimental|End Stage Renal Disease|End stage renal disease not on dialysis; GFR <15 ml/min
2570220|NCT02431481|Experimental|Mild renal impairment|Mild decrease in GFR (60-89 ml/min)
2570224|NCT02431481|Experimental|Moderate renal impairment|Moderate decrease in GFR (30-59 ml/min)
2570336|NCT02430896||ADHD group|Children and adolescents who met the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD and needed pharmacotherapy. Subjects will be taking Methylphenidate or Atomoxetine for 52 weeks.
2570339|NCT02430896||Normal control group|Children and adolescents will be recruited by advertisement, and will be assigned to normal group if they do not meet the Diagnostic and Statistical Manual IV Text Revision (DSM-IV-TR) diagnostic criteria for ADHD .
2570379|NCT02430428|Experimental|VisuMax lenticule removal|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
2570466|NCT02430116|No Intervention|negative control group|The myocardial tissues of the right atrial appendage were obtained at 3 min before CPB was established in the NEG group.
2570469|NCT02430116|Active Comparator|I/R group|The myocardial tissues of the right atrial appendage were obtained at 45 min after opening the aorta in the I/R group.
2570739|NCT02428088|Experimental|Dasotraline 2 mg|Dasotraline 2 mg
3208317|NCT00973570|Experimental|"Intervention group"|"The intervention group benefits from the TABADO program"
2569428|NCT02436603|Other|Nutrition/Mind-Body Coaching|The intervention will consist of weekly group sessions lasting 75-90 minutes during which participants will receive training in the FODMAP diet and mind-body skills.
2569431|NCT02436603|No Intervention|Waitlist Control Group|Waitlist subjects. At the end of the 12-week study period, waitlist subjects will be offered the four-week nutrition and mind-body intervention.
3208318|NCT00973570|No Intervention|"Control group"|"The control group not benefit from any specific intervention other than the treatment and education usually available"
3208319|NCT00973583|Active Comparator|vitamin D|
3208320|NCT00973583|Placebo Comparator|placebo|
3208321|NCT00973609|Active Comparator|Fluoropyrimidine + Bevacizumab|Standard therapy
3208322|NCT00973609|Experimental|Bevacizumab monotherapy|
2569745|NCT02434601|Other|Treatment of Dentin Surface|Treatment of Dentin Surface: Restoration made following the protocol recommended by the manufacturer of the materials.
2569748|NCT02434601|Experimental|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
2569750|NCT02434601|Experimental|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
2569775|NCT02434133||Case (Group A)|Group A (Immunomodulator) currently taking azathioprine or 6- mercaptopurine (Blood Draw)
2569778|NCT02434133||Case (Group B)|"Group B (Biologic group) currently taking anti-TNF therapy (infliximab, golimumab, adalimumab, or certolizumab).~(Blood Draw)"
2569784|NCT02434133||Case (Group C)|Group C (Combination therapy) currently taking anti-TNF therapy and an immunomodulator (including methotrexate) (Blood Draw)
2569790|NCT02434133||Control|"Individuals will be obtained from patients without an IBD diagnosis coming to Digestive Health Center for endoscopic procedures or clinic visits.~(Blood Draw)"
2569810|NCT02433821|Experimental|Pilates Group|The group will realize 2 classes per week, lasting one our, of Pilates under supervision of a trained instructor. The training program will last 3 months.
2569812|NCT02433821|No Intervention|Control group|The patients will keep the drug treatment and will be keep in a waiting list. After the 180 days of study the will be invited to realize the Pilates training.
2569850|NCT02433626|Experimental|COTI2|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
2569854|NCT02433626|Experimental|COTI2 + cisplatin|COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
2569906|NCT02433327|Active Comparator|PEWS - trigger tool|"Paediatric Early Warning Score:~Children randomized to PEWS - trigger tool"
2569911|NCT02433327|Active Comparator|RM - trigger tool|"Paediatric Early Warning Score:~Children randomized to Central Denmark Region (RM)- trigger tool"
2569964|NCT02433041|Active Comparator|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
2569967|NCT02433041|Active Comparator|Ketamine|Ketamine 1mg/kg at induction of anesthesia
2569968|NCT02433041|Active Comparator|Haloperidol + Ketamine|Combination of Haloperidol + Ketamine in same dosage at induction of anesthesia
2569969|NCT02433041|Placebo Comparator|Saline solution (NaCl 0.9%)|Placebo
2570007|NCT02432586|Other|Intensive Education|Attendance of 2 intensive education sessions
2570053|NCT02432391|No Intervention|Routine Care|Participants continue their routine medical care for type 2 diabetes
2570054|NCT02432391|Experimental|GEM|Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.
2570081|NCT02432066|Active Comparator|GTS-21|Participants in the GTS-21 arm will receive 150 mg/BID GTS-21 over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
2570086|NCT02432066|Placebo Comparator|Placebo|Participants in the Placebo arm will receive placebo compound twice daily over the course of 7 weeks. All participants will receive repeated neurobehavioral testing, laboratory assessment of cardiovascular and liver function, and provide weekly updates regarding smoking behavior, mood states, and side effects.
2570139|NCT02431819|Experimental|contention socks|Patients wear evolutive contention socks during 15 days.
2570232|NCT02431546|Experimental|Mobile Health Application Group|"VIDA is a mobile technology that is well positioned to provide healthcare coaching. After completing the CR program, each participant will have access to the VIDA mobile phone platform for the 12-week intervention, and be instructed to download the app on his/her smart phone. VIDA will assign an individual professional health coach selected from a pool of well-trained and experienced health professionals-nutritionists, fitness trainers, nurses and health educators. Each coach will engage their patient in a productive and meaningful health mentorship on a daily basis. The coach and patient work as a team to successfully set goals and make small changes that add up to significant improvements in the patients' dietary choices, physical activity, medication management, as well as understanding of their health status.~Physical Activity: A goal of total number of steps to attain daily will be provided by the Duke study team to the patient and monitored using a Fitbit activity tracker."
2570265|NCT02431156||monovision|Presbyopic patients that underwent mini-monovision correction with bilateral implantation of monofocal intraocular lenses. Their visual capacity in ADLs will be assessed.
2570741|NCT02428088|Experimental|Dasotraline 4 mg|Dasotraline 4 mg
3208323|NCT00973609|Experimental|No maintenance treatment|
3208914|NCT00979342|Experimental|Cervical Block, 2 injection sites|Subject will receive a cervical block of 1% lidocaine and 0.25% bupivacaine, with injections in the following locations: 10 cc at 4:00, and 10 cc at 8:00.
2569347|NCT02437123|Experimental|The Cedar Project mHealth Intervention|The Cedar Project mHealth intervention consists of a package of culturally-safe supports, including a mobile phone and long-distance cellular plan, weekly two-way text messaging, and support from community-based Cedar Advocates.
2569348|NCT02437123|No Intervention|Comparison group|The comparison group will be sampled from The Cedar Project, an ongoing cohort study of young Indigenous people who use drugs under its existing informed consent with no change whatsoever to their participation in the overall study.
2569510|NCT02436070|Active Comparator|Control|Subjects receive general, health-related text messages applicable for children with asthma.
2569511|NCT02436070|Experimental|Test group|Subjects receive specific, targeted text messages for post-emergency department discharge asthma care.
2569543|NCT02435797|Active Comparator|Nicorandil|Nicorandil for injection
2569547|NCT02435797|Placebo Comparator|normal saline|normal saline
2569672|NCT02434991|Experimental|Barostat|The barostat (a thin tube, with a deflated balloon attached at the end) will be placed through your mouth down your esophagus (swallowing tube) to where your stomach and esophagus meet. The 10-cm long balloon will then be inflated with step by step pressure increases of 4mmHg for 30 seconds each to a maximum pressure of 50mmHg. The patient will rate discomfort during each step of inflation
2569685|NCT02434731|Experimental|Buzzy® device|The Buzzy® device will be applied just above the selected site of the venipuncture; a ice pack will be attached under the device; the device will be turned on and after 15 second the procedure will be carried out.
2569688|NCT02434731|No Intervention|No intervention|No intervention for pain relief
2569710|NCT02434549|Active Comparator|Botulinum toxin-A (Dysport®)|Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
2569715|NCT02434549|Placebo Comparator|Normal saline|Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain
2569756|NCT02434224|Experimental|music therapy|two to three sessions per week: The therapist will stay with one hand on the infants' chest (or back) in order to continuously assess the infants' breathing pattern. Based on and oriented towards the assessed breathing pattern, the infants' behavioral state, facial and gestural expression, the therapist transforms the infants' rhythms and subtle expressions into infant-directed improvised humming.
2569757|NCT02434224|No Intervention|control|standard care
3172823|NCT00604994||Malignant|Patients with malignant gynaecological conditions including cancers of the cervix, uterus, ovary, vulva and vagina
2569833|NCT02433743|No Intervention|Control|Control group (n=33) didn't received intervention. The received the standard hospital diet
2569836|NCT02433743|Experimental|Ready-to-use therapeutic food (RUTF)|RUTF group (n=32) received the standard hospital diet combined with 100 g/day of RUTF
2569992|NCT02432781|Experimental|Carbohydrate group|Carbohydrate-rich drink 400 mL 3 h before surgery
2569994|NCT02432781|Active Comparator|Control group|10% dextrose solution mixed with insulin 16 unit 100 mL/h
2570024|NCT02432573|No Intervention|Standard care|Postpartum patients that receive physician rounding at current time
2570027|NCT02432573|Experimental|Delayed rounding|Postpartum patients that receive physician rounding at a delayed time
2570078|NCT02432261|Experimental|Group 1|5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
2570083|NCT02432261|Experimental|Group 2|4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders
2570149|NCT02431845|Experimental|SSRIs treatment as usual OCD gruop|SSRIs treatment as usual fluoxetine 40~80 mg dose equivalent (fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine)
2570199|NCT02431442|Active Comparator|Cohort 1: RM-493 SC Infusion 14 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 14 days (1 panel, all male subjects)
2570201|NCT02431442|Active Comparator|Cohort 2: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
2570203|NCT02431442|Active Comparator|Cohort 3: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
2570204|NCT02431442|Active Comparator|Cohort 4: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.015 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel)
2570206|NCT02431442|Active Comparator|Cohort 5: RM-493 SC Injection 14 days|Double-blind RM-493 will be administered at a dose of 0.0075 mg/kg every 12 hours via a subcutaneous injection for 14 days (1 panel)
2570209|NCT02431442|Active Comparator|Cohort 6: RM-493 SC Infusion 28 Days|Double-blind RM-493 will be administered at a dose of 0.01 mg/kg/24 hours via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
3172824|NCT00604994||Benign|Patients without malignant gynaecological cancers
3172825|NCT00605046|Experimental|Asses [123I] AV151 and SPECT imaging|
3172826|NCT00605059|Experimental|Assess [123I] AV94 and SPECT imaging|
3172827|NCT00605098|Active Comparator|1|
3172828|NCT00605098|Experimental|2|
3172829|NCT00605124|Experimental|exercise|progressive exercise, home-based exercise program, tree exercise sessions weekly, chec-up visits every third month
3172830|NCT00605124|Active Comparator|Conventional treatment|Normal treatment, single guidance to home exercise
3172831|NCT00605215|Experimental|Laquinimod|0.6 mg Laquinimod oral once daily
3172832|NCT00605215|Placebo Comparator|Placebo|oral placebo once daily
3172833|NCT00605215|Active Comparator|Interferon|Interferon β-1a (Avonex®) 30 mcg IM once weekly
3172834|NCT00605228|Experimental|1|
3172835|NCT00605228|Active Comparator|2|
3172836|NCT00605241|Other|GSK598809|Drug
3172837|NCT00605332|Experimental|1|Investigative Device (Crux Biomedical IVC Filter) will be evaluated for its ability to capture thrombus for the prevention of pulmonary embolism.
3172838|NCT00605371|Experimental|Subjects receiving regimen A|Eligible subjects will receive regimen A containing lamotrigine extended release tablet of 200 milligrams plus 50 milligrams in fasted state
3172839|NCT00605371|Experimental|Subjects receiving regimen B|Eligible subjects will receive regimen B containing lamotrigine extended release caplet of 250 milligrams in fasted state.
2569350|NCT02437214|Experimental|Use of music for anxiety in children|Children in the Exp group received the usual medical care in combination with the intervention. The intervention was started by the patients nurse without the knowledge of the research associate. In the intervention group, music was played until the CT scan was completed.
2569351|NCT02437214|No Intervention|Control|Children in the Con group received the usual medical care without listening to the music intervention.
3208324|NCT00973635|No Intervention|Traditional training|"Patients of subjects with no detailed curriculum for handoff skills during non-intervention months.~Learners provided a brief outline of how to perform discharge summaries (handout).~Learners given two core articles describing some of the communication issues regarding handoff safety.~Handoff teaching left to discretion of the subintern's team (typically the see one, do one, teach one method).~No feedback given to these subinterns on their performance of their handoff skills."
3208325|NCT00973635|Experimental|Intervention|Group that receives educational intervention.
3208326|NCT00973661|Experimental|Electronic tools|
2569440|NCT02436525|Active Comparator|Group I:|"will be treated using conventional stainless steel orthodontic brackets ligated with stainless steel ligature. Oromco - USA.~."
2569442|NCT02436525|Experimental|Group II|: will be treated using passive self-ligating stainless steel orthodontic brackets Oromco - USA.
2569443|NCT02436525|Experimental|Group III:|will be treated by active self-ligating stainless steel orthodontic brackets Oromco - USA .
2569486|NCT02436226|Active Comparator|Clomiphene citrate-HCG group|Women will receive clomiphene citrate and human chorionic gonadotropin (HCG)
2569491|NCT02436226|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate alone
2569516|NCT02435875||hypertensive|Patients with confirmed hypertension or systolic blood pressure≥140 mmHg or diastolic blood pressure≥90 mmHg without antihypertensive treatment.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
2569519|NCT02435875||nonhypertensive|systolic blood pressure <140 mmHg and diastolic blood pressure<90 mmHg.After anesthesia induction,baroreflex sensitivity will be measured by nitroglycerin.
2569556|NCT02435732|Placebo Comparator|Control group|Standard donor management + vehicle treatment (n=9)- placebo saline solution
2569557|NCT02435732|Experimental|CINRYZE 200 U/Kg IV|Intervention is CINRYZE 200 U/Kg IV single dose
2569559|NCT02435732|Experimental|200 units/kg IV CINRYZE with Heparin 20 U/kg/h IV|CINRYZE 200 units/kg IV single dose with Heparin at 20 units/kg/h IV maintenance until organ recovery
2569602|NCT02435459|Placebo Comparator|No lining|No lining material placed under amalgam dental restoration
2569604|NCT02435459|Active Comparator|Calcium hydroxide cement|Placement of calcium hydroxide cement under amalgam dental restorations
2569610|NCT02435459|Active Comparator|Bonding agent|Placement of Resin bonding agent under amalgam dental restorations
2569612|NCT02435459|Active Comparator|RMGI cement|Placement of rmgi lining under amalgam dental restorations
2569663|NCT02435095|Active Comparator|Maintenance treatment (Control)|287 female and male patients with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) will be directed randomly to the maintenance treatment group (control). Patients will be treated according to the current clinical standard of long-term maintenance antipsychotic treatment. Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental).
2569665|NCT02435095|Experimental|Intermittent Treatment (Experimental)|"287 female and male patients with schizophrenia according to DSM-V will be directed randomly to the intermittent treatment group (experimental). Patients directed to this group will be tapered off medication.~Study related procedures include safety assessments (physical examination, questionaires), laboratory assessments (blood sampling, urine analysis), efficacy assessments (questionaires) and volumetric Magnetic Resonance Imaging (structural MRI incl. volumetry). Study procedures are the same for both study groups (control/experimental)."
2569689|NCT02434692|Experimental|Single-arm intervention ARGOS-IO system|The ARGOS-IO Pressure sensor will be additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery.
3208327|NCT00973661|No Intervention|Usual care|
3208328|NCT00973687|Placebo Comparator|10 mg/mL Unsweetened Formulation|no prior vomiting
2569837|NCT02433769|Active Comparator|TOf-Watch-SX|Train-of-four (TOF) ratios will be measured with the TOF-Watch-SX and compared to TOF ratios measured simultaneously with the TOFscan
2569839|NCT02433769|Experimental|TOFscan|Train-of-four (TOF) ratios obtained from the TOFscan will be compared to TOF ratios measured simultaneously with the TOF-Watch-SX
2569870|NCT02433457|Experimental|CC-292 SDD (Spray Dried Dispersion)300mg - Fasted Condition|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets)
2569874|NCT02433457|Experimental|CC-292 SDD 300mg - Fed Condition|Single oral dose of 300 mg CC-292 SDD under fed conditions (100 mg SDD x 3 tablets)
2569879|NCT02433457|Experimental|375mg P22 - Fasted condition|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3)
2569880|NCT02433457|Experimental|375mg P22 Fed Condition|Single oral dose of 375 mg P22 under fed conditions (125 mg P22 x 3)
2569884|NCT02433457|Experimental|CC-292 SDD 100 mg Fasted Condition|Single oral dose of 100 mg CC-292 SDD under fasted conditions
2569886|NCT02433457|Experimental|SDD plus OMP (Oral Omeprazole)|Single oral dose of 300 mg CC-292 SDD under fasted conditions (100 mg SDD x 3 tablets) in the presence of 40 mg
2570089|NCT02432027|Active Comparator|IMP 4|Diprosis gel
3208329|NCT00973687|Experimental|1 mg/mL Ora Sweet Formulation|no prior vomiting
3208330|NCT00973687|Active Comparator|10 mg/mL Unsweetened with prior vomiting|with prior vomiting
3208331|NCT00973687|Experimental|1 mg/mL Ora Sweet with prior vomiting|with prior vomiting
3208332|NCT00973713|Experimental|RAD001 10mg/d|
3208333|NCT00973726|Other|Glucose|Subjects are given an oral glucose tolerance test.
3208334|NCT00973791|Active Comparator|Prior crystalloid|Crystalloid (Ringer's Lactate) was given before spinal anesthesia
3208335|NCT00973791|Active Comparator|Posterior crystalloid|Crystalloid (Ringer's Lactate) was given after spinal anesthesia
2569364|NCT02436863||Surgical perfomance (Internal fixation)|After the lesions inside the spinal canal were surgical removed by laminectomy, the pedicle screws (Thoracic and lumbar vertebra) or lateral mass (Cervical vertebra) and sticks were used for internal fixation.
2569424|NCT02436733|Experimental|Immediate pleurectomy/decortication|immediate P/D followed by three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks for non-progressing patients
2569432|NCT02436733|Active Comparator|Delayed pleurectomy/decortication|three cycles of pemetrexed 500mg/m2 IV and cisplatin 75 mg/m2 IV, both drugs given on day 1, every three weeks followed by P/D, for non-progressing patients.
3208336|NCT00973791|Active Comparator|Prior colloid|Colloid (6% hydroxyethyl starch) was given before spinal anesthesia
3208337|NCT00973791|Active Comparator|Posterior colloid|Colloid (6% hydroxyethyl starch) was given after spinal anesthesia
2569544|NCT02435823|Experimental|PulseRider|Endovascular treatment of intracranial aneurysms
2569583|NCT02435602|Active Comparator|NBI endoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy~Biopsy at the visually abnormal lesions~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
2569585|NCT02435602|Active Comparator|lugol chromoendoscopy|"GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy~Biopsy at the unstained lesions >= 5 mm diameter~Pathologic examination of all biopsy tissue specimens~Advises of endoscopic/surgical or oncological treatment will be given to participants who will be diagnosed with ESCC or high grade dysplasia of the esophagus."
2569625|NCT02435264|Experimental|Healthier Dining Program Intervention|Food centers that receive the Healthier Dining Program (HDP)
2569628|NCT02435264|No Intervention|Control centers|Food centers that do not receive the Healthier Dining Program (HDP)
2569653|NCT02435056|No Intervention|Classic Approach|Patient fills in a paper diary in order to quantify parameters of MOH (days with headache, acute drugs consumed, etc.)
2569658|NCT02435056|Experimental|IEPR Approach|Patient has to use the electronic diary to record days with headache, acute drugs consumed, etc.
2569714|NCT02434822|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
2569720|NCT02434822|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
2569723|NCT02434822|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
2569763|NCT02434211|Experimental|Questionnaire and Focus group|The children complete the questionnaire to better know their knowledge and cancer individual conceptions. Then, they will be interviewed during one hour in groups for the pre-testing phase. And after, for the testing phase, they just complete the questionnaire.
2569860|NCT02433548|Experimental|Fascia iliaca block|Fascia iliaca block (Injection of 30 mLs of bupivacaine 0.5% with epinephrine 5 mcg/mL below the fascia iliaca, Carbostesin®)
2569863|NCT02433548|Sham Comparator|Sham injection|No fascia iliaca block (Sham injection = Subcutaneous injection of 5 cc of normal saline, no intervention)
2569909|NCT02433262|Placebo Comparator|WHO (World Health Organisation)|"Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria:~Fasting glucose >6 2 hour glucose >7.7"
2569910|NCT02433262|Active Comparator|IADPSG|Participants will undergo oral glucose tolerance test involving drinking of 75g glucose and blood taking for fasting and 2 hours post glucose intake. Diagnosis of GDM will be made based on these criteria: (International Association of Diabetes & Pregnancy Study Group) Fasting glucose >5 2 hour glucose >8.4
2569974|NCT02433002||Main study|1300 participants will undergo baseline (month 0) and final (month 36) reference GFR, estimated GFR (eGFR) and urinary albumin-to-creatinine ratio (ACR) tests. Additionally they will provide ACR and eGFR tests at 6-monthly intervals.
2569983|NCT02433002||Sub-study of patterns of progression|A subset of the cohort (n=375) will receive annual reference GFR tests.
2569988|NCT02433002||Biological variability study|In a further sub-study 20 participants will undergo the reference test four times over four weeks.
2570004|NCT02432547|Active Comparator|Aflibercept Monotherapy|Intravitreal aflibercept injections according to a treat and extend regimen.
2570010|NCT02432547|Experimental|Targeted laser therapy with Aflibercept|Targeted laser photocoagulation therapy to areas of peripheral retinal ischaemia and intravitreal aflibercept injections using a treat and extend regimen.
3208338|NCT00973817|Experimental|ELAD|Use of ELAD for up to 6 days to stabilize liver function plus standard of care treatment plus standard of care treatment. Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
2570193|NCT02431585|Other|rechallenge|Double blind placebo controlled cross over
2570241|NCT02431286|Experimental|Aprepitant|patient will receive aprepitant 80 mg per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
2570243|NCT02431286|Placebo Comparator|placebo|patient will receive placebo per os one hour before surgery; palonosetron and dexamethasone will be intravenously administered during surgery
2570387|NCT02430272|Experimental|Anticholinergic premedication|Premedication with 0.005mg/Kg of glycopyrrolate
2570393|NCT02430272|No Intervention|Control group|Same volume of normal saline
2570440|NCT02430038||Acceptability and feasibilty|Where vaginal examinations are best avoided e.g. vaginismus or contraindicated (PPROM) with controls
2570444|NCT02430038||Predictive Model|Nulliparous term labouring women with cephalic presentation
2570556|NCT02429284||Patients newly diagnosed with CTEPH|Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.
2570616|NCT02429037|Experimental|rAd-p53 plus radiation and chemotherapy|rAd-p53 tumor injection combined with radio- and chemo-therapy.
2570619|NCT02429037|Active Comparator|radiation and chemotherapy|radiation combined with chemotherapy
2570672|NCT02428426||gastric intestinal metaplasia|patients were diagnosed gastric intestinal metaplasia
2570673|NCT02428426||gastritis|patients were diagnosed non atrophic gastritis
2570743|NCT02428088|Placebo Comparator|Placebo|Placebo
3208339|NCT00973817|Other|Standard of care|Standard of care for acute on chronic hepatitis patients including medications and treatments typically given to patients admitted with acute hepatitis (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
2569554|NCT02435745||Ehlers-Danlos Syndrome|Patients with the diagnosis of Ehlers-Danlos syndrome
2569555|NCT02435745||Controls|Patients/Subjects without the diagnosis of Ehlers-Danlos syndrome
2569590|NCT02435537|Active Comparator|Intrathecal Bupivacaine|intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
2569595|NCT02435537|Active Comparator|Intrathecal Morphine|intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
2569598|NCT02435537|Active Comparator|Intrathecal Morphine-Dex|intrathecal 10mg bupivacaine 0.5% in 2 ml volume intrathecal 0.5 mg morphine intrathecal 5 µg of dexmedetomidine in 1ml volume .
2569652|NCT02435173|Experimental|Part I: CDZ173|Part I was with-in patient dose escalation with CDZ173 10, 30 and 70 mg bid
2569660|NCT02435173|Placebo Comparator|Part II: Placebo|Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
2569661|NCT02435173|Experimental|Part II: CDZ173|Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo
2569691|NCT02434705||Antigen (wheat base soy sauce) spray|"Ten patients with active and ten with inactive eosinophilic esophagitis (defined by consensus guidelines) undergoing clinically indicated endoscopy and esophageal biopsies will participate in this study.~During the endoscopy two biopsies will be taken from the esophageal body, 10 cm above the gastroesophageal junction.~After biopsies are taken, approximately 10 cc of wheat based soy sauce (antigen spray) will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction."
2569707|NCT02434484||Symbenda|Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.
3208340|NCT00973830|Experimental|Carve-In|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling with a nurse or medical assistant from their clinic. Counseling focuses on behavioral changes patients can make to improve their diabetes.
3208341|NCT00973830|Experimental|Carve-Out|Patients in this arm are given the Diabetes Guide and engage in six sessions of brief counseling over-the-phone with a diabetes health educator stationed in Chicago, IL. Counseling focuses on behavioral changes patients can make to improve their diabetes.
3208342|NCT00973830|No Intervention|Control|Patients in this arm receive standard care. They receive no Diabetes Guide or brief counseling sessions
3208343|NCT00973882|Experimental|Carboplatin-Etoposide|
2570580|NCT02429128|Active Comparator|Lean PCOS training|14 weeks exercise training
2570582|NCT02429128|Other|Lean healthy controls|14 weeks exercise training
3208344|NCT00973908|Active Comparator|VSL#3|Patients will receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
2570695|NCT02428374|Active Comparator|rosuvastatin plus clopidogrel|rosuvastatin 40 mg and clopidogrel 75 mg
2570697|NCT02428374|Active Comparator|Rosuvastatin plus ticagrelor|Rosuvastatin 40 mg plus ticagrelor 90 mg bid
2570698|NCT02428374|Active Comparator|simvastatin plus clopidogrel|Simvastatin 40 mg plus clopidogrel 75 mg
2570699|NCT02428374|Active Comparator|Simvastatin plus ticagrelor|Simvastatin 40 mg plus ticagrelor 90 mg bid
3208345|NCT00973908|Placebo Comparator|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
2570908|NCT02426970||Lumbar spine pain inpatients|The study population corresponds to inpatient rehabilitative care for lumbar spine pain in the Departments of Physical Medicine and Functional Rehabilitation at the Nîmes and Montpellier University Hospitals.
3208346|NCT00973934|Experimental|Magnetic Seizure therapy (MST)|Eligible patients will be randomized to receive either a course of thrice weekly MST using either a focal or non focal stimulating coil.
2571040|NCT02426164|Active Comparator|Liposomal bupivacaine|Periarticular infiltration of 20cc of liposomal bupivacaine with 20cc of normal saline administered prior to cementation of knee implants
2571042|NCT02426164|Active Comparator|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone administered prior to cementation of knee implants
2571091|NCT02425774|Placebo Comparator|Sham stimulation + Placebo|"no stimulation~1 placebo tablet at two different timepoints before surgery"
2571093|NCT02425774|Active Comparator|Vagus stimulation + placebo|"Stimulation at the beginning and the end of the surgery~1 placebo tablet at two different timepoints before surgery"
2571095|NCT02425774|Active Comparator|Prucalopride + sham stimulation|"1 prucalopride tablet at two different timepoints before surgery~no stimulation"
2571153|NCT02425462||Cohort 1|Asian patients at least 18 years of age with clinical or surgical diagnosis of endometriosis, and patients with endometriosis associated pelvic pain.
2571192|NCT02425085|Experimental|multi-endodiathermy retinectomy group|Patients receive multi-endodiathermy retinectomy
2571200|NCT02425085|Active Comparator|relaxing retinectomy|Patients receive relaxing retinectomy
2571310|NCT02424487||Intracuff pressure during one-lung ventilation|Measurement of changes in intracuff pressure with one-lung ventilation during thoracic surgery.
3208347|NCT00973934|Active Comparator|Right Unilateral Electroconvulsive Therapy|
3208348|NCT00973947|Other|Control|Immobilisation: Standard headrest plus individual customised mask (orfit)
3208349|NCT00973947|Other|TRial Arm|Immobilisation: Customised headrest plus individual customised mask (orfit)
3208350|NCT00973986|Active Comparator|CYP3A4*1/*1|
3208351|NCT00973986|Active Comparator|CYP3A4*1/*1G|
3208352|NCT00973986|Active Comparator|CYP3A4*1G/*1G|
3208353|NCT00973999|Experimental|Injection into salivary gland|
3208354|NCT00974012|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
3208355|NCT00974012|Active Comparator|Depakote®|500 mg Extended Release Tablet
3208356|NCT00974025|Experimental|Vitamin C|High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks
3208357|NCT00974025|Placebo Comparator|Placebo|Placebo will be given in two-daily doses for four weeks
3172840|NCT00605371|Experimental|Subjects receiving regimen C|Eligible subjects will receive regimen C containing lamotrigine extended release caplet of 250 milligrams in fed state.
3172841|NCT00605397|Experimental|1|breast cancer pt receiving trastuzumab therapy will undergo two complete PET studies.
2569584|NCT02435589|Experimental|Intervention group|"Intervention:~systematic pain assessment~Notification of results of assessments to nurses and physicians. Pain Assessments will be done with the use of 2 different behavioral pain tools by independent assessors and the results of the assessments will be notified to the nurses and physicians and their respond will be observed and documented"
2569588|NCT02435589|Active Comparator|Control Group|Intervention. Systematic pain assessments. Assessments of pain will be done by independent assessors but results will not be notified to nurses or physicians
2569739|NCT02434393||Late Life Depression|120 participants who meet the criteria for Major Depression or Late Life Depression (LLD)
2569832|NCT02434068||stone residuals|all patients are going to be submitted to the same intervention: CT, US, KUB
3172842|NCT00605397|Experimental|2|breast cancer pt receiving trastuzumab therapy will undergo one complete PET studies
2569907|NCT02433210|Active Comparator|Solute Clearance|Solute clearance at 60 minutes for urea, creatinine, phosphate, beta 2 microglobulin, and myoglobin will be determined three times for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers at the 60 minute time point.
2569913|NCT02433210|Active Comparator|Hemocompatibility|Hemocompatibility will be determined using the markers C3a, C5a, thrombin/anti-thrombin complex and complete blood count with platelets will be determined one time for each dialyzer at session 2 and at time points 0, 15, 30, 60, and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers ..
2569914|NCT02433210|Active Comparator|Solute removal rate|Solute (urea, creatinine, phosphate, beta 2 macroglobulin, and myoglobin) removal rate will be determined time points 0 and 240 minutes for ELISIO-15H, Revaclear and Optiflux 160NR dialyzers .
2569981|NCT02432794|Experimental|delay phenomenon by arteriography|"intervention: delay phenomenon by arteriography. Patients who will be subjected a delay phenomenon by arteriographic procedure before esophageal resection surgery minimum 14 days before surgery.~An angiogram of the celiac trunk is performed through a femoral access before and after the embolization. A 4-5 Fr Simmons or Cobra catheter is used for the catheterization and embolization of the left gastric artery, and 0.035-inch platinum coils are proximally placed from the main trunk in the splenic artery. When accessory left gastric arteries are present, they are catheterized and embolized as well. The right gastric artery catheterization is realized by a 4-5 Fr catheter and coils or microcoils are proximally placed in the artery as well."
2569986|NCT02432794|No Intervention|control group|Patients who will be operated directly without gastric ischemic conditioning. The investigators don't performed any arteriography before the esophageal surgical resection
2570001|NCT02432599|Experimental|F18-choline PET|F18-choline PET examination will be performed before surgery
2570069|NCT02432365|Experimental|Weekly paclitaxel and cisplatin|7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy
2570159|NCT02431728|Active Comparator|Melatonin|capsule containing 5mg melatonin plus cellulose
2570164|NCT02431728|Placebo Comparator|Matched Placebo|capsule containing cellulose
2570198|NCT02431377|Experimental|S-26 Gold|Standard Infant Formula containing enriched with alpha-lactalbumin
2570501|NCT02429622|Experimental|Radical 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
2570506|NCT02429622|Experimental|Radical 2.17|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.17Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
2570512|NCT02429622|Experimental|Radical 2.21|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.21Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 5 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity."
2570513|NCT02429622|Experimental|Neoadjuvant 2.14|"Radiation：Patients undergo radiotherapy once daily 5 days a week for an average of 4.5 weeks in the absence of disease progression or unacceptable toxicity. IMRT simultaneous integrated boost technique is used to achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively.~Concurrent chemotherapy:Patients may receive a dosage range of Paclitaxel from 45 to 60 mg/m2 and Nedaplatin 25mg/m2 per week in the following 4 weeks after enrollment with radiotherapy at the same time in the absence of disease progression or unacceptable toxicity. Assessment of surgery: Patients eligible for surgery after multiple disciplinary consultation will receive esophagectomy after a 4-6 weeks break after chemoradiation in the absence of any contraindication."
2570747|NCT02428010|Experimental|Treatment|TMVR Implant
3172843|NCT00605410|Active Comparator|1|
3172844|NCT00605410|Placebo Comparator|2|
3172845|NCT00605436|Experimental|A|Restorative yoga therapy group: one orientation workshop for 3 hours, then twice-weekly group yoga therapy classes for first 5 weeks followed by once-weekly group yoga classes for another 5 weeks. The group will also be asked to practice their yoga postures at home for 30 minutes three times per week.
3172846|NCT00605436|No Intervention|B|The control group is a wait-list control group with no active intervention.
3172847|NCT00605488|Experimental|1|Pet Scan
3172848|NCT00605553|Experimental|1|Active medication Tozadenant 20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
2569540|NCT02435758|No Intervention|Excision of Denonvilliers Fascia|Standard TME surgery (U-shaped excision of Denonvilliers fascia) in Laparoscopy-assisted pelvic autonomic nerve preservation surgery with TME for male mid-low rectal cancer patients
2569579|NCT02435563|Experimental|Ticagrelor 180 mg|Single dose of 180mg ticagrelor administered orally
2569582|NCT02435563|Experimental|Ticagrelor adjusted dose+ritonavir 100mg|adpated dose of ticagrelor calculated after PK modelisation with the Simcyp® simulator administered simultaneously with 100 mg ritonavir
2569686|NCT02434666|Experimental|CPC-201|
2569700|NCT02434510||Sterile Water bath|Standard of Care group using a sterile water instrument bath
2569701|NCT02434510||CHG group|Study group using the 0.05% CHG solution in the instrument bath
2569744|NCT02434406|Experimental|Web-based intervention|Participants get access to the web-based intervention and are asked to work through the 8 modules of the intervention within eight weeks. The intervention program sends automated weekly email reminders about the current session. In addition, users are offered weekly optional 30-minute telephone support with a trained intervention coach.
2569747|NCT02434406|No Intervention|Wait-list control|Participants get standard care and will be offered access to the web-based intervention at 8-weeks post-randomization.
2569785|NCT02434172||Screening|There are no arms to the study. All participants will undergo screening. Preemptive treatment will only be provided to those who are CrAg positive.
2569811|NCT02433886|Experimental|Gamma Ventral Capsulotomy|
2569853|NCT02433652|Experimental|Trivalent dengue vaccine admixture + rDEN2Δ30-7169|Participants will receive the trivalent dengue vaccine admixture at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
2569857|NCT02433652|Experimental|Placebo + rDEN2Δ30-7169|Participants will receive a placebo vaccine at Day 0 and the rDEN2Δ30-7169 vaccine at Day 180.
2569899|NCT02433353|Experimental|EMDR + Venlafaxine XR|Participants will receive 12 one-hour sessions of EMDR while taking venlafaxine XR 150mg or 225mg for the duration of the 6 month study.
2569900|NCT02433353|Placebo Comparator|EMDR + Placebo|Participants will receive 12 one-hour sessions of EMDR while taking placebo 150mg or 225mg for the duration of the 6 month study.
3172849|NCT00605553|Placebo Comparator|2|Crossover from arm 1 to arm 2 with one week washout. One of the arms is placebo control
2570014|NCT02432612|Experimental|Sativex|Sativex will be administered by trained, clinical trial personnel, via a pump action oromucosal spray. Sativex will be administered as 2 actuations (sprays) under the tongue or inside the cheeks every 4 minutes until 6 sprays have been administered. Following the administration of the first and second set of 2 actuations, patients will be offered 50 mL water to drink; and following the final set of 2 actuations, 100 mL of water will be offered (i.e., a total of 200 mL water will be offered during the Sativex dosing). There must be a period of at least 2 minutes and no more than 3 minutes between Sativex administration and consumption of water. Patients will not be permitted their regular medication until 2 hours post dose of investigational medicinal product (IMP) to minimize any possible drug interactions.
2570062|NCT02432326|Experimental|Arm A|
2570254|NCT02431208|Experimental|Cohort A: ATZ (Run-In)|Cohort A will involve a safety run-in to evaluate atezolizumab administered as a single agent in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
2570257|NCT02431208|Experimental|Cohort B1: ATZ + LEN (Dose Escalation)|Cohort B1 will involve a dose escalation to evaluate atezolizumab administered in combination with ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort has been completed.
2570260|NCT02431208|Experimental|Cohort C: ATZ + LEN (Post-ASCT):|Cohort C will evaluate atezolizumab administered in combination with lenalidomide in participants with MM who have measureable disease after ASCT. NOTE: This cohort is closed to enrollment.
2570263|NCT02431208|Experimental|Cohort D1: ATZ + DAR (Run-in)|Cohort D1 will involve a safety run-in to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment.
2570267|NCT02431208|Experimental|Cohort D2: ATZ + DAR (Expansion)|Cohort D2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab in participants with relapsed or refractory MM who have received 2 but no more than 3 lines of prior treatment that must have included a PI and IMiD and are refractory to the last line of treatment.
2570271|NCT02431208|Experimental|Cohort D3: ATZ + DAR (Progressed)|Cohort D3 will involve an expansion to evaluate atezolizumab in combination with daratumumab in participants with relapsed or refractory MM who have received 2 or more lines of prior treatment and have progressed with an anti-cluster of differentiation (CD) 38 monoclonal antibody, either alone or in combination, and are refractory to both a proteasome inhibitor (PI) and immunomodulatory drug (IMiD).
2570274|NCT02431208|Experimental|Cohort E1: ATZ + DAR + LEN (Dose Escalation)|Cohort E1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose lenalidomide in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
3172850|NCT00605592|Experimental|1|Islet cell transplant
3172851|NCT00605605|Experimental|1|
3172852|NCT00605618|Experimental|Single Arm|
3172853|NCT00605631|Experimental|1|
3172854|NCT00605631|Active Comparator|2|
3172855|NCT00605631|Other|3|
3172856|NCT00605670||1|Postoperative Breast Surgery Patients
3172857|NCT00605670||2|Preoperative Breast Surgery Patients
3172858|NCT00605683|Active Comparator|1|50 mg/day Safinamide
3172859|NCT00605683|Active Comparator|2|Safinamide 100mg/day
3172860|NCT00605683|Placebo Comparator|3|Placebo 0mg/Safinamide
3172861|NCT00605709|Experimental|1|Active Cream 3% ; AM & PM
3172862|NCT00605709|Active Comparator|2|Placebo Cream AM; 3% Active Cream PM
3172863|NCT00605709|Active Comparator|3|Placebo Cream AM; 1.5% Active Cream PM
3172864|NCT00605709|Placebo Comparator|4|Placebo Cream AM & PM
3172865|NCT00605735|Experimental|A1|
3172866|NCT00605735|Placebo Comparator|P1|
3172867|NCT00605748|Active Comparator|1|Segmental PV-Isolation of the arrhythmogenic vein(s)
3172868|NCT00605748|Active Comparator|2|Segmental PV-Isolation of all veins
2569589|NCT02435641||ICU Questionnaires|"After enrollment, all subjects (patients and their primary caregiver) will be given baseline measures assessing: sociodemographics, depression, anxiety, distress, stress, PTSD, coping, mindfulness, quality of life, satisfaction with life, resiliency/self efficacy (patient only), patient caregiver interaction, caregiver preparedness (caregiver only), caregiver self efficacy (caregiver only), quality of adherence measure, and health care satisfaction.~Subjects will complete the same measures again at time 2 (3 months) and time 3 (6 months). The study endpoint is time 3 follow up (6 months)."
2569650|NCT02435316|Active Comparator|Group 1|Group 1 will receive 1 hour of compare-contrast basic science teaching of cell recognition to enhance recognition of those photographs, followed by 1 hour Case vignette-based teaching of cell recognition 2 weeks later
2569654|NCT02435316|Active Comparator|Group 2|Group 2 will receive 1 hour of Case vignette-based teaching of cell recognition followed by compare-contrast basic science teaching of cell recognition 2 weeks later
2569726|NCT02434783||1st level of arterial insufficiency|asymptomatic PAD patients
2569729|NCT02434783||2nd level of arterial insufficiency|Intermittent claudication patients
2569731|NCT02434783||3rd level of arterial insufficiency|Critical limb ischemia patients
2569732|NCT02434783||No arterial insufficiency|Healthy individuals (control)
2569830|NCT02434042|Active Comparator|BB536|Bifidobacterium longum BB536 (9 log CFU/day) and dextrin
2569834|NCT02434042|Placebo Comparator|Placebo|100% dextrin
2569984|NCT02432976|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
2569989|NCT02432976|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
2570028|NCT02432508|Active Comparator|laser acupuncture|One hundreds of hemodialysis patients include and give intervention with laser acupuncture (50mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to shame laser acupuncture treatment (5mW).
2570029|NCT02432508|Sham Comparator|sham laser acupuncture|One hundreds of hemodialysis patients include and give intervention with sham laser acupuncture (5mW) for 4 weeks. After 4 weeks of wash out period, these patients cross over to laser acupuncture treatment (50mW).
2570140|NCT02431624|Experimental|Test treatment|BTDS 40 milligram
2570144|NCT02431624|Active Comparator|Reference treatment|BTDS 20 milligram
3172869|NCT00605761|Experimental|Cohort 1|50 mg treatment
2570292|NCT02431026|Experimental|Cooling present|"Cooling pack activated before start of MRI scan for the condition cooling present."
2570293|NCT02431026|No Intervention|No cooling present|"Cooling pack will not be activated in the condition no cooling present."
2570301|NCT02430831|Active Comparator|Reuteri group|Milk formula added with probiotic L reuterii DSM 17938
2570302|NCT02430831|Placebo Comparator|Placebo|Milk formula without probiotic L reuterii DSM 17938
2570375|NCT02430623|Experimental|IRE Group|irreversible electroporation for Unresectable Urinary Bladder Neoplasms
2570376|NCT02430623|No Intervention|Control|The patients without treatment
2570456|NCT02430129|Active Comparator|Total knee arthroplasty/Persona|Total knee arthroplasty with Zimmer Persona posterior cruciate retaining prosthesis (Zimmer, Warsaw, IN)
2570459|NCT02430129|Experimental|Unicompartment knee arthroplasty/Oxford|Unicompartmental knee arthroplasty with Biomet Oxford mobile-bearing unicompartmental knee prosthesis (Biomet, Warsaw, IN)
2570492|NCT02429674|Other|TranS-C and IPT-A|12 sessions of weekly outpatient psychotherapy for adolescent depression.
2570551|NCT02429479|Active Comparator|Standard ACP/Patient Alone|Patients (without their family caregiver) complete a standard living will form online.
2570552|NCT02429479|Experimental|Decision Aid/Patient Alone|Patients (without their family caregiver) complete Making Your Wishes Known, an online decision aid for advance care planning.
2570554|NCT02429479|Active Comparator|Standard ACP/Together|Patients and their family caregiver together complete a standard living will form online.
2570557|NCT02429479|Experimental|Decision Aid/Together|Patients and their family caregiver together complete Making Your Wishes Known, an online decision aid for advance care planning.
2570629|NCT02428946|Active Comparator|Morning bromocriptine|Bromocriptine is taken in the morning
2570630|NCT02428946|Active Comparator|Evening bromocriptine|Bromocriptine is taken in te evening
2570660|NCT02428465|Experimental|Purposeful Parenting|Families randomized to the intervention group will receive their pediatric provider's usual anticipatory guidance plus Purposeful Parenting.
2570661|NCT02428465|No Intervention|Control Group|Families randomized to the control group will receive usual anticipatory guidance, delivered at the discretion of their pediatric provider, at each well-child visit in the first 12 months of life.
2570796|NCT02427633|No Intervention|Control|Randomized to standard care (control group) - observations only
2570799|NCT02427633|Experimental|UKRC 1997|Randomized to modified UKRC 1997 - Intervention and Observations
3172870|NCT00605761|Experimental|Cohort 2|150 mg treatment
3172871|NCT00605774|Experimental|1|Hyperinsulinemic euglycemic glucose clamps x 2 on Day 1 Hyperinsulinemic euglycemic glucose clamp with epinephrine infusion on Day 2
3172872|NCT00605774|Experimental|2|Day 1 euglycemic exercise period x 2 Day 2 hyperinsulinemic euglycemic glucose clamp with epinephrine infusion
3172873|NCT00605787|Active Comparator|Single group|Single group all treated similarly, outcome evaluated as changes within individuals during intervention
3172874|NCT00605800||1|normal healthy volunteers
3172875|NCT00605800||2|Patients undergoing major liver resections
3172876|NCT00605852|Experimental|Subjects receiving treatment in cohort I|Eligible subjects will receive three single doses of GSK835726 and one single dose of placebo in cohort I.
2569601|NCT02435472|Experimental|Arm A: Exercise|Arm A will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test (CPET) performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing. Archival biopsy tissue samples from before and after the intervention will also be requested.
2569603|NCT02435472|No Intervention|Arm B: Usual Care|"Arm B will receive print material with physical activity guidance which includes general physical activity information (e.g., Moving through Cancer - A Guide to Exercise for Cancer Survivors) at baseline, but no specific exercise program or goals. At the conclusion of the 16 weeks, subjects in this group will be provided with a heart rate monitor, an individualized aerobic exercise program based on their cardiorespiratory fitness test results, and opportunity to consult with study exercise physiologist (one-time)."
2569606|NCT02435472|Active Comparator|Arm C: Exploratory|Arm C is a non-randomized control group of men without cancer, which will receive all baseline and 16 week follow-up assessments (except tissue procurement) will engage in up to 4 aerobic sessions per week at 55% to 75% of the individually determined exercise capacity (VO2peak; determined from the cardiopulmonary exercise test performed at baseline) for 16 weeks. This exercise prescription will be achieved through ~ 4 sessions / week. Men are provided with a heart rate monitor to help ensure they exercise in their target zone. At baseline & week 16, all patients will complete: (1) lifestyle and quality-of-life questionnaires, (2) measurement of weight (3) collection of research fasting blood sample, (4) collection of urine sample, and (5) cardiorespiratory fitness testing.
2569611|NCT02435472|Active Comparator|Observational Non-Randomized Group|There is also a non-randomized observational component to the study where biospecimens and survey data will be collected and one CPET will be administered. Individuals who will be enrolled to this group include those who do not meet all eligibility criteria for the RCT, or those who do not wish to be in a RCT, but are interested to participate in some lifestyle research.
2569656|NCT02435082||Concussion with TCD|Any patient (adolescent/adult) receiving a Transcranial Doppler (TCD) for a head injury, suspected concussion, or suspected mild traumatic brain injury (sports related or not).
2569786|NCT02434874|Experimental|Immediate Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated immediately.
2569792|NCT02434874|Other|Delayed Activation|Subjects randomized to this group will have the StimGuard Sacral Nerve Stimulator System activated after 90 days.
2569813|NCT02433860|Experimental|pregnant nicotine users|watch video and tobacco cessation counselling using SCRIPT protocol
3208358|NCT00974038|Experimental|CBT, SP|cognitive behavioral therapy, supportive psychotherapy
2570055|NCT02432248|Experimental|Dehydroepiandrosterone|DHEA is considered as health supplement and is available over the counter. Side effects are minimal at present dosage (25mg or 50mg tds).
2570056|NCT02432248|Placebo Comparator|Placebo|Medical starch is considered as medicine components. Side effects are minimal at present dosage.
2570093|NCT02431988|Experimental|CAR19 T-cells|"Patients will receive a single infusion of CAR19 T-cells following standard pre-conditioning with cyclophosphamide and fludarabine.~The CAR19 T-cells are to be administered on day 0."
3208359|NCT00974064||A-Healthy Non smokers|Healthy nonsmokers. Defined as non-smokers by self report and urine cotinine levels consistent with a nonsmoker (urine cotinine <5 ng/mL).
2570211|NCT02431351|Experimental|Selinexor|60 mg once weekly
2570251|NCT02431221|Experimental|Intervention|Perhexiline maleate will be supplied in 100 mg and 25 mg tablets. It will be initially administered at a dose of 200 mg once a day in tablet form for at least six months. After initiation of dosing, perhexiline dosing will be determined using plasma level guided dose adjustment. Dosing decisions will be made by an unblinded dose control center.
2570253|NCT02431221|Placebo Comparator|Placebo|Placebo will be administered once a day in tablet form for at least six months. Tablets will be identical in size and shape to perhexiline tablets. Adjustments in placebo dosing will be made by an unblinded dose control center to mimic decisions made for subjects in the experimental arm.
2570289|NCT02431013|Experimental|Simvastatin+Cilostazol|Simvastatin 40 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Simvastatin 40 mg and Cilostazol 100 mg twice a day on Day 8.
2570298|NCT02431013|Active Comparator|Pravastatin+Cilostazol|Pravastatin 20 mg on Day 1. Cilostazol 100 mg twice a day for 6 days. Pravastatin 20 mg and Cilostazol 100 mg twice a day on Day 8.
2570337|NCT02430740|Other|control group|standard care recFSH
2570341|NCT02430740|Experimental|study group|modified dosage of recFSH for controlled ovarian stimulation based on AMH, BMI and AFC
2570428|NCT02430350|Experimental|Compound Edaravone|Compound Edaravone Injection 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
2570432|NCT02430350|Active Comparator|Edaravone|Edaravone Injection 30 mg/dose, one dose every 12 hours, continues for 14 days
2570534|NCT02429544|Experimental|Experimental Support Group (ESG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
2570681|NCT02428556|Active Comparator|"breakthrough with is warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
2570688|NCT02428556|Experimental|breakthrough only|"Scenario describes study results with breakthrough language, no cautions about conditional approval"
3208360|NCT00974064||B-Healthy smoker|"Healthy current smokers. Subjects categorized as healthy according to criteria under Collection (#1204012331) protocol."
3208361|NCT00974064||C-Healthy smoker to quit|Healthy smokers willing to quit. Defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL).
2569617|NCT02435407|Active Comparator|Education arm|Parents will participate in educational talks around the cause and management of feeding difficulties in children with autism spectrum disorder.
2569655|NCT02435134||Healthy participants|
2569771|NCT02434887|Experimental|Experimental group|
2569814|NCT02433964|Experimental|LED group|Treated by a device LED - LED: power 60mW, 627nm wavelength ± 10nm and 1,3cm2 beam output. The energy density used was 10J / cm2 with time of 2 minutes and 47 seconds per flash of the beam, which is unique for each ten points in the lateral region of the ankle edema. The volunteers underwent previous cleaning application points with cotton soaked in 70% alcohol, positioned for high stretcher in the supine position and wearing goggles. The LED was applied in a timely manner, wherein the skin contact surfasse at an angle of 90 °, the ten points were irradiated in a 1cm2 area selected by a single investigator. One session was performed every 24 hours for six consecutive days. Ice applications were made associated with semi-rigid compression bandage, with the patient lying supine and the affected limb in elevation under a foam wedge in the same period.
2569819|NCT02433964|Placebo Comparator|Placebo group|Both volunteers LED group and the placebo group were treated with the same procedure, with the LED device in the placebo group remained off.
2569849|NCT02433600|Active Comparator|Cow's milk-based infant formula|
2569852|NCT02433600|Experimental|Cow milk-based infant formula with enriched protein fractions|
3172877|NCT00605852|Experimental|Subjects receiving GSK835726 in cohort II|Eligible subjects will receive repeat doses of GSK835726 once daily for 7 days.
3172878|NCT00605852|Placebo Comparator|Subjects receiving placebo in cohort II|Eligible subjects will receive repeat doses of placebo once daily for 7 days.
2570067|NCT02432118|Experimental|Diagnostic (radiofrequency-guided localization)|Patients undergo radiofrequency-guided localization comprising RFID tag placement before lumpectomy and interactive detection of tag using RFID reader during lumpectomy.
2570138|NCT02431871||Treated for DDH in childhood|Subjects have had DDH in childhood. DDH has been diagnosed before age of 1,5 years and treated for.
2570142|NCT02431871||Control|Age an sex matched controls of DDH patients
2570305|NCT02430883|Active Comparator|first group|patients who have upper pole kidney stones treated with flexible renoscopy
2570308|NCT02430883|Active Comparator|second group|patients u who have mid pole kidney stones treated with flexible renoscopy
2570317|NCT02430883|Active Comparator|third group|patients who have lower pole kidney stones treated with flexible renoscopy
2570321|NCT02430883|Active Comparator|forth group|patients who have kidney stones in pelvis treated with flexible renoscopy
2570325|NCT02430883|Active Comparator|fifth group|patients who have multiple calixes kidney stones treated with flexible renoscopy
2570360|NCT02430545|Experimental|Glasdegib, Rifampin|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
2570388|NCT02430298|Placebo Comparator|Matched placebo|Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
2570391|NCT02430298|Active Comparator|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
2570465|NCT02429973|Experimental|Experimental|6 cycles of gemcitabine plus rapamycin
2570494|NCT02429713|Experimental|Short-duration tourniquet group|The tourniquet was inflated immediately before cement application and deflated after its hardening
2570497|NCT02429713|Active Comparator|Long-duration tourniquet group|The tourniquet was inflated immediately before incision and deflated after the hardening of the cement
2570570|NCT02429440|Experimental|Study Arm 1|Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
2570577|NCT02429440|Active Comparator|Study Arm 2|Intradermal application of peptide vaccine with Montanide ISA-51
2570603|NCT02428816|Experimental|Patients with Parkinson's Disease|Patients with PD will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
2570605|NCT02428816|Experimental|Patients with MSA|Patients with MSA will be submitted to an MRI acquisition and to behavioural evaluations in each visits (two visits planned)
2570606|NCT02428816|Experimental|Controls|30 healthy controls will be submitted to an MRI acquisition and to behavioural evaluations in a sole visit
2570653|NCT02428582|Active Comparator|bare stent inserted|Standard bare stent will be placed
2570654|NCT02428582|Experimental|Covered stent inserted|Covered stent will be placed
2570810|NCT02427529|Experimental|HCG Group|This group received daily subcutaneous injections of Human Chorionic Gonadotropin while eating a very low calorie diet of 500 calories per day.
2570816|NCT02427529|Placebo Comparator|Saline/Placebo|This group received daily subcutaneous injections of saline while eating a very low calorie diet of 500 calories per day.
2570866|NCT02427230|Active Comparator|Pelvic floor muscle training (PFMT)|Pelvic floor muscle training daily during 12 weeks.
2570869|NCT02427230|Active Comparator|PFMT and electrical stimulation|Pelvic floor muscle training and intravaginal neuromuscular electrical stimulation daily during 12 weeks.
2571134|NCT02425579|Placebo Comparator|Cohort 1 (placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
3172879|NCT00605852|Experimental|Subjects receiving treatment in cohort III|Eligible subjects will receive two single doses of GSK835726 and one single dose of placebo in cohort III.
3172880|NCT00605891|Experimental|A|carmoterol (CHF 4226) 1.0 μg once a day, in the morning
3172881|NCT00605891|Experimental|B|carmoterol (CHF 4226) 2.0 μg once a day, in the morning
3172882|NCT00605891|Experimental|C|carmoterol (CHF 4226) 4.0 μg once a day, in the morning
3172883|NCT00605891|Placebo Comparator|D|Placebo once a day, in the morning
3172884|NCT00605891|Active Comparator|E|Salmeterol 50 μg BID, in the morning and in the evening
3172885|NCT00605930|Active Comparator|Pyruvate, creatine, niacinamide|Pyruvate, creatine, niacinamide administered
3172886|NCT00605930|Placebo Comparator|Placebo|placebo
3172887|NCT00605956|Experimental|1|NatrOVA Creme Rinse - 1% Spinosad
2569633|NCT02435329||Type 2 diabetes without neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
2569635|NCT02435329||Type 2 diabetes with painful neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
2569637|NCT02435329||Type 2 diabetes with painless neuropathy|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
2569638|NCT02435329||Type 2 diabetes with Charcot foot|"10 patients~Anthropometric measures: Height, weight, BMI, waist circumference~Vital parameters: supine and standing blood pressure, pulse, respiratory rate and temperature~Laboratory assessment that includes markers of endothelial activation, inflammation and bone metabolism.~Assessment of skin microcirculation with Laser Doppler Iontophoresis~Assessment of calcaneal bone mineral density (BMD) with Bone Sonometer (ultrasound)~Advanced glycation end-products will be assessed by an AGE reader which uses the technique of skin autofluorescence"
2569673|NCT02434965|Experimental|Autologous Cord Blood and HPDSC|Autologous cord blood and placental blood will be collected after birth of child and administered in divided aliquots during the first week of life.
2569711|NCT02434718|Experimental|Cohort 1|IV infusion in cohorts assigned to low dose 1; 1 participant per cohort will receive placebo
2569712|NCT02434718|Experimental|Cohort 2|IV infusion in cohorts assigned to low dose 2; 1 participant per cohort will receive placebo
2569717|NCT02434718|Experimental|Cohort 3|IV infusion in cohorts assigned to high dose; 1 participant per cohort will receive placebo
2569721|NCT02434718|Experimental|Cohort 4|IV infusion in cohorts assigned to mid dose; 1 participant per cohort will receive placebo
2569808|NCT02433938|Experimental|Underwent tibial nerve stimulation|Patients that underwent standard postoperative protocol + tibial nerve stimulation for 3 days
2569809|NCT02433938|Sham Comparator|Did not undergo tibial nerve stimulation|Patients that underwent standard postoperative protocol + sham tibial nerve stimulation (standard postoperative protocol+sham tns)
2569859|NCT02433691|Active Comparator|Sequential Exercise and Memory Training|Aerobic exercise via stationary bicycling followed by memory training.
2569862|NCT02433691|Experimental|Simultaneous Exercise & Memory Training|Simultaneous aerobic exercise via stationary bicycling while receiving memory training.
2569866|NCT02433691|Placebo Comparator|Stretching and Toning|Anerobic stretching and toning followed by memory training
2569922|NCT02433223||2006 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation
2569926|NCT02433223||2011 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 results.
2569928|NCT02433223||2013 Patients|Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
2569930|NCT02433223||2015 Patients|Group added to reflect recency of practice. Comparison of Respiratory Chronic Disease Management provided against recommendations in 2005 Respiratory Nursing Guidelines through documentation. With comparison of data against 2006 & 2011 results.
2569991|NCT02432963|Experimental|Treatment (p53MVA, pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes followed by modified vaccinia virus Ankara vaccine expressing p53 SC at least 30 minutes later once in weeks 1, 4, and 7. Patients may receive additional doses of pembrolizumab in weeks 10, 13, 16, and 19, for a maximum of 7 doses if there are no signs of progressive disease. Treatment continues in the absence of disease progression or unacceptable toxicity.
2570023|NCT02432482|Active Comparator|Standard care|Brief advice to quit (less than 5 minutes) Self-help brochure Offer of nicotine patches
2570026|NCT02432482|Experimental|mobile Positively Smoke Free (mPSF)|"mPSF: a targeted, intensive behavioral cessation intervention for PLWH smokers~offer of nicotine patches"
2570087|NCT02432170|Experimental|Foot/Ankles imaged with tomosynthesis|"Intervention: Digital Tomosynthesis of Foot and Ankle~The intervention, digital tomosynthesis of the foot and ankle, will be done on eligible participants. The resulting images will be compared to radiography and weight-bearing CT images from the same participants."
3172888|NCT00605956|Experimental|2|NatrOVA Vehicle - no Spinosad
3172889|NCT00605956|Placebo Comparator|3|Blank Patch
2570347|NCT02430675|Experimental|Group A|irreversible electroporation for Unresectable Laryngeal Neoplasms
2570348|NCT02430675|No Intervention|Control|The patients without treatment
2570801|NCT02427633|Experimental|UKRC 2010|Randomized to modified UKRC 2010 - Intervention and Observations
3172890|NCT00605969|Active Comparator|FAI patients|This group consists of participants diagnosed with femoroacetabular impingement that are undergoing surgical correction.
3172891|NCT00605969|Placebo Comparator|Control|This group consists of healthy control participants with no hip problems.
3172892|NCT00605995|Experimental|Simvastatin|Simvastatin, 20 mg Tablet, given once daily. Dosage increased to 40 mg/day at the end of week 4 until endpoint.
3172893|NCT00605995|Placebo Comparator|Placebo|Placebo pill, similar in its appearance to Simvastatin, taken once daily for the duration of the trial.
3172894|NCT00606060|Experimental|Arm 1|
3172895|NCT00606073|Active Comparator|I|IVF Procedure-IVF Medium
3208362|NCT00974064||D-Current smoker w. COPD|Current smokers with COPD. COPD as defined by the GOLD criteria and currently smoking as defined by self-report and urine cotinine levels consistent with an active smoker (urine cotinine >50 ng/mL)
3208363|NCT00974064||E-Current COPD smoker to quit|Current smokers with COPD willing to stop smoking. Subjects have COPD as defined by the GOLD criteria
2569770|NCT02434562||Medical castration|Patients treated with androgen deprivation therapy (e.g. for hypersexuality, transgender subjects, ...)
2569772|NCT02434562||Male hypogonadism|Patients treated with testosterone replacement therapy (e.g. for late-onset hypogonadism, secondary hypogonadism)
2569776|NCT02434562||Thyroid disorders|Patients treated for hyperthyroidism or hypothyroidism (incl. during treatment for thyroid cancer)
2569782|NCT02434562||Obesity and weight loss|Patients treated for obesity with weight loss interventions (mainly bariatric surgery)
2569789|NCT02434562||Miscellaneous|Various disorders associated with alterations in SHBG, androgens and/or estrogens
2569815|NCT02433873|Placebo Comparator|Placebo|Ingredients that are in the placebo are: high maltose corn syrup (Satin Sweet™), water, and mannitol. Both Supplement A and Supplement B will be compared to this placebo arm.
2569821|NCT02433873|Experimental|Supplement A|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
2569824|NCT02433873|Experimental|Supplement B|Ingredients that are in the supplement are: isomalto-oligosaccharide, water, mannitol, maltose, glucose, and glycerol. Supplement A and B differ by degrees of polymerization.
2569855|NCT02433587|Experimental|Short Term|The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.
2569858|NCT02433587|Experimental|Long Term|The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.
3208364|NCT00974077|Other|Wait List Control|Patients do ot receive psychotherapy. The wait list control group will be assessed according to study protocol and offered MBCT after 6 month
2570399|NCT02430207|Experimental|Femoral Vein|patients receiving temporary pacing via femoral vein
2570403|NCT02430207|Experimental|Subclavian Vein|patients receiving temporary pacing via subclavian vein
2570441|NCT02430012|Active Comparator|Intervention group|The intervention group will take the secondary prevention quality improvement strategies into implementation.
2570443|NCT02430012|No Intervention|Control group|The control goup will maintain the routine practice pattern.
2570490|NCT02429817|Active Comparator|Aeroneb Solo|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo connected to the high flow nasal cannula.
2570496|NCT02429817|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via the jet nebulizer connected to the high flow nasal cannula.
2570565|NCT02429323|Active Comparator|sevoflurane concentration 8%|sevoflurane concentration 8% from the start
2570573|NCT02429323|Active Comparator|incremental sevoflurane (1-8%)|incremental increase of the concentration each few breaths from 1% to 8%
2570668|NCT02428686|Experimental|epoetin beta|
2570761|NCT02427945|Experimental|Control|Provision of information on safe water
2570768|NCT02427945|Experimental|Treatment traditional|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old.
2570770|NCT02427945|Experimental|Treatment couple|Provision of information on safe water and child nutrition. The information will be targeted to the mother of the child aged between 6 and 24 months old, and her husband.
2570789|NCT02427542|Active Comparator|CBT for DP|Six sessions of CBT covering psycho-education, formulation, enhancing coping strategies (including grounding) and cognitive restructuring techniques.
2570794|NCT02427542|Placebo Comparator|Treatment as usual|Participants will continue to receive their normal treatment - in most cases, this will be care coordination/case management delivered through a community mental health team and may include medication.
2570843|NCT02427321||Cystoscopy cohort|"Video recording of flexible cystoscopic examination. All participants enrolled on the study will have video from their flexible cystoscopic examination recorded.~Diagnosis and pathology information will be collected from the participants medical notes for a period of eight weeks following the recorded cystoscopy."
2570936|NCT02427022|Experimental|Online CTI Training|Services providers in this group received a novel online CTI training. The enhanced course combines depth of knowledge among trainers, skills-based and practical approaches to learning, new technologies, and opportunities for social networking. The course is divided the knowledge, skills, and tools associated with CTI into four two-week modules. The total instruction time for the course was 24 hours.
2570938|NCT02427022|Active Comparator|Face-to-Face CTI Training|Service providers in the group received 1.5-days of face-to-face CTI training at each study site with one trainer. There were a total of 8 hours of instructor led training per site. Face-to-face training sessions were followed by three assignments with feedback from trainers, and eight 60-minute telephone consultation sessions.
2571022|NCT02426437|Other|Early Pulmonary Rehabilitation (EPR)|Patients randomized to EPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 1 month of discharge. They will proceed through the program in a typical fashion.
3208365|NCT00974077|Experimental|Mindfulness Based Cognitive Therapy|The published protocol of MBCT will be used. This is an eight week group program. Participants learn mindfulness techniques but also cognitive techniques to prevent new depressive episodes
3208366|NCT00974103|Experimental|Chiropractic treatment, exercise|Chiropractic treatment and exercise
3208367|NCT00974103|Experimental|Exercises|Exercise advise
3208368|NCT00974129||Patients with Infantile Hemangiomas|
3208369|NCT00974155|Experimental|EMC (Early Medication Change)|
3208370|NCT00974155|Active Comparator|TAU (Therapy As Usual)|
3208371|NCT00974168|Active Comparator|A|Radiation Cumulative BED ≤ 100 Gy2
3208372|NCT00974168|Active Comparator|B|Cumulative BED ≤ 130 Gy2
3208373|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (10 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
2569683|NCT02434952|Active Comparator|DHA PP alone, G6PD deficiency|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
2569684|NCT02434952|Active Comparator|DHA PP alone, G6PD normal|Standard Dihydroartemisinin piperaquine (DHA PP) dosing according to national guidelines, oral administration of one dose per day for three consecutive days. Target dosing is 2-4 mg/kg for DHA and 20 mg/kg for PP. Children (<30kg) will receive tablets of 20mg DHA and 160mg PP, while adults will receive tablets of 40mg DHA and 320mg PP.
3208374|NCT00974181|Active Comparator|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Conor Medsystems COSTAR™ stent loaded with the antiproliferative compound paclitaxel (30 µg), pre-mounted on a rapid exchange, percutaneous transluminal coronary angioplasty balloon catheter.
3208375|NCT00974194|Experimental|SinglePort CCK|CCK using Triport
3208376|NCT00974194|Active Comparator|LS CCK|CCK using three or four trocars
2570005|NCT02432937|Placebo Comparator|Corever middle dose|
2570009|NCT02432937|Placebo Comparator|Corever high dose|
2570012|NCT02432937|Placebo Comparator|Placebo|
3208377|NCT00974272|Experimental|Exenatide|
3208378|NCT00974272|Placebo Comparator|Placebo|
2570135|NCT02431689|Active Comparator|Antagonist|"Antagonist protocol (fixed) for IVF/ICSI, with starting dose of human menopausal gonadotrophins (HMG) from 300-450 IU from day 1 of the cycle, antagonist start from day 6 stimulation. Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
2570137|NCT02431689|Active Comparator|Short|"Short protocol for IVF/ICSI, gonadotrophin releasing hormone analogue (GnRHa) starts from day 1 of the cycle, HMG starts in a dose from 300-450 IU from day 3, Follow-up by ultrasound and serum estradiol will be done. Triggering of ovulation using human chorionic gonadotrophin (HCG) 10000 IU I.M. when at least 2-3 follicles reach 17mm in diameter.~Cryopreservation of all embryos at will be done. Frozen embryo transfer in the following cycle will be attempted using estradiol valerate (6mg) for endometrial preparation after pituitary down regulation using long acting GnRH analogue . A maximum of 3 good quality embryos will be transferred."
3208379|NCT00974285|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3208380|NCT00974285|Placebo Comparator|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3208381|NCT00974298||Elbow replacement|There are no other arms other then an uncemented total elbow replacement.
2570300|NCT02430922|Experimental|iVolution stent|Patient's treated with the iVolution stent from iVascular for the treatment of femoropopliteal lesions.
2570338|NCT02430688|Experimental|IRE Group|irreversible electroporation for Unresectable Extremities Neoplasms
2570340|NCT02430688|No Intervention|Control|The patients without treatment
2570426|NCT02430519|Experimental|11 Patients with Grade II Manibular Molar Furcation|Group A- Furcation Treatment with PRF
2570430|NCT02430519|Experimental|11 Patients with Grade II Mandibular Molar Furcation D|Group B- Furcation Treatment with Allograft and GTR
2570482|NCT02429908|Other|Post market study of TM-Ardis Interbody|TM-Ardis TLIF MIS or Open single or multi level implant for lumbar fusion
3208382|NCT00974324|Experimental|treatment|endostar combined with CHOP regimen
3208383|NCT00974337||Shock|"Preterm VLBW infants with shock (BP <3rd centile for gestation and birth weight with at least one of the following:~Prolonged capillary refill time (>3sec)~Reduced urine output (<1 mL/kg/hr)~Metabolic acidosis (Base deficit >5)"
2570634|NCT02428725|Experimental|Acute coronary syndrome patient|Acute coronary syndrome patient undergoing PCI and eligible for ticagrelor therapy according to the guidelines accepting blood samples measuring platelets reactivity
2570669|NCT02428400|Experimental|TG1050|"TG1050 SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 MD cohort, administered SC as 3 once weekly injections:9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~TG1050 Part B cohort, dose(s) and schedule to be determined"
2570670|NCT02428400|Placebo Comparator|Placebo|"Placebo SD cohort, administered SC as a single injection: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo MD cohort, administered SC as 3 once weekly injections: 9.0 Log [10^9] 10.0 Log [10^10], 11.0 Log [10^11] virus particles~Placebo Part B cohort, dose(s) and schedule to be determined"
2570720|NCT02428062|No Intervention|Standard-of-Care|The intraoperative hemodynamic management of the patients assigned to this arm will be left to the discretion of the anesthesiologist, without any indication as to the intraoperative hemodynamic strategy to be adopted.
2570762|NCT02427932||Pregnant and Non-pregnant/Ampicillin and Gentamicin|pregnant participants who will receive Ampicillin and Gentamicin for conditions such as chorioamnionitis; non-pregnant participants who will receive Ampicillin and Gentamicin for a qualifying hospital admission
2570767|NCT02427932||Non-Pregnant/Gentamicin|non-pregnant participants who will receive Gentamicin for a qualifying hospital admission
3208384|NCT00974337||No shock|Hemodynamically stable infant with normal blood pressure, capillary refill time, and urine output
3208385|NCT00974402|Experimental|Patients with PTSD Symptoms|Patients with Post-Traumatic Stress Disorder (PTSD) symptoms willing to undergo Cognitive Behavioral Therapy in a primary care setting.
3208388|NCT00974428|Active Comparator|Wobenzym® N and placebo|Wobenzym® N 2 tablets of the treatment and 2 placebo tablets three times per day
3208389|NCT00974428|Active Comparator|Wobenzym® N|Wobenzym® N 4 tablets three times per day
3208390|NCT00974428|Placebo Comparator|Placebo|Placebo 4 tablets three times per day
3208391|NCT00974441|Experimental|Divalproex Sodium|500 mg Extended Release Tablet
3208392|NCT00974441|Active Comparator|Depakote®|500 mg Extended Release Tablet
3208393|NCT00974454|Active Comparator|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
2569817|NCT02433990||Adult Congenital Heart Disease|18 years and older with congenital heart disease
3208394|NCT00974454|Placebo Comparator|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3208395|NCT00974467|Experimental|After The Injury website|
2569972|NCT02432859|Active Comparator|Electrical stimulation|In the electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
2569978|NCT02432859|Placebo Comparator|Placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero
2570039|NCT02432560||Everolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking everolimus as part of their clinical care
2570040|NCT02432560||Sirolimus|women over age 18 who have LAM and are currently taking, have previously failed or been intolerant of, or who are considering taking sirolimus as part of their clinical care
2570065|NCT02432014|Other|PMTO-PTC Group clinic-based|PMTO-PTC = Oregon Parent Management Training program, Parenting Through Change groups provided at a clinic.
2570071|NCT02432014|Other|PMTO Individual home-based|PMTO = Oregon Parent Management Training program, delivered individually in the home.
2570080|NCT02432014|Other|PMTO Individual clinic-based|PMTO = Oregon Parent Management Training program, delivered individually at a clinic.
2570085|NCT02432014|Other|Services as Usual|Usual child-centered services (i.e. therapy) provided by the agencies at a clinic.
3208396|NCT00974467|Other|Usual care|Treatment as usual
3208397|NCT00974506|Active Comparator|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine therapy by general practitioner
3208398|NCT00974506|Active Comparator|Routine care therapy|Routine care therapy by general practitioner
2570359|NCT02430649|Experimental|IRE Group|irreversible electroporation for Unresectable Prostatic Neoplasms
2570361|NCT02430649|No Intervention|Control|The patients without treatment
2570385|NCT02430285|Other|Endoscopic Ultrasound|All consecutive patients entering the emergency department due to acute abdominal pain and showing biochemical and/or radiological findings consistent with possible acute biliary pancreatitis, undergo Endoscopic Ultrasound with linear array Olympus 180 series echoendoscopes (Olympus Europa Holding, Hamburg, Germany).
2570448|NCT02430051|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
2570449|NCT02430051|Experimental|Sensory Adapted Dental Environment|In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
3208399|NCT00974519|Active Comparator|Fuzheng 3|Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3208400|NCT00974519|Active Comparator|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
2570563|NCT02429206|Active Comparator|Positive Control|Each volunteer will be asked to self-apply a standard moisturizing cream (Glaxal Base) on one side of their body. Application twice a day during 14 days.
2570575|NCT02429206|Experimental|Experimental Cream|Each volunteer will be asked to self-apply the experimental product (SQIN with CanSATs technology) on the other side of their body. Application twice a day during 14 days.
2570658|NCT02428894||LVAD recipients|
2570685|NCT02428270|Experimental|GSK2256098 and Trametinib|"GSK2256098, orally, at 0.375 or 0.5 mg, once daily, continuously every 28 day cycles.~Trametinib, orally at 250 mg or 500 mg, twice daily, continuously every 28 day cycles."
2570746|NCT02428023||GrThalasaemia|estimation of IMT of the carotides arteries and calcium scoring
2570750|NCT02428023||GrNormal|estimation of IMT of the carotides arteries and calcium scoring
3208401|NCT00974519|Placebo Comparator|Placebo|Placebo, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
3208402|NCT00974532|Active Comparator|Subjects with normal kidney function|eGFR > 60 ml/min/m²
2570871|NCT02427191|Experimental|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
2570875|NCT02427191|Placebo Comparator|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
2570932|NCT02426775|No Intervention|Methylmalonic Acidemia Control Arm|patients with Methylmalonic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
2570940|NCT02426775|Experimental|Methylmalonic Acidemia Active arm|patients with Methylmalonic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)
2571135|NCT02425579|Experimental|Cohort 2|Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days
3208403|NCT00974532|Experimental|CKD late Stage 3 and Stage 4|eGFR 15-40 ml/min/m²
3208404|NCT00974558|Experimental|fan directed to cheeks|Blow draft of air generated by fan across cheeks
3208405|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin|Bevacizumab-ineligible non-small cell lung cancer (NSCLC) participants may receive up to 6 cycles (21-day cycle) of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941
3208406|NCT00974584|Experimental|GDC-0941+Paclitaxel+Carboplatin+Bevacizumab|Bevacizumab-eligible NSCLC particpants may receive up to 6 cycles of combination chemotherapy with paclitaxel and carboplatin along with GDC-0941 and bevacizumab.
3208407|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin|Bevacizumab-ineligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941.\n
3208408|NCT00974584|Experimental|GDC-0941+Pemetrexed+Cisplatin+Bevacizumab|Bevacizumab-eligible NSCLC participants may receive up to 6 cycles of combination chemotherapy with pemetrexed and cisplatin along with GDC-0941 and bevacizumab.\n
3208409|NCT00974610||Breast|
2569728|NCT02434744|Experimental|Cohort 3 200 mg KD026 BID|200 mg KD026 BID in combination with Metformin for 12 weeks
2569730|NCT02434744|Experimental|Cohort 4 100 mg KD026 TID|100 mg KD026 three times a day (TID) in combination with Metformin for 12 weeks
2569733|NCT02434744|Placebo Comparator|Cohort 1 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
2569735|NCT02434744|Placebo Comparator|Cohort 2 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
2569737|NCT02434744|Placebo Comparator|Cohort 3 Placebo|Matched Placebo Dose BID in combination with Metformin for 12 weeks
2569738|NCT02434744|Placebo Comparator|Cohort 4 Placebo|Matched Placebo Dose TID in combination with Metformin for 12 weeks
2569876|NCT02433535|Experimental|Simvastatin|Simvastatin 40 mg daily will be given for 12 weeks.
2569882|NCT02433535|Placebo Comparator|Placebo|A placebo capsule will be given daily for 12 weeks.
2569939|NCT02433171||Melanoma Brain Metastases|Stage 4 cancer patient population with melanoma with brain metastases previously treated with SRS
2569942|NCT02433171||Lung Cancer Brain Metastases|Stage 4 cancer patient population with non-small cell lung cancer with brain metastases previously treated with SRS
2569976|NCT02432807|Experimental|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1% dosed approximately 1 cm of ointment QID for 7 days
2569982|NCT02432807|Placebo Comparator|Placebo|Vehicle (placebo) ophthalmic ointment dosed approximately 1 cm of ointment QID for 7 days
2570049|NCT02432443|Experimental|Motor and pre-literacy program|First group to receive the motor and pre-literacy program.
2570050|NCT02432443|Active Comparator|Wait-list comparison|Second group to receive the motor and pre-literacy program after the experimental arm has completed the program.
2570074|NCT02432053|Experimental|Transplantation|Advagraf
3208410|NCT00974610||Lung|
3208411|NCT00974610||Melanoma|
3208412|NCT00974610||Pancreatic|
3208413|NCT00974610||Colorectal|
2570303|NCT02430805|Other|NOE|multicentric family-based cohort. prospective and transversal study
2570364|NCT02430662|Experimental|IRE Group|irreversible electroporation for Unresectable Gallbladder Neoplasms
2570367|NCT02430662|No Intervention|Control|The patients without treatment
2570394|NCT02430246|Experimental|Primary prevention - Urex Plus|Patients with Normal vaginal flora in the experimental arm will be treated with UREX PLUS
2570396|NCT02430246|Placebo Comparator|Primary prevention - Placebo|Patients with Normal vaginal flora in the Placebo arm will be treated with a capsule without active ingredient
2570400|NCT02430246|Experimental|Secondary prevention - Urex Plus|Patients with abnormal vaginal flora in the experimental arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given UREX PLUS
2570404|NCT02430246|Placebo Comparator|Secondary prevention - Placebo|Patients with abnormal vaginal flora in the Placebo arm will be treated with antibiotic (either clindamycin, metronidazole or both if one was not effective), Once AVF/BV was eradicated, the patient will be given placebo without active ingredient
2570405|NCT02430246|Experimental|Eradication - Urex Plus|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the experimental arm will be treated with UREX PLUS
2570406|NCT02430246|Placebo Comparator|Eradication - Placebo|Patients with persistent abnormal vaginal flora following treatment with clindamycin and metronidazole in the placebo arm will be treated with placebo without active ingredient
2570407|NCT02430246|Other|Lactobacilli transfer - probiotic capsule|Patients with Normal vaginal flora will be treated with a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months afterwhich they will receive no treatment for additional two months. Lactobacili colonization in the vaginal flora will be tested
2570408|NCT02430246|Other|Lactobacilli transfer - probiotic capsule after 2 months|Patients with Normal vaginal flora will be followed for two months without intervention afterwhich they will receive a probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14 for two months. Lactobacili colonization in the vaginal flora will be tested.
3208414|NCT00974623||Spinal Fusion|Patients who undergo a planned spinal fusion procedure requiring approved bone grafting materials (e.g., bone grft substitutes, allograft or autograft).
3208415|NCT00974636|Experimental|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day for two weeks
2570548|NCT02429271|Active Comparator|Ticagrelor|1st day 270 mg & from then onwards 180 mg per day
2570550|NCT02429271|Active Comparator|Clopidogrel|1st day 300 mg & from then onwards 75 mg per day
2570607|NCT02428933|Other|Before and after bromocriptine|Subjects will be investigated before and after the use of bromocriptine. They will use bromocriptine for two weeks in the evening (1.25mg/day during the first week and 2.5mg/day during the second week).
3208416|NCT00974636|Placebo Comparator|Ususal Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
2570696|NCT02428348|Experimental|Interview|Interview of epilepsy patients and their family about their opinion on different EEG-cap models in development.
3208417|NCT00974649|No Intervention|Included in questionnaire study|
3208418|NCT00974662|Experimental|WST11|Treatment with WST11-mediated VTP
3208419|NCT00974688|Active Comparator|Group 1|
3208420|NCT00974688|Active Comparator|Group 2|
3208421|NCT00974701|Experimental|Patients to undergo PillCam procedure|Patients presenting to ER with acute overt upper GI bleeding
3208422|NCT00974714|Experimental|1|Oral L-arginine 2 g twice a day, for 14 weeks
3208423|NCT00974714|Placebo Comparator|2|oral placebo twice a day for 14 weeks
3208424|NCT00974727|Experimental|Gardening Program|
3208425|NCT00974727|No Intervention|Control|Subjects received the standard of care for the summer.
3208426|NCT00974740|Placebo Comparator|atorvastatin matching placebo|atorvastatin matching placebo
3208427|NCT00974740|Experimental|atorvastatin|40 mg atorvastatin for 4 weeks (run-in period), then 80 mg atorvastatin, total treatment period was 18 months
3208428|NCT00974753|Placebo Comparator|PPV-MP + Placebo (Saline drops)|PPV-MP= pars plana vitrectomy membrane peel
3208429|NCT00974753|Active Comparator|PPV-MP + Ketorolac 0.5%|PPV-MP= pars plana vitrectomy membrane peel
3208430|NCT00974753|Placebo Comparator|PhacoVit-MP + Placebo (Saline drops)|PhacoVit-MP= phacovitrectomy membrane peel
2569889|NCT02433457|Experimental|P22 plus OMP|Single oral dose of 375 mg P22 under fasted conditions (125 mg P22 x 3) in the presence of 40 mg oral OMP
2569932|NCT02433106|Experimental|Intervention|GAA 15 Specific neuromuscular exercise training
2569936|NCT02433106|Active Comparator|Control|Control Usual training
2569973|NCT02432846|Experimental|Intuvax (INN: ilixadencel)+ Nephrectomy+Sunitinib|Two Intuvax (INN: ilixadencel) doses (10 million cells/dose) 14 days apart before nephrectomy, followed by Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
2569979|NCT02432846|Active Comparator|Nephrectomy+Sunitinib|Sunitinib treatment post-nephrectomy according to clinical practice until RECIST verified progressive disease or End-of-Study (78 weeks after screening).
2570043|NCT02432417|No Intervention|Standard|Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.
2570047|NCT02432417|Experimental|Experimental arm|"Radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM. This consists of 30 daily fractions of 2 Gray (Gy) or 33 daily fractions of 1.8 Gy to the tumor and surrounding margin in combination with TMZ 75 mg/m² Per os daily (po qd) and six adjuvant cycles of TMZ 150 - 200 mg/m² po qd.~In addition this treatment will be combined with a daily intake of the recommended phase two dose (RPTD) of chloroquine (CQ)."
2570242|NCT02431312|Experimental|Group A: low dose, standard regimen|Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
2570245|NCT02431312|Experimental|Group A: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
2570247|NCT02431312|Experimental|Group A: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
2570249|NCT02431312|Experimental|Group B: mid dose, standard regimen|Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
2570250|NCT02431312|Experimental|Group B: high dose, standard regimen|Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.
2570252|NCT02431312|Active Comparator|Active Control: nucleos(t)ide analogue treatment|Participants continued treatment with nucleos(t)ide analogue treatment.
2570333|NCT02430779|Experimental|IRE Group|irreversible electroporation for Unresectable Renal Pelvic and Ureteral Neoplasms
2570335|NCT02430779|No Intervention|Control|The patients without treatment
2570389|NCT02430506|Placebo Comparator|Placebo|1.0 mL sterile buffer administered by intramuscular (IM) injection to deltoid area on days 0 and 56.
2570392|NCT02430506|Experimental|AERAS-402|1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non-animal source) and water. Administered intramuscular (IM) injection to deltoid area on days 0 and 56.
2570452|NCT02430025||control subjects|people had no clinical history of cardiovascular diseases,no family history of premature cardiovascular diseases.
2570455|NCT02430025||coronary atherosclerosis|Subjects with CAD also had at least one <50% stenotic lesion on coronary angiography.
2570458|NCT02430025||stable coronary artery disease|Subjects with stable CAD had clinically established atherosclerotic vascular disease but had been stable for ≥3 months.
2570461|NCT02430025||acute coronary syndrome|Subjects with CAD also had at least one ≥50% stenotic lesion on coronary angiography or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. All subjects with ACS exhibited acute ECG changes consistent with myocardial ischemia or elevated troponin levels. ACS was confirmed with urgent coronary angiography; all subjects had at least one ≥50% stenotic lesion with ruptured plaque or thrombus.
3172896|NCT00606073|Active Comparator|II|IVF Procedure - ISM1 Medium
3172897|NCT00606073|Active Comparator|III|ICSI Procedure - IVF Medium
2570775|NCT02427854|No Intervention|No training|Incidence of obstetric perineal injuries in the participating hospitals before implementation of the manual perineal protection method.
3172898|NCT00606073|Active Comparator|IV|ICSI Procedure - ISM1 Medium
3172899|NCT00606099|Experimental|1|telbivudine
3172900|NCT00606099|Active Comparator|2|adefovir dipivoxil
3172901|NCT00606112|Placebo Comparator|1|
3172902|NCT00606112|Placebo Comparator|2|
3172903|NCT00606112|Placebo Comparator|3|
3172904|NCT00606112|Placebo Comparator|4|
3172905|NCT00606125|Experimental|Arm 1|
3172906|NCT00606164|Placebo Comparator|Placebo|
3172907|NCT00606164|Experimental|10 ug/m2 Bryostatin|
3172908|NCT00606164|Experimental|15 ug/m2 Bryostatin|
3172909|NCT00606190|Active Comparator|Retrograde brain perfusion|Pt may be randomized to retrograde brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
3172910|NCT00606190|Active Comparator|Antegrade brain perfusion|Pt may be randomized to antegrade brain perfusion when having a repair of the ascending aortic artery (aorta) including the aortic arch. This is one of the standard methods used while the body and the brain are cooled down to sub-normal levels (hypothermia). This will take place while on the heart-lung machine.
3172911|NCT00606203|Experimental|A|The aims of this study are to investigate the prophylactic effect of milnacipran in post stroke depression.
3172912|NCT00606203|Placebo Comparator|B|Placebo
3172913|NCT00606216||A|TBI and Chemotherapy Conditioning Regimen. Twenty (20) patients will undergo conditioning treatment with TBI and chemotherapy prior to receiving a myeloablative allogeneic or an autologous HSCT.
3172914|NCT00606216||B|Chemotherapy Alone Conditioning Regimen Twenty (20) patients will undergo conditioning treatment with an all chemotherapy regimen prior to receiving an allogeneic or an autologous HSCT.
2569915|NCT02433249|Experimental|3.Intrapersonal Motivation|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
2569918|NCT02433249|Experimental|4.Full Intervention|Small groups (4-7 people) meeting in community centers weekly for 90 minutes, over the course of 8 weeks. Curricula for meetings are manualized and include introducing and practicing Otago exercises, progressed according to individual capacity and preference, as well as falls prevention. The interventionist also facilitates discussions addressing the intrapersonal and interpersonal motivational intervention content. All participant receive Fitbit Ones and are asked to use them on a daily basis: Fitbit Ones are included in weekly discussions.
3172915|NCT00606216||C|A cohort of twenty (20) healthy controls, frequency matched on age, gender, and education, will be recruited at WCMC to participate in the study.
3172916|NCT00606242|Active Comparator|Low dose steroid|Fluticasone, 100 mcg per day
3172917|NCT00606242|Active Comparator|High dose steroid|Fluticasone, 1000 mcg per day
3172918|NCT00606255||A|Active training group: Electronic Pill-Boxes with SMS service 1/week, training material provided
3172919|NCT00606255||B|Passive training group: Electronic Pill-Boxes ,Training material provided
3172920|NCT00606255||C|Usual treatment group: Electronic Pill-Boxes, maintain current treatment method
3172921|NCT00606268|Experimental|1|1.0 mg/kg
3172922|NCT00606268|Experimental|2|1.5 mg/kg
2570234|NCT02431325|Experimental|Teduglutide|Teduglutide, subcutaneous injection, 0.05 mg/kg/day, 6 months duration
2570237|NCT02431325|Placebo Comparator|Placebo|Placebo, subcutaneous injection, 6 months duration
2570285|NCT02431091|Experimental|Definite Case|"Patients with abnormal response on both the screening questions and at least one of the cognitive screening tests.~Optical Coherence Tomography is performed in all definite cases"
2570286|NCT02431091|Active Comparator|Control|"Patients with normal response on both the screening questions and all the cognitive screening tests.~Optical Coherence Tomography is performed in matched control A patients"
2570312|NCT02430857|Experimental|OMT-Group|The OMT-group will get an osteopathic treatment once a week for 1 hour for 5 weeks. The blood will be screened again after the treatment.
2570316|NCT02430857|No Intervention|Controll Group|This group will receive no treatment. A blood screening is made again after 5 weeks.
2570365|NCT02430597|Experimental|IRE Group|irreversible electroporation for Unresectable Hilus Pulmonis Neoplasms
2570368|NCT02430597|No Intervention|Control|The patients without treatment
2570437|NCT02430233|Experimental|micronized progesterone 400 mg|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
2570439|NCT02430233|No Intervention|No treatment|No treatment
2570477|NCT02429921|Experimental|low-Se lentils|50 mg of low-selenium lentils per person consumed as soups
2570478|NCT02429921|Experimental|high-Se lentils|50 mg of high-selenium lentils per person consumed as soup
2570558|NCT02429505||Miltefosine|Miltefosine : target of 2.5 mg/kg/day for 28 days. Patients 45 kg or greater were to receive one 50 mg capsule 3 times daily for 28 consecutive days. This prospective observational study in which patients undergoing treatment for leishmaniasis with miltefosine in the United States who weighed >75 kg could volunteer to provide information about their clinical response to treatment up to 6 months after the start of treatment.
2570617|NCT02428998|Experimental|Korean Red Ginseng|Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses
2570623|NCT02428998|Placebo Comparator|Placebo|Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses
2570671|NCT02428556|Active Comparator|Facts only|"Scenario describes study results without breakthrough language, promising language, no cautions about conditional approval"
2570674|NCT02428556|Active Comparator|promising language|"study description describes drug as promising; no warning about conditional approval"
2570677|NCT02428556|Active Comparator|"breakthrough with may warning"|"study describes drug as breakthrough; warning that continued approval may be contingent on subsequent verification of clinical benefit in confirmatory trials"
3172923|NCT00606333|Experimental|Investigational arm|Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
3172924|NCT00606333|Active Comparator|Control Arm|Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
3172925|NCT00606359|Experimental|Study Group 1|
3172926|NCT00606359|Active Comparator|Study Group 2|
3172927|NCT00606372||1|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated with use of the cardio-pulmonary bypass
3172928|NCT00606372||2|Patients with ischemic heart disease, with EuroSCORE 6 additive points and more, operated without use of the cardio-pulmonary bypass
3172929|NCT00606385|Experimental|laparoscopic liver resection|Patients who underwent laparoscopic liver resection for HCC
3172930|NCT00606385|Active Comparator|open liver resection|Patients who underwent open liver resection for HCC
3172931|NCT00606411|Active Comparator|Topiramate|Study medication arm, 25-300mg of Topiramate
3172932|NCT00606411|Placebo Comparator|Placebo|Placebo arm of study, 25-300mg of sugar pill
3172933|NCT00606437|Experimental|I|Total Body Irradiation (TBI)/Flu Conditioning followed by combined UCB
3172934|NCT00606450|Experimental|20 mg Apremilast daily|20 mg of CC-10004 daily
3172935|NCT00606450|Experimental|20mg Apremilast twice daily|CC-10004 twice daily
3172936|NCT00606450|Placebo Comparator|Placebo|Placebo arm
3172937|NCT00606463|Experimental|(Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
3172938|NCT00606476|Active Comparator|1|0.15 mg/kg active bapineuzumab
3172939|NCT00606476|Active Comparator|2|0.5 mg/kg active bapineuzumab
3172940|NCT00606476|Active Comparator|3|1.0 mg/kg active bapineuzmab
2569943|NCT02433093|Experimental|Basimglurant: Healthy Cohort (4)|Healthy participants assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 4 will be selected in accordance with decision criteria on the basis of the incidence of severe AEs in preceding Cohorts 1, 2, and 3.
2569944|NCT02433093|Experimental|Basimglurant: MDD Cohort (5)|Participants with MDD assigned to basimglurant will receive a 22-day ascending dose regimen. The dosing scheme for Cohort 5 may differ from those previously evaluated; however, the titration steps and the highest dose tested will remain equal to or lower than the doses tested in Cohorts 1 to 4.
2569945|NCT02433093|Placebo Comparator|Placebo: Healthy Cohorts (1 to 4)|Healthy participants will receive a 22-day regimen of matching placebo capsules.
2569946|NCT02433093|Placebo Comparator|Placebo: MDD Cohort (5)|Participants with MDD will receive a 22-day regimen of matching placebo capsules.
2569977|NCT02432768|Active Comparator|Triheptanoin|14 days on Triheptanoin treatment including a 7 days titration period and a 7 days full dose treatment of 1mL/kg/day.
2569987|NCT02432768|Placebo Comparator|Placebo oil|14 days of diet on a placebo oil including 7 days titration period and 7 days full dose treatment of 1mL/kg/day.
2570141|NCT02431884||body fluids/tissues & history|collect body fluids/tissues & med history from subjects with polycystic ovary syndrome(PCOS), congenital uterine malformations, endocrine malfunctions, endometriosis, and infertility;
3208431|NCT00974753|Active Comparator|PhacoVit-MP + Ketorolac 0.5%.|PhacoVit-MP= phacovitrectomy membrane peel
3208432|NCT00974766|Active Comparator|Low-dose glucocorticoid|Low-dose steroid
2570311|NCT02430948|Active Comparator|Standard Support Outreach|Providers receive standard written screening recommendations and do not receive academic detailing (educational outreach)
2570318|NCT02430948|Experimental|Standard materials and academic detailing|Providers receive standard written screening recommendations and receive academic detailing (educational outreach)
2570323|NCT02430948|Experimental|Color-coded materials and no academic detailing|Providers receive color-coded written screening recommendations and do not receive academic detailing (educational outreach)
2570326|NCT02430948|Experimental|Color-coded materials and academic detailing|Providers receive color-coded written screening recommendations and receive academic detailing (educational outreach)
2570377|NCT02430402|Experimental|Climate therapy|Climate therapy consisting of 3 week stay at rehabilitation facility in Spain
2570381|NCT02430402|No Intervention|Usual care|Usual care provided as needed / agreed between patient and health care providers
2570453|NCT02430155|Active Comparator|Bakri balloon group|The women in this group will be managed by Bakri balloon
2570454|NCT02430155|Active Comparator|Condom loaded Foley's catheter group|The women in this group will be managed by condom loaded Foley's catheter
2570481|NCT02429739|Experimental|Working Memory Training|Behavioral: Cogmed RM working memory training. After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start immediately and will have 6 weeks to perform the 25 training sessions.
2570483|NCT02429739|No Intervention|Passive control group|"The control group will receive treatment as usual (Ordinary school days, special education if normally received)."
2570553|NCT02429531|Experimental|Healthy controls|Healthy volunteers who consented to participate in the study will be immunized with both Pneumovax 23 and Typhim Vi .
2570555|NCT02429531|Experimental|Patients|Patients presenting for immune evaluation because of recurrent ENT/lung infection or invasive infection with encapsulated bacteria, in whom evaluation of pneumococcal antibody response is indicated, will be immunized with both Pneumovax 23 and Typhim Vi .
2570615|NCT02428959|Experimental|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
2570676|NCT02428621|Experimental|Twicare® appliance|Group treated with the Twicare® appliance. This appliance is a removable mandibular propulsive adjustable preformed medical device. It is made out of soft and stiff thermoplastics. Its two gutters are linked to each other according to different antero-posterior positions. It is EC marked since 2011.
2570678|NCT02428621|Active Comparator|Removable Herbst appliance|Group treated with the removable Herbst appliance. This appliance is a medical device measured made composed of telescopic metallic hinges and resin gutters made-to-measure based on dental impression.
2570682|NCT02428621|No Intervention|Untreated|Children will not wear any interceptive activator. They will have a routine follow-up with their orthodontist waiting for the placing of a fixed appliance.
2570717|NCT02428075|Experimental|FCHV visit-normotensive|
2570718|NCT02428075|No Intervention|FCHV no visit-normotensive|
2570727|NCT02428075|Experimental|FCHV visit-prehypertensive|
2570736|NCT02428075|No Intervention|FCHV no visit-prehypertensive|
2570740|NCT02428075|Experimental|FCHV visit-hypertensive|
2570742|NCT02428075|No Intervention|FCHV no visit-hypertensive|
2570877|NCT02427165|Placebo Comparator|Placebo|Single dose of nebulised placebo solution
2570880|NCT02427165|Experimental|RPL554 Dose 1|0.4 mg single dose nebulised RPL554
2570881|NCT02427165|Experimental|RPL554 Dose 2|1.5 mg single dose nebulised RPL554
2570884|NCT02427165|Experimental|RPL554 Dose 3|6 mg single dose nebulised RPL554
3208433|NCT00974766|Active Comparator|High-dose glucocorticoid|High-dose steroid
2569957|NCT02433015|Active Comparator|Tobacco Cigarette Group|This group will not receive an electronic cigarette and will continue to smoke combustible tobacco cigarettes as previously.
2569959|NCT02433015|Experimental|Electronic Cigarette Group|This group will receive an electronic cigarette to use for the duration of the study.
2570032|NCT02432664|Experimental|ODM-108 Part I|Oral capsules dosage 0.2 - 240 mg once daily for one day
2570033|NCT02432664|Placebo Comparator|Placebo Part I|Oral capsules given once daily for one day
2570036|NCT02432664|Experimental|ODM-108 Part II|Oral capsules 4 dose levels to be decided after Part 1 of the study. 1 - 4 times a day for 7 days
2570038|NCT02432664|Placebo Comparator|Placebo Part II|Oral capsules 1 - 4 times per day for 7 days
2570041|NCT02432664|Experimental|ODM-108 Part III|Oral capsules 1-4 times daily for 7 to 10 days
2570042|NCT02432664|Active Comparator|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
3208434|NCT00974779|Experimental|HCO dialyzer|Hemodialysis with the HCO1100 hemodialyzer membrane with high molecular weight cut off.
3208435|NCT00974779|Active Comparator|Placebo|Regular dialysis using a polyamide high-flux hemodialyzer
3208436|NCT00974805|Experimental|Seretide 500 Accuhaler|Seretide 500 Accuhaler one inhalation BD
2570217|NCT02431338|Experimental|Intervention group|Remote ischemic conditioning through intermittent arm ischemia with four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff performed in the ambulance during transport to primary percutaneous coronary intervention.
2570221|NCT02431338|No Intervention|Control group|Standard treatment with primary percutaneous coronary intervention alone.
2570291|NCT02431039|Experimental|NEOSORB PLUS|Subjects who are treated by NEOSORB PLUS
2570296|NCT02431039|Active Comparator|NEOSORB|Subjects who are treated by NEOSORB
2570342|NCT02430766|Experimental|IRE Group|irreversible electroporation for Unresectable Lymph Node Metastase
2570343|NCT02430766|No Intervention|Control|The patients without treatment
2570395|NCT02430454|Experimental|Experimental|Subjected to increased cognitive load
2570401|NCT02430454|No Intervention|Control|Not subjected to increased cognitive load
2570450|NCT02430077|Experimental|Active capsule of Obeticholic acid|Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.
2570451|NCT02430077|Placebo Comparator|Pacebo for Obeticholic acid|Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.
2570488|NCT02429661|Experimental|RC (Girls First Resilience Curriculum)|The Girls First Resilience Curriculum is delivered in peer support groups of 12-15 students per group over 23 weekly 1-hour sessions. The curriculum draws from fields such as positive psychology, emotional competence/intelligence, and restorative practices, and aims to improve students' psychosocial assets and wellbeing.
2570499|NCT02429661|Experimental|HC (Girls First Health Curriculum)|The Girls First Health Curriculum is delivered in peer support groups of 12-15 students per group over 21 weekly 1-hour sessions. The curriculum covers topics such as nutrition, sexual and reproductive health, clean water, hygiene, and common diseases, and aims to improve students' physical health and wellbeing.
2570505|NCT02429661|Experimental|RC+HC (Girls First)|Girls First is a combination of the Girls First Resilience Curriculum (RC) and the Girls First Health Curriculum (HC).
2570511|NCT02429661|No Intervention|SC (School-as-usual control)|Participants receive no intervention and attend school as they usually would.
2570569|NCT02429453|Active Comparator|Fresh Frozen Plasma|Administration of a single dose of fresh frozen plasma based on INR per the following regimen: 2U for INR of 2-2.5; 3U for INR of 2.5-3; 4U for INR of 3-3.5; 5U for INR of 3.5-4; 6U for INR of 4+
2570576|NCT02429453|Experimental|Four Factor Prothrombin Complex Concentrate|Administration of a single dose of four factor prothrombin complex concentrate per the following dosing regimen: 25 U/kg for INR of 2-4; 35 U/kg for INR of 4-6; 50 U/kg for INR of 6+; maximum dosing weight of 100kg, patients may be dispensed +/- 10% of ordered dose
2570596|NCT02428842|Other|Tumor biopsies and blood sampling|"Patient will undergo standard care with tumor and blood sampling before and after treatment.~Blood and tumor sampling will also be performed at disease progression/relapse."
3208437|NCT00974831|Experimental|AA Drink|Amino Acid Drink Mixture
3208438|NCT00974831|Placebo Comparator|Glucose drink|
2570757|NCT02427880|Experimental|Acetazolamide|Each patient receives 250 mg of acetazolamide and 50 mg of hydrochlorothiazide daily for 1 week. Then they are prescribed 40 mg of furosemide daily for 2 weeks.
2570764|NCT02427880|Active Comparator|Furosemide|Each patient is prescribed 40 mg of furosemide and 50 mg of hydrochlorothiazide daily for 1 week. Then they receive 40 mg of furosemide daily for 2 weeks.
3208439|NCT00974857|Active Comparator|Study group|"Pre-dialytic overhydration(OH) will be estimated by Body Composition Monitor (BCM) at least once a month.~If OH is positive, dry weight will be reached by ultrafiltration without regard to the level of blood pressure.~If OH is negative and:~Systolic blood pressure(SBP)< 100 mmHg with/or intradialytic hypotension episodes(IDHE) and/or clothing and/or erythrocytosis(htc>36%);dry weight will be increased.~SBP normal(100-150 mmHg) w/o IDHE and clothing and erythrocytosis;dry weight will not be changed.~SBP normal(100-150 mmHg) with IDHE and/or clothing and/or erythrocytosis;dry weight will be increased.~SBP>150 mmHg captopril test(CT)will be done. If CT is positive, ACEI/ ARBs will be used and dry weight will be increased if IDHE and/or clothing and/or erythrocytosis(htc>36%) are present.~If CT is negative, BCM measurement will be repeated and if same,ABPM will be performed for confirmation."
3208440|NCT00974857|Other|Control Group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
2570922|NCT02426944|Experimental|LAAO group|Patients will be treated interventionally by left atrial appendage occlusion (LAAO). LAAO will be done using Amulet or Watchman device.
2570924|NCT02426944|Experimental|NOAC group|Patients will be treated by novel anticoagulants (NOAC).
2571017|NCT02426463|Active Comparator|Propofol|Plasma samples and patient data are collected prospectively from 40 neonates who receive propofol as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
2571139|NCT02425579|Placebo Comparator|Cohort 2 (Placebo)|Inhaled Medical Air for up to 90 minutes daily for 5 days
2569962|NCT02432924|No Intervention|Waiting List Control Group|Participants who have been randomised into the control arm will be put on a 3 month waiting list to receive the intervention described above. They will still attend assessment visits at week 6 and week 12 while they are not receiving any advice or feedback. Following their 12 week assessment, participants in the control arm will be invited to attend the same 60 minute set-up session as received by the intervention group and then provided with the armband monitor and display to then receive the intervention in full. No further post-intervention or follow-up assessments will be taken from these participants.
2570015|NCT02432677|Experimental|Remifentanil + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
2570017|NCT02432677|Other|Placebo + Active tDCS|"tDCS session: the procedure will initiate by placing an anode electrode on the primary motor cortex (contralateral to the dominant cortex) and the cathode electrode on the contralateral supra-orbital region. The current employed is 2mA of transcranial direct-current stimulation administered for 20 minutes.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
2570020|NCT02432677|Other|Remifentanil + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Remifentanil - 0,06mcg.kg.min - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
2570021|NCT02432677|Other|Placebo + Sham tDCS|"Sham tDCS: consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.~Placebo: Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests."
2570066|NCT02432092||Affected|participants with cardiomyopathy
2570076|NCT02432092||Family Members of affected|Family members of participants with cardiomyopathy (can be affected or unaffected)
3172941|NCT00606515|Experimental|A|Liposomal paclitaxel
3172942|NCT00606515|Active Comparator|B|Paclitaxel
3172943|NCT00606528||Group A|patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
2570485|NCT02429843|Experimental|Standard treatment + TRC105|In addition to standard treatment of paclitaxel, carboplatin, and bevacizumab, dosing of TRC105 will begin at 8 mg/kg. However a lower dose level has also been included (6 mg/kg) and will be enrolled if 8 mg/kg is found to exceed the maximum tolerated dose. Following the appropriate pre-medication regimen, the first weekly TRC105 dose (cycle 1 day 8) will be split into two doses whereby 3 mg/kg is administered on cycle 1 day 8 and the balance (e.g., 5 mg/kg for Dose Level 1) is administered on cycle 1 day 11. Beginning with cycle 1 day 15 and thereafter, the full TRC105 dose will be administered intravenously each week during the 21-day cycle. Intra-patient dose reductions are allowed beginning in cycle 2.
2570572|NCT02429518||Miltefosine|Miltefosine: target of 2.5 mg/kg/day for 28 days
2570663|NCT02428868|Experimental|Tranexamic acid - intravenous iron|"IV iron (Ferroven®) : 2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.~IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later."
2570664|NCT02428868|Active Comparator|Tranexamic acid|IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.
2570665|NCT02428868|Placebo Comparator|Placebo|20 mL saline, in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
2570786|NCT02427711|Active Comparator|Bipolar sealer|Prospective use of bipolar sealer for skin and knee capsule incision revisions of non-septic knee arthroplasty.
2570791|NCT02427711|Placebo Comparator|Scalpel|Conventional surgical incision with scalpel - data extracted from a retrospective group.
2570844|NCT02427347|Experimental|Intervention group|Intervention including acupuncture treatment and healthy education.
2570848|NCT02427347|Other|Control group|Healthy education is given as a baseline treatment.
3172944|NCT00606528||Group B|Healthy volunteers willing to donate blood on 2 separate occasions
3172945|NCT00606541|Experimental|1|Quetiapine XR 50mg-400mg per day
3172946|NCT00606541|Placebo Comparator|2|Placebo
3172947|NCT00606567|Active Comparator|1-treatment|remote monitoring with carelink every 3 months
3172948|NCT00606567|No Intervention|2- control|device interrogations in clinic every 3 months
3172949|NCT00606606|Experimental|I - Intervention units|nursing home units, provided HIT CDS intervention
3172950|NCT00606606|No Intervention|C - control units|nursing home units, not provided the HIT CDS intervention
3172951|NCT00606619|No Intervention|1|Conventional feeding : They begin ingesting sips of water on third postoperative day and continued with a liquid diet for the next two days. Patients were given a soft diet on sixth postoperative day.
3172952|NCT00606619|Experimental|2|Early oral feeding : The patients begin ingesting sips of water on the first postoperative day. If they are tolerable, they continued with a clear liquid diet the next day and a soft diet on the third post operative day.
3172953|NCT00606645|Experimental|1|XmAb2513
3172954|NCT00606658|Other|Oil dripping therapy|Single Arm
3172955|NCT00606671||1|lean control women without PCOS
3172956|NCT00606671||2|lean women with PCOS
3172957|NCT00606671||3|Obese control women without PCOS
3172958|NCT00606671||4|Obese women with PCOS
3172959|NCT00606671||1xx - 04 LC|lean control women
3172960|NCT00606671||1xx-04 LP|lean women with PCOS
3172961|NCT00606671||1xx-04 OC|obese control women
3172962|NCT00606671||1xx-04 OP|obese women with PCOS
3172963|NCT00606697|Active Comparator|Overall study|Male and female subjects, 18-64 years of age (inclusive), with a primary diagnosis of primary insomnia
2570077|NCT02432157|Active Comparator|Standard fluid|Routine fluid management strategy as pre-specified by our SAH management protocol at Jefferson University Hospital according to the American Heart Association and Neurocritical Care Guidelines for the management of SAH (this includes conventional intravenous fluids or normal saline solutions to maintain a normal hydration status and guided by the treating doctor and daily assessments of fluid balance).
2570134|NCT02431858|Experimental|Catheter Over Needle|"The femoral nerve catheter used will be the E-Catheter (Pajunk) device which is a novel catheter over needle system."
2570136|NCT02431858|Active Comparator|Catheter through needle|"The femoral nerve catheter used will be the Sonolong catheter (Pajunk) which is a traditional catheter through needle system."
2570191|NCT02431520|Experimental|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for Hybrid Capture II (HCII).
2570194|NCT02431520|Active Comparator|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
3208441|NCT00974883||Suspected GCA|Patients who present with new onset of headache and suspected diagnosis of GCA. They will all require a temporal artery biopsy to assist in the diagnosis
3208442|NCT00974883||Training cohort|Patients with any condition or healthy volunteers who are willing to consent ot have their temporal and axillary arteries examined using ultrasound, for training purposes
3208443|NCT00974896|Experimental|AMG 479 + Sorafenib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with sorafenib. AMG 479 will be given bi-weekly; sorafenib will be given daily.
2570344|NCT02430753|Experimental|IRE Group|irreversible electroporation for Lung Neoplasms accompanied by Respiratory Function Insufficiency
2570345|NCT02430753|No Intervention|Control|The patients without treatment
2570380|NCT02430415|Experimental|Group A|laryngoscope-assisted lightwand intubation - traditional lightwand intubation
2570383|NCT02430415|Experimental|Group B|traditional lightwand intubation - laryngoscope-assisted lightwand intubation
2570457|NCT02430103||Chemotherapy plus GnRHa|Patients of the group will receive (neo)chemotherapy plus GnRHa ( Goserelin 3.6mg will be administered every 28 days by subcutaneous injection starting at least 7-14 days before the first cycle of chemotherapy and continued throughout chemotherapy duration).
2570460|NCT02430103||Chemotherapy|Patients of the group will receive (neo)chemotherapy merely.
2570491|NCT02429700|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
2570498|NCT02429700|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
3208444|NCT00974896|Experimental|AMG 479 + Erlotinib cohorts|The aim is to determine the safety, tolerability and PK of AMG 479 with erlotinib. AMG 479 will be given bi-weekly; erlotinib will be given daily.
3208445|NCT00974909|Active Comparator|Treatment group|Treatment group
2570642|NCT02428647|Active Comparator|micronutrient powder (MNP)|preventive zinc supplements provided as MNP (containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate,) plus ORS and therapeutic placebo supplements for diarrhea
2570645|NCT02428647|Placebo Comparator|placebo powder|placebo powder plus ORS and therapeutic placebo supplements for diarrhea
2570648|NCT02428647|Active Comparator|preventive zinc supplements|preventive zinc supplements provided as dispersible zinc tablets (containing 7 mg zinc, to be given between meals) plus ORS and therapeutic placebo supplements for diarrhea
2570650|NCT02428647|Active Comparator|therapeutic zinc supplements|preventive placebo supplements provided as dispersible tablets plus ORS and dispersible therapeutic zinc tablets (containing 20 mg zinc) for diarrhea
2570703|NCT02428244|No Intervention|Arm 1, Control|Standard of care intervention: All patients at the University as a standard of care receive informational materials about smoking cessation. They are referred to the patient resource center at our institution. Patients will be provided this, also they will be provided with a smoking cessation Quitline Brochure
2570706|NCT02428244|Experimental|Standard of care + brief counseling|Patients who are randomized into this arm will receive the standard of care (outlined above). Additionally, patients will also receive a smoking education/counseling session. Patients will receive 10-30 minutes of guided discussion regarding the risks and benefits with regards to smoking and the healing of their traumatic injuries. The smoking educators, who will be trained in accordance with the guidelines provided by MdQuit.org will utilize motivational interviewing techniques to enhance interest in quitting. Patients will receive a description of the quitline, and the quitlined will be the recommended resource. If patients elect to enroll in the quitline, they will be consented using the standardized quitline protocols.
2570710|NCT02428244|Experimental|Standard of care + counseling/follow-up|"Patients who are randomized into this arm will receive the same intervention as patients in Arm 2, except when patients arrive for their follow-up, the smoking educator will check-in with their progress for approximately 5 minutes. The techniques utilized during this check-in visit will include repetition of previously described motivational interviewing, at this point patients who elect to be referred to the quitline will be given this opportunity."
2570744|NCT02427971||Perseus|Use of Perseus® A 500 with VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min)
2570745|NCT02427971||Aysis|Use of Aysis® Cs2 ventilator with automated control of end-tidal inhalation anesthetic concentration, EtControl® mode.
3208446|NCT00974909|Sham Comparator|sham group|Sham group
3208447|NCT00974935|Experimental|Cohort 1|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01 mcg intramuscular.
2570097|NCT02431975|Experimental|Early ART|All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
3208448|NCT00974935|Experimental|Cohort 2|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.1 mcg intramuscular.
3208449|NCT00974935|Experimental|Cohort 3|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.5 mcg intramuscular.
3208450|NCT00974935|Experimental|Cohort 4|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 2.5 mcg intramuscular.
3208451|NCT00974935|Experimental|Cohort 5|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 10 mcg intramuscular.
3208452|NCT00974935|Experimental|Cohort 6|Single dose of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular.
3208453|NCT00974935|Experimental|Cohort 7|Two doses of staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 20 mcg intramuscular 21 days apart.
2570411|NCT02430194|Experimental|lonafarnib/ritonavir - I|lonafarnib 100 mg BID + ritonavir 100 mg QD;
2570413|NCT02430194|Experimental|lonafarnib/ritonavir - II|lonafarnib 150 mg QD + ritonavir 100 mg QD;
2570415|NCT02430194|Experimental|lonafarnib/ritonavir - III|lonafarnib 75 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
2570418|NCT02430194|Experimental|lonafarnib/ritonavir - IV|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW on Week 12
2570421|NCT02430194|Experimental|lonafarnib/ritonavir - V|lonafarnib 100 mg BID + ritonavir 50 mg BID;
2570427|NCT02430194|Experimental|lonafarnib/ritonavir - VI|lonafarnib 100 mg QD + ritonavir 100 mg QD;
2570429|NCT02430194|Experimental|lonafarnib/ritonavir - VII|lonafarnib 50 mg BID + ritonavir 100 mg BID; + PEG IFN-a 180 ug QW;
2570433|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - VIII|lonafarnib 25 mg BID + ritonavir 100 mg BID + PEG IFN-a 180 ug QW;
2570436|NCT02430194|Experimental|lonafarnib/ritonavir/PEG IFN-a - IX|lonafarnib 50 mg BID + ritonavir 100 mg BID
2570438|NCT02430194|Experimental|lonafarnib/ritonavir - X|lonafarnib 25 mg BID + ritonavir 100 mg BID
2570515|NCT02429609|Experimental|Keratoconic subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
2570516|NCT02429609|Experimental|Healthy subjects|"Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)~Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)~Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)~Anterior eye examination (approx. 4 minutes)~Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)~Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)~Two measurements of visual acuity will be made:~Standard ETDRS logMAR acuity measurement (5 minutes)~Vanishing Optotype logMAR acuity measurement (5 minutes)"
2570567|NCT02429414|Experimental|Non-Video Double Lumen Tube (DLT) Group|Participants receive a non-video DLT for lung isolation before surgery. Once non-video DLT is in correct place, its final position before surgery checked with a fiberoptic bronchoscopy (FOB).
2570574|NCT02429414|Experimental|Video Double Lumen Tube (VDLT) Group|Participants receive a VDLT for lung isolation before surgery. Once VDLT is in correct place, its final position before surgery checked with the camera inside the tube.
2570655|NCT02428569|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
2570656|NCT02428569|Experimental|PREPARED Decision Support|Participants randomized to this arm of the study will receive the PREPARED educational book and video.
2570707|NCT02428257|Experimental|hypobaric|continuous spinal anesthesia with 2,5 mg boluses of hypobaric bupivacaine, prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
2570709|NCT02428257|Active Comparator|isobaric|continuous spinal anesthesia with 2,5 mg boluses of 0.5% isboaric bupivacaine
2570755|NCT02427932||Pregnant/Ampicillin|pregnant participants who will receive Ampicillin for conditions such as Group B Streptococcus
2570756|NCT02427932||Non-pregnant/Ampicillin|non-pregnant participants who will receive Ampicillin for a qualifying hospital admission
3208454|NCT00974948|Active Comparator|Neurolysis|Patients will undergo EUS followed by EUS-guided, bilateral neurolysis with bupivicaine and absolute alcohol.
3208455|NCT00974948|No Intervention|Conventional therapy|EUS will be performed with no celiac plexus neurolysis.
3208456|NCT00974961|Active Comparator|Levobupivacaine|Lumbar puncture with Levobupivacaine for spinal anesthesia
3208457|NCT00974961|Active Comparator|Bupivacaine|Lumbar puncture with Bupivacaine for spinal anesthesia
3208458|NCT00974987|Experimental|Treatment group|BNCT(boron neutron capture therapy), XRT(X-ray radiation treatment) and TMZ(temozolomide) treatment
3208459|NCT00975013||Bone Density Study Group|Morbidly obese, (BMI >40 kg/m2, or 35 kg/m2 with comorbidities) female patients who have given consent to undergo additional testing including bone densitometry, and lab testing preoperatively and at 6 and 12 months after undergoing elective laparoscopic roux-en-Y gastric bypass.
3208460|NCT00975026|Active Comparator|Massages|Chair massage for 30 minutes once a week.
3208461|NCT00975026|Active Comparator|Massages + Stretches|Chair massage for 30 minutes once a week in addition to stretching exercises, to be done twice daily for 20 minutes.
3208462|NCT00975026|No Intervention|No Intervention|
3208463|NCT00975039|Experimental|WST11|Treatment with WST11-mediated VTP
3208464|NCT00975052|Active Comparator|A|Sitagliptin alone
3208465|NCT00975052|Active Comparator|B|Metformin alone
3208466|NCT00975052|Experimental|C|Sitagliptin and metformin concomitantly
3208467|NCT00975052|Placebo Comparator|D|Placebo
3208468|NCT00975065|Experimental|Galvus group|"the combination of metformin plus Vildagliptin:~vildagliptin 50 mg bid plus metformin 1500mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy."
2570282|NCT02431143|Experimental|Miltefosine|allometric dosing
2570310|NCT02430909|Placebo Comparator|CZP / CZP + PBO / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+Placebo from Week 8 to Week 18"
2570319|NCT02430909|Experimental|CZP / CZP + UCB4940 / CZP|"Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two weeks) until Week 30~+ UCB4940 from Week 8 until Week 18"
2570322|NCT02430909|Other|CZP / CZP/ CZP|Certolizumab Pegol (400 mg at Weeks 0, 2, and 4 followed by 200 mg every two Weeks) until Week 30
2570434|NCT02430363|Active Comparator|MK-3475|"Pembrolizumab (MK-3475) is a humanized monoclonal antibody. Information from these studies suggests that Pembrolizumab (MK-3475) may be beneficial in Glioblastoma / Gliosarcoma.~Patients enrolling in phase 1 receive MK-3475 every 3 weeks, with the dose to be determined.~MK-3475 will be given intravenously over the course of 30 minutes"
2570435|NCT02430363|Experimental|Suppressor of the PI3K/Akt pathways|"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ. Patients will take the Pictilisib (capsules) orally with food. The dose should be taken every 3 weeks.~BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor. Inhibits ATR whileshown to be a poor inhibitor to Akt and PDK1.~Patients will take the BEZ235 (capsules) orally with food. The dose should be taken every 3 weeks.~Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 .~Patients will take the Ipatasertib (capsules) orally with food. The dose should be taken every 3 weeks.~The suggested dosage of inhibitors of the PI3K/Akt pathway orally as a single dose in capsule and Packed in plastic boxes, so that preparations can be taken at home"
2570503|NCT02429765|Active Comparator|ACL/FOR|The evening dose of twice-daily dual bronchodilator medication will consist of aclidinium/formoterol 400/12mcg . After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
2570510|NCT02429765|Placebo Comparator|Placebo|The evening dose of twice-daily dual bronchodilator medication will consist of a placebo inhaler. After 2-weeks of treatment with twice-daily aclidinium/formoterol 400/12mcg, subjects will be randomized to receive an evening dose consisting of active drug or placebo.
2570537|NCT02429362||Pregnant Women & their stillborn infants|All English speaking female patients who are seen in the Regional One Health perinatal clinics and/or deliver at Regional One Health are the group of study's focus. Likewise, when a delivery results in a stillbirth, the stillborn baby will also be an additional group of our study's focus.
2570542|NCT02429193|Experimental|Abiraterone / enzalutamide|Abiraterone + prednisone; Enzalutamide
2570612|NCT02429011||MDD|patients with current MDD
2570613|NCT02429011||Healthy Control (HC)|healthy control volunteers
2570641|NCT02428634|Experimental|Program SI! for Elementary 6 levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. The intervention is implemented during all the elementary levels (PSIE13+PSIE46).
2570643|NCT02428634|No Intervention|Normal curriculum|The schools on the control group keep their normal curriculum and don't join any school program about health until the end of the study.
2570646|NCT02428634|Experimental|Program SI! for Elementary first levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the first three levels (PSIE13).
2570649|NCT02428634|Experimental|Program SI! for Elementary last levels|The core intervention comprises classroom activities grouped in healthy challenges (about diet, physical activity, human body and heart, and emotions management) distributed across the different levels and implemented by the corresponding teachers. All the materials, formal training and a teaching guide are provided to the school staff by the SHE Foundation. Families receive family-challenges and key messages about their children's health. The school environment is intervened mainly through an annual Healthy Fair. To evaluate the effects of different exposures to the program, the intervention is implemented in the last three levels (PSIE46).
2570702|NCT02428322|Experimental|Intervention|2,000iu vitamin D3 per day for 15 weeks
2570704|NCT02428322|Placebo Comparator|Placebo|An identical placebo capsule daily for 15 weeks.
3208469|NCT00975065|Active Comparator|Diabex group|"metformin alone arm:~metformin 1500mg plus metformin 500mg or 1000mg~Additional SU therapy(After 12th week only under the following conditions): If A1c is ≥ 7.0% or investigator determines that the patient have metabolic problems at 12th week of therapy, investigator can prescribe additional sulfonylurea(glimepiride) to the current therapy"
3208470|NCT00975078|Experimental|adrenal insufficiency|
3208471|NCT00975091|Active Comparator|Entecavir 0.5|
3208472|NCT00975091|Active Comparator|Entecavir 1.0|
3208473|NCT00975104|Experimental|AMG 745 0.3 mg/kg|0.3 mg/kg AMG 745
3208474|NCT00975104|Experimental|AMG 745 1.0 mg/kg|1.0 mg/kg, AMG 745
3208475|NCT00975104|Placebo Comparator|Placebo|Placebo
3208476|NCT00975104|Experimental|AMG 745 3.0 mg/kg|3.0 mg/kg, AMG 745
3208477|NCT00975117|Placebo Comparator|Placebo|
3208478|NCT00975117|Experimental|Spermotrend|
3208479|NCT00975169||TZDs User|
2570110|NCT02431910|Experimental|Kinesio Taping group|The Kinesio Taping (KT) is applied on the vastus lateralis (VL), vastus medialis (VM) and rectus femoris (RF) muscles longitudinally from proximal to the distal. For the RF proximal anchor is applied 5cm below the anterior superior iliac spine and the distal anchor the upper edge of the patella. VL in the proximal and distal anchor will be fixed in greater trochanter of the femur and the lateral edge of the patella. As for the VM muscle proximal anchor will be applied to the middle third from the medial region of the thigh and the distal anchor on the medial edge of the patella. The anchors are applied with 0% tension and therapy area will follow on the belly of the muscles with a 50%. This application will be held with subjects standing on one foot, with the hip of the non-dominant limb at 0º and knee flexed at 90º.
2570161|NCT02431611|Active Comparator|Control condition|Control behavioral phone-based smoking cessation intervention
2570165|NCT02431611|Experimental|Biomarker Feedback Intervention|Biomarker feedback plus behavioral phone-based smoking cessation intervention
2570205|NCT02431429||miltefosine|miltefosine: target of 2.5 mg/kg/day for 28 days
3172964|NCT00606723|Experimental|1|"Group I: Relapsed AML-patients with blast cell reduction to <20% before the second course of induction therapy. These patients will receive conventional SCT.~Group II: Patients with non response to frontline treatment of AML, patients with blast cells <20% before the second course of induction therapy who do not achieve a second remission and relapsed AML-patients with blast cells >=20% before the second course of induction therapy. If these patients have a matched donor (MSD/MD) they will receive SCT with FLAMSA.~Group III: Patients who are eligible for Group II but have no matched donor. These patients will receive SCT from a haploidentical donor."
3172965|NCT00606736||patients|subjects with right ventricular outflow tract arrhythmia
3172966|NCT00606736||control|subjects ,age match,healthy
3172967|NCT00606762|Active Comparator|LPLC, HPLC|LPLC: Low pressure pneumoperitoneum is defined as intraabdominal pressure kept at8 mm Hg after initial trocar insertion at 12 mm Hg HPLC: High pressure pneumoperitoneum is defined as intra abdominal pressure kept at 12 mm Hg throughout the procedure
2570571|NCT02429141|Experimental|US-guided periarterial techique|Axillary brachial plexus block by an ultrasound-guided periarterial technique
2570578|NCT02429141|Experimental|US-guided multi-injection technique|Ultrasound-guided multi-injection perineural technique for axillary brachial plexus
2570598|NCT02428920|Experimental|Peer Groups|Individuals in Intervention Group Arm will attend biweekly or monthly peer support groups (approximately 10 people per group) for evaluating changes and promoting mutual support. 12-month duration.
2570601|NCT02428920|No Intervention|Control Arm|The control arm, will attend the initial educational group lectures at baseline assessment and will receive no intervention thereafter.
2570705|NCT02428673|Other|Load-measuring platform|A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.
2570749|NCT02427997|Experimental|Treadmill training with virtual reality|The TT+VR patients (i.e., the experimental arm) will receive 18 sessions (3 times per week x 6 weeks) of training that will consist of walking on a treadmill while wearing a safety harness (without body weight support, recall Figure 1), and while being provided with feedback from the system.
2570752|NCT02427997|Active Comparator|Treadmill training alone|TT alone will receive conventional treadmill training with no feedback from the system. They will train with a safety harness 18 sessions (3 times per week x 6 weeks).
2570807|NCT02427620|Experimental|Treatment (ibrutinib, rituximab, consolidation chemotherapy)|"PART I (IBRUTINIB PLUS RITUXIMAB): Patients receive ibrutinib PO QD on days 1-28 and rituximab IV over 6-8 hours on days 1, 8, 15, and 22 of cycle 1 and then over 4 hours on day 1 of cycles 3-12. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity or until patients achieve complete response.~PART II (CONSOLIDATION THERAPY): Patients receive rituximab IV over 6 hours on day 1; dexamethasone PO or IV on days 1-4; cyclophosphamide IV over 3 hours BID on days 2-4; doxorubicin hydrochloride IV over 15-30 minutes on day 5; and vincristine sulfate IV over 15-30 minutes on day 5 of cycles 1, 3, 5, and 7. Patients also receive rituximab IV over 6 hours on day 1; methotrexate IV over 24 hours on day 2; and cytarabine IV over 2 hours BID on days 3 and 4 of cycles 2, 4, 6, and 8. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
2571111|NCT02425657||Junior Doctors|Surgical trainees (PGY1, 2 and 3 - Danish equivalents: introduktionsstilling, hoveduddannelse 1, 2).
2571131|NCT02425423|Experimental|New thickened infant formula|
2571222|NCT02425267|Experimental|Telerehabilitation|Telerehabilitation at home from a clinic
2571225|NCT02425267|Active Comparator|Face-to-face intervention in a clinic|Conventional physiotherapy
2571244|NCT02424656||1|"Patients with TBI and DOC.~Experimental measures (MRI, TMS-EEG, and clinical scales) will be performed at 4 time points: within 2 weeks of admission, 6-10 weeks after admission, at discharge, 1-year follow-up after TBI episode. FDG-PET will be performed in a subset of 25 patients at 3 time points: at admission, at discharge, and at 1-year follow-up."
2571246|NCT02424656||2|"Healthy patient-matched controls.~Experimental measures (MRI, TMS-EEG, and FDG-PET) will be performed at 2 time points: within patient admission, and within patient discharge."
3172968|NCT00606775|Experimental|Carvedilol|
3172969|NCT00606775|No Intervention|Control|
3172970|NCT00606788|Active Comparator|AW|Patients received computer-driven protocolized weaning (= Automated Weaning)
3172971|NCT00606788|Active Comparator|CW|Patients received physician-directed non-protocolized weaning (= Conventional Weaning)
3172972|NCT00606827|Experimental|A|Bicarbonate
3172973|NCT00606827|Active Comparator|B|Saline
3172974|NCT00606840|Experimental|1|One arm is a large changes group in which participants will be asked to make periodic large changes in their eating and activity, aimed at producing initial weight loss, in order to prevent weight gain over time.
3172975|NCT00606840|Experimental|2|The second arm is a small changes group in which participants will be asked to make small changes to their eating and activity and maintain these changes forever in order to prevent weight gain.
3172976|NCT00606853|Experimental|1|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
3208480|NCT00975182|Experimental|A|
3208481|NCT00975234|Experimental|Skeletal myoblasts|Patients who are receiving skeletal myoblasts
3208482|NCT00975234|Placebo Comparator|Placebo|Revascularisation surgery
3208483|NCT00975247|Active Comparator|Received Booklet|Patients who have received colonoscopy preparation booklet
3208484|NCT00975247|No Intervention|Did not receive booklet|Patients who did not receive colonoscopy preparation booklet
3208485|NCT00975273|Experimental|Breathing Training|Patients will receive biofeedback assisted breathing training
3208486|NCT00975273|Active Comparator|Breathing Awareness|Patients will receive biofeedback assisted breathing awareness training.
2570290|NCT02431078||ZEB1 high-expression group|Participants with ZEB1 high-expression(ZEB1 expression values>the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
2570294|NCT02431078||ZEB1 low-expression group|Participants with ZEB1 low-expression(ZEB1 expression values<the ZEB1 cut-off point) in CTCs for gastric cancer will be assigned to this group.The ZEB1 cut-off point was set at the top quartile.Routine comprehensive treatment will be performed.
2570304|NCT02430792|Active Comparator|Football|Recreational football 1-hour twice weekly in a local football club on a disease specific team
2570313|NCT02430792|No Intervention|Control|A 15-30-minute guidance session upon group allocation to encourage engagement in the standard rehabilitation offered by the municipality
2570362|NCT02430558|Experimental|OD-PHOENIX|treatment of 1 to 5 osteochondral allograft cylinders in mosaic
2570382|NCT02430324||TBI, no cerebral infarction|patients with moderate or severe brain injury that do not develop posttraumatic cerebral infarction
2570384|NCT02430324||TBI, posttraumatic cerebral infarction|patients with moderate or severe brain injury that develops posttraumatic cerebral infarction
2570462|NCT02430142||Vasoocclusive testing in sepsis|Septic patients defined according to the Surviving Sepsis Campaign (SSC)
2570463|NCT02430142||Vasoocclusive testing in severe sepsis|Severe septic patients defined according to the Surviving Sepsis Campaign (SSC)
2570464|NCT02430142||Vasoocclusive testing in sepsic shock|Septic shock patients defined according to the Surviving Sepsis Campaign (SSC)
2570487|NCT02429635|Experimental|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshp.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan."
2570495|NCT02429635|Experimental|Control group - delayed intervention|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team workshops and training groups The control groups will consist of teams that will receive the team-based health promotion measures about 9 months after the Team-based health promotion measures group."
2570549|NCT02429466|Experimental|Guadecitabine (SGI-110)|
2570621|NCT02429024|No Intervention|Control|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM system only over a period of 24 weeks.
2570624|NCT02429024|Experimental|Intervention|Subjects with type 1 and type 2 diabetes will be provided with the OneTouch Verio® Flex BGM and the OneTouch Reveal® Mobile APP system over a period of 24 weeks.
2570679|NCT02428439||Increased suicidality|Increase in suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
2570684|NCT02428439||Non-increased suicidality|Non-increase of suicidal ideation after taking the standardized pharmacotherapy (bupropion or lamotrigine) during 8 weeks.
2570748|NCT02428049||Lung cancer patients|Lung cancer patients in stages IA-IIIA destined to have stereotactic radiotherapy or conventional radiotherapy and chemotherapy in curative intent
2570811|NCT02427659|Other|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
2570818|NCT02427659|Other|Audio (sounds of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care. The nurse will be doing the wound care."
2570822|NCT02427659|Other|control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
2570863|NCT02427061|Experimental|Intervention Program (Manhood 2.0)|"Curricular Content: The 18 hour content will be spread over 3 to 6 sessions (3 weeks duration up to a 2 month period). Youth are guided to explore social constructions of masculinity, describe healthy relationships, discuss healthy sexual behaviors, identify coercive and disrespectful behaviors, and practice skills to intervene when witnessing peers' disrespectful and harmful behaviors, with repeated reflection on gender norms throughout these sessions.~Module One focuses on themes of gender and masculinity. Module Two focuses on themes of violence and sexual consent. Module Three focuses on themes of sexual health and decision making."
2570864|NCT02427061|Active Comparator|Control Program (Job Skills Training)|"Youth in the control arm receive the same amount of time with an intervention -- 18 hours of curriculum divided into 3 to 6 sessions, over 3 weeks up to 2 months duration.~The control intervention focuses on job skills development."
2570937|NCT02426879|Other|surgery|esophagectomy with three-field lymphnode dissection
3208487|NCT00975299|Experimental|Arm 1|
3208488|NCT00975299|Experimental|Arm 2|
3208489|NCT00975312|Experimental|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand.
3208490|NCT00975325|Active Comparator|"Yohimbine, Yohimbine Spiegel"|
3208491|NCT00975325|Active Comparator|Yohimbine Yocon-Glenwood|
3208492|NCT00975338||Prospective LIFEspan|LIFEspan youths with Cerebral Palsy or Acquired Brain Injury
3208493|NCT00975338||Prospective Non-LIFEspan|LIFEspan youths with Spina Bifida
2570363|NCT02430636|Experimental|IRE Group|irreversible electroporation for Unresectable Stomach Neoplasms
2570366|NCT02430636|No Intervention|Control|The patients without treatment
2570390|NCT02430259|Experimental|Weekly Isoniazid / Rifapentine|Weekly INH / RRT given by DOT
2570398|NCT02430259|No Intervention|No preventive treatment|Follow up without intervention
2570468|NCT02429960|Other|Analgesia monitoring|Remifentanil is increased step-by-step according to the study protocol. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli consisting of the intracutaneous pain model and tetanic stimulation for the time period of 30 s with 80 milliampere, 50 Hz are applied. All stimulations are accompanied by the measurement of the analgesic monitoring-devices (PhysioDoloris®, SPI® and AlgiScan®). Moreover the investigators measure and inspect changes in heart rate and blood pressure as well as occurrence of defensive movements of the patients.
2570521|NCT02429596|Experimental|Experimental Treatment|AED(s) currently taken (CBZ, VPA, TPM, OXC, LEV, LTG) will be substituted, starting with the morning dose on day 2, with an equivalent formulation available in the market. Namely, a brand product will be switched to a generic, randomly chosen among those available in the market, while maintaining unaltered the dosing regimen and times of administration.Likewise, a generic product will be switched to the brand or another generic.
2570522|NCT02429596|No Intervention|No Experimental Treatment|When the randomized allocation requires continuation on the same product (control), the AED product(s) currently taken will be continued unaltered, with the same dosing regimen and times of administration.
2570540|NCT02429154|Active Comparator|Normocapnia|The Child will be ventilated in order to achieve an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa). Measurements will be performed after steady state condition. Then the ventilation will be reduced to allow ETCO2 to reach 6.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a normocapnia condition.
2570545|NCT02429154|Other|Mild Hypercapnia|The Child will be ventilated in order to achieve a ETCO2 of 6.5 kPa. Measurements will be performed after steady state condition. Then the ventilation will be increased to allow ETCO2 to reach 5.5 kPa before repeating the measurements. Finally, the child will be again ventilated to obtain a mild hypercapnic condition
2570609|NCT02429063|Experimental|Bright White Light|Participants use the bright white light intervention for 30 minutes upon waking each morning for 60 days.
2570610|NCT02429063|Experimental|Dim Red Light|Participants use the dim red light intervention for 30 minutes upon waking each morning for 60 days.
2570667|NCT02428491|Experimental|DTaP-IPV-HB-PRP~T Vaccine|All participants will receive 3 doses of 0.5 mL DTaP-IPV-HB-PRP~T combined vaccine, intramuscularly, at 2, 3 and 4 months of age (primary series), followed by a booster dose approximately 12 months after the completion of the primary series (at 16 to 17 months of age).
2570726|NCT02428179||Control group without Study intervention|Control group without Study intervention
2570728|NCT02428179||Group with Study intervention|Group with Study intervention
2570812|NCT02427763|Active Comparator|Retainer use|"The volunteer use a thermoplastic appliance (Essix) for 8hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
2570820|NCT02427763|Active Comparator|Aligner use|"The volunteer use thermoplastic appliance (Essix) for 22 hours~Interventions:~hours of use~collect biofilm~collect saliva~collect epithelium"
3172977|NCT00606853|Experimental|2|Standard Treatment plus prize contingency management for abstinence with an expected probability of winning about $560 in prizes and twice-weekly breath and urine samples.
3172978|NCT00606853|Experimental|3|Standard Treatment plus prize contingency management for attendance with an expected probability of winning about $250 in prizes and twice-weekly breath and urine samples.
3172979|NCT00606853|No Intervention|4|Standard Treatment
3172980|NCT00606866|Placebo Comparator|I|placebo pill
2571439|NCT02423512||Anti-TNF Exposure|Inflammatory Bowel Disease (IBD) patients scheduled to start vedolizumab therapy who have been previously exposed to anti-TNF therapy
2571440|NCT02423512||anti-TNF Naive|IBD patients scheduled to start vedolizumab therapy who have not been previously exposed to anti-TNF therapy
2571517|NCT02423083|Experimental|Treatment arm|
2571545|NCT02422537|Active Comparator|Unmodified wheat bran|One single dose om 20 g
2571546|NCT02422537|Active Comparator|Wheat bran with reduced particle size|One single dose of 20 g
2571548|NCT02422537|Active Comparator|Destarched pericarp-enriched wheat bran|One single dose of 20 g
2571550|NCT02422537|Other|No bran-based dietary platform|No wheat bran fractions is administered
2571631|NCT02422017|Experimental|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks in combination with dressings and compression.
2571632|NCT02422017|Other|Control|Local care treatment only (dressing and compression applied every other day)
2571686|NCT02421835|Placebo Comparator|Placebo control|2 capsules of 350 mg maltodextrin to be consumed daily for 12 weeks
2571691|NCT02421835|Active Comparator|Olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily for 12 weeks
2571696|NCT02421835|Placebo Comparator|Physical activity|2 capsules of 350 mg maltodextrin to be consumed daily combined with gradually increase physical activity levels over 12 weeks
2571700|NCT02421835|Active Comparator|Physical activity and olive leaf extract|2 capsules of 350 mg olive leaf extract equivalent 132 mg of oleuropein in olive leaf extract to be consumed daily combined with gradually increase physical activity levels over 12 weeks
2571730|NCT02421471||Ingenol mebutate treatment cohort|Patients who are prescribed ingenol mebutate gel for the first time by investigator's medical judgment.
3172981|NCT00606866|Active Comparator|II|Sorafenib, 200 mg bid
3172982|NCT00606866|Active Comparator|III|Sorafenib, 400 mg bid
3172983|NCT00606879|Experimental|Single arm|
3172984|NCT00606918||1|Individuals with ALS
3172985|NCT00606918||2|Healthy Adults
3172986|NCT00606970|Experimental|Intervention group|Seigen Alpha EV Treatment
3172987|NCT00606970|Placebo Comparator|2|Identically packaged placebo packets taken 3x daily for 3 months maximum
3172988|NCT00606983|No Intervention|1|
2570145|NCT02431780|Experimental|ANSeR Software System|The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures
2570200|NCT02431390|Experimental|RAPAELⓇ Smart Glove group|The experimental group includes 40 stroke patients. The group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) and RAPAELⓇ Smart Glove digital treatment system training. RAPAELⓇ Smart Glove digital treatment training will consist of games and play to facilitate the function of upper limbs and brain plasticity. RAPAELⓇ Smart Glove group will be provided the 20 training session. (30min per session, 5 times per week, during 4 weeks)
2570202|NCT02431390|Active Comparator|Additional occupation therapy group|The active comparator group includes 40 stroke patients.The occupational therapy group will receive the conventional occupational therapy(30min per session, 5 times per week, during 4 weeks of hand dexterity training) sessions twice. Additional conventional occupational therapy sessions are comprised of the training for upper limb and cognition. The additional occupational therapy group will be provided the 20 additional session (30min per session, 5 times per week, during 4 weeks)
2570288|NCT02431065|Experimental|Group 3, Direct injection group|Test group 2, Rectus sheath block will be performed under direct visualization. Ropivacaine (0.75%, 10ml) will be directly injected into the right and left rectus sheath at the end of the operation.
2570295|NCT02431065|Active Comparator|Group 2, ultrasonography group|Test group 1, Rectus sheath block will be performed under sonographic guidance. Ropivacaine (0.75%, 10ml) will be injected into the right and left rectus sheath under ultrasonographic guidance at the end of the operation.
2570299|NCT02431065|Placebo Comparator|Group 1|Control group, Rectus sheath block will be performed under sonographic guidance. Normal saline 10 ml will be injected into the right, left rectus sheath under ultrasonography guidance at the end of the operation.
2570332|NCT02430714||Arm 1|A prospective, centrally registered investigation will be conducted. The new administering participants are to be registered at the time of administration.
2570378|NCT02430493||ticagrelor|Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet
2570442|NCT02429999|Active Comparator|Letrozole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75 international unit(IU) /day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till human chorionic gonadotrophin (hCG) injection.
2570446|NCT02429999|Active Comparator|Standered protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225 international unit/day) from day 2. We will give them at first 225 international unit FSH for 5 days.
2570480|NCT02429804|Experimental|Diagnostic (18F NaF/18F FDG PET/MRI, contrast-enhanced MRI)|Patients receive 18F NaF and 18F FDG IV over 30 seconds-1 minute and then undergo PET/MRI and contrast-enhanced MRI after 45-60 minutes. Patients undergo imaging at baseline, after course 3 (12 weeks), and after course 6 (24 weeks) of treatment with Ra-223.
2570587|NCT02429102|Experimental|Single ascending dose, MT-8554 or Placebo|
2570590|NCT02429102|Experimental|Multiple ascending dose, MT-8554 or Placebo|
2570597|NCT02428751|Active Comparator|R-CHOP|This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
2570600|NCT02428751|Experimental|R-CDOP|This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.
2570680|NCT02428387|Experimental|Intervention|"The intervention group (Group 1) will receive instructions on how to access My Tools 4 Care for 3 months."
2570683|NCT02428387|No Intervention|Educational Control|An educational control group (Group 2) will receive a copy of the Alzheimer's Society' The Progression of Alzheimer's Disease - Overview Booklet.
2570808|NCT02427555|Experimental|Barley kernel bread|
2570813|NCT02427555|Sham Comparator|Whit wheat flour bread|
2570892|NCT02427243|Experimental|Crenezumab Formulation 2|A single dose given as two subcutaneous injections on Day 1
2570894|NCT02427243|Experimental|Crenezumab Formulation 3|A single dose given as two subcutaneous injections on Day 1
2570920|NCT02426697|Experimental|Pecfent|Patients will receive 100 µg of transmucosal Pecfent before radiotherapy session (or 200 µg in patients with a stable opioid background pain treatment)
2570921|NCT02426697|Placebo Comparator|Placebo|Patients will receive 100 µg of transmucosal placebo before radiotherapy session or 200 µg in patients with a stable opioid background pain treatment)
2571026|NCT02426450|Experimental|RFA+FOLFOX4|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).~Oxaliplatin + 5-Fluorouracil/Leucovorin:~4 weeks after RFA; Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
2571080|NCT02425878|Experimental|Experimental|Ulipristal Acetate 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
2571084|NCT02425878|Placebo Comparator|Control|Placebo, 10 mg, Oral administration. Dose: 10 mg per day, single dose, duration 12 weeks
2571130|NCT02425579|Experimental|Cohort 1|Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days
2570215|NCT02431442|Placebo Comparator|Cohort 1: Placebo SC Infusion 14 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 14 days (1 panel, all male subject)
2570219|NCT02431442|Placebo Comparator|Cohort 2: Placebo SC Infusion 28 Days|Double-blind Placebo will be via subcutaneous continuous infusion for 14 days (1 panel)
2570222|NCT02431442|Placebo Comparator|Cohort 3: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
2570226|NCT02431442|Placebo Comparator|Cohort 4: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel)
2570227|NCT02431442|Placebo Comparator|Cohort 5: Placebo SC Injection 14 days|Double-blind Placebo will be administered via a subcutaneous injection every 12 hours for 14 days (1 panel)
2570228|NCT02431442|Placebo Comparator|Cohort 6: Placebo SC Infusion 28 Days|Double-blind Placebo will be administered via subcutaneous continuous infusion for 28 days (1 panel, heterozygous MC4R subjects)
3208936|NCT00979524|Experimental|Comprehensive Mental Health Services|Intervention group participants will receive an array of mental health education and services based on their level of need. Study participants will fall into low, moderate, or elevated risk based on results of baseline screening. Services will be provided to each group as specified below. Low risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) education activities to promote knowledge and change attitudes around mental health; Moderate risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Short-term mental health services delivered by the LCSW-C, (c) Depression prevention intervention, (d) Education activities to promote knowledge and change attitudes around mental health; High risk group: (a) Initial meeting with one of the licensed clinical social workers (LCSW-C), (b) Mental health treatment services, (c) Education activities to promote knowledge and change attitudes around mental health.
2570420|NCT02430168|Active Comparator|RIRS|Retrograde intrarenal surgery
2570425|NCT02430168|Active Comparator|PCNL|Percutaneous nephrolithotomy
2570467|NCT02429947||INC Contact Registry Participants|Adult CMT patients who have self-registered at the Inherited Neuropathies Consortium (INC) Contact Registry, a web-based contact registry developed and supported by the Data Management and Coordinating Center (DMCC) for the Rare Diseases Clinical Research Consortium (RDCRN), located at the University of South Florida.
2570500|NCT02429687|Experimental|PT (Arm 1)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
2570507|NCT02429687|Active Comparator|BEP (Arm 2)|"Patients receive bleomycin IM daily for days 1-3, etoposide IV daily for days 1-5, cisplatin IV for days 1-5. Treatment repeats every 21 days for 3 or 4* courses in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients who have good risk will have 3 courses and those who have poor risks will have 4 courses."
2570581|NCT02429297|Experimental|Patient Only - HITCM-only|Patients enrolling without a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
2570584|NCT02429297|Experimental|Patient & CarePartner - HITCM-only|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team.
2570585|NCT02429297|Experimental|Patient & CarePartner - HITCM+CP|Patients enrolling with a CarePartner receive weekly Health Information Technology/Care Manager (HITCM) automated assessment and self-care support calls with feedback to the clinical team plus updates to their CarePartner via phone or email.
2570602|NCT02428764|Experimental|Intervention group|Patients were assigned to receive neoadjuvant nimotuzumab plus gemcitabine and carboplatin followed by surgery.
2570721|NCT02428127|Experimental|Test|20g Carbohydrate powder fortified with multiple micronutrients, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
2570729|NCT02428127|Active Comparator|Calorie matched protein powder|20g Calorie matched protein powder with 80% protein, reconstituted as a beverage in 200mL lukewarm water. This will be administered twice a day
2570737|NCT02428127|Placebo Comparator|Control|200mL lukewarm water given twice a day
3175206|NCT00631345|Experimental|Lifestyle|This Group-Based Lifestyle Intervention (Phases 1 and 2) will be led by lay health counselors (LHCs). The 6-month Phase 1 includes weekly meetings on nutrition and physical activity, psychosocial factors related to health behaviors, and question and answer periods. The 18-month Phase 2 will consist of monthly group meetings and individual telephone contacts. Intervention participants who choose to participate in the study continuation (Phase 3) will be further randomized to receive either extended group or self-directed maintenance. Those who are randomized to receive Extended Group Maintenance (Phase 3) will continue attending monthly meetings; those who receive Self-Directed Maintenance (Phase 3) will no longer attend groups.
2570904|NCT02426853|Experimental|Group 1 - UV Photography Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds. At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
2570905|NCT02426853|Active Comparator|Group 2 - Comparison Group|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education. Participants given handouts that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
2570978|NCT02426554|Active Comparator|Group 1|
2570982|NCT02426554|Placebo Comparator|Group 2|
2570994|NCT02426307||Transcatheter Aortic Valve Replacement|TAVR: Portico (St Jude Medical), CoreValve (Medtronic), Lotus (Boston Scientific), Edwards Sapien 3 (Edwards LifeSciences),
2570995|NCT02426307||Surgical aortic valve replacement|SAVR: Perimount (Edwards), Epic (St Jude Medical), Trifecta (St Jude Medical)
2571044|NCT02426099|Experimental|Low dose Spironolactone|Add-on low dose 25 mg Spironolactone to current hypertension treatment
2570223|NCT02431403|Experimental|ESHAP-Imatinib 400mg|"Imatinib 400 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
2570225|NCT02431403|Experimental|ESHAP-Imatinib 300mg|"Imatinib 300 mg combined with ESHAP~* ESAHP D1-4 Etoposide 40mg/m2 D1-4 Cisplatin 25mg/m2 D5 Cytarabine 2000mg/m2 D1-5 Methylprednisolone 250mg/m2 D6 Pegfilgrastim 6mg"
2570287|NCT02431104|Experimental|Laser Treatment|Treatment to unwanted tattoo using a 532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser
3208937|NCT00979524|Active Comparator|Usual Care (Employment Training Services)|"Newly enrolling Westside YO members will receive usual care services, which constitute a moderate level of mental health services and supports. The usual care services related to mental health at the Westside will include (1) the ACASI screen for all newly enrolling Westside YO members, (2) the initial visit with a LCSW-C, and (3) mental health training for Westside Case Advocates. More extensive mental health educational activities and services (e.g., additional sessions with LCSW-C, SOS Club) provided to the intervention group will not be available at the Westside YO Center during the initial study period. Also, Eastside Case Advocates will receive more extensive and ongoing mental health training."
3208938|NCT00979537|Experimental|Test: Nisoldipine ER Tablets, 40 mg|Nisoldipine Extended-release Tablets, 40 mg
3208939|NCT00979537|Active Comparator|Reference: Sular Tablets 40 mg|Sular Tablets, 40 mg
3208940|NCT00979589|Active Comparator|Combination Clopidogrel and asprin|
3208941|NCT00979589|Placebo Comparator|Asprin and placebo|
3208942|NCT00979641|Experimental|chemoterapy|docetaxel/paclitaxel + bevacizumab
3208943|NCT00979667|Experimental|Oseltamivir|
3208944|NCT00979667|Experimental|Zanamivir|
2570476|NCT02429895|Experimental|All subjects (open-label extension)|All subjects will start treatment with ABT-122
2570560|NCT02429232|Experimental|Pioglitazone|Pioglitazone 30 mg once daily will be administered orally for total 48 weeks.
2570564|NCT02429232|Active Comparator|Linagliptin|Linagliptin 5 mg once daily will be administered orally for total 48 weeks.
2570595|NCT02428829|Experimental|Intervention|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
2570599|NCT02428829|Active Comparator|Control|Control group will receive standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively
2570635|NCT02428660|Other|Controls (no analysis or testing)|MTM alone (i.e. Treatment As Usual)
2570636|NCT02428660|Experimental|Group 1|MTM + software-based drug & gene interaction risk analysis + pharmacogenetic testing
2570637|NCT02428660|Active Comparator|Group 2|MTM + software-based drug & gene interaction risk analysis only
2570687|NCT02428361|Experimental|Pouchitis patients receiving FMT|Pouchitis patients receiving biologically active human fecal material sourced from OpenBiome.The physician will administer 250 mL of the fecal suspension in aliquots of 50-60 mL through the endoscope. The material will be delivered to the most proximal point of insertion.
2570722|NCT02428114||5 days of filgrastim|Standard of care
2570733|NCT02428114||7 days of filgrastim|Standard of care
2570735|NCT02428114||10 days of filgrastim|Standard of care
2570787|NCT02427828|Active Comparator|Treatment Group|Assessment of Visensia Respiration Rate Estimation Service (product) to provide Respiration Rate from PPG signal, providing 3 vital signs (heart rate, oxygen saturation and respiration rate) to facilitate continuous Safety Index (VSI) calculation by Visensia, alongside standard routine intermittent observations (vital signs every 4 - 6 hours).
2570792|NCT02427828|No Intervention|Control Group|Using standard routine intermittent observation (vital signs every 4 - 6 hours) and calculation of NEWS/MEWS scores for early detection of patient deterioration.
2570856|NCT02427386|Active Comparator|dynamized estrogen in alcohol solution|Dynamized estrogen (17-beta estradiol) in the 12cH, 24cH and 18cH potencies.
2570860|NCT02427386|Placebo Comparator|placebo (alcohol solution)|This arm received alcohol solution during the 24-week study duration.
3208945|NCT00979667|Placebo Comparator|Placebo of Oseltamivir|
3208946|NCT00979680|Active Comparator|High-dose Radiotherapy|
2571038|NCT02426177|Active Comparator|group A|tab.labetalol is given to the patient with postpartum hypertension in dose of 100 mg 6 hourly increased to maximum 600 mg in 24 hours
2571039|NCT02426177|Active Comparator|group B|tab.nifedipine is given to the patient with postpartum hypertension in the dose of 10 mg twice a day to maximum dose of 60 mg per 24 hours
2571221|NCT02425124|Active Comparator|Control|PC101 Enhanced usual primary health care where non-physician clinicians have been equipped with the basic skills to identify stress and depression/anxiety but with limited access to doctors authorized to prescribe antidepressant medication, and with no specific psychosocial interventions.
3208947|NCT00979680|Active Comparator|Chemo-radiotherapy|
3208948|NCT00979693|Experimental|Full Dose|Participant will receive 25 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with each session scheduled seven to 14 days apart.
3208949|NCT00979693|Active Comparator|Active Placebo|The participant will receive 4 mg psilocybin during two day-long sessions of psychotherapy in combination with psilocybin, with sessions scheduled seven to 14 days apart.
3208950|NCT00979706|Active Comparator|HAART|Patients assigned to this arm will receive standard HAART
3208951|NCT00979706|Experimental|HAART + Immunotherapy|Patients assigned to this arm will receive HAART plus cyclosporin A during the first two months and after that will receive IFN, GM-CSF and IL-2.
3208952|NCT00979719|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
3208953|NCT00979719|Placebo Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, & Fuchs, 2007) Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.
3208954|NCT00979719|No Intervention|Passive Control Group (PCG)|patients are asked to answer the questionnaires only
2570297|NCT02431000||Male Chemo/Radiotherapy Candidates|"Adult and post-pubertal males, 13 years of age or older, presenting to clinic because diagnosed with cancer, who wish to preserve their future fertility. Sperm and blood collected for analysis. If minors, parents or guardians have to give consent to the procedure while the boys give their assent.~This is a prospective observational cohort study."
3208955|NCT00979758|Sham Comparator|Atorvastatin|Atorvastatin routine dose
3208956|NCT00979758|Placebo Comparator|Intensive Atorvastatin|Atorvastatin Intensive dose
3208957|NCT00979758|Active Comparator|Atorvastatin+Transplantation|Atorvastatin routine dose+ Mononuclear cells Transplantation
3208958|NCT00979758|Experimental|Intensive Atorvastatin+Transplantation|Atorvastatin intensive dose+ Mononuclear cells Transplantation
2570523|NCT02429570|Experimental|Meclofenamate|All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.
2570541|NCT02429219|Active Comparator|Transurethral Resection|Transurethral Resection of the Prostate in Saline irrigation with ethanol
2570547|NCT02429219|Experimental|Photoselective vaporisation|Photoselective vaporisation of the Prostate in Saline irrigation with ethanol
3208959|NCT00979771|Experimental|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
2570708|NCT02428283|Experimental|Nerve block|Scalp nerve block was performed with 0.25% ropivacaine.
2570711|NCT02428283|Active Comparator|Control|Remifentanil was administered intravenously.
3208960|NCT00979771|Placebo Comparator|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
3208961|NCT00979784|Active Comparator|1|
3208962|NCT00979784|Experimental|2|
2570896|NCT02427113|Active Comparator|Self-Select Music|Participants will be randomized to two groups. Self-select music will be used as treatment for managing pain. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
2570898|NCT02427113|Active Comparator|Sound Oasis Vibrating Chair|Participants will be randomized to two groups. Vibroacoustic therapy will be administered in the form of a vibrating chair. They will be required to listen to their preferred songs for 30 minutes per 7 days, recommended 5, for 3 weeks.
2570969|NCT02426671|Experimental|MuteButton sensory stimulation device|"Participants will be asked to use the Mutebutton, neuro-modulation device every day for 60 minutes for 12 weeks. Use of the device involves placing a 'lollipop' type sensor on the tongue and wearing earphones. The participant will hear pink noise through the earphones and will receive neuro-stimulation through the sensor. The participant will not feel any discomfort whilst using the MuteButton device."
2571030|NCT02426333||Abiraterone Acetate|abiraterone treatment, 1000mg, tablets, once daily, treatment is not adapted for the study
2571114|NCT02425917|Experimental|geko|
2571117|NCT02425917|Active Comparator|ipc-calf|intermittent pneumatic compression of the calf
2571178|NCT02425436|Active Comparator|Ginkgo Biloba Extract group|This group received Ginko Biloba, two tablets per day
2571179|NCT02425436|Placebo Comparator|Placebo group|This group received placebo two tablets per day .
3208963|NCT00979797|Experimental|Maternal & Child Health|Community-based interventions to promoto Maternal and Child Survival in collaboration with GoB, Donors and NGOs.
2571330|NCT02424448||Metastatic CRPC|Patients with metastatic prostate cancer post maximal androgen blockade (MAB) with primary or metastatic cancer deposits amenable to biopsy. Patients will have biopsies, blood and urine samples taken.
2571358|NCT02423954|Experimental|Arm 1|Temsirolimus 25 mg every 14 days + nivolumab
2571361|NCT02423954|Experimental|Arm 2|Irinotecan 150 mg/m2 every 14 days + nivolumab
2571362|NCT02423954|Experimental|Arm 3|Irinotecan + capecitabine + nivolumab irinotecan 175 mg/m2 on day 1 every 14 days + capecitabine 1000 mg PO BID days 1-5 on, days 6-7 off, each 7 day period
2571407|NCT02423564|Active Comparator|Healthy Population with Digesta Lac|Digesta Lac is Lactobacillus bulgaricus LB-51 at 2.0 billion cfu with non-medicinal ingredients: cellulose, potato powder, chick pea extract, vitamin c, L-leucine, vegetable capsule (hypromellose)
2571411|NCT02423564|Placebo Comparator|Healthy Population with Placebo|Placebo contains: cellulose, Organic Whole Grain Brown Rice Milk Concentrate, L-Leucine, potato powder, vegetable capsule (hypromellose)
3208964|NCT00979823|Experimental|Early SimCare Diabetes Group|This group will receive an email web-link to 3 simulated learning cases each month for 6 months. After 6 months (18 total learning cases), they will then complete 4 simulated assessment cases, a diabetes knowledge survey, and a satisfaction survey.
3208965|NCT00979823|Active Comparator|Delayed SimCare Diabetes Group|Beginning in the spring of 2011, residents in this group will receive an email web-link to complete 4 simulated assessment cases and a diabetes knowledge survey. They will subsequently be sent 3 learning cases a month for 6 months and a satisfaction survey to complete.
2571660|NCT02422082|Active Comparator|L. reuteri|Lactobacillus reuteri (L. reuteri) ATCC PTA 6475 at a dose of 5 000 000 000 CFU as a powder in a stick-pack, orally twice daily (morning and evening) yielding a total daily dose of 10 000 000 000 CFU per day, for 12 months.
2571661|NCT02422082|Placebo Comparator|Placebo|Placebo product identical to the active product (L. reuteri) in taste and appearance but without the active component, orally twice daily, for 12 months.
2571706|NCT02421692|No Intervention|Usual Care|SNF rehabilitation therapists provide all patients with usual standard of care.
3208966|NCT00979836|Experimental|Calcium Dobesilate|
3208967|NCT00979836|Placebo Comparator|Placebo|The placebo is a capsule with the same presence of experimental drug.
3208968|NCT00979849|Experimental|A|AZD8683
3208969|NCT00979849|Placebo Comparator|B|Placebo
3208970|NCT00979862|Experimental|Treatment cediranib maleate, cilengitide)|"Part A (dose finding): Patients receive cediranib maleate PO once daily on days 1-28 and cilengitide IV over 1 hour on days 1, 4, 8, 11, 15, 18, 22, and 25. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Part B (dose expansion): Patients are assigned to 1 of 2 groups according to prior anti-VEGF therapy (yes vs no). Patients in both groups receive cediranib maleate (administered at the safe dose determined in part A) and cilengitide as in part A."
3208971|NCT00979914|Experimental|Patient education programme|Patients with osteoarthritis who were referred to the patient education programme.The patients followed the patient education programme.
2570235|NCT02431546|No Intervention|Usual Care Group|Participants randomized to the usual care control arm will follow standard care as ordered by their individual, treating physician. Participants in the UC control arm will not receive any specific lifestyle recommendations from study personnel. They may, however, receive any lifestyle recommendations deemed appropriate by their usual clinical care providers. All participants will be contacted by study personnel in order to schedule visits at baseline and 12-weeks for the outcome assessments.
2570283|NCT02431130|Experimental|Low-fidelty instructor driven simulation training|participants receive simulation training
2570284|NCT02431130|No Intervention|No simulation training|
2570328|NCT02430935|Experimental|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a standardized approach to the use of environmental supports for improving multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia.
2570330|NCT02430935|Active Comparator|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
3208972|NCT00979914|No Intervention|Control|Patients randomized to control group
3208973|NCT00979927|Placebo Comparator|Saline|
2570504|NCT02429882|Experimental|Brodalumab|
2570508|NCT02429882|Placebo Comparator|Placebo|
2570566|NCT02429349|Experimental|Diagnostic Procedure|Surgery - Unilateral surgical removal of ovary, freezing of tissue, post cancer cure autotransplant
2570608|NCT02428777|Active Comparator|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
2570611|NCT02428777|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
2570614|NCT02428777|Placebo Comparator|Placebo|Women will receive an oral placebo 1 hour before the procedure
3208974|NCT00979927|Active Comparator|SPC3649|
3208975|NCT00979966|Experimental|A|Temsirolimus
2570760|NCT02427919|Experimental|Early G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will be started post chemotherapy D+7~D+10 when blasts disappear from peripheral blood smear.~When blasts reappear on peripheral blood smear, G-CSF will be discontinued.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
2570766|NCT02427919|Active Comparator|No or delayed G-CSF use|"Refractory AML undergoing salvage chemotherapy (MEC regimen in AML). After finishing application of chemotherapy, G-CSF will not be applied at least post chemotherapy D+25~D+28. If patient suffers from severe infectious complication and when no blasts are detected on peripheral blood smear, G-CSF can be started then.~Intervention type : Drug Intervention name : G-CSF (Filgrastim)~-> Comparison of the effect of G-CSF (Filgrastim) use"
2570781|NCT02427581|Experimental|Arm 1 - personlized synthetic long peptide vaccine|"Each subject will receive a single synthetic long peptide vaccine on Days 1, 4, 8, 15, 22, 50, and 78.~The first five injections must take place within +/- 1 day window and the remaining injections must take place within a +/- 2 week window.~The synthetic long vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, and D - Left Leg) by subcutaneous (SC) injection. Alternative anatomical locations for patients who are status post complete axillary or inguinal lymph node dissection or other contraindications that prevent injections to a particular extremity are the left and right midriff, respectively. The same pool should be administered to the same limb across doses."
2570851|NCT02427373|Active Comparator|fish oil ethyl ester|1.3g/d dose of DHA+EPA in fish oil EE (6 capsules) administered for 4 weeks
2570854|NCT02427373|Active Comparator|fish oil triglyceride|1.3g/d dose of DHA+EPA in fish oil TG (6 capsules) administered for 4 weeks
2570859|NCT02427373|Active Comparator|krill oil|1.3g/d dose of DHA+EPA in krill oil (6 capsules) administered for 4 weeks
2570943|NCT02426931|Experimental|tf-URS|Participants in tf-URS group undergo ureteroscopy using the tip-flexible ureterorenoscope.
2570949|NCT02426931|Active Comparator|f-URS|Participants in f-URS group undergo ureteroscopy using the classic flexible ureteroscope.
2570997|NCT02426359|Experimental|Q301 Cream|Q301 Cream
2570999|NCT02426359|Placebo Comparator|Vehicle|Vehicle
2571057|NCT02426060|Experimental|Imrecoxib&Warfarin|
2571115|NCT02425683|Experimental|Regorafenib|Regorafenib 120 or 160 mg by mouth every day for the first 21 days of each 28-day cycle. If the dose is tolerated during the first 2 cycles in the 120 mg group, in Cycle 3 the 120 mg dose will be increased to 160 mg by mouth each day for the first 21 days of each 28-day cycle for 4 more cycles for a total of 6 cycles or 6 months of therapy.
2571116|NCT02425683|No Intervention|Standard of Care (No Treatment)|No study drug (which is the standard care for Stage IIIC colorectal cancer patients after they've received FOLFOX chemotherapy).
2571136|NCT02425384|Experimental|Intervention Group|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and is linked to a motivational website. On the website, activity data from the activity meter can be viewed after uploading information from the meter to the website. The reward website allots points for participants based on the amount and intensity of physical activity. Points can be redeemed for rewards on the website, such as gift cards and digital badges.
2571226|NCT02425124|Experimental|Intervention|PC101 + Mental Health Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
3208976|NCT00979966|Experimental|B|Sunitinib
3208977|NCT00979979||HCV patients|HCV patients with detectable viremia; all sera are tested both by Abbott RealTime HCV genotype II test and by direct HCV sequencing both at 5'UTR and NS5B
3208978|NCT00979979||Non-HCV patients|Patient without evidence of HCV infection (negative both for anti-HCV and HCV RNA); all sera are both tested by Abbott RealTime HCV genotype II test and by direct HCV sequencing at 5'UTR and NS5B
3208979|NCT00980031|Placebo Comparator|Lactose Tablet|Compounded capsule using Lactose Monohydrate Powder
3208980|NCT00980031|Active Comparator|Eplerenone|25 mg tablet placed in a capsule filled with Lactose Monohydrate Powder.
2570270|NCT02431182|Experimental|Memory training group|"Memory training:The intervention consists of twelve 90-minutes group sessions given once a week by a specialized psychologist.~The groups are formed by around 15 people. Each session has its own objectives, material and activities. The content of the intervention is based on memory training from different perspectives as cognitive and emotional aspects or social and individual skills."
2570273|NCT02431182|No Intervention|Control group|No intervention will be administred until the delayed post-test is finished
2570306|NCT02430987|Active Comparator|Metabolic syndrome|"The MetS diagnosis was determined by following the guidelines defined by the Adult Treatment Panel (ATP III) (8): (1) Abdominal circumference (AC) ?88cm; (2) HDL-cholesterol < 50mg/dL; (3) triglycerides > 150mg/dL; (4) arterial blood pressure (SAH) > 130/85mmHg; and (5) fasting glucose > 110mg/dL. The women considered as carrying MetS were those with at least three of the components described.~Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese"
2570309|NCT02430987|Placebo Comparator|Obesity|women were stratified into 3 groups by body mass index (BMI): Group 1: BMI of 18.5 to 24.9kg/m2 (Normal BMI Group), Group 2: BMI of 25 to 29.9kg/m2 (Overweight Group); Group 3: BMI of 30kg/m2 to 34.5kg/m2 or higher) (Obese Group Sexual function was assessed by completion of the Female Sexual Function Index (FSFI), a questionnaire validated for Brazilian Portuguese
2570397|NCT02430467|Active Comparator|Caregiver-guided pain management training protocol (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques
2570402|NCT02430467|Active Comparator|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
2570447|NCT02429986|Other|ASV Arm|The measures are performed during the annual consultation required by the French Social Security for the renewal of the reimbursement of the ASV care.
2570484|NCT02429726|Experimental|rAdp53|2 x 10^12 viral particles of rAdp53 gene are given in 40 ml of saline by intra-cavity infusion at day of 7, 15 and 21
2570486|NCT02429726|Active Comparator|cisplatin|cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
2570489|NCT02429726|Experimental|rAdp53 plus cisplatin|2 x 10^12 viral particles of rAdp53 gene and cisplatin 40 mg in 40 ml of saline are given by intra-cavity infusion at day of 7, 15 and 21
2570544|NCT02429375|Experimental|Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35)|Patients with relapsed or refractory Hodgkin lymphoma will receive brentuximab vedotin combined with mocetinostat. For the phase I portion of the study, patients will be enrolled in a traditional 3 + 3 phase 1 design on sequential dosing cohorts in order to determine the maximum tolerated dose (MTD) of mocetinostat when given with brentuximab vedotin. Once the MTD is determined, (up to) an additional 26 patients will be enrolled on to the phase II portion of the study at the MTD to determine the response rate and toxicity associated with treatment. The phase Ib and II study will include a lead-in with mocetinostat alone for 1 week followed by the combined treatment beginning day 15 following initiation of mocetinostat.
2570618|NCT02429089|Experimental|Group I|The patients will receive the same molecules (cetuximab and LEE011) but this phase I study will determine the DLTs by dose escalation of LEE011 (400 mg and 600mg).
2570723|NCT02428153|Experimental|cases|static and dynamic stretching exercises
2570778|NCT02427789|No Intervention|Control|In this group patients will not have physical exercises
2570780|NCT02427789|Active Comparator|Physical Exercise|In this group patients will make physical exercise
3175207|NCT00631345|Other|Comparison|The comparison condition exceeds the usual care provided to similar community members and is an individual education program that builds on an increased awareness of existing community resources. In the initial trial, these subjects will receive two individual sessions with the RD and a monthly newsletter. In the study continuation, comparison participants will receive biannual nutrition counseling and a monthly newsletter.
2570858|NCT02427087|Active Comparator|Continuous Aerobic training|Aerobic training continuous (n=19 patients) carry a protocol continuous aerobic training twice a week for 24 weeks and the session will last 60 minutes/2 days/week with recommendation for healthy diet.
2570862|NCT02427087|Active Comparator|Healthy diet|Diet group (n=21 patients) only recommendation for healthy diet.
2571152|NCT02425371|Experimental|Intervention|screening and treatment of comorbidities
2571156|NCT02425371|Placebo Comparator|Control|No screening of comorbidity
2571254|NCT02424747||De Novo Acute Kidney Injury|Patients who developed Acute Kidney Injury during intensive care admission and not previously diagnosed with chronic kidney disease or end stage renal disease.
2571666|NCT02421861|Experimental|Anxiety Management (AM)|
3175208|NCT00631384|Experimental|1|Women to be asked to bring husbands for couple VCT
3175209|NCT00631384|Active Comparator|2|Women to receive individual VCT
3175210|NCT00631397||Premature Infants|Premature Infants weighing less than 1500 gms
3175211|NCT00631423||1|Patients with vena cava inferior thrombosis
3175212|NCT00631423||2|Patients with isolated lower-extremity DVT matched for gender and age
3175213|NCT00631436||1|If the individuals who meet the blast exposure criteria have a PCL score above 50 and meet the Hoge et al PCL criteria, thus indicating likely PTSD, they will be invited to participate as members of the Blast Exposed + PTSD group.
3175214|NCT00631436||2|Other individuals meeting the blast exposure criteria will be invited to participate in the as members of the Blast Exposed + No PTSD group if they have PCL scores below 30.
3175215|NCT00631436||3|Individuals reporting that they were not exposed to explosive blast will be recruited to participate. Those not exposed to blast but with PCL scores over 50 and meeting the Hoge et al PCL criteria will be invited to participate as members of the No Blast + PTSD group.
2570276|NCT02431208|Experimental|Cohort E2: ATZ + DAR + LEN (Expansion)|Cohort E2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the maximum tolerated dose (MTD) of lenalidomide determined in Cohort E1 in participants with relapsed or refractory MM who have received up to 3 lines of prior treatment. NOTE: This cohort is closed to enrollment.
2570277|NCT02431208|Experimental|Cohort F1: ATZ + DAR + POM (Dose Escalation)|Cohort F1 will involve a dose escalation to evaluate atezolizumab administered in combination with daratumumab and ascending-dose pomalidomide in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort has been completed.
2570278|NCT02431208|Active Comparator|Cohort F2: ATZ + DAR + POM (Expansion)|Cohort F2 will involve an expansion to evaluate atezolizumab administered in combination with daratumumab and the MTD of pomalidomide determined in Cohort F1 in participants with relapsed or refractory MM who have received 4 or more lines of prior treatment and are refractory to the last line of treatment. NOTE: This cohort is randomized.
2570279|NCT02431208|Active Comparator|Cohort F3: DAR + POM + Dexamethasone|Cohort F3 is an expansion control arm for cohort F2. Participants will receive daratumumab in combination with pomalidomide at the MTD and dexamethasone. NOTE: This cohort is randomized.
3208981|NCT00980070|Experimental|Positioning Device|use of positioning device
3208982|NCT00980070|Active Comparator|Control|institutional standard of care
2570445|NCT02430064|Experimental|Low PAMP diet then high PAMP diet|All subjects on study proceed from 7 days low PAMP diet to 4 days high PAMP diet
3208983|NCT00980083|Placebo Comparator|Placebo|
3208984|NCT00980083|Active Comparator|Exendin(9-39)|
2570539|NCT02429167|Experimental|PoNS Device|Cranial nerve non-invasive neuromodulation via PoNS device. The system delivers 19 V pulses to the tongue (a nominal 5.5 kilo-ohm load).
2570546|NCT02429167|Sham Comparator|Sham PoNS Device|The sham control device appears physically identical but uses a modified stimulus waveform parameter set designed to elicit a mild tactile sensation while minimizing the net energy delivered, thereby providing minimal, if any, cranial nerve non-invasive neuromodulation via PoNS device
2570620|NCT02429050|Active Comparator|intervention|sustained release morphine
2570625|NCT02429050|Placebo Comparator|control|placebo
2570675|NCT02428543|Experimental|Ponatinib arm|dose-escalation Arm _ 15, 30, 45mg Ponatinib per day. Each cohort will consist of 3 evaluable patients
3208985|NCT00980109|Placebo Comparator|placebo oseltamivir|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
3208986|NCT00980109|Active Comparator|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
3208987|NCT00980109|Placebo Comparator|placebo inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
2570984|NCT02426528|Experimental|Cultural and Social exposure A|Cultural and Social exposure
2570986|NCT02426528|No Intervention|Cultural and Social exposure B|Non Intervention (Control Group)
2571025|NCT02426294|Experimental|Pioglitazone|Pioglitazone is a Pioglitazone hydrochloride, and white circle-shaped tablet. It is administered once-daily with 15mg, with or without meals. The once-daily administration begins with 15mg, and if need increase, researchers can increase up to 30mg at week 12.
2571027|NCT02426294|Active Comparator|Glimepiride|The generic name of Glimepiride is Glimepiride, and it is a green snowman-shaped tablet. The once-daily administration begins with 2mg, and if need increase, researchers can increase up to 4mg at week 12.
2571081|NCT02425852|Active Comparator|Combination therapy arm|Infliximab 5 mg/kg plus Azathioprine 2-2.5 mg/kg/day. Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible to 2.5 mg/kg/d, or to 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake.
2571088|NCT02425852|Active Comparator|Azathioprine arm|"Intravenous steroids will be continue until day 2. Then, steroid therapy will be orally administered at a dose of 40-60 mg/day ou 1 mg/kg/day prednisolone (or equivalent) and progressively reduced by 10mg step every week to 20mg per day, and then reduced by 5mg step every week until stopped. Hydrocortisone intake to prevent steroid weaning will be authorized until supradrenal function normalization.~In patients with clinical response at day 7, Azathioprine will be introduced at day 5-7 and continued until week 52. Azathioprine dose regimen will be between 2 and 2.5 mg/kg/d, as close as possible of 2.5 mg/kg/d, or of 1.5 mg/kg/d for 6-mercaptopurine, in one daily intake."
2571167|NCT02425332|Experimental|Lokomat assessment|
2571215|NCT02425072|Experimental|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
2571291|NCT02424409|Active Comparator|1: Control|
2571292|NCT02424409|Experimental|2: Intervention|
3208988|NCT00980109|Active Comparator|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
2571427|NCT02423824|Active Comparator|Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
2571428|NCT02423824|Active Comparator|Non-Insulin Resistance|Adjunctive Liraglutide 1.2-1.8mg/day
2571459|NCT02423187||Arm 1|Participants with combination therapy (rabeprazole and low-dose aspirin)
3208989|NCT00980135|Experimental|Arm 1|
2571571|NCT02422732|Other|Children without reading disability|Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis.
3208990|NCT00980135|Experimental|Arm 2|
3208991|NCT00980135|Other|Arm 3|
3208992|NCT00980161||Peg-IFN + RBV with SVR|HCV patients receiving peginterferon alfa-2a and ribavirin with sustained virologic response
3208993|NCT00980161||Peg-IFN + RBV without SVR|HCV patients receiving peginterferon alfa-2a and ribavirin without sustained virologic response
3208994|NCT00980187|Active Comparator|Hydrochlorothiazide|
3208995|NCT00980187|Experimental|Indapamide SR|
3208996|NCT00980213||sunitinib|advanced renal cell cancer patients treated with sunitinib as first-line therapy
3208997|NCT00980239|Experimental|Group 1|Group 1 = Irinotecan + Bevacizumab
2570307|NCT02430974|No Intervention|Chemotherapy|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).
2570314|NCT02430974|Experimental|Chemotherapy & Icotinib|patients received four cycles of platinum-based doublet chemotherapy (150 mg/m2 paclitaxel plus 80 mg/m2 nedaplatin or 30mg/m2 lobaplatin on day one of a three-week cycle).Two weeks after chemotherapy completed, patients assigned to the consolidation therapy group began oral icotinib treatment (125 mg, thrice daily). Icotinib treatment continued for four to eight months, or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity.
2570369|NCT02430610|Experimental|IRE Group|irreversible electroporation for Unresectable Uterine Cervical Neoplasms
2570370|NCT02430610|No Intervention|Control|The patients without treatment
2570409|NCT02430181|Experimental|lonafarnib 200 mg BID|lonafarnib 200 mg BID; n=3
2570410|NCT02430181|Experimental|lonafarnib 300 mg BID|lonafarnib 300 mg BID; n=3
2570412|NCT02430181|Experimental|lonafarnib 100 mg TID|lonafarnib 100 mg TID; n=3
2570414|NCT02430181|Experimental|100 mg BID lonafarnib/PEG IFN-a|lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3
2570416|NCT02430181|Experimental|200 mg BID lonafarnib/PEG IFN-a|lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3
2570419|NCT02430181|Experimental|300 mg BID lonafarnib/PEG IFN-a|lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=3
2570423|NCT02430181|Experimental|lonafarnib/ritonavir|lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3
2570479|NCT02429830|Other|Single arm study|Previous LSG patient will be treated with the LINX device and serve as their own control
2570559|NCT02429388|Experimental|High dose spironolactone|This arm of the study will include addition of high dose spironolactone upto 100mg twice daily in adjunct to usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
2570561|NCT02429388|No Intervention|Usual Care|This arm of the study will continue the usual care of hospitalized acute decompensated heart failure patients with loop diuretics.
2570631|NCT02428881|Experimental|Complete retention- onabotulinumtoxinA|Women in complete urinary retention receiving onabotulinumtoxinA
2570633|NCT02428881|Experimental|Obstructed voiding- onabotulinumtoxinA|Women with obstructed voiding receiving onabotulinumtoxinA
2570639|NCT02428517||Young/MSD|Patients who are <55 years old, and will receive alloHCT for Young/MSD
2570640|NCT02428517||Young/MUD&FMD|Patients who are <55 years old, and will receive alloHCT for Young/MUD&FMD
2570644|NCT02428517||Old/MSD|Patients who are >=55 years old, and will receive alloHCT for Old/MSD
2570647|NCT02428517||Old/MUD&FMD|Patients who are >=55 years old, and will receive alloHCT for Old/MUD&FMD
3208998|NCT00980239|Experimental|Group 2|Group 2 = Irinotecan, Bevacizumab + Oxaliplatin
3208999|NCT00980239|Experimental|Group 3|Group 3 = Irinotecan, Bevacizumab + Cetuximab
3209000|NCT00980252|Experimental|CBT|UK-based intervention
2570961|NCT02426762|Experimental|Sealant skin closure|A quick skin sealant would be applied after laparoscopic surgery. All abdominal wounds are sealed by smearing the quick sealant (skin adhesive) twice. No additional gauges should be appended on wound areas. No further wound care should be applied unless any effusion or bleeding emerged around it.
2571008|NCT02426281|Experimental|nab-paclitaxel in combination with gemcitabine|nab-paclitaxel in combination with gemcitabine nab- paclitaxel 125mg/m2 in combination with gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
2571060|NCT02425995|Experimental|Arthroscopic intercondylar and posteromedial portal|
2571085|NCT02425722|Experimental|ASP0456 0.0625mg|oral
2571089|NCT02425722|Experimental|ASP0456 0.125mg|oral
2571092|NCT02425722|Experimental|ASP0456 0.25mg|oral
2571097|NCT02425722|Experimental|ASP0456 0.5mg|oral
2571098|NCT02425722|Placebo Comparator|Placebo group|oral
2571193|NCT02425059|Experimental|IRE Group|irreversible electroporation for Unresectable Rectal Neoplasms
2571199|NCT02425059|No Intervention|Control|The patients without treatment
2571236|NCT02424838|Active Comparator|22 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle using suction.
2571237|NCT02424838|Active Comparator|22 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 22 gauge needle without suction.
2571238|NCT02424838|Active Comparator|25 gauge with suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle using suction.
2571239|NCT02424838|Active Comparator|25 gauge without suction|EUS-FNA of pancreatic masses will be performed with a 25 gauge needle without suction.
2571266|NCT02424513|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
2571340|NCT02424006|Experimental|RHCIII-MPC cornea|Patients of this arm will undergo RHCIII-MPC bioengineered cornea transplantation using anterior lamellar keratoplasty technique
2571341|NCT02424006|Active Comparator|Donor cornea|Patients of this arm will undergo human donor cornea transplantation using anterior lamellar keratoplasty technique
2571383|NCT02423772|Experimental|Intervention|Treatment as usual, plus 12 weeks of group based intervention to improve functioning and decrease problematic effects of opioid use.
2571385|NCT02423772|No Intervention|Treatment as Usual|
2571401|NCT02423486|Experimental|Electromagnetic stimulation therapy|Electromagnetic stimulation therapy group
2571402|NCT02423486|Experimental|Electromagnetic stimulation therapy with biofeedback|Electromagnetic stimulation therapy with biofeedback group
2571434|NCT02423330|Experimental|Strattice-LIFT|
3209001|NCT00980304|Experimental|Rituximab in combination with ICE as salvage therapy|
3209002|NCT00980356|Active Comparator|Vildagliptin, 50 mg, peroral|
2571568|NCT02422732|Other|Children with reading disability|Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
3209003|NCT00980356|Placebo Comparator|Placebo pill|
3209004|NCT00980369||Chronic anal fissures|Group A: with vertical incision Group B: with parallel incision
3209005|NCT00980369||Parallel incision, vertical insicion|
3209006|NCT00980408|Placebo Comparator|Sugar pill, behavioral glutamic acid|Placebo condition for D-Cycloserine
2570470|NCT02430116|Experimental|I-postC group|The procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
2570502|NCT02429648|Active Comparator|PVI performed in Normal Sinus Rhythm|DCC first then PVI
2570509|NCT02429648|Active Comparator|PVI performed in Atrial Fibrillation|PVI then DCC after if patient remains in Atrial Fibrillation
2570579|NCT02429401|Experimental|Culturally adapted brief intervention|
2570583|NCT02429401|Active Comparator|Non-adapted brief intervention|
2570604|NCT02428790||ABI Patients|Patients with acquired brain injury.
2570769|NCT02427906||TIPS group|patients who have transjugular intrahepatic portosystemic shunt
2570771|NCT02427906||Non-TIPS group|patients who have endoscopic variceal ligation
2570897|NCT02427178|Experimental|Open label|"Hematopoietic allogeneic stem cells will be transplanted:~HLA testing will be performed on potential stem cell donors. HLA 10/10 matched donors are eligible, however there are additional criteria that will be applied to determine an acceptable donor. Patients will receive 2 X10 6 CD34 cells/kg weight."
2570933|NCT02426684|Experimental|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
2570996|NCT02426424|Experimental|Investigatory 1|The sleep study will be performed via Watchpat during the index hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP both during the hospital stay and after discharge for three months.
2570998|NCT02426424|Experimental|Investigatory 2|The sleep study will be performed via Watchpat at home three months after hospitalization with acute stroke. Following the diagnosis of sleep apnea, patients will be treated with C-PAP for three months.
2571047|NCT02426073||HE|Healthy elderlies
2571049|NCT02426073||DM|Elderlies with type 2 diabetes
2571050|NCT02426073||SA|Elderlies with sarcopenia
2571051|NCT02426073||DS|Elderlies with both type 2 diabetes and sarcopenia
2571082|NCT02425761|Active Comparator|Anterior Entry SIte|"Anterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the coronal suture, on the top of the head and near the front. Specifically, anterior entry is defined as ventricular catheter entry less than 1 centimeter anterior to the coronal suture near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using an anterior entry site."
2571087|NCT02425761|Active Comparator|Posterior Entry Site|"Posterior entry site is defined as shunt surgery with catheter entry into the brain from an opening near the lambdoid suture, on the back of the head. Specifically, posterior entry is defined as ventricular catheter entry 4 to 7 centimeters above the external occipital protuberance (inion), near the mid-pupillary line.~Subjects randomized to this arm will undergo ventriculoperitoneal shunt insertion surgery using a posterior entry site."
2571147|NCT02425475||Mole|Patients with suspicious moles
2571182|NCT02425189||LQT Positive (Group 1)|"Gene-positive LQTS patients~Gene negative LQTS patients with confirmed phenotypic diagnosis of LQTS (Schwartz score ≥4)"
2571183|NCT02425189||Asyptomatic Patients (Group 2)|Asymptomatic patients, those free of syncope on beta blocker, or gene negative unaffected family members
2571228|NCT02424942|Experimental|GZ389988|Single intraarticular injection of GZ389988 in the knee joint
2571230|NCT02424942|Placebo Comparator|Placebo|Single intraarticular injection of placebo for GZ389988 in the knee joint
3175216|NCT00631436||4|Individuals not exposed to blast with PCL scores below 30 will be invited to participate as members of the No Blast + No PTSD group.
3175217|NCT00631462|Experimental|1|
3175218|NCT00631501|Placebo Comparator|2|
3175219|NCT00631501|Experimental|Doxycycline|100 mg twice daily
2571314|NCT02424214|Experimental|Ca Ionophore group|Artificial Oocyte activation with Ca Ionophore for 20 min after Intracytoplasmic Sperm Injection
2571321|NCT02424214|Experimental|Strontium Chloride group|Artificial Oocyte activation with Strontium Chloride for 60 min after Intracytoplasmic Sperm Injection
2571326|NCT02424214|No Intervention|Only Intracytoplasmic Sperm Injection|after Intracytoplasmic Sperm Injection Oocytes will cultured and incubated
2571373|NCT02423889|Experimental|1|Stereotactic radiotherapy with a total dose of 36.25 Gy in 5 fractions (7.25 Gy per fraction, 2 fractions per week) in low risk prostate cancer patients is delivered to evaluate acute and subacute toxicty
3175220|NCT00631514|No Intervention|1|Hypertensive persons taking either lisinopril/hydrochlorothiazide fixed combination or amlodipine all the time.
3175221|NCT00631514|Experimental|2|Intervention: NSAID. Hypertensives with osteoarthritis taking already amlodipine (5-10 mg o.d. per os) were randomized to the following drug interventions: to take either acetaminophen (1000 mg t.i.d. per os), piroxicam (10-20 mg o.d. per os) or ibuprofen (400-600 mg t.i.d. per os) for 1 month
3175222|NCT00631514|Experimental|3|Hypertensives with osteoarthritis taking already lisinopril/hydrochlorothiazide (20/12.5 mg o.d. per os), were sequentially randomized to the following drug interventions: acetaminophen (1000 mg t.i.d.), ibuprofen (400-600 mg t.i.d.) or piroxicam (10-20 mg o.d.), for 1 month each
3175223|NCT00631527|Experimental|Sunitinib Malate, Hormone Ablation + RT|Sunitinib Malate + Hormone Ablation (Leuprolide or Goserelin + Bicalutamide) + Radiation Therapy (RT)
3175224|NCT00631592|Other|GSK1349572|GSK1349572
3175225|NCT00631605||1|
3175226|NCT00631605||2|
3175227|NCT00631618|Experimental|Suntinib|Suntinib
3175228|NCT00631631||Mifamurtide (L-MTP-PE)|Mifamurtide (L-MTP-PE), intravenous, at a dose of 2 mg/m^2 twice weekly (at least 3 days apart) for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks.
3175229|NCT00631683||MICU-1|Mechanically ventilated patients who are about to start a weaning trial at the medical intensive care unit of Memorial Hermann Hospital.
3175230|NCT00631709|Experimental|1|Pacemaker Patients
3175231|NCT00631722|Experimental|A|
3175232|NCT00631722|Active Comparator|B|
3175233|NCT00631761|Experimental|1|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas of the human bladder.
3175234|NCT00631761|Placebo Comparator|2|The control group will be instructed to read a urethrocystoscopy textbook chapter at home
3175235|NCT00631774|Active Comparator|1|a meal replacement program with Glucerna SR on top of the exchange-diet plan
3175236|NCT00631774|Active Comparator|2|an caloric-matched exchange-diet plan only.
3175237|NCT00631800|Placebo Comparator|Placebo|Placebo
2570626|NCT02428972|Experimental|intravenous anesthesia|propofol infusion @ 100-200 mcg/kg/min for maintenance of anesthesia
2570628|NCT02428972|Active Comparator|inhalational anesthesia|sevoflurane MAC between 0.8-1.2 for maintenance of anesthesia
2570666|NCT02428504||End of life decision|
2570715|NCT02428218|Experimental|BG00012|Participants will receive 120 mg capsule(s) BG00012 taken orally.
2570716|NCT02428218|Experimental|Placebo|Participants will receive matching placebo capsule(s) taken orally.
2570759|NCT02427893|Active Comparator|Cohort 1|Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib.
2570765|NCT02427893|Active Comparator|Cohort 2|Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
2570805|NCT02427503||Asthma with NP and require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will undergo FESS-BP.
2570806|NCT02427503||Asthma with NP and NOT require surgery|Patients receiving standardized treatment for nasal polyposis, according to the POLINA guidelines and for persistent asthma who will NOT undergo FESS-BP.
2570849|NCT02427269||Barrett's Esophagus (BE) Surveillance|Patients who have never received ablative therapy for Barrett's Esophagus and are receiving routine care surveillance upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
2570850|NCT02427269||Barrett's Esophagus (BE) Pre-Ablation|Patients who are receiving routine care upper endoscopy with ablative therapy for their Barrett's Esophagus for the first time. Subjects will have esophageal biopsies, blood, and data collected for this study.
2570853|NCT02427269||Barrett's Esophagus (BE) Post-Ablation|Patients with a history of Barrett's Esophagus who are status post ablation and are receiving routine care follow-up EGD for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
2570857|NCT02427269||Esophageal Cancer(ECA/IMC)|Patients with esophageal cancer who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
2570861|NCT02427269||Squamous Cell Carcinoma (SCC)|Patients with squamous cell cancer of the esophagus who are receiving routine care upper endoscopy for their condition. Subjects will have esophageal biopsies, blood, and data collected for this study.
2570900|NCT02426905|No Intervention|Retrospective|
2570903|NCT02426905|Other|Prospective|
2570988|NCT02426515|Experimental|Hilotherm® Device|Patients undergo removal of lower third molar with Hilotherm® cooling device applied.
2570991|NCT02426515|No Intervention|Control|Patients undergo removal of lower third molar without the Hilotherm® cooling device applied.
2571014|NCT02426203||Pulmonary Endarterectomy patients|Patients undergoing pulmonary endarterectomy surgery at Papworth Hospital
2571065|NCT02426034|Experimental|Treatment group|Apatinib Tablets
2571104|NCT02425696||group 1|Normal individuals without migraine
2571106|NCT02425696||group 2|Migraineurs
2571158|NCT02425501||Aflibercept (Eylea,BAY86-5321)|Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert
2571208|NCT02425202|Active Comparator|Ketamine infusion|Ketamine infusion at 0.1 mg/kg/hr up to maximum of 10 mg/hr
2571211|NCT02425202|Placebo Comparator|Saline infusion|Saline infusion
2571251|NCT02424669|Experimental|recently diagnosed ALS patients|
2571252|NCT02424669|Experimental|not recently diagnosed ALS patients|
2571253|NCT02424669|Active Comparator|patients with peripheral neuropathy, recently diagnosed|
2571298|NCT02424292||Physical activity|Physical activity in a personalised program
2571352|NCT02424084|Experimental|Intact scaphoid bone|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have an intact scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2571353|NCT02424084|Experimental|Intact metacarpal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2571354|NCT02424084|Experimental|Fractured scaphoid bone|"Group C (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured scaphoid.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2571357|NCT02424084|Experimental|Fractured metacarpal bone|"Group D (n=20): Consent-capable male and female patients ≥18 years of age who have a fractured metacarpal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2571668|NCT02421861|Placebo Comparator|Usual Care (UC)|
3175238|NCT00631800|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 7, 14
3175239|NCT00631800|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 7, 14
3175240|NCT00631813|Active Comparator|1|Prucalopride 0.5 mg
3175241|NCT00631813|Active Comparator|2|Prucalopride 1 mg
3175242|NCT00631813|Active Comparator|3|Prucalopride 2 mg
3175243|NCT00631813|Placebo Comparator|4|
3175244|NCT00631839||1|There is only one group in this study. The patients of this group will go through procedures as follow: basic pre-treatment information collected,treatment include platinum-based chemotherapy and 3-D conformal radiotherapy, blood test during RT 6am every Monday and follow-up visits with treatment-induced injury assessed.
3175245|NCT00631865|Experimental|cell transplantation group|Epidermal Cell transplantation in patients with vitiligo
3175246|NCT00631878|Placebo Comparator|Placebo|
3175247|NCT00631878|Experimental|10 mg/kg|10 mg/kg was given on Days 0, 14
3175248|NCT00631878|Experimental|30 mg/kg|30 mg/kg was given on Days 0, 14
3175249|NCT00631878|Experimental|60 mg/kg|60 mg/kg was given on Days 0, 14
3175250|NCT00631878|Experimental|90 mg/kg|90 mg/kg was given on Days 0, 14
3175251|NCT00631904||Single Observation|Patients with permanent pacemakers undergoing medically indicated MRI scanning.
3175252|NCT00631943|Experimental|1|
3175253|NCT00631982|Experimental|Group I|patients with PCO undergoing in vitro maturation and subsequently IVF and embryo transfer
2570535|NCT02429544|Experimental|Standard Support Group (SSG) - Residential Program|"Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.~Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
2570536|NCT02429544|Other|Standard of Care Group (SOC) - No Residential Program|"Questionnaires completed at baseline visit, 1 month after baseline. EEG performed with simultaneous computer testing. Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.~Questionnaires and testing repeated 7 days after the residential program ends, and then again about 3 months later."
3209007|NCT00980408|Placebo Comparator|Sugar pill, fMRI, glutamic acid|Placebo condition for D-Cycloserine, fMRI
3209008|NCT00980408|Placebo Comparator|Sugar pill, memantine, behavioral|Placebo condition Memantine, behavioral
3209009|NCT00980408|Placebo Comparator|Sugar pill, memantine, fMRI|Placebo condition Memantine, fMRI
2570652|NCT02428712|Experimental|PLX8394|"Group A: Phase 1-Dose Escalation: Adult patients.~Phase 2a-RP2D Confirmation/Redefinition (Formulation 2): Adult and adolescent patients.~Phase 2a-Dose Extension: Adult and adolescent patients with advanced unresectable solid tumors will be enrolled among two cohorts.~Cohort 1: Activating BRAF V600 mutations (glioma patients only)~Cohort 2: Activating BRAF non-V600 mutations"
3209010|NCT00980408|Active Comparator|D-Cycloserine behavioral|
3209011|NCT00980408|Active Comparator|D-Cycloserine, fMRI|
2570911|NCT02426957|Experimental|Motivational Enhancement Therapy|The 60-90 minute intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets. Personalized feedback for the intervention will be derived from the assessment battery and will be provided in both written and graphic formats. In addition to the 60-90 minute MI intervention delivered to the adolescent, a 30-45 minute intervention will be conducted with the adolescent and parent(s) the following day, in which the adolescent will review the goals, strategies, and change plan worksheets with the parent(s), facilitated by the therapist.
2570912|NCT02426957|No Intervention|Treatment As Usual|Treatment As Usual on inpatient psychiatric unit
2570928|NCT02426606|Experimental|White bread|
2570931|NCT02426606|Experimental|Lentil 1 + white rice|
2570934|NCT02426606|Experimental|Lentil 2 + white rice|
2570942|NCT02426606|Experimental|Lentil 3 + white rice|
2570948|NCT02426606|Experimental|White rice|
2570951|NCT02426606|Experimental|Lentil 1 + potato|
2570954|NCT02426606|Experimental|Lentil 2 + potato|
2570956|NCT02426606|Experimental|Lentil 3 + potato|
2570959|NCT02426606|Experimental|Potato|
2571033|NCT02426242||ICU PATIENTS|Patients with brain-injury
2571096|NCT02425839|Experimental|Experimental group|"ultrasound exam by Supersonic Shear Imaging® technique~EMG examination by electromyograph Keypoint system."
2571120|NCT02425540||patients with unclassified ovarian mass|
2571162|NCT02425345|Experimental|Physical Activity Intervention|The Physical Activity Intervention Group will receive guidance on being physically active, including aerobics, flexibility, balance, strength, and decreased sedentary time. The primary resource is the National Institute of Aging Go4Life exercise and physical activity materials. The materials are based on the United States national guidelines for physical activity for older adults
2571166|NCT02425345|No Intervention|Usual Activity Control|Usual activity
3209012|NCT00980408|Active Comparator|Memantine, behavioral|
2571334|NCT02424162|Experimental|2.75 group|Patients with 2.75 diopters multifocal intraocular lens
2571335|NCT02424162|Active Comparator|3.25 group|Patients with +3.25 diopters multifocal intraocular lens
2571377|NCT02423863|Experimental|Hiltonol Poly-ICLC|"Open labeled, non randomized adaptive 2-stage design protocol. 21 study subjects were enrolled in stage I of the protocol. Up to an additional 60 patients. . Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.~For purposes of analysis patients enrolled in Stage II of this study will be prospectively identified at initial screening as belonging to statistical Cohorts A, B, or C, which are based on patient status with regard to aPD1/aPDL1 therapy at study entry, (PD, SD, or treatment naïve). For purposes of this study, patient status is considered to be the primary eligibility variable, although sub analyses will also consider histology and particular checkpoint blocker used when possible."
2571398|NCT02423538|Experimental|single ascending doses|single ascending doses, oral tablets
2571399|NCT02423538|Placebo Comparator|Placebo|Placebo Comparator, oral tablets
3209013|NCT00980408|Active Comparator|Memantine, fMRI|
3209014|NCT00980421|Experimental|IT|Iron Tablet group (12.5 mg/d) + Placebo Biscuit
3209015|NCT00980421|Experimental|IZ|Iron (12.5mg/d)+Zinc (10 mg/d) Tablet Group + Placebo Biscuit
3209016|NCT00980421|Experimental|IB|Iron Fortified Biscuit Group(12.5 mg/d)+ Placebo Tablet
3209017|NCT00980421|Placebo Comparator|CO|Placebo Tablet + Placebo Biscuit
3209018|NCT00980434||1|patients with neurological symptoms
3209019|NCT00980434||2|patients without neurological symptoms
3209020|NCT00980447|Experimental|UMN-0501 45µg|Recombinant H5N1 vaccine 45µg
3209021|NCT00980447|Experimental|UMN-0501 90µg|Recombinant H5N1 vaccine 90µg
3209022|NCT00980447|Experimental|UMN-0501 135µg|Recombinant H5N1 vaccine 135µg
3258959|NCT01466140|No Intervention|Control group|Patients in the control group were asked to participate in a patient satisfaction study. They were asked to fill in a questionnaire with respect to patient satisfaction.
3260203|NCT01477281|Active Comparator|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
2570538|NCT02429180|Experimental|Rehabilitation training|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
2570543|NCT02429180|No Intervention|Control|Control: treatment as usual plus receipt of a UK Stroke Association booklet on exercise after stroke.
2570622|NCT02429076|Experimental|Propofol|Subjects in this arm will receive propofol general anesthesia
2570627|NCT02429076|Experimental|Sevoflurane|Subjects in this arm will receive sevoflurane general anesthesia
2570686|NCT02428452|Experimental|Treatment|Six-month Social ABCs parent-training program received immediately
2570691|NCT02428452|No Intervention|Control|Participants randomized to the Control group do not receive the Social ABCs parent training program for the 6-month control phase. Control participants may access other approved community services as outlined in the study protocol and consent during the Control Phase, which is considered 'treatment as usual'. After the 6-month Control Phase, participants are offered the Social ABCs parent training program.
2570724|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 1|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
2570732|NCT02428036|Experimental|TBI-1401(HF10) - Cohort 2|Oncolytic virotherapy, intratumoral administrations of TBI-1401(HF10)
2570779|NCT02427776|Experimental|IMP|
2570830|NCT02427464|Experimental|VM202|"Subjects randomized to the VM202 treatment arm will receive the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 / calf~Day 14 - 16 injections of 0.5mL of VM202 / calf~Day 90 - 16 injections of 0.5mL of VM202 / calf~Day 104 - 16 injections of 0.5mL of VM202 / calf"
2570832|NCT02427464|Placebo Comparator|Placebo|"Subjects in the placebo control group will receive the following intramuscular injections in each calf:~Day 0 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 14 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 90 - 16 injections of 0.5mL of VM202 vehicle / calf~Day 104 - 16 injections of 0.5mL of VM202 vehicle / calf"
2570893|NCT02427048|No Intervention|Pre-Intervention|Delayed feedback and peer comparison
2570895|NCT02427048|Experimental|Feedback with Peer Comparison|Individualized adherence feedback with peer comparison
2570964|NCT02426736|Active Comparator|Low dose intravenous dexamethasone|4 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2570966|NCT02426736|Active Comparator|High dose intravenous dexamethasone|8 milligrams dexamethasone administered once intravenously with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2570971|NCT02426736|Active Comparator|Low dose perineurial dexamethasone|4 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2570977|NCT02426736|Active Comparator|High dose perineurial dexamethasone|8 milligrams dexamethasone administered once perineurally with a 30 millilitres 0.5% bupivacaine interscalene brachial plexus block
2571001|NCT02426190|Active Comparator|Arm 1|Patients in Arm 1 receive standard of care rehabilitation protocol using a recumbent or Nu-step bike during warm-up, followed by individualized therapeutic exercise, and cool-down protocols. The warm-up phase in the study refers to therapeutic exercise. The therapeutic exercise aims to condition and prepare patients for subsequent functional or therapeutic activities. The active comparator (Arm 1) is to ask participants to use modalities, such as a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
2571004|NCT02426190|Experimental|Arm 2|Patients in Arm 2 will use an anti-gravity treadmill (AlterG) during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
2571006|NCT02426190|Experimental|Arm 3|Patients in Arm 3 will use a recumbent or Nu-step bike along with the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
2571007|NCT02426190|Experimental|Arm 4|Patients in Arm 4 will use both an anti-gravity treadmill (AlterG) and the PENS neuromuscular stimulation modality during warm-up, followed by individualized therapeutic exercise and cool-down protocols.
2571045|NCT02425969|Experimental|Optimal Medical Therapy|Patients will receive secondary prevention and optimal medical therapy to control their anginal symptoms according to international guidelines without PCI of their grey-zone FFR lesion
2571048|NCT02425969|Active Comparator|PCI with Optimal Medical Therapy|Patients will undergo PCI of their grey-zone FFR lesion as well as appropriate secondary prevention. Anti-anginal therapy will be administered as per clinical requirements according to international guidelines.
2571083|NCT02425735|Experimental|Group A|DC-CIK cells will be used against tumor cells.
2571086|NCT02425735|Experimental|Group B|γδ T cells will be used against tumor cells.
2571090|NCT02425735|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
2571122|NCT02425527|Experimental|The rehabilitation gaming|The rehabilitation gaming group (n=30) will use an internet browser-based digital brain training program CogniFit (https://www.cognifit.com), with a selection of about 33 games.The participants will use the rehabilitation gaming for at least 30 min per day over a period of 8 weeks.
2571123|NCT02425527|Active Comparator|The entertaining gaming|The entertaining gaming group (n = 30) will use commercial digital games with Sony Playstation 3 (PS3) consoles, played with wireless Sony DualShock gamepad controllers. The participants will be guided to play the console for at least 30 min per day over a period of 8 weeks
2571125|NCT02425527|No Intervention|"Do-nothing"|"The passive control group Do-nothing group (n = 30) will not have gaming activities organized by the project."
2571175|NCT02425319||patients with CapFlex-PIP© implant|
2571176|NCT02425319||patients with silicone implant|
2571177|NCT02425319||patients with healthy PIP joints|
2571197|NCT02425033|Experimental|Intervention|Patients undergoing POEM for spastic esophageal disorders such as achalasia at the University Health Network, Toronto, Canada
2571262|NCT02424643|No Intervention|No Incentive|Participants in this arm will receive no compensation for taking the online survey.
3260204|NCT01477294|Experimental|Caffeine|Intervention with Caffeine in a random order
2570784|NCT02427594|Experimental|Controlled diet first|In this arm participants will first consume a controlled diet plus added table salt (sodium chloride) for one week. They will then consume an identical controlled diet plus sodium bicarbonate for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
2570790|NCT02427594|Experimental|Sodium bicarbonate first|In this arm participants will first consume a controlled diet plus sodium bicarbonate for one week. They will then consume an identical controlled diet plus added table salt (sodium chloride) for one week. Sodium bicarbonate will be dosed as 2,600 mg divided three times daily if ideal body weight is <70 kg or 3,250 mg divided three times daily if ideal body weight is ≥70 kg. Added table salt will match the sodium content of the sodium bicarbonate dose (i.e. 31 or 39 mEq/day).
2570837|NCT02427282|Active Comparator|MS. Frog|miniscrew-supported frog molar distalizing appliance
2570838|NCT02427282|Experimental|Stand. Frog|Standard Frog appliance
2570906|NCT02427074|Active Comparator|Balloon Compression Rhizotomy|Patients that are submitted to Balloon Compression Rhizotomy
2570907|NCT02427074|Active Comparator|Radiofrequency Thermal Coagulation Rhizotomy|Patients that are submitted to Radiofrequency Thermal Coagulation Rhizotomy
2570981|NCT02426593||Subjects without heart failure|
2571029|NCT02426320|Active Comparator|Sedation Interruption Protocol + standard sedation protocol|Nurse directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
2571031|NCT02426320|Active Comparator|Standard sedation protocol|Nurse directed protocol for administering sedation and/or analgesia.
2571100|NCT02425930||C3 Depletion|Patients with persistent low-level of complement C3 within the perioperative period would be assigned into this main observational group. After a careful multidisciplinary treatment (MDT) discussion, a radical operation with gastrectomy plus D2 lymphadenectomy would be performed, followed by an adjuvant chemotherapy if required. Generally, SOX chemo regimen (S-1+Oxaliplatin) would be first considered for the candidates.
2571101|NCT02425930||Non-C3 depletion|Patients with normal plasma values of complement C3 within the perioperative period would be assigned into this control group. Those patients would undergo the same decision making process to determine the final treatment plan.
2571128|NCT02425488|Experimental|Nursing therapeutics education|People who are educated by the nurse (Behavioral intervention: Nursing therapeutics education) and follow all the program (12 months)
2571133|NCT02425488|No Intervention|Non NET|People who receive basic information without follow the educational program but clinically controlled
2571258|NCT02424890|Active Comparator|Repetitive Sim Group|9 simulation sessions
2571260|NCT02424890|Active Comparator|Control Group|3 simulation sessions
2571331|NCT02424435|Experimental|Methylprednisolone|This is an open-label study of methylprednisolone in patients with FRDA. Subjects will begin oral administration of 48 mg methylprednisolone at day 1 and will decrease their administered dose by 8 mg per day. After 6 days, subjects will spend 22 days off medication before repeating the same treatment cycle. Last dosing cycle of methylprednisolone will be administered at 24 weeks after baseline. Visits will occur at weeks 2, 6, 14, 26, and 30 following baseline.
2571355|NCT02423928|Experimental|Cryoimmunotherapy|"Patients with castration resistant prostate cancer and imaging proven metastases will be treated by autologous dendritic cell based cryoimmunotherapy of the prostatic tumor tissue assisted by immunomodulation consisting of low-dose metronomic cyclophosphamide for all patients plus ipilimumab for the latter half of all patients.~Update January 2019: The protocol was changed as approved by the Norwegian Medicines Agency and the Regional Ethical Committee in Western Norway for the 3 last patients of altogether 18 patients. Consequently, the 3 last patients received 200 mg i.v. of pembrolizumab (and no ipilimumab) post-CryoIT."
2571405|NCT02423642|Experimental|AKI requring CRRT and use regional citrate anticoagulation|CRRT use regional citrate anticoagulation
2571409|NCT02423642|Experimental|AKI requring CRRT and not use regional citrate anticoagulation|CRRT not use regional citrate anticoagulation
3175254|NCT00631995|Experimental|Group 1|
3175255|NCT00631995|Experimental|Group 2|
2571756|NCT02421328|Active Comparator|CPAP first|Infant will be given nasal CPAP for 60 minutes and then put on HHHFNC for another 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on nasal CPAP and HHHFNC. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
2571758|NCT02421328|Active Comparator|HHHFNC first|Infant will be given HHHFNC for 60 minutes and then switched to nasal CPAP for another 30 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of the 60 minute periods on HHHFNC and nasal CPAP. After the 2 h study period (2×60 minutes epochs) further respiratory support will be at the discretion of the clinical team
2572098|NCT02419131|Active Comparator|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
3175256|NCT00631995|Experimental|Group 3|
3175257|NCT00631995|Experimental|Group 4|
3175258|NCT00631995|Experimental|Group 5|
3175259|NCT00631995|Active Comparator|Group 6|
3175260|NCT00632008|Experimental|1|SBG
3175261|NCT00632008|Placebo Comparator|2|
3175262|NCT00632034|Experimental|1|
3175263|NCT00632060|No Intervention|1|Standard Care Control Group - Participants randomized to the standard care group will continue their use of non-prescription or prescription medication and reduced duty loads, as prescribed by the credentialed medical provider.
3175264|NCT00632060|Experimental|2|Manual / Manipulative Therapy Group: Participants randomized to the M/MT group will receive a course of M/MT along with standard care. The patient will see the chiropractor twice a week for the entire course of the study, regardless of manipulation or not.
3175265|NCT00632073|Experimental|VCV + Failing HAART|Vicriviroc plus failing highly-active antiretroviral therapy
3175266|NCT00632086|Experimental|1|Single oral dose of 325 mg aspirin administered as PA32540
3175267|NCT00632086|Experimental|2|aspirin core
3175268|NCT00632086|Active Comparator|3|active
3175269|NCT00632164||1|Cervical adjustments
3175270|NCT00632164||2|Thoracic adjustments
2570719|NCT02428205|Experimental|Propranolol arm|Propranolol will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session. To minimize risk, the bodyweight adjusted minimum dose of propranolol used safely for test anxiety in healthy adults (10mg) will be used: participants weighing > 30 kg will be given 4 mg, participants weighing 22.5 - 30 kg will be given 3 mg, participants weighing 15 - 22.5 kg will be given 2 mg. Participants weighing < 15 kg will be excluded for safety reasons.
2570730|NCT02428205|Placebo Comparator|Placebo arm|Placebo will be administered in the form of a liquid dose via oral syringe by the participants' parent/caregiver an hour before each EIBI session.The same bodyweight adjusted doses specified in the propranolol arm will be used for this arm.
2570888|NCT02427139|Experimental|ANSiStim|"The ANSiStim device is designed to administer auricular point stimulation treatment over several days. The advantage of using the ear for this treatment is that it provides numerous points for stimulation within a small area. Stimulation is performed by electrical pulses emitted through strategically positioned needles.~Three zinc air batteries with 1.4 V provide the required stimulation energy for 96 hours. This constant current source guarantees equivalent stimulation energy regardless of the individual impedance of the skin. The treatment period varies based on the severity of the pain. To minimize the risk of adaption or tolerance to the electrical stimulation, it is applied for 3 hours, followed by a pause of 3 hours."
2570935|NCT02426801|No Intervention|Control|Patients in this arm were given no intervention. Their self-reported medication adherence was assessed at the baseline (week 0) and follow-up (week 12) visits but during the study period they did not receive any intervention.
2570939|NCT02426801|Sham Comparator|Medication Sensor Only|"These patients received the medication use sensor (sham intervention) and downloaded a sham version of the mobile app. Thus, the medication use from these patients was able to be recorded but the patients did not receive reminders or incentives or the ability to see their medication use via the real mobile app.~Intervention: inhaler sensor"
2570944|NCT02426801|Experimental|Medication Sensor and Mobile App|"These patients received the medication use sensor and the mobile app with reminders (intervention arm).~Interventions: inhaler sensor and mobile application for asthma adherence"
2571002|NCT02426385||1POD26PFT|Patients implanted with the POD 26% FineVision Toric
2571005|NCT02426385||2POD26PT|Patients implanted with the POD 26% Toric
3260205|NCT01477294|Placebo Comparator|Placebo|Placebo (malt dextrin) administered in a random order
3260206|NCT01477307||hypocaloric diet|The included patients are assigned to a hypocaloric standardized diet for 3 weeks.
2571234|NCT02424903||with prosthetic joint infection|Patients admitted for a septic revision surgery
2571235|NCT02424903||without prosthetic joint infection|Patients admitted for an aseptic revision surgery
3260207|NCT01477346|Other|Nurse intervention|Nurse led package of care based on current recommended best practice.
3260208|NCT01477346|Other|Standard care|Continuing standard general practitioner led care
2571297|NCT02424318|Experimental|Topiramate|topiramate 25mg twice for 1 week -> topiramate 50mg twice for 7 weeks
2571339|NCT02424123||The study population|The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).
2571432|NCT02423395|Experimental|Orphenadrine(Norflex)|50 patients will be treated with orphenadrine 100 mg twice daily for 1 month
2571433|NCT02423395|Placebo Comparator|Placebo|50 patients will be given placebo
2571505|NCT02423096||Schizophrenia|Patients with schizophrenia will be treated with antipsychotic drugs as routine care (i.e., risperidone, haloperidol, sulpiride, olanzapine, quetiapine).
2571512|NCT02423096||Healthy controls|No special intervention will be provided for healthy controls.
2571562|NCT02422485|Experimental|Salsalate|All participants will be administered 2,250 mg daily [1,500 mg every day before noon (every AM) and 750 mg every night at bedtime (every HS)] for 6 months.
2571664|NCT02421913|Active Comparator|S(+)-ketamine group (SG)|Five minutes before surgery, patients in the SG group received an intravenous continuous infusion containing 0.3 mg.kg-1.h-1 of S(+)-ketamine
2571665|NCT02421913|Placebo Comparator|placebo group (PG)|PG received the same dose of saline.
2571690|NCT02421679|Experimental|TNX-102 SL|TNX-102 SL taken daily at bedtime for 12 weeks
2571839|NCT02421367|Experimental|TDENV-PIV (0-1)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168."
2571840|NCT02421367|Experimental|TDENV-PIV (0-1-6)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84."
2570731|NCT02428062|Experimental|Treatment|The anesthesiologist will have as hemodynamic target for patients assigned to this arm the maintenance of mean arterial blood pressure within 10% of the baseline blood pressure value (recorded at the preoperative evaluation). The strategy to reach this hemodynamic target will be left to the clinical judgment of the anaesthesiologist in charge. The possible strategies include a vasoconstrictor agent (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine), intravenous fluids, patient's positioning or reduction of depth of anesthesia.
2570738|NCT02428062|No Intervention|Control|"Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the Standard-of-Care and Treatment arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence."
3175271|NCT00632242|Experimental|TTP Remission Cohort 1|Patients will receive a total dose of 0.47 mg/kg of ARC1779 over 4 hours to achieve a target plasma concentration of 6 mcg/mL
3175272|NCT00632242|Experimental|TTP Remission Cohort 2|Patients will receive a total dose of 1.67 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 6 mcg/mL
2570914|NCT02427217||Fibrinogen Concentrate, Human (FCH)|A cohort of subjects who have retrospectively received FCH for the treatment of bleeding, routine prophylaxis and/or use in surgery, and who may continue to prospectively receive FCH at the discretion of the treating physician.
3260209|NCT01477359||CS screened as underlying etiology|"Patients with active Clinically Manifest CS~Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS"
2571137|NCT02426112|Active Comparator|Azithomycin|"Azithromycin tablets 250 mg, 30mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
2571143|NCT02426112|Placebo Comparator|Placebo|"Placebo tablets 250 mg, 30 mg/kg/week by mouth, once a week for 12 months.~10-20 kg: 250 mg~20-29 kg: 500 mg~30-39 kg: 750 mg~40-49 kg: 1250 mg"
2571203|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 50U|"Drug dilution and dosage:~Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline.~Prepare in 1 ml syringe to get 50U/ml :0.1 ml drawn from the mother solution and add 0.9 ml of 0,9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 50U are divided equally into 4 salivary glands, 12.5U each gland"
2571205|NCT02425176|Active Comparator|Botulinum toxin A (BoNT-A) 100U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum toxin A Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 100U/ml :0.2 ml drawn from the mother solution and add 0.8 ml of 0.9% saline. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 100U are divided equally into 4 salivary glands, 25U each gland"
2571209|NCT02425176|Active Comparator|Botulinum toxina A (BoNT-A) 200U|"Drug dilution and dosage:~1. Prepare a mother solution of 500 U/ml by diluting Botulinum ToxinA Dysport® with 1 ml of 0.9% saline. 2. Prepare in 1 ml syringe to get 200U/ml :0.4 ml is drawn from the mother solution and 0.6ml of 0.9% saline is added. Total volume of 1 ml.~Intervention: Botulinum toxin A (BTX-A) 200U are divided equally into 4 salivary glands, 50U each gland"
2571261|NCT02424682||HER 2 positive metastatic breast cancer|HER 2 positive metastatic breast cancer treated with Herceptin as per registered indication, until disease progression.
2571444|NCT02423525|Experimental|Afatinib|Afatinib tablets are taken by mouth. Dose Level 1: 80 mg every 4 days Dose Level 2: 120 mg every 4 days Dose Level 3: 180 mg every 4 days Dose Level 4: 280 mg every 7 days
2571502|NCT02423005|Experimental|Neurotech Vital Compact|The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
2571508|NCT02423005|Active Comparator|itouch Sure Pelvic Floor Exerciser|The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.
2571574|NCT02422420|Experimental|Individual Incentive|Participants receive a financial incentive every time they attend a class session and goal-based incentives for attending 75% of Core sessions, 75% of Post-Core sessions, separately achieving 5%, 7%, and 10% weight loss during the Core period (i.e. separate financial incentives for each goal reached at any point during the Core period), and 5%, 7%, or 10% weight loss by the end of Post-Core Session 8 (i.e., one financial incentive based on final weight loss).
2571578|NCT02422420|Experimental|Group Incentive|This arm receives the same routine attendance incentives as the Individual Incentive arm. Group goal-based incentives include 5% weight loss by an individual during the Core period and, separately, during the Post-Core period. Financial incentives are also received if the entire DPP group achieves 75% Core session attendance, 75% of Post-Core session attendance, 7% or 10% weight loss from baseline during the Core, and 7% or 10% weight loss from baseline at the end of the Post-Core period.
2571589|NCT02422420|Other|Minimal Incentive|Participants receive the full Diabetes Prevention Program (DPP), but receive a nominal $25 financial incentive for attendance only at the first DPP session and no other incentives for attendance or weight loss.
2571648|NCT02422108|Experimental|intervention|Denosumab (Prolia) 60 mg s.c.
2571698|NCT02421731|Experimental|Robot-assisted gait training|This group will receive rehabilitation treatment based on robot-assisted gait training.
2571701|NCT02421731|Active Comparator|Conventional therapy|This group will receive conventional rehabilitation therapy.
2571719|NCT02421432|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
2571766|NCT02421315|Experimental|OCD|Participants will have a current diagnosis of OCD.
2571823|NCT02421029|Experimental|edetate calcium disodium|Subjects who had a gadolinium-enhanced MRI within 1-4 weeks or within 3-6 months before enrollment will receive a single dose of edetate calcium disodium to evaluate levels of gadolinium in their urine, pre and post infusion.
2570776|NCT02427854|Active Comparator|Education by animated training video|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video only.
2570777|NCT02427854|Active Comparator|Interactive hands on bedside training|Incidence of obstetric perineal injuries in the participating hospitals, after the delivery unit staff has been educated and trained to a perineal support by an animated training video and additionally by an interactive hands-on bedside training.
2570829|NCT02427438|Active Comparator|Video Home Program Education|Subjects in this group will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a video with verbal instruction for guidance of proper technique and repetitions.
2570831|NCT02427438|Active Comparator|Handout Home Program Education|Subjects will complete the same 8 weeks of home program exercises for lumbar instability. The home program exercises will be completed using a handout with two dimensional pictures and written instructions for guidance of proper technique and repetitions.
2570883|NCT02427152||Lean|body mass index: 18-25 kg/m²
2570885|NCT02427152||Overweight/Obese|body mass index: >25 kg/m²
2570899|NCT02426840|Experimental|High dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily plus vitamin D2 (20,000 IU/cap) administered once weekly (a total of 1,200 mg of elemental calcium and 3,200 IU of vitamin D daily)
2570901|NCT02426840|Active Comparator|Normal dose vitamin D and calcium|Fixed-dose combination (FDC) of 1,500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3, administered orally twice daily (a total of 1,200 mg of elemental calcium and 400 IU of vitamin D daily)
2570941|NCT02426567|Experimental|Healthy Adult Participants A|Participants who will get two interventional diets, for 7 days each, but allocated to start with Exclusive Enteral Nutrition (EEN)
2570947|NCT02426567|Experimental|Healthy Adult Participants B|Participants who will get two interventional diets, for 7 days each, but allocated to start with Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
2571035|NCT02426346|Active Comparator|JOIN FOR ME|The JOIN for ME curriculum includes 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Weekly meetings are scheduled for 60 minutes and are facilitated by a YMCA coach. Interventions include behavioral weight control and parent-based incentives. Parents attend group at weeks 1, 2 and 16 with their teen.
2571037|NCT02426346|Experimental|TEEN JOIN|Similar to the JOIN FOR ME condition, adolescents in the TEEN JOIN condition attend 16 weekly in person sessions followed by 4 biweekly and 4 monthly maintenance sessions for a 10-month program. Interventions include behavioral weight control, group-based physical activity, and group-based incentives. Parents attend separate meetings at weeks 1, 2, and 16.
3175273|NCT00632242|Experimental|TTP Remission Cohort 3|Patients will receive a total dose of 3.34 mg/kg of ARC1779 over 24 hours to achieve a target plasma concentration of 12 mcg/mL
3175274|NCT00632242|Experimental|Acute TTP Cohort 4|Patients will receive up to a total dose of 40.78 mg/kg of ARC1779 for ≤ 14 days to achieve a target plasma concentration of 12 mcg/mL
3175275|NCT00632242|Experimental|vWD-Type2b Cohort 5|Subjects will receive either ARC1779, desmopressin or a combination of ARC1779 and desmopressin in a 3-period crossover design. The maximum dose of ARC1779 will be 0.47 mg/kg to achieve a target plasma concentration of 6 mcg/mL.
3175276|NCT00632255||1|Patients with CML who have been treated with Imatinib (Glivec) within 6 months of diagnosis as first line therapy. Initial therapy with Hydroxyurea is permitted
3175277|NCT00632268|Experimental|A|Drug:RAD001 Drug:Cisplatin Drug:5-FU
3175278|NCT00632294||Retrieved Allograft|Patients that require the retrieval of a bone allograft (transplant).
2571202|NCT02425007|Experimental|Spiro|Incentive spirometry
2571206|NCT02425007|No Intervention|Control|Control group
2571240|NCT02424864|Other|4D PET-CT|Other intervention: 4D PET-CT
2571417|NCT02423499||Autism Spectrum Disorder|Autism Spectrum Disorder adults without intellectual disability
2571420|NCT02423499||Bipolar Disorder|Bipolar Disorder adults during normothymic phase of illness
2571424|NCT02423499||Healthy Volonteers|Healthy adults
2571452|NCT02423252|Experimental|Intervention group|Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
2571455|NCT02423252|No Intervention|Control|Patients in control group will receive standard care only. Same records and outcome measures with intervention group will apply for control group as well.
2571532|NCT02422875||Healthy Controls|Subjects are healthy persons without any autoimmune conditions or infectious diseases
2572034|NCT02419638||Randomized Treatment Arm: Tecfidera|120 patients treated with Tecfidera (dimethyl fumarate)
3175279|NCT00632307||1|COPD
3175280|NCT00632307||2|lung cancer
3175281|NCT00632307||3|airway infection
3175282|NCT00632307||4|interstitial lung disease
3175283|NCT00632307||5|sleep apnea
3175284|NCT00632307||6|pulmonary disorders with pleural infusions
3175285|NCT00632307||7|sarcoidosis
3175286|NCT00632307||8|healthy persons
3175287|NCT00632320||S, 1, A|group (success or failure), case number, measurement method
3175288|NCT00632333|Experimental|1|
3175289|NCT00632346||1 group|200 patients presenting to the Adolescent Medicine Clinic at Brooke Army Medical Center between the ages of 18 and 23 years-old.
3175290|NCT00632372||HeartPOD™ System with Cardiac Resynchronization Therapy|All patients will receive both a HeartPod device and a CRT-D device.
3175291|NCT00632385|Experimental|A|
3175292|NCT00632398|Active Comparator|Attention control (reading)|Caregivers read to patients from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks.
3175293|NCT00632398|Experimental|Touch, Caring and Cancer DVD program|Caregivers apply the instruction of the Touch, Caring and Cancer DVD program for patients for recommended 20 minutes at least 3 times per week for 4 weeks.
3175294|NCT00632437||Speckle-Contrast Imaging|
3175295|NCT00632450||1|
3175296|NCT00632476|Placebo Comparator|A|Participants will receive a placebo capsule throughout pregnancy.
2570814|NCT02427516||NVAF-VKA cohort|NVAF patients who initiate a VKA treatment
2570819|NCT02427516||VTE-VKA cohort|VTE patients who initiate a VKA treatment
2570845|NCT02427308||miltefosine patients that become pregnant|
2570882|NCT02427009|Experimental|The study population|"The study population consists of adult women requiring an epidural blood patch for the treatment of post-dural puncture headache following vaginal delivery. Women who delivered by cesarean section are not included due to the discomfort of the prone position while there is an abdominal scar.~Intervention: Prone position for 1 hour after blood patch"
2570926|NCT02426827|Experimental|SCS in CV|
2571009|NCT02426489|No Intervention|Diagnostic accuracy with MRI alone|The MRI of the breast lesion will be examined. Measures of performance accuracy will be evaluated, including diagnostic sensitivity (true positives divided by true positives and false negatives), diagnostic specificity (true negatives divided by true negatives and false positives), and diagnostic accuracy, defined as the number of correct assessments divided by the number of all assessments.
2571011|NCT02426489|Experimental|Diagnostic accuracy with MRI + PEM image|The combined PEM/MRI image will be examined.
2571061|NCT02426047|Experimental|Modified Atkins diet plus betaquik®|Participants will continue on the modified Atkins diet (with a 20 net grams carbohydrate per day limit) and add betaquik® (a liquid emulsion of medium chain triglycerides) for 10 days per month for 5 months. The days chosen are based on their particular catamenial pattern (there are 3 types that have been identified in the literature).
2571108|NCT02425709|Active Comparator|Diclofenac|women will receive oral diclofenac 50 mg 1 hour before the procedure.
2571110|NCT02425709|Active Comparator|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure.
2571113|NCT02425709|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
2571145|NCT02425397||patients with grade 3 or 4 Brock ototoxicity|
2571148|NCT02425397||patients controls with no signs of ototoxicity|
2571196|NCT02425163|Active Comparator|suspicious for Prostate Cancer|"PSA >4ng/ml or PSA-Velocity >0.75ng/ml/a or suspicious rectal examination or Status after external beam therapy of the prostate in prostate cancer.~Patients who are able for transrectal ultrasound examination. Transrectal shear wave elastography of the prostate for Transrectal random biopsy of the prostate."
2571270|NCT02424773|Active Comparator|Venturi group|Venturi group : Oxygen is delivered using oxygen Venturi mask FiO2 is started at 60% (15l/min) and modified to maintain SpO2 over 94%.
2571273|NCT02424773|Experimental|HFNC group|HFNC group : Oxygen is delivered using HFNC. HFNC is started with FIO2 =1 and modified to maintain SpO2 over 94%, flow is settled at 40-50l/min.
2571324|NCT02424279|Active Comparator|Surgical treatment|Patients from the first group will undergo thoracoscopic splanchnicectomy. The surgery will be performed in general anaesthesia, with tracheal intubation in prone position. The greater splanchnic nerve will be identified at its origin in sympathetic trunk, dissected together with all collaterals all the way down to the diaphragm and excised. Additional splanchnic nerves (smaller, minimus) will be incised or excised if connected to the greater splanchnic nerve. Single sutures will be applied to the skin. Then the procedure will be repeated on the contralateral side.
2571328|NCT02424279|No Intervention|Conservative Treatment|Patients from the second group will be offered best available conservative pain treatment. The list of medication on stage 1 will include: paracetamol, ibuprofen, diclofenac. On stage 2: stage 1 + codeine and tramadol. On stage 3: stage 2 + morphine, fentanyl, oxycodone, pethidine. Oral and transcutaneous routes will be preferred to intravenous, intramuscular and subcutaneous. A need for elevation to the next step of analgesic ladder will be considered when the pain will be stronger than 6 points in Numeric Rating Scale (NRS) and will be present for more than 5 days.
2571342|NCT02423967|Active Comparator|Transplant uses fresh familial stool|Undergoes Fecal Microbial Transplant using fresh stool from a screened family member Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
2571348|NCT02423967|Experimental|Transplant uses frozen anonymous stool|Undergoes Fecal Microbial Transplant using stool collected from screened anonymous donor that has been frozen until time of Fecal Microbial Transplant Followed up and assessed for eradication of Clostridium difficile Quality of life assessed Stool assessed for inflammation and microbiome
2571391|NCT02423733|No Intervention|Control|In addition to their usual clinical care will also be given written information about web sites that provide information on depression but will not be specifically directed to The Journal.
2571393|NCT02423733|Experimental|Computerized Therapy|In addition to their usual clinical care they will receive an invitation to use The Journal supported by an e-therapy coach who will provide patients with weekly email or telephone contact. The e-therapy coach will have a guideline script for each lesson of The Journal to reinforce the topic of each lesson, help identify and support patients in their goals and to coach them in goal setting and the techniques of problem solving.
2571436|NCT02423421|Active Comparator|Treatment group|The treatment group will have faecal microbiota transplantation performed using stool from a healthy human donor
2571437|NCT02423421|Placebo Comparator|Placebo group|The placebo group will have autologous faecal microbiota transplantation performed.
2571587|NCT02422680||Patients referred to a colonoscopy|A min. of 800 patients referred to colonoscopy at Aalborg University Hospital. The 800 patients are from the out patient clinic. A mix of screening and non-screening patients.
2571652|NCT02422173|Experimental|Anodal tDCS|Participants in the acute post-stroke stage will receive anodal transcranial direct current stimulation
2571653|NCT02422173|Experimental|Cathodal tDCS|Participants in the acute post-stroke stage will receive cathodal transcranial direct current stimulation
2571656|NCT02422173|Experimental|Bilateral tDCS|Participants in the acute post-stroke stage will receive bilateral transcranial direct current stimulation
2571658|NCT02422173|Sham Comparator|Sham tDCS|Participants in the acute post-stroke stage will receive sham transcranial direct current stimulation
2571704|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
3260210|NCT01477372|Experimental|Exercise group|Supervised exercise program
2572886|NCT02414360|Active Comparator|Control|Full length systematic review
3260211|NCT01477372|No Intervention|Control|Sedentary pregnant woman
2570835|NCT02427425|Experimental|TENS group|It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
2570836|NCT02427425|Placebo Comparator|Placebo group|In Placebo group the same procedures of the TENS group were adopted, but did not occur electrical stimulus.
2571020|NCT02426216||Group A|Group A: Subjects who fullfil all eligibility criteria of the MCS-8 protocol and consent to enroll the study.
2571021|NCT02426216||Group B|Group B: Subjects who fullfil the definition of elevated risk for prostate cancer by the MCS-8 protocol but did not sign up for the MCS-8 study.
2571063|NCT02426008|Experimental|Culture media with growth factors and Cytokine|Growth factors and Cytokine adding to culture media to detect the deference and monitor the embryological outcome.
2571067|NCT02426008|Placebo Comparator|In Vitro culture media|culture media to monitor the embryological outcome as control group
2571105|NCT02425670|Experimental|Bone marrow derived stem cells (BMSCs)|BMSCs 30-500 million plus conventional management
2571107|NCT02425670|No Intervention|Control|Control: conventional management
2571144|NCT02425410||Isis-Virus|T1D patients of the Isis-Diab cohort with genetic data (GWAS) and specific environmental data on viral events during childhood
2571207|NCT02425150|Experimental|Corneal reshaping/crosslinking (CRXL)|Corneal crosslinking with compression of the cornea using a sutured rigid contact lens during the treatment.
2571212|NCT02425150|Active Comparator|Corneal crosslinking (CXL)|Standard corneal crosslinking using the Dresden protocol.
2571213|NCT02425150|No Intervention|Control group to CRXL|Healthy subjects, age- and sex-matched to the CRXL group.
2571218|NCT02425150|No Intervention|Control group to CXL|Healthy subjects, age- and sex-matched to the CXL group.
2571241|NCT02424786|Other|Intervention group|"Medication lists from the patients randomized in the intervention group will be evaluated by the research physician with the help of STOPP/START criteria.~Feedback of this screening will be given to the team responsible for patient treatment."
2571242|NCT02424786|No Intervention|Control|Patients in this arm will receive standard pharmacological treatment
3209028|NCT00980473|Active Comparator|Iridoplasty|
3209029|NCT00980473|Active Comparator|Control (Medication)|
2571337|NCT02424136|Other|Entire group|Children aged 2-17 years with suspected peanut allergy who require peanut food challenge to confirm clinical allergy, will be recruited for the study. They will undergo a preceding questionnaire, peanut skin prick testing, spirometry, fraction of exhaled nitric oxide (FeNO) measurement, serum peanut and Ara h2 specific immunoglobulin E (sIgE) antibodies, and collection of blood biomarker prior to food challenge. The primary endpoint will be anaphylaxis at open label peanut challenge, with the primary exposure of interest will be the serum biomarker.
2571384|NCT02423746|Placebo Comparator|Control Group|"The control group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
2571386|NCT02423746|Experimental|Intervention Group|"The intervention group will include 3 hearing aid (HA) and 3 cochlear implant (CI) caregiver-child dyads.~Intervention parents receive the initial assessment session followed by the 3-session Family Check Up Behavioral Parenting Training Program (BPT) within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
3209030|NCT00980486||BMI <30|BMI <30
3209031|NCT00980486||BMI 30-39|BMI 30-39
2571480|NCT02422784|Placebo Comparator|Control|Participants will be instructed to consume 240 mL of iced-tea daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
2571485|NCT02422784|Active Comparator|Rooibos Tea - Vitamin D3|Participants will be instructed to consume 240 mL of iced-tea fortified with 1000 IU water-soluable vitamin D3 daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
2571491|NCT02422784|Active Comparator|Rooibos Tea- Vitamin D3 & Calcium|Participants will be instructed to consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water-soluable vitamin D3 and 360 mg of calcium daily for 6 weeks. The iced-tea beverages do not contain added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
2571579|NCT02422628||EGFR mutation postive|Blood samples every 3 months till disease progression or intolerable due to side effect.
2571588|NCT02422628||EGFR mutation wild type|Blood samples before treatment once.
2571593|NCT02422628||Healthy Volunteers|Blood samples once.
2571625|NCT02422225|Experimental|Eldith DC-STIMULATOR group|"Intervention:~20-minutes of transcranial Direct Current Stimulation (tDCS) application 5 days a week for 2 weeks (30 applications for each 3 groups: total 90 applications)"
2571628|NCT02422225|Sham Comparator|sham-Eldith DC-STIMULATOR group|Intervention: 20-minutes of sham-tDCS application 5 days a week for 2 weeks (total 30 applications)
3209032|NCT00980486||BMI >40|BMI >40
3209033|NCT00980512|Experimental|Parent Training|Parent Training of foster parents
3209034|NCT00980512|No Intervention|Control|Control group
3260212|NCT01477385|Active Comparator|Resin Infiltration|Resin Infiltration 30% Silver Diammine Fluoride Placebo Dental Flossing
2570839|NCT02427295|Experimental|Group 2: Surgery + Medical treatment|"MRI : residual tumor 6 months post-op : IGF-1 >600 ng/ml~medical treatment : Sandostatin (Octreotide Acetate)"
2570840|NCT02427295|No Intervention|Group 3 : Rescue group|If IGF-1 levels fails to normalize till post-op 18 months post-op, medical treatment will be added.)
2570841|NCT02427295|No Intervention|Gruop1 : Surgery only group|"MRI : without residual tumor 6months post-operation~and IGF-1 <600ng/ml"
2570886|NCT02427035|Experimental|Low|A low dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
2570890|NCT02427035|Experimental|High|A high dose of either CSL112 or placebo is to be administered as a single intravenous (IV) infusion. The placebo will be administered at the same frequency, volume and duration as the CSL112 infusion.
2570970|NCT02426788|Experimental|CBT+SMC|"Cognitive behavioural therapy + Standard Medical Care (cognitive-behavioural therapy+SMC):~8 hour-long manual-based CBT sessions with a therapist, weekly or fortnightly."
2570974|NCT02426788|No Intervention|Standard Medical Care (SMC)|Participants assigned to the SMC group (i.e., control group) will receive all the treatment and support they would otherwise receive outside of a research trial.
2571028|NCT02426229|Experimental|dabigatran 75mg|dabigatran etexilate 75mg orally twice daily for 6 months
2571102|NCT02425904|Experimental|1-Recurrent or Refractory LCH|"Participants with multi-focal or multi-system disease who have recurred (or have refractory disease) after at least one prior systemic chemotherapy regimen.~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
2571103|NCT02425904|Experimental|2-LCH-related disorders|"Participants with LCH-related disorders who require systemic chemotherapy including:~Participants with RDD who have not responded to or recurred after treatment with corticosteroids. ECD subjects who have confirmed presence of BRAF V600E mutation must have not responded to, have recurred after, or be unable to receive treatment with a BRAF inhibitor.~Clofarabine administered via IV on days 1-5, 25 mg/m2/day, per cycle.~Evaluation of disease response will be performed after 2 cycles of Induction Therapy. In the absence of disease progression, participants will be eligible to receive up to 4 cycles of Maintenance Therapy, which is identical to the Induction Therapy."
2571155|NCT02425358|Experimental|BMC therapy within 24 hours|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 24 hours after successful primary PCI.
2571159|NCT02425358|Experimental|BMC therapy within 3-7 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 3-7days after successful primary PCI.
2571161|NCT02425358|Experimental|BMC therapy within 7-30 days|Patients with acute myocardial infarction who receive intracoronary infusion of BMC within 7-30days after successful primary PCI.
2571164|NCT02425358|Active Comparator|PCI only|Patients with acute myocardial infarction who were performed successful primary PCI.
2571180|NCT02425046|Experimental|health coaching and community screening|Family Health Coaching and community benefits screening
2571181|NCT02425046|Other|community screening|community benefits screening only
2571229|NCT02424955|Experimental|3D Perfusion Ultrasound|undergo 3D ultrasound perfusion imaging with perflutren
2571312|NCT02424188|Experimental|TRIUMPH intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
2571318|NCT02424188|No Intervention|Treatment as Usual|referral to quit line
2571429|NCT02423473|Active Comparator|Connective tissue graft (CTG)|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, the exposed root surface was gently scaled and planed until it became smooth. Afterward, a thin and small connective tissue graft that was sutured over the root surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
2571430|NCT02423473|Experimental|Connective tissue graft plus composite resin restoration.|After local anesthesia, the surgical procedure performed was the trapezoidal-type of CAF (de Sanctis & Zucchelli, 2007). After the flap was raised, a sterile rubber dam was placed to isolate the operative field and the non-carious cervical lesion restoration was performed with a nanocomposite resin (Filtek Supreme - 3M ESPE - St. Paul, MN, USA), following the manufacturer's instructions. Afterward, a thin and small connective tissue graft that was sutured over the restoration surface. Then, the flap was coronally positioned and sutured to completely cover the graft.
2571488|NCT02422953|Experimental|Intervention|Wheat Soya Blend, Wawa Mum, Micronutrient Powders, Behavior change and preventive health massages
2571493|NCT02422953|No Intervention|Control|Control group will receive routine public and private health services available in the area.
3175297|NCT00632476|Active Comparator|B|Participants will receive a vitamin C capsule throughout pregnancy.
3175298|NCT00632476|No Intervention|C|A group of non-smoking pregnant women will not receive placebo or vitamin C.
3175299|NCT00632515||Questionnaire|Patients with Colorectal Cancer and their First Degree Relatives (FDRs).
3175300|NCT00632528|Experimental|1|Administration of MEOPA gaz during postoperative physical therapy
2571642|NCT02422095||Pancreatic fluid collections|Patients with pancreatic fluid collections undergoing endoscopy-based (EUS-guided) interventions
2571645|NCT02422095||Pancreatic cysts|Patients with pancreatic cysts undergoing EUS examination and possible EUS-guided sampling of cystic fluid.
2571710|NCT02421692|Experimental|Progressive Rehabilitation|SNF rehabilitation therapists have been trained on principles of progressive rehabilitation strategies and will implement to all eligible patients as new standard of care.
2572041|NCT02419482|Experimental|4x4 minutes interval training|4x4 minutes high intensity interval training with 4 minute intervals
3175301|NCT00632528|Placebo Comparator|2|Administration of medical air during postoperative physical therapy
3175302|NCT00632554|Experimental|1|prednisolone therapy for three months
3175303|NCT00632554|Active Comparator|2|prednisolone therapy for six months
3175304|NCT00632567|Experimental|1|caesarean section
3175305|NCT00632567|Active Comparator|2|vaginal delivery
3175306|NCT00632580|Active Comparator|1|intraarticular injection with local anesthetic
2570842|NCT02427334|Active Comparator|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
2570846|NCT02427334|Active Comparator|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
2570847|NCT02427334|Placebo Comparator|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
2570923|NCT02426983|Active Comparator|Direct Current Stimulation active|Electrodes will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks.
2570925|NCT02426983|Sham Comparator|Direct Current Stimulation sham|In sham sessions, the device will have the same placement and intensity, but will only be turned on for 30 seconds. The DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. This will occur in two separate sessions, occurring within weeks.
2570927|NCT02426983|Active Comparator|NMDA antagonist active|Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON). Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
2570929|NCT02426983|Placebo Comparator|NMDA antagonist placebo|Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
2571010|NCT02426411|Experimental|EMA401 200 mg|2 X 50 mg capsules BID
2571012|NCT02426411|Experimental|EMA401 600 mg|2 X 150 mg capsules BID
2571015|NCT02426411|Placebo Comparator|Placebo|Placebo to match 2 capsules BID
2571062|NCT02425982||Conservative treatment|Patients who will opt conservative treatment or patients treated conservatively by surgeon decision.
2571066|NCT02425982||Operative treatment|Patients who opt for surgery when offered.
3209035|NCT00980525||IL-1 genotype positive|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
3209036|NCT00980525||IL-1 genotype negative|There are three known IL-1 genes arranged in a cluster on human chromosome 2q13. Although the clinical application is still debatable, polymorphism in the IL-1 gene cluster was found to be associated with increased susceptibility to periodontal diseases. Conflicting studies demonstrate that a possible relationship between IL-1 genotype and clinical parameters of gingivitis may exist.This study will involve 15 subjects who are genotype positive and 15 subjects who are genotype negative.
3209038|NCT00980551|Experimental|Topotecan/Vincristine with subtenon Carboplatin|
2571394|NCT02423551|No Intervention|Control|Usual diet
2571395|NCT02423551|Experimental|MRE|MRE consumption
2571448|NCT02423369|Experimental|neonates and infants requiring surgery|neonates and infants in whom blood samples for measurement of S-100 B protein in serum and NSE protein in serum are taken pre-operatively and 1-st, 2-nd and 3-rd post-operatively. During anesthesia cerebral near infrared spectroscopy is continuously applied until the wound closure.
2571481|NCT02422901||Vit C deficiency in acute diseases|Patients with vitamin C deficiency due to a acute underlying disease treated with Pascorbin® 7.5 g
2571489|NCT02422901||Vit C deficiency in chronic diseases|Patients with vitamin C deficiency due to a chronic underlying disease treated with Pascorbin® 7.5 g
2571726|NCT02421848||Cirrhotic Patients With Ascites|Cirrhotic Patients With Ascites
2571774|NCT02421276|Other|Persons without Down syndrome|White blood cell analysis from persons without Down syndrome assessed by absence of trisomy 21.
2571775|NCT02421276|Other|Persons with Down syndrome|White blood cell analysis from persons with Down syndrome assessed by presence of trisomy 21.
2571819|NCT02420990|Active Comparator|Behavioral Only- Treatment|All participants will receive behavioral interventions (CASH-AA): family psycho-education in ADHD symptoms, executive functioning, and developmental impacts; family-based motivation and ADHD accommodation interventions; and academic training focused on home environment support and organizational skills.
2571822|NCT02420990|Experimental|Integrated Treatment|Half of the participants will also receive medication decision-making interventions (MIP): ADHD medication psychoeducation, family decision-making interventions, and (for those who elect to start medication) coordinated medication management.
2571862|NCT02420665|Experimental|High-Resolution Microendoscopy (HRME) + Colposcopy|Visual inspection of cervix performed using 3 - 5% acetic acid to the cervix. Participants undergo standard colposcopy and abnormal lesions noted by quadrant. Then 0.01% proflavine applied topically to the cervix. High-resolution microendoscopy (HRME) then performed. HRME images obtained from one visually normal site and from up to 3 visually abnormal lesions based on visual exam and/or colposcopic findings. Study staff follow up with participant by phone one month after procedure.
2571921|NCT02420184|Experimental|CPAP Therapy|Participants will receive standard medical care for CKD as well as CPAP therapy for the duration of the study (1 year).
2571926|NCT02420184|Placebo Comparator|No CPAP|Participants will receive standard medical care for CKD.
2572010|NCT02419911|Other|FloShield|FloShield Air Laparoscopic Cleaning and Defogging System used during laparoscopic surgery
2572012|NCT02419911|Other|Clearify|Clearify Visualization System used during laparoscopic surgery
3209039|NCT00980577|Active Comparator|NS|stimulating catheter will be inserted using stimulator
3209040|NCT00980603|Active Comparator|docetaxel|
3209041|NCT00980603|Experimental|doctaxel plus cisplatin|
2570852|NCT02427412|Active Comparator|IA Tranexamic acid + IV Tranexamic Acid|3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
2570855|NCT02427412|Placebo Comparator|IA Saline Water + IV tranexamic Acid|30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.
2570910|NCT02426866||Patient with Efavirenz exposure|Patient with Efavirenz exposure
2570913|NCT02426866||Patient without Efavirenz exposure|Patient without Efavirenz exposure
2570946|NCT02426632|Experimental|Session 1: Sequence 1|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570952|NCT02426632|Experimental|Session 1: Sequence 2|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570953|NCT02426632|Experimental|Session 1: Sequence 3|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570955|NCT02426632|Experimental|Session 1: Sequence 4|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570957|NCT02426632|Experimental|Session 1: Sequence 5|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570960|NCT02426632|Experimental|Session 1: Sequence 6|Participants will sequentially receive 5 milliliter of each 6 JNJ-53718678 formulations (ABCDEF) in a random order, at a dosing interval of 1-2 hours.
2570965|NCT02426632|Experimental|Session 2: Sequence 7|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2570968|NCT02426632|Experimental|Session 2: Sequence 8|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2570973|NCT02426632|Experimental|Session 2: Sequence 9|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2570976|NCT02426632|Experimental|Session 2: Sequence 10|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2570980|NCT02426632|Experimental|Session 2: Sequence 11|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2570983|NCT02426632|Experimental|Session 2: Sequence 12|Participants will receive two best scoring formulations from Session 1 with a varying concentration of sucralose (M1M2M3N1N2N3) sequentially in a random order, at a dosing interval of 1-2 hours.
2571121|NCT02425553||Faculty and Delegates of Ascona II Meeting|
2571184|NCT02425293|Experimental|Intervention|Patients participating in a patient education seminar
2571185|NCT02425293|No Intervention|Control|Patients not participating in a patient education seminar
2571224|NCT02424916|Experimental|Autologous somatic cell therapy|Patients treated with melanoma antigens-specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
2571280|NCT02424695|Experimental|Single Gabapentin Enacarbil Arm|"Gabapentin Enacarbil (Gen) 600 mg will be administered once daily for 4 weeks~Matching placebo will be administered once daily for one week prior initiation of treatment with GEn"
2571309|NCT02424240||IGF-I/ IGFBP-3 ratio group|
2571315|NCT02424240||IGF-1 and IGFBP-3|
2571365|NCT02424045|Other|BCD chemotherapy|"All patients are scheduled to receive 2 cycles of three-weekly Bendamustine, carboplatin and dexamethasone combination chemotherapy(BCD Chemotherapy).~D1,D2 Bendamustine 80mg/m2 IV over 30-60min D1 Carboplatin AUC 5.0 IV D1-4 Dexamethasone 40mg #2 PO or IV"
2571418|NCT02423681|Active Comparator|Heated humidification as first intention (HH1st)|Subjects receive heated humidification as first intention with ThermoSmart
2571423|NCT02423681|Placebo Comparator|Non-heated humidification|Subjects will receive no humidification. However they can be switched to the humidification group if patients complains of nasal dryness, congestion, nose bleed or if they had significant leak that cannot be resolved by two changes of mask.
2571500|NCT02422979|Experimental|PART 1 - Cohort 1|3-6 patients
2571506|NCT02422979|Experimental|PART 1 - Cohort 2|3-6 patients
2571513|NCT02422979|Experimental|PART 1 - Cohort 3|3-6 patients
2571514|NCT02422979|Experimental|PART 2 - Cohort 1|Number of patients depend on Part 1
2571523|NCT02422979|Experimental|PART 2 - Cohort 2|Number of patients depend on Part 1
2571531|NCT02422979|Experimental|PART 3|Up to 30 patients
2571580|NCT02422394|Experimental|Eltrombopag|"Phase 1: Eltrombopag 50 mg/day for 3 weeks. At the end of these 3 weeks of treatment: platelet count higher than 100 x10e9/L and no spontaneous bleeding, end therapy. In the other cases, treatment with eltrombopag 75 mg/day for 3 additional weeks.~Phase 2: Eltrombopag will be administered for 16 weeks. Eltrombopag will be initially given at 25 mg/day for 4 weeks. Every 4 weeks, the dosage will be modified as follows. (1) Bleeding score (WHO bleeding scale) 0-1 and platelet count between 30 and 100 x10e9/L: continue at the current dose; (2) Bleeding score 0-1 and platelet count higher than 100 x10e9/L: switch to the next lower dose; (3) Bleeding score 2-4 or platelet count lower than 30 x 10e9/L: switch to the next higher dose. The following dosages of eltrombopag are considered: 12.5 mg/day; 25 mg/day; 50 mg/day; 75 mg/day."
3209042|NCT00980603|Experimental|docetaxel plus S-1|
2572185|NCT02418780|Experimental|Tai Chi|6-month Tai Chi training program combined with usual medical care
3209043|NCT00980616|Experimental|Ropivacaine, serum, adrenalin|235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin.
3209044|NCT00980616|No Intervention|No infiltration|B: no infiltration
3209045|NCT00980694|Experimental|Ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
3209046|NCT00980707|Experimental|inhaled corticosteroid|All asthmatics will start inhaled corticosteroids.
3260213|NCT01477385|Experimental|30% Silver Diammine Fluoride|30% Silver Diammine Fluoride Resin Infiltration Placebo Dental Flossing
3209047|NCT00980733|Active Comparator|Fortified Yoghurt|Yoghurt with fortification of Micronutrients, yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
3209048|NCT00980733|Placebo Comparator|Yoghurt|Plain Yoghurt same as in fortified arm but without fortification
3209049|NCT00980733|No Intervention|Control|Non blinded group given no intervention
3209050|NCT00980759|Experimental|EFI(Extended-Field Irradiation)|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
3209051|NCT00980759|Experimental|Pelvic RT|Pelvic Irradiation with chemotherapy(cisplatin)
2570918|NCT02426710|Experimental|Flutter ablation with intracardiac echocardiography|Atrial flutter ablation will be done using intracardiac echocardiography.
2570919|NCT02426710|Active Comparator|Flutter ablation without intracardiac echocardiography|Atrial flutter ablation will be done without intracardiac echocardiography.
2570993|NCT02426502|Experimental|Conversion to once daily dosing|The conversion to a once daily dosing regimen will be accomplished in three phases (1-conversion to Advagraf; 2-conversion of non-immunosuppressant drugs and; 3-conversion of patients taking twice daily MPA to once daily MPA). No control group.
3209052|NCT00980824|Experimental|therapy|Cognitive behavioural therapy. Six sessions of structured focused therapy.
3209053|NCT00980824|Active Comparator|Standard treatment|referral to specialised or generic mental health service
2571247|NCT02424552|Experimental|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks
2571250|NCT02424552|Placebo Comparator|Placebo|Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks
3209054|NCT00980850|Experimental|Groups A1 and A2|Baxter vaccine
3209055|NCT00980850|Experimental|Groups B1 and B2|GSK vaccine
2571404|NCT02423603|Active Comparator|Paclitaxel + AZD5363|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Capivasertib 400 mg was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
2571412|NCT02423603|Placebo Comparator|Paclitaxel + Placebo|Paclitaxel was administered as a once-per-week intravenous infusion of 90 mg/m2 over approximately 1 hour on days 1, 8, and 15 of each 28-day treatment cycle. Placebo was administered orally twice per day on an intermittent weekly dosing schedule, with treatment on days 2 to 5 of weeks 1, 2, and 3 within each 28-day cycle.
2571483|NCT02422810||No aspirin|Subjects who have not taken aspirin or other blood thinners in the previous 10 days
2571487|NCT02422810||Aspirin Daily|Subjects who have taken aspirin daily for the previous 10 or more days
2571494|NCT02422810||New to aspirin|Subjects newly started on aspirin during their visit
2571576|NCT02422719|Experimental|Radotinib|Radotinib treatement single arm
2571621|NCT02422134|Active Comparator|Cytokine plus Hyalurinan embryo transfer arm|To monitor the pregnancy and implantation of the patients in this arm after adding Cytokine to the embryo transfer medium.
2571622|NCT02422134|No Intervention|Hyalurinan embryo transfer group|To transfer the embryos using a Hyaluronan enriched medium only
3209056|NCT00980863|Active Comparator|Lifestyle intervention to increase physical activity|
2571723|NCT02421458|Active Comparator|arm 1: 6 fractions of radiation|radiation in a 6 fractions scheme and a daily dose of 6 Gy
2571727|NCT02421458|Active Comparator|arm 2: 16 fractrions of radiation|radiation in a 16 fractions scheme and a daily dose of 3.125 Gy
2571781|NCT02421107|Other|all patients|all patients
2571826|NCT02420886|Active Comparator|Cytokines supplemented In Vitro single culture media|We will add Cytokines (LIF, HB-EGF and GM-CSF) to LIFEGLOBAL culture media and assess the embryogenesis and pregnancy.
2571827|NCT02420886|No Intervention|Traditional Single step culture media|
2571902|NCT02420457||Back pain receiving epidural injection|Patients who have chronic back pain and are scheduled for an epidural injection to treat this pain will be receive a transforaminal epidural steroid injection as determined by routine care provider
3209057|NCT00980863|No Intervention|waiting control group|
3209058|NCT00980876|Active Comparator|Cipro HC|Reference product
3209059|NCT00980876|Experimental|Ciprofloxacin HCl and Hydrocortisone|Test product
3209060|NCT00980889|Active Comparator|steel|Insertion of Metalic Steel Stent, Wallstent® in malignant distal bile duct obstruction
3209061|NCT00980889|Active Comparator|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
3209062|NCT00980915||At risk for Acute Lung Injury|"Controls-High risk patients at risk of Acute Lung Injury(ALI) but do not develop ALI~Cases-High risk patients that do develop Acute Lung Injury"
3209063|NCT00980941|Experimental|Soup with no added starch|
3209064|NCT00980941|Experimental|Soup + 50 g of whole grain starch|
3209065|NCT00980941|Experimental|Soup + 50 g of high amylose corn starch|
3209066|NCT00980941|Experimental|Soup + 50 g of regular corn starch|
3209067|NCT00980941|Experimental|Soup + 50 g maltodextrin starch|
3209068|NCT00981006|Experimental|human cardiac stem cell therapy|single administration of 0.5 million cells/kg(patient body weight) of human cardiac stem cells and 200 microgram of bFGF at coronary artery bypass grafting (CABG)
3209069|NCT00981032|Experimental|Pre-visit Summary|Patients in this arm will receive a pre-visit summary prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
3209070|NCT00981032|Experimental|Clinical Decision Sharing Tool|Patients in this arm will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
3209071|NCT00981071||A platoon with TB outbreak|
3209072|NCT00981097||Specimen Collection|Subjects with a diagnosis of HIV and an untreated aggressive B-cell lymphoma.
2570887|NCT02427165|Experimental|RPL554 Dose 4|24 mg single dose nebulised RPL554
2570889|NCT02427165|Active Comparator|Salbutamol Dose 1|2.5 mg single dose nebulised salbutamol
2570891|NCT02427165|Active Comparator|Salbutamol Dose 2|7.5 mg single dose nebulised salbutamol
2570930|NCT02426723|Experimental|CWP232291|"Phase 1a: single administration of CWP232291 ,~Phase 1b: CWP232291 combination with Lenalidomide and Dexamethasone"
2571013|NCT02426398||People with Alzheimer's disease|People with Alzheimer's disease
2571016|NCT02426398||Healthy volunteers|Healthy volunteers
2571059|NCT02426021|Experimental|Cohort J1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in 6 healthy Japanese male adults
2571064|NCT02426021|Experimental|Cohort J1: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
2571068|NCT02426021|Experimental|Cohort J2:MLN1202 (105 mg)|Single subcutaneous administration of MLN1202 (105 mg) in 6 healthy Japanese male adults
2571069|NCT02426021|Experimental|Cohort J2: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
2571071|NCT02426021|Experimental|Cohort J3: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in 6 healthy Japanese male adults
2571073|NCT02426021|Experimental|Cohort J3: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
2571074|NCT02426021|Experimental|Cohort J4: MLN1202 (450 mg)|Single subcutaneous administration of MLN1202 (450 mg) in 6 healthy Japanese male adults
2571075|NCT02426021|Experimental|Cohort J4: placebo|Single subcutaneous administration of placebo in 2 healthy Japanese male adults
2571077|NCT02426021|Experimental|Cohort C1: MLN1202 (75 mg)|Single subcutaneous administration of MLN1202 (75 mg) in healthy Causacian male adults
2571078|NCT02426021|Experimental|Cohort C2: MLN1202 (150 mg)|Single subcutaneous administration of MLN1202 (150 mg) in healthy Causacian male adults
2571146|NCT02425592||Men on Active Surveillance|This study will include men between age 30-80 with Gleason 6 prostate cancer, prostate specific antigen (PSA) <20, clinical stage <cT3, and a life expectancy of at least ten years. To be eligible, men must have undergone an MRI-USG fusion prostate biopsy for an elevated PSA or abnormal prostate examination that demonstrates Gleason 6 prostate cancer. If a man is already on active surveillance, the MRI-USG fusion biopsy may be negative or confirm Gleason 6 prostate cancer. Eligible men will be approached at their post fusion-biopsy visit to discuss the biopsy results and offered enrollment in the trial.
2571268|NCT02424877|Experimental|SandRA|cell phone monitoring
2571272|NCT02424877|No Intervention|Control|conventional monitoring
2571332|NCT02424331|Experimental|Quiet Breathing or Pursed Lips Breathing|Free or natural breathing for six minutes.
2571364|NCT02423902|Experimental|Ad-RTS-hIL-12 + Veledimex|Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
2571421|NCT02423655|Experimental|Deffered Dialysis Initiation|"Algorithm for deferred dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 5 ml/min /1.73 m2 or less"
2571426|NCT02423655|Active Comparator|Routine dialysis Initiation|"Algorithm for routine dialysis intervention:~initiating dialysis in the absence of symptoms in patients with an eGFR of 7 ml/min /1.73 m2 (which is the average GFR for patients in Beijing to start dialysis )"
3209073|NCT00981110|Active Comparator|Mepore Self-adhesive absorbent dressing|Mepore Self-adhesive absorbent dressing
3209074|NCT00981110|Experimental|AQUAGEL Ag Hydrofiber Wound Dressing|AQUAGEL Ag Hydrofiber Wound Dressing
2571518|NCT02422758|Experimental|Active Prewarming 3M™ BairHugger™Blanket|Patients will have the whole body covered with the3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket of forced air warming system for 20 minutes, at average power.Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
2571524|NCT02422758|Placebo Comparator|Passive Prewarming|Passive prewarming with a cotton sheet and blanket for 20 minutes. Tympanic temperature will be measured, through electronic infrared tympanic thermometer GENIUS 2. Patients will be warmed with 3M™ Bair Hugger™ Upper Body Blanket, during intraoperative period.
3209075|NCT00981123||1|
3209076|NCT00981136|Active Comparator|SILS|Single Incision Laparoscopic Surgery (SILS) where a single incision in the umbilicus is all that is used to remove the appendix. The specific methods (staple/tie/port use/etc) will vary depending on surgeon.
3209077|NCT00981136|Active Comparator|3 port|Standard laparoscopic appendectomy with 3 ports and intracorporeal stapling.
3209078|NCT00981162|Experimental|Treatment (sorafenib tosylate and everolimus)|Patients receive everolimus PO once daily and sorafenib tosylate PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2571699|NCT02421822|Experimental|Fitwits Intervention|Fitwits office tool and games
2571731|NCT02421549|Active Comparator|Interrogation with unpaired remote monitoring transmitter|Interrogation with unpaired remote monitoring transmitter Interrogation with an unpaired remote monitoring transmitter for devices that are compatible.
2571733|NCT02421549|No Intervention|Interrogation with Programmer|Interrogation with programmer Interrogation with programmer according to usual standard of care
2571791|NCT02421237|Experimental|Experimental condition|Narrative enhancement and cognitive therapy (NECT) groups. Structured psychoeducational and skills-training groups focused on self-stigma and its impact on people with schizophrenia
2571798|NCT02421237|Active Comparator|Control condition|Supportive group therapy groups. Unstructured supportive groups not focused on self-stigma.
2571866|NCT02420782|Experimental|ASP6282 single ascending dose (fasted)|Part 1
2571869|NCT02420782|Placebo Comparator|Placebo single ascending dose (fasted)|Part 1
2571873|NCT02420782|Experimental|ASP6282 single dose (fed)|Part 1
2571881|NCT02420782|Placebo Comparator|Placebo single dose (fed)|Part 1
2571887|NCT02420782|Experimental|ASP6282 single dose (fasted)|Part 1 Period 1
2571891|NCT02420782|Experimental|Itraconazole multiple dose and ASP6282 single dose (fasted)|Part 1 Period 2
2572044|NCT02419482|Experimental|10x1 minute interval training|10x1 minute high intensity interval training with 1 minute intervals
3209079|NCT00981201|Experimental|Celecoxib + Placebo|
3209080|NCT00981201|Experimental|Celecoxib + Celecoxib|
3209081|NCT00981201|Active Comparator|Placebo + Celecoxib|
2570909|NCT02426996|Experimental|Study population|"The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.~Intervention: Scan of shoulder"
2570963|NCT02426619|Experimental|SDF regular|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush regularly once a year
2570967|NCT02426619|Experimental|SDF intensive|3 applications of a 30% SDF solution will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
2570972|NCT02426619|Active Comparator|NaF varnish|3 applications of a 5% NaF varnish will be applied onto the surface of dental caries lesions by a small brush at weekly interval at baseline
2571019|NCT02426255||ICU patients|Patients with severe trauma (with or without brain injury) or Patients with hemorrhagic shock Data concerning the ICU stay will be collected for these patients
2571142|NCT02425865|Other|open-label, uncontrolled trial|All patients will receive Standard regimen with golimumab 50 mg Q4W, or 100 mg Q4W if > 80 kg
3209082|NCT00981201|Placebo Comparator|Placebo + Placebo|
2571336|NCT02424110|Experimental|Argon beam coagulator ablation group|In the bipolar left atrial radiofrequency ablation, when the linear ablation was performed through along the lower edge of interatrial groove incision up to the mitral annulus, there is a gap between the ends of the ablation line and the mitral annulus And in the bipolar right atrial radiofrequency ablation, when the linear ablation was performed along the lower edge of the coronary sinus ostium up to the inferoseptal commissure and through the vertical incision on anterior wall of the right atrium up to the tricuspid annulus. There also have gaps between ends of the ablation line and the tricuspid annulus. In the experimental group the investigators plan to use conventional bipolar radiofrequency ablation and use argon beam coagulator to ablate these gaps.
2571338|NCT02424110|Experimental|Bipolar radiofrequency ablation group|Only use conventional bipolar radiofrequency ablation and do not deal with these gaps.
2571388|NCT02423811|Experimental|CCRT plus Fursultiamine|"Fursultiamine 100mg tid, po Radiotherapy 36Gy/18Fx Chemotherapy will include Cisplatin and 5-FU. Cisplatin 60-75 mg/m2 on days 1 and 29 with standard prehydration and antiemetic therapy.~5-FU 600-1000 mg/m2day administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1 through 4 and 29 through 32"
2571431|NCT02423460|Experimental|Threonine requirement|The threonine requirement in healthy male subjects and in patients with Crohn's disease and Ulcerative colitis
2571466|NCT02423148|Experimental|FluoSCOPE device|"All study interventions will occur intraoperatively during the subject's planned surgery. No deviation from standard of care will be performed with the exception of the following specific interventions:-~Intraoperative injection of indocyanine green (ICG) around tumor and imaging with the FluoSCOPE NIR endoscopic imaging system~Treatment will be administered on an inpatient basis"
2571479|NCT02422836|Experimental|Three Product Anti-Aging Regimen|"Three Product Anti-Aging Treatment Regimen:~Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks"
2571563|NCT02422693|Experimental|Aquatic exercises|Warm-up, lumbar mobilization, stretching and relaxation. 3x-week (9 weeks), indoor pool, 32o.C/89.6o.F.
2571564|NCT02422693|Active Comparator|Aquatic exercises + Deep-water running|Same as AEG with addition of 20 minutes of running without touch the ground, 3x-week (9 weeks), indoor pool, 30o.C/86o.F.
2571736|NCT02422277|Active Comparator|LI-ESWT group|Intervention include that patients will undergo penile low-intensity extracorporeal shock wave therapy, 6-12 sessions, 1500 shocks per session, two sesssions per week for 3 weeks then 3 weeks break and then 2 sessions per week for 3 weeks.
2571741|NCT02422277|Active Comparator|PDE-5 inhibitors group|"Intervention include that patients will intke oral tablets of PDE-5 inhibitors :~- Oral intake of 50 mg once daily for 6 months."
2571743|NCT02422277|No Intervention|Control group|Patients will be only followed up without any therapy for assisting erection.
3209083|NCT00981240|Experimental|Dose escalation|Cohorts of 3 to 6 patients will be included at each dose level. The starting dose is 1.2mg/m2/day. The dose will be increased in new cohorts of patients according to toxicities observed during the first 4-week treatment period. The escalation process will continue until the MTD is determined. Additional 15 patients will be included at the MTD.
3260214|NCT01477385|Active Comparator|Oral Hygiene|Dental Flossing 30% Silver Diammine Fluoride Placebo Resin Infiltration Placebo
3260215|NCT01477398|Active Comparator|inspired CO2|Inspired CO2
2571923|NCT02420249|Experimental|Qigong training group|Participants assigned to the Qigong group will receive Qigong training. The Qigong training programme will be run for 3 months with two supervised 1-hour sessions per week. Participants will learn the 18 Forms of Tai Chi Internal Qigong. The training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Association. Participants in the control group will receive no Qigong training during the study period. They will receive an 18 Forms of Tai Chi Internal Qigong training package after the study.
2571935|NCT02420249|No Intervention|Control group|Participants in the control group will receive no Qigong training.
2571961|NCT02419963|Other|IBS-D patients|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
2571963|NCT02419963|Other|Healthy Controls|Subjects on this arm will have an endoscopy for tissue biopsy, and provide blood samples and stool samples.
2571988|NCT02419729|Experimental|CO2 laser & Estrogen|Effective fractional CO2 laser therapy and effective estrogen vaginal cream
2571989|NCT02419729|Active Comparator|CO2 laser & Placebo of Estrogen|Effective fractional CO2 laser therapy and placebo of estrogen vaginal cream.
2571990|NCT02419729|Sham Comparator|Placebo of CO2 laser & Estrogen|Placebo fractional CO2 laser therapy and effective estrogen vaginal cream.
2572123|NCT02418962|Experimental|Group 1 (pilot group)|Group 1 will be comprised of 3 volunteers who will be vaccinated first before the rest for demonstration of safety. The safety volunteers will receive 2 escalating doses of PfSPZ vaccine at a two week interval, 1.35x10^5 and 2.7x10^5 PfSPZ.
2572125|NCT02418962|Experimental|Group 2|The second group of 14 - 20 volunteers will receive three vaccinations of 2.7x10^5 PfSPZ Vaccine that will be given at 0, 8 and 16 weeks
2572127|NCT02418962|Placebo Comparator|Group 3|The third group of 7 - 10 volunteers will act as control group for group 2 and will receive three injections of normal saline at 0, 8 and 16 weeks respectively.
2570945|NCT02426775|No Intervention|Propionic Acidemia Control Arm|patients with Propionic Acidemia will receive standard therapy only (protein restricted diet, L-carnitine, metronidazole and biotin)
2570950|NCT02426775|Experimental|Propionic Acidemia Active arm|patients with Propionic Acidemia will receive Carglumic Acid in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and biotin)
2571032|NCT02426372|Experimental|QBECO SSI 0.02 mL|0.02 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
2571034|NCT02426372|Experimental|QBECO SSI 0.05 mL|0.05 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
2571036|NCT02426372|Experimental|QBECO SSI 0.1 mL|0.1 mL administered subcutaneously, every other day for 16 weeks. After completion of the initial 16-week fixed dose treatment period, subjects deemed to be responders will be randomized to one of three maintenance dosing schedules (every second day, weekly, no treatment) for an additional 36 weeks.
2571223|NCT02424929|Other|Awake|"Original surgery intervention.~Patient will have DBS surgery done in the normal fashion. Asleep for the drilling of the burr holes, then awakened for the placement of the electrodes. No intervention will be given."
2571227|NCT02424929|Other|Asleep|"Sedation intervention.~Surgical intervention, anesthesia will be administered during entire placement of the system. Patient will not be awake at any point during procedure. All other aspects of surgery will be conducted normally."
2571316|NCT02424201|Experimental|study|Intramuscular oxytocin 10 units, 400 micrograms of misoprostol
2571322|NCT02424201|Other|control|Intramuscular oxytocin 10 units, 2 tablets of placebo which will be vitamin c
2571366|NCT02423941|Experimental|Retrograde reperfusion|During the transplant procedure the liver is initially reperfused retrogradely via hepatic veins. Venting of 300 ml blood is allowed via donor portal vein. After completion the portal vein anastomosis and retrograde venting of another 100 ml blood the antegrade portal reperfusion is performed.
2571368|NCT02423941|Active Comparator|Antegrade reperfusion|During the transplant procedure the liver is reperfused conventionally, antegradely via portal vein after completion of caval and portal anastomoses. Venting of 300 ml blood is allowed via tube placed in infrahepatiс caval anastomosis before unclamping the vena cava.
2571416|NCT02423616|Experimental|Healthy individuals|Study population was consisted by healthy volunteers from hospital staff of physical therapy department, Intensive Care Unit, and cleaning service. All subjects were men and women aged between 20 and 65 years old, who never had major problems with the respiratory system or with the hand flexors.
2571442|NCT02423304||test|"50 periodontitis patients~• Patients will be categorized by Periodontal Disease Index (PDI) by P. Ramfjord(1959) blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase( MMP)-13 in all the patients. studies showing that there is co relation of these genes with increase inflammation."
2571447|NCT02423304||control|50 periodontally healthy individuals blood samples collected from all patients serum separated and evaluated for77A/G AND 11A/12A associated gene polymorphism of Matrix Metallo Proteinase (MMP)-13 in all the patients
3175307|NCT00632580|Experimental|2|intracapsular injection with local anesthetic
3175308|NCT00632593|Active Comparator|Circular Stapled|Patients operated performing the gastric pouch of the gastric bypass with a circular staple device
3175309|NCT00632593|Active Comparator|Handsewn anastomosis|Patients operated performing the gastric pouch of the gastric bypass in a handsewn manner
2571799|NCT02420899|Experimental|Statins,lipid-lowering drugs|rosuvastatin 10mg or 20mg per day，pro
2571932|NCT02420340|Other|HOPES Group|Participants will participate in twice weekly sessions of the HOPES program until curriculum is completed (approximately 1 year) or discharge from Glencliff home
2572042|NCT02419950||No fixation of mesh in TEP|Patient having no mechanical fixation of the mesh in TEP. This will include both no fixation at all och glue fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
2572045|NCT02419950||Fixation of mesh in TEP|Patients having fixation of the mesh using mechanical, non absorbable fixating devices.This will include mechanical fixation of the mesh in total extraperitoneal placement of mesh by endoscopic technique
2572167|NCT02418702|Experimental|0.2mg/kg ketamine|After being assessed, and giving informed consent, participants would receive 0.2mg/kg ketamine. Their suicidal thinking, depression, and other symptoms would be monitored acutely for 240 min after drug infusion, and the for lasting changes the next day, at hospital discharge, 2 weeks, and 10 weeks.
2572174|NCT02418702|Placebo Comparator|placebo|After being assessed, and giving informed consent, participants would receive a placebo. Symptoms will be monitored.
2572229|NCT02418273|Experimental|Denosumab|These subjects will receive two sequential doses of denosumab
2572232|NCT02418273|No Intervention|No drug intervention|These subjects do not receive denosumab
2572300|NCT02418039|Placebo Comparator|MHE and normal protein diet|Normal protein content (0.8 g/kg/day)
2572305|NCT02418039|Experimental|MHE and high protein diet|Patients with minimal hepatic encephalopathy will received a high protein diet (1.5 g/kg/day)
3175310|NCT00632606|Active Comparator|Arm 1|magnesium sulfate 2 grams intravenously w/ acetaminophen 1 gram orally
3175311|NCT00632606|Active Comparator|Arm 2|metoclopramide 10 mg intravenously w/ 1 gram acetominophen orally
3175312|NCT00632645|Experimental|1|Olanzapine Mylan
3175313|NCT00632645|Active Comparator|2|Xenazine
3175314|NCT00632645|Active Comparator|3|Tiapridal
3175315|NCT00632658||Patients with cGVHD|Pediatric Patients with cGVHD will be asked to participate in an interview with their Physician. The interview will ask the pediatric patients questions about their cGVHD. The interview will be audio-recorded.
3175316|NCT00632671||Obese persons cohorte|constitution of a prospective data collection (biological, clinical, paraclinical and questionnaires) in morbidly obese persons.
3175317|NCT00632684|Active Comparator|1|Participants in Phase 1 will undergo four interviews, including a single treatment planning session.
2570975|NCT02426814|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: inhaler sensor"
2570979|NCT02426814|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application with reminders to allow self-management of medication use.~Interventions: inhaler sensor and mobile application for asthma adherence"
2571041|NCT02426151|Experimental|BEPO-A|Single subcutaneous injection of BEPO-A 4000 IU (Bioreactor manufacturing process)
2571043|NCT02426151|Active Comparator|REPO-A|Single subcutaneous injection of REPO-A 4000 IU (Roller bottle manufacturing process)
2571094|NCT02425800||Ancillary-Correlative (human prostate tissue model)|Tissue samples are collected from patients with benign prostatic hyperplasia for decellularization and preparation as human extracellular matrix for growing human prostate CSCs. Tissue samples are also collected from patients with prostate cancer for the analysis of TROP2+ cells by flow cytometry. Cytology Specimen Collection Procedure. Laboratory Biomarker Analysis.
2571127|NCT02425514|Experimental|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs(TM), which is the PEEK cage filled with b-TCP.
2571132|NCT02425514|Experimental|NovoMax™|The ACDF surgery will be carried out with NovoMax™, which is the bioactive glass ceramic intervertebral spacer
2571214|NCT02425254|Experimental|Preemptive paracetamol|1000mg intravenous paracetamol given ≥15 minutes before surgical incision and intravenous saline 15 minutes before the end of surgery
2571217|NCT02425254|Active Comparator|Postincision paracetamol|Intravenous saline ≥15 minutes before surgical incision and 1000mg intravenous paracetamol given 15 minutes before the end of surgery
2571255|NCT02424708|Placebo Comparator|Placebo|The study medication is packaged in sterile 1 ml pre-filled syringes, containing saline, which will be delivered intranasally.
2571257|NCT02424708|Active Comparator|Reduced Glutathione 100mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 100 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
2571259|NCT02424708|Active Comparator|Reduced Glutathione 200mg|The study medication is packaged in sterile 1 ml pre-filled syringes, containing 200 mg/ml of reduced glutathione (GSH), which will be delivered intranasally.
2571308|NCT02424266||Healthy subjects|None invasive imaging of the tear film for subjects with no eye disease
2571311|NCT02424266||keratoconjunctivits sicca (KCS) and Dry Eye Syndrome (DES)|None invasive imaging of the tear film for KCS and DES patients as confirmed by a cornea specialist
3209084|NCT00981266|Other|Augmentation|"The study population will consist of women aged 22 or over who are undergoing primary breast augmentation.~The Augmentation cohort will include candidates for general breast enlargement, post-lactational involution and/or asymmetry."
2571453|NCT02423174||Total Mesorectal Excision|Patients with an indication for surgical intervention for a total mesorectal excision
2571511|NCT02422992||PD|100 PD patients were patients diagnosed with Parkinson's disease
2571519|NCT02422992||Controls|242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients
3175318|NCT00632684|Experimental|2|Participants in Phase 2 will receive the adaptive treatment model.
3175319|NCT00632697|Active Comparator|1|
2571802|NCT02421016|Experimental|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
2571804|NCT02421016|Active Comparator|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
2571859|NCT02420704||Cleavage stage-thin endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2571861|NCT02420704||Cleavage stage-medium endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2571867|NCT02420704||Cleavage stage-thick endometrial|Patients transferred with cleavage stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2571870|NCT02420704||Blastocyst stage-thin endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≤7mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2571872|NCT02420704||Blastocyst stage-medium endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness 8-13mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2571880|NCT02420704||Blastocyst stage-thick endometrial|Patients transferred with blastocyst stage embryo, with endometrial thickness ≥14mm on the day of HCG (human chorionic gonadotropin) administration for fresh cycles, or on the day starting to use progesterone for frozen thawed cycles.
2572046|NCT02419482|No Intervention|control|Physical activity recommended
3175320|NCT00632697|Placebo Comparator|2|
3175321|NCT00632710|Experimental|b|laser
3175322|NCT00632710|Placebo Comparator|a|laser placebo
3175323|NCT00632762|Active Comparator|1|Amantadine MANTADIX
3175324|NCT00632762|Placebo Comparator|2|placebo
3175325|NCT00632775|Active Comparator|1|Subjects in this arm will receive hypotonic (0.45% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
3175326|NCT00632775|Active Comparator|2|Subjects in this arm will receive isotonic (0.9% NaCl/5% dextrose) intravenous (IV) maintenance fluids.
3175327|NCT00632788||intervention group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between March 1, 2007 and Oct. 31, 2007
3175328|NCT00632788||control group|patients presented with acute ST-elevation myocardial infarction and received emergency cardiac catheterization between April 1, 2006 and Feb. 28, 2007
3175329|NCT00632801|Other|A|Chewing gum or not
3175330|NCT00632840|Placebo Comparator|P|placebo group
3175331|NCT00632840|Active Comparator|Feno|Fenofibrate
3175332|NCT00632840|Active Comparator|ATV|Atorvastatin
2571018|NCT02426463|Active Comparator|Oxycodone|Plasma samples and patient data are collected prospectively from 40 neonates who receive oxycodone as part of their care in the neonatal intensive care unit at the Turku University Hospital, Turku, Finland.
3209085|NCT00981266|Other|Augmentation Revision|"The study population will consist of women aged 22 or over who are undergoing augmentation revision.~The Augmentation Revision cohort will include candidates with previous augmentation with silicone-filled or saline-filled implants."
2571129|NCT02425605|Experimental|CCRT-sorafenib group|
2571194|NCT02425241|Experimental|CPHPC|"CPHPC infusion over 26 hours to deplete SAP at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of CPHPC infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
2571198|NCT02425241|Placebo Comparator|0.9% w/v saline solution|"Placebo (normal saline) infusion over 26 hours at weeks 0,4 and 8. pSG2.HIVconsv DNA vaccine 4 mg at weeks 0, 4 and 8 after 24 hours of placebo infusion.~ChAdV63.HIVconsv booster vaccine 5 x 10^10 vp at week 12. MVA.HIVconsv booster vaccine 2 x 10^8 pfu at week 20"
2571299|NCT02424500|Experimental|d-Nav Device|"d-Nav Device: daily use to provide insulin dosage updates weekly - or sooner when needed based on analyzes and evaluates the historical blood glucose patterns.~Insulin dosage is adjusted as required"
2571301|NCT02424500|Active Comparator|Blood Glucose Monitoring System|"Patient's personal Over the Counter Blood Glucose Monitoring System (OTC BGMS) for daily glucose testing to determine insulin dosage needed.~Insulin dosage is adjusted as required"
2571356|NCT02424071|Active Comparator|Melatonin group|Patients will receive a pill containing 5mg of melatonin on the evening before the surgery. Patients will receive another pill containing 5mg of melatonin two hours prior to surgery.
2571360|NCT02424071|Placebo Comparator|Placebo group|Patients will receive a pill containing placebo on the evening before the surgery. Patients will receive another pill containing placebo two hours prior to surgery.
2571396|NCT02423694|Experimental|Electroacupuncture|"Baihui, Yintang, Guanyuan(dual), Zigong(dual), Sanyinjiao(dual), Hegu(dual), Taichong(dual).~Insert needles to the acupoints mentioned above after sterilized.Needle handles of Baihui and Yintang are connected with the electroacupuncture instrument wire. And needle handles of bilateral Zigong are conneted with the electroacupunture instrument wire. And needle handles of bilateral Tianshu are connected with the electroacupunture instrument wire. Density wave, frequency of 10/50Hz and current intensity is 0.5~1.0 mA for 30 minutes. 3 times per week. Each treatment interval of more than 24 hours, continuous treatment for 12 weeks."
2571397|NCT02423694|Active Comparator|escitalopram oxalate tablets|0.5 hour after breakfast oral taking 10mg escitalopram oxalate tablets, continuous treatment for 12 weeks.
2571458|NCT02423356||Echocardiography|All patients will receive 4 echocardiograms and 4 blood draws. The blood draws and echocardiograms will occur at the same visits.
2571490|NCT02422888|Experimental|Ticagrelor|Ticagrelor 90 mg twice a day, tablet Duration: 1 year after PCI
2571495|NCT02422888|Active Comparator|Prasugrel|Prasugrel 10 mg once a day, tablet Duration: 1 year after PCI
2571738|NCT02422121|Experimental|RNS60|RNS60, 4 ml twice daily
2571742|NCT02422121|Placebo Comparator|Placebo|Normal Saline, 4 ml twice daily
2571776|NCT02421198|Experimental|face-to-face|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
2571777|NCT02421198|Experimental|face-to-face + mobile hybrid|Delivery and testing of YMCA Family Diabetes Prevention Program (YFDPP) delivered face-to-face and via a mobile platform by YMCAs over 12 weeks to children age 9-12 and one parent/guardian.
3209086|NCT00981279||HIV seroposite patients|Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
3209087|NCT00981318|Other|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid|single arm
2571885|NCT02420561|Experimental|Motivational Interviewing|"The motivational interviewing (MI) intervention consisted of one 45-minute in-person MI session followed by two 15-minute telephone booster sessions"
2571890|NCT02420561|Active Comparator|Control|Participants received a brochure on alcohol and drug use risks.
3209088|NCT00981331|Experimental|Subtalar joint manipulation|Each subject in this group will recieve a subtalar joint manipulation to their symptomatic ankle
2571984|NCT02419703||Patients receiving Targeted Radiofrequency Ablation (t-RFA)|
3209089|NCT00981331|Sham Comparator|Sham Manipulation|Each subject in this group will recieve a sham subtalar joint manipulation to their symptomatic ankle
2572118|NCT02419092||Obstructive Sleep Apnea|Subjects scheduled to undergo bariatric surgery and with Obstructive Sleep Apnea
2572122|NCT02419092||No Obstructive Sleep Apnea, controls|Subjects scheduled to undergo bariatric surgery and without Obstructive Sleep Apnea, control group
3209090|NCT00981357|Experimental|PF-04457845 followed by placebo|
3209091|NCT00981357|Experimental|Placebo followed by PF-04457845|
3209092|NCT00981357|Active Comparator|Naproxen followed by placebo|
3209093|NCT00981357|Active Comparator|Placebo followed by Naproxen|
2575131|NCT02399280|Experimental|Lunch|Lunch as main meal(LM)+ Diet
3209094|NCT00981383|Experimental|Treatment|Omega-3 Fatty Acid Supplement, 1.9 g ω-3 FAs daily
3209095|NCT00981383|Placebo Comparator|Placebo|Matching placebo, less than 0.12 g ω-3 FAs daily
3209096|NCT00981396|Active Comparator|CBT|Cognitive Behavioral Therapy
3209097|NCT00981396|Experimental|EFT|Emotional Freedom Techniques, a novel but efficacious stress-reduction technique
3209098|NCT00981422||Glaucoma patients|POAG patients selected by an ophthalmologist from the Glaucoma Service, Ophthalmology Institute, University of Parma
3209099|NCT00981422||Healthy|healthy subjects with negative history for (a) neurodegenerative diseases, (b) autoimmune diseases, (c) cancer, (d) viral infection, (e) diabetes, and (f) systemic inflammation
2571023|NCT02426437|Other|Late Pulmonary Rehabilitation (LPR)|Patients randomized to LPR will be enrolled into the Breath Easy pulmonary rehabilitation (PR) program at the Centre for Lung Health within 3 months of discharge. They will proceed through the program in a typical fashion.
2571024|NCT02426437|Other|Usual Care|Usual care patients will be followed-up by their most responsible physician as determined by the admitting team.
2571099|NCT02425943|Experimental|Sculptra Aesthetic|
2571124|NCT02425566|Experimental|Study day with trimethaphan|After baseline measurements, autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min.
2571126|NCT02425566|Experimental|Radionuclide Study day with nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements. Outcome measurements will be repeated within 10 min after the nitroglycerin has dissolved
2571317|NCT02424227||Kidney Transplant Recipients|Adult living and deceased donor kidney transplant recipients will be eligible to participate in this study.
3175333|NCT00632853|Active Comparator|Arm A - Standard Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 3 weeks) XRT: 45 Gy BID (1.5 Gy/fx) starting on day 1 of Cycle 1 or 2, every day, for 3 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV Register/ on days 1, 2, and 3, every 21 days"
3175334|NCT00632853|Experimental|Arm B - High Dose Radiotherapy + Chemotherapy|"Radiotherapy (every day, Monday-Friday, for a total of 7 weeks) XRT: 70 Gy QD (2.0 Gy/fx), starting on day 1 of Cycle 1 or 2, every day, for 7 weeks~Chemotherapy (every 21 days for 4 cycles, for a total of 12 weeks):~Cisplatin 80 mg/m2 IV on day 1 OR Carboplatin AUC 5 IV day 1, every 21 days~Etoposide 100 mg/m2 IV on days 1, 2, and 3, every 21 days"
2571435|NCT02423434||Corneal Confocal Microscopy subjects|
3175335|NCT00632866|Experimental|1|Active treatment : Hydroxychloroquine
2571556|NCT02422576|Active Comparator|Control + Product 1|Control product (Thicken Up clear: TUC) + natural ingredient 1 (cinnamon extract)
2571558|NCT02422576|Active Comparator|Control + Product 2|Control product (Thicken Up clear: TUC) + natural ingredient 2 (lemon extract)
2571560|NCT02422576|Active Comparator|Control + Product 3|Control product (Thicken Up clear: TUC) + natural ingredient 3 (lemon extract+eucalyptus extract)
2571768|NCT02421302|No Intervention|Well-nourished HIV+ ART naive|These children aged between 6months-12years will be followed up for 12weeks to look at their nutrition, immune and pharmacological responses. They will receive routine nutritional and ART adherence counseling
2571771|NCT02421302|Active Comparator|Moderately-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
2571773|NCT02421302|Active Comparator|Severely acute-malnourished HIV+; RUTF|These children aged between 6months - 12years, ART naive or experienced, will be initiating ready-to-use-therapeutic(RUTF) food and will be followed up for 12 weeks to see the effect of nutrition supplementation on immune and pharmacological responses
2571789|NCT02420964|Other|Nurse instruction|Traditional injection teaching method. No video instruction
2571790|NCT02420964|Other|Video instruction|Video instruction that can be paused/repeated by subject
2571863|NCT02420795|Experimental|Treatment (Akt/ERK inhibitor ONC201)|Patients receive Akt/ERK inhibitor ONC201 PO on day 1 of every cycle or day 1 of every week. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2571936|NCT02420288|No Intervention|Control Group|Pregnant women not participating in supervised physical exercise program. The subjects in this group will be monitored during pregnancy to know if they make any kind of exercise on your own, to know which are really sedentary pregnant women.
2571940|NCT02420288|Experimental|Exercise Group|Pregnant women participating in supervised physical exercise program.
2572031|NCT02419638||Randomized Treatment Arm: Rebif|120 patients treated with Rebif (IFN β-1a subcutaneous three times per week)
2575140|NCT02399280|Experimental|Dinner|Dinner as main meal(DM)+ Diet
3175336|NCT00632866|Placebo Comparator|2|Placebo
3175337|NCT00632905||1|Normal - BMD with T-score at or above -1.0
3175338|NCT00632905||2|Osteopenic - BMD with T-score between -1.1 and -2.4
3175339|NCT00632905||3|Osteoporotic - BMD with T-score at or below -2.5
3175340|NCT00632957|Active Comparator|Fish oil|
3175341|NCT00632957|Placebo Comparator|Placebo|
3175342|NCT00632996|Experimental|1|
3175343|NCT00633035|Active Comparator|1|oral esomeprazole tablet dissolved in water given through NG tube
3175344|NCT00633035|Active Comparator|2|intravenous famotidine injection
3175345|NCT00633048|Experimental|NSA-789|active drug
3175346|NCT00633048|Placebo Comparator|placebo|placebo
3175347|NCT00633113|Active Comparator|1|- Medial Parapatellar Arthrotomy (MPPA) technique
3175348|NCT00633113|Active Comparator|2|- Subvastus (SV) technique
3175349|NCT00633178|Experimental|Group Interpersonal Therapy (IPT)|Participants will receive group interpersonal therapy.
3175350|NCT00633178|Active Comparator|Treatment as Usual (ETAU)|Participants will receive psychiatric treatment as usual.
3175351|NCT00633178|No Intervention|No Treatment|Participants are healthy and will receive no treatment.
3175352|NCT00633191|Experimental|Anti-pseudomonas IgY gargle|Intervention: Gargles with anti-pseudomonas IgY every night
3175353|NCT00633230|Active Comparator|1|standardized herbal formula, Sho-saiko-to (SST): 3 capsules containing 700 mg of the SST herbal extract/capsule and 28 mg of the excipients, magnesium stearate and silicon dioxide/capsule 2 x day
3175354|NCT00633230|Placebo Comparator|2|placebo capsules that look and smell identical to the active Sho-saiko-to (SST) capsules
3175355|NCT00633282|Experimental|Lifestyle intervention|Life style intervention including aerobic exercise and reducing energy intake(-500kcal) without drug
3175356|NCT00633282|Experimental|Life style intervention, pioglitazone|Life style intervention with pioglitazone 15mg qd for 16 weeks
3175357|NCT00633282|Experimental|Life style intervention, berberine|Life style intervention with berberine 0.5g tid for 16 weeks
3175358|NCT00633295|Experimental|nilotinib|
2571046|NCT02426099|Active Comparator|Routine|Routine intensification of anti hypertensive treatment based on existing guidelines
2571138|NCT02425748|Experimental|Group A|DC-CIK cells will be used against tumor cells.
2571141|NCT02425748|Experimental|Group B|γδ T cells will be used against tumor cells.
2571149|NCT02425748|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
2571201|NCT02425137|Experimental|S-1/Gemcitabine|single-arm
2571263|NCT02424812|Experimental|Intervention|school based handwashing education programme
2571265|NCT02424812|No Intervention|Control|no intervention
2571302|NCT02424396|Experimental|1 : IL2|Interleukin-2 (ILT-101)
2571304|NCT02424396|Placebo Comparator|2 : Placebo|Placebo
2571345|NCT02424032|Experimental|Exercise and connective tissue massage|Stabilization exercise and connective tissue massage have been applied
2571349|NCT02424032|Active Comparator|Exercise|Only stabilization exercise has been applied
2571422|NCT02423720|Other|Study Intervention|Audio-based mindfulness intervention A 8-week single arm pilot study will be conducted among Helen Diller Famiily Comprehensive Cancer Center (HDFCCC) patients with metastatic colorectal cancer receiving chemotherapy and their caregivers (44 participants, total). Participants will receive an informational booklet containing a practice log and an MP3 player containing an introductory lecture and guided meditations. Practice reminders will be sent via text messages. Weekly emails will contain practice instructions and links to validated questionnaires.
2571462|NCT02423226|Active Comparator|CT alone|Treated with systemic chemotherapy alone (FOLFIRI).
2571464|NCT02423226|Experimental|CT+BT|Treated with systemic chemotherapy (FOLFIRI) plus computed tomography guided radioactive seeds implant.
2571521|NCT02422862|Experimental|UC-TSM|Upper cervical translatoric spinal mobilization (UC-TSM). UC-TSM is a physical therapy technique used to improve range of movement, consisting on a manual stretching of the cervical spine of the patient during 30 minutes.
2571528|NCT02422862|No Intervention|Control|The control group receive no treatment intervention during 30 minutes (a similar time as the UC-TSM group).
2571569|NCT02422589|Experimental|Ceritinib|
2571643|NCT02422030|Experimental|Group1: TreatmentA+TreatmentB+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571646|NCT02422030|Experimental|Group2: TreatmentC+TreatmentA+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571649|NCT02422030|Experimental|Group3: TreatmentB+TreatmentC+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571650|NCT02422030|Experimental|Group4: TreatmentC+TreatmentB+TreatmentA|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571651|NCT02422030|Experimental|Group5: TreatmentB+TreatmentA+TreatmentC|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571654|NCT02422030|Experimental|Group6: TreatmentA+TreatmentC+TreatmentB|TreatmentA: Atorvastatin 40m*1T/day, TreatmentB: Fenofibric acid 135mg*1Cap/day, TreatmentC: Atorvastatin 40m*1T/day and Fenofibric acid 135mg*1Cap/day. Each treatment period was separated by a washout period of at least 8days.
2571735|NCT02421640|Experimental|Cisplatin+TIL|Cisplatin concurrent chemoradiotherapy(CCRT) combined with tumor-infiltrating lymphocyte (TIL)
2571739|NCT02421640|Active Comparator|Cisplatin|Cisplatin concurrent chemoradiotherapy(CCRT) only
2571796|NCT02421133|Experimental|Transitional care program.|The transitional care program from hospital to home will be implemented at three steps: during the patient's stay in hospital, the day of the discharge and during 4 weeks after discharge.
2571801|NCT02421133|Other|standard care program|No intervention liable to affect the care provided to the patients, the organization of care or the practices of health care professionals will be implemented during the control period (time steps without intervention).
2571883|NCT02420652|Experimental|Arm I (metformin hydrochloride, aspirin)|Patients receive metformin hydrochloride PO BID and aspirin PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
2571888|NCT02420652|Placebo Comparator|Arm II (metformin hydrochloride placebo, aspirin placebo)|Patients receive metformin hydrochloride placebo PO BID and aspirin placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
2571946|NCT02420080||Cohort A|"The primary endpoint for subjects in Cohort A is time to progression of AdV disease through Week 24 post initial AdV diagnosis, with progression of AdV disease defined as time to the following outcomes:~Clinical progression to probable or definitive disseminated AdV disease Death"
2571948|NCT02420080||Cohort B|The primary endpoint for subjects in Cohort B is time to all-cause mortality through Week 36 post diagnosis of disseminated AdV disease
2571966|NCT02419742|Experimental|Trastuzumab|Participants will receive trastuzumab as a part of either AC-TH or TCH treatment regimen. The choice of the regimen will be based on investigator's discretion referring the local prescribing document of trastuzumab. AC-TH consists of doxorubicin and cyclophosphamide followed by either paclitaxel or docetaxel. TCH consists of docetaxel and carboplatin. Trastuzumab will be common in both treatment regimens and could be administered weekly or every 3 weeks, as per investigator discretion. Each cycle will be of 3 weeks.
2572016|NCT02419534|Active Comparator|Polyethylene glycol|In our study parents will be asked to start at 1g per day if they are less than 1 year of age and 2g per day in divided doses if they are older and will be asked to titrate the does according to the response up to the a maximum does of .5g/kg/day. In titrating the dose parent will be asked to increase the dose every 2 days until the child pass one normal BM per day without significant efforts. They should titrate down or hold treatment if the child developed lose BM or diarrhea. Caregiver will be asked to use placebo ointment by applying 5mm on fingertip to the anal verge area twice a day for the duration of the study.
2572186|NCT02418780|No Intervention|Usual Care|Waitlist control group receiving usual medical care alone
2571079|NCT02425813|Experimental|Treatment (methylprednisolone sodium succinate, budesonide)|"STUDY AGENT: Patients receive methylprednisolone sodium succinate IA QD on days 1-3.~CONVENTIONAL THERAPY: Patients also receive conventional therapy comprising methylprednisolone sodium succinate IV every 12 hours on for 7-14 days beginning on day 1 and budesonide PO on days 1-56. Patients with response by day 7-14 may begin taper and receive methylprednisolone PO on days 28-56. Treatment continues in the absence of disease progression or unacceptable toxicity.~IST: Patients receive conventional IST or continue their previous prophylactic regimen beginning on day 1 to 56 (or beyond) at the discretion of the treating physician."
3209100|NCT00981448|Experimental|Zinc supplement|
3209101|NCT00981487|Experimental|Fed|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning. The Ondansetron dose will be administered after a 10-hour overnight fast and thirty minutes after consuming a high-fat, high-caloric breakfast.
3209102|NCT00981487|Experimental|Fasting|A single oral dose of EUR-1025 (1 x 24 mg) will be administered with approximately 240 ml of water in the morning after a 10-hour overnight fast.
3209103|NCT00981500||Gastric Bypass|morbidly obese subjects undergoing gastric bypass surgery
3209104|NCT00981500||gastric banding|morbidly obese subjects undergoing laparoscopic gastric banding surgery
2571219|NCT02424981|Experimental|inspiratory muscle training|Muscle training
2571220|NCT02424981|No Intervention|control|Control group
2571267|NCT02424825|Experimental|Rouxbe|Subjects will attend a one-month online cooking course, and be followed before, during, and after their participation for quality-of-life, fatigue, and blood biomarker changes.
3209105|NCT00981500||sleeve gastrectomy|morbidly obese subjects undergoing sleeve gastrectomy
2571503|NCT02422927|Placebo Comparator|Standard of Care + Placebo|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + once daily placebo
2571507|NCT02422927|Active Comparator|Nutraceutical combination|low-cholesterol/low-saturated fat diet and a regular aerobic physical activity schedule + Nutraceutical combination
2571585|NCT02422498|Experimental|Concurrent Cisplatin & Radiation Therapy|
2571747|NCT02422004|Active Comparator|Control|This constitutes the currently accepted regime and is therefore consider the control group (CTRL) with early range of motion and early weight bearing. The control group was allowed to have partial weight-bearing from day 0 and full weight-bearing from week 4. Furthermore, they were instructed in tendon strain exercise identical with the range of motion group.
2571749|NCT02422004|Experimental|Range of motion|Early range of motion and delayed weight bearing (ROM). The range of motion group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks. In addition to this, the patients were instructed to perform tendon strain exercises, five times a day, from week 2. The exercises were performed by removing the foot from the brace and then perform light dorsal ankle movement, 25 repetitions/time, when sitting on a table.
2571752|NCT02422004|Experimental|Immobilization|Delayed weight-bearing or range of motion (IMMOB). The immobilization group was restricted completely from weight-bearing until week 6, allowed partial weight-bearing after 6 weeks and full weight-bearing after 8 weeks.
2571795|NCT02421068||Preterm neonates|All neonates that receive at least one of the 9 drugs (phenobarbital, paracetamol, levetiracetam, midazolam, sildenafil, fentanyl, doxapram, ibuprofen, fluconazole) are included in the studied cohort
2571944|NCT02420405|Placebo Comparator|Routine gene testing|Routine gene testing of EGFR, ROS1 and ALK will be performed on those diagnosed with nonsquamous NSCLC.
2571945|NCT02420405|Experimental|Next-generation sequencing|Routine gene testing was performed in those diagnosed with nonsquamous NSCLC. NGS will be performed on these that have adequate rest tissues.
3209106|NCT00981513|Active Comparator|Influenza vaccination|Live attenuated influenza vaccine (seasonal and pandemic strains) by nasal spray
2572051|NCT02419417|Experimental|Monotherapy Treatment|Patients treated at various doses and schedules
2572053|NCT02419417|Experimental|Combination Therapy|Patients treated at selected doses and schdules
2572083|NCT02419118|Experimental|Dara len dex|Daratumumab in combination with lenalidomide and dexamethasone
2572084|NCT02419118|Active Comparator|Len dex|Lenalidomide in combination with dexamethasone
3209107|NCT00981513|Placebo Comparator|Saline placebo|Saline nasal spray
3209108|NCT00981539|Active Comparator|treatment : receives pre operative enema|one arm will receive pre operative enema
3209109|NCT00981539|No Intervention|no enema|this group will not receive pre operative enema
3209110|NCT00981552|Other|Cervix Cancer|Patients treated with cervical cancer in 2008 at Sunnybrook Odette Cancer Centre
3209111|NCT00981565|Active Comparator|Operative|
2572351|NCT02417493|Experimental|Simulation of Epinephrine Self-Injection|The patient will self-inject an empty syringe into his/her thigh simulating a self-injection of epinephrine during a routine outpatient visit to the allergist.
2572357|NCT02417493|No Intervention|Control Group|The patient will be encouraged to speak to their physician about self-injection, but will not undergo the self-injection protocol during a routine outpatient visit to the allergist.
2572410|NCT02417298|Active Comparator|Ketamine|Ketamine 0.3 mg/kg intravenous push followed by ketamine infusion at 0.1 mg/kg/hr for 3 hours
2572411|NCT02417298|Placebo Comparator|Saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
2572492|NCT02416869|Active Comparator|Intramuscular application|Intramuscular application of 4mg Dexamethasone
2572501|NCT02416869|Experimental|Submucosal application|Submucosal application of 4mg Dexamethasone
2572506|NCT02416869|Active Comparator|4mg Dexamethasone submucosal|4mg Dexamethasone submucosal application
2572509|NCT02416869|Experimental|8mg Dexamethasone submucosal|8mg Dexamethasone submucosal application
2572510|NCT02416869|Active Comparator|4mg Dexamethasone postoperative|4mg Dexamethasone postoperative application
2572512|NCT02416869|Experimental|4mg Dexamethasone preoperative|4mg Dexamethasone postoperative application
3209112|NCT00981565|Active Comparator|Conservative|
3209113|NCT00981591|Experimental|Inhaled Iloprost|
3209114|NCT00981591|Placebo Comparator|Inhaled Placebo|
2571140|NCT02425384|Active Comparator|Active Control|This group is provided an activity meter that tracks the amount and intensity of one's physical activity and a copy of the game Dance Dance Revolution (DDR). The activity meter will upload data to a secure server but will not be linked to the motivational website used by the intervention group. DDR is a dancing video game in which players view arrows timed to music on a TV screen and gain points by stepping on the corresponding arrows on a floor mat. Players obtain points in the game by stepping on the correct arrows at the right time to the beat of the music. The points earned with DDR cannot be redeemed for rewards.
2571150|NCT02425384|Placebo Comparator|Passive Control|This group is provided with an activity meter and will be asked to carry it with them as they go about their normal daily activities. Like in the Active Control group, participants in the Passive Control group will not have access to the motivational website. For this group, the activity meter functions solely as a monitor to track their activity levels. No other product or intervention will be introduced to the control group.
3209115|NCT00981604|Active Comparator|SILS Cholecystectomy|Single Incision Laparoscopic Cholecystectomy
3209116|NCT00981604|Active Comparator|Standard Laparoscopic Cholecystectomy|4 port laparoscopic cholecystectomy
2571329|NCT02424474|Experimental|Genetic NIPT and regular serum screening|All woman will be tested using the two tests, genetic NIPT (Non Invasive Prenatal Testing) and regular serum screening.
2571363|NCT02423915|Experimental|Phase I: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Mesna administered on Day -8 immediately following completion of the Fludarabine.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Three (3) participants treated at cell dose level 1: 1 x 10^6/kg fucosylated T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD transplant on Day 0.~Mycophenolate 15 mg/kg by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
2571367|NCT02423915|Experimental|Phase I: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~3rd party CB Treg infusion on Day -1.~Ten (10) participants treated with non-fucosylated T-reg cells at dose level 2: 1 x 10^7/kg T-reg cells. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
2571369|NCT02423915|Experimental|Phase II: Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
2571371|NCT02423915|Experimental|Phase II: Non-Fucosylated T-reg Cells + Chemotherapy|"Rituximab 375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.~Fludarabine 40 mg/m2 by vein on Days -8 to -5.~Cyclophosphamide 50 mg/kg by vein on Day -8.~Total body radiation 2 Gy delivered on Day -4.~Seventeen (17) participants treated with Non-Fucosylated T-reg cells at dose level 2: 1 x 10^7/kg. The cells are infused on Day -1.~Cord blood transplant, MRD, or MUD infused on Day 0.~Mycophenolate 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.~Sirolimus 12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.~G-CSF 5 mcg/kg/day subcutaneously beginning on D+0 for CORD blood stem cell transplant and D+7 for allogeneic stem cell transplant, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days."
3209117|NCT00981617|Experimental|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
3209118|NCT00981617|Experimental|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
2571577|NCT02422381|Experimental|MK-3475 + Gemcitabine|200mg MK-3475 200 given by IV infusion every 3 weeks, for 2 years, or until disease progression and Gemcitabine 1250 mg/m2 iv Days 1, 8 every 3 weeks, for maximum 6 cycles.
2571618|NCT02422056|Placebo Comparator|Placebo|Saline infusion: Group receiving saline as placebo during the surgical procedure
2571620|NCT02422056|Experimental|Intervention|Tranexamic acid infusion: Group that received a Tranexamic acid bolus of 10mg / kg, followed by continuous infusion of 1 mg / kg / hr until the end of the procedure.
2571708|NCT02421926||IDEAL-E observational group|Subjects who were newly diagnosed as chronic phase chronic myelogenous leukemia, were enrolled to 'IDEAL' study, finished the total study period of 'IDEAL' study or were dropped during the study period.
2572094|NCT02419131|Experimental|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
3209119|NCT00981617|Experimental|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) provided as capsules for daily oral administration
3209120|NCT00981617|Placebo Comparator|Placebo|Matching placebo (capsules without active study drug) provided for daily oral administration
3209121|NCT00981643|Experimental|Multiple Sclerosis, Meditation group|Multiple Sclerosis, Meditation instruction and practice group
3209122|NCT00981643|No Intervention|Multiple Sclerosis, Control group|Multiple Sclerosis, Control group
3209123|NCT00981643|Experimental|Peripheral Neuropathy, Meditation group|Peripheral Neuropathy, Meditation instruction and practice group
2571190|NCT02425280|Experimental|Narrative Exposure Therapy|For the intervention group receiving Narrative Exposure Therapy treatment, the intervention will last for approximately three months and include 10-12 weekly sessions of 60-90 minutes. The course of the intervention will follow the NET manual (Schauer et al., 2011).
2571191|NCT02425280|Active Comparator|Treatment as Usual|For the TAU control group, participants will receive the usual care for posttraumatic stress symptoms currently offered by each unit.
2571248|NCT02424851|Active Comparator|Arm A (BBD)|Bortezomib, Bendamustine and Dexamethasone
2571249|NCT02424851|Active Comparator|Arm B (BTD)|Thalidomide, Bendamustine and Dexamethasone
3209124|NCT00981643|No Intervention|Peripheral Neuropathy, Control group|Peripheral Neuropathy, Control group
3209125|NCT00981656|Experimental|TURBT + Concurrent RT + Chemotherapy|Transurethral resection of the bladder tumor (TURBT) + Concurrent Radiation Therapy (RT) + Chemotherapy
2571406|NCT02423707|Active Comparator|ALK Alutard Birch and/or 5-grasses|3 intralymphatic injections with dose 1000 SQ-U and dose interval 4 weeks.
2571408|NCT02423707|Placebo Comparator|ALK diluent|3 intralymphatic injections with dose interval 4 weeks.
2571443|NCT02423278|Experimental|D4 Lymphadenectomy|"This is the interventional group in which additional para-aortic lymph nodes are dissected meanwhile.~Under this arm, main therapeutic measures are listed as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D4 lymphadenectomy~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
2571445|NCT02423278|Experimental|D2 Lymphadenectomy|"This is the control group in which a classic surgical procedure for gastric cancer is performed.~Under this arm, main therapeutic measures are included as follows:~three-cycle SOX chemo regimen (S-1+Oxaliplatin) as neoadjuvant chemotherapy~radical gastrectomy plus D2 lymphadenectomy (Without para-aortic lymph nodes dissection)~five-cycle SOX chemo as adjuvant chemotherapy~five-year follow-up program to evaluate the prognosis."
2571482|NCT02422849|Other|own GP|The patient is cared for by own General Practitioner in the acute stage
2571486|NCT02422849|Other|Hospital specialist|The patient is cared for by a hospital specialist in the acute stage
2571557|NCT02422706|Active Comparator|group I|"Metronidazole(MTZ) 500mg twice daily ,Omeprazole 20 mg twice daily as (Proton Pump Inhibitor (PPI)& Clarithromycin 500 mg twice daily .for 14 days .~40 patients"
2571559|NCT02422706|Experimental|Group II|"Nitazoxanide(NTZ)500 mg twice daily ,PPI 20 mg twice daily & Clarithromycin 500 mg twice daily for 14 days.~40 patients."
2571561|NCT02422706|Experimental|Group III|"Levofloxacin 250 mg once daily,Omeprazole 40mg once daily(PPI),Nitazoxanide (NTZ) 500mg twice daily & Doxicycline 100 mg once daily (LOND).~40 patients"
2571617|NCT02422043|Experimental|type 1 diabetes adolescents cohort|The participants of the prospective cohort of adolescents will be 12 to 17 years of age, type 1 diabetics with insulin, included in TPE program
2571673|NCT02421965|Experimental|FOCUS (Smartphone Application)|FOCUS is a smartphone application system designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It delivers both system initiated (i.e. pre-programmed) and patient initiated (i.e. on demand) real-time assessment to individuals in their own environment.
2571674|NCT02421965|Active Comparator|WRAP (Wellness Recovery Action Planning)|WRAP is a clinic-based intervention designed to improve illness self-management and facilitate recovery in individuals with serious mental illness. It is conducted in group sessions that are delivered by trained facilitators with lived experience, using lecture, group discussion, and exercises.
2571713|NCT02421627|Experimental|Moxibustion group|Receiving moxibustion treatment
2571714|NCT02421627|Sham Comparator|Sham moxibustion group|Receiving sham moxibustion.
3209126|NCT00981695|Experimental|Vaccinees|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
2571809|NCT02420925|Experimental|Celiac Plexus Block|There is one treatment arm who undergoes celiac plexus block.
2571857|NCT02420730|Experimental|Cohort 1A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
2571858|NCT02420730|Experimental|Cohort 1B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose A in Cohort 1A is acceptable.
2571860|NCT02420730|Experimental|Cohort 1C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants if the safety and tolerability of Dose B in Cohort 1B is acceptable.
2571864|NCT02420730|Placebo Comparator|Cohort 1: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered in the study eye once daily for one day, followed by twice daily for 16 days in healthy participants.
2571868|NCT02420730|Experimental|Cohort 2A: AGN-232411 Dose A|One drop of AGN-232411 topical ophthalmic solution Dose A administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
2571871|NCT02420730|Experimental|Cohort 2B: AGN-232411 Dose B|One drop of AGN-232411 topical ophthalmic solution Dose B administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose A in Cohort 2A is acceptable.
2571874|NCT02420730|Experimental|Cohort 2C: AGN-232411 Dose C|One drop of AGN-232411 topical ophthalmic solution Dose C administered in the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease if the safety and tolerability of Dose B in Cohort 2B is acceptable.
2571879|NCT02420730|Placebo Comparator|Cohort 2: AGN-232411 Vehicle|One drop of Vehicle for AGN-232411 topical ophthalmic solution administered to the study eye once daily for one day, followed by twice daily for 27 days in participants with dry eye disease.
2571920|NCT02420158|Experimental|Vagal nerve stimulation|Trans-cutaneous vagal nerve electrical stimulation during 6 months
2571979|NCT02420002|Active Comparator|Usual care (MEOPA)|"Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing.~Intervention: Use of MEOPA during suturing Intervention: Stitch removal"
2572095|NCT02419131|Experimental|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
2571195|NCT02425020|Experimental|Meat protein|Post workout (training days) or breakfast (non training days) 20g of meat protein mixed with 250ml of orange juice and water
2571204|NCT02425020|Experimental|Whey Protein|Post workout (training days) or breakfast (non training days) 20g of whey protein isolate mixed with 250ml of orange juice and water
2571210|NCT02425020|Active Comparator|Carbohydrate|Post workout (training days) or breakfast (non training days) maltodextrin mixed with 250ml orange juice and water
2571515|NCT02423018|Active Comparator|Pregabalin|Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
2571529|NCT02423018|Placebo Comparator|Placebo|Placebo for 10 days
2571619|NCT02422069||Study Population|Gynecology outpatients who meet eligibility criteria will be enrolled and evaluated for the presence of PMO at screening. Women diagnosed with PMO will complete an additional visit to document the prescribed management plan.
3175359|NCT00633308|Experimental|A|Long hemodialysis
3175360|NCT00633321|Experimental|1|TA-NIC 100 μg
2571903|NCT02420470||healthy control group|fasting plasma glucose(FPG)<6.11mmol/L，and 2-h plasma glucose(2hPG)<7.77mmol/L；
2571905|NCT02420470||prodromal diabetes group|IFG：fasting plasma glucose(FPG) ≥5.6mmol/L (100mg/dl)，and<7.0mmol/L (126mg/dl)，oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) <7.8 mmol/L ；IGT：oral glucose tolerance test(OGTT) 2-h plasma glucose(2hPG) ≥7.8mmol/L (140mg/dl)，and<11.1mmol/L (200mg/dl)，fasting plasma glucose(FPG)< 5.6mmol/L
2571906|NCT02420470||diabetes group|fasting plasma glucose(FPG)>7.0mmol/L, or 2-h plasma glucose(2hPG)>11.1mmol/L
2571914|NCT02420145|Experimental|Yoga|This group will participate in 12 weeks of yoga
2571915|NCT02420145|No Intervention|Waitlist|No intervention
2571960|NCT02420028|Experimental|OptiVein IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
2571962|NCT02420028|Active Comparator|Vasofix Certo IV catheter|Insertion of an IV catheter into the patient's vein, defined as placement of the catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
2572090|NCT02419027|Experimental|GI Flora|Lactobacillus acidophilus LA1 1.312% Lactobacillus rhamnosus LR5 0.656% Lactobacillus paracasei LPC5 0.656% Bifidobacterium lactis BL3 1.312% Bifidobacterium breve BR3 1.312% Pediococcus pentosaceus SL4 1.312% Prolac-T(heat-killed L. acidophilus LA1) 24.286% Dextrose 60.000% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
2572092|NCT02419027|Placebo Comparator|placebo|Dextrose 89.846% Maltodextrin 7.154% Lemon flavor 1.000% Mg-stearate 1.000% TOTAL 100% (1.4g)%
2572146|NCT02418936||WS|WS diagositic kit
2572147|NCT02418936||LVAS|LVAS diagositic kit
2572172|NCT02418520|Experimental|Miswak chewing|Chewing Sticks
2572173|NCT02418520|No Intervention|H.Pylori|Oral H.Pylori
2572217|NCT02418260|Active Comparator|Open reduction and plate osteosynthesis|Open reduction and internal fixation with DCP 4.5mm plate.
2572226|NCT02418260|Experimental|Bridge Plate|Patients will be submitted to closed reduction and anterior bridge plate osteosynthesis (narrow 4.5mm DCP plate will be used)
3175361|NCT00633321|Experimental|2|TA-NIC 250 μg
3175362|NCT00633321|Placebo Comparator|3|
3175363|NCT00633347|Active Comparator|A|A: Antagonist
3175364|NCT00633347|Active Comparator|B|Agonist GnRH
3175365|NCT00633386|Experimental|A|
3175366|NCT00633386|Placebo Comparator|B|
3175367|NCT00633412|Experimental|1|20mg Oral tablet daily
3175368|NCT00633412|Experimental|2|40mg Oral tablet daily
3175369|NCT00633412|Active Comparator|3|150mg oral twice daily
3175370|NCT00633438|Placebo Comparator|B|
3175371|NCT00633438|Experimental|A|
3175372|NCT00633451|Experimental|1|Manual Therapy + Exercise
3175373|NCT00633451|Active Comparator|2|Exercise Only
3175374|NCT00633490|Experimental|A|
3175375|NCT00633503||A-Observation|All patients undergoing pedicle and free tissue transfer.
3175376|NCT00633516||Medical tool|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
3175377|NCT00633529|Experimental|I|Single arm: triple combination
3175378|NCT00633542|Experimental|TD|thalidomide-dexamethasone
3175379|NCT00633542|Active Comparator|ID|Interferon-dexamethasone
3175380|NCT00633568|Active Comparator|A|One course of chemotherapy with cisplatin and docetaxel followed by induction chemoradiotherapy followed by two courses of consolidation chemotherapy
3175381|NCT00633568|Experimental|B|Three courses of induction chemotherapy followed by consolidation chemoradiotherapy
3175382|NCT00633581|Experimental|1|Intravenous injections of 10 grams(20ml as a solution) of vitamin C with 100ml of normal saline over 30 minutes.
3175383|NCT00633581|Placebo Comparator|2|Intravenous injections of 120ml of normal saline over 30 minutes.
3175384|NCT00633620|Experimental|colonoscopy|Non-NBI HDTV colonoscopy
3175385|NCT00633633|Other|Group 1|Usual Care
3175386|NCT00633633|Experimental|Group 2|Exercise Training + Dietary Counseling
3175387|NCT00633646|Active Comparator|1|low protein diet
3175388|NCT00633646|Active Comparator|2|low protein diet with keto acids
3175389|NCT00633646|Active Comparator|3|high protein diet
3175390|NCT00633659|Experimental|Hemospan (MP4OX)|4.3 g/dL MalPEG-Hb solution
3175391|NCT00633659|Experimental|Control|Voluven (HES 130/0.4)
3175392|NCT00633672|Experimental|1|20mg Oral tablet daily
3175393|NCT00633672|Experimental|2|40mg oral tablet daily
3175394|NCT00633672|Active Comparator|3|150mg oral twice daily
3175395|NCT00633685|Experimental|Fluoxetine|Receives Fluoxetine at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
3175396|NCT00633685|Placebo Comparator|Placebo|
3175397|NCT00633698|Active Comparator|1|Nicotinic acid (niacin)
3175398|NCT00633698|Placebo Comparator|2|Placebo
3175399|NCT00633711|Active Comparator|fixed CPAP|
3175400|NCT00633711|Experimental|Auto-CPAP|"Auto-CPAP Weinmann Somnosmart2"
3175401|NCT00633724|Experimental|1|
3175402|NCT00633737|Experimental|1|Stress reduction intervention
2571256|NCT02424747||No Acute Kidney Injury.|Intensive care patients not diagnosed with acute kidney Injury during admission and not previously diagnosed with Chronic Kidney Disease or End Stage Renal Disease.
2571323|NCT02424461|Active Comparator|7 day-antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for seven days~Placebo of ofloxacine for 7 days"
2571325|NCT02424461|Active Comparator|14-day antimicrobial treatment|"Ceftriaxone : 1 injection 1 g per day for 2 days~Ofloxacine : 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days"
2571375|NCT02423850||Diabetic foot ulcers|Newly referred patients with diabetic foot ulcers from the multidisciplinary clinic: University Centre for Wound healing, Odense University Hospital, Denmark.
2571469|NCT02423135|Experimental|Blood bags without DEHP|Intervention : Autologous blood transfusion
2571470|NCT02423135|Experimental|Blood bags with DEHP|Intervention : Autologous blood transfusion
2571496|NCT02422823|Experimental|injection of 1.8mL|injections of 1.8 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
2571497|NCT02422823|Experimental|injection of 3.6mL|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
2571583|NCT02422472|No Intervention|Standard|Standard of care ultrasound guided peripheral IV placement
2571590|NCT02422472|Experimental|Experimental|Ultrasound guided peripheral IV placement with the use of a guidewire
2571637|NCT02422212|Active Comparator|healthy weight group|Postop RYGBP patients who underwent surgery at least 2 years previously and have healthy weight (at least 50% loss of excess weight) (HW group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
2571638|NCT02422212|Other|Obese group|Clinically severe obese patients (Body Mass Index greater than 40 kg/m2, without co-morbidities and greater than 35 kg/m2 with co-morbidities) (OB group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
2571640|NCT02422212|Active Comparator|weight regain group|Patients who suffered weight regain after RYGBP (at least 10% above the minimum weight after surgery and less than 50% loss of preop excess weight) (WR group) Intervention: Immediately after RMR measurement, a solid mixed meal was served (270 kcal: 62% carbohydrate, 12% protein and 26% lipid)
3175403|NCT00633737|No Intervention|2|Standard care
3175404|NCT00633763||1|Healthy individuals with normal C-peptide levels following i.v. glucagon challenge. These individuals will be administered 18F-fallypride and then subjected to PET-CT scanning of the pancreas and brain. The subject will be positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen carried out (with subjects breathing normally). A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame). The subject will then be repositioned for a low-dose CT scan of the head (15-20 secs) following which a 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).
2571849|NCT02420587|Experimental|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles. Participants receive AMG 208 until radiographic progression of disease and/or unequivocal clinical progression. Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
2572082|NCT02419222|Experimental|Prism Adaptation|Prism Adaptation Treatment is 20 minutes long, administered 10 consecutive days
2572091|NCT02419053||Pre-checklist|Surgical interventions performed for children before the introduction of the surgical safety checklist in Ontario, from October 2008 to September 2009.
2572093|NCT02419053||Post-checklist|Surgical interventions performed for children after the introduction of the surgical safety checklist in Ontario, from October 2010 to September 2011.
2572239|NCT02418481|Experimental|Group A|DC-CIK cells will be used against tumor cells.
2572243|NCT02418481|Experimental|Group B|γδ T cells will be used against tumor cells.
2572246|NCT02418481|Experimental|Group C|Combination of γδ T cells/ DC-CIK be used against tumor cells.
2572292|NCT02418065|Other|control group|oral nutritional supplementation
2572347|NCT02417506|Experimental|E-OA-07 (Lanconone)|500 mg two capsules to be taken stat at the site
2575206|NCT02398825|Experimental|Ponatinib|
3175405|NCT00633763||2|Patients with longstanding T1DM and <20% C-peptide levels following i.v. glucagon challenge will be consented. 18F-Fallypride injected intravenously and subjects allowed to wait for approx 1 hr for the uptake.(b) Subject positioned in the PET/CT scanner and a low-dose CT (15-20 secs) of the abdomen (pancreas) carried out (with subjects breathing normally).(c) A 30-min PET acquisition will then be started (three 10 min static frames or one 30 min static frame).(d) Subject repositioned for a low-dose CT scan of the head (15-20 secs).(e) A 20-min PET acquisition will then be started (two 10 min static frames or one 20 min static frame).(f) End of PET/CT scanning procedures. Subject taken out of the scanner.
3175406|NCT00633776|Experimental|1|Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 1; Formoterol 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 2
3175407|NCT00633776|Active Comparator|2|Formoterol fumarate 12 mcg (Foradil) via aerosolizer dry powder inhaler at Test Visit 1; Formoterol fumarate 20 mcg (Perforomist) nebulized via Pari C nebulizer at Test Visit 2
3175408|NCT00633789|Experimental|1|
3175409|NCT00633789|Placebo Comparator|2|
3175410|NCT00633802|Placebo Comparator|2|
3175411|NCT00633802|Experimental|1|
3175412|NCT00633815||Fontan patients|Subjects will undergo exercise testing in both the supine and upright positions
3175413|NCT00633815||Healthy controls|Subjects will undergo exercise testing in both the supine and upright positions
3175414|NCT00633828|Experimental|A Intervention group|Increased physical education in primary school (daily)
3175415|NCT00633828|No Intervention|B Control group|Normal physical education in primary school (typically once per week)
3175416|NCT00633841|Active Comparator|1|AFFITOPE AD02 without adjuvant
2571264|NCT02424643|Experimental|Monetary Incentive|Participants in this arm will receive a $20 Amazon.com incentive for participating in the online survey.
2571269|NCT02424643|Experimental|Altruistic Incentive|Participants in this arm will receive altruistic messages throughout the length of the survey in hopes of improving survey completion.
2571274|NCT02424643|Experimental|Dashboard Incentive|Participants in this arm will receive a dashboard at the end of the survey that will compare their data entered into the survey to other participants who have taken the survey. A preview of this dashboard will be shown at the beginning of the survey as a teaser in the hopes to improve survey completion.
2571300|NCT02424305|Experimental|face: LEO 43204 gel 0.018%|3 days treatment (once daily) on face: LEO 43204 gel 0.018%
2571303|NCT02424305|Experimental|arm: LEO 43204 gel 0.1%|3 days treatment (once daily) on arm: LEO 43204 gel 0.1%
2571305|NCT02424305|Experimental|scalp: LEO 43204 gel 0.037%|3 days treatment (once daily) on scalp: LEO 43204 gel 0.037%
2571343|NCT02424058||Neck pain|Patients aged between 18 and 65 years with persistent neck pain for more than 3 months
2571346|NCT02424058||Healthy|Acceptance to participate in the study, no previous neck oain (lifetime-to-date), no spinal surgery or deformity, and no radiological abnormalities detected
2571389|NCT02423759|Active Comparator|ciprofloxacin|standard chemoprophylaxis [500mg ciprofloxacin twice daily for 3 days]
2571390|NCT02423759|Experimental|ciprofloxacin and gentamycine|Augmented Chemoprophylaxis [standard chemoprophylaxis plus 160mg]
2571392|NCT02423759|Experimental|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
2571438|NCT02423382|Other|3-6 months group|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 3-6 months.
2571441|NCT02423382|Other|6-9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for 6-9 months.
2571446|NCT02423382|Other|>9 months|In this group, the patients will recieve the surgery of silicone oil removal when silicone oil has been filled into eye for more than 9 months.
2571484|NCT02422966|Experimental|Paracetamol|Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
2571492|NCT02422966|Active Comparator|Ibuprofen|Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
2571582|NCT02422602|Active Comparator|Taking conventional charge|No further information is given to the patient during the first and only contact with the nurse of the coordinator center. A time will be dedicated by the IDE to answer questions of the patient.
2571592|NCT02422602|Experimental|Personalized information intervention|The intervention of personalized information will be made as appropriate to the patient's needs and will include: Personalized telephone information carried by a nurse trained in therapeutic education. A time will be dedicated by the IDE to answer questions of the patient. The delivery of paper documents, a list of recommended websites and phone remote monitoring will be performed by the nurse at J30 and J45 to check understanding of the information provided, the actual reading of the paper documents, or effective consultation of websites. A time will be dedicated by the IDE to answer questions at the remote monitoring of the patient to J30 and J45.
2571667|NCT02421900||group 1|Atrial fibrillation patients
3209127|NCT00981695|No Intervention|Controls|18 breast-fed and 18 formula-fed infants at the age of 20 weeks
3209128|NCT00981708|Experimental|Treatment|Lenalidomide, Dexamethasone and cyclophosphamide
3209129|NCT00981721|Experimental|1|cediranib 20mg
3209130|NCT00981721|Experimental|2|cediranib 30mg
3209131|NCT00981773|Experimental|Immediate switch|"Continue current boosted protease inhibitor~Switch NRTI backbone to maraviroc 150 mg bid"
2571852|NCT02420613|Experimental|Arm I (vorinostat, radiation therapy, temsirolimus)|"CHEMORADIOTHERAPY PHASE: Patients receive vorinostat QD and undergo radiation therapy QD for 30 fractions over 6-7 weeks.~MAINTENANCE PHASE: Four to six weeks after the completion of radiation therapy, patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 10 cycles in the absence of disease progression or unacceptable toxicity."
2571856|NCT02420613|Experimental|Arm II (vorinostat, temsirolimus)|Patients receive vorinostat PO QD and temsirolimus IV over 30-90 minutes on days 1-8. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.
3209132|NCT00981773|Active Comparator|Continue current antiretroviral therapy|Continue current antiretroviral regimen until week 12 then switch therapy as per arm 1.
3209133|NCT00981786|Active Comparator|Brinzolamide/Timolol therapy|Chronic therapy for 3 months with brinzolamide/timolol drops given twice daily added to travoprost drops
2572064|NCT02419391|Experimental|Group 1|18-49 year old healthy subjects, receiving either 1x10E7TCID50 MVA BN RSV or Placebo
2572067|NCT02419391|Experimental|Group 2|18-49 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
2572068|NCT02419391|Experimental|Group 3|50-65 year old healthy subjects, receiving either 1x10E8TCID50 MVA BN RSV or Placebo
3209134|NCT00981786|Active Comparator|Brimonidine/Timolol therapy|Chronic therapy for 3 months with brimonidine/timolol drops given twice daily added to travoprost drops
3209135|NCT00981838|Experimental|1|Rituximab (375 mg/m2).
3209136|NCT00981851|Active Comparator|beta 2 agonist + anticholinergic aerosol|
3209137|NCT00981851|Placebo Comparator|placebo inhalation|
3209138|NCT00981864|Experimental|Concurrent Boost RT|
3209139|NCT00981877|Active Comparator|1|This group will receive S. Boulardii Probiotic and Oral rehydration as needed
2571344|NCT02424019|Experimental|ILUVIEN 0.19 MG|All patients will receive ILUVIEN (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg.
2571522|NCT02422745|Active Comparator|Cocoa extract + multivitamin|
2571527|NCT02422745|Active Comparator|Cocoa extract + multivitamin placebo|
2571530|NCT02422745|Active Comparator|Cocoa extract placebo + multivitamin|
2571534|NCT02422745|Placebo Comparator|Cocoa extract placebo + multivitamin placebo|
2571547|NCT02422407||Subgroup 1|Healthy Volunteers - subset of which 10 will receive salivary gland biopsy.
2571549|NCT02422407||Subgroup 2|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with positive biopsy result.
2571551|NCT02422407||Subgroup 3|Diagnosis of pSS based on the criteria of the American-European Consensus Criteria for Sjögren's Syndrome (AECCSS) with negative biopsy result.
2571552|NCT02422407||Subgroup 4|Presenting with sicca but not satisfying the criteria of the AECCSS for diagnosis of pSS.
2571707|NCT02421770|Experimental|Experimental Chamaemelum Nobile|"Experimental Chamaemelum Nobile 2% gel During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel twice daily with occlusion on the affected are"
2571711|NCT02421770|Placebo Comparator|Placebo|During the 6-week double-blind phase, all patients will be randomly assigned to receive vehicle ( placebo)twice daily with occlusion on the affected are
2571805|NCT02421185|Experimental|Part 1: Dose Escalation and Part 2: Dose Expansion|"Part 1: First, participants will receive 8 milligram (mg) (starting dose) tablet of JNJ-42756493 (erdafitinib) orally once daily from Day 1 to 7, then Day 15 to 21 of 28 days cycle or 8 mg orally once daily from Day 1 to 21 of 28 days cycle (intermittent dosing). After recommended Phase 2 dose (RP2D) is identified, enrollment of continuous dosing schedule will be open, starting at 8mg. In this cohort, participants will receive 8mg (starting dose) tablet of JNJ42756493 (erdafitinib) orally once daily from Day 1 to Day 28 in a 28-day cycle. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine RP2D.~Part 2: Participants will receive RP2D JNJ-42756493 (erdafitinib) dose determined in Part 1. Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent."
2571950|NCT02420054|Active Comparator|Intermittent fasting|Intermittent fasting conducted by a group of subjects with type 2 diabetes mellitus and an age- and BMI matched control group.
2571951|NCT02420054|Active Comparator|Time control|A time control period.
2571970|NCT02419794||Group with endovascular treatment|Group with additional endovascular treatment
2571973|NCT02419794||Group without endovascular treatment|Group without additional endovascular treatment
2572192|NCT02418507|Active Comparator|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
2572195|NCT02418507|Placebo Comparator|Placebo|The placebo is administered to randomized healthy participants
3175417|NCT00633841|Active Comparator|2|AFFITOPE AD02 with adjuvant
3175418|NCT00633854||1|30 volunteer subjects who are age 60 and older
2572345|NCT02417636|Experimental|Nurse-initiated and monitored ART|This is an experimental task shifting of ART initiation and monitoring from a clinician-led model to a nurse-led model. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
2572350|NCT02417636|Active Comparator|Clinician - initiated and monitored ART|This is Standard of Care for the Uganda Ministry of Health to compared with the experimental task shifting. Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Clinicians (Clinical Officer or Medical Officer) and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually.
2572927|NCT02414048|Other|Pimonidazole|All patients will receive Pimonidazole to demarcate hypoxia regions in the tumour
3175419|NCT00633906|Experimental|1|HORIZONS HIV Intervention. Two-session, group-based interactive intervention.
3175420|NCT00633906|Active Comparator|2|Enhanced standard-of-care session. One hour, video-based and brief discussion.
3175421|NCT00633958|Experimental|18F-FLT|All subjects will receive 18F-FLT prior to PET imaging.
3175422|NCT00633971|Experimental|A|Complex lymphedema therapy (which includes compression stocking use)
3175423|NCT00633971|Other|B|Standard of care (compression stocking use at 30-40 mm Hg)
3175424|NCT00633997|Experimental|1|Healthy volunteers
3175425|NCT00633997|Experimental|2|Type II diabetics
3175426|NCT00634062|Active Comparator|1|
3175427|NCT00634062|Placebo Comparator|2|
3175428|NCT00634075|Experimental|1|
3175429|NCT00634075|Placebo Comparator|2|
3175430|NCT00634140|Experimental|1|ezetimibe
3175431|NCT00634140|Placebo Comparator|2|placebo for 4-6 weeks
3175432|NCT00634192|Experimental|1|
3175433|NCT00634192|Experimental|2|
3175434|NCT00634205|Experimental|A|Continuous oral administration of valproate plus every 3 weeks, intravenous administration of doxorubicin
3175435|NCT00634218|Active Comparator|1|Mail-based Self Help (MSH) treatment. Participants will receive the self-help manual developed specifically for LGBT smokers.
3175436|NCT00634218|Active Comparator|2|Mail-based Self Help plus an Internet-based Smoking Treatment (IST). In the IST condition, participants will receive the manual plus access to an Internet-based intervention that includes social support.
3175437|NCT00634218|Active Comparator|3|Mail-based Self-Help plus Telephone Counseling (TC). In the TC condition, participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions.
3175438|NCT00634218|Active Comparator|4|Mail-based Self-Help plus an Internet-based Intervention plus Telephone Counseling. Participants will receive a self-help manual, have access to an internet-based smoking treatment and participante in 6 telephone counseling sessions.
2571359|NCT02424084|Experimental|Intact metatarsal bone|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who have an intact metatarsal bone.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2571410|NCT02423668||50% Partial adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 50% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
2571413|NCT02423668||No adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. The intra-ocular lens power selection for the second eye was performed irrespective of the first eye prediction error. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
2571415|NCT02423668||Full adjustment|The prediction error for the first (PE1) and second (PE2) eyes was calculated as the difference between the observed post-operative refraction in spherical equivalent and the predicted post-operative refraction by the IOL Master for the implanted intra-ocular lens. This was obtained for the 3 formulae. Second eye refinement in the intra-ocular lens power selection for the second eye was performed using a theoretical 100% partial adjustment of the PE1. To relate refractive outcomes to pACD values, we performed subgroup analysis based in consecutive 50µm increments in inter-ocular asymmetry of pACD (50-600).
2571449|NCT02423265|Active Comparator|Ranolazine|500mg bd ranolazine for 1 week then uptitrated to 1000mg bd to continue for 8 weeks
2571450|NCT02423265|Placebo Comparator|Placebo|Matching placebo, with up titration after 1 week as in active treatment arm
2571516|NCT02422914|Experimental|Nicotine|Smoking cessation program TFC and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (with nicotine) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
2571526|NCT02422914|Placebo Comparator|Nicotine-free|Smoking cessation program TFC-free and activity tracker. Three months low intensity counselling at distance program. Subject will also undergo a 3-months TFC (nicotine-free) program; subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity trackerand ad-hoc items.
2571533|NCT02422914|Active Comparator|No-cig|Smoking cessation program and activity tracker. Three months low intensity counselling at distance program;subjects smoking behaviour and wellbeing will be assessed at baseline, at 6 months and at one year. Life style will be evaluted by the use of an activity tracker and ad-hoc items.
2571584|NCT02422433|Experimental|OFDI Capsule Marking and Imaging|Subject will swallow the OFDI capsule, marking will be performed by making superficial cautery marks on the tissue. This will be followed by imaging using the OFDI Imaging system.
2571624|NCT02422199|Experimental|pyrotinib plus capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2571630|NCT02422199|Active Comparator|lapatinib plus capecitabine|lapatinib (1250 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
2571703|NCT02421809||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
2571709|NCT02421809||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
2571712|NCT02421809||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
2571728|NCT02421497||Normal Healthy Volunteer|
2571732|NCT02421497||Non-CKD Control|
2571734|NCT02421497||Chronic Kidney Disease (CKD)|
2571737|NCT02421497||Dialysis Patients|
2571740|NCT02421497||Renal Transplant Recipients|
3209140|NCT00981877|Active Comparator|2|This group will receive a mixed Probiotic preparation and oral rehydration as needed
3209141|NCT00981877|Placebo Comparator|3|This group will receive a placebo, and oral rehydration as needed
3209142|NCT00981890|Experimental|Sunitinib|
3209143|NCT00981903|Experimental|VTE Treatment Group|
3209144|NCT00981903|No Intervention|Control|
3209145|NCT00981929|Active Comparator|Tramadol|CYP2D6 metric
3209146|NCT00981929|Active Comparator|Omeprazole, losartan, caffeine|CYP2C19, CYP2C9 and CYP1A2 metrics
3209147|NCT00981929|Active Comparator|Tramadol, omeprazole, losartan and caffeine|CYP2D6, CYP2C19, CYP2C9 and CYP1A2 metrics
3209148|NCT00981955|Active Comparator|75mg caffeine|
3209149|NCT00981955|Active Comparator|50mg l-theanine|
3209150|NCT00981955|Active Comparator|75mg caffeine and 50mg l-theanine|
3209151|NCT00981955|Placebo Comparator|0mg caffeine/l-theanine|
3209152|NCT00981968|Experimental|Japanese Cohort|Single and multiple oral doses of sitaxentan sodium or placebo in 12 healthy subjects.
3209153|NCT00981968|Experimental|Western Cohort|Single oral dose of sitaxentan sodium in 10 healthy subjects.
3209154|NCT00981981|Placebo Comparator|Control|Wheat bran cereal
3209155|NCT00981981|Active Comparator|3g high MW|Cereal containing 3g high molecular weight oat beta glucan
3209156|NCT00981981|Active Comparator|4g medium MW|Cereal containing 4g oat beta glucan with medium molecular weight
3209157|NCT00981981|Active Comparator|3g medium MW|Cereal containing 3g oat beta glucan with medium molecular weight
3209158|NCT00981981|Active Comparator|4g low MW|Cereal containing 4g oat beta glucan with low molecular weight
3209159|NCT00981994|Experimental|Electronic Decision Support|Use of electronic decision support to provide the treatment algorithm for providers managing patients with acute respiratory infections.
2571400|NCT02423590|Active Comparator|Gemcitabine/Carboplatin|"Gemcitabine/carboplatin will be administered as standard 21-day treatment cycles according to normal clinical practice.~Gemcitabine will be given by 30 minute intravenous infusions on Day 1 and Day 8 of each 21-day Cycle.~On Day 1, carboplatin (AUC5) will be given by infusion over 30-60 minutes."
2571403|NCT02423590|Experimental|Gemcitabine/carboplatin + Apatorsen|"Apatorsen (OGX-427) will be administered as an intravenous infusion over 2 hours.~Apatorsen (OGX-427) treatment will begin with a loading dose period prior to the initiation of chemotherapy. Patients will receive three loading doses of 400 mg within a 9-day period with at least 48 hours between infusions and between the last loading dose infusion and Day 1 of initiating chemotherapy. Chemotherapy must be initiated within 7 calendar days once the last loading dose infusion has been completed.~Following the loading dose period, Apatorsen (OGX-427) will be given weekly at a dose of 400 mg by 2 hour intravenous infusions. On days when both chemotherapy and Apatorsen (OGX-427) are given, Apatorsen (OGX-427) should be given first followed by chemotherapy."
3175439|NCT00634231|Experimental|AdV-tk|AdV-tk + valacyclovir in combination with standard of care radiation
3175440|NCT00634257||Patients|Patients with advanced cancer receiving palliative care.
2571554|NCT02422563|Experimental|Arm A: NACT+radical hysterectomy|Arm A includes patients for dose dense chemotherapy using TP (paclitaxel, carboplatin) or TIP (cisplatin, paclitaxel, ifosfamide) weekly for six cycles. Radical hysterectomy is performed after the 6th week + lymphadenectomy
2571555|NCT02422563|Other|Arm B: Chemoradiation|Arm B includes patients undergoing primary cisplatin based chemo-radiation
2571627|NCT02422251|Experimental|Mobile high congruency bearing|Device B Braun Columbus total knee system using a rotating platform tibia and high congruency mobile bearing.
2571634|NCT02422251|Experimental|Fixed high congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and high congruency bearing.
2571635|NCT02422251|Experimental|Fixed low congruency bearing|Device B Braun Columbus total knee system using a fixed tibial platform and low congruency bearing.
2571636|NCT02422251|No Intervention|Control|Healthy control group
2571677|NCT02421783||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
2571679|NCT02421783||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group
2571682|NCT02421783||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group
2571895|NCT02420509||systemic chemotherapy after CRS/HIPEC|Single-arm, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).
2571925|NCT02420171|Active Comparator|In Vitro culture media with insulin|We will add insulin to the single step culture media to monitor the embryogenesis
2571929|NCT02420171|No Intervention|In Vitro culture media without insulin m|The embryos will be cultured in the media without insulin and compare this arm as the control arm with the interventional one.
2572036|NCT02419430|Active Comparator|MBRT ClassRoom and Phone Application|MBRT ClassRoom and Phone Application
2572039|NCT02419430|Active Comparator|Phone application only|Phone application only
2572043|NCT02419430|Active Comparator|Questionnaires|Questionnaires
2572107|NCT02419235|Placebo Comparator|20% Ethanol|Ten drops of unmedicated 20% ethanol must be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
2572112|NCT02419235|Experimental|Homoeopathic complex|Ten drops of 20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrum muriaticum 6cH and Scutellaria lateriflora 6cH will be administered under the tongue, three times per day, thirty minutes before or after meals, for six weeks.
2572138|NCT02418806|Experimental|Therapy group with follow up sessions|Weekly psychotherapy groups during 4 months with a monthly follow up period (12 months)
2572139|NCT02418806|Experimental|Therapy group without follow up sessions|Weekly psychotherapy groups during 4 months
2572140|NCT02418806|Active Comparator|Active comparator group|Weekly self-help groups during 4 months with a monthly follow up period (12 months)
2572180|NCT02418559|Experimental|JNJ-63623872 (300 mg) or Placebo|Participants will receive JNJ-63623872 300 milligram (mg) or placebo tablet orally once on Day 1 under fasted conditions.
2572183|NCT02418559|Experimental|JNJ-63623872 (600 mg) or Placebo|Participants will receive JNJ-63623872 600 mg (2*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
2572184|NCT02418559|Experimental|JNJ-63623872 (1200 mg) or Placebo|Participants will receive JNJ-63623872 1200 mg (4*300 mg) or placebo tablet orally once on Day 1 under fasted conditions.
2572214|NCT02418208||Test retest- 2 visits|Eligible participants will arrive for 2 testing visits a week apart and an optional third visit within 6-12 months.
2572221|NCT02418208||Single Visit|Eligible participants will arrive for a single testing visit
2572295|NCT02418052|Experimental|neck flexion group|Patients who fixed in neck flexion position after MIE
2572301|NCT02418052|No Intervention|control group|Patients without posture intervention after MIE
2572407|NCT02417675|Active Comparator|Standard of Care (SOC)|"Women who choose the SOC will receive postpartum antiretroviral therapy (ART) services at their nearest primary care clinic, following the Standard of Care for Mothers. Details are provided in the intervention description.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
2572424|NCT02417155|Active Comparator|EIN|The 'extensive instruction' group (EIN): a group of subjects (n=10) that will receive an extensive instruction course supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
2575643|NCT02395601|Experimental|CPI-1205|
3175441|NCT00634257||Caregivers|Primary caregivers of Patients with advanced cancer receiving palliative care.
3175442|NCT00634296|Active Comparator|G2|Inspiratory muscle training added by aerobic training to aerobic training alone
3175443|NCT00634309|Active Comparator|1|
3175444|NCT00634309|Placebo Comparator|2|
2571414|NCT02423629|Other|Agili C™|Candidates will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
2571451|NCT02423239|Experimental|Relapsed or refractory advanced tumours|Patients with selected relapsed or refractory tumour types to receive single agent dexanabinol.
2571454|NCT02423239|Experimental|Newly diagnosed hepatocellular carcinoma|Patients with hepatocellular carcinoma to receive dexanabinol in combination with standard chemotherapy.
2571456|NCT02423239|Experimental|Newly diagnosed pancreatic cancer|Patients with pancreatic cancer to receive dexanabinol in combination with standard chemotherapy
2571498|NCT02422771|No Intervention|Control group|Athletes in this group will continue with their usual warm-up for the duration of the indoor soccer season.
2571501|NCT02422771|Experimental|Intervention group|FIFA 11+ warm-up
2571581|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle A|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
2571591|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle B|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
2571595|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle C|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
2571596|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle D|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
2571597|NCT02422654|Experimental|Concentration 1 eliglustat in vehicle E|Single dose of 5 mL solution held in the mouth for 15 seconds with swishing but with no ingestion
2571598|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571599|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571600|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571601|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571603|NCT02422654|Experimental|Concentration 2 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571604|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle A|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571605|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle B|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571606|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle C|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571607|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle D|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571610|NCT02422654|Experimental|Concentration 3 eliglustat in vehicle E|Single dose of 5 mL liquid formulation held in the mouth for 15 seconds with swishing but with no ingestion
2571623|NCT02421978||Chemotherapy-treated breast cancer group|Female subjects with Stage I-III breast cancer treated with chemotherapy will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
2571629|NCT02421978||Non-Chemotherapy-treated breast cancer group|Non-chemotherapy treated female subjects with Stage I-III breast cancer will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
2571633|NCT02421978||Control group|Age and race-matched healthy women will complete the neuropsychiatric assessment battery, blood sampling, self-report forms and magnetic resonance spectroscopy (MRS) scans
3209160|NCT00981994|Experimental|Paper Decision Support|Use of paper based tools to provide the treatment algorithm for providers managing patients with acute respiratory infections.
3209161|NCT00981994|No Intervention|Usual Care|Usual Care
2571760|NCT02421393|Experimental|Exercise|Supervised exercise training on top of standard care (exercise, EXE, group; n=100)
2571761|NCT02421393|No Intervention|Control|Standard care including advises to maintain a physically active lifestyle, according to current guidelines, by performing any type of commuting, occupational, home and and leisure-time physical activity (PA) (control, CON, group; n=100).
3260216|NCT01477398|No Intervention|No intervention: Standard of Care|tidal volume and respiratory rate are not changed during recovery from anesthesia
2571875|NCT02420548|Active Comparator|Services as Usual|Participants continue with any services they may be receiving outside of the study.
2571884|NCT02420548|Experimental|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
2571931|NCT02420275|Placebo Comparator|Severe brain injury patient|Severe brain injury patients with placebo
2571938|NCT02420275|Experimental|Severe brain injury patient with device|"Severe brain injury patients withe with Luminette,Lucimed Belgium"
2571976|NCT02419872||Patient Participants|Patients are confirmed to have either Persistent Asthma or COPD
2572163|NCT02418728||persons with obesity|
2572169|NCT02418728||lean persons|
2572211|NCT02418364|Placebo Comparator|placebo reflexology|Placebo reflexology treatment
2572216|NCT02418364|No Intervention|control group|Data will be taken from questionnaires
2572223|NCT02418364|Experimental|reflexology treatment|Reflexology treatment
2572287|NCT02418065|Experimental|treated group|testosteron, oral nutritional supplementation, n3 polyunsaturated fatty acid, training on ergonomic bicycle
3209162|NCT00982046|Active Comparator|ACUVUE OASYS|Acuvue Oasys contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
3209163|NCT00982046|Active Comparator|AIR OPTIX AQUA|Air Optix Aqua contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
3209164|NCT00982046|Active Comparator|Biofinity|Biofinity contact lenses worn on a daily wear basis and cleaned nightly with one of three contact lens care solutions. Each solution was used for 2 weeks, and the order in which the solutions were used was randomized. A fresh pair of lenses was dispensed with each solution. Total duration of contact lens wear was six weeks.
2571608|NCT02422329|Experimental|Educational Video|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
2571611|NCT02422329|Experimental|Fact Sheet|Participants complete self-administered numerical rating scale (NRS) constipation questionnaire at baseline. Participants read educational material describing symptoms of constipation and importance of regular bowel movements. Participants then complete three self-administered questionnaires, post-educational material, Modified Rome III questionnaire, and Overall satisfaction of the educational material.
2571639|NCT02421991|Experimental|TALK study group|This is the experimental arm of the study. This includes 5 weekly sessions of experimental therapy via telephone. Therapy description withheld to protect the integrity of the study.
2571641|NCT02421991|Active Comparator|TALK control group|This is the control arm of the study. This includes 5 weekly sessions of control therapy via telephone.Therapy description withheld to protect the integrity of the study.
2571681|NCT02421796||NCWS patients|Consecutive adult patients with an irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
2571688|NCT02421796||CD patients|Sex- and age-matched subjects with CD, diagnosed according to standard criteria during the same study period and enrolled as first control group.
2571692|NCT02421796||IBS patients|Sex- and age-matched subjects with IBS unrelated to NCWS or other food 'intolerance', diagnosed according to standard criteria during the same study period and enrolled as second control group.
2571722|NCT02421575|Experimental|Group I, Arm I (lower dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD for 14 days and then undergo prostatectomy.
2571724|NCT02421575|Experimental|Group I, Arm II (higher dose hydroxychloroquine)|Patients receive hydroxychloroquine PO TID for 14 days and then undergo prostatectomy.
2571725|NCT02421575|Experimental|Group II (mid-dose hydroxychloroquine)|Patients receive hydroxychloroquine PO QD. Treatment continues until the beginning of local therapy or for up to 1 year.
3209165|NCT00982059||All|All patients enrolled in the study will be undergoing the same procedures.
3209166|NCT00982085||Soldiers|Soldiers: The soldiers who respond the questionnaires
3209167|NCT00982098|Experimental|Early Rehabilitation|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).~Patients will be instructed to carry on exercises at home for the following 11 months."
3209168|NCT00982098|No Intervention|Counseling and home-based exercises|"Before surgery: 15 minutes pelvic floor muscle training and 15 minutes biofeedback, for 4 sessions.~After surgery: Patients will be instructed to carry on pelvic floor exercises at home for the year after prostatectomy."
3209169|NCT00982124|Experimental|Treatment Arm (only)|Zoledronic acid infusion
2571897|NCT02420496|Experimental|Enteral fish oil|Infants will receive enteral fish oil at a dose of 1mg/kg/day divided in two daily doses given enterally.
2571899|NCT02420496|Active Comparator|UDCA (ursodeoxycholic acid)|Infants will receive UDCA at a dose of 10mg/kg/dose in two daily doses given enterally
2571900|NCT02420496|Placebo Comparator|Placebo|Infant will receive placebo in two daily doses given enterally
3209170|NCT00982150|Experimental|Talampanel|Talampanel 50mg tid
3209171|NCT00982176||1|
2571993|NCT02419651|Active Comparator|Tramadol|Women will receive oral Tramadol 100 mg before the procedure
2571994|NCT02419651|Active Comparator|Diclofenac|Women will receive oral diclofenac 100 mg before the procedure
2571997|NCT02419651|Placebo Comparator|Placebo|Women will receive oral placebo 1 hour before the procedure.
2577684|NCT02381743|No Intervention|Group 1|Weekly non-medical SMS messages
3209172|NCT00982202|Experimental|PGZ|
3209173|NCT00982202|Placebo Comparator|Placebo|
3209174|NCT00982241|Active Comparator|normal fluid intake|1500 ml /day (+/- 300 ml) for 2,5 days
3209175|NCT00982241|Active Comparator|high fluid intake|2400 ml/day (+/- 300 ml )for 2,5 days
3209176|NCT00982241|Active Comparator|low fluid intake|fluid intake 900 ml/day (+/- 300ml) for 2,5 days
3209177|NCT00982254|Experimental|Oral Insulin|oral insulin capsule formulation
3209178|NCT00982254|Active Comparator|Subcutaneous Insulin|Subcutaneous injection of regular human insulin
3209179|NCT00982267|Experimental|SU014813|
3209180|NCT00982293|Active Comparator|Active fields|
3209181|NCT00982293|Sham Comparator|Inactive device|"Placebo treated group, will receive the 3 times weekly for 13 weeks (39) sessions, however, the device will not be on."
3209182|NCT00982332|Active Comparator|betamethasone|patients treated with a single intramuscular injection of betamethasone
3209183|NCT00982332|Placebo Comparator|isotonic sodium chloride solution|
3209184|NCT00982358|Placebo Comparator|Placebo|
3209185|NCT00982358|Active Comparator|Valsartan|
3209186|NCT00982371||Controls|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; NO clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
3209187|NCT00982371||Type 2 Diabetes|female; >65 years old; BMI >25kg/m2; postmenopausal >5 yrs; clinical diagnosis of type 2 diabetes for >5 years (according to Canadian Diabetes Association criteria)
2571715|NCT02421614|Experimental|high olive oli|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The percentage of olive oil will be half of total fat.
2571717|NCT02421614|Experimental|high sunflower oil|A high fat (45%) low carbohydrate (35%) enteral feeding will be administered to acute respiratory failure patients. The total fat will be sunflower oil.
2571718|NCT02421614|No Intervention|kitchen formula|A high protein kitchen diet for tube feeding will be administered to acute respiratory failure patients.
2571782|NCT02420938|Experimental|Rituximab + Urelumab|Participants receive Rituximab 375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course. Urelumab 8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the course. Urelumab doses administered approximately 24 hours after the Rituximab doses. Up to two 12-week courses of treatment administered (total of maximum 12 doses of Rituximab and 8 doses of Urelumab).
2571838|NCT02420847|Experimental|Treatment (ixazomib, gemcitabine, doxorubicin)|Patients receive ixazomib citrate PO, gemcitabine hydrochloride IV over 90 minutes, and doxorubicin hydrochloride IV over 15-30 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2571928|NCT02420301|Experimental|Exercises on real points|Self administered exercises were done in real treatment points
2571937|NCT02420301|Placebo Comparator|Exercises on false points|Self administered exercises were done in false treatment points
2571987|NCT02419976|Experimental|fasting breath analysis|Individuals consenting to participation of this study will be asked to provide a breath analysis using the Aeonose. Following their scheduled standard of care endoscopic procedure the patient will repeat the breath analysis
3209188|NCT00982384|Experimental|Disease management|Comprehensive disease management in addition to best care according to clinical guidelines for COPD patients
2572099|NCT02419170|Experimental|Surgery/Apheresis/Cyclophosphamide/Vaccine|"Standard of care surgery~Apheresis (between Day -28 and Day -7) approximately 12 weeks after surgery~Cyclophosphamide 300 mg/m^2 intravenously (Day -4)~Personalized vaccine (Day 1)~Booster dose of personalized vaccine (Day 43)~Booster dose of personalized vaccine (Day 85)"
2572176|NCT02418715|Experimental|Water Aerobics Training|The training period was composed by a 12-week macrocycle with two sessions per week. The macrocycle was divided into three four-week mesocycles that were, in turn, divided into four one-week microcycles composed by two training sessions. Each training session took 45 min. Nine different water-aerobics exercises were used during the training period. These exercises were performed alternating the right and left limbs. Exercise intensities were controlled using the Borg Scale. Interval training was used alternating intensities ranged between 9 (easy) and 15 (hard). During the first mesocycle, participants performed sets of 3min at intensity 13 interspersed by 2min at intensity 9; during the second mesocycle, sets of 3min at intensity 15 followed by 2min at intensity 9 were performed; finally, sessions of the third mesocycle were composed by sets of 3min at intensity 15 followed by 2min at intensity 11.
2572181|NCT02418715|No Intervention|Control|No training, no intervention.
2572245|NCT02418390|No Intervention|No prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, without prophylactic central lymph node dissection
2572249|NCT02418390|Active Comparator|Prophylactic central dissection|Patients underwent total thyroidectomy for papillary thyroid carcinoma, with prophylactic central lymph node dissection
2572267|NCT02417922|Experimental|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that whole blood spinning is conducted for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (around 4 mls).~ACP is injected at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date."
2572274|NCT02417922|Placebo Comparator|Saline|Saline (4 mls) is injected around the ruptured achilles tendon at baseline, 2 weeks, 4 weeks and after 6 weeks from injury date.
2572360|NCT02417649|Experimental|Ismigen|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
2572368|NCT02417649|Placebo Comparator|Placebo|Treatment over 3 successive months. One sublingual tablet every day on the first ten days of each month, followed by twenty days of rest.
2572418|NCT02417155|Experimental|HTR|The 'Hoftraining' group (HTR): a group of subjects (n=10) that will be trained extensively by mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques. Total time training is 8 days.
3209189|NCT00982384|Active Comparator|Best care|Best care according to clinical guidelines for COPD patients
3209190|NCT00982436|Experimental|Neoadjuvant/Concomitant Chemoradiation|Three cycles of docetaxel/carboplatin neoadjuvant chemotherapy followed by chemoradiotherapy for 7 weeks with weekly carboplatin
2571535|NCT02422875||Autoimmune Disease|Subjects diagnosed with autoimmune disease including but not limited to: Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome (SS), Scleroderma, Myositis, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), inflammatory arthritis, undifferentiated connective tissue disease, idiopathic thrombocytopenic purpura (ITP), Graft vs Host Disease (GVHD), Autoimmune Lymphoproliferative Syndrome (ALPS) and IgG4-related disease
2571536|NCT02422875||Infectious Disease|Subjects diagnosed with an infectious disease including but not limited to: Hepatitis C, Epstein Barr Virus (infectious mononucleosis - EBV), Sepsis, Guillain-Barre syndrome (GBS), Mycoplasma pneumoniae or Human Immunodeficiency Virus (HIV)
2571537|NCT02422875||Autoimmune - Family|Subjects have a brother, sister, mother, father, or child with an autoimmune disease
2571538|NCT02422875||Vaccination|Subjects have received or will receive a vaccination as part of regular standard of care from their healthcare provider or other outside source
2571586|NCT02422459|Experimental|COMMENCE|ChrOnic pain self-ManageMent support with pain science EducatioN and exerCisE (COMMENCE)
2571594|NCT02422459|No Intervention|Wait-list control|No treatment assigned
2571626|NCT02422147||Ablation of PCL|Patients with pancreatic cysts will undergo ablation using alcohol under EUS-guidance
2571684|NCT02421874|Experimental|Use of electronic health record / outcomes monitoring|Use of electronic health record / outcomes monitoring via a specified electronic behavioral health information system
2571694|NCT02421874|Active Comparator|education about outcomes monitoring|Care coordination as usual with education about fidelity and outcomes monitoring but no use of EBHIS
2571751|NCT02421562|Experimental|training in hypnoanalgesia|training nurses in hypnoanalgesia to perform painful procedure in children
3209191|NCT00982449|Active Comparator|4 mCi of I-FIAU|GROUP B 1-3 days after any chemotherapy that may activate viral TK, 4 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-4.
3209192|NCT00982449|Active Comparator|2 mCi of I-FIAU|GROUP A 1-3 days after any chemotherapy that may activate viral TK, 2 mCi of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT-2.
3209193|NCT00982462|Placebo Comparator|Corn oil placebo|Micro-encapsulated powder containing corn oil placebo.
2571909|NCT02420444|Placebo Comparator|BCG SSI prime with Placebo|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231."
2571910|NCT02420444|Experimental|BCG SSI prime with Placebo and AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
2571911|NCT02420444|Experimental|BCG SSI prime with AERAS-404|"All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42.~AERAS-404 50/500 on Study Days 0, 56, and 231.~AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows:~H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.~IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl."
2572000|NCT02419989||CF patients|Male and female subjects with CF age 6 years and older who meet diagnostic criteria for NTM disease through participation in the PREDICT (Part A) study who are being offered NTM treatment.
2572097|NCT02419287|Experimental|crizotinib|250mg BID
2572164|NCT02418650|Experimental|Part 1|A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
2572170|NCT02418650|Experimental|Part 2|A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
2572238|NCT02418286||Low Back Pain Participant Registry|Patients with low back pain in traditional Korean medicine rehabilitation clinic
2572286|NCT02417987|Active Comparator|High Volume injection|"A total volume of 50 ml:~10 mls 0.5% bupivacaine hydrochloride and~20 mg of Depomedrol (hydrocortisone)~40 mls saline (NaCl) HVI is injected one time at baseline and thereafter the group received sham treatment at 2 weeks, 4 weeks and after 6 weeks."
2572291|NCT02417987|Active Comparator|Autologous conditioned plasma (ACP)|"Whole blood was drawn from the patients using arthrex system (total of 10 mls whole blood). After that the whole blood is spined for 5 minutes and ACP with platelets and growth factors is separated from the red and white blood cells (4 mls).~The ACP is injected 4 times (at baseline, 2 weeks, 4 weeks and after 6 weeks)"
2572298|NCT02417987|Sham Comparator|Placebo|A few drops of saline is injected in the soft tissue away from the tendon.
2572356|NCT02417519|Experimental|Sequence A|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance A was DAR-LIR-CTR
2572359|NCT02417519|Experimental|Sequence B|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance B was DAR-CTR-LIR
2572364|NCT02417519|Experimental|Sequance C|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance C was LIR-DAR-CTR
2572370|NCT02417519|Experimental|Sequence D|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance D was LIR-CTR-DAR
2572377|NCT02417519|Experimental|Sequence E|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance E was CTR-DAR-LIR
2572381|NCT02417519|Experimental|Sequence F|The meal study was performed with dark roast coffee (DAR), light roast coffe (LIR), or water (CTR) in a random sequence. Sequance F was CTR-LIR-DAR
2572399|NCT02417077||Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
2572479|NCT02416947|Placebo Comparator|0g SCF|Subjects will consume 0 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
2572481|NCT02416947|Active Comparator|10 g SCF|Subjects will consume 10 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
2571644|NCT02422368|Experimental|Methylprednisolone + ASTED|"ASTED (Antioxidant Supplements for Thyroid Eye Disease) includes : B-Carotene (6 mg)+ Vit.C (200 mg) + Vit.E (200 mg) + Nicotinamide(20mg) + Selenium(200mic.) + Zinc oxide (8 mg) + Copper gluconate or oxide (1mg) + Manganese chloride (1.8 mg), Twice a day for 6 months~Methylprednisolone includes :~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow up."
2571647|NCT02422368|Placebo Comparator|Methylprednisolone + Placebo|Placebo Twice a day for 6 months Methylprednisolone prescribes as the same as arm 1
3209194|NCT00982462|Experimental|Long-chain polyunsaturated fatty acids|Micro-encapsulated powder containing 1:1 ratio of the omega-3 long-chain polyunsaturated fatty acids, docosahexaenoic acid (DHA) and the omega-6 fatty acid, arachidonic acid (ARA) from algal and fungal sources, respectively.
3209195|NCT00982475|Active Comparator|PVI with robotic navigation|
2571924|NCT02420418|Active Comparator|NAC ( baseline )and 12 week|"subjects with tobacco use disorder (TUD) and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo at baseline for a period of 12 weeks The participants with TUD (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be asses laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
2571930|NCT02420418|Placebo Comparator|placebo ( baseline ) and 12 week|"subjects with tobacco use disorders (TUD and bipolar disorders who will receive N-acetyl-cysteine (NAC) or placebo for a period of 12 weeks.~The participants with TUD and bipolar disorders (n=72) and they will receive a 1800mg per day of NAC or matching placebo .~There will be assessed laboratory examinations for inflammatory and oxidative stress biomarkers at baseline and at 12 week"
2572050|NCT02419859|Experimental|PaQ® Insulin Delivery Device|The intervention is continuous subcutaneous U 100 Insulin, Asp(B28)-rapid-acting insulin, at a constant basal rate of either 20, 24, 32, 40 or 50 U per day over 3 days and and bolus insulin as needed at meals in 2 U increments.
2572100|NCT02419196||abdominal surgery|27 patients undergoing abdominal surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
2572105|NCT02419196||limb surgery|27 patients undergoing upper and lower limb surgery having an elevated risk for postoperative pulmonary complications will be examined by perioperative pulmonary function tests
2572111|NCT02419196||flail chest|10 patients undergoing an operative stabilization of a flail chest will be examined by perioperative pulmonary function tests
2572153|NCT02418793|Experimental|Dose Cohort 1|Lowest MOD-5014 dose tested in the study
2572157|NCT02418793|Experimental|Dose Cohort 2|MOD-5014 Dose cohort 2
2572159|NCT02418793|Experimental|Dose Cohort 3|MOD-5014 Dose cohort 3
2572160|NCT02418793|Experimental|Dose Cohort 4|MOD-5014 Dose cohort 4
2572162|NCT02418793|Experimental|Dose Cohort 5|MOD-5014 Dose cohort 5
2572166|NCT02418793|Experimental|Dose Cohort 6|Highest MOD-5014 dose tested in the study
2572251|NCT02418221|Experimental|DAOSiN®/ Placebo & ProvokAmin® Ingestion|A sample of blood is drawn from Patient, blood pressure & pulse are recorded. Patient will ingest 2 capsules of either DAOSiN® or Placebo, followed by 2 tablets of ProvokAmin 20 minutes later. After an additional 40 minutes blood pressure and pulse are recorded and another sample of blood is drawn. Patient is handed a questionaire for self-evaluation to record any symptoms for the following After between 7 and 15 days the whole cycle is repeated switching between active treatment and Placebo.
2572266|NCT02417883|Experimental|Furosemide Stress Test|Furosemide stress test will be perform to patients scheduled for kidney bipsy. The test consist in 1.5 miligrams per kilogram of weight of intravenous furosemide administration, along with urinary output follow up and measurement for 6 hours. The urinary output will be replaced intravenously with normal saline to avoid dehydration and/or hypotension.
2572363|NCT02417688|Experimental|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of 4-8 mCi of Cu[64]-25%-CANF-Comb with a mass no more than 100 μgrams followed by PET-MR Imaging
3209196|NCT00982475|Placebo Comparator|PVI manually|
3209197|NCT00982501|Experimental|WS® 1442 900 mg|
3209198|NCT00982501|Experimental|WS® 1442 1800 mg|
2572491|NCT02416609|Experimental|Gem-based doublets with LDR & sequential SBRT|Four Gem-based doublets cycles will be administered concurrent with LDR. If no progression, three fractions of SBRT will be administered.
2572556|NCT02416297|Experimental|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve accelerated orthodontic tooth movement. Topical and local anesthetic will be delivered in the area to be treated in accordance with standard practice.
2572559|NCT02416297|No Intervention|Control|Anterior retraction after premolars extraction will be done conventionally (slide mechanics)
2572702|NCT02415491|Experimental|ASO group|ASO group:Evaluation of Correlation of Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test for long term assessment after ASO and recommendation of physical activity of young adults after TGA
3209199|NCT00982501|Active Comparator|Nordic walking training 2x30 min|
3209200|NCT00982501|Active Comparator|Nordic walking training 4x45 min|
3209201|NCT00982514||Standard dose asparaginase|Children who according to the protocol NOPHO ALL 2008 receive standard dose asparaginase
3209202|NCT00982514||Reduced dose asparaginase|Children who receive reduced dose asparaginase according to NOPHO ALL 2008
3209203|NCT00982527|Placebo Comparator|Placebo|Saline blinded infusion
3209204|NCT00982527|Active Comparator|Fenoldopam|Drug infusion
3209205|NCT00982540|No Intervention|preemptive|Patients with persistent fever and neutropenia despite appropriate antibacterial therapy
3209206|NCT00982566|Experimental|Sequence I|
3209207|NCT00982566|Experimental|Sequence II|
3209208|NCT00982566|Experimental|Sequence III|
3209209|NCT00982566|Experimental|Sequence IV|
3209210|NCT00982566|Experimental|Sequence V|
3209211|NCT00982566|Experimental|Sequence VI|
3209212|NCT00982566|Experimental|Sequence VII|
3209213|NCT00982566|Experimental|Sequence VIII|
3209214|NCT00982566|Experimental|Sequence IX|
2571803|NCT02421003|Experimental|Patients|Patients undergoing heart surgery
2571907|NCT02420392|Experimental|Dapagliflozin treatment|Test incretin sensitivity after dapagliflozin treatment in type 2 diabetes patients
2571908|NCT02420392|No Intervention|Normal glucose tolerance|Test incretin sensitivity in subjects with normal glucose tolerance
2571933|NCT02420106|Active Comparator|OMM alone|Subjects who are not receiving botulinum treatment consenting to Osteopathic Manipulative Medicine intervention
2571939|NCT02420106|Active Comparator|OMM plus Botulinum|Subjects who are receiving botulinum treatment and will have osteopathic manipulative medicine intervention.
3175445|NCT00634335||sk|professional Israeli bicyclists
3175446|NCT00634348|Active Comparator|Aripiprazole|
2572179|NCT02418533|Experimental|Mono-menotropin protocol|Stimulation Group 1: Mono-Menotropin Protocol Fifty patients will undergo the standard of care COS for IVF using Menopur only. Patients will receive 300 IU of Menopur injected subcutaneously daily for the first five days of stimulation. Thereafter, Menopur may be adjusted (to optimize ovarian response by patient's physician) in 75 IU increments up to a total of 450 IU Menopur daily up to and including day of hCG trigger.
2572182|NCT02418533|Experimental|rFSH protocol|Stimulation Group 2: Recombinant follicle stimulating hormone (rFSH) Protocol Fifty patients will undergo the standard of care COS for IVF using Gonal-f (EMD Serono, USA) Protocol. Patients will receive Gonal-f (300 IU) administered subcutaneously daily for the first five days of stimulation. Thereafter, Gonal-f may be adjusted (to optimize ovarian response by the patient's physician) in 75 IU increments up to a total of 450 IU daily up to and including day of hCG trigger.
2572306|NCT02417779|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572312|NCT02417779|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572314|NCT02417779|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572318|NCT02417779|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572322|NCT02417779|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572324|NCT02417779|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572327|NCT02417779|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572328|NCT02417779|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572329|NCT02417779|Experimental|Hypertrophic burn scar|"Group I (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572332|NCT02417779|Experimental|Hypertrophic burn scar (repetitive)|"Group J (n=20): Consent-capable male and female patients ≥18 years of age suffering from a hypertrophic burn scar.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572335|NCT02417779|Experimental|Flap|"Group K (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572336|NCT02417779|Experimental|Flap (repetitive)|"Group L (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)"
2572353|NCT02417454|Experimental|Probiotic|Participants will undergo the same study procedures as for the comparator; however, the product given will be the active probiotic supplement (ProbioStick).
2572358|NCT02417454|Placebo Comparator|Placebo|Participants will undergo the same study procedures as for the probiotic; however, the product given will be a placebo, identical to the probiotic in taste, smell, colour, and comprised only of the same non-active ingredients in the probiotic supplement
2573016|NCT02413515|Experimental|Arm 1|Single arm study,the eligible subjects will receive Nifedipine GITS 60mg for 8 weeks
3175447|NCT00634348|Active Comparator|Ziprasidone|
3175448|NCT00634361|Experimental|A|
3175449|NCT00634374|No Intervention|1|Oral Syringe
3175450|NCT00634374|Active Comparator|2|Rx medibottle
3175451|NCT00634387|Active Comparator|A|Anthocyans
3175452|NCT00634387|Placebo Comparator|B|no effective agent
3175453|NCT00634400|Active Comparator|1|
3175454|NCT00634400|Placebo Comparator|2|
3175455|NCT00634413|Experimental|1|
3175456|NCT00634413|Placebo Comparator|2|
3175457|NCT00634426||1|De novo surgical cohort
3175458|NCT00634426||2|Nonoperative treatment cohort
3175459|NCT00634426||3|Secondary surgical treatment cohort
2571676|NCT02421653|Experimental|MNP90 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 90 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
2571678|NCT02421653|Experimental|MNP45 + INERT OIL|Daily micronutrient powders (14 micronutrients) containing 45 µg iodine as potassium iodate plus one inert oil capsule without iodine at the study start;
2571680|NCT02421653|Experimental|IODISED OIL + INERT MNP|Daily inert powder (maltodextrin, no micronutrients) plus one oral dose of 200 mg iodine as iodised poppy seed oil at the study start
2571685|NCT02421653|Active Comparator|NON-IODISED MNP + INERT OIL|Daily micronutrient powders (14 micronutrients) without iodine plus one inert oil capsule without iodine at the study start.
2571720|NCT02421406|Experimental|Internet Behavioral Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback
2571721|NCT02421406|Active Comparator|Internet Education Intervention|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors, but not behavioral strategies for changing these behaviors.
2571767|NCT02421289|Experimental|CYP2B6 guided group|Patients were assigned to perform CYP2B6 study before ART initiation. If CYP2B6 *6/*6 was found in CYP2B6 *6/*6, the patients will be initiated a low dose of 400 mg of efavirenz (2 tablets of 200 mg) with tenofovir 300 mg and lamivudine 300 mg.
2571769|NCT02421289|No Intervention|control group|Patients were promptly ART initiation regardless CYP2B6 results. Treatments were efvirenz 600 mg, tenofovir 300 mg and lamivudine 300 mg.
3175460|NCT00634439||A|All patients 18 years or older who received a first dispensing of atomoxetine during the time period of the study (January 1, 2003 through December 31, 2006) and had at least 6 months of continuous enrollment prior to first dispensing are included in the study cohort. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. The study entry date for this cohort is the date of first atomoxetine dispensing.
3175461|NCT00634439||B|All patients 18 years or older who received a first dispensing of a stimulant medication (methylphenidate or mixed salts of amphetamine) during the time period of the study with no dispensing of the same drug in the prior 6 months and had at least 6 months of continuous enrollment prior to the first dispensing are identified. Patients are excluded for presence of pre-existing arrhythmia and heart failure during the baseline period. Patients who are matched to atomoxetine initiators using this propensity score method are retained and followed as one comparator cohort. The study entry date is the date of the first dispensing of a comparator ADHD medication.
2572259|NCT02418117|Experimental|Stereolitographic template's accuracy|Evaluating the accuracy of stereolitographic template comparing the final implant insertion to the planned implant position at coronal and apical level
2572264|NCT02417792||control|group of healthy participants
2572270|NCT02417792||Topical psoriasis treatment|Group of patients who are treated with topical medications for psoriasis
2572279|NCT02417792||Systemic psoriasis treatment|Group of patients who are treated with systematic medications for psoriasis
3209215|NCT00982566|Experimental|Sequence X|
3209216|NCT00982566|Experimental|Sequence XI|
3209217|NCT00982566|Experimental|Sequence XII|
3209218|NCT00982566|Experimental|Sequence XIII|
2572419|NCT02417207|Sham Comparator|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
2572423|NCT02417207|Active Comparator|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
2572483|NCT02416804|Experimental|Buprenorphine|Buprenorphine group : They will apply 3 days after the spine operation.
2572490|NCT02416804|Active Comparator|Tramadol|Tramadol group : They will take a pill of tramadol analgesics.
2572540|NCT02416336|Experimental|Sentinella intraoperative use|"Standard of care intraoperative protocol~Localize SLN with the Gamma Probe for In vivo count~Optional (time permitting during surgical prep). Image same SLN with Sentinella (Pre-incision)~Surgically remove/excise localized SLN~Ex vivo count - excised SLN with Gamma Probe~In vivo background/roaming count with Gamma Probe~Repeat step 1-5, until no SLNs are found with the Gamma Probe (negative reading)~Sentinella intraoperative imaging protocol~Survey surgical field/Post-excision control with Sentinella for remaining SLNs~If focal uptake seen in step 1, search for these occult SLNs with Gamma Probe and remove localized additional SLNs~Record information on data sheet for each excised SLN with Gamma Probe and Sentinella"
3209219|NCT00982566|Experimental|Sequence XIV|
3209220|NCT00982566|Experimental|Sequence XVI|
2572684|NCT02415543|Active Comparator|GROUP A|Group A will undergo SIL-TEP inguinal hernia repair with a single port LESS (12 to 15 mm paraumbilical)
2572692|NCT02415543|Active Comparator|GROUP B|Group B will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
2572738|NCT02415270|Experimental|Reduced Nicotine Cigarettes|Participants will be randomized to receive low nicotine cigarettes to replace their usual high nicotine brand.
2573135|NCT02412839||Group 60-79|Patients aged from 60 to 79 years old. 15 males and 15 females.
3209221|NCT00982566|Experimental|Sequence XV|
3209222|NCT00982579|Experimental|Vaccinees|Vaccinated at 20 weeks of age (n=24)
3209223|NCT00982579|No Intervention|Controls|No experimental vaccine (n=24)
2571687|NCT02421744|Experimental|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
2571693|NCT02421744|Active Comparator|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
2571755|NCT02421523|Experimental|Aim 2 Exercise group|The 10 subjects randomized to the experimental group will participate in an isometric exercise strengthening intervention of the knee extensor and knee flexor muscles in both legs with a frequency of ~three times/week for 12 weeks.
2571757|NCT02421523|Active Comparator|Aim 2 Control group|The 10 subjects randomized to the control group will not participate in any exercise program during the 12 weeks and will be instructed to continue with their normal activities.
2571759|NCT02421523|Experimental|Aim 1 Exercise Dosing|In order to implement a pilot home exercise intervention, the dose response and safety of this intervention must first be determined. We will enroll 12 boys with DMD for this aim and testing will be performed on the right leg.
2571794|NCT02421042|Experimental|Lenvatinib|Subjects determined to be eligible for the protocol will receive either a 5- or 10-mg single oral dose of lenvatinib on Day 1, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
2571851|NCT02420717|Experimental|Cohort A (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2571853|NCT02420717|Experimental|Cohort B (dasatinib)|Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3209224|NCT00982605||non small cell lung cancer|cancer patients
3209225|NCT00982618|Experimental|LIDOCAINE group|LIDOCAINE group : Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
3209226|NCT00982618|Experimental|Epidural Group|Epidural Group: Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
3209227|NCT00982618|Active Comparator|PCA group|Beside general anesthesia, the patients will receive neither lidocaine nor epidural catheter. The patients will receive the same analgesia protocol consisting of PCA morphine for a total duration of 48 hours.
2572234|NCT02418494||Observational (ANCHOR HRQoL interview, cognitive interview)|Participants complete the ANCHOR HSIL HRQoL interview over 45-60 minutes, comparing the list of symptoms, concerns, or HRQOL impacts related to HSIL diagnosis and treatment. Some patients also undergo a cognitive interview for up to 3 sessions.
2572278|NCT02417909||Healthy volunteers|This group is composed of healthy teenagers that volunteered to participate in the trial and that will answer questionnaires about quality of life. Parents will anwser questionnaires too.
2572284|NCT02417909||Obese teenagers|This group is composed of obese teenagers that have been recruited to participate in the trial and that will answer different questionnaires quality of life. Parents will anwser questionnaires too.
2572432|NCT02417363||Group A|the control group,healthy individuals
2572435|NCT02417363||Group B|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium
2572439|NCT02417363||Group C|patients with periodontitis, but healthy renal conditions
2572440|NCT02417363||Group D|patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis
2572485|NCT02416843|Experimental|Lean|Consumption of a mixed meal relative to individual resting metabolic rate.
2572495|NCT02416843|Experimental|Overweight|Consumption of a mixed meal relative to individual resting metabolic rate.
2572499|NCT02416843|Experimental|Obese|Consumption of a mixed meal relative to individual resting metabolic rate.
2572549|NCT02416349|Active Comparator|Respiratory Muscles Stretching|Respiratory Muscles Stretching Neck stretching, upper chest stretching, pectoralis major stretching and lateral chest stretching.
2572552|NCT02416349|Placebo Comparator|Control Group|All volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
2572714|NCT02415309|Active Comparator|2 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 2mg melatonin.
2578038|NCT02379468|Active Comparator|Panthenol|Ointment
3209228|NCT00982631|Experimental|temsirolimus/PLD|temsirolimus (Torisel) with pegylated liposomal doxorubicin (PLD,Doxil,Caelyx);a dose escalating study in a 3+3 design
3209229|NCT00982670||Systemic lupus erythematosus|Patients should fulfill the diagnostic criteria of the 1997 American College of Rheumatology for systemic lupus erythematosus
3209230|NCT00982670||Normal control|Age- and sex-matched health volunteers will serve as controls.
3209231|NCT00982696|Experimental|Single Arm|Opioid Growth Factor (OGF)
3209232|NCT00982709|Active Comparator|Exercise Types|comparing two different exercise programs for PD
3209233|NCT00982722|Experimental|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2
3209234|NCT00982722|Active Comparator|calciumcarbonate|calcium carbonate 500 mg x 2
3209235|NCT00982748|Active Comparator|Group B|Study participants in this arm attend yoga breathing classes once per week over the span of one chemotherapy cycle.
3209236|NCT00982748|Experimental|Group A|Participants in this study arm attend weekly yoga breathing classes during two consecutive cycles of chemotherapy
2571729|NCT02421484|Experimental|allogeneic mesenchymal stromal cells|This is a Phase 1 dose escalation clinical trial that constitutes 3 dose cohorts with 3 participants per cohort who will receive intravenous doses of allogeneic bone marrow derived allogeneic mesenchymal stromal cells--0.3 million cells/kg, 1.0 million cells/kg, and 3.0 million cells/kg. We will proceed from the lower dose to the next higher dose if there are no safety concerns for each cohort.
2571783|NCT02421263|Experimental|Immediate Participation Group|Participants will begin psilocybin intervention immediately after study enrollment.
2571785|NCT02421263|Active Comparator|Delayed Participation Group|Participants will begin the psilocybin intervention 6 months after study enrollment.
2571828|NCT02420860|Experimental|Treatment (elotuzumab, lenalidomide)|Patients receive elotuzumab IV over 2-4 hours on days 1, 8, 15, and 21 of courses 1-2 and on day 1 of each subsequent course. Patients also receive lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2571876|NCT02420535|Experimental|Immediately Receive Tool|Caregiver/Care Recipient Dyad will be randomly assigned to immediately receive the WeCareAdvisor Tool for 4 weeks.
2571882|NCT02420535|Active Comparator|One Month Delay|Caregiver/Care Recipient Dyad will be randomly assigned to a 4 week delay (usual care activities only) before receiving the WeCareAdvisor Tool for 4 weeks.
3209237|NCT00982787|Experimental|1|
3209238|NCT00982787|Placebo Comparator|2|
3260217|NCT01477411|Experimental|PA21 and Digoxin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Digoxin will be 0.5 mg/day
2572387|NCT02417467|Experimental|Nicotine E-Cigarette and Counseling|"As with standard nicotine replacement therapies, participants are expected to self-regulate administration of nicotine e-cigarettes according to their withdrawal symptoms. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
2572388|NCT02417467|Other|Non-Nicotine E-Cigarette and Counseling|"Participants are expected to self-regulate administration of e-cigarettes. The manufacturer recommends each vaping session to last approximately 10 puffs, with one puff every 30 seconds over a span of approximately 4.5 minutes.~Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development."
2572389|NCT02417467|Other|Counseling|Smoking cessation/relapse prevention counselling will be provided for a minimum of 30 minutes at baseline, 10 minutes during telephone follow-ups, and 15 minutes at clinic visits (20 minutes at week 4). Counselling will consist of a number of approaches, including reviewing smoking history, development/revision of a quit plan, encouragement of self-monitoring, review of triggers and challenges, and skill development.
2572401|NCT02417051|Experimental|Resiliency Training|Intervention: Disaster Worker Resiliency Training (DWRT) Program.
2572405|NCT02417051|No Intervention|Waitlist|Waitlist control: Participants to be offered the program after completion of the trial.
2572486|NCT02416895||Army recruits|Army recruits at the start of basic training will complete an in vivo immunity model
2572548|NCT02416414||Solid Organ Transplant Recipients|Subjects who have received a Solid Organ Transplant.
2572550|NCT02416414||Healthy Controls|Healthy individuals.
2572613|NCT02416063|Active Comparator|caudal Dexmedetomidine|"Drug:Caudal Bupivacaine 0.25% 1ml/kg .~Drug:caudal Dexmedetomidine 1μg /kg.~Intravenous :10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
2572617|NCT02416063|Active Comparator|Intravenous Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Intravenous dexmedetomidine 1µg/kg in a 10 ml volume normal saline~Anesthesia was induced and maintained with sevoflurane"
2572624|NCT02416063|Placebo Comparator|Placebo|"Caudal: bupivacaine 0.25% 1ml/kg .~Intravenous: 10 ml Normal saline~Anesthesia was induced and maintained with sevoflurane"
2572672|NCT02415751||self-care education|All patients in the study will receive self-care education
2572718|NCT02415387|Experimental|Arm I (inactive typhoid vaccine, placebo)|Patients receive inactive typhoid vaccine IM at visit 1 followed by placebo IM 30 days later at visit 2.
2572720|NCT02415387|Placebo Comparator|Arm II (placebo, inactive typhoid vaccine)|Patients receive placebo IM at visit 1 followed by inactive typhoid vaccine IM 30 days later at visit 2.
2572777|NCT02415023|Experimental|fruquintinib+paclitaxel|fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle.
2572851|NCT02414711|Other|No depressed|"If the result of the HSCL25 scale is inferior than 1.75, then the patient is considered as no depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
2572856|NCT02414711|Other|Depressed|"If the result of the HSCL25 scale is superior or equal to 1.75, then the patient is considered as depressed.~50 of these patients have to have a psychological interview with the PSE9 questionary to validate the result of the HSCL25 scale."
2572883|NCT02414308|Experimental|Adipose tissue stem cell injection|The stem cell will be harvested by liposuction and injection will be at corpora cavernosa and dorsal penile artery
2572889|NCT02414061|Experimental|Breakfast - Carbohydrate + Whey Protein|Addition of whey protein isolate (20 g dissolved in flavoured water) to breakfast meal composition
2572893|NCT02414061|Placebo Comparator|Breakfast - Carbohydrate|Only flavoured water consumed with breakfast meal
2572896|NCT02414061|No Intervention|No Breakfast|Only water consumed at breakfast time point
2572965|NCT02413957|No Intervention|Controll-Group|Patient randomized to the Control-Group will receive the traditional care by physician and nurse on the ward.
2572971|NCT02413957|Experimental|MedRec-Group|Patient randomized to the MedRec-Group will receive the traditional care by physician and nurse on the ward and additional pharmacist led medication reconciliation.
2571754|NCT02421380|Experimental|Hyperpolarized Pyruvate MRI Reproducibility|This is a reproducibility study of hyperpolarized [1-13C] pyruvate MRI in patients with solid tumors. A total of 100 patients will be enrolled, 50 of whom will be imaged using 1D MR spectroscopy and the other 50 with 3D imaging sequence.
3209239|NCT00982800|Placebo Comparator|Placebo Sugar Pill|"Patients are stratified based on their initial pain score in the recovery room. patients with a pain numeric rating scale of greater than or equal to 7/10 are stratified to the high group. then randomized to receive gabapentin 200 mg tid x 9 doses, or placebo x 9 doses. Patients with a pain score equal to or less than 6/10 are stratified to the low group, then randomized to receive gabapentin 200mg tid x 9 doses or placebo x 9 doses.~All patients receive Acetaminophen 1gm every 6 hours for 3 days, Celecoxib 400mg as a loading dose then 200mg twice a day for 3 days. Patients also receive patient controlled analgesia (PCA) of hydromorphone for 24 hrs, then are transitioned to oxycodone 5-15 mg every 2 hours as needed."
2571854|NCT02420574|Active Comparator|ALB-BENDEX|albendazole, 400 mg, single oral dose, (BENDEX)
2571855|NCT02420574|Active Comparator|ALB-OVIS|albendazole, 400 mg, single-oral dose, (OVIS)
3209240|NCT00982800|Active Comparator|Gabapentin 200 mg tid x 9 doses|
3209241|NCT00982826|Experimental|1|ABT-072 tablet single ascending dose
3209242|NCT00982826|Experimental|2|Placebo tablet
3209243|NCT00982826|Experimental|3|ABT-072 tablet administered under non-fasting conditions.
2571995|NCT02419677|Other|RFA alone|Patients undergo radiofrequency ablation alone.
2571998|NCT02419677|Experimental|RFA+CIK|Autologous cytokine-induced killer cells were transfer via venous one week after RFA.
3209244|NCT00982826|Experimental|4|ABT-072 tablet administered under fasting conditions
3209245|NCT00982826|Experimental|5|ABT-072 tablet multiple ascending dose
2572124|NCT02418975|Experimental|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
2572126|NCT02418975|Active Comparator|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
2572168|NCT02418663|Other|Postoperative elective surgical patients|Patients undergoing major elective thoracic and abdominal, the latter group including upper gastrointestinal, esophageal, and colorectal procedures. In this group FR will predicted by administering a fluid challenge of 250 ml of Lactated Ringer's solution and measuring SV with the ccNexfin
2572244|NCT02418299|Experimental|IncontiLase Er:YAG laser treatment|Er:YAG laser treatment for stress and mixed urinary incontinence
3209246|NCT00982839|Active Comparator|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
2572400|NCT02417350|Experimental|Ketogenic diet first|Starting with ketogenic diet first and then switching to a NFA recommended diet
2572406|NCT02417350|Experimental|NFA recommended diet first|Starting with NFA recommended diet first and then switching to a ketogenic diet
2572494|NCT02416921|Experimental|Weight-gain Prevention|Subjects in this group will engage in a 4-week weight-gain prevention curriculum delivered via Facebook
2572502|NCT02416921|Active Comparator|Women's Health|Subjects in this group will engage in a 4-week women's health curriculum delivered via Facebook
2572539|NCT02416362|No Intervention|Control|The control group (No vibration) will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. The vibrating platform will remain off throughout intervention.
2572543|NCT02416362|Experimental|GE1|The GE1 (Vibration at 30 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 30 Hz.
2572546|NCT02416362|Experimental|GE2|The GE1 (Vibration at 50 Hz) group will hold an exercise protocol on the vibration platform, which is to stay on one foot on the non-dominant leg, with the knee held in 40 ° of flexion, hands together to the body and the trunk in the erect position. Altogether, the participant will perform 11 sets of 30 seconds with a rest interval of 30 seconds between sets. The knee angle will be monitored throughout the protocol by the second reviewer with a goniometer so that there is no change in it. During the sets the vibrating platform will be turned on at a vibration frequency of 50 Hz.
2572595|NCT02416141|Active Comparator|Fast release oro-dispersible tramadol|"This group receives a fast release oro-dispersible tramadol 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of fast release oro dispersible tramadol 50 mg"
2572596|NCT02416141|Placebo Comparator|Placebo-controlled arm|"This group receives a placebo 30 minutes before the vacuum aspiration procedure. A paracervical block with a 27-gauge spinal needle with lidocaine will be injected at the the start of the procedure.~Intervention: use of placebo"
2572640|NCT02415920|Experimental|Experimental|These participants will receive 24 international units (IU) of oxytocin via a nasal spray.
2572644|NCT02415920|Placebo Comparator|Control - Placebo|These participants will receive 24 international units (IU) of a saline solution via a nasal spray.
2572678|NCT02415582|Experimental|Aerobic exercise|Aerobic exercise on treadmill at 65-70% of the heart rate reserve during a session.
2572680|NCT02415582|Experimental|Combined exercises|A session combines resistance and aerobic exercises, with aerobic exercise on treadmill at 65-70% of the heart rate reserve, followed by 60 minutes for cardiorespiratory recovery, and resistance exercise.
2572681|NCT02415582|Sham Comparator|Control|Participants do not exercise and remain sitting for 45 minutes
2578397|NCT02377258||4|with on-going combination therapy
3209247|NCT00982839|Experimental|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
3209248|NCT00982852||Acute|Patients in acute need for angioplasty or left heart catheterization.
2571889|NCT02420483|Experimental|Patients|Cardiopulmonary resuscitation with measurement of tidal volume, airway pressure and flow by a pneumotachograph and airway, oesophageal pressure sensors
3209249|NCT00982852||Chronic or non-acute|Patients will planned angioplasty or left heart catheterization.
2571969|NCT02419768|Experimental|Physical Exercise|All patients will receive a circuit-group training including a specific work of balance, posture, gait, fitness, dual tasks and stretching.
2571971|NCT02419768|No Intervention|Control|All patients will not change their physical activities
2572001|NCT02419586|Experimental|bubble gum chewing and routine care|Start chewing gum on postoperative day at three times daily with no more than 30 minutes till discharged
2572002|NCT02419586|No Intervention|routine care|Non interventional group will receive existing routine care as usual
2572065|NCT02419404||Patients having cardiac surgery|Patients having cardiac surgery who have a pulmonary artery catheter will be eligible for inclusion in this study
2572101|NCT02419209|Experimental|Individualised Homeopathic Remedy|A single individualised homeopathic remedy will be administered to each participant in the form of medicated sucrose pillules. The potency, dosage and frequency of administration will be individualised for each participant in accordance with the laws that govern homeopathic prescribing.
2572178|NCT02418884|Other|CAD+DM|Using self controlled study to validate the hypothesis that the treatment of rosuvastatin could increase the score of CAC density in CAD patients with diabetes mellitus.
2572227|NCT02418325|Experimental|AllogeneicHumanUmbilicalCordTissue-DerivedMesenchymalStemCells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
3209250|NCT00982891|Experimental|Morphine, low dose, in addition to conventional treatment|Morphine dose titration
3209251|NCT00982904|Experimental|Fexinidazole|
2572391|NCT02417402|Active Comparator|Untrained Physical Therapists|The patients allocated to the Control group will be treated by physical therapists who did not receive any training about clinical practice guidelines and pain management. These patients will receive the usual care from their physical therapists.
2572393|NCT02417402|Experimental|Trained Physical Therapists|The patients allocated to the Experimental group will be treated by physical therapists who received training about clinical practice guidelines and pain management.
3209252|NCT00982904|Placebo Comparator|Placebo|
3209253|NCT00982917|Experimental|teachers taught curriculum|Teachers taught Stamp-in-Safety curriculum
2572487|NCT02416648|Experimental|CCC Counseling; baseline and 2 months|Intervention group 1 received 2 CCC Counseling sessions; at baseline and at 2 months. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
2572496|NCT02416648|Experimental|CCC Counseling; baseline|Intervention group 2 received a session CCC Counseling session at baseline only. The intervention was a 10 to 15 minute clinic based one on one counseling session between a clinician (counselor) and a HIV positive adult patient (client). Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
2572505|NCT02416648|No Intervention|Routine care|The control group received routine clinic care.
2572551|NCT02416388|Experimental|R1-IDA|Idarubicin
2572553|NCT02416388|Active Comparator|R1-DAUNO|Daunorubicin
2572555|NCT02416388|Active Comparator|R2-HDAC|High dose cytarabine
2572557|NCT02416388|Experimental|R2-IDAC|Intermediate dose cytarabine
2572560|NCT02416388|Active Comparator|R3-MAC-MTX|Methotrexate and mycophenolic acid
2572561|NCT02416388|Experimental|R3-MAC-MPA|Cyclosporine and mycophenolic acid
2572562|NCT02416388|Active Comparator|R3-RIC-CICLO|Cyclosporine
2572563|NCT02416388|Experimental|R3-RIC-MPA|Cyclosporine and mycophenolic acid
2572564|NCT02416388|Experimental|R4-VOS-IDAC|Intermediate dose cytarabine and vosaroxin
2572565|NCT02416388|Active Comparator|R4-IDAC (without VOS)|Intermediate dose cytarabine alone
2572566|NCT02416388|Experimental|R4-DEX-HDAC|High dose cytarabine and dexamethasone
2572567|NCT02416388|Active Comparator|R4-HDAC (without DEX)|High dose cytarabine alone
2572569|NCT02416388|Experimental|R4-VEN-IDAC|Intermediate dose cytarabine and venetoclax
2572571|NCT02416388|Active Comparator|R4-IDAC (without VEN)|Intermediate dose cytarabine alone
3209254|NCT00982917|Experimental|teachers do not learn curriculum|Teachers are not taught Stamp-in-Safety curriculum
3209255|NCT00982969||TB suspected|Soldiers who are clinically suspected with tuberculosis
3209256|NCT00982982|Active Comparator|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes"
3209257|NCT00982982|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
3209258|NCT00983008|Experimental|Protected Time Group|Interns working 30 hour shifts every 3rd night and an average of 80 hours per week in a medical intensive care unit.
2572941|NCT02414009|Experimental|CAPTEM|Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
2572950|NCT02413762||NGT, no insulin resistance|Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
3209259|NCT00983021|Experimental|A|
3209260|NCT00983021|Experimental|B|
3209261|NCT00983021|Active Comparator|C|
3209262|NCT00983021|Experimental|D|
2571780|NCT02421081|Active Comparator|having arteriel cut|30 patients who refer to Erciyes University emergency department because of wrist laceration with radial and/or ulnar artery incision,will be presenting to the study.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery,under a microscope using microsurgical techniques and polyamide suture will be held vascular repair.Patients will be assessed by Doppler ultrasonography again 4 weeks after surgery;flow velocity and vessel diameter will be measured at the anastomoses line and patient will be divided to 4 groups. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; The relationship between the anastomosis opening will be evaluated statistically.
2571784|NCT02421081|Active Comparator|having tendon cut|10 patients having similar age and sex with first group, who refer to Erciyes University emergency department because of wrist laceration without radial or ulnar artery cutting,will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography before surgery,as well as the healthy side and side of the cuts.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.Then after patients received surgery to repair tendons and/or nerves. Among these groups serum CD34,CD133,CD309 levels and distribution of lymphoid cells measured by immunohistochemistry; and will compare with first group.
2571786|NCT02421081|No Intervention|healthy control|10 healty having similar age and sex with first group,controls who accept to give blood to determine normal range of serum CD34,CD133 and CD 309 will be taken to compare with first group.All patient's flow rate will be evaluated by Doppler ultrasonography.Then 5 ml of blood samples will be taken from the systemic circulation,flowcytometric analysis of serum CD34,CD133 and CD309 levels to be measured.
2571845|NCT02420834|Experimental|Tear Supplement Hypromellose 0.15%|Preservative free Hypromellose Eye Drops BP 0.15% applied as required for 1 month
2571846|NCT02420834|Experimental|Tear Supplement Hypromellose 0.4%|Preservative free Hypromellose Eye Drops BP 0.4% applied as required for 1 month
2571847|NCT02420834|Experimental|Tear Supplement Carboxymethylcellulose|Tear Supplement 3: Preservative free 0.25% Carboxymethylcellulose, electrolyte balanced (Theratears) applied as required for 1 month
2571848|NCT02420834|Experimental|Tear Supplement Liposomal spray|Preservative free Phospholipid liposomal spray (Tears Again) applied as required for 1 month
2571967|NCT02419781|Active Comparator|Group with endovascular treatment|Group with additional endovascular treatment
2571968|NCT02419781|Active Comparator|Group without endovascular treatment|Group without additional endovascular treatment
2572021|NCT02419625|Other|subgroup-specific HEV in Israel|The study will involve patient interviews using questionnaires
2572077|NCT02419365||PCD|Individuals with Primary Ciliary Dyskinesia will be assessed in a pure observational design without intervention
2572096|NCT02419105|Active Comparator|Testosterone + Vitamin D|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
2572104|NCT02419105|Active Comparator|Testosterone + Placebo|Testosterone, transdermal gel, 75 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
2572110|NCT02419105|Active Comparator|Placebo + Vitamin D|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Colecalciferol, oral drink solution, 24000 IU, once per month, for 12 months
2572114|NCT02419105|Placebo Comparator|Control|Placebo: Testosterone, transdermal gel, 0 mg, once per day, for 12 months AND Placebo: Colecalciferol, oral drink solution, 0 IU, once per month, for 12 months
3209263|NCT00983034|Active Comparator|Membranous nephropathy|Patients with primary membranous nephropathy diagnosed by biopsy
3209264|NCT00983034|Active Comparator|IgA nephropathy|Patients with IgA nephropathy diagnosed by biopsy
3209265|NCT00983034|Active Comparator|Focal segmental glomerulosclerosis|Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy
2572240|NCT02418169||retrospective, severe traumatic brain injury|All patients in 2010-2014 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
2572241|NCT02418169||retrospective, craniofacial fracture|All patients in 2010-2014 with craniofacial fracture admitted to TUCH.
2572247|NCT02418169||prospective, severe traumatic brain injury|All patients in 2015-2017 with severe traumatic brain injury admitted to Turku University Central Hospital (TUCH)
2572250|NCT02418169||prospective, craniofacial fracture|All patients in 2015-2017 with craniofacial fracture admitted to TUCH.
3209266|NCT00983047|Active Comparator|Docetaxel|The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
3209267|NCT00983047|Experimental|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75mg/m2,efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD.No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment:Dose of 200mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxic."
3209268|NCT00983060|Experimental|NIM811|
3209269|NCT00983060|Placebo Comparator|Placebo|
3209270|NCT00983112|Experimental|Evicel|
2572421|NCT02417012|Experimental|U-TURN intervention|"The intervention group will receive an intensive lifestyle intervention including partly supervised aerobic and strength exercise, diet plans and counseling by clinical dietitians. All exercise will be supervised initially and the supervision will be reduced gradually across the 12-month intervention. Additionally, the participants will be offered educational classes on implementation of a healthy lifestyle and diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
3209271|NCT00983112|Placebo Comparator|Placebo|
3209272|NCT00983125|Experimental|clonidine|
3209273|NCT00983125|Other|no clonidine|
3209274|NCT00983138|Experimental|recombinant asparaginase|
3209275|NCT00983151|Experimental|Active|
3209276|NCT00983151|Placebo Comparator|Placebo|
2571806|NCT02421250|Experimental|Radical-7 Non-invasive Hgb Monitor|We use the Radical-7 Noninvasive Hgb Monitor device (provided by Masimo Corporation from Irvine USA) to measure hemoglobin levels in patients in the experimental group.
2571808|NCT02421250|No Intervention|Control|We will use standard-of-care for control group and not use the SpHb monitor.
2571850|NCT02420769||Threatened abortion|Pregnant patients > 8 weeks gestation coming to the ANC clinic with mild vaginal bleeding but healthy viable intrauterine pregnancy. Vaginal color doppler for uterine artery and corpus luteum together with serum progesterone and CA125 will be assessed.
2571912|NCT02420431|Experimental|metacognitive therapy plus CR|Group psychological treatment focused on reducing worry and rumination and modifying beliefs about thinking in addition to treatment as usual (standard cardiac rehabilitation)
2571913|NCT02420431|Active Comparator|CR alone (control)|Usual group-based cardiac rehabilitation (treatment as usual) involving stress management, exercise, education
3209277|NCT00983164|No Intervention|group I|group I - controls
3209278|NCT00983164|Experimental|group II|group II - patients with hepatitis C without treatment
2572078|NCT02419352|Active Comparator|Sugammadex|Sugammadex is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
2572079|NCT02419352|Active Comparator|Neostigmine/atropine|Neostigmine combined to atropine is administered to reverse rocuronium-induced neuromuscular blockade at the end of elective surgery.
2572116|NCT02419066||men and women with CD4 >=350|electronic monitoring of ARV adherence in men and women with CD4 >=350
2572117|NCT02419066||pregnant women with CD4 >=350|electronic monitoring of ARV adherence in pregnant women with CD4 >=350
2572120|NCT02419066||men and women with CD4 <200|electronic monitoring of ARV adherence in men and women with CD4 <200
2572148|NCT02418767|Experimental|Low dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
2572151|NCT02418767|Experimental|Mid dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
2572156|NCT02418767|Experimental|High dose|7 Japanese and 7 Caucasian subjects (randomized 6:1) administered a single dose of MOD-4023/Placebo
2572213|NCT02418403|Active Comparator|PREPARE|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP."
2572219|NCT02418403|Experimental|PREPARE+financial incentive|"Access to Prepare for Your Care website and written encouragement to discuss ACP with one's PCP; offer of $50 to complete the website and entry into $1000 lottery for discussing ACP with one's PCP."
2572293|NCT02418078||Geriatri|patients ageing ≥ 65 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
2572297|NCT02418078||non-geriatri|patients ageing 19-64 yr undergoing herniorrhaphy with local infiltration anesthesia and sedation
2572376|NCT02417597|Experimental|Experimental Group|Participants in this arm are aged over 65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
2572383|NCT02417597|Active Comparator|Immunogenicity Control Group|Participants in this arm are aged beteen 18-65 years and would receive three doses of Recombinant Hepatitis E Vaccine (Escherichia Coli)(Hecolin®) at o,1,6 month.
2572385|NCT02417597|No Intervention|Safety Control Group|Participants in this arm are aged over 65 years.
3209279|NCT00983164|Experimental|group III|group III - patients with hepatitis C treated weekly with pegylated interferon combined with daily ribavirin
3209280|NCT00983177|Active Comparator|colchicine|
3209281|NCT00983177|Placebo Comparator|Lactose capsule|
2572621|NCT02416206|Experimental|BeEAM|Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma
3209282|NCT00983190|Other|Single Group Assignment|
3209283|NCT00983203|Experimental|FID 114657|FID 114657
3209284|NCT00983203|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
3209285|NCT00983229|Active Comparator|CTrach|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of CTrach (sizes 3,4 or 5), establishment of ventilation.~Direct evaluation of laryngeal view through CTrach~Tracheal intubation through CTrach LMA~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3209286|NCT00983229|Active Comparator|Intubating Laryngeal Mask Airway (ILMA)|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of ILMA (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through ILMA using fibrescope~Tracheal intubation through ILMA using fibrescope.~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3209287|NCT00983229|Active Comparator|I-gel|"Induction to GA with 1mcg/kg fentanyl, and 1-3 mg/kg of propofol to loss of verbal contact and neuromuscular relaxation with 0.5 mg/kg of atracurium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification.~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation.~Evaluation of laryngeal view through I-gel using fibrescope~Tracheal intubation through I-gel using fibrescope~Maintenance of anaesthesia with 02, air and sevoflurane 1-2 MAC and positive pressure ventilation~At the end of surgery patient will be awoken as normal. Any sign of trauma to the oral cavity and airways and gastric fluid in trachea will be noted."
3209288|NCT00983255|Experimental|SAD/ Part A|Single IV infusions of placebo or TR-701 FA given at 50, 100, 200, and 400 mg.
3209289|NCT00983255|Experimental|MAD / Part B|Multiple IV infusion of placebo or TR-701 FA given daily for 7 days at 200 and 400 mg.
3209290|NCT00983255|Experimental|Bioavailability / Part C|TR-701 FA tablet given once orally as a 200 mg tablet or TR-701 FA for injection given once as a 200 mg IV infusion.
3209291|NCT00983255|Experimental|Venous Tolerability/ Part D|IV infusions of placebo and 200 mg TR-701 FA given daily for 3 days,
3209292|NCT00983268|Experimental|Treatment Arm|
3209293|NCT00983320|Experimental|medication|quetiapine
3209294|NCT00983320|Placebo Comparator|placebo|placebo
3209295|NCT00983333|Experimental|Web-based communication tool for health care professionals|
3209296|NCT00983333|Experimental|Web-based communication training tool for patients|
2571977|NCT02419664|Experimental|Ga-68 DOTATOC PET in pituitary adenomas|"To give Ga-68 DOTATOC in pituitary patients doing PET/CT~They are compared with Ga-68 DOTATOC PET performed in another study on patients with no pituitary disease."
3209297|NCT00983333|No Intervention|Usual care for patient participants|
3209298|NCT00983398|Experimental|Treatment (mannitol, melphalan, carboplatin, STS)|Patients receive mannitol IA over 30 seconds, melphalan IA over 10 minutes, and carboplatin IA over 10 minutes. Patients then receive sodium thiosulfate IV over 15 minutes at 4 and 8 hours after carboplatin. Treatment repeats every 4-6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
2572102|NCT02419144|Active Comparator|AMI followed by campaigns|Behavioral interventions
2572108|NCT02419144|Active Comparator|Campaigns followed by AMI|Behavioral interventions
3209299|NCT00983411||Healthy and OHS subjects|10 healthy subjects: 20 to 60 years old 10 patients with Obesity hypoventilation syndrome: 20 to 70 years old treated with nocturnal non invasive ventilation for at least three months.
3209300|NCT00983424|Experimental|Treatment arm|Cyclosporine A + nab-paclitaxel
2572260|NCT02418143||Implantable electronic device placement|CorMatrix CanGaroo ECM envelope for an implantable electronic device placement following a battery change out or upgrade.
2572262|NCT02417857|Experimental|Laparoscopic Cholecystectomy (SILC)|Group 1: Single Incision Laparoscopic Cholecystectomy (Intervention)
2572265|NCT02417857|Experimental|Laparoscopic Cholecystectomy (CLC)|Group 2: Conventional Laparoscopic Cholecystectomy (Intervention)
2572417|NCT02417311||Control group|40 healthy volunteers will serve as control group. Skin biopsy, genotyping and disease phenotyping
2572426|NCT02417311||DCM patients|20 patients with dilated cardiomyopathy
2572434|NCT02417311||HCM patients|20 patients with hypertrophic cardiomyopathy
2572484|NCT02416765|Active Comparator|Sensor-augmented pump therapy|Patients will use conventional pump therapy and freely implement their usual basal rate and CHO-matching full prandial bolus to regulate glucose levels.
2572489|NCT02416765|Active Comparator|Single-hormone CLS with full boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
2572498|NCT02416765|Active Comparator|Single-hormone CLS with partial boluses|Variable subcutaneous insulin infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
2572503|NCT02416765|Active Comparator|Dual-hormone CLS with full boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. Carbohydrate-matching full prandial bolus will be given 10 minutes before the meal. Each subject insulin-to-carbohydrate ratio will be used to calculate the insulin bolus to be given.
2572507|NCT02416765|Active Comparator|Dual-hormone CLS with partial boluses|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate postprandial glucose levels. A pre-meal partial prandial bolus will be given 10 minutes before the meal. The partial bolus will be based on the estimated meal size (snack-regular-large-very large). Meal size will be defined as: snack as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, very large meal for anything above 90g CHO.
2572685|NCT02415699|Experimental|DC-CIK Immunotherapy Plus Chemotherapy|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 12 cycles of DC-CIK therapy in this group
2572691|NCT02415699|Active Comparator|Chemotherapy Alone|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy alone.
2572737|NCT02415257|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board"
2572744|NCT02415257|No Intervention|Non-gentamicin|Rehabilitation exercises before and after both treatment and surgery Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented and exclusion from exercises would not be approved by the ethical board
2572779|NCT02414880|Active Comparator|Sugammadex/ Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
2572784|NCT02414880|Active Comparator|Neostigmine / Normal liver|"Patients with American Society of Anesthesiologists physical status (ASA) class I with normal preoperative liver functions undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
2572843|NCT02414659||Cesarean delivery, cord blood collected|Cesarean delivery patient who opted for cord blood collection during procedure. Cord blood was collected in-utero after delivery and after clamping of the umbilical cord. After cord blood collection operation was continued.
2579104|NCT02372500|No Intervention|Control|Normal post operative care
3209301|NCT00983450|Experimental|study group|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
3209302|NCT00983450|Experimental|CONTROL|People after a first ischemic or hemorrhagic stroke, up to 60 days following the event.
3209303|NCT00983463||Obese, bariatric surgery, liver biopsy|Obese subjects approved and scheduled for bariatric surgery at Vanderbilt University Medical Center
3209304|NCT00983463||Normal BMI, abdominal surgery, liver biopsy|Normal weight subjects having elective abdominal surgery at Vanderbilt University Medical Center.
2571841|NCT02421367|Experimental|TDENV-PIV (0-3)|"The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28."
2571877|NCT02420522|Experimental|Active-first|Participants randomly assigned to this arm will receive one week of active Repetitive Transcranial Magnetic Stimulation prior to one week of Sham Transcranial Magnetic Stimulation, separated by at least one week.
2571878|NCT02420522|Experimental|Sham-first|Participants randomly assigned to this arm will receive one week of Sham Transcranial Magnetic Stimulation prior to one week of active Repetitive Transcranial Magnetic Stimulation, separated by at least one week.
2571886|NCT02420522|Active Comparator|Full-course Active|Participants in this arm will receive three weeks (30 session, twice-daily) of active Repetitive Transcranial Magnetic Stimulation. This arm will not involve random assignment.
2571917|NCT02420197|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training.Three guided sessions will be offered during the home training period.
2571919|NCT02420197|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
2571975|NCT02419898||Feasibility Study|Nulliparous women of reproductive age (18-40 years), who are not pregnant but could have a planned or unplanned pregnancy during the duration of the study.
2572004|NCT02419599|Experimental|Group A|The group who will receive high energy density, low volume oral nutritional supplement, to be taken for 4 weeks (28 days)
2572006|NCT02419599|Active Comparator|Group B|The group who will receive the standard energy density oral nutritional supplement, to be taken for 4 weeks (28 days)
3209305|NCT00983463||Liver transplantation donors and recipients|All livers made available for implantation or explantation will be eligible.
2572103|NCT02419157|Active Comparator|Clearfil SE Bond Etch (CSE-E)|"CSE-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
2572109|NCT02419157|Active Comparator|Xeno V+ Etch (XV-E)|"XV-E (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Enamel margins were selectively etched with 36% phosphoric acid for 15s and subsequently thoroughly rinsed and air-dried. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~Selective enamel etching with 36% phosphoric acid"
2572113|NCT02419157|Active Comparator|Clearfil SE Bon Non-etch (CSE-NE)|"CSE-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
2572115|NCT02419157|Active Comparator|Xeno V+ Non-etch (XV-NE)|"XV-NE (n=28): After shade selection, teeth were restored under relative isolation. Lesions were cleaned with pumice and water in a rubber cup followed by rinsing and drying. An enamel bevel of 1-2 mm was prepared with a diamond bur operated in a high-speed handpiece under air-water spray. Adhesive system was applied according to manufacturers' instructions and light-cured with an LED for 10s. NCCLs were restored incrementally with a microhybrid composite resin. Increments were light cured for 20s. Afterwards, retraction cord was removed and finishing and polishing were performed with rubber points.~No selective enamel etching with 36% phosphoric acid"
2572171|NCT02418689|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval
2572225|NCT02418247|Active Comparator|low dose RAI|Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
2572230|NCT02418247|Sham Comparator|diagnostic RAI|Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
2572280|NCT02417974|Experimental|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT) via colonoscopy
2572288|NCT02417974|No Intervention|Control|No Fecal Microbiota Transplant (FMT) via colonoscopy
2572369|NCT02417662|Active Comparator|Systemic Anti-Cancer Therapy (SACT) alone|The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.
2572375|NCT02417662|Experimental|SACT + Radical Radiotherapy (Conventional RT and SABR)|"SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.~The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines."
2572844|NCT02414659||Cesarean delivery, control|Routine cesarean delivery patients.
3209306|NCT00983502||Integrative Medicine|Patients of MD practitioners trained in Complementary and Alternative Medicine
2571892|NCT02420782|Experimental|ASP6282 multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing. Midazolam dosing elderly only, exploratory for DDI purpose
2571894|NCT02420782|Placebo Comparator|Placebo multiple ascending dose (nonelderly and elderly)|Part 2. Germany only: once daily dosing, optional twice daily dosing
2571896|NCT02420782|Experimental|ASP6282 and pilocarpine|Part 3
2571898|NCT02420782|Other|Placebo and pilocarpine|Part 3
2572003|NCT02419820|Experimental|APD791 10mg single dose|APD791 10mg single dose
2572005|NCT02419820|Experimental|APD791 20mg single dose|APD791 20mg single dose
2572007|NCT02419820|Experimental|APD791 40mg single dose|APD791 40mg single dose
2572008|NCT02419820|Experimental|APD791 10mg|APD791 10mg single dose + Aspirin + Clopidogrel
2572009|NCT02419820|Experimental|APD791 20mg|APD791 20mg single dose + Aspirin + Clopidogrel
2572011|NCT02419820|Experimental|APD791 40mg|APD791 40mg single dose + Aspirin + Clopidogrel
2572013|NCT02419820|Experimental|APD791 80mg|APD791 80mg single dose + Aspirin + Clopidogrel
2572014|NCT02419820|Experimental|APD791 160mg|APD791 160mg single dose + Aspirin + Clopidogrel
2572015|NCT02419820|Experimental|APD791 240mg|APD791 240mg single dose + Aspirin + Clopidogrel
2572017|NCT02419820|Experimental|APD791 320mg|APD791 320mg single dose + Aspirin + Clopidogrel
2572022|NCT02419820|Placebo Comparator|APD791 Placebo|APD791 placebo for single dose + Aspirin + Clopidogrel
2572025|NCT02419820|Experimental|APD791 2mg MD|APD791 2mg multiple dose + Aspirin + Clopidogrel
2572026|NCT02419820|Experimental|APD791 5mg MD|APD791 5mg multiple dose + Aspirin + Clopidogrel
2572028|NCT02419820|Experimental|APD791 10mg MD|APD791 10mg multiple dose + Aspirin + Clopidogrel
2572029|NCT02419820|Experimental|APD791 20mg MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
2572033|NCT02419820|Placebo Comparator|APD791 placebo MD|APD791 placebo for multiple dose + Aspirin + Clopidogrel
2572129|NCT02418988|Experimental|TACE plus rAd-p53|TACE plus rAd-p53 artery injection'
2572130|NCT02418988|Active Comparator|TACE|TACE will be applied alone
2572177|NCT02418624|Experimental|Dose escalation|carboplatin, olaparib
3209307|NCT00983502||Naturopath Doctors|Patients of practitioners who are not MD's and are trained in Naturopathic Medicine
3209308|NCT00983502||Chronic Fatigue Specialists|Patients of MD's who specialize in treating Chronic Fatigue and related conditions
2572258|NCT02418130|Experimental|UDCA004|UDCA004
2572261|NCT02418130|Placebo Comparator|Placebo of UDCA004|Placebo of UDCA004
3209309|NCT00983502||Control Group|Patients treated by primary care MDs in practice-based research networks
3209310|NCT00983554|No Intervention|Placebo|
2572394|NCT02417428|Experimental|Citrulline|Participants that will be randomized in the first arm will be divided in either citrulline plus HIIT (CIT + HIIT or group A) or citrulline alone (CIT or group B).
2572396|NCT02417428|Placebo Comparator|Placebo|Participants that will be randomized in the second arm will be divided in either placebo plus HIIT (PLA + HIIT or group C) or placebo alone (PLA or group D).
2572397|NCT02417428|Experimental|Exercise|Participant that will be randomized in this arm will have an exercise program (HIIT) added to their respective dietary supplement.
2572398|NCT02417428|Other|Without exercise|Participant that will be randomized in this arm will not have an exercise program.
3209311|NCT00983554|Experimental|Anastrazole and Testosterone|
3209312|NCT00983554|Experimental|Dutasteride and Testosterone|
3209313|NCT00983554|Experimental|Testosterone|
2572652|NCT02415712||Fomepizole Intravenous Infusion|Fomepizole Intravenous Infusion
2572791|NCT02415088|Active Comparator|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
2572797|NCT02415088|Active Comparator|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
2572858|NCT02414581|Experimental|Chlorhexidine 0.12% & Ethyl Alcohol 7%|Chlorhexidine 0.12% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, twice day for 9 days.
2572860|NCT02414581|Active Comparator|Ethyl Alcohol 7%|Ethyl Alcohol 7% without chlorhexidine mouthwashes 15ml by 30 seconds, twice day for 9 days.
2572861|NCT02414581|Experimental|Chlorhexidine 2% & Ethyl Alcohol 7%|Chlorhexidine 2% and Ethyl Alcohol 7% mouthwashes 15ml by 30 seconds, once day for 3 days.
3209314|NCT00983567|Experimental|Teen web|Main web - with all components
3209315|NCT00983567|Active Comparator|Minimal teen web|Teen web minus behavioral components
3209316|NCT00983593|Experimental|Group Therapy|Group therapy following the Mind-Body Bridging program.
3209317|NCT00983606||1|32 to 35 WGA Infants less than six months of age by RSV season peak.
3209318|NCT00983632|Experimental|vagus stimulation|electrical vagus stimulation to X.nerve on neck
3209319|NCT00983658|Experimental|huMAb OX40L|
3209320|NCT00983658|Placebo Comparator|Placebo|
3209321|NCT00983671||children with asthma|children with diagnosed asthma, age 6-18 years
3209322|NCT00983671||cystic fibrosis|children with cystic fibrosis, age 6-18 years
3209323|NCT00983671||chronic lung disease|children with chronic lung disease, also known as bronchopulmonary dysplasia, age 6-18 years
3209324|NCT00983671||pneumonia|children with clinical signs of pneumonia, age 6-18 years
3209325|NCT00983684|Experimental|Intra-operative radiotherapy|A single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
3209326|NCT00983684|Active Comparator|Post-operative radiotherapy|Standard post-operative radiotherapy.
3209327|NCT00983697|Experimental|FDG PET/CT|Planning for Therapeutic conventional surgery of the N0 neck is documented prior to and immediately after review of the fludeoxyglucose F 18 (FDG)-PET/CT scan completed per protocol.
3209328|NCT00983710|Experimental|1|Participants will receive a new patient education program designed to help men manage side-effects related to treatment for localized prostate cancer. The intervention will be targeted to low health literacy men.
3260218|NCT01477411|Experimental|No PA21; Digoxin with food|The maximum dosage of Digoxin will be 0.5 mg/day
2571922|NCT02420236|Experimental|High-intensity resistance training|Full body, progressive strength training with Theraband® Elastic bands. Three times per week for 12 weeks - 3 weeks with supervised sessions at the clinic, and 9 weeks of home training. Three guided sessions will be offered during the home training period.
2571927|NCT02420236|Active Comparator|General physical activity|12 weeks of general physical activity - 3 weeks with supervised sessions at the clinic, and 9 weeks of individually adjusted home training. This include circle-training, low-intensity resistance exercises, endurance exercises, ball playing, body awareness, stretching, and relaxation techniques, and similar activities. Neither moderate nor high-intensity resistance exercise is included for participants in this group.Three guided sessions will be offered during the home training period.
2571980|NCT02419833|Experimental|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
2571983|NCT02419833|Active Comparator|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and within 2-72 hours of admission
2572032|NCT02419560|Experimental|ABT-199 and Ibrutinib Combination|Participants will take ABT-199 (dose 100-400 mg) and Ibrutinib (dose 280-560 mg).
2572137|NCT02418871|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
3209329|NCT00983710|Active Comparator|2|Usual care, including a booklet on coping with localized prostate cancer. After the 6-month primary outcome data are collected, control group men will be offered the opportunity to cross-over and receive the new educational intervention.
3209330|NCT00983736|Experimental|Active|
2572468|NCT02416960|Experimental|Low Glycemic Index Diet Group|Patients will follow a treatment with a hypocaloric diet with low glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
2572469|NCT02416960|Active Comparator|Conventional Diet Group|Patients will follow a treatment with a hypocaloric diet with high glycemic index/load for 12 weeks, immediately before the in vitro fertilization cycle.
2572470|NCT02416960|No Intervention|Control Group|Patients will follow their usual diet for 12 weeks, immediately before the in vitro fertilization cycle.
2572578|NCT02416531|Active Comparator|Corticosteroid|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
2572581|NCT02416531|Experimental|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
2572584|NCT02416531|Experimental|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks.
2572636|NCT02415933|Experimental|Trickle Up|Economic empowerment
2572638|NCT02415933|Experimental|Trickle Up Plus|Economic empowerment + child rights sensitization
2572641|NCT02415933|No Intervention|Wait-list|Women in villages assigned to the control arm do not receive any intervention during the study period, but are placed on a wait-list to receive the intervention upon completion of the evaluation phase.
2572683|NCT02415634|Experimental|Intervention|Intervention Participants in the experimental group will receive usual care plus the RECAP with ICU therapist follow up after ICU discharge. This will be provided for a period of 3 weeks after intensive care unit discharge.
2572687|NCT02415634|Active Comparator|Control|Control Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
2572727|NCT02415335|Placebo Comparator|Placebo|Injection of 2 ml isotonic NaCl intravenously minimum 30 minutes preoperative.
2572730|NCT02415335|Experimental|dexamethasone|Injection of 2 ml 4 mg/ml dexamethasone phosphate intravenously minimum 30 minutes preoperative.
2572775|NCT02414906|Experimental|Intervention group|Goal-directed therapy
2572780|NCT02414906|No Intervention|Control group|Control group
2572852|NCT02414763|No Intervention|Care as Usual|Participants will receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
2572853|NCT02414763|Experimental|Teachable Moment Brief Intervention|The brief intervention consists of engaging the patient in conversation regarding suicidal ambivalence (desire to live vs. desire to die), collaborative discovery of primary and secondary drivers of suicidality, functional analysis of the suicidal ideation and behaviors, and crisis response planning. Participants will also receive usual care services provided to suicide attempt survivors, including inpatient psychiatry, outpatient psychotherapy, and case management.
2572916|NCT02414334|Active Comparator|Immediate SABR|Immediate stereotactic ablative radiotherapy (standard arm)
2572918|NCT02414334|Experimental|Delayed SABR|Delayed stereotactic ablative radiotherapy (delayed= treatment six months after randomisation or at disease progression) (experimental arm)
2572959|NCT02413866|Experimental|Calorie Restriction Only|Participants in this group will be decreasing their caloric intake to approximately 95% of their resting metabolic rate. We will provide one meal for 4 days of the week, and participants will be required to keep an accurate dietary record of all food and drink. Participants assigned to this group will be instructed to keep a fixed sleep schedule based on their own sleep/napping habits.
2572967|NCT02413866|Experimental|Sleep & Calorie Restriction|Participants in this group will decrease their caloric intake to approximately 95% of their resting metabolic rate in addition to reducing their total time in bed by 90 minutes 5 days a week.
3209331|NCT00983736|Placebo Comparator|Placebo|
3209332|NCT00983762||MIS knee arthroplasty|Persons scheduled for Minimally Invasive Surgery Mini-Incision (MIS) Total Knee Arthroplasty (TKA)
3209333|NCT00983762||Unicompartmental knee arthroplasty|Persons scheduled for Unicompartmental knee arthroplasty
3209334|NCT00983762||Standard knee arthroplasty|Persons scheduled for Standard Para-patellar surgery TKA
3209335|NCT00983762||Heathly knee subjects|Persons with healthy knees
3209336|NCT00983775|Experimental|healthy low dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight.
3209337|NCT00983775|Experimental|healthy high dose insulin|16 healthy non-diabetic volunteers. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
2571941|NCT02420132||Main Study|Decentralized participant recruitment, participant and local ophthalmologist compliance, and use of the mVT mobile medical application in a more geographically diverse, decentralized cohort of participants with DME or nAMD receiving intravitreal ranibizumab therapy as part of standard-of-care treatment.
2571943|NCT02420132||Traditional Substudy|"Subset of participants enrolled through a single investigator who will determine visual acuity and anatomical markers of disease status using clinical gold standard assessments (certified ETDRS protocol visual acuity and macula OCT)."
3175462|NCT00634439||C|Patients with at least 6 months of continuous enrollment in the database, and without a history of arrhythmia or heart failure during the baseline period are sampled and frequency matched on age and gender to the atomoxetine cohort in a 2:1 ratio. Study entry dates are assigned so as to be similar to the distribution of study entry dates in the atomoxetine cohort. Patients identified and matched as initiators of atomoxetine or stimulant ADHD medications are not eligible for inclusion in this cohort
3175463|NCT00634452|Experimental|MDX-1401|MDX-1401 iv at various doses
2572038|NCT02419443|Placebo Comparator|Placebo|Patients randomized to the placebo-group were administered placebo-pills orally one hour prior to surgery, then three times a day for a maximum of 6 total doses.
2572040|NCT02419443|Active Comparator|Gabapentin|Patients randomized to the gabapentin-group were administered 300 mg orally one hour prior to surgery, then three times a day for a maximum of 6 total dose.
2572080|NCT02419261|Active Comparator|Adductor Canal Blockade|In this group, patient will benefit of an ultrasound guided adductor canal blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
2572081|NCT02419261|Active Comparator|Femoral Nerve Blockade|In this group, patient will benefit of an ultrasound guided femoral nerve blockade (20 ml of Ropivacaine 0.75%) as analgesic nerve blockade for their surgery of anterior cruciate ligament repair
2572085|NCT02419040|Experimental|Barbotage|Ultrasound guided needling, lavage and steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
2572087|NCT02419040|Active Comparator|Corticosteroid injection|Ultrasound guided steroid/lidocain injection (20 mg Triamcinolon/9 ml Lidocain 1%) and home exercises
2572089|NCT02419040|Sham Comparator|Lidocain injection (sham)|Ultrasound guided lidocain injection (10 ml Lidocain 1%, sham group) and home exercises
2572175|NCT02418741|Experimental|Degree of neck flextion|Two degrees of neck flexion were achieved using a 4 cm or 8 cm height of pillow
2572242|NCT02418416|Experimental|Double activation|The Oocytes in this arm will undergo double activation with Ca ionophore 5 micro mol for 20 min them Strontium chloride 10 micro mol for 60 min.
2572248|NCT02418416|No Intervention|Control arm|The Oocytes will undergo Intracytoplasmic sperm injection only
2572444|NCT02417025|Experimental|PE-HBT|Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
2572447|NCT02417025|Active Comparator|PE-SD|Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
2572504|NCT02416739|Experimental|Nicotinamide|"Nicotinamide with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~nicotinamide (500mg tab) - per oral, twice a day, until the event or censoring occurs"
2572508|NCT02416739|Placebo Comparator|Placebo|"Placebo tablet with EGFR-TKI:~gefitinib (250mg tab) or erlotinib (150mg tab) - per oral, once a day~placebo tablet - per oral, twice a day, until the event or censoring occurs"
2572568|NCT02416310|Experimental|TEAS group|TEAS are performed by a specific investigator on the specially acupoint.
2572570|NCT02416310|Sham Comparator|Sham group|TEAS are performed by a specific investigator on the non-acupoint.
2572572|NCT02416310|Placebo Comparator|Control group|Only place cutted electrodes but do not give any electrical stimulation.
2572627|NCT02416037|Experimental|Prone Proseva|
2572629|NCT02416037|Active Comparator|Prone Talmor|
2572667|NCT02415777|Experimental|udca003|udca003
2572670|NCT02415777|Placebo Comparator|placebo|placebo of udca003
2572728|NCT02415413|Experimental|Carlizomib lenalidomide and low dose dexamethasone|"Induction treatment: patients included in the trial will receive an induction treatment for approximately 6 months (6 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)). After the third cycle of KRd, all patients will be mobilized with colony stimulating factor (G-CSF) alone to collect peripheral blood stem cell for the ASCT.~High dose therapy followed by autologous stem cell transplantation: patients will receive melphalan 200 mg/m2 via intravenous followed by autologous stem cell transplantation (HDT-ASCT).~Consolidation treatment: approximately 3 months after the autologous stem cell transplantation, patients will receive consolidation treatment for 2 months (2 cycles of carfilzomib, lenalidomide and low dose dexamethasone (KRd)).~Maintenance treatment: subsequently they will start a maintenance treatment that will be administered for approximately 24 months (24 cycles of lenalidomide and low dose dexamethasone"
2572809|NCT02414789|Experimental|SRM / MS-MS|
2572839|NCT02414503|Active Comparator|8IU intranasal oxytocin|8IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
2572841|NCT02414503|Active Comparator|24IU intranasal oxytocin|24IU intranasal oxytocin delivered with the OptiNose Breath Powered Bi directional liquid device
2572842|NCT02414503|Placebo Comparator|Placebo|Placebo delivered with the OptiNose Breath Powered Bi directional liquid device
2572875|NCT02414425|Experimental|Rectal Injection of Botulinum toxin A|"Botulinum toxin A will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of experimental drug"
3175464|NCT00634465||1|
3175465|NCT00634478|Experimental|1|preleminiscal radiation deep brain stimulation
3175466|NCT00634478|Active Comparator|2|VIM deep brain stimulation
3175467|NCT00634491|Active Comparator|1|150 meq/l NaHco3 3cc/kg/hr one Hour before and 1cc/kg/hr 6 hour after angiography
3175468|NCT00634491|Active Comparator|2|Acetazolamide 250 mg + 1cc/kg/hr normal salin 6 hour before and after angiography
3175469|NCT00634491|Active Comparator|3|normal salin 1cc/kg/hr before and after angiography
3175470|NCT00634517|Experimental|T|Armstrong Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
2571981|NCT02420002|Experimental|Experimental arm (Hypnosis)|"Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing will therefore take place under hypnosis (and MEOPA if necessary).~Intervention: Use of Hypnosis during suturing Intervention: Stitch removal"
3175471|NCT00634517|Active Comparator|R|Proventil-HFA, Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
3175472|NCT00634530|Other|I, Intervention|
3175473|NCT00634556|Experimental|levodopa solution 2mg/ml for i.v. use|"levodopa solution in saline, given intravenously, dosed as per final protocol in Black et al 2003."
3175474|NCT00634556|Placebo Comparator|Placebo|normal saline i.v.
3175475|NCT00634595|Experimental|A|E10A combined with Cisplatin and Paclitaxel
3175476|NCT00634595|Active Comparator|B|Cisplatin and Paclitaxel
3175477|NCT00634608|No Intervention|Survey|Control group participants are sent a survey within one week of clinic visit
3175478|NCT00634608|Experimental|Health Information Prescription|Health Information Prescription is emailed to participants within 24 hours of clinic visit.
3175479|NCT00634634|Experimental|Sorafenib and Letrozole|
3175480|NCT00634660|Active Comparator|0.001 mg/kg|One subcutaneous injection of 0.001 mg/kg of rAvPAL-PEG.
3175481|NCT00634660|Active Comparator|0.003 mg/kg|One subcutaneous injection of 0.003 mg/kg of rAvPAL-PEG.
3175482|NCT00634660|Active Comparator|0.01 mg/kg|One subcutaneous injection of 0.01 mg/kg of rAvPAL-PEG.
3175483|NCT00634660|Active Comparator|0.03 mg/kg|One subcutaneous injection of 0.03 mg/kg of rAvPAL-PEG.
3175484|NCT00634660|Active Comparator|0.1 mg/kg|One subcutaneous injection of 0.1 mg/kg of rAvPAL-PEG.
3175485|NCT00634660|Active Comparator|0.3 mg/kg|One subcutaneous injection of 0.3 mg/kg of rAvPAL-PEG.
2572373|NCT02417415|Experimental|Local Heat Stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
2572379|NCT02417415|Sham Comparator|Control (Non-heating)|Commercial heating pad applied over the abdomen and part of the torso but turned off
3175486|NCT00634660|Active Comparator|1.0 mg/kg|One subcutaneous injection of 1.0 mg/kg of rAvPAL-PEG.
3175487|NCT00634673|Other|TT|patients homozygous for Thr54 (TT)
3175488|NCT00634673|Other|AA|patients homozygous for Ala54 (AA)
3175489|NCT00634686|Experimental|1|
3175490|NCT00634686|Placebo Comparator|2|
3175491|NCT00634699|Experimental|One|Ischemic Compression on Triggers Points on Muscles along the Median Nerve. Active Comparator
3175492|NCT00634712|Active Comparator|1|
3175493|NCT00634712|Placebo Comparator|2|
3175494|NCT00634725|Active Comparator|Arm 1 (A1) - Gemcitabine|Gemcitabine 2 months, then stop until progression
3175495|NCT00634725|Experimental|Arm 2 (B1) Gemcitabine + Erlotinib|B1 Gemcitabine + Erlotinib (100mg/d) 2 months, then erlotinib maintenance (150 mg/d)until progression
3175496|NCT00634725|Experimental|Arm 3 (A2) CRT|A2 CRT then stop until progression
3175497|NCT00634725|Experimental|Arm 4 (B2) CRT then erlotinib|B2 CRT then erlotinib maintenance (150mg/d) until progression
3175498|NCT00634738|Experimental|one|
3175499|NCT00634764||Pregnant|Pregnant women who present to MUSC's Cannon Place or Prenatal Wellness Center
3175500|NCT00634790|Active Comparator|alprazolam group|
3175501|NCT00634816||Chemotherapy recipients|Subjects who have undergone chemotherapy will receive DXA scan
3175502|NCT00634829|Experimental|T|Armstrong Albuterol HFA Inhalation Aerosol
3175503|NCT00634829|Active Comparator|R|2 inhalations Proventil-HFA Albuterol Sulfate, 108 mcg, prior to exercise
3175504|NCT00634829|Placebo Comparator|P|Placebo-HFA
3175505|NCT00634855||Complicated|Women with pregnancies complicated by intrauterine growth restriction or preeclampsia
3175506|NCT00634855||Normal|Women with normal pregnancies
3175507|NCT00634868|Sham Comparator|1|The device is emitting a sham light
3175508|NCT00634868|Experimental|2|The device is emitting curative light
3175509|NCT00634881|Experimental|Cohort A: Alemtuzumab i.v.|Intravenous administration of alemtuzumab according to the 3 + 3 dose escalation design.
3175510|NCT00634881|Experimental|Cohort B: Alemtuzumab s.c.|After i.v. MTD (maximum tolerable dosage) has been determined, subcutaneous dose escalation is performed according to the same escalation rules as for cohort A, starting with the recommended dose level of i.v. application.
3175511|NCT00634894|Experimental|Femara|
3175512|NCT00634894|Placebo Comparator|Placebo|
3175513|NCT00634946|Experimental|I|
3175514|NCT00634946|Experimental|II|
3175515|NCT00634946|Experimental|III|
3175516|NCT00634946|Placebo Comparator|IV|
3175517|NCT00634959|Experimental|1|
3175518|NCT00634959|Experimental|2|
3175519|NCT00634959|Experimental|3|
3175520|NCT00634959|Experimental|4|
3175521|NCT00634959|Placebo Comparator|5|
3175522|NCT00634985|Experimental|A|
3175523|NCT00634998|Placebo Comparator|2|1000mg Placebo capsules orally twice daily for 90 days
3175524|NCT00634998|Experimental|1|1000mg Vitamin C capsules orally twice daily for 90 days
3175525|NCT00635037|Experimental|A|"G1 (n=15)received trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~G2(n=15) was submitted to classical and trigger point acupuncture twice a week."
3175526|NCT00635063|Experimental|AD 923|
3175527|NCT00635063|Active Comparator|MSIR|
3175528|NCT00635076|Placebo Comparator|Placebo group|
3175529|NCT00635076|Active Comparator|Alprazolam XR group|
3175530|NCT00635115|Experimental|1|
3175531|NCT00635115|Active Comparator|2|
3175532|NCT00635141|Experimental|1|
3175533|NCT00635141|Experimental|2|
3175534|NCT00635180|Experimental|1|1: Healthy subjects
3175535|NCT00635193|Other|Cohort 1|Three subjects will be treated with liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab, 7.5 mg/kg qwk
3175536|NCT00635193|Other|Cohort 2|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk
3175537|NCT00635193|Other|Group A|liposomal doxorubicin, 40 mg/m2 q4wk
2572019|NCT02419534|Active Comparator|Polyethylene glycol with Diltiazem|Parents will be instructed to apply 5 mm of ointment on a fingertip at the anal verge twice daily for the duration of the study
2572106|NCT02419326|Experimental|Couples|The patient and their significant other receive psychotherapy treatment for the patient's BED.
2572154|NCT02418832|Other|Men with Azoospermia, sperm cell aspiration and TEFNA|Men between 16-80 with Obstructive and Non-Obstructive Azoospermia; Sperm cell aspiration,TEFNA and Ultrasound Guidance
2572420|NCT02417103|Active Comparator|GLP-1 (Liraglutide)|Daily subcutaneous injection of Lirglutide over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
2572427|NCT02417103|Placebo Comparator|Placebo Comparator|Daily subcutaneous injection of PL1/PR1 Placebo over 9 weeks prior to bariatric surgery with a dosing of 0,6-1,8 mg
2572477|NCT02416778|Experimental|Treatment Arm|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion will be administered in patients with COPD
2572573|NCT02416544|Experimental|Full participation|Participants in this group receive lunch which is calorie-restricted and low-salt during 12 weeks, the total duration of this study.
2572574|NCT02416544|Experimental|Two thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 4 weeks from the beginning of the study and maintain the diet during 8 weeks.
2572576|NCT02416544|Experimental|One thirds participation|Participants in this group starts lunch which is calorie-restricted and low-salt after 8 weeks from the beginning of the study and maintain the diet during 4 weeks.
2572635|NCT02415985|Other|rifabutin 150|rifabutin 150 mg (1 capsule) once daily
2572639|NCT02415985|Other|rifabutin 300|rifabutin 150 mg (2 capsules) 300 mg 3 times a week
3209338|NCT00983775|Experimental|type 1 diabetes mellitus|16 people with type 1 diabetes mellitus. The type of insulin tested will be the rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight.
3209339|NCT00983788|Experimental|Bezafibrate|
3209340|NCT00983788|Placebo Comparator|Placebo|
3209341|NCT00983814|Experimental|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID)
3209342|NCT00983814|Placebo Comparator|Placebo|Placebo
3209343|NCT00983840|Experimental|Family Eats|8-session program on health eating
2572986|NCT02413749||Stable PsA response to treatment|Individuals with psoriatic arthritis who are being treated standard of care with a stable DMARD or a biologic
2572988|NCT02413749||PsA inadequate response to DMARD|Individuals with psoriatic arthritis who have had an inadequate response to a DMARD and are being treated standard of care with a biologic.
3209344|NCT00983840|Active Comparator|Family eats- plain|Family eats without role model stories and goal setting
3209345|NCT00983866|Experimental|Tailored Telephone Counseling|
2573097|NCT02412969|Active Comparator|Lumbar Epidural|Control group will have standard of care Lumbar Epidural
2573101|NCT02412969|Experimental|Dural Puncture Epidural|Will receive Dural Puncture Epidural
2573132|NCT02412709|Experimental|Parent Performing ECG (PPE)|Parent Performing ECG (PPE) Group--When the baby is 2 weeks old, research staff will contact interested parents to schedule a home visit. During the visit, a research assistant will provide the parents with a kit that includes the QTScreen system and instructions. The parents will perform an ECG on their child using the QTScreen and instructions. If after attempting the ECG on their own parents encounter problems, parents can ask the research assistant for assistance.
2573138|NCT02412709|Active Comparator|Staff Performing ECG (SPE)|Staff Performing ECG (SPE) Group--When the baby is 2-4 weeks of age, research staff will contact the family to schedule a home visit. The QTScreen test will be done by a research assistant.
3209346|NCT00983866|No Intervention|Standard Trial Recruitment Procedures|
3209347|NCT00983944|Experimental|Arm I (EPOCH-R)|Patients receive rituximab IV on day 1; etoposide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 30 minutes on day 5; and oral prednisone twice daily on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3209348|NCT00983944|Experimental|Arm II (R-VACOP-B)|Patients receive rituximab IV and doxorubicin hydrochloride IV on day 1 of weeks 1, 3, 5, 7, 9, and 11; cyclophosphamide IV over 30 minutes on day 1 of weeks 1, 5, and 9; etoposide IV over 1 hour on day 1 and then orally on days 2 and 3 of weeks 3, 7, and 11; bleomycin sulfate IV and vincristine sulfate IV on day 1 of weeks 2, 4, 6, 8, 10, and 12; and oral prednisone on days 1-7 of week 1 and then every other day in weeks 2-10.
3209349|NCT00983970|Experimental|Interactive video cycling|Interactive video cycling arm utilized the Gamebike that interfaced a Sony Play Station 2 with a stationary bicycle and a 42 inch flat screen TV. The Gamebike has a handle bar mounted game controller allowing the participant to play most Sony Play Station 2 raced-based video games. The Gamebike reads the participants' speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks.Participants were told that they could exercise at any intensity or duration that they desired, and reading materials were provided for those who did not chose to exercise for the full 60 minute session.
2573329|NCT02411552||Intervention schools|These schools were promoting 4 strategies to increase physical activity in students.
2573332|NCT02411552||Control schools|These schools continued with standard programming for activity during year 1, and implemented intervention during years 2 and 3.
3209350|NCT00983970|Active Comparator|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device.
3209351|NCT00983996|Experimental|1|Alendronate Sodium Tablets, 10 mg
3209352|NCT00983996|Active Comparator|2|Fosamax Tablets, 10 mg
3209353|NCT00984035||Prospecitive Analysis|Patients currently receiving cisplatin as treatment for their cancer.
3209354|NCT00984035||Restrospective Analysis|Patients that have previously received cisplatin as treatment for their cancer.
3260219|NCT01477411|Experimental|PA21 with food and Digoxin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Digoxin will be 0.5 mg/day
2572086|NCT02419183||Sequence A|Participants will receive a computer administered Word List Recall (WLR) [SAMSTAR] on Test Day 1 and an examiner addminstered WLR [RAVLT] on Test Day 2 of the study.
2572088|NCT02419183||Sequence B|Participants will receive an examiner-administered WLR [RAVLT] on Test Day 1 and a computer adminstered WLR [SAMSTAR] on Test Day 2 of the study.
2572150|NCT02418858|Active Comparator|Awake DBS Surgery|"Deep brain stimulation surgery: Essential tremor patients undergoing traditional awake DBS surgery utilizing microelectrode recordings and intraoperative stimulation."
2572155|NCT02418858|Active Comparator|Asleep DBS Surgery|Deep brain stimulation surgery: Essential tremor patients undergoing DBS surgery under general anesthesia utilizing intraoperative imaging to verify the stereotactic accuracy of DBS electrode placement at the time of surgery.
2572233|NCT02418429|Active Comparator|waxy maize starch|pancake test meal - waxy maize starch
2572235|NCT02418429|Active Comparator|waxy maize starch and whey protein|pancake test meal - waxy maize starch and whey protein
2572236|NCT02418429|Active Comparator|resistant starch|pancake test meal - resistant starch
2572237|NCT02418429|Active Comparator|resistant starch and whey protein|pancake test meal - resistant starch and whey protein
3209355|NCT00984048||FOLFOX, XELOX or FOLFIRI +/- bevacizumab|Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.
3209356|NCT00984087|Experimental|Active rTMS treatment|
3209357|NCT00984100|Experimental|Notes Transvaginal Cholecystectomy|Patients who undergo a NOTES Transvaginal cholescystectomy.
3209358|NCT00984113|Experimental|A-Patients with mild renal impairment|
2572430|NCT02416999|Experimental|patient group|
2572472|NCT02416726|Experimental|Peripheral blood|The peripheral blood sample will be extrated with DNA and performed NGS using Illumina Nextseq500 sequencer.
2572473|NCT02416726|Experimental|Primary tumor|The gene testing of the primary tumor tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
2572476|NCT02416726|Experimental|Metastatic lymph node|The gene testing of the metastatic lymph node tissue diagnosed with nonsquamous NSCLC will be performed with NGS technique using Illumina Nextseq500 sequencer.
2572554|NCT02416440||screening for diabetes prevalence|blood samples
2572616|NCT02416115|Active Comparator|R group|Thirty minutes before end of surgery, patients in R group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, patients in R group received PCA morphine 1 mg/ml
2572620|NCT02416115|Active Comparator|N group|Thirty minutes before end of surgery, patients in N group (n=30) received normal saline. In the post anesthetic care unit, group N received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
2572625|NCT02416115|Experimental|RN group|Thirty minutes before end of surgery, patients in Ramosetron and naloxone (RN) group (n=30) received 0.3 mg ramosetron. In the post anesthetic care unit, group RN received PCA mixture of naloxone 1μg/ml and morphine 1 mg/ml.
2572664|NCT02415725|Experimental|lymphofluoroscopy|Indocyanine Green intradermal injection before surgery, and after 3, 6 and 12 monthes
3209359|NCT00984113|Experimental|B-Healthy subjects matched to Group A|
3209360|NCT00984113|Experimental|C-Patients with moderate renal impairment|
3209361|NCT00984113|Experimental|D-Healthy subjects matched to Group C|
3209362|NCT00984113|Experimental|E-Patients with severe renal impairment|
3209363|NCT00984113|Experimental|F-Healthy subjects matched to Group E|
3209364|NCT00984152|Active Comparator|1|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
3209365|NCT00984152|Active Comparator|2|TDF/FTC + Efavirenz (Atripla) Once-Daily
3209366|NCT00984178|No Intervention|Control group|standard treatment
3209367|NCT00984178|Experimental|Bone marrow mononuclear progenitors|intracoronary transplantation of bone-marrow mononuclear progenitor cells
3209368|NCT00984178|Experimental|GCSF|progenitor cells mobilization through Granulocite- Colony Stimulating Factor treatment (G-CSF)
3209369|NCT00984178|Experimental|GCSF plus bone marrow mononuclear cells|combined treatment (intracoronary transplantation plus cell mobilization with G-CSF).
3209370|NCT00984191|Experimental|99mTc positive|99mTechnetium-MIBI SPECT-CT positive compare : Scan - Pathologic report
3209371|NCT00984191|Experimental|99mTc Negative_Neck dissection|99mTc Negative but have neck dissection indication compare : 99mTc - Pathologic report
2572903|NCT02414191|No Intervention|Control|Participants in this study arm will receive no form of feedback.
2572909|NCT02414191|Other|Benchmarked Feedback|Participants in this study arm will receive benchmarked feedback regarding their perioperative temperature management.
2572911|NCT02414191|Other|Ranked Feedback|Participants in this study arm will receive ranked feedback regarding their perioperative temperature management.
3209372|NCT00984191|Experimental|99mTc Negative_No neck dissection|99mTc Negative and No other indication for neck dissection compare : 99mTc - 7. 131I (post-treatment) whole body scan
3209373|NCT00984217|Experimental|Panitumumab|Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-8 doses).
2573111|NCT02412891|Active Comparator|Patients receive active UroShield device|Patients receive active UroShield device
2573112|NCT02412891|Sham Comparator|Patients receive inactive UroShield device|Patients receive inactive UroShield device
2573194|NCT02412423|Experimental|treatment group|post-transplantation cyclophosphamide
2579129|NCT02372227|Experimental|VS-5584 and VS-6063|
3209374|NCT00984230|No Intervention|Breastfeeding (Reference)|
3209375|NCT00984230|Active Comparator|Basic starter formula: BSF|
3209376|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics + OS|
3209377|NCT00984230|Experimental|BSF + Lactoferrin + Probiotics|
3209378|NCT00984243|Experimental|Photodynamic Therapy|PHOTODYNAMIC THERAPY (PDT)
3209379|NCT00984269|No Intervention|No Tourniquet|Patients undergoing hand/wrist surgery without the use of a tourniquet.
3209380|NCT00984269|Experimental|Tourniquet|Patients undergoing hand/wrist surgery with the use of a tourniquet.
3209381|NCT00984321|Experimental|Psychoeducational Intervention Group|
3209382|NCT00984321|Experimental|Expressive Writing Intervention|
3209383|NCT00984321|Active Comparator|Control Group|
2572152|NCT02418572|Experimental|Transdermal testosterone gel|"Patients will receive once daily application of 0.55 gr TTG (Testosterone gel 1%; Laboratories Besins International,Paris,France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
2572158|NCT02418572|Placebo Comparator|Placebo transdermal gel|"Patients will receive once daily application of 0.55 gr identical placebo gel starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~Pituitary down-regulation will be induced by daily injections of 0.1mg triptorelin started on day 21 of the next cycle following enrollment in the study, up to and including the day of hCG administration.~After 2 weeks of down-regulation, daily SC injections of HP-hMG (Menopur®) (300 IU/day) will be administered up to the day of hCG administration.~Ovulation triggering will be induced with 250μg rhCG (Ovidrelle®) followed by oocyte pick-up ~36 hours later and ICSI. A maximum of 2 embryos, following each center's national criteria of single embryo transfer, will be transferred 3 days later.~Luteal phase support with be performed with progesterone tablets ( Utrogestan®) (200mg x3, intravaginally)."
3175538|NCT00635193|Other|Group B|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg q2wk (or other dose and schedule)
3175539|NCT00635193|Other|Group C|liposomal doxorubicin, 40 mg/m2 q4wk, and volociximab 15 mg/kg qwk (or other dose and schedule)
3175540|NCT00635206|Active Comparator|1|Auto M series device set to Bi Flex
3175541|NCT00635206|Active Comparator|2|Set to standard CPAP
2572302|NCT02418013|Experimental|Fresh cord blood(experimental group A)|16 males and 16 females are assigned to the experimental group A. Dropout is 20 percent in each gender.
2572307|NCT02418013|Experimental|Frozen cord blood(experimental group B)|16 males and 16 females are assigned to the experimental group B. Dropout is 20 percent in each gender.
2572311|NCT02418013|Experimental|Frozen plasma(experimental group C)|16 males and 16 females are assigned to the experimental group C. Dropout is 20 percent in each gender.
2572316|NCT02418013|Placebo Comparator|Placebo group|16 males and 16 females are assigned to the Placebo group. Dropout is 20 percent in each gender. Total participants are 64 in males and 64 in females.
2572402|NCT02417090||Metformin therapy|9-year-old children whose mothers used metformin for gestational diabetes
2572408|NCT02417090||Insulin therapy|9-year-old children whose mothers used insulin for gestational diabetes
2572488|NCT02416882|Other|Aerobic Exercise vs Sedentary Option|Relative Reinforcing Value of aerobic exercise versus sedentary activity will be determined.
2572497|NCT02416882|Other|Resistance Exercise vs Sedentary Option|Relative Reinforcing Value of resistance exercise versus sedentary activity will be determined.
2572579|NCT02416323|No Intervention|Usual Care|Community therapist delivers routine care to participant child with no training in AIM HI.
2572582|NCT02416323|Other|AIM HI Training|Therapist enrolls in AIM HI training
2572869|NCT02414438|No Intervention|Current Practice Arm|Physicians follow current care procedures
2572871|NCT02414438|Experimental|FirstStep and NextStep Information|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are able to order test results in Round 2
2572884|NCT02414360|Experimental|Shortened Format|Shortened format of a systematic review
3175542|NCT00635258||GnRH-ant|Patients were treated with a GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
3175543|NCT00635258||GnRH-a|GnRH long protocol using 0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state. Furthermore, the triptorelin administration was maintained until the day of donor's hCG administration.
3175544|NCT00635284|Experimental|ABI-009|
3175545|NCT00635297|Active Comparator|1|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty
3175546|NCT00635297|Experimental|2|50 osteoporotic patients with a vertebral insufficiency fracture will receive treatment of the vertebrae with standard vertebroplasty. The adjacent vertebrae will be treated with 3-5 ml of PMMA
3175547|NCT00635310|Active Comparator|HD patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with hemodialysis (HD), pretreated with DDAVP 0.3 ug/kg body weight infusion 30-60 minutes before percutaneous liver biopsies (PLBs)
3175548|NCT00635310|Active Comparator|Ordinary patients with CHC or CHB|Chronic hepatitis C (CHC) or chronic hepatitis B (CHB) patients with normal renal function (NRF) receiving percutaneous liver biopsies (PLBs)
3175549|NCT00635323|Experimental|A|
3175550|NCT00635375|Experimental|1|LED fiberoptic blanket phototherapy
3175551|NCT00635375|Experimental|2|metal halide phototherapy
3175552|NCT00635375|Active Comparator|3|LED bank phototherapy
3175553|NCT00635375|Experimental|4|Combination metal halide phototherapy plus LED fiberoptic blanket phototherapy
3175554|NCT00635388|Sham Comparator|1|
3175555|NCT00635388|Experimental|2|
3175556|NCT00635388|Experimental|3|
3175557|NCT00635401|Experimental|0.5 mg BID|
3175558|NCT00635414|Experimental|1|40mg administered orally
3175559|NCT00635414|Experimental|2|15 minute intravenous infusion
3175560|NCT00635440|Active Comparator|A|
3175561|NCT00635440|Sham Comparator|B|
3175562|NCT00635466|Experimental|Lap, 1|Patients undergoing laparoscopic surgery for rectal carcinoma
3175563|NCT00635505|Experimental|T|albuterol HFA 180 mcg QID
3175564|NCT00635505|Active Comparator|R|180 mcg QID 12 weeks
3175565|NCT00635505|Placebo Comparator|P|2 actuations QID 12 weeks or until use of rescue drug
3175566|NCT00635518|Other|I, Intervention|
2572128|NCT02419014|No Intervention|Usual Care|Participants in this group will continue receiving their previously prescribed therapy during the 8 week data collection period.
2572131|NCT02419014|Active Comparator|Active CES Device|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
2572133|NCT02419014|Placebo Comparator|Sham CES Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
2572161|NCT02418598|Experimental|Cohort1|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 200 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 50 µL per site) at a flow rate of 3 µL per minute.
2572165|NCT02418598|Experimental|Cohort2|The target putamen for AAV-hAADC-2 infusion is identified on MRI image that has been taken prior to the operation, and then subjects will be bilaterally infused with a total volume of 600 µL at a total of 4 sites (2 sites in left putamen, 2 sites in right putamen; 150 µL per site) at a flow rate of 3 µL per minute.
2572212|NCT02418338|Experimental|dmd children|echocardiography
2572220|NCT02418338|Other|healthy children|echocardiography
2572276|NCT02418104|Experimental|CHS-1701|CHS-1701 followed by CHS-1701
2572283|NCT02418104|Active Comparator|Neulasta|Neulasta followed by Neulasta
2572349|NCT02417623|Experimental|Smartphone intervention group|The experimental group will receive the standard diet intervention for weight loss plus free Smartphone app plus a wearable device.
2572354|NCT02417623|No Intervention|Control group|Control group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline
2572431|NCT02417337|Active Comparator|Group I|paracetamol 1000mg
2572436|NCT02417337|Experimental|Group II|ibuprofen 600mg + paracetamol 1000mg,
2572438|NCT02417337|Experimental|Group III|Mefenamic acid 500mg + Paracetamol 1000mg
2572441|NCT02417337|Experimental|Group IV|Diclofenac K 50mg + paracetamol 1000 mg
2572442|NCT02417337|Placebo Comparator|Group V|No medication
2572471|NCT02416674|Experimental|Transplant recipients|The intervention is transplantatoin of abdominal wall tissues from an organ donor who is deceased to a recipient with a large abdominal wall defect.
2572671|NCT02415946|Active Comparator|Sinus floor augmentation (lateral)|Maxillary sinus floor elevation using a lateral approach
2572676|NCT02415946|Experimental|Sinus floor augmentation (transcrestal)|Maxillary sinus floor elevation using a transcrestal approach (Smart Lift technique; Trombelli et al. 2008)
2572736|NCT02415348|Experimental|Fibroscan|Fibroscan under simultaneous cardiac monitoring
3209384|NCT00984347|Active Comparator|Oxytocin induction|women in need for induction of labor due to medical indications, will receive continuous IV oxytocin
3209385|NCT00984347|Active Comparator|Breast Stimultion|nipple stimulation with a breast pump, calibrated at the lowest suction strength,operated alternately: 15 min one breast, 15 min second breast, 15 min rest, till appearance of regular uterine contractions (3 contractions in 10 min). the manipulation will continue for 3 hours of regular contractions.
3209386|NCT00984360|Experimental|A118G|
2572981|NCT02413658|Active Comparator|Control|Dressings of best current clinical practice, sugar solution.
2572983|NCT02413658|Experimental|Phenytoin 1|Dressings using phenytoin solution 20mg/ml
2572984|NCT02413658|Experimental|Phenytoin 2|Dressings using phenytoin solution 40mg/ml
2573023|NCT02413411|Experimental|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
2573030|NCT02413411|Active Comparator|Attention Control|Patients randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides examples of exercises one could do to improve pain and reduce stiffness from knee OA.
2573069|NCT02413099|Experimental|KBMSI-2 6gm|Patients were instructed to take investigational products (KBMSI-2 6g) twice a day for 8weeks at least 1 hour after food intake
2573075|NCT02413099|Placebo Comparator|Placebo|Patients were instructed to take placebo twice a day for 8weeks at least 1 hour after food intake
2573117|NCT02412865|Experimental|Intervention|quit4baby + text4baby
2573120|NCT02412865|Other|Control|text4baby
2573186|NCT02412514|Active Comparator|Arm A|Infants assigned to Arm A will receive bOPV at 6, 10, and 14 weeks of age and IPV at 6 weeks of age.
2573188|NCT02412514|Active Comparator|Arm B|Infants assigned to Arm B will receive bOPV at 10 and 14 weeks of age and IPV at 6 weeks of age.
3209387|NCT00984360|Experimental|Wild-type|
2573318|NCT02411682|Active Comparator|YesB|On YesB day the patients will consume breakfast , lunch and dinner
2573320|NCT02411682|Experimental|NoB|On NoB Day The patient will consume only lunch and dinner
2573345|NCT02411435|Experimental|Treatment A(CAB 30mg)+B (RIF 600mg)+C (CAB 30mg and RIF 600mg)|Subjects will receive a single dose of CAB 30 mg on day 1. Subjects will then receive RIF 600 mg once daily on days 8-28 with co-administration of a single dose of CAB 30 mg on day 21.
2573379|NCT02411123|Experimental|IDgenetix Neuropsychiatric Test Panel Intervention|The medical provider for the IDgenetix Neuropsychiatric Test Panel-guided group will make treatment recommendations based on test results. Patient outcomes will be measured throughout the duration of the study.
2573398|NCT02411045|Active Comparator|Group 1: Control|Ask participants to take a picture of themselves
2573732|NCT02408952|No Intervention|Usual Care|Care is administered as usual
3209388|NCT00984386|Experimental|Intradermal Zesteem|
2572149|NCT02418637|Experimental|Farm workers|This is a one arm intervention including farm workers and owners
2572272|NCT02417805|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2572282|NCT02417805|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2572290|NCT02417805|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2572296|NCT02417805|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Remote Ischemic Preconditioning (by Blood Pressure Cuff)"
2572344|NCT02417610|Experimental|Polynucleotide - PNHA - Newart|50 patients will be enrolled and treated with three weekly injections of polynucleotide plus hyaluronic acid
2572346|NCT02417610|Active Comparator|Hyaluronic acid - HA - Ialart|50 patients will be enrolled and treated with three weekly injections of hyaluronic acid
3175567|NCT00635531|Placebo Comparator|Placebo group|
2572474|NCT02416752||remifentanil group|Group received intra op remifentanil infusion
2572480|NCT02416752||conventional opioid gropup|Group received only conventional opioids and No infusion of remifentanil
2572603|NCT02416505|No Intervention|Verbal Discussion: Control Group|"In this group, participants will receive a 10 minute Verbal Only Knee Osteoarthritis Steroid Injection Informed Consent discussion.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
2572604|NCT02416505|Active Comparator|Verbal+Anatomic Model|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Knee Model.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
2572608|NCT02416505|Active Comparator|Verbal+Video Presentation|"This intervention group will receive a 10 minute Knee Osteoarthritis Steroid Injection Informed Consent discussion with the aid of a Video.~This discussion will cover the relevant topics of Knee OA causes, relevant anatomy, symptoms, diagnosis, and treatment options. This discussion will also include the risks, benefits, and alternatives to a steroid injection."
2572650|NCT02415868||Low pH|Post Menopausal women with vaginal pH of 4.5 or below
2572651|NCT02415868||High pH|Post Menopausal women with vaginal pH of 5.5 or above
2572689|NCT02415517|Experimental|Experimental group|Intervention: Cognitive Training
2572693|NCT02415517|Active Comparator|Active control group|Intervention: Test of general knowledge
2572694|NCT02415517|No Intervention|Passive control group|No intervention
2572733|NCT02415283||HCC positive|¹³C-Octanoate Breath Test in 50 MRI proven HCC positive patients
2572740|NCT02415283||HCC negative|¹³C-Octanoate Breath Test in 50 MRI proven HCC negative patients
2572792|NCT02414971||Men with prostate cancer|men over 18 years of age diagnosed with prostate cancer receiving external beam radiation
2572862|NCT02414685|Experimental|intravenous chemotherapy|"TIP regimen:~Paclitaxel 250 mg/ m2 iv on day 1~Ifosfamide 1,2 g/ m2/ day iv x 5 days~Cisplatin 20 mg/ m2/ day iv x 5 days"
2572894|NCT02414178||Experimental F 18 T807|
2572961|NCT02413944|Experimental|healthy volunteers|ACTH stimulation test
2573092|NCT02412930|Active Comparator|Group Paravertebral Block|With ultrasound guidance at T10 to L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. 5 mL bupivacaine 0.5% was injected in each dermatome level.
2573095|NCT02412930|Placebo Comparator|Group tramadol|Patients in group T were given a loading dose of tramadol of 1 mgkg-1
2573244|NCT02412215|Experimental|Toric Nanoflex IOL|Phacoemulsification with toric Nanoflex IOL implantation
2573310|NCT02411864||Group 1|Low b=(0,50,150,200)，NEX=(1,3,2,2)
2573311|NCT02411864||Group 2|Low b=(0,30,50,100,200)，NEX=(1,3,3,2,2)
2573313|NCT02411864||Group 3|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,3,3,3,2,2,2,2)
2573316|NCT02411864||Group 4|Low b=(0,30,60,90,120,150,180,200)，NEX=(1,1,1,1,1,1,1,1)
2573319|NCT02411864||Group 5|Low b=(0,20,40,60,80,100,120,140,160,180,200)NEX=(1,3,3,3,3,2,2
2573341|NCT02411474||With or without newly diagnosed chronic GVHD after SCT|The patients developed chronic GVHD after SCT/ The patients did not developed chronic GVHD after SCT
2573391|NCT02411175|Experimental|20% Ethanol|20% ethanol will be medicated with the individualised homeopathic remedy as determined by the researcher and administered as drops. The potency, dose and frequency of the medicated 20% ethanol drops will be determined for each prescription, in accordance with the laws that govern homeopathic prescribing.
2573437|NCT02410876||Controls|No lower urinary tract symptoms undergoing cystoscopy in anesthesia for stone treatment or microhematuria assessment.
2583665|NCT02342158|Experimental|Locally advanced /metastatic cancer|
3175568|NCT00635531|Active Comparator|Alprazolam XR group|
3175569|NCT00635544|Experimental|1|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
3175570|NCT00635544|Active Comparator|2|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
3175571|NCT00635583|Experimental|Increased Dairy Consumption|Increased Dairy Consumption - Each subject in this arm will receive three additional servings of dairy to consume each day for 18 months.
3175572|NCT00635583|No Intervention|Control|This group will not receive the intervention but will continue their normal diet; they will act as the control.
3175573|NCT00635596|Experimental|I|
3175574|NCT00635622|Experimental|1|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
3209389|NCT00984386|Placebo Comparator|Placebo|
3209390|NCT00984399|Experimental|vaginal 17β-estradiol, questionnaire , symptom checklist|This is a prospective longitudinal pilot study, and the targeted patient population is postmenopausal women with breast cancer being treated with adjuvant aromatase inhibitors who are initiated on vaginal 17β-estradiol to relieve symptoms of atrophic vaginitis.
3209391|NCT00984412|Experimental|AATT|
3209392|NCT00984425|Experimental|Lapatinib and Sorafenib 1° level of dose|Lapatinib 750 mg/die + Sorafenib 200 mg bid
2572263|NCT02417818|Experimental|Second-Degree Burn|"Group A (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Plasma Therapy (PlasmaDerm)"
2572271|NCT02417818|Experimental|Skin Excision (for Skin Graft)|"Group B (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
2572277|NCT02417818|Experimental|Chronic Wound|"Group C (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Plasma Therapy (PlasmaDerm)"
2572285|NCT02417818|Active Comparator|Intact Skin|"Group D (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Plasma Therapy (PlasmaDerm)"
2572294|NCT02417818|Experimental|Second-Degree Burn (repetitive)|"Group E (n=20): Consent-capable male and female patients ≥18 years of age who have sustained a second-degree burn on ≥1% and ≤30% of the surface of the body.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572299|NCT02417818|Experimental|Skin Excision (for Skin Graft) (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572304|NCT02417818|Experimental|Chronic Wound (repetitive)|"Group G (n=20): Consent-capable male and female patients ≥18 years of age suffering from a wound that has not yet healed ≥3 weeks. The minimal size of the wound site must not be less than 1% of TBSA.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572310|NCT02417818|Active Comparator|Intact Skin (repetitive)|"Group H (n=20): Consent-capable healthy male and female probands ≥18 years of age serving as sham group. None of the the criteria of groups A-C must be evident.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572313|NCT02417818|Experimental|Hypertrophic burn scar|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572317|NCT02417818|Experimental|Hypertrophic burn scar (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who suffer from a hypertrophic burn scar.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572320|NCT02417818|Experimental|Flap|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572323|NCT02417818|Experimental|Flap (repetitive)|"Group F (n=20): Consent-capable male and female patients ≥18 years of age who received a flap.~Intervention: Repetitive Plasma Therapy (repetitive PlasmaDerm)"
2572361|NCT02417480|Active Comparator|Vegan arm|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. Researchers will ask participants on a vegan diet to follow their usual diet and exercise habits consistent for the two week study period.
2572367|NCT02417480|Experimental|Omnivorous arm|A diet containing all food groups. Researchers will ask participants on an omnivorous diet to follow habitual, usual diet and exercise habits for the first week. During the second week, participants will be asked to switch to a vegan diet for one week and to maintain their usual exercise habits.
3209393|NCT00984425|Experimental|Lapatinib and Sorafenib 2° level of dose|2° level (II cohort): Lapatinib 1000 mg/die + Sorafenib 200 mg bid
3209394|NCT00984425|Experimental|Lapatinib and Sorafenib 3° level of dose|3° level (III cohort): Lapatinib 1000 mg/die + Sorafenib 400 mg bid
2572530|NCT02416557|Experimental|Group P|Patients using positive end-expiratory pressure (PEEP) of 10 cmH2O (centimeter of water) intraoperatively
2572531|NCT02416557|No Intervention|Group C|Patients using no positive end-expiratory pressure (zero PEEP) intraoperatively
2572575|NCT02416271|Experimental|Teriparatide|20 micrograms per day teriparatide subcutaneous (SC) injection plus oral placebo for 18 months.
2572577|NCT02416271|Active Comparator|Alendronate|10 milligrams/day alendronate orally plus SC injection placebo for 18 months.
2572726|NCT02415192||Patients treated with Levacalm|"In this group, the patients will be enrolled treated with Levacalm tab. as an anti-hypertensive drug.~The number of this group will be double than the control group to get more information about safety and efficacy."
2572729|NCT02415192||Patients treated with Valsartan/amlodipine|In this group, the patients will be enrolled treated with Valsartan/amlodipine combination drug as an anti-hypertensive drug.
2572781|NCT02414984||Golimumab|Participants with rheumatoid arthritis in Colombia, for whom the treating physician has decided to treat with golimumab prior to enrolment. All participants will be observed for 24 months. Any changes including addition of new medications or dose modifications of existing medications will be entirely according to the treating physician's judgment.
2572849|NCT02414594|Experimental|IONIS-APO(a)-LRx|Drug: IONIS-APO(a)-LRx
2572854|NCT02414594|Placebo Comparator|Placebo (Normal Saline)|Drug: Sterile Normal Saline (0.9% NaCl)
3209395|NCT00984425|Experimental|Lapatinib and Sorafenib 4° level of dose|4° level (IV cohort): Lapatinib 1250 mg/die + Sorafenib 400 mg bid
3209396|NCT00984438|Experimental|BCNU wafter followed by chemotherapy|Surgical Implantable BCNU wafer followed by Chemotherapy with Irinotecan and Bevacizumab for up to one year
3209397|NCT00984477|Experimental|1|AZD5122 oral suspension (part A and B)
3209398|NCT00984477|Placebo Comparator|2|Placebo oral suspension (part A)
3209399|NCT00984477|Experimental|3|AZD5122 oral and IV infusion (part B)
3209400|NCT00984503|Experimental|Intradermal Juvista|
3209401|NCT00984503|Placebo Comparator|Placebo|
3209402|NCT00984503|Experimental|Intradermal and topical Juvista|
2572395|NCT02417389|Experimental|cinacalcet|Phase 1 (12 months): all patients treated with cinacalcet alone; Phase 2 (12 months): all patients treated with cinacalcet plus alendronate
2572404|NCT02417116|Placebo Comparator|Control|Minims Saline (Preservative Free) lubricant eye drops - daily for 90 days
2572412|NCT02417116|Active Comparator|Hypromellose - standard treatment|Tear Supplement: Hypromellose 0.3% eye drops - daily for 90 days
2572414|NCT02417116|Active Comparator|Combination treatment|Tear Supplement 2: Hylo-Forte 0.2% Sodium Hyaluronate eye drops, Omega 3 nutrition supplement: Omega-3 tablets, Eye bag: TranquilEyes Moist Heat Lid Compresses - Daily for 90 days;
3209403|NCT00984503|Placebo Comparator|Intradermal and topical placebo|
3209404|NCT00984516|Experimental|Intradermal Juvidex|
3209405|NCT00984516|Placebo Comparator|Placebo (vehicle)|
3209406|NCT00984529||1|Cardiologist´s office patients
3209407|NCT00984555||A1 (Inoculation with 7 timepoints)|Semen exposure via inoculation, Vaginal swabs at 7 time points
3209408|NCT00984555||A2 (Inoculation with 4 timepoints)|Semen exposure via inoculation, Vaginal swabs at 4 time points
2572643|NCT02415907|Experimental|Idalopirdine|"Period I: Initial administration of Lu AF67709 single dose at baseline.~Period II: Administration of Lu AF67708 single dose (week 4)"
2572673|NCT02415647||Child Proband with Psychiatric Disorder|Affected group of child probands with psychiatric disorders (ages 6-12 years).
2572677|NCT02415647||Normal Comparison Group|Non-disordered psychiatrically normal comparison group (ages 6-12 years).
3209409|NCT00984555||B1 (intercourse with 7 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 7 time points
3209410|NCT00984555||B2 (Intercourse with 4 timepoints)|Semen exposure via unprotected intercourse, Vaginal swabs at 4 time points
3209411|NCT00984581|Experimental|Intradermal avotermin|
3209412|NCT00984581|Placebo Comparator|Placebo|
2573411|NCT02411032|Experimental|Reminder control|Customers receive a mailing on a random day, which does not coincide with any of the predictable fresh start events.
2573412|NCT02411032|Experimental|Birthday framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
2573413|NCT02411032|Experimental|New Year's framed|Customers receive a mailing on 1/21/15, and the mailing frames the customers' birthday by emphasizing a fresh start associated with the customers' birthday.
2573415|NCT02411032|Experimental|Birthday un-framed|Customers receive a mailing on the most recent Wednesday before the customers' birthday, but the mailing does not frame the customers' birthday.
2573416|NCT02411032|Experimental|New Year's un-framed|Customers receive a mailing on 1/21/15, but the mailing does not frame New Year's.
3209413|NCT00984607|Experimental|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring.
3209414|NCT00984633|Experimental|0.6 mg/kg intubation dose + sevoflurane|
2573713|NCT02409225|Experimental|Home Monitoring|Remote monitoring od ICD/CRT-D function and patient condition. Device: HM provided by St Jude Medical, Biotronik or Medtronic.
2573715|NCT02409225|Active Comparator|HM option not active.|Regular visits in outpatient clinic. Device: no HM
2573784|NCT02408575|Experimental|Notched filtering (verum)|"The Hearing aid with notched amplification filters frequencies in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
2573786|NCT02408575|Experimental|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering~Intervention: Device: Conventional hearing aid type Carat 7bx with M-Receiver; Adjustment by Connexx 7.3"
2573792|NCT02408224||one arm|patients on Ticagrelor
2573869|NCT02407834|Experimental|S1 - 0.25% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.25% sodium hypochlorite during 20 minutes, once a day. This protocol was used during 7 days.
2573875|NCT02407834|Experimental|S2 - 0.5% sodium hypochlorite|Brushing with specific brush and neutral soap, three times a day. After, immesion in 0.5% sodium hypochlorite during 20 minutes, once a day.This protocol was used during 7 days.
3209415|NCT00984633|Experimental|0.9 mg/kg intubation dose + sevoflurane|
3209416|NCT00984633|Experimental|0.6 mg/kg intubation dose + propofol|
3209417|NCT00984633|Experimental|0.9 mg/kg intubation dose + propofol|
3209418|NCT00984646|Experimental|Intradermal Prevascar|
3209419|NCT00984646|Placebo Comparator|Placebo (vehicle)|
3209420|NCT00984672||Bone morphogenetic protein within an interbody cage|Transforaminal Lumbar Interbody Fusion with the use of BMP
3209421|NCT00984672||Other bone grafting techniques within cage (non-BMP)|Use of iliac crest autograft, allograft, or local autogenous bone grafting within the cage during Transforaminal Lumbar Interbody Fusion.
3209422|NCT00984685||depression|Patients diagnosed with depression before April 15, 2009
3209423|NCT00984724|Experimental|Standard Treatment|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Referral to Quitline.
3209424|NCT00984724|Experimental|MAPS-6|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period.
3209425|NCT00984724|Experimental|MAPS-12|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline.
3209426|NCT00984724|Experimental|Standard Treatment + NRT|Standard Treatment (ST): Mailed Packet with standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months). Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
3260220|NCT01477424|Experimental|PA21 and Warfarin with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day
2572215|NCT02418377||Obese children|"The obese subject must meet all of the following inclusion criteria to participate in this study:~Ideal body weight for height (WFH) of at least 140% or BMI for age above 97th percentile~Overweight before 10 years of age~Informed consent from both obese children subject and legal representative e.g. parents"
2572222|NCT02418377||Family members of obese children|"Family member must meet all of the following inclusion criteria to participate in this study:~Must be parent or direct sibling of obese subject~Informed consent from both subject and parent is subject is below 21 years of age"
2572268|NCT02418091|Experimental|Intervention Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
2572275|NCT02418091|No Intervention|Control/No Intervention|Group of subjects that will serve as a comparison group. These subjects will not be approached/enrolled for this study.
2572371|NCT02417701|Experimental|Treatment (sapanisertib)|Patients receive sapanisertib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2572463|NCT02416661||Participants diagnosed with Gaucher disease|Participants with genetically confirmed diagnosis of Gaucher disease type 1 older than 6 months old
2572592|NCT02416570|Active Comparator|Clarithromycin|Clarithromycin 250mg by mouth twice a day for 8 weeks
2572593|NCT02416570|Placebo Comparator|Placebo|Placebo matched capsule one capsule by mouth twice a day for 8 weeks
2572686|NCT02415621|Other|Abiraterone Acetate Therapy|Study schedule involves stopping FDA Approved abiraterone after participants achieve a good PSA response (50% or more decline of pre-abiraterone PSA) and then restarting abiraterone after their PSA reaches the level of pre-abiraterone PSA.
2572802|NCT02414997|Experimental|RIPC group|Surround left upper limb with cuff, inflate cuff to 200 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
2572805|NCT02414997|Sham Comparator|Sham RIPC group|Surround left upper limb with cuff, inflate cuff to 20 mmHg and maintain 5 minutes, than deflate to 0 mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
2572855|NCT02414607|Experimental|Elderberry Juice|Participants will drink 5ml of elderberry juice, diluted in 8oz of water, 3 times per day for three months.
2572857|NCT02414607|Placebo Comparator|Placebo|Participants will drink 5ml of colored water, diluted in 8oz of water, 3 times per day for three months.
3175575|NCT00635622|Placebo Comparator|2|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
3175576|NCT00635635|Active Comparator|1|Guided Imagery Audio
3175577|NCT00635635|Active Comparator|2|Music Audio
2572973|NCT02413853|Experimental|Arm I (PRI-724, mFOLFOX6/bevacizumab)|Patients receive CBP/beta-catenin antagonist PRI-724 IV continuously on days 1-7, bevacizumab IV over 30 minutes, leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV over 46 hours on day 8. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2572979|NCT02413853|Experimental|Arm II (mFOLFOX6/bevacizumab)|Patients receive bevacizumab, leucovorin calcium, oxaliplatin, and fluorouracil as in Arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
2573006|NCT02413281|Experimental|ALKS 5461 Dose 1|Sublingual tablets
2573008|NCT02413281|Experimental|ALKS 5461 Dose 2|Sublingual tablets
2573009|NCT02413281|Experimental|ALKS 5461 Dose 3|Sublingual tablets
2573010|NCT02413281|Active Comparator|Buprenorphine Dose 1|Sublingual tablets
2573011|NCT02413281|Active Comparator|Buprenorphine Dose 2|Sublingual tablets
2573012|NCT02413281|Placebo Comparator|Placebo|Sublingual tablets
2573078|NCT02413073|Sham Comparator|Sham of Whole Body Vibration|This group will receive placebo treatment on the platform we'll use a little engine that will produce a very small vibration stimulus in the platform.
2573082|NCT02413073|Experimental|Whole body vibration Group|This group will be a training na vibratory platform with 12 weeks (3 months), held twice a week on alternate days
2573118|NCT02412826||Acute pancreatitis|Patients presenting to the hospital with acute pancreatitis that will receive AbStats sensor
2573185|NCT02412527||Primary insomnia|Primary insomnia patients, without combined any other sleep disorders
2573187|NCT02412527||Periodic limb movement in sleep|Patients have periodic limb movement in sleep, without combined any other sleep disorders
2573189|NCT02412527||Simple snores|Simple snore patients, without combined any other sleep disorders
2573191|NCT02412527||Obstructive sleep apnea|Obstructive sleep apnea patients, including mild, moderate and severe types, without combined any other sleep disorders or CPAP treatment during PSG study
2573256|NCT02412007|Experimental|Group A|"Individualized comprehensive home centred activity based programme. Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to (a) Standing up from squatting position to catch an object of interest.~(b) Squatting from standing position to pick an object of interest. (c) Walking to reach an object of interest. (d) Climbing up steps to get an object of interest. (e) Climbing down steps to keep the above object of interest. (f) Cycling (g) Kicking a football (h) Dancing"
2573258|NCT02412007|Active Comparator|Group B|"Conventional Physiotherapy Conventional physiotherapy would include and would not be limited to~Passive stretching exercises for spasticity reduction~Gait exercises~Walking on treadmill~Lower limb strengthening exercises~Exercises for balance improvenet"
3175578|NCT00635674|Experimental|Group I - compliant|CPAP use for more than 4 hr/night
3175579|NCT00635674|Active Comparator|Group 2-noncompliant|CPAP for less than 4 hr/night
3175580|NCT00635687|Experimental|Fibroscan|
2572231|NCT02418260|Experimental|Intramedullary nail|Patients will be submitted to closed reduction and locked intramedullary nail osteosynthesis.
2572269|NCT02417948|Experimental|Arm I (educational brochure, online educational tutorial)|Participants receive a skin cancer educational and preventive brochure distributed by the National Cancer Institute and watch a 30-minute online tutorial video called X-Plain about skin cancer, preventative behaviors, and skin self-examinations.
2572273|NCT02417948|Active Comparator|Arm II (educational brochure)|Participants receive an educational brochure as in Arm I.
2572343|NCT02417584|Experimental|positive airway pressure (PAP)|Treatment with positive airway pressure (PAP)
3209427|NCT00984724|Experimental|MAPS-6 + NRT|Standard Treatment (ST) plus 6 proactive telephone counseling sessions; delivered 4 times (at Baseline, 6, 12, and 18 months). 6 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
3209428|NCT00984724|Experimental|MAPS-12 + NRT|Standard Treatment (ST) plus 12 proactive telephone counseling sessions; ST delivered 4 times (at Baseline, 6, 12, and 18 months). 12 MAPS proactive telephone counseling sessions over 2-year period. Referral to Quitline. Nicotine replacement therapy (NRT) consisting of 300 pieces of nicotine gum issued at baseline visit.
2572523|NCT02416583|Active Comparator|Oxytocin & Membrane sweeping|"Women assigned to Concurrent oxytocin with membrane sweeping had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, followed by oxytocin infusion the next day"
2572525|NCT02416583|Active Comparator|Oxytocin & Dinoprostone|"For women assigned to Concurrent oxytocin with dinoprostone vaginal insert: The 10mg dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening, followed by oxytocin infusion the next day"
2572580|NCT02416258|Active Comparator|LP0113 aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
2572583|NCT02416258|Placebo Comparator|Aerosol spray vehicle|No active ingredient, topical
2572585|NCT02416258|Active Comparator|LEO 90100 aerosol foam|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
2572586|NCT02416258|Active Comparator|Betamethasone dipropionate aerosol spray|Betamethasone (as dipropionate) 0.5 mg/g, topical
2572587|NCT02416258|Active Comparator|Calcipotriol aerosol spray|Calcipotriol (as monohydrate) 50 mcg/g, topical
2572589|NCT02416258|Active Comparator|Daivobet® gel|Calcipotriol (as monohydrate) 50 mcg/g and betamethasone (as dipropionate) 0.5 mg/g, topical
2572668|NCT02415673|Experimental|NiTi Af 37ºC|Patients were treatment with fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (37ºC).
2572674|NCT02415673|Experimental|NiTi Af 35ºC|Patients were treatment fixed orthodontics appliance and arch wire. Two nickel-titanium alignment and leveling sequences were employed - NiTi archwire: 0.012 in and 0.019 X 0.025 in; and thermal activated NiTi archwires: 0.018 in and 0.016 X 0.022 in with different austenite finish temperatures (35ºC)
2572794|NCT02415062|Experimental|high dose donepezil (23mg)|Patients with dementia in Parkinson's disease, who are treated with high dose donepezil (23mg)
2572796|NCT02415062|Active Comparator|standard dose denepezil (10mg)|Patients with dementia in Parkinson's disease, who are treated with standard dose donepezil (10mg)
2572845|NCT02414555|Active Comparator|NaCl 0.9% BBraun (normale saline)|154mmol/l sodium, 154mmol/l chloride
2572850|NCT02414555|Active Comparator|Elo-Mel Isoton (balanced acetat-based infusate)|sodium 140mmol/l, potassium 5.0mmol/l, calcium 2.5mmol/l, magnesium 1.5mmol/l, chlorid 108mmol/l, acetate 45mmol/l
2572928|NCT02414165|Experimental|Toca 511/Toca FC|"Resection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL)~Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks."
2572929|NCT02414165|Active Comparator|Lomustine, Temozolomide, or Bevacizumab|"Investigator selects one of the following:~Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure.~Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure.~Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options:~at a dose of 50 mg/m2 PO once daily continuously, or~at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles"
2573001|NCT02413619|Active Comparator|Start cataract|Patients start having cataract surgery. After one month they undergo vitrectomy
2573002|NCT02413619|Active Comparator|start vitrectomy|Patients start having vitrectomy. After one month they undergo cataract surgery.
2573003|NCT02413619|Active Comparator|combined surgery|Combined cataract surgery and vitrectomy at the same time
3209429|NCT00984750|Experimental|1|Statin and acetyl-L-carnitine
3209430|NCT00984750|Placebo Comparator|2|Statin and placebo
3209431|NCT00984763|Experimental|Group 1|AMA1-C1/Alhydrogel® + CPG 7909 vaccine given twice two months apart followed by malaria parasite challenge
3209432|NCT00984763|No Intervention|Group 2|Control: malaria parasite challenge without prior vaccinations
3209433|NCT00984789|Experimental|Arm 1|
3209434|NCT00984789|Active Comparator|Arm 2|
3209435|NCT00984802|Experimental|Low dose|
3209436|NCT00984802|Experimental|Mid Dose|
2583737|NCT02341469|Experimental|integrated ediagnostic approach|
3209437|NCT00984802|Experimental|High Dose|
3209438|NCT00984802|Placebo Comparator|Placebo|
3209439|NCT00984828|Experimental|vel 8 - ASCT|8 cycles of velcade with ASCT
3209440|NCT00984828|Active Comparator|vel4 - ASCT|4 cycles of velcade with ASCT
3260221|NCT01477424|Experimental|No PA21; Warfarin with food|The maximum dosage of Warfarin will be 10 mg/day
2572281|NCT02417896|Experimental|Spironolactone|The intervention group will receive spironolactone. The drug will be administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently, three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3.
2572289|NCT02417896|No Intervention|No spironolactone|Cardiac surgical patients requiring cardiopulmonary bypass and aortic cross clamp, randomised not to receive spironolactone will be followed for 10 days after surgery.
2572362|NCT02417571|Experimental|ABPM group|"Ambulatory blood pressure monitoring (ABPM) performed at 3, 6 months after randomization; adjusting drugs/doses based on ABPM results.~Target BP: daytime ABP < 135/85 mm Hg according to British NICE clinical guideline 127."
2572366|NCT02417571|No Intervention|Office BP group|"Conventional BP management using office BP according to KDIGO guideline on BP management.~Target BP: <140/90 mm Hg."
2572422|NCT02417220|Active Comparator|Weight Watchers Online 2015|
2572428|NCT02417220|Experimental|Weight Watchers Online 2015 Enhanced|
2572459|NCT02416817|Experimental|Blood Products only.|This arm will receive 1:1:1 Red blood cells : Fresh Frozen Plasma : Platelets upon a major trauma triggers. 1:1:1 Ratio for packs of blood products. The patient will be re-evaluated every hour again for the major bleeding triggers and another 1:1:1 intervention may or may not occur.
2572460|NCT02416817|Experimental|Point of care guided|This arm will receive Red blood cells, Human Fibrinogen and Prothrombinic complex concentrates (PCC) based on thromboelastometry. The dosis of each drug will be determined by the analyses of the thromboelastometry curves.
2572464|NCT02416635||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2572465|NCT02416635||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2572466|NCT02416635||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2572467|NCT02416635||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2572622|NCT02416024||No Refractory hypotension group|Patient who did not require more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia.
2572626|NCT02416024||Control|Patient who required more than 200 mcg of phenylephrine to maintain systemic blood pressure during 10 minutes after induction of general anesthesia
2572649|NCT02415816|Experimental|Participants|All patients who consent to participate in this protocol. They will have diffusion weighted magnetic resonance imaging performed at several time points.
2572695|NCT02415530|Placebo Comparator|Term infant control|term infant without intervention
2572696|NCT02415530|Placebo Comparator|VLBW infant control|very low birth weight infant without intervention
2572697|NCT02415530|Experimental|VLBW infant intervention|Combined home visiting and group intervention for very low birth weight infant
3209441|NCT00984841|Experimental|Tailored letter|Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
3209442|NCT00984841|Active Comparator|Usual Care|Patients in the usual care group were part of a practice wide quality improvement process.
3209443|NCT00984854|Experimental|Intradermal Juvidex|
3209444|NCT00984854|Placebo Comparator|Placebo (vehicle)|
2572902|NCT02414282||Experimental F 18 T807|
3209445|NCT00984880|Experimental|1|Intravenous solution given as a single ascending bolus dose
3209446|NCT00984880|Experimental|2|Intravenous solution given as a single ascending bolus dose followed by a single infusion
3209447|NCT00984893||Zoledronic acid|
2573107|NCT02412917|Experimental|FV-100 400 mg QD|FV-100 400mg QD
2573109|NCT02412917|Experimental|FV-100 400mg BID|FV-100 400mg BID(total daily dose of 800mg)
2573110|NCT02412917|Active Comparator|valacyclovir|valacyclovir 1000mg TID
2573158|NCT02412605||Fertile embryo biopsy|Fertile couples requesting sex selection for family balancing
2573161|NCT02412605||Infertile embryo biopsy|Infertile women having embryo biopsy
2573165|NCT02412605||IVF/ICSI|Infertile women undergoing IVF/ICSI without embryo biopsy
2573207|NCT02412345|Experimental|Extracorporeal Shockwave therapy|Extracorporeal shockwave therapy at the penis. 6 sessions.
2573211|NCT02412345|Sham Comparator|Sham treatment|Extracorporal shockwave therapy with a placebo probe. 6 sessions
2573262|NCT02412085|Experimental|Golimumab|Subcutaneous golimumab
3209448|NCT00984893||Oral Bisphosphonates|
3209449|NCT00984906|Other|Empty Easyhaler type A|
2573387|NCT02411318|Experimental|Cardiovascular Exercise|Participants will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes. For example, a 30 year old will have a target heart rate zone of 95-162 beats per minute. A baseline blood sample will be acquired before the participant begins exercising. In the following 30 minutes, participants will ride the exercise bike, and their heart rate and general status will be assessed continuously. Specifically, heart rate will be monitored using a chest strap heart rate monitor. Two additional lancet punctures will be performed after the exercise to measure the changes in neutrophil function: one immediately following the 30 minute exercise period and one 30 minutes after the exercise has been completed.
2573403|NCT02411045|Experimental|Group 2: Dress for Success|Ask participants to take a picture of themselves while wearing their workout gear
3209450|NCT00984906|Other|Empty Easyhaler type B|
3209451|NCT00984906|Other|Empty Turbohaler|
3209452|NCT00984932|Experimental|Rosuvastatin|
3209453|NCT00984945|Active Comparator|H5 VLP vaccine 5 µg|
3209454|NCT00984945|Active Comparator|H5 VLP vaccine 10 µg|
3209455|NCT00984945|Active Comparator|H5 VLP vaccine 20 µg|
3209456|NCT00984945|Placebo Comparator|Placebo (Formulation buffer)|
3209457|NCT00984958|Other|Bulkamid|Injection with Bulkamid
3209458|NCT00984958|Other|expectance|The expectance arm will after 2 month have the same treatment as the treatment arm
3209459|NCT00984971|Experimental|Tenofovir|
2572352|NCT02417506|Active Comparator|Ibuprofen|200 mg two capsule to be taken stat at the site
2572542|NCT02416427|Experimental|Arm A|Atorvastatin 80 mg/day for 3 weeks
2572547|NCT02416427|No Intervention|Arm B|Observation
3209460|NCT00984971|Placebo Comparator|HEC Placebo|
3209461|NCT00984971|Other|Open label tenofovir tablet|
3209462|NCT00984984|Experimental|methylprednisolone PO|
3209463|NCT00984984|Active Comparator|methylprednisolone IV|
3209464|NCT00984997|Experimental|Surgery + Radiotherapy + Chemotherapy|"Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.~Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional."
2572891|NCT02414087|Active Comparator|study group|ICB Medical Insoles
2572898|NCT02414087|Placebo Comparator|control group|without ICB Medical insoles
2572968|NCT02413970|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System.
3209465|NCT00985023|Active Comparator|Steel screw fixation|
3209466|NCT00985023|Experimental|Bioabsorbable screw fixation|
3209467|NCT00985036||Glioma|patients who are diagnosed with and are being treated for glioma
3209468|NCT00985036||meningioma|patients who are diagnosed with and are being treated for meningioma
3209469|NCT00985062|Active Comparator|Mild Ovarian Stimulation|
3209470|NCT00985062|Active Comparator|Conventional Ovarian Stimulation|
2573246|NCT02412202|Other|patients who undergo weaning from mechanical ventilation|consecutive mechanically ventilated critical ill patients who fulfil criteria for weaning will be included
2573283|NCT02411903|Active Comparator|atorvastatin and Clopidogrel|80 patients will be taking atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months。
2573285|NCT02411903|Experimental|rosuvastatin and Clopidogrel|80 patients will be taking rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months。
3209471|NCT00985101||diabetes no complications|
2573375|NCT02411240|Other|Air filtering in the living room|GENANO tubes, GENANO Benelux; Heusen-Zolder, Belgium
3209472|NCT00985101||diabetes with complications|
3209473|NCT00985127|Experimental|40 mg|40 mg BCX4208
2573503|NCT02410564|Active Comparator|CBTI treatment|cognitive behavioral therapy for insomnia (CBTI) treatment is a validated web based version of CBT-I, which will take place over seven weeks and will include a combination of face-to-face and telephone sessions, and email updates
2573507|NCT02410564|Placebo Comparator|Waitlist control condition|No advice regarding sleep will be given to the control group and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
3209474|NCT00985127|Experimental|80 mg|BCX4208
2573618|NCT02409771|Experimental|Intervention arm|Bilateral implantation with PRECIZON Presbyopic intraocular lens
3209475|NCT00985127|Experimental|120 mg|BCX4208
3209476|NCT00985127|Placebo Comparator|sugar pill|
3209477|NCT00985127|Experimental|160mg|BCX4208
3209478|NCT00985127|Experimental|240mg|BCX4208
3209479|NCT00985127|Experimental|320mg|BCX4208
3209480|NCT00985179|Experimental|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
3209481|NCT00985179|No Intervention|Waiting control group (WCG)|
3209484|NCT00985218|Experimental|experimental arm|Embryos cultured in SMART System
3209485|NCT00985218|Active Comparator|Control|Embryos cultured in microdrops in dishes
3209486|NCT00985244|Active Comparator|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin
3209487|NCT00985244|Placebo Comparator|Placebo|Subjects in this group will receive 3 times a week placebo
3209488|NCT00985270|Active Comparator|Rifampicin|
3209489|NCT00985270|Placebo Comparator|Placebo|
3209490|NCT00985283|Experimental|Preventive home visit|receives preventive home visit intervention 4 times over 1 year
3209491|NCT00985283|Active Comparator|comparison group|receives information packets on local services for older adults and health promotion material twice during 1 year
3209492|NCT00985296||Ragweed+ Dust Mite+ CAC w/ DM|
3209493|NCT00985296||Ragweed + Dust Mite + CAC w/Saline|
3209494|NCT00985296||Ragweed + Dust Mite - CAC|
3209495|NCT00985322|Experimental|ACE inhibitor Ramipril|
3209496|NCT00985322|Active Comparator|non-RAS inhibitor antihypertensive therapy|
3209497|NCT00985335|Experimental|External Application of Neem-based Cream|Non Controlled, non-randomized, single group pilot study.
3209498|NCT00985348|Experimental|Treatment 1/Treatment 2|
3209499|NCT00985348|Experimental|Treatment 2/Treatment 1|
3209500|NCT00985361|Experimental|Vitamin D 2000 international units daily|
3209501|NCT00985361|Active Comparator|Vitamin C 500mg daily|
3209502|NCT00985374|Experimental|1|
3209503|NCT00985387||Solifenacin treatment|Male and female OAB patients who were treated with solifenacin
3209504|NCT00985400|Experimental|Exercise Program|Arm I (exercise program): Oncologist advice; Resistance bands & pedometer with written/DVD instructions for resistance exercise twice a week for 16 weeks. Brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day. Monthly newsletters; Telephone counseling weekly for 4 weeks then monthly for 12 weeks; and tailored message telephone prompts once every 2 weeks during last 12 weeks of the study intervention.
2572374|NCT02417558|Experimental|Alterniity Augmented Reality (AAR)|AAR training Participants use the patent pending AAR exercise and gaming (exergaming) platform that combines a physical training component (PTC) and a cognitive training component (CTC) in closed-feedback loop with Personalized Brain Network Activity (PBNA) test from a portable EEG.
2572380|NCT02417558|No Intervention|Passive Control Participants|Passive Control Participants do not receive an intervention serving as passive controls
2572384|NCT02417558|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the Aristotle University of Thessaloniki. The software is called VideoGrade and uses videos from Youtube (YouTube) documentaries (VideoGrade).
2572403|NCT02417181|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the out-of-hours primary care service
2572409|NCT02417181|Experimental|Physician Assistants Care|Medical care provided by the Physician Assistant at the out-of-hours primary care service
2572518|NCT02416596|Experimental|Group Undergoing Hysterosopy|This group will include 340 women with unexplained primary infertility undergoing their first trial of IVF/ICSI (intracytoplasmic sperm injection). This group will undergo hysteroscopy in the mid luteal phase of the proceeding cycle.
2572521|NCT02416596|No Intervention|Group With No intervention|This group will include 340 women with unexplained primary infertility they will undergo their first trial of IVF/ICSI (intracytoplasmic sperm injection) without hysteroscopy in the mid Luteal phase of the proceeding cycle.
2572588|NCT02416284|Experimental|NFBDG|Multi-faceted, 2 week intervention to increase compliance to the NFBDG.
2572634|NCT02415972||All study participants|Patients with Stroke
2572705|NCT02415660|Experimental|SMT and TDN|Thoracic spinal manipulation and trigger point dry needling using Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
2572707|NCT02415660|Sham Comparator|SMT and Sham TDN|Thoracic spinal manipulation and trigger point dry needling sham. Exercise program consists of cervical range of motion exercises and posterior neck muscle activation exercise.
2572749|NCT02415140||COPD|Spirometry confirmed COPD patients
2572750|NCT02415140||Control|normal geriatric patients without lung disease
2572778|NCT02414893||Non obese|
2572782|NCT02414893||Morbidly obese|
2572787|NCT02414893||Sleeve gastrectomy|
2572846|NCT02414776|Experimental|hydroxychloroquine plus hormonal therapy|Add hydroxychloroquine to the current hormonal therapy
2572919|NCT02414373|Experimental|Ropivacaine|Ropivacaine 2mg/ml (ROPIVACAIN Sintetica 2 mg/ml ™, Sintetica-Bioren, Couvet, Schweiz)
2572922|NCT02414373|Active Comparator|Bupivacaine|Bupivicaine 1.25mg/ml (BUPIVACAIN Sintetica 0.125 % ™ (Bupivacain 1,25 mg/ml), Sintetica-Bioren, Couvet, Schweiz)
2572953|NCT02413788|Experimental|combined group (treadmill and resisted)|- 10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) and resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs (36 sessions)
2572957|NCT02413788|Active Comparator|aerobic group (treadmill)|10 minutes of warming, aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate) for 36 sessions
2573026|NCT02413437|Experimental|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided
2573036|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided
2573209|NCT02412319|Experimental|Experimental Group|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
2573213|NCT02412319|Placebo Comparator|Comparator Group|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
2573254|NCT02412124|Experimental|Supportive care (W2W program)|Patients participate in the W2W program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person.
3175581|NCT00635713|Experimental|1|Faslodex 125mg and Arimidex 1 mg
3175582|NCT00635713|Experimental|2|Faslodex 250mg and Arimidex 1mg
2573574|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 1|Clopidogrel-aspirin co-administration. Before this clinical trialClopidogrel/Aspirin co-administration.
2573578|NCT02410083|Experimental|Clopirin 2|Clopirin single-administration. Before this clinical trial Aspirin single-administration.
3175583|NCT00635726|Experimental|1|MVAC -> GEM+CDDP
3175584|NCT00635752|Experimental|1|Participants will receive trauma-focused cognitive behavioral therapy (TF-CBT)
3175585|NCT00635752|Active Comparator|2|Participants will receive sessions of treatment as usual (TAU)
3175586|NCT00635791|Experimental|Sorafenib tosylate and vorinostat|Patients receive sorafenib tosylate by mouth twice a day on days 1-21 and vorinostat by mouth every day on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3175587|NCT00635843|Experimental|MAVERICK™ Disc|
3175588|NCT00635843|Active Comparator|Fusion|
3175589|NCT00635869||ARCC standard|RNs on unit receiving basic ARCC information with staff nurse champion
3175590|NCT00635869||ARCC enhanced|RNs on unit receiving ARCC standard content plus with an EBP mentor
3175591|NCT00635869||C|RNs on the unit receiving the placebo intervention
3175592|NCT00635895|Active Comparator|1|Manual Lymph Drainage Therapy is a manual therapy method
3175593|NCT00635895|Active Comparator|2|Connective Tissue Massage
3175594|NCT00635921|Active Comparator|I ziprasidone|
3175595|NCT00635921|Placebo Comparator|II placebo|
3175596|NCT00635934|Experimental|A-MAV™disc|
3175597|NCT00635947|Active Comparator|1|isotonic solution - 1.5L
3175598|NCT00635947|Active Comparator|2|water- 1.5L
3175599|NCT00635947|Placebo Comparator|3|water-200mL
3175600|NCT00635960|Experimental|1|Patients randomly assigned to treatment
3175601|NCT00635960|Placebo Comparator|2|Patients randomly assigned to placebo
2572413|NCT02417675|Experimental|Intervention (AC)|"Women who choose the Community-based Adherence Clubs (AC) will receive postpartum antiretroviral therapy (ART) services at an AC, rather than at their nearest primary care clinic as in the SOC arm. Details are provided in the intervention section.~Infants receive the same care in each arm, according to the Standard of Care for Infants."
2572535|NCT02416479|Experimental|SystemCHANGE|SystemCHANGE supports patient-designed, interventionist-guided, small experiments to: 1) assess individual systems (including important others who shape medication taking) and the system's impact on medication taking and propose individual system solutions to improve MA, 2) implement the proposed individual systems' solutions to improve MA, 3) track MA data, and 4) evaluate MA data.
2572537|NCT02416479|Active Comparator|Patient-education attention-control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
2572612|NCT02416219||Cricoid Cartilage localization|The caregiver will be asked to palpate the cricoid cartilage and draw aline where he will apply cricoid pressure during rapid sequence induction
2572648|NCT02415829|Experimental|Neoadjuvant chemotherapy|A total of 55 cases of locally advanced colon cancer will be enrolled in this arm. After radiological staging, patients were treated first with 3 cycles of neoadjuvant chemotherapy consisting of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen), followed by tumor resection, and then with another 5 cycles of adjuvant chemotherapy with the XELOX regimen. Radiological response was evaluated after 2 cycles of neoadjuvant chemotherapy . A total of 3 cycles neoadjuvant chemotherapy was completed unless there was unacceptable toxicity, emergency operation condition or tumor progression during the period. Tumor responses, toxicities, and surgical complications were recorded. The pathological tumor response in the primary tumor was evaluated according to tumor regression grade (TRG) score.
2572682|NCT02415569|Experimental|group1|Subjects whose bristol stool forms are type 1 or 2, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
2572688|NCT02415569|Experimental|group2|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure. ( 2L PEG-ELP and 10mg bisacodyl )
2572690|NCT02415569|Active Comparator|group3|Subjects whose bristol stool forms are type 3 to 7, will receive standard bowel prep (2L PEG-ELP) the same-day of procedure.
2572722|NCT02415296||stage 1|French online gamblers.
2572723|NCT02415296||stage 2|Validation of problematic gamblers score on possible problematic gamblers.
2572724|NCT02415296||stage 3|240 problematic gamblers.
2572795|NCT02415036|Experimental|Melphalan/HDS treatment of patients with HCC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Hepatocellular carcinoma (HCC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
2572798|NCT02415036|Experimental|Melphalan/HDS treatment of patients with ICC|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System on patients with Intrahepatic cholangiocarcinoma (ICC).~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 2 cycles of treatment."
2572881|NCT02414412|Active Comparator|Ulmus|Ulmus macrocarpa water extract 250mg orally 2 times a day for 4 weeks
2572882|NCT02414412|Placebo Comparator|Placebo|placebo 250mg orally 2 times a day for 4 weeks
2572936|NCT02414113||Low GNOS donors|
2572939|NCT02414113||High GNOS donors|
2572960|NCT02413697|Active Comparator|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
2572966|NCT02413697|Experimental|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
2573056|NCT02413177|Active Comparator|EEG-RTNF|Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
2573057|NCT02413177|Active Comparator|EEG-no RTNF|Group 2 will receive EEG (no RTNF feedback). They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
2573067|NCT02412995|Experimental|Meal sequence 1-2-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-2-3
2573072|NCT02412995|Experimental|Meal sequence 1-3-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 1-3-2
2573077|NCT02412995|Experimental|Meal sequence 2-3-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-3-1
2573084|NCT02412995|Experimental|Meal sequence 2-1-3|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 2-1-3
2573086|NCT02412995|Experimental|Meal sequence 3-1-2|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-1-2
2573088|NCT02412995|Experimental|Meal sequence 3-2-1|The three meals, sea buckthorn puree, strawberry puree, or placebo (sugar drink) were allocated a number (1-3) in a blinded fashion and given to the participants in the order 3-2-1
3209505|NCT00985400|Experimental|Relaxation Intervention|Arm II (relaxation program): Oncologist advice; Written/CD audio instructions on diaphragmatic breathing and guided imagery. Practice relaxation techniques for 15 minutes/day, 5-7 days/week, for 16 weeks. Monthly newsletters, telephone counseling, and tailored-message telephone prompts as in arm I.
3209506|NCT00985452|Other|Group 2: Intervention|Subjects in Group two will received an activated GlowCaps system, which will remind them to take their medication.
2584914|NCT02333643|Placebo Comparator|Vehicle topical formulation|
3209507|NCT00985452|Other|Group 3: Intervention/financial incentive|Subjects in group 3 will receive an activated GlowCaps system, which will provide them with reminders to take their medication, Subjects in group 3 will also receive an additional financial incentive, the amount will be based on how often they remembered to take their medication during the 6-month study.
2572425|NCT02417012|Active Comparator|Standard care|"The reference group will receive diabetes education and support by trained nurses.~Participants in this group will have their pharmacological treatment regulated by the study endocrinologists using a standardized pharmacological treatment. The treatment is in accordance with the Danish guidelines."
3209508|NCT00985452|Other|Group 1: Control|Subjects in group one will receive a de-activated GlowCaps system, which will not provide the reminder service.
3209509|NCT00985478|Experimental|A|SLV342 suspension or capsule
3209510|NCT00985478|Placebo Comparator|B|matching placebo
3209511|NCT00985530|Experimental|Arm 1|Tamibarotene + Arsenic Trioxide
3209512|NCT00985556|Experimental|Arm I|Patients receive oral S-1 twice daily on days 1-14 and oxaliplatin IV over 2 hours on day 1.
3209513|NCT00985556|Experimental|Arm II|Patients receive oral capecitabine twice daily on days 1-14 and oxaliplatin as in arm I.
2572739|NCT02415218|Experimental|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
2572785|NCT02414945|Experimental|Tumor Infiltrating lymphocytes (TILs)|"Lymphodepleting preparative regimen: Cyclophosphamide, intravenously, at 60mg/kg/day x 2 days, and Fludarabine, intravenously at 25mg/m2/day x 5 days~Autologous tumor infiltrating lymphocytes (TILs): Intravenously at 1x10^10 - 1.6x10^11 cells~Low-dose interleukin-2: Subcutaneously at 125,000 IU/kg per day, for 2 weeks (2 days rest between each week)."
2572847|NCT02414568|Experimental|PVAB regimen|Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1
2572994|NCT02413801||Psoriasis|Individuals with psoriasis
2572996|NCT02413801||Healthy|Individuals that are healthy
3209514|NCT00985569||Lubiprostone|Subjects switching from current bowel medicines to lubiprostone
3209515|NCT00985608|Active Comparator|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
2573116|NCT02412800||Acute lung injury|Postoperative acute lung injury was diagnosed according to the latest 2012 Berlin definition of acute respiratory distress syndrome by the PaO2/FiO2< 300 and acute onset of bilateral infiltrates on the chest radiograph that were not fully explained by cardiac failure during postoperative day 1 to postoperative day 3.
2573176|NCT02412553|Active Comparator|Specific carbohydrate arm|The specific carbohydrate diet will be sufficient to meet 100% of the caloric requirements of the patient.
2573177|NCT02412553|Active Comparator|Elemental diet arm|The partial elemental diet will be sufficient to provide 50% of the daily caloric needs for each patient with the remainder from a standard low-residue diet
3209516|NCT00985608|Active Comparator|Group A: NCA 600mg +antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
3209517|NCT00985634|Experimental|LeGoo|Subjects in this arm, which is assigned at random, will receive the study device.
3209518|NCT00985634|Active Comparator|Control|Subjects in this arm will not receive the study device, but receive the standard of care for vessel occlusion (vessel loops.)
3209519|NCT00985647|Active Comparator|3TC 300mg/150mg|Group 1: Participants will be administered 3TC 300 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 150 mg once daily for 10 days
3209520|NCT00985647|Active Comparator|3TC 150mg/300mg|Group 2: Participants will be administered 3TC 150 mg once daily orally for 10 days. A 10 day wash-out period will follow (days 11-20). From day 21, participants will be administered 3TC 300 mg once daily for 10 days
2573431|NCT02410889||Patients with Epilepsy|A group of patients with a variety of types of epilepsy.
2584925|NCT02333266||Candidemia|0
3209521|NCT00985660|Experimental|Test:|Nisoldipine ER Tablets, 30 mg
3209522|NCT00985660|Active Comparator|Reference|Sular Extended-release Tablets, 30 mg
3209523|NCT00985764||placental previa|
3209524|NCT00985777|Experimental|Phase I Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days and one dose on Day 15.
3209525|NCT00985803|No Intervention|Group Control|
3209526|NCT00985803|Experimental|Endurance|
3209527|NCT00985803|Experimental|Cardiovascular|
3209528|NCT00985816|Active Comparator|L reuteri DSM 17938|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties (Connolly, 2005). The placebo consists of an identical formulation except that the L. reuteri is not present. This dose of the oil formulation with L. reuteri has been shown to induce significant colonisation in infants and is well-tolerated (Abrahamsson et al., 2007; Savino et al., 2007; Indrio et al., 2008).
3209529|NCT00985816|Placebo Comparator|Placebo|
3209530|NCT00985842|Other|Arm 1|Comparison of five different clinically used suspension and socket systems
3209531|NCT00985855|Experimental|Cisplatin, vinorelbine|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and vinorelbine associated with a weekly cetuximab infusion during the radiotherapy.
3209532|NCT00985855|Experimental|Cisplatin, etoposide|patients will receive induction chemotherapy (cisplatin, docetaxel) followed by a concomitant radio-chemothérapy including 2 cycles of cisplatin and etoposide associated with a weekly cetuximab infusion during the radiotherapy.
3209533|NCT00985881|Experimental|Arm 1: stochastic resonance|Mechanical stochastic resonance
3209534|NCT00985881|Other|Arm 2: current clinical practice|Current clinical practice
3209535|NCT00985894|Experimental|Teledermatology|Online Telemedicine Group
3209536|NCT00985894|Active Comparator|Usual Care|Conventional in-office care
3209537|NCT00985920|Experimental|Tranexamic acid, 1.5 g|1.5 g of tranexamic acid in 50 cc of normal saline solution is given to the patients.
3209538|NCT00985920|Experimental|Tranexamic acid, 3.0 g|3.0 g of tranexamic acid in 50 cc of normal saline is given to the patients.
3209539|NCT00985920|Placebo Comparator|Placebo, saline|50 cc of sterile normal saline solution is given to the patients.
3209540|NCT00985933|Experimental|1|180 mg of AZD8529
2572433|NCT02417155|Active Comparator|STR|The 'short training' group (STR): a group of subjects (n=10) that will receive only a short training of 1 hour (immediately prior to the study) by Mr. Hof and his team in both hyper/hypoventilation and strength ventilation breathing techniques.
2572437|NCT02417155|Active Comparator|SIN|The 'short instruction' group (SIN): a group of subjects (n=10) that will receive no training, but only an short instruction course of 1 hour (immediately prior to the study) supervised by the research team (in absence of Mr. Hof) in both hyper/hypoventilation and strength ventilation breathing techniques.
2572475|NCT02416700|Experimental|immediate implant surgery|Immediate implant surgery in one site.
2572478|NCT02416700|Active Comparator|conventional implant surgery|Conventional implant surgery in another site
3209541|NCT00985933|Experimental|2|50 mg AD8529
3209542|NCT00985933|Placebo Comparator|3|Placebo
3209543|NCT00985972||Intervention|Groups of school intervention that involves a combination of the physical activity and nutrition education in subjects 6 to 18 years of age
3209544|NCT00985972||Control|Groups included in the same school communities that serve as reference for individuals involved in intervention.
3209545|NCT00985998|Experimental|Nimotuzumab|
2572877|NCT02414516|Experimental|OBP-801|
2572890|NCT02414126|Active Comparator|Children with dilated cardiomyopathy with an ejection fraction|
2572892|NCT02414126|Active Comparator|Children with univentricular congenital heart disease|
2572895|NCT02414126|Active Comparator|Children with left valvulopathy|
2572931|NCT02413840|Experimental|Baduanjin qigong group|Doing exercise of Baduanjin qigong under the guidance of medical staff;psychological counseling at the same time.
2572933|NCT02413840|No Intervention|control group|Psychological counseling only.
2572999|NCT02413606|Experimental|Intervention|reduced follow-up schedule: 4 follow-up visits, after 3, 12, 24 and 36 months
2573000|NCT02413606|No Intervention|control|regular follow-up schedule according to the guideline, 10-13 visits during 5 years
3209546|NCT00986024|Experimental|aerobic exercise|
3209547|NCT00986024|Experimental|strength training|
3209548|NCT00986024|No Intervention|control group|
3209549|NCT00986037|Experimental|IV ABT-308 in asthmatics|ABT-308 single escalating doses in mild to moderate asthmatics
3209550|NCT00986037|Experimental|SC ABT-308 in asthmatics|ABT-308 multiple SQ doses in mild to moderate asthmatics
3209551|NCT00986037|Experimental|IV ABT-308 in healthy volunteers|ABT-308 single escalating IV doses in healthy volunteers
3209552|NCT00986050|Active Comparator|Bare metal stent (BMS)|
3209553|NCT00986050|Active Comparator|Drug eluting stent (DES)|
3209554|NCT00986050|Active Comparator|Abciximab|
2573469|NCT02410759|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly IM
2573470|NCT02410759|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5mg IM
2573486|NCT02410525|Experimental|[11C]PF-06427878|Single intravenous infusion of [11C]PF-06427878 in Periods 1, 2 and 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
2573490|NCT02410525|Experimental|PF-06427878 10 mg|Single oral dose of 10 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
2573498|NCT02410525|Experimental|PF-06427878 600 mg|Single oral dose of 600 mg PF-06427878 in Period 2 or 3 to investigate the liver and plasma radioactivity, radioactivity in organs relative to plasma, pharmacokinetics, and safety and tolerability
2573533|NCT02410226|Active Comparator|Palpation|Double-space combined spinal-epidural anesthesia, Sham ultrasound procedure
2573536|NCT02410226|Experimental|Ultrasound|Double-space combined spinal-epidural anesthesia, Preprocedure spinal ultrasound
3209555|NCT00986050|No Intervention|No abciximab|
2573612|NCT02409589|Experimental|ECG-guided PICC Tip Placement|New intracavitary ECG guiding method
3209556|NCT00986063|Active Comparator|Standard of care|AIDS patients taking care with standard of care
3209557|NCT00986063|Experimental|Genetic test|AIDS patients who required highly active antiretroviral therapy(HAART) whom genotype status will be determined before initiation of HAART
3209558|NCT00986076|Experimental|Enoxaparin infusion|"Congenital Cataract Surgery with IOL implantation~Intraocular infusion of Enoxaparin"
3209559|NCT00986076|Placebo Comparator|Balanced Salt Solution Infusion|Congenital Cataract Surgery with IOL implantation Intraocular infusion of Balanced Salt Solution
3209560|NCT00986089||women who have an IUD placed at the time of c-section|
3209561|NCT00986115|Active Comparator|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
3209562|NCT00986115|Placebo Comparator|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
3209563|NCT00986128|Experimental|001|
3209564|NCT00986128|Experimental|002|
3209565|NCT00986141||laser trabeculoplasty|Subjects with POAG and on medical treatment who are undergoing SLT
3209566|NCT00986141||Surgery|Glaucoma laser treatment
3260222|NCT01477424|Experimental|PA21 with food and Warfarin 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day
3260223|NCT01477437|Experimental|Intervention (experimental) Group|
3260224|NCT01477437|No Intervention|Control group|
2572482|NCT02416947|Active Comparator|20g SCF|Subjects will consume 20 g of SCF in two equal doses as a muffin and a drink, daily for 50 days.
2572541|NCT02416401|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
2572544|NCT02416401|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, 4-5 times weekly, one hour each session.
2572619|NCT02416128|Active Comparator|Iritis prevention after LPI: prednisolone|To use prednisolone acetate after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 2.
2572623|NCT02416128|Experimental|Iritis prevention after LPI: euphrasia|To use euphrasia after and peripheral laser iridotomy to determine efficacy and side effects compared to arm 1.
2572666|NCT02415764|Other|Pilot test Intervention OnTrack>The Game|"Consumers who have been referred to OnTrackNY sites at Washington Heights Community Service or Mental Health Association Westchester in the past six months will be recruited to participate in a product evaluation of OnTrack>The Game.~Intervention: This is a behavioral/attitudinal intervention, using OnTrack>The Game, which will include each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes)."
2572725|NCT02415452||Acute Coronary Syndrome (ACS) patients|Acute coronary syndrome (ACS) patients who underwent coronary angiography ,drug-eluting stent (DES) implantation, and eye fundus examination.
2572800|NCT02415049|Active Comparator|Incremental|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
2572804|NCT02415049|Experimental|Ad-lib|This arm of patients is fed ad lib following surgery and can feed with formula or breast milk at any time and with any frequency up to 12.5ml/kg/feed
2572848|NCT02414620|Experimental|Dental Vibe|New oscillating device for reduction in pain during dental anesthesia
2572935|NCT02414386||Acute Kidney Injury - CRRT|Multi-organ failure with acute kidney injury critically ill patients admitted to the critical care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
2572937|NCT02414386||Control|Multi-organ failure non acute kidney injury critically ill patients admitted to the critical care unit. Multi-organ failure is defined as a respiratory and circulatory failure. Biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels.
2572987|NCT02413710|Active Comparator|Usual Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
2572989|NCT02413710|Experimental|Soy Protein Group|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the USDA MyPlate program (www.choosemyplate.gov) with the incorporation of two servings of study food providing soy protein per day.
2573024|NCT02413424|Experimental|Drink Sucralose|Subjects will drink sucralose 10 min before drinking a glucose load
2573038|NCT02413424|Placebo Comparator|Drink Water|Subjects will drink water 10 min before drinking a glucose load
2573042|NCT02413424|Experimental|Taste and spit Sucralose|Subjects will taste and spit up sucralose 10 min before drinking a glucose load
2573104|NCT02413021|Experimental|deferasirox + cytarabine|deferasirox + cytarabine group will receive oral deferasirox at 20 mg/kg per day and cytarabine at20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
2573105|NCT02413021|Active Comparator|cytarabine|cytarabine group will receive just cytarabine at 20 mg/m^2 , SC , two times a day for 10 days every 30 days for 1 cycle.
3260225|NCT01477476|Active Comparator|Active Treatment|14 subjects with receive active treatment with Anakinra.
3260226|NCT01477476|Placebo Comparator|Placebo|7 subjects will receive the placebo comparator.
2573245|NCT02412189|No Intervention|control|Ordinary anesthesia, mean arterial pressure allowed to decrease to 60 mmHg. If it is lower the patients will receive a norepinephrine infusion in order to raise the mean arterial pressure to 60 mmHg.
2573247|NCT02412189|Active Comparator|Maintained blood pressure|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
2573297|NCT02411851|Active Comparator|Ingenol mebutate alone|At Visit 1, ingenol mebutate 0.015% alone on the second 25 cm2 treatment area. The treatment area receiving ingenol mebutate 0.015% alone will apply the medication as directed per approved drug labeling. Patients will apply ingenol mebutate gel on Day 2 and Day 3.
2573300|NCT02411851|Experimental|Ingenol mebutate and dermasil lotion|At Visit 1, ingenol mebutate 0.015% and dermasil lotion on one 25 cm2 treatment area. The treatment area receiving both ingenol mebutate 0.015% and dermasil lotion, will first apply ingenol mebutate 0.015% allow the gel to dry completely as per drug labeling on Day 1. The patient will allow at least 6 hours between the application of ingenol mebutate and dermasil lotion on Day 2 and 3. Patients will apply dermasil lotion daily on Day 2 until at least Day 8. At Day 8, the physician will reassess whether dermasil application should be continued to Day 15 or ceased. At Day 15, the physician will reassess whether dermasil application should be continued to Day 29 or ceased.
2573330|NCT02411500|Experimental|Formulation A|
2573333|NCT02411500|Experimental|Formulation B|
2573336|NCT02411500|Experimental|Formulation C|
2573339|NCT02411500|Experimental|Formulation D|
2573340|NCT02411500|Experimental|Formulation E|
2573342|NCT02411500|Experimental|Formulation F|
2573393|NCT02411136|Experimental|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
2573397|NCT02411136|Placebo Comparator|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
2585109|NCT02332356|No Intervention|observation step up|
3260227|NCT01477489|Experimental|Treatment|
2572493|NCT02416687|Active Comparator|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) was inserted in the first 48 h postpartum
2572500|NCT02416687|No Intervention|Control group|Postpartum women who used no contraceptive method in the first six weeks after delivery
2572545|NCT02416375||Observation|Adult Cystic Fibrosis patients
2572606|NCT02416167|Active Comparator|FYU-981 High dose|Drug: FYU-981 High dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
2572607|NCT02416167|Active Comparator|FYU-981 High middle dose|Drug: FYU-981 High middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 High middle dose arm receive active drug, FYU-981 High middle dose.
2572609|NCT02416167|Active Comparator|FYU-981 Middle dose|FYU-981 Middle dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
2572610|NCT02416167|Active Comparator|FYU-981 Low dose|Drug: FYU-981 Low dose, (Oral daily dosing for 8 week-maintenance period) Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
2572611|NCT02416167|Placebo Comparator|Placebo|Drug: Placebo, (Oral daily dosing for 12 weeks) Subjects randomized to the placebo arm receive placebo.
2572655|NCT02415803|Experimental|low-dose ticagrelor|To observe the safety and efficacy of low-dose ticagrelor in Chinese patients with non-ST-elevation acute coronary syndrome
2572658|NCT02415803|Active Comparator|conventional-dose ticagrelor|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose ticagrelor.
2572661|NCT02415803|Active Comparator|clopidogrel|To observe the different safety and efficacy between low-dose ticagrelor and conventional-dose clopidogrel.
2572711|NCT02415374|Placebo Comparator|Low-AVA oat flour cookies|Three low-AVA oat flour cookies
2572713|NCT02415374|Experimental|High-AVA oat flour cookies|Three high-AVA cookies
2572752|NCT02415114|Active Comparator|Healthy Population|Healthy Population with Omega Q Plus Resveratrol (with 50mg CoQ10)
2572753|NCT02415114|Active Comparator|Population taking Statins|Population taking Statins with Omega Q Plus Resveratrol (with 50mg CoQ10)
3209567|NCT00986167|Experimental|Quetiapine XR|The study population will be patients admitted to the acute psychiatry inpatient wards of St Vincent's or the Alfred and determined by a Psychiatrist to be experiencing a psychotic illness (including mania with psychotic features and drug-induced psychosis) and acting in an aggressive manner (determined by a score of at least 1 on the OAS).
3209568|NCT00986193|Active Comparator|Conventional Aortic Valve Surgery|Insertion of a biological valve
3209569|NCT00986193|Experimental|Transapical Aortic Valve Implantation|Transapical implantation of an Edwards SAPIENtm valve
3209570|NCT00986206||Biomarker testing|Collect serum for biomarker testing for LAP and HE4 and discovery of new biomarkers.
2572885|NCT02414347||Experimental F 18 T807|
2572951|NCT02413983||CI (conventional incision)|The living liver donors underwent hepatectomy using right subcostal incision with a midline extension (conventional incision)
2572956|NCT02413983||MI (midline incision)|The living liver donors underwent hepatectomy using upper midline incision (10cm) without laparoscopic assistance
2572964|NCT02413983||TI (transverse incision)|The living liver donors underwent hepatectomy using transverse incision with laparosocpic assistance
2573007|NCT02413502|Experimental|Bacillus Calmette-Guérin (BCG)|Tice brand BCG used to vaccinate BCG-Naïve adults.
2573157|NCT02412618|Active Comparator|Mifepristone|Mifepristone 200mg oral tablet, once Misoprostol 400 mcg tablets, vaginally, once
2573164|NCT02412618|Placebo Comparator|Placebo|Placebo oral tablets, odorless, colorless and matched to Mifepristone appearance Misoprostol 400 mcg tablets, vaginally, once
2573216|NCT02412332|No Intervention|Group 1 - Control|The patients will be followed during the course of 12 months and evaluated regarding disease progression. No interventions will be performed other than conventional (in-course) treatment.
2573218|NCT02412332|Experimental|Group 2 - BMMC|Patients will be submitted to bone marrow harvesting. Bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation and returned to patients by systemic infusion (1x10^8 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
2573222|NCT02412332|Experimental|Group 3 - ASC|Patients will be submitted to liposuction. The obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) will be returned to patients by systemic infusion (1x10^8 ASC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
2573223|NCT02412332|Experimental|Group 4 - BMMC + ASC|Patients will be submitted to liposuction and the obtained fat tissue will be cultivated by 21 days and adipose-derived stem cell (ASC) obtained. Patients will be submitted to bone marrow harvesting and bone marrow mononuclear cells (BMMC) will be obtained by Ficoll separation. BMMC and ASC will be returned to patients by systemic infusion (5x10^7 ASC + 5x10^7 BMMC in 30 mL saline). Three patients will be submitted to Lung perfusion scintigraphy with technetium for cell engraftment evaluation.
2573242|NCT02412020|Experimental|PA101|PA101, 40 mg administered via inhalation three times daily for 14 days
2573243|NCT02412020|Placebo Comparator|Placebo|Placebo PA101, administered via inhalation three times daily for 14 days
2573312|NCT02411812|Experimental|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
2573314|NCT02411812|Active Comparator|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
2573315|NCT02411812|Active Comparator|Twin-Block appliances|Group treated with Twin-Block appliance.
2573337|NCT02411409|Experimental|Intervention group|This group of patients receives the HealtheRx.
2573338|NCT02411409|No Intervention|Control group|This group of patients does not receive the HealtheRx
2573442|NCT02410876||Spinal cord injury/acontractile|"Patients with traumatic spinal cord injury (SCI) with no (neither spontaneous nor provoked) detrusor activity during the filling phase of urodynamics.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
3209571|NCT00986219||Asthma Language between patients and physicians|
3209572|NCT00986271|Other|With and without MODS developement|EVLI was determinated by PiCCO plus system.
3209573|NCT00986284|Experimental|Gefitinib, Neoadjuvant therapy|Patients with EGFR mutation will be recruited and treated with gefitinib.
2572735|NCT02415465|Active Comparator|Combined Spinal Epidural|Spinal Intraoperative Anesthesia with standard Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus) with standard post-operative analgesics.
2572745|NCT02415465|Active Comparator|General+Continuous Adductor Canal Block|General Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
2572748|NCT02415465|Active Comparator|Spinal+Continuous Adductor Canal Block|Spinal Intraoperative Anesthesia with standard post-operative Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr) with standard post-operative analgesics.
2572803|NCT02414815|Experimental|AF group|Atrial fibrillation
2572829|NCT02414672|Experimental|CareSTEPS|CareSTEPS provides skills training in six domains that are central to the caregiving role: self-care, stress management, symptom management, effective communication, problem-solving, and social support.
2572831|NCT02414672|No Intervention|Usual Medical Care (UMC)|Patients receive standard oncologic and generalist palliative care from their healthcare team.
2572867|NCT02414451|Experimental|Propranolol arm|"Propranolol will be administered via oral capsule(s) daily for a period of 10 weeks, involving gradual titration up from 40mg to 100mg and subsequent tapering off of the drug. The titration/tapering schedule will be as follows:~Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules"
2572868|NCT02414451|Placebo Comparator|Placebo arm|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
2572930|NCT02414217|Experimental|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
2572932|NCT02414217|Experimental|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
2572934|NCT02414217|No Intervention|Control|Participants were given written educational materials about diabetes.
2572949|NCT02413723|Active Comparator|Videolaryngoscope McGrath Mac|McGrath Mac videolaryngoscope will be used for laryngoscopy for patient's intubation
2572954|NCT02413723|Placebo Comparator|Standard laryngoscope|Macintosh laryngoscope will be used for laryngoscopy for patient's intubation
3209574|NCT00986297|Other|arm one|IGRT
3209575|NCT00986323|Active Comparator|Temeperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
2573202|NCT02412384||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2573205|NCT02412384||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2573210|NCT02412384||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
2573214|NCT02412384||Cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2573264|NCT02412033|Active Comparator|Misoprostol group|Going to receive 400 µg misoprostol vaginally 3 hours before IUD insertion.
2573269|NCT02412033|Placebo Comparator|Placebo group|Going to receive placebo.
3209576|NCT00986323|Placebo Comparator|Placebo TLA|Placebo TLA treatment
3209577|NCT00986336|Experimental|001|
2573419|NCT02411019||Observational group|Subjects in the period less than 24 weeks after the final administration of GX-188E
3209578|NCT00986336|Experimental|002|
2573583|NCT02410239|Experimental|Mesenchymal Stem Cell|Third party donor Mesenchymal Stem Cells (MSC) will be administered via intrathecal administration at the assigned dose on days 0, 7 and 14. Dose escalation will be guided by a fast track design. One patient is entered per dose level until a DLT is experienced. At that point, two additional patients will be enrolled at the same dose level. Dose levels will be 2.5 x 10e6 MSC/kg per dose, 5 x 10e6 MSC/kg per dose or 7.5 x 10e6 MSC/kg per dose.
3209579|NCT00986336|Experimental|003|
3209580|NCT00986336|Experimental|004|
3209581|NCT00986375|Experimental|Intervention Group (IG)|Patients in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
3209582|NCT00986375|Active Comparator|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
3209583|NCT00986414|Experimental|AFQ056-10mg|
3209584|NCT00986414|Experimental|AFQ056-25mg|
3209585|NCT00986414|Experimental|AFQ056-50mg|
3209586|NCT00986414|Experimental|AFQ056-75mg|
3209587|NCT00986414|Experimental|AFQ056-100mg|
3209588|NCT00986414|Placebo Comparator|Placebo|
3209589|NCT00986466|Experimental|exercise with vitamin D 800 IU/d|
3209590|NCT00986466|Active Comparator|exercise with placebo|
3209591|NCT00986466|Active Comparator|no exercise with vitamin D 800 IU/d|
3209592|NCT00986466|Placebo Comparator|no exercise with placebo|
3209593|NCT00986505|Experimental|Lidocaine|Comparison between intravenous lidocaine and saline infusion
3209594|NCT00986518|Experimental|adaptive cell immunotherapy|
3209595|NCT00986531|Experimental|1|80 mg AZD8529
2572558|NCT02416466|Experimental|anti-CEA CAR-T cells + Sir-Spheres|Three infusions of gene-modified anti-CEA T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach along with low dose IL-2. A single dose of Sir-Spheres will be given 2 weeks following the final T cell dose.
2572647|NCT02415881|Experimental|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye800 prior to their scheduled surgery.
2572699|NCT02415504|Experimental|Enhanced care transition|The enhanced care transition will offer: (1) an integrated behavioural care plan, (2) an in- person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
2572701|NCT02415504|Other|Standard care transition|The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
2572715|NCT02415231|Experimental|humor|humor group will watch humor video for 20 minutes
2572719|NCT02415231|No Intervention|control non humor|control group did not watch humor, they sat quietly for 20 minutes.
2572755|NCT02415101|Active Comparator|Resective surgery after 4-6 weeks|Resective surgery 4-6 weeks after completed chemoradiotherapy (CRT)
2572759|NCT02415101|Active Comparator|Resective surgery after 10-12 weeks|Resective surgery 10-12 weeks after completed chemoradiotherapy (CRT)
2572808|NCT02414802|Experimental|Combined thrombectomy device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis. Ten million U of urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
2572810|NCT02414802|Other|Catheter-directed thrombolysis|Participants will undergo catheter-directed thrombolysis alone. A total of 100,000 units urokinase will be pulse-spray injected through the catheter once every 4-6 h. Anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) at discharge
2572864|NCT02414477|Experimental|Smokeless tobacco study product|Smokeless tobacco product spiked with deuterated NNN.
3175602|NCT00635986|Experimental|A|group 1 (n = 14) patients received 5 mL of a 100 mcg Fentanyl solution in saline without preservative by the epidural route and 2 mL saline intravenously. Group 2 (n = 15) patients received 5 mL saline by the epidural route and 2 mL (100 mcg) Fentanyl intravenously
3175603|NCT00636012|Experimental|1|verum acupuncture
3175604|NCT00636012|Sham Comparator|2|sham acupuncture
2573113|NCT02412904|Other|drug to ovulation induction: rFSH|Patients submitted to IVF that will use rFSH (Puregon®, Organon Ltd., Ireland) for ovarian stimulation
2573114|NCT02412904|Other|drug to ovulation induction :HMG|Patients submitted to IVF that will use hMG (Menopur®, Ferring Pharmaceuticals, Denmark) for ovarian stimulation
3175605|NCT00636025||Observational|
3175606|NCT00636051||1|staff Registered Nurses receiving EBP peer mentoring
2573215|NCT02412293|Experimental|Intervention|"Health Education & Promotion: LHWs and CHWs will delivered the package via community awareness sessions and two one-to-one counselling sessions to pregnant women during third trimester and five newborn assessment visits in the neonatal period in intervention areas.~Training of Health Workers: The LHWs and CHWs will receive trainings on IMNCI-based training package.~Community Mobilization: For community mobilization and education, two types of tools will be used one group session by use of flip charts and group session by use of video."
2573219|NCT02412293|No Intervention|Control|Control areas will continue to receive the routine standard health services of governmental and non-governmental organizations in the area.
2573230|NCT02412059|Experimental|Prednisolone|Pred Forte (prednisolone acetate ophthalmic suspension, USP) 1% sterile
2573232|NCT02412059|No Intervention|Control|Patients in control group will not be given a corticosteroid as per usual standard of care.
2573260|NCT02411942|Experimental|Adapalene Gel 0.3%|Adapalene Gel 0.3% (Taro Pharmaceuticals Inc.)
2573265|NCT02411942|Active Comparator|Differin®|Differin® (adapalene gel 0.3%) (Galderma Laboratories, LP, US)
2573267|NCT02411942|Placebo Comparator|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
2573292|NCT02411708|Experimental|SANGUINATE|320 mg/kg
2573293|NCT02411708|Placebo Comparator|Placebo|Normal saline IV infusion
3175607|NCT00636051||2|staff Registered Nurses not receiving EBP peer mentoring
3175608|NCT00636064|Placebo Comparator|A|
3175609|NCT00636064|Experimental|B|
3175610|NCT00636064|Experimental|C|
3175611|NCT00636103|Experimental|CUF2|
3175612|NCT00636103|Placebo Comparator|Placebo|
3175613|NCT00636116|Experimental|Group 1|Anavip with Anavip Maintenance Therapy
3175614|NCT00636116|Experimental|Group 2|Anavip with Placebo Maintenance Therapy
3175615|NCT00636116|Active Comparator|Group 3|CroFab with CroFab Maintenance Therapy
3175616|NCT00636129||1|Relaxation Response + Stress Management Curriculum
3175617|NCT00636142|Active Comparator|1|Infliximab
3175618|NCT00636142|Placebo Comparator|2|Placebo
3175619|NCT00636233||Anencephaly|Fetuses with anencephaly, parents and siblings
3175620|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/4|
3175621|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/6|
3175622|NCT00636246|Active Comparator|sertraline-satellite|
3175623|NCT00636246|Active Comparator|sertraline-main|
3175624|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-satellite150/2|
3175625|NCT00636246|Placebo Comparator|Placebo|
3175626|NCT00636246|Experimental|Sertraline/[S,S]-Reboxetine-main|
3175627|NCT00636246|Active Comparator|[S,S]-reboxetine-main|
3175628|NCT00636285|Placebo Comparator|1|Placebo
3175629|NCT00636285|Experimental|2|BSYX-A110, Dosed intravenously, 3mg/kg
3175630|NCT00636285|Experimental|3|BSYX-A110, Dosed intravenously, 10mg/kg
2572590|NCT02416245|Experimental|Test beverage powder|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
2572591|NCT02416245|Placebo Comparator|Control beverage powder|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
3209596|NCT00986531|Placebo Comparator|2|Placebo
3209597|NCT00986596|Active Comparator|vitamin D3|vitamin D3 capsule 4000 IU p.o. daily
3209598|NCT00986596|Placebo Comparator|placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
3209599|NCT00986609|Experimental|Arm I|Patients receive MUC-1 peptide vaccine subcutaneously and poly-ICLC vaccine intramuscularly in weeks 0, 4, 8, 12, 52, and 56, in the absence of disease progression or unacceptable toxicity. Patients may receive additional vaccines in weeks 34 and 38 if anti-MUC1 immunity falls below the two-fold enhancement from baseline
3209600|NCT00986661|Experimental|PV-10 Injection (Intralesional)|Subjects in each of three cohorts will receive a single dose of PV-10 to one Target Lesion.
2572751|NCT02415153|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.
2572840|NCT02414750|Experimental|Treatment with BRAF/MEK inhibitor|"Treatment with vemurafenib 2dd 960 mg 28/28 plus cobimetinib 1dd 60 mg 21/28. During treatment patient will undergo PET scanning with FLT and FDG, to compare both types of PET scanning.~During the study biopsies and blood will be taken from the patients."
2573027|NCT02413567|Experimental|DMR Procedure|Subjects receive the endoscopic DMR procedure in this arm
2573090|NCT02413060|Experimental|Resistance training|Patients of treatment group will undergo resistance training every week sessions
2573093|NCT02413060|Other|Lifestyle counseling|Patients of control group will get the lifestyle counseling every 3 month
3209601|NCT00986687||Vitrified oocytes|
3209602|NCT00986687||Control oocytes|
3209603|NCT00986700|Other|different types of bad time food|Different types of bad time food
3209604|NCT00986752|Active Comparator|Stenting|Due to randomization one nitinol stent will be implanted after dilation with a conventional balloon.
3209605|NCT00986752|Experimental|Stenting after PEB|Due to randomization one nitinol stent will be implanted after dilation with a Paclitaxel eluting balloon.
3209606|NCT00986752|Experimental|Atherectomy|The third randomization arm is Atherectomy.
3209607|NCT00986765|Experimental|Lovenox® , 4000 UI/day (+ Aspegic®)|Lovenox® (enoxaparin), 4000 UI/day (+ Aspegic® (Aspirin), 100 mg)
3209608|NCT00986765|Active Comparator|Aspegic ®, 100 mg/day|Aspegic® (Aspirin),100 mg/day
3209609|NCT00986778|Active Comparator|Lamivudine plus Adefovir|
2573414|NCT02411344|Experimental|Pertuzumab, Trastuzumab, Letrozole|
2573489|NCT02410668|Active Comparator|Flaxseed|30 grams Flaxseed powder combine with dietary and exercise recommendation
2573493|NCT02410668|Placebo Comparator|control|dietary and exercise recommendation
3209610|NCT00986778|Active Comparator|Entecavir|
3209611|NCT00986778|Experimental|Entecavir plus Adefovir|
2573763|NCT02408939||Intervention|Patients resuscitated from in-hospital cardiac arrest and treated with stress-dose hydrocortisone for postresuscitation shock
2573766|NCT02408939||Control|Patients resuscitated from in-hospital cardiac arrest and treated according to contemporary standards that did not include stress-dose steroids for postresuscitation shock
2573809|NCT02408354|Active Comparator|Triheptanoin|"Triheptanoin/ Placebo Randomized to receive active Triheptanoin first for 12 weeks. At cross-over, participants will receive placebo for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between triheptanoine and placebo phases."
2573814|NCT02408354|Placebo Comparator|Placebo|"Placebo / Triheptanoin Randomized to receive active Placebo first for 12 weeks. At cross-over, participants will receive Triheptanoin for 12 weeks.~Each drug will be dispensed successively. A one-month wash out period is planned for 4 weeks between placebo and triheptanoin phases."
2573854|NCT02407951|Experimental|CBIT group|
2573858|NCT02407951|Placebo Comparator|Psycho-Educational group|
3209612|NCT00986791|No Intervention|Control group|Treatment as usual
3209613|NCT00986791|Experimental|GSP-A|Gold-Standard-Program for Alcohol cessation intervention (GSP-A): 6-week intensive patient education program with pharmaceutical support
3209614|NCT00986804|Experimental|Level 1|Decitabine 5.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3209615|NCT00986804|Experimental|Level 2|Decitabine 7.5 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3209616|NCT00986804|Experimental|Level 3|Decitabine 10.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3209617|NCT00986804|Experimental|Level 4|Decitabine 15.0 mg/m2/day on Days 1 thru 5 every 6 weeks for as many as 8 cycles.
3209618|NCT00986817|Experimental|Terlipressin|
3209619|NCT00986817|Placebo Comparator|Placebo|
3209620|NCT00986843|Experimental|HM30181AK tablet + Irinotecan tablets|HM30181AK tablet + Irinotecan tablets
3209621|NCT00986869||echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
3209622|NCT00986882|Experimental|SAF312A (2 doses in part B; 5 - 6 doses in part C)|
3209623|NCT00986882|Placebo Comparator|Placebo|
3209624|NCT00986882|Active Comparator|Ibuprofen|
3209625|NCT00986960|Active Comparator|Adrenocorticotropin hormone|Patients receive the hormone
3209626|NCT00986960|Placebo Comparator|Placebo|Patients receive placebo only
3209627|NCT00987012|Experimental|Pomegranate juice|
3209628|NCT00987012|Placebo Comparator|Placebo drink|
3209629|NCT00987025|Experimental|Telehealth|Telehealth participants will be recruited from centers that have a telehealth blood pressure station installed. Participants will be asked to use the station once per week. Blood pressure measures will be monitored by nurse researchers - out of range values will result in appropriate medical recommendations.
3209630|NCT00987025|Active Comparator|Control|Control participants will receive education material.
2572598|NCT02416076|Active Comparator|Group A - LT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at the default Energy Level [EL2].
2572599|NCT02416076|Active Comparator|Group B - RT side simulines Ulthera treatment at EL2|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at the default Energy Level [EL2] .
2572600|NCT02416076|Active Comparator|Group C - LT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
2572601|NCT02416076|Active Comparator|Group D - RT side simulines Ulthera treatment at EL4|Ulthera treatment using 'Ulthera System, prototype simulines transducers' on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFT side of the face at a higher Energy Level [EL4] .
2572602|NCT02416076|Active Comparator|Group E - LT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers' and 7-3.0 'Ulthera System, standard transducers' on the LEFT side of the face and 'Ulthera System, standard transducers' on the RIGHT of the face at a higher Energy Level [EL4].
2572605|NCT02416076|Active Comparator|Group F - RT side simulines/standard Ulthera treatment at EL4|Ulthera treatment using a 4-4.5 'Ulthera System, prototype simulines transducers'and 7-3.0 standard transducer on the RIGHT side of the face and 'Ulthera System, standard transducers' on the LEFTof the face at a higher Energy Level [EL4].
2572653|NCT02415790|Experimental|Part A: PK of E2027 in healthy adults|Part A consists of 6 sequential cohorts of healthy adults. There will be 8 participants in each cohort, with 6 participants randomized to E2027 and 2 participants to placebo.
2572654|NCT02415790|Experimental|Part B: PK and PD of E2027 in healthy adults|Part B consists of 4 sequential cohorts of healthy adult participants. There will be 8 participants in the 1st cohort, with 6 participants randomized to E2027 and 2 participants to placebo. In the 2nd to 4th cohorts, there will be 7 participants in each cohort, with 6 participants randomized to E2027 and 1 participant to placebo. Participants in the 2nd cohort will then receive placebo/the same dose of E2027 again after their washout period in the fed state for the evaluation of food effect.
2572657|NCT02415790|Experimental|Part C: PK of E2027 in elderly cohorts|In Part C, 1 cohort of 8 healthy elderly participants will be enrolled, with 6 participants randomized to E2027 and 2 participants to placebo.
2572660|NCT02415790|Experimental|Part D: PK of E2027 in healthy Japanese adults|In Part D, there will be 3 cohorts of 7 healthy adult Japanese participants, with 6 participants randomized to E2027 and 1 participant to placebo.
2572734|NCT02415361|No Intervention|Arm A|"Standard care consists of:~a phone call from a CLP-nurse after the referral from the local birth hospital has been received~telephone service at parents request and at the staffs availability~invitation to a one-day-information course before surgery"
2572741|NCT02415361|Active Comparator|Arm B|"Systematic follow up by a special trained nurse consists of:~telephone contact with the parents shortly after birth~visit at the maternity ward within 36 hours after the referral has been received~telephone follow ups at specific times and at parents request~guidance and support in feeding and treatment~written information~cooperation with the staff at the maternity unit and the health centre~follow up in accordance with a check-list and log~invitation to a one-day-information course before surgery"
3209631|NCT00987038|Other|PF-04171327 and Midazolam|
3209632|NCT00987051|Experimental|1|Patients with endometrial cancer
2572878|NCT02414464|Experimental|35% hydrogen peroxide|Volunteers of this group will receive a gel with 35% hydrogen peroxide - Whiteness HP 35% for whitening treatment.
2572879|NCT02414464|Experimental|35% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 35% for whitening treatment.
2572880|NCT02414464|Experimental|20% hydrogen peroxide with calcium|Volunteers of this group will receive a gel with 35% hydrogen peroxide with calcium - Whiteness HP Blue Calcium 20% for whitening treatment.
2572897|NCT02414100||Patient derived cancer cell lines|Patients receive gemcitabine hydrochloride IV qw 3/4 wk or gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV qw 3/4 wk in the absence of disease progression or recurrence per standard of care. Tissue and blood samples are collected for genetic analysis via sequencing.
2572972|NCT02413905||Senegal|Stool samples on Children with and without severe acute malnutrition in Senegal recruited in 3 locations (Dakar, Dielmo and Ndiop)
2572978|NCT02413905||Niger|Stool samples Children with and without severe acute malnutrition in Niger recruited in Niamey
2573017|NCT02413476|Experimental|Robotic-assisted Gastrectomy(RAG)|Robotic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
2573022|NCT02413476|Active Comparator|Laparoscopic-assisted Gastrectomy(LAG)|Laparoscopic-assisted Gastrectomy will be performed for the treatment of patients assigned to this group.
2573068|NCT02413112|Experimental|Training once per week|Subjects train once per week in the University gym. All training sessions are supervised by the researchers.
2573073|NCT02413112|Experimental|Training twice per week|Subjects train twice per week in the University gym. All training sessions are supervised by the researchers.
2573080|NCT02413112|Experimental|Thrice per week|Subjects train three times per week in the University gym. All training sessions are supervised by the researchers.
2573081|NCT02413112|No Intervention|Non-training Control group|Subjects continue with their normal daily lives, just performing measurements
2573129|NCT02412839||Group 20-39|Patients aged from 20 to 39 years old. 30 males and 30 females.
2573131|NCT02412839||Group 40-59|Patients aged from 40 to 59 years old. 30 males and 30 females.
3209633|NCT00987064|Active Comparator|Temperature controlled Laminar Airflow|Active treatment with Temperature controlled Laminar Airflow (TLA)
3209634|NCT00987064|Placebo Comparator|Placebo TLA|Placebo treatment with TLA (no filtration function)
3260228|NCT01477502|Active Comparator|individual homeopathic treatment|participants receive homeopathic treatment in addition to standard prevention measures for UTI
3260229|NCT01477502|Other|standard prophylaxis|
3260230|NCT01477515||End stage renal disease patient|
3260231|NCT01477515||Matched controls|
2572615|NCT02416089|Experimental|Tampostat|Tampostat™ is a self-regulating, low cost, pressure based emergency obstetric device designed specifically for use in low-resource settings. It has 6 parts: probe, condom, O ring, nerve centre, tube and bulb pump. It offers significant benefits over the current model by simplifying the insertion process, reducing the need for constant monitoring, eliminating leakage and the need for sterile saline, and using a pressure-based mechanism to apply consistent pressure to all women regardless of uterus size.Women who develop PPH even after applying AMTSL at the hospital or women who visit the hospital with PPH within 24 hours after delivery will be managed by Tampostat for the intervention arm or by the condom catheter tamponade in the control arm(172 patients in each arm)
2572618|NCT02416089|Active Comparator|Condom catheter tamponade|Condom catheter tamponade have been used by medical professionals for several years in the management of atonic (primary) PPH. In this approach, Sterile rubber catheter fitted with a condom as a tamponade balloon device and using normal saline to inflate the condom.
2572743|NCT02415179|Experimental|Inhaled Mometasone/formoterol|Inhaled Mometasone/Formoterol (100/5 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
2572746|NCT02415179|Active Comparator|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
2572799|NCT02414867||1|Normal weight mothers
2572801|NCT02414867||2|Overweight/Obese mothers
2572859|NCT02414737|Experimental|corifollitrophin alfa|corifollitrophin alfa used as COH stimulant in IVF
2572906|NCT02414295|Experimental|Mesenchymal stem cell injection|Bone marrow Mesenchymal stem cell injection in the testicular tubules and testicular artery
2572976|NCT02413931||Patients with MDR-TB|Patients with multidrug-resistant tuberculosis admitted for treatment at the Marius Nasta Institute will be included
2573031|NCT02413554|Experimental|Patch applied patients|"The investigators had enrolled consecutively the patients who were going to operation after femur neck fracture.~Participants were applied the 5 unit rivastigmine patches from 3 days before and 7 days after the femur neck operation."
2573040|NCT02413554|No Intervention|Patch non-applied patients|The participants who were going to operation after femur neck fracture were not applied the rivastigmine patches.
2573087|NCT02413125|Experimental|ChitoRino irrigation solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer 1 packet of ChitoRhino irrigation solution (premixed from manufacturer containing sea salt, Chitosan, and sodium bicarbonate). An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
2573089|NCT02413125|Experimental|Normal saline solution|The study participants will be provided a NeilMed irrigation bottle and instructed to administer nasal saline (250mL of 0.9% sodium chloride) irrigation solution. An informational sheet regarding care and cleaning of the irrigation bottle will be provided during the initial visit. Participants will be instructed to complete up to three nasal saline irrigations daily for 1 month and keep a log to determine compliance. After 1 month of use, the irrigation bottle will be returned at a second study visit.
2573122|NCT02412787|Experimental|Idursulfase-IT|Participants will receive 10 milligrams (mg) of idursulfase-IT intrathecally via intrathecal drug delivery device (IDDD) or lumbar puncture (LP) once every 28 days along with standard-of-care therapy with Elaprase for 480 weeks. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (greater than [>] 8 months to 30 months of age) and 10 mg (>30 months to 3 years of age) of idursulfase-IT.
2573192|NCT02412410|Experimental|Single|Single arm pilot study analyzing sleep data and calculated efficacy before and after fatigue avoidance education (comparator is same group after intervention)
2573237|NCT02412241|Other|LEF Measures|"PATIENT-REPORTED OUTCOME MEASURE: Validity of LSIDS-H&N will be assessed using 6 forms (e.g., Vanderbilt Head and Neck Symptom Survey (v2.0); Neck Disability Index; and Hospital Anxiety and Depression Scale).~CLINICIAN-REPORTED OUTCOME MEASURES: External LEF will be assessed using HN-LEF Grading Criteria, CTCAE (v4.03), and digital photos of the head and neck. Internal LEF will be scored using Modified Patterson Scale through an endoscopic exam. Both external/internal measures are re-assessed for intrarater and interrater reliability.~OBJECTIVE/TECHNICAL MEASURES: Patients undergo CT scans and ultrasound exams with results re-scored for intrarater and interrater reliability."
2573302|NCT02411890|Experimental|Adductor canal block|Adductor canal block (active) + Femoral nerve block (sham block)
2573305|NCT02411890|Active Comparator|Femoral nerve block|Femoral nerve block (active) + Adductor canal block (sham block)
3260232|NCT01477541|Experimental|PM/ON integration arm|Health centers where professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
2573404|NCT02411071||Patients starting cART|Patients starting cART. Grouping according to the time needed to reach viral loads below 1000, 500, 400, 200, 50 copies/ml, respectively.
2573407|NCT02411071||Patients with cART|Patients with cART. Grouping in patients without and with low-level-viremia (LLV) defined as two consecutive viral loads between 40 copies/ml and 200 copies/ml, 400 copies/ml, 500 copies/ml and 1000 copies/ml, respectively.
2573423|NCT02410902|Experimental|CM-AT|Active substance in single unit dose powder
2573425|NCT02410902|Placebo Comparator|Placebo|Placebo powder of inactive substance
2573487|NCT02410447|Experimental|Treatment Group|"Defocused shock waves were provided by an electromagnetic generator (DUOLITH® SD1 - Storz Medical AG, Tägerwilen, Switzerland).~The protocol consisted of a series of 3 sessions in 2 weeks, 2 treatments a week. For each patient, a different number of impulses per session was delivered, depending on wound size (300 impulses + 100 impulses per cm2 wound-surface), at an energy flux density of 0.15 mJ/mm2 and a frequency of 5 pulses/s."
2573539|NCT02410304|Other|Arm C (Clinical)|No drug and no placebo were used in this arm. Patients were followed only by clinical évaluation.
2573540|NCT02410304|Other|Arm B (Clinical + Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Clinical evaluation in combination with ultrasound (in B mode).
2573541|NCT02410304|Other|Arm D (Ultrasound)|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach in D mode.
2573610|NCT02409641|Experimental|30 healthy male and female subjects|30 healthy male and female subjects , age 18-35 years
2572717|NCT02415309|Active Comparator|10 mg Melatonin|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of 10mg melatonin.
2572721|NCT02415309|Placebo Comparator|Sugar Pill|To remain within the doses used for anxiolytic effects in past studies, we plan to study the effects of two different levels of melatonin versus placebo as premedication in patients undergoing a lumbar medial branch block (LMBB) procedure.
2572776|NCT02414919||HERC|Women who had an insertion of HERC (Mirena IUD, ParaGard IUD, Implanon or Nexplanon)
2572866|NCT02414724|Experimental|Treatment (ribociclib, gemcitabine hydrochloride)|Patients receive ribociclib PO on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3175631|NCT00636298|Experimental|A|Single arm treatment with combination of cetuximab and bevacizumab
3175632|NCT00636311|Active Comparator|1|IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine)
3175633|NCT00636311|Experimental|2|B-IGEV (Bortezomib + IGEV)
3175634|NCT00636324|Experimental|1|Nasal CPAP, level of 7 to 9 cmH2O
3175635|NCT00636324|Active Comparator|2|Nasal CPAP, level 4 to 6 cmH2O
3209635|NCT00987077|Experimental|Selective Retinatherapy (SRT)|Treatment was performed with the SRT-Laser system (Medical Laser Center Lübeck, Germany), which consists of a Q-switched frequency doubled Nd:YLF laser (527nm), operating with a pulse repetition rate of 100 Hz. The pulse duration (full width at half maximum) was 1.7 µs. The laser energy was transmitted via fiber to a Lumenis slitlamp allowing the application of a fixed spot size diameter of 200 µm in air. A Mainster central field contact lens with a magnification of 1.05 was used for all irradiations. Per foot switch, 30 pulses are emitted, the pulse energy was chosen by the physician up to a maximum of 370 µJ. According to the treatment protocol, prior to each treatment 5 test shots with increasing energy were applied adjacent to the vessel arcades, in each patient in order to determine the appropriate pulse energy for treatment by recording the OA-value.
3209636|NCT00987077|No Intervention|control group|Patients randomized to control group achieve no treatment and are followed up for three months.
2573014|NCT02413528|Sham Comparator|Standard Care with Medication Monitoring|"Patients will be given an inhaler sensor to monitor medication use and a sham version of the mobile app that will not include reminders or incentives.~Intervention: Inhaler sensor"
2573020|NCT02413528|Experimental|Medication Monitoring and Mobile App|"Patients will be given an inhaler sensor to monitor medication use and a mobile phone application that will send them reminders and provide an opportunity to see their own medication use and win incentives for adherence.~Interventions: Inhaler sensor and mobile application for asthma adherence"
2573060|NCT02413164|Experimental|Physical intervention group|12 weeks of groupal sessions of individualised multimodal physiotherapy programme of therapeutic exercises with education healthy-style-of-life based, 2 times for week.
2573061|NCT02413164|No Intervention|Control group|This group will receive usual care and will be in wait list status for the duration of study, later the intervention will be offered to this group.
2573091|NCT02412943|Experimental|PAPP-A2 Enzyme Replacement|A 20 cc/kg transfusion of Fresh Frozen Plasma will be given over 3 hours on day 0.
2573137|NCT02412774|Experimental|Diet Beverages (DBs)|Diet beverages after the main meal+ Diet
2573142|NCT02412774|Experimental|Water|Water after the main meal+ Diet
2573193|NCT02412449|Experimental|Treatment A|AKB-6548
2573195|NCT02412449|Experimental|Treatment B|AKB-6548
2573197|NCT02412449|Experimental|Treatment C|AKB-6548
2573239|NCT02412163||IM HTO Nail|Implant with the Ellipse IM HTO Nail
2573304|NCT02411838|No Intervention|Control group|Steroid treatment (10 total days), which is a standard therapy for significant MS relapses.
2573308|NCT02411838|Experimental|Calorie restriction|"The intervention in this group will be to undergo a regimen of calorie restriction through fasting every other day (named alternate day fasting).~Specifically this group will undergo alternate day fasting plus the same steroid regimen as the control group (CR GROUP).~During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of IVMP) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point."
2573364|NCT02411279||Groupe 1: experimental group|Equiped group with telemedicine systems
2573367|NCT02411279||Groupe 2: control group|Non equiped group with telemedicine systems
2573410|NCT02411097|Experimental|femoral nerve block|femoral nerve block will be administered before or after the surgery
3260233|NCT01477541|No Intervention|Control|
3260234|NCT01477554|No Intervention|Control|Hospitals randomized to the control arm do not receive any intervention.
2573636|NCT02409420|Experimental|PACT|PACT: a brief physiotherapy intervention based on ACT principles optimised to promote self-management. ACT aims to promote the acceptance of pain, the belief that it is not always necessary to change pain to move forward and the understanding that focusing on pain avoidance.
2573642|NCT02409420|No Intervention|Control|Usual care
2573723|NCT02409264|Experimental|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the determined individualised homeopathic remedy, in the potency decided by the researcher in accordance with the laws that govern homeopathic prescribing. The dose and repetition of the remedy will be determined by the researcher in accordance with the aforementioned laws. A remedy will be prescribed every 2 weeks, after its determination by the researcher. No remedy will be prescribed after week 8.
2573761|NCT02408744|Experimental|Pirfenidone|Pirfenidone 1200 mg in the form of prolonged-released tablets, orally administered two times a day (b.i.d.) to yield a daily dose of 2400 mg during three years.
2573829|NCT02408159|Experimental|Varicella Zoster Vaccine|Sterile, lyophilized white to off-white compact crystalline plug in a single-dose vial. Each vial contains one dose of lyophilized vaccine (approximately 0.65 mL when reconstituted as directed). The diluent (0.7 mL) is a sterile, clear, colorless fluid supplied separately in a 3 mL single-dose vial. A single dose will be administered to subjects at baseline.
2573832|NCT02408159|Placebo Comparator|0.9% Sodium Chloride|"United States Pharmacopeia (USP), preservative free for injection supplied in a single dose vial.~A single dose will be administered to subjects at baseline."
2573862|NCT02407808|Active Comparator|THC|Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.
2572742|NCT02415270|Experimental|Reduced ROS/RNS|Participants will be randomized to receive Reduced Oxidative/Nitrogen Species (ROS/RNS) cigarettes to replace their usual cigarettes.
2572747|NCT02415270|Placebo Comparator|Control Group|Participants will be assigned to continue smoking their usual brand of cigarettes.
3209637|NCT00987077|Experimental|crossover|After 3 months follow up patients of control group with persistence of disease activity were allocated to crossover group and received either SRT. Crossover group was followed up for further 3 months.
3209638|NCT00987090|Active Comparator|Alzheimer Disease|subjects who have developed symptoms of Alzheimer Disease aged from 45 to 85 years old
3209639|NCT00987090|Placebo Comparator|Control|subjects without symptoms of Alzheimer Disease aged from 45 to 85 years old.
3209640|NCT00987103|Experimental|Sublingual - Rectal - Oral|Administration order of rank: Sublingual - Rectal - Oral
3209641|NCT00987103|Experimental|Sublingual - Oral - Rectal|Administration order of rank: Sublingual - Oral - Rectal
2573357|NCT02411357|Active Comparator|Treatment as usual|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
2573358|NCT02411357|Experimental|WHO contraception protocol|The WHO contraception protocol condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits.
2573360|NCT02411357|Experimental|WHO contraception protocol + incentives|The WHO + incentives condition will receive the World Health Organization's contraception protocol and will be invited to attend follow-up visits, but will also receive financial incentives contingent on attending those follow-up visits.
2573399|NCT02411058|Experimental|Uninformed|Condition 1
2573401|NCT02411058|Experimental|Informed about Incentives and Purpose|Condition 2
2573434|NCT02410850||University of Montreal|Patients from University of Montreal in Canada
2573441|NCT02410850||University of Antwerp|Patients from University of Antwerp in Belgium.
2573445|NCT02410850||University of Sydney|Patients from University of Sydney in Australia.
2573449|NCT02410850||Angers University Hospital|Patients from Angers University Hospital in France.
2573452|NCT02410850||University of Gronigen|Patients from University of Gronigen in Netherlands.
2573453|NCT02410850||Kaiser Permanente|Patients from Kaiser Permanente from USA.
2573456|NCT02410850||Stanford University|Patients from Stanford University from USA.
2573458|NCT02410850||Laval University|Patients from Laval University in Canada.
2573460|NCT02410850||Cambridge University|Patients from Cambridge University in UK.
2573461|NCT02410850||Kyushu University|Patients from Kyushu University in Japan
2573465|NCT02410850||Japan Somnology Center|Patients from Japan Somnology Center in Japan.
2573467|NCT02410850||Uniformed Services University|Patients from the Uniformed Services University in USA.
2573468|NCT02410850||University of British Columbia|Patients from the University of British Columbia in Canada.
2573531|NCT02410369|Active Comparator|S-588410|Subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
2573532|NCT02410369|Placebo Comparator|Placebo|Subjects with HLA-A*2402 in the placebo arm will receive the subcutaneous administration of placebo.
2573570|NCT02409992|Experimental|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting intervention.
2573573|NCT02409992|Active Comparator|Parent Training Only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
3209642|NCT00987103|Experimental|Oral - Sublingual - Rectal|Administration order of rank: Oral - Sublingual - Rectal
2573683|NCT02409017|Active Comparator|Protocol A|Our current standard during labor
2573685|NCT02409017|Active Comparator|Protocol B|Another commonly accepted alternative for insulin drip management during labor
3209643|NCT00987103|Experimental|Oral - Rectal - Sublingual|Administration order of rank: Oral - Rectal - Sublingual
3209644|NCT00987103|Experimental|Rectal - Sublingual - Oral|Administration order of rank: Rectal - Sublingual - Oral
2573793|NCT02408276||dGEMERIC MRI technique|All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant.
3209645|NCT00987103|Experimental|Rectal - Oral - Sublingual|Administration order of rank: Rectal - Oral - Sublingual
3209646|NCT00987116|Active Comparator|Starting dose Prednisone Azathioprine|Classical Strategy
3209647|NCT00987116|Active Comparator|Starting dose Prednisone - Azathioprine|Rapid strategy
3209648|NCT00987142|Experimental|CX501|Cultured chimeric skin
3209649|NCT00987142|Active Comparator|Non adherent dressing|Occlusive non adherent dressing
3209650|NCT00987155|Experimental|high intensity interval training|8 weeks of high intensity 4 times 4 interval training at 85-90% of peak heart rate during hybrid cycling
3209651|NCT00987168|Experimental|Sandostatine LP|
3209652|NCT00987181||Angiography high risk|Patients with multiple risk factors, positive non-invasive test, or known pre-existing coronary artery/vascular disease. Patients with diabetes mellitus will be identified, and subject to a sub-group analysis.
3209653|NCT00987181||Angiography Low Risk|Patients with chest pain symptoms, minimal risk factors, and inconclusive evidence of myocardial ischaemia on non-invasive testing.
3209654|NCT00987207|Experimental|cyclosporine|A single bolus of 2.5 mg/kg cyclosporine is administered before aortic cross-declamping
3209655|NCT00987207|Other|Control|No cyclosporine A is administered before aortic cross-declamping
3209656|NCT00987220||Placebo|
3209657|NCT00987220||donepezil (Aricept)|
3209658|NCT00987233|Experimental|triamcinolone acetonide aqueous nasal spray|
3209659|NCT00987233|Active Comparator|Nasacort® AQ Nasal Spray|
3209660|NCT00987233|Placebo Comparator|Placebo|
3209661|NCT00987246|Experimental|LAS41005|
3209662|NCT00987246|Active Comparator|LAS106521|
3209663|NCT00987246|Placebo Comparator|Placebo|
3209664|NCT00987259||Post MI patients|Patients recruited following a successfully reperfused myocardial infarction using primary angioplasty.
3209665|NCT00987272|Experimental|Pataday+Pataday Vehicle|Olopatadine Hydrochloride Ophthalmic Solution 0.2%, 1 drop in 1 eye and Olopatadine 0.2% Vehicle in the contralateral eye
3209666|NCT00987272|Active Comparator|Patanol+Patanol Vehicle|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, 1 drop in 1 eye and Olopatadine 0.1% Vehicle in the contralateral eye
3209667|NCT00987285|Experimental|Computer Assisted Self Management plus Social Support|an interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media combined with enhanced support in the form of group Diabetes Care Management visits and live follow up phone calls from Diabetes Care Managers
3209668|NCT00987285|No Intervention|Usual care|will receive a health-risk appraisal, interactive CD-ROM program that provides standardized advice on behavior change, but not the hypothesized key intervention processes of goal setting, barriers identification, problem solving, or social environmental support.
3209669|NCT00987285|Experimental|Computer Assisted Self Management|An interactive, automated self-management (ASM) program that uses web and interactive voice recognition (IVR) media.
2573134|NCT02412748|Active Comparator|Financial Literacy Program|"The Financial Literacy Program (FLP) attention control condition will not receive any information on fatherhood. They will participate in a nine-session financial education program, called Money Smart, which has modules that will be facilitated by a group leader that focus on banking, borrowing, checking accounts, money management, saving, establishing and repairing a credit history, using credit cards responsibly and learning about borrowing and home ownership. They will also receive a booster session 6 weeks after the final session that focuses on setting financial goals."
2573141|NCT02412748|Experimental|BBTF Intervention|"The Building Bridges to Fatherhood (BBTF) intervention employs the following key features: a collaborative model for working with parents; vignettes of father-child models engaged in situations typical of non-resident fathers with young children for stimulating discussion and problem-solving; group discussion format, which allows fathers to support one another and share ideas on using program principles to fit within the contexts of fatherhood; homework assignments that help fathers practice the new skills at home; weekly handouts summarizing the major points discussed each week, which can be shared with others and used to gain greater support from extended family; and a Leader's Manual that standardizes the program across groups and group leaders."
2573196|NCT02412462|Experimental|AB-16B5|Single-arm study of AB-16B5 given as a 60-minute intravenous weekly infusion. One cycle of treatment will consist of 21 days. The dose levels that will be assessed are 1.5, 3.0, 6.0, 9.0 and 12 mg/kg.
2573235|NCT02412254|Active Comparator|Hearing intervention|Best practices hearing rehabilitative treatment
2573238|NCT02412254|Placebo Comparator|Successful aging intervention|Successful aging intervention
3209670|NCT00987298||Visceral fat mass|The study population will include adult men and women, ages 18 to 90 years. All subjects will be recruited at Oregon Health and Science University (OHSU). Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
3209671|NCT00987311|Active Comparator|1-Test product A|1-Dairy product containing probiotics A (test product A)
2573382|NCT02411630||Interactive Questionnaire System (iQS)|An Interactive Questionnaire System (iQS) will be administered twice. First at study entry (ATN 110/113 week 24 visit) and second at week 24 (ATN 110/113 week 48 visit). The questionnaire will assess adherence as well as how structural (physical settings) and partnership factors affect adherence of YMSM to PrEP with FTC/TDF (Truvada®).
3209672|NCT00987311|Active Comparator|2-Test product B|2-Dairy product containing probiotics B (test product B)
2573511|NCT02410486||EOS infant / mother with chorio|Infant with EOS (Gram-positive or Gram-negative) and mother with Chorioamnionitis
2573515|NCT02410486||EOS infant / mother without chorio|Infant with EOS (Gram-positive or Gram-negative) and mother without Chorioamnionitis
2573517|NCT02410486||EOS Gram-neg infant / mother with chorio|Infant with Gram-negative EOS and mother with Chorioamnionitis
2573518|NCT02410486||Gram-neg infant / mother without chorio|Infant with Gram-negative EOS and mother without Chorioamnionitis
2573521|NCT02410486||Gram-pos infant / mother with chorio|Infant with Gram-positive EOS and mother with Chorioamnionitis
2573598|NCT02409823||patients on atypical antipsychotics|
2573645|NCT02409537|Active Comparator|non cholesterolemic individuals|Individuals with normal cholesterol levels will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
2573647|NCT02409537|Active Comparator|Asymptomatic Hypercholesterolemics|individuals with high levels of cholesterol with no cardiovascular disease Those individuals will consume red wine for 1 month. There will be 1 month of wash out period. After 1 month of wash out period resveratrol will be consumed for 1 month and finally after 1 month wash out period placebo will be administered for 1 month.
2573704|NCT02409043||Control|Non-stroke participants. Blood drawn for analysis of biomarkers.
2573711|NCT02409043||Ischemic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
2573714|NCT02409043||Hemorrhagic Stroke|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, and MRI infarct size assessed in hospital. 3 month modified Rankin scale score collected by phone interview.
2573716|NCT02409043||Stroke Mimic|Participants presenting at the University of Florida Shands Emergency Department with signs and symptoms resembling a stroke, but which are determined to be from another cause. Blood drawn during initial emergency room evaluation.
2573736|NCT02408731|Experimental|Single dose of 0.005 mg/kg of PMZ-2010|A single dose of 0.005 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
2573738|NCT02408731|Experimental|Single dose of 0.01 mg/kg of PMZ-2010|A single dose of 0.01 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
2573741|NCT02408731|Experimental|Single dose of 0.05 mg/kg of PMZ-2010|A single dose of 0.05 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
2573744|NCT02408731|Experimental|Single dose of 0.10 mg/kg of PMZ-2010|A single dose of 0.10 mg/kg of PMZ-2010 (n=3) or placebo (n=1)
3209673|NCT00987311|Sham Comparator|3-Control|3-Dairy product without probiotics (control)
2572788|NCT02414880|Active Comparator|Sugammadex / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg."
2572790|NCT02414880|Active Comparator|Neostigmine / Liver cirrhosis|"Patients with liver cirrhosis, Child classification A with a Model for End-Stage Liver Disease (MELD) score <10 undergoing liver resection.~Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg."
2572863|NCT02414529|Placebo Comparator|Placebo group|"Placebo group B: single blinded to patients, receive 6 capsule PO (placebo) at once.~Subjects are blinded then they will crossover groups"
2572865|NCT02414529|Active Comparator|Treatment group|"Group A will receive 6 capsules (50.000 units/each) of vitamin D2(ergocalciferol) at once.~Subjects are blinded then they will crossover groups."
2572938|NCT02414230||Experimental F 18 T807|
3209674|NCT00987324|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent (Taxus)
2573015|NCT02413242||ICU subjects, S. aureus+ at ICU admission|"Adult ICU patients, with a positive colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Positivity of either of the two qualifies the patient to be enrolled as a subject in this group."
2573019|NCT02413242||ICU subjects, S. aureus- at ICU admission|"Adult ICU patients, with a negative colonization status for S. aureus at ICU admission, who are mechanically ventilated within 24 hours of ICU admission and have an expected length of stay of 48h or more.~Colonization status will be measured at ICU admission using a nose swab and an ETA (or sputum/throat if unavailable). Negativity of both qualifies the patient to be enrolled as a subject in this group."
3209675|NCT00987324|Active Comparator|Plain Balloon|plain balloon angioplasty
3209676|NCT00987324|Experimental|Paclitaxel-eluting balloon|SeQuent Please
3209677|NCT00987350|Active Comparator|Trivalent influenza vaccine by needle and syringe|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the standard needle and syringe method
2573263|NCT02411994|Experimental|Pyronaridine-artesunate|pyronaridine-artesunate: recommended dose according to body weight, once a day for three days.
2573268|NCT02411994|Active Comparator|Artemether-lumefantrine|artemether-lumefantrine: recommended dose according to body weight, twice a day for three days.
2573290|NCT02411721|Experimental|Animal assisted intervention|The Effects of Dog Intervention on Anxiety Levels in Children. The experimental group will receive standard training on the imaging process by the MRI technician plus intervention activity with a dog
2573291|NCT02411721|No Intervention|control group|The control group will receive the standard training on the imaging process by the MRI technician.
2573331|NCT02411617|Active Comparator|Single drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
2573334|NCT02411617|Active Comparator|Double drain in modified radical mastectomy|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
2573386|NCT02411214||<12 years|children under 12 years diagnosed with cancer questionnaire survey
2573390|NCT02411214||12-18 years|adolescents diagnosed with cancer questionnaire survey
2573394|NCT02411214||parents|parents of children and adolescents diagnosed with cancer questionnaire survey
2573433|NCT02410915|Experimental|Study Group|Intervention: Hybrid Assistive Limb (HAL); gait training in combination with conventional training. Training with the exosceleton Hybrid Assistive Limb (HAL) is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
2573440|NCT02410915|Active Comparator|Control Group|Intervention: Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
2573551|NCT02410265|Experimental|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
2573559|NCT02410265|Experimental|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
2573562|NCT02410265|No Intervention|Delayed Program|Subject assigned to this arm will receive one of the online programs in 9 months.
2573601|NCT02409862|Experimental|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
2573605|NCT02409862|Placebo Comparator|Placebo spray|This group will receive the single dose of 24 IU saline, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
2573648|NCT02409472|Other|minimal surveillance|Minimal program for colon cancer: Office visit and CEA at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, and 48 months. Liver echography* at 8, and 20 months.
3209678|NCT00987350|Experimental|Trivalent influenza vaccine by jet injection|Thirty volunteers will receive 1 intramuscular (IM) dose of licensed trivalent inactivated 2009-10 seasonal influenza vaccine by the experimental method of jet injection
3209679|NCT00987363|Experimental|Low dose (1x10 E8)|Dose of 1x10 E8 autologous bone marrow-derived mononuclear cells
2572873|NCT02414438|Experimental|FirstStep and NextStep Results|Providers receive informational webinar regarding FirstStepDx PLUS and NextStepDx PLUS between rounds and are specifically prompted to order test results in Round 2
3209680|NCT00987363|Experimental|Intermediate dose (5x10 E8)|Dose of 5x10 E8 autologous bone marrow-derived mononuclear cells
2572990|NCT02413632|Other|First period|"creation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
2572992|NCT02413632|Other|Second period|"validation of a STIs score risk~pharyngeal swab+urinary collection+blood specimens+rectal Chlamydia trachomatis l Neisseria gonorrhoeae (CT/GC) testing"
2573004|NCT02413268|Placebo Comparator|Placebo|Patient receives an antibiotic ointment with no vasoactive drug as a placebo for comparison.
2573005|NCT02413268|Active Comparator|Nitropaste|Nitroglycerin 2% ointment is applied above the compression surface on the skin, to evaluate its efficacy in reducing radial artery occlusion.
2573054|NCT02413216|Experimental|TicHelper|In this condition, participants will be provided with a secure username and login information for TicHelper.com. Participants will be asked to log in and use TicHelper.com for 8 weeks as instructed by the program (TicHelper recommends 30-60 minutes of website and therapeutic activity per day). TicHelper.com consists of 3 modules: Education, Assessment, and Intervention. The education module provides information about tic disorders and treatment. The assessment module tracks progress through the program. The intervention module uses interactive activities to teach tic management skills including habit reversal training (HRT). During HRT, patients learn to become more aware of tics and pre-tic sensations and to subsequently interrupt tics. Participants will also learn ways to interact with each other regarding tics, to identify and alter tic-worsening factors, and relaxation strategies to reduce stress.
2573055|NCT02413216|Active Comparator|Internet-Based Resources Condition|Participants who are assigned to the Internet-Based Resources (IBR) condition will receive a collection of materials with inks to the best available online resources about tic disorders and their treatment. The sites that are provided use a variety of online print, video, and animation materials to teach patients about various aspects of chronic tic disorders and their management. Participants will will be asked to explore and use the website information over the course of 8 weeks in any manner they find helpful. Participants will be asked to spend 30-60 minutes per day reviewing and discussing the information provided.
3209681|NCT00987363|Experimental|High dose (1x10 E9)|Dose of 1x10 E9 autologous bone marrow-derived mononuclear cells
3209682|NCT00987363|No Intervention|Control|Conventional treatment established by the good clinical practice
3209683|NCT00987376|Experimental|1|Prostate cancer patients
2573115|NCT02412813|Active Comparator|LEGION OXINIUM femoral component|
2573119|NCT02412813|Active Comparator|LEGION Cobalt Chrome femoral components|
3209684|NCT00987428|Experimental|groupe 1|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
2573281|NCT02411877|Active Comparator|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker), after which normothermia will attempt to keep core body temp between 38 and 36.5 degrees centigrade.
2573284|NCT02411877|Experimental|Mild hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using the Trevo Pro Retriever (Stryker). Subjects will also have a catheter placed in the femoral vein (Zoll Thermogard XP technology with the Quattro catheter) and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours, and then be rewarmed very slowly.
3209685|NCT00987428|Active Comparator|Groupe 2|usual procedure
3209686|NCT00987441|Active Comparator|Local anesthetic plus opioid 1|Local anesthetic (ropivacaine 0.125%) plus first opioid dose (sufentanil 0.3 microgram/ml) delivered peridural space
3209687|NCT00987441|Active Comparator|Local anesthetic plus opioid 2|Local anesthetic (ropivacaine 0.125%) plus second opioid dose (sufentanil 0.4 microgram/ml) delivered peridural space
2573548|NCT02410096|Active Comparator|Oil supplementation verum|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach ones daily 1190 mg of middle-chain and polyunsaturated fatty acids for four weeks. Before and after supplementation an exercise challenge in a cold chamber will be performed.
2573554|NCT02410096|Placebo Comparator|Oil supplementation placebo|30 patients aged 12-44 years with a diagnosis of exercise induced asthma undergo a methacholine challenge and a prick test. After randomization patients will receive in double blind approach placebo for four weeks. Before and after placebo treatment an exercise challenge in a cold chamber will be performed.
3209688|NCT00987441|Active Comparator|Local anesthetic plus opioid 3|Local anesthetic (ropivacaine 0.125%) plus third opioid dose (sufentanil 0.5 microgram/ml) delivered peridural space
2573730|NCT02408952|Experimental|Primary Care Physician|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered is by the primary care physician
2573731|NCT02408952|Experimental|Behavioral Medicine Specialist|If the adolescent is identified at risk for substance use, the screening and brief intervention referral to treatment delivered by the behavioral medicine specialist
3209689|NCT00987441|Active Comparator|Local anesthetic 1 plus opioid|First local anesthetic dose (ropivacaine 0.0625%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3209690|NCT00987441|Active Comparator|Local anesthetic 2 plus opioid|Second local anesthetic dose (ropivacaine 0.1875%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3209691|NCT00987441|Active Comparator|Local anesthetic 3 plus opioid|Third local anesthetic dose (ropivacaine 0.25%) plus opioid (sufentanil 0.4 microgram/ml) delivered peridural space
3209692|NCT00987454|Active Comparator|Erythropoietin|Epoetin alfa 40,000 international units will be given by subcutaneous injection to eligible patients, allocated to the treatment arm, on Study Days 1; 8 and15 during the intensive care unit stay.
3209693|NCT00987454|Placebo Comparator|Placebo|Sodium Chloride 0.9% in m/L will be given by subcutaneous injection to eligible patients, allocated to the placebo arm, on Study Days 1; 8 and15 during the intensive care unit stay.
3209694|NCT00987493|Experimental|Treatment with rituximab, bendamustine and lenalidomide|
3209695|NCT00987506||XIENCE V®|Participants receiving XIENCE V® EESS
2572876|NCT02414425|Placebo Comparator|Rectal Injection of physiologic serum|"physiologic serum will be injected during rectoscopy for patient with rectal incontinence.~Anorectal manometry will be performed for evaluation of efficacy of placebo"
2572923|NCT02414074|Other|Youth Behavioral Intervention|Teen Intervene Program
2572924|NCT02414074|Other|Parent Education|Everyday Parenting Program
2572940|NCT02413814|Experimental|Anger Reduction Treatment|The treatment consists of eight 30-minute IBM sessions. Participants will be presented with ambiguous scenarios and asked imagine themselves in these situations. In the first task, the scenario will be followed by a benign interpretation of the situation. Participants will answer a comprehension question designed to have participants endorse this benign interpretation. In the second task, participants will be presented with a word denoting an interpretation with either a negative/hostile or positive/benign connotation. Following this word, an ambiguous scenario will appear. Participants will indicate whether the word and the scenario were related. They will receive feedback training them to endorse positive interpretations and reject negative interpretations.
2572942|NCT02413814|Placebo Comparator|Control Condition|Participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors (i.e., topics of exercise, diet, hygiene, social support, healthy activities, and sleep, taken from protocols developed from our ongoing research). These participants will also view relaxing videos consisting of brief guided meditation instructions, pictures of nature scenes, and soft music. These sessions (psychoeducation and relaxing videos) will be matched for time with the active treatment condition, lasting 30 minutes each.
2572993|NCT02413671|Other|Lupin Protein|Subjects received a test meal rich in carbohydrates and supplemented with lupin protein.
2572995|NCT02413671|Other|Whey Protein|Subjects received a test meal rich in carbohydrates and supplemented with whey protein.
2572997|NCT02413671|Other|Reference|Subjects received a test meal rich in carbohydrates not supplemented with any protein.
3209696|NCT00987519||Acute bronchiolitis|Patients with acute bronchiolitis - the presence of nasal discharge, cough, wheezing and/or crackles on lung auscultation.
3209697|NCT00987519||Acute gastroenteritis|Patients with 3 or more loose or liquid stools in 24 hours prior to entering the study.
3209698|NCT00987519||Febrile convulsion|Patients with a cerebral paroxysm accompanied by fever without signs of central nervous system infection.
3209699|NCT00987519||Control group|Patients referred to pediatric surgery for elective surgical procedure - judged to be free of clinical signs and symptoms of infection.
3209700|NCT00987532|Experimental|parent intervention plus gym lessons|Parent-focused participatory preschool intervention in addition to twice weekly gym lessons over 6 months. The participatory intervention includes parents, teachers and children.
2573190|NCT02412475|Experimental|Treatment Plan - 2 treatment courses|Drug Method Used to Give Drug Days Cytarabine IT 0 or -1 Decitabine IV over 1 hour 1-5 Vorinostat PO 1-5 Fludarabine IV over 30 minutes 6-10 Cytarabine IV over 3 hours 6-10 Filgrastim (G-CSF) IV or SQ 5-12 Sorafenib PO 11-28
2573296|NCT02411825|Experimental|SAR425899 (healthy subjects)|Once daily SC doses of SAR425899
2573299|NCT02411825|Placebo Comparator|Placebo (healthy subjects)|Once daily SC doses of placebo
2573303|NCT02411825|Experimental|SAR425899 (T2DM Patients)|Once daily SC doses of SAR425899 and two up titration steps in each dose cohort with metformin as background therapy
2573307|NCT02411825|Placebo Comparator|Placebo (T2DM Patients)|Once daily SC doses of placebo and two up titration steps in each dose cohort with metformin as background therapy
2573344|NCT02411422|Experimental|Intubation using laryngoscope|"Intubation using Macintosh laryngoscope. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
2573346|NCT02411422|Experimental|i-gel blind intubation|"i-gel blind intubation means that blind endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
2573347|NCT02411422|Experimental|i-gel bronchoscopic intubation|"i-gel bronchoscopic intubation means that bronchoscopic endotracheal intubation will be performed after i-gel insertion.~i-gel will be used as a conduit. we will check procedure time according to kind of endotracheal tube, separately.~Two kinds of endotracheal tube will be used~Conventional endotracheal tube~Reinforced endotracheal tube"
3209701|NCT00987532|Active Comparator|gym lessons only|Twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
3209702|NCT00987545|Placebo Comparator|Placebo|
2573483|NCT02410512|Experimental|Dose Escalation: MOXR0916 + Atezolizumab|Cohorts of at least 3 participants each will be treated at escalating doses of MOXR0916 in combination with a fixed dose of atezolizumab to determine the MTD or maximum administered dose (MAD).
2573484|NCT02410512|Experimental|Expansion: MOXR0916 + Atezolizumab|Approximately 250-580 participants will be enrolled in the expansion stage to better characterize the safety, tolerability, pharmacokinetic variability, biomarkers of anti-tumor activity, and preliminary efficacy of MOXR0916 + atezolizumab in different cancer types.
2573569|NCT02410083|Experimental|Clopirin 1|Clopirin single-administration. Before this clinical trial Clopidogrel/Aspirin co-administration.
2573613|NCT02409589|Active Comparator|Conventional|Surface prediction length method
3209703|NCT00987545|Experimental|QAX576|
3209704|NCT00987571||Carpal Tunnel patients|These patients have documented carpal tunnel syndrome
3209705|NCT00987571||Normal Subjects|These individuals have no carpal tunnel syndrome
3209706|NCT00987597|Experimental|cognitive behavioural approach|specific technique of cigarette exposure and nicotinic treatment adjustment
3209707|NCT00987597|Active Comparator|usual approach|recommendations and nicotinic substitutes
2572905|NCT02414399|Experimental|Azithromycin|Azithromycin 10mg/kg for one day, then 5mg/kg for four days, a total of five days of experimental treatment.
2572910|NCT02414399|Placebo Comparator|Placebo|5 days of taste/appearance/bottle-matched placebo
2572980|NCT02413827|Experimental|Phase l: varlilumab and ipilimumab|
2572982|NCT02413827|Experimental|Phase ll: varlilumab & ipilimumab, +/- CDX-1401 & poly-ICLC.|
2573032|NCT02413385|Experimental|HealtheSteps Program|6 month evidence-based lifestyle Rx program: receive lifestyle Rx's for exercise, physical activity (step counts) and healthy eating and set goals around Rx's (in person sessions at set time points during 6-month period); take part in self-directed healthy living activities to achieve Rx's (Months 0-6); access to a suite of health technology support options for additional support and coaching (Months 0-6).
2573039|NCT02413385|No Intervention|Usual-care wait-list control|No active intervention (usual care).
2573070|NCT02413086|Experimental|Early-stage amputation+external herbs chitosan|Individuals with DFU were given early-stage amputation and wound was given herbs chitosan after amputation.
2573076|NCT02413086|Experimental|Early-stage amputation+traditional gauze|Individuals with DFU were given early-stage amputation and wound was given traditional gauze after amputation.
2573079|NCT02413086|Experimental|Amputation+external herbs chitosan|Individuals with DFU were given amputation and wound was given herbs chitosan after amputation.
2573083|NCT02413086|Experimental|Amputation+traditional gauze|Individuals with DFU were given amputation and wound was given traditional gauze after amputation.
2573139|NCT02412735|Experimental|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells"
2573145|NCT02412735|Experimental|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells"
2573148|NCT02412735|Placebo Comparator|Placebo|saline control: 2.0 mL saline solution
2573257|NCT02412137|Experimental|Counseled Patients|The counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will then be counseled for about 10 minutes or less regarding their brace-wear using the Brace Progress report as a checklist.
2573259|NCT02412137|Placebo Comparator|Non-counseled patients|The non-counseled cohort will have their brace wear compliance documented on the Brace Progress Report after the Orthotist downloads the time/temperature data onto a laptop from the sensor reader (A piece of computer hardware which the sensor clips into and is attached to the laptop via the USB port). The Orthotist will then reset the temperature logger discs and reinstall them into the padding in the inside front of the brace in order to monitor the next period of brace wear. This group will not be counseled, and will only receive standard clinical care.
2573335|NCT02411513|Experimental|Active|60 minutes of CEFALY stimulation as acute treatment of an on-going attack
2573370|NCT02411227|Experimental|1|Immediate Intervention
2573373|NCT02411227|No Intervention|2|Wait list
2573432|NCT02410980|Experimental|Tretinoin cream 0.1%|Assessment of the skin change
2573494|NCT02410655|Active Comparator|Conventional standard of care|Traditional administration of oxytocin at Lutheran Medical Center involves the use of two 20 IU / 1000 mL bags hung sequentially at a flow rate of 125 mL / hour each after the delivery of the anterior shoulder. This will total no more than 16 hours.
2573499|NCT02410655|Active Comparator|Evidence based protocol|The proposed evidence based protocol involves utilizing a single 30IU / 500mL bag of oxytocin. After the delivery of the anterior shoulder, an initial rapid infusion bolus of 50mL of the 30IU / 500mL at 999mL / hour. Three minutes after rapid infusion, uterine tone should be assessed. If inadequate uterine tone persists, a second rapid infusion at the same dose and rate as above should be given. If inadequate uterine tone persists, a third rapid infusion may be given. If adequate uterine tone is achieved after any rapid infusion, the remainder of the bag should be administered at a rate of 100mL / hour until finished. If adequate tone is not achieved, the remainder of the bag should be administered at 100mL / hour and additional uterotonic agents should be considered.
3209708|NCT00987610|Active Comparator|slender guidewire|Percutaneous coronary intervention (PCI) using guidewires with small distal tip equal to 0.010 inch or less
2573622|NCT02409615|Active Comparator|Hypnosis Group|Hypnosis Group: fifteen participants will receive Hypnosis therapy in addition to the standard postoperative pain management protocol
2573624|NCT02409615|Active Comparator|Healing Touch Group|Healing Touch Group: fifteen participants will receive Healing Touch therapy in addition to the standard postoperative pain management protocol
2573625|NCT02409615|No Intervention|Control Group|Control Group will receive standard postoperative pain management protocol
3209709|NCT00987610|Active Comparator|normal guidewire|Percutaneous coronary intervention (PCI) using guidewires with normal distal tip equal to 0.014 inch
3209710|NCT00987636|Experimental|R1|Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic acid in addition to induction and maintenance chemotherapy improves event-free survival in patients with localised Ewing sarcoma and good histological response or with initial tumour volume <200 mL compared to no add-on treatment.
3209711|NCT00987636|Experimental|R2|High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy, improves event-free survival in patients with localised Ewing sarcoma and poor histological response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus standard chemotherapy plus whole lung irradiation (R2pulm).
3209712|NCT00987636|Experimental|R3|Very High Risk R3: in a randomised trial, to examine whether the addition of high dose chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant chemotherapy alone, improves event-free survival in patients with primary disseminated disease.
3209713|NCT00987662|Active Comparator|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add HCZ 12.5 mg.
2572943|NCT02414009|Active Comparator|FOLFIRI|"Patients in Arm B will receive FOLFIRI chemotherapy starting Day~1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU 7 (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days. Treatment will continue for up to 12 cycles in Arm B or up to disease progression, unacceptable toxicity or informed consent withdrawal."
2572952|NCT02413645|Other|100 μg TriMix mRNA (TriMix_100)|"Cohort 1 (control group) 3 patients will receive 100 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a dose limiting toxicity (DLT), DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
2572958|NCT02413645|Other|300 μg TriMix mRNA (TriMix_300)|"Cohort 2 (control group) 3 patients will receive 300 μg of mRNA (i.e. 100 μg TriMix mRNA).If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
2572962|NCT02413645|Experimental|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 3 (experimental group) 3 patients will receive 600 μg of mRNA (300 μg HIV mRNA + 300 μg TriMix mRNA). If two or more of the three patients have a DLT, DSMB should be consulted and study will be terminated. If one or no patients have a dose limiting toxicity, three patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
2572969|NCT02413645|Experimental|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 4 (experimental group) 3 patients will receive 900 μg of mRNA (i.e. 600 μg HIV mRNA and 300 μg TriMix mRNA). If two or more of the three first patients have a DLT, then additional three patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients have a DLT, additional three patients will be enrolled at 900 μg dose level. If two or more of the six patients receiving 900 μg of mRNA have a DLT, then additional 3 patients will be enrolled at the previous level dose (dose will be reduced to 600 μg of mRNA per vaccination). If one or no patients of the six patients have a DLT, six patients will be enrolled at the next dose level.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
2572975|NCT02413645|Experimental|1200μg mRNA(900 μg HIV mRNA+300 μg TriMix mRNA)|"Cohort 5 (experimental group) 6 patients will receive 1200 μg of mRNA (i.e. 900 μg HIV mRNA + 300 μg TriMix mRNA) in case one or no patients of the six patients at the previous dose level have a DLT.~Each patient will receive 3 immunizations (at weeks 0, 2 and 4)."
3209714|NCT00987662|Active Comparator|Amplodipine|Treatment with amlodipine 10 mg for 4 weeks. If BP>135/85 mmHg add hydrochlorothiazide 12.5 mg
3209715|NCT00987688|Experimental|Hypothermia|Early and sustained hypothermia.
3209716|NCT00987688|No Intervention|Normothermia|Standard management
3209717|NCT00987701|Active Comparator|Crystalloid resuscitation|Crystalloid (Ringer's lactate) will be delivered before (15min) or after (15min) neuraxial anesthesia
2573421|NCT02411305||PCRC Palliative Care Clinicians|
2573492|NCT02410720|Active Comparator|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
2573497|NCT02410720|Experimental|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
2573575|NCT02410135||Patients with symptomatic LUTS and disordered sleep|Patients exhibiting symptoms of LUTS and disordered sleep and who meet all inclusion/exclusion criteria will be prescribed Mirabegron for 12 weeks.
2573619|NCT02409758|Active Comparator|VFE voice therapy|Voice therapy: Vocal Function Exercises applied during 6 weeks
2573620|NCT02409758|Experimental|CVRP voice therapy|Voice therapy: Comprehensive Voice Rehabilitation Program applied during 6 weeks
3175636|NCT00636337|Experimental|1|Participants meeting inclusion criteria will be provided with a laptop computer outfitted with a wireless card for the duration of the intervention and will be trained in the use of RoboMemo in the clinic by study personnel. Although many participants may have ready access to home computers, we decided that all participants will be required to use laptops provided by the study for two reasons: 1) to ensure that coaches and participants are blind to treatment condition (as described above), and 2) to ensure that participants will always have access to the intervention program (i.e., they will not compete with other family members for computer time). Once trained, children will complete the intervention at home. The intervention will consist of four 30- to 45-minute sessions per week for 8 weeks (total = 32 sessions). This intervention schedule is similar to the schedule employed by Klingberg and colleagues in their home-based CT trials with ADHD children.
3209718|NCT00987701|Active Comparator|Colloid resuscitation|Colloid (6% hydroxyethyl starch ) will be delivered before (15min) or after (15min) neuraxial anesthesia
2573884|NCT02407769|Experimental|Branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during the late evening (after 19:00 hours) daily by two months.
2573888|NCT02407769|Sham Comparator|Late evening snack|The patients will eat a snack with similar nutrimental facts that food supplement (480 Kcal, 19g of proteins and they were based in casein and vegetable proteins; 17g of lipids and 63g of carbohydrates) during the late evening (after 19:00 hours) daily by two months.
2573945|NCT02407509|Experimental|Twice weekly|RO5126766 will be administered twice weekly in 4 week cycles.
2573946|NCT02407509|Experimental|Three times weekly|RO5126766 will be administered three times weekly in 4 week cycles.
2574511|NCT02403570||Multiple Sclerosis|Brain MRI using advanced MR techniques
3209719|NCT00987714|Experimental|Protocolized Care|Algorithm to manage Pulse Pressure Variation, Cardiac Index, and Mean Arterial Pressure will be used in these donors.
3209720|NCT00987714|No Intervention|Standard Care|This is the Organ Procurement Organization current practices.
3209721|NCT00987740|Experimental|Hemolung Respiratory Assist System|
3209722|NCT00987753|Experimental|infusion of L-377202|
3209723|NCT00987766|Experimental|Treatment|Gemcitabine + Oxaliplatin + Erlotinib
3260235|NCT01477554|Experimental|PRONTO training|PRONTO training is delivered to medical teams at hospitals randomized to this arm.
2572955|NCT02413762||IFG/IGT/T2DM|Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
2572963|NCT02413762||Insulin resistance without IGT|e.g. polycystic ovarian syndrome. No intervention.
2572970|NCT02413762||IGT, no insulin resistance|e.g. T1DM. No intervention.
2572974|NCT02413762||Previous metabolic surgery|Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
2573028|NCT02413541|Experimental|High EAA and use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and use Polymyxin-B Hemoperfusion
2573037|NCT02413541|Experimental|High EAA and not use Polymyxin-B Hemoperfusion|EAA level > 0.6 or EAA = 0.6 and not use Polymyxin-B Hemoperfusion
2573041|NCT02413541|Active Comparator|Low EAA|EAA level < 0.6 and not use Polymyxin-B Hemoperfusion
3209724|NCT00987779|Experimental|Period I: Tablet(400 mg single dose)|Period I: Tablet in fasting state, Period II: Liquid formulation in fasting state, Period III: Liquid formulation in fed state
2573156|NCT02412579||Hepatocellular Carcinoma with Cirrhosis|Subjects with hepatocellular carcinoma and cirrhosis.
2573163|NCT02412579||Cirrhosis without Hepatocellular Carcinoma|Subjects with only cirrhosis.
2573201|NCT02412358|Active Comparator|Pulsar|Patients use Pulsar toothbrush for plaque removal
2573204|NCT02412358|Active Comparator|Crossaction|Patients use Crossaction toothbrush for plaque removal
2573208|NCT02412358|Active Comparator|Butler|Patients use Butler toothbrush for plaque removal
3209725|NCT00987779|Experimental|Period I: Liquid formulation(400 mg single dose)|Period I: Liquid formulation in fasting state, Period II: Tablet in fasting state, Period III: Liquid formulation in fed state
3209726|NCT00987792||Group 1|
3209727|NCT00987805|Experimental|Banhasasim-tang|
3209728|NCT00987805|Placebo Comparator|Placebo drug|The placebo of this study is corn-starch granules. It has the same form, color, flavor and amount like experimental herbal extracted formula
3209729|NCT00987818|Experimental|PCT guided antibiotic therapy|
2573513|NCT02410434|Experimental|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
2573547|NCT02410148|Active Comparator|Papilledema|non-invasive aICP measurement in patientes with papilledema
2573553|NCT02410148|Active Comparator|open angle glaucoma|non-invasive aICP measurement in patients with glaucoma
2573599|NCT02409849|No Intervention|control group|
2573603|NCT02409849|Experimental|Octreotide LAR treatment|The patients with unresectable or metastatic GEP or esophageal NEC who got CR/PR/SD after chemotherapy with IP or EP regimen qualified with the inclusion criteria are enrolled. All the patients enrolled in our study will be randomly assigned to receive octreotide LAR (group A) as maintenance treatment or follow up (group B) to disease progression.
2573626|NCT02409511||Type 1 diabetic, retinopathy, non cardiovascular disease|Type 1 diabetic patients with microalbuminuria, diabetic retinopathy and without cardiovascular disease
2573627|NCT02409511||Non-diabetic, hipertension|Non-diabetic patients with hypertension and microalbuminuria
2573629|NCT02409511||Type 2 diabetic, non diabetic retinopathy|Type 2 diabetic patients without diabetic retinopathy and microalbuminuria
2573630|NCT02409511||Type 2 diabetic with diabetic retinopathy|Type 2 diabetic patients with diabetic retinopathy and microalbuminuria
2573632|NCT02409511||Type 2 diabetic, with proven nephropathy|Type 2 diabetic patients with biopsy proven diabetic nephropathy.
2573703|NCT02409212|Experimental|Intervention|12 months of aerobic exercise training with behaviour change support
2573712|NCT02409212|Placebo Comparator|Comparison|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
3209730|NCT00987818|Placebo Comparator|Standard antibiotic therapy|
2573823|NCT02408172|Experimental|OSA-amlodipine|To observe the effects of amlodipine (5mg) on blood pressure variation after 12 weeks of treatment
2573826|NCT02408172|Experimental|OSA-metoprolol|To observe the effects of metoprolol (47.5mg) on blood pressure variation after 12 weeks of treatment
2573917|NCT02407587|Experimental|unilateral cochlear implants|"Study Group~PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
2573922|NCT02407587|No Intervention|Healthy volunteers|4 states and each state will be repeated 3 times Auditory stimulation Left ear only Auditory stimulation right ear only Binaural auditory stimulation Silence
2574002|NCT02406950|Experimental|Sitagliptin|All participant will exam brachial artery endothelium-dependent flow-mediated dilatation (FMD). After then, pneumatic cuff wiil be inflated to 200 mmHg for 15 minutes to induce brachial artery ischemia. At the end of ischemia, 15 minutes of reperfusion was performed to induce reperfusion injury. After ischemia-reperfusion (IR) injury, brachial artery FMD will be measured again. After randomization, sitagliptin group will be treated by single dose of sitagliptin (Januvia) 50mg. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
2574005|NCT02406950|Placebo Comparator|Placebo|After brachial artery FMD measurement, IR injury for each 15 minutes will be performed, and brachial artery FMD will be measured again. After randomization, placebo group will be treated by nothing. In 2 hours later, brachial artery FMD measurement, IR injury and brachial artery FMD measurement will be measured again.
2574020|NCT02406846||DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received DC-CIK treatment only, 1 day before and 2 days after the DC-CIK treatment.
3209731|NCT00987857|Active Comparator|2 yearly endoscopies|Two years endoscopies
3209732|NCT00987857|Experimental|endoscopy at need|Endoscopy only when patient reports symptoms
3209733|NCT00987870|Experimental|BFH772 cream 1%|
3209734|NCT00987870|Placebo Comparator|Placebo to BFH772 cream 1%|
3209735|NCT00987870|Experimental|BFH772 ointment 1%|
3209736|NCT00987870|Placebo Comparator|Placebo to BFH772 ointment|
3209737|NCT00987870|Active Comparator|calcipotriol/betamethasone ointment|
2572977|NCT02413957|Experimental|AMTS-Group|Patient randomized to the AMTS-Group will receive the traditional care by physician and nurse on the ward and additional pharmaceutical care by a pharmacist.
3209738|NCT00987883||Malnutrition cohort|The patients with undernutrition
2573136|NCT02412696|Active Comparator|Positive Airway Pressure|Positive airway pressure and nasal dilator strips during sleep.
2573143|NCT02412696|Placebo Comparator|Nasal Dilator Strips|Nasal dilator strips during sleep.
2573240|NCT02412150|Experimental|Dexmedetomidine (Group D)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued.~Then, dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage and duration of hospital staying, postoperative complications are measured until POD#3."
2573241|NCT02412150|Placebo Comparator|Normal Saline (Group N)|"After induction of anesthesia, anesthesia is maintained with desflurane and remifentanil during thyroidectomy.~Fifteen minutes before the end of surgery, infusion of remifentanil for surgery is discontinued. Then, normal saline has started infusion for 15 min (same rate as Group D). Vital signs and complications of testing drugs are measured before and after infusion of testing drugs.~Five minutes before the end of surgery, anesthetic gas (desflurane) is discontinued.~After patient has awake, extubation has done. Extubation time and Recovery time,Cough reflex,Ramsay Sedation Scale, Visual analogue scale, and surgical outcomes such as postoperative bleeding, time to remove drainage duration of hospital staying, postoperative complications are measured until POD#3."
2573476|NCT02410746|Active Comparator|standard chirocaine infiltration|non-targeted infiltration of 10ml 0.25% Chirocaine into breast pocket
2573477|NCT02410746|Experimental|targeted chirocaine pec block|pectoral muscle block with 10ml 0.25% chirocaine
2573510|NCT02410408|Active Comparator|Control|Information package about patient safety certification or how to conduct Root Cause Analysis
2573512|NCT02410408|Experimental|Experimental|Apps: Root Cause Analysis or patient safety ISO certification
3175637|NCT00636337|Placebo Comparator|2|The design will be a double-blind, placebo-controlled trial in which half of the participants will be randomized to the intervention condition and half will receive a comparison computer program. Specifically, participants assigned to the comparison (placebo) condition will complete a modified version of the CT at home. The treatment and comparison CT programs begin identically, at the lowest difficulty level. Those in the treatment condition will complete activities of increasing difficulty over the intervention period. Those in the placebo condition, in contrast, will complete the same basic tasks during each session of the intervention, regardless of performance. In this way, a true estimate can be obtained of the efficacy of the treatment program.
3175638|NCT00636376|Experimental|1|Single arm--no randomization. All subjects enrolled will have vitals collected and three ultrasounds at different levels of head of the bed elevations.
2573654|NCT02409394|Experimental|hetrombopag 7.5mg fasted to fed|Hetrombopag tablet, fasting conditions on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet with high fat, high calorie breakfast on day 11.
2573661|NCT02409394|Experimental|hetrombopag 7.5mg fed to fasted|Hetrombopag tablet with high fat, high calorie breakfast on day 1; 9 days wash-out; Than subjects will be crossover to have hetrombopag tablet, under fasting condition on day 11.
2573702|NCT02409186|Active Comparator|Nimotuzumab plus chemoradiotherapy|Nimotuzumab：400mg/w，d1, week 1-7 Paclitaxel：45mg/m2, d1, week 1-7 Cisplatin：20mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
2573710|NCT02409186|Placebo Comparator|placebo plus chemoradiotherapy|placebo：400mg/w，d1, week 1-7 Paclitaxel：45 mg/m2, d1, week 1-7 Cisplatin：20 mg/m2, d1, week 1-7 Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
2573737|NCT02408614||Slow-paced walking|Subjects will complete 47 minutes of walking at slow pace.
2573739|NCT02408614||Moderate-paced walking|Subjects will complete 47 minutes of walking at a moderate pace.
2573742|NCT02408614||Interval training|Subjects will complete 40 minutes of walking alternating between a moderate and fast pace.
2573801|NCT02408406|Experimental|Arm I (PatientCareAnywhere program system)|Patients are encouraged to use the PatientCareAnywhere program at least once weekly either in the clinic or at home. Patients receive reminder emails after 1 week of inactivity. If patients indicate they are experiencing moderate to severe symptoms, an alert message is sent to at least 1 member of the patient's support team along with a list of expected response times.
2573802|NCT02408406|Active Comparator|Arm II (usual care)|Patients receive usual care, including a one-time use of SupportScreen, a touchscreen questionnaire system that identifies patient issues before appointments, at the clinic during the first treatment consultation after diagnosis. Consultation, printed education materials, and specialist referrals may be generated based on SupportScreen responses.
3175639|NCT00636402|Experimental|1|Vessel Sealing System Tonsillectomy (VSST)
3175640|NCT00636402|Active Comparator|2|Cold Knife Tonsillectomy (CKT)
3175641|NCT00636415|Experimental|A|G1 patients received morphine intra-articular route G2 patients received bupivacaine without epinephrine.
3175642|NCT00636428|Active Comparator|1|Oral midazolam
2574145|NCT02406066|Placebo Comparator|Placebo|Subjects will receive capsules containing no active pharmaceutical ingredients.
2574147|NCT02406066|Active Comparator|Low Dose (Cohort 1)|270 mg metyrapone and 12 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
2574150|NCT02406066|Active Comparator|Medium Dose (Cohort 2)|540 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
2574224|NCT02405494|Other|Beverage 4|Liquid foam consisting of 98 ml liquid with 427% overrun (total volume 514 ml).
3175643|NCT00636428|Active Comparator|2|IV Midazolam
3175644|NCT00636454|Active Comparator|1|This group will serve as the control group and will receive only the care usually given to OA patients.
2573025|NCT02413307|Experimental|Intervention Group|Self-practice compassion focused therapy intervention following written or audio scripts. This includes instructions, an explanation of compassion and aims of the intervention. It includes several exercises designed to increase self-compassion including breathing exercises and compassionate imagery exercises focused on self and others
2573034|NCT02413307|No Intervention|Waiting List Control|Participants on the waiting list for trauma specific therapy. These will be participants who have consented to engaging in the research project but their intervention phase has a delayed start.
2573071|NCT02413138|Experimental|Phase 2: Somavaratan (VRS-317)|Active treatment arm
2573074|NCT02413138|Experimental|Phase 3: Somavaratan (VRS-317)|Somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
3209739|NCT00987883||Well nourished cohort|Patient that well nourished and without undernutrition
3209740|NCT00987896|Experimental|Megachannel Application|Colonoscopy with loaded Megachannel is performed
3209741|NCT00987909|Placebo Comparator|Placebo|Solution resembling the active solutions, but without allergen extract
3209742|NCT00987909|Experimental|Cat hair allergen extract, dose group 1|
2573253|NCT02412176|Experimental|Pacing site - right ventricular apex|The intervention will be the implantation of the lead into the right ventricular apex
2573255|NCT02412176|Experimental|Pacing site - septum|The intervention will be the implantation of the lead into the septum.
2573286|NCT02411786|Experimental|pTVG-AR biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
2573287|NCT02411786|Experimental|pTVG-AR staggered biweekly|pTVG-AR (dose: 100 µg) alone without rhGM-CSF. Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
2573288|NCT02411786|Experimental|pTVG-AR with rhGM-CSF biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 4, 6, 8, and 10 (biweekly) for 6 doses, then administered at week 12, week 24, week 36, and week 48 (quarterly) for 4 doses, or 10 total doses.
2573289|NCT02411786|Experimental|pTVG-AR with rhGM-CSF staggered biweekly|pTVG-AR (dose: 100 µg) with rhGM-CSF (200 µg). Administered at weeks 0, 2, 12, 14, 24, 26, 36, 38, 48 and 50 (staggered biweekly schedule) for 10 total doses.
2573378|NCT02411526|Experimental|Cohort 1|60 mg of ZX003 administered 4 times (every 4 weeks)
2573380|NCT02411526|Experimental|Cohort 2|90 mg of ZX003 administered 4 times (every 4 weeks)
2573383|NCT02411526|Experimental|Cohort 3|120 mg of ZX003 administered 4 times (every 4 weeks)
2573385|NCT02411526|Active Comparator|Cohort 4|Risperdal Consta administered 5 times (once every 2 weeks) NOTE: Oral risperidone 2 mg will be given with the first injection of Risperdal Consta and continued for 3 weeks (and then discontinued) to ensure adequate therapeutic plasma concentrations from Risperdal Consta.
2573572|NCT02410005|Active Comparator|Losartan alone|In the losartan alone group, subjects are prescribed: losartan 50mg twice daily.
2573577|NCT02410005|Experimental|Losartan and Calcitriol|In the losartan plus calcitriol group, subjects are prescribed: losartan 50mg twice daily and calcitriol 0.25mcg daily.
3209743|NCT00987909|Experimental|Cat hair allergen extract, dose group 2|
3209744|NCT00987909|Experimental|Cat hair allergen extract, dose group 3|
3209745|NCT00987922|Experimental|Hypothermia|
3209746|NCT00987922|No Intervention|Control|
2573907|NCT02407535|Experimental|Endometrial carcinoma patient|
2573973|NCT02407288|Active Comparator|active tDCS|patients will received 2 sessions per day for 5 consecutive days. Each session will last 20 minutes. The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
2573976|NCT02407288|Placebo Comparator|SHAM tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the 10 first seconds.
2574031|NCT02406820||No Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is not clinically indicated and who are registered to twice daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
2574034|NCT02406820||Indwelling PAC, Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to three times daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
2574038|NCT02406820||No Indwelling PAC, No Daily Testing|Acutely decompensated heart failure patients undergoing a right heart catheterization for whom a retained indwelling PAC is clinically indicated and who are registered to no daily non-invasive hemodynamic monitoring during an isometric handgrip stress test (IHGST).
3209747|NCT00987961|No Intervention|Treatment as usual|Participants in this arm will receive the standard detox treatment for individuals hospitalized with opioid dependence.
2574227|NCT02405494|Other|Beverage 5|Liquid foam consisting of 25 ml liquid with 250% overrun (total volume 88 ml).
2574228|NCT02405494|Other|Beverage 6|Liquid foam consisting of 110 ml liquid with 250% overrun (total volume 385 ml).
3209748|NCT00987961|Experimental|Linkage|Participants in this arm will receive a maintenance schedule of Suboxone during their hospital stay, and an appointment with an outpatient Suboxone provider for after their discharge.
3209749|NCT00987974|Experimental|rosuvastatin 3days|8 Subjects will use rosuvastatin 20 mg/day for 3 days
3209750|NCT00987974|Active Comparator|atorvastatin 3 days|8 Subjects will use atorvastatin 80 mg/day for 3 days.pj
3209751|NCT00987974|Placebo Comparator|placebo 3days|8 Subjects will use placebo for 3 days.
3209752|NCT00987974|Experimental|rosuvastatin 7 days|8 Subjects will use rosuvastatin 20 mg/day for 7 days.
3209753|NCT00987974|Active Comparator|atorvastatin 7 days|8 Subjects will use atorvastatin 80 mg/day for 7 days.
3209754|NCT00987974|Placebo Comparator|placebo 7 days|8 Subjects will use placebo for 7 days.
3209755|NCT00987987|Experimental|1|1
3209756|NCT00988026|Experimental|Minocycline 100 mg|Minocycline
3209757|NCT00988026|Active Comparator|Lymecycline 300 mg|Group B: Lymecycline
3209758|NCT00988039|Active Comparator|bPI + 2NRTIs|
3209759|NCT00988039|Experimental|bPI + raltegravir|
3209760|NCT00988039|Experimental|bPI monotherapy|
2573271|NCT02411981|Other|Autogenic drainage|"The autogenic drainage will be the chest physiotherapy technique used for this study.~Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity."
2573294|NCT02411669||Health care professionals|Physicians, nurses and managerial staff
2573402|NCT02411331|Experimental|Experimental group|90 patients will receive 10 injections of ethanol lock solution in implantable venous access port during the first 10 days of the study.
2573405|NCT02411331|Other|control group|90 patients will receive 10 injections of vancomycin lock solution in implantable venous access port during the first 10 days of the study
3209761|NCT00988078|Experimental|Metformin|Metformin 500mg three times a day for six months
3209762|NCT00988078|Placebo Comparator|Placebo|1 capsule three times a day for six months
3209763|NCT00988104|Active Comparator|Cognitive Behavioral Therapy|
3209764|NCT00988104|Active Comparator|Supportive Counseling|
2573505|NCT02410395|Active Comparator|Conventional technique|Closure of the uterotomy with a conventional two-layer technique
2573506|NCT02410395|Experimental|Modified technique|Closure of the uterotomy with a modified two-layer technique
3209765|NCT00988182|Experimental|whey protein, 5g|
3209766|NCT00988182|Experimental|whey protein, 10g|
3209767|NCT00988182|Experimental|whey protein, 20g|
2573686|NCT02408991|Experimental|AA and Neopogen|Patient undergoes treatment with Art-assist device and Neupogen
2573740|NCT02408913|Experimental|Group 2|MVA-EbolaZ 1x10(8) PFU
2573743|NCT02408913|Experimental|Group 3|cAd3-EBO 2x10(11) PU followed by MVAEbolaZ 1x10(8) PFU at 8 weeks
2573748|NCT02408913|Experimental|Group1|MVA-EbolaZ 1x10(7) PFU
2573755|NCT02408913|Experimental|Groups 4 to 7|MVA-EbolaZ 1x10(8) PFU administered in VRC 208 to participants who received cAd3-EBO or cAd3-EBOZ in VRC 207.
2573812|NCT02408328|Active Comparator|Inpatient Observation|Continued inpatient monitoring of apnea, bradycardia, and/or desaturation until an event free period of time (5 days per the current standard of care at each participating institution) has been established and deemed appropriate for discharge home per the discretion of the responsible provider.
2573821|NCT02408328|Active Comparator|Caffeine and Outpatient Monitoring|Patients will receive a loading dose of caffeine on day 1 with a daily maintenance dose thereafter. Infants will then receive continued inpatient monitoring of apnea/bradycardia/desaturation until an event free period of time has been established and deemed appropriate for discharge home per the discretion of the responsible provider. Infants discharged home on caffeine therapy will receive instructions regarding use of a home monitor. Follow up in the pulmonary clinic will be arranged at 42-43 weeks gestational age. At 43 weeks corrected gestational age, caregivers will be instructed to discontinue caffeine therapy. An outpatient recorded oximetry study will be arranged at least 1 week after discontinuation of caffeine therapy. Home pulse oximetry monitoring will be discontinued if no significant events, as previously defined, are recorded.
2573865|NCT02407938|Experimental|rice meal|High resolution manometry will be performed. Esophageal function will be tested using liquid swallows, solid swallows and a test meal (200g rice)
2573898|NCT02407678|Experimental|Treatment|Treated eye undergoes AAV-mediated REP1 gene replacement. AAV vector is delivered by subretinal injection.
2573901|NCT02407678|No Intervention|Control|Untreated eye
2573929|NCT02407444|Experimental|Physiotherapy treatment & leg cycling|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes. Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will have cycling training with leg cycle ergometer for 20 minutes.~This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
2573932|NCT02407444|Active Comparator|Physiotherapy treatment & music listening|"This group will receive conventional physiotherapy treatments, each session will last 30 minutes .Treatments include muscles strength exercises for upper and lower extremities, static and dynamic balance training in standing ,pain relief techniques and functional training (including transfers, sit to stand, walking and climbing stairs). The treatment program shall be consistent with the patient's problems and the degree of difficulty will rise depending on progress.~In addition this group will listen to music (while sitting on a chair) for 20 minutes.This treatment protocol will last for three weeks, five days a week, 50 minutes each session per day."
2573964|NCT02407119|Active Comparator|7 day H.pylori eradication|Treatment: Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
2573968|NCT02407119|Placebo Comparator|Placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + Placebo for two antibiotics (clarithromycin and amoxicillin) bid for 7 days
2574017|NCT02406846||Control|Use Flow cytometry (FCM) and RT-PCR to test peripheral blood mononuclear cells(PBMCs) from healthy volunteer.
2574019|NCT02406846||Cryosurgery group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients who received cryosurgery only, 1 day before and 2 days after the cryosurgery.
2574388|NCT02404376|Active Comparator|Exenatide|Sham Remote Ischemic Conditioning + exenatide
3209768|NCT00988182|Experimental|whey protein, 40g|
3209769|NCT00988182|Experimental|water control|
3209770|NCT00988195|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
3209771|NCT00988234|Experimental|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
3209772|NCT00988234|Experimental|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
3209773|NCT00988234|Experimental|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
3209774|NCT00988234|Experimental|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
3209775|NCT00988260|Experimental|Ganirelix 0.125 mg|
3209776|NCT00988260|Experimental|Ganirelix 0.25 mg|
3209777|NCT00988260|Experimental|Ganirelix 0.5 mg|
3209778|NCT00988273||Control|In patients undergoing endoscopy for indications other than Crohn's disease or ulcerative colitis
3209779|NCT00988273||Diseased group|Patients with Crohn's disease or ulcerative colitis undergoing endoscopy.
3209780|NCT00988286|Experimental|CEP|
3209781|NCT00988312|Experimental|s.c. vaccination|vaccine given subcutaneously
3209782|NCT00988312|Experimental|i.v. vaccination|vaccines are given intravenously
3209783|NCT00988338||Trinity Evolution|
3209784|NCT00988364|Active Comparator|Ezetimibe|Randomly chosen participants will receive ezetimibe 10mg daily for 3 months.
3209785|NCT00988364|Active Comparator|Simvastatin|Randomly chosen participants will receive Simvastatin 20mg daily for 3 months.
3209786|NCT00988364|Active Comparator|Vytorin|Randomly chosen participants will receive Vytorin 20/10mg daily for 3 months.
2573429|NCT02410993||CABG surgery|Candidates for CABG surgery for left main disease, three-vessel disease or two-vessel disease with proximal LAD stenosis indicated by current practice guideline
2573549|NCT02410317|Experimental|Continuous wound infusion group|Patients receive analgesia through a multiorifice wound catheter connected to ropivacaine infusion. Saline solution is given in the epidural bolus.
2573557|NCT02410317|Active Comparator|Epidural morphine group|Patients receive epidural analgesia through an epidural bolus of morphine. Saline solution is perfused through the wound catheter.
2573602|NCT02409836|Active Comparator|Crest Cavity Protection|Marketed Dentifrice
2573604|NCT02409836|Active Comparator|Crest for Kids Hawaiian Punch Paste|Marketed Dentifrice
2573606|NCT02409836|Active Comparator|Crest for Kids Bubble Gum Paste|Marketed Dentifrice
2573637|NCT02409498|Active Comparator|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine. 10 ml of Bupivacaine will be injected on either side using the pudendal nerve block tray.
2573643|NCT02409498|Placebo Comparator|no pudendal block|Saline
2573718|NCT02409095|Experimental|DISPOSABLE-SYRINGE JET INJECTOR (DSJI)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc
2573721|NCT02409095|Active Comparator|NEEDLE & SYRINGE (N-S)|Subjects in this arm will be given three deep intramuscular doses, 0.5 mL each dose 4 weeks apart, of Serum Institute of India Ltd.'s DTP-HB-Hib vaccine (Brand name: Pentavac) via conventional needle and Syringe
2573745|NCT02408679||All subjects|300 eligible subjects will perform a blood sampling for a dosage of serum vitamin D and will fill up a study questionnaire during one visit.
2573798|NCT02408471|Other|Ascension® MCP Finger Implant|Single arm study, patient treated with Ascension® PyroCarbon MCP implant.
3209787|NCT00988364|Placebo Comparator|Placebo|Randomly chosen participants will receive Placebo tab 1 daily for 3 months.
3209788|NCT00988377|Experimental|10 g whey protein|
3209789|NCT00988377|Experimental|20 g whey protein|
2573970|NCT02407314|Sham Comparator|Aspirin only|Clopidogrel 75 mg + aspirin 81 mg for the first month followed by aspirin 81 mg alone for months 2-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT) ankle brachial index (ABI) and six minute walk distance.
2573974|NCT02407314|Experimental|Aspirin + Ticagrelor|ticagrelor 90 mg bid + aspirin 81 mg for months 1-6 months post percutaneous peripheral intervention (PPI) intervention assessed by optical coherence tomography (OCT)ankle brachial index (ABI) and six minute walk distance.
2574061|NCT02406690||Case Group|Patients who failed to achieve adequate endometrial lining during a synthetic embryo transfer. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
2574067|NCT02406690||Control Group|Patients who have achieved an adequate endometrial lining. This group will undergo a Leuprolide prep cycle using estradiol valerate, progesterone in oil and subsequently undergo an endometrial biopsy and uterine aspiration.
2574107|NCT02406274|Experimental|Contrast Enhanced Spectral Mammography|
2574142|NCT02406040|Experimental|High Protein|2.4g protein/kg/d. The macronutrient composition will be 50:15:35 (carbohydrates:fat:protein) during Energy Restriction
2574409|NCT02404259|Other|ritonavir-boosted protease inhibitor|lopinavir/ritonavir atazanavir/ritonavir
3209790|NCT00988377|Experimental|30 g whey protein|
3209791|NCT00988377|Experimental|40 g whey protein|
3209792|NCT00988377|Experimental|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
3209793|NCT00988390|Other|Intervention, mothers living with HIV|Mothers living with HIV, Cognitive-behavioral intervention delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions)
3209794|NCT00988390|No Intervention|Control, mothers living with HIV|Mothers living with HIV, offered intervention at end of study (18 months after recruitment)
3209795|NCT00988390|No Intervention|Control, non-HIV-infected mothers|Neighborhood control mothers not infected with HIV, did not receive any intervention
3209796|NCT00988403|Experimental|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
3209797|NCT00988403|Experimental|Fructan - 10 grams|Subjects will consume 10 grams of fructan
3209798|NCT00988403|Experimental|Fructan - 12.5 grams|Subjects will consume 12.5 grams of fructan
3209799|NCT00988403|Experimental|5 grams Fructan|"Experimental - 5 grams Fructan~Subjects will consume 5 grams of Fructan."
3209800|NCT00988455|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3209801|NCT00988468|Experimental|Manual Therapy|Subjects will receive oscillatory (grade 1 & 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
3209802|NCT00988468|Experimental|Therapeutic Exercise|Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
3209803|NCT00988468|Placebo Comparator|Control|Subjects will watch a 15 minute instructional video on a health topic.
3209804|NCT00988494|Experimental|High concentration|DE-105 high concentration
3209805|NCT00988494|Experimental|Low concentration|DE-105 low concentration
3209806|NCT00988494|Placebo Comparator|Placebo|DE-105 placebo
3209807|NCT00988507|Experimental|Ferroquine high dose + artesunate|Ferroquine at 6 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
2573261|NCT02411955|Experimental|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% (Taro Pharmaceuticals Inc.)
2573266|NCT02411955|Active Comparator|Tazorac®|Tazorac® (tazarotene cream 0.1%) (Allergan LLC)
2573270|NCT02411955|Placebo Comparator|Placebo|Placebo (Vehicle of the test product) (Taro Pharmaceuticals Inc.)
2573321|NCT02411695|Experimental|Cohort 1|0.5 mg, Brexpipraxzole (OPC-34712)
2573322|NCT02411695|Experimental|Cohort 2|1mg, Brexpipraxzole (OPC-34712)
2573323|NCT02411695|Experimental|Cohort 3|2mg, Brexpipraxzole (OPC-34712)
2573324|NCT02411695|Experimental|Cohort 4|3 mg, Brexpipraxzole (OPC-34712)
2573326|NCT02411695|Experimental|Cohort 5|4mg, Brexpipraxzole (OPC-34712)
2573365|NCT02411266|Placebo Comparator|control|Subjects in this group will undergo sham preconditioning. A blood pressure cuff will be placed around the leg and inflated just lightly to a pressure of 30mmHg, not enough to affect arterial circulation. This will be maintained for 10min followed by 5min of deflation. This will constitute one conditioning cycle. There will be 3 sham conditioning cycles per treatment session.
2573368|NCT02411266|Active Comparator|treatment group|Study personnel will place a blood pressure cuff around the subject's leg and use it to interrupt the circulation to the leg for 10 minutes followed by release of the blood pressure for 5 minutes. This will be repeated for a total of 3 times every 24 to 48 hours up to 14 days. The cuff will be inflated for 10 minutes and then deflated for 5 minutes. There will be 3 cycles of this. The cuff will be inflated to 200mmHg to induce ischemia, confirmed by palpation of pedal pulses.
3209808|NCT00988507|Experimental|Ferroquine medium dose + artesunate|Ferroquine at 4 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
3209809|NCT00988507|Experimental|Ferroquine low dose + artesunate|Ferroquine at 2 mg/kg/d OD and artesunate 4mg/kg/d OD for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
2573550|NCT02410057|Active Comparator|Standard infant formula|Standard infant formula
2573558|NCT02410057|Experimental|Protein-reduced whey formula|Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula
2573561|NCT02410057|Experimental|Protein-reduced α-lactalbumin formula|Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula
2573563|NCT02410057|No Intervention|Breast-feeding|Exclusive breast-feeding
2573617|NCT02409797|Experimental|Flexion-Distraction spinal manipulation|Participants will receive Flexion-Distraction treatment from a licensed doctor of chiropractic. During the procedure the participant lies prone on a specially designed treatment table. The table is equipped with a movable lower body section, which can be directed by the study doctor to lower the participants legs, move them from side to side, or in a traction motion. Table movements can occur in combination with other motions, depending on the diagnosis and characteristics specific to the participant's condition. During this procedure, the doctor will also touch the lower or upper part of the participants back or neck with their hands to direct treatment toward specific spinal regions.
3209810|NCT00988507|Experimental|Ferroquine alone at medium dose|Ferroquine at 4 mg/kg/d OD alone for 3 days + ferroquine placebo capsules to maintain the blind between treatment groups.
2573778|NCT02408588||Childbirth and epidural|Pregnant women giving childbirth who receive an epidural.
2573779|NCT02408588||Childbirth and general anesthesia|Pregnant women giving childbirth who receive general anesthesia
2573780|NCT02408588||Fetal Intervention and epidural|Pregnant women receiving fetal intervention and an epidural
2573781|NCT02408588||Fetal Intervention and general anesthesia|Pregnant women receiving fetal intervention and general anesthesia
2573838|NCT02408146|Experimental|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia.
2573840|NCT02408146|Experimental|parecoxib|The second group has oral celecoxib before surgery, then receives parecoxib sodium intravenously guttae after surgery.
2573842|NCT02408146|Experimental|new intravenous infusion pump|The third group uses new intravenous infusion pump of patient-controlled analgesia after surgery.
3209811|NCT00988520|Experimental|0.6 mg/kg intubation dose under sevoflurane|
3209812|NCT00988520|Experimental|0.9 mg/kg intubation dose under sevoflurane|
2573999|NCT02406976|Experimental|G1- EXERCISE|The group will Participate in an physical exercise program twice a week. This program consists of 20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
3209813|NCT00988520|Experimental|continuous dose following 0.6 mg/kg intubation dose + propofol|
3209814|NCT00988520|Experimental|continuous dose following 0.9 mg/kg intubation dose + propofol|
3209815|NCT00988546|Other|1|exam documentation performed using dictation
3209816|NCT00988546|Experimental|2|exam documentation performed using computer based template
3209817|NCT00988572|Experimental|Intervention group|Vestibular rehabilitation, twice a week for 9 weeks
3260236|NCT01477580|Experimental|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|
2573228|NCT02412267|Experimental|O-ICE|"O-ICE:~Ofatumumab 1000mg intravenous (IV) infusion on Day 1 and Day 8 of cycle 1 of the salvage chemotherapy, and thereafter on Day 1 of each cycle; Ifosfamide 1667 mg/m2 IV infusion over 2 hours on days 1,2,3 of each cycle; Carboplatin 5 x ((25 + Creatinine clearance (CrCl)) IV in 250 ml Normal Saline over 1 hour on day 1 of each cycle; Etoposide 100mg/m2/day IV infusion day 1,2,3 over 45 to 60 minutes of each cycle."
2573272|NCT02411968||111In-Girentuximab DOTA SPECT|Patients >50 years of age with renal tumours ≤4 cm highly suspicious for a malignancy planned to undergo cryotherapy will undergo 111In-Girentuximab DOTA SPECT scanning.
2573317|NCT02411656|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over approximately 30 minutes on day 1. Courses repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
2573343|NCT02411383|Experimental|NeuRx Diaphragm Pacing System (DPS)®|The NeuRx Diaphragm Pacing System (DPS)® is placed in the diaphragm during lung transplant.
2573372|NCT02411149|Placebo Comparator|Local Inflitration Only|"This group will receive LIA and saline solution (placebo) in the adductor canal block with NO morphine in the spinal anesthesia:~30 ml normal saline~3ml 0.5% preservative-free bupivacaine"
2573376|NCT02411149|Active Comparator|Adductor Canal Block|"This group will receive LIA and the standard local anesthetic in the ACB with NO morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine"
2573377|NCT02411149|Active Comparator|Adductor Canal Block with Morphine|"This group will receive LIA with local anesthetic in the ACB and morphine in the spinal anesthetic:~ropivacaine 0.5% with 1:400,000 epinephrine~3ml 0.5% preservative-free bupivacaine with 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)"
2573430|NCT02410863|Experimental|Cohort A (BRAFi naïve)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily.
2573438|NCT02410863|Experimental|Cohort B (BRAFi / MEKi rechallenge)|Dabrafenib (BRAFi) and trametinib (MEKi) will be administered orally at their recommended doses for combination therapy of 150 mg twice daily (BID) and 2 mg daily
3209818|NCT00988572|No Intervention|Control group|The patients in the control group does nothing, except for normal treatment for their wrist fracture.
2573534|NCT02410070|Experimental|Though Volar Minimal Incision|Patients in group A were treated through a small Incision.
2573537|NCT02410070|Active Comparator|Though Convectional Incision|Patients in group B were treated through the conventional Incision
3209819|NCT00988585|Placebo Comparator|Olive Oil|Olive Oil 600 mg/day
2573658|NCT02409446|Experimental|Anthocyanin|34 patients will receive anthocyanin. We will analyze their blood samples both prior and after taking anthocyanin.
2573662|NCT02409446|No Intervention|Controls|Healthy Controls, 20 persons. Will be giving blood samples at study start and study end.
2573698|NCT02409121|Experimental|Open label|All participants will receive a tablet educational intervention (health IT platform) during the patient inpatient hospitalization for autologous or allogeneic transplant
3209820|NCT00988585|Active Comparator|EPA 1800|1800 mg/day
3209821|NCT00988585|Active Comparator|DHA|DHA 600 mg/day
3209822|NCT00988585|Active Comparator|EPA 600|EPA 600 mg/day
3209823|NCT00988624|Experimental|Period 1|
3209824|NCT00988624|Experimental|Period 2|
2574219|NCT02405494|Other|Beverage 1|Liquid foam consisting of 37 ml liquid with 73% overrun (total volume 65 ml).
2574220|NCT02405494|Other|Beverage 2|Liquid foam consisting of 37 ml liquid with 427% overrun (total volume 197 ml).
2574221|NCT02405494|Other|Beverage 3|Liquid foam consisting of 98 ml liquid with 73% overrun (total volume 169 ml).
3209825|NCT00988624|Experimental|Period 3|
3209826|NCT00988624|Experimental|Period 4|
3209827|NCT00988624|Experimental|Period 5|
3209828|NCT00988650|Active Comparator|North American diet|Control North American diet for five weeks in isocaloric conditions
3209829|NCT00988650|Experimental|Mediterranean diet|Mediterranean diet for five weeks in isocaloric conditions
3209830|NCT00988650|Experimental|weight loss period|Weight loss period of 20-week (minimum 5% reduction in body weight)
3209831|NCT00988650|Active Comparator|Weight stabilizing mediterranean diet|Mediterranean diet for five weeks in isocaloric weight stabilizing conditions
3209832|NCT00988663|Active Comparator|Memantine arm|Patient receiving ECT and Memantine
3209833|NCT00988663|Placebo Comparator|placebo|25 patients receiving ECT will will receive placebo
3209834|NCT00988676||colonoscopy|
3209835|NCT00988689|Experimental|Soup with no added starch|
3209836|NCT00988689|Experimental|Soup + 50 g of whole grain starch|
3209837|NCT00988689|Experimental|Soup + 50 g of high amylose corn starch|
3209838|NCT00988689|Experimental|Soup + 50 g of regular corn starch|
3209839|NCT00988689|Experimental|Soup + 50 g maltodextrin starch|
3209840|NCT00988702|Experimental|Dan Tian Breathing|subjects received one-month's training on the Dan Tian Breathing
3209841|NCT00988702|Active Comparator|Progressive muscle relaxation training|Subjects received one-month's conventional progressive muscle relaxation training
3209842|NCT00988715|Experimental|Treatment (PRIT, transplant)|Patients undergo pretargeted radioimmunotherapy comprising a test dose of BC8-SA conjugate IV on day -22 and 111In-DOTA-biotin IV on day -20, followed by a therapy dose of BC8-SA conjugate IV on day -14 and 90Y-DOTA-biotin IV on day -12. Patients receive fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and then peripheral blood stem cell transplant on day 0. Patients with matched related donors receive cyclosporine IV on days -3 to 56 and taper to day 180 and mycophenolate mofetil PO BID on days 0-27. Patients with matched unrelated donors receive cyclosporine IV on days -3 to 100 and taper to day 180 and mycophenolate mofetil PO TID on days 0-40 and taper to day 96.
3209843|NCT00988728|Experimental|SCH 900435|SCH 900435 (Org 25935): a Glycine Uptake Inhibitor
3209844|NCT00988728|Placebo Comparator|Placebo|
3209845|NCT00988728|Active Comparator|Olanzapine|
3209846|NCT00988741|Experimental|ARQ 197|
3209847|NCT00988741|Placebo Comparator|placebo|
3209848|NCT00988754|Active Comparator|A|Medical examination once per year, school and family-based lifestyle intervention including a weekly health lesson, school-affiliation to sports clubs and regularly trainings for teachers and parents
2573295|NCT02411773|Active Comparator|Exercise Training/Sodium Bicarbonate|Subjects with CKD will undergo exercise training on a stationary bicycle for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each exercise session three times a week.
2573298|NCT02411773|Active Comparator|Exercise Training/Placebo|Subjects with CKD will undergo exercise training on a stationary bicycle,for 20-45 minutes, 3 times per week, for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
2573301|NCT02411773|Active Comparator|Stretching/Sodium Bicarbonate|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 1300-2600 mg (2-4 pills) of sodium bicarbonate prior to each stretching session three times a week.
2573306|NCT02411773|Placebo Comparator|Stretching/Placebo|Subjects with CKD will undergo progressive whole body stretching and toning exercises 3 times a week for 20-45 minutes for 6-12 weeks. Additionally, subjects will take 2-4 placebo tablets prior to each exercise session three times a week.
2573309|NCT02411773|No Intervention|Control|Healthy subjects without CKD will not receive any interventions.
2573388|NCT02411188|Experimental|STEP Program Group|Arm: Intervention: The 12-week STEP Program intervention will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
2573392|NCT02411188|No Intervention|Usual Care Group|The usual care group will follow the routine model of care for post-discharge patients who do not participate in a CRP. Usual care group participants will be given the opportunity/option to participate in the STEP Program in 6 months.
2573417|NCT02410928|Experimental|fiberoptic nasal laringoscopy|the vocal cords ill be visualized with fiberoptic nasal laringoscopy
2573418|NCT02410928|Experimental|ultrasonography|the vocal cords ill be visualized with ultrasonography
2573420|NCT02410928|Active Comparator|Direct laringoscopy|the vocal cords ill be visualized with direct laringoscopy
2573502|NCT02410616|Experimental|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
2573508|NCT02410616|Active Comparator|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
2573542|NCT02410174|Experimental|Stereotactic Body Radiotherapy (SBRT)|Starting dose of 48Gy in 3 fractions, will escalate dose by 2 Gy per fraction (a 6Gy total dose) to a maximum dose of 20Gy x 3 fractions (TD 60 Gy in 3 fractions).
2573596|NCT02409888|Experimental|Intervention|Study participants receive either motivational enhancement therapy (MET) or cognitive behavioral therapy (CBT).
2573600|NCT02409888|Experimental|Assessment|IB Assessment study participants receive semi-annual assessments specific to their alcohol and other drug use and FC Assessment study participants receive quarterly assessments specific to diverse areas of functioning (e.g., alcohol and other drug use, social, occupational, legal, psychological/psychiatric, marital).
2573666|NCT02409485|Experimental|Couples Skill-Training (CST)|CST provides education about acute and long-term side-effects of HNC and teaches: 1) self-management skills to control/prevent side-effects; 2) communication skills to facilitate coordination of care; and, 3) strategies to improve communal coping and confidence in the ability to work as a team.
2573667|NCT02409485|No Intervention|Usual Medical Care (UMC)|Patients receive standard symptom management education by their health care team.
2573719|NCT02409108|Experimental|Exatherm-TBH system|One treatment of Total Body Hyperthermia
2573754|NCT02408822|Active Comparator|PBA (Plain Balloon Angioplasty)|"Patient receiving endovascular treatment of a vascular access stenosis by plain balloon angioplasty (mechanical action, without drug)~2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure"
2573758|NCT02408822|Experimental|PTX|(PacliTaXel-coated balloon angioplasty) Patient receiving endovascular treatment of a vascular access stenosis by drug-eluting balloon angioplasty (mechanical action + antiproliferative drug - Paclitaxel) 2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
2573796|NCT02408393|Placebo Comparator|Placebo|Saline (30 mL maximum)
2573799|NCT02408393|Experimental|Ropivacaine|Ropivacaine 7.5 mg/mL (0.35 mL/kg of solution)
2573860|NCT02408055|Experimental|Radiolabelled TA-8995|
3209849|NCT00988754|No Intervention|B|Medical examination and information on a healthy lifestyle.
3209850|NCT00988767|Experimental|intramuscular injections|Patients received 4 injections of DNA vaccine at M0, M2, M4 and M10
3209851|NCT00988780|Experimental|Maraviroc|"Maraviroc 600mg po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID"
3209852|NCT00988780|Placebo Comparator|Placebo|"Placebo po BID~Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID"
2574404|NCT02404259|Other|non-nucleoside reverse transcriptase inhibitor (NNRTI)|Efavirenz
3209853|NCT00988793|Active Comparator|Laparoscopic distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
3209854|NCT00988793|Active Comparator|Open distal pancreatectomy|Comparison between two different types of surgery, open vs. laparoscopic distal pancreatectomy
3209855|NCT00988806|Active Comparator|Levosimendan|infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours.
3209856|NCT00988806|Placebo Comparator|Placebo|infusion of placebo for 24 hours.
3209857|NCT00988819||No treatment|
3209858|NCT00988845|Experimental|Indole-3-carbinol|
3209859|NCT00988871||Liver transplantation (LT) recipients|LT recipients who had both PICC and CICC at the same time according to the LT protocol of our hospital
3209860|NCT00988897|Experimental|1|"Patients will receive modified FOLFOX-6 regimen:~oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)~LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)~5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)~A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician."
3209861|NCT00988910||Group 1|
3209862|NCT00988910||Group 2|
2573571|NCT02409953|Experimental|Bath|
2573576|NCT02409953|Placebo Comparator|Bed|
2573633|NCT02409745|Experimental|Young age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
2573634|NCT02409745|Active Comparator|Young age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
2573635|NCT02409745|Experimental|Advanced age group-Luteal phase|Endometrial injury in luteal phase (previous menstrual cycle) for patients undergoing Frozen thawed embryo transfer.
2573640|NCT02409745|Active Comparator|Advanced age group-Early follicular phase|Endometrial injury in early follicular phase for patients undergoing Frozen thawed embryo transfer.
2573724|NCT02409173|Experimental|Noninvasive Ventilation and Surgery|Noninvasive positive airway pressure flow generator device by full face or nasal mask and bariatric surgery.
2573726|NCT02409173|No Intervention|Control Group|
2573768|NCT02408666|Other|Interview|"Interview of epilepsy patients and their family about their experience with epilepsy, EEG registrations and daily life.~Interview of EEG-technologists and neurologists about their experience with EEG registrations and expections when thinking of a ideal EEG-cap."
3209863|NCT00988923|Experimental|group a: Hyperthermia (HT)|HT were treated for 20 minutes per session, a total of 8 sessions with device;
3209864|NCT00988923|No Intervention|group b: No intervention|device was switched in off, only bolus was active
2573894|NCT02407691|Experimental|Primary Care 101 Enhanced guideline|Primary Care 101 guideline with enhanced mental health
2573895|NCT02407691|Active Comparator|Standard of care|Primary Care 101 standard version guideline
3209865|NCT00988936|Experimental|[F-18]RDG-K5|
3209866|NCT00988949|Experimental|PF-04455242 18 mg|Subjects in this arm will receive a single 18 mg oral dose of PF-04455242 prior to spiradoline challenge
3209867|NCT00988949|Placebo Comparator|Placebo|Subjects in this arm will receive placebo prior to spiradoline challenge.
3209868|NCT00988949|Experimental|PF-04455242 30 mg|Subjects in this arm will receive a single 30 mg oral dose of PF-04455242 prior to spiradoline challenge.
3209869|NCT00988962|No Intervention|High-Risk No Treatment|
2574223|NCT02405481|No Intervention|Wait List Control|
2574225|NCT02405481|Experimental|SEPA III Intervention|SEPA brings together two important theoretical perspectives that will be effective and sustainable for HIV/AIDS prevention among Hispanic women in an inner city environment. The content and learning strategies of SEPA are based on the social cognitive theory and of HIV/AIDS prevention that prior research has shown to be the most effective in increasing HIV/AIDS prevention behaviors, modified to take into account the special needs of Hispanic women related to gender inequality and cultural values and practices. SEPA's conceptual framework integrates the Social Cognitive Model of behavioral change with Freire's Pedagogy of the Oppressed that guides the delivery and contextual tailoring.
2574241|NCT02405143|Experimental|Active tACS using DC-Stimulator MC|15 to 30 patients will be randomized to the arm receiving the active transcranial alternating current stimulation (tACS) treatment using DC-Stimulator MC.
2574250|NCT02405143|Sham Comparator|Sham stimulation using DC-Stimulator MC|The same number of patients as in the active arm, 15 to 30, will be randomized to receive sham stimulation using DC-Stimulator MC.
2574318|NCT02405000|Experimental|Intraoperative CT imaging|
3209870|NCT00988962|Experimental|High-Risk Treatment|
3209871|NCT00988962|No Intervention|Low-Risk|
3209872|NCT00988975|Active Comparator|Pelvicol graft|
3209873|NCT00988975|No Intervention|No graft material|No graft material
3209874|NCT00988988|Active Comparator|Steroid Cream|1% steroid cream
3209875|NCT00988988|Active Comparator|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled
3209876|NCT00988988|Active Comparator|placebo|inactive cream
3209877|NCT00989001|Experimental|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
3209878|NCT00989001|Placebo Comparator|Placebo|Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant
3209879|NCT00989027|No Intervention|No treatment|A control sample from each patient (no uterotonic drug applied) will be measured concurrently with samples treated with various drugs.
3209880|NCT00989027|Active Comparator|Treatment|Samples from each patient will be bathed in solutions containing varying concentrations of either oxytocin, carboprost and ergonovine, and contractility will be measured.
3209881|NCT00989053|Active Comparator|escitalopram|
3209882|NCT00989053|Placebo Comparator|placebo|
3209883|NCT00989079|Experimental|Cohort 1 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) ertugliflozin (E) 10 mg → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3209884|NCT00989079|Experimental|Cohort 1 Sequence 2|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 100 mg → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3209885|NCT00989079|Experimental|Cohort 1 Sequence 3|Period 1 (fasted) E 0.5 mg → Period 2 (fasted) E 10 mg → Period 3 (fasted) Placebo → Period 4 (fed) E 100 mg. Each dose of study drug will be separated by a minimum of 7 days.
3209886|NCT00989079|Experimental|Cohort 2 Sequence 1|Period 1 (fasted) Placebo → Period 2 (fasted) E 30 mg → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
3209887|NCT00989079|Experimental|Cohort 2 Sequence 2|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) Placebo → Period 3 (fasted) E 300 mg. Each dose of study drug will be separated by a minimum of 7 days.
3209888|NCT00989079|Experimental|Cohort 2 Sequence 3|Period 1 (fasted) E 2.5 mg → Period 2 (fasted) E 30 mg → Period 3 (fasted) Placebo. Each dose of study drug will be separated by a minimum of 7 days.
2573424|NCT02411006|No Intervention|Usual care control|No intervention, just usual care from the insurance company
2573426|NCT02411006|Experimental|Reminder control|Send a reminder to subjects every month
2573427|NCT02411006|Experimental|Anonymous prediction|Ask subjects to anonymously predict their upcoming medication adherence
2573428|NCT02411006|Experimental|Anonymous commitment|Ask subjects to anonymously commit to their upcoming medication adherence
2573435|NCT02411006|Experimental|Identified prediction|Ask subjects to predict their upcoming medication adherence and report it
2573439|NCT02411006|Experimental|Identified commitment|Ask subjects to commit to their upcoming medication adherence and report it
2573496|NCT02410499|Placebo Comparator|Placebo|MLN1202 placebo-matching solution, subcutaneous injection (SC), once, on Day 1 (loading dose), followed by MLN1202 placebo-matching solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
2573500|NCT02410499|Experimental|MLN1202 75 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 75 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
2573501|NCT02410499|Experimental|MLN1202 105 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 105 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
2573504|NCT02410499|Experimental|MLN1202 150 mg|MLN1202 450 mg, solution, SC injection, once, on Day 1 (loading dose), followed by MLN1202 150 mg, solution, SC, once, weekly, on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78.
2573546|NCT02410187|Active Comparator|Arm 1|systemic therapy+palliative RT
2573552|NCT02410187|Experimental|Arm 2|systemic therapy+SBRT
2573594|NCT02409810|Experimental|PCA-DEX Patients|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10mins by nurse staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg.
2573649|NCT02409550||113 patients with concomitant asthma and allergic rhinitis|113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of Pediatric Allergology & Pulmonology (PAP) of Respiratory Disease Research Center (RDRC) within the Institute of Biomedicine and Molecular Immunology (IBIM) of the National Research Council (CNR) of Palermo (RDRC-IBIM CNR), Italy.
2573707|NCT02409251|Experimental|Education and feedback|The intervention consisted of a one-hour, small group educational session. During this session information on rational ANA testing was provided and feedback on current ANA testing was provided to the rheumatologists. A booster session with the same components was held 6 months after the first session.
3209889|NCT00989118|Experimental|Laser treatment|
3209890|NCT00989118|Active Comparator|Endometrioma cystectomy|
2573811|NCT02408289|Placebo Comparator|Lo-Flav|Low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage
2573819|NCT02408289|Active Comparator|Hi-Flav|Cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
2573824|NCT02408289|Active Comparator|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage.
2573827|NCT02408289|Active Comparator|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
2573859|NCT02407860|Experimental|treatment|one single osteopathic treatment in addition to usual breastfeeding counselling
2573870|NCT02407860|Active Comparator|control|usual breastfeeding counselling. Osteopathic evaluation of entire body
2573897|NCT02407665|Experimental|Tai Chi|Participants who practice Tai Chi 2X/week for 12-weeks
2573900|NCT02407665|No Intervention|Healthy Control|24 healthy controls
2573930|NCT02407418|Active Comparator|Spinal Manipulation|In a repeated measures, crossover design, all subjects received spinal manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
2573933|NCT02407418|Sham Comparator|Sham Manipulation|In a repeated measures, crossover design, all subjects received the sham manipulation during the second or third session. The selection of spinal manipulation or sham was randomized.
2573959|NCT02407145||PVDF retropubic midurethral sling|Women with urodynamic stress urinary incontinence having a retropubic polyvinylidene fluoride midurethral sling (DynaMesh®-SIS soft).
2574056|NCT02406794|Experimental|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
2574057|NCT02406794|No Intervention|No Kinesio taping|No Kinesio taping
2574102|NCT02406313|Experimental|CTS + ETP|Patients following a standardized thermal cure (CTS) follow an additional program called Fibr'eaux (ETP) that consists in discussion groups and physical activities allowing patients to learn how to manage their illness.
2574105|NCT02406313|Active Comparator|CTS alone|Patients follow a standardized thermal cure that is a sedative, relaxing, antalgic and mobilizing treatment based on muds application, hydrotherapy and physiotherapy. The cure is made of 72 treatments selected among a list including muds application, massages, reeducation in thermal pool, baths and showers.
3209891|NCT00989131|Experimental|Paclitaxel, micellar (Paclical®)|
3209892|NCT00989131|Active Comparator|Paclitaxel, CrEL (Taxol®)|
3209893|NCT00989170|Experimental|Family Program for the Prevention of Weight Gain|Use of an enhanced Family Program on the prevention of weight gain in families with overweight children.
3209894|NCT00989170|Active Comparator|No enhanced Family Program|
3209895|NCT00989209|Active Comparator|A: myofunctional prior to botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group A, botulinum toxin was applied after myofunctional therapy.
3260237|NCT01477580|Experimental|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
2573371|NCT02411253|Experimental|rhIL-2|"0.5 MIU/m²/day of IL2 with a maximum of 1MIU/day in a volume of 1 ml for children and adolescents,~1MIU/day for adults.~Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351,~Regimen B injections every week between D15 and D351"
2573374|NCT02411253|Placebo Comparator|Placebo|"Placebo with a identical formulation and regimen of injections i.e. Subcutaneous injection every day (5 days) then:~Regimen A injection every two weeks between D15 and D351~Regimen B injections every week between D15 and D351"
3209896|NCT00989209|Active Comparator|B: myofunctional after botulinum|All the facial paralysis patients received treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol. To the participants of Group B, botulinum toxin was applied before myofunctional therapy.
2573580|NCT02409940|Experimental|Autologus Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant recipient's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
2573582|NCT02409940|Active Comparator|Allogeniec Mesenchymal Stem Cells|This group would get two doses of mesenchymal stem cell (MSCs) infusion, one day pre transplant and 30 days post transplant. These MSCs would be derived from transplant donor's bone marrow which are cultured in GMP compliant laboratories for 4-6 weeks.
2573585|NCT02409940|No Intervention|Control without Mesenchymal Stem Cells|This group would get no stem cell infusion.
3209897|NCT00989222|Other|Volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
3209898|NCT00989222|Other|External fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
2573772|NCT02408926|Experimental|Group A|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a hexavalent acellular pertussis containing vaccine (Infanrix hexa).
2573777|NCT02408926|Active Comparator|Group B|Women will be vaccinated with an acellular pertussis containing vaccine (Boostrix) between 27 and 36 weeks of gestation. Children born from these mothers will be vaccinated according to the official recommendations in Thailand at 2, 4, 6 and 18 months with a pentavalent whole cell pertussis containing vaccine (Quinvaxem). OPV (oral poliovirus vaccine) will also be administered at 2, 4, 6 and 18 months.
2573797|NCT02408237|Active Comparator|tDCS Ambulatory & Sham|Active tDCS Ambulatory: 1 mA of current of active tDCS applied for 20 minutes, single session of stimulation. Sham tDCS Ambulatory: applied for 20 minutes, single session of stimulation.
2573800|NCT02408237|Active Comparator|tDCS home use & Sham|Active tDCS home use: 11 active tDCS sessions: single session in the hospital and the remaining 10 in the subject's home, with duration of each active tDCS session of 20 min. Sham tDCS home use: 11 sessions of tDCS: single session in the hospital and the remaining 10 in the subject's home, with duration of each sham tDCS session of 20 min.
2573868|NCT02408042|Active Comparator|RICE and Pembrolizumab|non-Hodgkin's lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
2573877|NCT02408042|Active Comparator|ICE and Pembrolizumab|classical Hodgkin's lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
2573879|NCT02408042|Active Comparator|brentuximab vedotin and Pembrolizumab|classical Hodgkin's lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin
2573911|NCT02407483|Experimental|Laser Visual Guidance group|Will be tested using simulated laparoscopic tasks with the use of laser visual guidance
2573913|NCT02407483|Active Comparator|Normal 2D vision group|Will be tested using simulated laparoscopic tasks without the use of laser visual guidance
2573960|NCT02407210|Experimental|azilsartan group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
2573965|NCT02407210|Active Comparator|olmesartan medoxomil group|Once-daily oral administration of 20 or 40 mg tablet before or after breakfast
2574014|NCT02406872|Experimental|Remimazolam Tosilate 1|IV pumping of Remimazolam Tosilate at 6mg/kg/h for anesthesia induction
2574015|NCT02406872|Experimental|Remimazolam Tosilate 2|intravenous pumping of Remimazolam Tosilate at 12mg/kg/h for anesthesia induction
2574016|NCT02406872|Experimental|Remimazolam Tosilate 3|intravenous pumping of Remimazolam Tosilate at 18mg/kg/h for anesthesia induction
2574018|NCT02406872|Active Comparator|Propofol|single IV bolus of Propofol at 2.0-2.5mg/kg for anesthesia induction
2574064|NCT02406560|Experimental|4 tablets of 12.2 mg tafamdis free acid|
2574069|NCT02406560|Experimental|4 tablets of 12.2 mg tafamidis free acid|
2574072|NCT02406560|Experimental|5 tablets of 12.2 mg tafamidis free acid|
3209899|NCT00989248|Experimental|comparation VE/VO2 and VE/VCO2|
3209900|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 15 ug & trivalent|120 participants selected by random
2574202|NCT02405689|Active Comparator|remifentanil|In the remifentanil group, anesthesia was maintained with 0.5-1.5% sevoflurane and 0.125-0.25 μg/kg/min remifentanil infusion during surgery
2574210|NCT02405689|Active Comparator|dexmedetomidine|In the dexmedetomidine group anesthesia was maintained with 0.5-1.5% sevoflurane and 0.5 μg/kg dexmedetomidine loading dose during 10 minute and then 0.3-0.9 μg/kg/min infusion.
2574237|NCT02405169|Experimental|Test -4 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with four with titanium Cad/Cam framework.
2574440|NCT02403973|Other|Patient hotel group|
2574447|NCT02403973|Other|Ward group|
3209901|NCT00989274|Active Comparator|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|120 participants selected in random form
3209902|NCT00989274|Active Comparator|Vaccine Sanofi A(H1N1) 7.5 ug|120 participants selected in random form
3209903|NCT00989300|Experimental|Treatment group|patients received clopidogrel 75 mg with rabeprazole 20 mg, omeprazole 20 mg, or placebo in a crossover manner
3209904|NCT00989300|Placebo Comparator|Placebo group|
3209905|NCT00989313||1|
3260238|NCT01477580|Experimental|Medium-dose Non-adjuvanted V180|
3260239|NCT01477580|Experimental|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|
2573381|NCT02411123|No Intervention|control|The medical provider for the control group will not receive IDgenetix Neuropsychiatric Test Panel results and will make treatment recommendations as usual. Patient outcomes will be measured throughout the duration of the study.
2573444|NCT02410941|Experimental|Decision-support for MTBI|Clinical decision support will be provided on ordering CT scans for patients suspected to have Minor Traumatic Brain Injury (MTBI) to treating physicians randomized into this group. This arm will also serve as a control for the PE group.
2573448|NCT02410941|Experimental|Decision-support for PE|Clinical decision support will be provided on ordering CT scans for patients suspected to have Pulmonary Embolism (PE) to treating physicians randomized into this group. This arm will also serve as a control for the MTBI group.
2573520|NCT02410460|Other|PKA-BIS (intravenous anesthesia)|"Received the following medications:~clonidine 0.1-0.2mg glycopyrrolate 0.2mg propofol infusion titrated to BIS of 60-75 ketamine 50mg + additional ketamine not to exceed 200mg aggregate dosage throughout the case local anesthetic (lidocaine/marcaine mix)"
2573522|NCT02410460|Other|Inhalational anesthesia|"Received the following:~Pre-operatively:~famotidine 20mg scopolamine 1.5mg transdermal patch midazolam 2mg ondansetron 8mg metoclopramide 10mg glycopyrrolate - dose determined by anesthesiologist~During the case, medication choices and dosing were dependent on the anesthesiologist - all general anesthesia cases received inhalational anesthetic (type of anesthetic - desfluorane vs. sevofluorane - also varied based on anesthesiologist's choice)"
2573587|NCT02409966|Active Comparator|Quadrant-wise scaling|Patients underwent quadrant scaling under local anesthesia in four weekly sections.
2573588|NCT02409966|Experimental|Full-mouth 24-hour scaling|Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours.
2573628|NCT02409628|Experimental|EktoTherix|One application of the EktoTherix scaffold to a fresh wound resulting from a full thickness excision of skin cancer.
2573690|NCT02409290|Active Comparator|Regimen A|Regimen A locally-used WHO-approved MDR-TB regimen in accordance with 2011 WHO MDR-TB treatment guidelines.
2573691|NCT02409290|Active Comparator|Regimen B|"Regimen B is based on the regimen described by Van Deun 2010. With Version 8.0 of the protocol Regimen B (Regimen Bmox) is modified by replacement of moxifloxacin with levofloxacin (Regimen Blev). Regimen B without specification of which fluoroquinolone is in the regimen refers to either (Bmox or Blev).~Product and dose for [<33 kg, 33-50kg, >50 kg] respectively:~Moxifloxacin [400mg, 600mg, 800mg] OR Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg,100mg,100mg]; Ethambutol [800mg,800mg,1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid 300mg, 400mg, 600mg]; Prothionamide [250mg,500mg,750mg]; Kanamycin [15mg per kilogram body weight (maximum 1g)]."
2573692|NCT02409290|Experimental|Regimen C|"Regimen C is a 40-week all-oral regimen consisting of bedaquiline, clofazimine, ethambutol, levofloxacin, and pyrazinamide given for 40 weeks supplemented by isoniazid and prothionamide for the first 16 weeks (intensive phase).~Product and dose for [<33kg, 33-50kg, >50 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200 mg thrice weekly thereafter; Levofloxacin [750mg, 750mg,1000mg]; Clofazimine [50mg, 100mg, 100mg]; Ethambutol [800mg, 800mg, 1200mg]; Pyrazinamide [1000mg,1500mg, 2000mg]; Isoniazid [300mg, 400mg, 600mg]; Prothionamide [250mg, 500mg,750mg]."
2573693|NCT02409290|Experimental|Regimen D|"Regimen D is a 28-week regimen consisting of bedaquiline, clofazimine, levofloxacin, and pyrazinamide given for 28 weeks supplemented by isoniazid and kanamycin for the first 8 weeks (intensive phase).~Product and dose for [<33kg, 33 to<40kg, 40-50kg, >50-60 kg, >60 kg] respectively:~Bedaquiline 400mg once daily for first 14 days/200mg thrice weekly thereafter; Levofloxacin [750mg, 750mg, 750mg, 1000mg, 1000mg]; Clofazimine [50mg, 100mg, 100mg, 100mg, 100mg]; Pyrazinamide [1000mg,1500mg, 1500mg, 2000mg, 2000mg]; Isoniazid [400mg, 500mg, 600mg, 800mg, 900mg]; Kanamycin [15 mg per kilogram body weight (maximum 1g)]."
2573757|NCT02408601|Active Comparator|Group 1|"split mouth study. one side of the arch that is the lower left permanent 1st molar will be receiving resin based sealants.~Application of the resin sealants as per the standard instructions of the manufacturer~Helioseal -F ( Resin based sealant)~isolate the tooth surface~etch the fissure anatomy with 37% phosphoric acid for 20 seconds~wash the tooth surface and dry it. No salivary contamination is accepted~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~light cure the sealant~check for high points and the occlusion"
2573760|NCT02408601|Experimental|Group 2|"split mouth study. one side of the arch that is the lower right permanent 1st molar will be receiving ART sealants.~Application of the ART sealants as per the standard instructions of the manufacturer~isolate the tooth surface~condition the fissure anatomy using a GC conditioner for 10 seconds~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~dry the tooth surface~mix the GIC according to the standard powder: liquid ratio~place the mix onto the fissures using a plastic spatula~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~apply pressure for 10-15 sec and withdraw the finger in a sideways motion~scrap out the excess material~check for the high points and the occlusion~apply petroleum jelly onto the GIC mix~advice patient not to eat or drink for 30 minutes."
3175645|NCT00636454|Experimental|2|This group will take part in the 10-session treatment program that will teach patients cognitive and behavioral skills to cope with pain.
3175646|NCT00636467|Experimental|No label|Injection of Nanocis® or Nanocoll® (Tc-colloid) on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
2573909|NCT02407743||Surgical patients' clinical progression|Patients undergoing non-ambulatory surgery will be asked questions and complete surveys in an effort to characterize postoperative pain experience profiles. A blood sample will be obtained for genetic markers exploring a variety of pain-related genes.
2574059|NCT02406755|No Intervention|Control|This control group will not receive an intervention.
2574063|NCT02406755|Active Comparator|one-sensory self care|Daily moisturizing body care with an odorless moisturizer (Todo Dia® - Natura) for 30 days.
2574068|NCT02406755|Active Comparator|bi-sensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days.
2574071|NCT02406755|Active Comparator|multisensory self care|Daily moisturizing body care with a moisturizer with cotton fragance (Todo Dia® - Natura) for 30 days, and will watch a video with music and images of nature during self-care.
3175647|NCT00636480|Experimental|CHG 2%-26 ml|Chlorhexidine gluconate in an aqueous base, 26 ml applicator
2573389|NCT02411318|Experimental|Caffeine Consumption|Participants will be exposed to a moderate dose of caffeine (200 mg capsule in one sitting) from a common commercial product. After consent and screening, a baseline blood sample will be acquired using the lancet puncture procedure. The participant will then be instructed to swallow a 200 mg caffeine capsule. Two additional lancet punctures will be performed after the caffeine ingestion: one after 30 minutes post-ingestion and another one after 60 minutes.
2573395|NCT02411318|Experimental|Ethanol Ingestion|Participants will be weighed and their required alcohol dose determined according to the equation used by the Madison Police Department during alcohol training workshops: 1 mL of 80 proof (40%) alcohol per pound of body weight. Participants will be permitted to consume the drink at their own pace, although no slower than one drink per hour. Breath Alcohol Concentration (BAC) will be tested 20 minutes after drinking has ceased in order to clear mouth alcohol that may affect the BAC reading. Participants at 0.05 BAC and above will have blood drawn via lancet puncture. In addition to the lancet puncture done once the alcohol level is reached, an additional lancet puncture will be performed 1 hour later.
2573396|NCT02411318|Experimental|Glucose Ingestion|After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
2573400|NCT02411318|Experimental|Glucose and Caffeine Ingestion|After a baseline blood sample is acquired, participants will swallow 200mg of caffeine in capsule form and consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the caffeine and glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
3209906|NCT00989326|Active Comparator|CONTROL group|The patients receive standard of care for 18 months. The CONTROL group patients will be equipped with Home Monitoring. However, the Home Monitoring data will not be used for patient surveillance; i. e. the patient will be followed in the conventional manner.
3209907|NCT00989326|Experimental|ACTIVE group|The patients are followed by Home monitoring only. Every patient must be seen by his physician 18 months after enrolment for regular follow-up. Within this period, the additional Pace Maker follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception or patient/physician call
3209908|NCT00989339|Experimental|Twenty-four Hour TPN and Saline Infusion|Subjects will be admitted to the Grady research center on the evening before each study. The next morning, after an overnight fast, they will receive, in random order, Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr. The interval between admissions will be 1 month.
2573581|NCT02409979|Active Comparator|Carbon dioxide method|Colonoscopy performed as usual, with the minimal CO2 insufflation required to aid insertion and adequate distension during withdrawal for exploration. Washing allowed as needed. Considered to be standard procedure.
2573584|NCT02409979|Experimental|Water Exchange-CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using carbon dioxide insufflation.
2573586|NCT02409979|Experimental|Water Exchange-AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for opaque water. Air pockets and residual feces will be always aspirated. Withdrawal phase done using air insufflation.
2573621|NCT02409602||Women with BIIAL|Women who underwent bilateral internal iliac artery ligation due to postpartum hemorrhage within last 2 months
2573623|NCT02409602||Healthy puerperal women|Age-matched healthy puerperal women who delivered within last 2 months
2573678|NCT02409303|Experimental|Screen-Refer-Treat Intervention|PCPs and EI Providers receive training workshops on validated, evidence-based practices (i.e., Online M-CHAT-R/F, STAT, and RIT) and then receive TA (i.e., Screen-Refer-Treat Intervention). At the county level, providers are randomized to the order/timing at which they will receive this system intervention
2573679|NCT02409303|No Intervention|Control|No intervention received.
2573689|NCT02409004|Experimental|Ataluren|Ataluren 1375 mg powder for oral suspension administered once daily on Days 1 and 11 Rifampin 300 mg capsules administered twice daily on Day 3 to Day 12
2573790|NCT02408562|Experimental|sNN0031|sNN0031 Infusion Solution (in aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
2573791|NCT02408562|Placebo Comparator|Placebo|Articifial Cerebro Spinal Fluid (aCSF) for intracerebroventricular (i.c.v.) administration by an implanted infusion pump
2573841|NCT02408081|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in elderly medical patients.
2573843|NCT02408081|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
2573882|NCT02407795|Active Comparator|Arm 1|Conventional radiotherapy, 1x8Gy
2573883|NCT02407795|Experimental|Arm 2|Stereotactic radiotherapy, 1x20Gy
2573920|NCT02407496||ADHD|Adults with Attention Deficit Hyperactivity Disorder (ADHD)
2573928|NCT02407496||Control|Healthy individuals without ADHD
2573957|NCT02407184|No Intervention|Scheduled C-section|Babies that are scheduled to be born in a hospital via standard C-section procedure.
2573961|NCT02407184|No Intervention|Vaginal Delivery|Babies that are born via vaginal delivery, either at home, at a birthing center or hospital. Drugs may be administered during labor.
2573966|NCT02407184|Experimental|Scheduled C-section with Exposure|Babies that are scheduled to be born in a hospital via standard C-section procedure, as well as are swabbed with gauze containing their mother's vaginal microbiota just after delivery. The intervention: Newborn exposure to mother vaginal microbiota.
3209909|NCT00989365|Other|Patient cousenling|Improve medicine use Self control asthma crisis Ambient hygiene
3209910|NCT00989378||control|normal healthy men and women
3209911|NCT00989391|Experimental|Cohort 1|Subjects will be assigned to receive either PF-03654764 or placebo.
3209912|NCT00989391|Experimental|Cohort 2|Subjects will be assigned to receive either PF-03654764 or placebo.
3209913|NCT00989391|Experimental|Cohort 3|Subjects will be assigned to receive either PF-03654764 or placebo.
3209914|NCT00989404|Experimental|Period|10 mg BID Zanamivir or placebo for 5 days
2573406|NCT02411045|Experimental|Group 3: Exercise for Success|Ask participants to take a picture of themselves while wearing their workout gear and complete a 30-minute workout
2573436|NCT02410785|Active Comparator|Medical device polyglucosamine|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
2573443|NCT02410785|Placebo Comparator|Placebo|2 times daily 2 tablets with the two main meals with the highest fat content. Participants follow the German guideline with a hypo-caloric (-500 kcal daily) lifestyle and increased physical activity.
2573488|NCT02410590|Experimental|Rocuronium + Sugammadex|Participants will receive rocuronium administered at a dosage adequate to make intubation possible and provide deep NMB (defined as no response to train-of-four stimulation but at least one response to five post-tetanic count [PTC]) for the duration of surgery, until the end of the procedure. Sugammadex will be administered to participants once at a dosage of 4 mg/kg real body weight (RBW) IV at the end of surgical procedure. Sugammadex will be used as the only reversal drug in all participants who receive rocuronium as a neuromuscular blocker.
2573495|NCT02410590|Active Comparator|Succinylcholine + Cisatracurium + Neostigmine/Atropine|After receiving succinylcholine 1.0 mg/kg RBW for intubation, participants will receive cisatracurium administered at dosage adequate to have a moderate NMB (defined as a target of TOF ratio = 10% with a range: 2-3 twitches to TOF ratio of 20%) for the duration of surgery, until the end of the procedure. Neostigmine/Atropine will be administered to participants once at respective dosage of 0.05 mg/kg RBW and 0.01 mg/kg RBW at least after the reappearance of T2 after surgery completion. The maximum allowed dosage for Neostigmine is 5 mg. Neostigmine will be used as only reversal drug in all participants who received Cisatracurium as neuromuscular blocker.
2573651|NCT02409381|Experimental|Motore|Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours
2573659|NCT02409381|Active Comparator|Alivium|Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.
2573694|NCT02409069|Experimental|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the ramus auricularis of the vagus nerve (ear)
2573705|NCT02409069|Sham Comparator|Sham stimulation (Nemos®, Cerbomed GmbH)|Stimulation of the earlobe
2573709|NCT02409069|No Intervention|No stimulation|No stimulation
3175648|NCT00636480|Active Comparator|ChloraPrep 26 ml|ChloraPrep One-Step 26 ml Active drug contains chlorhexidine gluconate and alcohol
2573937|NCT02407366|Experimental|Icotinib with concurrent radiotherapy|Icotinib (125 mg ,three times daily)with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by maintenance icotinib (125 mg ,Three times daily) until disease progression or unacceptable toxicity.
2573940|NCT02407366|Active Comparator|Chemoradiotherapy|Pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days for three cycles with concurrent thoracic radiotherapy(TRT) (66 Gy/33 fractions), followed by consolidation chemotherapy with two cycles of pemetrexed(500mg/m2) + carboplatin (AUC，5) every 21 days.Maintenance pemetrexed(500mg/m2) will be administered after consolidation chemotherapy until disease progression or unacceptable toxicity .
2574011|NCT02407015|Active Comparator|3D gameplay|Participants will play a game for 30 minutes on the Nintendo 3DS in 3D.
2574012|NCT02407015|Active Comparator|2D gameplay|Participants will play a game for 30 minutes on the nintendo 3DS in 2D.
2574134|NCT02405975|No Intervention|Control|These participants will not receive the educational intervention
2574135|NCT02405975|Experimental|Intervention|"These participants will receive the online educational intervention SCRIPT"
2574176|NCT02405767|Experimental|Foot ulcer impedance|Diabetic patients with a diabetic foot ulcer
2574267|NCT02405416|Experimental|IIVCC group|The portal triad and infrahepatic inferior vena cava are dissected and taped with a vessel loop, respectively. During liver parenchymal resection，portal triad and infrahepatic inferior vena cava clampings are performed at the specified transection depth from liver surface successively.
2574269|NCT02405416|Active Comparator|SHVE group|In this group, the portal triad clamping and selective hepatic vascular exclusion of major hepatic veins are used. Different major hepatic veins are occluded by clamping forcep depending on the site of tumors. The clamping timepoints are same as the IIVCC group.
2574581|NCT02403141||Normal glucose tolerance|Patients with normal fasting glucose. Blood glucose less than 5.6mmol/L
3175649|NCT00636480|Placebo Comparator|Sterile Saline|Sterile salt water administered topically.
3175650|NCT00636493|Experimental|Vein Occlusion Eye|Eye with retinal vein occlusion receiving fluocinolone acetonide sustained drug delivery device
3175651|NCT00636519|Experimental|Stage A|Botulism Antitoxin Bivalent (Equine) Types A and B Vs. Placebo
3175652|NCT00636519|Experimental|Stage B|Botulism Antitoxin Heptavalent (Equine) Types A-G Vs. Placebo
3175653|NCT00636545|Experimental|Part 1|Cohort 1- Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a dose of 300 mg to the first subject enrolled and, in the absence of dose-limiting toxicity, in increasing increments of 100 mg to each successive subject enrolled to a maximum dose of 1000 mg.
3175654|NCT00636545|Experimental|Part 2|Genasense will be administered as a 2-hour intravenous infusion twice weekly for 3 weeks at a dose established based on Part 1 of the study.
3175655|NCT00636545|Experimental|Cohort 2|Also in Part 1 of the study, Genasense will be administered as a 2-hour intravenous infusion once weekly for 3 weeks at a starting dose of 1100 mg and increasing in increments of 100 mg to the MTD. Patients will be pretreated with a corticosteroid.
3175656|NCT00636558|Experimental|CVA21|IV administration of CVA21 in a dose escalation manner
3175657|NCT00636584|Experimental|1|arm1: sodium nitroprusside group
3175658|NCT00636584|Placebo Comparator|2|arm2: control group,saline infused instead of sodium nitroprusside
3175659|NCT00636597||1|
3175660|NCT00636623|Other|2|Pilates exercises
3175661|NCT00636623|Other|1|Connective tissue massage
3175662|NCT00636662||all|any patient exhibiting symptoms of influenza
3175663|NCT00636688|Experimental|1|Behavioral (Lifestyle Counseling)
3175664|NCT00636688|Active Comparator|2|Control group
3175665|NCT00636714|Experimental|Nurse-directed|Using nursing judgement to control blood glucose
3175666|NCT00636714|Active Comparator|Nomogram-directed|Blood glucose control directed by pre-approved paper nomogram
2573422|NCT02411162|Experimental|Open Label Arm|In Cohort 1, study medication (Cream A, 1%) will be applied as a thin layer onto a predefined area of the volar region of the forearm that is large enough to image and collect 3 biopsies (4 mm per biopsy). Vehicle will be applied on Day 1 only, onto a symmetrical location on the opposite forearm from Cream A. In cohort 2, subjects will be enrolled to evaluate Cream A (1%) and a different GSK2894512 Cream, Cream B (1%). Cream A, 1% and Cream B, 1% will be applied as a thin layer to the opposite forearms of the subject. Vehicle will be applied only on Day 1 to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied. Both Cream A and Cream B will continue to be applied OD to the same area of the same forearm for 7 days.
2573474|NCT02410694|Experimental|Ixazomib-Thalidomide-Dexamethasone|"Combination therapy of:~Ixazomib 4.0mg at days 1, 8, 15, Thalidomide 100mg at days 1 to 28 (50mg in patients aged ≥75 years), Dexamethasone 40mg (20mg in patients aged ≥75 years) at days 1, 8, 15 of a 28-day treatment cycle.~After 8 cycles of ITD therapy, maintenance treatment with 4.0mg ixazomib (3.0mg in patients aged ≥ 75 years at first day of maintenance phase) on days 1, 8, 15 of 28-day cycles will be administered to patients with ≥ MR for a maximum period of 12 months."
3209915|NCT00989417|Active Comparator|CONTROL Group - Without Home Monitoring|Patients receiving the standard of care. Due to safety concerns, the patients are followed every 6 months after a first follow-up, which is performed between 1 and 3 months after implantation.
3209916|NCT00989417|Experimental|ACTIVE GROUP With Home Monitoring|After a first follow-up (between 1 and 3 months after implantation), the patients are followed one time per year. Within this period, the additional ICD follow-up or therapeutic intervention will be primarily triggered on cardio-reports reception, Data/IEGM-online analysis on internet site or patient/physician call.
3209917|NCT00989430|Experimental|Prism Adaptation Treatment|Two weeks of prism adaptation treatment followed by 4 weekly assessments and long-term follow-ups at the 3rd and 6th months.
3260240|NCT01477580|Experimental|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
2573639|NCT02409576|Experimental|Expanded, activated NK Cells(NKEXPSARC)|Intravenous infusion of expanded, activated NK Cells Donor cell will be expanded and activated in the cGMP compliant TECT lab for 10 to 12 days prior to infusion into the patient.
2573722|NCT02409238|Experimental|Lifestyle Intervention and Metformin|Intensive lifestyle interventions at Lifestyle Intervention Centres and Metformin (if Diabetic)
2573725|NCT02409238|Active Comparator|Standard Level of Care|Standard lifestyle recommendations for the Control groups
2573787|NCT02408653|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
2573788|NCT02408653|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
2573789|NCT02408653|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
2573808|NCT02408185|Experimental|Colistin 6 million units + 240mg/8h|Loading dose of 6 million units of colistin+ 240mg/8h maintenance
2573816|NCT02408185|Experimental|Colistin 6 million units + 360mg/12h|Loading dose of 6 million units of colistin+ 360mg/12h maintenance
2573852|NCT02407899|Experimental|Metformin (and insulin) + saxagliptin|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5mg/d and Metformin 1.5g/d (and insulin at individual dose) for 104-week.
2573855|NCT02407899|Experimental|Metformin(insulin)+saxagliptin +vitamin D3|Patients who have diagnosed LADA are assigned to receive Saxagliptin tablets 5 mg/d, vitamin D drop 2000IU/d, Metformin 1.5g/d (and insulin at individual dose) for 104-week.
2573857|NCT02407899|Active Comparator|Metformin (and insulin)|Patients who have diagnosed LADA are assigned to receive Metformin 1.5g/d(and insulin at individual dose) for 104-week.
2573935|NCT02407353|Experimental|PF-06648671 High dose group|subjects receive a single oral dose of PF-06648671 at 300 mg
2573939|NCT02407353|Experimental|PF-06648671 Low dose group|Subjects receive a single oral dose of PF-06648671 lower than 300 mg dose
2573941|NCT02407353|Placebo Comparator|Placebo group|Subjects receive matching placebo
2573942|NCT02407353|Experimental|PF-06648671 Low dose group (2)|Optional arm. Subjects receive a single oral dose of PF-06648671 at second lower dose if 300 mg dose is not repeated in cohort 2
2574028|NCT02406729|Experimental|Dengue 1,2,3,4 (attenuated) vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
2574029|NCT02406729|Placebo Comparator|Placebo|Placebo Single dose, SC
2574152|NCT02406053||OSAS|Obstructive sleep apnea syndrome
2574156|NCT02406053||COPD|Chronic obstructive pulmonary disease
2574157|NCT02406053||LC|Lung cancer
2574159|NCT02406053||HC|Healthy controls
2574177|NCT02405611|Active Comparator|active control|mothers and children are in active control group and only receive the questionnaires
2574193|NCT02405611|Experimental|mother and student|an intervention group in which mothers and children receive the intervention and questionnaires
2574206|NCT02405611|Experimental|children|only the children receive the intervention and mothers and children receive the questionnaires
2574238|NCT02405208||Primary cohort|Primary cohort will receive the PyroTITAN HRA device
2574292|NCT02405026||HIV infected patients|HIV infected patients with asthma
2574293|NCT02405026||HIV uninfected patients|HIV uninfected patients with asthma
2574294|NCT02405026||HIV infected non-asthmatic patients|HIV infected patients without asthma
2574348|NCT02404675|Experimental|21 icotinib (250mg)|Patients with EGFR 21 exon positive are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 250 mg three times per day, till progressive disease or unaccepted toxicity.
2574350|NCT02404675|Active Comparator|21 icotinib (125mg)|Patients with EGFR 21 exon positive are randomly assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
2574352|NCT02404675|Experimental|19 icotinib (125mg)|Patients with EGFR del 19 exon positive are assigned to routine dose icotinib group to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
2574376|NCT02404376|Active Comparator|Remote Ischemic Conditioning|Remote Ischemic Conditioning + placebo
2574379|NCT02404376|Active Comparator|Combined treatment|Remote Ischemic Conditioning + exenatide
2574385|NCT02404376|Placebo Comparator|Placebo|Sham Remote Ischemic Conditioning + placebo
2573446|NCT02410876||Spinal cord injury/Detrusor overactivity|"SCI patients with proven detrusor (urodynamics) overactivity during the filling phase.~Bladder biopsy 6 weeks after trauma 6 months later urodynamic study and bladder biopsy"
2573451|NCT02410876||Prostatic obstruction/acontractile|"Low flow to no flow, no measurable detrusor activity on urodynamic evaluation, cystoscopy in line with obstruction.~Bladder biopsy at TURP (transurethral resection prostate) 3 months later urodynamic study and bladder biopsy"
2573454|NCT02410876||Prostatic obstruction/ obstructed|Obstruction according to Schäfer nomogram on urodynamic evaluation. Bladder biopsy at TURP 3 months later urodynamic study and bladder biopsy
2573481|NCT02410538||"families that received the list of FAQ"|"The intervention consists of the delivery to the relatives of ICU patients a list of 21 key issues in intensive care during the first 48h period of ICU stay, only for intubated and mechanically ventilated patients A formal interview is scheduled to relatives of ICU patients on D3 of inclusion"
2573482|NCT02410538||families that received information as usual|A formal interview is scheduled relatives of ICU patients on D3 inclusion
3175667|NCT00636727|Active Comparator|1|arthrocentesis
3175668|NCT00636727|Active Comparator|2|arthroscopy
2573677|NCT02409316|Experimental|FES PET/CT|All subjects will receive an [18F]FES PET/CT scan.
2573696|NCT02409030||Cognitively Healthy controls|"The neuropsychological test assessment must confirm that there is no cognitive impairment.~In the case of the cognitively healthy controls, CerebroSpinal Fluid tests performed within 24 months of inclusion will be accepted."
2573701|NCT02409030||Alzheimer Disease|Patients with AD will be classified based on currently valid and updated diagnostic algorithms in the NIA-Alzheimer's Association of America Clinical Guidelines (2011).
2573708|NCT02409030||Frontotemporal dementia|Inclusion criterion used will be prior diagnosis based on the diagnostic guidelines published by Dr. Rackovsky (Brain, 2011) for the behavioural variant; and those published by Prof. D. Neary (Neurology, 1998) for primary aphasia. A clinical and neuropsychological assessment is required, with the optional presence of alterations to the progranulin gene (and others) and there must be a compatible, previously performed imaging test (MRI, PET or SPECT) (predominantly frontal or frontotemporal atrophy).
2573746|NCT02408705|Active Comparator|Liraglutide|3-month treatment of liraglutide
2573750|NCT02408705|Placebo Comparator|Placebo|3-month treatment of placebo
2573914|NCT02407613|Experimental|MR-HIFU ablation|Ten patients undergo MR-HIFU ablation with the Sonalleve MR-HIFU Breast Tumor Therapy System (Profound Medical). According to a treat-and-resect protocol, these patients also undergo standard therapy consisting of breast cancer surgery 1 to 2 weeks after MR-HIFU treatment (+/- radiotherapy).
2573953|NCT02407262|Active Comparator|Treatment|"Black seed oil capsules~1g/day for 4 weeks"
2573955|NCT02407262|Placebo Comparator|Placebo|"Placebo (olive oil) capsules~1g/day for 4 weeks"
2574010|NCT02406963|Active Comparator|TTC|Current standard of care- a telephone call with the NP in the event of a post-operative concern where advice/interventions/reassurance is provided based on information provided by family
2574013|NCT02406963|Experimental|PEC|Experimental arm, the standard telephone call with the NP and the addition of a digital photograph of the surgical site for assessment prior to the administration of advice
2574065|NCT02406599|Other|SOC + Device|The surgeon will perform routine standard of care lumpectomy with adjunctive MarginProbe device use on the main ex-vivo lumpectomy specimen.
2574070|NCT02406599|Other|SOC + Additional Inspection|The surgeon will perform routine standard of care lumpectomy with additional inspection on the main ex-vivo lumpectomy specimen.
2574124|NCT02406144|Active Comparator|Lenalidomide|Oral administration of 15 mg/day of oral lenalidomide on days 1-21, and 20 mg/day of dexamethasone administered orally on days 1-4 and 9-12 for a period of two years
2574129|NCT02406144|Experimental|MLN9708 plus Lenalidomide|MLN9708 during the two year maintenance period, at a dose of 4 mg/day on days 1, 8 and 15 of the cycle.
2574214|NCT02405507|Experimental|wheat bread with wheat germ|wheat bread with wheat germ supplementation
2574218|NCT02405507|Placebo Comparator|wheat bread without wheat germ|wheat bread without wheat germ supplementation
2574243|NCT02405182||Patients|ALS patients (as well as patients with other motor neuron diseases such PLS and PMA) will be recruited from ALS clinics under the direction of ALS neurologists who are participating in this study. ALS patients should meet research criteria for possible, probable, probable laboratory-supported, or definite ALS. Patients with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Patients must be able to undergo a brain MRI for approximately an hour.
2574248|NCT02405182||Controls|Healthy controls who are age and gender matched to patients will be recruited. Controls with a history of CNS disease (e.g. stroke, head injury) or significant psychiatric disease will be ineligible. Controls must be able to undergo a brain MRI for approximately an hour.
2574295|NCT02404922|Experimental|CTP-730 Low Dose or Matching Placebo|Capsule, once daily.
2574296|NCT02404922|Experimental|CTP-730 Mid Dose or Matching Placebo|Capsule, once daily
2574298|NCT02404922|Experimental|CTP-730 High Dose or Matching Placebo|Capsule, once daily.
2574390|NCT02404584||The study population|"Patients with kidney cancer and will be starting treatment via sunitinib at the study start will be included.~Intervention: Blood drawn for genotyping Intervention: Blood drawn for pharmacokinetic measures"
2574445|NCT02404051|Experimental|ARM 1|Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)
2574452|NCT02404051|Experimental|ARM 2|Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)
2574490|NCT02403518|Active Comparator|Back Pain Only|Pain localized to the low back or buttocks.
3175669|NCT00636727|Active Comparator|3|arthroplasty
3175670|NCT00636740|Experimental|B|MER-101 20mg Tablets Regimen 1
3175671|NCT00636740|Experimental|C|MER-101 20mg Tablets Regimen 2
3175672|NCT00636740|Active Comparator|A|Zometa Injection
3175673|NCT00636753||1|schizophrenic patients
3175674|NCT00636753||2|controls
3175675|NCT00636766|Experimental|1|
3175676|NCT00636779||1|Up to five hundred eligible patients seen at each of the nine participating Integrative Medicine Centers will be approached (by mail, phone, at the time of their visit, etc.) and invited to consent to the paper and pencil study.
2573545|NCT02410031||Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Prescribers of Diane-35 who agree and fulfill the criteria inclusion to participate in the survey
2573595|NCT02409875||Risk groups|"For families that both parents have BMI>=24 or at least one of them BMI>=28, then calculated as high-risk group.~For families that both parents have BMI<24 or one parents with BMI<24 and one with 24<=BMI<28, then grouped as low-risk group."
2573653|NCT02409563|Experimental|Budesonide nasal (100 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: N1 (n = 8) = Budesonide nasal spray 100 mcg, 2 v / d; Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
2573660|NCT02409563|Experimental|Budesonide nasal (50 mcg bid)|The study will be randomized, controlled parallel group. After 1 week of phase baseline screening (Visit 1), patients will be randomized (1:4) with the assignment of a code (B-200_da 01 to 08, B-100_ 01 to 31) (day 0, Visit 2) in 2 groups: ; N2 (n = 31) = Budesonide nasal spray 50 mcg, 2 v / d. Patients return to control after the 1st week (day 7, Visit 3), after the 2nd week (day 14, Visit 4) and one week after the end of the treatment period (day 21, Visit 5). It will give a tolerance of ± 3 days for the timing of planned visits. In the phase of follow-up, (3 days after the last dose of drug) will be recorded the occurrence of adverse effects (Adverse Event, EA)
2573706|NCT02409147|Experimental|Patients|Healthy female volunteers wishing to have a childbirth via uterine transplantation
2573771|NCT02408718|Active Comparator|Training group|Subjects randomized to this group will receive a 6 week Assistive Device Training program in the use of their assistive device. They will have mobility assessments taken at baseline, after the training program has been completed, and 3 months later. During this time, their falls will be recorded monthly using prospective falls calendars. Members of this group will also receive MRI scans at baseline and after the completion of the training program.
2573775|NCT02408718|No Intervention|Wait-list control|Subjects in this group will participate in the same mobility assessments and completion of the falls calendars, but will receive no intervention during this time. These subjects will have the opportunity to receive the training sessions when all assessment visits have been completed. These subjects will not receive MRI scans.
2573813|NCT02408302|Active Comparator|oral midazolam|oral midazolam 0.5-0.7 mg/kg maximum 10 mg. one dose only before the invasive procedure.
2573820|NCT02408302|Active Comparator|intranasal midazolam|intranasal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
2573825|NCT02408302|Active Comparator|buccal midazolam|buccal midazolam 0.3-0.5 mg/kg maximum 5 mg. one dose only before the invasive procedure
2573849|NCT02407925||Endoscopists|Approximately 35 endoscopists whom are certified to perform colonoscopies on FIT-positive patients in the Dutch population screening program
2573850|NCT02407925||Colonoscopies|Colonoscopies on FIT-positive patients in the Dutch population screening program
2573853|NCT02407925||Device|Olympus colonoscopes with Narrow Band Imaging
2573943|NCT02407340|Active Comparator|Oxytocin|intranasal oxytocin - 40 International Units (IU) dose administered 3 times daily for 1 week
2573944|NCT02407340|Placebo Comparator|Placebo|Intranasal placebo administered 3 times daily for 1 week
2573978|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA, no NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
2573980|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA, no NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour without NBH. This treatment is administered twice a day for 5 days.
2573981|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA, no NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour, without NBH. This treatment is administered twice a day for 5 days.
2573982|NCT02407028|Experimental|Hyperbaric oxygen (1.5 ATA + NBH)|Hyperbaric oxygen at 1.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
2573983|NCT02407028|Experimental|Hyperbaric oxygen (2.0 ATA + NBH)|Hyperbaric oxygen at 2.0 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
2573986|NCT02407028|Experimental|Hyperbaric oxygen (2.5 ATA + NBH)|Hyperbaric oxygen at 2.5 ATA for 1 hour and NBH for 3 hours. This treatment is administered twice a day for 5 days.
2573987|NCT02407028|Experimental|Normobaric Hyperoxia (NBH)|Normobaric Hyperoxia (NBH meaning 100% O2 at 1.0 ATA) for 4.5 hours twice a day for 5 days.
2573989|NCT02407028|Active Comparator|Usual care|Usual care for severe TBI
3175677|NCT00636831|Placebo Comparator|cont|
2574174|NCT02405559|Experimental|Lymphatic occlusion pressure lower limb|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the leg to visualize at which pressure lymph flow is interrupted.
2574232|NCT02405455|Experimental|Cerclage|Cervical cerclage.
2574233|NCT02405455|Experimental|Cervical pessary|Cervical pessary
2574446|NCT02403960|Active Comparator|probiotic|The participants of the probiotic group were asked to let a probiotic tablet dissolve on their tongue 2 times a day for 3 months.
2574584|NCT02403141||Impaired fasting glycaemia|Patients with blood glucose between 5.6mmol/L - 7mmol/L
3175678|NCT00636831|Active Comparator|intervention|
3175679|NCT00636844||Group A|Patients receiving chemotherapy (anthracycline and/or adjuvant trastuzumab) for the first time
3175680|NCT00636857|Experimental|I|Perioperative fluid management based on body weight
3175681|NCT00636857|Active Comparator|II|Perioperative fluid management based on Lean Body Mass (LBM)
3175682|NCT00636896|Experimental|1|Olanzapine 10 mg plus modafinil 200 mg
3175683|NCT00636896|Placebo Comparator|2|Olanzapine plus Placebo
3175684|NCT00636909|Experimental|1|Study treatment arm with G-CSF
3175685|NCT00636922|Experimental|Everolimus with 5-azacitidine|Everolimus increasing oral doses days 5-21 each cycle 5-azacitidine 75mg sub cutaneously 7 doses in 21 days
3175686|NCT00636935|Experimental|1|Antibiotic only therapy in patients with PCP and a pO2 of > 70mmHg.
3175687|NCT00636935|Experimental|2|Antibiotics and Corticosteroid therapy in patients with PCP and pO2 >70 mmHg.
2573523|NCT02410421|Experimental|Individualized rTMS protocol|"The target region will be defined by comparing the rCBF scan of the patient to a control population (n = 80). rCBF will be measured using the QUIPS2 arterial spin labeling sequence on a Siemens 3T Verio.~The therapeutic protocol will be design to correct the rCBF anomaly first by defining each point where to deliver the stimulation than the stimulation protocol for each point (180% of active motor threshold, 4-second 10 Hz train duration, with 26-second intertrain interval for a total of 3000 pulses). The whole target will be homogeneously stimulated.~The active motor threshold will be assessed. The programmed protocol will be delivered while a figure of eight coil will be positioned by a robotic device (Axilum Robotics).~The procedure will be repeated twice a day for 10 days over 2 weeks."
2573524|NCT02410421|Active Comparator|High frequency rTMS as usual|"rTMS will be performed as usual using a figure-eight coil: Defining the active motor threshold. For each session positioning the coil 5 cm ahead of the abductor pollicis brevis muscle, stimulating at 180% of active motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session), twice a day for 10 days over 2 weeks.~Coil and stimulator will remain the same between individualized and as usual proceedures."
2573525|NCT02410421|Active Comparator|Trans-cranial direct current stimulation (tDCS)|tDCS will be performed as usual: After controlling for skin healthiness, the anode and the cathode will be respectively placed over F3 and F4. A commercial devices (MagStim), will deliver a constant current of 2 mA through 25 cm2 saline-soaked rubber sponges for 20 min per session. The procedure will be repeated twice a day for 10 days over 2 weeks.
2573544|NCT02410109|Experimental|SCRIPT intervention|
2573555|NCT02410109|No Intervention|Historical Control|
2573593|NCT02409901|Experimental|Exercise Rehabiliation|12 month personalized exercise rehabilitation in addition to standard clinical care
2573597|NCT02409901|No Intervention|Control|Standard clinical care only
2573638|NCT02409524|Experimental|Treatment|The treatment schedule of AlloVax includes: (1) Priming segment with ID injections of AlloStim on Days 0, 3, 7 and 10. (2) Vaccination segment with ID injections of AlloStim+CRCL on Days 14, 17, 21 and 24. (3) Activation segment with IV push infusion of AlloStim on Day 28. (4) Booster Segment with monthly (every 28 days) ID injections of CRCL alone beginning on Day 56. These injections will continue until all the vaccine is used or the death of the subject
2573695|NCT02409160|Experimental|Bariatric Surgery|Standard laparoscopic Roux-en-Y gastric bypass technique resulting in a gastric pouch with a volume of about 25 mL, a 100-cm-long Roux-limb, and a 75-cm-long biliopancreatic limb.
2573699|NCT02409160|No Intervention|Control Group|
2573885|NCT02407782|Experimental|Ivermectin|
2573887|NCT02407782|Experimental|Permethrin|
2573936|NCT02407379|Active Comparator|PAPD+SRP Quadrant|This quadrant, randomly selected in each patients, undergoes treatment with PAPD+ SRP
2573938|NCT02407379|Sham Comparator|Sham-laser + SRP|This quadrant, randomly selected in each patients, undergoes treatment with sham-laser + SRP
2573971|NCT02407080|Experimental|RG7388|"Part A: RG7388 as a single agent; given at a starting dose of 100 mg each day for five days for the first cycle which will be 56 days.~Part B: combination of RG7388 and Pegasys if subject does not achieve at least a PR by the end of 3 cycles of single agent RG7388"
2574044|NCT02406807|Experimental|HVLA manipulation|Osteopathic high velocity, and low amplitude spinal lumbar manipulation
2574046|NCT02406807|Sham Comparator|Sham Spinal lumbar manipulation|Just position in the side lying and not performed the high velocity and low amplitude
2574053|NCT02406482|Experimental|HIVRR + MF|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)) followed by financial literacy, micro-savings and vocational training (Behavioral: Microfinance intervention (MF)).
2574054|NCT02406482|Active Comparator|HIVRR only|Four sessions of education and intervention (Behavioral: HIV risk reduction (HIVRR)).
2574096|NCT02406339|No Intervention|Control|Are not subject to any intervention.
2574097|NCT02406339|Experimental|Electrotherapy|The athletes will be submitted to NMES of bilateral quadriceps. The stimulation will be held in order to induce the move flexion / extension involuntary knee in extension machine, with resistance of 30% of maximum voluntary strength.
2574099|NCT02406339|Experimental|Electrotherapy + Vascular Occlusion|The same as in Electrotherapy group, athletes are subjected to NMES associated total vascular occlusion of the members below the level of the groin.
2574148|NCT02406079|Experimental|tracheotomy|
2574175|NCT02405728|Experimental|Peripherally inserted central catheters|Peripherally inserted central catheters (PICCs) - Most commonly used vascular access in hematological patients - Randomization between CICCs and PICCs
2574194|NCT02405728|Active Comparator|Centrally inserted central catheter|Centrally inserted central catheter (CICCs) - New vascular access, with the aim to reduce the complications - Randomization between CICCs and PICCs
2574301|NCT02404779|Experimental|CISATRACURIUM|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
2574304|NCT02404779|Placebo Comparator|PLACEBO|To compare the evolution of intracranial pressure (ICP) of severely brain injured patients with intracranial hypertension after administration of cisatracurium versus placebo.
3175688|NCT00636935|Active Comparator|3|Standard of care therapy for patients with PCP and pO2 < 70mmHg.
3175689|NCT00637013|Active Comparator|Acromioplasty|Acromioplasty + physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3175690|NCT00637013|Active Comparator|Physiotherapy|Physiotherapy according to a standardized protocol following a 3 months period of active non-operative treatment
3175691|NCT00637052|Experimental|ARRY-520|
3175692|NCT00637065|Active Comparator|1|Bosentan tablets (62.5mg bd for first 4 weeks, then 125mg bd as tolerated)
3175693|NCT00637065|Placebo Comparator|2|Placebo tablets
3175694|NCT00637078|Active Comparator|1|Drug: Fix dose combination therapy
3175695|NCT00637078|No Intervention|2|Guidelines based management
3175696|NCT00637091|Experimental|EGFR expression|Patients' accrual will be adjusted by EGFR expression (positive vs. negative)
3175697|NCT00637104|Experimental|A - Mar-tyn|It includes the implant of the Mar-tyn TiN coated stent
3175698|NCT00637104|Active Comparator|B - Vision|Includes all the patients treated with the Vision stent
2573579|NCT02410083|Active Comparator|Clopidogrel/Aspirin co-administration 2|Clopidogrel-aspirin-co-administration. Before this clinical trial Aspirin single-administration.
2573614|NCT02409693||Myringotomy with tube insertion|Patients who received surgically inserted ear tubes.
2573652|NCT02409407|Experimental|Oral Misoprostol|oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.
2573656|NCT02409407|Experimental|Vaginal Misoprostol|vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)
2573665|NCT02409407|Placebo Comparator|Placebo|oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.
2573762|NCT02408835|Active Comparator|PICO™|Use of PICO™ system negative pressure wound therapy device on surgical wound for up to seven days.
2573765|NCT02408835|No Intervention|Conventional wound care|Usual wound dressings will be used as comparison group.
2573817|NCT02408419|Experimental|Local anesthetic|15 ml. of local anesthetic
2573822|NCT02408419|Placebo Comparator|Saline|15 ml. of saline
2574222|NCT02405468||case|patients with a myocardial infarction within one month to one year before the inclusion
2574226|NCT02405468||control|"patients without history of myocardial infarction, free of coronary disease in the view of one of the following test performed within one year before the inclusion : Effort test Echocardiographic stress test Myocardial perfusion scintigraphy Coronarography with >= 2 major cardiovascular risk factors :~Treated hypertension~Treated dyslipidemia~Current smoking~Diabetes mellitus"
2574244|NCT02405130|Active Comparator|epinephrine|intracoronary epinephrine is two ampoules each of 1:1000 epinephrine (1 μg/mL) diluted into 100 mL of normal saline (to 20 μg/mL epinephrine solution); a 5 ml syringe prepared will then contain 100 μg
2574253|NCT02405130|Other|no intracoronary epinephrine|no epinephrine
2574324|NCT02404974|Experimental|Exercise|This is a single arm pilot study. All participants who answer yes to interest in exercise question on the web-based osteoarthritis preference tool will be included in the exercise intervention. After completing baseline measures, they will be put in contact with the Fitness Instructor and follow the protocol described.
2574377|NCT02404467||Patients receiving transfermoral TAVI|TF TAVI
3209918|NCT00989430|No Intervention|Control: Standard Rehabilitation Care|Participants will continue with their standard inpatient rehabilitation care. They will be assessed with cognitive and functional scales for tracking their recovery.
2574547|NCT02403401|Experimental|Levonorgestrel (BAY98-7196)|Vaginal ring containing 170 mg levonorgestrel
3209919|NCT00989443|Experimental|Cidofovir|
3209920|NCT00989456|Experimental|exercise and education|Supervised physical exercise in groups, plus a self management education programme (patient education).
3209921|NCT00989456|Active Comparator|exercise only|Supervised physical exercise in groups.
2574800|NCT02401789|Experimental|test - implant placement|The possibility of counteracting unfavourable ridge modelling after multiple tooth extractions by placing implants in the fresh extraction sites
2574801|NCT02401789|No Intervention|control- natural healing|
3209922|NCT00989469|Experimental|Sorafenib and irinotecan|
3209923|NCT00989482|Experimental|Computer Kiosk Eduction|
3209924|NCT00989495|Experimental|Brace - Randomized|Participants were randomized to be braced
3209925|NCT00989495|No Intervention|Observation - Randomized|Participants were randomized to be observed only
2574930|NCT02400606|Experimental|Intervention|The intervention group were presented with a short case overview introducing four cardiopulmonary VP cases as well as the final diagnosis and had to complete the history, physical findings, and lab results, i.e. constructing VP cases.
2574937|NCT02400606|Active Comparator|Control|The participants were presented with a short case overview introducing four cardiopulmonary VP cases to be solved, i.e. solving VP cases.
3209926|NCT00989495|Experimental|Brace - preference based|Participants chose to be braced
3209927|NCT00989495|No Intervention|Observation - preference-based|Participants chose to be observed only
3209928|NCT00989508|Experimental|Perhexiline|Pre-operative administration of Perhexiline tablets according to dosing schedule
3209929|NCT00989508|Placebo Comparator|Placebo marked PEXSIG|Pre-operative administration of placebo tablets according to dosing schedule
3209930|NCT00989521|Placebo Comparator|placebo|normal saline for inhalation
3209931|NCT00989521|Active Comparator|PUR003|PUR003 for inhalation
3209932|NCT00989534|Experimental|Sleep loss and circadian alignment|Sleep restriction without circadian misalignment
3209933|NCT00989534|Experimental|Sleep loss and circadian misalignment|
3209934|NCT00989547|Active Comparator|A|
3209935|NCT00989547|No Intervention|B|
3209936|NCT00989560|Active Comparator|Active arm|
3209937|NCT00989560|No Intervention|Standard care arm|
3209938|NCT00989599|Experimental|compress of Chamomilla recutita infusion|Patients who developed phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
3209939|NCT00989599|Active Comparator|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
3209940|NCT00989625|Active Comparator|10mg Sumatriptan/60mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3209941|NCT00989625|Active Comparator|30mg Sumatriptan/180mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3209942|NCT00989625|Active Comparator|85mg Sumatriptan/500mg Naproxen|There is only one dose (one tablet) for each subject. Subject to be randomized to either: 10mg Sumatriptan/60 mg Naproxen or 30mg Sumatriptan/180mg Naproxen or 85mg Sumatriptan/500mg Naproxen.
3209943|NCT00989638||Women at high risk for breast cancer|
3260241|NCT01477580|Experimental|Medium-Dose V180 with Alhydrogel™ adjuvant|
3260242|NCT01477580|Experimental|High-dose Non-adjuvanted V180|
2573650|NCT02409472|Other|intensive surveillance|Intensive program for colon cancer: Office visit, complet blood count (CBC), CEA+ Carbohydrate Antigen (CA) 19.9 at 4,8,12,16,20,24,30,36,42,48, and 60 months. Colonoscopy at 12, 24, 36, 48,and 60 months. Liver echography* at 4,8,12,16,24,36,48, and 60 months. Chest X-ray at 12,24,36,48,and 60 months.
2573697|NCT02409199|Experimental|apatinib|Apatinib 850 mg qd po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2573700|NCT02409199|Active Comparator|Docetaxel|Docetaxel 60mg/m2 ivgtt every 3 weeks, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2573747|NCT02408809|Active Comparator|Control|
2573751|NCT02408809|Active Comparator|Intervention|
3209944|NCT00989651|Experimental|Regimen I (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes (beginning in course 2) on day 1. Patients also receive veliparib PO BID on days 1-21. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
3209945|NCT00989651|Experimental|Regimen II (paclitaxel, carboplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Patients also receive carboplatin, bevacizumab, and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment with bevacizumab repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
3209946|NCT00989651|Experimental|Regimen III (paclitaxel, cisplatin, bevacizumab, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1 and IP on day 8, and cisplatin IP on day 1 or 2. Patients also receive bevacizumab and veliparib as in Regimen I. Treatment repeats every 21 days for 6 courses. Patients then receive bevacizumab alone on day 1. Treatment repeats every 21 days for 16 courses in the absence of disease progression or unacceptable toxicity.
2573977|NCT02407067|Active Comparator|Voice Amplifier|Participant will be fit with a voice amplifier (ChatterVox) and it will be used during speech testing and during regular conversations over a one week period.
2573979|NCT02407067|Experimental|Personal Communication System|Participant will be fit with a personal communication system (Easy Listener FM system) and it will be used during speech testing and during regular conversations over a one week period.
2574024|NCT02406833|Experimental|TGF-β2 antisense oligonucleotide|"Core Study: Administered intravitreally at the time of trabeculectomy at escalating doses~Post-Study Follow-up: until 1 year after administration"
2574060|NCT02406534||Normal Pulmonary Function|
2574066|NCT02406534||Reduced Pulmonary Function|
2574115|NCT02406300|Active Comparator|Subarachnoid anesthesia|"Patients submitted to subarachnoid anesthesia for proximal femur fracture surgical repair.~Up to 12.5 mg of bupivacaine or levobupivacaine will be used"
2574119|NCT02406300|Active Comparator|PNB/GA|Patients are submitted to a femoral, a lateral cutaneous nerve of the thigh and an anterior obturator nerve blocks with ropivacaine and an inhalational general anesthesia with sevoflurane or desflurane
2574425|NCT02404246|Experimental|Intervention Arm|Intervention evaluated the feasibility, acceptability, and effectiveness of a structured peer support intervention based on the Certified Peer Specialist Program of the Depression and Bipolar Support Alliance (DBSA).
2574426|NCT02404246|No Intervention|Usual Care|Usual Care
2574466|NCT02403882|Experimental|Order|The investigators arrange the placement of the targeted good to see if the order affects selection.
2574468|NCT02403882|Experimental|Packaging|The investigators adjust the packaging of the targeted good to determine the effects on selection.
2574471|NCT02403882|Experimental|Pricing|In food pantries, few products are priced. The investigators use pricing of products to determine its effect on selection.
2574473|NCT02403882|Experimental|Relative Proportions|The investigators adjust the proportion of the products to determine the effect on the selection of the targeted product.
2574474|NCT02403882|Experimental|Default Option|The investigators provide a targeted product to subjects at one point. Later, investigators offer subjects the possibility to exchange the targeted product for a close substitute.
2574503|NCT02403609|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) on two consecutive days
2574539|NCT02403375|Experimental|Continuous Subcutaneous Insulin Infusion (CSII)|Continuous Subcutaneous Insulin Infusion (CSII) in Children and Adolescents 2-17 Years of Age
2574588|NCT02403063|Active Comparator|sugammadex|Selective relaxant binding agent
2574589|NCT02403063|Active Comparator|neostigmine|Acetylcholinesterase inhibitor
2574591|NCT02403063|Experimental|neostigmine-sugammadex|Acetylcholinesterase inhibitor followed by a selective relaxant binding agent
2574622|NCT02402816|Experimental|MPP ON|Patients will be randomized to the MPP-ON Arm vs Standard ICD
2574624|NCT02402816|Active Comparator|Standard ICD|Patients will be randomized to the MPP-ON Arm vs Standard ICD
2574668|NCT02402517|Placebo Comparator|Extruded snack control|100% corn flour
2574675|NCT02402517|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
2574682|NCT02402517|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
2574689|NCT02402517|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
2574691|NCT02402517|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
2574694|NCT02402517|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
2574760|NCT02402049|Active Comparator|1: Natrum muriaticum 30C|Natrum muriaticum 30C
2574762|NCT02402049|Active Comparator|2: Lachesis 30C|Lachesis 30C
2574763|NCT02402049|Active Comparator|3: Sepia 30C|Sepia 30C
2574764|NCT02402049|Active Comparator|4: Nux vomica 30C|Nux vomica 30C
2574766|NCT02402049|Active Comparator|5: Pulsatilla 30C|Pulsatilla 30C
2574769|NCT02402049|Active Comparator|6 Folliculinum 30C|Folliculinum 30C
2574773|NCT02402049|Placebo Comparator|1: Placebo Natrum muriaticum|Placebo Natrum muriaticum
2574775|NCT02402049|Placebo Comparator|2: Placebo Lachesis|Placebo Lachesis
2574776|NCT02402049|Placebo Comparator|3: Placebo Sepia|Placebo Sepia
2573655|NCT02409433|Experimental|lacosamide|The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours.
2573664|NCT02409433|Active Comparator|phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day. Levels will be checked accordingly.
2573684|NCT02409056|Experimental|workplace-tailored CDSMP|Group will receive the CDSMP program which has been modified to fit the unique characteristics of the workplace.
2573687|NCT02409056|Active Comparator|CDSMP usual care|Group will receive the standard CDSMP program which is currently being offered in a variety of community settings.
2573688|NCT02409056|No Intervention|control|Group will receive no intervention for the first 6 months (pre / post), then be randomly assigned to one of the above interventions.
2573752|NCT02408757||All study participants|The study population consists of consecutive patients undergoing clamping of EVD/LD treated at the Departments of Neurosurgery or Intensive Care Medicine at the University Hospital Bern
2573794|NCT02408458|Other|MIROMESH|Single-arm study. MIROMESH will be used in the surgical repair of ventral hernia.
2573835|NCT02408107|Experimental|Physical activity intervention|Received a 30 min physical activity counselling session which employed motivational interviewing to encourage the adoption of current recommended physical activity guidelines. This arm also received 3 support phone calls (1 at the end of months 1, 2 and 3) and a physical activity reminder postcard on months 4 and 5.
2573839|NCT02408107|No Intervention|Usual care|This arm received usual care (i.e. no physical activity counselling, support phone calls or post-cards).
2573866|NCT02407821|Active Comparator|Escitalopram|
2573871|NCT02407821|Placebo Comparator|Placebo|
2573924|NCT02407600|Active Comparator|Fosparepitant administered in 1st cycle|Fosaprepitant (Emend) for Injection 150 mg is administered, one time, intravenously on day 1 only, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects first chemotherapy cycle. An intravenous saline placebo will be administered on day 1 of the second chemotherapy cycle, in the same manor as EMEND for Injection.
2573927|NCT02407600|Sham Comparator|Fosaprepitant administered in 2nd cycle|Subject will receive a saline Placebo intravenously on day 1 of their first chemotherapy cycle. For the subject's second chemotherapy cycle, EMEND for Injection 150 mg is administered, one time, intravenously on day 1, as an infusion with a duration of 30 minutes. It will be initiated approximately 30 minutes prior to the subjects second chemotherapy cycle.
2573963|NCT02407106|Experimental|BLIS K12 treatment|Once daily tablet of Streptococcus Salivarius BLIS K 12 to be slowly dissolved orally every evening for six month
2574000|NCT02406898|Experimental|hysteroscopic surgery with morcellation technic|"The hysteroscope with the MH system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter ."
2574004|NCT02406898|Active Comparator|conventional hysteroscopy technic with resection.|"The hysteroscope with conventional resection system will be introduced. Resection of fibroids or both will be realized. The procedure will end or when the fibroids will be completely resected.~the procedure may be suspended before complete resection of fibroids or uterine perforation or higher operating time to 90 minutes or amount of liquid used distension than 9 liters or distension fluid deficit of more than one liter (4 )."
2574058|NCT02406664|Experimental|Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
2574062|NCT02406664|No Intervention|Control patients|15 matched controls receiving Intensive medical therapy
2574108|NCT02406287|Experimental|Active|Netarsudil (AR-13324) Ophthalmic Solution
2574110|NCT02406287|Placebo Comparator|Placebo|Netarsudil (AR-13324) Ophthalmic Solution Placebo
2574136|NCT02406014|Active Comparator|Treatment Group A|Ingenol mebutate gel 0.015%, once daily for 3 consecutive days for the first treatment course. At 8 weeks after treatment initiation, subjects who present with existing AKs or newly emergent AKs in the treatment area will receive one more treatment course of ingenol mebutate gel 0.015%, daily for 3 consecutive days.
2574139|NCT02406014|Active Comparator|Treatment Group B|Diclofenac sodium gel 3%, (0.5 grams), twice daily for 90 days.
2574179|NCT02405715|Placebo Comparator|Placebo Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a placebo nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total).
2574196|NCT02405715|Experimental|Oxytocin Spray And Interpersonal Psychotherapy|Participants will receive 6 sprays of a oxytocin nasal spray prior to the beginning of each session of interpersonal psychotherapy (16 sessions in total). Each spray will contain 4IU of oxytocin, for a total dose of 24IU.
2574234|NCT02405364|Experimental|Front line therapy|Induction: 4 cycles of 28 days of Carfilzomib/Lenalidomide/Dexamethasone Stem Cell Harvest+Intensification Consolidation 4 cycles of 28 days of Carfilzomib/ Lenalidomide/Dexamethasone Maintenance: Lenalidomide 13 cycles of 28 days
2574280|NCT02405065|Experimental|HM95573|single arm
2574330|NCT02404831|Active Comparator|Traditional hospital-based PR|Class based pulmonary rehabilitation
2574334|NCT02404831|Experimental|Web-based PR|web-based pulmonary rehab
2574357|NCT02404428|Active Comparator|standard broccoli soup|one portion (300 g each) per week of a soup containing standard broccoli
2574361|NCT02404428|Experimental|beneforte extra broccoli soup|one portion (300 g each) per week of a soup containing glucoraphanin-enriched broccoli named for the study 'Beneforte extra'
3209947|NCT00989677||Rheumatoid Arthritis|
3209948|NCT00989703|Experimental|1|GLPG0259 25/50/75 mg/day for 14 days
3209949|NCT00989703|Placebo Comparator|2|placebo for 14 days
2574488|NCT02403765||Family cases|Family-based Parkinson patients carrying genetic variants associated with the disease
2574491|NCT02403765||Family controls|Family-based Control subjects
3209950|NCT00989716|Active Comparator|Glyceryl trinitrate transdermal patch|
3209951|NCT00989716|Experimental|Continue or stop pre-stroke antihypertensives|
3209952|NCT00989729|Active Comparator|Methylprednisolone|75 patients will receive a single preoperative dosage of Methylprednisolone
3209953|NCT00989729|Placebo Comparator|Physiological Saline|75 patients will receive a single preoperative dosage of Physiological Saline
2573717|NCT02408978|Experimental|OXP005|1g naproxen
2573720|NCT02408978|Active Comparator|naproxen|1g naproxen
2573773|NCT02408770|Experimental|treatment|ulipristal acetate 5mg daily for 3 months
2573807|NCT02408341||Routine clinical practice of induction anesthesia|There was no intervention, just monitoring of clinical routine practice using non-invasive Doppler tissue imaging.
2573878|NCT02408029||Trauma Patients Group|Patients undergoing treatment for injuries and trauma.
2573916|NCT02407639|Active Comparator|co2 arm|insufflation with CO2
2573919|NCT02407639|Placebo Comparator|air arm|insufflation with air
2573956|NCT02407171|Experimental|Non Small Cell Lung Cancer, Phase I|Dose escalation cohort for patients with Non Small Cell Lung Cancer (NSCLC). The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
2573962|NCT02407171|Experimental|Non-Lung, Phase I|Dose escalation cohort for non lung cancer patients. The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction). If there is dose-limiting toxicity at the lowest cohort, that arm will be closed and SBRT to that site will be discontinued.
2573967|NCT02407171|Experimental|Melanoma Expansion Cohort|Phase 2a expansion cohort for patients with melanoma. Patients will be treated at the maximum tolerated dose discovered in phase I.
2573969|NCT02407171|Experimental|Non Small Cell Lung Cancer Expansion Cohort|Phase 2a expansion cohort for patients with NSCLC. Patients will be treated at the maximum tolerated dose discovered in phase I.
2574035|NCT02406768||HIV negative unexposed|HIV negative controls
2574037|NCT02406768||HIV negative exposed|HIV-negative children born to HIV-infected mothers
2574073|NCT02406456|Experimental|Neurofeedback|
3209954|NCT00989742|Active Comparator|Doxycycline|
2574207|NCT02405793|Experimental|Meloxicam low dose test capsule|Meloxicam SoluMatrix Capsules - low dose QD
2574212|NCT02405793|Experimental|Meloxicam high dose test capsule|Meloxicam SoluMatrix Capsules - high dose QD
2574217|NCT02405793|Active Comparator|Meloxicam tablets|Meloxicam Tablets QD
2574264|NCT02405221|Experimental|TA-CIN administration via thigh|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the thigh. Patients will be followed for 2 years after the 1st dose is given.
2574266|NCT02405221|Experimental|TA-CIN administration via arm|Each dose of TA-CIN vaccine is fixed, 100µg. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9), administered in the arm. Patients will be followed for 2 years after the 1st dose is given.
2574297|NCT02404844|Experimental|BKM120 + Tamoxifen|"BKM120 (Buparlisib): 100 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle~Tamoxifen: 20 mg/day, orally, on a continuous dosing schedule without interruption starting on day 1 in 28 day cycle"
2574380|NCT02404623|Experimental|Intervention Group|800 IU of Vitamin D once daily
2574383|NCT02404623|Other|Control Group|400 IU of Vitamin D once daily, the standard of care
2574465|NCT02403908|Experimental|PADN groups (radiofrequency denervation)|An 8-F long sheath will be inserted through the femoral vein and advanced to the main PA (MPA). The nMARQ Circular or Crescent (Biosense Webster) catheter will be advanced along this long sheath. After gently withdrawing the sheath and pushing the PADN catheter, the tip will be released from the sheath. Then, the tip of the catheter will be positioned first at the ostium of the left PA (Level 1 of ablation, <2 mm distal to orifice. After ablation at this level, the catheter tip will be positioned at the ostium of right PA (Level 2 of ablation, <2mm proximal to the bifurcation level). Finally, denervation of main pulmonary artery will be done by pulling the denervation catheter back into Level 3 of ablation (<2 mm proximal to both ostia of right and left PA-s) into main pulmonary artery.
2574467|NCT02403908|No Intervention|SHAM group|non-treated patients (controls)
2574510|NCT02403648|Experimental|BIOD-961, 1 mg IM|Intramuscular delivery of BIOD-961.
2574514|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg IM|Intramuscular delivery of Lilly glucagon.
2574518|NCT02403648|Active Comparator|Novo Glucagon, 1 mg IM|Intramuscular delivery of Novo glucagon.
2574520|NCT02403648|Experimental|BIOD-961, 1 mg SC|Subcutaneous delivery of BIOD-961,
2574522|NCT02403648|Active Comparator|Lilly Glucagon, 1 mg SC|Subcutaneous delivery of Lilly glucagon.
2574526|NCT02403648|Active Comparator|Novo Glucagon, 1 mg SC|Subcutaneous delivery of Novo glucagon.
2574554|NCT02403219|Experimental|Botulinum toxin type A injection|An injection of 4 international units of botulinum toxin type A will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
2574555|NCT02403219|Sham Comparator|Sham injection|An injection of 4 international units of sham will be applied in the medial in the medial part of the lower eyelid near the punctum directed along the medial canthal tendon in a single application by subcutaneous injection.
2574619|NCT02402985|Other|High animal protein diet group AP|6-weeks diet intervention with high animal protein
2574623|NCT02402985|Other|High plant protein diet group PP|6-weeks diet intervention with high plant protein
2574661|NCT02402595|Experimental|Sequence 1 - Period 1|AVP-923 and placebo matching AVP-786- BID Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
2574662|NCT02402595|Experimental|Sequence 1 - Period 2 (after 3-week washout)|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
2574663|NCT02402595|Experimental|Sequence 2 - Period 1|AVP-786 and placebo matching AVP-923 - BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
3209955|NCT00989742|Placebo Comparator|Placebo|
3260243|NCT01477580|Experimental|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|
3260244|NCT01477580|Experimental|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|
2573759|NCT02408640|Experimental|Intervention group|"Individuals randomized to the intervention group will directly after randomization answer questions about alcohol and drug use (other than alcohol and cannabis), depression, anxiety, a sense of context and whether they during the last 12 months has received professional help to reduce or quit their cannabis use or during the same period have raised this issue with their relatives or friends.~Further, they will fill out a survey about Internet-based services for individuals who wish to reduce or quit their cannabis use. The study participants will then be informed that they, within two days, will gain access to an internet based treatment program designed to help them quit their cannabis use and that they through the program will be able to communicate with a therapist. Within the next two days, they will gain access to the internet-based treatment program, they will have access to it for two months and they will be contacted again after three months to complete the follow-up."
2573764|NCT02408640|No Intervention|Control group|"Individuals randomized to the control group will undergo exactly the same procedure as the intervention group. The difference is that the control group will be informed that they in about three months will gain access to an internet based treatment program designed to help them quit their cannabis use (i.e. when the data collection for follow-up is completed).~Otherwise, participants in both groups will have the opportunity to use factual information that is available to everyone on Cannabishjalpen.se."
2573921|NCT02407392|Active Comparator|Non targeted quadrantic biopsies|Patients undergo current gold standard Barrett's surveillance with quadrantic Seattle protocol biopsies
2573926|NCT02407392|Experimental|Acetic Acid targeted biopsies|Patients undergo dye spray gastroscopy with Acetic Acid and targeted biopsies for areas of dysplasia.
2574113|NCT02406365|Experimental|Standard of care plus imaging with research devices|"Eligible patients who consent to participate in the research study will receive their standard of care colposcopy or treatment with the Loop Electrosurgical Excision Procedure (LEEP). Additionally, cervical images will be taken using the diagnostic imaging aid. The cervical images will be compared to the histopathology from the biopsies taken as part of the patients' standard of care for colposcopy. If the patient is presenting for the LEEP procedure, then she will be asked if one or two biopsies can be obtained prior to the procedure but after anesthesia has been administered.~The imaging device is not being used to make a diagnosis, but rather to develop an algorithm to make more efficacious and timely diagnoses of cervical neoplasias in the future."
2574149|NCT02405988|Experimental|Intravenous naloxone|0,4 mg/ml Naloxone B Braun 2,5 ML intravenously
2574183|NCT02405650||CRIC VAP cohort|"If eligible, the participant will have additional testing at regular annual CRIC Visit. The following will occur:~abdominal and pelvic Magnetic Resonance Imaging (MRI) scan~400 meter walk test for physical fitness"
2574242|NCT02405234|Experimental|Carbon Modular Radial Head|PyroCarbon Modular Radial Head replacement
2574249|NCT02405234|Active Comparator|Metal Radial Head|Metal Radial Head replacement
3175699|NCT00637130|Experimental|Travoprost 0.0008%|Travoprost ophthalmic solution, 0.0008%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3175700|NCT00637130|Experimental|Travoprost 0.001%|Travoprost ophthalmic solution, 0.001%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
2574384|NCT02404298|Experimental|IVIg|
3175701|NCT00637130|Experimental|Travoprost 0.0012%|Travoprost ophthalmic solution, 0.0012%, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
2574527|NCT02403505|Experimental|ABIRATERONE - Group 1|"ZYTIGA - ABIRATERONE ACETATE TABLET~Combined Chemotherapy~DELTASONE - PREDNISONE TABLET~ELIGARD - Leuprolide Acetate Kit"
2574530|NCT02403505|Experimental|ABIRATERONE - Group 2|"ZYTIGA - ABIRATERONE ACETATE TABLET~Combined Chemotherapy~DELTASONE - PREDNISONE TABLET~TRELSTAR - Triptorelin Pamoate Kit"
2574556|NCT02403193|Experimental|PBF-509_80 mg|
2574558|NCT02403193|Experimental|PBF-509_160 mg|
2574560|NCT02403193|Experimental|PBF-509_320 mg|
2574562|NCT02403193|Experimental|PBF-509_640 mg|
2574563|NCT02403193|Experimental|PBF509_160 mg +PDR001|
2574564|NCT02403193|Experimental|PBF509_320 mg+PDR001|
2574565|NCT02403193|Experimental|PBF509_640 mg +PDR001|
2574566|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno naïve|Immunotherapy naïve patients will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
2574567|NCT02403193|Experimental|RP2D (PBF-509+PDR001)_immuno treated|Patients previously treated with immunotherapy (previous immune checkpoint inhibitors; anti-CTLA-4, anti-PD-1, anti-PD-L1 and/or combinations) will be treated at the combination RP2D previously determined in the phase Ib, dose escalation portion of the trial.
2574653|NCT02402621|Active Comparator|Conventional analgesic group|fentanyl
2574656|NCT02402621|Experimental|Model based analgesic group|fentanyl
2574811|NCT02401685|Experimental|Adjuvant therapy alone|Women in this arm will have adjuvant therapy but no treatment to their armpit after surgery. Axillary and supraclavicular fossa radiotherapy is not allowed when randomised to this arm.
2574813|NCT02401685|Active Comparator|Adjuvant therapy plus axillary treatment|Women in this arm will have adjuvant therapy plus treatment to their armpit after surgery. Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
2574900|NCT02401113|Experimental|UA group|UA group who takes Ursolic acid of Loquat Extract , 500 mg/ day during 12 weeks for treatment of muscle function improvement with relatively health adults
2574903|NCT02401113|Placebo Comparator|placebo group|placebo group who takes a placebo, 500 mg/day for 12 weeks
2574959|NCT02400788|Experimental|Resminostat + Sorafenib|oral administration
3175702|NCT00637130|Active Comparator|TRAVATAN + Vehicle|TRAVATAN, one drop in study eye(s) once daily (8 PM), and Vehicle, one drop in study eye(s) once daily (8 AM), for two weeks
3175703|NCT00637130|Placebo Comparator|Vehicle|Vehicle, one drop in study eye(s) twice daily (8 AM and 8 PM), for 2 weeks
3175704|NCT00637143|Experimental|1|Oral
3175705|NCT00637143|Active Comparator|2|Oral
3175706|NCT00637169|Experimental|1|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 85-89%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
3175707|NCT00637169|Active Comparator|2|Supplemental oxygen to maintain functional arterial oxygen saturations in the range of 91-95%. Dose of oxygen is determined by the individual infant's need to achieve the target oxygen saturations.
2573749|NCT02408731|Experimental|3 doses equivalent to MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
2573753|NCT02408731|Experimental|3 doses equivalent to 2*MTD of PMZ-2010|Three equally divided doses (total dose/day equivalent to 2*MTD) of PMZ-2010 (n=3) or placebo (n=1) for 2 days
2573863|NCT02407873||Cardiac surgery|
2574164|NCT02405949||T2D 40%EWL|15 pacients who had type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
2574165|NCT02405949||nonT2D40%EWL|15 pacients without type 2 diabetes before bariatric surgery and presented with less than 40% of the excess weight loss after 12 month from surgery.
2574166|NCT02405949||T2D75%EWL|35 pacients who had type 2 diabetes befor bariatric surgery and presented with more than 75% of the excess weight loss after 12 month from surgery.
2574167|NCT02405949||nonT2D75%EWL|35 pacients without type 2 diabetes befor bariatric surgery and who presented with more than 75% of the excess weight loss after 12 month from surgery.
2574204|NCT02405598|Experimental|Salbutamol|"age 2-6 year: 0.1mg/kg tid x 2 weeks, then gradually increase to 0.2mg/kg tid (daily total maximal12mg)~age 6-12 year: 2mg tid x 2 weeks, then gradually increase to 4mg tid (daily total maximal 24mg)~age 12 year and above: 4mg tidx 2 weeks, then gradually increase to 8mg tid (daily total maximal 32mg)"
2574262|NCT02405338|Experimental|WT1/PRAME vaccination|
2574317|NCT02404961||Control (no vulvodynia)|Clinically-confirmed as a woman with no history of vulvodynia.
2574319|NCT02404961||Vulvodynia Case|Clinically-confirmed as a woman with vulvodynia.
2574453|NCT02404012|Active Comparator|Ferrous sulfate|Ferrous sulfate 65 mg. t.i.d is the standard of care for oral supplementation for iron deficiency
2574456|NCT02404012|Experimental|AspironTM 65 mg t.i.d.|AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
2574496|NCT02403726||osteoporosis associated vertebral fractures|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures.
2574537|NCT02403388||Multiprofessional primary care offices with PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
2574538|NCT02403388||Multiprofessional primary care offices without PRisM|25 multiprofessional primary care offices. Each professional of care of the offices (about 10 FTE / office) have to declare each adverse event that occurs in their office during 18 months.
2574657|NCT02402608|Active Comparator|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture (32 g)
2574658|NCT02402608|Placebo Comparator|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
2574697|NCT02402309|Experimental|Active topical NS2 1% dermatologic cream|NS2 1% topical cream for dermal application
2574699|NCT02402309|Placebo Comparator|Topical vehicle dermatologic|Vehicle placebo for dermal application
2574730|NCT02402114|Experimental|Intervention|Subject randomized to this group receives 1 oral dose of Hydrocortisone 120 mg
2574731|NCT02402114|Placebo Comparator|Placebo|Subject randomized to this group will receive an oral sugar/placebo pill that looks similar to the Hydrocortisone pill.
2574829|NCT02401477|Experimental|Ilaprazole + Amoxicillin|Noltec(Ilaprazole) 10mg 4 tablets BID + Ildong-Amoxicillin 500mg 1capsule and 250mg 1capsule QID by oral for 14 days
3175708|NCT00637208|Experimental|1|
3175709|NCT00637208|No Intervention|2|Watch-full follow-up
2575139|NCT02399384||HIV+/CAD+|HIV+/CAD+
2575151|NCT02399384||HIV+/CAD-|HIV+/CAD-
2575157|NCT02399384||HIV-/CAD+|HIV-/CAD+
2575198|NCT02398851|Other|TacTIC care model|Compare the 30-day readmission rate in adult patients who receive care in a trans-disciplinary chronic disease continuity of care model with integrated technology (mobile devices such as tablets, iPads and smartphones)
3175710|NCT00637234|Experimental|1|
3175711|NCT00637234|Placebo Comparator|2|
3175712|NCT00637260|Experimental|A|
3175713|NCT00637260|Sham Comparator|B|
3175714|NCT00637325|Experimental|A|"In the maintenance study:~ARM A: maintenance of trastuzumab~In the 2nd line study:~ARM A: trastuzumab plus chemotherapy treatment"
3175715|NCT00637325|No Intervention|B|"In the maintenance study:~ARM B: interruption of trastuzumab treatment~In the 2nd line study:~ARM B: chemotherapy alone"
3175716|NCT00637338|Experimental|PF-04603629|The dose range initially planned is 3 mg up to 70 mg, although the specific doses administered may be modified based on emerging study data.
3175717|NCT00637338|Placebo Comparator|Placebo|
3175718|NCT00637351||Group A|Subjects with diagnosed pneumonia & positive culture of streptococcus pneumoniae
3175719|NCT00637351||Group B|Subjects with diagnosed pneumonia & positive culture of non-typable haemophilus influenzae
3175720|NCT00637390|Experimental|one|
3175721|NCT00637403|Active Comparator|I|Megestrol acetate concentrated suspension in subjects with normal renal function
3175722|NCT00637403|Experimental|II|Megestrol acetate concentrated suspension in subjects with mild renal impairment
3175723|NCT00637403|Experimental|III|Megestrol acetate concentrated suspension in subjects with moderate renal impairment
3175724|NCT00637403|Experimental|IV|Megestrol acetate concentrated suspension in subjects with severe renal impairment
3175725|NCT00637403|Experimental|V|Megestrol acetate concentrated suspension in subjects with end stage renal disease
3175726|NCT00637429||General Co-infection|Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.
3175727|NCT00637442|Experimental|CASL-MRI|Drug monitoring with CASL-MRI for new diagnosed patients with mild to moderate Alzheimer's Disease treated with Reminyl
3175728|NCT00637468|Experimental|1|Local intra-arterial fibrinolysis (LIF)
3175729|NCT00637468|Active Comparator|2|Conservative standard therapy
3175730|NCT00637481|Experimental|Arm I (lower dose atorvastatin calcium)|Participants receive oral atorvastatin once daily for 3 months.
3175731|NCT00637481|Experimental|Arm II (atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm I) once daily for 3 months.
2573770|NCT02408627|Active Comparator|conventional EEG-registration type 1|conventional EEG-registration with wet bridge electrodes and conductive gel
2573774|NCT02408627|Active Comparator|conventional EEG-registration type 2|conventional EEG-registration with wet cup electrodes and collodion
2573776|NCT02408627|Experimental|EEG-registration with dry electrodes|EEG-registration with dry electrodes
2573810|NCT02408367||Exercise|30 minutes of active training at 75% of the Maximum heart rate achieved in a cardiopulmonary exercise test
2573815|NCT02408367||Relaxation|30 Minutes of passive relaxation
2573861|NCT02407912|Experimental|Cisplatin|75 mg of body surface area of ciplatin in distilled water is injected in to the chest through a chesttube.
2573873|NCT02407912|No Intervention|Control|No intervention was applied.
2573923|NCT02407626|Experimental|Sevoflurane|Volatile anesthesia for elective cardiac surgery
2573925|NCT02407626|Active Comparator|Propofol|Total intravenous anesthesia for elective cardiac surgery
3209956|NCT00989755|Experimental|Fax to Quit plus Enhanced Academic Detailing (F2Q + EAD)|Clinics in this group receive Fax to Quit materials and in person training from a Regional Outreach Specialist (ROS). The ROS also provides on-going training/technical assistance and performance feedback.
3209957|NCT00989755|Placebo Comparator|Fax to Quit alone|Clinics in this group receive Fax to Quit materials and can download materials from a website.
2574086|NCT02406469|Experimental|Sequence A1-A2|Oral consumption of milk containing both A1 and A2 type beta casein in intervention phase 1 and milk containing only A2 type beta casein in intervention phase 2.
2574090|NCT02406469|Placebo Comparator|Sequence A2-A1|Oral consumption of milk containing only A2 type beta casein in intervention phase 1 and milk containing both A1 and A2 type beta casein in intervention phase 2.
2574117|NCT02406157|Experimental|577-MPL|577nm micropulse laser photocoagulation(577MPL) treatment to the macular area of retinal thickening with a focal or grid pattern
2574121|NCT02406157|Active Comparator|532-SLP|532nm subthreshold laser photocoagulation(532-SLP) treatment to the macular area of retinal thickening with a focal or grid pattern
2574138|NCT02405897|Experimental|Cup forceps|4 biopsies (transbronchial lung biopsy) with Cup forceps
2574140|NCT02405897|Active Comparator|Alligator forceps|4 biopsies (transbronchial lung biopsy) with Alligator forceps
2574187|NCT02405754||Treatment Group|Patients receiving Age/Sex/Gene Expression Score (ASGES) or Corus CAD test
2574279|NCT02405403|Experimental|amyotrophic lateral sclerosis (ALS)|[18F]DPA-714 PET
2574338|NCT02404818||Survivors of Hodgkin's lymphoma|Cardiac Magnetic Resonance Imaging and Echocardiogram
3209958|NCT00989794|Experimental|GelrinC|GelrinC one step implantation to the femoral condyle lesion
3209959|NCT00989820|No Intervention|Surgery|This is the standard arm. Surgery without hyperbaric oxygen treatment
2574701|NCT02402413|Experimental|PCOS women|
2574736|NCT02402101|Active Comparator|active tDCS|Intensity : 2mA Duration : 20 minutes ramp up/ramp down 30sec anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
2574737|NCT02402101|Placebo Comparator|sham tDCS|Placebo built-in mode (30 sec ramp periods at the beginning and the end of the sham stimulation to mimic the somatosensory artifact of real tDCS) Same electrode montage than in the active group.
2574814|NCT02401802|Experimental|Low-residue diet|The experimental group will receive 4 days of low-residue diet Laxative 4 liters polyethylene glycol 4000 in split fashion.
2574815|NCT02401802|Active Comparator|Usual care|"The control group will receive 3 days of low-residue diet followed by 24 hours of liquid diet.~Laxative 4 liters polyethylene glycol 4000 in split fashion."
2574854|NCT02401347|Experimental|Cohort A - Triple-negative Breast Cancer|"Participants with advanced triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD) based on the Myriad HRD Assay.~Participants receive talazoparib 1 mg by mouth daily."
2574856|NCT02401347|Experimental|Cohort B - HER2-negative solid tumor|"Participants with advanced HER2-negative solid tumor with a deleterious hereditary or cancer somatic mutation in one of the following genes:~PTEN, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD50, RAD51C, RAD51D, MRE11, ATR, Fanconi anemia complementation group of genes.~Participants receive talazoparib 1 mg by mouth daily."
2574887|NCT02401035|Experimental|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight.
2574926|NCT02400645|Active Comparator|Group A: pre-incisional bupivacaine|Intervention: Pre-incisional wound infiltration with bupivacaine plain 0.25%. Ketorolac 30mg IV will be given following surgical procedure.
2574934|NCT02400645|Active Comparator|Group B: laparoscope to place TAP block|Intervention: laparoscope to place TAP block with liposomal bupivacaine and bupivacaine plain 0.25%. Ketorolac 30 mg IV will be given following surgical procedure.
2574987|NCT02400268|Experimental|7 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
2574994|NCT02400268|Active Comparator|14 days course of antibiotic treatment|Accepted antibiotic indicated for enterobacteriaceae infections, according to sensibility test performed and daily practice protocols or local guidelines.
2575047|NCT02399943|Experimental|Trametinib and Panitumumab|"Trametinib: 2 mg QD, orally, continuously.~Panitumumab: 6 mg/kg, intravenously, Q2W"
2575082|NCT02399644|Experimental|ACT|Acceptance and Commitment Therapy is a version of Cognitive behavioral Therapy that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
2575086|NCT02399644|Experimental|Physical activity|Participants are going to participate in a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
2575088|NCT02399644|No Intervention|Experience based discussion group|Participants are going to discuss their experiences of long term pain. The discussions is supervised by a heath care professional and is based on beforehand defined subjects, i.e. relations, spare time, economics, occupation. The meetings are hold for 7 weeks, 2 hours a week.
2573795|NCT02408536||Single cohort|Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma
2573836|NCT02408133|No Intervention|Control|The control group will be accompanied according to the service routine.
2573837|NCT02408133|Experimental|Exercise|The group will be instructed to perform home exercises autonomously for range of motion and muscular fitness
2573867|NCT02407847|No Intervention|General Practitioners Care|Usual medical care provided by General Practitioners at the Primary Out-of-Hours Service.
2573876|NCT02407847|Experimental|Nurse Practitioners Care|Medical care provided by both Nurse Practitioners and General Practitioners at the Primary Out-of-Hours Service.
2573896|NCT02407652|Experimental|cognitive control training|internet-delivered, 2 weeks
2573899|NCT02407652|Active Comparator|low cognitive load training|internet-delivered, 2 weeks
2573958|NCT02407275|Other|biological sample|Genomic & culturomic analyses
2573998|NCT02406924|Experimental|Sausage graft|Bone graft performed with a mixture of particulated autogenous and lyophilized bovine bone, stabilized with collagen membrane and pins.
2574003|NCT02406924|Active Comparator|Bone block graft|Bone graft performed with a block of autogenous bone stabilized by a screw associated with lyophilized bovine bone and collagen membrane.
3209960|NCT00989820|Experimental|Hyperbaric oxygen therapy with surgery|Intervention arm. Hyperbaric oxygen therapy with surgery.
2574146|NCT02406092|Experimental|Rituximab|Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP [cyclophosphamide+doxorubicin+vincristine+prednisone], CVP [cyclophosphamide+vincristine+prednisone] or FC [fludarabine+cyclophosphamide]) during induction.
2574184|NCT02405520|Experimental|low dosage HPV Vaccine|Participants in this arm would receive low dosage of HPV vaccines.
2574198|NCT02405520|Experimental|medium dosage HPV Vaccine|Participants in this arm would receive medium dosage of HPV vaccines.
2574211|NCT02405520|Experimental|high dosage HPV Vaccine|Participants in this arm would receive high dosage of HPV vaccines.
2574216|NCT02405520|Placebo Comparator|Placebo|Participants in this arm would receive placebo (Aluminium Adjuvant).
2574246|NCT02405156|Experimental|letrozole + misoprostol|Women will receive three tablets of letrozole vaginal as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for three days and will be followed by 200 mcg vaginal misoprostol or 100mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
2574251|NCT02405156|Placebo Comparator|placebo + misoprostol|Women will receive three tablets of placebo vaginal as a single dose, for three days and will be followed by 200 mcg vaginal misoprostol or 100 mcg vaginal misoprostol (according gestational age) soaked with saline every six hours up to maximum four doses.
2574362|NCT02404506|Experimental|Arm: Eribulin mesilate|
3209961|NCT00989846||lung disease|patients with various chronic or acute lung diseases
3209962|NCT00989859||Plethysmographic monitoring|Plethysmographic monitoring
2574499|NCT02403596|Experimental|Group 1: Exacyl®: Standard treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 then 1g Exacyl® placebo at H+7 and H+11
2574502|NCT02403596|Experimental|Group 2: Exacyl®: Extended treatment|Intravenous use. 1g Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g Exacyl® at H+3 / H+7 and H+11
2574505|NCT02403596|Placebo Comparator|Group 3: Placebo|This group will receive a placebo of Exacyl®: 1g placebo of Exacyl® at H0 (Hour = 0 in other term at the time of incision) then 1g placebo of Exacyl® at H+3 / H+7 and H+11
3209963|NCT00989885||Obstructive Sleep Apnea|475 patients that sought the CESF to probable diagnosis of some sleep disorder, subsequently diagnosed with Obstructive Sleep Apnea.
3209964|NCT00989898|Active Comparator|Closed-loops at Dinner|Automated closed-loop control starts at 18:00
2574772|NCT02401958|Experimental|Rheumatoid Arthritis Group|Resistance Training
2574774|NCT02401958|Active Comparator|Healthy control Group|Resistance Training
2574845|NCT02401581|Experimental|rate of early removal of the catheter|In our study, we propose to evaluate the failure rate of an early removal of the catheter 3 hours post-operative after a PVP procedure with GL 180 W/XPS in selected patients on general anesthesia or spinal anesthesia for limiting autonomic effects on the bladder and ensure fastest possible recovery of voiding .
2574891|NCT02401126|Active Comparator|Nitrate supplementation|Concentrated nitrate-rich beetroot juice
2574895|NCT02401126|Placebo Comparator|Placebo|Nitrate-depleted beetroot juice
2574947|NCT02400775|Experimental|Azilsartan|Azilsartan orally once daily in the morning, either before or after breakfast
2574975|NCT02400359|Placebo Comparator|Placebo|Subjects will be randomized to either placebo or Lorcaserin HCl.
2574976|NCT02400359|Active Comparator|Active|Subjects will be randomized to either placebo or Lorcaserin HCl.
2575020|NCT02400450|Experimental|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix. The food items will contain a standardized amount of functional ingredients.
3209965|NCT00989898|Active Comparator|Closed-loop at Bedtime|Automated closed-loop control starts at 21:00
3209966|NCT00989924||Diabetes mellitus|The Diabetic patient who receives follow-up at NTUH diabetics caring network
3209967|NCT00989976|Other|8.5 h sleep|Subjects will have normal sleep times
3209968|NCT00989976|Other|restricted bedtimes|4.5 h bedtimes
3209969|NCT00990002||Control|A children's milk-based beverage
3209970|NCT00990002||experimental probiotic 1|children's milk-based beverage containing a bioactive ingredient
3209971|NCT00990002||experimental probiotic 2|children's milk-based beverage containing a different bioactive ingredient
3209972|NCT00990015|Experimental|PF-04308515|
3209973|NCT00990015|Placebo Comparator|Placebo|
2573864|NCT02408003|Experimental|Levosimendan|"st dose: 12 µg/kg iv bolus for 10 min followed by 0,1 µg/kg/min for 20 min.~nd dose: 12 µg/kg iv bolus for 10 min followed by 0,2 µg/kg/min for 20 min."
2573872|NCT02408003|Experimental|Milrinone|"st dose: 48 µg/kg iv bolus for 10 min followed by 0,4 µg/kg/min for 20 min.~nd dose: 48 µg/kg iv bolus for 10 min followed by 0,8 µg/kg/min for 20 min."
2573948|NCT02407548|Experimental|combined group|each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.
2573950|NCT02407548|Experimental|CoQ10 group|each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.
2573952|NCT02407548|Other|placebo group|each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.
2574032|NCT02406716||HF|Heart failure patients
2574039|NCT02406716||Controls|Healthy donors
2574085|NCT02406521|Experimental|Arm A: Pazopanib with Radium-223|"No prior targeted therapy~Pazopanib oral, daily and at predetermined dosage per cycle~Radium-223 predetermined dosage via IV, per cycle"
2574091|NCT02406521|Experimental|Arm B: Sorafenib with Radium-223|"At least one line of prior targeted therapy:~Sorafenib at predetermined dosage, mouth twice daily~Radium-223 predetermined dosage via IV, per cycle"
2574137|NCT02406105|Experimental|Radiosurgical thalamotomy|Cyber Knife based functional radiosurgical thalamotomy, photons 6MV, single dose 70-110 Gy
2574306|NCT02404766|Experimental|Intervention group|C0-C1 dorsal glide mobilization in the cervical neutral position.
2574308|NCT02404766|Experimental|Intervention group 2|C7-T1 ventral cranial glide mobilization in the cervical neutral position
2574310|NCT02404766|No Intervention|Control group|Not receiving any intervention
2574374|NCT02404597|Experimental|NICOM|"Subjects with burns greater than 20% total body surface area (TBSA) will have a NICOM placed on them after the first 24 hours of admission if subject has an episode of hypotension (mean arterial pressure < 65 or a systolic blood pressure < 90mmHg). The NICOM will generate a number that reflects stroke volume of the heart. If the number is greater than 10 percent, subject will be given a bolus of crystalloid fluids. If the number is less than 10 percent, subject will start a medication to raise the blood pressure.~Physicians may also use traditional endpoints of resuscitation include base deficit values and urine output goals of 0.5cc/kg/hr as indications of adequate intravenous fluid resuscitation."
2574378|NCT02404597|No Intervention|Control|This is a retrospective comparison control group of patients with burns greater than 20% total body surface area (TBSA) admitted to the hospital from 7/1/2014-12/31/2014.
2574495|NCT02403791|Experimental|Lung Ultrasound|In infants allocated to this arm Lung ultrasound for detection of ARDS will be performed before chest radiography.
2574498|NCT02403791|Active Comparator|Chest Radiography|In infants allocated to this arm chest radiography will be performed for the detection of indirect signs of ARDS without ultrasound evaluation.
3175732|NCT00637481|Experimental|Arm III (higher dose atorvastatin calcium)|Participants receive oral atorvastatin (at a higher dose than in arm II) once daily for 3 months.
3175733|NCT00637481|Other|Arm IV (no intervention)|Participants do not receive treatment. Participants undergo blood sample collection and fine needle aspiration of breast tissue at baseline and at 3 months for correlative biomarker studies.
2575240|NCT02398500|Experimental|LMG324|SAD: LMG324 administered as a single IVT injection in 1 eye (study eye) in 1 of 4 doses, with 15-day follow-up
2575241|NCT02398500|Experimental|LMG324 + sham|Expansion: LMG324 administered as a single IVT injection in 1 eye (study eye), followed by sham injections, until implementation of SoC therapy as specified in the protocol, for 24 weeks
2575243|NCT02398500|Active Comparator|Lucentis + sham|Expansion: Ranibizumab 0.5 mg administered as monthly IVT injections in 1 eye (study eye) with interim sham injections, for 24 weeks
2575296|NCT02398071|Experimental|PEP interventon|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 5 cmH2O
2575299|NCT02398071|Sham Comparator|Sham intervention|Participants performed 6 PEP breaths using a water pressure threshold device (BreatheMAX) with expiratory load set at 0 cmH2O
2575344|NCT02397746||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® Gladiator femoral stem, MicroPort acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
2575391|NCT02397434|Experimental|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
2575454|NCT02397174|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
2575457|NCT02397174|Active Comparator|hypocaloric diet|The diet programme will be characterized by carbohydrates (50%),total lipids (30%) and proteins (20%). After calculating the patient's energy need, the amount of calories will be successively adjusted to create an 800 kcal deficit per day.
2575496|NCT02396615|Active Comparator|Active|Satin pineapple. Active juice with fibre and ginseng
3175734|NCT00637507|No Intervention|2|Patients treated solely with a pressure- and volume-limited ventilatory strategy (target plateau pressure of 30 cm H2O) aimed at minimizing lung stress and strain, and thus, ventilator-induced lung injury.
3175735|NCT00637507|Experimental|1|Intermittent application of High-frequency Oscillation (HFO) and Tracheal Gas Insufflation (TGI) according to pre-specified criteria described in the Detailed Description. HFO-TGI sessions are interspersed with lung protective conventional mechanical ventilation until the PaO2/FiO2 ratio stabilizes at >150 mm Hg.
3175736|NCT00637520||1|Subjects with NAFLD
3175737|NCT00637520||2|Subjects without liver disease
3175738|NCT00637520||3|Subjects with non-steatotic hepatitis
3175739|NCT00637533|Placebo Comparator|Placebo|Saline injection
3175740|NCT00637533|Experimental|Botulinum Toxin Type A|Sympathetic Blockade containing Botulinum Toxin Type A
2573874|NCT02407808|Placebo Comparator|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
2573915|NCT02407574|Experimental|Spontaneous rhythm first|Stepwise preload increase by repeated administration of 100 mL of fluid during spontaneous rhythm and then stepwise preload reduction by repeated drainage of 100 mL of fluid during atrial pacing.
2573918|NCT02407574|Experimental|Atrial pacing first|Stepwise preload increase by repeated administration of 100 mL of fluid during atrial pacing and then stepwise preload reduction by repeated drainage of 100 mL of fluid during spontaneous rhythm.
3175741|NCT00637546|Experimental|A,1|Physiotherapy
3175742|NCT00637559|Experimental|1|40mg twice daily
3175743|NCT00637559|Experimental|2|40mg three times daily
3175744|NCT00637559|Experimental|3|20mg three times daily
3175745|NCT00637598|Experimental|Tomosynthesis scans|This is a case-only study with only one group/cohort. All women receive both mammography and tomosynthesis imaging.
3175746|NCT00637624|Active Comparator|1|N-Acetylcysteine
3175747|NCT00637624|Placebo Comparator|2|Placebo
3175748|NCT00637650|Experimental|B|"Experimental group: patients in whom stone dust was left for spontaneous elimination"
3175749|NCT00637650|Other|A|Control group: Patients in whom all fragments resulting from laser lithotripsy of ureteral stones were actively retrieved
3175750|NCT00637663|Experimental|A|entecavir 0.5 mg QD
2574531|NCT02403466|Experimental|Resident Handoff Bundle|bundle of interventions designed to improve handoff, including: training of residents in teamwork and handoff techniques; redesign of verbal handoff processes; implementation of handoff mnemonic (I-PASS); implementation of structured written / computerized handoff tool; faculty training in handoffs
2574648|NCT02402699||Unresectable, recurrent or metastatic melanoma patients|All adult unresectable, recurrent, or metastatic melanoma patients with HBV or HCV treated with at least 1 dose of ipilimumab therapy in Taiwan
2574840|NCT02401568|Other|Normal subjects|"No morphologic changes in carpal ligaments or clinical signs of wrist instability.~Dynamic CT of the wrist will be performed before and after arthrography."
2574843|NCT02401568|Other|Wrist instability|Morphologic ligament changes (e.g. partial or complete rupture) Dynamic CT of the wrist will be performed before and after arthrography.
2574894|NCT02401152|Placebo Comparator|Placebo group|Sports drink containing maltodextrin
2574898|NCT02401152|Active Comparator|Sports drink 1|Sports drink with a specific source of carbohydrates (CHO).
2574901|NCT02401152|Active Comparator|Sports drink 2|Sports drink with a specific source of CHO.
3175751|NCT00637663|Active Comparator|B|lamivudine 100 mg QD
3175752|NCT00637676|Active Comparator|1|Implantation of PleurX-Pleural catheter plus talc pleurodesis
3175753|NCT00637676|Active Comparator|2|talc pleurodesis, no implantation of PleurX-Pleural catheter
3175754|NCT00637702|Experimental|ARRY-334543|
3175755|NCT00637741|Experimental|Everflex 200|study group treated with at least one 200 mm Everflex stent
3175756|NCT00637767|Experimental|radio-labelled anti-CD66 monoclonal antibody|Up to 4mg radio-labelled anti-CD66 monoclonal antibody. Plus standard treatment
3175757|NCT00637767|Active Comparator|No IMP - standard treatment|No IMP - standard treatment
3175758|NCT00637793|Placebo Comparator|1|Placebo capsules
3175759|NCT00637793|Experimental|2|2 capsules in the am of each treatment period
3175760|NCT00637793|Experimental|3|2 capsules in the am of each treatment period
3175761|NCT00637793|Experimental|4|2 capsules in am of each treatment period
3175762|NCT00637845|Experimental|1|40mg once daily
3175763|NCT00637845|Active Comparator|2|30mg twice daily
3175764|NCT00637858|Placebo Comparator|1|
3175765|NCT00637858|Active Comparator|2|Lyc-o-Mato 5mg
3175766|NCT00637858|Active Comparator|3|Lyc-o-Mato 15mg
3175767|NCT00637858|Active Comparator|4|Lyc-o-Mato 30mg
3175768|NCT00637858|Active Comparator|5|Lycopene capsules (non Lyc-o-mato) 15 mg
3175769|NCT00637871|Experimental|1|
3175770|NCT00637871|Active Comparator|2|
3175771|NCT00637897|Experimental|Paricalcitol (Zemplar)|Paricalcitol (Zemplar)
3175772|NCT00637910|Experimental|Erlotinib Arm|
3175773|NCT00637910|Active Comparator|Docetaxel Arm|
3175774|NCT00637936|Active Comparator|1|Group 1 is given 30% oxygen during and 2 hours after surgery
3175775|NCT00637936|Active Comparator|2|Group 2 is given 80% during and 2 hours after surgery.
3175776|NCT00637949|Experimental|1|
3175777|NCT00637949|Active Comparator|2|
3175778|NCT00637962|Experimental|Active product|CN54gp140 + gel
3175779|NCT00637962|Placebo Comparator|Gel alone|Gel alone
3175780|NCT00637975|Experimental|A|oxycodone 20 mg/day plus pregabalin at increasing dose starting from 50 mg/day for 15 days or until unacceptable toxicity develops
3175781|NCT00637975|Active Comparator|B|pregabalin 50 mg/day plus oxycodone at increasing dose starting from 20 mg/day. For 15 days or until unacceptable toxicity develops
3175782|NCT00637988|Experimental|1|Nexium 40mg
3175783|NCT00637988|Experimental|2|Nexium 40mg + aspirin
3175784|NCT00637988|Experimental|3|Nexium 40mg + Rofecoxib 25 mg
3175785|NCT00637988|Active Comparator|4|Rofecoxib 25mg
3175786|NCT00638040||1|The purpose of this study is to analyze the gene expression patterns associated with various microenvironmental stresses in tumors to understand their roles in tumor progression and treatment responses. To achieve this goal, we will perform gene expression analysis of the tumor samples collected from an IRB-approved study (IRB #: 4516-05-2R2) International Phase III Study of Chemoradiotherapy versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer directed by Dr. Mark Dewhirst. We will correlate the gene expression signatures of different microenvironmental stresses with the measured physiological parameters to understand their role in tumor progression, treatment response and clinical outcomes.
3175787|NCT00638053|Experimental|1|
3175788|NCT00638066|Experimental|1|
3175789|NCT00638066|Active Comparator|2|
3175790|NCT00638079|Experimental|A|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) with a high fat meal
3175791|NCT00638079|Active Comparator|B|Megestrol acetate 625 mg/5 mL oral suspension (Megace ES) following an overnight fast
2573880|NCT02407834|Experimental|S3 - 10% Ricinus communis|Brushing with specific brush and neutral soap, three times a day. After, immesion in 10% Ricinus communis solution during 20 minutes, once a day. This protocol was used during 7 days.
2573881|NCT02407834|Placebo Comparator|S4 - saline solution|Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
2573904|NCT02407522|Experimental|black rice group|Each subject in the experimental group will be provided with black rice (50 g/day).According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
2573905|NCT02407522|Placebo Comparator|white rice group|individuals in the control group will be subjected to follow-up. According to the clinical requirements, no specific rules are needed for other treatments of the two groups.
2573954|NCT02407301||Laryngeal function in cough|cough airflow measure, vocal tasks, true vocal fold movement, spirometry test, and maximum expiratory pressure (MEP) assessment will be performed in this group.
3209974|NCT00990028|Experimental|Rosuvastatin|20 mg oral during 10 days
3209975|NCT00990028|Placebo Comparator|Placebo|
2574082|NCT02406404|Experimental|spirometer training group|incentive spirometer training group
2574089|NCT02406404|No Intervention|No intervention group|no intervention group
2574118|NCT02406183|Experimental|Treatment (SBRT, Ipilimumab)|"Drug: Ipilimumab Dosage: Ipilimumab will be administered intravenously at 3 mg/kg every 3 weeks for 4 cycles,~Radiation: Stereotactic Body Radiotherapy Radiation therapy 24 Grays in 8 Grays fractions, Radiation therapy 30 Grays in 10 Grays fractions, Radiation therapy 36 Grays in 12 Grays fractions"
2574161|NCT02405923|Experimental|HRF (Rice formula)|Hydrolyzed Rice Protein Formula (HRF)
2574162|NCT02405923|Placebo Comparator|eHF (Extensive Hydrolysed Formula)|Extensive Hydrolysed Cow's Milk Protein Formula (eHF)
2574180|NCT02405572|Active Comparator|Formula 1|infant formula
2574192|NCT02405572|Active Comparator|Formula 2|infant formula
2574247|NCT02405299|Experimental|Experimental Group|neuropsychological reeducation disorder specific of inhibition (bottom-up and top-down protocol): 24 bi-weekly sessions (30 subjects)
2574252|NCT02405299|Placebo Comparator|Control Group|non-specific and general cognitive neuropsychological reeducation (comprehension, syntactic, visuospatial) : 24 bi-weekly sessions (30 subjects)
2574305|NCT02405013|Experimental|Sofosbuvir+Ribavirin|Sofosbuvir 400mg QD (Sovaldi®) + Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
2574307|NCT02405013|Experimental|Sofosbuvir+Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
2574359|NCT02404454|Experimental|hysteroscopic metroplasty|women undergoing hysteroscopic metroplasty for uterine septum resection
2574428|NCT02404233|Experimental|Darunavir/ cobicistat and Rilpivirine|"Single arm study:~Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food Rilpivirine tablet 25 mg once daily taken with food"
2574469|NCT02403843||Evaluation|A group of subjects with the RNS System implanted who elect to continue to receive RNS System responsive stimulation for the long term.
2574513|NCT02403557|Experimental|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
2574517|NCT02403557|Active Comparator|Waitlist|Weekly check-up.
2574576|NCT02403297||Healthy|"Saliva will be collected from 58 subjects determined to be healthy according to the protocol."
2574580|NCT02403297||Gingivitis|Saliva will be collected from 58 subjects determined to have gingivitis according to the protocol.
2574583|NCT02403297||Periodontal disease|Saliva will be collected from 58 subjects determined to have periodontal disease according to the protocol.
3209976|NCT00990041||PBMC|
3209977|NCT00990041||periodontitis|
2574708|NCT02402283|Experimental|Test Product|Metronidazole benzoate oral granules
2574709|NCT02402283|Active Comparator|Reference Product|Flagyl 400 mg Tablets
2574768|NCT02402010|Experimental|Adjunctive Yoga|Participants may be randomized to receive up to 10 weeks of group yoga class, as an adjunct to medication treatment as usual provided by community clinicians.
2574771|NCT02402010|Other|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
2574833|NCT02401594|Experimental|Group 1: Rivaroxaban treatment|Rivaroxaban active substance plus a placebo of enoxaparin
2574834|NCT02401594|Active Comparator|Grouyp 2: Enoxaparine treatment|Enoxaparin active substance plus a placebo tablet of Rivaroxaban
2574918|NCT02400944||patients with bladder cancer|
2574932|NCT02400567|Active Comparator|Chemotherapy|3 cycles of FEC 100 followed by 3 cycles of Docetaxel Drugs: Fluorouracile, Epirubicine, Cyclophosphamide, Docetaxel
2574935|NCT02400567|Experimental|Letrozole Palbociclib|Drugs: letrozole + palbociclib combination
3209978|NCT00990054|Experimental|plerixafor|
3209979|NCT00990067|Other|duloxetine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3209980|NCT00990080|Active Comparator|Group 1|Pediacel® at 2 and 4 months of age followed by Infanrix™-IPV/Hib at 6 months.
3209981|NCT00990080|Active Comparator|Group 2|Infanrix™-IPV/Hib at 2 months of age followed by Pediacel® at 4 and 6 months.
3209982|NCT00990119|Experimental|High FLow Therapy|Use of High Flow Therapy for support of Respiratory Insufficiency
3209983|NCT00990119|Active Comparator|NiPPV|
3209984|NCT00990132|Active Comparator|Long term oxygen therapy|LTOT will be established as per current national guidelines
3209985|NCT00990132|Experimental|Home mechanical ventilation|Patients will be set up on LTOT as per national guidelines and nocturnal non-invasive ventilation in accordance with study protocol.
3209986|NCT00990145|Experimental|Intervention|EDP-322 v. Placebo
3209987|NCT00990158|Active Comparator|Low dose vitamin K + usual warfarin|Low dose oral vitamin K (0.150 mg orally once daily) + warfarin continuation with usual warfarin monitoring
2573908|NCT02407470|Active Comparator|Rabbit antithymoglobulin （ATG）|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 with the goals of ablating host repressive T cells.
2573910|NCT02407470|Experimental|Rabbit ATG & AD-MSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own adipose derived mesenchymal stem cells (AD-MSCs) at a dose of 3000000/kg/d on day 1 to 3.
2573912|NCT02407470|Experimental|Rabbit ATG & AD-HSCs|Patient in this arm will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2 and then patient's own AD-MSC transdifferentiated HSCs (AD-HSCs) at a dose of 3000000/kg/d from day 1 to 4.
2573972|NCT02407093|Experimental|High-Intensity Functional Training|CrossFit will be the HIFT intervention framework with training elements, exercise programming, and scheduling set by CrossFit staff. Workouts will be comprised of one or more of three exercise modalities: aerobic/monostructural (e.g., running), gymnastics (e.g., pullups), and weightlifting/resistance training with workouts designed to maximize use of equipment available in deployed environments (e.g.,vehicle tires). All workouts will be individually scaled to each soldier's current level of fitness by a certified trainer. Sessions will be standardized across the 6 months of intervention so that each cluster will receive exactly the same training.
2573975|NCT02407093|Active Comparator|Army Physical Readiness Training|"The APRT program has combat readiness as the primary focus and is mandated for active duty personnel. For this study, APRT sessions have been standardized across the 6 months of the intervention according to FM 7-22 Army Physical Readiness Training manual so each cluster will receive the same training program using the Reset Phase. Sessions will consist of preparation, activities and recovery and will include strength, endurance, and mobility exercises that involve on-ground (e.g., running), off-ground (e.g., climbing), and combatives (e.g., striking and grappling) training, with supervision by a certified trainer."
2574030|NCT02406781|Experimental|Treatment strategy A|Combination of MK3475 with Metronomic CP. MK3475 will be administered intraveinously. Metronomic CP (Cyclophosphamide) will be adminstered orally.
2574033|NCT02406781|Experimental|Treatment strategy B|Combination of MK3475 with Metronomic CP and G100. MK3475 will be administered intravenously. Metronomic CP (Cyclophosphamide) will be administered orally. G100 will be administered by intra-tumoral injection.
2574080|NCT02406417|Experimental|Investigation for pituitary dysfunction|Further investigation for pituitary dysfunction by blood tests, dynamic function tests and pituitary imaging e.g. CT Scan with contrast. Patients identified as being at high risk of having pituitary dysfunction based on preliminary blood tests will have further tests added. If these results point to a likely pituitary dysfunction, the patient will be referred to the Endocrine team for further investigations including dynamic function tests and/or imaging.
2574123|NCT02406209|Experimental|NS2|NS2 ophthalmic drops (0.5%) in the affected eye
2574125|NCT02406209|Experimental|NS2 and Pred Forte|NS2 ophthalmic drops (0.5%) and Prednisolone acetate ophthalmic suspension (1%) in the affected eye
2574128|NCT02406209|Active Comparator|Pred Forte|Prednisolone acetate ophthalmic suspension (1%) in the affected eye
2574182|NCT02405806|Experimental|low carbohydrate food|"The subjects will be given a diet with moderate, low carbohydrate content for 3 months, or as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum as described previously.~Intervention: Food: Low carbohydrate food"
2574189|NCT02405806|Active Comparator|standard food|The subjects will be given a diet with standard food as a single test meal, and this will be evaluated in metabolic parameters, microbiota and biomarkers in serum, as described Intervention: Food: Standard food
3209988|NCT00990158|Placebo Comparator|Usual warfarin therapy + placebo|Patients continue usual warfarin and take one placebo per day
3209989|NCT00990171||PD-BCM|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
2574289|NCT02404740||VP shunt functioning|No intervention, just a physiological category--patients with VP shunts that are functioning normally.
2574290|NCT02404740||VP shunt malfunctioning|No intervention, just a physiological category--patients with VP shunts that are malfunctioning.
2574291|NCT02404740||No known intracranial pathology|No intervention, just a physiological category--patients without VP shunts that have no known intracranial pathology.
2574342|NCT02404688|Experimental|Active THC and Placebo Ethanol|
2574343|NCT02404688|Experimental|Active THC and Active Ethanol|
2574345|NCT02404688|Experimental|Placebo THC and Active Ethanol|
2574347|NCT02404688|Placebo Comparator|Placebo THC and Placebo Ethanol|
2574364|NCT02404337|Experimental|100 mg/kg of Betaine|Dose 1 : 100 mg/kg of Betaine
2574366|NCT02404337|Experimental|250 mg/kg of Betaine|Dose 2 : 250 mg/kg of Betaine
2574434|NCT02404207|Active Comparator|Soybean oil|
2574435|NCT02404207|Experimental|High-oleic soybean oil|
2574436|NCT02404207|Experimental|High-oleic soybean oil + fully hydrogenated soybean oil|
2574437|NCT02404207|Active Comparator|Palm olein + palm stearin|
3209990|NCT00990197|Active Comparator|Day 1|Patients randomized to wearing the patch on day 1 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 2.
3209991|NCT00990197|Active Comparator|Day 2|Patients randomized to wearing the patch on day 2 will apply a patch on the morning of their treatment day and keep it on for 24 hours. These patients will not wear a patch on day 1.
2574608|NCT02403050||Fiducial Markers Prospective cohort|2 fiducial markers (Visicoils) to be placed in the tumor area at the routine endoscopic ultrasound (EUS) appointment.
2574609|NCT02403050||Retrospective cohort|Images and clinical data from a retrospective group of patients without fiducial markers
2574649|NCT02402673|Other|Intervention|
2574677|NCT02402400|Active Comparator|Oral Ticagrelor|
2574684|NCT02402400|Experimental|Sub Lingual Ticagrelor|
2574778|NCT02402049|Placebo Comparator|4: Placebo Nux vomica|Placebo Nux vomica
2574779|NCT02402049|Placebo Comparator|5: Placebo pulsatilla|Placebo pulsatilla
2574780|NCT02402049|Placebo Comparator|6: Placebo Folliculinum|Placebo Folliculinum
2574792|NCT02401815|Experimental|Part 2e: PLX9486 500 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 500 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2573947|NCT02407509|Experimental|RO5126766 & Everolimus|RO5126766 and Everolimus will be given in combination once or twice weekly for 3 weeks of a 4 week cycle.
2573990|NCT02406989|Experimental|MS-553|MS-553 oral tablet BID x 14 days
2573991|NCT02406989|Placebo Comparator|Placebo|Placebo oral tablet BID x 14 days
2574074|NCT02406703||Chloroprocaine|Patient undergoing popliteal block with chloroprocaine
2574075|NCT02406703||Mepivacaine|Patient undergoing popliteal block with mepivacaine
2574111|NCT02406222|Active Comparator|Pomalidomide and Dexamethasone|"Pomalidomide and Dexamethasone will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22"
2574112|NCT02406222|Experimental|Pomalidomide Dexamethasone Cylcophosphamide|"Pomalidomide, Dexamethasone and Cyclophosphamide will be administered as part of a 28 day cycle. Patients will continue with their treatment until disease progression, intolerance, toxicity or withdrawal.~Dosing schedule:~Pomalidomide 4mg orally on days 1-21~Dexamethasone 40mg orally on days 1, 8, 15 and 22~Cyclophosphamide 500mg orally on days 1, 8 and 15"
2574185|NCT02405832|Experimental|Zinc - active arm|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
2574201|NCT02405832|Placebo Comparator|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
2574256|NCT02405312|Experimental|advance care planning|nephrologist empowers social worker to meet with patient and family.
2574316|NCT02404987||Nutritional Supplement|Free living and residing and nursing home malnourished patients
2574370|NCT02404558|Experimental|Sarilumab|Single subcutaneous (SC) dose of sarilumab
2574371|NCT02404558|Active Comparator|Tocilizumab|Single SC dose of tocilizumab
2574442|NCT02404116|Experimental|Metacognitive Therapy|12 weeks of Metacognitive Therapy
2574449|NCT02404116|Other|Wait List Control|The Waiting list control will control for time and repeated assessments during an initial 12 week period
2574546|NCT02403440|Experimental|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
2574572|NCT02403115||Lupus Nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies.
2574574|NCT02403115||Incident SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies, in order to evaluate the presence of nephritic manifestations.
2574577|NCT02403115||Prevalent SLE without nephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
2574579|NCT02403115||Rheumatoid arthritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to evaluate the presence of nephritic manifestations.
2574582|NCT02403115||Membranous glomerulonephritis|Collection of serum at onset and during subsequent follow-up at 6, 12, 24 and 36 months for the dosage of circulating autoantibodies in order to exclude secondary forms of the disease.
2574618|NCT02402868|Experimental|Intranasal ketamine and saline|Intranasal ketamine (each single dose, 8 mg/kg prepared in 0.9% NS in 3 mL syringe and atomizer, to a maximum of 6.4 mL) PLUS IV 0.9% NS 0.02 mL/kg
2574621|NCT02402868|Active Comparator|Intravenous ketamine and saline|Intravenous ketamine (single dose, 1 mg/kg, to a maximum 100 mg) PLUS intranasal 0.9% NS 0.08 mL/kg divided to both nares
2574696|NCT02402569|Experimental|Multi-electrodes / single electrode|Multi stimulation / single stimulation
2574700|NCT02402569|Experimental|Single-electrode / Multi electrodes|Single stimulation / Multi stimulation
2574795|NCT02401763||Nasopharyngeal carcinoma and salivary gland tumor|patients diagnosed and treated in National Taiwan University Hospital
2574861|NCT02401503|Experimental|Bendamustine + GA101 + ABT-199|Bendamustine: 70mg/m² i.v. GA101: 1000 mg i.v. ABT-199: 20 - 400 mg p.o.
2574936|NCT02400866|Placebo Comparator|Control|palonosetron + dexamethasone + placebo
2574943|NCT02400866|Experimental|Experimental|palonosetron + dexamethasone + olanzapine
2575135|NCT02399033|No Intervention|the control group|Patients in Control group were not received Xihuang Capsules.
2575145|NCT02399033|Experimental|Xihuang Capsules group|Patients in Xihuang Capsules group were received Xihuang Capsules (2g, bid), Continuously taking to cancer recurrence or death.
2575197|NCT02398864|Experimental|endobronchial ultrasound bronchoscopy|EBUS with TBNA
3175792|NCT00638092|Experimental|Iodine|This is the hypothetical active arm
2575347|NCT02398019|Experimental|CPB-OXIRIS®|Non emergent cardiac surgery patients with CPB requirement.
2575352|NCT02398019|No Intervention|CPB-Standard|Non emergent cardiac surgery patients with CPB requirement.
2575530|NCT02396472|Placebo Comparator|Order by time and topic|"Volunteers from the American Cancer Society's Cancer Survivors' Network (CSN) will see some of their messages delivered using CSN's default ordering, which shows messages within a conversational thread ordered by time stamp. Conversational threads are nested within a broad topic-based forum, like breast cancer or colorectal cancer survivors.~Note that this is a within-participant trial, so that all participants participate in all arms of the trial. Messages, not people, are randomly assigned to condition."
3175793|NCT00638092|Placebo Comparator|Placebo|this is the hypothetical placebo
3175794|NCT00638131|Experimental|1|Bosentan 62.5mg bid x4 weeks; up-titrated to 125mg bid x12 weeks;
3175795|NCT00638131|Placebo Comparator|2|placebo given bid same as experimental arm;
3175796|NCT00638144||1|patients with resolved infection
3175797|NCT00638144||2|chronically infected patients
3175798|NCT00638170|Active Comparator|A|Cranberry juice
3175799|NCT00638170|Placebo Comparator|B|Placebo juice
3175800|NCT00638196|Experimental|1|placebo/active crossover
3175801|NCT00638209|Active Comparator|I|
3175802|NCT00638209|Placebo Comparator|P|
3175803|NCT00638248|Active Comparator|1|Desmoteplase 90µg/kg BW
3175804|NCT00638248|Active Comparator|2|Desmoteplase 125 µg/kg BW
3175805|NCT00638248|Placebo Comparator|3|Placebo
3175806|NCT00638261|Other|left/right|left or right body side
3175807|NCT00638300|Experimental|1|large pore dialyzers (FX80, Fresenius, Germany)
2574001|NCT02406911|Experimental|Ticagrelor 90 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and low dose ticagrelor (ticagrelor 90 mg once a day) was treated for 14 days.
2574007|NCT02406911|Active Comparator|Ticagrelor 180 mg|After randomization, an initial loading dose of ticagrelor (180 mg) was given and usual dose ticagrelor (ticagrelor 90 mg twice a day) was treated for 14 days.
2574078|NCT02406625|Experimental|Diaclectical Behavioral Therapy|15 adolescents with history of suicidal behaviors receiving Dialectical Behavioral Therapy.
2574081|NCT02406625|Experimental|Support Therapy|15 adolescents with history of suicidal behaviors receiving Support Therapy.
2574088|NCT02406625|No Intervention|Controls|A group of 15 healthy controls that are not receiving any kind of therapy.
2574127|NCT02406170|Experimental|Regorafenib+Paclitaxel|Regorafenib tolerability will be tested in a dose escalation scheme with a cytotoxic backbone of paclitaxel 80mg/m2.
2574141|NCT02405910|Experimental|A - Nab-paclitaxel 100mg + Gemcitabine 1250mg|Nab-paclitaxel 100 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 21 day cycle. On days 1 and 8 of each cycle, nab-paclitaxel administration will be followed by the administration of gemcitabine 1250 mg/m2 as a 30 minute infusion (maximum 40 minutes).
2574143|NCT02405910|Experimental|B - Nab-paclitaxel 125mg + Gemcitabine 1000mg|Nab-paclitaxel 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on days 1, 8 and 15 of a 28 day cycle. Each nab-paclitaxel administration will be followed by the administration of gemcitabine 1000 mg/m2 as a 30 minute infusion (maximum 40 minutes) on days 1, 8 and 15. Treatments will be repeated until progression or intolerance.
2574200|NCT02405624|Experimental|CPAP training|Patients will be instructed and follow the continuous positive airway pressure (CPAP) training procedure
2574245|NCT02405377|Experimental|CVP guided hydration|The fluid rate was adjusted according to the CVP dynamically
2574254|NCT02405377|Active Comparator|Control|The control group was hydrated at 1 mL/kg per h.
2574302|NCT02404857|Experimental|Chronic post-stroke|Patients >6 months post-stroke with little to no hand movement. use of EEG based BCI in the neurorehabilitation process
3209992|NCT00990223|Experimental|Cohort 1|Healthy Volunteers - eplerenone versus placebo.
3209993|NCT00990262||Acute Chest Pain|Patients who presented to the emergency department with acute chest pain, with negative initial biomarkers and normal or non-ischemic ECG
2574443|NCT02403947|Experimental|Mesenchymal stem cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
2574450|NCT02403947|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
2574506|NCT02403700||All study participants|One group observation study
2574540|NCT02403336|Experimental|Behavioral group intervention|Professionals: 3 training sessions for updating the knowledge and learning skills. Patients: Health education workshop.
2574541|NCT02403336|Active Comparator|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
2574590|NCT02403089||neonates|neonates 24-41 weeks gestational age
2574592|NCT02403089||children|hematopoietic stem cell transplant recipient children (< 18 years old, donor source: cord blood or genoidentical donor)
2574611|NCT02402842|Experimental|DCF regimen|docetaxel 75 mg/m2 day, Cisplatin75 mg/m2 and 5Fluorouracil at 750 mg/m2/day for 5 days
2574672|NCT02402465|Placebo Comparator|Placebo|Placebo nasal spray that is similar to Dymista in all respects except the active ingredient
2574679|NCT02402465|Experimental|Fluticasone propionate|Fluticasone propionate nasal spray provided in a bottle similar to placebo and dymista
2574686|NCT02402465|Experimental|Dymista (fluticasone/azelastine)|Dymista is also provided as a nasal spray in bottles similar to the other two agents
2574742|NCT02402088|Active Comparator|Normal Weight|BMI18.5-24.9 (normal range)
2574744|NCT02402088|Experimental|Overweight|body mass index between 25.0 - 29.9 (overweight range)
2574746|NCT02402088|Experimental|Obese|body mass index between 30 and 35 (obese range)
2574796|NCT02401776|Experimental|small dose monster energy drink|This will be a small dose of monster energy drink
2574798|NCT02401776|Experimental|medium dose monster energy drink|This will be a medium dose of monster energy drink
2574799|NCT02401776|Active Comparator|coffee|This will be a coffee group and will drink Starbuck's K-cup Breakfast Blend. This will be mixed according to packing instructions and will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 11 ounce cup of coffee for a person weighing 75 kg).
2574838|NCT02401373|Experimental|low dose|30 participants will be firstly recruited and assigned to receive the low dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
2574842|NCT02401373|Experimental|High dose|After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose of Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV).
2574899|NCT02401217|Experimental|Phase 1-Arm 1 Infant Formula|Milk-based infant formula manufactured by an alternative method. Non-commercially available formula. To be fed ad libitum.
3209994|NCT00990275|Experimental|Post-alcohol|
3209995|NCT00990301|Experimental|Moexipril HCl/ Hydrochlorothiazide 15mg/25mg Tablets|
3209996|NCT00990301|Active Comparator|Uniretic® 15mg/25mg Tablets|
3209997|NCT00990327|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
3209998|NCT00990327|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson or the active comparator: adenosine.
3209999|NCT00990353||Prism adaptation therapy|Patients receive prism adaptation therapy by protocol (Frassinetti et al., 2002)
2574006|NCT02406976|Experimental|G2- EXERCISE AND LIFESTYLE|"This groups will receive the same intervention of G1 group, associated with the weekly group with a psychologist.~These groups worked techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors, as well as the reduction or elimination of undesirable conduct."
2574009|NCT02406976|Active Comparator|G3- CONTROL|This group will keep the routine treatment in outpatient of bariatric surgery. This treatment consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
3210000|NCT00990353||Bromocriptine pharmacotherapy|Patients receive bromocriptine pharmacotherapy by protocol (Barrett et al., 1999)
3210001|NCT00990366|Active Comparator|biliary stent without an antireflux valve|patients with biliary obstruction who need a biliary stent, selected for the stent without an antireflux valve arm
3210002|NCT00990366|Active Comparator|biliary stent with an antireflux valve|patients with biliary obstruction, who need a biliary stent, selected for the stent with an antireflux valve arm
2574203|NCT02405546|Experimental|Pre-Rotated Technique (Group R)|90° counterclockwise rotation of bevel of ETT
2574209|NCT02405546|Active Comparator|No rotation|No rotation of bevel of ETT
2574255|NCT02405260|Experimental|TTP399 400 mg|TTP399 once daily
2574257|NCT02405260|Experimental|TTP399 800 mg|TTP399 once daily
2574258|NCT02405260|Active Comparator|Sitagliptin 100 mg|Sitagliptin once daily
2574261|NCT02405260|Placebo Comparator|Placebo|Placebo once daily
2574312|NCT02404727|Active Comparator|cup fixation cemented|30 of the 60 patients will be randomized to cemented cup fixation
2574315|NCT02404727|Active Comparator|cup fixation cementless|30 of the 60 patients will be randomized to cementless cup fixation
2574358|NCT02404480|Experimental|Cohort 1|PTC 596 administered twice daily- Dose level 0.65mg/kg
2574360|NCT02404480|Experimental|Cohort 2|PTC 596 administered twice daily-Dose level 1.3mg/kg
2574363|NCT02404480|Experimental|Cohort 3|PTC 596 administered twice daily-2.6mg/kg
2574365|NCT02404480|Experimental|Cohort 4|PTC 596 administered twice daily-Dose level 5.2mg/kg
2574367|NCT02404480|Experimental|Cohort 5|PTC 596 administered twice daily-Dose level 10mg/kg
2574368|NCT02404480|Experimental|Cohort 6|PTC 596 administered twice daily-Dose level 7mg/kg
2574369|NCT02404480|Experimental|Cohort 7 (Bio Marker cohort)|PTC 596 administered twice daily-Dose level 5.2mg/kg
2574427|NCT02404077||Clonidine|Patients who received clonidine following prolonged dexmedetomidine infusions
3210003|NCT00990379||Controls|Healthy men and women, 18 years of age or older, who have no history of significant medical conditions.
3210004|NCT00990379||HIV positive|Men and women, 18 years of age or older, who have been diagnosed with HIV infection. Patients may be on or off of ARVs.
2574645|NCT02402712|Experimental|Herceptin SC + Perjeta IV + docetaxel IV|Single arm
2574844|NCT02401711|Active Comparator|Online training|Residents randomized to the control group will only participate in the Breakthroughs in Patient Safety (BIPS) online training (Education - BIPS course). All residents in the comparison arm will receive evaluations on their non-technical skills, but the results will not be fed back to them until after the study has been completed.
2574847|NCT02401711|Experimental|Online training & Safety curriculum & Evaluation and feedback|Those in the intervention group will participate in a formal safety education curriculum in addition to the currently required Breakthroughs in Patient Safety (BIPS) online training. The intervention will have three components: (1) the mandatory online BIPS course (Education - BIPS course), (2) the formal safety curriculum, and (3) ongoing evaluation and feedback of operating room performance.
2574897|NCT02401165|Other|patient|patient
2574955|NCT02400801|Active Comparator|oral oestroprogestogen pre-treatment|preparation with oral oestroprogestogens prior to downregulation in an assisted reproductive technology treatment (ART) cycle
2574964|NCT02400801|Experimental|gonadotropin-releasing hormone (GnRH) pre-treatment|preparation with gonadotropin-releasing hormone (GnRH) analogues prior to downregulation in an assisted reproductive technology treatment (ART) cycle
2575022|NCT02400255|Experimental|Cohort A|Cohort A will include patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) while in first or second complete remission with count recovery. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
2575024|NCT02400255|Experimental|Cohort B|Cohort B will include patients who underwent HSCT with incomplete count recovery although they had ≤%10 bone marrow blasts at the time of HSCT. Crenolanib besylate maintenance therapy will start at the earliest time no sooner than 45 days but no later than 90 days after allogeneic HSCT.
2575041|NCT02399891||Retrospective|MI prior to December 11, 2011
2575043|NCT02399891||Prospective|MI on or after December 11, 2011
2575080|NCT02399631|Experimental|ERAS group|early recovery program with no preoperative mechanical bowel preparation, early diet initiation, and prevention of postoperative ileus after elective laparoscopic colon cancer surgery
3210005|NCT00990379||Parkinson's Disease|Men and women, 18 years of age or older, who have been diagnosed with Parkinson's Disease.
3210006|NCT00990392|Experimental|Polysporin Triple Therapy|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
3210007|NCT00990392|Placebo Comparator|Placebo|Petroleum jelly
3210008|NCT00990405|Experimental|Lansoprazole+Clarithromycin+Amoxycillin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
3210009|NCT00990431|Active Comparator|Carbon dioxide laser treatment|
3210010|NCT00990431|Active Comparator|Erbium:YAG laser treatment|
3210011|NCT00990444|Placebo Comparator|Placebo|Treatment with vehicle capsule containing excipients only, taken in conjunction with standard meal.
3210012|NCT00990444|Active Comparator|Oral Insulin in Dextran|Treatment with fixed insulin dose taken in conjunction with standard meal.
3210013|NCT00990457|Active Comparator|Low-carbohydrate Diet Plus Exercise|Participants will follow a low-carbohydrate weight loss diet plus participate in a supervised exercise training program for 6 months.
2574008|NCT02406950|Other|Sitagliptin and glibenclimide|If sitagliptin treatment show preventive effects of IR injury, the investigator will perform additional experiment to explore the mechanism (Protocol 2 study). Additional 15 healthy volunteers will be treated 5 mg of glibenclamide (Euglucon) 1 hour before administration of 50 m g of sitagliptin. In 2 hours after sitagliptin administration, FMD measurement before and after IR injury will be performed as described above.
2574079|NCT02406638||TVT Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT 3 years before clinical and 3D pelvic floor ultrasound evaluation.
2574083|NCT02406638||TVT-O Group|Women who underwent to stress urinary incontinence surgery using Gynecare TVT Obturator System, inside-out approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation.
2574087|NCT02406638||TVT-S Group|"Women who underwent to stress urinary incontinence surgery using GynecareTVT-Secur System, in U approach, 3 years before clinical and 3D pelvic floor ultrasound evaluation."
2574122|NCT02406131|No Intervention|Control Group:|This group will be getting all the routine work up including Duplex scan . we will add request for inflammatory and coagulation markers in their blood samples before and after intervention . The pre-op blood sample will be collected within the 24 hours before intervention and the post intervention in the 24 hrs after (second RIPC window). The repeated duplex scan will be schedule after 6 months.
2574126|NCT02406131|Active Comparator|RIPC Group|Remote Ischemic Preconditioning Group (RIPC):This group will have all the tests as for the control group with the additional component will be preconditioning. One hour prior to procedure candidates in this group will have structured intermittent periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles, which needs 40 minutes.
2574190|NCT02405663|Experimental|manual removal group|Group will be assigned for manual removal of the placenta as the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby by caesarean section
2574197|NCT02405663|Experimental|cord traction group|Group will be assigned for controlled cord traction as the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery after the delivery of the baby by caesarean section
2574270|NCT02405351|Experimental|Training Group|Participants will be 10 individuals post stroke, living in the community. The intervention, adaptive working memory training, is a dual n-back working memory task. This training will take place once for 30 minutes per day, 5 days a week for 6 weeks, with one week dedicated for familiarizing participants to the program in the very beginning (i.e., Week 1).
2574372|NCT02404636||Alcoholic hepatitis|Individuals admitted to hospital with acute alcoholic hepatitis, defined as acute onset of jaundice in the context of recent hazardous alcohol use and the absence of other liver disease
2574375|NCT02404636||Hazardous alcohol use|Individuals admitted to hospital for any cause who drink hazardous quantities of alcohol but without evidence of alcoholic hepatitis or advanced liver disease
2574422|NCT02404142|Placebo Comparator|Control group (saline isotonic solution)|saline isotonic solution
2574423|NCT02404142|Experimental|Curar (Atracurium) group|Curar (Atracurium)
2574460|NCT02403869||Group 1|MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
2574512|NCT02403583|Other|Intervention- Home visits|Participants randomized to intervention arm receive 3 home visits conducted by one female and one male lay health worker.
2574516|NCT02403583|No Intervention|Standard Care|Participants will receive current standard clinic-based services including the option for women and partners to return to the clinic for male partner HIV testing or CHCT.
2574568|NCT02403258|Experimental|Plum-blossom needle group|Patients randomized into this group will receive plum-blossom needle as treatment. DU 20, DU 16, GB 20, EX-HN5, BL 15, BL 18, BL 23 will be selected as acupoints. Each point will be tapped gently one by one by plum blossom needle until the skin get slightly redness. The treatments will be given two sessions per week, consistently for 12weeks (24 sessions in all).
2574569|NCT02403258|Active Comparator|HRT group|Patients randomized into this group will receive habit reversal training (HRT) as treatment. Habit reversal training will consist of the following 4 parts: (1) self-monitoring, (2) competing responses, (3) relaxation training and (4) contingency management. The training will be given weekly in the 12 weeks (totally 12 sessions) by a special rehabilitation therapist, first two sessions 1.5 h, and remaining sessions 1 h for each treatment.
3210014|NCT00990457|Active Comparator|Low-Fat, Low-Calorie Diet Plus Exercise|Participants will follow a low-calorie, low-fat weight loss diet plus participate in a supervised exercise training program for 6 months.
3210015|NCT00990496|Experimental|GBM Treatment|
3210016|NCT00990522|Experimental|debridement|monthly vs weekly debridement
3210017|NCT00990535|Experimental|Octreotide-LAR|Patients will receive every 21 days an injection of octreotide-LAR 30 mg until progression is documented.
3210018|NCT00990548||Cardiovascular Service Line patients|Patients admitted to the Cardiovascular Service Line at a major teaching hospital during a consecutive 11-month period.
3210019|NCT00990574|Active Comparator|spinal anesthesia group (SAG)|Participants will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
3210020|NCT00990574|Active Comparator|The WSCG (wiley spinal catheter group)|The WSCG (wiley spinal catheter group) will undergo the standard procedures involved in placement of a spinal anesthetic in the sitting position.
3210021|NCT00990587|Experimental|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at escalating doses depending on when they enter into the trial.
3210022|NCT00990600|Experimental|Simplified one pill regimen|Fixed dose combination of tenofovir + emtricitabine + efavirenz
3210023|NCT00990613|Other|Cohort 1|
3210024|NCT00990613|Other|Cohort 2|
3210025|NCT00990626||1|Schizophrenic outpatients
3210026|NCT00990639|Experimental|candesartan+UDCA group|oral candesartan(8 mg/day) in addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months
3210027|NCT00990639|Placebo Comparator|UDCA group|ursodeoxycholic acid(UDCA,600 mg/day)only for 6 months
3210028|NCT00990678|Experimental|"Strong vitamin D"|Calcium 400 Mg + Vitamin D3 10 microg, 3 times daily Rocaltrol 1.25 mg to 2.5 mg daily
3210029|NCT00990678|Active Comparator|Vitamin D|calcium 400 mg + 10 microgram Vitamin D3, 3 times daily
3210030|NCT00990678|Placebo Comparator|Calcium|Tablet Calcium 400 mg x 3 daily
3210031|NCT00990691|Experimental|Desipramine high dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
2574055|NCT02406508|Experimental|Hepatic Delivery System Treatment followed by Sorafenib|"Percutaneous hepatic perfusion with melphalan hydrochloride for injection using the Hepatic Delivery System.~Melphalan hydrochloride is administered at a dose of 3mg/kg ideal body weight once every 6 weeks for a maximum of 3 cycles of treatment.~After the Melphalan/HDS treatment patients will be treated with sorafenib according to the package prescribing information."
2574109|NCT02406352|Experimental|Routine colposcopy and MDC with probe|The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure. A control biopsy will also be obtained from patients who agree to provide it. The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
2574151|NCT02406001|Experimental|Tigran PTG|Surgical intervention: open flap debridement and implantation of bone grafting material
2574153|NCT02406001|Other|Control|Surgical intervention: open flap debridement
2574181|NCT02405637|Experimental|SAFE group|simulated amniotic fluid 20cc/kg/day enterally divided according to number of feds (syringe for every fed). This amount provides enteral 4.5μg rhG-CSF / kg/day and enteral 88IU rhEPO / kg/day.
2574195|NCT02405637|Placebo Comparator|placebo|distilled water 2.5 ml/kg every 3 hours enterally
2574260|NCT02405273|Experimental|Interventional Group|Pulmonary rehabilitation
2574263|NCT02405273|Active Comparator|Control Group|Standard Care
2574311|NCT02404883|No Intervention|control group|care as usual (fertility preservation counseling)
2574314|NCT02404883|Experimental|intervention group|Intervention: use of an online decision-aid tool after fertility preservation counseling
2574381|NCT02404571|Experimental|GDP chemotherapy|GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
2574441|NCT02404129|Other|Non-fallers|"The subjects had to report having no difficulties with mobility, activities of daily living, or turning while walking and had no falls for a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
2574448|NCT02404129|Other|In a risk to fall|"Subjects who report about 1-2 falls in a year period. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
2574455|NCT02404129|Other|Multiple fallers|"Subjects who reported to have more than two falls per year. The test that will be performed: Turn 180 test, Timed Up and Go test, Tinetti Balanced Test, Berg Balance Scale."
2574494|NCT02403661|Active Comparator|Post surgical electrical stimulation|Balanced AC pulse at 20 Hz with less than 30V and 0.01 ms duration will be delivered for 1 hour.
2574497|NCT02403661|Placebo Comparator|Sham stimulation|Stimulation with the same parameters delivered only for 5 s.
2574543|NCT02403349|Experimental|Fimasartan|fimasartan potassium 60mg, 1 tablet by mouth, every day Angiotensin ll receptor blocker
2574545|NCT02403349|Active Comparator|Valsartan|valsartan 80mg, 1 tablet by mouth, every day angiotensin II receptor antagonists
2574548|NCT02403349|Active Comparator|Atenolol|atenolol 50mg, 1 tablet by mouth, every day beta-blocker
2574594|NCT02403037|Experimental|True Auricular Acupressure Group|Participants in this group will receive standard antiemetics before and during chemotherapy, and a 5-day auricular acupressure treatment protocol for controlling nausea and vomiting during the first cycle of chemotherapy.
2574598|NCT02403037|Sham Comparator|Sham Auricular Acupressure Group|Participants in this group will receive standard antiemetic medications before and during chemotherapy, and a 5-day sham auricular acupressure intervention protocol during the first cycle of chemotherapy.
2574599|NCT02403037|Other|Standard Care Group|Participants in this group will only receive standard anti-emetic treatment before and during chemotherapy.
2574629|NCT02402725|Experimental|Ultra-high dose dexamethasone|Ultra-high dose dexamethasone administered intravenously and orally
2574683|NCT02402530|Placebo Comparator|Placebo|Matching placebo administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
2574685|NCT02402530|Experimental|125 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1 and Day 4; matching placebo administered as intravenous infusion on Day 7 and Day 10
2574692|NCT02402530|Experimental|250 mg Neridronic acid|Neridronic acid 62.5 mg administered as intravenous infusion on Day 1, Day 4, Day 7 and Day 10
2574804|NCT02401750|Experimental|Oxycodone Naltrexone (a)|Double-Blind Oxycodone/Naltrexone, 1 capsule by mouth every 6 hours for 48 hours
2574805|NCT02401750|Experimental|Oxycodone Naltrexone (b)|Double-Blind Oxycodone/Naltrexone , 1 capsule by mouth every 6 hours for 48 hours
2574807|NCT02401750|Placebo Comparator|Placebo|Double-Blind Placebo to experimental Oxycodone/Naltrexone, 1 capsule every 6 hours for 48 hours
2574846|NCT02401386|Experimental|EB group|Trained and guided by EB certified physicians, patients in EB group received closely supervised, group-format EB program and practiced EB for one hour, twice weekly for 12 weeks in the Guang'anmen Hospital.
2574848|NCT02401386|No Intervention|Control group|The participants in usual therapy-controlled group will stay on their previous treatment through 12 weeks. As compensation, they will be invited to receive LEB training for 12 weeks after the end of the study.
2574917|NCT02401178||Well baby|"For cross-sectional study design:~The dependent variables are LCPUFA composition from buccal. The independent variables are 17 SNP from FADS genes.~For extended cross-sectional study design:~The dependent variable is atopic dermatitis, while independent variables are:~17 SNP; LCPUFA and FLG gene mutation"
2574933|NCT02400632|Experimental|MAGIC-TOUCH Drug-eluting balloon|in-stent restenosis treated with drug-eluting balloon
2574985|NCT02400424|Experimental|SBRT|Study treatment = SBRT for peripheral primary tumor.
3210032|NCT00990691|Experimental|Desipramine low dose|"12 patients with Rett syndrome receiving a daily dose of desipramine correlated with the weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
2574023|NCT02406846||cryosurgery with DC-CIK treatment group|Use Flow cytometry (FCM) and RT-PCR to test CTCs from patients received cryosurgery and DC-CIK treatment both, 1 day before and 2 days after the cryosurgery with DC-CIK treatment.
2574077|NCT02406547|Experimental|WLE-NBI|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly High Definition White Light Endoscopy (WLE) and secondly Narrow Band Imaging (NBI). All detected polyps will be classified macroscopically and resected in each withdrawal.
2574084|NCT02406547|Experimental|NBI-WLE|Participants will be evaluated by same endoscopist, back-to-back tandem colonoscopy. It consists of two withdrawal from the cecum to sigmoid colon using firstly Narrow Band Imaging (NBI) and secondly High Definition White Light Endoscopy (WLE). All detected polyps will be classified macroscopically and resected in each withdrawal.
2574130|NCT02406118|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
2574163|NCT02405858|Experimental|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily, concomitantly with oral prednisolone 10 mg per day. No food should be consumed for at least 2 hours before the dose of abiraterone acetate is taken and for at least one hour after the dose of abiraterone acetate is taken. A 28-daily dosing cycle will continue until disease progression or unacceptable toxicity is observed up to 2 years.
2574178|NCT02405533|Experimental|Group 1|AHCC 3 grams once a day on an empty stomach x 6 months then placebo once a day x 56 months.
2574191|NCT02405533|Placebo Comparator|Group 2|Placebo once a day on an empty stomach x 12 months
2574240|NCT02405286||Upeer gastrointestinal bleeding|"Adult Egyptian patients.~Patients with acute upper G.I hemorrhage.~Informed consent."
2574282|NCT02405052||Patients|Emergency department patients with unexplained chest pain
2574332|NCT02404753|Experimental|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
2574337|NCT02404753|Active Comparator|Open gastrectomy|Open distal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer after neoadjuvant chemotherapy.
3210033|NCT00990691|Placebo Comparator|Placebo|12 patients with Rett syndrome receiving a daily dose of placebo.
3210034|NCT00990717|Experimental|NK-92 cells|Preparation of irradiated NK-92 cells suspended in a saline and plasma solution. NK-92 working cell bank was established from a master cell bank supplied by Conkwest Inc. (San Diego CA).
3210035|NCT00990730||rheumatoid arthritis subjects|60 subjects with rheumatoid arthritis, defined by American College of Rheumatology Criteria, enrolled in the UCSF RA cohort
3210036|NCT00990730||healthy controls|20 matched controls without rheumatoid arthritis
3210037|NCT00990743|Experimental|SYL040012|
2574690|NCT02402335||1 Fracture of vertebra|Osteoporotic fracture of the vertebra
2574695|NCT02402335||2 Nerve Compression|Osteochondria, Spinal disc herniation, Nerve compression
2574740|NCT02402179|Experimental|Tryptophan Amino Acid|13.2, 26.4, 39.7, 52.9% of the mean tryptophan requirement of 3.78 mg/kg/d will be given to subjects.
2574785|NCT02401815|Experimental|Part 1: PLX9486 250 mg QD|Participants will receive PLX9486 250 milligrams (mg) orally once daily (QD) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574786|NCT02401815|Experimental|Part 1: PLX9486 350 mg QD|Participants will receive PLX9486 350 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574787|NCT02401815|Experimental|Part 1: PLX9486 500 mg QD|Participants will receive PLX9486 500 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574788|NCT02401815|Experimental|Part 1: PLX9486 1000 mg QD|Participants will receive PLX9486 1000 mg orally QD in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574789|NCT02401815|Experimental|Part 1: PLX9486 500 mg BID|Participants will receive PLX9486 500 mg orally twice daily (BID) in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574790|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Fasting)|Participants in fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574791|NCT02401815|Experimental|Part 2b: PLX9486 500 mg QD + Pexidartinib 600 mg (Non-Fasting)|Participants in non-fasting condition will receive PLX9486 500 mg orally QD in combination with pexidartinib 600 mg (administered as 1 capsule of 200 mg in the morning and 2 capsules of 200 mg in the evening) orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
3210038|NCT00990756|Experimental|PF-03526299 1.396 mg|
3210039|NCT00990756|Experimental|PF-03526299 4mg|
3210040|NCT00990795|Experimental|Cyclosporine|Cyclosporine Group: Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
3210041|NCT00990795|Placebo Comparator|Placebo|Placebo: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
3210042|NCT00990808|Experimental|Panel A|Period 1: atorvastatin + placebo to MK0859; Period 2: atorvastatin + MK0859
3210043|NCT00990808|Experimental|Panel B|Period 1: placebo to atorvastatin + placebo to MK0859; Period 2: MK0859 + placebo to atorvastatin
3210044|NCT00990834|Experimental|Statin exposure|Subjects' endpoints will be measured before and after one to eight months of statin exposure.
3210045|NCT00990847|Experimental|Procaterol|Procaterol inhalation solution 50 micro g per 0.5 mL diluted in 2mL of NaCl 0.9%, so that the volume of the inhalation solution will be similar to that of the comparator drug. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
2574144|NCT02406040|Experimental|Adequate Protein|1.2g protein/kg/d. The macronutrient composition will be 50:35:15 (carbohydrates:fat:protein) during Energy Restriction
2574392|NCT02404272||Preterm neonates|All preterm neonates of less than 34 weeks' of gestation admitted to the Neonatology and Neonatal Intensive Care unit of an university hospital located in Lyon, France
2574521|NCT02403492|No Intervention|Observational (No OSAS)|Comprised of obese children are not found to have obstructive sleep apnea and do not require cPAP
2574525|NCT02403492|Experimental|Experimental - cPAP, Continuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who continue using cPAP during the 2 week RCT
2574528|NCT02403492|Experimental|Experimental - cPAP Discontinuation|Comprised of those obese children who are diagnosed with obstructive sleep apnea, requiring cPAP, who discontinue using cPAP during the 2 week RCT
2574571|NCT02403232|Experimental|ASCs injection|Autologous adipose-derived stem cells (ASCs) injection with LIPOGEMS system.
2574659|NCT02402647|Experimental|CREST|"Compensatory Cognitive Training (CCT) is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
2574660|NCT02402647|Active Comparator|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
3175808|NCT00638300|Experimental|2|small pore dialyzers ( F8HPS, Fresenius, Germany)
3175809|NCT00638300|Experimental|A|dialysate bicarbonate concentration of 33 mEq/l
2575251|NCT02398487|Active Comparator|Personal Vaporizer|Personal Vaporizer loaded with nicotine
2575255|NCT02398487|Active Comparator|Cigalike|Cigalike loaded with nicotine
2575260|NCT02398487|No Intervention|Usual smoking|
2575345|NCT02398084|Experimental|Chewing of nuts|8 samples (4-5 g) of nuts (cashews or walnuts) on two separate visit days.
2575508|NCT02396628|Experimental|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
2575691|NCT02395263|Experimental|Yuxintine 200mg per day|Yuxintine 200mg oral, once a day, 6 weeks
3175810|NCT00638300|Experimental|B|dialysate bicarbonate concentration of 40 mEq/l
3175811|NCT00638300|Experimental|I|dialysate calcium concentration of 3 mEq/L
3175812|NCT00638300|Experimental|II|dialysate calcium concentration of 2.5 mEq/L
3175813|NCT00638313|Placebo Comparator|Placebo|
3175814|NCT00638313|Experimental|PF-04603629|
3175815|NCT00638326|No Intervention|1|Patients who show adequate response to 600 mg loading dose of clopidogrel and receive standard 1x75 mg clopidogrel
3175816|NCT00638326|Experimental|2|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x150 mg clopidogrel for 28 days
3175817|NCT00638326|Active Comparator|3|Patients who show suboptimal response to 600 mg loading dose of clopidogrel and receive 1x75 mg clopidogrel
3175818|NCT00638339||1|critically ill patients undergoing invasive mechanical ventilation in medical ICU and CCU
3175819|NCT00638339||2|critically ill patients undergoing noninvasive mechanical ventilation in medical ICU and CCU
3175820|NCT00638391||1|all patients treated with Anastrozole
3175821|NCT00638417|Experimental|maximal strength training|maximal dynamic strength training
3175822|NCT00638417|Other|conventional rehabilitation|rehabilitation as usual
3175823|NCT00638430||1|low myopic group
3175824|NCT00638430||2|moderate myopic group
3175825|NCT00638469|Other|left/right|left or right body side
3175826|NCT00638482|Experimental|1|Hydrochlorothiazide
3175827|NCT00638495|Experimental|1|
3175828|NCT00638495|Placebo Comparator|2|
3175829|NCT00638547|Experimental|Intent-to-Treat|All patients who have received at least one dose of Laronidase.
3175830|NCT00638560|Experimental|1|"Antioxidant treatment arm:~Vitamin E, 400 IU po, once daily Vitamin C, 1g po, twice daily"
3175831|NCT00638560|Placebo Comparator|2|Control
3175832|NCT00638586||1|Femoral access
3175833|NCT00638586||2|Radial access
3175834|NCT00638599|Experimental|1|LMA® is placed after anesthesia induction till the end of operation
3175835|NCT00638599|Active Comparator|2|Standard tracheal tube is inserted after anesthesia induction till the end of operation
3175836|NCT00638612|Experimental|A resectable|Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
3175837|NCT00638612|Experimental|B locally advanced|"Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B."
3175838|NCT00638638|Experimental|1|"Early Abciximab bolus during prehospital transportation in ambulance 0.25 mg/Kg iv with Heparin 40 UI/kg bolus.~Abciximab placebo bolus and Abciximab infusion 10 µg/Kg/min after coronary angiography and before angioplasty."
3175839|NCT00638638|Experimental|2|"Abciximab placebo bolus during prehospital transportation in ambulance with Heparin 40 UI/kg bolus.~Abciximab 0.25 mg/Kg bolus after coronary angiography and before angioplasty followed by Abciximab infusion 10 µg/Kg/min."
3175840|NCT00638677|Placebo Comparator|1|Sorbitol tablet
3175841|NCT00638677|Placebo Comparator|2|Xylitol tablet
2574154|NCT02406066|Active Comparator|High Dose (Cohort 3)|720 mg metyrapone and 24 mg oxazepam, given once for the single-dose phase of the study, followed by BID dosing for approximately one week
2574215|NCT02405585|Experimental|mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"SOC mFOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 93-100 Disease evaluated: Progressive disease = salvage therapy off study. Day 93-100 Disease evaluated: Stable disease or better = SBRT + HAPa on days 1 and 15 of radiotherapy Post SBRT: surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for 6 cycles.~Post adjuvant therapy: 6 monthly immunizations with HAPa"
2574273|NCT02405104|Active Comparator|THA+Klorz|All patients in this arm are treated surgically with a THA and medically with Chlorzoxazone
2574274|NCT02405104|Placebo Comparator|THA+Placebo|All patients in this arm are treated surgically with a THA and medically with placebo
2574277|NCT02405104|Active Comparator|TKA+Klorz|All patients in this arm are treated surgically with a TKA and medically with Chlorzoxazone
2574278|NCT02405104|Placebo Comparator|TKA+Placebo|All patients in this arm are treated surgically with a TKA and medically with placebo
2574331|NCT02404714||CF/CRMS|"Subject's with a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis will receive the institution's standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
2574335|NCT02404714||NON CF/CRMS|"Subject's without a previous cystic fibrosis or cystic fibrosis related metabolic syndrome (CRMS) diagnosis but referred to the sweat test lab on a clinical observation basis by a physician will receive standard iontophoresis sweat testing (Gibson-Cooke or Wescor Macroduct) to provide a diagnosis.~The patient will also receive a sweat test provided by the new CF Quantum Sweat Test System which includes the same process and principal of operation of iontophoretic stimulation, collection and analysis of sweat compared to the standard. The results of the new sweat test and the standard sweat test will be compared. The new sweat test will not be used to diagnose, treat or mitigate the patient's condition. Results are used only to compare to the standard of care."
2574419|NCT02404194|Experimental|Targeted Cognitive Training|40 hours of computerized cognitive training
2574421|NCT02404194|Placebo Comparator|Computer Games|40 hours of computer games
2574461|NCT02403856|Experimental|Experimental group (Sodium Chloride 0.9%)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
2574463|NCT02403856|Active Comparator|Control group (Methylprednisolone Acetate)|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
3210046|NCT00990847|Active Comparator|Salbultamol|Salbultamol inhalation solution for nebulization containing 2.5 mg in 2.5 mL aqueous solution. The nebule solution will be administered 3 times, i.e. at times 0, 20 and 40 minutes.
2574601|NCT02403011|Experimental|Soft tissue mobilization group|soft tissue mobilization was applied three times in a week and home program exercises were recommended which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
2574603|NCT02403011|Experimental|Home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations were recommended
3210047|NCT00990860|Experimental|Sorafenib|
2574666|NCT02402387|Active Comparator|Neutral|The patient's head will be in neutral position.
2574670|NCT02402387|Experimental|Flexed|The patient's head will be flexed.
2574676|NCT02402387|Experimental|Extended|The patient's head will be extended.
2574680|NCT02402387|Experimental|Rotated|The patient's head will be rotated.
2574739|NCT02402075||Brain tumor|patients with glioma
2574809|NCT02401828|Experimental|Group A - Direct Switch|Direct switch from cART to Dolutegravir mono-therapy at baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
2574812|NCT02401828|Experimental|Group B - Delayed Switch|Delayed switch from cART to Dolutegravir mono-therapy at week 24 from baseline. Dolutegravir single tablet 50mg QD, once a day. Duration = 48 weeks
2574859|NCT02401360|Experimental|Experimental Group|Oral care regimen
2574860|NCT02401360|Placebo Comparator|Control Group|Toothbrush and toothpaste
3210048|NCT00990886|Experimental|001|Oxybutynin chloride 15 mg once daily for 12 weeks
3210049|NCT00990886|Placebo Comparator|002|Placebo Once daily for 12 weeks
2575031|NCT02400112|Experimental|Vancomycin Powder|If the patient randomizes to the experimental group (vancomycin powder), the patient will receive open fracture care identical to the control group except that, prior to closure, 1 gram of vancomycin powder will be applied locally to the open fracture bed. The traumatic and surgical wounds will be closed over a sterile drain and dressed, and the extremity will be immobilized.
2575033|NCT02400112|No Intervention|Standard Treatment|If the patient randomizes to the control group (standard treatment), the patient will receive irrigation and debridement of the fracture site and surrounding soft tissues. The fracture will then be stabilized in standard fashion determined by fracture personality. Once stabilized, a sterile drain will be placed in the open fracture bed and the traumatic and surgical wounds will be closed and dressed. The extremity will then be immobilized.
2575098|NCT02399618|Experimental|Capsulized freeze-dried FMT|Reconstitution of normal flora with capsulized freeze-dried fecal inoculum
3210050|NCT00990912|Experimental|Carboplatin|
3210051|NCT00990912|Experimental|Irinotecan (12 (9) mg/m²/day)|
3210052|NCT00990912|Active Comparator|Irinotecan (10 (10) mg/m²/day|
3210053|NCT00990925|Experimental|Weight Loss Education Group|Involvement in weekly manualized, educational group on nutrition and lifestyle modifications to help with weight loss.
3210054|NCT00990925|Other|Usual Care|Treatment as usual
3210055|NCT00990951|Experimental|Senna alexandrina and associations|Association of Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
2574160|NCT02405884|Other|measurement of intraocular pressure|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
2574188|NCT02405676|Other|Risk group 1|Complete resection of stage I or II disease: 3 courses (A-B-A) and 3 intrathecal injections(Cytarabine/Methotrexate/Dexamethasone, age adjusted);
2574199|NCT02405676|Other|Risk group2|Not or incompletely resected stage I/II disease and LDH <2 times NL: 5 courses (A--B--A--B--A) and 8 intrathecal injections;
2574208|NCT02405676|Other|Risk group3|Stage III with high LDH < 4 times NL, or Stage I,II with LDH >=2 times NL: Preface followed by 6 courses (P(Cyclophosphamide/Vincristine/Prednisone)-A-BB-AA-BB-AA-BB) and 13 intrathecal injections; Dosage of Cytarabine, Methotrexate and Etoposide was increased in AA or BB compared with A or B. Vindelsine was used in AA/BB instead of Vincristine in A/B.
2574213|NCT02405676|Other|Risk group4|Stage III with LDH≥4N, or Stage IV, or B-AL: Preface followed by 4 dose of rituximab (375mg/m2) combined 6 courses of chemotherapy, together with 13 intrathecal injections: P-A-(Rituximab)BB-(Rituximab)AA-(Rituximab)BB-(Rituximab)AA-BB; rituximab is at D0 of each course.
2574820|NCT02401724|Active Comparator|Action Training|Training exercise which involves patients lifting up rods of different sizes and shifting their grip if this is too far to one side
2574821|NCT02401724|Experimental|tDCS|A constant 1mA current will be applied to the left (undamaged) side of the scalp with an electrode covered with a damp cotton pad (25 cm2). The current will be applied for 15 minutes per day, with a total of 10 sessions over 3 weeks.
2574823|NCT02401724|Experimental|Action Training + tDCs|This will involve the same procedure as in action training only but with tDCS applied for 15 minutes during the rodlifting.
2574824|NCT02401724|Placebo Comparator|Control training|For the control training, patients will be asked to simply reach for the right hand side of each rod with their right (unaffected) hand and lift it
3175842|NCT00638677|Active Comparator|3|Xylitol + BB12 tablet
3175843|NCT00638703|Experimental|I|Size 2 enteric coated capsule containg lyophilized Oxalobacter formigenes
2575027|NCT02400125||1|Patients underwent isolated or combined coronary artery bypass grafting surgery
2575029|NCT02400125||2|Patients underwent isolate or combined surgical treatment for heart valve disease
2575037|NCT02399878||Patients undergoing surgery|All non-cardiothoracic surgical patients aged 18 years or above receiving general anesthesia at Massachusetts General Hospital between January 2007 and August 2014.
2575109|NCT02399735|Experimental|Arm A|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
2575110|NCT02399735|Experimental|Arm B|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
2575112|NCT02399735|Experimental|Arm C|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
2575167|NCT02399046|Experimental|Total Knee System made in China|Patinet in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured in China
2575168|NCT02399046|Active Comparator|Total Knee System made outside of China|Patient in this arm will be implanted with Primary Total Knee Arthroplasty Devices Manufactured Outside of China
2575229|NCT02398669|Experimental|lorcaserin 10 mg|Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
2575290|NCT02398279|Experimental|L-Arginine-First|For the first three weeks, L-Arginine 3 g bid (500mg capsules 6 x 2), one week wash-out, then for the next three weeks placebo capsules (6 x 2)
2575291|NCT02398279|Experimental|Placebo-First|For the first three weeks, placebo capsules (6 x 2), one week wash-out, then for the next three weeks L-Arginine 3 g bid (500 mg capsules 6 x 2)
2575316|NCT02397798|Experimental|Intervention|Person-centered high-intense training three times a week under supervision (supervision two times a week) during 5 months
2575322|NCT02397798|Active Comparator|Control|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week during 5 months
2575386|NCT02397642|Active Comparator|Dual trigger|GnRH agonist plus 1000 IU of HCG to trigger final maturation
2575394|NCT02397642|Active Comparator|Booster HCG dose|GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
3175844|NCT00638703|Placebo Comparator|II|Size 2 enteric coated capsule containg placebo
3175845|NCT00638729|Active Comparator|Midazolam|Pre-anesthetic medication with midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
3175846|NCT00638729|Active Comparator|Clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
3175847|NCT00638729|Placebo Comparator|Placebo|Pre-anesthetic medication with an inert tablet, p.o., 60-90 min prior to estimated induction time
3175848|NCT00638742|Experimental|1|
3175849|NCT00638755|Experimental|1|The following treatment sequence: A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo)
3175850|NCT00638755|Experimental|2|The following treatment sequence: B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide)
3175851|NCT00638755|Experimental|3|The following treatment sequence: C (Nasal Carbon Dioxide), D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide)
3175852|NCT00638755|Experimental|4|The following treatment sequence: D (placebo), A (Nasal Carbon Dioxide), B (Nasal Carbon Dioxide), C (Nasal Carbon Dioxide)
3175853|NCT00638768|Active Comparator|Physiotherapy|Including 10 individual visits with a physiotherapist and home exercises
3175854|NCT00638768|No Intervention|2|Usual care
3175855|NCT00638781|Active Comparator|1|Desmoteplase 62.5 µg/kg BW i.v. bolus
3175856|NCT00638781|Active Comparator|2|Desmoteplase 90 µg/kg BW i.v. bolus
3175857|NCT00638781|Active Comparator|3|Desmoteplase 125 µg/kg BW i.v. bolus
3175858|NCT00638781|Placebo Comparator|4|Placebo i.v. bolus
3175859|NCT00638794||Surgical|Patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications.
3175860|NCT00638794||Observational|Consecutive patients with coronary artery disease undergoing stent-assisted percutaneous coronary intervention (PCI) using DES without major procedural complications
3175861|NCT00638807|Experimental|A|
3175862|NCT00638807|Placebo Comparator|B|
3175863|NCT00638833|Active Comparator|A|Memantine 30 mg/day
2574633|NCT02402738|Experimental|Interpersonal and Social Rhythm Therapy|Participants may be randomized to receive up to 20 outpatient sessions of Interpersonal and Social Rhythm Therapy, provided as an adjunct to community treatment as usual. Intervention sessions begin during pregnancy and continue through 8 weeks postpartum.
2574636|NCT02402738|Active Comparator|Enhanced Treatment as Usual|Those randomized to the Enhanced Treatment as Usual arm will follow their usual treatment plans in the community, with enhanced monitoring of symptoms and functioning through regular study assessments. With a release of information, we will provide community clinicians with a monthly standardized report that summarizes level of symptom severity and risk, designed to aid in continuity of care.
2574669|NCT02402504|Placebo Comparator|Extruded snack control|100% corn flour
2574674|NCT02402504|Experimental|Extruded snack with small particle size pea flour|60% corn flour and 40% small particle size pea flour
2574681|NCT02402504|Experimental|Extruded snack with large particle size pea flour|60% corn flour and 40% large particle size pea flour
2574687|NCT02402504|Experimental|Extruded snack with lentil flour|60% corn flour and 40% lentil flour
2574693|NCT02402504|Experimental|Extruded snack navy bean flour|60% corn flour and 40% navy bean flour
2574698|NCT02402504|Experimental|Extruded snack with pinto bean flour|60% corn flour and 40% pinto bean flour
2574974|NCT02400515|Other|Moderate Exercise|Aerobic physical exercise was applied during 3 months, 3x/week on women with type 2 diabetic. The evaluation occurred before and after exercise in the same (and only) group, considering that this is a quasi-experimental study.
2574981|NCT02400203|Active Comparator|Control|54 grams of hulled sesame seeds, consumed in 2 daily 27 gram portions, and 30 grams of soybean oil per day
2574992|NCT02400203|Experimental|Hemp foods|60 grams of hulled hemp seeds,consumed in 2 daily 30 gram portions, and 30 grams of hemp oil per day
2575056|NCT02400034|Active Comparator|FAST voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale. 5) If VAS scale >50 (=50%) the catheter will remain out, patient is discharged home without measuring a PVR 6) If VAS scale is from 0-49 (= 0-49%) a PVR will be checked via bladder scan. If PVR is <500 the patient will be discharged WITHOUT a catheter; If PVR is >500 the patient will be discharged WITH a catheter. If she is discharged with an indwelling foley catheter, she will have an in-office retrograde voiding trial in 2-5 days
2575083|NCT02399631|No Intervention|Congrol group|Traditional, conventional perioperative treatment
3175864|NCT00638833|Placebo Comparator|B|Placebo
3175865|NCT00638872|Experimental|1|PDRN
3175866|NCT00638872|Placebo Comparator|placebo|placebo
3175867|NCT00638898|Experimental|Arm I|See Detailed Description
3175868|NCT00638911||Patients with hypertention|
3175869|NCT00638950|Placebo Comparator|Placebo|
3175870|NCT00638950|Active Comparator|n-3 LC-PUFA|
3175871|NCT00638976|Other|1.Integrilin, GSK|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
3175872|NCT00638976|Placebo Comparator|2|Pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide (Integrilin, GSK) vs matched placebo.
3175873|NCT00639015|Experimental|1|Phenylephrine
3175874|NCT00639015|Active Comparator|2|Norepinephrine
3175875|NCT00639028|Other|1|Ankle echography
3175876|NCT00639028|Other|2|echography + stress radiography
3175877|NCT00639028|Other|3|stress radiography
3175878|NCT00639041|Placebo Comparator|placebo|
3175879|NCT00639041|Active Comparator|n-3 LC-PUFA|
3175880|NCT00639054||Newly diagnosed patients|Newly diagnosed high-dose therapy candidates. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
3175881|NCT00639054||Relapse patients|Formerly high-dose treated patients with progressive disease. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) and blood samples (24 ml of peripheral blood) for biochemical and genetic analyses regarding multiple myeloma, and granting access to clinical data relating to multiple myeloma.
3175882|NCT00639054||Healthy controls|Healthy blood and bone marrow donors. Participation means bone marrow examination (donating 7.5 ml of fresh bone marrow) for genetic analyses serving to compare normal bone marrow with bone marrow from multiple myeloma patients.
3175883|NCT00639067||1|"Asymptomatic High Risk Subjects. Smokers aged >=18 undergoing chest CT.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3175884|NCT00639067||2|"Symptomatic High Risk Subjects Without a Tissue Diagnosis. This group will comprise patients who are undergoing medical evaluation for a pulmonary symptom such as chronic unexplained cough or hemoptysis.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3175885|NCT00639067||3|"Symptomatic High Risk Subjects With a Tissue Diagnosis. This group will be found to include a. lung cancer, and b. diseases other than lung cancer e.g. sarcoidosis, COPD or pulmonary infection.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3175886|NCT00639067||4|"Apparently healthy individuals having no signs and symptoms of lung carcinoma.~Breath collected using Breath Collection Apparatus and analyzed for markers of lung cancer."
3175887|NCT00639080||Entire study population|All study subjects.
3175888|NCT00639106|Experimental|A|Expander Placement WITH Alloderm
3175889|NCT00639106|Active Comparator|B|Expander Placement WITHOUT Alloderm
2574186|NCT02405819|Other|Patient Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The research team will direct patients to their assigned condition by providing a hand-out directing them to the planning tool. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
2574205|NCT02405819|Other|Clinician Directed|We will collect baseline data, including sociodemographic information for the patients and an assessment of each patient's baseline supportive care needs and knowledge about survivorship care. Sociodemographic information will be self completed. All other data collection will be interviewer administered. The instruments used at baseline and follow-up are adapted from previously published surveys (Hodgkinson et al, 2007; Sprague et al, 2013; Griggs et al). The provider will be provided a hand-out with their patient's assigned condition and is responsible for implementing the survivorship care plan process. After 2 months, we will re-contact all randomized patients to determine whether the survivorship care planning occurred as intended.
2574259|NCT02405247||NSCLC without T790M mutation|NSCLC patients who have failed first line TKI treatment (defined radiological documentation of disease progression during treatment for advanced or metastatic NSCLC with an approved EGFR-TKI e.g. gefitinib, afatinib or erlotinib) and are screened for the AURA3 study and determined to be lacking the T790M mutation as determined using the AURA3 designated central laboratory using the cobas® EGFR Mutation Test (Roche Molecular Systems).
2574300|NCT02404909||Patients with liver tumors candidate to hepatectomy|
2574349|NCT02404662|Experimental|Supportive text messages intervention|Patients in the intervention group will receive twice daily supportive text messages to their mobile phone for 6 months following discharge from a 4-week in-patient dual diagnosis treatment programme. The messages will be sent by a computer programme at 10am and 7pm each day and will be set up and monitored by the research worker who will not participate in follow-up assessments. They will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The intervention group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
2574351|NCT02404662|Active Comparator|Control group|Patients in the control group will receive a fortnightly text message thanking them for participating in the study, and a brief phone call every 2 weeks to ensure that they are still using their phone and that they have received some messages. The control group will also receive treatment as usual, i.e. any follow-up after-care that they chose to participate in and regular AA/Lifering meetings.
2574389|NCT02404363|Experimental|Clopidogrel|Clopidogrel tablets 75 mg for six months:
2574394|NCT02404363|Placebo Comparator|Comparator|Placebo tablet 75 mg for six months:
2574429|NCT02404064|Other|Antibiotics perioperative|dose of perioperative antibiotics (cefamezin 1g IV; metronidazole 500 mg IV) This is the standard of care of the department
2574430|NCT02404064|Placebo Comparator|placebo - No Antibiotics perioperative|The intervention is No Antibiotics perioperative
3210056|NCT00990977|No Intervention|controls|assessment only
3210057|NCT00990977|Experimental|cases|MBSR including brief information session and assessments
2574515|NCT02403531|Active Comparator|Concurrent chemoradiotherapy|Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
2574519|NCT02403531|Experimental|Induction chemotherapy plus chemoradiotherapy|Patients assigned to this Arm first received two cycles of 3-weekly schedule of IC before definitive chemoradiotherapy, consisting of docetaxel 75 mg/m2 on day 1 and cisplatin 75 mg/m2 on day 1. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
3210058|NCT00990990|Experimental|Cohort 1|
3210059|NCT00990990|Experimental|Cohort 2|
2574612|NCT02402829||Hemophilia Patients|Subjects diagnosed with moderate or severe Hemophilia A or B who use a central venous line (CVL) for regular prophylaxis factor infusions and are at the clinic for a standard of care visit. As part of the study all subjects will have blood drawn through their CVL and will also undergo a peripheral vein blood draw.
2574665|NCT02402634||Mechanical ventilatory lung care|liver transplantation recipients under mechanical ventilatory lung care
2574711|NCT02402257||Traditionally-trained|Patients who undergo CVC procedures by traditionally-trained providers who have not undergone simulation-based mastery learning. This could be retrospective (before the study started) or at a site where the training was not implemented.
2574713|NCT02402257||CVC Train the Trainer|Patients who undergo CVC procedures by providers who have participated in simulation-based mastery learning.
2574793|NCT02401984||Screening|A Screening tool will be administered to the participants.
2574826|NCT02401490|Active Comparator|Human albumin|human albumin in the 24-48 hours after the hospitalization and at 48+/- 24 hours after the first dose.
2574828|NCT02401490|Placebo Comparator|placebo|saline serum 0.9%
2574868|NCT02401243|Experimental|Cohort 1 (INSIGHT titration algorithm)|INSULIN GLARGINE (U300): self-titration of insulin glargine 300 units/mL (U300) will be increased daily by 1 unit until fasting SMPG reaches the target range of 4.4 to 5.6 mmol/L
3210060|NCT00990990|Experimental|Cohort 3|
3210061|NCT00990990|Experimental|Cohort 4|
3210062|NCT00990990|Experimental|Cohort 5|
3210063|NCT00990990|Experimental|Cohort 6 (optional)|
3210064|NCT00990990|Experimental|Linezolid Cohort|
3210065|NCT00991003|Experimental|Colon capsule endoscopy and colonoscopy|Patients underwent CCE on day 1 and conventional colonoscopy on day 2
3210066|NCT00991016|Experimental|PF-04805712|
3210067|NCT00991042|Other|cytokine levels|Serum levels of pro-inflammatory cytokines were measured using the Enzyme Linked Immuno Sorbent Assay (ELISA) technique in 23 patients with pain due to herniated disk disease (G1) as well as in 10 control healthy subject
3210068|NCT00991055|Experimental|Pioglitazone|
3210069|NCT00991055|Placebo Comparator|Placebo|
2574229|NCT02405494|Other|Beverage 7|68 ml beverage consisting of 68 ml liquid with 0% overrun (total volume 68 ml).
2574230|NCT02405494|Other|Beverage 8|Liquid foam consisting of 68 ml liquid with 500% overrun (total volume 405 ml).
2574231|NCT02405494|Other|Beverage 9|Liquid foam consisting of 68 ml liquid with 250% overrun (total volume 236 ml).
2574281|NCT02405078|Experimental|Diagnostic (PET/CT, clonotype, metabolic profile)|"Patients receive standard salvage chemotherapy as determined by the treating physician.~Patients undergo FDG PET/CT scans at baseline (between days -21 to 0), on day 4 after completion of first high-dose chemotherapy, on day 21 after completion of the first course of chemotherapy, and on day 42 after the end of the second course of chemotherapy. Blood samples are also collected for tumor-specific clonotype and metabolic profile at baseline (days -5 to 0) and on days 4, 8, 21, and 42."
2574327|NCT02404701|Experimental|Aloe vera with cactus|1 capsule (500 mg), 2 times/day
2574329|NCT02404701|Experimental|Cranberry|3 capsules (810 mg), 2 times/day
2574336|NCT02404701|Experimental|Green tea extract|2 capsules (630 mg), 2 times/day
2574339|NCT02404701|Experimental|Bilberry|1 softgel (1000 mg), 2 times/day
2574340|NCT02404701|Experimental|Cinnamon|1 capsule (500 mg), 2 times/day
2574341|NCT02404701|Experimental|Milk thistle|1 capsule (250 mg), 3 times/day
2574344|NCT02404701|Experimental|Turmeric|1 capsule (450 mg turmeric + 50 mg turmeric extract), 1 time/day
2574346|NCT02404701|Experimental|Aloe vera|1 capsule (470 mg), 2 times/day
2574387|NCT02404324|Experimental|spectacles|"Esotropia is treated by full optical correction (spectacles prescription) in all children with refractive errors. Special attention is paid to astigmatism up to 0.5 Dptr.~Intervention: Prescription of spectacles"
3210070|NCT00991068|Experimental|Synera|Synera topical patch
3210071|NCT00991094||Observational (questionnaire)|Patients undergoing standard of care proton therapy are assessed for toxicities weekly during proton treatment, then from 1 to 3 times up to 90 days from the start of treatment and annually thereafter. Patients also complete questionnaires over 15-20 minutes at baseline, weekly during treatment, and every 2 weeks during follow up for up to 3 months.
3210072|NCT00991107|Experimental|HE3286|HE3286 20 mg (10 mg BID)
2574615|NCT02402920|Experimental|Part A (LS-SCLC, pembrolizumab, chemoradiotherapy)|Patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Patients also receive cisplatin IV over 2 hours or carboplatin IV over 30 minutes and etoposide IV over 4 hours on days 1, 2, and 3. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy, 4 courses for chemotherapy) in the absence of disease progression or unacceptable toxicity. Patients who achieve systemic disease control and do not exhibit severe (grade > 3) pembrolizumab related toxicity during/after completion of 16 courses may receive 16 additional courses of pembrolizumab in the absence of disease progression or unacceptable toxicity.
2574620|NCT02402920|Experimental|Part B (ES-SCLC, pembrolizumab, radiation therapy)|Beginning after the completion of chemotherapy, patients receive pembrolizumab IV over 30 minutes on day 1 and undergo radiation therapy BID 5 days a week for 3 weeks. Treatment repeats every 3 weeks for 16 courses (1 course for radiation therapy) in the absence of disease progression or unacceptable toxicity.
2574836|NCT02401633|Experimental|CO-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions only
2574841|NCT02401633|Active Comparator|S-CPR Bystander|Instructions by dispatcher to trained bystander to provide CPR with chest-compressions and rescue breaths in a 30:2 ratio
2574893|NCT02401139|Active Comparator|Treatment arm|Ketamine
2574896|NCT02401139|Placebo Comparator|Placebo arm|Placebo
2574931|NCT02400541|Experimental|Cognitive remediation therapy|10 sessions of the cognitive remediation therapy program conducted during five weeks
2574940|NCT02400541|Placebo Comparator|relaxation therapy|10 relaxation sessions during 5 weeks
2574989|NCT02400398||Tube feeding with peptide-base formula|The peptide-based formula (Peptamen) will be administered through a gastrojejunal or jejunal feeding tube and dosing will be calculated using the Mifflin St. Jeor equation. It will be administered for three 28-day cycles.
2575048|NCT02399995||patients following hepatectomy|
2575124|NCT02399410|Experimental|bevacizumab and CRS with oxaliplatin|Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin
2575188|NCT02398955||Study cohort|All comers patients with coronary artery disease treated with percutaneous coronary intervention and at least one Biomime stent
2575285|NCT02398539|Active Comparator|Group 1|Silver nitrate treatment will include weekly applications in the pediatric surgery office by a clinician.
2575286|NCT02398539|Active Comparator|Group 2|Triamcinolone cream, 0.5% applied three times per day by the patient's caregiver.
2575319|NCT02397876|Experimental|partially hydrolyzed whey formula|The group of patients who pass an oral food challenge to partially hydrolyzed whey formula and will be continued on it through out the study
2575329|NCT02397876|No Intervention|No intervention|Patients who do not pass an oral food challenge to partially hydrolyzed whey formula will continue on their prior diet of cows milk avoidance.
2575377|NCT02397603|Active Comparator|bupivacaine saline group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml normal saline perineurally in the paravertebral catheter
2575378|NCT02397603|Active Comparator|Dexmedetomidine- bupivacaine group|This group of patients will receive 20 ml bupivacaine plus 0.5 ml (50 microgram) dexmedetomidine administered perineurally in the paravertebral catheter.
2575523|NCT02396693|Experimental|NIPPV|NIPPV - Newborns randomized to this group underwent NIPPV, in noninvasive ventilation support intermittent, in TIME mode of the respirator.
2575526|NCT02396693|Placebo Comparator|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, in noninvasive ventilation continuous, in bubble NCPAP.
2575529|NCT02396693|Placebo Comparator|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, in noninvasive ventilation continuous, in NCPAP mode of the respirator.
2575692|NCT02395263|Experimental|Yuxintine 300mg per day|Yuxintine 300mg oral, once a day, 6 weeks
2574239|NCT02405169|Active Comparator|Control -6 implants-|Evaluate marginal bone level (MBL) changes at implants that are placed in total edentulous patient when they are treated with six with titanium Cad/Cam framework
2574321|NCT02405039|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day
2574322|NCT02405039|Placebo Comparator|Placebo or Vehicle control Comparator|One of two study arms: placebo or vehicle control topical administered 3 times per day
3210073|NCT00991133|Experimental|Clofarabine|Patients received a maximum of 2 cycles of the intravenous (IV) 5-drug regimen (clofarabine, etoposide,cyclophosphamide, PEG-asparaginase, and vincristine) plus intrathecal methotrexate, and then entered follow-up. Patients who achieved complete remission (CR) or complete remission with incomplete platelet recovery (CRp) after 1 cycle of study drugs were eligible to receive a second cycle of study drugs upon recovery of peripheral blood counts, and patients who did not have leukemic progression were eligible to receive a second treatment cycle at the investigator's discretion.
3210074|NCT00991146|Experimental|canakinumab|
3210075|NCT00991159|Experimental|RN316|
3210076|NCT00991172|Placebo Comparator|placebo injection|
3210077|NCT00991172|Experimental|active|subcutaneous injection of REGN475
2574487|NCT02403804|Other|All subjects|"All 3 weeks will occur during luteal phase of menstrual cycle with a two-to-three week washout period between weeks.~Week 1: Phosphatidylcholine 3600 mg qam and 2700 mg qpm~Week 2: Betaine anhydrous 588 mg qam and 412 mg qpm~Week 3: Betaine anhydrous 1000 mg BID"
2574500|NCT02403544|Experimental|CCRT Arm|Patients recruited will be treated by concurrent chemoradiotherapy with IGRT and two cytotoxic agents: capecitabine and oxaliplatin. Capecitabine will be taken orally twice a day, from D1 to D14 while oxaliplatin will be given intravenously on D1 and D8, every 21 days. The doses of the two drugs will be escalated alternatively in each level group. The radiation will be given by IGRT and the dose is between 45 to 54Gy, 1.8-3Gy per fraction.
2574570|NCT02403284|Experimental|Liraglutide|Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
2574573|NCT02403284|Placebo Comparator|Sugar pill|matching placebo and titration
2574628|NCT02402946|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor but not showed to the patients; in the biofeedback group, patients will be instructed to control, abdomino-thoracic muscle activity
2574631|NCT02402946|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patienst will take a pill of placebo and receive no instructions about controlling muscular activity.
2574671|NCT02402491|Active Comparator|24 months of P2Y12 receptor antagonist|Receive 24 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
2574673|NCT02402491|Placebo Comparator|12 months of P2Y12 receptor antagonist|Receive 12 months of dual antiplatelet therapy (with a P2Y12 receptor antagonist in addition to aspirin) after index procedure. All subjects receive aspirin for the duration of study.
2574729|NCT02402140|Experimental|1 with pharmaceutical intervention|"Patients allocated to group 1 with pharmaceutical intervention received instructions on the proper use of immunosuppressants as dosage, frequency and administration schedules, importance of immunosuppressive drugs and the risk of rejection.~No more interventions were applied."
2574732|NCT02402140|No Intervention|2 without pharmaceutical intervention|"Standard following of the Hospital do Rim, without pharmaceutical intervention. This group was just followed by the nurses of the hospital, but without a standardized intervention.~It was not a intervention, it was the control group"
2574777|NCT02401932||Hemophagocytosis|The group includes patients who have the evidence of hemophagocytosis in their bone marrow or other sites.
2574852|NCT02401620||single-group studies|Patients with RA diagnosed
3210078|NCT00991172|Experimental|active 2|subcutaneous injection of REGN475
3210079|NCT00991198|Experimental|A|Aria Regimens 0.5% conc
3210080|NCT00991198|Experimental|B|Aria Regimen (5 products) 0.25% conc
2575039|NCT02399826|Other|Standard of Care|Surgical debridement of diabetic foot ulcer, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice offloading, reassessment weekly at office visit
2575042|NCT02399826|Experimental|Amniotic Membrane / Amnioband|Application of Amnioband with dressing application, to be changed weekly following surgical debridement. Patient will practice offloading. If the ulcer is not closed completely Amnioband will be applied weekly at weeks 2-11
2575079|NCT02399553|Experimental|Soccer 2G|Soccer players who trained in second generation artificial turf
2575081|NCT02399553|Experimental|Soccer 3G|Soccer players who trained in third generation artificial turf
2575084|NCT02399553|Experimental|Soccer NG|Soccer players who trained in natural grass
2575087|NCT02399553|Experimental|Soccer NON-NG|Soccer players who trained in non-natural grass
2575089|NCT02399553|No Intervention|Control group|
2575166|NCT02399241|Experimental|Remote telemonitoring of clinical data|Bluetooth enabled nebuliser device (I-neb) providing breathing parameters and adherence data.
2575280|NCT02398513|Experimental|Regorafenib (Stivarga, BAY73-4506)|Patients enrolled in the study will start treatment with Regorafenib160 mg (given by four 40 mg tablets of Regorafenib) on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, Regorafenib 160 mg QD will be administered for 21 days, followed by 7 days off treatment. Treatment with Regorafenib will continue until the patient either progresses or meets one of the criteria for withdrawal prespecified in the study protocol.
2575321|NCT02397941||non-pregnant women|20 non-pregnant women, BMI < 30 kg/m2, Nulligravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound
2575330|NCT02397941||pregnant women|40 pregnant women, BMI < 30 kg/m2 before pregnancy, Primigravidas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, consecutive measurement during the course of pregnancy
3210081|NCT00991198|Placebo Comparator|C|Aria Regimen Control without O2
3210082|NCT00991211|Experimental|Bendamustine + Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
3260245|NCT01477580|Experimental|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|
2574271|NCT02405117|Experimental|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study.
2574272|NCT02405117|No Intervention|Treatment As Usual|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will be asked to provide limited self-report data via the phone.
2574309|NCT02404870|Experimental|Admission 1 or 2|Canagliflozin
2574313|NCT02404870|Placebo Comparator|Admission 2 or 1|Placebo
2574391|NCT02404519|Active Comparator|Menaquinone-7|Menaquinone-7 180 microgram tablet, by mouth, daily for 1 year
2574393|NCT02404519|Placebo Comparator|Placebo|Placebo tablet, by mouth, daily for 1 year
2574431|NCT02404038|Active Comparator|Arm A: Injectable|This arm will receive Nur-Isterate administered as an intramuscular injection administered bi-monthly (every 8 weeks).
2574432|NCT02404038|Active Comparator|Arm B: Intra-vaginal|This arm will receive the Nuvaring a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days.
2574433|NCT02404038|Active Comparator|Arm C: Oral|This arm will receive Triphasil a daily oral contraceptive of 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
3210083|NCT00991211|Active Comparator|CHOP + Rituximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
3210084|NCT00991224|Experimental|Arm 1|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a WT-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
3260246|NCT01477580|Experimental|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|
3260247|NCT01477580|Experimental|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|
2574652|NCT02402660|Experimental|ALK-001|Daily, oral administration of one capsule. See details below.
2574655|NCT02402660|Placebo Comparator|Placebo|Daily, oral administration of one capsule. See details below.
2574717|NCT02402270|Experimental|ECP-019 A (Group A)|
2574718|NCT02402270|Experimental|ECP-019 B (Group B)|
2574719|NCT02402270|Experimental|ECP-019 C (Group C)|
2574723|NCT02402270|Active Comparator|Group D|
2574727|NCT02402270|Active Comparator|Group E|
2574802|NCT02401880|Active Comparator|Empagliflozin plus Linagliptin|Linagliptin 5mg to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
2574803|NCT02401880|Placebo Comparator|Empagliflozin plus Placebo|Placebo to be adminstered for 30 days in T2DM patients on stable metformin and Empagliflozin
2574806|NCT02401880|Other|Empagliflozin|Empagliflozin 25mg will be adminstered for 30 days in T2DM patients
2574832|NCT02401399|Placebo Comparator|regular diet|The patients receive regular diet of 900 Kcal/day during 15 days before surgery
2574835|NCT02401399|Active Comparator|high protein formula|The patients receive high protein formula during 15 days before surgery
2574839|NCT02401399|Experimental|Immunonutrition|The patients receive Immunonutrition during 15 days before surgery
2574889|NCT02401191|Experimental|FEX60/PE10|Internal use of FEX60/PE10 combination tablet will be administered twice daily (1 tablet per intake) for 2 weeks
2574958|NCT02400827||cryopreservation|
2574986|NCT02400320|Active Comparator|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
2574995|NCT02400320|Experimental|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
2575004|NCT02400320|Other|Saline|Saline
2575052|NCT02400047|Experimental|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
2575055|NCT02400047|Experimental|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
2575057|NCT02400047|Active Comparator|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
2575073|NCT02399540|Sham Comparator|Sham|Day 1: sham stimulation Day 2: sham stimulation
2575075|NCT02399540|Active Comparator|Conventional Paired tDCS|Day 1: sham stimulation Day 2: conventional tDCS
2575076|NCT02399540|Active Comparator|Conventional Unpaired tDCS|Day 1: conventional tDCS Day 2: sham stimulation
2575078|NCT02399540|Experimental|Late LTP-like Plasticity tDCS|Day 1: late LTP-like Plasticity tDCS Day 2: sham stimulation
2575164|NCT02399358||High-dose Cyclophosphamide|Patients requiring infusion of high-dose cyclophosphamide in the period 2015-2017 will be included. After informed consent, patients will de follow up from the infusion of cyclophosphamide to 30 days after hospital discharge.
2575267|NCT02398357|No Intervention|Control|No anticoagulation，just routine follow-up
2575270|NCT02398357|Experimental|Anticoagulation|Nadroparin Calcium and Warfarin
2575320|NCT02398045|Experimental|Computerised CBT|Computerised CBT for OCD
2575419|NCT02397200|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
2575420|NCT02397200|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals.
2575460|NCT02396940|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic inguinal hernia repair performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
2575461|NCT02396940|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
3260248|NCT01477580|Placebo Comparator|Placebo|
3260249|NCT01477593|Experimental|Group I|
2574454|NCT02403960|Placebo Comparator|placebo|The participants of the control group were asked to let a placebo tablet dissolve on their tongue 2 times a day for 3 months.
2574501|NCT02403713|Experimental|Test Treatment|Fluticasone/formoterol 125/5 µg BAI
2574504|NCT02403713|Active Comparator|Active Comparator 1|Fluticasone/formoterol 125/5 µg pMDI with spacer
2574507|NCT02403713|Active Comparator|Active Comparator 2|Fluticasone/formoterol 125/5 µg pMDI without spacer
2574508|NCT02403713|Active Comparator|Active Comparator 3|Fluticasone/formoterol pMDI (125/5 μg) without spacer, low dose
2574509|NCT02403713|Active Comparator|Active Comparator 4|Formoterol (12 µg) without spacer
2574559|NCT02403245|Experimental|Psychosocial stimulation|One session of a social stimulation
2574561|NCT02403245|No Intervention|Control group|Residents are in a social controlled condition but without direct stimulation.
2574610|NCT02402998|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
2574650|NCT02402582|Experimental|Family-Centered Empowerment Model|Have the same in-patient, pre-intervention, and post-intervention follow-up care as Control Group. However, rather than routine care and follow-up during the intervention period, they recieved than 4 stage intervention using the Family Centered Empowerment Model.
2574651|NCT02402582|Active Comparator|Control|Same in-patient, pre-intervention, and post-intervention follow-up care as Experimental Group. However, rather than 4 stage intervention they receive routine care and follow-up.
2574716|NCT02402348|Experimental|Metformin|Metformin 850 mg orally once a day for 3 days, then 850 mg orally twice daily starting day 4 until 24hrs before surgery.
2574781|NCT02401971|Experimental|Arm A (thalidomide+CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles ,and oral thalidomide 100 mg/d qn. Maintenance therapy with thalidomide in the same dose is performed until disease progression.
2574783|NCT02401971|Experimental|Arm B (CPT-11)|Patients will receive CPT-11 180 mg/m^2 ivgtt ,over 90 minutes on day 1, every 21 days for one cycle, four cycles.
2574822|NCT02401438||pregnant women with preterm delivery|5D LB and 2D ultrasounds will be done to pregnant women between 28 and 34 weeks planned for termination of pregnancy for obstetric or medical causes.
2574862|NCT02401321|Experimental|Supportive care (Taking Care of Her program)|Patients and spouse caregivers complete the Taking Care of Her Program comprising 5 telephone-delivered intervention sessions over 45-60 minutes every 2 weeks. The intervention sessions are designed to provide training for spouse caregivers and patients to better manage the impact and emotional toll of recently diagnosed ovarian cancer, including its impact on their interpersonal communication and support about the cancer.
2574885|NCT02400957|Experimental|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized.
2574886|NCT02400957|Experimental|Placebo|Half of the mouth was applied placebo. Allocation was randomized.
2574963|NCT02400853|Experimental|preterm infants with intracranial hemorrhage|Cord blood analysis of preterm infants with radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
2574968|NCT02400853|Active Comparator|preterm infants without intracranial hemorrhage|Cord blood analysis of preterm infants without radiological finding of intracranial hemorrhage, detected by ultrasound between day 5 and day 7 post-birth (Standard cranial echography) will be collected and analysed
2574991|NCT02400229|Experimental|Computed Tomography Angiography (CTA)|Computed Tomography Angiography including coronary calcium scoring and coronary computed tomography angiography
2575000|NCT02400229|Active Comparator|Invasive coronary angiography (ICA)|Invasive coronary angiography
2575065|NCT02399800|Experimental|EUS with Celiac Block|Celiac Block with triamcinolone and bupivicaine Intra Plexus Triamcinolone and Bupivicaine Injection
2575066|NCT02399800|Active Comparator|EUS without Celiac Block|Patients will undergo EUS but no celiac block will be performed
2575108|NCT02399462|Experimental|Study Drug Arm|Acthar SC injections
2575154|NCT02399072||Geographic Atrophy Participants|Participants with unilateral GA or GA in one eye and choroidal neovascularization (CNV; active or treated) with or without GA, in the contralateral eye, will be evaluated for the progression of GA for up to approximately 60 months.
2575232|NCT02398591|Experimental|JNJ 53718678 250 milligram (mg)|Participants will receive either single oral dose of 250 mg of JNJ 53718678 or matching placebo on Day 1.
2575234|NCT02398591|Experimental|JNJ 53718678 500 mg|Participants will receive either single oral dose of 500 mg of JNJ 53718678 or matching placebo on Day 1.
2575237|NCT02398591|Experimental|JNJ 53718678 1000 mg|Participants will receive either single oral dose of 1000 mg of JNJ 53718678 or matching placebo on Day 1.
2575281|NCT02398214|Experimental|Sleep hygiene & standard care|Participants receive a light, activity, and sleep training (LAST) intervention consists of behavioral and educational strategies for increasing light exposure and physical activity to minimize sleep disturbance.
2575282|NCT02398214|No Intervention|Standard care|Participants receive usual care.
2575348|NCT02397902|Experimental|Dairy|Add 4 daily servings of high fat dairy to diet for a period of 4 weeks
2575353|NCT02397902|Active Comparator|Plant-based|Add 4 daily servings of fruit to diet and/or plant-based milk, remove all dairy from diet for a period of 4 weeks
2575384|NCT02397421|Active Comparator|Treatment|Dapagliflozin 10mg once daily
2575389|NCT02397421|Placebo Comparator|Control|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
2575438|NCT02397070|Experimental|Jaw exercise program|
2575447|NCT02397070|Active Comparator|Occlusal splint and counseling|
3210085|NCT00991224|Experimental|Arm 2|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 at the time of enrollment, a CD4 nadir >200 and a recorded historical viral load setpoint, will receive a α/6-gag-TCR modified autologous T cells, followed one week later by a 16 week treatment interruption.
3260250|NCT01477593|Active Comparator|Group II|
2575617|NCT02395952|Active Comparator|Lubrication|
2575623|NCT02395952|Active Comparator|Bandage Contact Lens|Acuvue Oasys Contact Lens
2575625|NCT02395952|Active Comparator|Prokera|Wet amniotic membrane mounted on plastic retaining ring
2575628|NCT02395952|Active Comparator|Ambiodisk|Freeze dried amniotic membrane
3210086|NCT00991224|Experimental|Arm 3|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir >200. Subject will undergo an 16 week treatment interruption during which a single infusion of WT-gag-TCR modified autologous T cells at 8 weeks post STI.
3210087|NCT00991224|Experimental|Arm 4|Subjects who are HIV positive, taking medication to control virus, have an undetectable viral load, CD4 count greater than 450 and a CD4 nadir of >200. Subject will undergo a 16-week treatment interruption during which a single infusion of α/6-gag-TCR modified autologous T cells at 8 weeks post STI.
3210088|NCT00991237|Experimental|Pain reduction|
3210089|NCT00991250|Experimental|SentoClone®|SentoClone®: Specific tumour-reactive lymphocytes located in lymph nodes directly draining primary tumours or metastases are identified and expanded. These lymphocytes are infused to the patient to treat metastatic disease.
2574587|NCT02403128|Experimental|Patients with macular edema from RAM|Intravitreal aflibercept 2.0 mg injection for eyes meeting eligibility criteria will be administered at baseline. Reinjection of the drug for protocol-defined criteria at least two months after previous injection.
2574614|NCT02402855|Experimental|Group Intervention: Financial support|
2574616|NCT02402855|Active Comparator|Group Control: no financial support|
2574667|NCT02402478||Stable coronary artery disease|Patients with chest pain
3210090|NCT00991250|Active Comparator|Temodal® or Dacarbazine Medac®|"To be decided by each centre as one of the following:~Temodal® (temozolomide)~Dacarbazine Medac® (dacarbazine) The reference treatment regimen should follow the general guiding principles for each of the two reference treatments."
3210091|NCT00991263||Group 1|Tissue blocks from CALGB-9344 and CALGB-9741 are utilized to purify RNA to be tested in the PAM50 assay (a 50-gene quantitative PCR assay, that provides an intrinsic breast cancer subtype diagnosis) and generate risk of relapse (ROR) scores. For more information, see Details section.
3210092|NCT00991328|Active Comparator|Cerebral Desaturation, i.e; SctO2 < 60 % for 5 minutes|Once the cerebral desaturation is established, the study personnel will attempt to optimize the level of oxygen within the brain of the study patients.
2574825|NCT02401516|Active Comparator|Reprogramming Insoles|EG - experimental group. Subjects will be subjected to the use of insoles with the artifact in the postural reprogramming insole that emits a electrogalvanic stream. Volunteers of this research must use the insole for at least 12 hours a day and have usage control through a daily chart.
2574827|NCT02401516|Placebo Comparator|Neutral Insoles|CG - control group. Subjects will be subjected to the use of insoles likewise the ones used by EG, but instead the artifact in the postural reprogramming insole made of metal, will be made of cork.
2574865|NCT02401282|Experimental|ABM|Attention bias modification
2574867|NCT02401282|Placebo Comparator|Placebo|Dot-probe task
3210093|NCT00991328|No Intervention|Patients with SctO2 less than 60 %.|The study patients will not get any intervention in this arm if the Sct02 falls below 60%
3210094|NCT00991354|Experimental|Group 1|Participants will receive 3 mg of PENNVAX-B vaccine or placebo at Months 0, 1, and 3.
2574967|NCT02400528|Other|Patients With Profound and Multiple Disabilities|
2575036|NCT02399969|Experimental|Battlefield Acupuncture Plus Standard of Care|Patients with low back pain that will receive ear acupuncture based on the Battlefield Acupuncture protocol.
2575040|NCT02399969|No Intervention|Standard of Care Alone|Patients with low back pain that will receive standard of care without study intervention.
2575093|NCT02399670||Decrease femoral offset|The FO of operated side was reduced more than 5mm compared with the contralateral side.
2575094|NCT02399670||Restored femoral offset|The FO of operated side was within 5mm restored compared with the contralateral side.
2575095|NCT02399670||Increased FO|The FO of operated side was increased more than 5mm compared with the contralateral side.
2575147|NCT02399332|Experimental|Community Pharmacist Involvement|"Patients would have a complex care plan completed by their clinical team, which will involve chronic disease management nurse and the family physician. This complex care plan would also involve discussion with the patient's community pharmacist who would follow-up with the patient monthly and send a report to the patient's physician. Patients would also continue to receive routine care at the clinic.~The monthly follow-ups with the community pharmacist would involve review of the goals of complex care plan and monitoring clinical targets, medication review and discussing adherence as well as patient education. This follow-up can be completed in person or by telephone. The pharmacist would then send a monthly report to patient's family physician."
3210095|NCT00991354|Experimental|Group 2|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
3210096|NCT00991354|Experimental|Group 3|Participants will receive 3 mg of PENNVAX-B vaccine and 1 mg of IL-12 vaccine or placebo at Months 0, 1, and 3.
3210097|NCT00991367|Experimental|A|Cicatrix
3210098|NCT00991367|Placebo Comparator|B|Placebo
3210099|NCT00991380|Experimental|Lifestyle counselling|
3210100|NCT00991380|Active Comparator|Usual Care|
3210101|NCT00991393||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3210102|NCT00991419|Experimental|A|[18F]4694
3210103|NCT00991432||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3210104|NCT00991445|Active Comparator|Group MIS|Minimal Invasive Surgery
3210105|NCT00991445|Active Comparator|Conventional Exposure|
3210106|NCT00991471|Experimental|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
3210107|NCT00991471|Experimental|Control: No MDRNSTAT|Control group
3210108|NCT00991484||control group|
3210109|NCT00991484||individuals from hernia-family|
3210110|NCT00991497|Active Comparator|24 hours compression bandaging|
3210111|NCT00991497|Active Comparator|5 days compression bandaging|
3210112|NCT00991523|Experimental|sweetened beverage|
3210113|NCT00991523|Placebo Comparator|placebo control|placebo
3210114|NCT00991536||Chronic respiratory failure|Patients with restrictive pulmonary disorders leading to progressive hypercapnic respiratory failure and requiring nocturnal non-invasive ventilation
3210115|NCT00991549|Experimental|1|interdisciplinary weight loss intervention
3210116|NCT00991549|Active Comparator|2|Small group seminars without interdisciplinary intervention
3210117|NCT00991575||Diabetes, type 1|
2574489|NCT02403752|Experimental|exercise intervention|"Exercise protocol based on the PLIÉ protocol, developed in consultation with experts worldwide, incl. traditional strength-building exercises, yoga, Tai Chi and Feldenkrais, that engage the muscles most needed to maintain independence--including lower body strength, balance, upper body strength, fine motor exercises , and pelvic floor exercises- combined them into a unique integrative exercise program, to be purposeful and to build procedural ('muscle') memory.~To be practiced at home in dyads of affected individuals and caregivers, called Paired PLIE Program."
2574613|NCT02402972|Experimental|IPC plus AC|"patients treated with intraoperative intraportal chemotherapy (IPC) plus adjuvant chemotherapy (AC; mFOLFOX6).; IPC: During the operation, one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein within 5 minutes just before ligation.~AC: All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0."
2574617|NCT02402972|Active Comparator|AC|patients treated with adjuvant chemotherapy (AC; mFOLFOX6) alone after surgery; Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy, consisting of a 2-h infusion of 85 mg/m2 oxaliplatin given simultaneously with a 2-h infusion of 400 mg/m2 LV, followed by a bolus of 400 mg/m2 5-FU, and then a continuous infusion of 2000 mg/m2 5-FU given on 2 consecutive days by intravenous pumping every 14 days for 12 cycles.[1] Adverse events were categorized according to National Cancer Institute Common Toxicity Criteria, version 3.0.
2574678|NCT02402556|Experimental|MOCEP|MOCEP is implemented over a period of 25 weeks, through weekly group meetings that last approximately three hours.
2574688|NCT02402556|Active Comparator|Waitlist Control Group|For ethical reasons, no one recruited will be excluded from the opportunity to benefit from the intervention. MOCEP group will be the primary intervention group and the second group will act as the wait-listed control group. Although the families in the wait-listed control group will start out as a control group (not receiving the intervention), they will have the opportunity to participate in the intervention in a later round of implementation, after the intervention group has completed the program.
3210118|NCT00991588||PCL, posterolateral reconstruction|All patients who are entered into study who receive a PCL and/or posterolateral knee ligament reconstruction
2574808|NCT02401659||naïve with CareLink|patients with a first implant of an implanted cardiac device naïve in CareLink or patients with a refill who have not used CareLink until the implant
2574810|NCT02401659||users of CareLink|patients with an implanted cardiac device who have used CareLink for more than one year
2574849|NCT02401425|Active Comparator|letrozole|Women will receive three tablets of letrozole(FemaraR, NOVARTIS) as a single dose, each tablet 2.5 mg (total dose 7.5 mg per day) for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
2574851|NCT02401425|Placebo Comparator|placebo|Women will receive three tablets of placebo as a single dose, for two days at home and will be told to bring back the empty packs. The third dose will be given on admission to hospital on day three and will be followed by 4 tablets of vaginal misoprostol (200 mcg) (MisotacR,SIGMA)soaked with saline every three hours up to maximum 2 doses.
2574890|NCT02401074|Experimental|Segmental bronchoprovocation with Allergen (SBP-Ag)|Following nasopharyngeal anesthesia, the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During SBP-Ag challenge, 15% of the Ag-PD20 allergenic extract will be instilled into the segment.
2574950|NCT02400814|Experimental|Arm I (concurrent cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 1, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
2574953|NCT02400814|Experimental|Arm II (induction cohort)|Patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of course 3, patients also undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions.
2574961|NCT02400814|Experimental|Arm III (sequential cohort)|Patients undergo SAR 2-3 times per week (with a minimum of 40 hours and a maximum of 96 hours between fractions) over 1.5-2 weeks for a total of 5 fractions beginning on day 1 of course 1. After completion of SAR (beginning on day 1 of course 2), patients receive anti-PD-L1 monoclonal antibody MPDL3280A IV over 30-60 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
2575099|NCT02399722|Active Comparator|VAC mono therapy|negative pressure wound therapy alone
2575100|NCT02399722|Active Comparator|WICVAC combined therapy|Polymeric membrane dressing combined with negative pressure wound therapy
3210119|NCT00991601|Experimental|biopsy arm|patients with tumors in liver and/or pancreas
3210120|NCT00991614||EVOLUTION® Duodenal Stent|
3210121|NCT00991627|Active Comparator|Pharmacological|Patients in this group will receive a basal infusion of ephedrine. Hypotension will be treated for a reduction in systolic blood pressure 20% below baseline values.
3210122|NCT00991627|Experimental|Non-Pharmacological|Patients in this group will undergo uterine lateral displacement through the use of a wedge-shaped cushion placed under their right hip. Hypotension will be treated for a reduction in systolic blood pressure 40% below baseline values.
2575236|NCT02398578|Experimental|Amphora OAB Device|Specialized cystoscope that facilitates visualization and radiofrequency (RF) therapy for the treatment of OAB.
2575259|NCT02398253|Experimental|CBT + Hypo-energetic Diet|
2575261|NCT02398253|Experimental|Hypo-energetic Diet only|
2575548|NCT02396173|No Intervention|Control group|In this group the medical staff will not be informed about the risk score (WORRK).
3210123|NCT00991640|No Intervention|Control|No intervention
3210124|NCT00991640|Experimental|Preceptorships|Preceptorships with e-learning
2574492|NCT02403518|Active Comparator|Leg Pain Only|Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
2574493|NCT02403518|Active Comparator|Back and Leg Pain|Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).
2574542|NCT02403362|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2574544|NCT02403362|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2574549|NCT02403362|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2574654|NCT02402686||Tocilizumab for RA in Routine Clinical Practice|Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.
2574710|NCT02402231|Experimental|Omalizumab|Omalizumab is given to protect the study object from severe allergic reactions while they are going through oral immunotherapy with peanuts. There wïll be only one arm. The study objects are their own controls by also having allergy to airborne allergens. The dose is calculated by the study objects body mass and number of total IgE antibodies.
2574765|NCT02401997|Active Comparator|sexual abstinence period group I|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group I male partners have sexual abstinence period of 2 days or less.
2574767|NCT02401997|Active Comparator|sexual abstinence period group II|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of 2 to 4 days.
2574770|NCT02401997|Active Comparator|sexual abstinence period group III|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination. Group II male partners have sexual abstinence period of more than 4 days
3210125|NCT00991653||Breast cancer|Diagnosed with breast cancer 1/1/2003 - 31/12/2007.
3210126|NCT00991666|Experimental|1|AMD Patients
3210127|NCT00991666|Active Comparator|2|healthy controls
2574973|NCT02400502|Experimental|I-CAT Therapy|Integrated Coping and Awareness Therapy is a six-month intervention designed to examine the physiological, biological, and psychological effects of meditation and mindfulness practice on individuals diagnosed with a psychotic disorder.
2574988|NCT02400164|Experimental|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
2575053|NCT02400008|Experimental|Patient with bilateral vocal fold paralysis|Patient with bilateral vocal fold paralysis in a closure position between 6 months to 36 months before et who has been treated by endoscopic treatment without satisfying result (voice or breathing).
2575091|NCT02399683||Trichuris trichiura eggs|One healthy volunteer
3210128|NCT00991679||Normal control subjects|Normal control subjects who did not show the clinical symptom and findings of dry eye syndrome.
2575169|NCT02399020|Experimental|SCIT group|Social Cognition and Interaction Training intervention group
2575196|NCT02398721|Other|FNAC|patients will then be randomized routine FNAC strategy
2575203|NCT02398721|No Intervention|No FNAC|patients will be randomized to watchful observation strategy (no FNAC)
2575246|NCT02398461|Experimental|rHIgM22|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
2575249|NCT02398461|Placebo Comparator|Placebo|Patients will be enrolled sequentially in 2 separate cohorts, representing escalating dose levels. Each dose cohort will comprise 15 subjects, randomly assigned to receive either rHIgM22 (n=10) or placebo (n=5).
2575326|NCT02397993||FNA, blood collection|blood collection prior to fine needle aspiration Endoscopic ultrasonography-guided fine needle aspiration of the pancreas blood collection after to fine needle aspiration
2575397|NCT02397525|Experimental|LIPO-202|
3210129|NCT00991679||dry eye patients|Patients with dry eye syndrome who had symptoms of dry eye for more than 3 months, low tear film break up time (BUT, ≤7 sec), low Schirmer test (<10 mm), low tear clearance rate (<8X), and positive fluorescein or rose bengal vital staining (≥3) and were not treated with anti-inflammatory agents such as topical cyclosporine or steroids were included in the study.
3210130|NCT00991692|Experimental|Treatment dosage levels examined|
2575536|NCT02396446||Intervention group|Inpatients at CSMC whose abdominal acoustic sounds will be measured using the AbStats device.
2575546|NCT02396173|Experimental|Risk Score for non-return to work|The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
3210131|NCT00991705|Other|Group B|Atorvastatin (7 days) → Fimasartan + Atorvastatin (7 days)
3210132|NCT00991705|Other|Group A|Fimasartan (7 days) → Fimasartan + Atorvastatin (7 days)
3210133|NCT00991718|Experimental|A|On Day 1, subjects received a single oral dose of non-labeled GDC-0449 and a single IV tracer dose of 14C-GDC-0449.
3210134|NCT00991718|Experimental|B|On Day 1, subjects received a single oral dose of 14C-GDC-0449.
3210135|NCT00991718|Experimental|C|On Days 1-7, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects also received a single IV tracer dose of 14C-GDC-0449.
3210136|NCT00991718|Experimental|D|On Days 1-6, subjects received a single oral dose of non-labeled GDC-0449. On Day 7, subjects received a single oral dose of 14C-GDC-0449.
3210137|NCT00991731|Active Comparator|Faith-based|Faith-based interventions incorporate tenets of the faith-based organization (e.g., religious beliefs, scriptural references) and involve the faith-based organization in the planning of the intervention from beginning to end
2574550|NCT02403427|Experimental|VoiceDiab expert system|the VoiceDiab system using before every main meal; three times per day.
2574551|NCT02403427|No Intervention|manual calculation|manula insulin calculation before every main meal; three times per day
2574600|NCT02403024|Experimental|InterWalk|The intervention program will prescribe that patients performing 150 min of interval training per week.
2574602|NCT02403024|Other|Waiting list Control|Patients allocated to the waiting-list control group will receive usual care control for the first 12 weeks of the study and will receive the same instructions for download and use of the InterWalk app in the final 12 weeks.
2574634|NCT02402751|Experimental|Acquisition of normative database|Development, implementation and initiation of normative database (image and data) quantitative ultra high field MRI paramaters
2574712|NCT02402543|Placebo Comparator|Control Arm|In pre-op, the subject is administered four placebo pills PO containing confectioners sugar, which are matched in color, size, and shape to the active pills.
2574714|NCT02402543|Experimental|Experimental Arm|In pre-op, the subject is administered four pills PO containing a total of 1000 mg of acetaminophen and 600 mg of gabapentin, which are matched in color, size, and shape to the placebo pills.
2574759|NCT02401841||Sugammadex|Patients treated with Sugammadex
2574761|NCT02401841||Neostigmine|Patients treated with Neostigmine
3210138|NCT00991731|Active Comparator|Non-faith-based|A curriculum designed for delivery without biblical references. In the traditional teachings of how to increase physical activity.
3210139|NCT00991731|No Intervention|Control|"This group will receive a printed pamphlet Energize Yourself! Stay Physically Active, published by the National Heart Lung and Blood Institute, that encourages participation in at least 30 minutes of daily physical activity all at once or in bouts lasting 10 minutes at a time."
2574916|NCT02400931|Active Comparator|mask ventilation|Mask ventilation will be performed before the tracheal intubation.
2574920|NCT02400931|Experimental|no mask ventilation|Mask ventilation will not be performed before the tracheal intubation.
2574927|NCT02400593|Experimental|Lovingkindness|A six-week formal meditation workshop for 1 hour per week.
2574939|NCT02400593|Placebo Comparator|Mindfulness|A six-week formal meditation workshop for 1 hour per week.
2574982|NCT02400476|Experimental|Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Loperamide daily for two 28-day cycles and then as needed.
2574998|NCT02400476|Experimental|Budesonide and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Anti-inflammatory treatment for 1 cycle and Loperamide to be administered daily for two 28-day cycles and then as needed, thereafter.
2575006|NCT02400476|Experimental|Colestipol and Loperamide|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered 1 cycle and then as needed, thereafter.
2575011|NCT02400476|Experimental|Colestipol with Loperamide as needed|240 mg Neratinib orally once daily with food for thirteen 28-day cycles. Colestipol for 1 cycle and loperamide to be administered as needed.
2575015|NCT02400476|Experimental|Neratinib Dose Escalation 1|120 mg Neratinib for Week 1, followed by 160 mg Neratinib starting for Week 2, followed by 240 mg Neratinib starting at Week 3 and thereafter (C1D15 to End of Treatment). Loperamide administered as needed.
2575017|NCT02400476|Experimental|Neratinib Dose Escalation 2|160 mg neratinib for the first 2 weeks, followed by 200 mg neratinib for the next 2 weeks, followed by 240 mg neratinib thereafter (C2D1 to End of treatment. Loperamide will be administered on an as-needed basis only.
2575115|NCT02399436|Experimental|School-Based Healthy Snacking Campaign|Students who attend middle and high schools in the experimental county that participate in the healthy snacking campaign intervention.
2575117|NCT02399436|No Intervention|Comparison Schools|Students who attend middle and high schools in the comparison county, which does not receive any intervention components.
2575119|NCT02399436|Experimental|Community Cooking Classes|Adults in the intervention county who enroll in group cooking classes (single-group pretest-posttest)
2575170|NCT02399007|Experimental|Total Hip System made in China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China
2575173|NCT02399007|Active Comparator|Total Hip System made outside of China|Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China
2575212|NCT02398656|Experimental|Tenecteplase (tNK)|Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
2575213|NCT02398656|Active Comparator|Control (Antiplatelet Agents)|Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.
2575356|NCT02397759|Experimental|Patients with severe SAH and vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) and presenting vasospasm
2575357|NCT02397759|Experimental|Patients with severe SAH without vasospasm|Patients with severe SAH from ruptured aneurysm requiring the establishment of an external ventricular derivation (EVD) without vasospasm
2575360|NCT02397759|Active Comparator|Patients with severe SAH without external ventricular derivati|Patients with severe severe SAH from ruptured aneurysm without necessitating a EVD subarachnoid hemorrhage
2575376|NCT02397382|Experimental|Guselkumab and Cytochrome P450 Probe Cocktail|Participants will be administered single dose of Guselkumab 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8 and Cytochrome P450 probe cocktail consist of midazolam, warfarin/vitamin K, omeprazole, dextromethorphan and caffeine orally once on Day 1,15 and 36.
2575495|NCT02396706|Active Comparator|Ivy Leaves Cough Liquid|Ivy Leaves Cough Liquid
2575499|NCT02396706|Placebo Comparator|Placebo|Placebo
3175890|NCT00639171||1|Subjects with suspicious breast lesions that warrant further evaluation will be followed to determination and confirmation of diagnosis.
2574626|NCT02402959||Cohort 1|Based on the first TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574627|NCT02402959||Cohort 2|Based on the second TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574630|NCT02402959||Cohort 3|Based on the third TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574632|NCT02402959||Cohort 4|Based on the fourth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574635|NCT02402959||Cohort 5|Based on the fifth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574637|NCT02402959||Cohort 6|Based on the sixth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574639|NCT02402959||Cohort 7|Based on the seven TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574641|NCT02402959||Cohort 8|Based on the eighth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574642|NCT02402959||Cohort 9|Based on the nineth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
2574644|NCT02402959||Cohort 10|Based on the tenth TCM expert's experience and his knowledge, the insomnia patients will be treated with the best individualized treatment options, which should be at least in accordance to the current China Traditional Chinese herbal medicine pharmacopoeia and the China adult insomnia diagnosis and treatment guidelines. In addition, the expert could determine the treatment in consideration of individual patient's preferences and best existed evidence. Therefore, the choices of medicine, dosage form, dosage, frequency and duration are not restricted.
3210140|NCT00991744|Experimental|Liposomal cytarabine|Intrathecal liposomal cytarabine (25 - 50 mg) combined with intrathecal prednisolone sodium succinate and oral dexamethasone 6 times during maintenance treatment for high-risk ALL
3210141|NCT00991744|Active Comparator|Intrathecal triple|Intrathecal methotrexate, cytarabine and prednisolone
2574782|NCT02401919|Experimental|Tell-us Card Intervention|Patients in the experimental arm will receive a Tell-us Card on a daily basis during their stay in the hospital. With this card patients are invited to state what is important to them for that day or before discharge from the ward.
2574784|NCT02401919|No Intervention|Care as usual|In the control arm, patients will receive care as usual.
3210142|NCT00991757|Experimental|001|carisbamate Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
3210143|NCT00991770|Experimental|Massage Therapy|Massage therapy provided by a certified Massage Therapist
2574941|NCT02400697||<30 wks gestation or 1500 grams|Preterm infants born at participating hospitals
2574965|NCT02400788|Active Comparator|Sorafenib|oral administration
3175891|NCT00639171||2|Normal subjects used to evaluate software and to develop and optimize MR sequences will be examined.
3210144|NCT00991770|Active Comparator|Control|Empathic support conversation
2574585|NCT02403141||Type 2 diabetes|Patients with blood glucose higher than 7mmol/L and negative IA2 and GAD antibodies.
2574586|NCT02403141||Type 1 diabetes|Patients on insulin and with positive IA2 and/or GAD antibodies.
2574704|NCT02402374|Experimental|PRP gel|Autologous platelet rich plasma gel
2574707|NCT02402374|Placebo Comparator|Placebo|Saline gel
2574757|NCT02402023|Active Comparator|Standard Care (SC)|Patients in the SC arm will receive 4 counseling sessions and nicotine patches as part of typical cessation measures delivered to patients.
2574758|NCT02402023|Experimental|Contingency Management (CM)|Patients in the CM arm will receive monetary payment contingent on smoking abstinence (in addition to SC: 4 counseling sessions and nicotine patches).
2574816|NCT02401737|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 28 days
2574817|NCT02401737|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 28 days
2574818|NCT02401737|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
2574819|NCT02401737|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
2574858|NCT02401295|Experimental|ATRA/celecoxib/itraconazole|"All maintenance drugs will be given on days 1-21 of each cycle, followed by 14 days off treatment. Cycles will be repeated every 35 days (+/- 3 days) for a total of five cycles.~Each patient enrolled will receive ATRA 20mg twice per day by mouth. Dose modifications are not allowed unless excessive toxicity occurs. In this case, ATRA will be de-escalated by 50% to 10mg twice per day by mouth.~The dose of celecoxib for all patients enrolled will be 400 mg twice per day by mouth. If creatinine level increases to more than 2 mg/dl and cannot be corrected by increased oral fluid intake or other measures, the dose of celecoxib will be decreased by 50%. If creatinine level does not drop below 2 mg/dl on the reduced dose, celecoxib will be discontinued.~The dose of itraconazole for all patients enrolled will be 200 mg twice per day by mouth. Dose modifications are not allowed."
2574942|NCT02400723|Experimental|BREATHE|Four weeks of DVD-delivered behavioral intervention. Intervention consists of diaphragmatic breathing and progressive muscle relaxation.
2574945|NCT02400723|Placebo Comparator|Psychoeducation|Four weeks of DVD-delivered psychoeducation as an attention placebo control.
2575195|NCT02398708||Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
2575207|NCT02398708||No Chronic Graft-Versus-Host Disease|This group will have questionnaires, clinical data, a blood sample and a stool sample collected to be compared with the other group.
2575297|NCT02398331|Experimental|arm|Standardised information and education on sexuality in women with spinal cord injury
2575300|NCT02398331|No Intervention|Control arm|Usual care (no structured information or education on sexuality)
2575428|NCT02396992|Other|Minimal-Massive Intervention|The minimal/basic intervention for a massive number of hospitalized patients.
2575519|NCT02396836|Active Comparator|6 step hand hygiene technique|Hand decontamination with alcohol hand rub using the World Health Organisations 6 step technique
2575520|NCT02396836|Experimental|3 step hand hygiene technique|Hand decontamination with alcohol hand rub using the 3 step technique
2575606|NCT02395705|Experimental|Neo-adjuvant chemotherapy group|"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles.~Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
2575608|NCT02395705|No Intervention|Surgery alone group|"Surgery:~2-3weeks after Neo-adjuvant chemotherapy~Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included)."
2575660|NCT02395406|Active Comparator|Totaltrack|OTI with Totaltrack
2575665|NCT02395406|Active Comparator|Airtraq|OTI with Airtraq
3175892|NCT00639184|Experimental|1|Home intervention program
3175893|NCT00639184|Active Comparator|2|health education counseling
3175894|NCT00639197|Active Comparator|1|To Tunnel
3175895|NCT00639197|Active Comparator|2|Not to tunnel
3175896|NCT00639210|Other|A|Supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.
3175897|NCT00639210|No Intervention|B|
3175898|NCT00639249|Placebo Comparator|P|Placebo
3175899|NCT00639249|Experimental|A1|SA4503
3175900|NCT00639249|Experimental|A2|SA4503
3175901|NCT00639262|Experimental|Cohort 1 - Brain Metastasis|Sorafenib and Radiotherapy
3175902|NCT00639262|Experimental|Cohort 2 - Gliomas|Sorafenib and Radiotherapy, plus Temozolomide
3175903|NCT00639288|Experimental|1|modified CPT-C
3175904|NCT00639301||1|Long term survivors of retinoblastoma
3175905|NCT00639314|Experimental|1|In PpPD, the proximal duodenum was divided 3-4cm distal to the pylorus ring
3175906|NCT00639314|Active Comparator|2|In PrPD, the stomach is divided just above the pylorus ring. the nearly total stomach more than 95% was preserved.
3175907|NCT00639327|Experimental|A|CPT-11+ S-1
3175908|NCT00639327|Active Comparator|B|CPT-11
3175909|NCT00639353|Active Comparator|spherical contact lens|Subjects will wear and evaluate a spherical soft contact lens daily for 2 weeks
3175910|NCT00639353|Experimental|toric contact lens|Subjects will wear and evaluate a toric soft contact lens daily for 2 weeks
3175911|NCT00639392|Placebo Comparator|2|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive placebo are 1 out of 3.
2574664|NCT02402595|Experimental|Sequence 2 - Period 2 (after 3-week washout)|AVP-923 and placebo matching AVP-786- BID on Day 1 until am of Day 15 Itraconazole - 200 mg BID on Day 9 followed by QD dosing on Days 10-15
2574721|NCT02402205|Experimental|Web Implementation of TF-CBT|"Web implementation (W)provides only web-based (distance learning) training and consultation to mental health therapists providing TF-CBT treatment to adjudicated youth in RTF. Therapists access the initial 10 hour training course(www.musc.edu/tfcbt) and follow-up consultation (www.musc.edu/tfcbtconsult) at their own convenience and as needed during the course of the study, with RTF administrators guaranteeing that therapists have time to do so. This implementation strategy is free and more convenient to therapists and administrators as it can be accessed whenever desired."
2574724|NCT02402205|Experimental|Web + Live Implementation of TF-CBT|"Web + Live (W+L) implementation provides web-based training and consultation as described in W, and also provides 1) face-to-face training and 2) twice monthly phone consultation with an expert TF-CBT trainer. W+L requires greater resource commitment from therapists and administrators and is less convenient, but provides more specific consultation on the therapists' personal TF-CBT treatment cases."
2574754|NCT02401945|Experimental|DE-120 Monotherapy|DE-120 intravitreal injection given as monotherapy on a PRN basis
2574755|NCT02401945|Experimental|Eylea® and DE-120 Concomitant Therapy|DE-120 intravitreal injection given on a PRN basis after Aflibercept (Eylea®) injection as an induction therapy.
2574830|NCT02401646|Experimental|Polygoni Multiflori Radix complex|Participants randomized to the experimental group will take one capsule of Polygoni Multiflori Radix complex extract (250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
2574831|NCT02401646|Placebo Comparator|Starch|Participants randomized to the placebo group will take one capsule of placebo(250mg) twice a day, 30 minutes after breakfast and dinner for 4 weeks.
2574855|NCT02401269|Experimental|Aspirin|Aspirin 325mg daily
2574857|NCT02401269|Placebo Comparator|Placebo|Placebo
2574929|NCT02400658|Experimental|IORT with CT-Guided HDR Brachytherapy|Patients will receive IORT with CT-guided HDR brachytherapy at the time of breast surgery.
2575003|NCT02400372|Experimental|research group|Medihoney Dressing
2575010|NCT02400372|No Intervention|control group|Paraffin gauze with saline Dressing
2575013|NCT02400372|No Intervention|3. Comparison group|Polymem dressing
2575046|NCT02400021|Experimental|Prometrium|Prometrium (progesterone capsules) intervention
2575051|NCT02400021|No Intervention|No treatment|no treatment arm
2575092|NCT02399514|Other|RePneum coils|Patients who needed lung volume reduction with RePneum coils
2575144|NCT02399293|Experimental|Patient N-back|Patients training the N-back task
2575156|NCT02399293|Active Comparator|Patient Visual Search|Patients training the Visual-Search task
2575162|NCT02399293|Experimental|Non-impaired N-back|Non-impaired training the N-back task
2575165|NCT02399293|Active Comparator|Non-impaired Visual Search|Non-impaired training the Visual-Search task
3175912|NCT00639392|Experimental|1|Patients will receive a single dose of Zoledronic Acid or placebo. The chances that a subject will receive Zolendronic Acid are 2 out of 3.
2575314|NCT02398136|Experimental|Ketamine|Intranasal ketamine up to 75 mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
2575315|NCT02398136|Active Comparator|Midazolam|Intranasal midazolam 3.75mg, delivered over 20 minutes, frequency: 3x/week for 4 weeks.
2575398|NCT02397590|Other|A Group|Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
2575404|NCT02397590|Other|B Group|Fimasartan (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days)
2575407|NCT02397590|Other|C Group|Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
2575408|NCT02397590|Other|D Group|Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan+Atorvastatin (7 days)
2575409|NCT02397590|Other|E Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days) → wash out (7days) → Atorvastatin (7 days)
2575410|NCT02397590|Other|F Group|Fimasartan+Atorvastatin (7 days) → wash out (7days) → Atorvastatin (7 days) → wash out (7days) → Fimasartan (7 days)
2575434|NCT02397005|Active Comparator|ZL-2102|Planned to be administrated in an ascending manner: 5,20,60,150,300,500,750mg
2575442|NCT02397005|Placebo Comparator|Placebo|Placebo matching ZL-2102
2575480|NCT02396784||High risk|One parent has a BMI of greater than or equal to 28, or both parents have a BMI of greater than or equal to 24
2575481|NCT02396784||Normal risk|Both parents have a BMI of smaller than 24
2575515|NCT02396524|Experimental|Hockey FIT program|12-week active phase - exercise and healthy living program (1x/week; 90 minutes/session); 40-week maintenance phase (individualized approach)
2575517|NCT02396524|No Intervention|Usual-care wait-list control|No active intervention (usual care)
3175913|NCT00639405||1|subjects who are diagnosed with parathyroid adenomas. There will be 6 subjects who have not had surgery and 25 subjects who have had surgery.
3175914|NCT00639431|Experimental|1|Direct observation of a sequence of right foot movements performed by the experimenter while visualizing moving the amputated or phantom right foot.
2575654|NCT02395315||Well-controlled diabetic (WC)|well-controlled diabetic controls (HbA1c ≤ 7.0%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
2575655|NCT02395315||Poorly controlled diabetics (PC)|Poorly controlled diabetics (HbA1c >7.5% & <10%), individuals will receive a single 4.1 Titanium-Zirconia, hydrophilic (Roxolid) implant placed in the posterior mandible, a bone core will be taken for histologic and histomorphometric analysis.
3175915|NCT00639431|Experimental|2|Direct observation of a sequence of left foot movements performed by the experimenter while visualizing moving the amputated or phantom left foot.
3175916|NCT00639431|Experimental|3|Direct observation of a sequence of left and right foot movements performed by the experimenter while visualizing moving the amputated or phantom left and right feet.
3175917|NCT00639431|Experimental|4|Mental visualization with closed eyes of a sequence movements performed with the right amputated or phantom foot.
2574728|NCT02402192|Active Comparator|Corifollitropin alfa|Under current practice, 67 participants will be stimulated with a single injection of 100 mg, sc of Corifollitropin alpha (Elonva®). From day 6 stimulation and even prior to induction of ovulation day, 0.25 mg / day was administered sc ganirelix (Orgalutran®). From day 8 stimulation and depending on the ovarian response, you can add recombinant FSH (Puregon) up to 150 IU by Puregon Pen® device. In the presence of 3 or more follicles ≥17 mm, ovulation is induced with a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) if there is no risk of OHSS, and 36 hours later he held the follicular puncture oocyte retrieval.
2574733|NCT02402192|Active Comparator|recombinant FSH|Under current practice, 67 participants will be stimulated with a daily dose of recombinant FSH. Administration of recombinant FSH (Puregon) starts at an initial dose of 150-225 IU / day by the Puregon Pen® device. From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of recombinant FSH according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg or Decapeptyl hCG 6500u (Ovitrelle) is given if there is no risk of OHSS, and 36 hours then held follicular puncture for recovering oocytes.
2574734|NCT02402192|Active Comparator|HP- hMG|Under current practice, 67 participants will be stimulated with HP-hMG, following the same pattern described for the group of recombinant FSH. In this case, the initial dose is 225-300 IU / day of HP-hMG (Menopur®). From day 6 stimulation 0.25 mg / day administered sc ganirelix (Orgalutran®). From this day may also vary the dose of HP-hMG according ovarian response. In the presence of 3 or more follicles ≥17 mm, a single dose of 0.2 mg Decapeptyl 6500u or hCG (Ovitrelle) is given if there is no risk of OHSS and 36 hours then held the follicular puncture for oocyte retrieval .
2574866|NCT02401451|Experimental|ECG acquisition|"ECG acquisition using the standard ECG machine~Intervention: An ECG will be performed on every participant using the novel device called the 'RhythmPadGP'"
2574892|NCT02401061|Experimental|PRTX-100|Patients will be assigned to consecutive PRTX-100 interventions as they are enrolled into the study. Between two and six patients will be enrolled per intervention level. Intervention levels range from one (1) to twenty four (24) micrograms of PRTX-100 per kilogram of patient weight. Patients may receive up to four weekly infusions of PRTX-100 over the study treatment period. PRTX-100 doses ≤ 500 μg will be infused intravenously over 30 minutes. PRTX-100 doses > 500 μg will be infused over 60 minutes. Patients will remain under observation for 4 hours after completion of PRTX-100 dosing for safety management.
2574928|NCT02400684||Deep endometriosis|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with only deep endometriosis without endometriomas.
2574938|NCT02400684||Deep endometriosis and endométriomas|The population is a female population, above 18 years and under 38 years who have stage III or IV endometriosis (which will remain to be confirmed after inclusion by intra-operative observations), and who undergo operative laparoscopy in our center, with deep endometriosis and endometriomas.
3210145|NCT00991796|Experimental|CS-1008|CS-1008 with carboplatin and paclitaxel
2575070|NCT02399774|Experimental|Post-partum primi and multiparous women|"Post-partum primipara and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control"
2575071|NCT02399774|Experimental|Post-partum women that have already begun breast feeding|2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
2575121|NCT02399423|Other|South Asian participants|30 South Asian male participants
2575122|NCT02399423|Other|European participants|30 European male participants
2575181|NCT02398981|No Intervention|Baseline|Baseline data collection ( 20 patients per ICU)
2575185|NCT02398981|Experimental|Checklist|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist 40 patients per ICU
2575250|NCT02398630|Other|Open Label|"This is a single arm open label study.~Its procedures involve:~Transvaginal Echography~Conventional Virtual Histerosalpingography~Virtual Histerosalpingography by MRI~Blood draw for Antimullerian Hormone Dosing"
2575306|NCT02398032|Experimental|CPAP nasal|Nasal continuous positive airway pressure, during the night
2575308|NCT02398032|Sham Comparator|sham CPAP nasal|Nasal sham continuous positive airway pressure, during the night
3210146|NCT00991796|Placebo Comparator|Placebo|Placebo with carboplatin and paclitaxel
3210147|NCT00991822|Active Comparator|1|Patients with open angle glaucoma
3210148|NCT00991822|Active Comparator|2|Patients with open angle glaucoma
2575433|NCT02396979|Experimental|Methadone Maintenance|Methadone induction and management provided
3210149|NCT00991848|Experimental|Lidocaine|Patients received 240 mg lidocaine diluted in 125 mL 0.9% saline. The solutions were infused over a period of 1 h, once a week, for 4 weeks (T1, T2, T3 and T4).
3210150|NCT00991861|Experimental|LAS41007 o.d.|Once daily
3210151|NCT00991861|Experimental|LAS41007 b.i.d.|Twice daily
3210152|NCT00991861|Active Comparator|LAS106521|
3210153|NCT00991900||Healthy subjects|
3210154|NCT00991913||Delirium|Delirium was determined by CAM-ICU
3210155|NCT00991913||no Delirium|no Delirium was determined by CAM-ICU
3210156|NCT00991926||orlistat plus normo-caloric diet|10 subjects received normo-caloric diet plus + orlistat (Xenical, Roche, UK) at a dose of 120 mg tid. The duration of follow-up was 10 days
3210157|NCT00991926||normo-caloric diet|10 subjects received normo-caloric diet without the additional treatment. The duration of follow-up was 10 days
3210158|NCT00991965||INFUSE® Bone Graft|all study participants will receive INFUSE® Bone Graft
3210159|NCT00991978|Experimental|89Zr-bevacizumab PET|89Zr-bevacizumab PET
3210160|NCT00992004|Experimental|Arantal®|Highly bioavailable turmeric extract (food supplement)
3210161|NCT00992004|Placebo Comparator|Placebo|Same capsule without the active ingredients (only excipients)
3210162|NCT00992030|Experimental|ARM A|Rituximab plus ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles
3260251|NCT01477593|Active Comparator|Group III|
2574794|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 25 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 25 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574797|NCT02401815|Experimental|Part 2e: PLX9486 1000 mg QD + Sunitinib 37.5 mg|Participants will receive PLX9486 1000 mg orally QD in combination with sunitinib 37.5 mg orally in 28-day dosing cycles. Treatment will continue until participant discontinuation, withdrawal, or study termination.
2574837|NCT02401334|Experimental|Hernia Repair|Surgical repair for hernia with implantation of the Cook® Antimicrobial Hernia Repair Device.
2574888|NCT02401204||Neonates admitted to QSNICH NICU|All neonates admitted to the QSNICH NICU over a period of one year from March 2015 to March 2016 meeting the inclusion and exclusion criteria will be enrolled in the study. Readmitted neonates will be eligible to be enrolled again into the study.
2574924|NCT02400840|Experimental|Heart graft rejection|Assessment of cardiac allograft recipient with rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
2574925|NCT02400840|Active Comparator|No rejection|Assessment of cardiac allograft recipient without any rejection by Cardiac MRI with gadobenic acid intravenous injection 0.2 ml/kg one time
2575007|NCT02400385|Experimental|Treatment|Sunitinib 50mg/day, 4 weeks on and 2 weeks off, and concurrent nivolumab 3mg/kg iv every 2 weeks, both for three years if tolerated.
2575059|NCT02399956||Survivors|"Participants will be recruited from the St. Jude Lifetime Cohort (SJLIFE protocol) and the After Completion of Therapy (ACT) Clinic at St. Jude Children's Research Hospital.~Intervention: Survey"
2575072|NCT02399566|Experimental|Experimental|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy
2575074|NCT02399566|Active Comparator|Comparator|followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy
2575116|NCT02399397|Active Comparator|Control group|Adult patients(18-50 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
2575118|NCT02399397|Experimental|Sepsis group|Adult patients (18-50 years old) ASAII and III with sepsis, systemic inflammatory response syndrome or septic shock submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
2575120|NCT02399397|Experimental|Elderly group|Elderly patients (> 65 years old) ASA I-II without sepsis submitted to small to medium sized surgery under general anesthesia are being recruited. All patients are being induced with individualized doses of rocuronium, midazolam, propofol and fentanyl. Serial blood sampling are being collected up to 6 h after administration of the drug for pharmacokinetic study. Neuromuscular blockade is being monitored by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF) at the same time as blood sampling. All patients are being submitted to blood testing for liver and renal function (creatinine, urea, albumin, aspartate aminotransferase and alanine aminotransferase).
2575210|NCT02398734|Experimental|Sonolysis|In patients randomized into sonolysis group, middle cerebral artery segment in a depth of 55 mm will be continuously monitored during intervention using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy. The probe will be fixed in a required position using a special helmet and sonolysis will start before the carotid intervention and will be stopped after the intervention, but at latest after 120 minutes. Transcranial Doppler machine with a 2-MHz diagnostic transcranial Doppler probe will be used. This non-diagnostic transcranial Doppler monitoring will be performed without detection of microembolic signals or detection of changes in blood flow. Device sound and Doppler wave imaging will be switched off. Only sonographer will be unblinded to the procedure.
2575211|NCT02398734|Sham Comparator|Shame sonolysis|In patients randomized into control group, the transcranial Doppler probe will be fixed in a required position using a special helmet as in sonolysis group patients, but middle cerebral artery segment in a depth of 55 mm will be only localized using a diagnostic 2-MHz transcranial Doppler probe with a maximal diagnostic energy and the transcranial Doppler monitoring will be stopped afterwards. Patients in the control group will undergo a sham procedure in which further sonolysis (transcranial Doppler monitoring) will not be conducted.
2575247|NCT02398383|Experimental|CF with Normal Glucose Tolerance|Individuals with CF without cystic fibrosis related diabetes
2575253|NCT02398383|Experimental|Cystic Fibrosis Related Diabetes|Individuals with cystic fibrosis and cystic fibrosis related diabetes
2575256|NCT02398383|Active Comparator|Control|Age matched control subjects
2575311|NCT02397980|No Intervention|Control|Basic information about dementia
2575312|NCT02397980|Active Comparator|Behavioral intervention|"Individual, 90 min a day, with an interval of 2 weeks~Education about dementia~psychological counselling~cognitive behavioral therapy"
2575318|NCT02397720|Experimental|Arm I (azacitidine, nivolumab)|Patients receive azacitidine IV over 1 hour or SC on days 1-7 or days 1-4 and 7-9. Patients also receive nivolumab IV over 60 minutes on days 1 and 14 (courses 1-4) or on day 1 (course 5 and all subsequent courses). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2575331|NCT02397720|Experimental|Arm II (azacitidine, nivolumab, ipilimumab)|Patients receive azacitidine and nivolumab as Arm I. Patients also receive ipilimumab IV over 90 minutes on day 1 and then every 6 or 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
2575400|NCT02397356|Experimental|Ketamine first AB|Patients in this group will first receive a dose of ketamine in the nebulised form when they ask for pain relief. The second time they ask for pain relief, they will receive physiological salt in the nebulised form.
2574870|NCT02401243|Experimental|Cohort 2 (EDITION titration algorithm)|INSULIN GLARGINE (U300): titration of insulin glargine 300 units/mL (U300) will be adjusted weekly or not more than every 3 days to achieve the target range of fasting SMPG of 4.4 to 5.6 mmol/L
2574922|NCT02400879|Active Comparator|Remifentanil|For anesthesia maintenance, TCI-remifentanil (fixed Cp of 20 ng/ml) and TCI-propofol (variable Ce < 2.0 µg/ml) for maintaining BIS 40-60
2574923|NCT02400879|Placebo Comparator|sevoflurane and sufentanil|TCI-sufentnail (Cp of 0.4-0.8 ng/ml) and sevoflurane (< 1.5 MAC) for maintaining 80-120 % of preoperative value and BIS < 60
2574957|NCT02400554|No Intervention|Wait List Control|Participants wait one year before receiving the intervention. Three assessments are taken over this period: Month 3, Month 9, and Month 12.
2574966|NCT02400554|Experimental|Yappalli|Yappalli: Participants attend a 12-month behavioral intervention.
2575009|NCT02400281|Experimental|Arm 1 crenolanib besylate combination|Arm 1 patients will receive crenolanib besylate, combined with standard chemotherapy (Idarubicin/Cytarabine, MEC;Mitoxantrone/Etoposide/Cytarabine, FLAG-Ida: Fludarabine/Cytarabine/G-CSF/Idarubicin
2575012|NCT02400281|Experimental|Arm 2 crenolanib besylate combination|Arm 2 patients will receive crenolanib besylate and azacytidine.
2575061|NCT02399787||infertile patients|Infertile patients with more than 5 oocytes retrieved and no endometriosis
2575096|NCT02399605|No Intervention|Control|No intervention, group control.
2575097|NCT02399605|Experimental|Stimulation|Subcutaneous Electrical Intervention
2575137|NCT02399189|Experimental|R-MT followed by auto-HSCT|"R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles~Auto-HSCT conditioning regimen:~BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3"
2575222|NCT02398799|No Intervention|control|The dyads in the control group received care as usual including traditional care in hospital and outpatient education and support. The care is mainly focused on the patient's needs. The partner is not systematically involved in the follow-up focusing on education and psychosocial support.
2575228|NCT02398799|Experimental|Psycho edcuactional support|The intervention psychoeducational support to the patient-partner dyads was delivered in 3 sessions through nurse-led face-to-face counseling, a computer-based CD-ROM program and other written teaching materials. All sessions lasted at least 60 minutes and were conducted in the dyads' homes or in the heart failure clinic. The first session 2 weeks after discharge and the two remaining sessions 6- and 12-weeks following discharge. Each session included education on heart failure and development of problem- solving skills to assist the dyads in recognizing and modifying factors that contribute to psychological and emotional distress. The intervention focused on changing thoughts and behaviors and implementing strategies for self-care.
2575283|NCT02398318|Active Comparator|Bilateral Nucleus Accumbens DBS|6 month period of active bilateral nucleus accumbens DBS
2575288|NCT02398318|Sham Comparator|Sham Bilateral Nucleus Accumbens DBS|6 month period of sham bilateral nucleus accumbens DBS
3210163|NCT00992030|Active Comparator|ARM B|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 4 cycles followed by involved field irradiation
3210164|NCT00992043|Placebo Comparator|exercise and placebo|
3210165|NCT00992043|Experimental|exercise and creatine|
3210166|NCT00992069|Experimental|TMC207 alone and with EFV|Participants will receive single-dose TMC207 alone and then single-dose TMC207 with EFV.
3210167|NCT00992082|Active Comparator|Group LIA|Local Infiltration Analgesia
3210168|NCT00992082|Active Comparator|Group M|Intrathecal morphine
2575565|NCT02396394|Experimental|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
2575597|NCT02395939|Active Comparator|CT guided core biopsy|In patients allocated to this arm a CT guided core biopsy will be performed
2575598|NCT02395939|Active Comparator|Cryo-biopsy via Radial EBUS navigation|"If the patient is randomised to this arm, the lesion will be located via R-EBUS.~Each patient will have 3 cryo biopsies and 3 forceps biopsies. The order of the cryo biopsy and forcep biopsy will be randomly allocated at the time of initial randomisation."
3210169|NCT00992121|Other|Part I and 2 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week intervals Part II - pazopanib dosing 2 weeks in 3-week cycles
2575701|NCT02394847|Other|propofol|dose of propofol according to the number of therapies
2575774|NCT02394782||Relapsing-remitting Multiple Sclerosis|
2575853|NCT02394379||Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
2575927|NCT02393963|Experimental|Tranexamic Acid|Intra-articular administration of low dose Tranexamic acid
2575935|NCT02393963|Placebo Comparator|Placebo|Sodium Chloride
2575967|NCT02393482|Active Comparator|Balanced estroprogestins|Women assigned to this arm will assume balanced monophasic estroprogestins (etinil-estradiol 100 mcg/levonorgestrel 20 mcg), one tablet orally daily, for 180 days.
2575974|NCT02393482|Active Comparator|GnRHa|Women assigned to this arm will assume Leuprorelin acetate (3,75 mg/2ml), one intramuscular administration every 28 days. After 45 days of treatment, therapy will be implemented with Tibolone 5 mg, one tablet daily orally, and Calcium carbonate/colecalciferol (500 mg/400 UI), one tablet daily orally. This therapy will be prosecuted for the remaining 135 days of treatment.
2576061|NCT02393014|Experimental|Low fall risk|low fall risk patients
2576068|NCT02393014|Experimental|Medium fall risk|medium fall risk patients
2576072|NCT02393014|Experimental|High fall risk|high fall risk patients
3210170|NCT00992121|Other|Part I and 3 week dosing Part II|Part I - bevacizumab 3 infusions at 2 week interval, Part II - pazopanib dosing 3 weeks in 3-week cycles
3210171|NCT00992147|Experimental|autologous cultured adipocytes|
3210172|NCT00992160|Experimental|Active|Vestipitant 15mg once daily
3210173|NCT00992160|Placebo Comparator|Placebo|Placebo
3210174|NCT00992173|Experimental|Ultratrace Iobenguane I 131|
2574919|NCT02400892||PFO|Subjects with a bedside Transthoracic Echocardiogram (TTE) bubble study positive for a PFO
2574921|NCT02400892||Control|Subjects with a bedside TTE bubble study negative for a PFO
2574954|NCT02400619|Active Comparator|shock waves|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS. The other group will receive botulinum toxin Type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected, Botox (4-8-12 U/Kg) Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
2574962|NCT02400619|Active Comparator|botulinum toxin|A comparative study with patients with spasticity in gastrocnemius and soleus where a group start having shockwave treatment and receive three sessions at weekly intervals, gastrocnemius and soleus applied in 2000 impacts at a frequency of 8hz and energy intensity is proposed between 2.2-2.4 Bars (0,10-0,12mj ). Swiss dolor clast EMS.The other group will receive botulinum toxin type A in the same muscles. The dose of toxin is in accordance with the weight of each patient, the dose normally used with each user and always with the same brand is always respected. Botox (4-8-12 U/Kg)Patients will be assessed before treatment, after three weeks, two months and three months after three months when the groups exchange the therapy.
2574980|NCT02400242|Experimental|ACY-241, Pomalidomide, and dexamethasone|Open label dosing cohorts will evaluate oral ACY-241 (dosing ranging from 180 mg to 480 mg days 1-21) in combination with oral pomalidomide (4 mg days 1-21), and oral dexamethasone (40 mg qd on days 1, 8, 15, 22).
2575143|NCT02399215|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2575227|NCT02398695||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
2575230|NCT02398695||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
2575302|NCT02398266|Experimental|Healthy subjects|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Normal healthy subjects (n=10) will be used for optimization of dose and acoustic settings for performing real-time contrast ultrasound perfusion imaging of the limb.
2575303|NCT02398266|Experimental|Patients with PAD and ABI 0.4-0.6|Intervention: administration of ultrasound contrast agent (drug) to assess muscle perfusion. Patients with moderate to severe PAD (ABI 0.4 to 0.6) will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm to determine whether symptoms better correlate with perfusion imaging than other measures of PAD severity.
2575305|NCT02398266|Experimental|Patients with PAD Undergoing Revascularization|Intervention: administration of ultrasound contrast agent (drug) to assess change in muscle perfusion produced by revascularization (surgical or percutaneous procedure). Patients with symptomatic PAD will be evaluated with contrast ultrasound perfusion imaging using methods optimized in the first Arm before and within 1 month of revascularization to determine whether improvement in symptoms correlate with perfusion imaging data.
2575323|NCT02397733|Active Comparator|Prophylactic cranial irradiation (PCI)|Radiation. Prophylactic cranial irradiation : 25 Gy in 10 daily fractions, five times a week
2575328|NCT02397733|Experimental|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation. 25 Gy in 10 daily fractions, five times a week
2575399|NCT02397577|Other|gastric emptying measurements|
2575431|NCT02397187|Experimental|LOOP intervention|"Patients enrolled in this arm will be treated by the LOOP interventional technique.~The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
2575439|NCT02397187|Active Comparator|TAU|Patients enrolled in this arm will be TAU, which is based upon short-term supportive PT.
3210175|NCT00992199|No Intervention|control arm|adjuvant intravenous system chemotherapy
3210176|NCT00992199|Experimental|IP Chemo arm|adjuvant system intravenous chemotherapy combined with adjuvant intraperitoneal chemotherapy
2575571|NCT02396069|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 for 60 min. (6 volunteers per each cohort, total 3 cohort)
2575575|NCT02396069|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo for 60 min. (2 volunteers per each cohort, total 3 cohort)
2575615|NCT02395796|Experimental|Epidural Pressure Waveform|"Study Population:~Term pregnancy~in labour~18 years of age or older."
2575663|NCT02395484||constipation|collect stool samples from constipation patients
2575672|NCT02395484||healthy controls|collect stool samples from healthy controls patients
3210177|NCT00992212|Experimental|Group A (Seasonal TIV + 7.5mcg HA+ full dose MF59)|
3210178|NCT00992212|Experimental|Group B (Ajuvanted Seasonal TIV + 7.5mcg HA+ full dose MF59)|
3210179|NCT00992212|Experimental|Group C (7.5mcg HA+ full dose MF59)|
3210180|NCT00992212|Experimental|Group D (7.5mcg HA+ full dose MF59 + Seasonal TIV)|
2575856|NCT02394145|Experimental|Ticagrelor 180mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
3210181|NCT00992212|Experimental|Group E (3.75mcg HA+ ½ dose MF59+ Seasonal TIV)|
2576184|NCT02392026|Experimental|Metronidazole Gel|Metronidazole Vaginal Gel
3210182|NCT00992238|Experimental|Flavoxate Hydrochloride Tablets, 100mg|
3210183|NCT00992238|Active Comparator|Urispas® Tablets, 100mg|
3210184|NCT00992277|Experimental|Facial|Skin rejuvenation treatments
3210185|NCT00992290|Experimental|Lactobacillus GG|
3210186|NCT00992290|Placebo Comparator|Placebo|
3210187|NCT00992316||Pf-04531083|To Investigate The Safety, Toleration And Pharmacokinetics Of Single Oral Doses Of PF-04531083 In Healthy Male Subjects
2574902|NCT02401217|Active Comparator|Phase 2- Arm 2 Infant Formula|Milk-based infant formula using current manufacturing and ingredients. Non-commercially available formula. To be fed ad libitum.
2574904|NCT02401217|Experimental|Phase 2- Arm 3 Infant Formula|Milk-based infant formula using a new protein. Non-commercially available formula. To be fed ad libitum.
2574990|NCT02400151|Other|Non-Obese group|"Non-obese patients will be recruited and frequency matched to obese groups according to sex and level of sexual maturation.~Intervention: Normal control"
2574999|NCT02400151|Experimental|Obese group, Vitamin D|"Subjects randomized to this group will receive vitamin D supplementation. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Vitamin D supplementation"
2575005|NCT02400151|Placebo Comparator|Obese group, placebo|"Subjects randomized to this group will receive a placebo supplement. They are recruited from the St Pierre Institute at Palavas-les-Flots, France.~Intervention: 3 months lifestyle and dietary management Intervention: Placebo"
3175918|NCT00639431|Experimental|5|Mental visualization with closed eyes of a sequence movements performed with the left amputated or phantom foot.
2575224|NCT02398877|Experimental|Depression with early trauma|stress
2575231|NCT02398877|Experimental|Depression without early trauma|stress
2575233|NCT02398877|Experimental|Healthy with early trauma|stress
2575235|NCT02398877|Experimental|Healthy without early trauma|stress
3175919|NCT00639431|Experimental|6|Mental visualization with closed eyes of a sequence movements performed with the left and right amputated or phantom feet.
3175920|NCT00639444|Active Comparator|Gluten free diet|the intervention in this group is keeping a gluten-free diet from 0 to 12 months
3175921|NCT00639444|No Intervention|Gluten containing diet|infants in this group are started on gluten-containing cereals at 6 months (control group)
2575317|NCT02397928|Experimental|TTFields concomitant to pemetrexed plus cisplatin/carboplatin|Patients will be treated continuously with TTFields, in addition to pemetrexed plus cisplatin/carboplatin
2575516|NCT02396771|Experimental|Massage|Women allocated to the uterine massage group will be provided with 2 minutes of trans-abdominal uterine massage starting promptly after placental delivery.
2575518|NCT02396771|Experimental|Compression|Women allocated to the uterine compression group will be provided with 2 minutes of sustained trans-abdominal uterine compression starting promptly after placental delivery.
2575569|NCT02396238|Experimental|Adipose Derived Regenerative Cells|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs administered in 2 injections per digit on both hands.
2575570|NCT02396238|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution mixed with small amount of study subject's own freshly drawn blood and administered in 2 injections per digit on both hands.
2575619|NCT02395744|Experimental|OPC Treatment|Paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC. Subjects will be treated with the endovascular intervention selected by the treating physician in reference vessels ranging from 2mm to 4mm in diameter. Following the achievement of optimal interventional results (≤ 30 percent residual stenosis without stenting and without flow-limiting dissection) the OPC will be placed at the interventional treatment area and paclitaxel will be delivered to the treated segment.
2575671|NCT02395445|Active Comparator|Totaltrack|Indirect laryngoscopy
2575675|NCT02395445|Active Comparator|Macintosh Laryngoscope|Direct laryngoscopy
2575870|NCT02394171|Experimental|Physical Activity|Women completed a physical activity group cohesion intervention which included six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase physical activity. A small team structure was used for peer problem solving and support throughout the intervention. Teams were given weekly physical activity goals, with slowly increasing weekly minutes milestones to gradually meet recommended amounts of physical activity. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a brisk 15-minute walk.
3175922|NCT00639483|Experimental|A|
3175923|NCT00639483|Placebo Comparator|B|
3175924|NCT00639496|Experimental|1|patients taking NAC 600 mg t.i.d.
3175925|NCT00639496|Placebo Comparator|2|
3175926|NCT00639522|Experimental|A|
3175927|NCT00639561|Experimental|A|diet composed of 10g of fibre per day
3175928|NCT00639561|Experimental|B|diet composed of 40g of fibre per day
3175929|NCT00639613||1|Patients with type 2 diabetes
3175930|NCT00639613||2|Healthy subjects
3175931|NCT00639639|Experimental|Arm I (first randomization)|Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
3175932|NCT00639639|Experimental|Arm II (first randomization)|Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
3175933|NCT00639639|Experimental|Arm I (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
3175934|NCT00639639|Experimental|Arm II (second randomization)|Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.
3175935|NCT00639652||1. 3D-histology|Nodular, micronodular, or sclerosing BCCs
3175936|NCT00639652||2. Shave excision|Superficial BCCs
3175937|NCT00639691|Experimental|1|
3175938|NCT00639730|Experimental|A|This is open-label - all patients are placed on the diet. There is no control or placebo arm.
3175939|NCT00639743|Experimental|group A|tenecteplase (group A)
3175940|NCT00639743|Placebo Comparator|group B|placebo ( group B)
3175941|NCT00639756|Other|1|Placebo
3175942|NCT00639756|Active Comparator|2|Allopurinol given for 2 weeks with diet
3175943|NCT00639782|Active Comparator|ONX|On-X heart Valve Replacement
2574910|NCT02400918|Experimental|Workbook|They will be directed to use the 8-week plan included in The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013), an ACT-based self-help book and to access mindfulness audio files located on the publisher's website (as described in the book).
2574911|NCT02400918|No Intervention|Control|Waitlist control
2574946|NCT02400671|Experimental|Two-way SMS|Participants will receive weekly push SMS messaging with a questions and have the ability to text back to the study nurse
2574948|NCT02400671|Experimental|One-Way SMS|Participants will receive weekly push SMS messaging
2574949|NCT02400671|No Intervention|Control|Participants will receive standard of care (no intervention)
3210188|NCT00992329|Experimental|ciprofloxacin tab1|formulation 1
3210189|NCT00992329|Experimental|ciprofloxacin tab2|formulation 2
3210190|NCT00992329|Experimental|ciprofloxacin tab 3|formulation 3
3210191|NCT00992329|Active Comparator|ciprofloxacin reference|reference product
2575152|NCT02399319|Experimental|Randomized to Internal Fixator|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal fixator.
2575159|NCT02399319|Experimental|Randomized to Symphyseal Plate|Patient signed consent and agreed to have their treatment method randomized and the randomization system determined that their surgical intervention would be internal plating of the symphysis.
2575161|NCT02399319|Active Comparator|Observational - Internal Fixator|Patient signed consent but did not want to randomize their procedure and the treating physician selected the internal fixator intervention based on their opinion of how best to treat the specific case.
2575163|NCT02399319|Active Comparator|Observational - Symphyseal Plate|Patient signed consent but did not want to randomize their procedure and the treating physician selected internal plating of the symphysis based on their opinion of how best to treat the specific case.
2575194|NCT02398760|Experimental|Motor Control Exercises|(Costa LOP et al. 2009; Hodges PW et al. 2009)
2575278|NCT02398474|Experimental|iliac crest bone graft with a TFP block|Regional anesthesia (RA) for the upper or lower limb depending on the surgery + general anesthesia (GA) + TFP block
2575279|NCT02398474|Active Comparator|local anesthetic infiltration of the surgical site.|RA for the upper or lower limb depending on the surgery + GA + ropivacaine infiltration of the iliac crest bone
3210192|NCT00992342|Experimental|PF-03893787 5 mg|
2575392|NCT02397317|Experimental|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
2575437|NCT02397083|Experimental|Arm I (LIUD)|Patients continue treatment with the LIUD for up to 9 months in the absence of disease progression or unacceptable toxicity.
2575446|NCT02397083|Experimental|Arm II (LIUD, everolimus)|Patients continue treatment with the LIUD and receive everolimus PO QD on days 1-28. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.
3210193|NCT00992342|Experimental|PF-03893787 15 mg|
3210194|NCT00992342|Experimental|PF-03893787 50 mg|
2575579|NCT02396082|Experimental|MIND-S Intervention|Participants (persons with dementia (PWD) and their family caregiver (CG)) in this group will receive up to 18 months of the MIND-S dementia care coordination intervention by an interdisciplinary team comprised of trained memory care coordinators (non-clinical), a psychiatric nurse, and geriatric psychiatrist. The intervention involves 4 key components: identification of needs and individualized care planning (PWD and CG needs); dementia education and skill building; coordination, referral and linkage of services; and care monitoring.
2575582|NCT02396082|Other|Augmented Usual Care|Participants (persons with dementia (PWD) and their family caregiver (CG)) and their primary care physicians in this group will receive an initial in-home needs assessment and then a written report indicating any unmet care needs identified and potential recommendations of care for meeting those needs. They will be able to pursue any interventions or treatments they or their treating physicians deem appropriate. They will also receive a standardized Aging and Caregiver Resource Guide developed in the previous MIND trial. The study team will perform another in-home needs assessment at 18 months and the written report along with recommendations for care will be provided to the family and the PWD's primary care physician.
2575601|NCT02395783|Active Comparator|Melatonin dose1|Melatonin 10 µg
2575603|NCT02395783|Active Comparator|Melatonin dose2|Melatonin 20 µg
2575604|NCT02395783|Placebo Comparator|Placebo|Placebo
2575687|NCT02395497|Experimental|Treatment: Transplantation|Penile transplantation with an immunomodulatory protocol consisting of monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.
3210195|NCT00992355|Active Comparator|Tobramycin 0.3% - Dexamethasone 0.1%|
3210196|NCT00992355|Active Comparator|Tobramycin-Dexamethasone plus Ketorolac tromethamine|
2575851|NCT02394262|Experimental|Serial CCTA and atherothrombosis markers|Sequential coronary CT-angiography and assesment of biomarkers involved in atherothrombosis after 1 year follow-up.
2575984|NCT02393391|Active Comparator|NIBS tDCS/tACS stimulation|Each patient will undergo initial diagnosis with NIBS algorithm utilizing EEG measurements combined with TMS. Initial diagnosis will last 10 minutes in which EEG measurement will be recorded 5 minutes and then in combination with TMS for another 5 minutes with no more than 500 TMS stimuli applied to cortex at low frequency of up to 5Hz. EEG recording will be analyzed by NIBS algorithm which will propose a course of treatment with the following limitations: stimulation of 2mA (32, 33) current after 30 seconds ramp up of 0.1mA increments, 20 min for each session, twice a week
3210197|NCT00992368|Active Comparator|reduction mammaplasty|submitted to surgery
3210198|NCT00992368|No Intervention|not reduction mammaplasty|not submitted to surgery
3210199|NCT00992381|Experimental|1|PN400
3210200|NCT00992381|Active Comparator|2|Naproxen
3210201|NCT00992420||GRAVITAS Study Arm A|"Tailored clopidogrel regimen - total first day dose 600-mg, then 150-mg every day for 6 months"
3260252|NCT01477606|Experimental|Midostaurin|
3260253|NCT01477619|Experimental|Smokers|Split into BMI categories
2574944|NCT02400697||30 wks to <34 wks gestation|Preterm infants born at participating hospitals
2574984|NCT02400411|Experimental|Wheat bread|Bread-based meal
2574996|NCT02400411|Experimental|Wheat bread with margarine and ham|Bread-based meal
2575002|NCT02400411|Experimental|Wheat bread with margarine, ham and soup|Bread-based meal
2575008|NCT02400411|Experimental|Rye bread|Bread-based meal
2575014|NCT02400411|Experimental|Rye bread with margarine and ham|Bread-based meal
2575019|NCT02400411|Experimental|Rye bread with margarine, ham and soup|Bread-based meal
2575044|NCT02399813|Experimental|ADXS11-001|
2575085|NCT02399592|Experimental|Bevacizumab and Tocotrienol|
2575146|NCT02399306|Experimental|Arm A|chemoradiotherapy with Enteral Nutrition intervention
2575160|NCT02399306|Placebo Comparator|Arm B|chemoradiotherapy
2575193|NCT02398812|Active Comparator|Active comparator|In addition to usual care, participants allocated to intervention group will receive medication assessment and treatment plan based on it
2575205|NCT02398812|No Intervention|Usual care|Usual care (reference group).
2575393|NCT02397486|Experimental|Intervention Group|"Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .~Pentoxifylline 400 mg oral tablets twice daily for 7 weeks. Vitamin E 1000 mg oral capsules once daily for 7 weeks."
2575402|NCT02397486|Active Comparator|Control Group|Platinum based concurrent chemoradiotherapy [cisplatin (100mg/m2) on day 1, 22 and 43 of Radiotherapy (at 2 Gy/ fraction to a dose of 70 Gy over 7 weeks] .
2575436|NCT02397031|Experimental|Mindfulness|As proposed in dialectical behavioral therapy, mindfulness training consist of a set of behavioral skills that aim at improving patient's attentional control and emotional regulation.
2575443|NCT02397031|Active Comparator|Interpersonal effectiveness|Interpersonal effectiveness skills are focused on improving interpersonal relationships and enhancing patient's ability to display social effective behavior.
2575506|NCT02396823|Experimental|Respiratory Muscle Training|Each training session will last about 45-60 min and will occur five times weekly during one month. During the RMT sessions, the patient will remain in their personal wheelchair. They will be asked to breath through a special device with regulated resistance to breathing air. In the 20 sessions starting from the lowest resistance, the goal will be to train the muscles they use to breathe by slowly increasing this resistance. They will perform six work sets, 5 minutes in duration, separated by rest intervals lasting 1-3 minutes.
2575514|NCT02396823|No Intervention|Control|Following screening process and recruiting, subjects from both Healthy Control and SCI Control groups will undergo the same procedures as subjects from SCI group excluding the training intervention.
2575555|NCT02396264|Experimental|Mediterranean Diet|The diet programme will be characterized by carbohydrates (60 %); proteins (20 %, half comprised of vegetable proteins); total fat (20 %; saturated fat < 10 %). After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
2575560|NCT02396264|Active Comparator|normocaloric diet|50% carbohydrates, 30% total lipids and 20% proteins. After calculating the patient's energy need, the amount of calories will be successively adjusted to mantain the same weight of the time of recruitment
2575609|NCT02395848|Experimental|Fidaxomicin|30-day Fidaxomicin ( 200mg twice daily x 10 days and 200mg once daily x 20 days.
3175944|NCT00639782|Active Comparator|SJM|SJM heart valve replacement
3175945|NCT00639795|Active Comparator|A|Patients randomized to receive thoracic paravertebral nerve blockade in addition to general endotracheal anesthesia during video assisted thoracoscopy procedure
2575910|NCT02393729|Other|children with DCD|Children with Developmental Coordination Disorder (DCD) will have neuropsychological assessment and MRI study
2575913|NCT02393729|Other|children with DD|Children with Developmental Dyslexia (DD) will have neuropsychological assessment and MRI study
2575920|NCT02393729|Other|children with DCD + DD|Neuropsychological assessment and MRI study
2575925|NCT02393729|Other|control children|Neuropsychological assessment and MRI study
2575982|NCT02393456|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
2575992|NCT02393456|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
2576050|NCT02393053|Sham Comparator|subepithelial connective tissue graft|Surgery: Treatment with subepithelial connective tissue graft for gingival recession
2576055|NCT02393053|Experimental|non-pedicled buccal fat pad graft|Surgery: Treatment with non-pedicled buccal fat pad graft for gingival recession
2576285|NCT02391532|Active Comparator|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA lozenges twice daily for 12 weeks
2576290|NCT02391532|Placebo Comparator|Placebo|Placebo lozenges twice daily for 12 weeks
3175946|NCT00639795|Sham Comparator|B|Patients randomized to receive sham single-injection thoracic peripheral nerve blockade (no injection) in addition to general endotracheal anesthesia
3175947|NCT00639808|Placebo Comparator|1|
3175948|NCT00639808|Experimental|2|TZP-101
3175949|NCT00639821||inflammatory bowel disease|Patients with refractory inflammatory bowel disease (ulcerative colitis and Crohn's disease) before and after treatment with infliximab.
3175950|NCT00639834|Experimental|1|Active MDX-1342 given in combination with Methotrexate
3175951|NCT00639847|No Intervention|group 1|this is the standard of care control group. The control group will be instructed to return to their regular physicians for routine follow up at a time to be specified by the physician.
3175952|NCT00639847|Active Comparator|Group 2|Group 2 will receive routine home visits from nurses provided by a home health care agency.
3175953|NCT00639847|Active Comparator|Group 3|In-home asthma management program (AMP) provided by respiratory therapists. The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
3210202|NCT00992420||GRAVITAS Study Arm B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets) and then clopidogrel 75-mg and 1 placebo tablet every day for 6 months."
2575049|NCT02399865|Experimental|YSBNT Group|Six 50 minute YSBNT sessions (delivered by a trained YSBNT practitioner) for over a maximum period of 12 weeks
2575054|NCT02399865|No Intervention|Treatment as Usual Group|Usual care delivered by treatment-as-usual practitioners
2575090|NCT02399657|Experimental|Intravitreal dexamethasone implant|Intravitreal dexamethasone 0.7mg implant (Ozurdex)
2575136|NCT02399137|Experimental|Arm A (Experimental Arm)|MM-141 in combination with nab-paclitaxel and gemcitabine
2575150|NCT02399137|Active Comparator|Arm B (Comparator Arm)|Placebo in combination with nab-paclitaxel and gemcitabine
2575158|NCT02399137|No Intervention|Observational Group|
2575225|NCT02398565||Cohort|"Patients with a history of ventral hernia repair (umbilical/epigastric and incisional) with subsequent pregnancy~Ventral hernia repair - perioperative factors of interest:~- mesh vs sutured repair, age, planned vs emergency repair, open vs laparoscopic approach,~Pregnancy and delivery - factors of interest:~- vaginal vs caesearan section, single vs multiple pregnancy~Subgroup of patients with mesh repair:~- subanalysis on main attributes~Subgroup of patients with sutured repair:~- mono- vs multifilament, slowly vs rapidly absorbable"
2575274|NCT02398305|Active Comparator|TR Band accelerated|Diminishing air pressure in the TR Band using accelerated protocol
2575276|NCT02398305|Other|TR band standard|Diminishing air pressure in the TR band according to standard care
2575342|NCT02398006|Active Comparator|Group 1: a standard arm sling|Group 1: the orthopaedic surgeon will apply a standard arm sling that will be used for four weeks; however, during these weeks, participants will be encouraged to discard the sling when their pain has subsided. After four weeks the same orientations of group 1 will be done to this group.
2575351|NCT02398006|Active Comparator|Group 2: a figure-of-eight bandage|Group 2: a figure-of-eight bandage will be used for four weeks, and every week the participants will return to check and adjust the immobilisation. In this way, the dominant hand can remain free and simple activities will be allowed (writing, keyboarding and other). After four weeks, participants will be encouraged to discard the bandage, but load bearing will not be allowed before osseous consolidation (around 10 weeks).
3210203|NCT00992420||GRAVITAS Study Arm C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets) and then the standard clopidogrel regimen of 75-mg and 1 placebo tablet every day for 6 months.
3210204|NCT00992472|Experimental|Prochlorperazine suppositories, 25mg|
2575468|NCT02396901|Experimental|GDT group|Patients randomized to the GDT Group will care from a protective strategy with the suspension of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 48 hours before surgery and receive hydration with lactated Ringer's solution at the rate of 1 mL/kg/h in the night before the surgery until the surgical procedure and perioperative hemodynamic therapy.
2575473|NCT02396901|Placebo Comparator|Control group|Patients randomized to the control group will be treated in accordance with the care in the institution's routine.
2575491|NCT02396641|Experimental|Single Study Arm|This study arm consists of providers who will identify their baseline in Best Supportive Care, then have the intervention of using a Best Supportive Care checklist.
2575563|NCT02396433|Experimental|Carboplatin, eribulin, and E7449|This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449.
2575635|NCT02395835||Normal weight (NW) pregnant women|"Pregnant women with Body Mass Index (BMI) > = 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
2575639|NCT02395835||Overweight (OW) pregnant women|"Pregnant women with Body Mass Index (BMI) < 30. Body weight and height were measured in an overnight fasting status using an adult scale (Seca, Hamburg, Germany). Prepregnancy BMI was calculated as weight in kg divided by height in meters squared based on the prenatal chart or on the self-reported weight of women with no prenatal chart.~Dietetic treatment was calculated according to height, weeks of gestation, and weight, considering an energy intake of 30 kcal/kg of ideal weight and a macronutrient distribution of: 55-65% carbohydrates, 10-20% fat, and the remainder as proteins."
2575662|NCT02395380|Experimental|C-reactive protein dosage|
2575740|NCT02395159|Experimental|Prevena™ IMS|The patients in the experimental arm will be treated with the Prevena™ IMS seven days after the surgery
2575745|NCT02395159|Other|sterile plaster dressings|The wound will be treated with the conventional wound management method of sterile plaster dressing.
3210205|NCT00992472|Active Comparator|Compazine® suppositories, 25mg|
3210206|NCT00992485|Experimental|autologous adipose derived stem cell|
2575852|NCT02394288||Adults without cardiac disease|Extremity orthopedic or trauma surgery
2575924|NCT02393976|Other|CONTROL|STANDARD NUTRITION
2575929|NCT02393976|Experimental|IMMUNONUTRITION|INMUNONUTRITION
3210207|NCT00992524|Active Comparator|Oral Titrated Misoprostol Solution|
2576078|NCT02392728|Experimental|Intervention VE|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
3210208|NCT00992524|Active Comparator|Vaginal Misoprostol|
3210209|NCT00992537|Experimental|IDeg|
3210210|NCT00992537|Experimental|IDegAsp|
3210211|NCT00992537|Active Comparator|IAsp|
3210212|NCT00992550|Experimental|Hookah visit, then cigarette visit|4-day inpatient stays for profile of biomarker excretion
3210213|NCT00992550|Experimental|Cigarette visit, then Hookah visit|4-day inpatient stay for profile of biomarker excretion
3210214|NCT00992563|Experimental|AL-39324 Concentration Level A|AL-39324 ophthalmic suspension, single intravitreal injection
3210215|NCT00992563|Experimental|AL-39324 Concentration Level B|AL-39324 ophthalmic suspension, single intravitreal injection
3210216|NCT00992563|Experimental|AL-39324 Concentration Level C|AL-39324 ophthalmic suspension, single intravitreal injection
3210217|NCT00992563|Experimental|AL-39324 Concentration Level D|AL-39324 ophthalmic suspension, single intravitreal injection
2574977|NCT02400177|Experimental|Emotion regulation training|This is a 4 sessions group workshop and 1 session individual pre-screening about parental emotion regulation and emotion co-regulation. In this study the facilitators will give information about efficient strategies to regulate parent emotions and their children's emotions.
2574978|NCT02400177|No Intervention|Control group|"In this condition we will take all the measurement before and after the waiting list period.~This group will go through the workshop after the measurements will be taken."
2575045|NCT02400099|Active Comparator|High-protein low calorie diet (HPLC)|900 Kcal; Protein 90 g (39%); CHO 75 g (30%); Lipid 32 g (31%)
2575050|NCT02400099|Placebo Comparator|Control low calorie diet (CLC)|900 Kcal; Protein. 50 g (22%); CHO 119 g (48%); Lipid 31 g (30%)
2575149|NCT02399202|Experimental|osilodrostat ( LCI699)|Each participant will undergo a 28 day screening /baseline period (day-28 to Day -1), followed by a 4 day treatment period ( a single 30 mg dose of LCI699 (Day 1) with 4 days of PK smple collection
2575202|NCT02398929|Other|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily following run-in placebo for 2 weeks
3210218|NCT00992563|Experimental|AL-39324 Concentration Level E|AL-39324 ophthalmic suspension, single intravitreal injection
2575327|NCT02398162||STP|Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
2575332|NCT02398162||STE|Scrub Typhus Exposed (STE, n=80) Cohort. Single blood sample collection.
2575335|NCT02398162||STH|Scrub Typhus Healthy (STH, n=30) Cohort. Single blood sample collection
2575385|NCT02397551|Active Comparator|Small doses of HCG|Supplementing the luteal phase with three small doses (500 IU) of HCG after trigger with GnRH agonist in antagonist IVF/ICSI cycles in high responders
2575388|NCT02397551|Active Comparator|Booster HCG dose|Booster HCG dose GnRH agonist only to trigger final maturation followed by a booster dose of 1500 IU of HCG on the day of ovum pickup
2575484|NCT02396875|Experimental|Group 1|40 patients undergoing CRT will have venous samples taken from two CS tributaries, peripheral venous and peripheral arterial sites at the time of CRT insertion at the time of device implant. Blood samples will be analysed for metabolites and novel biomarkers They will then undergo repeat sampling at 6 months to assess for changes in the biomarker profile including CS sampling.
2575485|NCT02396875|Active Comparator|Group 2|A control arm of 15 patients with heart failure and no dyssynchrony will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
2575486|NCT02396875|Active Comparator|Group 3|A control arm of 15 patients with normal hearts will undergo peripheral venous sampling for novel biomarkers and this will be repeated at 6 months. These samples will allow for control against the dyssynchronous heart failure group and also for temporal changes in biomarker expression.
2575487|NCT02396875|Experimental|Group A|"10 patients from Group 1~On the day preceding the CRT implant will attend hospital for a temporary invasive catheter study. The patient will have a radial sheath positioned in the arterial system. A pacing protocol will be performed using a pacing wire inserted into the right atrium. Coronary sinus venous blood sampling will be performed using a catheter placed via the femoral or internal jugular vein. At the chief investigator's discretion a specially designed exercise bicycle that allow supine exercise in the catheter lab will be used rather than the atrial pacing wire.~6 months post implant the patients will return to the catheter laboratory for a further study. This will repeat the protocol but with the device having been on for 6 months. This will require further study as described above."
2575488|NCT02396875|Active Comparator|Group B|"5 patients form Group 2.~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 2 for 6 month follow up"
2575489|NCT02396875|Active Comparator|Group C|"5 patients form Group 3~Patients will undergo a pacing or exercise protocol and have venous, coronary sinus and arterial blood sampled. They will revert to Group 3 for 6 month follow up"
2575556|NCT02396355||All subjects|This is a single arm study. Samples from each subject will be tested with the Investigational BD FACSPresto System, the BD FACSCalibur flow cytometer, and the Sysmex hematology analyzer KX-21.
2575614|NCT02395809|Active Comparator|LIS group|Lateral internal shincterotomy: A blade knife (No 11) was inserted between internal and external sphincter. The tip of the blade was angled medially pointing just above the dentate line and IS was divided. When the knife was felt beneath the intact mucosa, it was withdrawn.
2575620|NCT02395809|Active Comparator|TENS group|Posterior tibial nerve stimulation by transcutaneous electrical nerve stimulation by through a stimulating TENS unit.
2575661|NCT02395458|Experimental|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
2575667|NCT02395458|Active Comparator|Triple therapy|Patient receive Omeprazole plus clarithromycin and amoxicillin during 14 days
3210219|NCT00992563|Active Comparator|Lucentis|Ranibizumab 10 mg/mL solution, single intravitreal injection
3210220|NCT00992615|Experimental|Arm 20 cores|
3210221|NCT00992615|Active Comparator|arm 12 cores|
2575847|NCT02394314|Placebo Comparator|Placebo|Placebo administered subcutaneously
2575849|NCT02394314|Experimental|MEDI0382|MEDI0382 administered subcutaneously
3210222|NCT00992628|Active Comparator|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
3210223|NCT00992628|Active Comparator|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
3210224|NCT00992641|Experimental|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
3210225|NCT00992641|Active Comparator|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
3260254|NCT01477619|Experimental|Non-Smokers|Gender, age, and BMI matched to Smokers
3260255|NCT01477619|Experimental|Elderly|
3260256|NCT01477632|Experimental|A|
3260257|NCT01477632|Experimental|B|
3260258|NCT01477632|Active Comparator|C|
2574983|NCT02400138|Experimental|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscles seven times per week over eight weeks, during 40 minutes per day, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve device, regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
2574997|NCT02400138|Sham Comparator|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring, which will be also concealed. The control group will also attend the weekly sessions and undergo the same procedures, except for the load adjustments. If the training proves to be effective, the control subjects will be informed and have the choice to receive the training with proper loads.
2575060|NCT02399982|Active Comparator|CBT-GSH|Traditional CBT-GSH with paper and pencil self-monitoring
2575062|NCT02399982|Experimental|CBT-GSH + Noom Monitor|CBT-GSH with smartphone application for self-monitoring
2575077|NCT02399501|Experimental|uterine lesion ultrasound, hysteroscopy|evaluation of female with proved uterine lesion by two dimensional ultrasound, three dimensional ultrasound, saline sonohysterography and hysteroscopy
2575127|NCT02399267|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
2575128|NCT02399267|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
2575129|NCT02399267|Active Comparator|PS SBTs|In the 'PS SBTs arm', RTs will conduct SBTs using only PS =< 8 cm H2O with PEEP =< 5 cm H2O. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
2575133|NCT02399267|Active Comparator|T-piece SBTs|In the 'T-piece SBTs arm', RTs will conduct SBTs using only T-piece. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
2575214|NCT02398682|Experimental|After study Intervention arm Heartlands|"The trial has 4 arms in a Before and After design:~Arm 3. After/Heartlands area patients receiving the experimental intervention~Patients who have AKI and are either inpatients in the Intervention hospital or living within the surrounding catchment area are eligible. The intervention will be in the form of a telephone call to the primary clinician or visit to the patient. The intervention will include:~Rapid diagnosis of AKI cause; Rapid treatment of AKI cause; Stopping 'nephrotoxic' drugs; Early nephrology followup for stage 3 AKI survivors; and preventing recurrent AKI."
2575216|NCT02398682|Active Comparator|After study Control arm Good Hope|"The trial has 4 arms in a Before and After design:~Arm 4. After/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
2575218|NCT02398682|Active Comparator|Before study Heartlands area|"The trial has 4 arms in a Before and After design:~Arm 1. Before/Heartlands area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Heartlands Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
2575220|NCT02398682|Active Comparator|Before study Good Hope area|"The trial has 4 arms in a Before and After design:~Arm 2. Before/Good Hope area patients observed whilst receiving active comparator~Patients who have AKI, as shown by having an Alert for such, and are either inpatients in Good Hope Hospital or living within the surrounding catchment area. These patients will receive good standard care (active comparator), but none of the interventions listed for the Intervention group."
2575292|NCT02398201|Experimental|Interventional|Bezafibrate tablets (200-600mg) three times daily for 12 weeks.
2575324|NCT02397850|Experimental|30 min or 50 min|Patients receive either seven 30 minutes or 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
2575379|NCT02397629||Patients Undergoing Prostate Biopsy|Men referred for biopsy because of an abnormal or suspicious PSA digital rectal exam, or both.
2575425|NCT02397239||Six cycles|Maintenance pemetrexed 500 mg/m2 every 3 weeks for six cycles
2575430|NCT02397239||Until disease progression|Maintenance pemetrexed 500 mg/m2 every 3 weeks until disease progression
2575541|NCT02396862||Patients with moderate to severe Hemophilia A / Cohort 1|Patients aged over 16 years, with documented physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%)
2575586|NCT02396043|Experimental|Modifed BFM-95|All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.
2575693|NCT02395263|Experimental|Yuxintine 400mg per day|Yuxintine 400mg oral, once a day, 6 weeks
2575021|NCT02400450|Placebo Comparator|Control Ingredient Group|The control group will receive a comparable set of food items that contain an equivalent amount of calories per portion but without the added functional ingredients.
2575038|NCT02399904|Experimental|1|
2575104|NCT02399709|Experimental|simvastatin|oral administration, capsule of 20mg.
2575106|NCT02399709|Placebo Comparator|microcrystalline cellulose|oral administration, capsule of 20mg
2575132|NCT02399098|Experimental|External focus group|This group will be given instructions on how to focus on the external cue relevant to the task (e.g., focus on the center of the dart board).
2575138|NCT02399098|Experimental|Internal focus group|This group will be instructed how to focus on the arm movements (e.g., feel the bend in your elbow).
2575148|NCT02399098|No Intervention|Control|This group will be given general instructions on throwing techniques (e.g., hold the dart with four fingers and make sure it is in a stable position) but no attentional focus instructions will be given.
2575221|NCT02398916|Experimental|Music|"Listening to relaxing music for the entire period starting from waiting period in the surgical waiting area until the end of the LEEP procedure~Undergoing LEEP according to the usual protocol"
2575223|NCT02398916|No Intervention|Control|- Undergoing LEEP according to the usual protocol without listening to music
2575244|NCT02398344|Experimental|1- tDCS ACTIVE|1. Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes, intensity 2mA With Simulator anodic electro stimulation from bloodstream on right and left temporal cortex region (T3 area) and cathodic position in contralateral supraorbital region to anode (Fp2), associated Cardiac Frequency Variability (HRV) as measured by spectral analysis by spectral analysis Polar RS800 cx.
2575245|NCT02398344|Experimental|2- tDCS SHAM|Placebo tDCS will be administered using Tct Research 1 CH tdcs Simulator model 101 and will follow the same procedures as active tDCS active, but the tDCS device will only be switched on for 30 seconds.
2575304|NCT02398123|Active Comparator|Transversus abdominis plane block|Transversus Abdominis Plane block
2575307|NCT02398123|Placebo Comparator|Caudal block|Caudal block
2575346|NCT02397681|Experimental|Experimental|
2575401|NCT02397499|Experimental|LIPO-202|Experimental arm
2575406|NCT02397499|Placebo Comparator|Placebo|Placebo comparator
2575492|NCT02396563||epidural analgesia|women in labor with epidural analgesia
2575493|NCT02396563||no epidural analgesia|
2575551|NCT02396407|Active Comparator|Combined water, sanitation, and hygiene|Water quality, Sanitation, Handwashing
2575553|NCT02396407|No Intervention|Non-intervention arm|None. Households will continue their usual practices.
2575616|NCT02395926|Active Comparator|R|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
2575624|NCT02395926|Experimental|T1|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
2575626|NCT02395926|Experimental|T2|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
2575668|NCT02395419|Active Comparator|Totaltrack|OTI with TotalTrack
2575674|NCT02395419|Active Comparator|Airtraq|OTI with Airtraq
2575743|NCT02395029|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based on ultrasound guided measurements of penile plaque(s) post treatment and on patient reported treatment satisfaction.
2575780|NCT02394613|Experimental|ANX776|Using and increasing dose storer design, GLAUCOMA and NORMAL patients will be randomly grouped to received the intervention (0.1 mg, 0.2 mg, 0.4 mg, 0.5 mg). 1 NAION patient will receive each dose once it has been proven safe in GLAUCOMA and NORMAL patients, as part of the secondary objective of this trial.
2575889|NCT02394093|Experimental|Aspirin dry powder|500 mg Acetylsalicylic Acid (ASA) dry powder
2575893|NCT02394093|Active Comparator|Aspirin coated tablet|500 mg ASA coated tablet
2575899|NCT02394093|Active Comparator|Aspirin effervescent tablet|500 mg ASA effervescent tablet
2575955|NCT02393599|Experimental|Lorcaserin|Lorcaserin (10mg) will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
2575960|NCT02393599|Placebo Comparator|Placebo|Placebo will be administered 2 times per day from Days 3 to 9 and only one time on Day 10
2576031|NCT02393235||unexplained infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
2576034|NCT02393235||tubal infertility(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
2576040|NCT02393235||fertile group(n:75)|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure with doppler ultrasonography in the mid-luteal phase. ( 21th day)
2576125|NCT02392663|Active Comparator|Hypertonic saline solution|"Hypertonic saline (7%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
2576128|NCT02392663|Active Comparator|Hyaneb solution|"Hyaneb (acid hyaluronic + hypertonic saline [7%]) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
2576130|NCT02392663|Placebo Comparator|Isotonic saline solution|"Isotonic saline (0,9%) solution (5 ml) will be nebulized by all patients in a randomized order. Immediately after, patients will perform a bronchial drainage session. The airway clearance technique selected will be autogenic drainage (AD).~Both patients and physiotherapist will be blind to the intervention."
2576163|NCT02392117||Insulin degludec|
2576214|NCT02391922|No Intervention|No first aid course, No dipatch instruction|Participants' first aid skills are tested in two scenarios without prior first aid course and no dispatch instructions during the scenarios
2576218|NCT02391922|Active Comparator|First aid course, No dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and no dispatch instructions during the scenarios
2575058|NCT02400034|Active Comparator|Retrograde fill voiding trial method|1) Bladder drained with indwelling foley catheter, then retrograde filled with 300cc sterile water. 2) catheter is removed; 3) Patient voids within 20 minutes (if unable to void after 20 minutes, she will be discharged home with a catheter secondary to voiding dysfunction). 4) The patient will subjectively quantify their FOS via VAS scale (however this information will only be used for research purposes). 5) If she voids >/= 2/3 (200cc) the catheter will remain out as she will have passed her voiding trial. If she voids < 200cc she will be discharged home with a catheter and instructed to follow-up in 2-5 days for an in-office retrograde voiding trial in 2-5 days.
2575101|NCT02399579|Experimental|HypoScore|Provocation test. Recording symptoms of cat allergic participants with the cat owner's cat: Before and after petting the cat.
2575125|NCT02399124|Other|single arm, open label, treatment|single arm, open label, treatment; ProSenseTM Cryoablation treatment, post marketing surveillance
2575179|NCT02398968|Active Comparator|RURTI+IDA+iron therapy|children with iron deficiency anemia on therapeutic iron fumerate therapy (6mg/kg/d) for 3 months, then maintained on iron fumerate supplementation(1mg/kg/d) for 12 months
2575183|NCT02398968|Active Comparator|B1:RURTI+no anemia+iron maintenance|children with recurrent upper respiratory tract infection and no anemia receiving oral iron fumerate (1mg/kg/d) for 12 months
2575184|NCT02398968|No Intervention|B2:RURTI+no anemia|children with recurrent upper respiratory tract infection and no anemia followed up for 12 months
2575191|NCT02398643|Other|Early Pulmonary Education (EPE)|Patients randomized to EPE will receive focused education sessions by a Certified Respiratory Educator. Education sessions will start within two weeks of discharge from hospital.
2575208|NCT02398643|Other|Usual Care|Patients randomized to usual care will receive general education sessions by a Certified Respiratory Educator within the month of being discharged.
2575248|NCT02398422|Experimental|Filtered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (filtered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
2575252|NCT02398422|Experimental|Nonfiltered Music Intervention|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention (nonfiltered music). The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
2575257|NCT02398422|No Intervention|Assessment-only|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
2575293|NCT02398110|Experimental|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
2575294|NCT02398110|Active Comparator|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
2575325|NCT02397772|Active Comparator|Annual school-based deworming|Pre-school and school children (typically 2-14 years) will receive albendazole treatment from trained school teachers, as part of the ongoing national school-based deworming programme.
2575333|NCT02397772|Experimental|Annual community-based deworming|Standard school-based deworming supplemented by annual community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers.
2575336|NCT02397772|Experimental|Biannual|Biannual school- and community-based deworming (2-99 years). All household members who are not enrolled in school will receive albendazole treatment from trained community health workers
2575390|NCT02397538|Other|Cohort1|Treatment AB → ABC Treatment A+B (10days) → Treatment A+B+C (6days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
2575396|NCT02397538|Other|Cohort2|Treatment C → ABC Treatment C (6days) → Treatment A+B+C (10days) Treatment A: Fimasartan Treatment B: Amlodipine Treatment C: Rosuvastatin
2575463|NCT02397044||Implant loading Immediate|Dental implant surgery with immediate loading
2575466|NCT02397044||Implant Loading Early|Dental implant surgery with delayed loading
2575503|NCT02396654||normal pregnant women|Normal pregnant women between 37 and 42 weeks gestation.
2575543|NCT02396342|Experimental|Cohort 1|AAV5-hFIX 5 × 10E12 gc/kg intravenous single infusion
2575545|NCT02396342|Experimental|Cohort 2|AAV5-hFIX 2 × 10E13 gc/kg intravenous single infusion
2575683|NCT02395289|Experimental|Cognitive-Based Compassion Training (CBCT)|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to receive an 8-week program of Cognitive-Based Compassion Training (CBCT).
2575686|NCT02395289|Active Comparator|Health Discussion Control|HIV-1 positive subjects on antiretroviral therapy (ART) will be randomized to attend a health discussion group for 8 weeks.
2575794|NCT02394470|Other|Acute heart failure HF,Chronic HF,Advanced chronic HF|patient admitted to the hospital for acute heart failure (de-novo or exacerbation of chronic heart failure), for Chronic HF and for Advanced chronic heart failure
3175954|NCT00639873|Experimental|AS 2mg/kg|Artesunate monotherapy 2mg/kg/day for 7 days
2575918|NCT02394067||Idiopathic Intracranial Hypertension|All participants of our study will be in this arm. These will be patients with a diagnosis of IIH. These patients will be followed throughout their standard of care treatment, with neuro-radiological imaging.
2575979|NCT02393560||Gout subjects on stable dose of allopurinol (at least 300mg)|
2576046|NCT02392988|Placebo Comparator|Group receives sham treatment|Sham treatment will be given on points on the back, points that are not acupuncture points, so that the patient will not be able to know whether she is receiving sham treatment or a real treatment. The treatment will be every 48-72 hours, a maximum of three treatments.
3175955|NCT00639873|Experimental|AS 4mg/kg|Artesunate monotherapy 4mg/kg/day for 7 days
3175956|NCT00639873|Active Comparator|QD Control|Quinine-doxycycline for 7 days
3175957|NCT00639912|Active Comparator|A: low volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3175958|NCT00639912|Active Comparator|B: high volume saline|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath lab.
2575064|NCT02400060|Experimental|Supportive (text messages and interactive exchanges)|Patients receive daily text messages reminding them to take AHT and weekly interactive surveys delivered by a smart phone app for 3 months.
2575113|NCT02399449|Active Comparator|sodium ferric gluconate (brand)|brand-name sodium ferric gluconate
2575114|NCT02399449|Active Comparator|sodium ferric gluconate (generic)|generic sodium ferric gluconate
2575130|NCT02399059|Experimental|Antibiotic lavage|Peritoneal irrigation with Gentamycin - clndamycin solution
2575141|NCT02399059|Active Comparator|Normal saline lavage|Peritoneal irrigation with normal saline
2575215|NCT02398903||Obese women SG|Obese women operated by sleeve gastrectomy
2575217|NCT02398903||Normal weight women|Normal weight women
2575219|NCT02398903||Obese women GBP|Obese women operated by Rougastric bypass
3210226|NCT00992667|Experimental|Asthmatics|Ten nonsmoking patients, suffering from mild bronchial asthma participated in the study (mean age 30±9 years, 5 men, 5 women). Asthma was diagnosed based on GINA 2008 criteria. The patients were free of any medication, at least 7 days before, and had not suffered from any infectious diseases including upper respiratory tract infections for at least 3 months prior to the study. Patients who did not meet these criteria were excluded from the study.
3210227|NCT00992680|Experimental|Group A|Anastomotic Coupler System + standard of care per GOLD
3210228|NCT00992680|No Intervention|Group B|Standard of care per GOLD alone
3210229|NCT00992693|Experimental|Treatment with IV Ribavirin|In this open label treatment study, the investigators intend to treat all subjects who present with a tentative diagnosis of VHF and meet entry criteria with a 10 day course of IV Ribavirin.
2575476|NCT02396927|Placebo Comparator|2D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 2DHD viewing mode
2575477|NCT02396927|Active Comparator|3D HD laparoscopy|Elective laparoscopic cholecystectomy performed with the use of Olympus ENDOEYE FLEX in the 3DHD viewing mode
2575502|NCT02396576|No Intervention|Usual Care|NEVHC has two main Department of Mental Health (DMH) contracted clinical partners where the majority of the patients are referred to -these are Child and Family Guidance Center (CFGC) in the San Fernando Valley and Child and Family Center (CFC) in the Santa Clarita Valley.
2575510|NCT02396576|Experimental|Telehealth Intervention|The telehealth model will enhance patient coordination as well as clinician communication via live videoconferencing. Developmental behavioral services will be provided by a Developmental Behavioral Pediatrician (DBP) housed at UCLA from Children's Hospital Los Angeles (CHLA). Mental Health services will be provided by Child Family Center (CFC) and Child Family Guidance Center (CFGC). The location of the telehealth visit will be at the same clinic location as the index PCP visit with a telehealth coordinator facilitating the encounter between patient and clinicians.The clinician communication will be enhanced through monthly telehealth topic-based educational sessions as well as case-based educational sessions for the transfer cases.
3210230|NCT00992732|Experimental|HQK-1004 + Valganciclovir|
3210231|NCT00992745|Experimental|Previous ProstaScint®|Subjects with a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 alone.
2575605|NCT02395718|Experimental|QDU|Patients will undergo a fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation. Patients will have immediate access to all diagnostic tests and treatments that will be carried out all day (24 hours) on demand from the responsible physician. The QDU is both organisationally and physically integrated in the ED. Point of care ultrasonography can be performed round the clock. Additionally the Department of Radiology provides the QDU with more advanced diagnostic procedures such as e.g. CT scans or MRI scans on a fast track basis. There is access to additional specialist evaluations from the ED staff or from various in house specialists, when needed. Simultaneously to the medical treatment, physical therapists and occupational therapists train and optimise patients' level of functioning, including prevention of loss of function.
2575607|NCT02395718|Active Comparator|DIM|Patients in the control group are treated as conventionally at one of seven wards at the DIM. After initial admission including initial diagnostics and treatment have been carried out in the ED, patients are transferred to the DIM. Usually patients are seen primarily by the on-call physician for evaluation of acute symptoms. The following day, a Chief physician will work out a plan for further diagnostics and treatment. Treatment by physiotherapists and occupational therapists is available on request from a physician. Analyses of blood samples are performed at the central laboratory and radiological procedures at the Department of Radiology.
2575666|NCT02395510|Other|Flexible, open label dosing|Flexible dosing 5-20mg
2575711|NCT02395120|Active Comparator|Standard letter|Modified standard letter will be sent to caregivers.
2575719|NCT02395120|Experimental|Intervention letter|The CSM-based referral letter alone will be sent to caregivers
2575725|NCT02395120|Experimental|Reduced intervention letter|"The reduced (removing text corresponding to timeline) CSM-based referral letter alone will be sent to caregivers."
2575730|NCT02395120|Experimental|Intervention letter+DIG|The CSM-based referral letter with the dental information guide will be sent to caregivers.
2575733|NCT02395120|Experimental|Reduced intervention letter+reduced DIG|The reduced CSM-based referral letter with the reduced dental information guide will be sent to caregivers.
3210232|NCT00992745|Experimental|No Previous ProstaScint®|Subjects without a previous 111-In capromab pendetide image of sufficient quality obtained within 60 days of study enrollment will receive 123-I-MIP-1072 and 111-In capromab pendetide imaging.
3210233|NCT00992758|Experimental|Treatment, Non-Randomized, Open Label|Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
2575931|NCT02393742|Experimental|Sodium Nitrite Supplementation|80 mg/day (40 mg 2x/day) slow release sodium nitrite (TheraVasc, Inc) for 3 months
2575937|NCT02393742|Placebo Comparator|Placebo|placebo 2x/day for 3 months
2575968|NCT02393495|Experimental|Ultrasound guided group|the female will be asked to be full bladder. the trans-abdominal probe will be placed by an assistant on the suprapubic region. under speculum examination, the intrauterine device IUD (TCu 380A) will be placed till it reaches the fundus of the uterus and then released.
3210234|NCT00992771|Experimental|Varneicline|
3210235|NCT00992771|Placebo Comparator|Placebo|
3210236|NCT00992797|Experimental|Cholecalciferol|
2575102|NCT02399696|Experimental|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum.
2575103|NCT02399696|Active Comparator|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
2575123|NCT02399150||Acute Abdominal Pain|patients presenting to the ED with acute abdomen
2575171|NCT02398994|Active Comparator|Intravenous Methylprednisolone|"Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
2575174|NCT02398994|Experimental|Intravenous Immunoglobulin|"Paediatric patients <41.2kg - total dose of 2g/kg in divided doses over 2 days.~All other patients - total dose of 2g/kg in divided doses over 5 days.~PLUS Intravenous Methylprednisolone~Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.~Adult patients - 1g/day for 5 days."
2575189|NCT02398604|Experimental|Group A - Allo-hMSCs|Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
2575190|NCT02398604|Placebo Comparator|Group B|Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.
2575238|NCT02398448|Experimental|Zyloprim® 300 mg and three dissolution test formulations|Regimen A: Zyloprim® 300 mg; Regimen B: Allopurinol 300 mg; undergranulated, high hardness condition; Regimen C: Allopurinol 300 mg; alternative condition 2; Regimen D: Allopurinol 300 mg; alternative condition 3
3210237|NCT00992797|Placebo Comparator|Placebo|
3210238|NCT00992810|Experimental|Lateral-to-Medial Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
2575383|NCT02397512|Experimental|Lactulose group|Subjects will ingest 50g of lactulose once
2575387|NCT02397512|Placebo Comparator|Control group|Subjects will ingest 50g of sucrose once
2575448|NCT02397148|Experimental|patients with sinonasal pathology|Computed Tomography Cone Beam Computed Tomography
2575501|NCT02396810|Placebo Comparator|No intra-operative MRI|Patients undergo transsphenoidal surgery without an intra-operative MRI.
2575509|NCT02396810|Experimental|intra-operative MRI|Patients undergo transspheonidal surgery followed by intra-operative MRI.
2575572|NCT02396030|Active Comparator|Magnesium sulfate 50% - 1g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 1g/hour of intravenous magnesium sulfate, for 24 hours
2575578|NCT02396030|Experimental|Magnesium sulfate 50% - 2g/h|After loading dose of 6g of magnesium sulfate, patients will receive the maintenance dose of 2g/hour of intravenous magnesium sulfate, for 24 hours
2575600|NCT02395757|Experimental|Microperimetry|Microperimetry exam performed in addition to the usual ophthalmological examinations for monitoring AMD.
2575642|NCT02395588||Guideline based care|"Prior to discharge. Survey data will include descriptive characteristics, depression, heart failure knowledge. After patient education is complete prior to discharge patients will complete a readiness for discharge scale and heart failure self-care survey.~Phone call 48 hours after discharge. Discharge instructions will be reinforced.~Phone call 7 days after discharge. Survey data will include self management, complications, and satisfaction care.~Secondary data 30 days post discharge. The hospital electronic medical record system will be queried to determine if the patient has been readmitted within 30 days of discharge for heart failure or non-heart failure causes."
3210239|NCT00992810|Experimental|Medial-to-Lateral Approach|Needle approach to the brachial plexus nerves will be made using a lateral-to-medial direction.
2575713|NCT02394886|Experimental|ALLO-ASC-DFU|ALLO-ASC-DFU treatment with conventional care
3210240|NCT00992823|Active Comparator|Group 1:iron weekly supplementation|
3210241|NCT00992823|Active Comparator|Group 2: cycle supplementation|two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
2575896|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 210 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one subcutaneous (SC) injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
2575901|NCT02394028|Experimental|Induction Phase - Cohort 1 (Exploratory): Etrolizumab 105 mg|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
2575903|NCT02394028|Placebo Comparator|Induction Phase - Cohort 1 (Exploratory): Placebo|Cohort 1 enrolled participants first before Cohorts 2 and 3 in order to conduct an exploratory analysis on induction data. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
2575905|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 210 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking for the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
2575906|NCT02394028|Experimental|Induction Phase - Cohort 2 (Open-Label): Etrolizumab 105 mg|"Cohort 2 is enrolling participants after Cohort 1 and is considered a feeder cohort to help achieve the necessary sample size for the Maintenance Phase. Participants randomized to this arm will receive one SC injection of open-label etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking of the dose of etrolizumab, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12."
2575142|NCT02399176|Experimental|Yoga of minimal intensity|Does Yoga: At least 4 times/week.
2575199|NCT02398838|Experimental|Home administration of mifepristone|Home administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
2575209|NCT02398838|Active Comparator|Clinic administration of mifepristone|Clinic administration of 200 mg mifepristone. Choice of home or clinic administration of 400 mcg buccal misoprostol.
2575242|NCT02398370|Experimental|Injection of PMD-MSCs into the penis|Subjects will receive an initial injection of 1.0cc of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs). Subjects will be eligible for re-injection at 3 months and/or 6 months as determined by the clinician based patient reported treatment satisfaction.
2575313|NCT02398149||PwMS receiving care at the Mandell Center|
3260259|NCT01477645||Leaded ammunition|
2575380|NCT02397304|Experimental|Pre-exercise food|Pre-exercise food provision
2575382|NCT02397304|Experimental|Post-exercise food|Post-exercise food provision
2575452|NCT02397213|Placebo Comparator|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
2575455|NCT02397213|Active Comparator|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection.
2575542|NCT02396680||TR006 Subjects|Subjects that have previously been randomised into study TR006
2575558|NCT02396056|Sham Comparator|Occlusive Membrane (OM)|Five patients will be randomly assigned to the OM group.
2575564|NCT02396056|Experimental|Modified Perforated Membrane (MPM)|Five patients will be randomly assigned to the MPM group.
2575599|NCT02395900|Active Comparator|Flaxseed|30 grams Flaxseed powder
2575602|NCT02395900|Placebo Comparator|control|dietary and exercise recommendation
2575669|NCT02395562||OTR and viral reactivation|Organ transplant recipients with and without viral reactivation and skin cancer
2576016|NCT02393092|Experimental|BVA Only|Study participants in this arm will only receive a Brief Violence Awareness (BVA) intervention.
2576017|NCT02393092|Experimental|BVP Only|Study participants in this arm will only receive a Brief Violence Prevention (BVP) intervention.
2576018|NCT02393092|Experimental|Emerging Leaders plus BVP|Study participants in this arm will participate in the Emerging Leaders: East End curriculum at the Boys and Girls Club of Metro Richmond, Martin Luther King Jr. Middle School site. They will also receive a Brief Violence Prevention (BVP) intervention.
2576049|NCT02392871|Experimental|Radiotherapy|"Palliative radiotherapy in combination with dabrafenib and trametinib Eligible subjects are patients who have been on dabrafenib and trametinib for more than 2 weeks, as the current standard management for advanced stage melanoma.~Palliative RT will be delivered to symptomatic or bulky (>2cm) soft tissue, nodal or bony metastases concurrently with dabrafenib and trametinib. Up to 3 areas of disease can be irradiated at the same time.~Following RT, dabrafenib and trametinib alone will be continued until disease progression according to RECIST 1.1 criteria."
2576103|NCT02392585|Active Comparator|Single tourniquet|
2576112|NCT02392585|Active Comparator|Triple tourniquet|
2576326|NCT02391142|Experimental|cardiac sympathetic nerve block|lidocaine or ropivacaine epidural injection
2576331|NCT02391142|No Intervention|non-cardiac sympathetic nerve block|
2576368|NCT02390778|Experimental|Debrief Group|The debrief group participated in 3 consecutive face-to-face group debriefing sessions lasting 1.5-2 hrs each. Each session started with a fun ice-breaker to create a relaxed atmosphere and group cohesion. Session 1 focused on encouraging group participation, discussing primary trauma encountered and emotional reactions to these stories. Session 2 connected current experiences with the group members' own trauma histories and life experiences. The last session focussed on societal and community responses to violence, and employing personal agency to find constructive ways to address violence in communities.
2576374|NCT02390778|Placebo Comparator|Control Group|The control group was assigned to a leisure activity (film showing), for every session of debriefing undergone by the intervention group. The films were chosen for their light-hearted uplifting content and presented as a fun and relaxing activity.
3175959|NCT00639912|Active Comparator|C: low volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3175960|NCT00639912|Active Comparator|D: high volume sodium bicarbonate|Solution of 154 mEq/L of sodium bicarbonate. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours after the procedure, starting in the Cath Lab.
3175961|NCT00639925|Experimental|Phase I study|
3175962|NCT00639938|Active Comparator|1|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single dose of 2 mg/kg NVP taken orally within the first week after delivery"
2576491|NCT02389751|Experimental|Treatment (ganetespib, paclitaxel, carboplatin, radiation)|Patients receive ganetespib IV over 1 hour, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes once a week on day 1. Patients also undergo radiation therapy 5 days a week for 5.5 weeks or for a total of 28 treatments. Treatment continues for 28 treatment days (5.5 weeks) in the absence of disease progression or unacceptable toxicity
3175963|NCT00639938|Experimental|2|"Mother dosing regimen: Single dose of 200 mg NVP taken orally at onset of labor~Infant dosing regimen: 2 mg/kg NVP taken orally within the first week after delivery and 5 mg NVP taken orally daily from Day 8 through Week 6"
3175964|NCT00639938|Experimental|3|"Mother dosing regimen: Single 12 gm intravenous dose of HIVIGLOB at 36 - 37 weeks gestation and 200 mg NVP taken orally at onset of labor~Infant dosing regimen: Single 1.2 gm intravenous dose HIVIGLOB within 18 hours of birth and 2 mg/kg NVP taken orally within the first week after delivery"
3175965|NCT00639951|Active Comparator|A Normal dose Group|20 vials up front in a Single Dose of Antivipmyn in 500 ml of solution IV, administered in 60 minutes. After 12 hours, it has to be perfomed a clinical evaluation of the patient. Each patient is going to have clinical studies of coagulation time and also the fibrinogen measures, this at 2, 4, 6, 8, 10, 12, 48, 72, 96 hours.All patients who have received at least one dose of medication study will be contacted by telephone to investigate the presence of symptoms suggestive of continuing with effect snake venom, or the presence of an adverse event, or any signs or symptoms indicating the presence of a hypersensitivity response to Antivipmyn® including serum sickness. If symptoms suggestive of an adverse event were discovered, the patient will referred for appropriate treatment.
2575153|NCT02399371|Experimental|Treatment (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.
3175966|NCT00639951|Placebo Comparator|B Placebo Group|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®. The treatment schedule for each subject is a dose of 5 vials Antivipmyn® every 2 hours to complete 20 vials, the total duration is 6 hours of the treatment. Each dose IV shall apply in physiological solution 250ml, and finish its application in 15 minutes. For pediatric patients the volume administered should not exceed the recommended fluid volume according to your body weight. After the assessment at 12 hours, it can be administered at the discretion of more antivenom attending by the physician.
2575268|NCT02398292|Other|M3 Program|Non-randomized experimental group. The program is a six-week multi-modal intervention, including nutrition education and cooking classes, physical activity, and mindfulness. Outcomes will be compared to a non-randomized control group.
2575271|NCT02398292|Other|Control|Non-randomized control group. Outcomes will be compared at same time points (baseline, 6 weeks, 12 weeks).
2575349|NCT02398058|Experimental|Trabectedin plus olaparib|"All patients will be treated with trabectedin and olaparib in an open-label fashion.~The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment."
2575372|NCT02397369|Experimental|Tobacco users: Self Help|Self-help intervention is defined as any manual or programme to be used by individuals to assist a quit attempt not aided by counsellors or group support.They include written materials on the health effects of tobacco, audio-or video tape or computer programmes.
2575373|NCT02397369|Experimental|Tobacco users:Telephonic counseling|Telephone counseling is a way of providing individual counseling via telephone conversation or telephone hotlines. It can be proactive or reactive.
2575374|NCT02397369|Experimental|Tobacco users:Behavioural therapy Only|Behavioural therapy includes multiple sessions of Focus Group Discussion (FGD) and individual tobacco cessation counseling sessions. The participants in this group will be given advice to quit tobacco via multisession formal cognitive-behavioural therapy as per the Tobacco Cessation Clinic (TCC) guidelines.
2575375|NCT02397369|Experimental|Tobacco users:Pharmacologic|Pharmacotherapy in the form of Nicotine Replacement Therapy based on individual need assessment to relieve withdrawal symptoms in tobacco users when trying to quit.
2575440|NCT02397252|Experimental|Eve Medical self-collection system©|Device: Self-sampling swab from Eve Medical for collection of vaginal cells.
2575445|NCT02397252|Placebo Comparator|cobas® PCR Female swab self-sampling|Device: Regular polyester swab for collection of vaginal cells.
2575450|NCT02397252|Placebo Comparator|Physician-collected sampling|Routine colposcopy sample collected by a physician.
2575507|NCT02396719||LenSx|Phacoemulsification cataract surgery in at least 1 eye using LenSx® Laser technology
3260260|NCT01477645||Non-leaded ammunition|
2575714|NCT02394899|No Intervention|Control|The control dyad will receive usual care.
2575724|NCT02394899|Experimental|Intervened|Parents receive training in problem solving skills and play therapy with their infants.
2575867|NCT02394132|Experimental|Imiquimod|"Topical imiquimod 5% cream~application to treatment area for 5 days/week for a total of 12 weeks~dispensed at baseline visit along with patient diary"
2575869|NCT02394132|Experimental|Radiotherapy|"Radiotherapy~treatment regimen determined by treating radiation oncologist and as per standard practice at local institution~treatment to commence within 8 weeks of randomisation"
2575996|NCT02393274||28-day Survival|survive for at least 28 days after placement of extra-corporeal membrane oxygenation life support
2575999|NCT02393274||28-day Nonsurvival|not survive for 28 days after placement of extra-corporeal membrane oxygenation life support
3175967|NCT00639964|Other|type 1 diabetic pregnant women|type 1 diabetic pregnant women
3175968|NCT00639964|Other|type 2 diabetic pregnant women|type 2 diabetic pregnant women
2576037|NCT02392858|Other|influenza cohort|"Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.~1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.~Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms."
2576097|NCT02392520|Experimental|Antagonist|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
2576123|NCT02392689|No Intervention|Standard of Care|Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.
3175969|NCT00639964|Other|healthy pregnant women|healthy pregnant women with normal glucose tolerance
3175970|NCT00639977|Sham Comparator|2|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
3175971|NCT00639977|Active Comparator|1|20-minute session of acupuncture with needles inserted in specific points (Tong Zi Liao, Yang Bai and Jing Ming)
3175972|NCT00639977|No Intervention|3|
3175973|NCT00639990|Active Comparator|Control|Patients without lung injury and brain injury
3175974|NCT00639990|Experimental|Brain No ALI 1|Patients with brain injury and no lung injury within 72 hours from ICU entry
3175975|NCT00639990|Experimental|Brain No ALI 2|Patients with brain injury and no ALI after 72 hours from ICU entry
3175976|NCT00639990|Experimental|Brain ALI|Patients with brain injury and Acute Lung Injury (ALI)
3175977|NCT00640003|Experimental|1|
3175978|NCT00640003|Experimental|2|
3175979|NCT00640029|Experimental|1|Cervical - Arthroplasty
3175980|NCT00640029|Active Comparator|2|Cervical - Arthrodesis
3175981|NCT00640029|Experimental|3|Lumbar - Over 50 years - Arthroplasty
3175982|NCT00640029|Active Comparator|4|Lumbar - Over 50 years - Arthrodesis
3175983|NCT00640029|Experimental|5|Lumbar - Under 50 years - Arthroplasty
3175984|NCT00640055|Active Comparator|1|Coordinator (non-physician)
3175985|NCT00640055|Placebo Comparator|2|Physician
2575155|NCT02399332|No Intervention|Usual care|Patients have a complex care plan completed by their clinical team, which will involve the chronic disease management nurse and the family physician and then receive routine care and follow up. They will receive usual care from their community pharmacist.
2575192|NCT02398942||Proximal Pole Fracture of the Scaphoid|QuickDASH 6 months after injury CT scan 6 months after injury
2575254|NCT02398552|Active Comparator|Sunitinib 50mg/day schedule 4/2|Sunitinib 50mg/day 4 weeks on/2 weeks off per 6 weeks till disease progression or intolerable toxicity.
2575258|NCT02398552|Experimental|Sunitinib 50mg/day schedule 2/1|Sunitinib 50mg/day 2 weeks on/1 week off per 6 weeks till disease progression or intolerable toxicity.
2575309|NCT02397967|Experimental|Children NF1|Children diagnosed with NF1 according the NIH criteria Neuropsychological assessments
2575310|NCT02397967|Placebo Comparator|Control group|Control group children without NF1 with the same reading level Neuropsychological assessments
2575341|NCT02397668|Experimental|CorMatrix Cor TRICUSPID ECM Valve|Tricuspid valve replacement in patients for the surgical management of tricuspid valve disease, including tricuspid valve disease secondary to congenital heart disease. Enrollment will include up to 10 adults subjects and up to 5 pediatric subjects.
2575381|NCT02397395|Experimental|Simeprevir Co-administered with Daclatasvir|All participants will receive Simeprevir (SMV) 150 milligram (mg) capsule co-administered with Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks. Participants should take the study drugs (SMV and DCV together) orally and once daily with food.
3210242|NCT00992849|Experimental|Bevacizumab|Arm type to experimental based on single group assignment. Bevacizumab (trade name Avastin, Genentech/Roche) is a humanized monoclonal antibody that recognises and blocks vascular endothelial growth factor (VEGF).VEGF is a chemical signal that stimulates the growth of new blood vessels.
3210243|NCT00992862|Experimental|Moexipril HCl 15mg Tablets|
2575504|NCT02396485|Experimental|Early Feeding Arm|Patients will be started on regular diet within 6 hrs postoperative.
2575513|NCT02396485|No Intervention|Late Feeding Group|Patients will be remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs as standard postoperative protocol in the investigators' institution.
2575552|NCT02396303|Experimental|Patient receiving carbetocin|Experimental group subjects will receive intravenous Carbetocin during third stage of labour.
2575559|NCT02396303|Active Comparator|Patient receiving oxytocin|Comparator group subjects will receive intramascular Oxytocin during third stage of labour.
2575618|NCT02395913|Active Comparator|R|
2575622|NCT02395913|Experimental|T1|
2575627|NCT02395913|Experimental|T3|
2575629|NCT02395913|Experimental|T4|
2575658|NCT02395393|Other|Lung transplant recipients|In patients scheduled for bronchoscopy as part of regular clinical care/diagnostic workup, the investigators will offer the patient concurrent confocal microscopy imaging to be performed during the bronchoscopic procedure. A 1.4mm or 1.9mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli.
2575729|NCT02395146|Experimental|Monitoring|intraoperative EBSLN monitoring will take place
2575731|NCT02395146|No Intervention|Non-Monitoring|No intraoperative EBSLN monitoring will take place (standard practice)
2575839|NCT02394366|Experimental|Active|Original Healing Salve (Puremedy, Inc.) including 1x homeopathic dilutions of Calendula, Echinacea, and Sambucus extracts, plus extracts from pine and Balsam fir; acute effects only
2575843|NCT02394366|Placebo Comparator|Control|Original Health Salve olive oil and beeswax base only without homeopathic or herbal extracts; acute effects only
2575880|NCT02394015||Trabectedin+ PLD|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC.
3210244|NCT00992862|Active Comparator|Univasc® 15mg Tablets|
3210245|NCT00992888|Experimental|albumin liver dialysis|
2575972|NCT02393313|Experimental|Cataract surgery toric intraocular lens|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
2576064|NCT02393066|Active Comparator|propofol|these patients are sedated with propofol infusion during ICU admission
2576070|NCT02393066|Active Comparator|dexmedetomidine|these patients are sedated with dexmedetomidine infusion during ICU admission
2576102|NCT02392468|Experimental|BI 409306 low dose|low dose of BI 409306
2576109|NCT02392468|Experimental|BI 409306 high dose|high dose of BI 409306
2576162|NCT02392182||healthy volunteers|no intervention to be administered in this observational study, although all participants will undergo fiberoptic bronchoscopy.
2576192|NCT02391974|Experimental|PERIOSYAL FILL|n=15
2576194|NCT02391974|No Intervention|No treatment (untreated control)|n=15
2576247|NCT02391636|Experimental|Carbetocin arm|100 μg intravenous injection at delivery of the anterior shoulder
2576248|NCT02391636|Active Comparator|oxytocin arm|5 IU intravenous injection at delivery of the anterior shoulder
3210246|NCT00992888|No Intervention|Standard medial care without dialysis|
3210247|NCT00992901|Experimental|Exendin-(9-39)|To evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
2576347|NCT02390921|Active Comparator|Liosomated iron therapy|Fisiogen Ferro Forte 28mg every day po, during 3 months
2576349|NCT02390921|Experimental|Endovenous Iron Therapy|Venofer 300mg endovenously every 3 months
3210248|NCT00992901|Experimental|atropine|To evaluate the effect of neural activation on insulin secretion and glucose metabolism
3210249|NCT00992901|Experimental|GLP-1 and GIP|to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
3210250|NCT00992914|Active Comparator|Lidocaine injection|Stellate Ganglion Injection with Lidocaine
3210251|NCT00992914|Placebo Comparator|saline injection|Superficial subcutaneous injection
2575204|NCT02398851|Other|Standard of Care|Compare standard practice (patient-centered, coordinated care model without the integration of technology
2575273|NCT02398435|Experimental|Cohort 80 mg|Cohort 1 included 10 patients. Patients received Tadekinig alfa s.c with a dosage of 80mg. Safety assessments were conducted by data safety monitoring board. Non-responder patients were upscaled to next dose (160mg) after 3 weeks of treatment.
2575277|NCT02398435|Experimental|Cohort 160 mg|Cohort 2 included 13 patients. all patients were treated with Tadekinig alfa s.c with a dosage of 160mg. Safety was evaluated by data safety monitoring board.
3210252|NCT00992940|Experimental|Patient-Controlled Sedation/Analgesia|Patient controls the amount of sedation and analgesia delivered, according to their own requirements.
3210253|NCT00992940|Active Comparator|Anesthetist-Controlled Sedation/Analgesia|Patient sedation and analgesia requirements are delivered by the anesthetist.
3210254|NCT00992953|Experimental|Virtual Reality Therapy|10 Weeks of Virtual Reality Exposure with Stimulus Control, with up to twice a week, 90 min sessions
3210255|NCT00992953|Active Comparator|Treatment As Usual|Traditional Therapy and Psychiatric Medication
2575522|NCT02396550|Experimental|Positive Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into positive
2575525|NCT02396550|Experimental|Neutral Expectations|Procedure/Surgery: Mobilization with movement in patients with lateral epicondylalgia with modification of its expectations into neutral
3210256|NCT00992979|Experimental|Therapeutic Massage|
3210257|NCT00992979|Active Comparator|Relaxation Control|Relaxation Control Session
3210258|NCT00993005|Experimental|A|Cicatrix
3210259|NCT00993005|Placebo Comparator|B|Placebo
3210260|NCT00993018|Experimental|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
2575749|NCT02394821|Experimental|Metronidazole|metronidazole 0.8% solution - topical
2575753|NCT02394821|Experimental|Polihexanide|Polihexanide 2%
2575769|NCT02394587|Experimental|Mindfulness-Based Stress Reduction|Subjects assigned to the experimental group will participate in a MBSR foundation program, which includes weekly telephonic, group-based, 60-minute MBSR sessions for 6 weeks. The foundation program will introduce subjects to the concept of mindfulness with each week focusing on a different facet. Modeled after Kabat-Zinn's original program, breath awareness (focus on breath and observing thoughts without fighting or following them), body scan (promoting mindfulness of sensations in different parts of body), walking meditation (walking as form of meditation), loving kindness (projection of friendliness and kindness towards oneself and others), and choiceness awareness (awareness of all sensations with equal interest) will be taught.
2575771|NCT02394587|Other|Wait-listed control group|Subjects assigned to the wait-listed control group will not receive the MBSR program, but will receive weekly reminders of their study participation, be asked to complete the same questionnaires (per telephone script) once every three weeks, and receive the same financial incentives as the MBSR group. Upon completion of the 6-week session, the wait-list control group will be offered the same MBSR program. At that time, a new series of MBSR sessions will be scheduled and offered to the wait-listed control patients. Subjects who elect to participate in MBSR will receive the same packet of materials and measures received by the intervention group and be asked to complete the measures again at baseline, 1, 3, and 6 weeks.
2575846|NCT02394444|Experimental|Preterm intervention TRT group|"Parents with premature infants received the intervention called Triadic parent-infant's Relationship Therapy (TRT) :~the psychological intervention included home visits twice month during the first four months and then monthly visits in the neonatal ward until the 18 months corrected age resulting in a total of 22 visits during the whole intervention; TRT gave attention to emotional distress and the promotion of parenting skills and attachment security; The three sessions of intervention targeted objectives specific to each child's development; A basic manual was designed to ensure uniformity of the defined themes during each session"
2575848|NCT02394444|No Intervention|Preterm control group|Parents with premature infants without intervention program TRT (Triadic parent-infant's Relationship Therapy) received routine follow-up medical care with monthly visits to a practitioner for the first six months and then very three months
2575850|NCT02394444|No Intervention|Full-term control group|Parents with full-term infants without intervention program TRT
2575895|NCT02393937|Experimental|Test: Metronidazole Gel 1%|Metronidazole Gel 1% once daily for 70 days.
2575900|NCT02393937|Active Comparator|Reference: Metronidazole Gel 1%|Metronidazole Gel, 1% (MetroGel) Galderma S.A. once daily for 70 days.
2575904|NCT02393937|Placebo Comparator|Placebo|Placebo Gel once daily for 70 days.
2575956|NCT02393352|Experimental|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
2575959|NCT02393352|Active Comparator|Electrical Stimulation Therapy|Diadynamic fixed current phase in active trigger points, with pulses of 10msec, and intervals of equal duration.
2576033|NCT02393222||Patients with ESRD on HD|Adult patients with ESRD on HD. Observing the effect of a single HD session on cerebral blood flow (assessed by transcranial doppler) and cognitive function (assessed by neurocognitive questionnaires). Subgroup to undergo brain MRI.
2576121|NCT02392689|Experimental|PCT-guided|"Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.~PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended"
3210261|NCT00993018|Experimental|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
3210262|NCT00993018|Experimental|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
3210263|NCT00993018|Placebo Comparator|Placebo|Placebo will be administered as a single, subcutaneous injection every 28 days for up to 52 weeks.
2575284|NCT02398097|Active Comparator|Agripal|28 trivalent subunit inactivated intramuscular vaccine (Agripal) recipients: one vaccine injection administered on Day 0
2575287|NCT02398097|Active Comparator|IDflu9μg|30 reduced-content intradermal split vaccine (IDflu9μg) recipients: one vaccine injection administered on Day 0
2575289|NCT02398097|Active Comparator|IDflu15μg|28 standard-content intradermal split vaccine (IDflu15μg) recipients: one vaccine injection administered on Day 0
2575421|NCT02397330|Active Comparator|group BIS|scheduled for ultrasound guided interscalene blockade with 30 ml of bupivacaine 0.25%
2575422|NCT02397330|Experimental|group BS|scheduled for selective blockade of the ultrasound guided suprascapular (15 ml bupivacaine 0.25%) and supraclavicular (15 ml bupivacaine 0.25%) nerves blocks
2575472|NCT02396888|Experimental|Insulin|Half of the wound surface was treated daily with intermediate insulin. Allocation was randomized.
2575474|NCT02396888|Placebo Comparator|Placebo|Half of the wound surface was treated daily with normal saline. Allocation was randomized.
2575521|NCT02396602|Experimental|Intervention|After completing baseline the baseline questionnaire, women randomized to the intervention group will receive an iPad, along with a brief tutorial on iPad navigation, and use the miPlan app for up to 15 minutes. They will complete a post-intervention survey before proceeding to standard of care contraceptive counseling.
2575524|NCT02396602|No Intervention|Control|After completing baseline the baseline questionnaire, women randomized to the control arm will proceed to standard of care contraceptive counseling.
2575549|NCT02396225|Experimental|Inhaled voriconazole|12 patients inhale voriconazole 40 mg b.i.d for two days
2575550|NCT02396225|Active Comparator|Oral Voriconazole|12 patients ingest voriconazole tablets 400 mg b.i.d for one day followed by 200 mg b.i.d for one day
3210264|NCT00993057|Active Comparator|Q1 hour protocol|change of insulin infusion every hour
3210265|NCT00993057|Active Comparator|Q30min protocol|change of insulin infusion every 30 minutes
3210266|NCT00993070|Experimental|Capsaicin|
2575706|NCT02394938|Experimental|MUSIC|In addition to the standard care, heart failure patients assigned to the music group will listen recorded classical music.
2575723|NCT02394938|No Intervention|CONTROL|Heart Failure patients assigned to the control group will receive standard care only. The standard care will consist in nursing and medical counselling, self-care education and medication.
2575781|NCT02394691|Active Comparator|anodal stimulation|Patients receive an anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
2575787|NCT02394691|Placebo Comparator|sham stimulation|Patients receive a sham tDCS (on the left dorsolateral prefrontal cortex) every day for 4 weeks, 5 days per week (tDCS of 2mA during 5 secondes at the begining and the end of the stimulation to mimic the effects of tDCS). A CRS-R is performed at baseline (before the first stimulation) and after the tDCS session. A final CRS-R is performed 8 week after the end of the session to assess the potential long term effects of tDCS.
2575854|NCT02394353|Active Comparator|Sleeve Gastrectomy|Patients undergoing the sleeve gastrectomy surgery
2575859|NCT02394353|Active Comparator|Gastric Bypass|Patients undergoing the gastric bypass surgery
2575885|NCT02393898||Elderly Participants with Ovarian Cancer|Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.
3210267|NCT00993070|Placebo Comparator|placebo|
3210268|NCT00993083|Experimental|Vaccinated|14 volunteers (2 in lead safety group and 12 in main study group) to receive MVA-NP+M1 via the IM route. Volunteers will then be challenged with Influenza 30 days post vaccination.
3210269|NCT00993083|No Intervention|Control|12 volunteers who will not receive vaccine but will also be challenged with Influenza on day 30
3210270|NCT00993096|Experimental|IDegAsp low|
2576075|NCT02392754|Experimental|Screening|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
2576076|NCT02392754|No Intervention|Control|The control group receives standard care for 6 months (including a pulse check and heart auscultation by a physician at 6 months).
3210271|NCT00993096|Experimental|IDegAsp middle|
3210272|NCT00993096|Experimental|IDegAsp high|
2576274|NCT02391493|Experimental|healthy early bilinguals|healthy early bilinguals functional magnetic resonance imaging
2576278|NCT02391493|Experimental|healthy late bilinguals|healthy late bilinguals functional magnetic resonance imaging
2576284|NCT02391493|Experimental|bilingual patients|bilingual patients suffering from low-grade glioma in the language areas functional magnetic resonance imaging
2576318|NCT02391051|Experimental|Focal Brachytherapy|HDR-Brachytherapy, 2 fractions within at least 24 but max. 30 hours, each 13,5 Gy
2576353|NCT02390856|Active Comparator|Volar Plate|Patients in this group will undergo distal radius fracture fixation with a traditional volar plate.
2576356|NCT02390856|Experimental|Conventus DRS|Patients in this group will undergo distal radius fracture fixation with the Conventus DRS intramedullary fixation device.
3210273|NCT00993096|Experimental|BIAsp 30 low|
3210274|NCT00993096|Experimental|BIAsp 30 middle|
3210275|NCT00993096|Experimental|BIAsp 30 high|
3210276|NCT00993109|Experimental|Arm 1|
3210277|NCT00993109|Active Comparator|Arm 2|
3210278|NCT00993122|Active Comparator|ribavirin pre-treatment|patient will receive ribavirin in monotherapy for 8 weeks before the combined 48 weeks antiviral therapy
3210279|NCT00993122|Active Comparator|combined stardard therapy|patients will receive the standard combined therapy with ribavirin and pegylated interferon for 48 weeks
3210280|NCT00993161|Experimental|patients|Patients with neuromuscular disorder and controls
3210281|NCT00993161|Experimental|Controls|healthy controls
3210282|NCT00993174|Experimental|Topical anesthesia|Patients undergo strabismus surgery for esotropia using topical anesthesia (instillation of drops plus gel)
2575301|NCT02398175||Pediatric polytraumatized patients with thoracic injuries|Pediatric polytraumatized patients (age < 18), (ISS > 16) with thoracic injuries
2575354|NCT02397811|Experimental|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
2575355|NCT02397811|Experimental|Liposomal Astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 2.66 grams per dose
2575358|NCT02397811|Experimental|Standard Softgel|Standard softgel containing 4 mg per softgel. 3 softgels per dose
2575359|NCT02397811|Experimental|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
2575361|NCT02397811|Experimental|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
2575363|NCT02397811|Experimental|Standard Softgel with Astaxanthin Gel|Statndard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 softgels per dose
2575395|NCT02397343|Other|Session 1|HBO given the first day of study period and sensory test battery performed. 4 weeks later no intervention is given but the sensory test battery performed.
2575403|NCT02397343|Other|Session 2|No intervention first day of study period and sensory test battery performed. 4 weeks later HBO intervention is given and the sensory test battery performed.
2575462|NCT02397161|Experimental|AT-NMT|AT-NMT group - will receive a 12-week EEG biofeedback mental attention-neuromuscular training
2575464|NCT02397161|Experimental|NMT alone|NMT group - will receive a 12-week neuromuscular training
2575469|NCT02397161|Experimental|AT alone|AT group - will receive a 12-week EEG biofeedback mental attention training
2575475|NCT02397161|No Intervention|Control|Control group - no intervention for 12 weeks
2575494|NCT02396589|Active Comparator|Education Group|Participants in the Education group receive five 90 minute tailored stroke education sessions in the home.
2575497|NCT02396589|Experimental|Home Modifications Group|Participants in the treatment group receive a home assessment and home modifications tailored to functional abilities (pre discharge) and then five 90 minute occupational therapy treatment sessions at home (post discharge) to improve functional abilities and community participation.
2575554|NCT02396329|Experimental|chlorhexidine _based antisepsis|"Including cases undergoing elective&non elective caesarean section.Patients will be were prepared similarly by three applications of 2%chlorhexidine solution time given between each application about 30 seconds followed by drying with a sterile towel and three applications of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision.~."
2575561|NCT02396329|Active Comparator|povidone_iodine based antisepsis|Including cases undergoing elective&nonelective caesarean section.Patients will be scrubbed preoperative with an applicator that contain 10%povidone-iodine scrub aqueous solution(3 consecutive applications)followed by drying with sterile towel and 3 application of 70% alcohol after one minute The area scrubbed was from the xiphoid to the knee, reaching the midaxillary line laterally. In both groups, patients received preoperative prophylactic i.v antibiotics (cefotrixone 1 gm) one hour before skin incision
2575613|NCT02395861|Experimental|Electrophysiologic analyses|
2575670|NCT02395523|Experimental|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
2575704|NCT02395068|Experimental|Single-dose PK|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation. 1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
2575716|NCT02395068|Experimental|Weekly fixed dose|Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks.
2575727|NCT02395068|Experimental|Bioweekly fixed dose PK|Nimotuzumab 600mg, administered once every 2 weeks for 8 weeks. Dosing regimens can be adjusted according to the results of preliminary experiments. Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h
2575786|NCT02394626|Experimental|Surgery followed by adjuvant second-line therapy|Surgery followed by adjuvant second-line therapy
2575791|NCT02394626|Active Comparator|Second-line therapy alone|Second-line therapy alone
2575861|NCT02394197|Active Comparator|14-day treatment (T14)|"The operational treatment-dose was administered by mouth. The number of tablets of Chloroquine phosphate of 150 mg for three days (x-x-x/ number of tablets of Primaquine (15mg or 5 mg)), daily during 14 days. For 1 year old subjects only chloroquine (1-½-½/ ½ of 5 mg); for 2-5 years old (1-¾-1/ 1 of 5 mg); 6-12 years old (2-1-2/ 2 of 5 mg); 13 years old and over with about 60 kg of body weight (3-2-2/ 1 of 15 mg) and above 60 kg of body weight (4-3-3 / 1 of 15 mg).~According to the age group as indicated by the Mexican guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html) (Table 10)"
2575863|NCT02394197|Experimental|Intermittent single doses (ISD)|"The single dose medication was administered orally according to age group as the operational table: (number of tablets of chloroquine phosphate of 150 mg / number of tablets of primaquine (15mg or 5 mg)): for 1 year old (½ / 1 of 5 mg); for 2¬-5 years old (1 / 2 of 5 mg); 6-12 years old (2 / 4 of 5 mg); 13 years old and over of about 60 kg of body weight (3 / 2 of 15 mg), and above 60 kg of body weight (4 / 3 of 15 mg).~It is administered on Days 0 (after the detection of infection by microscopy), and Days 30, 60, 180, 210, 240 and 360 as indicated in the National guidelines for vector borne diseases control (http://www.salud.gob.mx/unidades/cdi/nom/032ssa202.html)."
2575942|NCT02393833|Active Comparator|Induction chemotherapy|Approved induction CT regimen after randomization
2575944|NCT02393833|Experimental|Induction chemotherapy followed by CM maintenance|Approved induction chemotherapy followed by 12 months of CM maintenance
2575989|NCT02393430|Experimental|experimental|The experimental group were treated with rebamipide 0.1g tid and optimization of life style.
2575998|NCT02393430|Placebo Comparator|control|The control group were only optimized their life style.
2576467|NCT02390141|Experimental|ZP4207|Five multiple doses of ZP4207 in ascending doses
2575334|NCT02397941||women who deliverd|20 pregnant women, BMI < 30 kg/m2 before pregnancy, Primiparas, no abdominal pre-operations, aged 20-45 years, measurement of the abdominal muscles and interrectal distance by ultrasound, measurement after delivery (10 after spontaneous delivery, 10 after elective cesarean section)
3175986|NCT00640068||1|All patients in whom a clinical CCTA was ordered by their physician at a participating site. Patient must have a prescription for CCTA ordered by their physician.
3175987|NCT00640081|Active Comparator|D|Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment
2575538|NCT02396459|Experimental|MCT8 deficiency patients|Triac treatment
2575544|NCT02396134|Experimental|Arm I (CMVpp65-A*0201 peptide vaccine)|Patients receive CMVpp65-A*0201 peptide vaccine SC on days 28 and 56 after HCT.
2575547|NCT02396134|Placebo Comparator|Arm II (placebo)|Patients receive placebo SC on days 28 and 56 after HCT.
2575699|NCT02395211|Active Comparator|Usual Physiotherapy|
2575700|NCT02395211|Experimental|Gloreha device|
2575709|NCT02394860||blood and cardiological examination|
2575783|NCT02394743||eGFR > 90|group whose eGFR is more than 90
2575788|NCT02394743||60 < eGFR <90|group whose eGFR is between 60 and 90
2575793|NCT02394743||eGFR < 60|group whose eGFR is less than 60
2575842|NCT02394327|Active Comparator|Endoscopic nasogallbladder drainage|If GB cannulation was achieved and the wire was coiled in the GB, 5 to 7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
2575845|NCT02394327|Active Comparator|Endoscopic gallbladder stenting|If GB cannulation was achieved and the wire was coiled in the GB, 7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA) was placed into the GB
2575890|NCT02393989|Experimental|Active comparator|posterior restorations
2575948|NCT02393651|Placebo Comparator|Sham|Motor training of the affected upper extremity combined with sham tDCS.
2575950|NCT02393651|Experimental|tDCS|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
2576043|NCT02392845|Experimental|Combination of Docetaxel (DTX) and Epirubicin (EPI)|
2576113|NCT02392715|Experimental|Intervention cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' inspiratory muscle training with Threshold by Respironics~Inspiratory muscle training intensity: 15% of maximal inspiratory pressure (PiMax) during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
2576116|NCT02392715|Sham Comparator|Control cohort|"36 sessions of 60 - 75 minutes with a frequency of 3x/week~30' endurance training, 15' strength training, 15' sham inspiratory muscle training with Threshold by Respironics~Sham inspiratory muscle training intensity : 5 centimeters of water (cmH20)"
2576213|NCT02391779|Experimental|BeneFlax® + walking training (Dash)|BeneFlax (0.8 g, twice a day) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
2576220|NCT02391779|Placebo Comparator|Placebo + walking training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with exercise training (30-60 minutes walking training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
2576223|NCT02391779|Experimental|BeneFlax® + flexibility training (Dash)|BeneFlax (0.8 g, twice a day) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
2576225|NCT02391779|Sham Comparator|Placebo + flexibility training (Dash)|Placebo (whey powder isocaloric to BeneFlax) with placebo exercise training (flexibility training, 5 times a week) for 8 weeks; all participants encouraged to follow Dash Eating Plan.
2576251|NCT02391324|Experimental|Lokomat (LOK)|Two 50-minute sessions per week. The manualized LOK walking protocol provides methods for progressing/tracking including a 5-minute overground walking session after the LOK to facilitate transfer of motor learning from the LOK to usual walking devices. The goal-based LOK program uses a standardized approach to progressing LOK body weight and guidance support and includes upper body activities while walking to encourage dual tasking and improved posture, and motor imagery practice.
2576254|NCT02391324|Experimental|Gait focused physical therapy (fPT)|Two 50-minute sessions per week. Each weekly fPT session consists of 50 minutes of active treatment, a 'dose' equivalent to time spent in active treatment in the LOK arm. Techniques that focus on body structure changes will be not be permitted (e.g., inhibitive casting, kinesiotaping, functional electrical stimulation).
2576469|NCT02390141|Placebo Comparator|Placebo|Five multiple doses of corresponding placebo in ascending doses
3175988|NCT00640081|Experimental|E|Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment
3175989|NCT00640094|Experimental|A: Melatonin|Melatonin: intravenous infusion and intracoronary bolus
3175990|NCT00640094|Placebo Comparator|B: Placebo of melatonin|Placebo: intravenosus infusion and intracoronary bolus
3175991|NCT00640120||1|Asthmatic subjects
3175992|NCT00640120||2|Healthy subjects
3175993|NCT00640159|Experimental|A|Open label switch from current oral selegiline dose to orally disintegrating selegiline (Zelapar) titrated to a dose of 2.5 mg QD.
3175994|NCT00640172||Anemic Elderly|
3175995|NCT00640172||Non-anemic adults (non-elderly, without bone marrow biopsy)|
3175996|NCT00640172||Non-anemic adults (non-elderly, with bone marrow biopsy)|
3175997|NCT00640172||Non-anemic Elderly (control without bone marrow biopsy)|
3175998|NCT00640172||Non-anemic Elderly (control, with bone marrow biopsy)|
3175999|NCT00640185|Placebo Comparator|1|
3176000|NCT00640185|Experimental|2|
3176001|NCT00640185|Experimental|3|
3176002|NCT00640198|Active Comparator|Group 1 Memantine|Patients included in this group will receive memantine alone followed by memantine combined with intensive speech-language therapy.
2575405|NCT02397356|Active Comparator|Placebo first BA|Patients in this group will first receive physiological salt in the nebulised form form when they ask for pain relief. The second time they ask for pain relief, they will receive a dose of ketamine in the nebulised.
2575435|NCT02397018|Experimental|Allogeneic Umbilical Cord Blood Infusion|All subjects in this study will receive an intravenous infusion of ABO/Rh matched umbilical cord blood.
2575479|NCT02396797|Experimental|The new atWork intervention|The intervention group will receive the new atWork intervention, which include a management course and workplace courses for all employees targeting mental health complaints and musculoskeletal complaints.
2575482|NCT02396797|Active Comparator|The original atWork intervention|The control group will receive the original atWork intervention, targeting musculoskeletal complaint, and peer support.
3210283|NCT00993174|Active Comparator|Sub-Tenon's anesthesia|Patients undergo surgery for strabismus (esotropia) using sub-Tenon's administration of anesthetic (xylocaine)
2575584|NCT02396121|Experimental|Interventional|Administration of 1 bottle of an oral nutritional supplement, Renutryl® Booster (600 kcal), during 28 days.
2575636|NCT02395874|Experimental|verum-tDCS|verum-tDCS+ speech therapy
2575638|NCT02395874|Sham Comparator|sham-tDCS|sham-tDCS + speech therapy
2575676|NCT02395328|Experimental|Care worker home visitation|Care Workers provide biweekly home visits and offer residing caregivers and children information and psychosocial support, and encourage their awareness and accessing of external health and social services.
2575679|NCT02395328|No Intervention|Wait List|Access to homework classes are made available to all participants' children at schools supported by the implementing organization.
2575705|NCT02395094|No Intervention|Group 1 (Standard Procedure)|Group 1 (Standard Procedure) will receive BCCH standard care, which consists of topical anesthetic cream, waiting with parents in the playroom in the surgical daycare unit preoperatively, parental presence in the OR, the BCCH 'parent hug' and standard distraction techniques
2575721|NCT02395094|Experimental|Group 2 (Child Life)|Group 2 (Child Life) will receive Child Life intervention applicable to the individual patient, on the day of surgery in addition to standard practices
2575778|NCT02394717|Other|Intervention|All YMCA programs will receive the Healthy Eating and Physical Activity Intervention throughout the study. All programs will receive the HEPA Strategies intervetion to assist them with achievement of the HEPA Standards.
2575840|NCT02394405||valve surgery|valve plasty/replacement surgery
2575841|NCT02394405||off-pump CABG|off-pump CABG
2575844|NCT02394405||CPB-CABG|CABG with CardioPulmonal Bypass
2575930|NCT02394054|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
2575938|NCT02394054|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
2575969|NCT02393508|Active Comparator|Fresh Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are less than or equal to 7 days of age from the time of donation.
2575973|NCT02393508|Active Comparator|Aged Human Red Blood Cells|Participants will receive transfusion of human donor red blood cells that are greater than 21 days and up to a maximum of 42 days of age from the time of donation.
2576027|NCT02393118|Experimental|BrainPort V200 Device|Single Arm
2576060|NCT02392780|Experimental|Cannabidiol|
3210284|NCT00993213|Active Comparator|Liposuction|Standard of Care with Liposuction
3210285|NCT00993213|Sham Comparator|No Liposuction|Standard of Care without Liposuction'
2576183|NCT02392052|Experimental|Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
2576185|NCT02392052|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
2576249|NCT02391454|Other|Group A|usual care
2576253|NCT02391454|Experimental|Group B|usual care + RunKeeper app
2576301|NCT02391207||patients having at least one CLM|Hepatic vein-sparing hepatectomy guided by intraoperative ultrasonography
2576339|NCT02390973|Active Comparator|Sleeve gastrectomy|
2576342|NCT02390973|Active Comparator|Roux-en-Y Gastric Bypass|
2576344|NCT02390973|Active Comparator|Biliopancreatic Diversion|
2576348|NCT02390973|Active Comparator|Control|the best medical management of their diabetes, non-surgical group
2576362|NCT02390570|Experimental|Implementation Arm|
2576408|NCT02390505|Experimental|Vitamin C|Patients receive vitamin C at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
2576409|NCT02390505|Placebo Comparator|Placebo|Patients receive placebo at a daily dose of 500 mg orally: 7 days before and during 6 weeks after surgery
2576420|NCT02390206||Botulinum toxin type A (BoNT-A) injection Naïve|Subjects naïve to BoNT-A treatment. Investigators follow their individual injection protocol for treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines).
2576493|NCT02389868|Experimental|Lovastatin|
2576573|NCT02389660|Experimental|Blended CBT|Internet based blended depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, and (4) relapse prevention. These will be delivered over 13 sessions (6 online and 7 face-to-face, session sequence - alternate, online platform - Moodbuster).
2576710|NCT02388412||Vulnerable plaque in optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels.
2575444|NCT02396979|Experimental|Holistic Health Recovery Program|Administration of the Holistic Health Recovery Program (HHRP-M), which is an eight-session substance abuse relapse prevention and harm reduction program administered by a trained substance abuse counselor.
2575449|NCT02396979|Experimental|Methadone Maintenance and Holistic Health Recovery Prorgram|Methadone induction and management provided in combination with the Holistic Health Recovery Program (HHRP-M).
2575451|NCT02396979|No Intervention|Standard of Care|Standard of care provided for substance abuse treatment. No methadone maintenance or holistic health recovery program intervention provided.
3210286|NCT00993239|Experimental|Birinapant (TL32711)|
3210287|NCT00993278|Active Comparator|Low-Carbohydrate (Modified Atkins) Diet|
3210288|NCT00993278|Active Comparator|Low-Fat (Heart Healthy) Diet|
3210289|NCT00993304|Experimental|A|
2575689|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in India)|Investigational products :Reference formulation Trade Name: Amaryl® M IR 2/1000 (manufactured in India) Dosage Form: Film coated tablet 1x1 Active Substance: Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Goa, India
2575690|NCT02395237|Experimental|Amaryl® M IR 2/1000 (manufactured in Turkey)|Dosage form: Film coated tablet 1x1 Active substance : Glimepiride/metformine HCl 2 mg/1000 mg Manufacturer: Zentiva TR, Lüleburgaz
3210290|NCT00993304|Placebo Comparator|B|
2575777|NCT02394535|Experimental|Treatment (chemotherapy, radiation therapy)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, 15, 22, and 29 and capecitabine PO BID on days 1-5 (Monday-Friday). Patients also undergo radiation therapy QD on days 1-5 (Monday-Friday). Treatment continues for 51/2 weeks in the absence of disease progression or unacceptable toxicity.
2575855|NCT02394210||Group 1|Patients in relapse/biological progression (under the criteria of the IMW (International Myeloma Workshop) Consensus Panel 1 not receiving treatment until clinical relapse.
2575858|NCT02394210||Group 2|"Patients in relapse/biological progression receiving anti-MM treatment at the time of relapse/biological progression): Patients in this group may receive conventional anti-myeloma treatment as per routine clinical practice at the participating site:~Upon relapse/biological progression, defined as per the criteria of the IMW (International Myeloma Workshop) Consensus Panel Panel1 Or~Upon a significant relapse of paraprotein, defined as:~Duplication of M-component in two consecutive readings taken ≤2 months apart; or~An increase in absolute levels of serum M-protein ≥1 g/dL or M-protein in urine at ≥500 mg/24h, or~Increase in light chain levels ≥20 mg/dL with an abnormal ratio in two consecutive readings taken ≤2 months apart), which suggests the presence of biological progression/relapse criteria, but without including any clinical details of those involved in clinical relapse."
2575908|NCT02393716|Other|Endovascular repair|Endurant Evo AAA Stent Graft System
2576000|NCT02393443|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
2576002|NCT02393443|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter. Participants will self-administer 5 puffs per nostril.
2576045|NCT02393001||Dermatology patients|Patients seen in the dermatology clinic with suspicious skin lesion to be biopsied will have 4 skin swabs, 2 of the skin lesion and 2 of an area of unafflicted skin.
3210291|NCT00993330||1|20 healthy subjects between 18 and 40 years
3210292|NCT00993330||2|20 healthy subjects between 41 and 50 years
2576311|NCT02391259|Experimental|AMG 557|AMG 557 administered as subcutaneous and intravenous doses.
2576313|NCT02391259|Placebo Comparator|Placebo|No active drug
2576385|NCT02390687|Placebo Comparator|Placebo Arm|Placebo Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
2576387|NCT02390687|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (3 Lozenges per day; 1 lozenge in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
2576427|NCT02390388|Active Comparator|pudendal block group|nerve stimulated pudendal nerve block performed under general anesthesia
2576435|NCT02390388|Active Comparator|Caudal block group|caudal block performed under general anesthesia
3210293|NCT00993330||3|20 healthy subjects between 51 and 60 years
3210294|NCT00993330||4|20 healthy subjects between 61 and 70 years
3210295|NCT00993330||5|20 healthy subjects between 71 and 80 years
3210296|NCT00993330||6|20 healthy subjects between 81 and 90 years
3210297|NCT00993343|Active Comparator|Cyclosporine + Methotreaxte|
3210298|NCT00993343|Active Comparator|sirolimus + tacrolimus|
3210299|NCT00993356|Other|Group 2|After a baseline evaluation, patients underwent transsphenoidal surgery (direct surgery group).
3210300|NCT00993356|Experimental|Group 1|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
3210301|NCT00993369||Healthy newborns conceived naturally|
3210302|NCT00993369||Healthy newborns conceived with IVF|
3210303|NCT00993382|Experimental|Celivarone 50 mg|Celivarone, 50 mg once daily up to 10-15 days before the common study end date
3210304|NCT00993382|Experimental|Celivarone 100 mg|Celivarone, 100 mg once daily up to 10-15 days before the common study end date
3210305|NCT00993382|Experimental|Celivarone 300 mg|Celivarone, 300 mg once daily up to 10-15 days before the common study end date
3210306|NCT00993382|Active Comparator|Amiodarone|Amiodarone, 600 mg once daily for 10 days (loading dose) then 200 mg once daily up to 10-15 days before the common study end date
3210307|NCT00993382|Placebo Comparator|Placebo|Matching placebo once daily up to 10-15 days before the common study end date
3210308|NCT00993395|Experimental|Peer Mentor Intervention|peer mentor-based disease management focusing on three domains: medical care, recovery, and social stabilization
3260261|NCT01477645||Modified non-leaded ammunition|
3260262|NCT01477658||Congenital AV Block|Patients diagnosed with Congenital Complete Atrioventricular Heart Block
2575490|NCT02396667||pregnant women with macrosomia|Pregnant wo.en between 37 and 42 weeks with fetal macrosomia as suspected by clinical estimation and 2D ultrasound.
3210309|NCT00993408|Experimental|ACT-293987 (NS-304) and matching placebo|"Subjects will be randomized to the study following screening.~Each subject will then undergo an acute hemodynamic study with right heart catheterization after a single oral administration of ACT-293987 (NS-304)on Day 0. The objectives are to collect data about the drug effect on the right heart hemodynamic parameters (PVR, calculated SVR and PVR/SVR) measured by right heart catheterization after single oral dose administration of NS-304 and to assess the safety and tolerability of a single oral dose of NS-304."
2575710|NCT02395198||HCV negative or in HCV treatment at T1|This group will be followed up at T2
2575795|NCT02394522|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
2575799|NCT02394522|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
2575833|NCT02394249|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing and 8 hours sleeping.
2575835|NCT02394249|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of >1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
2575943|NCT02394080|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
2575958|NCT02393469|Placebo Comparator|Group phase 1|Two months of education and self-management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
2575962|NCT02393469|Experimental|Group phase 2|Pulmonary rehabilitation for two months: The same patients enter phase 1 phase 2 performing this two months of pulmonary rehabilitation are also included new patients who participate directly in phase 2
2575964|NCT02393469|Experimental|Group phase 3|Pulmonary rehabilitation for ten months: Participate participants of phases 1 + 2 and 2, as well as new participants enter directly in phase 3
2576014|NCT02393196|Active Comparator|Group Preloading (Group P)|Group Preloading (Group P): 500 mL hydroxyethyl starch (6% HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible before spinal anesthesia.
2576015|NCT02393196|Active Comparator|Group Coloading (Group C)|Group Coloading (Group C): After the patients have been monitored, spinal anesthesia will be performed. Recognizing the cerebrospinal fluid, 500 mL hydroxyethyl starch (%6 HES 130/0.4) (Voluven®; Fresenius Kabi, Bad Homburg, Germany) will be infused via a pressure infusion system at a maximum speed as possible.
2576054|NCT02392884|Active Comparator|EON-MEM|Intervention: Cognitive Rehabilitation and compensatory strategies will be taught to subjects to help them remember routes, viral load count, CD4 count, faces of providers and managing their schedules. Over the course of 5 visits, subjects will receive this intervention.
2576057|NCT02392884|Active Comparator|Compensatory Cognitive Training|Cognitive Rehabilitation and physical reminders, such as calendars, smart phones, self-notes and other methods to help subjects remember to attend all medical appointments and take their HIV medication. Subject will be exposed to 5 sessions of this particular training.
2576058|NCT02392884|No Intervention|Psychoeducation|The psychoeducation group, which aims to teach subjects the importance of taking medications and attending all doctor's appointment for HIV treatment. If you subjects are assigned to this group, they will be followed and receive the care generally followed for individuals with this condition.
2576100|NCT02392546|Experimental|Elobixibat 10 mg|elobixibat
2576106|NCT02392546|Experimental|Elobixibat 15 mg|elobixibat
2576108|NCT02392546|Experimental|Elobixibat 20 mg|elobixibat
2576114|NCT02392546|Placebo Comparator|Placebo|placebo
3210310|NCT00993434|Active Comparator|Kid STRIDE Booklet|
2576212|NCT02391727|Other|SYN004|open label study
2576307|NCT02391428|Experimental|Children who diagnosed with ADHD|The ADHD children will be asked to consume omega3 capsules for 6 months. Blood will be taken for omega3 analysis in day 0, after 3 and 6 months.
2576309|NCT02391428|Experimental|Control group of children without ADHD|"Blood test:~The control group of 30 children (age and gender match) without ADHD and related neuropsychiatric syndromes, who were hospitalized due to surgical or orthopedic problems. Only when blood will be taken for clinical purposes, the investigators will ask the children and their parents to allow the collection of an additional small blood tube."
2576351|NCT02390882|Placebo Comparator|Placebo|Tamsulosin placebo (12 weeks)
2576352|NCT02390882|Experimental|Treatment 1|HGP0412 capsule (12 weeks)
2576355|NCT02390882|Experimental|Treatment2|HIP1402 capsule (12 weeks)
2576395|NCT02390544|Experimental|Melphalan in Patients Receiving HSCT|"The investigators will recruit approximately 30 patients who are scheduled to undergo allogeneic transplant with reduced intensity conditioning that includes melphalan. Approximately 10 patients who will receive melphalan as part of their conditioning regimen for an autologous transplant will also be recruited.~A test dose of melphalan will be administered prior to the start of the HSCT preparative regimen. The test dose will equal 10% of the standard dose. Blood samples will be drawn for pharmacokinetic measurement prior to and after the administration of the test dose and again around the full standard dose of melphalan. Urine samples will also be collected around the test dose and full standard dose of melphalan to measure markers of kidney injury."
2576445|NCT02390336|Experimental|Real mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the real mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
3210311|NCT00993434|Placebo Comparator|Safety Booklet|
2576674|NCT02388620|Experimental|Severe Hepatic Impairment|Child-Pugh Classification C (score 10-15)
2575498|NCT02396615|Placebo Comparator|Control|SATIN pineapple control. Control juice - normal juice prpoducts without added active ingredients
2575557|NCT02396368|Experimental|Radium 223 and Tasquinimod|"During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day.~Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks)."
2575610|NCT02395887||Intervational|Patients with back or neck pain who are a candidates for operational intervention.
2575612|NCT02395887||Control|Men or women who haven't seek for spine surgery consultation.
2575677|NCT02395549|Experimental|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
2575678|NCT02395549|Experimental|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
2575680|NCT02395549|Experimental|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel will be applied bid to the whole face for 12 weeks.
2575681|NCT02395549|Placebo Comparator|Vehicle Control Gel|Vehicle Control Gel will be applied bid to the whole face for 12 weeks.
2575702|NCT02394873|Experimental|ALLO-ASC-DFU|
3210312|NCT00993460||Normal body weight|Female subjects, ages 21-65 yrs, with BMI of 21-27 kg/m2 with normal glucose tolerance.
3210313|NCT00993460||Roux-en-Y gastric bypass|Female subjects ages 21-65 with insulin resistance and scheduled for Roux-en-Y gastric bypass at Vanderbilt University Medical Center will be studied before and 4-6 weeks after surgery.
3210314|NCT00993486|Experimental|L1 (dose 1.0x10E4 T-cells/kg)|
2575860|NCT02394158|Active Comparator|Intervention arm Metformin|Metformin (500mg tablets) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
2575864|NCT02394158|Placebo Comparator|Control arm placebo|Matched placebo tablets (500mg) to start at a dose of 500mg once daily with an increase of 500mg every five days until the maximum dose of 1000mg twice daily is reached.
2575881|NCT02393846|Experimental|ketoprofen|Topical ketoprofen (gel) is the experimental drug that is applied to the ankle in a dose of 2 gr.
2575882|NCT02393846|Placebo Comparator|Placebo|Topical placebo (gel) is identical in colour, form and smell with the ketoprofen gel.
2575945|NCT02393664|Experimental|Nonintubated group|Patients undergoing thoracoscopic surgery using nonintubated technique with propofol and bupivacaine.
2575946|NCT02393664|Active Comparator|Intubated group|Patients undergoing thoracoscopic surgery using intubated general anesthesia with sevoflurane and rocuronium.
2575957|NCT02393365|Other|HCV screening|All patients admitted to the one day clinic for surgery and gastroenterology.
3210315|NCT00993486|Experimental|L2 (dose 5.0x10E4 T-cells/kg)|
3210316|NCT00993486|Experimental|L3 (dose 1.3x10E5 T-cells/kg)|
3210317|NCT00993486|Experimental|L4 (dose 3.2x10E5 T-cells/kg)|
3210318|NCT00993486|Experimental|L5 (dose 7.9x10E5 T-cells/kg)|
3210319|NCT00993486|Experimental|L6 (dose 2.0x10E6 T-cells/kg)|
3210320|NCT00993486|Experimental|L7 (dose 5.0x10E6 T-cells/kg)|
3210321|NCT00993512|Experimental|TPCS2a|No comparative treatment is given in this open-label phase I, dose escalating safety study
3210322|NCT00993525|Experimental|Intravitreal anti-VEGF|Intravitreal injection of 0.5 mg of ranibizumab
2576433|NCT02390193|Experimental|Hemodialysis|Chronic kidney disease patients undergoing hemodialysis will be recruited consecutively and screened for eligibility using a standardised protocol.
2576559|NCT02389582|Experimental|Dabigatran|Dabigatran 150mg twice a day for five days
2576560|NCT02389582|Active Comparator|Enoxaparin|Enoxaparin 1mg/kg/day twice a day for five days
2576612|NCT02389231|Experimental|Low doses of Interleukine-2|Low doses of Interleukine-2 over a 9 week treatment period
2576727|NCT02388373|Active Comparator|Seretide 250|Seretide® Evohaler® 25 microgram /50 microgram per metered dose pressurised inhalation, suspension. 25 micrograms of salmeterol (as salmeterol xinafoate) and 250 micrograms of fluticasone propionate. This is equivalent to a delivered dose (ex actuator) of 21 micrograms of salmeterol and 220 micrograms of fluticasone propionate. 2 puffs twice daily for 12 weeks Phase 1.
2576728|NCT02388373|Active Comparator|Flutiform 250|flutiform® 250 microgram/10 microgram per actuation pressurised inhalation, suspensions. 250 micrograms of fluticasone propionate and 10 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 230 microgram of fluticasone propionate/9.0 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 1 and 12 weeks in Phase 2.
2576731|NCT02388373|Active Comparator|Flutiform 125|flutiform 125 microgram/5 microgram per actuation pressurised inhalation, suspensions. 125 micrograms of fluticasone propionate and 5 micrograms of formoterol fumarate dihydrate. This is equivalent to a delivered dose (ex-actuator) of approximately 115 microgram of fluticasone propionate/4.5 microgram of formoterol fumarate dihydrate. 2 puffs twice daily for 12 weeks in Phase 2.
3210323|NCT00993538|Experimental|1|
3210324|NCT00993551|Experimental|12 month surgery|Infants will receive primary surgery at age 12 months using Sommerlad technique
3210325|NCT00993551|Experimental|6 month surgery|Infants will receive primary surgery at age 6 months using Sommerlad technique.
3210326|NCT00993577|Experimental|Exercises|Global Postural Reeducation Static Stretching Exercises
3210327|NCT00993590|Experimental|M CHESS group|The intervention group will receive access for 12 months to M-CHESS via a smartphone to: (1) contact their case managers and primary provider; (2) communicate with the managed care organization case managers; (3) communicate with peers; (4) share information about changes in health status; (5) receive reminders to take medications and complete medical follow-up; (6) receive feedback on use of their asthma action plan; (7) receive tailored inquiries and insights regarding attendance or use of asthma resources; and (8) access audio and video versions of asthma educational materials and lower reading level versions of text materials; (9) provide monthly study outcome data monthly for 12 months.
3210328|NCT00993590|Active Comparator|Control group|The control group will receive standard care plus a smartphone for 12 months; they will provide study outcome data monthly for the next 12 months.
3210329|NCT00993603|Experimental|Lifestyle programme.|8 month lifestyle programme.
3210330|NCT00993629|Active Comparator|Arm 1|adjunctive pregnenolone
3210331|NCT00993629|Placebo Comparator|Arm 2|adjunctive placebo
3210332|NCT00993642|Experimental|All Participants|
2575500|NCT02396498|Placebo Comparator|D2 radical gastrectomy+Systemic chemotherapy|8 cycles of systemic chemotherapy were performed for stage Ⅲ patients after D2 gastrectomy .Systemic chemotherapy(SP): Cisplatin: 60mg/m^2, d1 , Intravenous infusion, every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks .Subjects should be given maximum 8 cycles, or progression/intolerance.
2575505|NCT02396498|Experimental|D2 radical gastrectomy+HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after D2 radical gastrectomy. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
2575573|NCT02396290|Experimental|fractional CO2 laser with PRP|fractional carbon dioxide laser followed by intradermal injection of platelet rich plasma
2575577|NCT02396290|Active Comparator|fractional CO2 laser with NS|fractional carbon dioxide laser followed by intradermal injection of NS
2575611|NCT02395770|Experimental|Subacromial pain group|Rehabilitation Program: The program was developed to target the deficits described in individuals with SPS. It included movement training, manual therapy, strengthening and stretching exercises, and patient education. Each supervised session lasted around 30 minutes, with 75% of the session for movement training. Three treating physiotherapists supervised the program and initially attended a training session to standardize the program.
3210333|NCT00993681|Experimental|1|900 subjects will receive a two vaccination regimen with an LT patch
3210334|NCT00993681|Placebo Comparator|2|900 subjects will receive a two vaccination regimen with a placebo patch
3210335|NCT00993707|Active Comparator|0.01% CTX-100 (formerly ETX-100)|
3210336|NCT00993707|Active Comparator|0.03% CTX-100 (formerly ETX-100)|
2575796|NCT02394496|Experimental|ARM 1|Fulvestrant + Placebo Lapatinib
2575798|NCT02394496|Experimental|ARM 2|Fulvestrant + Aromatase Inhibitors + Placebo Lapatinib
2575804|NCT02394496|Experimental|ARM 3|Fulvestrant + Lapatinib
2575809|NCT02394496|Experimental|ARM 4|Fulvestrant + Lapatinib + Aromatase Inhibitors
2575978|NCT02393586|Experimental|Faropenem/augmentin|Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
2575990|NCT02393586|Experimental|Rifampicin/faropenem/augmentin|Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg
2575997|NCT02393586|Experimental|Rifampicin|Rifampicin 10mg/kg
2576039|NCT02392949|Experimental|Experimental group|Passive mobilization on cervical spine
2576044|NCT02392949|Placebo Comparator|Control|Placebo exercise on arms
3210337|NCT00993707|Placebo Comparator|Placebo|
3210338|NCT00993720|Experimental|type 1 DM with betacell function: Liraglutide|
3210339|NCT00993720|Experimental|type 1 DM without betacell function: Liraglutide|
3210340|NCT00993720|No Intervention|type 1 DM without betacell function: Insulin|
3210341|NCT00993733|Experimental|CVVHDF on-line|CVVHDF using a central water treatment plant, providing dialysate directly to the patient. They will perform a continuous veno-venous haemodiafiltration.
2576425|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 1|8 subjects (6 receiving 10mg XEN-D0103, 2 receiving placebo)
2576430|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 2|8 subjects (6 receiving 30mg XEN-D0103, 2 receiving placebo)
2576437|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 3|8 subjects (6 receiving 60mg XEN-D0103, 2 receiving placebo)
2576443|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 4|8 subjects (6 receiving 120mg XEN-D0103, 2 receiving placebo)
2576450|NCT02390258|Experimental|Part 1: Single Ascending Dose - Cohort 5|8 subjects (6 receiving 200mg XEN-D0103, 2 receiving placebo)
2576456|NCT02390258|Experimental|Part 2: Fed-Fasted|17 subjects receiving 200mg XEN-D0103 with either a high fat meal or following an overnight fast.
2576459|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 1|10 subjects (8 receiving 30mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
2576462|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 2|10 subjects (8 receiving 60mg XEN-D0103 twice daily, 2 receiving placebo twice daily)
2576463|NCT02390258|Experimental|Part 3: Multiple Ascending Dose - Cohort 3|10 subjects (8 receiving 150mg XEN-D0103 once daily, 2 receiving placebo once daily)
3210342|NCT00993733|Experimental|classical CVVHDF|CVVHDF using a mobile generator with dialysate bags. They will perform a continuous veno-venous haemodiafiltration.
2576569|NCT02389426|Experimental|Patients with Multiple Sclerosis|One examination with TCD baseline and with NIRS baseline, and a second examination with TCD after bosentan administration and with NIRS after bosentan administration will be performed; The examination will be repeated only in the patients with MS (i.e. not in control subjects) 4 h after the oral intake of one tablet 62.5 mg bosentan (Tracleer®) (when peak plasma concentrations are expected).
2576571|NCT02389426|Experimental|Healthy controls|Only one examination with TCD baseline and NIRS baseline will be performed, without administration of bosentan.
3210343|NCT00993746|Active Comparator|Bupivacaine plus lidocaine|Group 1: bupivacaine 20 ml plus lidocaine 10 ml
2576699|NCT02388503|Placebo Comparator|Reference|No added fruit extract
2576703|NCT02388503|Active Comparator|Active 1|lowest dose of fruit extract
2576705|NCT02388503|Active Comparator|Active 2|low dose of fruit extract
2576707|NCT02388503|Active Comparator|Active 3|medium dose of fruit extract
3210344|NCT00993746|Experimental|Bupivacaine alone|Group 2: bupivacaine 30 ml
3210345|NCT00993759|No Intervention|No treatment|
3210346|NCT00993759|Experimental|3804-250A lotion|
3210347|NCT00993785|Experimental|OTW Catheter System|
3210348|NCT00993811|Experimental|Circumcision|Males undergoing circumcision
3210349|NCT00993837|Experimental|conversion|
3210350|NCT00993850|Other|Bipolar disorder education|Psychoeducation
3210351|NCT00993850|Other|Cognitive behavioral therapy|Cognitive behavioral therapy for insomnia
3210352|NCT00993863|Placebo Comparator|Placebo|
3210353|NCT00993863|Experimental|ADL5859 30 mg|
3210354|NCT00993863|Experimental|ADL5859 100 mg|
3210355|NCT00993863|Experimental|ADL5859 200 mg|
3210356|NCT00993863|Active Comparator|ibuprofen 400 mg|
3210357|NCT00993876|Experimental|Selective serotonin reuptake inhibitor (SSRI)|citalopram
2575511|NCT02396628|Active Comparator|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
3210358|NCT00993876|Experimental|Serotonin-norepinephrine reuptake inhibitor (SNRI)|reboxetine
3210359|NCT00993876|Active Comparator|IPT|interpersonal psychotherapy
2575641|NCT02395614|Experimental|Chlorhexidine irrigation|0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
2575644|NCT02395614|Active Comparator|triple antibiotic irrigation|triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and 80 mg of gentamicin in 500 mL of normal saline (NS). If the patient is allergic to either component - the allergen will not be used in the solution - for irrigation. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
2575688|NCT02395250|Experimental|anti-GPC3 CAR T|
2575770|NCT02394574|Active Comparator|Clean Cookstove|Subjects will use ethanol stoves using bioethanol
2575772|NCT02394574|Other|Traditional Cookstove|Subjects will use traditional firewood or kerosine cookstove and receive education on how to reduce air pollution exposures
2575826|NCT02394431||Sickle cell disease patients|Sickle cell disease patients
2575827|NCT02394431||Healthy patients|This is the control group for the sickle cell disease patients: each sickle cell disease patient will be matched with a healthy patient of the same sex and of similar age.
2575857|NCT02394184||patients with bicuspid aortic valve stenosis|
2575877|NCT02393872|Experimental|High-risk families component|School-based intervention and counselling sessions.
2575878|NCT02393872|Experimental|All-families component|School-based intervention.
2575879|NCT02393872|No Intervention|Control|Control group.
3210360|NCT00993889|Experimental|VR during Physical Therapy|The subject will receive virtual reality during painful physical therapy sessions.
3210361|NCT00993889|Experimental|VR background pain|The subjects receives virtual reality, not during a physical therapy procedure, another time of the day for background pain.
2576001|NCT02393287||Reproline|this is an observational trial ; there is no intervention
2576024|NCT02392962|Experimental|Experimental I|This group performed static stretching
2576025|NCT02392962|Active Comparator|Experimental II|This group performed dynamic stretching
2576062|NCT02392819|Experimental|test product|Arm: Panax ginseng
2576069|NCT02392819|Placebo Comparator|placebo product|Arm: a placebo with similar appearance but without Panax ginseng. The tablet include all the other non-active bulk ingredients.
3210362|NCT00993889|Experimental|No VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
2576187|NCT02392013|Experimental|Home Modification Group|A tailored home-modification (home-hazard removal) intervention delivered in the home by occupational therapists over three visits and with a booster session at six months.
2576188|NCT02392013|No Intervention|Usual Care Group|Usual care by an Area Agency on Aging
2576224|NCT02391805|Placebo Comparator|Placebo, Every Other Day (QOD)|Placebo orally (PO) QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576227|NCT02391805|Placebo Comparator|Placebo, Once a Week (QWk)|Placebo PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576228|NCT02391805|Experimental|RO6864018, 1200 milligrams (mg) QOD|RO6864018 1200 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576229|NCT02391805|Experimental|RO6864018, 1200 mg QWk|RO6864018 1200 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576230|NCT02391805|Experimental|RO6864018, 800 mg QOD|RO6864018 800 mg PO QOD for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576234|NCT02391805|Experimental|RO6864018, 800 mg QWk|RO6864018 800 mg PO QWk for 12 weeks + noninvestigational entecavir or tenofovir as prescribed by participant's physician
2576288|NCT02391246||Positron Emission Tomography Imaging|Dual time point imaging with 250 MBq of 18F-Fluorodeoxyglucose (18F-FDG)
2576319|NCT02391077|No Intervention|Control Arm|Standard PrePex Procedure
3210363|NCT00993902|Sham Comparator|Single IUI|Single IUI will be carried on after 36-38 hours of HCG administration
3210364|NCT00993902|Active Comparator|Double IUI|
3210365|NCT00993941|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were randomly assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3210366|NCT00993941|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were randomly assigned to Group B were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as Bone Mesenchymal Stem Cells(BMSC) transplantation via portal vein.
3210367|NCT00993980|Experimental|1|qigong
3210368|NCT00993980|Active Comparator|2|exercise therapy
3210369|NCT00993993||"group early intervention"|
3210370|NCT00993993||"group late intervention"|
3210371|NCT00994006|Active Comparator|Magnesium oxide tables|Subjects will be instructed to take Magnox 520 qd
3210372|NCT00994006|Active Comparator|Magnesium citrate tablets|Subjects will be instructed to take magnesium diasporal tablets t.i.d.
3210373|NCT00994032|Active Comparator|vertebroplasty|
3210374|NCT00994032|Active Comparator|Medical Treatment|
3210375|NCT00994045|Active Comparator|Fresh Frozen Plasma|
2575532|NCT02396472|Active Comparator|Order by information relevance|In this condition some messages will be highlighted if they match the type of content the user has previously shown interest in, by previously contributing or reading semantically similar material.
2575535|NCT02396472|Active Comparator|Order by social relationship|In this condition some messages will be highlighted because they come from people the user has previously shown interest in, by previously reading their posts or communicating with them.
2575539|NCT02396472|Active Comparator|Order by help giving|In this condition some messages will be highlighted because they seek help and therefore provide an opportunity for participants to provide social support to others.
2575540|NCT02396472|Active Comparator|Order by self-disclosure|In this condition some messages will be highlighted because in them the writer is self-disclosing, and they provide provide an opportunity for participants to self-disclose in return.
2575574|NCT02396108|Experimental|Paclitaxel + Carboplatin + ASLAN001|"Phase I:~A modified 3+3 study de-escalating dose design will be employed for dose determination. Subjects will receive treatment in 21-day cycles until disease progression, intolerable toxicities or withdraws consent. In the presence of intolerable toxicities to one or more of the drugs in the regimen (but not all 3), the drug in question may be discontinued and the other drugs continued with the patient remaining in the study, if the patient is deemed to be benefiting, after discussion with the Principal Investigator.~Phase II:~Patients with stage I-III HER2-positive breast cancer with a primary breast tumour of 2cm or greater will receive up to 4 cycles of pre-operative ASLAN001 and weekly paclitaxel/ carboplatin delivered in 21-day cycles. Prior to administration of chemotherapy, there will be lead-in dosing of single-agent ASLAN001 administered daily for 2 weeks at the recommended phase II dose."
2575659|NCT02395276|Active Comparator|Whole body hypothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for whole body hypothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Whole body hypothermia will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
2575664|NCT02395276|Placebo Comparator|Whole body normothermia|Children that had an event suspected for hypoxic ischemic brain injury, according to the inclusion criteria, will be randomly allocated for normothermia therapy. Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 36-37 °C . Treatment period will be 72 hrs.
2575673|NCT02395276|No Intervention|Control|A group of children that underwent a cardiac surgery and was not suspected to have an hypoxic ischemic brain injury. This group will be undergo the similar biomarkers collection as arm 1 and 2. The information will be used to measure the change in biomarkers between surgeries with no HII to those in arm 1+2.
2575828|NCT02394223||Full Field Optical Coherence Tomography (FFOCT) procedure|
2575872|NCT02394119|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~How: Ofatumumab IV: 1500 mg/1.73m2 at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~When and how much: once; diluted in 1000 ml of normal saline."
2575874|NCT02394119|Active Comparator|Rituximab|"Drug Name: Rituximab (RTX)~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: the same as for Ofatumumab Arm~How: Rituximab IV: 375 mg/m2; for dosage between 100 and 250 mg RTX will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg RTX will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg RTX will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.~When and how much: once; diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg."
3176003|NCT00640198|Placebo Comparator|Group 2|Patients included in this group will receive placebo alone followed by memantine combined with intensive speech-language therapy.
3176004|NCT00640211||PIPET B|Participants in this study will be health care and other essential workers receiving long term neuraminidase inhibitor prophylaxis.
3176005|NCT00640237|Experimental|1|Arm 1 - the patients will receive two large doses of vitamin D.
3176006|NCT00640237|No Intervention|2|Arm 2 - the patients vitamin D status will be checked during the hospitalization and they will receive the recommendation to treat the vitamin D deficiency in the out-patient department.
2576047|NCT02392897|Experimental|High Eating Frequency|6 Eating Occasions
2576052|NCT02392897|Experimental|Low Eating Frequency|3 Eating Occasions
3176007|NCT00640263|Experimental|1|infant peri-exposure prophylaxis with lopinavir/ritonavir
3176008|NCT00640263|Active Comparator|2|infant peri-exposure prophylaxis with lamivudine
3176009|NCT00640276|Active Comparator|T|Lifestyle modification + active drug(Pitavastatin)
3176010|NCT00640276|Other|C|Lifestyle Modification
3176011|NCT00640302||PIPET A|Patients presenting at study sites with the recognised clinical case definition for pandemic influenza (to be distributed by State and Commonwealth Departments of Health when first clinical case occurs) will be eligible to be enrolled on the study. Informed consent to participate in the study will be sought including parental/guardian consent for minors and presumed consent for adults who are incapacitated (consistent with NHMRC requirements).
3176012|NCT00640354|Experimental|1|Pediatric residents randomized to having an automated external defibrillator
3176013|NCT00640354|Active Comparator|2|Pediatric residents randomized to having a manual defibrillator
3176014|NCT00640367|Experimental|IA thrombolysis|IA recombinant tissue plasminogen activator and/or mechanical thrombolysis
3176015|NCT00640367|Active Comparator|IV rtPA|IV recombinant tissue plasminogen activator
3176016|NCT00640380|Experimental|1|CPVB with NS
3176017|NCT00640380|Active Comparator|2|CPVB with LOR
3176018|NCT00640406|Experimental|STN|Device: Dynamic Renal Stent plus Best Medical Treatment
3176019|NCT00640406|Active Comparator|BMT|Drug: Best Medical Treatment
3176020|NCT00640419|Experimental|1|
3176021|NCT00640419|Experimental|2|
3176022|NCT00640419|Placebo Comparator|3|
2575779|NCT02394639|Active Comparator|conventional video-EEG monitoring|conventional video-EEG monitoring with cup-electrodes and collodion
2575784|NCT02394639|Experimental|video-EEG monitoring with prototype|video-EEG monitoring of 5 hours with EEG-cap with dry electrodes
2575915|NCT02393768||patients|patients with documented atherosclerosis on a CCTA
2575921|NCT02393768||controls|patients without atherosclerosis on a CCTA
2575977|NCT02393573|Active Comparator|Metformin|Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
2575987|NCT02393573|Placebo Comparator|Placebo|Placebo will be administered exactly in the similar way to Metformin
2576026|NCT02393105||Breast cancer survivor|Females finished primary breast cancer treatment including surgical operation, radiation therapy and chemotherapy.
2576066|NCT02392793|Active Comparator|Arm A: Talazoparib Plus Irinotecan|"Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.~Arm A is closed to enrollment."
2576071|NCT02392793|Active Comparator|Arm B: Talazoparib Plus Irinotecan Plus Temozolomide|Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
2576256|NCT02391441||Pulmonary arterial hypertension|Patients who are on the waiting list for double-LTX for pulmonary arterial hypertension.
2576258|NCT02391441||Control group|Control patients without increased pulmonary artery pressure (i.e. RV peak pressure <35 mmHg measured with echocardiography) who are on the waiting list for double-LTX.
2576303|NCT02391220|Active Comparator|Symbiotic|LCA symbiotic fermented milk, 180 g pot, twice daily.
2576306|NCT02391220|Placebo Comparator|Placebo|heat-treated fermented milk, 180 g pot, twice daily.
2576341|NCT02390960|Active Comparator|Sildenafil|Sildenafil (SST-6006) is a preserved, white to off-white, topical cream. The active ingredient is 5% sildenafil citrate by weight. During the SST-6006 dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
2576343|NCT02390960|Placebo Comparator|Placebo|Placebo cream will be the same as SST-6006 without the active ingredient, sildenafil citrate. It will be matched in appearance, smell, consistency, and color to SST-6006 topical sildenafil cream. During the placebo cream dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. The plethysmography session will be approximately 75 minutes. This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
2576363|NCT02390583|Active Comparator|control|CBT treatment of internet dependence each two weeks during 3 months
2576364|NCT02390583|Experimental|intervention|CBT treatment of internet dependence plus CBT treatment of sleep disorders during 3 months
2576461|NCT02390492|Experimental|Ipatasertib/[14C]-ipatasertib|
2576709|NCT02388503|Active Comparator|Active 4|high dose of fruit extract
3176023|NCT00640432|Active Comparator|A|
3176024|NCT00640432|Experimental|B|
3176025|NCT00640445|Experimental|Expressive Writing|Participants assigned to the Expressive Writing (EW) condition will write about their deepest thoughts and feelings associated with their experience transitioning from being a soldier to being a civilian for 20 minutes a day for 4 days within a week.
3176026|NCT00640445|Active Comparator|Control Writing|Those assigned to control writing condition will write factually about the information needs of veterans transitioning from active duty to civilian status for 20 minutes on 4 days within one week.
3176027|NCT00640445|No Intervention|No Writing Control|Treatment As Usual
3176028|NCT00640458|Placebo Comparator|Placebo|Study Period 1 or 2
3176029|NCT00640458|Experimental|Experimental|Study Period 1 or 2
3176030|NCT00640471|Active Comparator|Brivanib|
3176031|NCT00640471|Active Comparator|Placebo|
3176032|NCT00640484|Experimental|A|CHF 4226 (carmoterol) 2 μg once a day, in the morning
3176033|NCT00640484|Experimental|B|CHF 4226 (carmoterol) 4 μg once a day, in the morning
3176034|NCT00640484|Placebo Comparator|C|placebo once a day, in the morning
3176035|NCT00640484|Active Comparator|D|salmeterol 50 μg twice daily, in the morning and in the evening
3176036|NCT00640497|Experimental|1|Treatment arm
3176037|NCT00640536||1|Newly diagnosed obstructive sleep apnea patients without systemic and pulmonary arterial hypertension
3176038|NCT00640536||2|Age, sex and and body mass index-matched matched healthy subjects
3176039|NCT00640549|Placebo Comparator|2|
3176040|NCT00640549|Active Comparator|1|
3176041|NCT00640575|Experimental|A|Local
3176042|NCT00640575|Active Comparator|B|Systemic
3176043|NCT00640588|Experimental|1|Telbivudine
3176044|NCT00640588|Active Comparator|2|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
3176045|NCT00640627|Experimental|A|
3176046|NCT00640627|Placebo Comparator|B|
3176047|NCT00640640|Experimental|A|All study patients will be evaluated in a similar way
3176048|NCT00640666|Experimental|Physical activity intervention|Behavior change intervention
3176049|NCT00640666|No Intervention|Standard of care with written materials|Written materials
2575591|NCT02396017|Active Comparator|Single-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 2 liters of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion.
2575592|NCT02396017|Experimental|Split-dose Polyethylene Glycol regimen|Drug: Polyethylene Glycol Intervention: 1 liter of Polyethylene Glycol will be given in the day before Capsule Endoscopy ingestion and another 1 liter Polyethylene Glycol will be given in the same day of Capsule Endoscopy ingestion.
2575621|NCT02395731|Experimental|MIND at Home- Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
2575682|NCT02395432|Active Comparator|Totaltrack|OTI with Totaltrack
2575685|NCT02395432|Active Comparator|Macintosh Laryngoscope|OTI with Macintosh Laryngoscope
2575703|NCT02394990|Experimental|Violence Brief Intervention|Participants receive a standard of care brief motivational intervention (BMI) to address alcohol consumption (ABI) based on self reported use and their relationship between consumption and behavior, followed by an additional BMI to address how involvement in violence (VBI) impacts their life, relationship to social norms, and strategies to avoid violence.
2575715|NCT02394990|Active Comparator|Control|Participants receive only ABI
2575785|NCT02394652|Experimental|Experimental: Metformin with Standard Chemoradiation|"Metformin: About 1 week prior to the start of chemoradiation, take 850 mg of metformin, orally, once a day for 3 days, followed by 850 mg twice a day and continued for the duration of external radiation.~Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and after about 1 week of metformin (just prior to the start of chemoradiation)"
2575790|NCT02394652|Active Comparator|Standard Chemoradiation|"Chemoradiation: Cisplatin will be given intravenously at 40 mg/m2 week for 5 doses, concomitantly with external beam radiation.~FAZA-PET scan at baseline and about 1 week later (just prior to the start of chemoradiation)."
2575891|NCT02394002|Experimental|Brain surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
2575897|NCT02394002|Experimental|Spine surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
2575902|NCT02394002|Active Comparator|General surgery|Somatosensory evoked potentials in relation to anasthesia (Propofol bolus) induced burst and suppression periods in electroencephalography
2575985|NCT02393612|Experimental|DP-R202|Patients administrate DP-R202 (Sarpogrelate 300mg) once a day for 12 weeks
2575994|NCT02393612|Active Comparator|Anplag tab|Patients administrate Anplag tab (Sarpogrelate 100mg) 3 times a day for 12 weeks
2576048|NCT02393027|Experimental|patients|10 idopathic parkinson disease
2576053|NCT02393027|Active Comparator|controls subjects|10 healthy controls (no parkinson disease)
2576134|NCT02392637|Experimental|Treatment (nab-paclitaxel, cisplatin, gemcitabine)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes, cisplatin IV over 60 minutes, and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2576206|NCT02391909||Group A|Vivotif 6.9-10.0 x109 CFU/capsule
2576210|NCT02391909||Group B|Vivotif 4.0-6.8 x109 CFU/capsule
2576275|NCT02391519||High Altitude (3000 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
2576283|NCT02391519||Low Altitude (1600 m)|Collection of myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
2576323|NCT02391064|Experimental|Patient|MS Relapsing-remitting under interferon beta-1b treatment in inclusion, Secondary progressive and Primary progressive MS forms
2576328|NCT02391064|Experimental|Control|healthy subject
2576367|NCT02390635|Experimental|Diagnostic (18F-FDG PET/CT, whole body PET/MRI)|Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.
2576477|NCT02390102|Active Comparator|Erythropoietin|Dose: darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose Administered at days 10 (±4) and 1 (±1) before the index procedure.
2576478|NCT02390102|Placebo Comparator|Placebo|Dosage: Saline solution 0.9% Administered at days 10 (±4) and 1 (±1) before the index procedure.
2576514|NCT02389686|No Intervention|Without Radiotherapy|Patients just accept nipple-sparing mastectomy (NSM) without radiotherapy.
2576519|NCT02389686|Experimental|Intraoperative Radiotherapy|Followed by nipple-sparing mastectomy (NSM),INTRABEAM IORT was carried out with a single dose of 16 Gy for nipple-areola complex (NAC).
3176050|NCT00640679|Active Comparator|Clopidogrel Tapering|
3176051|NCT00640679|Active Comparator|Abrupt Clopidogrel Interruption|
2576626|NCT02388984|Experimental|Compound danshen dripping pills|Compound danshen dripping pills,20pills,tid. Duration: 24 weeks.
2576629|NCT02388984|Placebo Comparator|Placebo|Placebo,20pills,tid. Duration: 24 weeks.
2576666|NCT02388620|Experimental|Normal Hepatic Function|Normal hepatic function; matched demography to hepatic impairment cohorts
2576669|NCT02388620|Experimental|Mild Hepatic Impairment|Child-Pugh Classification A (score 5-6)
2576671|NCT02388620|Experimental|Moderate Hepatic Impairment|Child-Pugh Classification B (score 7-9)
3210376|NCT00994045|Experimental|Fibrinogen concentrate|
3176052|NCT00640692||1|
3176053|NCT00640692||2|
3176054|NCT00640705|Active Comparator|A|Topical diclofenac sodium patch
2575633|NCT02395679|Experimental|MesoCancerVac|Autologous dendritic cells loaded with a mixture of 5 allogenic mesothelioma tumor cell lysates 3 to 5 vaccinations with 10x10e6, 25x10e6 or 50x10e6 loaded dendritic cells i.d. and i.v. administration every two weeks
2575656|NCT02395354|Other|Placing a self-expanding metallic stent|Placing a self-expanding metallic stent
2575657|NCT02395354|Other|A balloon dilatation|A balloon dilatation
2575717|NCT02395016|Experimental|Nimotuzumab and Gemcitabine|"nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
2575726|NCT02395016|Placebo Comparator|Placebo and Gemcitabine|"placebo,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.~Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test."
2575836|NCT02394418|Active Comparator|Sevoflurane|Treatment of delirium by inhaled sevoflurane
2575837|NCT02394418|Active Comparator|Propofol|Treatment of delirium by propofol i.v. infusion
2575838|NCT02394418|Active Comparator|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
2575914|NCT02393924||Participants With HER2-Positive Breast Cancer|Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/mBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.
2575981|NCT02393326|Experimental|Partial pulpotomy with biodentine|Biodentine is gently applied to the pulp stumps
2575988|NCT02393326|Other|Formocresol pulpotomy|A cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min.
2576067|NCT02393183|Experimental|ASTED|"Antioxidant Supplements for TED (ASTED):~to evaluate the effect of selected antioxidant vitamins and minerals supplement (Twice daily)~β- Carotene (3 mg)~Vit C (100 mg)~Vit E (Alpha-Tocopherol Acetate): 60 IU~Vit D (500 IU)~Zinc (4 mg, elemental)~Copper (0.5 mg, elemental)~Selenium 100 µg (as Sodium Selenite)"
2576073|NCT02393183|Active Comparator|Selenium|Selenium (100mic) Twice daily
2576074|NCT02393183|Placebo Comparator|Placebo|Placebo Twice daily
2576131|NCT02392429|Experimental|Diagnostic (anthracycline, cytarabine, FLT PET/CT)|Patients receive anthracycline IV on days 1-3 and cytarabine IV on days 1-7 for up to 2 courses. Patients then undergo FLT PET/CT within 3 days before or after the nadir bone marrow biopsy (between days 10-17 after initiation of first induction cycle and prior to reinduction). Patients may undergo an optional FLT PET/CT prior to induction chemotherapy if it does not interfere with commencement of treatment.
2576201|NCT02391857|Experimental|EGDgroup|Intervention (gastric decompression by naso(oro)-gastric tube insertion) was performed
2576250|NCT02391571|Experimental|Oxycodone/Naltrexone|Oxycodone/Naltrexone Capsules (over-encapsulated), on days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
2576252|NCT02391571|Active Comparator|Oxycodone|Oxycodone Tablets (Over-encapsulated), on Days 6-10, every 6 hours (at 09:00, 15:00, 21:00)
2576255|NCT02391571|Other|Placebo Lead-In|Placebo Lead-In: Placebo Capsules (matching to Active and Experimental) on days 4-5, every 6 hours (at 09:00, 15:00, 21:00)
2576300|NCT02391181|Experimental|test product|Iron sucrose injection solution 100mg (5 mL single dose ampoule 20mg/mL elemental iron as iron sucrose in water for injection)
2576305|NCT02391181|Active Comparator|reference product|Iron sucrose injection solution 100mg (5 mL single dose vial 20mg/mL elemental iron as iron sucrose in water for injection)
2576345|NCT02390934|Experimental|Radium 223|Radium-223 (Xofigo®) will be supplied in vials as a ready-to-use solution for intravenous administration. The activity (administered radioactivity) will be 50 kBq/kg b.w., and multiple treatment activities up to 6 injections will be administered at intervals of 4 weeks.
2576376|NCT02390648|Experimental|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
2576379|NCT02390648|Placebo Comparator|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
2576457|NCT02390414||Gets HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT and actually undergo HSCT.
2576460|NCT02390414||No HSCT|Patients with higher-risk myelodysplastic syndrome (MDS) aged 60-75 who are fit for HSCT but do not undergo HSCT.
2576485|NCT02389920|Experimental|Nilotinib|nilotinib 400mg BID for 12 months
2576538|NCT02389673|No Intervention|Without Radiotherapy|Patients just accept breast-conversing surgery without radiotherapy.
2576539|NCT02389673|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
2576567|NCT02389439|Experimental|Pyronaridine-artesunate|"Pyronaridine-artesunate (Pyramax®, Shin Poong Pharmaceuticals). One tablet contains 60mg artesunate+ 180mg pyronaridine. Dosing will be according to body weight.~It will be taken orally with water, once daily for 3 days. Each dose will be administered under the supervision. A dose will be repeated in full if vomiting occurs within 30 minutes of administration of the first day of administration only.~20 - < 24 kg = 1 tab 24 - < 45 kg = 2 tabs 45 - < 65 kg = 3 tabs 65 and above = 4 tabs"
2576607|NCT02389153|Experimental|collaborative care, CHD|Participants start with the collaborative care intervention at baseline directly after inclusion.
2576610|NCT02389153|Active Comparator|collaborative care CHD - waitlist|Participants start with the intervention 6 months after baseline, in the meantime they receive tau.
3210377|NCT00994058|Experimental|Intevention with Inhibitor|
2576697|NCT02388555||Pre-operative group|Respectively recruited patients with DLS. Patients in this group were not surgically treatment. Only pre-operative radiographic parameters were measured.
2576698|NCT02388555||Surgically treated group|All DLS patients received posterior osteotomy correction of spinal deformity. The immediate post-operative radiographic measurements were performed.
2576806|NCT02387788|Experimental|15 mg AKB-9778 BID for 84 days|Subcutaneous AKB-9778 15 mg BID (total dose of 30 mg/day) for 84 days
3260263|NCT01477658||Postoperative AV Block|Patients diagnosed with postoperative AV block
2575694|NCT02395263|Placebo Comparator|Placebo|Placebo oral, once a day, 6 weeks
3176055|NCT00640705|Placebo Comparator|B|Topical patch identical in appearance to active comparator, except without diclofenac sodium
3176056|NCT00640744|Other|A|An untreated carotid plaque will be obtained at the first endarterectomy. Atorvastatin 80mg will be administered for 3 months. The contralateral (treated) plaque will be obtained at the second endarterectomy. Hence, each patient will be his/her own control
2575888|NCT02393820|Experimental|pazopanib|Pazopanib per os, 800mg daily until progression
2575970|NCT02393521|Experimental|Vibration group|Patients in the vibration therapy group received 10 self-administered sessions of vibration therapy (45-50 Hz), one session per day, remaining on their Shindo® vibration mattress at home in supine for 15 min.
2575975|NCT02393521|No Intervention|Control group|Subjects in the control group did not receive vibration therapy
2576021|NCT02393144|Other|Spontaneous labor arm|Women with term pregnancies whose labor started spontaneously. Spontaneous labor is determined by either spontaneous rupture of membranes at term and/or powerful, regular uterine contractions that cause cervical change. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Labor augmentation will be performed for women with inadequate uterine contractions, i.e. contractions measuring less than Montevideo units, irregular weak uterine contractions. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
2576022|NCT02393144|Other|Induced labor arm|Women with term pregnancies who are induced for birth before the onset of spontaneous labor. Labor will be induced with either oxytocin infusion for women with high Bishop score, or labor will be induced with dinoprostone pessary for women requiring cervical ripening, i.e. poor. Women will be admitted to labor ward after initial assessment via transperineal ultrasonography. Analgesia will be provided via administration of 50 mg intramuscular meperidine at 2 hour intervals as required. Amniotomy will be performed for women with adequate cervical dilatation and fetal head-descent. Transperineal ultrasonography will be performed at irregular intervals to assess cervical dilatation, angle of progression and fetal head position. After birth, birth time, birth weight, APGAR scores, degree of perineal trauma, episiotomy use will be recorded.
2576059|NCT02392832|Experimental|Intervention arm|Fourstar® granule formulation, 90day and 180 day briquettes Bti/Bs in larval habitats of malaria vectors.
2576063|NCT02392832|No Intervention|Control arm|No larvicide application.
2576093|NCT02392533||Pre cohort group|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
2576096|NCT02392533||Post cohort group.|Following 3 months of data collection (pre-cohort group), education regarding the documented intervertebral space versus the actual intervertebral space that the neuraxial anesthetic was administered will be provided to each anesthesiologist and resident. Following delivery of this information, an additional 3 months of data collection will be performed (post-cohort group) (the same as the first 3 months) to evaluate whether a practice change took place.
2576168|NCT02392312||ATF-Fresenius S|intravenous
2576276|NCT02391285|Experimental|pelvic floor dynamometry|
2576332|NCT02391129||Hyperion Prosthesis|Patients treated with the second generation long-stem revision prosthesis
2576333|NCT02391129||Helios Prosthesis|Patients treated with the first generation long-stem revision prosthesis
2576336|NCT02391129||Locking compression plate|Patients treated with LCP
2576365|NCT02390700||Golimumab Intravenous|Participants with rheumatoid arthritis (RA) in Canada, will be observed for 24 months. Only data available from source documentation will be collected.
2576423|NCT02390375|Experimental|A|DW-0929
2576431|NCT02390375|Active Comparator|B|Rosuvastatin
2576592|NCT02389296||Forensic Psychiatric Nurses in Mental Health Centers|Psychiatric nurses working in forensic wards in mental health centers
2576594|NCT02389296||Psychiatric Nurses in General Hospitals|Psychiatric nurses working in general hospitals
2576638|NCT02389023|Other|standard gauze dressing|a standard post-operative dressing consisting of dry gauze and tape will be placed over the surgical site
2576641|NCT02389023|Other|Prevena Incision Management System|the Prevena™ Incision Management System (PIMS) or ActiVAC® with the PrevenaTM Dressings (Peel and Place™ or Customizable™) will be placed over the surgical site. The Prevena dressing is not considered experimental and has FDA approval for coverage of at risk closed-surgical incisions. The dressing is already in clinical use for vascular surgery bypass operations at the University of Vermont Medical Center.
2576744|NCT02388178|Placebo Comparator|Fluoride free, silica based toothpaste|Control toothpaste containing no anti-cavity ingredients
2576750|NCT02388178|Experimental|fluoride + amino acid in a silica toothpaste|Experimental toothpaste containing fluoride and amino acid (arginine)
2576755|NCT02388178|Active Comparator|1450 ppm fluoride in a silica base toothpaste|Fluoride toothpaste containing fluoride as the anti-cavity ingredient
3176057|NCT00640757|Active Comparator|Low Methionine 1|Methionine deficient diet
3176058|NCT00640757|Placebo Comparator|Placebo 2|Placebo comparator methionine complete diet
3176059|NCT00640770|Active Comparator|balloon angioplasty|balloon angioplasty
3176060|NCT00640770|Experimental|Drug eluting stent|CYPHER SELECT+ Coronary or Infrapopliteal Stent
3176061|NCT00640783|Experimental|1|Mediterranean diet
3176062|NCT00640783|Active Comparator|2|Control diet
3176063|NCT00640796|Experimental|Treatment|Participants undergo haploidentical donor derived natural killer cell infusion (cells obtained from donors and selected using CliniMACS cell selection system) and chemotherapy (cyclophosphamide, fludarabine, interleukin-2, mesna).
3176064|NCT00640809|Experimental|A|
3176065|NCT00640809|Placebo Comparator|B|
3176066|NCT00640809|Active Comparator|C|
3176067|NCT00640848|Experimental|1|
2575708|NCT02394977|Experimental|Compression with Feedback|CPR performed according to established international standards with chest compressions performed with the assistance of the Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) compression feedback device.
2575720|NCT02394977|Active Comparator|Standard chest compression|CPR performed according to established international standards with standard manual chest compression
2575773|NCT02394678|Experimental|Intervention - clot removal|Patients will undergo rheolytic thrombectomy for intraventricular hemorrhage
3210378|NCT00994084|Active Comparator|Lifestyle modification|This arm receives the intervention program that includes structured physical activities and nutrition and behavior lessons
3210379|NCT00994084|Placebo Comparator|Control|This arm receives no intervention
2575886|NCT02393911|Active Comparator|Study A - with diet|Patients with LPV, treated by Low Oxalate Diet for three months.
2575892|NCT02393911|Active Comparator|Study B- no diet|Patients with LPV, not treated by Low Oxalate Diet for three months.
2575898|NCT02393911|Active Comparator|Control|Healthy women without LPV, not treated by Low Oxalate Diet
2575983|NCT02393625|Experimental|Dose Escalation|
2575991|NCT02393625|Experimental|Dose Expansion|
2576023|NCT02392975|Experimental|Fast magnetic resonance imaging (Fast MR)|All subjects will undergo fast MR in addition to Computerized Tomography (CT) (the current criterion standard). Fast MR will be interpreted independently for research purposes by 2 blinded radiologists. Consensus interpretation will be compared to the clinical reading of the CT.
3210380|NCT00994097|Experimental|A: NGR-hTNF + cisplatin/gemcitabine or cisplatin/pemetrexed|NGR-hTNF with cisplatin/gemcitabine regimen in patients with squamous histology or with cisplatin/pemetrexed regimen in patients with nonsquamous histology
3210381|NCT00994097|Active Comparator|B: cisplatin/gemcitabine or cisplatin/pemetrexed|Cisplatin/gemcitabine regimen is administered in patients with squamous histology and cisplatin/pemetrexed regimen is administered in patients with nonsquamous histology
2576124|NCT02392364|Active Comparator|Variable Treatment Dosing Arm|Group 1 will receive injections every 4 weeks until diabetic macular edema on the OCT is decreased and stable. At that point, the length of time between injections may increase, depending on how the study eye is doing. The interval between study eye treatments may maintain, increase, or decrease once the variable treatment dosing has begun. This will be determined by an algorithm designed into a computer program
2576127|NCT02392364|Active Comparator|Monthly Treatment Arm|Group 2 will receive 5 intravitreal injections, monthly, for the first 5 months of the study. After those initial injections, visits/treatment will be every 8 weeks.
2576202|NCT02391883||Clopidogrel|Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
2576207|NCT02391883||Control|Patients NOT in anticoagulation treatment (Except acetylsalicylic acid) AND who are operated <24 hours after admission.
2576264|NCT02391623|Experimental|Cohort 1|Single dose level of PF-06427878 at 5 mg or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576267|NCT02391623|Experimental|Cohort 2|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 1 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576269|NCT02391623|Experimental|Cohort 3|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 2 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576270|NCT02391623|Experimental|Cohort 4|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 3 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576272|NCT02391623|Experimental|Cohort 5|Single dose level of PF-06427878 at a dose no more than 3.5-fold increase from Cohort 4 or placebo every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576273|NCT02391623|Experimental|Cohort 6|Single dose level of PF-06427878 (with the same total daily dose as Cohort 5) or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
2576317|NCT02391012|Experimental|Fecal microbial l transplantation|patients with active colitis who will undergo treatment by fecal microbial transplantation
2576386|NCT02390830|Experimental|Intervention|Participants in the intervention group received at least 25-45' of balance treatment. The balance treatments were aimed at improving participants' control of the position and movement of the center of mass and body segments during static, dynamic and transitional tasks.
2576389|NCT02390830|Active Comparator|Control|Participants in the control group were treated to reduce limitations at body function and activity levels, while treatment for balance disorders was restricted to a maximum of 10' per session. Treatment mainly focused on increasing range of joints motion, reducing of muscle contractures and strength training.
2576412|NCT02390401|Experimental|Vacuum-assisted closure (VAC)|Prevena (VAC) device
2576414|NCT02390401|Active Comparator|Standard sterile dressing|Standard sterile dressing
2576424|NCT02390180||Sorting all tastes|This group will receive 15 samples to taste and sort into groups. The samples included: a blank solution, hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, sodium chloride (2), citric acid, acetic acid, quinine, urea, monosodium glutamate, and inosine monophosphate.
2576432|NCT02390180||Sorting bitter tastes|This group will receive 12 samples to taste and sort into groups. The samples included: blank solutions (2), decenoic acid, oleic acid, linoleic acid, quinine (2), urea (2),caffeine, sucrose octaacetate, and propylthiouracil.
3210382|NCT00994136|Experimental|Normal saline|In the intervention group the use of heparin as locking solution in the catheter lumen (or lumina) when the catheter is not longer in use is omitted. Catheters are locked under positive pressure with normal saline in stead injecting an extra volume of heparinised saline (100IU/ml).
2576655|NCT02388802|Experimental|Uterine transplant|10 patients will be appropriately selected to undergo oocyte retrieval and freezing. Subsequently deceased donor allograft excision will take place prior to uterine transplantation. Immunosuppressive agents will be used to optimise graft success until successful In-vitro fertilisation and subsequent delivery by Caesarean Section
2576713|NCT02388529|Experimental|Low dose|
2576716|NCT02388529|Experimental|Intermediate dose|
2576719|NCT02388529|Experimental|High dose|
2576721|NCT02388529|Placebo Comparator|Placebo|
3176068|NCT00640848|Experimental|2|
2575797|NCT02394509|Experimental|HOBSCOTCH-IP (in person)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted in-person, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted in-person.
2575800|NCT02394509|Experimental|HOBSCOTCH-V (virtual)|Participants will receive the HOBSCOTCH intervention consisting of a first session conducted virtually, 3 weekly followed by 3 bi-weekly telephone coaching sessions, and a final session conducted virtually.
2575805|NCT02394509|Other|Control|Participants will be wait listed and given an option whether they prefer to enroll into HOBSCOTCH-IP or HOBSCOTCH-V. Subjects in Group 3 will receive HOBSCOTCH following a 6 month wait period.
2575831|NCT02394236|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
2575832|NCT02394236|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
2575875|NCT02394106|Experimental|Ofatumumab|"Drug Name: Ofatumumab~Why: Anti-body/antigen interaction results in cell apoptosis and reduced CD20 positive cell related activities~Procedures: methylprednisolone 2 mg/kg infused in 30' IV diluted in 100 ml of normal saline (NaCl 0,9%); oral paracetamol 15 mg/kg ; cetirizine 0,4 mg/kg IV infused slowly in 5 ml of normal saline (NaCl 0,9%) prior to Ofatumumab infusion to reduce common reactions~Who provides: registered nurse~How: Ofatumumab IV at 12 ml/hour in the first 30'. Thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 200 ml/hour.~Where: in Hospital~When and how much: once; diluted in 1000 ml of normal saline~Tailoring: 1500 mg/1.73m2~How well: expert nurse would assist administration"
2575876|NCT02394106|Placebo Comparator|Placebo|"Drug Name: Normal Saline (NaCl 0,9%)~Why: standard therapy could not be used as comparator for Ofatumumab, given its toxicity and lack of effectiveness. Moreover, although Rituximab, a chimeric monoclonal anti-CD20 antibody, is increasingly being used as a steroid-sparing treatment option for children with certain forms of INS (those that respond to and are dependent of steroids), this drug does not work in DR-INS and could not be used as a comparator.~Materials and Procedures: The placebo arm will receive the same infusion as the Ofatumumab Arm with the exception of the Ofatumumab."
2575961|NCT02393404|Experimental|PT-FMT|Functional movement-power training group
2575963|NCT02393404|Experimental|FMT alone|Functional movement training group
2575965|NCT02393404|No Intervention|Control|No intervention control group
3176069|NCT00640848|Experimental|3|
2576091|NCT02392390|Experimental|The study population|"A total of 10 leg ulcer patients will be recruted for this study. All will have the experimental treatment.~Intervention: Topical Dynamic Phototherapy (TDP)"
2576209|NCT02391935|Experimental|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
2576211|NCT02391935|Placebo Comparator|Placebo|cryomedium
2576350|NCT02390895|Experimental|Minimally-invasive endoscopic repair|endoscopic repair of myelomeningocele before 26 SA
2576366|NCT02390622|Other|FMT treatment|Treat the patients by fecal microbiota transplantation
2576429|NCT02390479|Active Comparator|Chronic periodontitis|"GCF samples were taken before and after treatment chronic periodontitis patients.~Intervention: Non- surgical periodontal treatment (SRP and oral hygiene instructions)"
2576438|NCT02390479|Placebo Comparator|clinically healthy periodontium|GCF samples were taken at baseline Intervention: oral hygiene instructions
2576668|NCT02388672|Experimental|Drink high-CGA|Participants will drink once 250ml of decaffeinated coffee enriched with chlorogenic acid (CGA) (6g decaffeinated coffee (5 mg caffeine) with high total CGA (560 mg)).
2576670|NCT02388672|Placebo Comparator|Drink low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA (224 mg)
2576673|NCT02388672|Experimental|Capsules high-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and 800mg green coffee bean extract supplement with total CGA (560mg)
2576675|NCT02388672|Placebo Comparator|Capsules low-CGA|6g decaffeinated coffee (250 ml) with normal total CGA and placebo
2576677|NCT02388672|No Intervention|Control|No treatment control group
2576821|NCT02387645|Experimental|Patients prior to surgery for EC/suspicion|Patient undergoing surgery for strong suspicion of EC
2576948|NCT02387073||Electrical version|Electrical version patient reported outcome questionnaire was used for patients who had filled-up same questionnaire in a paper version
2576980|NCT02386657||Emergency admitted sickle cell disease patients|Sickle Cell Disease Patients admitted inside the Emergency Department of the Brugmann Hospital for a vaso-occlusive crisis.
2577435|NCT02383498|Experimental|Vaccine|Radiation + GI-6301 Vaccine + Actigraph
3176070|NCT00640848|Experimental|4|
3176071|NCT00640848|Experimental|5|
3176072|NCT00640874||PIPET C|Contact group members of people with diagnosed influenza who are recommended to receive NA inhibitor prophylaxis for short periods of time will be enrolled following provision of informed consent.
3176073|NCT00640887|Experimental|1|RBT associated with EFV based ART
3176074|NCT00640887|Experimental|2|RBT associated with NVP based ART
3176075|NCT00640887|Experimental|3|RBT associated with LPV/r based ART
3176076|NCT00640900|Experimental|Commercial program at center|
3176077|NCT00640900|Experimental|Commercial program over the telephone|
3176078|NCT00640900|Other|Usual care|Weight loss counseling
3176079|NCT00640913||I|Twenty consecutive patients operated on with low anterior resection of the rectum for cancer with a defunctioning stoma who accept participation.
3176080|NCT00640939|Active Comparator|A|Topical diclofenac sodium patch
3176081|NCT00640939|Placebo Comparator|B|Topical patch identical in appearance to active comparator
3176082|NCT00640965|Experimental|A|DP-VPA
2575801|NCT02394483|Experimental|Cohort A active|2 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
2575807|NCT02394483|Placebo Comparator|Cohort A placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
2575811|NCT02394483|Experimental|Cohort B active|4 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
2575814|NCT02394483|Placebo Comparator|Cohort B placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
2575815|NCT02394483|Experimental|Cohort C active|6 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
2575817|NCT02394483|Placebo Comparator|Cohort C placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
2575819|NCT02394483|Experimental|Cohort D active|8 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
2575821|NCT02394483|Placebo Comparator|Cohort D placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
2575823|NCT02394483|Experimental|Cohort E active|10 mg/kg orally F901318 safety,F901318 tolerability and F901318 pharmacokinetics
2575824|NCT02394483|Placebo Comparator|Cohort E placebo|Matching placebo safety,placebo tolerability and placebo pharmacokinetics
2575883|NCT02394041|Experimental|acupuncture|"The first session of acupuncture treatment will be performed at the inclusion visit, 2 additional acupuncture sessions will be scheduled as 1 session per week for the next 2 weeks.~One or more additional session will be performed in the delivery room."
2575887|NCT02394041|Sham Comparator|Sham acupuncture|The same as active arm but with sham needles.
2575894|NCT02394041|No Intervention|control group|Standard care, no acupuncture session.
2575953|NCT02393638|Experimental|study group|Simulation and lecture
2575954|NCT02393638|Active Comparator|control group|Lecture only
2576006|NCT02393300|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
2576008|NCT02393300|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' before the tourniquet deflation and the second dose at 180' after the first dosage
2576010|NCT02393300|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the knee cavity for at least 3 minutes before wound closure and then sucked away.
2576038|NCT02392910|Other|Group A|Placebo
2576042|NCT02392910|Other|Group B|Iron Sucrose
3210383|NCT00994136|No Intervention|Heparin lock|
3210384|NCT00994149|Experimental|Diazoxide|Infants in this are will receive 10mg/kg/d of diazoxide divided and given every eight hours
3210385|NCT00994149|Placebo Comparator|Ora-plus|Liquid suspension modified to match intervention. Given every eight hours. Provided in shielded syringes.
3210386|NCT00994162|Experimental|Negative Pressure Wound Therapy|Application of NPWT therapy to the wound
3210387|NCT00994227|Experimental|surgery|
3210388|NCT00994253|Experimental|Aliskiren|"Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day.~Patients will be assigned to the treatment arm containing aliskiren. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + aliskiren 150-300mg"
3210389|NCT00994253|Active Comparator|Hydrochlorothiazide|"HCTZ will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day.~Patients will be assigned to the treatment arm containing HCTZ. The prescribed drugs will include: Lisinopril 40mg + amlo 5mg + HCTZ 12.5-25mg"
3210390|NCT00994266|Experimental|A|Diamel
3210391|NCT00994266|Placebo Comparator|B|Placebo
2576232|NCT02391649|Experimental|Self-learning program|The participants in the Problem-solving Based Self-learning Program will complete the self-help and problem-solving manual developed by the research team for caregivers of people with psychotic disorders over 20 weeks. In addition to the orientation, understanding about psychosis and its care and final review sessions (4 sessions in 3 weeks) facilitated by the research nurse, the caregivers will work independently through the modules over 15-17 weeks.
2576237|NCT02391649|Active Comparator|Psycho-education (in Phase 2)|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's and McFarlane and his colleagues' psychoeducation programs for psychosis. The program consists of 12 two-hour sessions held weekly/biweekly (similar to the self-learning program, completed in 5 months), with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and ''review and future plan'.
2576241|NCT02391649|No Intervention|Routine community care|Participants in the control group (and treatment groups) will receive routine psychiatric outpatient and family services.
2576327|NCT02391077|Experimental|Arm 1 - Maximal intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus~Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days"
3210392|NCT00994292|Experimental|1. YM150 Dose V, twice daily|
3210393|NCT00994292|Experimental|2. YM150 Dose W, once daily|
3210394|NCT00994292|Experimental|3. YM150 Dose X, twice daily|
3210395|NCT00994292|Experimental|4. YM150 Dose Y, once daily|
3210396|NCT00994292|Experimental|5. YM150 Dose Y, twice daily|
3210397|NCT00994292|Experimental|6. YM150 Dose Z, once daily|
3210398|NCT00994292|Placebo Comparator|7. Placebo|
3210399|NCT00994305|Active Comparator|N-acetylcysteine|N-acetylcysteine 600 mg bid po 0-7 PO
3210400|NCT00994305|Sham Comparator|control|No treatment: standard care provided. No N-acetylcysteine administration.
3210401|NCT00994331|Active Comparator|Group A-CT Coregistration|5 subjects with CT co-registration in a magnetically navigated PCI (Group A)
3210402|NCT00994331|Active Comparator|Group B-Angiographic|5 subjects with angiographic co-registration in a magnetically navigated PCI (Group B)
3210403|NCT00994331|Active Comparator|Group C-Standard Angiography|5 subjects with standard angiography in a conventional PCI (Group C)
2575862|NCT02394145|Active Comparator|Clopidogrel 75mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
2575865|NCT02394145|Active Comparator|Clopidogrel 150mg in ESRD patients|After randomization, ESRD patients on HD will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 150 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
2575866|NCT02394145|Active Comparator|Ticagrelor 180mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of ticagrelor (180 mg) and maintenance doses (ticagrelor 90 mg twice daily) for 14 days. Platelet reactivity and genetic polymorphism will be assessed
2575868|NCT02394145|Active Comparator|Clopidogrel 75mg in normal kidney|After randomization, patients with normal kidney function will be treated by an initial loading dose of clopidogrel 300 mg) and maintenance doses (clopidogrel 75 mg once a day) for 14 days. Platelet reactivity and genetic polymorphism will be assessed.
2575932|NCT02393807|Experimental|Open label single dose crossover study of PF-06260414|This will be a Phase 1, open label, randomized, single dose, 3 period, 3 way crossover study to evaluate the relative bioavailability of solid dose formulation of PF 06260414 under fasted conditions compared to the nanosuspension under fasted conditions
2575971|NCT02393534|No Intervention|Usual Care|Eligible patients that are randomized to the usual care arm will have a standard in-person clinic visit with their primary care provider.
2575980|NCT02393534|Experimental|Telephone visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
2576030|NCT02393157|Experimental|Central Nervous System (CNS) Negative|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
2576032|NCT02393157|Experimental|CNS Positive|All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
2576200|NCT02391896|Other|Digital Tomosynthesis|Patient will get tomosynthesis scan
2576205|NCT02391896|Other|Dual energy|Patient will get dual energy scan
3260264|NCT01477671||Study Group|Participants aged between 5 and 10 year-old on day of inclusion.
3176083|NCT00640965|Placebo Comparator|B|
2576442|NCT02390310|Active Comparator|Phase 1 - 7 Day Removal|Shang Ring No Flip Technique: Removal of Shang Ring and assessment of healing 7 days after circumcision with no-flip technique.
2576447|NCT02390310|Active Comparator|Phase 1 - Delayed Removal|Shang Ring No Flip Technique: Removal of ring or assessment of spontaneous detachment at more than 7 days to assess occurrence and safety following circumcision with the no-flip technique.
2576453|NCT02390310|Active Comparator|Phase 2 - Topical Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery using topical anesthesia.
2576458|NCT02390310|Active Comparator|Phase 2 - Injectable Anesthesia|Comparison of Anesthesia methods for Shang Ring circumcision: Assessment of pain during and after surgery when using injectable anesthesia.
2576490|NCT02389803|Experimental|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
2576499|NCT02389803|Placebo Comparator|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and mineral
2576682|NCT02389127||Group A|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Random glucose <200 mg/dL on at least 3 occasions~No use of insulin or any hypoglycemic agent~(Group A) patients with cirrhosis and varying degrees of liver dysfunction but no prior diagnosis of T2DM will have an OGTT performed after overnight fasting (8-12-hours). HbA1c will be obtained before OGTT along with the following tests: HbA1c, fructosamine, insulin, CBC, HFP, GGT, OP Chem 7, INR, and prealbumin."
2576685|NCT02389127||Group B|"Cirrhosis, either clinically- or biopsy-proven~Child-Pugh-Turcotte (CTP) A, B, and C (only biopsy-proven in the case of CTP-A)~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent~(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (?Dexcom, ?Medtronic) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks. On the day the continuous monitor is retrieved by the investigators, patients will have the following blood tests performed after overnight fasting (8-12-hours): HbA1c, fructosamine, CBC, HFP, GGT, BMP, INR, and prealbumin."
2576688|NCT02389127||Control|"Age 18 to 75~No known chronic liver disease~Prior diagnosis of T2DM as based on any of ADA criteria~Use of insulin or any hypoglycemic agent"
3176084|NCT00640991|No Intervention|Control|Patients assigned to the control arm will receive usual care for AMI, according to local practice of each participating centre.
2575871|NCT02394171|Active Comparator|Fruit and Vegetable|Women completed a fruit and vegetable group cohesion intervention which involved six content intensive intervention sessions over a 24 week period that focused on specific group dynamics team building strategies to increase fruit and vegetable consumption. A small team structure was used for peer problem solving and support throughout. Teams were given weekly fruit and vegetable consumption goals at each session, with slowly increasing weekly servings milestones to gradually meet recommended amounts of fruit and vegetable consumption. Sessions included brief instructions, team-based activities, and discussion with the entire group lead by a trained health educator. The intervention sessions ended with the health educator leading the teams in a fruit and vegetable taste test.
3176085|NCT00640991|Experimental|Intervention|The experimental arm will have an IV infusion of glulisine insulin started directly after randomization for at least 24 hours and for as long as CCU-level care is required, and the insulin infusion will be adjusted to achieve and maintain a target glucose range of 5.0-6.6 mmol/L (90-118 mg/dL). Once transferred to the ward, patients in the experimental arm will switch to glargine insulin and will continue this treatment for the remainder of their hospitalization and after hospital discharge, for a total duration of 30 days post randomization.
3176086|NCT00641004|Experimental|1|Rebamipide 100mg TID for 12 weeks
2576126|NCT02392338|No Intervention|Thoracoscopic ablation group|Patients who will undergo thoracoscopic ablation only
2576129|NCT02392338|Active Comparator|Hybrid procedure|Patients who will undergo hybrid procedure (thoracoscopic ablation and eletrophyologic study with or without additional ablation)
2576171|NCT02392143|Active Comparator|Printed Education Material|Participants received printed education materials (PEM) sent by first class mail.
2576176|NCT02392143|Active Comparator|Academic Detailing|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices.
2576179|NCT02392143|Active Comparator|Academic Detailing+Telephone Education|Participants' primary care physicians (PCPs) received academic detailing (AD) to improve colorectal cancer screening referral and follow-up practices and participants received tailored telephone education (TTE).
2576203|NCT02391818||Breast Cancer Patients receiving ACT|Adraimycin/Cytoxan/Taxol
2576208|NCT02391818||Breast Cancer patients receiving RT only|radiation therapy
2576299|NCT02391194|Experimental|AVB-620|Eligible subjects will receive a single dose of AVB-620 as an intravenous infusion before the surgical procedure.
2576335|NCT02390947|Experimental|Famitinib arms|Famitinib 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
2576337|NCT02390947|Placebo Comparator|Control arms|Placebo 25 mg p.o. qd and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3176087|NCT00641004|Active Comparator|2|Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks
2576428|NCT02390271|Experimental|emotion focused therapy training CCT|The general training includes in an individual adjusted way the following techniques: biofeedback-assisted breathing classes that erase negative emotion involving the cardiac and limbic neural pathways, control one's own and other's emotions, mastering positive cognition and enhance self-concept, anchoring positive memories, learning how to recognize psychological reversal in others
2576549|NCT02389413|Experimental|PQ912 oral|PQ912 will be administered orally twice daily for 12 weeks.
2576550|NCT02389413|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 12 weeks.
2576747|NCT02388256|Experimental|Acupuncture|Manual and electroacupuncture
2576752|NCT02388256|Active Comparator|Enhanced recovery program after surgery|Enhanced recovery program after surgery
2576798|NCT02387827|Experimental|Diet+ short -term physical activity (DST)|
2576800|NCT02387827|Experimental|Diet+ long -term physical activity (DLT)|
2576982|NCT02386761|Experimental|Single Ascending Dose (SAD)|"Dose 1 (SAD1): 6 inhalations of CHF 6001 400 µg giving a total dose of 2400 µg~Dose 2 (SAD2): 10 inhalations of CHF 6001 400 µg giving a total dose of 4000 µg~Dose 3 (SAD3): 12 inhalations of CHF 6001 400 µg giving a total dose of 4800 µg Placebo (P): the number of placebo inhalations will match that of the active CHF 6001 pertaining to the same dose period.~In case the actual doses are modified, the number of inhalations will be adapted accordingly."
3176088|NCT00641017|Experimental|1 and 2 - Adults|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3176089|NCT00641017|Experimental|3A - Seropositive Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3176090|NCT00641017|Placebo Comparator|3B - Seropositive Children|One dose of 1x10^6 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3176091|NCT00641017|Experimental|4A - Seronegative Infants and Children|One immunization of 1x10^5 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3176092|NCT00641017|Placebo Comparator|4B - Seronegative Infants and Children|One dose of 1x10^5 TCID50 rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3176093|NCT00641017|Experimental|5A - Seronegative Infants and Children|One immunization of 1x10^6 TCID50 rHPIV1 84/del170/942A administered intranasally via nose drops at study entry
3176094|NCT00641017|Placebo Comparator|5B - Seronegative Infants and Children|One dose of rHPIV1 84/del170/942A placebo administered intranasally via nose drops at study entry
3176095|NCT00641082|Experimental|1|Clevudine
3176096|NCT00641082|Active Comparator|2|Adefovir
3176097|NCT00641095|Experimental|Fludarabine/Cyclophosphamide/Rituximab|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3 Rituximab 375mgs/m2 day 1 iv infusion~Every 28 days"
3176098|NCT00641095|Active Comparator|Fludarabine/Cyclophosphamide|"Fludarabine 40mgs/m2 oral days 1-3 Cyclophosphamide 250mgs/m2 oral days 1-3~Every 28 days"
3176099|NCT00641134|Other|A|A:Home-Based exercise program,-at discharge from in-Hospital CR program-, with one reinforcement session each month for the first 6 months.
3176100|NCT00641134|No Intervention|B|Usual care, after CR, consisting of recommendation on usefulness of physical exercise and standard follow-up visits and functional assessment at 6 and 12 months.
3176101|NCT00641160|Experimental|Cohort 1|
3176102|NCT00641160|Experimental|Cohort 2|
2575907|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 210 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (210 mg) at Weeks 0, 2, 4, 8, and 12 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
2575909|NCT02394028|Experimental|Induction Phase - Cohort 3 (Pivotal): Etrolizumab 105 mg|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive one SC injection of etrolizumab (105 mg) at Weeks 0, 4, 8, 12 and one SC injection of etrolizumab-matching placebo at Week 2 during the 14-week Induction Phase. In order to preserve the masking, participants will also receive one SC injection of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12.
2575912|NCT02394028|Placebo Comparator|Induction Phase - Cohort 3 (Pivotal): Placebo|Cohort 3 is the last to enroll participants (after Cohort 2) and will be the pivotal cohort for the Induction Phase. Participants randomized to this arm will receive two SC injections of etrolizumab-matching placebo at Weeks 0, 4, 8, and 12 (and one SC injection of etrolizumab-matching placebo at Week 2) during the 14-week Induction Phase, in order to preserve the masking.
2575916|NCT02394028|Placebo Comparator|Maintenance Phase - Placebo Responders: Placebo|Participants who received placebo during the Induction Phase (from Cohorts 1 and 3) and achieved a CDAI-70 response at Week 14 will undergo a sham randomization into the Maintenance Phase. Placebo responders from induction will receive blinded maintenance treatment with an SC injection of placebo once every 4 weeks (q4w) from Week 16 to Week 64.
2575923|NCT02394028|Placebo Comparator|Maintenance Phase - Etrolizumab Responders: Placebo|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of placebo q4w from Week 16 to Week 64.
2575928|NCT02394028|Experimental|Maintenance Phase - Etrolizumab Responders: Etrolizumab 105 mg|Participants who received etrolizumab during the Induction Phase (from Cohorts 1-3) and achieved a CDAI-70 response at Week 14 without the use of rescue therapy will be re-randomized into the Maintenance Phase. Etrolizumab responders from induction who are re-randomized to this arm will receive blinded maintenance treatment with an SC injection of etrolizumab (105 mg) q4w from Week 16 to Week 64.
2575934|NCT02394028|No Intervention|Maintenance Phase - Non-Responders: Safety Follow-Up/GA29145|All participants from Cohorts 1-3 who are considered non-responders after the Induction Phase at Week 14 may be eligible to enter the open-label extension study GA29145 (NCT02403323) and/or undergo a 12-week safety follow-up.
2576216|NCT02391792||patients|patients with septic shock
2576219|NCT02391792||control|patients without septic shock
2576221|NCT02391792||healthy volunteers|
2576265|NCT02391480|Experimental|ABBV-075|Dose escalation cohorts of ABBV-075 monotherapy
2576268|NCT02391480|Experimental|ABBV-075 and venetoclax combination|Expansion cohorts of ABBV-075 and venetoclax combination therapy
2576271|NCT02391480|Experimental|ABBV-075 expansion|Expansion cohorts of ABBV-075 monotherapy
2576316|NCT02391025|Experimental|Gallium-68 citrate|
3210404|NCT00994344|Experimental|Darunavir/ritonavir|to switch from the triple therapy based regimens to Darunavir/ritonavir
3210405|NCT00994344|Active Comparator|Lopinavir/ritonavir|to switch from the triple therapy based regimens to Lopinavir/ritonavir
3210406|NCT00994357|Experimental|Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring at five times for up to 6 days during pregnancy, and during delivery, in addition to standard monitoring and treatment.
3210407|NCT00994357|Active Comparator|Control group|Standard monitoring and treatment of diabetic patients during pregnancy.
3260265|NCT01477697|Active Comparator|Omega-3|50 mg/kg per day of omega-3 fatty acids (DHA Omega-3, Martek Biosciences, Columbia, MD)
3260266|NCT01477697|Placebo Comparator|Placebo|50 mg/kg per day of vehicle
2576632|NCT02388945|Experimental|A APDGroup|PDGO APD machines used in the PD patients for 8 weeks
2576634|NCT02388945|Active Comparator|B CAPDGroup|CAPD used in the PD Patients for 8 weeks
2576678|NCT02388711|Experimental|Usual Care with C-TraC Intervention|Patients/caregivers randomized to this group will receive all routine hospital discharge education/materials (same as usual care group), but will also be enrolled in the C-TraC Program. C-TraC is a low-resource, telephone-based, protocol-driven program designed to reduce 30-day rehospitalizations and to improve care transitions during the early post-hospital period.
2576680|NCT02388711|No Intervention|Usual Care|Usual care group patients will receive all routine University of Wisconsin Hospital and Clinics (UWHC) discharge education/materials. This includes pharmacy-led medication teaching, physician discussions and routine nursing education. No post hospital education/contact is performed by these providers. Caregivers are sometimes, but not always, involved. Patients may receive home health services, depending on their physician's discharge plan.
2576712|NCT02388399||OCT and Pressure wire pullback tracing|This study is pilot study evaluating the feasibility of invasive measurement and estimation of hemodynamic stress acting on plaque as well as co-registration of hemodynamic data with plaque geometric data, which is obtained by optical coherence tomography
2576770|NCT02388113|Experimental|accumulated exercise|12 exercise sessions of 10 minutes each week, 2 per day, 1 day rest
2576772|NCT02388113|Active Comparator|traditional exercise|4 exercise sessions of 30 minutes each week, 3 in the training laboratory, 1 at home.
2576804|NCT02387879||Group 1|"Subjects should be chosen among relapse/refractory multiple myeloma patients who have received at least one prior antimyeloma chemotherapy regimen (excluding treatment regimens with steroid only) with adequate dose and duration (≥2 cycles) or who have relapse/refractory multiple myeloma after stem cell transplantation.~Patients who are eligible for the study will be consecutively enrolled in the study until the targeted patient number is reached. The responsible investigator will be requested to keep a log of subjects who are invited to enter the study. In the case of any of these subjects will not be enrolled in the study, this information will be documented together with its reason"
3260267|NCT01477723|Experimental|Experimental Oral Nutrition Supplement|Experimental ONS orally Two 8 fl oz servings/day
3260268|NCT01477723|No Intervention|No Product|
3260269|NCT01477736|Active Comparator|Botulinum toxin A|
2575976|NCT02393495|Experimental|Non ultrasound guided group|the intrauterine device TCu 380A will be inserted in the conventional method, and checked afterwards by transvaginal ultrasound.
2576028|NCT02393131|Experimental|Hippocampal avoidance WBRT|Conformal whole brain radiotherapy with hippocampal avoidance
2576029|NCT02393131|Active Comparator|Conformal WBRT|Conformal whole brain radiotherapy without hippocampal avoidance
2576077|NCT02392741|No Intervention|Control|The control group will follow the IMIP prenatal routine.
2576080|NCT02392741|Experimental|Physical exercise program|The intervention group witch will be submitted to an exercise program consisting of daily post prandial, 10' after breakfast, lunch and dinner.
3210408|NCT00994370||liver cancer|Patients referred for SIRT will be considered for this investigation. These patients will predominantly have stage IV colorectal metastases with liver dominant metastases or hepatocellular carcinoma. A team of oncologists, interventional radiologists, radiation oncologists and oncologic surgeons will determine that the patients are not candidates for surgical resection or ablative therapy. The patients will then be screened to confirm the patient's eligibility to receive standard of care SIRT treatment. SIRT treatment and imaging studies included in this investigation are standard of care for the patients' liver dominant disease.
3210409|NCT00994396|Placebo Comparator|Placebo pill|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos
2576231|NCT02391675||Appendicitis patients|Patients presenting with acute appendicitis
2576277|NCT02391389|Experimental|CPAP or PPV during DCC|Infant will receive CPAP or PPV from 30 to 90 seconds after birth while attached to the placenta, and then the umbilical cord will be cut at 90 seconds
3210410|NCT00994396|Experimental|Vitamin D|4000 IU vitamin D3 (cholecalciferol) per day for 6 months.
2576464|NCT02390154|Experimental|Arm 1|Open label non-randomized non-controlled mass balance study in Cycle 1
2576466|NCT02390154|Experimental|Arm 2|Open label non-randomized non controlled multiple dose study in Cycle 2 and subsequent cycles
2576579|NCT02389530||interventional group|All participants will receive the study intervention, intravenous administration of fluorescein dye prior to brain tumor removal.
3210411|NCT00994474|Active Comparator|Fractional carbon dioxide laser treatment|
3210412|NCT00994474|Active Comparator|Fractional Er:YAG laser treatment|
2576803|NCT02387918|Active Comparator|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
2576811|NCT02387918|Active Comparator|Acupuncture|Acupuncture at point Neiguan (Pericardium-6) bilaterally and at point CV13 (Shang Wen) with acupuncture needles (0.25x25 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed after 20 minutes
3210413|NCT00994487|Experimental|Breastfed child|Female, normal weight, 3 to 5 year old children, exclusively breastfed from birth to 3 months of age
3210414|NCT00994487|Active Comparator|Bottle Fed Child|Female, normal weight, 3 to 5 year old children, exclusively bottle fed from birth to 3 months of age
3210415|NCT00994500|Experimental|Treatment (vorinostat, bortezomib)|Patients receive oral vorinostat once daily on days 1-5 and 8-12 and bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
2576906|NCT02387151|Experimental|mesenchymal stromal cells|allogeneic mesenchymal stromal cell infusion
2576943|NCT02386852|Experimental|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (ginseng: group 1; ginkgo biloba: group 2).
2576951|NCT02386852|Experimental|Ginseng|Participants in the ginseng group received a medium, and higher dose of ginseng in addition to placebo capsules.
2576955|NCT02386852|Experimental|Ginkgo Biloba|Participants in the ginkgo biloba group received a medium, and higher dose of ginkgo in addition to placebo capsules.
2577029|NCT02386566||natalizumab|natalizumab 300 mg intravenous (IV) every 4 weeks; according to the approved product label of Tysabri in Switzerland
2577068|NCT02386007|Experimental|DW-3101_150mg|150mg a day
2577073|NCT02386007|Experimental|DW-3101_300mg|300mg a day
2577077|NCT02386007|Experimental|DW-3101_600mg|600mg a day
2577080|NCT02386007|Placebo Comparator|a tablet same as experimental agents in formation and shape|Placebo
2577133|NCT02385617|Experimental|Esophagectomy|Double blind single dose placebo-octreotide crossover
2577134|NCT02385617|Experimental|Total gastrectomy|Double blind single dose placebo-octreotide crossover
2577137|NCT02385617|Active Comparator|Control - no surgery|Double blind single dose placebo-octreotide crossover
2577138|NCT02385617|Experimental|Pancreaticoduodenectomy|Double blind single dose placebo-octreotide crossover
2577222|NCT02385188|Experimental|Imiquimod|Topical 5% imiquimod cream will be applicated to the vulvar skin lesion 3 times a week during 16 weeks.
2577289|NCT02384720||A|Gender: 10 Males, 10 Females
2577292|NCT02384720||B|Gender: 10 Males, 10 Females
2577295|NCT02384720||C|Gender: 10 Males, 10 Females
2577313|NCT02384304|Experimental|Choice|A self help program consisting of 8 modules. Patients will have access to therapist support through either messages or chat sessions
2577317|NCT02384304|Experimental|Messages|A self help program consisting of 8 modules. Patients will have access to therapist support through messages
2577326|NCT02384304|Active Comparator|Self help|A relapse intervention program consisting of 8 modules. Patients will have no access to therapist support
2577383|NCT02384018|No Intervention|Control|Patients will receive standard islet transplantation.
2577386|NCT02384018|Experimental|autologous mesenchymal stromal cell|Patients will receive MSCs together with standard islet transplantation.
2577476|NCT02383108|Experimental|DTG+DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
3210416|NCT00994513|Active Comparator|ALA|alpha lipoic acid 1200 mg/day
3210417|NCT00994513|Placebo Comparator|Placebo|placebo 1200 mg/day
3210418|NCT00994526|Placebo Comparator|Ham|
3210419|NCT00994526|Experimental|Ham + calcium|
3210420|NCT00994526|Experimental|Ham + vitamin E|
3210421|NCT00994552|Active Comparator|Pressure support ventilation|Pressure support ventilation
3210422|NCT00994552|Active Comparator|Pressure control ventilation|Pressure control ventilation
2575993|NCT02393391|Placebo Comparator|inactive electrodes|diagnosis and monitoring will be performed as in active treatment, but during treatment anodal/cathodal/alternate stimulation will begin and automatically stop after 30 seconds leaving subject with an inactive electrodes in place for the remainder of treatment duration
2576036|NCT02393170|Experimental|self-training using video-games|Participants will receive a video-game console and will be asked to play video-games for one hour a day X 6 days a week for 5 weeks.
2576041|NCT02393170|Active Comparator|traditional self-training|Participants will receive a manual and kit of a traditional self-training program and will be asked to perform the program one hour a day X 6 days a week for 5 weeks.
2576133|NCT02392676|Experimental|1/OLAPARIB|olaparib 300 mg oral tablets; twice daily
2576138|NCT02392676|Placebo Comparator|2/PLACEBO|placebo matching olaparib 300 mg oral tablets; twice daily
2576164|NCT02392039|Experimental|Group 1 - Loratadine|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
2576165|NCT02392039|Experimental|Group 2 - Placebo|"Pegfilgrastim 6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.~Cycle 1 and 3:~Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Cycle 2 and 4:~Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs."
2576215|NCT02391766|Active Comparator|empowerment group|empowerment intervention by us for us guides
2576217|NCT02391766|Placebo Comparator|no treatment group|dementia patients treatment as usual
2576281|NCT02391415|Experimental|HIV-unexposed infants VPM1002|HIV-unexposed infants vaccinated with VPM1002
2576286|NCT02391415|Active Comparator|HIV-unexposed infants BCG|HIV-unexposed infants vaccinated with BCG
2576289|NCT02391415|Experimental|HIV-unexposed infants VPM1002(Hyg+)|HIV-unexposed infants vaccinated with VPM1002(Hyg+)
2576291|NCT02391415|Active Comparator|HIV-exposed infants BCG|HIV-exposed infants vaccinated with BCG
2576292|NCT02391415|Experimental|HIV-exposed infants VPM1002|HIV-exposed infants vaccinated with VPM1002
2576372|NCT02390713|Experimental|MID-AVR|Tolerance and functionality of MID-AVR during surgery (Phase A) and after surgery (Phase B)
2576434|NCT02390453|Experimental|Combined Cognitive and Physical|This consists of 45 minutes of Cognitive arm + 45 minutes of Physical arm (90 minutes total), 3 days a week for 12 weeks (36 sessions).
2576440|NCT02390453|Active Comparator|Cognitive|This consists of 45 minutes of cognitive modules from Posit Science, 3 days a week for 12 weeks (36 sessions).
2576444|NCT02390453|Active Comparator|Physical|This consists of 45 minutes of multi-modal physical exercise, 3 days a week for 12 weeks (36 sessions).
2576451|NCT02390453|Sham Comparator|Control|This consists of 45 minutes of group discussion and instruction in health self-management and successful aging, 2 days a week for 12 weeks (24 sessions).
2576487|NCT02389842|Experimental|Palbociclib + Taselisib|The starting dose of palbociclib in combination with taselisib will be 100mg OD of palbociclib and 2mg taselisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
2576498|NCT02389842|Experimental|Palbociclib + Pictilisib|The starting dose of palbociclib in combination with pictilisib will be 100mg OD of palbociclib and 195 mg pictilisib OD, administered orally 21-days-on and 7-days-off, as part of a 28 day cycle.
2576566|NCT02389608|Experimental|1- tDCS 2--FES|"Transcranial stimulation ( tDCS ) will be administered using Tct Research 1 CH tdcs Simulator model 101. tDCS will be performed for 20 minutes and intensity 2mA associated active contraction of the TA muscle. Placebo tDCS will follow the same procedures as active tDCS with active, but the tDCS device will only be switched on for 20 seconds.~Functional electrical stimulation (FES) will be administered using QUARK® FES VIF 995 DUAL device. The duration of active FES will be 20 minutes, associated with active contraction of the TA muscle. The pulse width will be 250 µs, modulated at a frequency of 50 Hz, with one to two stimulation cycles (6 seconds on and 12 seconds off) and the intensity will be increased until reaching the motor threshold. Placebo FES will follow the same procedures as active FES , but the FES device will only be switched on for 20 seconds, following which the intensity will be gradually reduced to 0 mA."
2576617|NCT02389179|Active Comparator|25 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd). The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
2576620|NCT02389179|Active Comparator|50 000 IU monthly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
2576622|NCT02389179|Active Comparator|50 000 IU bi-weekly|The dose stated above are doses of Vitamin D3/Cholecalciferol which is formulated as spray dried powder stabilized with DL-alpha tocopherol (dry vitamin D3 100 SD/S)(DSM Nutritional Products Switzerland Ltd).The spray dried powder will be diluted in 10 mls of water and ingested orally by subjects under direct supervision in a clinic setting.
3210423|NCT00994565|No Intervention|Usual care|
3210424|NCT00994565|Active Comparator|Activity monitoring and distance counseling|
3210425|NCT00994578|No Intervention|Internet Only|Patients assigned to the internet only group will enter the initial CHESS portal which will take them to a window displaying a standard web search engine and common cancer information sites. We will monitor their internet usage via logins to the CHESS portal.
2577560|NCT02382835||Metal-on-Metal Hip Replacement|
3260270|NCT01477736|Active Comparator|oxybutynin|
2576009|NCT02393261|Experimental|A 2500mlGroup|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
2576011|NCT02393261|Active Comparator|B 2000mlGroup|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
2576104|NCT02392702|Active Comparator|C-10355, 25 mg|single oral dose.
2576111|NCT02392702|Active Comparator|C-10358, 25 mg|single oral dose.
2576115|NCT02392702|Active Comparator|C-10355 or C-10358, 75 mg|single oral dose.
2576117|NCT02392702|Active Comparator|C-10355 or C-10358, 150 mg|single oral dose.
2576119|NCT02392702|Active Comparator|Kalydeco, 150 mg|single oral dose.
2576120|NCT02392702|Active Comparator|C-10355 or C-10358, 300 mg|single oral dose.
2576169|NCT02392130|Active Comparator|Active Drug|Clobetasol propionate 0.05% ointment
2576172|NCT02392130|Experimental|Experimental Drug|LEO 130852A gel 1%
2576174|NCT02392130|Placebo Comparator|Placebo Drug|LEO 130852A placebo gel
2576199|NCT02391870|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
2576261|NCT02391506|Experimental|Cartiva|Synthetic Cartilage Implant
2576322|NCT02391155|Active Comparator|single lumen|Single lumen needle in oocyte retrieval
2576329|NCT02391155|Active Comparator|double lumen|Double lumen needle with follicle flushing during oocyte retrieval
2576382|NCT02390739|Experimental|Single Arm|All patients will receive a non-myeloablative lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine followed by antithyroglobulin mTCR PBL and aldesleukin.
2576416|NCT02390349|Experimental|CuraMed (BCM-95)|67 patients, treatment with CuraMed (BCM-95), one capsule (500 mg) orally, three times daily for 12 weeks
2576418|NCT02390349|Experimental|Curamin|67 patients, treatment with Curamin, one capsule (500 mg) orally, three times daily for 12 weeks
2576421|NCT02390349|Placebo Comparator|Placebo|67 patients, treatment with placebo, one capsule (500 mg) orally, three times daily for 12 weeks
2576489|NCT02389972||CML patients treated with dasatinib|Cohort of chronic myeloid leukemia patients treated with second-line dasatinib (Sprycel)
3210426|NCT00994578|Experimental|CHESS|Participants in the CHESS arm will be given access to the University of Wisconsin CHESS website, modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support. The participant's usage of the site will be monitored.
3210427|NCT00994578|Experimental|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each visit, and access to the patient's audio-recorded conversations for review. The participant's usage of the site will be monitored.
2576679|NCT02388698|Experimental|Cervical Swab, PET-CT and plasma HPV|Participants will have a cervical swab, and plasma HPV at baseline. In addition, a plasma HPV test drawn after completion of radiation. 3 months post chemoradiation, patients will have a PET-CT and plasma HPV completed. Plasma HPV will be drawn at progression/recurrence, if applicable.
2576825|NCT02387671|Experimental|mHealth Platform|The primary interventions employed in the study are wifi enabled tracking devices, text message communications and behavioral counseling.
2576880|NCT02387385|Active Comparator|Intervention|Whole body cooling to 33 degrees C to 34 degrees C
2576891|NCT02387385|No Intervention|Standard of Care|Standard of care
2576942|NCT02386930|Experimental|Behavrioal Lifestyle modification|
2576946|NCT02386930|No Intervention|Control|
2576989|NCT02386683|Active Comparator|Group L|lung-protective ventilation applied in anesthesia
2576992|NCT02386683|No Intervention|Group T|traditional ventilation applied in anesthesia
2577010|NCT02386358|Active Comparator|Benznidazole|Benznidazole pills of 100 mg, dose 5 mg/Kg/day, twice a day during 60 days
2577019|NCT02386358|Placebo Comparator|Placebo|Placebo pills 100 mg, dose 5mg/Kg/day, twice a day, during 60 days
2577085|NCT02386046||Reference Group|Late preterm infants without any pathology. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
2577088|NCT02386046||Study Group|Infants born 26-35 weeks requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital before and after caffeine instituted, and weekly thereafter until 46 weeks postconceptional age.
2577089|NCT02386046||Control Group|Infants born 26-35 weeks not requiring caffeine. Intervention: Pulse oxymeter measurements at the hospital and weekly thereafter until 46 weeks postconceptional age.
2577155|NCT02385591|Experimental|Telephone Support|Participants will receive bi-weekly 20 minute telephone calls from a trained professional facilitator offering physical activity advice with the goal of increasing moderate-to-vigorous intensity physical activity.
2577156|NCT02385591|Experimental|SMS Support|Participants will receive weekly text messages (3-5 text messages per week) offering physical activity advice with the aim of increasing moderate-to-vigorous intensity physical activity.
2577158|NCT02385591|Active Comparator|Attention-control|Participants will receive telephone-based general nutrition advice.
2577215|NCT02385162||Observation|Patients with a diagnosis of Glycogen storage diseases based upon biochemical and/or genetic criteria or profound suspicion for Glycogen storage disease
2577251|NCT02384785||Spinal Cord Stimulation|"Patients who underwent implantation of electrodes spine for treatment in chronic pain.~'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation (one after another)"
2577342|NCT02384603|Experimental|GPR and CBT|Global postural reeducation associated with cognitive behavioral therapy; 01 session per week for 10 weeks
2577343|NCT02384603|Active Comparator|SMSE and CBT|Segmental muscle stretching exercises associated with cognitive behavioral therapy; 01 session per week for 10 weeks
2577511|NCT02383004|Experimental|Acupuncture|"Same premedication, induction and maintenance protocol as the No Acupuncture (Standard of Care) group.~The intervention will be placement of 4 acupuncture needles. The needles will be placed after inhalational anesthesia induction and removed prior to leaving the operating room. A total of 4 needles will be placed, one in each wrist at the HT7 point and one in each ear at the shen men point."
2576051|NCT02392988|Experimental|Group receives acupuncture treatment|The women in this group will receive acupuncture treatment every 48-72 hours, a maximum of three treatments.
2576056|NCT02392988|No Intervention|Group doesn't receive any treatment|The women in this group will come for a follow-up check a week later, unless a spontaneous birth will develop.
2576090|NCT02392572|Experimental|Arm A: ONC201 Once Every 3 Weeks|"ONC201 dosed orally once every three weeks. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
2576092|NCT02392572|Experimental|Arm B: ONC201 Once Every 1 Week|"ONC201 dosed orally once every 1 week. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
2576095|NCT02392572|Experimental|Arm C: ONC201 On First Two Consecutive Days of Every Week|"ONC201 dosed orally on the first two consecutive days of every week. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
2576098|NCT02392572|Experimental|Arm D: ONC201 Once Daily|"ONC201 dosed orally once daily. One cycle defined as 21 days (3 weeks).~Phase I: Cohorts consisting of one new patient per dosing level treated sequentially at rising dose levels starting at 125 mg. Enrollment at each dose level requires that all patients enrolled at the prior dose level have completed one cycle of treatment (21 days) and that dose level is deemed safe. Dose escalation continues until an maximum tolerated dose (MTD) is reached or dose level 5 is reached (625 mg), which will be declared the maximum administered dose (MAD).~Phase II: Starting dose is MTD dose from Phase I."
2576105|NCT02392572|Experimental|Arm E: ONC201 Once Daily + Cytarabine|"ONC201 orally once daily in combination with low Cytarabine 20 mg subcutaneous twice daily for 10 days. One cycle defined as 28 days (4 weeks).~Once the highest dose for Arm D (625 mg) are deemed safe (<2/6 DLTs) or the MTD is reached before that, then Phase I part of the study for Arm E will begin. The starting dose of ONC201 will be 625 mg or the MTD with the same schedule as that in Arm D. 3 + 3 algorithm will be applied for dose de-escalation."
2576173|NCT02392156||rFVIIIFc for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
2576178|NCT02392156||non-Fc (fusion protein) replacement products for hemophilia A|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
2576180|NCT02392156||rFIXFc for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
2576182|NCT02392156||non-Fc factor replacement products for hemophilia B|Administered based on the clinical judgment of the Prescribing Physician and according to the local approved drug label
2576235|NCT02391688|Experimental|Treatment A|"Oral intake of:~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg"
2576238|NCT02391688|Experimental|Treatment B|"Oral intake of:~fexofenadine 25 mg"
2576240|NCT02391688|Experimental|Treatment C|"Oral intake of:~bupropion 20 mg"
2576244|NCT02391688|Experimental|Treatment D|"Oral Intake of Geneva cocktail (A+B+C):~caffeine 50 mg dextromethorphan 10 mg omeprazole 10 mg flurbiprofen 10 mg midazolam 1 mg fexofenadine 25 mg bupropion 20 mg"
2576397|NCT02390817|Active Comparator|Sugammadex|At the wakeup status Sugammadex 2 mg/kg single dose will perform.
2576399|NCT02390817|Placebo Comparator|Neostigmine|At the wakeup status Neostigmine 0,04 mg/kg single dose will perform.
3176103|NCT00641160|Experimental|Cohort 3|
3176104|NCT00641173|Experimental|1|paroxetine v placebo
3176105|NCT00641173|Placebo Comparator|2|placebo
3176106|NCT00641186|Experimental|A|sodium oxybate 4.5 to 9.0 gms per night
3176107|NCT00641199|Active Comparator|1|Jarrow-Dophilus EPS
3176108|NCT00641199|Placebo Comparator|2|Placebo
3176109|NCT00641212|Experimental|1|Budesonide
3176110|NCT00641212|Placebo Comparator|2|
3176111|NCT00641225|Experimental|1|SBI-087
3176112|NCT00641238||Early stage NSCLC|Early stage non-small cell lung cancer
3176113|NCT00641251|Active Comparator|1|intensive medical management
3176114|NCT00641251|Active Comparator|2|Roux-en-Y gastric bypass with intensive medical management
3176115|NCT00641303|Sham Comparator|Arm I (control)|Patients receive 8 weekly sessions of sham acupuncture treatment comprising 20 minutes of a non-penetrating device consisting of a retractable needle and an adhesive tube on the skin using the Park Sham Device (PSD) in 14 non-acupuncture points. Patients may receive 4 free acupuncture sessions (not sham) after the 12 or 24-week follow-up visit.
3176116|NCT00641303|Experimental|Arm II (treatment)|Patients receive 8 weekly sessions of acupuncture treatment comprising 20 minutes of needle insertion in 15 acupuncture points including CV 4, CV 6, CV12 and bilateral LI 4, MH 6, GB 34, ST 36, KI 3, BL 65.
3176117|NCT00641316|Experimental|1|Teeth extraction followed by natural healing
3176118|NCT00641316|Experimental|2- FDBA/TCP|
3176119|NCT00641316|Experimental|3 FDBA/TCP+PRP|
3176120|NCT00641316|Experimental|4 FDBA/TCP + PDGF|
3176121|NCT00641329|Experimental|1|
3176122|NCT00641329|Placebo Comparator|2|
3176123|NCT00641342|Active Comparator|onlay mesh|
3176124|NCT00641342|Active Comparator|sublay mesh|
3176125|NCT00641342|No Intervention|no mesh|
2576065|NCT02393040|Experimental|PRP/Saline|"PRP/Saline~Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride.~In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo).~This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6)."
3210428|NCT00994578|Experimental|CHESS/COPE|Participants in the CHESS+COPE arm will receive training in, and access to, both components on the CHESS website, with the accompanying levels of support. The participant's usage of the site will be monitored.
2576136|NCT02392325|Experimental|rDEN1Δ30 and rDEN2Δ30-7169|Participants will receive the rDEN1Δ30 vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
2576140|NCT02392325|Experimental|Placebo and rDEN2Δ30-7169|Participants will receive placebo vaccine at Day 0. They will receive the rDEN2Δ30-7169 vaccine at Day 270.
2576166|NCT02392091||critically ill patients|critically ill patients at the age ≥18, expected to stay in the ICU for ≥24h, with the clinical necessity for a urinary catheter and the absence of anuria
3210429|NCT00994591|Experimental|Pharmacokinetic dosing|
3210430|NCT00994617|Experimental|Combination Therapy|Patients treated with combination therapy of Hydrochlorthiazide plus Losartan. Losartan will be force-titrated from 50 to 100mg, Hydrochlorothiazide will be force-titrated from 12.5mg to 25mg
2576298|NCT02391233|Experimental|HIV/STI Risk Reduction|This intervention tests the comparative effectiveness of E-WORTH, streamlined HIV Testing and a 5-week multimedia intervention on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
2576304|NCT02391233|Active Comparator|Streamlined HIV Testing Alone|This intervention tests the comparative effectiveness of streamlined HIV Testing alone on primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
3210431|NCT00994617|Active Comparator|Monotherapy|Initial monotherapy Hydrochlorothiazide 12.5mg -25mg Crossed over with Losartan 50 -100mg at 8 weeks
3210432|NCT00994630||BP I patients manic phase|
3210433|NCT00994656||posterior spinal fusion subject|Subject will have a history of either idiopathic or neuromuscular scoliosis who is now scheduled to have a posterior spinal fusion.
3210434|NCT00994669||healthy control male|
2576475|NCT02390115|Active Comparator|Elastic Tape|"Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as paper tension and it is equivalent to 10-15% of the total elastic tape tension."
2576476|NCT02390115|Sham Comparator|Sham|The sham elastic tape will be placed using the same tape to the paretic shoulder. However, the rigid tape will be placed without tension with the upper limb supporting at 90 degree elbow flexion, 0 degrees abduction and adduction of the shoulder.
3210435|NCT00994669||lung cancer male|
3210436|NCT00994721||pancreatic cancer|resected pancreatic cancer
2576553|NCT02389387|No Intervention|Control|Two hundred twenty (220) dialysis facilities will follow standard of care practices in their management of ESRD patients. They will not receive interventions, but they will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
2576554|NCT02389387|Experimental|Intensive Intervention|Two hundred twenty (220) dialysis facilities will follow standard of care practices and the intensive intervention in their management of ESRD patients. The intensive intervention will consist of 1) A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX) to enhance coordination between dialysis and transplant staff and track ESRD patients through the seven primary steps to transplant , 2) educational webinars/seminars for staff, 3) facility-specific performance feedback reports, 4) assistance with and review of center-specific action plans to increase transplant referral, 5) scheduled bi-annual phone calls with an SETC member to monitor progress, 6) patient education on transplant via creation of an Education Station in facility lobby, and 7) development of a Peer Mentor program.
2576595|NCT02389309|Experimental|Treatment (dasatinib, cyclophosphamide, temsirolimus)|Patients receive dasatinib PO BID on days 1-21, cyclophosphamide PO QD on days 1-21, and temsirolimus IV over 30-60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing stable disease or better may continue treatment with the approval of the Study Chair.
2576658|NCT02388750|Other|No previous nausea and vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~No previous nausea and vomiting 24 hours prior to radiotherapy"
2576659|NCT02388750|Other|Previous nausea and/or vomiting|"Palonosetron 0.5 mg oral capsule given for the length of radiation treatment~Previous nausea and/or vomiting 24 hours prior to radiotherapy"
2576714|NCT02388516|Placebo Comparator|Group A|Prenatal Period 0 IU; Postpartum Period 0 IU (placebo) Overall: The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum.
2576717|NCT02388516|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
2576718|NCT02388516|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
2576720|NCT02388516|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 0 IU/week (placebo)
3210437|NCT00994734|No Intervention|clinic administration of mifepristone|
3210438|NCT00994734|Experimental|home administration of mifepristone|
3210439|NCT00994747|Active Comparator|Group EEEEEEE|Infant is fed Enfamil from 0.5-7.5 months of life
2576081|NCT02392728|Active Comparator|Intervention GI|Session of Immersive Virtual Reality (VR) and Session of Guided Imagery
3210440|NCT00994747|Experimental|Group ENEEEEE|Infant is fed Enfamil during 0.5-1.5 months of life, Nutramigen from 1.5-2.5 months of life and then Enfamil 2.5-7.5 of life.
2576312|NCT02391376|Experimental|moist heat pack group|Three sessions of 15 minutes of superficial heat through a moist heat pack on the lower back of healthy subjects
2576314|NCT02391376|Experimental|seed pack group|Three sessions of 15 minutes of superficial heat through a seed pack on the lower back of healthy subjects
2576315|NCT02391376|Experimental|gel pack group|Three sessions of 15 minutes of superficial heat through a gel pack on the lower back of healthy subjects
2576392|NCT02390843|Experimental|simvastatin + topotecan/cyclophosphamide|During dose escalation (phase I), standard 3+3 design will be followed.
2576417|NCT02390245|Experimental|Enhanced Intervention Group|Use of patient navigation and social worker: Patients randomized to Group 1 will be referred to a general ophthalmologist close to the current health center or PCP office where they received the undilated eye exam. Prior to all follow-up visits, patients in the enhanced group who have scheduled an appointment will receive a personal phone call reminding them to attend. These patients will receive any necessary interpretation services and educational materials.
2576422|NCT02390245|No Intervention|Usual care group|Patients randomized to Group 2 will be recommended to follow-up for eye care with a local ophthalmologist. These patients will be scheduled for their initial follow-up visit based on the recommendations of our study physicians so the research team is able to track outcomes. Group 2 represents a realistic choice currently available for patients. Practice patterns will vary depending on the resources, staff time, and services available within each local ophthalmology practice.
2576500|NCT02390063|Experimental|CHAMVA standard regime|ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
2576503|NCT02390063|Experimental|CHAMVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
2576504|NCT02390063|Active Comparator|MVA standard regime|Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
2576506|NCT02390063|Active Comparator|MVA+CTX standard regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
2576507|NCT02390063|Experimental|CHAMVA accelerated regime|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
2576509|NCT02390063|Experimental|CHAMVA+CTX accelerated regime|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
2576511|NCT02390063|Experimental|CHAMVA accelerated regime AS|ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
2576513|NCT02390063|Experimental|CHAMVA+CTX accelerated regime AS|One week of low dose cyclophosphamide pre-conditioning before each vaccination. ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later. Patients continue on active surveillance.
2576564|NCT02389400|Experimental|Experimental arm|methotrexate,1g/m2,iv.d1 cytosine arabinoside,0.1g/m2,iv.,d1-5
2576615|NCT02389218|Experimental|Cryoablation|Cryoballoon single ablation (as described in the reference) at entry after randomization to this group. Single procedure,not to be repeated.
2576616|NCT02389218|Active Comparator|Drug|Conventional, available anti arrhythmic drugs (propafenone, sotalol or flecainide), in a first stage, sequential, with amiodarone in second stage
2576737|NCT02388308||Patient volunteers|Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.
2576738|NCT02388308||Gold fiducial marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
2576739|NCT02388308||Electromagnetic marker group|Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.
2576740|NCT02388308||General patients|Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.
2576881|NCT02387346|Experimental|Real Stimulation|Participants in this group will receive Repetitive Transcranial Magnetic Stimulation, characterized by 900 pulses at 1Hz over the medial cerebellum at 120% resting motor threshold of the right first dorsal interosseous.
2576890|NCT02387346|Sham Comparator|Sham Stimulation|Participants will receive Sham Repetitive Transcranial Magnetic Stimulation by having the coil angled at 90 degrees to the scalp; this will allow adequate noise output from the stimulator in the absence on real magnetic stimulation.
2576968|NCT02387099|Active Comparator|Conventional Everolimus dosing according to label|"everolimus 10 mg/day, week 1-3: 4x2.5 mg/day (blinded); week 4-24: 10mg/day (open according to label)~+ further treatment according to standard of care"
2576969|NCT02387099|Experimental|3 week Dose Induction of Everolimus|"an escalating dose of everolimus as follows: week 1: 1x2.5 mg verum + 3x placebo/day; week 2: 2x2.5 mg verum + 2x placebo/day; week 3: 3x2,5 mg verum + 1x placebo/day; week 4-24: 10 mg/day (open according to label)~+ further treatment according to standard of care"
2577112|NCT02385890|Experimental|Bagel control|100% wheat flour
2577115|NCT02385890|Experimental|Bagel with pea flour|Pea flour
2577117|NCT02385890|Experimental|Bagel with pea fibre|Pea fibre
2577118|NCT02385890|Experimental|Bagel with pea protein|Pea protein
2577119|NCT02385890|Experimental|Bagel with pea flour + pea protein|Pea flour + pea protein
2577120|NCT02385890|Experimental|Bagel with pea fibre + pea protein|Pea fibre + pea protein
2577188|NCT02385305|Other|Pressure support ventilation|Usual anesthesia management
2577438|NCT02383498|Placebo Comparator|Placebo|Radiation + GI-6301 Placebo + Actigraph
2577489|NCT02383238|Active Comparator|Dapagliflozin|Dapagliflozin, 10 mg/day, oral administration, 6 weeks
2576101|NCT02392520|Placebo Comparator|Conventional|Women with severe early OHSS will be treated with conventional treatment, such as intravenous albumin administration, paracentesis of ascitic fluid, either on an outpatient or inpatient basis.
2576167|NCT02392260|Experimental|Vasculight prototype zero level|
3210441|NCT00994747|Experimental|Group EENEEEE|Infant is fed Enfamil 0.5-2.5 months of life, Nutramigen from 2.5-3.5 months of life and then Enfamil from 3.5 to 7.5 months of life
2576515|NCT02389699|Experimental|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
2576520|NCT02389699|Active Comparator|whole breast radiation|WRT:whole breast radiation after BCS with 46-50 Gy
2576547|NCT02389491|Active Comparator|normal density formula (Neocate)|In control group,infants intake normal density formula (Neocate,67kcal/100ml) when starting enteral nutrition after operation and continue for 7days
2576548|NCT02389491|Experimental|high density formula (Infatrini)|In the intervention group,infants intake high density formula (Infatrini, 100kcal/100ml) when starting enteral nutrition after operation and continue for 7days
2576568|NCT02389335||Group 1a|Patients with type 1 diabetes who have undetectable c-peptide ( ≤0.1 ng/mL) levels after mixed meal tolarance test: group 1a
2576570|NCT02389335||Group 1b|Patients with type 1 diabetes who have c-peptide levels between 0.1-0.8 ng/mL after mixed meal tolerance test: group 1b
2576572|NCT02389335||Group 1c|Patients with type 1 diabetes who have c-peptide levels ≥0.8ng/mL after mixed meal tolerance test: group 1c
2576574|NCT02389335||Control|Healthy subjects
2576604|NCT02389166|Experimental|Optiflow group|
2576605|NCT02389166|Active Comparator|Control group|
2576624|NCT02388867|Experimental|Group I|Intervention: Polytetrafluoroethylene (PTFE) bypass grafting.
2576625|NCT02388867|Experimental|Group II|Intervention: Autogenous vein bypass grafting.
3210442|NCT00994747|Experimental|Group EEENEEE|Infant is fed Enfamil from 0.5-3.5 months of life, Nutramigen from 3.5-4.5 months of life and then Enfamil from 4.5-7.5 months of life.
2576730|NCT02388451|Experimental|Feuerstein Program|15 subjects conforming to inclusion and exclusion criteria with a known clinical diagnosis of MCI and who provide informed consent will undergo cognitive and functional assessment to confirm the diagnosis of MCI. Baseline assessment using the Mindstreams Mild Cognitive Impairment Computerized Assessment Battery will be performed. Subjects will then participate 30 twice weekly meetings of 90 minutes duration each (for a total of 15 weeks). Mindstreams testing will be repeated after 15 sessions and at completion of the study.
2576802|NCT02387892|Placebo Comparator|Control|Cheese & yogurt
2576809|NCT02387892|Experimental|Treatment|Cheese & yogurt + Vitamin D
2576853|NCT02387489|Active Comparator|NBI|Nurse-delivered Brief Intervention
2576854|NCT02387489|Experimental|CBI|Computerized Brief Intervention
2576870|NCT02387307|Experimental|Cohort: Dose-Escalation and Expansion|"Dose-Escalation: Dose escalation in solid tumors utilizing a 3+3 design with intra-subject dose escalation. 4 dose levels of rSIFN-co are planned for determining the RD. Dose of rSIFN-co: 15, 21, 24, 27 and 30 ug.~Dose-Expansion: The Expansion Cohort will be initiated at the RD. Depending on the RD, the lead in period will occur accordingly. After the lead in period, a period from Cycle 1 to the final administration will be performed as the Treatment Phase during which subjects will undergo a standardized evaluation for the safety and efficacy of rSIFN-co at the RD. Follow-up evaluations will be performed 28 days (±5 days) after the last rSIFN-co administration."
2576945|NCT02387125|Experimental|Part 1 Dose Escalation of CMB305|Patients with melanoma, NSCLC, ovarian cancer, or sarcoma will be enrolled. Patients will receive CMB305, a sequential regimen of LV305 and G305. Two cohorts are planned based on LV305 dose.
2576960|NCT02387125|Experimental|Part 2 Expansion of CMB305|Arm A will enroll up to 9 patients each with NSCLC or ovarian cancer, or up to 18 patients with the sarcoma subtypes, synovial sarcoma or MRCL. Arm B will enroll up to 9 additional patients with selected sarcoma subtypes to explore subcutaneous (SC) dosing of LV305 and G305 on the same schedule. Arm C will enroll up to 9 patients with synovial sarcoma or MRCL for treatment with CMB305 and with oral metronomic CPA. Arm D will enroll up to 9 patients with synovial sarcoma or MRCL at selected sites for treatment with CMB305 and IT G100. Arm E will enroll up to 6 patients with soft tissue sarcoma any subtype for treatment with a higher dose of CMB305 than previous arms.
2577056|NCT02386215|Experimental|HIV Self-test|Following a baseline interview, participants in the intervention group will be shown how to correctly use the self-tests and given two HIV self-tests. Subsequently, we will contact participants periodically over a 3 month period to see if they have used the test(s) with their sexual partners and conduct a follow-up interview.
2577060|NCT02386215|No Intervention|Control|Following the baseline interview, participants in the control group will be given referral vouchers for themselves and their partners to obtain HIV testing at Voluntary Counseling & Testing (VCT) centers. We will contact the participants at the end of 3 months to see if they and/or their partner(s) have sought HIV testing.
2577105|NCT02385760|Experimental|Active|CTX-4430 oral capsule, 100 mg, once-daily for 12 weeks
2577109|NCT02385760|Placebo Comparator|Placebo|Placebo: identical oral capsule, without active ingredient, once-daily for 12 weeks
2577182|NCT02385396|Placebo Comparator|Group I|60 patients diagnosed with PCOS, not myo-inositol treated undergoing ICSI
2577185|NCT02385396|Experimental|Group II|52 patients diagnosed with PCOS undergoing ICSI, taking Inofolic (myo-inositol + folic acid)
2577187|NCT02385396|Placebo Comparator|Group III|105 patients not diagnosed with PCOS undergoing ICSI, not taking myo-inositol
2577226|NCT02385032|Experimental|AB|Ursodiol followed by URSO Forte
2577227|NCT02385032|Experimental|BA|URSO Forte followed by Ursodiol
2577291|NCT02384707|Experimental|allergic food|"Reintroduction procedure for small doses :~Administration of the first dose the first dose must be allergic food or placebo~Clinical monitoring for 45 minutes~Administration of the second dose"
2577305|NCT02384291|Experimental|Alpha-Bios GRAFT Natural Bovine Bone treatment|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
2577306|NCT02384291|Active Comparator|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
3210443|NCT00994747|Experimental|Group ENNNEEE|Infant if fed Enfamil from month 0.5-1.5 months of life, Nutramigen from 1.5 to 3.5 months of life and then Enfamil again 3.5-7.5 months of life.
3210444|NCT00994747|Experimental|Group NNNNNNN|Infant is fed Nutramigen from 0.5-7.5 months of life.
3210445|NCT00994773|Experimental|Simvastatin|Simvastatin orally
2576204|NCT02391844|Other|Oxycodone|Xartemis XR - Oxycodone with Acetaminophen Extended Release Tablet
3210446|NCT00994773|Experimental|Simvastatin and tenofovir|Simvastatin combined with tenofovir
3210447|NCT00994773|Experimental|Simvastatin and entecavir|Simvastatin combined with entecavir
3176126|NCT00641368|Experimental|1|R4Power Program
2576555|NCT02389478|Experimental|colostrums|Oropharyngeal administration of colostrums, every 4 hours，continue for 7days
2576557|NCT02389478|Other|Normal saline|Oropharyngeal administration of Normal saline,every 4 hours，continue for 7days
2576600|NCT02389270||Healthy children|Healthy children without lower urinary tract diseases, history of urinary tract infection, chronic diseases, anomalies of urinary or genital tract, and remarkable clinical examination.
2576810|NCT02387866|Experimental|50 mg AG-221 tablet|50 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
2576814|NCT02387866|Experimental|100 mg AG-221 tablet|100 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
2576816|NCT02387866|Experimental|300 mg AG-221 tablet|300 mg AG-221 tablet given by mouth with 240 mL of non-carbonated, room temperature water, under fasted conditions
2576851|NCT02387515|Experimental|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology.
2576863|NCT02387333|Experimental|Study group|in this arm -study group- : patients will receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
2576872|NCT02387333|Sham Comparator|Control group|in this arm -sham comparator- : patients will not receive mesh stoma reinforcement technique with ileal conduit urinary diversion.
2576939|NCT02387060|Experimental|H-Bupivacaine 11.5 mg + fentanyl 25 mcg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75% plus fentanyl 25 mcg.
2576940|NCT02387060|Active Comparator|H-Bupivacaine 11.5 mg.|Intrathecal administration of Hyperbaric Bupivacaine 1.5 ml 0.75%
2576985|NCT02386670|Experimental|tDCS + CR|"Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions promotes transfer of cognitive gains to everyday tasks.~During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely)."
2577093|NCT02385825|Experimental|Group 3: 75 μg RVEc|75 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
2577139|NCT02385565|Experimental|high fat diet|10 % proteins, 30 % lipids, 60 % carbohydrates
2577140|NCT02385565|Placebo Comparator|Normal fat diet|10 % proteins, 45 % lipids, 45 % carbohydrates
2577189|NCT02385266|Experimental|D-Cycloserine and Acetominophen|D-cycloserine 200mg/bid and Acetaminophen prn
3176127|NCT00641368|Other|2|Waitlist Control
3176128|NCT00641381|Experimental|Treatment (high-dose chemotherapy, anti-HIV therapy)|Patients undergo leukapheresis to obtain PBSCs for transplantation. At least 5 days later, patients with an adequate number of collected cells proceed to high-dose chemotherapy. Patients receive carmustine IV over 4 hours on days -7 to -5, etoposide IV over 4 hours on day -4, and cyclophosphamide IV on day -2. Patients receive an autologous PBSC infusion on day 0.
3176129|NCT00641394|Experimental|1|Psychotherapy: Emotional Freedom Techniques (EFT), a psychotherapy intervention with a somatic component
3176130|NCT00641394|Active Comparator|2|Psychotherapy: Cognitive Behavioral Therapy (CBT), a psychotherapy intervention
3176131|NCT00641394|No Intervention|3|
3176132|NCT00641407|Experimental|1|
3176133|NCT00641407|Active Comparator|2|
3176134|NCT00641420|Experimental|1|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 10mJ.
3176135|NCT00641420|Experimental|2|Patients receive fractional laser resurfacing to 17% of the face five times one month apart at 40mJ.
3176136|NCT00641433|Experimental|experimental|Subjects will daily dress their nail bed with oxidized regenerated cellulose collagen-silver, until healing occurs.
3176137|NCT00641433|Active Comparator|Control|Topical silver sulfadiazine cream will be applied daily to the wound bed until healing has occured.
3176138|NCT00641446|Experimental|1|Pulmicort
3176139|NCT00641446|Active Comparator|2|Varivax
3176140|NCT00641459||001|
3176141|NCT00641472|Experimental|1|Budesonide inhalation suspension
3176142|NCT00641472|Active Comparator|2|Montelukast sodium
3176143|NCT00641498|No Intervention|Control|Usual therapy
3176144|NCT00641498|Experimental|Active group|Individual supportive psychotherapy initiated in the Emergency department
3176145|NCT00641511|Experimental|1 (Medication arm - SYN117 aka Nepicastat)|"Veterans will be receiving the study medication Nepicastat initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily; During the 8 weeks (weeks: 7-14) extension phase, those from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed for an additional 8 weeks. Those who have a prior defined positive clinical response to the study medication, Nepicastat, will be continued on open label Nepicastat at 120mg once daily, in order to assess further improvement and safety; those who do not have a positive clinical response during the 6 weeks RCT will be offered the addition of the standard first-line PTSD pharmacotherapy, Paroxetine. Paroxetine is an allowed concomitant medication (i.e. rescue medication) and is not considered a research medication or subject of a research question during the 8 weeks extension phase."
2576222|NCT02391922|Active Comparator|First aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios 4 to 5 months after receiving a first aid course and they are given instructions from emergency dispatch by phone during the test scenarios
2576226|NCT02391922|Active Comparator|No first aid course, dispatch instructions|Participants' first aid skills are tested in two scenarios without prior first aid course, and they are given instructions from emergency dispatch by phone during the test scenarios
2576308|NCT02391402|Experimental|CABA|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
2576310|NCT02391402|Placebo Comparator|TAU|"Treatment as Usual (TAU) is the usual care that patients would normally receive at the VA. TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
2576354|NCT02390869|Experimental|R2-MANT|A) Rituximab B) Lenalidomide
2576357|NCT02390869|Active Comparator|R-MANT|A) Rituximab
2576415|NCT02390232||NAFLD with simple steatosis|Patients with NAFLD with simple steatosis: collection of stools, blood sample and liver biopsy
2576419|NCT02390232||NAFLD with steatohepatitis|Patients with NAFLD with steatohepatitis: collection of stools, blood and liver biopsy
3210448|NCT00994786|Experimental|pregabalin|
3210449|NCT00994786|Placebo Comparator|Placebo|
3210450|NCT00994799||ranibizumab group|patients receiving intravitreal ranibizumab for diabetic macular edema
2576606|NCT02389205|Placebo Comparator|control group|physical therapy
2576608|NCT02389205|Active Comparator|kinesio group|kinesio taping for ankle joint
2576618|NCT02388919|Experimental|Anlotinib|Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
2576621|NCT02388919|Placebo Comparator|Placebo|Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
2576741|NCT02388542|Experimental|lifestyle counseling|we will have a trained peer mentor educating employees regarding lifestyle modification for control of cardiovascular disease risk factors and following them up for a duration of 3 months
3210451|NCT00994799||laser|patients receiving macular grid-pattern laser therapy
3210452|NCT00994812|Experimental|Metformin|
3210453|NCT00994825|Placebo Comparator|Placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
2576991|NCT02386735|Experimental|Investigational treatment|Patients included in the placebo group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for three days followed by two days of placebo.
2576996|NCT02386735|Active Comparator|Standard treatment|Patients included in the control group are receiving systemic corticosteroid treatment (equivalent of 40mg prednisone daily) for five days as recommended in current guidelines.
3210454|NCT00994825|Experimental|Levosimendan|Levosimendan
3210455|NCT00994838|Active Comparator|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
2577090|NCT02385747|Experimental|women with anbormal bleeding|women with perimenopausal and postmenopausal bleeding who will be evaluated with transvaginal ultrasound, saline sonohysterography,hystroscopy and endometrial currettage
2577129|NCT02385578|No Intervention|The control group|no intervention
2577132|NCT02385578|Experimental|The experimental group|an educational intervention
2577184|NCT02385357|Placebo Comparator|Control|330 ml of commercial protein-enriched drink (2.5 g/100 ml of protein)
2577186|NCT02385357|Experimental|Experimental|330 ml of protein-enriched drink (6 g/100 ml of protein)
2577203|NCT02385045|Placebo Comparator|Narrow band imaging|Narrow band imaging function (Olympus endoscopes)
2577205|NCT02385045|Experimental|i-scan imaging|i-scan imaging (Pentax endoscopes)
2577268|NCT02384837||TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which include TCFA (>=1)
2577271|NCT02384837||NO-TCFA|EXCEL biodegradable polymer-coated sirolimus-eluting stent was implanted on lesions which is not include TCFA
2577327|NCT02384499|Experimental|ALLO-ASC group|Allogenic-adipose-derived mesenchymal stem cell (ALLO-ASC) with fibrin glue injection to the anal sphincter
2577332|NCT02384499|Placebo Comparator|Normal saline group|0.9% normal saline with fibrin glue injection to the anal sphincter
2577395|NCT02384057|Experimental|C8 sciences|cognitive rehabilitation with C8 sciences
2577402|NCT02384057|Active Comparator|Conventional cognitive rehabilitation|cognitive rehabilitation with conventional methods
3210456|NCT00994838|No Intervention|standard diet|
2577494|NCT02383238|Placebo Comparator|Placebo|Placebo, oral administration, 6 weeks
3210457|NCT00994851|Experimental|SENNA+ CASSIA|Daily administration (capsule) of Naturetti (SENNA+ CASSIA) at bedtime, during 30 days
3210458|NCT00994851|Placebo Comparator|Placebo|Daily administration (capsule) of placebo at bedtime, during 30 days
3210459|NCT00994864|Other|adjuvant FOLFOX (1 pre-operative cycle)|One cycle of preoperative standard FOLFOX chemotherapy followed by eleven cycles post-operatively. PET/CT before and after the pre-operative chemotherapy cycle.
3210460|NCT00994877||Septic Patients|
3210461|NCT00994877||Healthy Control|
3210462|NCT00994903|Placebo Comparator|Placebo|Placebo tablets (Inert calcium lactate)
2576233|NCT02391662|Experimental|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125 mg/m2 plus Gemcitabine 1000 days 1, 8 & 15 in a 28 days cycle
2576279|NCT02391298|Experimental|Mindfulness Meditation|All participants will complete baseline assessments of variables of interest (i.e., levels of mindfulness, contrast sensitivity, cognitive inhibition, and emotional regulation skills). Participants will then undergo 8 weeks of self-directed mindfulness training with re-assessments of variables of interest completed at week 4 and week 8. All participants will be given access to meditation recordings and asked to practice the exercises in a progressive manner from mindfulness of breath to a loving/kindness meditation (each exercise twice per week). Participants will be asked at the end of study for feedback on the acceptability of the program.
2576321|NCT02391103|Experimental|NMES group|Anterior muscles of both thighs were electrically stimulated twice a day (2×30 minutes of NMES with a break of at least 30 minutes between both sessions) 7 days a week during the entire ICU stay but no longer than 14 days, starting on postoperative day 1. Highest tolerable intensity was applied.
2576324|NCT02391103|Sham Comparator|Control group|In the control group, the electrodes were applied, connected to the stimulator, but no electricity was delivered.
2576370|NCT02390804|Experimental|single-port laparoscopic hysterectomy|total laparoscopic hysterectomy via transumbilical single port
2576373|NCT02390804|Active Comparator|multi-port laparoscopic hysterectomy|total laparoscopic hysterectomy via multi-port (3 port)
2576426|NCT02390440|Experimental|EXPAREL|single dose, 266mg (20mL) of EXPAREL injected to slowly infiltrate the soft tissue around the site of fracture
2576495|NCT02390011||MRI|Day 1
2576577|NCT02389647||Endovascular group|Subjects undergoing elective endovascular catheterization for coiling of unruptured cerebral aneurysms. Four blood draws of 5mL each: (1) prior to initiation of procedure; (2) at the time of catheterization of major cerebral vessels, (3) immediately after the procedure, and (4) 24-hours after the procedure.
2576583|NCT02389647||Ischemic stroke group|Subjects who present to the emergency department with ischemic infarcts of <6 hours. Four blood draws of 5mL each: (1) at time of enrollment but prior to tPA, (2) 6 hours post-tPA, (3) 12 hours post-tPA, and (4) 24 hours post-tPA.
2576586|NCT02389647||Intracranial hemorrhage|Subjects who present to the emergency department with intracranial hemorrhage. One 5mL blood draw within 24 hours of onset.
3176146|NCT00641511|Placebo Comparator|2 (Placebo arm)|During the 6 weeks ( weeks: 1-6) double- blind, randomized clinical trial (RCT) phase, the veterans who have been randomized to the placebo treatment group will be receiving placebo pills. During the 8 weeks (weeks: 7-14) extension phase, all veterans from both treatment groups of the RCT phase will start open-label, active Nepicastat (i.e. no chance of placebo) treatment and be followed by the study team for an additional 8 weeks. The veterans on the placebo during the RCT will receive the study medication at end of the study week 6, the medication will be initiated with a 3-day loading phase of 40 mg on day 1, 80 mg on day 2 and 120 mg on day 3 (orally) and be continued at 120 mg once daily for 8 weeks until the end of the study.
3176147|NCT00641524|Other|treatment|Iron depletion via phlebotomy
3176148|NCT00641537|Placebo Comparator|Cladribine Low/Placebo (LLPP)|
2576684|NCT02388685|Experimental|Home exercise|Patients will undergo home exercise therapy under the supervision of the exercise laboratory
2576687|NCT02388685|No Intervention|No exercise|Patients will continue with usual care
2576723|NCT02388360|Other|topical prostaglandin analogs|
2576746|NCT02388152|Experimental|Lu AF20513, low dose (Cohort 1)|10 Patients with mild Alzheimer's.
2576753|NCT02388152|Experimental|Lu AF20513, medium dose (Cohort 2)|10 Patients with mild Alzheimer's.
2576757|NCT02388152|Experimental|Lu AF20513, high dose (Cohort 3)|15 Patients with mild Alzheimer's.
2576761|NCT02388152|Experimental|Lu AF20513, double high dose (Cohort 4)|15 Patients with mild Alzheimer's.
3210463|NCT00994903|Experimental|Simvastatin|40mg of Simvastatin given 3-7 days pre-op and continued till 14 days post-op
2576867|NCT02387242|Experimental|Group 1|10mg/kg Rifampicin
2576877|NCT02387242|Experimental|Group 2|20mg/kg Rifampicin
2576886|NCT02387242|Experimental|Group 3|30mg/kg Rifampicin
2576930|NCT02387034|Experimental|Physical activity on prescription (PAP)|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
2576931|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about being active with cardiovascular exercise such as walking, cycling or otherwise in 30 minutes three times a week and do strength training functional during the day such as walk in stairs and getting up from a chair without hand support.
2576995|NCT02386748|Experimental|Chewing gum|Chewing sugarless gum
2576997|NCT02386748|Active Comparator|Oral fluids|Clear oral fluids
2576999|NCT02386748|Other|Intravenous fluids|No chewing gum No oral fluids Only intravenous fluids (Lactated Ringer's solution)
2577091|NCT02385825|Experimental|Group 1: 10 μg RVEc|10 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
2577092|NCT02385825|Experimental|Group 2: 50 μg RVEc|50 μg RVEc is to be administered in the lower two-thirds of the deltoid region by intramuscular (IM) injection with a needle and syringe (0.5 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
2577190|NCT02385266|Placebo Comparator|Placebo and Acetominophen|Placebo capsules (lactose)/bid and Acetaminophen prn
3176149|NCT00641537|Placebo Comparator|Cladribine High Dose/Placebo (HLPP)|
3176150|NCT00641537|Experimental|Cladribine Low/Low Dose (LLLL)|
3176151|NCT00641537|Experimental|Cladribine High/Low Dose (HLLL)|
3176152|NCT00641537|Experimental|Placebo/Cladribine Low Dose (PPLL)|
3176153|NCT00641537|No Intervention|Placebo/No Treatment|
3210464|NCT00994955|Experimental|selective retina therapy (SRT)|Focal laser treatment with an SRT-Laser which selectively affects the retinal pigment epithelium while sparing the photoreceptor layer.
2576280|NCT02391272|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
2576320|NCT02391090|Experimental|hypoxia|"The hypoxia group receives normobaric hypoxic air while sitting in a hypoxic chamber simulating 2800 meter above sea level.~Interventions: hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
2576325|NCT02391090|Sham Comparator|sham hypoxia|"The sham group receives normal air while sitting in a hypoxic chamber in about 360 meter above sea level (Graz, Austria).~Interventions: sham hypoxia in hypoxic chamber, asthma and Quality of Life Questionnaires, lung function testing, blood taking, FeNO measurement, pulse oximetry"
2576401|NCT02390596|Experimental|Anakinra|
2576439|NCT02390297||Single|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
2576494|NCT02390024||Critically ill patients|Mechanical Ventilation
2576561|NCT02389595||HIV positive subjects|This group will provide a blood sample.
2576563|NCT02389595||Non-infected control subjects|This group consist of de-identified blood samples from a commercial source.
2576700|NCT02389192|Experimental|OPEN|healthy volunteers between the ages of 18-50 to receive a one-time infusion of Zmapp at a dose of 50mg/kg.
2576754|NCT02388243|Experimental|Brief Intervention in Public Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in public clinic.
2576758|NCT02388243|Active Comparator|Screening results in Public Clinic|Written information after screening; No brief intervention; in public clinic.
2576762|NCT02388243|Experimental|Brief Intervention in Private Clinic|Written information after screening; 15 minutes or so brief intervention at recruitment with follow-up visit of about the same length after one month; in private clinic.
2576767|NCT02388243|Active Comparator|Screening results in Private Clinic|Written information after screening; No brief intervention; in private clinic.
2576796|NCT02387736|Experimental|Dialectical Behaviour Therapy-6 months|6 months of standard dialectical behaviour therapy treatment.
2576797|NCT02387736|Active Comparator|Dialectical Behaviour Therapy-12 months|12 months of standard dialectical behaviour therapy treatment
2576899|NCT02387203|Experimental|PrevPac|"Study intervention: PrevPac (Prevacid, Amoxicillin, Clarithromycin)twice daily x 14 days for 2 courses (preoperative and post-operative).~All eligible patients with a PMP diagnosis, undergoing CRS/HIPEC treatment, who consent to study participation will have a urea breath test prior to the first course of PrevPac.~After surgery, when tolerated, each patient will take a second course of PrevPac. Patients will be seen for follow-up as clinically indicated until year 5."
2576900|NCT02387203|No Intervention|PMP Historical Control|The historical control group will consist of all PMP patients who did not receive perioperative antibiotic treatment.
2576954|NCT02386904|Experimental|Phosphate Enema|Phosphate Enema consisting on Monobasic Sodium Phosphate (USP) 19.2 gm /120 ml and Dibasic Sodium Phosphate (USP) 7.2 gm/120 ml Dosage Form: Enema Frequency: One time; 30 minutes before Sigmoidoscopy
2576983|NCT02386644|Experimental|Suspected Membrane Rupture Arm|Women with suspected membrane rupture will be subject to following interventions; Ultrasound amniotic fluid index measurement, ultrasound transperineal assessment, nitrazine test, speculum examination, PAMG-1 Immunoassay
2577000|NCT02386306|Experimental|Treatment Cohort 1|Each study participant will be administered with one 1mg dose capsule per day of GC021109 for 28 days.
2577001|NCT02386306|Placebo Comparator|Placebo Cohort 1|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
2577002|NCT02386306|Experimental|Treatment Cohort 2|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 1 safety data through day 14
2577006|NCT02386306|Placebo Comparator|Placebo Cohort 2|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
2577011|NCT02386306|Experimental|Treatment Cohort 3|Each study participant will be administered with one dose per day of GC021109 for 28 days. Dose levels will be determined following a review of cohort 2 safety data through day 14
2577016|NCT02386306|Placebo Comparator|Placebo Cohort 3|Patients receiving placebo as part of each cohort will be dosed with a comparable capsule to those in the treatment arm of each cohort.
2577066|NCT02386033|Placebo Comparator|SRP plus placebo|SRP was done for all the subjects. Placebo gel was delivered subgingivally into the pocket
2577072|NCT02386033|Active Comparator|SRP plus Atorvastatin|SRP was done for all the subjects. Atorvastatin was delivered in the pocket subgingivally
2577128|NCT02385630|Experimental|Esophagectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
2577131|NCT02385630|Experimental|Gastrectomy|"Serial assessment:~Fasting gut hormones, post-prandial gut hormone response to a standardized 400kcal meal"
2577260|NCT02384954|Experimental|Phase I/II ALT-803 w/rituximab for rel/ref iNHL|
2577320|NCT02384473|Experimental|Real-time CEUS and SWE|Patients undergo real-time CEUS and SWE at baseline, 6 weeks after initiation of neoadjuvant therapy, and 9 weeks after initiation of neoadjuvant therapy (prior to surgery).
3260271|NCT01477775|Active Comparator|Standard of Care|The treating physician will be left free to give the oral P2Y12 receptor blocker, including clopidogrel,prasugrel or ticagrelor, which according to his/her clinical judgement is most appropriate for the individual patient.
2576257|NCT02391324|Experimental|LOK + fPT|Two 50-minute sessions per week. Children will receive both the LOK and the fPT protocols (content as described above for each) for the duration of the 8 to 10 week intervention phase. These will be given as two sessions of LOK one week alternating with two sessions of fPT the next week. The fPT will build on motor learning principles because the activities will allow the child to practice motor skills in a variety of different activities. Techniques focusing on body structure changes will be prohibited.
2576259|NCT02391324|No Intervention|Maintenance therapy|Consists of maintenance therapy and a weekly email from the centre's research assistant to monitor any co-interventions. Maintenance may include range of motion/stretching and basic isometric strength home program as well as up to 10 minutes per day of exercise bicycle or treadmill or general walking practice.
2576396|NCT02390726|Sham Comparator|Control|Sham FMT and Sham Microbial Maintenance plus standard therapy
2576398|NCT02390726|Experimental|Treatment|FMT and microbial maintenance plus standard therapy
2576446|NCT02390323|Experimental|Lumbar Sympathetic Block|Patients receiving a Lumbar Sympathetic Block as treatment for lower extremity pain. Skin conductance algesimeter will be used to measure sympathetic activity.
2576808|NCT02387931|Experimental|Vitamin D|Vitamin D3 2000 IU daily taken for 6 months
2576813|NCT02387931|Experimental|Fish Oil|Fish Oil 1000 mg daily for 6 months
2576817|NCT02387931|Placebo Comparator|Placebo|Placebo taken daily for 6 months.
2576865|NCT02387437|Experimental|SI recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
2576876|NCT02387437|Experimental|IP recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
2576884|NCT02387437|Experimental|PCV recruitment|Compare the effect of three recruitment maneuvers before and after recruitment maneuvers is implemented,PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
2576981|NCT02386774|Other|an ocular or ocular adnexa disease|patient presenting with an ocular or ocular adnexa disease in the Dermatology or Ophthalmology ward.
2576986|NCT02386774|Other|diabetic patients|
2577007|NCT02386267|Experimental|L-leucine pills|L-leucine , dose- 700mg/m2 , per os, three time a day, course duration 6 months
2577145|NCT02385916|Experimental|EstroSense®/MD|3 capsules per day during the study period
2577151|NCT02385916|Placebo Comparator|Placebo|3 capsules per day during the study period
2577211|NCT02385227|Experimental|Cohort A1|Exclusive blu™ e-cigarette A1
2577213|NCT02385227|Experimental|Cohort A2|Exclusive blu™ e-cigarette A2
2577217|NCT02385227|Experimental|Cohort A3|Exclusive blu™ e-cigarette A3
2577218|NCT02385227|Experimental|Cohort B1|Dual blu™ e-cigarette and usual brand B1
2577220|NCT02385227|Experimental|Cohort B2|Dual blu™ e-cigarette and usual brand B2
2577221|NCT02385227|Experimental|Cohort B3|Dual blu™ e-cigarette and usual brand B3
2577223|NCT02385227|Experimental|Cohort C|Nicotine product cessation C
2577262|NCT02384694|Experimental|Intervention|Zumba dance intervention
2577347|NCT02384564|Experimental|Ambu King Vision Video Laryngoscope aBlade System|The trachea will be intubated using the Ambu King Vision Video Laryngoscope with the appropriate sized blade (size 1 or 2) based on manufacturer guidelines and clinical judgement.
2577348|NCT02384564|Active Comparator|Direct Laryngoscope|The trachea will be intubated via direct laryngoscopy using a traditional straight blade laryngoscope, with appropriately sized blade based on manufacturer guidelines and clinical judgement.
2577391|NCT02383914||Subscapularis rupture|
2577468|NCT02383654|Other|Compassionate Treatment|ALS patients are received Intravenous and intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells (ADSCs), Rehabilitation.
3210465|NCT00994981|Experimental|magnesium|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
2577544|NCT02382770||Open Abdomen patients|All patients underwent to open abdomen procedure
2577616|NCT02382445|Experimental|Anesthesia depth monitor|Anesthesia depth is aimed to be between BIS 50-60
2577623|NCT02382445|Sham Comparator|Control group|Anesthesia depth is monitored but blinded to the anesthesiologist
2577694|NCT02381730|Experimental|Aflibercept|
2577749|NCT02381366|Experimental|PNEUMOSTEM®|Dose A: PNEUMOSTEM® 10 million cells per kg Dose B: PNEUMOSTEM® 20 million cells per kg
2577799|NCT02380989|Experimental|Ayurveda|
2577800|NCT02380989|Placebo Comparator|Placebo|
2577835|NCT02380599|Experimental|Experimental Group|Crossover assignment of mid-thoracic spinal manipulation, spinal mobilization, or sham ultrasound
2577913|NCT02380352|Experimental|Short-course|5 days amoxicillin 90 mg/kg/day divided TID followed by 5 days placebo TID
2577918|NCT02380352|Active Comparator|Standard|5 days amoxicillin 90 mg/kg/day divided TID followed by alternate formulation 5 days amoxicillin 90 mg/kg/day divided TID
2577964|NCT02379910|Experimental|SAD 1|AM1030-CREAM
2577975|NCT02379910|Experimental|SAD 2|AM1030-CREAM
2577987|NCT02379910|Experimental|SAD 3|AM1030-CREAM
2577992|NCT02379910|Experimental|MAD 1|AM1030-CREAM
2577995|NCT02379910|Experimental|MAD 2|AM1030-CREAM
2578031|NCT02379520|Experimental|Group A|HPV Specific T Cells
2578037|NCT02379520|Experimental|Group B|HPV Specific T Cells plus lymphodepletion (Cytoxan and Fludarabine) and nivolumab
2578158|NCT02378675||Healthy (1)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
3210466|NCT00994981|Placebo Comparator|normal saline|Using a table of random numbers, the patients were randomized to receive magnesium solution or normal saline. Allocation concealment was ensured using sequentially numbered, sealed opaque envelopes. Immediately after patient's arrival in the operating room, an anesthesiologist who was not involved in this study opened the envelopes and prepared the study solution outside the operating room.
3210467|NCT00994994|Active Comparator|Tranexamic acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit.
2576334|NCT02390999|No Intervention|24 hours of therapeutic hypothermia|24 hours of therapeutic hypothermia to a target temperature of 32-34 degrees in comatose cardiac arrest patients is standard treatment in Denmark.
2576338|NCT02390999|Experimental|48 hours of therapeutic hypothermia|48 hours of therapeutic hypothermia to a target temperature of 32-34 degrees
2576380|NCT02390674|Active Comparator|Ciclosporin|Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre)
2576384|NCT02390674|Placebo Comparator|Saline|Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention
3210468|NCT00994994|Placebo Comparator|Placebo|same volume of normal saline was given.
3210469|NCT00995033|Experimental|NicVAX conjugate vaccine|
2576483|NCT02389777|No Intervention|Control UV burn|No treatment of the UV Light burn will be given
2576484|NCT02389777|Active Comparator|ST266 treated UV burn immediately|ST266 will be applied topically immediately by spray to the UV light burn wound
2576488|NCT02389777|Active Comparator|ST266 treated UV burn delayed|ST266 will be applied topically by spray to the UV light burn beginning 6 - 12 hours after the burn
2576642|NCT02389114|Active Comparator|Low Protein Preload|The subjects consumed soybean curd preload containing low protein content.
2576644|NCT02389114|Experimental|Low Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing low protein content and polydextrose.
2576647|NCT02389114|Experimental|High Protein Preload|The subjects consumed soybean curd preload containing high protein content.
2576649|NCT02389114|Experimental|High Protein with Polydextrose Preload|The subjects consumed soybean curd preload containing high protein content and polydextrose.
2576667|NCT02388659||Brain MRI/MRS Patients|3 Tesla Scanning: MRI/MRS of glioma and non-glioma patients.
2576732|NCT02388464|Experimental|Low dose|
2576733|NCT02388464|Experimental|Intermediate dose|
2576734|NCT02388464|Experimental|High dose|
2576735|NCT02388464|Experimental|Placebo|
2576785|NCT02388022||degenerative disc disease|Patients who have had a transforaminal lumbar interbody fusion at 1-2 contiguous levels with the CALIBER® expandable spacer and have completed at least 2 year follow-up.
3210470|NCT00995033|Placebo Comparator|Placebo|Biological
3210471|NCT00995046|Active Comparator|usual prophylaxis regimen|All patients will receive their usual prophylaxis regimen during the first 6 months
3210472|NCT00995046|Experimental|individually tailored prophylaxis regimen|All patients will receive an individually tailored prophylaxis regimen in accordance with TGT results during the second 6 month-period.
3210473|NCT00995059|Experimental|Arm 1|CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.
2577094|NCT02385656|Experimental|Intervention group|Subjects who take modafinil for cancer-related fatigue for 4 weeks.
3210474|NCT00995098|Experimental|Early enteral nutrition|Twenty patient will be enrolled into this arm. Enteral nutrition administration will start within 24 hours after admission through naso-jejunal tube and continue for 7 days after admission.Naso-jejunal tube will be set up by endoscopy.
3210475|NCT00995098|Active Comparator|Control: Parenteral Nutrition|Twenty patient will be enrolled into this arm. PN administration will start within 24 hours after admission and continue for 7 days after admission.Parenteral nutrition will be administered through subclavian central venous catheter.
3210476|NCT00995124|Experimental|NeutraLice Lotion|Single application of head lice product.
2577272|NCT02384889|Experimental|Difluoromethylornithine|Subjects may be given daily dose of DFMO
2577275|NCT02384889|Placebo Comparator|Placebo|Subjects may be given daily dose of placebo
2577322|NCT02384421|Experimental|Activa PC+S Neurostimulator|Participants will be own controls and undergo both adaptive and continuous deep brain stimulation testing paradigms using Nexus D research tool
2577356|NCT02384109|Experimental|Intervention|Pharmacist-coordinated shared decision making about treatment for pre-diabetes (lifestyle change and/or metformin), using a decision tool
2577358|NCT02384109|Placebo Comparator|Usual Care|Usual care for patients with a diagnosis of pre-diabetes
2577393|NCT02383823|Active Comparator|Estrogens in menopausal women|Crossover of estrogens or placebo in random order, either 2 mg estradiol or placebo in three months in random sequence, age span 45-55
2577400|NCT02383823|No Intervention|Menopausal men|comparative to menopausal women, age span 45-55
2577405|NCT02383823|No Intervention|Elderly women|comparative to menopausal women, age span 65-80
2577408|NCT02383823|No Intervention|Elderly men|comparative to menopausal women, age span 65-80
2577409|NCT02383823|Placebo Comparator|Placebo in menopausal women|Crossover of estrogen or placebo in random order, either 2 mg estrogen or placebo in three months in random sequence, age span 45-55
3210477|NCT00995124|Experimental|NeutraLice Advance|single application of head lice product
3210478|NCT00995124|Active Comparator|Moov Head Lice Solution|Single application for head lice with 10 min application time.
3210479|NCT00995137|Experimental|relapse B-Lineage ALL|"All patients meeting the eligibility criteria.~Intervention: NK Cell Infusion"
3210480|NCT00995150|Experimental|LNG20|LNG20 levonorgestrel-releasing intrauterine system
2576330|NCT02391077|Experimental|Arm 2 - Medium intervention|"Foreskin disinfection with Povidone-Iodine~Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus"
2576371|NCT02390661|No Intervention|No drain|Control group
2576377|NCT02390661|Experimental|Penrose drain placement|Placement of a penrose drain after irradiation catheter is removed
2576454|NCT02390466|Experimental|VAC-3S|32µg/ml corresponding to 16µg/vaccination
2576492|NCT02389985|Experimental|CRLX101 and weekly paclitaxel|CRLX101 and weekly paclitaxel administered by IV on days 1 and 15 of a 28 day cycle. Paclitaxel only is administered by IV on day 8.
2576576|NCT02389504|Active Comparator|Standard Physical Therapy Protocol|Regular Physical Therapy Protocol. Standard treadmill running, monitoring heart rate
2576578|NCT02389504|Experimental|Exertion Physical Therapy Protocol|Exertional Physical Therapy Protocol. Dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
2576630|NCT02389062|Experimental|Placebo controlled group|This is a group of same number of subjects as in other arms, who will be given equivalent dose of placebo- cornstarch capsules i.e 5 capsules containing neutral substance- cornstarch(placebo) to be taken daily by mouth for a period of 12 weeks.
2576631|NCT02389062|Experimental|High dose gluten capsules|This group of subjects will be given high dose i.e 2.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
2576633|NCT02389062|Experimental|Low dose gluten capsules|This group of subjects will be given low dose i.e 0.5 g of gluten containing capsules, 5 capsules to be taken daily by mouth, for a period of 12 weeks.
3210481|NCT00995150|Active Comparator|Mirena|Levonorgestrel-releasing intrauterine system for contraception
3210482|NCT00995176||1|Women residing in areas from defined geographic areas with high HIV prevalence and poverty
2576822|NCT02387658||final TLG </=11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) < 11 mmHg regardless if revascularization is done or not.
2576827|NCT02387658||final TLG > 11 mmHg|includes all patients who have a final mean translesional gradient measurement (TLG) > 11 mmHg regardless if revascularization is done or not.
2576864|NCT02387424|Experimental|MBCT-PD|Mindfulness-based cognitive therapy adapted for perinatal women (MBCT-PD)
2576874|NCT02387424|Active Comparator|OAR|Ongoing Assessment and Referral (OAR)
3210483|NCT00995176||2|Men residing in areas from defined geographic areas with high HIV prevalence and poverty
3210484|NCT00995189|Experimental|OFR|Opti-Free RepleniSH contact lens care solution used for 30 days
3210485|NCT00995189|Active Comparator|RNM|ReNu MultiPlus contact lens care solution used for 30 days
2577033|NCT02386293|Placebo Comparator|Placebo|Sugar pill identical to Avapro provided for 7 day prescription
2577035|NCT02386293|Active Comparator|Irbesartan|150 mg of Avapro once daily for 7 days.
2577070|NCT02385981|Experimental|Stivax|an intermittent stimulation of afferent vagus nerve at earlap
2577095|NCT02385682||ST-segment elevation AMI|ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
2577096|NCT02385682||Non-ST-segment elevation AMI|Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
2577142|NCT02385513|Active Comparator|6 + 10 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 10 weeks of age with a booster at9 months of age and routine vaccines administered as per the Nepal EPI schedule
2577144|NCT02385513|Active Comparator|6 + 14 weeks of age PCV10 priming|10 valent pneumococcal conjugate vaccine administered (PCV10) at 6 and 14 weeks of age with a booster at 9 months of age and routine vaccines administered as per the Nepal EPI schedule
2577224|NCT02385214|Experimental|Arm A Wide Local Excision = 1cm Margin|"ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
2577225|NCT02385214|Active Comparator|Arm B Wide Local Excision = 2cm Margin|"ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy~+/- Reconstruction"
2577254|NCT02384681||Exposed|Medical regulation assistants working with headset
2577259|NCT02384681||Non-Exposed|Participants working without headset
3176154|NCT00641537|No Intervention|Cladribine 3.5 mg/kg/No Treatment|Participants who received cladribine 3.5 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
2577368|NCT02383979|Sham Comparator|Plasma Ball (Control)|"Subjects randomized to standard therapy will participate 14 days of daily mirror therapy sessions preoperatively which will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
2577370|NCT02383979|Experimental|Experimental|Subjects randomized to the mirror therapy limb will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb.
2577371|NCT02383979|No Intervention|Non-Surgical|Subjects will undergo 3 questionnaires and one functional fMRI exam. Imaging protocol will be identical to preoperative imaging protocol for amputation subjects. This data will aid in establishing baseline fMR activation values for all fMR paradigms tested. The control group will not be randomized to receive either perioperative plasma ball (sham) or mirror therapy.
2577513|NCT02382978|Experimental|nurse-provided well child care visit|these children will be seen by a nurse only for their regular, pre-scheduled well child care visit
2577515|NCT02383225|Experimental|Condition A|Substance use resistance skills; no Lakota language enhancement, no FaceBook supplement
2576486|NCT02390089|Active Comparator|Healthy control|Healthy age-matched adult participants with no history of Parkinson's disease Participants in this group will receive capsaicin vapor cough provocation test. The vapor will be delivered using a small hand-held nebulizer.
2576497|NCT02390089|Experimental|Parkinson's disease - no PA|People with Parkinson's disease without penetration or aspiration during swallowing; based on results of videofluoroscopic swallow evaluation. Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer.Participants in the group will also receive a fluoroscopic swallow evaluation.
2576501|NCT02390089|Experimental|Parkinson's disease - PA|People with Parkinson's disease with penetration or aspiration during swallowing;based on results of videofluoroscopic swallow evaluation.Participants in this group will receive capsaicin vapor and fog cough provocation test using a small, hand-held nebulizer. Participants in the group will also receive a fluoroscopic swallow evaluation.
2576556|NCT02389465|No Intervention|Control|This arm is for participants who are not depressed.
2576558|NCT02389465|Experimental|Experimental - treatment|Depressed participants will receive an antidepressant (escitalopram) AND either a non-steroidal anti-inflammatory drug (celecoxib) OR placebo (sugar pill) for 6 weeks.
2576599|NCT02389257|Experimental|MINIMAG / MEG|Cerebral magnetic fields
2576602|NCT02389257|Experimental|MINIMAG / ECG|Cardiac magnetic fields
2576619|NCT02388958||Women with GDM|
2576623|NCT02388958||Women without GDM|
2576683|NCT02388789|Experimental|active movement|use a light treadmill run to raise feet temperature
3210490|NCT00995241|Experimental|Raltegravir 800 mg / 24 hours|Raltegravir 800 mg / 24 hours
3210491|NCT00995254|No Intervention|Control group|Control group will ONLY receive SHI after completion of the study
2576902|NCT02387177|Experimental|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2576903|NCT02387177|Experimental|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
2576947|NCT02386891|Experimental|Cold|The cold treatment was 18-20°C (64.5-68°F), which is at the lower end of the thermalneutral zone in healthy adults.
2576957|NCT02386891|Experimental|Warm|The warm treatment was 25-27°C (77-80.6°F), which is above the range of the thermalneutral zone.
2576984|NCT02386631|Experimental|Orthotic|Custom made orthotic provided for study
2577031|NCT02386436|Experimental|Cohort 1- GSK2330811(0.1 mg/kg)|Subjects will be randomised to receive either 0.1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
2577037|NCT02386436|Experimental|Cohort 2- GSK2330811(0.3 mg/kg)|Subjects will be randomised to receive either 0.3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
2577039|NCT02386436|Experimental|Cohort 3- GSK2330811(1 mg/kg)|Subjects will be randomised to receive either 1 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
2577040|NCT02386436|Experimental|Cohort 4- GSK2330811(3 mg/kg)|Subjects will be randomised to receive either 3 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
2577042|NCT02386436|Experimental|Cohort 5- GSK2330811(6 mg/kg)|Subjects will be randomised to receive either 6 mg/kg GSK2330811 or placebo s.c single dose in a 3:1 ratio.
2577065|NCT02385955|Experimental|Myeloablative dUCBT|Myeloablative conditioning with (1) TBI, cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine, followed by double unit umbilical cord blood transplant
2577125|NCT02385695||Posterior Dynamic Stabilization|Surgical treatment with posterior dynamic stabilization
2577130|NCT02385695||Internal Fixation and Fusion|Surgical treatment with internal fixation and fusion
3210492|NCT00995254|Experimental|Intervention group|Intervention group will receive smoking hygiene intervention (SHI) at three individualized contacts.
3210493|NCT00995267|Experimental|behavioral intervention|Behavioral intervention arm comprises 5 joint parent-child school-based nutritional activities in which nutritional information was combined with Adler's behavioral concepts. and a 5-session parental workshop.
3210494|NCT00995267|No Intervention|control arm|
2577308|NCT02384434|Other|Single Arm|Low Level Laser Therapy
3210495|NCT00995280|Active Comparator|1|Single lumen needle use in oocyte retrieval
3210496|NCT00995280|Active Comparator|2|Double lumen needle with follicle flushing during oocyte retrieval
2577460|NCT02383394||aborted women|women who got pregnant and have 2nd trimesteric abortion, follow up antenatal care by ultrasound and clinical monitoring
2577464|NCT02383394||continued women|women who got pregnant and completed her pregnancy follow up antenatal care by ultrasound and clinical monitoring
2577508|NCT02382965|Experimental|ultrasound|
3210497|NCT00995293|Experimental|Docetaxel Cisplatin 5-Fluorouracil (DCF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Docetaxel 60mg/m² on day 1~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
3210498|NCT00995293|Experimental|Cisplatin 5-Fluorouracil (CF)|"4 cycles of the following products every 3 weeks (unless disease progression/relapse or unacceptable toxicity occured or the patient refused treatment):~Cisplatin 75mg/m² on day 1~5-FU 750mg/m²/day on day 1 to day 5"
3210499|NCT00995306|Active Comparator|1|Civamide Cream 0.075%
2577722|NCT02381236|Experimental|G-202|G-202 administered by intravenous infusion on 3 consecutive days of a 28-day cycle
2577802|NCT02381132|Active Comparator|MNK155|Hydrocodone Bitartrate/Acetaminophen Extended-Release Tablets
2577805|NCT02381132|Active Comparator|Norco 7.5mg/325mg|Norco 7.5mg/325mg
3210500|NCT00995306|Active Comparator|2|Civamide Cream 0.01%
3210501|NCT00995319||radiation patients|cancer patients with radiotherapy concerning the head and neck area/oral cavity
3210502|NCT00995332|Experimental|ATRA+valproc acid+low-dose cytarabine|
3210503|NCT00995358|Experimental|vaccination|
3210504|NCT00995384|Other|CT scan|CT Scan for endocarditis patients. All patients receive intervention.
3210505|NCT00995397|Experimental|Dexchlorpheniramine 1% lotion|
3210506|NCT00995397|Active Comparator|Dexchlorpheniramine 1% cream|
2576369|NCT02390609|Experimental|Group 1: Sequence 1 (ABC)|Participants will receive Treatment A (Ibrutinib 560 milligram [mg] capsules [reference] under fasted conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (plus [+] / minus [-] 2) days will be maintained between each treatment period.
2576375|NCT02390609|Experimental|Group 1: Sequence 2 (BCA)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576378|NCT02390609|Experimental|Group 1: Sequence 3 (CAB)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576381|NCT02390609|Experimental|Group 1: Sequence 4 (ACB)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 2; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576383|NCT02390609|Experimental|Group 1: Sequence 5 (BAC)|Participants will receive Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576388|NCT02390609|Experimental|Group 1: Sequence 6 (CBA)|Participants will receive Treatment C (Ibrutinib 560 mg suspension under fed conditions) in Period 1; followed by Treatment B (Ibrutinib 560 mg suspension under fasted conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576390|NCT02390609|Experimental|Group 2: Sequence 1 (AFDE)|Participants will receive Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 1; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 2; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 3; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576391|NCT02390609|Experimental|Group 2: Sequence 2 (DAEF)|Participants will receive Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 1; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 2; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 3; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576393|NCT02390609|Experimental|Group 2: Sequence 3 (EDFA)|Participants will receive Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 1; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 2; followed by Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 3; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576394|NCT02390609|Experimental|Group 2: Sequence 4 (FEAD)|Participants will receive Treatment F (Ibrutinib 560 mg sprinkle capsule granules suspended in water under fasted conditions) in Period 1; followed by Treatment E (Ibrutinib 560 mg sprinkle capsule granules under fed conditions) in Period 2; followed by Treatment A (Ibrutinib 560 mg capsules [reference] under fasted conditions) in Period 3; followed by Treatment D (Ibrutinib 560 mg sprinkle capsule granules under fasted conditions) in Period 4. A washout period of 7 (+/- 2) days will be maintained between each treatment period.
2576474|NCT02390128||mothers and babies|pregnant mothers (UK resident) and their babies (observational, not an intervention)
2576482|NCT02389790|Experimental|MT-1303|
2576551|NCT02389569|Experimental|Adhesive system treatment|Four groups ( Two will be treat with Etch-and-Rinse Adhesive System and two will be treated with two step Self-Etch Adhesive System).
2576552|NCT02389569|Experimental|Restoration protocol|Four groups ( Two will be treat with experimental Biosilicate and two will be the control groups).
2576601|NCT02389244|Experimental|Regorafenib|"For adult patients (≥18 years old) : 160 mg/d once daily for the 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent .~For children Age ≥10 years to <18 years old and BSA ≥1.30 m², regorafenib (82 mg/m²) once daily for the 3 weeks on/1 week off (without exceeding 160 mg/day) plus Best Supportive care (BSC) until progression (according to RECIST 1.1), intolerance or withdrawal of consent."
2576603|NCT02389244|Placebo Comparator|placebo|Placebo plus BCS until progression (according to RECIST V1.1) intolerance or withdrawal of consent. Patients who have received placebo will receive open-label regorafenib after objective tumor progression.
2576681|NCT02388828||Subjects who have received lentiviral-based CARTmeso therapy|
2576779|NCT02388035|Experimental|SBP-group 1|Spontanous bacterial peritonitis
2576780|NCT02388035|Experimental|CNNA-group 2|Culture negative neutrocytic ascites
2576781|NCT02388035|Experimental|MNBA-group 3|monomicrobial non-neutrocytic ascites
2576783|NCT02388035|No Intervention|group 4|no evidence of ascitic fluid infection
2576801|NCT02387775|Experimental|Esophageal temperature control|The Esophageal Cooling Device (ECD) will be inserted and utilized for temperature control for up to 36 hours in this arm. The ECD will be used for all three phases of therapeutic hypothermia; induction, maintenance, and rewarming. Conventional cooling or warming techniques (e.g. cold saline, ice packs, cooling or warming blankets) will still be made available to the treating ICU team to be used at their discretion.
3210507|NCT00995423|Active Comparator|CoroflexTM|highly flexible CoroflexTM Please-Stent features
3210508|NCT00995423|Active Comparator|TAXUS|Paclitaxel-eluting stent
2576449|NCT02390336|Sham Comparator|Sham mobilization-with-movement (MWM)|"In each volunteer of this group, the blind assessor will perform the pre-intervention measurements of intensity of pain, range of motion and physical function tests.~Next, the therapist will performed the sham mobilization-with-movement. Then, all measurements, before described, will be repeated, by the assessor."
2576496|NCT02389907||Total Hip Replacement Group|Adults who have undergone a total hip replacement
2576502|NCT02389907||Hysterectomy Group|Adults who have undergone a hysterectomy
2576562|NCT02389543|Experimental|A: Selinexor (1x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per dose-limiting toxicity (DLT criteria,) it will be increased to 25 mg for that arm. Selinexor will be started at 80 mg (~45 mg/m2) once weekly in combination with dexamethasone 40 mg once weekly with each dose of selinexor. If the selinexor 80 mg dose is tolerated per DLT criteria, the dose will be increased to 100 mg (~60 mg/m2) and evaluated for MTD, tolerability and efficacy.
2576565|NCT02389543|Experimental|B: Selinexor (2x/week), Lenalidomide, & Dexamethasone|Lenalidomide will be dosed initially at 15 mg daily, and if that dose is tolerated per DLT criteria, it will be increased to 25 mg for that arm. Selinexor will be started at 60 mg (~35 mg/m2) twice weekly in combination with dexamethasone 20 mg twice weekly with each dose of selinexor; dexamethasone 20 mg will also be given, without selinexor, on Days 22 and 24. If the selinexor 60 mg dose is tolerated per DLT criteria, the dose will be increased to 80 mg (~45 mg/m2) and evaluated for MTD, tolerability and efficacy.
2576609|NCT02389140|Experimental|Trigger point treatment|Trigger point release
2576611|NCT02389140|Sham Comparator|Ultrasound|Sham US at Trigger point
3210509|NCT00995462|No Intervention|Control|
3210510|NCT00995462|Experimental|Small-group seminar for 2 years|
2576892|NCT02387450|Active Comparator|Treated group|Sildenafil, oral, 100mg per day
2576895|NCT02387450|Placebo Comparator|Control group|placebo oral
2576936|NCT02386982|Experimental|HMS5552 dose 1|HMS5552 75mg.Oral administration,twice per day.
2576938|NCT02386982|Experimental|HMS5552 dose 2|HMS5552 75mg.Oral administration,once per day.
2576993|NCT02386722|Experimental|Intervention group|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
2576998|NCT02386722|No Intervention|Control group|Patients in the control group will receive a Smartinhaler/POEMS, which only records their adherence. The alarm function of the devices will be switched off, and these participants will not be reminded to take their inhalers. This group will not receive any calls, if they do not comply with the prescribed medication schedule or if they use their rescue medication too frequently.
2577009|NCT02386384||Control|Normal fertile
2577015|NCT02386384||Implantation Failure|Failure to conceive
2577022|NCT02386384||Recurrent Pregnancy Loss|2 or more unexplained miscarriages
2577057|NCT02386202||Patients with hemorrhagic stroke|All patients with hemorrhagic stroke admitted to the neurosciences ICU are eligible for study enrollment.
2577149|NCT02385786|Experimental|Mindfulness-Based Cognitive Therapy|Adult Participants with Major Depressive Disorder who Enroll in an open clinical trial of MBCT as Mono-therapy
3210511|NCT00995462|Experimental|Small-group seminars for 1 year followed by email intervention|
3210512|NCT00995514||Clopidogrel|Patients receiving clopidogrel 75 mg/day as prescribed by their physician, and are extensive metabolizers by CYP2C19 genotype
2577281|NCT02384746|Experimental|Combination Treatment|Fulvestrant (500mg) + MLN9708 (2.3, 3, and 4mg)
2577330|NCT02384330||Dysport® (abobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
2577334|NCT02384330||Botox® (onabotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
2577337|NCT02384330||Xeomin® (incobotulinumtoxinA)|Botulinum Toxin Type A (BoNT-A) preparation, injected doses, number of points, volume per point, in accordance with local Summary of Product Characteristics and locally agreed therapeutic guidelines.
2577373|NCT02384122|Active Comparator|Octreotide|Drug: Sandostatin LAR Sandostatin LAR 40 mg will be administered once every 4 weeks as a intramuscular injection
2577375|NCT02384122|No Intervention|Standard of care|Patients receive standard of care without a placebo.
2577423|NCT02383693|Active Comparator|repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment 5 days/week for up to 4 weeks
2577425|NCT02383693|Sham Comparator|Sham comparator|Placebo Comparator: Placebo Treatment 5 days/week for up to 4 weeks
2577536|NCT02383446|Experimental|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
2577577|NCT02382536||Infusion set|Each subject will receive a total of 4 simultaneous subcutaneous infusions of insulin diluent, two using the investigational device (BD Scarlett Infusion Set) and two using the the comparator (Medtronic QuickSet Infusion Set).
2577641|NCT02382289|Active Comparator|bipolar RF 6 points|Six RF needles will be put between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. After sensory and motor stimulation, bipolar lesion RF at 80oc for 90 sec will be applied between each successive pairs of needles.
2577647|NCT02382289|Active Comparator|monopolar RF 6 points|RF needle is inserted at six levels in the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
2577690|NCT02381743|Experimental|Group 2|Receipt of a daily SMS text message describing various aspects of clinical practice
3210513|NCT00995514||Prasugrel|Patients receiving prasugrel 5 or 10 mg/day as prescribed by their physician
3210514|NCT00995540|Placebo Comparator|Placebo|Placebo subcutaneous injection tid for 12 weeks
3210515|NCT00995540|Active Comparator|100 mg INGAP Peptide tid|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
3210516|NCT00995540|Active Comparator|200 mg INGAP Peptide tid|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
2576653|NCT02388841||Pulmonary embolism|Distribution of the characteristics of Pulmonary Embolism patients according to thrombus localization
2576654|NCT02388841||tomographic pulmonary angiography|Distribution of the characteristics of Pulmonary Embolism patients according to the localization of thrombi in the most proximal level of Main pulmonary artery and other arterial branches as confirmed by Computed tomographic pulmonary angiography
3210517|NCT00995579||Healthy college volunteers|
3210518|NCT00995592|Experimental|Mentor mothers|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
2576769|NCT02388048|Experimental|Ibrutinib + Ofatumumab|"IBRUTINIB 420 mg PO daily in 28-day cycles for a total of 7 cycles (28 weeks).~OFATUMUMAB 300 mg on day 1 of cycle 2 of Ibrutinib, followed by 2000 mg on D8, 15, 22 of cycle 2, D1, 8, 15, 22 of cycle 3, and Day 1 of cycle 4-7.~After induction treatment patients with HLA identical sibling or fully matched MUD donor will be addressed to reduced intensity allogeneic bone marrow transplant, while patients without a suitable donor or who refuse the transplant procedure will receive maintenance treatment by BTK inhibitor (IBRUTINIB 420 mg PO daily in 28-day cycles). Treatment will continue until disease progression or unacceptable toxicity."
3210519|NCT00995592|No Intervention|Control|Control cases were visited and their infants were weighed 4 times over one year period. After one year, mothers were provided Philani nutrition intervention program.
3210520|NCT00995605|Experimental|Groups SAD|AMAP102 or Placebo as single ascending doses in five groups
3210521|NCT00995605|Experimental|Groups MAD|AMAP102 or Placebo as multiple ascending doses twice daily for seven days in two groups
3210522|NCT00995618|Experimental|Tranilast|Tranilast tablets
2577111|NCT02385929|Experimental|Swallowing therapy & resistance training|"Mouth opening and swallowing exercise intervention by occupational therapist for half an hour 3 times a week for 5-6 weeks during radiotherapy.~Progressive resistance training by physiotherapist for 1 hour twice weekly for 5-6 weeks during radiotherapy."
2577116|NCT02385929|No Intervention|Standard Care|Patients in this arm are randomized to usual care / control group
2577161|NCT02385461||Inherited Thrombophilia|Women with Common Inherited Thrombophilias and previous foetal loss
2577164|NCT02385461||Other Thrombophilias with Pregnancy loss|Women with Thrombophilias other than common inherited thrombophilias and previous foetal loss
2577166|NCT02385461||No thrombophilia|Women without thrombophilias and previous foetal loss
2577204|NCT02385110|Experimental|Group 1: Alemtuzumab + Etoposide + Dexamethasone|"Induction Phase: Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide, and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Dexamethasone by vein on Days 1-7 of the induction phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Participants receive Alemtuzumab once every 4 weeks and Dexamethasone three times per week during the maintenance phase. Participants who have evidence of budding relapse during the maintenance phase may revert back to receiving Etoposide.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes."
2577208|NCT02385110|Experimental|Group 2: Etoposide + Dexamethasone + Tocilizumab|"Induction Phase: Participants receive Tocilizumab by vein over 60 minutes on Day 1 or Day 2 of the Induction phase. Participants receive Alemtuzumab daily on Days 1 - 4 with weekly Etoposide and Dexamethasone by vein on Days 1-7 during the 8-week induction phase. Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.~Maintenance Phase: The maintenance phase will last 16 weeks and starts after the Induction Phase. Tocilizumab not given in the Maintenance Phase. Dexamethasone three times per week during the maintenance phase.~If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes"
2577244|NCT02384733|Experimental|Hypofractionated loco-regional RT|40 Gy / 15 fractions, 2.67 Gy per fraction, 5 fractions weekly
2577248|NCT02384733|Active Comparator|Normofractionated loco-regional RT|50 Gy / 25 fractions, 2.00 Gy per fraction, 5 fractions weekly
2577309|NCT02384590|Experimental|CCBT + Care Manager Arm|Patients will be given a tablet device with unlimited data. The device will be pre-installed with a pain and mood diary app that will prompt them to enter their pain severity (0-10), pain location, and mood (0-10), once a day. They will also be registered on to the Beating the Blues website and asked to use the tablet device to complete eight 1-hour Beating the Blues CBT sessions, over the next 3-months. They will also be introduced to a care manager who will contact them on a weekly basis by telephone and throughout the week by email or text, for one-month and then as needed for two additional months. At the conclusion of 3 months participants will only have care manager support upon request but are free to continue using the Beating the Blues program for as long as they like.
2577311|NCT02384590|No Intervention|Treatment As Usual|Similar to the treatment arm, patients will be given a tablet device with unlimited data that comes pre-loaded with a pain and mood diary app. The app will prompt the usual care patients to complete diary data daily. No other activities are required as part of the study but the patients are free to use the tablet as much as they like for their own leisure. At the end of 3-months, patients who continue to report depressive or anxiety symptoms are invited to cross-over to the treatment arm where they will be registered for the Beating the Blues program and given care manger support.
2577420|NCT02384187|Placebo Comparator|Group C|Patients in this group will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
2577867|NCT02380586||Women in labor undergoing anesthesia care|Women in labor undergoing anesthesia care
3210523|NCT00995618|Active Comparator|Febuxostat|Febuxostat tablets
2576580|NCT02389322|Experimental|5μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
2576585|NCT02389322|Experimental|10μg/ml ESAT6-CFP10 after BCG immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after BCG immunization, according to a randomisation scheme .
2576587|NCT02389322|Placebo Comparator|5μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 5μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 5μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme .
2576588|NCT02389322|Placebo Comparator|10μg/ml ESAT6-CFP10 after placebo immunization|A within group paired comparison of 10μg/ mL ESAT6-CFP10 and TB-PPD in 48 person of study population II. The 10μg/ mL ESAT6-CFP10 and TB-PPD agents are given concomitantly to each volunteer in the right and left forearms 12 weeks after placebo controlled immunization, according to a randomisation scheme.
2576627|NCT02388971|Experimental|MLN1202 Dose|MLN1202 Dose, intravenously (IV), once on Days 1, 29 and 57.
2576628|NCT02388971|Experimental|MLN1202 Placebo|MLN1202 placebo, intravenously (IV), once on Days 1, 29 and 57.
3210524|NCT00995618|Experimental|Combination|Tranilast plus febuxostat
3210525|NCT00995631|No Intervention|Premenopausal, Control|Premenopausal women randomized to Control (delayed liposuction surgery)
3210526|NCT00995631|Active Comparator|Premenopausal, Surgery|Premenopausal women randomized to surgery (femoral lipectomy)
2576869|NCT02387398|Experimental|Interventional|Early Angiography with purpose of coronary revascularization within 120 minutes of admission to ED, post out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG
2576879|NCT02387398|No Intervention|Control Group|Standard of care treatment including therapeutic hypothermia in subjects post resuscitation, out-of-hospital cardiac arrest, suspicious for cardiac etiology and no ST segment elevation on ECG.
2576950|NCT02387021|Active Comparator|Continous femoral nerve block|Patients will receive ultrasound-guided (USG) continuous femoral nerve block with 20 ml ropivacaine 0.2% and USG Continuous adductor canal block with 20 ml of saline and USG infragluteal SNB with 20 ml of saline .
2576959|NCT02387021|Experimental|Continuous adductor canal block|Patients will receive ultrasound-guided continuous adductor canal block with 20 ml ropivacaine 0.2% and USG infragluteal SNB with 20 ml ropivacaine 0.2% and USG continuous FNB with 20 ml of saline .
2577148|NCT02385812|Experimental|High lung cancer risk|Individuals with lung cancer risk >= 1.5% over 6 years
2577150|NCT02385812|Experimental|Low lung cancer risk|Individuals with lung cancer risk <1.5% over 6 years
2577219|NCT02385175||Adults with suspected Eustachian tube dysfunction|Age 18+ with possible Eustachian tube dysfunction on the basis of symptoms and examination findings.
2577255|NCT02384798|Experimental|ventilatory support|noninvasive ventilatory support to 5cmH2O used before the session of interval training and resistance exercises performed three times a week for 12 weeks
2577263|NCT02384798|Active Comparator|interval training|sessions of interval training and resistance exercises performed three times a week for 12 weeks
2577436|NCT02383641||Observation|Patients with Wolman disease or high-grade suspicion for Wolman disease
2577490|NCT02383303|Experimental|Program|The program group is eligible to participate in the Individual Development Account savings program.
2577496|NCT02383303|No Intervention|Comparison|The comparison group cannot enter the Individual Development Account program.
2577525|NCT02382861|Experimental|NAVA group|Management of the difficult weaning from mechanical ventilation by the NAVA.
2577526|NCT02382861|Active Comparator|Control group|Conventional management of the difficult weaning from mechanical ventilation, with the pressure ventilation.
2577549|NCT02382679|Placebo Comparator|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
2577553|NCT02382679|Experimental|Experimental: Vitamin Mixture|Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.
2577695|NCT02381743|Experimental|Group 3|Receipt of a daily SMS text message describing various aspects of clinical practice, but phrased as multiple choice question
3210527|NCT00995631|No Intervention|Postmenopausal, Control|Postmenopausal women randomized to Control (delayed liposuction surgery)
3210528|NCT00995631|Active Comparator|Postmenopausal, Surgery|Postmenopausal women randomized to surgery (femoral lipectomy)
3210529|NCT00995657|Active Comparator|High dose ICS|Fluticasone Propionate 250mcg bid
3210530|NCT00995657|Active Comparator|Low dose ICS|Fluticasone propionate 50mcg bid
3210531|NCT00995683|Experimental|half sodium lactate|infusion of 0.5 ml/kg/day during 48 hours
3210532|NCT00995683|Active Comparator|isotonic sodium chloride|infusion of 0.5 ml/kg during 48 hours
3210533|NCT00995696|Experimental|PhaST|Group receiving PhaST IVR phone calls.
3210534|NCT00995696|No Intervention|Usual Care|Group NOT receiving IVR phone calls.
3210535|NCT00995735||Transgastric|Patients submitted to Transgastric NOTES surgery
3210536|NCT00995735||Transvaginal|Patients submitted to Transvaginal surgery
3210537|NCT00995787|Experimental|AZD1656|
3210538|NCT00995787|Placebo Comparator|Placebo|
3210539|NCT00995800|Active Comparator|Fluticasone propionate / Formoterol fumarate|
3210540|NCT00995800|Placebo Comparator|Fluticasone propionate / Formoterol fumarate placebo|
3210541|NCT00995826|Placebo Comparator|placebo|
3210542|NCT00995826|Experimental|CS-8958 DPI|
3210543|NCT00995839|Experimental|continuous terlipressin|
3210544|NCT00995839|Experimental|vasopressin|
3210545|NCT00995839|Experimental|terlipressin bolus dose|
3210546|NCT00995852|Active Comparator|bilateral|"Treatment arm B - incomplete bilateral treatment of in total two lobes (contralateral).~The study will only use Intrabronchial Valves™"
3210547|NCT00995852|Active Comparator|unilateral|Treatment arm A - unilateral treatment with complete closure of the worst lobe of the lungs
3210548|NCT00995878|Active Comparator|Focused Ultrasound (MRgFUS)|
3210549|NCT00995878|Active Comparator|Uterine Artery Embolization (UAE)|
2576593|NCT02389283||Rheumatoid arthritis(RA) patients|The patients will be evaluated according to clinical practice (clinical evaluation and inflammation markers) at baseline and 3 and 6 months after the initiation of the treatment with the biologic DMARD.
2576643|NCT02389010|Experimental|Allogeneic Cord Blood Platelet Gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
2576645|NCT02389010|Active Comparator|Standard Local Medications-SLM|1 administration every 3-4 days for 4 weeks. Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
2576661|NCT02388594|Experimental|ZFN Modified CD4+ T Cell|ZFN Modified CD4+ T Cell
2576664|NCT02388594|Experimental|ZFN Modified CD4+ T Cell with Cyclophosphamide|ZFN Modified CD4+ T Cell with Cyclophosphamide
2576725|NCT02388477|Active Comparator|Doxycycline|oral doxycycline, 2 weeks, twice a day,
2576729|NCT02388477|Placebo Comparator|sugar pill|sugar pill, same size, shape, and color as comparator, twice a day for 2 weeks.
2576786|NCT02388009|Active Comparator|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
2576787|NCT02388009|Active Comparator|Flexyn2a plus adjuvant|2 doses of 10 μg of Flexyn2a plus adjuvant will be injected intramuscularly 4 weeks apart
2576788|NCT02388009|Placebo Comparator|Placebo|2 doses of saline buffer plus adjuvant will be injected intramuscularly 4 weeks apart
2576805|NCT02387697|Experimental|Group A|Transfemoral implantation of an Edwards Sapien XT Valve into the vena cava inferior (VCI). For better stability and for downsizing of the VCI diameter the valve will be implanted after preparation of a landing zone. This includes implantation of one or two self expandable stents into the VCI prior to the final deployment of the valve.
2576812|NCT02387697|No Intervention|Group B|Control group (no surgery) with optimal medical treatment.
2576873|NCT02387567|Experimental|Lidocaine|Paraspinal infusion of 3ml lidocaine at 1%, once a week for three weeks, combined with standard treatment.
2576885|NCT02387567|Sham Comparator|Sham lidocaine|Sham Injection, without lidocaine, combined with standard treatment.
2576888|NCT02387567|Active Comparator|Standard treatment only|The only intervention is the standard treatment. No lidocaine or shame injection was used.
2576953|NCT02386917|Active Comparator|Gastric bypass|40 patients will undergo gastric bypass
2576961|NCT02386917|Active Comparator|Very low calorie diet|40 patients will undergo a very low calorie diet
2576964|NCT02386917|No Intervention|Gall bladder operation|20 patients will be asked to undergo one pharmacokinetic study only, and then finish the study. They will not undergo any weight loss intervention.
3210550|NCT00995917|Experimental|Vitamin K acupoint injection|Participants will receive the vitamin K intervention within 2 days of the onset of painful menstrual cramps.
3210551|NCT00995917|Sham Comparator|Saline Injection|Participants will receive the saline treatment within 2 days of the onset of painful menstrual cramps.
2577097|NCT02385851|Experimental|CHS-1701/Neulasta|CHS-1701 followed by Neulasta (crossover)
2577098|NCT02385851|Experimental|Neulasta/CHS-1701|Neulasta followed by CHS-1701 (crossover)
2577153|NCT02385500|Placebo Comparator|Placebo|Subjects will be started on placebo tablets, similar to fesoterodine 4 mg, and will have the option to escalate as well.
2577157|NCT02385500|Experimental|Fesoterodine|Drug intervention of fesoterodine 4 mg once a day in the morning after the two-week washout period. They will have the option to escalate to 8 mg (2 tablets of 4 mg each) after 4 weeks on fesoterodine. Patients will have the option to go back to one tablet (i.e., 4 mg) at any time in the study.
2577210|NCT02385149|Experimental|whole grain wheat|98g whole grain wheat per day for 12 weeks
2577214|NCT02385149|Experimental|refined wheat|coloured refined wheat control intervention
2577273|NCT02384759|Experimental|A|Aflibercept + LV5FU2
2577276|NCT02384759|Active Comparator|B|LV5FU2
2577433|NCT02383680||Patients under low dose methotrexate therapy|Patients with various underlying conditions (e.g. rheumatic diseases, dermatologic diseases) who have an indication for yellow fever vaccination
2577434|NCT02383680||Healthy controls|Healthy travelers who have an indication for yellow fever vaccination
2577466|NCT02383329|Experimental|Oral Nutritional Supplement (ONS)|Diet consultation for the child/family + ONS
2577467|NCT02383329|No Intervention|No Oran Nutritional Supplement (ONS)|Diet consultation for the child/family
2577495|NCT02383030|Experimental|Fulvestrant|In Arm A maintenance Fulvestrant will be given until disease progression, unacceptable toxicity or refused of patient to the treatment.
2577498|NCT02383030|No Intervention|No intervention|Patients will be randomized to receive fulvestrant (experimental arm) or no treatment
2577636|NCT02382523|Experimental|Acthar injection 2 times per week|Acthar 80 unit injection 2 times a week
2577640|NCT02382523|Experimental|Acthar injection 3 times per week|Acthar 80 unit injection 3 times a week
2577741|NCT02381496|Experimental|Part A: Cohort A1: ACT-453859 1 mg|"ACT-453859 1 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
2577743|NCT02381496|Experimental|Part A: Cohort A2: ACT-453859 3 mg|"ACT-453859 3 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
2577750|NCT02381496|Experimental|Part A: Cohort A3: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
3210552|NCT00995969|Placebo Comparator|Placebo only|Subjects will apply placebo cream to both target lesions
2576575|NCT02389660|Active Comparator|Treatment as usual|Treatment as usual (TAU) will be defined as the routine care CBT that subjects receive when they are diagnosed with depression in the setting of recruitment. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report (including TIC-P measurements).
3210553|NCT00995969|Active Comparator|Active plus placebo|Subjects will apply CT 327 to one target lesion and placebo to the other target lesion
3210554|NCT00995995||All patients|
3210555|NCT00996008|Placebo Comparator|Placebo only|Subjects will apply placebo cream to all 4 target lesions
2576971|NCT02386956|Experimental|Active stretching|10 minutes of Postural Global Reeducation for the posterior muscle chain
2576972|NCT02386956|Experimental|Dynamic Stretching|10 minutes of sciatic nerve manual movilization in two legs
2576974|NCT02386956|Placebo Comparator|Control|10 minutes with the patient lying on a machine off of magnetotherapy
2577044|NCT02386475|Placebo Comparator|Placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
2577046|NCT02386475|Active Comparator|citalopram 20 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
2577047|NCT02386475|Active Comparator|sinemet plus 100 mg|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
2577048|NCT02386475|Active Comparator|Sinemet Plus + citalopram group|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
2577121|NCT02385903|Other|Standard dressing procedure|One arm receive standard dressing procedure according to the wound
2577123|NCT02385903|Active Comparator|Flammacerium|"Necrosis covering with Flammacerium 3 mm thick each day during one week then one day on two.~On each dressing, remove excess and add flammacerium. Not to remove crust forming until eliminating furrow appears.~Cover Flammacerium by compress."
2577169|NCT02385370|Active Comparator|using standard method of applying MMC|applying MMC 0.02 % soaked sponges under conjunctival space for 1 to 3 minutes
2577176|NCT02385370|Active Comparator|intratendon injection of MMC|intratendon injection of 0.1 cc MMC 0.01% at the beginning of the procedure
2577231|NCT02385071|Experimental|Panel1: Sequence 1 (ABC)|Participants will receive Treatment A (150 milligram (mg) simeprevir (SMV) capsule with water under fed conditions) in Period 1; followed by Treatment B (3*50 mg capsules of SMV [including 50 mini-tablets of 1 mg each] with water under fed conditions) in Period 2; followed by Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577232|NCT02385071|Experimental|Panel1: Sequence 2 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577233|NCT02385071|Experimental|Panel1: Sequence 3 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577234|NCT02385071|Experimental|Panel1: Sequence 4 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577235|NCT02385071|Experimental|Panel1: Sequence 5 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577236|NCT02385071|Experimental|Panel1: Sequence 6 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577237|NCT02385071|Experimental|Panel 2: Sequence 1 (DEF)|Participants will receive Treatment D (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions) in Period 1; followed by Treatment E (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions) in Period 2; followed by Treatment F (3*50 mg SMV capsules [including 50 mini-tablets of 1 mg each] with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577238|NCT02385071|Experimental|Panel 2: Sequence 2 (EFD)|Participants will receive Treatment E in Period 1; followed by Treatment F in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577239|NCT02385071|Experimental|Panel 2: Sequence 3 (FDE)|Participants will receive Treatment F in Period 1; followed by Treatment D in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577240|NCT02385071|Experimental|Panel 2: Sequence 4 (FED)|Participants will receive Treatment F in Period 1; followed by Treatment E in Period 2; followed by Treatment D in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577241|NCT02385071|Experimental|Panel 2: Sequence 5 (EDF)|Participants will receive Treatment E in Period 1; followed by Treatment D in Period 2; followed by Treatment F in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577243|NCT02385071|Experimental|Panel 2: Sequence 6 (DFE)|Participants will receive Treatment D in Period 1; followed by Treatment F in Period 2; followed by Treatment E in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2577474|NCT02383108|Active Comparator|Standard of Care group (SOC)|triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI
2576582|NCT02389348|Experimental|combination OZ439 and DSM265|"Subjects will receive 1800 P falciparum infected red blood cells. Development of parasitemia will be monitored by quantitative PCR. When the parasitemia reached the threshold of 1000 p/ml subjects will receive a single oral dose of OZ439 and DSM265.~Subsequent doses in subsequent cohort(s) will be determined following a review of observed OZ439 and DSM265 safety, and pharmacokinetic and pharmacodynamic interaction outcomes as well as the activity of the drugs as defined by parasite clearance kinetics."
2576635|NCT02389036|No Intervention|Control group- standard care|Standard care- In Australia there are no national guidelines so local policy is determined by each ICU. We are recommending (but not mandating) that control and SDD group management be in line with these national guidelines. We will recommend control and SDD group management is in line with current national standards of practice that may or may not include a VAP bundle. We will monitor record data regarding the nature and delivery of the control and SDD group co-interventions.
2576639|NCT02389036|Experimental|SDD intervention group|"The intervention will entail:~A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx~A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube~A four-day course of an IV antibiotic. Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ dysfunction. Ciprofloxacin (400mg 12-hourly) may be used as an alternative if there is a contraindication to cephalosporins (e.g. allergy). Patients already receiving an alternative IV antibiotic to treat infection will not receive this additional IV antibiotic, but will continue the prescribed antibiotic for the usual duration of therapy."
2576676|NCT02388581|Experimental|Anti-H. pylori Therapy|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
2576711|NCT02388438|Experimental|Demineralized bone matrix|Applied demineralized bone matrix when investigator conduct hallux valgus surgery.
2576760|NCT02388230||Patients 4 or more years post radiotherapy|IMPORT or FAST trial patients who received breast RT previously and are receiving four years (or more) follow-up assessment and have hardening of their breast as a result of breast radiotherapy.
2576765|NCT02388230||Patients 0 to 2 years post breast radiotherapy|Patients who are (1) undergoing, or undergone recently breast RT (general population) and have undergone a clinical assessment either during RT or at 3 month follow-up that found moderate or severe oedema, or (2) IMPORT patients who have received RT and are receiving one or two year follow-up, at which moderate or severe oedema is reported.
2576794|NCT02387944||Cardiopulmonary bypass|Children with congenital heart defect undergoing surgery on cardiopulmonary bypass
2576795|NCT02387944||cardiac catheterism|Children with congenital heart defect undergoing cardiac catheterism
2576834|NCT02387619|Experimental|Group 1 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T during the period 1 and Rosuvastatin 20mg 1T and Telmisartan/Amlodipine 40/5mg 2T during the period 2
2576836|NCT02387619|Experimental|Group 2 of part 1|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T during the period 2
2576837|NCT02387619|Experimental|Group 1 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 2
2576838|NCT02387619|Experimental|Group 2 of part 2|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin 20mg 1T, Telmisartan/Amlodipine 40/5mg 2T during the period 1 and Telmisartan/Amlodipine 40/5mg 2T during the period 2
2576871|NCT02387255||Normal Volunteers|60 normal volunteers will be recruited. Each volunteer will undergo a single MRE scan (with Resoundant driver System ) of their abdominal aorta.
2576883|NCT02387255||Patients with AAA|Fifty to sixty five patients with AAA will be recruited. These patients will undergo MRE (with Resoundant driver system) of their AAA every six months for three years, or until the study ends or until the time of surgical repair or death due to rupture of AAA or other causes.
2576887|NCT02387255||Open Surgical Repair Patients|Fifty to sixty five patients patients undergoing open surgical repair will be recruited and undergo MRE (with Resoundant driver system) prior to surgery
3210556|NCT00996008|Active Comparator|Active plus placebo|Subjects will receive CT 327 on 2 of 4 target lesions located on one side of their body. On the remaining 2 target lesions on the other side of their body, placebo will be applied.
2577041|NCT02386579||Diabetics with Charcot foot|
2577055|NCT02386124|Other|frailty evaluation|"all consecutive patients admitted to hospital for acute cardiac disease aged more than 69 years will be evaluated with Short Portable Mental Status Questionnaire (SPMSQ), handgrip and Short Physical Performance Battery (SPPB).~These three tests (SPMSQ, SPPB and handgrip) are the intervention of the study. They are the assays to establish the frailty status"
2577146|NCT02385539|Active Comparator|Levobupivacaine (LB) 6 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 6 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB6F25 (LB 6 mg, Fentanyl 25 mcg), LB6F35 (LB 6 mg, Fentanyl 35 mcg), LB6S5 (LB 6 mg, Sufentanil 5 mcg), LB6S7 (LB 6 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
2577212|NCT02384980|No Intervention|Walk Group|This group of patients are part of the walk group. They will be encouraged to walk and will receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
2577256|NCT02384915|Experimental|Spinal anesthesia|Intrathecal injection of 2 ml (40 mg) of 2% hyperbaric prilocaine at L3-L4 interspaces through a 100mm Sprotte 25 G spinal needle (Pencan, b-brawn, Germay) in lateral decubitus position, (with limb to operate declive).
2577421|NCT02384187|Experimental|Group GAB|Patients in this group will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
3210557|NCT00996021|Experimental|Arm 1|This is a three way crossover study with 3 periods. Subjects will receive a single dose of either GSK1349572 250 mg suspension, placebo suspension or moxifloxacin 400 mg tablet in each of the three periods. The order in which the treatments are given will be randomized. There is a screening visit within 30 days prior to the first dose of study drug and a follow-up visit within 10-14 days after the last dose of study drug.
2576650|NCT02388854||Endometriosis|Sardinian Women with diagnosis of endometriosis
2576651|NCT02388854||Controls|Healthy blood Sardinian donors
2576662|NCT02388607||assessing attention span|"Electrophysiological measurements (evocated potentials and spectral densities)~Clinical scales and subjective assessments of difficulty of the tasks performed, and commitment to the task"
2576701|NCT02388490|Experimental|Brentuximab vedotin|Brentuximab vedotin is an antibody-drug conjugate (ADC) composed of the anti-CD30 chimeric immunoglobulin G1 (IgG1) monoclonal antibody cAC10 and the potent antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker. cAC10 binds to the CD30 antigen, which has a very low expression on normal cells but is found on some tumor cells.
3210558|NCT00996060|Experimental|Hydralazine and Valproic Acid|Starting dose of Hydralazine is 25 mg orally daily, days 1-28. (See Intervention for Dose Escalation Schema) Valproic acid 250 mg orally three times per day for days -14 through -8, then 500 mg orally three times per day daily for days -7 through 28, with the dose titrated to keep the serum level between 0.4 and 0.7 mM.
3210559|NCT00996073|Active Comparator|Autograft|Lumbar Interbody Fusion with Autograft
2576898|NCT02387190|Experimental|Telenursing monitoring|The protocol for telenursing allows the realization of standardized professional contacts with the patient and educational approach It is possible through questions and answers coded, that indicate the need for educational intervention or reinforcement of appropriate health behavior.1) Contact the patient by telephone, weekly; 2) Distribution and explanation of the educational booklet; 3) Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
2576901|NCT02387190|No Intervention|Control group|Placebo is considered as standardized education
2576949|NCT02386943|Experimental|Sitagliptin|Subjects are assigned to take one pill of sitagliptin(100mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
2576956|NCT02386943|Experimental|Saxagliptin|Subjects are assigned to take one pill of saxagliptin(5mg po once) at 7am on experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
2576963|NCT02386943|Experimental|Blank control|Subjects take no medication for blank control at experimental day,then the two-step hyperglycaemic clamp is initiated at 9am.
3210560|NCT00996073|Experimental|Low Dose|Lumbar Interbody Fusion with NeoFuse-Low Dose
3210561|NCT00996073|Experimental|High Dose|Lumbar Interbody Fusion with NeoFuse-High Dose
3210562|NCT00996086||CRT device-recipients|
3210563|NCT00996099|Active Comparator|CGM-eMPC|
3210564|NCT00996099|Other|Control|
3210565|NCT00996112||Historical|
2577439|NCT02383771|Experimental|Single Anti-platelet Treatment|Ticagrelor
2577441|NCT02383771|Experimental|Dual Anti-platelet Treatment|Aspirin + Ticagrelor
2577442|NCT02383771|Sham Comparator|Control|No Drug
2577446|NCT02383771|Other|CAD undergoing PCI|Patients with coronary artery disease undergoing percutaneous coronary intervention and receiving dual anti-platelet therapy (ticagrelor 90mg bid + aspirin 100mg daily)
2577477|NCT02383160|Active Comparator|Active LIPUS Unit|Low-intensity pulsed ultrasound treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
2577482|NCT02383160|Sham Comparator|Sham LIPUS Unit|Sham device treatment 20 minutes/day until the fracture is deemed united clinically and on CT scan.
2577556|NCT02382822||HIV infected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, mouth wash, eNO assessment, ankle brachial pressure index, fibroscan, blood sampling
2577559|NCT02382822||HIV uninfected|Exposure to: Computed tomography(CT) of chest and upper abdomen, CT angiography(CTa) of heart, spirometry, eNO assessment, ankle brachial pressure index, blood sampling
2577592|NCT02382380|Experimental|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
2577595|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. MRI protocols utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
2577628|NCT02382198|Active Comparator|Active Group|This arm will receive the study drug glycopyrrolate.
2577630|NCT02382198|Placebo Comparator|Placebo Group|Control arm to receive placebo
2577687|NCT02381912||Hematuria - NMIBC|Primary hematuria due to NMIBC.
2577692|NCT02381912||Hematuria - other cause|Other non-malignant cause of hematuria.
3210566|NCT00996112||Prospective|
2577908|NCT02380235|Experimental|PEG-somatropin|0.12mg/kg/w
3210567|NCT00996138|Other|Arm 1|Dose ranging
3210568|NCT00996138|Other|Arm 2|Dose ranging
3210569|NCT00996177|Experimental|IONSYS|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem
3210570|NCT00996177|Active Comparator|Patient-Controlled Analgesia|IV Morphine Patient-Controlled Analgesia (IV PCA)
3210571|NCT00996190|Active Comparator|Phenylephrine Intermittent Bolus|Bolus syringe will contain 120 micrograms/mL of phenylephrine. Infusion solution bag will contain placebo (saline solution).
3210572|NCT00996190|Active Comparator|Phenylephrine Continuous Infusion|Infusion solution bag will contain 120 micrograms/mL of phenylephrine. Bolus syringe will contain placebo (saline solution).
3210573|NCT00996229|Experimental|Caloric restriction + placebo supplementation|
3210574|NCT00996229|Experimental|Omega-3 supplementation|
2576715|NCT02388412||Non-vulnerable plaque in Optical coherence tomogrpahy|OCT-derived vulnerable plaque is defined as composite of thin-cap fibrous atheroma (cap thickness in optical coherence tomography < 60um), prominent macrophage, or prominent microvessels. OCT-derived non-vulnerable plaque is defined as a plaque without any of the findings
2576745|NCT02388204|Experimental|Parkinson's disease patients|Group description: PD patients with locomotion problems as the primary complain with no interventions other than medication and rehabilitation therapies Intervention: Implantable spinal cord stimulation.
2576751|NCT02388204|Experimental|DBS Parkinson's disease patients|"Group description: PD patients with locomotion problems as the primary complain after cardinal symptoms are controlled by DBS.~Intervention: Implantable spinal cord stimulation."
3210575|NCT00996229|Placebo Comparator|Placebo supplementation|
3210576|NCT00996229|Experimental|Resveratrol supplementation|
3210577|NCT00996242|Experimental|L-lysine|
2577030|NCT02386501|Experimental|ADXS31-164|Dose/Potency 5 x 108 CFU; 1 x 109 CFU; 5 x 109 CFU; 1 x 1010 CFU
2577074|NCT02386072||1. patients diagnosed with OAB taking mirabegron|patients diagnosed with OAB whose physician has decided to prescribe mirabegron as part of routine clinical practice
2577078|NCT02386072||2. patients diagnosed with OAB taking an antimuscarinic|patients diagnosed with OAB whose physician has decided to prescribe an antimuscarinic as part of routine clinical practice
2577245|NCT02384928|Experimental|Shinbaro pharmacopuncture group|The Shinbaro pharmacopuncture group will receive 8 interventional sessions of Shinbaro pharmacopuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and acupuncture at 5 acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
2577246|NCT02384928|Active Comparator|Acupuncture group|The acupuncture group will receive 8 interventional sessions of acupuncture at one Hyeopcheok (Huatuo Jiaji, EX B2) point and 5 other acupoints (GB30, BL40, BL25, BL23, GB34) 2 times/week over 4 weeks. All groups will take 4 educational program sessions supervised by physicians once a week.
2577249|NCT02384928|Active Comparator|Usual care group|The usual care group will receive conventional medicine 2 times/day and 2 sessions/week of physical therapy over 4 weeks. Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics, which include aceclofenac, tramadol hydrochloride, talniflumate, diclofenac sodium, and loxoprofen sodium. All groups will take 4 educational program sessions supervised by physicians once a week.
2577384|NCT02384031|Active Comparator|Traumatic group|Traumatic needle
2577387|NCT02384031|Active Comparator|Atraumatic group|Atraumatic needle
2577456|NCT02383563|Active Comparator|Metformin Treatment Arm|500 mg metformin Extended Release tablets - one tablet daily increased at 4 weeks to 2 tablets (1000 mg) daily.
2577457|NCT02383563|No Intervention|Observational Arm|Observation only
2577479|NCT02383186|Active Comparator|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
2577480|NCT02383186|Active Comparator|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
3210578|NCT00996255|Experimental|Dose-Escalation|
3210579|NCT00996268|Experimental|Part A|Three groups of sixteen healthy subjects will be randomized to single doses of 3 different formulations of GSK2212836.
3210580|NCT00996268|Experimental|Part B|Four cohorts of at least 10 subjects will participate in a 2-week repeat dose period with 4 dose levels (based on data obtained in Part A) of the GSK2212836 test formulations or placebo.
3210581|NCT00996294|Experimental|surgery|patients will be submitted to biliopancreatic diversion or gastric bypass
3210582|NCT00996320|Experimental|Intervention Schedule|Interns on the intervention schedule work the a modified ICU schedule averaging about 60 hours per week over 4 weeks, with maximum scheduled shift length 16 hours.
3210583|NCT00996320|No Intervention|Traditional Schedule|Interns on the traditional schedule work the usual ICU schedule averaging about 80 hours per week over 4 weeks, with maximum shift length 30 hours.
3210584|NCT00996359|Experimental|Irradiated allogeneic lymphocytes after Total Body Irradiation|
3210585|NCT00996385|Experimental|Velcade plus Eloxatin|Six 20-day cycles
3210586|NCT00996398|Experimental|Cold water immersion|14°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
3210587|NCT00996411|Experimental|Salvinorin A|
2577653|NCT02382146|Experimental|dexamethasone and ondansetron|dexamethasone 8 mg with ondansetron 4mg administered in group DO
2577654|NCT02382146|Active Comparator|dexamethasone and dimenhydrinate|dexamethasone 8 mg with dimenhydrinate 1mg/kg administered in group DD
3210588|NCT00996424|Experimental|Acetylcysteine|Inhalation with N-Acetylcysteine
3210589|NCT00996424|Placebo Comparator|normal saline|Inhalation with normal saline solution
3210590|NCT00996463|Active Comparator|IL SSG|Intralesional sodium stibogluconate
3210591|NCT00996463|Experimental|ETC+MWT|Electro-thermo-coagulation with subsequent moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
3210592|NCT00996463|Experimental|MWT|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
3210593|NCT00996515|Experimental|Cohort 5|Erlotinib 150mg/day PO Day 1-28 and Vidaza 100mg/m2/day SQ Day 1-4 and 15-18
3210594|NCT00996515|Experimental|Cohort 4|Erlotinib 200 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day SQ 1-4 and 15-18
3210595|NCT00996515|Experimental|Cohort 3|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-3 and 15-17
3210596|NCT00996515|Experimental|Cohort 2|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1-2 and 15-16
3210597|NCT00996515|Experimental|Cohort 1|Erlotinib 150 mg/day PO Day 1-28 and Vidaza 75 mg/m2/day IV Day 1 and 15
3210598|NCT00996528|Experimental|Philani Intervention Program|
3210599|NCT00996528|No Intervention|Standard Care|No intervention during study. Referral to clinic-based health care that is delivered by the province. Offered intervention at end of study, i.e. after 18 months.
3210600|NCT00996541|Experimental|Intervention|
2576722|NCT02388516|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3; Postpartum Period 28,000 IU/week
2576771|NCT02388087|Active Comparator|ROX COUPLER|Iliac arterio-venous anastamosis created by insertion of ROX coupler device.
2576774|NCT02388087|Sham Comparator|ROUTINE CARE|Right heart catheterisation and Routine care of Neurally mediated syncope.
3210601|NCT00996541|Placebo Comparator|Control|
3210602|NCT00996554|Experimental|Double-Layer-Suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
3210603|NCT00996554|Active Comparator|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread).
3210604|NCT00996567|Experimental|Cetuximab (Erbitux)|
3210605|NCT00996619||People undergoing GI tract endoscopy|
3210606|NCT00996645|No Intervention|Feedback report only|This arm will receive performance feedback reports but no worksheet to facilitate goal-setting and action plans.
2576962|NCT02386969|Experimental|Active rTMS then sham rTMS|Active rTMS in 1st period and sham rTMS in 2nd period
2576965|NCT02386969|Experimental|Sham rTMS then active rTMS|Sham rTMS in 1st period and active rTMS in 2nd period
2577005|NCT02386618|Other|Local residual neoplasia|Patients with local residual neoplasia in 3 months after endoscopic resection of colorectal lateral spreading tumors diagnosed endoscopically and/or histologically
2577099|NCT02385838|Experimental|5-Color Nutrition Label (5-CNL)|The 5-CNL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
2577100|NCT02385838|Experimental|Mutiple Traffic Lights (MTL)|The MTL front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
2577101|NCT02385838|Experimental|Guidelines Daily Amounts (GDA)|The GDA front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
2577102|NCT02385838|Experimental|Green Tick (Tick)|The Tick front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
2577103|NCT02385838|No Intervention|No label|No front-of-pack nutrition labeling is affixed on the front-of-pack of foodstuffs of the experimental web-based supermarket
2577159|NCT02385474|Experimental|38% SDF semi-annual|semi-annual application of 38% SDF
2577163|NCT02385474|Experimental|38% SDF annual|annual application of 38% SDF
2577165|NCT02385474|Active Comparator|12% SDF semi-annual|semi-annual application of 12% SDF
2577167|NCT02385474|Active Comparator|12% SDF annual|annual application of 12% SDF
3210607|NCT00996645|Experimental|Goal-Setting Worksheet|This arm will receive a theory-informed worksheet to facilitate the development of goals and action plans in response to the performance feedback reports.
3210608|NCT00996671|Experimental|Dose Escalation Cohorts|single dose administration escalating doses starting at 20 mg and continue escalation; the highest dose in this study will not exceed the mean Day 1 exposure in male dogs at the NOAEL dose (6 mg/kg/day).
3210609|NCT00996671|Experimental|Food effect Cohort|Dose to be selected based on emerging safety and PK data; subjects will be given FDA standard high fat meal followed by single dose of study drug.
3210610|NCT00996684|Experimental|microplasmin, intravitreal injection|Subjects will receive one intravitreal injection of microplasmin on Day 0.
3210611|NCT00996684|Placebo Comparator|Placebo|Subjects will receive one intravitreal injection of the placebo on Day 0.
2577315|NCT02384239|Experimental|Palbociclib 100mg|Treatment arm palbociclib dose 100mg + fulvestrant or tamoxifen
2577321|NCT02384239|Experimental|Palbociclib 125mg|Treatment arm palbociclib dose 125mg + fulvestrant or tamoxifen
2577389|NCT02384005|Other|Self-anal exam arm|Study only has one arm.
3210612|NCT00996697|Active Comparator|Triple therapy|Symbicort and tiotropium
3210613|NCT00996697|Placebo Comparator|Combination therapy|Symbicort and placebo
2577624|NCT02382328|Experimental|alpha lipoic acid|600mg/24 oral pills alpha lipoic acid 28 days before and 120 days after carpal tunnel release.
2577626|NCT02382328|Placebo Comparator|Placebo|Oral pills of mangensium inactivated 28 days before and 120 days after carpal tunnel release.
2577656|NCT02381964|Placebo Comparator|Placebo|Matched placebo
2577657|NCT02381964|Experimental|1RDA+CoQ10|Supradyn® (1RDA+CoQ10) containing vitamins and minerals at levels up to 100% of the 2008 European Union recommended dietary allowances (RDAs), plus 4.5 mg CoQ10 (1RDA+CoQ10).
2577658|NCT02381964|Experimental|3RDA|Supradyn® (3RDA) containing vitamins and minerals at levels up to 300% of the 1990 European Union RDAs (3RDA).
2577699|NCT02381691|Experimental|maternal breast milk odor|"In the first group breast milk, venipuncture was performed to the neonate while his mother's milk odor was being diffused."
2577700|NCT02381691|Placebo Comparator|no odor|In a second control group, venipuncture was performed to the neonate with an odorless diffusor.
2577786|NCT02381145|Placebo Comparator|Placebo|micro-cellulose-filled Placebo
2577789|NCT02381145|Active Comparator|EGCG+RSV-supplementation|EGCG+RSV: 300mg/d + 80mg/d
3210614|NCT00996723|Other|1|
3210615|NCT00996749|Experimental|Treatment (omega-3 fatty acid)|Patients receive long-term omega-3 PUFA supplementation PO.
2578078|NCT02379299|Experimental|Dual-hormone closed-loop control|Closed-loop glucose control by use of insulin and glucagon by use of DiaCon dual-hormone closed-loop glucose control algorithm
3210616|NCT00996762|Experimental|Part 1-3|2-period crossover, Period 1 (D1-7) will receive either the commercial formulation or the alternative formulation. Period 2 (D1-7) will receive the formulation not received in Period 1. There will be 3 parts with 3 different alternative formulations. Subjects will only participate in one part.
3210617|NCT00996788|Experimental|Rebamipide|Rebamipide 100 mg tid for 28 days
3210618|NCT00996814|Experimental|Proactive Ethics Intervention|These patients have an ethics consultant involved in their care beginning on the fifth day of treatment in the ICU
3210619|NCT00996814|No Intervention|Usual Care|These patients receive usual care in the ICU.
3210620|NCT00996853||Total vaccinated cohort|The Total vaccinated cohort will include all subjects with at least one vaccine administration documented.
3210621|NCT00996866|Placebo Comparator|Placebo|Half of subjects will be randomized to the placebo group.
2576862|NCT02387411|Active Comparator|Interval group|high-intensity interval exercise training
2576866|NCT02387411|Active Comparator|Combined group|combined exercise training
2576932|NCT02387138|Experimental|SIRINOX|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels).~Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle G-csf : d8 to d13 systematically"
2576990|NCT02386709|Experimental|Experimental Arm|"Diagnostic~PET1 : before the neoadjuvant treatment~start neoadjuvant treatment~PET2: two weeks after the start of the first course of chemotherapy~surgery"
2577014|NCT02386397|Experimental|Treatment|"Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
2577020|NCT02386397|Other|Standard treatment|"mGEMOX: infusion on days 1 and 8~Gemcitabine 900 mg/m² IV in 30 minutes~Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine"
2577064|NCT02386020|Placebo Comparator|Placebo|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
2577069|NCT02386020|Active Comparator|Aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
3176155|NCT00641537|No Intervention|Cladribine 5.25 mg/kg/No Treatment|Participants who received cladribine 5.25 mg/kg in previous study 25643 (NCT00213135) and completed were enrolled in this extension study and received no cladribine treatment and were followed up for safety assessment for 96 weeks (during the treatment period) and followed up for 24 weeks (during supplemental follow-up period).
3176156|NCT00641550|Experimental|2|Pregnant women starting to practice physical exercise at 13 weeks(Walking moderate activity)
2577207|NCT02385058|Experimental|Mebendazole + Quinfamide|Participants will receive mebendazole 600 milligram (mg) and quinfamide 200 mg tablets orally once starting on Day 1 and 21 in both Phase 1 and 2.
2577209|NCT02385058|Experimental|Mebendazole + Quinfamide + Placebo|Participants will receive mebendazole 600 mg and quinfamide 200 mg tablets orally once starting on Day 1 in Phase 1 and placebo tablets orally once starting on Day 21 in Phase 2.
2577242|NCT02384811|Experimental|Radiation group|Radiation therapy
2577279|NCT02384629|Experimental|AXXESS stent1|AXXESS stent (OCT-guided)
2577283|NCT02384629|Experimental|Conventional DES1|Conventional DES (Biomatrix flex stent, OCT-guided)
2577285|NCT02384629|Active Comparator|AXXESS stent2|AXXESS stent (Angio-guided)
2577288|NCT02384629|Active Comparator|Conventional DES2|Conventional DES (Biomatrix flex stent, Angio-guided)
2577316|NCT02384343|Active Comparator|Dexmedetomidine|Dexmedetomidine 4 mcg/ml, 30 mcg (7,5 ml), single intravenous bolus
2577324|NCT02384343|Placebo Comparator|Normal saline|NaCl 0,9% 7,5 ml, single intravenous bolus
2577600|NCT02382263|Experimental|Arm B|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
2577601|NCT02382263|Experimental|Arm C|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
2577602|NCT02382263|Experimental|Arm D|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
2577603|NCT02382263|Experimental|Arm E|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
3176157|NCT00641550|Experimental|3|Pregnant women starting exercise at 20 weeks
3176158|NCT00641550|No Intervention|1|Pregnant women without exercise practice.
2577770|NCT02381158|Experimental|Nebulized Beclomethasone dipropionate|Nebulized Beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg).
2577812|NCT02380911|Experimental|Intervention Group|The intervention group will receive a multifaceted educational intervention targeting physicians and pharmacist assistants to improve detection, treatment and control of hypercholesterolemia among uninsured patients with moderate-high cardiovascular risk in Argentina.
2577816|NCT02380911|No Intervention|No Intervention Group|This group will continue with the usual care. Irrespective of the assignment of the clinic to the intervention or control group, all physicians from participating PCCs have received previous training on global cardiovascular risk management, given by the Ministry of Health
3176159|NCT00641602|Experimental|1|Nexium
3176160|NCT00641602|Active Comparator|2|Prevacid
3176161|NCT00641615|Experimental|Phase 1|
3176162|NCT00641628||1|
3176163|NCT00641654|Active Comparator|A|Patients having previously received 24 weeks of therapy with pegylated interferon and ribavirin will be treated with pegylated interferon alfa-2a kD (PEGASYS) plus ribavirin, (Copegus) for a treatment period of 48 weeks, with a follow-up period of 24 weeks irrespective of the level of HCV-RNA measured in plasma on treatment day 27.
3176164|NCT00641654|Active Comparator|B|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having detectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 48 weeks, with a follow-up period of 24 weeks.
3176165|NCT00641654|Active Comparator|C|Patients having previously received less than 24 weeks but at least 12 weeks of therapy with pegylated interferon and Ribavirin and having undetectable HCV-RNA in a plasma sample obtained on treatment day 27 (i.e. the day before the 5th dose of pegylated interferon in this study) as analyzed by means of COBAS TaqMan 48TM will be treated with pegylated interferon alfa-2a KD (PEGASYS®) plus ribavirin, (Copegus®) for a treatment period of 24 weeks, with a follow-up period of 24 weeks.
3176166|NCT00641680|Experimental|1|Budesonide
3176167|NCT00641680|Active Comparator|2|Fluticasone propionate
3176168|NCT00641680|Placebo Comparator|3|
3176169|NCT00641693|Experimental|1|Nasal Spray
3176170|NCT00641693|Placebo Comparator|2|
3176171|NCT00641732|Experimental|TAK-442 40 mg QD|
3176172|NCT00641732|Experimental|TAK-442 80 mg QD|
3176173|NCT00641732|Experimental|TAK-442 10 mg BID|
3176174|NCT00641732|Experimental|TAK-442 20 mg BID|
3176175|NCT00641732|Experimental|TAK-442 40 mg BID|
3176176|NCT00641732|Experimental|TAK-442 80 mg BID|
2576768|NCT02388126|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
2576807|NCT02387905|Active Comparator|Arm I (standard of care)|Patients undergo stereotactic spinal radiosurgery per standard of care.
2576815|NCT02387905|Experimental|Arm II (vertebral body cement augmentation)|Patients undergo vertebral body cement augmentation within 4 weeks before or after standard stereotactic spinal radiosurgery.
2577021|NCT02386488|Experimental|Vortioxetine 10 mg single dose|8 men and 8 women
2577024|NCT02386488|Experimental|Vortioxetine 20 mg single dose|8 men and 8 women
2577027|NCT02386488|Experimental|Vortioxetine 10 mg multiple dose|8 men and 8 women
2577032|NCT02386488|Experimental|Vortioxetine 20 mg multiple dose|8 men and 8 women
2577067|NCT02385994|Experimental|enLighten Laser Treatment|Melasma, Cohort I or Lentigines, Cohort II will be treated with dual-pulse duration, dual-wavelength 532nm KTP/1064nm Nd:YAG laser.
2577075|NCT02385994|No Intervention|Control|Melasma subjects randomized to non-treatment will receive no treatments.
2577126|NCT02385643|Experimental|Intervention group|This group of subjects receives mobile support system and conventional treatment
2577127|NCT02385643|No Intervention|Control group|This group of patients receive conventional treatment only
2577173|NCT02385383||Patients with preoperative anemia following treatment protocol|Patients with preoperative anemia according to the WHO definition and treated with a protocol of Iitravenous iron prior to surgery
2577179|NCT02385383||Patients with preoperative anemia - Historical control|Cohort of preoperative anemic patients from the Lundbeckcentre Database. Serving as a historical control
2577257|NCT02384967|Experimental|Darunavir 400mg/d|Tri-therapy containing Darunavir at dose of 400 mg/d.
2577331|NCT02384525|Experimental|clinical-based ultrafiltration|
2577336|NCT02384525|Active Comparator|BIA-based ultrafiltration|
2577397|NCT02384083|Experimental|Filanesib, pomalidomide and dexamethasone|28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22
2577606|NCT02382406|Experimental|Arm A: Phase I Dose Finding Cohort|"Twelve subjects will be enrolled and treated with carboplatin AUC 6 IV on Day 1, nab-paclitaxel 100 mg/m^2 IV on Day 1, Day 8, and Day 15, pembrolizumab 2* mg/kg IV on Day 1 for 4 cycles. pembrolizumab (Phase I) treatment for Cohort 1 will continue for a maximum duration of 4 21-day cycles~Phase I, Cohort 1 Maintenance Therapy:~Participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles, maintenance therapy with MK-3475 2* mg/kg will continue on D1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or a maximum of 2 years from C1D1.~If unacceptable toxicity is seen in Phase I Cohort 1, 12 additional participants will be enrolled in Cohort 2 and treated with carboplatin AUC 6 IV on D1, nab-paclitaxel 100 mg/m2 IV on D1, D8, and D15, MK-3475 2*mg/kg IV on D1 starting C2. MK-3475 (Phase 1) treatment for Cohort 2 will continue for a maximum duration of 3 21-day cycles (C2-4 only)."
2577609|NCT02382406|Experimental|Arm B: Phase II Investigational Treatment|"Subjects will be treated with carboplatin AUC 6 given IV on Day 1, nab-paclitaxel 100 mg/m^2 given IV on Day 1, Day 8, and Day 15, and pembrolizumab 200mg IV on Day 1 of each cycle. Pembrolizumab Phase II treatment will continue for a maximum duration of 4 cycles (cycle = 21 days).~Maintenance Therapy For participants who have confirmed CR, PR, or SD (non-progression) after 4 cycles of induction therapy, maintenance therapy with MK-3475 2* mg/kg will continue on Day 1 of each 21-day cycle. Treatment will continue until progression of disease, unacceptable toxicity, or for a maximum of 2 years from C1D1.~*As additional data from ongoing trials becomes available, the dose of MK-3475 may be adjusted."
3176177|NCT00641732|Active Comparator|Enoxaparin 30 mg BID|
2577834|NCT02380573|Experimental|Healthy Aging MB|Methylene Blue (USP grade, 282mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577839|NCT02380573|Placebo Comparator|Healthy Aging Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577917|NCT02380235|Experimental|PEG-Somatropin|0.20mg/kg/w
3176178|NCT00641758|Placebo Comparator|Placebo|
3176179|NCT00641758|Active Comparator|Pycnogenol|
3176180|NCT00641771|Experimental|1|MK0217A
3176181|NCT00641771|Placebo Comparator|2|Placebo
3176182|NCT00641784|Experimental|1|Oral Nifedine
3176183|NCT00641784|Active Comparator|2|Intravenous Magnesium
3176184|NCT00641810|Experimental|A|After one week at usual levels of caffeine use, patients are asked to reduce their caffeine consumption to no more than 2 cups of coffee (or equivalent) for one week and then to zero for two weeks.
3176185|NCT00641823||1|
3176186|NCT00641823||2|
3176187|NCT00641823||3|
3176188|NCT00641849|Active Comparator|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
3176189|NCT00641849|Active Comparator|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
3176190|NCT00641888||1|10 patients starting on non-nucleoside reverse transcriptase inhibitor based regimen. 5 women and 5 men.
3176191|NCT00641888||2|10 patients starting a protease inhibitor based regimen. 5 women and 5 men.
3176192|NCT00641901||Observation|Pregnant women with gingivitis
3176193|NCT00641914|Experimental|1|
3176194|NCT00641914|Placebo Comparator|2|
3176195|NCT00641927|Experimental|1|Antidepressant
3176196|NCT00641927|Active Comparator|2|Drug
3176197|NCT00641940|Experimental|1|Girls in Transition (GT) program
3176198|NCT00641940|Other|2|Waitlist control
3176199|NCT00641953|Experimental|A|IMX-150 (0.3%) 0.5 g topically BID each foot
3176200|NCT00641953|Experimental|B|IMX-150(0.6%) 0.5 g topically BID to each foot
3176201|NCT00641953|Placebo Comparator|C|Placebo 0.5 g topically BID to each foot for 4 weeks
3176202|NCT00641979|Experimental|1|Rhinocort
3176203|NCT00641979|Placebo Comparator|2|
3176204|NCT00641992||1|Response to medical treatment
2576773|NCT02388061|Experimental|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
2576775|NCT02388061|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
2576799|NCT02387723|Experimental|Stem cell therapy|Treatment with direct intra-myocardial Injection of 100 million allogeneic adipose derived stem cells (CSCC_ASC) into the heart
2576860|NCT02387593|Experimental|colonoscopy with endocuff|To the usual colonoscopy will place a endocuff at the tip of the colonoscope
2576861|NCT02387593|No Intervention|standard colonoscopy without endocuff|Routine colonoscopy without endocuff
3210622|NCT00996866|Active Comparator|Vitamin D3|This is the study group that receives Vitamin D supplementation.
3210623|NCT00996879|Experimental|Midazolam + BMS-791325|
2576979|NCT02386787|Experimental|SEMI EMERGENCY SURGERY PATIENT|patient undergoing a non-elective surgery and having a preoperative fasting period of six hours.
2577023|NCT02386449|Experimental|Picoprep|sodium picosulfate, magnesium oxide and citric acid
2577026|NCT02386449|Active Comparator|Mannitol and Bisacodyl|
2577063|NCT02386085||Osteopathic manipulative treatment (OMT)|All participants will have received OMT to be eligible and will be followed for 1 week after treatment.
2577175|NCT02385422|Experimental|Carvedilol|Carvedilol，6.25mg-25mg/d,oral,6 months
2577181|NCT02385422|Active Comparator|Propranolol|Propranolol,30mg-160mg/d,oral,6 months
2577258|NCT02385006|Other|Arm kidney transplanted|Arm kidney transplanted: all patients who receive kidney transplantation
2577264|NCT02385006|Other|Arm pancreas-kidney transplanted|Arm pancreas-kidney transplanted: all patients who receive pancreas-kidney transplantation
3210624|NCT00996905|No Intervention|Beginner Conventional (BC)|Beginner level (residents) doing epidural insertions the conventional way (ie. no ultrasound scanning)
3210625|NCT00996905|Experimental|Beginner Ultrasound (BU)|Beginner level (residents) doing epidural insertions with the help of ultrasound scanning.
2577396|NCT02383810|Active Comparator|Elsiglutide 10 mg - target population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
2577401|NCT02383810|Active Comparator|Elsiglutide 20 mg - target population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving F-FU based chemotherapy
2577406|NCT02383810|Active Comparator|Elsiglutide 40 mg - target population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
2577410|NCT02383810|Placebo Comparator|Placebo - target population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy
2577411|NCT02383810|Active Comparator|Elsiglutide 10 mg - additional population|Elsiglutide 10 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
2577412|NCT02383810|Active Comparator|Elsiglutide 20 mg - additional population|Elsiglutide 20 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
2577413|NCT02383810|Active Comparator|Elsiglutide 40 mg - additional population|Elsiglutide 40 mg once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
2577415|NCT02383810|Placebo Comparator|Placebo - additional population|Placebo once daily as s.c. injection for 4 consecutive days in patients receiving 5-FU based chemotherapy with monoclonal antibody.
2577488|NCT02383212|Experimental|Monotherapy Cohort|Cemiplimab will be administered alone
2577491|NCT02383212|Experimental|Dual Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy~Doses of cemiplimab will be administered in combination with Cyclophosphamide~Doses of cemiplimab will be administered in combination with Docetaxel"
2577497|NCT02383212|Experimental|Triple Combination Cohorts|"Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus Cyclophosphamide~Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF~Doses of cemiplimab will be administered in combination with Carboplatin plus Paclitaxel~Doses of cemiplimab will be administered in combination with Carboplatin plus Pemetrexed~Doses of cemiplimab will be administered in combination with Carboplatin plus Docetaxel"
2577500|NCT02383212|Experimental|Quadruple Combination Cohorts|Doses of cemiplimab will be administered in combination with hypofractionated radiotherapy plus GM-CSF plus Cyclophosphamide
2577633|NCT02382341||Observational|BIOSURE™ HEALICOIL™ PK Interference Screw
2577661|NCT02382003|Experimental|Positive Training+Anxious Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Anxious Imagery Prime
2577662|NCT02382003|Experimental|Positive Training+Neutral Imagery Prime|Positive Cognitive Bias Modification - Interpretation training paired with a preceding Neutral Imagery Prime
2577663|NCT02382003|Active Comparator|50/50 Training+Anxious Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Anxious Imagery Prime
2577664|NCT02382003|Active Comparator|50/50 Training+Neutral Imagery Prime|50/50 Cognitive Bias Modification - Interpretation (half positive & half negative scenarios) paired with a preceding Neutral Imagery Prime
2577665|NCT02382003|Other|No Scenario+Anxious Imagery Prime|No scenarios paired with a preceding Anxious Imagery Prime
2577666|NCT02382003|Other|No Scenario+Neutral Imagery Prime|No scenarios paired with a preceding Neutral Imagery Prime
2577714|NCT02381639|Other|Patients|patients followed in the addiction service of the University Hospital of Nantes (consultations and / or hospitalizations) for restrictive anorexia nervosa
2577715|NCT02381639|Other|Healthy volunteers|control subjects matched for age and sex with the patients
2577783|NCT02381067|Other|NuCel with Allograft Bone|NuCel will be used with allograft bone for the surgical treatment of one, two or three level degenerative disease of the cervical spine.
3210626|NCT00996905|No Intervention|Experienced Conventional|Experienced level (fellows) doing epidural insertions the conventional way.
3210627|NCT00996905|Experimental|Experienced Ultrasound|Experienced level (fellows) doing epidural insertions with the help of ultrasound scanning.
3210628|NCT00996957|Experimental|ACE-041|Patients assigned to 1 of 9 possible dosing groups
3210629|NCT00996983|Experimental|A|
3210630|NCT00997009|Experimental|Arm A|chemotherapy plus cetuximab
2576896|NCT02387229|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg, orally, once daily, preferably at the same time of the day throughout the study.
2576897|NCT02387229|Active Comparator|standard of care|standard of care
2576933|NCT02386878|Experimental|Interpersonal Psychotherapy for Groups (IPTG)|The intervention consists of 16 weekly 60 to 90 minute psychotherapy sessions, implemented once a week by a trained lay facilitator.
2576934|NCT02386878|Experimental|Vhutshilo 2|The intervention consists of 13 group sessions, implemented once a week by a trained lay facilitator.
2576935|NCT02386878|Experimental|IPTG and Vhutshilo|Participants receive the IPTG intervention first, followed by Vhutshilo 2.
2576937|NCT02386878|No Intervention|No Intervention|No intervention
2576994|NCT02386696|Experimental|Ultrasound findings|"Thoracic ultrasound examinations in the following conditions:~Apnea;~Spontaneous regular breathing;~Valsalva maneuver, during which each subject will be asked for performing three forced expirations with closed glottis after one forced inspiration;~Muller maneuver, during which each subject will be asked for performing three forced inspirations after one forced expiration;~Hyperventilation."
2577013|NCT02386410|Experimental|Group parent training|The intervention Group parent training for anxious parents is delivered in groups of about five, in 90 minutes per session, for eight consecutive weeks. The parent training is delivered by a licensed psychologist.
2577018|NCT02386410|Experimental|Internet delivered parent training|In the internet delivered parent training for anxious parents, parents are asked to work with one chapter each week, for eight consecutive weeks. Each chapter mirrors a session in the group format. Parents are able to e-mail a licensed psychologist during the intervention.
2577025|NCT02386410|No Intervention|Wait-list|Parents in the wait-list condition will receive the intervention after 12-month follow-up.
2577059|NCT02386137|Experimental|Patient|Woman aged more than 18 years having one or two symptomatic fibroid with size < 15cm.
2577107|NCT02385773|Experimental|PTM202|PTM202
2577108|NCT02385773|Placebo Comparator|Enfamil Puramino|Formal Placebo
2577160|NCT02385448|Experimental|Dienogest|
2577162|NCT02385448|Active Comparator|Combined oral contraceptive pills|
3210631|NCT00997009|Active Comparator|Arm B|chemotherapy
3210632|NCT00997022|Experimental|Sorafenib|Daily sorafenib taken orally
2577372|NCT02384161|Experimental|Total RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a total obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
2577374|NCT02384161|Experimental|Partial RBF + Exercise Isometric|"Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant member associated with a partial obstruction of blood flow, which will be conducted through a cuff pressure applied to the proximal region of the dominant limb."
2577376|NCT02384161|Placebo Comparator|Free BR + Exercise Isometric|Volunteers will undergo a year of intermittent isometric handgrip (intervention) in the dominant limb with the free blood flow. A 'cuff' pressure on the member of the proximal region, but with a pressure that will not interfere with blood flow will be applied.
3210633|NCT00997048|Experimental|Laying open|
3210634|NCT00997048|Active Comparator|Sinus excision|
2577483|NCT02383147|Experimental|Tomographic Neurofeedback (TONF)|15x Neurofeedback Trainings, 1-2 times per week
2577484|NCT02383147|Active Comparator|Non Tomographic Neurofeedback (NTE)|15x Neurofeedback Trainings, 1-2 times per week
2577529|NCT02382900|Experimental|Cohort 1|11 year old boys enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Gustavo A. Madero, Iztacalco, Miguel Hidalgo, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
2577531|NCT02382900|Active Comparator|Cohort 2|Historical cohort of young women 18-24 years old recruited by Lazcano et. al. receiving a standard vaccination schedule (0-1-6 months). 500 subjects were recruited.
2577532|NCT02382900|Active Comparator|Cohort 3|11 year old girls enrolled in fifth grade of 40 public elementary schools of Mexico City, from the political demarcations of Azcapotzalco, Venustiano Carranza, Iztacalco and Tlalpan, reciving a two-dose vaccination scheme (0-6). 250 subjects will be recruited.
3210635|NCT00997061||HYCAMTIN|
3210636|NCT00997074|Experimental|ibuprofen|the group will receive 2 tablets of ibuprofen 400 mg at the time of misoprostol administration. The information about the effect of the analgesics on the pain, and on the course of medical abortion, will be prospectively gathered from questionnaires completed by the study participants
2577706|NCT02382120||Patients undergoing cardiovascular surgery|Patients ASA 3-4 undergoing cardiac surgery.
2577733|NCT02381262|Experimental|Intervention|"At the 2 week post-surgical visit, subjects will receive and be trained in the use of the Fitbit and data interface and meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit."
2577748|NCT02381353|Active Comparator|Plain bupivacaine|Intraoperative injection of local anesthetic agent, standard of care
2577751|NCT02381353|Experimental|Exparel (sustained release bupivacaine)|Intraoperative injection of local anesthetic agent, long acting agent
3210637|NCT00997074|No Intervention|placebo|this group will receive 2 placebo tablets together with the misoprostol
3210638|NCT00997087|Placebo Comparator|Sugar Pill, Placebo|
3210639|NCT00997087|Active Comparator|Flumazenil|
3210640|NCT00997100|Other|ABR-215757|
3210641|NCT00997152|Experimental|Dose 1 JTT-654|
3210642|NCT00997152|Experimental|Dose 2 JTT-654|
3210643|NCT00997152|Placebo Comparator|Placebo|
3210644|NCT00997165||Metabolic syndrome (MS)|Patients suspected of metabolic syndrome without sleep apnea or liver steatosis
3210645|NCT00997165||MS with sleep apnea|Metabolic syndrome with sleep apnea
3210646|NCT00997165||MS with Liver steatosis|Metabolic syndrome with liver steatosis
2576839|NCT02387606|Experimental|Cohort 1|Participants will receive placebo or JNJ-53718678 500 milligram (mg) or 200 mg once daily for 7 days.
2576840|NCT02387606|Experimental|Cohort 2|Participants will receive placebo or JNJ-53718678; dosing regimen in Cohort 2 will be decided based on Cohort 1 results.
2576841|NCT02387606|Experimental|Cohort 3|Participants will receive placebo or JNJ-53718678, 75 mg once daily for 7 days.
2576868|NCT02387320|Experimental|Self-Care Toolkit|Women randomized to self-care toolkit group will receive a toolkit which includes a spiral-bound instruction manual, a section of the manual that can be used as a journal, a portable mp3 player with 8 audiofile tracks with guided meditations to reduce stress and anxiety, and two acupressure wristbands to help prevent nausea.
2576878|NCT02387320|No Intervention|Standard Care|Women randomized to the standard care group will be informed that they will continue to receive standard of care as delivered by the SAMMC Oncology Department. The research team will inform women randomized to standard care that they will receive the self-care toolkit at their two week post-operative visit and will be able to use it subsequently if they choose to.
2576928|NCT02387086|Experimental|A:gefitinib and thalidomide/aspirin|intervention: drug: gefitinib and thalidomide/aspirin: gefitinib will be administered at 250mg QD continuously; thalidomide will be administered at 100mg QD at night continuously; aspirin will be administered at 100mg QD continuously;
2576929|NCT02387086|Placebo Comparator|B:Placebo|intervention: drug: gefitinib and placebo/aspirin: gefitinib will be administered at 250mg QD continuously; placebo will be given to patients in the same way as the thalidomide; aspirin will be administered at 100mg QD continuously;
3176205|NCT00641992||2|Failure to medical treatment (surgery or percutaneous resolution)
2577017|NCT02386462|Experimental|Dexmedetomidine|After an injection of pre-determined bolus dose of dexmedetomidine over 10 min, anaesthesia was induced with propofol 2.0 mg/kg. The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg).
2577280|NCT02384642|Active Comparator|COMPASS|The COMPASS program will involve a structured intervention for girls between the ages of 10-14 that is intended to engage adolescent girls, those who are influential in their lives, service providers and other stakeholders, with the ultimate goal of co-creating environments in which girls are valued and safe. The program is centered on establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
2577284|NCT02384642|Experimental|COMPASS plus parenting|In the COMPASS plus parenting intervention arm, girls will receive the COMPASS intervention, and In addition to the safe spaces for girls, the COMPASS project will also implement structured activities for the parents and caregivers of participants. The study will examine the relative impact of the parenting initiative in addition to the program for adolescent girls. The study will seek to determine whether the structured intervention with girls' parents has an added impact on outcomes improve girls' safety and well-being.
2577323|NCT02384408|Placebo Comparator|Control|Control Group: Women without hormone replacement therapy. Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study
2577328|NCT02384408|Experimental|Hormone treatment|"Group Drospirenone: To whom a continuous combined treatment with drospirenone 2 mg and 17β-estradiol 1 mg (DRSP/E2) will be administered daily for 24 weeks.~Group Tibolone: To whom treatment with tibolone 1.25 mg (Tib) will be administered daily for 24 weeks.~Transvaginal Ultrasound - Endometrial Thickness; Endometrial Biopsy. Endometrial Immunohistochemical Study"
2577514|NCT02383316|Experimental|Noonan Syndrome Children|"Children with Noonan Syndrome will be compared with age- and sex-matched healthy children. We hypothesize than Noonan Syndrome children have an increased insulin sensitivity compared to GHD children.~Study parameters will be collected including: clinical measurements (height, weight, body mass index, waist circumference, and blood pressure), glucose and insulin levels at baseline and after an oral glucose tolerance test (OGTT), body composition measured by dual-energy x-ray absorptiometry (DXA)."
2577543|NCT02382731|No Intervention|Usual care|Usual care (no intervention)
3176206|NCT00642005|Experimental|1|Humidified and warmed carbon dioxide laparoscopic insufflation.
3176207|NCT00642005|Placebo Comparator|2|Cold and dry carbon dioxide laparoscopic insufflation.
3176208|NCT00642031|Experimental|Triciribine|Triciribine 15 mg/m^2 intravenous (IV) Weekly Over 1 Hour On Days 1, 8, and 15.
3176209|NCT00642044|Experimental|A|The eye with the worst visual acuity receives the treatment. (the other eye serve as control).
3176210|NCT00642044|No Intervention|B|The eye with the best visual acuity do not receive the treatment.
3176211|NCT00642070||Host|Women with current symptoms of a urinary tract infection
3176212|NCT00642083|Experimental|1|viabahn stent-graft
3176213|NCT00642096|Experimental|1|Metoprolol Succinate + Hydrochlorothiazide
3176214|NCT00642096|Active Comparator|2|Metoprolol Succinate
3176215|NCT00642096|Active Comparator|3|Hydrochlorothiazide
3176216|NCT00642109|Other|TVT|Tension-free Vaginal Tape (TVT)
3176217|NCT00642109|Other|TOT|Transobturator Tape outside-in (TOT Monarc)
3176218|NCT00642109|Other|TVT-O|Transobturator Tape inside-out (TVT-O)
3176219|NCT00642122|Experimental|1|Pulmicort RESPULES
3176220|NCT00642122|Experimental|2|Pulmicort TURBUHALER
3176221|NCT00642135|Active Comparator|1|Premature newborns and neonates treated using Phenylephrine and tropicamide eyedrops
3176222|NCT00642135|Active Comparator|2|Premature newborns and neonates treated using insert Mydriasert®
3176223|NCT00642148|Active Comparator|Seretide|
3176224|NCT00642148|Placebo Comparator|Placebo|Placebo tablet
3176225|NCT00642148|Experimental|GW856553|
3176226|NCT00642187|Experimental|1|Pulmicort
3176227|NCT00642187|Placebo Comparator|2|Placebo
3176228|NCT00642200|Active Comparator|1|Patients receive Lichtenstein hernioplasty as a treatment for recurrent inguinal hernia.
3176229|NCT00642200|Active Comparator|2|Patients receive laparoscopic TEP as a treatment for recurrent inguinal hernia.
3176230|NCT00642213||ischemic stroke sample with DNA|We prospectively collected 450(1999), 502(2005), and 512(2010) ischemic stroke patients who agreed to participate and also most provided a sample for DNA. The cohort data consists of a baseline interview, medical record abstraction and various timeframes of followup interviews from 3 months to 3 years. See website (www.gcnkss.com for data forms)
2576845|NCT02387528|Experimental|1- Mindfulness Intervention|"Mindfulness-Based Intervention: The intervention model tested was Breathworks for Stress.The mindfulness intervention used in the study had a total of eight encounters, lasting 120 minutes, that took place once a week. In order to accommodate employees' schedule. There was a recommendation of daily practice lasting an average of 15 minutes, as well as the suggestion to use the tools in everyday life.~In each session a theme was presented, with distinct practices and well-defined objectives"
2576846|NCT02387528|Placebo Comparator|2- Relaxation Intervention|Relaxation-Based Intervention was composed of four meetings, of two hours duration, held every two weeks. The activities involved mutual help conversations about work situations, psychoeducation on stress and various techniques of stress inoculation, such as: diaphragmatic breathing, progressive muscle relaxation, relaxing visualization and stretching. Each session had its own objective to promote the relaxation response effect.
2576847|NCT02387528|Other|3- Wait List Control Group|The wait list passive control group did not receive any intervention while the study was been enrolling.
2576875|NCT02387281||"PD with FOG on"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as on freezing of gait (FOG) based on evaluation using motion capture"
2576882|NCT02387281||"PD with FOG off"|"Subjects diagnosed with Parkinson disease (PD) and sub-categorized as off freezing of gait (FOG) based on evaluation using motion capture"
2576889|NCT02387281||PD without FOG|Subjects with Parkinson disease (PD) and an absence of freezing of gait (FOG)
2576894|NCT02387281||Non-PD with FOG|Subjects with freezing of gait (FOG) and an absence of Parkinson disease (PD) (exception granted for those with FOG and atypical parkinsonism: PSP or MSA)
2576944|NCT02387112|Experimental|Early VAD implantation|The experimental intervention is early implantation of a left ventricular assist device (early VAD). Patients randomized to early VAD implantation will obtain a VAD within 28 days after randomization.
2576958|NCT02387112|No Intervention|Emergency VAD implantation|The control intervention is conservative heart failure treatment, with LVAD implantation in the case of worsening heart failure (emergency VAD). All patients randomized to the control intervention will be treated according to standard medical practice. In brief, these patients are closely monitored (scheduled regular visits to outpatient department depending on the patient's condition and at least every 6 months). If the condition worsens the patient may qualify for high urgency (HU) listing and/or for VAD implantation.
2577004|NCT02386423|Experimental|RESTIFFIC|RESTIFFIC™ Brand Pressure Application System
2577053|NCT02386150|Experimental|Group 1: 10 μg|10 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
2577054|NCT02386150|Experimental|Group 2: 20 μg|20 μg RVEc is to be administered given in the volar surface of the forearm by ID injection (in alternate arms for each vaccination unless there is a medical reason not to alternate arms) with a needle and syringe (ID adapter may be used) (0.1 mL/dose). There are 4 doses planned for this group: 1 primary dose on Days 0, 28, and 106, and a booster dose on Day 365 (1 year).
2577106|NCT02385877|Experimental|Protocol 1: [18F]4F-MHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 4-[18F]fluoro-meta-hydroxyphenethylguanidine ([18F]4F-MHPG) and receive a 90 minute PET scan.
2577110|NCT02385877|Experimental|Protocol 1: [18F]3F-PHPG|Subjects (n = 4) will be injected one time with 6.5 mCi of 3-[18F]fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) and receive a 90 minute PET scan.
2577113|NCT02385877|Experimental|Protocol 2: Biodistribution Studies|Subjects (n = 4) will be injected one time with 6.5 mCi of either [18F]4F-MHPG or [18F]3F-PHPG (whichever is selected based on Protocol 1 studies) and receive four whole-body PET scans, starting at 5 min, 60 min, 150 min and 360 min after tracer injection.
2577172|NCT02385435|Active Comparator|Bupivacaine|single shot caudal plain bupivacaine at a dose of 2mg/kg is used as a reference control drug.
2577178|NCT02385435|Active Comparator|dexmedetomidine 1μg.kg-1|Single shot Caudal dexmedetomidine 1μg.kg-1 used as the second arm intervention
2577183|NCT02385435|Active Comparator|dexmedetomidine 2μg.kg-1|Single shot Caudal dexmedetomidine 2 μg.kg-1 used as the second arm intervention
2577278|NCT02385019|Experimental|Administration of 0.5 x 10ˆ6 donor Treg/kg|First group of 5 patients will receive a total of 0.5 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
2577282|NCT02385019|Experimental|Administration of 1.0 x 10ˆ6 donor Treg/kg|Second group of 5 patients will receive a total of 1.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
2577286|NCT02385019|Experimental|Administration of 2.0-3.0 x 10ˆ6 donor Treg/kg|Third group of 5 patients will receive a total of 2.0-3.0 x 10ˆ6 donor Treg/kg. Part of Phase 1 study.
2577287|NCT02385019|Experimental|Administration of MTD of donor T reg|Preliminary Phase 2 study will include another 5 to 10 patients at the MTD identified in the Phase 1 study
2577314|NCT02384317|Experimental|CCX168|BID for 84 days
2577360|NCT02384135|Other|interventional|Patients with D-dimer levels between the usual cutoff and the age-adjusted cutoff will be left untreated and followed-up for three months
2577388|NCT02383797|Experimental|Cartilage-hair hypoplasia (CHH)|Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.
2577533|NCT02383615|Active Comparator|DTSNB|Distal transsartorial saphenous nerve block
2577534|NCT02383615|Active Comparator|ACSNB|Adductor canal saphenous nerve block
2577575|NCT02382601||Small for Gestational Age Pregancies (controls)|Small for gestational age (SGA) pregnancies that do not develop IUGR will be considered controls. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
2577576|NCT02382601||IUGR Pregnancies (cases)|Small for gestational age (SGA) pregnancies that do develop IUGR will be considered cases. Each subject will have an ultrasound, MRI, maternal blood and cord blood collection, placental analysis, neurological function assessments (infant), and body fat measurements (infant).
2577650|NCT02382289|Active Comparator|monopolar RF 3 points|RF needle is inserted at three levels in the upper , middle and lower part of the area between the SIJ and the lateral aspects of the ipsilateral dorsal sacral foramina. after sensory and motor stimulation, monopolar lesion RF at 80oc for 90 sec will be applied.
3210647|NCT00997178|Experimental|Non-surgical periodontal therapy|Non-surgical periodontal therapy consisted of scaling and root planing plus chlorhexidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months
2576952|NCT02386826|Experimental|INC280 + Bevacizumab|"Dose Escalation: 18 GBM patients received bevacizumab 10 mg/kg intravenously (IV) once every 2 weeks in combination with INC280 given by mouth (PO) starting at 100 mg twice daily and escalating on a 3+3 escalation pattern until the maximum tolerated dose (MTD) was determined.~Dose Expansion: Up to 45 GBM patients enrolled in 3 Cohorts:~Cohort A: 20 GBM patients - progressed during or after standard 1st-line therapy; Cohort B: 15 GBM patients - progressed during or after 2nd-line bevacizumab therapy; Cohort C: 10 unresectable GBM patients.~INC280: PO twice daily at the MTD. Bevacizumab: 10 mg/kg IV once every 2 weeks for Cohorts A and B; 15 mg/kg IV every 4 weeks for Cohort C Treatment cycles will be repeated every 28 days (4 weeks)."
2577036|NCT02386540|Experimental|Health Coaching|Patients randomized to the experimental arm receive six months of post-ED health coaching from the Alameda County Health Coach Program (ACHCP) in addition to usual care in the emergency department at enrollment.
2577038|NCT02386540|No Intervention|Usual Care|Patients randomized to the control arm receive usual care in the emergency department at enrollment.
2577058|NCT02386111|Experimental|Varlilumab and Sunitinib|
2577135|NCT02385734|Experimental|Concentrated growth Factor Membrane|Autogenous platelet and leukocyte fibrin material was obtained from blood.
2577136|NCT02385734|Active Comparator|Coronally Advanced Flap|Periodontal plastic surgery procedure in the treatment of gingival recession
2577191|NCT02385279|Experimental|MiStent®|Percutaneous Coronary Intervention with the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent. It is a balloon expandable sirolimus eluting stent with an absorbable polymer coating.
2577192|NCT02385279|Active Comparator|XIENCE EES|Percutaneous Coronary Intervention with the XIENCE EES (Everolimus Eluting) Coronary Stent System. The stents are balloon expandable drug eluting stents using everolimus with a non-erodible or durable polymer coating.
3210648|NCT00997178|Other|Delayed non-surgical periodontal therapy|No periodontal treatment for 6 months
3210649|NCT00997191|Active Comparator|Laser Group|Focal / grid Laser photocoagulation in diabetic macular edema
3210650|NCT00997191|Experimental|Triamcinolone group|Intravitreal triamcinolone associated to laser photocoagulation for diabetic macular edema
2577445|NCT02383524||Chronic Low Back Pain (Lumbar Facet Joints Mediated Pain)|
2577499|NCT02383251|Experimental|Pazopanib/Paclitaxel association|"Arm 1 :~Pazopanib alone during 1 week at 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Then:~Pazopanib 600 mg (1x400mg and 1x200mg), per day, taken orally without food at least one hour before or two hours after a meal.~Paclitaxel 65 mg/m2 i.v. on days 1, 8, 15 every 28 days until progression of disease or toxicity"
2577501|NCT02383251|Active Comparator|Paclitaxel alone|"Arm 2 :~Paclitaxel 80mg/m2 i.v. on days 1, 8, 15~every 28 days until progression of disease or toxicity"
2577564|NCT02382614|Experimental|Spiration Valve System|The treatment group will have valves deployed to achieve leak isolation.
2577566|NCT02382614|No Intervention|Medical Management|The control group for this study will receive standard chest tube drainage management and standard-of-care interventions. This group will be evaluated and followed in the same manner as the treatment group, but without having valves placed.
2577637|NCT02382250||Catheterization Group|These are patients recruited from Bellevue Hospital and NYU Hospital Cardiac Catheterization Laboratories
2577682|NCT02381717|Experimental|ultra-sound guided femoral nerve block|Patients in this arm will receive a bed-side ultrasound guided femoral nerve block with analgesia 0.5% bupivacaine (2mg/kg)
2577689|NCT02381717|Active Comparator|standard of care- IV morphine|Patients in this arm will have the femoral nerve block block with no ultrasound for guidance with analgesia (IV morphine)
3210651|NCT00997191|Experimental|Bevacizumab group|Intravitreal Bevacizumab associated to laser photocoagulation for diabetic macular edema
3210652|NCT00997256|Experimental|Verum|Neurapas balance, film-coated tablets
3210653|NCT00997256|Placebo Comparator|Placebo|Film-coated sugar-pill
3210654|NCT00997269|Experimental|CoQ-10 supplementation|
3210655|NCT00997269|Placebo Comparator|CoQ-10 placebo supplementation|
3210656|NCT00997282|Experimental|OPC-262 2.5 mg|orally administered once daily for 24 weeks
3210657|NCT00997282|Experimental|OPC-262 5 mg|orally administered once daily for 24 weeks
3210658|NCT00997282|Placebo Comparator|Placebo|orally administered once daily for 24 weeks
3210659|NCT00997295||Heat moisture exchanger (HME)|This group was submitted to general anesthesia with low flow gas and heat moisture exchanger
3210660|NCT00997295||Low flow gas (LFG)|This group was submitted to general anesthesia with only low flow gas
3210661|NCT00997295||Humidity of the respiration|"Heat and moisture group:~The first group (G1)will be submitted to low flow gas anesthesia and heat and moisture exchanger (HME)~Control group:~The second group(G2)Will be submitted to low flow gas anesthesia"
3210662|NCT00997295||HME and LFG|
3210663|NCT00997308|Experimental|AZD1446 Low|Low dose of AZD1446
3210664|NCT00997308|Experimental|AZD1446 High|High dose of AZD1446
3210665|NCT00997308|Placebo Comparator|Placebo|
3210666|NCT00997347|Experimental|64-70 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days
2578020|NCT02379715|Experimental|Remifentanil|When the particapants arrived into the operating room, the investigators applied standard monitoring and after preoxygenation, 2 mg remifentanil was diluted into 50 ml of normal saline (40 μg/ml solution) and was infused by Target concentration infusion (TCI) via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) using the pharmacokinetic model. Investigator started to infuse remifentanil at 4 ng/ml and after the Ce of remifentanil reached the target concentration level, opened the dial of desflurane vaporizer at 4 vol%. After 30 seconds, increase the concentration of desflurane 8% and 12% at last. If there is no spontaneous respiration or loss of consciousness, the muscle relaxant esmerone 0.6mg/kg is injected and after 90 seconds the tracheal intubation is performed.
2578077|NCT02379299|Active Comparator|Single-hormone closed-loop control|Closed-loop glucose control by use of insulin only by use of DiaCon single-hormone closed-loop glucose control algorithm
2578106|NCT02378974|Other|Cohort 1|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0
2576966|NCT02386813||Training cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2013;~Patients treated with non-anthracycline based therapy as an initial treatment."
2576970|NCT02386813||Validation cohort|"Patients diagnosed with ENKTL, nasal type between January 1, 1998 and December 31, 2014;~Patients treated with non-anthracycline based therapy as an initial treatment."
2577043|NCT02386592|Experimental|Intervention|Infection control package consisting of alcohol hand rub hand hygiene (HH), 2% chlorhexidine gluconate (CHG) body washes, infection control training, and text messages with basic Infection control reminders via SMS text
2577104|NCT02385942|Other|Tele-consultation system|compare the Live assessed wound size with the transmitted Smart phone-based wound size through Tele-consultation system
2577201|NCT02385487||Critical illness and type 2 MI|Critically ill adults with abnormal serum troponin I during hospitalization for critical illness.
2577202|NCT02385487||Critical illness without type 2 MI|Critically ill adults without an elevation in troponin I complicating critical illness.
2577267|NCT02384902|Experimental|low GI|low GI: participants were asked to consume low GI foods (GI<55) in abundant, medium GI in moderate and high GI (GI>70) rarely.
2577270|NCT02384902|Experimental|low GL|low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.
2577274|NCT02384902|Experimental|conventional diet|conventional diet: all carbohydrate were treated as the same.
2577319|NCT02384447||Knee Amputation|Patients that are scheduled to undergo above knee amputation due to complications associated with diabetes will be enrolled
2577444|NCT02383537||Pregnant women with diabetes|Pregnant women with diabetes type 1, type 2 or gestational diabetes
2577448|NCT02383537||Healthy pregnant women|Healthy pregnant women with no underlying illness
2577487|NCT02383277|Experimental|Stretching and Exercise|This group undergo a session of stretching aiming flexibility of the rib cage and later at an exercise test with constant load up to the limit of tolerance for exercise bike
2577492|NCT02383277|Sham Comparator|Control and Exercise|This group will carry out the exercise test with constant load up to the limit of tolerance for exercise bike after a period of rest under the same environmental conditions and the experimental group time. During this time the therapist will place their hands but not performing the stretch.
3210667|NCT00997347|No Intervention|57-63 days' gestational age|Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)
3210668|NCT00997360|Experimental|1|PKI-179
2577605|NCT02382172|Experimental|Social Cognition and Interaction Training for Autism (SCIT-A)|The measures the investigators are giving assess participants' initial level of social deficits and the extent to which the therapy did or did not help their social skills. The research team will compare the level of difficulty that participants first reported with their subjective evaluation of their experience in the group sessions to determine whether the program is clinically useful for further development. The investigators will also have the participants complete eye tracking paradigms to assess possible changes in social functioning after completing the Social Cognition and Interaction Training for Autism (SCIT-A) program.
2577610|NCT02382172|Other|Treatment As Usual (TAU)|Continuation of services being given upon study entry.
2577671|NCT02382055|Experimental|REACH|Psychotherapy
2577672|NCT02382055|Active Comparator|Supportive Psychotherapy|Psychotherapy
2577683|NCT02381600|Experimental|Intervention group- vitamin D|Include patients aged 65 years and older that are found to have below-normal serum levels of vitamin D on routine laboratory testing. After providing informed consent (the study was submitted for approval by the Ethics Committee of the Clalit Health Services) eligible subjects will undergo cognitive and affective assessment
2577744|NCT02381431|Experimental|Thermal Imaging|imaging using a thermal camera
2577776|NCT02381028|Experimental|Study area|Human milk and emollient: Apobase creme® (Actavis Norway AS)
2577780|NCT02381028|Active Comparator|Control area|Emollient: Apobase creme® (Actavis Norway AS)
2577822|NCT02380807|Experimental|Dry Needling Therapy|Dry Needly Therapy will be assesses in trigger points on latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourum muscle.
2577825|NCT02380807|Active Comparator|Cross Tape Therapy|Cross Tape is a grid-shaped bandage easy aplicacionen different parts of the body that regulates the tension.
2577911|NCT02380469|Experimental|Immediate intervention|Immediately after enrollment in the project, caregivers and patients receive the intervention
2577920|NCT02380469|Other|Delayed intervention (3 weeks later)|This group receives the same intervention as in the experimental group, but after the outcome assessment at 2 weeks
2577953|NCT02380001|Experimental|Dexketoprofen trometamol|A White round pill with 25 mg of dexketoprofen will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with placebo will be administered.
2577954|NCT02380001|Placebo Comparator|Preoperative control|A hard-gelatin capsule with placebo will be administered 30 minutes before the impacted third molar surgery start. Immediately after the surgery, a hard-gelatin capsule with 25mg of Dexketoprofen will be administered.
3210669|NCT00997399|Experimental|LBH589|
2578109|NCT02378974|Other|Cohort 2|Cordstem-ST 2.0 x 10^8 cells or Placebo on day 0 and day 7
3210670|NCT00997412|Experimental|MA|MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
3210671|NCT00997412|Active Comparator|AZA|AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
3210672|NCT00997451|Experimental|Behavioral Self-Management|Cognitive-behavioral self-management
3210673|NCT00997451|Active Comparator|Symptom Monitoring|
3210674|NCT00997451|No Intervention|Standard Medical Care|
3210675|NCT00997477|Experimental|Formoterol and Budesonide|
3210676|NCT00997490|Experimental|Verum|Neurapas balance, film-coated tablet
3210677|NCT00997490|Placebo Comparator|Placebo|
3210678|NCT00997529|Experimental|1|
3210679|NCT00997542|Active Comparator|Allopurinol|
3210680|NCT00997542|Placebo Comparator|Placebo|
3210681|NCT00997568||TEE Procedure|Patients who have been scheduled for a TEE procedure by their physician
3210682|NCT00997581|Experimental|apremilast|Experimental treatment for acute gout
2576987|NCT02386761|Experimental|Multiple Ascending Dose (MAD)|"Dose 1 (MAD1): Multiple doses of CHF 6001 - Total daily dose 2400 µg or placebo~Dose 2 (MAD2): Multiple doses of CHF 6001 - Total daily dose 4000 µg or placebo~Dose 3 (MAD3): Multiple doses of CHF 6001 - Total daily dose 4800 µg or placebo~Duration 14 days b.i.d."
2577003|NCT02386332||umbilical cord blood transplant (UCBT)|Patients to receive umbilical cord blood transplant (UCBT) are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan and anti-thymocyte globulin.). Also receive GVHD prophylaxis with cyclosporine A and prednisone and Additional Supportive Care
2577008|NCT02386332||HLA-haploidentical hematopoietic stem cell transplantation|Patients to receive HLA-haploidentical hematopoietic stem cell transplantation are conditioned with the myeloablative conditioning regimen (preparative therapy with thiotepa, fludarabine, intravenous busulfan). Also receive GVHD prophylaxis with cyclophosphamide, cyclosporine A and mycophenolate mofetil and Additional Supportive Care
3210683|NCT00997581|Active Comparator|indomethacin|Medication currently used for the treatment of acute gout
3210684|NCT00997607|Experimental|Ebola vaccine only|Participants will receive only the Ebola vaccine or a placebo injection.
2577141|NCT02385552||Experienced endoscopists|All of the experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rate every 3 months
2577199|NCT02385253|Active Comparator|Educational training program|PCPs randomized to the intervention group will receive the educational training program at the beginning of the study, extending over a maximum of five months.
2577200|NCT02385253|No Intervention|Control|PCPs randomized to the control group will have the option of receiving the educational training program at the end of the study.
2577266|NCT02384876|Experimental|Ephedrine, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|Dose escalation: 6 successive cohorts with a maximal increasing dose
2577269|NCT02384876|Active Comparator|Ephedrine, dose : 0.1 mg/kG, reference dose|Reference dose
2577346|NCT02384486|Experimental|intervention group|"intervention group will receive the Training to Reduce Stress in Mothers of Children with (ASD)"
2577349|NCT02384486|Other|control group|control group will receive nothing but for ethical purposes will receive the same intervention after the end of the trial for the intervention group
3210685|NCT00997607|Experimental|Marburg vaccine only|Participants will receive only the Marburg vaccine or a placebo injection.
3210686|NCT00997607|Experimental|Ebola and Marburg vaccine|Participants will receive both the Ebola and Marburg vaccines, one in each arm or placebo injections.
2577485|NCT02383069|Experimental|Intervention Group|The intervention group will have supervised rehabilitation program held twice a week, each session will have 60 minutes duration, with minimum interval of 24 hours, for a period of 8 weeks. Each session will consist of three parts: aerobic training, strength training and respiratory physiotherapy. The aerobic training will be held for 35 minutes (10 min of warm up, 20 min on target load and 5 min of slowdown) with initial intensity of 60% of the maximum load obtained in the maximal cardiopulmonary exercise testing or in incremental shuttle walk test (ISWT). The intensity will be gradually increased up to 80%, so that fatigue or dyspnea values are kept between 4 and 6, according to the modified Borg scale.
2577486|NCT02383069|Active Comparator|Control Group|The control group will be subjected to supervised respiratory physiotherapy and stretching exercises twice a week, each session with duration of 60 minutes, with minimum interval of 24 hours, for a period of 8 weeks. The oral high-frequency oscillation device (Flutter®) will be used for 10 minutes, 5 minutes in each lateral decubitus, followed by the stretching of upper and lower limbs for 40 minutes. All exercises will be active, performed in sitting and lying positions without increasing the heart rate. The remaining 10 minutes will be used to discuss doubts about the disease and the use of the booklet.
2577539|NCT02382874|Experimental|AD-MSC|The patients with FSGS who underwent intravenous injection of AD-MSC.
2577621|NCT02382510|Experimental|TRN-157|
2577627|NCT02382510|Placebo Comparator|Placebo|
2577629|NCT02382510|Active Comparator|Tiotropium|
2577708|NCT02381561|Experimental|Treatment (ropidoxuridine, IMRT)|Beginning 30 minutes to 2 hours before radiation therapy, patients receive ropidoxuridine PO QD on days 1-28 in the absence of disease progression or unacceptable toxicity. Beginning on day 8, patients undergo IMRT 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
2577781|NCT02381197||pregnant women|Women presenting for prenatal care will provide urine samples at each antenatal care visit. The sample will be used to perform a Congo Red Dot test.
2577827|NCT02380820|Experimental|AirsoftDuo first|"Patients randomized to this arm will be placed on the Airsoft Duo mattress, and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Softform Premium mattress (in static mode). The patient will then continue his/her stay with the Softform Premium mattress (in static mode) for 1 month.~Intervention: Airsoft Duo mattress Intervention: Softform Premier mattress (in static mode)"
2577830|NCT02380820|Experimental|Softform Premium first|"Patients randomized to this arm will be placed on the Softform Premium mattress (in static mode), and the investigator will proceed with 2 series (for reproductibility) of measures for 30 minutes with the bed headboard at 0°. A pause, consisting of ten minutes of sitting and 1 minute of verticalization is then carried out. The bed is then positioned at 30°, and the 2 series of measures over 30 minutes are repeated. The next day, all of the above are repeated with the Airsoft Duo mattress. The patient will then continue his/her stay with the Airsoft Duo mattress for 1 month.~Intervention: Softform Premier mattress (in static mode) Intervention: Airsoft Duo mattress"
2578004|NCT02380079|Experimental|SCD-101|SCD-101 dosed TID for 28-days
3210687|NCT00997633||Peritoneal carcinomatosis|Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment
3210688|NCT00997646||Patients in hospitalist-run ward|Patients was admitted from ER to a hospitalist-run ward.
3210689|NCT00997646||Patients in conventional ward|Patients was admitted from ER to a non hospitalist-run ward.
3210690|NCT00997659|Experimental|chromium picolinate|
3210691|NCT00997685|Experimental|Capecitabine plus oxaliplatin，mCRC|
3210692|NCT00997711|Experimental|Cypher|Sirolimus-eluting stent
2576988|NCT02386670|Sham Comparator|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session.~Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels.~During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely)."
2577028|NCT02386280|Experimental|Motivational Interviewing for Change of Parenting Styles|After measured parental style across the scale, the motivational interviewing will be applied in order to modify the parenting styles of risk for involvement with drug use and maintenance of protective factors. This approach will occur in 5 segments .
2577034|NCT02386280|Sham Comparator|Psicoeducation|General information about drugs and ways of prevention
2577071|NCT02386059|Placebo Comparator|PLACEBO Group|Received normal saline
2577076|NCT02386059|Active Comparator|DEXAMETHASONE Group|Received 4 mg Dexamethasone.
2577079|NCT02386059|Active Comparator|ONDANSETRON|Received 4 mg Ondansetron
2577081|NCT02386059|Active Comparator|DEXAMETHASONE + ONDANSETRON|Received 4mg Dexamethasone + 4mg Ondansetron
2577170|NCT02385409||Elective Total Hip- or Knee arthroplasty patients|Patients scheduled for elective Hip- or knee replacement at Hvidovre Hospital, Denmark.
2577229|NCT02385136|Experimental|WBRT plus TMZ arm|whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ)
2577230|NCT02385136|No Intervention|WBRT|whole brain radiotherapy (WBRT)
2577277|NCT02384655|Experimental|Fenugreek|Mothers will take fenugreek for 14 days
3210693|NCT00997724|Experimental|a-VATS|Patients with NSCLC underwent assisted-VATS sleeve lobectomy with bronchoplasty.
3210694|NCT00997737|Experimental|DB, VI and FV|Breathing exercises
2577385|NCT02383732|Experimental|Treatment|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
2577392|NCT02383732|Active Comparator|Waitlist Control|Pediatric subjects between the age of 4-12 years with autistic spectrum disorder and elopement will be assigned to the Waitlist Control group. The subjects will be offered the intervention after completion of the 12-week waiting period. The subjects will then begin the Elopement Prevention and Safety Training (EPST) program. EPST includes up to 12 120-minute weekly sessions delivered over approximately 12-14 weeks. EPST is a modular treatment, with three components: 1) Universal Safety Measures (USM), 2) Proximity training, and 3) Check-in training. All participants receive the USM module in the first two sessions. They then receive either the Proximity training or Check-in training module depending on the type of elopement exhibited by the child (i.e., bolting vs. wandering).
2577447|NCT02383511|Other|Sequence 1|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
2577450|NCT02383511|Other|Sequence 2|Drug: SMT C1100 or placebo 3-treatment (Period 1,2, and 3)
2577451|NCT02383511|Other|Sequence 3|Drug: SMT C1100 or placebo 3-treatment (Period 1,2 and 3)
3210695|NCT00997750|Experimental|Lornoxicam|Lornoxicam 8mg/day and 12mg/day for 15 days
3210696|NCT00997763|Active Comparator|XIENCE V|everolimus-eluting stent
2577620|NCT02382354|Experimental|i-gel|I-gel insertion was attempted during propofol and remifentanil anesthesia .
2577625|NCT02382354|Active Comparator|laryngeal mask airway|LMA insertion was attempted during propofol and remifentanil anesthesia .
2577679|NCT02381899||BR in CLL|Patients receive bendamustine hydrochloride 90mg/m2 IV on days 1 and 2 each cycle. Patients also receive rituximab 375 mg/m2 IV on day 1 at first cycle and 500 mg/m2 on day 1 all subsequent cycles.
2577731|NCT02381301||Venous blood sampling prior to CCTA.|In patients undergoing routine Cardiac Computed Tomography Angiography (CCTA) and given written informed consent blood sampling will be performed. The samples will be stored for a period of 15 years at the Biobank for future analyses.
2577784|NCT02381093|Active Comparator|Standard BLS Course|Participants will partake in a standard BLS course.
2577787|NCT02381093|Experimental|Contextual Interference|Participants will partake in a BLS course designed using contextual interference scheduling.
2577910|NCT02380391||People living with HIV (HIV+)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention.
2577916|NCT02380391||People without HIV (HIV-)|Adults experiencing first episode of ACS treated with percutaneous coronary intervention, matched to HIV+ on age, sex, known diabetes mellitus, and anti-platelet therapy.
2578001|NCT02380040||Term|Normal Term Newborn Intervention: PPG
2578006|NCT02380040||Preterm|Preterm babies admitted to the NICU not suffering from the conditions to be studied Intervention: PPG
2578007|NCT02380040||PDA|Patent Ductus Arteriosus Intervention: PPG
2578010|NCT02380040||PPHN|Persistent Pulmonary Hypertension Intervention: PPG
3176231|NCT00642213||stroke data from medical record review|The second part of the study is a retrospective medical record review of all potential ischemic strokes, TIAs, and Hemorrhagic strokes in our 5 county region that occurred in all study years.
3210697|NCT00997763|Active Comparator|CYPHER|Using Cypher stent
2578041|NCT02379338|Experimental|Dynamic Brain Cohort|The Dynamic Brain cohort will include up to 10 patients who will undergo a dynamic brain [18F]Fluortriopride PET/CT scan over a period of approximately 2 hours. Subjects in this cohort will also undergo a research brain MRI, generally on a separate day from the PET/CT.
2578116|NCT02378909|Active Comparator|Group 3|Diabetic neuroischemia with electrical stimulation device and standard of care.
3210698|NCT00997776|Experimental|Exercise|High intensity lower extremity exercise
3210699|NCT00997776|Sham Comparator|Attention control|lower extremity TENS
3210700|NCT00997789|Experimental|Rebamipide, Serum concentration, Tablet|The test preparation, Rebamide® (containing 100 mg of rebamipide; lot No. KP005; expiration date, April 2010; Kyungdong Pharmaceutical Company, Seoul, Korea) and the reference preparation, Mucosta® (containing 100 mg of rebamipide; lot No. MC704067; expiration date, May 2010; Korea Otsuka Pharmaceuticals Co., Ltd., Seoul, Korea)
3210701|NCT00997802|Other|CT colonography and optical colonoscopy|
2577206|NCT02385123|Experimental|Seasonal flu vaccine|0.5 ml of seasonal inactivated influenza vaccine (IIV) will be administered intramuscularly (IM) on day 0 of each study season. The study will enroll 10 subjects each season, in years 1, 2, 4 ,5, and 6 of the study for a total of n=50.
2577261|NCT02384850|Experimental|Selinexor + mFOLFOX6|Different Dose Levels of Selinexor will be evaluated in combination with mFOLFOX6 (see interventions)
3210702|NCT00997815|Experimental|Botulinum toxin A|The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.
2577394|NCT02383888|Placebo Comparator|Matching placebo for each dose groups|
2577399|NCT02383888|Experimental|BI 425809 Active dose group 1|
2577404|NCT02383888|Experimental|BI 425809 Active dose group 2|
2577407|NCT02383888|Experimental|Bi 425809 Active dose group 3|
2577458|NCT02383485|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
2577459|NCT02383485|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
2577475|NCT02383121||No patients|Study has been withdrawn
3210703|NCT00997815|Placebo Comparator|Placebo|Using normal saline
3210704|NCT00997828|Experimental|everolimus-eluting stent|everolimus-eluting stent
2577611|NCT02382224|Experimental|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
2577617|NCT02382224|Placebo Comparator|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
2577680|NCT02382042|Active Comparator|Intensive Referral Intervention|
2577685|NCT02382042|No Intervention|Standard Care|
2577761|NCT02381470|Experimental|Faropenem|Faropenem 600mg (with amoxicillin/clavulanic acid, 500mg/125mg) given three times daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
2577763|NCT02381470|Experimental|Cefadroxil|Cefadroxil 1g (with amoxicillin/clavulanic acid, 500mg/125mg) given twice daily for 7 days PLUS Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
2577766|NCT02381470|Active Comparator|Control|Rifampicin 10mg/kg once daily alone for the first 2 days then standard combination therapy (rifampicin, isoniazid, pyrazinamide, ethambutol, adjusted for body weight) for the following 5 days
2577923|NCT02380846|Other|Rice|Control session - white rice (equivalent to 50g available carbohydrates)
2577926|NCT02380846|Active Comparator|Rice with chicken|Treatment 1 - White rice and steamed chicken breast (25g protein)
2577927|NCT02380846|Active Comparator|Rice with fish|Treatment 2 - White rice and steamed fish (25g protein)
2577928|NCT02380846|Active Comparator|Rice with egg white|Treatment 3 - White rice and egg white (25g protein)
2577929|NCT02380846|Active Comparator|Rice with beancurd|Treatment 4 - White rice and steamed beancurd (25g protein)
2578025|NCT02379689|Active Comparator|injectable placental tissue extract called BioDGenesis|This study will compare injectable placental tissue extract called BioDGenesis (Active Product)
2578028|NCT02379689|Placebo Comparator|Placebo|injectable Tissue Suspension Solution (TSS) (Placebo). The Active Product is supplied by BioD, LLC (BioD).
3210705|NCT00997828|Active Comparator|coronary artery bypass graft surgery|coronary artery bypass graft surgery
3210706|NCT00997841|Active Comparator|POC algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following Point of Care based algorithm
3210707|NCT00997841|Active Comparator|conventional algorithm|cardiac surgery patients suffering from increased perioperative bleeding and being treated following conventional coagulation management algorithm
3210708|NCT00997854|Active Comparator|Group 1 Bolus Feeds|This group will receive feeds administered by bolus method over no more than 30 minutes per feed.
2578210|NCT02378363||Student 9 to 12 years|Students aged 9 to 12 years and enrolled in classes CM1, CM2 and 6th
2578262|NCT02378142|Experimental|Arm 1|Pazopanib 800mg oral daily
2578345|NCT02377661|No Intervention|Standard Care|Treatment of hypertension according to current guidelines
2578348|NCT02377661|Experimental|Experimental Care|Treatment of hypertension using a standardised and simplified titration regime with single pill combinations, comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide.
2578395|NCT02377141|Active Comparator|Endoscopic Variceal Band Ligation (EVBL)|Participants in this group will receive standard medical care consisting of vasoactive drugs (Terlipressin 2mg QDS (where there are no contraindications e.g. severe ischaemic heart disease), antibiotics, and entry into a variceal banding programme (in-patient or out-patient).
2578398|NCT02377141|Active Comparator|Early TIPSS|For those randomized to early TIPSS the Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure will be performed within 72 hours (and preferably within the first 24 hours) after initial endoscopy. Vasoactive drugs will be continued until the TIPSS is performed and antibiotics continued for 5-7 days.
2578448|NCT02376803|Experimental|Morning warfarin ingestion|Patients switch from taking warfarin in the evening to taking warfarin in the morning.
3210709|NCT00997854|Experimental|Group 2- Slow Infusion Feeds|This group will receive feeds administered by slow infusion over pump for 2 hours.
2577152|NCT02385539|Active Comparator|Levobupivacaine (LB) 8 mg|Patients will be stratified into three groups (80 patients) according to doses of Levobupivacaine (6, 8 or 12 mg, Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients who will receive 8 mg of Levobupivacaine will be randomized to one of four treatment groups (each 20 patients), by dose of intrathecal opioids: 25, 35 mcg of Fentanyl (Fentanyl, Janssen Cilag, amp. 50 mcg/ml) or 5, 7 mcg of Sufentanil (Sufenta, Janssen-Pharmaceutica, amp. 5 mcg/ml). The groups will be named according to dose and combination of Levobupivacaine and Fentanyl or Sufentanil that will be given intrathecally as LB8F25 (LB 8 mg, Fentanyl 25 mcg), LB8F35 (LB 8 mg, Fentanyl 35 mcg), LB8S5 (LB 8 mg, Sufentanil 5 mcg), LB8S7 (LB 8 mg, Sufentanil 7 mcg). Hemodynamic and opioid's side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered
2577154|NCT02385539|Placebo Comparator|Levobupivacaine (LB) 12 mg|"Patients will be stratified into three groups by 80 patients: those who will receive 6, 8 or 12 mg of Levobupivacaine intrathecally (Chirocaine, Abbot Laboratories, amp. 5 mg/ml). Patients will receive 12 mg of Levobupivacaine alone intrathecally.~Hemodynamic side effects will be recorded after intrathecal injection. The level and duration of sensory block, time until two-segment regression, T12 regression andl full skin sensory sensibility at the S1 segment will be registered"
2577228|NCT02385201|Experimental|Senza|Subjects with chronic, intractable pain of the upper limbs and/or neck will be implanted with a Senza Spinal Cord Stimulation (SCS) system designed to deliver electrical stimulation to the spinal cord.
2577252|NCT02384668|Active Comparator|Cholecalciferol|Cholecalciferol 70 mcg per day Other name: Vitamin D3.
2577253|NCT02384668|Placebo Comparator|Placebo|"Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.~The placebo regimen is identical to the vitamin D3 regimen."
2577318|NCT02384369|Experimental|SNC-102 sustained release tablet|SNC-102 sustained release tablet for oral administration, 1600 mg BID for 8 weeks
2577325|NCT02384369|Placebo Comparator|Placebo|Placebo tablet for oral administration, BID for 8 weeks
2577357|NCT02384148||Healthy|Healthy volunteers with no inflammation diseases, no neoplasia, no allergy to lidocaine.
2577359|NCT02384148||Type 2 diabetic non obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index 19-30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
2577361|NCT02384148||Type 2 diabetic obese|Type 2 diabetic patients with HbA1c>6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
2577362|NCT02384148||obese|Obese non diabetic patients with HbA1c<6.5%, body mass index >30 kg/m2, no inflammation diseases, no neoplasia, no allergy to lidocaine.
2577363|NCT02383849||Arm 1|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected and TB negative; infant receiving NVP prophylaxis but not TB prophylaxis or treatment
2577364|NCT02383849||Arm 2|Breastfeeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus isoniazid (INH) but not rifampicin (RIF) for TB prophylaxis
2577365|NCT02383849||Arm 3|Breastfeeding infants 7 to 14 days of age with birth weight less than 2500 grams born to HIV-infected mothers not receiving maintenance ARV therapy including NVP; Mother HIV-infected with active TB disease; infant receiving NVP prophylaxis plus INH plus RIF for TB prophylaxis or treatment
2577366|NCT02383849||Arm 4|Breast or formula feeding infants 7 to 84 days of age with birth weight less than or equal to 4000 grams born to HIV-uninfected mothers with active TB disease; infant receiving INH alone or INH plus RIF for TB prophylaxis
2577367|NCT02383849||Arm 5|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than or equal to 4000 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 5 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and not receiving RIF (but may be receiving INH)
2577369|NCT02383849||Arm 6|Breast or formula feeding infants newly diagnosed with HIV infection weighing less than 2500 grams at birth and are less than or equal to 12 weeks of age. Infants who were enrolled in Arms 1, 2 or 3 and later determined to be HIV infected are then are eligible to enroll in Arm 6 if started on an LPV/r regimen. Infants initiating treatment with LPV/r plus 2 NRTIs, and receiving RIF (and may be receiving INH)
2577437|NCT02383784|Experimental|Low-GI diet|Low glycemic index diet
2577440|NCT02383784|Experimental|High-GI diet|High glycemic index diet
2577493|NCT02383290|Experimental|Decision support|This is a feasibility trial so all patients will give a saliva sample and the pharmacist/ Family Physician will use the decision support for generating prescription recommendations
2577528|NCT02382887|Active Comparator|Tracheal intubation with Fiberscopy|tracheal intubation with a fiberscope
2577530|NCT02382887|Experimental|Tracheal intubation with Airtraq|tracheal intubation with an Airtraq
2577590|NCT02382575|Active Comparator|Tacrolimus|Tacrolimus: Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
2577593|NCT02382575|Experimental|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
3210710|NCT00997867|Active Comparator|Catheter 0-1cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 0-1cm past the needle tip. The patient will be called the following day by research staff to assess their post-surgical pain.
2577794|NCT02380976|Experimental|Test 1|First phase: DW330SR+DW1030 7 days after Second phase: DW340
2577796|NCT02380976|Experimental|Test 2|First phase: DW340 7 days after Second phase: DW330SR+DW1030
2577842|NCT02380573|Experimental|Mild Cognitive Impairment (MCI) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577863|NCT02380625|Experimental|Azithromycin|Azithromycin, IV fluids and laboratory testing
2577216|NCT02384980|Experimental|FES + Walk Group|This group of patients will participate in Functional Electrical Stimulation (FES) and exercise. This group will receive functional electrical stimulation as an intervention. The FES device will stimulate (activate) the calf and shin leg muscles of both legs while the patient is walking. This group will also receive standard care, defined as conservative (non-surgical) management of signs and symptoms, including prescriptive medications to improve circulation and manage pain, determined by their attending physician on a case by case basis.
2577300|NCT02384616|Active Comparator|Group High FiO2|Children will receive Fi02 100% during induction of anesthesia until end tidal oxygen concentration (Et 02) of 90% before intubation, anesthesia will be maintained with Fi02 of 80%. Then, shortly before the planned extubation, Fi02 will be increased to 100%.
2577302|NCT02384616|Active Comparator|Group Low FiO2|Children will receive Fi02 80% until Et 02 70% before intubation, anaesthesia will be maintained with Fi02 35%. Then, shortly before the planned extubation, Fi02 will be increased again to 80%.
2577310|NCT02384278|Experimental|Internet-based CBT for alcohol problems|A 12-week internet-based cognitive behavior treatment (CBT) and relapse prevention program. The subjects will have access to a psychologist guiding them through the program.
2577354|NCT02384174|Experimental|Resistant starch (RS)|Resistant starch (RS3)
2577355|NCT02384174|Experimental|Dietary fibre|Dietary fibre (Arabinogalactan, gum guar, pectin)
2577390|NCT02383875|Experimental|Opticourses education intervention|People living in the northern districts of Marseille with in very deprived social situation: very low incomes, heavy financial dependence on social benefits, over-representation of people covered by arrangements for controlling poverty and people covered by free social security
2577604|NCT02382562|Experimental|Brief Behavioral Activation Intervention|All eligible participants will undergo the Brief Behavioral Activation Intervention.
2577678|NCT02382081|Experimental|Patient-initiated shared care|"Patient-initiated shared care hospital reviews in which there were one planed hospital review every year and if needed additional reviews initiated by the patient.~Access to nurse-run telephone helpline with direct access to a contact nurse."
2577681|NCT02382081|No Intervention|Control|Traditional, routine hospital reviews every three-fourth month.
2577735|NCT02381444||Standard of Care|Participants with advanced Parkinson's Disease
2577739|NCT02381444||Levodopa Carbidopa Intestinal Gel|Participants with advanced Parkinson's Disease
2577811|NCT02380872|Active Comparator|Connective tissue graft|Connective tissue graft Soft tissue harvested from palatum of the subjects.
2577814|NCT02380872|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
3210711|NCT00997867|Active Comparator|Catheter placed 5-6cm past needle tip|Patients will be receiving a sciatic (popliteal), femoral, or interscalene nerve block and will be randomized to having the catheter placed 5-6cm past the needle tip. Patients will be called the following day by research staff to assess their post-surgical pain.
2578057|NCT02379325|Experimental|Lets Quit|Given text message
2578060|NCT02379325|Active Comparator|Pamplets education|Given pamplets on smoking and complication
2578084|NCT02379065|Active Comparator|Control nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines. For this arm, nebuliser will be standard of care.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
2578092|NCT02379065|Experimental|Treatment nebuliser treatment|"Both groups will receive the same bronchodilator pharmacotherapy, in keeping with National Institute of Clinical Excellence guidelines4. For this arm, nebuliser will be Aerogen.~Interventions:~Score on the Modified Borg Scale (an interval scale which runs from 0-10, with statements describing level of breathlessness as perceived by the patient) to be completed by both the patient and clinician~Heart rate (as a measure of severity of exacerbation and an indirect measure of salbutamol dosage)~Arterial blood gas changes - pH, pO2, pCO2"
2578171|NCT02378805||no-T: untreated patients|untreated patients, typically uncles or grandfathers of present patients. No Intervention (means no therapy until CKD stage V, on renal replacement therapy)
2578176|NCT02378805||T-III: late therapy in patients|patients treated with RAAS-Blockade after onset of renal failure (GFR below 60 ml/min) (starts at patients with CKD stages III and IV).
2578178|NCT02378805||T-II: early therapy in patients|therapy starts at patients with proteinuria >0.3 g/day or per gCreatinine
2578180|NCT02378805||T-I: very early tharpy in patients|starts at patients with microhematuria only (usually at birth) or microalbuminuria (30-300 mg protein per day or per gCreatinine in children).
2578183|NCT02378805||no therapy in heterozygous carriers|heterozygous carriers without therapy
2578184|NCT02378805||therapy in heterozygous carriers|heterozygous carriers with RAAS-blockade
2578243|NCT02378246|Experimental|Iodine containing multivitamin|multivitamin tablet containing 150 ug iodine, 1 tablet daily
2578244|NCT02378246|Placebo Comparator|Placebo: non-iodine containing multivitamin|non-iodine containing multivitamin, 1 tablet daily
2578311|NCT02377713|Experimental|KHK6640|KHK6640
2578313|NCT02377713|Placebo Comparator|Placebo|Placebo
3210712|NCT00997880|Experimental|Rosuvastatin calcium 40mg|high-dose (40mg rosuvastatin)
3210713|NCT00997880|Active Comparator|Rosuvastatin calcium10mg|low-dose statin (10mg rosuvastatin)
2578589|NCT02376075|Placebo Comparator|Placebo|Placebo, tablets, administered once daily as add on to pre-existing antihypertensive treatment
2578596|NCT02376075|Active Comparator|Linagliptin|Linagliptin, tablets containing 5 mg, administered once daily as add on to pre-existing antihypertensive treatment
2578652|NCT02375711|Experimental|Chronic Renal Failure|Patients with renal failure, with creatinine clearance between 60 and 15 ml/min. A blood sample is achieved at 0, 1, 3 and 6 months.
3210714|NCT00997906|Experimental|Arm I|Patients receive cisplatin IV over 2 hours once weekly on weeks 1-8 and undergo intensity-modulated radiotherapy once daily, 5 days a week, on weeks 1-7 (6½ weeks for a total of 33 fractions).
2577340|NCT02384252||obese patients|patients with BMI > 30
2577345|NCT02384252||no obese patients|norma weight patient (BMI<25) overweight patients ( 25< BMI >30)
2577540|NCT02383407|Experimental|Stimulation group 2 Hz|Patient will be randomized to a stimulation group of 2 Hz using Medtronic deep brain stimulation device
2577541|NCT02383407|Experimental|Stimulation group 5 Hz|Patient will be randomized to a stimulation group of 5 Hz using Medtronic deep brain stimulation device
3176232|NCT00642226|Active Comparator|1|Grid Laser
3176233|NCT00642226|Experimental|2|Vitrectomy in combination with 20 mg triamcinolone
3176234|NCT00642239|Placebo Comparator|2|Concurrent radiochemotherapy and placebo
3176235|NCT00642239|Experimental|1|concurrent radiochemotherapy and Sodium Glycididazole
2577668|NCT02381769|Experimental|Parenteral Nutrition|Soybean based lipid emulsion
2577720|NCT02381171|Sham Comparator|Both Sham rTMS and Neuroacupuncture|Subjects will be randomized to receive 10 sessions of both sham treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMSat 10hHz (1600pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
2577723|NCT02381171|Sham Comparator|Active rTMS and sham Neuroacupuncture|Subjects will be randomized to receive 10 sessions of active rTMS and sham neurofunctional electrical acupuncture treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture without current connection over peripheral region.
2577726|NCT02381171|Sham Comparator|Sham rTMS and Active Neuroacupuncture|Subjects will be randomized to receive 10 sessions of sham rTMS and active Neurofunctional Electrical Acupuncture. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS placebo coil over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
2577728|NCT02381171|Active Comparator|Both Active rTMS and Neuroacupuncture|Experimental Subjects will be randomized to receive 10 sessions of both active treatments. Stimulation will be given on consecutive days (Monday- Friday) for 2 weeks: rTMS at 10 Hz (1600 pulses) over the primary motor cortex area and neurofunctional electrical acupuncture at 1Hz, continuous, 10mA current for 20 minutes over peripheral region.
2577792|NCT02380898|Experimental|Ketorolac|
2577793|NCT02380898|Placebo Comparator|Normal saline 0.9%|
2577903|NCT02380365||Outpatients on the Waiting List and after Lung Transplantation|Electrocardiography
2578002|NCT02380027|Experimental|MRI-arm|Men in this arm will undergo multi-parametric MRI. In the presence of a suspicious area, a man will undergo MRI-targeted biopsy with cores targeted to the suspicious lesion. In the absence of a suspicious area, no biopsy will be taken.
2578005|NCT02380027|Active Comparator|TRUS-biopsy arm|Men in this arm undergo standard 12-core trans-rectal ultrasound guided prostate biopsy
2578085|NCT02379013|Experimental|Volunteer with MRI|All volunteer will be included in the arm MRI
2578165|NCT02378857||Patient group|Adolescents (15-18 years of age) With univentricular heart defects and Fontan type palliation.
2578173|NCT02378857||Control group|Age- and gender-matched healthy individuals
2578351|NCT02377505|Active Comparator|On-Stimulation|"Disease condition is assessed with stimulation turned on"
2578352|NCT02377505|Placebo Comparator|Off-Stimulation|"Disease condition is assessed with stimulation turned off"
2578417|NCT02377115|Other|Study cohort|Tablet computer application
3176236|NCT00642252|Experimental|B|226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
3176237|NCT00642252|Active Comparator|A|ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
3176238|NCT00642265|Experimental|1|operative treatment
3176239|NCT00642265|Active Comparator|2|conservative treatment
3176240|NCT00642291|Experimental|1|Treatment naive pediatric patients (Group 1: ages 3 to 24 months)were to receive emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
3176241|NCT00642291|Experimental|2|Treatment naive or experienced pediatric patients (Group 2: ages 7 to 12 years; Group 3: ages 13-17 years) received emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
3176242|NCT00642317||Asian Youth and Tobacco Control|Smoking Questionnaire for self-identified Chinese or Vietnamese participants.
3176243|NCT00642330|Active Comparator|I|
3176244|NCT00642330|Active Comparator|O|
3176245|NCT00642343|Placebo Comparator|1|Children with severe to profound deafness that have not received any intervention.
3176246|NCT00642343|Active Comparator|2|Children with an unilateral cochlear implant.
3176247|NCT00642343|Active Comparator|3|Children with bilateral cochlear implants.
3176248|NCT00642343|Active Comparator|4|Children who receive their second implant during the duration of the study.
3176249|NCT00642395|Experimental|1|bortézomib
3176250|NCT00642408|Experimental|MMN|multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
3176251|NCT00642408|Active Comparator|IFA|iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
3176252|NCT00642421|Experimental|Population A|Based on the dose of their previous Sandostatin-LAR treatment, Population A will receive 10 or 20 mg of C2L-OCT-01 PR at 5-week intervals.
3176253|NCT00642421|Experimental|Population B|Population B, naive patients and patients who have stopped their treatment with prolonged release octreotide for at least 12 weeks, will receive 20 mg C2L-OCT-01 PR at 5-week intervals.
3176254|NCT00642434|Active Comparator|1|study drug
3176255|NCT00642434|Active Comparator|2|study drug
3176256|NCT00642447|Experimental|1|
2577265|NCT02384915|Active Comparator|peripheral nerve block|Ultrasound-guided sciatic-femoral nerve block injecting 25 ml of a 2% mepivacaine solution,15 ml on femoral nerve and 10 ml on sciatic nerve through a 80 mm 22g eco-reflex needle (Sonoplex, Pajunk, Germany)
3176257|NCT00642486|Active Comparator|1|laboratory-based testing
2577688|NCT02381665|Experimental|Group A|Patient enrolled in this group will receive a device for effective interferential current stimulation.
2577693|NCT02381665|Placebo Comparator|Group B|Patient enrolled in this group will receive a device that does not deliver current stimulation
2577747|NCT02381405|Active Comparator|A|Enterade beverage
2577753|NCT02381405|No Intervention|B|Standard of care
2577785|NCT02381054||Translation and cross-cultural adaptation phase|In this phase 96 Italian-speaking patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the interviewer will elicit participants' feedback regarding item comprehension, symptomatic adverse event terms, attribute terms, 7-day recall period, and response options, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
2577790|NCT02381054||Test-retest phase|In this phase a minimum of 59 Italian-speaking patients who are receiving cancer treatment will be asked to independently complete the Italian version PRO-CTCAE questionnaire on 2 consecutive business days.
3176258|NCT00642486|Active Comparator|2|home-based testing
3176259|NCT00642499|Experimental|1|
3176260|NCT00642499|Placebo Comparator|2|
3176261|NCT00642512|Experimental|1|
3176262|NCT00642512|Active Comparator|2|
3176263|NCT00642512|Other|3|
3176264|NCT00642512|Placebo Comparator|4|
3176265|NCT00642525|Experimental|A|A prospective, blinded, intraindividual controlled study is conducted with patients with transthoracic esophagectomy due to esophageal cancer. A radiographic contrast study is performed prior to endoscopy at the 5th to 7th postoperative day.
3176266|NCT00642538|Experimental|1|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3176267|NCT00642538|Experimental|2|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3176268|NCT00642538|Experimental|3|1.5 mg dose of GLP-1 as MKC253 Inhalation Powder
3176269|NCT00642538|Placebo Comparator|4|TIP (placebo comparison)
3176270|NCT00642538|Active Comparator|5|10 ug subcutaneous control
3176271|NCT00642551|Active Comparator|MK-7|1 capsule per day existing of 180 µg menaquinone-7
3176272|NCT00642551|Placebo Comparator|Placebo|1 placebo capsule per day for three years
3176273|NCT00642564||001|
3176274|NCT00642577|Experimental|1|
3176275|NCT00642577|Active Comparator|2|
3176276|NCT00642590||1|Healthy couples who are planning their first pregnancy.
3176277|NCT00642629|Active Comparator|1|STA-5326 mesylate
3176278|NCT00642629|Placebo Comparator|2|Placebo
3176279|NCT00642681||1: TI Inhalation Powder|Technosphere® Insulin (TI) Inhalation Powder
3176280|NCT00642720|Other|pegvisomant-placebo|patients in this arm received(as addition)for the first 8 weeks Pegvisomant and the later for 8 weeks Placebo. This was divided by a 4 weeks wash-out period.
3176281|NCT00642720|Other|placebo-pegvisomant|Patient received for the first 8 weeks Pegvisomant and after a wash out period of 4 weeks the received 8 of placebo treatment
3176282|NCT00642733|Experimental|1|
3176283|NCT00642785||1|Patients with active oral or genital HSV skin lesions
3176284|NCT00642785||2|Patients with a history of recurrent oral or genital HSV but without an active lesion at the time of treatment
3176285|NCT00642785||3|Patients with active shingles/zoster
3176286|NCT00642785||4|Patients with post herpetic neuralgia
3176287|NCT00642824|Experimental|1|
3176288|NCT00642837||001|
3176289|NCT00642837||002|
3176290|NCT00642837||003|
3176291|NCT00642837||004|
3176292|NCT00642837||005|
3176293|NCT00642837||006|
3176294|NCT00642837||007|
3176295|NCT00642837||008|
3176296|NCT00642837||009|
3176297|NCT00642863|Experimental|Low birth iron|Infants with low birth iron who receive vitamins A and D + iron
3176298|NCT00642863|Experimental|Marginal birth iron 1|Infants with marginal birth iron randomized to receive vitamins A and D + iron
3176299|NCT00642863|Active Comparator|Marginal birth iron 2|Infants with marginal birth iron randomized to receive vitamins A and D without iron
3176300|NCT00642863|Active Comparator|Normal birth iron|Infants with normal birth iron who receive vitamins A and D without iron
3176301|NCT00642863|Experimental|Combined ID|Marginal-birth-iron vitamins only-treated infants who have IDA at 9 mo.
3176302|NCT00642863|Experimental|Early postnatal IDA|Infants with IDA at 9 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks
3176303|NCT00642863|Experimental|Late postnatal IDA|Infants with IDA at 18 months whose cord blood was collected at birth but who were not assessed and assigned to vitamins with or without iron at 6 weeks. These infants were also not anemic when screened at 9 months.
3176304|NCT00642876|Active Comparator|Control|The Control cohort are patients that receive the fusion treatment.
3176305|NCT00642876|Experimental|Investigational|The Investigational cohort are the study patients that received the PRESTIGE® Cervical Disc.
3176306|NCT00642889|Experimental|High Dose|150-200mg/day
3176307|NCT00642889|Experimental|Low dose|50-100mg/day
3176308|NCT00642889|Placebo Comparator|Placebo|
3176309|NCT00642928|Placebo Comparator|Placebo|
3176310|NCT00642928|Experimental|BF 2.649-5 mg|
3176311|NCT00642928|Experimental|BF 2.649 10 mg|
3176312|NCT00642928|Experimental|BF 2.649 20 mg|
3176313|NCT00642928|Experimental|BF 2.649 40 mg|
2577350|NCT02384265|Experimental|IM/SMS + Incentive Condition|"Participants in the intervention condition will consist of the PWD and their two STMs. The PWD and STM will receive the same protocols that the Usual Care participants receive, including an introductory educational session, written materials on diabetes, a blood glucose log, and a physical activity monitoring log. The PWDs in this condition will also receive training in action planning with their STMs. They will also receive SMS messages supporting diabetes self-care from the study team. The study team will also encourage the STMs to interaction in person and via text messages with the PWD."
2577351|NCT02384265|No Intervention|Control|Control group participants will consist of the person with diabetes (PWD) and their two support team members (STM). The PWD will receive regular medical care from their usual providers. They will also receive an introductory educational session and written materials on diabetes, the importance of its control, and diabetes self-care strategies, and a blood glucose and physical activity monitoring log. They will be invited for study visits at 3, 6, and 12 months to measure cholesterol, A1c (for those with diabetes), blood pressure, height, and weight measurement. PWDs and STMs in the control condition will receive generic health promotion information during in-person visits or by mail. They will receive follow-up messages by text to remind them about study related events.
2577398|NCT02383927|Experimental|Cohort 1|Thyroid Cancer
2577403|NCT02383927|Experimental|Cohort 2|Squamous Head and Neck Cancer
2577462|NCT02383368|Experimental|ASP4132 dose escalation|"Subjects will receive a single dose of the study drug on Day -4 (Single-Dose Period), followed by PK sampling prior to Multiple-Dose Period where they will receive the same dose as they received in the Single-Dose Period on one of four schedules:~Continuous - daily dosing for 28 days, Intermittent: Schedule A: 3 days on / 4 days off; Schedule B: 1 days on / 6 days off; Schedule C: 3 days on / 11 days off."
2577465|NCT02383368|Experimental|ASP4132 dose expansion|Subjects in Part 2 will be treated with ASP4132 at the MTD and dosing schedule identified from Part 1.
2577478|NCT02383095|Experimental|Art-therapy|16 Art-therapy sessions
2577481|NCT02383095|Active Comparator|Metacognitive therapy|16 Metacognitive therapy sessions
2577527|NCT02382926|Experimental|contactless heart-, breathing rate, ECG|
2577563|NCT02382666|Experimental|Rolapitant Cohort 1|Investigational Product: Rolapitant Dose 1 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577565|NCT02382666|Experimental|Rolapitant Cohort 2|Investigational Product: Rolapitant Dose 2 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577567|NCT02382666|Experimental|Rolapitant Cohort 3|Investigational Product: Rolapitant Dose 3 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577568|NCT02382666|Experimental|Rolapitant Cohort 4|Investigational Product: Rolapitant Dose 4 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577571|NCT02382666|Experimental|Rolapitant Cohort 5|Investigational Product: Rolapitant Dose 5 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577573|NCT02382666|Experimental|Rolapitant Cohort 6|Investigational Product: Rolapitant Dose 6 administered IV as a 30-minute infusion Dosage Form: 2 mg/mL solution
2577613|NCT02382315|Experimental|Intervention Group|Fear of Cancer Recurrence Intervention.
2577619|NCT02382315|No Intervention|Wait-list Control Group|Patients assigned to this arm will be asked to wait 6 weeks before being offered the fear of cancer recurrence intervention.
2577667|NCT02382068|Experimental|Supportive care (intratympanic dexamethasone)|Patients receive dexamethasone via intratympanic injection in one ear and placebo via intratympanic injection in the other ear. Cisplatin standard of care treatment.
2577702|NCT02381613|Active Comparator|Baked beef|A meal based on baked beef
2577703|NCT02381613|Experimental|Baked herring|A meal based on baked herring
2577705|NCT02381613|Experimental|Pickled herring|A meal based on pickled herring
2577803|NCT02381119|Experimental|Personalized advice|Dietitian provides Personalized dietary advice (based on genetic, blood and food intake profiles) (the type of advice is the intervention)
2577806|NCT02381119|Active Comparator|Regular care|Dietitian provides regular care for diabetes type 2 (regular advice is the control condition)
2577861|NCT02380521|Experimental|60 patients with T2DM|These patients will be treated with exenatide once weekly for a period of 8 months
2577947|NCT02380105|Experimental|Counseling Group|Patients allocated to the counseling group (Group I) were informed about possible etiological factors and educated to not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions, as a way of reinforcing the information provided during the initial consultation. In subsequent returns at 7, 15, 30 and 60 days of follow-up, the instructions were given again and patients were asked whether they had detected any habits related to the initiation and maintenance of painful symptoms of TMD, as a way to further highlight the association between the presence of these harmful behaviors and the worsening signs and symptoms of TMD.
2577949|NCT02380105|Active Comparator|Splint Group|Patients allocated to the splint group (Group II) were treated using interocclusal appliances, according to the following protocol: At baseline, an anterior bite plate (front-plateau) was made from acrylic resin that was placed in the maxillary arch to include the the canine to canine region and promote the disocclusion of the posterior teeth. Patients were instructed to use the device for 24 hours, interspersed with rests of equal length during the first week. After 7 days, the device was removed. A hard splint was then made. At 30 days of follow-up, the splint was fitted and the patients were also asked to use it when they were sleeping.
2578003|NCT02379819|Experimental|Nucleus Hybrid L24 Implant|Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
2578068|NCT02379377|Experimental|Diagnostic (18F-FSPG PET)|Patients undergo an 18F-FSPG PET scan within 4 weeks of surgery or OLT. Patients may also receive a second 18F-FSPG PET scan following standard-of-care treatment.
2578070|NCT02379377|Experimental|Diagnostic (11C-Acetate PET or 18F-FDG PET)|Patients may undergo either carbon-11 (11C)-Acetate PET or 18F-FDG PET scans within 4 weeks of surgery or OLT.
2578113|NCT02378909|Active Comparator|Group 1|Diabetic Neuropathy with electrical stimulation device and standard of care.
2578115|NCT02378909|No Intervention|Group 2|Diabetic neuropathy with standard of care.
2577449|NCT02383602||Retention strategies|In addition to telephone call(s) made within 1 week prior to scheduled visit, participants will receive at least biweekly communications from the study staff in order to establish and maintain a good relationship between participants and study sites. These communications will make use of various social networking tools (for example, Grindr, LINE and/or WhatsApp and/or SMS and/or Facebook and/or electronic mail).
2577506|NCT02383264||feeding intolerance|Development of feeding intolerance, defined as enteral feeding withholding for at least 1 day due to the onset ofgastrointestinal clinical symptoms
2577507|NCT02383264||normal feeding tolerance|no evidence of feeding intolerance during the hospitalization
2577550|NCT02382809|Experimental|DC071 (0.2% chlorhexidine digluconate)|
2577557|NCT02382809|Placebo Comparator|Placebo|
2577607|NCT02382302|Experimental|Telemedicine system|Telemedicine system
2577669|NCT02382094|Experimental|Arm AA(anti-androgen)|Bicalutamide 150 mg per os daily + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
2577670|NCT02382094|Other|Arm TAB (Total androgen blockade)|Bicalutamide 50 mg orally daily + Goserelin 3.6 mg subcutaneously every 28±2 days + if needed Tamoxifen 10 mg against breast tenderness/gynecomasti.
3210715|NCT00997906|Experimental|Arm II|Patients receive induction chemotherapy comprising gemcitabine hydrochloride IV over 30 minutes, carboplatin IV over 1 hour, and paclitaxel IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 3 courses. Beginning at least 3 weeks after the last dose of induction chemotherapy, patients receive cisplatin and undergo radiotherapy as in arm I.
3210716|NCT00997919|Experimental|A|
2577756|NCT02381184|Active Comparator|Clomiphene Citrate group (Group A)|Group A (n =68) assigned to receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
2577759|NCT02381184|Active Comparator|laparoscopic ovarian drilling (LOD) Group B|Group B (n =68) underwent LOD. Laparoscopy was performed under general anesthesia, using three-puncture technique. Each ovary was cauterized perpendicular to its antimesenteric border at four points, each for 4 seconds at 40 W with a mixed current, using a monopolar electrosurgical needle (Karl Storz, ND, Germany). Each puncture was about 4 mm in diameter and 6-8 mm in depth. The ovary was cooled by irrigation with normal saline solution. Any, intraoperative or postoperative complication was reported. The follow-up was started from the next cycle after ovarian drilling up to 6 months
2577797|NCT02380950|Other|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
3210717|NCT00997919|Experimental|B|
3210718|NCT00997945|Experimental|1|ZD4054 (Zibotentan) 10mg
2577969|NCT02379936|Active Comparator|The NeoHilda Point of care method|Evaluating baby including lactate dehydrogenase Levels measured in umbilical core blood using the fast point of care method called Neo Hilda
2577981|NCT02379936|Sham Comparator|No Measurement of LDH|Evaluating baby without Lactate dehydrogenase result
2578054|NCT02379533|No Intervention|sedentary control|
2578056|NCT02379533|Experimental|Home-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. The home-based exercise group exercise at home with telephone follow-up weekly and once a month will be held at the training center under the supervision of a physical education teacher.
2578059|NCT02379533|Active Comparator|Center-based aerobic exercise|The training program will be conducted in accordance with the recommendations of the American College of Sports Medicine. All training sessions will be preceded by stretching of large muscle groups and heating (5 minutes) and at the end by cool down and stretching (5 minutes). The program will consist of 24 weeks with three sessions per week on alternate days. The aerobic training will be continuous, with an increment of 10 minutes in duration every 4 weeks. The intensity will be prescribed according to ventilatory threshold, characterized by the highest intensity of physical exertion fully maintained by aerobic energy pathways. The intensity control was done by means of the heart rate value obtained at ventilatory threshold. However, a group exercise held in the center on a treadmill with the direct supervision of a physical education teacher.
2578098|NCT02379104||Healthy Volunteers|Healthy volunteers fulfilling inclusion/exclusion criteria for reference interval sample group are tested with ROTEM sigma
2578101|NCT02379104||Patients with expected coagulopathy|Patients with expected bleeding and coagulation problems during elective surgery or at the ICU, or trauma patients are tested with ROTEM sigma and ROTEM delta comparatively
3210719|NCT00997958|Experimental|CellCept|Administered in tablet form twice daily one hour after eating.
3210720|NCT00997971|Experimental|Modilac Rose 1|Infant formula with partially hydrolysed rice protein
3210721|NCT00997997||Group 1|
3210722|NCT00998036|Experimental|Temsirolimus, cisplatin, erlotinib|Cisplatin and temsirolimus will be administered weekly on days one and eight of a three week cycle. Erlotinib will be taken by mouth daily.
3210723|NCT00998062||1|Data from epidemiological studies performed after the year 2000 with patients between 35 and 74 years old
3210724|NCT00998075|Active Comparator|1|Esomeprazole 40 mg/ASA 325 mg Fixed Dose Combination Capsule
3210725|NCT00998075|Active Comparator|2|Esomeprazole Clinical Trial Capsule 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3210726|NCT00998075|Active Comparator|3|Esomeprazole MUPS Tablet 40 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3210727|NCT00998088|Experimental|Erythropoietin|
3210728|NCT00998088|No Intervention|Control arm|
3210729|NCT00998088|Experimental|cell saver|
3210730|NCT00998088|Experimental|drain|
3210731|NCT00998088|Experimental|Erythropoietin and cell saver|
3210732|NCT00998088|Experimental|Erythropoietin and drain|
3210733|NCT00998114|Experimental|Exercise and diastolic dysfunction|Aerobic exercise for 30-45 minutes five times a week for six months
3210734|NCT00998153|Experimental|1|RRFT
3210735|NCT00998153|Active Comparator|2|Usual care
3210736|NCT00998166|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Chemotherapy infusion on Day 1 of a 3-week cycle
2577642|NCT02382393|Experimental|BPT, Computerized Assessment|Participants will first take the Brain Performance Test (BPT) and then a third party validated assessment battery.
2577649|NCT02382393|Experimental|Computerized Assessment, BPT|Participants will take a third party validated assessment battery and then the Brain Performance Test (BPT).
2577717|NCT02381834|Experimental|Bladder stimulation technique|This is a two-person technique. A health care aide or nurse (RN) begins by holding the infant under the axillae with its legs dangling. A second RN or physician then performs bladder stimulation by gentle finger tapping on the lower abdomen in the midline just above the pubic symphysis at a frequency of 100 taps/min. If this is unsuccessful after 30 seconds, lower back stimulation in the lumbar paravertebral zone is performed by light massage in a circular motion using both thumbs. This too is performed for 30 seconds maximum. These two manoeuvres are repeated in succession, for a maximum of 5 minutes total, until urination occurs. Unsuccessful attempts at midstream urine collection will be followed by further feeding/fluid administration and bladder catheterization.
2577721|NCT02381210||CLINICALLY CONFIRMED PREECLAMPSIA|Pregnant women with clinical diagnosis of preeclampsia (severe, mild or superimposed) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
2577724|NCT02381210||CLINICALLY HEALTHY|Pregnant women admitted to the hospital for delivery of a healthy normal baby at term (induction of labor or an elective Caesarean Section) will provide a urine sample to determine the presence or absence of proteinuria using the Congo Red Dot test.
2577821|NCT02381106||Women with preeclampsia|Women delivered by cesarian section and with preeclampsia
2577824|NCT02381106||Women with dysfunctional labor|Women delivered with cesarian section due to dtsfunctional labor
2577826|NCT02381106||Women with cesarian section due to maternal request|Women with cesarian section due to maternal request
2577828|NCT02381106||Women with preamture labor|Women with pemature labor undergoing cesarian section
2577868|NCT02380508|Experimental|Group 1|32 BCG-naïve subjects receiving BCG SSI or BCG Sii at standard dose (2-8x10^5 cfu) via Intradermal route.
2577870|NCT02380508|Experimental|Group 2|8-16 control volunteers receiving no vaccination.
3210737|NCT00998179|Active Comparator|Acu-TENS|Application of Acu-TENS prior to exercise
3210738|NCT00998179|Placebo Comparator|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine) prior to exercise
2577970|NCT02379754|Experimental|Gentamicin treated|"Installation of gentamicin in the middle ear 6 weeks prior to surgery + rehabilitation exercises before and after both treatment and surgery.~Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board."
2577983|NCT02379754|No Intervention|Non-gentamicin|Rehabilitation exercises before and after surgery. Rehabilitation exercises are not considered to be an intervention since their benign impact on vestibular/postural compensation is well documented, and exclusion from exercises would not be approved by the ethical board.
3210739|NCT00998218|Experimental|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) for 4 weeks
3210740|NCT00998218|Placebo Comparator|Sugar pill|Placebo comparator BID for 4 weeks.
3210741|NCT00998231|Active Comparator|Major Depressive Episode (MDE)|20 subjects with major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
3210742|NCT00998231|Active Comparator|Control|20 subjects without major depressive episode will be included and followed during a 6 months interval which includes 4 visits (at the inclusion, 2 and 8 weeks later and finally 6 month later)
3210743|NCT00998244|Experimental|Very Low Carbohydrate Diet|Very Low Carbohydrate Diet
3210744|NCT00998244|Active Comparator|Low Fat Diet|Low Fat Diet
3210745|NCT00998257||Group 1|
3210746|NCT00998270|Active Comparator|Autologous arm|
3210747|NCT00998270|Experimental|Allogeneic arm|
2578222|NCT02378194|Placebo Comparator|Placebo group|
2578224|NCT02378194|Experimental|HD-003 (800mg/day)|
2578228|NCT02378194|Experimental|HD-003 (1600mg/day)|
2578299|NCT02377999|Experimental|Treatment of genetial warts with Picato|
2578401|NCT02377258||5|patients on vedolizumab (1 on vedolizumab alone and 1 on combination therapy)
2578403|NCT02377258||6|patients on ustekinumab (alone or on combination therapy)
2578453|NCT02376803|Active Comparator|Evening warfarin ingestion|Patients continue taking warfarin in the evening as per their usual routine.
3210748|NCT00998283|Experimental|Cohort 1|Administration of HM10460A 5μg/kg or Placebo
3210749|NCT00998283|Experimental|Cohort 2|Administration of HM10460A 15μg/kg or placebo
3210750|NCT00998283|Experimental|Cohort 3|Administration of HM10460A 45μg/kg or placebo
3210751|NCT00998283|Experimental|Cohort 4|Administration of HM10460A 135μg/kg or placebo
3210752|NCT00998283|Experimental|Cohort 5|Administration of HM10460A 350μg/kg or placebo
3210753|NCT00998348|No Intervention|Comparison Group|The comparison group will receive children's picture books (1 per month for the duration of the 8-month program).
3210754|NCT00998348|Experimental|Parenting Program|The parenting program is an 8-month obesity prevention intervention for parents with preschool-age children.
3210755|NCT00998361|Experimental|Stem Cell Transplant|All the patient who are affected by refractory or resistant or relapsed Soft tissue sarcoma o Ewing sarcoma who find an HLA compatible allogeneic donor and are submitted to Stem cell transplantation
3210756|NCT00998387||medical ICU|admitted to medical ICU at Seoul National University Hospital longer than 24 hours
3210757|NCT00998413|Experimental|Multifaceted intervention|Multifaceted intervention:physical exercise, nutrition, and behavioural intervention.
3210758|NCT00998413|No Intervention|Control|standard usual care
3210759|NCT00998439|Experimental|Paclitaxel coated balloon catheter|
2577512|NCT02383004|No Intervention|No Acupuncture (Standard of Care)|"If needed, the patient will receive a standard does of oral midazolam (0.5 mg /kg or less, up to 15mg) plus acetaminophen 12.5 mg/kg (V group). If the patient does not require premedication with midazolam, oral acetaminophen 12.5mg/kg will be given alone (NV group).~Induction of anesthesia by mask ventilation with sevoflurane in 50% nitrous oxide mixed with 50% oxygen. Sevoflurane will be incrementally titrated from 0% up to 8%. Nitrous oxide will be discontinued after induction. Anesthesia will be maintained with sevoflurane in an oxygen/air mixture. Sevoflurane concentration will be titrated to maintain the adequate depth of anesthesia. Prior to leaving the operating room, a dose of ketorolac 0.5mg/kg will be given intramuscularly."
2577535|NCT02382757||Children|
2577599|NCT02382549|Experimental|6MHP and dabrafenib and trametinib|"The vaccine drug product, 6MHP, consists of 6 class II MHC-restricted peptides derived from melanoma proteins. Each vaccine consists of 200 mcg of each of the six peptides. An aqueous solution of vaccine is mixed 1/1 with Montanide ISA-51 to form water-in-oil emulsions. Vaccines are administered days 1, 8, 15, 36, 57, 78. All peptide vaccines are administered intradermally and subcutaneously.~Dabrafenib is a small molecular BRAF inhibitor and will be administered in accordance with the prescribing information: 150 mg orally twice daily taken at least 1 hour before or at least 2 hours after a meal; the doses will be approximately 12 hours apart. Trametinib is a small molecular MEK1 and MEK2 inhibitor and will be administered in accordance with the prescribing information: 2 mg orally once daily taken at least 1 hour before or at least 2 hours after a meal. The medication will be taken at the same time each day with either the morning or evening dose of dabrafenib."
2577777|NCT02381379|Active Comparator|Peginterferon-α-2a (Pegasys®)|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year
2577782|NCT02381379|No Intervention|Observation|Stop tyrosine kinase inhibitor that was on and no active medication that might affect CML, for example any immune-modulatory agents, traditional herbs or medications, chemotherapeutic agents, growth factors, or colony stimulating factors is allowed during the trial period.
2577820|NCT02380729||Index patients|"Children between birth and 18 years of age manifesting with a suspected genetic disorder.~Investigation: First Gene Panel Sequencing and if no mutation ist found > Whole Genome Sequencing (WGS)"
2577823|NCT02380729||Parents of the index patient|"Both parents of the index patient.~Investigation: Whole Genome Sequencing (WGS) if no mutation is found by Gene Panel Sequencing of the index patient."
2577882|NCT02380417||Single lung transplant paravertebral catheter placement|Those patients who underwent single lung transplant either right or left.
2577884|NCT02380417||bilateral lung transplant paravertebral catheter placement|those patients who underwent bilateral lung transplantation
2578042|NCT02379598||Amino acid based formula|
2578045|NCT02379598||Whey protein formula|
2578160|NCT02378896|Experimental|CBT + Personalized Computer Program|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy and training with a personalized computerized inhibitory training program
2578231|NCT02378493||Exposure: Concordance between tests|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients whose antibiogrammes and Antibiofilmogrammes are concordant will fall into this group (the exposed group).~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
2578233|NCT02378493||Non exposure: Not concordance between tests.|"The study population is composed of diabetic patients with foot wounds (at least stage >=2) that are infected by at least 1 strain of S. aureus. Patients who do not fall into the concordance (exposure) group, will fall into the non exposure group. The latter includes semi-concordance or discordance between antibiogrammes and Antiobiofilmogrammes.~Upon inclusion, 1) all patients' wounds will be sampled, and 2) the associated bacterial strains identified via Vitek and 3) antibiograms performed; the latter are all part of routine procedure. 4) S. aureus isolates will be further analysed via an antiobiofilmogramme, which is an experimental element added by this research. At the end of the 1st regimen of antibiotics prescribed, if the treatment failed steps 1 to 4 can be repeated. 30 days after the end of the 1st regimen of antibiotics prescribed, steps 1 to 4 are systematically performed."
3210760|NCT00998439|Active Comparator|uncoated balloon catheter (POBA)|
2578381|NCT02377154|Other|Opthalmologically healthy individuals|Slit lamp, Autorefractor, IOLMaster 500, Pentacam HR, LenStar LS900, VERION Image Guided System
2578488|NCT02376452|Experimental|RALIRI|Raltitrexed combined with irinotecan
2578500|NCT02376452|Placebo Comparator|FOLFIRI|5-fluorouracil,folinate combined with irinotecan
2578551|NCT02376101|Active Comparator|Standard ETT size|Their tracheas will be intubated with an appropriately sized ETT using the standard formula. The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
2578554|NCT02376101|Experimental|ETT one size smaller|Their tracheas will be intubated with an ETT that is one size smaller (instead of a 5.0 ETT, we would use a 4.0 ETT). The cuff will be inflated to achieve a seal by the air-leak test when holding CPAP of 20 cmH2O and the intracuff pressure will be measured using a manometer.
2578749|NCT02374853|Placebo Comparator|Control|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
2578819|NCT02374281|Experimental|Glucose sucking|"The newborn will receive one minute before the painful care either a compress with sucrose.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Glucose 30% by oral route (1 ml)."
2577516|NCT02383225|Experimental|Condition B|FaceBook supplement; no Lakota language enhancement; no Substance Use resistance skills
2577520|NCT02383225|Experimental|Condition C|Lakota language enhancement; no FaceBook supplement; no Substance Use resistance skills
2577522|NCT02383225|Experimental|Condition D|Lakota language enhancement; FaceBook supplement; Substance Use resistance skills
2577547|NCT02382653|Other|oral perixicam|50 patients with Breakthrough pain will receive oral prioxicam for treament of breakthrough pain.
2577552|NCT02382653|No Intervention|oral fentanyl|50 patients with Breakthrough pain will receive sublingual fentanyl for treament of breakthrough pain.
2577614|NCT02382471|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
2577618|NCT02382471|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3210761|NCT00998452|No Intervention|MOVE!|Participants will receive the usual VA MOVE! Program. These elements include a baseline assessment, brief clinic counseling session about weight, printed targeted health information on weight management and behaviors, and opportunities to participate in group sessions at the VA site and telephone follow-up from MOVE! clinic staff.
2577848|NCT02380768|Experimental|Ambu AuraGain|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
2577852|NCT02380768|Active Comparator|LMA Supreme|Subjects will receive the Ambu AuraGain size 1.5 or 2.0 based on manufacturer guidelines
2577936|NCT02380274||Patients with CRPC|Patients with CRPC
2578067|NCT02379312|Active Comparator|Very low energy aerated beverage|Very low energy aerated beverage
2578069|NCT02379312|Active Comparator|Normal energy aerated beverage 1|Normal energy aerated beverage 1
2578071|NCT02379312|Active Comparator|Normal energy aerated beverage 2|Normal energy aerated beverage 2
2578072|NCT02379312|Active Comparator|Normal energy aerated beverage 3|Normal energy aerated beverage 3
2578120|NCT02378987||Typical developmental children|Normal children
2578121|NCT02378987||CP children with GMFCS level I and II|Children with CP were classified into Levels I-II based on the Gross Motor Function Classification System (GMFCS).
2578122|NCT02378987||CP children with GMFCS level III and IV|Children with CP were classified into Levels III-IV based on the Gross Motor Function Classification System (GMFCS).
2578153|NCT02378623|Active Comparator|Apixaban|Intervention group: Apixaban 5 mg by mouth two times daily in addition to usual medical therapy (or 2.5 mg two times daily for subjects who fulfilled any 2 of the following criteria: age≥80 years, body weight≤60kg, and/or serum creatinine≥1.5 mg/dL). Planned treatment duration is 2 years
2578154|NCT02378623|Placebo Comparator|Placebo|Control group: Matched placebo by mouth two times daily in addition to usual medical therapy. Planned treatment duration is 2 years.
2578370|NCT02377271|Experimental|Bosentan|Bosentan at a dose of 125 mg two times daily, will be administered orally, twice a day, during eight weeks
2578376|NCT02377271|Placebo Comparator|Placebo|placebo drug , twice a day, during eight weeks
2578483|NCT02376647|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation (≤13cmH2O)
2578496|NCT02376647|Active Comparator|Conventional ventilation|Mechanical ventilation with limited tidal volume (8mL/kg of predicted body weight) and plateau pressure (≤30cmH2O)
2578686|NCT02375243|Experimental|cases|children who receive midazolam 0.05 mg/kg/h + morphine 10 mcg/kg/h + dexmedetomidne 0.5 mcg/kg/h. Midazolam in administered until extubation, while morphine and dexmedetomidine are administered until removal of surgical drains.
2578687|NCT02375243|No Intervention|controls|standard care: children who receive midazolam 0.1 mg/kg/h + morphine 20 mcg/kg/h. Midazolam in administered until extubation, while morphine is administered until removal of surgical drains.
2578762|NCT02375048|Active Comparator|Hypofractionated WBI|Patients treated with hypofractionated Whole Breast Irradiation received Simultaneous Integrated Boost irradiation of the whole breast and surgical bed at two different dose levels using external intensity - modulated radiotherapy (VMAT RA).
2578767|NCT02375048|Experimental|Accelerated Partial Breast Irradiation|Patients treated with Accelerated Partial Breast Irradiation received the irradiation on surgical bed using external intensity - modulated radiotherapy (VMAT RA).
2578834|NCT02374424|Experimental|GA101_DHAP|"Patients receive: GA101-DHAP x 2, restaging, mobilization and collection of peripheral blood stem cells, + GA101-DHAP x 2, restaging with PET and CT and consolidation with BEAM and ASCT in patients in response (CR+PR).~During the treatment period of four cycles, all patients will receive a total of four 28-day courses of chemotherapy."
2578909|NCT02373891|Experimental|T1|
2578912|NCT02373891|Experimental|T0|
2578936|NCT02373683|Experimental|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
2578937|NCT02373683|No Intervention|Standard Care|Care dictated by clinical team.
2578981|NCT02373397|Experimental|Cacicol20|Instillation of Cacicol20 eye drops after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
2578983|NCT02373397|Placebo Comparator|Placebo|Instillation of placebo eye drops (vehicle missing the active ingredient) after laser corneal surgery. 3 eye drops total, to be given once immediately after surgery, once 2 days after surgery, and a final time 4 days after surgery.
2579015|NCT02373033|Active Comparator|Intervention: Natural food folate|Food group consumed folate-rich foods (providing additional 250 μg/d folate).
2579017|NCT02373033|Active Comparator|Intervention: Folic acid|Folic acid group received a folic acid supplement (providing additional 500 μg/d folic acid).
2579019|NCT02373033|Placebo Comparator|Intervention: Control|Control group received apple juice containing no folate or folic acid every day.
2579134|NCT02372643|Other|Sexually healthy women|20 sexually healthy volunteer women will be enrolled from subjects consulting our outpatient clinic (subjects free from sexual dysfunction). Hormonal and ultrasound parameters and self-administered questionnaires will be evaluated.
2579202|NCT02372019|Experimental|CBM With Active Fear Reactivation|
2579203|NCT02372019|Active Comparator|CBM With Inert Fear Reactivation|
2577517|NCT02382952|Experimental|Differential Dissector|For patients in the study device group, blunt dissection will be performed with the Differential Dissector whenever the surgeon believes its use is appropriate.
2577519|NCT02382952|Active Comparator|Standard Dissection Method|For patients in the control group, blunt dissection will be performed by standard method.
2577542|NCT02382718|Experimental|FAST fish mCyp c 1|"Subcutaneous injections of investigational medicinal product mCyp c 1 formulated in a solution (suspension) with aluminium.~Up-dosing (build-up) phase: each subject will receive 10 injections of active or placebo treatment. The first three injections will be given on the first day. For those on active treatment the dosing will begin at 6ng and conclude on week 8 with the administration of 60μg.~Maintenance phase: the maintenance dose of 60μg will be repeated once at two weeks and then monthly for a period of four months (four monthly injections)."
2577545|NCT02382718|Placebo Comparator|Placebo|Subcutaneous injections of exactly the same dosage, frequency and duration as Active Arm but all injections will be performed with placebo (has the same composition as the active drug suspension but no allergen mCyp c 1 is added).
2577645|NCT02382367|Experimental|Pulmonary emphysema|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
2577686|NCT02381951|Experimental|Spinal cord stimulation|
2577746|NCT02381457||Pregnancies undergoing prenatal microdeletion screening|"Pregnant women undergoing non-invasive prenatal screening for microdeletion and aneuploidy syndromes.~No drug will be administrated, this cohort will undergo a non invasive prenatal blood test and then follow up data and specimens will be collected for research analysis."
2577813|NCT02380885|Experimental|SCIT|Social Cognition and Interaction Training: psychosocial group intervention
2577815|NCT02380885|Experimental|TAFT|Therapeutic Alliance Focused Therapy
2577817|NCT02380885|No Intervention|TAU|Treatment as Usual
2577941|NCT02380443|Experimental|Dosing Schedule A|"The priming step with ID injections of AlloStim on Days 0, 7, and 14~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 21~The activation step with IV infusion of AlloStim on Day 28~The booster step with two IV booster infusions of AlloStim on Days 56 and 84~Protocol follow-up procedures continue until day 112. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
2577943|NCT02380443|Experimental|Dosing Schedule B|"The priming step with ID injections of AlloStim on Days 0, 3 and days 7 and 10~The vaccination step with cryoablation and IT (intratumoral) injection of AlloStim on Day 14~The activation step with IV infusion of AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
2577944|NCT02380443|Experimental|Dosing Schedule C|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~IV AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
2577945|NCT02380443|Experimental|Dosing Schedule D (reducing dose)|"The priming step with ID injections of AlloStim on Days 0, 3, 7, 10 and day 14~IV AlloStim on Day 21~The booster step with two IV booster infusions of AlloStim on Days 49 and 77~Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up Protocol follow-up procedures continue until day 105. Efficacy evaluation will continue monthly for each subject until death or loss to follow-up"
2577980|NCT02379767||Patients|Subjects aged between 18 and 60 years suffering from unipolar severe depression, who did not respond to conventional pharmacological antidepressant treatment (at least two adequate trials with antidepressants of different pharmacological classes over a minimum period of one month, equivalent to 150mg of tricyclic antidepressants). Concomitant psychotropic medication will be accepted during study participation, however, medication should remain stable throughout the study. Patients will undergo 6 to 14 ECT sessions in accordance with recent consensus statements and based on standard operation procedures (SOPs) of the Department of Psychiatry and Psychotherapy.
2577990|NCT02379767||Healthy subjects|Subjects will be age- and sex-matched to the patients and should present no psychiatric, or major neurological or internistic illness.
2578034|NCT02379507|Experimental|DEC033 Study Product|Apply twice a day
2578163|NCT02378831||PSG and WatchPAT200 in subjects age12-17|Adolescents refered to a sleep lab for sleep lab for full night PSG
2578225|NCT02378532|Experimental|Radiotherapy/Temozolomide + Chloroquine|"Eligible patients will receive radiotherapy and chemotherapy according to standard protocol for newly diagnosed GBM.~Chloroquine will be escalated in 3 dose-levels (200mg, 400mg and 600mg) up each containing a minimum of 3 and a maximum of 6 patients. Based on the results of the DSMB, an additional level of 300mg was added."
2578274|NCT02377960|Active Comparator|Usual care (Reference group)|Treatment is leaded by treating physician according to national guide lines with no study-specific medication or clinical appointment protocol.
2578277|NCT02377960|Experimental|An IMB model-based initiation of medication|"In addition to usual care, participants allocated to intervention group will receive~An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time"
2578281|NCT02377960|Experimental|Tailored SMS-text message support|"Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication.~After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments."
2578334|NCT02377492|Experimental|Paracervical & Intramyometrial|Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
2578335|NCT02377492|Active Comparator|Intramyometrial|Vasopressin will be placed intramyometrial (16mL, 8 units)
2578384|NCT02377258||1|without previous or ongoing exposure to IS or biologics, (5ASA and Steroids are allowed)
2578387|NCT02377258||2|with on-going anti-TNF monotherapy
2578394|NCT02377258||3|with thiopurines monotherapy
2577546|NCT02382731|Experimental|Usual care + letters|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians)
2577551|NCT02382731|Experimental|Usual care + letters + automated calls|Usual care plus a series of postal educational reminders (including information for patients to share with clinicians), plus automated reminder interactive voice response phone calls to identify patients at being at risk for non-adherence and a trained lay health worker to provide additional support and navigation for such patients via telephone.
2577615|NCT02382458|Experimental|Lifestyle intervention|Participants will receive a year-long comprehensive, dietary, exercise, and stress management intervention. They will be asked to bring a partner of their choosing with them for support. The intervention will include a behavioral program to reduce inflammation.
2577622|NCT02382458|Active Comparator|Information intervention|Participants will receive a year-long intervention that will involve receiving weekly (for the first 3 months) and then monthly (for the following 9 months) newsletters on cancer prevention and control (via e-mail or mail) that will provide the participant with information about cancer prevention and control strategies.
2577673|NCT02382029|Active Comparator|clonazepam|Twenty two patients took clonazepam two times a day (0.5 mg) in the morning and after two weeks one tablet (0.5 mg) in the morning and another tablet (0.5 mg) in the evening during the next two weeks.
2577674|NCT02382029|Experimental|acupuncture|"Traditional Chinese acupuncture was performed on 20 participants 3 times during one week for four weeks. Intervention was performed on acupuncture points as follows: the points ST 8 (stomach- tou wei), GB 2, TE 21, SI 19 (small intestine- ting gong), SI 18 (small intestine- quan liao), LI 4 (large intestine-Yuan) on both sides of the body as well as GV 20 (Governing vessel-bai hui).~Each session lasted half an hour. Sterile acupuncture needles made from surgical stainless steel silicone coated with spring handle were used. The dimensions of the chosen needles were 0.25 in diameter and 30 mm length, inserted at the depth of the 0.5-1 cm. The elicited response was of the type de qi accompanied by redness and a feeling of numbness around the needles."
2577788|NCT02381080|Experimental|Part 1: Ibrutinib+Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 milligram (mg) (4*140 mg capsules) once daily (QD) from Days 1- 4; on Days 5-11 ibrutinib 140 mg capsule QD in combination with erythromycin 500 mg tablet 3 times daily (TID); on Days 12-13 ibrutinib 140 mg capsule QD; on Days 14-18 ibrutinib 560 mg (4*140 mg capsules) QD; on Days 19-25 ibrutinib 140 mg capsule QD in combination with voriconazole 200 mg tablet twice daily (BD); on Days 26-27 ibrutinib 140 mg capsule orally QD; and on Day 28 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
2577791|NCT02381080|Experimental|Part 2: Ibrutinib+ Erythromycin+Voriconazole|Participants will receive oral treatment in six, 28-days cycles. In Cycle 1, participants will take ibrutinib 560 mg (4*140 mg capsules) QD from Days 1- 4; on Days 5-18 ibrutinib 560 mg (4*140 mg capsules) QD in combination with either erythromycin 500 mg tablet TID (Group 1) or voriconazole 200 mg tablet BD (Group 2); on Day 19 and in subsequent treatment Cycles (2-6) participants will continue oral treatment with ibrutinib 420 mg or 560 mg QD (depending on the subtype of B-cell malignancy).
2577869|NCT02380534|Experimental|active procedure|High cardiovascular risk patients will undergo H.E.L.P. apheresis.
3210762|NCT00998452|Active Comparator|MOVE*VETS|Participants will receive the same MOVE! program as the control group plus 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from volunteer veteran peer counselors.
2577966|NCT02379871|Experimental|Experimental Group|While lying in supine, subjects will receive a single posterior to anterior directed spinal manipulation to the mid-thoracic region (T4-5).
2577976|NCT02379871|Sham Comparator|Sham Group|Sham group will procedures will be identical with the exception of the spinal manipulation intervention. Sham shall not receive the spinal manipulation intervention.
2578061|NCT02379624|Placebo Comparator|EN group|5% glucose at a rate of 25 mL/h was given at day 1, followed with initial amount of EN (31.25g peptisorb dissolved in 250ml water) at 12.5 mL/h on day 2. From day 3 to day 6, the prescription is EN (62.5g peptisorb dissolved in 250ml water) at 12.5 mL/h. Since day 7, EN was began to advance to goal energy target as quickly as possibl
2578064|NCT02379624|Experimental|PEC/EN group|An additional amount of pectin was added 4 hours ahead of EN given from day 2 to day 6 (24g everday). Since day 7, EN was advanced to goal energy target as the same step
3210763|NCT00998465||Obese, hypertension|Obese patients with hypertension and a body mass index 40-50 kg/m2
3210764|NCT00998465||Control|Control subjects without hypertension and body mass index < 30 kg/m2
3210765|NCT00998465||Obese, normotension|Obese patients without hypertension and a BMI between 40-50 kg/m2
2578169|NCT02378675||GDM (2)|Adipocytokine levels of patients suffering from GDM are compared to healthy pregnant women
2578189|NCT02378649|Experimental|Sildenafil|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
3210766|NCT00998478|Experimental|Activity prescription|
3210767|NCT00998478|No Intervention|Normal Curriculum|Followed normal curriculum including physical education
3210768|NCT00998504|Placebo Comparator|placebo|starch pill
3210769|NCT00998504|Active Comparator|resVida|synthetic pill containing 75 mg of resveratrol
3210770|NCT00998530||African American HIV+|African American women with HIV and infected with Trichomonas
3210771|NCT00998530||Caucasian HIV-|Caucasian women who are HIV negative and infected with Trichomonas
3210772|NCT00998530||African American HIV-|African American women who are HIV negative and are infected with Trichomonas
3210773|NCT00998543||Smallpox Vaccine (LISTER Strain) Group|Participants were vaccinated with the second-generation smallpox vaccine in Study VVL04 (NCT 00258947).
3258960|NCT01466140|Experimental|Use of request card|Patients in the intervention group were told that the practice was participating in a patient satisfaction study, and they were given an envelope with information about the 'doorknob phenomenon' and a request card. The envelope for the control group only consisted of information about a patient satisfaction study, without any information on the 'doorknob phenomenon', and without a request card. Both groups received the same letter with patient information about the study.
2577548|NCT02382783|Other|FLARE Intervention Group|"In the FLARE Intervention Group, we ask that you participate in all of the following, over the course of two years:~Baseline Study Visit~Monthly: Complete FLARE Questionnaires, at home, and report results. The last question on this questionnaire will ask you if you feel you are having a flare of your disease.~FLARE Study Visit (if applicable): We will schedule you to be seen when/if you feel you are having a flare of your disease.~Follow-up Visits (minimum of every 6 months): These are done as the standard of care for your RA.~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
2577554|NCT02382783|No Intervention|Standard of Care (SOC) Group|"If you are randomized to the SOC Group, your care will not be any different than your usual care of rheumatoid arthritis (RA). You will be seen by a rheumatologist at a minimum of every six months, which is the standard of care for RA.~Additionally (for research), we ask the following of you...~At one time-point, during your first return visit after the baseline visit you will have an examination by ultrasound~Patient Satisfaction Surveys at three time-points: Baseline, 1 year, 2 year~Also, your rheumatology health care provider (RHCP) will be asked to participate in the study by completing three satisfaction surveys over the course of two years."
2577635|NCT02382432|Active Comparator|Pethidine 0.4mg/kg iv|interventional: Pethidine 0.4mg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
2577639|NCT02382432|Active Comparator|DEX. I|Interventional:Dexmedetomidine (Precedex) 0.5µg/kg intravenous bolus once to be repeated if shivering incompletely abolished.
2577643|NCT02382432|Active Comparator|DEX. II|Interventional: Dexmedetomidine (PRECEDEX) 0.3µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
2577648|NCT02382432|Active Comparator|DEX III|Interventional: Dexmedetomidine (PRECEDEX) 0.2µg/kg intravenous bolus given once to be repeated if shivering incompletely abolished.
2577676|NCT02381821||pregnant|women undergoing ICSI who became pregnant
2577677|NCT02381821||Not pregnant|women undergoing ICSI who fail to achieve pregnancy
2577725|NCT02381548|Experimental|Treatment (belinostat, WEE1 inhibitor AZD1775)|Patients receive belinostat IV over 30-90 minutes QD on days 1-5 and 8-12 and WEE1 inhibitor AZD1775 PO QD on days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Responding patients with CR, CRi, CRc, or CRm and do not go on to have stem cell transplant may only continue treatment for 3-4 additional courses after response.
2577798|NCT02380937|Experimental|ablation for typical atrial flutter|This group receives an MR-guide ablation for atrial flutter with the study device (catheter)
2577838|NCT02380638|Experimental|DS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
2577843|NCT02380638|No Intervention|DS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
2577847|NCT02380638|Experimental|NONDS-WBV|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform squat on a vibratory platform (3 times per week; 10 repetitions 30 to 60 seconds; Frequency: 25-30 Hz; Amplitude: 2 mm).
2577851|NCT02380638|No Intervention|NONDS-NONWBV|This group will continue with their day-to-day lifestyle during the course of the project.
2577932|NCT02380326||Lung transplant recipients|Lung transplant recipients with diffuse parenchymal abnormalities subjected to advanced endoscopic imaging modalities
2577934|NCT02380326||Diffuse intersitial lung disease|Patients suffering from diffuse intersitial lung disease without a certain diagnosis subjected to advanced endoscopic imaging modalities
2577977|NCT02379897|Experimental|LowGI+ModCarb|Low glycemic index + moderate carbohydrate/moderate fat diet
2577988|NCT02379897|Experimental|LowGI+HighCarb|Low glycemic index + high carbohydrate/low fat diet
2577993|NCT02379897|Experimental|HighGI+ModCarb|High glycemic index + moderate carbohydrate/moderate fat diet
2577996|NCT02379897|Experimental|HighGI+HighCarb|High glycemic index + high carbohydrate/low fat diet
2578021|NCT02379559|Experimental|Exercise Group|Eligible participants randomized into the intervention group will receive a mix of supervised moderate-intensity aerobic and light weight-resistance exercises.
2578022|NCT02379559|Active Comparator|Attention Control Group|Eligible participants randomized in the attention control group will be asked to maintain their current daily activities and exercise habits for 6-months.
2578055|NCT02379364|Experimental|Intervention group|Diacutaneous Fibrolysis treatment
3260272|NCT01477775|Experimental|Customized choice of the oral P2Y12 receptor blocker|The choice of the oral P2Y12 receptor blocker will be based on an algorithm which integrates phenotype information, including but not limited to residual on-treatment platelet reactivity assessed via Verifynow P2Y12 assay.
2578286|NCT02377856|Active Comparator|intervention|40 patients will receive pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks combination treatment, followed by 24 weeks of follow-up. 'pegylated interferon alpha 2a, ribavirin'
2578290|NCT02377856|No Intervention|observation|40 patients without treatment will be followed for the clinical course for 1.5 year
2578330|NCT02377635|Experimental|Treatment|Drug: Anhydrous selenite (Se-77), single dose 0.8mg, orally administered as a 100 ml purified water solution
2578331|NCT02377635|Placebo Comparator|Control|Drug: Placebo sodium chloride (table salt), orally administered as a 100 ml purified water solution
2578460|NCT02376777||Patient receiving NOAC|Follow up of patients receiving new oral anticoagulants (NOAC) medication
2578461|NCT02376777||Patient receiving VKA|Follow up of patients receiving vitamin K antagonist (VKA) medication
2578557|NCT02376374|Experimental|10% OPV|In this arm, 10% of the households in this community will receive OPV.
2578560|NCT02376374|Experimental|30% OPV|In this arm, 30% of the households in this community will receive OPV.
2578562|NCT02376374|Experimental|70% OPV|In this arm, 70% of the households in this community will receive OPV.
2578586|NCT02375854||Preterm infants|Less than 32 weeks' gestation
2578832|NCT02374385|Experimental|Group 2|5x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
2577561|NCT02382835||Other Hip Replacement|Other types of hip replacement, such as metal-on-polyethylene or ceramic-on-ceramic
2577588|NCT02382484|Experimental|Treatment|"The study was a single arm, unblinded, treatment only study. Each patient served as his or her own control.~Treatment delivered by a dual chamber pacing system (BackBeat Medical) which was able to generate stimulating patterns with characteristics that are different than the common pacemaker.~The study was limited to hypertensive patients who were also already scheduled to undergo an invasive electrophysiology procedure."
2577644|NCT02382237|Other|PET/TDM|Evaluation by PET/TDM at 2 times
2577779|NCT02381509||IVC Filter|IVC filter for the prevention of PE
2577919|NCT02380378||Myeloproliferative Neoplasms|Patients diagnosed with Myeloproliferative Neoplasms based on WHO 2008 criteria.
2577968|NCT02380053|Experimental|Bisoprolol|2.5mg once daily for 2 weeks then 5mg once daily for 2 weeks.
2577984|NCT02380053|Experimental|Celiprolol|200mg once daily for 2 weeks then 400mg once daily for 2 weeks.
3210774|NCT00998556|Experimental|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks, thereafter the patients continue to be observed in the follow-up part of the study up to month 6. The study medication is taken on top of standard therapy for heart failure. Part of this therapy are ACE inhibitors. ACE inhibitors are potentially harmful for the baby when getting into the breast milk, as bromocriptine stops milk production, no additional drug is needed.
3210775|NCT00998556|No Intervention|Control Group|The control group will receive standard therapy for heart failure. Part of this therapy are ACE inhibitors. Since ACE inhibitors are potentially harmful for the baby when getting into the breast milk, it is necessary to stop lactation in the control group as well.To stop lactation, application of bromocriptine (2.5mg/day) for up to one week.
3210776|NCT00998569|Experimental|Neurocognitive Enhancement|neurocongnitive enhancement
3210777|NCT00998569|Other|Wait List|no intervention
2578239|NCT02378181|Experimental|Toolkit (TK)|Patients in the TK condition will receive counseling sessions from participating counselors who have been trained to use the Health Education Toolkit (TK).
2578242|NCT02378181|Active Comparator|Treatment-as-usual (TAU)|Patients in the treatment-as-usual (TAU) condition will receive the same number of counseling sessions as patients in the TK condition from participating counselors who have not been trained to use the Health Education Toolkit. Counselors working with patients in this condition will receive a control training of the same length and intensity on recovery topics that are covered in the Health Education Toolkit, but will not be equipped with the Toolkit.
2578415|NCT02377024|Experimental|TF 600mg|TF 600mg/day
2578416|NCT02377024|Experimental|TF 1200mg|TF 1200mg/day
2578418|NCT02377024|Placebo Comparator|placebo|placebo
2578504|NCT02376686|Experimental|Music intervention|Patient receives Music Intervention before going to sleep.
2578513|NCT02376686|No Intervention|treatment as usual|Patient receives Treatment as usual.
2578567|NCT02376192|Experimental|Bolus Phenylephrine/Ephedrine Treatment'|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants who experience hypotension will receive bolus phenylephrine and/or ephedrine treatment as needed.
2578572|NCT02376192|Experimental|Phenylephrine Infusion Group|Initial MicroScan® (Microvision Medical) SDF measurement are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia. In the operating room participants will receive a standard spinal anesthetic (hyperbaric bupivacaine, fentanyl and preservative free morphine) followed by a second comparative MicroScan® (Microvision Medical) SDF measurement within 10 minutes of initiation of spinal anesthetic. Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
2578619|NCT02375802|Experimental|Experimental|Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
2578676|NCT02375490|Experimental|Intervention arm|The intervention arm will participate in Healthy Start.
2578679|NCT02375490|No Intervention|Control arm|Control arm will pursue daily activities at early childcare center as usual.
2578709|NCT02375074|Experimental|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
2578710|NCT02375074|Experimental|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment.
2578756|NCT02374788|Experimental|Group A|Participants in the intensive intervention group (A) receive a pedometer intervention and 12 group meetings over two years' time, with the majority of meetings being held in the first 6 months. The group meetings constitutes of a 30 min walk and 60 min group consulting based on techniques for behaviour change using an interactive program with positive feed-back following their steps on a website. One occasion is taking place at a gym with instruction for a home-based strength training program. Participants receive 10 individual consultations with a diabetes specialist nurse.
2578765|NCT02374788|Experimental|Group B|Participants in the pedometer group (B) receive a pedometer intervention. Henceforth they are left to continue by they own for two years.
2578772|NCT02374788|No Intervention|Group C|The control group (C) receive diabetes care as usual except for the extra measurements included in the study. Diabetes care as usual is meeting a diabetes specialist nurse and a general practitioner once a year receiving lifestyle advice and physical activity on prescription.
2578828|NCT02374385|Experimental|Group 1|1x10(5) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL
3210778|NCT00998595|Experimental|Promotora|This group receives additional education and proactive follow-up by removing barriers to already existing services and reminders by a lay community health workers (Promotora)
2577691|NCT02381847|No Intervention|without HIPEC|Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and postoperative chemotherapy (SOX or XELOX).
2577696|NCT02381847|Experimental|with HIPEC|"Patients will be treated with a D2 radical gastrectomy for advanced gastric cancer and intraperitoneal chemoperfusion with cisplatin and postoperative chemotherapy as described for the control group.~Cisplatin: 75mg/m2 (max 150mg/m2 max 5L )"
2577729|NCT02381314|Experimental|enoblituzumab plus ipilimumab|Enoblituzumab: Fc-optimized, humanized monoclonal antibody. Ipilimumab: Yervoy; recombinant, fully humanized IgG-1 CTLA-4 blocking antibody approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of unresectable or metastatic melanoma.
2577775|NCT02380963|Experimental|Colorado Diet with soy protein|
2577778|NCT02380963|Active Comparator|Colorado Diet|
2577818|NCT02380794|Active Comparator|Danshen Gegen Capsule|3 capsules (500 mg per capsule) twice daily for 24 weeks
2577819|NCT02380794|Placebo Comparator|Placebo|3 capsules (500 mg per capsule) twice daily for 24 weeks
2577876|NCT02380495||Allergic rhinitis with/without asthma, from 14 to 17 years age|600 adolescents with allergic rhinitis with/without asthma, from 14 to 17 years age, recruited from Pediatricians of the Italian territory.
2577877|NCT02380495||Without respiratory pathology|600 subject (5 for each participant Pediatrician) of the same age range, without respiratory pathology (patient family)
2577892|NCT02380170||Urosepsis|Sepsis derived from the urinary tract infection
2577965|NCT02380066|Experimental|Anyu Peibo 0.4g per day|Anyu Peibo Capsule, oral, 0.2g twice per day
2577973|NCT02380066|Experimental|Anyu Peibo 0.8g per day|Anyu Peibo Capsule, oral, 0.4g twice per day
2577985|NCT02380066|Experimental|Anyu Peibo 1.2g per day|Anyu Peibo Capsule, oral, 0.6g twice per day
2577991|NCT02380066|Experimental|Anyu Peibo 1.6g per day|Anyu Peibo Capsule, oral, 0.8g twice per day
2577994|NCT02380066|Placebo Comparator|Placebo|Placebo,oral, twice per day
2578035|NCT02379481|Experimental|NS 550mg|NS 550mg/day
2578040|NCT02379481|Experimental|NS 1100mg|NS 1100mg/day
2578043|NCT02379481|Placebo Comparator|placebo|placebo
3210779|NCT00998595|No Intervention|Standard of Care|These subjects receive the routine standard of postpartum care
2578193|NCT02378571|No Intervention|Usual care|Participants assigned to usual care will also be provided with a GlowCap prior to discharge and will be instructed to take their loop diuretic from this bottle and to notify the study team about prescribed dose changes. This information, however, will solely be used to measure medication adherence and will not be provided to a member of the study team nor to any of the participants' health care providers until the completion of the study period, at least 1 month later. Participants will not be provided with any advice on heart failure adherence.
2578196|NCT02378571|Experimental|Medication adherence telemonitoring|At discharge, participants in the intervention group will be instructed to take their loop diuretic exclusively from the GlowCap in the manner prescribed by their physician. A study team member will review the adherence data on a daily basis (except holidays and weekends) during the first 7 days after discharge, and then on, at minimum, a weekly basis. The study team member will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
2578219|NCT02378311||Cases|Those satisfying the inclusion & exclusion criteria whose injury involved impact with the handlebar end who have sustained an injury more severe than a skin or subcutaneous tissue contusion from an end-on handlebar impact
2578221|NCT02378311||Controls|Those satisfying the inclusion & exclusion criteria in whom the handlebars were not implicated in the mechanism of injury
2578349|NCT02377518|Experimental|oncologic patients|"Prediction of postoperative pulmonary function.~Patients with an operable lung cancer: dual energy computed tomography with Krypton will be tested to estimate the postoperative FEV1"
2578350|NCT02377518|Experimental|lung transplant recipients|"Detection of BOS~6 months+ lung transplant recipients will be tested using dual energy computed tomography with Krypton, with acquisition in the end-inspiratory and end-expiratory phase, in search of regional air trapping."
2578392|NCT02377180|Experimental|Part 1|Intramuscular injection of capsaicin for the study of pain and hyperalgesia
2578396|NCT02377180|Active Comparator|Part 2|Pain arising from supraspinatus muscle vs. pain arising from trapezius muscle. Nerve block is only expected to be effective in the former.
2578399|NCT02377180|Active Comparator|Part 3|Suprascapular nerve block vs. intramuscular local anesthetic against pain arising from the supraspinatus muscle.
2578457|NCT02376855|No Intervention|Control|Providers in the Control group followed standard care protocols. If they deemed a patient was in need of cardiology consultation, a referral was created using the standard process. The referral was processed by a referral coordinator and transmitted to an appropriate cardiologist. An appointment was then scheduled for the patient to have an in-person consultation with a cardiologist.
2578466|NCT02376465|Experimental|BLI4600 Regimen 1|Oral bowel preparation for colonoscopy
2578469|NCT02376465|Experimental|BLI4600 Regimen 2|Oral bowel preparation for colonoscopy
2578470|NCT02376465|Active Comparator|PEG based below preparation|Oral bowel preparation for colonoscopy
3210780|NCT00998608|Experimental|HR|risperidone 2mg/d + haloperidol 2mg/d
3210781|NCT00998621||Hepatitis C infection|
3210782|NCT00998621||Hepatitis C + HIV infections|
3210783|NCT00998634|Experimental|LITHIUM CARBONATE 150 and/or 300 mg|
3210784|NCT00998634|Placebo Comparator|PLACEBO|
2577608|NCT02382419|Experimental|Arm I (carrageenan-containing gel)|Participants apply carrageenan-containing gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
2577612|NCT02382419|Placebo Comparator|Arm II (placebo gel)|Participants apply placebo gel vaginally within 12 hours prior to each vaginal sex act and as soon as possible within 12 hours after each vaginal sex act and use condoms for 12 months.
2577659|NCT02381938|Experimental|Intervention|6-month intervention to increase physical activity and improve other health related behaviors
2577660|NCT02381938|Other|Control|6-month intervention to educate and improve financial health
2577745|NCT02381483|Experimental|Lean|Cold exposure
2577752|NCT02381483|Experimental|Obese|Cold exposure
2577795|NCT02381002|Experimental|Weight reduction|weight reduction program for 6 months
2577844|NCT02380664|No Intervention|Swimmers|Swimmers that continue their normal swimming activity
2577846|NCT02380664|Experimental|WBV swimmers|Swimmers that perform a whole-body vibration training
2577850|NCT02380664|Experimental|Plyometric swimmers|Swimmers that perform a plyometric training
2577854|NCT02380664|No Intervention|Sedentary controls|Controls that do not perform swimming or other physical activities
2577914|NCT02380339|Active Comparator|Psych-Educational and Bio Feedback (BF_|Participants in the control group will undergo Psych-Educational and BF sessions in which they will receive information about FOH and about ways of coping with FOH and BF training. More specifically, they will learn about factors associated with FOH, behavioral manifestations of FOH, negative consequences of these behavioral manifestations and about ways of coping with FOH. They will be instructed to practice BF for 15 minutes, at home for 5 initial training sessions during a week. After which they will receive another session of BF training and will be instructed to practice it at home for 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
2577921|NCT02380339|Experimental|Psych-Educational session and virtual reality (VR)|Participants in the intervention group will receive Psych-Educational session as the control group and in addition they will participate in training for VR system and will be asked to use it at home for 5 initial training sessions during a week. During this week, they will practice reducing their GSR levels as indicated by the BF device. Following this they will receive a combined biofeedback-virtual reality system and use it at home for a 10 sessions course, (5 weekly sessions for 2 weeks). Each session will be for 15 minutes.
2577979|NCT02379988|Experimental|Verify radiation dose to heart and lung|Subjects will undergo the standard of care CT simulation, which includes an additional breath hold CT. Inspiratory gated breath-hold will be used. Two radiation plans will be generated: one for the CT scan performed free breathing, and one for the CT scan performed with inspiratory gated breath hold. The cardiac and lung doses will be determined. At the discretion of the treating physician, the plan with the lower cardiac and lung dose may be used to treat the patient.
2578048|NCT02379650|Experimental|Hydroxychloroquine (HCQ)|Subjects in the experimental arm will take 400 mg hydroxychloroquine pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
2578049|NCT02379650|Placebo Comparator|Placebo|Subjects in the experimental arm will take placebo pills every day, starting before they get pregnant and continuing until 36 weeks of pregnancy or until the pregnancy is over.
2578083|NCT02379130|Experimental|Family Nurture Intervention Group|Children in the FNI group will continue to attend any intervention programs that they are already enrolled in. In addition, they will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks. During each visit, the mother-child will meet with trained Nurture Specialists. The Nurture Specialists will facilitate and encourage the mother and child to engage in nurturing and calming activities, including sustained touch, vocal soothing, and an odor cloth exchange. FNI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
2578091|NCT02379130|Active Comparator|Play and Nutrition Intervention Group|Children in the PNI group will continue to attend any intervention programs that they are already enrolled in. They will be asked to attend 1 clinic visit per week for 6 weeks over the course of 12 weeks to meet with clinical personnel who will collect measures regarding the child's behavior and development. At each visit, study staff will meet with mothers to facilitate a lesson plan on appropriate play and nutrition. NPI families will be asked to participate in a 6 month post-enrollment follow-up visit and a 12 month post-enrollment follow-up visit.
2578159|NCT02378766|Experimental|Website A|Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé.
2578164|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites.
2578211|NCT02378428|Experimental|MIBG|Research participants with MIBG avid tumors
2578275|NCT02378129|Experimental|Clinpro XT (3M ESPE, Minnesota, USA)|Resin-modified glass ionomer cement
2578276|NCT02378129|Active Comparator|Vidrion R (SS White, Gloucester, UK)|Conventional glass ionomer cement
3210785|NCT00998647||with modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
2578385|NCT02377193|Experimental|Simulect|Simulect IV 40 mg D0 and D4
2578386|NCT02377193|Active Comparator|ATG Fresenius|ATG IV min dose 3 mg/ kg/ day D0, D1, D3, D5
2578410|NCT02376829|Experimental|The Invisalign System|Class II correction of malocclusions
2578473|NCT02376712||Pre-renal AKI|"Three definitions of pre-renal AKI will be used separately:~Hemodynamic instability (any sign of tissue hypoperfusion) on AKI identification, and AKI recovery in 24-72 hours following hemodynamic stabilization.~AKI recovery in less than 72 hours after AKI identification.~Decreased renal blood flow measured by transesophageal echocardiography (TEE)."
2578475|NCT02376712||Renal AKI|"Three definitions of renal AKI will be used separately:~Hemodynamically stable at AKI identification; or hemodynamically instability (any sign of tissue hypoperfusion) on AKI identification, and AKI persistence in 24-72 hours following hemodynamic stabilization.~AKI persistence 72 hours after AKI identification.~Normal or increased renal blood flow measured by TEE."
3260273|NCT01477788||women, sonographic ovarian mass|women that will arrive to the sonographic unit of the gynecological department with the sonographic diagnosis of ovarian mass
2578841|NCT02374385|Placebo Comparator|Group 4|Group 4 will receive placebo (normal saline).
2577646|NCT02382185|Experimental|Usual care|No intervention apart from application of clearsight monitor. Prior to induction of anaesthesia the control group will have a Clearsight cardiac monitor probe placed on a suitable finger and baseline haemodynamic measurements will be taken. All fluid management and administration of vasopressor therapy will be at the discretion of the anaesthetist as per the current practice at the host institution. Data on stroke volume, heart rate, blood pressure, cardiac output, oxygen saturations, will be recorded at baseline and then every 5 minutes.
2577651|NCT02382185|Experimental|Fluid optimisation|Application of clearsight monitor, optimisation of blood pressure and fluid optimisation. A Clearsight cardiac probe is attached and after induction of anaesthesia stroke volume is optimised using 250ml boluses of Hartmann's solution. The SV measurement prior to the final fluid bolus will be the optimal SV. Mean arterial blood pressure will be maintained within 30% of baseline values using a phenylephrine infusion.Data on haemodynamics will be recorded at baseline and then every 5 minutes, as well as before and after a fluid bolus. Haemoglobin will be maintained at>10g/dL with blood transfusion as required.
3210786|NCT00998647||without modified ultrafiltration|"elective cardiac surgery patients undergoing complex surgical intervention:~coronary artery bypass grafting AND valve surgery double valve surgery aortic surgery Re-Dos"
2577727|NCT02381249|Experimental|Esophagectomy|Double-blind single dose octreotide-placebo crossover
2577730|NCT02381249|Experimental|Gastrectomy|Double-blind single dose octreotide-placebo crossover
2577734|NCT02381249|Active Comparator|Unoperated healthy control|Double-blind single dose octreotide-placebo crossover
2577738|NCT02381249|Experimental|Pancreaticoduodenectomy|Double-blind single dose octreotide-placebo crossover
2577801|NCT02380924|Active Comparator|DSP loaded RBC using EryDex System|Autologous RBC loaded with DSP using the EDS process, and treated RBC are infused to the subject.
2577804|NCT02380924|Sham Comparator|Sham treated RBC using the EryDex System|Autologous RBC are treated with buffer using the EDS process, and treated RBC are infused to the subject.
2577857|NCT02380560||pPROM|50 women with preterm premature rupture of membranes with gestational age from 24 to 34 weeks assessed by ultrasound examination
2577862|NCT02380560||term non-labor control|25 term non-labor control (T-CTR, n=25) with gestational age from 37 to 41 weeks assessed by ultrasound examination
2577864|NCT02380560||preterm non-labor control|25 preterm non-labor control (P-CTR, n=25) with gestational age from 24 to 34 weeks assessed by ultrasound examination
2577931|NCT02380222||ASM|
2577933|NCT02380222||SM-AHNMD|
2577935|NCT02380222||MCL|
2577937|NCT02380222||SSM|
2577938|NCT02380222||ISM|
2577997|NCT02379845|Experimental|Arm A|NBTXR3 + Radiotherapy
2577998|NCT02379845|Active Comparator|Arm B|Radiotherapy alone
2578052|NCT02379351|Experimental|In-Home Non-Stress Test Device|Patients with physician-ordered twice-weekly NSTs scheduled in the OB Diagnostic Center at University of Utah Hospital will be eligible for enrollment. After being taught how to use the Airstrip® Sense4Baby™ system machine, participants will use the device on a weekly basis (at home) until the time of delivery. Participants will also receive an in clinic NST once a week.
3210787|NCT00998673|Experimental|Arm 1|
3210788|NCT00998673|Other|Arm 2|
2578152|NCT02378701||Quality of Life in Myelodysplasia Scale (QUALMS-1)|Participants complete the Quality of Life in Myelodysplasia Scale (QUALMS-1) and the Anemia Subset of FACT (FACT-An), instrument twice: at the start of treatment, and after four cycles or discontinuation of treatment, whichever comes first.
2578218|NCT02378454||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
2578220|NCT02378454||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
2578301|NCT02378051|Experimental|Staying Strong with Schools Intervention|The Staying Strong with Schools Intervention includes: (a) a training of all school professionals, and (b) a year-long training and supervision of the school guidance counselor (RSL), by a Liaison-Trainer (LT).
2578303|NCT02378051|Placebo Comparator|Waitlist Control|The waitlist control schools will receive an educational pamphlet outlining resources useful to support military-connected children to be distributed to all educators at the beginning of the Year 1. They will then receive the Staying Strong with Schools Intervention in Year 2.
2578354|NCT02377453||Control|Control: Healthy adult
2578358|NCT02377453||Experimental|Experimental: patients with stroke
2578406|NCT02377128|Experimental|Bilateral salpingectomy|Cesarean section with bilateral salpingectomy
2578407|NCT02377128|Active Comparator|Tubal ligation|Cesarean section with tubal ligation
2578408|NCT02377128|No Intervention|No intervention|Cesarean section with no additional intervention
2578484|NCT02376608|Active Comparator|Pronova Pure 150:500 EE EU|2 × PronovaPure 150:500 EE EU
2578495|NCT02376608|Active Comparator|Pronovum PRF-037|2 × Pronovum PRF-037
2578511|NCT02376608|Active Comparator|Pronovum PRF-041|2 × Pronovum PRF-041
2578519|NCT02376608|Active Comparator|Eskimo-3|3 × Eskimo-3
2578565|NCT02376049|Active Comparator|Pimecrolimus cream|Pimecrolimus 1% cream once daily for 14 days
2578571|NCT02376049|Active Comparator|Betamethasone dipropionate cream|Betamethasone dipropionate 0.05% cream once daily for 14 days
2578573|NCT02376049|Active Comparator|Clobetasol propionate cream|Clobetasol propionate 0.05% cream once daily for 14 days
2578575|NCT02376049|Placebo Comparator|Glaxal Base cream vehicle|Glaxal Base cream vehicle once daily for 14 days
2578618|NCT02375789|Active Comparator|Active RhinoChill|"Following the initial 30 days (and minimum of 2 separate migraine attacks) of data collection the patient will be trained in the use and self administration of the RhinoChill device.~At the onset of an acute migraine, the patient will insert the RhinoChill Migraine Intranasal catheters and commence a 10 minute treatment on the Low Flow setting of the device.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
3210789|NCT00998686|Experimental|dutogliptin/PHX1149T|
3210790|NCT00998686|Active Comparator|sitagliptin|
3210791|NCT00998699|Active Comparator|XOMA 052|
3210792|NCT00998699|Placebo Comparator|Placebo|
2577697|NCT02381860|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
2577698|NCT02381860|Active Comparator|60mL of cherry concentrate with 100ml water|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
2577732|NCT02381327|Experimental|Binge Eating Disorder|Patients with Binge Eating Disorder will use Mandometer as an intervention to reduce food intake and speed of eating.
2577736|NCT02381327|Experimental|Control|Normal weight, healthy control subjects will use Mandometer to obtain data for comparison with the patients with Binge Eating Disorder.
3210793|NCT00998712||1|Black women in the third trimester of a pregnancy complicated by gestational diabetes.
3210794|NCT00998712||2|Black women in the third trimester of a normal, uncomplicated pregnancy.
3210795|NCT00998712||3|White women in the third trimester of a pregnancy complicated by gestational diabetes.
3210796|NCT00998712||4|White women in the third trimester of a normal, uncomplicated pregnancy.
3210797|NCT00998725||HIV+ARV+|
3210798|NCT00998725||HIV+ARV-|
3210799|NCT00998725||HIV negative|
3210800|NCT00998751|Experimental|masitinib (AB1010)|oral masitinib 7.5 mg/kg/day
3210801|NCT00998777|Experimental|Shoulder Strengthening|The shoulder strengthening program is a 6-week intervention aimed to improve shoulder and scapular stabilizer strength and scapular kinematics. The program includes 10 exercises: shoulder flexion, Ys,Ts,Ws, Throwing Acceleration, Throwing Deceleration, Low Rows, Dynamic Hug, IR @ 90, and ER @ 90. The program also includes 2 stretches: sleeper stretch and corner stretch.
3210802|NCT00998803||Immunocompromised participants|Immunocompromised (<= 21 years of age) due to cancer, receipt of stem cell transplant, human immunodeficiency virus (HIV) or Sickle cell disease
3210803|NCT00998816|Placebo Comparator|Placebo capsules|one placebo capsule will be administered 1 hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12h BID for 10 days following lateral thoracotomy.
3210804|NCT00998816|Active Comparator|pregabalin capsules|Pregabalin capsules (150mg) will be administered one hour before lateral thoracotomy, 12 hours following the thoracotomy and then every 12 hours (BID) for 10 days following lateral thoracotomy.
2578026|NCT02379455|Experimental|Comprehensive drug review|
2578029|NCT02379455|No Intervention|Control group|"Follow-up by family physician as usual."
2578094|NCT02379260|Other|Interview|Patients and urologists will be interview by a sociologist.
2578119|NCT02378909|No Intervention|Group 4|Diabetic neuroischemia with standard of care.
3210805|NCT00998829||Study population|The group comprises the entire study population
3210806|NCT00998842||healthy subjects|five male, five female, ages 18-64
3210807|NCT00998855||Adolescents|Post pubertal, sedentary lean and obese Hispanic adolescents
3210808|NCT00998894||decision-support alerts|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will be generated for clinicians.
3210809|NCT00998894||routine practice|In patients experiencing a Triple Low (a combination of low MAC, low MAP, and low BIS), a warning alert will not be generated for clinicians.
3210810|NCT00998907|Active Comparator|PDS II|PDS II® loop suture is used for abdominal wall closure
3210811|NCT00998907|Experimental|PDS plus|"antibacterial coated PDS plus is used for abdominal wall closure"
3210812|NCT00998920|Experimental|10mg BID|S-equol capsule, oral, single dose
3210813|NCT00998920|Experimental|20 mg BID|
3210814|NCT00998920|Experimental|40mg BID|
3210815|NCT00998920|Experimental|80 mg BID|
3210816|NCT00998920|Experimental|160 mg BID|
3210817|NCT00998920|Placebo Comparator|Placebo|
3210818|NCT00998933|Experimental|1|
3210819|NCT00998959|Experimental|Mindfulness based stress reduction and problem solving therapy|
3210820|NCT00998959|Other|Psychoeducation|
3210821|NCT00998972|No Intervention|control|control arm without any specific intervention
3210822|NCT00998972|Experimental|N-acetylcysteine|administration of 600 mg intravenous N-acetyl cysteine before and 2 hours after angiography performed for the diagnosis of brain death
3210823|NCT00998998|Experimental|1|6 or 12 month old infants with iron deficiency anemia assigned to receive home stimulation program via weekly home visits over 1 year
3210824|NCT00998998|Active Comparator|2|6 or 12 month old infants with iron deficiency anemia assigned to surveillance (weekly visits to monitor health and iron supplement) over 1 year
3210825|NCT00998998|Experimental|3|Nonanemic infants identified at 6 or 12 months assigned to receive home stimulation program via weekly home visits over 1 year
3210826|NCT00998998|Active Comparator|4|Nonanemic infants identified at 6 and 12 months assigned to surveillance (weekly visits to monitor health) over 1 year
3210827|NCT00999011|Active Comparator|One 20 minute period of activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
3210828|NCT00999011|Active Comparator|Two periods of 20 minute activity daily|passive and/or active range of motion, chair sitting, sitting at edge of bed, standing and walking
3210829|NCT00999024||Healthy subjects|20 healthy subjects will be included
3210830|NCT00999024||COPD Patients|20 Patients with Grade IV COPD will be included
3210831|NCT00999050|Experimental|diabetic pts <35BMI|All patients will be in a single arm receiving bypass surgery to assist with diabetes management
3210832|NCT00999076||Sputum with positive AFB smear|
3210833|NCT00999089|Active Comparator|CCAB|Conventional Coronary Artery Bypass
3210834|NCT00999089|Active Comparator|OPCAB|Off-Pump Coronary Artery Bypass
3210835|NCT00999089|Active Comparator|PACAB|Pump-Assisted Coronary Artery Bypass
3260274|NCT01477801|Experimental|CHOLECALCIFEROL|
2577737|NCT02381262|No Intervention|Control|"At the 2 week post-surgical visit, all subjects will then meet with the exercise physiologist or research coordinator to initiate MyLGHealth, lifestyle/activity data collection.~Subsequent data collection time-points correspond with follow-up post-surgical appointments either at each visit or the 2 week, 1 month, 4 month, 8 month or 12 month visit.~The control group will receive a current version of the Fitbit device at the end of their completion of the 12 month visit."
2577740|NCT02381262|No Intervention|Historical Control|The investigators will extract historical control data from the electronic health record using electronic queries and manual data extraction. Historical controls will have surgery and 12-month follow-up completed prior to the start of the RCT.
2577829|NCT02380781|No Intervention|Control|Patients will receive current standard postpartum contraceptive counseling.
2577831|NCT02380781|Experimental|Intervention|Patients will receive current standard postpartum contraceptive counseling and will be shown a 10 minute video from the CHOICE project which outlines the different contraceptive options
2577880|NCT02380430||ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
2578107|NCT02378948|Experimental|Early oral feeding|Liquid oral feeding directly after esophagectomy.
2578110|NCT02378948|No Intervention|Delayed oral feeding|Liquid oral feeding 5 days after esophagectomy
2578148|NCT02378688|Experimental|MT-1303|
2578150|NCT02378688|Placebo Comparator|Placebo|
3210836|NCT00999115|Experimental|Allogenic ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.
3210837|NCT00999128|Experimental|Part 1|
3210838|NCT00999128|Experimental|Part 2|
3210839|NCT00999180|Active Comparator|Btx-A and Kinesiotherapy|The botulinum toxin group will have the syringe filled with botulinum toxin type A (Dysport). During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
3210840|NCT00999180|Placebo Comparator|Saline and Kinesiotherapy|The control group will have the syringe filled with saline.During this period the patients will be followed by the IBR facility where will undergo a protocol of physical therapy comprising muscle strengthen, flexibility, endurance, and functional training.
3210841|NCT00999193|Active Comparator|Conservative Treatment|
2578481|NCT02376439||Siblings|Siblings will consume four test meals after 4 different exposures, including two types of koolaid, a control and a smell condition.
3210842|NCT00999193|Experimental|ORIF w. locking plate, no luxation|
3210843|NCT00999193|Experimental|Hemiarthroplasty, no luxation|
3210844|NCT00999206|Experimental|1|
2578696|NCT02375308|Experimental|Hypnotherapeutic Treatment|HDT (Hypnotherapeutic Treatment of Depression) focuses on the hypnotic activation and strengthening of individual resources, the use of regression techniques to rebuild positive and negative experiences and the development of positive imaginations for the future.
2578702|NCT02375308|Experimental|Cognitive Behavioral Treatment|ACDT (Activation-focussed Cognitive Treatment of Depression) focuses on psychoeducation, behavior activation, the use of cognitive techniques, and the improvement of social skills.
2578745|NCT02374866|No Intervention|Conventional monitoring|The control group will follow the current center: every four months for a year, combined with monitoring by email or regular mail during the year.
2578750|NCT02374866|Experimental|Closer monitoring|"The experimental group will follow a closer monitoring than the control group : every two months for one year in,stead of every 4 months for a year.~Follow by email or mail is identical to the control group."
2578811|NCT02374515|Active Comparator|Endocuff assisted Colonoscopy|Endocuff assisted Colonoscopy
2578812|NCT02374515|Active Comparator|Standard Colonoscopy|Standard colonoscopy
2578853|NCT02374151||Women with IUPC|Women at term in second or third phase of labor who are indicated to have an IUPC during active labor
2578969|NCT02373553|No Intervention|Group 1( G1): CONTROL GROUP|not be submitted to intervention, only receive informations about health education.
2578976|NCT02373553|Experimental|Group 2(G2) : HEALTH EDUCATION|The family will receive a booklet of guidance of exercises to be performed at home.
2578979|NCT02373553|Experimental|Group 3(G3): EXERCISES IN OUTPATIENTS UNIT|The postural reeducation through lengthening of the anterior muscles and strengthening of the posterior muscles of the trunk.
2579027|NCT02373150|Experimental|Group A1|Dose 1 or placebo
2579033|NCT02373150|Experimental|Group A2|Dose 2 or placebo
2579038|NCT02373150|Experimental|Group A3|Dose 3 or placebo
2579107|NCT02372578|Experimental|ASP3662|ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.
2579109|NCT02372578|Active Comparator|pregabalin|pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.
2579111|NCT02372578|Placebo Comparator|Placebo|ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.
3210845|NCT00999206|Experimental|2|
2579213|NCT02371720|Experimental|Adults - Mobile DOT|Subjects with SCD that are older than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
2579217|NCT02371694|Experimental|Fat Test drink (25g)|This drink contains 25g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
2579258|NCT02371499|Experimental|1st Arm|Treatment with Lactobacillus casei DG (Enterolactis plus®)
3210846|NCT00999206|Experimental|3|
3210847|NCT00999206|Active Comparator|4|
3210848|NCT00999219|Experimental|FK199B-first group|
3210849|NCT00999219|Experimental|Zolpidem-first group|
3210850|NCT00999232|Experimental|Erythromycin|
3210851|NCT00999232|Placebo Comparator|Placebo|
3210852|NCT00999245|Other|High Demand / Low Infusion|PCA dosing plan
3210853|NCT00999245|Other|Low Demand / High Infusion|PCA plan for Low Demand / High Infusion
3210854|NCT00999258|Active Comparator|sirolimus|the subjects will undergo conversion from tacrolimus to sirolimus OR they will continue to receive tacrolimus.
3210855|NCT00999258|No Intervention|tacrolimus|
3260275|NCT01477801|Placebo Comparator|PLACEBO|
2577754|NCT02381496|Experimental|Part A: Cohort A4: ACT-453859 30 mg|"ACT-453859 30 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
2577755|NCT02381496|Experimental|Part A: Cohort A5: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo~After a washout period of 10-20 days subjects will return for a second study period to receive the same treatment received in the first session but under fed conditions"
2577757|NCT02381496|Experimental|Part A: Cohort A6: ACT-453859 300 mg|"ACT-453859 300 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
2577758|NCT02381496|Experimental|Part A: Cohort A7: ACT-453859 800 mg|"ACT-453859 800 mg or placebo, single dose, administered orally in the fasted state~Six male subjects will receive ACT-453859~Two male subjects will receive matching placebo"
2577760|NCT02381496|Experimental|Part B: Cohort B1: ACT-453859 10 mg|"ACT-453859 10 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
2577762|NCT02381496|Experimental|Part B: Cohort B2: ACT-453859 100 mg|"ACT-453859 100 mg or placebo, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
2577764|NCT02381496|Experimental|Part B: Cohort B3: ACT-453859 800 mg|"ACT-453859 800 mg, once a day for 7 days, administered orally in the fasted state~Three male subjects will receive ACT-453859~Three female subjects will receive ACT-453859~One male subject will receive matching placebo~One female subject will receive matching placebo"
2577765|NCT02381496|Experimental|Part C: Treatment Periods I & II: Setipiprant|"Setipiprant 500 mg, twice daily for 7 days, administered orally in Treatment Period I (TPI) and setipiprant 1000 mg, twice daily for 7 days, administered orally in Treatment Period II (TPII)~Four male subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~Four female subjects will receive setipiprant 500 mg twice a day in TPI and 1000 mg twice a day in TPII.~There will be a washout period of 10 days between TPI and TPII"
2577836|NCT02380755|Placebo Comparator|Placebo|One pill every other day during 12 weeks
2577841|NCT02380755|Active Comparator|Clomiphene Citrate|Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks
2577883|NCT02380313|Experimental|Afuresertib 125 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 125mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
2577885|NCT02380313|Experimental|Afuresertib 150 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 150 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
2577886|NCT02380313|Experimental|Afuresertib 175 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 175 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
2577887|NCT02380313|Experimental|Afuresertib 200 mg + enzalutamide 160 mg|Participants will be receiving enzalutamide at the recommended dose for at least 4 weeks prior to enrolment into this cohort. Afuresertib 200 mg and enzalutamide 160 mg will be dosed continuously on a once daily schedule for 28-day intervals.
2577888|NCT02380313|Experimental|Afuresertib 125 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 125mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
2577891|NCT02380313|Experimental|Afuresertib 150 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 150mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
2577894|NCT02380313|Experimental|Afuresertib 100 mg + abiraterone 1000 mg + prednisone 5 mg|Participants will be receiving abiraterone at the recommended dose for at least 2 weeks prior to enrolment into this cohort. Afuresertib 100 mg and abiraterone 1000 mg will be dosed continuously on a once daily schedule for 28-day intervals. Continuous BID prednisone 5mg will be coadministered per the labelled recommendations.
2577895|NCT02380313|Experimental|RP2D of Afuresertib + enzalutamide 160 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to plus enzalutamide 160 mg once daily.
2577897|NCT02380313|Experimental|Afuresertib RP2D + abiraterone 1000 mg + prednisone 5 mg|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations.
2577899|NCT02380313|Experimental|Afuresertib RP2D + abiraterone + prednisone in PK cohort|Participants in this arm will receive RP2D of afuresertib established in escalation cohort in addition to abiraterone 1000 mg once daily and continuous BID prednisone 5 mg coadministered per the labelled recommendations
2577999|NCT02379780|Active Comparator|USG guided Subcostal TAP block|after preparing the skin, ultrasound probe was placed obliquely on the upper abdominal wall along the subcostal margin near the midline. the rectus abdominis muscles, transversus abdominis muscles and the fascial plane (TAP) between rectus abdominis and transversus abdominis muscles were identified. after identification, the block needle was introduced anteriorly in the plane of the ultrasound beam. the needle was directed the transversus abdominis plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
2578008|NCT02380079|Placebo Comparator|Placebo|Placebo dosed TID for 28-days
3210856|NCT00999271||Healthy subjects|30 healthy subjects without family history of diabetes or gastrointestinal disease, a normal oral glucose tolerance test (OGTT) and no intake of medicine
2578033|NCT02379468|Experimental|Pedyphar|Ointment
3210857|NCT00999284|Placebo Comparator|Placebo|Sham infusion of sodium chloride 0.9%
3210858|NCT00999284|Active Comparator|Low dose arm|Infusion of 0.3 mg/kg/h ZK200775 over 4 hours
2577858|NCT02380833|Active Comparator|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
2577859|NCT02380833|Active Comparator|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
2577865|NCT02380833|Active Comparator|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
2577872|NCT02380833|Active Comparator|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
2577906|NCT02380209|Experimental|Optimization|CEST MRI of the breast for estimation of tumor pH.
2578104|NCT02379156|Experimental|Cool Temperature Exposure / No Drug|Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
2578105|NCT02379156|Experimental|Cool Temperature Exposure with Drug|Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
2578155|NCT02378636|Experimental|600S|Modified 600C (axis marks) monofocal aspheric intraocular lens
2578223|NCT02378519|Experimental|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
2578226|NCT02378519|Active Comparator|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
3210859|NCT00999284|Active Comparator|High dose arm|Infusion of 0.75 mg/kg/h ZK200775 over 4 hours
3210860|NCT00999297|Placebo Comparator|Sugar pill (Placebo o mg/d)|0 mg/d sugar pill
2578383|NCT02377232|Active Comparator|Usual Care Outreach for Colon Cancer Screening|Receives standard of care outreach concerning colon cancer screening.
2578388|NCT02377232|Active Comparator|Decision Aid for Colon Cancer Screening|Receives colon cancer screening decision aid intervention in addition to outreach.
2578451|NCT02376907||EUS-BD or ERCP with duodenal SEMS|Patients who underwent endoscopic placement of a duodenal self-expandable metal stent (SEMS) for nonresectable malignant GOO and endoscopic biliary drainage for nonresectable distal MBO.
2578480|NCT02376400|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
2578501|NCT02376400|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
2578512|NCT02376400|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
2578520|NCT02376400|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
2578632|NCT02376062|Experimental|Bundled Intervention|"On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
2578657|NCT02375438||Cohort Group|Patients with a clinical presentation suggestive of mitochondrial cytopathy, in whom mitochondrial deletions above 20% have been found in muscle are considered eligible if they are older than 18 years and are willing and able to give written informed consent.
2578659|NCT02375438||Control Group|Twenty healthy individuals matched for age and gender will be included in the study and considered as controls.
2578715|NCT02375191|Active Comparator|fentanyl|0.2% ropivacaine+ 1 mcg/kg fentanyl
2578719|NCT02375191|Experimental|dexmedetomidine|0.2% ropivacaine+1 mcg/kg dexmedetomidine
2578766|NCT02374749|Active Comparator|comorbidities|Evaluation of the prevalence and the presence of the risks factors of the four most frequently observed comorbidities in spondyloarthritis (cardiovascular diseases, cancers, infections osteoporosis and gastro-intestinal) as it is recommended by the French Society of Rheumatology.
2578773|NCT02374749|Active Comparator|self-assessment|"During the initial visit, the clinical research nurse exempt a learning program of assessment of disease activity/severity :~for assessing the activity in SpA;~for the calculation of BASDAI and the ASDAS-CRP~for the transfer technique and for the calculation of the disease activity on a monthly basis during the next 12 months.~for the risk of tobacco exposure~for the benefit of an NSAID intake in case of painful episode of the disease~for the benefit of home exercises~for the spine and indication of a treatment under the supervision of a physiotherapist in case of severe disease~for learning the patient to calculate his BASDAI and ASDAS-CRP Then, the patient will return home with his calculator and his notebook. Each month, the patient will be asked to perform the BASDAI and ASDAS-CRP calculations and to report the data on the notebook. 12 months later, the patient comes for a visit in the current practice to assess both such program and comorbidities."
3210861|NCT00999297|Active Comparator|Dihydrocapsiate|Drug 3 mg/d or 9 mg/d including Placebo
3210862|NCT00999297|Active Comparator|3 mg/d or 9 mg/d Dihydrocapsiate|Drug including Placebo
3210863|NCT00999310||Klinefelter syndrome|
3210864|NCT00999310||Control men|
3210865|NCT00999310||Control women|
3210866|NCT00999310||parents of Klinefelter groupe|
3210867|NCT00999323||coronary artery disease|patients who have been revascularized by PCI with stent implantation due to an acute coronary syndrome
3210868|NCT00999336|Active Comparator|Group H|Healthy subjects matched to the renal impairment groups
3210869|NCT00999336|Experimental|Group A|Patients with mild renal impairment
3210870|NCT00999336|Experimental|Group B|Patients with moderate renal impairment
2577950|NCT02380118|Experimental|Olanzapine|intramuscular olanzapine injection (zyprexa), 5 mg/dose, first dose and an optional second dose.
2577951|NCT02380118|Active Comparator|Haloperidol|intramuscular haloperidol injection, 5 mg/dose, first dose and an optional second dose.
2577952|NCT02380118|Active Comparator|Midazolam|intramuscular midazolam injection, 5 mg/dose, first dose and an optional second dose.
2577978|NCT02379741|Experimental|ADC-1013 intratumoral|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intratumoral injection every second week for 8 weeks. Patients that do not progress will be offered continued treatment until complete response, confirmed progressive disease, or clinical deterioration.
2577989|NCT02379741|Experimental|ADC-1013 intravenous|ADC-1013 (agonistic human monoclonal IgG1 anti-CD40 antibody) administered by intravenous infusion every second week until complete response, confirmed progressive disease, or clinical deterioration.
2578046|NCT02379546|Experimental|BIS<50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values below 50.
2578047|NCT02379546|Active Comparator|BIS≥50|Anaesthesia will be maintained with desflurane in a 50% O2-Air mixture by titrating the concentration according to the Bispectral index monitoring to keep the Bispectral index values above 50.
3210871|NCT00999336|Experimental|Group C|Patients with severe renal impairment
3210872|NCT00999349|Experimental|Silymarin (LEGALON)|
2578191|NCT02378558|Experimental|Investigational Device|All patients will undergo breast localization and excision of a lesion using the MagneMark system. The radiologist will insert the MagneMarker clip into the area of concern using the MagneJector device. The surgeon will then locate the MagneMaker clip using the MagneProbe. The clip and breast tissue of concern will then be removed.
2578232|NCT02378324|Active Comparator|Intervention and control|Intervention arm: screening without fee.
2578236|NCT02378324|No Intervention|Control group|Control arm: screening with the regular fee, 100SEK.
3210873|NCT00999349|Placebo Comparator|Placebo|
3210874|NCT00999362||Early kidney-transplant recipients|Patients receiving a kidney transplantation at Aarhus University Hospital, Skejby and receiving tacrolimus as part of their immunosuppressive regime.
3210875|NCT00999362||stable kidney transplant recipients|Tacrolimus treated kidney-transplant recipients from the out-door clinic at Aarhus University Hospital, Skejby and more than two years after transplantation
3210876|NCT00999375|Experimental|Group A|
3210877|NCT00999375|Active Comparator|Group B|
3210879|NCT00999427|Experimental|A|The randomly selected group of subjects who will receive the intervention. The radiologist performing the transrectal prostate biopsy on these subjects will have a gauze soaked with Povidone-iodine over his/her index finger, and will insert this into the rectum. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin to the other. This will be allowed to dry for 2 minutes before proceeding with the biopsy.
2578584|NCT02375919|No Intervention|Control|Emergency physician will assess low risk patients for PE with conventional strategy, using D-Dimer testing with subsequent CTPA if positive
2578585|NCT02375919|Other|Intervention|PERC based Strategy : Emergency physician will assess low risk patients for PE first with calculation of PERC score. If all PERC criteria are negative, then no further testing for PE is recommended. If at least one criterion is positive, then the patient undergoes D-Dimer testing with subsequent CTPA if positive
2578612|NCT02375737|Experimental|m-health|Patients will receive text message, emails, and monthly phone calls
2578779|NCT02374944|Experimental|Hardware Removal|Removal of hardware at 6 months.
2578781|NCT02374944|No Intervention|Hardware Retention|Retention of hardware at 6 months
2578817|NCT02374372|Active Comparator|conventional hemodialysis|conventional hemodialysis
2578818|NCT02374372|Active Comparator|hemodiafiltration On-line|hemodiafiltration On-line
2578948|NCT02373488|Active Comparator|intervention-1|connective tissue manipulation
2578949|NCT02373488|Active Comparator|intervention-2|abdominal massage
3210880|NCT00999427|No Intervention|B|The randomly selected group of subjects who will receive the standard of care biopsy without any added intervention.
3210881|NCT00999440|Experimental|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done.Patients who start with any opiate and then switch to methadone, move to methadone follow up
3210882|NCT00999453|Experimental|LDL-cholesterol 70 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
3210883|NCT00999453|Active Comparator|LDL-cholesterol 100 mg/dL or lower|'Experimental arm' is defined as patients treated to lower the level of low-density lipoprotein to 70 mg/dl or lower. 'Control arm' is defined as patients treated to lower low-density lipoprotein to a level of 100 mg/dl or lower.
2577845|NCT02380573|Placebo Comparator|Mild Cognitive Impairment (MCI) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577849|NCT02380573|Experimental|Mild Alzheimer's Disease (AD) MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577853|NCT02380573|Placebo Comparator|Mild Alzheimer's Disease (AD) Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577855|NCT02380573|Experimental|Healthy Middle Age MB|Methylene Blue (USP grade, 282 mg oral, daily, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577856|NCT02380573|Placebo Comparator|Healthy Middle Age Placebo|Drug: FD&C Blue # 2 (USP grade, 282 mg oral, 2 weeks, 12 weeks) Phenazopyridine hydrochloride (97.5 mg oral, 2 weeks, 12 weeks)
2577939|NCT02380144|Experimental|Orange Fruit - Orange Juice|"Sequence of test foods during the intervention period:~1st: Orange fruit; 2nd: Orange juice"
2577940|NCT02380144|Experimental|Orange Juice - Orange Fruit|"Sequence of test foods during the intervention period:~1st: Orange juice; 2nd: Orange fruit"
2577963|NCT02379832||Cases|Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
2577971|NCT02379832||Control|Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
2578027|NCT02379663|Active Comparator|Oral direct Factor Xa inhibitor|Rivaroxaban
2578030|NCT02379663|Active Comparator|Low molecular weight heparin|Enoxaparin
2578032|NCT02379663|Placebo Comparator|Normal Saline|Normal Saline
2578099|NCT02379234|No Intervention|Control|"All nurses received a 4 hours formation, called conventional formation, given by a professional trainer, that included 2 hours of theorical formation and 2 hours of practical training, based on CVVH generator demonstration. In addition, the trainer was present in the ICU during the first week of CVVH implementation, to answer any questions and to help nurses with their first CVVH sessions"
2578102|NCT02379234|Experimental|Simulated|The 'Simulated formation',used high fidelity mannequin and CVVH generator, is composed of 3 training sessions of 2 hours each one. This formation is associated with the 'conventional formation'.
2578185|NCT02378779|Other|Interventional GP : GP trainned in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.~There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize)."
2578186|NCT02378779|Other|Usual care : GP did not trainnd in communication skills|"The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.~He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about"
3210884|NCT00999479|Experimental|Monophasic OCP|Patients randomized to this study arm will receive combined oral contraceptive pills. Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages
3210885|NCT00999479|Placebo Comparator|Placebo|Patients assigned to this arm will use non-hormonal, barrier contraceptives to prevent pregnancy.Patients will follow up at 2, 6, 12, 18 and 24 months. On follow up visits pts will have clinical assessment with vaginal and rectal examinations and with transvaginal ultrasonography. As a measure of compliance, patients will return their empty pill packages.
3210886|NCT00999505|Active Comparator|Amantadine|Amantadine 200mg twice a day
3210887|NCT00999505|Placebo Comparator|Placebo|Placebo capsules twice a day
3210888|NCT00999531|Experimental|1|GS-9411 9.6 mg
3210889|NCT00999531|Experimental|2|GS-9411 4.8 mg
3210890|NCT00999531|Experimental|3|GS-9411 2.4 mg
3210891|NCT00999531|Placebo Comparator|4|Saline Placebo
3210892|NCT00999557|Experimental|Arm I|Patients apply topical bimatoprost ophthalmic solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
3210893|NCT00999557|Placebo Comparator|Arm II|Patients apply topical placebo solution to base of upper eyelid margins OR to eyebrow region once daily for 4 months in the absence of unacceptable toxicity.
3210894|NCT00999570||Patients operated by AR trained surgeons|patients who had their total knee replacements performed by surgeons who have completed a fellowship training in adult reconstruction surgery
3210895|NCT00999570||Patients operated by non-AR surgeons|patients who had their total knee replacements performed by orthopaedic surgeons who did not complete an adult reconstruction fellowship training
2578995|NCT02373410|Active Comparator|Nipple|The height of the operating table which set at the needle insertion point, is the level of nipple of the anesthesiologist in a standing posture.
2579098|NCT02372500|Experimental|Chewing gum|Patients will chew sugar free gum three times a day
3210896|NCT00999583|Experimental|EPO|five injections maximum of 40000 UI EPO
3210897|NCT00999583|Active Comparator|Control|Classical take care
3210898|NCT00999635|Experimental|Custom made insole|Custom made functional moulded insole
3210899|NCT00999635|Active Comparator|Prefabricated Insole|Prefabricated accommodative moulded insole
3210900|NCT00999648|Experimental|Manual therapy|Myofascial trigger point pressure release
3210901|NCT00999648|Placebo Comparator|Control|Placebo myofascial trigger point pressure release
3210902|NCT00999700|Experimental|ARM A|Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
3210903|NCT00999700|Active Comparator|ARM B|RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
3210904|NCT00999739|Experimental|two vaccines|people allocated to arm two vaccines will receive one dose of heptavalent pneumococcal conjugate vaccine at day 0 and 23-valent polysaccharide vaccine at week4 , 110 HIV-infected people will be included Intervention: administration of two vaccines
2577866|NCT02380625|Experimental|Sunitinib and Erlotinib|Sunitinib, Erlotinib, IV fluids and laboratory testing
2577871|NCT02380625|Experimental|Atorvastatin and Irbesartan|Atorvastatin, Irbesartan, IV fluids and laboratory testing
2577873|NCT02380625|Other|IV fluids and laboratory testing|no additional treatment
2577902|NCT02380157|Experimental|Kaleorid|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
2577905|NCT02380157|Placebo Comparator|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
3210905|NCT00999739|Experimental|One vaccine|people allocated to arm one will receive only one doses of pneumococcal polysaccharide 23-valent vaccine. 110 HIV-infected adults will be included in this arm Intervention: administration of one vaccine
3210906|NCT00999752|Active Comparator|Arm A|Nebivolol to reach blood pressure control
2578194|NCT02378584|Other|natural cycle|Ultrasound controls and endocrine blood test to asses the day of ovulation for embryo transfer
2578197|NCT02378584|Active Comparator|hormonal cycle|Ultrasound controls and endocrine blood test to asses the endometrium thickness for embryo transfer
2578212|NCT02378285|Active Comparator|PRP group|ACP infiltration: 2 mL at 0 and 4 weeks with ultrasound guidance
2578213|NCT02378285|Placebo Comparator|Saline solution group|Saline solution infiltration: 2mL at 0 and 4 weeks with ultrasound guidance
2578270|NCT02378077|Experimental|Lean or Obese, Non-Diabetic|To determine whether eosinophil content of adipose tissue is related to insulin sensitivity. We will use euglycemic clamps, fat biopsy (obtained during a scheduled abdominal surgery) and fat aspiration for analysis of subcutaneous (Sc) and omental (OM) adipose tissue from obese, insulin resistant and lean, insulin sensitive volunteers to test the hypothesis that, as in mice, eosinophil content in human subcutaneous and omental white adipose tissue, inversely correlates with body weight, with skeletal muscle and hepatic insulin sensitivity.
2578271|NCT02378077|Experimental|Fish oil supplementation|Determine whether, in adipose tissue, levels of, anti-inflammatory molecules correlate with insulin sensitivity and whether these levels are altered by a treatment designed to promote resolution of inflammation. Volunteers will take a fish oil supplement for three months.
2578390|NCT02377167|Experimental|Early Tracheostomy|"Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 5 days from intubation.~Intervention: Procedure: Early Tracheostomy"
2578393|NCT02377167|Active Comparator|Prolonged Intubation|"Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy after intubation day 10.~Intervention: Procedure: Late Tracheostomy"
2578491|NCT02376660|Experimental|Oats|70 grams oats
2578506|NCT02376660|Placebo Comparator|usual diet and exercise|usual diet and exercise
2578534|NCT02376270|Experimental|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
2578535|NCT02376270|Placebo Comparator|Maltodextrin|This group group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
2578592|NCT02376036|Experimental|MGD010|Subjects will receive MGD010 through IV infusion.
2578598|NCT02376036|Placebo Comparator|Placebo|Subjects will receive placebo through IV infusion.
2578599|NCT02376036|Experimental|MGD010 and HepA vaccine|Subjects will receive MGD010 through IV infusion and HepA vaccine through an IM injection.
2578601|NCT02376036|Placebo Comparator|Placebo and HepA vaccine|Subjects will receive placebo through IV infusion and HepA vaccine through an IM injection.
2578641|NCT02375594|Experimental|Exercise in park equipment|Participants in the intervention arm will attend a 3-month long program of 2 weekly one-hour exercise sessions in the exercise park equipment, guided by a physical therapist. The sessions will comprise a combination of aerobic, strength, balance and flexibility exercises. Up to 20 participants exercising simultaneously in the equipment under the guidance of an experienced LAPPSET physical therapist.
2578642|NCT02375594|No Intervention|Control|Participants in the control arm will receive usual advice on healthy habits. During the study, they will be offered to attend the talks on healthy living for elderly periodically organised by their primary care centre (CAP Vallcarca - Sant Gervasi). At the end of the study, they will be invited to an exercise session at the exercise park equipment, conducted by the study physical therapist.
2578711|NCT02375334||Observational (medical chart review)|Patient lab and visit dates are monitored by the Cancer Center ORIS and EPIC based systems during the 42 days of the concurrent temozolomide and radiation therapy.
2578758|NCT02374801|Experimental|Treatment|"This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON (AV+VV)."
2578810|NCT02374476|Experimental|Bipolar Ablation|All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.
2578852|NCT02374125|Experimental|Fibrolysis Group|Actual Diacutaneous Fibrolysis and protocolized physiotherapy
2578855|NCT02374125|Experimental|Pressure Group|Trigger Point Pressure Release and protocolized physiotherapy
2578859|NCT02374125|Active Comparator|Control Group|Protocolized physiotherapy
2578927|NCT02373735|Active Comparator|Group A (SVV <10% group)|"infuse crystalloid (Hartmann's solution) 6-10 ml/kg/hr continuously during surgery~infuse colloid (Volulyte) 200 ml if SVV is ≥ 10% during the surgery~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte)"
2578928|NCT02373735|Experimental|Group B (SVV 10-20% group)|"infuse crystalloid (Hartmann's solution) 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy~infuse colloid (Volulyte) 200 ml if SVV is > 20%~infuse mannitol 0.5 g/kg or lasix 5 mg if SVV < 10%~Interventions: crystalloid (Hartmann's solution), colloid (Volulyte), mannitol, lasix"
2578986|NCT02373410|Experimental|Umbilicus|The height of the operating table which set at the needle insertion point, is the level of umbilicus of the anesthesiologist in a standing posture.
2578988|NCT02373410|Active Comparator|Lowest rib margin|The height of the operating table which set at the needle insertion point, is the level of lowest rib margin of the anesthesiologist in a standing posture.
2578991|NCT02373410|Active Comparator|Xiphoid|The height of the operating table which set at the needle insertion point, is the level of xiphoid of the anesthesiologist in a standing posture.
2579092|NCT02372747|Experimental|Delta-shaped anastomosis group|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
2577907|NCT02380404||Edentulous maxilla|Ibuprofen (600 mg - Film-coated Tablets) 3x/day before the surgery. Duration : 5 days Amoxicilline Teva (500 mg - dispersible tablets) 3x/day before the surgery. Duration : 16 days
2578012|NCT02379949|Experimental|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
2578013|NCT02379949|Active Comparator|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
2578014|NCT02379949|No Intervention|Waitlist|Participants assigned to wait list were re-randomized to virtual reality exposure therapy or exposure group therapy following the waiting period.
3210907|NCT00999752|Active Comparator|Arm B|Hydrochlorothiazide for blood pressure control
3210908|NCT00999765||Bipolar Disorder - stable|
2578295|NCT02377778|Experimental|Propofol|In this arm patients will be receiving propofol for anaesthesia at doses 3-5mg depending on the time needed to complete oocyte retrieval
2578298|NCT02377778|Active Comparator|Thiopental|In this arm patients will receive thiopental for anaesthesia at doses 7mg and a repeat dose of 2-3mg depending on the time needed to completed oocyte retrieval
2578363|NCT02377310||All patients|All patients will undergo coronary physiological study with measurement of resting Pd/Pa, iFR™, hyperaemic iFR and FFR.
2578434|NCT02377037|Experimental|Sitting|Remain seated in a chair, with hands placed on top of the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
2578441|NCT02377037|Experimental|Standing|Remain in an upright position (standing) with hands placed on the thighs for 10 minutes, remaining motionless in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured minute by minute.
2578449|NCT02377037|Experimental|Transitions sit/stand|The participant will perform one sit-to-stand followed by a stand-to-sit transition, every minute in which the calorimeter device is attached to the mask and breath-by-breath VO2 and VCO2 are measured.
2578463|NCT02376543|Active Comparator|19 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 19 gauge technique (ARM 1) of EUS guided fiducial marker technique.
2578464|NCT02376543|Active Comparator|22 Gauge EUS FNA BNX|Subjects receiving EUS and fluoroscopic guidance for placement of fiducial markers into the pancreas will have the 22 gauge technique (ARM 2) of EUS guided fiducial marker technique.
2578544|NCT02376348|No Intervention|Control|Individuals receiving the standard Ministry of Health Package
2578545|NCT02376348|Experimental|Intervention|Individuals receiving the targeted demand creation strategy to increase adult men taking up VMMC
3210909|NCT00999778|Active Comparator|Caregiver Education Intervention|10 1:1,one hour sessions weekly for 10 weeks with parent and interventionist. Behavioral education strategies will be targeted
3210910|NCT00999778|Active Comparator|Caregiver-Mediated Intervention|One hour 1:1 with parent, child and interventionist, each week, for 10 weeks social communication and joint engagement strategies will be targeted
3210911|NCT00999791|Active Comparator|Avastin|
2578771|NCT02374697||Before tele-expertise|Usual second opinion with pathological slides sent by mailing
2578776|NCT02374697||During Tele-expertise|Second opinion with tele-expertise
2578836|NCT02374359||atrial tachycardia group|Patients diagnosed of cryptogenic stroke with atrial tachycardia in holter
2578842|NCT02374359||Non atrial tachycardia group (control group)|Patients diagnosed of cryptogenic stroke with a normal holter
2578930|NCT02373995|Active Comparator|LAB4|In addition to conventional Anti Thyroid Drug (ATD), LAB4 probiotic preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store LAB4 at 8°C.
2578932|NCT02373995|Placebo Comparator|Placebo|In addition to conventional Anti Thyroid Drug (ATD) a LAB4 placebo preparation will be administered at the 2 cps x 2/die dosing with food for 6 months. It is key to properly store placebo at 8°C.
2578957|NCT02373475|Experimental|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
2578966|NCT02373475|Active Comparator|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
3210912|NCT00999791|Active Comparator|Diclofenac|
3210913|NCT00999817|Other|A|Single 30 mg dose of dextromethorphan
3210914|NCT00999817|Experimental|B|Single 45 mg dose of PF-00299804 plus a single 30 mg oral dose of dextromethorphan
3210915|NCT00999856|Active Comparator|Cohort 1|In the Cohort 1 an uncoated Insert and the photometer version 1 is used. Twelve trial subjects are appointed into 4 subgroups. The difference between these subgroups is the wearing time of the insert.
2579175|NCT02372032|Experimental|PLD combined with ozone|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy combined with ozone therapy.
2579178|NCT02372032|Active Comparator|pure PLD|Patients diagnosed as lumbar disc herniation undergoing percutaneous lumbar discectomy(PLD).
3210916|NCT00999856|Active Comparator|Cohort 2|Cohort 2 consists of 12 trial subjects who are appointed to 2 subgroups. One group will wear the insert for a minimum of 12 month and the other group for a minimum duration of 18 month. In Cohort 2 an improved insert is used. The photometer will be the same than in cohort 1.
3210917|NCT00999856|Active Comparator|Cohort 3|Cohort 3 only differs in the used photometer from cohort 2.
3210918|NCT00999856|Active Comparator|Cohort 4|Twelve trial subjects are appointed to two subgroups that differ in the minimum wearing duration of the insert (12 month and 18 month). In Cohort 4 a new insert will be tested together with a better photometer.
3210919|NCT00999856|Active Comparator|Cohort 5|The difference between Cohort 5 and Cohort 4 is that the best tested insert and the best evaluated photometer will be used.
2577912|NCT02380482|Other|Traumatic brain injury|"Two dimensional and speckle tracking transthoracic echocardiography in traumatic brain injured patients~Glasgow score < or = 9 or~Glasgow score between 9 and 13 (included) and Following Traumatic Coma Data Bank Tomographic Damages:~diffuse injuries type III or IV or mass lesion over 25ml and/or neurosurgical injuries"
2577922|NCT02380482|Other|Controls|"Two dimensional and speckle tracking transthoracic echocardiography in control patients paired with traumatic brain injured patient on age, BMI and sex with the following criteria:~Intubated and mechanically ventilated~Undergoing urgent non severe surgery"
2577967|NCT02379975|Experimental|rheumatoid arthristis|individuals with rheumatoid arthritis
2577974|NCT02379975|Active Comparator|health|healthy individuals
3210920|NCT00999869|Experimental|Botulinum toxin A|At first visit, patients will be randomized by blocked randomization into 2 sides of scalp. Experimental side will be injected with botulinum toxin A ( Botox) 2 units per 6.05 cm2 of lesion ( Concentration 2 units of Botox per 0.1 ml of normal saline ).
3210921|NCT00999869|Active Comparator|Triamcinolone acetonide|At visit0, patients will be injection with triamcinolone acetonide concentration at 10 mg/ml on the comparison side
3210922|NCT00999882|Experimental|AZD8055|Dose escalation
3210923|NCT00999895||Antipsychotic outpatients with schizophrenia|Switched treatment of antipsychotic outpatients with schizophrenia
3210924|NCT00999960|Active Comparator|1: without simulator|without simulator
3210925|NCT00999960|Experimental|2: with simulator|with simulator
3210926|NCT00999973|Active Comparator|Mitomycin c 0.02%|
3210927|NCT00999973|Placebo Comparator|Placebo|
3210928|NCT00999986|No Intervention|placebo|
3210929|NCT00999986|Active Comparator|cyclophosphamide|
3210930|NCT00999999|Active Comparator|Standard|Standard dural closure
3210931|NCT00999999|Experimental|Experimental|Experimental dural closure, adding of Investigational Medicinal Product (IMP)
2578268|NCT02378116|No Intervention|Control|On the control group is done MRI scans of the brain, and patients can be elected for monitoring and/or bicycle stress test to test for neurohormones.
2578269|NCT02378116|Active Comparator|Surgical Closure|During open heart surgery, the surgeon closes the left atrial appendage. The research group recommend a double closure with both a ligation and suture, but a single suture is also accepted.
2578278|NCT02377830|Experimental|Early Cycling and routine physiotherapy|Patients will receive 30 minutes of in-bed cycling in addition to routine physiotherapy, 5 days per week, for the duration of their ICU stay
2578283|NCT02377830|Active Comparator|Routine physiotherapy|Patients will receive routine physiotherapy per current institutional practice
2578342|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis treatment
2578344|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis treatment
2578346|NCT02377570|Experimental|THERANOVA 400 dialyzer prototype CC|THERANOVA 400 dialyzer prototype CC in hemodialysis treatment
2578347|NCT02377570|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis treatment
2578420|NCT02377102|No Intervention|Observational|Patients will be asked to continue for 12 weeks of nonoperative medical management without physical therapy. At 12 weeks they will be reevaluated regarding the need for total knee arthroplasty.
2578422|NCT02377102|Active Comparator|Physical Therapy|Patients will be provided a prescription for 12 weeks of physical therapy at a location of their choice. No set protocol will be issued to allow for adjustments based on patient activity level and the therapist's professional choice. The physical therapy techniques, consisting of active and passive physiological and accessory movements and soft tissue mobilization, active range of motion exercises, muscle strengthening, muscle stretching, and exercises such as riding a stationary bicycle will be applied at the discretion of the treating physical therapist primarily to the knee and surrounding structures.
2578482|NCT02376725|Active Comparator|Phaco/IOL|Cataract extraction using phacoemulsification technique with intraocular lens implant
2578494|NCT02376725|Active Comparator|Phaco/IOL + goniosynechialysis|Cataract extraction using phacoemulsification technique with intraocular lens implant with goniosynechialysis
3210932|NCT01000038|Experimental|Wii-Fit Intervention|Intervention: Subjects in this arm participate in Wii-Fit exercises
2578646|NCT02375646|Experimental|Continued Warfarin|continuous Warfarin therapy (aiming for therapeutic INR: 2-3) will be given throughout the study
2578648|NCT02375646|Active Comparator|LMW Heparin|Enoxaparin 1mg/kg SC bid (adjusted to renal function) will be given 5 days before the colonoscopy while withholding therapy with Warfarin. The day after procedure Warfarin therapy will be added, and Enoxaparin stopped when therapeutic INR will be reached
2578695|NCT02375269|Experimental|RIPC (Remote Ischemic Preconditioning)|Preoperatively in the operation theater a tourniquet will be applied to the left arm and RIPC will performed. Therefore the tourniquet will be insufflated to suprasystolic pressure levels for 5 minutes, followed by 5 minutes reperfusion (deflated). Three cycles are planned. Duration of the procedure is 30 minutes.
2578701|NCT02375269|No Intervention|Control|Preoperatively in the operation theater a tourniquet will be applied to the left arm. The tourniquet will not be insufflated. The tourniquet will be removed after 30 minutes.
3210933|NCT01000038|Active Comparator|Walking Intervention|Intervention: Subjects in this arm participate in walking
3210934|NCT01000077||Discarded Operating Room Tissue|The purpose of this research study is to use the discarded (tissue that would normally be thrown out) tissue from your surgery in order to obtain cells that can be grown in a laboratory to study how to use cells like these to fix sick and diseased organs. We will test if these cells can be used to build new and healthy tissues. This technique is called tissue engineering. In this study we will be comparing cells obtained from different individuals.
2578843|NCT02374216|Other|Dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 and August 31st 2017
2578929|NCT02373787|Experimental|creos xenoprotect|resorbable collagen membrane
2578931|NCT02373787|Active Comparator|Bio-Gide|Bio-Gide, resorbable collagen membrane
2578947|NCT02373488|Other|control|lifestyle advice
2577942|NCT02380131|Experimental|Herceptin|"drug: Oxaliplatin;Capecitabine;Herceptin A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.~To explore the effect of herceptin with chemotherapy for potentially resectable HER-2 positive gastric cancer with liver metastasis"
2577982|NCT02379806|Active Comparator|Active enoxaparin 40 mg|One 0.4 ml prefilled syringe containing 40 mg enoxaparin active substance administered once daily for 10 ± 4 days
2577986|NCT02379806|Placebo Comparator|Placebo of enoxaparin 40 mg|One 0.4 ml placebo syringe of enoxaparin 40 mg administered once daily for 10 ± 4 days
2578082|NCT02379000|Active Comparator|Transpupillary therapy alone|Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid
2578086|NCT02379000|Active Comparator|TTT+Triamcinolone Acetonide|transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.
2578167|NCT02378740|Placebo Comparator|Placebo|Placebo (.9 sterile normal saline) administered IV
2578175|NCT02378740|Active Comparator|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
2578214|NCT02378415|Placebo Comparator|Normal Saline Infusion|A single IV bolus dose of normal saline solution.
2578215|NCT02378415|Experimental|Subanesthetic IV Bolus Ketamine|a single sub-anesthetic rapid IV bolus dose of ketamine administered to acutely depressed patients with or without suicidality
2578280|NCT02378064|Experimental|Fimasartan and vytorin|fimasartan(60mg,QD)+Vytorin(10mg,QD)
2578287|NCT02378064|Experimental|Fimasartan and rosuvastatin|fimasartan(60mg,QD)+rosuvastatin(5mg,QD)
2578291|NCT02378064|Active Comparator|amlodipine and vytorin|amlodipine(5mg,QD)+Vytorin(10mg,QD)
2578292|NCT02378064|Active Comparator|amlodipine and rosuvastatin|amlodipine(5mg,QD+rosuvastatin(5mg,QD)
2578340|NCT02377596||Perceived Feeding Difficulties|To complete the study we will recruit at least 40 of the children perceived by their parents or guardian to have feeding difficulties.
2578366|NCT02377284|Experimental|Intervention (personalized chef card)|Restaurant employees received a personalized chef card, which included written information about a patron's food allergies and a photograph of the patron.
2578373|NCT02377284|No Intervention|Control (depersonalized chef card)|Restaurant employees received a depersonalized chef card, which included written information about a patron's food allergies, without a photograph of a patron.
2578411|NCT02377011|Experimental|PS CBT|"Problem solving cognitive behaviour therapy (PS CBT) will be delivered remotely by means of telephone or video calling by a cognitive behaviour therapist in addition to their usual care.~The duration of the intervention will be 10 sessions. Research measures will be completed at baseline, 3,6,9 and 12 months"
2578413|NCT02377011|No Intervention|Treatment as Usual|Participants will not receive any CBT therapy in addition to their usual care. Research measures will be completed at baseline,3,6,9 and 12 months.
2578490|NCT02376413||Traditional BCS|Breast-conserving surgery. Modified radical mastectomy.
2578505|NCT02376413||Oncoplastic-BCS|"Breast-conserving surgery. Modified radical mastectomy. Oncoplastic-BCS based on surgeon preference and/or tumor location.~Superior pedicle mammoplasty / inverted T~Superior pedicle mammoplasty / V scar~Batwing~Inferior pedicle mammoplasty~Racquet mammoplasty/radial scar~vertical-scar mammoplasty"
2578547|NCT02376127||pts with known spinal metastases|(20 patients from any solid cancer) who are to undergo radiation treatment (RT) will be recruited. The patients will undergo DCE-MRI before and after RT. RT will be classified as success based on evidence of tumor contraction on conventional MRIs, negative PET, or stability for more than 11 months and blinded from DCE MRI sequencing. For each patient, a scanning profile for the first scan will be saved and used for the follow-up scans to acquire the same locations over time. Each patient will be scanned 4 times (one pre-treatment and 3 follow up post treatment) during their consecutive clinical visits. The DCE MRI sequence is a part of MR sequences for standard care. No additional scans will be added in the standard clinical sequences.
2578625|NCT02375893||Coronary patients|Feces, blood sample, clinical and biological data. Presence (1) of coronary disease defined as the presence of atheroma during the coronary angiogram
2578629|NCT02375893||Healthy subjects (2)|Feces, blood sample, clinical and biological data. Absence (2) of atheroma during the coronary angiogram
2578685|NCT02375230|Placebo Comparator|Control|"Control group~Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise."
2578688|NCT02375230|Active Comparator|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. Each participant will receive five minutes of training at the start of each shift.~The educator will teach mask adjustment, and airway reposition. If either of these first steps is unsuccessful the participant will learn about mouth and nose suction, open mouth and increase of airway pressure. All participants will also learn and practice alternative airways placement including intubation and laryngeal mask airway placement."
2578784|NCT02374684|Experimental|Methosulide|Methosulide, oral administration
2578787|NCT02374684|Placebo Comparator|Placebo|Placebo, oral administration
2577972|NCT02379793|Experimental|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied topically at the same time. However, the location on which the treatments are applied is randomised in an investigator blinded manner.
2578050|NCT02379676|Experimental|Ticagrelor|Ticagrelor 90mg twice daily
2578051|NCT02379676|Active Comparator|Clopidogrel|Clopidogrel 75mg once daily
3210935|NCT01000077||Discarded Placenta|During a standard surgery or delivery of a baby unneeded tissue is usually discarded. We would like to explore the opportunity to grow the cells of these discarded tissues in the laboratory. The cells will be placed in special dishes and supplemented with a mixture of salts and nutrients that were designed to allow the cells to survive outside the body and grow. This procedure is called tissue culture of cells. We will attempt to isolate a population of cells from the tissue culture and study them in the laboratory.
3210936|NCT01000090||Acromegaly patients, somatostain analogues|
3210937|NCT01000090||Acromegaly patients, surgery|
3210938|NCT01000103|Active Comparator|1: Real rTMS treatment|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
2578341|NCT02377544|Placebo Comparator|Placebo|Saccharum lactis
2578343|NCT02377544|Experimental|Probiotic|Bifidobacterium animalis lactis
2578382|NCT02377219|Experimental|couples|couples attending an IVF or intra cytoplasmic sperm injection (ICSI) attempt have hormonal and blood analysis
2578439|NCT02376881|Experimental|EPO|20,000 IU recombinant human erythropoietin IV infusion in 100 ml normal saline in 2 hr for 3 successive days
2578445|NCT02376881|Placebo Comparator|control group|100 ml normal saline in 2 hr for 3 successive days
2578474|NCT02376595||Rocuronium Bromide|Rocuronium 0,3 mg/kg administered in less than five seconds, followed by a saline bolus.
2578555|NCT02376296||hormone naïve|Subjects with hormone naïve metastatic prostate cancer that have high-volume disease and have been on androgen deprivation therapy for less than 120 days prior to starting docetaxel therapy.
2578559|NCT02376296||castrate resistant|Subjects with castrate resistant prostate cancer (CRPC) [defined as having evidence of prostate specific antigen (PSA) progression despite androgen deprivation therapy] that have had at least four weeks elapse between the withdrawal of anti-androgens (Bicalutamide, Flutamide or Nilutamide) and the initiation of docetaxel therapy.
2578644|NCT02375633|Experimental|DW-330SR2|DW-330SR(Pelubiprofen) 45mg twice a day
2578647|NCT02375633|Active Comparator|Pelubiprofen|Active Comparator(Pelubiprofen) 30mg three times a day
2578690|NCT02375321|Experimental|Group A|Study Group: patients with OSA and depressive symptoms treated with CPAP and psychological support
2578691|NCT02375321|No Intervention|Group B|Control Group: patients with OSA and depressive symptoms treated with CPAP
2578742|NCT02374983||Research group|The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
2578821|NCT02374567|Experimental|Psychiatric drugs|
3210939|NCT01000103|Sham Comparator|2: Sham rTMS treatment|Simulation of rTMS
3210940|NCT01000116|Active Comparator|Fibrin glue|
3210941|NCT01000116|Active Comparator|Tacks|
2579232|NCT02371707|Experimental|Idalopirdine 60 mg formulation A (test)|
2579235|NCT02371707|Experimental|Idalopirdine 60 mg formulation B (reference)|
2579329|NCT02371083|No Intervention|Routine|Subjects will continue with regular pessary care every 12 weeks.
2579330|NCT02371083|Experimental|Extended|Subjects will have extended time between pessary care visits which will occur every 24 weeks.
2579402|NCT02370823||Knee OA Treated with Regenexx SD|20 subjects with unilateral knee osteoarthritis. Collection of synovial fluid from both knees will serve as the experimental condition, i.e. the osteoarthritic knee, and the matched control, i.e. the knee not demonstrating signs of osteoarthritis. Alterations in the concentration of the synovial fluid proteins and cellular components will be evaluated up to 6 weeks post-Regenexx® SD - Same Day Bone Marrow Concentrate Injection treatment.
2579450|NCT02370355||Group I (retrospective analysis)|Previously collected plasma samples are analyzed for ctDNA via PCR and NSG.
2579457|NCT02370355||Group II (prospective analysis)|Patients undergo collection of blood samples before and following systemic therapy for analysis of CTC enumeration, RNA expression, and ctDNA via PCR and NSG.
2579494|NCT02370108|Experimental|PD patient|Parkinson's disease patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
2579496|NCT02370108|Experimental|OT patients|others tremor patients will get the electrical muscle stimulation at the most tremulous hand at 50 Hz frequency, maximal tolerate pulse amplitude (not over 20 mA), duration of stimulation for 10 second.
2579517|NCT02369783|Experimental|Questionnaire and interview|The patient complete the questionnaire on the tablet to better know their social situation and any difficulties. Then, he will be interview during thirty minutes with a social worker and a nurse navigator. At the end of this intervention we will be offered to the patient monitoring and appropriate resources to its situation.
2579564|NCT02369679|Experimental|Precast Adjustable Compression Wrap|Precast Adjustable Compression Wrap will be adjusted by the physiotherapist each visit
2579568|NCT02369679|Active Comparator|Multilayer Compression Bandages|Multilayer Compression Bandages will be adjusted by the physiotherapist each visit
2579617|NCT02369276||post SND within 3 months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 3 months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
2579682|NCT02368912|Experimental|1. Single ascending dose (SAD), ASP1707 dose levels 1-7|healthy young male
2579685|NCT02368912|Experimental|2. Single ascending dose (SAD), placebo dose levels 1-7|healthy young male
2579686|NCT02368912|Experimental|3. Food effect (FE), ASP1707 fasted|Fasted healthy young male
3210942|NCT01000142|No Intervention|Treatment as Usual Control Group|
3260276|NCT01477814|Active Comparator|physician chart reminder|either a paper or an electronic reminder placed on the subject's medical record to remind the physician to screen for colorectal cancer
2578000|NCT02379780|Active Comparator|USG guided Paravertebral Block|prior to start surgery, was performed in the left lateral position. after preparing skin, ultrasound linear probe was placed, 2-3 cm lateral of the T7 / T8 level in the midline. After determining the transverse process and ribs as hyperechoic, the paravertebral space was identified as an area wedge-shaped bounded by the pleura and above the internal intercostal membrane.after identification of the paravertebral space, the block needle was introduced in plane / out of plane and 10 ml of bupivacaine (Marcaine 0,25 %) and 5 ml of lidocaine (2%) was injected after negative aspiration.
2578087|NCT02379286||14 to 17 years old French teenager|14 to 17 years old French teenager representative of French population from whom parental consent to particpare to the study has been given
2578161|NCT02378870|Experimental|A:Osteodex|3.0 mg/kg bodyweight solution for infusion
2578162|NCT02378870|Placebo Comparator|B: Placebo|NaCl 0.9% solution for infusion
2578237|NCT02378389|Experimental|Pyrotinib/Pyrotinib with Docetaxel|Subjects would be treated with Pyrotinib (Part 1) or Pyrotinib with Docetaxel (Part 2). A subject is only allowed to participant in one part of this trial.
3210943|NCT01000142|Sham Comparator|Light Touch Group|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
3210944|NCT01000142|Experimental|Standard OMT Group|
2578446|NCT02377089|Sham Comparator|Sham|The stimulators are the same device for the active and sham treatment conditions.
2578452|NCT02377089|Active Comparator|Active|The stimulators are the same device for the active and sham treatment conditions.
3210945|NCT01000168|Experimental|Treadmill therapy|"Patients assigned to the Treadmill therapy group received daily 30 minutes specific walking training on treadmill with body weight support alternatively overground, and 30 minutes functional training, treated by a physiotherapist."
3210946|NCT01000168|Active Comparator|Conventional walking therapy|Patients assigned to the comparative conventional walking therapy group received daily 30 minutes specific traditional walking training overground and 30 minutes functional training, treated by a physiotherapist.
3210947|NCT01000181||Patients undergoing carotid endarterectomy|
3210948|NCT01000194|Experimental|High polyunsaturated fat meal|A high fat milkshake containing 55g of fat, mainly PUFA
2578548|NCT02376023|Experimental|mHealth|Women in the mHealth group will receive text and voice messages, in addition to their habitual care from the health clinic they attend. The messages will remind them to schedule a PAP smear, and will be sent for 1 year following enrollment in the study.
2578550|NCT02376023|No Intervention|No mHealth|Women in the No mHealth group will not receive any text messages, and will only receive their habitual care from the health clinic they attend.
2578667|NCT02375516|Experimental|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions.
2578671|NCT02375516|No Intervention|Control group|Youths assigned to the control arm will receive no intervention.
2578716|NCT02375152|Experimental|Surgical Intervention|
2578737|NCT02374762||Hemodialysis Patients with AVF|Hemodialysis patients that use an arteriovenous fistula (AVF) to receive their dialysis treatments will be invited to have their AVF recorded by a digital camera for one minute prior to cannulation.
3210949|NCT01000194|Experimental|High monounsaturated fat meal|A high fat milkshake containing 55g of fat, mainly MUFA
2578856|NCT02374073|Experimental|Intervention group|Treated with protocolized physiotherapy and functional massage
2578858|NCT02374073|Experimental|Control group|Treated with protocolized physiotherapy
2578926|NCT02373800||The study population|"The study population is composed of pregnant women with a medical indication for the induction of pre-term (37-42 weeks of gestation) labor and who are consulting in the participating center.~Intervention: Cervical ultrasound with elastography"
2579051|NCT02373020||group 1|colonoscopic biopsies from patients with colorectal cancer patients
2579056|NCT02373020||(Group 2|colonoscopic biopsies from healthy controls
2579106|NCT02372604|Active Comparator|Group1 : Regulatory dosage|"In a first time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time,and after primary endpoint assessment, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 3 and 4)."
2579108|NCT02372604|Experimental|Group 2 : fourfold dosage|"In a first time, every day, one tablet of 10 mg of levocetirizine is taken the morning and a second tablet of 10 mg of levocetirizine is taken the evening, during 5 weeks (between visit 2 and 3).~In a second time, every day, one tablet of 5 mg of levocetirizine is taken the morning and a second tablet of placebo is taken the evening, during 5 weeks (between visit 3 and 4)."
2579156|NCT02372318|Experimental|Nalmefene Challenge|Participants will receive 18mg Nalmefene two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
2579164|NCT02372318|Placebo Comparator|Placebo|Participants will receive Placebo two hours prior to fMRI measurement. During fMRI scanning alcohol cues will be presented.
2579193|NCT02371824||MRI Sequence|
3210950|NCT01000194|Experimental|High saturated fat meal|A high fat milkshake containing 55g of fat, mainly SFA
3210951|NCT01000207|Experimental|1|Dose ranging
2579479|NCT02370264|Experimental|Supportive care (musculoskeletal screening, quality of life)|Patients complete the DASH and FACT-B questionnaires over 30-45 minutes.
3210952|NCT01000207|Experimental|2|Dose ranging
3210953|NCT01000220|Active Comparator|Omeprazole|
3210954|NCT01000220|Placebo Comparator|placebo|
2578156|NCT02378597|Active Comparator|Delayed Intervention: Control|Delayed intervention: Control was a a behavioral treatment for resiliency delivered in a single 4 hour session delivered in a delayed fashion (waitlist control)
2578166|NCT02378597|Experimental|Experimental: Intervention|Experimental: Intervention was a 4 hour behavioral resiliency intervention.
2578216|NCT02378441|Experimental|CJ-30056 20/750mg|fixed-dose combination of Atorvastatin 20mg and Metformin SR 750mg
2578217|NCT02378441|Experimental|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
3210955|NCT01000233|Active Comparator|Phytine (Phytate)|300 mg tid* 24 months
2578361|NCT02377401|Experimental|Zanamivir 300 mg|Subjects will receive a single dose of IV zanamivir 300 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will receive IV zanamivir 300 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 milliliter per hour [mL/hr]).
2578362|NCT02377401|Experimental|Zanamivir 600 mg|Subjects will receive a single dose of IV zanamivir 600 mg on Day 1 morning. The repeat dose session will begin on Day 3 evening. Subjects will be receive IV zanamivir 600 mg every 12 hours for 5 days. Each dose will be administrated intravenously at a constant rate over 30 minutes (500 mL/hr).
2578419|NCT02377050|Active Comparator|Higher Volume Feeding Goal|Infants randomized to this group will have higher volume feeding goals of 180-200 ml/kg/day.
2578421|NCT02377050|No Intervention|Usual Volume Feeding Goal|Infants randomized to this group will have feeding goals of 140-160 ml/kg/day.
2578515|NCT02376673|Active Comparator|Brochures|Mothers in this arm will receive safe sleep education from home visitors using standard brochures (including 1-page handouts and pamphlets) that are customarily used in this home visiting program.
2578523|NCT02376673|Experimental|Children's Book|Mothers in this arm will receive safe sleep education from home visitors using a specially-designed children's book incorporating American Academy of Pediatrics safe sleep guidelines.
2578552|NCT02376114|Other|Ginkgo-Placebo|Patients receive Ginkgo biloba and then placebo afterwards.
2578556|NCT02376114|Other|Placebo-Ginkgo|Patients receive placebo and then Ginkgo biloba afterwards.
2578623|NCT02375867|Active Comparator|prednisolone|This group includes patients with FHF without encephalopathy
2578627|NCT02375867|Active Comparator|methylprednisolone|This group includes patients with FHF with encephalopathy
2578630|NCT02375867|No Intervention|Non-intervention|FHF patients without any of the proposed intervention as controls
2578682|NCT02375412||Pre-operative HRV group|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery.
2578763|NCT02375113|Experimental|Intervention|Soy supplementation: Isoflavones 160 mg/day + 25 gram soy protein / day
2578769|NCT02375113|Placebo Comparator|Control|Placebo capsules + 25 gram whey protein / day
2578830|NCT02374411||HIPEC surgeons|
2578866|NCT02374047|Experimental|Cohort A1, Dose Level 1: CAT-2054 or placebo fasting|Single dose
2578868|NCT02374047|Experimental|Cohort A2, Dose Level 2: CAT-2054 or placebo fasting and fed|Single dose
2578869|NCT02374047|Experimental|Cohort A3, Dose Level 3: CAT-2054 or placebo fasting and fed|Single dose
2578873|NCT02374047|Experimental|Cohort A4, Dose Level 4: CAT-2054 or placebo fasting and fed|Single dose
2578875|NCT02374047|Experimental|Cohort A5, Dose Level 5: CAT-2054-C or placebo fasting and fed|Single dose
2578877|NCT02374047|Experimental|Cohort B1, Dose Level 1: CAT-2054 or placebo|Multiple dose for 14 days
2578880|NCT02374047|Experimental|Cohort B2, Dose Level 2: CAT-2054 or placebo|Multiple dose for 14 days
2578883|NCT02374047|Experimental|Cohort B3, Dose Level 3: CAT-2054 or placebo|Multiple dose for 14 days
2578885|NCT02374047|Experimental|Cohort B4, Dose Level 4: CAT-2054 or placebo|Multiple dose for 14 days
2578890|NCT02374047|Experimental|Cohort B5, Dose Level 5: CAT-2054 or placebo|Multiple dose for 14 days
2578895|NCT02374047|Experimental|Cohort B6, Dose Level 6: CAT-2054 with atorvastatin|Multiple dose for 14 days
2578896|NCT02374047|Experimental|Cohort B7, Dose Level 7: CAT-2054 or placebo|Multiple dose for 14 days
2578952|NCT02373423|Experimental|Advocacy program|A series of commonly used advocacy actions which will incorporate a theory of change model. Each advocacy action is targeted to change organizational capability, opportunity, or motivation of food companies to reduce salt in processed packaged foods. The intervention will span 24 months from 2013-2015.
2578954|NCT02373423|No Intervention|Control|No intervention program
2579070|NCT02372721||Sepsis with Severe AKI|"History of a pediatric admission with sepsis related AKI which lead to classification of injury or failure. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry."
2579071|NCT02372721||Sepsis without AKI|History of a pediatric admission with sepsis which lead to no classification of AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
2579097|NCT02372760|Active Comparator|BA classic anesthesia|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
3210956|NCT01000233|Placebo Comparator|Placebo|
3210957|NCT01000246|Experimental|influenza vaccine day 4|influenza vaccine day 4 of chemotherapy
3210958|NCT01000246|Experimental|influenza vaccine day 16|influenza vaccine day 16 of chemotherapy
3210959|NCT01000246|Active Comparator|influenza vaccine|influenza vaccine in patients with heartfailure
3210960|NCT01000259||Ancillary-Correlative|Previously collected tumor tissue samples are analyzed for TIL via immunohistochemistry and double immunofluorescence assays using standard immunostaining.
3210961|NCT01000298|Placebo Comparator|Placebo|
3210962|NCT01000298|Experimental|Amoxicillin|
3210963|NCT01000298|Experimental|cefdinir|cefdinir
3210964|NCT01000350|Experimental|Exercise Post Saline|Saline infusion 1L hours before exercise test
3210965|NCT01000350|Placebo Comparator|Placebo|Placebo given prior to exercise test
3210966|NCT01000363||Spanish speaking group|Diabetes medical group visits will be held at the Grady North DeKalb satellite clinic the third Thursday of the month starting in October 2009. There will be two cohorts of patients- English speaking patients and Spanish speaking patients. Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.
3210967|NCT01000363||English speaking group|"Each group will be scheduled for 4 2-hour group visits throughout a period of 9 months. These visits will be every 8 weeks for each group. During the visit, the patient will be seen by a physician, attend a diabetes education session, re-fill their diabetes medications, get orders for labs due, vaccinations and diabetes-related referrals.~This visit will only focus on the patient's diabetes care. Each patient will continue to see their regular physician for their health care.~All of the services that will be provided at the medical group visit are standard of care and are the same that the patient will receive in a one-on-one visit. However, this format will allow the patient to been seen by the physician and receive diabetes education in one visit."
3210968|NCT01000402|Other|Psychopharmacotherapy|No specific arms; Treatment decision based on available guidelines
2578118|NCT02378922|Experimental|Treatment (gene-modified stem cells)|"CONDITIONING: Patients undergo high-dose chemotherapy or chemoradiotherapy according to institutional guidelines.~STEM CELL INFUSION: Patients undergo hematopoietic stem cell transplant on day 0.~Note: Patients continue to receive HAART throughout treatment, with a 7-day break for apheresis. Patients may be eligible for a structured treatment interruption of up to 12 weeks after autologous hematopoietic stem cell transplant with gene-modified cells."
2578149|NCT02378610||Observation in High-stressed|Saliva and fecal samples will be collected from High-stressed persons
2578151|NCT02378610||Observation in Low-stressed|Saliva and fecal samples will be collected from Low-stressed persons
2578198|NCT02378545|Active Comparator|Hyperoxia|Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose. The oxygen delivery device will be set to deliver oxygen at 15 litres per minute. The oxygen will be continuously delivered throughout the patients stay in the Emergency Department.
2578199|NCT02378545|Active Comparator|normoxia|Oxygen will not be administered if a patient's oxygen saturations (as measured using a pulse oximeter) are less than 94%. If a patient's oxygen saturations are less than 94%, oxygen will be 'titrated' using a 'venturi' type oxygen delivery device to achieve target saturations of 94%. Following initial dynamic titration (to identify correct oxygen delivery level) the oxygen delivery device will be re-evaluated hourly during the patient's stay in the emergency department.
2578208|NCT02378259|Experimental|Bariatric surgery|Roux-en-Y gastric bypass surgery
2578209|NCT02378259|Active Comparator|Intense conservative treatment|Intense conservative treatment. 8 week LCD followed by outpatient visits 1/ month
2578285|NCT02378103||Case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. Simple aortic aneurysm and pseudoaneurysm were excluded. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
2578288|NCT02378103||Control|As the control group, patients without AD were obtained from the hospitalized patients in the same period.
2578337|NCT02377687||elderly >75 years|all patients aged ≥ 75 having an emergency GI laparotomy or laparoscopy
2578367|NCT02377323|Other|Treatment with Rebif|Patients treated with Rebif only, for at least two years, and for up to 18 years
2578372|NCT02377323|Other|Never treated|Patients never treated with a disease-modifying drug (DMD)
2578435|NCT02376959|Placebo Comparator|Control Group|"Application of 8 spiritist passe simulation sessions by people without spiritist training at the same time and in the same environment as the treatment group."
2578443|NCT02376959|Active Comparator|"Treatment Group (Spiritist passe)"|"Application of 8 sessions of spiritist passe by spiritists with more than 2 years of experience in controlled environments for the same period as the control group."
2578476|NCT02376582|Experimental|DNA and protein|4mg DNA and 600 mcg protein formulated with Alum co-administration (IM) at Month 0, 1 and 6 in Schisto infected individuals
2578477|NCT02376582|Active Comparator|Vaccination without S. mansoni infection|DNA Protein
2578588|NCT02376140||Women|Mothers of children 36-59 months old No intervention
2578593|NCT02376140||Children|Children 36-59 months old No intervention
3210969|NCT01000415|Experimental|Cisplatin plus gemcitabine|Experimental arm: neoadjuvant chemotherapy (cisplatin plus gemcitabine) followed by surgery Control arm: concurrent chemoradiation (cisplatin/carboplatin)during standard radiation
3210970|NCT01000441|Active Comparator|arm 1 (2d anti-TNF):|infliximab, etanercept, adalimumab
2578728|NCT02374879|Experimental|Blood Glucose monitoring System (BGMS)|Intervention: Blood Glucose monitoring System (BGMS) Results obtained from the BGMS for UP and SA are compared to a reference instrument (YSI)
2578782|NCT02374658|Experimental|Arts Intervention|This group will receive the weekly one-hour Living Through the Arts program in addition to their standard program of rehabilitation activities
2578783|NCT02374658|No Intervention|Control Group|This group of patients will only receive their standard program of rehabilitation activities
3210971|NCT01000441|Active Comparator|arm 2 (other biotherapy)|abatacept, rituximab or tocilizumab
3210972|NCT01000467|Active Comparator|2|Group 2(probucol 500mg BID)
2578959|NCT02373566|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
2578962|NCT02373566|No Intervention|STSG alone|STSG alone
2579026|NCT02373176|Experimental|[14C] PRC-4016 (Icosabutate)|Investigational medicinal product (IMP), [14C] PRC-4016 (Icosabutate) solution (600 mg in 2 mL, 200.0 μCi [7.4 MBq]). The radiochemical purity of [14C]PRC-4016 will be at least 97%.
2579088|NCT02372760|Experimental|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V).
2579722|NCT02368522||Patients treated with and without exposure|
3210973|NCT01000467|Active Comparator|1|Group 1(Probucol 250mg)
3210974|NCT01000467|Active Comparator|3|Group 3(Probucol 500mg once daily)
3210975|NCT01000519|Active Comparator|Aerobic Training|50 minutes of aerobic training, 18 sessions within 2 months period
2578044|NCT02379338|Experimental|Biodistribution Cohort|The Biodistribution cohort will include up to10 patients who will undergo a series of whole body biodistribution [18F]Fluortriopride PET/CT scans over a period of approximately 4 hours.
2578088|NCT02379169|Experimental|Sea buckthorn & lutein|Sea buckthorn oil complemented with lutein. Dose: 2 g/day as capsules taken twice/day for 6 months
2578097|NCT02379169|Placebo Comparator|Placebo|Triglycerides of medium-chain fatty acids. Dose: 2 g/day as capsules taken twice/day for 6 months
2578172|NCT02378818|Other|Schizophrenia patients|35 patients, Age between 18 and 65 years, with a diagnosis of schizophrenia and unchanged psychotropic treatment for at least three months before inclusion.
2578177|NCT02378818|Other|Healthy volunteers (schizophrenia)|35 healthy volunteers
2578179|NCT02378818|Other|Depressive patients|
2578181|NCT02378818|Other|Healthy volunteers (depression)|
2578227|NCT02378337||Retrospective development cohort|A total of 85 18F-FDG-PET adult studies were gathered over a 3-month period and retrospectively evaluated.
2578229|NCT02378337||Prospective validation cohort|To verify the application of methodology in clinical routine, we conducted a second phase of the study prospectively in 250 subjects (phase 2) using inclusion and exclusion criteria of the retrospective study (phase 1).
2578300|NCT02378012|Active Comparator|GROUP A (participants provide own computer or tablet device)|A member of the research personnel helps the participants install Netflix, Spotify, and Skype applications on their computers if they wish to do so. Participants will be given subscriptions to each application and usernames for access on days -5 to 10.
2578302|NCT02378012|Experimental|GROUP B (Apple BuckiPad)|Participants receive an iPad for days -5 to 10. Participants also receive the BuckiPad manual for instructions on how to use the iPad and Netflix, Skype, and Spotify applications. Participants are also directed to the official Apple's iPad user's manual on their device and have questions answered by research personnel on day -5.
2578305|NCT02378012|No Intervention|GROUP C (no intervention)|Participants do not receive an iPad for days -5 to 10.
2578353|NCT02377479|Active Comparator|Clomiphene alone|The patient will take 100mg clomiphene orally from cycle days 3-7
2578357|NCT02377479|Active Comparator|Letrozole alone|The patient will take 5mg Letrozole orally from cycle days 3-7
2578360|NCT02377479|Experimental|Combination Clomiphene and Letrozole|The patient will take a dose of 5mg Letrozole every night and 100mg clomiphene every day after lunch from cycle days 3-7.
3210976|NCT01000519|Experimental|Progressive Resistance Training|50 minutes of progressive resistance training consisting of nine resistance exercises, each conducted 3 sets of 10 repetitions. 18 sessions over 2 months period.
2578471|NCT02376491|Active Comparator|High Frequency Left repetitive|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
2578472|NCT02376491|Experimental|intermittent Theta Burst Stimulation (iTBS)|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks Magventure Cool B65 Coil with Magpro X100
2578532|NCT02376309|Experimental|Leu during inactivity|Leucine supplements
2578533|NCT02376309|Experimental|ND during inactivity|Nandrolone injection
3210977|NCT01000532||Pacemaker therapy|
2578615|NCT02375776|Experimental|Intervention|Download and use mobile health application - CORA- Device:smartphones for 12 weeks.
2578617|NCT02375776|No Intervention|Control|Usual Care - The control group will not use the study's mobile health application during the study.
2578698|NCT02375529|Experimental|Single Incision Cholesystectomy (SILC)|Single Incision Laparoscopic Cholecystectomy (SILC): The umbilicus is grasped and a 2 cm vertical skin and fascial incision is performed. A multiport (TriPort®) is inserted under direct vision. Principles of cholecystectomy are the same as traditional laparoscopic cholecystectomy.
2578700|NCT02375529|Active Comparator|Four Ports Cholecystectomy (4PCL)|Four Ports Conventional laparoscopic cholecystectomy (4PCL): A 10mm supraumbilical incision is made and the pneumoperitoneum insufflated through a Veress needle. 4 ports are introduced: 2 of 10mm in supraumbilical and left flank and 2 of 5mm in epigastric and right flank.
2578757|NCT02374931|Experimental|Diagnostic (18F-FES PET/CT)|Patients undergo 18F-FES PET/CT imaging over 30 minutes.
2578814|NCT02374320|Experimental|Exparel|20 mL liposomal bupivacaine injected once
2578849|NCT02374086|Experimental|Exercise Training|Subjects will exercise for 8 weeks
2578914|NCT02373839|Other|PlGF measurement|Determination of PlGF levels. If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks.
2578916|NCT02373839|No Intervention|Controls|induction of labour at 37 weeks of gestation.
2578956|NCT02373657|Experimental|WASH Intervention|"In these seven communities we built a well in a central location for all state team residents. We plan on providing tippy-taps (water and soap dispensers), instruction in soap-making, and hygiene education to these communities. We will also put fly traps in the communities to see if wells reduce flies. We plan on performing monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density."
2578961|NCT02373657|No Intervention|Control|In these seven communities, we plan to perform monitoring visits at 12 months and 24 months, in order to assess clinically active trachoma, ocular chlamydia infection, nasopharyngeal macrolide resistance, soil transmitted helminths, and childhood growth (height and weight). We will also perform assessments of the adequacy of the intervention, by conducting household surveys to assess hygiene behavior, access to water and latrines, and fly density.
2579002|NCT02373228|Experimental|Compressive signal processing algorithm|Participants compare music signals with preprocessing to the same music signals without compressive preprocessing.
2579054|NCT02372955|Experimental|dapagliflozin 10 mg daily|dapagliflozin, 10 mg daily for 16 weeks
2579058|NCT02372955|Active Comparator|glimpiride|glimpiride 4 mg daily for 16 weeks
2579205|NCT02372019|Placebo Comparator|Inert CBM With Inert Fear Reactivation|
2578081|NCT02379182|Active Comparator|Control group|Will not receive any treatment procedure. Patients allocated in the control group will be treated according to the standard clinical care of patients with dysphagia at our center, that includes: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary.
2578089|NCT02379182|Experimental|Sensory Group|Patients allocated in the sensory group will be treated with transcutaneous electrical stimulation at sensory level. In addition, they will receive the standard clinical care described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
2578093|NCT02379182|Experimental|Motor Group|Patients allocated in the motor group will be treated with transcutaneous electrical stimulation at motor level. In addition, they will receive the standard clinical care of patients with dysphagia described in the control group. The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
2578170|NCT02378727|Active Comparator|A Standard Care Group (SCG)|Standard Care Conventional Group (SCG): 158 subjects to receive lumbar epidural procedure with the loss of resistance syringe used to identify the epidural space
2578174|NCT02378727|Experimental|Experimental Procedure Group (EPG).|158 of subjects to receive lumbar epidural procedure with the CompuFlo® Epidural System used to identify the epidural space
2578206|NCT02378376|Experimental|Wheat derived fiber fraction 1|Arabinoxylan oligosaccharides
2578207|NCT02378376|Experimental|Wheat derived fiber fraction 2|Dietary fiber enriched bran
2578248|NCT02378155|Other|electrical cardioversion|Hemodynamic unstable patients with atrial fibrillation who are scheduled to undergo electrical reconversion to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
2578252|NCT02378155|Other|pharmacological cardioversion|Patients who develop atrial fibrillation after cardiac surgery. Pharmacological treatment with amiodarone is started in order to convert their irregular heart rhythm into a normal sinus rhythm. Cerebral tissue oxygen saturation is measured by means of SenSmart Model X-100, Nonin Medical.
2578315|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype AA|THERANOVA 400 dialyzer prototype AA in hemodialysis
2578317|NCT02377622|Experimental|THERANOVA 400 dialyzer prototype BB|THERANOVA 400 dialyzer prototype BB in hemodialysis
2578319|NCT02377622|Active Comparator|FX CorDiax 80 dialyzer|FX CorDiax 80 dialyzer in hemodialysis
2578321|NCT02377622|Active Comparator|FX CorDiax 800 dialyzer|FX CorDiax 800 dialyzer in high volume hemodiafiltration
2578364|NCT02377388|Active Comparator|treatment: DPP4 -i|"Use of DPP4-i :~sitagliptin 50 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 100 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)~OR~saxagliptin 2,5 mg (if glomerular filtration rate-GFR <50 ml/min at randomization) or 5 mg (if GFR>50 ml/min at randomization),during 30 days,once-daily(OD)"
2578369|NCT02377388|Placebo Comparator|control|placebo tablets identical to active comparator,administered according to GFR at randomization,during 30 days,OD
2578432|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
2578437|NCT02376972|Experimental|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG ADMINISTERED ONCE A DAY FOR 5 DAYS
2578447|NCT02376972|Placebo Comparator|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET ADMINISTERED ONCE A DAY FOR 5 DAYS
2578455|NCT02376972|Active Comparator|METROGEL VAGINAL|METROGEL VAGINAL ADMINISTERED ONCE A DAY FOR 5 DAYS
2578485|NCT02376426|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
2578497|NCT02376426|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
2578508|NCT02376426|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
2578516|NCT02376426|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
2578553|NCT02376088||GA1|subjects from coastal areas who initiated Methimazole treatment for the first time on enrollment
2578558|NCT02376088||GA2|subjects from coastal areas who were under Methimazole treatment and with an elevated TH level
2578561|NCT02376088||GA3|subjects from coastal areas who were under Methimazole treatment and with a normal TH level
2578564|NCT02376088||GB1|subjects from non-coastal areas who initiated Methimazole treatment for the first time on enrollment
2578569|NCT02376088||GB2|subjects from non-coastal areas who were under Methimazole treatment and with an elevated TH level
2578574|NCT02376088||GB3|subjects from non-coastal areas who were under Methimazole treatment and with a normal TH level
2578576|NCT02376088||NC|age-matched healthy checkup subjects
2578602|NCT02375815|Experimental|Statin Choice Implementation|
2578637|NCT02375607|Other|Algometer|Algometer used patients
2578746|NCT02374853|Experimental|Vancomycin|During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
2578837|NCT02374385|Experimental|Group 3|3x10(6) pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL.
2578090|NCT02379026|Experimental|Exercise & Protein Drink/Diet|High-protein (1.2-1.5 g protein per kg bodyweight; a milk-based protein drink will provide 50 g protein/day) energy-restricted (500 kcal deficit) diet and a multimodal exercise program (balance, flexibility, aerobic, resistance) 3 times/week, each lasting 1 hour. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
2578096|NCT02379026|Active Comparator|Exercise|A multimodal exercise program (balance, flexibility, aerobic, resistance) will take place 3 times/week, each one lasting 1 hour. Participants in this group will follow their habitual diet. 1 tablet of Vitamin D3 (25 micrograms) x three days/week. Total duration 16 weeks.
3210978|NCT01000545|Placebo Comparator|placebo gelcaps + best medical treatment|Patient will receive 4 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3210979|NCT01000545|Active Comparator|SLX 500LRU/day + best medical treatment|Patient will receive 1 SLX gelcap and 3 placebo gelcaps twice a day.Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3210980|NCT01000545|Active Comparator|SLX 1000LRU/day + best medical treatment|Patient will receive 2 SLX gelcaps and 2 placebo gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
3210981|NCT01000545|Active Comparator|SLX 2000LRU/day + best medical treatment|Patient will receive 4 SLX gelcaps twice a day. Best Medical Treatment (BMT)refers to the treatment currently acceptable and standard measures for the decrease in proteinuria. These are strict blood sugar control (HBA1c < 7.0%) and BP control (BP< 130/80)
2578310|NCT02377739|Experimental|non-invasive ventilation|patients will undergo about 14 nights of non-invasive ventilation during pulmonary rehabilitation
2578587|NCT02375932|Experimental|Pre-Visit Tool|Patients whose primary care physicians are allocated to the intervention arm will receive a secure electronic message shortly after scheduling an appointment with their provider asking them to complete a pre-visit prioritization survey using the kp.org patient portal
2578590|NCT02375932|Active Comparator|Usual Care Control|Patients whose primary care physicians are allocated to the control arm will continue with usual care
2578654|NCT02375685|Experimental|gevokizumab|
2578718|NCT02375178|Active Comparator|Sterile saline solution|sterile Saline solution 0,9%
2578721|NCT02375178|Experimental|chlorhexidine|chlorhexidine 0,12% mouthwash
2578724|NCT02375178|Experimental|polyhexamethylene|polyhexamethylene biguanide 0,07% mouthwash
2578741|NCT02374710|Experimental|ACL Reconstruction: Anterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed anterior (in front) of the 35% line.
2578743|NCT02374710|Active Comparator|ACL Reconstruction: Posterior Tunnel|During surgery prior to ACL reconstruction, a line will be measured to indicate 35% of the anterior-to-posterior (front to back) distance of the proximal tibia. The tibial tunnel will be placed posterior (in back) of the 35% line.
2578829|NCT02374541|Experimental|Patient Navigation|Assistance from Autism Patient Navigator (APN) to obtain diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
2578833|NCT02374541|No Intervention|Control|Standard referral for diagnostic evaluation / eligibility determination for possible autism spectrum disorder and, if indicated, early intervention services.
2578884|NCT02373956|Experimental|MELECTIS G|"In addition to usual care as described for the other arm, patients randomized to this arm will have MELECTIS G added to their wound dressing according to the manufacturer's instructions.~Intervention: Usual care Intervention: MELECTIS G"
2578888|NCT02373956|Active Comparator|Usual care|"Patients randomized to this are will receive usual care according the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).~Intervention: Usual care"
2578950|NCT02373449|Experimental|RS-fMRI|All subjects will be instructed to keep their eyes closed but to remain awake during the fMRI measurement. Resting State fMRI (RS-fMRI) will be performed within four weeks of planned infusion of ketamine, immediately after the end of infusion of ketamine on the fifth (last) day of infusion, and on the one month follow-up appointment after the infusion.
2579041|NCT02373280|Active Comparator|10 day sequential group|After proving H. pylori infection, the participant will receive the empirical 10 day sequential regimen (Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)+amoxicillin® 1 g bid 5 days (D1-D5)+clarithromycin, klaricid® 500mg bid 5 days (D6-D10)+metronidazole, flasinyl® 500mg tid 5 days (D6-D10) for treatment of H. pylori infection in this group.
2579047|NCT02373280|Experimental|7 days tailored PPI triple therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day tailored regimen [PPI triple therapy (Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+amoxicillin® 1 g bid 7 days (D1-D7)+clarithromycin, klaricid® 500mg bid 7 days (D1-D7)] in this group.
2579053|NCT02373280|Experimental|7 days tailored MEA therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day moxifloxacin triple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)+Amoxicillin® 1 g bid 7 days (D1-D7)] in this group.
2579057|NCT02373280|Experimental|7 or 14 days tailored EBMT therapy group|After proving H. pylori infection, the participant received endoscopic guided biopsy for H. pylori culture and MIC. Based on antimicrobial susceptibility testing, the participant will receive 7 day bismuth quadruple therapy [Esomeprazole, nexium® 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, denol® 300 mg qid 7 days (D1-D7)+Metronidazole, flasinyl® 500 mg tid 7 days (D1-D7)+Tetracycline® 500 mg qid 7 days (D1-D7)] in this group. If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
2579117|NCT02372474|Experimental|Stem Cell therapy in POF|POF cases were evaluated hormonally, HP and IH using ESS. Autologous MSC were prepared and laparoscopically transplanted.
2578100|NCT02379260|Other|Focus Groups|Focus groups contain 5-7 patients. Groups will be stratified according to socio-economic levels and according to treatment (radical prostatectomy with conservation or without preservation of the neuro vascular strips).
2578157|NCT02378792|Experimental|Vagus Verve Stimulation is on|
2578168|NCT02378792|Sham Comparator|Placebo Vagus Verve Stimulation is off|
2578251|NCT02378350|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only observe therapy treatment
2578256|NCT02378350|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only observe therapy treatment
2578279|NCT02377804|Experimental|Experimental intervention|The experimental intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity. In addition, during this intervention patients will also receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pectoralis mayor
2578282|NCT02377804|Active Comparator|Control intervention|The control intervention will consist of 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity.
2578325|NCT02377609||Kidney or Liver Transplant Patients|adult kidney or liver Advagraf® (tacrolimus) recipients
2578368|NCT02377297|Active Comparator|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
2578375|NCT02377297|Experimental|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
2578377|NCT02377297|Experimental|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
3210982|NCT01000571||H1N1 pandemic influenza vaccine recipient|Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in body weight with underlying conditions of cancer, HIV, sickle cell disease or receipt of a stem cell transplant more than a year prior to study entry and who will receive inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010 as part of their routine clinical care.Target total accrual of up to 400 children and young adults stratified based on their underlying diagnosis as follows: 150 children or young adults with cancer, 100 with human immunodeficiency virus (HIV), 100 with sickle cell disease, and 50 with receipt of a stem cell transplant more than a year prior to study entry.
2578614|NCT02376335|Active Comparator|Rituximab infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
2578616|NCT02376335|Placebo Comparator|Placebo infusion|Participants will be randomised to Rituximab therapy (1000 mg IV on days 1 and 15) or placebo (0.9% Sodium Chloride 250mls) control.
2578669|NCT02375503|Experimental|Calcium/Vitamin D|Dietary supplement distributed and consumed as one calcium and vitamin D fortified snack bar per day
2578673|NCT02375503|Placebo Comparator|Placebo|Placebo distributed and consumed as one isocaloric, unfortified snack bar per day
2578720|NCT02375126||Ages 18-35, no antidepressant use|Ages 18-35, up to 15 males and 15 females, no antidepressant use
2578723|NCT02375126||Ages 36-55, no antidepressant use|Ages 36-55, up to 15 males and 15 females, no antidepressant use
2578726|NCT02375126||Ages 18-55, with antidepressant use|Ages 18-55, up to 10 males and 10 females, taking antidepressants
2578752|NCT02374723|Experimental|NuCornea (Biosynthetic corneas)|6 patients will receive biosynthetic corneas when undergoing corneal transplantation
2578754|NCT02374723|Active Comparator|Donated human corneas|6 patients will receive a donated human cornea when undergoing corneal transplantation
2578951|NCT02373501|Experimental|intra-abdominal repair|intra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
2578953|NCT02373501|Experimental|extra-abdominal repair|extra-abdominal repair of uterine incision, after delivery of the fetus and the placenta.
2579044|NCT02373163|Active Comparator|Diuretic|Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM
2579049|NCT02373163|Active Comparator|Calcium-channel blocker|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
2579055|NCT02373163|Active Comparator|Angiotensin Receptor Blocker|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
2579076|NCT02372526||10 Roux-en-Y gastric bypass patients|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
2579078|NCT02372526||10 Healthy Control subjects|Isocaloric amounts of specific macronutrients is mixed with 4 g vegetable bouillon and tested against each others ability to induce GLP-1 secretion. The mealtest takes place at 4 different days with 3-14 days separation.
2579143|NCT02372188|Experimental|Water|125 mL water are administered during or before gastric pH measurement
2579151|NCT02372188|Experimental|Caffeine|150 mg Caffeine and 125 mL water are administered during or before gastric pH measurement
2579160|NCT02372188|Experimental|Caffeine + homoeriodictyol sodium salt|150 mg Caffeine + 30 mg homoeriodictyol sodium salt and 125 mL water are administered during or before gastric pH measurement
2579166|NCT02372188|Experimental|homoeriodictyol sodium salt|30 mg homoeriodictyol sodium salt and 125 mL water are administered during the gastric pH measurement
2579397|NCT02370745|Experimental|Intravenous (IV) amino acids- Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids"
2579399|NCT02370745|Experimental|IV amino acids, GLP-1, GIP -Young|"Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion"
2579580|NCT02369523|Active Comparator|continuous femoral nerve blocks (cFNB)|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
3210983|NCT01000584|Other|1|Group A: One dose of the licensed H1N1 vaccine and one dose of the seasonal influenza vaccine given concurrently
2578241|NCT02378168||cohort of RCT (StV 5-2007; NCT00924222)|Patient group with either sevoflurane or propofol sedation of the RCT (StV 5-2007; NCT00924222)
2578294|NCT02377973||Growth and Development|Growth and Development og healthy young children born by Obese mothers
2578329|NCT02377648|Experimental|ABSORB Bioresorbable Vascular Scaffold|Everolimus-Eluting Bioresorbable Vascular Scaffold implantation
2578389|NCT02377206|Experimental|Alzheimer Disease|Alzheimer Disease People ADAS-Cog evaluation PET imaging with [18F]DPA-714
2578425|NCT02376842|Active Comparator|Severe sepsis early warning best practice alert|Patients in this arm will actively generate the alert.
2578427|NCT02376842|Placebo Comparator|Standard care|This arm will be the current standard of care and will not generate the alert.
2578486|NCT02376621|Active Comparator|PronovaPure 150:500 triglycerides|3 × PronovaPure 150:500 triglycerides (TG) European Union (EU)
2578493|NCT02376621|Active Comparator|Pronovum PRF-048|3 × Pronovum PRF-048
2578507|NCT02376621|Active Comparator|Pronovum PRF-037|3 × Pronovum PRF-037
2578517|NCT02376621|Active Comparator|PronovaPure 500:200 TG|3 × PronovaPure 500:200 TG EU
2578522|NCT02376621|Active Comparator|Pronovum PRF-047|3 × Pronovum PRF-047
2578597|NCT02375997|Experimental|Standard oncology care plus palliative care|
2578600|NCT02375997|No Intervention|Standard oncology care|
3210984|NCT01000584|Other|2|Group B: One dose of seasonal influenza vaccine given 3 weeks after administration of one dose of the licensed H1N1 vaccine
3210985|NCT01000597|Other|Treatment Y|Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
2578722|NCT02375100|Active Comparator|Intrathecal bupivacaine&analgesics|Patients will be given standard care during perioperative period. They will undergo inguinal herniorraphy operation under spinal anesthesia (with 3ml of %0.5 hyperbaric bupivacaine intrathecally) and receive an parenteral pain regimen (acetaminophen for intravenous infusion in two doses routinely and intramuscular tramadol 50 mg when pain score is higher than 4) in postoperative period.
2578725|NCT02375100|Experimental|TAP Block with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive transversus abdominis plane block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
2578727|NCT02375100|Experimental|IlNB with bupivacaine|In addition to standard perioperative care (spinal anesthesia and parenteral pain regimen) patients will receive Ilioinguinal nerve block (with 20ml of %0.25 isobaric bupivacaine) just before surgery is initiated.
3210986|NCT01000597|Other|Treatment Z|A single intravenous dose of 250mcg FF given over 20 minutes (Day 1).
3210987|NCT01000623|Experimental|Arm I|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
3210988|NCT01000623|Active Comparator|Arm II|Patients receive oral venlafaxine once or twice daily in weeks 2-8. Patients see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
2578987|NCT02373618|Experimental|Experimental: DN and Conventional PT|
2578989|NCT02373618|Active Comparator|Active Comparator: Conventional PT|
2579045|NCT02373072|Experimental|Cohort 1|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
2579050|NCT02373072|Experimental|Cohort 2|Three single doses over three periods. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by at least one week.
2579096|NCT02372461|Placebo Comparator|Experimental|Placebo
2579103|NCT02372461|Active Comparator|Control|Amoxicillin Liquid
2579165|NCT02372305|Active Comparator|FlexHD|Patients randomly assigned to receive FlexHD for breast reconstruction.
2579169|NCT02372305|Active Comparator|Alloderm|Patients randomly assigned to receive Alloderm for breast reconstruction.
2579220|NCT02371811|Experimental|v care group|In this group we will use (v care) uterine manipulator during abdominal hysterectomy.
2579224|NCT02371811|No Intervention|control group|In this group we will do abdominal hysterectomy without v care.
2579267|NCT02371473|Experimental|#1 (Acetazolamide-placebo)|The arm #1 consists of 6 eligible patients who receive Acetazolamide 250mg once daily an hour before sleep for first six nights and after two weeks washout they receive placebo for six nights in the same order. After each six-day period they undergo polysomnography.
2579270|NCT02371473|Experimental|#2 (Placebo-acetazolamide)|The arm #2 consists of 6 eligible patients who receive placebo once daily an hour before sleep for first six nights and after two weeks washout they receive acetazolamide 250mg for six nights in the same order. After each six-day period they undergo polysomnography.
2579347|NCT02371161|Experimental|R-DHAP/R-ICE|High-dose myeloablative therapy (R-DHAP or R-ICE) and conditioning therapy (BEAM or FEAM) in elderly patients with relapsed NHL or resistant to firs line therapy
2579443|NCT02370446||patient gets personalized medication log|Patients in the intervention group will receive a personalized medication log that includes all treatment medications (IV and oral), days of treatment and medication specific information such as timing or diet restrictions. The personalized medication log and patient education materials (fact cards) will be placed in a clear plastic envelope that the patient can carry with them throughout treatment.
2579576|NCT02369523|Active Comparator|liposomal bupivacaine (LB) (Exparel)|Mixture of 50 milliliters (mL) of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
3210989|NCT01000623|Active Comparator|Arm III|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn hypnosis in weeks 2-5. Patients continue hypnosis at home in weeks 6-8.
3210990|NCT01000623|Active Comparator|Arm IV|Patients receive oral placebo once or twice daily in weeks 2-8. Patient see a therapist once a week to learn focused attention in weeks 2-5. Patients continue focused attention at home in weeks 6-8.
3210991|NCT01000688|Experimental|vildagliptin treatment first, acarbose treatment second|
3210992|NCT01000688|Experimental|acarbose treatment first, vildagliptin treatment second|
3210993|NCT01000740|Experimental|1|Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment
2578249|NCT02378272|Experimental|Care manager for depression|A district nurse will apply around 15-25% of working time as care coordinator (care manager for depression) at PCC for management of care for all recruited patients with depression
2578254|NCT02378272|No Intervention|Treatment As Usual|Management of recruited patients with depression continued as usually applied at PCC
2578272|NCT02377895|Experimental|Nasapaque Nasal Solution|250 ul in each nostril at Day 1 and Day 8
2578273|NCT02377895|Active Comparator|Placebo Saline Nasal Solution|250 ul in each nostril at Day 1 and Day 8
2578320|NCT02377726|Experimental|Internet self-help with support|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules. Patients will have access to Alkoholhjälpen counselor support through secure comments at every module they complete.
2578322|NCT02377726|Experimental|Internet self-help|eChange Alkoholhjälpen is an internet based self help program consisting of 5 modules.
2578323|NCT02377726|Active Comparator|Information|Brief information on resources that can be accessed through the open access website Alkoholhjälpen: Information on alcohol and health, where and how to find treatment and an internet discussion forum.
2578365|NCT02377336|Experimental|GS-6615|GS-6615 30 mg (5 x 6 mg) on Day 1, followed by 6 mg twice daily
2578374|NCT02377336|Placebo Comparator|Placebo|Placebo to match GS-6615 (5 tablets) on Day 1, followed by placebo to match GS-6615 twice daily
3210994|NCT01000740|No Intervention|2|Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP
2578479|NCT02376634|Active Comparator|Hypnosis|"The hypnosis group will receive a semi-structured intervention by primary investigator. The intervention is somewhat individualized based on the recipients personal characteristics (e.g., age, gender, medical history). The intervention will begin with an induction phase during which the participant is guided to relax and to focus their attention on one stimuli. The intervention will then proceed with a suggestion phase. Suggestions used in this phase will all be directed toward decreasing the patient's anxiety and post-operative pain. Patients will be taught self-hypnosis to decrease distress and reframe painful experiences."
2578502|NCT02376634|No Intervention|Control|This group will receive the standard of care of Nationwide Children's Hospital.
2578607|NCT02376218|Experimental|Hypertonic 50% dextrose pleurodesis|
2578636|NCT02375620|Experimental|PEG-somatropin: Low dose|0.1 mg/(kg.w), once per week for 52 weeks.
2578638|NCT02375620|Experimental|PEG-somatropin: High dose|0.2 mg/(kg.w), once per week for 52 weeks.
2578689|NCT02375282|Experimental|Ambulation Orderly Intervention|Patients that are in this group are those randomized to receive visits from the ambulation orderly (ambulation group). The patients in this group will receive the visits from the ambulation orderly in addition to the standard of care that occurs with the rest of the hospital and with the control group.
2578692|NCT02375282|No Intervention|Control Group|This is for the patients who are randomized to receive the standard care of Baystate Medical Center. The standard of care will be nurse-directed ambulation, as is currently done in all other nursing floors at Baystate Medical Center. Nurses will be instructed to walk with the patients as they did before the initiation of the ambulation orderly and as they do when the orderly is on vacation, at conferences, training, or away for illness. These patients will not receive visits from the ambulation orderly.
2578732|NCT02374996||APIGT|Bipolar subjects treated with antipsychotics and having impaired glucose tolerance
2578735|NCT02374996||APNGT|Bipolar subjects treated with antipsychotics and having normal glucose tolerance
2578739|NCT02374996||LINGT|Bipolar subjects treated with lithium and having normal glucose tolerance
2578794|NCT02374645|Experimental|Volitinib (AZD6094) 600mg + gefitinib 250 mg|Cohort 1: Volitinib（AZD6094） 600 mg od + gefitinib 250 mg od
2578795|NCT02374645|Experimental|Volitinib (AZD6094) 800mg + gefitinib 250 mg|Cohort 2: Volitinib（AZD6094） 800 mg od + gefitinib 250 mg od
2578846|NCT02374190||Hospital Admitted STEMI Patients|The analytical cohort for this study consisted of STEMI patients aged over 18 years admitted directly to '24/7' PPCI-capable hospitals for PPCI. STEMI patients were identified based on their discharge diagnoses and were selected as having received PPCI according to their initial reperfusion strategy. Hospitals performing only sporadic PPCI procedures, which we defined as less than 20 procedures per year, and only performing PPCIs during regular hours were not included in the analysis. Interhospital transfers were not included in the analysis, and we limited our analysis to PPCIs conducted within 6 hours on hospital arrival on the assumption that patients with a DTB time beyond this did not receive PCI as a primary reperfusion strategy. The analysis was conducted for the time period for which data were available-1 January 2007 to 31 December 2012. We conducted a complete-case analysis.
2578889|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 1|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) and Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578893|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 2|Each subject will receive a single dose of Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) and Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578898|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 3|Each subject will receive a single dose of Treatment B (DTG/RPV 50 mg/25 mg: Product Code AS), Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578899|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 4|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM) and Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578192|NCT02378649|Placebo Comparator|Placebo|"PDEI or placebo will be administered in the surgical ICU 4-6 hours after arriving from the Operative Room. The initial Dose will be 20mg X 3 NG and can be increase to 40mg X 3, it will be administered PO if the patient extubated.~PDEI or placebo will continue up to 8 days or discharge."
2578230|NCT02378298|Active Comparator|Non-responder RTX+MTX|"Patients with moderate-severe TAO with an inflammatory CAS of ≥ 4 that do not respond to iv GC (deltaCAS <2 compared to baseline after 4 weeks of iv GC ) or do relapse (deltaCAS ≥2 and total CAS ≥4) after steroid treatment compared to previous CAS measurement at 12 weeks. Rituximab (1000 mg iv with 2 weeks in between) is combined with methotrexate (15-20 mg once a week) to minimize the risk of antibody developement. MTX is always combined with RTX and is never given as a monotherapy in this study.~rituximab and methotrexate"
2578234|NCT02378298|Active Comparator|Relapse RTX+MTX|Patients that respond to iv GC (Methylprednisolone iv) but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) rituximab and methotrexate
2578235|NCT02378298|Active Comparator|Relapse po GC+MTX|"Patients that respond to iv GC but relapse after 6 weeks will be randomised to either RTX+MTX or per oral GC (po GC+MTX) This is the conventional therapy arm.~methotrexate and methylprednisolone"
2578238|NCT02378298|No Intervention|Responders without relapse|Patients that respond to iv GC and have no relapse at 18 weeks of study.
2578240|NCT02378298|Active Comparator|Methylprednisolone iv|All patients in the study have a 4 weeks period of 500 mg methylprednisolone iv/week. Depending of the response patients are classified as non- responders (and are given RTX and MTX) or responders. The responders continue with intravenous infusion of Methylprednisolone 500 mg /week in 2 weeks and thereafter 250 mg iv/week in 6 weeks.
2578284|NCT02377843|Experimental|Participatory|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the participatory study arm will receive a 1-hour in-person communication training.
2578289|NCT02377843|Experimental|Efficient|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the efficient study arm will receive a 1-hour in-person communication training.
2578293|NCT02377843|No Intervention|Control|This arm includes 10 pediatric or family medicine clinics located within a 2-hour driving distance of Chapel Hill, NC, and have 100 or more 11-12 year old patients with active records in the NCIR. Clinics randomized to the control study arm will not receive a 1-hour in-person communication training.
2578327|NCT02377583||Diabetic children|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI"
2578328|NCT02377583||Controls|"physical examination~Glucocorticoid sensitivity index~DNA sample~Anxiety and depression questionnaires~depression questionnaire~MRI~Laboratory tests"
3210995|NCT01000740|No Intervention|3|Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being
3210996|NCT01000753||Observational (specimen collection)|See Detailed Description
3210997|NCT01000766||Acute drug-induced liver injury|
3210998|NCT01000779|Active Comparator|Endoscopic Variceal Ligation|endoscopic therapy to obliterate varices
2578579|NCT02375958|Experimental|Triple Negative Breast Cancer|
2578581|NCT02375958|Experimental|Head and Neck Cancer|
2578582|NCT02375958|Experimental|Esophageal Cancer|
2578631|NCT02375763|Experimental|Sortware suggestions|Children will fill a questionnaire regarding their dietary habits. Afterwards a dietary analysis will be performed using a computer software, and dietary instructions will be given to the children.
2578633|NCT02375763|Placebo Comparator|Traditional suggestions|
2578666|NCT02375477|Experimental|Health services research (isolation protocol education)|Residents and nurses are given an educational intervention on isolation protocols for diarrhea and enteric pathogens approved by Infection Control and covering their recommendations.
2578704|NCT02375139|Experimental|DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
2578706|NCT02375139|Experimental|E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 2.5/500mg x 2 Tablets E : Evogliptin 5 mg M : Metformin XR 1000 mg
2578734|NCT02374827|Active Comparator|Standard postpartum tubal ligation|In this arm, patients will receive the standard postpartum tubal ligation by accepted methods (procedure names are the following: Modified pomeroy technique or Parkland method). These methods are procedures for completing a partial salpingectomy.
2578738|NCT02374827|Experimental|Complete Salpingectomy|In this arm, patients will receive a complete salpingectomy by documented accepted methods.
2578933|NCT02373774|No Intervention|Standard Anatomic Palpation Technique|Participants randomized to this group will receive standard of care treatment with providers using the palpation technique to select an interspace to perform lumbar puncture.
2578934|NCT02373774|Experimental|Pre-Procedural Ultrasound|Participants randomized to this group will receive an ultrasound of the interspace selected via the palpation method prior to performance of the lumbar puncture to determine measurements of appropriate angle and depth and evaluation of any overlying vasculature.
2578990|NCT02373462|Experimental|olmesartan group|olmesartan (20mg qd then 40mg qd for titrating BP <140/90 mmHg)
2578992|NCT02373462|Active Comparator|other group|other anti-hypertensive drug (titrating BP <140/90 mmHg)
3210999|NCT01000779|Active Comparator|Propranolol|drugs to decrease portal pressure
3211000|NCT01000792|Experimental|Levocetirizine|Levo 5 mg o.d.
2579133|NCT02372123|Other|control|lifestyle advice
2579135|NCT02372123|Active Comparator|intervention|connective tissue manipulation
2579212|NCT02371694|Experimental|Fat Test drink (50g)|This drink contains 50g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
2579215|NCT02371694|Experimental|Fat Test drink (38g)|This drink contains 38g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
3211001|NCT01000831|Active Comparator|Adjuvanted Arepanrix 2 doses|Two doses of adjuvanted H1N1 Arepanrix vaccine given 3 weeks apart
2578263|NCT02378467|Experimental|Active Treatment Group|7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
2578266|NCT02378467|Active Comparator|Control Group|0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks
2578312|NCT02377765|Active Comparator|Percutaneus Stimulation|PTNS performed bilaterally every 4 weeks within the Physiotherapy Department.
2578314|NCT02377765|Experimental|Transcutaneous Stimulation|TPTNS applied bilaterally, using two surface, self-adhesive, round electrodes (3 cm in diameter) in each leg at least 3 times per week.
2578355|NCT02377414|Experimental|Cohort 1: Retosiban/placebo|Each subject in cohort 1 will receive an intravenous (IV) bolus infusion of 6 milligrams (mg) retosiban or placebo over 5 minutes, followed by a continuous infusion of 6 milligram per hour (mg/h) retosiban or placebo for 24 h. At 24 h of dosing, an additional 6 mg retosiban or placebo will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h. Subjects administered with placebo will receive an equal volume of normal saline as an IV bolus as well as an equal rate of continuous infusion of normal saline as of retosiban.
2578359|NCT02377414|Experimental|Cohort 2: Retosiban|Each subject in cohort 2 will receive a bolus infusion of 6 mg retosiban over 5 minutes, followed by a continuous infusion of 6 mg/h retosiban for 24 h. At 24 h of dosing, an additional 6 mg retosiban will be administered over 5 minutes followed by a 12 mg/h infusion over the next 24 h, for a total time of infusion of 48 h.
2578431|NCT02377076|Experimental|DAIRY|Dietary calcium supplementation
2578436|NCT02377076|Placebo Comparator|CONTROL|Control
2578503|NCT02376556||Blepharoplasty|patients undergoing upper eyelid blepharoplasty
2578514|NCT02376556||blepharoplasty and muller muscle resection|patients undergoing a combined blepharoplasty and muller muscle resection surgery
2578621|NCT02376244|Experimental|High intensity interval training (HIIT)|"Patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 16-17 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
2578626|NCT02376244|Active Comparator|Standard Care|"Patients assigned to this group will participate in usual standard care of cardiac rehabilitation.~Commonly, patients will undergo a 15-minute warm-up, followed by a 24-minute conditioning phase, and a 10-minute cool-down. The conditioning phase will include a combination of aerobic exercise (e.g. cycling or walking) and resistance exercise (e.g. squats, bicep curls). Patients will complete 5 intervals of 3 minutes with 2 minute rest periods interspersed. The intensity will correspond to 11-15 on the Borg 6-20 Rating of perceived exertion scale.~Patients will exercise once a week for 8 weeks."
2578683|NCT02375451||Radioiodine|Patients with a history of childhood treatment with radioiodine will be assessed for symptoms of salivary function and measurement of saliva production. These data will be compared to a normal control group.
2578684|NCT02375451||Control|Patients who are similar in age to those in the Radioiodine group, but who did not recieve I-131 therapy.
2578712|NCT02375061|Experimental|e-BPS intervention|"Participants are asked to write and imagine about a future in which they have reached all their goals in four different domains: personal, professional, social and health domain. They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform (TEO-Emotional Therapy Online) in which they can visualize all the content they had developed previously."
2578713|NCT02375061|Placebo Comparator|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
2578748|NCT02374775||Group A (Culprit lesion)|The plaque in the culprit vessel of acute myocardial infarction will be defined the Group A.
2578753|NCT02374775||Group B (Non-culprit lesion)|The plaque in the non-culprit vessel of acute myocardial infarction will be defined as internal control, Group B.
2578792|NCT02374502|Experimental|Brief Intervention Group|Participants in this intervention group will receive a twelve week 'Brief Intervention' delivered by a physiotherapist. Participants will have an initial consultation with a physiotherapist, followed by a number of follow-up sessions. The number and timing of follow-up sessions will be at the participant's discretion (a minimum of 3 and a maximum of 11 over the duration of the study). The follow-up sessions can be face-to-face, over the telephone, or video conferencing depending on participant preference. Participants may additionally opt-in for a weekly email or text message reminder of physical activity goals.
2578793|NCT02374502|No Intervention|Control Group|Participants in this control group will be asked to continue with their current levels of physical activity.
2578958|NCT02373644|Experimental|HVLA Thrust Manipulation and DN|
2578967|NCT02373644|Active Comparator|Conventional Physical Therapy|
2579004|NCT02373241|Active Comparator|Standard Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <95th percentile
2579007|NCT02373241|Experimental|Experimental Blood Pressure Management|Participants initiated on 25mg of losartan daily and randomized to lower in-clinic BP to <75th percentile
2579043|NCT02372890||All patients|Patients with head and neck squamous cell carcinoma with advanced primary tumor stages (cT3 or cT4), clinical suspicion of cervical lymph node metastases, cervical lymph node metastasis of unknown primary tumor (CUP) or patients with tumor recurrence scheduled for neck dissection.
2579087|NCT02372734||Sepsis with acute kidney injury (AKI)|Prior admission for sepsis with a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
2579094|NCT02372734||Sepsis without acute kidney injury (AKI)|Prior admission for sepsis without a diagnosis of AKI as a child. Intervention: The subjects will be administered the Peds QL survey.
2578324|NCT02377531|Other|Early glucose screen group|Participants with high risk factors for gestational diabetes, will be randomly assigned to an early glucose screen group: it consists of an oral load of 50 grams of glucose followed by a measurement of serum glucose 1 hour later, and if abnormal (higher than 130mg/dl), will undergo a 100 gram oral load of glucose followed by serum glucose levels drawn 1,2 and 3 hours after the load. If abnormal according to Carpenter-Cousant criteria, the participant will undergo standard of care for Gestational Diabetes.
2578326|NCT02377531|Other|Standard glucose screen group|The participants in this group will be randomized to undergo the testing process previously described at 24 to 28 weeks.
2578371|NCT02377375|Experimental|Micro-assisted|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
2578378|NCT02377375|Active Comparator|Standard|In each patient, one electrode will be implanted using the standard technique and one electrode will be implanted using the micro-electrode assisted technique. The side is randomized.
2578440|NCT02376985|Placebo Comparator|Brushing instruction group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Brushing and gargling with saline after every meal (initially instructed by a dental/oral surgeon)."
2578450|NCT02376985|Experimental|Dental oral management group|"Drug: Everolimus and Exemestane Everolimus, 10 mg/day Exemestane, 25 mg/day Administration on consecutive days once daily after breakfast until tumor progression or for a minimum 8 weeks.~Oral treatment:~Scaling and enamel polishing will be performed by a dental and oral surgeon or dental hygienist before everolimus treatment, and once weekly after everolimus treatment.~Brushing and gargling with Neostelin Green 0.2% mouthwash solution after every meal (initially instructed by a dental/oral surgeon)."
2578489|NCT02376504|Experimental|Treadmill workstation|Participants will be provided with a treadmill workstation to be more active at the workplace Active Workplace
2578498|NCT02376504|Experimental|Sit-to-Stand workstation|Participants will be provided with a sit-to-stand workstation to be decrease sitting time at the workplace Active Workplace
2578510|NCT02376504|No Intervention|Control|Participants will be asked to engage in three 10 min walking bouts each work day
2578546|NCT02376231|No Intervention|Standard Surgery without trial (PJ) device|Standard debulking surgery for EOC without interventional device
2578549|NCT02376231|Active Comparator|Surgery with trial (PJ) device|Debulking surgery for EOC with interventional trial device (PJ)
2578622|NCT02375880|Experimental|150 mg DKN-01 Part A|Patients will receive 150 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
2578624|NCT02375880|Experimental|300 mg DKN-01 Part A|Patients will receive 300 mg of DKN-01 followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
2578628|NCT02375880|Experimental|MTD mg DKN-01 Part B|Patients are treated at the maximum tolerated dose (MTD) of DKN-01 (or highest dose tested in Part A if the MTD is not defined) followed by gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 on Days 1 and 8 of each 21-day cycle.
2578677|NCT02375295|Experimental|Arm A: 2 weeks Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose.
2578680|NCT02375295|Active Comparator|Arm B: 12 weeks/3 months Abx post PCNL|Oral antibiotics: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin are administered for 2 weeks at full dose followed by a suppressive dose for another 10 weeks (total = 12 weeks or 3 months).
2578755|NCT02374905|Experimental|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
2578761|NCT02374905|Active Comparator|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
2578796|NCT02374437|Active Comparator|PART A (single dose)-200 mg|200 mg ARAMCHOL
2578797|NCT02374437|Active Comparator|PART A (single dose)-400 mg|400 mg ARAMCHOL
2578798|NCT02374437|Active Comparator|Part B ( food effect)- -Fasting|600 mg Aramchol tablets under fasting conditions (fasting for at least 10 hours before and 4 hours after dosing)
2578803|NCT02374437|Active Comparator|Part B ( food effect)- -Fed|600 mg Aramchol tablets under fed conditions (fasting for at least 10 hours before dosing, consumption of a high calorie high fat meal within 30 minutes prior to drug administration and no food for additional 4 hours after dosing)
2578804|NCT02374437|Active Comparator|Part C ( multiple doses)- 200 mg|200 mg Aramchol tablets for ten consecutive days.
2578807|NCT02374437|Active Comparator|Part C ( multiple doses)- 400 mg|400 mg Aramchol tablets for ten consecutive days.
2578808|NCT02374437|Active Comparator|Part C ( multiple doses)- 600 mg|600 mg Aramchol tablets for ten consecutive days.
2578809|NCT02374437|Placebo Comparator|Part C ( multiple doses)- Placebo|Placebo tablets for ten consecutive days.
3211002|NCT01000857|Experimental|Open label treatment with 2-period crossover design|"Group 1: Paroxetine CR 25 mg/day for 14 days / Paroxetine IR 20 mg/day for 14 days.~Group 2: Paroxetine IR 20 mg/day for 14 days / Paroxetine CR 25 mg/day for 14 days.,~PK results will be compared between the Paroxetine CR treatment period and the Paroxetine IR treatment period."
3211003|NCT01000870|Experimental|Access MNI-513 and PET Imaging|
2578994|NCT02373332||Healthy subjects|Healthy subjects for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
2578997|NCT02373332||Type 2 diabetes mellitus (T2DM) patients|T2DM patients for oxylipin effect Platelets from healthy donors will be assessed for regulation of platelet reactivity by fatty acids and 12-lipoxygenase oxylipins.
2579011|NCT02373046|Experimental|Treatment A|1 × 400-mg LX4211 tablet (fasted conditions)
2579012|NCT02373046|Experimental|Treatment B|2 × 200-mg LX4211 tablets (fasted conditions)
2579072|NCT02372721||Control|No history of an admission for AKI. This group will have urinary and serum studies to measure glomerular filtration rate, renal plasma flow followed by cardiovascular assessments using blood pressure monitoring, peripheral arterial and applanation tonometry.
2579101|NCT02372747|Experimental|Billroth II anastomosis group|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
2579119|NCT02372448|Other|ALK-positive|ALK positive analysis on CTCs detected by ISET
2579121|NCT02372448|Other|ALK-negative|ALK negative analysis on CTCs detected by ISET
2578409|NCT02376816|Experimental|Cohort 1: Low Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 3E11 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
2578412|NCT02376816|Experimental|Cohort 2: High Dose|The rAAVrh74.MCK.micro-Dystrophin vector will be injected to the Extensor Digitorum Brevis (EDB) muscle of a single foot at a total dose of 1E12 vg. The contralateral EDB muscle will injected with normal saline placebo as a comparator. Both physician and study team will be blinded as to which muscle received vector vs placebo. A minimum of three (3) patients with DMD will be enrolled in this cohort.
2578462|NCT02376478||TNF-alpha inhibitors|TNF-alpha Inhibitors: patients with psoriasis or inflammatory bowel diseases under TNF-alpha inhibitor monotherapy
2578465|NCT02376478||Purine/folic acid analogues|Purine/folic acid analogues: patients with psoriasis or inflammatory bowel diseases receiving monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate
2578467|NCT02376478||Combination therapy|Combination therapy: patients with psoriasis or inflammatory bowel diseases receiving combination therapy with TNF-alpha blocker plus purine or folic acid analogues
2578468|NCT02376478||Alternative/no medication|Alternative/no medication: patients with psoriasis or inflammatory bowel diseases receiving alternate therapy, such as phototherapy, fumaric acid, mesalazine, or no medication
2578605|NCT02376153|Experimental|ABS deployed and active|Air Barrier System (ABS) will be deployed onto the surgical field and activated.
2578609|NCT02376153|Sham Comparator|ABS deployed and NOT active|Air Barrier System (ABS) will be deployed onto the surgical field and NOT activated. This is a sham comparator to reduce the influence of the presence of the device and provide user blinding.
2578693|NCT02375568||103024-F|For patients who have an operation of total knee replacement, two removed tissues (synovial membrane and infrapatellar fat pad) will be collected for mesenchymal stem cell isolation.
3211004|NCT01000896|Experimental|AZD0530 + carboplatin and paclitaxel|AZD0530 in combination with carboplatin and paclitaxel
3211005|NCT01000922|Experimental|Regular Human Insulin|Single injection
2578850|NCT02374177||Propofol group|Patient anesthetized using propofol
2578857|NCT02374177||Sevoflurane group|Patients anesthetized using sevoflurane
2578910|NCT02373878|Active Comparator|Telecoaching plus plate|Telecoaching plus portion control plate
2578913|NCT02373878|Active Comparator|Usual Care|Usual Care
2578939|NCT02373670|Experimental|Parent Mentor|Parent mentors using positive deviance findings to promote healthy behaviors
2578940|NCT02373670|Active Comparator|Education|Community health workers providing health education to promote healthy behaviors
2578965|NCT02373358|Experimental|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
2579013|NCT02373189|Experimental|Bright light|
2579032|NCT02372851|Active Comparator|Pureit As+ Filter|Each household will receive one water filter and a replacement battery for free during distribution. The intervention will be distributed door-to-door by the implementation team. Households will be trained on use and maintenance of the device according to the manufacturer's instructions. Households will be advised to drink exclusively from the water filter and to carry water with them if attending school or work. Households will also be advised to clean and cook their rice with filtered water only.
2579037|NCT02372851|No Intervention|Control arm|The control arm will be advised to continue with their traditional drinking water and cooking practices. The control arm will receive the intervention at the end of the study period.
2579085|NCT02372669|Experimental|Chitosan|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair with the additional use of a chitosan nerve tube.
2579095|NCT02372669|Active Comparator|Gold standard alone|Enrolled participants presenting with traumatic sensory nerve lesions of the hand without defect zone that were randomized to primary microsurgical repair without the additional use of a chitosan nerve tube.
3211006|NCT01000922|Experimental|Lispro|Single injection
3211007|NCT01000922|Experimental|VIAject|Single injection
3211008|NCT01000922|Experimental|VIAject 50%|Single injection
3211009|NCT01000922|Experimental|VIAject/Insulin glargine|Single injection
2579366|NCT02370992||Receiving I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
2579380|NCT02370654|Experimental|Tai Chi|12 week Tai chi intervention, 3 sessions per week, 90 minutes per session
2579384|NCT02370654|Active Comparator|Conventional exercise|12 week conventional exercise intervention, 3 sessions per week, 90 minutes per session
3211010|NCT01000922|Experimental|Insulin Glargine/VIAject|Single injection
3211011|NCT01000935|Active Comparator|Platelet Rich Plasma|The platelet concentrate extracted from patient's own blood (PRP) will be applied to the surgical site after completion of the repair.
2579513|NCT02369965|Experimental|albuvirtide, lopinavir-ritonavir|albuvirtide once a week and lopinavir-ritonavir twice daily for 48 weeks
2579520|NCT02369965|Active Comparator|lopinavir-ritonavir,tenofovir,lamivudine|lopinavir-ritonavir twice daily, tenofovir once daily and lamivudine once daily for 48 weeks
3211012|NCT01000935|No Intervention|Surgical repair (standard-of-care)|Patients will have a rotator cuff repair without the PRP application.
3211013|NCT01000948|Experimental|ZD4054|The study had only one arm: intervention
3211014|NCT01001013|Experimental|LC15-0444 200 mg|LC15-0444 200 mg
3211015|NCT01001013|Experimental|Pioglitazone 30 mg|Pioglitazone 30 mg
3211016|NCT01001013|Experimental|LC15-0444 200 mg + pioglitazone 30 mg|LC15-0444 200 mg + pioglitazone 30 mg
3211017|NCT01001026|Other|1|Adults: One doses of H1N12009 vaccine
3211018|NCT01001026|Other|2|Children: Two doses of H1N12009 vaccine given 3 weeks apart
2578459|NCT02376855|Experimental|eConsult|"The intervention consisted of an eConsult pathway and standardized protocol for PCPs to obtain cardiology consults using a secure messaging peer to peer (P2P) module embedded within the EHR. Intervention providers were asked to send all cardiology referrals for their adult patients through the eConsult system. Providers could bypass the eConsult pathway for patients with established relationships with a cardiologist or for whom providers felt a consult was urgent (required a face-to-face visit within a week or less). eConsults contain reason for consult, relevant test results, records or reports but are sent electronically to a Cardiology Consultant for review. eConsults were responded to within two business days. Responses were case-specific and generally contained recommendations for management, additional testing, or a face-to-face cardiology visit. The PCP was responsible for considering/acting upon recommendations and determining when an eConsult was complete."
2578478|NCT02376517|Active Comparator|Educational program|Participants randomized to the intervention group will receive the educational program at the baseline visit.
2578492|NCT02376517|No Intervention|Control|Participants randomized to the control group will receive the educational program at the follow-up visit.
2578563|NCT02376205|Experimental|bupivacaine hydrochloride 0.5% solution|Bupivacaine hydrochloride 0.5% 10 mL solution poured into the retropharyngeal space intraoperatively before wound closure during anterior cervical discectomy and fusion procedure
2578568|NCT02376205|Placebo Comparator|0.9% NaCl solution|0.9% NaCl 10 mL solution poured into the retropharyngeal space intraoperatively before wound closureduring anterior cervical discectomy and fusion procedure
2578606|NCT02375828|Experimental|Patients with neonatal diabetes|Patients with neonatal diabetes
2578639|NCT02375581|Experimental|Icotinib & Radiotherapy|Icotinib, 125mg, Po, Tid, during the course of radiotherapy; Thoracic radiotherapy, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
2578640|NCT02375581|Active Comparator|Radiotherapy alone|Thoracic radiotherapy alone, 50-60Gy, conventional fraction, 3D-CRT/IMRT.
2578697|NCT02375256|Experimental|AERAS-402|3 x10^10 viral particles per 0.5 mL suspended in 10 mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL.
2578699|NCT02375256|Active Comparator|Placebo|1.0 mL sterile vaccine buffer containing 10mM Tris buffer, 1 mM MgCl2, 75 mM NaCl, 5% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80), 0.1 mM EDTA, 10 mM l-histidine, 0.5% v/v ethanol and water. The dose volume administered was 0.5 mL
2578729|NCT02374892|Experimental|Intervention|"Adolescents will attend a single one-on-one session with a nurse. Sessions will be youth-oriented, interactive, and engaging. They will make a health passport, go over their cardiac anatomy, watch videos among other things.~The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up."
2578730|NCT02374892|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
2578786|NCT02374632|Other|Low EBL|"Gastric bypass operated patients with low postoperative excess body weight loss (EBL) <50%.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
2578789|NCT02374632|Other|High EBL|"Gastric bypass operated patients with high postoperative excess body weight loss (EBL) >70% matched with respect to age, gender and preoperative BMI in the LowEBL group.~Interventions: Meal tests after saline/octreotide injection in a randomized order, sham feeding."
2578823|NCT02374242|Active Comparator|Cohort 1 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
2578824|NCT02374242|Active Comparator|Cohort 2 Nivolumab Monotherapy|Nivolumab 3mg/kg every 2 weeks, until disease progression, withdrawn consent, unacceptable toxicity or death.
2578825|NCT02374242|Active Comparator|Cohort 3 Nivolumab and Ipilimumab|Nivolumab 1mg/kg every 3 weeks x four doses and ipilimumab 3mg/kg every 3 weeks x four doses. After 12 weeks, nivolumab 3mg/kg alone every 2 weeks until disease progression, withdrawn consent, unacceptable toxicity or death.
2578945|NCT02373592|Placebo Comparator|Thermometry-only group|"Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet.~Some alarm signs have been pre-specified: 1) thermal image shows yellow spots in any area of feet for two consecutive days, 2) thermal image shows different colors in contralateral areas of the feet for two consecutive days or, 3) a dermal lesion. In any of these three scenarios, subjects will be instructed to contact the study nurse by phone. (See Detailed Description for more detail on the actions after an alarm sign has been observed)"
2578946|NCT02373592|Experimental|Thermometry plus SMS and voice messaging|"Thermometry-related intervention activities will be the same as those established for the thermometry-only group. In addition, this group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages has been developed and validated through both SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
2579036|NCT02373306|Active Comparator|NIPS-sensitive group|Patients who had sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation.
2579039|NCT02373306|No Intervention|Control group|Patients who had no sustained or hemodynamically unstable arrhythmias induction during non-invasive programmed stimulation.
2579147|NCT02372630|Placebo Comparator|Placebo|Patients will be treated for 12 weeks with placebo once daily
2579157|NCT02372630|Active Comparator|Linagliptin 5mg per day|Patients will be treated for 12 weeks with Linagliptin 5mg once daily.
3211019|NCT01001039||control|Patients seen in the Otology clinic who have not had sinus surgery in the past 2 months or a history of sinusitis in the last 6 months.
2579266|NCT02371434|Experimental|Treatment arm|"Patients in ONEnTreg13 will be treated with four immunosuppressive agents, all of which are classified as an Investigational Medicinal Products (IMPs):~nTregs~Prednisolone~MMF~Tacrolimus"
3211020|NCT01001039||cases|Patients seen in the Rhinology Clinic with a complaint of facial pain. They must have evidence of chronic sinusitis.
3211021|NCT01001091|Experimental|AL-38583 0.01%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3211022|NCT01001091|Experimental|AL-38583 0.05%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3211023|NCT01001091|Experimental|AL-38583 0.2%|AL-38583 ophthalmic solution, 1 drop instilled in each eye 3 times per day for 2 weeks
3211024|NCT01001091|Placebo Comparator|AL-38583 Vehicle|AL-38583 ophthalmic solution vehicle, 1 drop instilled in each eye 3 times per day for 2 weeks
3211025|NCT01001091|Active Comparator|MAXIDEX|Dexamethasone ophthalmic suspension, 0.1%, 1 drop instilled in each eye 3 times per day for 2 weeks
3211026|NCT01001117|Experimental|Laser treated|Eye treated with LensAR Laser System
2578610|NCT02375945|Active Comparator|current compression stocking Comprinet®|"Immediately post operatively 24 hours compression therapy starts with Elastomull Haft ®, an elastic bandage, combined with a Comprinet stocking (BSM Medical®) for anti thrombotic purposes. The anti thrombosis stocking is worn 6 weeks post operatively. After 4 hours the patient is ambulated and the physical therapy starts."
2578611|NCT02375945|Experimental|New non-elastic compression kit|"Juxta Reduction Kit ® Immediately post operative compression starts with the Juxta Reduction Kit® for the knee region, combined with an anti thrombosis stocking (Struva 2, for prevention of trombo-embolism). Both the stocking and the Juxtra Pro are used for six weeks. After 4 hours the patient ambulated and the physical therapy starts.~For the first 24 hours and longer if necessary (depending on the skills of the patient) Juxta experienced staff will apply the device and the fit and the use of the device will be checked.~In the second phase between approximately 24 hours and 6 weeks patients may adjust the Juxta-pro according to their needs and comfort by themselves."
2578643|NCT02375542||Cardiac Reoperation|Patients who have previously undergone a cardiac operation with the use of BioGlue and are now undergoing a reoperation
3211027|NCT01001117|Active Comparator|Control Eye|Contralateral eye treated with conventional phaco-emulsification
2578733|NCT02375009|Experimental|Treatment Cohort|All subjects will receive bilateral 360 degree Selective Laser Trabeculoplasty therapy in a single session, but will be randomized to one of three treatment sessions at times 0, Month 3 and Month 6. Subjects will be washed out of current IOP-lowering therapy 4-6 weeks pre-SLT. Subjects continuing on meds beyond time 0 will provide a comparator to early SLT to quantify regression to the mean.
2578839|NCT02374229|Experimental|The study group|"Procedure: mitral valve surgery, surgical ablation of ganglion plexus pulmonary artery.~Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. During the operation, a standard surgical procedure for the treatment of heart valve disease will be complemented by the ablation zone of bifurcation of the pulmonary artery, surgical ablation of ganglion plexus pulmonary artery.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement.~Procedure will be considered effective in the face of declining average pressure in the pulmonary artery for invasive monitoring of 10mm Hg and more."
2578844|NCT02374229|Active Comparator|The control group|"Procedure:mitral valve surgery. Will include 15 patients with mitral stenosis or insufficiency subject to correction, complicated by high pulmonary hypertension. Patients will be made standard procedure correction mitral valve disease without pulmonary artery denervation.~For mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement only."
3211028|NCT01001130||fluticasone furoate group|Korean patients administered fluticasone furoate according to the Prescription information
3211029|NCT01001143|Experimental|Dose Level 1|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 100 mg/m2 PO daily for each 28 day cycle."
2578970|NCT02373384|Experimental|Study group|"Eligible patients, who fulfilled the study criteria, will be instructed For;~Oral alkalinization~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females), will receive Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily.~Life style modification Adequate fluid intake in order to maintain urine volume between 2-3 L per day.~Dietary recommendations~In hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) ;~- Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables."
2579040|NCT02373111|Active Comparator|Isoflavone and Astaxanthin|Each subject takes one active tablet per day for 24 weeks. Each tablet contains isoflavone 27mg and astaxanthin 4mg.
2579046|NCT02373111|Placebo Comparator|Placebo|Each subject takes one placebo tablet per day for 24 weeks.
2579146|NCT02372565|Experimental|Facebook and Text Message|Participants randomized to the technology-based physical activity intervention will receive a culturally-relevant physical activity promotion intervention delivered via text messages and the social media website Facebook. The purpose of the intervention materials is to encourage participants to achieve a minimum of 150 minutes/week of moderate-intensity aerobic physical activity each week.
2579154|NCT02372565|Active Comparator|Standard Print-based Intervention|Participants randomized to the standard print-based physical activity intervention group will be mailed 4 self-help booklets promoting physical activity produced by the American Heart Association. Booklets will be mailed one at a time in 2 week intervals over the 1st 6-weeks of the intervention. These high quality booklets provide general information on the benefits of physical activity, tips and strategies to increase daily physical activity, and encourage recipients to perform a minimum of 10,000 steps per day.
2579204|NCT02371941|Experimental|Oral cromolyn|"Subjects randomized to the experimental arm will receive oral cromolyn sodium. The dose will be per current package insert for oral cromolyn:~Subjects 2-12 years of age - 100 mg (1 ampule) 4 times daily Subjects 13-18 years of age - 200 mg (2 ampules) 4 times daily"
2579208|NCT02371941|Placebo Comparator|Placebo|Subjects randomized to placebo will receive normal saline ampules Subjects 2-12 years of age - 1 ampule 4 times daily Subjects 13-18 years of age - 2 ampules 4 times daily
2579244|NCT02371512|Experimental|Percutaneous mitral valve repair (MitraClip system )|Percutaneous mitral valve repair (simultaneous left atrial and ventricular pressure assessment suggested) with MitraClip system (Abbott)
3211030|NCT01001143|Experimental|Dose Level 2|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 200 mg/m2 PO daily for each 28 day cycle."
3211031|NCT01001143|Experimental|Dose Level 3|"Decitabine 20 mg/m2 IV days 3-7 of cycle 1 and days 1-5 of subsequent cycles. Each cycle is 28 days.~Bexarotene 300 mg/m2 PO daily for each 28 day cycle."
3211032|NCT01001182||Non interventional|Patients with RA diagnosis receiving any treatment for RA (DMARDS or biologics)
2578634|NCT02375750|Experimental|GBO and GBG|0.2 g-0,5 g GBO and 1 GBG once after decontamination of implant surface
2578635|NCT02375750|Active Comparator|Standard treatment|Decontamination of surface of implant
2578660|NCT02375386|Experimental|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
2578663|NCT02375386|Sham Comparator|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
2578731|NCT02375022|Experimental|Endostar and icotinib|Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
2578790|NCT02374619|Experimental|Iron supplement|Oral supplementation
2578791|NCT02374619|Placebo Comparator|Control|Oral supplementation
2578826|NCT02374268|Experimental|Exercise program alone|There will be 2 site sessions and 1 home session per week for 12 weeks. Each site exercise session will begin and end with a 5-10 minute warm-up and cool-down routine. The first part of the exercise program consists of 20-30 minute chair-based resistance exercises using Thera-Bands for muscle groups in both the upper and lower body. To target the development of muscle power in both the lower and upper extremities, participants will be instructed to perform each concentric movement 'as rapidly as possible,' and the eccentric movement in a slow and controlled manner. A 5-minute rest period will be given prior to the start of the second part of the exercise program that consists of aerobic exercises such as ball games using fitballs or Taichi. Participants will be asked to spend an hour/week on home exercise. Thera-Bands and a leaflet showing the exercise procedures will be given to them and their caregivers.
2578827|NCT02374268|Experimental|Exercise program plus nutrition supplement|This group will receive both the exercise program as well as the nutrition supplement. The components of the exercise program will be same as those of the exercise program alone group. Participants will also be asked to consume two sachets of Ensure NutriVigor every day during the 12-week intervention period. Ensure NutriVigor (one sachet of 54.1 g powder) contains 231 calories, 8.61 g protein, 1.21 g hydroxyl-methyl-butyrate (HMB), 130 IU vitamin D, and 0.29 g omega 3 fatty acid per serving. Participants will be instructed on how to prepare the supplement.
2578831|NCT02374268|Other|Waitlist control group|This group will be asked to maintain their usual physical activities and dietary habits during the first 6 months of study period. After they complete the 24-week measurement, they will receive the same 12-week exercise program as of the exercise program alone group.
2578882|NCT02373943|Experimental|β-carotene biofortified maize|Participants will ingest porridge bF: this will be the β-carotene fortified maize porridge where each 250 g will be made with 50 g of dry maize flour obtained from fortified corn seeds. The contents of β-carotene and other provitamin A carotenoids in this flour will be determined before preparing the porridges.
2578886|NCT02373943|Active Comparator|white maize supplemented with β-carotene|Participants will ingest porridge F: this will be also a β-carotene fortified maize porridge but in this case it will be made with 50 g of dry maize flour obtained from non fortified corn seeds and supplemented with a 500-1500 µg β-carotene reference dose. The exact dose of β-carotene that will be added to these porridges will be established according to the amount of β-carotene found in the flour used with porridges BF.
2578891|NCT02373943|Sham Comparator|white maize|Participants will ingest porridge N which will be the control porridge and will be made with 50 g of dry maize flour obtained from non fortified corn seeds.
2578955|NCT02373722|Experimental|Group I (video, text message)|Patients watch an educational video about Mohs surgery before their surgery, a video about wound care after the surgery and receive text messages about wound care on days 1-5 after the surgery. Patients also receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are instructed to apply petroleum jelly BID to the wound area.
2578960|NCT02373722|Experimental|Group II (educational video)|Patients watch an educational video about Mohs surgery before their surgery, an educational video about wound care after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients apply petroleum jelly BID to the wound area
2578972|NCT02373722|Experimental|Group III (text message)|Patients receive text messages about wound care on days 1-5 after the surgery and receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound are.
2578977|NCT02373722|Experimental|Group IV (control)|Patients receive no video or text messages. Patients receive instructions to reduce movement and use a Fitbit activity tracker. Beginning 48 hours after surgery, patients are also instructed to apply petroleum jelly BID to the wound area.
2579035|NCT02372877|Experimental|Amicus Red Cell Exchange in SCD patients|Open arm. Patients with sickle cell disease (SCD) treated using one Amicus Red Cell Exchange procedure.
2579077|NCT02372591|Placebo Comparator|Placebo|
2579080|NCT02372591|Active Comparator|Hydromorphone|
2579082|NCT02372591|Experimental|Buprenorphine|
3211033|NCT01001260||No Aspirin Treatment|
3211034|NCT01001260||81 mg Aspirin Treatment|
3211035|NCT01001260||325 mg Aspirin|
3211036|NCT01001273|Experimental|Study Group|Hyperinsulinemic Normoglycemic Clamp will be started at the time of surgery (before incision) and will be continue for 3 days.
3211037|NCT01001273|No Intervention|Control Group|Patients in the control group will receive standard care.
2578591|NCT02376322|Experimental|Radiotherapy in bone metastases|The purpose of this one armed, phase II trial is to determine the efficacy and safety profile of a hypofractionated radiotherapy regimen, 16 Gy in 2 fractions with an interval of one week, for the palliation of complicated bone metastases in patients with poor performance status.
3211038|NCT01001286|Active Comparator|Youth Club|The intervention will be compared to a waitlist comparison group. The group will enter NFE after the four-month posttest. During the four months, the youth will be offered a biweekly recreational youth club. The club will be led by Jordanian university student volunteers out of community-based organizations. Club activities will take place approximately every two weeks, including games, sports, arts and crafts, cultural activities, and trips. The Club will not include any significant education components or youth empowerment methodology--the hypothesized active ingredients of QS NFE.
2578736|NCT02374970|Experimental|Intervention group|Actual Lumbar stability exercises involving co-contraction of the transversus abdominis and Protocolized Physiotherapy (therapeutic exercises and thermotherapy during 12 sessions)
2578740|NCT02374970|Active Comparator|Control group|Protocolized Physiotherapy treatment: therapeutic exercises and thermotherapy during 12 sessions.
2578800|NCT02374554|Other|Respiratory Rate Measurement Comparision|To demonstrate equivalence of the Thora-3Di Structured Light Plethysmography device and a Clinician Over-scored End Tidal C02 (COSC)derived from a BCI Capnograph 9004 (Smiths Medical) for measurement of Respiratory Rate
3211039|NCT01001286|Experimental|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
3211040|NCT01001312|Experimental|Daxor Blood Volume Analysis|Subjects in this treatment arm will receive guideline recommended treatment based on direct blood volume measurement for assessment of volume status.
2579021|NCT02372994|Experimental|Intervention Group|The randomization is at the level of attending healthcare professional who identifies patients for recruitment. For each participant in the intervention arm, a secure space (called a Patient Loop) is created in the online clinical communication system. A Patient Loop can be accessed by the patient, their caregiver, and the healthcare providers who have permission to do so through an algorithm of invitation, authentication and careful partitioning. In each Patient Loop, team members can post messages that can be read and responded to by the entire team. Each Patient Loop consists of a patient, their caregiver and at least two healthcare professionals.
2579023|NCT02372994|No Intervention|Control Group|Participants receive usual care.
2579091|NCT02372695|Experimental|Treatment|Patient will take one pill of paricalcitol a day.
2579099|NCT02372695|No Intervention|Usual treatment.|Patient allocated to this arm will only take his/her habitual treatment
2579137|NCT02372422|Experimental|Transvaginal Cervical Length Group|Clinicians managing the patients were aware of the transvaginal cervical length ultrasound measurements.
2579139|NCT02372422|Other|Routine Care|Clinicians managing the patients were not aware of any transvaginal cervical length ultrasound measurements.
3211041|NCT01001312|Active Comparator|Clinical volume status assessment|Subjects in this treatment arm will receive guideline recommended treatment based on clinical assessment of volume status.
3211042|NCT01001338|Experimental|RDEA594 200 mg qd|RDEA594 200 mg qd plus allopurinol qd
3211043|NCT01001338|Experimental|RDEA594 200 mg, 400 mg qd|"RDEA594 200 mg then 400 mg qd plus allopurinol qd.~Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
3211044|NCT01001338|Placebo Comparator|Matching Placebo|"RDEA594 matching placebo qd plus allopurinol qd, then allopurinol qd alone in open label period.~Patients on allopurinol qd alone were discontinued after protocol amendment 16 dated 07 October 2015."
3211045|NCT01001338|Experimental|RDEA594 600 mg qd|"RDEA594 200 mg then 400 mg then 600 mg plus allopurinol qd~Patients on lesinurad 600 mg had their dose changed to lesinurad 200 mg after protocol amendment 16 dated 07 October 2015."
2579524|NCT02369770|Experimental|Study group|Subjects in the Study group will receive stretching and active movement training with robotic guidance and intelligent control
2579526|NCT02369770|Experimental|Control group|Subjects in the Control group will receive stretching and active movement training without robotic guidance.
3211046|NCT01001351|Placebo Comparator|Placebo|
3211047|NCT01001351|Experimental|PRT-201|
3211048|NCT01001364|Experimental|Formoterol/Budesonide|
2579744|NCT02368353|Experimental|Cognitive behavioral therapy group|weekly group stress-management CBT (SM-CBT) - 1/week 3 months
2579745|NCT02368353|Active Comparator|Reference group|weekly supportive therapy - 1/week 3 months
2579770|NCT02368015|Other|Patients with a large hepatic cyst|"During this study all subjects undergo aspiration sclerotherapy and receive antibiotic prophylaxis with a single dose of cefazolin (intravenous infusion 1000mg) following standard care.~In order to secure patient safety and allow accurate measurement of cefazolin concentrations, an additional peripheral intravenous cannula (IVC) will be placed to allow blood withdrawal at three timepoints."
3211049|NCT01001364|Active Comparator|Foraseq|
3211050|NCT01001455||blood pressure monitor|Cuff circumference:22cm-36cm
3211051|NCT01001455||stethoscopy|Cuff circumference: 22cm-36cm
3211052|NCT01001468|Experimental|VB-201 20 mg|
3211053|NCT01001468|Experimental|VB-201 80 mg|
3211054|NCT01001468|Placebo Comparator|Placebo|Single daily dose of oral placebo
3211055|NCT01001481||001|
3211056|NCT01001507|Experimental|Integrated HIV/FP services|Family planning services are integrated into HIV care and treatment services at this facility.
3211057|NCT01001507|No Intervention|Standard (non-integrated), referral-based, services|Patients from the HIV care and treatment clinic will be referred for family planning services, and will not receive FP services by the HIV care provider
3211058|NCT01001533||Children sedated by DEX|All pediatric patients (1 month to 18 years of age) eligible for Radiology Sedation Service for CT scan and Nuclear Medicine Scan procedure.
2578620|NCT02375789|Placebo Comparator|Placebo RhinoChill|"The same procedure will be followed for the placebo comparator as in the active comparator. The RhinoChill device looks identical and functions in a very similar way to the active device however through some minor design changes the device has been altered to provide a sufficient placebo treatment.~At the onset of an acute migraine headache the patient will insert the RhinoChill Migraine Intranasal catheters and the 10 minute treatment is commenced on Low Flow.~During this time the patient will complete the basic data record sheets to document current symptoms and changes in severity throughout the period of treatment and then at specific time points thereafter.~The patient remains in the trial until two separate migraines have been treated."
2578656|NCT02375425||No contraceptive use|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
2578658|NCT02375425||levonorgestrel IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
2578661|NCT02375425||paraguard IUD|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
2578664|NCT02375425||DMPA|BV-/HSV- BV-/HSV+ BV+/HSV- BV+/HSV+
2578714|NCT02375165||Cohort with lymphedema|Participants with a history of acquired lymphedema of at least 6 months' duration, will have phlebotomy for serum and plasma.
2578717|NCT02375165||Cohort without lymphedema|Healthy volunteers; will have phlebotomy for serum and plasma.
2578751|NCT02374736|Experimental|Human normal immunoglobulin G (IgG > 98 % purity)|"All subjects will be treated for 6 months. The treatment will start the day of inclusion (M0).~Privigen will be given as 2 g/kg for 2 days/month. The maximum daily dose authorized will be 80g.~The infusion rates are the recommended rates for Privigen in other indications and are in line with the market authorization for Privigen:~Infusions should start at a rate of 0.5 mg/kg/min (0.005 mL/kg/min; 0.3 mL/kg/h; 30 mg/kg/h). If well tolerated within 30 min, the rate can be increased in a first step to 1.0 mg/kg/min (0.01 mL/kg/min; 0.6 mL/kg/h; 60 mg/kg/h) for another 30 min.~If well tolerated, a stepwise increase to a maximum of 8 mg/kg/min (0.08 mL/kg/min; 4.8 mL/kg/h; 480 mg/kg/h) is allowed at the discretion of the investigator."
2578813|NCT02374489|Experimental|single-arm studies|"LDK378 in suitable patients:~Collect tumor tissue for immunohistochemistry staining to confirm the status of ROS1 or ALK expression. If the patient fits all criteria, LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle"
2578851|NCT02374112|Experimental|Experimental|Creatine supplementation
2578854|NCT02374112|Placebo Comparator|Control|Placebo supplementation
3211059|NCT01001585|Experimental|slow induction with sevoflurane|Only children with a BIS greater than 95 prior to inhalation of sevoflurane will be included in the study. Inductions will be done using a tight fitting mask with continuous monitoring of end tidal gas concentrations. During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached. Inspired sevoflurane will be increased only after end tidal concentration of sevoflurane is constant for at least one minute. Each induction (except for the patients requiring very low doses of sevoflurane) will take approximately 10 minutes.
3211060|NCT01001611|Experimental|CKD-501 0.5mg|
3211061|NCT01001611|Placebo Comparator|Placebo|
3211062|NCT01001624|Experimental|A|Melanil facial cream
3211063|NCT01001624|Active Comparator|B|Hydroquinone 2% cream
2579277|NCT02371421||Allopurinol|Participants with history of gout indicated by the use of allopurinol or participants who have high serum uric acid without contraindication to use allopurinol.
2579327|NCT02371200||Brain Sentinel Seizure Detection and Warning System|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
3211064|NCT01001637|Active Comparator|curcumin|
3211065|NCT01001637|Placebo Comparator|Placebo|
2579485|NCT02370069|Active Comparator|Previous immunization with PPV23|Participants who have received a previous vaccination with 1 or more dose of PPV23 at least 12 months previously will receive one dose of 0.5 mL Prevnar 13 study vaccine.
2579492|NCT02370069|Active Comparator|Naive to PPV23|Participants who have never received a previous vaccination with PPV23 will receive one dose of 0.5 mL Prevnar 13 study vaccine.
3211066|NCT01001650|Experimental|Group 1|4 doses of 7,500 PfSPZ/immunization.
3211067|NCT01001650|Experimental|Group 2|4 doses of 30,000 PfSPZ/immunization
2579598|NCT02369380|Experimental|Hyaluronic acid|Injections of hyaluronic acid under metatarsal heads
3211068|NCT01001650|Experimental|Group 3|4 doses of 135,000 PfSPZ/immunization
3211069|NCT01001650|Experimental|Group 4|4 or 6 doses of 135,000 PfSPZ/immunization.
2579734|NCT02368626|Experimental|RF ablation treatment|'EndyMed Pro™ RF Micro-Needles' - RF ablation treatments for wrinkle appearance reduction
3211070|NCT01001663|Experimental|FemoSeal®|Closure device for femoral artery access closure
3211071|NCT01001663|Active Comparator|Manual compression|Conventional manual compression
3211072|NCT01001676|Active Comparator|Conventional Balloon Angioplasty|
3211073|NCT01001676|Experimental|Drug Eluting Balloon Angioplasty|
3211074|NCT01001689|Experimental|Nutritional counseling + exercise groups|Women in this arm will receive 2 telephone consultations on nutritional health during pregnancy, be invited to 2 evening meetings with nutritional topics and have access to a password protected internet site with topics related to nutrition and fitness in pregnancy. They will also be enrolled in an exercise group which will meet twice weekly, and be encouraged to exercise on their own 1-2 times each week.
3211075|NCT01001689|No Intervention|control|Women in this arm of the study will receive routine pregnancy care.
3211076|NCT01001715|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
3211077|NCT01001715|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
3258961|NCT01466205|Experimental|DAR 0-100A|The examination of SPD subjects, who are more likely than schizophrenia patients to show significant cognitive improvement after the use of single doses of dopamine agonists, such as DAR-0100A provides an excellent opportunity to demonstrate the effectiveness of D1 agonists on cognition in the schizophrenia spectrum.
2578645|NCT02375659||Focus group|Each focus group (4 total) will be approximately 90 minutes in duration. A trained facilitator will pose 8 scripted questions to the focus group participants and manage the conversation, ensuring all participants have an opportunity to respond and steering the conversation to remain on task. A note-taker will also be present at the focus group to document via handwritten notes the flow and content of the focus group conversation. All focus groups will be audio taped and transcribed.
2578662|NCT02375360||Children 8-12- control|Children aged 8-12 years with food allergy who are not undergoing oral immunoterapy
2578665|NCT02375360||Parents 0-12 - control|Parents to children aged 0-12 years with food allergy who are not undergoing oral immunoterapy
2578668|NCT02375360||Children 8-12 - OIT|Children aged 8-12 years with food allergy who are undergoing oral immunoterapy
2578672|NCT02375360||Teenagers 13-17 - OIT|Teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
2578674|NCT02375360||Adults >18 - OIT|Adults> 18 years with food allergy who are undergoing oral immunoterapy
2578675|NCT02375360||Parents 0-12 - OIT|Parents to children aged 0-12 years with food allergy who are undergoing oral immunoterapy
2578678|NCT02375360||Parents 13-17 - OIT|Parents to teenagers aged 13-17 years with food allergy who are undergoing oral immunoterapy
2578785|NCT02374528|Experimental|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
2578788|NCT02374528|Active Comparator|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
2578838|NCT02374294|Experimental|Epiflo|After the surgery, but before the application of dressing to the surgical site the kit containing the investigation device (and four cannula) is opened. The EPIFLO cannula (sterile package) is opened and applied to the surgical site and sealed with the dressings per protocol. The EPIFLO device is connected to the cannula after making sure the switch is in the ON position.The EPIFLO device is mounted on the patient's body in a convenient location using the Pouch and Arm band provided. At Treatment Visit 3 (Postoperative day #14, +/- 1 day) a new device is given and the old one disposed of. Intermittent dressing changes will take place as needed.
2578840|NCT02374294|No Intervention|Standard of Care|After the surgery, but before the application of dressing to the surgical site if upon opening, the kit contains only a weighted block, then, the regular wound dressing protocol, standard of care, will be followed. Intermittent dressing changes will take place as needed.
2578894|NCT02374021|Active Comparator|Triple therapy (MTX+SSZ+HCQ)|Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
2578897|NCT02374021|Active Comparator|TNF inhibitor (etanercept or adalimumab)|etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.
3258962|NCT01466205|Placebo Comparator|Placebo|Some subjects receive placebo, instead of the study drug, in a double-blind randomized fashion. This allows for performance comparison between SPD subjects on DAR-0100A and those on placebo. The hypothesis is that SPD subjects on DAR-100A will show improvement on primary measures greater than SPD subjects randomized to placebo between baseline and post-drug.
3258963|NCT01466218||WTC Volunteers and Workers|Any current participant of the World Trade Center Health Program-Clinical Center of Excellence, formerly known as World Trade Center Medical Monitoring and Treatment Program
2579014|NCT02372929||Endoscopic Ultrasound Staging|Prospective study of esophageal cancer patients referred for endoscopic ultrasound
2579102|NCT02372812|Active Comparator|group1|12 mg( 3 mls) of dexamethasone given 15 mins after induction of anesthesia
2579105|NCT02372812|Placebo Comparator|group2|3 mls of placebo( normal saline) given 15 mins after induction of anesthesia
2579128|NCT02372279|No Intervention|No embryo observation (NEO)|Study group. No embryonic observation from day one to day five of embryo development.
2579130|NCT02372279|Experimental|Embryo observation (EO)|Control group. Conventional embryonic observations performed in day two, three and five of embryo development.
3258964|NCT01466231|Experimental|everolimus 10 mg po daily|everolimus 10 mg po daily
2579249|NCT02371603|Experimental|Part A: GSK1278863, pioglitazone and rosuvastatin|Subjects will receive single, oral 15 milligram (mg) pioglitazone, 10 mg rosuvastatin and 25 mg dose of GSK1278863 (Treatment A) or 15 mg pioglitazone and 10 mg rosuvastatin (Treatment B) on Day 1 and a 25 mg dose of GSK1278863 alone on Day 2 in two treatment periods as per treatment sequence AB or BA. The 2 treatment periods will be separated by a wash out period of approximately 7 days
2579253|NCT02371603|Experimental|Part B: GSK1278863 and trimethoprim|Subjects will receive a single, oral 25 mg dose of GSK1278863 on Day 1 and Day 6 morning. The subjects will also receive 200 mg dose of trimethoprim twice daily from Day 3 to 6, with Day 6 dosing being concomitant with morning dosing of GSK1278863
2579336|NCT02371135||patients having lower endoscopy|At least 2 weeks prior to scheduled lower endoscopy, consented study participants will be mailed a Brief Diet and Lifestyle Questionnaire, a stool collection kit with detailed instructions and a Stool Collection Data Sheet. No more than one week prior to the lower endoscopy but prior to initiation of bowel preparation, the consented participants will provide a stool specimen and fill out the two questionnaires. The routine lower endoscopy will be performed according to routine clinical procedures. Clinical biopsies of suspicious areas and/or lesions will be taken as per standard clinical care with all such tissue samples sent to pathology for routine clinical analysis. For the sole purposes of research, at the routine lower endoscopy, up to 8 additional colonic biopsies will be taken from normal appearing colon mucosa
2579401|NCT02370706|Experimental|Dose Escalation Arm 1|
2579403|NCT02370706|Experimental|Dose Escalation Arm 2|
2579404|NCT02370706|Experimental|Dose Escalation Arm 3|
2579405|NCT02370706|Experimental|Dose Expansion Arm 1|
2579409|NCT02370706|Experimental|Dose Expansion Arm 2|
2579412|NCT02370706|Experimental|Dose Expansion Arm 3|
2579481|NCT02370212|Experimental|Creatine|"Creatine will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.05 g/kg body mass of creatine with 0.05 g/kg flavoured dextrose per dose).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
2578703|NCT02375217|Active Comparator|Group 1 : (NS)|"Group 1 Drug combination:~patients receive half of the recommended dose of sugammadex plus dose of neostigmine~Sugammadex IV= -1 mg/kg( moderate NMB) or~2 mg/kg (deep NMB)~neostigmine IV = 50mcg/kg~glycopyrrolate 10 mcg/kg"
2578705|NCT02375217|Active Comparator|Group 2 : (S)|"patients receive Full recommended dose of sugammadex~Sugammadex IV= 2mg/kg (Moderate NMB) 4mg/kg ( Deep NMB)"
2578759|NCT02374814|Active Comparator|Rabies vaccine IM 3 dose|This is standard FDA approved schedule
2578764|NCT02374814|Experimental|Rabies vaccine ID 3 dose|This is using alternative administration method
2578770|NCT02374814|Experimental|Rabies vaccine IM 2 dose|This is using alternative dose schedule
2578775|NCT02374814|Experimental|Rabies vaccine ID 2 dose|This is using alternative dose schedule and administration
2578777|NCT02374814|Placebo Comparator|Placebo IM 1 dose|Albumin and saline comparator
2578780|NCT02374814|Placebo Comparator|Placebo ID 1 dose|Albumin and saline comparator
2578835|NCT02374333|Experimental|huCART19|CART19 cells transduced with a lentiviral vector to express humanized anti-CD19 administered by IV injection
2578887|NCT02374008|Experimental|Combined nerve block|Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone
2578892|NCT02374008|Active Comparator|Local infiltrationanalgesia|Ropivacaine, Adrenalin and Ketorolac combined with systemic high dose dexamethasone
2578935|NCT02373709||Cases: Perinatal depression|Cases will be defined as those with a depressive episode with onset during the antenatal or postnatal period.
2578938|NCT02373709||Controls: No perinatal depression|Controls will be defined as those who score < 7 on Edinburgh Postnatal Depression Scale and/or no episode of clinical depression from pregnancy until 6 months postnatal.
2578980|NCT02373436|Experimental|Constraint Induced Therapy|"All participants will receive a glove that limits the use of the fingers and wrist, and can be placed by the participant. They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The intervention training will consist of 30 minutes of exposure of the transfer package, the interview with the items in the MAL, and 2 hours and 30 minutes with about four task Shaping, which may vary according to the needs of each individual, and Task Practice, standardized to be the same for all individuals."
2578985|NCT02373436|Other|Control|They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
3211078|NCT01001728|Active Comparator|Prone Position|Patients will lie on their fronts on an in-house designed board comprising an arm positioning device registerable to the couch-top, together with a styrofoam/ memory foam mattress. The ipsilateral breast will drop through an aperture in the mattress. The distance from the nipple to the superior, inferior and lateral aspects of the aperture will be recorded along with the distance of the nipple from the couch-top. Arms will be extended as far as possible above the head and the position of the arm immobilisation handles recorded. The head will be turned to the contralateral side. The contralateral breast will be pulled laterally such that it is as flat as possible beneath the patient. Measurements will be taken in order to relate the position of the bi-lateral tattoos to the orthogonal lasers. A fourth tattoo will be marked on the patient's back in line with the A-P laser. The position will be reproduced at treatment using measurements from the tattoo to the laser.
2579073|NCT02372539||Non-diabetes|Patients without diabetes will serve as the control group
2579074|NCT02372539||Diabetes|Patients with diabetes will be further stratified based upon antihyperglycemic medications (insulin versus oral medications)
2579115|NCT02372435|Experimental|Short interval|"Re-Implantation of the prosthesis after a short interval of 2-3 weeks after explantation (fast-track-arm)."
2579116|NCT02372435|Active Comparator|Long interval|Re-Implantation of the prosthesis after a Long interval of 6-10 weeks (standard surgical treatment).
2579170|NCT02372214|No Intervention|Group 1|30 patients/5 vascular surgery residents The residents of the last year of vascular surgery will perform the procedure under supervision of a senior surgeon
2579172|NCT02372214|Experimental|Group 2|30 patients/5 vascular surgery residents Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
2579260|NCT02371590|Experimental|Lenalidomide-Obinutuzumab|All patients receive the combination of lenalidomide and obinutuzumab. There is no randomization or comparator arm.
3258965|NCT01466296|Experimental|Re-Step|"Mechatronic shoe with a sole made to change slopes in the swing phase of walking.~This unpredictable change will introduce a situation of necessary adaptation to keep balance"
3258966|NCT01466296|Experimental|Dummy shoes|The shoes are in the same shape and weight of the Re-Step without the perturbations.
2579651|NCT02368769||During tele-expertise|Remote site interpretation of frozen section
2579654|NCT02368769||Before tele-expertise|Usual (on site) frozen section
2579740|NCT02368639|Experimental|Positive airway pressure (PAP) device|Fisher & Paykel Healthcare PAP Device. Participants will sleep overnight using themodified positive airway pressure device. Their pressures will be titrated by a qualified sleep technician, they will then be optimised during the night.
2579785|NCT02368067|Active Comparator|Standard of Care Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which standard clinical dye will be used.
2579788|NCT02368067|Experimental|Installation of Study Sentinal Node Dye|Surgery route, as determined by the patient and clinician, will determine which study dye will be used for delivery by the experimental route.
2579821|NCT02367755|Experimental|Propofol|propofol infusion at a rate of 3 mg/kg/hr during TH.
2579825|NCT02367755|Active Comparator|Lorazepam|lorazepam infusion at a rate of 0.5 mg/kg/hr during TH.
2579894|NCT02367378||MIS|Those who received minimally invasive surgical procedures
2579901|NCT02367378||Control|Those who received treatments which include surgical resection, chemotherapy, and radiotherapy.
2579922|NCT02367053|Experimental|ZP4207|single dose of ZP4207 in ascending doses (s.c. and i.m.)
2579925|NCT02367053|Active Comparator|native glucagon|single fixed dose of glucagon
2580837|NCT02361177|Experimental|oxytocin|Intranasal 24 IU oxytocin self-administration.
3176314|NCT00642967|Experimental|Methoxy Polyethylene Glycol-epoetin Beta|Participants will receive subcutaneous methoxy polyethylene glycol-epoetin beta every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 micrograms (mcg) will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
3176315|NCT00642980|Active Comparator|Clindamycin Cure 1|Arm 1
2578993|NCT02373319|Experimental|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
2578996|NCT02373319|Experimental|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
2578999|NCT02373319|Active Comparator|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
2579001|NCT02373319|Active Comparator|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
2579025|NCT02373007|Other|Classic Scopinaro Surgery|Patients will get the Bariatric surgery using the Classic Scopinaro Techniques
2579029|NCT02373007|Other|Modified Scopinaro Surgery|Patients will get Bariatric surgery using the Modified Scopinaro Techniques
2579228|NCT02371772|Other|Self-management anticoagulation treatment|Trained to monitor INR and dose warfarin
2579229|NCT02371772|No Intervention|Conventional anticoagulation treatment|Before enrolment
2579273|NCT02371460|Experimental|DHA-rich algal oil|1200mg DHA per day
2579275|NCT02371460|Placebo Comparator|Placebo|No supplementation in DHA
2579339|NCT02371070||Rivaroxaban|N=20
2579340|NCT02371070||Apixaban|N=20
2579342|NCT02371070||Dabigatran|N=20
2579487|NCT02370173|Experimental|PTSD wavelength-1 bright light|30 minutes of daily light exposure for 6 weeks
2579491|NCT02370173|Placebo Comparator|PTSD wavelength-2 bright light|30 minutes of daily light exposure for 6 weeks
2579511|NCT02369861|Experimental|ST266|Eye drops
2579516|NCT02369861|Placebo Comparator|Artificial tears|Refresh lubricant eye drops
3176316|NCT00642980|Active Comparator|Clindamycin Cure 2|Arm 2
3176317|NCT00642980|Placebo Comparator|Placebo|Arm placebo
2579792|NCT02367963|Experimental|Intervention|A Training period and a Peer-group intervention are asigned to this arm. Peer-group intervention is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
2579794|NCT02367963|Other|Control|"A Training period intervention is asigned to this arm. Once the workshops have been carried out, the control group will be provided with written and visual documentation of risk factors and overall health habits. The members of this group will have access to the study website, where they will be able to find information on risk factors and health habits and links to the same websites related to health as the intervention group.~They won't participate in the sessions of peer education group dynamics for a period of 12 months."
2579824|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,7|0.5ml experimental vaccine on day 0,7 and a booster dose 12 months later
3176318|NCT00643019|Experimental|SAFE Intervention|Behavioral Intervention
3176319|NCT00643019|Other|Control|Sexually Transmitted Infection Risk Reduction Counseling
3176320|NCT00643032|Active Comparator|I|
3176321|NCT00643032|Active Comparator|II|
3176322|NCT00643045|Experimental|1|Low dose (50-100mg/day)
3176323|NCT00643045|Experimental|2|High dose (150-200 mg/day)
3176324|NCT00643045|Placebo Comparator|3|
3176325|NCT00643058|Experimental|1|Sterile Saline, LPS endotoxin
3176326|NCT00643071|Experimental|1|
3176327|NCT00643084|Experimental|1|patients will consume a low residue diet prior to surgery and have no routine bowel preparation
3176328|NCT00643084|Other|2|standard bowel preparation
3176329|NCT00643136|Experimental|Pregabalin|
3176330|NCT00643136|Placebo Comparator|Placebo|
3176331|NCT00643149|Experimental|1|
3176332|NCT00643149|Experimental|2|
3176333|NCT00643175||1|Osteoporosis in patients with fragility hip fractures.
3176334|NCT00643188|Experimental|1|"Radiofrequency ablation of atrial fibrillation:~Subjects assigned to the catheter AF ablation strategy will undergo ablation within 48 hours after baseline evaluation. The aim of the procedure is to achieve isolation of all Pulmonary Veins (PVs) and to restore sinus rhythm. Only radiofrequency catheter based AF ablation is permitted; other methods, like cryoablation, ultrasound and laser, are not permitted in this study.~Before ablation, a transesophageal echocardiogram must be performed in order to rule out presence of atrial thrombi.~Anticoagulation should be initiated, or continued, for at least six months post ablation. Six months after successful ablation and in absence of any recurrence of AF, antiarrhythmic drugs should be discontinued."
3176335|NCT00643188|Active Comparator|2|"Conventional treatment:~Subjects assigned to the conventional treatment strategy will be treated according to current guidelines for the management of patients with chronic heart failure and/or atrial fibrillation. Efforts to maintain sinus rhythm in this study arm are recommended.~Anticoagulation will be initiated, if not already started, and maintained throughout the study according to current guidelines."
3176336|NCT00643214|Experimental|1|Twice daily topical application
3176337|NCT00643214|Placebo Comparator|2|Twice daily topical application
3176338|NCT00643227|Experimental|1|
3176339|NCT00643227|Experimental|2|
3176340|NCT00643240|Experimental|111 In-BU-12|111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.
3176341|NCT00643253|Experimental|1|Receipt of behavioral interventions to encourage breastfeeding.
2578845|NCT02374203|Experimental|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
2578922|NCT02373917||study group|patient who in the biopsy showed lung cancer
2578925|NCT02373917||control group|patient who in the biopsy showed not to have lung cancer
2578975|NCT02373579|Active Comparator|Intervention arm with Omega 3 FA|"included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
2578978|NCT02373579|Active Comparator|control group|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
2579024|NCT02373085|Experimental|A: Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria beyond 2 months after transplantation and during the first 2 years after transplantation
2579030|NCT02373085|No Intervention|B: no treatment|No treatment of any episode of asymptomatic bacteriuria beyond 2 months after transplantation in kidney transplant recipients.
2579075|NCT02372656|Placebo Comparator|Placebo Group|Placebo gel without active ingredient to be delivered at baseline, 3, 6 and 9 months.
2579079|NCT02372656|Active Comparator|1% Metformin|1% metformin gel to be delivered at baseline, 3, 6 and 9 months.
2579081|NCT02372656|Active Comparator|1.2% Simvastatin|1.2% Simvastatin to be delivered at baseline, 3, 6 and 9 months.
2579152|NCT02372292|Active Comparator|Group 1|Patients with type 1 cardiorenal syndrome who had improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
2579162|NCT02372292|Active Comparator|Group 2|Patients with type 1 cardiorenal syndrome who did not have improvement of renal functions along with diuretic therapy. Intravenous furosemide treatment.
2579189|NCT02371915|Experimental|Videoconference follow-up|These subjects will remain in or near their home communities for rheumatology follow-up visits. Follow-up visits will occur via telehealth/videoconferencing, with a physiotherapist present, performing the in-person assessment, supported by the rheumatologist via videoconference.
2579190|NCT02371915|No Intervention|Control|These subjects will continue to travel into Saskatoon for the rheumatology visits, as they normally would for routine follow-up visits with their rheumatologist.
2579225|NCT02371655|Active Comparator|Diet included|Diet is included in bowel preparation
2579227|NCT02371655|Experimental|Diet not included|Diet is not included in bowel preparation
2579387|NCT02370836|Experimental|Psycho-oncological education|One 60 minute psycho-oncological education session on late effects, fatigue and stress management.
2579391|NCT02370836|No Intervention|Usual Care|Usual care includes completion of a symptom checklist by the nurse practitioner
2579440|NCT02370433|Experimental|Bowel Evacuation via IV|The study design will consist of an intravenous (IV) screening visit to determine each individual's response to neostigmine and glycopyrrolate (NG).
2579441|NCT02370433|Experimental|Bowel Evacuation Titration|This design will consist of a dose titration for those subjects who respond positively to IV. These subjects will receive either a low dose and/or a high dose of NG via iontophoresis to determine their responsiveness.
2579442|NCT02370433|Experimental|Bowel Evacuation Iontophoresis|This design will consist of the incorporation of iontophoresis administration into clinical bowel care. The subject will receive the exact dose they responded to during the titration 3x per week for 2weeks.
2579493|NCT02370225|Experimental|aerobic exercise|Subjects were submitted to a supervised walking, 3 times a week for 16 weeks.
2579495|NCT02370225|No Intervention|no exercise|Subjects randomized to control group did not participate of the walking exercise initially, but after completing 16 weeks they were invited to participate of the training group.
2579629|NCT02369120|Active Comparator|Normal care by GP|"Control group: Will follow conventional treatment provided by the family physician in primary care. This treatment is based on the clinical guidelines of the Institut Català de la Salut (http://www.gencat.cat/ics/professionals/guies/docs/guia_lumbalgies.pdf)."
2579632|NCT02369120|Experimental|Educational intervention using a website|This group of subjects will be given access to our web-site in where they will find information related to CLBP. This information will be provided in different formats: explanatory video by the author, animated video about the neurophysiology of pain, written format using metaphors, and FAQs. All this information will be based on the information provided by the subjects on QUAL. The aim of this educational intervention is to change patient´s misbeliefs about CLBP with the last outcome of reducing pain intensity, improving function, and reducing disability.
2579660|NCT02368834|Experimental|intervention group|A psychoeducation program was delivered to the parents/caregivers
2579674|NCT02368834|No Intervention|control group|This group waited for 3 months, only receiving general consultation.
3176342|NCT00643253|No Intervention|2|Standard of Care
3176343|NCT00643266|Experimental|1|Recollection training via graduated increases in task difficulty, carried out over 36 sessions over 9 training days
3176344|NCT00643266|Active Comparator|2|Computer-delivered information sessions about memory and aging with Jeopardy-like games to engage participants
3176345|NCT00643292|Experimental|1|
3176346|NCT00643292|Experimental|2|
3176347|NCT00643305|Experimental|1|Skills Building with Motivational Interviewing (SB-MI)- combines education and general skills-building participants can use to reduce their at-risk behavior for HIV with increasing motivation to change HIV risk behaviors
3176348|NCT00643305|Active Comparator|2|Skills Building (SB) - provides education and general skills-building for reduction of HIV risk behaviors.
3176349|NCT00643318|Experimental|CyberKnife Stereotactic Radiosurgery|
3176350|NCT00643331|Experimental|1|Exercise performed at the gym and at home
3176351|NCT00643331|No Intervention|2|Usual care no additional exercise
3176352|NCT00643344|Experimental|CALMM+|Participants receiving CALMM intervention, ie program that combines stress reduction, mindful eating practices with diet and exercise
3176353|NCT00643344|Active Comparator|TLC|Participants receiving diet and exercise classes only
3176354|NCT00643357|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox® 170 bar)
2578820|NCT02374281|Active Comparator|Water sucking|"The newborn will receive one minute before the painful care either a compress with water.~The puncture made in the veins of the back of the hand, will be performed only once per patient per test.~Sterile water by oral route (1 ml)."
2578822|NCT02374281|Placebo Comparator|No sucking|The puncture made in the veins of the back of the hand, will be performed only once per patient per test.
2578864|NCT02374034|Experimental|Treatment|Experimental group (n=20) completed a corrective exercise routine, as per the Egoscue Method, at least five days per week for two weeks.
2578865|NCT02374034|No Intervention|Control|The control group maintained their current lifestyle for the two-week duration of the study.
2578920|NCT02373748|Experimental|BioGaming YuGo System|
2578982|NCT02373605|Experimental|Dry Needling,Thrust Manipulation|
2578984|NCT02373605|Active Comparator|Exercise,Non-thrust Mobilization|
2579020|NCT02373059|Experimental|Pharmaceutical care with shared decision making|Use of Diabetes Issue Cards Decision Aids
2579022|NCT02373059|Active Comparator|Usual Pharmaceutical care|Usual Care
2579110|NCT02372773||Frontotemporal Dementia - MAPT|Frontotemporal Dementia with microtubule associated protein tau (MAPT) mutation
2579112|NCT02372773||Frontotemporal Dementia - PGRN|Frontotemporal Dementia with progranulin (PGRN; also known as granulin or GRN) mutation
2579113|NCT02372773||Frontotemporal Dementia - C9OR72|Frontotemporal Dementia with chromosome 9 open reading frame 72 (C9ORF72) mutation.
2579114|NCT02372773||Control|Member of family with a known mutation in one of the three major FTD related genes: MAPT, PGRN, and C9ORF72.
2579153|NCT02372162||Group A - TACE|"Patients with transarterial chemoembolization (TACE) will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
2579163|NCT02372162||Group B - Sorafenib|"Patients with Sorafenib treatment will get an Image Fingerprint and Molecular Fingerprint for tumor characterization in vivo."
2579206|NCT02371798|Experimental|Double dose of Gadopentetate dimeglumine|Subjects with a clinical diagnosis of unilateral Meniere Disease (MD) will undergo 3T MR imaging with a double dose of intravenous (IV) gadolinium contrast injection: 0.2 mmol/kg of Gd-DTPA (Magnevist)
2579259|NCT02371538|Experimental|Donor Breastmilk|Donated human milk is subjected to pasteurization prior to use. Milk consumption is to be overseen by a Registered Dietician. Oral or enteral milk feeding will begin at 180 ml/day and will be advanced as quickly as tolerated to a goal of 360 ml/day for 6 weeks. If symptoms and stool tests for norovirus do not improve after 6 weeks, milk administration may continue for an additional 6 weeks.
2579332|NCT02371278|Other|Higher daily protein|"Diets will provide protein intakes of 1.2 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
2579333|NCT02371278|Other|Lower daily protein|"Diets will provide protein intakes of 0.8 g/kg/d.~Placebo with meals for 3 days, and leucine with meals for 3 days."
2579375|NCT02370680|Experimental|Durlaza™, 1 capsule|Aspirin run-in, followed with Durlaza™, one capsule QD (quaque die), for 14 ± 4 days and an in-patient visit
2579376|NCT02370680|Experimental|Durlaza™, 2 capsules|in a rollover with 10 subjects from the first arm, an aspirin run-in, followed by Durlaza™, two capsules QD, for 14 ± 4 days and an in-patient visit
3211079|NCT01001728|Active Comparator|Supine position|For the supine position, patients will be positioned on a customized supine breast board co-registerable to the couch-top to CT and the treatment machines. Arms will be placed above the head in supports. Arm and head position will be recorded along with the angle of the board (which is adjusted such that the sternum is parallel to the couch-top). Tattoos will be marked bi-laterally and medially in a defined relationship to orthogonal lasers. The position will be reproduced at treatment using the above measurements, tattoos and lasers.
3211080|NCT01001754|Experimental|PEG-rIL-29 at 120 µg|
3211081|NCT01001754|Experimental|PEG-rIL-29 at 180 µg|
3211082|NCT01001754|Active Comparator|Peginterferon alfa-2a at 180 µg|
2579668|NCT02368925|Experimental|Ultherapy™ System|Ultherapy™ System
2579817|NCT02368223|Experimental|YouGrabber training|Home-based YouGrabber training
2579886|NCT02367508|Experimental|MODEL Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) is a mindfulness meditation-based intervention to facilitate timely advance care planning (ACP) and end-of-life conversations with greater ease. Participants are taught a variety of mindfulness practices (e.g., breath awareness, sitting meditation, mindful movement through gentle yoga, and mindful communication) that can be used to enhance end-of-life coping.
3211083|NCT01001780|Experimental|Pentostatin, Cyclophosphamide, Rituximab|
2579987|NCT02366676|Experimental|treatment group|-Intervention: combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IALURIL®) ( 1st month: once a week, 2nd~5th month:once a month)
2580147|NCT02365766|Experimental|Arm A - Phase 1b Dose Finding Cohort:|Cisplatin-eligible subjects will receive pembrolizumab at starting dose of 200mg (dose level 0), and/or 120mg (dose level -1) in combination with gemcitabine and cisplatin. The MTD will be the highest pembrolizumab dose level in combination with gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days). Once the MTD is established, this portion of the study will close and the phase II will open to cohorts I and II at the recommended phase II dose (RP2D).
2580154|NCT02365766|Experimental|Arm B - Phase II Cohort I:|Cisplatin-eligible subjects receive gemcitabine/cisplatin every 21 days, repeated for 4 cycles. (Subjects with Ccr of 50-59 mL/min must follow split dosing of cisplatin over two days) . Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. Note: the last dose of pembrolizumab falls on what would be day 8 of a 5th 'chemo' cycle, however gemcitabine/cisplatin is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
2580380|NCT02364375|Experimental|Pillows|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (pillows) and Comparison Menai Standard mask (pillows) for 7 nights each.
2580407|NCT02363777|Active Comparator|Standard of Care|Epidural placed for postoperative pain control
2580409|NCT02363777|Experimental|Experimental Intervention|Bilateral paravertebral catheters placed for postoperative pain control
3211084|NCT01001819||1|Chronic Rhinosinusitis w/o nasal polyps
3211085|NCT01001819||2|No sinus disease
3211086|NCT01001845|No Intervention|Lifestyle counseling|
3211087|NCT01001845|Active Comparator|vit E|200mg 2 times per day for 3 weeks
3211088|NCT01001845|Experimental|Milk Thistle extract|1 tablet (equivalent to 140 mg silymarin) 3 times a day for 3 weeks
3211089|NCT01001845|Experimental|vit E + Milk Thistle Extract|200mg vit E twice a day + 1 tablet of Milk Thistle extract 3 times a day for 3 weeks
2578963|NCT02373631|Experimental|Dry Needling, Conventional PT|
2578973|NCT02373631|Active Comparator|Conventional PT|
2579003|NCT02373215|Experimental|Cohort 1 - Groups 1-3|HD patients dosing up to 180mg BID
2579006|NCT02373215|Experimental|Cohort 1 - Group 4|HD patients dosing up to 240mg BID
2579009|NCT02373215|Experimental|Cohort 2|Healthy patients dosing up to 180mg BID
2579042|NCT02372942|Experimental|Lattoferrin|Use of Lattoferin for prevention of preterm delivery
2579048|NCT02372942|Experimental|Progesterone|Use of Progesterone for prevention of preterm delivery
2579086|NCT02372552|Experimental|CROMA|Microwave coagulation of small blood vessels
2579131|NCT02372409|Experimental|Arm A (MRI-guided laser ablation)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~Every 12 weeks (+/- 7 days) for the first year or until disease progression"
2579132|NCT02372409|Experimental|Arm B (MRI-guided laser ablation, doxorubicin, etoposide)|"MLA is a minimally invasive laser surgery currently FDA approved for cytoreductive treatment of brain tumors, both primary and metastatic. MLA employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MR imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.~Within 7 days of MLA (range 2-14 days) doxorubicin will be given intravenously on an outpatient basis weekly for 6 weeks at a dose of 25 mg/m^2 over 5-30 minutes~Following the completion of doxorubin, etoposide 50 mg/m^2/day will be given orally for 21 days of each 28-day cycle (treatment can continue up to 24 cycles)~Participants will undergo DCE and DSC-MRI imaging at the following time points:~no more than 3 weeks prior to MLA (OPTIONAL)~within approximately 4 days after MLA~2-4 weeks after MLA~every 8 weeks (+/- 7 days) until 2 years have elapsed or disease progression, whichever comes first"
2579257|NCT02371733|Active Comparator|Training Group|Intervention:Training group will receive upper extremity aerobic exercise training using arm ergometer and breathing exercises.
2579264|NCT02371733|Sham Comparator|Control Group|Sham: Control group will receive alternative upper extremity exercises and breathing exercises.
2579299|NCT02371239|Experimental|Sitting regime|The subjects will follow the sitting regime during four days. Each day: 14 hours sitting, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
2579301|NCT02371239|Experimental|Sit Less regime|Subjects will follow the sit less regime during four days. Each day will consist of 3 hours walking, 4 hours standing, 9 hours sitting and 8 hours sleeping or lying. The additional 2 hours of walking and 3 hours of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1 hour. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
2579303|NCT02371239|Experimental|Exercise regime|Subjects will follow the exercise regime during four days. Each day will consist of 13 hours and 15 minutes sitting, ± 45 minutes supervised cycling on an ergometer, 1 hour walking and 1 hour standing for daily care and 8 hours sleeping or lying.
2579338|NCT02370979|Experimental|Dolutegravir|
2579378|NCT02370745|Experimental|Post absorptive insulin without GLP-1|"Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition."
2579382|NCT02370745|Experimental|Postabsorptive insulin with GLP-1|"Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
2579386|NCT02370745|Experimental|Postprandial insulin without GLP-1|"Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition"
2579390|NCT02370745|Experimental|Postprandial insulin with GLP-1|"Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L ."
2579394|NCT02370745|Experimental|Oral amino acids-Young|"Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink."
2579578|NCT02369523|Active Comparator|Ropivacaine cocktail (PIC)|400 milligrams (mg) Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
3211090|NCT01001858|Active Comparator|Domiciliary group|In this group OSA diagnosis was performed at patient's home by mean of non-attended RP. All follow-up visits were conducted by a trained nurse in patient's home.
3211091|NCT01001858|Active Comparator|Hospital Group|In this group diagnosis was made by in-hospital PSG. Follow-up was performed at hospital by a specialist Physician
3211092|NCT01001858|Active Comparator|Mixed Group|In this group diagnosis was made by home RP, and follow-up at hospital
3211093|NCT01001871|Experimental|Vitamin/mineral fortificant with iron|
3211094|NCT01001871|Placebo Comparator|Vitamin/mineral fortificant without iron|
3211095|NCT01001884|Experimental|counseling|caregiver psychoeducational consultation program (CPCP)
3211096|NCT01001897|Experimental|misoprostol|400 micrograms of misoprostol inserted buccally or vaginally prior to IUD insertion
2578968|NCT02373527|No Intervention|Standard - Strict Fasting|No food after midnight the night before the procedure and will be allowed to drink clear liquids up to 2 hours prior to the procedure.
2578974|NCT02373527|Experimental|Non Fasting|No Fasting prior to catheterization. Usual meal on the day of the procedure and allowed to drink as usual.
2579005|NCT02373254|Active Comparator|Ibuprofen 400 mg|Ibuprofen 400 mg po q 8 hours as needed (PRN) for pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
2579008|NCT02373254|Active Comparator|Ibuprofen 800 mg|Ibuprofen 800 mg po q 8 hours PRN pain. Subjects will receive Norco, 5/525 mg po q 6 hours PRN if pain relief with Ibuprofen is not sufficient.
2579010|NCT02373254|Active Comparator|Norco|Norco (acetaminophen/hydrocodone) 10/325 mg po q 6 hours PRN pain. If pain is not relieved, physician should be contacted.
2579052|NCT02372903|Experimental|Endometriosis|Symptomatic patients with laparoscopic diagnosis of endometriosis
2579118|NCT02372617||Group A|bone graft - autologous
2579120|NCT02372617||Group B|bone graft - ceramic
2579141|NCT02372175|Experimental|Low dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single low dose (0.5 mL of 6.5 x 10^3 plaque forming units/milliliter (PFU/mL) inoculated subcutaneously
2579145|NCT02372175|Experimental|Medium dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single medium dose (0.5 mL of 6.5 x 10^4 PFU/mL) inoculated subcutaneously
2579155|NCT02372175|Experimental|High dose DENV-1-LVHC|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC) single high dose (0.5 mL of 6.5 x 10^5 PFU/mL) inoculated subcutaneously
3211097|NCT01001897|Placebo Comparator|Placebo|Troches identical to experimental drug inserted buccally or vaginally prior to IUD insertion
3211098|NCT01001923|Experimental|REGN475/SAR164877|REGN475/SAR164877, single injection, dose depending on the participant's body weight
2579291|NCT02371343|Active Comparator|Fish-Oil|"The pregnants with gestational diabetes given fish oil:~(Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, German) During third trimester of pregnancy, Once in a day"
2579292|NCT02371343|Placebo Comparator|Sunflower oil|"The pregnants with gestational diabetes given sunflower oil:~Sunflower oil capsules will be prepared in the pharmacy as the same size and colour with fish oil capsules During third trimester of pregnancy, Once in a day"
2579349|NCT02371018|No Intervention|Standard Hemodialysis|Participants will be monitored during their normal hemodialysis treatment with no intervention administered
2579351|NCT02371018|Experimental|Hemodialysis with Nutrition Supplement|Participants will be monitored during a normal hemodialysis treatment in which they consume 1-8oz can of Nepro.
2579354|NCT02371018|Experimental|Nutrition Supplement|Participants will be monitored while drinking 1-8oz can of Nepro with no hemodialysis treatment.
3211099|NCT01001923|Placebo Comparator|Placebo|Placebo (for REGN475/SAR164877), single injection
3211100|NCT01001936|Experimental|1|
3211101|NCT01001949|Experimental|Wheat Bran Extract|
2579571|NCT02369614|Active Comparator|Active Comparator:1 Hz rTMS|Active Comparator: 1 Hz rTMS
2579573|NCT02369614|Active Comparator|Active Comparator:10 Hz rTMS|Active Comparator:10 Hz rTMS
2579575|NCT02369614|Sham Comparator|Sham Comparator:Sham rTMS|Sham Comparator: Sham rTMS
2579577|NCT02369614|No Intervention|OASIS treatment as usual|OASIS treatment as usual
3211102|NCT01001949|Placebo Comparator|placebo|
3211103|NCT01001962|Active Comparator|Metformin|527 Patients treated with Metformin 850x2mg titrated to 1000x2mg Daily oral
3211104|NCT01001962|Active Comparator|Empagliflozin|527 Patients treated with empagliflozin 10mg titrated to 25 mg Daily oral
3211105|NCT01002014|Experimental|Nipple Sparing Mastectomy|Patients who undergo nipple sparing mastectomy with preservation of the nipple areolar complex.
3211106|NCT01002027|Active Comparator|CBT-counselling with Nurse|CBT-counselling with Maternal Health Nurse, adjunctive to management by general medical practitioner
3211107|NCT01002027|Active Comparator|CBT-Counselling by Psychologist|CBT-counselling with Psychologist, adjunctive to management by general medical practitioner
3211108|NCT01002027|No Intervention|Routine management|Ongoing management by general medical practitioner
3211109|NCT01002040|Active Comparator|One Dose Influenza vaccine|Arepanrix H1N1 Influenza vaccine (one dose)
3211110|NCT01002040|Active Comparator|Two Doses Influenza vaccine|Arepanrix H1N1 Influenza vaccine (2 doses, 3 weeks apart)
3211111|NCT01002053||Diabetics with peripheral neuropathy|Patients with diabetes and peripheral neuropathy.
3211112|NCT01002079|Experimental|BMS-708163|
3211113|NCT01002079|Other|Rifampin|
3211114|NCT01002079|Experimental|Rifampin + BMS-708163|
3211115|NCT01002092|Active Comparator|Chemotherapy|
3211116|NCT01002092|Experimental|Endostar plus Chemotherapy|
3211117|NCT01002131||Digital Volume tomography|three-dimensional digital imaging using cone beam tomography (CBCT)
3211118|NCT01002157|Experimental|Vitamin K2 supplementation|
3211119|NCT01002157|Placebo Comparator|Placebo control|
3211120|NCT01002183|No Intervention|single arm|Fos-clin/Arte
3211121|NCT01002196|Experimental|stimulus fading procedures|
3211122|NCT01002196|Active Comparator|guidance of defocused communication|
3211123|NCT01002209|Sham Comparator|Sham Hyperbaric Oxygen Treatment|
3211124|NCT01002209|Experimental|Hyperbaric oxygen treatment (HBO)|
3211125|NCT01002222|Experimental|MCS-2|
3211126|NCT01002235|Experimental|Cohort 1|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 4 mg.
3211127|NCT01002235|Experimental|Cohort 2|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 8mg.
3211128|NCT01002235|Experimental|Cohort 3|Two divided doses of VM202 injected into the calf muscle on Day 0 and Day 14 for a total dose of 16mg.
3258967|NCT01466296|Active Comparator|treadmill|A treadmill with safety adaptation and all the usual characteristics of speed and slopes of fitness treadmills.
2578900|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 5|Each subject will receive a single dose of Treatment C (DTG/RPV 50 mg/25 mg: Product Code AM), Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), and Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK) in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578901|NCT02373930|Experimental|Part 1 Cohort 1- Sequence 6|Each subject will receive a single dose of Treatment E (DTG/RPV 50 mg/25 mg: Product Code AK), Treatment D (DTG/RPV 50 mg/25 mg: Product Code AQ) and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet), in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication. All treatments will be administered in fed state.
2578903|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 1|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fasted state, Treatment F (DTG/RPV FDC-1) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578905|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 2|Each subject will receive a single dose of Treatment F (DTG/RPV FDC-1) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment F (DTG/RPV FDC-1) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578907|NCT02373930|Experimental|Part 2 Cohort 2- Sequence 3|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state, Treatment F (DTG/RPV FDC-1) in fasted state and Treatment F (DTG/RPV FDC-1) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578908|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 4|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fasted state, Treatment G (DTG/RPV FDC-2) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578911|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 5|Each subject will receive a single dose of Treatment G (DTG/RPV FDC-2) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578915|NCT02373930|Experimental|Part 2 Cohort 3- Sequence 6|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment G (DTG/RPV FDC-2) fasted state and Treatment G (DTG/RPV FDC-2) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578917|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 7|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fasted state, Treatment H (DTG/RPV FDC-3) in fed state and Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578918|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 8|Each subject will receive a single dose of Treatment H (DTG/RPV FDC-3) in fed state, Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) in fasted state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2578919|NCT02373930|Experimental|Part 2 Cohort 4- Sequence 9|Each subject will receive a single dose of Treatment A (DTG 50 mg tablet plus RPV 25 mg tablet) in fasted state and Treatment H (DTG/RPV FDC-3) fasted state and Treatment H (DTG/RPV FDC-3) in fed state in period 1, period 2 and period 3 respectively with a washout period of >=9 days between doses of study medication.
2579028|NCT02372981|Experimental|DG-HAL with mucopexy|Mucopexy with DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
2579034|NCT02372981|Active Comparator|mucopexy alone|Mucopexy without DG-HAL is performed using the same specific device consisting of a proctoscope equipped with a Doppler probe and a light source as described above.
2579090|NCT02372708||Experimental|diluted dinitrophenyl(DNP) Vaseline (which equaled to 2% DNP 0.1ml) was started to be directly spread on the surfaces of primary or metastatic tumors of malignant melanoma patients since the first day of every circle of chemotherapy, simultaneously laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2. The tumors were wrapped and blocked for two days to induce contact dermatitis. If lymph nodes had been cleared, sensibilization of 2×2cm was performed at occipital region. It was repeated once a week.
2579100|NCT02372708||Control|only diluted DNP Vaseline was spread and the operation were the same with the treatment group
2579148|NCT02372331|No Intervention|Conventional perioperative management|"Preop usual biliary drainage~Preop smoking and alcohol~Preop parenteral nutrition~Oral bowel preparation (mechanical bowel preparation )~Preoperative fasting > 12 hours~Pre-anesthetic medication~Anti-thrombotic prophylaxis~Antimicrobial prophylaxis and skin preparation~Intravenous analgesia : PCA~Prevention of postoperative nausea and vomiting (PONV) (X)~Incision : surgeon direction~Avoiding hypothermia~Nasogastric intubation (O)~Postop glycemic control~Positive fluid balance~Perianastomotic drain removal over POD #5~Somatostatin analogues~Transurethral catheter removal~Delayed gastric emptying(DGE) (+) , parenteral nutrition (+)~Postop routine artificial nutrition (O), soft diet at POD #5~Early and scheduled mobilization"
2579159|NCT02372331|Experimental|ERAS perioperative management|"behavioral intervention (counselling, audit)~dietary supplement~procedure (preoperative and postoperative)~drug"
2579271|NCT02371902|Active Comparator|ESWT Group|Focused Extracorporeal Shock Wave Therapy: 3 sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2
2579274|NCT02371902|Active Comparator|Cryo-US Group|Therapeutic cryoultrasound: 12 sessions was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each.
2579323|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 1|Therapy Setting 1
2579324|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 2|Therapy Setting 2
2579326|NCT02371122|Active Comparator|RestoreSensor or RestoreUltra Setting 3|Therapy Setting 3
2579059|NCT02372916||Dry AMD|Patients with pre-existing GA secondary to AMD NOT requiring intravitreal injections (i.e. Dry AMD)
2579060|NCT02372916||Wet AMD and treatment-naive|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and are treatment-naïve patients
2579061|NCT02372916||Wet AMD with history of intravitreal injections|Patients with pre-existing GA and CNV secondary to AMD requiring intravitreal injections (i.e. Exudative AMD) and have received previous intravitreal injections
2579083|NCT02372487|Active Comparator|fluid therapy and sildenafil citrate|Patients in first group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour in addition to sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily during hospitalization. After discharge patients in first group will be asked to continue sildenafil citrate therapy (Viagra®) as 25 mg 3 times daily plus a daily oral fluid intake of 2 liters
2579093|NCT02372487|Active Comparator|fluid therapy|Patients in second group will receive 2 liters of isotonic saline through intravenous infusion over a period of 4 hours using a rate of 250 ml per hour. After discharge patients wil be asked to have 2 liters daily oral fluid
2579142|NCT02372240|Experimental|VLX1570 and dexamethasone|"VLX1570 IV (0.05, 0.15, 0.3, 0.6, 1.2, 2.0 mg/kg) on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle~Dexamethasone 20 mg PO/IV"
2579207|NCT02371993|Experimental|Choline 650 mg twice daily|See above
2579209|NCT02371993|Placebo Comparator|Placebo|See above
2579272|NCT02371486|Experimental|Nich Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~hysteroscopic repair of cesarean section defect~IVF cycle"
2579276|NCT02371486|Sham Comparator|No Repair|"Interventions to be administered:~Ultrasound Scan~Diagnostic Hysteroscopy~IVF cycle Operative hysteroscopy WILL NOT BE PERFORMED"
2579308|NCT02371109||selftaken vs clinical taken swabs|
3176355|NCT00643357|Placebo Comparator|B|50%Oxygen/50% Nitrogen premix
3176356|NCT00643370||1|single arm study
3176357|NCT00643383|Active Comparator|1|
3176358|NCT00643383|Placebo Comparator|2|
3176359|NCT00643409|Experimental|1|
3176360|NCT00643409|Experimental|2|
3176361|NCT00643422||Observation|
3176362|NCT00643435|Experimental|1|These residents receive training provided by standardized patient instructors, in use of self-efficacy enhancing interviewing techniques to support patient health behavior change,
3176363|NCT00643435|Active Comparator|2|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
3176364|NCT00643461||Adhesive A|
3176365|NCT00643461||Adhesive B|
3176366|NCT00643461||Adhesive C|
3176367|NCT00643474|Experimental|A|
3176368|NCT00643474|Experimental|B|
3176369|NCT00643526|Experimental|Injection Site: First Thigh Then Abdomen|Participants will self inject subcutaneously placebo using auto injector at thigh followed by self injection of placebo subcutaneously at abdomen on Day 1.
2579505|NCT02370017|Experimental|ANKL combined with chemotherapy|combination of ANKL and doublet chemotherapy as 3rd and 4th course in patients who get stable response after initial x2 courses
3176370|NCT00643526|Experimental|Injection Site: First Abdomen then Thigh|Participants will self inject subcutaneously placebo using auto injector at abdomen followed by self injection of placebo subcutaneously at thigh on Day 1.
2579663|NCT02368782||ketamine group|ketamine 2mg/kg bolus IV once
2579677|NCT02368782||propofol group|propofol 2mg/kg ıv bolus once
2579830|NCT02367664|Experimental|0.5ml experimental vaccine on day 0,28|0.5ml experimental vaccine on day 0,28 and a booster dose 12 months later
2579833|NCT02367664|Active Comparator|0.5ml active comparator vaccine on day 0,7|0.5ml active comparator vaccine on day 0,7 and a booster dose 12 months later
3176371|NCT00643539|Experimental|1|
3176372|NCT00643539|Experimental|2|
3176373|NCT00643591||Observational|Patients with a primary glioblastoma
3176374|NCT00643617|Other|Heterogeneous dose|38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery
3176375|NCT00643630|Experimental|1|Twice daily topical application
3176376|NCT00643630|Placebo Comparator|2|Twice daily topical application
3176377|NCT00643643|Experimental|A|
3176378|NCT00643643|Experimental|B|
3176379|NCT00643643|Experimental|C|
3176380|NCT00643643|Experimental|D|
3176381|NCT00643643|Placebo Comparator|E|
3176382|NCT00643656|Experimental|A|Mixture of 50% nitrous oxide and 50% oxygen
3176383|NCT00643656|Placebo Comparator|B|Mixture of 50% oxygen and 50% nitrogen
3176384|NCT00643669|Experimental|AL-3789|AL-3789 Sterile Suspension, single depot administration of 0.8 mL in the study eye
3176385|NCT00643669|No Intervention|No treatment|Fellow eye, as randomized
3176386|NCT00643695|Experimental|1|Home-based walking program
3176387|NCT00643695|Other|2|educational intervention
3176388|NCT00643708||A|14 cases
3176389|NCT00643708||B|14 cases
3176390|NCT00643708||C|14 cases
3176391|NCT00643708||D|14 Cases
3176392|NCT00643721||D,FR|Young healthy athletes
3176393|NCT00643734|Experimental|1|
3176394|NCT00643734|Experimental|2|
3176395|NCT00643747|Experimental|A|Injection of vector
3176396|NCT00643773|Experimental|A|Leucine supplement
3176397|NCT00643773|Placebo Comparator|B|Wheat flour
3176398|NCT00643786|Experimental|A|Oxygène
3176399|NCT00643786|Placebo Comparator|B|Air Médical
3176400|NCT00643799|Experimental|A|
3176401|NCT00643799|Active Comparator|B|
3176402|NCT00643799|Placebo Comparator|C|
3176403|NCT00643812|Experimental|1|"The Early intervention arm received a gun locker at baseline"
3176404|NCT00643812|Active Comparator|2|Households in this arm received a gun locker at 12 months following the baseline survey
3176405|NCT00643825|Active Comparator|A: prolonged adj TMZ|
3176406|NCT00643825|Other|B : Stop and Go|Rechallenging patients with TMZ at relapse
2578923|NCT02373904|Experimental|Photodynamic Bone Stabilization System (PBSS)|The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
2578964|NCT02373514|Active Comparator|Paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with rapid infusion
2578971|NCT02373514|Active Comparator|Dexketoprofen|Intravenous 50 mg dexketoprofen in 100 ml saline with rapid infusion
3211129|NCT01002248|Experimental|Perifosine added to combination|"Perifosine added to the combination of Bortezomib and Dexamethasone. Perifosine is is supplied as a film-coated tablet containing 50 mg of active ingredient. Perifosine will be administered orally on an outpatient basis throughout the study. Daily administration will be one 50 mg tablet.~The first dose of perifosine should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1)."
3211130|NCT01002248|Placebo Comparator|Perifosine Placebo added to combination|Perifosine placebo added to the combination of Bortezomib and Dexamethasone. The placebo for perifosine is provided in 256 mg white to off-white, round, biconvex film-coated tablets to permit a blinded trial with perifosine 50 mg film coated tablets. Placebo will be administered orally on an outpatient basis throughout the study. Daily administration will be one perifosine placebo tablet. The first dose of placebo should be taken on the same day that bortezomib and dexamethasone are administered (Cycle 1 Day 1).
2579124|NCT02372370|Active Comparator|Interventions|All participants receive all interventions.
2579144|NCT02372110|Experimental|HPA, ANS stimulation|Oral administration of 400mg caffeine and 20mg hydrocortisone will stimulate HPA axis and ANS activity, respectively
2579150|NCT02372110|Placebo Comparator|Two cellulose placebo capsules|two cellulose capsule filled with acidophilus powder will be administered orally
3211131|NCT01002261||Liver cirrhosis / healthy subjects|10 patients with liver cirrhosis and 10 sex and age-matched healthy subjects
2579294|NCT02371226|Experimental|Cohort 1|1 mg/kg AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) administered once weekly x 8 weeks
2579296|NCT02371226|Experimental|Cohort 2|3 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
2579298|NCT02371226|Experimental|Cohort 3|6-9 mg/kg AGT-181 (HIRMAb-IDUA) administered once weekly x 8 weeks
2579361|NCT02370953|Experimental|VERION|In this group the VERION-tools (Digital Marker) are used for the alignment of the toric IOL
2579364|NCT02370953|Active Comparator|Conventional, manual ink-marking|In the group the conventional manual marking is used for the alignment of the toric IOL
2579395|NCT02370576||control|Healthy women after elective cesarean section.Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
2579398|NCT02370576||emergency|Healthy women after emergency cesarean section. Questionnaire/ rating scale application. Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
2579459|NCT02370342|Experimental|Treatment (robot-assisted laparoscopic HIFU)|Patients undergo robot-assisted laparoscopic HIFU thermal ablative therapy during partial nephrectomy.
3211132|NCT01002261||Liver cirrhosis and healthy subjects|Patients with liver cirrhosis and healthy subjects
3211133|NCT01002274|Experimental|MCS-2|2 soft-gel capsules Qd for 40 weeks
2579544|NCT02369627|Experimental|Rapid HIV Self-Test|Participants will perform a rapid HIV self-test using the OraQuick® In-home HIV Test.
2579545|NCT02369627|Active Comparator|Conventional Home-Based HIV Test|Participants will perform a conventional home-based HIV test using the Home Access Express HIV-1 Test System.
2579547|NCT02369627|Active Comparator|Community/Medical-Based HIV Test|Participants will receive a link to a CDC website (https://gettested.cdc.gov) that allows them to search for HIV testing locations of their choice.
2579582|NCT02369432|Experimental|Group of healthy volunteers and group of patients|"Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed~Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed"
2579612|NCT02369198|Experimental|Single arm, open label TargomiRs|"TargomiRs are IV injected.~Phase 1 Planned dose levels~Dose level 1: 5 billion once a week Dose level 2: 5 billion twice a week Dose level 3: 5 billion once a week with cardiac monitoring Dose level 4: 2.5 billion twice a week with cardiac monitoring Dose level 5: as for dose level #3 with a dexamethasone challenge~All patients begin on a micro dose of one billion and increase their dose over 2 weeks and reach their phase 1 dose level on week 3.~Schedule of assessments includes laboratory and physical assessments in the 24 hours after each treatment as well as periodic assessments such as PET and CT scans for tumour assessment.~100% of the data will be source data verified. Analysis will be simple phase 1 analysis based on a 3+3 model."
2579661|NCT02368951|Experimental|BAY1187982|"Dose-escalation phase:~Approximately 30 subjects will participate in the dose-escalation phase The total number of subjects will depend on the number of cohorts necessary to identify the MTD.~MTD expansion phase:~Once the MTD has been determined, two expansion cohorts in FGFR2 expressing indications are planned:~Cohort 1: Triple negative breast cancer (TNBC). This cohort will enroll 80 subjects (N=40 with low to moderate FGFR2 expression and N=40 with high FGFR2 expression) Cohort 2: Other indications expressing FGFR2. This cohort 40 subjects will be enrolled."
2579765|NCT02368379|Other|Assessment of Central Adrenal Insufficiency|Patients will undergo low dose ACTH stimulation test followed by overnight metyrapone test to assess for central adrenal insufficiency.
2579864|NCT02367534|Experimental|Umbilical vein|umbilical vein catheterization
2579931|NCT02366975|No Intervention|Eugonadal patients|Patients without hypogonadism has been enrollend but not randomized
3211134|NCT01002313||normal control|
3211135|NCT01002313||Patient treatment group|Treatment with prednisone
3211136|NCT01002326|Experimental|Cognitive-Behavioral Therapy|
3211137|NCT01002365|Active Comparator|Post op care|
3211138|NCT01002365|Active Comparator|Oxygen administration- different %|
3211139|NCT01002378|Experimental|Arm 1|
3211140|NCT01002378|Experimental|Arm 2|
3211141|NCT01002378|Experimental|Arm 3|
2579016|NCT02372864|No Intervention|Care as usual|"All participants in the intervention and control group receive the care as usual. The care as usual consists of a clinic appointment with the research nurse. In this appointment the RRSO-induced menopausal complaints will be discussed in more detail. Depending on the complaints at hand, information, reassurance and life style advice will be offered. A leaflet with relevant information will be provided for. Furthermore, the usual medical care may include prescription of (non-)hormonal medicationsTwelve weeks after the clinic appointment, the research nurse will contact all participants per telephone to ask whether there are issues that remain to be addressed.~Participants are allowed to continue the use of all their current medication."
2579018|NCT02372864|Experimental|Mindfullness based stress reduction|
2579084|NCT02372786|Other|Acne Keloidalis Nuchae|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.
2579089|NCT02372786|Other|Tattoo|2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.
2579136|NCT02372201|Experimental|Hydro Colon Therapy plus probiotic|Hydro Colon therapy including 2-5 washes in 3 weeks, probiotic intervention for 5 weeks after end of hydro Colon therapy
2579362|NCT02370940|Experimental|High Phytate Diet|The high phytate diet group was required to consume a high phytate diet for 8 weeks. The high phytate foods were provided for subjects. They received whole grain ready-to-eat cereals, whole wheat pasta/spaghetti, tortillas, bagels, bread and dinner rolls, corn tortillas, brown rice, canned black beans, edamame and tofu, and were encouraged to consume generous amounts of nuts and other legume products high in phytate.
2579363|NCT02370940|Experimental|Low Phytate Diet|The low phytate diet group was required to consume a low phytate diet for 8 weeks. They received foods similar to those for the high phytate diet group but which were made from refined wheat and white rice, eggs and cheese, and were instructed to avoid high phytate foods.
2579381|NCT02370628|Experimental|Percutaneous vertebroplasty (PV)|The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae.
2579385|NCT02370628|Active Comparator|Facet block|injection of anti-inflammatory and analgesic drugs
3176407|NCT00643838|Experimental|A|Misture of 50% nitrous oxide and 50% oxygen
3176408|NCT00643877|Experimental|B|PHRAC was performed 7 days before surgery. Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
2579667|NCT02369042|Experimental|Cohort I|Patients admitted with the primary diagnosis of HF and are currently being assessed with clinically indicated hemodynamic monitoring.The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected through hemodynamic monitoring. The device will be worn for 60 days post hospital discharge.
2579673|NCT02369042|Experimental|Cohort II|Patients admitted with the primary diagnosis of HF and are being assessed with or without hemodynamic monitoring. The Kyma device will be worn by the patient and data collected from the device will be compared to the data collected while the patient is hospitalized. The device will be worn for 60 days post hospital discharge.
2579711|NCT02368483|Experimental|Neuromuscular training|
2579753|NCT02368262||CP- incontinent|Children with CP and daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
2579755|NCT02368262||CP- continent|Children with CP without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
2579757|NCT02368262||NoDev - incontinent|Children with normal development with daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
2579758|NCT02368262||NoDev - continent|Children with normal development without daytime incontinence. Evaluation consisted of a questionnaire and micturition and drinking diaries, uroflowmetry, pelvic floor EMG and bladderscan.
2580037|NCT02366325|Experimental|EPO-018B 0.025 mg/kg|EPO-018B starting dose of 0.025 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2580038|NCT02366325|Experimental|EPO-018B 0.05 mg/kg|EPO-018B starting dose of 0.05 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2580039|NCT02366325|Experimental|EPO-018B 0.08 mg/kg|EPO-018B starting dose of 0.08 milligram per kilogram (mg/kg) administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 6 doses
2580931|NCT02360579|Experimental|Cohort 1|Lifileucel (LN-144) without cryopreservation (Gen 1 infusion product) (Closed)
3176409|NCT00643877|No Intervention|A|Adjuvant chemotherapy using FOLFOX7 was done for 8 cycle with 28 days after surgery.
3176410|NCT00643903|Experimental|1|Participants will receive five individual sessions of coping effectiveness training.
3176411|NCT00643903|Active Comparator|2|Participants will receive standard care and one delayed group workshop of coping effectiveness training.
3176412|NCT00643929||Observational|Subjects who have participated in a prior eltrombopag study, receiving either placebo or eltrombopag
3176413|NCT00643942||1|
3176414|NCT00643955||DS|Individual with Down Syndrome
3176415|NCT00643968|Active Comparator|1|TDF+EFV
3176416|NCT00643968|Experimental|2|TDF+3TC+EFV
3176417|NCT00643994|Experimental|CyberKnife Stereotactic Radiosurgery|
3176418|NCT00644007|Placebo Comparator|Group 1|
3176419|NCT00644007|Experimental|Group 2|
3176420|NCT00644020||Group 1|the Tyroserleutide for injection at the dosage of 3mg/d
3176421|NCT00644020||Group 2|the Tyroserleutide for injection at the dosage of 6mg/d
3176422|NCT00644020||Group 3|the Tyroserleutide for injection at the dosage of 12mg/d
3176423|NCT00644020||Group 4|the placebo group
3176424|NCT00644033|Active Comparator|1|
3176425|NCT00644033|Active Comparator|2|
3176426|NCT00644033|Placebo Comparator|3|
3176427|NCT00644046|No Intervention|1|Chronic kidney disease patient with standardized nephrology care
3176428|NCT00644046|Active Comparator|2|chronic kidney disease patient with multidisciplinary predialysis care
2579138|NCT02372266|Experimental|Early Discharge Group|If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.
2579140|NCT02372266|Active Comparator|Routine Stay Group|Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.
2579198|NCT02371954|Experimental|Health Promotion|Happy Older Latinos are Active (HOLA) is multicomponent health promotion intervention led by a community health worker (CHW). First component is a social and physical activation session. Participants meet individually with CHW for 30 minutes once at week 1, then again at week 8 (the midway point). Second component is a moderate intensity group walk. Groups will consist of 6 participants and will meet for one hour, 3 times a week, for 16 weeks. Third component is pleasant events scheduling during cool down phase of the group walk.
2579200|NCT02371954|Active Comparator|Psychoeducation|Participants will be given a fotonovela and will meet once a month after they receive the fotonovela to discuss their thoughts on the materials they received. These discussion groups will last one hour and will consist of 10 participants.
2579245|NCT02371577|Experimental|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
2579300|NCT02371304|Active Comparator|Total Mesorectal Excision|After local excision patients will receive additional TME surgery
2579302|NCT02371304|Experimental|Adjuvant chemoradiotherapy|After local excision. Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
2579331|NCT02370966|Placebo Comparator|Potato starch|Potato powder will be incorporated in the placebo product.
2579335|NCT02370966|Active Comparator|Berry powder|Several different berry powders including rose hip, bilberry, blackcurrant, sea buckthorn, and lingonberry will be prepared and studied.
2579379|NCT02370771|Experimental|Patient with hand osteoarthritis|Biological sampling and Radiographic evaluation of patient with erosive and non erosive hand osteoarthritis
2579453|NCT02370459|No Intervention|control|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive no AFIX consultation.
2579456|NCT02370459|Experimental|AFIX in-person consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90 clinics. Clinics randomly assigned to this arm will receive an in-person AFIX consultation. Consultations will be delivered by state health department staff.
2579461|NCT02370459|Experimental|AFIX webinar consultation|This arm includes 30 high-volume primary care clinics in each of three states (Washington, Illinois, Michigan) for a total of 90. Clinics randomly assigned to this arm will receive an AFIX consultation via interactive webinar. Consultations will be delivered by state health department staff.
2579488|NCT02370082|Experimental|SAVI SCOUT device|SAVI SCOUT device used to localize breast lesion which will then be removed surgically. The SAVI SCOUT is the intervention for localization of breast lesions.
3211142|NCT01002391|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
3211143|NCT01002391|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
3211144|NCT01002404|Active Comparator|angled tipped guide wire|angled tipped guide wire used to deep biliary cannulation
2579801|NCT02367950|Experimental|Single Arm Study|All participants receive active treatment (exercise) tailored to their level of health ad fitness
2579835|NCT02367638|Experimental|MG1111|
2579843|NCT02367638|Active Comparator|VARIVAX|
2579904|NCT02367443|Experimental|one group|Radiation: Hypofractionated accelerated Radiotherapy with concomitant full dose Chemotherapy
2579942|NCT02367001|Other|1: standard invitation|"Group 1: sending a standard invitation signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : Normal invitation"
2579944|NCT02367001|Experimental|2: Revised invitation|"Group 2: Sending a revised invitation ( text, layout) signed by the coordinating doctor (send by the structure responsible for organized screenings)~Intervention : revised invitation signed by the coordinating doctor"
2579947|NCT02367001|Experimental|3 : revised invitation signed by the attending physician|"Group 3: Sending a revised invitation signed by the attending physician (send by the structure responsible for organized screenings)~Intervention : Revised invitation signed by the attending physician"
2579979|NCT02366754|Experimental|Active rTMS|The intervention consists of 30 active rTMS sessions. Each session is comprised of 300 trains of paired pulses with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Pulse intensity will be set at 110% of each participant's motor threshold. Active rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left dorsolateral prefrontal cortex. Two Magstim-2002 units and a Bistim2 module will be used to administer active rTMS. Participants assigned to the active rTMS group will receive a total of 1.8 seconds of stimulation. Active rTMS will be administered 2 times daily with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
2579980|NCT02366754|Sham Comparator|Placebo rTMS|The intervention consists of 30 placebo rTMS sessions. Each session is comprised of 300 paired-pulse trains with the following parameters: 100µs paired pulses separated by 100ms inter-pulse-intervals and a five second inter-train-interval. Placebo rTMS sessions will be provided two times per day with a 70mm figure-of-eight coil over the left DLPFC. Two Magstim-2002 units and a Bistim2 module will be used to administer placebo rTMS. The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. Participants assigned to the placebo rTMS group will receive 0 seconds of stimulation. Placebo rTMS will be administered with the following weekly schedule: 2 days of rTMS, 1 day of rest, 2 days of rTMS, 2 days of rest.
2580032|NCT02366416|Experimental|Exercise training|12 weeks of one hour exercise training twice weekly
3211145|NCT01002404|Active Comparator|straight tipped guidewire|straight guide wire used to deep biliary cannulation
3211146|NCT01002417|Placebo Comparator|Placebo|Both the phase 2b and phase 3 parts of the study have the placebo arm.
3258968|NCT01466309|Experimental|treatment|patients treated with Somnoguard
2579149|NCT02372084|Experimental|osilodrostat (LCI699)|Each participant will undergo a 28-day screening/baseline period (day -28 to day -1), followed by a 5 day treatment period (a single 30 mg dose of LCI699 ( Day 1) with 5 days of PK sample collection).
2579194|NCT02371928|Active Comparator|Neuromuscular exercise program|"A 12-week physiotherapeutic, supervised exercise program with focus on neuromuscular shoulder control besides incorporation of kinetic chain exercises.~The exercise program contains the following focal points: Scapula and glenohumeral setting/control, dynamic shoulder stability, muscle co-contractions (weight-bearing upper extremity exercises) and proprioceptive training."
2579195|NCT02371928|Active Comparator|Standard home exercise program|"One physiotherapeutic-supervised instruction in 12 weeks of active exercises for the rotator cuff and scapular muscles.~Information about the shoulder injury and how to avoid pain provoking movements besides future implications is given. Also, participants receives one phone call after six weeks of training from a physiotherapist to ensure good compliance and answer any questions that the patient may have."
2579243|NCT02371564|Active Comparator|High flow humidified oxygen first|High flow humidified oxygen then standard oxygenotherapy with a two-hour non invasive ventilation session in between.
2579246|NCT02371564|Active Comparator|Standard oxygen therapy first|Standard oxygenotherapy then high flow humidified oxygen with a two-hour non invasive ventilation session in between.
2579286|NCT02371317|Experimental|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
2579287|NCT02371317|Active Comparator|Stress Management Education|The Stress Management Education intervention includes eight 2.5-hour weekly group sessions and an all-day retreat.
2579290|NCT02371317|Other|AHA Recommended Self-Care|All participants will receive the American Heart Association - Understanding and Controlling Your High Blood Pressure Brochure and information on the Dietary Approach to Stop Hypertension from the National Institutes of Health. These brochures describe ways that individuals can improve their lifestyle through better diet and exercise. Participants will get a chance to try and make healthy lifestyle changes on their own, using this information.
2579341|NCT02371005|Other|Measurement of the periodontal ligament space|Evaluation of the width of the ligament in patients with SSc and comparison to the width found in control.
2579344|NCT02371005|Other|Radiographic analysis of oro-facial manifestations|Establishment of a complete clinical phenotypic description of oral manifestations associated with SSc and comparison with the control group.
2579374|NCT02370732|Other|Roux en Y Gastric Bypass|"Participants recruited for this protocol will be those planning to undergo Roux-en-Y Gastric Bypass (RYGB). Upon study screening completion, participants will take part in a total of 4 laboratory assessment days where a fixed dose of alcohol will be given.~2 pre-surgery research appointments where participants will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day.~2 post-surgery (1 year) research appointments where you will be given alcohol: a driving simulator day and a cognitive testing and reinforcement testing day."
3211147|NCT01002417|Active Comparator|MCS-2 15 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 15 mg/day is selected as the optimal dosage.
3211148|NCT01002417|Active Comparator|MCS-2 30 mg/day|For the phase 2b part of the study. It can also be used in the phase 3 part of the study if MCS-2 30 mg/day is selected as the optimal dosage.
2579587|NCT02369419||CRT|Patients over 70 years age, selected for CRT according to the ESC 2013 guidelines.
3211149|NCT01002430|Experimental|Gene therapy|
3211150|NCT01002430|No Intervention|Control|Control patients will have electroanatomic mapping procedure but no gene injections.
2579689|NCT02368704||control|"control subjects with :~Nondiabetic subjects (blood glucose <7.0 mmol/l without hypoglycemic treatment).~The control subjects should be matched to patients for age (± 5 years), sex, and BMI (± 2 kg/m2)."
2579692|NCT02368704||case|"Diabetic patients with :~Having type 2 diabetes for at least 6 months~HbA1c ≤ 8%~Treat by lifestyle and dietary rules associated or not to a hypoglycemic therapy (metformin and / or sulfamid) and / or insulin secretors dependent glucose as inhibitors of DPP4 (dipeptidyl peptidase-4): Vildagliptin, Sitagliptin, Saxagliptin~No modification of hypoglycemic therapy and / or insulin secretors for at least 3 months"
2579731|NCT02368392||Cardiac Arrest|Those who get in-hospital cardiac arrests
2579733|NCT02368392||Non Cardiac Arrest|Those who do not get in-hospital cardiac arrest
2579791|NCT02368106||Radiation Therapy|Participants receiving one of the 11 listed therapy modalities.
2579820|NCT02367742|Other|Endurance Activity (EA)|The subjects have followed a program of endurance (aerobic) activity (EA).
2579826|NCT02367742|Other|EA + Resistance Training (RT)|The subjects have followed a program of endurance activity (EA) and resistance training (RT).
2579913|NCT02367469||Brain Tumors|Patients with newly diagnosed or recurrent brain tumors will be studied.
2579929|NCT02366897|Other|Tolerability and sensitivity|Stage 1: tolerability as per study design Stage 2: sensitivity as per study design - either quetiapine or risperidone. The intervention is the use of the Manus sensor pen
2579978|NCT02366819|Experimental|Treatment (mFOLFIRINOX, surgery)|"PREOPERATIVE THERAPY: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo conventional surgery.~POST-OPERATIVE THERAPY: Beginning 5-10 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours continuously on day 1. Courses repeat every 2 weeks for 4 more courses in the absence of disease progression or unacceptable toxicity."
2580021|NCT02366481|Placebo Comparator|Placebo-Control|The placebo-control group will take two placebo softgel capsules every day for 8 weeks.
3211151|NCT01002443|Active Comparator|H. pylori eradication|
3211152|NCT01002443|Placebo Comparator|placebo|
3211153|NCT01002469|Experimental|sodium [1-13C] acetate|
3211154|NCT01002495|Experimental|Cohort 1|Eight endocardial injection for a total dose of 1mg VM202
3211155|NCT01002495|Experimental|Cohort 2|Eight endocardial injections for a total dose of 2mg VM202
3211156|NCT01002495|Experimental|Cohort 3|Twelve endocardial injections for a total dose of 3mg VM202
3211157|NCT01002521||Cases|Persons With Diabetes (PWD) who have current non-healing ulcer(s)
2579158|NCT02372357|Experimental|Posaconazole 120mg/m² tid|"Pediatric patients admitted to receive chemotherapy or hematopoietic stem cell transplantation for the treatment of a hematological malignancy are receiving Posaconazole prophylaxis 120 mg/m² tid.~At steady state, blood sampling will be performed: 9 blood samples will be taken during 1 dosing interval to evaluate the pharmacokinetics of posaconazole."
2579191|NCT02371837|Experimental|pilates group|Pilates based protocol for 6 weeks
2579192|NCT02371837|No Intervention|control group|No treatment group
2579265|NCT02371447|Experimental|VPM1002BC Induction|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)~Maintenance: 3 instillations of VPM1002BC at months 3, 6 and 12"
2579306|NCT02371096|Experimental|RGB-03|
2579307|NCT02371096|Active Comparator|MabThera (rituximab)|
2579352|NCT02370927|Placebo Comparator|Control|100% Wheat Flour
2579355|NCT02370927|Experimental|Cereal w/ pea protein|Pea protein
2579357|NCT02370927|Experimental|Cereal w/ pea starch|Pea starch
2579358|NCT02370927|Experimental|Cereal w/ pea starch + pea fibre|Pea starch + pea fibre: 5g
2579359|NCT02370927|Experimental|Cereal w/ pea protein + pea starch|Pea protein + pea starch: 10g
2579360|NCT02370927|Experimental|Cereal w/ pea protein + pea fibre + pea starch:|Pea protein + pea fibre + pea starch: 20g
2579410|NCT02370563|Experimental|Arm 1|18F-FSPG will be administered to 30 patients with brain tumors or brain metastases.
2579452|NCT02370329|Experimental|Treatment (PEG-proline-interferon alpha-2b)|Patients receive PEG-proline-interferon alpha-2b SC on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3211158|NCT01002521||Controls|Persons With Diabetes (PWD) with no current ulcers and no history of ulcers
3211159|NCT01002534|No Intervention|baseline|visit 1
3211160|NCT01002534|Active Comparator|Vardenafil|nasal instillation of Vardenafil ( visit 2 or 3)
2579637|NCT02369081|Active Comparator|Spironolactone|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase.
2579638|NCT02369081|Placebo Comparator|Placebo|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
2579640|NCT02369081|Active Comparator|Doxazosin|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
2579642|NCT02369081|Active Comparator|Bisoprolol|Each patient will patients will receive in random order 12 weeks treatment with each of the three active drugs (spironolactone, bisoprolol, doxazosin) or placebo. The dose will be doubled at the six week visit half-way through each phase
2579681|NCT02368717|Experimental|Mesalazine|Mesalazine Enema
2579684|NCT02368717|Placebo Comparator|Placebo|Placebo Enema
2579705|NCT02368418||PCP and SRS|participants had received two interventions (PCP and SRS)
2579706|NCT02368418||PCP only|participants had received PCP intervention only
2579707|NCT02368418||SRS only|participants had received SRS intervention only
2579709|NCT02368418||control group|participants had received usual care (neither PCP nor SRS)
3211161|NCT01002534|Placebo Comparator|Placebo|Nasal instillation of placebo (visit 3 or 2)
3211162|NCT01002560||Malignant melanoma tumour tissue|
2579905|NCT02367326||Patients with Inflammatory Bowel Disease|patients with Crohn's Disease or Ulcerative Colitis meeting clinical, endoscopic and histological criteria and on thiopurines at stable doses for at least 3 months, monotherapy or combined with corticotherapy
3211163|NCT01002560||Benign pigmented lesions & other skin cancers|Normal skin, benign melanocytic tumours, and skin cancers from lineages other than melanocytic, to be used as negative controls
3211164|NCT01002586|Experimental|Wii-Fit arm|Half hour daily, five days a week, for 8 weeks
2579983|NCT02366546|Experimental|Low dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
2579991|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 1|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
2579995|NCT02366546|Experimental|High dose TBI-1301 with pre-treatment 2|TBI-1301(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
2579998|NCT02366546|Experimental|TBI-1301 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
3211165|NCT01002586|Active Comparator|Walking arm|Half hour daily, five days a week, for 8 weeks
3211166|NCT01002599|Experimental|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
2580168|NCT02365532|Placebo Comparator|Placebo to match GS-6615|Placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
2580169|NCT02365532|Experimental|GS-6615|GS-6615 or placebo to match GS-6615 + dofetilide or placebo to match dofetilide twice daily
2580222|NCT02365181|Experimental|IAL|intra-articular local anesthetic infiltration with catheter
2580225|NCT02365181|Active Comparator|ISB|interscalene block with catheter
2580303|NCT02364557|No Intervention|Arm 1 (standard of care)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician.
2580312|NCT02364557|Experimental|Arm 2 (stereotactic radiosurgery, surgery)|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician. Patients also undergo stereotactic radiosurgery in 1, 3, or 5 fractions within 3 weeks and/or surgery at the discretion of the treating physician.
3211167|NCT01002599|Active Comparator|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
2580603|NCT02362815|Active Comparator|Apple juice|Patient are allowed to drink up to 400 ml of apple juice
2579161|NCT02372149|Experimental|IVIg--Washout--0.9% NaCl (CROSSOVER)|"10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)~Washout period~0.9% sodium chloride in water - equal volume to IVIg - Monthly x4"
2579167|NCT02372149|Experimental|0.9% NaCl--Washout--IVIg (CROSSOVER)|"0.9% sodium chloride in water - equal volume to IVIg - Monthly x4~Washout period~10% caprylate-chromatography purified intravenous immunoglobulin (IVIg) Initial dose: 1.0gm/kg/day for 2 days (maximum 80gm/day). Maintenance dose (monthly x3): 1.0mg/kg/day for 1 day (maximum 80gm/day)"
3211168|NCT01002625|Experimental|1. PF-04457845 followed by placebo|PF-04457845 followed by placebo
3211169|NCT01002625|Experimental|2. Placebo followed by PF-04457845|Placebo followed by PF-04457845
3211170|NCT01002638|Experimental|Occlusive Dressing|
3211171|NCT01002638|Active Comparator|Surgery|
3211172|NCT01002651|Experimental|Wheat Bran Extract (high dose)|
3211173|NCT01002651|Experimental|Wheat Bran Extract (low dose)|
3211174|NCT01002651|Placebo Comparator|placebo|
3211175|NCT01002664|Active Comparator|MCS-2|Drug Name: MCS-2 Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
2579406|NCT02370550|Experimental|Cyclosporin A(CsA)+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure (FVC absolute decrease >15% of predicted values after 4 weeks of treatment) are suggested to switch to intravenous glucocorticoid + cyclophosphamide(CYC) 0.5-1 g/m2 every 4 weeks as the rescue therapy after unblinding, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who experience a second treatment failure should be withdrawn from the trial and be given empirical treatment. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators should decide whether a visit should be increased to complete subsequent examinations.
2579408|NCT02370550|Placebo Comparator|placebo+glucocorticoid|A. The efficacy/safety are evaluated at V3, V4, V5 and V6, and the treatment is adjusted accordingly. Patients who experienced treatment failure are suggested to switch to glucocorticoid + CsA 2-3mg/kg/d, BID as the rescue therapy, and continue to complete the subsequent follow-up. Each patient can only have one chance to be rescued. Patients who did not experience treatment failure continued to receive current treatment. B. For subjects with aggravated shortness of breath and dyspnea in between of two consecutive visits, the investigators in each center should decide whether a visit should be increased.
2579476|NCT02370290||Observational (QIM)|Patients' clinical and imaging data are collected from routine multiphase CECT imaging and used to establish and validate the classification/prediction rule for QIM.
2579498|NCT02370030|Active Comparator|Intervention|Oral or nasogastric administration of 10 g citrulline malate daily. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
2579502|NCT02370030|Placebo Comparator|Placebo|10 g of maltodextrin will be substituted for the citrulline. Blood and urine samples to determine biomarkers of endothelial damage (IL 6, IL 10 , nitric oxide and microalbuminuria), with a second sampling after 7 days of intervention. Disease severity will be measure with various scales, including APACHE II, SOFA
2579592|NCT02369718|Experimental|Implanted subjects|Listening to 12 Fournier's lists of words
2579593|NCT02369718|Active Comparator|Normal hearing subjects|Listening to 48 Fournier's lists of words
2579649|NCT02369107|Experimental|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
2579653|NCT02369107|Sham Comparator|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
2579708|NCT02368678|Active Comparator|Scaling and Root Planning (SRP)|Scaling and root planing (SRP) (n=15): the traditional mechanical periodontal therapy consisting of quadrant-wise (30 min. per quadrant) scaling and root planning performed at weekly sessions (one or two weeks of interval between session) and completed within 2 months.
2579710|NCT02368678|Active Comparator|Full Mouth Scaling (FMS)|Full mouth scaling (FMS) (n=15): the alternative mechanical periodontal therapy consisting of full-mouth scaling and root planning completed in a single stage within 24 hours; i.e two sessions (60 min. per session) in two consecutive days.
2579799|NCT02368249|Placebo Comparator|Control Group|Patients receiving post-operative placebo (Ringer lactate solution) treatment to preserve the renal function
2579800|NCT02368249|Experimental|Terlipressin Group|Patients receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
2579840|NCT02367612|Experimental|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
2579850|NCT02367612|Placebo Comparator|Placebo|Placebo
2579921|NCT02367079|Active Comparator|Switched on diathermy|Switched on diathermy was used on DOMS compared to sham diathermy
3211176|NCT01002664|Placebo Comparator|Placebo|Drug Name: MCS-2 placebo Dosage: 2 soft-gel capsules Frequency: Qd per day after dinner Duration: 12 weeks
3211177|NCT01002677|Experimental|Curriculum|
3211178|NCT01002677|Active Comparator|Self-directed|
3211179|NCT01002690|Experimental|Etoricoxib|10-13 days treatment with etoricoxib
3211180|NCT01002703|Experimental|RBP|Lenalidomide and Bendamustine and Prednisone
3211181|NCT01002768|Experimental|IDeg|
3211182|NCT01002768|Experimental|IGlar|
3211183|NCT01002794|Experimental|Arthroscopic partial meniscectomy|Standard arthroscopic partial meniscectomy - NGD 1
3211184|NCT01002794|Experimental|Exercise Therapy|Supervised neuromuscular- and strength training
3211185|NCT01002807|Other|FDC of dapagliflozin/metformin XR|
3211186|NCT01002807|Other|FDC of dapagliflozin/reduced mass metformin XR|
3211187|NCT01002807|Other|dapagliflozin and Glucophage® XR|
3211188|NCT01002820|Experimental|participants|all subjects participating in 0602 are receiving ganaxolone for seizure control
3211189|NCT01002833|Experimental|PfA|Exposure of human volunteers to bites of mosquitoes infected with the A strain of Plasmodium falciparum
2579321|NCT02371031|Experimental|Arm 1: FDOPA-PET/MRI|"Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.~In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.~When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling."
2579388|NCT02370849|Experimental|NCS|nimotuzumab plus cisplatin and S-1
2579392|NCT02370849|Active Comparator|CS|cisplatin and S-1
2579455|NCT02370316|Experimental|MIT - SA|Metacognitive Interpersonal Therapy -standard approach (MIT-SA) is a cognitive behavior-based psychotherapeutic approach that works to increase metacognitive abilities and to improve interpersonal relationships
2579460|NCT02370316|Active Comparator|Clinical Structured Treatment (CST)|Clinical Structured Treatment (CST) is a structured case management and symptom-targeted medication
3211190|NCT01002833|Experimental|PfB|Exposure of human volunteers to bites of mosquitoes infected with the B strain of Plasmodium falciparum
3211191|NCT01002833|Active Comparator|NF54|Exposure of human volunteers to bites of mosquitoes infected with the NF54 strain of Plasmodium falciparum
2579613|NCT02369328|Experimental|multimodal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for patients whom suffering stroke
2579614|NCT02369328|Active Comparator|multimocal MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) and clinical evaluation will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months for healthy subjects
2579636|NCT02368977|Experimental|All subjects|All subjects will undergo examination with a Third Eye Panoramic device in conjunction with a standard colonoscope to evaluate the feasibility of using the study device to provide video imaging of areas of the colon that are difficult to evaluate with the colonoscope alone.
2579683|NCT02368743||mesalazine|Treatment according to standard clinical practice.
2579712|NCT02368444|Experimental|Intervention Group|Cognitive Behavioral Therapy and Yoga
2579774|NCT02368236|Other|Intervention Group|Patients randomized to the intervention group will use CRIS. Then intervention group patients and their physicians will receive a tailored printout generated by the CRIS recommending risk-appropriate colorectal testing and ways to overcome perceived barriers to testing. A member of the research team will hand the patient a printout and will deliver the other printout to the physician.
2579781|NCT02368236|No Intervention|Comparison Group|Patients randomized to the comparison group will use CRIS, but receive a non-tailored standard information about multiple types of cancer screening (e.g., content from an American Cancer Society cancer screening brochure) while physicians receive standard electronic chart prompts indicating the patients were age-eligible but not currently adherent for colorectal cancer screening.
2579786|NCT02368236|No Intervention|True No-contact Control Group|A screening baseline for the true no-contact group will be established by conducting a retrospective chart review for patients who did not receive an invitation to participate in this study. The same randomization procedure will be used as the comparison and intervention groups. The purpose is to conduct analysis with the comparison and intervention group to see if individuals who participate in CRIS have a higher screening rate for colorectal cancer compared to the non-contact group.
2579832|NCT02367846|Experimental|Combined Oral Contraceptive (COC)|We are testing the effects of a COC (Apri (Reclipsen); 30 µg EE, 150 µg desogestrel). On the first day of the intervention, the participants randomized to COC will begin taking the pill. One pill will be ingested orally at the same time each day for days 1-49 of the intervention. Pills ingested during days 1-21 and during days 29-49 will be active tablets. Pills ingested on days 22-28 will be tablets without active ingredients. Each participant in the COC group will ingest a pill from the first pack each day for the first 28 days then begin the second pack. If a participant is unable to collect a 24-h urine sample on day 49, she will take active tablets from the third pill pack until she has collected the 24-h urine sample.
2579834|NCT02367846|Experimental|Contraceptive Vaginal Ring (CVR)|We are testing the effects of the vaginal ring (Nuva Ring; 15 µg/d EE, 120 µg/d etonogestrel). When randomized to CVR, participants will insert the contraceptive ring into their vagina . The ring will be worn during weeks 1-3, and again during weeks 5-7. During week 4, no ring will be worn to allow for withdrawal bleeding. If a participant is unable to collect a 24-h urine sample on day 49, they will insert a third ring which will remain in the vagina until she has collected a 24-h urine sample.
2579890|NCT02367404|No Intervention|Control|Keigel's exercise
2579896|NCT02367404|Active Comparator|Duloxetine|Duloxetine 60mg for 3 months
2579903|NCT02367404|Active Comparator|Duloxetine + PMFT|Duloxetine 60mg for 3 months PMFT weekly for 3 months
2579906|NCT02367404|Active Comparator|Pelvic Floor Muscle Training|PMFT weekly for 3 months
2579958|NCT02366949|Experimental|Arm 1|Experimental Treatment (combination of BAY1217389 with paclitaxel in an intermittent dosing schedule) Expansion Cohort - Maximum tolerated dose of BAY1217389 and Paclitaxel
2579961|NCT02366949|Placebo Comparator|Arm 2|Standard Treatment (Single-agent Paclitaxel )
2579984|NCT02366598|Experimental|20g Hemp protein shake|Hemp protein shake, 20 grams, given once at beginning of acute trial
3211192|NCT01002846|Experimental|traditional acupuncture|Procedure : ST 36 and PC 6 are selected, subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth
3211193|NCT01002846|Sham Comparator|sham acupuncture|Procedure : Beside 1cm of ST 36 and PC 6 are selected( not meridian point), subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
3211194|NCT01002859|Active Comparator|cyclosporin|Intravenous cyclosporin injection.
2579251|NCT02371525|No Intervention|Standard of Care|
2579252|NCT02371525|Experimental|Prepmate|
2579343|NCT02371057||patients under follow-up known to have sleep apnoea|
2579346|NCT02371057||patients attending the sleep apnoea clinic for assessment|Patients who are attending clinic who have not yet been diagnosed.
2579389|NCT02370758|Active Comparator|Low CMV CMI|Patients that show low levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) continued for an additional 2 months at half dose.
2579393|NCT02370758|No Intervention|High CMV CMI|Patients that show high levels of cell-mediated immunity against CMV will have their antiviral therapy (oral Valganciclovir or Intravenous Ganciclovir) stopped.
2579523|NCT02369939|Active Comparator|control arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33
2579528|NCT02369939|Experimental|Experimental arm|Irradiation 1.8Gy/d; T2N0 55.8Gy; T3N0-T4N0 59.4Gy Chemotherapy: Mitomycin C 10mg/m^2/d on d1 and 29; 5-Fluorouracil 1000mg/m^2/d on d1-5, 29-33 Hyperthermia: 6
2579555|NCT02369471|Experimental|Group 1a|Subjects on inducer AEDs will administer GWP42006.
2579557|NCT02369471|Active Comparator|Group 2a|Subjects on inhibitor AEDs will administer GWP42006.
2579561|NCT02369471|Experimental|Group 3a|Subjects on AEDs that are neither inducers nor inhibitors will administer GWP42006.
2579566|NCT02369471|Placebo Comparator|Group 1b|Matching placebo control for Group 1a.
2579569|NCT02369471|Placebo Comparator|Group 2b|Matching placebo control for Group 2a.
2579574|NCT02369471|Placebo Comparator|Group 3b|Matching placebo control for Group 3a.
2579633|NCT02369094|Experimental|Acupressure Group|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
2579634|NCT02369094|Other|Waiting Control Group|"No acupressure therapy will be provided during the 1st 12 weeks' of study.The enrolled elderly will join a group activity, resembling the other group activities that held in that particular center, their caregivers will be requested to spend two 20 minutes sessions per week with the elderly doing homework assigned by the activity group and log down the timing in the log book.This arrangement is to account for the placebo effect of additional social interaction time and attention that the treatment group will receive during this period.~After completing the 1st 12 weeks' participation in the Waiting Control Group, the subject dyads in the waiting control group will receive the same training and treatment as the treatment group."
2579665|NCT02368821||normal pregnancy|placental from normal pregnancy
2579672|NCT02368821||complacted pregnancy|placental from complicated pregnancy ( intrauterine growth restriction, preeclampsia , placenta accrete
2579735|NCT02368600|Experimental|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
2579737|NCT02368600|No Intervention|Usual care|Women will have their first AN booking visit generally on or before 12 week gestation. For women who are primigravida, their AN visit appointments will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-28 weeks, and every 2 weeks after 28 weeks. For women who are multigravida, the corresponding schedules will be set at every 6 weeks before 24 weeks, every 4 weeks between 24-36 weeks, and every 2 weeks after 36 weeks. Body weight of the pregnant woman will be monitored by nurses and basic nutrition advice will be briefly given by nurses in case she is slightly overweight. They will be provided with an educational pamphlet on diet and exercise during pregnancy. They will also be offered optional antenatal classes which subjected to quotas availability.
2579836|NCT02367573|Active Comparator|2D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with two dimensional view
2579846|NCT02367573|Experimental|3D TAPP|Trans-abdominal pre-peritoneal laparoscopic inguinal hernia repair operated with three dimensional view
2579956|NCT02366858|Active Comparator|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle.
2579957|NCT02366858|Active Comparator|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle.
3176429|NCT00644085|Experimental|1|oral administration of aspirin 100 mg
3176430|NCT00644085|Placebo Comparator|2|oral administration of placebo
3176431|NCT00644098|Placebo Comparator|Placebo|cellulose and soybean oil
3176432|NCT00644098|Experimental|Intervention|soluble fibre complex and medium chain triglycerides
3176433|NCT00644111|Placebo Comparator|1|Control group receiving saline placebo through an epidural catheter
3176434|NCT00644111|Active Comparator|2|Experimental group receiving active medication through the epidural catheter
3176435|NCT00644124|Experimental|Aflibercept RCHOP 14|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 2 weeks. A dose of 2.0 mg/kg administered as Dose Level 1, 4.0 mg/kg as Dose Level 2, and 6.0 mg/kg dose as Dose level 3.
3176436|NCT00644124|Experimental|Aflibercept RCHOP 21|Aflibercept (25 mg/ml by IV over an hour) in combination with fixed dose of rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) administered every 3 weeks. A dose of 3.0 mg/kg administered as Dose Level 1, 6.0 mg/kg as Dose Level 2, and 8.0 mg/kg dose as Dose level 3.
3176437|NCT00644137|Experimental|A|pregabalin 300mg/day given in conjunction with smoking cigarettes.
3176438|NCT00644137|Experimental|2|cigarettes given in conjunction with pregabalin
3176439|NCT00644150|Experimental|1|Physicians of county level will receive Ai Shi Zi training provided by experts in the fields of HIV/STIs, behavioral counseling, and stigma reduction.
3176440|NCT00644150|Experimental|2|Physicians of township level will receive Ai Shi Zhi training provided by the county level physicians.
3211195|NCT01002859|Placebo Comparator|Pacebo|Intravenous injection of NaCl solution.
3211196|NCT01002872|Active Comparator|Lanthanum Carbonate|
3211197|NCT01002872|Placebo Comparator|Placebo|
3211198|NCT01002898|Experimental|lopinavir/ritonavir|
3211199|NCT01002911|Experimental|Aggressive Antibiotic therapy|Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.
3211200|NCT01002911|Active Comparator|Conventional Antibiotic Therapy|Preoperative intravenous antibiotics
3211201|NCT01002924|Experimental|All Participants|All participants invited to enroll on study will receive EC145 (vintafolide) 2.5 mg by intravenous bolus on Monday, Wednesday, and Friday of Weeks 1 and 3 in each 4-week cycle.
2579484|NCT02370134|Experimental|Parkinson's glove|Parkinson's glove 14 days use with 4 times follow-up
2579489|NCT02370134|Placebo Comparator|sham glove|sham glove (with light and sound)14 days use with 4 times follow-up
2579527|NCT02369822|Experimental|Vitamin C supplemented|patients with refractory idiopathic epilepsy will receive vitamin C supplement according to age for 1 month
2579529|NCT02369822|No Intervention|None supplemented|followed up for 1 month
2579584|NCT02369562||Dental implant patients|All patients rehabilitated with dental implants.
2579624|NCT02369146|Experimental|cohort 1|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly
2579627|NCT02369146|Experimental|cohort 2|Subjects will receive 8 doses of the UB-421 by intravenous infusion at 25 mg/kg weekly
2579664|NCT02368847|Other|Diagnostic tests|For any patient with a suspected urinary tract infection during the course of the study a basic questionnaire will have to be filled out and diagnostic tests (urine sample for culture, dipstick assay for the detection of nitrites and leukocyte- esterase and a POC CRP test) will have to be perform.
2579714|NCT02368496|Experimental|Children and young adults on long-term parenteral nutrition|long-term parenteral nutrition : 2 years
2579771|NCT02368197|Active Comparator|Standard balloon angioplasty|Dilatation of stenosis with standard non drug eluting balloon catheter
2579778|NCT02368197|Experimental|Drug eluting balloon angioplasty|Dilatation of stenosis with paclitaxel eluting balloon catheter
2579847|NCT02367703|Experimental|standard instrument|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
2579852|NCT02367703|Other|less than 3 millimeter diameter's instruments|That is why we propose a randomized comparative study between standard instrument and less than 3 millimeter diameter's instruments to achieve in daily practice laparoscopic hysterectomy
2579888|NCT02367313|Placebo Comparator|Placebo|Placebo
2579892|NCT02367313|Active Comparator|Vapendavir 264 mg|Vapendavir 264 mg and matching placebo
2579899|NCT02367313|Active Comparator|Vapendavir 528 mg|Vapendavir 528 mg and matching placebo
2580048|NCT02366156|Placebo Comparator|Placebo|Inactive capsules
2580058|NCT02366156|Active Comparator|Low Dose Grape Blend|Low dose grape blend providing 375 mg whole grape extract + 375 mg grape seed extract/d (750 mg total botanical extracts/d).
2580065|NCT02366156|Active Comparator|High Dose Grape Blend|High dose grape blend providing 500 mg whole grape extract + 500 mg grape seed extract/d (1000 mg total botanical extracts/d)
2580137|NCT02365792|Active Comparator|CDSS1|The CDSS1 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
2580145|NCT02365792|Active Comparator|CDSS2|The CDSS2 will provide decision support according to existing protocols for clinical procedures and medical treatment, mainly starting from specific symptoms or diagnostic related patients groups. The symptom oriented approach is categorised in a specific list of predetermined conditions.
2580151|NCT02365792|Placebo Comparator|Booklet|The control group will provide prehospital patient care with usual decision support: a pocket-size booklet, backed by a mobile phone through which the PIT can get in contact with an Emergency Physician.
2580293|NCT02365051|No Intervention|usual care|Older adults with dementia and their family caregivers receive all services for which they are eligible in the Connecticut Home Care Program for Elders.
2580295|NCT02365051|Experimental|COPE plus usual care|Older adults with dementia and their family caregivers receive Usual care plus the intervention: Care of Persons with Dementia in their Environments.
3211202|NCT01002937||Tumour tissue, renal cell carcinoma|> 2mm x 2mm of tumour tissue obtained from paraffin blocks taken from biopsies or nephrectomy specimens.
3211203|NCT01002950|Experimental|ACU-4429 tablet|
3211204|NCT01002950|Placebo Comparator|Matching placebo tablet|
3211205|NCT01002963|Experimental|PF-04418948 30 mg|
3211206|NCT01002963|Experimental|PF-04418948 100 mg|
3211207|NCT01002963|Experimental|PF-04418948 300 mg|
3211208|NCT01002963|Experimental|PF-04418948 1000 mg|
3211209|NCT01002963|Experimental|PF-04418948 3000 mg|
3211210|NCT01002963|Experimental|PF-04418948 4500 mg|
3211211|NCT01002963|Experimental|PF-04418948 6000 mg|
3211212|NCT01003002||PD Cohort|The cohort for this study is Parkinson's disease patients that are beginning oral levodopa treatment within one month of the screening visit. This cohort has not previously (to the screening visit) been treated with oral levodopa.
3211213|NCT01003015|Experimental|Arm 1|
3211214|NCT01003028|Experimental|Limited|Limit the maximum plasma concentration target to 9.8 ng/ml
3211215|NCT01003028|Active Comparator|Control|Use 20 ng/ml as max plasma concentration
3211216|NCT01003041||lifestyle counseling|in the future parents will be advised to expose their infants to phonetic sounds in order to develop their phonetic categories in the future
3211217|NCT01003054|Experimental|Autologous Transplantation|Busulfan 130 mg/m^2 intravenous (IV) every 24 hours Days -7 to -4; Cyclophosphamide 60 mg/kg over 4 hours Day -3 and -2; Imatinib Mesylate Starting dose 100 mg/day, and Autologous Stem Cell Transplantation on Day 0.
3211218|NCT01003093|Experimental|Antigen group + high adjuvans|The antigen group + high adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (500 nmol KLK + 20 nmol ODN1a) two months apart.
2579196|NCT02371967||No Gorlin Syndrome Participants With No Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
2579197|NCT02371967||No Gorlin Syndrome Participants With Prior HPI Exposure|BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
2579199|NCT02371967||Gorlin Syndrome Participants With/Without Prior HPI Exposure|BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study.
2579268|NCT02371551||1|All patients
2579325|NCT02371148|Experimental|Bortezomib-Rituximab-Bendamustine|Bortezomib-Rituximab-Bendamustine (BRB) combination in patients with relapsed/refractory lymphoplasmocytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia after one line of therapy.
3211219|NCT01003093|Experimental|Antigen group|The antigen group received two injections of antigen (Ag85B + ESAT-6) two months apart.
3211220|NCT01003093|Experimental|Antigen + low adjuvans group|The antigen group + low adjuvans group received two injections of antigen (Ag85B + ESAT-6) + IC31 (100 nmol KLK + 4 nmol ODN1a) two months apart.
2579475|NCT02370277||Group A (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (before surgery), at 1 week before initiation of adjuvant chemotherapy (after surgery), and at 1 and 4 months after completion of adjuvant chemotherapy.
2579477|NCT02370277||Group B (stool collection after adjuvant chemotherapy)|Patients undergo collection of stool samples at baseline (after surgery), at 1 week before initiation of adjuvant chemotherapy, and at 1 and 4 months after completion of adjuvant chemotherapy.
2579478|NCT02370277||Group C (stool collection after neoadjuvant chemotherapy)|Patients undergo collection of stool samples at baseline, 1 month after completion of neoadjuvant chemotherapy (before surgery), and at 1 and 4 months after surgery
2579515|NCT02369926|Active Comparator|Group 1|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 2.
2579519|NCT02369926|Active Comparator|Group 2|Participants will be separated into two groups for scheduling purposes. Each group will complete the Multiple Sclerosis Functional Composite (MSFC) once weekly at the study site and once weekly at home for three weeks. They will alternate their visit dates with Group 1.
3211221|NCT01003119|Experimental|A CHESS|Those in the ACHESS arm will also be given a smart-phone with access to the ACHESS system (the intervention) for a full 12 months. The ACHESS intervention includes: 1) the Core CHESS system that has been tested in several diseases, 2) a proactive computer-based relapse prevention system, 3) data transfer from the phone to a computer accessible by the patient's counselor/care manager, and 4) systems for the patient to maintain contact with his/her Care Manager
3211222|NCT01003119|No Intervention|Usual Care|Those randomized into the Usual Care group will receive usual medical care.
2579675|NCT02368795|Placebo Comparator|Pharmacological Prevention|Combination of rectal indomethacin, sublingual isosorbide dinitrate and intravenous hydration with Ringer's lactate serum without pancreatic stenting
2579679|NCT02368795|Active Comparator|Pancreatic Stent|Pancreatic Stent PLUS Pharmacological Prevention
2579772|NCT02368366|Experimental|Therapist Guided Face to Face FPST|Therapist Guided Face to Face Family Problem Solving Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
2579779|NCT02368366|Experimental|Therapist Guided Online FPST|Therapist Guided Online Family Problem Solving Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
2579782|NCT02368366|Experimental|Self-Guided Online FPST|Self-Guided Online Family Problem Solving Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
2579818|NCT02367677||Clinical measurements|Measurements are made with a paper ruler
2579822|NCT02367677||Smartphone|Measurements are made with ImageJ from pictures taken with an iPhone 6
2579829|NCT02367677||Digital camera|Measurements are made with ImageJ from pictures taken with a Nikon D700
2579928|NCT02366884|Experimental|Anti-bacterial agents|Combination of two selected anti-bacterial agents with documented anti-cancer properties
2579930|NCT02366884|Experimental|Anti-fungal agents|Combination of two selected anti-fungal agents with documented anti-cancer properties
2579933|NCT02366884|Experimental|Anti-protozoal agents|Combination of two selected anti-protozoal agents with documented anti-cancer properties
2579936|NCT02366884|Experimental|Anti-bacterial + anti-fungal + anti-protozoal agents|Combination of six selected anti-bacterial agents, anti-fungal agents, and anti-protozoal agents with documented anti-cancer properties
2579216|NCT02371720|Active Comparator|Adults - standard of care then Mobile DOT|Subjects with SCD that are older than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
2579218|NCT02371720|Experimental|Children - Mobile DOT|Subjects with SCD that are younger than 21 years old will receive comprehensive medication adherence management (Mobile DOT) after 1 month assessment period. The subjects will receive the Mobile DOT intervention for 24 months.
2579221|NCT02371720|Active Comparator|Children - standard of care then Mobile DOT|Subjects with SCD that are younger than 21 years old will receive standard of care for the first 12 months. They will then crossover to the comprehensive medication adherence management plan (Mobile DOT) after 1 month assessment period for the remaining 12 months.
2579312|NCT02371213|Experimental|social networking on mobile phone|Audio-video media via social networking on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly plus usual antenatal care group-health education
2579316|NCT02371213|No Intervention|no social networking on mobile phone|usual antenatal care group-health education
2579365|NCT02370875|Experimental|Real rTMS stimulation|Repetitious transcranial magnetic stimulation (rTMS) will be delivered using the Magstim RapidStim2 over each anterior cingulate cortex, using a figure-of-eight coil. The investigators will apply rTMS with 0.2 Hz frequency to the ACC. 180 stimuli will be delivered with a stimulator output of 100% active motor threshold (AMT). AMT will be assessed at the tibialis anterior muscle with the coil. The AMT will be defined as the lowest stimulation intensity required to evoke a 150 μV potential in the target muscle. To determine the stimulation site for ACC, the coil will be placed over Fz and then moved over the midline of the brain in 0.5-cm steps anteriorly, until the point of maximum motor evoked potential in the orbicularis oculi (OO) muscle. The coil position will be marked on the skin. These rTMS sessions will be repeated daily for 10 days.
2579369|NCT02370875|Sham Comparator|Sham rTMS Stimulation|During sham repetitious transcranial magnetic stimulation (rTMS), subjects will undergo the same procedure for identifying stimulus location as used in patients receiving real rTMS using the sham Magstim RapidStim2 coil. This coil will be placed on the patient's head in an identical manner however will not be connected to the Magstim device. Instead another coil will be connected to provide stimulation sound. In each stimulation condition, the Magstim will be placed behind the patient and not visible to him or her. Placebo sham coil which produces discharge noise and vibration similar to a real coil without stimulating the cerebral cortex. During rTMS, all patients will continue to wear ear plugs as instructed during the real stimulation sessions.
3211223|NCT01003132|No Intervention|Treatment As Usual|Treatment as usual as determined by the clinical team responsible for the individual's care
3211224|NCT01003132|Active Comparator|Acceptance and Commitment Therapy|Up to 10 sessions of Acceptance and Commitment Therapy plus treatment as usual
2579554|NCT02369497||Primary cohort|Primary cohort of subjects who receive the HRA device.
2579606|NCT02369302|Experimental|DWC20141|multiple dose of DWC20141
2579609|NCT02369302|Experimental|DWC20142|multiple dose of DWC20142
2579611|NCT02369302|Experimental|DWC20141+DWC20142|multiple dose of DWC20141 and DWC20142
2579666|NCT02368964|Experimental|High dose hCG|The hCG group- will be triggered for final follicular maturation with high dose hCG (500 mcg)-38 hours prior to oocyte aspiration
2579671|NCT02368964|Experimental|Double trigger|Double trigger Group- will receive GnRH agonist (Decapeptyl 0.2mg) 40 hours prior to oocyte aspiration and hCG (250mcg) 34 hours prior to the oocyte aspiration
2579703|NCT02368405|Active Comparator|Control|Control group will receive standard of care
2579704|NCT02368405|Experimental|Treatment|"Participants in the treatment group will receive six interactive nutrition lectures over the course of three weeks. The treatment program is titled Eat Smart, Live Better"
2579746|NCT02368288|Experimental|entecavir with PEG-IFN a-2a|after enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks.
2579747|NCT02368288|No Intervention|peginterferon alpha 2a|in this group, patients will be continue treated only with PEG-IFN a-2a for 48 weeks after enrolled.
2579773|NCT02367989|Placebo Comparator|Control without fibre|"Intervention: 0g barley β-glucan no fibre.~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
2579780|NCT02367989|Experimental|low barley β-glucan|"Intervention: 2g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
2579787|NCT02367989|Experimental|medium barley β-glucan|"Intervention: 4g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
2579790|NCT02367989|Experimental|high barley β-glucan|"Intervention: 6g barley β-glucan~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
2579793|NCT02367989|Placebo Comparator|control with fibre|"Intervention: 0g barley β-glucan with fibre~Dose provided in waffles given as breakfast to fasting participant at 1 of 5 visits."
2579841|NCT02367625|Experimental|Arm 1|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
2579849|NCT02367625|Active Comparator|Arm 2|20 women with normal cervical cytology will be randomized to receive MedGYn MGC 200 therapy
2579895|NCT02367365||Treatment Naive NVAMD Patients|Patients with treatment naive NVAMD diagnosed in the last three months
2579900|NCT02367365||Newly Reactivated NVAMD Patients|Patients with newly reactivated NVAMD which has been previously quiescent off treatment
2579941|NCT02366988|Active Comparator|Endoscopic Biliary Stenting|Temporary self-expandable metallic covered stent
2579945|NCT02366988|Active Comparator|Surgical treatment|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
2579985|NCT02366715|Experimental|HeatedHumidifiedHighFlowNasalCannula|Treatment for moderate-severe cases of Bronchiolitis while monitoring medical parameters
2580045|NCT02366351|Experimental|SHR3824 Placebo|once daily, 12 weeks
2580051|NCT02366351|Experimental|SHR3824 5 mg|once daily, 12 weeks
2580055|NCT02366351|Experimental|SHR3824 10 mg|once daily, 12 weeks
2580064|NCT02366351|Experimental|SHR3824 20 mg|once daily, 12 weeks
2579219|NCT02371694|Experimental|Fat Test drink (13g)|This drink contains 13g sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
2579222|NCT02371694|Placebo Comparator|Fat Test drink (3g)|This drink contains no sunflower oil and vehicle (almond milk, chocolate drink powder, sweetener)
2579226|NCT02371694|Active Comparator|Carbohydrate Test drink|This drink contains 20g of glucose from de-gassed lucozade energy.
2579280|NCT02371408|Experimental|1a: Treatment-naive patients, without ribavirin (RBV)|PPI-668 + sofosbuvir for 12 weeks
2579281|NCT02371408|Experimental|1b: Treatment-naive patients, with RBV|PPI-668 + sofosbuvir + ribavirin (RBV) for 12 weeks
2579282|NCT02371408|Experimental|2a: Non-cirrhotic previous non-responders, without RBV|PPI-668 + sofosbuvir for 12 weeks
2579283|NCT02371408|Experimental|2b: Non-cirrhotic previous non-responders, with RBV|PPI-668 + sofosbuvir + ribavirin for 12 weeks
2579284|NCT02371408|Experimental|3a: Cirrhotic previous non-responders 12 weeks|PPI-668 + sofosbuvir + ribavirin for 12 weeks
2579285|NCT02371408|Experimental|3b: Cirrhotic previous non-responders 16 weeks|PPI-668 + sofosbuvir + ribavirin for 16 weeks
3211225|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0|"15 μg HA (0.5 mL) per injection, 1 injection~50 adults (aged 18~60 years) were assigned to receive one injection of H1N1 vaccine"
3211226|NCT01003145|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|"15 μg HA (0.5 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
3211227|NCT01003145|Experimental|H1N1 vaccine of 30 μg HA on Day 0 and 21|"30 μg HA (1 mL) per injection, 2 injections~50 adults (aged 18~60 years) and 50 elders (aged over 60 years) were assigned to receive two injections of H1N1 vaccine 3 weeks apart"
3211228|NCT01003158|Experimental|Monotherapy part|AZD8931 monotherapy
3211229|NCT01003158|Experimental|Combination part|AZD8931 plus paclitaxel
2579509|NCT02369978|Experimental|Nifurtimox (NFX)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
2579510|NCT02369978|Active Comparator|Benznidazole (BZN)|60 days of active treatment with full-dose, or 120 days of active treatment with half-dose (allocation ratio 1:1). The 60-day group will receive active treatment in the first or second half of a 120-day treatment window, as per random allocation. The active treatment period will be followed/preceded by matching placebo (see placebo arm below)
2579512|NCT02369978|Placebo Comparator|Placebo|120 days of treatment with matching placebo
2579608|NCT02369315|Experimental|Treatment (Invited entry 2012)|Children offered entry to music program in September 2012
2579610|NCT02369315|Experimental|Control (Invited entry 2013)|Children offered entry to music program delayed until September 2013
2579647|NCT02368990||NSCLC T790M positive|NSCLC patients who have had 1st line treatment with an approved EGFR targeted TKI, who are known to be T790M mutation positive and who have been prescribed platinum based doublet chemotherapy (pemetrexed + cisplatin/carboplatin) as a 2nd line treatment as part of their standard care.
2579808|NCT02368340||Adults with pulmonary fibrosis|This group includes adults with HPS who have known pulmonary fibrosis. Subjects in this group will provide blood and urine specimens.
2579810|NCT02368340||Adults at-risk|"This group includes adults with HPS with subtypes at-risk for pulmonary fibrosis, but who do not have known pulmonary fibrosis.~Subjects in this group will undergo chest CT and pulmonary function testing, and provide blood and urine specimens."
2579815|NCT02368340||HPS adults not at-risk|"This group includes adults with HPS subtypes considered not at-risk for pulmonary fibrosis.~Subjects in this group will provide blood and urine specimens."
2579816|NCT02368340||Children with HPS at-risk|This group includes children with HPS subtypes at-risk for pulmonary fibrosis. Subjects in this group will undergo pulmonary function testing, and provide blood and urine specimens.
3211230|NCT01003171|Experimental|MCS-2|
3211231|NCT01003197||complication group < III|
3211232|NCT01003197||complication group >= III|
2580185|NCT02365194|Other|Prehabilitation|physical conditioning and weight loss intervention done pre-operatively
2580188|NCT02365194|Other|Standard Counseling|initial clinic counseling
2580327|NCT02364726|Experimental|Acupuncture|"As part of routine clinical care, a chemotherapy nurse, research nurse, or physician will assess the patient's symptoms including CIPN based on the NCI-CTC 4.0 criteria to determine the grade of CIPN. Once these patients develop National Cancer Institute-Common Toxicity Criteria (NCI-CTC) grade 2 CIPN, they will be recruited for the intervention phase of the study. Severity of CIPN as defined by NCI-CTC is listed in Appendix A. Patients who consent to the intervention phase of the study will then be treated with weekly acupuncture until the end of chemotherapy. No concomitant anti-neuropathy medication will be permitted.~Subjects will receive acupuncture in bilateral ear points: shen men, point zero, two additional auricular acupuncture point where electrodermal signal is detected and bilateral body acupuncture points: LI4, TE5, LI11, ST40, Ba Feng, Ba xie."
2580347|NCT02364219|No Intervention|Standard|"Study arm in which patients are treated according to standard operating procedures. Acting as control arm."
2580838|NCT02361177|Placebo Comparator|placebo|Intranasal placebo. 125 mg of 0.5% cholorobutanol to 50 ml saline, with approximately 5 pH. The solution will then be sterilized using a 0.22 micron filter.
3211233|NCT01003223|Experimental|PKM modeling with graphical report|
3211234|NCT01003236|Placebo Comparator|placebo|1 tablet 3 times daily
3211235|NCT01003236|Experimental|Milk Thistle extract|1 tablet of the extract (equivalent to 140 mg silymarin) 3 times per day
3211236|NCT01003262|Experimental|Emergency Department Observation|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
3211237|NCT01003262|Active Comparator|Unstructured, inpatient evaluation|
3211238|NCT01003314|Experimental|Group 1|
3211239|NCT01003314|Experimental|Group 2|
3211240|NCT01003327|Other|I-gel inserted first|The I-gel airway is insewrted first, then the LMA-Unique
3211241|NCT01003327|Other|LMA-Unique inserted first|LMA-Unique airway is inserted first, then the I-gel
3211242|NCT01003340|Experimental|Wee Wheezers asthma education|6 lesson asthma education delivered at home by Community Health Workers
2579248|NCT02371512|Active Comparator|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
2579288|NCT02371265|Experimental|Adherence and retention intervention|Implementation of adherence and retention package
2579289|NCT02371265|No Intervention|Control|Clusters continue without intervention package
2579350|NCT02371044||Rivaroxaban|N=20
2579353|NCT02371044||Apixaban|N=20
2579356|NCT02371044||Dabigatran|N=20
3211243|NCT01003366|Experimental|bevel down|approaching the IJV with the needle bevel facing down
3211244|NCT01003366|Active Comparator|bevel up|approaching the IJV with the needle bevel facing up
2579482|NCT02370147|Experimental|Smoking reduction intervention arm|Smoking reduction intervention arm (SRI) consisting of a minimal face-to-face individual smoking reduction intervention lasted for about one minute, and five follow-up interventions lasted for about one minute each.
2579490|NCT02370147|Active Comparator|Control arm|Control arm (UC) consisting of a brief face-to-face individual exercise and dietetic advices lasted for the same intervention time as SRI, and five follow-up interventions lasted for about one minute each with different intervention contents.
3211245|NCT01003379|Experimental|TC-5619|TC-5619 capsules will be administered once a day in a forced titration scheme at 1 mg for 4 weeks, 5 mg for 4 weeks and 25 mg for 4 weeks (12 weeks total).
3211246|NCT01003379|Placebo Comparator|Placebo|
2579599|NCT02369354|No Intervention|Usual Care|Usual medical care at the Duke Kidney Transplant Clinic
2579602|NCT02369354|Other|TALKS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings
2579603|NCT02369354|Other|TALKS PLUS|Usual Care plus TALKS Social Worker Intervention: Includes video, book, and Social Worker meetings plus live donor financial assistance intervention
2579655|NCT02369029|Experimental|Arm 1|To determine maximum tolerated dose (MTD) of BAY 1238097
2579727|NCT02368470|Active Comparator|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
2579728|NCT02368470|Experimental|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
2579769|NCT02368080||Cystic fibrosis adults (CF)|No treatment, comparison of LCI values obtained with two devices
2579777|NCT02368080||Healthy adults (HC)|No treatment, comparison of LCI values obtained with two devices Free of respiratory disease or others diseases likely to disturb respiratory system.
3211247|NCT01003392||Normal|Normal volunteers, with no diagnosed chronic disease.
3211248|NCT01003392||Coronary artery disease|Group of patients with diagnosed coronary artery disease.
3211249|NCT01003392||Diabetes|Diabetic patients.
3211250|NCT01003405|Experimental|KUC-7483|
3211251|NCT01003431|Experimental|1|RotaTeq™ + DTwP
3211252|NCT01003431|Active Comparator|2|Rotarix™ + DTwP
2580302|NCT02364479|Experimental|50mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week, Subcutaneous injection
2580313|NCT02364479|Experimental|25mg etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injectio, 25mg per week, Subcutaneous injection
2580317|NCT02364479|Placebo Comparator|Placebo|Placebo, Subcutaneous injection per week
2580953|NCT02360241|Experimental|Robot|A robot will be used and it's position will be evaluated
3211253|NCT01003431|Active Comparator|3|RotaTeq™ + DTaP
3211254|NCT01003444|Experimental|Cohort 1|Muscle biopsy in healthy volunteers
3211255|NCT01003457||detrusor overactivity|
3211256|NCT01003470|Experimental|acupuncture|
3211257|NCT01003470|Active Comparator|rehabilitation|
3211258|NCT01003470|Active Comparator|acupuncture and rehabilitation|
3211259|NCT01003483|Experimental|Orlistat|The dose of 120 mg orlistat was taken three times daily and the dose remained constant throughout the study period.
3211260|NCT01003483|Experimental|Metformin|The dose of metformin was increased step - wise, from 500 mg once daily for the first week to 500 mg twice daily for the next week, and to 500 mg three times daily for the remaining study period .
3211261|NCT01003496|Active Comparator|Treatment as Usual (TAU)|
3211262|NCT01003496|Experimental|TAU + Long-Term Recovery Management (LTRM)|
3211263|NCT01003509|No Intervention|study, control|Control: Only modified shouldice repair performed Study: Modified Shouldice + Moloney repairs performed
3211264|NCT01003509|No Intervention|modified shouldice and double|one arm is only modified shouldice, other one is double
3211265|NCT01003522|Other|Treatment Arm A|Stenting of central lesion and subsequent standard palliative treatment and dyspnoea symptom control
3211266|NCT01003522|Other|Treatment Arm B|Standard palliative treatment and standard dyspnoea symptom control.
3211267|NCT01003535||[123I]5-IA-85380 SPECT|
3211268|NCT01003548|Active Comparator|Static culture|Embryos individually cultured in microdrops of 40 microliters of G-IVFplus series V
3211269|NCT01003548|Experimental|Smart plataform|Embryos culture in dynamics microfluidic culture system
3211270|NCT01003561|Experimental|ultrasonographic exam|
3211271|NCT01003574|Other|Control Arm|Control arm will receive standard care for risk of cardiac sequelae - a mailed, tailored (neither generic nor targeted) print summary of individualized information about the survivor's treatment, late effects risks, and recommended follow-up and lifestyle modifications.
3211272|NCT01003574|Other|Test Arm|Test arm will receive standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
3211273|NCT01003587|Experimental|District health information package|
3211274|NCT01003587|No Intervention|No Intervention|
3258969|NCT01466322|Experimental|Oral formulations of GSK2018682|Three oral formulations of GSK2018682. A: CD2 Capsule; B: CD3 non-micronised Tablet; C: CD3 micronised Tablet; D: CD3 non-micronised Tablet in fed state
2579262|NCT02371499|Placebo Comparator|2nd Arm|Treatment with equivalent product without bacteria (Enterolactis placebo)
2579311|NCT02371174||HALAVEN treatment group of primary or secondary chemotherapy|Patients with HER2-negative recurrent breast cancer who have received 0 or 1 chemotherapy regimen for recurrent breast cancer.
2579314|NCT02371174||HALAVEN treatment group of tertiary or later chemotherapy|Patients with HER2-negative inoperable or recurrent breast cancer who have received 2 or more chemotherapy regimens for inoperable or recurrent breast cancer.
3211275|NCT01003600||Questionnaire|This study is a cross-sectional survey study to be administered to adults who completed treatment for nonmetastatic colorectal cancer at MSKCC or at Queens Cancer Center (QCC) at Queens Hospital between 6 months and 2 years ago and have no evidence of disease at the time of study enrollment.
2579448|NCT02370485|Experimental|LY2801653 Reference - Fasted|Single oral dose of LY2801653 (Reference Formulation) administered in fasted state in one of three study periods.
2579451|NCT02370485|Experimental|LY2801653 Test - Fasted|Single oral dose of LY2801653 (Test Formulation) administered in fasted state in one of three study periods.
2579458|NCT02370485|Experimental|LY2801653 Test - Fed|Single oral dose of LY2801653 (Test Formulation) administered with a high fat meal in one of three study periods.
3211276|NCT01003613|Active Comparator|Tranilast|CAT with FG and Tranilast and MMC 0.02%
2579556|NCT02369549|Active Comparator|Micro-particle curcumin|"Three 30 mg capsules once daily, self-administered for 6 months.~Curcumin is a nutraceutical, which are products isolated or purified from foods. The rhizomes of the plant Curcuma longa produces turmeric, a spice commonly used in Indian cuisine. Turmeric is comprised of three curcuminoids, of which curcumin is the most abundant. Curcumin is a polyphenol molecule that has been investigated for anti-inflammatory and anti-neoplastic properties since the 1970s."
2579559|NCT02369549|Placebo Comparator|Placebo|"Three 30 mg capsules taken once daily, self-administered for 6 months.~Placebo capsules are identical to the curcumin capsules in color, taste, smell, size and shape."
2579623|NCT02369250|Placebo Comparator|OFD+ PLACEBO GEL|furcation defect site is surgically debrid and placed a placebo gel
2579628|NCT02369250|Active Comparator|OFD+ PRF + BONE GRAFT|Following surgical debridment of furcation site autologous PRF and bone graft is placed in defect as a competator drug used is platelet rich fibrin and porus hydroxyapatite bone graft
2579631|NCT02369250|Experimental|RSV1.2% gel + PRF+ BG|Following surgical debridment of furcation site Rosuvastatin 1.2% in situ gel combined with autologous PRF and bone graft is placed
2579652|NCT02368860|Experimental|OXIRI|OXIRI regimen: oxaliplatin, irinotecan, capecitabine
2579713|NCT02368665|Experimental|AML 5mg|- Amlodipine 5mg, once a day for 8 weeks
2579715|NCT02368665|Experimental|AML 5mg / CC 16mg|- Amlodipine 5mg and Candesartan cilexetil 16mg, once a day for 8 weeks
2579717|NCT02368665|Experimental|AML 10mg / CC 16mg|- After 8 weeks of treatment period, Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
2579762|NCT02367976|Experimental|rhprouk|rhprouk to be administrated in 60 minutes.
2579767|NCT02367976|No Intervention|controlled|The controlled arm patients will be administrated in 90 minutes after randomized.
3211277|NCT01003613|Placebo Comparator|Control|CAT with FG and MMC 0.02%
3211278|NCT01003626|Experimental|IFP Measurement|Tumor interstitial fluid pressure (IFP) assessments
3211279|NCT01003652||Harmonic Focus /conventional haemostasis|
2580060|NCT02366221||All subjects|Subjects with a history of complex arm trauma
2580082|NCT02365896|Other|TLDG or LADG|To complete the distal gastrectomy with Billroth-II reconstruction and D2 lymphadenectomy for locally advanced gastric cancer with TLDG or LADG
2580101|NCT02365675|Active Comparator|Cotton gauze with petrolatum|The dressing to be used is regular cotton gauze impregnated in petrolatum (a mixture of solid hydrocarbons) creating a film that reduces the adherence of the gauze to the wound.
2580102|NCT02365675|Active Comparator|Cellulose acetate with petrolatum|The dressing to be used is a mesh or tulle base of cellulose acetate polymers that do not easily adhere to the wound impregnated in petrolatum (a mixture of solid hydrocarbons).
2580103|NCT02365675|Active Comparator|Nanocrystalline silver|The dressing to be used consists of two layers of a silver-coated, high-density polyethylene mesh, enclosing a single layer of an apertured non-woven fabric of rayon and polyester. The three components are ultrasonically welded together to maintain the integrity of the dressing in use. Silver is applied to the polyethylene mesh by a vapour deposition process, which results in the formation of microscopic 'nanocrystals' of metallic silver.
2580104|NCT02365675|Active Comparator|Carboxymethylcellulose with ionic silver|The dressing to be used is a soft, sterile, non- woven pad dressing made from sodium carboxymethylcellulose containing 1.2% silver in an ionic form.
2580190|NCT02365415|Experimental|Sirolimus|Patients randomized to this arm will receive 8 weeks of enteral Rapamycin (sirolimus), with dosage titrated to achieve target blood levels.
2580200|NCT02365415|No Intervention|Control|No treatment.
2580243|NCT02364986|Experimental|Rebif/Avonex|Rebif® 44µg (day 1, 3, 5 and 8) s.c. Avonex 30µg (day 1 and 8) i.m.
3211280|NCT01003652||Harmonic Focus|
3211281|NCT01003652||new surgical device|
3211282|NCT01003652||Harmonic Focus / conventional haemostasis|Harmonic Focus group refers to the use of ultracision shears for haemostasis and conventional haemostasis group refers to the tie-and-clamp technique in total thyroidectomy
3211283|NCT01003665||Intensive Care treatement|ASA status 3 or 4 patients with invasive blood pressure measurement on the intensive care unit
3211284|NCT01003678|Experimental|Level 1|1 mg daily for 5 consecutive days followed by 23 days off drug
3211285|NCT01003691|Experimental|Arm 1|
3211286|NCT01003704||General Anesthesia only|
3211287|NCT01003704||Peripheral nerve block|
3211288|NCT01003704||spinal|
3211289|NCT01003717||Endeavor|Patients treated with at least 1 Endeavor, zotarolimus-eluting, Stent as the primary treatment for acute coronary syndrome
3211290|NCT01003730|Active Comparator|1|High tidal volume (15mL/kg PBW0 with low PEEP (3cm H2O
2579417|NCT02370524|Experimental|[18F]T807|At the [18F]T807 PET imaging visit, subjects will be given a bolus injection of no more than 10 mCi (370 MBq) of [18F]T807
3211291|NCT01003730|Active Comparator|2|Low tidal volume (6mL/kg PBW) and high PEEP (3cm H2O)
3211292|NCT01003730|Active Comparator|3|low tidal volume (6mL/kg PBW) and high PEEP (10cm H2O)
2579583|NCT02369445|Experimental|Moisture Pager (MP) Intervention Group|"This group receives the innovative toilet training intervention comprised of a wireless moisture pager (i.e., an app based on an iPod that communicates via electronic signal with a disposable moisture sensor located in the child's underwear)."
2579586|NCT02369445|Active Comparator|Standard Behavioral Intervention Group|This group receives standard-of-care intervention as presented in the Autism Treatment Network's Toilet Training Tool Kit (https://www.autismspeaks.org/site-wide/atn-tool-kits).
2579622|NCT02369133|Active Comparator|Group Paracetamol (Group P),|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol
2579626|NCT02369133|Placebo Comparator|Group Saline (Group S)|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group S (n = 30) received 100 ml iv %0,9 saline
2579670|NCT02368873|Active Comparator|Intervention group|Patients with IPOM Dynamesh mesh around the straight permanent colostomy.
2579676|NCT02368873|No Intervention|Control group|Patients with the straight permanent colostomy without a mesh.
2579716|NCT02368509|Experimental|Bronchial cancer|Patients with bronchial cancer will perform sensory tests before and after a 6-week period of chemotherapy.
2579719|NCT02368509|Placebo Comparator|Control group|Healthy individuals will perform sensory tests before and after a 6-week period without chemotherapy.
3211293|NCT01003756|Experimental|Knee Intervention|Patients undergoing Total Knee Replacement. Exercise 8-10 weeks preoperatively
3211294|NCT01003756|No Intervention|Knee Control|Patients undergoing Total Knee Replacement. Receives standard instructions
2580002|NCT02366585|Experimental|Treatment with Ciclosporin|Treatment of two periodontal pockets with ciclosporin gel Non-treatment of two periodontal pockets in same patient as comparator
3211295|NCT01003756|Experimental|Hip Intervention|Patient undergoing Total Hip Replacement. Exercise 8-10 weeks preoperatively
2580105|NCT02365701|Experimental|Motilitone 30mg|Motilitone will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this medication for 4 weeks.
2580114|NCT02365701|Placebo Comparator|Placebo|Placebo (same formulation as Motilitone but without the active ingredients) will be administered in tablet form, 3 times daily to subjects randomized to this arm of the study. Subjects will be expected to take this tablet for 4 weeks.
2580182|NCT02365454|Experimental|Thoracic Aortic Disease Single Arm Study|Thoracic Aortic Disease treated by Stent Graft Placement
2580247|NCT02365077||Control|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week without the symptom of femur head necrosis after 1 year.
2580248|NCT02365077||Necrosis|The patients of necrosis group was defined by a history of taking 1800 mg prednisolone or an equivalent over 4 week with the diagnosis of femur head necrosis.
2580289|NCT02364765|Other|Orthognatic surgery|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour.
2580339|NCT02364414|Other|Cohort|Orthodontic patients, aged 11-18 who fulfill the inclusion/exclusion criteria and provide written informed consent to participate will undergo intra-oral scan. This will be repeated 2 weeks later.
2580391|NCT02364089|Experimental|Surgery followed by intensive medical care|Laparoscopic surgical removal of the adrenal tumor
2580393|NCT02364089|Active Comparator|Intensive medical treatment only|Standardized medical treatment of hypertension by SAHR.
2580847|NCT02360930||Tanner Stage >/= 4|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
2580891|NCT02360657|Experimental|JNJ-54861911, 10 mg|JNJ-54861911, 10 milligram (mg) (2*5 mg tablet) orally once daily for 4 weeks.
3211296|NCT01003756|No Intervention|Hip Control|Patients undergoing Total Hip Replacement. Receives standard instructions
3211297|NCT01003795||Promus|Patients treated with at least one Promus, everolimus-eluting, Stent
3211298|NCT01003808|Experimental|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
3211299|NCT01003834|Placebo Comparator|Control|Screening only
3211300|NCT01003834|Active Comparator|Assessment|Screening plus assessment
3211301|NCT01003834|Experimental|Computer Intervention|Screening, assessment, and computer-delivered intervention
2579367|NCT02370862|Experimental|Bowel Evacuation Study with NEO and GLY|The study design will consist of a screening visit to determine each individual's response to a previously established IV dose of NEO and GLY, followed by a dose titration study (two visits) of iontophoresed NEO and GLY. Study visits will be separated by no less than 2 days and no more than 14 days.
3211302|NCT01003834|Active Comparator|Therapist Intervention|Screening, Assessment, and therapist-delivered intervention
3211303|NCT01003847|Active Comparator|fenofibrate|
2579546|NCT02369666|Experimental|LycoRed (code 40051) product|Dietary supplement, LycoRed (code 40051) product, experimental: Mixture of tomato-based carotenoids and phytochemicals in medium chain triglycerides (MCT). One capsule each day with the morning meal, for 4 weeks.
2579548|NCT02369666|Placebo Comparator|Placebo|Dietary supplement placebo: Only MCT oil. One capsule each day with the morning meal, for 4 weeks.
2579585|NCT02369406|Experimental|Antepartum Cohort|"40 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART < 7 days after birth. This cohort will include at least 15 children who start ART < 3 days after birth.~All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine."
2579589|NCT02369406|Experimental|Peripartum Cohort|"10 children who test HIV-negative within 96 hours after birth but test HIV-positive <57 days after birth (peripartum HIV infection) and who are able to initiate ART <57 days after birth. This cohort will include at least 10 children who start ART < 21 days after birth.~The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine."
2579591|NCT02369406|No Intervention|Control Cohort|25 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.
2579669|NCT02369003|Experimental|Peripheral Nerve Graft|The intervention includes the surgical implantation of autologous peripheral nerve graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with Parkinson's Disease that are undergoing Deep Brain Stimulation (DBS).
3211304|NCT01003847|Active Comparator|fatty acid|drug
3211305|NCT01003847|Active Comparator|Placebo|
2579776|NCT02368028||Caries Free|Participants who do not have caries (cavities) will have oral samples collected.
2579783|NCT02368028||Caries Active|Participants who do have caries (cavities) will have oral samples collected.
3211306|NCT01003860||0.5% Ropivicaine (150 mg)|
3211307|NCT01003860||0.75% Ropivicaine (225 mg)|
2580083|NCT02366013|Experimental|Group 1|1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
2580084|NCT02366013|Experimental|Group 2|1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
2580085|NCT02366013|Experimental|Group 3|1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
2580087|NCT02366013|Experimental|Group 4|1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
3211308|NCT01003873||Bypass gastric|First arm is represented by obese patients that will be studied before and after a gastric bypass. They will be studied before surgery as well as 1 month and 6 months after surgery.
3211309|NCT01003873||Lifestyle intervention|The second group is represented by obese patients that will be studied before lifestyle intervention, 6 months after the beginning of the intervention and after a time that will allow patients to lose the same amount of weight that patients that had been through surgery had lost one month after surgery.
2580221|NCT02365129|No Intervention|Usual care group (control)|Participants randomly assigned to the usual care (control) group will receive general advices from the exercise-training specialist about the positive effects of physical activity at the start of the study. The investigators will prepare informative pamphlets describing the benefits of physical activity that the investigators group has prepared for the Region of Andalucía (Southern Spain),http://www.juntadeandalucia.es/salud/servicios/contenidos/andaluciaessalud/docs/130/Guia_Recomendaciones_AF.pdf.
2580224|NCT02365129|Experimental|Moderate-intensity group|Exercise training based on recommendations for adults (WHO)
2580234|NCT02365129|Experimental|Vigorous-intensity group|Exercise training based on recommendations for adults (WHO)
2580268|NCT02364856||Children with cerebral palsy|
2580305|NCT02364609|Experimental|Arm I (afatinib dimaleate, pembrolizumab)|DOSE DE-ESCALATION COHORT: Patients receive afatinib dimaleate PO QD on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Courses repeat every 21 days (for up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
2580316|NCT02364609|Experimental|Arm II (pembrolizumab, afatinib dimaleate)|EXPANSION COHORT: Patients receive pembrolizumab IV over 30 minutes on day 1 for 2 courses. Beginning course 3, patients receive afatinib dimaleate PO and pembrolizumab IV as in Arm I. Courses repeat every 21 days (up to 2 years for pembrolizumab) in the absence of disease progression or unacceptable toxicity.
3211310|NCT01003873||Control subjects|The third group is a control group of normal weight people that will be studied at one time and after 6 months with stable weight.
3211311|NCT01003925||Usual Care|Patients randomized to the control group will be sent the post-test measures suitably modified to reflect the fact that they did not participate in the conjoint analysis program. Four weeks after the post-test measures are completed, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (same measurements given to treatment group).
3211312|NCT01003925||Conjoint Analysis Group|Patients randomized to the experimental group will meet the research staff to complete the conjoint analysis software and post-test measures. The post-test measures include preparedness for decision-making, personal uncertainty, osteoarthritis knowledge, arthritis self-efficacy, and satisfaction with the results of the conjoint analysis program. The in-person visit takes approximately 60 minutes to complete. Four weeks after the in-person visit, a staff member will call the subject to complete a 10 minute follow-up questionnaire to assess if any changes in treatment have occurred and to take further measurements (i.e. global pain assessment, arthritis self-efficacy, personal uncertainty, and osteoarthritis knowledge).
2579328|NCT02371122|Sham Comparator|RestoreSensor or RestoreUltra Setting 4|Therapy Setting 4
2579463|NCT02370381||Epistaxis|Patients with active anterior epistaxis
2579514|NCT02369913||Heart failure subjects|Heart failure subjects undergoing cardiac resynchronization will have a blood drawn for this study.
2579518|NCT02369913||Heart arrhythmia patients|Heart arrhythmia patients undergoing ablation will have a blood drawn for this study.
2579588|NCT02369640|Experimental|Error-avoidance training|Study group 1: Error-avoidance training (Focusing on achieving the highest possible metrics score by avoiding errors).
2579590|NCT02369640|Experimental|Error-management training|Study group 2: Error-management training (Focusing on making errors and thinking of them in a positive way).
3211313|NCT01003951|Experimental|Acupuncture|Each patient will receive two acupuncture treatments each week for four consecutive weeks. At the end of four weeks, the intervention will be complete.
2579736|NCT02368613|Placebo Comparator|placebo group|Placebo
2579738|NCT02368613|Active Comparator|test1 group|DW-3102 125mg
2579741|NCT02368613|Active Comparator|test2 group|DW-3102 250mg
2579743|NCT02368613|Active Comparator|test3 group|DW-3102 500mg
2579761|NCT02368054|Active Comparator|Bupivacaine-adrenaline|Paracervical block. Bupivacaine 2,5 mg/ml Adrenaline 5 microg/ml; 20 ml
2579766|NCT02368054|Active Comparator|Bupivacaine|Paracervical block. Bupivacaine 2,5 mg/ml; 20 ml
2579819|NCT02367690|Experimental|Cohort 1|"Cohort 1 will be randomized to one of the following treatment groups:~a) Standard-of-care (SOC) + Selinexor gel, 10 μM~, b) SOC + vehicle gel c) SOC alone."
2579827|NCT02367690|Experimental|Cohort 2|"Cohort 2 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 30 μM~SOC + vehicle gel~SOC alone."
2579831|NCT02367690|Experimental|Cohort 3|"Cohort 3 will be randomized to one of the following treatment groups:~Standard-of-care (SOC) + Selinexor gel, 70 μM~SOC + vehicle gel~SOC alone."
2580141|NCT02365649|Active Comparator|Induction Period ABT-494 Twice Daily Medium/High Dose|Induction Period ABT-494 Twice Daily Medium/High Dose orally dosed twice a day
2580146|NCT02365649|Active Comparator|Extension Phase ABT-494 High Dose|Extension Phase ABT-494 High Dose orally dosed twice a day
2580152|NCT02365649|Placebo Comparator|Induction Period Placebo|Induction Period Placebo orally dosed twice a day
2580155|NCT02365649|Active Comparator|Induction Period ABT-494 Low Dose|Induction Period ABT-494 Low Dose orally dosed twice a day
2580157|NCT02365649|Active Comparator|Induction Period ABT-494 Once Daily Medium/High Dose|Induction Period ABT-494 Once Daily Medium/High Dose orally dosed once a day
2580161|NCT02365649|Active Comparator|Extension Phase ABT-494 Low Dose|Extension Phase ABT-494 Low Dose orally dosed twice a day
2580163|NCT02365649|Active Comparator|Induction Period ABT-494 High Dose|Induction Period ABT-494 High Dose orally dosed twice a day
2580165|NCT02365649|Active Comparator|Induction Period ABT-494 Low/Medium Dose|Induction Period ABT-494 Low/Medium Dose orally dosed twice a day
2580166|NCT02365649|Active Comparator|Extension Phase ABT-494 Medium Dose|Extension Phase ABT-494 Medium Dose orally dosed twice a day
2580214|NCT02365220|Active Comparator|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training
2580220|NCT02365220|Experimental|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training"
2580228|NCT02365220|Experimental|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training"
2580233|NCT02365220|Experimental|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training"
2580264|NCT02364843|Experimental|Dietary Threonine Intake|Physiological establishment of enteral intake of amino acid threonine required by infants ages 1 - 6 mos
2580324|NCT02364635|Experimental|Icosabutate dose 1|Dose 1
2580329|NCT02364635|Experimental|Icosabutate dose 2|Dose 2
2580330|NCT02364635|Experimental|Icosabutate dose 3|Dose 3
2580331|NCT02364635|Placebo Comparator|Placebo|Placebo (medium chain triglycerides)
2580332|NCT02364635|Experimental|Icosabutate dose 4|Dose 4
2580415|NCT02363920|Placebo Comparator|spontaneous breathing trial|the patients will be asked to breathe spontaneously using their acutal low oxygen flow
2580417|NCT02363920|Active Comparator|HOF20|the patients will be asked to breathe with HOF of 20 L/min
2580418|NCT02363920|Active Comparator|HOF30|the patients will be asked to breathe with HOF of 30 L/min
2580419|NCT02363920|Active Comparator|noninvasive mechanical ventilation (NIV)|the patients will be asked to breathe with the support of a ventilator via a oro-nasal interface
2580450|NCT02363387|Experimental|Incentive Group|Incentive group participants will receive the standard HIV medical care offered in their clinic. In addition, Incentive group participants will receive incentives for viral suppression. These incentives will be presented if the participants maintain suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
2580451|NCT02363387|Other|Usual Care Group|Usual Care Control participants will receive the standard HIV medical care offered in their clinic.
2580523|NCT02363192|Experimental|Pharmacist Intervention Group|
2580524|NCT02363192|No Intervention|Usual Care Group|
2580850|NCT02361073||Healthy|
2580855|NCT02361073||ACS|
2579334|NCT02371291|Experimental|Memory Flexibility Training|The MemFlex programme draws on cognitive bias modification and memory specificity training techniques (Raes et al., 2009; Dalgleish et al., 2014), and was developed by clinical psychologists. MemFlex is primarily self-guided and aims to reduce autobiographical memory biases associated with depression. The training material is presented over one face-to-face session and eight self-guided sessions. In the initial session, the researcher introduces cued-recall tasks which are used throughout the workbook, and guides the participant in completion of these tasks. When understanding of the basic principles is satisfactory, the researcher assists the participant to set a schedule for completion of the workbook over the following four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress.
2579337|NCT02371291|Placebo Comparator|Psychoeducation|The psychoeducation condition will also complete an initial face-to-face session. This session will cover the symptoms and causes of depression, and the workbook will be introduced. As in the MemFlex condition, the workbook will consist of eight self-guided sessions that the individual will be required to complete over four weeks. The participant will receive weekly emails during this period, encouraging them to complete the workbook. They will also receive a phone call from a team member at the beginning of week three to check progress, and clarify any difficulties with the workbook material. The workbook content will cover the presentation of depression and basic information on factors associated with depression, such as worry, procrastination, and sleep difficulties. Each session consists of information on psychological theories of the topic, followed by a series of questions about the material to ensure participant engagement. The workbook was developed by clinical psychologists.
2579377|NCT02370719|Experimental|Intervention Group|Mobile application plus standard of care
2579383|NCT02370719|No Intervention|Control Group|Standard of care
2579438|NCT02370472|No Intervention|control group|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes proficiency noted final evaluation
2579439|NCT02370472|Experimental|Experimental|complete pre-study form 10 minute familiarization time with equipment view video demonstration of task perform task 3 times assessed using scoring form - pretest assigned to group practice task again for 30 minutes - subjects will use tool developed using cameras and a computer to visualize hand and needle movements as well as the position of the transducers along with the image from the ultrasound on a computer screen proficiency belief noted final evaluation
3211314|NCT01003964|Experimental|ERCC1 negative - GP|Gemcitabine (1250 mg/m2) IV on D 1, 8. Cisplatin (75 mg/m2) IV on D1 every 3 weeks.
2579522|NCT02369757|Experimental|Intervention of navigators|Navigators accompany the target population towards OCCS.
2579525|NCT02369757|No Intervention|No Intervention|Population is not accompanied by navigators
2579560|NCT02369588|Experimental|100% Portion Sizes|Food portion size Test meal consists of baseline (100%) portion size of all foods
2579565|NCT02369588|Experimental|133% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 133% the size of baseline portions
2579570|NCT02369588|Experimental|167% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 167% the size of baseline portions
2579572|NCT02369588|Experimental|200% Portion Sizes|Food portion size Test meal consists of portion sizes of all foods that are 200% the size of baseline portions
2579648|NCT02369289||vegans|a vegan diet in the last 3 years
2579650|NCT02369289||omnivores|aminal-based diet, comsumption of aminal products at least 3 times a week
3211315|NCT01003964|Experimental|ERCC1 positive - IP|Irinotecan (65 mg/m2) IV on day1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
2579754|NCT02368275||prospective cohort of patients undergoing mastectomy|Prospective cohort
2579756|NCT02368275||cross sectional cohort of patients|Cross sectional cohort
2579805|NCT02367924||Yondelis|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
2579838|NCT02367560|Active Comparator|NDSSI|Participants in this arm of the trial will be referred for Needle decompression with subacromial steroid (Depo medrol) injection (NDSSI) as their treatment for calcific tendinitis
2579845|NCT02367560|Active Comparator|SWT|Participants in this arm of the trial will be referred for Shockwave therapy (SWT) using an Ultrasound device, delivered by a physiotherapist, as their treatment for calcific tendinitis
2579887|NCT02367261|Experimental|SPI dental implant|Subjects implanted with SPI implant
2579918|NCT02367027|Experimental|Arm 1 - BAY59-7939|10 mg oral suspension (dry powder) in fasted conditions
2579919|NCT02367027|Experimental|Arn 2 - BAY59-7939|20 mg oral suspension (dry powder) in fed conditions.
2579920|NCT02367027|Experimental|Arm 3 - BAY59-7939|10 mg oral suspension in fasted conditions
2579924|NCT02367027|Experimental|Arm 4 - BAY59-7939|10 mg tablet in fasted conditions.
2579970|NCT02366793|Experimental|Accessory joint mobilization|Humeral head slides, anterior, posterior and caudal slides.
2579971|NCT02366793|Experimental|Nerve mobilization|neural tissue longitudinal slide using the median neurodynamic test 1 (Butler).
2580005|NCT02366572|Placebo Comparator|Cereal control|100% Wheat Flour
2580012|NCT02366572|Experimental|Cereal with pea protein|Pea protein
2580014|NCT02366572|Experimental|Cereal with pea starch|Pea starch
2580016|NCT02366572|Experimental|Cereal w/ pea starch + pea fibre: 5g|Pea starch + pea fibre: 5g
2580019|NCT02366572|Experimental|Cereal w/ pea protein + pea starch: 10g|Pea protein + pea starch: 10g
2580023|NCT02366572|Experimental|Cereal w/ pea protein + pea fibre + pea starch: 20g|Pea protein + pea fibre + pea starch: 20g
3211316|NCT01003964|Experimental|ERCC1 positive - GP|Gemcitabine (1250 mg/m2) IV on day1, 8 Cisplatin (75 mg/m2) IV on day1 every 3 weeks
2580851|NCT02360878||Non-diabetic subjects|Obese (BMI > 30 kg/m2) with normal glucose tolerance implanted with the EndoBarrier Gastrointestinal liner
3211317|NCT01003964|Experimental|ERCC1 negative - IP|Irinotecan (65 mg/m2) IV on day1, 8 Cisplatin (30 mg/m2) IV on day 1, 8 every 3 weeks
3211318|NCT01003977||Xience V|Patients treated with a Xience V everolimus-eluting stent
3211319|NCT01004016|Placebo Comparator|Placebo|
2579400|NCT02370745|Experimental|Oral amino acids- Older|"Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink"
3211320|NCT01004016|Experimental|KPS-0373|
3211321|NCT01004055|Experimental|Procellera™ Wound Dressing|
2579656|NCT02368899|Experimental|Computerized Alcohol Misuse Intervention|Arm 1 is a cross-over randomized controlled trial (XRCT) comparing the short-term effects of the computerized alcohol misuse intervention (CAMI) vs. a generic health education attention-control (AC) condition in reducing past 30 day: (a) days of alcohol use, (b) days of heavy episodic drinking, (c) typical number of drinks consumed on a day of drinking, and (d) alcohol use in dangerous situations; (2) investigate changes in (a) patient motivation and (b) perceived norms as mediators of intervention effectiveness.
2579658|NCT02368899|Placebo Comparator|Attention Control (AC)|Arm 2 is not an active intervention but an attention control condition - it is not expected to exert any real intervention effect. Hence, any observed effects for the AC condition can be attributed to natural change via regression-to-the-mean, assessment reactivity, or a placebo effect. The effect size estimate of the intervention, both from an efficacy standpoint (i.e., above and beyond what change would have normally occurred) and an effectiveness standpoint (i.e., the magnitude of behavior change that can be expected in real-world implementation), can be readily calculated.
3211322|NCT01004055|Active Comparator|ACTICOAT™|
3211323|NCT01004055|Active Comparator|Mepilex® Ag|
2579806|NCT02367898|Experimental|Cognitive Training|Lumosity cognitive training program.
2579807|NCT02367898|Active Comparator|Crossword Puzzles|Timed online crossword puzzles
2579839|NCT02367547|Experimental|Hexylaminolevulinate cream|2% Hexylaminolevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream
2579848|NCT02367547|Experimental|Aminolevulinic Acid Nano Emulsion|78 mg/g Aminolevulinic Acid Nano Emulsion
2579851|NCT02367547|Active Comparator|Methylaminolevulinate cream|160 mg/g Methylaminolevulinate cream
2579891|NCT02367248|Active Comparator|Deferoxamine|Deferoxamine mesylate supplied in vials containing 500 mg of sterile, lyophilized, powdered deferoxamine mesylate. The drug will be reconstituted for injection, by dissolving in 20 ml of sterile water.
2579898|NCT02367248|Active Comparator|Xingnaojing injection|Xingnaojing injection supplied in vials containing 20 ml liquid xingnaojing.
2579902|NCT02367248|Placebo Comparator|Normal Saline|0.9% sodium chloride
3211324|NCT01004068|Experimental|SET-diet plus clomiphene|Structured exercise program plus hypocaloric diet for two months and received one-cycle of clomiphene citrate for one cycle
3211325|NCT01004068|Active Comparator|Clomiphene citrate|One month of observation followed by one-cycle of clomiphene citrate therapy
3211326|NCT01004068|Experimental|SET plus diet|Lifestyle modifications for two months.
3211327|NCT01004081|Experimental|BIIB021 BID + exemestane|BIIB021 100 mg BID + exemestane 25 mg QD
2580050|NCT02366078|Experimental|Stress management|Participants will receive SMART traiing
2580089|NCT02365909|Active Comparator|Acitve|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
2580092|NCT02365909|Placebo Comparator|Placebo|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
2580106|NCT02365610|Experimental|GWP42006|GWP42006
2580110|NCT02365610|Placebo Comparator|Placebo control|Placebo
3211328|NCT01004081|Experimental|BIIB021 TIW + exemestane|BIIB021 450 mg TIW + exemestane 25 mg QD
2580250|NCT02364921|Experimental|Two-layer compression bandage|Two multilayer compression bandage: Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.Measure the ankle circumference and choose the correct kit accordingly (ankle size 18-25cm or 25-32cm). Apply one to seven days
2580253|NCT02364921|Active Comparator|crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
2580290|NCT02364674|Experimental|HRCT scans|HRCT scan will be taken
2580336|NCT02364427||Arterial stiffness|Arterial stiffness - Vicorder to measure pulse wave velocity
2580383|NCT02364115|Experimental|Stereotactic Body Radiotherapy|MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).
2580384|NCT02364115|No Intervention|Conventional Radiotherapy|Delivery of a single fraction of 8 Gy using virtual simulation
3211329|NCT01004094|Experimental|simple goal setting|This group will only set a goal.
3211330|NCT01004094|Experimental|goal setting plus action intentions|This group will set goals and form action intentions (plans) to facilitate goal attainment.
2580498|NCT02363218|Experimental|CyberKnife|Hepatocellular Carcinoma Patients Treated With CyberKnife
3211331|NCT01004094|Experimental|goal setting plus coping intentions|This group will set goals and form coping intentions (plans) to facilitate goal attainment.
3211332|NCT01004094|Experimental|goal setting plus action intentions plus coping intentions|This group will set goals, form action intentions (plans), and form coping intentions (plans) to facilitate goal attainment.
2580766|NCT02361463|Experimental|3D group|Will practice under 3D vision conditions on a laparoscopic virtual reality simulator
2580770|NCT02361463|Active Comparator|2D group|Will practice under 2D vision conditions on a laparoscopic virtual reality simulator
3211333|NCT01004120|Placebo Comparator|MDn|
3211334|NCT01004120|Active Comparator|B-GOS|
3211335|NCT01004133||Subjects 80 years of age or older without chronic diseases.|
3211336|NCT01004198|Experimental|MP4OX - 250|250 mL dose
3211337|NCT01004198|Experimental|MP4OX - 500|500 mL dose
3211338|NCT01004198|Active Comparator|Ringers Lactate solution|500 mL dose
3211339|NCT01004211|Active Comparator|Standard transurethral resection|Patients will be submitted to standard white light transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer
3258970|NCT01466335|Experimental|Ronacaleret 100mg once daily|1 x 100mg oral tablet
2579445|NCT02370446||patient gets standard of care|Current MSKCC standards of professional nursing practice require the professional nurse to develop a plan of care that includes teaching the patient and support system the prescribed prescriptions / regimen and all doses, route, length of treatment, side effects and safety precautions.
2579483|NCT02370199|Experimental|670 nm light|Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2. Contrast images will be obtained up to 5 minutes after the commencement of light.
3211340|NCT01004211|Experimental|Narrow band imaging transurethral resection|The system will be switched to narrow band imaging by simply pushing a button. Transurethral resection and/or cold cup biopsies of all visible lesions known or suspected to be bladder cancer will be performed; 6 random cold cup biopsies from healthy mucosa of bladder trigone, anterior, posterior and lateral walls will be taken in case of a second transurethral resection of newly diagnosed high grade non muscle invasive bladder cancer or of recurrent high grade non muscle invasive bladder cancer.
3211341|NCT01004224|Experimental|BGJ398|
3211342|NCT01004237|Active Comparator|pravastatin|
2579723|NCT02368652|Experimental|CC 16mg|Candesartan ceilexetil 16mg, once a day for 8 weeks
2579726|NCT02368652|Experimental|AML 10mg / CC 16mg|Amlodipine 10mg and Candesartan ceilexetil 16mg, once a day for 8 weeks
2579882|NCT02367495|Experimental|PCB|Paclitacel-coated balloon (Agent, Boston Scientific)
2579939|NCT02367118|Experimental|Prednisone|Intervention: prednisone 5 mg tablets taken orally, in decreasing doses. Beginning with 6 tablets (30 mg) daily for 7 days, then 3 tablets (15 mg) daily for 7 days, then 1 tablet (5 mg) daily for 7 days. Total days of treatment: 21 days.
2579943|NCT02367118|Placebo Comparator|Placebo|Intervention: placebo tablets taken orally (similar to prednisone), in decreasing doses. Beginning with 6 tablets daily for 7 days, then 3 tablets daily for 7 days, then 1 tablet daily for 7 days. Total days of treatment: 21 days.
2579981|NCT02366741|Other|Pilot group|Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
2580062|NCT02366364|Placebo Comparator|Drug: Placebo|Single oral administration on Day 1
2580068|NCT02366364|Experimental|Drug: NRX-1074 375 mg|Single oral administration on Day 1
2580070|NCT02366364|Experimental|Drug: NRX-1074 500 mg|Single oral administration on Day 1
2580073|NCT02366364|Experimental|Drug: NRX-1074 750 mg|Single oral administration on Day 1
2580115|NCT02365740|Experimental|Cases|gastric emptying test gut hormones determination Continuous Glucose Monitoring Insulin single bolus Insulin double-wave bolus
2580119|NCT02365740|Sham Comparator|Controls|gastric emptying test gut hormones determination
2580184|NCT02365337||vitamin D levels < 20ng/ ml|Vitamin D levels < 20ng/ ml
2580186|NCT02365337||vitamin D levels>20ng/ ml|Vitamin D levels >20ng/ ml
2580279|NCT02365038|Experimental|Driving pressure limited ventilation|Driving pressure limited ventilation
2580281|NCT02365038|Active Comparator|Conventional ventilation|Mechanical ventilation as proposed in the ARDSNet protocol.
2580300|NCT02364505|Experimental|Telemedicine mindfulness intervention|Participants are assigned to a telemedicine mindfulness intervention group. The protocol lasts 8 weeks and it is composed by one online course session each week and home exercises. The course sessions, with a synchronous communication, will be conducted by a trainer, through teleconferences, that will explain how to practice the exercises to develop mindfulness attitude, following the mindfulness-based intervention-multiple sclerosis protocol. Subjects will be able to take part of these sessions everywhere, through a computer, tablet o mobile. During these sessions, individuals will interact with the trainer with teleconference or textual communications.
2580301|NCT02364505|Active Comparator|Psycho-education control group|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
2580360|NCT02364310|Experimental|Baroreceptor stimulation on top of the best medical care|Baroreceptor stimulation with Barostim Neo TM
2580364|NCT02364310|No Intervention|Best medical care|Best medical care
2580408|NCT02363842|Experimental|Skin IQ™ MCM Coverlet|Skin IQ™ MCM coverlet used over a commercially available pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
2580410|NCT02363842|Active Comparator|Pressure redistribution surface|Commercially available pressure redistribution surface already in use at participating study sites (SOC) to manage patients at risk for tissue breakdown
3211343|NCT01004237|Active Comparator|valsartan|
2580554|NCT02362802|Active Comparator|Antitachycardia Pacing|Implantable cardioverter defibrillator placement with Antitachycardia Pacing. Apart from that usual standard of care.
2580562|NCT02362802|No Intervention|No Antitachycardia Pacing|"Implantable cardioverter defibrillator placement without Antitachycardia Pacing.~Apart from that usual standard of care."
2580583|NCT02362568|No Intervention|Cervical ultrasound exploration|A cervical ultrasound exploration will be performed in all patients admitted for a planned surgery performed under general anesthesia during the stay in the postoperative room.
3211344|NCT01004237|Active Comparator|pravastatin combined with valsartan|
2580856|NCT02360878||T2DM subjects|Obese (BMI > 30 kg/m2) with type 2 diabetes implanted with the EndoBarrier Gastrointestinal liner
3211345|NCT01004276|Experimental|Improved module|
3211346|NCT01004276|No Intervention|Standard module|
2579486|NCT02370212|Placebo Comparator|Placebo|"The placebo will be ingested after interval training and at supper time on training days and in the morning and afternoon on non-training days (0.1 g/kg flavoured dextrose per dose, isocaloric to the creatine).~Both experimental and placebo groups will perform the same high intensity interval training protocols (3x/week for 4 weeks)."
2579530|NCT02369809|Experimental|Neovasculgen®|Single group prospective treatment
2579532|NCT02369809|Active Comparator|standard care|
2579595|NCT02369393|Experimental|Behavioral Activation|BA treatment for depression is a simple, cost-effective method. There is evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression. One of the main objectives of the treatment is to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions. Treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components are: 1) psycho-education, 2) identifying important values and significant activities, 3) activity structuring and scheduling, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
2579596|NCT02369393|No Intervention|Waiting list control group|In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
2579597|NCT02369393|Experimental|Physical Activity|There is evidence to suggest that the addition of cognitive behavioral therapies, specifically exercise, can improve treatment outcomes for many patients. Exercise is a behavioral intervention that has shown great promise in alleviating symptoms of depression. The treatment will be delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the PA treatment are: 1) psychoeducation: understand the mental health benefits of physical activity, 2) learn about the types and amounts of physical activity recommended, 3) motivation to perform and maintain physical activities, 4) relapse prevention. These will be delivered over 4 modules. There will be a minimal therapist support.
2579645|NCT02369055||Stroke survivors in North Norway|Patients with ischemic or heamorrhagic stroke admitted to stroke units in UNN Tromso, Narvik or Harstad (Norway), and living in the defined geographic area of these 3 hospitals.
2579646|NCT02369055||Stroke survivors in Denmark|Patients with ischemic og heamorrhagic stroke admitted to a stroke unit in Aarhus University Hospital and living in the municipalities of Randars or Favrskov in Central Denmark Region
2579657|NCT02368730||desmopressin|Treatment according to standard clinical practice.
2579729|NCT02368561|Experimental|Hyaluronic Acid Injection|Hyaluronic Acid Injection in 20 adult patients with IAT
2579750|NCT02368171||Obstructive sleep apnea with pulmonary hypertension|Patients with AHI> 5/h and pulmonary hypertension with RVSP>35 mmHg on Echo
2579751|NCT02368171||control|patients with AHI<5/h and RVSP<35 mmHg on Echo
2579752|NCT02368171||OSA with no Pulmonary hypertension|patients with AHI>5/h, but RVSP<35 mmHg on Echo
2579803|NCT02367937|Experimental|PRC-4016 (Icosabutate)|
3211347|NCT01004289|Active Comparator|Control|Primary angioplasty and stenting without additional intervention.
3211348|NCT01004289|Experimental|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion.
2579889|NCT02367222||Exposed to Arepanrix™ Cohort|All individuals with Manitoba Immunization Monitoring System (MIMS) record of H1N1 (Arepanrix™) and/or seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
2579897|NCT02367222||Unexposed to Arepanrix™ Cohort|All individuals registered with Manitoba Health (MH) during the study period but with no MIMS record for H1N1 (Arepanrix™) and seasonal influenza vaccination during the influenza season 2009/2010 (15 September 2009 to 15 March 2010).
2579934|NCT02366962|Experimental|ASP7374 group|
2579982|NCT02366806||In-Depth Education|A. Standard radiotherapy discussion including rationale, number of fractions, side effects, +/- beam arrangements, potential and likely short and long-term toxicity, status checks, skin care, nursing and physician accessibility B. Radiotherapy plan review to include, but not limited to: beam arrangement, total dose, dose per fraction, target area(s), description of isodose lines, DVH review and discussion of prescription constraints for OARs
2580033|NCT02366429|Experimental|ICBT|Internet-based CBT for antenatal depression
2580034|NCT02366429|Active Comparator|TAU|Treatment as usual provided at antenatal clinics and other health care instances
2580061|NCT02366117|Experimental|Training|"Data collected during the first pahse of the study will be presented and discussed in a specialist focus group, which will work with the study team as advisors and trainers, to decide on the type of training to be developed.~This training intervention will be applied to the facilities presenting half the patient sample size."
2580069|NCT02366117|No Intervention|No Training|Facilities representing half the sample size will not be trained as in the Experimental Arm and continue their standard of care for these patients.
3211349|NCT01004302|Sham Comparator|Sham surgery|
3211350|NCT01004302|Active Comparator|Active radiosurgery|
3211351|NCT01004315|Experimental|KUC-7483|
3211352|NCT01004315|Placebo Comparator|Placebo|
3211353|NCT01004315|Active Comparator|Tolterodine|
2580297|NCT02364687||Participants|Participants will have previously had an MRI scan and will undergo a CT scan.
2580376|NCT02364375|Experimental|Full Face|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (full face) and Comparison Menai Standard mask (full face) for 7 nights each.
2580379|NCT02364375|Experimental|Nasal|Participants will trial the same mask type/variant (full face, nasal, pillows) as the variant they are using as part of their current treatment. Participants in this arm will trial the Menai mask (nasal) and Comparison Menai Standard mask (nasal) for 7 nights each.
2581014|NCT02359786||Genetic Testing Subjects undergoing genetic testing|
3211354|NCT01004328|Experimental|Intervention Group 1|All participants
3211355|NCT01004341|Other|Family-based weight control|Group-based family therapy for weight loss in children age 8-12 years.
3258971|NCT01466335|Experimental|Ronacaleret 100mg twice daily|1 x 100mg oral tablet twice daily
2579680|NCT02368938||Several communities in the north of Shanghai|
2579739|NCT02368587|Placebo Comparator|Intracoronary infusion WJMSCs|Intracoronary infusion WJMSCs or placebo in patients with ischemic heart failure
2579742|NCT02368587|Placebo Comparator|Intravenous infusion WJMSCs|Intravenous infusion WJMSCs or placebo in patients with ischemic heart failure.
2579789|NCT02368041||InSpectraTM StO2|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
2579883|NCT02367235|Experimental|Traditional vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed endo anal sizer.
2579885|NCT02367235|Experimental|Colpassist vaginal positioning device|Patients will undergo their robotic-assisted sacrocolpopexy using a vaginally placed Colpassist vaginal manipulator.
2580107|NCT02366026|Experimental|IR103 REMUNE + AMPLIVAX 1.0|IR103 Vaccine contain the same active component as REMUNE® (Inactivated HIV-1 Antigen Drug Substance at 10 μg/mL p24 dose), and have one dose of Amplivax™ (HYB2055) Adjuvant (1.0 mg) added before emulsification in Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
2580113|NCT02366026|Placebo Comparator|AMPLIVAX 1.0 + IFA|AMPLIVAX 1.0 mg Amplivax™ (HYB2055) Adjuvant (1.0 mg) + IFA Incomplete Freund's Adjuvant (the same adjuvant and in the same ratio that is used in REMUNE).
2580196|NCT02365441|Active Comparator|Arm A|imatinib 400mg orally daily continuously
2580205|NCT02365441|Experimental|Arm B|alternating 28-day periods of imatinib 400mg orally daily for 21 to 25 days followed by a washout (drug free) period of 3 to 7 days, then regorafenib 160mg orally daily for 3 weeks followed by a 7 day washout (drug free) period.
2580389|NCT02364050||Elderly patients with DLBCL|Elderly patients (Age ≥ 65 years) with large B-cell lymphoma classified FIT or UNFIT or FRAIL by Multidimensional Geriatric Assessment (MGA)
2580502|NCT02363595||Papillary Microcarcinoma|This clinical trial protocol describes implementation of a prospective observation protocol to standardize data collection and obtain permission to collect samples of PMC tumors in a cohort of PMC patients being followed with active surveillance. This will allow PMC tumors to be accurately classified as either stable or progressive over time and used for comprehensive molecular profiling if surgical removal is required during follow-up
3176441|NCT00644150|Experimental|3|HIV/STI patients will receive standard of care and specialized care from physician participants trained in Ai Shi Zi.
3176442|NCT00644150|No Intervention|4|Physicians of county level who will not participate in Ai Shi Zi training
3176443|NCT00644150|No Intervention|5|Physicians of township level who will not participate in Ai Shi Zi training
3176444|NCT00644150|Sham Comparator|6|HIV/STI patients who will receive standard care only
2580703|NCT02362022|Placebo Comparator|Group Saline|Group Saline (Group S) received i.v saline 0.9 % in 10 ml volume (n=30)
2580704|NCT02362022|Active Comparator|Group Morphine 1|Group Morphine 1 (Group M1) received i.v morphine 0.1 mg kg-1, in 10 ml volume (n=30)
2580705|NCT02362022|Active Comparator|Group Morphine 2|Group Morphine 2 (Group M2) received i.v morphine 0.2 mg kg-1, in 10 ml volume (n=30)
2580735|NCT02361645|No Intervention|Control Group|No NSAIDs were administered prior to surgery
2580736|NCT02361645|Experimental|Ketorolac eyedrops|Ketorolac 0.5% eyedrops were administered prior to surgery
2580740|NCT02361645|Experimental|Indomethacin eyedrops|Indomethacin 0.5% eyedrops were administered prior to surgery
2580752|NCT02361645|Experimental|Nepafenac eyedrops|Nepafenac 0.1% eyedrops were administered prior to surgery
2580759|NCT02361645|Experimental|Bromfenac eyedrops|Bromfenac 0.09% eyedrops were administered prior to surgery
2580864|NCT02360787|Experimental|Energy restriction|Energy restriction (-500 kcal/day) (N=40), where participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits to support weight loss. Participants will also be asked to avoid all nuts during the intervention period.
2580869|NCT02360787|Experimental|Energy restriction with almonds|Energy restriction (-500 kcal/day) with dry-roasted, lightly salted almonds supplying 15% of estimated energy requirement. Participants will receive dietary counseling to reduce energy intake to achieve 500 kcal/day deficits. Energy from almonds will be accounted for during dietary modeling so that a 500 kcal/day deficit is achieved.
2580932|NCT02360579|Experimental|Cohort 2|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product) (Closed)
3176445|NCT00644163|Experimental|1|Participants will receive Eban HIV/STD Risk Reduction Intervention.
3176446|NCT00644163|Active Comparator|2|Participants will receive Eban Health Promotion Intervention.
3176447|NCT00644176|Experimental|1|
3176448|NCT00644176|Experimental|2|
3176449|NCT00644202|Experimental|Group 1|Intervention Group
3176450|NCT00644202|No Intervention|Group 2|Usual Care Group
3176451|NCT00644215|Experimental|1|5-FU injection has been done
3176452|NCT00644215|Experimental|2|Mitomycin drop has been administrated
3176453|NCT00644241|Experimental|stem cell|
3176454|NCT00644254||Resected DPAC|145 consecutive resections for primary ductal pancreatic adenocarcinoma (DPAC)performed between 1998 and 2005.
3176455|NCT00644267|Active Comparator|1|Subjects will use a telemedicine system for blood pressure control
3176456|NCT00644267|No Intervention|2|Patients with hypertension receiving usual care by a primary care physician
3176457|NCT00644293|Experimental|1|
3176458|NCT00644293|Experimental|2|
3176459|NCT00644306|Placebo Comparator|A|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
3176460|NCT00644306|Active Comparator|B|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
3176461|NCT00644371|Experimental|1|
3176462|NCT00644397||Blade Plate Group|95-degree Angled Blade Plate
3176463|NCT00644397||Locking Plate Group|4.5mm Condylar Locking Plate
2579618|NCT02369276||post SND within >3- 6months|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within >3- 6months, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
2579620|NCT02369276||post SND within 6 months -1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within 6 months -1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
2579625|NCT02369276||post SND within more than 1 year|20 Head and Neck Cancer(HNC) complicated with ipsilateral shoulder disability post SND within more than 1 year, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
2579630|NCT02369276||without shoulder disability|20 Head and Neck Cancer(HNC) post SND without shoulder complication at the control group, evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
2579659|NCT02368808|Experimental|Abangane Support Group|Bereavement support group for adolescents
2579662|NCT02368808|No Intervention|Wait List|Wait-listed adolescents will be able to participate in Abangane at the close of the study.
2579721|NCT02368548|Experimental|Pharmaceutical care program|"Initiated in the Emergency Department (ED):~Review of home medication and medication reconciliation based on Primary Care data~Patient interview. Assessment of the patient's knowledge on the pharmacological treatment~Development of the pharmacological history and registration in the medical record~Adequacy of drug therapy. Identification of Drug Related Problems including reconciliation errors (DRP) and communication to medical team~Pharmacotherapy monitoring~Treatment validation and medication reconciliation at discharge~During the hospitalization (if admission from the ED):~Treatment review and medication reconciliation~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness. DRP identification and communication to medical team~Pharmacotherapy monitoring~Validation and medication reconciliation at discharge~Patient education at discharge"
2579725|NCT02368548|Other|Standard Care|"Stages:~Pharmaceutical care program in the episode at the Emergency Department:~a. There was no monitoring of the patient by the pharmacist. Retrospective validation of the prescriptions was not performed.~During the hospitalization (if admission from the ED):~Pharmacokinetics monitoring~Retrospective validation of prescriptions and assessment of drugs appropriateness."
2579775|NCT02368158|Experimental|Cardiologic Patient|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors
2579784|NCT02368158|Experimental|Control Proband|"The same intervention as in arm cardiologic patients :Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors"
2579878|NCT02367183|Experimental|GED-0301 160mg QD 12 WK|GED-0301 160 mg once daily (QD) for 12 weeks
2579880|NCT02367183|Experimental|GED-0301 160 mg QD 8 WK|GED-0301 160 mg QD for 8 weeks followed by 4 weeks of placebo
2579884|NCT02367183|Experimental|GED-0301 160 mg QD 4 WK|GED-0301 160 mg QD for 4 weeks followed by 8 weeks of placebo
2579972|NCT02366728|Experimental|Group I: Unpulsed DC pre-conditioning|0.4 mLs of 1 x 10^6 autologous unpulsed DCs in saline will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
2579973|NCT02366728|Experimental|Group II: Tetanus pre-conditioning|Tetanus diptheria toxoid (Td), 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. pp65 DC Vaccine #4 is 111In-labeled DCs for migration studies.All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
2579974|NCT02366728|Experimental|Group III: Basiliximab and Tetanus pre-conditioning|Basiliximab infusions prior to human CMV pp65-LAMP mRNA-pulsed autologous DC vaccines #1 and #2 with Td pre-conditioning 1 flocculation unit, will be administered to a single side of the groin, and 0.4 mLs of saline administered to the contralateral side 1 day prior to the fourth human CMV pp65-LAMP mRNA-pulsed autologous DCs vaccine. All patients will be vaccinated with pp65 DCs in conjunction with subsequent TMZ cycles every 5 ± 1 weeks for a total of 6 to 12 cycles after RT.
2580009|NCT02366494||Androgen blockade|Androgen DeprivationTherapy or Complete Androgen Blockade
2580013|NCT02366494||Hormonal Therapy and Chemotherapy|Hormonal therapy, novel oral hormonal therapy (abiraterone/apalutamide/enzalutamide) and chemotherapy (docetaxel)
2580148|NCT02365987|Experimental|Interesterified|Interesterified blend of palm kernal and plam stearin. 50g fat.
2580153|NCT02365987|Active Comparator|Un-interesterified|Un-interesterified blend of palm kernal and plam stearin. 50g fat.
2580172|NCT02365311|Experimental|one lung group|
2580178|NCT02365155|Experimental|Intervention group.|Multicomponent training intervention; Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
2580179|NCT02365155|Active Comparator|Control group.|Nutrition intervention; Cognitive intervention; D-vitamin intervention; Occupational intervention; Heart failure follow up.
2580246|NCT02364973||PET-MRI|Patients with chronic inflammatory bowel disease who are treated at Turku University hospital outpatient clinic or ward
2580306|NCT02364739|Experimental|Written information|Written information
2580315|NCT02364739|Experimental|Written and oral information|Written and oral information
2580319|NCT02364739|No Intervention|No intervention|Control
2580960|NCT02360072||Asthma|Accompanied by typical asthma symptoms and Δ FEV1≥12% in response to a short-acting bronchodilator or bronchial hyperreactivity(BHR) in the methacholine provocation test (PC20≤2.504mg)
2579687|NCT02368912|Experimental|4. Food effect (FE), ASP1707 fed|Fed healthy young male
2579688|NCT02368912|Experimental|5. Multiple ascending dose (MAD), ASP1707 dose levels 1-4|healthy elderly male
2579690|NCT02368912|Experimental|6. Multiple ascending dose (MAD), Placebo, dose levels 1-4|healthy elderly male
2579691|NCT02368912|Experimental|7. Multiple ascending dose (MAD), ASP1707, dose levels 1-2|healthy pre-menopausal female
2579693|NCT02368912|Experimental|8. Multiple ascending dose (MAD), Placebo dose levels 1-2|healthy pre-menopausal female
2579694|NCT02368912|Experimental|9. Parallel multiple dose, ASP1707 dose levels 1-3|healthy pre-menopausal female
2579695|NCT02368912|Experimental|10. Parallel multiple dose, Placebo|healthy pre-menopausal female
3176464|NCT00644410|Active Comparator|1|The number of mesenchymal stromal cells reached after two culture expansion passages.
3176465|NCT00644410|Placebo Comparator|2|Saline
2580029|NCT02366455||Thoracic CT-Scan|Measurement of the length of the right main stem bronchus and of the right upper lobe bronchus antero-posterior angulation on consecutive thoracic CT-Scan reconstruction
2580072|NCT02366208|Experimental|PEG-Tα1|PEG-Tα1 (1.6 mg/ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
2580074|NCT02366208|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) for 24 weeks and adefovir (10 mg, once daily, taken orally) for 48 weeks
2580127|NCT02365662|Experimental|Arm 1|Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
2580194|NCT02365402|Experimental|entecavir with PEG-IFN a-2a|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow up after treatment.
2580203|NCT02365402|No Intervention|control group|In this group, patients will be continue treated only by PEG-IFN a-2a for 48 weeks after enrolled and receive 24 weeks of follow up.
2580576|NCT02362698|Experimental|electro-acupuncture|Receiving electro-acupuncture treatment once every other day, half an hour per treatment, 10 times as one treatment course, subjects received 2 courses of treatment.
2580579|NCT02362698|Active Comparator|psychological intervention|Receiving cognitive behavioral therapy once every four days, each time two hours. Five times intervention as one treatment course, subjects received 2 courses of treatment.
2580878|NCT02360761|Active Comparator|Lobectomy|Patients undergo lobectomy by thoracotomy or thoracoscopy/Video assisted thoracoscopic surgery(VATS).
2580880|NCT02360761|Experimental|Sublobar resection|Patients undergo sublobar resection(wedge resection or anatomic segmentectomy) by thoracotomy or thoracoscopy/VATS.
2580964|NCT02360306|Active Comparator|Conventional EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the conventional EBUS scope rather than the hybrid EBUS scope. Subjects in this arm, like in the Hybrid EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
2580967|NCT02360306|Experimental|Hybrid EBUS|Subjects in this arm will have endobronchial ultrasound bronchoscopy done by the hybrid EBUS scope rather than the conventional EBUS scope. Subjects in this arm, like in the conventional EBUS arm, may or may not receive transbronchial forcep biopsies, airway brusings, and/or radial EBUS, depending on clinical need.
2581142|NCT02359266|Experimental|Vitamin D supplement|20,000 IU cholecalciferol p.o for the first 7 days, and weekly thereafter for 6 months
2581145|NCT02359266|No Intervention|Controls|These patients had normal vitamin D levels and did not receive any treatment with vitamin D.
2581267|NCT02358291|Active Comparator|open discectomy|patients diagnosed as lumbar disc herniation undergoing open simple discectomy(OD)
2581269|NCT02358291|Active Comparator|microendoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy(MED)
2581271|NCT02358291|Active Comparator|transforaminal endoscopic discectomy|patients diagnosed as lumbar disc herniation undergoing transforaminal endoscopic lumbar discectomy(TELD)
3176466|NCT00644436|Experimental|1|Single topical application
3176467|NCT00644436|Active Comparator|2|Single topical application
3176468|NCT00644449|Experimental|1|
3176469|NCT00644449|Experimental|2|
3176470|NCT00644462||1|Asthmatic subjects
3176471|NCT00644462||2|Healthy subjects
3176472|NCT00644475|Experimental|2|Imidapril
3176473|NCT00644475|Active Comparator|1|Candesartan
3176474|NCT00644488|Experimental|A1|Active
3176475|NCT00644501|Experimental|1|
3176476|NCT00644514|Experimental|LPS endotoxin inh f/u bronchoscopy|Participants receive inhalation of LPS endotoxin, followed by bronchoscopy in this study.
3176477|NCT00644527|Experimental|1|Listening to one of two different specific music programs (Group A), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
3176478|NCT00644527|Experimental|2|Listening to one of two different specific music programs (Group B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
3176479|NCT00644527|Sham Comparator|3|Control I (Group C) : Listening 30 min in the morning and 30 min in the evening to unspecific music (Mozart) over 5 weeks.
3176480|NCT00644527|No Intervention|4|Control II (Group D): Waiting list. - Each 50% of the subjects will be assigned randomly to either Group A (arm 1) and B (arm 2) after 5 weeks of waiting time.
3176481|NCT00644540|Experimental|1|
3176482|NCT00644540|Active Comparator|2|
3176483|NCT00644553|Active Comparator|A|
3176484|NCT00644553|Active Comparator|B|
3176485|NCT00644566|No Intervention|TAU|Treatment as usual. These subjects and their providers were told to pursue treatment services as they normally would do.
3176486|NCT00644566|Experimental|shared care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
3176487|NCT00644579|Active Comparator|1|bLAC high dose
2579700|NCT02368574|No Intervention|Class III hysterectomy Arm|Class III hysterectomy (radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. Perivesical space and perirectal space should be opened, and the ureteral tunnel is completely separated and pushed down to the junction of ureter and urinary bladder. The uterine arteries are ligated at the level of internal iliac artery, and all the supporting ligaments and connective tissues around the uterus should be separated and abscised. The uterosacral ligament is removed near the sacrum, the cardinal ligament is removed near the pelvic wall, and the vagina is removed after the excision of peivaginal connective tissues, about 3-4cm from the cervical lesion. The pelvic lymph nodes are usually dissected at the same time.
2579702|NCT02368574|Experimental|Class II hysterectomy Arm|Class II hysterectomy (modified radical hysterectomy): This procedure may be performed through laparotomy or laparoscope. The scope of surgery is more extensive than Class I epifascial panhysterectomy, demanding the excision of more parametrium but reservation of the blood supply for distal ureter and urinary bladder. The ureter is separated from the ureteral tunnel, the vesicouterine ligament should be intact, and 1/2 uterosacral ligament and 1cm vagina are excised. The pelvic lymph nodes are usually dissected at the same time.
2579718|NCT02368327|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine
2579720|NCT02368327|Active Comparator|Fendrix|Participants receive one dose of Fendrix vaccine
2579724|NCT02368327|Placebo Comparator|Placebo|Participants receive one dose of saline placebo
2579760|NCT02368119|Experimental|Group 1|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=10) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=10). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
2579763|NCT02368119|Experimental|Group 2|VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp (n=20) or VRC-EBOADC069-00 VP (cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp (n=20). Randomization to booster of MVA-EbolaZ or PBS placebo will be completed 4 to 16 weeks after priming dose.
2579837|NCT02367651|Experimental|Pazopanib|Subjects will receive pazopanib 800 mg once daily during each 28-day treatment period until disease progression, unacceptable adverse event (AE)/serious adverse event (SAE), death or withdrawal of consent
2579844|NCT02367651|Placebo Comparator|Placebo|Subjects will receive placebo once daily during each 28-day treatment period until disease progression, unacceptable AE/SAE, death or withdrawal of consent
2579893|NCT02367482||NovoTTF|NovoTTF treatment will be administered as usual during the imaging study either in monotherapy or in combination with other treatments (initiated prior to NovoTTF therapy). The treatment plan or intervention will not be altered in any way. Two AMT-PET scans will be added to the management scheme: a baseline PET shortly before and a follow-up PET scan 2-3 months after the start of NovoTTF treatment.
2580049|NCT02366299|Active Comparator|dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
2580057|NCT02366299|Active Comparator|propofol|Treatment of delirium by propofol i.v. infusion
2580088|NCT02365857|Active Comparator|DEX-5|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
2580091|NCT02365857|Active Comparator|DEX-10|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
2580094|NCT02365857|Active Comparator|DEX-15|Dexmedetomidine & Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
2580095|NCT02365857|Active Comparator|Control|Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.
3176488|NCT00644579|Active Comparator|2|bLAC low dose
2580345|NCT02364154||Control group-Blood sampling|-subjects with a normal colonoscopy
2580346|NCT02364154||Study group-Blood sampling|- subjects with colorectal cancer after colonoscopy
2580398|NCT02364024||Arm A|Patients with no or low immune response (score 1 or 2) with linear quantification of CD3+ cells
2580399|NCT02364024||Arm B|Patients with high immune response (score 3 or 4) with linear quantification of CD3+ cells
2580412|NCT02363712|Experimental|APOS|APOS(All Phase Of Step)-shoe
2580414|NCT02363712|Sham Comparator|Sham APOS|Sham APOS(All Phase Of Step)-shoe
2580511|NCT02363517|No Intervention|Group A|"Primary (n=40) and secondary (n=100) participants will receive supportive care only (includes a clinical review, questionnaire and blood sample collected at baseline and weeks 12, 24, 36, 48, 60, 72 and 84).~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
2580514|NCT02363517|Active Comparator|Group B|"Primary participants (n=40) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Secondary participants (n=100) will receive supportive care only.~Participants with HCV not allocated to treatment arms will receive deferred treatment at the end of the follow-up period."
2580961|NCT02360072||AR+Asthma|Diagnosed allergic rhinitis concomitant asthma symptoms
3176489|NCT00644579|Placebo Comparator|3|
3176490|NCT00644605|Active Comparator|Arm 1|
3176491|NCT00644605|Active Comparator|Arm 2|
3176492|NCT00644605|Active Comparator|Arm 3|
3176493|NCT00644605|Placebo Comparator|Arm 4|
3176494|NCT00644618|Active Comparator|A|
3176495|NCT00644618|Experimental|B|
3176496|NCT00644631|Active Comparator|Arm 1|
3176497|NCT00644631|Placebo Comparator|Arm 2|
3176498|NCT00644644||1|monitored
3176499|NCT00644644||2|control
3176500|NCT00644670|Experimental|Previous Treatment with a Usual Maintenance Dose of a Statin|
3176501|NCT00644670|Experimental|Statin-Naive|
3176502|NCT00644696|Experimental|Irinotecan and Bortezomib|Irinotecan and Bortezomib will both be administered
3176503|NCT00644709|Experimental|Arm A|
3176504|NCT00644722|Active Comparator|1|Single use metallic blades
3176505|NCT00644722|Active Comparator|2|Classic reusable metallic blades
3211356|NCT01004380|Experimental|Farletuzumab|2.5 mg/kg once weekly administered i.v. during the Combination treatment period and 7.5 mg/kg Q3W administered i.v. during the Maintenance period
2579938|NCT02367092|Experimental|Exercise Program|The exercise intervention consists of a 30 minute exercise session led by an instructor through a DVD or a video available on the internet.
2579940|NCT02367092|No Intervention|Standard of care|Standard of care which consists of encouragement to exercise by the subject's transplant clinician.
3211357|NCT01004419|Experimental|Vandetanib plus fulvestrant|vandetanib by mouth once daily for 28 days plus fulvestrant intra-muscular injection each cycle
3211358|NCT01004445|Experimental|Arm 1|
2580123|NCT02365948|Experimental|Certolizumab Pegol 100 mg|"Subjects will receive100 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment on Day 1.~To achieve an injectable CZP 100 mg dose, a manual process will be applied by the unblinded site pharmacist."
2580126|NCT02365948|Experimental|Certolizumab Pegol 200 mg|Subjects will receive 200 mg of CZP given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 100 mg. Dose escalation will be suspended according to the predefined criteria and process.
2580129|NCT02365948|Experimental|Certolizumab Pegol 400 mg|Subjects will receive 400 mg of CZP (two injections of CZP 200 mg) given by subcutaneous injections in healthy Chinese subjects. The dose group begins treatment staggered by a minimum of 14 days from CZP 200 mg. Dose escalation will be suspended according to the predefined criteria and process.
2580132|NCT02365948|Placebo Comparator|Placebo|For assessment of the Adverse Event (AE) profile, there are 2 placebo controls in each dose group. The placebo subjects receive the injection of saline (NaCl 0.9 %) at the same time (and of the same volume) as the CZP subjects.
3211359|NCT01004445|Experimental|Arm 2|
3211360|NCT01004445|Placebo Comparator|Arm 3|
2580307|NCT02364752|Experimental|Healthy|Part 1: Blood is obtained from healthy participants on 3 consecutive days, and participants undergo Cardiac Magnetic Resonance Imaging (CMR) and two-dimensional speckle tracking echocardiography (2DSTE) on one of those 3 days.
2580311|NCT02364752|Experimental|Mild/moderate heart failure (HF)|Part 1: Blood is obtained from participants with mild/moderate HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
2580320|NCT02364752|Experimental|Severe HF|Part 1: Blood is obtained from participants with severe HF on 3 consecutive days, and participants undergo CMR and 2DSTE on one of those 3 days. Part 2: Within 5 days of completing Part 1 participants have a 24 hour loop diuretic withdrawal, and 15 hour 0.9% normal saline infusion; followed by a blood draw, CMR and 2DSTE.
3211361|NCT01004458|Active Comparator|Early treatment group|The experimental group receiving CBT
3211362|NCT01004458|No Intervention|Waiting list group|The waiting list group served as referents during the trial
2580425|NCT02363660|Experimental|Arm I|will receive standard dose (0.5mL) delivered by standard intramuscular injection using a needle and syringe.
2580431|NCT02363660|Experimental|Arm II|will receive standard dose (0.5mL) delivered by intramuscular injection using the Pharmajet needle-free Stratis device.
2580435|NCT02363660|Experimental|Arm III|will receive a reduced-dose (0.1 mL) delivered by intradermal injection using the PharmaJet needle-free Tropis device
2580454|NCT02363452|Experimental|AGS|Reverse transcriptase inhibitors
2580492|NCT02363179|No Intervention|Non Music Group|500 non-intervention patients will be consented to serve as the control group
2580497|NCT02363179|Experimental|Music Intervention Group|500 intervention patients will be consented to participate in the live preferential music intervention
2580526|NCT02363075|Experimental|Dexamfetamine sulphate|Dexamfetamine Sulphate 5 mg Tablets
2580527|NCT02363075|Placebo Comparator|placebo|Aspect tablets identical to the active
3211363|NCT01004484|Active Comparator|Yogurt with probiotics and inulin|A probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving).
3211364|NCT01004484|Placebo Comparator|Placebo|Acidified dairy snack without yogurt cultures, probiotic or inulin.
2580668|NCT02361996||Coronary Bypass Surgery|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary bypass surgery.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
2580669|NCT02361996||Coronary Stenting|"inclusion criteria:~presence of at least one coronary stenotic lesion above 50% with clinical indication for coronary vessel dilatation/stenting.~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extant of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
3211365|NCT01004497|Experimental|Modified Hyper-CVAD + Dasatinib|Dasatinib: 100 mg once daily, PO, for 4 weeks Cyclophosphamide: 300 mg/m2, IV, every 12 hours, days 1~3 Vincristine: 1.4 mg/m2/day (maximum 2 mg/day), IV, days 4 & 11 Daunorubicin: 45 mg/m2/day, IV, days 4 & 11 Dexamethasone: 40 mg/day, IV, days 1~4 & days 11~14 Cytarabine: 2 g/m2, IV, every 12 hours, days 1~5 Mitoxantrone: 12 mg/m2/day, IV, days 1~2
3211366|NCT01004523||Single group|Previously preserved paraffin-embedded tissue blocks are obtained and used for biomarker studies. Blood samples obtained during treatment are also obtained. Loss of heterozygosity of specific chromosomal regions are performed using PCR analysis of microsatellite repeats (41,118-120) on DNA extracted from the paraffin-embedded archival specimens. FISH and flow cytometry may also be used to assess chromosomal loss of deletion. Immunohistochemistry is also performed.
3211367|NCT01004536|No Intervention|no treatment|The other half of cesarean section wound that is to be left untreated.
3258972|NCT01466335|Experimental|Ronacaleret 200mg once daily|2 x 100mg oral tablet
2579877|NCT02367287||Sampling strata|Stratified analyses of primary and secondary outcomes based on variables of interest (e.g. sex, age, or BMI) may occur prior to achieving the target for total study enrollment.
2579959|NCT02367157|Experimental|Experimental: Kinesio taping|Epicondilar and epitroclear muscle Kinesio Taping with a Space Correction on the wrist according Kenzo Kase Method
2579960|NCT02367157|No Intervention|No intervention: Control|
3176506|NCT00644735|Experimental|1|Nexium
2580189|NCT02365493|No Intervention|Standard therapy|"Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study"
2580198|NCT02365493|Experimental|Standard therapy + Beta-Lactam|In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) <10, if they desire.
2580355|NCT02364401|Experimental|Impedance Guided Ablation Group|Impedance guided ablation group performs pulmonary vein(PV) isolation guided by annotation criteria with minimum time of 10 seconds, maximum range of 2 mm, and minimum impedance decrease over 5 Ohms instead of CF parameters. In the impedance guided group, operators are blinded to contact force data during PV isolation.
2580358|NCT02364401|Active Comparator|Contact Forced Guided Ablation Group|Contact force(CF) guided ablation group performs pulmonary vein (PV) isolation guided by automated annotation criteria with minimum time of 10 seconds, maximum range of 2mm, CF over time of 50% and minimum CF of 10 g.
2580396|NCT02363985|Other|Multiple vitamin A exposer|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)~Promotion of orange flash sweet potato production and consumption in collaboration with international potato center (CIP) in one of the study area"
2580397|NCT02363985|Other|Only vitamin A supplementation|"55 children who are using~Mega-dose vitamin A supplementation~Food diversification (promotion and education on vitamin A rich food consumption)"
2580422|NCT02363790|Other|LVHR PFC|Ventral hernia repairs in the primary fascial group will be performed similarly except prior to placement of the mesh, the defect will be closed. After the defect size is measured, the mesh will be chosen based upon the unclosed defect size and size will not be adjusted. The hernia defect will be closed as described previously 9,10 with 0-prolene transfascial sutures placed every 1-2 cm. The two caudal-most and cranial-most sutures will be placed. The abdomen will be desufflated and these sutures will be secured. The abdomen will be reinsufflated to 15 mm Hg and the defect progressively closed. Upon completion of fascial closure, the mesh will be placed in the standard fashion as describe above. The lateral overlap will be increased due to the fascial closure.
2580423|NCT02363699|Active Comparator|Lidocaine|Group treated with lidocaine solution
2580430|NCT02363699|Placebo Comparator|Placebo|Group treated with saline solution
2580480|NCT02363426|Other|Medical Device: INVOcell Culture Device|5 day oocyte incubation using INVOcell Culture Device within the vaginal cavity.
2580484|NCT02363426|Active Comparator|Medical Device: IVF Incubator|5 day oocyte incubation using traditional IVF incubation.
2580485|NCT02363465||Participants aged 18-30 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 18-30 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
2580489|NCT02363465||Participants aged 31-40 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 31-40 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
2580493|NCT02363465||Participants aged 41-50 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 41-50 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
2580495|NCT02363465||Participants aged 51-65 years|"Echographic measurement of skin thickness at the proximal forearm and the deltoid region in participants aged 51-65 years.~aimed number: 12 male & 12 female maximum number: 15 male & 15 female"
3176507|NCT00644735|Active Comparator|2|Prevacid
3176508|NCT00644748|Experimental|Gabapentin group|
2580581|NCT02363088|No Intervention|No intervention, 24-29 years|No intervention, group 24-29 years. Women will receive the written invitation to screening only
2580585|NCT02363088|Experimental|Messenger text message reminder, 24-29|Messenger text message reminder, group 24-29 years.
3176509|NCT00644761|Other|Treatment Arm 1|Adefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
3176510|NCT00644774|Active Comparator|1|
3176511|NCT00644774|Active Comparator|2|
3176512|NCT00644800|Experimental|Arm A|
3176513|NCT00644813||Scapular with glenoid neck fractures|Collect outcome and radiological data on patients with scapular fractures involving the glenoid neck (bone joining the shoulder joint and the scapular body) for a period of 1 year.
3176514|NCT00644826|Experimental|1|
3176515|NCT00644826|No Intervention|2|
3176516|NCT00644839|Experimental|CP-945,598|
3176517|NCT00644852||001|
3176518|NCT00644891|Active Comparator|1|
3176519|NCT00644891|Active Comparator|2|
3176520|NCT00644904|Experimental|Treatment|Starting dose of 4,000 IU per day of Vitamin D3 titrating up to a dose of 40,000 IU per day of Vitamin D3 by month six. In the second six-month part of the trial, patients titrate back down to 4,000 IU per day of Vitamin D3 and then discontinue it completely at the end of the 12 month trial period.
3176521|NCT00644904|Other|Control|Patients are allowed to supplement with up to 4,000 IU per day of Vitamin D3 if desired.
2580001|NCT02366650||Lund ED|appr 100-200 patients at Lund ED
2580003|NCT02366650||Helsingborg ED|appr 100-200 patients at Helsingborg ED
2580006|NCT02366650||Vancouver ED|appr 100 patients at St Paul's hospital ED
2580010|NCT02366650||Bern ED|appr 100 patients at Bern ED
2580099|NCT02365974|Active Comparator|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps (mA) will be adjusted depending on the sensitivity of each individual patient. The arrangement thereof will be parallel on each side of the C7 (channel 1) and T4 (channel 2) vertebral spinous processes.
2580100|NCT02365974|Sham Comparator|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment without be submitted to stimulation.
2580308|NCT02364544|Other|Health Technology Program|"The components of the treatment model include: 1) Prescriber Decision Assistant (PDA) 2) relapse prevention plan, 3) the daily support website 4) FOCUS, an interactive smart phone text-messaging application 5) a web-based, cognitive-behavioral therapy (CBT) program~All patients will be provided with pharmacological treatment (PDA), brief in-person relapse prevention counseling, and an Android mobile phone. The other program components will be provided to patients using a shared decision-making approach to assess need and preference."
2580357|NCT02364141|Experimental|Trunk restraint therapy|Reaching training with trunk restraint by a harness that limited the trunk movements.
2580362|NCT02364141|Active Comparator|Trunk unrestraint therapy|Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
2580428|NCT02363673|Experimental|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy in aqua distilla according to their symptoms and characteristic manifestations of their disorder. Although different individualised remedies may be dispensed, each remedy will be homoeopathic. Remedies will be dispensed in aqua distilla. Each individualised homoeopathic remedy will have an individualised dosage, frequency and duration based on the laws of individualised homoeopathic prescribing.
3176522|NCT00644930|Experimental|1|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated.
2580471|NCT02363244||Pap group|Per speculum examination will be done.Pap test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for pap test will be collected and send to laboratory for further evaluation.
2580473|NCT02363244||HPVDNA GROUP|Per speculum examination will be done.HPVDNA test will be collected for the women as per allotement.A via (visual inspection with acedic acid)test will be done.A repeat cervical cell for HPVDNA will be collected and send to laboratory for further evaluation.
2580496|NCT02363491|Experimental|OPN-305|OPN-305
2580525|NCT02363153|Experimental|Diet and Exercise|Patients will be given an individualized diet and exercise plan by a physical therapist and registered dietician. The diet and exercise plan will be carried out by the participant for 16 weeks. The exercise plan, an aerobic and strength training regimen, will be performed under the supervision of a personal trainer or certified exercise physiologist that is local to the participant. The participant will complete core-stabilizing exercises which can be performed at home or in an approved group class. The participant will wear an activity tracker at all times during this 16 week period, and will be asked to manually enter data into a phone app, such as daily food intake and weight.
2580539|NCT02363049|Experimental|colectomy|surgery followed by chemotherapy +/- targeted therapy regime according to each centre
2580540|NCT02363049|Active Comparator|no colectomy|Chemotherapy +/- targeted therapy alone, regime according to each centre.
2580678|NCT02362152||Ingenol mebutate|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
2580680|NCT02362152||5-fluorouracil|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
2580683|NCT02362152||Imiquimod|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
2580684|NCT02362152||Diclofenac|Adults with actinic keratosis eligible to receive topical treatment with one of the four treatments
2580730|NCT02361697|Other|DTI-MRI|MRI of the brain with specific DTI-sequences according to a specific investigation protocol
3176523|NCT00644930|Active Comparator|2|Patients in the standard therapy group without indications for urgent intubation were only given standard medical therapy (such as oxygen, antibiotics, and bronchodilators), and IMV through an endotracheal tube was applied when intubation criteria were met.
3176524|NCT00644943|Active Comparator|1|
3176525|NCT00644943|Active Comparator|2|
3176526|NCT00644956|Active Comparator|Arm 1|
3176527|NCT00644956|Active Comparator|Arm 2|
3176528|NCT00644982|Experimental|Sertaline group|
3176529|NCT00644982|Active Comparator|Venlafaxine group|
3176530|NCT00645021|Experimental|Mild hepatic function|
3176531|NCT00645021|Experimental|Moderate hepatic function|
3176532|NCT00645021|Experimental|Normal hepatic function|
3176533|NCT00645034|Active Comparator|Arm 1|
3176534|NCT00645034|Placebo Comparator|Arm 2|
3176535|NCT00645060|Experimental|Y-90-DOTA-M5A anti-CEA antibody|
3176536|NCT00645073|Active Comparator|A|
3176537|NCT00645073|Active Comparator|B|
3176538|NCT00645086|Active Comparator|A|
3176539|NCT00645086|Active Comparator|B|
3176540|NCT00645112|Active Comparator|1|
3176541|NCT00645112|Active Comparator|2|
3176542|NCT00645125|Active Comparator|1|
3176543|NCT00645125|Active Comparator|2|
3176544|NCT00645138|Active Comparator|Paravertebral Block|Patients receiving Paravertebral Block.
3176545|NCT00645138|Active Comparator|General Anesthesia|Patients receiving General Anesthesia.
3176546|NCT00645151|Experimental|High Risk|
3176547|NCT00645151|Experimental|Low Risk|
3176548|NCT00645151|Experimental|Medium Risk|
2579923|NCT02367079|Sham Comparator|Switched OFF diathermy|Switched OFF diathermy was used on DOMS compared to REAL diathermy
3211368|NCT01004536|Experimental|silicone gel|Randomly-designated half of cesarean section wound that is to be subject to application ot silicone gel
3211369|NCT01004549||Bilateral intraocular lens implantation.|
3211370|NCT01004575|Experimental|Kaname|patients that are treated by implanting Kaname Cobalt-Chromium coronary stent
3211371|NCT01004588|Experimental|Protein drink|protein drink
2580112|NCT02365831||Prospective|Observation of treatment management of patients with metastatic breast cancer that have been treated or not with hormonal therapy and candidate for a first line chemotherapeutic treatment in the years 2014-2015 will be observed until the end of the study.
2580120|NCT02365831||Retrospective|Observation of treatment management of patients with metastatic breast cancer that have been treated with a first, second or following line of chemotherapeutic treatment for metastatic disease in the years 2012-2013.
2580193|NCT02365428|Experimental|Control: Group 1|The control group will receive three standard Text4Baby messages per week at noon on Mondays, Wednesdays, and Fridays.
2580202|NCT02365428|Experimental|Group 2|Intervention group 1 will receive two physical activity messages and one standard Text4Baby message each week at noon on Mondays, Wednesdays, and Fridays.
2580206|NCT02365428|Experimental|Group 3|Intervention group 2 will receive six physical activity messages and one standard Text4Baby message per week at a random time per day.
2580208|NCT02365428|Experimental|Group 4|Intervention group 3 will receive six physical activity messages and one standard Text4Baby message per week at a time of the participant's choice per day.
2580249|NCT02364934||Propofol|Propofol is intravenously administrated during anesthesia maintenance in patients (18-65 years old)
2580251|NCT02364934||Sevoflurane|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (18-65 years old)
2580254|NCT02364934||Propofol (elderly)|Propofol is intravenously administrated during anesthesia maintenance in patients (≥65 years old)
2580256|NCT02364934||Sevoflurane (elderly)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in patients (≥65 years old)
2580258|NCT02364934||Propofol (men)|Propofol is intravenously administrated during anesthesia maintenance in men (18-65 years old)
2580260|NCT02364934||Sevoflurane (men)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in men (18-65 years old)
2580261|NCT02364934||Propofol (women)|Propofol is intravenously administrated during anesthesia maintenance in women (18-65 years old)
2580262|NCT02364934||Sevoflurane (women)|Sevoflurane (inhalation) is administrated during anesthesia maintenance in women (18-65 years old)
2580314|NCT02364583|Active Comparator|14 day dose regimen|0.5 mg/kg oral Primaquine administered daily for 14 days
2580318|NCT02364583|Active Comparator|7 day dose regimen|1.0 mg/kg oral Primaquine administered daily for 7 days
2580322|NCT02364583|Active Comparator|3.5 day dose regimen|1.0 mg/kg oral Primaquine administered twice daily (bd) for 3.5 days
2580342|NCT02364245|Experimental|Kinect|Receive computer games training for 30 minutes and 30 minutes traditional OT.There are 3 sections for 1 week; the intervention period will be 8 weeks.
2580343|NCT02364245|Placebo Comparator|Traditional|The control group will receive traditional OT for 1 hour. There are 3 sections for 1 week; the intervention period will be 8 weeks.
2580382|NCT02364063|Experimental|Children with CP - Therapy|Children receive incontinence treatment during one year, after which a follow-up period of 6 months will be applied. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
2580385|NCT02364063|No Intervention|Children with CP - Control|Children are followed for 6 months, not receiving any treatment. After this follow-up period, children also receive incontinence treatment for 6 months.
2580387|NCT02364063|Active Comparator|Children without CP|Children receive incontinence treatment during 1 year. Intervention includes standard urotherapy with or without pharmacotherapy/specific urotherapy
2580420|NCT02363790|Other|Bridging LVHR|"Laparoscopic ventral hernia repair without closure of central defect (bridging repair)~Upon completion of the lysis of adhesions, the margins of the hernia defect will be measured and marked. The hernia defect size will be measured with the abdomen completely desufflated and insufflated at 15 mm Hg externally (on the skin).~A coated mesh with at least four cm of overlap on all sides will be placed. Mesh will be secured with at least four but no more than eight trans-fascial sutures. Titanium tacks will be placed in a double crown technique where tacks are placed every 1 cm on the periphery and every 3 cm along the fascial edge (bridged or closed)."
2580442|NCT02363556|Experimental|Misoprostol Alone|Subjects enrolled into this arm of the study will receive misoprostol 400-mcg only.
2580445|NCT02363556|Experimental|Dilapan with Misoprostol|Subjects enrolled into this arm of the study will receive Dilapan with 400-mcg misoprostol.
2581018|NCT02359786||Topicals Subjects using topical compounds|
3211372|NCT01004588|Placebo Comparator|Placebo drink|Placebo drink
3211373|NCT01004601|Active Comparator|low dose docetaxel|Low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)
3211374|NCT01004601|Active Comparator|Pemetrexed|Pemetrexed (500 mg/m2 every 3 weeks)
3211375|NCT01004627|No Intervention|Control group - selective duplex|Patients will receive a duplex ultrasound only if specifically requested following physical examination.
3211376|NCT01004627|Experimental|Obligatory Duplex scan|Patients will receive a duplex ultrasound regardless of clinical findings. Arterial and venous duplex ultrasound examination
3211377|NCT01004640||Group 1|"Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.~Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis."
3211378|NCT01004653|Experimental|H1N1 influenza A Vaccine (Split virion), Inactivated|15 μg H1N1 influenza A Vaccine (Split virion), Inactivated
3211379|NCT01004666||Women with equivocal findings on Mammography, US and/or MRI|Women with equivocal findings on Mammography, US and/or MRI
2579932|NCT02366975|Active Comparator|Hypogonadal patients A|Patients with hypogonadism has been randomized to testosterone gel solution 2%
2579935|NCT02366975|Placebo Comparator|Hypogonadal patients B|Patients with hypogonadism has been randomized to placebo solution gel
2579989|NCT02366780|Experimental|Manual expression followed by electric pump|Mothers will be assigned to first express breast milk manually followed by electric pump
2579996|NCT02366780|Experimental|Electric pump followed by manual expression|Mothers will be assigned to first express breast milk by electric pump followed by manual expression
2580046|NCT02366377|Experimental|SHR3824 Placebo|SHR3824 Placebo , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
2580053|NCT02366377|Experimental|SHR3824 5 mg|SHR3824 5 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
2580056|NCT02366377|Experimental|SHR3824 10 mg|SHR3824 10 mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
2580063|NCT02366377|Experimental|SHR3824 20 mg|SHR3824 20mg , once daily, 12 weeks, Metformin, Three times daily, 500mg, background drug.
2580138|NCT02365779|Experimental|bilateral laparoscopic salpingectomy|
2580191|NCT02365389|Active Comparator|Group A received in situ MTZ vaginal gel|Received in situ MTZ vaginal gel once daily for 5 days. Treatment in this group was offered in the form of a bottle of an aqueous liquid (100 mL of a preparation composed of 0.8% MTZ, 20% pluronic F-127, 10% pluronic F-68, and 0.01% benzalkonium chloride). Women were asked to put 5 cc of the liquid into the vagina once daily for 5 days using a graded syringe and 10-cm long soft applicator.
2580199|NCT02365389|Active Comparator|Group B received conventional MTZ vaginal gel|Group B (control group) received conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days, using the supplied nozzle, which applies about 5 gm of gel again in the same laying back position.
2580267|NCT02365025|Experimental|Experimental group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the experimental group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will participate in 6 meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.~Step 4: Re evaluation by questioners after the 6 meetings participation. Step 5: 3 months follow up after the intervention (Meetings)."
2580269|NCT02365025|No Intervention|Control group|"Step 1: Patients and parents enrolment. Step 2: The parents of the children assigned to the control group will fill a questionaire related to familial and social background, electronic media exposure and sleep characteristics of their children.~Step 3: Parents of the children assigned to this group will not participate in the meetings as described in the experimental group.~Step 4: Re evaluation by questioners after the time that the experimental group participated in the meetings.~Step 5: 3 months follow up."
2580326|NCT02364661|Experimental|Hepatitis B virus infected patients|HBV patients with detectable viremia will be analyzed for their level of viremia following an over-night starvation (fasting) versus fed state
2580365|NCT02364323|Experimental|Personalized risk counselling|Intervention includes risk counseling to patients with diabetes on future risk of diabetic complications based on an established genetic counseling framework for common polygenic disorders which will be delivered to patient in a counselling sesssion 6 weeks after genetic testing
2580367|NCT02364323|Placebo Comparator|Normal usual care|Intervention includes normal usual care. General education on diabetes and diabetic complications
3211380|NCT01004666||Discrepancy between clinical examination and imaging|Women with discrepancy between clinical examination and breast imaging
3211381|NCT01004666||Women with dense breast|Women with dense breast
2580508|NCT02363361|Experimental|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
2580551|NCT02362750||Participating Program Administrators|Eligible survivorship program administrators at selected Commission on Cancer-accredited institutions will complete an organizational interview and organizational survey.
2580563|NCT02362750||Participating Cancer Survivors|"Survivors receiving follow-up care surveys at selected Commission on Cancer-accredited institutions will complete four surveys:~Survivor Survey (1): Pre-Visit Baseline Survivor Survey (2): 1 Week Post-Visit Survivor Survey (3): 3 Months Post-Visit Survivor Survey (4): 6 Months Post-Visit"
2580571|NCT02362750||Participating Clinicians|Survivorship clinicians from clinical survivorship programs at selected Commission on Cancer-accredited institutions will complete a clinician survey.
2580578|NCT02363023||VAP suspects|Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
2580615|NCT02362399|Active Comparator|sildenafil citrate|50 mg single oral dose
2580616|NCT02362451|Experimental|1/Lead-in TARP DC vaccine treatment|All patients to receive autologous multi-epitope TARP DC vaccine before randomization
2580620|NCT02362399|Active Comparator|placebo|single tablet of placebo
2580623|NCT02362451|Experimental|2/Active TARP DC vaccine treatment|Autologous multi-epitope TARP DC vaccine after randomization
2580627|NCT02362451|Placebo Comparator|3/Placebo|Autologous elutriated monocyte vaccine placeboafter randomization
2580674|NCT02362139|Experimental|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
2580675|NCT02362074||Adalimumab subjects|Subjects starting Adalimumab treatment at time of enrollment.
2580679|NCT02362139|No Intervention|The control group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were not treated with IM Papverine
2580714|NCT02361827||A, Vitamin D deficient|Vitamin D level on the day of HCG administraion < 20 ng/mL Embryo transfer after oocyte retrieval.
2580716|NCT02361827||B, Vitamin D insufficient|Vitamin D level on the day of HCG administraion 20-29.9 ng/mL Embryo transfer after oocyte retrieval.
2581024|NCT02359786||Patients undergoing Spinal Surgery using IOM|
3211382|NCT01004666||Women in high risk for Breast Cancer|Women in high risk for Breast Cancer. Including patients with genetic high risk and/or strong family history.
3258973|NCT01466335|Experimental|Ronacaleret 200mg twice daily|2 x 100mg tablets twice daily
3258974|NCT01466335|Experimental|Ronacaleret 400mg once daily|4 x 100mg tablets
3211383|NCT01004731|Experimental|Cetuximab in combination with Carboplatin/Gemcitabine|Approximately 30 patients with advanced NSCLC will be enrolled. Patients will receive 3-week cycles of Cetuximab in combination with Carboplatin/Gemcitabine.
3211384|NCT01004757|Active Comparator|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled, aerobic exercise
2579988|NCT02366533||Sites Implementing the LTC Program|This study will be conducted at the 15 ATN-funded clinical sites, known as the Adolescent Medicine Trial Units (AMTU). Each enrolling site must have the capability to input field data that can be used to evaluate the effectiveness of the Strategic Multisite Initiative for the Identification, Linkage, and Engagement in Care of Youth with Undiagnosed HIV Infection (SMILE in CARING for YOUTH) Project.
2580052|NCT02366234||Fracture of Distal Tubercle of Scaphoid|"Questionnaires~Quick DASH after trauma (< 2 weeks)~11-point ordinal measure of overall pain intensity 6 months after trauma~11-point ordinal measure of satisfaction with treatment 6 months after trauma"
2580116|NCT02366000|Experimental|Brief Parental Training Intervention|Participants will have to attend two 3-hour Brief Parental Training Intervention Programme, with three weeks apart. There will also be two telephone follow-up sessions to reinforce learnt strategies and skills for home practice between workshops.
2580121|NCT02366000|Other|Wait-list Group|Participants will receive the same Brief Parental Training Intervention Programme as the intervention group. However, they will wait until the questionnaires have been completed by the intervention group for the second time (i.e. immediately after intervention) before they receive their programme.
2580213|NCT02365090|Active Comparator|patching (occlusion therapy)|2 hours per day patching of the sound eye (for strabismic, anisometropic, and combined mechanism amblyopia) or current patching regimen (deprivation amblyopia)
2580219|NCT02365090|Experimental|binocular games|1 hour per day (5 days per week) binocular game play
2580272|NCT02364869|Experimental|Fructooligosaccharide|12g daily, for 12 weeks
2580275|NCT02364869|Placebo Comparator|Maltodextrin|12g daily, for 12 weeks
3211385|NCT01004757|Active Comparator|Low Fat diet|cross over design of three weeks Low Fat diet followed by two weeks LOGI diet always combined with heart rate controlled aerobic exercise
3211386|NCT01004809||Dutasteride|Patients administrated dutasteride with male hair loss
3211387|NCT01004835||Migraine Disease|Patients 10 to 18 years of age with the diagnosis of Migraine disease and at least one of their biologic parents will be included in this study.
3211388|NCT01004887||Single group|Patients with newly diagnosed high-grade gliomas participating in NCCTG/Alliance or Mayo protocols. Previously collected blood and tissue samples are analyzed via PCR, IHC, flow cytometry, and FISH.
3211389|NCT01004900|Active Comparator|Trabeculoplasty|
3211390|NCT01004900|Active Comparator|Control (Medication)|
2580490|NCT02363231||patients under mechanical ventilation|
3211391|NCT01004926|Experimental|Echelon|
2580529|NCT02363140|No Intervention|Group One patients in age group 18--20 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
2580532|NCT02363140|Active Comparator|Group Two patients in age group 35-45 years,|"Patients should be aged 18--20 years or 35--45years~Asymptomatic knee for past 6 months.~Painless flexion-extension movements at knee joint."
2580534|NCT02363140|Active Comparator|Group Three Patients aged 75|"Patients should be aged 75 or older~Knee X-ray showing no more than Kellgren-Lawrence grade II osteoarthrtis~No clinical suspicion of meniscus tear~Painless flexion-extension movements at knee joint."
2580536|NCT02363140|Active Comparator|Group Four, any age due to undergo a surgical meniscus repair|1. Patients should have presented with clinical signs to suggest meniscus tear indicating potential need for surgical meniscus repair
2581028|NCT02359786||Spine Patients undergoing cervical or lumbar surgery|
3211392|NCT01004965||Group 1|"Samples are obtained: 1) pretreatment, 2) at the time of documentation of refractory disease in acute myeloid leukemia (AML) patients who do not achieve complete response (CR) after induction therapy, and 3) at the time of first relapse in patients who achieve CR.~Marrow cells are preferentially used for all samples, but peripheral blood is acceptable if marrow is not available and the blood contains 20% or more blasts."
3211393|NCT01004978|Experimental|Arm I (sorafenib tosylate and TACE)|Patients receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of sorafenib tosylate is reached, patients undergo TACE comprising doxorubicin hydrochloride, mitomycin C, and cisplatin (closed to accrual as of 10/1/2010); conventional chemoembolization comprising doxorubicin hydrochloride only; or chemoembolization comprising doxorubicin-eluting beads. Treatment with TACE repeats approximately every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3211394|NCT01004978|Active Comparator|Arm II (placebo and TACE)|Patients receive placebo PO BID in the absence of disease progression or unacceptable toxicity. Beginning within 2 weeks after a stable dose of placebo is reached, patients undergo TACE as in Arm I.
3211395|NCT01005004|Experimental|HuCNS-SC cells|Intracerebral implantation of HuCNS-SC via direct injection during surgery
3211396|NCT01005017|Active Comparator|Percutanous RF lesioning|Radiofrequent lesioning uses a high frequency alternating current to heat tissues leading to thermal coagulation. It produces predictable and accurate lesions of the splanchnic nerves.
3211397|NCT01005017|No Intervention|Optimal medical treatment|
3211398|NCT01005030||PostCEPT Subjects|Subjects with current Parkinson Disease Diagnosis currently enrolled in PostCEPT study
3211399|NCT01005030||Control Subjects|Non-blood relatives of PostCEPT Subjects matched for age and other demographics
3211400|NCT01005043|Experimental|heavy ion radiotherapy|Heavy ion radiotherapy of osteosarcoma with 60 to 66 GyE (20-22 days). Before and after radiotherapy, but not during radiotherapy, chemotherapy is recommended to standard therapy protocols like EURAMOS 1 which is not part of this study.
3211401|NCT01005056||Marvelon®|Single arm study. All participants receive Marvelon® according to the approved dosage and administration method.
3211402|NCT01005069|Experimental|Treatment I|
3211403|NCT01005069|Experimental|Treatment II|
3211404|NCT01005069|Experimental|Treatment III|
3211405|NCT01005069|Experimental|Treatment IV|
3211406|NCT01005069|Placebo Comparator|Placebo|
3211407|NCT01005082|Experimental|Low salt diet plus water therapy|
2579977|NCT02366832|Experimental|Cryoablation|Amputee subjects experiencing phantom limb syndrome (PLS) will receive cryoablation
2580007|NCT02366520|No Intervention|control visit|The child receives dental treatment without the handheld mirror. The child cannot see the dental treatments that are conducted in his or her mouth.
2580011|NCT02366520|Experimental|intervention visit|The child receives dental treatment with handheld mirror. The child may see the dental treatments that are conducted in his or her mouth by the handheld mirror.
2580035|NCT02366247|Experimental|PEG-Tα1|PEG-Tα1 (3.2 mg/ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
2580036|NCT02366247|Placebo Comparator|Placebo to match PEG-Tα1|PEG-Tα1 placebo (1ml, once a week, taken subcutaneously) and adefovir (10 mg, once daily, taken orally) for 48 weeks
2580093|NCT02365935|Experimental|Group A to administer 4 cycles|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
2580096|NCT02365935|Experimental|Group B to administre 6 cycles|In Group B, all patients received instead 6 cycles of adjuvant chemotherapy every three weeks according to the same chemotherapic regimen.
3211408|NCT01005082|Active Comparator|water therapy alone|
3211409|NCT01005095|Experimental|High dose vitamin D|800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
2580173|NCT02365246|Experimental|immunoadsorption group|All patients will be treated with 10 immunoadsorptions with an IgE-specific adsorption column :
2580230|NCT02365142|Active Comparator|Platelet Rich Plasma (PRGF)|Platelet Rich plasma (PRGF) 3 intraarticular onjections sepataded by 7 days.
2580236|NCT02365142|Active Comparator|BMMSC with Platelet Rich Plasma (PRGF)|Single intraarticular injection of 100 million Bone marrow mesenchimal stem cells and three intraarticular injections of plateler Rich Plasma (PRGF) separatede by 7 days.
2580291|NCT02364830|Active Comparator|Anise-oil EC|Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks. Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
2580292|NCT02364830|Placebo Comparator|Placebo|Placebo Group: One Placebo Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
2580294|NCT02364830|Active Comparator|Colpermin®|Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks. Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
2580374|NCT02364362|Experimental|Famitinib + docetaxel|Low, medium and high dose of famitinib and 60 mg/m^2 docetaxel every 3 weeks
2580427|NCT02363894||Subjects enrolled in DEFINITIVE AR|
2580515|NCT02363517|Active Comparator|Group C|Primary (n=40) and secondary participants with chronic HCV infection (approx. n=50%*100) will be treated with 'Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) for 12 weeks. Participants in Group C who have evidence of HCV re-infection will be offered re-treatment with SOF + LDP for 12 weeks.
2580520|NCT02363569||case-|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed to the Women ER 24 hours after bleeding or bleeding secretions due to intercourse."
2580521|NCT02363569||control|"Pregnant women (age 18-40) at 4-23 weeks of pregnancy that have appealed the women ER due to spontaneous bleeding or bleeding secretions"
2580550|NCT02362893|Experimental|Direct Observed Therapy|Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
2580565|NCT02362893|No Intervention|Control|Standard care
2580606|NCT02362932|Experimental|Intervention|Sanitation
2580609|NCT02362932|No Intervention|Control|No sanitation
2580622|NCT02362542|Experimental|Sham tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
2580626|NCT02362542|Experimental|Real tDCS|Subjects will receive tDCS two times, one is active stimulation and the other is sham stimulation. Both stimulations will be separated at least one week and the order of sham and active tDCS will be counterbalanced across subjects.
2580673|NCT02362178|Experimental|Thromboelastography (TEG)|Patients in the TEG group received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, only if INR was higher than 1.8 and r time longer than 40 minutes. They received platelets at the amount of 1 apheresis Unit, only if platelets count was lower than 50000/μl and MA was shorter than 30 millimeter.
2580676|NCT02362243|Placebo Comparator|Control Group|Participants in the control arm will complete the placebo comparator intervention.
2580677|NCT02362178|Active Comparator|Standard of Care (SOC)|In the SOC group patients received fresh frozen plasma at the dose of 10 ml/kg of ideal body weight, when INR was higher than 1.8. They received platelets at the amount of 1 apheresis Unit, when platelets count was lower than 50000/μl.
2580681|NCT02362243|Experimental|Supervised Exercise Group|Participants in the supervised exercise intervention arm will perform the experimental intervention under direct 1-on-1 supervision of an exercise specialist.
2580682|NCT02362243|Experimental|Web-based Exercise Group|Participants in the web-based exercise intervention arm will perform the experimental intervention with use of a web-based exercise system for exercise instruction and guidance, and without direct 1-on-1 on-site supervision.
2580715|NCT02361814|Experimental|Amniotic membrane allograft group|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
2580741|NCT02361541||HCV screening|All adult patients of an existing HIV cohort
3211410|NCT01005095|Active Comparator|Low dose vitamin D|800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
3211411|NCT01005108|Experimental|placebo pill|
2580782|NCT02361294||Patient|Patients with a newly diagnosed deep venous thrombosis and/or pulmonary embolism. The thrombembolism is idiopathic or caused by immobilisation. Three blood samples are taken during the study period. A thrombophilia screening is carried out.
2580783|NCT02361294||Control|Patients that present with a suspicion of deep venous thrombosis which is excluded by duplex sonography. One to two blood samples are taken during the study period.
2580843|NCT02361073||Takotsubo|
3211412|NCT01005108|Experimental|placebo accupuncture|
3211413|NCT01005108|Experimental|accupuncture|
3211414|NCT01005108|Experimental|gabapentin|
2579992|NCT02366598|Experimental|40 g hemp protein shake|Hemp protein shake, 40 grams, given once, at beginning of acute trial
2579993|NCT02366598|Active Comparator|20 g Soybean protein shake|Soybean protein shake, 20 grams, given once, at beginning of acute trial
2579997|NCT02366598|Experimental|40 g Soybean protein shake|Soybean protein shake, 40 grams, given once, at beginning of acute trial
2579999|NCT02366598|Placebo Comparator|Control shake|non-protein control shake, given once, at beginning of acute trial
2580086|NCT02365922||Patients with FTLD or family members|Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.
2580111|NCT02365571|Experimental|LY3154207 (Part A)|LY3154207 administered in ascending doses once orally in two of three study periods
2580118|NCT02365571|Placebo Comparator|Placebo (Part A)|Placebo matching LY3154207 administered once orally in one of three study periods.
2580124|NCT02365571|Experimental|LY3154207 (Part B)|LY3154207 administered once orally.
2580128|NCT02365571|Placebo Comparator|Placebo (Part B)|Placebo matching LY3154207 administered once orally.
2580130|NCT02365571|Experimental|LY3154207 (Part C)|LY3154207 administered once orally on Day 1
2580131|NCT02365571|Experimental|LY3154207 + Itraconazole (Part C)|Itraconazole administered orally (twice daily on Day 3 and then once daily to Day 12). LY3154207 co-administered once orally, on Day 9. Timing and duration of itraconazole dosing may be adjusted based on data from Part A.
2580192|NCT02365350|Experimental|STEINER-TAN Needle®|All visible follicles regardless of size in both ovaries will be aspirated and flushed three times by the STEINER-TAN Needle.
2580201|NCT02365350|Active Comparator|17G single lumen needle|In the control group all visible follicles regardless of size in both ovaries will be aspirated by the 17G single lumen needle.
3211415|NCT01005121|Experimental|colchicine|patients will receive 2 mg of colchicine daily
3211416|NCT01005147|Experimental|Tranexamic acid arm|
3211417|NCT01005147|Placebo Comparator|Control arm|Will receive a placebo in place of tranexamic acid treatment
3211418|NCT01005160|Experimental|CKD501|
3211419|NCT01005173||Group A|Subjects receiving recommended doses of acetaminophen in the hospital. 140 Subjects
2580537|NCT02362919||A cohort of elderly individuals|A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
2580555|NCT02363127|Experimental|Prolutex|Subcutaneous progesterone
2580561|NCT02363127|Active Comparator|Progeffik|Vaginal progesterone
2580577|NCT02362711|Experimental|NPC-16 Standard Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
2580580|NCT02362711|Experimental|NPC-16 Continuous Dosing Regimen Group|Levonorgestrel 0.09mg, Ethinylestradiol 0.02mg
2580582|NCT02362711|Placebo Comparator|Placebo Group|Placebo for NPC-16
2580612|NCT02362516|Experimental|BI 425809|
3211420|NCT01005173||Group B|Healthy Volunteers - No acetaminophen exposure within 14 days of enrollment 23 Subjects
3211421|NCT01005173||Group C|Acetaminophen Overdose Subjects - Hospitalized 90 Subjects
2580687|NCT02362230|Experimental|Icotinib|Icotinib 125 mg BID
2580693|NCT02361983||DLT versus bronchial blockers|double lumen tube versus bronchial blockers
2580745|NCT02361723|Experimental|ovarian cancer, fallopian cancer, or primary peritoneal cancer|60mg BID oral.
2580748|NCT02361775|Experimental|Paravertebral catheter|a paravertebral catheter is placed and an elastomeric pump is connected to infuse 0.2% ropivacaine postoperatively
2580753|NCT02361775|Active Comparator|IV PCA|opioid PCA consisting of hydromorphone is connected to patient in the post anesthesia care unit
2580754|NCT02361723|Experimental|Breast Cancer|60mg BID Ora
2580761|NCT02361723|Experimental|Prostate Cancer|60mg BID Oral
2580762|NCT02361723|Experimental|Small Cell Lung Cancer|60mg BID Oral
2580763|NCT02361723|Experimental|Gastric Cancer|60mg BID Oral
2580825|NCT02361138|Experimental|Cohort SHR3824/Placebo 1.25 mg|SHR3824 1.25 mg/day or placebo for 10 days.
2580826|NCT02361138|Experimental|Cohort SHR3824/Placebo 2.5 mg|SHR3824 2.5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
2580827|NCT02361138|Experimental|Cohort SHR3824/Placebo 5 mg|SHR3824 5 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
2580828|NCT02361138|Experimental|Cohort SHR3824/Placebo 10 mg|SHR3824 10 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
2580830|NCT02361138|Experimental|Cohort SHR3824/Placebo 25 mg|SHR3824 25 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
2580832|NCT02361138|Experimental|Cohort SHR3824/Placebo 100mg|SHR3824 100 mg/day or placebo for 10 days. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohort.
3211422|NCT01005186|Experimental|Active|Active
3211423|NCT01005186|Experimental|Active 2|Active
2580870|NCT02360917|Other|Waitlist|Participants assigned to the control group will be placed on a wait list for the Haze program. While they are waiting for admittance to the program, they will receive the same surveys as the participants who are taking the Haze class. Additionally, participants assigned to the control group will receive the surveys again when taking the class in order to allow comparison of the effects of the program on the control group. Participants assigned to the wait list will be enrolled in the following Haze series.
2580892|NCT02360709||CRE8 group|CRE8 sirolimus-eluting stent
2580920|NCT02360345|Experimental|q1week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1, 8, 15 and 22 of repeated 28-day treatment cycles.
3211424|NCT01005199|Experimental|Arm A: Sorafenib standard|• Arm A (standard treatment): Sorafenib 2 x 400 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (46 patients).
3211425|NCT01005199|Experimental|Arm B: Sorafenib + everolimus|• Arm B (investigational treatment): Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily until progressive disease, unacceptable toxicity, or consent withdrawal. (60 patients)
3211426|NCT01005225||Solid tumors|Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
2580075|NCT02366052|Active Comparator|Nutritional Counseling|The nutritional counseling group will receive dietary counseling focusing on a reduction of fructose intake by a trained nutritionist for 12 weeks every 3 weeks.
2580076|NCT02366052|Experimental|Nutritional Counseling and LCS|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks in addition to the nutritional counseling every 3 weeks.
2580078|NCT02366052|Experimental|Lactobacillus Casei Shirota|The dietary supplement LCS (Lactobacillus casei shirota ) will be given 2 times a day for 12 weeks.
2580109|NCT02365753|Placebo Comparator|SofPulse nonfunctional device.|The Sofpulse non-functional device is placed over the incision after cesarean delivery and then turned on. The device only appears to be function correctly because the lights turn on, but does not emit a pulsed electromagnetic frequency..
2580117|NCT02365753|Active Comparator|Active|The Sofpulse Pulsed electromagnetic frequency device is placed over the incision after cesarean delivery and then turned on. Device appears to be operational and functions correctly.
3211427|NCT01005238|Active Comparator|telbivudine|patients in this arm will continue to take telbivudine
3211428|NCT01005238|Experimental|lamivudine|patients in this arm will take lamivudine
2580263|NCT02364908|Other|Patients with Systemic Lupus|
2580325|NCT02364596|Experimental|1|SA4Ag vaccine
2580354|NCT02364258|Experimental|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
2580359|NCT02364258|Experimental|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
3211429|NCT01005264|Active Comparator|non-removable fiberglass|Softcast3M®, 3M Health Care, St. Paul, MN (USA) were used for construction of the pressure-relief apparatus
3211430|NCT01005264|Active Comparator|Stabil-D®|Composed of a specifically designed rigid, boat shaped, and fully rocker bottom sole
2580541|NCT02362763|Experimental|Study group|Subjects received five acupuncture sessions designed to treat pain in the vulvar area
2580542|NCT02362763|Active Comparator|Controls|Controls received five acupuncture sessions designed for sedation
2580546|NCT02362958|Experimental|Lapatinib and Capecitabine or Vinorelbine|Lapatinib 1250mg qd and Capecitabine 1000mg/m2 bid or Vinorelbine 25mg/m2 iv (d1,d8)
2580594|NCT02362659||Antiplatelet agent plus anticoagulant|an antithrombotic regimen comprising one single antiplatelet agent plus an anticoagulant
2580595|NCT02362659||DAPT alone|an antithrombotic regimen consisting of dual antiplatelet therapy (DAPT) alone
2580596|NCT02362659||DAPT plus anticoagulant|an antithrombotic regimen consisting of DAPT plus anticoagulant therapy
2580600|NCT02362633|Experimental|Real tDCS|Subjects will receive real tDCS treatment for ten times for two weeks (five times per week).
2580602|NCT02362633|Sham Comparator|Sham tDCS|Subjects will receive sham tDCS treatment for ten times for two weeks (five times per week).
2580628|NCT02362347|Active Comparator|Usual care + exercise|Usual care + exercise
2580631|NCT02362347|No Intervention|No care, no exercise|No care, no exercise
2580632|NCT02362347|Experimental|Usual care + exercise + compression vest|Usual care + exercise + London Health Sciences Centre - Compression Vest
2580646|NCT02362295||census|qualitative interview
3211431|NCT01005303|Placebo Comparator|Placebo|
3211432|NCT01005303|Active Comparator|Micronutrient|
2580737|NCT02361684|Experimental|Blended CBT treatment|
2580743|NCT02361684|Active Comparator|Treatment as usual|
2580767|NCT02361489|Active Comparator|Titration Algorithm A|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm A will use a fixed starting dose of either 2 clicks per meal (if on the V-Go 20) or 3 clicks per meal (if on the V-Go 30).
2580771|NCT02361489|Active Comparator|Titration Algorithm B|All patients that are initiated on a V-Go 20 will have a starting bolus dose of 6 clicks (12 units) during the day and all patients who are initiated on a V-Go 30 will have a starting bolus dose of 9 clicks (18 units) during the day. All patients randomized to Algorithm B will have 50% of their initial bolus dose given at the largest meal with less bolus insulin at the other meals as noted below:
2580784|NCT02361242|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate and 1 white capsule containing 6 mg of baclofen are taken orally b.i.d during 24 weeks.
2580785|NCT02361164||Mother/child pair|Mother/child pair.
2580792|NCT02361242|Experimental|PXT00864 Dose 2|1 orange capsule containing 1 mg of acamprosate and 1 white capsule containing 15 mg of baclofen are taken orally b.i.d during 24 weeks.
2580797|NCT02361242|Experimental|PXT00864 Dose 3|1 orange capsule containing 20 mg of acamprosate and 1 white capsule containing 12 mg of baclofen are taken orally b.i.d during 24 weeks.
2580849|NCT02360956|Experimental|Olmesartan medoxomil|Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
2580854|NCT02360956|Active Comparator|Antihypertensive medication|"Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs).~The drug dose must be individualized."
3211433|NCT01005342|Experimental|Mixture of fiber|Single intake of a mixture of spray-dried oat drink, rye bran and sugar beet fiber
3211434|NCT01005342|Experimental|Sugar beet fiber|Single intake of sugar beet fiber
3211435|NCT01005342|Experimental|Rye bran|Single intake of rye bran
3211436|NCT01005342|Experimental|Oat bran|Single intake of oat bran
3211437|NCT01005342|Experimental|Spray-dried oat drink|Single intake of spray-dried oat drink
3211438|NCT01005342|Placebo Comparator|Control|Single intake of a meal with no added fiber
2580025|NCT02366481|Active Comparator|Low-Dose Vitamin K2 (90-mcg/d)|The low-dose vitamin K group will take one 90-mcg vitamin K2 (menaquinone-7) softgel capsule and one placebo softgel capsule every day for 8 weeks.
2580028|NCT02366481|Active Comparator|High-Dose Vitamin K2 (180-mcg/d)|The high-dose vitamin K group will take two 90-mcg vitamin K2 (menaquinone-7) softgel capsules every day for 8 weeks.
3176549|NCT00645177|Active Comparator|A|"In study, this arm is a randomized (blinded) to ABT-869 arm plus paclitaxel.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
3211439|NCT01005368||Group 1|Blood and bone marrow is collected at baseline, 3 months after completion of induction therapy, 2 months after completion of consolidation therapy, 1 year after completion of study treatment, and at disease relapse. Samples are analyzed by FISH for interphase cytogenetics, PCR for IgV_H mutational status, flow cytometry for surface expression of CD38 cells, western blot to assess Mcl-1, Bcl-2, BAK-1, ATM, ZAP-70, and Bar expression, and sequencing for p53 and ATM function.
3211440|NCT01005381|Experimental|Small Particle Size Calcium Carbonate|Subjects are given small particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
2580217|NCT02365116|Experimental|Peer Mentorship intervention|A Peer Specialist will be making weekly follow-up contact with study participants in the community or by telephone for 3 months following hospital discharge. The content of the peer mentorship interactions will be based on the manual developed by the study team and will include components such as hope and belongingness.
2580227|NCT02365116|Active Comparator|Enhanced Usual Care|Patients will continue to receive usual care which typically consists of referral to an outpatient psychiatrist. Participants will also receive a phone call within 24-72 hours from a member of the inpatient unit clinical staff to assess barriers to follow-up care and safety. The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
2580265|NCT02364895|Experimental|Male arm|Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
2580270|NCT02364895|Experimental|Female arm|Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
2580299|NCT02364518|Experimental|Snoreplasty|Treatment of Snoring and/or mild obstructive sleep apnea with snoreplasty.
2580381|NCT02364349|Active Comparator|Bee Venom (BV) group|All subjects are injected with Bee Venom (BV, intervention), randomly assigned to the right or left forearm. Raw BV used dried BV prepared through collection from bee venom sacs and removal of impurities. The BV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
2580386|NCT02364349|Experimental|essential Bee Venom (eBV) group|All subjects are injected with essential Bee Venom (eBV, intervention), randomly assigned to the right or left forearm. eBV was prepared through the following methods: BV was collected from bee venom sacs and dried. LC/MS was used to analyze subdivisions of dried BV dissolved in purified water and passed through a sephadex G-25 column to collect histamine-free units. Collected units were filtered to eliminate allergenic substances including PLA2 of molecular weight 10 kDa or higher. The eBV administration site on each subject was on the palmar side of the designated arm 5 cm below the middle of the elbow crease as it is convenient for observation and has high responsiveness. Pharmacopuncture sessions were also conducted in the morning for higher responsiveness.
2580436|NCT02363751|Experimental|1|Patients will be treated for a maximum of 6 (21 days) chemotherapy cycles (Gemcitabine+platinum salt+bevacizumab)
2580476|NCT02363335|Placebo Comparator|Placebo|Randomized, double blind, placebo-controlled cross-over study
2580479|NCT02363335|Experimental|Roflumilast|Randomized, double blind, placebo-controlled cross-over study
2580482|NCT02363335|Experimental|Roflumilast/Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
2580486|NCT02363335|Experimental|Sitagliptin|Randomized, double blind, placebo-controlled cross-over study
3211441|NCT01005381|Active Comparator|Large Particle Size Calcium Carbonate|Subjects are given a large particle size calcium carbonate supplement twice daily (total of 625 mg/d from supplement).
3211442|NCT01005381|Placebo Comparator|Calcium Placebo|Subjects are given two placebo tablets daily, which are identical to the large and small particle size calcium carbonate supplements.
2580549|NCT02362971||Included|Patients included into the randomized controlled trial
2580557|NCT02362971||Non-consenters|Patients eligible for participation in the randomized controlled trial but did not give their informed consent and thus excluded in the randomized controlled trial.
2580569|NCT02362971||Excluded|Patients, by different reasons excluded from participation in the randomized controlled trial.
3211443|NCT01005381|Active Comparator|No Vitamin D supplement|Subjects are given calcium carbonate supplement once daily (325 mg/d from supplement).
3211444|NCT01005381|Experimental|Vitamin D supplement|Subjects are given a calcium supplement once daily (325 mg/d from supplement) with 1000 IU/d vitamin D supplement.
3211445|NCT01005394||Navigated TMS|single arm study where all subjects will be studied using the Navigated TMS device
3258975|NCT01466335|Placebo Comparator|Placebo|Matching number of identical placebo tablets
2580694|NCT02361970||severe sepsis and septic shock|patients were diagnosed severe sepsis or septic shock
2580697|NCT02361970||patient control|Patients after elective surgeries presented with SIRS but without sepsis
2580700|NCT02361970||volunteer|Health persons
2580751|NCT02361749|Active Comparator|Myectomy group|Subjects will undergo anal myectomy for their anal sphincter.
2580876|NCT02360722|Experimental|Oral Nutritional Supplement|ONS + Nutritional education
2580071|NCT02366065|Experimental|Acetaminophen|study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
2580133|NCT02365805|Active Comparator|Standard FEC Regimen|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel
2580134|NCT02365805|Experimental|No or Low BRCA1 expression|Epirubicin + Cisplatin + Fluorouracil
2580135|NCT02365805|Experimental|Normal or High BRCA1 expression|Docetaxel + Ciclofosfamide
2580187|NCT02365272|Active Comparator|amikacin standard dose|amikacin in a single standard dose
2580195|NCT02365272|Active Comparator|amikacin dose for critical care patients|amikacin in a single dose for critical care patients
2580277|NCT02365012|Placebo Comparator|Placebo|Placebo given three times a day for 2 weeks
2580280|NCT02365012|Active Comparator|Midodrine|Midodrine 2.5 mg given three times a day for one week followed by 5 mg given three times a day for one week
2580296|NCT02364531||Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
3211446|NCT01005420|Experimental|Blueberry Powder|"A blueberry smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~206.4 Kcals~40.3 g Carbohydrate~11.5 g Protein~0.08 g Fat~0.05 g Sat fat~4.2 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~22.5 g Freeze-dried blueberry powder~5.0 g Imitation vanilla flavor~1.0 g Splenda~16 oz plastic cup with lid~Smoothie total weight - 378.5 g"
2580424|NCT02363647|Experimental|Tumor Genomic Analysis|Personalized Therapy Plan Patients with Metastatic Medullary or Colon Cancer being treated with the Personalized Treatment Plan developed during the different tumor genomic analysis study.
3211447|NCT01005420|Placebo Comparator|Placebo|"A placebo smoothie will be consumed at the breakfast and dinner meals.~Nutritional Value:(based on one 16oz smoothie and subjects had to consume two a day)~201.3 Kcals~40.3 g Carbohydrate~10.7 g Protein~0.08 g Fat~0.05 g Sat fat~4.3 g Fiber~Ingredients:~245.0 g Dannon Light & Fit yogurt~105 .0 g Skim milk~5.0 g Benefiber~12.0 g Sugar~4.0 g Artificial blueberry flavor(liquid & powder)~1.5 g Red food color~0.7 g Blue food color~16 oz plastic cup with lid~Smoothie total weight - 373.2 g"
3258976|NCT01466374|Experimental|Cohort 1: Induction|Placebo
2580607|NCT02362854|Active Comparator|Conventional peri-implantitis treatment|Peri-implantitis treatment according to the Cumulative interceptive supportive (CIST) therapy.
2580608|NCT02362854|Experimental|DL application in peri-implantitis|Adjunct Diode Laser application.
2580610|NCT02362490|Experimental|peginterferon alpha 2a|in this group, patients who were on treatment of Nucleoside (Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will switch to treatment of peginterferon alpha 2a for 72 week.
2580619|NCT02362490|No Intervention|control group|in this group, patients who were on treatment of Nucleoside(Acid) Analogues and had achieved HBsAg level ≤250 IU/ml will be continue to treatment of Nucleoside(Acid) Analogues for 72 week.
2580667|NCT02362126||Patients undergoing EFTR|Patients with non-lifting adenomas, adnomas at difficult anaotomic locations , T1-carcinomas or submucosal colorectal tumors
2580686|NCT02362217|Experimental|Group 1|"Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
2580688|NCT02362217|Experimental|Group 2|"Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8.~Subjects: 8 healthy volunteers."
2580689|NCT02362217|Experimental|Group 3|"Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8.~Subjects: 16 healthy volunteers."
2580708|NCT02361866|Experimental|GC1107|0.5ml, intramuscular, a single dosing
2580709|NCT02361866|Active Comparator|Tetanus and Diphtheria(Td vaccine)|0.5ml, intramuscular, a single dosing
2580744|NCT02361554|Experimental|Deep Brain Stimulation Implant|Unblinded treatment arm, deep brain stimulation of the substantia nigra pars reticulata for treatment resistant schizophrenia.
2580760|NCT02361619|Experimental|1|
2580788|NCT02361333|Experimental|Teaching Intervention|Patients will be taught how to install and use a remote monitor.
2580793|NCT02361333|No Intervention|No Intervention|Patients will not be taught how to install and use a remote monitor
2580823|NCT02361151|Active Comparator|TECH (standard program)|"Receive 3-month healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with paper records; based on standard behavior change recommendations and materials (e.g., Diabetes Prevention Program)~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities and self-monitoring."
2580824|NCT02361151|Experimental|TECH+ (enhanced program)|"Receive 3-month family-based healthy eating and physical activity intervention delivered via email newsletters and mobile apps plus self-monitoring with special study website~Intervention: remotely-delivered evidence-based intervention to support healthy eating and physical activity; use of supporting app-based games and activities; enhanced self-monitoring and family activities via special study website"
2580862|NCT02360826|Experimental|Pravastatin|Pravastatin 20mg tablet (age 8-13 years), 40mg tablet (>14 years); 1 time dose given per oral at at the start of the study day.
2580866|NCT02360826|Experimental|Simvastatin|Simvastatin 10mg tablet (ages 8-13 years), 20mg tablet (>14 years); 1 time dose given per oral at the start of the study day.
2580879|NCT02360722|Other|Control Group|Nutritional education only
2580910|NCT02360514|Experimental|hantaan virus vaccine|
2580916|NCT02360423|Experimental|CRE8 group|CRE8 sirolimus-eluting stent system
2580917|NCT02360423|Active Comparator|RESOLUTE group|RESOLUTE zotarolimus-eluting stent system
3211448|NCT01005433|Active Comparator|Dexmedetomidine 0.6 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
3211449|NCT01005433|Active Comparator|Dexmedetomidine 0.4 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 4 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia
2580499|NCT02363400|Experimental|Adjuvant Chemotherapy|MEP followed by oral Tegafur-uracil
2580503|NCT02363400|No Intervention|control arm|closely followed with frequency similar to the experiemental arm
2580552|NCT02362984|Placebo Comparator|Control Group|Placebo will be administered orally, 3 x 1 tablet daily, for 8 days of study period
2580558|NCT02362984|Experimental|DLBS1033 Group|DLBS1033 will be administered orally, 3 x 1 tablet daily, for 8 days of study period
2580587|NCT02363088|No Intervention|No intervention, 30-64 years|No intervention group 30-64 years, Women will receive the written invitation to screening only
2580588|NCT02363088|Experimental|Neutral text message reminder, 30-64|Neutral Text message, group 30-64 years
2580589|NCT02363088|Experimental|Messenger text message reminder, 30-64|Messenger text message reminder, group 30-64
2580590|NCT02363088|Experimental|Social Norms A reminder, 30-64|Social Norms (population proportion) text message reminder, group 30-64 years
2580591|NCT02363088|Experimental|Social Norms B reminder, 30-64|Social Norms (population total) text message reminder, group 30-64 years
2580592|NCT02363088|Other|Framed gain text reminder, 30-64|Framed gain text message reminder, group 30-64 years
2580593|NCT02363088|Experimental|Framed loss text reminder, 30-64|Framed loss text message reminder, group 30-64 years
2580611|NCT02362529|Experimental|Minocycline|The dose of minocycline would be 50mg per day on week 1, 50mg bid on week 2 and 100mg bid weeks 3-8. For tapering, the dose will be reduced to 50mg bid for a week, and then stopped.
2580618|NCT02362529|Placebo Comparator|Placebo|The number and appearance of the pills would be identical to those in the minocycline arm.
2580625|NCT02362529|Other|Celecoxib|This will be an open label trial for those with Hamilton Depression Rating Scale score ≥ 8 following the minocycline v. placebo trial or those not eligible for Phase 2. Dose of celecoxib will be 100 mg bid for the first week and 200mg bid for weeks 2-8. For tapering, the dose of celecoxib will be reduced to 100mg bid for one week, and then stopped.
3211450|NCT01005433|Active Comparator|Dexmedetomidine 0.2 µg/kg/h|The dexmedetomidine group will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia.
3211451|NCT01005433|Placebo Comparator|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 20 min before induction of anesthesia
2580671|NCT02362061||pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they became pregnant
2580672|NCT02362061||Non pregnant|These patients are then assigned to receive fertility treatment (ovulation induction, ICSI, intrauterine insemination and IVF). They undergo a 3D vaginal ultrasound before treatment to measure the junctional zone thickness and followed up after treatment to determine the rate of implantation and they remained non pregnant
2580738|NCT02361840||Exposed cohort: TI>0.05ng/ml|We call Exposed group to increased TI > or = 0.05ng/ml We call Event to the onset of ARDS
2580739|NCT02361918||Anastomotic leakage|Patient had anastomotic leakage
2580749|NCT02361840||No Exposed cohort: TI<0.05ng/ml|We cal no Exposed group to increased TI (<0.05ng/ml) We call Event to the onset of ARDS
2580750|NCT02361918||No anastomotic leakage|Patient had no anastomotic leakage
2580778|NCT02361281||Sarcoidosis patients|Clinically relevant sarcoidosis patients with different stages and treatments.
2580779|NCT02361281||Healthy controls|Healthy people without any pulmonary conditions
3211452|NCT01005446||RSP Device|Post Market Study
3211453|NCT01005472|Experimental|sunitinib malate, temozolomide|
2580836|NCT02361112|Experimental|pyrotinib combined with capecitabine|
2580863|NCT02360904|Experimental|start yoga classes immediately|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence concurrently with the start of chemotherapy.
2580868|NCT02360904|Active Comparator|Start yoga classes after 3 months|12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training that will commence 3 months after start of chemotherapy
2580886|NCT02360748|Experimental|single|Pilot Study in which patients will be adding food items to improve their nutritional status
3211454|NCT01005485||Group A|Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
2580921|NCT02360527||Type 2 diabetic patients with AD|35 patients
2580923|NCT02360527||Type 2 diabetic patients with MCI|35 patients
2580927|NCT02360527||Type 2 diabetic patients controls|35 patients
2580929|NCT02360527||Non-diabetic patients with AD|35 patients
2580934|NCT02360579|Experimental|Cohort 3|Retreatment cohort: patients from Cohort 1, Cohort 2 or Cohort 4 may rescreen for a second TIL regimen therapy if they meet all Inclusion and Exclusion Criteria (except exclusion criterion b).
2580936|NCT02360579|Experimental|Cohort 4|Cryopreserved lifileucel (LN-144) (Gen 2 infusion product)
2580954|NCT02360176|Experimental|Sleeve gastrectomy single port|Sleeve gastrectomy single port
2580955|NCT02360176|Active Comparator|Sleeve gastrectomy multi trocar|Sleeve gastrectomy multi trocar
2580962|NCT02360072||Control group|non-atopic subjects with neither a history of rhinitis nor asthma
3211455|NCT01005485||Group B|Healthy controls will be recruited from the general medical population, community.
3211456|NCT01005485||Acute Myocardial Infarction|Patients with acute myocardial infarction with or without ST segment deviation.
3211457|NCT01005498|Experimental|Low carbohydrate diet (F)|The group attended to low carbohydrate diet
3211458|NCT01005498|Active Comparator|Traditional diet (K)|The group attended to traditional diet
3211459|NCT01005511|Experimental|Grindcare|24 patients receiving active treatment
3258977|NCT01466374|Experimental|Cohort 2: Induction|Anti-IP-10 Antibody
2580122|NCT02365727|Experimental|Exparel plus Adductor Canal Block|Adductor canal block with 20 cc 0.5% Ropivacaine with 1:400,000 epinephrine and 100mcg of clonidine
2580125|NCT02365727|Placebo Comparator|Exparel plus Placebo Block|Adductor canal block with 20 cc saline
2580216|NCT02365363|Experimental|Bagel control|100% wheat flour
2580229|NCT02365363|Experimental|Bagel with pea flour|Pea flour (30%)
2580232|NCT02365363|Experimental|Bagel with pea fibre|Pea fibre (11g)
2580237|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre|Pea flour (30%) + pea fibre (11g)
2580238|NCT02365363|Experimental|Bagel w/ pea flour + pea protein|Pea flour (30%) + pea protein (24g)
2580239|NCT02365363|Experimental|Bagel w/ pea flour + pea fibre + pea protein|Pea flour (30%) + pea fibre (11g) + pea protein (24g)
2580278|NCT02364791|Active Comparator|standard treatment|standard techniques to achieve air leak control after complex thoracic surgical procedures
2580282|NCT02364791|Experimental|standard treatment plus hemopatch|the addition of hemopatch to standard techniques to achieve air leak control after complex thoracic surgical procedures
3211460|NCT01005511|Placebo Comparator|Placebo treatment|24 patients receive a placebo treatment
3211461|NCT01005550|Experimental|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
2580448|NCT02363634|Active Comparator|Magnesium threonate (Magtein)|Those randomized to receive the Magtein
2580449|NCT02363634|Placebo Comparator|Placebo|Those randomized to placebo
2580483|NCT02363309||Healthy Volunteers|Subjects without liver disease or metabolic syndrome
2580488|NCT02363309||NAFLD subjects|Subjects with Non-Alcoholic Fatty Liver Disease
2580491|NCT02363309||non-NAFLD metabolic syndrome|Subjects who have metabolic syndrome but do not have Non-Alcoholic Fatty Liver Disease
2580604|NCT02363114||Stroke Prevention Clinic Patients|All consecutive patients presenting to six high volume Regional Stroke Prevention Clinics.
2580605|NCT02362815|No Intervention|Control|Patient are not allowed to drink
2580635|NCT02362308||Adrenalectomy|Subjects will undergo assessment before and after adrenalectomy for treatment of primary aldosteronism
2580637|NCT02362308||Medical Therapy|Subjects will undergo assessment before and after medical treatment of primary aldosteronism
3211462|NCT01005550|Experimental|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
3211463|NCT01005550|Experimental|10 mg of ropivacaine|10 mg of ropivacaine are used for the spinal anaesthesia
2580690|NCT02362035|Experimental|ACP-196 (Acalabrutinib) +PEM|"PART 1 & PART 2- Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) in combination with Pembrolizumab 200 mg will be administered every 3 weeks (Q3W) by IV infusion.~PART 3 - Acalabrutinib 100 mg will be orally administered (PO) twice daily (BID) for 6 weeks followed by continuation of acalabrutinib monotherapy or combination therapy with acalabrutinib 100mg BID and pembrolizumab 200 mg Q3W as per Investigator discretion."
2580717|NCT02361801|Active Comparator|Liberal dobutamine group|All patients will receive dobutamine at the cardiopulmonary bypass weaning
2580719|NCT02361801|Active Comparator|Restrictive dobutamine group|Patients will only receive dobutamine if they present clinical signs of cardiogenic shock
2580721|NCT02361567|Active Comparator|Tramacet|Tramacet 1-2 tabs PO q4h prn
2580722|NCT02361567|Active Comparator|Percocet|Percocet (5/325) 1-2 tab PO q4h PRN
2580726|NCT02361515|Active Comparator|Moderate Hypofractionated radiotherapy (62Gy)|20 fractions of 3.1Gy
2580732|NCT02361515|Experimental|Stereotactic radiotherapy (37.5Gy)|5 fractions of 7.5Gy)
2580780|NCT02361268|Experimental|Intra-dialysis yoga|The experimental intervention in this study is intra-dialysis yoga.
2580781|NCT02361268|Active Comparator|Educational program|The active comparator for the study is an educational program.
2580861|NCT02361060|Experimental|Sugammadex|sugammadex 4 mg/kg
2580867|NCT02361060|Active Comparator|Neostigmine + Atropine|Neostigmine 40µg/kg in combination with atropine 10µg/kg.
2580871|NCT02361047|Experimental|Phone Coaching Program|Participants will receive a nutrition and physical activity phone coaching program, in addition to standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
2580872|NCT02361047|No Intervention|Standard Care Control|Participants will receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
2580893|NCT02360657|Experimental|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
2580897|NCT02360657|Placebo Comparator|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
2580909|NCT02360501|Experimental|treatment arm|docetaxel 75mg/㎡,d1; cisplatin 25mg/㎡,d1-3; capecitabine 2g/㎡, d1-14. repeated every three weeks
2580922|NCT02360462|Experimental|Active tDCS|Active tDCS will be applied in the head of the patients in 20 minute sessions, twice. First session will be applied in the night before and the second session, in the morning before the surgical procedure. The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current
2580924|NCT02360462|Sham Comparator|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
3211464|NCT01005550|Experimental|12 mg of ropivacaine|12 mg of ropivacaine are used for the spinal anaesthesia
3211465|NCT01005563|Experimental|Arm 1: Beef/Pork|Participants consuming diet with beef/pork as predominate sources of protein
3211466|NCT01005563|Experimental|Arm 2: Soy/Legumes|Participants consuming diet with soy/legumes as predominate sources of protein
3211467|NCT01005615|Sham Comparator|No FES Cycling|
3211468|NCT01005615|Active Comparator|FES Cycling|
3211469|NCT01005628||001|bortezomib Injection into a vein 1.3 mg/m2 twice a week for 21 days
3211470|NCT01005641|Experimental|A|phase II
2580139|NCT02365818|Experimental|CG0070|Single arm intervention with CG0070 to be given at a dose of 1e12 vp weekly for six weeks. Patients who achieve a partial response or a complete response at 6 months post first intravesical intervention will be maintained with the same induction cycle of weekly times six. Patients will be followed every 3 months through Month 24.
2580174|NCT02365259|Experimental|Phototherapy|This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.
2580175|NCT02365259|Placebo Comparator|Shame phototherapy|This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.
2580212|NCT02365103|Other|Test meal I (given with water)|Test meal with water
2580218|NCT02365103|Other|Test meal II (simultaneously with tea)|Test meal with tea (simultaneously)
2580223|NCT02365103|Other|Test meal III (1 hour after test meal)|Test Meal with tea given 1 hour after test meal
2580231|NCT02365103|Other|Reference Iron Dose|Reference iron dose administered
2580266|NCT02364817||Post-Detox Cohort|"All the patients included should meet Diagnostic and Statistical Manual 4th edition revised (DSM-IV-Tr) criteria for Alcohol Dependance. They are all recruited at the end of an inpatient alcohol detoxification process (see inclusion criteria).~The initial screening is performed just before the end of hospitalization. The subsequent follow-up is 12 weeks-long. There is no drug for abstinence maintenance during the study. The psychosocial intervention is based on the BRENDA model."
2580309|NCT02364622|Sham Comparator|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by traditional fiberoptic bronchoscopy.
2580310|NCT02364622|Experimental|Modified fiberoptic bronchoscopy|The accurate placement of left-sided double lumen endobronchial tube into the left main bronchus was facilitated by modified fiberoptic bronchoscopy.
2580321|NCT02364622|Experimental|Flexible Trachway intubating stylet|We used Flexible Trachway intubating stylet to facilitate the accurate placement of left-sided double lumen endobronchial tube into the left main bronchus.
2580353|NCT02364284||Urinary Tract Infection (cUTI)|Patients ≥18 years with diagnosis of urinary tract infection.
2580356|NCT02364284||Intra Abdominal Infection(cIAI)|Patients ≥ 18 years with diagnosis of Intra Abdominal Infection
2580361|NCT02364284||Nosocomial Pneumonia (NP)|Patients ≥ 18 years with diagnosis of Hospital acquired pneumonia
2580402|NCT02363764||Expectorating CF patients|"(=able to expectorate sputum spontaneously)~Nasal swab~Cough swab~Spontaneous expectorated sputum~Questionnaire"
2580403|NCT02363764||Non-expectorating CF patients|"(=unable to expectorate sputum spontaneously)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Questionnaire"
2580405|NCT02363764||Bronchoscopy CF patients|"(=undergoing clinically indicated bronchoscopy)~Nasal swab~Cough swab~Induced sputum after inhalation of hypertonic saline (NaCl 6%)~Bronchoalveolar lavage (BAL)"
2580487|NCT02363374|Active Comparator|Arm A: Chemotherapy -> Chemoradiotherapy|Induction chemotherapy followed by chemoradiotherapy before surgery
2580494|NCT02363374|Experimental|Arm B: Chemoradiotherapy -> Chemotherapy|Combined chemoradiotherapy followed by three cycles chemotherapy before surgery
2580543|NCT02362776||breast cancer patients|
2580544|NCT02362776||lung cancer patients|
2580545|NCT02362776||control subjects|
2580584|NCT02362620||Docetaxel|Docetaxel 75mg/m2 IV every 3 weeks
2580586|NCT02362620||Cabazitaxel|Cabazitaxel 20-25mg/m2 IV every 3 weeks
3211471|NCT01005667|Experimental|BirthTrack Monitor|
2580660|NCT02362256|Experimental|Intervention|"Opioid antagonist induction. Day 4. Duration 12-16 hours.~Naltrexone gradual increase from 50 µg p/o to a total dose of 12,5 mg according to a predefined protocol:~st hour 50 µg~nd hour 50 µg~rd hour 100 µg~th hour 100 µg~th hour 200 µg~th hour 400 µg~th hour 800 µg~th hour 1600 µg~th hour 3200 µg~th hour 6000 µg~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
2580661|NCT02362256|Active Comparator|Control|"Opioid antagonist induction. Day 4. Duration 12-16 hours. Naltrexone single dose 12,5 mg p/o~Correction of symptoms for opioid abstinence:~Clonidine 150 µg p/o every 4 hours (Day 3 and Day 4) Lorazepam 5 mg p/o every 4 hours (Day 3 and Day 4), Lorazepam 2,5 mg po every 4 hours (Day 5, Day 6)"
2580747|NCT02361905|Experimental|Ulipristal acetate|women will be treated with an oral dose of ulipristal acetate 5 mg/day for 3 months
2580757|NCT02361905|Active Comparator|Leuprolile acetate|Women will be treated with an intramuscular (IM) injection of leuprolide acetate 11.25 mg in the luteal phase
3211472|NCT01005667|No Intervention|Control - no BirthTrack Monitor|
3211473|NCT01005771|Experimental|GF-001001-00 2%|
2580834|NCT02361190|Placebo Comparator|Placebo nasal spray|Subjects will inhale approximately 40ml aqueous solution via intranasal route
2580835|NCT02361190|Experimental|Testosterone nasal spray|Subjects will inhale approximately 40ml aqueous, testosterone-containing solution via intranasal route
2580858|NCT02361034|Active Comparator|GRC 27864|Test treatment GRC 27864
2580859|NCT02361034|Placebo Comparator|Placebo|Placebo treatment
2580895|NCT02360735|Active Comparator|Control|Patients randomized to this arm will follow the current standard for post-operative care.
2580896|NCT02360670|Placebo Comparator|Control imaging (NCCT)|Standard imaging
2580899|NCT02360735|Experimental|Experimental|Patients randomized to this arm will follow the current standard for post-operative care as well as 2 daily sessions of manual lymphatic drainage.
2580900|NCT02360670|Experimental|additional multimodal imaging|CT + CTA + CTP
2580912|NCT02360332|Experimental|PS-ASD|Treatment Condition, participants assigned to this condition will receive the treatment, one school year (9 months) of Project SEARCH plus ASD Supports
2580913|NCT02360332|No Intervention|High School As Usual|Control Condition, Participants assigned to this condition will have no interaction or intervention with the research team with the exception of data collection at the specified time points.
3211474|NCT01005771|Experimental|GF-001001-00 1%|
3211475|NCT01005771|Experimental|GF-001001-00 0.25%|
3211476|NCT01005771|Placebo Comparator|Placebo|
3211477|NCT01005784|Active Comparator|fixed|
3211478|NCT01005784|Experimental|flexible|
3258978|NCT01466374|Experimental|Cohort 3: Induction|Anti-IP-10 Antibody
2580156|NCT02365766|Experimental|Arm C - Phase II Cohort II:|Cisplatin-ineligible subjects receive gemcitabine every week every 28 days for 3 cycles. Pembrolizumab at RP2D is given every 21 days for 5 doses starting C1D8. NOTE: due to the timing of gemcitabine cycles every 4 weeks, and every 3-week dosing of pembrolizumab, there are two doses of pembrolizumab given during cycle 2: D1 and D22. Additionally, the last dose of pembrolizumab falls on what would be D8 of a 4th 'chemo' cycle; however gemcitabine is NOT GIVEN. Subjects will then have consolidative surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
2580197|NCT02365168|Experimental|Food Challenge with cod|
2580204|NCT02365168|Experimental|Food Challenge with salmon|
2580207|NCT02365168|Experimental|Food Challenge with mackerel|
2580209|NCT02365168|Placebo Comparator|Food Challenge with placebo|
2580252|NCT02364882|Placebo Comparator|1|1 g (placebo) 0 mg sildenafil 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
2580255|NCT02364882|Active Comparator|2|1 g 50 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
2580257|NCT02364882|Active Comparator|3|2 g 100 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
2580259|NCT02364882|Active Comparator|4|4 g 200 mg sildenafi 50% external (i.e. labia minora and clitoral area) / 50% intravaginal
2580323|NCT02364648|Experimental|MitoQ|4 week 20mg oral daily dose of MitoQ
2580328|NCT02364648|Placebo Comparator|Placebo|4 week 20mg oral daily placebo
2580351|NCT02364232|Experimental|Home-based|"Participants in home-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the home-based training, a four-week wash-out period followed. Then, patients will receive the clinic-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
2580352|NCT02364232|Active Comparator|Clinic-based|"Participants in clinic-based training graoup will receive 1.5 hours/ day, 3 days a week, for 4 contious weeks at home. Participants will receive 2 training stages, including bilateral training with mirror feedback for 30-45 minutes and functional training for 45-60 minutes. Each training stage hase to include above 2 activities.After the end of the clinic-based training, a four-week wash-out period followed. Then, patients will receive the home-based training for 4 continuous weeks.~Before and after the treatment, a total of 4 evaluations were conducted, including clinical assessments and blood test (each 9c.c.). One month after the end of the course of treatment will be assessed."
2580404|NCT02363725|Other|Conventionnal treatment|"Optimal conventional treatment used for patients admitted for STEMI (ESC guidelines 2012):~Double anti-aggregation~IEC (or sartan) at best tolerated dose~Beta-blocker at best tolerated dose~High dose statin (usually atorvastatin 80 mg daily)~If ventricular dysfunction; inhibitor minérolcorticoïdes (the eplerenone more often)~Any other treatment will be logged."
2580406|NCT02363725|Experimental|Conventionnal + Colchimax®|Optimal conventional treatment + Colchimax®
2580444|NCT02363543|Active Comparator|Hyalomatrix|Sterile, single use, flexible, and conformable wound dressing comprised of a derivative of hyaluronic acid which acts as a three dimensional regenerative matrix.
2580447|NCT02363543|Active Comparator|Integra|Sterile, single use, wound care dressing comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan
2580510|NCT02363348|Placebo Comparator|Placebo (A)|"were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same.~dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner."
2580512|NCT02363348|Experimental|L arginine (B)|were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.
2580573|NCT02362945|Experimental|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl (sodium chloride)0.9% solution IV). ( the oxytocin is the routine practice in our department).
2580574|NCT02362945|No Intervention|Control:|Treatment with oxytocin after fetal extraction (10 units in 100ml NaCl 0.9% solution IV). as commonly given for Post-Partum Hemorrhage (PPH) at our obstetrical ward.Active Comparator: (this is the routine practice in our department).
3211479|NCT01005797|Experimental|Expansion A|Expansion A -RCC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
3211480|NCT01005797|Experimental|Expansion B|Expansion B -NSCLC cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 given on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
3211481|NCT01005797|Experimental|Expansion C|Expansion C -STS cohort expansion phase at RP2D: Sorafenib bid daily continuously from cycle 1 (28 day cycle), LBH589 on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of a 28 day cycle.
2580670|NCT02361996||Aortic Valve Replacement|"inclusion criteria:~presence of aortic valve disease (stenosis) with clinical indication for aortic valve replacement without coronary vessel stenosis above 50%~list of medication timely related to the procedure~signed informed consent~exclusion criteria:~intolerance to contrast agent~multiple myeloma, pheochromocytoma, thyroid dysfunction, acute infection~renal failure~severe arrhythmia~pregnancy~reduction of cognitive capabilities to understand the purpose and the extent of the study~participation in a medical-scientific study using X-rays in the last ten years~lack of Russian knowledge to fill the forms~lack of signed study agreement"
2580710|NCT02361853||Active labor at term|Women in active labor normal pregnancy at term
2580712|NCT02361853||Non-active labor at term|"Women, normal pregnancy at term who come for usual follow up without signs for labor ( contraction / show discharge/ rupture of membranes)."
2580713|NCT02361853||Active labor, pre-term|Women in active pre term labor (34- 37w) normal pregnancy.
2580842|NCT02360930||Tanner Stage </=2|Patients will be stratified by phase of treatment, and they will be classified into Tanner stage ≤ 2 or ≥ 4, based on physical examination. We plan to have 15 patients in Tanner staging ≤ 2 and 15 patients in Tanner staging ≥ 4.
3211482|NCT01005823|Active Comparator|LEO 29102 cream 0.3 mg/g|
3211483|NCT01005823|Active Comparator|LEO 29102 cream 1.0 mg/g|
3211484|NCT01005823|Active Comparator|LEO 29102 cream 2.5 mg/g|
2580333|NCT02364440|Experimental|Ultherapy™ System|Ultherapy™ System
2580344|NCT02364206|Experimental|LY2228820 + TMZ + Radiotherapy|"addition of LY2228820 to standard radiotherapy and concomitant treatment by temozolomide (TMZ).~LY2228820 will be administered orally for two 28 day cycles, from one week before the beginning of radiotherapy, and during standard chemoradiotherapy. Three dose levels of LY2228820 will be tested.~After a 4 week break after concomitant treatment, patient were then received up to 6 cycles of adjuvant TMZ according to the standard 5-day schedule every 28 days ."
3211485|NCT01005823|Placebo Comparator|LEO 29102 placebo cream|
3211486|NCT01005836|Experimental|Cognitive-behavioral therapy: Anxiety|CBT for child anxiety. Coping Cat.
2580452|NCT02363582|No Intervention|Breast fed|healthy term infants on exclusively breast feeding , enrollment age: 30-50days old
2580453|NCT02363582|Experimental|Formula fed|healthy term infants on exclusively formula fed , enrollment age: 30-50days old
2580509|NCT02363205|No Intervention|control|Weekly check-up
2580513|NCT02363205|Experimental|internet-delivered CBT|Tailored Internet-administrated CBT-Treatment
2580559|NCT02362997|Experimental|Diffuse large B cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
2580568|NCT02362997|Experimental|Classical Hodgkin lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
2580572|NCT02362997|Experimental|Peripheral T cell lymphoma|Pembrolizumab 200mg IV every 3 weeks up to 8 cycles
2580614|NCT02362477|Active Comparator|Control CPT|'Cognitive Processing Therapy in-person. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
2580621|NCT02362477|Experimental|Experimental CPT via VTC|'Cognitive Processing Therapy through videoteleconference. Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
2580665|NCT02362100|Placebo Comparator|nonoperative management|"Treatment will consist of sling immobilization for a period of 6 weeks. Details and treatment timeline as follows:~0 - 3 weeks: immobilization with a shoulder sling, range of motion of elbow, hand and wrist~3 - 6 weeks: same as 0-3 weeks, with addition of pendulum exercises every two hours~After 6 weeks: Active mobilization and removal of sling. Light activity permitted and physiotherapy for range of motion permitted as tolerated.~After 6 months: no further restriction will be placed. Full home and work activity permitted."
2580666|NCT02362100|Active Comparator|locking plate surgical fixation|"Standardized operative management protocol as follows:~Pre-operative medical clearance established via anesthesia consults if required for medically complex patients.~Provision of pre-operative intravenous (IV) antibiotic prophylaxis:~Administration of general anesthetic.~Patient positioning and preparation:~Patient is carefully placed in the beach-chair position,~Deltopectoral approach Fracture reduction and fixation with confirmation with intraoperative fluoroscopy images."
2580711|NCT02361892|Experimental|Ulipristal acetate|Women will be treated with 5mg/die of Ulipristal acetate for 2 courses of 3 months each
2580718|NCT02361827||C, Vitamin D replete|Vitamin D level on the day of HCG administraion > 30 ng/mL Embryo transfer after oocyte retrieval.
2580746|NCT02361502|Placebo Comparator|placebo|mirabegron placebo qd
2580756|NCT02361502|Experimental|mirabegron|mirabegron 50mg qd
2580764|NCT02361528|Experimental|Leukine|Sargramostim: Leukine (Genzyme USA), 125µg/m2 , once per day during 5 days, by subcutaneous route
2580765|NCT02361528|Placebo Comparator|placebo|placebo, once per day during 5 days by subcutaneous route
2580810|NCT02361086|Experimental|Regimen 1: 7dayPM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week with a 2-week dose titration.
2580814|NCT02361086|Experimental|Regimen 2: 7dayPM-DT|VT-464: given orally once daily in 28 day cycles. Dosing in the evening before bed 7-days a week without dose titration.
2580817|NCT02361086|Experimental|Regimen 3: 7dayAM+DT|VT-464: given orally once daily in 28 day cycles. Dosing in the morning 7-days a week with a 2-week dose titration.
2580819|NCT02361086|Experimental|Regimen 4: 7dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 7-days a week without dose titration.
2580821|NCT02361086|Experimental|Regimen 5: 5dayPM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the evening before bed 5-days a week without dose titration.
2580822|NCT02361086|Experimental|Regimen 6: 5dayAM-DT|VT-464: given orally once daily in 28 day cycles.Dosing in the morning 5-days a week without dose titration.
2580865|NCT02360917|Experimental|Intervention|Participants in the intervention group will undergo 6 weeks of psycho-educational classes provided in a live setting at Cedars Sinai and a web based setting at The University of Kansas. Each class will focus on a different realm of coping with chemo-brain.
3211487|NCT01005836|Other|Usual care: Anxiety|Usual clinic care
3211488|NCT01005836|Experimental|Cognitive behavioral therapy: depression|CBT for youth depression. The Primary and Secondary Control Enhancement Training protocol.
3211489|NCT01005836|Other|Usual care: Depression|Usual clinic care for depression
3211490|NCT01005849|Experimental|Protecflor|
3211491|NCT01005849|Placebo Comparator|Placebo|
3211492|NCT01005862|Experimental|PF-04360365|
3211493|NCT01005862|Placebo Comparator|Placebo|single dose administered intravenously
3211494|NCT01005927|Placebo Comparator|No Fructooligosaccharide|0 g fructooligosaccharide added to calcium-containing beverage
3211495|NCT01005927|Active Comparator|3 g Fructooligosaccharide|3 g fructooligosaccharide added to calcium-containing beverage
3211496|NCT01005940|Experimental|Mandibular advancement device|Subject is evaluated when receiving intervention with mandibular advancement device.
3258979|NCT01466374|Experimental|Cohort 1: Maintenance|Placebo
2580287|NCT02364713|Experimental|Arm A (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2580288|NCT02364713|Active Comparator|Arm B (DOXIL, GEM, TOPA, TAXOL)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 1 hour on day 1, or gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15, or paclitaxel IV over 1 hour on days 1, 8, and 15. Patients may also receive bevacizumab IV over 30-90 minutes on days 1 and 15 with pegylated liposomal doxorubicin hydrochloride, topotecan hydrochloride, or paclitaxel. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3211497|NCT01005940|No Intervention|No mandibular advancement device|Subject is evaluated when not receiving treatment with mandibular advancement device.
3211498|NCT01005953||Professionals treating autistic children|Special educators, occupational therapists, speech pathologists, behavior analysts who work with children on the spectrum.
3211499|NCT01005953||Families with autistic children (3-10)|
3211500|NCT01005979|Experimental|A|
3211501|NCT01005992|Experimental|Laser treated scar|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
3211502|NCT01005992|Active Comparator|Standard scar management|The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
3211503|NCT01006031|Experimental|PegIFN alfa-2a and Ribavirin|HIV-coinfected patients with compensated cirrhosis by hepatitis C virus, genotype 1 or 4.
3211504|NCT01006044|Experimental|Vaccination|Autologous Dendritic cells loaded with tumor lysate
3211505|NCT01006057|Experimental|ESRD|
3211506|NCT01006057|Experimental|Mild|
3211507|NCT01006057|Experimental|Moderate|
3211508|NCT01006057|Experimental|Normal|
3211509|NCT01006057|Experimental|Severe|
3211510|NCT01006070||Patients with existing spinal fractures|Myeloma patients with documented x-ray evidence of spinal fractures.
3211511|NCT01006070||Patients without spinal fractures|Myeloma patients with bony disease in the spine without existing fractures.
2580720|NCT02361593|Experimental|Cap group|Patients will receive endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices with assistance of a transparent cap in front of gastroscopy.
2580725|NCT02361593|Active Comparator|Control group|Patients will receive routine endoscopic sclerotherapy(lauromacrogol injection) for esophageal varices(no transparent cap involved).
2580727|NCT02361710||vitamin D deficient patients|Serum 25- (hydroxide) OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
2580731|NCT02361710||vitamin D sufficient patients|Serum 25- (hydroxide) OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (Vitamin D levels are measured on the day of embryo transfer)
2580816|NCT02361385||this is a pilot study|All patients will undergo PET-CT with PBR28, with the CT being localised to one group of joints only
2580829|NCT02361398|Experimental|EIT group|the Individualized PEEP titration by EIT was administered to the patients in the EIT group.
2580831|NCT02361398|No Intervention|control group|If patients are assigned to the control group, the Individualized PEEP Setting was by PEEP-FiO2 table based on ARDS-net protocol.
2580845|NCT02360852|Experimental|A4250|A4250 once daily
2580848|NCT02360800|Experimental|TISSEEL|Spray Fibrin Sealant
2580853|NCT02360800|Active Comparator|CONTROL|Traditional hemostasis and chest closure routine
2580894|NCT02360644|Experimental|Arm 1: Drug Metabolism and Transport|"The aim of Arm 1 is to determine the effect of vitamin D deficiency and repletion on xenobiotic clearance in vivo. The study will evaluate the in vivo function of targeted metabolism and transport pathways in 40 CKD and 18 healthy volunteer subjects (controls) under the influence of a vitamin D depleted state and repeated under a vitamin D replete state with cholecalciferol.~The function of two major phase I drug metabolizing enzymes (CYP2B6, CYP3A), and three transporters [P-gp, MRP2, and MATE1/2K] will be assessed by administering oral bupropion, midazolam, olmesartan, and fexofenadine."
2580898|NCT02360644|Experimental|Arm 2: Vitamin D Pharmacokinetics|The aim of Arm 2 is to determine the effect of CKD on the in vivo function of individual CYP450s responsible for vitamin D metabolism and their functional relevance on the pharmacokinetics of cholecalciferol. A total of 90 CKD subjects will be enrolled [30 per group: group I (CKD stage 1/2), group II (CKD stage 3), and group III (CKD stage 4/5, pre-ESRD)], as well as 30 healthy controls.
2580903|NCT02360696||Peds/Adol Pts w/ FD - CMH GI APT clinic|"Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (> or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.~Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.~Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis."
2580911|NCT02360618|Experimental|Metformin and Simvastatin Treatment|Patients in this group will receive 850 mg of Metformin and 20 mg of Simvastatin daily from the time they are enrolled in the study until the day before their surgery (approximately 12 weeks), in the absence of any safety or tolerability concerns.
2580937|NCT02360592|Active Comparator|1, conventional control group|Entecavir 0.5 mg po daily for 72 weeks
2580938|NCT02360592|Experimental|2, combination and sequential group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks
2580939|NCT02360592|Experimental|3, multitarget group|Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks
3211512|NCT01006083||Low-risk patients, not on APAs|Patients not at risk of coronary and/or cerebrovascular disease, and not consuming APAs
3258980|NCT01466374|Experimental|Cohort 2: Maintenance|Anti-IP-10 Antibody
2580348|NCT02364219|Experimental|Standard + Microdialysis|Study arm in which patients are treated according to standard operating procedures but also receive Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue.
2580349|NCT02364219|Experimental|Prewarm|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
2580350|NCT02364219|Experimental|Prewarm + Microdialysis|Study arm in which patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia and Microdialysis through a small catheter which is inserted into subcutaneous upper arm fatty tissue
3211513|NCT01006083||High-risk patients, not on APAs|Patients at high risk for cardio/cerebrovascular disease (diabetes mellitus, cigarette smoking, hypercholesterolemia, hypertension, morbid obesity), but not taking APAs.
2580538|NCT02362867|No Intervention|Total Knee Replacement|Total knee replacement is indicated for patients suffering from severe knee pain and disability. Specific indications include femoral, tibial and patellar replacement due to degenerative bone disease such as osteoarthritis, rheumatoid arthritis, primary and secondary traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyles, or complications from a previous prosthesis. The Balanced Knee System (BKS) will be used to treat patients undergoing a total knee replacement.
2580575|NCT02362685||metabolic exercise testing|All the subjects referred to performed a metabolic exercise testing.
2580613|NCT02362464|Experimental|1|intradermally given vaccine given at weeks 3, 6, 9, 12, 15 and 24.
3211514|NCT01006083||APA for primary prevention|High-risk patients with cardiovascular risk factors (as above), in whom APA is prescribed as primary prevention of coronary artery disease (CAD).
2580723|NCT02361632|Experimental|Group 1|"Dietary Supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 20% milk added~Coffee with 50% milk added"
2580729|NCT02361632|Experimental|Group 2|"Dietary supplement. Participants drink coffee with or without milk in following order:~Coffee with 20% milk added~Black coffee~Coffee with 50% milk added"
2580734|NCT02361632|Experimental|Group 3|"Dietary supplement. Participants drink coffee with or without milk in following order:~Black coffee~Coffee with 50% milk added~Coffee with 20% milk added"
2580755|NCT02361749|Active Comparator|Botox Group|Subjects will undergo Botulinum toxin injection into their anal sphincter.
2580808|NCT02361255||Drug-induced parkinsonism|subjects with drug-induced parkinsonism
2580813|NCT02361255||antipsychotic treated non-parkinsonian control|subjects treated with antipsychotic but without parkinsonism
2580841|NCT02360865|Experimental|COPD|Acute exercise bouts
2580844|NCT02360865|Active Comparator|Healthy|Acute exercise bouts
2580846|NCT02360891||patients|follow up of patients with amyotrophic lateral sclerosis from the first signs to the end of the disease
2580852|NCT02360891||neurological controls|patients with other neurological disease
2580857|NCT02360891||healthy controls|age matched healthy controls
3211515|NCT01006083||APA for secondary prevention|Patients with a history of a coronary syndrome (stable/unstable angina); MI; transient ischemic attack (TIA)/stroke; severe carotid artery stenosis/stenting; or peripheral vascular disease, on APAs for secondary prevention.
3211516|NCT01006096|Experimental|Erlotinib|
3211517|NCT01006096|Placebo Comparator|Placebo tablets|
3211518|NCT01006148|Experimental|Bone substitute|Enrollees will receive Allogenix Plus(TM), a demineralized bone matrix, to fill in calvarial gaps after cranial vault remodeling and fronto-orbital advancement.
3211519|NCT01006161|Experimental|Low dose SCH 527123|
2580947|NCT02360410|Experimental|Check Yourself App With Feedback|Adolescents complete Check Yourself, an electronic health screening app and receive personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to highlight discrepancies. Primary care providers receive a summary report of health risk behaviors from Check Yourself prior to their adolescent patient's primary care appointment.
2580948|NCT02360410|No Intervention|Usual Care|Participants are asked to complete health risk screening on a tablet computer. No personalized feedback is provided to adolescents and primary care providers do not receive a summary report of the adolescent's health risk behaviors.
2580956|NCT02360033|Experimental|Systemic Therapy|Systemic Therapy deals with the experience in private social systems (e.g. couples. Family, friends) and organizational systems (e.g. work teams), their appraisals and the attitude of the members towards each other within the system. It is analyzed how these systems can lead to the development and maintenance of psychological disorders.
2580959|NCT02360033|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy deals with individual behavior as well as individual attitude, thoughts, appraisals and beliefs, which can have an influence on the development and maintenance of psychological disorders.
2580963|NCT02360046|Other|Higher hydrocortisone dose|Established hydrocortisone replacement therapy plus 10mg of hydrocortisone
2580966|NCT02360046|Other|Lower hydrocortisone dose|Established hydrocortisone replacement therapy plus placebo
2580969|NCT02360150|Experimental|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
3211520|NCT01006161|Experimental|Medium dose SCH 527123|
3211521|NCT01006161|Experimental|High dose SCH 527123|
3211522|NCT01006161|Placebo Comparator|Placebo|
3211523|NCT01006174|Experimental|A|Subjects will be assigned to consume 3 grams soybean oil, 8 grams canola oil, and 20 grams butter that is added to a salad.
3211524|NCT01006174|Experimental|B|Subjects will be assigned to consume 8 grams soybean oil, 20 grams canola oil, and 3 grams butter that is added to a salad.
3211525|NCT01006174|Experimental|C|Subjects will be assigned to consume 20 grams soybean oil, 3 grams canola oil, and 8 grams butter that is added to a salad.
3211526|NCT01006187|Active Comparator|Group 1|1 liposomal lidocaine 4% cream .
3211527|NCT01006187|Active Comparator|Group 2|Vapocoolant spray
3211528|NCT01006187|Active Comparator|Group 3|Rubbing adjacent to the injection site
2580366|NCT02364167|Experimental|Verum acupuncture|Each patient will receive 16 permanent indwelling acupuncture needles, embedded in adhesive tape, bilaterally in addition to standard postoperative analgesia
2580368|NCT02364167|Placebo Comparator|Placebo acupuncture|Each patient will receive 16 adhesive tapes mimicking the indwelling acupuncture needles bilaterally in addition to standard postoperative analgesia
2580369|NCT02364167|Active Comparator|Standard therapy|Each patient will receive just standard postoperative analgesia
2580429|NCT02363855|Experimental|BAY 1841788(ODM-201)|Cohort 1: Safety, tolerability and PK of 300 mg dose given twice daily. Escalation to cohort 2 in case no safety relevant adverse event has been observed within 28 days after start of multiple dose (MD) Cohort 2: Safety, tolerability and PK of 600 mg dose given twice daily
2580501|NCT02363504||Healthy older controls|7 Tesla MRI with memory task and non-invasive neurostimulation
2580505|NCT02363504||Prodromal Alzheimer's disease patients|7 Tesla MRI with memory task and non-invasive neurostimulation
2580553|NCT02363036||Active labor|Women in active labor normal pregnancy at term.
2580564|NCT02363036||Planned Cesarian Section|Women, normal pregnancy at term who came for elective Cesarean Section without signs of labor (pain/contractions, etc).
2580629|NCT02362607|Experimental|Integrated Diabetes Management Protocol|Smartphone apps for food diary, activity monitor, blood glucose will be used for three months.
2580633|NCT02362607|Active Comparator|Standard Diabetes Management Protocol|Subjects will receive standard diabetes management protocol with standard education and standard blood glucose measurement devices.
2580728|NCT02361879|Experimental|Ulipristal acetate|Womens will be treated with 5 mg/day of oral ulipristal acetate for 3 months
2580733|NCT02361879|Active Comparator|Leuprolile acetate|women will be treated with 1 IM injection of leuprolide acetate 11,25 mg in in the luteal phase
2580774|NCT02361450|Experimental|Retrograde Colonic Irrigation with usual care|In the experimental group, retrograde colonic irrigation sessions will be scheduled in addition to conventional treatment according to a progressive volume program.
2580776|NCT02361450|Active Comparator|Usual Care|In the comparator group, patients will receive conventional care, according to each clinical center habits.
2580789|NCT02361320|Experimental|Computed Tomography Scans (CT)|Participants to receive 2 computed tomography (CT) scans that are part of their regular cancer care. One (1) scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist. Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit.
2580809|NCT02361099|Experimental|Monitoring by SENTINEL application|Patients randomized to this arm will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application.
2580812|NCT02361099|No Intervention|Conventional Monitoring|Patients randomized to this arm will have a CT-scan every 3 months.
2580833|NCT02360943||PEAGE|Patients older than 75 years receiving an anticoagulant treatment for a symptomatic and confirmed PE
2580882|NCT02360813|Experimental|Cognitive Remediation Therapy|Principle driven cognitive remediation therapy, cognitive rehabilitation, cognitive training, cognitive enhancement.
2580887|NCT02360813|Active Comparator|Treatment as Usual|Usual care.
2580918|NCT02360449|No Intervention|Wait List|
2580919|NCT02360449|Experimental|Social Initiation Motivation Intervention|
2580925|NCT02360345|Experimental|q2week schedule|ONX-0801 will be administered over a 1-hour IV infusion on Days 1 and 15 of repeated 28-day treatment cycles.
3211529|NCT01006187|Active Comparator|Group 4|Distraction by means of self-selected reading material or internet
2580958|NCT02360202|Experimental|Bullous pemphigoid patient treated with clobetasol propionate|Impedance analysis in patient with bullous pemphigoid treated by Clobetasol Propionate cream treatment.
2580965|NCT02360163|Active Comparator|Landmark Technique Attempt|Patients will undergo an additonal TLT attempt
2580970|NCT02360163|Experimental|USGPIVA Technique Attempt|Patients will be offered a USGPIVA attempt after two failed attempts using the traditional landmark technique (TLT)
2580971|NCT02360254||Patients shifting to insulin degludec|Patients shifting from twice daily glargine or detemir to once daily degludec. This change in therapy will have to be decided by the diabetologist and the patient, not done for the purpose of the study.
2580972|NCT02360254||Patients remaining on twice daily glargine/detemir|Patients continuing on twice daily glargine or detemir
2580973|NCT02359994|Experimental|Cardiac Surgery|For cardiac procedures, the site of evaluation for satisfaction of intraoperative eligibility criteria will be any bleeding sites on the epicardium, along an aortic anastomotic suture line, or an aortotomy suture line. For example, the surgeon will perform dissection of adhesions per his or her conventional methods and bleeding will be controlled using means continually employed by the surgeon prior to surgical closure. Prior to application along an aortic anastomotic suture line or an aortotomy suture line, suture line gaps > 2mm and large needle holes > 2mm will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the epicardium, or along an aortic anastomotic suture line, or an aortotomy suture line meeting the eligibility criteria will be evaluated for satisfaction. PerClot should be applied after drug reversal and the patient is taken off by-pass.
2580974|NCT02360007|Experimental|Interim Buprenorphine Treatment|IBT participants will visit the clinic every 2 weeks while receiving the IBT package. Our integrative IBT treatment package includes five key components, each strategically chosen to maximize patient access to pharmacotherapy for opioid dependence while minimizing nonadherence, abuse and diversion: (1) Buprenorphine (BUP), (2) Computerized adherence monitoring (CAM), (3) Mobile health clinical support, (4) Urinalysis and adherence monitoring, and (5) HIV+Hepatitis Education.
3211530|NCT01006200||Structural /dynamic airway obstruction|Obstructive granulation tissue formation after SEMS implantation was defined as granulation tissue obstructing the lumen of the SEMS under bronchoscopic examination.
2580979|NCT02360007|No Intervention|Waitlist Control|WLC participants will remain on the waitlist for their treatment of choice but complete the same scheduled follow-up assessments as IBT participants.
3211531|NCT01006213|Experimental|Lifestyle counseling vs motivational intervention|
3211532|NCT01006226|Experimental|64Cu-ATSM PET|
3211533|NCT01006239||Biorepository|Patients undergoing surgical resection of a solid tumor.
2580371|NCT02364193|Experimental|Thoracic fluid status assessment|"Cardiac MRI by a 1.5 Tesla scanner:~Left ventricular ejection fraction (LVEF), tracing short axis endocardial borders.~CO, phase contrast angiography.~Fluid challenge by auto-transfusion by distal leg compression using inflatable cuffs (Lympamat Digital Gradient system).~DCE-MRI, bolus injection of Gd-CA intravenously by an injector. Each subject will receive repeated injections (10% of maximum dose).~BIS, impedance will be measured continuously using ImpediMed-SFB7 and surface electrodes on the thorax. ."
2580411|NCT02363868||CML subjects receiving Dasatinib|CML receiving dasatinib as first or second line therapy will be conducted to assess healthcare costs
2580413|NCT02363868||CML subjects receiving Nilotinib|CML receiving nilotinib as first or second line therapy will be conducted to assess healthcare costs
2580455|NCT02363608||standard post surgery care|An initial cohort of consecutive patients admitted to the 15th floor of the hospital on a Monday or Tuesday will form the usual care control arm of the study. Once this cohort is completed, the Caring Canines program will start.
2580456|NCT02363608||Caring Canines program|Once the standard of care cohort is completed, the Caring Canines program will start making visits on the 15th floor and a second cohort of consecutive patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.patients admitted to M15 on a Monday or Tuesday will form the intervention (experimental) arm of the study.
2580457|NCT02363608||staff canine-assisted|For the staff portion of this study a longitudinal pre and post intervention design will be used. Baseline staff assessments will occur prior to the Caring Canine program being implemented on the unit. The assessments include questions about compassion satisfaction and compassion fatigue as well as some open ended questions about your thoughts on the Caring Canines program. Post assessment will occur after the program has been active on the unit for at least 6 weeks. Only staff who work at least one Monday - Friday day shift each week will be eligible to participate.
2580522|NCT02363166||Acute Abscess Group|Adults and pediatric patients presenting to the UFHealth Shands Emergency Department with evidence of an acute abscess, or skin/soft tissue infection, which can be sampled for culture and sensitivity testing will be recruited.
2580528|NCT02362880|Active Comparator|mutation carrier|
2580530|NCT02362880|Sham Comparator|mutation non-carrier|
2580560|NCT02362737|Experimental|Active and Healthy Brotherhood (AHB)|16-week behavioral intervention
2580567|NCT02362737|No Intervention|Control|Usual care.
2580630|NCT02362581|Experimental|On demand treatment, prophylaxis treatment|"On demand treatment arm:Patients received factorVIII concentrate(Hemofil M) when they had bleeding episodes.~Prophylaxis arm: patients received factorVIII concentrate (Hemofil M) 30-35 unit/kg once a week"
2580664|NCT02362113||Isfahani adults|GI/GL
2580706|NCT02361931|Experimental|Treatment group (erythropoietin)|10 patients receive RMD-G1 (gel with 2000 IU/ml of erythropoietin) as an adjunct therapy to standard of care (SOC). Topical application on wound bed, daily for 12 weeks.
2580707|NCT02361931|Placebo Comparator|Control group (standard of care)|10 patients receive SOC alone daily for 12 weeks. A moisturizing gel is applied on wound bed as a part of SOC.
3211534|NCT01006278||Surgical group with knee pain|patients 18 years of age or greater with a history of knee pain for more than three but less than six months who failed conservative management with the presence of mechanical symptoms including locking, catching, or giving way; positive physical exam findings including joint line tenderness, McMurray's exam, or Steinman's exam; and MRI of the knee positive for meniscus tear in a location correlating with physical examination. Exclusion criteria were as follows: the presence of high grade gonarthrosis including Kellgren-Lawrence grade IV; a history of prior knee surgery or trauma; ligamentous incompetence on examination or MRI; and diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases.
3211535|NCT01006278||Group 2|volunteer group
2580786|NCT02361203|No Intervention|No Exercise|
2580791|NCT02361203|Experimental|Exercise Pre|30 minutes of aerobic exercise before exposure therapy
2580796|NCT02361346|Experimental|MT-3724 Phase 1 5 mcg/kg/dose|Phase 1: MT-3724 5 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2580798|NCT02361346|Experimental|MT-3724 Phase 1 10 mcg/kg/dose|Phase 1: MT-3724 10 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2580799|NCT02361346|Experimental|MT-3724 Phase 1 20 mcg/kg/dose|Phase 1: MT-3724 20 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2580801|NCT02361346|Experimental|MT-3724 Phase 1 50 mcg/kg/dose|Phase 1: MT-3724 50 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2580803|NCT02361346|Experimental|MT-3724 Phase 1 100 mcg/kg/dose|Phase 1: MT-3724 100 mcg/kg/dose IV for 6 doses over 12 days, followed by dose escalations (Phase 1) until recommended phase 2 dose of MT-3724 is determined
2580804|NCT02361346|Experimental|MT-3724 Phase 1 75 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724 (subject will continue with dose that was tolerated in the Phase 1 portion of the study)
2580805|NCT02361346|Experimental|MT-3724 Phase 1b 50 mcg/kg/dose|Phase 1b: MT-3724 IV for 6 doses over 12 days of 21-Day cycle for up to 4 additional cycles to explore safety, tolerability and tumor response to repeat doses of MT-3724
2580806|NCT02361346|Experimental|MT-3724 Phase 2 50 mcg/kg/dose|Phase 2: MT-3724 IV for 6 doses administered within 14 days of 21-Day cycle up to 6 Cycles. If the Subject exhibits stable disease or PR after end of Cycle 6 and investigator determines ratio is favorable, treatment with MT- 3724 may be continued for up to additional 6 cycles.
2580881|NCT02361008|Experimental|TPDC group|Patients who matched inclusion criteria and randomly divided into TPDC group underwent the TEE-guided perventricular device closure without CBP. But of them,who underwent TPDC failure during the procedure would be dropped out of the trial.
2580883|NCT02361008|Experimental|SR group|Patients who matched inclusion criteria and randomly assigned into SR group underwent the surgery repair with CBP.
2580908|NCT02360683||patients with Parkinson's disease|Large population of Parkinson's patients who benefit from subthalamic stimulation
2580946|NCT02360384|Experimental|FODMAP diet|The FODMAP diet will be introduced in patients with irritable bowel syndrome of the alternating subtype for 28 days.
2580372|NCT02364297|Active Comparator|Early TIPS|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Performance of TIPS in the first 5 days following acute gastric variceal bleeding."
2580375|NCT02364297|Placebo Comparator|Control|"Standard treatment to achieve initial hemostasis: vasoactive drugs (somatostatin or terlipressin) + endoscopic injection of tissue adhesives according to the center protocol.~Standard combined endoscopic and pharmacological therapy as a secondary prophylaxis (beta-blockers or carvedilol + repeated injection of tissue adhesives until the erradication of the fundal varices)."
2580416|NCT02363829|Experimental|Treatment|Nelfinavir and Cisplatin
2580500|NCT02363530|Experimental|HPMC group|Patients use the intervention Hydroxypropyl ethylcellulose (HPMC) 2% gel during the cataract surgery.
2580504|NCT02363530|Placebo Comparator|BSS group|Patients use balanced salt solution (BSS) during the cataract surgery.
2580531|NCT02362906|Experimental|Injection,medications and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules; external application: Fu-xiong San."
2580533|NCT02362906|Experimental|Injection and medications|"Intravenous injection:~bacterial pneumonia：second generation cephalosporin; mycoplasma pneumonia：erythromycin or azithromycin; viral pneumonia：Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; Medications: according to TCM syndrome differentiations; Wind-heat blocking lungs pattern(feng re bi fei zheng): wind-heat formula granules; phlegm-heat blocking lungs pattern(tan re bi fei zheng): phlegm-heat formula granules."
2580535|NCT02362906|Experimental|Injection and application|"Intravenous injection:~bacterial pneumonia: second generation cephalosporin; mycoplasma pneumonia: erythromycin or azithromycin; viral pneumonia: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co.,Ltd; external application: Fu-xiong San."
2580617|NCT02362555||ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
2580624|NCT02362555||Non ossification of nuchal ligament|check neck function, radiography characteristics and complete functional disability questionnaire
2580691|NCT02362165|Experimental|CyBorD regimen|this arm will receive cyclophosphamide (500mg/d,once-weekly),bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), and dexamethasone (40mg/d,once-weekly)(CyBorD) as induction therapy.
2580692|NCT02362165|Active Comparator|PAD regimen|this arm will receive bortezomib(1.3mg/㎡，once-weekly,subcutaneous injection), dexamethasone (40mg/d,once-weekly), and doxorubicin (9mg/㎡，d1-4)(PAD) as induction therapy.
2580724|NCT02361606|Experimental|Internet CBT intervention|Eligible candidates were offered to participate in an internet cognitive behavioral intervention.
2580787|NCT02361437|Placebo Comparator|placebo|placebo
2580795|NCT02361437|Experimental|Vasculera|diosmin
2580811|NCT02361424|Experimental|PXT00864 Dose 1|1 orange capsule containing 0.4 mg of acamprosate , and 1 white capsule containing 6 mg of baclofen These 2 capsules are taken orally b.i.d. during 8 weeks.
2580815|NCT02361424|Experimental|PXT00864 Dose 2|"1 orange capsule containing 1 mg of acamprosate , and 1 white capsule containing 15 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
2580818|NCT02361424|Experimental|PXT00864 Dose 3|"1 orange capsule containing 20 mg of acamprosate , and 1 white capsule containing 12 mg of baclofen .~These 2 capsules are taken orally b.i.d. during 8 weeks."
2580820|NCT02361424|Placebo Comparator|Placebo of PXT00864|"1 orange capsule containing placebo of acamprosate , and 1 white capsule containing placebo of baclofen .~These 2 capsules are taken orally b.i.d. during 4 weeks"
2580860|NCT02360969||healthy subjects waiting for surgery|patients for whom surgery under general anesthesia with administration of curare is planned will be offered an examination of the eyes before and during surgery
3211536|NCT01006317|No Intervention|Control|Financial coverage of MCH care within the local reimbursement system (CMS).
3211537|NCT01006317|Experimental|Clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
3211538|NCT01006317|Experimental|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
3211539|NCT01006317|Experimental|Financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
3211540|NCT01006330||Elderly medical inpatients|
3211541|NCT01006343|Experimental|Higher Protein (HP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The HP menus will contain 30% protein, 45% carbohydrate, and 25% fat. Subjects in the HP group will be provided with portioned, cooked and frozen pork products as part of their HP menu plan.
2580926|NCT02360553|Experimental|Intervention|ObeseGO!-web-based intervention
2580928|NCT02360553|Other|Control|Given pamphlets education mainly on diet and physical activity
2580930|NCT02360566|Experimental|Participatory Video Intervention Group|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
3258981|NCT01466374|Experimental|Cohort 3: Maintenance|Anti-IP-10 Antibody
3258982|NCT01466374|Experimental|Cohort 1: Open Label|Anti-IP-10 Antibody
2580957|NCT02360072||AR group|Allergic rhinitis without any typical asthma symptoms
3211542|NCT01006343|Experimental|Lower Protein (LP)|Subjects will be required to follow their seven day menu plan for the 12 weeks of intervention. The LP group menus will contain 18% protein, 57% carbohydrate, 25% fat. The LP group will follow a lacto-ovo vegetarian menu with no striated tissue foods. Subjects in the LP group will be provided with selected, portioned dairy products.
3211543|NCT01006382||Adolescents and young adults with food allergy|Adolescents aged 13-21 years with a diagnosis of food allergy
3211544|NCT01006395|Active Comparator|zoledronic acid|intervention
2579879|NCT02367196|Experimental|Part A: CC-90002|CC-90002 will be given by intravenous (IV) infusion on a 28 day cycle
2579881|NCT02367196|Experimental|Part B: CC-90002 with Rituximab|CC-90002 in combination with Rituximab will be given by intravenous (IV) infusion on a 28 day cycle in subjects with CD20-positive NHL
3211545|NCT01006395|Placebo Comparator|Placebo|
2579986|NCT02366702||Individuals with Bilateral Transfemoral Amputation|
2580059|NCT02366390|Experimental|Psychoeducative intervention|A psychoeducative dialogue and one telephone booster session
2580066|NCT02366390|No Intervention|Usual care|Usual care according to current guidelines.
2580090|NCT02365883||Prostate Cancer Group|
2580140|NCT02365623|Experimental|TMC207 (bedaquiline) + Background Regimen (BR)|Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days). From Week 3, participants will receive 200 mg (2 tablets) TMC207 (bedaquiline) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase. After TMC207 is stopped, the BR will be continued up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
2580180|NCT02365324|Experimental|Peer-education Family Fitness Program|Peer educators (children in grade 8) recruited from the schools participating in the study will be trained and will then be implementing the 12 week Peer-education Family Fitness Program (PE-FFP) intervention to children in 6th and 7th grade.
2580181|NCT02365324|Other|Family Fitness Program (FFP)|Adult educators recruited from the University of Illinois Extension or the community will be trained and will then be implementing the 12 week Family Fitness Program (FFP) intervention to children in 6th and 7th grade.
3211546|NCT01006408|Active Comparator|Low Level Laser|Low Level Laser twice a week for 8 weeks
3211547|NCT01006408|Sham Comparator|Placebo and Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
2580334|NCT02364453|Experimental|Placebo to PACAP38|Pre-treatment with placebo. PACAP38 8pmol/kg/min
2580335|NCT02364453|Experimental|Clemastin 1 mg/ml to PACAP38 8pmol/kg/min|Pre-treatment with Clemastin 1 mg/ml PACAP38 8 pmol/kg/min
2580377|NCT02364128|No Intervention|Control|Potential bariatric surgery patients who receive both the baseline questionnaire and follow-up questionnaire.
2580378|NCT02364128|Other|Decision Aid|Potential bariatric surgery patients who receive both the baseline questionnaire decision aid/conjoint analysis and follow-up questionnaire.
2580468|NCT02363413|Active Comparator|IniVAH|Initiation of the NIV in hospital : current care. 3 days hospitalization to start-up the NIV as usual.
2580469|NCT02363413|Experimental|IniVAD|Initiation of the NIV at home : experimental care.
3211548|NCT01006434||Thrombolysis group (Pilot phase)|Patients receiving intravenous thrombolysis for acute ischemic stroke. Pilot phase (100 Patients).
2580696|NCT02361957|Active Comparator|Probiotics|Multispecies probiotic product Ecologic 825, 2x10-9 colony forming units per gram, 6 grams per day.
2580702|NCT02361957|Placebo Comparator|Placebo|Similar in appearance as the probiotics, but not containing any bacteria.
2580790|NCT02361372|Experimental|Kefir and CaCO3|Kefir were administered 1,600 mg kefir-fermented milk per day and an accompanying supplement of 1,500 mg CaCO3 for 6 months
2580794|NCT02361372|Placebo Comparator|Placebo and CaCO3|Placebo and 1,500 mg of CaCO3 daily for 6 months
2580875|NCT02360982||propofol and esmeron(rokuronyum)|In group G, anesthesia was induced with iv propofol (2 mg.kg-1) and maintained with 2% sevoflurane in a mixture of 65 % nitrous oxide and 35 % oxygen with a total gas flow rate of 6 L min-1. Neuromuscular relaxation was induced with iv rocuronium (esmeron) (0.5 mg.kg-1). Intravenous infusion of 0.9% saline was administered at a volume of 5 mL/kg/h. Patients received morphine (0.1mg/kg) for postoperative analgesia 30 minutes before the end of the operation. Anesthesia was terminated and neuromuscular blockade was antagonized with neostigmine (0.05 mg.kg-1)and atropine sulphate (0.01 mg.kg-1).
2580877|NCT02360982||marcaine and fentanyl|"We inserted a 18-G Tuohy needle at the L3/L4 or L2/L3 intervertebral epidural space using an epidural loss of resistance technique and thus performed needle-through-needle technique for subarachnoid injection of 2 mL bupivacaine (marcaine)(0.5%) and fentanyl (25 mcg) by 27-G spinal needle. After subarachnoid injection, epidural catheter was advanced and fixed.~At the end of the surgery 5 mL of bupivacaine 0.5% plus morphine (1 mg), adding to 4 mL saline was injected via epidural catheter for postoperative analgesia.Epidural catheter was removed at 24th hours"
2580944|NCT02360384|Placebo Comparator|Sham diet|The placebo intervention will be healthy eating advice in patients with irritable bowel syndrome of the alternating subtype for 28 days.
2580945|NCT02360384|Active Comparator|Lincalotide|All patients with constipation predominant IBS will receive linaclotide 280mcg po od for 28 days.
3211549|NCT01006434||Thrombolysis group|Patients receiving intravenous thrombolysis for acute ischemic stroke.
3211550|NCT01006447|Active Comparator|Instructor contact 1 class|
3211551|NCT01006447|Active Comparator|Instructor contact 4 classes|
3211552|NCT01006460|Experimental|Adapt 232|
3211553|NCT01006460|Experimental|Arctic root group|
3211554|NCT01006460|Active Comparator|Ginseng group|
3211555|NCT01006460|Placebo Comparator|Placebo group|
3258983|NCT01466400||infants two to six months of age|
3260277|NCT01477814|Active Comparator|chart reminder, educational mat'ls, FIT|physician chart reminder plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test
3211556|NCT01006473|Experimental|Exercise training group|Exercise training is performed in subgroups of 6 patients supervised by two physiotherapists. Exercise prescription consisted of a 15-min warm-up, walking up to 30 min, followed by a 15-min cooling-down. The exercise intensity during the first 2 weeks corresponds to 55% at 65% of the HR peak reached at the baseline exercise test. In posterior sessions, individual adjustments are performed with gradual increases in order to reach the adequate target HR training intensity, as determined by the Karvonen formula {(maximal HR - HR at rest) x 50 to 70% + HR at rest}. Exercise training is performed in the morning, three times a week (on alternate days) for a total of 12 weeks (36 sessions).
3211557|NCT01006473|No Intervention|Inactive control group|No intervention
2581048|NCT02359656|Other|non operative treatment|specif non operative treatment protocol
2581053|NCT02359656|Other|operative treatment|dorsal atlanto-axial C1-C2 Arthrodesis
2581094|NCT02359422|Experimental|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health program developed based upon the Message Interpretation Processing model designed to increase critical thinking skills about media messages and reduce risky sexual behaviors.
2581097|NCT02359422|No Intervention|Wait-list control|
2581206|NCT02359097|Experimental|Diagnostic (DSC/DCE-CBV, SS-CBV mapping)|Patients receive 2 doses (2nd dose optional) of gadoteridol IV and undergo MRI including DSC or DCE-CBV mapping over approximately 45-60 minutes on day 1. Within 3 days, patients receive 3 doses of ferumoxytol non-stoichiometric magnetite IV and undergo MRI including DSC and SS-CBV mapping after each dose over approximately 90 minutes. Patients undergo MRI without contrast 24 hours after ferumoxytol non-stoichiometric magnetite over approximately 30 minutes. This 3 day series of imaging repeats at different stages of disease and may be performed up to 5 times: prior to surgery, prior to chemoradiation therapy, 4-6 weeks post-chemoradiation therapy, at time of progression on gadolinium MRI per RANO criteria, and again at time of progression (if the previous time of progression showed pseudoprogression).
2581252|NCT02358421||Initial cohort|Patients at risk of developing OHSS according to the inclusion criteria
2581314|NCT02358200|Experimental|Treatment|BMN-673: Oral, every day, Days 1-21; Carboplatin: intravenous, every week, 750 μg/day; Paclitaxel: intravenous, every week, 0.75 x Maximum Tolerated Dose μg/day
2581362|NCT02357693|Experimental|aprepitant|aprepitant 80 mg one hour before surgery
2581364|NCT02357693|Placebo Comparator|placebo|oral placebo one hour before surgery
2581421|NCT02357381||TMS Treatment|TMS( transcranial magnetic stimulation) -treatment for headache
2581465|NCT02356952|Experimental|Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
2581468|NCT02356952|Experimental|Low Glycemic Index Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
2581470|NCT02356952|Experimental|Low Glycemic Index Mediterranean Diet|Randomized prescription with indication about type of foods that can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
2581527|NCT02356744||surgery done less than 1 year|Pregnant women who had bariatric surgery done within the last year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
2581534|NCT02356744||surgery done more than 1 year|Pregnant women who had bariatric surgery done more than 1 year before pregnancy. Ultrasound fetal monitoring,biophysical profile assessment and maternal follow up investigations and blood pressure monitoring through all pregnancy
2581560|NCT02356224|Experimental|Cohort 1|SHR3824 2.5 mg/day or placebo.
2581561|NCT02356224|Experimental|Cohort 2|SHR3824 5 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581562|NCT02356224|Experimental|Cohort 3|SHR3824 10 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581563|NCT02356224|Experimental|Cohort 4|SHR3824 25 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581564|NCT02356224|Experimental|Cohort 5|SHR3824 50 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581565|NCT02356224|Experimental|Cohort 6|SHR3824 100 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581569|NCT02356224|Experimental|Cohort 7|SHR3824 200 mg/day or placebo. The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
2581629|NCT02355756|Experimental|Active|Intradermal injection of maxadilan solution
2581632|NCT02355756|Placebo Comparator|Placebo|Intradermal injection of placebo (=vehicle) solution
3211558|NCT01006486|Experimental|Anticoagulation clinic|Anticoagulation clinic, including all procedures related to a standardized use of coumarins.
3211559|NCT01006486|Active Comparator|Standard care|Standard use of coumarins, as prescribed by their physicians.
3211560|NCT01006499|Placebo Comparator|Placebo group|Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).
3211561|NCT01006499|Active Comparator|Pentoxifylline group|Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.
3211562|NCT01006499|Active Comparator|Pentaglobin group|Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days
3211563|NCT01006499|Active Comparator|Pentoxifylline plus Pentaglobin group|Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.
2582093|NCT02352558|Experimental|Arm 4|Patients with chronic myeloid leukemia treated with BBI608
3211564|NCT01006525||Insomniacs|Primary insomniacs, ages 21-70, in good general health.
3211565|NCT01006551|Experimental|Ziprasidone|
2580977|NCT02359994|Experimental|General Surgery|"For liver resection procedures, the resected liver surface will be the site of evaluation. The surgeon will perform resection of the diseased portion of the liver per his/her conventional methods. Bleeding from discrete vessels will be controlled using means conventionally employed by the surgeon. Vessels > 2mm in diameter will be ligated and any observed bile leaks controlled prior to assessment of intraoperative eligibility criteria.~For total splenectomy procedures, the site of evaluation for satisfaction of the intraoperative eligibility criteria will be the retroperitoneal surface. The surgeon will perform the splenectomy per his/her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria.~Any bleeding site on the retroperitoneal surface/cavity or exposed parenchymal surface will be evaluated for satisfaction of the eligibility criteria."
2580982|NCT02359994|Experimental|Urologic Surgery|"For on-clamp partial nephrectomies, the site of evaluation will be the kidney bed surface. The surgeon will perform resection of the kidney per his or her conventional methods. Vessels > 2mm in diameter will be ligated and entries into the collecting system controlled prior to assessment of intraoperative eligibility criteria. Any bleeding site on the kidney bed will be evaluated for satisfaction of the eligibility criteria after clamp release.~For radical nephrectomies, the site of evaluation will be the retroperitoneal surface/cavity. The surgeon will perform the procedure per his or her conventional methods. Vessels > 2mm in diameter will be ligated prior to assessment of intraoperative eligibility criteria. Any bleeding site on the retroperitoneal surface/cavity will be evaluated for satisfaction of the eligibility criteria."
2581056|NCT02359721|Experimental|test group|Base line scaling and root planing was done. Clarithromycin tablet 500 mg( Clarino-500) was given for a period of 7 days orally two times per day
2581059|NCT02359721|No Intervention|control|scaling and root planing
2581115|NCT02359331|Active Comparator|14 days PBMT group|Giving the 14 days bismuth quadruple regimen as 2nd rescue therapy for eradication of persistent H. pylori infection Drug regimen Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d
2581121|NCT02359331|Experimental|7 days tailored therapy group|According the antimicrobial susceptibility testing, the H. pylori isolates were resistant to moxifloxacin, 7 days PBMT regimen were prescribed; if the isolates were resistant to metronidazole, 7 days moxiflxacin based triple regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d) were prescribed.
2581396|NCT02357602|Experimental|1. GS-7340 25mg|The first 8 women on study will be assigned to take a single dose of 25mg TAF (1 tablet) orally.
2581398|NCT02357602|Experimental|2. GS-7340 10mg|The 2nd group of 8 women will be sequentially assigned to take a single dose of 10mg TAF (1 tablet) orally.
2581401|NCT02357602|Experimental|3. GS-7340 5mg|The final 8 women on study will be sequentially assigned to take a single dose of 5mg TAF (1/2 tablet) orally.
2581430|NCT02357212|Other|Early Invasive|Patients assigned to an early invasive strategy will undergo coronary angiography within 48 hours and have percutaneous coronary intervention or coronary artery bypass grafting performed as soon as possible during the initial hospitalization if deemed appropriate.
2581438|NCT02357212|Other|Conservative management|Patients assigned to conservative management will be treated with anti-anginal medications, aspirin, clopidogrel, atorvastatin, and other guideline recommended medicines. Patients will have an echocardiogram and adenosine stress testing
2581471|NCT02357004|Experimental|Carvedilol|Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
2581474|NCT02357004|Experimental|Chlorthalidone|Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
3176550|NCT00645177|Placebo Comparator|B|"In study, this arm is a randomized (blinded) to placebo for ABT-869 plus paclitaxel arm.~Note: Prior to randomization, approximately 6-12 subjects will be enrolled in open-label lead-in to assess the tolerability of the combination. The initial open-label, lead-in cohort of six subjects will be monitored for 2 cycles (8 weeks) to assess the PK interactions and the safety of the combination of 0.20 mg/kg QD ABT-869 and paclitaxel (90 mg/m2). Enrollment into the randomized portion will begin after a cohort has completed two cycles (8 weeks) of therapy and no toxicities prohibit the cohort from continuing on to Cycle 3.~Alternative doses may be explored based on the tolerability of the combination"
3176551|NCT00645203|Other|1|
3176552|NCT00645216|Experimental|CP-945,598 with Grapefruit Juice|CP-945,598 with Grapefruit Juice
3176553|NCT00645216|Experimental|CP-945,598 alone|CP-945,598 alone
2581679|NCT02355639|Experimental|Clobetasol propionate 0.05 % ointment|Active drug
2581680|NCT02355639|Experimental|Betamethasone dipropionate 0.064 % ointment|Active drug
2581681|NCT02355639|Placebo Comparator|Petrolatum ointment|Placebo drug
2581718|NCT02355093|Experimental|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
2581816|NCT02354404|Experimental|Group 1d: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581824|NCT02354287||Patients having outpatient Colonoscopy.|Patients with Polyps ≤7mm that are deemed appropriate to be removed by cold forceps polypectomy with pre lift
3176554|NCT00645229|Experimental|Arm A|
3176555|NCT00645242|Experimental|Arm A|
3176556|NCT00645255|Other|1|Single-blind Placebo Run-in with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
2580978|NCT02360020|Experimental|XLimus patients|participants must have symptomatic ischemic heart disease attributable to critical (that is, >70% visual estimate) stenotic lesions of native coronary arteries. Inclusion criteria are 1) chronic total occlusion (CTO), 2) severe calcification, and 3) severe tortuosity. CTO is defined as the presence of TIMI 0 flow within the occluded segment and angiographic or clinical evidence of an occlusion duration of ≥3 months. Calcification is defined severe when larger than 3x vessel diameter, and comprising the vessel wall totally in two perpendicular views. Tortuosity is defined severe when: one or more bends >= 90°, or three or more bends of 45-90° proximal to the diseased segment.
2581005|NCT02359760|Experimental|Piezocision group|The experimental group will consist of 14 adults, subjects from 18 to 40 years-old (10 women, 4 men).
2581006|NCT02359760|No Intervention|conventional orthodontics|The control group will consist of 30 matched patients with the same inclusion and exclusion criteria, who have been already treated by conventional orthodontics in the orthodontic clinic of the University of Montreal.
2581070|NCT02359591||text-based or multimedia|Subject fills in a questionnaire regarding whether the child meets developmental milestones for his/her developmental age, both the text-based and the multimedia version. A total score will be calculated and compared.
2581084|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI|High Strength fixed combination
2581085|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI|Medium Strength fixed combination
2581088|NCT02359292|Experimental|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|High Strength fixed combination plus Charcoal Block
2581089|NCT02359292|Active Comparator|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|Medium Strength fixed combination plus Charcoal Block
2581093|NCT02359292|Placebo Comparator|Placebo pMDI|Placebo
3211566|NCT01006577|Other|colon j pouch|Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
3211567|NCT01006577|Experimental|side-to-end anastomosis (STE)|Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon is closed with a linear stapler. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
3211568|NCT01006642||Healthy controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3211569|NCT01006642||Functional dyspepsia-EPS|Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
3211570|NCT01006642||Functional dyspepsia-PDS|Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
3211571|NCT01006668|Experimental|Sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
3211572|NCT01006668|Active Comparator|Propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary
2581404|NCT02357498|Active Comparator|microscopic|Microscopic transsphenoidal surgery, including endoscopic-assisted approach (350 subjects)
2581405|NCT02357498|Active Comparator|endoscopic|Fully endoscopic transsphenoidal surgery (350 subjects)
2581475|NCT02356991|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
2581477|NCT02356991|Placebo Comparator|Placebo|Placebo 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3211573|NCT01006681|Experimental|Monovalent MF59-Adjuvanted vaccine|
3211574|NCT01006694|Active Comparator|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
2581597|NCT02356081|Experimental|ASyMS intervention Group|Patients in the intervention group will be instructed to use the ASyMS intervention once daily (and whenever they feel unwell) for up to 6 cycles of chemotherapy treatment.
2581599|NCT02356081|No Intervention|Control Group|Patients in the control group will receive standard care as is currently available at their clinical site.
3211575|NCT01006694|Experimental|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
2581671|NCT02355340||DXA and pQCT Scan|"Dual energy x-ray absorptiometry (DXA): Assessment of bone mineral density~Peripheral quantitative computed tomography (pQCT): Assessment of bone mineral density"
2581720|NCT02355106|Experimental|Treatment|Atrial flutter Ablation
2581747|NCT02354885|No Intervention|Tranexamic Acid|TXA administered to multiple trauma patients in the helicopter or ambulance
3211576|NCT01006720||Sgx 0.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3211577|NCT01006720||Sgx 0.5|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3211578|NCT01006720||Sgx 0.75|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3211579|NCT01006720||Sgx 1.0|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3211580|NCT01006720||Sgx 1.25|Sugammadex group: Different doses of sugammadex for reversal of shallow neuromuscular blockade
3211581|NCT01006720||Neo 10|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3211582|NCT01006720||Neo 25|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3211583|NCT01006720||Neo 40|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3211584|NCT01006720||Neo 55|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
3211585|NCT01006720||Neo 70|Neostigmine group: Different doses of neostigmine for reversal of shallow neuromuscular blockade
2581010|NCT02359682||Age 20-39|Patients aged from 20 to 39 years old.
2581012|NCT02359682||Age 40-59|Patients aged from 40 to 59 years old.
2581017|NCT02359682||Age 60-79|Patients aged from 60 to 79 years old.
2581109|NCT02359526|Experimental|ILUVIEN 190 ug intravitreal implant|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
2581192|NCT02358980||Study group|Participants will receive FLC removal HD undertaken using an extended dialysis schedule on KIDNEY therapy system. Treatments (4 hours each) were carried out for 8 consecutive days and then every other day.
2581219|NCT02358694|Experimental|Active Treatment Group|Patients who weigh less than 40 Kg will receive 5 g daily (2.5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate Patients who weigh 40 Kg or more will receive 10 g daily (5 g PO BID) of Serum-derived bovine immunoglobulin/ protein isolate
2581221|NCT02358694|Placebo Comparator|Placebo Arm|The placebo group will receive a hydrolyzed gelatin protein for next 4 weeks on a daily basis.
2581262|NCT02358304|Active Comparator|a:Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received nasal spray calcitonin 200 IU/ day for 3 months after surgical curettage was done.
2581264|NCT02358304|Placebo Comparator|b; Patients with aggressive CGCG|Patients had been clinically with CGCG and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, size, and site of the lesions , duration of disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups . second group received placebo after surgical curettage for 3 months
2581288|NCT02358057|Experimental|Dexmedetomidine and Alfentanil|"Patients included in the study will receive an injection of dexmedetomidine via a TIVA Injectomat Agilia, specially programmed for the injection of dexmedetomidine.~At time zero, the patient will receive a bolus 1 mcg/ kg of dexmedetomidine during 10 minutes.~Patients over 65 years will receive a bolus of 0.5 mcg/kg of dexmedetomidine during 10 minutes.~Afterwards, the patient will receive a continuous injection of 0.6 mcg/kg/h of dexmedetomidine~Patients will also receive a dose of alfentanil 1 mcg /kg, 1 minute before the technical act.~A new alfentanil dose of 0.5 mcg / kg may be injected if pain reported by the patient corresponds to an EN > 50.~The maximum dose of alfentanil the patient can receive is 5 mcg / kg."
2581345|NCT02357784|Experimental|Current Perception Threshold Testing|The subjects in this study will undergo Current Perception Threshold Testing and fill out several questionnaires both before their Sacral Nerve Modulator device implantation and again 3 months after the device implantation.
2581389|NCT02357589|Active Comparator|2D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with two dimensional view
2581393|NCT02357589|Experimental|3D laparoscopic cholecystectomy|The normal laparoscopic cholecystectomy with three dimensional view
2581420|NCT02357238||Uveitis|Uveitis or infectious uveitis patients
3211586|NCT01006720||Saline|Saline group: Saline as placebo
2581581|NCT02356354|Other|Skin biopsy|On the same patient, a biopsy of post-burn scar is removed. A second one is removed from healthy skin.
2581613|NCT02355925|Experimental|uhCG|The patients who receive Intrauterine injection of 500 IU of uhCG (0.5ml) before embryo transfer
2581619|NCT02355925|Placebo Comparator|Placebo|The patients who underwent Intrauterine injection of placebo (normal saline 0.5 ml) before embryo transfer
2581622|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
2581685|NCT02355444|Experimental|High-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with high-dose blackberry polyphenols (250mL/day for 6 weeks).
2581686|NCT02355444|Placebo Comparator|Low-dose blackberry polyphenol beverage|Each participant will consume a blackberry beverage with minimal blackberry polyphenols (250mL/day for 6 weeks).
2581749|NCT02354755||Cold room|Anesthesia providers intraoperatively placed in ambient room temperature of 65 degreees (cold room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
2581753|NCT02354755||Hot room|Anesthesia providers intraoperatively placed in ambient room temperature of 80 degreees (hot room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
2581759|NCT02354755||Control Room|as a control placed Anesthesia providers in ambient room temperature of 75 degreees (neutral room), completing a 10-minute psychomotor vigilance test (PVT), followed up by a questionnaire on SurveyMonkey
3211587|NCT01006733|Experimental|Target INR 1.8 and Pharmacogenetic|The target International Normalized Ratio (INR) is 1.8. Warfarin initiation is via Pharmacogenetic dosing.
3211588|NCT01006733|Experimental|Target INR 2.5 and Pharmacogenetic|The target INR is 2.5. Warfarin initiation is via Pharmacogenetic dosing.
3211589|NCT01006733|Experimental|Target INR 1.8 and Clinical|The target INR is 1.8. Warfarin initiation is via clinical dosing.
3211590|NCT01006733|No Intervention|Target INR 2.5 and Clinical|The target INR is 2.5. Warfarin initiation is via clinical dosing.
2582410|NCT02350374|Other|carbohydrate counting|patients must fill their logbook during 28 days
3211591|NCT01006746||ICD patient and Home Monitoring|Patients primo implanted with ICD
3211592|NCT01006759|Experimental|leprosy disability|intervention of a series of cases with leprosy that made treatment in a Clinical Hospital
3211593|NCT01006772|No Intervention|Control Group|Control group patients receive usual clinical practice provided by Stroke Unit at Stobhill Hospital in Glasgow. They receive physiotherapy and early mobilisation as deemed appropriate to treat their oown impairments.
3211594|NCT01006772|Experimental|Experimental group|Intervention Group patients receive custom made solid ankle foot orthosis (AFO)treatment.
3211595|NCT01006785|Experimental|Treatment I|DLBS1425 150 mg three times daily
3211596|NCT01006785|Experimental|Treatment II|DLBS1425 300 mg three times daily
2581350|NCT02357888|Experimental|Sequence 1|Treatment group sequence: Test Product on Day 1 and Placebo on Day 2
2581351|NCT02357888|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product on Day 2
2581403|NCT02357511|Experimental|Study goup|Vital values are being measured for the time of two hours at postoperative setting at postanesthesia care unit. A novel method is compared to golden standard: invasive measurement. Also Saturation measurements are being compared between standard and study monitor.
2581419|NCT02357225|Experimental|Acute Dose of Pyridostigmine|Subjects will receive an acute administration of pyridostigmine bromide, calculated on their body weight at clinical exam (1 mg/kg, 60mg max starting dose), and will be monitored for 2 hours post administration. Subjects will also receive a pre- and post-administration single-fiber EMG, respiratory tests and strength tests in order to evaluate the function of the neuromuscular junction. All study subjects will be enrolled in this arm.
2581427|NCT02357225|Experimental|Prolonged Use of Pyridostigmine|This arm will evaluate the impact of pyridostigmine bromide on respiratory and skeletal muscle function during a 90-day administration period. On Days 1 - 7 subjects will receive 0.5mg/kg of the study drug every 4 hours while awake. On Days 8 - 90 subjects will receive 1.0 mg/kg every 4 hours while awake. Quality of life will also be measured with the SF-36 health survey. Data collection will occur at multiple time points (Days 30 and 90) throughout the study. Subjects will also be contacted at least weekly via telephone. All study subjects will be enrolled in this arm.
2581472|NCT02356978|Experimental|Arm 1|"Each patient will be treated before using the active usual homemade device, and after using the experimental new DRAP device.~This new sheet was designed by weaving optical fibers connected to LEDs ( BROCHIER Technology). The LIGHTEX technology ® is a principle of weaving mill of optical fibres with side lighting connected to LEDs and allowing to realize flexible or stiff bright surfaces with very weak congestions, low consumption and high life cycle. The energy illumination of this device varies between 3 and 4 mW / cm ² ( average 3,6 mW / cm ².)"
3211597|NCT01006798|Experimental|Cohort 1|three vaccinations of 10^7vp Ad4-H5-Vtn or placebo
3211598|NCT01006798|Experimental|Cohort 2|three vaccinations of the 10^8vp Ad4-H5-Vtn or placebo
3211599|NCT01006798|Experimental|Cohort 3|three vaccinations of 10^9 Ad4-H5-Vtn or placebo
2581669|NCT02355613|Active Comparator|Radiosurgery with Gamma Knife Perfexion|A single dose of 24 Gy at 50% isodose will be prescribed at metastases with diameter ≤ 20 mm, while a dose of 20 Gy at 50% isodose will be prescribed for metastases with diameter 21-30 mm
2581673|NCT02355613|Active Comparator|Linac-based Radiosurgery with EDGE|A single dose of 24 Gy will be prescribed at mean dose to PTV at metastases with diameter ≤ 20 mm, while a dose of 20 Gy will be prescribed for metastases with diameter 21-30 mm
2581708|NCT02355119|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/sqm on days 1,8,15 every 28 days
2581716|NCT02355119|Experimental|FOLFOXIRI|
2581742|NCT02354820|No Intervention|Control|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. No intervention is given to providers to help them with constipation management.
2581744|NCT02354820|Experimental|Experimental|Patients are identified by the pre-screener form given to parents as having constipation or encopresis. Evidence based reminders and patient educational materials are given to providers to help them with constipation management.
3211600|NCT01006798|Experimental|Cohort 4|three vaccinations of 10^10 Ad4-H5-Vtn or placebo
3211601|NCT01006798|Experimental|Cohort 5|three vaccinations of 10^11 Ad4-H5-Vtn or placebo
3211602|NCT01006811|Experimental|modified Atkins diet|
3211603|NCT01006824|Experimental|1|Capsule Endoscopy
3211604|NCT01006824|Active Comparator|2|Dedicated small bowel contrast radiography
3211605|NCT01006863|Active Comparator|Ephedrine 0.15 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1.5 mg/kg of ephedrine
3211606|NCT01006863|Active Comparator|Ephedrine 0.1 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 1 mg/kg of ephedrine
3211607|NCT01006863|Active Comparator|Ephedrine 0.07 mg/kg|received intravenous injection of 0.1 mL/kg of a study solution containing 0.7 mg/kg of ephedrine
3211608|NCT01006863|Placebo Comparator|Placebo|received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution
2582000|NCT02353221||Subjects|Entry criteria include being at least 18 years old at screening visit, being able to understand the information given to them and to give written informed consent, willingness to comply with the requirements of the data collection, absence of a diagnose of autoimmune disease or inflammatory arthritis, and absence of a previous treatment with any disease modifying anti-rheumatic drug (DMARD). We will exclude patients that are pregnant or intend to become pregnant during the time of follow up.
2582003|NCT02353000|Other|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases:
2582103|NCT02352558|Experimental|Arm 5|Patients with multiple myeloma treated with BBI608 and dexamethasone
3211609|NCT01006863|Active Comparator|Phenylephrine|received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/kg of phenylephrine
3211610|NCT01006876|Active Comparator|Study Arm|Patients receive continuous Coumadin therapy throughout the study.
3211611|NCT01006876|Active Comparator|Control Arm|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
3211612|NCT01006902||Individuals age 65 or older|Individuals age 65 or older receiving chemotherapy for cancer or short term androgen deprivation therapy for individuals 65 or older with prostate cancer.
3211613|NCT01006915|Experimental|Surgical decompression|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
3211614|NCT01006915|No Intervention|Standard medical care|Standard diabetic care and medical care provided for diabetic sensorimotor polyneuropathy
3211615|NCT01006928||Mothers|Mother of infants in NICU
3211616|NCT01006941|Experimental|Trichuris suis ova|
3211617|NCT01006954|Active Comparator|Flare Up|Flare up protocol in poor responders for IVF/ICSI
3211618|NCT01006954|Experimental|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
3211619|NCT01006993|Experimental|NeuroFlo Treatment|
2581162|NCT02359136|Placebo Comparator|LIA placebo|local infiltration anesthesia using saline i addition to multimodal analgesic regimen
2581169|NCT02359136|Experimental|LIA Ropivacaine|local infiltration anesthesia using Ropivacaine and Epinephrine i addition to multimodal analgesic regimen
2581257|NCT02358655|Other|Phase 1: Retrospective Chart Review|Retrospective chart review of all patients who presented to the emergency department (ED) with ECG-documented AF during 1 year prior to study commencement. The main purpose of Phase 1 is to determine if oral anticoagulants were prescribed for eligible AF patients at ED discharge.
2581258|NCT02358655|Other|Phase 2: Low-Intensity Intervention|Low-intensity intervention will be applied in the ED during 6 months, involving physician education, distribution of an AF patient education package, short-term oral anticoagulant prescription, and a follow-up letter to the patient's family physician.
2581261|NCT02358655|Other|Phase 3: High-Intensity Intervention|Phase 3 incorporates the Phase 2 intervention, and adds immediate follow-up (within 48-72 hours) in a community AF clinic run by a nurse/pharmacist who is supervised by a specialist in AF.
2581384|NCT02357823||Group 1|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 2 PCV13 doses received from more than 3 years that have prescription for a single booster dose of PCV13.
2581385|NCT02357823||Group 2|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years that have prescription to receive 2 doses (priming + boost) of PCV13.
2581386|NCT02357823||Group 3|HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count < 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
2581388|NCT02357823||Group 4|Immunological and microbiological status of HIV- positive adults that have never received a pneumococcal vaccine (naive) and have a CD4+ cell count > 200 cells/ul that have prescription to be primed with a single dose of PCV13 then boosted with a single dose of PPV23.
2581395|NCT02357823||Group 5|Immunological and microbiological status of HIV- positive adults with pneumococcal vaccinal status of 1 PPV23 dose received from more than 3 years and that that have prescription to receive a single dose of PCV13.
2581514|NCT02356809|Experimental|pl-vegf165|Patients of this group will receive 2,4 mg of pl-vegf165 administered by intramuscular injection which is given in the hand
2581516|NCT02356809|No Intervention|standard care|Patients of this group will receive standard therapy accepted in a clinical centre
2581616|NCT02356016|Active Comparator|Whole body Electromyostimulation (WB-EMS)|18 min of WB-EMS/week (one session/week)
2581623|NCT02356016|Active Comparator|WB-EMS and Nutritional Supplements|18 min of WB-EMS/week (one session/week) and supplements with high protein (Leucin) contents
2581626|NCT02356016|Sham Comparator|Control|Monthly dietary counseling for 6 months
2581661|NCT02355431|Experimental|Itacitinib plus erlotinib|
2581662|NCT02355431|Active Comparator|Placebo plus erlotinib|
3176557|NCT00645255|Placebo Comparator|2|Double-blind Treatment with behavioral intervention called Health Management Resources Maintenance Program which provided weekly classes for 12 months with meal replacement
3176558|NCT00645268|Active Comparator|Arm 1|
2581928|NCT02353689|Experimental|low FODMAP group|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
2581929|NCT02353689|Experimental|moderate FODMAP group|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
2581930|NCT02353689|Experimental|high FODMAP group|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
3176559|NCT00645268|Placebo Comparator|Arm 2|
3176560|NCT00645268|Other|Open-Label Arm|
3176561|NCT00645281|Experimental|tolterodine ER group|
3176562|NCT00645294|Other|Treatment Group A|ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
3176563|NCT00645294|Other|Treatment Group B|ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
3176564|NCT00645294|Other|Treatment Group C|ADV 10 mg single dose on Day 1 in 12-17 year old age group
3176565|NCT00645320|Experimental|A|
3176566|NCT00645346|Experimental|1|Subjects will receive either 5, 10 or 20 mcg of the vaccine
3176567|NCT00645346|Placebo Comparator|2|Subjects will receive placebo control
3176568|NCT00645372|Active Comparator|A|
3176569|NCT00645372|Experimental|B|
3176570|NCT00645385||MRS of the neural system|MRS to study epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism.
3176571|NCT00645398|Experimental|A|
3176572|NCT00645398|Experimental|B|
3176573|NCT00645398|Experimental|C|
3176574|NCT00645398|Placebo Comparator|D|
3176575|NCT00645424|Experimental|Arm A|
3176576|NCT00645424|Experimental|Arm B|
3176577|NCT00645424|Experimental|Arm C|
3176578|NCT00645463|Experimental|Group A|
3176579|NCT00645463|Experimental|Group B|
3176580|NCT00645489|Other|1|Control condition is wait-list control.
3176581|NCT00645489|Experimental|2|Active treatment condition: psychoeducational intervention for patients with HF
3176582|NCT00645515|Experimental|Arm A|
3176583|NCT00645515|Active Comparator|Arm B|
3176584|NCT00645541|Experimental|Axillary Reverse Mapping (ARM)|
3176585|NCT00645580|Experimental|A|
3176586|NCT00645606|No Intervention|Observation|Observation every 8 weeks during 2 years
3176587|NCT00645606|Experimental|rituximab arm|rituximab :500 mg/m² every 8 weeks during 2 years
3176588|NCT00645619||1|Patients with pure viral pneumonia
3176589|NCT00645619||2|Patients with viral pneumonia along with secondary bacterial pneumonia
3176590|NCT00645619||3|Patients with significant bacterial pneumonia
3176591|NCT00645619||4|Patients with congenital heart disease undergoing cardiopulmonary bypass who have no pneumonia
3211620|NCT01007006|Experimental|TMRDU|Telepharmacy Robotic Medicine Delivery Unit (TMRDU) group will receive TMRDU plus medication management
3211621|NCT01007006|No Intervention|Control|Control arm will receive only medication management, no TMRDU.
3211622|NCT01007019|Experimental|YH4808 30mg|"1.Single dose~2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
2581055|NCT02359617|Experimental|glucose sensing and insulin delivery|"Subcutaneous insulin delivery with an insulin pump plus glucose sensing with a continuous glucose sensor placed at the site of subcutaneous insulin delivery.~In parallel, capillary glucose determinations using a conventional glucose meter as well as glucose sensing in subcutaneous, insulin-unexposed tissue using a continuous glucose sensor."
2581113|NCT02359318|Experimental|Resin infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the no infiltration and de-bonding arm. The teeth that are included in this intervention arm are treated by resin infiltration using Icon (DMG, Germany) according to the manufacturers´ instruction. This is followed by bonding of new brackets (Gemini metal brackets, 3M Unitek). These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
2581117|NCT02359318|Placebo Comparator|No infiltration and de-bonding|"Patients with brackets and white spots are included in this group. After removal of the old brackets the quadrants are randomized to this intervention arm and the resin infiltration and de-bonding arm. The teeth that are included in this intervention arm are left untreated new brackets (Gemini metal brackets, 3M Unitek) are bonded. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
2581123|NCT02359318|Other|Control and de-bonding|"Patients with brackets and without white spots are included in this group. After removal of the old brackets, new brackets (Gemini metal brackets, 3M Unitek) are bonded again. These new brackets are finally de-bonded 4 weeks after the treatment, with silicon impressions taken before adhesive removal.~Bonding and debonding of brackets is performed by one clinician (Roberto Vogel) using the same bonding and de-bonding techniques and materials for all patients."
2581147|NCT02358928|Other|Low calorie diet|Calorie-restricted diet is composed of 50% carbohydrate, 15-20% protein and 30-35% fat.
2581148|NCT02358928|Other|Low carbohydrate diet|Carbohydrate-restricted diet is composed of 20% carbohydrates, 35% protein and 45% fat.
2581159|NCT02358824|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
2581173|NCT02358824|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
2581228|NCT02358616||Former VOICE (MTN-003) participants|Qualitative interviews and focus group discussions conducted on former VOICE participants. All participants to receive interviews.
2581280|NCT02358265|Active Comparator|10 mg Rupatadine on demand|Rupatadine 10 mg, on demand
2581283|NCT02358265|Active Comparator|10 mg Rupatadin|Rupatadine 10 mg, continuously
2581284|NCT02358265|Active Comparator|20 mg Rupatadine|Rupatadine 20 mg, continuously
2581285|NCT02358265|Active Comparator|10 mg rupatadine on demand (sham upd.)|Rupatadine 10 mg, on demand (sham updosing to 20 mg)
2581327|NCT02357914||Individuals with paraplegia|Individuals with a spinal cord injury below T1
2581376|NCT02357719|Experimental|VistaO2 FLUX device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate, the nasal flow and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
2581414|NCT02357329||Taste and hedonic ratings of NEFA|Linoleic acid solutions from 0.005% to 1.58%. Participants swish and spit 10 - 7.5mL solutions.
2581464|NCT02357121|Experimental|Laser ablation|All patient will undergo focal ablation of prostate tissue utilizing laser energy.
2581522|NCT02356523||Cardiac Intensive Care Unit Patients|Patients admitted at Cardiac Intensive Care Unit for any condition
2581614|NCT02355873|Experimental|AN69ST|AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter
2581620|NCT02355873|Active Comparator|AN69|AN69:original Polyacrylonitrile Membrane Hemofilter
2581666|NCT02355522|Active Comparator|Lidocaine gel group|3ml of 2% lidocaine gel on the cervix and 5ml of intrauterine normal saline
2581670|NCT02355522|Active Comparator|Intrauterine lidocaine group|3ml of KY jelly on the cervix and 5ml of 2% intrauterine lidocaine
2581675|NCT02355522|Placebo Comparator|Placebo group|3ml of KY jelly on the cervix and 5mL of intrauterine normal saline
2581721|NCT02355080|Experimental|On-site bundled rapid HIV/HCV testing|Participants will receive the on-site bundled rapid HIV/HCV testing intervention. In the intervention group, all patients will receive an offer to participate in rapid HIV/HCV testing. Those who accept this offer will: receive pre-test information about testing procedures and education, be tested, receive results during the same visit as testing, and be provided post-test counseling and support services by trained test counselors. Patients with a preliminary positive (i.e., reactive) HIV and/or HCV test result(s) will be actively linked immediately to a health care provider for further evaluation and confirmatory HIV and/or HCV RNA testing.
2581825|NCT02354326||Diagnostic (VNC DECT)|Patients undergo CT scans. Additional images will be processed with virtual non-calcium (VNC) dual energy CT (DECT) information. Comparison will be made between images with and without addition of VNC.
3211623|NCT01007019|Experimental|YH4808 50mg|"1.Single dose~2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3211624|NCT01007019|Experimental|YH4808 100mg|"1.Single dose~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3211625|NCT01007019|Experimental|YH4808 200mg|"1.Single dose~2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3211626|NCT01007019|Experimental|YH4808 400mg|"1.Single dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3211627|NCT01007019|Experimental|YH4808 100mg(repeat doses)|"1.Repeat doses~2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
2580992|NCT02360358|Experimental|autologous cultured skin|autologous cultured skin patches (Tiscover) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size. Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new Tiscover patches.
2580995|NCT02360358|Active Comparator|acellular donor dermis|"acellular donor dermis (AS210) is applied on wound in 2-step procedure with 1 week interval. Dosage: number of patches depends on wound size.~Application week 0 is removed after one week (week1). Week 1: wound is completely covered with new AS210 patches."
3176593|NCT00645684|Experimental|A|one layer running suture technique
2581175|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose|ASP6858 arm
2581189|NCT02359032|Placebo Comparator|Part 1: Placebo single ascending dose|Placebo arm
2581193|NCT02359032|Experimental|Part 1: ASP6858 single ascending dose (fasting cohort)|ASP6858 arm
2581197|NCT02359032|Experimental|Part 2, Sequence 1: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
2581200|NCT02359032|Experimental|Part 2, Sequence 2: ASP6858 multiple ascending dose & placebo|ASP6858 and placebo arm
2581247|NCT02358564|Active Comparator|Healthy Volunteers|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
2581253|NCT02358564|Experimental|Irritable Bowel Syndrome Patients|Participants will receive a Gastrointestinal Permeability Test, Upper Endoscopy, Rectal Barostat and Infusion of Fats.
2581300|NCT02358070||HCC group|
2581308|NCT02358070||control group|
2581359|NCT02357849|Active Comparator|Aripiprazole|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (2mg wk1, 5mg wk2, 10mg wk3, 5-30 mg wk4-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need (5-30mg).
2581360|NCT02357849|Active Comparator|Fluoxetine|To increase homogeneity and assure treatment with a clinically effective dose, patients will undergo a fixed titration phase during the first four weeks (5mg wk1, 10mg wk2, 20mg wk3, 10-60mg wk3-24), with the option to slow or halt the titration or decrease the target dose if intolerability develops. After 3 weeks, dosing will be flexible and left up to clinical choice and need(10-60mg).
2581431|NCT02357433|Experimental|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization
2581437|NCT02357433|No Intervention|Control Group|Standard practice
2581573|NCT02356419|Experimental|experimental 0.5 ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
2581576|NCT02356419|Experimental|experimental 1.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
2581583|NCT02356419|Experimental|experimental 2.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
2581588|NCT02356419|Experimental|experimental 3.0ug/kg|there are four groups in this study and healthy subjects of all groups receiving different doses of recombinant erythropoiesis stimulating protein
2581690|NCT02355223|Other|FAST Implementation|This single center study will consist of introducing a TB screening program called FAST (Find cases Actively, Separate safely, and Treat Effectively) within the hospital among patients presenting for care who have cough or TB risk factors, and testing them for tuberculosis using a combination of rapid screening and diagnostics tools. The study will evaluate the process of implementation as well as the impact on reducing tuberculosis transmission to health care workers over successive years.
2581849|NCT02354248|Experimental|Stroke patients|The patients will be submitted to a triple stimulation examination.
2581850|NCT02354248|Active Comparator|Control Subjects|This group of patients did not suffer from a stroke. They will also be submitted to a triple stimulation examination.
3176594|NCT00645684|Experimental|B|two-layer suture technique
2581934|NCT02353611|Experimental|6% bleaching agent|One upper hemiarch will be bleached with 6% hydrogen peroxide with titanium oxide nanoparticles, activated by a led/laser hybrid light. Whitening compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of one upper hemiarch. In each bleaching session the gel will be applied twice for 12 minutes each and activated with continuous irradiance using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
2582114|NCT02352558|Experimental|Arm 6|Patients with multiple myeloma treated with BBI608 and bortezomib
3176595|NCT00645723|Experimental|A|Intravenous colistin and nebulized colistin
3176596|NCT00645723|Placebo Comparator|B|intravenous colistin and saline solution nebulized
3176597|NCT00645736||1|Single cohort
3176598|NCT00645749|Experimental|Helminth ova|Subjects serving as their own controls (baseline - end-of-treatment) will receive a dose of 2,500 ova, in liquid form, every 2 weeks
3176599|NCT00645775|Placebo Comparator|1|Compare active to placebo
3176600|NCT00645801|Active Comparator|1|Patients will receive both Amitiza and GoLYTELY
3176601|NCT00645801|Placebo Comparator|2|Patients will receive Amitiza Placebo plus GoLYTELY
3176602|NCT00645814|Placebo Comparator|A|
3176603|NCT00645814|Active Comparator|B|
3176604|NCT00645814|Active Comparator|C|
3176605|NCT00645879|Experimental|OKG, Glutamine, and Disodium Citrate|Ornithine Alpha Ketoglutarate for 4 weeks, followed by 2 week washout period. 4 weeks Glutamine, followed by 2 week washout period. 4 weeks Disodium Citrate, followed by 2 to 12 week washout period. Then continue an additional 30 weeks on Disodium Citrate (drug producing the best increment in plasma glutamine levels).
3176606|NCT00645892|Active Comparator|A|
3176607|NCT00645892|Placebo Comparator|B|
3176608|NCT00645905|Active Comparator|A|
3176609|NCT00645905|Placebo Comparator|B|
3176610|NCT00645918|Active Comparator|A|"Tailored clopidogrel regimen - an additional clopidogrel 600-mg loading dose (eight 75-mg tablets taken orally; daily 150 mg clopidogrel dose plus additional 450 mg clopidogrel) on the day of randomization and then 150-mg clopidogrel every day thereafter for 6 months."
2580993|NCT02360137||Patients with carotid plaque|Patients with carotid plaque treated using only drugs
2580996|NCT02360137||Patients with carotid stenosis|Patients with carotid stenosis indicated to carotid endarterectomy
2581047|NCT02359630|Active Comparator|EasyTube|Use of EasyTube during general anesthesia
2581050|NCT02359630|Experimental|Endotracheal tube|Use of endotrachel tube during general anesthesia
2581098|NCT02359357|Placebo Comparator|Placebo single dose|Placebo administered as a single dose
2581100|NCT02359357|Experimental|Single dose (Dose level 1)|FDL169 (Dose level 1) administered as a single dose
2581101|NCT02359357|Experimental|Single dose (Dose level 2)|FDL169 (Dose level 2) administered as a single dose
2581103|NCT02359357|Experimental|Single dose (Dose level 3)|FDL169 (Dose level 3) administered as a single dose
2581105|NCT02359357|Experimental|Single dose (Dose level 4)|FDL169 (Dose level 4) administered as a single dose
2581106|NCT02359357|Experimental|Single dose (Dose level 5)|FDL169 (Dose level 5) administered as a single dose
2581107|NCT02359357|Experimental|Single dose (Dose level 6)|FDL169 (Dose level 6) administered as a single dose
2581108|NCT02359357|Experimental|Single dose (Dose level 7)|FDL169 (Dose level 7) administered as a single dose
2581110|NCT02359357|Experimental|Single dose (Dose level 8)|FDL169 (Dose level 8) administered as a single dose
2581116|NCT02359357|Experimental|Additional single dose 1|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581122|NCT02359357|Experimental|Additional single dose 2|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581125|NCT02359357|Experimental|Additional single dose 3|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581127|NCT02359357|Experimental|Additional single dose 4|Single dose of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581130|NCT02359357|Experimental|Food effect - fasted|Single dose of FDL169 in fasted conditions
2581131|NCT02359357|Experimental|Food effect - fed|Single dose of FDL169 in fed conditions
2581133|NCT02359357|Placebo Comparator|Placebo - multiple dose|Repeat doses of placebo
2581135|NCT02359357|Experimental|Multiple dose - Dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581136|NCT02359357|Experimental|Multiple dose - Dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581137|NCT02359357|Experimental|Multiple dose - Dose level 3|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581139|NCT02359357|Experimental|Multiple dose - Dose level 4|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581140|NCT02359357|Experimental|Multiple dose - additional dose level 1|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581144|NCT02359357|Experimental|Multiple dose - additional dose level 2|Repeat doses of FDL169 to be administered at a dose level to be determined (up to Dose level 8)
2581157|NCT02358837||Conventional Sonography|Conventional Sonography to detect breast lesion
2581167|NCT02358837||Ductosonography Technique|Ductosonography Technique to detect breast lesion
2581222|NCT02358759|Active Comparator|Giant Oocytes after ICSI|abnormally produced oocyte after ART or Controlled ovarian stimulation. Correction of abnormally fertilized oocytes using nucleus removal.
2581223|NCT02358759|Active Comparator|3PNs zygotes developed after ICSI|Abnormally developed embryos these produced 3PNs. Correction of abnormally fertilized oocytes using nucleus removal.
2581250|NCT02358395|Experimental|BBI608 puls Sorafenib|
3211628|NCT01007019|Experimental|YH4808 200mg(repeat doses)|"1.Repeat doses~2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)"
3211629|NCT01007019|Experimental|YH4808 400mg(repeat doses)|"1.Repeat dose~2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
2581378|NCT02357524|Experimental|Oritavancin|Subject will receive a single oritavancin dose of 1200 mg in 1000 mL of D5W administered as a constant rate IV infusion over 3 hours via a single dedicated peripheral venous line.
3211630|NCT01007019|Experimental|YH4808 600mg|"1.Single dose~2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
3211631|NCT01007019|Experimental|YH4808 800mg|"1.Single dose~2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)"
2581506|NCT02356796|Experimental|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
2581508|NCT02356796|Active Comparator|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
2581525|NCT02356510||Culprit lesion|Patients who underwent culprit lesion only PCI during primary intervention
2581531|NCT02356510||Culprit vessel|Patients who underwent culprit lesion only PCI during primary intervention
2581571|NCT02356289|Experimental|MYK-461|single-dose, tablet formulation
2581574|NCT02356289|Placebo Comparator|Placebo|single-dose, tablet formulation
3211632|NCT01007019|Placebo Comparator|Placebo|
3211633|NCT01007019|Active Comparator|Esomeprazole 40mg|
3211634|NCT01007045||"Clinically likely"|Subjects deemed clinically likely to have DVT based on modified Well's criteria
3211635|NCT01007045||"Clinically unlikely"|Subjects deemed clinically unlikely to have DVT based on modified Well's criteria
3211636|NCT01007058||Response Markers|Urine Collection and Bladder wash of Bladder Cancer Patients with Treatment of BCG or BCG plus interferon
3211637|NCT01007084|Experimental|Propranolol|
3211638|NCT01007084|Placebo Comparator|Sugar pill|
3176611|NCT00645918|Placebo Comparator|B|"Standard clopidogrel regimen - a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months."
3176612|NCT00645918|Placebo Comparator|C|Responders: A random sample of clopidogrel responders treated with a placebo loading dose (six placebo tablets taken orally plus daily dose of one placebo tablet plus 75 mg clopidogrel) on the day of randomization followed by one placebo tablet plus 75 mg clopidogrel every day thereafter for 6 months.
3176613|NCT00645957|Active Comparator|2|This group will have a red rubber drain(s) placed during surgery. This drain(s) will be irrigated intra and post-operatively
3176614|NCT00645957|Active Comparator|1|This group will have a penrose drain(s) placed during surgery to facilitate drainage post-operatively. This drain (s) will not be irrigated.
3176615|NCT00645983|Experimental|1|Chamomile Extract
3176616|NCT00645983|Placebo Comparator|2|Anxiolytic Therapy
2581069|NCT02359578|Experimental|Lymphatic occlusion pressure|injection of 100µg Indocyanine Green in the first interdigital space and application of increasing pressure around the arm to visualize at which pressure lymph flow is interrupted.
2581156|NCT02359253|Experimental|IntelliArm with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
2581161|NCT02359253|Experimental|IntelliArm with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the IntelliArm for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the IntelliArm.
2581174|NCT02359253|Experimental|The hand robot with passive stretching|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will complete up to 30 minutes of strong passive stretching, then followed by 45-60 minutes of active movement training with the hand robot.
2581182|NCT02359253|Experimental|The hand robot with passive movement|Groups are split into 2 conditions based on stretching and 2 conditions based on target of intervention (arm or hand). Subjects will wear the hand robot for up to 30 minutes with gentle passive movement or little stretching, then followed by 45-60 minutes of active movement training with the hand robot.
2581233|NCT02358512|Experimental|Intermittent enteral feeding|The intermittent feeding regimen will consist of six bolus feeds (one bolus every four hours).
2581234|NCT02358512|Active Comparator|Continuous enteral feeding|The continuous feeding regimen consists of the total volume of feed administered over 24 hours.
2581312|NCT02358187|Experimental|HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|All subjects will receive vaccine plus Poly-ICLC. Injections will be given every 3 week for a total of 8 vaccines.
2581379|NCT02357745||Pre-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
2581382|NCT02357745||Post-menopausal with periodontitis|non surgical periodontal therapy ( scaling and root planing)
2581428|NCT02357316||All participants|All individuals visiting the museum who want to participate and sign a consent form.
2581482|NCT02357056|Active Comparator|Wet Lab|Subjects in the wet lab group will perform dissections of the internal thoracic artery and placement of annuloplasty stitches in the mitral valve in pig models until time proficiency is reached based on the performance of our expert robotic surgeons.
2581483|NCT02357056|Active Comparator|Dry Lab|Subjects in the dry lab group will perform exercises form the fundamentals of laparoscopic surgery (FLS) program adapted for the daVinci robot. These exercises included, camera and clutching, peg transfer and intracorporeal knot tying. Participants will repeat these tasks until time proficiency is reached based on the performance of our expert robotic surgeons.
2581492|NCT02357056|Active Comparator|Virtual Reality|Subjects in the virtual reality group will perform exercises from a 9 task curriculum, on the daVinci Skills Simulator. These exercises included, camera and clutching, energy switching, peg board, energy dissection, matchboard, ringwalk, suture sponge, and vertical defect suturing. Participants will repeat these tasks all metrics are passed and an overall score is reached based on the performance of our expert robotic surgeons.
2581498|NCT02357056|No Intervention|Control|The control group will receive no training after they complete the initial assessment and undergo randomization. They will be invited back after several weeks to complete the final assessment to control for any improvement in performance from the initial assessment alone and normal progression through surgical training outside of this project.
2581523|NCT02356627|Experimental|The Cancer Home Life Intervention|"One or more of the following:~prioritisation of resources and everyday activities~adaptation of activities~adaptation of posture and seating positioning~provision of assistive devices~modification of the physical home environment And usual care from hospital and municipality"
2581529|NCT02356627|No Intervention|Control|Usual care from hospital and municipality
2581575|NCT02356276|Experimental|HIPEC group|"Postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is performed after radical surgery, followed by 6-8 cycles of systemic chemotherapy. The first HIPEC is conducted within 48 h after surgery: Paclitaxel 75 mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX or SOX regimens):~XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen is also permitted. The regimen is Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid, po, day 1-14, every 3 weeks for a total of 6-8 cycles."
2581692|NCT02355262||Arm I (Independent Tool Implementation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication at baseline.
3176617|NCT00645996|Experimental|1|
3176618|NCT00645996|Placebo Comparator|2|Cornflour
3176619|NCT00646009|Experimental|1|budesonide/formoterol
3176620|NCT00646009|Active Comparator|2|fluticasone/salmeterol
3176621|NCT00646009|Active Comparator|3|albuterol
3176622|NCT00646035|Placebo Comparator|A|
3176623|NCT00646035|Placebo Comparator|B|
2580998|NCT02359773||Group 1 - Non ischemic chest pain|No coronary artery disease (CAD) as confirmed by myoview, MRI or stress echo. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
2581001|NCT02359773||Group 2 - Myocardial infarction|Myocardial infarction confirmed by a troponin test (>50ng/l) 12 hours after the onset of chest pain. Subjects will receive one MCG scan (intervention) using the QI Model 1.0 Magentocardiogram. This will be in addition to their current care and it will not be used to support clinical decision making.
2581049|NCT02359643|Placebo Comparator|with high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) and high dose aspirin (>50mg/kg/day) since diagnosed, then taper to low dose aspirin (3-5mg/kg/day) when fever subside.
2581052|NCT02359643|Experimental|Without high dose aspirin|KD patients treated with high dose IVIG (2gm/kg) without high dose aspirin (>50mg/kg/day) since diagnosed, then low dose aspirin (3-5mg/kg/day) when fever subside.
2581114|NCT02359344|Experimental|CNV1014802|CNV1014802 150mg three times a day (tid) 7 days plus a single dose on day 8
2581118|NCT02359344|Placebo Comparator|Placebo|Placebo tid 7 days plus a single dose on day 8
2581178|NCT02358954|Experimental|Vestibular Pain interactions|
2581292|NCT02358629|Experimental|Prospective, non-randomized|use the NovaCross™micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of femoropopliteal and infra-popliteal Chronic Total Occlusion (CTO) lesion
2581352|NCT02357862||Mitral Valve Annuloplasty|All eligible patients
2581380|NCT02357537|Active Comparator|Traditional|"Subjects in Study Arm 1 will undergo a screening process, and if randomized, will follow a traditional, site-based clinical trial model and undergo a baseline visit and 3 more in-person visits with the Principal Investigator (total of 4 visits).~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
2581383|NCT02357537|Active Comparator|Remote|"Subjects in Study Arm 2 will undergo a screening process, and if randomized, will undergo one Baseline visit at the local Gastroenterologist's office and 4 video visits with the Principal Investigator. A mobile nurse will visit subjects at a distant location (such as their home) to obtain blood samples at visits 1 and 4.~Subjects in each Study Arm will be randomized (2:1) to follow one of two dietary regimens during the study: the Combined Anti-Inflammatory Diet (CAID) or Control (standard nutritional advice)."
3211639|NCT01007097|Experimental|TAK-875 6.25 mg QD|
3211640|NCT01007097|Experimental|TAK-875 25 mg QD|
2581542|NCT02356432||NOACs group|Medication with dabigatran, rivaroxaban, apixaban, or edoxaban will not be assigned, but will be freely prescribed by each attending doctor based on assessment of the condition of each patient.
2581546|NCT02356432||Warfarin group|Medication with warfarin: PT-INR should be controlled in accordance with the JCS2008 guideline concerning the drug treatment of atrial fibrillation, that is, INR 2.0 to 3.0 in patients younger than 70 years, or INR 1.6 to 2.6 in patients not younger than 70 years.
2581559|NCT02356250||PORTAL HYPERTENSION|PAIEBT WITH PORTAL HYPERTENSION
2581625|NCT02356055|Experimental|Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 3 hours/day, 5 days/week for 2 weeks. Participants will choose functional goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. For the intensive protocol, each hour of training will focus on 1 of 3 identified goals and will include 50 minutes of intervention and a 10 minute break."
2581627|NCT02356055|Active Comparator|Less-Intensive Protocol|"Participants in this group will receive the Skill-building through Task-Oriented Motor Practice (STOMP) intervention 1 hour/day, 2 days/week for 2 weeks. Participants will choose goals that have an identifiable beginning and concluding step for creation of practice-able steps for task-oriented training. Practice-able steps will embed both task modifications and assistive technology determined by the OT to support performance and will be situated contextually within the participant's habits and environment. Each group will practice the task as many times as possible during their allotted time in training. In the less-intensive protocol, each of the 3 ADL goals will be practiced as many times as possible within 20 minutes of the scheduled hour."
2581687|NCT02355509|Placebo Comparator|Placebo|A placebo drug is given for three months
2581688|NCT02355509|Experimental|Acarbose|Acarbose is given for three months
2581758|NCT02354989|Active Comparator|RR on first|Rate Response on first
2581761|NCT02354989|Active Comparator|RR off first|Rate Response off first
2581809|NCT02354404|Experimental|Group 1a: cAd3-EBOZ at 1x10(10) PU|Part 1: cAd3-EBOZ at 1x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581810|NCT02354404|Experimental|Group 1b: cAd3-EBOZ at 1x10(11) PU|Part 1: cAd3-EBOZ at 1x10(11) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581812|NCT02354404|Experimental|Group 1c: cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0; Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581897|NCT02353936|Experimental|afatinib group|
3211641|NCT01007097|Experimental|TAK-875 50 mg QD|
3211642|NCT01007097|Experimental|TAK-875 100 mg QD|
3211643|NCT01007097|Experimental|TAK-875 200 mg QD|
3211644|NCT01007097|Active Comparator|Glimepiride 2 mg or 4mg QD|
3211645|NCT01007097|Placebo Comparator|Placebo QD|
3211646|NCT01007175|Experimental|Cohort 1|
3211647|NCT01007175|Experimental|Cohort 2|
3211648|NCT01007175|Experimental|Cohort 3|
3211649|NCT01007175|Experimental|Cohort 4|
3211650|NCT01007175|Experimental|Cohort 5|
3211651|NCT01007188|Active Comparator|1.5PD|average American diet plus 1.5 oz per day almonds
3211652|NCT01007188|Other|Base|average American diet without almonds
3211653|NCT01007188|Active Comparator|3.0PD|average American diet plus 3.0 oz per day almonds
2580999|NCT02359747||In Vitro Fertilization treatment|culture medium discarded after IVF treatment
2581045|NCT02359604|Other|Single Arm Study -microbiome|This is a single-arm study. The patients will serve as their own controls. The PPI administered for PPI-therapy is already FDA approved. A stool sample will be obtained for intestinal microbiome testing before PPI, under PPI and after PPI therapy.
3211654|NCT01007201|Experimental|H1N1 vaccine of 15 μg HA on Day 0 and 21|15 μg HA (0.5 mL) per injection, 2 injections 50 children (aged over 3 years old to 6 years old) and 50 children/teenagers (aged over 6 years old to 18 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
3211655|NCT01007201|Experimental|H1N1 vaccine of 7.5 μg HA on Day 0 and 21|7.5 μg HA (0.25 mL) per injection, 2 injections 50 toddlers (aged over 1 year old to 3 years old) were assigned to receive two injections of H1N1 vaccine 3 weeks apart
2581164|NCT02358850|Active Comparator|Tonsillectomy and Norco|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Norco (Hydrocodone and Acetaminophen)
2581179|NCT02358850|Active Comparator|Tonsillectomy and Percocet|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Percocet (Oxycodone and Acetaminophen)
2581187|NCT02358850|Active Comparator|Tonsillectomy and Dilaudid + Tylenol|This represents patients who will be randomized (1:3 chance) to postoperative pain control with Dilaudid (hydromorphone) and Tylenol (Acetaminophen)
2581245|NCT02358551|Other|Axillary vein|Lead Placement Through the Axillary Vein Technique
2581249|NCT02358551|Other|Subclaivan vein|Lead Placement Through the Subclavian Vein Technique
2581290|NCT02358096|Experimental|ASP8232|ASP8232 administered once daily
2581299|NCT02358096|Placebo Comparator|Placebo|Placebo administered once daily
3211656|NCT01007214|Experimental|Prostate cancer|A total of 30 patients diagnosed with prostate cancer who have elected to undergo radical prostatectomy are enrolled over a six year period.
3211657|NCT01007227|Other|Lifestyle instruction|
3211658|NCT01007240|Experimental|soft liner with nano particles|the obturators of this patients will be relined with soft liner, with incorporated nano particles. after a week, the soft liner will be taken off, and will be checked for bacterial adhesion.
3211659|NCT01007266|Other|Group A|Buddy Group - Individuals with type 2 diabetes receive conventional diabetes treatment and are assigned a patient partner (Buddy)
2581633|NCT02356042||Nursing home residents practicing GIA activity|
2581635|NCT02356042||Nursing home residents no practicing GIA activity|
2581674|NCT02355457||Suspected acute myocardial infarction|Patients with recent onset symptoms suggesting acute myocardial infarction
2581700|NCT02355145||Patient group in moment 1 of evaluation|Study group enrolled in moment 1 of evaluation (Feb - Mar 2015)
2581701|NCT02355145||Patient group in moment 2 of evaluation|Study group enrolled in moment 2 of evaluation (Feb - Mar 2016) - 1 year distance from moment 1
3211660|NCT01007266|Active Comparator|Group B|Individuals receive conventional treatment for type 2 diabetes
3211661|NCT01007279|Active Comparator|CLOPIDOGREL|
2581820|NCT02354300||TCD Ultrasound|Transcranial doppler ultrasound monitoring during flow diverter placement.
2581861|NCT02354170|Experimental|Cohort 1 (m300)|One (1) 300-mg mifepristone tablet, taken once daily for 4 weeks
2581864|NCT02354170|Experimental|Cohort 2 (m900)|Three (3) 300-mg mifepristone tablets (900-mg dose), taken once daily for 4 weeks
2581866|NCT02354170|Placebo Comparator|Cohort 3 (Placebo)|Placebo taken once daily for 4 weeks
2581878|NCT02353884||MCIp,MCIs|progressive MCI：those convert to AD in two years, stable MCI
2581879|NCT02353884||MCI，HC|mild cognitive impairment, healthy control
2581956|NCT02353273|Experimental|WH-1 ointment|WH-1 ointment(1.25%),15g ointment per tube.
2581986|NCT02353117|Active Comparator|Intervention|Behavioral intervention. The intervention will be multifaceted, tailored by formative research, and include: 1) opinion leaders, reminders, monitoring, and feedback; 2) point-of-care rapid tests and immediate treatment if the rapid test is positive; and 3) locally packaged treatment kits (benzathine penicillin 2.4 MIU, syringe and needle, instructions, and information on side-effects).
2581987|NCT02353117|No Intervention|Control|Prenatal care providers at control clinics will be invited to participate in a training workshop. They will be given refresher concepts on the prenatal care package and maternal and congenital syphilis and will be trained in syphilis case detection and management, using their standard and available screening methods. They will also be trained on how to document the screening and treatment process, using the same system as the intervention clinics. No other activities are planned in the control group; providers will be encouraged to disseminate and implement any strategy they consider useful to improve screening and treatment. Study personnel will ensure the availability of screening tests already in-use, as well as ensure the availability of benzathine penicillin at all control prenatal clinics.
2582031|NCT02352883|Experimental|Arm A (MRI)|Patients undergo MRI prior to surgery. Patients undergo additional imaging and/or biopsies if indicated based on MRI.
2582034|NCT02352883|Experimental|Arm B (mastectomy)|Patients undergo a mastectomy. Patients do not register for Step 3.
2582045|NCT02352883|Experimental|Arm C (wide local excision)|Patients undergo wide local excision +/- re-excision. Patients may cross-over to Arm B if mastectomy is indicated. Tissue samples collected during surgery are used to calculate the DCIS score using genetic analysis testing. Patients may then proceed to Step 3.
2582048|NCT02352883|Experimental|Arm D (endocrine therapy)|Patients undergo endocrine therapy as directed.
2582050|NCT02352883|Experimental|Arm E (radiation therapy, endocrine therapy)|Patients undergo radiation therapy and endocrine therapy as directed.
2582222|NCT02351791|Experimental|Patch 1, 3 and 5|"Patch 1, Patch 3 and Patch 5 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
2582227|NCT02351791|Experimental|Patch 2, 4 and 6|"Patch 2, Patch 4 and Patch 6 applied on peristomal skin.~Measurements of skin at three locations of each patch: Center, Leakage pocket and Adhesive."
2582268|NCT02351141|Other|Asthma Patients|All enrolled asthma patients will undergo hyperpolarized noble gas MRI with Helium-3 and/or Xenon-129, Pulmonary Function Tests, Quality of Life Questionnaires, dyspnea scales in two visits over three years.
2582398|NCT02350322|Experimental|Schoolmeal with fatty fish|Fatty fish diet
2582405|NCT02350322|Experimental|Schoolmeal without fish|Meat/cheese diet (non-seafood)
2581092|NCT02359227|Experimental|Cenderitide|Cenderitide will be administered as four, 48-hour, continuous, subcutaneous infusion rates of 0.5, 1.0, 2.0 and 3.0 ng/kg/min totaling up to eight sequential days of dosing.
2581239|NCT02358382|No Intervention|Alpha Stat|Standard CPB blood gas management conditions
2581242|NCT02358382|Experimental|pH Stat|pH stat blood gas management conditions.
2581315|NCT02358174|Experimental|Group I|Patients with symptomatic hemorrhoids - Grade I to IV sec. Goligher. Grade III to IV underwent Hemorrhoidectomy. Blood sampling for MMPs and NGAL plasma levels evaluation will be performed. Tissue sampling (obtained during hemorrhoidectomy) for MMPs and NGAL tissue levels evaluation will be performed in grade III-IV patients.
2581320|NCT02358174|Experimental|Group II|Healthy subjects without hemorrhoids as control groups for MMPs and NGAL plasma evaluation will be performed by means of Blood sampling.
2581357|NCT02357628||Research Group I|Wound treatment with RO-NPT 40%
2581358|NCT02357628||Research Group II|Wound treatment with RO-NPT 60%
2581361|NCT02357628||Research Group III|Wound treatment with RO-NPT 40% and irrigation
2581422|NCT02357407|Experimental|Patients in intensive care|30 patients in intensive care treated with ciprofloxacin IV
2581429|NCT02357407|Experimental|Osteoarticular infected patients|30 patients in orthopedics treated with oral ofloxacin
3176624|NCT00646061|Experimental|1|morphine, ketorolac, and buscopan
3176625|NCT00646061|No Intervention|2|morphine and ketorolac
2581572|NCT02356380|Experimental|Mobilization|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
2581618|NCT02355899|Experimental|PD P 506 A-PDT|One PD P 506 A-patch will be administered to each great toenail for 4 hours. After removal of the study medication the study nail(s) s will be illuminated with red light of defined wavelength (PDT).
2581658|NCT02355548||Outpatient Treatment|All patients eligible for the study will have their PE treated in the outpatient setting.
2581704|NCT02355327|Experimental|Laselle Kegel Exerciser|
2581713|NCT02355327|Active Comparator|Pelvic floor muscle exercises|
2581754|NCT02354807|Experimental|Experimental group|Subjects that undergo both cold exposure and one-time dose of 100mg of Mirabegron drug
3176626|NCT00646074|Experimental|1|Self-Care TALK
3176627|NCT00646074|No Intervention|2|
3176628|NCT00646087|Experimental|Ketamine (6K)|6K: 6 ketamine injections (0.5 mg/kg of ketamine) every other day for 12 days
3176629|NCT00646087|Active Comparator|Ketamine/Placebo (2K4P)|2K4P = two active ketamine injections(2K) and four placebo (saline) injections over 12 days.
2581862|NCT02354105||CZP treatment|axSpA patients who have been newly prescribed Certolizumab Pegol (CZP).
2581954|NCT02353325|Experimental|non-encapsulated FeSO4|Maize porridge with salt fortified with non-encapsulated FeSO4
2581955|NCT02353325|Experimental|encapsulated FeSO4, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added before cooking
2581957|NCT02353325|Experimental|encapsulated FeSO4, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4, added after cooking
2581958|NCT02353325|Experimental|non-encapsulated FeSO4 + ascorbic acid|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid
2581959|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, before cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added before cooking
2581961|NCT02353325|Experimental|encapsulated FeSO4 + ascorbic acid, after cooking|Maize porridge with salt fortified with non-encapsulated FeSO4 and ascorbic acid, added after cooking
2582125|NCT02352441|Experimental|Implementation Intentions|This group will receive training in Implementation Intentions during 3 sessions, 1 day/week, over 3 weeks. They will receive usual care through the standard program, 1 day/week during these 3 weeks.
2582127|NCT02352441|No Intervention|Usual Care|This group will participate in the usual group intervention provided to Service members experiencing executive dysfunction associated with mild traumatic brain injury, 2 days / week during 3 weeks.
2582154|NCT02352142|No Intervention|Standard Care|Mothers are given infant care instruction as part of standard care
2582155|NCT02352142|Experimental|Facilitated infant care|Family Nurture Intervention
2582156|NCT02352142|Other|Full Term EEG|Small group of healthy, Full-Term infants will receive two sleep EEGs (one in unit, and one 4 weeks post discharge) for healthy control comparison to preterm infants
2582243|NCT02351804|Experimental|Ropivacaine + dexamethasone|20 ml ropivacaine 0.5% + 0.5 ml dexamethasone 4 mg7ml
3176630|NCT00646100|Active Comparator|TACE|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization
3176631|NCT00646100|No Intervention|control|best support care
3176632|NCT00646126|Active Comparator|1|1:Active comparator sulfadoxine-pyrimethamine plus artesunate
3176633|NCT00646126|Placebo Comparator|2|2:placebo comparator
3176634|NCT00646178|Active Comparator|A|
3176635|NCT00646178|Placebo Comparator|B|
3176636|NCT00646191|Active Comparator|A|
3176637|NCT00646191|Active Comparator|B|
3176638|NCT00646191|Active Comparator|C|
3176639|NCT00646204|Experimental|1|memantine 10 mg bid
3176640|NCT00646204|Placebo Comparator|2|2 tabs bid
3176641|NCT00646217|Experimental|1|SELF CARE Talk
3176642|NCT00646217|No Intervention|2|Comparison Group
3176643|NCT00646230|Experimental|Single arm of CIV infusion of emulsion 4-HPR|Single arm study of continuous intravenous infusion (CIV) of emulsion 4-HPR
3176644|NCT00646243||1 Heart Failure|216 consecutive consenting patients with refractory heart failure candidate to cardiac resynchronization therapy by clinical and electrocardiographic criteria
3176645|NCT00646243||2 Healthy subjects|120 healthy subject includes defined as absence of history and symptoms of any cardiovascular disease, normal physical examination and ECG.
3176646|NCT00646256|No Intervention|no training|
3176647|NCT00646256|Experimental|COGPACK training|
3176648|NCT00646269|Active Comparator|1|
3176649|NCT00646269|Experimental|2|
3176650|NCT00646269|Experimental|3|
2581009|NCT02359981|Active Comparator|Generic suggestions|Control group participants received suggestions generated by the a nutritionist and exercise trainer. These suggestions didn't relate to user's life or their past behavior.
2581011|NCT02359981|Experimental|MyBehavior|Experiment group participants received personalized suggestions from MyBehavior that relates their life and past behavior.
2581149|NCT02359500|Experimental|68Ga-DOTATOC PET|patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)
2581191|NCT02358811||Eldery SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 70 years old and more
2581196|NCT02358811||Eldery SAOS-|People without obstructive sleep apnea (AHI<10) 70 years old and more
2581198|NCT02358811||Adult SAOS+|Patients with severe obstructive sleep apnea (AHI>30) 18 < Age < 55 years old
2581199|NCT02358811||Adult SAOS-|People without obstructive sleep apnea (AHI<10) 18 < Age < 55 years old
2581251|NCT02358330||EHR Enhanced Clinic Referral|"A set of standard EHR modifications will be implemented in 18 clinics as part of the MBD (multiple baseline design) experiment.The key new EHR functions that will be implemented and tested are: 1) a modified screen for smoking sta-tus to enhance the identification and documentation of all smokers visiting targeted primary care clinics; 2) a Smoker Registry to track smokers, document their receipt of treatment services, and organize direct-to-consumer communications; 3) a 1-click referral system to evidence-based smoking treat-ment with UW-CTRI case managers; 4) a closed-loop feedback feature to communicate to the clinician the fate of a referral, documenting receipt of the referral and treatment engagement; and 5) EHR-based communication options to inform smokers of treatment resources"
2581254|NCT02358330||Standard care (control) clinics|10 control clinics will also be inducted into the study. These clinics will use existing EHR resources to identify smokers (e.g., the expanded vital signs) and to document their smoking status, and then use the standard paper fax-to-quit methods to refer patients to the Wisconsin Tobacco Quit Line
2581297|NCT02358109|Experimental|Intervention arm|Intervention group receive directed classes of physical conditioning, 3 hours/week during a period of 16 weeks
2581304|NCT02358109|No Intervention|Control arm|Control group do not receive physical conditioning intervention but usual care advice and are measured at the beginning and at the end of the study
2581346|NCT02357797|Active Comparator|Vortioxetine|Vortioxetine will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of vortioxetine can be lowered to 10 mg for tolerability reasons.
2581347|NCT02357797|Placebo Comparator|Placebo|Matching placebo pills will be initiated at 10 mg / day for 1 month, followed by 20 mg /day for the remainder of the trial. The dose of placebo can be lowered to 10 mg for tolerability reasons.
2581377|NCT02357550|Placebo Comparator|Control|Saline infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
2581381|NCT02357550|Experimental|Hyperketonaemia|Ketone infusion. FDG-PET Scan. O2-PET scan. H2O-PET scan Muscle biopsy
2581418|NCT02357303|Placebo Comparator|Placebo|Group A - 100mL of water by mouth, 15 to 30 minutes before endoscopy
2581425|NCT02357303|Active Comparator|Simethicone|Group B - 100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
2581433|NCT02357303|Active Comparator|Simethicone plus N-acetylcysteine|Group C - 100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
2581479|NCT02356913|Experimental|Gum A|4 mg nicotine gum; single dose; chewed 30 minutes
2581484|NCT02356913|Experimental|Gum B|4 mg nicotine gum; single dose; chewed 30 minutes
2581491|NCT02356913|Experimental|Gum C|4 mg nicotine gum; single dose; chewed 30 minutes
2581497|NCT02356913|Active Comparator|Nicorette Freshmint|4 mg nicotine gum; single dose; chewed 30 minutes
3211662|NCT01007279|Experimental|ROSUVASTATIN|
2581705|NCT02355314|Experimental|ICU patients requiring mechanical ventilation|
2581757|NCT02354794|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention: see below"
2581813|NCT02354495|Experimental|Diet intervention arm|Individualized diet prescription following food record, indirect calorimetry (for energy requirement) and body composition assessments. repeat assessments after 12 weeks on interventional diet.
2581869|NCT02354209||HIV-1 patients receiving bPI ARV|"Non interventional study. Interventions will be clinically directed rather than by protocol.~The following procedures will be carried out:~Questionnaire on compliance and adherence~Clinic Visit~20ml blood sample to be taken for Virological Resistance Testing and Next Generation Sequencing (only if plasma viral load is detectable)"
2581918|NCT02353559|Experimental|EASE|Patients assigned to the intervention arm will receive 8 - 12 psychotherapy sessions lasting 30 - 60 minutes each, delivered by a trained therapist at our center. Patients will receive specialized symptom control from a nurse/physician team in our Palliative Care Service, when indicated by routine symptom screening.
2581920|NCT02353559|No Intervention|Usual Care|Usual care
2581984|NCT02353429|Experimental|Toremifene treatment|Patients will receive 60 mg daily of Toremifene and the dose will be escalated to 180 mg daily in case of progression
2582037|NCT02352935|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
2582043|NCT02352935|No Intervention|Control|The patients without any treatment
2582089|NCT02352610|Active Comparator|LRTI without a Biotenodesis Screw|Ligament Reconstruction Tendon Interposition without a Biotenodesis Screw
2582098|NCT02352610|Active Comparator|LRTI with Biotenodesis Screw|Ligament Reconstruction Tendon Interposition with Biotenodesis Screw
3211663|NCT01007292|Experimental|YM155 plus rituximab|
2582208|NCT02351583||preclampsia|10 with diagnosis of preeclampsia will be examined with both NIRS and cytocam to obtain data
2582209|NCT02351583||normal pregnancy|10 with normal pregnancy will be examined with both NIRS and cytocam to obtain data
3211664|NCT01007305|Experimental|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy for benign conditions.
2582457|NCT02350023|Active Comparator|Topical latanoprost|Topical latanoprost 0.005%
2582458|NCT02350023|Active Comparator|Topical betamethasone|Topical betamethasone 0.05%
3211665|NCT01007305|Active Comparator|Ovarian conservation|No ovaries or fallopian tubes removed at the time of hysterectomy for benign conditions.
3176651|NCT00646269|Experimental|4|
3176652|NCT00646295|Experimental|A|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes
2581126|NCT02359409|Active Comparator|water immersion only|Colonoscopy will be performed using the water immersion technique.
2581129|NCT02359409|Experimental|water immersion with goggle balloon|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique
2581165|NCT02358967|Placebo Comparator|Placebo|Standard renal care + 300 mg placebo daily for 1 year
2581184|NCT02358967|Active Comparator|Treatment|Standard renal care + 300 mg TRF daily for 1 year
2581231|NCT02358642|Experimental|Angiotensin converting enzyme inhibitor|Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
2581232|NCT02358642|Placebo Comparator|Placebo|Placebo
2581313|NCT02358226|Experimental|Soccer League (SL)|In the SL arm, participants will be invited to participate in a Soccer League, led by coaches who meet the criteria of: 1) soccer skills, 2) being a role model, and 3) social competence. Coaches will undergo intensive training in ethics; role-playing the delivery of health messages; conducting brief interventions for alcohol; how to acquire information on HIV, TB, alcohol use and employment; linkages to local clinics, data collection; and Street Smart, an evidence-based intervention for high-risk youth. Coaches will provide pre- and post-game talks, incorporating the topics of alcohol and drugs; interacting positively with health care providers, partners and family members; HIV, diabetes; daily routines; healthy social networks; making and saving money; loyalty and national success.
2581316|NCT02358226|Experimental|Soccer League/Vocational Training (SL-V)|The SL-V arm will include both the SL intervention as well as access to Vocational Training through either Silulo Ulutho Technologies, which offers computer courses, or Zenzele Training and Development programs, which provides training in woodwork and wielding. Both programs are located in Khayelitsha, which is close to participants' homes, thus avoiding transport-related barriers. Additionally, the training programs occur in a mentor-mentee context so that participants can develop the interpersonal skills required for employment.
2581322|NCT02358226|No Intervention|Control Condition (CC)|Participants in the CC arm will routinely receive flyers with picture stories regarding HIV prevention strategies and how to access these strategies: HIV testing, circumcision, HIV treatment, including ARV, condoms and sexually transmitted diseases.
2581366|NCT02357667||Exposed cases|African American women with concern for severe preterm (37 weeks gestation) preeclampsia who are admitted to the inpatient obstetrical unit at HUP.
2581371|NCT02357667||Unexposed controls|African American women without preeclampsia or medical comorbidity who are matched by gestational age, maternal age, and BMI in the outpatient setting.
2581490|NCT02357108|Active Comparator|Group 1: Video/Doctor Sequence 1|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
2581496|NCT02357108|Active Comparator|Group 2: Video/Doctor Sequence 2|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
2581502|NCT02357108|Active Comparator|Group 3: Video/Doctor Sequence 3|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
2581504|NCT02357108|Active Comparator|Group 4: Video/Doctor Sequence 4|Participants watch two videos with varying video/doctor sequence and complete 3 surveys (one before the first video and one survey after each video)
2581541|NCT02356458|Experimental|Ibrutinib & Bortezomib|Combination therapy (trial treatment of ibrutinib in combination with bortezomib) followed by ibrutinib maintenance therapy
2581591|NCT02356094||Cases|Patients with primary open angle glaucoma, randomly selected from the Glaucoma Outpatient Clinic to be submitted to Pentacam examination
2581593|NCT02356094||Controls|Control group of age and central corneal thickness matched healthy subjects, randomly selected from the General Ophthalmology Outpatient Clinic to be submitted to Pentacam examination
2581634|NCT02355795|Experimental|low-fat diet|Participants will be provided low-fat diet for 6 months
2581637|NCT02355795|Experimental|moderate-fat diet|Participants will be provided moderate-fat diet for 6 months
2581638|NCT02355795|Experimental|high-fat diet|Participants will be provided high-fat diet for 6 months
2581799|NCT02354625|Experimental|ahSC transplantation|Autologous human Schwann cells
2581896|NCT02353923|Experimental|OcuStem Supplementation|Twice daily supplementation with OcuStem. Subjects will take 2 capsules in the morning and 2 capsules at night for a total of 2800 mg/day of active ingredients.
2581990|NCT02353338|Experimental|Group A: Surgical|Individuals in Group A will receive surgery to correct their radial fracture
2581992|NCT02353338|Active Comparator|Group B: Conservative Treatment|Individuals in Group B will be immobilized in a cast, as per usual standard of conservative treatment.
2582028|NCT02352792|Active Comparator|Standard therapy|Standard radiochemotherapy (70 Gy, 5-fluorouracil 600 mg/m2 d1-5, mitomycin C d1+36 or cisplatinum 40 mg/m2 weekly for 5 weeks)
2582040|NCT02352792|Experimental|dose escalation|Standard plus 10% dose escalation to the hypoxic volume
2582094|NCT02352571|Experimental|Single group assignment|GC1118 recombinant human anti-EGFR antibody
2582190|NCT02351908|Experimental|Arm 2|Isentress® (Raltegravir 400 mg) 1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
3176653|NCT00646308||I|Adult patients with GH deficiency due to a nonsecreting pituitary tumor
3176654|NCT00646308||2|Adult patients with a nonsecreting pituitary tumor but without GH deficiency
3176655|NCT00646321|Experimental|1|budesonide/formoterol
3176656|NCT00646321|Active Comparator|2|budesonide
3176657|NCT00646334|Experimental|A|Optilene® Mesh Elastic
3176658|NCT00646334|Active Comparator|B|Ultrapro® Mesh
3176659|NCT00646347|Experimental|A|Conventional stroke upper limb rehabilitation is given
3176660|NCT00646347|Active Comparator|B|Neuro Hand Orthosis Program is given
3176661|NCT00646360|Experimental|1|Docosahexonic acid (400 mg/day)
3176662|NCT00646360|Placebo Comparator|2|
3176663|NCT00646386|Active Comparator|A|
3176664|NCT00646386|Placebo Comparator|B|
3176665|NCT00646412|Experimental|A|A-Part® Gel
3176666|NCT00646412|No Intervention|B|untreated control group
2581015|NCT02359734||Brigham and Women's Hospital.|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Brigham and Women's Hospital. In these unit, the intervention bundle was implemented.
2581021|NCT02359734||Johns Hopkins University Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Johns Hopkins University Hospital. In these unit, the intervention bundle was implemented.
2581026|NCT02359734||Winchester Medical Center|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Winchester Medical Center. In these unit, the intervention bundle was implemented.
2581030|NCT02359734||Central DuPage Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Central DuPage Hospital. In these unit, the intervention bundle was implemented.
2581033|NCT02359734||Vanderbilt University|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Vanderbilt University Medical Center. In these unit, the intervention bundle was implemented.
2581037|NCT02359734||Massachusetts General Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Massachusetts General Hospital. In these unit, the intervention bundle was implemented.
2581038|NCT02359734||University of California, San Diego|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at University of California, San Diego. In these unit, the intervention bundle was implemented.
2581040|NCT02359734||Maricopa Integrated Health System|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Maricopa Integrated Health System. In these unit, the intervention bundle was implemented.
2581041|NCT02359734||Danbury Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Danbury Hospital. In these unit, the intervention bundle was implemented.
2581042|NCT02359734||Candler Hospital|Patients who had IV medications with smart pumps in one surgical unit, one medical unit, one Medical ICU, and one surgical ICU at Candler Hospital. In these unit, the intervention bundle was implemented.
2581082|NCT02359240||sepsis|Patients with a diagnosis of sepsis or severe sepsis,immobilization for 3 days at least. Therapy according to the SSC guidelines will be applied. therapy according to SSC guidelines and muscle biopsy
2581083|NCT02359240||Patients with femoral fractures|non septic patients with a femoral fracture,who need an fixation surgery.standard surgery for femoral fracture and muscle biopsy will be performed.
2581143|NCT02359149|Experimental|nurse|intravitreal injections with anti-VEGF agents given by a nurse
2581146|NCT02359149|Active Comparator|physician|intravitreal injections with anti-VEGF agents given by a physician
2581387|NCT02357563|Experimental|Ulipristal acetate|Women will be treated with an oral dose of ulipristal acetate 5 mg/day for 2 courses of 3 months each
2581394|NCT02357563|Active Comparator|Leuprolile acetate|Women will be treated with an injection IM on leuprolide acetate 11,25 in the luteal phase repeated 3 months later
2581426|NCT02357199|Experimental|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
2581435|NCT02357199|No Intervention|Standard oral care|Standard oral care protocol consisting of referral by staff in the Department of Nephrology to general dental practitioner followed by patient self-administration of tooth brushing, fluoride toothpaste and oral lubricants.
2581473|NCT02357017|Active Comparator|Low salt diet|The low-salt meals will be formulated to provide 50 mmol of sodium per day. Two diets with different caloric amounts (2000 or 2500) will be available.
2581476|NCT02357017|Active Comparator|High salt diet|High dietary salt intake, NaCl tablets (6 grams/day) will added to the subject's study diet in order to increase dietary sodium intake to >250 mmol/day.
3176667|NCT00646425|Experimental|1|Basiliximab
3176668|NCT00646425|Placebo Comparator|2|
2581580|NCT02356172||Healthy Controls|Healthy males or females who are greater than or equal to 18 years old.
2581586|NCT02356172||Patients|Males or females with a diagnosis of IGD (Isolated GnRH Deficiency) who are greater than or equal to 18 years old.
2581982|NCT02353507|Active Comparator|Aquacel Ag+|Absorbent, antibacterial, barrier dressing
3176669|NCT00646438|Active Comparator|1|strict glucose control (study arm)
3176670|NCT00646438|No Intervention|2|standard insulin treatment (control arm)
3176671|NCT00646464||2|Children 6-12 years old diagnosed as not suffering from ADHD
3176672|NCT00646464||1|children 6-12 diagnosed as ADHD
3176673|NCT00646477|Experimental|A|Phase 1 : manual Phase 2 : automatic Descent rate pressure : slow
3176674|NCT00646477|Experimental|B|Phase 1 : manual Phase 2 : automatic Descent Rate Pressure : fast
3176675|NCT00646477|Experimental|C|Phase 1 : automatic Phase 2 : manual Descent rate pressure : slow
3176676|NCT00646477|Experimental|D|Phase 1 : automatic Phase 2 : manual Descent Rate Pressure : fast
3176677|NCT00646490||A|patients with parapneumonic pleural effusion due to community acquired pneumonia
3176678|NCT00646490||B|patients with pleural effusion of other etiologies
3176679|NCT00646503|Experimental|1|600 mg/day, oral telbivudine for 52 weeks
3176680|NCT00646516|Experimental|1|
3176681|NCT00646529|Experimental|1|budesonide/formoterol
3176682|NCT00646529|Active Comparator|2|budesonide
3176683|NCT00646542|Experimental|1|
3176684|NCT00646542|Placebo Comparator|2|
3176685|NCT00646594|Experimental|1|budesonide/formoterol
3176686|NCT00646594|Active Comparator|2|fluticasone/salmeterol
3176687|NCT00646607|Experimental|A|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 3 months or XELOX (capecitabine and oxaliplatin) for 12 weeks.
3176688|NCT00646607|Active Comparator|B|FOLFOX-4 (infusional 5-Fluouracil, leucovorin and oxaliplatin) for 6 months or XELOX (capecitabine and oxaliplatin) for 24 weeks.
3176689|NCT00646620|Experimental|1|budesonide/formoterol
3176690|NCT00646620|Active Comparator|2|fluticasone/salmeterol
2581016|NCT02359942|Experimental|Citric acid group|Giving the citric acid (4g) as test meal before UBT
2581020|NCT02359942|No Intervention|Controlled group|No use of test meal
3176691|NCT00646620|Active Comparator|3|albuterol
2581160|NCT02358902|Experimental|Group A|tDCS (tDCS - DC stimulator, Neurocom, Germany) / AE Group in which will receive active intervention of aerobic exercise training and active tDCS intervention
2581176|NCT02358902|Experimental|Group B|AE group which will receive active intervention of aerobic exercise and placebo tDCS (tDCS - DC stimulator, Neurocom, Germany)
2581185|NCT02358902|Experimental|Group C|tDCS group which will receive placebo AE and active intervention for tDCS (tDCS - DC stimulator, Neurocom, Germany)
2581224|NCT02358590|Experimental|HAPA menu-based mini-video|This group will watch mini-videos, which are multi-target menu-based interventions designed to deliver information about vitamin D adherence and its effect on osteoporosis
2581225|NCT02358590|Active Comparator|Standard care|This group will be advised by the treating physician to take vitamin D
2581268|NCT02358317|Experimental|Video Game Motor Training|Participants in the treatment group will come to the University of Wisconsin lab for six weeks to train 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes and will include playing our in-house Ninja Training game combined with balance games from the Wii Fit.
2581270|NCT02358317|Active Comparator|Sedentary Video Game Training|Participants randomly assigned to this condition will come to the lab for six weeks to play sedentary video games 3-5 days each week under research staff supervision. Each training session will last 30-60 minutes. Pre-and post assessments will be done identically to the Experimental group.
2581289|NCT02358005|Experimental|60mJ ESWT|ESWT (0.04 mJ/mm2, 1500 shock + sham stimulation 2500) / total dose per treatment : 60mJ
2581298|NCT02358005|Experimental|120mJ ESWT|ESWT (0.04 mJ/mm2, 4000 shock) / total dose per treatment : 160mJ
2581306|NCT02358005|Placebo Comparator|sham ESWT stimulation|ESWT (0 mJ/mm2, sham stimulation 4000) / total dose per treatment : 0mJ
2581368|NCT02357771|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
2581369|NCT02357771|Experimental|Probiotic Arm|Lactobacillus brevis CD2 Lozenges (4 Lozenges per day; 2 lozenges in morning and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
2581411|NCT02357472|Experimental|High dose group|dehydroepiandrosterone,DHEA,capsule, 50mg/capsule, one capsule t.i.d..
2581412|NCT02357472|Experimental|Standard dose group|dehydroepiandrosterone,DHEA, capsule, 25mg/capsule, one capsule t.i.d.
2581487|NCT02357082||MRI Scan|Patients with a previously implanted Cardiac Implantable Electronic Device who are undergoing an MRI Scan for clinically indicated, diagnostic purposes.
2581579|NCT02356315||Healthy subjects|Functional magnetic resonance imaging of healthy subjects
2581584|NCT02356315||Chronic neck pain patients|Functional magnetic resonance imaging of chronic neck pain patients
2581624|NCT02355834|Experimental|Group 1 (IBD Nurse CONSULT + BOOKLET)|IBD nurse intervention-Will have 3-4 x 30 minute face-to-face sessions over 3 months with an IBD specialist nurse specifically focusing on bowel control. Participants completing at least 3 sessions will be considered to have completed the intervention. They will also be given a booklet and access to all usual care, including nurse-led IBD helpline
2581628|NCT02355834|No Intervention|Group 2 (BOOKLET alone)|Will receive the same booklet and access to usual care as Group 1.
2581682|NCT02355418||Patients for early surgery|A prospective, cross sectional comparison of asymptomatic patients before and after mitral valve repair surgery for chronic severe primary degenerative mitral regurgitation.Once established, it is our intention to restudy subjects in 5 years to provide information on late outcome following surgery.
2581683|NCT02355418||Patients against early surgery|In order to establish the natural history of diffuse fibrosis in mitral regurgitation, an additional cohort of patients with asymptomatic mitral regurgitation who do not wish to consider early repair will be followed.
2581732|NCT02355041|Experimental|Meal Replacement-based Weight Loss Diet|Experimental participants will be instructed to replace 2 meals per day with a PROBAR meal replacement and consume a dinner under 1000 calories or a dinner under 800 calories and a 200 calorie snack for 90 days. No further nutritional advice or education shall be provided.
2581733|NCT02355041|Active Comparator|Educational Video|"Control participants will view The Weight of the World, a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web."
2581748|NCT02354716||EndoFLIP Measurements|To define the role of a functional luminal imaging probe (EndoFLIP) in benign upper GI luminal narrowing. EndoFlip measurement of the cross sectional area of the narrowing will be obtained prior to and after endoscopic dilation. Patients will follow up for repeat endoscopy and dilation if indicated. EndoFLIP measurements will be made again before and after dilation. The use of EndoFlip may offer insight in to the clinical and endoscopic predictors of successful stricture dilation.
2581819|NCT02354560|Experimental|Erythromycin|Oral treatment with Erythromycin 250-500mg (will be determined according to body weight) twice a day.
2581883|NCT02354183|Experimental|Commitment|A 1-hour orientation session consisting of DBT commitment strategies plus psychoeducation. Therapists will also use commitment strategies to discuss goals related to self-harm. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
2581889|NCT02354183|Active Comparator|Psychoeducation|A 1-hour orientation session consisting of psychoeducation only. The psychoeducation will consist of information about DBT's biosocial theory and about why people self-harm. All participants will complete a DBT skills training group after their orientation.
3176692|NCT00646633|Active Comparator|Acupuncture & educ|Patients will receive a total of 8 acupuncture treatments. In each of the first four sessions, they will also receive patient education.
2581019|NCT02359799|Experimental|Lab group|Lab-based intervention includes 18 training sessions using the IntelliStretch in the lab .
2581025|NCT02359799|Experimental|Home group|Home-based intervention includes 18 training sessions using the IntelliStretch at home.
2581102|NCT02359487|Experimental|Intervention|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
2581104|NCT02359487|Placebo Comparator|Control|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
2581229|NCT02358460|Active Comparator|Pressure-limited ventilation|
2581230|NCT02358460|Active Comparator|Volume-targeted ventilation|
2581279|NCT02358252||Orthostatic hypotension|"Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV).~Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension."
2581282|NCT02358252||Non-orthostatic hypotension|Collection of information of body mass index, modified Ashworth scale, maximal voluntary contraction(MVC), heart rate variability(HRV) Tilt table test was used in this study to identify if the subjects with or without orthostatic hypotension.
2581301|NCT02357966|Experimental|514G3|Phase I of the study will include a single dose of 514G3 at three different dose levels. Phase II utilizes a single dose of 514G3 at the highest dose level. Standard antibiotic therapies will be used in both phases.
2581307|NCT02357966|Placebo Comparator|Placebo|Both Phase I and II will include a single dose of placebo in addition to standard antibiotic therapies.
2581367|NCT02357654|Experimental|GnRH agonist|
2581370|NCT02357654|Placebo Comparator|Placebo|
2581424|NCT02357355|Active Comparator|CMT 1A Group|Patients with CMT 1A will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
2581436|NCT02357355|Active Comparator|Control Group|Patients without CMT 1A who are our normal controls will undergo a driving simulation study. The intervention will be the SIREN driving simulator.
2581478|NCT02357030|Experimental|Methyl-P plus GWI Nutrient Formula|Methylphenidate hydrochloride plus a GWI Nutrient Formula (K-PAX Synergy), both taken twice daily.
3176693|NCT00646633|No Intervention|2. Standard care|Patients in the control arm will continue to receive standard care from their physician.
2581621|NCT02355717||Prospective Cohort|400 otherwise healthy children and adolescents aged 9-15 years will be recruited to participate in a 2-year longitudinal study.
2581663|NCT02355561|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram [mg] formulation 1 [reference] under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg formulation 2 [test] under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg formulation 2 under fed conditions) in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2581668|NCT02355561|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A in Period 1; followed by Treatment C in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2581672|NCT02355561|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B in Period 1; followed by Treatment A in Period 2; followed by Treatment C in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2581676|NCT02355561|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B in Period 1; followed by Treatment C in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2581677|NCT02355561|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C in Period 1; followed by Treatment A in Period 2; followed by Treatment B in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
2581678|NCT02355561|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C in Period 1; followed by Treatment B in Period 2; followed by Treatment A in Period 3. A washout period of at least 7 days will be maintained between each treatment period.
3176694|NCT00646685|Other|1|
3176695|NCT00646685|Other|2|
2581782|NCT02354664||Pompe subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
2581785|NCT02354664||Control subjects|These subjects will receive a thoracic MRI, spirometry, inspiratory load compensation, maximal inspiratory pressure, resting breathing pattern, respiratory muscle endurance test.
3176696|NCT00646698||1|Premenopausal Upper Body Obese (UBO) women with waist-hip ratio > 0.85 and BMI > 28
3176697|NCT00646698||2|Premenopausal Lower Body Obese (LBO) women with waist hip ratio < 0.8 and BMI > 28
3176698|NCT00646698||3|Premenopausal lean women with BMI < 25
3176699|NCT00646711|Experimental|Sequence Group I|Depakote Delayed Release/Depakote Sprinkle
3176700|NCT00646711|Experimental|Sequence Group II|Depakote ER
3176701|NCT00646724|Experimental|1|cotransplantation of islet and mesenchymal stem cell
3176702|NCT00646737|Experimental|1|Mycophenolate sodium
3176703|NCT00646750|Experimental|1|BEAM preceded by Ybritumomab Tiuxetan (Zevalin)
3176704|NCT00646789|Experimental|1|MK0633
3176705|NCT00646802|Active Comparator|A|Progesterone 200 mg
3176706|NCT00646802|Placebo Comparator|B|Placebo
2581023|NCT02359838|Other|Usual Care|Frail/pre-frail hematologic oncology patients receive usual care
2581027|NCT02359838|Active Comparator|Geriatrician Co-Management|Frail/pre-frail hematologic oncology patients receive co-management by a geriatrician
2581150|NCT02359474|Experimental|Trabectedin with regional hyperthermia|"Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.~Additional treatment with regional hyperthermia (RHT): RHT treatment of the tumor area and the surrounding tissue (41-44°C for 60 min treatment time) is applied at the end of Trabectedin infusion (+/- 4 hrs)."
2581151|NCT02359474|Active Comparator|Trabectedin|Trabectedin 1.5 mg/m², 24 hrs continuous i.v. infusion, repetition after 21 days, until progress of disease.
2581180|NCT02358798|Experimental|Preschool aged children detected of CF in neonatal period|Preschool aged children detected of Cystic Fibrosis in neonatal period
2581237|NCT02358746|Experimental|combined endo/epicardial approach|combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
2581241|NCT02358746|Active Comparator|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
2581295|NCT02358161|Experimental|LDE225|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer.
2581372|NCT02357732|Experimental|Nivolumab and Dabrafenib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV every 2 weeks (q2 weeks); Dabrafenib 100mg by mouth (PO) twice a day(BID) every day (QD); Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID QD;
2581373|NCT02357732|Experimental|Nivolumab and Trametinib Combination (doublets)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Trametinib 2mg PO QD;
2581375|NCT02357732|Experimental|Nivolumab, Dabrafenib and Trametinib Combination (triplet)|Level -1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 1mg PO QD; Level 1, Nivolumab 1mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD; Level 2, Nivolumab 3mg/kg IV q2 weeks; Dabrafenib 150mg PO BID; Trametinib 2mg PO QD;
2581413|NCT02357251|Active Comparator|Enhanced recovery protocol|Aspects of perioperative care will be standardized. Specific protocol for pre-operative, intra-operative, and post-operative care will be followed in this group.
2581415|NCT02357251|No Intervention|Standard of care|Treating physicians will determine all aspects of patients' perioperative care. Specifically, the individual surgeon, nurse, resident, fellow, and anesthesiologist caring for the patient will determine the patients' pre-operative counseling, bowel preparation, postoperative nausea and vomiting prophylaxis, IV fluid replacement, use of drains, timing of urinary catheter removal, mobilization, post-operative nutrition, pain medication, and bowel stimulation.
2581466|NCT02357095|Experimental|hysteroscopic monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under hysteroscopic monitoring.The brand of hysteroscope machine is STORZ.
2581467|NCT02357095|Experimental|ultrasonography monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under ultrasonography monitoring.The brand of ultrasonograph is mindray(Z6).
2581469|NCT02357095|Experimental|no monitoring|Method used for the treatment of CSP：Uterine artery chemo-embolization followed by suction curettage under no monitoring
2581520|NCT02356770|Experimental|Collagen Matrix 10808|Mucosal split-thickness flap in combination with the Collagen Matrix 10808.
2581521|NCT02356770|Other|Connective tissue graft (gold standard)|Mucosal split-thickness flap in combination with the connective tissue graft.
2581568|NCT02356328||NovaTears®|
2581696|NCT02355184|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
2581764|NCT02354963|No Intervention|Control arm|No intervention is performed. Assessment of antral follicle count. IVF treatment.
2581766|NCT02354963|Experimental|Experimental arm|"Perform intervention described: Laparoscopy. In vitro fragmentation of the ovarian tissue.~Assessment of antral follicle count. IVF treatment."
2581912|NCT02353702|Experimental|Infusion of Ropivacaine during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of Ropivacaine using parietal catheter at the following dose :~20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml)"
2581914|NCT02353702|Placebo Comparator|Infusion of placebo during 48 hours|"Evaluation of diaphragmatic function with Sniff test after 48h continuous parietal infiltration of placebo using parietal catheter at the following dose :~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour (NaCl 0.9 %)"
2581989|NCT02353234|Active Comparator|WHOLEGRAIN BREAD|Subjects feed with wholegrain bread, for which ferulic acid content has been quantified.
2581991|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 4|Subjects feed with white bread with aleurone fraction in the same portion as wholegrain bread.
2581994|NCT02353234|Active Comparator|WHITE BREAD WITH ALEURONE - 8|Subjects feed with white bread with aleurone fraction, which contains the same quantity of ferulic acid as wholegrain bread.
2582100|NCT02352649|Experimental|Neovasculgen 1|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 0,6 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
2582109|NCT02352649|Experimental|Neovasculgen 2|Gene therapy drug Neovasculgen will be administered by several intraneural injections after surgical nerve reconstruction before wound closing. A dose is 1,2 mg will be dissolved in 1 ml of aqueous vehicle (water for injection) prior to injection.
2582118|NCT02352649|Placebo Comparator|water for injections|Instead of the gene therapy drug, 1 ml of aqueous vehicle (water for injections) will be administered by several intraneural injections.
2582173|NCT02352038|Experimental|LLLT group|LLLT group: orthodontic treatment and low-level laser therapy
2582175|NCT02352038|Placebo Comparator|control group|Control group: orthodontic treatment and no laser treatment.
2582217|NCT02351713|Experimental|Threshold based method|Exercise Week 1 Heart rate (HR) < first ventilatory threshold (VT1) 3 days 20 min/day Week 2 HR < VT1 4 days 25 min/day Week 3 HR < VT1 4 days 30 min/day Week 4 HR < VT1 5 days 30 min/day Week 5-6 HR ≥ VT1 to < second ventilatory threshold (VT2) 5 days 30 min/day Weeks 7-8 HR ≥ VT1 to < VT2 5 days 30 min/day Weeks 9-12 HR ≥ VT2 5 days 30 min/day
3176707|NCT00646815|Experimental|a|the aim of the present study is to characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in 12 adult patients, recently diagnosed with growth hormone deficiency
3176708|NCT00646815|No Intervention|Control|Intramyocellular, intrahepatic and intraabdominal lipid content, lean body mass and body fat percentage, are assessed in ten healthy controls matched on age, gender and BMI.
2581213|NCT02358772||Pre-hospital thrombolysis|Patients with acute ischemic stroke who are cared in a specialized STroke Emergency MObile (STEMO) before admission to the Hospital and receive thrombolytic therapy (either in STEMO or in Hospital).
2581215|NCT02358772||In-hospital thrombolysis|Patients with acute ischemic stroke who receive thrombolytic therapy after admission to an University Hospital.
2581317|NCT02357927|Placebo Comparator|control|simple general telephone call
2581323|NCT02357927|Experimental|Mini-AFTERc Intervention|20-30 minute structured conversation with breast cancer patient using Mini-AFTERc Manual
2581374|NCT02357641||Patients with thoracal disorder|"300 patients with thoracal disorder, cardiac or non- cardiac, are enrolled prospectively to undergo routinely examinations such as clinical and hemodynamic chemistry as well as echocardiography for strain analysis refering to myocardial deformation.~Especially analysis of strain data (circumferential and radial), regional and global left and right ventricular wall movement data and diastolic parameters will be analysed retrospectively to investigate a probable cut off value corresponding to acute coronary disease or non cardiac disorder (Intervention: retrospective echographic myocardial strain analysis refering to acute coronary syndrome)."
2581537|NCT02356679|Experimental|Eupasidin-s tab.|three times per day, 1 tab for each time, PO, during 2weeks
2581545|NCT02356679|Active Comparator|Stillen tab.|three times per day, 1 tab for each time, PO, during 2weeks
2581587|NCT02356120||Suspected Pulmonary Embolus|Patients with suspected pulmonary embolus who are getting a CTPA
2581617|NCT02355847|Other|Healthcare Worker Education|Educational Lectures
2581762|NCT02354937|Experimental|Subjects with renal impairment|Subjects with severe renal impairment will receive single oral dose of 744 30 mg
2581763|NCT02354937|Active Comparator|Subjects with normal renal function|Subjects with normal renal function will receive single oral dose of 744 30 mg
2581827|NCT02354430|Active Comparator|Water-exercise|
2581833|NCT02354430|No Intervention|Control group|
2581871|NCT02354131|Experimental|Niraparib monotherapy|Niraparib mono therapy until progression
2581872|NCT02354131|Experimental|Niraparib-bevacizumab combination|Niraparib-bevacizumab combination therapy until progression
3176709|NCT00646828||without PHA1|patients without mineralocorticoid receptor mutation
2582010|NCT02353078|Experimental|Sucralfate|This is a pilot study in which 6 patients with active EoE defined by consensus criteria (ref) who have undergone recent endoscopy will be administered sucralfate slurry 1 gram four times daily for four weeks following which repeat endoscopy with esophageal biopsies will be performed. Patients will be those who had not had medical treatment for EoE or those who have not responded to proton pump inhibitors.
2582012|NCT02353078|Experimental|Intraluminal Impedance|This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
2582092|NCT02352584|Experimental|GC3110A(Quadrivalent)|0.5ml, intramuscular, a single dosing
2582104|NCT02352584|Active Comparator|GC Flu (Trivalent)|0.5ml,intramuscular,a single dosing
2582115|NCT02352584|Active Comparator|GC3110A(Trivalent)|0.5ml,intramuscular,a single dosing
2582161|NCT02352129|Experimental|Cardiomyopathy dilated patient|Cardiomyopathy dilated patients wil be evalueted by CMR using T1 mapping technique to evalueted the level myocardial fibrosis
2582166|NCT02352129|Active Comparator|healthy subjects|healthy subject wil be evaluated by CMR using T1 mapping technique to know the baseline of myocardial fibrosis in healthy subjects
3176710|NCT00646828||PHA 1|patients with a rare disease, pseudohypoaldosteronism type 1, due to heterozygous inactivating mutations of the mineralocorticoid receptor
3176711|NCT00646841|Experimental|A|
3176712|NCT00646854|Active Comparator|Arm A|
3176713|NCT00646854|Experimental|Arm B|
3176714|NCT00646867|Experimental|1|Experimental
3176715|NCT00646867|Placebo Comparator|2|Placebo
3176716|NCT00646880|Active Comparator|Propiverine/tolterodine group|
3176717|NCT00646880|Active Comparator|Tolerodine/propiverine group|
3176718|NCT00646893|No Intervention|1|Control: assisted hatching, without Preimplantation Genetic Diagnosis
3176719|NCT00646893|Experimental|2|Test: embryo biopsy with Preimplantation Genetic Diagnosis
3176720|NCT00646919||1|All pre-operative pediatric patients in our outpatient clinic
3176721|NCT00646932|Experimental|1|
3176722|NCT00646932|Experimental|2|
3176723|NCT00646932|Experimental|3|
3176724|NCT00646932|Experimental|4|
3176725|NCT00646945|Experimental|A|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)
3176726|NCT00646945|Placebo Comparator|B|50% oxygen/50% Nitrogen premix
3176727|NCT00646971|Experimental|1|CPAP
3176728|NCT00646971|Sham Comparator|2|sham CPAP
3176729|NCT00646984|Active Comparator|1|Standard continuous antiretroviral therapy
3176730|NCT00646984|Experimental|2|CD-4 guided interruption arm
3176731|NCT00646984|Experimental|3|Viral load driven treatment interruption
3176732|NCT00646997||1|Patients with postoperative atrial fibrillation
3176733|NCT00646997||2|Patients without postoperative atrial fibrillation.
3176734|NCT00647023|Experimental|A|
3176735|NCT00647036|Active Comparator|1|Dipeptiven (L-glutamine- Lalanine)
3176736|NCT00647036|Placebo Comparator|2|Isonitrogenous Vaminolact
3176737|NCT00647049|Experimental|A|first diagnosis of PCNSL: combined chemotherapy with methotrexate
3176738|NCT00647049|Experimental|B|Patients with relapse or progressive disease of PCNSL after methotrexate containing chemotherapy
3176739|NCT00647075|Experimental|1|Yunzhi extract 3.5 g/day
3176740|NCT00647075|Placebo Comparator|2|Placebo
2581031|NCT02359929|Experimental|Dose Level 1: Infusion of MSCs|First three subjects enrolled will receive a single infusion of mesenchymal stromal cells based on their individual weight
2581035|NCT02359929|Experimental|Dose Level 2: Infusion of MSCs|Subsequent subjects enrolled will receive two infusions (a week apart) of mesenchymal stromal cells based on their individual weight
2581039|NCT02359929|Experimental|Dose Level 3: Infusion of MSCs|Subsequent subjects enrolled will receive four infusions (a week apart) of mesenchymal stromal cells based on their individual weight
2581111|NCT02359461|Experimental|Stendo group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
2581119|NCT02359461|Other|control group|Subjects will be randomized into two groups determining the sequence: stendo then control, or control then stendo
2581163|NCT02358993|Experimental|Methenamine|Methenamine hippurate is a medication that exhibits antibacterial activity by converting to formaldehyde in the presence of acidic urine. It is currently FDA approved for the prophylaxis of recurrent urinary tract infections. It has been previously used in studies for prevention of UTI after gynecologic surgery. Dosage will be methenamine hippurate 1g, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
2581172|NCT02358993|Active Comparator|Ciprofloxacin|Ciprofloxacin is a commonly used antibiotic commonly used for prevention of UTI after catheterization. It belongs to a class of antibiotics known as the fluoroquinolones. Dosage will be ciprofloxacin 500 mg, 1 tablet by mouth every 12 hours for 24 hours (total of two doses), with the first dose taken at least one hour prior to catheter removal.
2581226|NCT02358577|Experimental|Cycle ergometry|Participants will receive In-bed cycling for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first).
2581227|NCT02358577|Active Comparator|Usual care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization
3211666|NCT01007318|Active Comparator|Single port|Single port through the transumbilical incision was made by wound retractor combined with surgical glove and then 3 trocal was inserted to the finger part of the surgical glove. Laparoscopic instrument was working through the single port and resected appendix removed through it.
3211667|NCT01007318|Active Comparator|3 port|3 port laparoscopic appendectomy was done by conventional method
3211668|NCT01007344|Active Comparator|flaxseed|2 muffins and 1 slice of bread for a total of 30g flaxseed per day
3211669|NCT01007344|Placebo Comparator|whole wheat flour|2 muffins and 1 slice of bread containing whole wheat flour per day
3211670|NCT01007357|No Intervention|Body MRI healthy volunteers|Body MRI to optimize sequences in healthy individuals and in disorder subjects
2581551|NCT02356406|Experimental|Celiac Plexus Radiosurgery|"The study has a prospective, single arm design. It will be composed from an initial run-in safety assessment that will include 6 patients and then continue as a phase II trial.~All eligible patients will receive the same protocol of celiac plexus radiosurgery"
2581566|NCT02356146||All KT recipient|
3211671|NCT01007370|Active Comparator|LMA-Fastrach|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through LMA-Fastrach using fibrescope (one out of ten patients)~Tracheal intubation through the LMA-Fastrach~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3211672|NCT01007370|Active Comparator|I-gel|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel (sizes 3,4 or 5), establishment of ventilation~Evaluation of glottic view through I-gel using fibrescope (one out of ten patients)~Tracheal intubation through the I-gel~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3211673|NCT01007383|Experimental|LEO 27847 oral solution (0.05 mg/mL)|LEO 27847
2581697|NCT02355236|Experimental|Test Group|Naproxen/Esomeprazol 500/20mg and Comparator-Placebo for 12 weeks
2581699|NCT02355236|Active Comparator|Comparator Group|Celecoxib 200mg and Naxozol-Placebo for 12 weeks
2581775|NCT02354677|Experimental|Heathy volunteers, smokers and COPD|
3211674|NCT01007383|Experimental|LEO 27847 oral solution (0.75 mg/mL)|LEO 27847
2581880|NCT02354027|Experimental|SHR3824 25mg/metformin 1000mg|Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
2581925|NCT02353767||Cases|Presence of metabolic syndrome according to the International Diabetes Foundation (IDF)
2581926|NCT02353767||Controls|"age ± 7 years from cases~duration of HIV-1 infection ± 3 years from cases~HIV-1 viral load matched to cases according to 3 thresholds: 50 - 500, 501 - 1000 or > 1000 copies/mL"
2581971|NCT02353364|Experimental|Group A|Transfer of 1 or 2 biopsied euploid embryo of high morphological grade based on NGS testing using CNV-Seq (PGS)
2581973|NCT02353364|No Intervention|Group B|Transfer of 1 or 2 non-biopsied embryo of high morphological grade (no PGS)
2582005|NCT02353013|Active Comparator|Standard Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
3211675|NCT01007383|Placebo Comparator|LEO 27847 oral solution (placebo)|Placebo
3211676|NCT01007409|Active Comparator|Group B|Period 1: fed control → Period 2: fasted control
3211677|NCT01007409|Active Comparator|Group A|Period 1: fasted control → Period 2: fed control
3211678|NCT01007422||Supportive Care|
3211679|NCT01007461|Experimental|IK-1001|IK-1001 Sodium Sulfide (Na2S) for Injection
3211680|NCT01007461|Placebo Comparator|Placebo|0.9% Sodium Chloride (NaCl)
3211681|NCT01007500|Experimental|Group Dexamethasone|
3211682|NCT01007500|Active Comparator|Group Ondansetron|
3211683|NCT01007513||At risk patient for preterm delivery|Patient referred to the MFM clinic for a risk evaluation for preterm delivery.
3211684|NCT01007539|Experimental|CDP-choline|
2581032|NCT02359786||Total Joint Patients undergoing knee and hip replacement|
2581036|NCT02359786||UDT (unrinary drug test) Patients who are given a UDT|
2581079|NCT02359539|Experimental|PRF|Platelets rich fibrin,
2581080|NCT02359539|Experimental|MPP|Marginal periosteal pedicle
2581158|NCT02359188|Active Comparator|tVNS|Transcutaneous vagal nerve stimulation with 25 Hz
2581168|NCT02359188|Sham Comparator|Sham-tVNS|Sham transcutaneous vagal nerve stimulation with 1 Hz
2581218|NCT02358707|Experimental|phonophoresis in knee osteoarthritis|Ibuprofen phonophoresis in patients with knee osteoarthritis
2581235|NCT02358447||SPECT/CT before/after navigated TKR|SPECT/CT in patients before and after navigated TKR (assessment of bone tracer uptake, 3D CT component position)
2581236|NCT02358447||SPECT/CT before/after conventional TKR|SPECT/CT in patients before and after conventional TKR (assessment of bone tracer uptake, 3D CT component position)
2581286|NCT02358213|Other|Procedure|5 ultrasounds were done on 20 patients by 5 different sonographers
3211685|NCT01007539|Placebo Comparator|Placebo (fructose)|
2581417|NCT02357277|Experimental|Budesonide 360 mcg|Budesonide dry powder inhaler 2 puffs of 90 mcg twice daily for 4 weeks
2581423|NCT02357277|Experimental|Budesonide 720 mcg|Budesonide dry powder inhaler 2 puffs of 180 mcg twice daily for 4 weeks
2581434|NCT02357277|Placebo Comparator|Placebo|Placebo inhaler 2 puffs twice daily for 4 weeks
2581480|NCT02356926||Control|Usual care and routine management
2581485|NCT02356926||Cross checking|Systematic cross checking between emergency physicians at 11:30, 14:00 and 16:30
2581528|NCT02356718|Experimental|Experimental|Computerized cognitive training activities
2581533|NCT02356718|Active Comparator|Control|Non-adaptive computerized cognitive training activities
3211686|NCT01007565|Experimental|periarticular injection, pain level|
3211687|NCT01007578|Experimental|Paclitaxel treatment|Paclitaxel-coated balloon catheter angioplasty treated subjects
2581659|NCT02355652|Active Comparator|Cemented TKA|
2581660|NCT02355652|Active Comparator|Uncemented TKA|
2581691|NCT02355249|Experimental|A group (MIE)|Via minimally invasive thoracol-laparoscopic esophagectomy.
2581695|NCT02355249|Active Comparator|B group (OE)|Via traditional three incisions esophagectomy.
2581768|NCT02354651||Pompe subjects receiving NeuDx DPS|Patients will receive resting breathing pattern evaluation, phrenic nerve stimulation, maximal inspiratory pressure (MIP) testing, forced expiratory testing, and EMG.
2581806|NCT02354365||Normal lungs|Mechanically ventilated patients without pulmonary parenchymal disease or lower airway disease as measured by flow volume loops consistent with expiratory flow obstruction (e.g. seizures, apnea, upper airway obstruction).
2581807|NCT02354365||Acute Hypoxic Respiratory Failure|Mechanically ventilated patients with two consecutive Saturation to FiO2 (SF) ratio < 265 or PaO2 to FiO2 (PF) ratio < 300 (e.g. pneumonia, ARDS).
2581808|NCT02354365||Obstructive airway disease|Mechanically ventilated patients with flow volume loops consistent with expiratory flow obstruction (e.g. asthma, bronchiolitis).
3211688|NCT01007604|Active Comparator|Exercise and lifestyle counselling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
3211689|NCT01007604|Experimental|PCD with peristaltic pulse waveform|Daily use for two hours
2581904|NCT02353819|Experimental|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy (SABR)
2581943|NCT02353533|Other|EMR|Standard EMR technique
2581944|NCT02353533|Experimental|FTRD|
3211690|NCT01007630|Active Comparator|Rasagiline|0.5mg of Rasagiline for 14 days, then switch to 1mg of Rasagiline for remainder of the study (approximately 10 weeks total).
3211691|NCT01007630|Placebo Comparator|Placebo|0.5mg of placebo for 14 days, then switch to 1mg of placebo for remainder of the study (approximately 10 weeks total)
3211692|NCT01007669|Active Comparator|Reference|Health check only
3211693|NCT01007669|Experimental|Intervention|Physical activity and Health check
2582124|NCT02352428|Experimental|Skin Cancer Screening Training|Recruited family physicians and dermatologists in Calgary, Canada, take part in a 5.5-hour face-to-face skin cancer screening training program. Screening for skin cancer will be conducted by trained physicians according to instructions they received in the training program.
2582126|NCT02352428|No Intervention|No Skin Cancer Screening Training|Recruited family physicians and dermatologists in Edmonton, Canada, WILL BE TRAINED AFTER THE SCREENING PHASE, i.e. during the screening phase non-trained physicians will carry out skin cancer screenings according to standard medical practice.
2582141|NCT02352181|Placebo Comparator|S group|S Group: will be transfused patients according to standard management based on conventional coagulation profile of the laboratory
2582143|NCT02352181|Experimental|R group|The R group will consist of patients transfused according to an algorithm based on the data of the coagulation ROTEM analysis.
2582159|NCT02351973|Active Comparator|Hydrochlorthiazide|Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg Administration: oral
2582165|NCT02351973|Active Comparator|Amiloride|Amiloride ATC class: C03DB01 Form: Tablet Dose range: Phase 1: 10mg (2 x 5mg tablet) Phase 2: 20mg (4 x 5mg tablet) Maximum allowed dose: 20mg Administration: oral
2582167|NCT02351973|Active Comparator|Hydrochlorthiazide and Amiloride|Hydrochlorothiazide (HCTZ) + Amiloride Form: Tablets (separate tablet of each drug) Dose range: Phase 1: HCTZ 12.5mg (1 tablet) + Amiloride 5mg (1 tablet) Phase 2: HCTZ 25mg (2 x 12.5mg tablet) + Amiloride 10mg (2 x 5mg tablet) Maximum allowed dose: HCTZ 25mg/ Amiloride 10mg Administration: oral
2582234|NCT02351843|Experimental|500 mA ECT|Right unilateral, ultra brief pulse ECT, with 500 mA current amplitude
2582237|NCT02351843|Active Comparator|800 mA ECT|Right unilateral, ultra brief pulse ECT, with 800 mA current amplitude
3211694|NCT01007682|No Intervention|Screening for working memory capacity|
3211695|NCT01007682|Experimental|Distressing movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
2581043|NCT02359708|Experimental|OR nurse group|OR nurses (14) who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. When surgery were completed and before disposal of gloves and gown the fourth culture were taken where the glove cuff meets the gown sleeve, under and above, the inner glove of all OR nurses.When gloves were removed cultures were taken again at three sites on the hand, approximately 2-3 hours.
2581044|NCT02359708|Experimental|Non-hospital group|Non-hospital volunteers who agreed to participate were asked to perform a surgical hand disinfection accordingly to clinic routine. When hands were dry cultures were first obtained at 3 sites, using a moist with saline nylon flocked swab (Copan ESwab, Italia SpA). After hand disinfection; 1) in right hand palm, 2) between index finger and middle finger, 3) nail/cuticle of index finger. This group whore gowns and gloves for approximately 2-3 hours but not kept sterile. The Culture at the glove cuff were left out. When gloves were removed cultures were taken again at three sites on the hand.
2581099|NCT02359448|Experimental|Melatonin|Patients will be prescribed and dispensed from pharmacy sustained -release Melatonin (Circadin) 2mg. This will be taken every night for twelve weeks.
3211696|NCT01007695|Experimental|All patients|All participants enrolled.
3211697|NCT01007708|Experimental|IDP-108|
3211698|NCT01007708|Placebo Comparator|Vehicle|
3211699|NCT01007721|Experimental|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 25 mg plus 2 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
3211700|NCT01007721|Experimental|BI 671800 ED 400 mg|2 capsules of BI 671800 ED 100 mg plus 2 capsules of placebo (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
3211701|NCT01007721|Active Comparator|Montelukast 10 mg|1 over-encapsulated montelukast 10 mg tablet (qd in the morning) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
2581513|NCT02356848|Experimental|Tailored intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence.
2581515|NCT02356848|Placebo Comparator|Current Practice (CP)|This group will receive all the enhancements that the VA has targeted to improve foot risk in diabetes including full EMR functionality, clinical reminders to improve care, and Patient-Centered Medical Home (PCMH) implementation with its benefits for diabetes care. To control for attention and preserve blinding, this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease. This arm will have biweekly calls for the first two months and then monthly calls for the next four months followed by texts or mailings for months 7-18 with the frequency determine by level of treatment adherence to general health recommendations
3211702|NCT01007721|Active Comparator|Fluticasonepropionate nasal spray 200¿g|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 ¿g per nostril) plus 4 capsules of BI 671800 ED placebo (bid in the morning and evening) plus 1 overencapsulated montelukast placebo tablet (qd in the morning)
2581601|NCT02356068||liver transplantation recepient|every patient who had a liver transplantation. 3 blood samples (2.7ml) for the ROTEM analysis
2581684|NCT02355535|Experimental|Open label|Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
3211703|NCT01007721|Placebo Comparator|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening), plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
3211704|NCT01007721|Experimental|BI 671800 ED 800 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening) plus 1 over-encapsulated montelukast placebo tablet (qd in the morning) plus fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
3211705|NCT01007734||1|
3211706|NCT01007747|Experimental|Geranium oil|
3211707|NCT01007760|Placebo Comparator|Room air|
3211708|NCT01007760|Active Comparator|Low dose exposure second-hand smoke|
3211709|NCT01007760|Active Comparator|High dose exposure second-hand smoke|
3211710|NCT01007773|Experimental|Dexmedetomidine|In conjunction with conventional sedative and analgesic agents.
3211711|NCT01007773|Active Comparator|Standard of Care|Patients randomized to conventional sedation will have as the main pharmacologic agents to achieve sedation and analgesia propofol and fentanyl, respectively.
3211712|NCT01007799|Placebo Comparator|Placebo|Placebo pills to take for 12 weeks
3211713|NCT01007799|Active Comparator|Vitamin D|Vitamin D supplement for 12 weeks
3211714|NCT01007851|Experimental|GnRH agonist|
3211715|NCT01007851|Placebo Comparator|Saline|
3211716|NCT01007864|Experimental|piribedil|
3211717|NCT01007864|Active Comparator|pramipexole or ropinirole|
3211718|NCT01007877|No Intervention|No break|
3211719|NCT01007877|Placebo Comparator|Placebo Energy Drink|During a 15 minute break, subjects consume a placebo energy drink
3211720|NCT01007877|Experimental|Red Bull Energy Drink|during a 15 minute break, subjects consume Red Bull Energy Drink
3211721|NCT01007903|No Intervention|Usual Care|
3211722|NCT01007903|Experimental|Tai Chi|
3211723|NCT01007929|Experimental|1|14C-AZD1236
3211724|NCT01007955||Severely Obese|Severely obese individuals scheduled to undergo gastric bypass surgery
3211725|NCT01007968|Experimental|HDACi|
3211726|NCT01007981||CRT device|Patients with Cardiac Resynchronization Therapy(CRT) device implanted in the last 5 years will be studied by the new echo modality.Study doesn't involve acute device implantation.
3211727|NCT01008007|Experimental|A|Viusid in combination with the conventional treatment for acute fever of viral etiology
2581046|NCT02359695|Experimental|GH cycle|Subsequent IVF cycle, supplemented with a low dose of growth hormone.
2581090|NCT02359383|Active Comparator|Chest Physiotherapy group|Conventional medical treatment plus Chest Physiotherapy
2581095|NCT02359383|No Intervention|Control grup|Conventional medical treatment
2581255|NCT02358538|Experimental|Ganaxolone|Maximum of 1800 mg/day or 63 mg/kg/day
3211728|NCT01008007|Active Comparator|B|Conventional treatment for acute fever of viral etiology
3211729|NCT01008020|No Intervention|Dietary supplement: placebo|
3211730|NCT01008020|Active Comparator|Tea catechin extracts|
3211731|NCT01008033|Experimental|IDP-108|
2581505|NCT02356861|Active Comparator|Real, Active LED Treatment Series|These participants will first receive a series of 12, sham LED treatments, At 1 week post completion of the Sham LED treatment series, participants in this group receive a series of 12 real LED treatments from the helmet housing LEDs that deliver photons of light in the infrared range.
2581507|NCT02356861|Sham Comparator|Sham LED Treatment Series|These participants will first receive an initial series of 12 sham LED treatments from the helmet containing the sham LEDs.
2581519|NCT02356536|Experimental|Experimental|
2581585|NCT02356341||NovaTears®|
2581604|NCT02355808|No Intervention|Non Superfast|
2581605|NCT02355808|Other|Non Superfast GP intervention|
2581606|NCT02355808|Other|Non Superfast Tailored Leaflet|
2581607|NCT02355808|Other|Non Superfast GP + Tailored Leaflet|
2581608|NCT02355808|No Intervention|Superfast|
2581609|NCT02355808|Other|Non Superfast GP|
2581610|NCT02355808|Other|Superfast Tailored Leaflet|
2581611|NCT02355808|Other|Superfast GP + Tailored Leaflet|
2581664|NCT02355470|Experimental|Intervention|Participants will receive the GIFTSS intervention provided by college health center staff and clinicians
2581667|NCT02355470|Active Comparator|Control|Participants will receive a brief alcohol use reduction intervention based on NIAAA guidelines provided by college health center staff and clinicians
2581719|NCT02355132||Insurance Intervention Arm|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were randomly chosen to apply for insurance coverage via the Oregon Experiment
2581724|NCT02355132||Control|Oregon OCHIN patients that put their names on the reservation list for the Oregon Experiment and were not chosen to apply for insurance coverage via the Oregon Experiment
2581828|NCT02354313|Experimental|Lenalidomide|lenalidomide 10-15 mg once daily on days 1-21, every 28 day, for two years
2581832|NCT02354313|No Intervention|Observation|no therapy is planned but only observation
2581902|NCT02353845||aMCI|aMCI means a group of patients who do not qualify for a diagnosis of dementia but do display memory impairment beyond what is expected for their age and with regards to the educational history and with positive β-amyloid PET
2581905|NCT02353845||normal control|
2581906|NCT02353845||aMCIp|progressive aMCI：aMCI subjects who will convert to AD during the follow-up period
2581907|NCT02353845||aMCIs|stable aMCI：aMCI subjects who will not convert to AD during the follow-up period
2581923|NCT02353546|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
2581924|NCT02353546|No Intervention|Usual Care|
2581976|NCT02353390|Active Comparator|Oral Water Hydration|Subjects will be given up to 15 minutes to drink up to 500 mL of water prior to the first IM vaccination.
2581978|NCT02353390|No Intervention|Usual Care|Subjects will receive usual care prior to the first IM vaccination. No water or food will be offered.
2582101|NCT02352636|Active Comparator|Treatment arm 1|"Subjects will receive magnetotherapy (MAT). The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm. The experimental object will be applied to the reactive region of each of the six selected acupoints as detected by an acupoint detector. The justifications for selecting these acupoints are described below. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation prior to the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during therapy administration."
2582120|NCT02352558|Experimental|Arm 7|Patients with chronic myeloid leukemia treated with BBI608 and imatinib
2582122|NCT02352558|Experimental|Arm 8|Patients with chronic lymphocytic leukemia treated with BBI608
2582123|NCT02352558|Experimental|Arm 9|Patients with chronic lymphocytic leukemia treated with BBI608 and ibrutinib
2582128|NCT02352402|Experimental|Ticagrelor|Ticagrelor 90mg twice daily for 1 year on top of ASA
2582130|NCT02352402|Placebo Comparator|Placebo|Placebo matching ticagrelor 90mg twice daily on top of ASA
2582182|NCT02351908|Experimental|Arm 1|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat150mg/150mg/200mg/245mg) tablet 1 once daily for 48 weeks
3211732|NCT01008033|Placebo Comparator|Vehicle|
3211733|NCT01008046|Experimental|combined N-acetyl cysteine - CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
2581051|NCT02359669|Active Comparator|Growing up milk (GUM)|GUM associated with StimuLearn intervention.
2581054|NCT02359669|Placebo Comparator|Skimmed Milk|Control group given skimmed milk without StimuLearn intervention.
2581091|NCT02359370|Active Comparator|Magnesium Group|Magnesium Sulphate was administered through continuous infusion, immediately before induction of anesthesia
2581096|NCT02359370|Active Comparator|Lidocaine Group|Lidocaine was administered through continuous infusion, immediately before induction of anesthesia
2581256|NCT02358356|Active Comparator|PRRT|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 1 every 8 weeks for 4 cycles.
2581259|NCT02358356|Active Comparator|CAPTEM|Oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 every 28 day cycle, up to 8 cycles.
2581260|NCT02358356|Experimental|PRRT/CAPTEM|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV) on day 10 every 8 weeks for 4 cycles, with concurrent oral capecitabine 750mg/m2 b.i.d. days 1-14 and temozolomide 75mg/m2 b.i.d. days 10-14 up to 4 cycles.
2581291|NCT02357992|Experimental|Stereotactic Radiotherapy (SRT)|"Participants receive stereotactic body radiotherapy (SABR) once a day for 3-4 days in a row.~50Gy delivered in 4 fractions for central tumor, or 54Gy delivered in 3 fractions for peripheral tumor."
2581432|NCT02357160|Experimental|Choice|Patients given choice over artwork on wall
2581439|NCT02357160|Active Comparator|No choice|Patients not given choice over artwork on wall
2581441|NCT02357160|Placebo Comparator|No artwork|Patients not receiving any artwork on wall
2581489|NCT02356965|Experimental|Ketamine 70 mg Sublingual Wafer|Single dose of 70 mg ketamine sublingual wafer
2581493|NCT02356965|Experimental|Ketamine 100 mg Sublingual Wafer|Single dose of 100 mg ketamine sublingual wafer
2581499|NCT02356965|Placebo Comparator|Placebo|Single dose of placebo sublingual wafer
2581536|NCT02356549|Active Comparator|GROUP 1: (EMR) Tailoring Alone|Patients will be randomized to receive tailored messages based on demographic and disease information extracted from Massey Cancer Center (MCC) electronic medical records (EMR) that will include a) demographic information: age, income, education and health insurance status, b) disease variables: cancer type and severity and c) trial variables: phase of trial being offered and prior trial participation.
2581538|NCT02356549|Active Comparator|GROUP 2:EMR Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from the EMR as in Group 1. Physicians also receive a summary of tailored messages provided to patients.
2581543|NCT02356549|Active Comparator|GROUP 3:EMR+Survey Tailoring alone|Patients will be randomized to receive tailored messages based on EMR data as in Group 1. Patients will complete a survey that will be used to provide a deeper level of tailored messages
2581548|NCT02356549|Active Comparator|GROUP 4:EMR+Survey Tailoring+Feedback|Patients will be randomized to receive tailored messages based on information extracted from their EMR as in Group I. Patients will complete a survey that will be used to provide a deeper level of tailored messages as in Group 3. Physicians also receive a summary of tailored messages provided to patients as in Group 2.
2581639|NCT02355704|Active Comparator|Atorvastatin|22 patients received oral atorvastatin 40 mg 1 time for day for 4 weeks
2581643|NCT02355704|Placebo Comparator|Placebo|22 patients received oral placebo 40 mg 1 time for day for 4 weeks
2581727|NCT02355379|Experimental|GROUP1 -ARM A|LV5FU2 or capecitabine
2581729|NCT02355379|Experimental|GROUP1-ARMB|FOLFOX4 or XELOX
2581730|NCT02355379|Experimental|GROUP2- ARM C|Observation
2581731|NCT02355379|Experimental|GROUP2-ARM D|LV5FU2 or capecitabine
2581970|NCT02353455||healthy|"donors/patients without liver disease, with and without ongoing drug therapy including buffy coat samples of healthy blood / thrombocyte donors.~After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed . Buffy coats are obtained anonymously."
2581972|NCT02353455||prior to therapy|History will be obtained and blood sampling will be performed in patients in whom a drug therapy with a drug with DILI potential is planned.
2581974|NCT02353455||iDILI|Patients with clinical suspicion of idiosyncratic drug-induced liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
2581977|NCT02353455||non DILI|Patients with other forms of liver injury. After pseudonymisation a detailed history and clinical data are obtained and blood sampling will be performed.
3176741|NCT00647088||aortic stenosis|various age and disease severity
2582083|NCT02352558|Experimental|Arm 1|Patients with multiple myeloma treated with BBI608
2582085|NCT02352558|Experimental|Arm 2|Patients with lymphoma treated with BBI608
2582087|NCT02352558|Experimental|Arm 3|Patients with acute myeloid leukemia or myelo-dysplastic syndrome treated with BBI608
3176742|NCT00647088||Controls|Controls free of valvular disease
3176743|NCT00647101|Experimental|Latanoprost group|
3176744|NCT00647114|Experimental|1|V930
3176745|NCT00647114|Experimental|2|V932
3176746|NCT00647127|Active Comparator|Buprenorphine|
3176747|NCT00647127|Active Comparator|Fentanyl|
3176748|NCT00647127|Placebo Comparator|Placebo|
3176749|NCT00647140|Experimental|1|18F-L6DOPA PET
3176750|NCT00647153|Experimental|Radiation: iodine I 123 anti-CEA recombinant diabody T84.66|
3176751|NCT00647166|Experimental|1|Drug: corticosteroid and azathioprine
3176752|NCT00647166|Placebo Comparator|2|Drug: corticosteroid and placebo
3176753|NCT00647179||1|Patients recently diagnosed with acromegaly
3176754|NCT00647192|Active Comparator|1|Eplerenone treatment
3176755|NCT00647192|Placebo Comparator|2|
3176756|NCT00647205|Sham Comparator|1|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count > 350/mm3
3176757|NCT00647205|Sham Comparator|2|HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 < 350/mm3)
3176758|NCT00647205|Sham Comparator|3|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 < 350/mm3)
3176759|NCT00647205|Sham Comparator|4|HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 > 350/mm3)
3211734|NCT01008046|Active Comparator|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles.
3211735|NCT01008072||without buprenorphine preparation|
2581153|NCT02359175|Active Comparator|Active Epidural analgesia|Epidural catheter: Bupivacain 1,0 mg/ml + Fentanyl 2 micrograms/ml. Oral analgesia: Paracetamol, NSAID and placebo tablets.
2581155|NCT02359175|Active Comparator|Placebo Epidural analgesia|Epidural analgesia: Placebo. Oral analgesia: Paracetamol, NSAID and opioids tablets.
2581248|NCT02358499|Experimental|Posaconazole Injection|We will give a single dose of intravenous posaconazole and collect blood samples for pharmacokinetics (PK). The study pool will be enriched by selecting participants with known sequence variations. Every effort will be made to balance age and disease state (HSCT vs. non-HSCT).
2581296|NCT02358122|Active Comparator|Refined wheat|Refined wheat grain, a variety of cereal foods providing no wholegrain
2581305|NCT02358122|Experimental|Wholegrain wheat|Wholegrain wheat grain, a variety of cereal foods providing >100g wheat wholegrain/day
2581310|NCT02358122|Experimental|Wholegrain rye|Wholegrain rye grain, a variety of cereal foods providing >100g rye wholegrain/day
2581363|NCT02357680|Experimental|Intervention group|"Relatives randomized to the intervention group is provied with a diary. Nurses advice relatives on how to write and use the diary under and after the patients stay in the ICU. A written description on how to use the diary is also provided.~At least two photographs of the patient is taken by nurses. Photographs will first be included in the diary when full consent from the patient has been obtained.~Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU."
2581365|NCT02357680|No Intervention|Control group|Standard Care. Patients and relatives recieve a questionaire 3 months after the patient has been dismissed from the ICU.
3211736|NCT01008072||with buprenorphine preparation|
3211737|NCT01008085|Experimental|Self-expanding stent|Stentys stent
3211738|NCT01008085|Active Comparator|Balloon-expandable stent|VISION/Driver
2581567|NCT02356237|Experimental|No episiotomy|Episiotomy will not be performed in this group. Deviation from protocol (i.e. episiotomy performance) will be allowed only according to the discretion of obstetrician in charge of the delivery, in cases of unequivocal benefit to the fetus.
2581570|NCT02356237|No Intervention|Selective episiotomy|The decision to perform episiotomy in this group will be based on routine delivery care, i.e. indistinguishable from any other delivery not participating in the trial.
2581640|NCT02355938|Experimental|Fidaxomicin Arm|Oral Fidaxomicin 200 mg every 12 hours (Placebo for 2 doses) for 10 days
2581642|NCT02355938|Active Comparator|Vancomycin Arm|Oral Vancomycin 125 mg every 6 hours for 10 days
2581665|NCT02355353|Experimental|Imaging arm|
3211739|NCT01008098|Experimental|PTSD group|
2581783|NCT02354638|Experimental|Tobacco users: behavioural counseling|The cab drivers using tobacco will be invited to participate in the tobacco cessation programme at the TCC and will receive three monthly follow-up for one year. Thus intervention will be in the form of behavioural therapy and pharmacotherapy (if required)
2581786|NCT02354638|No Intervention|Non Users|The cab drivers who are not using tobacco in any form will not receive any type of intervention
2581811|NCT02354391|Experimental|Ingenol mebutate and MAL PDT|Participants will recieve Ingenol mebutate 0.015% topical gel treatment applied day 2,3 and 4 to quadrant 1. Patients will recieve ingenol mebutate 0.015% applied on day 1 followed by methyl aminolevulate and photodyamnic therapy on day 5 to quadrant 2. Particpants will recieve methyl aminolevulate and photodynamic therapy on day 5 to quadrant 3, and quadrant 4 will act as the control, with no treatment.
3211740|NCT01008111|Active Comparator|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
3211741|NCT01008111|Placebo Comparator|Dermabond-Placebo Comparator|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
2581947|NCT02353403|Placebo Comparator|Sugar|Control group consuming a dairy dessert containing 35g of dextrose.
2581948|NCT02353403|Experimental|FOS|Group consuming a dairy dessert in which 30% of the dextrose was replaced by FOS.
2582004|NCT02353143|Experimental|MEN1112|Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation
2582081|NCT02352675||Congenital Heart Disease|Infants with congenital heart disease (CHD) who are scheduled to undergo an elective cardiac catheterization lab procedure at Boston Children's Hospital
2582084|NCT02352675||Non Congenital Heart Disease|Infants who do not have congenital heart disease (No-CHD) and are scheduled to undergo a non-cardiac surgery (such as craniofacial surgery, neurosurgery, or orthopedic surgery) in the operating room at Boston Children's Hospital.
2582164|NCT02351999|Experimental|TSP Crosser Transseptal Access System|The TSP Crosser Transseptal Access System is a novel integrated system combining an extendable radiopaque loop wire to aid in localizing the fossa ovalis (FO); an innovative flexible needle to enable controlled selection of the FO puncture site; and a steerable sheath for enhanced maneuvering and orientation of catheters during LA navigation.
2582408|NCT02350322|Experimental|Supplement|Omega-3 capsules
2581132|NCT02359201|Experimental|Sequence 1|Treatment group sequence: Test Product (V0018) on Day 1 and Placebo on Day 2
2581134|NCT02359201|Experimental|Sequence 2|Treatment group sequence: Placebo on Day 1 and Test Product (V0018) on Day 2
2581171|NCT02358915|Experimental|Peri-auricular muscles voluntary contraction training paradigm|The whole training paradigm consists of two steps. At the first step of training, the electrical stimulation (FastStart neuromuscular electrical stimulator) will be applied to facilitate the voluntary contractions of the ear muscles, and the motion of the outer ear in two directions (up/down, forward/backward) will be videotaped and played back to the participants so that they can get real-time visual feedback about their ear movement. At the second step of training, surface EMG electrodes will be placed on the skin around participants' ears. During the training, they are required to move a cursor to a specific target that will randomly appear on the computer screen. The cursor will be controlled by the electrical signal from the contraction of their bilateral peri-auricular muscles. In the computer game, contraction of the left ear muscles will move the cursor to the left side and contraction of your right ear muscles will move the cursor to the right side.
2581293|NCT02358720|Experimental|A: single fraction IMRT with 1 x 24 Gy|single fraction IMRT with 1 x 24 Gy on bone metastasis
2581302|NCT02358720|Active Comparator|B: fractionated RT with 10 x 3 Gy|fractionated RT with 10 x 3 Gy on bone metastasis
2581526|NCT02356640|Active Comparator|EUS-guided celiac ganglion neurolysis|Endoscopic ultrasound guided celiac ganglion neurolysis would be performed
2581532|NCT02356640|Active Comparator|Percutaneous celiac plexus neurolysis|Percutaneous celiac plexus neurolysis would be performed
3176760|NCT00647205|Sham Comparator|5|HIV infected patients with active TB
3176761|NCT00647205|Sham Comparator|6|HIV negative patients with active TB
2581648|NCT02355678|Experimental|IV Dex|dexamethasone 0.5 mg/kg IV with placebo pre-incision infiltration
2581649|NCT02355678|Experimental|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 1.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 3 ml lidocaine 2%, 3 ml lidocaine 2% with epinephrine 1/200 000, 3 ml of bupivacaine 0.5%, 0.5 ml fentanyl 50 µg ml-1, and 0.3 ml clonidine 150 µg ml-1
2581694|NCT02355301||patients with orthopedic disorders|Patients with muscular skeletal impairments receiving a treatment (A, B, C...). The investigators compare these treatments (A, B, C...) in function of ICF model in order to improve the quality of care in orthopedic department.
2581772|NCT02354950|Experimental|Part 1 Cohort 1 (Moderate hepatic impairment subjects)|Subjects with moderate hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
2581774|NCT02354950|Experimental|Part 1 Cohort 2 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
2581778|NCT02354950|Experimental|Part 2 Cohort 3 (Mild hepatic impairment subjects)|Subjects with mild hepatic impairment will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
2581780|NCT02354950|Experimental|Part 2 Cohort 4 (Healthy control subjects)|Healthy control subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by pharmacokinetic sampling for total concentrations of GSK1265744 in plasma
2581885|NCT02353975|Experimental|SHR3824 10mg fasted to fed|SHR3824 tablet, fasting conditions day 1, visit 2, 7 days wash-out, SHR3824 tablet, high fat, high calorie breakfast day 1, visit 3.
2581891|NCT02353975|Experimental|SHR3824 10mg fed to fasted|SHR3824, high fat, high calorie breakfast day 1, visit 2, 7 days wash-out, SHR3824, fasting conditions day 1, visit 3.
2581910|NCT02353741|Experimental|EGFR-TKIs combined with radiotherapy|EGFR-TKIs combined with concurrent thoracic radiotherapy. Receive oral erlotinib 150mg per day with concurrent thoracic radiotherapy, within 2 weeks, pGTV54～60Gy/27～30f/5.5～6w.
2581981|NCT02353507|Active Comparator|Opticell Ag+|Absorbent, antibacterial, barrier dressing
3176762|NCT00647218|Experimental|Experimental|
3176763|NCT00647231|Experimental|A, 2, II, HKT-500 Topical Patch|A Randomized, Multicenter, Double-Blind, Single Dose Study of the Analgesic Properties of HKT-500 and Placebo in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
3176764|NCT00647231|Placebo Comparator|Placebo Patch|Treatment with placebo patch
3176765|NCT00647244|Active Comparator|1|Tenofovir
3176766|NCT00647244|Active Comparator|2|Abacavir
3176767|NCT00647257|Active Comparator|A|
3176768|NCT00647257|Placebo Comparator|B|
3176769|NCT00647283|Experimental|1|Stable liver transplant recipients fulfilling inclusion criteria.
3176770|NCT00647309||1|
3176771|NCT00647309||2|
3176772|NCT00647322|Experimental|1|Reduction in anti-epileptic medications
3176773|NCT00647322|Active Comparator|2|No change in medication. Unchanged treatment
3176774|NCT00647335||1|Women with diagnosis of PCOS
3176775|NCT00647361|Experimental|NAVA|
3176776|NCT00647374||1|
3176778|NCT00647413|No Intervention|1|
3176779|NCT00647413|Experimental|2|expert system intervention on smoking behaviour + feedback of a biomarker
3176780|NCT00647452|Experimental|1|Healthy male volunteers
3176781|NCT00647452|Experimental|2|Healthy female volunteers
3176782|NCT00647465|Active Comparator|1|IFNalpha 2b
3176783|NCT00647465|Placebo Comparator|2|Placebo
3176784|NCT00647478||1|AD
3176785|NCT00647478||2|Control elderly subjects with normal cognitive function
3176786|NCT00647478||3|MCI
3176787|NCT00647491|Experimental|20 mg|20 mg adalimumab eow
3176788|NCT00647491|Experimental|40 mg|40 mg adalimumab eow
3176789|NCT00647491|Experimental|80 mg|80 mg adalimumab eow
3176790|NCT00647491|Placebo Comparator|Placebo|Placebo eow
3176791|NCT00647504||1|Restenosis in Bare metal stent
3176792|NCT00647504||2|Restenosis in Drug eluting stent
3176793|NCT00647504||3|Stent thrombosis
3176794|NCT00647504||4|Control group
3176795|NCT00647517|Experimental|ultracet|
2581064|NCT02359812||Healthy|Healthy volunteers with no history of neurological disorders
2581066|NCT02359812||Stroke|Patients had a recent stroke, two weeks or earlier prior to enrollment
2581081|NCT02359279|Experimental|Contrast|All subjects will be in one group who will have a control radiograph before applying sodium iodide to interproximal surfaces of teeth when another radiograph will be taken to test for the presence of caries cavitation.
2581170|NCT02359162|Experimental|P-Gemox|"P-Gemox:gemcitabine :1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
2581188|NCT02359162|Active Comparator|EPOCH|"EPOCH:Patients received the EPOCH chemotherapy regimen every 3 weeks. The EPOCH regimen included a 24 h continuous infusion of etoposide (50 mg/m 2 /day), vincristine (0.4 mg/m 2 /day) and doxorubicin(10 mg/m 2 /day administered on days 1-4, followed by cyclophosphamide (750 mg/m2 /day) over 15 min intravenously on day 5 and prednisone (60 mg/m 2 /day) on days1- 5 orally.~IMRT：IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions."
2581244|NCT02358486|Experimental|Acupuncture|Participants in this group are given 10 times of real acupuncture treatment for 4 weeks.
2581246|NCT02358486|Sham Comparator|Sham acupuncture|Participants in this group are given 10 times of sham acupuncture treatment for 4 weeks.
2581294|NCT02358083|No Intervention|Arm 1. HPV + Control + Control|HPV is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
2581303|NCT02358083|Experimental|Arm 2. HPV + Control + Strong|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
2581309|NCT02358083|Experimental|Arm 3. HPV + Control + Disclosure|HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
2581319|NCT02358083|Experimental|Arm 4. HPV + Safety + Control|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
2581321|NCT02358083|Experimental|Arm 5. HPV + Safety + Strong|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
2581324|NCT02358083|Experimental|Arm 6. HPV + Safety + Disclosure|HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
2581325|NCT02358083|No Intervention|Arm 7. Flu + Control + Control|Flu is target vaccine. No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
2581326|NCT02358083|Experimental|Arm 8. Flu + Control + Strong|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
2581328|NCT02358083|Experimental|Arm 9. Flu + Control + Disclosure|Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
2581329|NCT02358083|Experimental|Arm 10. Flu + Safety + Control|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
2581331|NCT02358083|Experimental|Arm 11. Flu + Safety + Strong|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
2581333|NCT02358083|Experimental|Arm 12. Flu + Safety + Disclosure|Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
2581390|NCT02357615|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 8-week treatment period.
2581397|NCT02357615|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 8-week treatment period.
3211742|NCT01008124|Experimental|Liberatory Maneuver|Liberatory Maneuver
3211743|NCT01008124|Placebo Comparator|Placebo Maneuver|Placebo Maneuver
2581494|NCT02356874|Experimental|Exercise group|Exercise
2581501|NCT02356874|No Intervention|Control group|Participants in the control group will be asked to continue their usual physical activity habits
3211744|NCT01008137|Experimental|Group 1: Day 0-PANFLU.1; Day 21-ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine; Day 21: 15 μg ANFLU vaccine.
2581603|NCT02356029||EMS Healthcare Providers|Healthcare Providers working in Emergency Medical Services and directly involved in treatment of cardiac arrest patients (out-of-hospital or in the Emergency Department)
2581615|NCT02355730|Experimental|Warfarin Patients|Single Arm - blood collection by venepuncture in patients undergoing Warfarin Therapy
3211745|NCT01008137|Experimental|Group 2: Day 0-ANFLU; Day 21-PANFLU.1|50 subjects to receive-Day 0: 15 μg ANFLU vaccine; Day 21: 15 μg PANFLU.1 vaccine.
3211746|NCT01008137|Experimental|Group 3: Day 0-PANFLU.1+ANFLU|50 subjects to receive-Day 0: 15 μg PANFLU.1 vaccine+ANFLU vaccine.
2581894|NCT02353962|Experimental|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. 5 sessions per week, 30-45 minutes per training for 3 weeks, with an intensity individually adjusted by the treating therapist according to the progress of the participating patient.
2581941|NCT02353676|Experimental|BUPIVACAINE GROUP|1.5 ml of 0.5% Bupivacaine solution to be injected into the operative site postoperatively.
3211747|NCT01008163|Experimental|1|YY-351, PO, 1T tid. / Placebo, 1T tid.
3211748|NCT01008163|Experimental|2|YY-351. PO, 2T bid. / Placebo 2T qd.
3211749|NCT01008163|Experimental|3|YY-351, PO, 2T tid.
3211750|NCT01008163|Placebo Comparator|4|Placebo, PO, 2T tid.
3211751|NCT01008189|Active Comparator|Self study comparison group|Caregivers and children and adolescents each received three books about coping with grief after the death of a loved one and a syllabus to guide reading
3211752|NCT01008189|Experimental|Family Bereavement Program|12- session group for caregivers and bereaved children and adolescents plus 2 individual sessions
2581086|NCT02359214|Active Comparator|Vitamin D3 Supplement|This group will receive a daily dose of 5000IU (125µg) vitamin D3 (which is half of the recommended safe tolerable upper intake level of vitamin D for healthy individuals) for eight weeks.
2581087|NCT02359214|Placebo Comparator|Placebo|This group will receive 100% lactose placebo daily for eight weeks.
2581166|NCT02359071||Handovers with lower durations|equal or lower than 20 minutes
2581181|NCT02359071||handovers with higher durations|Higher than 20 minutes
2581240|NCT02358733|Experimental|Treatment|Intra-cytoplasmic Morphologically-selected Sperm Injection (IMSI)
2581243|NCT02358733|Active Comparator|Control|Intracytoplasmic sperm injection (ICSI)
2581311|NCT02358148||STEMI / NSTEMI|All patients (100%) admitted to the participating hospitals during the study period with the diagnosis of Acute ST Segment Myocardial Infarction (STEMI) or Non-ST Segment Myocardial Infarction (NSTEMI) will be selected for inclusion in the study. In order to assure rapid door-to-reperfusion times, Study Investigators will obtain consent and interview these patients AFTER cardiac catheterization and intervention. A minimum number of 25 STEMI and 25 NSTEMI patients will be enrolled in the study.
2581318|NCT02358148||Elective / Non-emergent Cardiac Cath|This group will include both admitted and outpatients, with possible diagnoses of Unstable Angina (UA), Low Risk Chest Pain (LRCP), and those having cardiac catheterization for any other reason (eg: elective, medical clearance for surgery, failed stress test, etc.). To maintain integrity of the study, these patients will be randomly selected, with written consent obtained, prior to cardiac catheterization.
3211753|NCT01008215|Experimental|Algorithm|Algorithm (available in paper version and web-based version) will be used for warfarin maintenance dosing.
3211754|NCT01008215|No Intervention|Care as usual|Control group
3211755|NCT01008228|Active Comparator|tube thoracic drainage|drainage performed with tube drainage CH 16 or ch 20
2581645|NCT02355964|Experimental|exercise|exercise (Aerobe training) 3 times per week
2581647|NCT02355964|Experimental|Diet|A diet with an overall high protein content and a low glycemic index
2581651|NCT02355964|Experimental|Diet+Exercise|A diet with an overall high protein content and a low glycemic index combined with exercise (Aerobe training) 3 times per week.
2581652|NCT02355964|No Intervention|control|Regular lifestyle (no intervention)
2581689|NCT02355366|Experimental|Family Focused Therapy (FFT)|Participants will receive Family-Focused Therapy (FFT). It will consist of twelve, 1-hour long sessions, over a period of 4 months. The 12 sessions will include psychoeducation (sessions 1-4), training in communication enhancement (sessions 5-8) and training in relation to problem-solving skills (sessions 9-12).
2581693|NCT02355366|Active Comparator|Brief Educational Treatment|Participants will be receive 1-2 educational sessions which will include diagnostic feedback, recommendations for further treatment and crisis intervention if required.
3211756|NCT01008228|Experimental|exsufflation|exsufflation with a specific thoracentesis system
3211757|NCT01008241||Adult Residents of South Florida|Persons 18 years of age or older, residing in Broward or Miami-Dade Counties.
3211758|NCT01008254|Experimental|Musical prompt|
2581969|NCT02353182|Experimental|Active open label single arm|"Dexmedetomidine- remifentanil- caudal based anaesthetic for lower abdominal/lower extremity surgery.~Dexmedetomidine (Precedex): loading dose: 1 mcg/kg over 10 minutes. Infusion: Start 1 mcg/kg/hr; titrate up or down within 50% of starting doses as needed~Remifentanil (Ultiva): loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed~Caudal- Bupivacaine (Marcaine) 0.175%-0.25% or Ropivacaine (Naropin) 0.2% with dose at discretion of anaesthetist"
2582029|NCT02352870|Experimental|Computerised CBT with therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly plus they receive three telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future~In addition to completing the seven online sessions the intervention arm received three 30 minute telephone support calls at weeks two, four, and six to facilitate engagement and understanding of the contents of the website."
2582039|NCT02352870|Active Comparator|Computerised CBT without therapist support|"Participants complete seven online cognitive behavioural therapy sessions weekly but do not receive any telephone support calls. The content of each of the sessions are summarised below:~Session 1: Psycho-education about end-stage renal failure Session 2: Generation of CBT hot cross bun model of psychological distress Session 3: Coping strategies for managing negative emotions, including: acceptance, relaxation, expression and tips for improving sleep quality.~Session 4: Identifying and challenging unhelpful thoughts Session 5: Goal setting and problem solving Session 6: Managing difficult social relationships Session 7: Progress recap and preparing for the future"
2582077|NCT02352545|Experimental|Experimental: Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
2582078|NCT02352545|Placebo Comparator|Placebo Comparator|Patients in placebo treatment arm were given placebo tablets(main excipient lactose monohydrate,p.o., 10mg, q.d.). All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
3211759|NCT01008254|Active Comparator|Delayed musical prompt|
3211760|NCT01008254|No Intervention|No musical prompt|
3211761|NCT01008267||SWL under general anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general anesthesia.
3211762|NCT01008267||SWL under general selective anesthesia|Patients who failed in SWL under sedation(a standard protocol), will undergo a second SWL process under general selective anesthesia, using a bronchial blocker.
3211763|NCT01008293|Experimental|VSL#3|
3211764|NCT01008293|Active Comparator|Lactulose|30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
3211765|NCT01008306||Renal transplanted children and young adults|"Renal transplanted children and adolescents (2-18yrs) transplanted between 1993-2006.~Renal transplanted young adults aged 20-35 yrs old, transplanted from 1983 onwards."
3211766|NCT01008332|Experimental|Cohort 1|ToleroMune HDM, subjects to receive either active or placebo comparator
2581183|NCT02359123|Experimental|Cannabics 5mg|Patients will be treated initially for 3-4 days with 1x5mg Cannabics capsules per day for gradual adaptation. From the 5th day, patients will be treated 2x5mg capsules per 24 hours for a period of 3 months. However, since some patients may suffer from side effects mainly, dizziness and or anxiety, dosage for these patients will be reduced to 5mg per day.
2581217|NCT02358681|Experimental|Ketorolac, intranasal|"Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route, single dose.~Placebo, intravenous."
2581220|NCT02358681|Active Comparator|Ketorolac, intravenous|"Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route, single dose.~Placebo, intranasal."
2581287|NCT02358239|Experimental|Efficacy and safety of acupuncture for dizziness and vertigo|To evaluate the efficacy and safety of acupuncture in treating patients with dizziness and vertigo in ED.
3211767|NCT01008332|Experimental|Cohort 2|ToleroMune HDM, subjects to receive either active or placebo comparator
3211768|NCT01008332|Experimental|Cohort 3|ToleroMune HDM, subjects to receive either active or placebo comparator
2581509|NCT02356835|Experimental|APT001|The APT001 is a medical device that generates a plasma flow containing nitric oxide intended to be applied topically to wound sites. The nitric oxide / plasma flow will be directed at the wound site and surrounding skin at a distance of 11.5 to 15 centimeters from the skin surface. Dose will be 10 seconds / cm2 wound surface area. Administration of the therapy will include a 2 cm border around the defined edges of the wound site.
2581511|NCT02356835|Sham Comparator|SHAM|Treatment with a sham device to deliver non-medicated, heated room air to the wound in the same manner and dose as the active treatment device.
2581524|NCT02356445||Cytotoxic drug|Patients treated for sarcoidosis
2581630|NCT02355990|Experimental|MIMS|Minimally Invasive Micro Sclerostomy
2581703|NCT02355496|Experimental|Displaying medicare fee data|The active arm is the intervention group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will have medicare fee data displayed in the computerized provider order entry system.
2581711|NCT02355496|No Intervention|Control Arm|The control arm is the group of randomly selected inpatient laboratory tests (about 15 most frequently ordered and about 15 most expensive) that will not have medicare fee data displayed.
2581751|NCT02354898|Experimental|BBI503, BBI503 and Sorafenib|
2581815|NCT02354547|Experimental|SGT-53 with Topotecan/Cyclophosphamide|There will be 4-6 cycles (21 days/cycle) of therapy in this trial. In cycle 1, SGT-53 will be given as a single agent twice weekly starting at 1.4 mg/m² of DNA per infusion to evaluate single-agent toxicity. Pharmacokinetic studies will be performed. In the absence of dose limiting toxicity, patients will proceed to cycle 2 even if they have progressive disease. Starting in cycle 2, SGT-53 will be administered twice-weekly in combination with topotecan and cyclophosphamide administered daily for 5 days, days 1-5 of each cycle. Day 1 of each combination cycle is the first day on which topotecan and cyclophosphamide are administered with SGT-53. If a subject has at least stable disease after four cycles of therapy and is tolerating protocol therapy, two additional cycles may be considered.
2581887|NCT02354079|Other|genetic analysis|
2581931|NCT02353728|Experimental|All Patients|Nilotinib at a dose of 300 mg P.O. twice a day (BID) daily
2581975|NCT02353312|Experimental|Initial Intervention Arm|Kuvan® supplementation in addition to standard care for heart failure for three months. At the end of three months, stop Kuvan®, patients will only receive Standard care for heart failure for another 3 months
2581979|NCT02353312|Active Comparator|Delayed Intervention Arm|Standard care for heart failure for three months. At the end of three months, Starting Kuvan® supplementation in addition to Standard care for heart failure for another 3 months
2582041|NCT02352987|Experimental|Patients treated with 3 drugs|Neem plus propylene glycol plus salicylic acid: Neem extract, propylene glycol (40%) and salicylic acid (10%) once daily on palm for 12 weeks
2582046|NCT02352987|Active Comparator|Patients treated with 1 drug|Salicylic acid once daily on palm for 12 weeks
2582086|NCT02352519|Experimental|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
2582088|NCT02352519|Active Comparator|Local infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision.
2582137|NCT02352246|Experimental|steady-state exercise (SSE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
2582138|NCT02352246|Other|high intensity intermittent exercise (HIIE)|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
2582168|NCT02352012|Experimental|Autologous blood group A|Autologous blood was perfused to the target pulmonary segment
2582171|NCT02352012|Experimental|Bronchial plug group B|Bronchial plug was placed to the target pulmonary segment
2582172|NCT02352012|No Intervention|control group|Control group was given to continuous negative pressure drainage
2582225|NCT02351726|Experimental|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
2582302|NCT02351219|Experimental|FOLFOXIRI|
2582318|NCT02350751|Experimental|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) supplied as 50 mg/mL solution for infusion. MEDI8852 is being evaluated for treatment of patients hospitalized with influenza A.
2582319|NCT02350751|Placebo Comparator|Placebo|Solution containing no active ingredients
3211769|NCT01008332|Experimental|Cohort 4|ToleroMune HDM, subjects to receive either active or placebo comparator
2581120|NCT02359396|Experimental|5.0g of MZRW|The participants will receive 5.0g of MZRW at 9 am .
2581124|NCT02359396|Experimental|7.5g of MZRW|The participants will receive 7.5g of MZRW at 9 am.
2581128|NCT02359396|Experimental|10g of MZRW|The participants will receive 10g of MZRW at 9 am.
2581190|NCT02358941|Experimental|Training in a school setting|"A minimum of 30 sessions (45 min.) over at least 12 weeks in the schools of the participants.~Half of the children will be assigned to NF training, the other half to CCT."
2581194|NCT02358941|Experimental|Training in a clinical setting|"A minimum of 30 sessions (45 min.) over approx. 12 weeks at the Department of Child and Adolescent Psychiatry (treatment as usual).~Half of the children will be assigned to NF training, the other half to CCT."
3211770|NCT01008332|Experimental|Cohort 5|Toleromune HDM, subjects to receive either active or placebo comparator
3211771|NCT01008345|Experimental|ezetimibe|will receive the active treatment with ezetimibe and statin
3211772|NCT01008345|Placebo Comparator|placebo|
3211773|NCT01008371||Obese|Healthy obese subjects
3211774|NCT01008371||Non-obese|Healthy non-obese subjects
2581707|NCT02355288|Active Comparator|Minimally Invasive Coronary Bypass|Minimally invasive bypass surgery (MICS CABG) would be conducted to treat the left anterior descending (LAD) artery disease in diabetic patients. This would be a surgical intervention, and differs from the stent procedure arm.
2581714|NCT02355288|Active Comparator|Percutenous Coronary Intervention|Percutaneous coronary intervention (PCI) with drug eluting stents would be used to treat left anterior descending (LAD) artery disease in diabetic patients. This would be an intervention induced by cardiology, and differs from the surgical intervention arm.
3211775|NCT01008384|No Intervention|placebo|
3211776|NCT01008384|Experimental|Vitamin D3|Vitamin D3 given for 8 weeks
2581823|NCT02354274|Active Comparator|Standard: Homogeneous dose plan|Treatment will be given over 33 treatments. The dose is 66 Gy.
2581829|NCT02354274|Experimental|Escalation: Inhomogeneous dose plan|"Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.~Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration"
2581882|NCT02354040|Experimental|Talking Rx|Assigned to receive Health Literacy and Reminder Updates via the IT based intervention Talking Rx, in addition to Usual Care for patients in the intervention group. The physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
2581886|NCT02354040|No Intervention|Usual Care, Prescriptions and Counselling|Assigned to receive a standard prescription and Counselling only, there are no cointerventions in this group
3211777|NCT01008397|Experimental|AHIST for seasonal allergic rhinitis|AHIST for SAR: each green tablet contains 12mg chlorpheniramine tannate.
3211778|NCT01008436|Active Comparator|Control|Traditional best-practice surgical hemostasis
2582030|NCT02352857|Placebo Comparator|Sugar|Control group consuming sponge cakes containing in total 24g of dextrose.
2582035|NCT02352857|Experimental|FOS|Group consuming sponge cakes in which 30% of the dextrose was replaced by FOS.
2582079|NCT02352597|Active Comparator|clomiphene citrate|only50 mg orally every 8 hours started from cycle day 3 for 5 days
2582080|NCT02352597|Active Comparator|estradiol valerate and CC|2mg estradiol valerate orally daily from cycle day 7 - 11 in addition to CC
2582082|NCT02352597|Active Comparator|Phytoestrogen and CC|20mg of cimifuga racemosaorally from day 1- 12) in addition to CC
2582152|NCT02352168|Active Comparator|Budesonide nasal spray|Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks.
2582153|NCT02352168|Placebo Comparator|Placebo|Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks.
2582215|NCT02351856|Experimental|ARRY-371797|
2582260|NCT02351466||Children with Type 1 Diabetes|Subjects with T1 diabetes will undergo a physical exam and blood test as well as structural and functional brain MRI, neurocognitive testing and wear a continuous glucose monitor every 3 months for 24 months.
2582261|NCT02351466||Healthy Controls|Subjects will undergo a physical exam and blood test as well as structural and functional brain MRI at baseline and after 24 months.
2582303|NCT02351102|Active Comparator|Valacyclovir|Participants will receive Valacyclovir at a dose of 8g/d starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
2582304|NCT02351102|Placebo Comparator|Placebo|Participants will receive placebo pills (same daily amount as the intervention group) starting at time of proof of primary maternal CMV infection and until amniocentesis (minimum 21 weeks gestation)
2582322|NCT02350725|Experimental|Group 1|Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
2582339|NCT02350725|Experimental|Group 2|Oral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.
3211779|NCT01008436|Experimental|Omni-stat Celox|Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis
3211780|NCT01008488|Active Comparator|Antibiotic|
2582476|NCT02349737||Electromagnetic Interference|
3211781|NCT01008488|No Intervention|No antibiotic|
3211782|NCT01008501||Experimental|Individuals with recurrent or sporadic hydatidiform moles and their first-degree family members. Sometimes additional family members are also enrolled.
3258984|NCT01466413|Experimental|Restylane|"Patients with an even subject identification number (SIN) (02, 04, 06, 08, 10, 12, 14, 16) will have ELAPR to the right arm and the control to the left, where patients with an odd subject identification number (01, 03, 05, 07, 09, 11, 13, 15) will have the ELAPR to the left arm and the control to the right.~Patients will receive either device ELAPR002c or ELAPR002e. This will alternate to minimise bias between the right and left arms.~The first group of eight patients (01 - 08) will have their biopsy performed at day 169. The second group of eight patients (09 - 16) will have their biopsy at day 85."
3211783|NCT01008527|Experimental|Infusion and Peptide Administration|Patients get the study drug Oncovir poly IC:LC with or without CP 870-893. Up to 6 groups of 3 to 10 patients each will be treated in this study. The first group (between 3 and 6 patients) gets peptide vaccine with poly IC:LC. Second, third and fourth groups of 3 to 6 patients receive peptide vaccine with poly IC:LC and the antibody CP 870,893 at increasing doses from 0.01, 0.025 and 0.05 mg/kg. CP 870-893 will be given to 10 patients at a dose of 0.1 mg/kg to patients in the fifth group, and 0.2 mg/kg to the sixth group. The CP 870,893 will be given as an intravenous infusion over 30 minutes and will be given once every 2 weeks for the first 6 infusions. CP-870-893 will then be given every 4 to 6 weeks for 3 injections. The final 3 injections of CP 870,893 will be given every 8 to 12 weeks. These infusions will take place on weeks 1, 3, 5, 7, 9, 11, 17, 21, 25, 33, 41, and 53 for a total of 12 infusions.
3211784|NCT01008566|Experimental|Treatment (cixutumumab, sorafenib tosylate)|Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3211785|NCT01008592||Group 1|Subjects with chronic idiopathic urticaria exhibiting dermatographism.
2581481|NCT02357069|Experimental|LBEC0101|Etanercept
2581486|NCT02357069|Active Comparator|Enbrel|Etanercept
3211786|NCT01008631|Experimental|dialysis|Two doses of sodium thiosulfate
3211787|NCT01008631|Experimental|healthy volunteer|One dose of sodium thiosulfate
3211788|NCT01008644|Experimental|Saline|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min.
3211789|NCT01008644|Experimental|Water|The subjects will drink tap water for 2 hours, the volume calculated as 20ml/kg/hour
3211790|NCT01008657|Experimental|"extranodular no touch multipolar RFA"|
2581765|NCT02354729|Experimental|Intervention|Participants received text messages and financial incentives after successfully documenting that they were carrying their epinephrine auto-injectors, based on principles of behavioral economics.
2581767|NCT02354729|No Intervention|Control|Participants received text messages.
3211791|NCT01008657|Active Comparator|intranodular multipolar RFA|
2582019|NCT02353039|Experimental|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
2582022|NCT02353039|Experimental|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
2582024|NCT02353039|Experimental|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
2582032|NCT02353039|Placebo Comparator|Placebo|Administer placebo t.i.d for 2 weeks.
2582108|NCT02352454|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
2582117|NCT02352454|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
3211792|NCT01008670||Device Implant Recipients|Patients undergoing CRT implantation, or candidates for future CRT devices currently undergoing ICD or pacemaker implantation.
3211793|NCT01008683||Stem cell and and heart transplant patients|Stem cell and and heart transplant patients
2582253|NCT02351531|Experimental|New Thickened Extensively Hydrolyzed formula|
2582278|NCT02351193||Group I|poor responder females with age less than 35
2582289|NCT02351193||Group II|poor responder females with age more than 35
2582336|NCT02350920|Active Comparator|Acceptance and Committment Therapy (ACT)|This group will consist of patients who will receive ACT therapy.This intervention will run with 8-12 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
2582348|NCT02350920|No Intervention|Control|The control group will consist of patients who will receive no ACT therapy during the 26 week st udy period
3211794|NCT01008709|Placebo Comparator|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur
2582459|NCT02349880|Active Comparator|control|5 hour cognitive training
2582460|NCT02349880|Experimental|intervention|5 hour shared decision making training
2582543|NCT02349607|Experimental|PF-05089771 300 mg|
2582550|NCT02349607|Experimental|PF-05089771 300 mg + pregabalin 300 mg|
2582553|NCT02349607|Placebo Comparator|Placebo|
2582557|NCT02349607|Active Comparator|pregabalin 300 mg|
2582560|NCT02349607|Active Comparator|ibuprofen 600 mg|
2582592|NCT02348970|Experimental|mandibular advancement devices ONIRIS®|The patients will use the mandibular advancement devices ONIRIS®
2582605|NCT02348970|Active Comparator|laboratory devices TALI|The patients will use the laboratory devices TALI
2582658|NCT02348541|Other|CollaGUARD|
2582687|NCT02348463||treatment of bacterial vaginosis|women with bacterial vaginosis will be offered treatment with clindamycin-2-phosphate
2582692|NCT02348255|Experimental|Treatment (bevacizumab, carmustine, NovoTTF-100A)|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks beginning on day -7 for up to 13 doses and carmustine IV over 4 hours every 8 weeks beginning on day 1 for up to 3 doses. Patients also undergo NovoTTF-100A according to standard procedures starting one week before the first dose of carmustine.
3211795|NCT01008709|Active Comparator|Aesculap U-Clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur.
3211796|NCT01008735||women with hodgkin lymphoma treated with chemotherapy|
3258985|NCT01466426||DVT confirmed|
3258986|NCT01466426||DVT ruled out|
3258987|NCT01466426||PE confirmed|
3258988|NCT01466426||PE ruled out|
2581577|NCT02356276|Placebo Comparator|Control group|"6-8 cycles of systemic chemotherapy (XELOX or SOX regimens) were performed after radical gastrectomy with D2 lymphadenectomy.~XELOX regimen is Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~If XELOX regimen is not conducted in some collaborators, SOX regimen as comment systemic chemotherapy in Asia is also permitted to treat the patients. The treatment bundles are listed as follows: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40-60 mg/m^2 bid (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid), po, day 1-14, every 3 weeks for a total of 6-8 cycles."
3211797|NCT01008761|Active Comparator|Zithromax, 100 mgmgs; 5mls suspension|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
3211798|NCT01008761|Placebo Comparator|Suspension placebo,|placebo (suspension produced by CDC Edmonton.) given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days.
3211799|NCT01008774|Experimental|A|
3211800|NCT01008774|Active Comparator|B|
2582384|NCT02350621|Active Comparator|ACDF|Anterior Cervical Discectomy and Fusion
2582389|NCT02350621|Active Comparator|miPCF|minimal invasive Posterior Cervical Foraminotomy
2582442|NCT02350166|Experimental|Laparoscopic group|Laparoscopic group, laparoscopic surgery or laparoscopic-assisted small-incision for resection of laparoscopic colorectal tumor combined with synchronously small-incision open resection of liver metastasis
2582443|NCT02350166|No Intervention|Conventional group|Conventional group, conventional laparotomy for simultaneously resection of both primary colorectal tumor and liver metastasis
2582470|NCT02349724|Other|Pancreatic cancer|Pancreatic cancer treated with Anti-CEA-CAR T.
2582471|NCT02349724|Other|Lung cancer|Lung cancer treated with T cells modified with Anti-CEA-CAR T.
2582472|NCT02349724|Other|Gastric cancer|Gastric cancer treated with T cells modified with Anti-CEA-CAR T.
2582473|NCT02349724|Other|Breast cancer|Breast cancer treated with T cells modified with Anti-CEA-CAR T.
2582475|NCT02349724|Other|Colorectal cancer|Colorectal cancer treated with T cells modified with Anti-CEA-CAR T.
2582535|NCT02349464|Active Comparator|Intervention|For infants receiving pediatric care at one of the seven intervention practices, mothers will receive the Specialized Preterm Infant/Mother Dyad Lactation Support which includes home equipment and pediatric clinic-lactation support to support lactation for four months post-hospital discharge.
2582544|NCT02349464|No Intervention|Control|For infants receiving pediatric care at one of the seven control practices, mothers will receive standard support.
3211801|NCT01008774|No Intervention|C|
3258989|NCT01466439|Other|high frequency rTMS|
2582768|NCT02347891|Experimental|Belimumab + Standard of Care|"Patients in this arm will be given belimumab with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will continue to receive belimumab during the open label phase of the study (week 40 - week 64)"
2582769|NCT02347891|Active Comparator|Placebo + Standard of Care|"Patients in this arm will be given a placebo with a background of standard of care therapy during the randomized controlled treatment period.~Patients in this arm will receive belimumab during the open label phase of the study (week 40 - week 64)."
2582848|NCT02347384|Experimental|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will be implanted with Delta PLUS Femoral Head & SL-TWIN Stem
2582850|NCT02347384|Active Comparator|BIOLOX forte ball head + SL-PLUS Stem|Subject will be implanted with BIOLOX forte ball head & SL-PLUS Stem
2582932|NCT02346955|Experimental|Cohort A Monotherapy Dose Escalation|Participants will be enrolled in a staggered manner starting at a dose of 0.01 mg/kg of CM-24 (MK-6018) and continuing to 0.03, 0.1, 0.3, 1.0, 3.0, and 10 mg/kg to determine the recommended Phase 2 dose (RP2D). The dose will be escalated after a 6- to 8-week DLT window. Participants will be treated for 12 weeks during Cycle 1. Afterwards participants with clinical benefit and no dose-limiting toxicites (DLTs) are treated for up to 6 cycles.
2582933|NCT02346955|Experimental|Cohort B Combination Dose Escalation|Participants will be enrolled at the recommended phase 2 dose (RP2D) of CM-24 (MK-6018), determined by escalation studies, minus 1 dose level of MK-6018 in combination with a fixed dose of 200 mg pembrolizumab. Participants will be escalated to the RP2D of MK-6018 + 200 mg pembrolizumab. If the RP2D of MK-6018 + 200 mg pembrolizumab is not tolerated, the dose of MK-6018 will be de-escalated but will not fall below 1 mg/kg. Participants will be treated for 6 weeks during Cycle 1 and 2. Afterwards participants with clinical benefit and no DLTs are treated for up to 35 cycles.
2582934|NCT02346955|Experimental|Cohort C Monotherapy Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
2582936|NCT02346955|Experimental|Cohort D Monotherapy Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
2582937|NCT02346955|Experimental|Cohort E Monotherapy Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24 (MK-6018) for up to 17 cycles.
2582941|NCT02346955|Experimental|Cohort C1 Combination Expansion|Participants with advanced or recurrent cutaneous melanoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
2582944|NCT02346955|Experimental|Cohort D1 Combination Expansion|Participants with advanced or recurrent colorectal cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
2582948|NCT02346955|Experimental|Cohort E1 Combination Expansion|Participants with advanced or recurrent gastric cancer will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
2582969|NCT02346656||Treated subjects|All subjects recruited and treated with the Axium neurostimulator
3258990|NCT01466439|Other|low frequency rTMS|
2581612|NCT02355912|Experimental|Evaluate a real-time adaptive neural control system|The prosthesis will be tuned, for each subject: level-ground walking, walking up and down slopes and walking up and down stairs. We anticipate that participants will visit the laboratory approximately 6-9 times over 2 months (2-3 visits for socket duplications and modifications, 2-3 visits for control system tuning, and an additional 2-3 visits for practice using the tuned system). By the end of these visits, the goal is to have a properly fitting socket and for the subjects to ambulate proficiently with the powered prosthesis. After tuning, the subjects will complete 20 ambulation circuits (level ground walking, walking up and down slopes, up and down stairs). This will provide training data for our pattern recognition control systems.
2581702|NCT02355197|Active Comparator|antioxidant|1 gram L-ascorbic acid (vitamin C capsule) orally once per day from the time of diagnosis until the time of delivery in addition to treatment for gestational diabetes mellitus in the form of diet and insulin
2581712|NCT02355197|No Intervention|control|Only treatment for gestational diabetes mellitus in the form of diet and insulin
2581773|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, BA|1; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, BA
2581776|NCT02354872|Experimental|Mini-Lozenge, BR, 5Rs, No BA|2; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, 5Rs, No BA
2581781|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, BA|3; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, BA
2581784|NCT02354872|Experimental|Mini-Lozenge, BR, No 5Rs, No BA|4; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, BR, No 5Rs, No BA
2581787|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, BA|5; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, BA
2581788|NCT02354872|Experimental|Mini-Lozenge, No BR, 5Rs, No BA|6; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, 5Rs, No BA
2581790|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, BA|7; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, BA
2581791|NCT02354872|Experimental|Mini-Lozenge, No BR, No 5Rs, No BA|8; This arm of the project will address the following question: How effective is the following intervention? Mini-Lozenge, No BR, No 5Rs, No BA
2581792|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, BA|9; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, BA
2581793|NCT02354872|Experimental|No Mini-Lozenge, BR, 5Rs, No BA|10; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, 5Rs, No BA
2581795|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, BA|11; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, BA
2581798|NCT02354872|Experimental|No Mini-Lozenge, BR, No 5Rs, No BA|12; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, BR, No 5Rs, No BA
2581800|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, BA|13; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, BA
2581801|NCT02354872|Experimental|No Mini-Lozenge, No BR, 5Rs, No BA|14; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, 5Rs, No BA
2581802|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, BA|15; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, BA
2581803|NCT02354872|Experimental|No Mini-Lozenge, No BR, No 5Rs, No BA|16; This arm of the project will address the following question: How effective is the following intervention? No Mini-Lozenge, No BR, No 5Rs, No BA
3211802|NCT01008787|No Intervention|Focus Group|Qualitative interviews examining social support for PA conducted with African American (AA) women recruited from Wheeler Avenue Baptist Church located in Houston used to design Culturally-Appropriate Peer-based Motivational Interviewing (CAPMI) intervention.
3211803|NCT01008787|Active Comparator|Intervention Group 1|CAPMI Intervention: Training + Weekly Partner Questionnaire + Interview + PA Newsletter
2581935|NCT02353585||Intracranial hemorrhage|Intracranial hemorrhage occuring in patients on novel oral anticoagulants (NOAC) or vitamin-K antagonists
2581938|NCT02353585||Acute ischemic stroke|Acute ischemic stroke occuring in patients on novel oral anticoagulants (NOAC) or vitamin K antagonists (VKA)
2581960|NCT02353260|Experimental|Ultrasound Hyperthermia+Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)~The treatments will be administrated in accord with the guideline for other types of cancer.~Ultrasound Hyperthermia: Ultrasound hyperthermia d1,3,5,7,9/21d for 2 cycles"
2581962|NCT02353260|Active Comparator|Chemotherapy|"Chemotherapy:~Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2cycles)~The treatments will be administrated in accord with the guideline for other types of cancer."
2581980|NCT02353104|Experimental|Onion-Pumpkin Extract|Take two capsules, twice daily before breakfast and dinner
2582002|NCT02353000|Experimental|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases:
3211804|NCT01008787|Active Comparator|Intervention Group 2|Interview + PA Newsletter
3211805|NCT01008800|Experimental|Center-Based classroom intervention|Four days a week for 2.5 hours a day the child will participate in a classroom with peers in an attempt to increase social communication, language abilities, and other skills. Parents will also receive education sessions 1-3 times per month for 1-2 hours each. Treatment will last for 6 months.
3211806|NCT01008800|Active Comparator|Parent Training|Parents are taught strategies on how to interact with their children to increase their skills. Parent training sessions are given 2 times a month at our center and once a month at home for 60-90 minutes each. Treatment will last for 6 months.
3211807|NCT01008813|Experimental|adjuvanted A(H1N1)v influenza vaccine|Two injections at day 0 and day 21
2581698|NCT02355262||Arm II (Tool Implementation with Interactive Facilitation)|Participants receive CATCH-UP tools which include a panel management/data aggregator system that identifies patients who may be eligible for public coverage but are not yet insured, or who are nearing coverage expiration, coupled with automated patient outreach and communication. Participants also receive additional implementation support such as trainings, assistance with workflows, and practice facilitation.
2581755|NCT02354911|Experimental|Immunoregulatory Dendritic Cells (iDC)|Biological intervention consisting of autologous dendritic cells treated in vitro to convert to active immunoregulatory dendritic cells.
2581760|NCT02354911|Placebo Comparator|Placebo Control|Saline injections administered blinded to subject and all study staff except for research pharmacist who is not involved in study conduct
2581870|NCT02354196||CCTA|Subjects who underwent a CCTA
2581899|NCT02353858|Experimental|RtChx + Hyperthermia|Radiotherapy: 5 x 1,8 Gy/Week, cumulative dose 50,4 Gy (ICRU) Chemotherapy: 5-fluorouracil d1-5 and d29-d33 Deep regional hyperthermia: 2x/week
2581949|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 1|Participants will recieve crenezumab dose level 1 once every 4 weeks.
2581950|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 2|Participants will receive crenezumab dose level 2 once every 4 weeks.
2581951|NCT02353598|Experimental|Double-blind treatment window: Crenezumab dose level 3|Participants will receive crenezumab dose level 3 once every 4 weeks.
2581952|NCT02353598|Placebo Comparator|Double-blind treatment window: Placebo|Participants will receive placebo matched to crenezumab once every 4 weeks.
2581953|NCT02353598|Experimental|Optional OLE window: Crenezumab|Participants will receive crenezumab dose levels 1 2, or 3 once in every 4 weeks.
2582007|NCT02353065|Active Comparator|Control|Assessment of adequacy of reduction by bedside x-ray during period of intravenous regional anaesthesia (Biers block)
2582008|NCT02353065|Experimental|Ultrasound|Assessment of adequacy of reduction by bedside ultrasound performed by the treating clinician during period of intravenous regional anaesthesia (Biers block)
2582068|NCT02352714|Active Comparator|Paracervical Nerve Block|Ten milliliters of 1% lidocaine paracervical anesthetic will be injected at three cervical locations: 1 mL at the tenaculum site (12 o'clock on a clock face) and 4.5 mL each at the 4 o'clock and 8 o'clock positions. A 3 minute waiting period will be used between the administration of the paracervical nerve block and the insertion of IUS to allow the paracervical block to take effect.
2582070|NCT02352714|Sham Comparator|Sham Paracervical Block|To perform the sham cervical block, the cervix will be touched with the blunt end of a Q-tip at the three locations described above for the paracervical block. The cervical mucosa will not be broken during the sham block. A 3 minute waiting period will again occur between administration of the sham block and IUS insertion to be consistent with the procedure used for the nerve block.
2582096|NCT02352467|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment and usual and customary care, which can include advanced therapeutics.
2582107|NCT02352467|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive usual and customary care, which can include advanced therapeutics.
2582157|NCT02351986|Experimental|Subacromial Impingement Syndrome|Subjects between 18 to 45 years, with Subacromial Impingement Syndrome at least one week.
2582158|NCT02351986|No Intervention|Control|Healthy subjects between 18 to 45 years.
2582275|NCT02351388|Active Comparator|Active stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
2582285|NCT02351388|Sham Comparator|Sham stimulation|Duration: 30 minutes Intensity: 2 mA Placement: left dorsolateral prefrontal cortex and right supraorbital area Size of electrodes: 5 cm x 7 cm Frequency: 5 days a week for three weeks
2582333|NCT02350842|Experimental|Triple-site biventricular pacing|Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.
2582346|NCT02350842|Active Comparator|Standard biventricular pacing|Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.
2582414|NCT02350400|Experimental|DEBIRI|For unilobar disease, two treatments will be planned, separated by four weeks. For bilobar disease, there will be four treatments planned, alternating between right and left lobe, separated by 2 weeks duration.
2582487|NCT02349906|Experimental|Treosulfan|"One Treosulfan dose per day administered i.v. on three consecutive days (-6, -5 and -4); given over 2 hours as part of background conditioning prior to allogeneic stem cell transplantation.~The dose has to be calculated as follows:~If the BSA (m2) is equal or less than 0.3, the Treosulfan dose should be 10g/m2/day.~If the BSA (m2) is greater than 0.3 and equal or less than 0.8, the Treosulfan dose should be 12g/m2/day.~If the BSA (m2) is greater than 0.8, the Treosulfan dose should be 14g/m2/day."
2582488|NCT02349906|Active Comparator|Busulfan|Total daily Busilvex dose (3.2 to 4.8 mg/kg/day, based on body weight) according to authorised dosage for children and adolescents administered i.v. as part of the background conditioning regimen on four consecutive days (days -7, -6, -5 and -4); given in 1, 2, or 4 portions per day according to the respective hospital's standard.
2582525|NCT02349321|Experimental|School Strengthening|Skhokho Supporting Success for Schools: (a) Full year Grade 8 Life Orientation Learner Workbook (following the national curriculum), Educator Guide, and LO Educator support workshops; (b) Educator workshops including values, positive discipline skills, adolescent development, and stress and coping; (c) Learner club workshops (Grade 8s-11s) including creating change for a safe and vibrant school community, human rights at school, communication and conflict resolution skills, and stress and coping.
2582604|NCT02348931|Active Comparator|Surgery plus device (Nasella)|Person in need of surgery has cast for one week, then use of customized nasal brace for nose (Nasella) deformities during 8 weeks.
3258991|NCT01466452|Active Comparator|Aspirin 100|
3258992|NCT01466452|Active Comparator|Aspirin 200|
2581723|NCT02355093|Active Comparator|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
2581743|NCT02354742|Active Comparator|Early Goal Directed Therapy (EGDT)|EGDT is currently standard of care in management of septic shock, so assignment to this treatment arm will confer no additional risk above that of standard of care. EGDT utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications. EGDT uses central venous catheter to assess central venous pressure and ScVO2.
2581746|NCT02354742|Experimental|Echo Guided Fluid Resuscitation|The echo arm also utilizes placement of a central venous catheter, an arterial catheter, and administration of intravenous fluid and vasoactive medications, all of which are interventions found in standard care. The central venous pressure will not be monitored in this arm. Instead, decisions for giving fluids will be directed by the results of Echocardiography. Echocardiography poses no known risk to the patient, and it is non-invasive. The only risk of echocardiography is that of misdiagnosis.
2581814|NCT02354573|Active Comparator|Active arm|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
2581817|NCT02354573|Placebo Comparator|Placebo arm|All subjects will receive matching placebo tablets twice daily for 2 weeks in a double-blind randomized crossover design.
2581863|NCT02354118|Active Comparator|Control Group|Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
2581865|NCT02354118|Experimental|Intervention Group|Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
3176796|NCT00647517|Placebo Comparator|placebo|
3176797|NCT00647530|Experimental|Pre&Post Op Chemo|12 weeks of OxFP neuoadjuvantly followed by surgery and 18 weeks of OxFP
3176798|NCT00647530|Experimental|Pre&Post Op Chemo with P-mab|12 weeks of OxFP and panitumumab neuoadjuvantly followed by surgery and 18 weeks of OxFP alone.
3176799|NCT00647530|Active Comparator|Post Op Chemo|surgery followed by 24 weeks of OxFP.
3176800|NCT00647543|Experimental|High Risk|
3176801|NCT00647543|Experimental|Low Risk|
2582363|NCT02350699||Control|Nautilus BrainPulse
2582369|NCT02350387|Experimental|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
2582370|NCT02350387|Experimental|Low Intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
2582446|NCT02350244|Experimental|Experimental group|Subjects of the experimental group will have to follow an intervention for one month, consisting in active breaks from computer work
2582447|NCT02350244|Other|Control group|Control group patients had no intervention
2582502|NCT02349698|Other|Acute Lymphoblastic Leukemia|Acute lymphoblastic leukemia treated with chimeric antigen receptor modified T cells targeting CD19.
2582506|NCT02349698|Other|Chronic Lymphcytic Leukemia|Chronic lymphocytic leukemia with chimeric antigen receptor modified T cells targeting CD19.
2582507|NCT02349698|Other|Non-Hodgkin Lymphoma|Non-hodgkin lymphoma treated with chimeric antigen receptor modified T cells targeting CD19.
2582609|NCT02348931|Experimental|Surgery, no device thereafter|Person in need of surgery has cast for 1 week; thereafter no use of customized nasal brace (Nasella) .
3176802|NCT00647543|Experimental|Medium Risk|
3176803|NCT00647569|Experimental|A|No previous major abdominal surgery
3176804|NCT00647569|Experimental|B|Previous major abdominal surgery
3176805|NCT00647595|Experimental|A|Women in this group will exercise 3x per week at a moderate/vigorous level for 45 min per session through their 36 week of pregnancy.
3176806|NCT00647595|No Intervention|B|Women in this group will continue their usual activities throughout their pregnancy.
3176807|NCT00647608|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
3176808|NCT00647608|Active Comparator|2|Inderal® LA Capsules 160 mg
3176809|NCT00647621|Experimental|1|Extended Phenytoin Sodium Capsules 100 mg
3176810|NCT00647621|Active Comparator|2|Dilantin® Kapseals® 100 mg
3176811|NCT00647634|Experimental|1|Alprazolam Extended-Release Tablets 3 mg;
3176812|NCT00647634|Active Comparator|2|Xanax XR® Tablets 3 mg
3176813|NCT00647647|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
3176814|NCT00647647|Active Comparator|2|Lamisil® Tablets 250 mg
3176815|NCT00647660|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
3176816|NCT00647660|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
3176817|NCT00647673|Experimental|1|Verapamil HCL Extended-Release Capsules 300 mg
3176818|NCT00647673|Active Comparator|2|Verelan® PM Extended-release Capsules 300 mg
3176819|NCT00647686|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
3176820|NCT00647686|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
3176821|NCT00647712|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
3176822|NCT00647712|Active Comparator|2|Depakote ER® Tablets 500 mg
3176823|NCT00647725|Active Comparator|I|Active phrase analgesia
3176824|NCT00647725|Active Comparator|II|Latent phrase analgesia
3176825|NCT00647738|Experimental|1|
3176826|NCT00647738|Active Comparator|2|
3176827|NCT00647751|Experimental|1|Lamotrigine Tablets 25 mg
3176828|NCT00647751|Active Comparator|2|Lamictal® Tablets 25 mg
3176829|NCT00647764|Experimental|Single Arm|
3176830|NCT00647777|Experimental|1|Olanzapine Tablets 5 mg
3176831|NCT00647777|Active Comparator|2|Zyprexa® Tablets 5 mg
3176832|NCT00647790||1|Patients with a confirmed diagnosis of invasive breast cancer who are undergoing surgery.
3176833|NCT00647816|Experimental|1|Propranolol Hydrochloride Extended-Release Capsules 160 mg
2581726|NCT02355080|Active Comparator|Standard of care (SOC)|Participants will receive the standard of care (SOC) at the study sites. The SOC entails venipuncture whole blood HIV testing + venipuncture whole blood HCV testing. Blood draws are sent to an external laboratory for processing, and patients must return for test results in another visit. Patients may not receive pre-test information or results and post-test counseling, especially if non-reactive or negative test result(s). Reflex testing is not standard practice, therefore some patients may require another visit and blood draw for confirmatory HIV and/or HCV RNA testing. Linkage to care in the SOC is accomplished by referral to a health care provider, either within the participating substance use disorder treatment organization or passive referral to other health facilities.
2581752|NCT02354768|Experimental|lanreotide and anti-diarrheal treatments|"Lanreotide: 1 single injection at day 0 (lanreotide 120 mg)~Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~hydration"
2581756|NCT02354768|Active Comparator|Current anti-diarrheal treatments alone|"Diosmectite (3 g) 6 / day for 72 hours (fromD0 to D3)~Chlorhydrate of Loperamide (2 mg capsule or tablet) 6 / day for 72 hours (D0 to D3)~Hydration"
2581893|NCT02354053|Active Comparator|Current ART|Current ART + adherence support
2581895|NCT02354053|Experimental|Triumeq|Triumeq + adherence support
2581932|NCT02353637|Active Comparator|Male High Protein, Restricted Carbo, Partial Meal Replacement|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
2581933|NCT02353637|Active Comparator|Female High Protein, Restricted Carbo, Partial Meal Replaceme|A high protein, restricted carbohydrates diet that utilizes partial meal replacements
2581983|NCT02353286|Experimental|Post-cholecystecomy bile leak|Endoscopic insertion of biodegradable biliary stent
2581985|NCT02353286|Experimental|Benign biliary stricture|Endoscopic insertion of biodegradable biliary stent
2582026|NCT02352909|Active Comparator|Control|Education will be given on how to modify running training to encourage improvement of symptoms.
2582038|NCT02352909|Experimental|Muscle recruitment|Subjects will receive an additional exercise program targeting non task-specific strengthening and motor control exercises of the lower limb.
2582044|NCT02352909|Experimental|Reduction of knee loading|Subjects will receive additional personalized advice on how to modify running gait in order to reduce mechanical loads at the knee (gait retraining).
2582091|NCT02352532|Experimental|Low Back Pain - Dry Needling|
2582105|NCT02352532|Sham Comparator|Low Back Pain - Sham|
2582116|NCT02352532|Active Comparator|Asymmptomatic - Dry Needling|
2582144|NCT02352194||Assessment|"One part of this study is to quantify physical capacity of patients with Multiple sclerosis.~Thirty patients will be enrolled in this study and performed assessments."
2582147|NCT02352194||Rehabilitation|A second part of this study is to quantify the benefit of a usual rehabilitation program in the day hospital. Thirty patients will be enrolled in this study and receive rehabilitation. They will be assessed before and after the rehabilitation program (physiotherapy and physical activity)
2582366|NCT02350439|Experimental|Adenosine intravenous infusion at 200μg/Kg/min|Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min
2582377|NCT02350335|Active Comparator|NRT|"Active smokers with acute aneurysmal hemorrhage randomly assigned to transdermal nicotine replacement after securing of the aneurysm.~Patient management for all patients is according to the institutional treatment guidelines and independent of group assignment.~The dose is dependent on smoke consumption prior to the ictus. Nicorette 7 mg/day for smokers smoking 1-10 cigarettes /day Nicorette 14mg/day for smokers smoking 11-19 cigarettes/day Nicorette 21 mg/day for smokers smoking 20 or more cigarettes daily"
2582379|NCT02350335|No Intervention|no NRT|Active smokers with acute aneurysmal hemorrhage that were assigned to not receive transdermal nicotine replacement.
2582385|NCT02350335|No Intervention|non-smokers|Non-smokers with acute aneurysmal hemorrhage. Non-smokers do not receive transdermal nicotine replacement. This group is to be compared to the group of active smokers receiving transdermal nicotine replacement and to the group of active smokers not receiving transdermal nicotine replacement.
2582440|NCT02350153||Patients with verified Cushing's Disease|Patients with verified Cushing's Disease
3176834|NCT00647816|Active Comparator|2|Inderal® LA Capsules 160 mg
2582526|NCT02349516|Experimental|Squalamine Solution BID 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
2582538|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% BID|Vehicle Ophthalmic Solution 0.2% administered twice a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
2582551|NCT02349516|Experimental|Squalamine Solution 0.2% QID|Squalamine Lactate Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranibizumab as needed from week 24 through week 52
2582555|NCT02349516|Placebo Comparator|Vehicle Solution 0.2% QID|Vehicle Ophthalmic Solution 0.2% administered four times a day for 52 weeks in combination with monthly intravitreal injections of ranibizumab 0.3mg from baseline through week 20 and ranbizumab as needed from week 24 through week 52
2582612|NCT02349022|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
3176835|NCT00647829|Active Comparator|Arm 1|
3176836|NCT00647829|Active Comparator|Arm 2|
3176837|NCT00647829|Placebo Comparator|Arm 3|
3176838|NCT00647842|Experimental|1|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay
3176839|NCT00647842|Active Comparator|2|Fentanyl Transdermal System 25 mcg/h
3176840|NCT00647855|Experimental|1|Levothyroxine Sodium Tablets 300 μg
3176841|NCT00647855|Active Comparator|2|Synthroid® Tablets 300 μg
3176842|NCT00647868|Experimental|Groups 1 and 2|Twice daily (7:00 am and 12:00 am or 7:00 am and 10:00 pm) dosing with intranasal testosterone for 14 days
3176843|NCT00647868|Experimental|Groups 3a and b|Single daily administration of testosterone (at 7:00 am or 10:00 pm) for 14 days
3176844|NCT00647868|No Intervention|Group 4|24-h blood sampling in healthy eugonadal controls
3176845|NCT00647881|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
2581821|NCT02354404|Experimental|Group 2a:cAd3-EBO at 2x10(10) PU|Part 1: cAd3-EBO at 2x10(10) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581831|NCT02354404|Experimental|Group 2b: cAd3-EBO at 2x10(11) PU|Part 1: cAd3-EBO at 2x10(11) PU intramuscularly at Day 0 (as a boost to prior receipt of the Ebola DNA WT vaccine); Part 2: Option to receive MVA-EbolaZ at 1x10(8) PFU intramuscularly after Study Week 36 as a boost to the Part 1 study vaccination
2581901|NCT02353988|Experimental|bicalutamide|This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
2581903|NCT02353988|Active Comparator|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable
2582009|NCT02353130||Memantine-XR|Boys ages 8-12 with ASD treated with Memantine-XR daily for 8 weeks
2582095|NCT02352688|Active Comparator|Enhanced Colorectal Geriatric Care|Multidisciplinary team involving in the elderly colorectal cancer patients' pre-, peri- and postoperative care.
2582106|NCT02352688|No Intervention|Standard Surgical Care|Standard care given to elderly patients undergoing colorectal cancer resection.
2582132|NCT02352324|Experimental|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
3211808|NCT01008813|Experimental|non-adjuvanted A(H1N1)v influenza vaccine|Two injection at day 0 and day 21
3211809|NCT01008826|Experimental|glucoraphanin-rich broccoli extract|
3211810|NCT01008826|Experimental|sulforaphane-rich broccoli extract|
2582267|NCT02351427|Active Comparator|Bortezomib|"Bortezomib (subcutaneous) 1.3mg/m2 on day 1, 4 and 7~with~Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage"
2582269|NCT02351427|Active Comparator|Steroid|Steroid - Methylprednisolone (intravenous) Day 1 - 7: 500 mg/500 mg/500 mg/250 mg/250 mg/125 mg/125 mg After day 7: prednisolone (oral) 30 - 60 mg, then taper the dosage
2582352|NCT02350972|Experimental|Autologous cytokiines|Autologous cytokines obtained from patients' blood mononuclear cells injected in volumes of 0.1 ml
2582394|NCT02350504|Experimental|Full interactive instruction|Full interactive instruction- which will include an instructional booklet, a movie and a simulator's practice
2582402|NCT02350504|Placebo Comparator|Partial instruction|Partial instruction which included the booklet only.
3211811|NCT01008839||Old age group of healthy women|Old women over 70 years old
3211812|NCT01008839||young group of healthy women|aged 25-35 years
2582562|NCT02349243|Experimental|entacapone|An approach of 200mg entacapone at a time and 4 times a day(0.5 hour after every breakfast, lunch and supper and at 0.5 hours before bedtime) is adopted. Every participant is required to record his/her diet, exercise, and drug intake condition in a standard record card which is provided by the researchers.
2582563|NCT02349243|Placebo Comparator|placebo|Except for taking the placebo rather than the entacapone, any intervention in the placebo group is the same with that in the entacapone group.
2582699|NCT02348320|Experimental|Personalized polyepitope DNA vaccine|Participants will be treated by electroporation with 4 mg of a personalized polyepitope DNA vaccine at Day 1, Day 29 (+/1- 7 days), and Day 57 (+/- 7 days) with at least 21 days between injection days. Each DNA vaccination with be 4 mg vaccine administered intramuscularly using a TriGrid electroporation device.
2582758|NCT02348138|Experimental|Home-based isometric handgrip training|All participants that will be assigned to home-based isometric handgrip training (HBT) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction; however, the training will be performed without daily supervision. Therefore, the subjects will receive a logbook to record the exercise sessions. In addition, visits will be scheduled at weeks 1, 3, 6, 9 and 11 to provide feedback to individuals and discuss potential problems in conducting training.
2582760|NCT02348138|Experimental|Supervised isometric handgrip training|All participants that will be assigned to supervised isometric handgrip training (ST) will train three times per week for a total of 12 weeks, will perform a bout of isometric handgrip exercise: four sets of 2-min isometric contractions (using alternate hands) at 30% of maximal voluntary contraction with. The training will be performed with daily supervision.
2582761|NCT02348138|No Intervention|Control group|Subjects randomized to the control group (CG) will be encouraged to increase the level of physical activity and make healthy eating, without, however, receive specific recommendations
2582788|NCT02347618|Experimental|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
2582872|NCT02347111|Experimental|flecainide 1st|flecainide x 6 months, then crossover to sotalol x 6 months
2582874|NCT02347111|Experimental|sotalol 1st|sotalol x 6 months, then crossover to flecainide x 6 months
2582908|NCT02346786|Experimental|Mineral Water|mineral water
3211813|NCT01008852|Experimental|Treatment Group 1|
3211814|NCT01008852|Experimental|Treatment Group 2|
3211815|NCT01008852|Experimental|Treatment Group 3|
3211816|NCT01008852|Experimental|Treatment Group 4|
3211817|NCT01008852|Placebo Comparator|Treatment Group 5|
3211818|NCT01008865|Experimental|Studer Pouch|Studer Pouch orthotopic urinary diversion
3211819|NCT01008865|Experimental|T-Pouch|T-Pouch orthotopic urinary diversion
3258993|NCT01466452|Active Comparator|Aspirin 100 x 2|
2581846|NCT02354261|Experimental|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.
2581881|NCT02354001|Experimental|Raloxifene Hydrochloride|120 mg per capsule (1 tablet daily)
2581890|NCT02354001|Placebo Comparator|placebo tablet|1 tablet daily for 12 weeks
2581913|NCT02353663||All study participants|Schoolgoing children 5 to 16 years of age
2581964|NCT02353481||Heart Failure|All patients in the audit that meets the eligibility criteria
2582016|NCT02353052||Treatment observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose postoperative Imatinib treatment are labeled treatment group.
2582018|NCT02353052||Control observation group|According to the morphological criteria, the NIH scheme, and the WHO standard, GIST patients are divided into two groups, benign group and malignant group. In fully informed of their illness, patients are free to choose the sequence treatments according to their own gene mutation status and economic conditions. Patients who choose no Imatinib treatment are labeled observation group.
2582097|NCT02352623||Cutaneous melanoma AJCC stage IB-III|Patients treated for cutaneous melanoma (AJCC stage IB-III) will fill out a questionnaire, undergo clinical examination and DXA scan
2582142|NCT02352233||colonoscopy group|consecutive patients undergoing for colonoscopy for any formal indication. Patients were submitted to colonoscopy using RETROVIEW colonoscope
2582181|NCT02351921|Experimental|iTBS to primary motor cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
2582189|NCT02351921|Experimental|iTBS to primary somatosensory cortex|Intermittent TBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS TMS coil will be placed over the primary somatosensory cortex located 2cm posterior to the motor hotspot for the representation of the flexor carpi radialis muscle.
2582196|NCT02351921|Sham Comparator|Sham iTBS to primary motor cortex|Sham iTBS will be delivered using the 30 Hz, 600 pulse protocol targeting the primary motor cortex of the left hemisphere. The iTBS sham coil will be placed over the motor hotspot for the representation of the flexor carpi radialis muscle.
2582210|NCT02351635||IBD|Adult subjects with inflammatory bowel disease, confirmed by endoscopy and histologic support. Fecal calprotectin Level.
2582211|NCT02351635||IBS|Adult subjects with Irritable Bowel Syndrome meeting the Rome III criteria. Fecal calprotectin Level.
2582212|NCT02351635||other GI disorders|Adult subjects with gastrointestinal disorders other than IBD or IBS. Fecal calprotectin Level.
2582213|NCT02351635||pediatric|Pediatric patients (2-21 y) diagnosed with IBD, IBS, or other gastrointestinal disorders. Fecal calprotectin Level.
2582214|NCT02351635||healthy controls|Normal adult subjects with no abdominal complaints. Fecal calprotectin Level.
2582279|NCT02351375|Experimental|high protein, low carbohydrate|a high-protein/low-carbohydrate diet (26,7E% protein, 38.2E% carbohydrate)
2582288|NCT02351375|Experimental|low protein, high carbohydrate|a low-protein/high-carbohydrate diet (7E% protein, 59.6E% carbohydrate)
2582330|NCT02350790|Active Comparator|Robotic ablation|Half of the patients in the study will be randomized to robotic ablation of endometriosis with the argon beam coagulator (ABC).
2582345|NCT02350790|Active Comparator|Robotic Excision|Half of the patients in the study will be randomized to robotic excision of endometriosis.
2582406|NCT02350517|Experimental|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14.
2582495|NCT02349997||OSA group|"Of the 180 heart failure patients,20 OSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
2582496|NCT02349997||CSA group|"Of the 180 heart failure patients,20 CSA were enrolled. Clinical evaluations including NYHA class, electrocardiographic, echocardiographic, arterial blood gas analysis findings, baseline medication, and 6-minute walk test (6MWT) were recorded.~The fluid index, head and neck CT and pharyngeal resistance were tested at 20:00. Then a full night PSG and percutaneous PaCO2 were performed. The fluid index, head and neck CT and pharyngeal resistance were repeated at 6:00 after PSG.~The volume of fluid shift from legs to head and neck,inside diameter of the upper airway, and water content of neck soft tissue were calculated. The lung-to-finger circulation time and loop gain were measured."
3211820|NCT01008917|Experimental|single treatment-non randomized study|Phase I study is to test the safety of the combination of sorafenib with temsirolimus at different dose levels
3211821|NCT01008930|Experimental|PEM Scan|HR PEM images (High Resolution PEMFlex Solo II scan images)
3211822|NCT01008956|Experimental|Single Group|Subjects enrolled in this group will be stratified by age (18 to 40 years and 41 to 64 years)
3211823|NCT01008982|Experimental|single arm|
3211824|NCT01009008|Experimental|Post-mastectomy|Post-mastectomy patients undergoing expander reconstruction
3211825|NCT01009021|Other|Placebo first (scheme 2)|scheme 2 patients (n=15) received a brown-coated tablet of saccharine (placebo) 45 minutes before the first PRP episode [placebo treatment episode (PTE)] at baseline to the right eye and two weeks after received one 50 mg tablet of potassium diclofenac 45 minutes before the second PRP episode [diclofenac treatment episode (DTE)] to the left eye
3211826|NCT01009021|Other|Diclofenac first (scheme 1)|scheme 1 patients (n=15) received one 50 mg tablet of potassium diclofenac 45 minutes before the first PRP episode [diclofenac treatment episode (DTE)] at baseline to the right eye and two weeks after received an identical brown-coated tablet of saccharine (placebo) 45 minutes before the second PRP episode [placebo treatment episode (PTE)] to the left eye
3211827|NCT01009073|Experimental|Arm A (ABT-263 and erlotinib)|
3258994|NCT01466465|Experimental|Vigantol|
2581873|NCT02354066|Experimental|Hallux valgus Surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy, Chevron, SCARF, Austin, etc.)
2581874|NCT02354066|Experimental|Hallux valgus and forefoot surgery|Measurement of the Brake Response Time by Pat. undergoing hallux valgus surgery (first metatarsal osteotomy; Chevron, Austin, SCARF, etc.) and additional forefoot surgery (PIP arthrodesis, second/third/etc. metatarsal osteotomy, etc.; Peg-in-Hole, WEIL-Osteotomy, etc.)
2581875|NCT02354066|Experimental|Control Run|Measurement of the Brake Response Time by Healthy Participants; control run; brake response time measurement with normal shoe and both foot orthoses
3211828|NCT01009073|Experimental|Arm B (ABT-263 and irinotecan)|
3211829|NCT01009073|Experimental|Arm C (ABT-263 monotherapy)|
3211830|NCT01009112|Experimental|CBT for Insomnia|"Patients change their sleep times and habits in order to reduce alertness and over thinking when they are trying to sleep. This helps them learn how to sleep overnight in one solid block of time"
2581993|NCT02353156|Experimental|Electronic bidet|Electronic bidet for 3min at early morning for 4 weeks after hemorrhoidectomy
2581996|NCT02353156|Active Comparator|Sitz bath|Wamr sitz bath for 3min at early morning for 4 weeks after hemorrhoidectomy
3211831|NCT01009112|Experimental|Imagery Rehearsal Therapy|"Patients rescript the narrative of a nightmare to eliminate the distressing elements and create a new pleasant dream scene. They then rehearse this scene in their imagination at least twice each day. This reduces the frequency and intensity of the target nightmare and often reduces other nightmares, too."
3211832|NCT01009112|Experimental|Prolonged Exposure|This behavioral treatment for PTSD involves 1) systematic and repeated exposure to objects and situations that are avoided due to trauma-related distress, 2) prolonged, repeated recounting of trauma memories through visualization, and 3)therapist-guided discussions of thoughts and emotions related to the exposure exercises. The goals of PE are to reduce the anxiety and distress elicited by trauma-related memories and situations, show patients these memories and situations are distinct from the trauma, and teach patients they can tolerate the distress caused by these memories and situations.
2582129|NCT02352376|Other|Conventional ventilator|30 minutes of non-invasive ventilation was performed with conventional ventilator.The order of the procedures was determined by randomization.
2582131|NCT02352376|Other|Specific ventilator|30 minutes of non-invasive ventilation was performed with specific respirator. The order of the procedures was determined by randomization.
2582200|NCT02352077|Experimental|NeuroRegen Scaffold with BMMCs or MSCs transplantation|
2582239|NCT02351622|Experimental|caffeic acid tablet and dexamethasone|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
2582241|NCT02351622|Active Comparator|Placebo and dexamethasone|Oral administration of placebo tablet 0.3g three times per day for 1 year. Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
2582270|NCT02351206||The experimental group|Patients with intervertebral disc protrusion, extrusion, or migration at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
2582271|NCT02351206||The control group|Patients with normal or disc bulging readings at L4/5 randomly selected from a population pool of 665 patients with L-spine X-ray and L-spine MRIs taken within a week of the other test.
2582320|NCT02351011|Experimental|Cohort 1|1 x 10^6 MSCs
2582332|NCT02351011|Experimental|Cohort 2|10 x 10^6 MSCs
2582343|NCT02351011|Experimental|Cohort 3|50 x 10^6 MSCs
2582383|NCT02350426|Experimental|Arm 1|As per randomization schedule, subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-FDG followed by PET/CT2 scan with 18F-GE-180 in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
2582388|NCT02350426|Experimental|Arm 2|As per randomization schedule, , subjects will undergo two half body PET/CT scans (PET/CT1 and PET/CT2). During visit 1 subject will undergo PET/CT1 scan with 18F-GE-180 followed by PET/CT2 scan with 18F-FDG in visit 2. A sub-group of patients will participate in an additional dynamic PET/CT scan with 18F-GE-180 prior to their 18F-GE-180 PET/CT half body scan.
3211833|NCT01009112|Active Comparator|Suportive Care Therapy|This is an active therapy where the focus of the intervention is on helping patients better understand their emotional response to their PTSD and sleep symptoms.
3211834|NCT01009125|Experimental|$2 cash incentive|
3211835|NCT01009125|Experimental|$5 cash incentive|
3211836|NCT01009151|Experimental|Heart Care Self Tracker|Web-based Home Tele-monitoring system
3211837|NCT01009177|Experimental|Bosentan|
2582736|NCT02348190|Active Comparator|Lipid/heparin|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) lipid/heparin co-infusion for 8 hours.
2582737|NCT02348190|Placebo Comparator|Control|16 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and without (n=16) lipid/heparin co-infusion for 8 hours.
3211838|NCT01009177|Placebo Comparator|Placebo|
2582840|NCT02347306||cohort of patients with suspected coronary artery disease|a cohort of patients with suspected coronary artery disease going forward for conventional angiography and (2) whether CT-TCFA is associated with future adverse cardiovascular events.
3211839|NCT01009190|Experimental|ARM A|Carboplatin plus PF-01367338
3211840|NCT01009190|Experimental|ARM A EXPANSION|Carboplatin plus PF-01367338
3211841|NCT01009216|Experimental|ABT-384|
3211842|NCT01009229|Other|1|
3211843|NCT01009242|Experimental|0.1mg/kg and 1mg/kg CDP6038 IV and Placebo IV|Cohort 1, Group 1 will compare 0.1mg/kg, 1mg/kg CDP6038 and placebo IV.
3211844|NCT01009242|Experimental|1 mg/kg CDP6038 SC and Placebo SC|Cohort 1, Group 2 will compare 1mg/kg CDP6038 and placebo sc.
3211845|NCT01009242|Experimental|Optimized CDP6038 SC|Cohort 2, Group 3 will compare optimized sc doses of CDP6038 based on outcome of Cohort 1 with placebo.
3211846|NCT01009255|Experimental|GSK239512|Oral tablets
2581877|NCT02353949|Experimental|Flutmetamol Group|PET-MR-Scan with 80-140 MBq Flutemetamol before observational period for diagnostic purpose
2581916|NCT02353793|Experimental|ReadyHeat® blanket|Patient warming with ReadyHeat® blanket
2581917|NCT02353793|Active Comparator|Cotton wool blanket|Patient warming with cotton wool blanket
2581966|NCT02353416|Placebo Comparator|INRAM guidelines' diet|Intervention in this arm consists in some general dietary advice about healthy dietary components, serving size and frequency of servings following the Italian official guidelines.
2581968|NCT02353416|Active Comparator|Low Glycemic Index Mediterranean Diet|Intervention in this arm consists in a Low Glycemic Index Mediterranean Diet with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
2582014|NCT02353026|Experimental|Intravenous Artesunate|Intravenous Artesunate administered on Day 1 and 8 every 3 weeks
2582111|NCT02352662||Study Group|Three blood samples will be collected intra-operatively from each subject enrolled
3211847|NCT01009255|Placebo Comparator|Placebo|Placebo to match GSK239512.
3211848|NCT01009294|Experimental|Ataluren|Ataluren was provided as a vanilla-flavored powder to be mixed with water, apple juice, or milk. Study drug dosing was based on milligrams of drug per kilogram of body weight. The dose level for ataluren was 20 milligrams/kilograms (mg/kg) in the morning, 20 mg/kg at midday, and 40 mg/kg in the evening. Administration within 30 minutes after a meal was recommended. Study drug was taken for up to 50 days.
2582177|NCT02351882|Active Comparator|Nabilone|Participants randomized into the nabilone arm will be prescribed nabilone for 6 weeks. After one-week placebo washout, they will be taking placebo for an additional 6 weeks.
2582178|NCT02351882|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be receiving placebo for 6 weeks. After one-week placebo washout, they will be prescribed nabilone for an additional 6 weeks.
3176846|NCT00647881|Active Comparator|2|Paxil CR™ Tablets 25 mg
3176847|NCT00647894|Experimental|1|Alprazolam Extended-Release Tablets 1 mg
2582272|NCT02351310|Active Comparator|Betamethasone|Betamethasone: 12 mg given intramuscularly (IM), 24 hours apart or if as in some hospitals occasionally occurs and betamethasone is unavailable - • 4 doses of Dexamethasone IM 6 mg, 12 hours apart
2582273|NCT02351310|Placebo Comparator|Normal Saline|Quantity Sufficient (QS) of Normal Saline (NS) given intramuscularly (IM), 24 hours apart or if hospital is using Dexamethasone in place of Betamethasone then administer NS x 4 doses 12 hours apart
2582371|NCT02350673|Experimental|Cergutuzumab+Atezolizumab (Part I)|Participants will receive escalated IV doses of cergutuzumab amunaleukin in combination with atezolizumab. This is a Part I dose escalation phase of the study. Cergutuzumab amunaleukin will be escalated from a starting dose of 6 milligrams (mg) and dosing schedules of every week (qw) and every 2 weeks (q2w) may be explored. Atezolizumab will be administered in fixed flat doses of either 840 mg q2w or 1200 mg every 3 weeks (q3w). Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
2582372|NCT02350673|Experimental|Cergutuzumab +Atezolizumab (Part II)|This is a Part II expansion phase of the study. Participants will receive cergutuzumab amunaleukin at maximum tolerated dose (MTD) (or recommended dose) identified during Part I in combination with atezolizumab. Treatment will be continued until loss of clinical benefit, unacceptable toxicities, or withdrawal of consent for a maximum treatment period of 24 months for both cergutuzumab amunaleukin and atezolizumab and may be modified if emerging data suggest longer treatment period is needed.
2582463|NCT02350036||preeclmapsia|women developed preeclampsia. ultrasound monitoring and uterine artery Doppler
2582464|NCT02350036||control|women with normal blood pressure all through pregnancy. ultrasound monitoring and uterine artery Doppler
2582536|NCT02349581|Experimental|Block|Patients with persistent pain after breast cancer surgery receive the ultrasound guided PECS block of 20mls 0.25% bupivacaine
2582545|NCT02349581|No Intervention|Sonoanatomy|16 patients awaiting surgery for breast cancer were scanned using ultrasound to determine the sonoanatomy of the PECS block
2582663|NCT02348788|Active Comparator|Artemether-lumefantrine + Primaquine|"1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet.~Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, <35kg = 0.5mg/kg"
2582666|NCT02348788|Active Comparator|Chloroquine + Primaquine|"1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; >35kg = 30mg, 10-35kg = 0.5mg/kg"
2582743|NCT02348164|Experimental|Treatment 1|Volunteers receive pink grapefruit first followed by tangerines two weeks later
2582747|NCT02348164|Experimental|Treatment 2|Volunteers receive tangerines first followed by pink grapefruit two weeks later
2582778|NCT02347748|Experimental|Group A - Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
2582779|NCT02347748|Experimental|Group B - Reading pre-extubation script|Patients will be read a pre-extubation script;
2582780|NCT02347748|Experimental|Group C - Reading 2 scripts|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area Patients will be read a pre-extubation script
3176848|NCT00647894|Active Comparator|2|Xanax XR Tablets 1 mg
3176849|NCT00647907|Experimental|A|
3176850|NCT00647920|Experimental|40 mg|
3176851|NCT00647920|Placebo Comparator|Placebo|
3176852|NCT00647933|Experimental|Org 36286 15 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 15 μg.
3176853|NCT00647933|Experimental|Org 36286 30 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 30 μg.
2581936|NCT02353611|Active Comparator|35% bleaching agent|Together with the experimental agent application, the other upper hemiarch will be bleached with 35% hydrogen peroxide whitening compound. The compound will be mixed according to manufacturer's instructions and distributed uniformly over the buccal surface of the teeth of the corresponding hemiarch. The gel will be applied twice for 12 minutes each and irradiated using the LED/laser light (Whitening Lase Plus-DMC Equipamentos, São Carlos, SP, Brazil). Three bleaching sessions will be completed with an interval of 7 days between them.
2581988|NCT02353247|Other|Norethindrone acetate (aygestin)|Norethindrone acetate (aygestin) will be used to manage bothersome bleeding. Patients will be prescribed aygestin 5 mg by mouth twice daily for one month, followed by aygestin 5 mg by mouth once daily for two months. Medication will then be discontinued. Patients will be evaluated in the office three months after medication initiation, and then again six months after medication initiation. If the patient is unable to take norethindrone acetate (aygestin) due to medical contraindications or cost, they will receive medroxyprogesterone acetate (provera) 10 mg once daily as alternate oral progesterone. Figure 1 below highlights the study
3211849|NCT01009320||Pacemaker with magnets|Patients with pacemakers who will be tested for magnetic interference with a magnetic drape.
2582102|NCT02352480|Experimental|Aurix + UCC|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Aurix treatment plus usual and customary care, which can include any advanced therapeutics.
2582112|NCT02352480|No Intervention|Usual and Customary Care|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week there after while receiving usual and customary care, but actual frequency of visits will be determined by the treating physician. Usual and customary care, which can include any advanced therapeutics.
2582183|NCT02352025|Experimental|S-equol|After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
2582219|NCT02351674||Heart rate ≤70bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate ≤70 BPM.
2582224|NCT02351674||Heart rate between 71 to 80bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 2 will be defined as subjects' mean heart rate between 71 to 80bpm.
2582230|NCT02351674||Heart rate between 81 to 90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 1 will be defined as subjects' mean heart rate between 81 to 90bpm.
2582232|NCT02351674||Heart rate>90bpm|15,000 patients in the retrospective cohort will be divided into 4 groups according to their mean heart rate during PCI. Group 4 will be defined as subjects' mean heart rate>90bpm
2582292|NCT02351154|Other|Atrophic gastritis|gastric glands (crypts) with atrophic gastritis were measured using the Cellvizio Viewer software
2582325|NCT02350894||mTBI subjects|mTBI subjects with ongoing symptoms
3211850|NCT01009359|Experimental|Arm 1|
3211851|NCT01009359|Experimental|Arm 2|
2582479|NCT02349971|Experimental|All Patients|Patients will undergo a one-time procedure of MR-HIFU ablation of OO under sedation or anesthesia. Patients will be monitored for disease status and adverse events for at least 12 months following procedure.
2582514|NCT02349529|Experimental|Psychosocial group intervention|
2582517|NCT02349529|Other|Waiting List control|Participants in the waiting list control will continue in TAU but will then start the intervention once the first group of participants have completed the 3 month follow up in the psychosocial group intervention arm.
2582571|NCT02349204|Experimental|Exposure to music|The participants in this groups will have to complete the tasks on the intraocular surgery simulator while listening to Mozart's sonata for 2 pianos in D-440
2582573|NCT02349204|No Intervention|No exposure|The participants in this groups will have to complete the tasks on the intraocular surgery simulator in silence
3211852|NCT01009359|Experimental|Arm 3|
3211853|NCT01009372|Experimental|breaks during laparoscopic surgery|Intraoperative Breaks were instituted in the intervention group. The other group operated conventionally without breaks
3211854|NCT01009385|Active Comparator|prone position|
3211855|NCT01009385|Active Comparator|sitting position|
3211856|NCT01009411||Control|Patients in active phase of labor not augmented
3211857|NCT01009411||Augmented|Augmentation leading to normal progress
3211858|NCT01009411||Caesarean section|Augmentation leading to Caesarean section
3211859|NCT01009424|Experimental|1|R7103 (dose 1) followed by placebo or placebo followed by R7103 (dose 1)
3211860|NCT01009424|Experimental|2|R7103 (dose 2) followed by placebo or placebo followed by R7103 (dose 2)
3211861|NCT01009424|Experimental|3|R7103 (dose 3) followed by placebo or placebo followed by R7103 (dose 3)
3211862|NCT01009424|Experimental|4|R7103 (dose 4) followed by placebo or placebo followed by R7103 (dose 4)
3211863|NCT01009424|Experimental|5|R7103 (dose 5) followed by placebo or placebo followed by R7103 (dose 5)
3211864|NCT01009424|Experimental|6|R7103 (dose 6) followed by placebo or placebo followed by R7103 (dose 6)
3211865|NCT01009437|Active Comparator|Control Arm - No Ritonavir|Five ER+, HER2- breast cancer patients meeting all study eligibility will be enrolled prior to the start of phase I recruitment to act as controls (no ritonavir will be given-will receive therapeutic conventional surgery) to confirm that anesthesia does not affect EET levels. Core biopsies, surgical tumor/normal tissue and pre- and post- surgery blood samples will be collected for comparison with the treatment group.
3211866|NCT01009437|Experimental|Ritonavir - Escalating Doses (I)|"Standard phase I dose escalation (with therapeutic conventional surgery) will be used with 3 levels of ritonavir given - 200 mg bid, 400 mg bid, and 600 mg bid for the following groups:~ER+, HER2-~ER+, HER2+~ER-, HER2+~ER-, PR+, HER2-~ER-, PR-, HER2-"
3211867|NCT01009437|Experimental|Ritonavir - Maximum Tolerated Dose (II)|Phase II: Once the maximum tolerated dose (MTD) of ritonavir is established, 19 ER+, HER2- patients will be enrolled at MTD during the phase II component along with therapeutic conventional surgery.
3258995|NCT01466465|Placebo Comparator|neutral oil (vigantol carrier)|
3258996|NCT01466478|Experimental|LEO 29102 plus calcipotriol|
3258997|NCT01466517|Active Comparator|Reference Drug|
2581937|NCT02353715||Enzalutamide|Subjects will be administered enzalutamide per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
2581939|NCT02353715||Abiraterone|Subjects will be administered abiraterone acetate per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
2581940|NCT02353715||Sipuleucel-T|Subjects will be administered sipuleucel-T per standard of care under the care of their treating physician. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline and 21 weeks.
2581995|NCT02353208|Active Comparator|Sham Feeding of Bacon Bits|"In addition to the standard procedure, subjects will be asked to perform sham feeding on two occasions: 1) Immediately after having swallowed the capsule and 2) One hour after having swallowed the capsule.~Sham feeding will be performed as follows: The patients will be asked to chew 10 times on a piece of bacon over a period of 30 seconds, prior to spitting saliva and bacon into a container. This will be repeated 10 times at one minute intervals.~The patient will then complete the capsule study as per the standard procedure.~Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada."
2581998|NCT02353208|Placebo Comparator|Placebo|The control group will not chew bacon bits while undergoing capsule endoscopy.
2582011|NCT02352766||Routine FNA for thyroid nodules|Patients that undergo a clinically diagnostic thyroid FNA will be asked by their clinician, who is a study co-investigator, if they are interested in participating in the research study. A small part of FNA material will be collected for molecular analysis.
2582090|NCT02352701||Noltec®,ChongkundangAmoxicillin®,Cravit®|Noltec tab 10mg, Chongkundang Amoxicillin Cap 500mg 2caps and Cravit tab 500mg by oral, twice a day for 10 days
2582169|NCT02352155|Active Comparator|Second look endoscopy|Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
2582170|NCT02352155|Placebo Comparator|observation only|NO second look endoscopy (Observation)
2582238|NCT02351752|Experimental|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate 0.1 Tid (eGFR 30-59), 0.2 Bid(eGFR >60)
2582287|NCT02351336||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
2582415|NCT02350270||cognitively healthy individuals (CHI)|CHI were participants without objective cognitive impairment
2582416|NCT02350270||mild cognitive impairment (MCI)|MCI was diagnosed if participants met the following criteria: presence of spontaneous cognitive complaints and objective cognitive impairment
2582419|NCT02350270||mild and moderate dementia|Diagnoses of dementia were assigned according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV TR, 2000; Association, 2000; 22) at consensus diagnostic case conferences
2582438|NCT02349893|Experimental|RFA treatment|RFA treatment performed with CelonProSleep plus device
2582552|NCT02349282|Experimental|Calcifediol 10 ug/day|Capsule with 10 ug/day Calcifediol taken together with breakfast for a total period of 24 weeks.
2582558|NCT02349282|Experimental|Vitamin D3 20 ug/day|Capsule with 20 ug/day Vitamin D3 taken together with breakfast for a total period of 24 weeks.
2582559|NCT02349282|Placebo Comparator|Placebo|Capsule without active ingredients, taken together with breakfast for a total period of 24 weeks.
2582591|NCT02348983|Experimental|Interventional Arm|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
3211868|NCT01009450|Active Comparator|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
2582715|NCT02348281|Experimental|bicalutamide|150mg, po, qd, d1-28
2582762|NCT02348047|Active Comparator|Conventional ventilation|Conventional ventilation - manual mode
2582764|NCT02348047|Experimental|ASV|Intellivent ASV ( Adaptative Support Ventilation )Ventilation- automatic mode
3258998|NCT01466517|Active Comparator|Test Drug|
3258999|NCT01466530|Placebo Comparator|Placebo|sublingual two moistened white coated placebo tablets
2582972|NCT02346513||A: Ceramic on Metal THA|"Subgroup A1: Consist of ceramic on metal THAs with short term follow-up (less than 2years)~Subgroup A2: Consist of ceramic on metal THAs with midterm follow-up (more than 2years)~Subgroup A3: Consist of bilateral ceramic on metal THAs"
2582974|NCT02346513||B: Non-Ceramic on Metal THA|Patients have THA with non COM bearing
2582975|NCT02346513||C: Healthy subjects|Patients without any implant or systemic disease, to served as controls
2583015|NCT02346227|Active Comparator|AV2|Drug: application of topical spray on the cervix one time (2 puffs) topical application of 100µl AV2 antiviral spray( natural essential oil components in equal volumes diluted 50% in olive oil)
2583018|NCT02346227|Placebo Comparator|Placebo|Drug: application of topical spray on the cervix one time (2 puffs) topical spray of 100 µl on the cervix.
2583068|NCT02345876||Dyslexic children|Longitudinal follow-up without intervention
2583072|NCT02345876||Normal reading children|Longitudinal follow-up without intervention
2583138|NCT02345577|Active Comparator|Physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time with vibration of increasing frequency starting at 1Hz / Noise 4 going up to 6Hz / Noise 5 depending on patients' tolerability and with a fixed 3mm amplitude.
2583147|NCT02345577|Sham Comparator|Sham physiotherapeutical intervention|3 WBV-sessions per week for 3 consecutive months. Each session consists of 5 series with a duration of 60 sec with 60 sec rest-time at 1 Hz / Noise 1 and 3mm amplitude.
2583271|NCT02344732|Active Comparator|Standard Group|topical Maxitrol™ six-hourly and homatropine 2% six-hourly
2583280|NCT02344732|Experimental|Oxygen Group|standard medical treatment of topical Maxitrol™ six-hourly and homatropine 2% six-hourly, plus systemic oxygen via simple face mask at 10 litres/min for one hour, in 12-hourly sessions for 3 days
3259000|NCT01466530|Active Comparator|Misoprostol|sublingual misoprostol (400 µg)
2581942|NCT02353676|Placebo Comparator|PLACEBO GROUP|1.5 ml of saline solution to be injected into the opposite site postoperatively.
2581997|NCT02353195|Experimental|Radio-frequency group|The equipment used, (INDIBA® activ 902, (448kHz)). The electricity was administered in the following manner: cream was applied to the site with the severe rest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient. Therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total)
2581999|NCT02353195|Placebo Comparator|Placebo group|All patients were treated with the same device in a nonfunctional application (no energy source) and the therapy was conducted for 12 minutes, two times per week over four weeks (eight sessions in total).
3211869|NCT01009450|Active Comparator|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
3211870|NCT01009476||001|
3211871|NCT01009476||002|
2582133|NCT02352285|Experimental|Tolvaptan|Tovaptan tablet 15mg, 30mg, 60mg, once a day, oral
2582135|NCT02352285|Placebo Comparator|placebo|placebo tablet 15mg, 30mg, 60mg, once a day, oral
2582186|NCT02352064|Experimental|PET-CT at day 150+/-15 days|Patient will have PET (18-FDG) following allogeneic stem cell transplantation
2582223|NCT02351687|No Intervention|No Intervention|No specific intervention given after recovery from moderate acute malnutrition.
2582226|NCT02351687|Experimental|Package of interventions|Package of interventions given after recovery from moderate acute malnutrition -- includes lipid-nutrient supplement for 2 months, malaria chemoprophylaxis for 3 months during malaria season, an insecticide-treated bed net, a one-time albendazole treatment, and 14 days of zinc.
3211872|NCT01009502|Experimental|Sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
3211873|NCT01009528|Experimental|Intervention|Admission to electronic feedback system
3211874|NCT01009528|No Intervention|control|Control group. No special attention
2582448|NCT02350218|Experimental|Eglandin 720㎍|Eglandin® (Alprostadil) 720㎍
2582449|NCT02350218|Active Comparator|Eglandin 360㎍|Eglandin® (Alprostadil) 360㎍
3211875|NCT01009541|Experimental|Pregabalin controlled release, 82.5 mg|
3211876|NCT01009541|Experimental|Pregabalin controlled release, 165 mg|
3211877|NCT01009541|Experimental|Pregabalin controlled release, 330 mg|
2582600|NCT02348866|Active Comparator|Group 1|home laundered/home-donned
2582613|NCT02348866|Active Comparator|Group 2|Hospital laundered/home-donned
2582619|NCT02348866|Active Comparator|Group 3|Home laundered/hospital donned
2582620|NCT02348866|Active Comparator|Group 4|Hospital laundered/hospital donned
3211878|NCT01009541|Other|Pregabalin immediate release, 150 mg|Reference Treatment
3211879|NCT01009567|Sham Comparator|Control|Receive human albumin 20% infusion
2582730|NCT02348229|Experimental|ERAS group|ERAS protocols
2582731|NCT02348229|Other|conventional pathway group|using conventional pathway
2582791|NCT02347709||Group 1/Diabetic Foot Ulcer|Group 1 will be recruited from the Wound Center, and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥5.9%), and a diabetic foot ulcer (defined as a break in the skin on the foot). Subjects in this group will complete a survey, undergo a Comprehensive Neuropathy Evaluation, and have a photograph and biopsy of their Diabetic Foot Ulcer in addition to the standard of care.
2582800|NCT02347709||Group 2/Diabetic Neuropathy|Group 2 will be recruited from the Neurology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) and neuropathy. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
2582807|NCT02347709||Group 3/Type 2 Diabetes|Group 3 will be recruited from the Endocrinology clinic and will include patients with a diagnosis of Type 2 Diabetes (defined as HgA1c ≥ 5.9%) who currently do not have a diagnosis of neuropathy or a diabetic foot ulcer. Subjects in this group will complete a survey and undergo a Comprehensive Neuropathy Evaluation in addition to the standard of care.
3211880|NCT01009567|Experimental|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
3211881|NCT01009593|Experimental|ABT-869|
2583078|NCT02346019|Experimental|Surgical: Medial thighplasty|Perform a standard medial thighplasty with our without additional thigh liposuction on up to three obese transfemoral amputee subjects. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
2583175|NCT02345603|Experimental|Cryo-therapy|Cryo-therapy of renal arteries
2583176|NCT02345603|No Intervention|Control|No intervention in renal arteries
2583195|NCT02345018||GSV with diameters >/= 12 mm|30 patients with primary insufficiency of the GSV with diameters >/= 12 mm, treated with mechano-chemical ablation (MOCA)
2583197|NCT02345018||Antero-lateral branches|30 patients with insufficient antero-lateral branches, treated with mechano-chemical ablation (MOCA)
2583199|NCT02345018||GSV below-knee|30 patients with below-knee GSV insufficiency, treated with mechano-chemical ablation (MOCA)
2583282|NCT02344706||Mini-EEG, NCSE|Unconscious patients due to seizures, of whom EEG is registered
2585114|NCT02332356|Active Comparator|step down|Procedure: MREC patients receive therapeutic step down
3211882|NCT01009593|Active Comparator|Sorafenib|
3211883|NCT01009606|Active Comparator|Arm 1 : Control : usual strategy|
3211884|NCT01009606|Experimental|Arm 2: Comparator : modified strategy|
3211885|NCT01009632|Experimental|Voice rest|
3211886|NCT01009632|Experimental|Resonant voice exercise|
3211887|NCT01009632|Experimental|Spontaneous speech|
3211888|NCT01009658|Active Comparator|MSG first|
3211889|NCT01009658|Placebo Comparator|NaCl first|
2582001|NCT02353221||Controls|Healthy control subjects will be recruited based on similar criteria as study subjects. Our effort will be to include age and gender matched control subjects in the registry. We will be also aiming to match environmental characteristics (i.e. partners living in same location as registry subject or in a radius of 10 miles for at least one year previous to the date of evaluation) or genetic background (i.e. by asking the participation of first-degree relatives)
2582017|NCT02352805||(1) veno-venous ECMO|ECMO - Patients being connected to veno-venous extracorporeal membrane oxygenation (ECMO)
2582021|NCT02352805||(2) veno-arterial ECLS|ECLS - Patients being connected to veno-arterial extracorporeal life support (ECLS)
2582023|NCT02352805||(3) LVAD (Heart Mate II)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate II)
2582025|NCT02352805||(4) LVAD (Heart Ware)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Ware)
2582033|NCT02352805||(5) LVAD (Impella)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Impella)
2582042|NCT02352805||(6) Dialysis system|Patients being connected to a dialysis system
2582047|NCT02352805||(7) LVAD (Heart Mate III)|LVAD - Patients being connected to a left ventricular assist device (LVAD) (Heart Mate III)
2582049|NCT02352805||(8) HLM|HLM = Heart Lung Machine - patients undergoing coronary artery bypass grafting surgery and / or aortic valve replacement with cardiopulmonary bypass
2582099|NCT02352506||AKI|Patients developing AKI during the ICU stay
2582110|NCT02352506||No AKI|Matched controls not developing AKI during the ICU stay
2582185|NCT02352311|Experimental|Arm 1 AVODART, CIALIS, DKF-313|In Period 1, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose. In Period 2, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose.
2582191|NCT02352311|Experimental|Arm 2 DKF-313, AVODART, CIALIS|In Period 1, DKF-313 tablet (dutasteride 0.5 mg and tadalafil 5 mg) is administered as single dose. In Period 2, AVODART (dutasteride) soft gelatin capsule and CIALIS (tadalafil) tablet 5 mg are administered as single dose.
2582228|NCT02351596|Active Comparator|Intervention Group 7-12 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
2582233|NCT02351596|Active Comparator|Control Group 7-12 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
2582235|NCT02351596|Active Comparator|Clontarf Intervention Group 13-17 years|"Intervention consists of attending a Physiotherapy Core stability group programme for 8 sessions over 4 weeks. Each session lasts 60 minutes (mins).~Dosage: 60minsX 2 =120mins/week X 4 = 480 mins total dosage of intervention Participants also given a home exercise programme with a diary to record how long they practice for every day."
2582236|NCT02351596|Active Comparator|Clontarf Control Group 13-17 years|Participants continue with usual care but do not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration, type and frequency of this intervention is recorded.
2582293|NCT02351245||lip hemangiomas|
2582328|NCT02350959|Experimental|High dose statin|In high dose statin group, atorvastatin 40mg will be used
2582342|NCT02350959|Active Comparator|Moderate dose statin|in moderate dose statin group, atorvastatin 10mg will be used
2582382|NCT02350530|Experimental|A (FOLFOXIRI + Bevacizumab)|FOLFOXIRI + Bevacizumab
2582387|NCT02350530|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
2582490|NCT02349945|Experimental|Arm 1|FSHR A680G SNP homozygous for allele N treated with follitropin alpha
2582491|NCT02349945|Experimental|Arm 2|FSHR A680G SNP homozygous for allele S treated with follitropin alpha
2582515|NCT02349373|Active Comparator|Preconditioning running|An 8 week preconditioning period. The variables of interest are running distance and running intensity: running speed >80% VO2max (maximal oxygen uptake).
2582518|NCT02349373|Active Comparator|Follow-up period|"The Volume group progress 23% in total weekly running distance in the last adaptation week in the prior 4 week block.~The Intensity group progress 23% in weekly distance of running above 80% VO2 max (maximal oxygen uptake), based on the distance of running above 80% VO2max in the last adaptation week in the prior 4 week block."
2582576|NCT02349191|Experimental|Interventional cohort|Omental transposition for mild Alzheimers Disease
2582602|NCT02348879|Experimental|AMG 403|AMG 403 administered as subcutaneous and intravenous doses
2582615|NCT02348879|Placebo Comparator|Placebo|No active drug
2582654|NCT02348710|Experimental|exercise outcome expectation workbook|Intervention arm participants will receive: 1) the ACS exercise and diet guidelines; and 2) an exercise outcome expectation workbook. The workbook contains self-directed activities to increase OE importance, certainty, and accessibility. The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many positive exercise outcomes breast cancer survivors may experience. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes.
2582656|NCT02348710|Active Comparator|diet workbook|Attention control participants will receive via mail 1) the ACS exercise and diet guidelines; and 2) a diet workbook. The diet workbook contains the same activities as the exercise outcome expectation workbook but is focused on diet instead of exercise.
2582700|NCT02348437|Experimental|Repair|Repair of the pronator quadratus muscle
2582710|NCT02348437|Active Comparator|Non-repair|Non-repair of the pronator quadratus muscle
2582744|NCT02347956|Experimental|Reduced port group|
3211890|NCT01009671|Experimental|ART 44|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
3211891|NCT01009671|Active Comparator|ART 50|Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12
3211892|NCT01009684||DNG/EV|Users of the oral contraceptive containing Dienogest and Estradiol valerate
2582006|NCT02353013|Experimental|Enhanced Protein Group|For infants in this group, the target protein-energy ratio (PER) will be ~4 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula. In addition, liquid protein will be added to provide protein supplementation and increase the PER.
2582148|NCT02352350||Cardiac Arrest Patients|All adult patients with non traumatic cardiac arrest in Alachua County Florida will have blood lactate levels taken and neurological outcomes performed based on the Cerebral Performance Categories (CPC) Scale
2582174|NCT02351895||Copper linens|One ward during each period (23 weeks each) used copper impregnated linen on the bed and as patient gowns. The second ward used regular linen on the bed and as patient gowns
3211893|NCT01009684||Other OCs|Users of oral contraceptives (OCs) containing other progestins and estrogens
3211894|NCT01009749|Experimental|MESA|
2582281|NCT02351089|Placebo Comparator|Placebo|capsules containing corn starch
2582290|NCT02351089|Active Comparator|Probiotic low dose|capsules containing probiotic powder and corn starch
2582296|NCT02351089|Active Comparator|Probiotic high dose|capsules containing probiotic powder and corn starch
2582329|NCT02350868|Experimental|Arm 1|Subjects will be treated with oral doses of MPT0E028 in consecutive, 28-day cycles, and will be evaluated regularly for safety. Subjects who tolerate the drug and who do not experience progressive disease may continue to receive MPT0E028 at the discretion of the principal Investigator for up to 6 cycles.
3211895|NCT01009749|Active Comparator|MESH|
3211896|NCT01009775|Experimental|YM155 plus docetaxel|
2582497|NCT02349854||Cases|patients with scalp itch and seborrheic dermatitis who will get biopsy
2582499|NCT02349854||Controls|patients without scalp itch and without seborrheic dermatitis who will get biopsy
2582531|NCT02349399||Drug Utilisation / Cohort 1|New users of CPA/EE in 2011/2012 and in 2014
2582596|NCT02349126|Experimental|Treatment Group|ARC-520 Injection
2582712|NCT02348372|Placebo Comparator|GSK1278863A Placebo|5, 25 and 100 mg matched
2582717|NCT02348372|Experimental|GSK1278863A 10mg|A round, biconvex, white film coated tablet
2582719|NCT02348372|Experimental|GSK1278863A 25mg|A round, biconvex, white film coated tablet
2582721|NCT02348372|Experimental|GSK1278863A 50mg|A round, biconvex, white film coated tablet
2582722|NCT02348372|Experimental|GSK1278863A 100mg|A round, biconvex, white film coated tablet
3211897|NCT01009788|Experimental|TMZ/ABT888|Combination therapy with temozolomide and veliparib
3211898|NCT01009801|Active Comparator|Arm I|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
2582835|NCT02347462|Experimental|BiPAP plus standard care|Bilevel Positive Airway Pressure (BiPAP) plus standard care according to the hospital's severe asthma protocol
2582837|NCT02347462|Active Comparator|Standard care alone|Standard care according to the hospital's severe asthma protocol
3211899|NCT01009801|Experimental|Arm II|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
3211900|NCT01009827||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at the 15 sites and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
3211901|NCT01009866|Experimental|MR1-1|All subjects are enrolled onto this arm. All subjects will receive MR1-1.
3211902|NCT01009879|Experimental|Etanercept|
2583002|NCT02346214||Preterm and term neonates|A. Preterm and term neonates B. Singleton live births between 26 and 42 weeks gestation (determined by first of early-second trimester ultrasound dating) at three referral hospitals
2583079|NCT02346058|Experimental|Esarin Gel|"Dosage form:One tube of Esarin Gel contains 20 gm of compound. Each gm contains:10 mg Heparinoid, 10 mg Escin, 50 mg Diethylamine Salicylate.~Dosage and frequency: Approx. 3-5 cm Gel was applied topically on skin.twice daily.~Duration: 28 days."
2583135|NCT02345564|Other|osteochondral lesions in knee/ankle|patients with traumatic and atraumatic osteochondral lesions in knee/ankle, implantation of MaioRegen fleece into osteochondral lesion
3211903|NCT01009892|Active Comparator|Codeine Sulfate, 30 mg|tablet
3211904|NCT01009892|Active Comparator|Codeine Sulfate, 60 mg|tablet
2583851|NCT02340910|Experimental|Long duration|Long Duration WBV consists of 16 bouts 45-sec of 50Hz WBV followed by a 1-minute seated rest
3211905|NCT01009892|Active Comparator|Codeine Sulfate, 15 mg|tablet
3211906|NCT01009905||A|
3211907|NCT01009944|Experimental|Lisinopril, Atenolol|
3211908|NCT01009957|Experimental|Everolimus|Everolimus + standard therapy for CKD
3211909|NCT01009957|No Intervention|Control|Standard therapy for CKD
3211910|NCT01009970|Experimental|1|R-COMP
3211911|NCT01009996||Coronary bifurcation lesions|
3211912|NCT01010022|Experimental|1|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
3211913|NCT01010022|Active Comparator|2|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
3211914|NCT01010035||type 2 diabetes|patients with diagnosis of Type 2 diabetes mellitus
3211915|NCT01010035||Control|non type 2 diabetes mellitus
3211916|NCT01010048|Experimental|progesterone,tamsulosin,propantheline Bromide and nifedipine|different effect of these drugs use to treat urinary calculus after ESWL
3211917|NCT01010087|Active Comparator|Standard Oseltamivir dose 75 mg bid|Standard dosing
3211918|NCT01010087|Experimental|High Dose Oseltamivir arm 225mg bid|High dose arm of the study
3211919|NCT01010100|Experimental|Arm 1|
3211920|NCT01010100|Placebo Comparator|Arm 2|
3211921|NCT01010113|Placebo Comparator|Test formula 1|Standard formula with prebiotics
3211922|NCT01010113|Experimental|test product|Infant formula with synbiotics
3211923|NCT01010152|Experimental|Codeine Sulfate|30 mg tablet
3211924|NCT01010152|Active Comparator|Tylenol #3|30 mg tablet
3211925|NCT01010165||septic arthritis|
3211926|NCT01010165||crystal arthritis|
2582180|NCT02352116|Experimental|Additional education|Subjects undergoing ambulatory surgery who receive standard of care management with additional face-to-face education in postoperative pain management.
2582187|NCT02352116|Active Comparator|No additional education|Subjects undergoing ambulatory surgery who receive standard of care management with no additional education in postoperative pain management.
2582240|NCT02351648|Experimental|Intervention'|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
2582242|NCT02351648|Active Comparator|Control'|Patients receive usual standard of care from the internal medicine team
3211927|NCT01010165||rheumatismal disease|
3211928|NCT01010178|Experimental|Macrolid, Theophylline, Corticosteroids|Approved drug in this setting
2582355|NCT02350712|Experimental|All Participants - Period 1|All participants receive patritumab with cetuximab plus platinum-based therapy (cisplatin or carboplatin) in Period 1 - Initial phase of the trial.
2582357|NCT02350712|Experimental|All Participants - Period 2|Participants deriving clinical benefit enter Period 2 - Extension phase, during which they continue to receive patritumab with cetuximab, but not platinum-based therapy.
3211929|NCT01010191|Experimental|Cellulose pill|The active intervention is a sugar pill.
3211930|NCT01010191|No Intervention|No treatment|The control arm is wait list control
3211931|NCT01010256||Subjects diagnosed with CMML|Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
3211932|NCT01010256||Control Group|The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
3211933|NCT01010269|Active Comparator|Vanguard Complete Knee|Vanguard Completed Knee with Microplasty Tibial Tray is designed to hold the tibial knee bearings in a microplsty knee procedure. The Co-Cro-Mo trays are designed with a shorter stem.
3211934|NCT01010269|Active Comparator|Vanguard High Flex RP|VGRD High Flex RP knee is an extension to the exsting Vanguard Knee and has been specifically desinged to facilitate greather than 135 degrees of knee flextion as required by certain patients.
3211935|NCT01010295|Experimental|doxycycline|doxycycline 100 mg twice daily for 3 weeks
3211936|NCT01010308|Experimental|Intervention Group:|"The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement~Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group"
2582910|NCT02346864|Experimental|Three-stair-position group|The infants in the study group (n=72) received three-stair-position (TSP) intervention (head up 15°) for a week.
2582912|NCT02346864|Other|head elevated tilt position group|The control group(n=72)received head elevated tilt position (HETP) intervention (head up 15°) for a week．
2582985|NCT02346578|Experimental|Enzalutamide|Enzalutamide 160 mg administered orally once a day as four 40-mg soft capsules
2582987|NCT02346578|Active Comparator|Flutamide|Flutamide 125 mg administered orally three times a day as one tablet after meal
2582991|NCT02346175|Experimental|Cohort1|5-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
2582993|NCT02346175|Experimental|Cohort2|10-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
2582995|NCT02346175|Experimental|Cohort3|20-mg/day SHR3824 or placebo once daily on Day 1 and on Days 4 through 10.
2583058|NCT02345967|Experimental|Study Group|Device: Model 100 Sensor
3211937|NCT01010308|No Intervention|Historical control group|Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
3211938|NCT01010308|No Intervention|Angiogenesis marker control group|The angiogenesis marker control group will consist of 6 -10 patients seen in the Dermatology clinic for conditions other than IH and not receiving corticosteroids or beta blockers.
2583145|NCT02345278|Placebo Comparator|Placebo|once daily sublingual administration for 1 month
2583155|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 10,000 AU/mL|once daily sublingual administration for 1 month
2583163|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 25,000 AU/mL|once daily sublingual administration for 1 month
2583168|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 50,000 AU/mL|once daily sublingual administration for 1 month
2583170|NCT02345278|Active Comparator|SUBLIVAC FIX Mite mixture 100,000 AU/mL|once daily sublingual administration for 1 month
2583216|NCT02344927|Active Comparator|Non-Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Standard management of pain and other symptoms in the terminal phase."
2583218|NCT02344927|Active Comparator|Clinically Assisted Hydration arm|"The interventions utilised within this trial are representative of standard clinical practice~Continuance of oral intake (if appropriate)~Regular (4 hourly) mouth care~Clinically-assisted hydration~Standard management of pain and other symptoms in the terminal phase"
2583893|NCT02340494|No Intervention|Control group|Women without access to the website.
3211939|NCT01010321||all study Population|all
3211940|NCT01010334|Active Comparator|Arm 1|Standard of Care Treatment
2582055|NCT02352740|Experimental|Healthy subjects with 'hypertriglyceridemic waist'|"Subjects with overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
2582059|NCT02352740|Experimental|Healthy subjects|"Control subjects, i.e. without overweight, elevated waist circumference and elevated fasting triglyceridemia.~Intervention : A form arginine and B form arginine"
3211941|NCT01010334|Experimental|Arm 2|Treatment Arm of a separate protocol (physician discretion)
3211942|NCT01010347|Active Comparator|Splint|Preformed velcro volar splints are compared to traditional circumferential casting.
2582323|NCT02351024|Experimental|OXP005|
2582335|NCT02351024|Active Comparator|Naproxen|
2582396|NCT02350634|Experimental|Autopsy Cohort|End-of-life subjects (life expectancy < 6 months) consenting to brain donation at autopsy. Subjects will receive a single IV bolus injection of 370 MBq(10 mCi) of 18F-AV-1451.
2582429|NCT02350114|Experimental|Functional Capacity|6 Minute Walk Test
2582492|NCT02349841|Experimental|Meropenem;amoxycillin/clavulanic acid|Meropenem 2g will be administered intravenously 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
2582493|NCT02349841|Experimental|Faropenem; amoxycillin/CA|Faropenem 600mg will be administered orally 8-hourly; plus amoxycillin/CA 500mg/125mg will be administered orally 8-hourly for 14 days
2582494|NCT02349841|Active Comparator|Rifafour e-275|Rifafour e-275 will be administered orally once daily for 14 days as per South African National TB Treatment Guidelines
2582509|NCT02349334|Sham Comparator|Sham electrical stimulation|Sham electrical stimulation to forefoot by TENS
2582510|NCT02349334|Active Comparator|Percutaneous tibial nerve stimulation|Active PTNS via Urgent PC Neuromodulation device, Uroplasty
2582561|NCT02349256||Diagnosed with Somatic Syndrome Disorder|Group of participants that are screened and meet criteria for diagnosis of Somatic Syndrome disorder will be asked if they wish to take part in a 1-1 qualitative interview with the researcher.
2582616|NCT02349113|Experimental|Estrogens|Estrogens treatment: Intervention with short course (3 weeks) of treatment with transdermal estrogen (0.1mg/d)
2582716|NCT02348476||Simbrinza™|Patients treated with Simbrinza™ (brinzolamide 1%/brimonidine 0.2%) as standard of care in clinical practice. No study drug is administered in this study.
2582757|NCT02348125|Experimental|Mitochondrial Cocktail|"The precise content of the Mitochondrial Cocktail will be:~ubiquinol (liquid form, 150 mg/kg subject weight/day~carnitine, 50 mg/kg subject weight/day~alpha-lipoic acid, 100 mg/ day"
3211943|NCT01010347|Placebo Comparator|Cast|The circumferential cast is the standard of treatment against which the splint is compared.
3211944|NCT01010373|Experimental|AS101 infusions|In addition to induction chemotherapy AS101 will be given intravenously. The patient will also receive AS101 infusions during the time break till the next chemotherapy course, as long as the patient does not achieve complete remission and the platelet count is <20,000/μl; ANC <1000. AS101 will be administered likewise up to two consolidation or equivalent chemotherapy courses (re-induction or salvage in the event that no CR is achieved following first induction chemotherapy), i.e., total of three chemotherapy courses.
3211945|NCT01010386|Placebo Comparator|atmospheric (20%) oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
2582870|NCT02347163|Experimental|Zoledronate|Patients fulfilling the eligibility criteria will receive a pre-operative, single administration of zoledronate (4mg i.v.), 7 days before definitive breast surgery
2582915|NCT02346838|Experimental|Inulin|Participants will receive 10 g of inulin powder each day for 6 weeks.
2582918|NCT02346838|Placebo Comparator|Placebo|Participants will receive 10 g of maltodextrin each day for 6 weeks.
2582988|NCT02346526|Experimental|Radium-223 dichloride|"After the screening procedures confirm that a patient is eligible to participate in the research study.~Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments. These treatments are designed to be entirely standard. Extra testing during and after that six month period will be added to standard testing and monitoring.~Blood Tests~CT scan~Bone scan~FACBC PET/MRI in a subset of participants"
2583031|NCT02346097|Experimental|Optimal electrical resynchronization|"Cardiac Resynchronization Therapy: LV lead implant according to electrical activation mapping of available epicardial veins to identify the latest electrical activated myocardial region. Post-implant interventricular (VV) electrical optimization for narrowing the paced QRS width. Post-implant standard pacemaker settings: Atrioventricular (AV) interval 100-130 ms and VV interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Programming of the VV interval to obtain the narrowest QRS-width"
2583032|NCT02346097|Active Comparator|Routine CRT-strategy, imaging guided|"Cardiac Resynchronization Therapy: LV lead implant guided by echocardiography and Rb-PET towards the latest mechanically activated myocardial segment and separate from scar. Post-implant VV electrical optimization for narrowing the paced QRS width. Standard pacemaker settings for both groups: AV-interval 100-130 ms and VV-interval settings with simultaneous biventricular pacing.~Day 1 after implantation: ECG, AV-optimization guided by echocardiography, high-pitch cardiac CT to verify LV lead position.~Continue standard interventricular pacing interval settings with simultaneous pacing in both ventricular leads."
2583045|NCT02345824|Experimental|Ribociclib (LEE011) Treatment|Patients will be treated with ribociclib (LEE011) (recommended phase 2 dose of 600 mg/day) for 8-21 days prior to surgery. For preliminary evaluation of efficacy and toxicity, patients with Rb-positive tumors will resume treatment with ribociclib at 14-28 days post-surgery on a schedule of 21 days on, 7 days off in a 28-day cycle. Patients will be treated until unacceptable toxicity is observed, or until disease progression as assessed by radiographic or clinical metrics.
2583115|NCT02345655|Experimental|Urine Drug Testing|GPs of the intervention group will dedicate an average 5 minutes during the consult to perform OS-UDT. Patients will be asked to collect a urine sample at the GP's medical office. GP will read and communicate the results immediately to the patients. GPs will keep free of their management according to OS-UDT results.
2583116|NCT02345655|Other|No test|Patients will not have to performed the OS-UDT test
3211946|NCT01010386|Active Comparator|physiologic (5%) oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
2582113|NCT02352636|Active Comparator|Treatment arm 2|Subjects will receive laser auriculotherapy (LAT). A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use12, 26. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection. Similarly, a plaster without magnetic pellets that mimics MAT treatment will be applied on these six acupoints after LAT.
2582119|NCT02352636|Experimental|Treatment arm 3|Subjects will receive a combined approach using MAT and LAT. LAT will be administered prior to the application of MAT on the selected auricular points, which would be implemented similar to the procedures in treatment arm 1 and 2.
2582121|NCT02352636|Placebo Comparator|Placebo arm|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
3211947|NCT01010412|Experimental|Ultrasound|Ultrasound guided nerve localization through direct visualization of the nerves and surrounding structures.
3211948|NCT01010412|Active Comparator|Nerve Stimulation|Standard of Care
2582244|NCT02351557||Reference|Baseline cardiac index more than or equal to 2.1 liters per minute per square meter
2582247|NCT02351557||Low cardiac output|Baseline cardiac index less than 2.1 liters per minute per square meter
2582276|NCT02351362|Experimental|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
2582284|NCT02351362|No Intervention|Control Group|Standard of care
2582326|NCT02350933|Other|0° rigid endoscope|Endoscopy of the trachea is performed using a 0° rigid endoscope
2582392|NCT02350556|Other|hemiplegic patients|Dynamic Avoidance Task
2582400|NCT02350556|Other|healthy volunteers|Dynamic Avoidance Task
2582480|NCT02350049||Investigational|Cementless Medial Partial Knee
2582483|NCT02350049||Control|Cemented Medial Partial Knee
2582532|NCT02349555|Experimental|Nutritional Supplement Blend|The nutritional supplement contains a proprietary blend consisting of 15 unique nutritional ingredients.
2582614|NCT02349100||Treated group|Patient group treated with Nellix Endoprosthesis.
2582652|NCT02348736|Experimental|SensaScope|Time for tracheal intubation with the SensaScope
2582655|NCT02348736|Experimental|McGrath Series 5|Time for tracheal intubation with the McGrath Series 5
2582698|NCT02348450|Experimental|Irinotecan plus Cisplatin|first line: irinotecan 65mg/m2 d1,8. Cisplatin 30mg/m2，d1,8, 21days/cycle×6 cycles Second-line: etoposide alone OR etoposide plus cisplatin, dosage will be same as first line or on investigator's discretion.
2582707|NCT02348450|Experimental|Etoposide plus Cisplatin|first line: etoposide 60mg/m2 d1-5 Cisplatin 75mg/m2，d1(recommended), or administer three times with same total daily dose , 21days/cycle×6 cycles Second-line: irinotecan alone or irinotecan plus cisplatin, dosage is same as first line or on investigator's discretion.
2582756|NCT02347904|Experimental|Adjuvant S-1 and Oxaliplatin|Adjuvant treatment with s-1 and oxaliplatin after neoadjuvant chemoradiation and esophagectomy in patients with resectable esophageal cancer
2582776|NCT02347644|Experimental|Brief Motivational Interview|Given a brief motivational interview encouraging reduced use of alcohol and drugs.
2582777|NCT02347644|No Intervention|Youth Control Group|Given a brochure with all available organizations in the community for help with alcohol and drug problems.
2582846|NCT02347449|Experimental|Early stage breast cancer|"Women with node positive (1-3 nodes), ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.~Study subjects will have ONCOTYPE Dx assay performed on their breast tumors, and will complete study questionnaires."
2582895|NCT02347033|Active Comparator|Sertraline|The pharmacological arm of the trial is the Selective Serotonin Reuptake Inhibitor (SSRI) Sertraline, prescribed at a daily dose of between 25 and 150mg by the patient's general practitioner (GP). If the medication is well tolerated and associated with reported clinical improvement we are asking the patients in this arm to continue taking it for 12 months.
2582900|NCT02347033|Active Comparator|Cognitive Behavioural Therapy (CBT)|The psychological therapy arm of the trial is Cognitive Behavioural Therapy (CBT) delivered by high intensity psychological therapists from local IAPT services. They will provide 14 to 16 sessions of a manualised treatment developed specifically for use in GAD and will be trained in its delivery.
2582922|NCT02346760|Experimental|UB-621|Intervention drug: UB-621
2582989|NCT02346565|Other|Exercise ECG|Patients will undergo an exercise test using the standard Bruce protocol. Standard end points of exercise testing will include: fatigue, severe ischaemia (severe chest pain, >2mm ST depression on ECG), hypertension (systolic BP>220mmHg), hypotension, pre-syncope or arrhythmia.
2582990|NCT02346565|Other|Stress Echocardiography|"A two-dimensional echocardiogram will be performed in the lateral decubitus position. Digitized images of the left ventricle (LV) will be obtained in the parasternal long-axis, short-axis, and apical four-, two-, and three-chamber views.~In the case of exercise stress echo, images will be acquired at rest and immediately (within 90 seconds) after peak exercise.~In the case of dobutamine stress echo, images will be acquired at rest, at the end of stage one of dobutamine administration (10mcg/Kg/min) and at peak stress."
2583042|NCT02346084|Experimental|Female Participants - Arms 1A through 9A|"Female Participants 9 Arms (1A through 9A) 3 Product Sequences~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR Rx3- MVC 1% gel PV~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC 1% gel PV Rx3- MVC tablet PO~Product Sequence 3 Rx1- MVC 1% gel PV Rx2- MVC tablet PO Rx3- MVC 1% gel PR~3 Biopsy Schedules D8- (~2-hr after the 8th dose) D9- (~24-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
2583043|NCT02346084|Experimental|Male Participants - Arms 1B through 4B|"Male Participants 4 Arms (1B through 4B) 2 Product Sequences 2 biopsy schedules~Product Sequence 1 Rx1- MVC tablet PO Rx2- MVC 1% gel PR~Product Sequence 2 Rx1- MVC 1% gel PR Rx2- MVC tablet PO~Biopsy Schedule D8- (~2-hr after the 8th dose) D10- (~48-hr after the 8th dose)"
2583166|NCT02345382|Experimental|240 mg BAY1143572|Subjects received BAY1143572 240 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
2582134|NCT02352272|Experimental|Sleep extension|Subject spend 10 hours Time in bed per day during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
2582136|NCT02352272|Sham Comparator|Habitual sleep|Subject respect their habitual Time in bed during 6 nights. This period is follow by a total sleep deprivation intervention (i.e. 39 hours awaking) in laboratory.
2582160|NCT02352051|Active Comparator|Atomoxetine group|The drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
2582163|NCT02352051|Active Comparator|Methylphenidate group|The drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg.
2582256|NCT02351492|Active Comparator|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography (IOC) to investigate bile ducts.
2582257|NCT02351492|Active Comparator|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography (MRCP) first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
2582423|NCT02350257|Experimental|ICBT|Internet-based cognitive behavior therapy
2582424|NCT02350257|No Intervention|Supportive control|Control participants has weekly contact with a therapist and receives internet-based training in child directed play. Participants are informed that this training will not likely reduce anxiety.
3176854|NCT00647933|Experimental|Org 36286 60 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 60 μg.
2582627|NCT02348814||normal weight|BMI 20-25
2582629|NCT02348814||overweight|BMI 25-30
2582631|NCT02348814||obese|BMI 30-35
2582633|NCT02348814||morbidly obese|BMI > 35
2582635|NCT02348814||non-diabetic|HgbA1c (<5.7%) and blood glucose (65-99 mg/dL) within normal range as defined at UCLA Clinical Lab
2582637|NCT02348814||diabetic|HgbA1c (>6.5%) and blood glucose (>100 mg/dL) as defined at UCLA Clinical Lab
2582638|NCT02348814||non-cirrhotic|Normal liver function tests (AST/SGOT, ALT, SGPT, alkaline phosphatase, bilirubin) as defined at UCLA Clinical Lab
2582639|NCT02348814||dyslipidemic|Abnormal lipid profile (Total cholesterol >170 mg/dL, LDL >100 mg/dL, HDL >130 mg/dL, triglycerides >150 mg/dL) as defined at UCLA Clinical Lab
2582669|NCT02348528|Experimental|Lenalidomide and dexamethasone|"Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.~The starting doses of Rd regimen will be the same last doses that the subjects received in Study CC-5013-MM-021, unless event(s) that require dose adjustments (dose modifications, reductions and interruptions) per protocol occurred prior to roll-over."
2582694|NCT02348294|Other|Healthy volunteers|Shear- force 19 newton and 3,9 kpa pressure for half an hour
2582701|NCT02348294|Other|Diabetes Mellitus type 2 without neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
2582711|NCT02348294|Other|Diabetes Mellitus type 2 with neuropathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
2582714|NCT02348294|Other|Charcot Osteoarhtopathy|Shear- force 19 newton and 3,9 kpa pressure for half an hour
2582813|NCT02347839|Experimental|Intervention group|Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.
2582838|NCT02347280|Experimental|Loop ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
2582839|NCT02347280|Active Comparator|Total abdominal colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
2583054|NCT02346006|Experimental|Physical activity|Subject from schools with more physical activity.
3176855|NCT00647933|Experimental|Org 36286 120 μg + Lyndiol®|After a pill-free period of 7 days, participants took 1 oral tablet of Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) daily for a total period of at least 6 weeks to suppress endogenous gonadotropin secretion. After 3 weeks of Lyndiol® intake, participants received a single subcutaneous dose of Org 36286 120 μg.
3176856|NCT00647946|Experimental|A|Stop zidovudine (ZDV) or stavudine (d4T) and start tenofovir DF 300mg once daily along with the other antiviral drugs that are used as part of their HAART regimen
3176857|NCT00647946|Active Comparator|B|Stop zidovudine (ZDV) or stavudine (d4T) and start abacavir 300mg twice daily along with the other antiviral drugs that are used as part of their HAART regimen
3176858|NCT00647959|Experimental|1|Doxycycline Tablets, 150mg
3176859|NCT00647959|Active Comparator|2|Adoxa Tablets 150 mg
3176860|NCT00647972|Experimental|1|Olanzapine Tablets 20 mg
3176861|NCT00647972|Active Comparator|2|Zyprexa® Tablets 20 mg
3176862|NCT00647985|Experimental|1|Fexofenadine Tablets 180 mg
3176863|NCT00647985|Active Comparator|2|Allegra® Tablets 180 mg
3176864|NCT00648011|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3176865|NCT00648011|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
3176866|NCT00648024|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
3176867|NCT00648024|Active Comparator|2|Agrylin® Capsules 1 mg
3176868|NCT00648050|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3176869|NCT00648050|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
3176870|NCT00648063|Experimental|1|Letrozole Tablets 2.5 mg
3176871|NCT00648063|Active Comparator|2|Femara® Tablets 2.5 mg
3176872|NCT00648076|Experimental|1|Divalproex Sodium Extended-Release Tablets 500 mg
3176873|NCT00648076|Active Comparator|2|Depakote ER® Tablets 500 mg
3176874|NCT00648089|Experimental|1|
3176875|NCT00648089|No Intervention|2|
2582145|NCT02352207||identification of a pulmonary malformation in the fetus|pregnant women referred to a prenatal Center, because of the identification of a pulmonary malformation in the fetus
2582184|NCT02351947|Experimental|persons with chronic stroke|upper limb rehabilitation for chronic stroke
2582192|NCT02351947|No Intervention|Healthy, age matched control group|Healthy aged match control group undergoing MRI/EEG testing
2582216|NCT02351661||medica/surgical|Medical or surgical patients from 18 hospitals
2582258|NCT02351479|Other|Hula|Hula is an ancient, Native Hawaiian dance form of cultural expression and physical activity. Participants will attend one-hour hula classes twice a week for six months.
2582282|NCT02351180|Experimental|Inhaled beclomethasone|Inhaled beclomethasone 320 mcg twice daily for 180 days.
2582294|NCT02351180|Placebo Comparator|Placebo|Inhaled placebo twice daily for 180 days.
3211949|NCT01010425|Experimental|ACP-001, dose-level 1|
3211950|NCT01010425|Experimental|ACP-001, dose-level 2|
3211951|NCT01010425|Experimental|ACP-001, dose-level 3|
3211952|NCT01010425|Experimental|ACP-001, dose-level 4|
2582439|NCT02350231|Active Comparator|The progesterone vaginal pessary group|Where they will have progesterone vaginal pessary (Prontogest 400 mg) daily at bed time from 28 weeks of pregnancy till delivery in addition to tonic and calcium
2582441|NCT02350231|Placebo Comparator|Tonics group|Where they will receive only tonics and calcium from 28 weeks of pregnancy till delivery
2582461|NCT02349750|Active Comparator|endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed.
2582462|NCT02349750|No Intervention|Non endometrial scratch injury|Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Group C received IUI without ESI and after 24 to 36 hours, IUI was performed.
2582527|NCT02349594|Active Comparator|treatment order A|Participants in this arm first receive 'Omegaven 10%' and after crossing over the 'Intralipid 20%'
2582539|NCT02349594|Active Comparator|treament order B|Participants in this arm first receive 'Intralipid 20%' and after crossing over the 'Omegaven 10%'
2582598|NCT02349009|Placebo Comparator|placebo|C-82 Topical Gel, Placebo
2582608|NCT02349009|Active Comparator|Active|C-82 Topical Gel, 1%
2582657|NCT02348645|Active Comparator|Decompression with fusion|Spinal decompression surgery with instrumented spinal fusion
2582659|NCT02348645|Active Comparator|Decompression alone|Midline-sparing spinal decompression alone
2582693|NCT02348268|Active Comparator|Manual Therapy + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally this group was treated with manual therapy (for 15 minutes).
2582703|NCT02348268|Experimental|Myofascial Release + Analgesic therapy|The intervention for this group consisted of analgesic treatment in accordance with the guidelines of the FREMAP Protocol for the treatment of mechanical NP and additionally, this group was treated with myofascial release therapy (for 15 minutes).
2582748|NCT02348034|Experimental|Prevena Dressing|This group will receive prevena dressing after the elective colorectal surgery
2582752|NCT02348034|No Intervention|Conventional dressing|This group will receive conventional dressing after the elective colorectal surgery
2582782|NCT02347670|Active Comparator|Group 1M- Community Site|"Participants randomized to Group 1-Main will attend follow-up visits at one of the four main community sites. A glaucoma specialist will perform the comprehensive eye examination and a ophthalmic technician will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
2582787|NCT02347670|Active Comparator|Group 2- Office-Based|"Office-Based, Follow-Up Eye Care with Patient Navigation Protocol: Participants randomized to Group 2 will attend follow-up visits at the Wills Eye Hospital Glaucoma Research Center. A glaucoma specialist will perform the eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
2582909|NCT02346786|Active Comparator|Tap Water|usual water intake
2583004|NCT02346149|Other|Patient with impaired glucose tolerance|Bold-MRI before and after glucose injection
3211953|NCT01010438||Adults|Adult patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
3211954|NCT01010438||Children (1-17)|Pediatric patients referred for sleep studies, including both patients with suspected OSA and patients that have been invited to a sleep lab for reasons not related to OSA such as insomnia, para-insomnia and similar.
3211955|NCT01010451|Experimental|Antimicrobial pulpotomy|Pulpotomy of primary molars with pulp inflammation or necrosis due to carious lesions using an antimicrobial paste
3211956|NCT01010451|Active Comparator|Calcium hydroxide pulpectomy|Pulpectomy of primary molars with pulp inflammation or necrosis due to carious lesions using a calcium hydroxide paste as intracanal medication
3211957|NCT01010464|Experimental|Adhesion Reduction Plan|Lysis of adhesions and application of Seprafilm
3211958|NCT01010464|No Intervention|Standard Management|Standard management and no application of Seprafilm
3211959|NCT01010490|Experimental|Torsional ultrasound|Torsional ultrasound with the INFINITI phacoemulsification system (Alcon Lab, USA)
3211960|NCT01010490|Active Comparator|Longitudinal ultrasound (INFINITI)|Longitudinal ultrasound with the INFINITI phacomachine (Alcon Lab, USA)
2582201|NCT02351869|Active Comparator|Nitrous oxide|N2O-condition participants will inhale an initial mixture of 10% N2O in oxygen (O2) for 5 minutes, followed by 25% N2O in O2 for 20 minutes. N2O-condition participants will also receive 5ml intravenous saline concomitantly with 10% N2O, and again with 25% N2O.
2582204|NCT02351869|Placebo Comparator|Midazolam|Inhaled room air plus intravenous midazolam bolus (total 2mg). Midazolam-condition participants will receive intravenous infusions of 0.5mg midazolam in 5ml saline (start of 1st inhalation epoch), followed by 1.5mg midazolam in 5ml saline (start of 2nd inhalation epoch).
2582274|NCT02351401|Experimental|Education with ultrasonography|Intervention includes education of self-assessment of synovitis using ultrasonography as a feedback training tool
2582286|NCT02351401|No Intervention|Standard Care|Normal standard care where patients are not taught how to self-assess for synovitis, without ultrasonography a training tool
2582331|NCT02350946|Experimental|Cross over Oxytocin and Placebo|fMRI measurement and blood examinations following 26 IU Oxytocin (Syntocinon) on day 1 and following placebo on day 14
2582344|NCT02350946|Experimental|Cross over Placebo and Oxytocin|fMRI measurement and blood examinations following placebo on day 1 and following 26 IU Oxytocin (Syntocinon) on day 14
2582395|NCT02350491||RA group|Pregnant women suffering from Rheumatoid Arthritis.
2582401|NCT02350491||SLE group|Pregnant women suffering from Systemic Lupus Erythematosus.
2582404|NCT02350491||healthy group|Healthy pregnant woman.
2582594|NCT02348905|Experimental|ACTHAR Gel 40 units twice weekly|ACTHAR Gel at a dose of 40 units twice weekly sub cutaneous injections between Baseline and week 12.
2582606|NCT02348905|Experimental|ACTHAR Gel 80 units twice weekly|ACTHAR gel at a dose of 80 units twice weekly sub cutaneous injections between Baseline and week 12.
2582745|NCT02347930||Confirmed acute kidney injury|Confirmed acute kidney injury
2582938|NCT02346799|Experimental|Control|Participants in the control group will not receive any additional treatment, apart from receiving daily emails 15 minutes before the start of their self-reported workout window. This is to control for reminder effects that may be present in the other treatment conditions. Participants in this condition will also receive a lump payment upon completion of an exit survey at the end of the intervention to equalize overall compensation.
2582939|NCT02346799|Experimental|Flexible Incentive|Participants in the flexible incentive condition will be paid $3 or $7 for each workout they complete during the treatment period (with a limit of one incentivized workout per day, and twelve incentivized workouts during the four-week treatment period). These participants will receive daily emails 15 minutes before the start of their self-reported workout window, but they can work out anytime of the day and still receive their incentive payment.
2582945|NCT02346799|Experimental|Routine Incentive|Participants assigned to the routine incentive condition will receive the same treatment as those in the flexible incentive condition except that, in order to receive their incentive payment, they must begin their workout within their two-hour workout window. For instance, if an employee chooses a 2pm to 4pm workout window, she will receive a reminder to exercise at 1:45 pm and must swipe into the gym between 2pm and 4pm in order to receive the $3 or $7 incentive payment.
2582949|NCT02346799|Experimental|Social Routine Incentive|Participants assigned to this condition will have an identical experience to those in the routine incentive except that both partners who sign up for the study will be required to coordinate and select a common workout window. Thus, both partners will receive their daily reminders at the same time (and will be incentivized for working out at the same time). The incentive payment, however, will not be linked to whether or not a participant's partner completes a workout - only to the participant's own exercise decision.
2582953|NCT02346799|No Intervention|Holdout Control|If experimental enrollment exceeds target, exercise data will be collected for these additional participants, but they will receive no intervention of any kind.
2583070|NCT02345993|Active Comparator|Extra fine Formoterol/Beclomethasone|"Group receiving the drug additional to standard treatment standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline, 0, 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
2583073|NCT02345993|Placebo Comparator|Placebo|"Group receiving placebo additional to standard treatment consisting in:~Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ Placebo, 3 puffs administered via aerochamber at baseline (0), 20, 40 minutes"
2583142|NCT02345551|Experimental|Exercise|The behaviour change intervention to promote an increase in moderate-vigorous physical activity (to meet the cancer prevention guidelines of 150 min/week) will be guided by the Health Action Process Approach (HAPA) model. This model aims to promote behaviour change through increasing self-efficacy for intention, planning and maintenance of physical activity. As a compliment to the behavioural counseling sessions, participants will be asked to track their physical activity using the FitBit, a wrist-worn activity monitor (www.fitbit.com) which monitors step counts, distance covered, and active minutes and also tracks sleep. The FitBit synchronizes wirelessly to the participants' computer and/or smartphones, thus minimizing the need for daily data entry tracking by participants.
3176876|NCT00648128|Active Comparator|2|
3176877|NCT00648128|Experimental|1|
3176878|NCT00648141|Experimental|A|
3176879|NCT00648141|Experimental|B|
3176880|NCT00648141|Active Comparator|C|
3176881|NCT00648154|Experimental|1|Letrozole Tablets 2.5 mg
3176882|NCT00648154|Active Comparator|2|Femara® Tablets 2.5 mg
3176883|NCT00648180|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
3176884|NCT00648180|Active Comparator|2|Adoxa Tablets 100 mg
3176885|NCT00648193|Experimental|1|Paroxetine hydrochloride 40 mg tablet
3176886|NCT00648193|Active Comparator|2|Paxil® 40 mg Table
3176887|NCT00648206||1|drivers of motorised vehicles suspected of driving under the influence of psychoactive drugs or alcohol
3176888|NCT00648206||2|drivers stopped in police traffic controls and breathalysed positive for alcohol
2582246|NCT02351544|Experimental|Botulinum toxin|Patients in this arm will receive botulinum toxin for migraine headaches
2582251|NCT02351544|Experimental|Surgery|Patients in this arm will receive surgery for migraine headaches
3211961|NCT01010490|Active Comparator|Longitudinal ultrasound (LEGACY)|Longitudinal ultrasound with the LEGACY phacomachine (Alcon Lab, USA)
3211962|NCT01010516|Active Comparator|High-dose rosuvastatin|40 mg of rosuvastatin
3211963|NCT01010516|Active Comparator|Stain plus fenofibrate|existing statin plus micronized fenofibrate 200 mg
3211964|NCT01010516|Active Comparator|Statin plus niacin ER/laropiprant|existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
3211965|NCT01010529|Experimental|occupational therapy|
2582413|NCT02350296|Experimental|KSL 40 mg|Ketoprofen lysine salt (KLS) immediate release tablets 40 mg, corresponding to 25 mg of ketoprofen free acid
2582418|NCT02350296|Active Comparator|OKi® 80 mg|OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid)
2582474|NCT02349932||Healthy Adults|The following samples will be collected: fecal, blood, and saliva
2582534|NCT02349568||High risk group|High risk group was defined when CBD stones was detected by ultrasound ( US ) / computed tomography ( CT ) or dilated duct with abnormal LFT.
2582547|NCT02349568||Intermediate risk group|Intermediate risk group was defined when US/CT showed normal bile duct with abnormal LFT or dilated duct with normal LFT.
3211966|NCT01010529|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (3 months).
3211967|NCT01010542|Active Comparator|ILV-095|
3211968|NCT01010542|Placebo Comparator|placebo|
3211969|NCT01010581|Experimental|SC12267 (4SC-101) + Methotrexate|
2582789|NCT02347514|Experimental|Diabetes Group Visit|"Subjects in this arm will be asked to attend one group visit at their health center each month for six months. The group visits will involve various staff and providers at the health center who will teach them how to take care of their diabetes. Subjects will be scheduled to attend the same group visit appointments as the other subjects, and health center staff will encourage the group to share their own experiences about living with diabetes with the rest of the group.~If subjects at the health center additionally implementing the text-messaging intervention consent to enroll in the study, their phone number will also be entered into a secure system that will allow the group visit healthcare team to send them text messages during the course of the six months they are in the program. These text messages are intended to offer the subjects additional support in taking care of their diabetes."
2582798|NCT02347514|No Intervention|Usual care|Patients in the control arm will be selected after the follow-up period is over for the intervention arm. They will receive the care they normally receive at their health center.
3211970|NCT01010581|Placebo Comparator|Placebo + Methotrexate|
3211971|NCT01010594|Active Comparator|Fruit restricted|Type 2 diabetics are advised to restrict their fruit intake to two pieces or less daily.
2582952|NCT02346695||Hypertensives|Untreated consecutive patients with newly diagnosed essential hypertension
2582955|NCT02346695||Controls|Normotensive individuals
3211972|NCT01010594|Active Comparator|Fruit ad libitum|Type 2 diabetics are advised to eat at least two pieces of fruits daily
3211973|NCT01010607|Experimental|Vibraton Mirror (VM)|subjects will receive tendon vibration AND mirror therapy
3211974|NCT01010607|Active Comparator|Mirror (M)|Subjects will receive treatment only with Mirror, together with sham vibration (over bone instead of tendon)
2583131|NCT02345382|Experimental|20 mg BAY1143572|Subjects received 20 milligram (mg) BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
2583132|NCT02345382|Experimental|40 mg BAY1143572|Subjects received 40 mg BAY1143572 tablet orally once daily from Cycle 1 Day 1 of each cycle.
2583134|NCT02345382|Experimental|80 mg BAY1143572|Subjects received BAY1143572 80 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
2583144|NCT02345382|Experimental|120 mg BAY1143572|Subjects received BAY1143572 120 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
2583153|NCT02345382|Experimental|160 mg BAY1143572|Subjects received BAY1143572 160 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
2583162|NCT02345382|Experimental|200 mg BAY1143572|Subjects received BAY1143572 200 mg tablet orally once daily from Cycle 1 Day 1 of each cycle.
3211975|NCT01010607|Sham Comparator|Sham (S)|Opaque board instead of mirror, bone vibration instead of tendon vibration
3211976|NCT01010620||Screening|Screening Assessment battery. Specific to study(or studies) the individual is screening for.
3211977|NCT01010646|Experimental|GP1N IFN alfa-2bXL 27 MUI + Ribavirin|IFN alfa-2bXL 27 MUI, powder and solvent for solution injection
3211978|NCT01010646|Experimental|GP2N IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI, powder and solvent for solution injection
3211979|NCT01010646|Active Comparator|GP3N IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg,administered once a week for 12 weeks by subcutaneous injections
3211980|NCT01010659|Experimental|Lacrimal Tube|Dacryocystorhinostomy with silicone lacrimal intubation
3211981|NCT01010672|Experimental|Ridaforolimus 40 mg|
3211982|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 1|formulation 1
3211983|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 2|formulation 2
3211984|NCT01010698|Experimental|cimetidine (or acyclovir) capsule 3|formulation 3
3211985|NCT01010698|Active Comparator|cimetidine (or acyclovir) reference|reference product
3211986|NCT01010711|Other|migraine dietary supplement|"the average days of migraine during a 4 week-run-in-period are compared with the average days of migraine during intervention with a specific dietary supplement from week 8 - 12"
2582194|NCT02351908|Experimental|Arm 3|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir) 1 tablet once a day for 48 weeks
2582248|NCT02351609|Experimental|Intervention|Patients in this arm will receive a low literacy smoking cessation educational brochure and a list of resources for smoking cessation. Patients will also receive navigation from a trained navigator Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 6-month period. Patients will receive financial incentives for biochemically confirmed smoking cessation.
2582250|NCT02351609|Active Comparator|Enhanced Traditional Care control|Patients receive information about smoking cessation resources and an educational brochure developed by the Massachusetts Department of Public Health.
2582265|NCT02351232|Experimental|Intervention|Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months
2582266|NCT02351232|Placebo Comparator|Placebo|Placebo; daily subcutaneous injection; 1.8 mg; 6 months
2582338|NCT02350985|Active Comparator|Propranolol|Propranolol up to 160 mg/day
2582349|NCT02350985|Active Comparator|Venlafaxine|Venlafaxine up to 150 mg/day
2582393|NCT02350465|Experimental|Eccentric Exercise|Supervised strengthening exercise using eccentric muscle actions.
2582399|NCT02350465|Active Comparator|Concentric Exercise|Supervised strengthening exercise using concentric muscle actions.
2582477|NCT02349958|Other|Ovarian peritoneal|CDDP Cisplatin 75 mg/m2 @T0 Ovarian peritoneal fallopian tube Uterine
2582481|NCT02349958|Other|Appendix Psuedomyxoma|MMC Mitomycin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0 Appendix Psuedomyxoma colorectal small bowel
2582484|NCT02349958|Other|Gastric and Pancreato-biliary|MMC Mitomycin + CDDP Cisplatin 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
2582486|NCT02349958|Other|Mesothelioma and Sarcoma|CDDP Cisplatin + Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
2582524|NCT02349386|Experimental|BHR-200 Low Dose|3 mg estradiol per 1 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
2582542|NCT02349386|Experimental|BHR-200 Mid Dose|6 mg estradiol per 2 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
2582549|NCT02349386|Experimental|BHR-200 High Dose|9 mg estradiol per 3 mL 0.36% BHR-200 (transdermal 17β-estradiol gel) applied daily to the skin for up to 52 weeks.
2582554|NCT02349386|Placebo Comparator|Placebo|1, 2 or 3 mL of Placebo gel containing 0 mg estradiol applied daily for up to 52 weeks.
2582599|NCT02348892||With coordinator|Elderly patients, in complex situation, taken care by coordinator
2582611|NCT02348892||Without coordinator|Elderly patients, in complex situation, taken care by the classic plan
3211987|NCT01010724|Experimental|bIAP|Dosage 200 IU bIAP/kg: 1000 IU prior to anaesthesia administered as a bolus followed by intravenous continuous infusion of 5,6 IU/kg/hr for approximately 36 hours.
2582697|NCT02348307|Active Comparator|FYU-981|
2582706|NCT02348307|Placebo Comparator|Placebo|
2582797|NCT02347696|Other|Control|The subjects will follow a diet based on INRAN guidelines without doing any physical activity.
2582806|NCT02347696|Other|LGIMD|The subjects will follow a Low Glycemic Index Mediterranean Diet without doing any physical activity.
2582810|NCT02347696|Other|Endurance Activity (EA)|The subjects will follow a program of endurance (aerobic) activity (EA) without following a specific diet.
2582815|NCT02347696|Other|EA+Resistance Training (RT)|The subjects will follow a program of endurance activity (EA) and resistance training (RT) without following a specific diet.
2582818|NCT02347696|Other|LGIMD+EA|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA).
2582819|NCT02347696|Other|LGIMD+EA/RT|The subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) togheter with a program of endurance activity (EA) and resistance training (RT).
2582867|NCT02347202|Experimental|Online counseling via Zoom teleconferencing|Each participant will be assigned a random number which is linked to group assignment. The numbers will be assigned consecutively to participants as they enroll. All caregivers in the treatment group will receive 6 counseling sessions in 4 months, using teleconferencing. The first session will be an individual session. The caregiver will be asked to select family members to participate in the next 4 sessions. The 4 family sessions will be followed by another individual session with the spouse/partner caregiver. The counselor will send the primary caregiver an email to be forwarded to family members with instructions on how to access the TTDC training on using the teleconferencing technology. All caregivers in the control group will be able to call the counselor for resource information and support.
2582868|NCT02347202|Other|Telephone support as needed|All caregivers in the control group will be able to call the counselor for resource information and support as needed.
3211988|NCT01010724|Placebo Comparator|Placebo|
3211989|NCT01010737|Experimental|Multimeric-001 250 mcg|250mcg of Multimeric-001 was administered twice at an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
2583009|NCT02346292||1|Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation
2583094|NCT02345733|Experimental|Ulcerative Colitis Diet|Patients will receive a structured novel diet termed the UCD for 6 weeks, and those in remission at week 6 will receive the step down diet for another 6 weeks.
2583097|NCT02345733|Experimental|Antibiotic Treatment|This antibiotic treatment will be given as an open label for patients who refuse diet therapy or for patients who show no improvement by week 3 , deteriorate by week 6, or patients who are not in full remission by week 6 will receive a 14 day course of antibiotics as previously described by Kato and colleagues.
2583122|NCT02345421||At risk population|
2583185|NCT02345109|Experimental|Transtek DUT|Which measured by DUT: GBF-835-N2, GBF-835-N2 Plus, LS202-B1, Ls202-B1 Plus, LS206-E1, LS206-E1 Plus, GBF-1251-B1, and GBF-1251-B1 Plus.
2583187|NCT02345109|Experimental|Reference|Measured by Reference: TRANSTEK® Glass Body Fat Analyzer GBF-1251-B, Tanita® Body Composition Monitor BC-533.
3211990|NCT01010737|Active Comparator|Adjuvant: Montonide isa 51 VG|Adjuvanted PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
3211991|NCT01010737|Active Comparator|Placebo|PBS was administered twice with a 19-23 day interval via the IM route to 10 participants and then a TIV boost was administered.
3211992|NCT01010737|Experimental|Multimeric-001 500 mcg|500mcg of M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3211993|NCT01010737|Experimental|Adjuvanted Multimeric-001 500mcg|5000mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
2582324|NCT02350855|Experimental|Intervention group|Patients in the intervention group were given dietary supplement (Improved Atta: 100 g) daily along with nutritional counseling and physical activity counseling for six months.
2582334|NCT02350855|Other|Control group|Patients in the control group were given nutritional and physical activity counseling for six months every fortnight.
2582381|NCT02350413||Endometriosis|Women referred to five Obstetrics and Gynecological Department for the treatment of endometriosis
2582435|NCT02350140|Experimental|Text messaging from beginning|Half of the health facilities will be randomly allocated to receive the TextIT intervention during the first time period (six months), while the other half to continue with current standard care (first step)
2582437|NCT02350140|Active Comparator|Text messaging after 6 months of control|Half the facilities will receive standard of care for six months (first time period). After the first time period, the these facilities will then also receive the TextIT intervention (second step)
2582489|NCT02349776|Experimental|All patients for allograft transplant|For the testimonial part all patients who have received an allograft transplant in the last five years will be eligible for participation if they have capacity to consent and can speak English fluently.
2582523|NCT02349490|Active Comparator|Group A first line therapy|In group A, Seraseal is applied as initial method for hemostasis. If successful, the bleeding site isthen observed for 5 minutes. If bleeding remains active or recurs the institutional standard of care for hemostasis is applied.
2582537|NCT02349490|Active Comparator|Group B rescue therapy|In group B, Seraseal is applied as rescue therapy after an initial failure of the institutional standard method. If Seraseal was successful, the bleeding site was then observed for 5 minutes. If the bleeding remains active or recurs after Seraseal, alternative methods of hemostasis would be applied.
3211994|NCT01010737|Experimental|Adjuvanted Multimeric-001 250mcg|250mcg of Adjuvanted M-001 was administered twice with an interval of 19-23 days via the IM route to 10 participants as a primer and then a TIV boost was administered.
3211995|NCT01010789|Experimental|Armodafinil|Flexible dose 150-250mg/day
2582695|NCT02348333|Active Comparator|FYU-981|
2582704|NCT02348333|Placebo Comparator|Placebo|
3176889|NCT00648219|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
3176890|NCT00648219|Active Comparator|2|Benicar® Tablets 40 mg
2582781|NCT02347527|Experimental|Active Implicit Priming|Participants will complete active implicit priming, in which food images are implicitly primed (i.e., below conscious awareness) with images of positive or negative affect.
2582784|NCT02347527|Placebo Comparator|Control Implicit Priming|Participants will complete a control implicit priming intervention, which matches the active intervention, but with neutral stimuli as primes.
3211996|NCT01010789|Placebo Comparator|Mathing Placebo|
2582950|NCT02346734|Active Comparator|MSHAT|The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and the intervention group will receive access to the MSHAT system via a website in which they will utilize each day. The study participants in the intervention group will login to the MSHAT system, go through a pre-exercise symptom diary to determine their eligibility to exercise, perform exercise while watching a video demonstration and report results real-time. The intervention group will also be able to send and receive messages via the MSHAT system. The time to complete the daily exercises will vary from patient to patient ranging for 10-30 minutes.
2582954|NCT02346734|No Intervention|Control|The study participants randomized to group 2 will serve as the control. The study participants will receive a clinical physical therapy evaluation and a physical therapy program to do at their own pace in the home and will be given a paper diary to report their exercise completion. The control group will bring their paper diary showing their exercise completion results to their 3 month and 6 month follow-up visits.
2583013|NCT02346448|Active Comparator|endoscopic sphincterotomy|performing endoscopic sphincterotomy of papilla of Vater during ERCP Device: standard sphincterotome
2583017|NCT02346448|Active Comparator|balloon dilatation for 3 minutes|Balloon dilatation of papilla of Vater for 3 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10mm size)
2583023|NCT02346448|Active Comparator|balloon dilatation for 6 minutes|Balloon dilatation of papilla of Vater for 6 minutes during ERCP using 10mm balloon Device: standard dilation balloon catheter (10 mm size)
2583056|NCT02345837|Active Comparator|clomiphene and endometrial sampling|Couples who will undergo endometrial sampling in the luteal phase of the cycle preceding ovulation induction by clomiphene citrate.
2583062|NCT02345837|Active Comparator|clomiphene citrate|Couples who will undergo ovulation induction with clomiphene citrate.
2583212|NCT02344888|Active Comparator|Clomiphene citrate-Prednisolone group|Women will receive clomiphene citrate and prednisolone
2583213|NCT02344888|Active Comparator|Clomiphene citrate-placebo group|Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
2583262|NCT02344602|Experimental|Febuxostat (trade name Uloric®)|Oral tablet, 80mg, OD, 8 weeks
2583326|NCT02344303|Experimental|Part A|Fixed sequence, open label
2583329|NCT02344303|Experimental|Part B|4 way cross over, double blind
2583359|NCT02343991|Experimental|Transcranial ExAblate|MR Guided Focused Ultrasound
2583402|NCT02343562|Active Comparator|Probiotics Group|Will receive Sachet-form probiotics
3176891|NCT00648232|Experimental|A|Participants will receive voluntary brief HIV counseling and testing plus enhanced linkage to care.
3176892|NCT00648232|Experimental|B|Participants will receive voluntary brief HIV counseling and testing plus routine referral to care.
3176893|NCT00648232|Experimental|C|Participants will receive voluntary longer, more detailed HIV counseling and testing plus enhanced linkage to care.
3176894|NCT00648232|Experimental|D|Participants will receive voluntary longer, more detailed HIV counseling and testing plus routine referral to care.
3176895|NCT00648232|Active Comparator|E|Participants who are found to be healthy will receive voluntary brief HIV counseling and testing only.
2582218|NCT02351713|Experimental|Relative percent method|Exercise Week 1 40-45% heart rate reserve 3 days 20 min/day Week 2 40-45% heart rate reserve 4 days 25 min/day Week 3 40-45% heart rate reserve 4 days 30 min/day Week 4 40-45% heart rate reserve 5 days 30 min/day Week 5-6 50-55% heart rate reserve 5 days 30 min/day Weeks 7-8 50-55% heart rate reserve 5 days 30min/day Weeks 9-12 60-65% heart rate reserve 5 days 30 min/day
2582221|NCT02351713|No Intervention|Control|Non-exercise control group
2582280|NCT02351440|Experimental|Duloxetine|duloxetine 60mg PO
2582291|NCT02351440|Placebo Comparator|Placebo|placebo
2582327|NCT02350829|Active Comparator|Cardiomyopathy|"Clinically established diagnosis of dilated, hypertrophic or arrhythmogenic right ventricular cardiomyopathy~Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
2582341|NCT02350829|Active Comparator|Congenital Heart Disease|"Diagnosis of Transposition of the great arteries after arterial switch operation, repaired Tetralogy of Fallot, patients after single ventricle palliation at the Fontan stage, native and repaired Aortic Coarctation Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Administering Multihance 0.2ml/kg as part of clinical scan~Obtaining bloodwork for assessment of hematocrit and collagen biomarkers"
2582351|NCT02350829|Active Comparator|Controls|Patients undergoing a non-cardiac MR investigation (musculoskeletal / abdomen / brain) without a history of cardiac disease Adding limited cardiac sequence to the clinical magnetic resonance scan including T1 mapping Administering Multihance 0.2ml/kg as part of clinical scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
2582391|NCT02350543|Active Comparator|Aspirin continuation|Continued use of Acetylsalicylic acid at prior dosage (75mg or 100mg tablet one-per-day).
2582397|NCT02350543|No Intervention|Aspirin discontinuation|Discontinuation of Acetylsalicylic acid ten days prior to surgery, and re-initiation two weeks after hospital discharge.
2582432|NCT02350075|Experimental|Short implants group|Patients receive short dental implants installation (6mm) without additional augmentation procedures.
2582433|NCT02350075|Other|Standard implants with OSFE group|Patients receive standard dental implants installation (10mm) combined with osteotome sinus floor elevation.
2582465|NCT02349802|Experimental|Arm 1|exenatide suspension - 9 mg / 0.85 mL
2582466|NCT02349802|Experimental|Arm 2|exenatide suspension - 9 mg / 0.85 mL
2582467|NCT02349802|Experimental|Arm 3|exenatide suspension - 4.5 mg /1.1 mL
2582468|NCT02349802|Experimental|Arm 4|exenatide suspension - 9 mg / 1.1 mL
2582469|NCT02349802|Experimental|Arm 5|exenatide suspension - 9 mg / 1.5 mL
2582512|NCT02349503|Experimental|NBI-77860 Dose Group1|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours).
2582516|NCT02349503|Experimental|NBI-77860 Dose Group 2|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
2582519|NCT02349503|Experimental|NBI-77860 Dose Group 3|NBI-77860 administered orally on Night 1 at bedtime (at approximately 2200 hours). Dosing will not commence until all safety and PK results from the dose group 2 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
2582589|NCT02349165|Active Comparator|epithelium off CXL|epithelium removal + 30 minute isotonic riboflavin eye drops (3 minute interval) + 30 minutes ultraviolet-A irradiation (riboflavin every 5 minutes)
2582590|NCT02349165|Experimental|Ricrolin TE CXL|Ricrolin-TE eye drops for 15 minutes (2 minute interval) and 15 minute Ricrolin TE pooled on the cornea using a silicone ring + 30 minutes ultraviolet-A irradiation (Ricrolin TE every 5 minutes).
2582647|NCT02348801|Active Comparator|Healthy Lifestyle Group|Group diabetes educations sessions that focus on diet, exercise, and social support.
2582649|NCT02348801|Experimental|Weight Loss plus Exercise Group|Behavioral therapy for weight loss and exercise training
3211997|NCT01010802|Experimental|Erythropoietin|"There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin."
3211998|NCT01010815||UC group|clinically and microscopically confirmed UC patients between the age of 19 and 75 years
2582904|NCT02347020|Experimental|Normal Sleep/ Normal Meal|sleep 0000-0800 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
2582905|NCT02347020|Experimental|Normal Sleep/ Late Meal|Ns/Lm: sleep 0000-0800 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
2582906|NCT02347020|Experimental|Late Sleep/ Normal Meal|sleep 0330-1130 h, meals at 1, 5, 11, and 12.5 (snack) h after awakening
2582907|NCT02347020|Experimental|Late Sleep/ Late Meal|sleep 0330-1130 h, meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening
2582979|NCT02346617|Experimental|allogeneic HSCT|The present study will investigate in a single-center (Samsung Medical Center), open-label, single arm by direct infusions of donor-derived CMV-spefic IFN-γ positive T-cells for the treatment of refractory CMV infection in allogeneic hematopoietic stem cell transplant (HSCT) recipients.
2583003|NCT02346201|Active Comparator|Methylphenidate|Methylphenidate, target dose 20 mg per day (range 10-20 mg per day), in 5 mg over-capsulated tablets, and psychosocial intervention
2583007|NCT02346201|Placebo Comparator|Placebo|Matching over-encapsulated placebo and psychosocial intervention
3211999|NCT01010815||Control group|normal healthy controls
3212000|NCT01010828|Active Comparator|Tri-Vector Approach|
3212001|NCT01010828|Experimental|Mini Mid-Vastus Approach|
3212002|NCT01010841|Active Comparator|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
3212003|NCT01010841|Experimental|Low-glycemic-load diet + medical food|Modified Mediterranean-style, low-glycemic-load diet + medical food
2582220|NCT02351765|Experimental|Acelarin & Cisplatin|"The maximum tolerated dose (MTD) of Acelarin in combination with 25mg/m2 Cisplatin will be determined.~The starting dose will be 625mg/m2 Acelarin which will be escalated to 725mg/m2 if the criteria for dose escalation is met (i.e. the proportion of dose limiting toxicities is acceptable as detailed in the protocol). Escalation will continue in accordance with the protocol up to a maximum of 925mg/m2. Only if the MTD is exceeded at the starting dose level (at least 2 of 3 participants or at least 2 of 6 participants have DLT at the first dose level) will there be a de-escalation to 500mg."
2582283|NCT02351323|Experimental|Glutamine + Lifestyle change|Glutamine 30 grams/day X 12-14 weeks, Lifestyle change
2582295|NCT02351323|Placebo Comparator|No glutamine + Lifestyle change|Lifestyle change
2582337|NCT02350803|Placebo Comparator|distraction osteogenesis|treatment of maxillary deficiency was done just by distraction osteogenesis and no mini plate was used after removal of distractor
2582350|NCT02350803|Active Comparator|distraction osteogenesis+ mini plate|treatment of maxillary deficiency was done just by distraction osteogenesis and after removal of distractor 4 mini plate L shaped was used after removal of distractor as an intervention
2582386|NCT02350582|Experimental|Telerehabilitation|Resistence and endurance exercise adapted to individual requeriment using internet to monitor progression during chemotherapy treatment. Telerehabilitation eCUIDATE system
2582390|NCT02350582|No Intervention|Control group|usual care offered to patients during chemotherapy treatment
2582434|NCT02350179|Experimental|cases|Women assigned to the study group will receive 1 gr of Tranexamic acid injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
2582436|NCT02350179|Placebo Comparator|control|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
2582478|NCT02349763|Active Comparator|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
2582482|NCT02349763|Experimental|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
3212004|NCT01010893|Experimental|Influenza vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose).
3212005|NCT01010893|Experimental|Influenza vaccination and co-vaccination|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
2582702|NCT02348515||Heart failure or coronary disease|This group will have small samples collected from the apex core (that would be routinely discarded at the time of the implantation procedure) by undergoing a left ventricular assist device implantation. In addition, a blood sample will be collected.
2582709|NCT02348515||Heart transplant patients|This group will have multiple samples collected including, excess myocardial biopsy samples that will not be utilized by pathology. In addition, a blood sample will be collected.
2582713|NCT02348515||Orthotopic Heart Transplant Patients|This group will have myocardial tissue samples collected from the diseased heart. In addition, a blood sample will be taken.
2582718|NCT02348515||Heart Surgery Patients|This groups will have samples collected from the left atrial appendages that are routinely removed to prevent thrombosis during atrial fibrillation surgery and a piece of the right atria will be cut in order to implant the cannula. In addition, a blood sample will be taken.
2582741|NCT02347995|Placebo Comparator|Resistive Training|Participants will drink a placebo beverage after each resistance training session.
2582742|NCT02347995|Experimental|Resistive Training + Protein|Participants will drink 30 grams of whey protein after each resistance training session.
2582774|NCT02347735||Anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
2582775|NCT02347735||No anastomotic leakage|Of the entire cohort, data collected from patients suffering from anastomotic leakage will be evaluated and compared to patients that did not develop anastomotic leakage. No interventions, only data collection.
2582859|NCT02347436||benign prostatic hypertrophy|patients who are diagnosed with lower urinary tract symptoms caused by prostatic hypertrophy, undergo transurethral resection of the prostate, and post-surgery 24-hr ambulatory blood pressure measurement.
2582863|NCT02347436||inguinal hernia or hydrocele|patients who are diagnosed with lower urinary tract symptoms caused by inguinal hernia or hydrocele, undergo surgical inguinal hernia repair or hydrocele repair, and post-surgery 24-hr ambulatory blood pressure measurement
2582926|NCT02346981|Experimental|Intervention gruop|The intervention group was submitted to a resistance training program that consisted of eight exercises performed in two sets of 10 to 15 repetitions, three times per week.
2582929|NCT02346981|No Intervention|Control group|The control group performed a stretching training program for the major muscle groups, in sessions of 30 minutes, twice a week
2582980|NCT02346539|Experimental|Nicotine|"2mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time.~4mg of nicotine in the form of a nicotine polacrilex lozenge will be administered orally, one time."
2582983|NCT02346539|Placebo Comparator|Placebo|Placebo comparator
2582996|NCT02346162|Experimental|Intervention|Weight management intervention
2582998|NCT02346162|Other|Usual Care Control|Usual Care for planning healthy pregnancy
2583052|NCT02345954|Experimental|Supracervical Hysterectomy and Sacropexy|Laparoscopic Supracervical Hysterectomy and Sacropexy
2583059|NCT02345954|Experimental|Hysteropexy|Laparoscopic Hysteropexy
2583173|NCT02345590|Experimental|Eplerenone|25mg Eplerenone once daily for 12 months
2583174|NCT02345590|Placebo Comparator|Matching placebo|Matching placebo once daily for 12 months
2583371|NCT02344017|Experimental|ODM-204 Phase I dose escalation|Dose escalation
2583372|NCT02344017|Experimental|ODM-204 Phase II dose expansion|
2582245|NCT02351804|Placebo Comparator|Ropivacaine + placebo|20 ml ropivacaine 0.5% + 0.5 ml isotonic saline ad
2582262|NCT02351297|Experimental|Casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
2582263|NCT02351297|Experimental|Soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
2582264|NCT02351297|Placebo Comparator|Maltrodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
2582299|NCT02351050|Experimental|Sonolysis|continual transcranial Doppler monitoring with maximal intensity during endovascular procedure
2582301|NCT02351050|Placebo Comparator|placebo|sham transcranial Doppler monitoring during endovascular procedure
2582340|NCT02350738|Experimental|MCET_Mock group|Period I: MCET for 8 weeks (3 sessions/ week); Washout for 4 weeks and cross-over; Period II: mock therapy for 8 weeks (3 sessions/week)
2582347|NCT02350738|Experimental|Mock_MCET group|Period I: mock therapy for 8 weeks (3 sessions/week); Washout for 4 weeks cross-over; Period II: MCET for 8 weeks (3 sessions/ week);
2582378|NCT02350452|Experimental|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
2582380|NCT02350452|Active Comparator|Bipolar coaugulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
2582444|NCT02350192|Experimental|e-health educational intervention (eHEI)|Participants in the intervention group received usual care and additional individualized educational intervention administered by a trained nurse who was experienced in cardiac nursing. The exercise prescription had been set as walking exercise for 30 minutes per day for 5 days per week. The exercise dosage might be modified with physician's order to suit the individual's physical condition and agreed goals if necessary. The 30- minutes educational intervention was conducted in a private room of the clinic. The content covered general information related to coronary heart disease and benefit of performing exercise, the e-health educational intervention (eHEI) link demonstration and re-demonstration. In addition, one telephone follow-up was conducted at week 2 to facilitate the usage of the e-HEI link.
2582445|NCT02350192|No Intervention|Control group|Control group received standard care only. The control group also received standard usual care comprising the doctor follow up with medication. During an individualized educational session conducted by a trained research assistant , a briefing on healthy life style and an an additional educational leaflet about coronary heart disease which is customarily given to patient with cardiovascular risks was given to the patient. In the control group, no e-health educational intervention has been provided to the patients of the control group.
3212006|NCT01010945|Experimental|erlotinib, gemcitabine, nab-paclitaxel|Patients receive the following treatment in 28-day cycles: 1) erlotinib: orally once daily from days 1 through 28 continuous dosing; 2) gemcitabine (following nab-paclitaxel): intravenously over 30 minutes on days 1, 8 and 15 every 28 days; and 3) nab-paclitaxel: intravenously over 30 minutes on days 1, 8 and 15 every 28 days.
3212007|NCT01010958|Experimental|Valproate|Valproic Acid taken orally, daily to reach serum levels between 50 to 100 µg/mL.
2582564|NCT02349230|Experimental|Astym treatment|Astym treatment is a manual therapy intervention applied by certified therapists with specialized instruments
2582565|NCT02349230|Sham Comparator|Sham Astym|A sham Astym treatment applied with non-therapeutic pressure and
2582570|NCT02349230|No Intervention|Control|12 minutes of rest
2582597|NCT02348996|Other|Clinical assessment|Patients would have dry weight determined by clinical evaluation (blood pressure levels, peripheral edema, pulmonary auscultation and symptoms).
2582607|NCT02348996|Experimental|Bioimpedance|Patients would have dry weight determined according to volume status with a body composition monitor (BCM)
2582661|NCT02348749|Experimental|pts with primary or metastatic neuroendocrine tumors|For phase I, a single dose of 18F-MFBG will be injected intravenously in patients. For all patients, pharmacokinetics and bio distribution will be evaluated using non invasive PET scanning and blood assays at multiple time points post injection. In the expansion phase, a single dose of 18F-MFBG will be injected intravenously followed by a single time point imaging using PET MR scanner or PET/CT. In expansion cohort, an additional 50 patients with NB will be imaged. Patients will receive a single dose of 18F-MFBG intravenously, followed by a whole body PET scan on PET/CT or PET/CT scanner at 60-90 minutes post injection. Patients who show lesion detection by MFBG may be eligible for repeat imaging scan with 18 F- MFBG, at the discretion of PI or study investigator(s). All parameters and technical details of scanning will be as per the study and first imaging.
3212008|NCT01010997||Dry AMD|Intermediate AMD subjects
3212009|NCT01010997||Wet - treated AMD|AMD subjects under treatments
3212010|NCT01011010|Other|Single Arm|Single Arm Trial
3212011|NCT01011023|Experimental|WITHOUT NASOGASTRIC TUBE|1. Experimental group (EG): without NGT, by removing the NGT at the end of the surgery, once the stomach had been aspirated,
2582844|NCT02347215|Other|All patients|All patients undergo quality of life assessment at 2-3 time points and stress imaging at two time points
2582878|NCT02347046|Experimental|Moderately-decreased group|(eGFR: >=30mL/min/1.73m^2 and < 60mL/min/1.73m^2)
2582879|NCT02347046|Experimental|Slightly-decreased group|(eGFR: >=60mL/min/1.73m^2 and < 90mL/min/1.73m^2)
2582880|NCT02347046|Experimental|Normal group|(eGFR: >=90mL/min/1.73m^2)
2582957|NCT02346812|Experimental|Brassica|Brassica vegetables will be consumed daily as part of a controlled diet.
2582958|NCT02346812|Other|Control|Typical American diet will be consumed, without any Brassica vegetables.
2582976|NCT02346422|Experimental|MYDICAR|Single intracoronary infusion of MYDICAR, a viral vector (adeno-associated virus serotype 1 [AAV1]) carrying the gene for sarcoplasmic reticulum Ca++-adenosine triphosphatase (SERCA2a), at a dose of 2.5 x 10^13 DRP. Administered in MYDICAR Phase 1 and MYDICAR Phase 2.
2582977|NCT02346422|Placebo Comparator|Placebo|Single intracoronary infusion of placebo (Sodium Chloride Injection, USP) (Placebo Phase 2 only).
3259001|NCT01466543|Active Comparator|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, once
3259002|NCT01466543|Placebo Comparator|Placebo|placebo medication
3259003|NCT01466556||Obese children|
3259004|NCT01466569|Experimental|AbGn-7 phase 1a cohort 1|
3259005|NCT01466569|Experimental|AbGn-7 phase 1a cohort 2|
3259006|NCT01466569|Experimental|AbGn-7 phase 1a cohort 3|
2582297|NCT02351128|Experimental|Only one arm|All patients receive Lanreotide.
2582373|NCT02350361|Experimental|Endostar Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Recombinant human endostatin 15mg/day, day 1 - 14
2582374|NCT02350361|Active Comparator|Standard Arm|Gefitinib re-challenging, oral daily use Docetaxel 60mg/m2 and Cisplatin 70mg/m2, 21 days Placebo
2582453|NCT02350205|Experimental|Treatment (SASS)|All patients will receive both Self assembled skin substitute (SASS) and Split-thickness autograft (paired samples).
2582455|NCT02350205|Active Comparator|Control (split-thickness autograft)|All patients will receive both SASS and Split-thickness autograft (paired samples).
2582622|NCT02348827|Experimental|Family psychoeducation|The intervention consists of group-based family psychoeducation-program aimed at the patients' relatives. Each group will consist of 5 participants and the patients will not be present at group sessions. The program consists of four weekly sessions each consisting of both short lectures on relevant topics as well as interactive séances designed to give participants problem-solving skills.
2582624|NCT02348827|Active Comparator|Social support group|Relatives in the social support group will attend the same number of sessions of the same duration, as the relatives in the intervention group (family psychoeducation). The psychiatric nurse who will be in charge of the social support group will not give any psychoeducational intervention.
2582660|NCT02348554|Experimental|Controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 1h30 They wore 3 research sensors that estimated energy expenditure: Fitmate, Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
2582662|NCT02348554|Experimental|Free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimated energy expenditure: Armband and Actiheart. They also wore smartphones (in front pant pockets) that collected accelerometry data.
2582720|NCT02348398|Experimental|Pazopanib + Topotecan|"Pazopanib 600 mg taken orally continuously while Topotecan 0.25 mg taken orally for 21 days continuously followed by 7 days off. A cycle will be defined as 28 days.~During follow up if disease gets worse, participant called by study staff every 3 months."
2582750|NCT02348021|Other|Drug Coated Stent|All patients in the one arm will be treated by PCI with the Drug Coated Stent.
2582785|NCT02347722||Retrospective|Heart failure patients where the etiology of their heart failure has been diagnosed. This cohort will consist of 3 groups: 1) Ischemic cardiomyopathy, 2) dilated cardiomyopathy and 3) diastolic heart failure
2582793|NCT02347722||Prospective|This cohort will consist of symptomatic heart failure patients diagnosed within 2 years.
2582801|NCT02347722||Healthy volunteers|Age matched healthy volunteers for comparison with heart failure patients
2582861|NCT02347358|Experimental|IV r-tPA with JRecanTM blood FR device|Dual IV r-tPA therapy and adjunctive treatment with JRecanTM blood flow recanalisation device
2582866|NCT02347358|Active Comparator|IV r-tPA|IV infusion of r-tPA
2582927|NCT02346929|Experimental|ultrasound-guided hematoma block|Patients in this arm will receive a bed-side ultrasound guided hematoma block with analgesia (0.25% bupivacaine)
2582930|NCT02346929|No Intervention|traditional hematoma block|Patients in this arm will have the hematoma block of the distal radius fracture with no ultrasound for guidance with analgesia (0.25% bupivacaine)
2583029|NCT02346487|Experimental|LPV/RTV pellets and AZT/3TC or ABC/3TC|Only 1 arm. No comparator
2583044|NCT02345798|Active Comparator|Arm I (standard care)|Patients and caregivers receive standard care during routine clinic visits.
2583047|NCT02345798|Experimental|Arm II (video-assisted intervention)|Patients view Parts 1 and 2 of the video program, which focus on what to expect before surgery and after surgery in the hospital, on a tablet over approximately 8 minutes at a scheduled pre-operative visit. Patients then receive an educational handbook and discuss the video with a nurse. After surgery and before hospital discharge, patients view Part 3 of the video over approximately 6 minutes, which focuses on what to expect after going home.
2583246|NCT02344810|Experimental|Arm A (AMG 337, mFOLFOX6)|Patients receive c-Met inhibitor AMG 337 PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
2583247|NCT02344810|Active Comparator|Arm B (placebo, mFOLFOX6)|Patients receive placebo PO QD on days 1-28; and oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 46-48 hours on days 1 and 15.
3176896|NCT00648232|Active Comparator|F|Participants who are found to be healthy will receive voluntary longer, more detailed HIV counseling and testing only.
2583403|NCT02343562|Placebo Comparator|Placebo Group|Will receive off-the-shelf oral multivitamin
3176897|NCT00648245|Experimental|1|
3176898|NCT00648245|Experimental|2|
3176899|NCT00648245|Experimental|3|
3176900|NCT00648245|Placebo Comparator|4|
3176901|NCT00648245|Experimental|5|
3176902|NCT00648258|Active Comparator|Arm 1|
3176903|NCT00648258|Active Comparator|Arm 2|
3176904|NCT00648271|Experimental|1|Metoprolol Tartrate Tablets 25 mg
3176905|NCT00648271|Active Comparator|2|Lopressor® Tablets 50 mg
3176906|NCT00648297|Experimental|1|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg
3176907|NCT00648297|Active Comparator|2|Corzide® Tablets 80 mg/5 mg
3176908|NCT00648310|Active Comparator|1|arm 1: Tolterodine 4 mg once daily for 12 weeks
3176909|NCT00648310|Experimental|2|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks
3176910|NCT00648323|Experimental|A|
3176911|NCT00648336|Experimental|1|Mercaptopurine 50 mg
3176912|NCT00648336|Active Comparator|2|Purinethol® Tablets 50 mg
3176913|NCT00648349|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
3176914|NCT00648349|Active Comparator|2|Aciphex® Delayed-Release Tablets 20 mg
3176915|NCT00648362|Experimental|1|Glimepiride Tablets 1 mg
3176916|NCT00648362|Active Comparator|2|Amaryl® Tablets 1 mg
3176917|NCT00648388|Experimental|1|Cilostazol Tablets 100 mg
3176918|NCT00648388|Active Comparator|2|Pletal® Tablets 100 mg
3176919|NCT00648401|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3176920|NCT00648401|Active Comparator|2|Verelan® PM Extended-Release Capsules, 300 mg
2582277|NCT02351414||Primary Total Knee Arthroplasty|Single study group previously implanted with the EVOLUTION® TKA System with cruciate sacrificing (CS) inserts
3176921|NCT00648414|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
2582403|NCT02350595|Experimental|Lean fish|Participants eat 750g of lean fish per week for 8 weeks.
2582407|NCT02350595|Experimental|Fatty fish|Participants eat 750g of fatty fish per week for 8 weeks.
2582409|NCT02350595|No Intervention|Control|Participants eat as normal, but avoid fish and seafood for 8 weeks.
2582430|NCT02350088|Active Comparator|Fast-track Surgery|probiotics,oral,b.i.d.
2582431|NCT02350088|Active Comparator|Traditional Group|placebo,oral,b.i.d.
2582498|NCT02349828|Active Comparator|Zovirax|Adult dose - 400 mg twice daily generic name: Acyclovir
2582500|NCT02349828|No Intervention|No treatment|standard of care
3259007|NCT01466569|Experimental|AbGn-7 phase 1b cohort 1|
3259008|NCT01466569|Experimental|AbGn-7 phase 1b cohort 2|
2582595|NCT02348944||15 healthy volunteers|Other: serum and urine sample
2582668|NCT02348762|Experimental|Cysteine/glycine|Older subjects will be studied before and after taking oral cysteine (as n-acetylcysteine) and glycine for 6 months
2582705|NCT02348411|Experimental|ExAblate Treatment group|
2582755|NCT02348151|Experimental|Treadmill|The Shuttle is going to play on treadmill
2582759|NCT02348151|Active Comparator|Corridor|The Shuttle is going to play on corridor
2582794|NCT02347592|Active Comparator|straight Tenckhoff|The straight Tenckhoff catheter (sT) is the most common used catheter for peritoneal dialysis (PD).
2582803|NCT02347592|Active Comparator|self-locating catheter|A new, more expensive, self-locating catheter (sLC) has been developed by Di Paolo.
2582852|NCT02347293|Experimental|+ ind. CHO|Test meals: intake of high levels of indigestible carbohydrates the evening prior to measurements of variables
2582857|NCT02347293|Experimental|- ind. CHO|Reference meal: scarce intake of indigestible carbohydrates the evening prior to measurements of variables
2582911|NCT02346968||All study participants|Patients with end stage renal disease (ESRD) planned to undergo kidney transplantation.
2582981|NCT02346591|Experimental|Jauntly|Mobile app designed to take advantage of the known connections between positive emotions, stress reduction and stress resilience; goal was to lead users through research-proven positive emotion enhancing exercises and relevant educational materials. Intervention activities covered five well-being generating content areas: 1) promoting the experience and recognition of gratitude; 2) encouraging positive social relationships and feelings of social support; 3) improving stress resilience via mindfulness and other relaxation-focused activities; 4) focusing and capitalizing on individual strengths (as opposed to limitations and weaknesses); and 5) general positive mood inducing activities.
2582984|NCT02346591|Active Comparator|Online stress management information|The control participants were emailed links to vetted online information about stress and encouraged to visit the websites.
2583024|NCT02346188|Experimental|Ferrous fumarate|Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
2583028|NCT02346188|Experimental|Zinc oxide|Tablet formulated as zinc oxide, 30 mg. Given once daily by mouth for 6 months.
2583030|NCT02346188|Experimental|Ferrous fumarate and zinc oxide|Tablet, formulated as ferrous fumarate 30 mg plus zinc oxide 30 mg. Given once daily by mouth for 6 months.
2583033|NCT02346188|Placebo Comparator|Placebo|Sugar tablet formulated to look like the experimental arms of the study. Given daily by mouth for 6 months.
2583050|NCT02345785||Group 1|pediatric patients who need urologic surgery and caudal block
2583108|NCT02345694|Experimental|Effective CPAP|Continuous Positive Airway Pressure (RESMED S9™ Series), all the nights, during 8 weeks.
2583109|NCT02345694|Sham Comparator|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (RESMED S9™ Sham-Continuous Positive Airway Pressure System), validated placebo of Continuous Positive Airway Pressure, all the nights, during 8 weeks.
2583124|NCT02345356||Standard-of-Care|the standard clinical approach will be followed
2583128|NCT02345356||Genotype-guided|algorithmically guided personalized therapy of warfarin, using a pharmacogenetic model developed in Caribbean Hispanics
2583204|NCT02345122|Other|Enhanced Usual Care|This group will receive Enhanced Usual Care. The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life . If the subjects primary care provider chooses, they can use this information to construct the subject's treatment plan.
2583209|NCT02345122|Experimental|Intervention: Mental Health Technician|The subject's Primary Care Provider will receive results of baseline, four, eight, and twelve month assessments examining the subject's symptoms of depression, anxiety, and other mental health problems, use of alcohol and illicit substances, physical pain, and quality of life and recommendations for treatment. Over a 3-12 months period, the Intervention group will receive a brief, telephone-based intervention by a Mental Health Technician that will focus on monitoring symptoms, treatment adherence, and providing psychoeducation.
2583314|NCT02344381|Experimental|Sucrose|Sucrose ingestion post-exercise
2583316|NCT02344381|Active Comparator|Glucose|Glucose ingestion post-exercise
2583355|NCT02344082|No Intervention|Standard of Care|The control arm will receive face-to-face pharmacy clinic visits per usual care.
2583357|NCT02344082|Active Comparator|Intervention Arm|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
2583396|NCT02343757|Other|PET/CT vs. PET/MRI|"Patients will be included if presenting with the clinical suspicious of AD, Mild Cognitive Impairment (MCI) or other cognitive impairment to be further determined.~Patients will undergo two doubles scans in two steps with a maximum of 2 week between both: the first step will be one day double scan with FDG imaged by PET-CT and PET-MRI; and the second step will be one day double scan with 18F-florbetapir imaged by PET-CT and PET-MRI at a different timepoints as shown in figure 1."
3259009|NCT01466582||HIV-negative controls|A group of HIV-negative controls, aged 45 years and above, that is recruited at the STD-clinic of the Public Health Service Amsterdam or at the existing Amsterdam Cohort Studies.
3212012|NCT01011023|Active Comparator|WITH NASOGASTRIC TUBE|2. Control group (CG): with NGT, with radiographic corroboration of correct placement after the surgery. Both groups were given: 5-day fasting because it was the therapeutic gold standard at our hospital and our country, intravenous solutions and antibiotics for 5 days, ranitidine, and analgesics, without use of any antiemetic drug. Once the fasting period ended, in the CG the NGT was clamped and withdrawn, and in both groups oral fluids and diet were started. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
2582367|NCT02350686|Experimental|capecitabine+oxaliplatin|XELOX every 3 weeks
2582417|NCT02350283|Experimental|Solitaire Device|Interventional treatment with Solitaire. After the procedure, the patients will be admitted to intensive care unit. Standard medical management will be provided to these patients.
2582420|NCT02350283|No Intervention|Medical treatment|Standard medical treatment alone.
2582450|NCT02349919|Experimental|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
2582451|NCT02349919|Placebo Comparator|Placebo|Placebo twice daily for 4 weeks
2582533|NCT02349659|No Intervention|Conservative Medical Management|Continued medical management restricted to exclude interventional pain treatments
2582546|NCT02349659|Active Comparator|Axium Group|As the CMM group but also treated with Dorsal Root Ganglion stimulation using the Axium neurostimulator
2582617|NCT02349139|Experimental|ASN001: Escalating dose Part A|The dose of ASN001 will be based on the assigned study group. The initial dose level of ASN001 will be 50 mg daily. After a safety review, the dose may be escalated for the next group of subjects. Additional dose levels are 100 mg, 200 mg, 300 mg, and 400 mg.
2582651|NCT02348580|No Intervention|Treatment as usual|Schools in which regular curriculum is delivered and teachers do not receive any additional training in child centered methodologies.
2582653|NCT02348580|Experimental|Child centered teaching of life-skills|Training of teachers and weekly implementation of hour long sessions based on child centered teaching of life-skills education over the course of the school year in P6 and S3 classes as designed by Aflatoun Stichting Child Savings International and the Association of Microfinance Institutions in Rwanda (AMIR). The life-skills curriculum is known as Aflatoun's Child Social and Financial Education program. The training of teachers element of the intervention is known as Aflatoun Academy, which trains teachers in active learning, child centered methodologies as well as how to implement the life-skills curriculum of Aflatoun Child Social and Financial Education.
2582696|NCT02348424|Experimental|Female solithromycin|14 females will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
2582708|NCT02348424|Experimental|Male solithromycin|14 males will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted) administered orally.
2582746|NCT02348073|Active Comparator|PS-OMEGA 3, capsules twice daily|Vayarin®, supplementation of n-3 PUFA: each capsule contains 8.5 mg of docosahexaenoic acid (DHA), 21.5 mg of eicosapentaenoic acid (EPA) and 75 mg of phosphatidylserine.
2582749|NCT02348073|Placebo Comparator|PLACEBO, capsules twice daily|The placebo will be made of cellulose and a small amount of fish powder to maintain the double-blind in odor and taste. The supplementation in n-3 PUFA in the placebo group may be considered as negligible. Placebo will be administered as indistinguishable capsules, identical to the active product.
2582786|NCT02347579||Patients with CRPS|Patients with Complex Regional Pain Syndrome, Type I
2582795|NCT02347579||Patients with CLBP|Patients with chronic low back pain
2582804|NCT02347579||Healthy controls|
3212013|NCT01011036|Other|1|
2582920|NCT02346890|Experimental|AZD1722 alone|15 mg BID
2582923|NCT02346890|Experimental|AD1722 with Renvela|AZD1722 15 mg BID and Renvela 800 mg TID
3212014|NCT01011036|Other|2|
3212015|NCT01011036|Other|3|
3212016|NCT01011062|Experimental|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
3212017|NCT01011062|Experimental|Losartan + hyperinsulinaemia|
2583152|NCT02345668|Experimental|Transdiagnostic Internet-based Treatment|Intervention group that carries out the Emotion Regulation Protocol and receives support by the therapist (a brief weekly two-minute phone call without clinical content and two weekly orientative text messages)
3212018|NCT01011062|Placebo Comparator|Saline|Infusion of Saline as a volume control intervention
3212019|NCT01011088||Early phase|Psychoses within the first 3 months after baby born
3212020|NCT01011088||Delayed phase|Psychoses > 3 months to one year after baby born
3212021|NCT01011114|Active Comparator|Cincalcet|cinacalcet will be titrated as needed to achieve serum phosphorus of > 2.5 mg/dl randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mg/l.
3212022|NCT01011114|Placebo Comparator|Control|"subjects will receive placebo pill titrated as needed to achieve phosphorus > 2.5 mg/dl.~randomized, placebo-controlled trial comparing the effect of cinacalcet to placebo in controlling serum phosphorus. All subjects will receive oral phosphorus supplementation and Vitamin D as needed to maintain baseline Phosphorus at ~ 2.5 mEq/l."
3212023|NCT01011127||pravastatin|
3212024|NCT01011127||rosuvastatin|
3212025|NCT01011140||Online Survey|Survey of Palliative care physicians from Latin America and Spain
3212026|NCT01011166|Experimental|IDX184 50 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo once daily (QD) in combination with Peg-IFN/RBV on Days 14-28 and Peg-IFN/RBV on Days 14-28.
3212027|NCT01011166|Experimental|IDX184 100 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 50 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
3212028|NCT01011166|Experimental|IDX184 100 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo twice daily (BID) in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV alone on Days 14-28.
3212029|NCT01011166|Experimental|IDX184 150 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 150 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
3212030|NCT01011166|Experimental|IDX184 200 mg QD + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 100 mg or placebo QD in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
2582503|NCT02349620|Active Comparator|A:partialy edutolus patients|In this group surface treated implant with PRF will be inserted.Immediately after the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequency analysis (RFA), using the smart peg type 1, then stability will be measured every 2 weeks up to 3 months .Bone height will be measured in mesial and distal side immediately after placement and in months 3 and 6 with Intra Oral Peri Apical xray (IOPA x-ray)
2582505|NCT02349620|Placebo Comparator|B: partialy edutolus patients|In this group implant with out PRF will be inserted.Immediately after the surgery the implant stability will be measured with the Osstell mentor to verify the resonance frequence analysis (RFA ), using the smartpeg type 1, then stability will be measured every 2 weeks up to 3 months. Bone height was measured in mesial and distal side immediately after placement and in months 3 and 6 with IOPA xray
2582529|NCT02349308||CentrosFLO Long Term Hemodialysis Catheter|Schedule placement of catheter. Arterial tip of the catheter should be placed at or just above the junction of the right atrium and superior vena cava, with the arterial lumen on the left side of the catheter. The venous limb will extend into the right atrium. Catheter will be locked with the usual heparin lock solution for a newly placed catheter (at least 500 units per lumen). Fluoroscopic images will document tip position.
2582603|NCT02349035|Experimental|TMR surgery to evaluate pattern recognition control|Perform Targeted Muscle Reinnervation (TMR) surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.
2582773|NCT02347852||Physical activity / Cohort 1|The non influenced and non triggered habitual physical activity of patients will be assessed by pedometer and physical activity questionnaire. The study population will consist of patients with metastatic CRC (mCRC) who are included in the NIS CORRELATE, have been previously treated with other approved regimens for metastatic disease and for whom a decision has been made by the physician to treat with regorafenib according to local health authority approved label prior to and independent of the inclusion into this observational study.
2582809|NCT02347501|Experimental|A|"Sitagliptin 100mg once daily orally or 50mg once daily for participants with moderate kidney disease for 24 weeks and narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
2582817|NCT02347501|No Intervention|B|"No additional treatment other than narrowband ultraviolet-B (NBUVB) phototherapy.~NBUVB light therapy is continued until the participants' psoriasis clears (<1% body surface area involved)."
2582836|NCT02347254|Experimental|Transcranial ExAblate|Transcranial ExAblate MRgFUS
2583169|NCT02345408|Experimental|CCX872-B|150 mg once or twice daily given orally for at least 12 weeks
2583377|NCT02343861|Active Comparator|Tailored leaflet group|Participants (parents of children with atopic dermatitis) receive a tailored leaflet about the detailed amount of emollients as well as general information about use of emollients.
2583379|NCT02343861|Placebo Comparator|Control group|Participants (parents of children with atopic dermatitis) receive general information about use of emollients only.
3176922|NCT00648414|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
2583523|NCT02342951|Other|LCI|Measure of lung clearance index
2583553|NCT02342626|No Intervention|Control|No use of the decision aid dashboard before, during or after the treatment decision time period.
2583555|NCT02342626|Experimental|Dashboard|Use of the decision aid dashboard before, during and after the treatment decision time period.
2583572|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 30 mg BID|Subjects are randomized to receive 30 mg twice daily of enoxaparin.
2583573|NCT02342444|Active Comparator|Enoxaparin Sodium Injection 40 mg QD|Subjects are randomized to receive 40 mg once daily of enoxaparin.
2583641|NCT02342262|Experimental|Probiotics|EcologicBarrier, 5x10E9 cfu/day
2583642|NCT02342262|Placebo Comparator|Placebo|carrier material of Ecologic Barrier, not containing bacterial strains
2583683|NCT02342002|Experimental|Mifepristone-misoprostol regimen|After a woman is determined eligible and signs the informed consent document, she will receive 200 mg mifepristone and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
2583685|NCT02342002|Placebo Comparator|Misoprostol alone regimen|After a woman is determined eligible and signs the informed consent document, she will receive a placebo (of same shape and size of mifepristone) and advised to swallow the pill when they arrive at home. 24 hours after administration of the mifepristone, women will administer the four tablets of 200 mcg misoprostol sublingually.
3176923|NCT00648414|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
3176924|NCT00648414|Experimental|4|Duragesic 25 mcg/h + Clinical Procedure 1 - blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
3176925|NCT00648414|Experimental|5|Duragesic 25 mcg/h + Clinical Procedure 2 - tourniquet applied just below patch application site and above blood draw site
3176926|NCT00648414|Experimental|6|Duragesic 25 mcg/h + Clinical Procedure 3 - tourniquet applied just above patch application site
3176927|NCT00648427|Experimental|1|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg
3176928|NCT00648427|Active Comparator|2|Paxil CR™ Tablets 25 mg
3176929|NCT00648440|Experimental|1|Midodrine HCl Tablets 5 mg
3176930|NCT00648440|Active Comparator|2|ProAmatine® Tablets 5 mg
3176931|NCT00648466|Experimental|1|Sumatriptan Succinate Tablets 100 mg
3176932|NCT00648466|Active Comparator|2|Imitrex® Tablets 100 mg
3176933|NCT00648479|Experimental|1|
3176934|NCT00648479|Active Comparator|2|
3176935|NCT00648492|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3176936|NCT00648492|Active Comparator|2|Glucophage® XR 500 mg
3176937|NCT00648505|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
3176938|NCT00648505|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
3176939|NCT00648518|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
3176940|NCT00648518|Active Comparator|2|Glucophage® XR Tablets 750 mg
3176941|NCT00648531|Experimental|1|Balsalazide Disodium Capsules 750 mg
3176942|NCT00648531|Active Comparator|2|Colazal® Capsules 750 mg
2582511|NCT02349672||Healthy Control|The healthy control group will have 500-800uL (less than 1 mL) of blood collected. This sample will be obtained at the same time that the neonate is already having a standard blood screenings drawn at 24 and 48 hours of life.
2582513|NCT02349672||Clinical Control|The clinical control group will be healthy neonates that are being evaluated for jaundice, with multiple blood samples drawn between birth and 48 hours of life to monitor serum bilirubin. With these already scheduled lab draws, we will draw an additional 0.8-1 mL of blood.
2582574|NCT02349217|Experimental|Mindfulness Based Stress Reduction Intervention (MBRE)|"Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
2582575|NCT02349217|Active Comparator|Standard of Care|"Participants receive self-help materials that have been previously developed by MD Anderson's Office of Public Education, the American Cancer Society, and the National Cancer Institute.~Pain assessment administered at baseline and at follow up visit. Questionnaires completed at baseline and at follow up visit. Neurocognitive tests administered at baseline and at follow up visit. Cortisol testing performed after baseline visit and at follow up visit. Interviews conducted after follow up visit. These interviews are audio-taped and transcribed."
2582601|NCT02348853|Experimental|Healthy Weight For Living (HWL)|HWL is a behavioral intervention designed to effectively facilitate hunger suppression with several concurrent approaches. Hunger suppression is a core behavioral goal of the intervention, and strategies will be used to support that goal, for example increasing meal frequency and encouraging the use of highly satiating low-energy foods to reduce hunger acutely. A unique combination of healthy dietary goals will be recommended that support hunger suppression and/or maintenance of satiety: high total dietary fiber, moderately high protein, moderately low glycemic load (GL) and low energy density.
2582610|NCT02348853|Experimental|Current Best Practice (CBP)|This intervention is an adapted version of Group Lifestyle Balance which is a validated weight loss program for community groups and military populations that is an official adaptation of the gold standard Diabetes Prevention Program Lifestyle Balance intensive research intervention. It has both training programs for interventionists and program material available on the web and is also slightly modified from the Diabetes Prevention Program study to take into account changing national nutrition recommendations.
3259010|NCT01466582||HIV-positive patients|A group of HIV-1-infected patients, aged 45 years and above, that is recruited at the HIV outpatient clinic of the Academic Medical Center.
2582728|NCT02348242|Experimental|Aqueous gel|In the same patient : one eye receives regular administration of aqueous gel (experimental treatment 1) and the other eye receives regular administration of artificial tears (active comparator)
2582729|NCT02348242|Experimental|Eyelid occlusion dressing|In the same patient : one eye is closed with an eyelid closure dressing (experimental treatment 2) and the other eye receives regular administration of artificial tears (active comparator)
2582754|NCT02347969|Experimental|X34|Arm supplemented with X34
2582962|NCT02346669|Active Comparator|FMT from a lean donor+ high fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start high fat low fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
2582964|NCT02346669|Sham Comparator|FMT from a lean donor+ sham diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start sham diet (no change in fat/fiber consumption) 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
2582966|NCT02346669|Active Comparator|FMT from lean donor+ low fat diet|"Patients will undergo FMT (Fecal Microboita Transplantation) from a lean donor twice during study through a gastroscopy:~at time 0~after 6 weeks Patient will start low fat high fiber diet 2 weeks before first FMT and continue on consuming the same diet 9 weeks after the first FMT. Patient will be followed up by a nutritionist through the the study."
2583000|NCT02346266|Active Comparator|SMART|The intervention group of school-aged children will receive education on the F.A.S.T. (Face, Arm, Speech and Time) acronym, additional signs and symptoms of stroke and the need for immediate activation of Emergency Medical Services (EMS) by calling 911.
2583005|NCT02346266|No Intervention|Usual Care|This group will not receive stroke education.
2583080|NCT02346045|Experimental|Renal sympathetic denervation|Renal sympathetic denervation procedure plus antihypertensive medication (doses and types of medication are maintained as previously prescribed)
2583087|NCT02346045|Sham Comparator|Medical therapy|renal angiogram plus antihypertensive medications (doses and types of medication are maintained as previously prescribed)
3176943|NCT00648544|Experimental|1|
3176944|NCT00648544|Active Comparator|2|
2583221|NCT02345057|Experimental|CS-3150 0.625 mg|One CS-3150 0.625 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
2583223|NCT02345057|Experimental|CS-3150 1.25 mg|Two CS-3150 0.625 mg tablets administered orally, once daily after breakfast.
2583227|NCT02345057|Experimental|CS-3150 2.5 mg|One CS-3150 2.5 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
2583230|NCT02345057|Experimental|CS-3150 5.0 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast
2583235|NCT02345057|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
3176945|NCT00648557|Experimental|1|Levothyroxine Sodium Tablets 200 mg
3176946|NCT00648557|Active Comparator|2|Synthroid Tablets 200 mg
3176947|NCT00648570|Experimental|1|Escitalopram Oxalate Tablets 20 mg
3176948|NCT00648570|Active Comparator|2|Lexapro® Tablets 20 mg
3176949|NCT00648583|Experimental|1|Ondansetron Tablets 24 mg
3176950|NCT00648583|Active Comparator|2|Zofran® Tablets 24 mg
3176951|NCT00648596|Placebo Comparator|Arm 2|
3176952|NCT00648596|Active Comparator|Arm 1|
2582541|NCT02349321|Experimental|School + Family Strengthening|"Skhokho Supporting Success for Schools: See description above.~Skhokho Supporting Success for Families: Participatory four-day workshop for parents/caregivers and their young adolescent children including parallel and joint dialogue sessions. This workshop aims to promote supportive, open relationships between parents/caregivers and their teens and includes communication, negotiation and conflict resolution skills; positive discipline skills; challenging traditional gender constructions; understanding the impact of child abuse; stress and coping."
2582548|NCT02349321|No Intervention|Arm 3: Control (Delayed Intervention)|"This group will continue with treatment as usual (i.e: school services, activities, and textbooks without specialised intervention). At the end of primary data collection, these schools will be eligible to receive the Schools Strengthening Intervention."
2582593|NCT02349074|Experimental|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy during Intensive Care Unit stay after out-of-hospital cardiac arrest
2582665|NCT02348567|Active Comparator|announced hospital surveys|Eleven hospitals will receive announced surveys (control group)
2582667|NCT02348567|Experimental|unannounced hospital surveys|12 hospitals will receive unannounced surveys (intervention group).
3212031|NCT01011166|Experimental|IDX184 200 mg BID + Peg-IFN/RBV|Participants randomized 4:1 (active:placebo) to receive IDX184 200 mg or placebo BID in combination with Peg-IFN/RBV on Days 1-14 and Peg-IFN/RBV on Days 14-28.
3212032|NCT01011192||ke0 of 0.26 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 0.26 min-1 (Asena PK® - Cardinal Health)
3212033|NCT01011192||ke0 of 1.21 min-1|Individual volunteers using Marsh's pharmacokinetic target-controlled infusion model with ke0 of 1.21 min-1 (Primea Orchestra® - Fresenius-Kabi basis)
2582871|NCT02347137|Active Comparator|Isolated Whey Protein|20 g isolated whey protein + 15 g non-essential amino acids
2582873|NCT02347137|Experimental|Micellar Whey Protein|20 g micellar whey protein + 15 g non-essential amino acids
2582875|NCT02347137|Experimental|Micellar Whey Protein + Citrulline|20 g micellar whey protein + 5 g citrulline
2582940|NCT02346825|Experimental|Intensive Plus Cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
2582943|NCT02346825|Experimental|Intensive Plus Splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
2582946|NCT02346825|Experimental|Intensive no Constraint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks but will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
3212034|NCT01011205|Experimental|Dosing Regimen 1|Advagraf + MMF + Corticosteroids (Bolus)
3212035|NCT01011205|Experimental|Dosing Regimen 2|Advagraf + MMF + Basiliximab + Corticosteroids (Bolus)
3212036|NCT01011205|Experimental|Dosing Regimen 3|Advagraf (5 days delay) + MMF + Basiliximab + Corticosteroids (Bolus)
2583085|NCT02345746|Experimental|Hepatic Artery Infusion|Hepatic Arterial Infusion (HAI) with the drugs Oxaliplatin, Folinic Acid and 5 Fluorouracil
2583117|NCT02345447|Active Comparator|Herbal-based Medication|"Trade Name of active comparator: Otovowen® Substances: Aconitum napellus Dil. D6; Capsicum annuum Dil. D4; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum Dil. D6; Hydrastis canadensis Dil. D4; Iodum Dil. D4; Natrium tetraboracicum Dil. D4; Sambucus nigra; Sanguinaria canadensis.~Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of Upper respirtory tract infection until symptoms resolve (maximally 8 weeks of continuous application)."
2583118|NCT02345447|Placebo Comparator|Placebo|Placebo Substance: Aqueous ethanol solution non-distinguishable from verum. Manufacturer: Weber & Weber, Inning/Ammersee Dose: Three times daily 7 drops Mode of Application: orally Duration of Treatment: at first signs of URI until symptoms resolve (maximally 8 weeks of continuous application).
2583191|NCT02345213|Experimental|E2020|"Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg.~Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg."
2583193|NCT02345213|Placebo Comparator|Placebo|"Treatment period: Weeks 1-12 placebo~Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg."
2583248|NCT02344836|Active Comparator|Theory-based podcast|"Receive a 3-month weight loss intervention delivered via theory-based podcast (TBP) plus self-monitoring using a commercially-available calorie and weight tracking app (current most popular diet self-monitoring method).~Intervention: podcast + mobile diet app"
2583249|NCT02344836|Experimental|Theory-based podcast + Social POD|"Receive a 3-month weight loss intervention delivered via Theory-based Podcast (TBP) plus self-monitoring and social support/incentive points for participating with the Social POD app (TBP+Social POD).~Intervention: podcast + theory-based mobile diet app"
2583281|NCT02344524|Experimental|Small bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using small bore chest drain
2583285|NCT02344524|Active Comparator|Large bore chest drain|Intercostal drainage for traumatic hemothorax and pneumothorax using large bore chest drain
2583320|NCT02344264|Other|RP|first blockade: ropivacaine 7,5mg/ml 8 ml second blockade: placebo: saline 8 ml
2583321|NCT02344264|Other|PR|first blockade: placebo: saline 8 ml second blockade: ropivacaine 7,5mg/ml 8 ml
3212037|NCT01011244|Experimental|ADIPOPLUS|patients with a fistula in Crohn's disease
3212038|NCT01011257|Active Comparator|Aspirin 81 mg, 1 tab twice daily|All participants to take one aspirin (81mg per tab) twice daily.
2583689|NCT02341846||Patients with cancer pain|Qualitative semi-structured interviews with patients who have experienced cancer pain
2583894|NCT02340494|Experimental|Intervention group|Women with access to the website.
3212039|NCT01011257|Active Comparator|Clopidogrel 75 mg 1 tab daily|Only stable CAD participants will take Clopidogrel (75mg per tab) daily.
3212040|NCT01011270||Back pain|The aim of this study was to investigate the effect of rehabilitation of the dynamic ;(RDM) in balance and balance of industrial operators. The sample consisted of industrial operators, individuals with low back pain, referred to the industry of Physical Therapy
2582853|NCT02347423|Experimental|1/3 IPV-Al SSI|3 vaccinations of 1/3 IPV-Al SSI given at 6, 10 and 14 weeks of age
2582856|NCT02347423|Experimental|1/5 IPV-Al SSI|3 vaccinations of 1/5 IPV-Al SSI given at 6, 10 and 14 weeks of age
2582862|NCT02347423|Experimental|1/10 IPV-Al SSI|3 vaccinations of 1/10 IPV-Al SSI given at 6, 10 and 14 weeks of age
2582865|NCT02347423|Active Comparator|IPV Vaccine SSI|3 vaccinations of IPV Vaccine SSI given at 6, 10 and 14 weeks of age, The comparator IPV Vaccine SSI contains: Type 1: 40DU, Type 2: 8 DU and Type 3: 32 DU.
2582914|NCT02346851|Experimental|triggered FES|
2582917|NCT02346851|Active Comparator|conventional FES|
2582919|NCT02346851|No Intervention|control group|
2582971|NCT02346552|Experimental|Group 1|Procedures will be performed with the AutoLpap system used for holding and controlling the movement of the laparoscope.
2582973|NCT02346552|No Intervention|Group 2|Procedures will be performed with the assistance of human camera holder.
2583001|NCT02346279||Persons in physical therapy treatment|Questionnaires (MSQPT, HAQUAMS, Transition Questionnaire for Patient and treating physiotherapist), physical tests (9HPT, 6MTWT, BBS, 6MWT), EDSS
2583049|NCT02346032|Experimental|refametinib|refametinib medication
2583119|NCT02345681|Experimental|Test Furosemide|We will test our furosemide algorithm in one arm
2583121|NCT02345681|No Intervention|Classical Strategy|It's a classical strategy without diuretics
2583432|NCT02343536|Experimental|Oral Azacitidine (CC-486) and R-CHOP|Will examine four escalating dose-levels of CC- 486 (100 mg, 150 mg, 200 mg and 300 mg).
2583433|NCT02343536|Active Comparator|R-CHOP|R-CHOP, (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) * rituximab, cyclophosphamide, doxorubicin, and vincristine are administered on Day 1; while prednisone is administered Days 1-5
3176953|NCT00648609||Home-based palliative care services|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
3176954|NCT00648609||Standard of care|Patients who are 60 or more years of age and have a diagnosis of COPD.Patients who have received two or more unscheduled acute care visits during the 12 months prior to the start of the study.
3176955|NCT00648622|Experimental|1|Carvedilol Tablets 12.5 mg
3176956|NCT00648622|Active Comparator|2|Coreg® Tablets 12.5 mg
3176957|NCT00648635||PET + QOL|Survey of how recurrent rectal cancer treatment affects well being + QOL
2583490|NCT02343289|Experimental|Esketamine Regimen|All participants will first receive 28 milligram (mg) of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, followed by 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, followed by 84 mg of intranasal esketamine on Day 1 of Period 3 and then 500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4 and 84 mg of intranasal esketamine on Day 1 of Period 4. Each period will be separated by a washout period of up to 21 days in between.
2583539|NCT02342782|Experimental|Treatment (yttrium Y 90 basiliximab, BEAM, AHCT)|Patients receive yttrium Y 90 basiliximab IV on days -21 and -14, carmustine IV over 1-2 hours on days -7 and -6, cytarabine IV BID on days -5 to -2, etoposide IV BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic stem cell transplant on day 0.
3176958|NCT00648661|Experimental|1|Escitalopram Oxalate Tablets 20 mg
3176959|NCT00648661|Active Comparator|2|Lexapro® Tablets 20 mg
3176960|NCT00648674|Experimental|1|Apligraf
3176961|NCT00648687|Experimental|I|this group will receive oral water and glucose prior to eye exam
3176962|NCT00648687|No Intervention|II|this group is the control group.
3176963|NCT00648700|Experimental|1|Levothyroxine Sodium Tablets 300 μg
3176964|NCT00648700|Active Comparator|2|Levothroid® Tablets 300 μg
3176965|NCT00648713|Experimental|1|Terbinafine Hydrochloride Tablets 250 mg
3176966|NCT00648713|Active Comparator|2|Lamisil® Tablets 250 mg
3176967|NCT00648726|Active Comparator|Arm 1|
3176968|NCT00648726|Active Comparator|Arm 2|
3176969|NCT00648726|Active Comparator|Arm 3|
3176970|NCT00648765|Experimental|1|Anagrelide Hydrochloride Capsules 1 mg
3176971|NCT00648765|Active Comparator|2|Agrylin® Capsules 1 mg
3176972|NCT00648778|Experimental|1|Loxapine Succinate Capsules 25 mg
3176973|NCT00648778|Active Comparator|2|Loxitane® Capsules 25 mg
3176974|NCT00648791|Experimental|1|Finasteride Tablets 5 mg
3176975|NCT00648791|Active Comparator|2|Proscar Tablets 5 mg
3176976|NCT00648804|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
3176977|NCT00648804|Active Comparator|2|Zofran ODT® Tablets 8 mg
3176978|NCT00648817|Placebo Comparator|Group 1|"Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the first 14 days of the study.~Tenofovir DF placebo tablet QD for the last 14 days of the study."
3176979|NCT00648817|Active Comparator|Group 2|"Tenofovir DF placebo tablet QD for the first 14 days of the study.~Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil) for the last 14 days of the study."
3176980|NCT00648830|Experimental|1|Clarithromycin 250 mg immediate-release oral tablet
3176981|NCT00648830|Active Comparator|2|Biaxin® (Clarithromycin) 250 mg tablet
3176982|NCT00648843|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
3176983|NCT00648843|Active Comparator|2|Ditropan XL® Tablets 5 mg
3176984|NCT00648856|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
3176985|NCT00648856|Active Comparator|2|Zoloft® Tablets 100 mg
3176986|NCT00648882|Experimental|1|LEVOTHYROXINE SODIUM TABLETS,USP 300 mcg;
3176987|NCT00648882|Active Comparator|2|SYNTHROID® 300 mcg Tablets
3176988|NCT00648921|Experimental|1|Olanzapine Tablets 5 mg
3176989|NCT00648921|Active Comparator|2|Zyprexa® Tablets 5 mg
3176990|NCT00648934|Experimental|1|Topiramate Sprinkle Capsules 25 mg
3176991|NCT00648934|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
3176992|NCT00648947|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
3176993|NCT00648947|Active Comparator|2|Plavix® Tablets 75 mg
3176994|NCT00648960|Experimental|1|
3176995|NCT00648960|Active Comparator|2|
3176996|NCT00648973|Experimental|1|Diphenhydramine 50 mg
2582618|NCT02348931|Active Comparator|Only device (Nasella)|No need for surgery; use of customized nasal brace (Nasella) for nose deformities is made to improve look (cosmetic reason).
2582766|NCT02347878|Experimental|treatment arm|this treatment arm will received aprepitant 1 hour before lumbar puncture and intrathecal treatment.
2582767|NCT02347878|No Intervention|control arm|this arm will received nothing 1 hour before lumbar puncture
2582808|NCT02347566|Experimental|Physical activity enhancing programme|Usual care + physical activity enhancing programme (PAEP) (Study group, [S]), which includes both pulmonary rehabilitation programme plus the PAEP using an activity monitor (DirectLife) with set targets of physical activity levels to stimulate and increase physical activity in daily life.
2582814|NCT02347566|Other|Control|Usual care (control, [C]) that includes only the pulmonary rehabilitation programme with the use of an activity monitor (DirectLife) in daily routine without any feedback or incentive to increase physical activity in daily life.
2582855|NCT02347241|No Intervention|Control period|Assessment of resuscitation quality and clinical outcomes prior to educational intervention
2582860|NCT02347241|Experimental|Educational intervention|Assessment of resuscitation quality and clinical outcomes after educational intervention consisting of debriefing and rolling refreshers.
2582902|NCT02346994|Experimental|Melt test blend 3.2|
2582903|NCT02346994|Active Comparator|Corn Oil|
3176997|NCT00648973|Experimental|2|Diphenhydramine 25 mg
3176998|NCT00648973|Active Comparator|3|Pseudoephedrine 120 mg
2583008|NCT02346318|Experimental|KS injection arm|Radiation and chemotherapy and compound Kushen Injection
2583010|NCT02346318|No Intervention|Control arm|Radiation and chemotherapy
2583046|NCT02345902|Experimental|Haloperidol and non-pharmacologic|"Haloperidol 1.25mg PO q. d. during nine days~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
2583048|NCT02345902|Active Comparator|Placebo and non-pharmacologic|"Placebo 1.25 mg PO q.d during nine days.~Non-pharmacologic measures:~A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)"
2583263|NCT02344589|Experimental|ACB 10|ACB in right leg with 10ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
2583270|NCT02344589|Experimental|ACB 20|ACB in right leg with 20ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
2583276|NCT02344589|Experimental|ACB 30|ACB in right leg with 30ml of lidocaine 10mg/ml. Subject and assessor blinded, randomized. given on day 1, 2 or 3
2583284|NCT02344589|Active Comparator|FNB|FNB in left leg with 20ml of lidocaine 10mg/ml on day 1. Unblinded arm, used for model control
2583286|NCT02344589|Placebo Comparator|Placebo|ACB in left leg with 30ml of isotonic saline on day 2. Unblinded arm used for model control
2583345|NCT02344186|Experimental|Liraglutide|Liraglutide will be started first with 0.6 mg/d for 1 week, then increased to 1.2 mg/d from week 2 to week 12, followed by 1.8 mg/d from week 12 to week 24.
2583346|NCT02344186|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks.
2583373|NCT02343913|Experimental|PAC checklist|Pictorial checklist which illustrates these signs and symptoms
2583412|NCT02343510||primary tubal cancer group|Paraffin blocks of cases of primary tubal cancer
2583422|NCT02343510||high grade serous ovarian cancer group|Paraffin blocks of cases of high grade serous ovarian cancer
2583427|NCT02343510||Low Grade Serous Ovarian Cancer|Paraffin blocks of cases of low grade serous ovarian cancer
2583429|NCT02343510||normal tubes group|Paraffin blocks of tubes of hysterectomies due to non-oncologic causes
2583602|NCT02342301|Experimental|Standing Desk|Will use standing desk for 3 months
2583610|NCT02342301|Active Comparator|Traditional Desk|Will use traditional desk for 3 months
3176999|NCT00648986|Experimental|1|Uncontrolled, Open-Label Pilot Study
3177000|NCT00648999|Active Comparator|1|
3177001|NCT00648999|Active Comparator|2|
3177002|NCT00649012|Experimental|1|Pioglitazone HCl Tablets 45 mg
3177003|NCT00649012|Active Comparator|2|Actos® Tablets 45 mg
3177004|NCT00649025|Experimental|1|FlutiForm 250/10ug
3177005|NCT00649025|Active Comparator|2|SKP Fluticasone 250ug
3177006|NCT00649025|Active Comparator|3|Flovent Fluticasone HFA
3177007|NCT00649038|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3177008|NCT00649038|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
3177009|NCT00649051|Experimental|1|Metolazone Tablets 2.5 mg
3177010|NCT00649051|Active Comparator|2|Zaroloxyn® Tablets 2.5 mg
3177011|NCT00649064|Experimental|Ziprasidone|
3177012|NCT00649077|Experimental|1|Meloxicam Tablets 15 mg
3177013|NCT00649077|Active Comparator|2|Mobic® Tablets 15 mg
3177014|NCT00649090|Active Comparator|Exemestane group|
3177015|NCT00649103|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
3177016|NCT00649103|Active Comparator|2|Accupril® Tablets 40 mg
3177017|NCT00649116|Experimental|1|Metoprolol Tartrate Tablets 100 mg
3177018|NCT00649116|Active Comparator|2|Lopressor® Tablets 100 mg
3177019|NCT00649129|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
3177020|NCT00649129|Active Comparator|2|Ditropan XL® Tablets 10 mg
3177021|NCT00649142|Active Comparator|A|Open sutured mesh repair
3177022|NCT00649142|Active Comparator|B|Laparoscopic mesh glue fixation
2582790|NCT02347683||Benign pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days, 4, 6, and 12 weeks
2582799|NCT02347683||Malignant pathology|We will measure serum Tg , Tg Ab levels , and TSH at 7-14 days ; 4, 6, and 12 weeks and 6 and 12 months
2582849|NCT02347397|Experimental|SS Bipolar Head + SL-TWIN Stem|Subject will be implanted with the SS Bipolar Head & SL-TWIN Stem
2582851|NCT02347397|Active Comparator|Bipolar Head + SL-PLUS Stem|Subject will be implanted with the Bipolar Head & SL-PLUS Stem
2582924|NCT02346942||Patients who have no history of bDMARD therapy use|
2582928|NCT02346942||Patients who have a prior history of bDMARD therapy use|
2582997|NCT02346604||Mild COPD|Symptomatic smokers with mild COPD
2582999|NCT02346604||Healthy Control|Non-smokers, matched to mild COPD group for age (at least 50 years) and gender
2583065|NCT02346071|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization.
2583069|NCT02346071|Experimental|Acceptance and Commitment Therapy (ACT)|Clinical psychiatric and somatic assessment. Standard psychiatric consultation (SPC) given 2 weeks after randomization. ACT-based group therapy.
2583123|NCT02345525|Active Comparator|mCIMT|2 hours intensive upper limb practice with shaping techniques supervised by an experienced physiotherapist + 2 hours ADLs at home (supervised by a caregiver) Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily.
2583126|NCT02345525|Experimental|hCIMT|"2 hours intensive upper limb practice with shaping techniques + 2 hours ADLs supervised by a caregiver.~Patients are supposed to wear a mitt on the unaffected hand for 4 hours daily."
2583183|NCT02345200|Active Comparator|Ataxia telangiectasia|26 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
2583184|NCT02345200|Active Comparator|Healthy subjects|26 age and sex matched subjects without any chronic disease or hormone displacement will be examined with bioelectrical impedance analysis (BIA), muscle force measurement, calipometry and get a blood draw
2583225|NCT02344862|Active Comparator|FYU-981 High dose|
2583228|NCT02344862|Active Comparator|FYU-981 Middle dose|
2583232|NCT02344862|Active Comparator|FYU-981 Low dose|
2583234|NCT02344862|Placebo Comparator|Placebo|
2583288|NCT02344563|Experimental|Meropem|0.5g/vial,one vial
2583289|NCT02344563|Active Comparator|Mepem|0.25g/vial ,two vials
2583401|NCT02343731|Experimental|Dog Introduction|Participants will receive a dog from the Humane Society of Southern Arizona's (HSSA) foster care program to live with them for three months.
2583437|NCT02343367|Active Comparator|Standard Care|Brief patient-centered behavioral counseling using the Healthy Lifestyle Prescription, health education materials and a community resource guide. Follow-up visits scheduled at 1, 6, and 12 months. Parent receives weekly general health education cell phone text messages for 12 months
2583438|NCT02343367|Experimental|Pediatric Obesity Management|All elements of standard care plus a family-based face to face counseling session with a health educator, telephone counseling, mailed newsletters and regularly scheduled cell phone text messages with tips and motivational messages for healthy eating and PA, as well as information on community events and resources.
2583481|NCT02343094|Experimental|PBA 7,5g/d|Treatment for 14 days
2583487|NCT02343094|Experimental|PBA 15g/d|Treatment for 14 days
2583522|NCT02342860|Experimental|WASH in Schools (WinS) programme|Schools in the intervention group will receive the UNICEF/Department of Foreign Affairs and Trade (DFAT)-supported WinS programme that includes a new water supply, 3 latrines (boys, girls, handicapped), and handwashing facilities. It will also include behavior change education.
2583524|NCT02342860|No Intervention|Control|Schools in the control group will receive no additional WinS programming.
3177023|NCT00649155|Experimental|1|Ciprofloxacin Extended-Release Tablets 500 mg
3177024|NCT00649155|Active Comparator|2|Cipro® XR Tablets 500 mg
2583671|NCT02341911|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin combination)
2583673|NCT02341911|Active Comparator|Gemcitabine,carboplatin|GC (gemcitabine and carboplatin combination)
2583706|NCT02341677|Experimental|Biopsy|Single Arm Study. Biopsy Intervention.
2583724|NCT02341404|Experimental|Liproca Depot|A parenteral controlled release depot formulation of 2-hydroxyflutamide (2-HOF) is given as a single dose injection into the prostate gland within the lobe area where the tumour tissue is localized.
2583804|NCT02341300|Experimental|Cast-Iron Pot|The treatment arm will receive a 12 inch pre seasoned cast iron pot
2583807|NCT02341300|Placebo Comparator|Aluminum Pot|12 inch nonstick aluminum fry pan
2583839|NCT02340910|Experimental|Short duration|Short Duration WBV consists of 8 45-sec bouts of 50Hz WBV followed by a 1-minute seated rest
2585338|NCT02331186||obese women who underwent bariatric surgery|obese women who underwent bariatric surgery
3177025|NCT00649168|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
3177026|NCT00649168|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
3177027|NCT00649181|Experimental|1|Metolazone Tablets 5 mg
3177028|NCT00649181|Active Comparator|2|Zaroloxyn® Tablets 5 mg
3177029|NCT00649194|Experimental|1|Rabeprazole Sodium Delayed-Release Tablets 20 mg
3177030|NCT00649194|Active Comparator|2|Aciphex® Tablets 20 mg
3177031|NCT00649207|Experimental|1|"This is an open label study; therefore, there are no numbered/labeled study arms.~This is a dose escalation study, ABT-888 dose will be escalated in conjunction with two schedules of whole brain radiation therapy (WBRT). Subjects may be treated WBRT for 3 weeks (15 days) or 2 weeks (10 days)."
3177032|NCT00649233|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
3177033|NCT00649233|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
3177034|NCT00649246||1|"controls:~healthy individuals with no family history of type 1 diabetes"
3177035|NCT00649246||2|"high-risk:~Subjects with islet autoantibodies or high-risk diabetes genes"
3177036|NCT00649246||3|"type 1 diabetes:~subjects with type 1 diabetes"
2582740|NCT02348177|Experimental|TB/HIV co-infection|Superboosting lopinavir with ritonavir in 1:1 ratio during TB/HIV co-infection and treatment of HIV with lopinavir/ritonavir 4:1
2583036|NCT02346110|Active Comparator|Bupivacaine-adrenalin + sodium chloride|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL sodium chloride solution"
2583039|NCT02346110|Experimental|Bupivacaine-adrenaline + Dexamethasone|"Single shot saphenous block:~10 mL of 5 mg/mL bupivacaine with 5 μg/mL adrenalin = 50 mg bupivacain and 50 μg adrenalin~1 mL of 4 mg/mL dexamethasone = 4 mg dexamethasone"
2583057|NCT02345759||Keto-diet group|Vegetarian very low protein regimen (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
2583060|NCT02345759||Conventional LPD group|0.6 g/kg per day, including high biological value proteins
2583114|NCT02345616|Experimental|Nitric oxyde|
3177037|NCT00649259|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
2583226|NCT02344849|Experimental|Mesenchymal stem cell|Patients will receive single intracavernous injection of Mesenchymal stem cell. Oral PDE5-inhibitor can take on demand.
2583266|NCT02344615|Active Comparator|NS-guided infraclavicular block|NS-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
2583275|NCT02344615|Experimental|US-guided infraclavicular block|US-guided infraclavicular block is performed using 35 ml of 0.5% ropivacaine.
2583362|NCT02343926|Experimental|Gemigliptin|GEMIGLIPTIN LS15-0444 administered once a day for 24 weeks as add-on therapy to metformin
2583365|NCT02343926|Active Comparator|Vildagliptin|Vildagliptin administered twice a day for 24 weeks as add-on therapy to metformin
2583525|NCT02342925|Experimental|RG1662 plus metformin|
2583526|NCT02342925|Experimental|metformin alone|
2583670|NCT02342054|Experimental|MRI-TRUS fusion guided Single Frac HDR|Patients treated with a Single Fraction Real-Time High-Dose-Rate (HDR 19Gy)
2583740|NCT02341651|Experimental|"Multicomponent combination"|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
2583741|NCT02341651|No Intervention|Usual Care|No active intervention
2583812|NCT02341222|Experimental|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
2583815|NCT02341222|Active Comparator|PR (parietene) mesh device|A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
2583928|NCT02340247|Experimental|Placebo|150mL water
2583930|NCT02340247|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid (750mg) dissolved in 150mL water
2583932|NCT02340247|Experimental|Chenodeoxycholic acid|Chenodeoxycholic acid (1250mg) dissolved in 150mL water
2583987|NCT02339935|Experimental|ABA Treatment Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
3177038|NCT00649259|Active Comparator|2|Ditropan XL® Tablets 10 mg
3177039|NCT00649272|Experimental|1|Oxybutynin Chloride Extended-Release Tablets, 15 mg
3177040|NCT00649272|Active Comparator|2|Ditropan XL® Extended-release tablets, 15 mg
3177041|NCT00649285|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
3177042|NCT00649285|Active Comparator|2|Macrobid® Capsules 100 mg
3177043|NCT00649298|Experimental|extended hours|24 or more hours per week of hemodialysis
3177044|NCT00649298|Active Comparator|standard hours|18 or less hours per week of hemodialysis
3177045|NCT00649311|Experimental|Eplerenone group|
3177046|NCT00649311|Active Comparator|Losartan group|
3177047|NCT00649324|Experimental|1|Hydrochlorothiazide Tablets 50 mg
3177048|NCT00649324|Active Comparator|2|Hydrochlorothiazide Tablets 50 mg
3177049|NCT00649337|Experimental|1|Adjunct screening with sonocine
3177050|NCT00649350|Experimental|1|Metformin Hydrochloride ER Tablets 750 mg
3177051|NCT00649350|Active Comparator|2|Glucophage XR 750 mg
3177052|NCT00649363|Experimental|1|Ondansetron Orally Disintegrating Tablets 8 mg
3177053|NCT00649363|Active Comparator|2|Zofran ODT® Tablets 8 mg
3177054|NCT00649376|Experimental|1|Fexofenadine Tablets 180 mg
3177055|NCT00649376|Active Comparator|2|Allegra® Tablets 180 mg
3177056|NCT00649402|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
3177057|NCT00649402|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
3177058|NCT00649415|Active Comparator|Arm 1|
3177059|NCT00649415|Active Comparator|Arm 2|
3177060|NCT00649441|Experimental|1|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3177061|NCT00649441|Active Comparator|2|Accuretic™ Tablets 20 mg/25 mg
3177062|NCT00649454|Experimental|1|Glipizide and Metformin HCl Tablets 5 mg/500 mg
3177063|NCT00649454|Active Comparator|2|Metaglip® Tablets 5 mg/500 mg
3177064|NCT00649467|Experimental|1|Topiramate Sprinkle Capsules 25 mg
2582770|NCT02347865||wave 1|postmenopausal women with osteoporosis treated with Prolia
2582771|NCT02347865||wave 2|postmenopausal women with osteoporosis treated with Prolia
2582811|NCT02347540||PE|"Cases: women with a history of preeclampsia. Measurements will be performed in a postpartum interval from 0.5 years until 30 years after the first complicated pregnancy.~This group will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure."
2582816|NCT02347540||Control|Controls include women with a history of uncomplicated pregnancies. The controlgroup will further be subdivided in a subgroup with Heart Failure and a group without Heart Failure.
2582841|NCT02347319|Experimental|Pennel|This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.
2582843|NCT02347319|Active Comparator|Legalon|This group will treated with Silymarin 140mg for 12 weeks.
2582845|NCT02347319|Placebo Comparator|Placebo|This group will treated with Placebo for 12 weeks.
2582921|NCT02347007|Experimental|Almond|
2582925|NCT02347007|Active Comparator|Cereal Bar|
2582970|NCT02346500|Experimental|Transrectal ultrasound|TRUS and TRUS-Robot will be used during PVP
2583025|NCT02346253|Experimental|Treatment (HDR brachytherapy, ADT and LHRH agonist therapy)|Patients undergo high-dose-rate brachytherapy over 2 fractions. Patients also receive ADT comprising bicalutamide PO QD. Patients may also receive LHRH agonist therapy comprising leuprolide acetate IM or SC, goserelin acetate SC, triptorelin pamoate IM, or degarelix SC for 4-6 months (intermediate-risk patients receiving ADT) or 6-36 months (high-risk patients) at the discretion of the treating physician.
2583100|NCT02345707|Experimental|Part A|Subjects will receive reference cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) and Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) in one of six sequences ABC, ACB, BCA, BAC, CAB, CBA in three treatment periods under fasting condition
2583101|NCT02345707|Experimental|Part B|Subjects will receive reference Cabotegravir 30 mg current formulation (Treatment A), Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) and Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) in one of six sequences ADE, AED, DAE, DEA, EAD, EDA in three treatment periods under fasting condition
2583136|NCT02345395|Experimental|Transpalpebral Approach|Aneurysm Clipping - Patients will be submitted to a Transpalpebral Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
2583148|NCT02345395|Experimental|NanoPterional Approach|Aneurysm Clipping - Patients will be submitted to a Modified MiniPterional Approach (Nanopterional) to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital on the next day.
2583156|NCT02345395|Sham Comparator|Classical Pterional Craniotomy|Aneurysm Clipping - Patients will be submitted to a Classical Pterional Approach to Unruptured Anterior Circulation Aneurysm and they will be discharged from the hospital 4-5 days after the procedure.
2583188|NCT02345044|Experimental|CS-3150 1.25 mg|One CS-3150 1.25 mg tablet and one placebo tablet to match CS-3150 tablet administered orally, once daily after breakfast.
2583189|NCT02345044|Experimental|CS-3150 2.5 mg|Two CS-3150 1.25 mg tablets administered orally, once daily after breakfast.
2583190|NCT02345044|Experimental|CS-3150 5 mg|Two CS-3150 2.5 mg tablets administered orally, once daily after breakfast.
2583192|NCT02345044|Placebo Comparator|Placebo|Two placebo tablets to match CS-3150 tablet, administered orally, once daily after breakfast.
2583194|NCT02345044|Active Comparator|Eplerenone, 50-100 mg (Open Label)|One or two 50mg eplerenone tablet(s) administered orally, once daily after breakfast.
2583258|NCT02344797|Active Comparator|Intervention|Remote ischemic preconditioning, 4 cycles of 5 minutes ischemia and 5 minutes reperfusion of the forearm before surgery.
2583260|NCT02344797|No Intervention|Control|
2583324|NCT02344368|Experimental|0.2 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
2583327|NCT02344368|Experimental|0.5 ml sucrose|on 2 occasions within 1 week 0.2 ml sucrose 25% or 0.5 ml sucrose 25% will be given in randomized order to the same infant during blood sampling
2583356|NCT02343978|Experimental|KWA-0711 High dose|
2583358|NCT02343978|Experimental|KWA-0711 Low dose|
2583404|NCT02343692|Experimental|Radiofrequency abalation|"Intervention: Endoscopic Ultrasound (EUS) guided radiofrequency ablation (RFA) of cystic tumours of the pancreas~Device: An RFA generator (ERBE VIO 300D, Dolby medical products, Scotland)~Procedure: Delivery of sequential doses of electrical energy at 10W for a total of up to 4 minutes 30 seconds (3 x 90 second applications) to ablate the cystic lesion.~Ablation of cystic tumours of the pancreas"
2583496|NCT02343172|Experimental|HDM201+LEE011|
2583558|NCT02342691|Experimental|BLXA4-ME oral rinse|The topical oral rinse dosage form of BLXA4-ME (also known as ClinRinse-1) will consist of drug substance prepared at a concentration of 1.0 μM in an aqueous vehicle solution
2583559|NCT02342691|Placebo Comparator|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
2583561|NCT02342691|No Intervention|No Rinse Control|The no-rinse control group will use no oral rinse, in order to assess the effect of the rinsing action independent of the active ingredients
3212041|NCT01011270||Balance|the treatment with RDM reflected in significant improvement in back pain and postural balance of industrial operators.
2583703|NCT02341950|Experimental|SCI Hard|This arm plays the SCI HARD game
2583705|NCT02341950|No Intervention|Control|Plays an alternate, publicly available game
2583770|NCT02341391|Experimental|TissueGene-C(Low dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^6 cells
2583778|NCT02341391|Experimental|TissueGene-C(Medium dose)|Single intra-articular injection to the damaged knee joint at doses of 1.0 x 10^7 cells
2583780|NCT02341391|Experimental|TissueGene-C(High dose)|Single intra-articular injection to the damaged knee joint at doses of 3.0 x 10^7 cells
2583820|NCT02341079|Active Comparator|Femoral Nerve Blockade|Femoral nerve block delivered via indwelling femoral nerve catheter
2583824|NCT02341079|Experimental|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of bupivacaine liposome
3212042|NCT01011296|Experimental|Single IV Dose 1|
2583895|NCT02340364|Experimental|Education + PN Arm|208 patients randomized to self-care education+ Patient navigator-delivered self-care plan.
2582783|NCT02347748|No Intervention|Group D|Patients will not be read any script
3177065|NCT00649467|Active Comparator|2|Topamax® Sprinkle Capsules 25 mg
2582888|NCT02347059|Experimental|L-dopa|L-dopa will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
2582890|NCT02347059|Active Comparator|Dopamine agonist|Dopamine agonists (either pramipexole or ropirinole) will be administered as monotherapy. The dosage and the frequency of intakes are not pre-specified and will be individualized.
2582956|NCT02346773|Active Comparator|ω-3 LC-PUFA group|The intervention product was a full fat (80%) margarine. The active intervention product contained 590 mg docosahexaenoic acid (DHA) and 650 mg eicosapentaenoic acid (EPA) per 10-g daily serving.
2582959|NCT02346773|Placebo Comparator|Placebo group|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
2583006|NCT02346396|Experimental|Patients with neuropathic chronic pain|
2583077|NCT02345980|Active Comparator|Sildenafil|Patient in this arm will receive sildenafil citrate 50 mg tablet once daily after ureteral stent fixation.
2583084|NCT02345980|Placebo Comparator|Placebo|Patient in this arm will receive placebo daily after ureteral stent fixation.
2583112|NCT02345473||Cystectomy patients|Arm of patients undergoing radical cystectomy for bladder cancer providing peripheral blood samples for detection of circulating cancer cells
2583113|NCT02345473||Healthy volunteers|Arm of healthy subjects not undergoing radical cystectomy providing peripheral blood samples for detection of circulating cancer cells
2583139|NCT02345343||Drug: Apixaban|Patients with VTE who are being given apixaban for the treatment and/or prevention of recurrence of DVT and PE at the sentinel site
2583203|NCT02345096|Active Comparator|Saccharomyces cerevisiae CNCM I-3856|In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.
2583206|NCT02345096|Placebo Comparator|placebo|In this arm, subjects will be asked to consume one capsule of placebo per day.
2583387|NCT02343809|Experimental|Intervention Group|Actual Diacutaneous Fibrolysis and Protocolized Physiotherapy
2583390|NCT02343809|Sham Comparator|Placebo Group|Sham Diacutaneous Fibrolysis and Protocolized Physiotherapy
2583391|NCT02343809|Other|Control Group|Protocolized Physiotherapy
2583435|NCT02343419|Experimental|Bronchial challenge test|Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
2583497|NCT02343146|Experimental|Type One Training (TOT)|The intervention group will receive the proposed intervention composed of peer parent consultants, telephone and in-person sessions with a trained interventionist, and SMS text messaging aimed at improving child glycemic control through improved nutrition and physical activity.
2583505|NCT02343146|No Intervention|Comparison|The comparison group will receive usual care with the diabetes team.
2583536|NCT02342834|No Intervention|Control|"During the control study, each subject ingest 500 ml of water 30 minutes before a standard 75 g Oral Glucose Tolerance Test"
2583544|NCT02342834|Experimental|Small mixed protein and lipid meal|"During the preload study, each subject ingest a small mixed meal 30 minutes before a standard 75 g Oral Glucose Tolerance Test. The meal is composed by 50 g of parmesan cheese, one small size boiled egg and 300 ml of water (250 kcal, 23 g protein, 17 g fat and 2 g of carbohydrate)."
2583654|NCT02342106||Poor responders|In order to define the poor response in IVF, at least two of the following three features must be present: (i) advanced maternal age or any other risk factor for poor ovarian response; (ii) a previous poor ovarian response; and (iii) an abnormal ovarian reserve test . Two episodes of poor ovarian response after maximal stimulation are sufficient to define a patient as poor responder in the absence of advanced maternal age or abnormal ovarian reserve test. By definition, the term poor ovarian response refers to the ovarian response, and therefore, one stimulated cycle is considered essential for the diagnosis .
2583657|NCT02342106||Good responders|"Total number of antral follicles : 22-35 Normal (good) antral count, should have an excellent response to ovarian stimulation.Likely to respond well to low doses of FSH drugs.~Very low risk for IVF cycle cancellation. Some risk for ovarian overstimulation if a Lupron trigger is not used for final egg maturation injection.~Excellent pregnancy success rates."
2583678|NCT02341872|No Intervention|Control|The investigators won't do any application , the oral hygiene konwledge will be given only.
2583680|NCT02341872|Active Comparator|Fluoride + Calcium varnish|The investigators will do fluoride+ calcium varnish( Clinpro White Varnish) application on white spot lesions.
2583682|NCT02341872|Experimental|Polipeptide solution|The investigators will do polipeptide ( Curodont Repair) solution application on white spot lesions.
2583686|NCT02341872|Experimental|Fluoride + calcium + polipeptide|The investigators will do polipeptide ( Curodont Repair) solution and fluoride + calcium varnish (Clinpro White Varnish) application on white spot lesions.
2583729|NCT02341573|Experimental|chinese medicine group|Children of chinese medicine group will be treated with experienced chinese herbal formula based on different stages and different symptoms.Patients at the acute stage of asthma will be given Shegan mixture ,at the remission stage, will be treated with Huangqi Bushen mixture-based formulation with modification according to their symptoms,10-30 mL , 2 times a day, for 3 months.
2583734|NCT02341573|Active Comparator|western medicine group|Children of western medicine group will be treated with leukotriene receptor antagonist and a bronchial relaxant.Children at the acute stage of asthma will be treated with etinoline,twice a day for 7 days.At the remission stage, they will be given leukotriene receptor antagonist Singulair, once daily for 3 months.
2585432|NCT02330419|Placebo Comparator|Placebo|Placebo 50mg, as needed
3177066|NCT00649480|Experimental|1|BALSALAZIDE DISODIUM CAPSULES, 750 MG
3177067|NCT00649480|Active Comparator|2|COLAZAL® Capsules 750 mg
3177068|NCT00649493|Experimental|1|Rabeprazole Sodium Tablets 20 mg
3177069|NCT00649493|Active Comparator|2|Aciphex® Tablets 20 mg
3177070|NCT00649506|Experimental|1|Nitrofurantoin Macrocrystals 100 mg Capsules
3177071|NCT00649506|Active Comparator|2|Macrodantin® 100 mg Capsules
3177072|NCT00649519|Experimental|1|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg
2582792|NCT02347670|Active Comparator|Group 3- Office-Based|"Group 3- follow-up eye care at the Wills Eye Hospital. There will be no charge or co-pay for these visits. Those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire. These participants will receive a phone number to call and schedule their appointment and will receive a reminder phone call similar to the standard appointment-reminding procedure commonly used at the Wills Eye Hospital. Group 3 represents a realistic choice currently available for patients and thus will be used to compare with usual care and will have 2-3 visits over the one-year period depending on diagnosis.~Intervention: Office-Based Usual Care"
2582805|NCT02347670|Active Comparator|Group 1R- Community Site|"Participants randomized to Group 1-Randomized will attend follow-up visits at one of the four main community sites, these participants were randomized from the 40 community sites to the closest community location. A glaucoma specialist will perform the comprehensive eye examination. Ophthalmic technicians will conduct the testing. There will be no charge or co-pay for these visits. Group 1 participants will test the efficacy of the patient navigator to improve follow-up adherence. During the first and final follow-up visit, those enrolled will undergo the National Eye Institute-Visual Function Questionnaire-25 and the Geriatric Depression Scale-15 and Research Participation Questionnaire.~Intervention: Efficacy-patient navigator to improve follow-up adherence"
2582854|NCT02347267|Experimental|Caloric and non-caloric SSBS reduction|Sweetened beverages (SSBS) caloric and non-caloric were not permitted and allowed only plain water
2582858|NCT02347267|Active Comparator|Caloric SSBS reduction|Only plain water and non-caloric sweetened beverages (SSBS) were allowed
2582864|NCT02347267|No Intervention|All beverages|Beverages were not restricted
3177073|NCT00649519|Active Comparator|2|Lotrel® Capsules 10 mg/20 mg
3177074|NCT00649532|Experimental|1|Ondansetron Tablets 24 mg
3177075|NCT00649532|Active Comparator|2|Zofran® Tablets 24 mg
2583055|NCT02345941|Experimental|Invervention|The intervention group will get tailored information on the Parent Action Report and the Parent Portal about child safety seats and booster seats.
2583063|NCT02345941|Active Comparator|Control|The control group will get tailored information in the Parent Action Report and the Parent Portal about smoke alarms.
2583127|NCT02345538||Women with Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women with chronic pelvic pain and determine if resting tone correlates with severity of pain.
2583130|NCT02345538||Women without Chronic Pelvic Pain|Use of perineometer to measure pelvic resting tone and contraction in women without chronic pelvic pain
2583178|NCT02345239|Experimental|Pantoprazole|Pantoprazole
2583318|NCT02344394|Other|Hybrid Ablation-cryoballoon alone|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation consisting of pulmonary vein isolation with no further catheter ablation. This will be achieved using the nContact and Medtronic cryoballoon
2583319|NCT02344394|Other|Hybrid ablation-cryoballoon plus RF|This group receives the hybrid surgical ablation (epicardial-endocardial ablation) with epicardial ablation and endocardial ablation. Endocardial portion consists of pulmonary vein isolation using the cryoballoon with further catheter ablation, which may consist of ablation of complex fractionated electrograms and linear lesions. This will be achieved using the nContact and Medtronic Cryoballoon plus Thermocool Catheter.
2583366|NCT02344043||Critical illness|This prospective cohort of critically ill patients will have brain tissue oxygen levels recorded for 24 hours after admission with near infrared spectroscopy.
2583405|NCT02343666|Experimental|Treatment (gene modified HPSC)|See Detailed Description.
2583466|NCT02343016||Near-InfraRed Spectroscopy (NIRS)|The NIRS Group will be monitored with the interventional system (NIRS) and with the standard one (ecodoppler)
2583540|NCT02342912|Experimental|Social Media Targeted Treatment|Participants randomly assigned to this treatment arm will receive weight loss materials via text messages, Facebook postings, on-line videos, and weekly reports. The topics relate to relate to behavioral and lifestyle changes associated with weight-loss (e.g., nutrition, exercise, social support, and self-monitoring). Calorie and physical activity targets also are set. Participants will receive a suggestion to track diet, physical activity, and weight.
2583547|NCT02342912|Experimental|Social Media Tailored Treatment|Participants randomly assigned to this treatment arm receive all of the same weight loss materials (as well as weight, calorie, and physical activity targets) as the Targeted group above. Weekly reports will be more personalized to help participants track diet, physical activity, and weight. Additionally, participants will be asked to report on their weight, exercise and calorie goals, and receive feedback.
2583549|NCT02342912|Active Comparator|Social Media Contact Control|Participants randomly assigned to this treatment arm receive health information via text messages, Facebook postings, on-line videos, and weekly reports. Topics relate to having a healthy body weight through a healthy mind, body, and energy. Some topics include stress management, importance of sleep, and importance of accepting one's body. Participants will receive a suggestion to track stress, body image, and energy levels.
2583607|NCT02342483|Active Comparator|1g|METHYLSULFONYLMETHANE
2583615|NCT02342483|Active Comparator|3g|METHYLSULFONYLMETHANE
2583621|NCT02342483|Active Comparator|6g|METHYLSULFONYLMETHANE
2583660|NCT02342132|Experimental|Respiratoy Therapy Devices|Non-Invasive Bipap Ventilator, Mechanical Insufflator-Exsufflator, and High Frequency Percussive Oscillator are the three respiratory therapy devices that all participants will be using in a random order, in three consecutive days, one device per day.
2583732|NCT02341469|No Intervention|Standard-of-care|
3177076|NCT00649558|Experimental|1|Pioglitazone HCl Tablets 45 mg
3177077|NCT00649558|Active Comparator|2|Actos® Tablets 45 mg
3177078|NCT00649571|Experimental|1|Doxycycline Monohydrate Tablets 100 mg
3177079|NCT00649571|Active Comparator|2|Adoxa Tablets 100 mg
3177080|NCT00649584|Experimental|1|SGN-35 alone or in combination with gemcitabine
3177081|NCT00649597|Experimental|1|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
3177082|NCT00649597|Active Comparator|2|Lotensin HCT® Tablets 20 mg/25 mg
3177083|NCT00649610|Active Comparator|Arm 1|
3177084|NCT00649610|Active Comparator|Arm 2|
3177085|NCT00649623|Experimental|1|Olmesartan Medoxomil Tablets 40 mg
3177086|NCT00649623|Active Comparator|2|Benicar® Tablets 40 mg
2582869|NCT02347150||ICU LOS>24h|30-110 patients discharged from the ICU
2583021|NCT02346409|Experimental|LFP-MEG recording with tACS of the cerebellum|To explore how cerebellar stimulation (using tACS) will alter oscillations and coupling along the CTC pathway, relating these changes in brain activity to clinical improvement.
2583026|NCT02346409|Active Comparator|tACS of the cerebellum vs VIM-DBS|To evaluate the differential effects of non invasive high-frequency stimulation tACS of the cerebellum, as compared to high-frequency stimulation of the thalamus (using DBS of the VIM).
2583208|NCT02345187|Active Comparator|Treatment Arm|Entire content of a sachet of the beverage powder fortified with multiple micronutrients and bacopa monnieri extract will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
2583210|NCT02345187|Placebo Comparator|Control arm|Entire content of a sachet of the non-fortified isocaloric beverage powder will be emptied in a graduated drinking tumbler and reconstituted with 180 mL potable lukewarm water. Water will be added to the tumbler gradually with stirring to avoid lump formation. The reconstituted beverage will be administered to the participants orally twice daily for 17 weeks
2583267|NCT02344680||HIV-HBV co-infected|HIV-HBV co-infected patients receiving anti-retroviral therapy
3177087|NCT00649636|Experimental|1|Fluoxetine Capsules 40 mg
3177088|NCT00649636|Active Comparator|2|Prozac Pulvules 40 mg
2583495|NCT02342977|Placebo Comparator|Placebo|Patient will randomly receive a placebo
2583506|NCT02342977|Experimental|Experimental|Patients will randomly receive experimental drug (lacosamide).
2583552|NCT02342730|Experimental|Weight Loss Referral|Patients are referred to a weight loss specialist for assistance with weight loss and medical chart reviews are performed at baseline and every 3 months for 24 months. Patients complete Quality-of-Life Assessment (EORTC- QLQ-C30 and EORTC-QLQ-EN24) at baseline, 12, and 24 months. Patients are also contacted at 90 days to determine whether they have initiated any weight loss interventions.
2583603|NCT02342392|Active Comparator|treatment group|intralesional ranibizumab injected
2583613|NCT02342392|No Intervention|control group|no intralesional ranibizumab injected.
2583661|NCT02342145|Active Comparator|group A|The patients were used cycloaporine A:2mg/kg combined with methotrexate 15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d and basiliximab: 10mg each time, 0d and +4 d for prevention of graft-versus-host-disease.
2583664|NCT02342145|Experimental|group B|The patients were used cyclosporine A 2mg/kg,methotrexate,15mg/m2 +1d，10mg/m2 +3,+6,+11d,mycophenolate mofetil: 0.25g/d, -1d to 90d for prevention of graft-versus-host-disease.
2583726|NCT02341690|Active Comparator|Control|Standard rehabilitation with exercise
2583728|NCT02341690|Experimental|Intervention (Interval Walking Training)|"Interval Walking Training with the InterWalk app, 3 times per week, 60 min. per sessions for 52 weeks. The intervention period is divided into~a period that follows standard care in the municipality (from 8-14 weeks according to the municipality.~a period (from week 8-14 to week 52) the patients will do Interval Walking on their own.~After the intervention at the promotion centre (8-14 weeks), the intervention group will be divided into to groups - a Interval Walking group (IWT) and a Interval Walking group with support (IWTsupport).~IWTsupport: Patients in this group (after intervention at the promotion centre) will in addition to the IWT receive motivational support from week 8-14 to week 52 by the health professionals at the promotion centre."
2583805|NCT02341274|Active Comparator|Fresh Brand Name Tacrolimus (Prograf®)|Oral administration of 5 mg capsule of fresh brand name tacrolimus (Prograf®) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
2583808|NCT02341274|Active Comparator|Fresh Generic Tacrolimus|Oral administration of 5 mg capsule of fresh generic tacrolimus to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
2583810|NCT02341261|Experimental|Standard Care Counseling|Participants randomized to the control group will receive diet and exercise counseling at baseline and 9 months. Participants will wear an ActivePAL for 7 days at baseline, 9 months, and 18 months without stimulation.
3177089|NCT00649649|Experimental|1|Quinapril Hydrochloride Tablets 40 mg
3177090|NCT00649649|Active Comparator|2|Accupril® Tablets 40 mg
3177091|NCT00649662|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
3177092|NCT00649662|Active Comparator|2|Cipro® XR Tablets 1000 mg
3177093|NCT00649675|Experimental|1|Meloxicam Tablets 15 mg
3177094|NCT00649675|Active Comparator|2|Mobic® Tablets 15 mg
3177095|NCT00649688|Experimental|1|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
3177096|NCT00649688|Active Comparator|2|Lopressor HCT® Tablets 100/50 mg
3177097|NCT00649701|No Intervention|1|
3177098|NCT00649701|Experimental|2|Text-based webpage
3177099|NCT00649701|Experimental|3|Talking about HIV video
3177100|NCT00649701|Experimental|4|The Morning After video
3177101|NCT00649701|Experimental|5|Both videos
3177102|NCT00649714|Experimental|1|Zonisamide Capsules 100 mg
3177103|NCT00649714|Active Comparator|2|Zonegran® Capsules 100 mg
3177104|NCT00649727|Experimental|1|Oxybutynin Chloride ER Tablets 10 mg
3177105|NCT00649727|Active Comparator|2|Ditropan XL® Tablets 10 mg
3177106|NCT00649740|Experimental|1|Topiramate Sprinkle Capsules 25 mg
3177107|NCT00649740|Active Comparator|2|Topamax® Sprinkle Capsule 25 mg
3177108|NCT00649753|No Intervention|A|
3177109|NCT00649753|Experimental|B|
3177110|NCT00649753|Experimental|C|
3177111|NCT00649753|Experimental|D|
3177112|NCT00649766|Active Comparator|1|tailored print messages to encourage eye examination behavior
3177113|NCT00649766|Active Comparator|2|targeted print messages to encourage eye examination behavior
2582951|NCT02346955|Experimental|Cohort F Combination Expansion|Participants with advanced or recurrent non-small cell lung adenocarcinoma will be enrolled and treated at the recommended phase 2 dose of CM-24+ 200 mg of Pembrolizumab for up to 17 cycles and may continue to receive 200 mg of Pembrolizumab as monotherapy for up to an additional 18 cycles (up to 35 total cycles).
2583051|NCT02345915|Other|Young adult acute leukemia-survivor|
2583140|NCT02345629|Experimental|Cordotomy Group|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours. Quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call. Participants undergo quantitative sensory testing on day prior to procedure, and on postoperative days number 1 and 7. Sensory testing to include sharpness and heat detection.
2583151|NCT02345629|Active Comparator|Comprehensive Medical Management Group|Participants receive best supportive care for 1 week. Depending on pain level after the first week, they may have a cordotomy at that time. Pain and symptom questionnaire completed at baseline, over the phone during the first week of study, and at each follow up visit/phone call.
2583252|NCT02344979||Group rHuTPO|Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.
2583254|NCT02344979||Group rHuIL-11|Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.
2583297|NCT02344459|Experimental|80mL double balloon catheter (Cook catheter®)|
2583298|NCT02344459|Active Comparator|30mL single Foley balloon catheter|
2583492|NCT02343224|Experimental|Pegylated interferon alpha-2b|Subjects will receive PEG-Intron based on their weight (1 mcg/kg/dose) once a week
2583534|NCT02342808|Experimental|Structured center-based lifestyle intervention|The Structured center-based Lifestyle Intervention (C-LIFE) will include individualized plans for the DASH diet, weight management, and aerobic exercise.
2583543|NCT02342808|Experimental|Standard education and physician advice|The Medical Management with Standardized Education and Physician Advice (SEPA) will consist of encouragement to achieve an ideal body weight and engage in exercise as part of routine counseling in primary care, but no special program will be delivered to enhance the participants' ability to comply with these recommendations.
2583574|NCT02342522|Active Comparator|Remote ischemic conditioning|AutoRIC device will be placed on the upper arm and an active RIC protocol will be delivered (4x5 min cycles of inflation to 200mmHg and deflation) prior to PPCI.
2583575|NCT02342522|Sham Comparator|Sham control|Sham AutoRIC device will be placed on the upper arm and a sham RIC protocol will be delivered prior to PPCI.
2583690|NCT02341963|Experimental|Oral Ketamine|Subjects will receive Oral Ketamine (1.0 mg/kg) ) presurgery and 3 days postsurgery (including surgery day).
2583725|NCT02341560|Active Comparator|single dose or multiple dose|QPI-1007 Injection - 1.5 mg
2583727|NCT02341560|Active Comparator|single or multiple dose|QPI-1007 Injection - 3.0 mg
2583730|NCT02341560|Sham Comparator|Sham|Sham injection procedure
2583830|NCT02340702||Patient with COPD and those without COPD|The participants of acute decompensated heart failure national registry would be stratified in to two group: those with COPD and those without COPD, to determine prognostic implication of COPD in participants with acute decompensated heart failure
2583923|NCT02340585|Experimental|Next Generation Neuroform Stent System|The Next Generation Stent System is a self-expanding, open cell, nitinol stent designed to provide support of the coil mass within the aneurysm and minimize stent deflection.
2584000|NCT02339753|Experimental|Carboplatin-treatment arm|"Arm description : Carboplatin intravenous administration once daily for 3 to 4 days~Topotecan + Thiotepa + Carboplatin : carboplatin 500mg/m2/day, for 3 days~MEC for 2nd PBSCT : carboplatin 350 mg/m2/day, for 4 days~MEC for other solid tumor : carboplatin 400 mg/m2/day, for 4 days~MEC + MIBG Tx for 2nd PBSCT (neuroblastoma) : carboplatin 300 mg/m2/day, for 4 days"
2584075|NCT02339493|Experimental|Alert Group|If the patient is randomized to the alert group, their ordering provider will receive a computer electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy.
2584077|NCT02339493|No Intervention|Control Group|If the patient is randomized to the control group, the computer program will not issue an on-screen electronic alert.
2584107|NCT02338947|Active Comparator|Off-pump coronary-artery bypass grafting - OPCAB|"Pre-frail and frail patients will be randomly assigned to OPCAB after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
2584110|NCT02338947|Active Comparator|On-pump coronary-artery bypass grafting - CABG|"Pre-frail and frail patients will be randomly assigned to CABG after the evaluation of the target vessels by an internet-based, password protected database program. The surgery will be performed as described in the intervention section and the patients will be followed up for two years."
2584164|NCT02338557|Experimental|GROUP A|Subjects in Group A received MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects.
2584168|NCT02338557|Active Comparator|GROUP B|Group B received Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
3212043|NCT01011296|Experimental|Single IV Dose 2|
3212044|NCT01011296|Experimental|Single IV Dose 3|
2585437|NCT02330419|Active Comparator|Naltrexone|Naltrexone 50mg, as needed
3212045|NCT01011322|Experimental|LT-02 Dose 1|0.2g IMP per dose
3212046|NCT01011322|Experimental|LT-02 Dose 2|0.4g IMP per dose
3212047|NCT01011322|Experimental|LT-02 Dose 3|0.8g IMP per dose
2582961|NCT02346682|Active Comparator|LDQS group|"Liver Depression and Qi Stagnation (LDQS)group,Liver Depression and Qi Stagnation Syndrome should include at least the following 5 symptoms and signs: emotional depression or sadness, pessimism, short breath, sigh, dysphoria，thin coating，stringy pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week venlafaxine administration."
2582963|NCT02346682|Active Comparator|DBHS group|"Deficiency of Both Heart and Spleen (DBHS) group,Deficiency of Both Heart and Spleen Syndrome should include at least following 6 symptoms and signs: emotional depression, thinking torpidity, tiredness, forgetfulness, insomnia, loose stool, sweating, pale tongue body, thin tongue coating, and thin and deep pulse Drugs use generic name :Venlafaxine; Dosage form:capsule Dosage, frequency and duration:Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks.~The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline and after 6-week ."
2582965|NCT02346682|No Intervention|the normal controls group|The normal controls group including the healthy volunteer None drug The biomarkers of neurobiochemistry, metabonomics and neuroimaging would be tested at the baseline .
2583011|NCT02346331|Experimental|WHO intervention|This arm will be treated with the 2011 WHO sepsis recommendations for the first 6 hours of their hospitalization. The WHO recommendations involve fluid boluses guided by vital signs and physical exam, frequent patient monitoring, rapid and early administration of empiric antibiotics, oxygen delivery, correction of hypoglycemia, and correction of severe anemia.
2583016|NCT02346331|No Intervention|Standard care|This arm will be managed per standard care by the hospital clinicians.
3212048|NCT01011322|Placebo Comparator|Sugar pill|placebo matching to 0g of IMP,
3212049|NCT01011348|Other|Placebo vs Q10 100mg vs Q10 300mg|
2583141|NCT02345291|Experimental|NRD135S.E1 A|A = 10 mg NRD135S.E1 once daily PO for 21 days
2583150|NCT02345291|Experimental|NRD135S.E1 B|B = 40 mg NRD135S.E1 once daily PO for 21 days
2583158|NCT02345291|Experimental|NRD135S.E1 C|C = 150 mg NRD135S.E1 once daily PO for 21 days
2583167|NCT02345291|Placebo Comparator|Placebo to match NRD135S.E1 D|D = Placebo once daily PO for 21 days
2583214|NCT02344914|Experimental|receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
2583217|NCT02344914|No Intervention|do not receive Laboraide|After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the control group.
2583265|NCT02344667|Experimental|Cyberknife|Cyberknife based SBRT 36.25 Gy in 5 fractions
2583278|NCT02344667|Experimental|Volume Modulated Arc Therapy|Volume Modulated Arc Therapy based SBRT 36.25 Gy in 5 fractions
3212050|NCT01011348|Other|Q10 100mg vs Placebo vs Q10 300mg|
3212051|NCT01011348|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
2583385|NCT02343796|Experimental|Fibre-reinforced composite|Fibreglass reinforced composite restoration-everStick as a medical device intervention will be applied on each subject by using either direct or indirect method. everStick (GC, Belgium) will be used as a fibre reinforcement material.
2583443|NCT02343328|Active Comparator|Fecal Microbiota Transplant Capsules|Fecal microbiota transplant capsules
2583444|NCT02343328|Placebo Comparator|Placebo Capsules|Placebo capsules made from a mixture of natural cocoa powder and gelatin
3212052|NCT01011348|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
3212053|NCT01011426|Active Comparator|Bisacodyl|
2583562|NCT02342613|Experimental|MILs treatment|Patients treated with the activated PTCy-MILs
2583609|NCT02342366|Placebo Comparator|Placebo|Placebo
2583620|NCT02342366|Experimental|GHB|GHB, Gamma-Hydroxybutyrate, two doses (20 and 35 mg/kg p.o.)
2583669|NCT02342080|Experimental|Interventional group|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period. For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
2583702|NCT02341807|Experimental|Dose Group 1|Single, unilateral administration of a single low dose range of AAV2-hCHM.
2583704|NCT02341807|Experimental|Dose Group 2|Single, unilateral administration of a single high dose range of AAV2-hCHM.
2583768|NCT02341378|Experimental|TissueGene-C (Low dose)|Single intra-articular injection to the damaged knee joint at a dose of 6.0 x 10^6 cells
2583771|NCT02341378|Experimental|TissueGene-C (High dose)|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
2583817|NCT02341105|Active Comparator|Medical therapy|Amiodarone treatment. Amiodarone will be given at a loading dose of 400 mg per day for two week and then lowered to 200 mg daily for 6 months at which point the dose will be lowered to 1000 mg per week. The dose of amiodarone will then be lowered every six, as long as the patient has a satisfactory response. The minimum dose will be 700 mg per week.
2583823|NCT02341105|Active Comparator|Catheter ablation|A standard pulmonary vein isolation procedure will be done. Additional ablation will be permitted (roof and mitral lines/ CFAE )
2583833|NCT02340793|Experimental|Counterweight Plus Dietary Intervention|Weight management programme including total diet replacement with soups and shakes; approximately 800 calories/day
2583959|NCT02340065|Active Comparator|standard colonoscopy|total polyp/adenoma detection with standard colonoscopy, polyp/adenoma detection in the right colon with standard colonoscopy
3212054|NCT01011426|Placebo Comparator|empty opague capsule|
3212055|NCT01011452|Active Comparator|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
3212056|NCT01011452|Placebo Comparator|Placebo|
2583012|NCT02346357|Active Comparator|Obturator nerve block|Ultrasound-guided single-injection obturator nerve block with 20 mL ropivacaine 0.5%
2583019|NCT02346357|Placebo Comparator|Sham block|Placebo arm. Ultrasound-guided injection of 3-5 mL normal saline in the subcutaneous tissue in the same location as would for an obturator nerve block.
2583066|NCT02345863|Experimental|Bendamustine + GA101 + Ibrutinib|"Bendamustine 70mg/m² i´v~GA101: 1000 mg iv~Ibrutinib: 420 mg po daily"
2583125|NCT02345499|Experimental|Laparoscopic radical cystectomy|Surgery: Laparoscopic radical cystectomy with open urinary diversion
2583129|NCT02345499|Active Comparator|Open radical cystectomy|Surgery: Open radical cystectomy with open urinary diversion
2583202|NCT02345174|Experimental|Imaging Phase + Continuation Phase|In Part 1 of the study, participants will receive a dose of 89Zr-GSK2849330 (Dose 1), with an activity of no more than 37 MegaBequerel (MBq) and a variable total dose of GSK2849330. PET scans will be acquired within 7 days. Two weeks after Dose 1 participants will receive second dose of 89Zr-GSK2849330 (Dose 2) and a variable total dose of GSK2849330. Participants will continue to receive unlabelled GSK2849330 (in Part 2) either at established dose level or as decided by medical monitor.
2583268|NCT02344719|Active Comparator|6 capsules Taurin per day|After baseline HVPG (Hepatic Venous Pressure Measurement)patients take 6x1g capsules of GMP produced Taurin per day, on day 28, after intake of the 6x1g Taurin capsules, HVPG measurement will be repeated.
2583277|NCT02344719|Placebo Comparator|6 capsuless placebo per day|After baseline HVPG measurement patients take 6x1g capsules of placebo per day, on day 28, after intake of the 6x1g placebo capsules, HVPG measurement will be repeated.
2583374|NCT02343874||Alcohol consumption|"Patients over 17 years old with alcohol consumption registered in the electronic medical record (31st December 2012).~No intervention is going to be administered but exposure to alcohol will be analysed"
2583399|NCT02343588|Experimental|The Health Lifestyles Interventions|"Creating a supportive school, family and community environment;~Health lifestyles educational strategies;~Instruct and promote school physical education;~The monitoring and instruction of obesity related behaviors (focus group)"
2583400|NCT02343588|No Intervention|Receive no intervention|Usual practice
2583479|NCT02342964|Other|MUCO-FIBRO|Measures of hepatic elasticity
2583709|NCT02341729|Other|starting with ticagrelor|"Patients, after CPR because of an ACS, will receive 2 crushed tablets of ticagrelor (180mg) through a gastric tube. After this dose twice a day 90mg is given for the duration of 1 year. The 1st blood sample is taken before administration. In total 10 blood samples are taken for determination of platelet aggregation and plasma concentrations.~When patients receive a semi-urgent CABG, ticagrelor has been interrupted for 3 days. Postoperative the patients get crushed tablets of ticagrelor, the 1st dose will be 90mg, and every 12h 90mg is given, for the duration of 1 year. The 1st blood sample is taken before the 1st dose. In total 9 blood samples are taken for determination of platelet aggregation and plasma concentrations."
3177114|NCT00649779|Experimental|1|albuterol sulfate extended-release 8 mg tablets
3177115|NCT00649779|Active Comparator|2|VoSpire™ ER 8 mg tablets
2584205|NCT02338375|Experimental|Cartistem|For control group patients currently standard treatment of arthroscopic curettage and microfracture is performed, and for study group patients allogenic umbilical cord blood-derived mesenchymal stem cell product(Cartistem®) is added on the lesion after above mentioned procedure.
2584207|NCT02338375|Active Comparator|standard treatment|standard treatment of arthroscopic curettage and microfracture for osteochondral lesion of talus
2584228|NCT02338063|Experimental|1|Virtual Reality
2584233|NCT02338063|Experimental|2|Health Promotion
2584262|NCT02337842|Experimental|Cohort 1|N= 9 subjects will receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units and N=1 single oral dose Placebo.
2584265|NCT02337842|Experimental|Cohort 2|N=9 subjects will receive single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units and N=1 single oral dose of Placebo.
2584270|NCT02337842|Experimental|Cohort 4|N=36 subjects will receive single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units , N=4 subjects receive a single oral dose of Placebo
2584274|NCT02337842|Experimental|Cohort 3|N=18 subjects will receive single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units and N=2 single oral dose of Placebo
3177116|NCT00649805|Experimental|1|Verapamil Hydrochloride Extended-Release Capsules, 300 mg
3177117|NCT00649805|Active Comparator|2|Verelan® PM extended-release capsules controlled-onset 300 mg
3177118|NCT00649818|Experimental|1|Lorazepam Tablets 2 mg
3177119|NCT00649818|Active Comparator|2|Ativan Tablets 2 mg
3177120|NCT00649831|Active Comparator|Group 2|
3177121|NCT00649831|Active Comparator|Group 1|
3177122|NCT00649844|Active Comparator|A|
3177123|NCT00649844|Experimental|B|
3177124|NCT00649857|Experimental|1|Cetirizine HCl Tablets 10 mg
3177125|NCT00649857|Active Comparator|2|Zyrtec® 10 mg
3177126|NCT00649870|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
3177127|NCT00649870|Active Comparator|2|Valtrex® Tablets 1000 mg
3177128|NCT00649883|Experimental|1|
3177129|NCT00649883|Active Comparator|2|
3177130|NCT00649896|Experimental|1|Mylan Estradiol Transdermal System 0.025 mg/day
3177131|NCT00649896|Active Comparator|2|Climara® Transdermal System 0.025 mg/day
3177132|NCT00649909||Observation|Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c >8%.
3177133|NCT00649922|Placebo Comparator|Double Blind|
3177134|NCT00649922|Experimental|Open Label|
3177135|NCT00649935|Experimental|1|Azithromycin Tablets 600 mg
3177136|NCT00649935|Active Comparator|2|Zithromax® Tablets 600 mg
3177137|NCT00649948|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3177138|NCT00649948|Active Comparator|2|Glucophage XR 500 mg
3177139|NCT00649974|Experimental|1|Valacyclovir Hydrochloride Tablets 1000 mg
3177140|NCT00649974|Active Comparator|2|Valtrex® Tablets 1000 mg
3177141|NCT00649987|Experimental|1|Albuterol Sulfate Extended-Release Tablets 8 mg
3177142|NCT00649987|Active Comparator|2|VoSpire® ER Tablets 8 mg
3177143|NCT00650000|Experimental|1|Modafinil Tablets 200 mg
3177144|NCT00650000|Active Comparator|2|Provigil® Tablets 200 mg
2583020|NCT02346123||Single group|Group which contains all the patients of the study.
2583053|NCT02345928|Experimental|Part 1: Dose 1|Drug CNTO7160 or Placebo administered IV infusion Dose 1.
2583061|NCT02345928|Experimental|Part 1: Dose 2|Drug CNTO7160 or Placebo administered IV infusion Dose 2.
2583064|NCT02345928|Experimental|Part 1: Dose 3|Drug CNTO7160 or Placebo administered IV infusion Dose 3.
2583067|NCT02345928|Experimental|Part 1: Dose 4|Drug CNTO7160 or Placebo administered IV infusion Dose 4.
2583071|NCT02345928|Experimental|Part 1: Dose 5|Drug CNTO7160 or Placebo administered IV infusion Dose 5.
2583074|NCT02345928|Experimental|Part 1: Dose 6|Drug CNTO7160 or Placebo administered IV infusion Dose 6.
2583076|NCT02345928|Experimental|Part 1: Dose 7|Drug CNTO7160 or Placebo administered IV infusion Dose 7.
2583083|NCT02345928|Experimental|Part 1: Dose 8|Drug CNTO7160 or Placebo administered IV infusion Dose 8.
2583089|NCT02345928|Experimental|Part 1: Dose 9|Drug CNTO7160 or Placebo administered IV infusion Dose 9.
2583092|NCT02345928|Experimental|Part 2 (Asthma): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
2583093|NCT02345928|Experimental|Part 2 (Asthma): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
2583096|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 1|Drug CNTO 7160 or Placebo administered IV infusions Dose 1 (3 dose administrations over 4 weeks).
2583099|NCT02345928|Experimental|Part 2 (Atopic Dermatitis): Dose 2|Drug CNTO 7160 or Placebo administered IV infusions Dose 2 (3 dose administrations over 4 weeks).
2583182|NCT02345148|Experimental|Cohort 1|Elder participants will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
2583186|NCT02345148|Experimental|Cohort 2|Younger adults will receive esketamine hydrochloride solution (containing 14 milligram (mg) of esketamine base per 100 microliter [mcl] of intranasal spray) by intranasal route using nasal spray pump at 0, 5 and 10 minutes on Day 1.
2583224|NCT02344875|Experimental|Male elder subjects|Male 65- Years
2583229|NCT02344875|Experimental|Male non-elder subjects|Male 20-35 Years
2583231|NCT02344875|Experimental|Female elder subjects|Female 65- Years
2583233|NCT02344875|Experimental|Female non-elder subjects|Female 20-35 Years
3212057|NCT01011478|Placebo Comparator|Group 1: placebo|Patients receive oral placebo once daily for 5 years.
3212058|NCT01011478|Experimental|Group 2: rosuvastatin|Patients receive oral rosuvastatin once daily for 5 years.
2583397|NCT02343744|Experimental|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
2583491|NCT02343029|Experimental|Intervention|Participants in the Intervention group exercise three times a week for 30 minutes on a bicycle ergometer (optibike med, ergoline GmbH, Bitz, Germany) in the integrated gym hall of one of the participating residencies. Training is individualised as respective performance is adapted to the power at the first ventilator threshold (assessed during cardiopulmonary exercise test).
2583501|NCT02343029|Active Comparator|Waiting Control|Participants of Waiting Control continue their regular physical activity behaviour for 12 weeks. They will start the same exercise intervention after a reassessment at week 12 for the next upcoming 12 weeks. (13-24)
2583530|NCT02342756|Experimental|Group 1: CMV - HFOV|"Patients in group 1 will start with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O) and then will be ventilated with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O)~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
2583537|NCT02342756|Experimental|Group 2: HFOV - CMV|"Patients in group 2 will start with high frequency oscillatory ventilation (D- mPaw so that PL = 0 cmH2O, E- mPaw so that PL = 15 cmH2O, F- mPaw so that PL = 0 cmH2O) and then will be ventilated with conventional mechanical ventilation with different values of PEEP (A-PEEP so that PLEEO = 0 cmH2O, B- PEEP so that PLEIO = 15 cmH2O, C- PEEP so that PLEEO = 0 cmH2O).~Intervention: Device: Targeting transpulmonary pressure to avoid VILI"
2583587|NCT02342496|Placebo Comparator|Placebo|Powder consisting of maltodextrine, treated to resemble the Active product in appearance and taste.
2583590|NCT02342496|Active Comparator|Active, only probiotics|Powder consisting of freezedried bacteria at 10 billions cfu/daily dose and maltodextrine, treated to resemble the Active product in appearance and taste.
2583592|NCT02342496|Active Comparator|Active, blend of berries and probiotics|Powder consisting of freezedried berries , probiotics at 10 billions cfu/daily dose and maltodextrine.
2583645|NCT02342210|Other|Group-A - Immediate Intervention|Immediate Mindfulness Ambassador Council for Early Psychosis (MAC-EP)
2583648|NCT02342210|Other|Group-B - Delayed Intervention|3 month treatment as usual waitlist followed by Mindfulness Ambassador Council for Early Psychosis (MAC-EP).
2583696|NCT02341846||Caregivers for those with cancer pain|Qualitative semi-structured interviews with caregivers who have cared for those who have experienced cancer pain.
2585859|NCT02327299|Experimental|FePP|Bouillon fortified with 4mg FePP
3212059|NCT01011491|Experimental|Medifast 5 & 1 Plan|Medifast's 5 & 1 Plan is a meal replacement plan for weight loss and weight maintenance.
3212060|NCT01011491|Active Comparator|Food-based|The food-based arm followed a meal plan of self-selected foods that provided the same number of calories as the Medifast 5 & 1 plan.
2583196|NCT02344992|Experimental|Biochaperone Insulin Lispro|
2583198|NCT02344992|Active Comparator|Humalog®|
3177145|NCT00650013|Experimental|1|Midodrine HCl Tablets 5 mg
2583368|NCT02344069|Active Comparator|Fibrinogen|Immediate intravenous administration as a single dose of fibrinogen concentrate (Riastap®, CSL Behring), when haemostatic resuscitation is deemed necessary by the clinician.
2583369|NCT02344069|Placebo Comparator|Placebo|Saline 0.9%
2583410|NCT02343653|Active Comparator|Nutrition|Participants receive a controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks according to guidelines for enteral nutrition and patients with cirrhosis. The group receives dietary guidance and protein supplements.
2583418|NCT02343653|Experimental|Nutrition and strength training|"Participants in this group receive same controlled diet consisting of 1.2-1.5 g of protein/kg/day for 12 weeks as the No intervention-group. Participants will also receive supervised strength training 3 x 60 min./week for 12 weeks. The group receives dietary guidance and protein supplements, which on training days should be consumed within 30 minutes after exercise."
2583560|NCT02342600|Experimental|Trametinib with Pazopanib|Participants will take pazopanib (800mg) and trametinib (2mg) by mouth daily for a 28 day cycle.
2583606|NCT02342353|Experimental|Phase I (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; dosing will depend on the dose level the patient is enrolled.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
2583616|NCT02342353|Experimental|Phase II (pacritinib and erlotinib)|"Pacritinib will be administered orally twice a day; the dose used will be the dose determined to be the MTD in phase I.~Erlotinib will be taken by mouth on an outpatient basis daily at a dose of 150 mg.~A 28-day interval is defined as a cycle"
2583659|NCT02342093|Active Comparator|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
2583666|NCT02342093|Active Comparator|20EE+DRSP|Combined oral contraceptive containing 20 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
2583692|NCT02341833|Active Comparator|Sevoflurane|1 MAC of sevoflurane for 15 minutes before organs procurement.
2583698|NCT02341833|No Intervention|No intervention|No volatile anesthetics during organs procurement
2583789|NCT02341183|Active Comparator|A: Treatment order: tPAD treatment, then no treatment|Subjects will receive one overnight treatment with 7% hypertonic saline administered via the tPAD device. They will then have one overnight stay without treatment.
2583790|NCT02341183|Active Comparator|B: Treatment order: no treatment, then tPAD treatment|Subjects will have overnight stay w/o treatment, and one overnight treatment with 7% hypertonic saline administered via the tPAD device.
2583846|NCT02341001|No Intervention|Standard care|Patients are discharged from the bariatric service at 18 months after surgery.
2583855|NCT02341001|Experimental|Standard care with text message support|Patients are discharged from the bariatric service at 18 months after surgery but receive a daily text message for one year.
2584006|NCT02339844|Active Comparator|antipsychotic treatment|individual doses of aripiprazole for all patients
2584011|NCT02339844|No Intervention|no treatment|no treatment for all healthy controls
2584053|NCT02339441||Methotrexate|Patients treated with Methotrexate at the entry of the study.
2584056|NCT02339441||Mycophenolate Mofetil|Patients treated with Mycophenolate Mofetil at the entry of the study.
2584058|NCT02339441||Cyclophosphamide|Patients treated with Cyclophosphamide at the entry of the study
2584062|NCT02339441||No Immunosuppressant|Patients without immunosuppressant treatment at the entry of the study
2585862|NCT02327299|Experimental|FePP + Stabilizer|Bouillon fortified with 4mg FePP + Stabilizer
3177146|NCT00650013|Active Comparator|2|ProAmatine® Tablets 5 mg
3177147|NCT00650039|Active Comparator|Arm 1|
3177148|NCT00650039|Active Comparator|Arm 2|
3177149|NCT00650039|Placebo Comparator|Arm 3|
3177150|NCT00650052|Experimental|1|Zonisamide Capsules 100 mg
3177151|NCT00650052|Active Comparator|2|Zonegran® Capsules 100 mg
3177152|NCT00650065|Experimental|1|Cetirizine HCl Tablets 10 mg
3177153|NCT00650065|Active Comparator|2|Zyrtec® Tablets 10 mg
3177154|NCT00650117|Experimental|1|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)
3177155|NCT00650117|Experimental|2|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
3177156|NCT00650117|Experimental|3|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
3177157|NCT00650117|Experimental|4|Duragesic 25 mcg/h + Scotch Duct Tape (3M)
3177158|NCT00650117|Experimental|5|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
3177159|NCT00650117|Experimental|6|Duragesic 25 mcg/h + Microfoam Tape (3M)
3177160|NCT00650130||1|drivers of motorised vehicles suspected of being under the influence of psychoactive drugs
3177161|NCT00650143|Active Comparator|1|"Application G-CSF (10µg/kg/d divided in two doses subcutaneously) over a period of 5 days and Sitagliptin 100 mg each day for 28 days.~n=74"
3177162|NCT00650143|Placebo Comparator|2|"NaCl 0.9% applied twice daily over a period of 5 days and oral Placebo given once a day for 28 days.~n=74"
3177163|NCT00650156|Experimental|40 mg adalimumab|
3177164|NCT00650156|Experimental|80 mg Adalimumab|
3177165|NCT00650169|Experimental|1|Clopidogrel Bisulfate Tablets 75 mg
3177166|NCT00650169|Active Comparator|2|Plavix® Tablets 75 mg
3177167|NCT00650195|Experimental|1|Metolazone Tablets 10 mg
3177168|NCT00650195|Active Comparator|2|Zaroloxyn® Tablets 10 mg
3177169|NCT00650208|Experimental|1|Lamotrigine Tablets 25 mg
3177170|NCT00650208|Active Comparator|2|Lamictal® Tablets 25 mg
3177171|NCT00650221|Experimental|1|
3177172|NCT00650221|Active Comparator|2|
3177173|NCT00650234|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3177174|NCT00650234|Active Comparator|2|Glucophage® XR Tablets 500 mg
3177175|NCT00650247|Experimental|1|Sumatriptan Succinate Tablets 100 mg
3177176|NCT00650247|Active Comparator|2|Imitrex® Tablets 100 mg
3177177|NCT00650273|Experimental|1|Azithromycin Tablets 600 mg
2583133|NCT02345304|Experimental|Treatment 3|single dose of midazolam + BI drug
2583137|NCT02345304|Experimental|Treatment 4|single dose of probe drugs + BI drug
2583146|NCT02345304|Experimental|Treatment 5|single dose of digoxin + BI drug
2583157|NCT02345304|Experimental|Treatment 1|single doses of probe drugs
2583164|NCT02345304|Experimental|Treatment 2|single dose of digoxin
2583237|NCT02344901||atrial fibrillation patients|>18 year old. Atrial fibrillation patients without mitral stenosis or any prosthesis.
2583291|NCT02344446|Experimental|Skilled Therapy|Differential physical therapy treatment, based on assessment results, with follow-up visits for PT treatment 1 - 2 times per week until patient achieves at least 1 primary outcome. They will pragmatically design an individualized and progressive treatment plan, including manual therapy (manipulation and/or mobilization), neuromotor control strategies, and vestibular rehabilitation techniques, depending on the findings at assessment and patient response. Therapists can also tailor education regarding mental and physical rest according to specific parameters provided by the treating physician. Patients may also be prescribed a home exercise program and exercise education. The precise treatment strategies will be recorded.
2583328|NCT02344212|Experimental|ESENCIAL Para Vivir|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
2583367|NCT02344030|Experimental|standard blade|Standard Blade: tracheal intubation with standard blade
2583370|NCT02344030|Experimental|channeled blade|Channeled Blade: tracheal intubation with channeled blade
3212061|NCT01011517|Experimental|grape seed supplement|Nature's Pearl 650 mg, two capsules daily
3212062|NCT01011517|Placebo Comparator|placebo|placebo
2583482|NCT02343055|Experimental|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
2583488|NCT02343055|Placebo Comparator|Usual Care|A Certified Respiratory Educator (CRE) will meet with subjects to obtain a detailed COPD history and do a breathing test. Subjects will receive COPD care as usually provided by their physician.
2583581|NCT02342574|Experimental|A active|Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
2583584|NCT02342574|Placebo Comparator|A placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583586|NCT02342574|Experimental|B active|Six subjects receiving F901318 3 mg/kg intravenously for eight days
2583589|NCT02342574|Placebo Comparator|B placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583591|NCT02342574|Experimental|C active|Six subjects receiving F901318 4 mg/kg intravenously for eight days
2583593|NCT02342574|Placebo Comparator|C placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583594|NCT02342574|Experimental|D1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
2583595|NCT02342574|Placebo Comparator|D1 placebo|Two subjects receiving F901318 placebo intravenously for one day
2583596|NCT02342574|Experimental|E1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
2583598|NCT02342574|Placebo Comparator|E1 placebo|Two subjects receiving F901318 placebo intravenously for one day
2583600|NCT02342574|Experimental|F1 active|Six subjects dosed for one day with F901318 intravenously dose to be determined
2583612|NCT02342574|Placebo Comparator|F1 placebo|Two subjects receiving F901318 placebo intravenously for one day
2583619|NCT02342574|Experimental|D2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
2583624|NCT02342574|Placebo Comparator|D2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583627|NCT02342574|Experimental|E2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
2583628|NCT02342574|Placebo Comparator|E2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583631|NCT02342574|Experimental|F2 active|Six subjects dosed for eight days with F901318 intravenously dose to be determined
2583633|NCT02342574|Placebo Comparator|F2 placebo|Two subjects receiving F901318 placebo intravenously for eight days
2583693|NCT02341885||One Group|This is an observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
2583743|NCT02341612|Experimental|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion (CWI) immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
2583745|NCT02341612|Experimental|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
2583747|NCT02341612|Experimental|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
2583749|NCT02341612|Experimental|whole body criotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
2583754|NCT02341612|Experimental|passive recovery|The control group was not exposed to treatment after the EIMD protocol.
3212063|NCT01011530|Experimental|MLN4924|MLN4924 via IV infusion
3212064|NCT01011543|Active Comparator|Endoscopic approach|CT thorax is done in all patients to localize the exact anatomical site of the disease. This evaluation is followed by fluoroscopy-guided bronchoscopy for BAL (bronchoalveolar lavage) and TBB (transbronchial biopsies). A sputum sample immediately after the endoscopy will be collected if possible.
2583299|NCT02344472|Experimental|Chemotherapy with docetaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583300|NCT02344472|Experimental|Chemotherapy with paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583301|NCT02344472|Experimental|Chemotherapy with vinorelbine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583302|NCT02344472|Experimental|Chemotherapy with capecitabine|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583303|NCT02344472|Experimental|endocrine therapy with exemestane|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.
2583305|NCT02344472|Experimental|endocrine therapy with fulvestrant|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.
2583307|NCT02344472|Experimental|endocrine therapy with anastrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.
2583309|NCT02344472|Experimental|endocrine therapy with letrozole|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.
2583311|NCT02344472|Experimental|Chemotherapy with nab-Paclitaxel|dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583313|NCT02344472|Experimental|Chemotherapy with eribulin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).
2583315|NCT02344472|Experimental|endocrine therapy with leuprorelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.
2583317|NCT02344472|Experimental|endocrine therapy with goserelin|dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.
3212065|NCT01011543|Active Comparator|Induced sputum|Sputum induction after administration of 6-8 mL 3% NaCl aerosol by an ultrasonic nebulizer; sputum will be collected 15-30 minutes after administration of the aerosol. This process will be done twice in every patient.
3212066|NCT01011569||cage|patient who underwent stand alone cage insertion after discectomy
3212067|NCT01011569||plate|patient who underwent plate fixation and autologous ilia bone graft after discectomy
3212068|NCT01011582||Novel H1N1 influenza|
2583718|NCT02341703|Active Comparator|letrozole-metformin group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + metformin 500 mg three times daily from the first day of the cycle and continuous for three months unless pregnancy occurred. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
2583719|NCT02341703|Active Comparator|letrozole-metformin-pioglitazone group|"this group will receive letrozole 2.5 mg daily from day 3 of the cycle and for 5 days + (metformin 850 mg + pioglitazone 15 mg) once daily from the first day of the cycle and for 10 days. treatment will continue for 3 cycles unless pregnancy occurred.~for this group: transvaginal ultrasound will monitor follicular enlargement laboratory investigations in the form of day 3 FSH, LH, TSH and serum testosterone will be done day 12 E2 day 21 serum progesterone"
2583818|NCT02341248||A) Newly diagnosed with Crohn's disease|"Children undergoing endoscopic investigations (colonoscopy) for colonic inflammation including Crohn's disease [children who are found not to have Crohn's disease will not participate further].~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day] per day"
2583821|NCT02341248||B) Existing diagnosis of Crohn's disease|"Previously diagnosed patients with Crohn's disease due to start an 8 week standard course of treatment with EEN due to disease flare up.~[Intervention - clinical, not research decision - Exclusive Enteral Nutrition for 8 weeks; usually 330ml 6 times per day]"
2583825|NCT02341248||c) Healthy control group|Healthy children unrelated to Crohn's disease patients No intervention
3212069|NCT01011582||Seasonal influenza|
3212070|NCT01011608|Experimental|Medical Food Supplement|Medical food supplement to be given in divided portions in morning, afternoon and evening
2583904|NCT02340364|Active Comparator|Educational Control Arm|- 208 patients randomized to self-care education alone.
2583997|NCT02339805|Experimental|next generation sequencing|Determination of clonotypic evolution of the minimal residual disease by next generation sequencing.
3212071|NCT01011608|Active Comparator|standard hospital food|standard hospital diet
3212072|NCT01011621|Experimental|0.5% prednisolone acetate cream|
3212073|NCT01011621|Active Comparator|0.1% betamethasone valerate cream|
3212074|NCT01011647||Acute coronary conditions|"Patients hospitalized with the following conditions~Unstable angina~Acute myocardial infarction~Congestive heart failure"
3212075|NCT01011660|Active Comparator|A,1,IV|A means active; 1 means Amlodipine+Amiloride Compound; IV means phase IV
3212076|NCT01011660|Active Comparator|A,2,IV|A means active; 2 means Amlodipine+Telmisartan; IV means phase IV
2583159|NCT02345668|Experimental|Treatment as Usual|Intervention group that receives psychological and/or pharmacological treatment from a clinician of the mental health unit.
3212077|NCT01011660|Active Comparator|A,3,IV|A means active; 3 means Amlodipine+Amiloride Compound with or no Simvastatin; IV means phase IV
3212078|NCT01011660|Active Comparator|A,4,IV|A means active; 4 means Amlodipine+Telmisartan with or no Simvastatin; IV means phase IV
2583253|NCT02344511|Experimental|Dalbavancin|"Patients with Creatine Clearance (CrCl) greater than 30 mL/min and patients receiving regular hemodialysis or peritoneal dialysis will receive 15 mg/kg Intravenous (IV) dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1500 mg per administration in children at least 12 years and not to exceed 1000 mg per administration in children less than 12 years of age.~• Patients with CrCl < 30 mL/min who are not receiving regular hemodialysis or peritoneal dialysis will receive 10 mg/kg IV dalbavancin over 30 (+/- 5) minutes on Day 1 and on Day 8, not to exceed 1000 mg per administration in children at least 12 years and not to exceed 750 mg per administration in children less than 12 years of age.~Additionally, subjects randomized to the dalbavancin group will receive an IV placebo infusion at times corresponding to comparator group dosage times for the first eight days."
2583255|NCT02344511|Active Comparator|4 Comparators|"cefazolin, oxacillin, nafcillin or vancomycin according to the commercial label~Patients with normal renal function will receive either vancomycin 15 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour) not to exceed a daily total dose of 4000 mg, with dose adjustment based on local standard of care to achieve serum trough concentrations of 10 μg/mL to 20 μg/mL; or cefazolin 25 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour); or nafcillin or oxacillin 50 mg/kg/dose, infused over 60 (+/- 10) minutes, every 6 hours (+/- 1 hour)."
2583306|NCT02344433|Experimental|VICKY|"Relational agent, virtual counselor for collecting family health history (VICKY: VIrtual Counselor for Knowing Your Family History)."
2583308|NCT02344433|Active Comparator|MFHP|Online family health history collection tool (MFHP: My Family Health Portrait).
2583360|NCT02344095|Experimental|weekly paclitaxel with oncothermia|Paclitaxel group are treated with weekly paclitaxel and oncothermia for 4-cycles.
2583361|NCT02344095|Experimental|weekly cisplatin with oncothermia|Cisplatin group are treated with weekly cisplatin and oncothermia for 4-cycles.
2583414|NCT02343640||Baseball players|Members of the baseball team, both pitchers and fielders, who participate in repetitive baseball throwing and are exposed to damage of the ulnar collateral ligament in the arm that is used for throwing.
3212079|NCT01011686|Experimental|ANT-SM|autologous adipose-derived stem cell
3212080|NCT01011699|Active Comparator|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
2583554|NCT02342652|Experimental|ASLAN003|Substance: ASLAN003 Administration route: Oral. Dosage form: Hard gelatine 50 mg capsules. Frequency: 100 mg (2 capsules) once daily for 14 consecutive days
2583556|NCT02342652|Placebo Comparator|Matched Placebo|Substance: Placebo Administration route: Oral Dosage form: Hard gelatine capsules Frequency: 2 capsules once daily for 14 consecutive days
3212081|NCT01011699|Active Comparator|nicotinamide|"Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of nicotinamide dose up to 4 tablets, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
3212083|NCT01011725|Experimental|Postmenopausal Women- Active Agent Group|
2583721|NCT02341443|Experimental|Rigid|Surgery using mandibulo-maxillary fixation, implants providing rigid fixation on most anterior fracture and non-rigid fixation on the most posterior fracture.
2583722|NCT02341443|Active Comparator|Non-rigid|Surgery using mandibulo-maxillary fixation and implants providing non-rigid fixation on both fracture sides.
2583798|NCT02341209|Experimental|Doxycycline monohydrate|Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months.
3212084|NCT01011725|Placebo Comparator|Postmenopausal Women- Placebo|Placebo
3212085|NCT01011751|Experimental|Cyproterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, cyproterone acetate 50 mg, tablet-in-capsule, along with cyproterone acetate placebo-matching capsule, orally, once daily in the morning and cyproterone acetate 50 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Cyproterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
3212086|NCT01011751|Experimental|Medroxyprogesterone acetate|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, medroxyprogesterone acetate 10 mg, tablet-in-capsule, along with medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning and medroxyprogesterone acetate 10 mg, tablet-in-capsule, orally, once daily in the evening for 8 weeks. Medroxyprogesterone acetate placebo-matching capsule, orally, once daily in the morning for the next 2 weeks.
3212087|NCT01011751|Experimental|Venlafaxine|Leuprorelin 11.25 mg, injection, subcutaneously at Months 0, 3, and 6, and flutamide 250 mg, tablet, orally, thrice daily for first 30 days from first leuprorelin administration. From Month 6, venlafaxine 75 mg, capsule, orally, once daily in the morning and venlafaxine placebo-matching capsule, orally, once daily in the evening for 8 weeks. Venlafaxine 37.5 mg, capsule, orally, once daily in the evening for the next 2 weeks.
3259011|NCT01466608|Experimental|Rosuvastatin|Rosuvastatin 20 mg will be administered once a day for 8 weeks (open-label, one-arm, single-sequence design)
2583949|NCT02340182|Experimental|Antibiotics|"All volunteers will self-administer the following antibiotics for 7 consecutive days (concomitantly):~Vancomycin 250mg 3dd2;~Ciprofloxacin 500mg 2dd1;~Metronidazole 500mg 3dd1."
3259012|NCT01466621||Previously RV Paced|Patients who were RV paced prior to receiving a cardiac resynchronization therapy device.
2583205|NCT02345135|Active Comparator|Ataxia Telangiectasia|All A-T patients presented for 3 study visits. In all visits patients had a clinical examination, a blood collection and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
2583207|NCT02345135|Active Comparator|Healthy Control|All healthy controls presented for 3 study visits. In all visits patients had a clinical examination and a lung function measurement. Furthermore symptom diaries were distributed and collected on these visits.
2583272|NCT02344654|Experimental|Fluorescence cholangiography|After induction of anaesthesia 2.5-7.5 mg of indocyanine green (0.05 mg/kg) is injected intravenously. The operation field is routinely inspected in the fluorescence imaging mode before dissection of Calot´s triangle. During dissection, the fluorescence imaging mode is used when needed, before division of any tubular structure and after division of the cystic duct and artery.
2583279|NCT02344654|Active Comparator|X-ray cholangiography|The cholangiography is performed after dissection of the cystic duct by cannulation of the cystic duct with a catheter using either a Kumar- or Olsen grasper. A mobile X-ray C-arm system is used, and the monochrome X-ray image is shown on a separate screen. After satisfactory identification of the extra-hepatic biliary ducts, the intraoperative cholangiography is discontinued and the gallbladder is removed in a standardized manner.
3212088|NCT01011764|Active Comparator|SKILLS group|The SKILLS intervention targets a specific set of social skills over 8 bi-weekly sessions. The intervention is delivered to a small group of children with autism at school during lunchtime. The content delivered to the group of young children with autism including lessons developed from a manual by Seattle Children's Hospital Research Foundation. Children are given weekly homework assignments to reinforce the topics discussed in the group sessions.
3259013|NCT01466621||Non-Previously RV Paced|Patients who received a CRT device without being previously RV paced.
2583375|NCT02343848|Experimental|treatment|smart bracelet.
2583413|NCT02343601|No Intervention|Control group|Control group using a hemodynamic standard protocol
2583423|NCT02343601|Other|Photoplethysmography group|Hemodynamic optimization using Photoplethysmography device (ClearSight, Edwards Lifesciences, Irvine, CA)
2583502|NCT02343250|Experimental|Cinidipine/Valsartan tablet|Cinidipine/Valsartan tablet
2583507|NCT02343250|Active Comparator|Cilnidipine+Valsartan|coadministration of cilinidipine and valsartan
2583535|NCT02342717|Experimental|Reference|single dose BI 425809
2583541|NCT02342717|Experimental|Test|multiple doses of Itraconazole + single dose BI 425809
2583580|NCT02342470|Placebo Comparator|Placebo|Placebo Comparator / Bid
2583583|NCT02342470|Experimental|PMK-S005 1|Total 50mg, by mouth, bid
2583585|NCT02342470|Experimental|PMK-S005 2|Total 100mg, by mouth, bid
2583588|NCT02342470|Experimental|PMK-S005 3|Total 150mg, by mouth, bid
3259014|NCT01466634||permanent polymer DES|
3259015|NCT01466634||bioabsorbable polymer DES|
2583828|NCT02340871||Genetic Neurological Diseases|The group consists of patients with a neurological disease that are tested for finding the genetic basis of their disease.The neurological signs and symptoms include ataxia, intellectual disability, seizures, movement disorders, migrational disorders, macrocephaly, microcephaly and various other signs and symptoms. The group consists of patients from 1-year-old until 90 years who are having a neurological disease as stated above or who are the parents or siblings of the affected patients. Blood specimens will be taken from them and DNA will be extracted for next generation studies like whole exome sequence or whole genome sequence. This process is called genetic testing. The current proposal will assist in diagnosing children and families with a neurological disease for genetic counseling.
2583921|NCT02340624|No Intervention|Control group|No intervention(control group)
2583925|NCT02340624|Experimental|condition 2|Intervention:Smokefreemoms texting
2583927|NCT02340624|Experimental|condition 3|Intervention: Quitline referral
2583929|NCT02340624|Experimental|condition 4|Intervention:Smokefreemoms texting and quitline referral
2583931|NCT02340624|Experimental|condition 5|Intervention: Brief intervention
2583933|NCT02340624|Experimental|condition 6|Intervention:Smokefreemoms texting and Brief intervention
2583934|NCT02340624|Experimental|condition 7|Intervention: Quitline referral and Brief intervention
2583935|NCT02340624|Experimental|condition 8|Intervention:Smokefreemoms texting, Quitline referral and Brief intervention
2584015|NCT02339896||WHO category 2|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times
2584018|NCT02339896||WHO category 3|Children patient who have experienced WHO category II exposure will receive rabies vaccine (SPEEDA) 0.1 ml intradermal two site for 4 times with ERIG
2584051|NCT02339428|Experimental|Diclophenac sodium 100mg p.o.|Patients will be given 100mg of diclophenac sodium two hours prior to colonoscopy.
2584055|NCT02339428|Placebo Comparator|Placebo|Patients will be given placebo tablets of same appearance as the intervention.
2584101|NCT02339064|Experimental|Apomorphine infusion|Continuous subcutaneous apomorphine infusion
2584186|NCT02338570|Other|Everolimus|All patients will receive everolimus 10 mg orally per day. Treatment will continue until progression, unacceptable toxicity, patient refusal or medical decision
2584238|NCT02338206|Active Comparator|Long + Growth hormone|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously along with Growth hormone (Norditropin, Novo nordisk) co-treatment daily in a dose of 2.5 mg S.C. till the day of hCG administration.. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG and growth hormone, were continued till the day of hCG administration.
2584245|NCT02338206|No Intervention|Long protocol only|Patients in this group were given a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) starting on the day 21 of preceding cycle at a dose of 0.1 mg/day, subcutaneously. On the second day of menstruation, Human menopausal gonadotrophin HMG (75 IU, Merional, IBSA) was started, and this was associated with reduction of triptorelin dose to 0.05 mg/day. This reduced daily dose, in addition to HMG, were continued till the day of hCG administration.
3259016|NCT01466647|Other|AXL1717 in combination with Gemcitabine HCL and Carboplatin|AXL1717 in combination with Gemcitabine HCL and Carboplatin
2583211|NCT02344940|Experimental|toremifene|patients who will be treated with toremifene.
2583215|NCT02344940|Active Comparator|tamoxifen|patients who will be treated with tamoxifen.
2583264|NCT02344641|Experimental|Exenatide|exenatide group receive exenatide (5μg, subcutaneous injection, Bid）
2583273|NCT02344641|No Intervention|control group|control group do not receive exenatide
3212089|NCT01011764|Experimental|ENGAGE group|The ENGAGE intervention targets two social domains, and two learning contexts. The two social domains are peer acceptance and social engagement with peers. The social group will be small and include children with ASD as well as their typical peers. There will be a greater number of typical peers included to model social behaviors and foster friendships. The typical peers will be selected based on results from the friendship survey and teacher nominations. The two learning contexts are direct instruction in a group social skills format during lunchtime and individualized embedded generalization activities in the school day.
3212090|NCT01011777|Experimental|Autologous Muscle Derived Cells|Surgeon will endoscopically inject previously harvested autologous muscle derived cells (MDC) into the same bladder exstrophy patient's urinary sphincter to improve outflow resistance and rhabdosphincter contractility. We will assess tolerability and induction of continence.
2583395|NCT02343705|Experimental|Latella Knee Implant System|
2583436|NCT02343393|Experimental|H-ISDN|Eligible patients randomised to treatment arm will be initiated on a starting dose of hydralazine 60mg and ISDN 30mg daily (20/10mg three times daily). After 7 days following the first dose, if the starting medication is well-tolerated, the patient is instructed to double the dose of study medication to the target maintenance dose of hydralazine 120mg and ISDN 60mg daily for 24 weeks
2583439|NCT02343393|No Intervention|Standard Medical Therapy|Current standard HF therapy include the use of beta-blockers, ACE inhibitors/ARBs and diuretics.
2583469|NCT02343107|Experimental|1|Subgroup of subjects who benefit of the e-coaching
2583471|NCT02343107|No Intervention|2|Subgroup of subjects who are asked to follow the conventional nutritional recommendations of the treatment of abdominal obesity and diabetes
2583528|NCT02342899|Active Comparator|Control Goup|Inpatient initiation of noninvasive ventilation.
2583529|NCT02342899|Active Comparator|Intervention Group|Initiated on NIV during an elective outpatient clinic review during which an arterial blood gas measurement will be obtained to confirm the presence of chronic respiratory failure.
3212091|NCT01011790|Experimental|Stress Management Tool|All subjects will use the Healing Rhythms™ meditation program for 4 weeks.
3212092|NCT01011803|Experimental|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
2583753|NCT02341352|No Intervention|Control|Only behavioral education for Caregiver
2583757|NCT02341352|Experimental|fluoride varnish|fluoride varnish every 6 months
2583760|NCT02341352|Experimental|ImmunoglobulinY|anti-S.mutans Immunoglobulin yolk for everyday use
2583764|NCT02341352|Experimental|Probiotics|Probiotics use for 1 months
3212093|NCT01011842|Experimental|radiation therapy arm|
3212094|NCT01011855|Active Comparator|Radiant warmer bed sequence 1|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3212095|NCT01011855|Active Comparator|Radiant warmer bed sequence 2|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3212096|NCT01011855|Active Comparator|Radiant warmer bed sequence 3|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
2584030|NCT02339688|Other|convential MS rehabilitation|Investigation of the quality (psychometric properties) and clinical utility of several measures of mobility
2584141|NCT02338830|Active Comparator|Progesterone group|Women received vaginal progesterone suppositories
2584142|NCT02338830|No Intervention|No treatment group|Women received no treatment
2584182|NCT02338518|Experimental|SEEOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, oxaliplatin 100 mg/m2, etoposide 80 mg/m2, and pharmorubicin 30 mg/m2 were administered from the celiac artery on day 1. 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
2584183|NCT02338518|Active Comparator|SOX group|A three-cycle neo-adjuvant chemotherapy was performed in all cases. In every cycle, patients received intravenous oxaliplatin 130 mg/m2 on day 1, and 80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks. The second cycle was scheduled following a 1-week rest after the first cycle.
2584374|NCT02337192|Experimental|Group 1|Negative control - Moutwash with 1,5mL of dimethyl sulfoxide at 5% (DMSO) in water solution - During 2 minutes.
2584375|NCT02337192|Experimental|Group 2|Mouthwash with Swish with Curcumin
2584376|NCT02337192|Experimental|Group 3|Moutwash with Swish with Curcumin + SDS
2584378|NCT02337192|Experimental|Group 4|Experiment use dental irradiation with blue light (LED) only.
2584379|NCT02337192|Experimental|Group 5|Antimicrobial Photodynamic Therapy (APDT) with blue light and Curcumin salt.
2584381|NCT02337192|Experimental|Group 6|Antimicrobial Photodynamic Therapy (APDT) with blue light, Curcumin salt and surfactant.
2584384|NCT02337192|Experimental|Group 7|Positive control - Use of mouthwash with Chlorhexidine only
2584530|NCT02336048|Active Comparator|Placebo + Obinutuzumab + Chlorambucil|Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
2584533|NCT02336048|Experimental|Tocilizumab + Obinutuzumab + Chlorambucil|Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.
2583236|NCT02344823|Active Comparator|Vardenafil Phase A|HVPG (Hepatic Venous Pressure Measurement) at baseline and Response to Vardenafil 10mg per oral for 7 days at day 7 IIEF5 at baseline and day 7
2583238|NCT02344823|Placebo Comparator|Placebo Phase A|HVPG (Hepatic Venous Pressure Measurement) Measurement at baseline and Response to Placebo per oral for 7 days at day 7 IIEF 5 at baseline and day 7
2583239|NCT02344823|Active Comparator|Vardenfil Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Vardenafil 10mg per oral ad libidum in 28 days at day 28
2583241|NCT02344823|Placebo Comparator|Placebo Phase B|IIEF 5 (International Index of Erectile Function) at baseline and Response to Placebo per oral ad libidum in 28 days at day 28
2583293|NCT02344498||Urban|HBV patients in Addis Abeba. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
2583294|NCT02344498||Rural|HBV patients in Harar. Eligible patients treated with tenofovir disoproxil fumarate 245 mg OD.
2583349|NCT02344134|Experimental|NBP607|cell culture-derived trivalent inactivated subunit influenza vaccine
2583351|NCT02344134|Active Comparator|Agrippal S1|egg-derived trivalent inactivated subunit influenza vaccine
2583389|NCT02343835|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
2583392|NCT02343835|No Intervention|Control|The patients without treatment
2583411|NCT02343484|Active Comparator|Gelified ethanol|Gelified ethanol (Discogel) is a sterile, implantable medical solution containing ethyl alcohol, cellulose derivative product and an opaque agent (tungsten). The implant is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. The implant causes migration of fluid (by hydrophilic and osmotic phenomena) from the periphery towards the center, causing disk reinforcement. Filling of the annulus fibrosus tears interrupts the outflow of inflammatory factors towards dorsal root ganglions, dura and posterior longitudinal ligament.
2583420|NCT02343484|Active Comparator|Gelified ethanol combined to pulsed radiofrequency|Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain.Intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
2583494|NCT02343185|Experimental|diaphragmatic treatment|Subjects in this arm receive different manual techniques for the low back pain and diaphragmatic treatment.
2583503|NCT02343185|Placebo Comparator|Placebo|Subjects in this arm receive different manual techniques for the low back pain and a sham diaphragmatic treatment.
2583527|NCT02342769||Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
2583608|NCT02342405|Placebo Comparator|30% oxygen|Inhalation of 30% oxygen
2583617|NCT02342405|Experimental|80% oxygen|Inhalation of 80% oxygen
2583662|NCT02342119|Experimental|KTFT+TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are receiving the Talking About Living Kidney Donation intervention
2583663|NCT02342119|Active Comparator|KTFT+No TALK|Patients who are being evaluated for a kidney transplantation via Kidney Transplant Fast Track and who are not receiving the Talking About Living Kidney Donation intervention
2583684|NCT02341781||Relapsed,Progressed,Refractory or Intolerant to ibrutinib|MCL subjects who received lenalidomide after having relapsed or progressed on ibrutinib treatment or were refractory or intolerant to ibrutinib treatment
3212097|NCT01011855|Active Comparator|Radiant warmer bed sequence 4|Clinical care provided on three different types of cleared radiant warmer beds with temperature measurements taken for 20 hours on each of the three radiant warmer beds.
2583829|NCT02340923||Healthy Subjects|Healthy subjects aged 0-18 years old. Subjects cannot have a presence or past history of a neurological disorder or other disease that would be expected to substantially impact health.
2583831|NCT02340923||Duchenne Muscular Dystrophy Subjects|Male subjects aged 0-18 years old with genetic or histopathologic diagnosis of duchenne muscular dystrophy, or signs and symptoms of DMD and genetic or histopathologic diagnosis in a family member. Additionally, subjects cannot have the presence of a superimposed neuromuscular or other medical condition that substantially impacts the individual's health or ability to cooperate.
2583900|NCT02340572|Experimental|PRS-080#022-DP|hepcidin antagonist, single administration, ascending doses
2583911|NCT02340572|Placebo Comparator|PRS-080-Placebo#001|Comparotor treatment, single administration
2583951|NCT02340052||Frederiksberg Hospital|100 patients undergoing planned total hil arthroplasty
2583957|NCT02340052||Koege hospital|100 patients undergoing planned total hil arthroplasty
2583960|NCT02340052||Naestved Hospital|100 patients undergoing planned total hil arthroplasty
2583965|NCT02340052||Hilleroed Hospital|100 patients undergoing planned total hil arthroplasty
2583968|NCT02340052||Nykoebing Falster Hospital|100 patients undergoing planned total hil arthroplasty
2584341|NCT02337413|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
2584344|NCT02337413|Other|Urothearpy alone|This group will receive standard behavioral urotherapy alone
2584377|NCT02337179|Experimental|Voluntary medical male circumcision|Eligible men will be circumcised according to protocol
2584413|NCT02336880|Experimental|Intervention group|4 weeks guided internet-delivered cognitive behavioural therapy program. The program consists of psychoeducation, exposure to physical activity, and a breathing-based relaxation exercise
2584415|NCT02336880|No Intervention|Control group|Care as usual
2584442|NCT02336659|Placebo Comparator|Saline|Mixed meal test and ad libitum meal test duing infusion of saline
2584445|NCT02336659|Experimental|Exendin 9-39|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min
2585866|NCT02327299|Experimental|FeSO4|Bouillon fortified with 4mg FeSO4
3212098|NCT01011855|Experimental|Radiant warmer bed sequence 5|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
2583256|NCT02344537|Experimental|Meditation Group Therapy|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
2583257|NCT02344537|No Intervention|Wait-List Controls|The wait-list group will not take part in study treatment (daily meditation or stretching) during the study wait of 8 weeks in order for us to compare change related to the study intervention to change associated with no active treatment ( treatment-as-usual). (After completing 8 weeks of no study treatment as part of the wait-list group, these patients will be offered the opportunity to receive 8 weeks of treatment.)
2583325|NCT02344355|Experimental|ascorbate, radiation, temozolomide|"Concomitant therapy:~Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions~Adjuvant therapy:~Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions"
3212099|NCT01011855|Experimental|Radiant warmer bed sequence 6|Clinical care provided on three different types of cleared radiant warmer beds with infant temperature measurements taken for 20 hours on each of the three radiant warmer beds.
3212100|NCT01011881||patients with pleuritis|
3212101|NCT01011920|Experimental|MTX+ AraC|Arm A Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
3212102|NCT01011920|Experimental|Ara-C +Rituximab|Arm B Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3
3212103|NCT01011920|Experimental|Ara-C + rituximab+thiotepa|Arm C Rituximab 375 mg/m2 conventional infusion d -5 & 0 Methotrexate 3.5 g/m2 0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion d 1 Cytarabine 2 g/m2 1 hr infusion, twice a day (every 12 hs.) d 2 - 3 Thiotepa 30 mg/m2 30 min. Infusion d 4
2583672|NCT02341898|Experimental|Updated original programme|Educational programme for all nurses (90 min. single information session); training and structured support for nominated key nurses (one-day training workshop); provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
2583674|NCT02341898|Experimental|Concise updated programme|Training and structured support for nominated key nurses (one-day training workshop); nurses' training will be carried out by key nurses as facultative option; key nurses receive an additional train-the-trainer module to apply the educational programme; provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives); supportive material (poster, mugs etc.)
2583675|NCT02341898|Active Comparator|Optimized usual care|Provision of printed study material (evidence-based practice guideline; short versions for nurses, legal guardians, and others; information brochures for relatives) only
3212104|NCT01011920|Experimental|WBRT 36 Gy +/- boost 9 Gy|ARM D: WBRT with 36 Gy in the case of CR to primary chemotherapy or the same WBRT dose followed by a tumor-bed boost of 9 Gy with 1-2 cm of margin surrounding enhanced residual lesion (total tumor-bed dose 45 Gy) in patients who achieved a PR or SD after primary chemotherapy. Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions.
2583826|NCT02341066||Rheumatoid Arthritis|Rheumatoid arthritis patients free of overt cardiovascular disease. Endothelial Dysfunction evaluation by EndoPAT
3212105|NCT01011920|Experimental|BCNU + Thiotepa + APBSCT|Arm E BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6 Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4 Reinfusion of PBSC ≥5 x 106 CD34+ cells/kg day 0
3212106|NCT01011959|Active Comparator|1|dose 1 vs. placebo
3212107|NCT01011959|Active Comparator|2|dose 2 vs. placebo
3212108|NCT01011959|Active Comparator|3|dose 3 vs. placebo
3212109|NCT01011959|Active Comparator|4|dose 4 vs. placebo
3212110|NCT01011959|Active Comparator|5|dose 5 vs. placebo
3212111|NCT01011959|Active Comparator|6|dose 6 vs. placebo
3212112|NCT01011972|Experimental|XMT-1107|Dose escalation groups of XMT-1107, I.V. (in the arm) beginning at 6 mg/m^2, doubling in dose to 24 mg/m^2, then 40 mg/m^2, then 60 mg/m^2, then 80 mg/m^2 with subsequent doses at 33% of the previous until disease progression or unacceptable side effects are experienced.
2584023|NCT02339597|Experimental|APAP Lab|standard Initiation of APAP therapy in sleep laboratory.
2584024|NCT02339597|Experimental|APAP Home|initiation of APAP therapy in homely environment with additional continuous telemetric support.
2584049|NCT02339337|Experimental|RGT group|For subjects who were randomized into the RGT group, the duration of Peg-IFN and RBV therapy was abbreviated to 24 weeks in subjects with HCV genotype 1, a pre-treatment low viral load (LVL, < 400000 IU/mL) and RVR (defined asHCV RNA <50 IU/mL at 4th week of therapy); the duration was 16 weeks in subjects with HCV genotype 2/3 and RVR.
2584050|NCT02339337|Active Comparator|GGT group|Subjects who were randomized into the GGT group received Peg-IFN and standard dose RBV (1200 mg/day) for 48 weeks in subjects infected with HCV genotype 1 or Peg-IFN and low dose RBV (800 mg/day) for 24 weeks in subjects infected with HCV genotype 2/3; the patients were then followed for 6 months.
3212113|NCT01011985||AVF|Initial access is an AVF
3212114|NCT01011985||AVG|Initial vascular access is an AVG
3212115|NCT01011985||TC|Initial vascular access is a tunneled catheter, with or without a maturing AVF or AVG
3212116|NCT01012011||Group 1|
3212117|NCT01012050|Experimental|NV Group|Performed nebulization coupled with noninvasive ventilation
3212118|NCT01012050|Active Comparator|NEB group|Performed nebulization alone.
3212119|NCT01012063|Experimental|group IE|The group IE received iron sucrose and erythropoietin-β (Epo-β) during the operation
3212120|NCT01012063|Placebo Comparator|group C|The group C received saline as same method.
3212121|NCT01012076|Active Comparator|Active Control|The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning. Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to improve the parent's ability to successfully promote the child's social and emotional competency.
2583259|NCT02344550|Experimental|Everolimus arm|Everolimus 10mg p.o. daily Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
2583261|NCT02344550|Active Comparator|Control arm|Letrozole 2.5 mg p.o. daily Leuprorelin (Leuprolide) 3.75mg SC every 4 weeks
3212122|NCT01012076|Experimental|Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). Over the course of the intervention, parent and interventionist cover a hierarchy of intervention topics, aiming to promote the ability of the parent-child dyad to successfully manage shared toy play.
3212123|NCT01012102|Experimental|Group 1|EMD 640744 30μg and Montanide® ISA 51 VG
3212124|NCT01012102|Experimental|Group 2|EMD 640744 100μg and Montanide® ISA 51 VG
2583393|NCT02343770|Experimental|idiopathic juvenile arthritis|blood sample
2583394|NCT02343770|Other|control|blood sample
2583415|NCT02343497|Experimental|Astaxanthin|Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks
2583421|NCT02343497|Placebo Comparator|Placebo|filling agent, in lipid capsules, 2 caps per day, duration 12 weeks
2583493|NCT02343237|Experimental|Osteopathy +|75 patients will make 6 osteopathic sessions
2583504|NCT02343237|Active Comparator|Osteopathy -|75 patients will make 6 factitious osteopathic sessions
2583532|NCT02342795|Experimental|cigarette substitute|The QuitSmart cigarette substitute is a plastic tube that looks like a real cigarette and is designed to provide the same draw resistance as a smoker's usual cigarette. There is no drug delivery with this product. Two cigarette substitutes and a product manual are provided to participants following randomization and replacement products are provided throughout the intervention period (24 weeks).
2583545|NCT02342795|Experimental|e-cigarette (with 0 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 0 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
2583548|NCT02342795|Experimental|e-cigarette (with 8 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 8 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
2583550|NCT02342795|Experimental|e-cigarette (with 36 mg/ml nicotine)|The e-cigarette used will be the EGO e-cigarette (marketed by www.liquidexpress.com). Each participant randomized to an ECIG condition will receive 2 e-cigarette batteries, 1 wall adapter, 1 USB charger, and a user manual. Cartomizers containing 36 mg/ml nicotine will be provided throughout the intervention period (24 weeks).
2583577|NCT02342457|Experimental|Child suspected of Hirschsprung disease|Children admitted for biopsy, so that Hirschsprungs desease may be ruled out or diagnosed, whom are planned for rectal biopsy, by clinical decision.
2583647|NCT02342236|Other|cemented|Primary hip arthroplasty with bone cement use.
2583650|NCT02342236|Other|cementless|Primary hip arthroplasty without bone cement use.
2583742|NCT02341638|Experimental|Part A Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583744|NCT02341638|Experimental|Part A Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583746|NCT02341638|Experimental|Part A Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583748|NCT02341638|Experimental|Part A Panel 4: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583751|NCT02341638|Experimental|Part A Panel 5: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583755|NCT02341638|Experimental|Part A Panel 6: BMS-986141 or Placebo|BMS-986141 or Placebo single dose by mouth as specified
2583759|NCT02341638|Experimental|Part A Panel 7: BMS-986141|Single dose by mouth as specified
2583762|NCT02341638|Experimental|Part A Panel 8: BMS-986141|Single dose by mouth as specified
2583765|NCT02341638|Experimental|Part B Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583766|NCT02341638|Experimental|Part B Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583772|NCT02341638|Experimental|Part B Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583774|NCT02341638|Experimental|Part C Panel 1: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583776|NCT02341638|Experimental|Part C Panel 2: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583777|NCT02341638|Experimental|Part C Panel 3: BMS-986141 or Placebo|BMS-986141 or Placebo by mouth as specified
2583779|NCT02341638|Experimental|Part D Panel 1: BMS-986141 and Aspirin|BMS-986141 and Aspirin by mouth as specified
2583781|NCT02341638|Placebo Comparator|Part D Panel 1: Placebo matching BMS-986141 and Aspirin|BMS-986141 placebo and Aspirin by mouth as specified
2583782|NCT02341638|Experimental|Part E Panel 1: BMS-986141 and Itraconazole|BMS-986141 and Itraconazole by mouth as specified
2583840|NCT02340754|Experimental|Mindfulness-base Stress Reduction|Mindfulness-based stress reduction is a formalized, experiential, 8-week stress-management program. Participants attend weekly two-hour classes and a half-day retreat during which they learn mindfulness meditation, breath work, yoga postures, self-reflection and awareness.
2583853|NCT02340754|Active Comparator|MS Education Control|The MS Education Control program is matched to MBSR for time and attention yet has no overlap with intervention content. Each two-hour class uses a pamphlet published by the National MS Society to present information about a different MS topic such as Fatigue; Bowel and Bladder Problems; Diet; Spasticity; and Nutritional Supplementation: Vitamins, Minerals, and Herbs.
2583888|NCT02340481|Experimental|Loperamide Hydrochloride + Simethicone|Participant will take 2 loperamide hydrochloride and simethicone chewable tablets + 2 loperamide hydrochloride placebo capsules orally, as their first dose, and subsequently 1 loperamide hydrochloride and simethicone chewable tablet + 1 loperamide hydrochloride placebo capsule orally, in the event of unformed stool (provided that no more than 4 tablets/capsules are taken within a 24-hour period) up to 48 hours.
2585868|NCT02327299|Experimental|FeSO4 + Stabilizer|Bouillon fortified with 4mg FeSO4 + Stabilizer
2583269|NCT02344758|Experimental|Celiac adult|Patient >16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
2583274|NCT02344758|Experimental|Celiac child|Patient <16 years, initially diagnosed based on the detection of IgA anti-endomysial and anti-tissue transglutaminase antibodies in serum and confirmed by a small intestinal biopsy, on a GFD for >2 years
2583283|NCT02344758|Active Comparator|Healthy adult|Healthy individual > 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
2583287|NCT02344758|Active Comparator|Healthy child|Healthy individual < 16 years. Exclusion criteria: the presence of family history of CD, digestive disease symptoms, known medical disease, use of prescription medications, and use of antibiotics and probiotics in the previous 2 months to the inclusion in the study.
2583350|NCT02344108|Experimental|Inspire® Upper Airway Simulation System|Subjects meeting inclusion criteria, including sleep study and drug induced sleep endoscopy criteria, will undergo surgical placement of a hypoglossal nerve simulator (Inspire® Upper Airway Simulation System Model 3028 IPG). The simulator will be activated one month after surgery and subjects will undergo repeat sleep study evaluation and device titration at one, two, six and twelve months after implantation. Subjects will be followed for one year to determine safety and efficacy of the device.
2583382|NCT02343822|Experimental|Multiple PRP Injection|2 PRP Injections 2 months apart
2583383|NCT02343822|Experimental|Single PRP Injection|1 PRP Injection and Saline Injection 2 months apart
2583386|NCT02343822|Active Comparator|Saline Injection|2 Saline Injections 2 months apart
2583419|NCT02343445|Experimental|P-1037 in Hypertonic Saline (HS)|P-1037 Solution for Inhalation, 85 μg twice daily (BID) (28.3 μg/mL) in hypertonic saline (4.2% saline) BID
2583424|NCT02343445|Experimental|P-1037 in Saline|P-1037 Solution for Inhalation, 85 μg BID (28.3 μg/mL) in 0.17% saline BID
2583428|NCT02343445|Placebo Comparator|Saline|Placebo (0.17% saline) BID
2583430|NCT02343445|Sham Comparator|Hypertonic Saline|Hypertonic saline (4.2% saline) BID
3212125|NCT01012102|Experimental|Group 3|EMD 640744 300μg and Montanide® ISA 51 VG
3212126|NCT01012154|Experimental|All patients|
2583576|NCT02342587|Experimental|single arm|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
2583643|NCT02342249|Placebo Comparator|VX-787 Placebo BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of matching placebo of VX-787 and Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
2583646|NCT02342249|Active Comparator|VX-787 300 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 300 milligram (mg) tablet along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
2583649|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir Placebo BID|Subjects will receive 10 doses of VX-787 600 mg (2*300 mg tablets) along with matching placebo of Oseltamivir twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
2583651|NCT02342249|Active Comparator|VX-787 600 mg BID + Oseltamivir 75 mg BID|Subjects will receive 10 doses of VX-787 600 mg tablets (2*300 mg tablets) along with 75 mg Oseltamivir capsule twice daily (BID) with approximately 12 hour (+/- 2) intervals, over 5-6 days.
3212127|NCT01012193|Active Comparator|adjunctive cilostazol|adjunctive cilostazol 100mg bid to dual antiplatelet therapy
3212128|NCT01012193|Active Comparator|high maintenance-dose clopidogrel|double dose of clopidogrel 150mg/day
2583912|NCT02340325|Other|Acute Sensitivity Test to FS2 cream|Twenty (20) healthy volunteers will be assigned volunteer numbers and will have a testing areas identified by permanent marker on their backs. Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area once for 24 hours. The pouch order will be random, generated by the www.random.org list generator each application. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
2583918|NCT02340325|Other|Chronic Sensitivity Test to FS2 cream|Twenty (20) randomized healthy volunteers will be assigned numbers and will have a single testing area identified by permanent marker on either shoulder or upper back. Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30.
3212129|NCT01012206|No Intervention|Control group|Children in control group obtained no lifestyle counseling (intervention).
3212130|NCT01012206|Active Comparator|Intervention group|Children in the intervention group and their parents were given lifestyle counseling and participated in an intervention program regarding food habits and physical activity.
3212131|NCT01012232|Active Comparator|low volume local anesthetic|bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
3212132|NCT01012232|Experimental|high volume local anesthetic|bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL)
3212133|NCT01012284|Experimental|Panel A|8 patients with moderate hepatic impairment classified as moderate as per the Child Pugh Classification.
3212134|NCT01012284|Experimental|Panel B|8 healthy participants who will match to patients with hepatic impairment in Panel A with regards to sex, age (more or less to 5 years), and body mass index.
3212135|NCT01012310|Experimental|Cohort 1|
3212136|NCT01012310|Experimental|Cohort 2|
3212137|NCT01012310|Experimental|Cohort 3|
3212138|NCT01012310|Experimental|Cohort 4|
3212139|NCT01012349|Experimental|Test|Administration of GeoLab Association (acetylsalicylic acid, sodium bicarbonate and citric acid)
3212140|NCT01012349|Active Comparator|Comparator|Acetylsalicylic acid - (Aspirin - Bayer)
3212141|NCT01012375|Experimental|1|AZD1446 tid
3212142|NCT01012375|Experimental|2|AZD1446 tid
3212143|NCT01012375|Experimental|3|AZD1446 qd
3212144|NCT01012375|Placebo Comparator|4|Matching placebo capsule
3177178|NCT00650273|Active Comparator|2|Zithromax® Tablets 600 mg
2583353|NCT02343965|Experimental|Touch-massage group|Patient receive 3 sessions of touch-massage (the duration of a session of touch massage is 15 minutes) ,once a week, for 3 weeks
2583354|NCT02343965|No Intervention|without touch-massage group|
2583388|NCT02343783|Experimental|Healthy + Atopic Dermatitis + Allergic Asthmatic Participants|Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. Participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed for the use of induced skin blisters after allergic skin reaction (ASR).
2583409|NCT02343432|Experimental|Epidural Volume 10mL|Epidural Volume 10mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 10mL Intervention: Drug: Bupivacaine 12.5mg
2583416|NCT02343432|Experimental|Epidural Volume 15mL|Epidural Volume 15mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 15 mL Intervention: Drug: Bupivacaine 12.5mg
2583426|NCT02343432|Experimental|Epidural Volume 20mL|Epidural Volume 20mL, Intervention: Drug: Triamcinolone 80 mg Intervention: Drug: Epidural Volume 20 mL Intervention: Drug: Bupivacaine 12.5mg
2583480|NCT02343120|Experimental|BGB-3111|All patients will undertake 160MG BID of BGB-3111.
3177179|NCT00650286|Experimental|1|Modafinil Tablets 200 mg
2583604|NCT02342340|Active Comparator|Navy Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583614|NCT02342340|Active Comparator|Red Kidney Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked red kidney beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583622|NCT02342340|Active Comparator|Pinto Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked pinto beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583625|NCT02342340|Active Comparator|Black Beans (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked navy beans. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583626|NCT02342340|Active Comparator|Lentils (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked lentils. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583630|NCT02342340|Placebo Comparator|White Rice (cooked)|At one of the six visits, participants will consume a ¾ cup of cooked white rice. Participants will be provided with 100 ml of water with the food, and will be allowed to drink water whenever necessary during the 6 hour test period. The participants will not be blinded to the order and the type of food product they receive at a visit, however, the samples will be assigned a number to ensure the analytical team is blinded to the test product until the end of the study. Should the need to re-administer a test product arise, the participant will receive the test product from the same treatment number again at an extra visit after the original 6 visits have been completed.
2583676|NCT02342041|Placebo Comparator|Single ascending dose|Single dose of SUVN-G3031or placebo in healthy male subjects
2583677|NCT02342041|Placebo Comparator|Multiple ascending dose|Multiple doses of SUVN-G3031 or placebo in healthy male subjects
2583733|NCT02341586|Experimental|Lucky Iron Fish|This group will receive a Lucky Iron Fish to use during cooking.
2583736|NCT02341586|Active Comparator|18 mg iron|This group will receive a daily oral iron supplement.
2583739|NCT02341586|Other|Control group|This group will receive nutrition education
2583795|NCT02341196|Experimental|CEA + Polyester patch|225 Patients
2583802|NCT02341196|Experimental|CEA + Patch Polyurethane|225 Patients
2583837|NCT02340988|Experimental|Oritavancin and Warfarin|Oritavancin 1200 mg Single-Dose IV Oritavancin Diphosphate given simultaneously with 25mg dose of Warfarin
2583852|NCT02340988|Experimental|Warfarin 24 hours post dose|25mg dose of Warfarin given 24 hours post 1200 mg Single-Dose IV Oritavancin Diphosphate.
2583901|NCT02340507|Experimental|High glycemic index|The subject will consume a high glycemic index glutinous rice for breakfast (75g available carbohydrates), and a high glycemic index white bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
3177180|NCT00650286|Active Comparator|2|Provigil® Tablets 200 mg
3177181|NCT00650299|Experimental|1|Alprazolam Extended-release Tablets 3 mg
2583330|NCT02344329|Active Comparator|Control|TCC-EZ and Standard Wound Care (Topical wound dressing) Two dressing and cast changes in week one followed by weekly applications until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
2583331|NCT02344329|Experimental|Intervention|TCC-EZ and Human Amnion Allograft One dressing and two cast changes in week one followed by dressing change every two to three weeks and weekly cast changes until 12 weeks or closure which ever occurs first. Usual wound care would involve assessment, debridement, moist wound environment, and off-loading.
2583352|NCT02343952|Experimental|Experimental Arm|Pembrolizumab
2583434|NCT02343614|Experimental|ARM A|Patients undergoing treatment with oral celecoxib
2583486|NCT02343198|Experimental|Stimulation|Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
2583500|NCT02343198|Placebo Comparator|Placebo-control|Custom-built research muscle stimulator. Muscle stimulator is set to provide sensory stimulation but will not cause an active muscle contraction. Stimulation is also delivered to the soleus muscle through two 5x5cm electrodes.
2583538|NCT02342847||Pateints with metastatic pancreatic cancer|"Patients diagnosed with metastatic pancreatic cancer confirmed histologically or cytologically, who will be treated with chemotherapy as first-line treatment of metastatic pancreatic cancer.~This study is designed to observe patients treated in routine clinical practice, without the exclusion limitations of a clinical trial. The decision to treat patients will be performed prior to the decision to include the patient in the study.~The follow-up of patients will be performed according to standard clinical practice of each site"
2583605|NCT02342431|Active Comparator|Forced air compressible warming|Warming with a compressible forced air mattress
2583611|NCT02342431|Experimental|Forced air non-compressible|Warming with a non-compressible forced air mattress
3212145|NCT01012401|Experimental|CHESS with Clinician Report + Internet access|An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
3212146|NCT01012401|Active Comparator|Usual care with Internet access|Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
2583767|NCT02341339|Experimental|Fallopian Tube Co-culture|fallopian tube biopsy for co-culture of embryos
2583827|NCT02341053|Other|Load-measuring platform|"Load-sensing platform A load-sensing platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will gradually increase their duration of standing by up to 75% after the baseline phase."
3212147|NCT01012427|Experimental|Patients with 3.0 cm or smaller renal cancer|The interventions in this study are part of clinical care and include percutaneous image-guided biopsy, percutaneous renal tumor cryoablation, CT/MR imaging of the ablation bed, and repeat pathologic sampling of the tumor bed with percutaneous biopsy. The cryoablation is done as the therapeutic intervention in patients with small renal cancer. The CT/MR imaging is done to evaluate the treatment for residual disease after the ablation. The repeat biopsy (e.g. three cores) is done to confirm that the neoplasm has been eradicated. These patients have continued imaging, and if necessary, percutaneous biopsy to ensure no recurrent disease.
3212148|NCT01012453|No Intervention|Hand Eczema in health care workers|
2584037|NCT02339649|Other|Sepsis/septic Shock|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80; fulfill the criteria of sepsis and/or septic shock patients according to theThird International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3, Singer et al, 2016).~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
2584038|NCT02339649|Other|Postoperative ICU Patients|"Men and women seen at the intensive care units of the Anesthesiology Department of the University Hospital Bonn aged 25-80:~Admitted to the intensive care units of the Anesthesiological-Operative Intensive Care Unit of the University Hospital Bonn, which includes a surgical ICU, an anesthesiological ICU, and a cardio-surgical ICU~Duration of ICU stay must be a minimum of 24 hours.~Mini-Mental State Examination (MMSE) Score of 25 or above~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
2584039|NCT02339649|Other|Healthy Controls|"Healthy Controls will only be included in the study if they meet all of the following criteria: Written informed consent of the subject, Aged 25-80 years, Male or female.~Interventions: Neurocognitive Assessment, Clinical Scales, Questionnaires, Blood Sample, voluntary Lumbar Puncture, Resting State EEG, MRI"
2584104|NCT02339103|No Intervention|Shivering only|Pt placed in sleeping bag and warmed by shivering only
2584111|NCT02339103|Experimental|Warmed IV fluids|2 Liter of 42 degree celsius normal saline
2584115|NCT02339103|Experimental|Warmed perfusion pads|Warmed perfusion pads placed to palms and soles to rewarm through arteriovenous anastomoses
2584150|NCT02338739|Active Comparator|REC; Outreach if Failure|
2584152|NCT02338739|Active Comparator|REC; SMS + Voucher if Failure|
2584154|NCT02338739|Active Comparator|REC; Navigator if Failure|
2584156|NCT02338739|Active Comparator|SMS; Outreach if Failure|
2584158|NCT02338739|Active Comparator|SMS; Outreach if Failure; Stop SMS if Success|
2584159|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure|
2584160|NCT02338739|Active Comparator|SMS; SMS+Voucher if Failure; Stop SMS if Success|
2584162|NCT02338739|Active Comparator|SMS; Navigator if Failure|
2584165|NCT02338739|Active Comparator|SMS; Navigator if Failure; Stop SMS if Success|
2584167|NCT02338739|Active Comparator|Voucher; Outreach if Failure|
2584169|NCT02338739|Active Comparator|Voucher; Outreach if Failure; Stop Voucher if Success|
2584171|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure|
2584173|NCT02338739|Active Comparator|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|
2584177|NCT02338739|Active Comparator|Voucher; Navigator if Failure|
2584181|NCT02338739|Active Comparator|Voucher; Navigator if Failure; Stop Voucher if Success|
2584276|NCT02337855|Placebo Comparator|Group C|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
2583363|NCT02344056|Experimental|having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
2583364|NCT02344056|Experimental|skipping lunch/having lunch|no lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
2583406|NCT02343679|Experimental|Ceritinib for ALK + patients|all ALK + hematologic malignancies patients will receive ceritinib
2583446|NCT02343315|Experimental|TENS|Participants will receive Active-TENS along with SMCE and UHEP. Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
2583448|NCT02343315|Experimental|SMCE|Participants will receive SMCE and UHEP. Six sessions of supervised Motor control exercises will be provided over the period of two weeks.
2583450|NCT02343315|Active Comparator|UHEP|Unsupervised home exercise program will be prescribed with home exercise leaflet and education leaflet in the form of back book on first treatment session.
2583489|NCT02342990|Experimental|Cluster B|After the first neuropsychological assessment (T1), children will start CogMed working memory training. Children will be retested (T2) about six or seven weeks later.
2583498|NCT02342990|Other|Cluster A|After the first neuropsychological assessment (T1), children will not start any training. Children will be retested (T2) about six or seven weeks later and will start CogMed working memory training. The group will be again retest (T3) after six or seven weeks after ended training.
3212149|NCT01012479|Experimental|Candesartan QD + Hydrochlorothiazide QD|
2583635|NCT02342275|Active Comparator|Propranolol|Propranolol
2583638|NCT02342275|Active Comparator|Atenolol|Atenolol
2583679|NCT02342028||OSA|"The study group enrolled patients with OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~Has not received any treatment for OSA~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
2583681|NCT02342028||Control|"The control group enrolled age-, gender- and BMI-matched individuals without OSA, fulfilling the following requirements~20~60 years ago, female or males~Agree participate the study and sign informed consent~No obvious comorbidities (including autoimmune diseases)~No history of sarcoidosis and tuberculosis~No use of steroid and immunosuppressant"
3177182|NCT00650299|Active Comparator|2|Xanax XR® Tablets 3 mg
3177183|NCT00650312|Experimental|1|Metformin Hydrochloride ER Tablets 500 mg
3177184|NCT00650312|Active Comparator|2|Glucophage® XR Tablets 500 mg
3177185|NCT00650325|Experimental|1|Sertraline Hydrochloride Tablets 100 mg
2583838|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants immediately postpartum|LNG contraceptive implants provided within 5 days of delivery
2583849|NCT02341027|Active Comparator|Levonorgestrel (LNG) implants 6 weeks postpartum|LNG contraceptive implants provided 6-8 weeks postpartum
2583898|NCT02340429|Experimental|video otoscopy|children under 18y admitted to the pediatric emergency room for any reason, will undergo video otoscopy
2583908|NCT02340429|No Intervention|standard otoscopy|children under 18y admitted to the pediatric emergency room for any reason, undergoing routine otoscopy
2583943|NCT02340208|Experimental|L-DOS47|Patient will be recruited into cohorts of L-DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L-DOS47 will be 0.12 μg/kg; further possible dose levels include 0.21, 0.33, 0.46, 0.59, 0.78, 1.04, 1.38, 1.84, 2.45, 3.26 and 4.33 μg/kg.
2583984|NCT02339857||No-touch vein grafts to LAD|
2584076|NCT02339220|Experimental|Standard CI Therapy Group|This group will receive Constraint-Induced Movement Therapy (CIMT) with the Standard Transfer Package (sTP).
2584078|NCT02339220|Experimental|Enhanced CI Therapy Group|This group will receive CIMT with the enhanced Transfer Package (eTP).
2584080|NCT02339220|Active Comparator|Standard Fitness Training Group|This group will receive Lakeshore Enriched Fitness Training (LEFT) with the standard Transfer Package (sTP).
2584083|NCT02339220|Active Comparator|Enhanced Fitness Training Group|This group will receive LEFT with the enhanced Transfer Package (eTP)
2584124|NCT02338869|Experimental|Dialogue-based psychosocial intervention|Participants receive six individual meetings with trained health care professional in additional to usual rehabilitation and care. Dialogues focus on individual psychosocial challenges and needs and provide emotional and informational support to encourage and facilitate coping.
2584127|NCT02338869|No Intervention|Usual care Control group|Participants receive usual rehabilitation and care.
2584176|NCT02338674|Experimental|COM|COM group receives combination therapy of tenofovir and telbivudine (TDF and LdT) for at least 48 weeks
2584180|NCT02338674|Active Comparator|TDF|TDF group receives single therapy of tenofovir (TDF) for at least 48 weeks
2584277|NCT02337868|Experimental|Low Dose Expanded|15 subjects will receive 1 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
2584278|NCT02337868|Experimental|Low Dose Sentinel|5 subjects will receive 1 mcg intramuscularly (IM) of HydroVax-001 and 1 subject will receive placebo IM on Days 1 and 29.
3177186|NCT00650325|Active Comparator|2|Zoloft® Tablets 100 mg
3177187|NCT00650338|Experimental|1|<described in intervention>
3177188|NCT00650338|Experimental|2|<described in intervention>
3177189|NCT00650338|Experimental|3|<described in intervention>
3177190|NCT00650338|Placebo Comparator|4|<described in intervention>
3177191|NCT00650338|Active Comparator|5|<described intervention>
3177192|NCT00650351|Experimental|1|Ciprofloxacin Extended-Release Tablets 1000 mg
3177193|NCT00650351|Active Comparator|2|Cipro® XR Tablets 1000 mg
3177194|NCT00650364|Experimental|1|Midodrine HCl Tablets 5 mg
3177195|NCT00650364|Active Comparator|2|ProAmatine® Tablets 5 mg
3177196|NCT00650377|Experimental|1|Finasteride Tablets 5 mg
3177197|NCT00650377|Active Comparator|2|Proscar® Tablets 5 mg
3177198|NCT00650403|Experimental|1|Paroxetine hydrochloride 40 mg tablet
3177199|NCT00650403|Active Comparator|2|Paxil® 40 mg Tablet
3177200|NCT00650416|Experimental|1|Carvedilol Tablets 12.5 mg
3177201|NCT00650416|Active Comparator|2|Coreg® Tablets 12.5 mg
3177202|NCT00650429|Experimental|Arm A|
3177203|NCT00650442|Experimental|1|Estradiol Transdermal System Placebo - Alternate Adhesive
2583376|NCT02343887|Active Comparator|control group|"patients without taking into cognitive or psychological treatment for 6 months (period 1) and~if the situation improves in the neuropsychological assessment of M6 further with simple monitoring neuropsychological evaluation M12~or persistence or worsening of the disorder, the beginning of a cognitive remediation program for 6 months (period 2)."
2583378|NCT02343887|Experimental|group with cognitive rehabilitation,|"patients treated for 6 months Cognitive remediation (period 1), then~Stop if the situation improves in the evaluation and monitoring of M6 to M12 with neuropsychological assessment,~or persistence or worsening of the disorder, further cognitive remediation for 6 months (period 2)."
2583380|NCT02343887|Experimental|group with psychological support.|"patients treated with counseling for six months (period 1) and~Stop if the situation improves with neuropsychological assessment and monitoring to M12,~or if persistent or worsening unrest in the neuropsychological assessment of M6, the beginning of a cognitive remediation program for 6 months (period 2)."
3212150|NCT01012505||20 preterm infants|20 preterm infants without active disease
3177204|NCT00650442|Placebo Comparator|2|Estradiol Transdermal System Placebo - Current Adhesive
3177205|NCT00650455|Active Comparator|Arm 2|
2584012|NCT02339610||ATTUNE Primary, Cemented Total Knee Replacement|"Subjects will receive one of four available ATTUNE total knee implants:~(CR FB, CR RP, PS FB, PS RP)."
3177206|NCT00650455|Placebo Comparator|Arm 3|
2584226|NCT02338089|No Intervention|Control (no oxytocin) pretreatment|Physiological saline solution (PSS). Every 15-minutes, the PSS will be flushed and fresh PSS will be added.
2584229|NCT02338089|Active Comparator|Continuous oxytocin (desensitizing) pretreatment|Continuous oxytocin 10-5M. This desensitizing treatment is based on previous experiments in our laboratory demonstrating this phenomenon (reference 25 of Internal Review). The desensitizing pretreatment mimics the clinical setting of labor augmentation. Every 15-minutes, the 10-5M oxytocin will be flushed and fresh 10-5M oxytocin will be added.
2584237|NCT02338089|Active Comparator|Pulsatile oxytocin pretreatment|15-minutes of 10-5M oxytocin, followed by PSS for 15-minutes, followed by 10-5M oxytocin, followed by 15-minutes PSS, and so-on, for a total duration of two-hours,
2584266|NCT02337855|Experimental|Group A|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113
2584271|NCT02337855|Experimental|Group B|N=10 subjects will receive single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
2584446|NCT02336659|Experimental|DPP-4 Inhibition|Mixed meal test and ad libitum meal test during intake of sitagliptin 100 mg * 2
3177207|NCT00650455|Active Comparator|Arm 1|
3177208|NCT00650468|Experimental|1|early steroid cessation
3177209|NCT00650468|Experimental|2|long-term maintenance steroids
3177210|NCT00650481|Experimental|1|Oxybutynin Chloride Extended-release Tablets 5 mg
3177211|NCT00650481|Active Comparator|2|Ditropan XL® Tablets 5 mg
3177212|NCT00650494|Experimental|1|Valacyclovir Hydrochloride Tablets 1000mg
3177213|NCT00650494|Active Comparator|2|Valtrex® Tablets 1000 mg
3177214|NCT00650507|Experimental|1|
3177215|NCT00650507|Active Comparator|2|
3177216|NCT00650520|Experimental|1|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL)and BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg
3177217|NCT00650520|Active Comparator|2|Metoclopramide Hydrochloride Injection Sandoz Standard 5mg/mL (10mg/2mL) and Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
3177218|NCT00650533|Experimental|1|Glimepiride Tablets 1 mg
3177219|NCT00650533|Active Comparator|2|Amaryl® Tablets 1 mg
3177220|NCT00650559|Experimental|1|Experimental surgical intervention.
3177221|NCT00650572|Experimental|ARRY-380|
3177222|NCT00650598|Active Comparator|Arm 1|
3177223|NCT00650598|Active Comparator|Arm 2|
3177224|NCT00650611|Active Comparator|Low-Dose Ziprasidone|
3177225|NCT00650611|Active Comparator|High-Dose Ziprasidone|
3177226|NCT00650624|Active Comparator|Arm 1|
3177227|NCT00650624|Active Comparator|Arm 2|
3177228|NCT00650624|Active Comparator|Arm 3|
3177229|NCT00650624|Placebo Comparator|Arm 4|
3177230|NCT00650637|Experimental|1|
3177231|NCT00650637|Experimental|2|
3177232|NCT00650663|Experimental|Ezetimibe + Simvastatin|
3177233|NCT00650663|Active Comparator|Simvastatin|
3177234|NCT00650676||A|
3177235|NCT00650689|Experimental|Ezetimibe + Atorvastatin|
3177236|NCT00650689|Active Comparator|Atorvastatin|
3177237|NCT00650702|Experimental|1|Low Latanoprost-PPDS
3177238|NCT00650702|Experimental|2|Medium Latanoprost-PPDS
3177239|NCT00650702|Experimental|3|High Latanoprost-PPDS
3177240|NCT00650715|Active Comparator|VG|Vibration Group (VG) underwent a protocol with whole-body vibration exercise twice a week for a total of six weeks. The group continued with their usual pharmacological treatment.
3177241|NCT00650715|Placebo Comparator|CG|The Control Group (CG) underwent the same protocol of exercises than VG but without vibratory stimulus. The CG continued with their usual pharmacological treatment.
3177242|NCT00650741||1|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), no repetition of test
3177243|NCT00650741||2|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), Repetition with Nitroglycerin
3177244|NCT00650741||3|10 subjects, Half with Endothelial Dysfucntion (according to previous ultrasound FMD) , Half with no endothelial dysfucntion (according to previous ultrasound FMD), repetition of test with the Endotect
3177245|NCT00650754|Experimental|DHEA|Dehydroepiandrosterone (DHEA) administered at a dose of 25 mg tid po. DHEA is a weak androgen produced naturally by the adrenal in men and women. DHEA production is diminished with increasing age. Peak levels of DHEA occur in the late teenage years.
3177246|NCT00650754|Placebo Comparator|Placebo|Blinded placebo
3177247|NCT00650780||1|All of the subjects will have measurements of Gc concentration and phenotype
3177248|NCT00650819|Experimental|Ezetimibe + Simvastatin|
3177249|NCT00650819|Active Comparator|Simvastatin|
3177250|NCT00650819|Active Comparator|Ezetimibe|
2583398|NCT02343718|Experimental|Vinblastine and Temsirolimus|"Vinblastine starting dose:~Weight >12 kg 4mg/m^2 Weight ≤ 12 kg 0.13mg/kg IV push for 1 minute Days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles.~Temsirolimus starting dose:~Weight >12 kg 15mg/m^2 Weight ≤ 12 kg 0.5 mg/kg IV for 1 hour on days 1, 8, 15, 22, 29 and 36. Cycle length is 6 weeks up to 6 cycles."
2583464|NCT02343341|Experimental|Preschool Health Promotion Education Program|Children randomized to the intervention arm will receive a 4-month health promotion education program along with their parents/caregivers and teachers.
2583465|NCT02343341|Other|Control:Standard Curriculum|"The Standard curriculum control arm will receive the standard curriculum in their schools.~Children randomized to the control arm will receive the health promotion education program for 4 months after the intervention arm has completed it"
2583512|NCT02342938|Experimental|Patient|
2583514|NCT02342938|Experimental|Volunteers|
3212151|NCT01012518|Active Comparator|Conventional PCT|PCT performed without video guidance, as conventionally performed
3212152|NCT01012518|Experimental|Video-assisted PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
2583667|NCT02342067|Experimental|Group 1 (Cenicriviroc, PGZ, CVC+PGZ)|Treatment A: CVC 150 mg QD for 10 days followed by 10-day washout Treatment B: PGZ 45 mg QD for 10 days Treatment C: co-administration of PGZ 45 mg QD + CVC 150 mg QD for 10 days
2583668|NCT02342067|Experimental|Group 2 (Pioglitazone, CVC, CVC+PGZ)|Treatment B: PGZ 45 mg QD for 10 days followed by 10-day washout Treatment A: CVC 150 mg QD for 10 days Treatment C: co-administration of CVC 150 mg QD + PGZ 45 mg QD for 10 days
2583701|NCT02341794|Experimental|Rosuvastatin|
2583803|NCT02341287|Active Comparator|Warming hydrogel glove|"Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Warming hydrogel device"
2583806|NCT02341287|Placebo Comparator|Non thermal hydrogel glove|"Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.~Non thermal hydrogel device"
2583841|NCT02340936|Experimental|LR-ESHAP (lenalidomide 5 mg)|Intervention: lenalidome 5mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 5 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
2583854|NCT02340936|Experimental|LR-ESHAP (lenalidomide 10mg)|Intervention: lenalidome 10mg combined with R-ESHAP( 3 cycles of treatment every 21 days: lenalidomide 10 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
2583858|NCT02340936|Experimental|LR-ESHAP (lenalidomide 15mg)|Intervention: lenalidome 15mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 15 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
2583859|NCT02340936|Experimental|LR-ESHAP (lenalidomide 20mg)|Intervention: lenalidome 20mg combined with R-ESHAP (3 cycles of treatment every 21 days: lenalidomide 20 mg/day (day 1 to 14 except cycle 2 that will be administered from day 1 to 10), etoposide 40 mg/m2/day (day 1 to day 4), methylprednisolone 500 mg/day (day 1 to day 5), cisplatin 25 mg/m2/day (day 1 to day 4), cytarabine 2000 mg/m2 (day 5) and rituximab 375 mg/m2 (day 1 or 5)).
2583896|NCT02340351|Active Comparator|Auricular acupuncture|Within this arm, patients were treated with auricular acupuncture according to the NADA protocol. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes and took place twice a week over a period of 4 weeks.
2583906|NCT02340351|Active Comparator|Progressive muscle relaxation|Within this arm, patients were treated with who chose treatment with progressive muscle relaxation. Each setting involved not more than eight patients at a time and was performed in a sitting position. Each session lasted 30 minutes, took place twice a week over a period of 4 weeks.
2583953|NCT02340130|Experimental|DP/MG/14-1|DP/MG/14-1: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised B. tropicalis 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
2583958|NCT02340130|Experimental|DP/MG/14-2|DP/MG/14-2: Depigmented modified allergen extract of D. pteronyssinus 50% / Depigmented, glutaraldehyde-polymerised L.destructor 50% (200DPP/mL) The administration regimen will consist of a rush build-up régimen and a follow up period
2583993|NCT02339792|Other|Intervention|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
2583996|NCT02339792|Other|Control|e-learning program of medical education, focused on teaching only geriatric pharmacological notions (GPNs)
3212153|NCT01012531|Active Comparator|highly polymerized allergen extract|
2584161|NCT02338817||GSD 1|These will be subjects with GSD I. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
2584163|NCT02338817||GSD 0, III, VI, or IX|These will be subjects with GSD 0, III, VI, or IX. The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
2584252|NCT02337998|Experimental|Healthy men|each individual will serve as his own control by comparing baseline values to post intervention values
2584267|NCT02337868|Experimental|High Dose Expanded|15 subjects will receive 4 mcg of HydroVax-001 IM and 4 subjects will receive placebo IM on Days 1 and 29.
2584272|NCT02337868|Experimental|High Dose Sentinel|5 subjects will receive 4 mcg of HydroVax-001 IM and 1 subject will receive placebo IM on Days 1 and 29.
3212154|NCT01012531|Placebo Comparator|Placebo|
3212155|NCT01012544|Active Comparator|stent thrombosis patients|Patients with a history of a stent thrombosis
3212156|NCT01012544|Active Comparator|Patients without a history of a stent thrombosis|Patients without a history of stent thrombosis
3212157|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 7.5 mcg H1N1v full MF59 adjuvant|
3212158|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 3.75 mcg H1N1v half MF59 adjuvant|
2583417|NCT02343471|Experimental|20 g whey protein|20 g whey protein dissolved in 200 milliliter (mL) water is consumed as a pre-meal 15 min prior to the main meal. Additionally, 200 mL water is consumed as a part of the main meal.
2583425|NCT02343471|Placebo Comparator|Water|200 milliliter (mL) water consumed as pre-meal 15 min prior to the main meal. 20 g whey protein dissolved in 200 mL water is consumed as a part of the main meal.
2583484|NCT02343211|Experimental|immunoglobulin|
2583533|NCT02342873|Active Comparator|NS-guided interscalene block|NS-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
2583546|NCT02342873|Experimental|US-guided interscalene block|US-guided interscalene block is performed using 20 ml of 0.75% ropivacaine.
2583578|NCT02342509|Experimental|Desflurane|Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
2583579|NCT02342509|Experimental|Sevoflurane|Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
2583582|NCT02342509|Active Comparator|Isoflurane|Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
2583644|NCT02342184|Experimental|GB-0998|
2583691|NCT02341976|Other|Vibratory platform exercises|Vibratory platform exercises: different positions on a vibratory platform in different frequencies
3212159|NCT01012557|Active Comparator|Pregnant women (>20 weeks), 15 mcg H1N1v unadjuvanted|
3212160|NCT01012557|Active Comparator|Non-pregnant mothers, 7.5 mcg H1N1v full MF59 adjuvant|
3212161|NCT01012596||Creighton Model|New and return users of the Creighton Model FertilityCare System, a method of Natural Family Planning.
3212162|NCT01012635||Neurofeedback, tDCS (2 levels), Self-hypnosis, Meditation|
3212163|NCT01012700|No Intervention|intranasal or IV|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
2583864|NCT02340650||Bladder Cancer Patients|High resolution images of normal bladder tissue and suspicious bladder lesions will be collected from patients who present to the study site for clinical evaluation.
2583887|NCT02340455|Experimental|Pregabalin_male|
2583889|NCT02340455|Experimental|Pregabalin_female|
2583891|NCT02340455|Active Comparator|Placebo_male|
2583892|NCT02340455|Active Comparator|Placebo_female|
3212164|NCT01012700|Active Comparator|Hiltonol (poly ICLC)|Each study group consists of 12 volunteers randomized in a 2:1 ratio to receive poly ICLC or placebo: in group 1, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, subcutaneously; and in group 2, 8 volunteers will be administered poly ICLC and 4 volunteers will be administered placebo, intranasally. A total of up to 24 volunteers will be enrolled in the study.
2584025|NCT02339636||case group|100 patients with vulgaris psoriasi without arthritis
2584028|NCT02339636||control group|100 age-matched patients with other skin diseases without arthritis
2584073|NCT02339272||NOA|Infertile males with non obstructive azoospermia
2584074|NCT02339272||OA|Post-vasectomized patients with proven fertility before vasectomy
3212165|NCT01012752|Active Comparator|modified allergen extract|
2584317|NCT02337504|No Intervention|clinic-based care|Will receive HIV care at the clinic from the nurses and clinical officer on their regular schedule
2584319|NCT02337504|Active Comparator|Community-based care|Will receive HIV care in their community from a community health worker every month as part of a group of 6-10 people
3212166|NCT01012752|Placebo Comparator|Placebo|
3212167|NCT01012778|Experimental|Climbup ADHD and Dyslexia Program|"Open label - intervention with pre and post parameters collected~Intervention: Yoga, Meditation, Play therapy for children with ADHD and Dyslexia twice a week in classroom with 6 week and 12 month, primary outcomes in terms of Vanderbilt ADHD scores"
3212168|NCT01012791|Experimental|Zumba exercise group|
3212169|NCT01012791|No Intervention|Non-Zumba exercise group|
3212170|NCT01012817|Experimental|Treatment (veliparib and topotecan hydrochloride)|Patients receive veliparib PO on days 1-3, 8-10, and 15-17 (veliparib is omitted on days 1-3 of course 2) and topotecan hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3212171|NCT01012830|Experimental|Huperzine A|200 micrograms (mcg) of HuperzineA taken twice daily.
3212172|NCT01012843|Active Comparator|Antibiotic|Patients who received antibiotic treatment after abscess drainage
3212173|NCT01012843|Placebo Comparator|Placebo|Patients who received placebo after abscess drainage
3212174|NCT01012856|Active Comparator|Cognitive-Behavioral Therapy for Depression (CBT)|
3212175|NCT01012856|Experimental|Exposure-Based Cognitive Therapy for Depression (EBCT)|
3212176|NCT01012869|Experimental|everolimus-eluting stent|patients undergoing treatment of a coronary chronic total occlusion (at least 3-months old) using everolimus-eluting stents (Xience, Abbott Vascular) or Promus (Boston Scientific)
2584657|NCT02335190|Experimental|PSN block and RF ablation|Participants will first undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. On a separate visit, participants will then undergo ablation of the PSN at the lateral crest under ultrasound-guidance.
3212177|NCT01012882|Experimental|sublingual application of allergen extract|
3212178|NCT01012882|Placebo Comparator|sublingual application of placebo|
3212179|NCT01012895|Experimental|Arm 1: Sentinel A|BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
3212180|NCT01012895|Experimental|Arm 2: Sentinel B|BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
3212181|NCT01012895|Experimental|Arm 3: Expansion A1|BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
3212182|NCT01012895|Experimental|Arm 4: Expansion A2|BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
3212183|NCT01012895|Experimental|Arm 5: Expansion B1|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
3212184|NCT01012895|Experimental|Arm 6: Expansion B2|BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
3212185|NCT01012895|Experimental|Arm 7: Expansion B3|BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin
2583442|NCT02343354|Experimental|Nutrition/physical activity intervention|There will be five in-person group sessions (3 to 4 weeks appart) with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website, telephone calls and phone applications.
2583485|NCT02343133|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
2583499|NCT02343133|Placebo Comparator|Placebo|Single subcutaneous dose
3212186|NCT01012908|Experimental|Norzyme|Pancreatic Enzymes - Norzyme (Bergamo)
3212187|NCT01012908|Active Comparator|Creon (Solvay)|Pancreatic Enzymes - Creon (Solvay)
3212188|NCT01012934|Experimental|1|Alendronate Sodium Tablets, 70 mg
3212189|NCT01012934|Active Comparator|2|Fosamax Tablets, 70 mg
2583835|NCT02340689||Genetic testing|Genetic Analysis
2583903|NCT02340390|Experimental|Hip implant1|The Biomet G7 Acetabular System is a modular acetabular system, offering two types of acetabular shells. The shells are available in either a solid shell design, with an apical plug, or a limited hole with an apical plug and optional screw holes. Components are available in numerous designs and sizes intended for both primary and/or revision applications.
2583913|NCT02340390|Experimental|Hip implant2|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
2583982|NCT02340026|Experimental|Conventional Therapy|"The conventional treatment group will receive traditional, therapist-directed pediatric physical therapy. Therapy will focus on early gait training strategies and encouragement of normal movement patterns for walking and other age-appropriate movements, with manual guidance or correction of atypical movements from the therapist. This group may use assistive devices, orthoses, and may receive static body weight support for gait training. Therapy activities will be performed in blocks of practice, with the specific activities and level of therapist assistance tailored to each child."
2583983|NCT02340026|Experimental|Dynamic Supported Mobility|Children will receive dynamic weight support during all DSM treatment time. The environment will be arranged to encourage active motor exploration, somewhat similar to a play gym for toddlers, to promote the motor variability, engagement, and error experiences that characterize the typical development of upright motor skills and walking. The floor area within 3 feet below either side of the overhead track for a distance of 20 feet (approximately 120 ft2 total) will be defined with colorful thin rubber interlocking mats and arranged with pediatric toys and activities, tailored to the child's interests and to encourage motor skills just beyond his/her current ability. The therapist will minimally assist the child as needed to perform the movements he/she initiates.
2584004|NCT02339623||threatened preterm labour|"Women who are diagnosed as having threatened preterm labour based on the American college of obstetricians and gynaecologists guidelines (ACOG,2003) :~Presence of uterine contractions ( at least 4 in 20 minutes or 8 in 60 minutes )~Cervical dilataion >1cm, &/or~Cervical effacement ≥ 80%"
2584059|NCT02339467|Experimental|GO-OUT program|An outdoor walking workshop with stations to learn various outdoor walking skills and information, followed by a supervised, group based outdoor walking program, twice a week for 60 minutes, for 3 months.
2584063|NCT02339467|Active Comparator|Task-oriented outdoor walking workshop|An outdoor walking workshop with stations to learn various outdoor walking skills and information.
2584151|NCT02338765|Experimental|Buddy|Physical activity plus having a buddy
2584153|NCT02338765|Active Comparator|Control|Physical activity only
2584202|NCT02338427|Experimental|proteomic|
2584231|NCT02338102|Experimental|Treatment Group|Subjects in this group will perform twice daily nasal irrigations. Nasal irrigations will be performed by using premeasured salt packets mixed with distilled water in NeilMed irrigation bottles. The subject will be instructed to lean forward over the sink, place the bottle up to the nostril, and hold their breath while gently squeezing the bottle. One bottle is used to irrigate both nostrils, using half the solution on each side.
2584235|NCT02338102|No Intervention|Control Group|Subjects randomized to this arm receive no intervention.
2584414|NCT02337088|Active Comparator|30 seconds|For subjects in the 30 second arm, the umbilical cord will be clamped at 30 seconds after delivery.
2584416|NCT02337088|Experimental|60 seconds|For subjects in the 60 second arm, the umbilical cord will be clamped at 60 seconds after delivery.
2584448|NCT02336633|Experimental|1|Resveratrol (80mg/j = 4 capsules/day)
2584449|NCT02336633|Placebo Comparator|2|Placebo (4 capsules/day)
3212190|NCT01012960|Placebo Comparator|Placebo|Placebo= normal saline
3212191|NCT01012960|Active Comparator|methylnaltexone|peripheral opioid antagonist
3212192|NCT01012986||2nd Grade|students of 2nd grade
3212193|NCT01012986||4th Grade|students of 4th Grade
2584573|NCT02335944|Experimental|INC280 plus EGF816|Recruitment in Phase I dose escalation part is completed. Recruitment in Phase II dose expansion is ongoing.
2584652|NCT02335138|Placebo Comparator|Control Arm|Each participant will receive an at-home test kit and will be asked to test and return results to investigator.
2584661|NCT02335138|Active Comparator|Intervention Arm|Each participant will receive an at-home test kit and will be asked to take the test in conjunction with an online CHTC session.
2584729|NCT02334605|Other|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
3212194|NCT01013012|Active Comparator|Group A|Group A : saline 1 ml + ramosetron 6μg/kg
3212195|NCT01013012|Experimental|Group B|Group B : dexamethasone 4 mg + ramosetron 6μg/kg
3177251|NCT00650884|No Intervention|1|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CONTROL PATIENTS will only be treated with Standard of Care during this 12 week trial, but will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch after completion of this study.
3177252|NCT00650884|Experimental|2|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). EXPERIMENTAL PATIENTS will also be treated with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
3177253|NCT00650884|Other|3|ALL PATIENTS WILL BE TREATED WITH STANDARD OF CARE (Orthoses, NSAIDs, Home therapy instructions). CROSS-OVER patients will be initially treated only with Standard of Care, and after six weeks, they will be Crossed-Over and fit with the Ankle Dorsiflexion Dynasplint System which delivers a low-load, prolonged-duration stretch while sleeping.
3177254|NCT00650897|Experimental|A|Patients with Diabetes Mellitus and Major Depression
3177255|NCT00650910|Experimental|lapatinib + digoxin|All subjects received 0.5mg digoxin on Days 1 and 9 with daily dosing of 1500mg oral lapatinib starting on Day 2 and continuing through Day 9. Subjects could continue past Day 9 on daily oral lapatinib until Week 10 when they could transfer into a rollover study (EGF19060 or EGF111767).
3177256|NCT00650923|Experimental|Arm 1|See Detailed Description
2583700|NCT02341742||Patients|follow up of patients (children and adolescent) with inflammatory bowel disease in looking for the relationship between the bone mineral density and physical activity.
2583873|NCT02340637|Experimental|Coping Kids|"A Program for Managing Anxiety and Depression (P.C Kendall et al., 2013) is a newly developed group intervention targeting children aged 8 to 13 years who experience difficulty with symptoms of anxiety, depression, or both. The program is designed as an indicated prevention intervention to reduce the symptom levels and reduce the likelihood of the development of an anxiety disorder and/or depression.~The youth-focused sessions are designed for implementation in school settings, and the program includes parent group meetings.~All groupleaders participate in a three days training, followed by supervision. Manuals and workbooks are provided by the project. In addition is the same presentation as in TAU offered to the schools."
2583874|NCT02340637|Active Comparator|TAU|The teachers and school-nurses in the control schools will conduct treatment as usual (TAU).The project offers a 2,5 hours presentation to the schools, providing general information about the research study, the prevalence of emotional disorders and how to handle emotional disorders in treatment as usual. No materials are provided by the project.
2583974|NCT02340013|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate 10mg per os x 10 days prior to starting clomiphene citrate 50mg once daily days 3 - 7 of bleeding after stopping medroxyprogesterone acetate
2583976|NCT02340013|No Intervention|Control|Women are assigned to start clomiphene citrate 50mg tabs x 5 days on an assigned day, without any vaginal bleeding
2584019|NCT02339727|Active Comparator|Omega-6/omega-3=2/1 milk formula|Preterm infants will receive a formulas supplemented with Docosahexaenoic acid and Arachidonic acid with a relationship omega 6/omega 3 = 2/1.
2584021|NCT02339727|Active Comparator|Omega-6/omega-3=1/1 milk formula|preterm infants will receive other formulas with Docosahexaenoic acid and Arachidonic acid, but with a ratio of 1/1.
3177257|NCT00650949|Experimental|CYT997|
3177258|NCT00650962|Active Comparator|CPR first|Compression First (CF)
3177259|NCT00650962|Active Comparator|Analysis First|Rhythm analysis first
3177260|NCT00650975|Active Comparator|ELCA|Laser Thromboablation
3177261|NCT00650975|Active Comparator|PTCA|PTCA (Direct Stenting)
3177262|NCT00650988|Experimental|Barrett's Esophagus with intramucosal carcinoma (IMCA)|
3177263|NCT00650988|Experimental|Barrett's Esophagus with High Grade Dysplasia (HGD)|
3177264|NCT00651014|Experimental|Ezetimibe|
3177265|NCT00651014|Placebo Comparator|Placebo|
3177266|NCT00651027|Experimental|A|
3177267|NCT00651027|Experimental|B|
3177268|NCT00651027|Experimental|C|200 mg
3177269|NCT00651066|Experimental|1|RBT (150 mg TPW during 3 weeks switch to 150mg OD for the following 3 weeks) associated with LPV/r based ART
3177270|NCT00651066|Experimental|2|RBT (150 mg OD during 3 weeks switch to 150mg TPW for the following 3 weeks) associated with LPV/r based ART
3177271|NCT00651092|Active Comparator|A1|since the two methods of turbinectomy are in used on a regular basis there is no way to perform double blind study- both the surgeon and the patients are well aware of the operation they are about to go. we just compare several parameters in patients who are anyway about to undergo an operation in a specific method that is used by their surgeon
3177272|NCT00651092|Active Comparator|A2|the resection of the inferior turbinates will be performed endonasally with an endoscopical instruments
3177273|NCT00651105|Experimental|1|
3177274|NCT00651105|Placebo Comparator|2|
3177275|NCT00651144|Experimental|Ezetimibe + Rosuvastatin|
3177276|NCT00651144|Active Comparator|Ezetimibe|
3177277|NCT00651144|Active Comparator|Rosuvastatin|
3177278|NCT00651144|Placebo Comparator|Placebo|
3177279|NCT00651196||1|Type 1 diabetics
3177280|NCT00651196||Healthy controls|Healthy age and sex matched controls
3177281|NCT00651209|Experimental|1|Sub-group 1- continue telbivudine if HBV DNA non-detectable at week 24 Sub-group 2- tenofovir added to telbivudine in patients if HBV DNA detectable at week 24
3177282|NCT00651222||1|All deceased patients who underwent brachytherapy at Chicago Prostate Center between 10/14/1997 and 6/15/2007
3177283|NCT00651235|Experimental|B|In combination therapy,the maximal dose of Losartan is 100 mg/day for adult and 50 mg/day for children. 50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children
3177284|NCT00651235|Active Comparator|A|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
3177285|NCT00651274|Experimental|Ezetimibe|
3177286|NCT00651274|Placebo Comparator|Placebo|
3177287|NCT00651287|Active Comparator|quinapril 20 mg|
3177288|NCT00651287|Active Comparator|quinapril 20 mg+hydrochlorothiazide 12.5 mg|
3177289|NCT00651287|Active Comparator|quinapril 40 mg|
3177290|NCT00651300|Experimental|Group 1|
3177291|NCT00651300|Placebo Comparator|Group 2|
2583694|NCT02341924|Experimental|Portfolio of functional foods|"A portfolio of functional foods provided as packaged shelf-stable food products (Step One Treatment) which will include foods such as oatmeal, pancakes, cranberry bars, chocolate bars, smoothies, and a sprinkle offering which can be added to almost any food to enhance its nutritional impact.~All products are interchangeable in terms of their nutrients of interest and contain a minimum of 5 g of fibre, 1800 mg of omega-3 fatty acids, 1000 mg of phytosterols and 1800 µmol antioxidants per serving. Calorie counts range from 110-190 kcal per serving."
2583697|NCT02341924|Placebo Comparator|Control foods|Control products will be like-items drawn from the general grocery marketplace. Test and control products will be packaged and coded identically.
2583731|NCT02341521|Experimental|OC000459 50 mg|OC000459 50 mg daily for 8 days
2583800|NCT02341313||Newborns at risk of hypoglycaemia|Measurement of ketones
2583848|NCT02341014|Experimental|Carfilzomib, Romidepsin, Lenalidomide|All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle. Once a MTD is determined this dosing level will be used for the phase IIa portion. Cycles will be continued as above until the patient's wishes to be removed from the study, unacceptable toxicity develops, disease progression, treating physician recommends removal, or termination of study occurs.
2583897|NCT02340403|Experimental|Oxaliplatin and neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
2583907|NCT02340403|Other|Oxaliplatin without neuropathic pain|The objective of this study is to demonstrate a significant increase in choline concentration in the insular cortex of patients with an oxaliplatin induced neuropathy. Other objectives will assess the correlation between metabolite concentrations in the insular cortex and frequency / intensity of pain and neuropathic symptoms, cold and heat-induced pain and comorbidities (anxiety, pain, quality of life).
3212196|NCT01013025||Patients treated with Vantas implant|Patients were enrolled if they had had a Vantas implant placed for treatment of adenocarcinoma of the prostate, and if the patients were scheduled for explant of the implant, and the physician had difficulty locating the implant.
2584005|NCT02339662|Active Comparator|gabapentin|900 mg per day total, 3 pills of 300mg.
2584007|NCT02339662|Active Comparator|amitriptyline|20 mg total, 1pill
2584102|NCT02339090|Experimental|somavaratan|somavaratan long acting recombinant human growth hormone administered subcutaneously twice-monthly
2584108|NCT02339090|Active Comparator|Daily rhGH|Daily recombinant growth hormone therapy administered subcutaneously every day
2584174|NCT02338700|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
2584178|NCT02338700|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
2584240|NCT02338297|Experimental|TACE+EGM|Occlude APS with EGM and perform TACE sequentially
2584247|NCT02338297|Active Comparator|TACE+PVA|Occlude APS with PVA and perform TACE sequentially
3212197|NCT01013038|Active Comparator|Conventional percutaneous coronary intervention|
2584394|NCT02337205|Experimental|KX2-391 Ointment|
2584453|NCT02336828||MEWS alarm and mortality|Reach MEWS Alarm, Not reach MEWS Alarm, With 7 day mortality, Without 7 day mortality
2584497|NCT02336412|Experimental|SMS reminder|Daily SMS medication reminder
2584498|NCT02336412|No Intervention|No SMS reminder|No daily SMS medication reminder
3212198|NCT01013038|Experimental|Thrombus aspiration|
3212199|NCT01013051||Post Gastric Bypass|
3212200|NCT01013051||Obese Controls|age, BMI, gender matched
3212201|NCT01013064|Experimental|Cohort1|
3212202|NCT01013064|Experimental|Cohort2|
2584680|NCT02335047|Other|lower back pain|
2584718|NCT02334826|Active Comparator|PCI - BVS|percutaneous coronary intervention with the use of bioresorbable scaffolds (Absorb)
2584719|NCT02334826|Active Comparator|CABG|coronary artery bypass grafting
2584772|NCT02334462|Experimental|Group 1- Mali|Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530
2584773|NCT02334462|Experimental|Group 1-U.S|Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.
2584775|NCT02334462|Experimental|Group 2- Mali|Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530
2584777|NCT02334462|Experimental|Group 2-U.S|Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.
2584779|NCT02334462|Experimental|Group 3- Mali|Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530
2584780|NCT02334462|Experimental|Group 3- U.S.|Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.
2584781|NCT02334462|Active Comparator|Group 4- Mali|Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530
3212203|NCT01013064|Experimental|Cohort3|
3212204|NCT01013064|Experimental|Cohort4|
3212205|NCT01013064|Experimental|Cohort5|
3212206|NCT01013064|Experimental|Cohort6|
3212207|NCT01013077|Experimental|Optive|Commercial drop.
3212208|NCT01013077|Experimental|Soothe|Commercial drop.
3212209|NCT01013077|Experimental|New Emulsion|New formulation.
3212210|NCT01013090|Active Comparator|Epidural crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
2583699|NCT02341846||Healthcare professionals|Healthcare professionals whose role involves the management of cancer pain.
2583720|NCT02341534|Other|BioMonitor arm|BioMonitor group (standard of care and implantation with investigational device)
2583723|NCT02341534|No Intervention|Control arm|Control group (standard of care)
2583844|NCT02340858|Experimental|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
2583857|NCT02340858|No Intervention|Control|The patients without treatment
3212211|NCT01013090|Active Comparator|Epidural colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-epidural anesthesia in patients undergoing Cesarean section
3212212|NCT01013090|Active Comparator|Spinal crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
3212213|NCT01013090|Active Comparator|Spinal colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-spinal anesthesia in patients undergoing Cesarean section
3212214|NCT01013090|Active Comparator|CSEA crystalloid|Crystalloid (Ringer's Lactate) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
2584089|NCT02339194|Experimental|Simplified protocol|"The application of a simplified denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Obtainment of maxillary and mandibular casts by using irreversible hydrocolloid in stainless steel stock trays for record bases fabrication.~Adjustment of record bases according to vertical dimension and centric relation measurements, with no use of facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Insertion of finished dentures."
2584091|NCT02339194|No Intervention|Traditional protocol|"The importance of a second impression for denture fabrication technique will be tested for patients presenting severely resorbed mandibular alveolar bones according to the following steps:~Maxillary and mandibular casts obtained by using irreversible hydrocolloid in stainless steel stock trays for maxillary record base and mandibular custom tray fabrication.~Mandibular second impression with border molding using compound and impression rubber in custom tray.~Record bases adjustments without facebow transfer. Casts will be mounted in semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationship.~Finished dentures insertion."
3212215|NCT01013090|Active Comparator|CSEA colloid|Colloid (6% hydroxyethyl starch) is given pre-, co- and post-CSEA anesthesia in patients undergoing Cesarean section
3212216|NCT01013103|Other|Atorvastatin, Ischemic Heart Disease|
2584203|NCT02338388|Active Comparator|Single-layer unlocked closure|
2584204|NCT02338388|Active Comparator|Single-layer locked closure|
2584206|NCT02338388|Active Comparator|Double-layer closure|The first layer was continuous and unlocked and a second, continuous non-locking imbricating layer was applied over the first suture.
3212217|NCT01013103|Placebo Comparator|Atorvastatin vs Placebo Cardiac Surgery|
2584282|NCT02337699||Treated Subjects|All subjects recruited into the main study treated with the Axium neurostimulator
2584286|NCT02337699||QST Group|A sub-set of the main study group who also consent to take part in the Quantitative Sensory Testing based feasibility study
2584326|NCT02337543|Experimental|Active: NEO6860|NEO6860 suspension is the drug under evaluation
2584329|NCT02337543|Placebo Comparator|placebo|Placebo matching NEO6860 suspension formulation
2584350|NCT02337283|Experimental|BI 425809 very low dose - part I|Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days
2584351|NCT02337283|Placebo Comparator|Placebo - part I|Part I only - placebo tablet, oral administration with 240ml water, over 14 days
2584353|NCT02337283|Experimental|BI 425809 low dose - part I|Part I - low dose tablet, oral administration with 240 ml water, over 14 days
2584354|NCT02337283|Experimental|BI 425809 medium dose - part I|Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days
2584355|NCT02337283|Experimental|BI 425809 high dose -part I|Part I only - high dose tablet, oral administration with 240 ml water, over 14 days
2584356|NCT02337283|Experimental|BI 425809 low dose - part II|Part II - one low dose tablet on day 1 of visit 2 and 2a
2584361|NCT02337283|Experimental|BI 425809 very high dose -part I|Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days
2584396|NCT02336997|Experimental|FAT-GRAFT|Fat graft transplantation
2584399|NCT02336997|Experimental|SVF-TRANSPLANTATION|Transplantation of resuspended SVF
2584402|NCT02336997|Placebo Comparator|CONTROL|Same volume saline injection
2584466|NCT02336672|No Intervention|Group A Chemotherapy|Patients receiving chemotherapy alone. These patients start standard chemotherapy right after the oncologist's evaluation according to accepted Guidelines of the Italian Association of Medical Oncologists (AIOM). Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
2584469|NCT02336672|Experimental|Group B Chemotherapy + HybridTherm|Patients receiving chemotherapy plus EUS-guided Cryothermal Ablation with HybridTherm probe. These patients are first treated by cryothermal ablation and one week after they start with chemotherapy. Cryothermal ablation can be performed up to three times, with interval of 4 +/- 1 weeks. Restaging is performed 2, 4 and 6 months after chemotherapy onset, with MDCT scan and DW-MRI.
2584508|NCT02336334|Experimental|With macular hole|"Inclusion of patients with macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch Closure rate of macular holes"
2584510|NCT02336334|Experimental|Without macular hole|"Inclusion of patients without macular holes and randomized allocation to sensor-types and information-types~Interventions:~Positioning measurement Patient feedback Usefulness of a sketch"
3212218|NCT01013116|Experimental|modified allergen extract of house dust mites|
3212219|NCT01013116|Placebo Comparator|Placebo|
3212220|NCT01013142|Experimental|MN-221|
3212221|NCT01013142|Placebo Comparator|MN-221 Placebo|
3212222|NCT01013168|Experimental|OncoSorb® column|
2583902|NCT02340598|Experimental|cold vest|Participants are given a cold vest that the pre-cool in a freezer. They are encouraged to use it daily to activate metabolism through brown adipose tissue and shivering.
2583914|NCT02340598|No Intervention|control|No intervention, just recording of risk factors and basal metabolic rate.
2583952|NCT02340169|Experimental|Topicort® Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25%, twice a day for 28 days
2584009|NCT02339870|Experimental|Arm I (expressive disclosure)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about their emotions pertaining to managing and providing care for the cancer patient.
2584014|NCT02339870|Experimental|Arm II (benefit finding)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about any benefits that have arisen because of the cancer diagnosis.
2584016|NCT02339870|Sham Comparator|Arm III (control)|Participants complete an anonymous 20 minute writing exercise at home on their computer once per week for 2 weeks (days 2, 9, and 16 for a total of 3 sessions). Participants write about an emotionally neutral topic.
2584052|NCT02339324|Experimental|This study has one arm that consists of 3 phases or steps.|"Induction phase (first 6 weeks): Pembrolizumab and High Dose IFNα-2b (HDI) Pembrolizumab I.V. every 3-4 weeks for 2 doses concurrently with HDI I.V. x 5 consecutive days every week for 4 weeks, followed by S.C. every other day 3x each week for 2 weeks.~Surgery phase (week 6-8).~Maintenance phase (following recovery from surgery): Pembrolizumab I.V. infusion every 3 weeks given concurrently with HDI S.C. QOD (e.g. M,W,F) TIW every week for 46 additional weeks"
2584105|NCT02339116|Experimental|Folfoxiri/bev --> folfoxiri/bev|"FOLFOXIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 165 mg/sqm iv over 60 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluorouracil 3200 mg/sqm 48 h-continuous infusion, starting on day 1 At the time of disease progression, patients will re-introduce FOLFOXIRI plus bev at the same doses and schedule previously tolerated, for a maximum of 8 cycles. If no progression occurs during FOLFOXIRI plus bev, patients will receive maintenance 5-FU/LV plus bev at the same dose used in the last cycle of the induction treatment."
2584113|NCT02339116|Active Comparator|folfox/bev-->folfiri/bev|"mFOLFOX-6 plus bev (to be repeated every 2 weeks for a maximum of 8 cycles) Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Oxaliplatin 85 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1~At the time of disease progression patients will receive FOLFIRI plus bev (to be repeated every 2 weeks for a maximum of 8 cycles):~Bevacizumab 5 mg/kg iv over 30 minutes, day 1 Irinotecan 180 mg/sqm iv over 2 hours, day 1 L-Leucovorin 200 mg/sqm iv over 2 hours, day 1 5-fluoruracil 400 mg/sqm iv bolus, day 1 5-fluoruracil 2400 mg/sqm 48 h-continuous infusion."
2584194|NCT02338466|Placebo Comparator|rt-PA|"Patients treated by thrombolysis with rt -PA within 4h30 of the onset of symptoms to a proximal middle cerebral artery occlusion visible on a MRI 1 are pre- included. A second MRI ( IRM2 ) is performed between 1 hour and 1.5 hours after administration of rt-PA in the usual way .~After the treatment by rt-PA, if there is no recanalization (TIMI score: 0,1, 2a), the patient is included. A patient included will be randomized either in the arm rt-PA treatment only or in the arm rt-PA + tenecteplase treatment. If he is included in the arm rt-PA only, he will not receive any other treatment for the study."
2584195|NCT02338466|Active Comparator|rt-PA + tenecteplase|"If patient is in the arm rt-PA + tenecteplase, he will receive tenecteplase (50UI/Kg) treatment. A third MRI will be performed at 24hour that will assess the recanalization status (TIMI), the final volume infarct and the hemorrhagic complications."
2584232|NCT02338141|Experimental|Portable colposcopy|Diagnostic evaluation with 8x magnification portable colposcopy after visual inspection with acetic acid
2584236|NCT02338141|Active Comparator|Conventional colposcopy|Diagnostic evaluation with standard 25x magnification conventional colposcopy after visual inspection with acetic acid
2584260|NCT02337816||Endometriosis|Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery.
2584261|NCT02337816||Controls|Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery.
2584323|NCT02337634|Placebo Comparator|Placebo|Matched dosage of milk thistle daily.
2584330|NCT02337634|Active Comparator|Milk Thistle|Capsule form, 150mg BID to 300mg BID
3177292|NCT00651326|Active Comparator|Antiandrogen; LHRH; Docetaxel, Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard) Docetaxel
3177293|NCT00651326|Active Comparator|Antiandrogen; LHRH; Radiation Therapy|Antiandrogen (Flutamide or Bicalutamide) LHRH agonist (Eligard)
3177294|NCT00651339||A|
2584433|NCT02336854|Experimental|Tacrobell tab. 2mg|2mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
2584434|NCT02336854|Active Comparator|Prograf cap. 2mg|1mg/capsule, PO, 2 capsule once daily for Period I & II D1(crossover)
2584458|NCT02336477|Experimental|1|Mexiletine / Placebo
2584460|NCT02336477|Experimental|2|Placebo / Mexiletine
2584552|NCT02336295|Other|Food Frequency Questionnaires|Filling out a Food Frequency Questionnaires (FFQ)
2584731|NCT02334605|Other|capsaisin nasal spray|one puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
3177295|NCT00651352|Experimental|2 mg nicotine prototype|2 mg nicotine prototype
3177296|NCT00651352|Active Comparator|2 mg nicotine lozenge|marketed formulation
3177297|NCT00651352|Experimental|4 mg nicotine prototype|4 mg
3177298|NCT00651352|Active Comparator|4 mg nicotine lozenge|4 mg
3177299|NCT00651365|Experimental|001|
3177300|NCT00651378|Experimental|Rosuvastatin|
3177301|NCT00651378|Active Comparator|Ezetimibe + Atorvastatin|
3177302|NCT00651378|Active Comparator|Double Atorvastatin|
3177303|NCT00651391|Experimental|Ezetimibe + Simvastatin|
2583715|NCT02341716|Active Comparator|Walk advice|All WA patients receive best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and are recommended outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The WA patients are unsupervised during the study period and are followed by a blinded observer at baseline, three, six and 12 months.
2583716|NCT02341716|Active Comparator|Hospital-based supervised exercise|All SET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The SET group in addition receives three times weekly during six months in-hospital muscle exercise therapy in a group supervised by a physiotherapist. After the six months of supervised exercise therapy, the SET patients are recommended to continue the same muscle exercise therapy at home, but without feedback, between seven and 12 months.
2583717|NCT02341716|Active Comparator|Home-based supervised exercise|All HET patients receive the same basic treatment as WA patients: best medical treatment (BMT) including control of risk factors for arteriosclerosis, simvastatin 40 mg daily, aspirin 75 mg daily and recommendation of outdoor walking with Nordic Poles at least 30 minutes at least three times per week. The HET group patients in addition perform the same muscle exercise therapy three times weekly during six months as the SET patients, but in their homes, and are supervised and given feedback by phone calls every 14th day by a physiotherapist. After six months of supervised exercise therapy, the HET patients are recommended to continue the same muscle exercise therapy, but without feedback, between seven and 12 months.
2583769|NCT02341326||Healthy nonsmokers|"n=20 for Aim 1 n=20 for Aim 2~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 2.To test the hypothesis that FGFR2 signaling is necessary for normal SAE BC stem cell function and suppression of FGFR2 caused by inhibitors and smoking associated factors (EGF and TGF- beta)leads an altered stem cell functional phenotype similar to SAE BC from COPD smokers with reduced capacity as characterized by Aim 1."
2583773|NCT02341326||Healthy smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
2583775|NCT02341326||COPD smokers|"n=20- for Aim 1 n=20 for Aim 3~Aim 1.To determine whether BC from the SAE of COPD smokers have reduced capacity to generate normally differentiated SAE, e.g initiate airway branching and repair in response to injury in vitro but generate airway epithelium with the phenotype similar to that present in SAE of COPD smokers in vivo.~Aim 3.To assess the hypothesis that increasing FGFR2 signaling and suppressing smoking induced EGF receptors and TGF-beta pathways will restore the FGFR2 expression and normalize the capacity of SAE BC stem cells to generate and maintain normally differentiated SAE."
2583791|NCT02341131|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes & Reeder, 2005)
2583792|NCT02341131|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
2583794|NCT02341131|No Intervention|Healthy Controls|No intervention
2583922|NCT02340273|Experimental|Therapeutic ultrasound device|Patients receive treatment from the long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.
2583926|NCT02340273|Placebo Comparator|Placebo therapeutic ultrasound device|"Patients receive the sham long duration therapeutic ultrasound device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound."
3177304|NCT00651391|Active Comparator|Simvastatin|
2584281|NCT02337712|Experimental|q.d. RT|q.d. RT (65 Gy in 26 fractions) to the chest and concurrent etoposide and cisplatin
2584285|NCT02337712|Active Comparator|b.i.d.RT|b.i.d.RT (45Gy in 30 fractions) to the chest and concurrent etoposide and cisplatin
3177305|NCT00651391|Placebo Comparator|Placebo|
3177306|NCT00651404|Experimental|Ezetimibe|
3177307|NCT00651404|Placebo Comparator|Placebo|
3177308|NCT00651417|Active Comparator|1|Organic Germanium tablets 5 times a day
3177309|NCT00651417|Placebo Comparator|2|Placebo tablets 3 -5 times per day
3177310|NCT00651430||A|
3177311|NCT00651443|Experimental|1|
3177312|NCT00651456|Active Comparator|1|Standard Chemotherapy
3177313|NCT00651456|Experimental|2|Standard Chemotherapy + bevacizumab (Avastin)
3177314|NCT00651469|Experimental|Arm 1|
3177315|NCT00651469|Placebo Comparator|Arm 2|
3177316|NCT00651495|Experimental|1|Participants receive a $50 financial incentive if they view at least 3 of 5 patient decision aids in a group screening.
3177317|NCT00651495|Active Comparator|2|No financial incentive for watching patient decision aids in group screenings
3177318|NCT00651508|Experimental|Single Arm 25mg/m2|KOS-1584 25mg/m2
3177319|NCT00651521||1|CKD stage 1 patients
3177320|NCT00651521||2|CKD stage 2 patients
3177321|NCT00651521||3|CKD stage 3a patients
3177322|NCT00651521||4|CKD stage 3b patients
3177323|NCT00651521||5|CKD stage 4 patients
3177324|NCT00651521||6|CKD stage 5 patients
3177325|NCT00651547|Experimental|1|
3177326|NCT00651547|Active Comparator|2|
3177327|NCT00651547|Active Comparator|3|
3177328|NCT00651586|Experimental|1|Gatifloxacin 0.3% ophthalmic solution
3177329|NCT00651586|Active Comparator|2|Ciprofloxacin 0.3% ophthalmic solution
3177330|NCT00651599|Placebo Comparator|Arm 2|
3177331|NCT00651599|Experimental|Arm 1|
3177332|NCT00651612|Experimental|1|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
3177333|NCT00651612|Active Comparator|2|Concurrent Brimonidine 0.2% and 0.5% Timolol
2583735|NCT02341508|Experimental|Lpathomab|0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab,
2583738|NCT02341508|Placebo Comparator|Placebo|Saline solution for intravenous infusion
2583819|NCT02341170|Experimental|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation (25 Gy in 10 fractions)
2583822|NCT02341170|No Intervention|Observation|Observation
2583847|NCT02340845|Active Comparator|Bromalian 10 mg/kg/day|The number of patients suffering from well-documented malignancies to be assigned to this group will be at least 30: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 500 mg/day, divided into two doses of 250 mg/dose and taken with meals.
2583856|NCT02340845|Active Comparator|Bromalian 50mg/kg/day|The number of patients suffering from well-documented malignancies with be at least 60: with mixed types of carcinoma of breast, lung, colon, gastro-intestinal, ovarian, cervical, uterine, prostatic, bladder, hepatic, lymphoma, melanoma and so forth. These patients will be given Bromelain at 2400 mg/day, divided into two doses of 1200 mg/dose and taken with meals.
2583948|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group A)|8 patients with severe renal impairment and not on dialysis
2583954|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group B)|8 healthy subjects
2583956|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group C)|"Group C will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with moderate renal impairment"
2583961|NCT02340195|Experimental|Idalopirdine (Lu AE58054) 60 mg (Group D)|"Group D will not be tested, if severe renal impairment does not alter the pharmacokinetics to a clinically relevant extent, based on results from group A and B~8 patients with mild renal impairment"
2584079|NCT02339207|Placebo Comparator|Placebo|Placebo dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
2584082|NCT02339207|Experimental|AL-335|AL-335 dosed once in human volunteers in increasing dosages or once daily for seven days in patients with chronic Hepatitis C in increasing dosages.
2584128|NCT02338934|Experimental|Cinacalcet with Vitamin D arm|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
2584242|NCT02338258|Experimental|The Anti-rotational plate group|The method was used to control the rotational unstabilization at the fracture site
2584244|NCT02338258|Placebo Comparator|Exchanged Intramedullary nailing group|the method Provided the axial and rotational stability
3177334|NCT00651651|Experimental|1|Symbicort
3177335|NCT00651651|Active Comparator|2|budesonide
2584359|NCT02337348|Experimental|OCT guided coronary intervention|Coronary angiography and optical coherence tomography imaging
2584363|NCT02337348|Active Comparator|Conventional coronary intervention|Coronary angiography
2584421|NCT02337049||Previously early onset preeclampsia|Women with a history of early onset preeclampsia 10 years ago
2584422|NCT02337049||Previously late onset preeclampsia|Women with a history of late onset preeclampsia 10 years ago
2584424|NCT02337049||Previously normotensive pregnancy|Women with a history of normotensive pregnancies 10 years ago
2584461|NCT02336568|Experimental|intervention|intervention: Oxytoine treatments - 20 PTSD patients
2584463|NCT02336568|Placebo Comparator|Placebo treatments|Other: Placebo treatments- 20 PTSD patients
2584607|NCT02335814|Experimental|FLX925|
2584638|NCT02335255|Experimental|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% (Taro Pharmaceuticals Inc.)
2584640|NCT02335255|Active Comparator|Naftin® Gel 2%|Naftin® (Naftifine Hydrochloride) Gel 2% (Merz Pharmaceuticals, LLC)
2584641|NCT02335255|Placebo Comparator|Placebo Topical Gel|Placebo Topical Gel (Taro Pharmaceuticals Inc.)
2584911|NCT02333643|Experimental|CLS003|Topical digoxin/furosemide
2584912|NCT02333643|Experimental|Digoxin topical formulation|
2584913|NCT02333643|Experimental|Furosemide topical formulation|
3177336|NCT00651651|Active Comparator|3|formoterol
3177337|NCT00651677|Active Comparator|HAL Proctectomy|Hand-assisted laparoscopic proctectomy
3177338|NCT00651677|Active Comparator|SL Proctectomy|"straight laparoscopic proctectomy"
3177339|NCT00651690|Experimental|1|Botulinum Toxin Type A
3177340|NCT00651690|Placebo Comparator|2|Saline
3177341|NCT00651703|Experimental|1|
3177342|NCT00651703|Experimental|2|
3177343|NCT00651703|Experimental|3|
3177344|NCT00651703|Experimental|4|
3177345|NCT00651716||Allogeneic Stem Cell Transplant Patients|Patients undergoing allogeneic stem cell transplant (SCT). Potential study candidates will be identified by participating physicians.
3177346|NCT00651729|Experimental|1|Botulinum Toxin Type A
3177348|NCT00651768|Experimental|1|
3177349|NCT00651768|Sham Comparator|2|
3177350|NCT00651781|Experimental|1|"Phase I:3 dose levels Cytarabine (200 mg/m2- 500 mg/m2-1000 mg/m2) with scheme Flag-Ida in combination with Velcade until determinate the appropriate dose.~Phase II:~Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade administration. Each 28-day treatment, patients will be evaluated, and in absence of disease progression or unacceptable toxicity, patients will start second cycle with Bortezomib in monotherapy two times per week followed by a 10 days rest period. That is, patients who response with acceptable toxicity will receive the combined sequential scheme twice (as induction and consolidation)."
2583797|NCT02341235|Experimental|Game intervention|Participants will receive narrative-based games on a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
2583799|NCT02341235|Active Comparator|Standard intervention|Participants will receive an electronic activity monitor with a mobile device and telephone counseling (weekly for the first 12 weeks, then once per month until 6 months)
3212223|NCT01013220|Experimental|Depression Product Detailing|Employers receive education on how to purchase high quality depression management products to improve the quality of depression treatment depressed employees receive. Materials delivered in this arm of the study are available at www.caremanagementfordepression.org
3212224|NCT01013220|Placebo Comparator|Depression HEDIS Detailing|Employers receive education on how to obtain and use HEDIS depression indicators to encourage health plans to improve the quality of depression treatment depressed employees receive
2583920|NCT02340260|Other|High intensity interval training|High intensity interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 10x1-minute intervals at 90 % of HRmax, with 75 seconds of active recovery at 70 % of HRmax between each interval. Exercise is completed with a three minute cool down. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
2583924|NCT02340260|Other|Sprint interval training|Sprint interval training starts with warming up for 3 minutes at 70 % of maximum heart rate before treadmill training 2x20 seconds of maximum intensity intervals, with 3 minutes and 20 seconds of active recovery at 70 % of HRmax between each interval, followed by 3 minutes cooling down at the same intensity. All training sessions are supervised by an exercise physiologist. Treadmill inclination and/or speed will be adjusted to make sure prescribed intensity is met throughout the intervention.
2583995|NCT02339714|Experimental|Acupuncture combined moxibustion|Acupuncture at Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14). Needle warming moxibustion at Dazhui(Du14). Patients will be treated once per day for 30 min, 3 times in a weeks for 4 weeks.
2584001|NCT02339714|Active Comparator|loratadine|Loratadine taken orally, 10mg/day in the morning
3212225|NCT01013233|Experimental|training|Patients in this group start the cognitive training over 6 weeks directly after randomization.
3212226|NCT01013233|Placebo Comparator|control|In this control group begin the training in a cross-over design 7 weeks after randomization.
2584137|NCT02338856|Experimental|MB12066 200mg|
2584138|NCT02338856|Placebo Comparator|Placebo|
3212227|NCT01013246|Experimental|Video game play|
3212228|NCT01013259|Placebo Comparator|Placebo|
3212229|NCT01013259|Experimental|Mutaflor|
3212230|NCT01013272|Active Comparator|Entecavir|Ongoing entecavir 0.5mg daily
3212231|NCT01013272|Active Comparator|Lamivudine|Switch to lamivudine 100mg daily
3212232|NCT01013298|Experimental|Video-guided PCT|Patients that will be extubated and re-intubated with the ETT-TVT, and monitored throughout intubation and PCT
3212233|NCT01013311||Cardiac Sarcoidosis|Patients with Cardiac Sarcoidosis who had an ICD implanted
3212234|NCT01013324|Experimental|Single Arm|All subjects will receive single-agent XL147 dosed daily
3212235|NCT01013337|Experimental|Arm I (Acupuncture)|Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments).
3212236|NCT01013337|Sham Comparator|Arm II (Placebo)|Patients undergo 10, 20-minute sessions of sham acupuncture treatments over 8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at non-acupuncture points.
3212237|NCT01013337|No Intervention|Arm III (Control)|Wait-list control patients are contacted by phone at the same frequency as real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
3212238|NCT01013363|No Intervention|No music|Participants will not use the digital music player during their procedure.
3212239|NCT01013363|Experimental|Music|Participants will use the digital music player during their procedure.
3212240|NCT01013376|Experimental|Active|Topical administration of MC-1101
3212241|NCT01013376|Placebo Comparator|Vehicle|Vehicle
2584653|NCT02335060|Experimental|Active N-acetylcysteine and Active Delta-9-THC|
2584659|NCT02335060|Placebo Comparator|Placebo and Active Delta-9-THC|
2584662|NCT02335060|Experimental|Active N-acetylcysteine and Placebo|
2584663|NCT02335060|Placebo Comparator|Placebo and Placebo|
3212242|NCT01013389|Experimental|Actifuse ABX|Actifuse ABX bone substitute
3212243|NCT01013389|Active Comparator|INFUSE, plus master granules (MGG)|synthetic bone substitute used in posterolateral instrumented lumber fusion with interbody fusion
3212244|NCT01013402|Experimental|volunteers for insulin hypoglycemia test|None of the subjects had diabetes mellitus or any other metabolic diseases. They were not taking any medicine and they did not have anemia or polycythemia. Also none of the patients had any condition causing hypoxia or any compromise in peripheral circulation.
3212245|NCT01013415|Experimental|ARM 1|Arm I (N=5) received antiretroviral therapy (ART) plus low dose IL-2 (1.2 million units/m2) subcutaneously daily for 56 days
2584902|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 10 mcg, 1 capsule/day before breakfast, Duration: 6 months
3212246|NCT01013415|Experimental|ARM 2|Arm 2 (N=5) received ART plus a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
3212247|NCT01013415|Experimental|ARM 3|Arm 3 (n=5) received ART plus IL-2 (1.2 million units/m2) and a single infusion of approximately 5 to 11 billion CD4-zeta gene modified T cells.
3212248|NCT01013441|Experimental|Treatment Arm|
3212249|NCT01013454|Experimental|Varenicline transdermal delivery system|
3212250|NCT01013467|Active Comparator|color coded bloodpressure booklet|
3212251|NCT01013480|Active Comparator|STX209|
3212252|NCT01013493||myopic|
3212253|NCT01013493||non myope-healthy|
3212254|NCT01013506|Experimental|Letrozole +/-goserelin, OSI-906 (Arm I )|Patients receive oral letrozole once daily on days 1-28 plus subcutaneous goserelin (the latter for pre-menopausal women only) on day 1 and oral IGF-1R inhibitor OSI-906 twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
2583809|NCT02341274|Active Comparator|Low Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 10-30% crystallized generic tacrolimus (Low Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
2583811|NCT02341274|Active Comparator|High Crystal Generic Tacrolimus|Oral administration of 5 mg capsule of 40-60% crystallized generic tacrolimus (High Crystal) to healthy volunteer on an empty stomach. Blood samples will be collected from the indwelling venous catheter (∼10 ml) after 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after dosing. The volunteers will be allowed to eat a normal lunch 3 hours after taking their tacrolimus dose. After the 24-hour blood sample has been collected, the volunteer will be discharged.
2583836|NCT02340884|Experimental|PRISM|Promoting Resilience In Stress Management Intervention (skills-based intervention designed to teach stress-management, goal-setting, cognitive reframing, and meaning-making skills)
2583845|NCT02340884|No Intervention|Control|Standard psychosocial supportive care
2583885|NCT02340533|Experimental|adenomyosis|females attending the gynecology outpatient clinic complaining of chronic pelvic congestion will get enrolled in the study. Two dimensional ultrasonography will be performed to asses the presence or absence of adenomyosis or any associated lesions. All the patients were then be subjected to office hysteroscopy and endo-myometrial biopsies will be taken. Histopathological examination of the samples will then be done. From these recruited patients, some will be indicated to perform hysterectomy. The final diagnosis will then be based on the histopathological examination of the specimen retrieved from hysterectomy. The accuracy of the ultrasound and the hysteroscopic endo-myometrial biopsy will then be compared and assessed.
2583944|NCT02340143|Active Comparator|Control|Marketed partially hydrolyzed cow's milk protein infant formula
2583946|NCT02340143|Experimental|Investigational|Partially hydrolyzed cow's milk infant formula with a probiotic
2584042|NCT02339532|Experimental|TOP2A amplified|"If TOP2A amplified: FEC x 3 then THP x 3 3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m²~Epirubicin 100 mg/m²~Cyclophosphamide 500 mg/m²~Followed by 3 cycles of Trastuzumab-Pertuzumab-Docetaxel:~Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m² IV escalating at 100 mg/m² IV as tolerated q3w"
2584044|NCT02339532|Experimental|TOP2A not amplified|"If TOP2A not amplified: TCHP x 6 TCHP administered IV q3w for 6 cycles~Trastuzumab 8 mg/kg loading dose administered IV followed by 6 mg/kg IV q3w in subsequent cycles.~Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.~DOCETAXEL 75 mg/m² IV q3w~CARBOPLATIN AUC 6 IV q3w~The Calvert formula will be used to calculate the dose of carboplatin:~Dose (mg) = target AUC (mg/mL x min) x [GFR mL/min + 25] Dose (mg) = 6 x [GFR mL/min + 25] NOTE: the Calvert formula gives the dose in mg, not mg/m². GFR, glomerular filtration rate The maximum dose of CARBOPLATIN must not exceed 900 mg."
3212255|NCT01013506|Experimental|Letrozole +/- goserelin, OSI-906, erlotinib (Arm II)|Patients receive oral letrozole and subcutaneous goserelin (the latter for pre-menopausal women only) and oral IGF-1R inhibitor OSI-906 as in arm I. Patients also receive oral erlotinib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3212256|NCT01013532|Experimental|Cilostazol+ Probucol|100mg cilostazol bid plus probucol plus placebo of aspirin
2584196|NCT02338505|Experimental|Telelap ALF-X in obese patients with gynecological disease|
2584225|NCT02338180|No Intervention|Control group A|Children with no caries lesion on adjacent surfaces of second primary molar and first permanent molar
2584227|NCT02338180|Experimental|Group B Preventive sealant|Children with active caries lesion on distal surfaces of second primary molar and sound mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received a proximal preventive sealants, and the other remain as a control
2584230|NCT02338180|Experimental|Group C Therapeutic sealant|Children with active caries lesion on distal surfaces of second primary molar and active lesion on mesial surface of first permanent molar. In every children a split mouth design was applied, in one mesial surfaces of first molar randomize selected received proximal therapeutic sealant, and the other remain as a control
2584263|NCT02337803|Experimental|Strength Training Group|Participants will meet three times a week for one hour strength training sessions for twelve weeks.
2584269|NCT02337803|Active Comparator|Usual Care|Participants will be given access to the strength training program after the twelve week study ends.
2584322|NCT02337582|Active Comparator|Intervention|
2584332|NCT02337582|Other|Control|
2584352|NCT02337309|Other|SF1126|Patients will receive SF1126 IV over 90 minutes on Days 1 and 4 of each week during each cycle.
2584392|NCT02336971|Experimental|CBCT for PTSD|"CBCT for PTSD is a time-limited, problem-focused treatment that aims to improve PTSD and relationship functioning. The study investigators have developed a 15-session treatment plan each session lasting 75-minutes.~The treatment is sequenced such that the rationale and psychoeducation provide the basis for the behavioral skills training designed to improve communication and relationship functioning, and to overcome behavioral and experiential avoidance. These skills are used in the final phase of the treatment that is focused on cognitive mechanisms contributing to PTSD and relationship dysfunction."
2584395|NCT02336971|Experimental|Prolonged Exposure|"PE for combat-related stress disorders [13-14] serves as the comparison treatment.~The therapy is usually conducted in 10-12 sessions, each lasting 90-minutes, with the majority of the sessions devoted to imaginal exposure to traumatic memories and homework assignments that include in vivo exposure assignments. In the present study, participants will complete 12 sessions of PE to equate the number of sessions with those of CBCT. Partners of individuals with PTSD are not typically incorporated into the treatment program and so for this study a revised version of PE [1-3] will be administered in which the partner is seen during the second session to discuss PTSD, other reactions to trauma and the treatment procedures."
2584748|NCT02334670||CrAg(+) and CM(+)|Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management.
3212257|NCT01013532|Active Comparator|Aspirin + Probucol|aspirin plus placebo cilostazol plus probucol
3212258|NCT01013532|Experimental|Cilostazol|cilostazol plus placebo of aspirin
2583813|NCT02341261|Experimental|Supervised Exercise and Counseling|"Participants randomized to the intervention will perform supervised aerobic, resistance and balance training twice weekly for 12 weeks, and weekly thereafter. Actigraphy-based counseling to reduce sedentary behavior will follow a similar taper. Daily text messages, tweets, emails, and social media posts at random times during waking hours will be used to provide reminders and motivational messages. Participants will have 11 separate 7-day continuous ActivePAL training session incorporating vibrostimulatory feedback spread across the treatment period."
2583834|NCT02340897||Nontuberculous lung disease|Patients with Nontuberculous Mycobacteria satisfying American Thoracic Society and British Thoracic Society guidelines
2583842|NCT02340897||pulmonary tuberculosis|Patients with culture confirmed tuberculosis
2583850|NCT02340897||bronchiectasis|Patients with bronchiectasis based on chest CT findings as well as symptoms
2583905|NCT02340611|Experimental|Cediranib and Olaparib|Cediranib, 20 mg , orally, once a day, every day. Olaparib, 150 mg or 200 mg (depending on previous treatment dose), orally, once a day, every day.
2583978|NCT02339974|Experimental|Severe Tricuspid Regurgitation|
2583991|NCT02339701|Other|IMRT|Patients will receive 38 fractions of radiation, each fraction size will be 2Gy. The total dose will be 78Gy to PTV 1. Whereas the total dose will be 70Gy over 38 fractions to PTV 2. The treatment will be delivered 5 fractions per week consecutively except public holiday, and the total duration of treatment will be 7.5 to 8 weeks.
2583992|NCT02339701|Other|SBRT|Patients will receive 5 fractions of radiation; each fraction size will be 7.25Gy. The total dose will be 36.25 Gy to PTV1. Whereas the total dose will be 32.5Gy over 5 fractions to PTV2. The 5 treatments will be scheduled to be delivered twice aweek over approximately 15-17 days. A minimum of 72 hours and a maximum of 96 hoursshould separate each treatment. No more than 2 fractions will be delivered per week. The total duration of treatment will be no shorter than 15 days and no longer than 17 days.
3212259|NCT01013532|Active Comparator|Aspirin|aspirin plus placebo of cilostazol
3260278|NCT01477814|Active Comparator|CR, ed mat'ls, FIT, phone call|physician chart reminder (CR) plus mailed educational materials, including the Centers for Disease Control CRC Screen for Life, the ACS DVD on CRC screening, a fecal immunochemical test with postage-paid return mailer, a magnet reminding individuals to get screened, and a CRC screening preference sheet where subjects could indicate their preferred CRC test, and a motivational telephone call designed to elicit barriers and preferences and motivate individuals to complete a CRC screening test.
2584096|NCT02339168|Experimental|enzalutamide and metformin hydrochloride|Patients receive enzalutamide PO QD and metformin hydrochloride PO BID. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2584148|NCT02338778|Active Comparator|Control|Patients in this group will be receiving standard treatment according to National Comprehensive Cancer Network (NCCN) guide line
2584149|NCT02338778|Experimental|MV+control|Patients in this group will be receiving both standard treatment according to NCCN guide line and simultaneous injection of mix vaccine (MV)
2584199|NCT02338401|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
2584200|NCT02338401|Placebo Comparator|Placebo Pill|Oral ingestion of 3 capsules of a placebo olive oil pill (Swanson Health Products, PO Box 2803 - Fargo, ND 58108 USA) per day for 12 weeks.
2584389|NCT02337127|Active Comparator|Arm A|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive Lamivudine extending therapy for 5 years.
2584390|NCT02337127|No Intervention|Arm B|250 treatment-naïve CHB patients who received at least 3-year of oral antiviral agents will receive follow-up.
2584472|NCT02336789|Placebo Comparator|placebo|250 ml of normal saline (sham transplantation).
2584475|NCT02336789|Active Comparator|intervention|250 ml of diluted fecal material prepared from a screened donor
2584553|NCT02336256|Experimental|TEP SILS|Procedures of hernia repair. Patients operated due to inguinal hernia using modified single incision laparoscopic surgery (SILS) methods.
2584554|NCT02336256|Active Comparator|Typical TEP|Procedures of hernia repair. Patients operated due to inguinal hernia using typical totally extra peritoneal.
2584617|NCT02335723|Active Comparator|Alteco LPS Adsorber|Hemoperfusion and Standard therapy
2584619|NCT02335723|Placebo Comparator|Placebo|Placebo and Standard therapy. The placebo comparator device differs from Alteco® LPS Adsorber only in that no peptide component (i.e. active component) has been attached to the matrix.
2584655|NCT02335177|Active Comparator|Interventionnal arm|Interventional arm : patients at home with technologies for autonomy and tailored physical activity program.
2584658|NCT02335177|No Intervention|Control arm|Control arm : patients with usual care home
2584699|NCT02334930||Patients|Patients who will have biopsy or surgery for Perivascular epithelioid cell tumor (PEComa) or vascular pediatric tumor (Rapidly Involuting Congenital Hemangioma (RICH), Non Involuting Congenital Hemangioma (NICH), hemangioma or pyogenic granuloma)
2584754|NCT02334657||non-aneurysmal subarachnoid hemorrhage|patients with non-aneurysmal subarachnoid hemorrhage, short-term outcome measured by modified Rankin Scale and long-term outcome by SF-36
2584760|NCT02334657||perimesencephalic SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
2584762|NCT02334657||non-perimesencephalic (NPM) SAH|subgroup of non-aneurysmal subarachnoid hemorrhage
2584764|NCT02334657||subgroup of NPM-SAH with Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and a Fisher 3 bleeding pattern
2584766|NCT02334657||subgroup of NPM-SAH w/o Fisher 3|patients with non-aneurysmal (non-perimesencephalic) SAH and not a Fisher 3 bleeding pattern
2584804|NCT02334163|Experimental|Nitazoxanide group|"12 patients will receive the following for 7 days:~Oral lactulose~500 mg nitazoxanide tablets twice daily"
2584809|NCT02334163|Active Comparator|Metronidazole group|"12 patients will receive the following for 7 days:~Oral lactulose~250 mg metronidazole tablets every 8 hours"
2584814|NCT02334163|Active Comparator|Rifaximine group|"12 patients will receive the following for 7 days:~Oral lactulose~Two 200 mg rifaximine tablets every 8 hours"
2584879|NCT02333864||PWD testing POGO® BGMS|All enrolled persons with diabetes
2584917|NCT02333565|Experimental|Combinaison everolimus and octreotide|
2585204|NCT02332005|Placebo Comparator|Group 3|Tablet administered twice daily morning and evening containing placebo
2583832|NCT02340741|Other|conventional prophylaxis of aeroembolism|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main operation phase all heart cavities are sealed, left vent drainage is stopped, ascending aorta is punctured and cardiac massage is performed, ventilation is started and the heart is filled with volume. Operating table is positioned in the Trendelenburg position, and aorta is opened. The amount of air in the cavities is evaluated by transesophageal echocardiography."
2583843|NCT02340741|Other|conventional prophylaxis plus CO2 insufflation|"Procedure: cardiac surgery with opening of heart chambers.~Will be including 167 patients to undergo cardiac surgery. After the main phase of the operation standard measures of aeroembolism prevention are carried out. The amount of air in the cavities is evaluated by transesophageal echocardiography."
2583899|NCT02340442||Low risk group|40 subjects: Healthy, pregnant women
2583910|NCT02340442||High risk group|"40 pregnant women:~20 Pregnant women with preeclampsia~20 Obese pregnant women"
2583917|NCT02340442||Healthy control subjects|40 subjects
2583989|NCT02339948|Active Comparator|SBRT only|Patients assigned to this arm receive 8.0 Gy per fraction for 5 fractions for a total of 40 Gy
2583990|NCT02339948|Active Comparator|IMRT plus SBRT Boost|Patients assigned to this arm receive 1.8 Gy per fraction for 25 fractions over 5 weeks for a total of 45.0 Gy followed by an SBRT boost of 5.5 Gy per fraction for 4 fractions after IMRT for a total of 22.0 Gy
2584054|NCT02339480|No Intervention|Healthy volunteers|Healthy volunteers'hypothalamus picture of fMRI will compare with Obesity group' , no intervention and remaining unchanged lifestyle.
2584057|NCT02339480|Active Comparator|Obesity group|An intervention group of patients is put on a waiting list for massage therapy.Observing the Curative effect and hypothalamus picture of fMRI compare with healthy volunteers
2584109|NCT02339129|Experimental|SST-0225|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
2584114|NCT02339129|Placebo Comparator|Placebo|Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
2584170|NCT02338687|Active Comparator|Education|Educational sessions
2584172|NCT02338687|Experimental|Education plus supplement|Educational sessions and 500 mg calcium per day
2584210|NCT02338271|Other|a single, open clinical trial|"a single-group, open, investigator-initiated clinical study~: autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) plus Tissuefill (hyaluronic acid derivatives) 1mL/syringe"
2584221|NCT02338024|Experimental|MARTAS intervention|Structured motivational sessions and further communication between linkage coordinators and HIV-positive patients focused on engagement in HIV medical care.
2584223|NCT02338024|No Intervention|Standard of care|"Oral referrals to a network of government AIDS Centers or their departments (Trust offices) located in each study region."
2584264|NCT02337790||Cohort 1|Subjects will have a pacemaker, implanted cardioverter-defibrillator, or ventricular assist device.
2584333|NCT02337608|Experimental|GLPG1205 100mg QD|GLPG1205 100mg daily dosing in the morning
2584335|NCT02337608|Placebo Comparator|Placebo|Placebo daily dosing in the morning
2584398|NCT02337023||healthy subjects|
2584403|NCT02337023||patients with Kleine-Levin Syndrome|
2584452|NCT02336750|Experimental|treatment group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3 Mirtazapine:15mg D2-4
2584455|NCT02336750|Experimental|control group|D1:Chemotherapy Dexamethasone:7.5mg D2-4 Aprepitant:125mg D1, 80mg D2-3
2584546|NCT02336347|Experimental|Group 1 - Period 1|Twice daily dosing of AVP-786 orally for 8 days
2584547|NCT02336347|Active Comparator|Group 1 - Period 2|Twice daily dosing of AVP-923 orally for 8 days
2584548|NCT02336347|Active Comparator|Group 2 - Period 1|Twice daily dosing of AVP-923 orally for 8 days
2584550|NCT02336347|Experimental|Group 2 - Period 2|Twice daily dosing of AVP-786 orally for 8 days
2584622|NCT02335632|Placebo Comparator|Placebo|For Probiotics, 7 days
2584624|NCT02335632|Active Comparator|Probiotics|Probiotics of 120 mg/day for 7days
2584673|NCT02335164|Experimental|HA 45ug|recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses
2584675|NCT02335164|Experimental|HA 45ug+Advax1|recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
2584677|NCT02335164|Experimental|HA 45ug+Advax2|recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
2584678|NCT02335164|Experimental|HA 15ug+Advax1|recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
2584681|NCT02335164|Experimental|HA 15ug+Advax2|recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
2584684|NCT02335164|Experimental|HA 5ug+Advax1|recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses
2584686|NCT02335164|Experimental|HA 5ug+Advax2|recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
2584689|NCT02335164|Experimental|HA 2.5ug+Advax2|recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses
2584690|NCT02335164|Experimental|HA 15ug|recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses
2584727|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
2584784|NCT02334332|Active Comparator|Cohort I (standard care)|Participants receive standard post-operative care.
3177351|NCT00651807|Active Comparator|Arm 1|etonogestrel
3177352|NCT00651807|Placebo Comparator|Arm 2|Placebo
2585092|NCT02332148|Experimental|3Vm1001|3VM1001 topical cream containing 10 mg/day of copper, for 30 days
2585096|NCT02332148|Placebo Comparator|Placebo|Placebo for 3VM1001, topical cream without 3VM1001
2585325|NCT02331251|Experimental|Arm 1|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 on day 1 and day 8 every 21 days
2585330|NCT02331251|Experimental|Arm 2|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 900 mg/m2 on day 1 and 8 and docetaxel 75 mg/m2 on day 8 every 21 days
2585337|NCT02331251|Experimental|Arm 3|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on day 1 and day 8 every 21 days
2585340|NCT02331251|Experimental|Arm 4|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Gemcitabine 1000 mg/m2 and vinorelbine 25 mg/m2 on day 1 and day 8 every 21 days
2585342|NCT02331251|Experimental|Arm 5|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Irinotecan 300 mg/m2 on day 1 every 21 days
2585345|NCT02331251|Experimental|Arm 6|Pembrolizumab 2mg/kg administered intravenously over 30 minutes every 3 weeks Liposomal doxorubicin 30 mg/m2 on day 1 every 21 days
2585407|NCT02330328|Experimental|No Telemetry Monitoring|The participants in this arm will be admitted to a bed without telemetry monitoring
2585409|NCT02330328|Active Comparator|Telemetry|The participants in this arm will be admitted to a bed with telemetry monitoring
2585469|NCT02330120|Experimental|propofol|Propofol infusion 0.5-2 mg/kg/h for sedation in mechanically ventilated patients
2585472|NCT02330120|Active Comparator|dexmedetomidine|dexmedetomidine infusion 0.2-0.7 mcg/kg/h for sedation in mechanically ventilated patients
2585564|NCT02329756|Active Comparator|Treatment|Tranexamic acid (TXA) will be compared with matching placebo (sodium chloride 0.9%).
2585570|NCT02329756|Placebo Comparator|Control|Matching placebo (sodium chloride 0.9%) will be compared with treatment group
2585608|NCT02329106|Experimental|NanoKnife LEDC System|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System, alao called Irreversible electroporation (IRE), 90 pulses of 70 microseconds each in duration will be administered per electrode pair.
2585618|NCT02329106|No Intervention|Control|The patients without treatment
2585675|NCT02328898|Experimental|Cre8 stent|PCI with the Polymer Free Amphilimus Eluting Stent 'Cre8™'
2585679|NCT02328898|Active Comparator|Resolute Integrity Stent|Comparison of the Cre8 stent with the Permanent Polymer Zotarolimus Eluting Stent 'Resolute Integrity™'
2585747|NCT02328365|No Intervention|Standard|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to standard follow-up
2585753|NCT02328365|Experimental|Intervention|Patients screened positive for cardiopulmonary disease and having a medical (pulmonary and/or cardiology) visit preoperatively, but randomized to structured medical follow-up after operation
3177353|NCT00651833|Experimental|1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. Patient will also receive cisplatin, 75 mg/m2 as a 1- to 3-hour infusion on Day 1 of each cycle.
3177354|NCT00651846|Experimental|Arm 1|
2585808|NCT02327559|Experimental|Mind in Labor (MIL)|Mind in Labor: Working with Pain in Childbirth (MIL) is a 16-hour mindfulness-based childbirth education course. It is an abbreviated weekend workshop form of the 9-week Mindfulness-Based Childbirth and Parenting (MBCP) education program, which is a tailored form of Mindfulness-Based Stress Reduction.
2585820|NCT02327559|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU) refers to standard hospital- and community-based childbirth preparation courses (high quality childbirth education that excludes a mindfulness or mind/body stress reduction focus).
2585875|NCT02327403|Active Comparator|B7-1 positivity on kidney allograft biopsy|Belatacept conversion
2585878|NCT02327403|Active Comparator|B7-1 negativity on kidney allograft biopsy|Belatacept conversion
2585930|NCT02327065|Active Comparator|EUS-FNA Group|FNA,Fine needle aspiration
2585935|NCT02327065|Active Comparator|EUS-FNB Group|FNB,Fine needle biopsy
2586064|NCT02325999|Experimental|ESD and LRLD|The experimental group accept Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection.
2586067|NCT02325999|No Intervention|Endoscopic Submucosal Dissection (ESD)|The group accept Endoscopic Submucosal Dissection only.
3177355|NCT00651846|Active Comparator|Arm 2|
3177356|NCT00651859|Experimental|1|Bimatoprost 0.01% Ophthalmic Solution
3177357|NCT00651859|Experimental|2|Bimatoprost 0.03% Ophthalmic Solution
3177358|NCT00651859|Placebo Comparator|3|Bimatoprost Vehicle Ophthalmic Solution
3177359|NCT00651872||Marx|
3177360|NCT00651885|Placebo Comparator|2 arm|
3177361|NCT00651885|Experimental|1 arm|treprostinil dienthalomine
3177362|NCT00651898||A|This group will receive the circulating water garment
3177363|NCT00651898||B|This group will receive the circulating water mattress and be covered by a forced air warming device for both the upper body and lower body connected to two warmers.
3177364|NCT00651950||Operator Dependence|
3177365|NCT00651976|Experimental|treatment|
3177366|NCT00651989||A|healthy individuals
3177367|NCT00652002|Experimental|1|
3177368|NCT00652002|Active Comparator|2|budesonide
3177369|NCT00652002|Active Comparator|3|formoterol
3177370|NCT00652015||1|Patients having developed an in-stent-thrombosis (40 SAT, 40 LT)
3177371|NCT00652015||2|Patients having not developed an in-stent-thrombosis after stent implantation using PTCA
3177372|NCT00652041|Experimental|1|Induction: 6 alternating cycles Bortezomib-Melfalan-Prednisone or Bortezomib- Adriamycine-Melfalan-Prednisone and Thalidomide-Cyclophosphamide-Dexamethasone, followed by other 6 maintenance cycles
3177373|NCT00652054|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
3177374|NCT00652067||1|Only one patient is being treated under a single patient IND.
3177375|NCT00652106|Experimental|1|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution
3212260|NCT01013545|Experimental|JAE-EMT|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. This intervention condition uses spoken language as the mode of communication. Individual, single word targets will be selected based on the child's level of language production and specific interests. The targets are systematically modeled in response to child actions and attention during play. A sequence of milieu teaching prompts will also be used to elicit targets from the child when use of the target language is functional for the child.
2583936|NCT02340234|Experimental|Lebrikizumab 250 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 250 milligrams (mg) SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
2583938|NCT02340234|Experimental|Lebrikizumab 125 mg Single Dose + TCS Cream|Participants will receive lebrikizumab 125 mg SC single dose on Day 1 followed by placebo on Week 4 and Week 8. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
2583940|NCT02340234|Experimental|Lebrikizumab 125 mg Q4W + TCS Cream|Participants will receive lebrikizumab 125 mg SC every 4 weeks (Q4W) for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
2583941|NCT02340234|Placebo Comparator|Placebo Q4W + TCS Cream|Participants will receive placebo Q4W for a total of 3 doses. Participants will continue to apply TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily to active skin lesions throughout the 12-week treatment period.
2584067|NCT02339259||Febrile patients|Febrile patients admitted to CMCH who have had malaria film and scrub typhus and murine typhus rapid test will be screened for enrolment.
2584069|NCT02339259||Healthy|Healthy subjects with no recent history of fever will be recruited to provide control samples for the blood and plasma assays.
2584123|NCT02339025||Tricare Participants|From WRNMC
2584187|NCT02338752|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
2584190|NCT02338752|Active Comparator|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
2584241|NCT02338245|Experimental|Treatment Arm A|ASLAN001 + Capecitabine
2584243|NCT02338245|Active Comparator|Treatment Arm B|Lapatinib + Capecitabine
2584325|NCT02337439|Experimental|Sensory Information Processing Training|Computerized training designed to improve sensory processing
2584328|NCT02337439|Active Comparator|Active Control Training|Commercially available computer exercises that were not designed specifically to improve sensory information processing.
2584365|NCT02337296|Other|Phase 1 - Intervention|Five patients will be enrolled consecutively for the ADHERE intervention and be followed in order to refine the intervention as needed. This permits the investigation of the process of change at baseline, after the intervention, and across the phases.
2584366|NCT02337296|No Intervention|Phase 2 - Control Group|Following completion of Phase 1 and prior to initiation of enrollment in the intervention group, patients will be enrolled in the control group and will receive usual care.
2584367|NCT02337296|Experimental|Phase 2 - Intervention Group|Following enrollment of all control group patients, the intervention group will be recruited and enrolled and the ADHERE intervention will be conducted by the trained APRN interventionist at cancer center.
2584410|NCT02336984|Experimental|Combination Therapy|Combination Therapy: HER-2 pulsed DC1 vaccine with trastuzumab and pertuzumab.
2584482|NCT02336620|Experimental|Ringer Acetate|Ringer acetate 10-20 ml/kg IV bolus when patient need fluid bolus
2584486|NCT02336620|Active Comparator|Normal saline|NSS 10-20 ml/kg IV bolus when patient need fluid bolus
2584541|NCT02336191||LDLT Recipients|Patients subjected to living donor liver transplantation
2584578|NCT02335827|Experimental|Group A|irreversible electroporation with voltage in level A for renal tumors
2584580|NCT02335827|Experimental|Group B|irreversible electroporation with voltage in level B for renal tumors
2584582|NCT02335827|Experimental|Group C|irreversible electroporation with voltage in level C for renal tumors
2584616|NCT02335528|Experimental|SimCoach intervention|"Participants randomized to the SimCoach intervention arm interacted with Bill Ford, a simulated human (avatar) enacted in the SimCoach program. This white male avatar representing himself as an Army veteran who spoke to participants in a conversational manner. Participants interacted with him using a chat interface, where they could type responses to him. Bill Ford asked participants a series of questions that corresponded to validated PTSD or depression screening questionnaires. SimCoach then provided personalized recommendations for a symptom if the user reported experiencing the symptom at one of the two highest frequencies on the response scale. These recommendations consisted of a behavioral recommendation with an accompanying link to a website or online article on the topic."
2584618|NCT02335528|No Intervention|Content Matched Control|Participants assigned to the Content Matched Control condition arm completed text-based versions of the PCL PTSD screening inventory and PHQ-9 depression screening inventory. These instruments used standard, validated language and did not use the modified conversational versions used in the SimCoach intervention condition. The same personalized recommendations provided to the SimCoach group were provided as conventional text and links. After receiving personalized recommendations, participants completed text versions of primary help-seeking, perceived barriers to seeking help, and secondary outcome (user experience) measures.
3260279|NCT01477827||Healthy volunteers|Healthy adolescents aged 12-15 years
3260280|NCT01477840|Experimental|Misoprostol|
2584785|NCT02334332|Experimental|Cohort II (educational brochure)|Participants receive a 2-page educational brochure after surgery and prior to discharge home.
3260281|NCT01477866|Experimental|citogenex|citogenex + conventional therapy
2583890|NCT02340481|Active Comparator|Loperamide Hydrochloride|Participant will take 2 loperamide hydrochloride capsules + 2 loperamide hydrochloride and simethicone chewable placebo tablets orally, as their first dose, and subsequently 1 loperamide hydrochloride capsule + 1 loperamide hydrochloride and simethicone chewable placebo tablet orally, in the event of unformed stool (provided that no more than 4 capsules/tablets are taken within a 24-hour period) up to 48 hours.
2583942|NCT02340039|Experimental|Blackcurrant &Apple|600 mg blackcurrant anthocyanins + 600 mg apple polyphenols delivered in a low sugar fruit drink
2583947|NCT02340039|Experimental|Apple|1200 mg apple polyphenols delivered in a low sugar fruit drink
2583950|NCT02340039|Placebo Comparator|Control drink|No polyphenols delivered in a low sugar fruit drink
2583998|NCT02339818||HCPs|HCPs involved in using Eliquis (apixaban)
2584003|NCT02339818||Patients|Patients taking Eliquis for any of the three currently approved indications
2584031|NCT02339519|Active Comparator|group LMA supreme|Patients who received Laryngeal Mask Airway; LMA supreme
2584032|NCT02339519|Active Comparator|group LMA classic|Patients who received Laryngeal Mask Airway; LMA classic
2584034|NCT02339519|Active Comparator|group Fastrach|Patients who received Laryngeal Mask Airway; LMA fastrach
2584081|NCT02339233|Experimental|Epidural Stimulator|Eligible participants will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord
2584189|NCT02338622|Experimental|Schedule A: 4 days on, 3 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 4 days on, 3 days off~Schema for dose escalation in schedule A (4-days-on, 3-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 240mg~Olaparib: 300mg, AZD5363 320mg~Olaparib: 300mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg"
2584191|NCT02338622|Experimental|Schedule B: 2 days on, 5 days off|"300mg olaparib + intrapatient dose escalation of AZD5363 2 days on, 5 days off~Schema for dose escalation in schedule B (2-days-on, 5-days-off AZD5363)~-1. Olaparib: 200mg, AZD5363 400mg~Olaparib: 300mg, AZD5363 480mg~Olaparib: 300mg, AZD5363 560mg~Olaparib: 300mg, AZD5363 640mg"
3212261|NCT01013545|Experimental|JAE-AAC|The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist. The mode of communication introduced in this intervention condition is a developmentally chosen augmentative communication device. These devices are provided with a set of individually selected visual-graphic symbols and a relevant lexicon. The use of the device is taught within natural communicative exchanges within play routines and daily activities.
3212262|NCT01013558|Active Comparator|remifentanil|
3212263|NCT01013558|Placebo Comparator|saline|
2584358|NCT02337231|Other|GG genotype|Healthy participants with genotype GG at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
2584360|NCT02337231|Other|GT genotype|Healthy participants with genotype GT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
2584364|NCT02337231|Other|TT genotype|Healthy participants with genotype TT at rs174537 will take gel capsules that contain soybean oil (4-weeks) and borage oil (4-weeks) in a crossover study.
2584405|NCT02337036|Experimental|Arm 1: Pharmacokinetic and Pharmacogenetic|Liver Transplant Children treated with tacrolimus
2584437|NCT02336698|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
2584438|NCT02336698|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
2584439|NCT02336698|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks).
3212264|NCT01013571|Experimental|1|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; health care professional-managed
2584679|NCT02335099|Active Comparator|ticagrelor|90 mg of ticagrelor to be given orally twice a day for 6 months
2584683|NCT02335099|Placebo Comparator|Placebo|Placebo drug to be given twice a day for 6 months
2584720|NCT02334735|Experimental|DC Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptide-pulsed DCs:~DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) and KLH will be administered intracutaneous as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
2584722|NCT02334735|Active Comparator|Montanide Vaccine|"Study subjects receive KLH and NY-ESO-1 and Melan-A/MART-1 peptides and Montanide® ISA-51 VG:~Vaccine consisting of NY-ESO-1 peptide, Melan-A/MART-1 peptide, and KLH with an oil phase containing Montanide ISA-51 VG adjuvant will be administered subcutaneously as a single vaccine product followed by a subcutaneous injection of Poly-ICLC (Hiltonol®)."
2584799|NCT02334410|No Intervention|Reference|
2584803|NCT02334410|Experimental|Whole body vibration (WBV)|Vibration therapy
2584855|NCT02333981|Experimental|Passive oral motor therapy group|All the subjects received passive treatment which included light touch, stroking, vibration, tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
2584938|NCT02333617|Experimental|Dry Needling and Exercise|Dry Needling to treat gluteus medius trigger points followed by hip and core exercises.
2584946|NCT02333617|Active Comparator|Soft Tissue Mobilization|Soft tissue mobilization to treat gluteus medius trigger points followed by hip and core exercises.
2584956|NCT02333617|Placebo Comparator|Placebo Control|Placebo to control for hands on time and attention from therapist followed by hip and core exercises.
3260282|NCT01477866|Active Comparator|conventional therapy|conventional therapy
2585052|NCT02332525|Experimental|Intervention|20 elders (10 mild cognitive impairment, 10 cognitive normal elders) those who received oral vibrational stimulation
2583909|NCT02340559|Experimental|Meta-cognitive Training|"The metacognitive training program is comprised of eight modules targeting common cognitive errors in schizophrenia. The modules are : attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).~The treatment group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group."
2583916|NCT02340559|Active Comparator|Psychoeducational group|In the control group the modules worked were: 1. Healthy Habits, 2. Risk Behaviors, 3. Prevention of relapse, 4 and 5.Videoforum, 6. Resources of work and development of curriculum vitae 7. Leisure activities, and 8. Resources of the community. The psychoeducational group consist of 8 weekly sessions of 45-60 minutes with a total of 4 to 8 patients per group.
3212265|NCT01013571|Experimental|2|12-week run-in phase with Glargine +/- OADs followed by 24-week treatment phase with glulisine (AM) + glargine ; patient-managed
3212266|NCT01013584|Active Comparator|1,000 IU|1,000 IU/day of vitamin D3
2584029|NCT02339675|Other|convential MS rehabilitation|Investigate the quality (psychometric properties) and clinical utility of several measures of the upper limb function
2584103|NCT02339051|Experimental|One leg jumping|Study subjects will jump on one leg on repeated occasions (incremental daily repetitions) for a period of three months. The same leg will be used for jumping throughout the study. The other leg will serve as control.
2584147|NCT02338791|Experimental|Manual Mobilization|Grade I, II and III manual mobilizations in the inferior, posterior and distractive directions.
2584192|NCT02338453|Active Comparator|Attention Bias Modification Treatment|Participants will receive an attention bias modification protocol designed to divert attention away from socially-threatening stimuli via repeated trials of a dot-probe task.
2584193|NCT02338453|Placebo Comparator|placebo-control condition|Participants will receive an placebo control protocol using the same task and stimuli but not designed to change attention patterns
2584222|NCT02338167||Advanced/metastatic breast cancer|3,500 patients with locally advanced, inoperable/metastatic breast cancer in any line of treatment (e.g. 1st, 2nd, 3rd, or ≥ 4th line).
2584224|NCT02338167||Early breast cancer|10,000 patients with breast cancer in the neoadjuvant and adjuvant (early breast cancer) setting independent of treatment regimen.
3212267|NCT01013584|Active Comparator|5,000 IU|5,000 IU/day of vitamin D3
2584391|NCT02337166|Active Comparator|Control|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap
2584393|NCT02337166|Experimental|Test|open instrumentation of the root surfaces and bone defects via flap modified papilla preservation flap and application of a rhFGF-2/HA in the intrabony defect
2584431|NCT02336776|Experimental|Functional electrical stimulation group|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20s time off, intensity as patient tolerance, total session time ranged from 20 to 34 minutes.
2584432|NCT02336776|No Intervention|Control group|The patients in this group were evaluated at baseline and reassessed after eight weeks of follow-up.
2584457|NCT02336503|Experimental|BBI-4000 Dose 1|Low concentration of BBI-4000
2584459|NCT02336503|Experimental|BBI-4000 Dose 2|Middle concentration of BBI-4000
2584462|NCT02336503|Experimental|BBI-4000 Dose 3|High concentration of BBI-4000
2584465|NCT02336503|Placebo Comparator|Vehicle|Vehicle (placebo)
2584557|NCT02336139|Experimental|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose combination
2584597|NCT02335671|Experimental|Intra-operative Magnetic Resonance Imaging (MRI)|"Preoperative diagnostic MRI~Intra-operative MRI~Standard lumpectomy and sentinel node biopsy if indicated, or standard axillary dissection if clinically indicated~Specimen to Pathology and Mass Spectrometer (Analysis of Tissue Sample)"
3212268|NCT01013584|Active Comparator|10,000 IU|10,000 IU/day of vitamin D3
2584802|NCT02334345|Experimental|EVOSKIN|Patients are to apply Evoskin ( topical agent) in the half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
2584807|NCT02334345|Active Comparator|TRIXIERA|Patients are to apply Trixiera ( topical agent) in the other half of the irradiated breast 3 hours after radiothérapy and may be applied again later the same day.
2584842|NCT02333955|Experimental|3 mg IV push|GCS-100
2584897|NCT02333721|Experimental|D2 Lymphadenectomy including No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
2584900|NCT02333721|Active Comparator|D2 lymphadenectomy excluding No. 10|Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-preserving No. 10 lymph node dissection will be performed for the treatment of patients assigned to this group
2584939|NCT02333318|Experimental|Single Dose_VVZ-149 injection|"Cohort A (50-64 years old), Cohort B (65-84 years old)~For 2.5, 5mg/kg~4-hr intravenous infusion of VVZ-149 injection~6 subjects will be administered within each age group. Total 24 subjects will participate."
2584950|NCT02333318|Experimental|Loading/Maintenance_VVZ-149 injection|"Cohort A (50-64 years old) This trial is conducted only in the Cohort A one week after the single IV infusion.~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~4 subjects will be randomly assigned within each dose group, respectively. Total 8 subjects will participate."
2584955|NCT02333318|Placebo Comparator|Loading/Maintenance_Placebo|"Cohort A (50-64 years old)~For Loading + Maintenance dose: 0.75 mg/kg+ 0.55 mg/kg/h, 1.5 mg/kg + 1.10 mg/kg/h~intravenous infusion~2 subjects will be randomly assigned within each dose group, respectively. Total 4 subjects will participate."
2585115|NCT02332213||4. Group of control (colorectal)|Patients having undergone colonoscopy without an evidence for colorectal lesions fulfilling Group 1 or Group 2 or Group 3 criteria. Prior to removal of the lesions.
2585121|NCT02332213||5. Gastric cancer|Patients with histologically confirmed gastric cancer (adenocarcinoma)
2585124|NCT02332213||6. Gastric dysplasia|Patients without gastric adenocarcinoma but with histologically confirmed dysplasia (either high- or low-grade) of the stomach
2585940|NCT02327078|Experimental|(Phase 1, Part 1) : Nivolumab + Epacadostat|
3212269|NCT01013610|Active Comparator|Multiple Dose|
3212270|NCT01013610|Placebo Comparator|Placebo|
3260283|NCT01477879|Active Comparator|Versabase/20% S. purpurea extract|
2583915|NCT02340507|Experimental|Low glycemic index|The subject will consume a low glycemic index parboiled basmati rice for breakfast (75g available carbohydrates), and a low glycemic index multigrain bread for snack (25g available carbohydrates). The lunch is a standardized, weighed portion buffet.
2583945|NCT02340117|Experimental|SGT-53 with gemcitabine/nab-paclitaxel|A course of therapy will include 7 weeks of treatment. SGT-53, at 3.6 mg DNA/infusion, will be administered bi-weekly on days 1 and 5 in weeks 1-3, weekly on day 3 in week 4, and weekly on day 1 in weeks 5-7. Patients who are responding to treatment may receive two additional courses (7 weeks) of SGT-53/gemcitabine/nab-paclitaxel therapy at investigator discretion. If still responding to treatment, they may continue on SGT-53/gemcitabine/nab-paclitaxel at investigator discretion with the approval of the sponsor.
2584010|NCT02339779|Experimental|Autologous fat transfer reconstruction|Breast reconstruction achieved by serial autologous fat transfer (AFT) procedures, accompanied by external tissue expansion of the breast.
2584013|NCT02339779|Active Comparator|Reconstruction with breast implants|Control group will receive implant-based reconstruction, in some cases preceded by the implantation of a tissue expander.
2584086|NCT02339298|Active Comparator|Music group|music application
2584088|NCT02339298|Sham Comparator|Control group|only headphones
2584120|NCT02338895||acutly oliguric patients with ultrasound|Patients with septic shock and acute oliguria that will undergo bedside ultrasonographic assessment of inferior vena caval diameter, respiratory variation and renal perfusion.
2584250|NCT02338011|Experimental|Gefitinib alone|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib 250mg per day until progression of disease.
2584251|NCT02338011|Experimental|Gefitinib concurrent WBRT|Patients harboring an EGFR mutation with multiple BM from NSCLC will receive Gefitinib concurrent WBRT until progression of disease.Gefitinib was given 250mg per day. WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
3260284|NCT01477879|Placebo Comparator|placebo (versabase gel only)|placebo used will be versabase gel alone
2584423|NCT02337075|Experimental|Now Group - PATH Program|The Now Group will receive the PATH program. They will participate in a brief education session, use a wearable physical activity tracker, and physical activity mentoring by an Activity Mentors. In Month 1 and 2, participants will meet with their Activity Mentor once every 2 weeks to review their physical activity status, activity goals, and the health programs available at the Centre. In Month 3 and 4, they will continue to use physical activity tracker but will no longer have regular meetings with the Activity Mentor.
2584425|NCT02337075|Active Comparator|Later Group|The Later Group will receive the PATH program in Month 1-2. Intervention will be provided two months later (i.e., Month 3 and 4).
2584481|NCT02336542|Experimental|TB subjects|96 TB subjects are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
2584484|NCT02336542|Active Comparator|non-TB subjects with lung disease|96 non-TB subjects with lung disease are divided into four groups average .24 TB subjects are injected 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm,24 TB subjects are injected 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm.
2584536|NCT02336152|Experimental|Body suit|The patients will receive a body suit at least 30 min before start of general anaesthesia, and will keep the suit on until warm and comfortable in the post-operative unit. The suit is supplied with multiple snap openings to allow for draping, washing and surgery.
2584538|NCT02336152|Active Comparator|Forced warm air|The patients will receive forced warm air on their lower body when placed on operating table, ready for surgery.
2584561|NCT02335840|Experimental|One dose of coffee|Ingestion of one dose of 150 ml of coffee (144 mg of caffeine) ingested 10 minutes post-exercise (denominated CAF-1)
2584565|NCT02335840|Experimental|Two doses of coffee|Ingestion of two doses of 150 ml of coffee (144 mg of caffeine) ingested 10 and 20 minutes post-exercise (denominated CAF-2)
2584566|NCT02335840|Experimental|Three doses of coffee|Ingestion of three doses of 150 ml of coffee (144 mg of caffeine) ingested 10, 20 and 30minutes post-exercise (denominated CAF-3)
2584568|NCT02335840|Experimental|Three doses of decaffeinated coffee|Ingestion of three doses of 150 ml of decaffeinated coffee (144 mg of caffeine) ingested 10, 20 and 30 minutes post-exercise (denominated DESC)
2584601|NCT02335593|Experimental|Zinc group|Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.
2584605|NCT02335593|Active Comparator|Placebo group|Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.
2584646|NCT02335281|Experimental|Standardized FMT|The group include 20 patients. They will receive standardized FMT. The FMT was given to mid-gut by nose-jejunum nutrition tube. It was given only once.
2584647|NCT02335281|Active Comparator|Mesalazine|This group include 20 patients . The patients will receive traditional medicine of mesalazine treatment.
2584752|NCT02334644|Experimental|1|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
2584759|NCT02334644|Placebo Comparator|2|Placebo
2584787|NCT02334202|Active Comparator|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program for adolescent military dependents."
2584796|NCT02334202|Experimental|Interpersonal Psychotherapy-Weight Gain|IPT-WG is designed to decrease excessive weight gain among adolescents who are at risk for adult obesity. IPT-WG involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. The IPT-WG program has been adapted to be appropriate for military dependents.
2584845|NCT02333994|Experimental|GROUP A|EDUCATION PROGRAMME AND BALANCE TRAINING EXERCISES
2584846|NCT02333994|Active Comparator|GROUP B|BALANCE EXERCISES
2584893|NCT02333734|Experimental|Type 2 diabetic subjects|Type 2 diabetic subjects physical training (interval training 3 times at week) in a period of 8 weeks.
2583964|NCT02340065|Active Comparator|Endocuff-assisted colonoscopy|total polyp/adenoma detection with Endocuff-assisted colonoscopy, polyp/adenoma detection in the right colon with Endocuff-assisted colonoscopy
3177376|NCT00652106|Active Comparator|2|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution
3177377|NCT00652106|Active Comparator|3|0.2% brimonidine ophthalmic solution
3177378|NCT00652119|Experimental|Paclitaxel + Carboplatin + Avastin|"Paclitaxel Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.~Carboplatin Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.~Avastin Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle."
2584047|NCT02339350|No Intervention|Rapid early responder group|"RER Consolidation BM exam on day 63: M1, M2 -> IM M3 or residual CNS ds or Bx proven extramedullary ds - off protocol~RER Interim Maintenance #1~RER Delayed Intensification~RER Interim Maintenance #2~RER Maintenance (12 weeks=84 days)"
2584048|NCT02339350|Experimental|Slow early responder group|"Includes : SER, Testis(+), CNS 3, T-cell (non ETP), Initial PB WBC ≥ 100,000/μL~1. SER Consolidation~Intrathecal triple chemotherapy at d0, 7, 14, 21 2. SER Interim Maintenance #1~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 3. SER Delayed Intensification #1~Intrathecal triple chemotherapy at d0, 28, 35 4. SER Interim Maintenance #2~high dose methotrexate included~Intrathecal triple chemotherapy at d0, 28 5. SER Delayed Intensification #2~Intrathecal triple chemotherapy at d0, 28, 35 6. SER Maintenance~Intrathecal triple chemotherapy at d0"
2584100|NCT02339142|Experimental|Combined radiotherapy and iv corticosteroid|"Therapy: iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 weeks~+ External beam radiotherapy: 100 Rads to each orbit x 10 doses"
2584106|NCT02339142|Active Comparator|iv Corticosteroid|iv MP 500 mg iv weekly for 6 weeks, then 250 mg iv weekly for 6 week No Radiotherapy administered
2584347|NCT02337400|Experimental|Smoking Reduction Program|"Cognitive behavioral smoking reduction program Smoke_less Duration: 5 weeks with 4 weekly sessions over 2,5 hours and two phone calls"
2584348|NCT02337400|Active Comparator|Counseling Interview|15 minute counseling interview
2584349|NCT02337400|No Intervention|Waiting Control Group|
2584397|NCT02337140|Experimental|Pacemaker|Patient who have been implanted with a pacemaker after TAVI
2584404|NCT02337140|Active Comparator|No Pacemaker|Patient who have not been implanted with a pacemaker after TAVI
2584487|NCT02336724|Experimental|Famitinib|25 mg qd p.o.,28 days as one cycle,treatment discontinued when disease progression determined or intolerable toxicity or patients withdrawal of consent
2584576|NCT02335957|Other|Intentional irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast and nodal areas(axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
2584577|NCT02335957|Experimental|Incidental irradiation of lymph nodes|Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
2584695|NCT02334839||Preeclampsia|women with diagnosed preeclampsia
2584697|NCT02334839||gestational hypertension|women with diagnosed gestational hypertension without preeclampsia
2584701|NCT02334839||healthy|women without gestational hypertension or preeclampsia
2584735|NCT02334592|Experimental|Low Pressure 100W sunbed|
2584741|NCT02334592|Experimental|Low Pressure 160W sunbed|
2584747|NCT02334592|Experimental|High Pressure sunbed|
2584749|NCT02334592|No Intervention|Control group|
2584790|NCT02334293|Other|Omegaven|
2584874|NCT02334085||HOW study participants|
2584990|NCT02333136||IVRS studied|subjects will be monitored for changes in hematocrit based on results of in vivo raman spectroscopy scatter
2585265|NCT02331615|Sham Comparator|sham|The stimulator will be turned on for only a very short duration of time (msec) no meaningful stimulation is believed to be administered in such a way.
3177379|NCT00652132|Active Comparator|Arm I (cisplatin)|Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3177380|NCT00652132|Experimental|Arm II (cisplatin + STS)|Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
3177381|NCT00652158|Experimental|A|
3177382|NCT00652171|Active Comparator|1|17 Patients - Mean age of 26 years old, 14 female and 3 male - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
3177383|NCT00652171|Placebo Comparator|2|17 Patients - 11 females and 6 males mean age of 29 years old - with major depressive disorder in single or recurrent episodes, with moderate to severe intensity. Besides, They also had a history of treatment-resistant depression stage II or above according to the criteria of by Thase and Rush: failure to respond to treatment with at least 2 antidepressants of different classes, at the maximum tolerated dose for at least 6 weeks and absence of psychotic symptoms.
3177384|NCT00652184|Placebo Comparator|1|Placebo cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
3177385|NCT00652184|Active Comparator|2|Placebo cream BID for 10 days and active valaciclovir caplets TID from days 1-10
2583988|NCT02339935|Other|Control Group|20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
3212271|NCT01013623|Active Comparator|Best Medical Therapy|The best medical therapy group will not initially undergo surgery, but will be treated with the therapy that medical oncologists or surgeons feel is best for the patient. This treatment may include standard or experimental therapies.
2584139|NCT02338804|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line
2584140|NCT02338804|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line and simultaneous injection of mix vaccine (MV).
2584188|NCT02338531|Experimental|Therapeutic regimen|oral administration of PF-03084014, 9 days at 150 mg q.d. (day 1 and 9) and 150 b.i.d. (day 2 till 8)
2584234|NCT02338232|Experimental|160 mg Telmisartan|60 patients will receive 160 of Telmisartan (2 80 mg tablets) for 101 days
2584268|NCT02337881|Active Comparator|nifedipen and sildenafil|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours, at the same time sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
2584273|NCT02337881|Active Comparator|nifedipen only|nifedipine alone in the same regimen and duration described before.
3212272|NCT01013623|Active Comparator|Surgery Alone|The surgery alone group will undergo complete resection (surgical removal) of all known disease, if possible. After surgery, patients will be followed regularly and monitored for disease recurrence.
3212273|NCT01013623|Active Comparator|Surgery + BCG|The Surgery + BCG group will first have a complete resection (surgical removal) of all known disease, if possible. After recovery from surgery, two doses of BCG will be given two weeks apart. Each dose is given as 8 separate injections into the skin (called intradermal injections).
3212274|NCT01013636||Anaplasma|
2584427|NCT02336867|Experimental|Experimental group|closure clip (OTSC® Proctology Laboratory: OVESCO and French Distributor: Life Partners)
2584429|NCT02336867|Other|Control group|advancement flap technique
2584473|NCT02336529|Experimental|ICBN, active|Ultrasound guided injection of bupivacain, 10mL, 0.5% in proximity of the ICBN
2584477|NCT02336529|Placebo Comparator|ICBN, placebo|Ultrasound guided injection of NaCl, 10mL in proximity of the ICBN
2584479|NCT02336529|Experimental|Tenderpoint, active|Ultrasound guided injection of bupivacain, 20mL, 0.25% in the tenderpoint
2584483|NCT02336529|Placebo Comparator|Tenderpoint, placebo|Ultrasound guided injection of NaCl, 20mL in the tenderpoint
2584535|NCT02336009|Experimental|total wrist arthroplasty, Trimed|This is a pilot study where all patients will be operated with the Trimed total wrist arthroplasty.
2584579|NCT02335853||women with metabolic syndrome and overactive bladder|"women with urinary urgency+frequency+nocturia and current ATP III criteria define the metabolic syndrome as the presence of any three of the following five traits:~Abdominal obesity, defined as a waist circumference in men ≥88 cm~Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated triglycerides~Serum HDL cholesterol <40 mg/dL (1 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C~Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure~Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose"
2584581|NCT02335853||women with overactive bladder|women with urinary urgency+frequency+nocturia
2584584|NCT02335853||healthy control group|women not overactive bladder and metabolic syndrome
2584598|NCT02335554|Experimental|MoodHacker|Participants in the treatment condition were emailed a link to the MoodHacker mobile-web app and instructed to use the program for the next six weeks. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline.
2584599|NCT02335554|Active Comparator|Alternative Care|Alternative care participants were emailed and encouraged to browse links to vetted online information about depression. Participants were asked to complete 2 follow-up assessments, 6 weeks and 10 weeks after baseline and were given access to the MoodHacker program after the 10-week assessment
2584649|NCT02335359|Experimental|Tranexamic Acid|A 500 mg loading dose of tranexamic acid diluted in 100 ml of saline solution will be slowly administered intravenously to patients 20 minutes before surgery, followed by a continuos infusion of 250 mg/h of tranexamic acid from surgical incision until skin closure.
2584650|NCT02335359|Placebo Comparator|Placebo|Saline
2584693|NCT02334904||Aripiprazole|Participants receiving treatment of only aripiprazole, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
2584696|NCT02334904||Risperidone|Participants receiving treatment of only risperidone, as prescribed to them by their psychiatrists, for a minimum of at least 3 continuous months.
2584702|NCT02334904||Controls|Healthy participants who are not taking any antipsychotic medications.
2584753|NCT02334579|Experimental|CyberKnife Stereotactic Radiosurgery|This treatment concentrates large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. CyberKnife Stereotactic Radiosurgery is not investigational and is considered standard of care.
2584786|NCT02334254|Experimental|Dual antithrombotic therapy (DAT)|Dual Antithrombotic Therapy (DAT) regimen of rivaroxaban 2.5mg/5mg b.i.d. plus ticagrelor 90mg b.i.d.
2584792|NCT02334254|Active Comparator|Triple antithrombotic therapy (TAT)|Triple antithrombotic therapy (TAT) regimen of aspirin 100mg q.d., clopidogrel 75mg q.d. plus warfarin (INR 1.8-2.5).
2584850|NCT02334020|Experimental|Training course|12 hour training course in Mental Health First-aid
2584851|NCT02334020|Other|Waiting list|Waiting list design, hence delayed offering of Mental Health First-aid
2584907|NCT02333656|No Intervention|Control group|Usual care. The participants enrolled in the control period will receive OA treatment as it is currently offered in primary health care services.
2584909|NCT02333656|Experimental|Intervention group|New OA model. Health professionals attend an interactive workshop, implementation of international recommendations for OA care, multidiciplinary collaboration
3212275|NCT01013649|Active Comparator|Arm I (gemcitabine hydrochloride or combination chemotherapy)|Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
2584064|NCT02339454|Active Comparator|Active treatment group|"Patients in this group receive actual shockwave therapy. Study treatment consists of 9 sessions, with 3 sessions per week 1, 5 and 9. 100 shocks are delivered per spot, 1200 shocks per session.~During 1st treatment week ESMR will be delivered 3 times (every other day) to basal segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 2nd treatment week ESMR will be delivered 3 times (every other day) to middle segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions).~During 3rd treatment week ESMR will be delivered 3 times (every other day) to apical segments (2 spots in each wall in apical 4-, 2-, 3- chamber positions)."
2584066|NCT02339454|Placebo Comparator|Placebo group|This group of patients undergoes the same procedure as the treatment group; however shockwaves are not delivered to the heart.
3177386|NCT00652184|Experimental|3|Active cream BID for 10 days and placebo valaciclovir caplets TID from days 1-3 and active valaciclovir caplets 1 gram TID from days 4-10
3177387|NCT00652184|Other|4|Active cream BID for 10 days and active valaciclovir caplets TID from days 1-10
3177388|NCT00652197||Extraventricular Drainage|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
3177389|NCT00652210|Experimental|MPM|Subject tissue was reviewed using multiphoton microscopy
3177390|NCT00652223|Experimental|1|
2584184|NCT02338635|Experimental|URSA group|Drug: Ursodeoxycholic acid Other Name: URSAⓇ (Daewoong Pharmaceutical Co., Ltd) Ursodeoxycholic acid (100 mg/tablet) 300 mg/day ( 100mg tid) for 6 months 3 times after meal
2584185|NCT02338635|Placebo Comparator|Placebo group|Placebo drug 1 tablet tid for 6 months
2584218|NCT02338310|No Intervention|No Aromatase Inhibitor|No aromatase inhibitor given around the time of surgery
2584220|NCT02338310|Experimental|Aromatase Inhibitor|Aromatase Inhibitor given perioperatively for 4 weeks (two weeks before and two weeks after surgery) Choice of AI is according to centre policy and may be either anastrozole (1mg/day) or letrozole (2.5mg/day)
2584400|NCT02337101|Active Comparator|Enhanced Usual Care (EUC)|Clinical psychiatric and neurological assessment. Information and advice.
2584407|NCT02337101|Experimental|EUC + Early intervention programme|Clinical psychiatric and neurological assessment. Information and advice. Individually targeted treatment programme.
2584443|NCT02336711|Experimental|Dose escalation|Dose escalation
2584542|NCT02336061||male|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
2584544|NCT02336061||female|It will be stratified based on biological sex, age and smoking to guarantee homogeneity between the cohorts.
3177391|NCT00652236||FCT|Patients passing a function- centred rehabilitation
2584757|NCT02334709|Experimental|SBRT + fixed dose Tyrosine Kinase Inhibitor|Single arm phase I trial with 3 dose-escalation arms
2584898|NCT02333773|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Portal Venous Tumor Emboli
2584899|NCT02333773|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Portal Venous Tumor Emboli
2584901|NCT02333773|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Portal Venous Tumor Emboli
2585090|NCT02332369|Experimental|Device|Polymethylmethacrylate Capsular Tension Ring introduced into the posterior chamber of the eye following cataract surgery before the implantation of an intraocular lens.
2585138|NCT02332044|Experimental|Erdosteine 300mg|
2585140|NCT02332044|Experimental|Bepotastine besilate 10mg|
2585141|NCT02332044|Experimental|Erdosteine 300mg + Bepotastine besilate 10mg|
2585165|NCT02331745|Experimental|Granulocyte colony-stimulating factor|"Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).~Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time"
2585174|NCT02331745|Active Comparator|standard treatment|Standard treatment alone
2585241|NCT02331433|Experimental|Experimental: 1|
2585244|NCT02331433|Placebo Comparator|Placebo Comparator: 2|
2585948|NCT02327078|Experimental|(Phase 2): Nivolumab + Epacadostat|
3177392|NCT00652236||PCT|Patients passing a pain-centred rehabilitation
3177393|NCT00652249||Extraventricular Drainage/Pressure|Includes pediatric hydrocephalus patients that are in recovery from shunt explanation.
3177394|NCT00652262|Experimental|Arm 1|
3177395|NCT00652275|Experimental|A|"Biological/Vaccine: 189 volunteers will receive the Malaria vaccine MSP3 Long Synthetic Peptide (LSP)~Arms: MSP3 LSP vaccine Biological/Vaccine:MSP3 LSP 30 micrograms of MSP3 LSP~Arms: I, MSP3 LSP vaccine"
3177396|NCT00652275|Active Comparator|B|189 volunteers will receive standard vaccine against rabies on the similar schedule on days 0, 28, and 56
3177397|NCT00652288|Active Comparator|Catheter day 4|Adolescents with type 1 diabetes with catheters day #4
3177398|NCT00652288|Active Comparator|Catheter day 1|Adolescents with type 1 diabetes with catheter day #1
3177399|NCT00652288|Active Comparator|Aspart and Detemir|Adolescents with type 1 diabetes
3177400|NCT00652288|Active Comparator|Lispro and Glargine|Adolescents with type 1 diabetes
3177401|NCT00652301|Experimental|1|ezetimibe 10 mg tablet plus simvastatin 20 mg tablet
3177402|NCT00652301|Active Comparator|2|ezetimibe 10 mg tablet
3177403|NCT00652301|Active Comparator|3|simvastatin 20 mg tablet
3177404|NCT00652301|Placebo Comparator|4|matching placebo
3177405|NCT00652353|Experimental|Intervention|Participants will be given a standardized information sheet providing a mnemonics to help remember the Ottawa Ankle and foot Rules.
3177406|NCT00652353|Placebo Comparator|0|control group
3177407|NCT00652379|Experimental|1|Co-treatment with Pegvisomant (15-30 mg twice a week) and a 50 percent reduced somatostatin-analog dose
3177408|NCT00652379|Active Comparator|2|Somatostatin analog, unaltered dosage
3177409|NCT00652392|Experimental|1|
3177410|NCT00652392|Placebo Comparator|2|
3177411|NCT00652405|Experimental|treatment A|four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks)
3177412|NCT00652405|Placebo Comparator|Treatment B|Four weeks of water
3177413|NCT00652418|Active Comparator|Arm 1|
3177414|NCT00652418|Experimental|Arm 2|
2584070|NCT02339376|Experimental|Group 1|Low-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 1-Hz continuous stimulation at 95% resting motor threshold, with one session each day over 10 consecutive weekdays
2584071|NCT02339376|Experimental|Group 2|High-frequency repetitive transcranial magnetic stimulation: 30-minute sessions of 10-Hz continuous stimulation at 110% resting motor threshold, with one session each day over 10 consecutive weekdays
2584072|NCT02339376|Sham Comparator|Group 3|Sham repetitive transcranial magnetic stimulation: use of a specially fabricated coil that provides no magnetic stimulation but has a similar appearance and creates an auditory artifact that mimics TMS
3212276|NCT01013649|Experimental|Arm II (gemcitabine hydrochloride, erlotinib hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 4/2/14)
3212277|NCT01013649|Experimental|Arm III (chemotherapy)|Patients receive the same treatment as in arm I for 1 month.
2584275|NCT02337972|Experimental|Diabetic patients|Patients with Diabetes Mellitus and macular edema who were determined by their treating physician to require at least 3 serial injections with an anti-Vascular epithelial growth factor (VEGF). Prior to each injection a use of povidone-iodine 4% drops will be performed to clean the conjunctival sac
2584316|NCT02337569|Experimental|NPC-02|Oral dose
2584320|NCT02337569|Placebo Comparator|Placebo|Oral dose
3212278|NCT01013649|Experimental|Arm IV (chemotherapy, chemoradiotherapy)|Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO BID 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
3212279|NCT01013662|Active Comparator|glycemic control between 180 and 220 mg/dl|
3212280|NCT01013662|Active Comparator|glycemic control for levels between 80 and 110 mg/dl|
3212281|NCT01013675|Experimental|1|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
3212282|NCT01013675|Active Comparator|2|15 mcg hemagglutinin (HA) per viral strain; 0.5 mL single dose
3260285|NCT01477905|Experimental|Remi50 no prime|For using experimental target control infusion device (TCIs), targeting an effect-site concentration (Ceff) of 4.0 ng/ml, were randomly performed using 50 μg/ml (Remi50) of remifentanil, and without PRIMING,
2584549|NCT02335970|Experimental|Training group|Training program: Daily exercises for 3 months
2584551|NCT02335970|No Intervention|Controls|Standard care
2584575|NCT02335788|Other|Single arm - EMBA PED|The EMBA Peripheral Embolization Device when indicated for arterial and venous embolization in the peripheral vasculature.
2584625|NCT02335385|Active Comparator|SIL-V|single incision laparoscopic varicocelectomy
2584627|NCT02335385|Active Comparator|CTL-V|conventional transperitoneal laparoscopic varicocelectomy
2584654|NCT02335086||Stable angina patients|"Patients with stable angina not responding to 2 anti-anginals presenting for coronary angiography with the possibility of proceeding to stent implantation at Ashford and St. Peter's Hospital.~Clinical and angiographic exclusion criteria as stated in the study protocol."
2584660|NCT02335086||NSTEMI patients|"Patients presenting to Ashford and St. Peter's Hospital with an non ST-elevation myocardial infarction defined by :~Detection of a rise and/or fall of cardiac biomarker values (troponin I) with at least one value above the 99th percentile upper reference limit at analysing laboratories at Ashford and St. Peter's Hospital along with at least one of the following:~Symptoms of ischaemia~Development of pathologic Q waves in the electrocardiogram (ECG)~New or presumed new significant ST-segment-T wave (ST-T) changes on ECG.~Identification of an intracoronary thrombus by angiography.~Imaging evidence of new loss of viable myocardium or a new regional wall motion abnormality."
2584700|NCT02334969|Experimental|Experimental group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Naoxintong capsule, 2 times a day, three granule per time
2584703|NCT02334969|Active Comparator|Control group|On the basis of the secondary prevention of ischemic stroke，Volunteers will be taken Placebo capsule，which is identical with Naoxintong capsule in the appearance, shape, color and content, 2 times a day, three granule per time
2584776|NCT02334449|Experimental|Single dose study part|there will be 8 cohorts of healthy volunteers dosed with single doses of LML134 (8 planned dose levels) or with placebo and 2 potential additional cohorts (also dosed with single dose of LML134 or placebo)
2584778|NCT02334449|Experimental|Multiple dose study part|there will be 3 cohorts of healthy volunteers dosed with multiple doses of LML134 (3 planned dose levels) or placebo and one potential additional cohort (also dosed with multiple doses of LML134 or placebo)
2584821|NCT02334150|Experimental|CSEA group|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
2584822|NCT02334150|No Intervention|Control group|Women in the control group were not provided any analgesia during labor.
2584839|NCT02333903|Experimental|Personalized Physical Activity|Patients will undergo a personalized physical activity program after sleeve gastrectomy.
2584840|NCT02333903|No Intervention|Regular Activity|Patients will have regular physical activity after sleeve gastrectomy.
2584891|NCT02333747|Experimental|the TEAS group|Patients in the TEAS group received pre-operative TEAS for 30 min before the induction of anesthesia using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China) in the holding area. TEAS was applied to two pairs of acupoints: bilateral Hegu (LI4) and Neiguan (PC6).
2584896|NCT02333747|Sham Comparator|the sham group|In the sham group, the patients were connected to the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China), but electronic stimulation was not applied.
2584958|NCT02333305|Experimental|1|Coenzyme Q10 (CoQ10) - is a Dietary complement that contains Coenzyme Q10 (Ubidecarenone) well characterized nano particles.
2585119|NCT02332356|No Intervention|observation step down|
2584087|NCT02339363|Experimental|Sitting Meditation|4 weeks (45-min sessions, 2x per week) of sitting meditation, based on MBSR. The sitting meditation condition consisted of three parts: (a) breathing techniques, (b) meditation, and (c) discussion. Participants in the sitting meditation group learned new types of sitting meditation each week. Participants in the sitting meditation group received a CD that consisted of audio meditations that they could follow along at home. The sitting meditation participants were encouraged to practice formal sitting meditation for 15 to 30 minutes every day and asked to record details of their practice on their daily home practice logs.
2584090|NCT02339363|Experimental|Hatha Yoga|4 weeks(45-min sessions, 2x per week) of Hatha Yoga. The adolescent hatha yoga curriculum was used with permission from Shanti Generation Yoga © (2009) created by Abby Wills. The hatha yoga sessions consisted of three parts: (a) breathing techniques, (b) yoga poses, and (c) discussion. Participants in the hatha yoga group learned a series of new yoga poses each week, as well as reviewed old poses. During the first session, participants in the hatha yoga group received a DVD that contained five yoga lessons corresponding to the yoga poses being taught in the intervention. Participants were encouraged to practice the series of yoga poses at home for 15 to 30 minutes each day and record their home practice in their daily home practice logs.
2584092|NCT02339363|No Intervention|Waitlist Control|4-week waitlist control condition. Completed all study measures at same time points as experimental groups. Were randomly assigned to one of the two active treatment conditions after completing the waitlist period.
2584118|NCT02338908|Experimental|Experimental group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks. In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
2584122|NCT02338908|Active Comparator|Control group|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
2584145|NCT02338648|Experimental|SUN-131 1.5% TDS|Subjects will be randomly assigned to receive SUN-131 1.5% TDS for the affected eye. All patches will be worn for 16±4 hours each day for 21 days.
2584146|NCT02338648|Placebo Comparator|Placebo TDS|Placebo Patch for Blinding Purposes
2584197|NCT02338440|Experimental|lipoprostaglandin E1 treatment arm|"lipoprostaglandin E1 1mcg/kg/day, continuous infusion~lipoprostaglandin E1 1.5mcg/kg/day, continuous infusion (for patients with elevating total bilirubin, hepatomegaly, right upper quadrant abdominal pain, unexplained weight gain)"
2584239|NCT02338219|Active Comparator|vaginal delivery|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
2584246|NCT02338219|Active Comparator|elective cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
2584248|NCT02338219|Active Comparator|urgent cesarean section|postpartum female pelvic floor muscle affection postpartum sexual function in Egyptian women.
2584318|NCT02337647|Other|DCDC app|Subjects will evaluate the DCDC app
3212283|NCT01013688|Experimental|left atrial RF ablation groups|Excised the left atrial appendage Encircling the left pulmonary veins and an extension to the posterior mitral valve annulus From the left atrial appendage to the left superior pulmonary vein A connecting line between both islands of pulmonary veins From the middle of the mitral valve ablation line down towards the base of the atria ligament of Marshall
3212284|NCT01013688|Experimental|Bi-atrial radiofrequency ablation group|In the basis of left atrial group,excised the right atrial appendage; from the amputated right atrial appendage towards the inferior vena cava; from the midterm of interatrial septum to the AV groove; ablation between the superior and inferior caval cannulation sites; radiofrequency ablation for Waterston's groove
2584485|NCT02336490|No Intervention|Usual Care|discharge medication prescriptions are printed or sent electronically to a patient's pharmacy of choice
2584488|NCT02336490|Active Comparator|Meds-in-Hand|discharge medication delivery service: discharge prescriptions are filled at the hospital pharmacy and delivered to patients before they leave the hospital
2584540|NCT02336217|Experimental|Functioning App|These subjects have the complete algorithm functioning and communicated via the App.
2584545|NCT02336217|Placebo Comparator|Non-functioning App|These subjects receive routine instructions via the App but not the complete algorithm.
2584630|NCT02335437||Acute EBV infection|
2584632|NCT02335437||Healthy controls|
2584704|NCT02334943|Experimental|Treated HIV-1 infected patients|Treated HIV-1 infected patients for Blood test
2584705|NCT02334943|Experimental|No treated HIV-1 infected patients|No treated HIV-1 infected patients for Blood test
2584708|NCT02334943|Experimental|Healthy witness|Healthy witness for Blood test
2584726|NCT02334540|Other|purses or a calorie/protein matched smoothie|
3212285|NCT01013688|No Intervention|Amiodarone group|No radiofrequency ablation procedure during the valve surgery; Amiodarone 200 mg/day for 12 months after surgery
2584854|NCT02333812||copd patients|Adult patients with COPD
2584860|NCT02333812||healthy smokers|Adult patients with smoking history and no clinical manifestation of COPD who will be recruited form the institute of pulmonary medicine and the otolaryngology outpatient clinic.
2584863|NCT02333812||Adult patients with lung disease unrelated to smoking|Adult patients with lung disease unrelated to smoking
2584923|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (7-36)|"GLP-1 (7-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (7-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min.~A DPP-IV inhibitor - Januvia 100 mg is given the evening before and ½ an hour before the infusion is started."
2584924|NCT02333591|Active Comparator|GlucagonLikePeptide-1 (9-36)|GLP-1 (9-36) is diluted in saline and human serum albumin. Plasma levels of GLP-1 (9-36) are rapidly raised and then maintained stable with 5,91 pmol/kg/min (0-2 min) reduced to 2,53 pmol/kg/min (2-4 min) reduced to 2,34 pmol/kg/min (4-6 min) reduced to 2,2 pmol/kg/min (6-8 min) reduced to 2,02 pmol/kg/min (8-10 min) and then maintained stable for 2½ hours with 1.5 pmol/kg/min
2585103|NCT02332356|Active Comparator|step up|Procedure: MREC patients receive therapeutic step up
3212286|NCT01013714|Active Comparator|Routine Care + Cardiac Sympathetic Denervation (CSD)|"Patients in this arm receive routine care and undergo cardiac sympathetic denervation. The procedure must be scheduled to occur within one month of randomization.~Follow-up Visits~Follow up at 4 weeks after optimization of medical therapy and surgery~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
2584155|NCT02338596|Experimental|Conventional stem|total hip replacement operated with conventional stem (Profile; DePuy, Leeds, United Kingdom)
2584157|NCT02338596|Active Comparator|Ultra-Short stem|total hip replacement operated with ultra-short stem (Proxima; DePuy, Leeds, United Kingdom)
2584201|NCT02338414|Other|Romiplostim|Patients receiving romiplostim due to ITP
2584256|NCT02338115||Weekly paclitaxel treatment group|Breast cancer patients initiating paclitaxel 80mg/m2 weekly x 12 weeks for curative treatment will be followed prospectively for collection of samples and longitudinal neuropathy data.
3212287|NCT01013714|Placebo Comparator|Routine Care|"Patients in this arm remain on prescribed drug regimen and will not undergo CSD.~Follow-up Visits~Medical follow up at 4 weeks after optimization of medical therapy.~All patients are followed at the ICD clinic at 7 months or as needed.~Information regarding ICD therapy and arrhythmias will be obtained from ICD interrogations at the follow up visits.~Monthly phone calls will be used to determine for interval events, including presence of side-effects.~VT Ablation is permitted in both arms for ICD shock after optimization."
3212288|NCT01013727|Experimental|Postural Reconstruction|
3212289|NCT01013727|Active Comparator|muscular stretching|
2584450|NCT02336802||Healthy Control Group|Volunteers that meet no diagnostic criteria for mental disorders.
2584451|NCT02336802||Panic Disorder Group|Volunteers that meet diagnostic criteria for Panic Disorder.
2584454|NCT02336802||Phobic Disorder Group|Volunteers that meet diagnostic criteria for a Phobic Disorder.
2584456|NCT02336802||PTSD group|Volunteers that meet diagnostic criteria for Post-Traumatic Stress Disorder
2584523|NCT02336386|Experimental|CDD Plus Bortezomib|Patients will receive Bortezomib (1.3mg/m2) Subcutaneous injection on Days 1, 4,8,11 and plus dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, Liposome doxorubicin 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity.
2584524|NCT02336386|Active Comparator|CDD|Dexamethasone 20 mg/day PO on Days 1-4, 9-12,Cyclophosphamide 300mg/m2 D1-4, doxorubicin Dexamethasone 40mg D4 of each 28-day cycle; Patients may continue to receive treatment until PD or unacceptable toxicity
2584555|NCT02335996|Active Comparator|patients with active hypercortisolism|
2584556|NCT02335996|Active Comparator|Patients in remission of their hypercortisolism after surgery|
3212290|NCT01013766|Other|AM/PM/BID|Subjects will receive a dose of 100mg in the AM on Day 1, followed by a dose of 100mg in the PM on Day 4, and a dose of 50mg BID on Day 6.
3212291|NCT01013766|Other|PM/AM/BID|Subjects will receive a dose of 100mg in the PM on Day 1, followed by a dose of 100mg in the AM on Day 4, followed by 50mg BID on Day 6.
3212292|NCT01013779|Experimental|Arm A|Conventional radical radiotherapy in this trial means that those patients with microscopic disease receive a dose of 50Gy using daily incremental fractions of 2Gy over 25 fractions and those with macroscopic disease receive 54Gy in 27 fractions.
3212293|NCT01013805|Experimental|Arm 1|Integrated Preoperative Radiotherapy (external beam radiotherapy) and Chemotherapy (Oxaliplatin, Fluorouracil and Leucovorin), then surgical resection.
2584793|NCT02334280|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
2584797|NCT02334280|No Intervention|Usual-Care Control|Usual-care consumers agreed to delay participation in In SHAPE for 12 months.
2584885|NCT02333669||Control group|The control blood samples, which were collected from healthy neonatal umbilical cord blood, were obtained from the maternity ward of 80 hospitals in Chongqing and nearby areas
2584888|NCT02333669||RDS group|Newborns with RDS were consecutively recruited for this study from the neonatal intensive care unit (NICU) at Daping Hospital, Third Military Medical University, Chongqing, China, a tertiary care facility
2584940|NCT02333448||patients with suspected invasive candidiasis|
2584989|NCT02332941|Experimental|Single Arm|This is a pilot study. It will be an interventional, prospective, observational, clinical study that seeks to evaluate the effect of intravitreal rituximab over a period of one month.
3212294|NCT01013818|Experimental|HGS1029|
3212295|NCT01013831|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
3212296|NCT01013857|Active Comparator|Health coaching|Phone patients every week to discuss medication adherence
3212297|NCT01013857|Experimental|Health coaching plus home-titration|Health coaches call patients every week to discuss medication adherence and to intensify medications if appropriate according to physician-created algorithm
3212298|NCT01013896|Active Comparator|Cystic Fibrosis Education|This intervention is designed to increase knowledge and enhance the skills needed to optimize CF-management. The strategies used to achieve improved adherence include providing didactic education and skills training, and proscriptively using behavioral modification strategies, such as positive reinforcement for desired behaviors, and problem-solving training to overcome barriers.
3212299|NCT01013896|Experimental|Motivational Interviewing|The Counselor's overarching goal for the intervention is to motivate and assist the participant to improve his/her adherence to the CF pulmonary medications. The intervention will begin by providing the patient personal feedback on their adherence (using pharmacy refill data) and health outcomes (e.g., trajectory of lung function values, frequency of exacerbations) as well as clinic-level figures showing the association between adherence and health outcomes.
3212300|NCT01013909|Experimental|Arm 1|
3212301|NCT01013909|Experimental|Arm 2|
3212302|NCT01013909|Placebo Comparator|Arm 3|
3212303|NCT01013909|Placebo Comparator|Arm 4|
3212304|NCT01013909|Active Comparator|Arm 5|
3212305|NCT01013922||No treatment|Patients with a smoking history of 15 pack years or more.
2584217|NCT02338323|Experimental|Febuxostat|take orally, 40mg per day, for 1 year
2584219|NCT02338323|Experimental|Benzbromarone|take orally, 50mg per day, for 1 year
3212306|NCT01013935|Active Comparator|Full CARE+ Spanish computer-counseling group|
3212307|NCT01013935|Active Comparator|Brief risk assessment study group only (control)|
3212308|NCT01013948||N/A (Survey study)|
3212309|NCT01013974|Experimental|GSK573719 250 microgram (μg) arm|Each subject will receive the first dose of GSK573719 250 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
2584611|NCT02335684|Experimental|CF-LVAD patients.|Patients are compared with themselves during submaximal exercise testing with baseline pump speed vs. submaximal exercise testing with increased pump speed.
2584665|NCT02335112|Experimental|Group A|irreversible electroporation with voltage in level A for Unresectable Head and Neck Neoplasms
2584667|NCT02335112|Experimental|Group B|irreversible electroporation with voltage in level B for Unresectable Head and Neck Neoplasms
2584671|NCT02335112|Experimental|Group C|irreversible electroporation with voltage in level C for Unresectable Head and Neck Neoplasms
3212310|NCT01013974|Experimental|GSK573719 500 μg arm|Each subject will receive the first dose of GSK573719 500 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
2584801|NCT02334176|Active Comparator|single injection|Axillary plexus block performed with single injection dorsally to the artery
2584808|NCT02334176|Active Comparator|Double injection|Axillary plexus block performed with 2 injections: one over musculocutaneous nerve the second one dorsally to the artery
2584865|NCT02333929||VTE prevention|Prophylaxis of VTE in patients undergoing knee or hip replacement surgery (10 mg OD): orthopaedic department of the hospital will be in charge of the sample collection.
2584869|NCT02333929||DVT/PE treatment|Treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and risk reduction of DVT and PE recurrence; (15 mg BID for 3 weeks then 20 mg OD): different departments of the hospital will be in charge of the sample collection (samples can come e.g., from emergency room, vascular lab or cancer unit).
2584877|NCT02333929||SPAF|Stroke prevention and reduction of systemic embolism in non-valvular patients with atrial fibrillation (SPAF) (20 mg OD): cardiology department of the hospital will be in charge of the sample collection.
3212311|NCT01013974|Experimental|GSK573719 1000 μg arm|Each subject will receive the first dose of GSK573719 1000 μg on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3212312|NCT01013974|Placebo Comparator|Placebo|Each subject will receive GSK573719 matching placebo on Day 1 followed by once daily dosing for 7 days from Day 4 to Day 10 via a novel dry powder inhaler.
3212313|NCT01014000|Active Comparator|Empirical|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
2585016|NCT02332785||Composite Data Collection of Endoscopy of Serrated Polyps|Goal is to collect data from endoscopy reports & electronic medical record system to complete a descriptive analysis of the demographics, colonoscopy resection procedure, and outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 010/01/2014 - 12/31/2025.
2585056|NCT02332603|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
2585059|NCT02332603|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
2585100|NCT02332213||1. Colorectal cancer|Patients with histologically confirmed colorectal cancer (adenocarcinoma)
2585107|NCT02332213||2. Colorectal high-risk lesions|Patients without colorectal adenocarcinoma, but carrying high-risk adenomatous polyps being described by one of the following: 1) size≥1 cm; 2) high-grade dysplasia; 3) villous component. Prior to removal of the lesions.
2585111|NCT02332213||3. Colorectal low-risk adenoma|Patients without colorectal adenocarcinoma and without colorectal high-risk lesions as described under Group 2 criteria
2585308|NCT02331069|Active Comparator|Dextrose 5% (D5W) Injection|Glucose injection in 5% concentration, administered weekly X 4 times in a volume of 12 ml or less.
3212314|NCT01014000|Experimental|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
3212315|NCT01014039|Active Comparator|Flexible Sigmoidoscopy Screening arm|Intervention by flexible sigmoidoscopy screening
3212316|NCT01014039|No Intervention|Control arm|No intervention (no screening)
3212317|NCT01014065||1|Patients with renal cell carcinoma scheduled to receive sunitinib
3212318|NCT01014078|Experimental|Azithromycin Ophthalmic Solution, 1%|
3212319|NCT01014078|Placebo Comparator|Placebo|
3212320|NCT01014104|Experimental|Case|Administration of Methylprednisolone
3212321|NCT01014104|Sham Comparator|Control|
3212322|NCT01014117|Placebo Comparator|Placebo|"The Placebo treatment group will be administered eight oral placebo capsules once daily for 7 days.~A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days."
3212323|NCT01014117|Active Comparator|Placebo and 2.0g SRT2104|This treatment group will be administered eight oral placebo capsules once daily for 6 days followed by 2.0g SRT2104 administered as eight oral SRT2104 capsules on Day 7. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
2584209|NCT02338349|Experimental|Elacestrant|"Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant.~Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D.~Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD.~Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history"
2584259|NCT02338050|Experimental|Moxetumomab Pasudotox|Moxetumomab pasudotox 32 mcg/kg/dose IV every other day for a total of 6 doses. Dexamethasone 2.5 mg/m2/dose (or corticosteroid equivalent) will be administered before and after each dose of moxetumomab pasudotox.
2584418|NCT02336919|Experimental|Txt2Prevent|The treatment group will receive all the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the Txt2Prevent text-messaging program. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living texts. There will be two streams, one for current/recent smokers and one for non-smokers. Texts will be sent out every 1-3 days for 60 days. All participants in the same stream will receive the same texts in the same order.
2584420|NCT02336919|No Intervention|Usual Care|The usual care group will receive all standard discharge treatment, instructions and information for patients with acute coronary syndrome, but no text-messaging program. Nurses typically go over important information with patients before they leave as well as give them printed materials.
2584464|NCT02336581|Experimental|Acceptance and Commitment Therapy (ACT)|ACT which includes individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
2584467|NCT02336581|Active Comparator|Enhanced Treatment as Usual (eTAU)|Enhanced treatment as usual (eTAU) which includes other individual and group sessions during hospitalization and follow-up phone contacts the first month following hospital discharge.
2584511|NCT02336321|Experimental|BNCI hand-exoskeleton|Hand motor function before, during and after application of the device
2584534|NCT02336113|No Intervention|Control group|Standard care during hospital stay, without pharmacist involved
2584537|NCT02336113|Experimental|Pharmacist intervention|A pharmacist is included in the multidisciplinary treatment team during the hospital stay
2584610|NCT02335918|Experimental|Varlilumab and Nivolumab|
2584644|NCT02335151|Experimental|Desflurane|General anesthesia with Desflurane
2584645|NCT02335151|No Intervention|Propofol|General anesthesia with Propofol
2584713|NCT02334956|Experimental|Patient|Patient with addiction
2584714|NCT02334956|Experimental|Control|healthy subject
2584756|NCT02334514||Adults with influenza|Patients diagnosed with influenza by PCR testing
2584996|NCT02333019|Experimental|Let's Talk About Sex|Participants assigned to the treatment condition viewed a multimedia web site designed to help parents of pre-adolescent children, aged 10 to 14 years old, build skills to communicate effectively about parental values and issues relating to sexuality, sex and relationships, and preventing pregnancy and sexually transmitted infections.
2585004|NCT02333019|Active Comparator|Websites; preventing teen pregnancy|Participants assigned to the control condition were emailed urls for websites with information similar to the Let's Talk about Sex program. Parents were directed to the parents section of the National Campaign to Prevent Teen and Unplanned Pregnancy and children were directed to Nemours' KidsHealth website.
3177415|NCT00652431|Experimental|Vytorin + Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 + VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
3177416|NCT00652431|Active Comparator|Vytorin|VYTORIN 10/20 mg (1 x 10/20 mg tablet containing ezetimibe 10 mg and simvastatin 20 mg) once-daily in the morning for 7 days
3177417|NCT00652431|Active Comparator|Niaspan|NIASPAN 1000 mg (1 x 1000 mg tablet) once-daily in the morning on Days 1 to 2, followed by NIASPAN 2000 mg (2 x 1000 mg tablets) once-daily in the morning on Days 3 to 7 for a total of 7 days of treatment
3177418|NCT00652444|Experimental|1|Coadministration arm: simvastatin 20mg and ezetimibe 10mg
3177419|NCT00652444|Experimental|2|Monotherapy arm: simvastatin 20mg and ezetimibe placebo
3177420|NCT00652470|Active Comparator|ETV|
3177421|NCT00652470|Active Comparator|CSF Shunt|
3177422|NCT00652483|Experimental|1|Brimonidine ophthalmic solution 0.1%
3177423|NCT00652483|Active Comparator|2|Brimonidine ophthalmic solution 0.2%
3177424|NCT00652496|Experimental|1|Bimatoprost 0.01% ophthalmic solution
3177425|NCT00652496|Experimental|2|Bimatoprost 0.015% formulation 1 ophthalmic solution
3177426|NCT00652496|Experimental|3|Bimatoprost 0.015% formulation 2 ophthalmic solution
3177427|NCT00652496|Experimental|4|Bimatoprost 0.02% ophthalmic solution
3177428|NCT00652496|Active Comparator|5|Bimatoprost 0.03% ophthalmic solution
3177429|NCT00652509|Experimental|1|IDEA
3177430|NCT00652509|Active Comparator|2|IE
3177431|NCT00652509|No Intervention|3|UC: Patients receive no research intervention.
3177432|NCT00652522|Active Comparator|A|Best Medical Treatment, ICD/CRT implant
3177433|NCT00652522|Experimental|B|AF Ablation, ICD/CRT implant
3177434|NCT00652561|Experimental|1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks.
3177435|NCT00652574|Experimental|Dasatinib|Dasatinib = BMS-354825, Sprycel
3177436|NCT00652587|Experimental|A, LRTACE|hepatectomy with adjuvant transcatheter arterial chemoembolization
3177437|NCT00652587|Active Comparator|B, LR|hepatectomy alone
3177438|NCT00652600|Experimental|A|Subjects received Par formulated product under fed conditions
3177439|NCT00652600|Active Comparator|B|Subjects received Wyeth Pharmaceuticals formulated product under fed conditions
3177440|NCT00652613|Active Comparator|1|3 dimensional conformal radiotherapy
3177441|NCT00652613|Experimental|2|Intensity Modulated Radiation Therapy (IMRT)
2584253|NCT02337985|Experimental|Treatment (R-EPOCH, rHIV7-shI-TAR-CCR5RZ-transduced HSPC)|"Patients receive prednisone PO BID on days 1-5; rituximab IV on day 1; etoposide IV over 96 hours, doxorubicin hydrochloride IV over 96 hours and vincristine sulfate IV over 96 hours on days 1-4; and cyclophosphamide IV over 30-60 minutes on day 5. Patients then receive filgrastim SC QD beginning on day 6 and continuing until absolute neutrophil count recovers. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Patients then receive lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic stem/progenitor cells IV on day 0 (48 hours after the final combination chemotherapy course.)"
2584327|NCT02337621||pectus excavatum surgical candidates|Any person who is eligible to undergo the Nuss procedure for surgical correction of pectus excavatum
2584368|NCT02337322|Active Comparator|ABC+3TC+DTG|Abacavir+lamivudine+Dolutegravir, QD, Single tablet Regimen
2584369|NCT02337322|Active Comparator|ABC+3TC+DRV/r|Abacavir+lamivudine+ritonavir-boosted darunavir, QD
2584430|NCT02336945||Type 2 diabetes|Subjects with type 2 diabetes who meet one of the therapy conditions
2584478|NCT02336516|Experimental|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ®
2584480|NCT02336516|Placebo Comparator|Glucose solution 10%|Glucose solution 10%
2584539|NCT02336230|Experimental|Active Treatment|
2584621|NCT02335645||Body Weight Supported Treadmill|Post surgical ACL patients who will complete standard ACL protocol with the addition of body weight supported treadmill use.
2584668|NCT02335242|Placebo Comparator|Placebo tablets (resembling Revatio)|Placebo Drug: Placebo tablets (resembling Revatio)
2584672|NCT02335242|Experimental|Sildenafil 20 mg tablets (Revatio)|Active Drug: Sildenafil tablets (Revatio)
2584728|NCT02334475|Experimental|GROUP (P)|Ultrasound guided sacroiliac joint injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml) per course. Single injection per course is being given.
2584730|NCT02334475|Active Comparator|GROUP (S)|Ultrasound guided sacroiliac joint injection of 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml). Single injection per course is being given.
2584838|NCT02333916|Experimental|Overfeeding + exercise pre/post training|"overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period."
2584927|NCT02333474|Active Comparator|control|Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.
2584936|NCT02333474|Experimental|MV+control|Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given
2585018|NCT02333006|Other|Traumatic brain injury questionnaires|Traumatic brain injury patients with anosognosia will answer to quetionnaires about Anosognosia compare to the answer of participant without neurological deficits
3177442|NCT00652639|Experimental|A|Subjects received the kali formulated products under fasting conditions
3177443|NCT00652639|Active Comparator|B|Subjects received the Roche formulated products under fasting conditions
2585172|NCT02331719||MiSPACE Eligible Cohort|This will be a prospective record review of patients where the MiSPACE technique is being/was used for the treatment of their ICH.
2585185|NCT02331719||Historical Cohort|This is a retrospective records review of patients who received either medical intervention or conventional surgical intervention for the treatment of their ICH.
2585354|NCT02330835|Experimental|In the Driver's Seat|Treatment materials. In the Driver's Seat: A Roadmap to Managing Student Behavior on the Bus is a comprehensive multimedia program that guides transportation departments in creating and maintaining a safe, responsible, and positive environment on the school bus through effective student behavior management. The program includes three components: 1) In the Driver's Seat: Transportation Supervisor Program for transportation department administrative staff, 2)In the Driver's Seat: Group Lessons DVD for Drivers. The DVD-based curriculum is designed to be facilitated by a transportation supervisor or driver trainer in groups and 3)In the Driver's Seat: Bus Driver Program. This CD-ROM-based program for bus drivers.
2585356|NCT02330835|Active Comparator|School bus driver training videos|Control materials. Bus drivers in the control condition viewed two linear videos on study computers. In Session 1 of the intervention, Control drivers viewed School Bus Driving, Part 1, 2nd Edition, © 1991, AIMS Media, 23-minute linear video showing defensive driving techniques. In Session 2, Control drivers viewed Decide Smart, Arrive Safe, © 2005, Operation Lifesaver, Inc., a video about school bus safety at railroad crossings produced in conjunction with the National Association of State Directors of Pupil Transportation services. Supervisors in the control condition received no materials until completing the study (waitlisted).
2585415|NCT02330497|Experimental|Radiofrequency|Procedure/Surgery Thermal Radiofrequency Ablation under endoscopic ultrasonography guidance of the pancreatic neuro endocrine tumor or mucinous cyst.
3177444|NCT00652665|Experimental|A|Subjects received kali product under fasting conditions
3177445|NCT00652665|Active Comparator|B|Subjects received Aventis product under fasting conditions
3177446|NCT00652704|Experimental|A|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fed conditions
3177447|NCT00652704|Active Comparator|B|Subjects received the reference product, Monodox (Oclassen) under fed conditions
3177448|NCT00652704|Experimental|C|Subjects received the test product, Doxycycline Monohydrate Capsules (Par) under fasting conditions
3177449|NCT00652717|Experimental|1|arm 1 - Ezetimibe 10 mg daily that was added on Statin Therapy (prescribed clinically suitable dose by the physician).
3177450|NCT00652717|Active Comparator|2|arm 2- simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
3177451|NCT00652730|Experimental|A|Subjects received the Par formulated product under fasting conditions
2584258|NCT02338037|Experimental|Treatment (eribulin mesylate)|Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0. Beginning at least 24 hours later, patients receive eribulin mesylate IV over 2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
2584296|NCT02337660|Experimental|Healthy, lean|"15 healthy, lean subjects.~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
2584299|NCT02337660|Experimental|Obese, otherwise healthy|"15 obese, otherwise healthy subjects~Will have a liver biopsy, and on the experimental day a pancreatic clamp will be performed."
2584334|NCT02337452||Observational (family outreach program)|Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
3212324|NCT01014117|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight oral SRT2104 capsules once daily for 7 days. A trained investigative site member will administer the test material to subjects on Day 1, 2, and 7. On Days 1, 2 and 7 the subjects will receive SRT2104 or placebo approximately 15min following the consumption of a standardized meal at the study center. During non-clinic days, the subject will self-administer the test material approximately 15 min following consumption of a standardized meal at home. Test material should be administered with approximately 400mL of water. On Days 1 and 7, dosing will occur at approximately 7AM. Dosing on Days 2-6 will occur before 9AM. Subjects must wait at least 1-2 hrs after dosing before consuming additional calories on all dosing days.
3212325|NCT01014130|Active Comparator|Arm 2|Conventionally Fractionated Radiotherapy (ConRT) - Standard of Care
2584468|NCT02336841|Experimental|Intervention|Participants in this condition will receive the guided self-help intervention.
2584471|NCT02336841|Active Comparator|Control|Participants in this condition will not receive the guided self-help intervention. They will receive treatment as usual and weekly feedback on their eating disorder symptoms for a period of 6 weeks.
2584563|NCT02335879|Experimental|Recombinant Human Follitropin|
2584613|NCT02335697|Other|Intervention|Attitude change towards female circumcision
2584614|NCT02335697|Other|No intervention|No intervention
2584626|NCT02335307||Control|Patients will continue to receive their current pain management therapy. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
2584628|NCT02335307||Implementation|Patients will undergo CYP2D6 genotyping, with results entered into the medical record to assist the physician with prescribing pain medication. In addition, a pain assessment questionnaire will be administered at baseline and 3 months.
2584629|NCT02335307||Physician assessment|At the end of the study, a 20-item survey will be administered to physicians who treated patients enrolled in the study. The survey will assess whether having CYP2D6 genotype results is useful to inform prescribing decisions for pain medication from the physician's perspective.
2584848|NCT02334111|No Intervention|(Control)|Patients will receive standard of care
2584849|NCT02334111|Experimental|(Intervention)|Patients will receive RESPECT-Plus intervention
2584884|NCT02333695|Experimental|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
2584929|NCT02333409|Active Comparator|Electroacupuncture|A Hong Kong registered Chinese Medicine practitioner will give Electroacupuncture treatments. Patients will be treated in a comfortable prone position. Jiaji (Ex-B2) points form T8 to T12 bilaterally are chosen based on traditional Chinese medicine (TCM) theory and neurophysiologic basis of Jiaji points. After De Qi sensation is achieved, the handles of needles on homolateral T8-T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1 mA with a disperse-dense waveform. The needles remained for 30 min. The treatment was given twice weekly on week 1 and week 3.
2584944|NCT02333409|Sham Comparator|Sham|For placebo acupuncture, sham placebo acupuncture needles (DongBang AcuPrime Acupuncture Inc., South Korea) will be used. Its validity and credibility have been well demonstrated. The needles with blunt tips are quickly put onto the same points used in the electroacupuncture group without inserting into the skin. The needles on homolateral T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
3212326|NCT01014130|Experimental|Arm 1|Hypofractionated radiotherapy (HypoRT) - Investigational
2585234|NCT02331654|Experimental|Experimental Treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes: the anode will be placed on the thoracic spinal cord (over the spinal process of the tenth thoracic vertebra) and the cathode (reference) above the right shoulder. Stimulating electrodes will be thick (6 mm), rectangular pieces of saline-soaked synthetic sponge. The sDCS polarity (anodal) will refer to the electrode over the spinal cord.
2585237|NCT02331654|Placebo Comparator|Placebo treatment|For sham sDCS (placebo), electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s.
2585295|NCT02331225||Systemic sclerosis, no pulmonary hypertension|This group will be systemic sclerosis patients without pulmonary hypertension
2585296|NCT02331225||Systemic sclerosis/pulmonary hypertension|This group will be systemic sclerosis patients with pulmonary hypertension
2585297|NCT02331225||Healthy controls|These will be healthy age- and sex-matched controls
2585301|NCT02330926|Experimental|multimodal intervention|standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)
2585304|NCT02330926|Active Comparator|standard care|standard palliative care
2585486|NCT02330133|Experimental|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
2584279|NCT02337855|Experimental|Group D|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
2584284|NCT02337855|Experimental|Group E|N=10 subjects will receive single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
2584287|NCT02337855|Placebo Comparator|Group F|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
2584288|NCT02337855|Experimental|Group G|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113
2584289|NCT02337855|Experimental|Group H|N=10 subjects will receive single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113
2584290|NCT02337855|Placebo Comparator|Group I|N= 4 subjects will receive single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113
2584321|NCT02337426|Experimental|Treatment (dimethyl fumarate, temozolomide, radiation therapy)|"CONCOMITANT THERAPY: Between 21 days (3 weeks) and 42 days (6 weeks) following the last surgical procedure, patients receive temozolomide PO QD for 42-49 days and dimethyl fumarate PO BID or TID continuously. Patients also undergo radiation therapy 5 days a week over 6 weeks for a total of 30 fractions~MAINTENANCE THERAPY: Patients continue to receive dimethyl fumarate PO BID or TID continuously. Four weeks after completing concomitant temozolomide and radiation therapy, patients also receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity."
2584417|NCT02336906|Active Comparator|Urotherapy + Constipation Treatment|This group will be treated with standard behavioral urotherapy in addition to receiving active stool softening with PEG3350 and standard constipation instruction.
2584419|NCT02336906|Other|Urotherapy alone|This group will receive standard behavioral urotherapy alone.
3212327|NCT01014156|Experimental|epoprostenol intraveneously|epoprostenol iv versus placebo iv, both on top of low molecular weight heparin
3212328|NCT01014182||Early PCI|Routine invasive strategy with early PCI performed in STEMI patients within 24 hours from successful fibrinolysis
3212329|NCT01014182||Standard Therapy|Standard therapy in STEMI patients with fibrinolysis and/or conventional ischaemic-guided therapy.
3212330|NCT01014195||Group 1|"Survivors of pediatric leukemia treated on Total Therapy Protocol XV (TOTXV) at St. Jude Children's Research Hospital (SJCRH), who are ≥ 8 years of age and ≥ 5 years from diagnosis.~Intervention: Neurocognitive and behavioral evaluation"
3212331|NCT01014221|Experimental|Acupuncture group|acupuncture administered in 8 sessions over 4 weeks
2584715|NCT02334917|Experimental|Absorbable suture closure|Patients will have half of their surgical wound closed using one kind of absorbable superficial sutures, and the other half with a different kind of absorbable superficial suture. Which half receives which suture will be randomly determined.
3212332|NCT01014221|Active Comparator|Steroid group|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
2584836|NCT02334046|Experimental|Elderly|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in elderly patients.
2584837|NCT02334046|Active Comparator|Adult|Remifentanil was maintained at predetermined effect-site concentration during the emergence period in adult patients.
2584852|NCT02333786|Experimental|Infant|Radial artery or posterior tibial artery of patients younger than 1 year old are either cannulated with short-axis/out-of-plane or long-axis/in-plane US-guided arterial catheterization technique.
2584853|NCT02333786|Experimental|Preschool child|Radial artery or posterior tibial artery of patients older than 1 year old and younger than 5 years old are either cannulated with long-axis/in-plane or short-axis/out-of-plane US-guided arterial catheterization technique.
2584935|NCT02333578|Experimental|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
2585009|NCT02333084|Experimental|Joint Health Product|natural dietary supplement
2585010|NCT02333084|Placebo Comparator|Placebo|vegetable oil placebo
2585012|NCT02333084|Active Comparator|Combination with Omega-3|combination with omega-3 fish oil
2585045|NCT02332564||Coronary Artery Disease|Patient with significant coronary artery disease
2585048|NCT02332564||No Coronary Artery Disease|Patient without significant coronary artery disease
2585118|NCT02332109||ODM 5-group|
2585200|NCT02331953||delirium group|the patients with delirium after spine surgery
2585203|NCT02331953||no delirium group|the patients without delirium after spine surgery
2585262|NCT02331615|Experimental|Right|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: Right hemisphere anodal stimulation of the dorso lateral frontal area (F3), left hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of 1.5 mA (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
2585264|NCT02331615|Experimental|left|Electrode positioning will be determined according to the EEG 10-20 international system for EEG electrode placement: left hemisphere anodal stimulation of the dorso lateral frontal area (F3), right hemisphere catodal stimulation of the dorso lateral frontal area (F4). Intensity of mA1.5 (milliampere) for duration of 15 minutes. A total of 9 sessions: 4 sessions a week for 2 weeks.
2585317|NCT02331069|Active Comparator|Physical Therapy|Physical therapy for a month in the posterior deltoid region 3 times a week.
3212333|NCT01014234|Experimental|Rapamycin|Maintenance treatment with rapamycin + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
3212334|NCT01014234|Active Comparator|cyclosporine|Maintenance treatment with cyclosporine + mycophenolate + prednisone. This treatment will be introduced one month after renal transplantation.
3212335|NCT01014247|Active Comparator|Arm 1|
3212336|NCT01014247|Placebo Comparator|Arm 2|
3212337|NCT01014260|Placebo Comparator|Placebo|placebo
3212338|NCT01014260|Active Comparator|Doxycycline|Doxycycline
3212339|NCT01014273|Active Comparator|Trans-femoral access|Femoral artery PCI access site
3212340|NCT01014273|Active Comparator|Trans-radial access|Radial artery PCI access site
2584280|NCT02337894|Experimental|Essential amino acids plus arginine|Children randomized to the intervention group will receive a supplement containing essential amino acids plus arginine in the form of a drink which they will have to take for 8 weeks. Measurement of liver lipid content, hepatic apoptosis, plasma lipids, apolipoprotein B-100 levels, hepatic fatty oxidation, whole body insulin sensitivity, body composition and whole body protein turnover will be compared with the the placebo group, and before and after the intervention.
2584283|NCT02337894|Placebo Comparator|Control drink|The control drinks will be indistinguishable from the intervention drinks in taste and volume, but will contain placebo rather than essential amino acids plus arginine.
2584324|NCT02337556|Experimental|Intervention Group|Peptamen Bariatric
2584331|NCT02337556|Active Comparator|Control Group|Replete
2584357|NCT02337257|Active Comparator|cholecalciferol|Subjects will take 4000 IU per day for 30 days
2584362|NCT02337257|Placebo Comparator|Placebo|Subjects will take placebo everyday for 30 days
2584401|NCT02337010|Active Comparator|Control|In the control group if the mean arterial pressure fall below 60 mm Hg and the central venous pressure (CVP) is low fluid bolus is administered if the central venous pressure is in normal range vasopressor is given.
2584408|NCT02337010|Experimental|CeVOX|In the ScvO2 group patients receive interventions in two options: if the ScvO2 fall below 75% or more than 3% or if the mean arterial pressure fall below 60 mm Hg. In the former case the mean arterial pressure in the latter the ScvO2 values determined if tha patient received fluid or vasopressor or both.
2584470|NCT02336646|Experimental|Low Dose Allogenic MSC|Low dose allogenic mesenchymal stem cells with IM injection
2584474|NCT02336646|Experimental|High Dose Allogenic MSC|High dose allogenic mesenchymal stem cells with IM injection
2584476|NCT02336646|Placebo Comparator|Placebo|normal saline with Intramuscular injection
2584558|NCT02336243|Experimental|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA) 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
2584560|NCT02336243|Placebo Comparator|Placebo|Placebo 200 mg capsules, 3 capsules by mouth every day, from early gestation until the end of pregnancy
2584687|NCT02335034|Experimental|Study group|Intervention: study group will attend two days of classes (two months apart) with the seven professional teams, covering what is the disease arthritis, its causes and treatment options; what is disease, being ill, and the role of the patient in the treatment to obtain behavioral change; the importance of exercise in relieving symptoms, the importance of rest and proper ergonomics at home and at work; proper alimentation; the difference between labor work and regular physical activity as well as the importance of strength resistance and stretching exercises; and the importance of leisure. The second intervention verifies the acquired concepts.
2584688|NCT02335034|Experimental|Control Group|The control group will only make evaluations / consultations with all professional teams without classes for 2 years, then will attend the courses and will be followed by two more years.
2584740|NCT02334488|Active Comparator|Everolimus-Tacrolimus|"Tacrolimus (Prograf®) started at 0,1 mg/kg/day since Day0, then adapted to C0 concentration (4-7 ng/ml),~Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml)."
2584746|NCT02334488|Experimental|Everolimus-Mycophenolate sodium|"Everolimus (Certican®) started within 24h after reperfusion, to be adapted to C0 concentration (3-8 ng/ml),~Tacrolimus (Prograg®) started at 0,1 mg/kg/day from J0 then to be adapted to C0 concentration (4-7 ng/ml), then replacement by mycophenolate sodium (Myfortic®) at M3 (3 months visit) started at 1440 mg/day."
2584828|NCT02334137||iPad app|This group will have unlimited access to educational iPad app while waiting for ophthalmology visits.
2584831|NCT02334137||Educator sessions|This group will have unlimited access to educational iPad app AND at least one appointment with a certified diabetes educator or registered dietitian while waiting for ophthalmology visits.
2584832|NCT02334137||Educator sessions + retinal photos|"This group will have same access as iPad app + education sessions and in addition will be able to briefly review their own retinal photos (compared to normal retina) with a resident ophthalmologist during timeline of pilot program."
2584880|NCT02333838|Experimental|Reduced toxicity conditioning regimen|"Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.~The conditioning regimen will include:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)~In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:~IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)~IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)~IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)~IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)"
2584930|NCT02333344|Experimental|Zoledronic acid 5mg|interventional group which receive yearly Zoledronic acid 5mg/100ml infusion treatment for two years
2584943|NCT02333344|No Intervention|blank|blank group
2585058|NCT02332733|Experimental|TV003 Vaccine|Participants will receive a single injection of TV003 at Days 0 and 180.
2585062|NCT02332733|Placebo Comparator|Placebo vaccine for TV003|Participants will receive a single injection of placebo for TV003 at Days 0 and 180.
3177452|NCT00652730|Experimental|B|Subjects received the Par formulated product under fed conditions
3177453|NCT00652730|Active Comparator|C|Subjects received the Bristol-Myers Squibb formulated product under fed conditions
2585198|NCT02332005|Active Comparator|Group 1 150 mg|150 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of either 150 mg diepalrestat choline or placebo
2585202|NCT02332005|Active Comparator|Group 2 300 mg|300 mg diepalrestat choline administered as twice daily dosing morning and evening with an oral tablet of 150 mg diepalrestat choline
3177454|NCT00652756|Experimental|1|Patient is placed on a transport ventilator.
3177455|NCT00652756|Other|2|Patient is ventilated using the current standard at this institution.
2584406|NCT02337114|Experimental|Intervention group|Treatment as Usual and Acceptance & Commitment Therapy
2584409|NCT02337114|Other|Comparison group|Treatment as Usual
2584440|NCT02336685|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase in addition to opioids as standard of care.
2584441|NCT02336685|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase in addition to opioids as standard of care.
2584444|NCT02336685|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase in addition to opioids as standard of care.
3177456|NCT00652769|Active Comparator|B|Control arm: Current practice for diagnosing and staging lung cancer. Most patients with intra-thoracic disease suspected of lung cancer will undergo bronchoscopy (or CT guided biopsy), PET scan and possibly mediastinoscopy.
2584612|NCT02335515|Experimental|Soctec / Capsule|HS intakes one(1) Soctec Capsule after standardized breakfast
2584651|NCT02335398|Experimental|methadone|single group
2584691|NCT02334878|Experimental|Stem cells,Mesenchymal|Periurethral injection of autologous bone-marrow derived stem cells.
2584692|NCT02334878|Active Comparator|surgery (TVT)|Tension-free vaginal tape operation: a midurethral sling operation
2584755|NCT02334631|Experimental|High volume simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
2584761|NCT02334631|Active Comparator|Standard volume simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
2584833|NCT02334189|Experimental|Letter|Patients receive a letter containing information on alternative healthcare options for non-emergency health concerns.
2584834|NCT02334189|No Intervention|No letter|Patients receive no letter (this is the usual care).
2584867|NCT02333877|Experimental|Skinlink|applying Skinlink on simple laceration (length < 5cm)
2584873|NCT02333877|Other|Nylon|applying conventional suture using nylon on simple laceration (length < 5cm)
2584934|NCT02333539|Experimental|Tailored feedback|Participants are provided a Tailored Feedback report based on data downloaded from their insulin pumps. Summaries are provided about insulin pump adherence behaviors and recommendations for improvement are made.
2584949|NCT02333539|Experimental|Problem Solving|Participants receive a problem-solving session based on data downloaded from their insulin pumps. An insulin pump adherence behavior that needs improvement is targeted; goals are set and solutions generated.
2584952|NCT02333539|No Intervention|Treatment as Usual|Standard of care as provided by the endocrinologist occurs.
3212342|NCT01014312|Experimental|Depression Care Management (DCM)|Participants will receive Depression Care Management.
3212343|NCT01014312|Active Comparator|Enhanced Care|Participants will receive the standard of care from their primary care physicians enhanced by a summary of the study's diagnostic interview.
2585066|NCT02332408|Experimental|Cybernetic microradiosurgery|Hypofractionated microradiosurgery using Cyber Knife to the vertebral hemangioma to the total dose of 25 Gy in 5.0 Gy per fraction, 2 or 3 days a week over the period of 2 weeks,
2585075|NCT02332408|Active Comparator|Conventional radiotherapy|Conventionally fractionated external beam conformal radiotherapy to the vertebral hemangioma to the total dose of 36 Gy in 2.0 Gy per fraction, 5 days a week over the period of 3,5 weeks,
2585097|NCT02332174|Experimental|200-mg group|Ten healthy subjects were administered a single oral dose of 200 mg rufinamide tablets in fasted and fed state at day 1 and then received repeated oral doses of rufinamide (200 mg) once daily for 6 days.
2585102|NCT02332174|Experimental|400-mg group|Ten healthy subjects were administered a single oral dose of 400 mg rufinamide tablets in fasted state.
2585108|NCT02332174|Experimental|800-mg group|Ten healthy subjects were administered a single oral dose of 800 mg rufinamide tablets in fasted state.
2585112|NCT02332174|Experimental|1200-mg group|Ten healthy subjects were administered a single oral dose of 1200 mg rufinamide tablets in fasted state.
2585188|NCT02331849|Other|Eosinophilic esophagitis|Patients with eosinophilic esophagitis after exclusion of GERD
2585239|NCT02331498|Other|A Pazopanib|Open label study with one group
2585310|NCT02331238|No Intervention|Control School|"Control schools (where the coaches do not receive the Coaching Boys into Men training until following academic year ;wait list control)"
2585321|NCT02331238|Experimental|Intervention School|"Intervention schools (where coaches receive the Coaching Boys into Men training at start of each sports season).~Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
2585360|NCT02330796|Experimental|Arm A|Bucillamine (900 mg total dose over 7 days)
2585366|NCT02330796|Experimental|Arm B|Bucillamine (1,800 mg total dose over 7 days)
2585370|NCT02330796|Active Comparator|Arm C|Colchicine (1.8 mg total dose in 2 doses taken 1 hour apart)
2585405|NCT02330367|Experimental|AC0010|Oral AC0010 monotherapy
2585485|NCT02329912|Experimental|Patients after abdominal surgery|SmartPill application after abdominal surgery
2585495|NCT02329912|Sham Comparator|Patients after extraabdominal surgery|SmartPill after extraabdominal surgery
2585556|NCT02329613|Active Comparator|Standard evening meal|"Patients randomized to this arm will receive standard evening meals.~Intervention: Standard evening meals."
2585558|NCT02329613|Experimental|Improved evening meal|"Patients randomized to this arm will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.~Intervention: Improved evening meal"
2585649|NCT02329236||children with constitutional growth delay|
2585650|NCT02329236||children with Familial short stature|
2584435|NCT02336893|No Intervention|Pre-intervention|Family members of patients admitted to the ICU from August to December 2013 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
2584436|NCT02336893|Experimental|Post-intervention|Family members of patients admitted to the ICU from March to August 2014 that consented to participate in the satisfaction survey and had been in the ICU for 72 h.
2584512|NCT02336308|Active Comparator|Ketamine|Ketamine 50mg/1mL will be diluted with 9mL of normal saline to create 50mg in the 10mL syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
2584515|NCT02336308|Placebo Comparator|Placebo|Placebo will be 10mL of normal saline in the syringe. Administered twice via intravenous administration; the first dose 10 minutes prior to the dressing change and a second dose 20-30 minutes into the dressing change procedure. The study will provide study drug for up to five dressing change procedures (i.e. ten total doses).
2584531|NCT02336087|Experimental|Treatment (gemcitabine, Abraxane, metformin, DS)|Patients receive gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation IV on days 1, 8, and 15. Patients also receive metformin hydrochloride PO BID starting day -6 and dietary supplement PO BID starting day -3. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
2584594|NCT02335736|Active Comparator|Normal|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
2584595|NCT02335736|Active Comparator|Poor responders|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
2584596|NCT02335736|Active Comparator|Polycystic ovarian disease|Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant(Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC
3212344|NCT01014325|Experimental|Allergen extract|
2584721|NCT02334774|Experimental|Participants receiving an SOC Program|Participants following prolonged endotracheal intubation receiving a up to 14-day daily Swallowing and Oral Care Program.
3212345|NCT01014325|Placebo Comparator|Placebo|
3212346|NCT01014338|Active Comparator|ACE-inhibitor|
2584859|NCT02333890|Experimental|Chloroquine|The daily oral dose per patient is 500 mg of chloroquine. Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
2584862|NCT02333890|Placebo Comparator|Placebo|The daily oral dose per patient is 500 mg of placebo (lactose). Patients may be taking the drug for 2-6 weeks leading up to the date of the surgery. The last dose will be taken the evening before surgery.
2584928|NCT02333500|Experimental|olfactory workshop|Influence of sensory therapy on the rate of oxytocin
2584942|NCT02333500|Active Comparator|other workshop|Influence of other workshop on the rate of oxytocin
2584951|NCT02333500|Other|control group|Rate of oxytocin of the control group
2584992|NCT02332993||Supplementation Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive the FPP supplementation to take 3 times a day for 12 weeks (3g/dose).
2584999|NCT02332993||Control Group|15 Type 2 Diabetics receiving Negative Wound Pressure Therapy will receive no supplementation for 12 weeks.
2585272|NCT02331563|Experimental|0.5% bupivacaine|group 1 receiving TAP block with 0.25% bupivacaine 20 ml for each side of abdomen Bupivacaine is a local anaesthetic agent. transvers abdominis plane block with %0.5 Bustesin which is diluated with normal saline
2585274|NCT02331563|Active Comparator|dexmedetomidine added bupivacaine|group II receiving TAP block with 0.25% bupivacaine + 0.5 mcg/kg dexmedetomidine each side of abdomen
2585326|NCT02331030|Experimental|Combined (C)|Ultrasound-guided supraclavicular brachial plexus block with Ropivacaine 0.5% 20ml and Pecs II block with Ropivacaine 0.5% 10ml.
2585333|NCT02331030|Active Comparator|Supraclavicular (S)|Ultrasound-guided supraclavicular BPB with Ropivacaine 0.5% 20ml and sham block (grade 1)
3212347|NCT01014338|Placebo Comparator|Sugar Pill|
3212348|NCT01014364|Experimental|Corticosteroids|Hydrocortisone
2585659|NCT02328963|Experimental|Everolimus|Everolimus + reduced dose of cyclosporine A
2585662|NCT02328963|Active Comparator|mycophenolic acid|mycophenolic acid + standard dose of cyclosporin A
2585724|NCT02328417||Control|Consecutive radical cystectomies up to 94 patients in 13 participating hospitals in Madrid, Spain. These patients will be taken care of as it is done regularly in each of participating hospitals. All study variables will be prospectively collected in this group
2585725|NCT02328417||Active Treatment|"After recruiting cotrol group, another consecutive radical cystectomies up to 94 patients in 13 participating hospitals will be recruited and the following measures will be followed with them:~I.-PREOPERATIVE MEASURES: (eight measures according to Protocol) II.- INTRAOPERATIVE MEASURES: (six measures according to Protocol) III.- POSTOPERATIVE MEASURES: (eight measures according to Protocol)"
2585771|NCT02328118|Experimental|Ranibizumab 0.5 mg|All subjects in this group will receive Ranibizumab (0.5mg/0.05ml) intravitreal injection.
2585781|NCT02328118|Experimental|Triamcinolone Acetonide 4mg|All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
2585955|NCT02327078|Experimental|(Phase 1, Part 2): Nivolumab + Epacadostat + Chemotherapy|
3212349|NCT01014364|Placebo Comparator|Control|isotonic saline
3212350|NCT01014416|Experimental|Arm 1|Single dose, Tolvaptan 15mg or Placebo/day
3212351|NCT01014416|Experimental|Arm 2|Single dose, Tolvaptan 30mg or Placebo/day
3212352|NCT01014416|Experimental|Arm 3|Single dose, Tolvaptan 60mg or Placebo/day
3212353|NCT01014429|Experimental|1|
3212354|NCT01014468|Active Comparator|Ranibizumab|Intravitreal injection of Ranibizumab (3 monthly injection followed by monthly injections as long as required)
3212355|NCT01014468|Active Comparator|Bevacizumab|Intravitreal injection of Bevacizumab (3 monthly injection followed by monthly injections as long as required)
2584447|NCT02336659|Experimental|Exendin 9-39 / DPP 4-Inhibition|Mixed meal test and ad libitum meal test duing infusion of exendin 9-39, 900 pmol/kg/min and intake of sitagliptin 100 mg * 2
2584528|NCT02336126|Experimental|Biopsychological intervention|
2584572|NCT02335931||Charcot foot|Patients with Charcot foot and diabetes mellitus 1 or 2
2584574|NCT02335931||No charcot foot|patients with diabetes mellitus type 1 or 2
2584602|NCT02335606||Patients treating with Abatacept|Patients who are abatacept naive and are initiating abatacept treatment (either IV or SC) including those that are switching from another bDMARD, as well as, patients currently being treated with IV or SC abatacept some of which may have switched from IV abatacept to SC abatacept
2584631|NCT02335411|Experimental|Cohort 1: Pembro monotherapy, previously treated|Participants receive pembrolizumab (Pembro) 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 24 months
2584633|NCT02335411|Experimental|Cohort 2: Pembro combination therapy, treatment naive|Participants receive pembrolizumab 200 mg IV Q3W for up to 24 months + cisplatin 80 mg/m^2 IV Q3W for up to 6 cycles + 5-FU 800 mg/m^2 IV on Days 1-5 every 3 weeks or (Japan only) capecitabine 1000 mg/m^2 orally, twice per day (BID) on Days 1-14 of each 3-week cycle
2584634|NCT02335411|Experimental|Cohort 3: Pembro monotherapy, treatment naive|Participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 24 months
2584707|NCT02335008|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
2584710|NCT02335008|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
2584739|NCT02334566|Experimental|NET TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis.
2584745|NCT02334566|Active Comparator|Delayed TX|Behavioral intervention for PTSD (NET/KIDNET) with 8-12 sessions administered on a weekly basis, started following a three-month wait period
2584791|NCT02334319|Experimental|Treatment (ganetespib, surgery)|Patients receive ganetespib IV over 1 hour twice weekly for 2 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery the day after the last dose of ganetespib.
2584872|NCT02333968|Experimental|Intervention group|Self-management support
2584876|NCT02333968|No Intervention|Control group|Care as usual
2585013|NCT02333110|Experimental|GRID radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
2585082|NCT02332629|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
2585084|NCT02332629|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
2585131|NCT02332083|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & Exergame) - T2
2585135|NCT02332083|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
2585169|NCT02331758|Experimental|Lifestyle counseling|The investigators use several methods to educate patients of controllable factors like lifestyle counseling, and monitor the factors like BMI and other index until the statistics become normal.
2585179|NCT02331758|No Intervention|No treatment|Patients without any intervention and still have abnormal factors like BMI, etc.
2585291|NCT02331641||Major hepatectomy (MH)|Patients who underwent MH for CLM instead of multiple minor hepatectomy (MMH)
2585293|NCT02331641||Multiple minor hepatectomy (MMH)|Patients who underwent MMH for CLM instead of MH
2585328|NCT02330965||Subjects Assigned to BAF312|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.
2585335|NCT02330965||Subjects Assigned to Placebo (Controls)|Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.
2585411|NCT02330484|Experimental|incentives to physicians|Give incentives to physicians according to patients' HbA1c improvement
2585418|NCT02330484|Experimental|incentives to patients|Give incentives to patients according to their HbA1c improvement
2585422|NCT02330484|Experimental|incentives to both physicians and patients|intervention mode: Give incentives to physicians and patients according to patients' HbA1c improvement
2585423|NCT02330484|No Intervention|Group with no incentives|
2585476|NCT02330029|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
2585477|NCT02330029|Active Comparator|Pinaverium|
2585480|NCT02330029|Placebo Comparator|Placebo|Placebo is blindly given to patients
2585548|NCT02329457|Experimental|ID varicella zoster vaccine (VZVv) group|intradermal 0.65 mL Zostavax
2585553|NCT02329457|Active Comparator|SC VZVv group|subcutaneous 0.65 mL Zostavax
2585554|NCT02329457|Placebo Comparator|ID NS Group|intradermal 0.65 mL normal saline
2585557|NCT02329457|Placebo Comparator|SC NS Group|subcutaneous 0.65 mL normal saline
2585627|NCT02329145|Experimental|Active treatment|Renal denervation
2585632|NCT02329145|No Intervention|Observational|
2585653|NCT02328729||Mandibular block with Epinephrine|Lidocaine 2% with 1:100,000 Epinephrine
2585654|NCT02328729||C-CLAD-IL with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
2585655|NCT02328729||Infiltration with Epinephrine|Lidocaine 2% and 1:100,000 Epinephrine
2585660|NCT02328729||Mandibular block without Epinephrine|Mepivacain HCl 3% without Epinephrine
2585663|NCT02328729||Infiltration without Epinephrine|Mepivacain 3% without Epinephrine
2585665|NCT02328729||CCLAD-IL without Epinephrine|Mepivacain HCl 3% without Epinephrine
2585772|NCT02328443|Experimental|midazolam alone|midazolam administration alone
2585779|NCT02328443|Experimental|midazolam and itraconazole|Itraconazole 200 mg PO twice; midazolam iv single administration
2585782|NCT02328443|Experimental|midazolam and rifampicin|rifampicin 150 mg PO for 9 days administration, midazolam iv single administration
2584526|NCT02336100|Experimental|GERD patient|36 GERD patients without obviously abnormality were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
2584529|NCT02336100|Experimental|Control|18 control patients were were examined by FICE and then followed by pCLE to evaluate minimal change esophagitis
3177457|NCT00652769|Experimental|A|Active arm: A new pathway for the diagnosis and staging of lung cancer with endobronchial (EBUS) or endoscopic ultrasound (EUS) as a first test. If EBUS or EUS is negative the patient will have PET scan +/- mediastinoscopy.
3177458|NCT00652782|Experimental|1|rolofyline 2.5 mg IV QD
2584806|NCT02334241|Experimental|Sorbact®|The basic Sorbact® presentation is an antimicrobial, non-adhesive absorbent wound dressing. It consists of a highly absorbent hydropolymer matrix with an antimicrobial Sorbact® mesh (Sorbact® acetate fabric coated with dialkyl carbamoyl chloride - DACC) and is covered by a semipermeable polyurethane film.
2584812|NCT02334241|Active Comparator|Best local cares|Dressing requirements in this study have to be consistent with international guidelines.
2584866|NCT02333851|Experimental|Premixed insulin|Mixtard 30:70 Novonordisk® twice daily, before breakfast and before dinner.
2584870|NCT02333851|Experimental|Basal-bolus|'Lantus® once daily and Apidra® before meals
2584937|NCT02333513|Experimental|case group|
2585002|NCT02333032|Experimental|hemiplegic patient|
2585081|NCT02332694|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
2585117|NCT02332187|Sham Comparator|Sham electrical stimulation|The intervention will consist of sham electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
2585123|NCT02332187|Active Comparator|Active electrical stimulation|The intervention will consist of active electrical stimulation using an All Stim stimulator of each quadriceps leg muscle for 30 minutes per day for a total of 7 days.
2585175|NCT02331823|Experimental|arm A: super-short retreatment regimen|A regimen of 5 drugs is to be administered. Isoniazid Aminosalicylate Tablets,0.3g tid po for 5 mon moxifloxacin tab, 0.4g qd po for 5 mon rifabutin capsule,0.3g qd po for 5 mon ethambutol tab, 0.75g qd po for 5 mon pyrazinamide tab, 0.5g tid po for 5 mon
2585186|NCT02331823|Active Comparator|arm B:standardized retreatment regimen|8-9 months of standardized regimen is to be administered. regimen 1.2SHREZ/6HRE streptomycin injectable,0.75g qd intramuscular for 2 mon isoniazid tab,0.3g qd po for 8 mon rifampicin capsule,0.45-0.6g po for 8 mon ethambutol tab, 0.75g qd po for 8 mon pyrazinamide tab, 0.5g tid po for 2 mon or regimen 2.3HREZ/6HRE isoniazid tab,0.3g qd po for 9 mon rifampicin capsule,0.45-0.6g po for 9 mon ethambutol tab, 0.75g qd po for 9 mon pyrazinamide tab, 0.5g tid po for 3 mon
2585279|NCT02331381|Experimental|MRI|Participants will have a custom immobilization device created for them for the purpose of the study. They will be scanned from one to four occasions during radiation treatment. If enrolled in the study prior to the first radiation treatment, the first imaging scan may be scheduled prior to the first radiation treatment, with subsequent scans during treatment separated by at least one day. Patients will be in the scanner for approximately 30 minutes to one hour, either prior to or following their standard of care radiotherapy treatment.
2585341|NCT02331082|Active Comparator|Control|Existing healthcare system
2585344|NCT02331082|Experimental|Health System Improvement|Structured Quality Improvement Chronic Care Model Integrated Electronic Medical Record Solar-powered electrical supply Performance-based financing
2585389|NCT02330471|Experimental|Spray|cervical coagulation using a superficial electrical coagulation mode, ie spray coagulation
2585390|NCT02330471|Active Comparator|Forced|cervical coagulation using a deep tissue electrical coagulation mode, ie forced coagulation
2585451|NCT02330250|Experimental|Pharmaceutical Care|The patients will receive guidance from a pharmacist based on the Dader Method for Pharmaceutical Care, in addition to the medical care habitually delivered by the hospital.
2585455|NCT02330250|Sham Comparator|Control|The control group will receive the medical care habitually provided by the hospital, and the follow-up by a non-pharmacist professional.
2585505|NCT02329834|Experimental|Treatment Sequence 1|Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours followed by i.v. Furosemide Injection, USP (80 mg)by i.v. bolus in second period
2585513|NCT02329834|Experimental|Treatment Sequence 2|Furosemide Injection, USP (80 mg) by i.v. bolus, followed by Furosemide Injection Solution for subcutaneous administration (80mg) over 5 hours in second period.
2585567|NCT02329535|Experimental|Treatment group|Treatment with 400 mg Micronized progesterone (Utrogestan) daily up to 6 weeks of geastation
2585573|NCT02329535|No Intervention|No treatment|No treatment. Regular follow up
2585629|NCT02329158||Arm: Exposed: Hydroxyethyl starch|Cardiac surgical patients exposed to 6% hydroxyethyl starch (130/0.4).
2585634|NCT02329158||Arm: Unexposed: Hydroxyethyl starch|Cardiac surgical patients not exposed to 6% hydroxyethyl starch (130/0.4).
2585773|NCT02328001|No Intervention|Pre-intervention phase/phase 1|No intervention will be applied in phase 1
2585777|NCT02328001|Other|Post-intervention phase/phase 2|Intervention will be applied in phase 2 i.e; Debriefing endoscopists of the procedure accessory costs and pathology specimen costs
2585815|NCT02327754|Active Comparator|Active comparator|Topiroxostat, (Oral daily dosing for 28 weeks)
2585824|NCT02327754|Placebo Comparator|Placebo comparator|Placebo, (Oral daily dosing for 28 weeks)
2585865|NCT02327416|Active Comparator|1,conventional control group|Drug: Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks. Entecavir 0.5mg po daily or plus ADV （adefovir dipivoxil）10mg po daily.
2585959|NCT02326753|Experimental|No. 7 oral airway|
2585963|NCT02326753|Experimental|No. 8 oral airway|
3177459|NCT00652782|Experimental|2|rolofyline 15 mg IV QD
3177460|NCT00652782|Experimental|3|rolofyline 30 mg IV QD
3177461|NCT00652782|Experimental|4|rolofyline 60 mg IV QD
3177462|NCT00652782|Placebo Comparator|5|placebo for rolofyline IV QD
3177463|NCT00652795|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
3177464|NCT00652795|Active Comparator|B|Subjects received the Oclassen's product (Monodox) Capsules under fasting conditions.
3177465|NCT00652808|Active Comparator|Arm 1|
3177466|NCT00652808|Active Comparator|Arm 2|
2584527|NCT02336035|No Intervention|Cast immobilization|"Cast immobilization for 5 weeks from primary injury/reduction. Thereafter active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
2584532|NCT02336035|Experimental|Operation|"Operation with a volar plate. Cast immobilization for 2 weeks after operation, thereafter active motion without weight for 4 weeks. 6 weeks after operation the patients are allowed active exercise within the range of pain.~Both groups will be followed after 3, 6 and 12 months, and after 2 and 5 years."
2584583|NCT02335866|Experimental|Test groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
2584585|NCT02335866|Active Comparator|Control groups.|This clinical study was designed as a split-mouth, randomized, controlled clinical trial. Bilateral gingival recession defects were randomly assigned to the test (CAF+PRF) or the control (CAF+SCTG) groups with the use of computer-generated randomization table after assessment of clinical parameters at baseline.
3212356|NCT01014481|Experimental|start antiretroviral treatment|the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment
2584674|NCT02335203|Experimental|Depot medroxyprogesterone acetate|Women randomized to receive one intramuscular injection of 400mg depot medroxyprogesterone acetate prior to hysterectomy.
2584676|NCT02335203|Placebo Comparator|Placebo injection|Women randomized to receive one intramuscular injection of 1mL normal saline prior to hysterectomy.
3212357|NCT01014494|Experimental|Active - Adaprev|Adaprev (Class III medical device)
3212358|NCT01014494|No Intervention|Standard Care|No different treatment to normal
3212359|NCT01014507|Active Comparator|A|
3212360|NCT01014507|Experimental|B|
3212361|NCT01014520|Experimental|Gabapentin|Neurontin
3212362|NCT01014520|Experimental|Amitriptyline|Elavil
3212363|NCT01014546|Experimental|Treatment (arsenic trioxide with or without ascorbic acid)|Patients receive arsenic trioxide PO QD in orange juice on days 1-21. Patients may also receive ascorbic acid PO QD on days 1-21. Treatment repeats every 28 days for up to 168 days in the absence of disease progression or unacceptable toxicity.
3212364|NCT01014559|Active Comparator|Prolonged release tablet|OxyCodone Naloxone controlled release tablet
2584841|NCT02333942||Alzheimer's Disease|Nautilus NeuroWaveTM System'
2584843|NCT02333942||Mild Cognitive Impairment|Nautilus NeuroWaveTM System'
2584844|NCT02333942||Frontotemporal Lobar Degeneration|Nautilus NeuroWaveTM System'
2584847|NCT02333942||Age-Matched Controls|Nautilus NeuroWaveTM System'
2584886|NCT02333708||GCA group|
2584889|NCT02333708||Inflammatory syndrome (without GCA) group|
2584892|NCT02333708||Without inflammatory syndrome and without GCA group|
2584920|NCT02333396|Experimental|PICU Supports|Participants will receive the PICU Supports intervention.
2584921|NCT02333396|Active Comparator|Educational Brochure|Participants will receive an educational brochure about the pediatric intensive care unit.
2584961|NCT02333188|Experimental|Treatment (FOLFIRABRAX)|Patients receive FOLFIRABRAX comprising paclitaxel albumin-stabilized nanoparticle formulation IV over 0.5 hours, leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 1.5 hours, and fluorouracil IV over 46 hours on days 1 and 15. Courses repeat every 4 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.
2584983|NCT02332837|Experimental|Digital informed consent|"Traditional digitally signed text based informed consent~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
2584984|NCT02332837|Experimental|Multi-media informed consent|"Informed consent with images, text and auditory presentation~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
2584985|NCT02332837|Experimental|Test to train informed consent|"Informed consent with images, text, auditory presentation and test to train feature where participants get feedback on comprehension responses throughout the consent and can change them~Intervention A: questionnaire accuracy Intervention B: Questionnaire speed of completion Intervention C: Questionnaire completion rate"
2585032|NCT02332759|Experimental|Materna Device|The device will be inserted vaginally for one hour during active phase of labor to dilate the vaginal canal.
2585063|NCT02332551|Experimental|NanoKnife IRE System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
2585069|NCT02332551|No Intervention|Control|
2585110|NCT02332265||Program Participant Study SAFE area, control area|"Participants from two types of areas of rural central Malawi: traditional authorities (TA) selected by CARE to receive the SAFE program (intervention group) and TAs receiving other unrelated CARE programming (controls).~Intervention TAs: 598 program participants (398 women, 200 men) were interviewed at baseline and 18- and 36-month follow-ups;~Control TAs: 301 control households were interviewed at baseline and 18- and 36-month follow-ups"
2585126|NCT02332213||7. High-risk gastric lesions|Patients graded Stage III-IV according to OLGIM (Operative Link of Gastric Intestinal Metaplasia Assessment) staging system, but excluding those with dysplasia (Group 5)
2585128|NCT02332213||8. Normal and low-risk gastric lesions|Staged 0-III according to OLGIM. Dysplasia should be excluded
3212365|NCT01014559|Active Comparator|Tablet|Oxycodone PR Tablets
3212366|NCT01014572|Experimental|Aerobic Exercise Training + Placebo|
3212367|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Placebo|
3212368|NCT01014572|Experimental|Aerobic Exercise Training + Alagebrium|
3212369|NCT01014572|Experimental|Tai Chi and/or Yoga Training + Alagebrium|
3212370|NCT01014598|Experimental|Treatment (cisplatin)|Patients receive cisplatin intra-arterially via isolated lung suffusion over 2 hours. Beginning approximately 2 weeks later (6-8 weeks if indicated for patients with sarcoma undergoing surgery after cisplatin), patients receive standard chemotherapy regimen.
3212371|NCT01014611||Class II NYHA Heart Failure|Fraction of ejection between 40% and 30%
3212372|NCT01014611||Class III NYHA Heart Failure|Fraction of ejection lower than 30%
3212373|NCT01014611||Healthy volunteers|Matched with patients on age and physical activity
3212374|NCT01014637|Active Comparator|Amorolfine 5%|
2584600|NCT02335619|Active Comparator|Early Palliative Care|During their first oncology appointment, the intervention arm patients will self-report any symptoms related to their cancer or treatment to the study team; scores at or above a defined benchmark will be seen by Pain and Symptom Management/Palliative Care team members during or immediately after their oncology appointment. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
2584604|NCT02335619|No Intervention|Standard Care|During their first oncology appointment, the control arm patients will self-report any symptoms related to their cancer or treatment to the study team; self-reports will be collected but not shared with the Pain and Symptom Management/Palliative Care team, and patients will continue with their oncology appointment as per standard procedure. Patients will be asked to self-report symptoms once a month following recruitment, for 4 months.
2584635|NCT02335372|Experimental|Multi-Modal Optical Imaging of Cervix|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes before application of 3-6% acetic acid. The clinician will identify all sites required for biopsy according to clinical impression, marking each location on the recorded unpolarized white light image. Topical application of 0.01% proflavine solution will then be applied for 1 minute, after which wide-field imaging in fluorescence mode will be performed. The clinician will then select up to 2 additional sites for biopsy based on the appearance of this wide-field fluorescence image, recording the location of each. The high-resolution microendoscope will then be used to acquire images at all sites selected for biopsy, followed by collection of biopsy specimens.
2584706|NCT02335021|Experimental|Sucralose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucralose.
2584709|NCT02335021|Experimental|Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with sucrose.
2584711|NCT02335021|Experimental|Sucralose + maltodextrin|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + maltodextrin .
2584712|NCT02335021|Experimental|Sucralose + Sucrose|Participants will rate sweetness, sourness, saltiness, bitterness and umami intensity of various taste stimuli. Next they will consume a flavored beverage with Splenda + sucrose.
2584725|NCT02334501|Experimental|Treatment A (Period 1) and Treatment B (Period 2)|Treatment A (240mg Neratinib x1) Treatment B (30mg Lansoprazole X 7 days + 240mg Neratinib x1)
2584789|NCT02334397|Active Comparator|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program. Specifically, Total Control is a comprehensive pelvic fitness and wellness program designed by board-certified female pelvic medicine and reconstructive surgery (FPMRS) practitioners as well as physical therapists that combines pelvic floor and core muscle strengthening. Subjects will participate in 1 standardized class per week during their second trimester for a total of 6 weeks. Women will also participate in a weekly educational session which will include keynote speakers who are experts in various aspects of the labor and delivery process. Women in this group will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
2584795|NCT02334397|No Intervention|Control Group|This group will consist of eligible women who were not randomized to the fitness and education program. Participants will complete questionnaires and consent to use of their delivery outcomes. Women will also wear pedometers to track daily general activity.
2584857|NCT02334098|Experimental|Omega-3 supplemented drink|A 200 ml. drink product with 1.1 grams of omega-3 from Smartfish (Smartfish: Forsiden in Norway).
2584861|NCT02334098|Placebo Comparator|Placebo Drink|exactly the same fruit drink contained in the same packaging, but will contain no omega-3.
2584868|NCT02334098|No Intervention|treatment-as-usual controls|No drinks are taken.
2584993|NCT02333123|Experimental|Aspirin|Aspirin 300mg capsule by mouth once a day for 24 weeks.
2585000|NCT02333123|Placebo Comparator|Placebo|Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.
3212375|NCT01014637|Experimental|RV4104A-cylcopiroxolamine-ciclopirox|
3212376|NCT01014650|Placebo Comparator|IV normal saline|Single IV dose of normal saline as a control for safety and tolerability observations
2585346|NCT02330861|Other|Normal coronary artery|
2585371|NCT02330653|Experimental|Fecal Microbiota Transplant (FMT)|Induction retention enema for the first week of treatment followed by once weekly administration of 15 capsules of study treatment (the equivalent of 7.5 grams of human stool) will be (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study treatment, study subjects on FMT who have shown improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks of once weekly FMT capsule administration.
2585375|NCT02330653|Placebo Comparator|Placebo|Induction placebo enema for the first week of treatment followed by once weekly administration of 15 capsules of study placebo (administered within 60 minutes of thawing once weekly) for 7 weeks. After completing 8 weeks of blinded study placebo, study subjects on placebo who DO NOT demonstrate improvement will be given the option to receive open-label maintenance FMT weekly for an additional 8 weeks, beginning with a FMT induction enema followed by 7 weeks of weekly FMT capsule administration.
3212377|NCT01014650|Experimental|IV GLYX-13|Single IV dose of GLYX-13
3212378|NCT01014650|Experimental|SC GLYX-13|Single SC dose
3212379|NCT01014663|Active Comparator|Therapeutic Exercise|
3212380|NCT01014663|Active Comparator|Non-Contact Boxing Training|
3212381|NCT01014676|Active Comparator|Probiotic milk|
3212382|NCT01014676|Placebo Comparator|Standard milk|
3212383|NCT01014702|Experimental|Laser Treatment|
3212384|NCT01014702|Active Comparator|Phacoemulsifcation|
3212385|NCT01014715|Other|Single Arm|Phase II-Preoperative Radiation followed by Lumpectomy
3212386|NCT01014754||NSF|Biopsy-proven diagnosis of NSF
3212387|NCT01014754||Kidney dysfunction plus gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have had a medical imaging procedure using GBCA in the 2 years prior to skin biopsy.
3212388|NCT01014754||Kidney dysfunction without gadolinium exposure|Those on dialysis or with eGFR ≤ 30 ml/min/1.73 m2 who have never been exposed to GBCA and have had skin biopsy.
3212389|NCT01014754||Normal kidney function with gadolinium exposure|Those with normal kidney function who have undergone a medical imaging procedure using Gd-based contrast agent (GBCA) in the 2 years prior to a skin biopsy.
3212390|NCT01014754||Normal kidneys without gadolinium exposure|Those with normal kidney function who have never been exposed to GBCA and have had a skin biopsy.
3212391|NCT01014754||Controls|Existing skin tissue from neonatal skin (<6 months) will be used as controls, as they presumably have never been exposed to gadolinium
3212392|NCT01014780||Normal (non-dry) dry eye subjects|These are healthy individuals, age 18 and above, who do not exhibit dry eyes by signs and symptoms
2584835|NCT02334371|Other|MR-PET|Preoperative whole-body MR-PET with 18F-FDG
2584887|NCT02333825|Other|Surgical Intervention|The surgical intervention to be studied in this arm is medial patellofemoral ligament reconstruction surgery using hamstring tendon. The tendon used will generally consist of autograft semitendinosus. If the hamstrings have been previously harvested or injured (i.e. in the setting of anterior cruciate ligament reconstruction or proximal tibial surgery), or if the patient/his or her family prefers to minimize donor site morbidity, allograft may be used.
2584890|NCT02333825|Other|Conservative treatment|The intervention to be studied in this arm is a rehabilitation program directed by physical therapists. If patients in this arm are found to have a small loose body, a simple arthroscopy will be performed to remove the loose body, but no stabilization of the patellofemoral joint will be performed. The rehabilitation program will be compiled into a booklet and distributed for use by the physical therapist chosen by the patient.
2584953|NCT02333422|Experimental|NIRS Neurofeedback|NIRS Neurofeedback training of frontal and pre frontal lobes activation. The intervention consist of 24 NIRS neurofeedback sessions over 12 weeks, 2 sessions per week.
2584988|NCT02332967|Active Comparator|Whey predominant starter formula|Whey predominant starter formula
2584991|NCT02332967|Experimental|Whey predominant starter formula + 40% palmitic acid|Whey predominant starter formula + 40% palmitic acid in sn-2 position
2584997|NCT02332967|Experimental|Whey predominant starter formula + 50% palmitic acid|Whey predominant starter formula + 50% palmitic acid in sn-2 position
2585065|NCT02332655|Experimental|Cannabidiol|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 48 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of epilepsy in patients with Sturge-Weber syndrome.
2585116|NCT02332200||Early referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is less than or equal to 10 weeks.
2585122|NCT02332200||Later referral to therapy|Patients with a confirmed diagnosis of spondylolysis or spondylolisthesis whose physicians median referral to physical therapy time is >10 weeks.
2585196|NCT02331810|Experimental|SAR113244|Single subcutaneous dose of SAR113244
2585199|NCT02331810|Placebo Comparator|Placebo|Single subcutaneous dose of placebo
2585242|NCT02331485|Experimental|PICO + Acticoat group|Patients randomized to negative pressure group will received negative pressure dressing (Pico Wound Management System - manufacture by Smith & Nephew) associated with Acticoat Flex dressing which will be applied immediately after skin closure in a conventional way and left in place for 7 days. Negative pressure dressing will be changed once during 7 days period - after day 2 to 4. Wound complications within first 30 days of surgery will be recorded on clinical examination.
2585245|NCT02331485|Active Comparator|Standard Wound management|If a patient is randomized to standard wound treatment group - he/she will receive standard skin closure and standard Mepore dressing, which will be changed on a daily basis.
2585305|NCT02331160|Experimental|Rebozo|Intervention by Rebozo
2585319|NCT02331160|No Intervention|Control|Standard
2585393|NCT02330822|Experimental|Hyaluronic Acid Group|In this Group, Hyaluronic acid will be injected following extraction.
2585395|NCT02330822|No Intervention|Traditional Extraction Group|In this group, traditional extraction procedures will be followed.
2585449|NCT02330237|Active Comparator|patients|natural gels
2585454|NCT02330237|Placebo Comparator|subjects|These patients will receive that placebo (vehicle) products.
2585460|NCT02329899||Possible MBD|"Defined by:~a bleeding score >= 4 in adults;~a bleeding score >= 2 in children (for girls, up to menses);~a past medical history that include menorrhagia, haemorrhage from the umbilical stump, bleeding at circumcision, cephalhematoma at birth, hematuria, whatever the bleeding score is;~a past medical history suggestive of a MBD with no haemostatic challenge and a low bleeding score.~In this group, the second step of investigations will be performed."
2585490|NCT02330068||Controls|Males and females ages 18-55 without Major Depressive Disorder, Bipolar I or Bipolar II who are not on an antidepressant and do not have a first degree relative with a diagnosis of Major Depressive Disorder and not currently taking citalopram.
3212393|NCT01014780||Dry eye subjects|These are subjects, age 18 years and above, who do exhibit signs and symptoms of dry eye.
3212394|NCT01014793||Responders to cabergoline|patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
3212395|NCT01014806|Experimental|Low dose|
3212396|NCT01014806|Experimental|High dose|Investigational Influenza VLP Vaccine 60ug/strain
3212397|NCT01014806|Active Comparator|TIV|Trivalent Influenza Vaccine 15ug/strain, Commercially Licenced
3212398|NCT01014832|Experimental|Uncontrolled diabetes|Uncontrolled diabetes
3212399|NCT01014845|Experimental|Hepatitis E vaccine|Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3212400|NCT01014845|Placebo Comparator|HBV vaccine|Hepatitis B vaccine, containing 5mcg of HBsAg recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3212401|NCT01014858|Experimental|Donepezil|5mg of Donepezil for the first 8 weeks raising to 10mg thereafter if patient adjusted to 5mg dose. 10mg does continues for the remainder of the study.
3212402|NCT01014858|Placebo Comparator|Placebo|Patient commences medication to match appearance of 5mg donepezil for first 8 weeks then 10mg for the remainder of the study.
2584620|NCT02335528|No Intervention|No-Treatment Control|Participants randomized to the No-Treatment Control arm completed measures of the primary outcome (intentions to seek help) prior to being given a choice of SimCoach or the conventional screening administered in the other two arms of the study. After the help-seeking intention questionnaire was administered, participants were told that they would be asked some questions about any PTSD or depression symptoms that they might be having and were given the choice between chatting online with a virtual human or using an online form (options were presented in random order to prevent any influence of ordering on selection of the tool). After either interacting with SimCoach or filling out an online form, participants completed a questionnaire assessing user experience.
2584636|NCT02335268|Experimental|Group 1|"Stratification into group 1 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are +3~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
2584637|NCT02335268|Experimental|Group 2|"Stratification into group 2 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -1 or -2~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
2584639|NCT02335268|Experimental|Group 3|"Stratification into group 3 if Score (Baseline-TPO Level and previous thrombocyte transfusions) are -6~TPO based model to predict subsequent response to romiplostim in MDS patients with IPSS Low/Int-1 according to a model developed by Sekeres et. al./ BJH 2014"
2584856|NCT02334124|Experimental|Home|Patients will be treated at home through the Hospital-In-The-Home program with intravenous once daily ceftriaxone (50mg/kg once daily), administered by a nurse/doctor visiting once daily.
2584858|NCT02334124|Active Comparator|Ward|Patients will be admitted to hospital ward and treated with six hourly flucloxacillin (50mg/kg), administered by a ward nurse as per routine practice.
2584960|NCT02333461|Placebo Comparator|Placebo|333 mg capsule comprised of silicified microcrystalline cellulose, magnesium stearate, modified cellulose gum, silicon dioxide, dextrose, corn starch, and caramel color. Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
2584962|NCT02333461|Experimental|Apple|333 mg capsule comprised of apple peel extract (115:1, standardized to 80% polyphenol and 5% phlorizin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
2584966|NCT02333461|Experimental|Grape|333 mg capsule comprised of grape extract (8000:1, standardized to 75% total polyphenol, 50% oligomeric proanthocyanidin). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
2584969|NCT02333461|Experimental|Red Raspberry|333 mg capsule comprised of red raspberry leaf extract (4:1, standardized to 6% ellagic acid). Consumed as six capsules once daily (total of 2 g/day) with the morning meal for a period of seven days.
2584970|NCT02333461|Experimental|Apricot/Nectarine|333 mg capsule comprised of apricot/nectarine extract (40:1, standardized to 50% polyphenol).
3212403|NCT01014884|Other|Control Group|The control group will receive usual care as provided by your Health Plan.
3212404|NCT01014884|Other|Intervention group|Additional visits will be conducted by a member of the multidisciplinary team (case manager/nurse, social worker and/or pharmacist that will be either face to face or by telephone.
2585049|NCT02332473|Active Comparator|Arm A|Ypeginterferon alfa-2b,sc. Qw. 48 weeks.
2585050|NCT02332473|Experimental|Arm B|Ypeginterferon alfa-2b,sc. Qw. 48 weeks. Granulocyte-macrophage colony stimulating factor,sc.qd, the first three day of every 28 days, starting from interferon treatment week 13.
2585132|NCT02332096||Patients with Atrial Fibrillation|We propose to enroll 100 patients with symptomatic paroxysmal or persistent AF without a known diagnosis of sleep apnea who are referred for an AF ablation procedure at BIDMC. All enrolled subjects will undergo pre-procedure screening sleep study using the Berlin questionnaire and home sleep study using an FDA approved home sleep testing device (HST).
2585182|NCT02331797|Experimental|Endoscopic Technique|All patients are operated under the endoscope. The endoscope passed through external auditory canal (transcanal approach) to visualize tympanic remnant.
2585189|NCT02331797|Active Comparator|Microscopic Technique|All patients are operated under the microscope.A postauricular or transcanal approach is chose depend on ear canal size and size of perforation. When the ear canal is too small, the postauricular is used.
2585228|NCT02331472||Interstitial cystitis|Patients who have been diagnosed with interstitial cystitis/bladder pain syndrome. The group includes both patients with or without Hunner lesion on cystoscopy
2585230|NCT02331472||Control|Adult participants without history of interstitial cystitis/bladder pain syndrome
2585286|NCT02331277|Experimental|Multiple dose|Weekly dosing for four weeks
2585289|NCT02331277|Placebo Comparator|Placebo|Placebo
3212405|NCT01014897|Experimental|subcortical|Subcortical stroke patients will receive tDCS stimulation and sham in random order
2585417|NCT02330536|Experimental|Flowrate A|insufflation of carbon dioxide at 8L/min, 8mmHg
2585420|NCT02330536|Experimental|Flowrate B|insufflation of carbon dioxide at 20 L/min, 8mmHg
2585491|NCT02330146|Experimental|RCT-01|Cultured, autologous hair follicle cells suspended in cryomedium
2585497|NCT02330146|Placebo Comparator|Placebo|cryomedium
2585628|NCT02329366||Diabetic Foot Ulcer Group|Subjects in this group will have tissue specimens collected from their Diabetic Foot Ulcer during Standard of Care debridement.
2585633|NCT02329366||Control Group|Skin tissue samples will be collected from subjects undergoing routine surgical procedures during which normal skin is removed
2585678|NCT02328690|Experimental|Music with BBT|Music embedded with special tones.
2585683|NCT02328690|Placebo Comparator|Music without BBT|Music not embedded with special tones.
2585737|NCT02328378|Active Comparator|Quadratus Lumborum block group (QL)|patients will receive a bilateral Quadratus Lumborum block using Bupivicaine 0.125%
2585740|NCT02328378|Placebo Comparator|Control Group|patients will receive a bilateral placebo block
3212406|NCT01014897|Experimental|cortical|subjects will receive active and sham tDCS in random order
3260286|NCT01477905|Experimental|Remi20 no prmie|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and without PRIMING
2585966|NCT02326753|Active Comparator|No. 9 oral airway|
3260287|NCT01477931|Experimental|Wellbutrin XL|
2584694|NCT02334865|Experimental|Group A (vaccine and week-4 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 0, 2, 4, and 6 for up to 4 doses and then receive a booster in week 12. Beginning in week 4, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
2584698|NCT02334865|Experimental|Group B (vaccine and week-0 lenalidomide maintenance therapy)|Patients receive SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant SC and sargramostim SC every 2 weeks at weeks 4, 6, 8, and 10 for up to 4 doses and then receive a booster in week 16. Beginning in week 0, patients receive lenalidomide maintenance therapy PO QD in the absence of disease progression or unacceptable toxicity.
3260288|NCT01477957|Experimental|Surgery|bariatric surgery
2584894|NCT02333799|Experimental|Bedaquiline + PA-824 + Linezolid|bedaquiline 400 mg once daily for 2 weeks then 200mg 3 times per week plus PA-824 200mg once daily plus linezolid 1200mg once daily .
2584954|NCT02333292||IFN|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing pegylated interferon in combination with any DAA
2584957|NCT02333292||IFN-free|HCV-infected patients, pre-treated or treatment-naïve, who start a regimen containing one or more DAA
2585019|NCT02332811|Experimental|CKD patients not on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
2585022|NCT02332811|Experimental|CKD patients not on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
2585026|NCT02332811|Experimental|CKD patients on dialysis 800 mg|Sevelamer carbonate 800 mg in tabs 3 times per day with meals
2585028|NCT02332811|Experimental|CKD patients on dialysis 2.4 g|Sevelamer carbonate 2.4 g powder carbonate per day
2585051|NCT02332512|Experimental|Apatinib|Apatinib tablet administered orally, 750 mg,once daily until progression
2585053|NCT02332512|Placebo Comparator|Placebo|Placebo tablet administered orally, once a day until progression
2585091|NCT02332330|Experimental|VEST|
2585144|NCT02332031|Experimental|Sorafenib (Nexavar, BAY43-9006) & Levothyroxine|Sorafenib be administrated without and with levothyroxine orally
2585170|NCT02331732|Active Comparator|Control|Patients receive DOT as normal - involves patient going to polyclinic to be observed taking treatment every day
2585178|NCT02331732|Experimental|Treatment|Patients receive VOT - involves patient sending a video of themselves taking their treatment over M-health app which will be reviewed remotely by observers
2585268|NCT02331628|No Intervention|Control|Usual care only will be provided during Baseline period and Follow-up period.
2585270|NCT02331628|Experimental|ESWT - Extracorporeal Shockwave Therapy|Participants will receive 4 applications of extracorporeal shockwave therapy to the affected hip and/or knee over a period of 8 weeks (one dose every 2 weeks).
2585343|NCT02331056||thoracoscopic pulmonary lobectomy|to observe a fluid responsiveness in patients who receives scheduled thoracoscopic pulmonary lobectomy
2585349|NCT02331056||open pulmonary lobectomy(thoracotomy)|to observe a fluid responsiveness in patients who receives scheduled open pulmonary lobectomy(thoracotomy)
3177467|NCT00652821|Experimental|A|Subjects received Kali product under fed condition
2585698|NCT02328599||Surgical|Prior Bariatric surgery
2585705|NCT02328599||Non-surgical|Medical / Lifestyle management
2585839|NCT02327819|Active Comparator|BCAA supplement|Branched-chain amino acids supplement, 12 g/day
2585842|NCT02327819|Sham Comparator|non-BCAA protein supplement|non-BCAA protein supplement
3177468|NCT00652821|Active Comparator|B|Subjects received Ortho-Mcneil product under fed conditions
3177469|NCT00652847|Experimental|group 1|group 1: ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by an observational phase of 6 months.
3177470|NCT00652847|Active Comparator|Group 2|Group 2: patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase.
3177471|NCT00652873|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fed conditions
3177472|NCT00652873|Active Comparator|B|Subjects received the reference product, Dostinex under fed conditions
3177473|NCT00652886|Experimental|A|Subjects received Kali's products under fasting conditions
3177474|NCT00652886|Active Comparator|B|Subjects received BTG products under fasting conditions
3177475|NCT00652912|Experimental|A|Subjects received the Kali formulated products under fasting conditions
3177476|NCT00652912|Active Comparator|B|Subjects received the Roche's product under fasting conditions
3177477|NCT00652925|Experimental|High Dose|
3177478|NCT00652925|Experimental|Low Dose|
3177479|NCT00652925|Active Comparator|Naproxen|Control comparator, 15 mg/kg/dy target dose
3177480|NCT00652964||Observation|a family of congenital central hypoventilation syndrome
3177481|NCT00652977|Active Comparator|I|The delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head.
3177482|NCT00652977|Other|II|Standard care at delivery: Manual support of the perineum
3177483|NCT00653003|Experimental|A|Subjects received Kali formulated product under fed conditions
3177484|NCT00653003|Active Comparator|B|Subjects received Aventis formulated products under fed conditions
3177485|NCT00653055|Experimental|A|Subjects received the test product, Cabergoline 0.5 mg tablets under fasting conditions
3177486|NCT00653055|Active Comparator|B|Subjects received the reference product, Dostinex under fasting conditions
2584737|NCT02334553|Active Comparator|S1226 (8%)|The drug S1226(8%), consists of Perflubron and 8% CO2 in a medical gas mixture. The dosage is 3ml delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer.
2584743|NCT02334553|Placebo Comparator|Placebo|The comparator is normal saline delivered as an aerosol with compressed medical air with a Circulaire nebulizer.
3212407|NCT01014923|Experimental|Intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
3212408|NCT01014923|No Intervention|Control|Parents receive a Department of Transportation booklet on teen driving
3212409|NCT01014949|Other|Control, Diabetes and Metabolic Syndrome|
2584965|NCT02333214|Experimental|Exergame + conventional physiotherapy|This group will be submitted to 30 minutes of conventional physiotherapy and 20 minutes of therapy using interactive games Xbox 360 Video Game and Entertainment Microsoft System with Kinect sensor, intervention twice a week for 12 weeks. Each game has three difficulty levels that can be used according to the performance of each participant. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
2584968|NCT02333214|Active Comparator|Conventional physiotherapy|The control group will receive 50 minutes of conventional physiotherapy intervention twice a week for 12 weeks. The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain.
3212410|NCT01014962|Experimental|Albaconazole 400 mg cohort 1|Albaconazole 400 mg
2585067|NCT02332538|Active Comparator|Greenlight (532nm-laser) PVEP|532nm-laser photoselective vapo-enucleation of the prostate)
2585076|NCT02332538|Active Comparator|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prostate
2585080|NCT02332538|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
2585133|NCT02332122||COPD patients with bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
2585134|NCT02332122||COPD patients without bronchiectasis|"All patients will receive standard therapy for AECOPD.~Additional for this study are:~Sputum induction, Skin prick test, Questionnaires"
2585164|NCT02331771|Active Comparator|donepezil|Subjects will receive donepezil 5 mg before before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
2585173|NCT02331771|Placebo Comparator|Placebo|Subjects will receive the placebo before they start ECT and continue the agent through the ECT procedures up to 4 weeks.
2585269|NCT02331511|Placebo Comparator|placebo|No antiplatelet drug
2585276|NCT02331511|Active Comparator|Aspirin|Aspirin 80 mg daily
2585278|NCT02331511|Active Comparator|Clopidogrel|Clopidogrel 75mg daily
2585309|NCT02330991|Experimental|Arm1 ,one-week on/one-week off regimen|One-week on/one-week off regimen is administered for 12 cycles of 28 days. Arm 1 receives temozolomide 150 mg/m2 daily during days 1 to 7 and 15 to 21 of each cycle.Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
2585320|NCT02330991|Experimental|Arm 2,continuous dose-intense regimen|Continuous dose-intense regimen is administered for 12 cycles of 28 days .Arm 2 receives temozolomide 50mg/m2 daily during days 1 to 28 of each cycle. Treatment will continue until tumor progression, development of excessive toxicity, withdrawal of consent, or completion of 12 cycles.
2585394|NCT02330783|Experimental|Bevacizumab plus Sorafenib|Bevacizumab 5mg/kg Q2w Sorafenib 400mg Bid
2585397|NCT02330783|Active Comparator|Sorafenib|Sorafenib 400mg Bid
2585483|NCT02330185|Experimental|spinal anesthesia for knee arthroscopy|The intervention is spinal anesthesia. Tenth rib line or Tuffier's line will be examined as application landmarks by ultrasonography for spinal anesthesia.
2585565|NCT02329704||Density Gradient processing|"Semen portion processed using Density Gradient (80/40 %) Spin on 1200 r.p.m./20min Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
2585569|NCT02329704||Swimming down Processing|"Semen portion processed using swimming down (100 %) 30 min at room temperature processing for swim down Wash on 1200 r.p.m./5min Rewash on 1200 r.p.m./5min~then evaluation to be done using : Diff-Quik staining for morphology evaluation Motility Evaluation for grade A and B Concentration (mil/ml) 24 H half life 48 H half life HBA Testing Bacterial contamination"
2585715|NCT02328573|Experimental|Communal singing|Participants in the study group will join the choir and participate in a weekly hour rehearsal for six months and will be assessed for aphasia, mood, and quality of life outcomes
2585716|NCT02328573|No Intervention|Control|The control group will not participate in the choir for the first six months. At the end of the six months study period, all participants will be evaluated again for changes in aphasia, language, mood and quality of life
2585750|NCT02328170||EUROIMMUN Allergy|Immunoblot assay
2585752|NCT02328170||ImmunoCap|Fluoroallergosorbent test
2585814|NCT02327858|Experimental|Supportive text message group|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months .
2585827|NCT02327858|No Intervention|No supportive text message group|Patients in the control group will only receive a text message once every two weeks thanking them for participating in the study. The aim of this will be to help increase the retention rate for the study.
2585861|NCT02327377|Experimental|Online Cognitive Behavior Therapy|Online cognitive behavior therapy for coping with pain
2585864|NCT02327377|Active Comparator|Online Education|Educational information about pain
2585923|NCT02327091|Placebo Comparator|white rice flour capsule|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo for 12 weeks
2585926|NCT02327091|Active Comparator|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
3212411|NCT01014962|Placebo Comparator|Placebo cohort 1|Placebo once daily
3212412|NCT01014962|Experimental|Albaconozole 400 mg cohort 2|Albaconozole 400 mg every 12 hours
2584750|NCT02334670||CrAg(+) and CM(-)|Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months.
2584751|NCT02334670||CrAg negative|Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines
2584788|NCT02334228|Experimental|In SHAPE Lifestyles|In SHAPE Lifestyle is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
2584794|NCT02334228|Active Comparator|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
2584864|NCT02334072|Experimental|Classical|Laryngeal mask airway (LMA) is manufactured from medical grade silicone rubber and is reusable. It consists of 3 main components: An airway tube, inflatable mask and mask inflation line. The airway tube is slightly curved to match the oropharyngeal anatomy, semirigid to facilitate atraumatic insertion and semitransparent, so that condensation and regurgitated material is visible. The distal aperture of the airway tube opens into the lumen of an inflatable mask and is protected by two flexible vertical rubber bars, called mask aperture bars, to prevent the epiglottis from entering and obstructing the airway. The laryngeal mask classical application will be done following anesthesia induction.
2584871|NCT02334072|Experimental|I-Gel|I-Gel LMA is anatomically designed mask made of a gel-like thermoplastic elastomer. It has a drain tube for gastric aspiration. I-gel laryngeal mask application will be done following anesthesia induction.
2584875|NCT02334072|Experimental|Cobra|Cobra LMA consists of a translucent silicone airway tube with an inflatable cuff sited approximately two-thirds of the way to the tip, a 15-mm standard adapter and an expanded distal end with a smooth posterior surface. The cuff forms a seal in the upper pharynx and the distal end sits in the laryngopharynx. The distal grill is designed to sit over the laryngeal inlet.Cobra laryngeal mask application will be done following induction of anesthesia
2584878|NCT02334072|Experimental|Supreme|The Supreme LMA is a single-use polyvinyl chloride supraglottic device. High oropharyngeal leak pressures are important as they indicate airway protection, feasibility of positive pressure ventilation and likelihood of successful LMA placement.Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia.
2584881|NCT02334072|Experimental|Proseal|The ProSeal LMA is the most complex of the specialized laryngeal mask devices.The primary design goal was to construct a laryngeal mask with improved ventilatory characteristics that also offered protection against regurgitation and gastric insufflation. The principal new features are a modified cuff and a drain tube.Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia.
3212413|NCT01014962|Placebo Comparator|Placebo cohort 2|Placebo every 12 hours
3212414|NCT01014962|Experimental|Albaconozole 400 mg cohort 3|Albaconozole 400 mg every 8 hours
3212415|NCT01014962|Placebo Comparator|Placebo cohort 3|Placebo every 8 hours
3212416|NCT01015001|Active Comparator|Active rTMS|1Hz rTMS sessions applied to the left temporoparietal cortex of the subjects
3212417|NCT01015001|Placebo Comparator|Sham rtms|Same number of pulses but applied with and angled coil (90 degrees) and placed over the fronto´temporal region
3212418|NCT01015014|Active Comparator|AN3365|
3212419|NCT01015014|Placebo Comparator|Saline|
3212420|NCT01015027|Experimental|Dose 1|(3:1, active:placebo)
3212421|NCT01015027|Experimental|Dose 2|(3:1, active:placebo)
3212422|NCT01015027|Experimental|Dose 3|(3:1, active:placebo)
2585290|NCT02331264||MoM >7ppb|Patients with Metal on Metal hip implants and blood metal ions above the Medicines and Healthcare Products Regulatory Agency (MHRA) threshold of 7 parts per billion
2585292|NCT02331264||MoM <7ppb|Patients with Metal on Metal hip implants and blood metal ions below the MHRA threshold of 7 parts per billion
2585294|NCT02331264||Non MoM|Patients with non Metal bearing hip implants such as Ceramic on Ceramic or Plastic
2585306|NCT02330952|Experimental|Prednisone|
2585315|NCT02330952|Placebo Comparator|Placebo|
2585434|NCT02330666|No Intervention|Comparison|Standard care
2585440|NCT02330666|Experimental|Intervention|Communication skills training Mission Possible: Parents & Kids Who Listen
2585990|NCT02326584|Experimental|Induction with SGN-CD33A|7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A
3212423|NCT01015027|Experimental|Dose 4|(3:1, active:placebo)
3212424|NCT01015040|Active Comparator|solifenacin succinate tablet (fasting)|
3212425|NCT01015040|Experimental|solifenacin succinate suspension (fasting)|
3212426|NCT01015040|Experimental|solifenacin succinate suspension (fed)|
3212427|NCT01015053|Experimental|Regional block|"An ultrasound-guided rectus sheath block will be performed by the regional block anesthesiologist in the regional block arm."
3212428|NCT01015053|Active Comparator|Wound infiltration|"Local wound infiltration will be performed by the surgeon in the wound infiltration arm."
3212429|NCT01015066|Active Comparator|buprenophine/naloxone|Participants with this arm will receive 4-16 mg/d buprenorphine/naloxone (Suboxone).
3212430|NCT01015066|Experimental|Naltrexone|Participants assigned to this arm will receive 50 mg/d naltrexone.
3212431|NCT01015079||Entire Taiwan women|
3212432|NCT01015092||unselected HIV outpatient attendees|All HIV patients attending for general HIV care at 2 London Hospitals
3212433|NCT01015105||patients with hip fracture|
3212434|NCT01015144||Atorvastatin|
3212435|NCT01015144||No statin|
3212436|NCT01015157|Active Comparator|Standard stapling without reinforcement|Standard Echelon 60 linear stapling with GOLD cartridges
3212437|NCT01015157|Active Comparator|Seamguard gastric stapling line reinforcement|
3212438|NCT01015183|Experimental|Intervention|Received Zinc Sulfate
3212439|NCT01015183|Placebo Comparator|Control|Control group
3212440|NCT01015196|Active Comparator|Idarubicine|
3212441|NCT01015196|Experimental|Daunorubicine|
2584882|NCT02334007|Experimental|LMWH: Dalteparin|Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
2584883|NCT02334007|Placebo Comparator|Placebo|After undergoing lung resection these patients will research standard post-op TE prophylaxis and upon discharge will be administered a placebo injection of subcutaneous saline for 30 days duration.
2584918|NCT02333435|Experimental|Purified EPA group|3g per day of purified EPA, capsules, to be taken once a day, for 14 months.
2584919|NCT02333435|Experimental|Placebo group|3 g per day of high-oleic sunflower oil capsules, to be taken once a day, for 14 months.
2584963|NCT02333227|No Intervention|Control|Cluster of sites not receiving xylitol gum. This is a cluster randomized trial, whereby 4 sites will not receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
2584967|NCT02333227|Experimental|Xylitol|Cluster of sites receiving xylitol gum.
2584998|NCT02332954|Other|vortioxetine naive|vortioxetine 10 mg 100 patients with Major Depressive Disorder who have not been treated with another antidepressant for the current MDE
2585006|NCT02332954|Other|Switch|vortioxetine 10 mg 100 patients with Major Depressive Disorder that require a switch from their current antidepressant due to inadequate response
2585061|NCT02332421|Experimental|modified dentoalveolar distractor|Canine retraction will be accomplished using a modified dentoalveolar distractor
2585073|NCT02332421|No Intervention|conventional dentoalveolar distractor|Canine retraction will be accomplished using a conventional dentoalveolar distractor
3212442|NCT01015209|Active Comparator|Cohort 1: 18 healthy subjects|18 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3% (6 subjects per group)
3212443|NCT01015209|Active Comparator|Cohort 2: 12 healthy patients|12 healthy subjects receiving Chitosan- N- Acetylcysteine eye drops at a dose of 0.1%, 0.2% or 0.3%
2585250|NCT02331602|Active Comparator|rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
2585254|NCT02331602|Active Comparator|dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months according to a computer-generated randomization sequence at the central registration center. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
2585307|NCT02330913|Experimental|Intracorporeal esophagojejunostomy|Patient group with intracorporeal esophagojejunostomy with linear stapler
2585361|NCT02330809|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
2585369|NCT02330809|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
2585372|NCT02330809|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals~Intervention-B: Drink extra water at anytime over 24 hours"
2585378|NCT02330809|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
2585433|NCT02330302|Active Comparator|Femoral nerve block|Procedure: Ultrasound-guided femoral nerve block Drug: Ropivacaine 0.5% 30mls
2585438|NCT02330302|Active Comparator|Fascia Iliaca block|Procedure: Ultrasound-guided suprainguinal approach to fascia iliaca block Drug: Ropivacaine 0.5% 30mls
2585464|NCT02329977||Recurrent group|Patients with history of recurrent common bile duct stone after successfully ERCP stone remove.
2585465|NCT02329977||Control group|Patients without history of recurrent common bile duct stone after successfully ERCP stone remove.
2585531|NCT02329782|Experimental|ARP intervention|Adherence counseling intervention
2585534|NCT02329782|No Intervention|usual care|no intervention, standard care practices regarding adherence support
2585541|NCT02329509|Active Comparator|one stage cleft palate surgery|Subjects submitted to one stage palate surgical repair after 9 months old and before 24 months old ,
2585545|NCT02329509|Active Comparator|two stage palate repair|Subjects submitted to two stage palate surgical repair (first soft palate repair between 6 and 12 months old and hard palate closure at 3 to 4 years old)
2585595|NCT02329288|Active Comparator|Triamcinolone Acetonide|40mg/1ml
2585597|NCT02329288|Placebo Comparator|placebo|1ml
2585605|NCT02329054|Experimental|Favipiravir|Favipiravir (oral administration, 200 mg light yellow, round-shaped, coated divisible tablets that can be crushed and mixed with liquid)
2585669|NCT02328820|Other|All patients|All lesions undergo simultaneous assessment with a combined pressure and flow sensor
2585755|NCT02328313|Experimental|Intervention Cohort|Breast cancer patients 65 and older undergoing chemotherapy and participating in a home-based physical activity intervention.
2585816|NCT02327910|No Intervention|Conventional group|Conventional group:The patients of conventional group were extubated when standard criteria were met;
2585822|NCT02327910|Experimental|TOF group|TOF group: patients had a TOF ratio of greater than 0.90 as an additional extubation criterion;
2585837|NCT02327910|Experimental|TOF unit TcPCO2 group|Qualitative TOF and transcutaneous partial pressure of carbon dioxide monitoring(Unite group):the patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
2585964|NCT02326779|Experimental|Experimental Arm|Experimental Arm: acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
2585967|NCT02326779|No Intervention|Comparator Arm|Non-aspirin use arm as comparator
2586024|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have same data collected during the procedure using the Steerable intracardiac electrode catheter.
2584895|NCT02333734|Experimental|Healthy subjects|Healthy subjects physical training (interval training 3 times at week) in a period of 8 weeks.
2584994|NCT02332850|Experimental|Arm I (20 mg dexamethasone, isatuximab, carfilzomib)|"20 mg dexamethasone IV given on days 1, 8, 15, 22 (pre- SAR650984 and carfilzomib), then dexamethasone 4 IV or PO mg Day 2, 9, 16.~All patients will receive a fixed dose of Isatuximab (SAR650984) according to their assigned dose cohort. Patients receive isatuximab IV over 4-6 hours on days 1 and 15 of every cycle for the starting cohort, and days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles. Carfilzomib IV will be administered over 10 minutes on days 1, 2, 8, 9, 15, and 16 . Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may continue treatment after 8 courses if clinical benefit is present at the investigator's discretion (carfilzomib may be switched to days 1, 2, 15, and 16 after 8 cycles per investigator discretion)."
2585003|NCT02332850|Experimental|Arm II (40 mg dexamethasone, isatuximab, carfilzomib)|"40 mg dexamethasone IV given on Days 1, 8, 15 and 22 (use as premed to isatuximab).~All patients will receive a fixed dose of Isatuximab (SAR650984) according to the assigned dose. Patients receive isatuximab IV over 4-6 hours on day 1, 3-4 hours on Day 8, 15, and 22 of cycle 1 and then on days 1 and 15 of subsequent cycle (patients may be eligible for rapid siatuximab given over 75 minutes), and carfilzomib IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity."
2585071|NCT02332486|Active Comparator|Intervene|For Qingxuan Decoction there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China. Qingxuan Decoction is given two times after breakfast and dinner in 56 days.
2585078|NCT02332486|No Intervention|Blank|There is no intervention for people in the blank group.
3212444|NCT01015222|Experimental|Dasatinib, Bevacizumab + Paclitaxel|"Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15~Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation."
3212445|NCT01015235|Placebo Comparator|Arm 1: Placebo|Placebo
2585210|NCT02331693|Experimental|anti-EGFR CAR T|
2585273|NCT02331303||Group1|"This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden.~This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period."
2585334|NCT02331121|Active Comparator|Text-only Online Training|Text-only evidence-based training content on CPR, choking relief & first aid
2585339|NCT02331121|Experimental|Family First Aid Online Training|Interactive multimedia evidence-based training content on CPR, choking relief & first aid
2585414|NCT02330679|Other|Desvenlafaxine|2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine
3212446|NCT01015235|Active Comparator|A2: KAI-1678|Test Drug
3212447|NCT01015235|Active Comparator|A3: Ketorolac|Active Comparator
2585613|NCT02329353|Experimental|Smoker group|30 chronic periodontitis patients, having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
2585615|NCT02329353|Experimental|Non-smoker|30 chronic periodontitis patients, not having habit of smoking, with probing pocket depth of equal or greater than 5 mm with bleeding on probing and radio-graphic evidence of bone loss in at at least 2 sites at each quadrant will be given three probiotic lozenge per day for 8 weeks
2585670|NCT02328859|Experimental|Virtual reality gait rehabilitation|Subjects will be trained using a custom treadmill with a virtual environment
2585673|NCT02328859|Active Comparator|Treadmill training gait rehabilitation|Subjects wil be trained using a standard treadmill without any visual display
2585738|NCT02328508|Experimental|hyperbaric oxygen therapy|The experimental group received treatments in a hyperbaric chamber for 120-min per session, once per day, and five days per week for four consecutive weeks (20 treatment sessions).
2585739|NCT02328508|No Intervention|Control|The control group received only routine care.
2585748|NCT02328053|Experimental|Collagen crosslinking group|patients not resolving to standard antifungal therapy were assigned to receive adjuvant collagen crosslinking with riboflavin and Ultraviolet-A along with topical medical therapy
2585754|NCT02328053|Active Comparator|standard medical therapy|patients were continued on topical antifungal therapy namely Natamycin eye drops and voriconazole eye drops
2585804|NCT02327663|Experimental|HBeAg positive CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
2585806|NCT02327663|Experimental|HBeAg negativie CHB group|1000 patients take generic emtricitabine capsule(200 mg one time per day) for 96 weeks,and for patients who have HBV DNA > 500 copies/ml, adefovir dipivoxil were combined
3212448|NCT01015248|Experimental|Rituximab and Bendamustine|
3212449|NCT01015261|Experimental|Bone Marrow Transplantation|
3212450|NCT01015261|Active Comparator|Chemotherapy|
3212451|NCT01015274||Healthy control male|
3212452|NCT01015313|Experimental|intensive sodium management|
3212453|NCT01015313|No Intervention|standard care|
3212454|NCT01015339|Active Comparator|Cisplatin plus capecitabine|
3212455|NCT01015339|Experimental|Paclitaxel plus Capecitabine|
3212456|NCT01015352|Active Comparator|Arm A|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days for 6 courses and 12 additional maintenance courses in responders.
3212457|NCT01015352|Active Comparator|Arm B|"Azacitidine: 75mg/sqm SQ per day for 5 days every 28 days for 6 courses AND~Epoetin beta : 60000U weekly SQ injections (to be adapted according to Hb as described above)~12 additional maintenance courses are planned in responders"
2584903|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 15 mcg, 1 capsule/day before breakfast, Duration: 6 months
2584904|NCT02333682|Experimental|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
2584906|NCT02333682|Active Comparator|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol), Dose: 20 mcg, 1 capsule/day before breakfast, Duration: 6 months
2584922|NCT02333279||Organ transplant recipients|Follow-ups in regular intervals following the organ transplant date.
2584971|NCT02333175|Active Comparator|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
2584973|NCT02333175|No Intervention|Care as usual|Care as usual
3212458|NCT01015365|Other|Surgical revision|Surgical cementless One-stage revision of the chronic infected hip arthroplasty
3212459|NCT01015378||Diverticulitis of the sigmoid colon - first episode|
2585070|NCT02332395||Emergency caesarean section|patients whose underwent emergency caesarean section operation
2585079|NCT02332395||Elective caesarean section|patients whose underwent elective caesarean section operation
2585095|NCT02332278|Experimental|Early feeding|Early feeding (fluid diet), four hours after cesarean section.
2585105|NCT02332278|Active Comparator|Late feeding|Late feeding (fluid diet) 12 hours after cesarean section.
2585195|NCT02331979|Experimental|Stimulation of Non-Naive|Evaluate neuromodulation in 6 subjects with prior motor training.
2585197|NCT02331979|Experimental|Stimulation of Naive|Evaluate neuromodulation in 6 naive subjects.
2585201|NCT02331979|Experimental|Stimulation|Apply parameters discovered in Arm 1 and Arm 2 to evaluate neuromodulation in 12 naive subjects.
2585222|NCT02331420|Experimental|Bariatric Surgery|Gastric bypass
2585224|NCT02331420|Active Comparator|Optimal Medical Therapy|planned visits, optimized hypoglycemic treatment, diet and lifestyle modification
2585283|NCT02331290||All patients|20 newly diagnosed patients with small-cell lung cancer and adenocarcinoma of the lung stage III or IV
2585311|NCT02331043|Placebo Comparator|Placebo biscuit|Biscuit without plant stanol ester
2585322|NCT02331043|Experimental|Plant stanol ester biscuit|Biscuit with plant stanol esters
2585359|NCT02330757|Active Comparator|HRT group|Women will be subjected to HRT using Estradiol valerate before FET
2585365|NCT02330757|Active Comparator|MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
2585429|NCT02330406|Active Comparator|Anagliptin|Anagliptin 100 mg bid for 52 weeks. Can increase to 200 mg bid if needed.
2585435|NCT02330406|Active Comparator|Sitagliptin|Sitagliptin 50 mg qd for 52 weeks. Can increase to 100 mg qd if needed
2585484|NCT02329925|Experimental|Tongue Stabilizing Device Treatment|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
2585537|NCT02329665|Experimental|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
2585588|NCT02329379|Experimental|Unigoiter, ATA (+), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
2585589|NCT02329379|Active Comparator|Unigoiter, ATA (-), AUS (+) on Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
2585590|NCT02329379|No Intervention|Unigoiter, ATA (+), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
2585591|NCT02329379|No Intervention|Unigoiter, ATA (-), AUS (+) without Tx|The patients who have uninodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
2585592|NCT02329379|Experimental|Multigoiter, ATA (+), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
2585593|NCT02329379|Active Comparator|Multigoiter, ATA (-), AUS (+) on Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance will take eltroxin for TSH suppression therapy to ameliorate of goiter
2585594|NCT02329379|No Intervention|Multigoiter, ATA (+), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and positive autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
2585596|NCT02329379|No Intervention|Multigoiter, ATA (-), AUS (+) without Tx|The patients who have multinodular goiter demonstrated by thyroid sono and negative autoantibody of thyroglobulin with pathological reports of fine needle aspiration showing atypical undetermined of significance decide not to take eltroxin for TSH suppression therapy; instead, only observation with following will be conducted
2585607|NCT02329041|Experimental|McGrath Series 5|DLT intubation with McGrath Series 5 videolaryngoscope
2585611|NCT02329041|Active Comparator|Airtraq|DLT intubation with Airtraq videolaryngoscope
2585692|NCT02328586|Experimental|Group Acupuncture|Participants will then be invited to participate in an 8-week, group-based acupuncture treatment intervention delivered by a licensed acupuncturist. The group will meet weekly for 8 consecutive weeks, each session lasting about 75 minutes.
3212460|NCT01015391|Experimental|T2|
3212461|NCT01015391|Active Comparator|AZA|
3212462|NCT01015404|Experimental|Experimental H|high volume (0.6mL、0.3% Trafermin)
2584926|NCT02333591|Placebo Comparator|NaCl|Saline is infused with a flow rate of 240 ml/h for 10 min and then reduced to 86 ml/h for 2½ hours.
3177487|NCT00653081|Active Comparator|A|Supervised Exercises performed at ulleval Hospital for patients with shoulder pain. Dosage: 45 minutes each time, max 2-3 times a week in max 12 weeks
3177488|NCT00653081|Active Comparator|B|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
2585035|NCT02332746||Middle-aged women|Middle-aged women (35-64 years)
2585083|NCT02332499|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2585085|NCT02332499|Placebo Comparator|Placebo|Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
2585168|NCT02331901||MTBI SYMP|Mild Traumatic Brain Injury subjects with symptoms
2585177|NCT02331901||MTBI NO SYMP|Mild Traumatic Brain Injury subjects without symptoms
2585251|NCT02331667|Experimental|Seafood|Intervention with meals consisting of seafood (herring and mackrell).
2585258|NCT02331667|Experimental|Non-seafood|Intervention with meals constisting of non-seafood (meat).
2585313|NCT02331147|Sham Comparator|Standard of Care|Surgical debridement of DFU, The wound will be debrided and cleaned. Patient ulcers will be assessed and measured weekly in cm length by width. Application of collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice off loading
2585323|NCT02331147|Active Comparator|Human Dermis|"Application of Human Allogenic Dermis with Dressing Application, to be changed weekly. Patient would will be measured in cm length by width weekly Patient will practice Offloading.~If the ulcer has not closed completely, an additional piece of Human Dermis will be applied weekly at weeks 2-11 in a similar fashion"
2585383|NCT02330640|Experimental|ticagrelor|90mg Bid for 30days after first dose
2585386|NCT02330640|Active Comparator|clopidogrel|75mg Qd for 30days first dose
2585387|NCT02330640|Other|asprin|100mg Qd all patients will be given asprin 100mg Qd within 24hours after CABG
2585427|NCT02330315|Experimental|Active tDCS + Active TUS|Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
2585431|NCT02330315|Sham Comparator|Sham tDCS + Sham TUS|Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
2585566|NCT02329418|Experimental|Written document|Accompanying relatives with a written document when discussing withholding and withdrawing life-sustaining therapies . All other procedures are standard.
2585572|NCT02329418|Active Comparator|Standard|Discussing withholding and withdrawing life-sustaining therapies following standard procedure without written document
2585606|NCT02329184|Experimental|MYK-461|
2585719|NCT02328521|Experimental|Nicorandil group|Drug: Nicorandil (Chugai Pharmaceutical Co, Japan). The first dose is given 8h before selective percutaneous coronary intervention, 10mg, oral. After the percutaneous coronary intervention, nicorandil is given for 30 days, 5mg each time, 3 times daily oral.
2585720|NCT02328521|Placebo Comparator|Control group|Drug: Nicorandil placebo (Sihuan Pharmaceutical Co, China). The first dose is given 8h before selective percutaneous coronary intervention, 2 tablets, oral. After the percutaneous coronary intervention, placebo is given for 30 days, 1 tablet each time, 3 times daily oral.
2585849|NCT02327611|Experimental|Custodiol|Renal perfusion with Custodiol (cold crystalloid solution enriched with histidine-tryptophan-ketoglutarate).
2585850|NCT02327611|Active Comparator|enriched Ringer's lactate solution|Renal perfusion with cold Ringer's lactate solution enriched with methylprednisolone 125 mg /L and mannitol 12.5 g /L.
2585893|NCT02327195|Experimental|Methylphenidate|Quillivant XR - Methylphenidate HCL Extended Release oral suspension - (after reconstruction with water - 5mg/mL) 20 mg (PO) given 2 hours prior to surgery
2585897|NCT02327195|Placebo Comparator|Placebo|20 mg Placebo (PO) given 2 hours prior to surgery
3177489|NCT00653094|Other|A|
3177490|NCT00653107|Experimental|A|Stent followed by 3 brachytherapy fractions
2586020|NCT02326350|Experimental|Aspirin 75mg|Aspirin 75mg enterally once daily for a maximum of 14 days
2586026|NCT02326350|Placebo Comparator|Placebo|Lactose powder placebo enterally once daily for a maximum of 14 days
2586072|NCT02326051|Active Comparator|Early Enoxaparin initiation|Women will start Enoxaparin therapy once positive pregnancy test is established
2586074|NCT02326051|Active Comparator|Later Enoxaparin initiation|Women will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation
3177491|NCT00653107|Active Comparator|B|3 fractions of brachytherapy
3177492|NCT00653120|Experimental|A|Subjects received Par Products under fasting conditions
3177493|NCT00653120|Active Comparator|B|Subjects received Wyeth Pharmaceuticals product under fasting conditions
3177494|NCT00653146|Experimental|Mindfulness-based stress reduction|The MBSR program includes meditation techniques, body scan, awareness of breathing, mindful yoga, eating meditation, and walking meditation, and meets for 2 hours, once weekly for 8 weeks.
3177495|NCT00653146|Placebo Comparator|Healthy Lifestyles Program|The Healthy Lifestyles Program includes information on nutrition and physical activity, and meets for 2 hours, once weekly for 8 weeks.
3177496|NCT00653172|Experimental|1|NXL103
3177497|NCT00653172|Active Comparator|3|
3177498|NCT00653172|Experimental|2|NXL103
3177499|NCT00653185|Experimental|SYR-472 25 mg QD|(with lifestyle modification and/or metformin therapy)
3177500|NCT00653185|Experimental|SYR-472 50 mg QD|(with lifestyle modification and/or metformin therapy)
3177501|NCT00653185|Experimental|SYR-472 100 mg QD|(with lifestyle modification and/or metformin therapy)
3177502|NCT00653185|Experimental|SYR-472 200 mg QD|(with lifestyle modification and/or metformin therapy)
3177503|NCT00653185|Placebo Comparator|Placebo QD|(with lifestyle modification and/or metformin therapy)
3177504|NCT00653198||A|Cases
3177505|NCT00653198||B|Controls
2584931|NCT02333357|Experimental|Toolkit|Counselors randomized to the toolkit (TK) condition will receive a one to three hour standardized toolkit orientation that will include a description of the overall goal of the toolkit curriculum comprised of five modules, the purpose of each individual element of the toolkit, and an introduction to the toolkit teaching aids such as counselor guides, posters, and patient materials (hand-outs, sampling menus, worksheets, etc). TK counselor participants then conduct group treatment sessions using the toolkit materials with their patient participants.
2584945|NCT02333357|Active Comparator|Treatment as Usual|Counselors assigned to the Treatment as Usual (TAU) attention control condition complete a training that reviews the same five 12-step topics that are included in the toolkit, but they do not receive any toolkit materials. TAU counselor participants then conduct group treatment sessions on the 12-step topics without using toolkit materials.
2585064|NCT02332434|Experimental|sleeve gastrectomy|bariatric surgery procedure based exclusively on the gastric restriction (the sleeve gastrectomy).
2585074|NCT02332434|Experimental|gastric bypass|bariatric surgery procedure associating a malabsorption (the gastric bypass).
2585101|NCT02332252|Active Comparator|Scalpel|Skin incision performed with a scalpel during cesarean section.
2585106|NCT02332252|Experimental|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
2585193|NCT02331888|Experimental|Scalp electrode, fetal doppler and EUM|Once in labor, the parturient will be connected to the routine fetal doppler and EUM. When necessary according to clinical indications, the scalp electrode will be connected. Tracing will be recorded simultaneously from all three devices until delivery.
2585252|NCT02331576|Placebo Comparator|rocaine|continuous femoral nerve block with ropivacaine alone.
2585259|NCT02331576|Active Comparator|rocaine with fentanyl|continuous femoral nerve block with combination of ropivacaine and fentanyl.
2585542|NCT02329496|Experimental|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System
2585637|NCT02329275||Azoospermic men|
2585639|NCT02329275||Men with proven fertility|
2585700|NCT02328703|Experimental|Reiki Therapy by a Reiki Master|The Reiki Master will take approximately 30 minutes to perform a hand placement sequence that will allow the direction of energy toward the site of pain.
2585707|NCT02328703|Placebo Comparator|Sham Reiki Therapy by a Clinician|The Clinician, who has not trained in Reiki, will mimic the same 30 minute hand placement protocol as the Reiki Master.
2585931|NCT02327104|Experimental|Mindfulness Based Relapse Prevention|The Experimental Group (EG) will undergo eight sessions of MBRP after Brazilian Ministry of Health Protocol (BMHP) for Tobacco dependence treatment. MBRP Program: the first three sessions: focus on practicing mindful awareness and integrating mindfulness practices into daily life (body scan, sitting meditation, walking meditation); The next three sessions: emphasize acceptance of present experience and application of mindfulness practices to relapse prevention; The final two sessions: expand to include issues of self-care, support network, and lifestyle balance.
2585934|NCT02327104|Other|Brazilian Ministry of Health Protocol|The Control Group (CG) is undergo the protocol of the Brazilian Ministry of Health Protocol (BMHP): clinical evaluation, four sessions of cognitive-behavioral approach and Nicotine Replacement Therapy and/or Bupropion as needed, as the Experimental Group. And during the eight sessions of MBRP (EG) both groups (EG and CG) are subjected to eight maintenance sessions of BMHP.
2585989|NCT02326545|Experimental|MindLight|MindLight is the video game being tested for effectiveness to reduce child anxiety
2585999|NCT02326545|Active Comparator|Online CBT|Online CBT program for children
3177506|NCT00653237|Other|1|crossover trial. insertion of both devices consecutively, computer randomized order
3177507|NCT00653250|Experimental|Therapeutic Intervention|Correlative
3177508|NCT00653276|Active Comparator|Treatment A|Treatment A: subjects will be given a single oral dose of cyclosporine 100 mg capsules on Day 1.
3177509|NCT00653276|Active Comparator|Treatment B|Treatment B: subjects will receive single oral daily doses of ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through 6, followed by coadministration of a single oral dose of ezetimibe 20 mg (2 x 10 mg tablets) and cyclosporine 100 mg capsule on Day 7.
3177510|NCT00653302|Experimental|1|Lantus once a day plus Glucophage 1000mg, twice a day per os
3177511|NCT00653315|Experimental|A|Subjects received kali product under fasting conditions
3177512|NCT00653315|Active Comparator|B|Subjects received Ortho-Mcneil product under fasting conditions
3177513|NCT00653354|Active Comparator|Arm 1|
3177514|NCT00653354|Active Comparator|Arm 2|
3177515|NCT00653354|Placebo Comparator|Arm 3|
3177516|NCT00653367|Experimental|NS|Nerve section of intercostal nerve during surgery
3177517|NCT00653367|No Intervention|Control|Control
3177518|NCT00653380|Experimental|A|Subjects received the Par product (Doxycycline Monohydrate) under fasting conditions.
3177519|NCT00653380|Active Comparator|B|Subjects received Oclassen's product (Monodox) under fasting conditions.
3177520|NCT00653393|Experimental|A|Subjects received Kali product under fasting conditions
3177521|NCT00653393|Active Comparator|B|Subjects received Parnate product under fasting conditions
3177522|NCT00653419|Experimental|A|Subjects received the Par formulated product (Buspirone HCl) under fasting conditions
3177523|NCT00653419|Active Comparator|B|Subjects received the Bristol-Myers Squibb formulated product (Buspar) under fasting conditions
3177524|NCT00653445|Experimental|1|Rosuvastatin 40mg/Ezetimibe 10mg combination therapy
3177525|NCT00653445|Experimental|2|Rosuvastatin 40 mg
2584933|NCT02333253|Active Comparator|Delayed start protocol|First group received 300 U r FSH +150 U urinary GN from day 2 till day of HCG ,dose adjusted according to the response then 0.25 cetrotide S.c was added on when leading follicle reach >12 mm, HCG was given only if we have at least 3 mature follicles >14 mm and the leading one >17mm then OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
2584947|NCT02333253|Active Comparator|conventional antagonist protocol|Second group were received cetrotide 0.25 mg s.c alone from day 2 to day 8then we initiate GN therapy by same initial GN dose (300FSH+150U urinary GN).same adjustment of dose were done and antagonist restarted when DF >12mm, till day of HCG, OPU done after 36 hrs of HCG, oocytes were denuded and fertilized by ICSI to avoid low fertilization rate by conventional IVF,embryo transfer were done on day 3 when we have at least one embryo GI other wise cancelled ET, then cyclogest 800mg were given intravaginal for 14 days then quantitative BHCG done and considered positive if > 5miu/ML
2584995|NCT02333058|Experimental|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA. One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
2585072|NCT02332447|Experimental|NALOXONE|
2585077|NCT02332447|Placebo Comparator|PLACEBO|
2585166|NCT02331875|Experimental|single arm|IPH2201 followed by standard surgery and standard postsurgical adjuvant therapy
2585247|NCT02331459|Experimental|Intervention group|"Multicomponent training intervention :~3 sessions a week of 45 minutes of resistance activity (24 weeks) 2 sessions a week of 45 minutes of strength training (24 weeks) 5 sessions a week of 15 minutes of proprioceptive training (24 weeks)"
2585256|NCT02331459|Placebo Comparator|Control group|Normal routine during 24 weeks.
3212463|NCT01015404|Experimental|Experimental L|low volume (0.2mL、0.3% Trafermin)
3212464|NCT01015417|Active Comparator|Amoxicillin clavulanic acid|Postoperative administration of 2g of Augmentin, 3 times daily for 5 days.
3212465|NCT01015417|Other|No medication|no postoperative antibiotics
3212466|NCT01015430|Placebo Comparator|Placebo (for RO4917523 ascending doses)|
3212467|NCT01015430|Placebo Comparator|Placebo (for RO4917523 fixed dose)|
3212468|NCT01015430|Experimental|RO4917523 ascending doses|
2585446|NCT02330263|Experimental|carbohydrate group|Randomly selected patients of the carbohydrate group are given 400ml of 12.8 g/100 ml carbohydrate beverage in the evening before their surgery and in the morning of the operation day (3 hours before their scheduled operation).
2585452|NCT02330263|No Intervention|control group|Patients in the control group consume no food or drink after midnight before surgery.
2585461|NCT02329990|Active Comparator|phosphorus|phosphorus ingestion (375mg) with each main meal ( breakfast, lunch, dinner)
2585463|NCT02329990|Placebo Comparator|placebo|ingestion of placebo tablets with each meal ( breakfast, lunch, dinner)
2585518|NCT02329808||Mycophenolic acid|Patients treated for their regular patient care with mycophenolic acid.
2585520|NCT02329808||Cyclosporin|Patients treated for their regular patient care with cyclosporin.
2585523|NCT02329808||Tacrolimus|Patients treated for their regular patient care with tacrolimus.
2585525|NCT02329808||Sirolimus|Patients treated for their regular patient care with sirolimus.
2585526|NCT02329808||Everolimus|Patients treated for their regular patient care with everolimus.
2585527|NCT02329808||Voriconazole|Patients treated for their regular patient care with voriconazole.
2585529|NCT02329808||Posaconazole|Patients treated for their regular patient care with posaconazole.
2585530|NCT02329808||Itraconazole+metabolite|Patients treated for their regular patient care with itraconazole.
2585533|NCT02329808||Fluconazole|Patients treated for their regular patient care with fluconazole.
2585538|NCT02329444|Experimental|Remote Ischemic Preconditioning|Patients treated with Remote Ischemic Preconditioning
2585544|NCT02329444|Active Comparator|Sham ischemic preconditioning|Patients treated with sham ischemic preconditioning
2585640|NCT02329262|Experimental|Mentoring to be Active|Trained teen mentors will deliver the physical activity curriculum to high school students in a school setting. Physical activity will be measured with accelerometers.
2585642|NCT02329262|Active Comparator|Planning to be Active|High school teachers will deliver the physical activity curriculum (usual care) to high school students enrolled in health education courses. Physical activity will be measured with accelerometers.
2585651|NCT02328638|Active Comparator|Manual-based Behavioral Treatment|up to 16 weekly behavioral therapy sessions (intervention) following the CHANGE obesity manual, lasting approximately 45 minutes and nutritional therapy sessions, lasting approximately 30 to 60 minutes.
2585652|NCT02328638|Placebo Comparator|Parent Education Program|up to 16 weekly behavioral therapy sessions following the parent education program
2585717|NCT02328560||Paramedical ad consultation|Monitoring will be the same in the 2 groups; That paramedical consultation announcement is made in current practice.
2585718|NCT02328560||No paramedical ad consultation|Monitoring will be the same in the 2 groups
3212469|NCT01015430|Experimental|RO4917523 fixed dose|
3212470|NCT01015456|Experimental|1|Oral mycophenolate sodium 1440 mg per day for 12 months
3212471|NCT01015456|Active Comparator|2|Intravenous cyclophosphamide monthly for 6 months
3212472|NCT01015469|Active Comparator|Group A|Conventional laparoscopic Roux-en-Y gastric bypass (Golden Standard)
3212473|NCT01015469|Experimental|Group B|Conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring
3212474|NCT01015482|Experimental|Remifentanil|Remifentanil Infusion
3212475|NCT01015482|Active Comparator|Midazolam|Active Placebo
3212476|NCT01015495|Experimental|ranibizumab|
2584964|NCT02333305|Placebo Comparator|2|Placebo of CoQ10 is a translucent nano-emulsion of well characterized nano particles. Lecithin (and) Alcohol (and) Glycerin (and) Aqua
3177526|NCT00653458|Experimental|A|Subjects received Kali formulated products under fed conditions
3177527|NCT00653458|Active Comparator|B|Subjects received GlaxoSmithKline's formulated products under fed conditions
2585057|NCT02332681||With insufficiency fracture|Patients with acute pain that sustained a knee insufficiency fracture
2585060|NCT02332681||Without insufficiency fracture|Patients with acute pain that did not sustained a knee insufficiency fracture
2585099|NCT02332304|Other|Preterm fetus|Patients with pregnancies between 26 and 36 6/7 weeks of pregnancy. Before the birth, a sample of amniotic fluid was taken and analyzed using optical density at 650nm. A value above 0.15 was considered an indication of fetal lung maturity.
2585163|NCT02332018||Limb Torsion|adult patients, lower limb assessment retrospectively limb length and limb axis, torsion biplanar x-ray images
2585167|NCT02332018||Limb Length and Axis|adult patients, lower limb assessment prospectively limb length and limb axis biplanar x-ray images
2585176|NCT02332018||Spine|adult patients, spine assessment prospectively Cobb angles, plumbline biplanar x-ray images
2585248|NCT02331524|No Intervention|Control/Usual Care|Usual care only
2585255|NCT02331524|Experimental|Activity Feedback and Encouragement|Weekly Feedback about daily activity using the FitBit Zip
2585261|NCT02331524|Experimental|Health Coaching/Home Exercise|Weekly contact from physical therapist to develop and progress home exercise program and by health coach for goal setting and support
2585348|NCT02331134|Other|Melanoma, head and neck|10 μg/kg/day of Filgrastim will be given subcutaneously for 4 days
2585385|NCT02330601|No Intervention|control group|The papilla orifice could be enlarged by asphincterotomeif necessary. The stones were retrieved by a basket or a retrieval balloon
2585388|NCT02330601|Other|EPLBD group|a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
2585426|NCT02330354|Experimental|Intervention group|Centers in this group will participate in the Healthy Me, Healthy We program.
2585430|NCT02330354|Other|Control Group|Centers in this group will participate in the Healthy Me, Healthy We program after follow-up measures are collected.
2585487|NCT02330042||Group A|"Patients with:~Type 1 or Type 2 diabetes mellitus~severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR)."
2585493|NCT02330042||Group B|"Patients with:~Type 1 or Type 2 diabetes mellitus~with or without mild to moderate NPDR"
2585498|NCT02330042||Group C (controls)|Patients without diabetes or evidence of any form of eye disease
2585562|NCT02329717|Experimental|PBI 05204|PBI 05204 capsules dosed at 0.2255 mg/kg/day, continuous dosing
2585690|NCT02328911|Experimental|Laser treatment|Twice-per-week laser treatment for 4 weeks and once-per-week laser treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
2585693|NCT02328911|Sham Comparator|Sham treatment|Twice-per-week sham treatment for 4 weeks and once-per-week sham treatment for 8 weeks. Inflammatory markers, functional status, and quality of life will be examined.
2585767|NCT02328287|Experimental|ALLOB® Implantation|
2585803|NCT02327780|Other|FODMAP diet|participants will be put on a low FODMAP diet.
2585855|NCT02327533||Patients with Aggressive Periodontitis|The periodontal diagnosis of subjects with GAgP was established on the basis of clinical and radiographic criteria and was defined by the 1999 International World Workshop for a Classification of Periodontal Diseases and Conditions.(Lang et al., 1999)
2585856|NCT02327533||Controls|Control subjects had no radiographic evidence of bone loss or any sign of past and present periodontitis.
2585918|NCT02327156|No Intervention|group L|receive 4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU diluted with 1mL normal saline
2585919|NCT02327156|Active Comparator|group LD|4 mL of levobupivacaine 0.75% plus hyaluronidase 15 IU and dexmedetomidine 20 μg diluted with 1mL normal saline
2585958|NCT02326740|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
2585962|NCT02326740|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
2585965|NCT02326740|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
3177528|NCT00653471|Active Comparator|Lean|Lean patients
3177529|NCT00653471|Active Comparator|Obese no OSA|Obese patients without osa
3177530|NCT00653471|Active Comparator|Obese osa|Obese patients with osa
3177531|NCT00653484|Experimental|Physical Activity Only|Physical Activity
3177532|NCT00653484|Experimental|Dietary Energy Restriction|Energy restriction
3177533|NCT00653484|Experimental|Physical Activity+Dietary Energy Restriction|Physical Activity ad Energy Restriction
3177534|NCT00653497|Experimental|1|Community-based aquatic exercise program (Arthritis Foundation Aquatics Program). Two classes per week, 45-60 minutes in duration.
3177535|NCT00653497|No Intervention|2|Usual care; abstention from initiation of new exercise programs. Invited to participate in Arthritis Foundation Aquatics Program after study completion.
3177536|NCT00653510|Experimental|Euglycemic|The patients will be examined with a blood glucose at around 5-7 mmol/L.
3177537|NCT00653510|Experimental|Hyperglycemic|The patients will be examined with a blood glucose at around 18-20 mmol/L
3177538|NCT00653549|Experimental|A|Subjects received Par formulated product under fasting conditions
3177539|NCT00653549|Active Comparator|B|Subjects received Roche formulated product under fasting conditions
3177540|NCT00653562|Experimental|1|Patients will receive placebo in one part and zolpidem in the other part
3177541|NCT00653575||1|Women who report a history of childhood sexual abuse
3177542|NCT00653575||2|Women who do not report a history of childhood sexual abuse
3177543|NCT00653588|Experimental|1|rosuvastatin (40 mg)
2584976|NCT02333162|Experimental|Treatment (IMTMI, combination chemotherapy, PBSCT or BMT)|"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes daily on days -7 to -3 and melphalan IV on day -2. Patients also undergo IMTMI BID for 2 to 5 days between days -7 to -3.~TRANSPLANT: Patients undergo allogeneic PBSCT or BMT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV continuously over 24 hours or PO BID on days -2 to 180 with taper thereafter and mycophenolate mofetil IV every 8 hours or PO on days 0-28 (for matched donors) or days 0-40 (for alternative donors) with taper to day 60."
2585015|NCT02332772||Data Collection Endoscopy of Colon Polyps|Data collected from endoscopy reports and electronic medical record system to complete a descriptive analysis of the 1) demographics, 2) colonoscopy resection procedure, and 3) outcome of resection - immediate and delayed complications, tumor recurrence, and cancer during follow-up 01/01/2014 - 12/31/2025.
2585086|NCT02332616|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
2585087|NCT02332616|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride
2585184|NCT02331836|Active Comparator|Arc Endocuff (AEC 110, 120, 130, 140)|Endocuff-assisted colonoscopy Colonoscopy with the Endocuff attached at the distal tip of the scope
2585190|NCT02331836|Active Comparator|Cap|Cap-assisted colonoscopy Colonoscopy with the transparent Cap attached at the distal tip of the scope
2585194|NCT02331836|Active Comparator|Standard Colonoscope|Standard colonoscopy without any additional device
3212477|NCT01015508|Other|High predisposition|High predisposition for weight regain
2585314|NCT02330900|No Intervention|Study group|Evaluation of interference
2585376|NCT02330770|Active Comparator|Dual trigger group|Trigger with concomitant GnRHa and HCG (single low-dose) administration
2585380|NCT02330770|Active Comparator|Single low-dose HCG group|Trigger with GnRHa then HCG (single low-dose) administration in luteal phase
2585384|NCT02330770|Active Comparator|Multiple low-doses HCG group|Trigger with GnRHa then HCG (multiple low-doses) administration in luteal phase
2585413|NCT02330289|Experimental|Report card arm|The intervention arm will receive an email report card describing their lab use compared to their peers as well as a link to a website visually tracking the team's daily ordering of common lab tests compared to the peer teams.
2585419|NCT02330289|No Intervention|Control arm|Physicians in the control arm will not receive the email or website link.
2585489|NCT02330159||Novel Wound Healing Protocol|Subjects who have pilonidal disease that are being scheduled for surgical excision with our novel wound healing protocol. The disease can be actively infected or chronic.
2585549|NCT02329691||Changes in the WHO checklist|Specific changes in the WHO checklist will be performed after observational studies to enhance the WHO checklist at the specific institution
2585657|NCT02328794|Active Comparator|Control|Participants randomized to this arm will receive a standardized Vitality program aimed at promoting tobacco cessation. This program includes existing employee benefits for quitting and the use of text/email messages to encourage tobacco cessation. No incentives will be given to participants randomized to this arm. Free cessation aids will not be available to participants in this arm. They will receive compensation for completing study related activities (sample submissions).
2585661|NCT02328794|Experimental|E-cigarette free access|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes only. These products can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
2585664|NCT02328794|Experimental|E-cigarette/NRT/Zyban/Chantix Choice|Participants randomized to this experimental arm will receive the standardized program including text/email messaging and will have access to free e-cigarettes, conventional Nicotine Replacement Therapy (NRT), Zyban, or Chantix. Each of these can be ordered directly, free of charge, through the web-based interface. No incentives will be given to participants randomized to this arm. They will receive compensation for completing study related activities (sample submissions).
2585667|NCT02328794|Experimental|Outcome Incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition, they will also be able to earn incentives across six months for testing negative for tobacco use (see Incentive payout, below). They will also receive compensation for completing study related activities (sample submissions).
2585668|NCT02328794|Experimental|Loss framing incentive arm|Participants randomized to this experimental arm will receive the standardized program and access to free e-cigarettes, NRT, Zyban, or Chantix. In addition they will also be able to earnincentives across six months through a pre-funded deposit or precommitment account. They will be notified that money has been placed into an account for them. At each time point they will lose a portion (see below) of this initial funding if they do not provide biochemical evidence of abstinence. They will also receive compensation for completing study related activities (sample submissions).
2585727|NCT02328456|Other|SMS and free eye drops group|the patient after trabeculectomy surgery in the SMS associated with free eye drops group will receive free eye drops and a SMS reminder message about the revisit time.
2585729|NCT02328456|No Intervention|the control group|the patient after trabeculectomy surgery in the control group won't get any free eye drop and reminder message before the appointment.
2585775|NCT02328144|Active Comparator|Metronidazole|22 patients received oral metronidazole 500mg 3 times for day for 7 days
2585780|NCT02328144|Placebo Comparator|Placebo|22 patients received oral placebo 500mg 3 times for day for 7 days
2585840|NCT02327715|Experimental|Chinese naive pregnant HBsAg positive patients|single group patients were enrolled to receive emtricitabine(200mg one time per day) till 24 weeks after dilivery,patients and followed up for 24 weeks.
2585869|NCT02327273|Experimental|Part A SAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
2585874|NCT02327273|Experimental|Part B MAD: BMS-963272 or Placebo|BMS-963272 or Placebo oral capsule on specific days
2585939|NCT02327039|Experimental|Dapagliflozin|Dapagliflozin 10 mg tablet once daily for 12 weeks
2585946|NCT02327039|Placebo Comparator|Placebo|Placebo 10 mg tablet once daily for 12 weeks
3212478|NCT01015508|Other|low predisposition|low predisposition for weight regain
3212479|NCT01015508|Other|Medium predisposition|Medium predisposition for weight regain
2584981|NCT02333240|No Intervention|Usual care|"Women randomised to usual care will have their blood pressure monitored by their community midwife, and will have their anti-hypertensive medication adjusted by their general practitioner. There will be no intervention in this group.~All women will be followed up at ten days, four and six weeks, then three and six months postpartum and have their blood pressure measured by one of the study team."
2584982|NCT02333240|Experimental|Self-management|Self-management of postnatal anti-hypertensive treatment. Women will be provided with, and taught to use, a validated home blood pressure monitor, and perform daily BP readings. When treatment is discontinued we will ask them to continue daily BP measurements for 1 week. Provided these are <140/90 mmHg they will be asked to check their BP weekly for the remainder of the trial period. The self-monitoring BP data will be collated centrally through the use of a smart phone app or SMS based system. This service will respond to participants regarding the level of their BP and what action is required. Women in the self-management group will have an individualised medication adjustment schedule developed by the research team in conjunction with the participant's obstetric team.
3177544|NCT00653588|Active Comparator|2|atorvastatin (80 mg)
3177545|NCT00653601||1|Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
3177546|NCT00653601||2|"Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.~# of RF for stent thrombosis~types of stents~time frame when the stents were placed~procedure type"
2585098|NCT02332135|Experimental|microwave ablation group|patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
2585104|NCT02332135|Active Comparator|control group|patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
2585181|NCT02331862|Experimental|UTI treated with Methylprednisolone|UTI treated with Methylprednisolone in addition to the effective antibiotics
2585191|NCT02331862|No Intervention|UTI not treated with Methylprednisolone|UTI treated with effective antibiotics only
2585300|NCT02330939|Active Comparator|Low fat- Low glycemic index|Participants consumed a meal with low glycemic index and poor in fat
2585303|NCT02330939|Experimental|MUFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in MUFA
2585316|NCT02330939|Experimental|SAFA- Low glycemic index|Participants consumed a meal with low glycemic index and rich in SAFA
2585327|NCT02330939|Active Comparator|Low fat- High glycemic index|Participants consumed a meal with high glycemic index and low in fat
2585332|NCT02330939|Experimental|MUFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in MUFA
2585336|NCT02330939|Experimental|SAFA- High glycemic index|Participants consumed a meal with high glycemic index and rich in SAFA
2585398|NCT02330575|Active Comparator|Standard Care|Participants in this group will receive standard education on the importance of physical activity in the recovery from cancer and how to become more active. Participants assigned to this group will have the option to participate in the exercise program after the 16-week follow-up assessment.
2585399|NCT02330575|Experimental|Supervised Community-based Exercise|Participants in this group will take part in an 8-week supervised exercise program at the YMCA. Following the 8-week intervention, participants will have the option to continue for an additional 8-weeks at the YMCA (fee for service) or follow an 8-week self-directed program.
2585532|NCT02329769|Experimental|PRO044 SC 6 mg/kg|Weekly subcutaneous (SC) dosing with 6 mg/kg
2585535|NCT02329769|Experimental|PRO044 IV 6 mg/kg|Weekly intravenous (IV) dosing with 6 mg/kg
2585536|NCT02329769|Experimental|PRO044 SC 9 mg/kg|Weekly intravenous (IV) dosing with 9 mg/kg
2585581|NCT02329470|Experimental|No device, n=50|Withdrawal of device, continuous positive airway pressure treatment during 5 nights
2585585|NCT02329470|No Intervention|Continue using device, continuous positive airway pressure treatment n=50|Control group, Continue with device, continuous positive airway pressure treatment
2585619|NCT02329080|Experimental|MATRIX - R-ICE - Conditioning and ASCT|"MATRIX (courses 1,2,3): Rituximab 375 mg/m2 d0/Methotrexate 3.5 g/m2 d1/Cytarabine 2 g/m2 d2 & d3/Thiotepa 30 mg/m2 d4/Liposomial Cytarabine 50 mg* d5~R-ICE (courses 4,5,6):Rituximab 375 mg/m2 d1/Etoposide 100 mg/m2 d1,d2, d3/Ifosfamide 5 g/m2 d2/Carboplatin 5 AUC d2/Liposomial Cytarabine 50 mg* d4~*If liposomal cytarabine is not available, standard intrathecal chemotherapy with methotrexate 10 mg + cytarabine 40 mg + hydrocortisone 50 mg can be administered. Oral steroids are suggested for 2-3 days after intrathecal liposomial cytarabine delivery to prevent chemical or aseptic meningitis/ arachnoiditis.~Conditioning and ASCT: BCNU (carmustine)** 400 mg/m2 d-6/Thiotepa 5 mg/kg d-5 & d-4 ASCT: 5 x 106 CD34+cells/kg d0~**In case of BCNU unavailability, the recommended conditioning regimen (Phase IV) is: Thiotepa 5 mg/kg d-6 & d-5/Busulfan 3.2 mg/kg d-4,d -3,d-2/Clonazepam 2 mg/d d-4,d -3,d-2 ASCT: 5 x 106 CD34+cells/kg d0"
2585726|NCT02328469||unidentified aseptic meningitis|Patients with etiologically unidentified aseptic meningitis will be treated with symptomatic therapy and will be asked to complete a questionnaire.
2585728|NCT02328469||tick-borne encephalitis|Patient with aseptic meningitis in whom serological diagnosis of tick-borne encephalitis will be established. Patients will be treated with symptomatic therapy and will be asked to complete a questionnaire.
2585730|NCT02328469||Lyme neuroborreliosis|Patients with acute aseptic meningitis in whom Lyme neuroborreliosis will be proven or suspected according to microbiological criteria. Patients will be treated with antibiotic therapy (ceftriaxone or doxycycline) and will be asked to complete a questionnaire.
2585731|NCT02328469||healthy controls|Patients will be asked to refer a spouse to serve as a control . If unmarried they will be asked to refer a family member or a friend of +/- 5 years to serve as a control.
2585732|NCT02328469||identified aseptic meningitis|Patients with microbiologically identified cause of acute aseptic meningitis/meningoencephalitis will receive symptomatic therapy. If the identified causative agent will be Herpes Simplex Virus or Varicella Zoster Virus, patients will be treated with acyclovir and will be asked to complete a questionnaire.
2585769|NCT02328209|Experimental|ranibizumab|ranibizumab
2585805|NCT02327676|Experimental|naive child CHB group|200 patients take generic emtricitabine capsule(200 mg one time per day) for 48 weeks
2585007|NCT02332980|Experimental|Treatment (pembrolizumab, idelalisib, or ibrutinib)|"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator. Patients with CLL or CLL with Richter's transformation experiencing stable disease without partial remission or progressive disease at 3 months of treatment with pembrolizumab proceed to the treatment continuation phase.~CONTINUATION PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Patients also receive idelalisib PO BID on days 1-21 OR ibrutinib PO QD on days 1-21. Treatment repeats every 21 days for up to 12 or 24 months in the absence of disease progression or unacceptable toxicity. Patients receiving benefit may continue to receive treatment for an additional 12 months at the discretion of the investigator."
2585068|NCT02332460||Infliximab|Patients treated with Infliximab
2585125|NCT02332317|No Intervention|Control arm|150 patients will receive standard oncology treatment.
2585127|NCT02332317|Active Comparator|Intervention arm|150 patients will receive standard oncology treatment alongside a 12-week specialized palliative rehabilitation program
2585267|NCT02331316|Experimental|Daily extra water intake 2L|"Timing of daily extra water intake~intervention-A: extra water intake: 8 8oz glasses of water a day (2L) - 2 first thing in the morning before breakfast, 2 before midday or midday meal, 2 before afternoon meal and 2 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
2585271|NCT02331316|Experimental|Daily extra water intake 1L|"Timing of daily extra water intake~Intervention-A: 4 8oz glasses of water a day (1L) - 1 first thing in the morning before breakfast, 1 before midday or midday meal, 1 before afternoon meal and 1 before evening meal.~Intervention-B: Drink extra water at anytime over 24 hours"
2585275|NCT02331316|Experimental|Daily extra water intake 500ml|"Timing of daily extra water intake~Intervention-A: 2 8oz glasses of water a day (500ml) - each half an hour before a meals.~Intervention-B: Drink extra water at anytime over 24 hours"
2585277|NCT02331316|Experimental|Daily extra water intake 120ml|"Timing of daily extra water intake~Intervention-A: 1/2 a glass of water on waking (120ml). If you forget to drink your water first thing, do not drink it later in the day, just skip this day and drink ½ a glass the next day on waking.~Intervention-B: Drink extra water at anytime over 24 hours"
2585312|NCT02331017|Experimental|Bimodal users|"Bilateral-bimodal users with moderate-to-severe hearing loss who use hearing aids for at least 75% of their waking hours.~Administration of Speech perception tests and self-rating questionnaire"
2585357|NCT02330744|Experimental|Approach-positive AAT|Computerized AAT procedure designed to increase automatic approach responses for positive social cues.
2585363|NCT02330744|Placebo Comparator|Control AAT|Computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
2585641|NCT02328989|Experimental|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
2585643|NCT02328989|No Intervention|No pessary|No pessary will be placed in the vagina.
2585697|NCT02328651|Experimental|Ribavirin treatment plus testing drug|
2585702|NCT02328651|Active Comparator|Ribavirin treatment|
2585760|NCT02328300||FLT PET/MR|"All participants will have known brain lesion in the central nervous system (CNS) scheduled to have surgical biopsy of the lesion, identified by the UNC Brain Tumor Board and will have the clinical question of radiation necrosis vs. recurrence.~All participants will receive a FLT PET/MR scan."
3177547|NCT00653614|Experimental|Arm 1|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for one day and placebo for three days in a 28 day cycle
3177548|NCT00653614|Experimental|Arm 2|E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for 24 days and DRSP (ZK 30595) dose 1 (SHT04984F) for two days and placebo for two days in a 28 day cycle
3177549|NCT00653614|Experimental|Arm 3|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, and placebo for days 25-28 in a 28 day cycle
2586091|NCT02326012|Experimental|Emotion Regulation Individual Therapy for Adolescents|
3177550|NCT00653614|Experimental|Arm 4|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 1 (SHT04984E) for days 9-16, E2/DRSP (BAY 86-4891) dose 3 (80458755) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 1 (SHT04984F) for one day in a 28 day cycle
3177551|NCT00653614|Experimental|Arm 5|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891) dose 5 (80458712) for days 17-24, and placebo for 4 days in a 28 day cycle
3177552|NCT00653614|Experimental|Arm 6|E2/DRSP (BAY 86-4891) dose 2 (80458739) for days 1-8, E2/DRSP (BAY 86-4891) dose 4 (80458720) for days 9-16, E2/DRSP (BAY 86-4891)dose 5 (80458712) for days 17-24, placebo for 3 days, and DRSP (ZK 30595) dose 2 (80458690) for one day in a 28 day cycle
3177553|NCT00653627|Experimental|A|Study of BCG quantification and immunogenicity 2 weeks after BCG vaccination
3177554|NCT00653627|Experimental|B|Study of BCG quantification and immunogenicity 4 weeks after BCG vaccination
3177555|NCT00653640|Experimental|1|body weight supported treadmill training
3177556|NCT00653640|Placebo Comparator|2|traditional physical therapy
3177557|NCT00653653||Group A|Recruited patients will be prospectively observed as one cohort with genotyping/medication interaction analysis after 3 months, followed up by a further 3 month observational period.
3177558|NCT00653692||Observational|Poly drug dependent women
3177559|NCT00653705|Active Comparator|Probiotic|Children given probiotic BB12 enriched yogurt drink.
3177560|NCT00653705|Placebo Comparator|Control|Children given dairy drink.
3177561|NCT00653731|Experimental|Snoezelen ©|
3177562|NCT00653731|Experimental|Reminiscence|
3177563|NCT00653731|Experimental|10 min activation|
3177564|NCT00653731|Active Comparator|Talk|
3177565|NCT00653744|Experimental|1|Rosuvastatin
3177566|NCT00653744|Active Comparator|2|Atorvastatin
3177567|NCT00653770|Experimental|1|FP85A at day 0
2585113|NCT02332265||Community Impact Study, non-SAFE participants|We conducted random surveys (n = 1002)--501 living in the intervention areas but not directly receiving the SAFE intervention and 501 living in the control areas not receiving the SAFE intervention with a 36-month assessment interval, prior to and after implementation of SAFE. Thus, we examined intervention outcomes both in direct SAFE program participants and their larger communities. We used multilevel modeling to examine mediators and moderators of the effects of SAFE on HIV outcomes at the individual and community levels and determine the ways in which changes in HIV outcomes feed back into economic outcomes and food security at later interviews.
2585120|NCT02332265||Qualitative SAFE program participant in-depth interview & FGD|We conducted a qualitative end-of-program evaluation consisting of in-depth interviews with 90 SAFE participants.
2585187|NCT02331914||Gastro-intestinal stromal tumors|"A bio-databank consisting of TKI drug level and serum for analysis of mutations in circulating tumor DNA will be set up. This bio-databank will be used to study whether changes in the amount of the primary KIT mutation is an early predictor of treatment response and/of failure. Moreover, secondary TKI resistant mutations in circulating tumor DNA will be assessed.~To be able to assess those mutations, a tumor biopsy will be performed at the time of radiologic progressive disease. Vena puncture for blood collection will be performed at routine out patient visits."
3212480|NCT01015521|Experimental|Aminoflavone Prodrug|Aminoflavone to treat ER positive breast cancer patients
2585298|NCT02331004|Active Comparator|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
2585299|NCT02331004|Placebo Comparator|Support to activities of daily living|Performing of general activities planned in the centres where the participants are included
2585391|NCT02330731|Other|N-butyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
2585392|NCT02330731|Other|iso-amyl-2-cyanoacrylate|injection sclerotherapy for gastric varices
2585396|NCT02330731|Other|72% chromated glycerin|injection sclerotherapy for gastric varices
2585450|NCT02330224|Experimental|Hypertension Management Intervention|Multifaceted hypertension management intervention
2585453|NCT02330224|No Intervention|Usual Care|Control group
2585488|NCT02329938|Active Comparator|Lichtenstein tension free reair|mesh repair of inguinal hernia
2585494|NCT02329938|Active Comparator|Desarda's repair|non-mesh repair of inguinal hernia
2585550|NCT02329639||case group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy with bevacizumab
2585552|NCT02329639||control group|genetic interaction analysis of women with HER2 negative metastatic breast cancer performing a first-line chemotherapy without bevacizumab
3212481|NCT01015521|Experimental|Aminoflavone Prodrug with pretreatment|Aminoflavone Prodrug to treat Triple Negative Breast Cancer
3212482|NCT01015547|Experimental|Infliximab plus Methotrexate|infliximab 3-5 mg/kg every 6 weeks, plus methotrexate 15 mg/m2 weekly given orally (dose escalation if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
3212483|NCT01015547|Experimental|Combination of DMARDs|methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75), plus standard doses of sulfasalazine and hydroxychloroquine. no oral prednisolone. intra-articular steroids allowed.
2585743|NCT02328482|Experimental|Arm 1|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
2585744|NCT02328482|No Intervention|Arm 2|no-treatment concurrent control; follow-up over 52 weeks
3212484|NCT01015547|Active Comparator|Methotrexate alone|Conventional drug therapy: methotrexate 15mg/m2 weekly given orally (dose escalation and parenteral injection if ACR Pedi less than 75). no oral prednisolone. intra-articular steroids allowed.
2585889|NCT02327520||Colitis with CDI|Patients who diagnosed with CDI will be analysed
2585943|NCT02326948||Gallbladder cancer case group|Gallbladder cancer case group was defined as newly diagnosed gallbladder cancer diagnosed as GBC at the Department of Internal Medicine in Cheju Halla General Hospital, Jeju, Korea from 2009 to 2013.
2585953|NCT02326948||Age and sex matched control group|Age and sex matched control group was determined as age-sex matched subjects selected from the participants of Health Promotion Center in the same institute from 2009 to 2012.
3212485|NCT01015573|Experimental|healthy subjects|
2586054|NCT02325986|Experimental|Weekly PF with radiation|4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).
3177568|NCT00653770|Experimental|2|MVA85A at day 0 and FP85A at day 28
3177569|NCT00653770|Experimental|3|FP85A at day 0 and MVA85A at day 28
3177570|NCT00653796|Experimental|Ezetimibe + Atorvastatin|
3177571|NCT00653796|Active Comparator|Atorvastatin|
3177572|NCT00653809||A, 1, I|Caucasian women without preeclampsia or PIH, delivering their first child
3177573|NCT00653809||A, 1, II|Caucasian women with preeclampsia or PIH, delivering their first child
3177574|NCT00653809||A, 2, I|African-american women without preeclampsia or PIH, delivering their first child
3177575|NCT00653809||A, 2, II|African-American women with preeclampsia or PIH, delivering their first child
3177576|NCT00653809||B, 1, I|Caucasian women without preeclampsia or PIH, delivering at least their second child
3177577|NCT00653809||B, 1, II|Caucasian women with preeclampsia or PIH, delivering at least their second child
3177578|NCT00653809||B, 2, I|African-american women without preeclampsia or PIH, delivering at least their second child
3177579|NCT00653809||B, 2, II|African-american women with preeclampsia or PIH, delivering at least their second child
3177580|NCT00653822|Experimental|1a|IV
2585129|NCT02332213||9. Average risk population|Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer.
2585208|NCT02331706|Experimental|Subject Recipients|
2585209|NCT02331706|Experimental|Subject Donors|
3212486|NCT01015599|Experimental|HOP'N After-School Program|After-school program with daily physical activity following CATCH guidelines, daily fruit/vegetable snack, and weekly nutrition and physical activity education based on social cognitive theory.
2585302|NCT02330887|Experimental|Intervention Cohort|We will use a cohort of 60 women from intervention village clusters for the group antenatal care intervention.
2585318|NCT02330887|Active Comparator|Control Cohort|We will use a cohort of 60 women from control village clusters as an active comparison.
2585408|NCT02330510||Alzheimer's Disease|Individuals with early Alzheimer's Disease (AD) or amnestic or multi-domain Mild Cognitive Impairment who have extensive Periventricular White Matter Hyperintensities
2585412|NCT02330510||Transient Ischemic Attack/Mild Subcortical Stroke|Individuals who have had a mild subcortical stroke or a Transient Ischemic Attack (TIA) with extensive Periventricular White Matter Hyperintensities in the absence of cortical infarcts
2585474|NCT02330003|Experimental|IL-YANG PFS|IL-YANG FLU Vaccine Prefilled Syringe INJ.
2585475|NCT02330003|Active Comparator|TIV PFS|Fluarix Prefilled Syringe
3260289|NCT01477983|Active Comparator|ATP guide additional ablation - AAD|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: AAD for 90 days
3260290|NCT01477983|Active Comparator|Control - AAD|UNDER-ATP trial: Control, EAST-AF trial: AAD for 90 days
2585630|NCT02329028||Prehospital mini-EEG|Feasibility of prehospital EEG device in unconscious patients.
2585677|NCT02328742||No intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to not have an intracavitary pathology. (The first 20 such patients will be retained in this group.)~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Telephone call"
2585680|NCT02328742||Synechia|"During the first diagnostic hysteroscopy, patients in this group are found to have synechia.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
2585684|NCT02328742||Intracavitary pathology|"During the first diagnostic hysteroscopy, patients in this group are found to have an intracavitary pathology.~Intervention: Hysteroscopy + endometrial biopsy~Intervention: Resection + endometrial biopsy~Intervention: Follow-up hysteroscopy + endometrial biopsy~Intervention: Telephone call"
2585762|NCT02328222|No Intervention|CONTROL GROUP|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
2585763|NCT02328222|Experimental|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
2585809|NCT02327806|Other|10 minutes of pulsed electromagnetic field therapy|10 minutes of pulsed electromagnetic field therapy
2585831|NCT02327806|Other|20 minutes of pulsed electromagnetic field therapy|20 minutes of pulsed electromagnetic field therapy
2585834|NCT02327806|Other|30 minutes of pulsed electromagnetic field therapy|30 minutes of pulsed electromagnetic field therapy
2585881|NCT02327442||Volunteers|Healthy Volunteers undergo whole-body 68Ga-NOTA-NFB PET/CT scans 0, 0.5, 1.0, 2.0, and 3.0 hours after tracer injection. During the imaging period, 1 mL blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, and 180 minutes after the injection, for time-activity curve calculations.
2585882|NCT02327442||Glioma Patients|Glioma Patients enrolled for the clinical study of diagnosing glioma are performed with both 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scans before surgery.
2585885|NCT02327442||Breast Cancer Patients|68Ga-NOTA-NFB PET/CT and 18F-FDG PET/CT scans will undergo in patients with breast cancer before and after neoadjuvant chemotherapy.
2585915|NCT02326961|Experimental|Celution ADRCs; Low Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
2585916|NCT02326961|Experimental|Celution ADRCs; High Dose|Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
2585917|NCT02326961|Placebo Comparator|Placebo|Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
2585974|NCT02326688|Experimental|stroke patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
2585975|NCT02326688|Experimental|control patients|"Kinematic measurement of the amount of trunk displacement during a grasping task~Two separated measurements are recorded with a 6-hours interval~A third measurement provided by a second examinator is conducted"
2586019|NCT02326376||CAPS patients|CAPS patients treated with anakinra, using the Kineret graduated syringe
2586043|NCT02326129||Obese with Type 2 Diabetes|Obese adolescents with Type 2 Diabetes
2586047|NCT02326129||Obese without Type 2 Diabetes|Obese adolescents without Type 2 Diabetes
2586049|NCT02326129||Normal weight|Normal weight adolescents
2585130|NCT02332057|Active Comparator|Diclofenac plus lidocaine|Diclofenac(100 mg) is administered 1 hour before IUD insertion and lidocaine gel is placed on cervix three minutes before IUD insertion
2585136|NCT02332057|Placebo Comparator|Placebo|Placebo tablets is administered 1 hour before IUD insertion and placebo gel is placed on cervix three minutes before IUD insertion
2585171|NCT02331784|Experimental|Computerized Plasticity-based Software|Computerized Plasticity-based software training requiring a total maximum of 50 treatment sessions, 4-5 times weekly, 40 minutes each session.
2585180|NCT02331784|Active Comparator|Commercially available video game|Commercially available video game training. Treatment is software based, will occur up to 50 times throughout study duration, 4-5 times per week, 40 minutes each session..
2585249|NCT02331550|Experimental|Expectant treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with observation and evaluation at 6 and 12 months after diagnosis.
2585253|NCT02331550|Experimental|Ablative treatment|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions that were managed with an ablative treatment and evaluated at 6 and 12 months after diagnosis.
2585331|NCT02331199|Experimental|preterm labour|200 women with preterm prelabour ruptured membranes or undergoing preterm CS
3177581|NCT00653822|Placebo Comparator|1b|IV
3177582|NCT00653822|Experimental|2a|Lower SC dose
2585504|NCT02329821||HCC group|patients with hepatocellular carcinoma
2585511|NCT02329821||donor group|patient for liver transplantation donation
2585546|NCT02329561|Active Comparator|Tramadol extended release and CP/T|Tramadol extended release: 200mg Single-dose, extended-release, once-daily, tablet; Current Perception and Tolerance (CP/T)
2585551|NCT02329561|Placebo Comparator|Placebo and CP/T|Single-dose, placebo identical in appearance to an extended release once-daily tablet; Current Perception and Tolerance (CP/T)
2585622|NCT02329171|Experimental|Imiquimod treatment arm|Patients in this group will be treated with imiquimod during 16 weeks. Colposcopy with diagnostic biopsies will be performed after 10 weeks. In case of progressive disease, the treatment will be ended and appropriate surgical excision will be performed. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies.
2585625|NCT02329171|Active Comparator|Standard treatment arm|Large loop excision of the transformation zone (LLETZ) will be performed in this group, as standard treatment.
2585674|NCT02328716|Active Comparator|Comparator|Comparator
2585681|NCT02328716|Experimental|Experimental|Experimental
2585892|NCT02327247|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
2585899|NCT02327247|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
2585933|NCT02326909|Experimental|optical coherence tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
2585986|NCT02326506|Experimental|Pump speed variation|VA-ELS pump speed variations
3177583|NCT00653822|Placebo Comparator|2b|SC to match lower dose
3177584|NCT00653822|Experimental|3a|Higher SC dose
3177585|NCT00653822|Placebo Comparator|3b|SC to match higher dose
3177586|NCT00653835|Experimental|Ezetimibe + Simvastatin|
3177587|NCT00653835|Active Comparator|Simvastatin|
3177588|NCT00653848|Experimental|Docetaxel arm|six of docetaxel every third week + hormonal treatment
3177589|NCT00653848|No Intervention|Control|hormonal treatment only
3177590|NCT00653874|Experimental|1: TcB|transcutaneous bilirubinometry (TcB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
3177591|NCT00653874|Active Comparator|2: CaB|clinical assessment of jaundice (CaB) was used for deciding the need for blood sampling to measure serum total bilirubin (STB)
3177592|NCT00653887|Active Comparator|A|biofeedback (active group)
3177593|NCT00653887|Placebo Comparator|B|discussion about digestive tract (placebo group)
3177594|NCT00653900||1|All patients undergoing elective, invasive cardiac procedure on plavix prior to admission
3177595|NCT00653913|Active Comparator|Group A|SCH 58235 (Period 1) Pitavastatin (Period 2) Coadministration (Period 3)
3177596|NCT00653913|Active Comparator|Group B|SCH 58235 (Period 1) Coadministration (Period 2) Pitavastatin (Period 3)
3177597|NCT00653913|Active Comparator|Group C|Pitavastatin (Period 1) SCH 58235 (Period 2) Coadministration (Period 3)
3177598|NCT00653913|Active Comparator|Group D|Pitavastatin (Period 1) Coadministration (Period 2) SCH 58235 (Period 3)
3177599|NCT00653913|Active Comparator|Group E|Coadministration (Period 1) SCH 58235 (Period 2) Pitavastatin (Period 3)
3177600|NCT00653913|Active Comparator|Group F|Coadministration (Period 1) Pitavastatin (Period 2) SCH 58235 (Period 3)
3177601|NCT00653926|Active Comparator|A|Group A (Active) receives a multimodal injection intra- and postoperatively
3177602|NCT00653926|Placebo Comparator|P|Group P (Placebo) receives no injection intraoperatively and a saline injection postoperatively
3177603|NCT00653952|Experimental|001|
3177604|NCT00653952|Active Comparator|002|
3177605|NCT00653965|Experimental|1|Rosuvastatin
3177606|NCT00653965|Active Comparator|2|Atorvastatin
3177607|NCT00653978|Experimental|1|patients receiving one stent
3177608|NCT00653978|Active Comparator|2|patients receiving two stents
3177609|NCT00654017|Placebo Comparator|placebo|
3177610|NCT00654017|Active Comparator|sildenafil|
3177611|NCT00654043|Experimental|A|Subjects received Par formulated products under fed conditions
3177612|NCT00654043|Active Comparator|B|Subjects received Roche formulated products
3177613|NCT00654056|Experimental|L1|Actrapid infusion, 0.5 mU/kg/min.
3177614|NCT00654056|Experimental|L2|Actrapid infusion 1.5 mU/kg/min
3177615|NCT00654056|Experimental|H1|Actrapid infusion 3.0 mU/kg/min
3177616|NCT00654056|Experimental|H2|Actrapid infusion 5.0 mU/kg/min
3177617|NCT00654082|Active Comparator|Arm 1|
3177618|NCT00654082|Placebo Comparator|Arm 2|
2585351|NCT02330848|Active Comparator|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum.
2585355|NCT02330848|Active Comparator|Walnut Calorie Controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan. Participants will receive on-going instruction to preserve an isocaloric condition after the addition of walnuts. The study dietitian will customize dietary adjustments to make room for walnuts in the diet, while accommodating the priorities of each study participant. The general approach will emphasize general reduction in portion sizes; participants will also receive advice, based on baseline dietary intake analysis, of food eliminations that they might want to consider.
3177619|NCT00654108|Experimental|Cohort 1: vaccine dosage level 1 or placebo|Vaccine dose level 1: 1 X 10^7 colony forming unit (CFU) or placebo, treated with Cipro on days 7-11.
3177620|NCT00654108|Experimental|Cohort 2: vaccine dosage level 2 or placebo|Vaccine dose level 2: 1 X 10^8 CFU or placebo, treated with Cipro on days 7-11.
3177621|NCT00654108|Experimental|Cohort 3: vaccine dosage level 3 or placebo|Vaccine dose level 3: 1 X 10^9 CFU or placebo, treated with Cipro on days 7-11.
3177622|NCT00654108|Experimental|Cohort 4: vaccine dosage level 4 or placebo|Vaccine dose level 4: 1 X 10^10 CFU or placebo, treated with Cipro on days 7-11.
3177623|NCT00654121|Active Comparator|1|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
3177624|NCT00654121|No Intervention|2|
2585580|NCT02329392||SPP|Patients undergoing cardiac surgery with perioperative monitoring of Skin Perfusion Pressure
2585601|NCT02329119|Experimental|G1-SCZ|patients with schizophrenia as defined in DSM IV-TR
2585602|NCT02329119|Active Comparator|G2-TAB|patients with bipolar affective disorder (BD) type I as defined by the DSM IV-TR
2585656|NCT02328664|Other|Flexible sigmoidoscopy or colonoscopy|Subjects will undergo these investigation to take biopsies from the polypectomy scar.
2585749|NCT02328183|Experimental|Polymyxin B|Polymyxin B 1.5-2.5 mg/kg/day intravenous q 12 hrs duration 7-14 days
3177625|NCT00654173|Experimental|1|Rosuvastatin
3177626|NCT00654173|Active Comparator|2|Simvastatin
2585960|NCT02326766|Experimental|KRG|5g Korea red ginseng (KRG)
2585961|NCT02326766|Placebo Comparator|Placebo|5 g placebo (corn starch)
2585985|NCT02326558|Experimental|microwave enucleation|zero ischemia laparoscopic microwave ablation-assisted enucleation of the tumor
2585991|NCT02326558|Active Comparator|laparoscopic partial nephrectomy|conventional laparoscopic partial nephrectomy with clamping of the renal artery
2586071|NCT02326207|Experimental|Weekly ventilator circuit change|Ventilator circuit change every 7 days until extubation
2586073|NCT02326207|Active Comparator|No routine ventilator circuit change|No routine ventilator circuit change until soiling or malfunction or extubation
3177627|NCT00654173|Active Comparator|3|Atorvastatin
3177628|NCT00654212|Active Comparator|1|endoluminal stenting followed by laparoscopic resection (endo-laparoscopic limb, the study group)
3177629|NCT00654212|Other|2|emergency open surgery (open limb, the control group)
3177630|NCT00654225|Experimental|1|Rosuvastatin
3177631|NCT00654225|Active Comparator|2|Atorvastatin
3177632|NCT00654264|Other|1|Patients will have water immersion on first day and sitting in a tub without water on the second day.
3177633|NCT00654264|Other|2|Patients will sit in a tub without water on the first day and have water immersion on the second day.
3177634|NCT00654277|Experimental|A|Subjects received Kali formulated products under fasting conditions
3177635|NCT00654277|Active Comparator|B|Subjects received GlaxoSmithKine product under fasting conditions
3177636|NCT00654290|Experimental|P|Propranolol from 7 days pre-operation to 5 days post CABG
3177637|NCT00654290|Active Comparator|A|Amiodarone treated 7 days pre-operation to 5 days post CABG
3177638|NCT00654290|Active Comparator|AP|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
3177639|NCT00654303|Experimental|1|Rosuvastatin
3177640|NCT00654316|Experimental|1|BCG delivered intradermally into the deltoid region in volunteers who have received BCG 10 - 20 years previously.
3177641|NCT00654342|Other|1|In vivo injection group
3177642|NCT00654342|Other|2|Ex vivo injection group
3177643|NCT00654394|Experimental|1|
3177644|NCT00654407|Experimental|1|Rosuvastatin
3177645|NCT00654407|Active Comparator|2|Atorvastatin
3177646|NCT00654407|Active Comparator|3|Simvastatin
3177647|NCT00654433|Experimental|I|
3177648|NCT00654446|Experimental|1|Rosuvastatin
3177649|NCT00654446|Active Comparator|2|Simvastatin
3177650|NCT00654459||A|
3177651|NCT00654459||B|
3177652|NCT00654472||A|Mitral valve area above 1.5 cm2
3177653|NCT00654472||B|Mitral valve area 1.5 cm2 and below 1.5 cm2
3177654|NCT00654485|Experimental|1|Rosuvastatin
3177655|NCT00654485|Active Comparator|2|Atorvastatin
3177656|NCT00654524|Experimental|1|Patients in this arm will be treated with goserelin depot-3.6mg plus add-back therapy.
3177657|NCT00654524|No Intervention|2|The patient with advanced endometriosis（stage III-IV）confirmed histologically after conservative laparoscopic surgery will be suggested to prepare for spontaneous pregnancy rather than any medical administration.
3177658|NCT00654537|Experimental|1|Rosuvastatin
3177659|NCT00654537|Active Comparator|2|Atorvastatin
3177660|NCT00654537|Active Comparator|3|Pravastatin
3177661|NCT00654537|Active Comparator|4|Simvastatin
3177662|NCT00654550|Experimental|1|
3177663|NCT00654576|Active Comparator|1|the comparator arm will only receive one of the seven antipsychotic
3177664|NCT00654576|Experimental|2|the experimental group will receive one of the seven study drugs combination with psychosocial intervention
2585183|NCT02331927|No Intervention|Randomized Part: Arm A|Conventional switch of chemotherapy together with the antiangiogenic treatment: Bevacizumab and mFOLFOX6 (continuation of same regimen until progressive disease (PD) according to RECIST v1.1, followed by switch to aflibercept and FOLFIRI after PD).
2585192|NCT02331927|Experimental|Ramdomized Part: Arm B|Early marker-driven switch of anti-angiogenic agent and maintenance of chemotherapy: Bevacizumab and mFOLFOX6 will be administered until change of the CAF-profile and at least stable disease according to RECIST v1.1. Change to Aflibercept and mFOLFOX6 (change of bevacizumab to aflibercept and continuation of mFOLFOX6) until PD according to RECIST v1.1, followed by change to FOLFIRI after PD).
2585257|NCT02331537|Experimental|Internet-based cognitive-behavior therapy|The experimental group will go through active internet-based treatment. The treatment is 10 weeks long and is based on the principles of exposure i.e. the participant is instructed to stay with the frightening thought until it is no longer associated with anxiety.
2585260|NCT02331537|No Intervention|Waitlist|Waitlist control that will get the internet-based treatment when the first group has finished (i.e. Week 10). There are no active treatment for these participants at all.
2585324|NCT02331173||Main Study Group|All subjects enrolled in this study will be seen every 6 months following the screening visit. During the 3 main study visits, a series of tests will be performed to assess visual function. Some of these tests are part of routine care that patients would receive on an annual basis regardless of study participation. Other tests are being performed to determine if they are effective at monitoring disease progression in this population. For each of the 3 main study visits, testing may be spread over multiple days to ensure completion of all tests.
2585329|NCT02331173||Carbonic anhydrase inhibitor sub-study|Subjects with maculoschisis may be offered topical treatment with CAIs. These subjects will be asked to visit the study site at 1 month and 3 months after starting topical treatment. During these additional visits, subjects will undergo a dilated eye exam, BCVA, and SD-OCT imaging to assess efficacy of treatment (i.e. reduction of maculoschisis).
2585362|NCT02330705|Active Comparator|Group A|IUI at time of HCG
2585367|NCT02330705|Active Comparator|Group B|IUI 12 hours after HCG
2585373|NCT02330705|Active Comparator|Group C|IUI 34-36 hours after HCG
3212487|NCT01015625|Other|A: Surgical Therapy|Local therapy consists of lumpectomy or mastectomy with or without radiotherapy (according to center tumor board decision) with a resection free margin of at least 1 mm or more demonstrated on paraffin embedded histological sections. Intraoperative frozen sections are allowed but not definitive for margin assessment. Sentinel node biopsy may be performed and has always to be followed by axillary dissection of level I and II (axillary surgery level I and II is mandatory).
3212488|NCT01015625|Other|B: Surgery on Demand|In Arm B (no local therapy) it may be necessary to perform local therapy on demand (surgery, radiotherapy). Reasons may be uncontrolled bleeding or infected exulcerations with a septic component and no treatment benefit from conservative therapy. This will be considered as protocol deviation. However, the patient's follow up is recorded and data are available for analyses as intention to treat.
2585603|NCT02329340|Active Comparator|Am Academy of Pediatrics print materials|In-person session to read online version of American Academy of Pediatrics The Injury Prevention Program (TIPP sheets) childhood injury prevention print materials, followed by access to the TIPP sheets for 30 days.
2585604|NCT02329340|Experimental|Family Safety 1-2-3|In-person session to view video and text-based interactive web site on injury prevention information and strategies, followed by 8 emails delivered over a 30-day period inviting participant to view additional child safety videos.
2585793|NCT02327962||Hemodialysis|Hemodynamic measurements with PWV
2585794|NCT02327962||Control|Hemodynamic measurements with PWV
2585851|NCT02327637|No Intervention|Bedrest|"Bedrest is a standard recommendation for patients with PPROM. Subjects randomized to this arm of the study will undergo the following:~Receive recommendation for bedrest (standard of care).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
2585853|NCT02327637|Experimental|Moderate Activity|"Subjects randomized to this arm of the study will undergo the following:~Receive recommendation to ambulate 150 feet, twice per day (interventional study procedure). Prior to each session of ambulation, an ultrasound will be performed to ensure adequate amniotic fluid volume and appropriate fetal position, and a fetal heart rate tracing will be obtained to ensure that there is reassuring fetal status (observational study procedure). During each session of ambulation, the fetal heart rate tracing will be monitored continuously (observational study procedure).~Have maternal mood and muscle strength evaluated on enrollment and after delivery (observational study procedure).~Wear a pedometer to measure activity when out of bed (observational study procedure)."
3212489|NCT01015651|Active Comparator|remifentanil-2|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.
3212490|NCT01015651|Active Comparator|remifentanil-4|In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.
3212491|NCT01015690||unexplained infertility|patients with unexplained infertility
3212492|NCT01015690||healthy controls|women who wish to conceive, no more tha 3 previous cycles, age above 18
3212493|NCT01015690||references|lesbian women with a regular cycle without use of anticonception and not at risk of becoming pregnant
3212494|NCT01015716|Active Comparator|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
3212495|NCT01015716|Experimental|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
3212496|NCT01015729|Active Comparator|1|Esomeprazole 20 mg/ASA 81 mg Fixed Dose Combination Capsule
3212497|NCT01015729|Active Comparator|2|Esomeprazole Clinical Trial Capsule 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3212498|NCT01015729|Active Comparator|3|Esomeprazole MUPS Tablet 20 mg and 1 Aspirin® Non Enteric Coated Immediate Release Tablet 325 mg
3212499|NCT01015742|Experimental|Experimental|Stem cell Transplant using two unrelated umbilical cord blood units.
3212500|NCT01015755|Experimental|thirst intervention|
3212501|NCT01015794|Experimental|Adrenergic agonist|
3212502|NCT01015846|Experimental|Intervention|
3212503|NCT01015846|Active Comparator|Core stability exercise|Traditional core stability exercise
3212504|NCT01015859|No Intervention|DDD long AV delay|Pacemaker is programmed in DDD mode with long AV delay (250 msec)
3212505|NCT01015859|Active Comparator|AAI SafeR|Pacemaker is programmed in AAI SafeR mode
3212506|NCT01015872|Experimental|CPAP|the subjects introduced with CPAP treatment
3212507|NCT01015898|Experimental|BCC, ALA-PDT|Patients with histologically proven basal cell carcinoma who were candidates for treatment with ALA-PDT
3212508|NCT01015911|Experimental|1|SGN-75
3212509|NCT01015924|Active Comparator|Elastic Stable Intramedullary Nailing|Operative intervention with closed or open reduction and intramedullary stabilization of midshaft clavicle fractures
3212510|NCT01015924|Active Comparator|Plate osteosynthesis|Open reduction and plate fixation of midshaft clavicle fractures
3212511|NCT01015937|Active Comparator|Turmeric|"diabetic nephropathy patient~more than 300 mg/proteinuria"
3212512|NCT01015937|Active Comparator|ACE inhibitor + ATI blocker|"diabetic nephropathy~more than 300 mg/day proteinuria"
3212513|NCT01015950|Experimental|Pumpy'Sup|Lipid-based nutrient supplement
3212514|NCT01015950|Experimental|SCSB|Processed, fortified, cereal-based food blend (SCSB for malnourished children)
3212515|NCT01015950|Experimental|Misola|Locally processed, fortified food blend (Misola)
3212516|NCT01015950|Active Comparator|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, oil) and a multiple micronutrient powder (Mix-Me) are provided to simulate the currently recommended enhanced home-prepared rehabilitation food mixture (farines enrchies) according to the national Mali CMAM protocol."
3212517|NCT01015963||Ancillary-correlative (DNA sample analysis)|Blood samples collected on clinical trial CLB-9871 are examined via ABCC2 and SLC01B3 genotyping using TaqMan analysis. Other genes related to the pharmacokinetics and side effects of docetaxel may be considered for future genotyping. In some cases, panels of drug response SNPs on high-density arrays may be genotyped.
3212518|NCT01015989|Active Comparator|CARE+ Kenya brief computer risk assessment session (control)|
3212519|NCT01015989|Active Comparator|Full CARE+ Spanish computer-counseling group|
3212520|NCT01016002|Experimental|Intervention|
3212521|NCT01016028||Questionnaire + Sensory Tests + Interview|
3212522|NCT01016041|Experimental|everolimus stent|
3212523|NCT01016041|Active Comparator|paclitaxel eluting|
3212524|NCT01016054|Experimental|A. PLD plus AGS-8M4|Women with platinum resistent ovarian cancer
3212525|NCT01016054|Experimental|B. Carboplatin and gemcitabine plus AGS-8M4|Women with platinum sensitive ovarian cancer
3212526|NCT01016080|Active Comparator|oral glutathione|glutathione, 500 mg, taken orally twice daily
3212527|NCT01016080|Placebo Comparator|placebo capsules|identical-appearing placebo capsules
3212528|NCT01016093|Experimental|Intervention|Patients in this arm received zoledronic acid.
3212529|NCT01016093|Placebo Comparator|Control|Patients in this arm received placebo as control group
3212530|NCT01016119|Placebo Comparator|Placebo|In this group we will use Placebo cream, in the early rehabilitations in the upper extremity
3212531|NCT01016119|Experimental|Folrex|In this group we will use Folrex cream, in the early rehabilitations in the upper extremity
3212532|NCT01016145|Active Comparator|First generation antipsychotic|Subjects randomized to this arm will receive treatment with haloperidol or chlorpromazine.
3212533|NCT01016145|Experimental|Second generation antipsychotics|Subjects randomized to this arm will receive treatment with a second-generation antipsychotic: risperidone or olanzapine or aripiprazole or quetiapine or ziprasidone
3212534|NCT01016158|Experimental|umbilical cord serum eyedrops|patients with recurrent corneal erosions were treated with 20% umbilical cord serum eye drops 3 to 4 times a day in addition to artificial tears
3212535|NCT01016184|Active Comparator|vitamin D|
3212536|NCT01016184|Active Comparator|placebo|
3212537|NCT01016197|Active Comparator|Conservative|Four weeks of splinting followed by mobilisation.
3212538|NCT01016197|Experimental|Surgery|Surgical repair of the tendon with a bone anchor followed by four weeks of splinting and then mobilisation.
3212539|NCT01016210|Experimental|60 infertile women|Candidates for IVF-ET treatment
3212540|NCT01016210|No Intervention|control|no treatment
3212541|NCT01016223|Active Comparator|Beclomethasone dipropionate inhaler|
3212542|NCT01016223|Placebo Comparator|Matched inhaler|
3212543|NCT01016249|Active Comparator|Treatment 1. 5% Saline + Epinephrine|Nebulization with 4ml of 5% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3212544|NCT01016249|Other|Treatment 3. 3% Saline + Epinephrine|Nebulization with 4ml of 3% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3212545|NCT01016249|Other|Treatment 2 . 0.9% Saline + Epinephrine|Nebulization with 4ml of 0.9% saline mixed with 1.5 ml of epinephrine every 4 hours thereafter until ready for discharge. Immediately before nebulization, just after, and 2 hours after, the following measurements were collected for each patients: bronchiolitis severity score, oxygen saturation on room air, and heart rate.
3212546|NCT01016275||Iliac lesions TASC A or B|All lesion types belonging to the iliac TASC A or B.
3212547|NCT01016288||22 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 22 G needle
3212548|NCT01016288||25 G Needle EUS-FNA|Patients referred for an EUS examination and EUS-FNA of a solid mass lesion adjacent to the upper GI tract using a 25 G needle
3212549|NCT01016301|Active Comparator|Pharmacist service,|The pharmacist service consists of medication review, drug treatment discussion with the patient, and a medication report.
3212550|NCT01016301|No Intervention|Control|Usual care
3212551|NCT01016314|Experimental|Aspen Spinous Process System|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
2585350|NCT02331212||Ancillary-correlative (role of HAS2+ in CSCs)|Blood and bone marrow samples are collected and analyzed via flow cytometry and PCR. Cells are also transplanted into mice and studied.
2585492|NCT02329873|Experimental|Experimental group|Respiratory rehabilitation exercise training 2 times/day, 10-30 minutes per session for 4 days.
2585500|NCT02329873|No Intervention|Control group|Control group received usual care and health education.
2585547|NCT02329626||Study population|"The study population consists of patients with paralysis, motor weakness or abnormal movements meeting DSM-IV criteria for motor conversion disorder consulting via the Emergency or Neurology department of participating centers.~Intervention: PET CT 18 FDG"
2585620|NCT02329249|Experimental|Smokefree Partners: 21 Days to Freedom|Smoking cessation website program with live personal coach
2585623|NCT02329249|Other|Wait-list control|120-day wait-list and then provided access to the smoking cessation website
3177665|NCT00654589|Experimental|deferasirox|
2585813|NCT02327949|Experimental|WP group|WP group:treated with W-Shaped Angular Plate
2585829|NCT02327949|Active Comparator|RP group|RP group:treated with Reconstruction Plate
2585890|NCT02327390|Experimental|X-ACT lymph node cell dose and schedule|"All patients will begin at dose level 1 and will be moved to higher dosing levels as long as the patient does not experience two or more dose limiting toxicities and maintains an acceptable performance status. A minimum of three patients will be enrolled per dose level and no patients will be enrolled on higher dose levels if dose limiting toxicities are encountered.~Dose level 1: 0.5 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level 2: 1.0 x 10^10 X-ACT cells. 1 infusion~Dose level 3: 0.5 x 10^10 X-ACT cells. 4 infusions 4 weeks apart~Dose level 4: 1.0 x 10^10 X-ACT cells. 2 infusions 4 weeks apart~Dose level -1: 0.5 x 10^10 X-ACT cells. 1 infusion (if necessary)"
3177666|NCT00654667|Placebo Comparator|2|Placebo
3177667|NCT00654667|Experimental|Experimental 1|Resveratrol
3177668|NCT00654680|Experimental|Arm 1|
2585996|NCT02326480||Syndromic obesity|Identification of genetic causes of obesity
2586003|NCT02326480||Familial obesity|Identification of genetic causes of obesity
2586008|NCT02326480||Isolated obesity|Identification of genetic causes of obesity
2586055|NCT02326194|Placebo Comparator|Placebo group (one shot)|one dose
2586056|NCT02326194|Placebo Comparator|Placebo group (two shots)|two doses, with one dose to each arm at a same time.
2586057|NCT02326194|Experimental|Low dose vaccine group|one dose, low dose Ebola Zaire vaccine (Ad5-EBOV)
2586058|NCT02326194|Experimental|High dose vaccine group|two doses, high dose, with one dose to each arm at a same time
3177669|NCT00654680|Placebo Comparator|Arm 2|
3177670|NCT00654693||monitored|patients hospitalized for longer than 24 hours and are located on the 4th, 5th, and 6th floors of the Vanderbilt University Medical Center Round Wing
3177671|NCT00654706|Experimental|Sertindole|
3177672|NCT00654706|Active Comparator|Quetiapine|
3177673|NCT00654719|Active Comparator|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
3177674|NCT00654719|Placebo Comparator|Placebo|
3177675|NCT00654758|Experimental|1|Escalating doses of volociximab at 10, 20, and 30 (or 15) mg/kg with carboplatin and paclitaxel.
3177676|NCT00654771||1|women undergoing evaluation for pre-eclampsia
3177677|NCT00654797|Experimental|eProtocol|
3177678|NCT00654810|Experimental|1|Low intensity group (40% of maximal exercise capacity)
3177679|NCT00654810|Experimental|2|High intensity group (80% of maximal exercise capacity)
3177680|NCT00654849|Experimental|1|compare security and effectiveness of use Electrosurgical Bipolar Plasmakinetic Vessel Sealing
3177681|NCT00654849|Active Comparator|2|traditional abdominal hysterectomy technique with the use of sutures
3177682|NCT00654862|Experimental|1|Subjects with stage 1 hypertension
3177683|NCT00654862|Experimental|2|Subjects with optimal blood pressure
3177684|NCT00654888|Active Comparator|1|Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
3177685|NCT00654888|Active Comparator|2|automated lamellar keratectomy without mitomycin
3177686|NCT00654914|Experimental|Arm 1|
3177687|NCT00654966|Experimental|1|Heart failure patients
3177688|NCT00654966|Active Comparator|2|Healthy subjects
3177689|NCT00654979|Experimental|Single arm|SafeFlo IVC Filter
3177690|NCT00655018|Experimental|Vitamin group|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3177691|NCT00655018|Placebo Comparator|2|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
3177692|NCT00655031|Experimental|1|Pomegranate concentrate (POMx)
3177693|NCT00655031|Placebo Comparator|2|Fruit flavored juice low in antioxidants
3177694|NCT00655044||Type 1 and type 2 diabetes patients|
2585377|NCT02330614||bleaching patients|Patients who agreed to be bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications , before and after this procedure was applied again the NEO-FFI personality test form, had 30 minutes to answer it.
2585381|NCT02330614||Control group|Patients who refused to be bleached were administered the personality test NEO-FFI, had 30 minutes to answer it.
2585406|NCT02330432|Experimental|Mycobacterium w group|Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
2585410|NCT02330432|Active Comparator|Best standard care|Best standard care for sepsis
2585478|NCT02330107|Experimental|Treatment arm 1|"Subjects will receive MAT and placebo LA. The magnetic pellets will be applied to the six selected acupoints as detected by an acupoint finder. To achieve a blinding and placebo effect of the subject, the laser device will be switched to power off mode (i.e. deactivated laser) for acupoint stimulation before the application of MAT. Subjects will be asked to wear a pair of laser protective goggles to blind them during treatment."
2585479|NCT02330107|Experimental|Treatment arm 2|Subjects will receive a combined approach that includes the use of MAT and LA. A laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use (King et al., 1990; Round et al., 2013). This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear. Laser protective goggles will be provided to the subjects and the researchers for eye protection.
2585482|NCT02330107|Placebo Comparator|Treatment arm 3|"Subjects will serve as a placebo control and will receive LA at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plasters centred with a small portion of Junci Medulla (mimicking the MAT treatment)."
2585539|NCT02329678|Active Comparator|collagen membrane group and control group|GTR group: a bioresorbable collagen membrane (Healiguide, Advanced Biotech Products (P) Ltd., Encoll Corp., Fremont, CA, USA) was placed over the apicomarginal defect, covering 2-3mm of the healthy bone around all the margins after periodical surgery.
2585543|NCT02329678|Active Comparator|Control group|Control Group:No membrane was placed after periapical surgery.
2585636|NCT02329327|Experimental|Andexanet|Participants received andexanet as an intravenous bolus administered over ~15 to 30 minutes, followed immediately by a continuous infusion administered over ~120 minutes.
2585766|NCT02328339|Experimental|Black tea|Approximately 400 mg total polyphenols in 240 ml hot water (loading dose; 2 hours before the start of measurements; t=0) and 130 mg total polyphenols in 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
2585768|NCT02328339|Placebo Comparator|Placebo|Caramel colour, maltodextrin and tea flavour in 240 ml hot water (2 hours before the start of measurements; t=0) and 120 ml hot water (maintenance dose just before start of the measurements; t=120 min)
2585819|NCT02327793|No Intervention|Mean Arterial Pressure <100 mmHg|Patients with mean arterial pressure <100 mmHg at the time of the perfusion weighted magnetic resonance imaging will not be treated. After 15 minutes of the baseline perfusion imaging a repeat perfusion weighted magnetic resonance imaging would be performed.
2585830|NCT02327793|Experimental|Mean Arterial Pressure 100-120 mmHg|Patients with mean arterial pressure between 100-120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with sublingual 0.3 mg nitroglycerin. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of nitroglycerin administration. After a sustained drop of blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
2585836|NCT02327793|Experimental|Mean Arterial Pressure >120 mmHg|Patients with mean arterial pressure >120 mmHg at the time of the perfusion weighted magnetic resonance imaging will be treated with intravenous 10-20mg labetalol injection. A repeat blood pressure would be assessed at 5min, 10min, 15min and 20 min of labetalol injection. After a sustained drop in blood pressure (>10% of the baseline reading) as defined by two reading 5minutes apart, a perfusion weighted magnetic resonance imaging will be performed.
3212552|NCT01016314|Active Comparator|Pedicle Screw Fixation|Subjects randomized to the pedicle screw group will have the pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
3212553|NCT01016327|Experimental|1|
3212554|NCT01016340|Active Comparator|MCS-5|Group 1: MCS-5 5 mg/day for 16 weeks;Group 2: MCS-5 10 mg/day for 16 weeks;Group 3: MCS-5 20 mg/day for 16 weeks
2585971|NCT02326714|Experimental|Auricular acupressure|The magnetic beads will be taped to the seven pressing points: Hunger point, Ovary, Uterus, Endocrine point, liver, kidney and spleen.
2585972|NCT02326714|Placebo Comparator|Placebo auricular acupressure|The magnetic beads will be taped to the three pressing points:Tonsil, eye and elbow.
2585994|NCT02326389|Experimental|Exercise and Cognitive Remediation|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down. The experimental group will participate in the exercise intervention as well as cognitive remediation.
2586005|NCT02326389|Active Comparator|Cognitive Remediation Only|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
2586080|NCT02326142|Experimental|OBE001|
2586082|NCT02326142|Placebo Comparator|Placebo|
3212555|NCT01016340|Placebo Comparator|Placebo|Group 4: Placebo for 16 weeks
3212556|NCT01016366|Experimental|Lu AA24493|
3212557|NCT01016366|Placebo Comparator|Placebo|
3212558|NCT01016405||Severity of dry eye in patients undergoing cataract surgery|
2585416|NCT02330445|Experimental|Part A|Up to 12 Part A recipients will have rheumatoid arthritis since this was an entry criterion for Study 104. All subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses followed by 5 monthly doses of PRTX-100. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 8 months. Subjects will be evaluated for adverse events, rheumatoid arthritis activity and the development of anti-PRTX-100 antibodies. The feasibility of different assessment methods of disease activity may be explored. Novel methods of joint evaluation will be explored. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
2585421|NCT02330445|Experimental|Part B|Five healthy subjects will be allocated to the single treatment group at a fixed dose of 6 μg/kg of IV PRTX-100. Subjects will receive four weekly doses. All subjects will have a serum collection requiring approximately 600 mL of blood. Since subjects will be followed for 28 days after their last dose, the total duration of the study is approximately 3 months. Subjects will be evaluated for adverse events and the development of anti-PRTX-100 antibodies. Adverse events will be evaluated for at least four weeks after the last dose of PRTX-100.
3212559|NCT01016418|Experimental|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
2585583|NCT02329405|Experimental|Rifampicin|Rifampicin 600 mg tablet once a day orally for a week.
2585587|NCT02329405|Placebo Comparator|Placebo|Placebo tablet once a day orally for a week.
2585610|NCT02329067|Experimental|walnut-CH|Western type diet including walnuts (43g/day); Walnuts substitute carbohydrates
2585617|NCT02329067|Experimental|Walnut-SFA|Western type diet including walnuts (43g/day); Walnuts substitute saturated fatty acids
2585624|NCT02329067|Experimental|Walnut-LIB|Western type diet including walnuts (43g/day); no specific recommendation
2585626|NCT02329067|No Intervention|Control|Isocaloric western type diet w/o nuts, nut butters or nut oils of any kind
2585658|NCT02328768|Experimental|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 8-24 hours every day until the patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
3212560|NCT01016431|Experimental|Rate adaptive|Patients will have their ICD programmed in a AAI-R mode, with peak atrial rate set at 85% of age-adjusted predicted maximal HR
3212561|NCT01016431|Active Comparator|Control|ICDs will be programmed in the usual VVI backup pacing mode at 40 bpm
2585800|NCT02327975|Experimental|Training group|Participants in this group received twice-weekly non-consecutive sessions of physical exercise for 10 weeks. Each session lasted approximately 60-70 minutes. Exercise program consisted of strength training and aerobic exercise. Each session began with a warm low intensity (10 min), then the main part of the session (25 min) and aerobic training and recovery period (25-35 min) was performed. The equipment used during the procedure was the Thera-Band elastic band.
2585801|NCT02327975|Experimental|Mobile group|Intervention content was the same in both intervention arms; only the delivery mode differed. Participants in this group received two podcast (digital multimedia file available for download in a media player) per week for 10 weeks of the intervention, each podcast lasted about 5 min. Participants in this group received a weekly message with the aim of fostering motivation toward physical activity. Subjects in this group performed two sessions per week on non-consecutive days, the days could be chosen by the participants themselves.
2585802|NCT02327975|Other|Control group|No received intervention.
2585845|NCT02327546|Experimental|AKB-6548|AKB-6548
2585847|NCT02327546|Experimental|AKB-6548 plus Ferrous Sulfate|AKB-6548 plus ferrous sulfate
2585895|NCT02327208|Placebo Comparator|Control|3 Combat rations only per day. No additional experimental food items (those assigned to the active comparator groups will consume isoenergetic carbohydrate and protein-based food products).
2585900|NCT02327208|Active Comparator|Protein|Consume 4 whey protein-based snack-bars in addition to 3 combat rations each day during training.
2585906|NCT02327208|Active Comparator|Carbohydrate|Consume 4 carbohydrate-based snack-bars in addition to 3 combat rations each day during training.
2585938|NCT02326792|Experimental|G1-Three sets of exercise|G1 group - the participants will perform three sets of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
2585947|NCT02326792|Experimental|G2-One set of exercise|G2 group - the participants will perform only one set of 15-20 repetitions of the trunk extensor exercise on a roman chair machine with the hips at 45 degrees relative to horizontal; performing trunk flexion-extension cycles for a total of 4 seconds (2 s concentric and 2 s eccentric contraction). The relative load for initial training will be placed at 20% back maximal voluntary contraction (MVC) and will be progressive during the training. The time session of training will be of 10 weeks.
2585954|NCT02326792|No Intervention|G3-Control|G3 group - the participants will be the control group, which not participating of exercise program in any time during the study.
2586016|NCT02326623|Experimental|iPad distraction|The intervention will be the use of an iPad that will include a selection of child-appropriate games. We will select popular, age-appropriate items to include on the iPad, chosen based on the most current online consumer ratings. Children and parents will be able to select their choice of distraction and can change their selection as desired during the course of the procedure. These choices will be recorded for study purposes.
2586021|NCT02326623|Other|standard care|The control group will receive standard care, which generally includes the use of topical anesthetic cream.
3212562|NCT01016444||Albuterol responsive|Those who respond clinically to albuterol.
3212563|NCT01016444||Albuterol unresponsive|Albuterol non-responsiveness is defined as a failure of the PEFR in an acutely ill asthmatic to exceed 40% of predicted following ≥7.5 mg of albuterol (2.5 mg albuterol aerosols q.20 min x3).
3212564|NCT01016470|Placebo Comparator|B|Placebo
3260291|NCT01477983|Active Comparator|ATP guide additinal ablation - Control|UNDER-ATP trial: ATP guide additional ablation, EAST-AF trial: Control
2585425|NCT02330380||Methotrexate|Methotrexate will be dosed weekly. Methotrexate is given as a single, weekly dose and is will be started at 15mg after a first week test dose of 2.5 mg to minimize side effects and achieve efficacy. Weekly dosages will be 15mg.
2585428|NCT02330380||Ustekinumab|Ustekinumab is given as a subcutaneous injection of 45mg if the patient is <100Kg or 90mg if the patient is >100Kg at weeks 0, 4, 16, and every 12 weeks thereafter.
2585436|NCT02330380||Etanercept|Etanercept will be given in the first 3 months of treatment as 50 mg twice a week (3 or 4 days apart). After 3 months, a reduced dose of 50 mg will be given once per week.
2585439|NCT02330380||Adalimumab|Adalimumab will be given in a dose of 40 mg subcutaneously every other week.
2585441|NCT02330380||Acitretin|Acetretin will be prescribed as daily with 25mg if the patient is <80Kg or 35mg if the patient is >80Kg.
2585443|NCT02330380||UVB Excimer Laser|Dose determination will be determined by a physician per standard-of-care by performing a Sunburn Test/Minimal Erythemal Dose Test, or by visually evaluating the patient's skin type and thickness of psoriasis plaque. Initial laser dose will be 1-4X the MED depending on the thickness of the plaque. Escalation will be 25-50% increase in dose per treatment if there is no residual erythema, 25% increase per treatment if there is mild residual erythema, and 0% increase per treatment if there is moderate residual erythema. Investigators also have the option to skip a treatment, if there is above moderate erythema, or significant patient discomfort. Patients will receive treatment twice a week.
2585447|NCT02330380||Narrowband UVB|Narrowband UVB (311nm) will be used to treat patients 3X per week with 311nm of UVB light. Uninvolved areas of skin will be covered where possible to minimize excess sun exposure. Patients will be tested for their minimal erythemal dose (MED), after which, based upon Fitzpatrick Scale skin type, a patient will typically beginning with 1-2 minutes based on skin type and gradually increased by 10-15% per treatment dose as tolerated.
2585506|NCT02329860|Experimental|Apatinib|750 mg orally (p.o.) every day (qd), 28 days as one cycle
2585514|NCT02329860|Placebo Comparator|Placebo|orally (p.o.) every day (qd), 28 days as one cycle
2585540|NCT02329548|Experimental|Alizarin Red|All participating patients will undergo the Alizarin Red intervention.
2585631|NCT02329301|Experimental|MDA with DHAp (Eurartesim)|All consenting community members eligible to receive DHAp will be provided age-appropriate treatment dose of DHAp regardless of the malaria rapid diagnostic test (RDT) result. Treatment will be administered in a house-to-house campaign.
2585635|NCT02329301|Experimental|Focal MDA with DHAp (Eurartesim)|All consenting household members eligible to receive DHAp and living in a household where anyone in the household tests positive with a malaria rapid diagnostic test (RDT) will receive the age-appropriate treatment dose of DHAp. If no one in the household tests RDT positive then no one in the household will receive DHAp. Treatment will be administered in a house-to-house campaign.
2585638|NCT02329301|No Intervention|Standard of Care (Control)|The standard of care arm will reflect no community-based treatment interventions but will have the standard of care offered by the Ministry of Health and Ministry of Community Development, Mother and Child Health which applies to all arms. This includes available mosquito net coverage, indoor residual spraying and passive case detection of individuals seeking treatment from a health provider at a clinic or health post.
2585686|NCT02328677||ColoCare FHCRC|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=611
2585687|NCT02328677||ColoCare Moffitt (affiliated cohort)|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=835
2585688|NCT02328677||University Hospital Heidelberg|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=683
2585689|NCT02328677||ColoCare Huntsman Cancer Institute|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=294
2585691|NCT02328677||Cedars-Sinai Medical Center|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=203
2585695|NCT02328677||University of Washington St. Louis|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=195
2585703|NCT02328677||University of Tennessee|Active patient recruitment, follow-up, and multiple specimen collection Repeated sampling at multiple timepoints Longitudinal assessment of biomarkers and health behaviors Recruitment Status April 30, 2020: n=153
2585735|NCT02328248|Experimental|Biological patch|Use biological patch (Biodesign Surgisis Tissue Graft from Cook Biotech Incorporated) to repair hiatal hernia laparoscopically
2585736|NCT02328248|Placebo Comparator|Plastic patch|Use plastic patch (Parietex Composite from Sofradim Production) to repair hiatal hernia laparoscopically
2585774|NCT02328066|Experimental|NBI used by trained endoscopists|Assessment with NICE classification and NBI technology of colonic lesions (Paris classification type 0) greater than 1 cm found in a routine colonoscopy. This assessment was performed by previously trained endoscopists.
2585807|NCT02327728|Experimental|medial lower eyelid waived|Botulinum toxin A 10U per eye subcutaneous injection at orbicularis oculi
2585821|NCT02327728|Active Comparator|full injection pattern|Botulinum toxin A 12.5U per eye subcutaneous injection at orbicularis oculi
2585894|NCT02327221|Active Comparator|Ovasave - Dose 10e4|
2585898|NCT02327221|Active Comparator|Ovasave - Dose 10e6|
2585904|NCT02327221|Active Comparator|Ovasave - Dose 10e7|
2585907|NCT02327221|Placebo Comparator|Placebo|
2585970|NCT02326727|Active Comparator|General Anesthesia|Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery
2585973|NCT02326727|Active Comparator|Combined anesthesia|Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery
3260292|NCT01477983|Active Comparator|Control - Control|UNDER-ATP trial: Control, EAST-AF trial: Control
2585462|NCT02329899||MBD unlikely|"Patients without criteria for possible MBD as listed above.~In this group, no further investigation will be performed if the first step is normal. The second step of investigations will be performed only in case of significant abnormalities in the first step of investigation."
2585528|NCT02329795||Standard chemoradiotherapy|Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
2585555|NCT02329522||Stable COPD patients|Patients will be assessed using USCOM and spirometry. For those with FEV1 to FVC ratio smaller than 70%, they will be classified as COPD.
2585559|NCT02329522||AECOPD patients|Patients will be assessed using USCOM and spirometry. Spirometry will be assessed after 2 to 4 weeks post-hospital discharge.
2585560|NCT02329522||Patient Controls|Patients will be assessed using USCOM and spirometry. For those with COPD symptoms but FEV1 to FVC ratio greater than 70%, they will be classified as non-COPD.
2585563|NCT02329522||Healthy Controls|Healthy subjects, with no history of COPD or other significant chronic illness will be recruited as healthy controls. Subjects will be matched for age and gender with the patient groups. They will be assessed using USCOM.
2585621|NCT02329093|Experimental|Bone Signal Changes|
2585758|NCT02328079|Active Comparator|Steroid Group|prednisolone 60 mg /day IM /IV for 6 consecutive days then reduced by 10 mg /day (for a total treatment time for 12 days)
2585759|NCT02328079|Active Comparator|Steroid + Antiviral Group|Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days)
2585818|NCT02327832|Experimental|Autologous BMSCs|Infusion of cultured autologous bone marrow derived mesenchymal stem cells
2585992|NCT02326311|Active Comparator|Fixed INTERIM TKI|"Intervention: fixed intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)"
2586000|NCT02326311|Experimental|Progressive INTERIM TKI|"Intervention: progressive intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)"
3177698|NCT00655109|Active Comparator|1|Olopatadine
3177699|NCT00655109|Active Comparator|2|Fluticasone
3177700|NCT00655109|Placebo Comparator|3|Placebo nasal spray
3177701|NCT00655109|Placebo Comparator|4|Placebo Eyedrops
3177702|NCT00655122|Active Comparator|Dalteparin sodium|
3177703|NCT00655122|Placebo Comparator|Placebo|
3177704|NCT00655135|Placebo Comparator|1|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received placebo administered intravenously to patients on Day 1 and Day 29.
3177705|NCT00655135|Experimental|2|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 0.5 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
3177706|NCT00655135|Experimental|3|Patients were assigned to arms in a 1:1:1 ratio. Patients in this arm received 2 mg/kg of LDP-02 administered intravenously to patients on Day 1 and Day 29.
3177707|NCT00655148|Experimental|A|DTaP-IPV vero vaccination at 2, 3½, 5 and 16 months of age
3177708|NCT00655148|Active Comparator|B|DTaP-IPV mkc vaccination at 2, 3½, 5 and 16 months of age
3177709|NCT00655174|Placebo Comparator|1|
3177710|NCT00655174|Experimental|2|
3177711|NCT00655174|Experimental|3|
3177712|NCT00655187||Group A|Cases
3177713|NCT00655187||Group B|Controls
3177714|NCT00655200||A|
3177715|NCT00655213|Active Comparator|1|AAISafeR mode programming
3177716|NCT00655213|Active Comparator|2|DDD with long AV Delay programming
3177717|NCT00655213|Active Comparator|3|DDDAMC mode programming
3177718|NCT00655213|Other|4|AAISafer mode programming in non randomized patients
3177719|NCT00655226|Experimental|CBT skills based group sessions|Cognitive Behavioral Therapy skills based group sessions
3177720|NCT00655226|Active Comparator|Hepatitis C educational support groups|Hepatitis C educational support groups
3177721|NCT00655239|Active Comparator|Control|Participants will use commercially available computer games.
3177722|NCT00655239|Experimental|Active|Participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3177723|NCT00655239|Active Comparator|Healthy Control|Healthy participants will receive targeted neuroadaptive cognitive training with neuroplasticity-based software created by Posit Science Corporation.
3177724|NCT00655265|Experimental|Colesevelam hydrochloride film-coated tablets|
3177725|NCT00655265|Placebo Comparator|Placebo|
3177726|NCT00655278|Experimental|1|T2000 at 600-1000 mg daily
3177727|NCT00655291|Placebo Comparator|A|
3177728|NCT00655291|Experimental|B|
3177729|NCT00655304|Active Comparator|1|Treatment with 6-8 hours of Prometheus (R) liver support dialysis
3177730|NCT00655304|Active Comparator|2|Treatment with 6-8 hours of CVVHDF
3177731|NCT00655317|Active Comparator|1|Treatment Acupuncture Group (Therapeutic Acupuncture Treatment): treatment with actual acupuncture needles
3177732|NCT00655317|Sham Comparator|2|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
3177733|NCT00655330|Active Comparator|1|Valsartan (160mg/day)is given in combination with Placebo
3177734|NCT00655330|Experimental|2|Valsartan (160mg/day) + Probucol (750mg/day)
3177735|NCT00655343|Experimental|ATG-F|"ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)~cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
3177736|NCT00655343|No Intervention|non-ATG-F|"cyclosporine A (target trough level > 200ng/ml (day -1 until day +100)~methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11"
3177737|NCT00655369|Experimental|15 mg|
3177738|NCT00655369|Experimental|25 mg|
3177739|NCT00655369|Experimental|35 mg|
3177740|NCT00655369|Experimental|5 mg|
3177741|NCT00655369|Experimental|50 mg|
3177742|NCT00655369|Placebo Comparator|Placebo|
2585481|NCT02330016|Experimental|Voluma XC|Injections of Voluma will be accomplished using a serial puncture and fanning technique with the needle inserted to the periosteal plane as well as in the subcutaneous plane. The treatment area will include the medial and lateral chin as defined: lateral chin landmark is the depressor anguli oris.
2585561|NCT02329652|Experimental|Intervention - implant neuroprosthesis|Receives implanted networked neuroprosthetic system for hand, arm, and trunk function. Undergoes functional training and assessment.
2585666|NCT02328781|Experimental|Experimental|Drug-eluting stent
2585721|NCT02328534||Density Gradient semen|"ICSI Cases processed using DG semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
2585722|NCT02328534||Swimming down semen|"ICSI Cases processed using SD semen processing and evaluated by~Blastocyst Formation Rate Blastocyst Rate Pregnancy Rate"
2585810|NCT02327624|Active Comparator|Clopidogrel|The standard antiplatelet treatment for patients is pretreatment with aspirin and clopidogrel. In this trial patients will be randomised in clopidogrel orTicagrelor of two doses
2585828|NCT02327624|Experimental|Ticagrelor 60|Ticagrelor 60 is a new dosage to be tried in this trial.
2585833|NCT02327624|Experimental|Ticagrelor 90|Ticagrelor 90 is used following clopidogrel as maintenance therapy with aspirin 75 mg daily and clopidogrel 75 mg daily following PCI for at least 1 month.
2585872|NCT02327286|Experimental|Intervention|Promote and support healthy behaviors
2585876|NCT02327286|No Intervention|Control|Conventional care for women with prior GDM.
2585988|NCT02326415|Active Comparator|"Clinical Pathway With Fast-Track"|All the clinical performances that the health personal have to do about the patient with uncomplicated acute appendicitis is already established in a care maps since the patient comes to hospital until the discharge.
2585997|NCT02326415|Active Comparator|Postoperative Usual Protocol|The postoperative time and the clinical cares in patients with uncomplicated acute appendicitis, are defined by responsability sugery as he thinks he should be according to the literature.
2586078|NCT02326181|No Intervention|control group|without inspiratory and expiratory pressure threshold training
2586084|NCT02326181|Experimental|inspiratory pressure training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
2586087|NCT02326181|Experimental|mixed training group|The patients will perform daily in 2 sessions of 30 minutes, using a pressure threshold trainer.
3177743|NCT00655395|Experimental|1|"Laromustine 300 mg/m2 (cohort 1) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3177744|NCT00655395|Experimental|2|"Laromustine 400 mg/m2 (cohort 2) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3177745|NCT00655395|Experimental|3|"Laromustine 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3177746|NCT00655395|Experimental|5|"Laromustine will be administered at the recommended phase II dose on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3177747|NCT00655395|Experimental|4|"Laromustine 600 mg/m2 (cohort 4) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
3177748|NCT00655408|Active Comparator|A|"For infants with ages between six and 24 months, iron supplementation is the main treatment for iron deficiency.This study was carried out using two intervention groups. All children received 12 weekly doses of 25 mg of elemental iron.~Group 1 administered in the government healthcare clinic. Group 2 administered children's home.~The study showed treatment compliance in both groups."
3177749|NCT00655421|Experimental|Unaided|Unaided Visual Inspection of the Oral Cavity
3177750|NCT00655421|Experimental|VelScope|VelScope assisted examination of the oral cavity
3177751|NCT00655421|Experimental|Toluidine|Examination of oral cavity after the local application of Toluidine Blue dye
3177752|NCT00655434||SAA|Sexually Active Adults- Intercourse in the last twelve months with at least one sexual partner. Subjects must be ≥ 18 years old. No more than 60% of one gender.
3177753|NCT00655447||1|all women having a hysterectomy with oophorectomy
3177754|NCT00655447||2|all women having a hysterectomy without removal of ovaries
3177755|NCT00655460|Experimental|eProtocol|
3177756|NCT00655512|Active Comparator|1|
3177757|NCT00655512|Active Comparator|2|
3177758|NCT00655512|Active Comparator|3|
3177759|NCT00655512|Active Comparator|4|
3177760|NCT00655512|Placebo Comparator|5|
3177761|NCT00655525|Active Comparator|1|
3177762|NCT00655525|Placebo Comparator|2|
3177763|NCT00655577|No Intervention|2|Control group
3177764|NCT00655577|Experimental|1|Exercise group
3177765|NCT00655590|Experimental|Arm 1|
3177766|NCT00655590|Active Comparator|Arm 2|
3177767|NCT00655590|Placebo Comparator|Arm 3|
3177768|NCT00655603|Experimental|1|10 patients with Type 2 Diabetes Mellitus
3177769|NCT00655603|Experimental|2|10 healthy, matched control participants
2585496|NCT02330133|Active Comparator|Online sexual health content|Online general text-based information about reproductive health issues and STD prevention strategies
3212565|NCT01016470|Experimental|A|VIUSID/ALZER. The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with early PD by UPDRS motor
2585609|NCT02328976|Experimental|chronic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
2585614|NCT02328976|Experimental|Episodic migraineurs|functional Magnetic Resonance Imaging (fMRI) analysis to compare connectivity of hypothalamus
2585699|NCT02328924|Other|LH value in fixed group|LH value predictive of IVF in 104 patients entered in fixed protocol
2585704|NCT02328924|Other|LH value in flexible group|LH value predictive of IVF in 109 patients entered in flexible protocols
2585770|NCT02328352|Experimental|BP selfstanding felt|"laparotomy intervention with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.~V-Loc 180 (ref VLOCL0024, lot. A1D0899)"
2585776|NCT02328352|Active Comparator|PP mesh|"intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PP mesh was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia.~Other names: V-Loc 180 (ref VLOCL0024, lot. A1D0899) PR Parietene mesh Tyco (ref. PP3030, lot. SIK00587)"
2585783|NCT02328352|Experimental|BP intraperitoneal mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply for entering into the abdominal cavity. In five rabbits (BPR21-BPR25). A 2x2cm2 BP intraperitoneal mesh was then be inserted with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut.
2585784|NCT02328352|Active Comparator|control group|Five rabbits (R26-R30) will be used as control group.
2585844|NCT02327650||RA and OA|Every 2 or 3 months, plain radiograph, blood and urinary tests, and MRI are performed in the painful joints of RA.
2585983|NCT02326441|Experimental|KX2-361|
2586053|NCT02326246|Experimental|men with low-risk PC|men newly diagnosed with low-risk prostate cancer and put in an active surveillance (AS) program. Eight weeks post TRUS-guided biopsies they are scanned with a multi-parametric magnetic resonans imaging (mMRI). If the scans shows a PIRADS 4 or 5 lesion, MRI-guided biopsies are performed. Otherwise the patients will continue in the AS program as usual. The mMRI will in these cases be repeated after 1 year.
3177770|NCT00655616|Active Comparator|1|The active comparator arm consists of Flixotide® (fluticasone propionate) via accuhaler (Diskus) dry powder inhaler device as per current inhaled steroid dose plus oral montelukast
3177771|NCT00655616|Placebo Comparator|2|The placebo comparator arm consists of Seretide® (salmeterol plus equivalent dose of fluticasone) via accuhaler dry powder inhaler device as per current inhaled steroid dose plus placebo for montelukast
3177772|NCT00655655|Experimental|Arm I|See Detailed Description
3177773|NCT00655681|Experimental|A|Receives pamidronate 1mg/kg
3177774|NCT00655681|Placebo Comparator|B|receives saline injection
3177775|NCT00655720|Active Comparator|1|
3177776|NCT00655720|Experimental|2|
3177777|NCT00655720|Experimental|3|
3177778|NCT00655785|Experimental|Phase 1/2 study|
3177779|NCT00655798|Placebo Comparator|1|
3177780|NCT00655798|Active Comparator|2|
3177781|NCT00655798|Active Comparator|3|
3177782|NCT00655798|Active Comparator|4|
3177783|NCT00655824|Experimental|Ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
3177784|NCT00655837|Experimental|1|
3177785|NCT00655902|Experimental|1|
3177786|NCT00655902|Placebo Comparator|2|
3177787|NCT00655915||Injection Patients|Those patients who receive corticosteroid injections for carpal tunnel syndrome
3177788|NCT00655941|Experimental|1|Dietary instruction (low-energy diet. This is given by instructions in groups of 8
3177789|NCT00655941|Active Comparator|2|Exercise
3177790|NCT00655941|No Intervention|3|Control
3177791|NCT00655954||Healthy volunteers non smoker|18 volunteers
3177792|NCT00655954||Healthy volunteers smoker|15 volunteers
3177793|NCT00655954||Chronic Obstructive Pulmonary Disease COPD|39 volunteers
3177794|NCT00655967|Experimental|1|Acamprosate(Campral)
3177795|NCT00655993|Placebo Comparator|1|placebo drug
3177796|NCT00655993|Active Comparator|2|simvastatin
3177797|NCT00656032|Active Comparator|1|SOC medication for treatment of renal osteodystrophy
3177798|NCT00656032|Active Comparator|2|alternate SOC medication for treatment of renal osteodystrophy
3177799|NCT00656045|Experimental|A|Arm A focuses on increasing the participant's physical activity level.
3177800|NCT00656045|Experimental|B|Arm B focuses on decreasing the amount of time the participant spends watching Television.
3177801|NCT00656071||1|Control -- postoperative mechanical ventilation patients without ARDS
3177802|NCT00656071||2|Cases -- postoperative mechanical ventilation patients with ARDS
3177803|NCT00656097|Experimental|A|CL184 combined with rabies vaccination
3177804|NCT00656097|Active Comparator|B|HRIG combined with rabies vaccination
3177805|NCT00656097|Placebo Comparator|C|Placebo combined with rabies vaccination
3177806|NCT00656110|Experimental|1-T|Treatment Group
3177807|NCT00656110|Placebo Comparator|2-P|Placebo comparator
3177808|NCT00656123|Experimental|CY and colon GVAX|
2585499|NCT02330068||Cases|Male or female participants ages 18-55 with Major Depressive Disorder, Bipolar I or Bipolar II whom antidepressant treatment is deemed necessary will be given citalopram.
2585694|NCT02328612|Experimental|First arm|250,000 cells/kg will be administered via intravenous infusion.
2585701|NCT02328612|Experimental|Second arm|1,000,000 cells/kg will be administered via intravenous infusion.
2585706|NCT02328612|Experimental|Third arm|4,000,000 cells/kg will be administered via intravenous infusion.
2585708|NCT02328612|Placebo Comparator|Fourth arm|Placebo (Ringer's lactate solution) volume according to subject's weight.
2585757|NCT02328261|Experimental|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily
2585825|NCT02327923|Active Comparator|Lidocaine|Intravenous bolus administration of lidocaine at the time of induction followed by infusion till the last suture.
2585835|NCT02327923|Active Comparator|Esmolol|Intravenous bolus administration of esmolol at the time of induction followed by infusion till the last suture.
2585950|NCT02326935|Experimental|Adipose derived mesenchymal cells|"Intervention: Autologous adipose derived mesenechymal stem cells, 150 million cells deployed via two (2) treatments via intravenous injection~Other Names:~ADSC, mesenchymal cells, stromal cells"
2585984|NCT02326571||spontaneous intracerebral hemorrhage|
3177809|NCT00656149|Active Comparator|Telerehabilitation of hand function|Intervention: for one hour per day participants perform exercise therapy on a home-based tele-rehabilitation workstation, the Rehabilitation Joystick for Computerized Exercise (ReJoyce) with which participants play computer games associated with activities of daily life. A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system. Hand grasp-release is assisted with functional electrical stimulation (FES) triggered voluntarily by the participant with the use of a wireless earpiece with a sensor that detects toothclicks.
3177810|NCT00656149|Active Comparator|Conventional exercise therapy|Intervention: for one hour per day participants perform conventional range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 with the use of the ReJoyce tele-rehabilitation min). A remote therapist coaches each one-hour session A remote therapist coaches each one-hour session over the Internet, with the use of the ReJoyce tele-rehabilitation system.
3177811|NCT00656188|Placebo Comparator|Arm 2|
3177812|NCT00656188|Active Comparator|Arm 1|
3177813|NCT00656214|Active Comparator|A|Patients with symptomatic oral lichen planus
3177814|NCT00656214|Placebo Comparator|B|Patients with symptomatic oral lichen planus
3177815|NCT00656240|Experimental|1|
3177816|NCT00656240|Experimental|2|
3177817|NCT00656253|Experimental|A|
3177818|NCT00656253|Placebo Comparator|B|
3177819|NCT00656266|Placebo Comparator|tacrolimus & corticosteroids|Standard post-transplant immunosuppression medications: tacrolimus and corticosteroids
3177820|NCT00656266|Experimental|low-dose tacrolimus + steroids + MMF|Comparison arm: low-dose tacrolimus + steroids + MMF
3177821|NCT00656279|Experimental|1|Intensive dietary phosphorus education
3177822|NCT00656279|No Intervention|2|Standard dietary education consists of the dietitian assessing laboratory values and dietary intake and providing dietary education for abnormal values using handouts developed for specific nutrients.
3177823|NCT00656318||Group 1 (Zovia)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
3177824|NCT00656318||Group 2 (Necon)|Subjects will be randomized to receive either the oral contraceptive pill (OCP) Zovia or Necon for 2 months. Prior to beginning the OCP, women will undergo 1 imaging scan. Upon completion of the scan they will receive their first dose of their OCP. Three hours later they will undergo a 2nd imaging scan. Each scan last approximately 1 hour and 15 minutes. This test day is typically scheduled on a Saturday, and lasts approximately 7 hours. Upon completion of the Saturday test day, subjects will remain on their OCP for the remainder of that month and continue taking the pill for a 2nd month. At the end of the 2 months on the pill, subjects will have the option of discontinuing the pill or receiving 1 additional month at no charge before being discharged from the study.
3177825|NCT00656331|Active Comparator|1|Amlodipine
3177826|NCT00656331|Active Comparator|2|HCTZ
3177827|NCT00656357|Placebo Comparator|A|SYN117 placebo and Ascending doses of cocaine (10, 20, 40 mg) and placebo
3177828|NCT00656357|Experimental|B|Ascending doses of SYN117 (placebo, 80 mg, 160 mg) and ascending doses of cocaine (10 mg, 20 mg, 40 mg) and placebo
3177829|NCT00656383|Active Comparator|1|Client is randomized to receive leg ulcer treatment in the home
3177830|NCT00656383|Active Comparator|2|Client randomized to receive leg ulcer care in the clinic
3177831|NCT00656396|Active Comparator|Control|Standard care
3177832|NCT00656396|Experimental|Intervention|Point of care monitoring used
3177833|NCT00656422|Experimental|insulin Levemir|
3177834|NCT00656422|Experimental|insulin Lantus|
3177835|NCT00656435|Experimental|A|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
3177836|NCT00656435|No Intervention|B|Patients will not receive bevacizumab pretreatment
3177837|NCT00656461|Experimental|1|
3177838|NCT00656500|Active Comparator|1|Brief assistance with smoking abstinence
3177839|NCT00656500|Experimental|2|Brief intervention to promote quitline utilization
3177840|NCT00656526|Placebo Comparator|A01L|
3177841|NCT00656526|No Intervention|B01C|
3177842|NCT00656539|Experimental|1|AzaSite®
3177843|NCT00656539|No Intervention|2|
3177844|NCT00656565||1|subjects with bronchiectasis
3177845|NCT00656578|Experimental|1|4975
3177846|NCT00656578|Placebo Comparator|2|Drug, Single dose, solution
2585571|NCT02329483||High responder infertile patients|Ovarian high responder patients who are being planned for low-dose step-up protocol ovulation induction and intrauterine insemination.
2585612|NCT02329197|Experimental|Group A|women undergoing IVF treatment will be subjected for intrauterine injection of 10 IU of human chorionic gonadotropin (HCG) (diluted in 0.025ml of tissue culture), 10 minutes before embryo transfer procedure.
2585616|NCT02329197|No Intervention|Group B|women undergoing IVF treatment will embryo transfer procedure performed in the standard way without intrauterine injection of HCG.
2585671|NCT02328833|Experimental|Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation will be done
2585672|NCT02328833|No Intervention|No Active Implementation of Guidelines|Primary Care Centers where the experimental strategies of guidelines implementation not will be done
2585741|NCT02328495|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
2585742|NCT02328495|Active Comparator|bladder Filling|Uterine straightening by bladder filling before office hysteroscopy
2585846|NCT02327585|Experimental|Executive function training|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of executive function training weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
2585891|NCT02327234|Experimental|Ibuprofen|400mg (2X200mg) ibuprofen single dose once
2585903|NCT02327234|Placebo Comparator|Placebo|identical appearing lactose capsules single dose 2 capsules once
2585942|NCT02326857||Women with breast cancer|Observational study of women with Stage II/III locally advanced breast cancer in Latin America
2585993|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 100 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
2586004|NCT02326454|Active Comparator|Talaporfin sodium/Light dose 200 J/cm|Single 1 mg/kg dose of talaporfin sodium is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours
2586009|NCT02326454|Placebo Comparator|Saline/Light dose 100 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 100 J/cm delivering light for 60 minutes of the 2-hour treatment period
2586011|NCT02326454|Placebo Comparator|Saline/Light dose 200 J/cm|0.9% Sodium Chloride is administered intravenously with Drug Activator 200 J/cm delivering light for 2 hours.
3177847|NCT00656604|Experimental|Women with breast cancer|Patients undergo DCE-MRI and MRS prior to their breast cancer surgery.
3177848|NCT00656604|No Intervention|Healthy volunteers|Women without breast cancer undergo DCE-MRI and MRS.
3177849|NCT00656643|Experimental|1|
3177850|NCT00656643|Experimental|2|
3177851|NCT00656643|Experimental|3|
3177852|NCT00656643|Placebo Comparator|4|
3177853|NCT00656682|Active Comparator|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian. Registered Dietitian Counseling Alone
3177854|NCT00656682|Experimental|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based diabetes prevention lifestyle intervention offered by the community. Dietitian Counseling Plus Community Group Lifestyle Intervention.
3177855|NCT00656695|Experimental|1|taking Iminoral
3177856|NCT00656695|Active Comparator|2|taking Neoral
3177857|NCT00656708|Experimental|PB|All patients admitted to the burn unit during the prospective portion (interventional portion) of the study who have open wounds will have Kerlix AMD applied to their wounds; only those patients consenting to the study will have data abstracted.
3177858|NCT00656721|Experimental|Flutter Valve|This a crossover study, so all subjects performed both, control and experimental interventions. In Flutter Valve intervention the subjects remained comfortably seated, breathing through the device for 15 minutes, starting off from the total pulmonary capacity, and being free to cough. Thereafter, a 5-min session of cough ensued. In the control intervention the subjects followed the same sequence of the Flutter Valve intervention, but the metallic sphere and the cover of the device were removed. Since the patients were not acquainted with the valve, they did not know its proper assembly. As in the Flutter Valve intervention, during 15 minutes the patients could expectorate spontaneously and return to the device. A 5-min coughing session took place.
3177859|NCT00656734|Experimental|MDX 1411|Dose Escalation Cohorts
3177860|NCT00656747|Active Comparator|Arm 2|
3177861|NCT00656747|Experimental|Arm 1|
3177862|NCT00656760|Experimental|A|All patients have PET/CT and biopsies with the surgeon blinded to the result of PET/CT. Additional biopsies are performed (or not) after the surgeon has the PET/CT results revealed.
3177863|NCT00656773|Experimental|1|
2585676|NCT02328872|Experimental|Intervention (HPV Arm)|"Molecular testing for HPV with partial genotyping for types 16/18, with referral of the HPV16/18-positive group for diagnostic evaluation, and secondary randomisation of women testing positive for other oncogenic HPV infection (not 16/18), to either image-read cytology screening or dual-stained (DS) cytology testing with p16/Ki67 - the HPV arm. Screening performed 5 yearly."
2585682|NCT02328872|Active Comparator|Control (LBC Arm)|"Image-read liquid based cytology (LBC) screening with reflex HPV triage testing for low grade smears, the LBC arm. Screening performed 2.5 yearly."
2585751|NCT02328157|Experimental|Cataract with ERM and astigmatism|Eyes that have cataract and ERM with a preoperative corneal cylinder of more than 0.75 diopter.
2585811|NCT02327936|Experimental|Fesoterodine 4mg|Fesoterodine 4 mg Po Die, dose could be increased to 8mg Po Die after 4 weeks, for a total of 8 weeks
2585826|NCT02327936|Active Comparator|Oxybutynin XL 10mg|Oxybutynin XL 10 mg Po Die, dose could be increased to 20 mg Po Die after 4 weeks, for a total of 8 weeks
2585860|NCT02327338|Experimental|continuous low level heat for neck|30 subjects to use ThermaCare heat wraps on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps are not used.
2585863|NCT02327338|Experimental|Ibuprofen and continuous low level heat|30 subjects to use 1200 mg per day Ibuprofen dosed in 3 dosages 4 hours apart on the same days as heat wraps were to be used. ThermaCare heat wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where heat wraps and ibuprofen are not used.
2585867|NCT02327338|No Intervention|control|15 subjects with no heat or ibuprofen just physical therapy 2 times per week.
2585871|NCT02327338|Sham Comparator|sham heat and sham ibuprofen|30 subjects to use 1200 mg per day Ibuprofen sham dosed in 3 dosages 4 hours apart on the same days as sham heat wraps were to be used. ThermaCare heat sham wraps to be used on their necks for 6 hours before home exercise programs each day for 10 days. Physical therapy 2 times per week will be used on days where sham heat wraps andsham ibuprofen are not used.
2585937|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(fasted)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
2585945|NCT02326987|Experimental|GLA5PR GLARS-NF1 tab.150mg(after high fat meal)|GLA5PR GLARS-NF1 tab. 150mg/day(Pregabalin 150mg once a day)
2585956|NCT02326987|Active Comparator|Lyrica Capsule 75mg(after high fat meal)|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
2586018|NCT02326493|Experimental|CRT implantation|Patients who have a class I indication for cardiac resynchronization therapy according to current international guidelines
2586045|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 1.0%|One drop in each eye
2586051|NCT02326090|Active Comparator|cis-UCA ophthalmic solution 2.5%|One drop in each eye
2586052|NCT02326090|Placebo Comparator|Placebo ophthalmic solution|One drop in each eye
3177864|NCT00656773|Active Comparator|2|
3177865|NCT00656786|Experimental|Group 1|Subjects will be treated if, after starting treatment with an EGFRi, acute signs and symptoms of rash on the face/neck and/or upper chest emerge, that are suspected of being related to the EGFRi treatment.
3177866|NCT00656786|Experimental|Group 2|Subjects will receive pre-emergent rash treatment starting 1 day prior to beginning EGFRi therapy
3177867|NCT00656812|Experimental|Treatment Arm|Combination therapy Rituximab plus 2CdA
3177868|NCT00656825|Active Comparator|Panel I|The first 12 subjects will be selected and ranodmized in order to receive the first treatment dose of 100 μg/mL or placebo in a 8:4 ratio
3177869|NCT00656825|Active Comparator|Panel II|The second 12 subjects will be selected and randomized in order to receive the second treatment dose of 200 μg/mL or placebo in a 8:4 ratio
3177870|NCT00656825|Active Comparator|Panel III|The third 12 subjects will be selected and randomized in order to receive the third treatment dose of 300 μg/mL or placebo in a 8:4 ratio
3177871|NCT00656825|Placebo Comparator|Placebo|Patients from each panel will be given placebo in a 4:8 ratio.
3177872|NCT00656838|Active Comparator|1|Patient has had PCP contact (letter, phone call, office visit, educational materials).
3177873|NCT00656838|No Intervention|2|Usual Care
3177874|NCT00656864|Active Comparator|1|Pioglitazone arm
3177875|NCT00656864|Placebo Comparator|2|Placebo arm
3177876|NCT00656890|Placebo Comparator|2|sterile saline for injection
3177877|NCT00656890|Experimental|1|MDX-1100 for injection
3177878|NCT00656929|Active Comparator|1|Vitamin D3 50 mcg (2000 IU) daily
3177879|NCT00656929|Placebo Comparator|2|Placebo tablets
3177880|NCT00656942||Healthy|"subjects with no pain and no opioid treatment for at least six months~subjects receive quantitative sensory testing (QST)"
3177881|NCT00656942||Pain, no opioid|"subjects have chronic pain but have not taken any opioid medication for at least 3 months~subjects receive QST"
3260293|NCT01477996|Active Comparator|Group 1|27-gauge needle
2585745|NCT02328092|Active Comparator|Real group|The real group received biphasic rSMS using a Magstim Super Rapid (Magstim, Whitland, UK) stimulator connected to a 120-mm outer diameter figure-of-8 air film cooling coil positioned in the midline over the sacral vertebrae (approximately 5 cm above the natal cleft, which approximates to the level of S2). Stimulation was delivered at 15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upward. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off.
2585746|NCT02328092|Sham Comparator|Sham Group|The control group received sham rSMS stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
2585787|NCT02327988|Experimental|Cryotherapy|To the cryotherapy group a 1kg ice pack was strapped over the entire brachial biceps muscle and adjacent muscles of the arm under study using a bandage, and the application lasted 25 minute laser
2585789|NCT02327988|Experimental|Laser therapy|The laser therapy group received laser application to the muscle belly of the non-dominant upper limb brachial biceps at four different points.
2585791|NCT02327988|No Intervention|Control|The control group did not undergo any intervention and remained at rest for 25 minutes.
2585817|NCT02327689|Experimental|compensated HBV related cirrhosis patients|Chinese naive compensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
2585823|NCT02327689|Experimental|decompensated HBV related cirrhosis patients|Chinese naive decompensated HBV related cirrhosis patients were treated with generic emtricitabine capsule(200 mg one time per day) plus adefovir dipivoxil(10 mg one time per day) for 96 weeks
2585857|NCT02327312|Experimental|Surgical|Implantation of two Trabecular Meshwork stents into the study eye
2585858|NCT02327312|Active Comparator|Laser|Laser Trabeculoplasty
2585922|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day, after meal)
2585925|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day, after meal)
2585927|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 450mg|GLA5PR GLARS-NF1 tablet 450mg/day(Pregabalin 150mg 1 tablet and Pregabalin 300mg 1 tablet, 1 times a day, after meal)
2585928|NCT02327000|Experimental|GLA5PR GLARS-NF1 tablet 600mg|GLA5PR GLARS-NF1 tablet 600mg/day(Pregabalin 300mg, 2 tablets 1 times a day, after meal)
2586012|NCT02326532|Experimental|PRO data utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm and provided to the treating physicians.
2586014|NCT02326532|Sham Comparator|PRO data not utilized|PRO data derived from the patient-completed MDHAQ/RAPID3 questionnaire will be collected from this arm but will not be provided to the treating physicians.
2586044|NCT02326077||Intervention group|"Clinical evaluation in active labor: Leopold manoeuvres, vaginal digital examination.~Transabdominal and transperineal ultrasound evaluations of the mechanism of labor: fetal head position, progression and rotation.~Investigation by questionnaire regarding the psychological impact of labor monitoring assisted by sonoraphy."
3177882|NCT00656942||Pain, opioid|"subjects have chronic pain and have been taking opioid medication for at least 3 months~subjects receive QST"
3177883|NCT00656955||Renal cancer patients|Renal cancer patients
3177884|NCT00656981|Experimental|Arm 1|
3177885|NCT00656981|Placebo Comparator|Arm 2|
3177886|NCT00656994|Experimental|Ramelteon 16 mg QD|
3177887|NCT00656994|Placebo Comparator|Placebo|
3177888|NCT00657007|Placebo Comparator|Placebo|IV infusion over 2 hours
3177889|NCT00657007|Experimental|Belimumab 1 mg/kg|1 mg/kg IV infused over 2 hours
3177890|NCT00657007|Experimental|Belimumab 4 mg/kg|4 mg/kg IV infused over 2 hours
3177891|NCT00657007|Experimental|Beimumab 10 mg/kg|10 mg/kg IV infused over 2 hours
3177892|NCT00657007|Experimental|Belimumab 20 mg/kg|20 mg/kg IV infused over 2 hours
3177893|NCT00657033|Experimental|Arm 1|
3177894|NCT00657033|Experimental|Arm 2|
3177895|NCT00657059|Active Comparator|Pred group|Pred Group: Prednisone treatment Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.
3177896|NCT00657059|Active Comparator|MMF Group|MMF Group: MMF treatment Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month.
3177897|NCT00657059|Active Comparator|Pred plus MMF Group|"Pred plus MMF Group: Prednisone plus MMF treatment. Patients will give methylprednisolone intravenously at a dose of 0.5 g/day for 3 days at the start of months 1, 3, and 5; then take oral prednisone (0.5 mg/kg/d) on alternate days. Prednison will be tapered 5 mg per month from the seventh month to the 12th month.~Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt < 50kg) for the first 6-month of drug treatment phase, then 0.5 bid for the remaining 6-month."
3177898|NCT00657098||Observation|
3177899|NCT00657111|Experimental|A1|Subjects 01-08; 5 mg CS-8958
3177900|NCT00657111|Placebo Comparator|A2|Subjects 01-08; placebo
3177901|NCT00657111|Experimental|B1|Subjects 09-16; 10 mg CS-8958
3177902|NCT00657111|Placebo Comparator|B2|Subjects 09-16; placebo
3177903|NCT00657111|Experimental|C1|Subjects 17-24; 20 mg CS-8958
2585795|NCT02327767|Experimental|Resonating Arm Exerciser|The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
2585796|NCT02327767|No Intervention|Physical Therapy|The control group will continue with existing physical therapy treatment of passive range of motion (PROM) and therapeutic exercise to their involved upper extremity by the physical therapist.
2585884|NCT02327455|Experimental|Stress Dobutamine Echocardiographic 4DE Image System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
3177904|NCT00657111|Placebo Comparator|C2|Subjects 17-24; placebo
3177905|NCT00657111|Experimental|D1|Subjects 25-32; 40mg CS-8958
3177906|NCT00657111|Placebo Comparator|D2|Subjects 25-32; placebo
3177907|NCT00657124|Experimental|1|receive a preoperative supplementation with carbohydrate and branched-chain amino acids-enriched nutrient
3177908|NCT00657124|Placebo Comparator|2|receive a preoperative supplementation without carbohydrate and branched-chain amino acids-enriched nutrient
3177909|NCT00657137|Experimental|A|apricoxib + lapatinib + capecitabine
3177910|NCT00657137|Placebo Comparator|B|placebo + lapatinib + capecitabine
3177911|NCT00657163|Experimental|1|fluoxetine
3177912|NCT00657163|Placebo Comparator|2|Placebo
3177913|NCT00657189|Experimental|1|MEDI-545
3177914|NCT00657189|Experimental|2|MEDI-545
3177915|NCT00657189|Experimental|3|MEDI-545
3177916|NCT00657189|Experimental|4|MEDI-545
3177917|NCT00657189|Placebo Comparator|5|Placebo
3177918|NCT00657202|Experimental|Ranibizumab|
3177919|NCT00657228|Placebo Comparator|2|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) plus an equal volume bolus of normal saline after the first doses are administered.
3177920|NCT00657228|Experimental|1|Standard therapy plus a one-time bolus of heparin at 80 U/kg (maximum dose of 10,000 Units) given immediately after the first doses of standard treatment.
3177921|NCT00657241|Active Comparator|A|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
3177922|NCT00657241|Active Comparator|B|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
3177923|NCT00657254|Experimental|Arm 1|
3177924|NCT00657293|Sham Comparator|C|In an attempt to make the groups comparable in terms of attention, the control group will receive a sham.
3177925|NCT00657293|Active Comparator|ATP|Patients will undergo a specific arm training program (ATP).
3177926|NCT00657306|Experimental|1|Hydrocortisone, 50 mg/6 h per day
3177927|NCT00657306|Placebo Comparator|2|dextrose solution 5%
3177928|NCT00657319||A|
3177929|NCT00657345||1|This is a tissue acquisition and collection protocol that will analyze potential cellular changes that occur after treatment with trastuzumab.
3177930|NCT00657384|Experimental|acid tranexamic|acid tranexamic
3177931|NCT00657384|Placebo Comparator|2|Nacl 0.9%
3177932|NCT00657397|Experimental|A|Methadone inducted by a primary care physician
3177933|NCT00657397|Active Comparator|B|Methadone inducted (in CSAPA)
3177934|NCT00657410|Experimental|ARM A - PDN|PDN is administered orally at the daily dose of 1 mg/Kg for 4 consecutive weeks (from day 0 to day 28), then, therapy is tapered within 14 days. The patients considered NOT RESPONDER at day 42 or WHO HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be crossed to ARM B.
3177935|NCT00657410|Experimental|ARM B - DXM|"DXM is administered orally at single fixed daily doses of 40 mg for 4 consecutive days, every 14 days, for 3 consecutive courses. If platelet count is £ 20x109/L or bleeding symptoms related to thrombocytopenia are present, lowdose DXM (0.035 mg/Kg/day) between courses is given. The patients (either from ARM A+B or from ARM B) considered NOT RESPONDER at day 46 or who HAVE LOST THE RESPONSE within the evaluation of final response (see paragraph 8.1), will be considered OFF TREATMENT.~For these patients a second line therapy will be considered, according to the medical practice of the Centre (splenectomy or other)."
3177936|NCT00657423|Experimental|1|
3177937|NCT00657423|Active Comparator|2|
3177938|NCT00657449|Active Comparator|Arm 1|
3177939|NCT00657449|Active Comparator|Arm 2|
3177940|NCT00657462|Experimental|A|Receives the intervention (reminders displayed at the startup of the application) for both periods (period 1 and period 2) of the study.
3177941|NCT00657462|Active Comparator|B|Receives the intervention (reminders displayed at the application startup) only during the second period (period 2) of the study.
3177942|NCT00657475|Experimental|2|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin low dose (150 UI/Kg).
3177943|NCT00657475|Active Comparator|1|Cardiac surgery with Mini Extra Corporeal Circulation (MECC). Heparin Full Dose (300 UI/Kg)
3177944|NCT00657488|Experimental|A|Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
3177945|NCT00657488|Active Comparator|B|Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
3177946|NCT00657501|Experimental|testosterone gel|1% testosterone transdermal gel
3177947|NCT00657501|Placebo Comparator|Placebo gel|placebo transdermal gel
3177948|NCT00657514|Active Comparator|A|Drug arm - 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
3177949|NCT00657514|Placebo Comparator|P|Placebo arm - 1 tablet po bid up to 2 tablets po bid if tolerated
3177950|NCT00657527|Experimental|1|Rosuvastatin
3177951|NCT00657527|No Intervention|2|Diet
2585797|NCT02327871|Experimental|Esophageal cooling|Specific treatment: The placement of the ECD will follow standard recommendations as per Instructions for Use. The ECD will be connected to the Gaymar console (Meditherm III, Gamida, France). In our institution, TH is performed in all patients resuscitated from an OHCA except those presenting exclusion criteria. TH can be initiated as soon as possible by administration of cold saline at 4°C if necessary followed by application of the available cooling device (blankets, endovascular methods, etc) aiming a target temperature of 32-34°C for 24 hours as recommended. 8-11,13 For all enrolled patient, the ECD will hereby replace the other cooling device usually used in our ICU.
3177952|NCT00657566|Active Comparator|1|antibiotics received for up to two days following normalization of white blood cell count, temperature, and gastrointestinal function
2586034|NCT02326285|Experimental|Treatment phase|Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
2586076|NCT02325973|Other|IMR evaluation|Assessment of IMR index in coronaries through PressureWire Certus guidewire
3177953|NCT00657566|Experimental|2|4 +/- 1 days of antibiotics
3177954|NCT00657579|Experimental|1|
3177955|NCT00657579|Experimental|2|
3177956|NCT00657579|Experimental|3|
3177957|NCT00657579|Placebo Comparator|4|
3177958|NCT00657631|Experimental|A|Acceptance and Commitment Therapy will be administered to all subjects.
3177959|NCT00657644|Experimental|Arm 1|
3177960|NCT00657670|Experimental|1|Ready-made spectacles
3177961|NCT00657670|Active Comparator|2|Spectacles
3177962|NCT00657683|Experimental|1|
3177963|NCT00657683|Placebo Comparator|2|
3177964|NCT00657696||Group 1|Physicians and staff in VA non-contract primary care outpatient clinics and patients seen in last 12 months in the same clinics
3177965|NCT00657696||Group 2|Patients seen in last 12 months in Group 1 clinics
3177966|NCT00657722|Experimental|1|Angiography and Computed Tomography
3177967|NCT00657735|Experimental|1|Deep TMS treatment
3177968|NCT00657735|Sham Comparator|2|inactive stimulation
3177969|NCT00657748|Experimental|1|
3177970|NCT00657761|Placebo Comparator|Placebo|Saline solution 0.9% sc/12h for 7 days
3177971|NCT00657761|Experimental|Enfuvirtide|Enfuvirtide 90 mg/12h sc for 7 days
3177972|NCT00657774|Experimental|1|FlutiForm 250/10 ug
3177973|NCT00657774|Experimental|2|FlutiForm 100/10 ug
3177974|NCT00657774|Active Comparator|3|Oral Prednisone 10 mg
3177975|NCT00657774|Placebo Comparator|4|Placebo inhaler and/or placebo tablets
3177976|NCT00657787||PTSD|Combat-exposed men and women with PTSD deployed to OIF/OEF.
3177977|NCT00657787||High Utilizers|A comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD
3177978|NCT00657787||Not OIF/OEF|A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones
3177979|NCT00657800|Experimental|Group 1|Behavioral - Intensified coordinated inpatient diabetes education program (IDEP)
3177980|NCT00657800|No Intervention|Group 2|Diabetes education as is typically provided by clinical staff
3177981|NCT00657813|Experimental|Access [123I]MNI-330 and SPECT Imaging|
3177982|NCT00657826|Experimental|19mm arotic valve implant|Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.
3177983|NCT00657839|Experimental|Arm 1|
3177984|NCT00657839|Placebo Comparator|Arm 2|
3177985|NCT00657852|Experimental|Pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
3177986|NCT00657852|Placebo Comparator|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
3177987|NCT00657865|Active Comparator|1|Ramipril
3177988|NCT00657865|Placebo Comparator|2|Placebo
3177989|NCT00657878|Experimental|non platinum based chemotherapy|a non platinum based therapy (corresponding to stealth liposomal doxorubicin, or topotecan, or gemcitabine,or any other drug approved in clinical practice for the treatment of patients with ovarian cancer after previous platinum-based chemotherapy) followed by a platinum based chemotherapy at disease progression
3177990|NCT00657878|Active Comparator|platinum based chemotherapy|platinum based chemotherapy (corresponding to the combination of carboplatin + paclitaxel, or carboplatin + gemcitabine for patients with significant but lower than grade 3 neuropathy at baseline) followed by a non platinum based chemotherapy at disease progression
3177991|NCT00657891|Placebo Comparator|1|Placebo Injection
3177992|NCT00657891|Experimental|2|Xolair at 0.016 mg/kg/IgE(iu/ml)/4 wks
3177993|NCT00657904|Experimental|1|
3177994|NCT00657904|Placebo Comparator|2|
3177995|NCT00657930||A|
3177996|NCT00657943|Experimental|1M|Metformin + Levemir x1
3177997|NCT00657943|Placebo Comparator|1P|Placebo + Levemir x1
3177998|NCT00657943|Experimental|2M|metformin + NovoMix
3177999|NCT00657943|Placebo Comparator|2P|Placebo + NovoMix
3178000|NCT00657943|Experimental|3M|Metformin + 4x therapy
3178001|NCT00657943|Placebo Comparator|3P|Placebo + 4x therapy
3212566|NCT01016496|Experimental|Action observation plus repetition|Observation of actions and repetition of the same actions
2585848|NCT02327702|Experimental|Chinese naive pregnant chronice hepatitis B|Chinese naive pregnant chronice hepatitis B were enrolled to take emtricitabine (200 mg one time per day) till 48 weeks after delivery.
2585901|NCT02327182|Experimental|MT-4666 low dose|Low Dose, Tablet, Once Daily, For 52 Weeks
2585905|NCT02327182|Experimental|MT-4666 high dose|High Dose, Tablet, Once Daily, For 52 Weeks
2585952|NCT02326870|Experimental|The AutoLap system|Use of the AutoLap system for controlling the laparoscope during the procedure
2586022|NCT02326610|Active Comparator|hGH, ZOMACTON® (somatropin)|For infants in the treatment group receiving ZOMACTON® (somatropin) growth hormone by injection
2586025|NCT02326610|No Intervention|No human growth hormone|No growth hormone is given.
2586086|NCT02326155||Remsima™|Patients who are taking Remsima™ for the treatment
3178002|NCT00657969||1|CAD-group (Cervical Artery Dissection - group): consecutive patients with cervical artery dissection, with or without associated cerebral ischemia, hospitalized in one of the participating neurological centers; standardized inclusion and exclusion criteria apply
3178003|NCT00657969||2|IS-group (Ischemic Stroke - Group): patients selected among consecutive patients hospitalized for an ischemic stroke without CAD, in the same centers as patients from group1, frequency-matched on age and gender with group1; standardized inclusion and exclusion criteria apply
3178004|NCT00657969||3|HC-group (Healthy Control - Group): DNA of healthy individuals from existing DNA-databases will be used as controls for the Belgian, French, German and Swiss centers; the other centers are recruiting their own age- and sex-matched healthy controls; individuals from the 3 groups (CAD, IS and HC) are strictly matched on geographical origin in order to avoid stratification bias
3178005|NCT00657982|Experimental|1|RAD001 10 BID 6 weeks before definite treatment for localized prostate cancer
3178006|NCT00657995|Experimental|2|Thirty patients who underwent pancreatic resection for pancreatic neoplasm were prospectively randomized. Perioperative blood glucose levels were continuously monitored using an artificial endocrine pancreas (STG-22). Glucose levels were controlled using either the sliding scale method or the artificial pancreas.
3178007|NCT00658008|Experimental|PD 0332334 175 mg BID|
3178008|NCT00658008|Experimental|PD 0332334 225 mg BID|
3178009|NCT00658008|Experimental|PD 0332334 75 mg BID|
3178010|NCT00658008|Active Comparator|Paroxetine 20 mg QD|
3178011|NCT00658008|Placebo Comparator|Placebo BID|
3178012|NCT00658034|Active Comparator|1|Acupuncture
3178013|NCT00658034|Sham Comparator|2|Placebo Acupuncture
3178014|NCT00658047|Experimental|0.25 mg CH-1504|0.25 mg CH-1504
3178015|NCT00658047|Experimental|0.5 mg CH-1504|0.5 mg CH-1504
3178016|NCT00658047|Experimental|1.0 mg CH-1504|1.0 mg CH-1504
3178017|NCT00658047|Active Comparator|Methotrexate|Methotrexate (MTX) 10 mg/week for 2 weeks, 15 mg/week for 2 weeks, 20 mg/week for 8 weeks
3178018|NCT00658060||1|"1.Fulfilling the Tel Hashomer criteria for the diagnosis of FMF [5].~2.Suffering from episodes of exertional leg pain and or exertional ankle edema~3.18-45 years old~4.On a stable (≥ 2 weeks) dose of oral colchicine therapy~5.Non-smokers"
3178019|NCT00658060||2|"Control group~1.Healthy subjects~2.18-45 years old~3.Non-smokers"
3178020|NCT00658073|Active Comparator|A|Patients in Group A will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive standard regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF.
3178021|NCT00658073|Active Comparator|B|Patients in Group B will receive MSCs instead of anti-interleukin 2 receptor antibody for induction therapy. The first MSCs infusion intravenously will be right at releasing renal artery clamp to establish allograft blood flow and the second infusion of MSCs will be performed two weeks after transplantation. Patients will receive 80% less of calcineurin inhibitor than in Group A. Other immunosuppressive agents such as glucocorticoid and MMF remained the same doses as in Group A.
3178022|NCT00658073|Active Comparator|C|Patients in Group C will receive anti-interleukin 2 receptor antibody (Basiliximab)for induction therapy. Patients will receive the same doses of regular immunosuppressive agents including calcineurin inhibitor, glucocorticoid, and MMF as in Group A.
3178023|NCT00658086|Active Comparator|1|ALN-RSV01
3178024|NCT00658086|Placebo Comparator|2|Normal saline
3178025|NCT00658099||A|
3178026|NCT00658099||B|
3178027|NCT00658125|Experimental|Experimental|
3178028|NCT00658164|Experimental|1|
3178029|NCT00658177|Experimental|Arm 1|
3178030|NCT00658177|Placebo Comparator|Arm 2|
3178031|NCT00658190||1|Women obtaining routine Pap tests for cervical cancer screening
3178032|NCT00658203|Active Comparator|1|PEA optimized CRT
3178033|NCT00658203|Other|2|Standard optimized CRT
3178034|NCT00658216||Longitudinal|Prospective study : cohort of consecutive patients recruited over 2 years
3178035|NCT00658229|Experimental|Strength training group|A four months strength training program during androgen deprivation therapy for prostate cancer patietns.
3178036|NCT00658229|No Intervention|Control group|Patients in the control group are not discouraged from performing normal activities. They are however asked not to start a strength training program or increase their activity level in the same period as the experimental group is performing their strength training program. We will offer the control group a modified strength training program after the post-intervention assessment.
3178037|NCT00658242||I|Subjects having Craniofacial surgery
3178038|NCT00658255|Experimental|1|
3178039|NCT00658255|Active Comparator|2|
3178040|NCT00658268|Experimental|1|
3178041|NCT00658268|Placebo Comparator|2|
3178042|NCT00658281||OBI KV System + CBCT Scanning|Breast cancer patient radiation treatment set up using OBI KV system and CBCT scanning or CT-on-rail system to verify standard EPID for positioning.
3178043|NCT00658307|Experimental|1|
3178044|NCT00658307|Experimental|2|
3178045|NCT00658307|Sham Comparator|3|
3178046|NCT00658346||1|HIV-1 group O infected patients
2585870|NCT02327416|Experimental|2，combination and sequential group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
2585873|NCT02327416|Experimental|3, multitarget group|Drug: Y peginterferon Alfa-2b 180 micrograms sc/week for 96 weeks; Drug: Granulocyte-macrophage colony stimulating factor is used for 48 weeks; Drug: Entecavir and or adefovir dipivoxil are used for 48 weeks. Entecavir 0.5mg po daily for 48 weeks or plus ADV 10mg po daily.
2585929|NCT02326922|Experimental|Metraplant-E First prototype|Metraplant-E (first prototype) levonorgestrel-releasing intrauterine device
2585932|NCT02326922|Experimental|Metraplant-E second prototype|Metraplant-E (second prototype) levonorgestrel-releasing intrauterine device
3212567|NCT01016496|Active Comparator|repetition only|repetition of gestures
3178047|NCT00658346||2|HIV-1 group M infected patients
3178048|NCT00658372|Experimental|PD 0332334 225 mg BID|
3178049|NCT00658372|Experimental|PD 0332334 300 mg BID|
3178050|NCT00658372|Active Comparator|Paroxetine 20 mg QD|
3178051|NCT00658372|Placebo Comparator|Placebo BID|
3178052|NCT00658398|Experimental|ICP to prevent alcohol misuse.|Interactive Computer Program (ICP) to prevent alcohol misuse.
3178053|NCT00658398|Sham Comparator|ICP to enhance balanced diet|2. Interactive Computer Program to enhance balanced diet (sham intervention)
3178054|NCT00658450|Experimental|Cognitive rehabilitation training|Children in this arm will the receive the intervention comprising of 16 cognitive rehabilitation training (CRT) exercises for 8 weeks. These exercises will train different cognitive skills including attention, visual spatial processing, logical skills and memory.
3178055|NCT00658450|No Intervention|Treatment as usual|Children in this group will not receive any intervention, they will undergo the usual post discharge treatment for brain injured children at Mulago Hospital (the study site). This is the treatment as usual (TAU) group.
3178056|NCT00658463|Experimental|1|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
3178057|NCT00658463|Placebo Comparator|2|The study is designed with a one-month steady state period with placebo then on a cross-over design with two 6-week periods of placebo or rosuvastatin (20 mg). An in vivo kinetic study will be performed at the end of each 6-week period.
3178058|NCT00658476|Experimental|Omega-3 Fatty Acids|Adolescents receive cognitive behavior therapy in combination with Omega-3 fatty acid supplements.
3178059|NCT00658476|Placebo Comparator|Placebo|Adolescents receive cognitive behavior therapy in combination with placebo.
3178060|NCT00658489|Active Comparator|1|Residents randomized to the promotion of oral health group will receive training consisting of 7 modules (3 on the Bright Futures curriculum and 4 on oral health promotion). They will then enroll 3 patient-child dyads from their practice who present for a well child care visit. Outcomes will be obtained by completing pre- and post-study surveys. Residents will be observed by a faculty preceptor during 3 different patient encounters, and will receive feedback at the end of the 6 month study period.
3178061|NCT00658489|Active Comparator|2|Residents randomized to the prevention of iron deficiency group will complete one web-based module.
3178062|NCT00658502||1|
3178063|NCT00658502||2|
3178064|NCT00658580|Active Comparator|A|Every 3 weeks intravenous cisplatin plus etoposide
3178065|NCT00658580|Experimental|B|Every 3 weeks intravenous epirubicin plus ifosfamide plus etoposide
3178066|NCT00658593|Active Comparator|GEMCAP|Gemcitabine 1000mg/m2 IV days 1 and 8 ever 21 days; Capecitabine 650mg/m2 PO BID days 1-14 every 21 days.
3178067|NCT00658593|Active Comparator|Gemcitabine Alone|Gemcitabine 1000mg/m2 IV days 1, 8 and 15 every 28 days
3178068|NCT00658645|Experimental|Bifeprunox|
3178069|NCT00658645|Placebo Comparator|Placebo|
3178070|NCT00658645|Active Comparator|Quetiapine|
3178071|NCT00658671|Experimental|1|Dose-escalation
3178072|NCT00658671|Experimental|2|Advanced cancer, excluding patients with colorectal or ovarian cancers
3178073|NCT00658671|Experimental|3|Recurrent or resistant epithelial ovarian cancer
3178074|NCT00658671|Experimental|4|Colorectal cancer patients who have progressed and/or failed on irinotecan- and oxaliplatin-based regimens
3178075|NCT00658710|Active Comparator|1|patients who continue physical therapy sessions during two months.
3178076|NCT00658710|No Intervention|2|patients who stop physical therapy sessions during two months
3178077|NCT00658749|Experimental|1|AIR645 (an IL-4/IL-13 dual cytokine signaling inhibitor) solution (diluent: physiologic saline solution)
3178078|NCT00658749|Placebo Comparator|2|Physiologic saline solution
3178079|NCT00658762|Experimental|PD 0332334 225 mg BID|
3178080|NCT00658762|Experimental|PD 0332334 300 mg BID|
3178081|NCT00658762|Active Comparator|Paroxetine 20 mg q am|
3178082|NCT00658762|Placebo Comparator|Placebo BID|
3178083|NCT00658827||Group 1a: Remicade Cohort|Female patients who were exposed to Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3178084|NCT00658827||Group 1b: Remicade Cohort|Infants born to Group 1a patients.
3178085|NCT00658827||Group 2a: Other Anti-TNF agents Cohort|Female patients who were exposed to anti-TNFs other than Remicade at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3178086|NCT00658827||Group 2b: Other Anti-TNF agents Cohort|Infants born to Group 2a patients.
3178087|NCT00658827||Group 3a: Non-biologic Systemic Therapy Control Cohort|Female patients who were exposed to systemic therapy other than biologic agents at any time during pregnancy (and up to 3 months prior to LMP, if this information is available).
3178088|NCT00658827||Group 3b: Non-biologic Systemic Therapy Control Cohort|Infants born to Group 3a patients.
2585879|NCT02327507||Toothpaste & Telephone Support|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions in both English and Spanish will be mailed to the homes of all OHP children and adolescents every three months. Half the populations will be assigned to also receive telephone support.
2585880|NCT02327507||Toothpaste only|A tool kit with toothpaste and toothbrushes for the whole family along with oral hygiene instructions will be mailed every three months
2585920|NCT02327026|Experimental|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative
2585921|NCT02327026|Active Comparator|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management.
2585976|NCT02326675|Active Comparator|Cryotherapy Group (Group A)|Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
2585977|NCT02326675|Active Comparator|Standard Oral Care Group (Group B)|Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
2586023|NCT02326337|Active Comparator|Topical Wound Oxygen Device|"Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.~Other Names:~Topical Wound Oxygen Therapy~TWO2"
2586028|NCT02326337|Placebo Comparator|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
3212568|NCT01016509|No Intervention|control|No hyperglycemia patient group
3178089|NCT00658827||Group 4a: Population Control Cohort|Female patients with no record of the diseases of interest and no exposure to biologic or non-biologic systemic therapy at any time during pregnancy (and up to 3 months prior to LMP, if the information is available).
3178090|NCT00658827||Group 4b: Population Control Cohort|Infants born to Group 4a patients.
3178091|NCT00658840|Experimental|1|"Primary objectives :~To evaluate the tumor response rate, local control rate and compliance (acute and late toxicity, esp. gastrointestinal tract toxicity) of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma~Secondary objectives :~To evaluate the impact of concurrent chemo-radiotherapy with oral capecitabine in patients with unresectable locally advanced pancreatic carcinoma by analyzing the progression-free survival rate and overall survival rate."
3178092|NCT00658853|Active Comparator|1|High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a 5% graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
3178093|NCT00658853|Active Comparator|2|4 times 4 minutes interval training in hyperoxia - 100% oxygen
3178094|NCT00658853|Active Comparator|3|One leg at a time training 4 times 4 minutes interval training using cycling ergometer
3178095|NCT00658905|Active Comparator|rhBSSL|
3178096|NCT00658905|Placebo Comparator|Placebo|
3178097|NCT00658918|Active Comparator|1|Ciclesonide 200µg
3178098|NCT00658918|Active Comparator|2|Ciclesonide 100µg
3178099|NCT00658918|Active Comparator|3|Ciclesonide 25µg
3178100|NCT00658918|Placebo Comparator|4|Placebo
3178101|NCT00658931|Experimental|Treatment|
3178102|NCT00658944||A|Patients suffering from stress or mixed urinary incontinence
3178103|NCT00658957|Experimental|A|Daily standard wound care and topical application of the gentamicin-collagen sponge twice weekly
3178104|NCT00658957|Placebo Comparator|B|Daily standard wound care and topical application of the placebo sponge twice weekly
3178105|NCT00658983|Experimental|1|Autologous Platelet Enriched Gel
3178106|NCT00658983|Active Comparator|2|Metalloproteinase Inhibitor (Promogran)
3178107|NCT00659009|Active Comparator|1|Barometric pressure equivalent to sea level (760 mm Hg).
3178108|NCT00659009|Experimental|2|Barometric pressure equivalent to 6000 feet (609 mm Hg)
3178109|NCT00659009|Experimental|3|Barometric pressure equivalent to 8000 feet (565 mm Hg).
3178110|NCT00659022|Active Comparator|A|immediate surgery of the primary colorectal tumor, no neoadjuvant therapy
3178111|NCT00659022|Experimental|B|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
2585896|NCT02327481|Experimental|3D Laparoscopic Surgery|3D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
2585902|NCT02327481|Active Comparator|2D Laparoscopic Surgery|2D Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
2585987|NCT02326662|Experimental|Paraplegics Acute|Acute [1-6 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
2585998|NCT02326662|Experimental|Paraplegics Sub-chronic|Sub-chronic [6-12 mo.] patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
2586002|NCT02326662|Experimental|Paraplegics Chronic|"Chronic [1- 5 years]) patients (paraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
2586007|NCT02326662|Experimental|Tetraplegics Acute|Acute [1-6 mo.] patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix.
2586010|NCT02326662|Experimental|Tetraplegics Sub-chronic|"sub-chronic [6-12 mo.] patients (tetraplegics) with complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells as needed.~Intervention: Autologous Stem Cell Transplantation with a 3D biomatrix."
2586013|NCT02326662|Experimental|Tetraplegics Chronic|Chronic [1- 5 years]) patients (tetraplegics) with major complete traumatic spinal cord injury that will undergo autologous neural stem cell transplantation including RMx Biomatrix as scaffold for the stem cells Intervention: Autologous Stem Cell Transplantation & Biomatrix
2586066|NCT02326038|Experimental|Ritalin|Methylphenidate, capsule, 20 mg, single oral administration
2586068|NCT02326038|Placebo Comparator|Placebo|Placebo, capsule, single oral administration
3178112|NCT00659022|Experimental|C|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
3178113|NCT00659022|Experimental|D|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
3178114|NCT00659035||IT|Subjects receiving 1-10 mg/day of morphine or its equivalent doses of opioid medications through intrathecal route. Intrathecal medications are administered through a catheter in spinal cord
3178115|NCT00659035||Oral|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone), but not also receiving anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
3178116|NCT00659035||Oral + Anticonvulsant|Subjects receiving oral opioids (morphine, oxycodone, hydrocodone, methadone) and anticonvulsants (gabapentin, pregabalin, topiramate), but not also receiving muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK
3178117|NCT00659035||Control -Pain|Subject not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
3178118|NCT00659035||Control -No Pain|Age-matched volunteers (NO PAIN) not receiving opioid medications, anticonvulsants (gabapentin, pregabalin, topiramate), muscle relaxants, benzodiazepines, or diphenylhydramine for at least a week before testing; low dose antidepressants and/or NSAIDs are OK.
3178119|NCT00659048|Active Comparator|1|Ciclesonide 200µg
3178120|NCT00659048|Placebo Comparator|2|Placebo
3178121|NCT00659074|Experimental|A|Ondansetron ODT
3178122|NCT00659074|Active Comparator|B|Zofran ODT
3178123|NCT00659087|Experimental|Femoral Block|Those receiving femoral block in addition to usual pain management
3178124|NCT00659087|Active Comparator|Usual Care|Those receiving only usual pain management without a femoral block
3178125|NCT00659100|Experimental|A|
3178126|NCT00659152||1: ALI/ARDS|
3178127|NCT00659178|Experimental|SB-485232 plus pegylated liposomal doxorubicin|Subjects will receive one dose of pegylated liposomal doxorubicin on Day 1 plus two doses of SB-485232 on Day 3 and Day 9 in each cycle.
3178128|NCT00659204|Experimental|nano-silver gel|
3178129|NCT00659204|Active Comparator|alcohol-based gel|
3178130|NCT00659217|Experimental|2|mesenchymal stem cell Autologous MSC transplantation
3178131|NCT00659243|Experimental|rhBSSL|
3178132|NCT00659243|Placebo Comparator|Placebo|
3178133|NCT00659282||A|biphasic insulin aspart
3178134|NCT00659321|Active Comparator|1|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
3178135|NCT00659321|Placebo Comparator|2|16 weeks treatment with placebo
3178136|NCT00659347|Active Comparator|1|
2585981|NCT02326428|Experimental|Thrombectomy|Thrombectomy arm consists of patients undergoing thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reasons.
2585982|NCT02326428|Active Comparator|Control|Control arm patients are treated with standard stroke care including IVT but do not receive Thrombectomy. Control arm consists of patients fulfilling criteria for thrombectomy according to accepted critera in the judgement of investigator. Patients may be included even if they are not treated with intravenous thrombolysis because of contraindication or other reason.
3178137|NCT00659347|Placebo Comparator|2|
3178138|NCT00659386|Experimental|A|Patients with chronic idiopathic cardiomyopathy and EMB proven high PVB19 virus load.
3178139|NCT00659412|Experimental|Course A1|
3178140|NCT00659412|Placebo Comparator|Course A2|
3178141|NCT00659412|Experimental|Course B|Open-label extension
3178142|NCT00659451|Experimental|2|Losartan
3178143|NCT00659451|Active Comparator|1|Amlodipine
3178144|NCT00659464||1|Children who present to the heart center exercise stress lab for investigation of syncope
3178145|NCT00659477|Experimental|single arm|
3178146|NCT00659503|Active Comparator|1|Ciclesonide 200µg
3178147|NCT00659503|Placebo Comparator|2|Placebo
3178148|NCT00659516||1|intubated patients
3178149|NCT00659516||2|non intubated patients
3178150|NCT00659542|No Intervention|1|mesh fixation by absorbable sutures
3178151|NCT00659542|Experimental|2|mesh fixation by cyanoacrylate glue
3178152|NCT00659555|Experimental|Treatment A receivers|Subjects received pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution in Period 1
3178153|NCT00659555|Experimental|Treatment B receivers|Subjects received ketoconazole, daily 400 mg oral dose on Days 1 to 8; pazopanib, single dose as 2 x 40 microliter drops of 5 mg/mL solution on Day 5 in Period 2
3178154|NCT00659594|Active Comparator|1|Ciclesonide 200µg
3178155|NCT00659594|Placebo Comparator|2|Placebo
3178156|NCT00659620|Experimental|1|transplantation of mesenchymal stem cell
3178157|NCT00659659|Experimental|1|MEDI-563
3178158|NCT00659659|Experimental|2|MEDI-563
3178159|NCT00659659|Placebo Comparator|4|Placebo
3178160|NCT00659659|Placebo Comparator|5|Placebo
3178161|NCT00659685|Experimental|A|Subjects received Kali formulated products under fasting conditions
3178162|NCT00659685|Active Comparator|B|Subjects received GlaxoSmithKline formulated products under fasting conditions
3178163|NCT00659698|Experimental|1|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
3178164|NCT00659698|No Intervention|2|glucose levels were controlled using a manual injection of insulin according to the commonly used sliding scale
3178165|NCT00659711|Active Comparator|Januvia 100mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
3178166|NCT00659711|Placebo Comparator|placebo|will be placed on a placebo for 12 weeks.
3178167|NCT00659750|Active Comparator|1|Ciclesonide 200µg
3178168|NCT00659750|Placebo Comparator|2|Placebo
3178169|NCT00659763||A|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill the ROM III criteria for IBS
3178170|NCT00659763||B|Patients suspected of irritable bowel syndrome referred from GP´s, who fulfill he ROME III criteria for IBS
3178171|NCT00659776|Active Comparator|1|Subjects with MS or any other inflammatory process
3178172|NCT00659776|Active Comparator|2|Subjects with stroke
3178173|NCT00659776|Active Comparator|3|Subjects receive ferumoxytol before cardiac surgery or CNS vascular surgery
3178174|NCT00659776|Active Comparator|4|Subjects receive ferumoxytol after cardiac surgery or CNS vascular surgery
3178175|NCT00659841|Active Comparator|1|Ciclesonide 200µg
3178176|NCT00659841|Placebo Comparator|2|Placebo
3178177|NCT00659854|Placebo Comparator|Non milk or soy based formula|25 infants , non milk or soy based formula .
3178178|NCT00659854|Active Comparator|2|Intervention with milk based formula will be given to 25 infants.
3178179|NCT00659867|Experimental|A|Chromoscopy-guided endomicroscopy with targeted biopsies
3178180|NCT00659867|Active Comparator|B|Standard endoscopy with random and targeted biopsies
3178181|NCT00659893|Experimental|1|Cohort 1 One 25 cm2 treatment area; on one arm
3178182|NCT00659893|Experimental|2|Cohort 2 One 50cm2 contiguous treatment area; on one arm
3178183|NCT00659893|Experimental|3|Cohort 3 Two 25cm2 treatment areas; one on each arm
3178184|NCT00659893|Experimental|4|Cohort 4 One 25cm2 treatment area; and one 50cm2 contiguous treatment area; one on each arm
3178185|NCT00659893|Experimental|5|Cohort 5 One 75cm2 contiguous treatment area; on one arm
3178186|NCT00659893|Experimental|6|Cohort 6 Two 50cm2 contiguous treatment area; one on each arm
3178187|NCT00659893|Experimental|7|Cohort 7 One 25cm2 treatment area; and one 75cm2 contiguous treatment area; one on each arm
3178188|NCT00659893|Experimental|8|Cohort 8 One 100cm2 contiguous treatment area; on one arm
3178189|NCT00659906|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3178190|NCT00659906|Active Comparator|2|Flexibility training 3 times a week for 12 months
3178191|NCT00659919|Placebo Comparator|Placebo|The patients in this arm received placebo
3178192|NCT00659919|Active Comparator|Trazodone|The patients on this arm received Trazodone for 3 consecutive days
3178193|NCT00659932|Experimental|1|
3178194|NCT00659932|Active Comparator|2|
3178195|NCT00659958|Experimental|1|
3178196|NCT00659971|Experimental|1|PAC113 0,15% mouthrinse
3178197|NCT00659971|Experimental|2|PAC113 0,075% mouthrinse
3178198|NCT00659971|Experimental|3|PAC113 0,0375% mouthrinse
3178199|NCT00659971|Active Comparator|4|Nystatin suspension
3178200|NCT00659997|Active Comparator|1|1 Individuals treated with Albendazole
2585995|NCT02326584|Experimental|Consolidation with SGN-CD33A|High dose cytarabine for consolidation + SGN-CD33A (28-day cycles)
2586001|NCT02326584|Experimental|SGN-CD33A Maintenance|SGN-CD33A Monotherapy (42-day cycles)
2586006|NCT02326584|Experimental|Induction and Consolidation with SGN-CD33A|7+3 (standard dose cytarabine for induction and daunorubicin) + SGN-CD33A and High dose cytarabine for consolidation + SGN-CD33A
3178201|NCT00659997|Active Comparator|2|Individuals treated with Levamisole
3178202|NCT00660036|Experimental|Gemtuzumab ozogamicin/Mitoxantrone/Etoposide|
3178203|NCT00660062|Experimental|Escitalopram 10 mg daily|Escitalopram 10 mg daily
3178204|NCT00660062|Experimental|Escitalopram 20 mg daily|Escitalopram 20 mg daily
3178205|NCT00660062|Experimental|escitalopram 30 mg daily|escitalopram 30 mg daily
3178206|NCT00660062|Active Comparator|Nortriptylin 100 mg daily|Nortriptylin 100 mg daily
3178207|NCT00660088||1|10 gram x 7 days, then 20 gram x 7 days active ingredient of original formulation
3178208|NCT00660088||2|20 grams x 14 days active ingredient of original formulation
3178209|NCT00660088||3|10 grams x 7 days; then 20 grams x 7 days of low protein formulation
3178210|NCT00660088||4|20 grams x 14 days of low protein formulation
3178211|NCT00660088||5|10 grams x 7 days; then 20 grams x 7 days of high protein formulation
3178212|NCT00660088||6|20 grams x 14 days of high protein formulation
3178213|NCT00660101|Experimental|1|5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3178214|NCT00660101|Experimental|2|2.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3178215|NCT00660101|Experimental|3|0.5 million OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells
3178216|NCT00660140|Experimental|Gemcitabine + Carboplatin|"Gemcitabine 1000 mg/m2 IV for 30 minutes on days 1 and 8 of 21 day cycle. Maximum of 9 cycles.~Carboplatin AUC 5 IV for 1 hour on day 1 of 21 day cycle. Maximum of 9 cycles."
3178217|NCT00660153|Experimental|single arm; multiple cohort|Single arm; multiple cohort
3178218|NCT00660166|Experimental|1|
3178219|NCT00660205||operation|Patients with upper gastro intestinal cancer who underwent surgery
3178220|NCT00660205||palliation|Patients with upper gastro intestinal cancer who did not underwent surgery
3178221|NCT00660205||control|Persons with no cancer who accepted to be control with blood samples and flow doppler ultrasound examination of both legs.
3178222|NCT00660231|Experimental|GemBex|Gemcitabine days 1 and 8 of a 3 week cycle (4 cycles total - 12 weeks) Bexarotene daily: in combination with Gemcitabine during first 12 weeks, then Bexarotene maintenance until disease progression.
3178223|NCT00660244||1|
3178224|NCT00660257|Experimental|No.1: 1.25 ug|
3178225|NCT00660257|Experimental|No.2: 2.5 ug|
3178226|NCT00660257|Experimental|No.3: 5.0 ug|
3178227|NCT00660257|Experimental|No. 4: 10 ug|
3178228|NCT00660270|Experimental|Arm 1|"Surgery (pancreaticoduodenectomy, either standard or pylorus-preserving, with either standard or extended lymph node dissection, with or without portal vein resection) should occur at 8 weeks (plus or minus 2, not to exceed 10)~Radiation therapy will occur 8 weeks (plus or minus 2, not to exceed 10) postoperatively. Daily dose of 1.8 Gy five days per week. The first 45 Gy will be given to planning target volume 1. After 45 Gy, portals will be reduced to encompass planning target volume 2. The boost dose will be 5.4 Gy.~Cisplatin IV 25 mg/m2 on days 1, 8, 15, 22, 29, and 36 during radiation.~5-FU CIVI at 175 mg/m2/d on days 1-38 without interruption during radiation.~Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.~Gemcitabine IV 1000 mg/m2 4 weeks after conclusion of radiation (on a 3 weeks on/1 week off schedule) on days 71, 78, 85, 99, 106, and 113."
3178229|NCT00660296|Other|2|Air insufflation in colonoscopy
3178230|NCT00660296|Other|1|CO2 insufflation in colonoscopy
3178231|NCT00660322|No Intervention|Control|Families assigned to the control arm will receive usual asthma care from the child's primary care provider.
3178232|NCT00660322|Experimental|Intervention|The Telephone Asthma Program and usual care.
3178233|NCT00660335|Experimental|1|
3178234|NCT00660361||A|individuals co-infected with HIV-HBV and receiving tenofovir as aprt of their HAART regimen
3178235|NCT00660374|Active Comparator|A|
3178236|NCT00660374|Experimental|B|
3178237|NCT00660413|Experimental|AMG|Acceleromygraphy monitoring
3178238|NCT00660413|Active Comparator|MMG|Mechanomyography monitoring
3178239|NCT00660426|Experimental|Dose Level 1 (starting level)|"Oxaliplatin 85 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3178240|NCT00660426|Experimental|Dose Level 2|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3212569|NCT01016509|Active Comparator|Insulin 1|Conventional insulin treatment
3178241|NCT00660426|Experimental|Dose Level 3|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 800 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3178242|NCT00660426|Experimental|Dose Level 4|"Oxaliplatin 100 mg/m2 IV on days 1 and 15.~Gemcitabine 1000 mg/m2 IV on days 1 and 15.~Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.~Each cycle is 28 days."
3178243|NCT00660439|Experimental|A|Treatment group, receives Narrative Exposure Therapy immediately after first assessment. Patients are assessed 1 and 6 months after treatment.
3178244|NCT00660439|No Intervention|B|Waiting list control group, receives no intervention for 3 months after first assessment. A second assessment is then administered and patients receives Narrative Exposure Therapy. Patients are assessed 1 and 6 months after treatment.
3178245|NCT00660452|Active Comparator|1|360 active patients with house dust mites related asthma with or without allergic rhinitis
3178246|NCT00660452|Placebo Comparator|2|180 patients in the placebo group with house -dust mites related asthma with or without allergic rhinitis.
3178247|NCT00660465||A18|
3178248|NCT00660478|Active Comparator|1|Zotarolimus eluting stent
3178249|NCT00660478|Active Comparator|2|Sirolimus stent
3178250|NCT00660491|No Intervention|1|Control
3178251|NCT00660491|No Intervention|2|moderate exercise training group
3178252|NCT00660491|Experimental|3|high intensity exercise group
3178253|NCT00660569||1|Asthmatic patients with a diagnose of at least 12 months of duration before study inclusion, previously treated with Pulmicort chlorofluorocarbons (CFC) who have changed their treatment to Pulmicort HFA
3178254|NCT00660634|No Intervention|B|
3178255|NCT00660634|Experimental|A|Endovascular angioplasty/stenting
3178256|NCT00660647|Experimental|methotrexate + adalimumab|Methotrexate and intraarticular triamcinolone hexacetonide plus adalimumab.
3178257|NCT00660647|Placebo Comparator|methotrexate + placebo|Methotrexate and intraarticular triamcinolone hexacetonide and placebo
3178258|NCT00660686|Experimental|1|Progressive resistance training program 3 times a week for 12 months
3178259|NCT00660686|Active Comparator|2|Seated flexibility training 3 times a week for 12 months
3178260|NCT00660712||1|Patients with bipolar disorder
3178261|NCT00660725|Other|Vandetanib/GEMOX|All subjects receive the same combination study drug and follow the same study schedule. As a phase 1 study, only the doses will vary between subjects.
3178262|NCT00660738||01|Patients with clinical and spirometric diagnosis of COPD, with FEV1<80%
3178263|NCT00660751|Active Comparator|1|
3178264|NCT00660751|Placebo Comparator|2|
3178265|NCT00660764||1|Patients eligible for the study were patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C ≥ 3.2 mmol/l. Patients were aged ≥ 18 years and ≤ 70 years (men) and ≤ 75 years (women), according to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention. The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation. Patient approved to place anonymous results at the disposal of AstraZeneca
3178266|NCT00660777|Sham Comparator|1|Control Group
3178267|NCT00660777|Active Comparator|2|Therapy Group
3178268|NCT00660803||1|Postmenopausal women with hormone-receptor positive, advanced breast cancer who have failed at least one previous endocrine therapy and who have been treated at any one of the participating centres with fulvestrant.
3178269|NCT00660842|Experimental|A|weekly chemotherapy
3178270|NCT00660842|Active Comparator|B|every 3 weeks chemotherapy
3178271|NCT00660855|Other|Arm 1|
3178272|NCT00660868||1|Patients with posttraumatic, idiopathic, and postinflammatory cause of smell loss; patients age between 18 and 50 years. Odor threshold better than 1.
3178273|NCT00660881|Experimental|EMAB|1200 mg epratuzumab given in 2 doses every other week in 12 week treatment cycles.
3178274|NCT00660894|Experimental|tegafur-gimeracil-oteracil potassium|Patients receive tegafur-gimeracil-oteracil potassium(S-1) orally twice daily for 28 days with a subsequent pause of 14 days. This repeats 4 times every 6 weeks.
3178275|NCT00660894|Active Comparator|tegafur-uracil and folinate calcium|Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days. This repeats 5 times every 5 weeks.
3178276|NCT00660920|Experimental|ponatnib|Comparison of different dosages of ponatinib given orally once per day.
3178277|NCT00660933|Active Comparator|Group A|Group A: Administration of intravenous iron sucrose.
3178278|NCT00660933|Placebo Comparator|Group B|Group B: Administration of intravenous NaCl 0,9%.
3178279|NCT00660946||37 dialysis patients|37 chronic hemodialysis patients on warfarin requiring Laboratory INR monitoring for anticoagulation management.
3178280|NCT00660959|Experimental|Active Comparator|lixivaptan
3178281|NCT00660959|Placebo Comparator|Placebo|placebo
3178282|NCT00660972|Experimental|1|Oral RAL and FTC/TDF for 72 weeks
3178283|NCT00660998|Experimental|Arm 1|
3178284|NCT00660998|Placebo Comparator|Arm 2|
3178285|NCT00661011|Experimental|A|Lobectomy followed by mediastinal concomitant chemoradiotherapy
3178286|NCT00661024|Placebo Comparator|1|RLN visualization alone
3178287|NCT00661024|Experimental|2|IONM of the RLN
3178288|NCT00661063|Experimental|K|drug - ketamine 1% gel
3178289|NCT00661063|Placebo Comparator|P|vehicle gel
3178290|NCT00661063|Experimental|M|association of ketamine and clonidine gel
3178291|NCT00661063|Experimental|C|clonidine gel
3178292|NCT00661076|Experimental|1|
3178293|NCT00661076|Experimental|2|
3178294|NCT00661076|Active Comparator|3|
3178295|NCT00661102|Experimental|1|
3178296|NCT00661102|Active Comparator|2|
3178297|NCT00661102|Placebo Comparator|3|
3178298|NCT00661115|Experimental|Arm 1|
3178299|NCT00661115|Placebo Comparator|Arm 2|
3178300|NCT00661128||1|European American people who have experienced SCA.
3178301|NCT00661128||2|European American people who have not experienced SCA.
3178302|NCT00661128||3|African American people who have experienced SCA.
3178303|NCT00661128||4|African American people who have not experienced SCA.
3178304|NCT00661167|Experimental|1|ABI-007
3178305|NCT00661180|Experimental|Arm 1|
3178306|NCT00661206|Active Comparator|Clopidogrel|
3178307|NCT00661206|Placebo Comparator|Placebo|
3178308|NCT00661219|Active Comparator|Arm 1|
3178309|NCT00661219|Placebo Comparator|Arm 2|
3178310|NCT00661245|Experimental|TOGA|The TOGA procedure is an incision-free treatment using a set of flexible staplers introduced into the mouth and esophagus to create a sleeve in the stomach (transoral formation of a gastric sleeve). The TOGA sleeve limits the amount of food that can be eaten and gives the patient a feeling of fullness after a small meal.
3178311|NCT00661245|Sham Comparator|Control|A gastric sleeve is not formed.
3178312|NCT00661284||Ⅰ|Subject who have participated in previous studies and achieved DAS28 of < 3.2 at the last observation and at least one time point among the two previous assessment time points in a previous studies.
3178313|NCT00661297|Experimental|Arm 1|
3178314|NCT00661297|Placebo Comparator|Arm 2|
3178315|NCT00661310|Experimental|I|Intervention by team consisting of Doctor, pharmacist and nurse
3178316|NCT00661310|No Intervention|C|
3178317|NCT00661323||1|Healthy volunteers will be recruited through the use of an approved study recruitment flyer.
3178318|NCT00661323||2|Chemotherapy patients will be approached at the time of their nuclear scan to rule out cardiac disease prior to chemotherapy. These patients will be referred to the study by their doctor for the assessment of heart function.
3178319|NCT00661349|Active Comparator|1|Nevirapine
3178320|NCT00661349|Experimental|2|Lopinavir/ritonavir
3178321|NCT00661375|Experimental|Arm 1|
3178322|NCT00661440|Other|1|
3178323|NCT00661440|Other|2|
3178324|NCT00661518||1|Patients scheduled for conventional aneurysm repair
3178325|NCT00661518||2|Patients scheduled for endovascular aneurysm repair
3178326|NCT00661596|Experimental|Arm 1|
3178327|NCT00661596|Placebo Comparator|Arm 2|
3178328|NCT00661635|Active Comparator|Arm 1|
3178329|NCT00661635|Active Comparator|Arm 2|
3178330|NCT00661635|Placebo Comparator|Arm 3|
3178331|NCT00661648|No Intervention|1|glucose levels were controlled using sliding scale
3178332|NCT00661648|Experimental|2|received programmed infusions of insulin determined by the control algorithm of the artificial pancreas
3178333|NCT00661700|Placebo Comparator|Arm 2|
3178334|NCT00661700|Experimental|Arm 1|
3178335|NCT00661739|Experimental|Singular Arm|Bendamustine treatment
3178336|NCT00661752||FBP studies|standard filtered backprojection image processing/reconstruction of full-time acquisition data
3178337|NCT00661752||half-time WBR|wide-beam reconstruction of simulated half-time acquisitions from standard full-time acquisitions
3178338|NCT00661752||Quarter-time stress|4 seconds per stop post-stress SPECT acquisitions reconstructed by the wide-beam reconstruction method
3178339|NCT00661752||Quarter-time rest|6 seconds per stop rest SPECT acquisitions reconstructed by the wide-beam reconstruction method
3178340|NCT00661765|Active Comparator|Chantix immediate release tablet formulation|
3178341|NCT00661765|Experimental|Varenicline transdermal delivery system|
3178342|NCT00661791|No Intervention|A|Control Group receives routine care.
3178343|NCT00661791|Experimental|B.|massage group, receives massage only.
3178344|NCT00661791|Experimental|C.|Massage and Exercise group, receives both massage and exercise.
3178345|NCT00661804||Thalassemia cohort|"Thalassemia as documented by clinical diagnosis, including:~thalassemia (intermedia or major); HbH disease; HbH with non-deletional mutations, e.g., HbH Constant Spring E beta-thalassemia; Homozygous alpha-thalassemia (i.e., 4-gene alpha deletion or equivalent null alpha mutation); Other thalassemic conditions not explicitly excluded; Thalassemia intermedia due to heterozygous beta mutation with alpha-gene excess."
3178346|NCT00661804||Successful SCT cohort|Individuals who have received a successful hematopoietic SCT, defined as engraftment of all three cell lines and transfusion independence by 100 days post-transplant, for any of the disorders listed above;Monitored for end-organ injury related to thalassemia prior to their successful SCT;Participants who were enrolled in TCRN Registry or had a successful SCT after 01 Jan 2002.
3178347|NCT00661817|Active Comparator|1|Participants in this group will receive usual medical care and reading materials on weight loss.
3178348|NCT00661817|Experimental|2|Participants in this group will take part in the lifestyle modification program.
3178349|NCT00661843|Experimental|1|Intervention group: Intervention constitutes of 2 supervised yoga classes per week incorporating gentle Yoga postures, relaxation and meditation sequences In addition: daily home based sessions of yogic relaxation and meditation using a pre-recorded audio CD
3178350|NCT00661843|No Intervention|2|Control in waiting to be crossed over after control phase completed. Participants of this group studied using same objective and subjective outcome measures.
3178351|NCT00661856|Active Comparator|1|Soy Protein group 25g of Soy protein with no Isoflavones
3178352|NCT00661856|Experimental|2|Soy Isoflavone group 25g of Soy Protein with 90mg of Isoflavones
3178353|NCT00661856|Placebo Comparator|3|25g of Milk protein
3178354|NCT00661869|Active Comparator|Wellness Group|
3178355|NCT00661908||1|insulin-treated diabetic subjects of North-western part of Switzerland
2586046|NCT02326103|Active Comparator|Ciprofloxacin|Oral administration of Ciprofloxacin 500mg twice daily
2586050|NCT02326103|Placebo Comparator|Placebo|Oral administration of Placebo pill twice daily
3178356|NCT00661921|Active Comparator|40 mg AMG 108 Q2W|
3178357|NCT00661921|Active Comparator|150 mg AMG 108 Q2W|
3178358|NCT00661921|Active Comparator|75 mg AMG 108 Q2W|
3178359|NCT00661921|Placebo Comparator|Placebo Q2W|
3178360|NCT00661934||1|Dialysis Group
3178361|NCT00661934||2|Cardiac Malfunction Group
3178362|NCT00661947||Public|General public. Those who are not currently taking any medication besides birth control pills.
3178363|NCT00661973|Experimental|overall|
3178364|NCT00661986|Experimental|1|dark chocolate 6 g/day
3178365|NCT00661986|Active Comparator|2|dark chocolate 25 g/day
3178366|NCT00662051||OCP Users|
3178367|NCT00662051||Non-users of OCPs|
3178368|NCT00662064||1|Patients with lower urinary tract dysfunction
3178369|NCT00662064||2|Controls with normal lower urinary tract function
3178370|NCT00662077|Experimental|1|Ibandronate + Lifestyle modifications
3178371|NCT00662077|Other|2|Lifestyle modifications
3178372|NCT00662103|Active Comparator|progressive, aerobic exercise program|Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
3178373|NCT00662103|Active Comparator|progressive, resistance exercise program|Patients undergo resistance exercise training 3 days a week for 18 months.
3178374|NCT00662103|Active Comparator|flexibility and relaxation training [control]|Patients perform a series of whole body flexibility (stretching) and relaxation (guided imagery, progressive neuromuscular relaxation, focused breathing) exercises 3 days a week for 18 months.
3178375|NCT00662116|Experimental|1|
3178376|NCT00662116|Placebo Comparator|2|
3178377|NCT00662142|Experimental|1|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
3178378|NCT00662168||observation|Individuals with a diagnosis of carcinoid carcinoma
3178379|NCT00662181||H, NH|HIV positive patients with and without lipodystrophy
3178380|NCT00662194||1|HIV-HBV co-infected and receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
3178381|NCT00662194||2|HIV-HBV co-infected and receiving ART and CD4 count 200-500 cells/mm3
3178382|NCT00662194||3|HIV-HBV co-infected and receiving ART and CD4 count <200cells/mm3
3178383|NCT00662194||4|HIV-HBV co-infected and not receiving ART
3178384|NCT00662194||5|HIV-HCV co-infected & receiving anti-retroviral therapy (ART) and CD4 count > 500cells/mm3
3178385|NCT00662194||6|HIV-HCV co-infected and receiving ART and CD4 count 200-500 cells/mm3
3178386|NCT00662194||7|HIV-HCV co-infected and receiving ART and CD4 count <200cells/mm3
3178387|NCT00662194||8|HIV-HCV co-infected and not receiving ART
3178388|NCT00662220|Active Comparator|Standard dose|Standard-dose ribavirin (12-15 mg/kg/day) in combination with peginterferon 180µg QW
3178389|NCT00662220|Experimental|High dose|High-dose ribavirin (25-29 mg/kg/day) in combination with peginterferon 180µg QW
3178390|NCT00662246|Experimental|1|"Primary objectives :~to determine the recommended dose (i.e., the safest and most effective dose) by evaluating frequency of patients developing unacceptable (grade 3 or higher) acute toxicities attributable to proton beam radiotherapy for HCC."
3178391|NCT00662272|Experimental|1|Arm includes treatment with Fluzone® vaccine mixed with study product JVRS-100 adjuvant
3178392|NCT00662272|Active Comparator|2|Arm includes treatment with half adult dose of Fluzone® vaccine
3178393|NCT00662272|Active Comparator|3|Arm includes treatment with full adult dose Fluzone® vaccine
3178394|NCT00662285|Other|A: Niferex|100 mg Fe++
3178395|NCT00662324||1|Trial experienced cancer patients and their primary caregivers.
3178396|NCT00662324||2|Trial naive cancer patients and their caregivers.
3178397|NCT00662324||3|Health care professionals who are involved in running Phase I, II or III clinical trials.
3178398|NCT00662337|Experimental|1|Diphenydramine HCl
3178399|NCT00662350||Symptomatic Benign Protate Hypertrophy|Symptom Score (IPSS) greater than 15, requiring invasive treatment, Prostate size greater than 25 g, Prostatic urethra length between 2.0 cm and 5.5 cm
3178400|NCT00662376|Experimental|Test|oral nutritional supplement (assignment: according to consecutive random numbers)
3178401|NCT00662376|Placebo Comparator|Control|placebo (assignment: according to consecutive random numbers)
3178402|NCT00662402|Experimental|1-Extensive Consultations|Intervention- Receives extensive consulting services
3178403|NCT00662402|No Intervention|2-Regular levels of service|Control - Receives regular levels of service; one hour free services from each of the 4 units, with option to pay for more.
3178404|NCT00662415|Other|1|12 non-amputee control subjects will be scanned at 0, 2 and 4 weeks but will not recieve mirror therapy.
3178405|NCT00662415|Experimental|2|24 unilateral lower extremity amputee subjects will recieve daily mirror therapy for phantom limb pain and will be scanned at 0, 2, and 4 weeks.
3178406|NCT00662428|Experimental|Intervention|
2586079|NCT02326168|Experimental|non-muscle invasive bladder cancer|"Every patient meeting eligibility criteria will receive a standard WHO adult potency Bacillus Calmette-Guerin (BCG) immunization (1cc/50mg live mycobacilli) in the right or left deltoid. Following a 19 - 31day wait period after BCG vaccination patients will then receive standard strength BCG intravesical therapy returning once a week for 6 consecutive weeks. Cystoscopy will be performed at 3 and 6 months.~Interventions: BCG immunization in deltoid and BCG intravesical therapy once a week for 6 weeks."
3178407|NCT00662428|Active Comparator|Control|
3178408|NCT00662441|Experimental|Arm 1|
3178409|NCT00662454|Active Comparator|I|10 normal weight women (BMI < 25 kg/m2)
3178410|NCT00662454|Active Comparator|II|10 obese women (BMI >30 kg/m2)
3178411|NCT00662467|Active Comparator|1|aspirin and clopidogrel
3178412|NCT00662467|Experimental|2|aspirin, clopidogrel, and warfarin
3178413|NCT00662480|Experimental|1|Invited to screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm
3178414|NCT00662480|No Intervention|2|Participants which are not offered vascular screening
3178415|NCT00662493|Experimental|1|Motor control retraining program
3178416|NCT00662506|Experimental|Treatment (enzyme inhibitor therapy, chemotherapy, IMRT)|See Detailed Description
3178417|NCT00662519|Experimental|Neulasta|Subjects will receive Neulasta subcutaneously every 2 weeks for 12 weeks (6 doses). In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
3178418|NCT00662519|Placebo Comparator|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. In addition, the following test will be done: Mixed Meal Tolerance Test (MMTT), Hemoglobin A1C (HbA1c) blood test, and Human Leukocyte Antigen (HLA) DNA Test.
3178419|NCT00662571||A|"Our hypothesis is that effective acamprosate response in alcohol dependent subjects may be influenced by genetically controlled variation in the functionality of the N-methyl-D-aspartate receptor (NMDA) and/or the type 5 metabotropic glutamate receptor (mGluR5). Hypothesis confirmation could lead to development of effective individualized treatment recommendations for alcohol dependent patients based on pharmacogenomically relevant genetic variations.~There will be no placebo drug given. Just measurement of genetic response."
3178420|NCT00662584|Experimental|1|This was an open-label study - all subjects received the intervention (rTMS treatment)
3178421|NCT00662597|Experimental|ASA404|
3178422|NCT00662597|Placebo Comparator|ASA40 Placebo|
3178423|NCT00662610|Experimental|naproxcinod 375 mg - 750 mg -1125 mg bid|dose escalating
3178424|NCT00662610|Active Comparator|naproxen 250 mg -500 mg -750 mg bid|dose escalating
3178425|NCT00662623|Experimental|1|
3178426|NCT00662623|Active Comparator|2|Usual Care (Standard Care)
3178427|NCT00662636|Experimental|Arm I|Patients receive oral dasatinib and lapatinib ditosylate once daily on days 1-28.
3178428|NCT00662662||Oropharyngeal Cancer|
3178429|NCT00662662||Non-Oropharyngeal Cancer|
3178430|NCT00662688|Active Comparator|chemotherapy|chemotherapy at investigator's discretion
3178431|NCT00662688|Experimental|dalteparin|dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.
3178432|NCT00662701|Active Comparator|1|Catheter RF ablation with complete circumferential ablation around the right and PVs, and additional lines between the lower and upper PVs, and towards the mitral valve ring.
3178433|NCT00662701|Active Comparator|2|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
3178434|NCT00662714|Experimental|1|Repaglinide; oral
3178435|NCT00662714|Active Comparator|2|short-acting Insulin (Actrapid)
3178436|NCT00662727|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
3178437|NCT00662727|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
3178438|NCT00662740|Experimental|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
3178439|NCT00662740|Active Comparator|Tiotropium QD|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
3178440|NCT00662740|Active Comparator|Salmeterol BID|Salmeterol Inhalation Powder, hard PE capsule
3178441|NCT00662740|Active Comparator|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
3178442|NCT00662740|Placebo Comparator|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
3178443|NCT00662753|Active Comparator|home monitoring|home blood pressure monitor
3178444|NCT00662753|Experimental|monitor & phone call|home blood pressure monitor + phone calls
3178445|NCT00662779|Experimental|1|15 mcg arformoterol nebulizer + 1 inhalation of placebo inhalation powder
3178446|NCT00662779|Active Comparator|2|1 inhalation of formoterol fumarate inhalation powder (12 mcg/inhalation) + 2 ml of normal saline nebulizer
3178447|NCT00662779|Placebo Comparator|3|1 inhalation of placebo inhalation powder + 2 ml of normal saline nebulizer
3178448|NCT00662805||Salmeterol/Fluticasone propionate (50/500 μg)|Open label, 6 visits, single arm study
3178449|NCT00662844|Placebo Comparator|A1 vitamin D3 400IU|Orally for one year
3178450|NCT00662844|Placebo Comparator|A2 vitamin D3 800IU|Orally for one year
3178451|NCT00662844|Placebo Comparator|A3 vitamin D3 1600IU|Orally for one year
3178452|NCT00662844|Placebo Comparator|A4 Vitamin D3 2400 IU|Orally for one year
3178453|NCT00662844|Placebo Comparator|Placebo|Placebo for one year
3178454|NCT00662870|Experimental|DAPTACEL Lot 1|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 1
3178455|NCT00662870|Experimental|DAPTACEL Lot 2|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 2
3178456|NCT00662870|Experimental|DAPTACEL Lot 3|Participants receiving Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine (DAPTACEL) Lot 3
3178457|NCT00662870|Active Comparator|Pentacel|Participants receiving Pentacel vaccine
3178458|NCT00662883|Experimental|A|"PMI-150 (intranasal ketamine HCl), day 1~mometasone furoate, days 2-15~PMI-150 (intranasal ketamine HCl), day 15"
3178459|NCT00662896|Experimental|naproxcinod 375 mg bid|
3178460|NCT00662896|Active Comparator|naproxen 250 mg bid|
3178461|NCT00662896|Active Comparator|ibuprofen 600 mg tid|
3178462|NCT00662896|Experimental|naproxcinod 750 mg bid|
3178463|NCT00662896|Active Comparator|naproxen 500 mg bid|
3178464|NCT00662922||1|patients with hypoglycemia during intensive care
3178465|NCT00662922||2|patients without hypoglycemia during intensive care
3178466|NCT00662935|Experimental|2|the sequence of stimulation begins by OFF
3178467|NCT00662935|Experimental|1|the sequence of stimulation begins by ON
3178468|NCT00662948|Experimental|A|Consolidation with one dose of 90Y Ibritumomab tiuxetan (Zevalin®) 0,4 mCi/Kg
3178469|NCT00662948|Active Comparator|B|Maintenance with 375 mg/m2 of Rituximab every 8 weeks during 24 months
3178470|NCT00662961|Experimental|1|Periosteum
3178471|NCT00662961|Experimental|2|Bone
3178472|NCT00662974|Experimental|A|parturients during the second stage of labor massaged by Wheat Germ Oil
3178473|NCT00662974|Experimental|B|parturients during the second stage of labor massaged by almond oil
3178474|NCT00662987|Placebo Comparator|Group B|Received 3 days of amoxicillin followed by 4 days of placebo
3178475|NCT00662987|Active Comparator|Group A|Received 7 days of amoxicillin
3178476|NCT00663000||acromegalics|"Acromegaly in adult subjects either controlled or uncontrolled (Diagnosis should be based on OGTT where Acromegaly is defined as a lack of suppression of GH nadir to < 0.5 ng/dL, after oral administration of 75 g of glucose, OGTT and IGF-I levels at least 10 % above the normal value ± 2 SD).~Written informed consent"
3178477|NCT00663013|Active Comparator|1|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
3178478|NCT00663013|Active Comparator|2|The first treatment session will involve 5-7 minutes of burn wound care while distracted by VR, and 5-7 minutes of burn wound care without the distraction of VR. The second session of burn wound care (performed within the next 3 days) will involve 5-7 minutes of burn wound care without the distraction of VR, and 5-7 minutes of burn wound care with the distraction of VR. The treatment order will be randomized.
3178479|NCT00663052|Experimental|Group A|A
3178480|NCT00663052|Experimental|Group B|B
3178481|NCT00663065|Experimental|arm 1|
3178482|NCT00663078|Experimental|A|Group A: Women from GP practices and area of Knowle West, Bristol
3178483|NCT00663078|Experimental|B|Group B: Women from Wellspring, GP practice or geographical area of Barton Hill Bristol.
3178484|NCT00663091|Experimental|Bacteriophages|
3178485|NCT00663104|Active Comparator|1|exercise (3 sessions/week)
3178486|NCT00663104|Active Comparator|2|"exercise and phytoestrogen (cimicifuga racemosa)"
3178487|NCT00663104|Placebo Comparator|3|wellness control, placebo
3178488|NCT00663130|Experimental|Arm 1|
3178489|NCT00663130|Active Comparator|Arm 2|
3178490|NCT00663143||Stromal Cell Sample|
3178491|NCT00663156|Experimental|subject|10 subjects receiving breast augmentation with fat grafting
3178492|NCT00663156|Other|control|10 control will have breast augmentation using breast implants
3178493|NCT00663182|Experimental|A|Patients with decompensated HBV-related cirrhosis
3178494|NCT00663182|No Intervention|B|Untreated
3178495|NCT00663221|Placebo Comparator|1|
3178496|NCT00663221|Experimental|2|
3178497|NCT00663247|Placebo Comparator|B|placebo used as control for comparison with active drug
3178498|NCT00663247|Active Comparator|A|
3178499|NCT00663273|Experimental|1|Lactic acid in small quantity during 21 days.
3178500|NCT00663286|Experimental|1|
3178501|NCT00663286|Active Comparator|2|
3178502|NCT00663286|Active Comparator|3|
3178503|NCT00663286|Placebo Comparator|4|
3178504|NCT00663299|Other|Trufill Detachable Coil System|There is only one treatment arm in the registry and it is all patients receiving treatment with Trufill Detachable Coil System. The use of bare platinum coils for the endovascular occlusion of cerebral aneurysms.
3178505|NCT00663325|Experimental|1|Lactic acid in small quantity during 21 days
3178506|NCT00663338|Experimental|A|All patients receive placebo or rotigotine at some stage in the trial but the exact point is randomized.
3178507|NCT00663351|Active Comparator|1|Investigational: Reflection Ceramic-Ceramic Hip System. Ceramic femoral head component and the ceramic acetabular cup insert are composed of Biolox forte aluminum oxide material.
3178508|NCT00663351|Active Comparator|2|Control: Reflection FSO V (5 hole). Acetabular shell with a ultra high molecular weight polyethylene insert and an alumina ceramic femoral head with a Synergy or Spectron EF femoral stem. The Synergy femoral stem are composed of implant grade titanium while the Spectron EF stem is composed of implant grade cobalt chrome.
3178509|NCT00663364|Active Comparator|I|Physiogel AI Lotion
3178510|NCT00663364|Active Comparator|II|Physiogel Lotion twice daily
3178511|NCT00663390|Experimental|I|
3178512|NCT00663416|Experimental|1|
3178513|NCT00663416|Placebo Comparator|2|
3178514|NCT00663442|Experimental|1|OROS methylphenidate 18, 36, 54m placebo in randomized order (except never starting with highest dose)
3178515|NCT00663455|Other|A|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
3178516|NCT00663455|No Intervention|B|Standard CSA-dosing without reduction. Therapy control by C2-monitoring.
3178517|NCT00663468||A|
3178518|NCT00663481|Experimental|1|CoFactor
3178519|NCT00663481|Experimental|2|CoFactor
3178520|NCT00663481|Active Comparator|3|Leucovorin
3178521|NCT00663520||1|"Women with chest pain and Clean heart vessels"
3178522|NCT00663520||2|Healthy volunteers
3178523|NCT00663533|No Intervention|Device study only.|
3178524|NCT00663559|Other|1|This study has only one arm with Sunitinib
3178525|NCT00663585|Experimental|1|Structured Intervention Group
3178526|NCT00663585|Active Comparator|2.Comparison group|Unstructured comparison group
3178527|NCT00663598|Experimental|Arm 1|
3178530|NCT00663624|Experimental|Experimental|Subcutaneous aspart insulin every 2 hours
3178531|NCT00663624|Placebo Comparator|Active Comparator|Usual care as prescribed by the ED physicians
3178532|NCT00663650|Active Comparator|1|Permanent Section Control
3178533|NCT00663650|Active Comparator|2|Frozen Section Control
3178534|NCT00663663|Experimental|1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
3178535|NCT00663663|Experimental|2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
3178536|NCT00663689|Experimental|1|non-randomized open-label uncontrolled phase II trial erlotinib 150mg qd until disease progression or unacceptable toxicity
3178537|NCT00663715||1|Pediatric Patients of ages 11-17
3178538|NCT00663728|Experimental|Arm 1|
3178539|NCT00663728|Placebo Comparator|Arm 2|
3178540|NCT00663741|Experimental|Arm 1|
3178541|NCT00663741|Experimental|Arm 2|
3178542|NCT00663741|Experimental|Arm 3|
3178543|NCT00663754|Active Comparator|1|Participants will receive a mailed brochure about body image only.
3178544|NCT00663754|Active Comparator|2|Participants will receive the 4-hour dissonance-based eating disorder prevention program.
3178545|NCT00663754|Experimental|3|Participants will receive the 8-hour dissonance-based eating disorder prevention program.
3178546|NCT00663767|Placebo Comparator|Placebo|
3178547|NCT00663767|Experimental|Placebo, ARRY-371797|
3178548|NCT00663767|Experimental|ARRY-371797, Placebo|
3178549|NCT00663767|Experimental|ARRY-371797|
3178550|NCT00663767|Active Comparator|Celecoxib, Placebo|
3178551|NCT00663767|Experimental|Celecoxib, ARRY-371797|
3178552|NCT00663806|Experimental|Arm 1|
3178553|NCT00663806|Experimental|Arm 2|
3178554|NCT00663832|Experimental|LBH589|
3178555|NCT00663845|Experimental|Arm 1|
3178556|NCT00663845|Placebo Comparator|Arm 2|
3178557|NCT00663884|Experimental|M|Mitiglinide
3178558|NCT00663884|Active Comparator|V|Voglibose
3178559|NCT00663897|Experimental|1|Treatment with lansoprazole (30 mg) once daily for 14 days
3178560|NCT00663897|Active Comparator|2|Treatment with mosapride (5 mg) thrice daily for 14 days
3178561|NCT00663936|Experimental|1|T-817MA once daily
3178562|NCT00663936|Placebo Comparator|2|Placebo once daily
3178563|NCT00663949|Active Comparator|A,1,II|patients in this arm takes 25 mg captopril q8h
3178564|NCT00663949|Active Comparator|A,2,II|
3178565|NCT00663975|Experimental|1|DCI-1020 Capsules contain an enteric-coated buffered microspheres of pancrelipase, encapsulated in clear capsules. Capsules are equivalent to 4,000 USP units of lipase
3178566|NCT00663988|Experimental|III|The effect of human partial facial allotransplantation
3178567|NCT00664001|Placebo Comparator|Control|Placebo tablet
3178568|NCT00664001|Active Comparator|Intervention|Anti-oxidant supplementation
3178569|NCT00664014|Experimental|Tolvaptan|
3178570|NCT00664014|Placebo Comparator|Placebo|
3178571|NCT00664027|Experimental|25 mg|25 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3178572|NCT00664027|Experimental|75 mg|75 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3178573|NCT00664027|Experimental|150 mg|150 mg RTA 402 (Bardoxolone methyl)/Stratum 1
3178574|NCT00664027|Experimental|25/75 mg|25 mg -> 75 mg RTA 402 (Bardoxolone methyl)/Stratum 2
3178575|NCT00664053|Experimental|1|DHEA and Yoga
3212570|NCT01016509|Experimental|Insulin|Intensive insulin treatment
3178576|NCT00664053|Active Comparator|2|DHEA and exercise
3178577|NCT00664053|Active Comparator|3|Placebo and Yoga
3178578|NCT00664053|Placebo Comparator|4|Placebo and exercise
3178579|NCT00664079||1|Patients who are receiving vasoactive medications and/or are mechanically ventilated.
3178580|NCT00664092|No Intervention|1|Usual Aftercare Condition
3178581|NCT00664092|Experimental|2|Oxford House Condition
3178582|NCT00664092|Experimental|3|Therapeutic Community Condition
3178583|NCT00664118|Active Comparator|1|Doula combined epidural analgesia in the latent phase of first stage of labor
3178584|NCT00664118|Sham Comparator|2|Epidural analgesia in the latent phase of the first stage of labor without doula accompany
3178585|NCT00664131||1|
3178586|NCT00664157|Other|2|40 patients with an idiopathic Parkinson's disease and 40 healthy paired volunteers (control group)
3178587|NCT00664170|Experimental|1|ANX-514
3178588|NCT00664170|Active Comparator|2|Taxotere
3178589|NCT00664183|Experimental|1|
3178590|NCT00664183|Experimental|2|
3178591|NCT00664196|Experimental|1|
3178592|NCT00664248|Experimental|1|
3178593|NCT00664248|Active Comparator|2|
3178594|NCT00664248|Active Comparator|3|
3178595|NCT00664248|Placebo Comparator|4|
3178596|NCT00664274|Other|CRT Group|
3178597|NCT00664287|Experimental|Group 1|Patients will remain on existing lipid-modifying therapy throughout the study. Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
3178598|NCT00664287|Placebo Comparator|Group 2|Patients will remain on existing lipid-modifying therapy throughout the study. Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
3178599|NCT00664300||2|One group with Gilles de la Tourette's Syndrome One group with healthy paired volunteers
3178600|NCT00664313|Experimental|1|Linezolid 600 mg po QD
3178601|NCT00664313|Placebo Comparator|2|Placebo
3178602|NCT00664339|Active Comparator|Vaccine|Flu Vaccine
3178603|NCT00664339|Other|Control|Conventional treatment therapy for heart failure
3178604|NCT00664352|Experimental|1|
3178605|NCT00664352|Experimental|2|
3178606|NCT00664352|Experimental|3|
3178607|NCT00664352|Experimental|4|
3178608|NCT00664352|Other|5|
3178609|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 1|Eligible subjects will receive GSK958108 with a starting dose of 1 milligram. The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
3178610|NCT00664365|Experimental|Subjects receiving GSK958108 + placebo in cohort 2|Eligible subjects will start dosing once the cohort 1 has completed the treatment phase and the initial dose will be the same as top dose in Cohort1.The dose escalation will be continued up to 4 ascending doses. Subjects will also receive placebo. Each treatment period will be separated by at least 7 days washout period.
3178611|NCT00664378|Experimental|I|CYT997
3178612|NCT00664391|Experimental|1|
3178613|NCT00664404|Other|fMRI|Functional Magnetic Resonance Imaging (fMRI)
3178614|NCT00664417|Experimental|1|
3178615|NCT00664417|Experimental|2|
3178616|NCT00664417|Experimental|3|
3178617|NCT00664417|Experimental|4|
3178618|NCT00664417|Experimental|5|
3178619|NCT00664417|Experimental|6|
3178620|NCT00664417|Active Comparator|7|
3178621|NCT00664417|Active Comparator|8|
3178622|NCT00664417|Placebo Comparator|9|
3178623|NCT00664443||Dispatch-assisted CPR|Emergency ambulance dispatcher interaction to provide dispatch-assisted CPR instructions in order to determine bystander CPR rates and the impact of instructions on survival to hospital discharge
3178624|NCT00664456|Active Comparator|AHT group|Randomized patients undergo 3-month neoadjuvant therapy (NHT)within 14 days and receive 9-month adjuvant therapy (AHT) following after Iodine I-125 implantation (TPPB).
3178625|NCT00664456|Active Comparator|Non-AHT group|Rondomized patients undergo 3-month neoadjuvant therapy (NHT) within 14 days and receive Iodine I-125 implantation therapy (TPPB). 40 weeks observation is followed under no further treatment.
3178626|NCT00664469|Experimental|EZE+statin|ezetimibe 10 mg per day is added to actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
3178627|NCT00664469|Active Comparator|Stat2|patients on statins has their dose doubled for 6 weeks followed by another 6 weeks in which ezetimibe is added or the statin dose is doubled again.
3178628|NCT00664482|Experimental|1|AGS-006
3178629|NCT00664495|No Intervention|C|Control
3178630|NCT00664495|Active Comparator|DWL|Diet Weight Loss
3178631|NCT00664495|Active Comparator|EWL|Exercise Weight Loss
3178632|NCT00664495|Active Comparator|EWS|Exercise Without Weight Loss
3178633|NCT00664508|Active Comparator|Lateral approach|Lateral approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3178634|NCT00664508|Active Comparator|Anterior approach|Anterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3178635|NCT00664508|Active Comparator|Posterior approach|Posterior approach Intervention: Motion Analysis. Standard AP/Lateral x-rays of the hips, functional assessment questionnaires and 3D joint mechanic assessment at the Biomechanics Laboratory
3178636|NCT00664547|No Intervention|C|
3178637|NCT00664547|Active Comparator|DWL|Diet Weight Loss
3178638|NCT00664547|Active Comparator|EWL|Exercise Weight Loss
3178639|NCT00664547|Active Comparator|EWS|Exercise without weight loss
3178640|NCT00664573|Experimental|Group 2|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3178641|NCT00664573|Experimental|Group 1|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3178642|NCT00664573|Experimental|Group 3|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3178643|NCT00664573|Experimental|Group 4|Drug: BG9924 - dose administered as per Biogen-Idec protocol
3178644|NCT00664586|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) will be administered as an intravenous infusion over 24 hours, weekly. Dose will commence in the first cohort with 100 mg per hour (2400 mg in a 24 hour period)with escalation in the 5 cohorts of 3 to 6 patients with increments of 25 mg per hour to a maximum of 200 mg/hr (4800 mg/24 hour period) or until MTD is defined. When the MTD has been declared, then 11 additional subjects will be enrolled at the MTD dose level (to total 14 subjects treated in dosage cohort).
3178645|NCT00664599|Experimental|1|Rituximab
3178646|NCT00664599|Active Comparator|2|Cytotoxics combination
3178647|NCT00664612|Experimental|1|Air Traq then Macintosh
3178648|NCT00664612|Experimental|2|Macintosh then AirTraq
3178649|NCT00664625|Experimental|1|"BMS-791325 (100 mg)~or~placebo match for (100 mg)"
3178650|NCT00664625|Experimental|2|"BMS-791325 (300 mg)~or~placebo match for (300 mg)"
3178651|NCT00664625|Experimental|3|"BMS-791325 (900 mg)~or~placebo match for (900 mg)"
3178652|NCT00664625|Experimental|4|"BMS-791325 (potential dose between 10-800 mg)~or~placebo match for (10-800 mg)"
3178653|NCT00664664|Experimental|1|APD125 20 mg
3178654|NCT00664664|Experimental|2|APD125 40 mg
3178655|NCT00664664|Placebo Comparator|3|Matching Placebo
3178656|NCT00664677|Experimental|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off).
3178657|NCT00664690|Experimental|1|celebrex
3178658|NCT00664690|Placebo Comparator|2|placebo
3178659|NCT00664703|Experimental|Lobeline 7.5 mg|Sublingual tablet
3178660|NCT00664703|Experimental|Lobeline 15 mg|Sublingual tablet
3178661|NCT00664703|Experimental|Lobeline 30 mg|Sublingual tablet
3178662|NCT00664703|Active Comparator|Methylphenidate HCl 15 mg|Capsule
3178663|NCT00664703|Active Comparator|Methylphenidate HCl 30 mg|Capsule
3178664|NCT00664703|Placebo Comparator|Lobeline 0 mg (placebo)|Sublingual tablet
3178665|NCT00664703|Placebo Comparator|Methylphenidate HCl 0 mg (placebo)|Capsule
3178666|NCT00664716|Placebo Comparator|Placebo|subcutaneous administration of placebo given for 12 weeks
3178667|NCT00664716|Experimental|One Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3178668|NCT00664716|Experimental|Second Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3178669|NCT00664716|Experimental|Third Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3178670|NCT00664716|Experimental|Fourth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3178671|NCT00664716|Experimental|Fifth Dose|BG9924 - dosage level administered as per Biogen Idec protocol
3178672|NCT00664729|Active Comparator|1|Caloric Restriction
3178673|NCT00664729|Experimental|2|Caloric restriction + Moderate-intensity aerobic exercise
3178674|NCT00664729|Experimental|3|Caloric restriction + Vigorous-intensity aerobic exercise
3178675|NCT00664768|Experimental|New Neocate|new Neocate
3178676|NCT00664768|Active Comparator|Neocate Infant|Neocate Infant formula
3178677|NCT00664794|Active Comparator|without acromioplasty|
3178678|NCT00664794|Active Comparator|with acromioplasty|
3178679|NCT00664820|Experimental|Treatment group|Will receive two Urex-CAP-5 (probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14) capsules daily for 3 months.
3178680|NCT00664833|Experimental|Arm 2|
3178681|NCT00664833|Other|Arm 4|
3178682|NCT00664833|Experimental|Arm 3|
3178683|NCT00664833|Experimental|Arm 1|
3178684|NCT00664846|Experimental|1|
3178685|NCT00664846|Active Comparator|2|
3178686|NCT00664872|Experimental|case management|
3178687|NCT00664885|Experimental|CSCT|
3178688|NCT00664898|Experimental|1|
3178689|NCT00664911|Other|Chemotherapy|chemotherapy regimen
3178690|NCT00664937|Placebo Comparator|I|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3178691|NCT00664937|Placebo Comparator|II|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3178692|NCT00664937|Placebo Comparator|III|Three period crossover study, 7 week duration: During periods I-III patients will receive oral medication as a single dose before exercise challenge. For the three periods of this study patients will receive in a randomized sequence one dose of montelukast 10mg and a matching placebo during the other 2 periods.
3178693|NCT00664950|Active Comparator|SHS|sliding hip screw
3178694|NCT00664950|Active Comparator|InterTAn IM Nail|interTAN IM nail
3178695|NCT00664963|Experimental|1|YUKON Sirolimus-eluting Stent
3178696|NCT00664963|Active Comparator|2|YUKON Stent (uncoated)
3178697|NCT00664976|Experimental|1|Electroconvulsive therapy
3178698|NCT00664976|Active Comparator|2|Treatment as usual
3178699|NCT00665028||1|Postoperative myocardial ischemia
3178700|NCT00665041|Experimental|PR1|
3178701|NCT00665041|Placebo Comparator|PL1|
3178702|NCT00665054|Experimental|Arm 1|
3178703|NCT00665054|Placebo Comparator|Arm 2|
3178704|NCT00665093||A|
3178705|NCT00665093||B|
3178706|NCT00665106|Experimental|cohort 1|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
3178707|NCT00665106|Experimental|cohort 2|5 up to 6 patients per arm. Emulsion at 0.8% of drug product.
3178708|NCT00665106|Experimental|cohort 3|5 up to 6 patients per arm. Emulsion at 3.2% of drug product.
3212571|NCT01016522|Experimental|KetoCal|KetoCal tube feeding formula
3178738|NCT00665405||PN|Control - Induced or natural labor under anesthesia
3178739|NCT00665405||PC|Case - Cesarean section under anesthesia
3178740|NCT00665418|Experimental|1|
3178741|NCT00665483|Experimental|1|Skin Prick Test
3178742|NCT00665496|Experimental|Arm 1|
3178743|NCT00665496|Placebo Comparator|Arm 2|
3178744|NCT00665509|Experimental|1|
3178745|NCT00665522||001|fentanyl iontophoretic transdermal system (40mcg) No Placebo 40 mcg per dose maximum of 6 doses/hourtotal maximum 80 doses/24 hours
3178709|NCT00665106|Experimental|cohort 4|5 up to 6 patients per arm. Oily solution at 3.4% of drug product.
3178710|NCT00665119|Experimental|treatment|Any patient alternatively receive both remifentanil and isotonic saline (placebo)infusion. The order of infusion is randomized. An interval of 30 minutes is planned between the two infusions.
3178711|NCT00665145|Experimental|1|Cohort 1
3178712|NCT00665145|Experimental|2|Cohort 2
3178713|NCT00665145|Placebo Comparator|3|Cohort 3
3178714|NCT00665145|Experimental|4|Cohort 4
3178715|NCT00665158|Active Comparator|UC|Usual Care Group
3178716|NCT00665158|Active Comparator|BI|Behavioural Intervention Group
3178717|NCT00665184|Experimental|High force LE resistance training|High force lower extremity resistance training + Standard exercise care. The high force lower extremity resistance training group will participate in a 3 day per week progressive eccentric ergometry program that will be gradually increased over 3 weeks from 5-20 minutes per day and remain at that duration for the next 9 weeks. In addition, they will engage in exercises including moderate intensity aerobic training, concentric upper extremity resistance training and stretching (axial mobility exercises).
3178718|NCT00665184|Active Comparator|Standard Care Control Group|"Standard care exercise group: The standard care control group is an active control group, i.e., individuals who will engage in our standard of care (an evidence based exercise program). These exercises include moderate intensity aerobic training (15 minutes), concentric upper extremity resistance training (5-10 minutes), balance training (5 minutes), and stretching (axial mobility exercises-5-10 minutes)."
3178719|NCT00665197|Active Comparator|Protracted Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 30 Gy in 10 fractions of 3.0 Gy"
3178720|NCT00665197|Experimental|Short Course Radiotherapy|"High Dose Rate brachytherapy 8.0 Gy x 2~External beam radiotherapy 20 Gy in 5 fractions of 4.0 Gy"
3178721|NCT00665223|Experimental|ACR16 - once daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, ACR16 45 mg capsule and one placebo capsule were taken as two separate doses.
3178722|NCT00665223|Experimental|ACR16 - twice daily dose|Participant received ACR16 45 mg once daily for four weeks. Weeks 5-26, an ACR16 45 mg capsule was taken twice daily as two separate doses (total dose: 90 mg).
3178723|NCT00665223|Placebo Comparator|Placebo|Participant received a placebo capsule once daily for four weeks. Weeks 5-26, a placebo capsule was taken twice daily as two separate doses.
3178724|NCT00665236|Experimental|1|Craniosacral therapy administered once a week for an hour by a trained craniosacral therapist.
3178725|NCT00665236|Active Comparator|2|Low-strength static magnets placed around the body for periods of up to an hour once a week.
3178726|NCT00665249|Active Comparator|Full Motivational Interviewing|"This condition consisted of all the standard elements of MI, both the non-directive and directive strategies (Miller & Rollnick, 2002). Rogerian elements, such as warmth, egalitarianism, genuineness, and a client-centered approach to the therapeutic relationship, are commonly referred to as MI Spirit (Moyers, Martin, Manual, Hendricksen, & Miller, 2005). MI is comprised of MI spirit and includes specific directive strategies geared to focus the client toward targeted behavior change, such as confidence and importance rulers, visualization of behavior change, or a decisional balance. The directive elements of MI are those that selectively reinforce positive change talk or enhance discrepancy between a client's wish to change and stay with the status quo."
3178727|NCT00665249|Active Comparator|No Intervention: Self Change|Participants in this condition were not assigned to treatment, but were asked to attempt to change on their own during the 8-week follow-up period. SC participants were told that research had shown that some individuals could reduce their drinking without professional help; that participating in the IVR might facilitate their efforts; and that they would be offered professional treatment at the end of the 8-week period. As noted in the Introduction, SC was selected rather than a traditional wait-list control because the aim of the study was to decompose MI into its 3 hypothesized components that include self-change.
3178728|NCT00665249|Active Comparator|Spirit-Only Motivational Interviewing|While this condition retained the Rogerian elements to MI, directive elements were excluded. For example, SOMI consisted of the non-directive elements including therapist stance (warmth, genuineness, egalitarianism), emphasis on client responsibility to change, extensive use of reflective listening skills (e.g., open-ended questions, simple reflections), and avoidance of MI-inconsistent behaviors (advise, confront, take expert role, interpretation). Reflective listening was focused on the whole experience of the client and the client's affect, and targeting a particular behavior or eliciting change talk about drinking was proscribed. Furthermore, tools utilized frequently in MI to develop discrepancy, such as amplified or double-sided reflections, were proscribed.
3178729|NCT00665262|Experimental|1|comibined use of tramacet and naloxone infusion perioperatively
3178730|NCT00665314|Experimental|AMD3100 added to a G-CSF Mobilisation regimen|AMD3100 added to a G-CSF Mobilisation regimen
3178731|NCT00665314|Active Comparator|G-CSF plus placebo|G-CSF plus placebo
3178732|NCT00665327|Experimental|Arm 1|
3178733|NCT00665327|Active Comparator|Arm 2|
3178734|NCT00665340|Placebo Comparator|Arm 1|
3178735|NCT00665340|Experimental|Arm 2|
3178736|NCT00665379|Active Comparator|1|Regular compression therapy with non elastic trico bandaging
3178737|NCT00665379|Active Comparator|2|New two layer compression bandage coban 2
3178746|NCT00665522||002|IV PCA with standard of care opioid analgesia per 24 hour period
3178747|NCT00665535|Other|2. High Risk|High risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 10-12)
3178748|NCT00665535|Other|1. Moderate Risk|Moderate risk for pressure ulcers according to the Braden Scale for Predicting Pressure Sore Risk (Score 13 and 14)
3178749|NCT00665548||Normal Subjects|Female subjects scoring Kellgren & Lawrence grade 0.
3178750|NCT00665548||OA Subjects|Female subjects with Kellgren & Lawrence score of 2 or 3.
3178751|NCT00665574|Experimental|1|ActaVisc
3178752|NCT00665574|Experimental|2|ActaVisc Mx Intra-articular Injection
3178753|NCT00665574|Placebo Comparator|3|Saline
3178754|NCT00665574|Active Comparator|4|Corticosteroid
3212572|NCT01016535||Children, Health Professionals|
3178755|NCT00665587||A = MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation together with MAZE procedure
3178756|NCT00665587||B = non-MAZE|Patients indicated to a cardiac surgery (bypass, valve repair or combinated surgery)with documented atrial fibrillation in 6 preoperative months undergo the operation (without MAZE procedure).
3178757|NCT00665600|Experimental|1|Levalbuterol 0.63 mg TID
3178758|NCT00665600|Experimental|2|Levalbuterol 1.25 mg TID
3178759|NCT00665600|Active Comparator|3|Racemic Albuterol 2.5 mg TID
3178760|NCT00665600|Placebo Comparator|4|Placebo TID
3178761|NCT00665639|Experimental|1|Daily dose
3178762|NCT00665639|Active Comparator|2|
3178763|NCT00665639|Experimental|3|Every other day dose, alternating with placebo
3178764|NCT00665665|Experimental|A|
3178765|NCT00665665|Experimental|B|
3178766|NCT00665665|Experimental|C|
3178767|NCT00665665|Experimental|D|
3178768|NCT00665678|Experimental|1|paroxetine
3178769|NCT00665678|Placebo Comparator|2|placebo
3178770|NCT00665691||1|
3178771|NCT00665717|Active Comparator|A|Pravastatin 40 mg QD for 4 days
3178772|NCT00665717|Active Comparator|B|Raltegravir 400mg BD for 4 days
3178773|NCT00665717|Experimental|C|Interaction between pravastatin and raltegravir
3178774|NCT00665730|Experimental|Sepraspray|Sepraspray Powder applied on the viscera directly under the midline incision followed by incision closure. Sepraspray dose applied was between 2 g and 4 g per patient.
3178775|NCT00665730|No Intervention|Control|No anti-adhesion treatment used.
3178776|NCT00665743|Experimental|A|PN400 (naproxen/esomeprazole)
3178777|NCT00665743|Active Comparator|B|naproxen 500 mg
3178778|NCT00665743|Active Comparator|C|naproxen 500 mg
3178779|NCT00665756|Active Comparator|1|second trabeculectomy
3178780|NCT00665756|Active Comparator|2|Ahmed silicone drainage device implantation
3178781|NCT00665769|Placebo Comparator|Hypercapnia|Hypercapnic ventilation. The goal will be to maintain transcutaneous CO2 55 mm Hg (50-60 mm Hg) during the first week of life, or until extubation. A written, laminated hypercapnic ventilator algorithm will be placed at the bedside.
3178782|NCT00665769|Active Comparator|Normocapnia|Normocapnic ventilation. The goal will be to maintain transcutaenous CO2 40 mm Hg (35-45 mm Hg) during the first week of life, or until extubation. A written, laminated normocapnic ventilator algorithm will be placed at the bedside.
3178783|NCT00665795||1Patients with Graves´orbitophathy.|Patients with Graves´orbitophathy.
3178784|NCT00665795||2 Patients with detected DON|Patients with Graves´orbitophaty and detected dysthyroid optic neuropathy (DON)
3178785|NCT00665808||A|
3178786|NCT00665808||B|
3178787|NCT00665834|Placebo Comparator|1|Rosuvastatin 20 mg versus placebo 20 mg
3178788|NCT00665834|Active Comparator|2|rosuvastatin 20 mg versus atorvastatin 80 mg
3178789|NCT00665860|Placebo Comparator|1|Placebo
3178790|NCT00665860|Active Comparator|2|
3178791|NCT00665860|Active Comparator|3|
3178792|NCT00665873|Active Comparator|A|Antibiotics
3178793|NCT00665873|Active Comparator|B|No Antibiotics
3178794|NCT00665886|Experimental|1|"Experimental Group (Closed System):~Nexiva® Safety IV Catheter from BD (Becton Dickinson). The catheter has wings, a passive safety feature, an integrated Y extension tubing integrated and needle-less access using a split septum BD QSyte®. In order to completely close the Y connector a second Q-Syte® is added from the moment of catheter insertion"
3178795|NCT00665886|Active Comparator|2|"Control group (Open System):~A 'mounted' system consisting of the Vasocan® Safety catheter of B. Braun Medical, SA. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3, from BD) is added. This comes as one unit (tap and tubing are integrated). When not in use the three-way tap ('stopcock') remains closed using a red cork Luer/Luer-Lock Sollner®, made by Amebil, SA."
3178796|NCT00665899|Experimental|Cancer-Focused Relationship Enhancement|Cancer-Focused Relationship Enhancement
3178797|NCT00665899|Experimental|Couple's Cancer Education|Couple's Cancer Education
3178798|NCT00665899|No Intervention|Usual Care|Cancer-Related Community and Internet Resources
3178799|NCT00665912|Other|1|Standard post-lobectomy wound care plus use of PRP and PPPc in the thoracic cavity.
3178800|NCT00665912|Active Comparator|2|Standard post-lobectomy wound care in the thoracic cavity
3178801|NCT00665938|Active Comparator|1|
3178802|NCT00665938|Experimental|2|
3178803|NCT00665938|Experimental|3|
3178804|NCT00665951|Active Comparator|A|Kaletra tablets
3178805|NCT00665951|Experimental|B|Lopimune granules
3178806|NCT00665951|Experimental|C|Lopimune tablets
3178807|NCT00665964|Experimental|X-3|X-3 polyethylene which is a new highly cross-linked poly that is theorized to be more durable in vivo
3178808|NCT00665964|Active Comparator|N2Vac polethylene|conventional polyethylene
3178809|NCT00665977|Sham Comparator|A|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
3178810|NCT00665977|Active Comparator|Double Blind Treatment Group 2|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
3178811|NCT00665977|Active Comparator|Double Blind Treatment Goup 1|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
3260294|NCT01477996|Active Comparator|Group 2|30-gauge needle
3178812|NCT00665990|Other|Treatment|All participants will receive bevacizumab, sorafenib, and cyclophosphamide until maximum tolerated dose is reached.
3178813|NCT00666016|Experimental|1|TRO19622 500 mg
3178814|NCT00666042|Experimental|A|Vigamox delivered as spray
3178815|NCT00666042|Active Comparator|B|Patients will receive the commercially available Vigamox drops
3178816|NCT00666055||Group 1|30 post-menopausal HIV-infected women
3178817|NCT00666055||Group 2|12 pre-menopausal HIV-infected women
3178818|NCT00666068|Experimental|1|"Patients with hypopituitarism~Cross over design: see interventions 1-2"
3178819|NCT00666068|Placebo Comparator|2|"Parallel design:~Healthy controls to be compared with placebo condition in patients with hypopituitarism"
3178820|NCT00666081|Experimental|Cohort 1|GSK690693 for injection. This is a dose escalation study.
3178821|NCT00666094|Active Comparator|endurance training|supervised endurance training
3178822|NCT00666094|Experimental|strength training|Supervised strength training
3178823|NCT00666120|Active Comparator|1|Cow's milk based infant formula
3178824|NCT00666120|Active Comparator|2|Partially hydrolyzed cow's milk based infant formula
3178825|NCT00666133|No Intervention|2|Women in Group II (standard of care) will receive an 8 mL loading dose containing 4g magnesium sulfate administered manually per standard hospital protocol. The solution will be diluted with normal saline according to standard hospital practice, and given IV over 20 minutes. For women in Group II, the IV loading dose will be followed immediately with 20 mL treatment by IM injection, given as 10 mL (5 g magnesium sulfate) into each buttock. This dose will be followed by 10 mL treatments (5g magnesium sulfate) every four hours, injected into alternate buttock. Treatment will be discontinued when clinically indicated.
3178826|NCT00666133|Experimental|1|Women in Group I (Springfusor® arm) will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4will be administered using the Springfusor® pump. For women in Group I, the administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours for upto 24 hours postpartum.
3178827|NCT00666146||1|Case Families ( Family with a schizophrenia proband)
3178828|NCT00666146||2|Control Families
3178829|NCT00666146||3|Control subjects
3212573|NCT01016548|Experimental|Two doses of vaccine|Second dose is given 21 days after the initial dose. The same dose and route of administration are used.
3212574|NCT01016548|Active Comparator|One dose of vaccine|Given at baseline only.
3212575|NCT01016574|Other|women with stage I or II breast cancer|
3212576|NCT01016587||COPD patients|Not hospitalized COPD patients, degree 2-4.
3212577|NCT01016613||Chronic Kidney Disease Cohort|chronic kidney disease patients with any type of kidney disease
3212578|NCT01016613||Matched Control Group|Healthy controls
3212579|NCT01016613||Trios|First degree relatives of pediatric chronic kidney disease cohort members
3212580|NCT01016626|Experimental|CKD-4101 tablet|
3212581|NCT01016626|Active Comparator|Mycophenolate Mofetil capsule|
3212582|NCT01016639|Experimental|Chemoradiotherapy|
3212583|NCT01016665|Placebo Comparator|Placebo|Placebo
3212584|NCT01016665|Other|Tamoxifen|Tamoxifen 20 mg day 26 days
3212585|NCT01016665|Other|Anastrozole|Anastrozole 1mg 26 days
3212586|NCT01016704|No Intervention|Control|
3212587|NCT01016704|Experimental|Incentive|
3212588|NCT01016717|Active Comparator|Omeprazole|Patients will be taking omeprazole tablets 40 mg QD for 30 days
3212589|NCT01016717|Active Comparator|Pantoprazole|Patients will be taking Pantoprazole tablets 40 mg QD for 30 days
3212590|NCT01016730|Experimental|Treatment (bortezomib)|Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3260295|NCT01478022|Active Comparator|Isosorbide Dinitrate 20 mg|Isosorbide Dinitrate 10 mg b.i.d
3212591|NCT01016743|Active Comparator|Active repetitive transcranial Stimulation|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
3212592|NCT01016782|Experimental|Test|Test product that contains active pharmaceutical ingredient
3260296|NCT01478022|Active Comparator|Ibuprofen 200 mg|Ibuprofen 200 mg daily, capsule
3212593|NCT01016782|Active Comparator|Reference|Reference product that contains active pharmaceutical ingredient
3212594|NCT01016782|Placebo Comparator|Vehicle|Placebo that contains no active pharmaceutical ingredient
3212595|NCT01016795|Active Comparator|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
3212596|NCT01016795|Active Comparator|Cyclophosphamide and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
3212597|NCT01016808|Experimental|Q8003 12 mg/8 mg|Combination
3212598|NCT01016808|Active Comparator|Morphine sulfate 12 mg|Single component
3212599|NCT01016808|Active Comparator|Oxycodone HCl 8 mg|Single component
3212600|NCT01016821|Other|Oxycodone, labour pain|
3212601|NCT01016860|Experimental|OSI-906 and/or irinotecan|Dose Escalation Phase: Treatment for Cycle 1 will commence on Day -3 of a 21-day cycle (3 weeks) when a single dose OSI-906 is given with full pharmacokinetics(PK) sampling at predetermined time points. Irinotecan will be administered intravenously over 90 minutes on Day 1 and Day 8 with full PK sampling on Day 1. The institution of oral dosing of OSI-906 2-4, 8-10, 15-17 (for cycle 1 only) will be given followed by full PK sampling of both drugs on Day 8. Pre-dose samples of OSI-906 will be drawn on Cycle 1 Days 8, 10, 15, 17 and Cycle 2 Days 1, 8, 10, 15 and 17. For Cycle 2 and thereafter, both drugs will be administered starting on Day 1.
3212602|NCT01016886|Experimental|1|
3212603|NCT01016899||Non-melanoma skin cancer|Early stage squamous or basal cell carcinoma
3212604|NCT01016925|No Intervention|Control|
3212605|NCT01016925|Experimental|femoral tunnelized perineural catheter|
3212606|NCT01016951|Experimental|A|AZD9164
3212607|NCT01016951|Placebo Comparator|B|Placebo
3212608|NCT01017068|Experimental|A1 (glaucoma)|
3212609|NCT01017068|Experimental|A2 (glaucoma)|
3212610|NCT01017068|Experimental|A3 (glaucoma)|
3212611|NCT01017068|Experimental|A1 (normals)|
3212612|NCT01017068|Experimental|A2 (normals)|
3212613|NCT01017068|Experimental|A3 (normals)|
3212614|NCT01017081|Active Comparator|Control|Non-mandatory request to maintain lateral positioning to improve air exchange, to cough in order to clear secretion, and to perform diaphragmatic and deep breathing, for five minutes, once a day, during hospital stay.
3212615|NCT01017081|Experimental|Physiotherapy|"Physiotherapy: Children younger than 5 years: Manual Thoracic vibration (TV), thoracic compression (TC), positive expiratory pressure (PEP), and forced exhalation with the glottis open (huffing). Children aged 5 years or older: same procedures in addition to the ventilatory patterns, and a forced expiratory technique (FET), consisting of one or two huffs (forced expirations) followed by a period of relaxed, controlled diaphragmatic breathing, three times per day, for 10 to 12 minutes, during hospital admission."
3212616|NCT01017094|Experimental|dry dressing|local application
3212617|NCT01017107|Experimental|Activated protein C|
3212618|NCT01017133|Other|Arm I|With 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10 minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18 (18F-FDG) PET at 1 hour and 3 hours after injection of 18F-FDG.
3212619|NCT01017159|Active Comparator|Subcutaneous immunoglobulin|
3212620|NCT01017159|Placebo Comparator|Saline|
3212621|NCT01017185|Experimental|Oncolytic virotherapy, intratumoral injection of HF10|
3212622|NCT01017198|Experimental|BIIB021 and Food|The food phase will assess the effect of a high fat meal on the pharmacokinetics of BIIB021.
3212623|NCT01017198|Experimental|BIIB021 and Antacid|Antacid phase will assess the effect of an antacid on the pharmacokinetics of BIIB021.
3212624|NCT01017211|Experimental|auricular acupuncture protocol|
3212625|NCT01017211|Sham Comparator|sham auricular acupuncture|
3212626|NCT01017276|Experimental|ASP group|
3212627|NCT01017289|Experimental|Quantum|In this single arm study, the Quantum nailing system will be used in all patients.
3212628|NCT01017302|Experimental|1|
3212629|NCT01017302|Placebo Comparator|2|
3212630|NCT01017302|Experimental|3|
3212631|NCT01017302|Placebo Comparator|4|
3212632|NCT01017315|Experimental|No application of baby talcum|control
3212633|NCT01017328||surgery with general anesthesia|
3212634|NCT01017341|No Intervention|No hip protector|no hip protector
3212635|NCT01017354|Experimental|High-dose vitamin D3|monthly high-dose vitamin D3 supplement dose (60'000 IU/month, equivalent to 2000 IU daily)
3212636|NCT01017354|Experimental|standard vitamin D + 25(OH)D|standard vitamin D3 supplement dose combined with 25(OH)D (24'000 IU/month, equivalent to 800 IU daily PLUS 300 mcg 25(OH)D, equivalent to 10 mcg per day)
3212637|NCT01017354|Active Comparator|standard vitamin D|standard vitamin D3 supplement dose (24'000 IU/month, equivalent to 800 IU daily)
3212638|NCT01017367|Experimental|MDX-1100|MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
3212639|NCT01017367|Placebo Comparator|Placebo|Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71
3212640|NCT01017380|Experimental|placebo|identical placebo
3212641|NCT01017393|Experimental|ketamine|epidural ketamine added to the patient controlled epidural analgesia regimen
3212642|NCT01017393|Active Comparator|ketamine free|epidural ketamine NOT added to the patient controlled epidural analgesia regimen
3212643|NCT01017406|Experimental|Plantar fascia stretching exercise|Patient perform plantar fascia stretching 3 times per day
3212644|NCT01017419||Audiology counseling|
3212645|NCT01017445|Experimental|Quadricep strengthening exercise|Quadricep strengthening exercise
3212646|NCT01017458|Experimental|1|MK0773 + placebo injection
3212647|NCT01017458|Active Comparator|2|placebo to MK0773 + testosterone injection
3212648|NCT01017458|Placebo Comparator|3|placebo to MK0773 + placebo injection
3212649|NCT01017471|Experimental|control|carpal tunnel release using standard incision
3212650|NCT01017484|Experimental|DASH|The Dietary Approaches to Stop Hypertension Dietary pattern.
3212651|NCT01017484|Experimental|Control|The typical American diet as estimated from the NHANES survey.
3212652|NCT01017523|Experimental|1 (Couples)|Diabetes self-management education, telephone support and behavior change for couples.
3212653|NCT01017523|Active Comparator|2 (Individual)|Diabetes self-management education, telephone support and behavior change for individuals.
3212654|NCT01017523|Placebo Comparator|3 (Control)|Diabetes self-management education only.
3212655|NCT01017562||condition of joint implant|
3212656|NCT01017588|Experimental|back exercise|strengthening back exercise
3212657|NCT01017614|Experimental|Monofer|"administered as intravenous infusions (A1)~administered as intravenous bolus injections (A2)"
3212658|NCT01017614|Active Comparator|Iron Sulphate|tablets administered orally
3212659|NCT01017627|Other|Early anemia management|Upon return to the dialysis unit following hospitalization, patients will be immediately identified and have immediate implementation of the unit anemia protocol rather than waiting for the next regularly scheduled unit labs and regular follow-up. Thus, labs will be obtained within the first 3-7 days following hospitalization and appropriate titration of Epo and iron medications within the 7 days after discharge from hospital and under the direction of the pre-specified algorithm used in the patient's facility; all drug dosing will comply with package insert instructions
3212660|NCT01017627|Other|case control|"Each case will be data-matched to an intra-facility (primary control), and then an inter-facility (validation control) control patient. Matching criteria will be by age, gender, diabetic status, attending nephrologist, length of hospitalization stay, and hospital discharge date (to minimize the difference in the date between the case and control). These patients did not have early intervention but followed the usual practice of waiting for the next regularly scheduled dialysis unit labs with anemia management to follow using the regular unit algorithm."
3212661|NCT01017640|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID in the absence of disease progression or unacceptable toxicity.
3212662|NCT01017640|Experimental|Arm II (veliparib and mitomycin C)|Patients receive veliparib PO BID on days 1-7, 1-14, or 1-21. Patients also receive mitomycin C IV over 10-20 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3212663|NCT01017666|Experimental|Rosiglitazone 8mg PO|Cohort 1
3212664|NCT01017666|Experimental|Midazolam 2mg PO, Warfarin 25mg PO|Cohort 2
3212665|NCT01017679|Experimental|1|Oral Drug gefitinib(Iressa) 500 mg Everyday
3212666|NCT01017679|Active Comparator|2|Oral Drug gefitinib(Iressa) 250 mg Everyday
3212667|NCT01017692||Lumbar Spinal Stenosis|Subjects who have undergone or will undergo an MRI, with symptoms of LSS
3212668|NCT01017757||Renal transplant patients|
3212669|NCT01017770|Experimental|Artemether -lumefantrine|Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso
3212670|NCT01017770|Experimental|Artesunate-amodiaquine|Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso
3212671|NCT01017783|Other|Healthy Choices|
3212672|NCT01017783|Experimental|Diet Substitution A|
3212673|NCT01017783|Experimental|Diet Substitution B|
3212674|NCT01017796|Experimental|A. Experimental|1200mg acetylcysteine and 2g ascorbic acid at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
3212675|NCT01017796|Placebo Comparator|B. Control|200ml 0,9% normal saline IV
3212676|NCT01017809|Other|Oxali/Topotecan|Patients enrolled to NYU 03-67 will be receiving Oxaliplatin 85 mg/m2 IV over 120 minutes on Day 1 and 15 Topotecan 0.4mg/m2/day CIV from D1 to 15 (in addition to the assigned intervention)
3212677|NCT01017835||statin treatment, isolated hypertension|treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
3212678|NCT01017835||placebo treatment, isolated hypertension|treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
3212679|NCT01017848||Adults, nondiabetics|adults who are nondiabetic, no CKD, no urinary tract infection, no bladder dysfunction
3212680|NCT01017861||Pregnant, 12th week|Pregnant women in the 12th week of pregnancy.
3212681|NCT01017861||Pregnant, 28th week|Pregnant women in the 28th week of pregnancy.
3212682|NCT01017861||Pregnant, full term|Pregnant women at full term, in hospital for an elective cesarean section.
3212683|NCT01017861||Non pregnant women|Non pregnant women
3212684|NCT01017887||Airseal port for laparoscopic surgery|Airseal access port for laparoscopic surgery with standard ports.
3212685|NCT01017887||Standard Laparoscopy ports|Uses standard laparoscopy ports.
3212686|NCT01017913|Active Comparator|Electrotherapy equipment|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms with two channels.
3212687|NCT01017913|Active Comparator|electrotherapy equipment|The CI was adjusted with 4000 HZ bases frequency, modulation frequency range 20 HZ, ∆F10 HZ, slope 1/1 and quadripolar manner.
3212688|NCT01017913|No Intervention|Control|The patients of the Control group stayed without any treatment in the same period
3212689|NCT01017926|Active Comparator|Triazolam Reference Arm|There will be a clearance period of at least 3 days between the two phases of the study.
3212690|NCT01017926|Experimental|Triazolam Trial Arm|
3212691|NCT01017939|Experimental|Group A: abiraterone + prednisone + dextromethorphan|Group A will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP2D6 using 2 single doses of dextromethorphan hydrobromide as a probe drug.
3260297|NCT01478022|Experimental|Isosorbide dinitrate and Ibuprofen|Isosorbide dinitrate 20 mg daily and Ibuprofen 200 mg daily
3212692|NCT01017939|Experimental|Group B: abiraterone + prednisone + theophylline|Group B will assess the effect of multiple doses of abiraterone acetate plus prednisone on CYP1A2 using 2 single doses of theophylline as a probe drug.
3212693|NCT01017978|Other|MRI Scan|MRI scan of soft tissue tumor
3212694|NCT01017991|Experimental|Infant formula with probiotic|Infant formula with probiotic for 0 to 12 months of age
3212695|NCT01017991|Placebo Comparator|Standard infant formula|Infant formula for 0 to 12 months of age
3212696|NCT01018017|Active Comparator|2.0g SRT2104|The 2.0g SRT2104 treatment group will be administered eight SRT2104 capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
3212697|NCT01018017|Placebo Comparator|Placebo|The placebo treatment group will be administered eight placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following consumption of a standard morning meal at home (200 cc of Ensure Plus®).
3212698|NCT01018043||001|Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
3212699|NCT01018069|Active Comparator|AEG35156|Patient receive AEG35156 prior to chemotherapy
3212700|NCT01018069|Sham Comparator|Control|Patients receive chemotherapy only
3212701|NCT01018108|Other|I|Patients undergo acupuncture twice weekly for 2 weeks and then once weekly for 6 weeks. Patients undergo single photon emission computed tomography imaging with iodine 123-I ADAM before and after completion of acupuncture.
3212702|NCT01018121|Experimental|Clinic and Home Behavioral Intervention|
3212703|NCT01018121|Active Comparator|Pediatrician Counseling|
3212704|NCT01018147|Experimental|CT Imaging|Patients undergo 4-D, 4-dimensional computed tomography, CT imaging prior to radiotherapy sessions and once a week at the end of treatment.
3212705|NCT01018160||001|
3212706|NCT01018173|Placebo Comparator|placebo|
3212707|NCT01018173|Experimental|taspoglutide|
3212708|NCT01018199|Experimental|Group 1- C-reactive protein (CRP) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating RCP levels
3212709|NCT01018199|Active Comparator|Group 2 - procalcitonin (PCT) guided antibiotic therapy|Intervention on antibiotic therapy will be based on circulating PCT levels
3212710|NCT01018212|Experimental|A|Cicatrix cream
3212711|NCT01018225|Experimental|darifenacin|
3212712|NCT01018225|Placebo Comparator|Sugar Pill|
3212713|NCT01018238|Placebo Comparator|Placebo arm|
3212714|NCT01018238|Experimental|Cohort 1|
3212715|NCT01018238|Experimental|Cohort 2|
3212716|NCT01018238|Experimental|Cohort 3|
3212717|NCT01018238|Experimental|Cohort 4|
3212718|NCT01018251|Experimental|Arm I|Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-[18F] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
3212719|NCT01018290||Navigated TMS examination|20 patients with brain tumor in the vicinity of the central motor region scheduled for elective surgery will undergo pre-operative Navigated TMS examination to determine the localization of primary motor cortex and motor representation areas of specific muscles
3212720|NCT01018303|Experimental|Antioxidant-enriched multivitamin supplement|
3212721|NCT01018329|Experimental|I|Patients undergo multimodality MRI imaging at baseline, weeks 1, 2, 3, 5, and 6 and then 4-6 weeks after completion of radiation therapy.Patients undergo MRI imaging at baseline, weeks 1, 2, 3, 5, 6 and then 6 weeks after radiation therapy.
3212722|NCT01018342|Experimental|1|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
3212723|NCT01018342|Active Comparator|2|Macrobid® Capsules 100 mg
3212724|NCT01018355|Experimental|Device closure of PFO|Device closure of PFO followed by 6 month treatment with clopidogrel 75 mg and 75 - 150 mg of aspirin daily followed by a life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
3212725|NCT01018355|Active Comparator|Medical anticoagulative treatment|Life long treatment with dipyridamol 200 mg twice daily plus 75-150 mg aspirin daily
3212726|NCT01018368|Experimental|VX-770|
3212727|NCT01018368|Experimental|Rifampin|
3212728|NCT01018381|Active Comparator|Conventional Therapy|Conventional therapy is given, including PEIT, TOCE, PEIT + TOCE, TOCE + RFA for hepatocellular carcinoma or Entecavir for hepatitis B virus.
3212729|NCT01018381|Experimental|Conventional Therapy plus MGN-3|
3260298|NCT01478035|Experimental|phenytoin prophylaxis|Patients with suspected or proven pneumococcal meningitis are allocated to receive phenytoin prophylaxis or placebo to avoid seizures during the 10 days of antibiotic therapy starting after the antibiotic therapy
3212730|NCT01018407|Experimental|Discrete Trial Training|Targets nonverbal imitation, match-to-sample, verbal imitation, imitation of play activities, receptive language, and expressive language. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
3212731|NCT01018407|Experimental|Interpersonal Developmental Approach|Targets Joint Attention and Symbolic Play. 5 hours per week of individual instruction for 4 months (Two 30-minute sessions per day, five days per week) with reductions in classroom pull out sessions in months 5 and 6 with implementation of 1 hour per week of in-home parent training for the last 2 months.
3212732|NCT01018433|Experimental|T-SIB|Treatment for self-injurious behaviors; study intervention
3212733|NCT01018433|Other|Treatment as Usual|
3212734|NCT01018446|Experimental|Busulfan, Pharmacokinetic|To develop a method to determine optimal dose of busulfan through pharmacokinetic study in hematopoietic stem cell transplantation.
3212735|NCT01018459|Experimental|Group D: 10^11 vp/mL or placebo|10 subjects will receive 10^11 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3212736|NCT01018459|Experimental|Group A: 10^9 vp/mL or placebo|10 subjects will receive 10^9 viral particles (vp)/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3212737|NCT01018459|Experimental|Group B: 10^10 vp/mL or placebo|10 subjects will receive 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3212738|NCT01018459|Experimental|Group C: 5 x 10^10 vp/mL or placebo|10 subjects will receive 5 x 10^10 vp/mL Ad35.CS.01 and 2 subjects will receive placebo at 0, 1 and 3 months.
3212739|NCT01018472|Experimental|Bifidobacterium infantis|
3212740|NCT01018472|Placebo Comparator|Placebo|
3212741|NCT01018485|Experimental|Botulinum Toxin First Dose|Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A
3212742|NCT01018485|Experimental|Botulinum Toxin Second Dose|20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study
3212743|NCT01018498|Experimental|Restricted FODMAPs diet|Restricted fermentable substrate diet for 1 week
3212744|NCT01018524|Active Comparator|small hernias - suture repair|
3212745|NCT01018524|Active Comparator|small hernias - mesh repair|
3212746|NCT01018524|Active Comparator|large hernias - sublay mesh|
3212747|NCT01018524|Active Comparator|large hernias - onlay mesh|
3212748|NCT01018550|Experimental|AMG 853|
3212749|NCT01018550|Placebo Comparator|Placebo|
3212751|NCT01018576|Experimental|Delayed cord clamping|
3212752|NCT01018589|Experimental|A|Cicatrix cream
3212753|NCT01018602|Active Comparator|vildagliptin|
3212754|NCT01018602|Placebo Comparator|inactive pill without active agent|participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.
3212755|NCT01018615|Experimental|low dose silymarin and low dose EGCG|
3212756|NCT01018615|Experimental|high dose silymarin and low dose EGCG|
3212757|NCT01018628|Active Comparator|Cohort 1 - Dose Level A (25 mg/day)|Cohort 1 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 25 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 25 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3212758|NCT01018628|Active Comparator|Cohort 2 - Dose Level B (75 mg/day)|Cohort 2 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 75 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 75 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3212759|NCT01018628|Active Comparator|Cohort 3 - Dose Level C (250 mg/day)|Cohort 3 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 250 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 250 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3260299|NCT01478035|Placebo Comparator|placebo|placebo vials and pills labeled as phenytoin prophylaxis vials and pills
3260300|NCT01478061|Active Comparator|anastomoses in blood vessels and grafts|
3260301|NCT01478074|Experimental|FLAG + NK Cells + ALT-801|
3212760|NCT01018628|Active Comparator|Cohort 4 - Dose Level D (500 mg/day)|Cohort 4 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 500 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 500 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3212761|NCT01018628|Active Comparator|Cohort 5 - Dose Level E (1000 mg/day)|Cohort 5 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 1000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 1000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3260302|NCT01478126|Experimental|Glutamine|Intravenous glutamine infusion perioperatively and 24 hours after surgery
3260303|NCT01478126|Placebo Comparator|Placebo|
3260304|NCT01478139|Experimental|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
3260305|NCT01478139|Experimental|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
3212762|NCT01018628|Active Comparator|Cohort 6 - Dose Level F (2000 mg/day)|Cohort 6 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 2000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 2000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3212763|NCT01018628|Active Comparator|Cohort 7 - Dose Level G (3000 mg/day)|Cohort 7 will be administered at approximately the same time every dosing day after fasting for 10hrs. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving 3000 mg SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving 3000 mg SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The other cohorts will be dosed sequentially allowing for a comprehensive safety assessment prior to initiation of an escalated dose in a subsequent cohort.
3260306|NCT01478152|Experimental|Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
3260307|NCT01478165|Placebo Comparator|Tiva group (Group T)|
3260308|NCT01478165|Active Comparator|TIVA plus palonosetron group (Group T+P)|
3212764|NCT01018628|Active Comparator|Cohort 8 - Dose Level H (500 mg/day in fed state)|Cohort 8 will be administered at approximately the same time every dosing day and 30 minutes following the start of consumption of a standardized high-fat meal. Two subjects will be dosed on Day 1 of the single dose period with one subject receiving SRT2379 and one subject receiving placebo. The remainder of subjects in this cohort will be dosed on Day 2 of the single dose period with five subjects receiving SRT2379 and one subject receiving placebo, assuming that no significant safety issues arise in the two subjects dosed on Day 1. Subjects will remain on a fixed dose of test material for all dosing days in the study. The dose of SRT2379 administered to subjects in the fed state is planned to be 500 mg, however this may be modified upwards or downwards following evaluation of safety and pharmacokinetic data from earlier cohorts. The fed cohort will be the final cohort dosed in the study.
3212765|NCT01018641|Experimental|1|SA3Ag in both stage 1 and stage 2
3212766|NCT01018641|Experimental|2|SA3Ag in stage 1 followed by placebo in stage 2.
3212767|NCT01018641|Placebo Comparator|3|Placebo in both stage 1 and stage 2
3212768|NCT01018641|Experimental|4|SA3Ag in stage 1 and no vaccine in stage 2.
3212769|NCT01018641|Placebo Comparator|5|Placebo in stage 1 and no vaccine in stage 2.
3212770|NCT01018654|Experimental|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
3212771|NCT01018654|Active Comparator|Standard Cognitive-Behavioral Treatment|Standard Cognitive-Behavioral Treatment for Substance Abuse
3212772|NCT01018667||CRT group|
3212773|NCT01018667||OPT group|
3212774|NCT01018693|Experimental|VAK694 AND Immunotherapy (alutard)|
3212775|NCT01018693|Experimental|: VAK694 placebo AND Immunotherapy (alutard)|
3212776|NCT01018693|Experimental|VAK694 placebo AND Immunotherapy (alutard) placebo|
3212777|NCT01018706||STEMI patients treated with PCI|Four hundred patients with STEMI treated with primary PCI or rescue PCI.
3212778|NCT01018719||Left side breast cancer|
3212779|NCT01018719||Right side breast cancer|
3212780|NCT01018745|Experimental|BMS-907351 (XL184)|
3212781|NCT01018758|Experimental|palonosetron|
3212782|NCT01018771|Experimental|Actifuse ABX|Actifuse ABX bone substitute
3212783|NCT01018771|Active Comparator|INFUSE, plus Mastergraft granules|
3212784|NCT01018784|Experimental|MORAb-009|
3212785|NCT01018797|Experimental|INTRASTROMAL CORNEAL RING SEGMENT|Eighteen eyes of 18 patients, 8 men and 10 women, with high levels (> 5 diopters [D]) of postkeratoplasty astigmatism were studied in a nonrandomized, retrospective, observational case series. PK was performed to treat keratoconus in 15 patients, corneal scar after trauma in 2 patients, and Fuchs endothelial dystrophy in 1 patient.
3212786|NCT01018823|Experimental|Ertugliflozin 1 mg|Ertugliflozin 1 mg, oral, once daily for 14 days
3212787|NCT01018823|Experimental|Ertugliflozin up to 5 mg|Ertugliflozin up to 5 mg, oral, once daily for 14 days
3212788|NCT01018823|Experimental|Ertugliflozin up to 25 mg|Ertugliflozin up to 25 mg, oral, once daily for 14 days
3212789|NCT01018823|Experimental|Ertugliflozin up to 100 mg|Ertugliflozin up to 100 mg, once daily for 14 days
3212790|NCT01018823|Placebo Comparator|Placebo|Placebo to Ertugliflozin once daily for 14 days
3212791|NCT01018836|Experimental|Riluzole; Radiation Therapy|
3212792|NCT01018849|Active Comparator|Vitamin D (cholecalciferol)|Subjects receive 150,000 IU of Vitamin D3 every 2 months
3212793|NCT01018849|Placebo Comparator|Placebo|Subject will receive a placebo - an exact replica of the Vitamin D3 capsule that does not contain the active ingredient, Vitamin D3
3212794|NCT01018875|Experimental|Arm 1, Dose 1, ABT-288|Low Dose
3212795|NCT01018875|Experimental|Arm 2, Dose 2, ABT-288|High dose
3212796|NCT01018875|Active Comparator|donepezil|
3212797|NCT01018875|Placebo Comparator|sugar pill|
3212798|NCT01018888|Experimental|Keratoprosthesis|
3212799|NCT01018901|Experimental|Arm I|Patients and their partners complete surveys. Sexual function of men is assessed by the International Index of Erectile Function; sexual function of women is assessed by the Female Sexual Function Index.
3212800|NCT01018914|Active Comparator|Prograf with Myfortic|
3212801|NCT01018914|Experimental|Advagraf with Myfortic|
3212802|NCT01018927||Additional MRI images|Prospective review of 100 CMR studies performed on multiple myeloma patients referred for cardiac evaluation by MRI. Three additional MRI images will be performed to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
3212803|NCT01018940||Plavix|
3212804|NCT01018940||Prasugrel|
3212805|NCT01018966|Experimental|Ixabepilone|
3212806|NCT01019005|Experimental|Tibial|
3212807|NCT01019005|Experimental|Wound|
3212808|NCT01019005|No Intervention|Sham|
3212809|NCT01019018|Active Comparator|Stevens cannula|Subtenon with stevens cannula
3212810|NCT01019018|Experimental|Olive tip|Olive tip group
3212811|NCT01019044||Rectal mucosa biopsy|Rectal mucosa samples collection
3212812|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh A|
3212813|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh B|
3212814|NCT01019070|Active Comparator|BMS-650032 in Child-Pugh C|
3212815|NCT01019070|Active Comparator|BMS-650032 in Healthy Subjects|
3212816|NCT01019083|Placebo Comparator|zinc supplementation-Placebo|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
3212817|NCT01019083|Placebo Comparator|Anti Parasite Drug- Placebo|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
3212818|NCT01019083|Experimental|Effect of Arsenic in Dukoral- Control|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
3212819|NCT01019083|Experimental|zinc supplementation|Determine if the immunogenicity of oral typhoid can be enhanced in children by introducing zinc supplementation: Our recent studies on the interactions of oral cholera vaccine with breast milk and zinc provide some basis for improving immunogenicity, but additional work is needed to improve many of the oral vaccines. In this study we also plan to evaluate if the immune response to Cholera and Vivotif can be enhanced by supplementation with zinc using methods described earlier. We would like to study children, 2-5 years of age for this purpose.
3212820|NCT01019083|Experimental|administration of antiparasitic drugs|There is a high burden of enteric parasites in the gut of people living in densely populated areas of less developed countries. The effect of concurrent parasitic infestations on immune responses has not been studied widely, although it is an area of utmost importance for natural protection as well as vaccine immuno-prophylaxis. In this study we plan to determine the impact of pretreatment with antiparasitic agents (albendazole and secnidazole) on the immunogenicity of the oral cholera and typhoid vaccines in children, 2-5 years of age
3212821|NCT01019083|Experimental|Effect of arsenic on Dukoral response|In this study, we aim to evaluate if immunogenicity of the oral cholera vaccine is modified in children living in a high arsenic contaminated area in Bangladesh. The plan is to study children 2-5 year old living in Shahrasti thana near Matlab where the tubewell water is highly contaminated with arsenic and this study will not be randomized double-blind, and compare their responses with responses of age matched children living in arsenic free area, such as in Mirpur area of Dhaka city. We only plan to study the effect of Dukoral vaccinees since this vaccine has been widely studied in Bangladesh. If an impact of arsenic is seen on immune response to this vaccine, future studies could be done with other vaccines including Vivotif.
3212822|NCT01019109||Titanium rod|Titanium rods used as a part of PSF construct
3212823|NCT01019109||CoCr Rod|Cobalt Chrome rods used as a part of PSF construct
3212824|NCT01019122||Dexa Scan|Eligible patients from 2003 study will receive a follow-up Dexa scan.
3212825|NCT01019161|Experimental|AZD1152|100 mg Lyophile 5 mL Diluent
3212826|NCT01019161|Experimental|C14 AZD1152|AZD1152 radiolabelled IV solution. 1.05 mg/ml will be presented as a 15 ml fill in a 20 ml vial.
3212827|NCT01019174|Active Comparator|oral application|oral application Cyclophosphamide
3212828|NCT01019174|Active Comparator|intravenous application|intravenous application Cyclophosphamide
3212829|NCT01019187|Placebo Comparator|Arm I|Patients receive oral placebo twice daily for 47 days.
3212830|NCT01019187|Experimental|Arm II|Patients receive oral armodafinil twice daily for 47 days.
3212831|NCT01019187|Experimental|Arm III|Patients receive oral placebo twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia comprising sleep restriction therapy, stimulus control instruction, sleep hygiene guidelines, and a session of cognitive therapy for 7 weeks.
3212832|NCT01019187|Experimental|Arm IV|Patients receive oral armodafinil twice daily for 47 days. Patients undergo cognitive behavioral therapy for insomnia as in Arm III for 7 weeks.
3212833|NCT01019200||Psoriasis|Individuals with a diagnosis of psoriasis as confirmed by the principle investigator will comprise the psoriasis or case group. Participants must meet inclusion and exclusion criteria as defined below. This group will consist of 100 individuals.
3212834|NCT01019200||Control|Individuals without psoriasis, but meeting inclusion and exclusion criteria, will be selected to be within the control group. For each patient with psoriasis within the psoriasis group, an age, sex, and BMI-matched control will be selected. The group will consist of 100 individuals.
3212835|NCT01019213|Placebo Comparator|Septal pacing|Septal lead will be activated.
3212836|NCT01019213|Experimental|His-pacing|His lead will be activated 80 ms before septal lead
3212837|NCT01019226||cardiac MRI|Ischemic cardiomyopathy, non ischemic cardiomyopathy, myocarditis, cardiomyopathy
3212838|NCT01019239|Experimental|Laparoscopic Washout|Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed. Intravenous antibiotics will be continued for a minimum of 72hours and oral antibiotics will be continued for one week. Oral fluids will be commenced on the first postoperative day and diet will be introduced subsequently, depending on clinical status. Early mobilisation will be encouraged.
3260309|NCT01478178|Experimental|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
3212839|NCT01019239|Active Comparator|Conventional Treatment|Operative procedure will be similar to that previously described.Patients randomised to the second arm will undergo standard management (according to local preference) which will consist of Hartmanns Procedure or Primary resection of the diseased segment and anastomosis. Post operative care will be standardised between arms as described in the protocol
3212840|NCT01019265|Experimental|Norspan patch (Buprenorphine TDS)|
3212841|NCT01019265|Active Comparator|TramadolSR tab (Tridol SR tab)|
3212842|NCT01019278|Experimental|Arm I|Patients undergo external proton beam radiotherapy once daily, 5 times per week, for up to 9 weeks. Patients also receive cisplatin IV once weekly for 6 weeks during radiotherapy.
3212843|NCT01019291|Experimental|NO2|NO2 400 µg/m3
3212844|NCT01019291|Experimental|Formaldehyde|Formaldehyde 100 µg/m3
3212845|NCT01019291|Experimental|NO2 + Formaldehyde|mixture of Formaldehyde and NO2
3212846|NCT01019291|Placebo Comparator|Placebo|
3212847|NCT01019330||Femoral|Subjects receiving femoral artery cardiac catheterization
3212848|NCT01019330||Radial|Subjects receiving radial artery cardiac catheterization
3212851|NCT01019356|Experimental|Rosiglitazone|Lean and obese PCOS women
3212852|NCT01019356|Active Comparator|Acarbose|Obese PCOS women
3212853|NCT01019356|No Intervention|Control|Obese and lean healthy women evaluated only at baseline
3212854|NCT01019382|Experimental|All patients|All patients entering the trial
3212855|NCT01019395|Experimental|Group 1|Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion.
3212856|NCT01019395|Experimental|Group 2|Group 2: Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion
3212857|NCT01019395|Experimental|Group 3|Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
3212858|NCT01019408|Active Comparator|CQ25|Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.
3212859|NCT01019408|Active Comparator|CQ40|Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.
3212860|NCT01019421|Experimental|Lu AE58054|
3212861|NCT01019421|Placebo Comparator|Placebo|
3212862|NCT01019434|Other|Temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
3212863|NCT01019434|Experimental|Temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
3212864|NCT01019447|Active Comparator|Study group|The study group in which Triclosan-coated polyglactin 910 antimicrobial sutures will be used.
3212865|NCT01019447|Active Comparator|Control group|The control group in which polyglactin 910 antimicrobial sutures will be used.
3212866|NCT01019473|Experimental|AFQ056A|
3212867|NCT01019473|Placebo Comparator|Placebo|
3212868|NCT01019499|Active Comparator|berry products|Berry products
3212869|NCT01019499|Placebo Comparator|control products|Control products
3212870|NCT01019512|Active Comparator|Arm I|Patients undergo complex decongestive therapy comprising daily compression garment (sleeve and glove) use, daily manual lymphatic drainage (self-administerd), and nighttime bandaging with low stretch Comprilan bandages.
3212871|NCT01019512|Experimental|Arm II|Patients undergo daily compression with garments (sleeve and glove), nighttime bandaging with low stretch Comprilan bandages, and daily Flexitouch treatment over 1 hour every evening.
3212872|NCT01019512|Experimental|Arm III|Patients undergo daily compression with garments (sleeve and glove) and daily Flexitouch treatment over 1 hour every evening.
3212873|NCT01019525||Mouth Breathing|Children aged between 8-12 years, with clinical diagnosis of mouth breathing
3212874|NCT01019525||Nasal Breathing|Children aged between 8-12 years old, with normal breathing
3212875|NCT01019551|Experimental|ARM A : ART intensification alone|Raltegravir PO 400 mg BID Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen
3260310|NCT01478230|Experimental|N1/3-I5|5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits
3212876|NCT01019551|Experimental|ARM B : ART intensification + Immunomodulation|Raltegravir PO 400 mg BID during 56 weeks Maraviroc PO 150, 300 or 600 mg BID depending on the concomitant ART regimen during 56 weeks 3 weekly injections of r-hIL-7 (CYT107) at a 20 micrograms/kg dose starting at Week 8
3212877|NCT01019564|Experimental|Easy Rub MPS|Complete Easy Rub Formula MPS
3212878|NCT01019564|Active Comparator|Aquify MPS|
3212879|NCT01019577|Experimental|Ixabepilone|
3212880|NCT01019590|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
3212881|NCT01019590|Active Comparator|2|Benicar HCT ® Tablets 40 mg/25 mg
3212882|NCT01019603|Experimental|1|Tazarotene foam 0.1%
3212883|NCT01019603|Active Comparator|2|Tazaroc Gel 0.1%
3212884|NCT01019642|Experimental|Vitamin D|Cholecalciferol, 4,000 IU/d for 6 months
3212885|NCT01019642|Placebo Comparator|Placebo|placebo
3212886|NCT01019655|Experimental|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
3212887|NCT01019655|No Intervention|Control|No intervention other than usual care at the study site
3212888|NCT01019668|Active Comparator|verteporfin PDT, half-dose|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
3212889|NCT01019668|Active Comparator|verteporfin PDT, half-fluence|use different modification of verteporfin PDT to treat prolonged unresolved central serous chorioretinopathy
3212890|NCT01019681|Experimental|UBC injection into one leg of PVD pt|25 participants with severe peripheral vascular disease in leg(s) and they do not qualify for surgical treatment.
3212891|NCT01019733|Experimental|Patients|Children whom will receive intrathecal autologous stem cells
3212892|NCT01019746|Experimental|control propofol administration|
3212893|NCT01019759|No Intervention|No add-on AF-surgery|patient undergoing only scheduled valve and/or coronary bypass surgery
3212894|NCT01019759|Experimental|PV isolation|patient undergoing add-on epicardial microwave energy pulmonary vein isolation
3212895|NCT01019772|Experimental|LBVH0101|
3212896|NCT01019772|Active Comparator|Hiberix|
3212897|NCT01019785|Active Comparator|High dose Vitamin D|
3212898|NCT01019785|Sham Comparator|Low dose Vitamin D|
3212899|NCT01019798|Experimental|open label|
3212900|NCT01019824|Experimental|Low Dose|160 mg dose
3212901|NCT01019824|Experimental|High Dose|320 mg dose
3212902|NCT01019824|Placebo Comparator|Placebo|Placebo Comparator
3212903|NCT01019837|Experimental|Monovalent MF59- Adjuvanted vaccine|Focetria (Monovalent MF59-Adjuvanted vaccine) 7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate Intra muscular
3260311|NCT01478230|Active Comparator|NX-I10|10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.
3260312|NCT01478269||Cases of aggressive B-cell lymphoma|Cases of aggressive B-cell lymphoma diagnosed between 2001 to 2007 in Italy
3260313|NCT01478282|Active Comparator|Rivaroxaban|Healthy donors subjected to 20mg/day for 5 days
3260314|NCT01478282|Active Comparator|Dabigatran|Healthy volunteers subjected to 150 mg/12hours for 5 days
3212904|NCT01019850|Other|Treatment for All Patients|Patients on study will receive vorinostat orally once daily on days 1 to 14. The starting dose level is 180 mg/M2. The maximum dose is 400 mg. Patients will receive 131- I Metaiodobenzylguanidine on day 3, 1hr after vorinostat dosing. Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg. Peripheral Blood Stem Cell Infusion is planned for 2 weeks after MIBG infusion (day 17). The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing. Patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines.
3212905|NCT01019863|Experimental|Oxaliplatin|oxaliplatin associated with Rituxan,Gemcitabine, and Dexamethasone in patients with refractory or relapsed Non hodgkinien lymphoma
3212906|NCT01019876|Experimental|Fludarabine|
3212907|NCT01019876|Experimental|Cyclohosphamide 200|
3212908|NCT01019876|Experimental|Cyclophosphamide 40|
3212909|NCT01019876|Experimental|Cyclophosphamide 30|
3212910|NCT01019889|Experimental|Placebo|Placebo (encapsulated starch + lactose)
3212911|NCT01019889|Experimental|SCRT(Socheongryong-tang )|encapsulated Socheongryong-tang extract
3212912|NCT01019889|Experimental|YPS (Yeongyopaedok-san)|Encapsulated Yeongyopaedok-san extract
3212913|NCT01019915|Other|Heart failure patients. Intervention CRT|CRT implantation in heart failure. Effect of intervention after 6 months of treatment.
3212914|NCT01019941|Other|1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.|
3212915|NCT01019941|Other|1st cycle:Taxotere inj.-> 2nd cycle:CKD-810|
3212916|NCT01019993|Active Comparator|good pulmonary functions (group N)|The patients were allocated if they have forced vital capacity (FVC %) and/or forced expiratory volume in 1 sec (FEV1%) of 80% of predicted or more
3212917|NCT01019993|Active Comparator|pulmonary dysfunction (group PD)|The patients were allocated if they have FVC and/or FEV1 of 50%-79% of predicted
3212918|NCT01020032|Experimental|Music therapy|"Individual receptive music therapy by U sequence method"
3212919|NCT01020045||HIV-seropositive, HIV seronegative|No intervention - biologic samples were collected from both HIV positive and HIV negative subjects
3212920|NCT01020045||Treatment naive subjects|HIV-seropositive subjects naive to antiretroviral therapy. HIV-seronegative subjects otherwise healthy.
3212921|NCT01020058|Active Comparator|Lichtenstein in local anesthesia (LLA)|Patient operated in local anesthesia, with an anterior mesh repair according to Lichtenstein
3212922|NCT01020058|Active Comparator|TEP|Patient receives a totally extraperitoneal laparoscopic repair
3212923|NCT01020071|Other|laser treatment|laser peripheral iridotomy and laser peripheral iridoplasty
3212924|NCT01020084||Control|Subjects with normal salivary flow rate
3212925|NCT01020084||Hyposalivation|Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy.
3212926|NCT01020097|Other|Arm I|Patients undergo fluorine F-18 EF5 positron emission tomography imaging. Scana are performed 180 minutes following injection.
3212927|NCT01020136|Experimental|Sequence 1 (BABA)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: B -> A -> B -> A
3212928|NCT01020136|Experimental|Sequence 2 (ABAB)|Treatment A: 5-mg Form IV tablet; Treatment B: 5-mg Form XLI tablets Subjects in this sequence will participate in 4 periods in the following order: A -> B-> A -> B
3212929|NCT01020162|Active Comparator|Non-surgical|TENS, amitriptyline, gabapentin.
3212930|NCT01020162|Active Comparator|Surgical intervention|Resection of the ilioinguinal nerve
3212931|NCT01020175|Other|Bone marrow transplantation|Patients received bone marrow transplantation
3212932|NCT01020175|Other|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
3212933|NCT01020201||PONV group|patients with postoperative nausea and vomiting
3212934|NCT01020201||Control group|patients without postoperative nausea and vomiting
3212935|NCT01020214|Experimental|1|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg
3212936|NCT01020214|Active Comparator|2|Benicar HCT® Tablets 40 mg/25 mg
3212937|NCT01020227|Experimental|Integrative Therapies|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
3212938|NCT01020227|No Intervention|Standard Care|Patients were given no intervention but were contacted at 6 weeks and 6 months for data collection purposes
3212939|NCT01020240|No Intervention|Avaliation|This group will have 15 women in puerperium and will be realize an interview to avalide the cesarean discomforts in immediate puerperium. These dates will be use for elaborate the orientations guide.
3212940|NCT01020240|No Intervention|Orientation|In this group will be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory and in the second post operatory wil be realize a new interview.
3212941|NCT01020240|Experimental|Guide|in This group wiil be realize an interview to avalide the cesarean discomforts in immediate puerperium or in the first post operatory, will be realize the orientations and the guide will be give, and in the second post operatory will be realize a new interview.
3212942|NCT01020253|Active Comparator|Alendronate medication|
3212943|NCT01020253|Active Comparator|Alfacalcidol medication|
3212944|NCT01020253|No Intervention|Non-medication|
3212945|NCT01020266|Active Comparator|Electroacupuncture|
3212946|NCT01020266|Sham Comparator|Control|
3212947|NCT01020279|Other|Parallel Group A|Celecoxib 200 mg (Active Comparator) ; Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
3212948|NCT01020279|Other|Parallel Group B|oral Placebo (Placebo Comparator); Ketoprofen in Transfersome® Gel (Experimental); Placebo Gel (Placebo Drug)
3212949|NCT01020292|Experimental|NFV and Concurrent ChemoRads|
3212950|NCT01020331|Experimental|ACTIVE|
3212951|NCT01020344|Active Comparator|Lung volume reduction surgery|This group will receive lung volume reduction surgery
3212952|NCT01020344|No Intervention|No lung volume reduction surgery|This group will not receive LVRS during the 3 months of the study
3212953|NCT01020357|Active Comparator|caffeine|
3212954|NCT01020357|Placebo Comparator|placebo|
3212955|NCT01020370||Alemtuzumab Group|
3212956|NCT01020370||Interferon Beta-1a SC Group|
3212957|NCT01020383|Experimental|ALX-0081|
3212958|NCT01020383|Active Comparator|GPIIb/IIIa inhibitor|
3212959|NCT01020396|Experimental|1|Metronidazole Vaginal Gel, 0.75% (Teva Pharmaceuticals, USA)
3212960|NCT01020396|Active Comparator|2|MetroGel-Vaginal® metronidazole vaginal gel, 0.75% (3M Pharmaceuticals)
3212961|NCT01020409||cardiac surgery with CPB use|Adult patients, who signed the informed consent, intervention: first-time scheduled heart surgery with CPB use.
3212962|NCT01020422|No Intervention|Breast hypertrophy|Patients with macromastia will be evaluated in regard to sexual function and depression predictors at 3 moments: initial interview, after 3 months and after 6 months
3212963|NCT01020422|Experimental|Reduction Mammaplasty|Breast hypertrophy patients randomized to this group will immediately be scheduled for reduction mammaplasty and will be will be evaluated in regard to sexual function and depression predictors preoperatively and 3 and 6 months postoperatively
3212964|NCT01020461|Experimental|Venous blood sampling|To use Accuvein to improve the effectiveness of venous blood sampling
3212965|NCT01020461|Experimental|Peripheral IV catheter placement|To use Accuvein to improve the effectiveness of placing peripheral IV catheter
3212966|NCT01020539|Experimental|Matched Family Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from a related family donor using bone marrow or cord blood stem cells. Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression. Graft-versus-host-disease (GVHD) prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
3212967|NCT01020539|Experimental|Unrelated Donor|"Patients will receive a reduced intensity fludarabine (6 days)/busulfan (2 days) conditioning regimen followed by a stem cell transplant from an unrelated donor using matched bone marrow or cord blood stem cells.Then followed by Gemtuzumab Ozogamicin, once at about 2-6 months post alloSCT and once at least 2 months after the first dose. Patients with JMML will also receive cis-retinoic acid (Isotretinoin).~During and following transplantation patients will receive methylprednisolone for immune suppression and unrelated donor transplant recipients will additionally receive Anti-Thymocyte Globulin. GVHD prophylaxis will consist of tacrolimus, mycophenolate mofetil and additionally methotrexate in recipients of unrelated adult transplants."
3212968|NCT01020565|Experimental|Entecavir (0.1 mg)|
3212969|NCT01020565|Experimental|Entecavir (0.5 mg)|
3212970|NCT01020578||Impaired glucose tolerance|Patients diagnosed with impaired glucose tolerance
3212971|NCT01020578||Control|Patients with normal blood glucose
3212972|NCT01020630|Experimental|Sunitinib|25 mg (2 capsules of 12.5 mg) for oral administration
3212973|NCT01020630|Placebo Comparator|Placebo|2 capsules for oral administration
3212974|NCT01020643|Experimental|controlled sedation using propofol|
3212975|NCT01020656||group 1|patients with no anticoagulants used as the control group
3212976|NCT01020656||group 2|patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
3212977|NCT01020656||group 3|patients treated with aspirin
3212978|NCT01020656||group 4|patients treated with clopidogrel therapy
3212979|NCT01020656||group 5|patients treated with both anticoagulant and aspirin medications
3212980|NCT01020656||group 6|patients treated with both anticoagulant and clopidogrel medications
3212981|NCT01020656||group 7|patients treated with both aspirin and clopidogrel medications
3212982|NCT01020695||PTSD veterans|18 PTSD veterans
3212983|NCT01020695||controls|20 controls
3212984|NCT01020708|Active Comparator|Comparator|Mesalamine enema
3212985|NCT01020708|Experimental|ALTH12-1:4|ALTH12-1:4 experimental treatment dose
3212986|NCT01020708|Experimental|ALTH12-2:4|ALTH12-2:4 experimental treatment dose
3212987|NCT01020721||Glaucoma|South korean patients with primary congenital glaucoma
3212988|NCT01020734|Experimental|transplantation|perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
3212989|NCT01020760|No Intervention|No posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to avoid supine posturing for seven days after surgery, but will not be advised to posture in the face down or prone position.
3212990|NCT01020760|Experimental|Face down posture|Patients will undergo routine phacoemulsification, pars plana vitrectomy, ILM peel and gas fluid exchange with 14% C3F8. They will be advised to posture in the face down or prone position for 50 minutes per hour for seven days.
3212991|NCT01020825||ASCs|Patients randomized to experimental treatment (ASC transplantation) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3212992|NCT01020825||Fibrin glue|Patients randomized to the control treatment (application of fibrin glue) in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3212993|NCT01020825||ASCs + Fibrin Glue|Patients randomized to the control treatment (application of fibrin glue) + intralesional injection of ASCs in the FATT-1 randomized controlled trial [ClinicalTrials.gov identifier: NTC00475410]
3212994|NCT01020851|Experimental|tailored intervention|Participants in this arm will receive 6 monthly telephone calls of a behaviorally tailored intervention based on the transtheoretical model.
3212995|NCT01020851|Active Comparator|attention placebo|Participants in this arm will receive 6 monthly telephone delivered counseling sessions about general health topics
3212996|NCT01020864|Experimental|Chemotherapy|"Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.~Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment."
3212997|NCT01020916|Experimental|Target Temperature 33°C|
3212998|NCT01020916|Active Comparator|Target Temperature 36°C|
3212999|NCT01020942|Experimental|Pretreatment|
3213000|NCT01020942|No Intervention|Control|
3213001|NCT01020955|Active Comparator|NutropinAq and Increlex|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and Increlex (15 µg/kg/day for 1 month and 30 µg/kg/day for 5 months).
3213002|NCT01020955|Placebo Comparator|NutropinAq and placebo|NutropinAq (0.15 mg/day for 1 month, 0.3 mg/day for 5 months) and placebo for 6 months.
3213003|NCT01020968|Experimental|Ixmyelocel-T|The treatment arm of the study will receive catheter-based injections of the study cellular product.
3213004|NCT01020968|Placebo Comparator|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control.
3213005|NCT01020994|Experimental|LAS41003|
3213006|NCT01020994|Active Comparator|LAS189962|
3213007|NCT01020994|Active Comparator|LAS189961|
3213008|NCT01021046|Experimental|GCCT,corneal allograft survival ,DALK|experimental group: deep anterior lamellar keratoplasty using glycerin-cryopreserved corneal tissue
3213009|NCT01021046|Experimental|FCT,corneal allograft survival ,DALK|control group: deep anterior lamellar keratoplasty using fresh corneal tissue
3213010|NCT01021059|Experimental|1|rh IL-15 daily for 12 days of 42 days cycle.
3213011|NCT01021072|Experimental|MTD|The study will utilize a standard 3+3 design for dose escalation. Once the maximum tolerated dose has been reached, an expansion cohort, as well as tumor specific expansion cohorts will be explored.
3213012|NCT01021085||Pregnant women|Pregnant women who have conceived via ART and are between days 36 and 56 of gestation
3213013|NCT01021098||Natural History Study|The core Natural History Study of ILI is an observational, longitudinal cohort study using data from clinical findings, medical chart review, and diagnostic, virologic and immunologic laboratories to describe the epidemiology and immunology of ILI. This study aims to describe the clinical history of influenza and other viral respiratory pathogens in a population of US military active duty members and their dependents. The primary focus will be the etiology, natural history and immunology of ILI in otherwise healthy adults and children. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
3213014|NCT01021098||HIV-Positive Cohort|In addition, given a number of human immunodeficiency virus (HIV)-infected subjects who serve in the active duty force, we will also examine a subset of HIV-positive military beneficiaries as part of this consortium. An additional objective of the study will be to descriptively examine the clinical and laboratory characteristics of ILI events among HIV-infected persons using the military's substantial experience in following a stable HIV-infected population. We will recruit subjects with ILI in both the outpatient and inpatient setting, and will serially collect biological specimens (e.g. nasal/throat swabs, blood, rectal swabs) over a 28-day period. In addition, we will collect a single buccal (cheek) swab.
3213015|NCT01021124||QFT (+) vs QFT (-)|
3213016|NCT01021150|Experimental|Ombrabulin/cisplatin|AVE8062 combined with 75 mg/m2 of cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
3213017|NCT01021163|Placebo Comparator|N-acetylcysteine , saline|
3213018|NCT01021176|Placebo Comparator|0mg 0 spray|No Diltiazem
3213019|NCT01021176|Active Comparator|2mg 2 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 2mg/2 spray Diltiazem
3213020|NCT01021176|Active Comparator|4mg 4 Spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 4mg/4 spray Diltiazem
3213021|NCT01021176|Active Comparator|8mg 8 spray|Staff member will administer an atomizer (device that changes a liquid into a fine spray) that will go into both nostrils. The atomizer will contain diltiazem, RxC Use 8mg/8 spray Diltiazem
3213022|NCT01021189|Experimental|1|AZD1446
3213023|NCT01021189|Placebo Comparator|2|Placebo
3213024|NCT01021202|Experimental|Early tracheostomy|Percutaneous dilation tracheostomy < 72h on mechanical ventilation
3213025|NCT01021202|Experimental|Late tracheostomy|Percutaneous dilation tracheostomy > 10 days on mechanical ventilation
3213026|NCT01021228||group1|continuous volatile anesthesia (sevoflurane) during the liver resection
3213027|NCT01021228||group2|continuous intravenous anesthesia (propofol) during the liver resection
3213028|NCT01021228||group3|preconditioning volatile anesthesia (sevoflurane) 30 minutes before ischemia (inflow occlusion)
3213029|NCT01021241|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner
3213030|NCT01021267|Experimental|Saw palmetto berry extract|Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
3213031|NCT01021280||Type II BS|Adolescents and young adults with type II Bartter syndrome
3213032|NCT01021280||Type IV BS|Adolescents and adults with type IV Bartter syndrome
3213033|NCT01021280||Controls|Age and sex- matched controls
3213034|NCT01021319||Acute ischemic stroke|Patients with acute ischemic stroke confirmed by acute or follow-up MRI with defined andwell-known symptom onset.
3213035|NCT01021358|Experimental|Arm A (ABT-263 and Ketoconozole)|
3213036|NCT01021371|Experimental|Patient interview and communication to GP from hospital|Intervention group: The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group about their rehabilitation needs and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus.
3213037|NCT01021371|No Intervention|Control group: Usual practice, no intervention|
3213038|NCT01021384|Other|Problem Solving Education|
3213039|NCT01021397|Experimental|1|Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
3213040|NCT01021397|Placebo Comparator|2|Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
3213041|NCT01021410||Acetaminophen Group|Subjects who completed COMIRB 06-1265 and were assigned to the acetaminophen treatment group for that study.
3213042|NCT01021436|Experimental|Amikacin inhalation solution|Subjects received 125 mg/mL of aerosolized amikacin via the PDDS clinical device at a nominal dose of 400 mg every 12 h for 7-14 days
3213043|NCT01021449||Control|Healthy subjects
3213044|NCT01021449||Schizophrenia|Schizophrenic patients
3213045|NCT01021462|Experimental|Period 1 + Period 2|graded infusion of intravenous glucose
3213046|NCT01021475|Experimental|Usual drug FD therapy + Visceral Manipulation|
3213047|NCT01021475|Active Comparator|Usual drug FD therapy|
3213048|NCT01021488|Experimental|Experimental: Rosuvastatin + enoxaparin arm|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
3213049|NCT01021488|Active Comparator|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
3213050|NCT01021501|Experimental|nifedipine controlled release tablets|Prospective, open, non-randomized, non-controlled study to evaluate the effect and safety of nifedipine controlled release tablets in hypertensive patients on chronic maintenance hemodialysis and the influence of hemodialysis on the plasma concentration of nifedipine
3213051|NCT01021514||Type 2 DM, Healthy control|Type 2 DM patients are treating in the Diabetic Clinic of Korea university Guro hospital, and their age- and sex-matched healthy controls are underwent a routine health checkup at Korea university Guro hospital.
3213052|NCT01021514||Type 2 DM, Heatlhy control|
3213053|NCT01021527|Experimental|Treatment Sequence 1|A-B-C-C
3213054|NCT01021527|Experimental|Treatment Sequence 2|B-C-A-C
3213055|NCT01021527|Experimental|Treatment Sequence 3|C-A-B-C
3213056|NCT01021527|Experimental|Treatment Sequence 4|A-C-B-C
3213057|NCT01021527|Experimental|Treatment Sequence 5|B-A-C-C
3213058|NCT01021527|Experimental|Treatment Sequence 6|C-B-A-C
3213059|NCT01021566|Experimental|Combined hemoperfusion-hemodialysis|On admission thirty patients will receive the combined hemoperfusion-hemodialysis treatment regimen three hours everyday for three days.
3213060|NCT01021566|Active Comparator|Methadone, conventional treatment for opiate detoxification|On admission thirty patients receive the 10-day methadone treatment regimen.
3213061|NCT01021579|Active Comparator|Metformin plus Simvastatin|PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)
3213062|NCT01021579|Placebo Comparator|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
3213063|NCT01021592||001|
3213064|NCT01021605|Experimental|Hemolung Respiratory Assist System|
3213065|NCT01021631|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hematocrit is lower than 30%
3213066|NCT01021631|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hematocrit is lower than 24%
3213067|NCT01021644|Experimental|aerobic exercise-training|
3213068|NCT01021644|Active Comparator|stretch exercise|
3213069|NCT01021657||Glaucoma|
3213070|NCT01021670||001|Dapoxetine hydrochloride One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
3213071|NCT01021670||002|Alternate care/non-dapoxetine hydrochloride treatment(s) As prescribed or directed
3213072|NCT01021696|No Intervention|Treatment as usual|Control group
3213073|NCT01021696|Active Comparator|Paracetamol|Intervention group
3213074|NCT01021696|Active Comparator|Morphine|Intervention group, individual pain treatment
3213075|NCT01021696|Active Comparator|Buprenorphine plaster|Intervention group, individual pain treatment
3213076|NCT01021696|Active Comparator|Pregabalin|Intervention group, individual pain treatment
3213077|NCT01021709|Experimental|tDCS with alternative electrode montage|Treating major depression with either alternative tDCS electrode montage.
3213078|NCT01021722|Experimental|Modified suture technique|Sutured in a modified manner
3213079|NCT01021722|No Intervention|Historical sphincter group|The outcome of historical sphincter tears
3213080|NCT01021722|No Intervention|Normal primaparous deliveries|Normal deliveries
3213081|NCT01021735|Active Comparator|Anti-TNF therapy|Etanercept or adalimumab by s/c injection
3213082|NCT01021735|Experimental|Rituximab therapy|Rituximab given by IV infusion
3213083|NCT01021774|Active Comparator|Advancement flap surgery|
3213084|NCT01021774|Active Comparator|Collagen plug|
3213085|NCT01021800|Experimental|Cell infusion|
3213086|NCT01021826||Hip and knee replacements recipients|Osteoarthritis patients undergoing elective primary hip and knee replacement and being followed-up in this study.
3213087|NCT01021839|Active Comparator|Bovine Carotid Artery Graft|
3213088|NCT01021839|Active Comparator|Expanded Polytetrafluoroethylene Grafts|
3213089|NCT01021865||With type 2 Diabetes|
3213090|NCT01021865||Without type 2 diabetes|
3213091|NCT01021891|Experimental|Non-Diabetic Subj. w/o COPD|Single dose, 30 units
3213092|NCT01021891|Experimental|Non-Diabetic Subj. with COPD|Single dose, 30 units
3213093|NCT01021917||Other Dieters (OD)|Those participating in weight loss programs other than Medifast Direct or Take Shape For Life.
3213094|NCT01021917||Take Shape For Life (TSFL)|Those using Medifast meal replacement products for weight loss while working closely with a Take Shape For Life certified Health Coach.
3213095|NCT01021917||Medifast Direct (MD)|Those using Medifast meal replacement products specifically for weight loss that were purchased directly from the company and individually monitored by the customer.
3213096|NCT01021930|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
3213097|NCT01021930|Active Comparator|Group B: Non-DM|Coronary artery disease without diabetes mellitus
3213098|NCT01021943|Placebo Comparator|Placebo|Half of the subjects will be assigned to receive either spironolactone or placebo for 6 months
3213099|NCT01021943|Active Comparator|spironolactone|Half of the subjects will be randomized to receive spironolactone for 6 months
3213100|NCT01021982||Glaucoma|Glaucoma Patients with visual field defects
3213101|NCT01021982||Retinitis Pigmentosa|Retinitis Pigmentosa Patients with visual field defects
3213102|NCT01021995|Experimental|echinacea|
3213103|NCT01021995|Placebo Comparator|placebo|
3213104|NCT01022008|Experimental|Osteodistraction techniques|Osteodistraction techniques
3213105|NCT01022021|Active Comparator|rituximab|
3213106|NCT01022021|Active Comparator|bendamustine|bendamustine, 90 mg/M2
3213107|NCT01022034|Active Comparator|Pexy group|This group of patients with full thickness rectal prolapse will receive standard sacral rectopexy with mesh or sutures
3213108|NCT01022034|Sham Comparator|Non-pexy group|These patients will receive full rectal mobilization from the sacrum but without rectopexy
3213109|NCT01022047|Experimental|Noex|The patients shall use the NOEX drug only once a day (one application in each nostril) during the 12 weeks of treatment
3213110|NCT01022047|Active Comparator|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
3213111|NCT01022060|Experimental|A|Renalof
3213112|NCT01022060|Placebo Comparator|B|Placebo
3213113|NCT01022086||early stage/adjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3213114|NCT01022086||locally advanced/neoadjuvant|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3213115|NCT01022086||metastatic|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3213116|NCT01022086||anthracycline-containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3213117|NCT01022086||non-anthracycline containing|Analyses will also be stratified according to the patient's stage of disease (i.e. early stage/adjuvant, locally advanced/neoadjuvant, and metastatic) and type of chemotherapy regimen (i.e. anthracycline-containing vs. non-anthracycline).
3213118|NCT01022099|Active Comparator|navigated TKA|
3213119|NCT01022099|Other|conventional TKA|
3213120|NCT01022138|Experimental|HER2Bi-armed activated T cells/Cyclophosphamide/biomarker|"HER2Bi-armed activated T cells Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.~Cyclophosphamide After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide~Laboratory biomarker analysis The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored."
3213121|NCT01022151|Placebo Comparator|Placebo [group P]|
3213122|NCT01022151|Active Comparator|Aminophylline 2 mg/Kg [group A2]|
3213123|NCT01022151|Active Comparator|Aminophylline 3 mg/Kg [group A3]|
3213124|NCT01022151|Active Comparator|Aminophylline 4mg/Kg [group A4]|
3213125|NCT01022151|Active Comparator|Aminophylline 5 mg/Kg [group A5]|
3213126|NCT01022151|Active Comparator|Doxapram 1 mg/kg [group D]|
3213127|NCT01022164|Other|fibrin glue|
3213128|NCT01022177|Active Comparator|diabetics|subjects with HbA1c >7,0 and pathological glucose tolerance testing
3213129|NCT01022177|Active Comparator|healthy|healthy subjects with HbA1c <7,0 and negative glucose tolerance testing
3213130|NCT01022216|Active Comparator|V.A.C.® Therapy|Vacuum Assisted Closure device that utilizes controlled negative pressure
3213131|NCT01022216|Experimental|Procellera™ Wound Dressing with V.A.C.® Therapy|Procellera wound dressing used as a primary contact layer on the wound bed, used in conjunction with NPWT
3213132|NCT01022229|Experimental|Compound Natural Health Product|15 study participants who will receive the compound natural health product.
3213133|NCT01022229|Placebo Comparator|Placebo|15 participants will receive placebo natural health product.
3213134|NCT01022255|Experimental|Arm 1|
3213135|NCT01022268||Infection, inflammation or allergy|"Children presenting via any means to St Mary's Hospital; this would include the A&E department, the general and infectious disease wards and the paediatric intensive care unit.~Children needing blood tests for any clinical reason Children who, in the clinical judgement of the doctor assessing them, have presented because of a condition consistent with an infectious, inflammatory or allergic process"
3213136|NCT01022268||controls|children who do not have an infectious, inflammatory or allergic condition, who anyway require blood tests for clinical reasons
3213137|NCT01022281||Normal Controls|Normal age matched controls without exfoliation
3213138|NCT01022281||Exfoliation Syndrome|Patients with exfoliation syndrome
3213139|NCT01022294|Experimental|Arm 1|Inhalation of nitrousoxide-oxygen during the first experimental session; inhalation of atmospheric air during the second session
3213140|NCT01022294|Experimental|Arm 2|Inhalation of atmospheric air during the first experimental session; inhalation of nitrousoxide-oxygen during the second session
3213141|NCT01022320|Experimental|Surgical outcome|20 consecutive cases of patients who underwent the lateral pharyngoplasty
3260315|NCT01478295|Experimental|CuidaCare Intervention|Regular care in consultation or home and Structured nursing care (CuidaCare intervention): improved strategies for coping, health education on self-care and dependent care and emotional support. 10 visits are structured, with a periodicity of approximately 2 visits per month and last for 30 to 40 minutes each
3260316|NCT01478295|Active Comparator|Control Group/Usual Care|Usual care in consultation or home, which is to respond to the specific demands of care of the caregiver, using the resources of the nursing discipline.
3260317|NCT01478334|Experimental|Exercise then control|
3213142|NCT01022333|Experimental|DIM group (BRCA1 carriers)|This group will have up to 100 women who are carriers of a BRCA1 deleterious mutation. To ensure safety, women in this group will not be able to participate in the study if they are under medications with warfarin, theophylline, or anticonvulsants; or if they are pregnant, breast-feeding or planning to become pregnant within 6 months of the research project. Women in this group will receive 300 mg per day of Rx Balance BioResponse DIM for six weeks. Supplements will be given free of charge. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be during the six weeks of DIM supplementation (4-6 weeks after the first clinic visit).
3213143|NCT01022333|No Intervention|No DIM group (BRCA1 carriers)|This group will have up to a 100 women who are carriers of a BRCA1 deleterious mutation. This group will not receive DIM. Women that choose not to take DIM will be in this group. A blood sample (20cc) and a urine sample (20cc) will be collected from these women during two clinic visits; the second visit will be 4-6 weeks after the first clinic visit.
3260318|NCT01478334|Experimental|Control then exercise|
3260319|NCT01478386|Other|Viscosupplementation injections|Control group will receive a series of three viscosupplementation injections into the affected knee
3260320|NCT01478386|Experimental|Off-loading knee brace|
3260321|NCT01478386|Experimental|Viscosupplementation and knee brace|
3213144|NCT01022333|No Intervention|General Control Group|This group will have up to 100 women who do not carry a BRCA1 mutation but who come from BRCA1 carrier family (a family with at least one individual that has tested positive for a BRCA1 mutation). A control subject is considered negative for a BRCA1 mutation if she has been confirmed by direct DNA sequencing to not be a carrier of this gene. A blood sample (20cc) and a urine sample (20cc) will be collected from these women at a single clinic visit.
3213145|NCT01022346|Placebo Comparator|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
3213146|NCT01022346|Experimental|RO5217790|RO5217790 will be administered at a dose of 5*10^7 plaque forming unit (pfu) subcutaneously on Days 1, 8, and 15.
3213147|NCT01022372||control group|
3213148|NCT01022372||endometriosis group|
3213149|NCT01022372||endometrioma group|
3213150|NCT01022385|No Intervention|12-hour fast|
3213151|NCT01022385|Active Comparator|24-hour low-residual diet and 12-hour fast|
3213152|NCT01022411|Experimental|A|Brown rice
3213153|NCT01022411|Placebo Comparator|B|White rice
3213154|NCT01022437|Experimental|Geranium Oil and component PN-34|
3213155|NCT01022463|Active Comparator|Ivabradine|Crossover study to compare ivabradine and atenolol
3213156|NCT01022463|Placebo Comparator|Atenolol|
3213157|NCT01022476|Experimental|Raltegravir potassium|raltegravir 400 mg twice a day
3213158|NCT01022489|Experimental|Transcranial magnetic stimulation: rTMS|rTMS : 4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
3213159|NCT01022489|Placebo Comparator|placebo (sham coil) treatment|
3213160|NCT01022515||patients with pheochromocytoma|Patients with pheochromocytoma / paraganglioma are being followed as recommended according to international standards. No intervention is expected except regular measurement of plasma CgA (as usual) and EM66 (research purpose) levels.
3213161|NCT01022515||Patients with essential hypertension|Patients with essential hypertension will be selected as controls. EM66 and CgA plasma levels will be assessed in these patients after having excluded the presence of a pheochromocytoma / paraganglioma with normal urinary metanephrines / normetanephrines excretion levels.
3213162|NCT01022528|Experimental|Dexamethasone|
3213163|NCT01022528|Placebo Comparator|Saline|
3213164|NCT01022541|Other|This is a single arm study|This is a single arm study
3213165|NCT01022606|Other|Patients with walking limitation|Patients with claudication and Walking-Induced Transient Hack (W.I.T.H.) tcpO2 profiles are tested on treadmill with invasive pO2 arterial sampling and body temperature recording
3213166|NCT01022619||Premature labor|Women at the third trimester of pregnancy with premature contractions and cervical dilation of effacement
3213167|NCT01022619||Control|Women at the third trimester of pregnancy with uncomplicated pregnancy
3213168|NCT01022619||Pre-eclampsia|Women at the third trimester with pre-eclampsia
3213169|NCT01022619||Gestational diabets|Women at the third trimester of pregnancy with gestational diabetes requiring insulin
3213170|NCT01022632|Active Comparator|Fluoxetine|Fluoxetine : 20 mg Once a day in morning after taking food for 6 weeks
3213171|NCT01022632|Experimental|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
3213172|NCT01022632|Experimental|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
3213173|NCT01022645||Levonorgestrel IUD|
3213174|NCT01022645||Copper IUD or Tubal Ligation|
3213175|NCT01022658|Active Comparator|detemir|Insulin detemir at dinner or bedtime
3213176|NCT01022658|Active Comparator|aspart|Insulin aspart before each meal
3213177|NCT01022658|Active Comparator|detemir and aspart|
3213178|NCT01022671|Experimental|Belotecan|Single arm
3213179|NCT01022684||Healthy patients|
3213180|NCT01022697|Active Comparator|A|Glucose drink
3213181|NCT01022697|No Intervention|B|Fasting
3213182|NCT01022710||Group 1|Veterans with sensorineural hearing loss
3213183|NCT01022723||Lung Cancer patients|Lung Cancer (particular focus on non smokers with adenocarcinoma)
3213184|NCT01022723||Patients with Nasopharyneal carcinoma|Patients with Nasopharyneal carcinoma
3213185|NCT01022723||Breast Cancer patients|Breast cancer patients
3213186|NCT01022723||Prostate Cancer patients|Prostate cancer patients
3213187|NCT01022723||Colorectal Cancer patients|Colorectal cancer patients
3213188|NCT01022723||Gastric Cancer patients|Gastric cancer patients
3213189|NCT01022736|Experimental|gabapentin|patients scheduled for cardiac bypass surgery will be administered gabapentin (600mg, orally). Blood will be drawn and plasma gabapentin levels determined 1 hour before surgery, 10 minutes into surgery, 10 minutes before separation from bypass, 30 minutes following bypass, and then before and 2 hours after each dose of gabapentin.
3213190|NCT01022749|Experimental|2|patients with IBD receiving immunosuppressants (TNF blockers excluded) (n=100)
3213191|NCT01022749|Experimental|3|patients with IBD receiving immunosuppressants including TNF blockers (n=100)
3213192|NCT01022749|Experimental|1|patients with IBD not receiving immunosuppressant (n=100)
3213193|NCT01022749|Active Comparator|4|patients with IBD receiving immunosuppressants including TNF blockers (n=20)
3213194|NCT01022775|Experimental|1: Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
3213195|NCT01022775|Active Comparator|2: Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
3260322|NCT01478399|Experimental|Impaired Renal Function|Subjects have impaired renal function matched to subjects with normal renal function by age and weight.
3213196|NCT01022788|Experimental|Home-based counselling visits by volunteers|Home-based counselling in pregnancy and the first few days of life to encourage women and families to adopt key newborn care behaviours
3213197|NCT01022788|No Intervention|Standard care through existing health system|
3213198|NCT01022801|Experimental|Entecavir (0.01 mg)|
3213199|NCT01022801|Experimental|Entecavir (0.1 mg)|
3213200|NCT01022801|Experimental|Entecavir (0.5 mg)|
3213201|NCT01022814||Pregnant woman|
3213202|NCT01022827|Experimental|posterior shoulder stiffness massage group|The inclusion criteria of patients with glenohumeral internal rotation limitation and posterior shoulder stiffness were: [1] limitation of internal rotation ROM compared to the sound side; [2] mild glenohumeral joint hypomobility according to joint play assessment; [3] stiffness in the posterior shoulder region.
3213203|NCT01022827|Placebo Comparator|posterior shoulder stiffness placebo group|
3213204|NCT01022840|Placebo Comparator|Placebo|Placebo as saline solution
3213205|NCT01022840|Experimental|Low dose|S-Ketamine
3213206|NCT01022840|Active Comparator|High dose|
3213207|NCT01022892||Phase 1 - Pilot phase|Total of 10 patients currently undergoing EVAR Surveillance. These 10 patients include 5 patients with endoleak known from a recent CT scan and 5 patients with no endoleak and shrinking aneurysm.
3213208|NCT01022892||Phase 2 - Blinded from CT Scan|This phase of study involves recruitment of 150 patients currently under post-EVAR surveillance. The physicians and ultrasound technologists will be blinded to the result of the CT Scan when performing and interpreting the CUS. The current schedule for EVAR Surveillance will be maintained so that an individual may receive more than one enhanced CT Scan and CUS during the 18 months of the study.
3213209|NCT01022905|Experimental|High-risk patients ( 5 cohorts)|
3213210|NCT01022905|Active Comparator|Healthy controls|
3213211|NCT01022918|Experimental|Bevacizumab/Irinoecan|"Neoadjuvant Treatment Patient will receive bevacizumab 10mg/kg plus irinotecan 125mg/m² 4 times every two weeks.~Radiochemotherapy Then they will receive conformational radiotherapy for 6 weeks (30 Gy, 2Gy/fractions) associated with Temodal ( 75mg/m²/day) from first day up to the end of radiotherapy and 4 injections of Avastin (15mg/kg Day 1, day 15, day 29 and day 43).~Adjuvant treatment:~Patients will receive bevacizumab 15mg/kg plus irinotecan 125mg/m² 12 times every two weeks."
3213212|NCT01022918|Active Comparator|Stupp|patient will receive 6 weeks chemotherapy treatment associating conformational 30 Gy (2Gy/ fraction)and Temodal(75mg/m²/day, followed by 6 months adjuvant therapy consisting in 5 days every 28 days of Temodal (150-200mg/m².
3213213|NCT01022944|Other|Group 2 :|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
3213214|NCT01022944|Other|Group 1|Children with chronic middle ear effusion having adenoidectomy.
3213215|NCT01022957|Experimental|Study group|Neurological, ophthalmological, olfactive exams and cerebral MRI
3213216|NCT01022970|Placebo Comparator|Placebo|
3213217|NCT01022970|Active Comparator|QAX576|
3213218|NCT01022983|Active Comparator|Levosimendan|
3213219|NCT01022983|Placebo Comparator|Povidon, waterfree etanol, glucosis 5%|
3213220|NCT01023009||eye occlusion|
3213221|NCT01023048|Experimental|PGD testing|
3213222|NCT01023087||Treatment|Patients with sepsis treated with polymyxin E (colistin)
3213223|NCT01023087||Control|Patients with sepsis treated with other, non-nephrotoxic antibiotic medication
3213224|NCT01023100|Experimental|Open label|
3213225|NCT01023113|Experimental|PASCAL laser, PRP in 2-3 sitting at 3 days interval.|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by PASCAL laser
3213226|NCT01023113|Active Comparator|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery by conventional laser
3213227|NCT01023126|No Intervention|EO|Exercise three times a week, one under supervision and two freely chosen by the participant
3213228|NCT01023126|Experimental|EGT|Exercise three times a week, one under supervision and two freely chosen by the participant
3260323|NCT01478399|Experimental|Normal Renal Function|Subjects have normal renal function matched to subjects with impaired renal function by age and weight.
3213229|NCT01023139|No Intervention|Standard of care (SOC)|No intervention following phase 1 of the study is done during this 2nd phase. Participants will have their height and weights examined at 3 month and 6 month following end of phase 1. During these two visits, they will receive counseling from the physician regarding food choices and exercise maintenance.
3213230|NCT01023139|Experimental|Continuing Behavioral Therapy (CoBT)|This arm follows the end of the phase 1 which incorporates behavioral therapy, nutrition counseling and pharmacotherapy with Sibutramine while medically supervised. Participants randomized to this arm no longer receive medication and will receive behavioral therapy once a month and then evaluated at 3 months and six months for weight loss maintenance.
3213231|NCT01023152|Experimental|Automated cuff-inflator|
3213232|NCT01023165|Experimental|IV bolus insulin, metabolic integrity|Diabetic patients will complete diagnostic testing and complete quality of life questionnaires at baseline and every six months thereafter while enrolled in the study to monitor and assess progress with metabolic integrity and complications resulting from their diabetes. Comparisons will be performed on lab values performed at baseline and every six months thereafter. Supervising physician may request testing be performed more frequently as deemed medically necessary, testing may include retinal photography, nerve conduction and labs. Meds and medical intervention information is collected weekly at the Intravenous Bolus Insulin treatment sessions. An annual evaluation is performed to review clinical data collected and evaluate progress for analysis and comparison.
3213233|NCT01023191|Active Comparator|Percutaneous insertion|To undergo insertion of catheter using percutaneous technique under local anaesthetic
3213234|NCT01023191|Active Comparator|Open insertion|To undergo insertion of catheter using open technique under general anaesthetic
3213235|NCT01023204|Experimental|Paclitaxel|
3213236|NCT01023230|Experimental|DV-601|
3213237|NCT01023243|Placebo Comparator|1 CAre of the Feet for Those at Risk|secular trends for physician documentation in the medical record for care of the feet for high risk patients
3213238|NCT01023243|Active Comparator|Care of the feet for those at risk|the impact of 1) patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam and 2) patient education material: Care of the Foot For Those at Risk, on documentation of foot examination in the medical record
3213239|NCT01023243|Active Comparator|Impact of Quality Survey|Impact of patient survey regarding last foot exam, tobacco and aspirin use on documentation of foot exam in the medical record
3213240|NCT01023282|Experimental|ACR325|
3213241|NCT01023282|Placebo Comparator|Placebo|
3213242|NCT01023295|Placebo Comparator|Placebo|single dose
3213243|NCT01023295|Experimental|15 mg/m^2|15 mg/m^2 fosbretabulin, single dose
3213244|NCT01023295|Experimental|25 mg/m^2|25 mg/m^2 fosbretabulin, single dose
3213245|NCT01023295|Experimental|35 mg/m^2|35 mg/m^2 fosbretabulin, single dose
3213246|NCT01023295|Experimental|45 mg/m^2|45 mg/m^2 fosbretabulin, single dose
3213247|NCT01023321|Experimental|1|single ascending doses
3213248|NCT01023321|Placebo Comparator|2|single dose placebo
3213249|NCT01023321|Experimental|3|multiple dose, 7 or 14 days, oral solution
3213250|NCT01023321|Placebo Comparator|4|multiple dose, 7 or 14 days, oral solution
3213251|NCT01023334|Experimental|Intraocular lidocaine,topical anesthesia,MSICS|experimental group:manual small incision cataract surgery under topical anesthesia with intracameral lidocaine
3213252|NCT01023334|Experimental|intracameral balanced salt solution,topical anesthesia,MSICS|control group:manual small incision cataract surgery under topical anesthesia with intracameral balanced salt solution.
3213253|NCT01023347|Active Comparator|Paclitaxel (Genexol®) and Cisplatin|
3213254|NCT01023347|Experimental|Paclitaxel loaded polymeric micelle (Genexol-PM®) & Cisplatin|
3213255|NCT01023360|Experimental|Clopidogrel and proton pump inhibitors|all participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
3213256|NCT01023373|Experimental|B:PTRS|B: the same medical therapy, as previously described in group A, associated with PTRS
3213257|NCT01023373|Active Comparator|A:medical therapy|hypotensive drugs, statins and antiplatelet therapy
3213258|NCT01023399|Experimental|Artesunate + Amodiaquine|"Oral fixed combination of artesunate (AS) and amodiaquine (AQ)~Once daily, dose according to age~Infants 2-11 months: AS 25/AQ 67,5 mg (3 tablets/ blister)~Toddlers 1-5 years: AS 50/AQ 135 mg (3 tablets/ blister)~Children: 6-13 years: AS 100/AQ 270 mg (3 tablets/ blister)~Adults: >= 14 years: AS 100/AQ 270 mg (6 tablets/ blister)~3 day-treatment"
3213259|NCT01023412|Active Comparator|Nutritional product|Oral nutritional supplement containing immuno nutrients
3213260|NCT01023412|Placebo Comparator|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
3213261|NCT01023425|Experimental|switching group|switching patients with Alzheimer's disease(AD) from galantamine or rivastigmine to donepezil because they were not responding adequately
3213262|NCT01023425|Experimental|naive group|naive patients with AD who initiated therapy with donepezil
3213263|NCT01023438|Experimental|Assisted uptitration|Uptitration of recommended drugs by primary care physician with specialist support
3213264|NCT01023438|Active Comparator|Usual care|Usual communication strategy from cardiologist to primary care physician
3213265|NCT01023464|Other|Period 1|FID 114657 or SootheXP
3213266|NCT01023464|Other|Period 2|FID 114657 or SootheXP
3213267|NCT01023490|Placebo Comparator|Placebo|
3213268|NCT01023490|Active Comparator|Vitamin D|34,500 IU vitamin D per week
3213269|NCT01023503||1|Adults, with a new statin prescription or a change in their stain treatment
3213270|NCT01023529||Prostate cancer|Patients with incurable prostate cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
3213271|NCT01023529||Rectal Cancer|Patients with incurable rectal cancer requiring palliation of symptoms from a soft-tissue pelvic tumor.
3260324|NCT01478412||Males with prostate adenocarcinoma|English speaking males with histologically confirmed prostate adenocarcinoma and diagnosis of low risk or intermediate risk prostate cancer.
3260325|NCT01478425|Experimental|Active|Lipidic Microemulsion
3260326|NCT01478425|Placebo Comparator|Control|Saline nose-spray device
3213272|NCT01023542|Active Comparator|1|Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.
3213273|NCT01023542|Active Comparator|2|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).
3213274|NCT01023542|Experimental|3|Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (will be switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).
3213275|NCT01023555|No Intervention|0.5cc 2 Bottles|
3213276|NCT01023555|Active Comparator|1cc single bottle|
3213277|NCT01023594|Active Comparator|External stent|Feeding tube insert at pancreatojejunostomy site as a stent. And stent tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall.
3213278|NCT01023594|Active Comparator|Internal stent|short(5cm)internal stent insertion at pancreatojejunostomy site
3213279|NCT01023607|Active Comparator|Group A:|Atorvastatin 20mg
3213280|NCT01023607|Experimental|Group B:|Atorvastatin 60mg
3213281|NCT01023607|Active Comparator|Group C:|Rosuvastatin 10mg
3213282|NCT01023633|Active Comparator|Arm A: FOLFOX 4 continuous (Oxaliplatin, LV, 5-FU)|The arm A (FOLFOX4 continuous arm):receive FOLFOX4 every 2 weeks until progression or for maximum 24 cycles.
3213283|NCT01023633|Experimental|Arm B: FOLFOX4 Stop and go (Oxaliplatin, LV, 5-FU)|The arm B will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles
3213284|NCT01023646|Other|carbohydrate load|Food challenge - Carbohydrate load
3213285|NCT01023646|Other|Carbohydrate + Protein|Food challenge - carbohydrate + protein
3213286|NCT01023646|Other|Carbohydrate + Fat|Food challenge - carbohydrate + fat
3213287|NCT01023646|Other|Fiber|Food challenge - carbohydrate + fiber
3213288|NCT01023685|Experimental|CAD106|
3213289|NCT01023698|Experimental|photocoagulation|Laser photocoagulation
3213291|NCT01023750||Fenofibrate|
3260327|NCT01478438|Experimental|Treat and Excise|All subjects will be treated with Interstitial Laser Therapy (ILT) followed by excision no later than 28 days post ablation.
3213292|NCT01023763|No Intervention|Usual care|"Nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual (hospital admissions for intravenous treatment).~In control nursing homes that had not completed the training program (intervention period), nursing home residents who require intravenous fluids and intravenous antibiotics was treated as usual. The majority of these patients were admitted to hospital for intravenous treatment. A few nursing homes or nursing home departments had sufficient expertise and capacity to provide treatment locally."
3213293|NCT01023763|Other|A training program in iv treatment|"A structured training program in intravenous treatment in nursing homes:~Each of 30 participating nursing homes sequentially received theory and practical training in intravenous treatment. In nursing homes that had completed the training program (intervention period), and had sufficient expertise and capacity, nursing home residents in need of intravenous fluids or antibiotics were treated locally; otherwise they were hospitalized."
3213294|NCT01023802||Neoadjuvant therapy for breast cancer|Women who present to the Internal Medicine Breast Cancer Clinic with breast cancer and who after discussion with the consulting surgeon and oncologist have agreed to undergo neoadjuvant chemotherapy or neoadjuvant hormone therapy.
3213295|NCT01023828||TOBACCO SMOKING|Group of patients with diagnosis of NSCLC and exposure to tabacco smoking
3213296|NCT01023828||WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to wood smoke
3213297|NCT01023828||TABACCO SMOKING AND WOOD SMOKE|Patients whit diagnosis of NSCLC and exposure to tabacco smoking and wood smoke
3213298|NCT01023828||WHITOUT EXPOSURE|Patients whit diagnosis of NSCLC and whitout exposure to risk factor
3213299|NCT01023854|Experimental|Continuous Paravertebral block|Continuous Paravertebral block
3213300|NCT01023854|Placebo Comparator|Placebo|Placebo
3213301|NCT01023867|Experimental|Alzheimer's disease group|Patients with Alzheimer's disease treated donepezil
3213302|NCT01023867|Experimental|Mixed Dementia group|Patients with Mixed Dementia treated donepezil
3213303|NCT01023880|Experimental|1|CEP-18770
3213304|NCT01023893||End-stage renal disease|
3213305|NCT01023906||18-49 years|Younger
3213306|NCT01023906||50-85 years|Older
3213307|NCT01023919|Active Comparator|Group B: Non-DM|Coronary artery disease with diabetes mellitus
3213308|NCT01023919|Active Comparator|Group A: DM|Coronary artery disease with diabetes mellitus
3213309|NCT01023932||Auditory Neuropathy Patients|
3213310|NCT01023945|Experimental|ASP1941 high dose group|oral
3213311|NCT01023945|Experimental|ASP1941 low dose group|oral
3213312|NCT01023945|Placebo Comparator|Placebo group|oral
3213313|NCT01023971||Group A|Patients investigated with mfERG and MP-1
3213314|NCT01023971||Group B|Patients investigated by Laser Doppler Flowmetry
3213315|NCT01023984|Active Comparator|TEM - Transanal Endoscopic Microsurgery|TEM under general anesthesia
3213316|NCT01023984|Active Comparator|ESD - Endoscopic Submucosal Dissection|ESD under sedation
3213317|NCT01023997||primary open-angle glaucoma|
3213318|NCT01023997||ocular hypertension patients|
3213319|NCT01023997||normal controls|
3213320|NCT01023997||Exfoliation patients|patients with exfoliation syndrome or exfoliative glaucoma
3213321|NCT01024023|Active Comparator|PPAM Aid|Suitable participants randomised to the treatment arm will receive the non articulated pneumatic early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
3213322|NCT01024023|Active Comparator|AMA Aid|Suitable participants randomised to the treatment arm will receive the articulated early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
3213323|NCT01024049||Asymptomatic LVD|patients over 18 years old with patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history) and asymptomatic left ventricular dysfunction (LVD).
3213324|NCT01024049||healthy controls|individuals over 18 years old free of disease and treatments.
3213325|NCT01024049||patients with cardiovascular risk|patients with cardiovascular risk (obesity, diabetes, dyslipidemia, arterial hypertension, age, gender, familial history)
3213326|NCT01024049||chronic heart failure patients|patient with chronic heart failure
3213327|NCT01024049||acute heart failure patients|acute heart failure patients
3213328|NCT01024062|Experimental|Paclitaxel|
3213329|NCT01024075|Placebo Comparator|Saline|Sinufoam is mixed with saline and placed within the ethmoid cavity at the completion of sinus surgery
3213330|NCT01024075|Active Comparator|Dexamethasone|Sinufoam is mixed with dexamethasone and placed within the ethmoid cavity at the completion of sinus surgery
3213331|NCT01024088||GBS PATIENT|
3213332|NCT01024088||CONTROL|
3213333|NCT01024101|Experimental|Paclitaxel|
3213334|NCT01024114||Positive MBI scan|Women who are previously enrolled in an MBI study that present with a positive MBI scan.
3213335|NCT01024127||Ancillary-correlative (predictors of AML treatment outcomes)|Germline DNA is obtained from previously collected peripheral blood or bone marrow samples for array-based genotyping studies, including genome-wide association studies (single nucleotide polymorphisms) and fine mapping genotyping. Clinical trial simulations are performed to test the clinical applicability of using genetic variation data in the management of infectious complications.
3213336|NCT01024140|Experimental|Escitalopram|Flexible dose (5-20mg/day) of escitalopram monotherapy.
3213337|NCT01024153|Experimental|Active video game play|
3213338|NCT01024166||Patient|Patient computer system use questionnaire
3213339|NCT01024166||Caregiver|Caregiver computer system use questionnaire
3213340|NCT01024166||Healthcare Provider|Physician and Nurse computer system use questionnaire
3213341|NCT01024179|Active Comparator|Group B: CTO|Chronic total occlusion
3213342|NCT01024179|Active Comparator|Group A : Non-CTO|"Non-chronic total occlusion :~Fibrous plaque+fibro-calcific plaque + Lipid plaque(<2 quadrants )~Lipid-rich plaque ( ≥2 quadrants )"
3213343|NCT01024192|Experimental|1|Zolpidem 12.5mg tablet at bed time during 12 weeks
3213344|NCT01024257|Experimental|conjunctival autograft plus beta-irradiation|
3213345|NCT01024257|Active Comparator|conjunctival autograft|
3213346|NCT01024270|Experimental|sublingual, oral and vaginal administration of misoprostol|
3213347|NCT01024322||Ciprofloxicine or Vigamox or other.|
3213348|NCT01024322||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
3213349|NCT01024322||Steroid (FML, Pred Forte, Flarex, etc.)|
3213350|NCT01024348|Active Comparator|Tramadex-OD|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
3213351|NCT01024348|Active Comparator|Control group|Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
3213352|NCT01024361|No Intervention|Routine|Routine protocol of the service
3213353|NCT01024361|Experimental|CPAP-DR|Infants randomized to this arm will have nasal CPAP installation at delivery room before the 15th minute of life
3213354|NCT01024400|Experimental|vaccine|
3213355|NCT01024413|Experimental|erlotinib|erlotinib 150 mg oral till disease progression
3213356|NCT01024413|Active Comparator|gefitinib|gefitinib 250mg oral till disease progression.
3213357|NCT01024426|Experimental|Health Facility intervention|In the clusters randomized to enhanced health facility-based care, the intervention is designed to address these barriers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
3213358|NCT01024426|Other|Standard of care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
3213359|NCT01024439|Active Comparator|single port|Patients will undergo transumbilical single incision laparoscopic appendicectomy.
3213360|NCT01024439|Active Comparator|conventional Lap|Patients will undergo conventional laparoscopic appendicectomy.
3213361|NCT01024452|Experimental|DAWN AC|
3213362|NCT01024452|Active Comparator|Hamilton Nomogram|
3213363|NCT01024491|Experimental|paroxetine 15mg|Active treatment with daily dose of paroxetine 15mg.
3213364|NCT01024491|Experimental|paroxetine 20 mg|Active treatment daily dose of paroxetine 20 mg
3213365|NCT01024491|Experimental|placebo|placebo
3213366|NCT01024504|Experimental|XELOX/Avastin|Capecitabine Oxaliplatin Bevacizumab
3213367|NCT01024517|Experimental|Single oral dose, solution|
3213368|NCT01024517|Experimental|Single oral dose, solid, fasted|
3213369|NCT01024517|Experimental|Single oral dose, solid, fed.|
3213370|NCT01024543|Sham Comparator|Placebo|Placebo
3213371|NCT01024543|Experimental|Angiotensin II|Angiotensin II
3213372|NCT01024543|Active Comparator|Phenylephrine|Phenylephrine
3213373|NCT01024582|Experimental|accelerated partial breast irradiation|pre-operative radiation of the in situ tumor in the breast
3213374|NCT01024595||Without treatment|
3213375|NCT01024621|Experimental|1|confocal laser endomicroscopy
3213376|NCT01024621|Active Comparator|2|standard endoscopy
3213377|NCT01024634|Other|African American Group|A group of young African American males and females
3213378|NCT01024634|Other|Caucasian Group|a group of young Caucasian men and women
3213379|NCT01024647|Active Comparator|Loss of Reponse Reinduction Responders|Loss of Response Reinduction Responders:certolizumab pegol (Cimzia) 200 mg every 2 weeks
3213380|NCT01024647|Active Comparator|Response loss Reinduction Non-Responders|Response Loss Reinduction Non-Responders:certolizumab pegol(Cimzia) 400 mg every 2 weeks
3213381|NCT01024647|Active Comparator|Responders|Responders: certolizumab pegol(Cimzia) 400 mg every 4 weeks
3213382|NCT01024647|Active Comparator|Non-Responders|Non-Responders: certolizumab pegol (Cimzia) 400 mg every 2 weeks
3213383|NCT01024660|Active Comparator|1|5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
3213384|NCT01024660|Placebo Comparator|2|
3213385|NCT01024673||patients with H1N1|patients who are clinical found to be positive for H1N1 will be enrolled
3213386|NCT01024699||XLIF|This group will have the XLIF procedure done.
3213387|NCT01024699||MAS TLIF|This group will have the MAS TLIF procedure done.
3213388|NCT01024725||Not (yet) vaccinated persons|The participants do not want to take the vaccine (available only in the national vaccination campaign) or have not received it yet
3213389|NCT01024725||Vaccinated persons|The participants have taken the vaccine according to the national vaccination campaign
3213390|NCT01024777|Active Comparator|High dose cholecalciferol|Patients in the high dose arm will receive 10,000 international units of cholecalciferol daily.
3213391|NCT01024777|Active Comparator|Low dose cholecalciferol|Patients enrolled in the low dose arm will receive up to 1000 international units of cholecalciferol daily.
3213392|NCT01024790|Experimental|Exercise group|
3213393|NCT01024790|No Intervention|Usual care|
3213394|NCT01024816|Experimental|Restorative yoga intervention|
3213395|NCT01024816|Active Comparator|Stretching group|
3213396|NCT01024829|Other|Whole tumor boost|Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole
3213397|NCT01024829|Other|Boost 50% SUV area|Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)
3213398|NCT01024842|Experimental|Low dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu.
3213399|NCT01024842|Experimental|High dose vaccinees|Individuals will receive three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu.
3213400|NCT01024842|Placebo Comparator|Low dose placebo|Individuals will receive three intramuscular injections of low dose placebo
3213401|NCT01024842|Placebo Comparator|High dose placebo|Individuals will receive three intramuscular injections of high dose placebo
3213402|NCT01024868||TAP block|Patients before undergoing laparoscopic or other abdominal surgery
3213403|NCT01024881|Active Comparator|group 1|neutral shoulder position during infraclavicular subclavian catheterization
3213404|NCT01024881|Experimental|group 2|lowered shoulder position during infraclavicular subclavian catheterization
3213405|NCT01024894|Experimental|CYT107|
3213406|NCT01024907|Experimental|Arm I|Patients undergo proton beam radiation therapy for 6 weeks in the absence of disease progression or unacceptable toxicity.
3213407|NCT01024933|Placebo Comparator|Educational and Behavioral|The Education and Behavioral Contract (Control group) will receive an educational workbook and behavioral contract. Each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
3213408|NCT01024933|Experimental|PASA group-intervention|The PASA group (Positive Affect/Self-Affirmation/Motivational Interviewing) will receive a positive-affect and self-affirmation intervention with motivational interviewing.These patients will also receive an educational workbook and behavioral contract. This is the intervention.
3213409|NCT01024985||multiple sclerosis|
3213410|NCT01024985||neuromyelitis optica|
3213411|NCT01024985||controls|
3213412|NCT01024998|Experimental|2 x 10^8 vector genomes (vg) AAV2-sFLT01|
3213413|NCT01024998|Experimental|2 x 10^9 vector genomes (vg) AAV2-sFLT01|
3213414|NCT01024998|Experimental|6 x 10^9 vector genomes (vg) AAV2-sFLT01|
3213415|NCT01024998|Experimental|2 x 10^10 vector genomes (vg) AAV2-sFLT01|
3213416|NCT01025011||healthy volunteers, anemic patients|healthy volunteers from the eye and gynecology department pregnant patients with anemia
3213417|NCT01025024||POAG group|Elevated intraocular pressure normal open angle glaucomatous optic nerve head abnormality glaucomatous visual field defect
3213418|NCT01025024||Normal control|Normal intraocular pressure No optic disc abnormality No visual field defect No significant ocular and systemic disease
3213419|NCT01025050|Experimental|Group A|In this group the smallest ring diameter will be applied.
3213420|NCT01025050|Experimental|Group B|In this group the intermediate ring diameter will be applied.
3213421|NCT01025050|Experimental|Group C|In this group the biggest ring diameter will be applied.
3213422|NCT01025063||Lucentis (PRN group)|
3213423|NCT01025063||Lucentis (3 Injections over three months)|
3213424|NCT01025063||PDT (Reduced Fluence) and Lucentis|
3213425|NCT01025089|Experimental|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|This is a multicenter, open-label phase II trial of neoadjuvant chemotherapy and concurrent cetuximab in patients with clinical Masaoka stage II-IVA thymoma or thymic carcinoma.. Patients will initially receive weekly cetuximab for 4 weeks to assess tumor response to cetuximab alone. Patients will then undergo weekly cetuximab along with concurrent CAP for 4 cycles. At the completion of this regimen, patients will undergo surgical resection and the specimen will be evaluated for CPR.
3213426|NCT01025102|Experimental|Naropin 0.1%|
3213427|NCT01025115|Experimental|A|Diamel
3213428|NCT01025115|Placebo Comparator|B|Placebo
3213429|NCT01025128|Active Comparator|group A low D|ultra-Orthodox clinics patients aged 18-39 with lowest vitamin D levels
3213430|NCT01025128|No Intervention|group A high D|ultra-Orthodox clinics patients aged 18-39 with highest vitamin D levels
3213431|NCT01025128|Active Comparator|group B low D|mixed population clinics patients aged 18-39 with lowest vitamin D levels
3213432|NCT01025128|No Intervention|group B high D|mixed population clinics patients aged 18-39 with highest vitamin D levels
3213433|NCT01025141|Experimental|MINISCREW|device
3213434|NCT01025141|Active Comparator|Reference|dental anchorage
3213435|NCT01025167|Experimental|Test|Supportan(R) (500 ml)/disease-specific enteral tube feed for oncologic patients with special key substrates
3213436|NCT01025167|Placebo Comparator|Control|Fresubin(R) energy fibre (500 ml)/a nutritionally complete enteral standard feed (isoenergetic)
3213437|NCT01025180|Other|Procalcitonin level|duration of the antibiotic treatment guided by procalcitonin level
3213438|NCT01025180|No Intervention|physician's appreciation|duration of the antibiotic treatment based on physician's appreciation
3213439|NCT01025206|Experimental|BI-505|
3213440|NCT01025245|Experimental|remifentanil, MgSO4|Experimental 1 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and MgSO4 30 mg/kg IV at the induction followed by intraoperative infusion at 10 mg/kg/hr Drug : remifentanil, MgSO4 Experimental 2 : Intraoperative remifentanil infusion at 0.2 ㎍/㎏/min and normal saline Drug : remifentanil Active comparator : Intraoperative remifentanil infusion at 0.05 ㎍/㎏/min and normal saline Drug : remifentanil
3213441|NCT01025258|Active Comparator|frequent clinic visits|
3213442|NCT01025297|Experimental|CYT107|
3213443|NCT01025323|Active Comparator|Minimal Intervention Group|Participants in this arm receive advice and printed guidelines but no counseling or systematic instruction.
3213444|NCT01025323|Active Comparator|Enhanced Intervention Group|Participants in this group receive advice and the same printed guidelines as the Minimal Intervention Group, together with dietary and physical activity counseling provided by a dietician and/or coordinator, periodic professional reviews of their progress and systematic instruction.
3260328|NCT01478451|Experimental|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
3213445|NCT01025349|Experimental|metastatic breast cancer|Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
3213446|NCT01025362|Experimental|Lactation counseling|"Intervention arm: The mother and child health centres will implement The Baby-Friendly Initiative to improve their lactation counseling.~Other Names: The Baby Friendly Community Health Service"
3213447|NCT01025362|Active Comparator|Standard care|The comparison group was mother and child health centres which continued offering standard care.
3213448|NCT01025401|No Intervention|Motor manifestations during seizures|
3260329|NCT01478451|Experimental|Exercise|exercise (shoulder shrugs with elastic resistance) will be performed for 10 minutes at the left or right trapezius (randomized)
3260330|NCT01478451|No Intervention|Control|control shoulder (randomized)
3260331|NCT01478464|No Intervention|Control group|Control group, does not receive any intervention
3213449|NCT01025440|Active Comparator|CPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: The CPAP pressure will be set to the individual subject's therapeutic pressure -as determined by PSG on Night 2.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
3213450|NCT01025440|Active Comparator|HFCPAP|"Continuous Positive Airway Pressure (CPAP) is the gold-standard treatment for OSA. CPAP mechanically splints the upper airway open during sleep to prevent collapse and in this way ameliorates OSA.~Dose: During HF CPAP 35 L/min wil be administered.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)"
3213451|NCT01025466|Active Comparator|rivastigmine patch monotherapy|
3213452|NCT01025466|Active Comparator|Combination therapy with memantine|
3213453|NCT01025518|Experimental|resistance training and dietary supplement|
3213454|NCT01025518|Placebo Comparator|Resistance training and placebo ingestion|12 weeks of resistance training and placebo ingestion
3213455|NCT01025531||patients with newly diagnosed Hepatitis C|Hepatitis C patients newly diagnosed
3213456|NCT01025544|Active Comparator|Arm 1|
3213457|NCT01025544|Active Comparator|Arm 2|
3213458|NCT01025557|Experimental|Chocolate milk|
3213459|NCT01025557|Experimental|Milk|
3213460|NCT01025557|Experimental|Infant formula|
3213461|NCT01025557|Experimental|Soy beverage|
3213462|NCT01025557|Experimental|Water|
3213463|NCT01025570|Experimental|Gem/Bos|"Gemcitabine 1000 mg/m2, D1,8,15 of each cycle~Bostutinib 400 mg daily concurrently with Gemcitabine"
3213464|NCT01025583|Active Comparator|group 1 (standard ORS)|Children with acute diarrhea receive standard hypotonic ORS.
3213465|NCT01025583|Active Comparator|Group 2 (hypotonic super-ORS)|Children with acute diarrhea receive hypotonic super-ORS containing zinc and prebiotics.
3213466|NCT01025596|Experimental|CYT107|
3213467|NCT01025648|Experimental|T1 - E004 90 mcg/actuation|T1 - E004 (epinephrine inhalation aerosol) 90 mcg/actuation - treatment by 2 actuations of E004 at 90 mcg/actuation
3213468|NCT01025648|Experimental|T2 - E004 125 mcg/actuation|E004 (epinephrine inhalation aerosol), 125 mcg, 2 actuations
3213469|NCT01025648|Experimental|T3 - 160 mcg/actuation|E004 (epinephrine inhalation aerosol), 160 mcg - E004 (epinephrine inhalation aerosol), 160 mcg/ actuation, 2 actuations
3213470|NCT01025648|Experimental|T4 - 220 mcg/actuation|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations
3213471|NCT01025648|Active Comparator|A - Active control|epinephrine inhalation aerosol, CFC propelled 220 mcg Epinephrine Inhalation Aerosol, CFC-MDI, 2 actuations
3213472|NCT01025648|Placebo Comparator|P, Placebo HFA|E004 placebo single treatment with 2 inhalations
3213473|NCT01025661|No Intervention|Waiting list control|The waiting list controls did not receive any intervention during the study period.
3213474|NCT01025674|Experimental|7 Treatment Schools|The Positive Action program was implemented over 6 years, starting with Grade 3, then continuing through Grade 8.
3213475|NCT01025674|No Intervention|7 Control Schools|Standard educational practice
3213476|NCT01025687|Experimental|glucose beverage|
3213477|NCT01025687|Experimental|noncaloric beverage with TV|
3213478|NCT01025687|Experimental|glucose beverage with TV|
3213479|NCT01025687|Experimental|noncaloric beverage|
3213480|NCT01025700|Experimental|Cesemat|
3213481|NCT01025700|No Intervention|Placebo|
3213482|NCT01025713|Experimental|1|GS-9411 2.4 mg
3213483|NCT01025713|Experimental|2|GS-9411 4.8 mg
3213484|NCT01025713|Placebo Comparator|Placebo|Placebo
3213485|NCT01025726|Experimental|Full Intervention|Police Patrolled Walking Program plus Social Marketing Intervention
3213486|NCT01025726|Experimental|Walking Only|Police Patrolled Walking Only Intervention
3213487|NCT01025726|Active Comparator|General Health|General Health Education Intervention
3213488|NCT01025765|No Intervention|Standard care of CHC|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3213489|NCT01025765|Experimental|Pioglitazone|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3213490|NCT01025765|Experimental|Acarbose|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3213491|NCT01025765|Experimental|Metformin|From week 5, all the patients will receive Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg) for 48 weeks.
3213492|NCT01025778|Experimental|Remission induction and haplo-SCT|Remission induction with Clofaranie, Etoposide and Cyclophosphamide combination followed by haplidentical stem cella transplantation if remission achieved.
3213493|NCT01025804||Infants|
3213494|NCT01025856|Active Comparator|high fibre/low glycemic index diet - P A|patients will follow for two months a diet high fibre/low glycemic index without physical activity program
3213495|NCT01025856|Active Comparator|Rich in MUFA diet - PA|Patients will follow for two months a rich in MUFA diet without a physical activity program.
3213496|NCT01025856|Active Comparator|high fibre/low glycemic index diet+PA|Patients will follow for two months a high fibre and low glycemic index diet associated with a physical activity program.
3213497|NCT01025856|Active Comparator|Rich in MUFA diet+PA|Patients will follow for 2 months a rich in MUFA diet with a physical activity program.
3213498|NCT01025869|Other|Stent System|Cinatra™ Corolimus Eluting Coronary Stent System
3213499|NCT01025882|Experimental|Regimen 1|Patients undergo a single fraction of margin-intensive stereotactic body radiotherapy (SBRT) on day 1. Patients undergo pancreatoduodenectomy between days 15-43.
3213500|NCT01025882|Experimental|Regimen 2|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients undergo a single fraction of SBRT between days 21-28 followed by pancreatoduodenectomy between days 35-63.
3213501|NCT01025895|Active Comparator|single bundle|acl reconstruction - single bundle technique
3213502|NCT01025895|Experimental|double bundle|acl reconstruction - double bundle technique
3213503|NCT01025908|Experimental|Cognitive Behavioral Therapy|25 panic disorder patients
3213504|NCT01025908|Active Comparator|Supportive psychotherapy|25 panic disorder agoraphobia
3213505|NCT01025921|Placebo Comparator|Inhaled colistin|They will receive inhaled colistin three times daily for 10 days.
3213506|NCT01025921|Placebo Comparator|Inhaled normal saline|Inhaled normal saline three times daily for 10 days
3213507|NCT01025934|Active Comparator|7 days|
3213508|NCT01025934|Active Comparator|20 days|
3213509|NCT01025934|Sham Comparator|sham|
3213510|NCT01025947||Study group|Patients with cryptogenic stroke (TOAST criteria) and with an implantable EKG loop recorder implanted
3213511|NCT01025960|Other|Standard Inspection Colonoscopy|The colonoscope will be inserted rapidly to reach the cecum. Inspection of the large bowel will occur during the withdrawal of the colonoscope.
3213512|NCT01025960|Active Comparator|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
3213513|NCT01025973||Diabetes Mellitus|Patients with type 1, type 2 or gestational diabetes mellitus
3213514|NCT01025973||Normal pregnancy|Patient without diabetes mellitus
3213515|NCT01025986||Noninfectious Uveitis|
3213516|NCT01025999||RYGB|UWMC patients undergoing RYGB surgery with routine placement of Gastrostomy tube.
3213517|NCT01026025|Experimental|Duet TRS|This is a single arm study.
3213518|NCT01026064|Experimental|Part C- Azithromycin|2 x 250 mg once daily over 3 days
3213519|NCT01026064|Placebo Comparator|Part C- Placebo|Once daily over 3 days
3213520|NCT01026090|Experimental|Dronedarone pre-cardioversion|Dronedarone 400 mg twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
3213521|NCT01026090|Placebo Comparator|Placebo pre-cardioversion|Placebo (for dronedarone) twice a day for 5-7 days prior to cardioversion, then dronedarone 400 mg twice a day for 6 months after cardioversion
3213522|NCT01026116|Active Comparator|EC-wP|epirubicin/cyclophosphamide followed weekly paclitaxel
3213523|NCT01026116|Experimental|EP-wP|epirubicin/paclitaxel followed by weekly paclitaxel
3213524|NCT01026129|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia.
3213525|NCT01026129|Experimental|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia.
3213526|NCT01026129|Active Comparator|Lidocaine|Bolus dose of intravenous remifentanil 1mg/kg given once before emergence of general anesthesia.
3213527|NCT01026155|Experimental|Respiratory muscle traininig|Low caloric diet and physical activities + Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
3213528|NCT01026155|Active Comparator|Control|Low caloric diet and physical activities
3213529|NCT01026207||Chronic Obstructive Pulmonary Disease|Patients recruited from the Pneumology Clinic of UNIFESP, diagnosed with COPD stage II and III of Global Initiative for Chronic Obstructive Lung Disease, stable for three months, and with symptoms suggestive of Obstructive Sleep Apnea Syndrome.Patients has been underwent one night by polysomnography and one night with portable monitoring.
3213530|NCT01026233|Experimental|1|brentuximab vedotin
3213531|NCT01026246|Experimental|Group B: 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 20 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3213532|NCT01026246|Experimental|Group A: 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 5 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3213533|NCT01026246|Experimental|Group C: 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant|18 subjects to receive 80 mcg EBA-175 + 500 mcg aluminum phosphate adjuvant; 2 subjects to receive placebo.
3213534|NCT01026259|Experimental|Local incision warming|Local warming applied to surgical incision for 6 treatments beginning in post anesthesia recovery through the second postoperative day.
3213535|NCT01026259|Active Comparator|No warming to surgical incision|Incisions covered with same postoperative dressing as in Arm 1 but without warming treatments.
3213536|NCT01026272||healthy subjects|subjects with no sign of inflammatory disease, or diagnosis of MS
3213537|NCT01026272||Patients with MS|
3213538|NCT01026285||antipsychotic treatment|Risperidone Long-Acting injectable or oral antipsychotics According to label
3213539|NCT01026298|No Intervention|Control Group|8 weeks, no intervention for OSA
3213540|NCT01026298|Active Comparator|CPAP group|8-week randomized-controlled period of CPAP treatment
3213541|NCT01026311|Placebo Comparator|placebo|
3213542|NCT01026311|Active Comparator|Coenzyme Q10|200mg of coenzyme Q10
3213543|NCT01026337||Arm I|"Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity.~Patients undergo dynamic contrast-enhanced MRI at baseline and after the first 4 weeks of sunitinib malate."
3213544|NCT01026350|Experimental|study group|
3213545|NCT01026363|Experimental|ergocalciferol|Ergocalciferol intervention arm
3213546|NCT01026363|Experimental|calcitriol|calcitriol intervention arm
3213547|NCT01026415|Experimental|1|midazolam +/- brentuximab vedotin
3213548|NCT01026415|Experimental|2|brentuximab vedotin +/- rifampin
3213549|NCT01026415|Experimental|3|brentuximab vedotin +/- ketoconazole
3213550|NCT01026415|Experimental|4|special populations
3213551|NCT01026428|Experimental|Safinamide + Levodopa|
3213552|NCT01026428|Placebo Comparator|Placebo + Levodopa|
3213553|NCT01026441|Other|Treatment for cellulite and circumference reduction|All subjects will be treated with the device
3213554|NCT01026467||Supportive Care (frailty index, geriatric assessment, chemo)|Patients complete a frailty index and geriatric assessment prior to beginning chemotherapy. Patients receive standard-of-care chemotherapy comprising carboplatin IV and paclitaxel IV on day 1. Treatment repeats every 21 days for up to 2 courses
3213555|NCT01026480||IPAA Patients|Patients who have had their IPAA procedures performed by Dr. Becker
3213556|NCT01026519|Experimental|Dose 1|Active dose
3213557|NCT01026519|Experimental|Dose 2|Active dose
3213558|NCT01026519|Experimental|Dose 3|Active 3
3213559|NCT01026519|Placebo Comparator|Dose 4|Placebo dose
3213560|NCT01026532||Segmental antigen challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
3213561|NCT01026545|Experimental|Cohort 1|
3213562|NCT01026545|Experimental|Cohort 2|
3213563|NCT01026545|Experimental|Cohort 3|
3213564|NCT01026545|Experimental|Cohort 4 (optional)|If intermediate or repeat dose level is needed; dose will not exceed 1100 mg.
3213565|NCT01026545|Experimental|Cohort 5 (Japanese)|
3213566|NCT01026545|Experimental|Cohort 6 (Japanese)|
3213567|NCT01026558|Active Comparator|Ceftobiprole (not morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
3213568|NCT01026558|Experimental|Ceftobiprole (morbidly obese subjects)|Ceftobiprole 500 mg single-dose over 2 hours.
3213569|NCT01026571||Bicuspid aortic valve|Collection of patients who are known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
3213570|NCT01026571||Relative|Collection of patients who are a relative to a patient known to have bicuspid aortic valve disease, diagnosed by prior cardiac imaging
3213571|NCT01026584|Other|drug|
3213572|NCT01026597|Experimental|Cohort 1|Dose 1 versus placebo
3213573|NCT01026597|Experimental|Cohort 2|Dose 2 versus placebo
3213574|NCT01026597|Experimental|cohort 3|Dose 3 versus placebo
3213575|NCT01026597|Experimental|cohort 4|Dose 4 versus placebo
3213576|NCT01026597|Experimental|cohort 5|Dose 5 versus placebo
3213577|NCT01026610|Experimental|LB80380 90 mg|LB80380 90 mg (90 mg + placebo), once daily oral dose
3213578|NCT01026610|Experimental|LB80380 150 mg|LB80380 150 mg (60 mg + 90 mg), once daily oral dose
3213579|NCT01026610|Active Comparator|entecavir 0.5 mg|entecavir 0.5 mg, once daily oral dose
3213580|NCT01026636|Experimental|Ceftobiprole|Ceftobiprole 7mg/kg - 15mg/kg per day as 2h infusion
3213581|NCT01026649|Experimental|2 stage|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
3213582|NCT01026649|Active Comparator|1 stage|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
3213583|NCT01026662||Abdominoplasty|Subjects scheduled for abdominoplasty surgery
3213584|NCT01026675||Pregnant women 6-13 weeks|
3213585|NCT01026688|Experimental|Intervention|
3213586|NCT01026688|Other|Control|
3213587|NCT01026701||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
3213588|NCT01026714|Experimental|flurbiprofen 50mg po|
3213589|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inducer|
3213590|NCT01026714|Experimental|flurbiprofen 50 mg po + CYP2C9 inhibitor|
3213591|NCT01026727|Experimental|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|MPC-4326 300 mg or 400mg BID plus a 2-3 drug optimized background regimen (OBR)for 24 weeks.
3213592|NCT01026727|Active Comparator|3-4 drug antiretroviral drugs|3-4 commercially available antiretroviral (ARV)drugs for 24 weeks.
3213593|NCT01026740|Experimental|001|Ceftobiprole 500 mg, single infusion over 2 hours
3213594|NCT01026753|No Intervention|FOBT by laboratory requisition or directly by PCP|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit.
3213595|NCT01026753|Experimental|FOBT by lab req. or directly from PCP + study magnet|The family physician indicates fecal occult blood test on the patient's laboratory requisition (i.e. the patient receives the fecal occult blood test at the lab) or provides the patient with an FOBT kit. The family physician provides each patient with a study magnet containing a PHCC telephone number and study specific website address.
3213596|NCT01026766||Non obese/ Warming blankets|
3213597|NCT01026766||Non obese/ Warming intravenous fluids|
3213598|NCT01026766||Obese/ Warming intravenous fluids|
3213599|NCT01026766||Obese/ Warming blankets|
3213600|NCT01026779||Cases of rotavirus gastroenteritis|Patients will be eligible as cases if they have been identified by the investigator's ongoing rotavirus surveillance studies as having been hospitalized with laboratory-confirmed rotavirus gastroenteritis between January 1, 2007 and June 31, 2009. To be eligible as a case, the child must meet the following criteria: 1) immunocompetent; 2) born after April 15, 2006 (to select a population that would have been in the age group eligible for at least 1 dose of RV5 (RotaTeq); and 3) > 2 months of age on the day of admission.
3213601|NCT01026779||Control Subjects|Three controls for each case will be identified using KIDSNET, the state child health registry. Controls will be matched to cases by age and county of residence at birth.
3213602|NCT01026857|Experimental|PLC Colon release tablet 1 g|40 patients each arm
3213603|NCT01026857|Experimental|PLC colon release tablet 2 g|40 patients each arm
3213604|NCT01026857|Placebo Comparator|Placebo PLC colon release tablet 2 g|40 patients each arm
3213605|NCT01026870|Active Comparator|Mometasone furoate (MF) metered-dose inhaler 100 mcg BID|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks
3213606|NCT01026870|Placebo Comparator|Placebo metered-dose inhaler BID|2 inhalations from a matching placebo inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
3213607|NCT01026883|Other|Healthy subjects|Hematocrit level of each subject will be assessed by two different techniques
3213608|NCT01026922||SmartPill Participants|It is a single-center study, children aged 8-17 years with severe upper GI symptoms (ie, nausea, vomiting, retching, abdominal pain) referred for antroduodenal manometry (ADM) studies underwent a wireless motility capsule (smartpill) test. The scintigraphic gastric emptying study was done when clinically indicated either at the time of the ADM or at a different time within 1 year of the wireless motility capsule test. In summary, we studied symptomatic adolescents using scintigraphic gastric emptying studies, ADM, and the wireless motility capsule test, with the goal of identifying the diagnostic yield of each test and exploring how they compare in detecting motor abnormalities in the GI tract.
3213609|NCT01026935|Experimental|sutured mesh|200 patients are randomized to inguinal hernia repair with sutured light weight (38g/m2) polypropylene mesh (Lichtenstein repair)
3213610|NCT01026935|Experimental|non-sutured mesh|200 patients are randomized to receive a light weight mesh that adheres to tissues with polylactic micro hooks without sutures
3213611|NCT01026961|Experimental|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
3213612|NCT01026961|Active Comparator|Phenylephrine hydrochloride|Phenylephrine hydrochloride 10mg
3213613|NCT01026987|Experimental|Related Donors: G-CSF & AMD3100|G-CSF 10 ug/kg SC daily for 5 days. AMD3100 320 mcg/kg IV over 30 min on Day 5. Leukapheresis on Day 5.
3213614|NCT01026987|Other|Recipient|Stem Cell Infusion on Day 0
3213615|NCT01027013|Experimental|rebamipide 2% ophthalmic suspension|
3213616|NCT01027013|Placebo Comparator|Placebo eye drops|
3213617|NCT01027026|Experimental|Group 1 Fast Track Group|The patients are discharged the same day after coronary angiography to the refering Hospital
3213618|NCT01027026|Active Comparator|Group 2: Ordinary care|Ordinary Cardiology care in the Intervention hospital
3213619|NCT01027039||Patients using noise-reducing headphones|Patients using noise-reducing headphones
3213620|NCT01027039||Patients using no headphones|Patients using no headphones
3213621|NCT01027039||Patients using headphones with music|Patients using headphones with music
3213622|NCT01027052|Active Comparator|Hamburger meat patty with Spice Blend|Hamburger meat patty containing spice blend will be consumed on 3 separate occasions
3213623|NCT01027052|Placebo Comparator|Hamburger meat patty with salt|Hamburger meat patty containing salt will be consumed on 3 separate occasions
3213624|NCT01027065|Experimental|Tritherapy: CYT107+ vaccine+ antiviral|
3213625|NCT01027065|Experimental|Bitherapy: CYT107 + antiviral|
3213626|NCT01027078||OSA|patients diagnosed with obstructive sleep apnea who do not have existing cardiovascular disease
3213627|NCT01027078||control|patients without obstructive sleep apnea who are matched in weight and age to the OSA patients
3213628|NCT01027091||patients with positive slope|patients with positive slope in the levels of free serum calcium levels between 6th and 12th postoperative hour
3213629|NCT01027091||patients with negative or no slope|patients with negative or no slope in the levels of free serum calcium levels between 6th and 12th postoperative hour.
3213630|NCT01027117|Active Comparator|Treatment A|Revatio 20 mg intact tablet. This is the reference treatment arm.
3213631|NCT01027117|Experimental|Treatment B|Treatment B: Revatio 20 mg crushed tablet mixed with apple sauce.
3213632|NCT01027117|Experimental|Treatment C|Treatment C: Revatio 20 mg extemporaneously prepared suspension (EP).
3213633|NCT01027130||healthy control|240 female subjects without preeclampsia
3213634|NCT01027130||preeclampsia|120 female subjects with preeclampsia
3213635|NCT01027143|Experimental|omega-3 fatty acids|3 softgels (EPA, DHA) twice daily
3213636|NCT01027143|Placebo Comparator|control|Soybean oil: 3 matched softgel caps twice daily
3213637|NCT01027156|Experimental|High Intensity Exercise|
3213638|NCT01027169|Experimental|Arm 1|subjects with mild hepatic impairment
3213639|NCT01027169|Experimental|Arm 2|subjects with moderate hepatic impairment
3213640|NCT01027169|Experimental|Arm 3|matched subjects with normal hepatic function
3213641|NCT01027182|No Intervention|Raltegravir|
3213642|NCT01027208|Experimental|Ixabepilone|
3213643|NCT01027221|No Intervention|0|primarily resectable pancreatic cancer patients
3213644|NCT01027221|Active Comparator|0,5 Gy|neoadjuvant Radiation of 0,5 Gy two days before resection
3213645|NCT01027221|Active Comparator|2 Gy|neoadjuvant Radiation of 2 Gy 2 days before resection
3213646|NCT01027221|Active Comparator|5 Gy|neoadjuvant Radiation of 5 Gy 2 days before resection
3213647|NCT01027234|Experimental|1|
3213648|NCT01027234|Placebo Comparator|2|
3213649|NCT01027260|Active Comparator|Itopride 50 mg|
3213650|NCT01027260|Active Comparator|Itopride 100 mg|
3213651|NCT01027260|Placebo Comparator|Placebo|
3213652|NCT01027299|Active Comparator|Standard pacing|Standard pacing settings prescribed by the cardiac surgeon or intensivist after revascularisation.
3213653|NCT01027299|Active Comparator|BiVentricular pacing (BiV).|The group of patients receiving biventricular pacing after cardiac surgery.
3213654|NCT01027312||Glaucoma Patients|Glaucoma patients covering the entire range of visual field loss from none to advanced.
3213655|NCT01027312||Control Group|Aged matched people with no eye diseases.
3213656|NCT01027325|Experimental|High CHO/Low Amylose|55% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 25% Fat
3213657|NCT01027325|Experimental|Low Carbohydrate/Hi Amylose|40% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 40% Fat
3213658|NCT01027325|Experimental|High CHO/High Amylose|55% Carbohydrate (26.3% Amylose, 11.2% Amylopectin) 20% Protein 25% Fat
3213659|NCT01027325|Experimental|Low Carbohydrate/Low Amylose|40% Carbohydrate (11.2% Amylose, 26.3% Amylopectin) 20% Protein 40% Fat
3213660|NCT01027325|Active Comparator|Baseline|40% Carbohydrate 20% Protein 40% Fat
3213661|NCT01027338|Experimental|Tai Chi Exercise|
3213662|NCT01027338|No Intervention|Usual Care|
3213663|NCT01027377|Experimental|A|Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
3213664|NCT01027377|Experimental|B|Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments
3213665|NCT01027390|Experimental|1 hr training 50% supervision|1 hr training 50% supervision
3213666|NCT01027390|Experimental|3 x 20 min training 50% supervision|3 x 20 min training 50% supervision
3213667|NCT01027390|Experimental|3 x 20 min training initial instructions|3 x 20 min training initial instructions
3213668|NCT01027390|Experimental|10 x 6 min training 50% supervision|10 x 6 min training 50% supervision
3213669|NCT01027390|No Intervention|reference|no training
3213670|NCT01027403||Healthy volunteers|
3213671|NCT01027403||Acute decompensated heart failure|
3213672|NCT01027429|Active Comparator|procaine penicillin and gentamicin|Procaine penicillin, 50,000 IU/kg by intramuscular injection plus gentamicin, 5 mg/kg intramuscular injection, both given once daily for 7 days
3213673|NCT01027429|Experimental|Amoxicillin and gentamicin|Oral amoxicillin (80-90 mg/kg) divided twice daily and intramuscular gentamicin, 5 mg/kg once daily, both given for 7 days
3213674|NCT01027429|Experimental|procaine penicillin, gentamicin, and amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
3213675|NCT01027442|Placebo Comparator|Conventional implant placement method|"The patients in ths group will be treated by conventional, free-hand implant placement"
3213676|NCT01027442|Active Comparator|Computer-guidedimplant placement|In this group, the patients will be treated by implants placed via computer generated SLA guides
3213677|NCT01027455|Placebo Comparator|Dry Cold|Dry (0% relative humidity) and cold (20 degrees Celsius - Room Temperature) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
3213678|NCT01027455|Experimental|Humidification|Humidified (98% relative humidity) and warm (37 degrees Celsius) carbon dioxide gas intraperitoneal insufflation for laparoscopic appendicectomy
3213679|NCT01027494||Treatment|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension, 4 drops in outer ear canal of infected ear(s) while awake 2 times per day for 7 days
3213680|NCT01027494||Healthy|No intervention
3213681|NCT01027520|Experimental|Intervention|Application of Coban dressing
3213682|NCT01027533||Restor +3|patients will be implanted bilaterally with Restor + 3
3213683|NCT01027533||restor +4|Patients will be implanted bilaterally with Restor +4
3213684|NCT01027546|Placebo Comparator|placebo, tranexamic acid|
3213685|NCT01027572|Experimental|Thalamic stimulation|Patients in Vegetative or Minimally Conscious State
3213686|NCT01027611|Experimental|proparacaine HCL 0.5%|
3213687|NCT01027611|Experimental|proparacaine + lidocaine|
3213688|NCT01027611|Experimental|lidocaine gel|
3213689|NCT01027624||Hyperchlesterolaemia|Participants undertreated with hypercholesterolaemia
3213690|NCT01027637|Experimental|Alloderm reconstruction|All patients recieving the intervention Alloderm for breast reconstruction
3213691|NCT01027663|No Intervention|Iron Deficiency Anemia|
3213692|NCT01027663|No Intervention|Hereditary Hemochromatosis|
3213693|NCT01027663|Active Comparator|Iron Supplements|
3213694|NCT01027676|Experimental|study arm|single arm Gefitinib plus vorinostat
3213695|NCT01027689|Active Comparator|Alprazolam commercial immediate release oral tablet|
3213696|NCT01027689|Experimental|Alprazolam test sublingual tablet|
3213697|NCT01027715|Experimental|EEG seizure treatment group|EEG data available to physicians. Treatment based on EEG seizures. Treatment will be dictated by the detailed treatment protocol. Standard antiepileptic medications will be used.
3213698|NCT01027715|No Intervention|Clinical Seizure treatment Group|Seizure treatment in this group will be based on standard care - treating clinical seizures only. While EEG data will be collected in this group, the data will not be available to the treating physicians. A one-hour EEG report will be available to the treating team. Continuous EEG monitoring and treatment will only be allowed if the initial EEG shows status.
3213699|NCT01027728|Experimental|CCX354-C|
3213700|NCT01027741|Experimental|Phone Referral|Participants receive phone referral to cancer control and prevention services.
3213701|NCT01027741|Experimental|Tailored Cancer Communication|Participants will receive phone referral to cancer control and prevention services as well as tailored materials in the mail.
3213702|NCT01027741|Experimental|Cancer Control Navigator|Participants will receive phone referral to cancer control and prevention services as well as a personal cancer control navigator.
3213703|NCT01027741|No Intervention|Control|Participants receive only recommendation to talk to health care professional.
3213704|NCT01027767||Surgery/Radiation Arm|Patients that have had surgery along with radiation therapy
3213705|NCT01027767||Surgery Arm|Patients that have had surgery of a benign lesion.
3213706|NCT01027832|No Intervention|Control arm|no intervention
3213707|NCT01027832|Experimental|Experimental arm|antibiotics
3213708|NCT01027858|Experimental|1|AT (aerobic-based exercise training)
3213709|NCT01027858|Active Comparator|2|CON (control; usual care)
3213710|NCT01027923|Experimental|Dose Level 1|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 320 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3213711|NCT01027923|Experimental|Dose Level 2|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 420 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3213712|NCT01027923|Experimental|Dose Level 3|"Mitoxantrone 8 mg/m2/day IV over 30 minutes once daily on days 1-5~Plerixafor 560 mcg/kg/day IV over 30 minutes on days 0-5~Etoposide 100 mg/m2/day IV over 60 minutes once daily on days 1-5~Cytarabine 1000 mg/m2/day IV over 60 minutes once daily on days 1-5"
3213713|NCT01027936||Normal Healthy Volunteers|
3213714|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training using software packages donated by Posit Science.
3213715|NCT01027962|No Intervention|Control Intervention|Commercially available computer games that do not contain violent stimuli but are appealing to youth between 10 and 19 years of age.
3213716|NCT01027962|No Intervention|Healthy Control Group|No participation in computer activity.
3213717|NCT01028040|Experimental|AZD3043|
3213718|NCT01028066|Active Comparator|Traditional|Traditional nutritional counseling
3213719|NCT01028066|Experimental|Behavioral|Dialogic nutritional counseling
3213720|NCT01028079|Active Comparator|Arm 2|
3213721|NCT01028079|Placebo Comparator|Arm 3|
3213722|NCT01028079|Experimental|Arm 1|
3213723|NCT01028092|Active Comparator|Control|anti R-IL2 induction + Mycophenolate Mofetil + cyclosporine A + corticosteroids
3213724|NCT01028092|Experimental|CNI-free|Thymoglobulin + Mycophenolate Mofetil + everolimus + corticosteroids
3213725|NCT01028092|Experimental|Switch|anti R-IL2 + Mycophenolate Mofetil + (Cyclosporine then Everolimus) + corticosteroids
3213726|NCT01028105|No Intervention|No MRSA screening, Group b|Standard of care
3213727|NCT01028105|Other|MRSA screening, Group a|MRSA preoperative screening
3213728|NCT01028118|Other|Therapy for Women reporting violence|Asking about life experience with violence and Cognitive Behavior Therapy.
3213729|NCT01028144|Experimental|ACT Program|Motivational and Behavioral Skills Physical activity after-school program
3213730|NCT01028144|Active Comparator|General Health|General health education after-school program
3213731|NCT01028157|Placebo Comparator|General Health Control|
3213732|NCT01028157|Experimental|HIV Risk Reduction & Relapse Prevention|
3213733|NCT01028170|Experimental|Furosemide with Hypertonic Saline|Furosemide with 150 mL of 2.4% NaCl
3213734|NCT01028170|Active Comparator|Pulse Furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
3213735|NCT01028183||Extremely Premature Infants|< 30 weeks gestation (N=5000)
3213736|NCT01028183||Premature Infants|30-36 weeks gestation (N=2000)
3213737|NCT01028183||Hospitalized Term Infants|>=37 weeks gestation (N=2000)
3213738|NCT01028183||Healthy Term Infants|>=37 weeks gestation (N=1000)
3213739|NCT01028196||1 - schizophrenia|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with schizophrenia as they routinely attend the clinic or are examined in hospital in a consecutively manner.
3213740|NCT01028196||2 - recurrent depression|Psychiatrists will enrol patients meeting inclusion/exclusion criteria with recurrent depression as they routinely attend the clinic or are examined in hospital in a consecutively manner.
3213741|NCT01028209|Experimental|Assess [18F] PBR06 and PET imaging|
3213742|NCT01028235||Obstructive Dysphagia|Patients who complained of dysphagia, which had an obstructive etiology for their symptoms at the time of endoscopy (ring, mass, stricture, etc)
3213743|NCT01028235||Non-obstructive Dysphagia|Patients whose endoscopy was normal and without any obvious etiology for their symptoms noted.
3213744|NCT01028248|Active Comparator|2.0 mg Ranibizumab|
3213745|NCT01028248|Active Comparator|0.5 mg Ranibizumab|
3213746|NCT01028261|Experimental|ZGN-433|
3213747|NCT01028261|Placebo Comparator|Normal Saline|
3213748|NCT01028274|Placebo Comparator|Placebo|
3213749|NCT01028274|Experimental|Investigational Product 1|
3213750|NCT01028274|Experimental|Investigational Product 2|
3213751|NCT01028287|Active Comparator|ACTH-16 units|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
3213752|NCT01028287|Active Comparator|ACTH-32 units|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
3213753|NCT01028313|Experimental|1|Systemic Therapy
3213754|NCT01028326|Experimental|Group A|Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later
3213755|NCT01028326|Experimental|Group B|Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.
3213756|NCT01028326|Active Comparator|Group C|Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.
3213757|NCT01028339|Active Comparator|Mannitol|
3213758|NCT01028339|Experimental|Hypertonic saline|
3213759|NCT01028365||No treatment|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
3213760|NCT01028404|Experimental|Trial part 1|
3213761|NCT01028404|Experimental|Trial part 2|
3213762|NCT01028417|Experimental|Group 1|Group 1 receives the intervention - insertion of platinum microcoil followed by nodule excision
3213763|NCT01028417|No Intervention|Group 2|Group 2 receives the standard of care - nodule excision, but without the microcoil insertion
3213764|NCT01028430||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3213765|NCT01028443|Active Comparator|Cyclosporine A 2%|
3213766|NCT01028443|Placebo Comparator|Artificial tears|
3213767|NCT01028456|Placebo Comparator|100 lux|100 lux / 30 minutes day
3213768|NCT01028456|Experimental|Light Therapy 10,000 lux|10,000 lux / 30 minutes a day for 3 months
3213769|NCT01028469|Experimental|Artelon MTP Spacer|Metatarsophalageal hemi-implant
3213770|NCT01028482|Experimental|sertraline, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
3213771|NCT01028482|Placebo Comparator|placebo, psychotherapy|"both study groups will receive concomitant psychotherapy treatment. There will be 2 main comparison groups: 1) an sertraline treated group and 2) a drug placebo - controlled group. While this design lacks a blinded drug-only condition, we will have an open drug-only arm that will be of considerable value. Furthermore, while a true placebo group is also lacking, and a certain response to psychotherapy is expected, we believe that the drug condition will show a definite superiority to the psychotherapy + placebo condition. The rational for including psychotherapy in the treatment protocol is the fact that this is a well-established treatment for PPD, and for ethical considerations it is unreasonable not to administer any active treatment to women suffering from PPD. It is our conviction that this is the only design, albeit its limitations, which will allow a comparison between medication-treated vs. placebo-treated PPD patients."
3213772|NCT01028495|Experimental|gemcitabine and RX-0201|"Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.~RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off."
3213773|NCT01028508|Active Comparator|PHARM|lithium and venlafaxine
3213774|NCT01028508|Experimental|STABLE|ECT + VLF + Li
3213775|NCT01028521|Experimental|CM3.1-AC100|
3213776|NCT01028521|Placebo Comparator|Placebo|
3213777|NCT01028534|Active Comparator|ARB plus increased ARB|angiotensin II receptor blockers for the first 3 months and increasing dose of angiotensin II receptor blockers for the next 3 months
3213778|NCT01028534|Active Comparator|ARB plus CCB|angiotensin II receptor blockers for the first 3 months and adding calcium channel blockers for the next 3 months
3213779|NCT01028534|Active Comparator|CCB plus ARB|calcium channel blockers for the first 3 months and adding angiotensin II receptor blockers for the next 3 months
3213780|NCT01028547|Active Comparator|dexamethasone 8mg|
3213781|NCT01028547|Placebo Comparator|normal saline|
3213782|NCT01028573|Active Comparator|Group 1|4L of PEG-ELS (Golytely) consumed on the evening before colonoscopy
3213783|NCT01028573|Experimental|Group 2|2L of PEG-ELS (Golytely) consumed on the evening before and 2L consumed on the morning of colonoscopy
3213784|NCT01028573|Experimental|Group 3|238g of PEG-3350 mixed with 2L of Gatorade
3213785|NCT01028573|Experimental|Group 4|1L of PEG-3350 + Gatorade
3213786|NCT01028586|Active Comparator|Arm 1|Number of Cycles: until progression or unacceptable toxicity develops.
3213787|NCT01028586|Active Comparator|Arm 2|Number of Cycles: until progression or unacceptable toxicity develops.
3213788|NCT01028586|Placebo Comparator|Arm 3|Placebo
3213789|NCT01028599|Experimental|Exercise|
3213790|NCT01028612|Experimental|thermal ablation with external beam radiation|
3213791|NCT01028625|Active Comparator|Cognitive Behavior Therapy|
3213792|NCT01028625|Other|Usual Care|Participants who are randomly assigned to usual care will receive whatever treatment (if any) for depression their own physician may prescribe. In most cases, treatment (if any is provided) is likely to consist of a serotonin reuptake inhibitor (SSRI) antidepressant such as sertraline or citalopram.
3213793|NCT01028638||Renal Cancer|Renal Cancer patients treated with everolimus
3213794|NCT01028664|Experimental|Glaucoma or ocular hypertension patients|
3213795|NCT01028690|Active Comparator|Lactobacillus reuteri|L. reuteri is one species of lactobacillus that naturally inhabits the gastrointestinal tract of humans
3213796|NCT01028690|Placebo Comparator|placebo|Placebo will be delivered in a chewable tablet form (1.5g per dose)
3213797|NCT01028703||Donors|"110 will be cases that undergo uninephrectomy"
3213798|NCT01028703||Controls|"110 controls"
3213799|NCT01028716|Experimental|Treatment (nonmyeloablative HCT, TBI)|Patients receive fludarabine IV over 30-60 minutes daily on days -6 through -2 and cyclophosphamide IV over 1-2 hours on days -6, -5, and 3-4. Patients undergo total-body irradiation on day -1. Patients undergo donor peripheral blood stem cell transplant on day 0. Patients then receive tacrolimus IV once daily or PO BID on days 5-180 (may be continued if active GvHD is present), mycophenolate mofetil IV or PO TID on days 5-35 (may be continued if GvHD present), and filgrastim IV beginning on day 5 until the ANC is >= 1,000/mm^3 for three consecutive days.
3213800|NCT01028729|Experimental|Endostar with chemotherapy|All eligible patients will receive Endostar in combination with Gemcitabine plus Platinum-based chemotherapy for 4 cycles (21 days for each cycle). Endostar treatment will continue after completion of chemotherapy cycles until disease progression.
3213801|NCT01028755|Experimental|Arm 1|
3213802|NCT01028768|Experimental|Teduglutide|
3213803|NCT01028781|Other|Thalidomide|Thalidomide was administered and pain reports were recorded over the course of 6 months.
3213804|NCT01028794|Experimental|autologous bone marrow mononuclear cell|On day 7-10 after stroke, patient has 25ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
3213805|NCT01028794|Experimental|autologous bone marrow mononuclear cells|On day 7-10 after stroke, patient has 50ml of bone marrow cells aspiration. Mononuclear cells are purified by Ficoll and administrated intravenously.
3213806|NCT01028807|Experimental|1. Experimental group: Early feeding:|After 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
3213807|NCT01028807|Active Comparator|Control group : Obligatory 5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
3260332|NCT01478464|Experimental|Massage group|Massage will be performed on the left or right hamstring muscle (randomized) for ten minutes with a massage roller. The contralateral leg will not be massaged, but serve as a non-massaged control leg to assess possible cross-over effects from the massaged leg
3260333|NCT01478477|Experimental|Arm I (omega-3 fatty acid supplement)|Omega 3 Polyunsaturated Fatty Acids(n-3 PUFA)
3213808|NCT01028833|Experimental|Power mobility|Intervention included provision of power wheelchair and power mobility training program. Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
3213809|NCT01028833|No Intervention|Control|Children in the control group will not receive any additional intervention, but will continue to receive the early intervention or other services they were receiving prior to enrollment in this study.
3213810|NCT01028846|Active Comparator|Diazoxide|1-2 mg/kg total dose given intravenously during pancreatic clamp study
3213811|NCT01028846|Placebo Comparator|Placebo|Intravenous normal saline during pancreatic clamp study
3213812|NCT01028859|Experimental|CKD-516 inj|
3213813|NCT01028872|Sham Comparator|Sensar IOL|
3213814|NCT01028872|Active Comparator|Tecnis IOL|
3213815|NCT01028872|Active Comparator|AcrySof IQ|
3213816|NCT01028885|Experimental|Arm I|"Patients undergo MRI and CT scan-based simulation for treatment planning with endorectal balloon target immobilization. The treatment target volumes and surrounding organs at risk are contoured, treatment plan developed and approved.~Patients then undergo 39 fractions of image-guided intensity-modulated radiotherapy over 8 weeks. Patients also undergo weekly MRI scans of the pelvis (in the planned treatment position) during radiotherapy."
3213817|NCT01028924|Experimental|Teduglutide 5 mg|Treatment A, subcutaneous injection
3213818|NCT01028924|Experimental|Teduglutide 20 mg|Treatment B, subcutaneous injection
3213819|NCT01028924|Placebo Comparator|Placebo|subcutaneous injection
3213820|NCT01028924|Active Comparator|Moxifloxacin|400 mg, oral
3213821|NCT01028950|Experimental|YM150 group|
3213822|NCT01028963|Placebo Comparator|Placebo|
3213823|NCT01028963|Active Comparator|Active control|
3213824|NCT01028963|Experimental|Active Study Medication (Group C)|CCX140-B
3213825|NCT01028963|Experimental|Active Study Medication (Group D)|CCX140-B
3213826|NCT01028976|Placebo Comparator|Placebo|Two tablets, daily, for 8 weeks
3213827|NCT01028976|Experimental|Vitamin C|Two tablets, daily, for 8 weeks
3213828|NCT01028989|Other|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
3213829|NCT01028989|Other|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
3213830|NCT01029002|Experimental|Vitamin D 50000 IU|Patients randomized to this arm will receive 50,000 IU of ergocalciferol in one unmarked pill once weekly.
3213831|NCT01029002|Placebo Comparator|Placebo|Patients randomized to this arm will receive a placebo pill once weekly.
3213832|NCT01029015||Group 1 -OAB|Subjects with overactive bladder (OAB)
3213833|NCT01029015||Group 2 - Insomnia|Subjects with insomnia
3213834|NCT01029015||Group 3 - Normal|Normal Subjects
3213835|NCT01029041|Experimental|Strengthening exercise|This group does global strengthening exercise
3213836|NCT01029041|Experimental|Stretching exercise|This group does global stretching exercise
3213837|NCT01029041|No Intervention|Control|This group does nor do any kind of exercise during the study
3213838|NCT01029067|Active Comparator|Cognitive Remediation|Computerized cognitive remediation (CogPack training). A fixed series is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with group MCT, eight sessions are administered. Each session lasts approximately 45-60 minutes.
3260334|NCT01478477|Placebo Comparator|Arm II (placebo)|Typical American Diet oils (TAD)
3213839|NCT01029067|Experimental|Metacognitive Training|The group metacognitive training program (MCT) is fully documented (Moritz, Woodward, & Metacognition Study Group, 2007; VanHam Campus Press) and can be obtained in more than 15 languages cost-free via the following link: www.uke.de/mkt. The group program is delivered to groups of 3-10 patients by trained psychologists addressing delusion-related metacognitive biases (e.g., jumping to conclusions). The eight modules are presented via a video projector using pdf-converted Power-Point slides. Each group session lasts approximately 45-60 minutes. Individualized MCT (MCT+) follows group sessions and accords to the general guidelines for cognitive-behavioral therapy. For each patient, 8 one-to-one sessions were carried in addition to one session relating to the medical history.
3213840|NCT01029080||Sepsis|All patients with sepsis defined by actually sepsis guidelines
3213841|NCT01029132|Experimental|non-responder group|patients who did not maintained or improved cognitive function
3213842|NCT01029132|Experimental|responder group|patients who maintained or improved cognitive function
3213843|NCT01029145||1|Bipolar patients that experience a new episode of any type
3213844|NCT01029158|Experimental|1a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3213845|NCT01029158|Experimental|1b|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3213846|NCT01029158|Experimental|1c|250 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3213847|NCT01029158|Experimental|1d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3213848|NCT01029158|Experimental|2a|250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 250 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3213849|NCT01029158|Experimental|2b|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure.
3213850|NCT01029158|Experimental|2c|500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then a further 500 ng Juvista or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose.
3213851|NCT01029158|Experimental|2d|500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin immediately after wound closure. Then 500 ng RN1006 or placebo injected intradermally down each 1 cm of wound margin 24 (+/- 4) hours after administration of the first dose (i.e. two doses in total).
3213852|NCT01029171|Experimental|1|OEP (Otago Exercise Program; home-based balance and strength retraining program)
3213853|NCT01029171|Active Comparator|2|CON (control; usual care)
3213854|NCT01029184|Active Comparator|complete non allergenic cereals|existing commercialized product
3213855|NCT01029184|Experimental|complete non allergenic cereals plus|commercialised product with the addition of a novel ingredient
3213856|NCT01029197|Experimental|CBT Intervention|The CBT intervention includes psychoeducation and coping and social skills delivered in a group format, and exposure therapy delivered in individual sessions
3213857|NCT01029197|Active Comparator|Treatment as Usual|The TAU Condition will receive usual services at the community clinic, which may include medications, individual or group therapy
3213858|NCT01029223|Experimental|ivabradine|
3213859|NCT01029223|Experimental|metoprolol|
3213860|NCT01029223|Placebo Comparator|placebo|
3213861|NCT01029249||ACTG A5257 participants|Participants in this study will also be enrolled in ACTG A5257.
3213862|NCT01029275|Experimental|Arm A|pre-operative medical treatment with Sandostatin
3213863|NCT01029275|No Intervention|Arm B|pituitary surgery as a first line treatment
3213864|NCT01029288|Active Comparator|Statin Choice Decision Aid|Subjects will receive an intervention of Statin Choice Decision Aid and usual care for antihyperglycemic medication discussion with their clinician.
3213865|NCT01029288|Active Comparator|Diabetes Medication Choice Decision Aid|Subjects will receive an intervention of Diabetes Medication Choice Decision Aid and usual care for lipid therapy medication discussion with their clinician.
3213866|NCT01029301|Experimental|Experimental: Endymed study group|
3213867|NCT01029314||Cardiopulmonary bypass surgery|Thirty to fifty cardiac surgery patients undergoing cardiopulmonary bypass will have serial triplicate temperatures taken by both the Genius 2 tympanic thermometer and the Exergen-TAT 5000 temporal artery thermometer at predetermined perioperative time points. These temperature readings will be compared to at least one core temperature (i.e., pulmonary artery).
3213868|NCT01029327||Healthy subjects|
3213869|NCT01029379||200 patients,ASA 1|
3213870|NCT01029418|Experimental|AZD6244 and sorafenib|AZD6244+ sorafenib
3213871|NCT01029431|Experimental|1|All subjects will have both Air-Q ILA & PLMA
3213872|NCT01029444|Experimental|Insulin|Brittle diabetic patients or patients with uncontrolled blood sugars will complete blood sugar diaries weekly and have hemoglobin A1c lab tests performed quarterly to evaluate progress in stabilizing blood sugars.
3213873|NCT01029470|Experimental|Luveris|Those subjects who experience hyponresponse to FSH stimulation during mid-follicle phase after pituitary downregulation will receive Luveris 75IU or 150IU IH injection daily till HCG day.
3213874|NCT01029483|Experimental|Low carbohydrate diet|6 week ad libitum low carbohydrate diet; research diet provided at 120% of estimated energy requirement for weight maintenance; carbohydrate intake limited to 28g/d
3213875|NCT01029483|Active Comparator|High Carbohydrate Diet-ad libitum|High complex carbohydrate diet (55% carbohydrate, 18% protein, 27% fat. 120% of estimated energy needs for weight maintenance provided, participants allowed to eat as much or as little as desired to satisfy appetite
3213876|NCT01029483|Active Comparator|High Carbohydrate Diet-Energy-matched|High carbohydrate diet (55% carbohydrate, 18% protein and 27% fat). Energy intake restricted to ~68% of energy needs for weight maintenance. Participants required to eat all food provided and nothing else
3213877|NCT01029509|Experimental|OPB-31121|OPB-31121 200 mg twice daily for 21 days followed by 7 days of rest
3213878|NCT01029522|Experimental|Lipilou 20mg|
3213879|NCT01029522|Active Comparator|Lipitor 20mg|
3213880|NCT01029561|Active Comparator|CPAP and diet|The patients with severe OSA (AHI>=30) who do not fulfill the specific exclusion criteria wil be randomized. In the CPAP and diet arm, patients wil receive Continuous Positive air pressure therapy and the regular dietary treatment.
3213881|NCT01029561|Active Comparator|Diet|The diet arm wil receive the Conventional diet treatment that usually receive the patients included in the Bariatric Surgery Program
3213882|NCT01029574|Experimental|Rotator cuff repair plus PRP|Conventional arthroscopic repair of rotator cuff with application of PRP.
3213883|NCT01029574|Placebo Comparator|Rotator cuff repair alone|Conventional arthroscopic repair of rotator cuff without application of PRP
3213884|NCT01029600|Active Comparator|Arthroscopic Capsulotomy|Arthroscopic capsular release
3213885|NCT01029600|Active Comparator|Distention with steroid|Arthrographic distention with contrast, saline, steroid and local anaesthetic
3213886|NCT01029613||Rheumatoid arthritis|
3213887|NCT01029626|Other|Endoscopy|If the Glasgow-Blatchford score is zero, the endoscopy is delayed as an outpatient
3213888|NCT01029639|No Intervention|Treatment|Diabetic patients will complete hypoglycemia unawareness questionnaires at baseline and quarterly thereafter to monitor and assess progress with complications resulting from their diabetes. Comparisons will be performed on low blood sugar incidences reported by subjects requiring heath care intervention other than by the subject themselves.
3213889|NCT01029639|Experimental|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
3213890|NCT01029665||CDH survivors|School age (ages 4-6) Congenital Diaphragmatic Hernia survivors treated at Duke University Medical Center.
3213891|NCT01029678|Experimental|experimental|
3213892|NCT01029717|Experimental|Standard polyurethane Central Venous Catheter|"Standard polyurethane Central Venous Catheter~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3213893|NCT01029717|Active Comparator|Antibiotic impregnated polyurethane CVC|"Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3213894|NCT01029717|Active Comparator|Heparin bonded polyurethane CVC|"Heparin bonded polyurethane CVC~All CVCs used in the trial are CE marked medical devices used for their intended purpose."
3213895|NCT01029743||Group 1|
3213896|NCT01029743||Group 2|
3213897|NCT01029756|Active Comparator|Macintosh Laryngoscope|
3213898|NCT01029756|Active Comparator|Pentax AWS Videolaryngoscope|
3213899|NCT01029769|Active Comparator|initial olanzapin|
3213900|NCT01029769|Active Comparator|initial amisulpride|
3213901|NCT01029769|Active Comparator|early responders|
3213902|NCT01029769|Active Comparator|early non-responders switched|
3213903|NCT01029769|Active Comparator|ealy non-responders non-switched|
3213904|NCT01029821|Other|Low-Molecular-Weight Heparin for DVT|Low-Molecular-Weight Heparin for DVT Prophylaxis after Open Reduction and Internal Fixation of ankle fractures
3213905|NCT01029834|Experimental|Intervention- Lifestyle family based|Behavioral family based
3213906|NCT01029834|Active Comparator|Information control|Child intervention only
3213907|NCT01029847|Placebo Comparator|Placebo|
3213908|NCT01029847|Active Comparator|Adalimumab|TNF-alpha inhibitor
3213909|NCT01029873|Experimental|ALT-801|
3213910|NCT01029938|Active Comparator|Covered stent|The Willis covered stent specifically designed for intracranial vasculature was developed by our institution and the MicroPort Medical Company (Shanghai, China), and coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
3213911|NCT01029938|Active Comparator|Coil|Coil embolization, which has been widely applied for nearly two decades, is currently the endovascular approach that is first recommended for intracranial aneurysm treatment.
3213912|NCT01029964|Active Comparator|6-9 years|Age at start of treatment
3213913|NCT01029964|Active Comparator|10-13 years|Age at start of treatment
3213914|NCT01029964|Active Comparator|14-16 years|Age at start of treatment
3213915|NCT01029964|No Intervention|Control 6-9 years|Untreated control group
3213916|NCT01029990|Experimental|Telephone arm|A midwife tries to contact the woman by telephone and offer her an appointment for a PAP-smear
3213917|NCT01029990|Experimental|Self-test arm|
3213918|NCT01029990|No Intervention|Control arm|No intervention other than what is routine in the screening program
3213919|NCT01030016|Experimental|atenolol|subjects received 6 weeks of atenolol
3213920|NCT01030029|Active Comparator|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
3213921|NCT01030029|Placebo Comparator|pstim device without acupuncture|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
3213922|NCT01030042|Experimental|Cetuximab/Irinotecan|Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)
3213923|NCT01030042|Active Comparator|FOLFOX 4|FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab
3213924|NCT01030055|Experimental|TKI258 - bioavailability|
3213925|NCT01030055|Experimental|TKI258 - food|
3213926|NCT01030068|Experimental|Yoga|Yoga plus smoking cessation
3213927|NCT01030068|Active Comparator|Wellness|Health & Wellness classes plus smoking cessation therapy
3213928|NCT01030081|Experimental|Amlodipine (Norvasc®)|
3213929|NCT01030081|Active Comparator|Nifedipine GITS (Adalat® XL 30)|
3213930|NCT01030094||Topiramate|Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
3213931|NCT01030094||Carbamazepine|Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
3213932|NCT01030094||Valproic acid|Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
3213933|NCT01030094||Normal Control|Healthy female participants will be observed in Normal control group.
3213934|NCT01030107||Children with Insufficient Sleep|Children who sleep approximately 9-10 hours/night
3213935|NCT01030120|Active Comparator|etanercept|etanercept 50mg BIW
3213936|NCT01030120|Placebo Comparator|placebo|matching placebo
3213937|NCT01030146|Other|NeilMed® Sinus Rinse™ System|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
3213938|NCT01030159||001|
3213939|NCT01030185|Experimental|NovaShunt's Automated Fluid Shunt|The Automated Fluid Shunt (AFS) Device
3213940|NCT01030211|Active Comparator|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
3213941|NCT01030211|Other|Supportive care|No platelet transfusion for patients with platelet count <20x10^3/uL
3213942|NCT01030224|Experimental|AZD9742 IV Infusion|Active
3213943|NCT01030224|Placebo Comparator|Placebo to AZD9742 IV Infusion|Placebo
3213944|NCT01030237|Experimental|FID 114657|FID 114657
3213945|NCT01030237|Active Comparator|Soothe XP Lubricant Eye Drops|Soothe XP Lubricant Eye Drops
3213946|NCT01030250||Under 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those under 65 years of age will be prospectively evaluated for outcome.
3213947|NCT01030250||Over 65 years|Breast cancer patients receiving adjuvant chemotherapy. Those over 65 years of age will be prospectively evaluated for outcome.
3213948|NCT01030263|Experimental|CEM|Biopsies obtained with fluorescence-aided confocal endomicroscopy.
3213949|NCT01030263|Other|RFQ|Random four-quadrant biopsies.
3213950|NCT01030276|Experimental|Bright light|
3213951|NCT01030276|Placebo Comparator|"Inactive placebo-light"|
3213952|NCT01030302||001|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
3213953|NCT01030315|Experimental|Cohort 1|The lowest dose level of HM10760A
3213954|NCT01030315|Experimental|Cohort 2|Second dose level of HM10760A
3213955|NCT01030315|Experimental|Cohort 3|Third dose level of HM10760A
3213956|NCT01030315|Experimental|Cohort 4|Fourth dose level of HM10760A
3213957|NCT01030315|Experimental|Cohort 5|The highest dose level of HM10760A
3213958|NCT01030328|Active Comparator|TriLipix + Atorvastatin|Two tables of TriLipix + Atorvastatin taken once a day by mouth.
3213959|NCT01030328|Placebo Comparator|2|2 sugar pills
3213960|NCT01030354|Active Comparator|Dietary Intervention and Higher protein meal replacement|A higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass
3213961|NCT01030354|Active Comparator|Dietary Intervention and Standard Protein Meal Replacement|Standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
3213962|NCT01030367|Experimental|1|PETN
3213963|NCT01030367|Experimental|2|ISDN
3213964|NCT01030367|No Intervention|3|
3213965|NCT01030380|Experimental|Slendertone Face NMES|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
3213966|NCT01030380|No Intervention|Control Group: No NMES|Control Group: No NMES over the course of 12 weeks.
3213967|NCT01030393|Experimental|intrauterine hCG|"Experimental arm : intrauterine injection of 100 iu(group1)or 200 iu (group2) of hCG before embryo transfer.~Intrauterine injection of 500 iu hCG before embryo transfer"
3213968|NCT01030419|Experimental|FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
3213969|NCT01030419|Placebo Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 12-month follow-up testing.
3213970|NCT01030432|Experimental|Phase 2a: Arm 1|
3213971|NCT01030432|Placebo Comparator|Phase 2a: Arm 2|
3213972|NCT01030432|Experimental|Phase 2b: Arm 1|
3213973|NCT01030432|Placebo Comparator|Phase 2b: Arm 2|
3213974|NCT01030445||Elevated Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation above the mean based on age
3213975|NCT01030445||Decrease Mean Arterial Blood Pressure|Mean arterial pressure greater than 1 standard deviation below the mean based on age
3213976|NCT01030445||Normal Mean Arterial Blood Pressure|Mean arterial pressure within the standard deviation of the mean based on age
3213977|NCT01030471|Experimental|Lifestyle counseling|
3213978|NCT01030471|No Intervention|Wait list control group|
3213979|NCT01030484||NAFLD|adult patients with non-alcoholic fatty liver disease (NAFLD).
3213980|NCT01030510|Active Comparator|group R|In group R, remifentanil was infused first before administrating propofol and rocuronium
3213981|NCT01030510|Active Comparator|group P|in group P, remifentanil was administered last after the propofol and rocuronium injection
3213982|NCT01030562||Alternate Arm|Subjects who meet eligibility requirements but do not fit into any of the primary experimental arms.
3213983|NCT01030562||Control Arm|Subjects with an on-time interval between Dose 1 and 2 and an on-time interval between Dose 2 and 3.
3213984|NCT01030562||Experimental/Primary Arm 1|This primary arm will consist of subjects receiving the second dose on time/third dose substantially late.
3213985|NCT01030562||Experimental/Primary Arm 2|This primary arm will consist of subjects receiving the second dose substantially late/third dose on time.
3213986|NCT01030562||Experimental/Primary Arm 3|This primary arm will consist of subjects receiving the second dose substantially late/third dose substantially late.
3213987|NCT01030601|No Intervention|Control|Diabetics undergoing routine cataract surgery
3213988|NCT01030601|Experimental|Treatment|Diabetics undergoing cataract surgery with injection of 0.5mg in 0.05cc of dexamethasone at the end of surgery
3213989|NCT01030614|Active Comparator|Dexamethasone group|One hundred five patients were randomized to receive intravenous dexamethasone (8 mg) before laparoscopic cholecystectomy
3213990|NCT01030614|Placebo Comparator|Placebo group|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
3213991|NCT01030640|Placebo Comparator|placebo|formulation without active drug
3213992|NCT01030640|Active Comparator|tanezumab|
3213993|NCT01030679|Experimental|CKD-501 0.5mg|
3213994|NCT01030679|Experimental|CKD-501 1mg|
3213995|NCT01030679|Experimental|CKD-501 2mg|
3213996|NCT01030679|Placebo Comparator|Placebo|
3213997|NCT01030692|Placebo Comparator|Placebo|Placebo capsules as control
3213998|NCT01030692|Active Comparator|Rivastigmine 3 mg|Rivastigmine 3 mg
3213999|NCT01030692|Active Comparator|Rivastigmine 6 mg|Rivastigmine 6 mg
3214000|NCT01030692|Active Comparator|Huperzine A 0.4 mg|Huperzine A 0.4 mg
3214001|NCT01030692|Active Comparator|Huperzine A 0.8 mg|Huperzine A 0.8 mg
3214002|NCT01030731|Experimental|Ceftobiprole (end-stage renal disease subjects).|Ceftobiprole 250mg single dose over 2 hours.
3214003|NCT01030731|Active Comparator|Ceftobiprole (healthy subjects)|Ceftobiprole 250 mg single dose over 2 hours.
3214004|NCT01030744||Gestational Diabetes|Women with gestational diabetes who are referred to and followed in the Vanderbilt Eskind Diabetes Clinic and are participants in the gestational diabetes educational program.
3214005|NCT01030770|Experimental|Arm A (treatment)|Arm A: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls) (Lucentis®)
3214006|NCT01030770|Placebo Comparator|Arm B (control):|Arm B: Single subconjunctival injection of 0.05mls of 0.9% sodium chloride (Minims Saline®)
3214007|NCT01030809|No Intervention|Usual Care practice|Patients managed according to usual care practices
3214008|NCT01030809|Active Comparator|Treatment Algorithm|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
3214009|NCT01030848||Patients with knee osteoarthritis|
3214010|NCT01030887|Active Comparator|Exercise Programme|This will consist of an 8-week exercise programme, performed twice per week.
3214011|NCT01030887|Placebo Comparator|Usual Care|Standard practice including opportunistic exercise advice and patients' self-directed physical activity
3214012|NCT01030900|Experimental|1|EPOCH + Rituximab + campath every 3 weeks for six cycles
3214013|NCT01030913||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3214014|NCT01030926|Experimental|A1, first period|
3214015|NCT01030926|Active Comparator|A2, second period|
3214016|NCT01030926|Active Comparator|B1, first period|
3214017|NCT01030926|Experimental|B2, second period|
3214018|NCT01030939|Experimental|Cohort 1: SB-649868|Healthy adult male subjects
3214019|NCT01030939|Experimental|Cohort 2|Healthy adult female subjects
3214020|NCT01030939|Experimental|Cohort 3|Healthy male elderly subjects
3214021|NCT01030939|Experimental|Cohort 4|Healthy female elderly subjects
3214022|NCT01030978|Experimental|Family-based Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
3214023|NCT01030978|Active Comparator|Standard Diet & Activity Education (Control)|
3214024|NCT01030991||HFpEF|HFpEF cohort (observational study)
3214025|NCT01031017|Placebo Comparator|placebo|group taking placebo
3214026|NCT01031017|Active Comparator|study group|group taking progesterone
3214027|NCT01031082||HIV-negative Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-negative/ presumed negative subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-negative/ presumed negative subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
3214028|NCT01031082||HIV-positive Group|This group is sub-divided into two sub-groups. One sub-group includes HIV-positive subjects with a new episode of acute otitis media who have not yet received antibiotic therapy for the episode and the other sub-group includes HIV-positive subjects with treatment failure who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment.
3214029|NCT01031108|Other|Type 2 Diabetic Group|The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
3260335|NCT01478477|Experimental|Clinical Assessments|Brief Pain Inventory (BPI), Stanford's Health Assessment-Disability Index (HAS), FACT-B and endocrine subscale (FACT-ES)
3214030|NCT01031108|Other|Otherwise Healthy Cigarette Smoking Group|The Otherwise Healthy Cigarette Smoking Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
3214031|NCT01031147||Magnetic resonance angiography|Three-dimensional time-of-flight magnetic resonance angiography(3D-TOF-MRA) was used to detect the intracranial aneurysms in this study
3214032|NCT01031186|Experimental|Cohort 1, Session 1|In Dosing Session 1, the subjects will be administered 0.5 mg GSK356278 and placebo in a fasted state.
3214033|NCT01031186|Experimental|Cohort 1, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (0.5 mg and 1.5 mg) and placebo in a fasted state.
3214034|NCT01031186|Experimental|Cohort 1, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (1.5 mg and 4 mg) and placebo in a fasted state.
3214035|NCT01031186|Experimental|Cohort 1, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (4 mg and 8 mg) and placebo in a fasted state.
3214036|NCT01031186|Experimental|Cohort 1, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 8 mg and placebo in a fasted state.
3214037|NCT01031186|Experimental|Cohort 2, Session 1|In Dosing Session 1, the subjects will be administered 8 mg GSK356278 and placebo in a fasted state.
3214038|NCT01031186|Experimental|Cohort 2, Session 2|In Dosing Session 2, the subjects will be administered GSK356278 (8 mg and 16 mg) and placebo in a fasted state.
3214039|NCT01031186|Experimental|Cohort 2, Session 3|In Dosing Session 3, the subjects will be administered GSK356278 (16 mg and 30 mg) and placebo in a fasted state.
3214040|NCT01031186|Experimental|Cohort 2, Session 4|In Dosing Session 4, the subjects will be administered GSK356278 (30 mg and 50 mg) and placebo in a fasted state.
3214041|NCT01031186|Experimental|Cohort 2, Session 5|In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
3214042|NCT01031199|Experimental|Arm 1|
3214043|NCT01031199|Experimental|Arm 2|
3214044|NCT01031225|Experimental|1|
3214045|NCT01031264||Social drinkers|
3214046|NCT01031290|Experimental|Group A|Active TMS
3214047|NCT01031290|Sham Comparator|Group B|Sham TMS
3214048|NCT01031303|Experimental|Study Group|
3214049|NCT01031316|Experimental|Nondisclosure|
3214050|NCT01031316|Active Comparator|Disclosure|
3214051|NCT01031329||Complicated Acute otitis media Group|"This group was divided into 3 sub-groups.~One sub-group includes treatment failure subjects who have had a diagnosis of acute otitis media and showed no clinical improvement within 48-72 hours of antibiotic treatment or reappearance of symptoms within 10 days following the end of antibiotic treatment.~The second sub-group includes subjects with recurrent acute otitis media, who have had new episodes of acute otitis media within the past 6 months or the fourth (or greater) new episode within the past year.~The third sub-group includes subjects with spontaneous otorrhoea if perforation has occurred < 24 hours prior to the visit."
3214052|NCT01031342|Experimental|Early colonoscopy|Colonoscopy performed within 12 hours of presentation
3214053|NCT01031342|Active Comparator|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
3214054|NCT01031355|Experimental|Arm 1|
3214055|NCT01031355|Active Comparator|Arm 2|
3214056|NCT01031355|Active Comparator|Arm 3|
3214057|NCT01031368|Experimental|Treatment (chemotherapy, G-CSF, cord blood infusion)|"INDUCTION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients receive an infusion of non-HLA matched ex vivo expanded cord blood progenitors on day 6. G-CSF is administered SC on days 0-5 and from day 7 until blood counts recover. Treatment modifications may apply according to response.~CONSOLIDATION THERAPY: Patients receive clofarabine IV over 1 hour and cytarabine hydrochloride IV over 2 hours on days 1-5. Patients also receive G-CSF SC beginning on day 0 and continuing until blood counts recover."
3214058|NCT01031394|Active Comparator|Group 1|1 aerobic and 1 resistance training per week
3214059|NCT01031394|Active Comparator|Group 2|2 aerobic and 2 resistance training each per week
3214060|NCT01031394|Active Comparator|Group 3|3 aerobic and 3 resistance training per week
3214061|NCT01031459||Group 1|
3214062|NCT01031472|Experimental|Part A|Subjects will be randomized in a three way crossover design to either a single dose of GSK2248761 100mg Gelucire capsule administered with food and a single dose of 100mg of formulation 1 or a single dose of 100mg of formulation 3 administered in the fed and fasted state
3214063|NCT01031472|Experimental|Part B|A total of twelve subjects who complete Part A will participate in Part B. Subjects from Part A will be asked to participate on a first come first serve basis until there are 12 subjects, at which time enrolment to Part B will be closed. Part B will be a 2 way cross over study design. Subjects will be randomized to one of a single dose of GSK2248761 100mg Formulation 2 or 4 (based on the evaluation of Part A data) administered with food or in the fasted state. Subjects in Part B will not receive the reference formulation since they previously received this in Part A
3214064|NCT01031485|Active Comparator|Spread with milk peptides and plant sterols|
3214065|NCT01031485|Placebo Comparator|Standard spread|
3214066|NCT01031511|Experimental|Treatment Group - CBT|
3214067|NCT01031511|No Intervention|Control Group|
3214068|NCT01031524|Experimental|vaccine|30 µg of PfCS102 formulated in Montanide ISA 720
3214069|NCT01031524|Placebo Comparator|adjuvant|Montanide ISA 720
3214070|NCT01031602||Psych Needs Assessment|Female Sexual Function Index (FSFI), Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire given to underserved and minority women with a gynecologic cancer or premalignant condition.
3214071|NCT01031615|Experimental|Child and Family Traumatic Stress Interv|4-session secondary prevention model that focuses on family communication about symptoms of a child aged 7-16.
3214072|NCT01031615|Active Comparator|Psychoeducational Comparison|4-sessions focused on individual child using psychoeducation and relaxation skills
3214073|NCT01031693|Active Comparator|Group A|Active TMS
3214074|NCT01031693|Sham Comparator|Group B|Sham TMS
3214075|NCT01031719|Experimental|Group A: High Risk Population|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3214076|NCT01031719|Experimental|Group B: High Risk Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3214077|NCT01031719|Experimental|Group C: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3214078|NCT01031719|Experimental|Group D: Healthy Subjects|Each subject will receive two doses of the assigned vaccine, the first on Study Day 1, and the second on Study Day 22
3214079|NCT01031732|Experimental|Two-incision|MIS-2 THA
3214080|NCT01031732|Experimental|Watson-Jones|MIS-WJ
3214081|NCT01031732|Experimental|MIS-AL|
3214082|NCT01031732|Experimental|MIS-PL|
3214083|NCT01031745|Experimental|Contingency|
3214084|NCT01031745|Active Comparator|Control|
3214085|NCT01031758|Other|Group 1|Group 1 is comprised of 6 healthy subjects with HDL-C levels between the 25th and 75th percentile.
3214086|NCT01031758|Other|Group 2|Group 2 is comprised of 6 healthy subjects with high HDL-C levels > 75th percentile.
3214087|NCT01031758|Other|Group 3|Group 2 is comprised of 6 healthy subjects with low HDL-C levels < 25th percentile.
3214088|NCT01031784|Experimental|Holmium-166 microspheres, intra-arterial|intra-arterial administration of holmium-166 microspheres in the liver
3214089|NCT01031797||High SLEDAS|High SLE disease activity score
3214090|NCT01031797||Low SLEDAS|SLE patient with low score
3214091|NCT01031823|Experimental|Social Skills Training|All participants will take part in this arm of the study.
3214092|NCT01031849|Experimental|Kaletra, all patients|Patients will change actual treament for monotherapy LPV/r. They only will take Kaletra 2/day
3214093|NCT01031862|Other|Healthy Volunteers|12 healthy volunteers
3214094|NCT01031888|Active Comparator|1|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy receiving topical insulin eye drops in addition to conventional postoperative eye drops
3214095|NCT01031888|Active Comparator|2|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving topical insulin eye drops in addition to conventional postoperative eye drops
3214096|NCT01031888|Placebo Comparator|3|Corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for diabetic retinopathy treated with conventional postoperative eye drops
3214097|NCT01031888|Placebo Comparator|4|corneal epithelial wound healing in patients who received pars planar vitrectomy (PPV) for penetrating keratoplasty receiving conventional postoperative eye drops
3214098|NCT01031901|Placebo Comparator|TSC Placebo Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating alone to facial angiofibromas
3214099|NCT01031901|Experimental|TSC 1% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to facial angiofibromas
3214100|NCT01031901|Experimental|TSC 5% Arm|TSC subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to facial angiofibromas
3214101|NCT01031901|Placebo Comparator|NF1 Placebo Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating alone to cutaneous neurofibromas
3214102|NCT01031901|Experimental|NF1 1% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to cutaneous neurofibromas
3214103|NCT01031901|Experimental|NF1 5% Arm|NF1 subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to cutaneous neurofibromas
3214104|NCT01031940|Active Comparator|macintosh|
3214105|NCT01031940|Active Comparator|C-MAC|
3214106|NCT01031940|Active Comparator|Airtraq|
3214107|NCT01031966|Active Comparator|H1N1sw monovalent vaccine|
3214108|NCT01031966|Experimental|Thymosin alpha 1 3.2mg|
3214109|NCT01031966|Experimental|Thymosin alpha 1 6.4 mg|
3214110|NCT01031992|Experimental|Group I|First verum (3 times 1 g Tranexamic acid daily) for three months, than placebo for 3 months.
3214111|NCT01031992|Experimental|Group II|First placebo for 3 months, than verum for 3 months (3 times 1 g Tranexamic acid daily).
3214112|NCT01032005|Placebo Comparator|Fortified salt|Common table salt that has been fortified with iodine only
3214113|NCT01032005|Experimental|Double fortified salt|Common table salt that has been fortified with iron and well as the usual iodine
3214114|NCT01032031|Active Comparator|Green tea + vit C high dose|
3214115|NCT01032031|Placebo Comparator|Placebo|
3214116|NCT01032057|Active Comparator|Gemcitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po) followed by gemcitabine 300mg/m2 weekly (IV) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
3214117|NCT01032057|Active Comparator|chemoradiotherpay with capecitabine|GEMCAP induction chemotherapy (28 day cycle of IV gemcitabine 1000mg/m2 day 1, 8,15 and capecitabine 830mg/m2 bd for 21 days po), followed by capecitabine 830mg/m2 bd (po, Mon-Fri) + 50.4Gy radiation over five and half weeks (1.8Gy per fraction, Monday-Friday)
3214118|NCT01032083|Active Comparator|Citalopram|An SSRI antidepressant
3214119|NCT01032083|Placebo Comparator|Placebo|
3214120|NCT01032109|Experimental|Bevacizumab|
3214121|NCT01032122|Experimental|rituximab|
3214122|NCT01032148|Experimental|LBH589|LBH589 administered orally as once daily dose of 20 mg po q M, W, F on a q 28 day cycle, escalating to a maximum dase of 60 mg
3214123|NCT01032161||Delirium|Delirium was determined by RASS-PAEDS
3214124|NCT01032161||no Delirium|no Delirium was determined by RASS-PAEDS
3214125|NCT01032187|Active Comparator|Meglumine antimoniate|20mg/kg/day IV for 20 days
3214126|NCT01032187|Experimental|Anfo B|Amphotericin B-deoxycholate, 1mg/kg/day IV for 14 days
3214127|NCT01032213|Placebo Comparator|group C|control group
3214128|NCT01032213|Experimental|group M|magnesium group
3214129|NCT01032252|No Intervention|observational|Control group: followed by monthly falls calenders and four testing periods
3214130|NCT01032252|Experimental|Exercise group|16 week intervention, and followed by monthly fall calenders as well as 4 testing periods
3214131|NCT01032278|Experimental|Cardiac Biomarker Testing|Biomarker testing for cardiac biomarkers, B-type natriuretic peptide (BNP) and Troponin I (TnI), and symptom questionnaires of participants undergoing anthracycline-based chemotherapy.
3214132|NCT01032304|Experimental|Erdosteine|600 mg/day for 12 months
3214133|NCT01032304|Placebo Comparator|Placebo|Placebo for 12 months
3214134|NCT01032317|Other|Single-arm Study|This study was completed prior to the implementation of the requirement for specific identification of study arms. As the requirement was not made retroactive to completed studies, we believe this study to be exempt from the stipulation. Also, per PRS definition, since this is for a single-arm/feasibility study, the data elements are optional.
3214135|NCT01032343|Active Comparator|Omega-3 PUFA capsule|
3214136|NCT01032343|Placebo Comparator|Gelatine capsule|
3214137|NCT01032356|Experimental|Dynasplint|Patients will be treated with the current standard of care and the Wrist Extension Dynasplint.
3214138|NCT01032369|Experimental|CBT|with behavioral intervention-CBT.
3214139|NCT01032369|Other|Without CBT|Without behavioral intervention-CBT
3214140|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Fluad®), the first on Study Day 1, and the second on Study Day 22.
3214141|NCT01032395|Experimental|Chronic Disease Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
3214142|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria® or Flaud®), the first on Study Day 1, and the second on Study Day 22.
3214143|NCT01032395|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22.
3214144|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
3214145|NCT01032408|Experimental|HIV-1 Infected Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
3214146|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine with Adjuvant|Each subject received two doses of vaccine with adjuvant (Focetria®), the first on Study Day 1, and the second on Study Day 22
3214147|NCT01032408|Experimental|Healthy Subjects Receiving Vaccine without Adjuvant|Each subject received two doses of vaccine without adjuvant (Begrivac®), the first on Study Day 1, and the second on Study Day 22
3214148|NCT01032421||GNRH|Observational (IVF is not done as part of the study)
3214149|NCT01032434|Experimental|sertraline|sertraline: 50-200mg/day
3214150|NCT01032460|Active Comparator|macintosh|
3214151|NCT01032460|Active Comparator|C-MAC|
3214152|NCT01032460|Active Comparator|Airtraq|
3214153|NCT01032473||GAD|Children between the ages of 7-11 years diagnosed with Generalized Anxiety Disorder (GAD)
3214154|NCT01032473||Control|Children between the ages of 7-11 years free of significant medical or behavioral problems (matched to children diagnosed with GAD based on age, gender, and ethnicity).
3214155|NCT01032486||Azilect|Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
3214156|NCT01032499|Active Comparator|oxytetracycline|
3214157|NCT01032499|Experimental|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
3214158|NCT01032512|Experimental|IMMUNE-ENHANCING|"40 patients will be instructed to consume 600 ml of the special immune-enhancing formula plus 20 g glutamine (Supportan R + Glutamine plus R, which contain 900 Kcal and 60 g protein/day, with 24.4 g glutamine, 2,2 g arginine and 4.4 g of omega 3 fatty acids, in a lower volume due to its higher energy density)."
3214159|NCT01032512|Sham Comparator|CONTROL|40 patients that do not agree to participate, do not have enough time before the operation, do not tolerate the product and/or drink less than 100 cc/day.
3214160|NCT01032551|Experimental|Vascular Access Patient Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
3214161|NCT01032551|No Intervention|Usual Care|"The control group (those not randomized to the PtDA) will have usual care. Usual care involves a brief discussion, just prior to the CA procedure, with the treating physician, regarding the patient's eligibility for both vascular accesses, followed by the advantages and disadvantages of both. The details and duration of the discussion is left to the discretion of the treating physician as per their individual standard of care. There will be no access to a formal PtDA in this group."
3214162|NCT01032577||cardiomyopathy, with implant indications|30-50 volunteers age >18, male and female with ability to give informed consent, who are expected to live more than one year, with indication for defibrillator implant and who are not pacemaker dependent.
3214163|NCT01032590|Experimental|Arm I|Arm I (12-week Internet-based weight-loss intervention): After a baseline evaluation, subjects will start a 12 week Internet-based weight-loss intervention.
3214164|NCT01032590|Active Comparator|Arm II|Arm II (wait-list control): Patients are instructed to continue their usual dietary and physical activity routines during a 12-week wait period. After the waiting period, patients receive the Internet-based weight-loss intervention for 12 weeks as in arm I.
3214165|NCT01032616|Experimental|Study Period 1|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
3214166|NCT01032616|Experimental|Study Period 2|AA given by parenteral and enteral routes with tracer 1-13C phenylalanine given to observe differences
3214167|NCT01032642|Experimental|thin catheter group|group of women where thin catheter will be used for hysterosalpingography
3214168|NCT01032655|Experimental|sequential, susceptibility guided|single arm
3214169|NCT01032668|Experimental|high dose clopidogrel|
3214170|NCT01032681|Experimental|Group 1|Dose escalation of EMD 521873 monotheraphy 3 doses per cycle
3214171|NCT01032681|Experimental|Group 2|Low dose CPA + Dose escalation of EMD 521873 three doses per cycle
3214172|NCT01032681|Experimental|Group 3|Dose escalation of EMD 521873 monotheraphy 1 dose per cycle
3214173|NCT01032720|Experimental|Ultrasound-guided knee CS injection|Ultrasound will be used to image knee joint and guide needle for intra-articular knee CS injection.
3214174|NCT01032720|Sham Comparator|Sham Ultrasound knee CS injection|CS knee injection will be performed in the same method as the US-guided knee injection but the US machine will be turned off.
3214175|NCT01032772|Experimental|CHOICES Plus Intervention|A two session intervention utilizing a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, and smoking. The interventions will (a) provide norms-based-but personalized-feedback, (b) encourage attendance at a contraceptive counseling visit, (c) encourage participation in the smoking cessation program, (c) increase motivation to change each of the target behaviors, (d) decrease temptation to engage in risk behaviors, (e) increase confidence to avoid risk behaviors, and (f) develop a personalized, tailored change plan.
3214176|NCT01032772|Active Comparator|Information|Women in the information condition receive advice and educational material from the research assistant about women's health and related referrals.
3214177|NCT01032785||Healthy term newborn|Any healthy term newborn born in Wolfson Medical Center
3214178|NCT01032811||Study Participants|St. Jude Children's Research Hospital patients from Leukemia, Neuro-Oncology, Radiation Oncology, and After Completion of Therapy (ACT) clinics.
3214179|NCT01032824|Experimental|Intervention|Individual telephone counseling intervention.
3214180|NCT01032824|Other|Group Arm|Attention-matched comparison arm
3214181|NCT01032824|Other|Book Arm|Information-matched control arm.
3214182|NCT01032863||Young healthy Indian adults|Persons aged between 25 and 40 years of age who are relatives of patients being treated in Amrita Institute of Medical Sciences (Inpatient or Outpatient) and voluntary blood donors at the same institute who are willing to participate in the study.
3214183|NCT01032876|Experimental|Deep Hypothermic Circulatory Arrest|
3214184|NCT01032876|Experimental|Antegrade Cerebral Perfusion|
3214185|NCT01032902||Known HIV positive|Patients from HIV clinics with documented infections
3214186|NCT01032902||High Risk for Infection with HIV|Patients from defined HIV high-risk populations - i.e. intravenous drug users, or patients presenting with symptoms of sexually transmitted disease.
3214187|NCT01032902||Low-Risk for Infection with HIV|"Individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
3214188|NCT01032941|Placebo Comparator|Placebo|Patients in this group will be given placebo 2 packets BID for 8 weeks.
3214189|NCT01032941|Experimental|VSL#3|Patients in this group will be given 2 packets of VSL#3 BID for 8 weeks.
3214190|NCT01032967|Active Comparator|Surgery, esophagectomy|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
3214191|NCT01032967|Active Comparator|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
3214192|NCT01032980||HUMENZA Vaccine Group|Participants vaccinated with HUMENZA according to the recommendations provided in the product leaflet and local recommendations.
3214193|NCT01032980||PANENZA Vaccine Group|Participants vaccinated with PANENZA according to the recommendations provided in the product leaflet and local recommendations.
3214194|NCT01033006|Active Comparator|Arm 1: catheter injection|40 ml of LA through the catheter
3214195|NCT01033006|Active Comparator|Arm 2: transarterial injection|30 ml deep and 10 ml superficial to the artery
3214196|NCT01033006|Active Comparator|Arm 3: catheter and transarterial injection|20 + 10 ml transarterial block and 10 ml through the catheter
3214197|NCT01033058|Active Comparator|usual care|
3214198|NCT01033058|Experimental|intensive statin treatment|
3214199|NCT01033084|Experimental|Sham stimulation / sertraline|In this arm, patients will receive sham stimulation and sertraline 50mg/day. In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation.
3214200|NCT01033084|Sham Comparator|Sham stimulation / placebo pill|"Placebo pills are sugar pills having the same size and shape of the active pills.~In sham stimulation, the tDCS device is set in the same fashion as the active stimulation, but the device is turned off after one minute of stimulation."
3214201|NCT01033084|Experimental|Active stimulation / Sertraline|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Patients will receive Sertraline 50mg/day."
3214202|NCT01033084|Experimental|Active stimulation / placebo pill|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~Placebo pills are sugar pills having the same size and shape of the active pill"
3214203|NCT01033097|Experimental|DNK333 5 mg|
3214204|NCT01033097|Placebo Comparator|Placebo to DNK333 5mg|
3214205|NCT01033097|Experimental|DNK333 25 mg|
3214206|NCT01033097|Placebo Comparator|Placebo to DNK333 25 mg|
3214207|NCT01033097|Experimental|DNK333 100 mg|
3214208|NCT01033097|Placebo Comparator|Placebo to DNK333 100 mg|
3214209|NCT01033097|Active Comparator|Betamethasone 4 mg|
3214210|NCT01033097|Experimental|DNK333 1 mg|
3214211|NCT01033097|Placebo Comparator|placebo 1mg|
3214212|NCT01033123|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
3214213|NCT01033149|Other|N-acetylcysteine|open label N-acetylcysteine, flexible dose
3214214|NCT01033162|No Intervention|Usual Care|A group using a Basic ICCS provided by KPNW
3214215|NCT01033162|Experimental|Intervention|A group using an enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)
3214216|NCT01033175|Other|COPD patients with ACD|"In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of cases).ACD is defined by low Hb levels (men: <13 mg/dl, women: <12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity."
3214217|NCT01033175|Other|COPD patients without ACD|"Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the controls)"
3214218|NCT01033188|Active Comparator|Single-bundle technique|Anatomic single-bundle technique
3214219|NCT01033188|Active Comparator|Double-bundle technique|Anatomic double bundle technique
3214220|NCT01033201||Lung transplant|All lung transplant patients presenting for screening/surveillance and diagnostic bronchoscopies at Mayo Clinic Florida are eligible for participation.
3214221|NCT01033214|Experimental|TAArget Thoracic Stent Graft|those treated with the investigational device
3214222|NCT01033253|Experimental|Computerized Tailored Intervention|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
3214223|NCT01033253|No Intervention|Control|Computerized assessments of Transtheoretical Model constructs at 0, 2, 6, and 12 months
3214224|NCT01033266||CPET CPAP|
3214225|NCT01033279|No Intervention|Usual care|Patients followed by usual care at the hospital's anticoagulation clinic
3214226|NCT01033279|Experimental|Self-management|Self-monitoring and self-adjustment of oral anticoagulation according to predefined algorithms
3214227|NCT01033292|Experimental|BSI-201|BSI-201 in combination with gemcitabine and carboplatin.
3214228|NCT01033305|Placebo Comparator|Placebo|
3214229|NCT01033305|Experimental|CyCol™|
3214230|NCT01033318|Experimental|Part 1 A-1|"Part 1; Panel A; Sequence 1:~2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan"
3214231|NCT01033318|Experimental|Part 1 A-2|"Part 1; Panel A; Sequence 2:~Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809"
3214232|NCT01033318|Experimental|Part 1 A-3|Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
3214233|NCT01033318|Experimental|Part 1 A-4|Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
3214234|NCT01033318|Experimental|Part 1 A-5|"Part 1; Panel A; Sequence 5:~Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809"
3214235|NCT01033318|Experimental|Part 1 B-1|"Part 1; Panel B; Sequence 1:~5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food"
3214236|NCT01033318|Experimental|Part 1 B-2|"Part 1; Panel B; Sequence 2:~5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food"
3214237|NCT01033318|Experimental|Part 1 B-3|"Part 1; Panel B; Sequence 3:~5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food"
3214238|NCT01033318|Experimental|Part 1 B-4|"Part 1; Panel B; Sequence 4:~Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food"
3214239|NCT01033318|Experimental|Part 1 B-5|"Part 1; Panel B; Sequence 5:~Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food"
3214240|NCT01033318|Experimental|Part 2 C-1|"Part 2; Panel C; Sequence 1:~50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan"
3214241|NCT01033318|Experimental|Part 2 C-2|"Part 2; Panel C; Sequence 2:~50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809"
3214242|NCT01033318|Experimental|Part 2 C-3|"Part 2; Panel C; Sequence 3:~Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo"
3214243|NCT01033318|Experimental|Part 2 C-4|"Part 2; Panel C; Sequence 4:~50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809"
3214244|NCT01033318|Experimental|Part 2 C-5|"Part 2; Panel C; Sequence 5:~Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809"
3214245|NCT01033344|Placebo Comparator|Placebo|Solution resembling active solution but without peptides
3214246|NCT01033344|Experimental|Group 1|Cat-PAD dose group 1
3214247|NCT01033344|Experimental|Group 2|Cat-PAD Dose group 2
3214248|NCT01033357|Active Comparator|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
3214249|NCT01033357|Placebo Comparator|Graft|Lifespan® ePTFE Vascular Graft Only
3214250|NCT01033370|Other|Open label, non-randomized, pilot study|All subjects who provide consent for trial participation with an acute aortic emergency and elevated BP (systolic blood pressure [SBP] ≥120 mm Hg) requiring IV antihypertensive therapy for up to 48 hours will be administered an infusion of clevidipine to evaluate the efficacy and safety of the IV drug.
3214251|NCT01033396|Experimental|PF-03654764 + Allegra|
3214252|NCT01033396|Experimental|PF-03654764|
3214253|NCT01033396|Active Comparator|Allegra-D|
3214254|NCT01033396|Placebo Comparator|Placebo|
3214255|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^7|Arm 1 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^7 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^7 CFU oral dosage through Day 28.
3214256|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^8|Arm 2 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^8 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^8 CFU oral dosage through Day 28.
3214257|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^9|Arm 3 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^9 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^9 CFU oral dosage through Day 28.
3214258|NCT01033409|Experimental|S. Typhi-vectored pneumo vaccine 10^10|Arm 4 will evaluate three attenuated S. Typhi strains administered to 3 groups of 5 subjects in single oral doses (10^10 CFU) for safety and immunogenicity. Dose escalation for each strain will proceed after demonstrating the safety and tolerability of 10^10 CFU oral dosage through Day 28.
3214259|NCT01033435||chronic Hemodialysis patients, treated in our unit.|
3214260|NCT01033435||chronic Hemodialysis patients , No intervention|chronic Hemodialysis patients, treated in our unit.
3214261|NCT01033461|Experimental|calcium and probiotic|intervention
3214262|NCT01033461|Experimental|probiotic|intervention
3214263|NCT01033461|Placebo Comparator|placebo|placebo, no intervention
3214264|NCT01033474||donor eggs|
3214265|NCT01033474||infertile patients|
3214266|NCT01033500|Experimental|SIK|Basiliximab induction with maintenance immunosuppression consisting of belatacept, sirolimus or everolimus, and mycophenolate after simultaneous islet kidney transplantation.
3214267|NCT01033513||Literature Only (Control)|The participants on this arm served as the control group. Five types of literature were mailed to the participants in the literature only arm. A letter was included with the materials thanking participants for their participation, requesting that the participants read the literature, and encouraging them to contact the RDs with any questions. The Clinical Study Manager's telephone number was provided for questions about diet or lifestyle changes. The RDs documented all contacts with participants on a phone summary. Other than the delivery of literature and responses to specific questions asked by the participant or the participant's primary caregiver through telephone calls, the RDs had no further interaction with the participant until the conclusion of the participant's trial period.
3214268|NCT01033513||Meals Only|Participants in the meals only arm received a pre-intervention assessment (but no nutrition counseling). The RDs gave the participants in the meals only arm a phone number and encouraged them to phone with questions or problems, especially problems associated with the meals. Subsequently, the meals only participants received seven diagnosis-appropriate therapeutic meals a week, delivered once per week. The meals were specially designed to address the participants' medical diagnoses. They were developed using the ADA MNT protocols for caloric and nutrient content requirements for individuals with the specified diagnoses, in addition to meeting AoA Nutrition Program dietary requirements. The meals were provided primarily in frozen form. However, some shelf-stable and refrigerated components were also included. In conformance with AoA regulations, appropriate meals were also offered to the spouse of any participant receiving a therapeutic meal.
3214269|NCT01033513||MNT Only|The participants in this arm received MNT from the project RDs, who employed the Hyperlipidemia Medical Nutrition Therapy MNT Protocol, developed by ADA (2002). Because ADA had not finalized MNT protocols for hypertension, the RDs followed the protocol for hyperlipidemia for participants diagnosed with either hyperlipidemia or hypertension, with adjustments, as appropriate, to benefit those individuals who were diagnosed with hypertension.All MNT sessions were in the participants' homes, and if a caregiver was required for the individual to participate in the project, every effort was made to include this person in the MNT sessions. The MNT intervention took place over at least three sessions, and, in conformance with the ADA protocol, each participant received individualized counseling and education.
3214270|NCT01033513||Meals and MNT|The participants assigned to the MNT plus meals arm received both of the interventions, as described above.
3214271|NCT01033526|Placebo Comparator|Arm 2|
3214272|NCT01033526|Experimental|Arm 1|
3214273|NCT01033539|Active Comparator|Placebo control|Placebo control without probiotics ATCC PTA 4659
3214274|NCT01033539|Active Comparator|ATCC PTA 4659 Low dose|
3214275|NCT01033539|Active Comparator|ATCC PTA 4659 high dose|
3214276|NCT01033552|Experimental|Transplant in Epidermolysis Bullosa|
3214277|NCT01033578|No Intervention|Control|Receive hepatectomy and thrombectomy alone, no postoperative adjuvant treatments
3214278|NCT01033578|Experimental|PVIC Group|Portal Vein Infusion Chemotherapy (PVIC): 5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) was continuously infused into portal vein through tube by a infusion pump implanted in operation. Treatment started 2 weeks after the operation and was repeated every 4 weeks for six cycles.
3214279|NCT01033578|Experimental|TACE Group|Transcatheter Arterial Chemoembolization (TACE): 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles.
3214280|NCT01033578|Experimental|PVIC+TACE Group|Combination of PVIC and TACE. PVIC started 2 weeks after operation and TACE started 6 weeks after operation. Both PVIC and TACE were repeated at 8 weeks intervals for 3 cycles.
3214281|NCT01033591|Experimental|Exercise|Supervised exercise + Optimized treatment according to the European Society of Cardiology guidelines
3214282|NCT01033591|Other|Control|Optimized treatment according to the European Society of Cardiology guidelines
3214283|NCT01033604|Experimental|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
3214284|NCT01033604|Active Comparator|Split skin graft alone|Full thickness defects treated with split skin graft alone.
3214285|NCT01033617|Placebo Comparator|Placebo|Saline solution with autologous plasma.
3214286|NCT01033617|Experimental|CD133+ stem cells|Autologous CD133+ intramyocardial injection at time of coronary artery bypass grafting.
3214287|NCT01033630|Placebo Comparator|Placebo|Image-matched placebo of active treatment
3214288|NCT01033630|Active Comparator|D&G 1g|Randomly allocated into three groups, D&G capsule 1g/day
3214289|NCT01033630|Active Comparator|D&G 2g|Randomly allocated into three groups, D&G capsule 2g/day
3214290|NCT01033656|Experimental|Anakinra|experimental drug of study
3214291|NCT01033656|Active Comparator|comparator|comparators:methotrexate, azathioprine, leflunomide or supfasalazine
3214292|NCT01033669||Dry Powder Inhalers|
3214293|NCT01033708|Active Comparator|treatment as usual|Treatment as usual
3214294|NCT01033708|Experimental|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
3214295|NCT01033760|Experimental|arm 1|darunavir, ritonavir, emtricitabine/tenofovir, maraviroc, raltegravir
3214296|NCT01033760|Active Comparator|arm 2|darunavir, ritonavir, emtricitabine/tenofovir
3214297|NCT01033799|Sham Comparator|Control Product|
3214298|NCT01033799|Active Comparator|Tested Product|
3214299|NCT01033812||Index Recruiter|Young African American or Latina women who served as index recruiters in ATN 067 and members of their female friendship network members who tested HIV positive based on HIV screening and a confirmatory test result that was conducted in ATN 067.
3214300|NCT01033812||Male Sexual Partners|Any male partner who engaged in at least one episode of oral, vaginal or anal sex during the course of their lifetime with an 084 index recruiter.
3214301|NCT01033838|Active Comparator|laparoscopic-assisted rectosigmoid resection|
3214302|NCT01033838|Experimental|laparoscopic rectosigmoid resection and transrectal retrieval|
3214303|NCT01033877|Experimental|TdaP vaccine|
3214304|NCT01033877|Active Comparator|Td vaccine|
3214305|NCT01033903|Experimental|Misoprostol 800 micrograms intravaginally|
3214306|NCT01033903|No Intervention|expectant managment|
3214307|NCT01033916|No Intervention|STRICT Glucose Control (80-120 mg/dL)|The STRICT arm of the study will have a target Blood Glucose level ranging from 80-120 mg/dL. This is currently the standard of care for post CABG patients.
3214308|NCT01033916|Active Comparator|LIBERAL (Target Glucose:121-180 mg/dL)|
3214309|NCT01033929|Experimental|0.01µg C-Tb|12-24 patients depending on a safety evaluation will receive a low dose of 0.01 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
3214310|NCT01033929|Experimental|0.1µg C.Tb|12-24 patients depending on a safety evaluation will receive a high dose of 0.1 µg/0.1 mL C-Tb without phenol in the RIGHT or LEFT arm and 0.01 µg/0.1 mL C-Tb with phenol in the opposite arm, in a double blind manner.
3214311|NCT01033955|Experimental|Drug (Rosuvastatin) Crestor|The first dose of encapsulated study drug or placebo (day 1) will be administered within 4 hours of randomization as a loading dose of 40 mg. The placebo will be identical in appearance to Rosuvastatin. Thereafter, doses of 20 mg will be administered daily starting on the next calendar day at 10 pm daily (+/- 4 hours) as a maintenance dose from days 2 to 14. If the patient is of Asian descent, is <18 years, or serum creatinine is greater than or equal to 248 μmol/L (2.8 mg/dL) dose adjustments will be made according to a dose adjustment algorithm.
3214312|NCT01033955|Placebo Comparator|Placebo|An identical appearing placebo will be administered to patients in the second study arm.
3214313|NCT01033981||Central America and Caribbean|Dominican Republic, Guatemala, Panama, Costa Rica, Honduras, Trinidad & Tobago
3214314|NCT01033994|Experimental|AS902330|
3214315|NCT01033994|Placebo Comparator|Placebo|
3214316|NCT01034007|Experimental|Tissue Engineered Vascular Grafts|
3214317|NCT01034046|Active Comparator|Insulin Sensitive Study Participants|Insulin sensitive subjects stratified using fasting insulin levels.
3214318|NCT01034046|Active Comparator|Insulin Resistant Study Subjects|Insulin resistant subjects stratified using fasting insulin levels.
3214319|NCT01034098||Post-menopausal women|Post-menopausal women (without hormone replacement therapy)
3214320|NCT01034124|Placebo Comparator|Water|
3214321|NCT01034124|Active Comparator|Cranberry juice|
3214322|NCT01034150|Active Comparator|Somatosensory stimulation|Active group
3214323|NCT01034150|Placebo Comparator|Control group|Placebo stimulation
3214324|NCT01034189|Experimental|Targeted therapy|Concurrent chemoradiotherapy with cetuximab, paclitaxel, and cisplatin followed by, if feasible, esophagectomy
3214325|NCT01034202|Experimental|Norditropin® SimpleXx® 0.02 mg/kg + NNC126-0083|
3214326|NCT01034202|Experimental|Norditropin® SimpleXx® 0.04 mg/kg + NNC126-0083|
3214327|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.02 mg/kg + placebo|
3214328|NCT01034202|Placebo Comparator|Norditropin® SimpleXx® 0.04 mg/kg + placebo|
3214329|NCT01034202|Experimental|NNC126-0083|
3214330|NCT01034202|Placebo Comparator|Placebo|
3214331|NCT01034215|Active Comparator|Imagery Practice, live trainer|Patients attend a five week training program, with the instructor in the room with them, and actively practice imagery techniques, both in the classroom, and daily, outside of the classroom. Classes are four hours a week for five weeks. Patients practice what they learn for a full 17 weeks, beginning with the first week of class.
3214332|NCT01034215|Active Comparator|"Envision the Rhythms of Life /video"|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD.
3214333|NCT01034215|No Intervention|Waitlist Control Group|No treatment delivery during the 17 weeks of testing live delivery (trainer in the room with patients) vs. distance delivery (trainer delivers program via telemedicine/videoconferencing equipment)
3214334|NCT01034228|Active Comparator|Isoleucine|Glucose ORS with L-Isoleucine
3214335|NCT01034228|Placebo Comparator|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
3214336|NCT01034241|Experimental|Control|Diet consists of 15% dairy protein and low Glycemic Index (GI < 40), 55 En% carbohydrates and 30 En% fat
3214337|NCT01034241|Experimental|High dairy protein|Diet consists of 25% dairy protein and low GI (GI < 40), 45 En% carbohydrates and 30 En% fat
3214338|NCT01034241|Experimental|vegetable protein|Diet consists of 15 En% vegetable protein and low GI (GI < 40), 55 En% carbohydrates and 30 En% fat
3214339|NCT01034241|Experimental|High GI|Diet consists of 15 En% dairy protein and high GI(GI > 60, 55 En% carbohydrates and 30 En% fat
3214340|NCT01034254|Experimental|influenza vaccine|Pregnant women assigned to the intervention group will receive one dose of seasonal influenza vaccine at the time of enrollment. The vaccine that will be given will be the current seasonal influenza recommended vaccine at the time of enrollment.
3214341|NCT01034254|Placebo Comparator|saline placebo|Pregnant women assigned to the control group will receive one dose of placebo (normal saline).
3214342|NCT01034267|Experimental|1|(Open-label) F2695 SR capsules, oral administration, once daily, flexible dosing
3214343|NCT01034293|Experimental|low feeding frequency (3x)|
3214344|NCT01034293|Experimental|High feeding frequency (14x)|
3214345|NCT01034319|Experimental|Diabetes Genetic Counseling|Subjects will have been genotyped and will received genetic counseling based on their results
3214346|NCT01034319|Placebo Comparator|No Genotyping or Counseling|Patients will not be genotyped and will therefore not receive genetic counseling
3214347|NCT01034332|Experimental|One-cycle induction chemotherapy|TP-HDFL, TP-CCRT, Esophagectomy
3214348|NCT01034345|Experimental|Sirolimus|Patients randomized to this arm will discontinue maintenance immunosuppression based on calcineurin inhibitors and start treatment with sirolimus.
3214349|NCT01034345|Active Comparator|Calcineurin inhibitor|Patients randomized to this arm will keep the same maintenance immunosuppression based on calcineurin inhibitors.
3214350|NCT01034371|Experimental|One-stop hybrid revasularization|
3214351|NCT01034371|Active Comparator|Off-pump coronary artery bypass|
3214352|NCT01034410|Active Comparator|Control|cytarabine 2g/m2 bid Days 4-7
3214353|NCT01034410|Experimental|AS1411-40|AS1411 40mg/kg/day d1-7 plus cytarabine 2g/m2 bid days 4-7
3214354|NCT01034410|Experimental|AS1411-80|AS1411 80mg/kg/day d1-7, cytarabine 2g/m2 bid days 4- 7/ bid d4-7
3214355|NCT01034423|Experimental|omega-3 high quality|
3214356|NCT01034423|Experimental|omega-3 low quality|
3214357|NCT01034423|Placebo Comparator|placebo|
3214358|NCT01034436|Placebo Comparator|Low intake of ALA and triacylglycerols|Sunflower oil
3214359|NCT01034436|Experimental|high intake of ALA and triacylglyceroles|Canola and linseed oils
3214360|NCT01034436|Experimental|high intake of ALA and diacylglycerols|Canola and linseed oils
3214361|NCT01034475|Experimental|CPI-613|CPI-240 mg/m2
3214362|NCT01034488|Active Comparator|Heparin sodium - APP|5000UI / mL
3214363|NCT01034488|Experimental|Heparin - Eurofarma|5000 UI/ mL
3214364|NCT01034501|Active Comparator|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
3214365|NCT01034501|Sham Comparator|sham procedure|Not activation of laser device
3214366|NCT01034514|Experimental|4DCT arm|Patients breathe in 99mTc-DTPA and then undergo ventilation scans using a SPECT scanner over 2 hours. Patients also receive 99mTc-MAA IV and then undergo perfusion scans using a SPECT scanner over 2 hours. Patients may also undergo a pre- and post-treatment Xe-CT ventilation scan over 15 minutes and a pre-treatment 4D-CT scan over 5-10 minutes.
3214367|NCT01034566|Experimental|Arm I|Patients undergo proton beam radiotherapy 5 days a week for 6 (preoperative patients) or 8 (post-operative patients) weeks in the absence of disease progression or unacceptable toxicity.
3214368|NCT01034605|Experimental|inulin|oligofructose
3214369|NCT01034618|Placebo Comparator|Placebo|
3214370|NCT01034618|Experimental|Intact protein|
3214371|NCT01034618|Experimental|Protein hydrolysate|
3214372|NCT01034644||PRISMS patients|This single group includes all the patients from the PRISMS study
3214373|NCT01034670|Experimental|endoscopy arm|imaging performed in conjunction with the regularly scheduled endoscopy during which the newer imaging techniques will be used to detect premalignant conditions. includes wide field fluorescence, microscopy, Raman spectroscopy and/or ultrasound.
3214374|NCT01034683|Experimental|Esophageal Carcinoma|
3214375|NCT01034722||Western Diet|Volunteer mothers with western diet.
3214376|NCT01034722||Vegetarians|volunteer mothers with vegetarians diet
3214377|NCT01034722||Bedouins|Volunteer mothers who are Bedouins
3214378|NCT01034735|Experimental|Arm A|
3214379|NCT01034735|Experimental|Arm B|
3214380|NCT01034735|Experimental|Arm C|
3214381|NCT01034748|Experimental|1|Single 45 mg oral dose of [14C]PF-00299804
3214382|NCT01034761|Experimental|Pop-up alerts|Providers will receive pop-up alerts in the electronic medical record when prescribing one of the specified medications from the Beers list.
3214383|NCT01034761|No Intervention|Usual care|
3214384|NCT01034774|Active Comparator|ACHN-490 Injection|ACHN-490 Injection will be given either 1 or 5 consecutive days at a dose of 15mg/kg.
3214385|NCT01034774|Placebo Comparator|Placebo is Normal Saline|Placebo will be given either 1 or 5 consecutive days to mask when ACHN-490 Injection is given.
3214386|NCT01034787|Experimental|Open Label CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of every 90-day cycle for up to 4 cycles or until disease progression or intolerance of toxicity.
3214387|NCT01034813||Burn Range of motion|burn patients with hypertropic scar
3214388|NCT01034813||control range of motion|control subjects without scaring
3214389|NCT01034826||life style modification|everyone in this study was advised about their life style, diet, exercise habits.
3214390|NCT01034839||acute myeloid leukemia, adults|Adults treated for acute myeloid leukemia in our hospital between 1978 and 2007
3214391|NCT01034852||Surgical ablation|Patients undergoing surgical ablation for Atrial Fibrillation that have failed one or more previous attempts at catheter ablation for Atrial Fibrillation
3214392|NCT01034865||HCC PTS|Patients with HCC with either: (i) a hepatic mass larger or equal to 5cm, or; (ii) a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection, or; (iii) a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
3214393|NCT01034865||LD|Patients with chronic liver disease without evidence of HCC
3214394|NCT01034878|Experimental|Sunitinib|50 mg once daily 6 weeks cycle 4 weeks on and 2 weeks off
3214395|NCT01034904||Patients|Patients who have moderate or severe Hemophilia A, living in Canada and who are using Helixate FS either on-demand or prophylaxis
3214396|NCT01034917|Experimental|Etravirine group|To switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
3214397|NCT01034917|Active Comparator|Control group|Continue with the same antiretroviral regimen
3214398|NCT01034930|Active Comparator|Retentive Anchors|23 patients will receive as retention system for overdentures Retentive Anchors (Straumann).
3214399|NCT01034930|Active Comparator|Magnets|23 patients will receive Magnets (Straumann) as retention system for overdenture.
3214400|NCT01034930|Active Comparator|Locator System|23 patients will receive Locator System (Straumann) as retention for the mandibular overdenture.
3214401|NCT01034943|Active Comparator|External fixation|Operation with external fixation and optional addition of k-wire
3214402|NCT01034943|Active Comparator|Volar plate|Operation with Synthes volar two column plate (TCP)
3214403|NCT01034956||Facial Soft Tissue Filler Patients|Patients previously treated by Principal Investigator with facial soft tissue fillers within the past 2 years
3214404|NCT01034969||Participants with hereditary angioedema (HAE)|All participants with hereditary angioedema (HAE) who are administered Cinryze (C1 inhibitor [human]) or Firazyr (Icatibant) for the treatment or prevention of angioedema attacks in routine clinical practice will be included into the study.
3214405|NCT01034982|Experimental|1|tosylate salt tablet
3214406|NCT01034982|Experimental|2|free suspension
3214407|NCT01034982|Experimental|3|tosylate salt tablet
3214408|NCT01034982|Experimental|4|free suspension
3214409|NCT01034995|Experimental|SSR125543 20 mg|1 capsule of SSR125543 20 mg + 1 capsule of placebo
3214410|NCT01034995|Experimental|SSR125543 50 mg|1 capsule of SSR125543 50 mg + 1 capsule of placebo
3214411|NCT01034995|Experimental|SSR125543 100 mg|2 capsules of SSR125543 50 mg
3214412|NCT01034995|Active Comparator|escitalopram 10 mg|1 capsule of escitalopram 10 mg + 1 capsule of placebo
3214413|NCT01034995|Placebo Comparator|placebo|2 capsules of placebo
3214414|NCT01035008|Experimental|Diagnostic|The investigators are testing a new method called confocal laser endomicroscopy to see if it can detect pre-cancerous abnormalities in the lining of the cysts found in your pancreas. This will involve using a very thin fiber-shaped microscope which will be passed through a needle during the EUS procedure.
3214415|NCT01035021|Active Comparator|group N|Anesthesia is induced with propofol and remifentanil and LMA is inserted by the standard technique according to eht manufacturer's instruction. Rocuronium is administered for the operation.
3214416|NCT01035021|Active Comparator|group R|Anesthesia is induced with a propofol and remifentanil and rocuronium 0.06 mg/kg is injected. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction.
3214417|NCT01035034|Experimental|One-stop hybrid coronary revasularization|Percutaneous Coronary Intervention; Coronary Artery Bypass
3214418|NCT01035034|Active Comparator|PCI with stenting|Percutaneous Coronary Intervention
3214419|NCT01035086|Experimental|Boregine|Intervention: Lupinus angustifolius Boregine; 25 g lupin kernel fibre per day over 4 weeks; lupin kernel fibre was incorporated in different food
3214420|NCT01035086|Active Comparator|Reference|Intervention: Reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood ingredients); 25 g citrus fibre per day over 4 weeks; the citrus fibre was incorporated in different food
3214421|NCT01035086|Placebo Comparator|Placebo|different food without added fibre
3214422|NCT01035112||MRI|Contrast-enhanced MRI using the standard department of Radiology MRI screening procedures. The duration of scanning may be variable, but will not exceed 90 minutes.
3214423|NCT01035125|No Intervention|Waiting list|
3214424|NCT01035125|Experimental|Self-management program|One week self-management program
3214425|NCT01035164|Experimental|Arm 1|
3214426|NCT01035164|Experimental|Arm 2|
3214427|NCT01035164|Experimental|Arm 3|
3214428|NCT01035177||Control|Women without hip fracture, matched on age to the cases
3214429|NCT01035177||Patient|Female patients aged 60 and older with hip fracture
3214430|NCT01035190|Experimental|inhaled Budesonide|
3214431|NCT01035203|Active Comparator|Cognitive behavioural therapy|
3214432|NCT01035203|Experimental|Exercise|Endurance training (walking on a treadmill) 3 x weekly for 4 weeks
3214433|NCT01035216|Experimental|GNKG168|The starting dose will be 0.25 mg/kg. If the dose is tolerable, subsequent cohorts will be enrolled and treated with 0.5, 0.75, 1.0 and 1.5 mg/kg. If 0.25 mg/kg proves to be intolerable, the dose will be reduced to 0.15 mg/kg.
3214434|NCT01035242|Experimental|"association splitting"|Association splitting (6 sessions) delivered by psychologists.
3214435|NCT01035242|Active Comparator|cognitive remediation|CogPack training(6 sessions) delivered by either psychologists or psychology students at an advanced master level.
3214436|NCT01035268|Experimental|surgery by fatty tissue transfer|
3214437|NCT01035268|No Intervention|simple supervision|
3214438|NCT01035281|Experimental|Nabilone|A one-week screening period will occur, during which pain scores and sleep scores will be tabulated. Following screening, a 4-week period of single blind treatment with flexible dosing of nabilone at 0.5 - 4 mg/day will initiate.
3214439|NCT01035281|Placebo Comparator|Placebo|All subjects who experience at least a 30% reduction in their weekly mean pain score during the single blind flexible dosing phase will be considered a responder, and will be further continued in the study. During the double-blind portion of the study, subjects randomized to nabilone will continue on the dose of nabilone achieved at the completion of the single-blind phase, and this dose will be maintained throughout the double-blind phase. Subjects randomized to placebo will receive 1 mg of nabilone daily for one week, followed by 4 consecutive weeks of placebo. This dose of nabilone will permit a tapering for those subjects achieving a higher daily dose of nabilone during the single-blind phase, or will maintain those who were taking only 1 mg per day in the single-blind phase, preventing an abrupt termination of treatment in subjects who are randomized into the placebo portion.
3214440|NCT01035294|Experimental|mindfulness based intervention|
3214441|NCT01035294|Active Comparator|usual care (UC)|
3214442|NCT01035307||Genomic and Proteomic Profiling|
3214443|NCT01035320|Experimental|simvastatin + ezetimibe|Cross-over study with placebo only run-in period. All patients participate in this arm with simvastatin + ezetimibe either as first treatment period (8-10 weeks)or second treatment period (8-10 weeks). The primary comparison is ezetimibe vs. placebo on top of simvastatin. A secondary comparison will be simvastatin vs. placebo run-in.
3214444|NCT01035359|Active Comparator|external fixation|Operation with external fixation and optional addition of k-wire
3214445|NCT01035359|Experimental|Volar plate|Operation with a Synthes volar two column plate (TCP)
3214446|NCT01035372|Experimental|dried plum|subjects will have 25% by weight (~ 600 kcal if eat 2500 kcal diet) of their usual diet substituted by dried plum powder
3214447|NCT01035385|Experimental|FOFLOX4,resectable liver metastasis from CRC|
3214448|NCT01035411|Experimental|1|AZD9668 2X30mg tablet
3214449|NCT01035437|Experimental|HPPH|HPPH
3214450|NCT01035450|Experimental|Everolimus-eluting stent|
3214451|NCT01035450|Active Comparator|Sirolimus-eluting stent|
3214452|NCT01035476|Experimental|Data Card Report|Patients receive detailed reports of acceptance and adherence, with linked recommendations to optimize NIPPV.
3214453|NCT01035476|No Intervention|Standard NIPPV Care|Patients receive routine monitoring and care related to NIPPV.
3214454|NCT01035489|Active Comparator|CRT; RV apical lead placement|Right ventricular apical lead placement in CRT
3214455|NCT01035489|Active Comparator|CRT; RV high posterior septum|High posterior septal lead placement in CRT
3214456|NCT01035502|Experimental|Elacytarabine plus idarubicin|
3214457|NCT01035515|Experimental|Arm One|Arm 1 of 6 cross-over arms
3214458|NCT01035515|Experimental|Arm Two|Arm 2 of 6 cross-over arms
3214459|NCT01035515|Experimental|Arm Three|Arm 3 of 6 cross-over arms
3214460|NCT01035515|Experimental|Arm Four|Arm 4 of 6 cross-over arms
3214461|NCT01035515|Experimental|Arm Five|Arm 5 of 6 cross-over arms
3214462|NCT01035515|Experimental|Arm Six|Arm 1 of 6 cross-over arms
3214463|NCT01035528|Active Comparator|insulin glargine|antidiabetic treatment with Lantus o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
3214464|NCT01035528|Active Comparator|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
3214465|NCT01035541||P group|Fluid Management according to measurements with PiCCO®
3214466|NCT01035541||C group|Conventional fluid management
3214467|NCT01035554|Active Comparator|Usual Care (UC) + Printed Materials (PM)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
3214468|NCT01035554|Experimental|UC + Self-Paced Program Instruction (SPPI)|If the participant is assigned to UC, they will receive standard care. They will not receive a HBPM to use for the study, but will be given one to keep at the 3 month Follow-Up Visit. If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials from the National Institutes of Health.
3214469|NCT01035554|Experimental|Home Blood Pressure Monitor (HBPM) + PM|If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them. If they are also assigned to PM, they will then be given written materials (pamphlets from the NIH) regarding hypertension education and will be asked to review the information in its entirety. The coordinator will be available to answer any questions they might have.
3214470|NCT01035554|Experimental|HBPM + SPPI|"If the participant is assigned to HBPM, they will be asked to use the monitor once a day in the morning and once before they go to bed any 3 days of the week, each week of the study (total = 12 weeks). They will be asked to record their BP values in diaries they will be given to take home with them.~If they are also assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the PM from the National Institutes of Health."
3214471|NCT01035567|Active Comparator|Hybrid revascularization|
3214472|NCT01035567|Active Comparator|Coronary Artery Bypass Grafting|
3214473|NCT01035580|Experimental|curcurim|This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.
3214474|NCT01035593|Active Comparator|Standard of Care (PP + IVIG)|Plasmapheresis and IVIG 100mg/kg every other day x 5 treatments
3214475|NCT01035593|Experimental|PP + IVIG + rhC1INH|Plasmapheresis + 100mg/kg IVIG every other day x 5 treatments plus rhC1Inh 100u/kg IV daily x 7 consecutive days (once daily on PP days, twice daily on non-PP days).
3214476|NCT01035619|Experimental|Moxidectin|
3214477|NCT01035645|Experimental|GSK1070806 or placebo|This is a single dose escalating study. On enrolment into the study, each subject will be assigned to a group. These groups will be aligned to specific dose levels of GSK1070806. All subjects will be randomised to receive either a single intravenously administered dose of GSK1070806 or matching placebo (saline). The randomisation is generated by GSK prior to study start.
3214478|NCT01035671|Experimental|Low Dose|A0001 (0.5 g BID)
3214479|NCT01035671|Experimental|High Dose|A0001 (0.75 g BID)
3214480|NCT01035671|Placebo Comparator|Placebo|Placebo
3214481|NCT01035775|Experimental|Insertion|Inspection on colonoscope insertion in addition to inspection during withdrawal from the cecum.
3214482|NCT01035775|Active Comparator|Withdrawal|Inspection during withdrawal (usual care) without deliberate inspection during insertion.
3214483|NCT01035801|Experimental|IN105|Prandial Oral Insulin
3214484|NCT01035801|Active Comparator|Insulin Lispro Injection|
3214485|NCT01035879|Experimental|MBX-2982 25 mg|
3214486|NCT01035879|Experimental|MBX-2982 100 mg|
3214487|NCT01035879|Experimental|MBX-2982 300 mg|
3214488|NCT01035879|Active Comparator|Sitagliptin 100 mg|
3214489|NCT01035879|Placebo Comparator|Placebo|
3214490|NCT01035983|Experimental|Frovatriptan 2.5 mg|Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.
3214491|NCT01036035|Active Comparator|Treatment B|Study drug
3214492|NCT01036035|Active Comparator|Treatment D|Study drug
3214493|NCT01036035|Placebo Comparator|Treatment E|Placebo
3214494|NCT01036035|Active Comparator|Treatment A|Study Drug
3214495|NCT01036035|Active Comparator|Treatment C|Study Drug
3214496|NCT01036048||cabg disease|pts with saphenous vein graft disease
3214497|NCT01036061|Experimental|GSK618334 low Dose|GSK618334 Low Dose
3214498|NCT01036061|Experimental|GSK618334 Medium Dose|GSK618334 medium dose arm
3214499|NCT01036061|Experimental|GSK618334 High Dose|GSK618334 High Dose Arm
3214500|NCT01036061|Experimental|GSK618334 Placebo|Placebo for all 3 dose levels
3214501|NCT01036087|Experimental|PNC + FEC|"PNC = Panitumumab + Nab-paclitaxel + Carboplatin, and~FEC = 5-fluorouracil, epirubicin, and cyclophosphamide"
3214502|NCT01036113|Experimental|Experimental: EZN-2208|Experimental: EZN-2208 EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
3214503|NCT01036139|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
3214504|NCT01036139|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
3214505|NCT01036243|Experimental|Test formula 1|Hydrolyzed formula with probiotics
3214506|NCT01036243|Active Comparator|test formula 2|acidified hydrolyzed formula.
3214507|NCT01036243|Active Comparator|Test formula 3|hydrolyzed formula without probiotics
3214508|NCT01036243|Active Comparator|reference product|standard infant formula
3214509|NCT01036282|Experimental|Computerized Cognitive Remediation|Two arms: 1. Computerized Cognitive Remediation treatment using COGPACK. and 2. PositScience. Each arm is further randomized to either MindReader or no Mindreader.(Social Cognition Training).
3214510|NCT01036282|Experimental|CRT + Social Cognition Training|Two 45-minute sessions of Computerized Cognitive Remediation using COGPACK, one 45-minute discussion session, plus one 45 minute Mind Reader Interactive Guide to Emotions per week for 12 weeks. compared to two 45-minute sessions of PositScience, plus one 45-min Discussion session plus one minute of Mind Reader, Interactive Guide to Emotions
3214511|NCT01036308|Experimental|TypTop|Lupinus albus Typ Top (lupin kernel fibre, dietary fibre content: 83%)
3214512|NCT01036308|Experimental|Soy fibre|Glycine max Hefeng (soy fibre; dietary fibre content: 77%)
3214513|NCT01036308|Experimental|Boregine|Lupinus angustifolius Boregine (lupin kernel fibre, dietary fibre content: 87%)
3214514|NCT01036360||physical activity|
3214515|NCT01036399|Experimental|Revlimid|"Oral Revlimid is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.~After this induction phase, the CR, PR and SD will continue Revlimid with the same schedule for other 8 months."
3214516|NCT01036412|Experimental|Chlorhexidine Gel Therapy|Following 2 x 5-minute applications of 2.5 ml in clinic, 2 x 5.0 ml syringes of 1% chlorhexidine gluconate gel, self-administered for a 5-minute application Week 2 & Week 4
3214520|NCT01036633||Control Group no mucositis|Control patients with multiple myeloma who are not currently receiving chemotherapy and who do not suffer from oral mucositis
3214521|NCT01036633||Non-control Group Mucositis|Patients with multiple myeloma suffering from WHO Grade 3/4 Oral Mucositis
3214522|NCT01036646||BSTE-0125-Original Protocol|
3214523|NCT01036646||BSTE-0125.a-Amended Protocol|
3214524|NCT01036659|Active Comparator|Ecallantide in conjunction with Conventional Therapy|
3214525|NCT01036659|Placebo Comparator|Conventional therapy and placebo|
3214526|NCT01036659|No Intervention|Historical Evaluation|
3214535|NCT01036841|Active Comparator|desmopressin tablet|
3214536|NCT01036841|Experimental|desmopressin MELT-formulation|
3214537|NCT01036854|Experimental|Regime 1|Regime 1 will be orally administered once daily in the morning over 6 consecutive days.
3214538|NCT01036854|Active Comparator|Regime 2|Regime 2 will be orally administered twice daily at 12 hours interval (morning and evening) over 6 consecutive days
3214539|NCT01036854|Active Comparator|Regime 3|Regime 3 will be orally administered three times daily at 8 hour intervals (morning, afternoon, evening) over 6 consecutive days.
3214540|NCT01036854|Experimental|Regime 4|Regime 4- Day 1- a single dose will be given. Day 2- one placebo capsule; Day 3- a single dose will be given . Day 4 & 5- two placebo capsules on each day; Day 6- a single does will be given.
3214541|NCT01036893|No Intervention|oral contraceptives without prucalopride|
3214542|NCT01036893|Active Comparator|oral contraceptives with prucalopride|prucalopride
3214543|NCT01036932|Active Comparator|G-CSF group|Patients with Acute on chronic liver failure after baseline investigations for the etiology of the acute event and the underlying chronic disease were given Granulocyte Colony Stimulating Factor therapy for a total duration of one month.
3214544|NCT01036932|Placebo Comparator|Placebo|After baseline characterization and work up for underlying acute and chronic liver disease, patients were given placebo along with the standard therapy
3214545|NCT01037023||Patients administrated Topotecan|There is only one group. This group includes patients administrated Topotecan
3214546|NCT01037036|Experimental|Latanoprost Punctal Plug Delivery System followed by Xalatan|Subjects will have the Latanoprost Punctal Plug Delivery System placed for 4 week or until loss of efficacy. After removal of the Latanoprost Punctal Plug Delivery system, subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
3214547|NCT01037049|No Intervention|Group 1|Patients who have surgery at 6 weeks after radiotherapy/chemoradiotherapy
3214548|NCT01037049|Experimental|Group 2|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy
3214549|NCT01037062|Experimental|Entecavir|
3214550|NCT01037101|Active Comparator|IVET+DCS|
3214551|NCT01037101|Experimental|VRET+DCS|
3214552|NCT01037101|Experimental|VRET+Placebo|
3214553|NCT01037101|Active Comparator|IVET+Placebo|
3214554|NCT01037101|No Intervention|Wait-List|3 weeks Wait-List
3214555|NCT01037140|Active Comparator|cholecalciferol|
3214556|NCT01037140|Placebo Comparator|placebo|
3214557|NCT01037166|Experimental|Entecavir (0.5 mg)|
3214558|NCT01037166|Experimental|Entecavir (1mg)|
3214559|NCT01037179|Experimental|AL-4943A|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, 2 drops instilled in each eye twice daily for 10 weeks
3214560|NCT01037205|Active Comparator|DAS181 High Dose|DAS181 Dry Powder 10 mg qd x 3 days
3214561|NCT01037205|Active Comparator|DAS181 Low Dose|DAS181 Dry Powder 10 mg Day 1 Lactose Placebo Day 2 and Day 3
3214562|NCT01037205|Placebo Comparator|Lactose Placebo|Lactose (Respitose ML006 (DMV-Fonterra)) 1 capsule qd x 3 days
3214563|NCT01037231|Experimental|Oxabact (tm)|
3214564|NCT01037231|Placebo Comparator|Placebo|
3214565|NCT01037283|Other|Interpersonal and Social Rhythm Therapy|All participants receive eight sessions of Interpersonal and Social Rhythm Therapy.
3214566|NCT01037296|Other|manual ablation|
3214567|NCT01037296|Experimental|robotic ablation|
3214568|NCT01037322|Active Comparator|cannabidiol in drops|cannabidiol given in drops of olive oil sub lingual 5 mg twice daily
3214569|NCT01037322|Placebo Comparator|placebo in drops|olive oil given in drops sub lingual
3214570|NCT01037335|Placebo Comparator|control group|10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly.
3214571|NCT01037335|Active Comparator|intramuscular morphine|10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly
3214572|NCT01037335|Active Comparator|donor site morphine|5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
3214573|NCT01037348|Experimental|ranibizumab 0.5mg|
3214574|NCT01037374|Experimental|Difficult Airway Assessment Form|
3214575|NCT01037387|Active Comparator|Control|Conventional treatment for COPD
3214576|NCT01037387|Experimental|NIMV group|NIMV: Conventional treatment plus noninvasive mechanical ventilation
3214577|NCT01037400||Total Knee Replacement Patients|Forty men and women ages 18-75 undergoing unilateral (n = 20) or bilateral (n = 20) knee replacement surgery with no musculoskeletal injury requiring medical attention in the past 3 months or producing pain in the previous 2 weeks and no inflammatory disease other than osteoarthritis.
3214578|NCT01037426|Other|Study group|Falls before versus after pacemaker implant
3214579|NCT01037439|Active Comparator|Conventional ASV|Current adaptive servoventilation therapy algorithm for non invasive ventilation treatment of Cheyne-Stokes Respiration.
3214580|NCT01037439|Experimental|Modified ASV|Modified adaptive servoventilation algorithm for improved treatment of nocturnal breathing disorders
3214581|NCT01037465|Active Comparator|N-acetylcysteine|N-acetylcysteine
3214582|NCT01037465|Placebo Comparator|Placebo|Placebo
3214583|NCT01037478|Experimental|Resminostat (4SC-201)|oral administration
3214584|NCT01037491|Active Comparator|aspirin|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
3214585|NCT01037491|Active Comparator|clopidogrel|Patients who have taken aspirin for more than 1 month and are found to have PUD by upper endoscopy will receive PPI (rabeprazole 20 mg once daily) to treat their PUD.patients will be randomly assigned rabeprazole (20 mg/day) plus aspirin (100 mg/day) or rabeprazole (20 mg/day) plus clopidogrel (75 mg/day) for 12 weeks.
3214586|NCT01037504|Experimental|A|Drug: AZD5423
3214587|NCT01037504|Placebo Comparator|B|Drug: Placebo
3214588|NCT01037517|Active Comparator|Successful Mobilizers|Successful Mobilizers are defined as having a peripheral blood CD34 > 10X106/L.
3214589|NCT01037517|Experimental|Poor Mobilizers|Poor Mobilizer are defined as patients who on Day -1 have a peripheral blood [CD34] ≤ 10 X106/L
3214590|NCT01037530|Experimental|Ramipril|
3214591|NCT01037543|Experimental|Cohort 1|1.1 mcg/kg of HM10460A, placebo, or Neulasta
3214592|NCT01037543|Experimental|Cohort 2|3.3 mcg/kg HM10460A, placebo or Neulasta
3214593|NCT01037543|Experimental|Cohort 3|10 mcg/kg of HM10460A, placebo, or Neulasta
3214594|NCT01037543|Experimental|Cohort 4|30 mcg/kg of HM10460A, placebo, or Neulasta
3214595|NCT01037543|Experimental|Cohort 5|90 mcg/kg or HM10460A, placebo, or Neulasta
3214596|NCT01037543|Experimental|Cohort 6|270 mcg/kg of HM10460A, placebo, or Neulasta
3214597|NCT01037556|Experimental|Arm 1: PR104|
3214598|NCT01037582|Experimental|Trial part 1|
3214599|NCT01037582|Experimental|Trial part 2|
3214600|NCT01037595|Experimental|turmeric|turmeric 500 mg tid orally for 8 weeks
3214601|NCT01037595|Placebo Comparator|plasebo|placebo tid orally for 8 weeks
3214602|NCT01037634|Experimental|Oseltamivir|Participants will receive Oseltamivir to treat influenza.
3214603|NCT01037647||Type 2 diabetic men|Men with type 2 diabetes
3214604|NCT01037647||Healthy men|Healthy men
3214605|NCT01037660|Experimental|Metformin|Metformin
3214606|NCT01037673|Experimental|PT progressive exercises|A progressive program of movement and strength exercises for the rotator cuff and scapular muscles combined with mobilisation of the joint capsule when needed
3214607|NCT01037673|Active Comparator|Movement exercises neck and shoulder|General movements for the neck and shoulder,
3214608|NCT01037686|Other|PD, DBS, healthy controls|Patients with idiopathic PD before or after DBS surgery (during on or off-stimulation) and healthy controls.
3214609|NCT01037699|Active Comparator|FSH YOUNGER|
3214610|NCT01037699|Active Comparator|FSH OLDER|
3214611|NCT01037699|Experimental|FSH LH YOUNGER (Recombinant Luteotrophin alfa)|
3214612|NCT01037699|Experimental|FSH LH OLDER|
3214613|NCT01037712|Experimental|ZELITREX|ZELITREX
3214614|NCT01037712|Placebo Comparator|Placebo|placebo
3214615|NCT01037725|Experimental|AZD5847 oral suspension|Active
3214616|NCT01037725|Placebo Comparator|Placebo to AZD5847|Placebo
3214617|NCT01037738|Active Comparator|ACS - Orthokin|Autologous conditioned serum (ACS) - Orthokin containing endogenous anti-inflammatory cytokines including IL-1Ra and growth factors (IGF-1, PDGF and TGF-ß1, among others) in the liquid blood phase.
3214618|NCT01037738|Placebo Comparator|Placebo|Physiologic solution
3214619|NCT01037751||Interview + Questionnaires|1-on-1 interview + Questionnaires, Part 1 of Study
3214620|NCT01037751||Questionnaires|Questionnaires Only, Part 2 of Study
3214621|NCT01037764|Experimental|alloHCT|alloHCT arm: For HLA-matched sibling HCT, if a patient is 55 years old or less and without co-morbidity, the patient will receive Bu-Cy conditioning therapy and be transplanted with bone marrow cells. Patients who are older than 55 years or with co-morbidity will receive Bu-Flu-ATG conditioning and be transplanted with mobilized peripheral blood hematopoietic cells. For HLA-matched unrelated donor or HLA-mismatched familial donor HCT, the patient will receive Bu-Flu-ATG conditioning and well be transplanted with mobilized peripheral blood hematopoietic cells.
3214622|NCT01037777||presymptomatic carriers|
3214623|NCT01037777||non carrier relatives|
3214624|NCT01037816|Active Comparator|FS-67 patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
3214625|NCT01037816|Placebo Comparator|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
3214626|NCT01037829||Pregnancy women|Comparison of pregnancy outcomes between (Novartis) H1N1 vaccinated women and (Novartis) H1N1 unvaccinated women.
3214627|NCT01037842|Active Comparator|Metformin+Mitiglinide|mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
3214628|NCT01037842|Placebo Comparator|Metformin+Placebo|placebo three times a day added to metformin 500 mg three times a day
3214629|NCT01037855||Group 1: 6-23 months|
3214630|NCT01037855||Group 2: 2-8 years|
3214631|NCT01037855||Group 3: 9-17 years|
3214632|NCT01037855||Group 4: 18-44 years|
3214633|NCT01037855||Group 5: 45-60 years|
3214634|NCT01037855||Group: >60 years|
3214635|NCT01037868|Experimental|Supportive SMS messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
3214636|NCT01037868|No Intervention|No supportive SMS text message|Patients in the non-intervention group would also receive text messages once every fortnight thanking them for participating in the study and a monthly phone call which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
3214637|NCT01037894|Experimental|Acupuncture|Acupuncture and conventional rehabilitation
3214638|NCT01037894|Active Comparator|Control|Conventional rehabilitation only
3214639|NCT01037907|Experimental|BGC20-0134 (Pleneva TM)|Structured lipid
3214640|NCT01037907|Placebo Comparator|Placebo control|Placebo - dummy pill
3214641|NCT01037920|Experimental|Intervention|subjects in the intervention arm will complete a self-affirmation exercise prior to a physician visit
3214642|NCT01037920|Active Comparator|Control|subjects in the intervention arm will complete a sham exercise prior to a physician visit
3214643|NCT01037933|Active Comparator|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
3214644|NCT01037933|Active Comparator|Non-humor intervention|"A 45-minute non-humorous DVD The A to Z of Steam Railways using a portable DVD player."
3214645|NCT01037946|No Intervention|Standard Care Arm|Families living with HIV, offered intervention at the end of study (24 months after recruitment)
3214646|NCT01037946|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
3214647|NCT01037959|Active Comparator|Norfloxacin|Patients with severe cirrhosis treated with norfloxacin
3214648|NCT01037959|Placebo Comparator|Placebo|Patients with severe cirrhosis treated with placebo
3214649|NCT01037972||Whole body vibration|
3214650|NCT01037972||Conventional physiotherapy|
3214651|NCT01037998|Active Comparator|A|Iressa 250 mg daily treatment plus UFUR twice daily treatment
3214652|NCT01037998|No Intervention|B|Gefitinib 250 mg daily treatment
3214653|NCT01038024|Experimental|Antioxidant Supplements|
3214654|NCT01038063|Experimental|Artemether-lumefantrine|Children in this study arm will be treated with artemether-lumefantrine during a three year follow-up period each time a child develops uncomplicated malaria.
3214655|NCT01038063|Active Comparator|Dihydroartemisinin-piperaquine|Children in this study arm will be treated with dihydroartemisinin-piperaquine during a three year follow-up period each time a child develops uncomplicated malaria.
3214656|NCT01038076|Experimental|MedCHEC Tablet Computer & Adherence Care|Patients assigned to the intervention answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates provider and patient reports. Patients may be referred to an Adherence Care Manager on the basis of the reports. In addition, patients will receive standard information about adherence.
3214657|NCT01038076|No Intervention|Adherence Information Only|Patients assigned to the active comparator arm will receive standard information about adherence.
3214658|NCT01038089|Experimental|resveratrol|Resveratrol
3214659|NCT01038102|Active Comparator|PUFA diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%)
3214660|NCT01038102|Active Comparator|SFA diet|Diet high in saturated fat (15 E%)
3214661|NCT01038115|Active Comparator|Cryoballoon|
3214662|NCT01038115|Active Comparator|Radiofrequency|
3214663|NCT01038115|Active Comparator|Cryoballoon + Radiofrequency together|
3214664|NCT01038141|Active Comparator|Milligan Morgan|
3214665|NCT01038141|Active Comparator|Recto Anal Repair|
3214666|NCT01038154|No Intervention|control|Not Receive pravastatin
3214667|NCT01038154|Experimental|Pravastatin|
3214668|NCT01038167|Experimental|Part A|Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
3214669|NCT01038167|Experimental|Part B|Part B will be administered in two periods, separated by a washout. In Period 1, subjects will receive tacrolimus alone. In Period 2, subjects will receive tacrolimus in combination with telaprevir.
3214670|NCT01038180||pacemaker group|
3214671|NCT01038193||aSAH patients|Cognitive assessment
3214672|NCT01038206|Experimental|Family Function Intervention|Familias Unidas Intervention Program
3214673|NCT01038206|No Intervention|Treatment as Usual|The Public School system mandates that all high school students receive at least 5 lessons (55 minutes each) per year of HIV prevention.
3260336|NCT01478477|Experimental|Assessment of therapy complications|Adverse events will be monitored by self-reporting of signs and symptoms. Patients will maintain a daily diary of time of supplement intake and any possible ill effects, with instructions to contact the PI or Research Nurse to discuss and manage any possible side effects.
3260337|NCT01478477|Experimental|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained
3260338|NCT01478477|Experimental|Correlative/special studies|Enrolled participants will have peripheral blood samples drawn for plasma and RBC n-3 PUFA levels within 4 weeks of starting AI therapy.
3260339|NCT01478490|Experimental|Treatment Arm 1A|mirabegron, poor metabolizers
3260340|NCT01478490|Experimental|Treatment Arm 1B|mirabegron, extensive metabolizers
3260341|NCT01478490|Experimental|Treatment Arm 2|mirabegron/metoprolol
3260342|NCT01478503|Experimental|Treatment Arm A|mirabegron
3260343|NCT01478503|Placebo Comparator|Treatment Arm B|matching placebo
3260344|NCT01478516|Experimental|Plasmin|eyes with macular edema
3214674|NCT01038219||fever measurements|"1000 estimates and measurements of children's body temperatures will be carried out by parents and nurses in children's emergency and pediatric units as part of the routine work. The estimates and the measurements will be carried out on children who are referred to an emergency unit and who are hospitalized in the pediatric department-- both boys and girls of all ages. A patient might be measured several times.~The measurements will be gathered in the course of one year. Before the routine taking of temperature, the accompanying parent will be asked to estimate the patient's temperature by feeling his forehead (with the back of the hand, the palm, lips). The parent will record his evaluation (without telling the nurse). Afterwards the nurse will do a similar evaluation (excepting the lip test), record it, and then the routine temperature measurement will be taken."
3214675|NCT01038258|Other|No arms|No arms
3214676|NCT01038271|Active Comparator|Standard Palliative Care Group|
3214677|NCT01038271|Active Comparator|Integrated Palliative Care Group|
3214678|NCT01038284|Sham Comparator|Control|
3214679|NCT01038284|Active Comparator|Patient education|
3214680|NCT01038362|Active Comparator|Almonds|National Cholesterol Education Program Step I diet plus almonds for 6 weeks
3214681|NCT01038362|Placebo Comparator|No Almonds|National Cholesterol Education Program Step 1 diet without almonds for 6 weeks
3214682|NCT01038375||Adherence counseling|
3214683|NCT01038375||Usual care|
3260345|NCT01478529|Experimental|Treatment Arm A|low dose of mirabegron
3260346|NCT01478529|Experimental|Treatment Arm B|high dose of mirabegron
3260347|NCT01478568|Experimental|mirabegron / desipramine|
3260348|NCT01478607|Experimental|1. Qutenza 30 minutes + SOC|
3260349|NCT01478607|Experimental|2. Qutenza 60 minutes + SOC|
3214684|NCT01038388|Experimental|Bortezomib, lenalidomide, dexamethasone, vorinostat|"Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; lenalidomide by mouth once a day on days 1-14; dexamethasone by mouth once a day on days 1, 2, 4, 5, 8, 9, 11, and 12; and vorinostat by mouth on days 1-14. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.~After 8 courses, patients may receive maintenance therapy comprising lenalidomide by mouth once a day on days 1-21, dexamethasone by mouth once a day on days 1, 2, 8, and 9, and bortezomib IV over 3-5 seconds or subcutaneously on days 1 and 8. Courses may repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3214685|NCT01038401|Other|HIV-1-infected patients on effective HAART|
3214686|NCT01038401|Other|Non Infected HIV Volunteers|
3214687|NCT01038414|Placebo Comparator|Brief-Duration Counseling|3-Month Duration
3214688|NCT01038414|Active Comparator|Moderate Duration Counseling|6-Month Duration
3214689|NCT01038414|Active Comparator|Extended Duration Counseling|12-Month Duration
3214690|NCT01038440|Placebo Comparator|Control|
3214691|NCT01038440|Active Comparator|EPA 0.5 g/d|
3214692|NCT01038440|Active Comparator|EPA 1.5 g/d|
3214693|NCT01038440|Active Comparator|EPA 3.0 g/d|
3214694|NCT01038440|Experimental|SDA 0.5 g/d|
3214695|NCT01038440|Experimental|SDA 1.5 g/d|
3214696|NCT01038440|Experimental|SDA 3.0 g/d|
3214697|NCT01038440|Experimental|SDA 6.0 g/d|
3214698|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 35 µg|Dietary Supplement: Cholecalciferol (Vitamin D3) 35 µg per day
3214699|NCT01038453|Active Comparator|Cholecalciferol (Vitamin D3) 70 µg|Dietary supplement: Cholecalciferol (Vitamin D3) 70 µg per day
3214700|NCT01038453|Placebo Comparator|placebo|
3214701|NCT01038466||CHAT trial participants|CHAT trial participants whose data was used in the final data analysis for the CHAT study
3214702|NCT01038479|Active Comparator|Childsmile programme with xylitol|Childsmile program with maternal xylitol consumption;
3214703|NCT01038479|Placebo Comparator|Childsmile programme only|Childsmile programme
3214704|NCT01038492|Experimental|p16 Methylation in Sputum Testing|"Patients tested for smoking-related changes in their breathing~shown a presentation on development of lung cancer~complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic detail~given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits"
3214705|NCT01038505|Active Comparator|Tacrolimus and Myfortic|Immunosuppressive
3214706|NCT01038505|Active Comparator|Tacrolimus and Sirolimus|Immunosuppressive
3214707|NCT01038518||Health2010|Cross-sectional general population study
3214708|NCT01038531|Active Comparator|low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
3214709|NCT01038531|Experimental|APRV|APRV allows spontaneous breathing.
3214710|NCT01038570|Experimental|Oxytocin|
3214711|NCT01038570|Placebo Comparator|Physiological serum|
3214712|NCT01038583||Aspirin|100 mg enteric-coated aspirin
3214713|NCT01038583||Placebo|Placebo
3214714|NCT01038596||osteoarthritic donors|pelvic compartment advanced-stage (Kellgren and Lawrence grade 3 or 4) osteoarthritic donors
3214715|NCT01038596||healthy donors|age-matched healthy donors
3214716|NCT01038622|Active Comparator|L-arginine|5-day L-arginine treatment (200 mg/kg)
3214717|NCT01038622|Placebo Comparator|placebo|5-day placebo treatment
3214718|NCT01038648|Placebo Comparator|1|Advice life style at baseline only
3214719|NCT01038648|Active Comparator|sitagliptin arm : 2|"100mg/day sitagliptin~advice on life style modification at baseline only"
3214720|NCT01038661|Experimental|First line treatment: docetaxel 75 mg/m² + cisplatin 75 mg/m²|Docetaxel 75 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
3214721|NCT01038661|Experimental|First line treatment:: docetaxel 60 mg/m² + cisplatin 75 mg/m²|Docetaxel 60 mg/m² + cisplatin 75 mg/m² on day 1, repeated every 3 weeks, up to 4 cycles
3214722|NCT01038661|Experimental|Maintenance treatment: docetaxel (60 mg/m2)|Docetaxel 60 mg/m² on day 1, repeated every 3 weeks until progressive disease or up to 6 cycles
3214723|NCT01038661|Active Comparator|Maintenance treatment: best supportive care (BSC)|BSC until progressive disease
3214724|NCT01038674|Experimental|Anti-IL-20|
3214725|NCT01038674|Placebo Comparator|Placebo|
3214726|NCT01038726|Active Comparator|Exercise Training|
3214727|NCT01038726|Active Comparator|Combined Cognitive/Exercise Training|
3214728|NCT01038726|Active Comparator|Cognitive Training|
3214729|NCT01038726|Active Comparator|Combined Low Intensity Training|
3214730|NCT01038739|Experimental|A|
3214731|NCT01038739|Experimental|B|
3214732|NCT01038739|Placebo Comparator|C|
3214733|NCT01038765|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3214734|NCT01038765|No Intervention|Waiting list control group|3-month waiting list group
3214735|NCT01038791|Active Comparator|usual ventilation|application of usual mechanical ventilation without humidification system
3214736|NCT01038791|Experimental|heated humidifier|mechanical ventilation with heated humidifier
3214737|NCT01038791|Experimental|heat and moisture exchanger|mechanical ventilation with heat and moisture exchanger
3214738|NCT01038804|Experimental|A. YM155 plus docetaxel|
3214739|NCT01038804|Active Comparator|B. docetaxel alone|
3214740|NCT01038817|Active Comparator|fluoride varnish|"Duraphat:~Application of fluoride varnish on one side of the mandibles (left or right, randomly selected)"
3214741|NCT01038817|No Intervention|control|no application on the other side
3214742|NCT01038843|Experimental|VA106483 1mg|
3214743|NCT01038843|Experimental|VA106483 2mg|
3214744|NCT01038843|Experimental|VA106483 4mg|
3214745|NCT01038843|Placebo Comparator|Sugar pill|
3214746|NCT01038882|Active Comparator|Midazolam|The patients of this arma receives midazolam before the flexible bronchoscopy to maintain conscious sedation
3214747|NCT01038882|Placebo Comparator|Physiological serum|
3214748|NCT01038895|Active Comparator|Ramipril|10 mg/daily
3214749|NCT01038895|Experimental|Aliskiren|300 mg/ daily
3214750|NCT01038908|Active Comparator|1|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
3214751|NCT01038908|Active Comparator|2|Each patient will receive an injection of technetium-99m sulfur colloid directed subareolar or around the tumor. The material will be prepared as per manufacturer's specifications. The dose will be 20mBq given the same day of 80mBq given the day before. The Nuclear Medicine Department at St Paul's Hospital will perform the injection as per normal sentinel lymph node mapping protocol.
3214752|NCT01038934|Experimental|buccal cytobrhsh|healthy young
3214753|NCT01038947|Experimental|Uricase-PEG 20|Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner. The study will enroll both single dose cohorts and multi-dose cohorts.
3214754|NCT01038960|Experimental|Exercise training|training
3214755|NCT01038960|No Intervention|Not training|No organized training
3214756|NCT01038986||CureXcell treated|Patients with chronic and/or refractory wounds for at least 4 weeks with no improvement that have been referred by their physician for CureXcell treatment
3214757|NCT01038999||A HIV1-infected naive patients|
3214758|NCT01038999||B HIV1-infected patients|in 1st line of ARV therapy for at least 12 months
3214759|NCT01038999||C= control Non infected HIV volunters|
3214760|NCT01039012|Other|Tai Chi plus Standard Care|
3214761|NCT01039012|Other|Standard Care|
3214762|NCT01039025|Experimental|TMC|Topotecan, Melphalan, and Cyclophosphamide
3214763|NCT01039051|Experimental|Diet and Lifestyle counseling|increasing consumption of vegetables and fruits; maintaining energy balance through reducing excessive energy from meat, eggs and brown sugar and increasing energy expenditure from appropriate physical activity, such as doing maternal keep-fit exercises.
3214764|NCT01039077|Active Comparator|Single incision laparoscopic gastric banding|Patients in this group will undergo laparoscopic gastric banding through a single periumbilical incision.
3214765|NCT01039077|Active Comparator|Five port laparoscopic gastric banding|Patients in this group will undergo conventional laparoscopic gastric banding using 5 small incisions.
3214766|NCT01039090|Active Comparator|Per os dopaminergic treatment|
3214767|NCT01039090|Experimental|Continuous Apomorphine infusion|
3214768|NCT01039103|Experimental|Nanocort|PEG-liposomal prednisolone sodium phosphate (Nanocort) 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
3214769|NCT01039103|Active Comparator|Solu-Medrol|Methylprednisolone (Solu-Medrol) 1 g, IV, infusion over 2 hours on days 1, 2 and 3
3214770|NCT01039116|Experimental|Level of intervention intensity|"High Intensity: Behavioral Experimental:Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.~Active Comparator: Low-intensity Participants were provided with educational materials 4 times yearly."
3214771|NCT01039129|Experimental|Endoscopic Cholecystectomy|20 patients in this arm will undergo cholecystectomy, or removal of the gallbladder, through this experimental approach. This arm will compose of patients with symptomatic gallstones (cholelithiasis).
3214772|NCT01039129|Experimental|Endoscopic Appendectomy|Participants will with chronic appendicitis will undergo appendectomy through this experimental approach.
3214773|NCT01039129|Experimental|Endoscopic Peritoneoscopy|20 patients in this arm will undergo diagnostic peritoneoscopy with or without biopsy for any indication.
3214774|NCT01039142|Active Comparator|25 mg acitretin|capsule acitretin 25 mg/day will be administered to each patient for a period of 12 weeks
3214775|NCT01039142|Active Comparator|35 mg acitretin|capsule acitretin 35 mg/day will be administered to each patient for a period of 12 weeks
3214776|NCT01039142|Active Comparator|50 mg acitretin|capsule acitretin 50 mg/day will be administered to each patient for a period of 12 weeks
3214777|NCT01039155|Experimental|Treatment (azacitidine, oxaliplatin)|Patients receive azacitidine IV over 15-30 minutes on days 1-5 and oxaliplatin IV over 2 hours on days 2-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3214778|NCT01039168|Active Comparator|Workplace dialogue|Clinical examination and dialogue with supervisor to find solutions to reduce job-person mismatch and facilitate return to work
3214779|NCT01039168|Sham Comparator|Care as usual|No intervention besides of the care as usual being available for the patient
3214780|NCT01039194|Active Comparator|galantamine 8 mg (ER)|
3214781|NCT01039194|Active Comparator|galantamine 16 mg (ER)|
3214782|NCT01039194|Active Comparator|BMS-708163|
3214783|NCT01039233|Experimental|Bicalutamide 50 mg Tablet|
3214784|NCT01039233|Active Comparator|Casodex® 50 mg Tablet|
3214785|NCT01039259||subjects with lip piercing|
3214786|NCT01039259||subjects with tongue piercing|
3214787|NCT01039272||oral cancer|patients with oral squamous cell carcinoma
3214788|NCT01039272||control group|healthy patients without any oral pathology
3214789|NCT01039285|Experimental|Surfactant instillation|2.5 ml/kg of Surfactant will be instilled in the trachea
3214790|NCT01039285|Placebo Comparator|Placebo instillation|2.5 ml/kg of Air will be instilled in the trachea
3214791|NCT01039298|Active Comparator|A|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The Control arm. Surgical boundaries for oral lesions will be defined under regular white light."
3214792|NCT01039298|Experimental|B|"All subjects in this study will receive surgery to treat their oral lesions. The margins (or boundaries) of the tissue to be removed during surgery will be defined by 2 different procedures (or study arms) in the operating room.~The FV arm (experimental arm). Surgical boundaries for oral lesions will be defined by FV."
3214793|NCT01039311||Optical Coherence Tomography|Examine OCT images and compare them to conventional biopsies in same subject.
3214794|NCT01039324|Experimental|Intermediate Intervention (arm #1)|Care transition reports sent to primary care clinics, care transition letters sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
3214795|NCT01039324|Experimental|Full Intervention (arm #2)|E-mail notices sent to care managers about care transitions plus care transition reports sent to primary care clinics, care transition reports sent to patients, release of information requests about care transitions sent on behalf of primary care clinics.
3214796|NCT01039324|Experimental|Control (arm #3)|"Subjects assigned to the control group will receive usual care which is the standard of care coordination currently existent between patients, providers and care managers."
3214797|NCT01039337|Active Comparator|Hip school|This group will receive hip school during the intervention period of 6 weeks.
3214798|NCT01039337|Active Comparator|Hip School and Manual Treatment|This group receives both hip school and manual treatment during the 6 weeks.
3214799|NCT01039337|Active Comparator|Minimal control intervention|An information leaflet including exercises.
3214800|NCT01039363|Experimental|Vorinostat|Vorinostat combined with salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat maintenance
3214801|NCT01039389|Experimental|Collateral promotion; PCI after 6 months|
3214802|NCT01039389|Experimental|Collateral promotion; PCI at baseline|
3214803|NCT01039402||1|Adults ≥ 50 years old
3214804|NCT01039441|Placebo Comparator|instillation of normal saline 50ml under the diaphragm|
3214805|NCT01039441|Experimental|the instillation of 0.5% bupivacaine under the diaphragm|
3214806|NCT01039441|Experimental|CO2 removal by means of a pulmonary recruitment maneuver|
3214807|NCT01039441|Experimental|the instillation of bupivacaine + CO2 removal by maneuver|
3214808|NCT01039454|Placebo Comparator|Placebo|2 way cross over.
3214809|NCT01039454|Active Comparator|Active|2 Way cross over
3214810|NCT01039480||dual therapy (ASS/CLO)|patients with a prescription for dual antiplatelet therapy with aspirin AND clopidogrel
3214811|NCT01039480||clopidogrel users (CLO)|patients with a prescription for clopidogrel
3214812|NCT01039480||aspirin users (ASP)|patients with a prescription for aspirin
3214813|NCT01039493||Patients|
3214814|NCT01039493||Providers|
3214815|NCT01039506||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 based regimens
3214816|NCT01039532||Basal Bolus regimen|Basal Bolus regimen
3214817|NCT01039532||Biphasic human insulin|Biphasic human insulin
3214818|NCT01039545|Active Comparator|antibiotic|Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
3214819|NCT01039545|Experimental|symptomatic|Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary
3214820|NCT01039558|Active Comparator|lansoprazole + ecabet sodium|
3214821|NCT01039558|Placebo Comparator|lansoprazole + placebo|
3214822|NCT01039597|Experimental|Active study drug|ORE1001 300 mg oral capsules
3214823|NCT01039597|Placebo Comparator|Placebo control|300 mg oral capsules containing placebo material
3214824|NCT01039610|Experimental|Part A|GSK945237 2400mg single dose
3214825|NCT01039610|Experimental|Part B Cohort 1|GSK945237 400 mg QD, 7 Days 4 subjects GSK945237:2 subjects Placebo
3214826|NCT01039610|Experimental|Part B Cohort 2|GSK945237 400 mg QD, 14 Days 4 subjects GSK945237:2 subjects Placebo
3214827|NCT01039610|Experimental|Part B Cohort 3|GSK945237 400 mg BID, 14 Days 4 subjects GSK945237:2 subjects Placebo
3214828|NCT01039610|Experimental|Part B Cohort 4|GSK945237 800 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
3214829|NCT01039610|Experimental|Part B Cohort 5|GSK945237 1200 mg BID, 14 Days 9 subjects GSK945237:3 subjects Placebo
3214830|NCT01039610|Experimental|Part B Cohort 6|GS945237 1600 mg QD, 14 Days 9 subjects GSK945237:3 subjects Placebo
3214831|NCT01039610|Active Comparator|Part C|Linezolid 600 mg BID, 14 Days 9 subjects Linezolid:3 subjects Placebo
3214832|NCT01039610|Active Comparator|Part D|"2 period crossover Period 1: Placebo 1 day; GSK945237 dose to be determined, 5 Days Period 2: Placebo 5 days; moxifloxacin 400 mg single dose~16 subjects"
3214833|NCT01039636|Experimental|FBS0701 - 5 escalating doses|5 escalating doses of FBS0701 in 5 cohorts of 4 patients each.
3214834|NCT01039649||Lung Radiation|Patients with tumors in the lung that require radiation therapy
3214835|NCT01039662|Experimental|Oolong tea containing L-arabinose and indigestible dextrin|
3214836|NCT01039662|Placebo Comparator|Oolong tea|
3214837|NCT01039701|Experimental|1|AZD1446 60mg once daily + donepezil 10mg
3214838|NCT01039701|Experimental|2|AZD1446 60mg three times daily + donepezil 10mg
3214839|NCT01039701|Experimental|3|AZD1446 30mg three times daily + donepezil 10mg
3214840|NCT01039701|Placebo Comparator|4|placebo + donepezil 10mg
3214841|NCT01039714||Total Thyroidectomy|
3214842|NCT01039727|No Intervention|care as usual|care as usual
3214843|NCT01039727|Experimental|autosuggestive support|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
3214844|NCT01039727|Experimental|autosuggestive support ++|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
3214845|NCT01039740|Experimental|Responders|Reponders is a patients group who showed 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
3214846|NCT01039740|Experimental|Non-responders|Non-responders is a patients group who did not show 50% or greater decrease in the HAM-D score at 6 weeks after treating with mirtazapine
3214847|NCT01039766|Experimental|oxytocin|
3214848|NCT01039766|Placebo Comparator|Placebo|
3214849|NCT01039779|Active Comparator|Lower-extremity exercise training|This training will be tailored by physical therapists for each participant. A series of exercises will be applied to increase the stability of the trunk muscles and to strengthen the leg muscles.
3214850|NCT01039779|Active Comparator|Tai chi exercise|Yang-style tai chi with 18 movements will be taught every week over the 6-month intervention period at a subject's residence by tai chi instructors
3214851|NCT01039805|Experimental|Cohort 1|Subjects randomized to either GSK962040 (50 mg) or placebo
3214852|NCT01039805|Experimental|Cohort 2|Subjects randomized to either GSK962040 (75 mg) or placebo
3214853|NCT01039818|Active Comparator|Radiodine-200µCi|A subgroup of patients with Graves' Disease and goiter ≥48ml treated with 200µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU, from a randomized controlled trial run at our institution between February 1997 and March 2000, serves as a historical control.
3214854|NCT01039818|Experimental|Radiodine-250µCi|Patients with Graves' Disease and goiter ≥48ml, prospectively assigned to receive 250 µCi of ¹³¹I/ml thyroid tissue, corrected by 24h-RAIU.
3214855|NCT01039831||Patients with Parkinson's Disease|Consecutive patient sampling
3214856|NCT01039844|Experimental|Weekly LOC-paclitaxel Injection|LOC-paclitaxel IV by a 1 hour infusion on Day 1, 8, 15, 22 and 29; repeated every 42 days (6 weeks) per cycle.
3214857|NCT01039857|Other|Structured solution focused therapy|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy
3214858|NCT01039857|Experimental|Integrative clarification therapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
3214859|NCT01039870|Experimental|PVB|Paravertebral block initiated at the later part of thoracotomy is used for postoperative pain control
3214860|NCT01039870|Active Comparator|TEA|Thoracic epidural block initiated before the surgical incision is used for postoperative pain control.
3214861|NCT01039883|Experimental|1|Subjects randomized to study product sequence 1 will receive the single albaconazole 400-mg tablet during the first dosing period and the four 100-mg albaconazole capsules during the second dosing period.
3214862|NCT01039883|Experimental|2|Subjects randomized to study product sequence 2 will receive the four 100-mg albaconazole capsules during the first dosing period and the single albaconazole 400-mg tablet during the second dosing period.
3214863|NCT01039896|Experimental|Group1|SLM0807
3214864|NCT01039896|Experimental|Group2|SLM0807 and HKB0701
3214865|NCT01039909|Placebo Comparator|Placebo|"The Placebo treatment group will be administered 8 placebo capsules per day. Placebo will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive placebo approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
3214866|NCT01039909|Active Comparator|2.0g SRT2104|"The 2.0g SRT2104 treatment group will be administered 8 SRT2104 0.25g capsules per day. 2.0g SRT2104 will be administered orally once daily for twenty-eight consecutive days.~During the clinic visits, the subjects will receive SRT2104 approximately 15 minutes following the start of consumption of a standardized meal. During non-clinic days, the subject will self-administer the test material approximately 15 minutes following the start of consumption of a standardized meal. Test material should be administered with approximately 400 mL of water at approximately the same time every dosing day. Subjects must wait at least 2 hours before consuming additional calories."
3214867|NCT01039922||1|Patients with a histologically confirmed diagnosis of a neuroendocrine tumor irrespective of primary tumor location
3214868|NCT01039948|Experimental|Phase 2: AV-299 + gefitinib|Phase 2: AV-299 (formerly SCH 900105) administered IV at RP2D (as determined by Phase 1b portion) in combination with gefitinib 250 mg/day orally.
3214869|NCT01039948|Active Comparator|Phase 2: Gefitinib|Phase 2: Gefitinib 250 mg/day, orally.
3214870|NCT01039961|Experimental|1 mg IV|Unit Dose Strength: 0.4 mg/mL
3214871|NCT01039961|Experimental|?mg IV|dose to be determined based on PK of first IV dose
3214872|NCT01039961|Experimental|15 mg (oral)|two 7.5 mg tablets
3214873|NCT01039974|Experimental|Cohorts 1-2|Cohorts 1 and 2 will complete both periods Period 1 GSK962040 single dose Period 2 Ketoconazole repeat dose (10 days), GSK962040 single dose
3214874|NCT01040000|Experimental|NPC-1C/NEO-102|
3214875|NCT01040013|Experimental|Laparoscopy|Laparoscopic Left-Sided Colectomy
3214876|NCT01040013|Active Comparator|laparotomy|Laparotomic Left-Sided Colectomy
3214877|NCT01040026|Experimental|NK cell infusions|10 NK cell infusions day 3-30; Treatment with in vitro expanded haploidentical NK cells
3214878|NCT01040039||HCV+HIV+|
3214879|NCT01040039||HCV+HIV-|
3214880|NCT01040078|Experimental|7.5ug H1N1 vaccine|360 subjects to receive two doses 7.5ug H1N1 influenza vaccine on Day 0 and Day 21.
3214881|NCT01040078|Experimental|15ug H1N1 vaccine|360 subjects to receive two doses 15ug H1N1 influenza vaccine on Day 0 and Day 21.
3214882|NCT01040078|Placebo Comparator|seasonal influenza vaccine|180 subjects to receive two doses seasonal influenza vaccine on Day 0 and Day 21.
3260350|NCT01478607|No Intervention|3. SOC|Subjects randomized to this group will receive treatment optimized for them on an individual basis. The investigator will be free to provide whatever pharmacological or other treatment is considered optimal for management of the subject's pain.
3214883|NCT01040091|Active Comparator|HIV-Infected Participants|HIV-infected participants will receive FTC, TDF, and EFV for 60 days by prescription from their physicians. Participants will receive Truvada (FTC/TDF) and EFV for the first 30 days. After Day 30, participants may switch to the TDF/FTC/EFV co-formulation through Day 60 as directed by their physician.
3214884|NCT01040091|Active Comparator|HIV-Uninfected Participants|HIV-uninfected participants will receive Truvada (FTC/TDF) for 30 days.
3214885|NCT01040104||Regular wound healing, young|Regular skin repair, controlled wound healing conditions in young individuals
3214886|NCT01040104||Regular wound healing, aged|Regular skin repair, controlled wound healing conditions in aged individuals
3214887|NCT01040104||Hypertrophic scarring, young|Skin repair with and without hypertrophic scarring in young individuals
3214888|NCT01040104||Hypertrophic scarring, aged|Skin repair with and without hypertrophic scarring in aged individuals
3214889|NCT01040104||Non-diabetic, young|Skin repair in non-diabetic young individuals
3214890|NCT01040104||Non-diabetic, aged|Skin repair in non-diabetic aged individuals
3214891|NCT01040104||Diabetic, young|Skin repair in young diabetic individuals
3214892|NCT01040104||Diabetic, aged|Skin repair in aged diabetic individuals
3214893|NCT01040117|Experimental|Sensory-motor Integration Training|
3214894|NCT01040117|Active Comparator|Conventional neurorehabilitation|
3214895|NCT01040156||LAmb|
3214896|NCT01040156||Cas|
3214897|NCT01040182||ischemic stroke patients|
3214898|NCT01040182||healthy subjects without cerebrovascular disease|
3214899|NCT01040195|Active Comparator|Combination DMARD|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily. All patients will also receive folic acid 5 mg thrice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. In the absence of any contraindication, patients will be randomized into two groups Group 1 to receive Combination Disease Modifying therapy with Sulfasalazine, Methotrexate and hydroxychloroquine (HCQ). Patient will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day.
3260351|NCT01478633|Experimental|Galantamine|
3214900|NCT01040195|Placebo Comparator|Placebo|All patients included in the study, will be started on Sulfasalazine 1 gm once daily and in the absence of side effects increased to 2gm daily All patients will also receive folic acid 5 mg twice weekly. At the end of four weeks the patients will be reassessed with baseline hemogram, SGPT, SGOT and serum Creatinine. Group 2 patients will receive Sulfasalazine and placebo for methotrexate and hydroxychloroquine.
3214901|NCT01040221|Experimental|Trichuris Suis Ova (TSO)|the eggs of intestinal helminthes (trichuris suis ova) administered as 2500 ova doses every two weeks.
3214902|NCT01040221|Placebo Comparator|Placebo|placebo dosage received every two weeks.
3214903|NCT01040234||Active pain treatment|Bilateral dual TAP block
3214904|NCT01040247|Experimental|Day 0 Embryo Transfer|Embryo transfer will be performed on the same day as oocyte aspiration and fertilization
3214905|NCT01040247|Active Comparator|Day 2,3 Embryo Transfer|Embryo Transfer will be performed 2 or 3 days after oocyte aspiration and fertilization
3214906|NCT01040273|Experimental|Experiment|Anesthetics intraarticular injection
3214907|NCT01040273|Placebo Comparator|Placebo|saline intraarticular injection
3214908|NCT01040286|Experimental|Flurbiprofen Chip|
3214909|NCT01040286|Active Comparator|Chlorhexidine chip|
3214910|NCT01040299|Experimental|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
3214911|NCT01040299|Sham Comparator|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
3214912|NCT01040299|Active Comparator|control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
3214913|NCT01040312||UGT1A1 genotyped patients|UGT1A1 genotyped patients receive CPT-11 with platinum analogues
3214914|NCT01040325|Experimental|Active|358 subjects receive a two vaccination regimen with an LT patch
3214915|NCT01040325|Placebo Comparator|Placebo|358 subjects receive a two vaccination regimen with placebo patch
3214916|NCT01040338||OPRM1 A118G AA genotype|Individuals with the AA genotype at the OPRM1 A118G polymorphism.
3214917|NCT01040338||OPRM1 A118G AG or GG genotype|Individuals with the */G allele at the OPRM1 A118G polymorphism
3214918|NCT01040364||Interna hernia after primary gastric bypass|
3214919|NCT01040377||Inadequate initial weight loss after gastric bypass|
3214920|NCT01040416||Bleeding marginal ulcer after RYGB|
3214921|NCT01040429|Active Comparator|Clonidine capsula|
3214922|NCT01040429|Placebo Comparator|Lactose capsula|
3214923|NCT01040442|Experimental|vibration stimuli|
3214924|NCT01040455|Experimental|lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
3214925|NCT01040455|Placebo Comparator|placebo|placebo once daily for eight weeks
3214926|NCT01040468|Active Comparator|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss
3214927|NCT01040468|Active Comparator|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss
3214928|NCT01040468|Active Comparator|Intensive Lifestyle Modification|Lifestyle intervention for weight loss
3214929|NCT01040481||Malabsorptive distal gastric bypass|
3214930|NCT01040494|Experimental|Aliskiren, add-on|HF patients will be randomized to receive add-on aliskiren 150 mg for 6 months
3214931|NCT01040494|Placebo Comparator|placebo, add-on|patients will be randomized to receive add-on placebo for 6 months
3214932|NCT01040507||primary laparoscopic gastric bypass|
3214933|NCT01040533||Failed / complicated jejunoileal bypass|
3214934|NCT01040546|Experimental|Individualized education|Individualized consultation of health problem, dietary intake and exercise
3214935|NCT01040546|Experimental|Grouped education|Grouped consultation of health problem, dietary intake and exercise
3214936|NCT01040559|Experimental|Idarubicin|Dose escalation: level0 = idarubicin 5mg, level1 = idarubicin 10mg, level2 = idarubicin 15mg, level3 = idarubicin 20mg, level4 = idarubicin 25mg
3214937|NCT01040572||Obesity recidivism after gastric bypass|
3214938|NCT01040585||Central America and the Caribbean|Panama, Costa Rica, Honduras, El Salvador and Nicaragua
3214939|NCT01040611|Experimental|Music therapy|This study examined the effectiveness of music therapy on anxiety, depression and physiological responses for patients with tuberculosis.
3214940|NCT01040611|No Intervention|Placebo|No music therapy apply to this arm
3214941|NCT01040637|Experimental|TD-1211 dose level 1|Ascending doses
3214942|NCT01040637|Experimental|TD-1211 dose level 2|Ascending doses
3214943|NCT01040637|Experimental|TD-1211 dose level 3|Ascending doses
3214944|NCT01040637|Experimental|TD-1211 dose level 4|Ascending doses
3214945|NCT01040637|Experimental|TD-1211 OIC dose level 1|Ascending doses
3214946|NCT01040637|Experimental|TD-1211 OIC dose level 2|Ascending doses
3214947|NCT01040637|Experimental|TD-1211 OIC dose level 3|Ascending doses
3214948|NCT01040637|Experimental|TD-1211 OIC dose level 4|Ascending doses
3214949|NCT01040637|Experimental|TD-1211 OIC dose level 5|Ascending doses
3214950|NCT01040637|Placebo Comparator|Placebo|Ascending doses
3214951|NCT01040650||Normal Controls|Normal Controls
3214952|NCT01040650||Statin associated myopathy|subjects with statin associated myopathy
3214953|NCT01040663|Other|Dash Diet|Subjects receive DASH diet for 4 weeks
3214954|NCT01040663|Other|Low GI Diet|Subjects will receive Low GI diet for 4 weeks
3214955|NCT01040663|Other|Western Style Diet|Subjects will receive western style diet for 4 weeks
3214956|NCT01040676|No Intervention|Control Group|"Patients in this (the control group) will be eligible to receive the intervention (see Intervention Group) after 12 weeks (essentially when the trial is over)."
3214957|NCT01040676|Experimental|Intervention Group|Patients in the intervention group will receive automated telephone calls at regular intervals twice a week. The system will be programmed to call them at these intervals until contact. The ATNS system will solicit information from them in a culture specific manner, inquiring as to what foods they are eating each meal, each day, and each month. The ATNS system will then make proactive suggestions regarding low glycemic index foods, giving encouragement and feedback as appropriate.
3214958|NCT01040702|Experimental|ADHD -MPH|adults with ADHD diagnosis who receive a single dose of Methylphenidate
3214959|NCT01040702|Placebo Comparator|ADHD-placebo|adults with ADHD diagnosis who received placebo
3214960|NCT01040702|Experimental|non-ADHD-MPH|healthy adults who received a single dose of Methylphenidate
3214961|NCT01040702|Placebo Comparator|non-ADHD-placebo|healthy adults who received placebo
3214962|NCT01040715|Experimental|TNFa Kinoid dose 1|
3214963|NCT01040715|Experimental|TNFa Kinoid dose 2|
3214964|NCT01040715|Experimental|TNFa Kinoid dose 3|
3214965|NCT01040741||Group 1: 6-23 months|
3214966|NCT01040741||Group 2: 2-8 years|
3214967|NCT01040741||Group 3: 9-17 years|
3214968|NCT01040741||Group 4: 18-44 years|
3214969|NCT01040741||Group 5: 45-60 years|
3214970|NCT01040741||Group: >60 years|
3214971|NCT01040754|Active Comparator|Acupuncture|
3214972|NCT01040754|No Intervention|Waitlist Control|
3214973|NCT01040767|Active Comparator|Class|
3214974|NCT01040767|Active Comparator|Web|
3214975|NCT01040767|No Intervention|Control|
3214976|NCT01040806|Experimental|Health coaching|Patients with poorly controlled diabetes will receive counseling from a peer health coach -- a patient with diabetes trained in health coaching
3214977|NCT01040806|Active Comparator|Usual care|Patients will receive usual care
3214978|NCT01040884|Experimental|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
3214979|NCT01040897|Active Comparator|Active Control Arm|At Active Comparative Sites, Pediatric Residents will be trained to address injury prevention issues using The Injury Prevention Program (TIPP) approach
3214980|NCT01040897|Experimental|Health Communication and Obesity Prevention|Pediatric Residents will be training in effective health communication skills and given a toolkit of literacy/numeracy sensitive educational materials to use with families with children age 2 months to18 months during each well child visit
3214981|NCT01040910|Active Comparator|cannabis smoking for IBD|patients with active disease receiving active cannabis for smoking
3214982|NCT01040910|Placebo Comparator|patients smoking non active cannabis|patients with active disease receiving cannabis from which active ingredients have been chemically removed
3214983|NCT01040923||Cardiac CT|All patients in the study will be those presenting themselves for cardiac CT angiography who meet the proper inclusion / exclusion criteria
3214984|NCT01040936|Active Comparator|conventional group|patients will be treated by atorvastation 20mg/d after randomization, and continued for one year.
3214985|NCT01040936|Experimental|intensive group|patient will be loaded with 80mg atorvastatin, continued by atorvastatin 40mg/d for 30d, then receive atorvastatin 20mg/d for the following 11 months.
3214986|NCT01040949|Active Comparator|a self help smoking cessation guide|Guia, a culturally relevant self-help smoking cessation guide in Spanish
3214987|NCT01040949|Experimental|couple-based counseling for smoking cessation plus Guia|couple-based counseling for smoking cessation plus Guis, culturally relevant self-help smoking cessation guide for Latinos
3214988|NCT01040962||Falls Risk Assessment, Diabetic Peripheral Neuropathy Patients|
3214989|NCT01040975|Experimental|Motivational Interviewing intervention|Web-based intervention targeting MD communication and Summary Report
3214990|NCT01040975|No Intervention|Control|MD receives Summary Report only
3214991|NCT01040988||Pacemaker|Patients meeting entry criteria with a pacemaker in place.
3214992|NCT01040988||ICD|Patients meeting entry criteria with an ICD in place.
3214993|NCT01041001|Experimental|Cartistem|A single dose of 500㎕/㎠ of cartilage defect
3214994|NCT01041001|Active Comparator|Microfracture treatment|
3214995|NCT01041014|Experimental|Professional medical interpreter|Limited English proficient Spanish-speaking patients seen in the treatment arm were provided with the services of a professionally-trained medical interpreter to facilitate communication between the patient and emergency department staff
3214996|NCT01041014|No Intervention|Control, Usual Language Services|Patients randomized to the control arm receive the services of the emergency departments' usual language services (i.e., a telephone language line or ad hoc interpreters).
3214997|NCT01041027|Experimental|Treatment (paclitaxel, carboplatin, radiation therapy)|"CHEMOTHERAPY (weeks 1-9, 13-21): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 3 courses during weeks 13-21.~RADIATION THERAPY (weeks 8-13 or 8-15): Patients with stage I disease undergo HDR brachytherapy once weekly for a total of 5 fractions during weeks 8-13. All other patients undergo EBRT QD 5 days a week for a total of 25 fractions during weeks 8-12 and HDR brachytherapy once weekly for a total of 3 fractions during weeks 13-15."
3214998|NCT01041066|Active Comparator|group L|0.4 mg/kg labetalol
3214999|NCT01041066|Active Comparator|group N|20 ㎍/kg nicardipine
3260352|NCT01478646|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
3260353|NCT01478646|Experimental|Reflectory breathing therapy|first: reflectory breathing therapy second: conventional breathing therapy
3215000|NCT01041079||Chronic marginal ulcer after RYGB|Patients with intractable or chronic marginal ulcer disease after gastric bypass complaining of abdominal pain, GI bleeding, obstruction, perforation and penetration. Sometimes with other associated diagnosis such as narcotic and tobacco dependence, protein-calorie malnutrition, excessive weight loss, poor pouch emptying syndrome, weight regain, inadequate initial weight loss, severe dumping syndrome among others.
3215001|NCT01041092|Placebo Comparator|sugar pill|
3215002|NCT01041092|Active Comparator|raloxifene hydrochloride|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
3215003|NCT01041105||Gastric bypass after previous Nissen|
3215004|NCT01041131||Failed and/or Complicated VBG|
3215005|NCT01041144|Experimental|Lifestyle counseling|
3215006|NCT01041157|Experimental|1|resistance training
3215007|NCT01041183|Active Comparator|group I|0.3 mg IV ramosetron
3215008|NCT01041183|Active Comparator|group II|0.1 mg oral ramosetron
3215009|NCT01041183|Active Comparator|group III|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron
3215010|NCT01041196||perforated ulcer after gastric bypass|
3215011|NCT01041222|Experimental|Arm 1|0.15 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3215012|NCT01041222|Experimental|Arm 2|0.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3215013|NCT01041222|Experimental|Arm 3|1.5 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3215014|NCT01041222|Experimental|Arm 4|3.0 mg ISIS 333611 continuous intrathecal infusion over 12 hours
3215015|NCT01041222|Placebo Comparator|Placebo (phosphate buffered saline)|
3215016|NCT01041235|Experimental|ATI-1123|
3215017|NCT01041261|No Intervention|Control arm|Subjects will be issued control study product (Carnation Instant Breakfast, no sugar added)
3215018|NCT01041261|Experimental|Treatment arm|Medical food
3215019|NCT01041313|Active Comparator|Opiate Naive|Subjects who have not taken opiate medication in previous 6 weeks before surgery
3215020|NCT01041313|Active Comparator|Opiate tolerant|Subjects who have taken opiate medications for the 6 weeks before surgery
3215021|NCT01041326|Experimental|Leve 1 Radiation|Subjects in Group 1 will receive 39.6 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3215022|NCT01041326|Experimental|Level 2 Radiation|Subjects in Group 2 will receive 45 Gy (at 1.8 Gy/fx) to the whole pelvis. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3215023|NCT01041326|Experimental|Level 3 Radiation|Subjects in Group 3 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 50.4 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3215024|NCT01041326|Experimental|Level 4 Radiation|Subjects in Group 4 will receive 45 Gy to the whole pelvis, followed by a boost to the prostate and periprostatic tissue, for total doses of 54 Gy. The subject will then undergo radical prostatectomy between 4-8 weeks after completion of radiation.
3215025|NCT01041339||acute chest pain ST elevation|patients admitted with acute chest pain sharing ST elevation in ER-ECG and elevated troponin
3215026|NCT01041339||controls|asymptomatic patients
3215027|NCT01041352|Active Comparator|Endotracheal group|airway management: endotracheal tube
3260354|NCT01478659|Active Comparator|Control bar and yogurt|
3215028|NCT01041352|Active Comparator|laryngeal mask group|airway management: laryngeal mask
3215029|NCT01041365||Healthy adolescents|Healthy adolescent African American and Caucasian females, ages 14-18
3215030|NCT01041391||Surgical treatment for Lumbar disc herniation|Patients who had or will have surgery for Lumbar disc herniation
3215031|NCT01041391||Non-surgical treatment for Lumbar disc herniation|Patients that have chosen conservative treatment for lumbar disc herniation
3215032|NCT01041430|Active Comparator|Day Surgery Group|discharge planned on day of surgery, inguinal hernia repair
3215033|NCT01041430|Active Comparator|Inpatient Group|overnight admission at the hospital, inguinal hernia repair
3215034|NCT01041443|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive FdCyd IV over 3 hours and THU IV over 3 hours on days 1-10. Courses repeat every 21days in the absence of disease progression or unacceptable toxicity.
3215035|NCT01041456||complicated and/or failed BPD|
3215036|NCT01041469||with abnormalities|Down syndrome patients presenting with at least one sign of auto immune abnormality
3215037|NCT01041469||without abnormality|Down syndrome patients without any sign of recognized auto immune condition
3215038|NCT01041482|Experimental|sorafenib|To study the efficacy of Sorafenib as an adjuvant therapy for reducing recurrence rate in locally advanced renal-cell carcinoma (RCC) after radical nephrectomy.
3215039|NCT01041508|Active Comparator|A|Stratum A are those patients with related stem cell donors.
3215040|NCT01041508|Active Comparator|B|Stratum B are those patients with unrelated stem cell donors.
3215041|NCT01041534||Adjustable Gastric Band (AGB) surgery|Patients who have undergone adjustable gastric band (AGB) surgery at the UWMC or other sites that have agreed to cooperate with our site (letter of cooperation and HIPAA waiver approved by our IRB) between April 1, 2007 and July 1, 2008.
3215042|NCT01041547||Healthy adults|healthy adults with BMI below 32, between ages 19-60 yrs, both males and females
3215043|NCT01041560||Stoke|Hemiplegia with unilateral changes in tone and muscle strength
3215044|NCT01041586|Experimental|BTVA|
3215045|NCT01041599||Diabetic patients|Hypertensive and normotensive patients with type 2 diabetes mellitus
3215046|NCT01041599||Hypertensive patients|Patients with essential hypertension
3215047|NCT01041599||Healthy subjects|Healthy subjects
3215048|NCT01041612|Active Comparator|Group A: C-SEMS, inserted above SO|-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.
3215049|NCT01041612|Active Comparator|Group B: C-SEMS, inserted across SO|-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.
3215050|NCT01041625|Experimental|Apremilast|Apremilast 20 mg PO administered BID over 12 weeks
3215051|NCT01041677|Experimental|001|R256918 10 mg capsule twice daily
3215052|NCT01041677|Experimental|002|R256918 15 mg capsule twice daily
3215053|NCT01041677|Placebo Comparator|003|placebo placebo capsule twice daily
3215054|NCT01041690|Experimental|Bevacizumab|
3215055|NCT01041729|Experimental|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
3215056|NCT01041729|Active Comparator|Control|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment"
3215057|NCT01041742|Experimental|OPCAB|
3215058|NCT01041755|Experimental|Intravenous infusion of L- Ornithine L- Aspartate|a) 20 g L-ornithine-L-aspartate
3215059|NCT01041755|Active Comparator|Lactose enemas|b) 20% Lactose enemas
3215060|NCT01041768|Active Comparator|antidiabetic medical therapy|
3215061|NCT01041768|Experimental|Bariatric Surgery|
3215062|NCT01041794||1|
3260355|NCT01478659|Experimental|Fiber bar and yogurt|
3215063|NCT01041807||All participants|Participants with hypertension treated with amlodipine/losartan(Cozaar XQ)
3215064|NCT01041820|Experimental|Exercise group|Children will participate in a 10-week moderate to vigorous exercise program
3215065|NCT01041820|No Intervention|non-exercising|Participants will receive no intervention
3215066|NCT01041833|Experimental|atRA group|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
3215067|NCT01041833|Placebo Comparator|Placebo Group|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
3215068|NCT01041846||Decitabine|
3215069|NCT01041872|Active Comparator|Propofol Astrazeneca|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3215070|NCT01041872|Experimental|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3215071|NCT01041872|Experimental|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3215072|NCT01041872|Experimental|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3215073|NCT01041872|Experimental|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
3215074|NCT01041872|Experimental|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
3215075|NCT01041885|Experimental|INSTRUCT|INSTRUCT scaffold implantation
3215076|NCT01041911|Active Comparator|Euphorbia 50 mg|This arm subjects will be given 50 mg Euphorbia prostrata
3215077|NCT01041911|Active Comparator|Euphorbia 100 mg|In this arm subjects will be given 100 mg Euphorbia
3215078|NCT01041911|Active Comparator|Euphorbia 200 mg|In this arm subject will be given 200 mg Euphorbia tablets
3215079|NCT01041911|Placebo Comparator|Placebo|In this arm subjects will be given placebo tablets
3215080|NCT01041937|Active Comparator|Cemented Tibia|Assessing the clinical outcomes of the different type of fixation
3215081|NCT01041937|Active Comparator|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
3215082|NCT01041950|Experimental|Lumbar drainage|
3215083|NCT01041950|No Intervention|Control|
3215084|NCT01041963|Active Comparator|Enalapril|
3215085|NCT01041963|Active Comparator|Enalapril plus Losartan|
3215086|NCT01041963|Placebo Comparator|Control|Drug: antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Administration of antihypertensive agents will select as follows : CCB→β-blocker→α-blocker-->hydralazine
3215087|NCT01041989|No Intervention|Standard health counseling at baseline|
3215088|NCT01041989|Experimental|Lifestyle counseling|Multi-domain lifestyle counseling including nutritional guidance, increased physical activity, cognitive training, increased social activity and intensive monitoring of vascular and metabolic risk factors.
3215089|NCT01042002|Experimental|High intensity exercise|
3215090|NCT01042002|No Intervention|Control|
3215091|NCT01042015|Active Comparator|Concurrent controls|These subjects would undergo standard resuscitative efforts.
3215092|NCT01042015|Experimental|Emergency preservation and resuscitation|These subjects would undergo the complete EPR protocol, including rapid induction of hypothermia, resuscitative surgery, and resuscitation with cardiopulmonary bypass.
3215093|NCT01042028|Experimental|Phase II: Arm A|Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B
3215094|NCT01042028|Active Comparator|Arm B|Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.
3215095|NCT01042041|Experimental|Arm I|Patients receive oral sorafenib tosylate twice daily. Beginning 2 weeks later, patients undergo chemoembolization with cisplatin, doxorubicin hydrochloride, and mitomycin C. Chemoembolization repeats once a month for up to 4 procedures in the absence of disease progression or unacceptable toxicity.
3215096|NCT01042054|Active Comparator|Epidural|Patients will follow a standard optimised recovery protocol, including epidural analgesia for the first 48 hours postoperatively.
3215097|NCT01042054|Experimental|Wound catheter|Patients will follow a standard optimised recovery protocol, but analgesia in the first 48 hours will be delivered through local anaesthetic wound catheters and additional patient-controlled analgesia, instead of epidural analgesia.
3215098|NCT01042067||Warfarin treatment group|Open label study. Patients in need of warfarin treatment (standard indications) are included in the study at the onset of warfarin treatment.
3215099|NCT01042080|Active Comparator|PSV-ET 25|Pressure support ventilation with expiratory trigger set at 25 %.
3215100|NCT01042080|Active Comparator|PSV-ET 50|Pressure support ventilation with expiratory cycling set at 50 %.
3215101|NCT01042080|Experimental|NAVA|NAVA level is adjusted to achieve similar peak inspiratory pressure levels than during PSV.
3215102|NCT01042106|Experimental|DSP-8658|DSP-8658 2.5, 10, 20, 40 mg once daily
3215103|NCT01042106|Placebo Comparator|Placebo|Placebo 2.5, 10, 20, and 40 mg doses once daily
3215104|NCT01042119||Botox|patients who received intravesical injections of botulinum neurotoxin type A
3215105|NCT01042132|Active Comparator|1) IMN and EF/IMN|"Two parts of the study are randomized;~1)initial intramedullary reaming and primary external fixation with secondary intramedullary nailing"
3260356|NCT01478672|No Intervention|Standard care|
3260357|NCT01478672|Experimental|Health coaching and and Life-long Monitoring|
3215106|NCT01042132|Active Comparator|2) TR and RIA|Two parts of the study are randomized; 2)traditional reaming (TR)is compared to a new reaming device, RIA, which is a reamer connected to suction and flushing for prevention of increased intramedullary pressure
3215107|NCT01042184|Experimental|Group A|Group A: Sequential therapy for 14 days D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bid
3215108|NCT01042184|Experimental|Group B: Sequential therapy for 10 days|
3215109|NCT01042184|Active Comparator|Group C: Triple therapy for 14 days|
3215110|NCT01042197|Active Comparator|2|Body surface area: 12 %
3215111|NCT01042197|Active Comparator|1|Body surface area: 6 %
3215112|NCT01042197|Active Comparator|3|Body surface area: 24 %
3215113|NCT01042197|Active Comparator|4|Body surface area: 6 %
3215114|NCT01042197|Active Comparator|5|Body surface area: 12 %
3215115|NCT01042197|Active Comparator|6|Body surface area: 24 %
3215116|NCT01042197|Active Comparator|7|Body surface area: 6 %
3215117|NCT01042197|Active Comparator|8|Body surface area: 12 %
3215118|NCT01042197|Active Comparator|9|Body surface area: 24 %
3215119|NCT01042210||Mothers, preeclampsia|Mothers with preeclampsia diagnosed according to the Guidelines by the Czech Society of obstetrics and gynecology as development of hypertension after the 20th week of pregnancy (systolic blood pressure, ≥140 mmHg; and/or diastolic blood pressure, ≥90 mmHg; measured at rest on two consecutive occasions at least 24 h apart) in previously normotensive women, and the onset of proteinuria (>300 mg of urinary protein/L over 24 h).
3215120|NCT01042210||Newborns, physiological pregnancy-delivery|The newborns from the physiological pregnancies with spontaneous, uncomplicated delivery.
3215121|NCT01042210||Newborns, pregnancy with preeclampsia|Newborns from the pregnancies complicated by preeclampsia.
3215122|NCT01042210||Mothers, Physiological pregnancy-labour|The cohort of non-preeclamptic mothers with physiological, uncomplicated conception, pregnancy and delivery.
3215123|NCT01042249|Experimental|Treatment|Treated with Pelvic Floor Muscle Training in 12 weeks
3215124|NCT01042249|No Intervention|Control|Receives standard rehabilitation after stroke
3215125|NCT01042262|Experimental|Oxygen Group|Subjects received 100% oxygen via nasal cannula (flow =2 L/min)
3215126|NCT01042262|Placebo Comparator|Control Group|Subjects were attached to a nasal cannula without any oxygen flow.
3215127|NCT01042275||TOT|transobturator sling, outside-in (TOT)
3215128|NCT01042275||TVT-O|Tension-free transobturator tape, inside-out (TVT-O)
3215129|NCT01042275||IVS|retropubic Intravaginal Sling (IVS)
3215130|NCT01042275||TVT|retropubic tension-free vaginal tape (TVT)
3215131|NCT01042275||REMEEX|Re-adjustable mechanical external sling (REMEEX)
3215132|NCT01042301|Experimental|Long-term type 1 diabetic patients|Long-term type 1 diabetic patients
3215133|NCT01042301|Active Comparator|control patients|control patients
3215134|NCT01042301|Experimental|diabetic and transplanted patients|diabetic and transplanted patients
3215135|NCT01042301|Experimental|subjects with high risk for diabetes|subjects with high risk for diabetes
3215136|NCT01042301|Experimental|patients with recent type 1 diabetes|patients with recent type 1 diabetes
3215137|NCT01042301|Experimental|patients with Latent Autoimmune Diabetes|patients with Latent Autoimmune Diabetes
3215138|NCT01042314|Experimental|Donepezil and BMS-708163|
3260358|NCT01478685|Experimental|Arm A: CC-486 plus Carboplatin|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability. Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
3215139|NCT01042327|Experimental|dialyzer comparison|"Stable chronic kidney dialysis patients, currently dialyzing on the main Royal Free hospital dialysis unit will be asked to participate in the study. It is aimed to recruit 15 patients currently dialysing using the Fresenius FX100 dialyzer, who have used Fresenius polysulphone membranes for > 3 months.~During a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility.~Thereafter patients would be switched to dialyse using the ELISIOTM-H dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated"
3215140|NCT01042340|Experimental|Intervention with energy dense formula|Patients were randomised to intervention with the energy dense formula Calogen.
3215141|NCT01042340|No Intervention|Control group|The patients that were randomised to control group were assigned to ordinary treatment.
3215142|NCT01042353|Experimental|E test|
3215143|NCT01042353|Active Comparator|standard culture method|
3215144|NCT01042379|Active Comparator|Standard Therapy|Paclitaxel, Herceptin followed by Doxorubicin and Cyclophosphamide treatment depending on HR/HER-2 status.
3215145|NCT01042379|Experimental|AMG 386 with or without Trastuzumab|Arm is closed.
3215146|NCT01042379|Other|AMG 479 plus Metformin|Arm is closed.
3215147|NCT01042379|Experimental|MK-2206 with or without Trastuzumab|Arm is closed.
3215148|NCT01042379|Experimental|T-DM1 and Pertuzumab|Arm is closed.
3215149|NCT01042379|Active Comparator|Pertuzumab and Trastuzumab|Novel Control Investigational Agent
3215150|NCT01042379|Experimental|Ganetespib|Arm is closed.
3215151|NCT01042379|Other|ABT-888|Arm is closed.
3215152|NCT01042379|Other|Neratinib|Arm is closed.
3215153|NCT01042379|Experimental|PLX3397|Arm is closed.
3215154|NCT01042379|Experimental|Pembrolizumab 4 cycle|Arm is closed.
3215155|NCT01042379|Experimental|Talazoparib plus Irinotecan|Arm is closed.
3215156|NCT01042379|Experimental|Patritumab with or without Trastuzumab|Arm is closed.
3215157|NCT01042379|Experimental|Pembrolizumab 8 cycle|Arm is closed.
3215158|NCT01042379|Experimental|SGN-LIV1A|Arm is closed.
3215159|NCT01042379|Experimental|Durvalumab plus Olaparib|Arm is closed.
3215160|NCT01042379|Experimental|SD-101 + Pembrolizumab|Arm is closed.
3215161|NCT01042379|Experimental|Tucatinib|Arm is closed.
3215162|NCT01042379|Experimental|Cemiplimab|Novel Investigational Agent
3215163|NCT01042379|Experimental|Cemiplimab plus REGN3767|Novel Investigational Agent
3215164|NCT01042379|Experimental|Trilaciclib with or without trastuzumab + pertuzumab|Novel Investigational Agent
3215165|NCT01042379|Experimental|SYD985 ([vic-]trastuzumab duocarmazine)|Novel Investigational Agent
3215166|NCT01042379|Experimental|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab|Novel Investigational Agent
3215167|NCT01042379|Experimental|Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab|Novel Investigational Agent
3215168|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant Monotherapy|Novel Investigational Agent
3215169|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant + Abemaciclib|Novel Investigational Agent
3215170|NCT01042379|Experimental|Endocrine Optimization Pilot: Amcenestrant + Letrozole|Novel Investigational Agent
3215171|NCT01042418|Experimental|Whole kernel breakfast|
3215172|NCT01042418|Placebo Comparator|Wheat reference breakfast|
3215173|NCT01042418|Active Comparator|Milled kernel breakfast|
3215174|NCT01042431||Ward population|Patients hospitalized in the Orthopedics B Ward in the Hillel Yaffe Medical Center that choose to participate in the study
3215175|NCT01042444|Experimental|Embolic Protection Device|The study will involve up to 20 patients to be enrolled using the GARDEX system during clinically indicated percutaneous intervention of SVG and followed through 30 days post procedure. Patients will be enrolled at up to 3 investigative sites. The study is a prospective multi center registry with sequential enrollment of qualified patients who consent to participate and meet the eligibility criteria.
3215176|NCT01042457|Other|Mycophenolate mofetil|
3215177|NCT01042470||control group|female patients without pelvic organ prolapse, stage 0 or I (POP-Q)
3215178|NCT01042470||pelvic organ prolapse|female patients with pelvic organ prolapse stage II or higher (POP-Q)
3215179|NCT01042522|Experimental|Arm I (paclitaxel, carboplatin)|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3215180|NCT01042522|Experimental|Arm II (bleomycin sulfate, etoposide phosphate, cisplatin)|Patients receive bleomycin sulfate IV on day 1 and etoposide IV over 1 hour and cisplatin IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3215181|NCT01042561|Placebo Comparator|placebo|This group will recieve the current standard of care for infants in the NICU, recieving infant formula that provides less than 400 IU of vitamin D a day.
3215182|NCT01042561|Experimental|Vitamin d|This group will recieve standard of care infant formulas that provide less than 400 IU of vitamin D a day, in addition they will be supplemented with 400 IU of vitamin D3 daily.
3215183|NCT01042587|Active Comparator|bright light|Bright light has been shown to entrain circadian rhythm so our treatment arm will use thirty minutes of early morning exposure to bright blue light for a four week period.
3215184|NCT01042587|Sham Comparator|red light|Low level red light is a weak entrainment stimulus of circadian rhythm. Elders in the control group will be exposed to low level red light as a placebo for thirty minutes daily for four weeks.
3215185|NCT01042626|Experimental|Normocalcemic Hyperparathyroidism|
3215186|NCT01042626|Experimental|Hypercalcemic Hyperparathyroidism|
3215187|NCT01042626|Active Comparator|Healthy subjects|
3215188|NCT01042639|Active Comparator|physical activity once a day|
3215189|NCT01042639|Experimental|physical activity twice a day|
3215190|NCT01042639|No Intervention|control|
3215191|NCT01042652|Active Comparator|Nevirapine|
3215192|NCT01042652|Experimental|Raltegravir|
3215193|NCT01042665||primary open angle glaucoma|"Patients with glaucomatous optic neuropathy defined as narrowing of the neuroretinal rim, notching, excavation, or RNFL defect; and repeatable standard automated perimetry abnormality defined as a glaucoma hemifield test (GHT) outside normal limits or pattern standard deviation (PSD) outside 95% normal limits were included."
3215194|NCT01042665||Ocular Hypertensive group|Ocular hypertension defined as an intraocular pressure ≥ 24 mm Hg and ≤ 32 mm Hg in one eye and IOP ≥ 22 mm Hg and ≤ 32 mm Hg in the fellow eye, with normal optic disc, normal visual field defined as follows mean Deviation (MD) or Pattern Standard Deviation (PSD) of p>5%, normal Glaucoma Hemifield Test (GHT) and reliable visual field exam
3215195|NCT01042691|Experimental|Oxaliplatin|Subjects who are planning to undergo surgery for placement of HAI therapy pump will be considered for enrollment. Standard HAI therapy requires a laparotomy and placement of an intrahepatic arterial catheter that is connected to one of several commercially available subcutaneous electronic pumps. The pump is then used to deliver FUDR and Leucovorin directly to the liver, usually beginning four weeks after surgery and lasts on average for a period of six to twelve months after the study. This study will examine the addition of a one hour isolated hepatic perfusion with oxaliplatin to this standard treatment
3215196|NCT01042704|Experimental|Bendamustine, Lenalidomide and Dexamethasone|Treatment with Bendamustine in combination with Lenalidomide and Dexamethasone will be administered on an outpatient basis. Each treatment cycle will be 28 days dosed according to the Dose Escalation Schema.
3215197|NCT01042717|Experimental|Plerixafor|Plerixafor 16 hours
3215198|NCT01042730|Active Comparator|Pitavastatin 1 mg daily|
3215199|NCT01042730|Active Comparator|Pitavastatin 4 mg daily|
3215200|NCT01042743|Experimental|RAP|individuals who underwent robot-assisted surgery for primary right-sied colon cancer
3215201|NCT01042743|Active Comparator|LAP|Individuals who underwent laparoscopic surgery for primary right-side colon cancer
3215202|NCT01042769|Experimental|Aleglitazar|
3215203|NCT01042769|Placebo Comparator|Placebo|
3215204|NCT01042782|Experimental|RAD-MitC|RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks
3215205|NCT01042808||1|HIV-1 Infected patients treated with Isentress
3215206|NCT01042821|Active Comparator|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
3215207|NCT01042821|Active Comparator|Group 2|The flap comprised mucosa, submucosa only
3215208|NCT01042834||Air pollution|The subjects will have to live in districts where important atmospheric pollution is established
3215209|NCT01042860|Active Comparator|supplement|lutein supplement
3215210|NCT01042860|Placebo Comparator|placebo|Placebo
3215211|NCT01042873|Other|Intravenous dobutamine|3 hours infusion of dobutamine
3215212|NCT01042886|Experimental|Family plus community focused intervention|
3215213|NCT01042886|Active Comparator|Standard Behavioral Weight Loss Maintenance Intervention|
3215214|NCT01042899|Experimental|Teen Online Problem Solving (TOPS)|Web intervention
3215215|NCT01042899|Experimental|Teen Online Problem Solving---Teen Only|Web Intervention
3215216|NCT01042899|Active Comparator|Internet Resources Comparison|Web Intervention
3215217|NCT01042925|Experimental|Arm 1|XL147 in combination with trastuzumab
3215218|NCT01042925|Experimental|Arm 2|XL147 in combination with trastuzumab and paclitaxel
3215219|NCT01042951|Active Comparator|ShanChol Cholera Vaccine|
3215220|NCT01042951|Placebo Comparator|Placebo|
3215221|NCT01042990|Active Comparator|Home Exercise Only|Participants receive education and instruction on a home exercise program which they do on their own, with intermittent encouragement from study personnel.
3215222|NCT01042990|Experimental|APA|Participants exercise in a gym setting 3x/week for six months, performing gait and balance exercises along with a progressive walking program.
3215223|NCT01042990|Experimental|APA+TM|Participants exercise in a gym setting 3x/week for six months, performing a combined program of adaptive physical activity (gait and balance training) and progressive treadmill walking.
3215224|NCT01043003|Experimental|Arm I|Patients and caregivers undergo the Bilingual Breast Cancer Educational Intervention (BBCEI) comprising teaching sessions over 50-65 minutes about 4 specific domains (i.e., physical, psychological, social, and spiritual well being) once weekly during month 1 and also undergo evaluation sessions at months 1, 4, and 7. Patients and caregivers receive reinforcement telephone calls every other week.
3215225|NCT01043003|Active Comparator|Arm II|Patients and caregivers undergo usual care comprising evaluation sessions at months 1, 4, and 7. Patients and caregivers may undergo the 4 BBCEI teaching sessions during month 7. Patients and caregivers receive reinforcement telephone calls every other week.
3215226|NCT01043016|Experimental|Photocyanine injection|Patients receive intravenous injection of Photocyanine injection from dosage of 0.1 mg/kg,0.2 mg/kg,0.33 mg/kg,0.5 mg/kg to 0.6 6mg/kg till the dose-limiting effect occur.
3215227|NCT01043029|Experimental|aleglitazar|
3215228|NCT01043029|Active Comparator|pioglitazone|
3215229|NCT01043042||Hospitalized patients|patients hospitalized at VUH between 4/1/2008 to 10/31/2009
3215230|NCT01043055||Breast Cancer Patients|
3215231|NCT01043055||Healthy Control Group|
3215232|NCT01043068|Experimental|Pain control|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
3215233|NCT01043107||Compuer radiaton group|
3215234|NCT01043107||control group|
3215235|NCT01043120|Experimental|Barusiban|
3215236|NCT01043120|Placebo Comparator|Placebo|
3215237|NCT01043172|Experimental|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
3215238|NCT01043224|Experimental|Clobetasol propionate plus calcipotriol|
3215239|NCT01043250||Risperidone|Receiving risperidone treatment
3215240|NCT01043250||Olanzapine|Receiving olanzapine treatment
3215241|NCT01043250||Aripiprazole|Receiving aripiprazole
3215242|NCT01043263|Experimental|EN3324 (axomadol)|
3215243|NCT01043263|Placebo Comparator|Placebo|
3215244|NCT01043276|Experimental|Treatment A|
3215245|NCT01043276|Experimental|Treatment B|
3215246|NCT01043276|Experimental|Treatment C|
3215247|NCT01043276|Experimental|Treatment D|
3215248|NCT01043276|Experimental|Treatment E|
3215249|NCT01043289|Experimental|Bright light therapy|Early morning white light @ 7,000 lux for 60 minutes daily (4.2 x 10^5 lux-min) for 5 weeks
3215250|NCT01043289|Placebo Comparator|Dim red light|Early morning dim red light @ 70 lux for 60 minutes daily (3.0 x 10^3 lux-min) for 5 weeks
3215251|NCT01043302||Surgery+chemotherapy|Primary mass was resected and systemic chemotherapy was performed as an adjuvant treatment
3215252|NCT01043302||Chemotherapy|Only treated with chemotherapy
3215253|NCT01043315||Hospitalized Cardiac Patient|Adults admitted to Coronary intensive unit being treated for acute cardiovascular conditions
3215254|NCT01043328||GROUP OSCC|"The study group is composed by patients with a condition that requires a procedure/surgery for oral squamous cell carcinoma treatment.~INTERVENTIONS: Collect blood, saliva and oral tissue."
3215255|NCT01043328||CONTROL GROUP|"Group without oral squamous cell carcinoma but with a condition that requires prosthetic procedure/surgery.~INTERVENTIONS: Collect blood, saliva and oral tissue."
3215256|NCT01043341|Active Comparator|behavioral|the women received a folder about HPV infection and vaccines and answered a questionaire about sexual behavior, HPV infection and vaccines.
3215257|NCT01043341|No Intervention|no intervention|the women answered a questionaire about sexual behavior, HPV infection and vaccines
3215258|NCT01043354|Experimental|stage-matched intervention|Transtheoretical Model-based stage-matched intervention
3215259|NCT01043354|Experimental|framing effects intervention|counseling based on prospect theory
3215260|NCT01043354|Active Comparator|attention placebo intervention|counseling about general health topics
3215261|NCT01043367|Experimental|A|Deprexil
3215262|NCT01043367|Placebo Comparator|B|Placebo
3215263|NCT01043380|Experimental|LZ group|
3215264|NCT01043380|Active Comparator|L group|
3215265|NCT01043406|Experimental|Single Arm, Device Implant|
3215266|NCT01043419|Experimental|LENOXe™ (xénon 100 % v/v)|Influence of LENOXe™ (xénon 100 % v/v) anesthesia on Sympathetic Nervous Activity and Security under LENOXe™ (xénon 100 % v/v) anesthesia
3215267|NCT01043445|Experimental|GPR119 agonist, 2-oleoyl glycerol|2-oleoyl glycerol; 2g. and vehicle
3215268|NCT01043445|Active Comparator|Oleic acid|oleic acid; 3.2g and vehicle
3215269|NCT01043445|Placebo Comparator|Vehicle|5 ml. of glycerol and 5 ml 96% ethanol
3215270|NCT01043458|Experimental|1|ABT-126 Low Dose
3215271|NCT01043458|Experimental|2|ABT-126 High Dose
3215272|NCT01043458|Experimental|3|Placebo for ABT-126
3215273|NCT01043471|Experimental|Chewing gum|
3215274|NCT01043471|Placebo Comparator|Water|
3215275|NCT01043484|Experimental|A|Bevacizumab + Capecitabine + Radiotherapy
3215276|NCT01043484|Active Comparator|B|Capecitabine + Radiotherapy
3215277|NCT01043510|Experimental|A1, first period|
3215278|NCT01043510|Active Comparator|A2, second period|
3215279|NCT01043510|Active Comparator|B1, first period|
3215280|NCT01043510|Experimental|B2, second period|
3215281|NCT01043536|Experimental|radiotherapy + temozolomide|"Radiotherapy:~dose given at PTV-g will be 70 Gy/28 fractions level 1 75 Gy/30 fractions level 2 80 Gy/32 fractions level 3~dose given at PTV-a will be 56 Gy/28 fractions level 1 60 Gy/30 fractions level 2 60.8 Gy/32 fractions level 3~Chemotherapy:~temozolomide given at the dose of 75mg/m2"
3215282|NCT01043549|Active Comparator|Stimulation|Repetitive transcranial stimulation of the posterior parietal cortex
3215283|NCT01043549|Sham Comparator|Sham stimulation|
3215284|NCT01043575|Experimental|1|Rifapentine
3215285|NCT01043575|Active Comparator|2|Rifampin
3215286|NCT01043588|Other|1 : TURP|Surgery: TransUrethral Resection of the Prostate
3215287|NCT01043588|Other|2 : PVP|Surgery: Photo selective Vaporization of the Prostate
3215288|NCT01043601|Experimental|Inhaled PT005 7.2 µg|
3215289|NCT01043601|Experimental|Inhaled PT005 9.6 µg|
3215290|NCT01043601|Placebo Comparator|Inhaled Placebo|
3215291|NCT01043601|Active Comparator|Formoterol Fumarate 12 µg (Foradil Aerolizer)|
3215292|NCT01043614|Experimental|Peer group education|Small groups of female college freshmen facilitated by peer educators
3215293|NCT01043666|Experimental|YM178 group|oral
3215294|NCT01043666|Placebo Comparator|placebo group|oral
3215295|NCT01043666|Experimental|tolterodine ER group|oral
3215296|NCT01043679|Active Comparator|Seroquel|Efficacy and Safety of Seroquel
3215297|NCT01043679|Active Comparator|Utapine|Efficacy and Safety of Utapine
3215298|NCT01043692|Experimental|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
3215299|NCT01043718|Experimental|More-Intensive|
3215300|NCT01043718|Active Comparator|Less-Intensive|
3215301|NCT01043731||Ginven indication for laparoscopic anterior resection|
3215302|NCT01043744|Experimental|Artemether-Lumefantrine|Receive artemether-lumefantrine with direct observation of am dose on days 0, 1, and 2 of study
3215303|NCT01043744|No Intervention|No treatment|No antimalarial treatment given on day 0.
3215304|NCT01043757|Experimental|Control|1) Control Group. Receives daily step goals via emails and has access to the study website to allow them to track their progress. Eligible for check-in incentives.
3215305|NCT01043757|Experimental|Fixed|"Receives control intervention plus are incentivized to attain their daily step goals through daily lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot. Participants who meet their step goal for the day and who upload their data will be entered into the same lottery each day, where the small jackpot is $10 and the large jackpot is $100."
3215306|NCT01043757|Experimental|Ascending|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Each day, we will draw a two-digit number. If the first digit OR the second digit of this daily number matches the participant's lucky number, they win the small jackpot. If both digits match, they receive the large jackpot.~Participants can increase their daily jackpots by meeting their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $4 and the large jackpot is $40; if they successfully meet their step goal on the first day of the week, the jackpots for the second day increase to $6/$60, and so on such that if they reach their goals each day, the jackpots on day seven will reach $16/$160."
3215307|NCT01043757|Experimental|Decreasing|"Receives control intervention plus incentivized to attain daily step goals through lotteries:~Daily drawing procedure same as Ascending condition; structure of incentives is different: Participants can decrease their daily jackpots by failing to meet their step goals. Those who meet their goal for the first day of the week and who upload their data will be entered into a lottery where the small jackpot is $16 and the large jackpot is $160; if they successfully meet their step goal on the first day of the week, the jackpots will remain at $16/$160; if they do not meet their goal the jackpots will decrease to $14/$140, and so on such that if they fail to reach their goals each day, the jackpots on day seven will decrease to $4/$40."
3215308|NCT01043770|Experimental|Group lifestyle education|Multi-component behaviour change intervention
3215309|NCT01043770|No Intervention|Routine care|Routine care
3215310|NCT01043796|Experimental|Insecticide treated nets and wall liners|
3215311|NCT01043796|Active Comparator|Insecticide treated nets alone|
3215312|NCT01043809|No Intervention|1|Randomly selected schools will not receive handwashing intervention
3215313|NCT01043809|Experimental|2|Randomly selected schools will get standard commercial school-based handwashing promotion
3215314|NCT01043809|Experimental|3|Randomly selected schools will receive standard commercial school-based handwashing promotion program, plus an added level of handwashing promotion (varies by country)
3215315|NCT01043835|Experimental|Laparoscopy-assisted gastrectomy|
3215316|NCT01043835|Active Comparator|Open gastrectomy|
3215317|NCT01043848|Experimental|Early pudendal stimulation|Subjects in this arm will start with the intervention within 2 weeks after SCI
3215318|NCT01043848|Experimental|Late pudendal stimulation|Subjects in this arm will start with the intervention 12 weeks after SCI
3215319|NCT01043848|No Intervention|Control|Subjects in this arm will be treated according to standard therapy but will receive no pudendal stimulation
3215320|NCT01043887|Experimental|Patients with Moderate Hepatic Insufficiency|Patients with moderate hepatic insufficiency (a score of 7 to 9 on the Child-Pugh's scale) received a single 10 mg dose of ridaforolimus.
3215321|NCT01043887|Experimental|Healthy Control Subjects|Healthy control subjects were matched by race, age, gender, and body mass index (BMI) to the patients with moderate hepatic insufficiency. The healthy control subjects also received a single 10 mg dose of ridaforolimus.
3215322|NCT01043900|Placebo Comparator|Sham rTMS|Patients with stable medication regimen receiving 30 daily sessions of PLACEBO rTMS delivered to the right dorsolateral prefrontal cortex
3215323|NCT01043900|Active Comparator|Active rTMS|Patients with stable medication regimen receiving 30 daily sessions of active rTMS delivered to the right dorsolateral prefrontal cortex
3215324|NCT01043913|Experimental|Guaraná extract 50mg q12 hours|Guaraná extract pills of 50mg q12 hours for 21 days
3215325|NCT01043913|Placebo Comparator|Placebo 1 tab q12 hours|Placebo pills 1 tab q12 hours for 21 days
3215326|NCT01043952|Active Comparator|Control|"Patients receive general anesthesia with Propofol and Remifentanil following clinical practice.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
3215327|NCT01043952|Experimental|Bispectral Index Monitor|"Patients receive a general anesthesia with Propofol and Remifentanil where the amount of anesthetics administered is decided taking into consideration the Bispectral Index Monitor.~Stratification by age (1-3 y, 4-11y, 12-17y, 18-65y) will be performed to ensure balanced allocation of age groups and allow for identification of age and weight specific effects.~Stratification by operation type will be performed to ensure the identification of the effects of the duration of anaesthesia and of the use of longer acting opioids (Fentanyl) on outcome parameters."
3215328|NCT01043965|Active Comparator|Diabetes|Type 2 diabetes patients without obstructive coronary disease. Interventional group: lifestyle changes and treatment with metformin.
3215329|NCT01043965|No Intervention|Control|Control group - normal, healthy individuals.
3215330|NCT01043978|Experimental|Novel nipple|
3215331|NCT01043978|Active Comparator|Coventional nipple|
3215332|NCT01043991|Experimental|EPO|single bolus of EPO, 150 µg
3215333|NCT01043991|Placebo Comparator|Placebo|NaCl
3215334|NCT01044004|Experimental|Post treatment remission armodafinil|Armodafinil 150 mg/day for 13 weeks
3215335|NCT01044004|Placebo Comparator|Post treatment remission placebo|Placebo 150mg/day for 13 weeks
3215336|NCT01044004|Experimental|Chemotherapy armodafinil|Armodafinil 150 mg/day for 13 weeks
3215337|NCT01044004|Placebo Comparator|Chemotherapy placebo|Placebo 150mg/day for 13 weeks
3215338|NCT01044017|Experimental|A|
3215339|NCT01044017|Experimental|B|
3215340|NCT01044017|Placebo Comparator|C|
3215341|NCT01044069|Experimental|Pts with B Cell Acute Lymphoblastic Leukemia|This is a phase I study. Patients with CD19+ ALL (CR, relapsed, MRD, or refractory) are eligible for enrollment. B-ALL patients in first CR will be enrolled but only treated if they develop MRD or a frank relapse, while patients with MRD or with documented relapsed/refractory disease are eligible for immediate treatment. The T cell doses originally proposed in this study were based on doses administered safely in prior autologous T cell adoptive therapy trials but the dose has been modified based on the toxicities observed in patients with morphologic evidence of disease. Patients will be treated with different doses of T cells depending on the amount of disease at the time of T cell infusion. Patients in Cohort 1 (<5% blasts in the BM) will continue to receive 10^6 19-28z+ T cells/kg as previously. Patients in Cohort 2 (≥5% blasts in the BM) will receive the reduced dose of 1x106 19-28z+ T cells/kg).
3215342|NCT01044082|Experimental|controlled cord traction|Controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs.
3215343|NCT01044082|Active Comparator|clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
3215344|NCT01044095|Active Comparator|Autologous prime boost regimen 1|FluMist® live intranasal vaccine (LAIV) 0.2mL (0.1mL per nostril): 2 doses separated by 8 weeks (+/- 7 days)
3215345|NCT01044095|Active Comparator|Autologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine intramuscularly: 2 doses separated by 8 weeks (+7 days)
3215346|NCT01044095|Experimental|Heterologous prime boost regimen 1|FluMist® live, intranasal vaccine single dose, followed by Fluzone® inactivated influenza virus vaccine 8 weeks (+/-7 days) later
3215347|NCT01044095|Experimental|Heterologous prime boost regimen 2|Fluzone® inactivated seasonal influenza virus vaccine single dose, followed by FluMist® live, intranasal seasonal influenza vaccine 0.2mL 8 weeks (+/- 7 days) later
3215348|NCT01044108|Experimental|Trial, part 1 (males only)|
3215349|NCT01044108|Experimental|Trial, part 2 (males and females)|
3215350|NCT01044121|Experimental|Mattress Firmness|
3215351|NCT01044134|Experimental|Diet + Water|"Participants will be counseled to follow a standard weight-reducing diet including consumption of 1) ample vegetables, fruits, and legumes; 2) whole rather than refined grains; and 3) high-quality proteins at most meals and snacks. Moreover, we will recommend limiting intake of added fats and sugars and avoiding juices and sugar-sweetened beverages (per standard practice). Participants will also be counseled to increase their water intake to 8 cups per day, consistent with the popular 8 × 8 recommendation (eight 8-oz glasses of water)."
3260359|NCT01478685|Experimental|Arm B: CC-486 plus ABI-007|"CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability~ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2"
3260360|NCT01478685|Experimental|Arm C: CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
3215352|NCT01044134|Active Comparator|Diet|Participants will be counseled on the same standard weight-reducing diet, as described above, with no specific advice regarding water consumption. Furthermore, no specific dietary recommendations will be provided on altering fluid/beverage intake, other than to decrease calorie-containing beverages as noted above. When participants ask for a recommendation regarding water intake, they will be advised that drinking plain water is the best way to satisfy thirst and instructed to drink when thirsty.
3215353|NCT01044147|Experimental|VLM-S|"Participants in this arm receive standard lifestyle coaching, which is delivered on a specified schedule. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
3215354|NCT01044147|Experimental|VLM-M|"Participants in this arm receive modulated lifestyle coaching, where coaching frequency may be adjusted according to whether the participant is meeting program goals for program use and targeted behaviors. They will also receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle."
3215355|NCT01044147|Active Comparator|OGR|Participants in this arm will receive online information about evidence-based lifestyle goals and links to reputable resources for helping to achieve a healthy lifestyle, but not personalized lifestyle coaching.
3215356|NCT01044160||Oncology Group|The study will recruit from outpatient clinics with procedures designed to obtain a representative sample of research participants, in terms of diagnosis and time since diagnosis.
3215357|NCT01044160||Control Group|The study will first identify a large cohort of children who are willing to participate, and then call them back individually as they are found to match participants in the cancer group.
3215358|NCT01044186|Experimental|ICL670|
3215359|NCT01044199|Experimental|1: Pre-EP ID|Group of participants receiving PCEC rabies vaccine intradermally with the Pre-Exposure schedule.
3215360|NCT01044199|Active Comparator|2: Pre-EP IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Pre-Exposure schedule.
3215361|NCT01044199|Experimental|3: Booster ID|Group of participants receiving PCEC rabies vaccine intradermally with the Booster schedule.
3215362|NCT01044199|Active Comparator|4: Booster IM|Group of participants receiving PCEC rabies vaccine intramuscular with the Booster schedule.
3215363|NCT01044225|Active Comparator|Cilengitide EMD 121974|A dose of 2000 mg by iv administration 2 weekly.
3215364|NCT01044225|Active Comparator|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
3215365|NCT01044238|Experimental|active medication (methylphenidate)|Condition receiving active medication: 18mg/day during week 1; 36mg/day during week 2; 54mg/day during remainder of study
3215366|NCT01044238|Placebo Comparator|Placebo|Condition randomly assigned to receive placebo, provided to appear identical to active medication
3215367|NCT01044251|Placebo Comparator|Placebo|10 days of treatment with placebo in a bid fashion that will look like the study medication.
3215368|NCT01044251|Experimental|Frovatriptan|Frovatriptan 2.5 mg po bid for 10 days
3215369|NCT01044277|Experimental|Group A|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
3215370|NCT01044277|Experimental|Group B|"Glutathione supplementation-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo~Other name Gluthathione peroxidases"
3215371|NCT01044277|Placebo Comparator|Group C|Placebo-Double-Blind - GSH 500 mg/GSH 125 mg/Placebo
3215372|NCT01044316|Active Comparator|Arm 1|
3215373|NCT01044316|Active Comparator|Arm 2|
3215374|NCT01044329|Active Comparator|Intravitreal bevacizumab|
3215375|NCT01044329|Active Comparator|Intravitreal triamcinolone|
3215376|NCT01044342|Experimental|A|Single dose of AZD1446 10 mg
3215377|NCT01044342|Experimental|B|Single dose of AZD1446 80 mg
3215378|NCT01044342|Active Comparator|C|Single Dose of Donepezil 5 mg
3215379|NCT01044342|Placebo Comparator|D|Single dose of placebo to match AZD1446
3215380|NCT01044355|Active Comparator|auto-titrating|Patients being treated for 6 weeks with auto-titrating continuous airway pressure.
3215381|NCT01044355|Active Comparator|Fixed|Patients receiving 6 weeks of treatment with fixed continuous positive airway pressure.
3215382|NCT01044368|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3215383|NCT01044368|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
3215384|NCT01044381|Experimental|Luliconazole Solution, 10%|
3215385|NCT01044394|Experimental|same day, reduced volume PEG-ELS prep|Patients with colonoscopies scheduled in the afternoon will complete 2 liters of PEG-ELS solution the morning of their colonoscopy.
3215386|NCT01044420|Experimental|mFOLFIRI|
3215387|NCT01044446|Experimental|Icodextrin|peritoneal dialysate
3215388|NCT01044446|Active Comparator|Glucose-based dialysate|peritoneal dialysate
3260361|NCT01478698|Experimental|Single dose|The first 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled into a dialysate bag and infused for a 4 hour intraperitoneal dwell.
3260362|NCT01478698|Experimental|2 doses|The next 5 consented participants will be administered t-PA 10mg + DNase 5mg instilled twice a day for one day
3260363|NCT01478698|Experimental|4 doses|The next 5 consented participants will be administered tPA 10mg + DNase 5mg twice a day for 2 days.
3260364|NCT01478698|No Intervention|control|Any potential participants that have not consented into the intervention arms will be approached to be consented into a non-intervention observational control group. A maximum of 5 participants will be recruited into this control group.
3260365|NCT01478711|Active Comparator|Intervention|A clinical decision support tool for the care and management of premature infants will be embedded into the electronic health record.
3215389|NCT01044485|Other|lapatinib + docetaxel|"dose level Lapatinib (OD) Docetaxel (q3wks) Systematic Growth factor Minus 0 1250 mg 75 mg/m2 + systematic growth factor support~0, 1250mg 75 mg/m2 No~+1 1500mg 75mg/m2 No~Minus +1* 1500mg 75mg/m2 + systematic growth factor support~+2 1250mg 100mg/m2 No~Minus +2* + systematic growth factor support~+3 1500mg 100mg/m2 No~Minus +3* + systematic growth factor support~Apart within the minus dose levels, G-CSF support should be added only as rescue strategy if severe neutropenia occurred during the first cycle of studied dose.Patients will receive 4 cycles of the association. In case of benefit of the treatment, they should continue the treatment with lapatinib until progression.* patients will be included at level minus X only if 2 DLT out of 6 patients based on febrile neutropenia occurred at level X"
3215390|NCT01044511|Experimental|Home visit|After SEMS placement, 2 home visits and a phonecall are made by a specialist nurse
3215391|NCT01044511|Active Comparator|Standard|Standard contact via Hotline and traditional referring methods
3215392|NCT01044524|Experimental|1|SLV 334
3215393|NCT01044550|Other|Treatment|Laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury
3215394|NCT01044550|Active Comparator|Control|Assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.
3215395|NCT01044563|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3215396|NCT01044563|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3215397|NCT01044602|Active Comparator|Best Medical Management|Patients elect to treat obesity and type 2 diabetes mellitus through best medical management.
3215398|NCT01044602|Active Comparator|Surgical Treatment|Patients with type 2 diabetes mellitus choice to treat obesity with Roux-en-Y gastric bypass.
3215399|NCT01044615||Mild traumatic brain injury patients|Subjects who have a verifiable diagnosis of mild traumatic brain injury sustained within 24 months prior to enrollment
3215400|NCT01044615||Normal Control|Normal, healthy adults with no history of brain injury.
3215401|NCT01044628|Experimental|Nocturnal oxygen therapy (N-O2)|Oxygen will be delivered overnight to the patients to allow their oxygen saturation to be >90%
3215402|NCT01044628|Sham Comparator|Sham concentrator|Sham therapy with ambient air will be given to the patients at night
3215403|NCT01044654|Experimental|Cohort 1|3 Subjects will receive a single infusion of 0.5-1.0 x 1010 SB-728-T
3215404|NCT01044654|Experimental|Cohort 2|3 Subjects will receive a single infusion of 2.0 x 1010 SB-728-T
3215405|NCT01044654|Experimental|Cohort 3|3 Subjects will receive a single infusion of 3.0 x 1010 SB-728-T
3215406|NCT01044654|Experimental|Cohort 4|Up to 4 HAART failure subjects will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T
3260366|NCT01478711|No Intervention|No Intervention|No intervention, No clinical decision support tool will be used for non-intervention sites.
3260367|NCT01478724|Placebo Comparator|Placebo|Animal proteins
3260368|NCT01478724|Experimental|Milk protein fraction dose 1|
3215407|NCT01044654|Experimental|Cohort 5|"Up to 20 subjects with heterozygote CCR5 delta-32 mutation will receive a single intravenous infusion of 0.5 to 3.0 x 1010 SB-728-T.~Cohort 5 subjects will undergo a structured treatment interruption 2 months following infusion in which their anti-retroviral therapy will be discontinued for 16 weeks. HAART will be reinstituted in subjects whose CD4+ cell counts drop to <350 cells/mm3 and/or whose HIV-RNA increases to >100,000 on three consecutive weekly measurements.~At the end of the STI, subjects with a sustained detectable viral load will be reinstituted on HAART. Subjects with HIV RNA levels below the limit of detection will remain off HAART. Subjects with an undetectable viral load will remain off HAART until HIV RNA levels are detectable or their CD4 count drops below 350 cell/mm3 on three consecutive weekly measurements."
3215408|NCT01044667|Other|Patients taking Myfortic|Lung transplant patients converted from MMF to Myfortic as part of standard of care treatment will have GI and Quality of Life assessments done at the time of conversion to Myfortic and at 60 days, 90 days and 180 days.
3215409|NCT01044680|Experimental|Nutriose|17 g NUTRIOSE consumed twice daily for 12 weeks
3215410|NCT01044680|Placebo Comparator|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
3215411|NCT01044719|Active Comparator|10 days|
3215412|NCT01044719|Active Comparator|14 days|
3215413|NCT01044719|Active Comparator|21 days|
3215414|NCT01044810||Simultaneous interruption (Exposure gr)|stopped all drugs in NNRTI-based regimens simultaneously after allergic reactions to NVP-based regimens, and later started EFV-based regimens
3215415|NCT01044810||Naive (Control group)|HIV-1-infected patients who started EFV-based regimens as their initial ARV regimens.
3215416|NCT01044810||staggered interruption (exposure group)|"after having allergic reactions to NVP-based regimens, stopped NNRTIs first, continued the other NRTIs for a period of time, i.e. staggered interruption, and later started EFV-based regimens"
3215417|NCT01044823||Adult RA|
3215418|NCT01044823||pediatric JRA|
3215419|NCT01044836|Experimental|Etanercept|
3215420|NCT01044875|Active Comparator|green laser 532 nm conventional|Current type of laser used for treatment of proliferative diabetic retinopathy
3215421|NCT01044875|Active Comparator|Yellow 577 nm laser|new laser wavelength for treatment of PDR
3215422|NCT01044927|Experimental|Proactive Integrated Care|COPD-specific education, self-management instruction, remote monitoring and enhanced communication with a coordinator
3215423|NCT01044927|Active Comparator|Standard Care Control|No intervention other that measurements taken at 0, 3, 6 and 9 months of the study.
3215424|NCT01044940||Birth asphyxia|Babies suffering from birth asphyxia
3215425|NCT01044940||Blood transfusion|Babies who receives blood transfusion
3215426|NCT01044940||Heart Surgery|Babies who need heart surgery
3215427|NCT01044953||Soccer Players|German professional soccer players
3215428|NCT01044992|Experimental|Drug and radiation|Levodopa and H215O PET
3215429|NCT01045005|Active Comparator|Type 1 Diabetes|Subjects with type 1 diabetes mellitus who are administered oxygen and carbon dioxide
3215430|NCT01045005|Active Comparator|Control Subjects|Healthy volunteers administered oxygen and carbon dioxide via respiratory apparatus
3215431|NCT01045018|Active Comparator|mesalamine 400 mg tablet|
3215432|NCT01045018|Active Comparator|Asacol 400 mg Delayed Release Tablet|
3215433|NCT01045018|Placebo Comparator|Placebo delayed release tablet|
3215434|NCT01045044||Breast cancer, chemotherapy|Up to 15 women with breast cancer who are to undergo systemic anthracycline based chemotherapy.
3215435|NCT01045044||Normal control|Up to 15 normal, healthy women.
3215436|NCT01045070||coronary heart disease|
3215437|NCT01045083|Experimental|1|
3215438|NCT01045109|Experimental|open-label vitamin D3|One arm: open-label receiving vitamin D3 4,000 IU daily
3215439|NCT01045148|Other|CyberKnife Radiosurgery|CyberKnife Radiosurgery
3215440|NCT01045200||Follow-up|Patients curatively operated for rectal cancer
3215441|NCT01045213|Experimental|Proactive Integrated Care|COPD education, self-management education, remote monitoring (Health Buddy, pulse oximeter, pedometer, spirometer) and enhance communication with cell phone contact with a coordinator.
3215442|NCT01045226|Experimental|Arm I|Patients undergo proton radiotherapy once daily 5 days a week for approximately 9 weeks in the absence of disease progression or unacceptable toxicity.
3215443|NCT01045239|Experimental|Micropulse 577 nm yellow diode laser|
3215444|NCT01045239|Active Comparator|532 nm green diode laser|
3215445|NCT01045252||congenital heart disease|Neonates that are enrolled in the NICU and are confirmed of congenital heart diseases.
3215446|NCT01045252||sepsis|Neonates that are enrolled in the NICU and are diagnosed as sepsis.
3215447|NCT01045252||Health|Neonates that are enrolled in the NICU and have no congenital heart diseases and sepsis.
3215448|NCT01045291|Active Comparator|Fusion Pacing OFF|Subjects initially randomized to the Fusion Pacing OFF Arm will receive the Fusion Pacing software download at the implant visit, but the Fusion Pacing software will be programmed OFF. At 4 months subjects in this arm will crossover to the Fusion Pacing ON Arm.
3215449|NCT01045291|Experimental|Fusion Pacing ON|Subjects initially randomized to the Fusion Pacing ON Arm will receive the Fusion Pacing software download at the implant visit, and the Fusion Pacing software will be programmed ON. At 4 months subjects in this arm will crossover to the Fusion Pacing OFF Arm.
3215450|NCT01045304|Experimental|Gencitabine + iniparib twice weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 5.6 mg/kg IV over 60 minutes on Days 1, 4, 8 and 11 of 3-week cycles"
3215451|NCT01045304|Experimental|Gencitabine + iniparib weekly|"Gemcitabine, 1000 mg/m² IV over 30 minutes and carboplatin, area under the curve (AUC) = 2, IV over 60 minutes, both on Days 1 and 8 of 3-week cycles.~Iniparib, 11.2 mg/kg IV over 60 minutes on Days 1 and 8 of 3-week cycles"
3215452|NCT01045317|Experimental|intravenous or oral administration|
3215453|NCT01045330|No Intervention|Usual Care Group|Usual care consists of standard hospital services provided by physicians, nurses, and support staff (e.g., physical therapist, dietitian) in the general surgery units.
3215454|NCT01045330|Experimental|Experimental Group|The intervention consisted of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
3215455|NCT01045343|Active Comparator|Control Arm|
3215456|NCT01045343|Experimental|Integrated Diagnostics Arm|
3215457|NCT01045356||children less than 2 months old|
3215458|NCT01045356||children 2 months to 12 months old|
3215459|NCT01045356||Children > 2 months old and less than or equal to 20 kg|
3215460|NCT01045369|Experimental|Kaletra And Intelence|This is a Phase IV, 48-week, open-label, pilot study in 30 ARV-naïve patients examining the safety, viral response, and tolerability of Kaletra® and Intelence™ tablets.
3215461|NCT01045382|Experimental|Mensenchymal Stem Cells|"Efficacy of MSC infusion on one-year overall survival of patients transplanted with HLA-mismatched PBSC.~Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2 Gy total body irradiation.~MSC cells (1,5-3,0 x 10E6 MSC/Kg BW) will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
3215462|NCT01045382|Placebo Comparator|Placebo|"Patients will receive a conditioning regimen consisting in fludarabine (total dose 90 mg/square meter) and 2Gy total body irradiation.~Isotonic solution will be injected will be injected, followed, at least one hour later, by the infusion of HLA-mismatched PBSC from related or unrelated donor."
3215463|NCT01045395|Placebo Comparator|Corn starch, 90mg/d|Corn starch, 90mg/d
3215464|NCT01045395|Experimental|Unique Marine Algae Concentrate (UMAC). 90mg/d|
3215465|NCT01045395|Experimental|Golden brown algae, 90mg/d|
3215466|NCT01045408|Placebo Comparator|Berry|
3215467|NCT01045408|Placebo Comparator|Placebo|
3215468|NCT01045434|Experimental|Omeprazole Magnesium DR 20 mg Capsules|Omeprazole Magnesium DR 20 mg Capsules of Dr Reddys Laboratories Limited
3215469|NCT01045434|Active Comparator|Prilosec 20 mg Tablets|Prilosec 20 mg Tablets of Procter and Gamble
3215470|NCT01045486|Active Comparator|Group A|Group A received active medication (ATP mixed probiotics) for 6 weeks followed by a crossover to 6 weeks of placebo after 4-weeks washout period.
3215471|NCT01045486|Placebo Comparator|Group B|Group B received placebo medication for 6 weeks followed by a crossover to 6 weeks of active medication (ATP mixed probiotics) after 4-weeks washout period.
3215472|NCT01045512|Active Comparator|statins, standardised physical training|
3215473|NCT01045512|No Intervention|to continue with current lifestyle|
3215474|NCT01045525|Experimental|Phlebotomy + lifestyle and diet advices|
3215475|NCT01045525|Active Comparator|Lifestyle and diet advices|
3215476|NCT01045538|Experimental|Vorinostat plus XP|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
3215477|NCT01045564|Experimental|A|One dose of study vaccine (GSK 1557484A) on Day 0, Day 182, and Day 364
3215478|NCT01045564|Experimental|B|One dose of study vaccine (GSK 1557484A) on Day 0, Day 91, and Day 364
3260369|NCT01478724|Experimental|Milk protein fraction dose 2|
3215479|NCT01045564|Experimental|C|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3215480|NCT01045564|Experimental|D|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3215481|NCT01045564|Experimental|E|One dose of study vaccine (GSK 1557484A) on Day 0, Day 21, and Day 364
3215482|NCT01045577|Active Comparator|Masitinib (AB1010)|Masitinib (AB1010)
3215483|NCT01045577|Placebo Comparator|Placebo mactching masitinib|Placebo matching masitinib
3215484|NCT01045590|Active Comparator|glibenclamide + Rosiglitazone|glibenclamide plus rosiglitazone
3215485|NCT01045590|Placebo Comparator|glibenclamide + placebo|
3215486|NCT01045616||Prematurity|
3215487|NCT01045629||SchizoComp|Competence Ability of schizophrenia
3215488|NCT01045629||NonSchizoComp|Competence of Non-schizophrenia
3215489|NCT01045642|Active Comparator|Prilosec 20 mg Tablets|
3215490|NCT01045642|Experimental|Omeprazole Magnesium DR 20 mg Capsules|
3215491|NCT01045655|Experimental|MOMCare intervention|Depression care treatment with study depression care specialist (brief interpersonal psychotherapy or pharmacotherapy)
3215492|NCT01045655|No Intervention|Care Plus|Usual care group; referral to community mental health treatment
3215493|NCT01045668|Active Comparator|Clinical VT ablation|
3215494|NCT01045668|Active Comparator|clinical VT and substrate ablation|
3215495|NCT01045681|Experimental|BVD|Bendamustine, Velcade and Dexamethasone
3215496|NCT01045720|Placebo Comparator|Placebo Comparator|
3215497|NCT01045720|Experimental|ChinesMed|
3215498|NCT01045733|Experimental|IQ Toric IOL|AcrySof IQ Toric intraocular lens (IOL) randomly assigned to one eye, with AcrySof IQ Aspheric IOL with Limbal Relaxing Incision (LRI) procedure in the fellow eye for contralateral implantation.
3215499|NCT01045733|Active Comparator|IQ Aspheric IOL + LRI|AcrySof IQ Aspheric intraocular lens (IOL) with Limbal Relaxing Incision (LRI) procedure randomly assigned to one eye, with AcrySof IQ Toric IOL in the fellow eye for contralateral implantation
3215500|NCT01045746|Experimental|Group 1|T0, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T1, 16 days wash-out period; T2, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T3
3215501|NCT01045746|Experimental|Group 2|T0, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T1, 16 days wash-out period;T2, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T3
3215502|NCT01045772|Experimental|IL-1 trap|
3215503|NCT01045785||aspirin responsive|PFA Col/EPI normal
3215504|NCT01045785||aspirin resistance|PFA Col/epi showed resistance
3215505|NCT01045811|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3215506|NCT01045811|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3215507|NCT01045837|Active Comparator|Prednisolone and Gluten free diet|Gluten free diet and prednisolone in the dose of 1 mg/kg/d over a period of 4 weeks.
3215508|NCT01045837|Placebo Comparator|Gluten free diet|Gluten free alone will be given in this group
3215509|NCT01045863|Experimental|PART A: Ascending Cohorts|Single ascending dose cross-over. (0.05, 0.15, 0.5, 1.5, 5, 15 mg)
3215510|NCT01045863|Experimental|PART B: Food effect|Food effect on PF-03382792 PK
3215511|NCT01045863|Experimental|PART C: CSF Cohort|Optional CSF Cohort
3215512|NCT01045876|Experimental|Dexamethasone|
3215513|NCT01045876|Placebo Comparator|Placebo|
3215514|NCT01045889|Experimental|R-CHOP + PBSCT|All patients will receive chemoimmunotherapy with Rituximab + CHOP regimen for 6 cycles followed by high dose cyclophosphamide and stem cell collection, then high dose therapy with BEAM conditioning regimen and peripheral blood stem cell transplantation
3215515|NCT01045902|Experimental|Arm 1|
3215516|NCT01045902|Active Comparator|Arm 2|
3215517|NCT01045915|Experimental|Plasmid AMEP electrotransfer|
3215518|NCT01045928|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21 and rituximab IV on day 1of courses 1, 3, 5, 7, 9, and 11.
3215519|NCT01045941|Experimental|Patients with distal pancreatic cancer|Patients with distal pancreatic cancer amenable to a laparoscopic distal pancreatectomy
3215520|NCT01045980|Experimental|Bioimpedance and Vitamin D|
3215521|NCT01045980|Experimental|Usual care and Vitamin D|Vitamin D3
3215522|NCT01045980|Experimental|Bioimpedance and Placebo|
3215523|NCT01045980|Placebo Comparator|Usual Care and Placebo|
3215524|NCT01046006|Experimental|Bortezomib, Rituximab, Dexamethasone|BDR will be administered in one 21-day treatment cycle followed by four 35-day treatment cycles to patients with WM. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of Bortezomib, dexamethasone 40mg iv and Rituximab 375 mg/m2 iv will be administered. A total of 8 infusions of rituximab will be administered. Subsequently patients rated as CR, PR, MR or SD will be followed without any treatment until there is evidence of progressive disease.
3215525|NCT01046032|Active Comparator|Metformin|Drug (including placebo)
3215526|NCT01046032|Placebo Comparator|Sugar pill|Drug (including placebo)
3215527|NCT01046045|Active Comparator|Everolimus|before and after everolimus; in other words, comparison of specified outcome before and after treatment with everolimus
3215528|NCT01046045|Active Comparator|Calcineurin-inhibitor immunosuppression|Cyclosporin-based immunosuppression without everolimus
3215529|NCT01046058|Experimental|Panel A: TMC435 150 mg|Participants enrolled in Panel A had moderate hepatic failure and received TMC435 150 mg once daily for 7 days.
3215530|NCT01046058|Experimental|Panel B: TMC435 150 mg|Participants enrolled in Panel B had severe hepatic impairment and received TMC435 150 mg once daily for 7 days after the safety of TMC435 150 mg once daily for 7 days was evaluated in participants enrolled in Panel A.
3215531|NCT01046071|Experimental|transversus abdominis plane block|transversus abdominis plane block with ropivacaine
3215532|NCT01046071|Placebo Comparator|block with saline|20 ml of isotonic saline bilateral
3260370|NCT01478737|Sham Comparator|Sham|Vitrectomy only
3260371|NCT01478737|Active Comparator|Intravitreal Ozurdex|Intravitreal Ozurdex after vitrectomy
3215533|NCT01046097||Synflorix Group|Subjects receiving Synflorix™ according to local Prescribing Information. Subjects were administered with Synflorix by investigators in the course of their normal clinical practice. The vaccination schedule consisted of three doses/two doses/one dose or the booster dose of 10Pn-PD-DiT to be administered as per the local PI. First dose of the vaccine could be administered to infants as early as 6 weeks of age and minimum interval between subsequent primary doses was 4 weeks.
3215534|NCT01046123|Experimental|Whole brain radiotherapy|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy
3215535|NCT01046149|Experimental|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
3215536|NCT01046149|Active Comparator|Stress management|Cognitive reconstructive strategies for stress management
3215537|NCT01046162|Active Comparator|Tafil Tablets 2 mg Pharmacia Upjohn|
3215538|NCT01046162|Active Comparator|Xanax Tablets 2 mg Pfizer LLC|
3215539|NCT01046175|Experimental|Airstacking with manual resuscitator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
3215540|NCT01046175|Active Comparator|Air-stacking with ventilator|Air-stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a ventilator.
3215541|NCT01046188|Experimental|Web-based Teaching Group|Patients randomized to the intervention group will receive a unique login and password to a link on the Ottawa Fertility Centre website. This will allow them access to a secure site containing required teaching modules. They will then complete an interactive teaching tool that contains the same educational content as the traditional presentation. Patients will be able to access a module that is specific to their stimulation protocol. The teaching tool does not need to be completed all at one time. Once completed, the information can still be accessed as many times as required.
3260372|NCT01478750|Experimental|emulsified fat, orally|At 09:00, subjects will ingest the test load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80
3260373|NCT01478750|Experimental|intragastric administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intragastrically
3215542|NCT01046188|Active Comparator|Control group|Participants randomized to the control arm of the study will participate in a traditional didactic teaching session. This session will be carried out by the nurse educator. This session will be attended by up to 10 other couples that may or may not be participating in the study. The nurse educator administering the session will not know which couples are participating in the study. Slides shown and information conveyed will be the same as that provided to the web-based group, however all three stimulation protocols will be presented to the participants regardless of their actual treatment protocol.
3215543|NCT01046201||Obese Children|
3215544|NCT01046214|Experimental|Budeprion XL™|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
3215545|NCT01046214|Active Comparator|Wellbutrin XL®|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
3215546|NCT01046227||Serology after Novel H1N1 vaccination|This study is designed to investigate the antibodies titers before and after the novel H1N1 influenza vaccination in pediatric haemato-oncology patients.
3215547|NCT01046240|Active Comparator|Intravenous palonosetron|Intravenous palonosetron: control arm (standard treatment)
3215548|NCT01046240|Experimental|subcutaneous palonosetron|subcutaneous palonosetron
3215549|NCT01046266|Experimental|A|
3215550|NCT01046266|Active Comparator|B|
3215551|NCT01046279||Glioma Patient receiving Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
3215552|NCT01046292|Experimental|Ginkgo biloba|
3215553|NCT01046292|Placebo Comparator|Placebo control|
3215554|NCT01046305||Part 1: Interview & Questionnaires|Patients interviews and questionnaires about CML symptoms once.
3215555|NCT01046305||Part 2: Symptoms Rating|Importance of symptoms to CML patients rated by physicians, nurses, patients, and caregivers.
3215556|NCT01046305||Part 3: MDASI-CML Questionnaires|Patients questionnaires about CML symptoms over 1 year using M. D. Anderson Symptom Inventory (MDASI) module (the MDASI-CML)
3215557|NCT01046318|Experimental|OPC-262 5 mg|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
3215558|NCT01046331||Adult H1N1|Patients admitted to adult ICU with confirmed or suspected H1N1 Influence infection
3215559|NCT01046331||Pediatric H1N1|Patients admitted to pediatric ICU with confirmed or suspected H1N1 Influenza infection
3215560|NCT01046357|Experimental|Active|AZD7687 oral suspension
3215561|NCT01046357|Experimental|Placebo|placebo oral suspension
3215562|NCT01046370|Experimental|ARP intervention|
3215563|NCT01046370|No Intervention|No intervention|
3215564|NCT01046383|Experimental|IMN1207|"Dietary Supplement: IMN1207~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
3215565|NCT01046383|Placebo Comparator|Casein|"Dietary Supplement: Casein.~Stratum A: CRP <40 mg/L and WBC < 11x109/L (i.e. subjects with relatively low levels of inflammation).~Stratum B: CRP ≥ 40 mg/L and/or WBC ≥ 11x109/L (i.e. subjects with relatively high levels of inflammation."
3215566|NCT01046409||Main vessel, side branch vessel|
3215567|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment A)|
3215568|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment B)|
3215569|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment C)|
3215570|NCT01046422|Experimental|BMS-770767 ± metformin (Treatment D)|
3215571|NCT01046422|Placebo Comparator|Placebo ± metformin (Treatment E)|
3215572|NCT01046435|Placebo Comparator|Supragingival scaling plus placebo|Plaque control instructions, supra gingival scaling and two placebos
3215573|NCT01046435|Experimental|Root planing plus antibiotics|Plaque control instructions, subgingival scaling,root planing, metronidazole 250 mg and amoxicillin 500 mg. three times a day for 7 days
3215574|NCT01046448||4C|Children with chronic kidney disease stage IIIb to V (GFR 10 to 45 ml/min/1.73m²) at screening.
3215575|NCT01046461|Experimental|Ramosetron, Aprepitant, Dexamethasone|
3215576|NCT01046474|Experimental|reducing beverages and sugar and increase physical activity|reduction of beverages and sugar and increasing physical activity
3215577|NCT01046474|No Intervention|control -no intervention|
3215578|NCT01046500|Active Comparator|metformin|
3215579|NCT01046500|Active Comparator|myo-inositol|
3215580|NCT01046539|Active Comparator|RDC-0313 + Buprenorphine|Cohort 1 (1 and 4 mg) + 8 mg Cohort 2 (dependent on Cohort 1 results)
3215581|NCT01046539|Placebo Comparator|Placebo|
3215582|NCT01046552|Active Comparator|PES/LC|preoperative ES followed by LC within the same hospital admission
3215583|NCT01046552|Active Comparator|LC/IOES|laparoscopic cholecystectomy with intraoperative ercp under the same anesthesia
3215584|NCT01046578|Experimental|Single Dose 12mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
3215585|NCT01046578|Experimental|Single Dose 18mm follicle|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
3215586|NCT01046578|Experimental|Single Dose Post Ovulation|Single dose (20mg) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 post ovulation
3215587|NCT01046578|Experimental|Multi Dose 12mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 12 mm
3215588|NCT01046578|Experimental|Multi Dose 18mm follicle|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated at follicle diameter of 18 mm
3215589|NCT01046578|Experimental|Multi Dose Post Ovulation|Multi dose (2.5mg/day for 5 days) of an aromatase inhibitor (Letrozole/Femara(TM); n = 10) initiated 24-48 hours post ovulation
3215590|NCT01046578|No Intervention|Control|No intervention given, followed for course of study on a natural cycle
3215591|NCT01046591||Cleft|Those with a repaired cleft palate
3215592|NCT01046591||Comparison|Those without a cleft palate repair
3215593|NCT01046604|No Intervention|No treatment|This is the group of patients that will not undergo any treatment with Lovaza prior to mitral valve repair surgery. This is the 'control' group.
3215594|NCT01046604|Active Comparator|Lovaza treated|This arm will be the group of patients that will be treated with Lovaza prior to undergoing mitral valve repair surgery.
3215595|NCT01046630|Experimental|1|single infusion
3215596|NCT01046630|Active Comparator|2|single infusion
3215597|NCT01046630|Placebo Comparator|3|single infusion
3215598|NCT01046708|Experimental|micronized progesterone|
3215599|NCT01046708|No Intervention|no utrogestan|
3215600|NCT01046721|Active Comparator|Exenatide|subcutaneous administration of Exenatide (0.02ml)
3215601|NCT01046721|Placebo Comparator|0.9% Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
3215602|NCT01046734||Adult Community|
3215603|NCT01046734||Adult Hospital|
3215604|NCT01046734||Children Hospital|
3215605|NCT01046734||Children Community|
3215606|NCT01046747|Active Comparator|Pre-drill|These pins will be pre-drilled
3215607|NCT01046747|Active Comparator|No pre-drill|these pins will not be pre-drilled, but will rely on the self drilling function of the pin for insertion
3215608|NCT01046760||Rolandic Epilepsy|Patients older than seven years old with clinical and electroencephalographic diagnosis of Rolandic Epilepsy
3215609|NCT01046773|Active Comparator|Children with Crohn's disease less than 35 kg|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
3215610|NCT01046773|Active Comparator|Children with Crohn's disease 35 kg or greater|These are children ages 8 to 18 years inclusive, with mild to moderately active Crohn's disease.
3215611|NCT01046786|Active Comparator|Group A|Intraspinal injection of 1.6 million cord blood mononuclear cell
3215612|NCT01046786|Active Comparator|Group B|Intraspinal injection of 3.2 million cord blood mononuclear cell
3215613|NCT01046786|Active Comparator|Group C|Intraspinal injection of 6.4 million cord blood mononuclear cell
3215614|NCT01046786|Active Comparator|Group D|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone
3215615|NCT01046786|Active Comparator|Group E|Intraspinal injection of 6.4 million cord blood mononuclear cell plus 30 mg/kg methylprednisolone plus 6 week course of oral lithium, titrated to maintain 0.6-1.0 mM serum level
3215616|NCT01046799|Experimental|Entecavir|
3215617|NCT01046825|Other|Group A|"Completely resected stage I or completely resected abdominal stage II lesions.~Group A will include: COPAD x 2 cycles."
3215618|NCT01046825|Other|Group B|"All cases not eligible for Group A or Group C. (Murphy Stage III and non-CNS Stage IV)~Group B will include the intervention COP, COPD M3, CYM as follows:~Pre-Phase: COP~Induction: COPAD M3 x 2 cycles~Consolidation: CYM x 2 cycles."
3215619|NCT01046825|Other|Group C|"Any CNS involvement and/or bone marrow involvement ≥ 25% blasts. For CNS involvement one or more of the following applies:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal~Group C will include the intervention COP, COPADM8, CYVE as follows:~Pre-Phase: COP~Induction: COPADM8 cycle 1~Induction: COPADM8 Cycle 2~Consolidation: CYVE x 2 cycles~and Maintenance"
3215620|NCT01046838|Placebo Comparator|Placebo|placebo 3 x daily
3215621|NCT01046838|Active Comparator|sildenafil|40 mg sildenafil 3 x daily
3215622|NCT01046851|Active Comparator|Nopan|
3215623|NCT01046851|Placebo Comparator|Placebo|
3215624|NCT01046864|Experimental|Arm 1|
3215625|NCT01046864|Experimental|Arm 2|
3215626|NCT01046864|Experimental|Arm 3|Japanese Population
3215627|NCT01046890|Experimental|darunavir/ritonavir + root of Echinacea purpurea|darunavir/ritonavir + root of Echinacea purpurea
3215628|NCT01046916|Experimental|TAK-700|
3215629|NCT01046929|Experimental|limonene|
3215630|NCT01046942|Experimental|Clopidogrel+Aspirin, hypercoagulabel|
3215631|NCT01046942|Active Comparator|Aspirin,hypercoagulabel control|
3215632|NCT01046955|Active Comparator|1mg/kg Thymoglobulin|LD kidneys receiving 1mg/kg Thymoglobulin for 7 days starting at the day of surgery.
3215633|NCT01046955|Active Comparator|Campath-1H at 0.3 mg/kg|Recipients of LD kidneys receiving Campath-1H at 0.3 mg/kg once on the day of surgery and again 3 days post-operatively.
3215634|NCT01046955|Active Comparator|Zenapax 1 mg/kg|Recipients of LD kidneys receiving Zenapax 1mg/kg on the day of surgery followed by the same dose every 2 weeks for a total of 5 dosages.
3215635|NCT01046968|Experimental|Lepticore|
3215636|NCT01046981|Experimental|Tumescent Antibiotic Delivery|TAD followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours
3215637|NCT01046981|Experimental|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum and interstitial tissue fluid sampling for antibiotic concentration of subsequent 24 hours.
3215638|NCT01046994|Experimental|surgery|biliopancreatic diversion
3215639|NCT01046994|Active Comparator|standard medical care|patients treated according to the rules of good clinical practice
3215640|NCT01047020||ALL survivors|The study sample for this research will be recruited from participants in an institutionally funded cohort study, St. Jude Life, as well as from active ACT patients that meet eligibility criteria. The young adults in St. Jude Life are a highly motivated group who were followed in the After Completion of Therapy Clinic until age 18 years and a minimum of 10 years after their treatment ended if they were older than age 11 at the end of therapy
3215641|NCT01047020||Comparison Group|Potentially eligible comparison group participants will be recruited from the parent, older sibling, relative or friend population who accompany the ACT patient for follow-up at SJCRH. Parents (or siblings, relatives or friends who are 18 years or older) of children in remission, both from the active follow-up cohort (within five years of last treatment) and the After Completion of Therapy (ACT) cohort will be invited to complete the same assessments that the ALL survivor participants will complete. Comparison group participants are frequency matched to potentially eligible participants by race/ethnicity (white, black, other) age group (18 to 29, 30-39, 40-49 years) and gender.
3215642|NCT01047033|Active Comparator|Microcredit only|
3215643|NCT01047033|Experimental|Microcredit plus health education|Thirty minutes of a health education module administered to clients by loan officer at their monthly group meetings over the course of 8 months.
3215644|NCT01047046||SNM device placement|Patients who have undergone a placement of a SNM device to treat refractory OAB. A retrospective chart review will be performed on all patients who underwent a one or two-stage placement of an SNM device, which includes an implantable pulse generator (IPG), for refractory urge incontinence and urgency frequency symptoms. The patients will be those of Dr. Karen Noblett, having their device placed after 2001.
3215645|NCT01047059|Experimental|Trial Intervention|150mg Erlotinib daily, 15mg/kg b.w. Bevacizumab on d1, d22, d43 as medication FDG-PET, FLT-PET and DCE-MRI as diagnostical tools
3215646|NCT01047072|Experimental|Arm I (transplant)|Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
3215647|NCT01047072|Active Comparator|Arm II (nontransplant)|Patients receive mycophenolate mofetil PO twice daily for 16 months, rituximab IV on days 1 and 15 and then repeated at 6 months, and cyclophosphamide IV at 28-32 day intervals or orally once daily for 16 months.
3215648|NCT01047085|Active Comparator|Control group|Control group: Impedance pH measurements of healthy controls are performed to compare the results with the study group.
3215649|NCT01047085|Experimental|Study group|Study group: Pre-operative and post-operative impedance pH measurements are performed to patients in which elective cholecystectomy is planned.
3215650|NCT01047098|Experimental|Iron with meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken with meals
3215651|NCT01047098|Experimental|Iron between meals|Prenatal vitamin without iron plus capsule containing 27 mg of iron taken between meals
3215652|NCT01047098|Placebo Comparator|Placebo|Prenatal vitamin without iron plus capsule containing calcium carbonate (placebo) taken between meals
3215653|NCT01047111|Active Comparator|Ivor-Lewis Procedure|Arm A: Esophagectomy was conducted through right side thoracotomy plus midline laparotomy approach:Ivor-Lewis Procedure.
3215654|NCT01047111|Active Comparator|Sweet Procedure|Arm B: Esophagectomy was conducted through left side thoracotomy or thoracoabdominal incision: Sweet Procedure
3215655|NCT01047124|Experimental|Intervention|Specialist mood disorders team: treatment plan according to need
3215656|NCT01047124|No Intervention|Treatment as usual|
3215657|NCT01047137|Placebo Comparator|Control|Participants will meet with a psychiatry resident once a week for six consecutive weeks for general supportive therapy, which will not provide psychological stress intervention.
3215658|NCT01047137|Experimental|Intervention|Participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques.
3215659|NCT01047150||Tetrofosmin Rest patients|Patients that had a Rest myocardial perfusion study using Tc99m tetrofosmin
3215660|NCT01047150||Sestamibi stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Sestamibi
3215661|NCT01047150||Tetrofosmin stress patients|Patients that had a stress myocardial perfusion imaging study using Tc99m Tetrofosmin
3215662|NCT01047150||Sestamibi rest patients|Patients that had a rest myocardial perfusion imaging study using Tc99m Sestamibi
3215663|NCT01047163||Statin|Men aged 65-75yr on Simvastatin therapy presenting with muscle soreness
3215664|NCT01047163||Control|Men, aged 65-75yr not on Statin therapy
3215665|NCT01047176||1|Male or female > 18 year of age with indication to PCI
3215666|NCT01047202|Experimental|Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
3215667|NCT01047202|Experimental|Group 2 : 15 μg pandemic influenza A/H1N1 vaccine|120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
3215668|NCT01047202|Sham Comparator|Group 3 : 7.5 μg seasonal trivalent vaccine|60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart
3215669|NCT01047215|Active Comparator|Aripipazole|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
3215670|NCT01047215|Active Comparator|Quetiapine|Heart rate change in schizophrenic and bipolar patients under the aripipazole and quetiapine medication
3215671|NCT01047254|Active Comparator|Bupropion|Buproprion 150-300 mg in a flexible dose
3215672|NCT01047254|Placebo Comparator|placebo capsule|Placebo
3215673|NCT01047280|Placebo Comparator|Safflower oil|This arm of the study constitutes the control phase
3215674|NCT01047280|Experimental|Clarinol G-80®|
3215675|NCT01047280|Experimental|G-c9, t11|
3215676|NCT01047371||Patients with Osteoarthrosis|All consecutive patients scheduled for total hip or knee arthroplasty
3215677|NCT01047384|Experimental|Experimental|acupuncture-moxibustion therapy
3215678|NCT01047384|Active Comparator|Regular therapy|Regular therapy
3215679|NCT01047397|Experimental|Group 1|Active Drug
3215680|NCT01047397|Placebo Comparator|Group 2|Placebo
3215681|NCT01047410|No Intervention|Usual care|Patients assigned to the usual care group receive the standard medical care (usual care) during the 15 months lasting study period. Physical training does not form a part of the usual care of renal transplant and dialysis patients. After randomisation, patients assigned to the usual care group receive the advice to meet the 'Nederlandse Norm Gezond Bewegen (NNGB), i.e. the advice to perform 30 minutes of moderately intense physical activity at at least five but preferably all days of the week.
3215682|NCT01047410|Experimental|Exercise intervention|The exercise intervention in this group is identical to the exercise-only group. Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
3215683|NCT01047410|Experimental|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
3215684|NCT01047423|Experimental|Simvastatin|40mg Simvastatin once daily for 12 weeks followed by 4 week washout period followed by placebo for 12 weeks
3215685|NCT01047423|Placebo Comparator|Placebo|Placebo for 12 weeks followed by 4 week washout period followed by 40mg Simvastatin once daily for 12 weeks
3215686|NCT01047449|Active Comparator|SVG harvest - conventional, placebo|
3215687|NCT01047449|Experimental|SVG harvest - no-touch, fish oils|
3215688|NCT01047449|Placebo Comparator|SVG harvest - no-touch, placebo|
3215689|NCT01047449|Active Comparator|SVG harvest - conventional, fish oils|
3215690|NCT01047462|Active Comparator|Laparoscopic lavage|
3215691|NCT01047462|Active Comparator|Primary resection|
3215692|NCT01047488|Active Comparator|Imipramine|Imipramine tablets and placebo capsules to pregabalin
3215693|NCT01047488|Active Comparator|Pregabalin|Pregabalin capsules and placebo tablets to imipramine
3215694|NCT01047488|Experimental|Imipramine plus pregabalin|Imipramine tablets and pregabalin capsules
3215695|NCT01047488|Placebo Comparator|Placebo|Placebo tablets to imipramine and placebo capsules to pregabalin
3215696|NCT01047501|Placebo Comparator|Placebo|
3215697|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
3215698|NCT01047501|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
3215699|NCT01047514|Experimental|Online Chronic Disease Self-management|6 week, online, small group online self-management workshop
3215700|NCT01047540|Experimental|Dose regimen 1|
3215701|NCT01047540|Experimental|Dose regimen 2|
3215702|NCT01047540|Experimental|Dose regimen 3|
3215703|NCT01047540|Experimental|Dose regimen 4|
3215704|NCT01047540|Placebo Comparator|Placebo|
3215705|NCT01047566|Experimental|Addition of dronedarone|Addition of Dronedarone to existing rate control medication (beta blocker and/or calcium antagonist)
3215706|NCT01047566|Active Comparator|Dose Increase|Dose increase of existing rate control medication (beta blocker or calcium antagonist or digoxin)
3215707|NCT01047579|Other|Rivastigmine transdermal|
3215708|NCT01047592|Active Comparator|sarcosine|
3215709|NCT01047592|Active Comparator|sarcosine+ BE|
3215710|NCT01047592|Placebo Comparator|Placebo|
3215711|NCT01047605|Experimental|PP1|Neurapas balance
3215712|NCT01047605|Experimental|PP2|Pascoflair 425 mg
3215713|NCT01047605|Placebo Comparator|PL1|P-Tabletten weiß
3215714|NCT01047618||Thromboembolism|
3215715|NCT01047631|Experimental|Functional circuit training and lifestyle counseling|
3215716|NCT01047631|Active Comparator|Health education and independent walking|
3215717|NCT01047644|Experimental|3-month flushing schedule|3-month port-flushing schedule
3215718|NCT01047657|Experimental|weight loss|
3215719|NCT01047657|No Intervention|Control|
3215720|NCT01047670|Experimental|1|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
3215721|NCT01047670|Placebo Comparator|2|placebo
3215722|NCT01047683|Placebo Comparator|Placebo|
3215723|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 2 g/day|
3215724|NCT01047683|Experimental|AMR101 (ethyl icosapentate) - 4 g/day|
3215725|NCT01047696|No Intervention|Open fire|Households continuing to use an open fire for cooking and heating
3215726|NCT01047696|Experimental|Chimney stove|Households randomized to receive a chimney stove (plancha) for cooking and heating
3215727|NCT01047722|Active Comparator|Patient drinks aspirin in Gatorade.|Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
3215728|NCT01047722|Placebo Comparator|Gatorade Placebo|Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
3215729|NCT01047735|Experimental|Roux-en-Y Gastric Bypass Surgery|Roux-en-Y Gastric Bypass Surgery
3215730|NCT01047735|Experimental|Laparoscopic Adjustable Gastric Banding|Laparoscopic Adjustable Gastric Banding
3215731|NCT01047735|Experimental|Lifestyle/Behavioral Weight Loss|Lifestyle Weight Loss Intervention
3215732|NCT01047748|Active Comparator|intra-fetal injection|Subjects will receive an intra-fetal digoxin injection one day prior to their second-trimester surgical abortion
3215733|NCT01047748|Active Comparator|intra-amniotic injection|Subjects will receive an intra-amniotic digoxin injection one day prior to their second-trimester surgical abortion
3215734|NCT01047761|Experimental|exercise|Multimodal exercises that include walking, breathing exercises, dynamic balance, and core strengthening.
3215735|NCT01047774|Experimental|Soy protein|
3215736|NCT01047774|Placebo Comparator|Milk protein|
3215737|NCT01047787||CHF Patients|Congestive Heart Failure Patients
3215738|NCT01047800|Experimental|Counseling group|Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician
3215739|NCT01047800|No Intervention|Control|Usual management in GI specialty clinic
3215740|NCT01047813||Type 2 diabetes|This group contains 25 participants with type 2 diabetes
3215741|NCT01047813||control group|This group contains 25 participants withput type 2 diabetes. The control group is matched with age, education and lifestyle to the diabetes group.
3215742|NCT01047826|Experimental|M.I.P.O. Group|subjects who have been randomized to the M.I.P.O. group
3215743|NCT01047826|Experimental|Intramedullary Nail group|Subjects who have been Randomized to the I.M. group
3215744|NCT01047852|Experimental|NIV|
3215745|NCT01047852|No Intervention|Control|
3215746|NCT01047865||pancreas-kidney transplant|pancreas-kidney transplant recipients with type 1 diabetes.
3215747|NCT01047891|Experimental|Experimental|
3215748|NCT01047904|Experimental|Iontophoresis-treated|Healthy volunteers will evaluate reliability and performance of Iontophoresis System in delivery of local anesthesia to the TM.
3215749|NCT01047917|Experimental|Meditation DVD|All participants will receive a Meditation DVD to practice at home daily for a total of 4 weeks.
3215750|NCT01047930|Other|AM-Ex; PM-Ex; C|within subject design, with each participant receiving all three conditions
3215751|NCT01047943|Experimental|Psoriasis therapy|
3215752|NCT01047956|Experimental|MethNAC|Methadone and N-acetylcysteine for opioids abstaining
3215753|NCT01047956|Active Comparator|Methadone|Methadone alone
3215754|NCT01047982|Active Comparator|myo-inositol|
3215755|NCT01047982|Placebo Comparator|placebo|acid folic 400 mcg twice per day
3215756|NCT01047995|Active Comparator|Group 1|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
3215757|NCT01047995|Active Comparator|Group 2|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2,~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
3215758|NCT01048008|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
3215759|NCT01048021||Supraclavicular Block|
3215760|NCT01048034|Experimental|Azacitidine +/- erythropoetin|
3215761|NCT01048047|Experimental|aliskiren/amlodipine|aliskiren, 300 mg/amlodipine 10 mg
3215762|NCT01048047|Active Comparator|amlodipine|amlodipine 10 mg
3215763|NCT01048086|Experimental|Retinoic Acid|
3215764|NCT01048086|Placebo Comparator|Placebo|
3215765|NCT01048112|Experimental|Repeated dose group|Will receive one dose of Campylobacter jejuni strain CG8421 at day 0 and a second dose at approximately day 98.
3215766|NCT01048112|Active Comparator|Single dose group|Will receive one dose of Campylobacter jejuni strain CG8421
3215767|NCT01048138|Experimental|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
3215768|NCT01048138|Placebo Comparator|Placebo|5mg IV(in the vein)every 6 hours for 10 days
3215769|NCT01048151|Experimental|Single|TNFerade™ Biologic + Radiation
3215770|NCT01048164|Active Comparator|10 Massages|This group consists of individuals that wear lead aprons, and they will receive ten, 30-minute scheduled massage appointments during the hours the participant is working in the cardiac lab, over a 10 week period.
3215771|NCT01048164|Active Comparator|5 Massages|This group consists of individuals that wear lead aprons, and they will receive five, 30-minute scheduled massage appointments, during the hours the participant is working in the cardiac lab, over a 5 week period. This arm will not receive massages for the first 5 weeks and then will receive their massages during the second 5 week period.
3215772|NCT01048164|No Intervention|Control Group|This group will consist of those individuals that wear lead aprons with no desire to participate in the massage study yet are willing to provide information through questionnaires. They will be given the same questionnaire as those in the two massage therapy arms of the study, at the beginning, middle, and end of study.
3215773|NCT01048177|Experimental|Treatment|
3215774|NCT01048190|Experimental|Infants I-1|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains). Group I-1: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
3215775|NCT01048190|Experimental|Infants I-2|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
3215776|NCT01048190|Experimental|Infant I-3|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
3215777|NCT01048203|Experimental|ABR-215050|
3215778|NCT01048229|Experimental|Rasagiline|
3215779|NCT01048229|Active Comparator|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
3215780|NCT01048255|Experimental|VX-765|
3215781|NCT01048268|Experimental|Healthy volunteers|
3215782|NCT01048268|Experimental|Patients with Type 1 diabetes mellitus|
3215783|NCT01048268|Experimental|Patients with type 2 diabetes mellitus|
3215784|NCT01048294|Active Comparator|Standard Light Treatment|30 min of Standard bright light treatment (color 5000K)
3215785|NCT01048294|Experimental|Blue enriched Light treatment 20 min|20 minutes of Blue enriched light treatment (color 17000K)
3215786|NCT01048294|Experimental|Blue enriched light treatment 30 min|30 minutes of Blue enriched light treatment (color 17000K)
3215787|NCT01048307|Experimental|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system)."
3215788|NCT01048307|Placebo Comparator|Saline irrigation (standard care control)|"Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
3215789|NCT01048320|Other|Treatment|Gemcitabine plus Oxaliplatin in combination with imatinib mesylate
3215790|NCT01048346|Experimental|supported employment|Study consists of one experimental group and one control group. The intervention group received IPS
3215791|NCT01048359|Experimental|Brief Intervention|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk.
3215792|NCT01048359|Active Comparator|Brief advice|This condition of the experiment acts a control and will be a short session in which the therapist will provide brief advice about drug use and give the patient a pamphlet.
3215793|NCT01048359|Experimental|Brief Intervention plus Booster|30-45 minute motivational interviewing based intervention with feedback addressing drug use, injury prevention and HIV risk plus a brief phone booster session at 1 month post-intake to review feedback, 2) assess progress, 2) renew motivation to change, and 3) evaluate and affirm commitment to change.
3215794|NCT01048372||Early HIV infection|HIV infected adults with early evidence of suppressed cell-mediated immunity but whose disease has not progressed far enough to indicate antiretroviral therapy.
3215795|NCT01048372||Control|Healthy adults without HIV infection.
3215796|NCT01048385|Experimental|CoQ10|This group will be treated concomitantly with Coenzyme Q10
3215797|NCT01048385|Placebo Comparator|Control|Treated with capsules containing the vehicle.
3215798|NCT01048398|Experimental|Remifentanil|
3215799|NCT01048398|Active Comparator|Paracetamol|intravenous paracetamol 1g
3215800|NCT01048411|Active Comparator|Naja-comp.|s.c. injection of naja comp (homeopathic remedy) three times a week
3215801|NCT01048411|Placebo Comparator|Placebo|s.c. injection of placebo (NaCl-solution) three times a week
3215802|NCT01048437|No Intervention|Standard transplant education|Missouri Kidney Program's standard Patient Education Program (PEP) transplant module.
3215803|NCT01048437|Experimental|Transplant education with video|Explore Transplant transplant module featuring video
3215804|NCT01048437|Experimental|Transplant education with speakers|Explore Transplant transplant module featuring live guest speakers.
3215805|NCT01048450|Experimental|Treatment|Those who were diagnosed with hallux limitus/rigidus (end stage degeneration at the 1st metatarsal phalangeal joint)
3215806|NCT01048463|Placebo Comparator|EN|The subjects take in 150g of Nutriall per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d. During the test period patients are treated with the first course of XELOX.
3215807|NCT01048463|Experimental|ENLDEPA|The subjects take in the same dose of Nutriall for the same duration as those in EN group. In addition, they take in 3 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
3215808|NCT01048463|Experimental|ENHDPEA|The subjects take in the same dose of supportan for the same duration as those in EN group. In addition, they take in 6 grams of EPA per day during the 21 days of treatment. The patients are treated with the first course of XELOX.
3215809|NCT01048476|Active Comparator|Group L20|Dietary Supplement: 20mg Lutein; daily supplementation one year
3215810|NCT01048476|Active Comparator|Group L10|Dietary Supplement: 10mg Lutein; daily supplementation one year
3215811|NCT01048476|Placebo Comparator|Group Placebo|Dietary Supplement: Placebo, 0 mg Lutein
3215812|NCT01048476|Active Comparator|Active Comparator: Group LZ|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
3215813|NCT01048489|Other|Lifestyle counseling|
3215814|NCT01048489|No Intervention|No counseling|
3215815|NCT01048515|Experimental|Caffeine|
3215816|NCT01048515|Placebo Comparator|Placebo|
3215817|NCT01048528|Experimental|Stress Management|Stress Management and Relaxation Training workshops
3215818|NCT01048528|No Intervention|Wait-list|Wait-list comparison group
3215819|NCT01048554|Other|Temozolomide/Bevacizumab|Patients will be treated with a combination of temozolomide at 75 mg/m2/day for six continuous weeks, followed by a two-week rest period and bevacizumab 10 mg/kg every 2 weeks without interruption. Cycles will be repeated every 8 weeks. Patients will be restaged every 8 weeks.
3215820|NCT01048567|Active Comparator|Lactobacillus acidophilus/rhamnosus|
3215821|NCT01048567|Placebo Comparator|Placebo|
3215822|NCT01048580|Experimental|Perifosine +Capecitabine|One cycle of therapy will be defined as 3 weeks (21 days). Perifosine 50 mg qd (Days 1-21) + Capecitabine 1000 mg/m2 BID (Days 1-14).
3215823|NCT01048619|Experimental|ON 01910.Na|The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
3215824|NCT01048632|Experimental|Oxandrolone|Following clinical evaluation, all patients will be receive oxandrolone in addition to their usual medications. Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
3215825|NCT01048645|Placebo Comparator|P/PC arm|Patients were assigned to receive placebo (P/PC) 1 week prior to treatment until completing two cycles
3215826|NCT01048645|Experimental|RA/PC arm|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two cycles
3215827|NCT01048684|Active Comparator|20% Mannitol 0.7 g/kg (low-dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 0.7g/kg over 30 minutes after induction of general anesthesia.
3215828|NCT01048684|Experimental|20% Mannitol 1.4 g/kg (high dose)|Study subjects will be randomized to receive an infusion of 20% mannitol 1.4 g/kg over 30 minutes after induction of general anesthesia.
3215829|NCT01048710||Tomofix_small|Surgical treatment using TomoFix TM Small
3215830|NCT01048710||Conservative treatment|"In the control group, patients who refused to have surgery will be allowed to be treated using different options of conservative treatment. The frequency of applications depends on the hospital and will therefore be documented in the study. An arthroscopy is not obligatory under this treatment group, but is permitted.~The following conservative treatment methods are allowed:~Physical therapy~Specific exercises for the muscles~Injections into the knee joint~Brace~Medication~No therapy"
3215831|NCT01048736|Active Comparator|Exercise|All treatment groups will receive 4d/wk of exercise
3215832|NCT01048736|Experimental|Exercise + Diet (-250 kcal/d deficit)|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss),
3215833|NCT01048736|Experimental|Exercise + Diet (-600 kcal/d deficit)|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
3215834|NCT01048749|Active Comparator|aquatic vertical supsension|Spinal height measurement using a stadiometer following aquatic vertical suspension
3215835|NCT01048749|Active Comparator|land-based supine flexion condition|Spine height will be measured with a stadiometer following completion of the supine land-based flexion position.
3215836|NCT01048762|Active Comparator|supervised exercise training|Intervention: supervised exercise training and dyspnea counseling in groups for 10 weeks Instruction on home based exercise training
3215837|NCT01048762|Sham Comparator|one instruction on homebased exercises|One instruction on home based exercise training and dyspnea management
3215838|NCT01048801|Active Comparator|Rapid diagnostic test and treatment|
3215839|NCT01048801|Other|Treatment without rapid daignostic test|
3215840|NCT01048814||Ovarian, Peritoneal, Fallopian Cancer|Recurrent, Peristent or Refractory
3215841|NCT01048827|Experimental|experimental|dose-escalation Busulfan
3215842|NCT01048840||Subject with History of GERD|Children and adolescents ages 12-17 years, inclusive, seen at Children's Hospital, Boston or Massachusetts General Hospital between 1977 and 1990 for symptoms of GERD and also had biopsies and / or a pH probe that was positive for GERD.
3215843|NCT01048840||Controls with out GERD|Individuals that do not have a history of GERD or other GI problems prior to age 21 and whose date of birth are with in a year of a subjects
3215844|NCT01048853|Experimental|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
3215845|NCT01048892|Experimental|Treatment (NTX-010)|
3215846|NCT01048918||No Treatment|
3215847|NCT01048931|Experimental|single-port LAVH|single port LAVH
3215848|NCT01048970|Other|Control arm|Patients will receive nutritional assessment one week prior to treatment until completing two cycles
3215849|NCT01048970|Experimental|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
3215850|NCT01048983|Other|Questionnaires and Phone Calls|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
3215851|NCT01048983|Active Comparator|Curcumin Only|
3215852|NCT01048983|Active Comparator|Armodafinil Only|
3215853|NCT01048983|Active Comparator|Minocycline Only|
3215854|NCT01048983|Active Comparator|Bupropion Only|
3215855|NCT01048983|Active Comparator|Curcumin + Armodafinil|
3215856|NCT01048983|Active Comparator|Curcumin + Minocycline|
3215857|NCT01048983|Active Comparator|Curcumin + Bupropion|
3215858|NCT01048983|Active Comparator|Armodafinil + Minocycline|
3215859|NCT01048983|Active Comparator|Armodafinil + Bupropion|
3215860|NCT01048983|Active Comparator|Minocycline + Buproprion|
3215861|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline|
3215862|NCT01048983|Active Comparator|Curcumin + Armodafinil + Bupropion|
3215863|NCT01048983|Active Comparator|Curcumin + Minocycline + Bupropion|
3215864|NCT01048983|Active Comparator|Armodafinil + Minocycline + Bupropion|
3215865|NCT01048983|Active Comparator|Curcumin + Armodafinil + Minocycline + Bupropion|
3215866|NCT01048996||Non ALI/ARDS|Those patient who enrolled in the study but did not develop ALI or ARDS during their hospital course.
3215867|NCT01048996||ALI/ARDS|Those patients who enrolled in the study and developed ALI or ARDS during their hospital course.
3215868|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 1|
3215869|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 2|
3215870|NCT01049022|Experimental|Moxifloxacin (Avelox, BAY12-8039), Cohort 3|
3215871|NCT01049035|Experimental|Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein (MenACYW) Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 12 along with Prevnar 7 or Prevnar 13 vaccine at the age of Months 2, 4, 6, and 12, Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, and M-M-RII and VARIVAX vaccines at the age of 12 months.
3215872|NCT01049035|Experimental|Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4, 6, and a booster vaccination at the age of Month 15 along with Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
3215873|NCT01049035|Experimental|Group 3: MenACYW Conjugate Vaccine: 2, 4, and 12 Months|Participants aged 2 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Months 2, 4 and a booster vaccination at the age of Month 12 along with Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, M-M-RII and VARIVAX vaccines at the age of Month 12, and Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12.
3215874|NCT01049035|Experimental|Group 4: MenACYW Conjugate Vaccine: 6 and 12 Months|Participants aged 6 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of Month 6 along with Pentacel, Prevnar 7 or 13, Hepatitis-B and Rotavirus vaccines, and a booster vaccination of MenACYW at the age of Month 12 along with M-M-RII and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2 and 4, and Hepatitis-B vaccine at the age of Month 2.
3215875|NCT01049035|Experimental|Group 5: MenACYW Conjugate Vaccine: Month 12|Participants aged 12 months (at the time of enrollment) received MenACYW Conjugate vaccine at the age of 12 months along with Prevnar 7 or 13, M-M-RII, and VARIVAX vaccines. Before enrollment, participants were vaccinated with Pentacel, Prevnar, and Rotavirus vaccines at the age of Months 2, 4, and 6, and Hepatitis-B vaccine at the age of Months 2 and 6.
3215876|NCT01049035|Other|Group 6: Control: 2, 4, 6, and 12 Months|Participants aged 2 months (at the time of enrollment) received Pentacel and Rotavirus vaccines at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12 and M-M-RII and VARIVAX vaccines at the age of 12 months.
3215877|NCT01049035|Other|Group 7: Control: 2, 4, 6, 12, and 15 Months|Participants aged 2 months (at the time of enrollment) received Rotavirus vaccine at the age of Months 2, 4, and 6, Hepatitis-B vaccine at the age of Months 2 and 6, Prevnar 7 or 13 vaccine at the age of Months 2, 4, 6, and 12, and M-M-RII and VARIVAX vaccines at the age of 12 months, and Pentacel vaccine at the age of Months 2, 4, 6, and 15.
3215878|NCT01049048|Placebo Comparator|Control|This group receives placebo chocolate cookies with no vitamin D3 added.
3215879|NCT01049048|Experimental|Vitamin D3|This group receives 2500 IU of Vitamin D3 added to a chocolate cookie daily.
3215880|NCT01049061|Experimental|MORAb-003|
3215881|NCT01049074|Experimental|Verus acupuncture|
3215882|NCT01049074|Sham Comparator|Sham acupuncture|
3215883|NCT01049100|Experimental|operative staging (A)|operative staging and systemic lymphadenectomy, paraaortal and pelvine, laparoscopic or open
3215884|NCT01049100|No Intervention|Standard (B)|No surgical intervention. Clinical Staging (FIGO) CT Abdomen / pelvic enlarged or suspicious lymphnodes--> CT controlled biopsy and histological analysis.
3215885|NCT01049113|Experimental|ON 013105|ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.
3215886|NCT01049126||Late stage endometrial cancer|
3215887|NCT01049139|No Intervention|No Supplemental Information|Participants will be administered a standard HIV vaccine trial consent form but no additional information.
3215888|NCT01049139|Experimental|Supplemental information with 1-sided message|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
3215889|NCT01049139|Experimental|Supplemental information with 2-sided messages|Participants will be administered a standard HIV vaccine trial consent form and supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
3215890|NCT01049152||nondiabetic patients|nondiabetic patients with ESRD undergone hemodialysis
3215891|NCT01049152||diabetic patients|diabetic patients with ESRD undergone hemodialysis
3215892|NCT01049165|Active Comparator|Arm 1 (BMS-813160 or placebo)|
3215893|NCT01049165|Active Comparator|Arm 2 (BMS-813160 or placebo)|
3215894|NCT01049165|Active Comparator|Arm 3 (BMS-813160 or placebo)|
3215895|NCT01049165|Active Comparator|Arm 4 (BMS-813160 or placebo)|
3215896|NCT01049165|Active Comparator|Arm 5 (BMS-813160 or placebo)|
3215897|NCT01049165|Active Comparator|Arm 6 (BMS-813160 or placebo)|
3215898|NCT01049165|Active Comparator|Arm 7 [14C] BMS-813160|
3215899|NCT01049165|Active Comparator|Arm 8 (BMS-813160 or placebo)|
3215900|NCT01049165|Active Comparator|Arm 9 (BMS-813160 or placebo)|
3215901|NCT01049178|Experimental|Oral silymarin dose|Dose escalation study
3215902|NCT01049178|Placebo Comparator|placebo|A randomized, double-masked, placebo-controlled cross-over clinical pilot investigation of an inducer of endogenous antioxidant enzymes, silymarin, in humans with atopic asthma.
3215903|NCT01049191||Fracture|Subjects experiencing a prior osteoporotic fracture.
3215904|NCT01049191||Control|These will be age and bone density matched controls to the fracture group.
3215905|NCT01049204|Active Comparator|Group 1|Nadir CD4 count >200 cells/µl blood and randomised to Maraviroc 150mg BD
3215906|NCT01049204|Placebo Comparator|Group 2|Nadir CD4 count >200 cells/µl blood and randomised to placebo twice daily for 24 weeks
3215907|NCT01049204|Active Comparator|Group 3|Nadir CD4 count ≤200 cells/µl blood and randomised to Maraviroc 150mg BD
3215908|NCT01049204|Placebo Comparator|Group 4|Nadir CD4 count ≤200 cells/µl blood and randomised to placebo twice daily for 24 weeks
3215909|NCT01049230|Experimental|Proton beam radiation|Radiation therapy with proton beam
3215910|NCT01049269||1:one group|
3215911|NCT01049282|Experimental|12 TST negative volunteers antigen only|
3215912|NCT01049282|Experimental|12 TST negative volunteers|
3215913|NCT01049282|Experimental|12 BCG vaccinated volunteers|
3215914|NCT01049282|Experimental|12 with Latent TB infection >= 2 years ago|
3215915|NCT01049295|Experimental|oil fish pearls|patients with invasive breast cancer who received 640 mg oil fish pearls 3 times a day
3215916|NCT01049295|Placebo Comparator|placebo|patient with invasive breast cancer who received corn oil pearls as placebo 3 times a day
3215917|NCT01049321|Experimental|DASH diet|DASH: Dietary approaches to stop hypertension eating plan
3215918|NCT01049321|Placebo Comparator|Diabetic diet|Diabetic diet: a usual diabetic diet
3215919|NCT01049347|Active Comparator|amitriptyline|
3215920|NCT01049347|Active Comparator|paroxetine|
3215921|NCT01049386|Active Comparator|Sugar absorption test|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine.
3215922|NCT01049386|Experimental|Sugar absorption test and high-fat breakfast|In 150 mL of water four different sugars will be dissolved. Absorption will be calculated based on concentrations of sugars in 0-5 hours urine and 0-24 h collected urine. Subjects will eat a high-fat breakfast together with the sugar drink, to investigate the disturbance caused by fat in intestinal absorption.
3215923|NCT01049399|Placebo Comparator|Placebo|once daily administration of powder for oral suspension.
3215924|NCT01049399|Experimental|NP031112 800 mg|Group dosed with 800 mg once daily for 52 weeks
3215925|NCT01049399|Experimental|NP031112 600 mg|Group treated with 600 mg once daily for 52 weeks
3215926|NCT01049425|Active Comparator|Epirubicin and Cyclophosphamid followed by Docetaxel|4 cycles of EC on day one every three weeks followed by 4 cycles of Docetaxel on day one every three weeks
3215927|NCT01049425|Experimental|Combination of Docetaxel and Cyclophosphamid|intravenous infusion on day one every three weeks
3215928|NCT01049438|Experimental|Nasal, body, and systemic decolonization|
3215929|NCT01049451|Experimental|ACTH IM monthly|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
3215930|NCT01049451|Active Comparator|MP IV monthly|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months.
3215931|NCT01049464|Placebo Comparator|5%D/W|The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.
3215932|NCT01049464|Experimental|Magnesium sulphate|The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours
3215933|NCT01049477|Experimental|Music therapy|Experimental arm includes women undergoing cesarean section delivery listening to music before and after c/s. STAI will be completed pre and post operatively.
3215934|NCT01049477|No Intervention|No music group|Subjects will not listen to music before and after c/s. STAI will be completed pre and post operatively.
3215935|NCT01049490|Active Comparator|Intramuscular|15 mcg H1N1 vaccine delivered via intramuscular injection (control)
3215936|NCT01049490|Active Comparator|Intradermal|Intradermal: H1N1 vaccine delivered via intradermal injection: Experimental
3215937|NCT01049516|Other|Minimal Contact Control|
3215938|NCT01049516|Experimental|PE-Massed|
3215939|NCT01049516|Active Comparator|PE-Spaced|
3215940|NCT01049516|Active Comparator|Present-Centered Therapy (PCT)|
3215941|NCT01049529|Placebo Comparator|Placebo group|This group is receiving sunflower oil (the excipient for DHA)
3215942|NCT01049529|Active Comparator|DHA group|This group is receiving the docosahexaenoic acid (DHA) supplement
3215943|NCT01049542|Experimental|Astressin 2B|Healthy volunteers will receive incremental doses of intra arterial Astressin 2B (a selective and potent Urocortin 2 & 3 antagonist). This serves as a dose finding Protocol for Astressin 2B, which will be used in subsequent protocols.
3215944|NCT01049555|Other|Alzheimer and apathy|Alzheimer's disease patients with apathy
3215945|NCT01049555|Other|alzheimer without disease|Alzheimer's disease patients without apathy
3215946|NCT01049555|Other|Case control|subject without apathy neither Alzheimer's disease
3215947|NCT01049568|Experimental|Cell Phone Intervention|
3215948|NCT01049568|No Intervention|Control|"Control group participants will participate in all on-study evaluations, except the intervention exit interviews.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
3215949|NCT01049594||Preterm infants|Delivery at less than 33 completed weeks of gestation
3215950|NCT01049607|Active Comparator|Clamp-Crush technique|
3215951|NCT01049607|Experimental|Stapler hepatectomy|
3215952|NCT01049620|Experimental|Xelox+RAD001|
3215953|NCT01049646|Active Comparator|Angiotensin II|
3215954|NCT01049646|Placebo Comparator|Saline infusion|
3215955|NCT01049659|Other|neuropsychological tests|neuropsychological assessment of children around their second birthday
3215956|NCT01049672|Active Comparator|Alfentanil|Hospice in-patients who require subcutaneous strong opioid administration will be given alfentanil
3215957|NCT01049672|Active Comparator|Diamorphine|Hospice in-patients who require strong opioids will be given diamorphine
3215958|NCT01049685|Active Comparator|Efavirenz Group|Naïve-treatment HIV patients, who started therapy with Efavirenz
3215959|NCT01049685|Active Comparator|Lopinavir/r Group|Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir
3215960|NCT01049698|Active Comparator|1. Resistance Training|3 d/wk resistance training
3215961|NCT01049698|Experimental|2. Resistance Training + Diet|Resistance training plus caloric restriction
3215962|NCT01049711||erythropoietin|
3215963|NCT01049724||PRK|Those patients undergoing photorefractive keratectomy
3215964|NCT01049724||LASIK|Those undergoing Laser-assisted insitu keratomileusis
3215965|NCT01049750||type 2 diabetic patients|males; type 2 diabetic patients
3215966|NCT01049763|Experimental|Regimen A|oseltamivir 75 mg single dose
3215967|NCT01049763|Active Comparator|Regimen B|oseltamivir 150 mg single dose
3215968|NCT01049789|Active Comparator|TAU|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement TAU will receive that treatment method.
3215969|NCT01049789|Experimental|COMB|Sites participating in Phase I and Phase II will be randomized to implement this treatment method or the other treatment method. All ATN 080 participants at a site randomized to implement COMB will receive that treatment method.
3215970|NCT01049815|Experimental|Sevelamer hydrochloride|
3215971|NCT01049815|Active Comparator|Calcium carbonate|
3215972|NCT01049828||Slightly or Non-Bothered Tinnitus Group|
3215973|NCT01049841|Experimental|perifosine + temsirolimus|This is a single arm, phase I study. Eligible patients will receive a loading dose of oral perifosine on the first day, followed by a maintenance dose starting on the second day until progression. Each patient is assigned to a group according to their body surface area (BSA). Temsirolimus will be combined with perifosine at four dose levels to determine the MTD for the combination therapy. Temsirolimus dosing will start on the same day as the perifosine load.
3215974|NCT01049854|Experimental|Thiotepa/Cyclophosphamide/ATG|Full intensity with TBI
3215975|NCT01049854|Experimental|Busulfan/Melphalan/ATG|Full intensity without TBI
3215976|NCT01049854|Experimental|Busulfan/Fludarabine/Alemtuzumab|Reduced Intensity Chemotherapy
3215977|NCT01049854|Experimental|Fludarabine/Cyclophosphamide/ATG|Reduced Intensity Chemotherapy for Fanconi Anemia
3215978|NCT01049880|Experimental|Ascorbate|
3215979|NCT01049893|Experimental|AC220|Dose finding study. Number of arms dependant upon dose limiting toxicities.
3215980|NCT01049906|Active Comparator|Nerve stimulation and Ultrasound|
3215981|NCT01049906|Active Comparator|Ultrasound without nerve stimulation|
3215982|NCT01049932|Experimental|All subjects|TMC278LA 600mg injected intramuscularly (i/m)
3215983|NCT01049971|Active Comparator|no wound protector|instead of wound protector, a woven drape is applied
3215984|NCT01049971|Experimental|wound protector|after minilaparotomy, wound protector is applied
3215985|NCT01049997||NSTEMI75+|Patients, 75 years old or older, with Non ST Elevation Myocardial Infarction (NSTEMI)
3215986|NCT01050010|Other|Dedicated extremity MRI|Structural deterioration radiographic assessed by dedicated extremity MRI
3215987|NCT01050023|Experimental|1 - Active Treatment|Provant device activated to emit RF energy
3215988|NCT01050023|Sham Comparator|2 - Inactive Treatment|Provant device not activated to emit RF energy
3215989|NCT01050036|Experimental|HCT recipients|"Patient with CBF AML will be eligible in his/her 1st complete remission (CR1) status. Patients who have relapsed or have achieved 2nd complete remission should not be included in this study.~1st postremission therapy after CR1 will be performed with high-dose cytarabine (HDAC) chemotherapy, consisting of intravenous cytarabine 3 g/m2 infusion during 3 hours twice a day on days 1, 3, and 5.~After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information."
3215990|NCT01050049||Before guidelines implemented|
3215991|NCT01050049||After guidelines implemented|
3215992|NCT01050075|Experimental|Arm I|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
3215993|NCT01050075|Experimental|Arm II|Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.
3215994|NCT01050088|Experimental|Sucrose|5cc sucrose solution
3215995|NCT01050088|Placebo Comparator|Saline|5cc saline p/o
3215996|NCT01050101|Placebo Comparator|High GI low fiber meal|No fiber control meal
3215997|NCT01050101|Active Comparator|Low GI high fiber viscous meal|80:20 ratio of viscous polysaccharide fiber to insoluble non-viscous producing fiber
3215998|NCT01050101|Active Comparator|Low GI high fiber non-viscous meal|20:80 ratio of viscous polysaccharide fiber source to insoluble non-viscous producing fiber
3215999|NCT01050114|Other|ARM 1: onaBoNT-A injection + placebo|onaBoNT-A 200 U (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and placebo oral capsule daily
3216000|NCT01050114|Other|ARM 2: Placebo injection + oxybutynin ER|Placebo injection (treatment 1)/ onaBoNT-A 200 U (treatment 2)/ onaBoNT-A 200 U (treatment 3) and oxybutynin ER 10 mg capsule daily
3216001|NCT01050127|Experimental|Low dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
3216002|NCT01050127|Experimental|Mid Dose ABT-436|ABT-436 or placebo administered once daily for 7 days.
3216003|NCT01050127|Experimental|High Dose ABT-436|ABT-436 or placebo administered once daily for 14 days.
3216004|NCT01050140|Experimental|fructose|25% dietary energy from fructose
3216005|NCT01050140|Active Comparator|glucose|25% dietary energy from glucose
3216006|NCT01050166||Labeled islets|Type 1 diabetic recipients after islet transplantation with islets labeled by iron contrast agent
3216007|NCT01050244|Experimental|Soy Protein|30g of soy protein from whole soybean soymilk powder given daily for 3 weeks
3216008|NCT01050244|Placebo Comparator|Milk Protein|30g of milk protein from whole milk powder given daily for 3 weeks
3216009|NCT01050270|Other|Ondansetron /acetylcysteine 20.25h|Ondansetron followed by conventional acetylcysteine regimen
3216010|NCT01050270|Other|Placebo/acetylcysteine 20.25h|placebo followed by conventional acetylcysteine regimen
3216011|NCT01050270|Other|Ondansetron/acetylcysteine 12h|ondansetron followed by modified acetylcysteine regimen
3216012|NCT01050270|Other|Placebo/acetylcysteine 12h|placebo followed by modified acetylcysteine regimen
3216013|NCT01050283|Experimental|1|[18F]-FDG-PET/CT (Computed Tomography) Imaging
3216014|NCT01050309|Active Comparator|Cervix|
3216015|NCT01050309|Active Comparator|colon|
3216016|NCT01050309|Active Comparator|Intravenous|
3216017|NCT01050322|Active Comparator|Capecitabine Lapatinib|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3216018|NCT01050322|Experimental|Vinorelbine Lapatinib|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3216019|NCT01050322|Experimental|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
3216020|NCT01050335||Surgical resident or attending|
3216021|NCT01050348|Active Comparator|Atorvastatin calcium|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
3216022|NCT01050348|Placebo Comparator|Sugar Pill|Patients will receive study medication upon admission to hospital prior to percutaneous intervention of the culprit artery
3216023|NCT01050361|Experimental|EGHEM|The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.
3216024|NCT01050361|No Intervention|SHEM|"The control group will be~called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution."
3216025|NCT01050374|Placebo Comparator|1|albendazole + praziquantel
3216026|NCT01050374|Active Comparator|2|mebendazole + praziquantel
3216027|NCT01050400||Observant|Individuals within this group will receive pharmacotherapy according to the established institutional guidelines.
3216028|NCT01050400||Prospective CYP2D6 genetic screening|Individuals within the prospective group will receive their CYP2D6 genotype results prior to pharmacotherapy and their analgesic regimen will be tailored to their genetic results.
3216029|NCT01050413||1|colon cancer, prostate cancer, lung cancer, ovarian cancer
3216030|NCT01050426|Active Comparator|Group 1|UFT/LV + RT
3216031|NCT01050426|Active Comparator|Group 2|UFT/LV + RT + Cetuximab
3216032|NCT01050439|Experimental|UDAlloSCT + Therapy|This is a non-randomized study to test the safety and response of unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT) with either myleoablative (full intensity) or reduced intensity conditioning therapy in patients with selected malignant and non-malignant disorders. UDAlloSCT has been performed in both adults and children as an alternative transplant for patients who lack and HLA-matched family donor in both malignant and non-malignant disease with varying degrees of response.
3216033|NCT01050452|Placebo Comparator|1|albendazole treatment
3216034|NCT01050452|Active Comparator|2|mebendazole treatment
3216035|NCT01050452|Active Comparator|3|ivermectin treatment
3216036|NCT01050452|Active Comparator|4|albendazole + ivermectin treatment
3216037|NCT01050452|Active Comparator|5|mebendazole + ivermectin treatment
3216038|NCT01050465|Active Comparator|email|Patients randomized to this arm will receive an email health information prescription.
3216039|NCT01050465|Active Comparator|paper|Patients randomized to this arm will receive a paper health information prescription.
3216040|NCT01050478|Experimental|Paliperidone ER|Paliperidone ER: recommended dose: 6 mg/day. Can be 9 mg/day for patients with an acute exacerbation of schizophrenia. A benzodiazepine for sedation and/or rescue medication can be added with a maximum of 7.5 mg/day, at the investigators' discretion.
3216041|NCT01050491|Placebo Comparator|sitaxsentan, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
3216042|NCT01050491|Placebo Comparator|placebo, airway remodeling|Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
3216044|NCT01050517|Active Comparator|1|albendazole + ivermectin + praziquantel
3216045|NCT01050517|Placebo Comparator|2|albendazole + ivermectin + (1 week later) praziquantel
3216046|NCT01050556|Placebo Comparator|Placebo|Placebo daily
3216047|NCT01050556|Experimental|Folic Acid 400 ug|400 µg folic acid daily
3216048|NCT01050556|Experimental|Folic Acid 800 ug|800 µg folic acid daily
3216049|NCT01050556|Experimental|Creatine|creatine daily
3216050|NCT01050556|Experimental|Creatine + Folic Acid|creatine + folic acid daily
3216051|NCT01050595|Active Comparator|Methylnaltrexone Bromide|
3216052|NCT01050595|Placebo Comparator|Placebo|
3216053|NCT01050608||Sprixx Device Group|Treatment group utilizing multimodal hand hygiene device
3216054|NCT01050608||Standard Hand Hygiene Group|Utilizing wall mounted dispensers and CDC based guidelines.
3216055|NCT01050686|Active Comparator|subcutaneous wound drain|subcutaneous wound drain inserted
3216056|NCT01050686|Experimental|no subcutaneous wound drain|no subcutaneous wound drain inserted
3216057|NCT01050699|Experimental|Dexmedetomidine|Dexmedetomidine plus saline
3216058|NCT01050699|Active Comparator|Usual Care|Midazolam and Fentanyl
3216059|NCT01050712|Experimental|Carbon Monoxide|
3216060|NCT01050712|Placebo Comparator|Synthetic Air|
3216061|NCT01050725||Radiation therapy patients|Individuals receiving radiation therapy as definitive or neo-adjuvant therapy for selected malignancies, including head and neck, lung, esophageal, rectal cervical and prostate cancers.
3216062|NCT01050738|Active Comparator|Intracapsulare position|
3216063|NCT01050738|Active Comparator|Extracapsulare position|
3216064|NCT01050751|Experimental|Lersivirine (new formulation)|
3216065|NCT01050751|Active Comparator|Lersivirine (old formulation)|
3216066|NCT01050777|Experimental|Liposomal Paromomycin|Liposomes containing 10% Paromomycin
3216067|NCT01050777|Experimental|Liposomal meglumine antimoniate|Liposomes containing meglumine antimonate
3216068|NCT01050777|Placebo Comparator|Placebo|
3216069|NCT01050803|Experimental|FDSME group|In the FDSME group, sessions will be held interactive; and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions.
3216070|NCT01050803|Active Comparator|Control group|
3216071|NCT01050829|Experimental|Arm 1|
3216072|NCT01050829|Active Comparator|Arm 2|
3216073|NCT01050842|Experimental|Arm I|Patients receive oral bicalutamide and oral raloxifene on days 1-28.
3216074|NCT01050855|Experimental|RIC: Distal Campath|"Day Treatment~Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) (subcutaneously) over 2 hours~Day - 21 to-19 Alemtuzumab IV/ SQ (subcutaneously)~Day - 7 to -3 Readmission to hospital Fludarabine IV~Day - 2 Melphalan IV~Day - 1 Begin cyclosporine infusion~Day 0 Transplant: Bone marrow or cord blood infusion"
3216075|NCT01050855|Experimental|RIC:Intermediate Campath|"Day Treatment~Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 to -3 Fludarabine IV~Day - 2 Melphalan 140 mg/m2 IV~Day - 1 Cyclosporine infusion starts~Day 0 Transplant: Bone marrow or cord blood infusion"
3216076|NCT01050855|Experimental|RIC: Mini Busulfan|"Day Treatment~Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)~Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV~Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV~Day - 3 Fludarabine IV~Day - 2 Fludarabine IV Cyclosporine infusion~Day - 1 Rest~Day 0 Transplant: Bone marrow or cord blood infusion"
3216077|NCT01050868|Experimental|Single Arm|
3216078|NCT01050881||Positive Blood Donors|Blood donors testing positive for HIV, HBV, HCV or HTLV in 2008 and 2009. Donors and patients notified of increased risk of vCJD in 2005.
3216079|NCT01050894||osteoarthritis patients|
3216080|NCT01050920||Blood Collection|
3216081|NCT01050933|Experimental|Carbon Monoxide|Healthy volunteers will receive 250 ppm of carbon monoxide by face mask. This dose will be administered for 1 hour with continuous COHb monitoring. At baseline and at each half hour time point, a blood sample will be drawn to be analyzed by the gas chromatograph. After 1 hour, the volunteer will be excused and asked to return in 4 hours and this procedure repeated. At any point, if the COHb level reaches 10%, administration of CO will be terminated.
3216082|NCT01050972|Experimental|Cognitive and physical program|Experimental: Cognitive and physical program. Non randomized residents in the territory of Piedmont (Piemonte) Italy.
3216083|NCT01050985|Experimental|temsirolimus and capecitabine|Treatment with the combination of temsirolimus and capecitabine
3216084|NCT01051011|Experimental|1|
3216085|NCT01051011|Experimental|2|
3216086|NCT01051011|Active Comparator|3|
3216087|NCT01051024|Experimental|A|Diamel
3216088|NCT01051024|Placebo Comparator|B|Placebo
3216089|NCT01051037|Experimental|Arm 1|Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.
3216090|NCT01051050|Other|Mandatory use of surgery wiki|Mandatory participation in journal club wiki which will include adding to and reviewing the information posted on the wiki. Contribution to the wiki will be required at least once during the study period.
3216091|NCT01051050|Other|Voluntary use of surgery wiki|Voluntary participation in the journal club wiki
3216092|NCT01051076|Experimental|Factor VIII and von Willebrand Factor|
3216093|NCT01051089|Experimental|Lifestyle modification|supervised exercise with diet education
3216094|NCT01051089|No Intervention|Control|Control (ordinary care with usual education)
3216095|NCT01051102|Experimental|IDegAsp|
3216096|NCT01051102|Active Comparator|BIAsp 30|
3216097|NCT01051115|Experimental|Dasatinib|Patients will be treated with dasatinib monotherapy 100mg daily. At four weeks patients will be re-evaluated. Patients with less than a partial response will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib.
3216098|NCT01051128|Experimental|Spasticity. Baclofen|This study is a non-randomized, open-label, multi-center study of the Prometra Programmable Implantable Pump System in the administration of Lioresal® intrathecal (baclofen) in patients suffering from severe muscle spasticity of spinal origin.
3216099|NCT01051141|Active Comparator|CBI in ED with AMET at 3 months|computer brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3216100|NCT01051141|Active Comparator|CBI in ED with EUC at 3 months|
3216101|NCT01051141|Active Comparator|IBI in ED with AMET at 3 months|
3216102|NCT01051141|Active Comparator|IBI in ED with EUC at 3 months|
3216103|NCT01051141|Active Comparator|EUC in ED with AMET at 3 months|
3216104|NCT01051141|No Intervention|EUC in ED with EUC at 3 months|
3216105|NCT01051154|Active Comparator|Docosahexaenoic acid (DHA)|This group will be receive the DHA supplement
3216106|NCT01051154|Placebo Comparator|Placebo|This group will be receive placebo
3216107|NCT01051167|Experimental|Cetuximab + Folfox-6-regime|"Cetuximab 500 mg/m² administered as an intravenous infusion over 120 minutes on day 1 every 2 weeks. Combined with the following FOLFOX-6-regime:~Oxaliplatin 85 mg/m² i.v. for 2 h on day 1, Folinic acid 400 mg/m² i.v. for 2 h concurrently with Oxaliplatin on day 1, Fluorouracil 400 mg/m² i.v. bolus after Folinic Acid on day 1, followed by Fluorouracil 2400 mg/m² i.v. over 46 h."
3216108|NCT01051180||Doppler|Those patients where the doppler was randomised to be on
3216109|NCT01051180||Non doppler patients|those with no doppler guidance
3216110|NCT01051193|Experimental|TRI476|TRI476
3216111|NCT01051219|Active Comparator|Losartan, daily medication|50 milligrams Losartan to be taken orally daily
3216112|NCT01051219|Placebo Comparator|Placebo|A matched placebo will be given for patients to take once daily
3216113|NCT01051232|Placebo Comparator|Cohort 1|PF-00868554 (filibuvir) 100 mg or placebo
3216114|NCT01051232|Placebo Comparator|Cohort 2|PF-00868554 (filibuvir) 300 mg or placebo
3216115|NCT01051232|Placebo Comparator|Cohort 3|PF-00868554 (filibuvir) 500 mg or placebo
3260374|NCT01478750|Experimental|intraduodenal administration of fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, well emulsified with Tween-80 intraduodenally
3216116|NCT01051245|Active Comparator|Case management|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
3216117|NCT01051245|Placebo Comparator|Usual care group|Usual care provided by primary care physician and/or specialist. Free access to diabetes educational workshops. Regular delivery of educational brochures (not personally targeted).
3216118|NCT01051271|Active Comparator|diphenhydramine|
3216119|NCT01051271|Placebo Comparator|saline|
3216120|NCT01051284|Experimental|Cyberknofe and Gemcitabine|Cyberknife radiation and 6 cycles Gemcitabine
3216121|NCT01051297||VTE -PROSPECTIVE|Patients diagnosed with VTE
3216122|NCT01051297||sleep study group -PROSPECTIVE|patients undergoing sleep study
3216123|NCT01051297||VTE-Retrospective|patients with VTE , chart review
3216124|NCT01051297||OSA-retrospective|PATIENT WITH OSA -CHART REVIEW
3216125|NCT01051297||OSA group -PROSPECTIVE|patients diagnosed with OSA
3216126|NCT01051336|Experimental|TARIS Placebo|
3216127|NCT01051336|Sham Comparator|Sham Procedure|
3216128|NCT01051362|No Intervention|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
3216129|NCT01051375|Experimental|Waitlist Group|The intervention involves completion of a single workshop, provision of psychoeducational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list, within a month of our receiving the referral.
3216130|NCT01051375|No Intervention|Standard of Care|These patients continue to receive the standard of care while awaiting formal assessment.
3216131|NCT01051388|Active Comparator|Group I|Low-dose PPI (Rabeprazole sodium 10 mg)
3216132|NCT01051388|Active Comparator|Group II|High-dose PPI (Rabeprazole sodium 20 mg)
3216133|NCT01051388|Active Comparator|Group III|Non-PPI (Gefarnate)
3216134|NCT01051401|Experimental|Arm I (rosuvastatin)|Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
3216135|NCT01051401|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
3216136|NCT01051414|Experimental|BMS-790052 + BMS-650032|
3260375|NCT01478750|Experimental|intragastric, non-emulsified fat|At 09:00, subjects will receive the load, consisting of 460 water and 40 ml sunflower oil, non emulsified, intragastrically
3216137|NCT01051427|Active Comparator|Nasal catheter|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized not to put Surgiflo. So they receive the usual treatment with a nasal catheter balloon into the nose.
3216138|NCT01051427|Experimental|Surgiflo|In this arm will be the patients with epistaxis that cannot be stopped with anterior nasal packing and are randomized to put into the nose Surgiflo.
3216139|NCT01051479|Experimental|C11-Choline|
3216140|NCT01051505|Experimental|1|
3216141|NCT01051505|Placebo Comparator|2|
3216142|NCT01051531|Experimental|Paliperidone palmitate|
3216143|NCT01051544|Active Comparator|von Willebrand factor-free FVIII concentrates|Patients treated with FVIII concentrates
3216144|NCT01051544|Active Comparator|FVIII/VWF concentrates|Patients treated with FVIII/VWF concentrates
3216145|NCT01051583|Experimental|Avastin , diode laser cyclophotcoagulation|Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation
3216146|NCT01051583|Active Comparator|Diode Laser cyclophotocoagulation|Diode laser cyclophotocoagulation to control intraocular pressure
3216147|NCT01051609||Intervention Group|There is only one arm in this trial. Please see interventions for more detailed descriptions.
3216148|NCT01051622|Experimental|PBMC Trafficking|In part B, Patients undergo a blood draw (up to150 mL) and the PBMC's are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.
3260376|NCT01478776|Active Comparator|diabetes, omega-3|patient with type 2 diabetes who receive 4gr/day omega-3
3260377|NCT01478776|Placebo Comparator|placebo, diabetes|patient with type 2 diabetes who receive 4 cap of placebo/day
3260378|NCT01478789|Experimental|Water dispersible Plant Sterol (WD-PS)|WD-PS dairy product (a novel formulation for dispersible free sterols in aqueous media produced)2g/d of free plant sterol
3260379|NCT01478789|Experimental|Esterified plant sterol (PS-Ester)|PS-Ester enriched dairy product (2g/d free plant sterol)
3216149|NCT01051622|Experimental|T Lymphocyte Trafficking|"In part B, Patients undergo a blood draw (up to150 mL) and the T lymphocyte cells are separated and selected or 99mTc-HMPAO labeling. The purified and labelled cells will be re-introduced into the patient by intravenous infusion and one SPECT scan and up to 8 serial planar scintigraphy scans will initially be conducted over up to 6 hours within 1 scan session. All suitable patients showing evidence of cellular uptake in the ileo-caecal region and/or small bowel at Visit 1 will be progressed to an identical second cell labeling and scanning session at Visit 2 (48 hours later). Subjects showing no evidence of cellular uptake in the ileo-caecal region or small bowel at Visit 1 (negative scan) will be withdrawn from the study and proceed to the follow-up.~visit."
3216150|NCT01051648|Experimental|Triamcinolone acetenoide|Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery
3216151|NCT01051674|Experimental|High fiber diet|
3216152|NCT01051674|Experimental|Low-carbohydrate diet|
3216153|NCT01051687|No Intervention|control skin patches|no intervention will be given to the patches
3216154|NCT01051687|Active Comparator|botulinum toxin A|Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
3216155|NCT01051700|Experimental|5 mg|GW786034
3216156|NCT01051700|Experimental|10 mg|GW786034
3216157|NCT01051700|Experimental|20 mg|GW786034
3216158|NCT01051700|Placebo Comparator|Placebo|Placebo
3216159|NCT01051713|Experimental|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
3216160|NCT01051713|Experimental|Technology Supported condition|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
3216161|NCT01051713|No Intervention|Self-Guided|Participants in the Self-Guided condition will receive DPP DVDs (3 DVDs and 1 CD) at the beginning of the study. This condition will not receive any direct dietary or physical activity interventions outside of the DVDs. Although Self-Guided participants will be receiving the same 7% weight loss goal as the other two groups, they will not be receiving physical activity or diet goals. The DVDs cover the initial 12-weekly sessions of the DPP, with the sessions portrayed by professional actors. They will also be provided with a supplemental DVD which includes a manual for each of the 12 sessions. They will also be giving the Keeping Track booklets and asked to record their diet and activity daily.
3216162|NCT01051726|Experimental|Aromatherapy group 1|Participants will be given essential oil consisting of (Peppermint, Lavender, Clary Sage and Frankincense) together with a swab to put the oil on.
3216163|NCT01051726|Placebo Comparator|Control group 2|Participants receive a bottle of non essential oil and a swab.
3216164|NCT01051726|No Intervention|Control group 3|Standard maternity care to measure baseline.
3216165|NCT01051752||NTM infection|Patients with NTM infection are generally middle aged or higher aged, white males with COPD or bronchiectasis. They will be recruited from the outpatient clinics of University Centre for Chronic Diseases Dekkerswald, Tuberculosis Centre Beatrixoord or other outpatient clinics in The Netherlands. Both newly diagnosed and already treated patients with NTM disease will be recruited.
3216166|NCT01051765|Experimental|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin: 30mg/m2, d1,d2 every three weeks
3216167|NCT01051804|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3216168|NCT01051804|Active Comparator|Optive|Optive Lubricant Eye Drops
3260380|NCT01478789|Placebo Comparator|placebo|100 g/d yogurt with no added plant sterol
3260381|NCT01478802|Active Comparator|CMV Arm|Patients with moderate-to-severe Acute Respiratory Distress Syndrome treated solely with lung protective, low volume high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description section.
3216169|NCT01051830|Experimental|Interdisciplinary group|Diabetes intervention and rehabilitation program. The rehabilitation program includes geriatric consultation, the rehabilitation program (interventions to improve ROM, muscle strength and endurance, proprioceptive enhancement, balance capacity, aerobic and anaerobic capacity, flexibility, and body composition), and discharge-planning services. The DM intervention includes: dietary and DM education, blood pressure control, dyslipidemia management, a glycemic treatment regimen, and exercises.
3216170|NCT01051830|No Intervention|Control group|Routine care
3216171|NCT01051869|Active Comparator|simple decompression|
3216172|NCT01051869|Active Comparator|anterior subcutaneous transposition|
3216173|NCT01051882|Experimental|MSC-NTF cells IM|Intramuscular administration in early stage patients
3216174|NCT01051882|Experimental|MSC-NTF cells IT|Intrathecal administration in progressive stage patients
3216175|NCT01051895|Experimental|HPV testing|Women randomized to this arm will undergo high risk HPV DNA testing using Hybrid Capture 2®.
3216176|NCT01051895|Active Comparator|Routine colposcopy|Women will be followed in the colposcopy clinic as usual, with no standardized protocol, tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
3216177|NCT01051947|Experimental|Nebivolol|Nebivolol therapy for 2-6 weeks depending on blood pressure readings
3216178|NCT01051947|Experimental|Metoprolol|Metoprolol therapy for 2-6 weeks depending on blood pressure readings
3216179|NCT01051973|Experimental|Cognitive behavior therapy|
3216180|NCT01051973|Active Comparator|Stress management|
3216181|NCT01051999|Experimental|Glutamine|Patients randomized to the glutamine arm will receive 0.7g/kg of oral glutamine powder per day
3216182|NCT01051999|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive 0.7g/kg of oral isonitrogenous L-alanine powder per day
3216183|NCT01052025|Experimental|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
3216184|NCT01052025|No Intervention|Placebo|
3216185|NCT01052051|Experimental|vitamin D3 and calcium carbonate|Daily vitamin D3 2000 IU/day and calcium carbonate 1500mg/day supplementation
3216186|NCT01052051|Placebo Comparator|Placebo for vitamin D3 and calcium carbonate|Placebo for daily vitamin D3 and calcium carbonate
3216187|NCT01052064|Experimental|Transcranial magnetic stimulation|There are evidences that rTMS has a modulating effect in cortical and subcortical neural networks, reinforcing or depressing synaptic activity by mean of long term potentiation or depression like mechanism. Depression is the most study neuropsychiatric condition in which rTMS is useful as a therapeutic option; but in other diseases such as ADHD there are many pathophysiological elements that make it very likely that rTMS could be useful for symptomatic treatment modulating activity in prefrontal and basal ganglia neuronal networks.
3216188|NCT01052090|Experimental|Lifestyle counseling|
3216189|NCT01052129|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr.Reddy's Laboratories Limited
3216190|NCT01052129|Active Comparator|Anaprox DS 550 mg Tablets|Anaprox DS 550 mg Tablets of Roche Pharmaceuticals Inc
3216191|NCT01052142|Experimental|Lipovaxin-MM|
3216192|NCT01052168|Active Comparator|Speed Group|The Speed Group, (n=20) will train in laparoscopic suturing on the validated FLS suturing model until the expert level of speed (i.e. task duration < 70 seconds) has been achieved on two consecutive attempts.
3216193|NCT01052168|Experimental|Motion Group|The Motion Group, (n=20) will train in laparoscopic suturing until expert levels of motion (pathlength 6700 and smoothness 560) have been achieved.
3216194|NCT01052168|Experimental|Speed and Motion Group|The Speed and Motion Group (n=20) will train in laparoscopic suturing until expert levels of speed AND motion have been achieved.
3216195|NCT01052181|Experimental|Vitamin D supplementation|Cholecalciferol sachets 120,000 IU monthly for 12 months
3216196|NCT01052181|Placebo Comparator|placebo|placebo with same taste, color, odor
3216197|NCT01052194|Experimental|25 mg b.i.d. VX-509|
3216198|NCT01052194|Experimental|50 mg b.i.d. VX-509|
3216199|NCT01052194|Experimental|100 mg b.i.d. VX-509|
3216200|NCT01052194|Experimental|150 mg b.i.d. VX-509|
3216201|NCT01052194|Placebo Comparator|Placebo|
3216202|NCT01052220|Experimental|BP Education and Self Regulation of BP|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will received a BP educational session at baseline and were asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI made weekly visits with the intervention participants in the HD unit to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
3216203|NCT01052220|No Intervention|Usual Care|Participants in the usual care group did not receive the intervention but continued to receive their standard care in the hemodialysis unit which involved follow-up by the medical provider and BP medication adjustments as needed. .
3216204|NCT01052233|Active Comparator|Arthroscopic partial meniscectomy|Arthroscopic partial resection of degenerative tear of medial meniscus
3216205|NCT01052233|Sham Comparator|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
3216206|NCT01052246|Experimental|Clindamycin 1% + benzoyl peroxide 5% & pulsed dye laser|
3216207|NCT01052246|Active Comparator|Clindamycin 1% + benzoyl peroxide 5%|
3216208|NCT01052259|Experimental|Deoxyspergualin, Treatment,|
3216209|NCT01052285|Placebo Comparator|Placebo|TAP block with 25 ml of saline Ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline.
3216210|NCT01052285|Active Comparator|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% Local infiltration with 40 ml of ropivacaine 0,375% Tap block with 25 ml of saline
3216211|NCT01052285|Experimental|Transversus abdominis plane block|25 ml of Ropivacaine 0,75%, Ilioinguinal block with 10 ml saline and local infiltration with 40 ml of saline.
3216212|NCT01052298|Experimental|Arm 1|
3216213|NCT01052298|Experimental|Arm 2|
3216214|NCT01052298|Experimental|Arm 3|
3216215|NCT01052298|Placebo Comparator|Arm 4|
3216216|NCT01052311|Placebo Comparator|Placebo|Placebo pills once daily
3216217|NCT01052311|Active Comparator|Active treatment|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) = tredaptive once daily from day 1 to 30. From day 31 to day 90 2 g of extended-release niacin and 20 mg of laropiprant once daily.
3216218|NCT01052337|Active Comparator|propofol|
3216219|NCT01052337|Active Comparator|sevofluorane|
3216220|NCT01052350||Parkinson disease|individuals with Parkinson disease
3216221|NCT01052350||healthy control|individuals without Parkinson disease
3216222|NCT01052363|Experimental|CA4P + Avastin|
3216223|NCT01052363|Experimental|Avastin + CA4P|
3216224|NCT01052389|Experimental|Aripiprazole|Aripiprazole (N05AX12)
3216225|NCT01052389|Experimental|Olanzapine|Olanzapine (N05AH03)
3216226|NCT01052389|Experimental|Haloperidol|Haloperidol (N05AD01)
3216227|NCT01052402|Experimental|Dose A|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose A) followed by a heterologous booster vaccination (Dose A) on Day 360
3216228|NCT01052402|Experimental|Dose B|Two intramuscular injections (21 days apart, i.e. Days 0 and 21) of H5N1 Influenza Vaccine (Dose B) followed by a heterologous booster vaccination (Dose B) on Day 360
3216229|NCT01052415|No Intervention|Standard care|Service providers and HIV patients, offered intervention at the end of study
3216230|NCT01052415|Experimental|Intervention|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
3216231|NCT01052441||CT Scan|Subjects with typical or atypical chest pain suspected of coronary artery disease and referred for an elective invasive coronary angiography (ICA), and scheduled to undergo CCTA before ICA or after ICA, if no intervention has been performed.
3216232|NCT01052454|No Intervention|Wait list|Women assigned to the waitlist have the opportunity of taking the MBSR program at no cost following final study assessment
3216233|NCT01052454|Experimental|Mindfulness-based stress reduction|Women in the MBSR arm attend eight weekly MBSR classes
3216234|NCT01052506|Placebo Comparator|Placebo|Single dose of saline solution (8 cohorts IV; 1 cohort SC)
3216235|NCT01052506|Experimental|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV; 1 cohort SC)
3216236|NCT01052519|No Intervention|obese control|
3216237|NCT01052519|Active Comparator|obese goal-directed|
3216238|NCT01052519|Active Comparator|non-obese goal directed|
3216239|NCT01052532||Mitral Regurgitation pre&post operation|Patients with severe Mitral Regurgitation without evidence of ischemia are tested prior to surgery and after valve repair.
3216240|NCT01052558|Active Comparator|Cataract Surgery Only|
3216241|NCT01052558|Experimental|Treatment with Cataract Surgery & Stents|Ab interno trabecular micro-bypass stent surgery
3216242|NCT01052571|Active Comparator|Without Steroids|Group I patients receiving lumbar transforaminal epidural injections with an injection of local anesthetic (lidocaine 1% or bupivacaine 0.25%
3216243|NCT01052571|Active Comparator|steroids|Group II patients will receive lumbar transforaminal epidural injections with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
3216244|NCT01052584|Experimental|Chloroquine-P. vivax|P. vivax randomized to receive chloroquine 3-day regimen
3216245|NCT01052584|Experimental|Artemether-Lumefantrine: P. vivax|
3216246|NCT01052584|Experimental|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
3216247|NCT01052597|Placebo Comparator|Placebo|
3216248|NCT01052597|Experimental|Curcumin|
3216249|NCT01052610|Active Comparator|Active group|Group of children with bronchial asthma and/ or allergic rhinitis 6-18 years old receiving annually house dust mites sublingual allergen extract
3216250|NCT01052610|Placebo Comparator|Placebo group|Group of children with bronchial asthma and/or allergic rhinitis 6-18 years old receiving placebo in sublingual applicator
3260382|NCT01478802|Experimental|HFO-RMs Arm|Patients with moderte-to-severe Acute Respiratory Distress Syndrome treated initially with a 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO)-Recruitment Maneuvers (RMs), and then with lung protective CMV interspersed to additional HFO-RMs sessions (if required according to study protocol). The protocolized use of HFO-RMs may extend until day 10 post-randomization, according to pre-specified oxygenation criteria. Full details are provided in the Detailed Description Section.
3260383|NCT01478815|Placebo Comparator|Standard Care|
3216251|NCT01052623|Experimental|Growth hormone-testing (GH/IGF-1-testing)|"Patients (girls over 8 years and boys over 10 years) are primed with estradiol 1 mg orally for 2 days, to help avoid false results of growth hormone (GH) levels in blood samples. Then provocation testing is done, with two tests back to back. It determines blood levels of GH and the body's response to testing with drugs called arginine and clonidine. Patients are admitted to the pediatric inpatient unit and will have an intravenous (IV) line placed in the arm. Arginine is given by IV over 30 minutes, and blood samples are taken as indicated.~The next day, the clonidine test is performed according to current guidelines. Then the IGF-1 generation test is done to see if the patient has the ability to generate IGF-1 in response to injections of GH for 5 consecutive days."
3216252|NCT01052636|No Intervention|Control group|Patients receive only routine hospital care
3216253|NCT01052636|Experimental|Experimental group|Patients receive regular hospital routine care and interdisciplinary intervention program
3216254|NCT01052649||Healthy volunteers|
3216255|NCT01052675||Pharmacodependance cases|Case report from one of the French CEIP for drug and substance problematic use, abuse or dependence except alcohol and tobacco.
3216256|NCT01052688||Pregnant Women|Pregnant women who have been definitively diagnosed as carrying a fetus with aneuploidy.
3216257|NCT01052727|Other|overnight stay group|Group of patients who rests at least one night in Hospital
3216258|NCT01052727|Other|day-care Group|Group of patients who is discharged tha same day of operation
3216259|NCT01052753||ADHD group|
3216260|NCT01052753||Control group|
3216261|NCT01052766|Experimental|PET/CT and BH PET/CT|In collaboration with the Department of Radiation Oncology and the Interventional Radiology Service, patients with lung or liver cancer or lung or liver metastases in whom FDG PET/CT is part of the clinical standard of care for disease evaluation and response assessment will be enrolled in this study. We will perform a clinical PET/CT and BH PET/CT (for two bed positions covering the entire chest) prior to, and again 1-2 weeks after SBRT or RFA. This early time point is chosen because a few weeks after the completion of treatment, acute radiation injury in the lung begins and will likely be detectable as abnormal uptake on follow-up PET imaging making it difficult to assess tumor recurrence.
3216262|NCT01052792|Experimental|Naproxen Sodium 550 mg Tablets|Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited
3216263|NCT01052792|Active Comparator|Anaprox DS 550mg Tablets|Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc
3216264|NCT01052805||harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
3216265|NCT01052818||Stage IV NSCLC|Stage IV non small-cell lung cancer patients will be recruited for this protocol
3216266|NCT01052857|Experimental|1|acupuncture daily fo 7 days
3216267|NCT01052857|No Intervention|2|observation
3216268|NCT01052870|Other|androgen receptor gene polymorphism|Medication response will be assessed according to androgen receptor genotype
3216269|NCT01052870|Active Comparator|finasteride|medication for treating androgenetic alopecia in women
3260384|NCT01478815|Experimental|Contingency management for abstinence from drugs|
3216270|NCT01052883|Experimental|1|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A] then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
3216271|NCT01052883|Experimental|2|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
3260385|NCT01478841|Experimental|Polyphenols|9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
3216272|NCT01052883|Experimental|3|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C] then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
3216273|NCT01052883|Experimental|4|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D] then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
3216274|NCT01052896|Experimental|Gabapentin|Half of the 100 patients enrolled will be placed on Gabapentin therapy to determine if they have improved dyspepsia symptoms.
3216275|NCT01052896|Placebo Comparator|Placebo|Half of the 100 patients will be placed on placebo look-alike of the gabapentin.
3216276|NCT01052909|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
3216277|NCT01052909|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
3216278|NCT01052922|Active Comparator|2 sample InSure|
3216279|NCT01052922|Active Comparator|1 sample OC-Micron|
3216280|NCT01052922|Active Comparator|3 sample g-SENSA|
3216281|NCT01052935|No Intervention|Arm 1|This is a phlebotomy study.
3216282|NCT01052961|No Intervention|Non-intervention arm|patients may receive oseltamivir 75 mg bd for 5 days, decided by the managing physicians
3216283|NCT01052961|Active Comparator|oseltamivir, higher dose|oseltamivir 150 mg bd for 5 days for patients presented within 96 hours from onset
3216284|NCT01052974|Placebo Comparator|physiological serum|ropivacaïne controlled by placebo (physiological serum).
3216285|NCT01052974|Active Comparator|ropivacaine|ropivacaïne controlled by placebo (physiological serum).
3216286|NCT01052987|Experimental|Tranilast|Tranilast tablets
3216287|NCT01052987|Active Comparator|Allopurinol|Allopurinol tablets
3216288|NCT01052987|Experimental|Combination|Tranilast plus Allopurinol
3216289|NCT01052987|Active Comparator|High dose Allopurinol|400 mg Allopurinol
3216290|NCT01052987|Experimental|High dose combination|Combination of Tranilast 300 mg and Allopurinol 400 mg
3216291|NCT01053039|Active Comparator|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
3216292|NCT01053039|Placebo Comparator|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
3216293|NCT01053052|Experimental|Sonography with FemVue vs. HSG|FemVue sonography and HSG
3216294|NCT01053065|Active Comparator|Atorvastatin 10 mg/day|Arm composed of 20 patients, receiving atorvastatin 10 mg/day
3216295|NCT01053065|Active Comparator|Atorvastatin 80 mg/day|Arm composed of 20 patients, receiving atorvastatin 80 mg/day
3216296|NCT01053065|Active Comparator|Cholestyramine - Sitosterol|Arm composed of 20 patients receiving cholestyramine 8 g/day plus sitosterol 2.5 g/day
3216297|NCT01053091|Experimental|Exercise|exercise
3216298|NCT01053091|No Intervention|Control|control
3216299|NCT01053104||capecitabine 2000mg/m2 (Colorectal)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and oxaliplatin 130mg/m2 d1 q 3 weekly (CAPOX)
3216300|NCT01053104||capecitabine 2500mg/m2 (Colorectal)|capecitabine 2500mg/m2 d 1-14, q 3 weekly
3216301|NCT01053104||capecitabine 2000mg/m2 (Breast)|capecitabine 2000mg/m2d 1-14, q 3 weekly
3216302|NCT01053104||docetaxel 75mg/m2 (Breast)|capecitabine 2000mg/m2 d 1-14, q 3 weekly and docetaxel 75mg/m2 d1 q 3 weekly
3216303|NCT01053117|Experimental|Protocolized approach|Protocolized approach to convert catheter to arteriovenous fistula
3216304|NCT01053117|No Intervention|Current Care Model|
3216305|NCT01053130|Experimental|weight loss surgery|laparoscopic sleeve gastrectomy
3216306|NCT01053130|Active Comparator|Lifestyle Intervention|Diet and exercise with or without pharmacotherapy
3216307|NCT01053143|Experimental|Study Group|Participants aged 18 years and older at enrollment.
3216308|NCT01053169||Prophylaxis Cohort|Patients with coagulopathy due to liver disease or other condition requiring correction of coagulopathy who require surgical or diagnostic intervention
3216309|NCT01053169||Treatment Cohort|Patients experiencing acute bleeding perioperatively
3216310|NCT01053182|Active Comparator|Ivor-Lewis|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
3216311|NCT01053182|Active Comparator|Sweet|Esophagectomy via Left Side Thoracotomy
3216312|NCT01053195|Experimental|Lifestyle counseling|In the project areas, lifestyle counseling will be given every three months to individuals having prediabetes and every six months to those with normal glucose levels.
3216313|NCT01053195|No Intervention|Control|No intervention activity will be assigned for participants enrolled from the control areas.
3216314|NCT01053208|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
3216315|NCT01053208|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
3216316|NCT01053234|Experimental|Insulin aspart|
3216317|NCT01053234|Experimental|NPH insulin|
3216318|NCT01053260|Active Comparator|LEARN Program|Participants will receive weekly weight loss counseling based on the LEARN Program for Weight Management.
3216319|NCT01053260|Experimental|LEARN Plus Contingency Management|Participants will receive weekly counseling based on the LEARN Program for Weight Management plus contingency management. Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
3216320|NCT01053273|Active Comparator|Caudal epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
3216321|NCT01053273|Active Comparator|Percutaneous Adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone
3216322|NCT01053299|Active Comparator|No treatment|Every child, without exception, born in the peroid 1.2.1998 - 31.12.2006, still alive, will be called for to take a Xray of their hips aimed at comparing the ultrasound-values taken newborn.
3216323|NCT01053325|Experimental|CTX in HIV-negative women|CTX daily prophylaxis in HIV-negative pregnant women
3216324|NCT01053325|Experimental|CTX in HIV-positive women|CTX daily prophylaxis in pregnant women who are infected with HIV
3216325|NCT01053325|Active Comparator|SP IPT in HIV-negative women|Intermittent Preventive Treatment with SP in HIV-negative pregnant women
3216326|NCT01053325|Active Comparator|IPT SP in HIV-positive women|Intermittent Preventive Treatment with SP in HIV-positive pregnant women
3216327|NCT01053325|Active Comparator|CTX in HIV-positive pregnant women with CD4<350|Daily prophylaxis with cotrimoxazole in HIV-positive pregnant women with CD4<350
3216328|NCT01053338|Experimental|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200 mg/38 mg Caplets of Dr. Reddy's
3216329|NCT01053338|Active Comparator|Advil|Advil PM 200 mg/38 mg Tablets of Wyeth
3216330|NCT01053364|Experimental|Implant|
3216331|NCT01053377|Active Comparator|Tamiflu|
3216332|NCT01053377|Placebo Comparator|Placebo Tamiflu|
3216333|NCT01053390|Active Comparator|epirubicin,cisplatin,LV（Leucovorin）、5-FU (5-Fluorouracil)|conventional regimen
3216334|NCT01053390|Experimental|Somatotatin|Conventional chemotherapy regimen plus somatostatin
3216335|NCT01053403|Active Comparator|MDMA|
3216336|NCT01053416|No Intervention|observation|
3216337|NCT01053416|Experimental|Yag laser iridotomy|the enrolled eyes will undergo an iridotomy performed by using a Yag-laser
3216338|NCT01053442|Experimental|NaFeEDTA|The maize porridge is fortified with 2.5mg iron as NaFeEDTA
3216339|NCT01053442|Active Comparator|FeSO4|The maize porridge is fortified with 2.5 mg iron as ferrous sulphate plus ascorbic acid.
3216340|NCT01053455||Starting on NCPAP|randomized to start on NCPAP
3216341|NCT01053455||Starting on SiPAP|randomized to SiPAP
3216342|NCT01053468|Experimental|PA Behavior Intervention|Physical Activity Resource Kit
3216343|NCT01053468|Active Comparator|Standard Materials|Receive physical activity handout from the Canadian Public Health Agency
3216344|NCT01053481|Experimental|Vitamin D|Vitamin D supplement
3216345|NCT01053494|Active Comparator|Arm I (WAITLIST CONTROL GROUP)|Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
3216346|NCT01053494|Experimental|Arm II (TOUCH)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks."
3216347|NCT01053494|Experimental|Arm III (TOUCH+)|"Caregivers undergo a 60-minute training session on simple massage techniques, including the Massage Toolkit, comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist."
3216348|NCT01053520|Experimental|Sequence I|
3216349|NCT01053520|Experimental|Sequence II|
3216350|NCT01053520|Experimental|Sequence III|
3216351|NCT01053533|Experimental|Chinese herbal medicines plus western therapy|
3216352|NCT01053533|Active Comparator|western therapy|including supportive therapy and antivirus therapy when necessary
3216353|NCT01053546|Experimental|Arm I (Early exercise group)|Patients perform swallowing exercises comprising lingual press, head lift, breath hold, Masako swallow, high pitch e, effortful swallow, and neck stretch and massage for 2 weeks prior to beginning radiotherapy and again immediately after completion of radiotherapy.
3216354|NCT01053546|Experimental|Arm II (Late exercise group)|Patients begin performing swallowing exercises as in arm I 1 month after completion of radiotherapy.
3260386|NCT01478841|Placebo Comparator|placebo|9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).
3216355|NCT01053559|Other|certolizumab pegol|Subjects will receive FDA approved Cimzia injections as indicated on the product label. Subjects will undergo 3 wireless capsule endoscopies, one at screening,Day 84 and Day 168 as well as monthly bloodwork.
3216356|NCT01053572|Active Comparator|Celestone|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
3216357|NCT01053572|Active Comparator|sodium chloride solution|Group II will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
3216358|NCT01053572|Active Comparator|sodium choride solution|Group III will receive adhesiolysis, local anesthetic, normal sodium chloride solution instead of 10% hypertonic sodium chloride solution and non-particulate Celestone;
3216359|NCT01053572|Active Comparator|Double substitutes|Group IV will receive adhesiolysis, local anesthetic, and 0.9% sodium chloride solution to substitute for the 10% hypertonic sodium chloride, and 0.9% sodium chloride solution to substitute for non-particulate Celestone
3216360|NCT01053585|Active Comparator|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
3216361|NCT01053585|Placebo Comparator|Placebo|Placebo suspension (single dose 90 minutes prior to physiologic measurement)
3216362|NCT01053611|Active Comparator|Group 1 BIS value 30|
3216363|NCT01053611|Active Comparator|Group 2 BIS value 30|
3216364|NCT01053611|Active Comparator|Group 3 BIS value 30|
3216365|NCT01053611|Active Comparator|Group 4 BIS valaue 30|
3216366|NCT01053611|Active Comparator|Group 1 BIS value 50|
3216367|NCT01053611|Active Comparator|Group 2 BIS value 50|
3216368|NCT01053611|Active Comparator|Group 3 BIS value 50|
3216369|NCT01053611|Active Comparator|Group 4 BIS value 50|
3216370|NCT01053611|Active Comparator|Group 1 BIS value 70|
3216371|NCT01053611|Active Comparator|Group 2 BIS value 70|
3216372|NCT01053611|Active Comparator|Group 3 BIS value 70|
3216373|NCT01053611|Active Comparator|Group 4 BIS value 70|
3216374|NCT01053637|Experimental|Hydrocodone/acetaminophen|Patients will receive 0.17 mg/kg hydrocodone component to a max of 10 mg hydrocodone.
3216375|NCT01053637|Placebo Comparator|Sugar water|Placebo
3216376|NCT01053676|Experimental|Arm 1|
3216377|NCT01053676|Active Comparator|Arm 2|
3216378|NCT01053689|Experimental|Glimepiride|Glimepiride tablets 1 mg of Dr. Reddy's Laboratories Limited
3216379|NCT01053689|Active Comparator|Amaryl|Amaryl 1 mg tablets of Aventis Pharmaceuticals Inc
3216380|NCT01053702|Experimental|Dose 1|R475
3216381|NCT01053702|Experimental|Dose 2|R475
3216382|NCT01053702|Placebo Comparator|Dose 3|Placebo to match R475 dose
3216383|NCT01053728|Experimental|Cohort 1 : SAR161271 0.3 U/kg|Cross-over design of four formulation of SAR161271 0.3U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3216384|NCT01053728|Experimental|Cohort 2 : SAR161271 0.6 U/kg|Cross-over design of four formulation of SAR161271 0.6U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3216385|NCT01053728|Experimental|Cohort 3 : SAR161271 1.2 U/kg|Cross-over design of four formulation of SAR161271 1.2 U/kg or insulin glargine administered as a single dose in the morning between about 11h00 and about 12h00; fasting for about 12h before and for the duration of the clamp
3216386|NCT01053767|No Intervention|Arm 1|This is a phlebotomy study.
3216387|NCT01053793|Active Comparator|Glucose Standard|
3216388|NCT01053793|Experimental|Potato Variety|
3216389|NCT01053832|Other|Ventricular Pace Suppression- ON|
3216390|NCT01053832|Other|Ventricular Pace Suppression- OFF|
3260387|NCT01478867||Celiac patients|
3216391|NCT01053858|Active Comparator|bevacizumab|intravitreal bevacizumab or triamcinolone determined by single physician
3216392|NCT01053858|Active Comparator|triamcinolone|
3216393|NCT01053871|Experimental|1|sedation using propofol
3216394|NCT01053871|Experimental|2|sedation using midazolam with fentanyl
3216395|NCT01053884|Other|Anidulafungin, safety, antifungal drug|single arm study
3216396|NCT01053910|Experimental|Ramipril|Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)
3216397|NCT01053923||MRI Scan|
3216398|NCT01053936|Experimental|Bardoxolone methyl: 5 mg|
3216399|NCT01053936|Experimental|Bardoxolone methyl: 10 mg|
3216400|NCT01053936|Experimental|Bardoxolone methyl: 15 mg|
3216401|NCT01053936|Experimental|Bardoxolone methyl: 30 mg|
3216402|NCT01053936|Experimental|Bardoxolone methyl: 2.5 mg|
3216403|NCT01053949|Active Comparator|Drug on 21 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
3216404|NCT01053949|Active Comparator|Drug on 28 days per 28 days cycle|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
3216405|NCT01054001|Active Comparator|Early|men with on- demand sildenafil 100mg dosing from the early postoperative period
3216406|NCT01054001|Active Comparator|Delayed|men with on- demand sildenafil 100mg dosing from the delayed postoperative period
3216407|NCT01054014|Experimental|001|JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
3216408|NCT01054014|Experimental|002|JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
3216409|NCT01054014|Experimental|003|JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
3216410|NCT01054027|Experimental|0 Drop|Left eye dose
3216411|NCT01054027|Experimental|1 Drop|Left eye dose
3216412|NCT01054027|Experimental|2 drop|Left eye dose
3216413|NCT01054027|Active Comparator|3 drops|Right eye dose for all groups
3216414|NCT01054040|No Intervention|Standard nutrition cardiac care|Patients will receive standard care of group nutrition counselling and individual counselling if requested
3216415|NCT01054053||1|children born between 06/04/2004 and 17/04/2008 and called to menBvac vaccination and living around Neufchatel en Bray.
3216416|NCT01054092|Experimental|before meal group|ASP1941 will be administered before meal
3216417|NCT01054092|Experimental|after meal group|ASP1941 will be administered after meal
3216418|NCT01054105||Step I: BMPR-2 gene analysis|BMPR-2 gene analysis on 100 IPAH or heritable PAH Patients
3216419|NCT01054105||Step-II: Iloprost and Exercise Echo|Illoprost inhalation for 3 months & Check-up before and after treatment; WHO functional classification Assessment of exercise capacity (6M walk test) Cardiopulmonary exercise echocardiography NT-proBNP
3216420|NCT01054118|Experimental|001|JNJ-38431055 Liquid suspension of JNJ-38431055 administered as a single dose
3216421|NCT01054118|Active Comparator|002|Sitagliptin 100 mg Capsule containing 100 mg of sitagliptin administered as a single dose
3216422|NCT01054118|Experimental|003|JNJ-38431055 + Sitagliptin 100 mg Liquid suspension of JNJ-38431055 administered as a single dose and capsule containing 100 mg of sitagliptin administered as a single dose
3260388|NCT01478880|Experimental|cTBS|
3216423|NCT01054118|Placebo Comparator|004|Placebo Placebo suspension and placebo capsule administered as single doses
3216424|NCT01054196|Experimental|all patients|subjects will receive daily doses of lenalidomide starting on Day -5 of transplant and melphalan on Days -2 and -1.
3216425|NCT01054235|Experimental|experimental|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes). For control ,none of the intervention will be given.
3216426|NCT01054248|Experimental|MAS3|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
3216427|NCT01054248|Active Comparator|ALN+|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet)
3216428|NCT01054248|Experimental|DP|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
3216429|NCT01054261|Other|Normal|Normal renal function
3216430|NCT01054261|Other|Mild|Mild renal impairment
3216431|NCT01054261|Other|Moderate|Moderate renal impairment
3216432|NCT01054274|Active Comparator|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
3216433|NCT01054274|Experimental|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
3216434|NCT01054287|Experimental|Falls prevention|
3216435|NCT01054287|Placebo Comparator|Usual care|
3216436|NCT01054313|Experimental|Docetaxel + Sirolimus|Starting doses of Docetaxel 30 mg/m^2 IV every 3 weeks + Sirolimus 1 mg daily
3216437|NCT01054326|Experimental|Supervised physical therapy focusing of rotatorcuff exercises|Patients did specific exercises supervised by a physical therapists twice a week during two months. Focus was on early activation of rotator cuff and scapula stabilizers following different phases in a rehabilitation program Assessments before surgery,1 week after as well as 1,2,3 and 6 months after surgery.
3216438|NCT01054326|Active Comparator|Home exercises|Patients did home exercises following a programme during three months. Assessment considering shoulder function and pain was done before surgery, 1w after as well as 1,2,3 and 6 months after surgery,
3216439|NCT01054352|Experimental|001|JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added
3216440|NCT01054352|Experimental|002|JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
3216441|NCT01054352|Experimental|003|JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers
3216442|NCT01054352|Experimental|004|JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3.
3216443|NCT01054365||Delayed Discharge Group (DDG)|D/C at least 24 hours after procedure or at usual discharge time (n =200)
3216444|NCT01054365||Early Discharge Group (EDG)|D/C 6 hours after procedure if no indication for extended stay after randomization (n=200)
3216445|NCT01054391|Experimental|NEC Arm|Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
3216446|NCT01054417||Appendicitis|Patients with suspected appendicitis who are to be operated upon by diagnostic laparoscopy
3216447|NCT01054430|Other|Normal|Subjects with normal hepatic function
3216448|NCT01054430|Other|Mild Hepatic Dysfunction|Subjects with mild hepatic impairment
3216449|NCT01054430|Other|Moderate hepatic dysfunction|Subjects with moderal hepatice impairment
3216450|NCT01054469|Placebo Comparator|TAP block with placebo|
3216451|NCT01054469|Active Comparator|TAP block with ropivacaine|
3216452|NCT01054482|Experimental|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
3216453|NCT01054482|Active Comparator|Pre-operative concurrent chemoradiation therapy|
3216454|NCT01054495|Active Comparator|Acupuncture|Needle acupuncture at acupuncture point pericardium 6
3216455|NCT01054495|Sham Comparator|Sham acupuncture|Non-penetrating sham needling at acupuncture point pericardium 6
3216456|NCT01054495|Placebo Comparator|Laser acupuncture|Laser stimulation at acupuncture point pericardium 6
3216457|NCT01054508|Other|Arm 1: Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks)|Placebo (4 weeks) --> Placebo (12 weeks) --> Placebo (4 weeks) --> Tredaptive (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
3216458|NCT01054508|Other|Arm 2: Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks)|Placebo (4 weeks) --> Tredaptive (12 weeks) --> Placebo (4 weeks) --> Placebo (12 weeks) There were two interventional periods of 12 weeks during which patients received either Placebo or Tredaptive (nicotinic acid/laropiprant). Patient who received Tredaptive were given dosages of 1g/20mg for 4 weeks followed by 2g/40mg for 8 weeks.
3260389|NCT01478880|Sham Comparator|Sham cTBS|
3260390|NCT01478893|Experimental|SEL-068|
3260391|NCT01478893|Placebo Comparator|Saline|
3260392|NCT01478906||elderly ,adult|
3260393|NCT01478932|Experimental|Diaphragmatic Breathing Retraining|
3216459|NCT01054521|Experimental|Temperature-controlled RF (TCRF)|The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
3216460|NCT01054521|Active Comparator|Bipolar RF (BRF)|The bipolar RF (BRF) probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
3216461|NCT01054534|Other|Placement of interstim lead|Placement of interstim lead using US image fusion technology
3216462|NCT01054547|Placebo Comparator|Liposomal ropivacaine, topical|The topical anesthetics were applied at the region of right and left maxillary lateral incisors at the buccal mucosa.
3216463|NCT01054547|Placebo Comparator|Liposomal ropivacaine, palatal mucosa|Topical formulations were applied at the palatal mucosa at the right canine region and efficacy of topical formulations was accessed through insertion of a 30 gauge needle and injection of anesthetic solution.
3216464|NCT01054638||HIV infected patients: HAART naive or experienced|Patients with a claims diagnosis of HIV infection (HIV, AIDS, or ARC) in the NHI or Impact Databases, according to either of the 3-digit International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes 042 HIV disease and V08 Asymptomatic HIV infection status
3216465|NCT01054638||Patients with HIV infection HAART naïve|A naïve subcohort of patients consisting of HAART initiators. Among the primary cohort, we will exclude patients with a dispensing for any HAART in the 6-month baseline period prior to the cohort entry date.
3216466|NCT01054651|Experimental|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
3216467|NCT01054651|Active Comparator|Praziquantel|
3216468|NCT01054664||impaired liver enzymes|
3216469|NCT01054664||normal liver enzymes|
3216470|NCT01054664||hepatitis C antibodies positive|
3216471|NCT01054677|Experimental|Educational intervention on antibiotic prescribing|The participants in this group received an educational intervention.
3216472|NCT01054677|No Intervention|No educational intervention|The participants in this group did not receive the educational intervention
3216473|NCT01054690|Experimental|Silver alloyed urinary catheter|
3216474|NCT01054690|Placebo Comparator|Silicone urinary catheter|
3216475|NCT01054794|Active Comparator|Stimulation ON|
3216476|NCT01054794|Sham Comparator|Stimulation OFF|
3216477|NCT01054807|Other|GalyfilconHL/Galyfilcon8.7/Galyfilcon8.3|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)
3216478|NCT01054807|Other|Galyfilcon8.7/Galyfilcon8.3/GalyfilconHL|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
3216479|NCT01054807|Other|GalyfilconHL/Galyfilcon8.3/Galyfilcon8.7|Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)
3216480|NCT01054807|Other|Galyfilcon 8.7/Galyfilcon HL/Galyfilcon 8.3|Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator) /Galyfilcon A 8.3 BC (Experimental)
3216481|NCT01054807|Other|Galyfilcon8.3/GalyfilconHL/Galyfilcon8.7|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)/Galyfilcon A 8.7 BC (Experimental)
3216482|NCT01054807|Other|Galyfilcon8.3/Galyfilcon8.7/GalyfilconHL|Galyfilcon A 8.3 BC (Experimental)/Galyfilcon A 8.7 BC (Experimental)/Galyfilcon A Habitual Lens (Active Comparator)
3216483|NCT01054833|Experimental|Needleless sling|Needleless® sling
3216484|NCT01054859|Experimental|Treatment A|0.5 g/Kg alcohol plus 200 mg avanafil tablet
3216485|NCT01054859|Active Comparator|Treatment B|0.5 g/kg alcohol
3216486|NCT01054859|Active Comparator|Treatment C|200 mg avanafil tablet
3216487|NCT01054872|Experimental|Monozygotic (MZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
3216488|NCT01054872|Experimental|Dizygotic (DZ) Twins|Participants will receive the DNA vaccine at baseline and Months 1 and 2. They will then receive the rAd5 vaccine at Month 6.
3216489|NCT01054898|Experimental|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
3216490|NCT01054898|Active Comparator|Usual community services|Standard care for abused women in the community
3216491|NCT01054924||U.S. CRC screening population|
3216492|NCT01054937|Experimental|4SC-203|
3216493|NCT01054937|Placebo Comparator|Placebo|
3216494|NCT01054950|Experimental|Education and counseling|Phone calls using behavioral techniques
3216495|NCT01054950|Placebo Comparator|Control|Single phone call
3216496|NCT01054989|Active Comparator|Fat intravenously|Intravenous application of fat
3216497|NCT01054989|Active Comparator|Fat orally|Oral fat load
3216498|NCT01054989|Active Comparator|LPS intravenously|Lipopolysaccharide (LPS; US Standard Reference endotoxin)
3216499|NCT01054989|Placebo Comparator|Glycerol intravenously|Intrevenous glycerol infusion
3216500|NCT01055002|Active Comparator|Artemether/lumefantrine tablets|Artemether (20 mg) and Lumefantrine (120 mg) tablets: Four tablets taken as a single dose twice a day with fatty food for three days (total dose of 24 tablets in 6 doses) on days 6-8
3216501|NCT01055002|Active Comparator|Atovaquone/Proguanil HCl tablets|Atovaquone (250 mg) and Proguanil HCl (100 mg) tablets: Four tablets taken as a single dose daily for 3 days (total dose of 12 tablets) on days 6-8
3216502|NCT01055015|Experimental|1|Q8003, Flexible dose
3216503|NCT01055015|Experimental|2|Q8003, Low dose
3260394|NCT01478945|Active Comparator|Dermfix 1000 active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB"
3216504|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period .All three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
3216505|NCT01055041|Experimental|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all three participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks
3216506|NCT01055041|Experimental|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
3216507|NCT01055080|Placebo Comparator|Cow's milk formula|
3216508|NCT01055080|Active Comparator|Bovine insulin-free whey based formula|
3216509|NCT01055080|Active Comparator|Whey-based hydrolysed formula|
3216510|NCT01055093||Diabetes Cohort|Prospectively followed cohort of newly diagnosed patients with diabetes mellitus, aged 18-69 years at inclusion into the study
3216511|NCT01055093||Control Cohort|Prospectively followed cohort of glucose tolerant humans, aged 18-69 years at inclusion into the study
3216512|NCT01055106|Active Comparator|1D|
3216513|NCT01055106|Active Comparator|3D|
3216514|NCT01055106|Active Comparator|5D|
3216515|NCT01055106|Active Comparator|Metronidazole|
3216516|NCT01055119|Active Comparator|Omega-3 fatty acids|
3216517|NCT01055119|Placebo Comparator|Olive oil|
3216518|NCT01055145|Active Comparator|levofloxacin|Levofloxacin 750mg po per day for 3 months
3216519|NCT01055145|Active Comparator|moxifloxacin|Moxifloxacin 400mg po per day for 3 months
3216520|NCT01055158|Experimental|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes.
3216521|NCT01055158|Active Comparator|Control|Enhanced Usual Care
3216522|NCT01055236|Placebo Comparator|hydroxyzine|
3216523|NCT01055236|Placebo Comparator|placebo|starch tablet
3216524|NCT01055249|Other|Group A|Ibuprofen 600 mg (active comparator); Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
3216525|NCT01055249|Other|Group B|Oral Placebo (placebo comparator), Hydrocortisone 15 microl/cm2 (active comparator); Placebo Gel (placebo comparator)
3216526|NCT01055275||Cook Iliac Branch Graft|Patients implanted with a Cook Iliac Branch Graft
3216527|NCT01055301|Experimental|treatment|"Ind (1cycle):~bort 1mg/m2 IV/SQ D1,4,8,11 D1-4: thalid 200mg/d & dex 20mg/d PO; cisplatin & dox 10mg/m2/d, cyclophos 400mg/m2/d, etoposide 40mg/m2/d contIV; enoxaparin 40mg/d SQ prn.~PBSC Coll: at recovery per local standard~Bridging (before/between trans/after Cons):~thal 50mg/d D1-21 & dex 20mg D1,8,15 PO~Tandem Trans (x2):~bort 1mg/m2 IV/SQ D-4,-1 D-4to-1: mel 50 mg/m2 IV, thal 200mg/d & dex 40mg/d PO PBSC >/=200x10^6 cells~Cons (1cycle):~same as Ind except cis/dox 7.5mg/m2/d, cyclo 300mg/m2/d, no enox~Maint(</= 3 yrs):~D1,8,15,22:bort 1mg/m2 IV/SQ, dex 20mg/d PO; len 20mg/d PO D1-20"
3216528|NCT01055327||Infants/foetuses w/malformations registered in EUROCAT network|Pregnancies resulting in foetus/infant with malformation registered through participating registers within the EUROCAT network
3216529|NCT01055340|Experimental|Treatment sequence 1|OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min - Placebo
3216530|NCT01055340|Experimental|Treatment sequence 2|OXM 0.6 pmol/kg/min - Placebo - OXM 3.0 pmol/kg/min
3216531|NCT01055340|Experimental|Treatment sequence 3|Placebo - OXM 3.0 pmol/kg/min - OXM 0.6 pmol/kg/min
3216532|NCT01055340|Experimental|Treatment sequence 4|OXM 3.0 pmol/kg/min - Placebo - OXM 0.6 pmol/kg/min
3216533|NCT01055340|Experimental|Treatment sequence 5|Placebo - OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min
3216534|NCT01055340|Experimental|Treatment sequence 6|OXM 0.6 pmol/kg/min - OXM 3.0 pmol/kg/min - Placebo
3216535|NCT01055366|Experimental|Elazop (Azarga)|Elazop Treatment arm
3216536|NCT01055379|Experimental|Rasagiline|
3216537|NCT01055379|Placebo Comparator|Placebo|
3216538|NCT01055392|Experimental|Lithium|Patients received low doses of lithium salts (from 150 mg to 450 mg of lithium salts daily) to achieve sub-therapeutic lithium levels (target serum lithium level of 0,25 - 0,5 mEq/L). Lithium doses were administered twice a day. Lithium doses were titrated to achieve the target serum lithium levels within the first two weeks after study recruitment. After achieving the target serum lithium level, lithium salts doses remained stable until the end of the study.
3216539|NCT01055392|Placebo Comparator|Placebo|Identical placebo tablets were administered twice-a-day for two years.
3216540|NCT01055405|Experimental|Sildenafil plus pulmonary rehabilitation|
3216541|NCT01055405|Placebo Comparator|Placebo plus pulmonary rehabilitation|
3216542|NCT01055418|Placebo Comparator|placebo|
3216543|NCT01055418|Experimental|Vitamin C|
3216544|NCT01055431|Placebo Comparator|Control|Control bread
3216545|NCT01055431|Active Comparator|Teff bread|Teff bread
3216546|NCT01055444|Experimental|Heated lidocaine/tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
3216547|NCT01055470|Active Comparator|Diclofenac|Tab.Diclofenac 50 mg ,Orally, 12 hrly in morning and in evening after taking food for 3 months.
3216548|NCT01055470|Experimental|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
3216549|NCT01055483|Experimental|LBH589|
3216550|NCT01055509|Experimental|Cognitive Adaptation Training|Cognitive adaptation training and treatment as usual
3260395|NCT01478945|Active Comparator|Waldmann active 311 nm NB-UVB|"Active hand held NB-UVB unit:~Manual device administering NB-UVB (Waldmann)"
3216551|NCT01055509|No Intervention|Treatment as ususal|Pharmacological treatment, weekly contact to professionals (often in patient's homes), psychoeducation, social skill training in groups and psychosocial intervention with relatives.
3216552|NCT01055522|Experimental|ARM 1: L19IL2 + Dacarbazin|
3216553|NCT01055522|Experimental|ARM 2: L19IL2 + Dacarbazin|
3216554|NCT01055522|Active Comparator|ARM 3: Dacarbazin|DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first
3216555|NCT01055535|Experimental|Microplasmin|
3216556|NCT01055548||Parents of babies born before 33 weeks gestation|
3216557|NCT01055561|Experimental|Patients|
3216558|NCT01055561|Experimental|Healthy volunteers|
3216559|NCT01055574||ProDisc-L|Subjects who received single-level ProDisc-L total disc replacement prior to physical capability evaluations
3216560|NCT01055574||anterior lumbar interbody fusion (AILF)|Subjects who received single-level anterior lumbar interbody fusion prior to physical capability evaluations
3216561|NCT01055587||major abdominal surgery|The investigators compare the levels of biomarkers in patients with and without complications in the early postoperative course following major abdominal surgery
3216562|NCT01055587||severe burn injury|The investigators compare levels of biomarkers within the first 20 days in patients with and without complications following severe burn injury
3216563|NCT01055600|Experimental|Study|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
3216564|NCT01055652|Experimental|1|
3216565|NCT01055678|Experimental|All Patients|Single arm study analyzing tumor hypoxia after EF5 injection
3216566|NCT01055691|Experimental|1|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
3216567|NCT01055691|Experimental|2|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
3216568|NCT01055691|Experimental|3|Fixed dose combination dapagliflozin/metformin IR tablets followed by free combination of dapagliflozin tablet and metform IR tablet
3216569|NCT01055691|Experimental|4|Free combination of dapagliflozin tablet and metform IR tablet followed by fixed dose combination dapagliflozin/metformin IR tablets
3216570|NCT01055717|Placebo Comparator|Placebo muffin made with no oats|
3216571|NCT01055717|Active Comparator|Test muffin made with AV-enriched oats|
3216572|NCT01055730||Pulmonary rehabilitation|
3216573|NCT01055743|Experimental|Radical resection + Fluorouracil Implants|
3216574|NCT01055743|Active Comparator|Radical resection|
3216575|NCT01055756|Experimental|Test (Cloratadd D)|Loratadine + Pseudoephedrine sulfate Test
3216576|NCT01055756|Active Comparator|Comparator (Claritin D)|Loratadine + Pseudoephedrine Comparator
3216577|NCT01055795|Experimental|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
3216578|NCT01055808||Type 2 diabetes treated with insulin|
3216579|NCT01055821|Active Comparator|Arm A|Standard of care (SOC)
3216580|NCT01055821|Experimental|Arm B|Vaccine and Standard of care
3216581|NCT01055821|Experimental|Arm C|vaccine and standard of care
3216582|NCT01055847|Experimental|AI 75 mg|Aztreonam for Inhalation 75 mg twice daily
3216583|NCT01055847|Experimental|AI 225 mg|Aztreonam for Inhalation 225 mg twice daily
3216584|NCT01055847|Placebo Comparator|Placebo|Placebo
3260396|NCT01478945|Sham Comparator|Dermfix 1000 placebo|Manual placebo hand held NB-UVB unit
3216585|NCT01055860||Robotic sacral colpopexy|Our study population will be women who underwent Robotic assisted laparoscopic sacral colpopexy at the Morristown Memorial Hospital for correction of pelvic organ prolapse using a synthetic polypropylene mesh.
3216586|NCT01055899|Experimental|Dose 1|First dose of SC REGN88
3216587|NCT01055899|Experimental|Dose 2|Second dose of SC REGN88
3216588|NCT01055899|Experimental|Dose 3|Third dose of SC REGN88
3216589|NCT01055912|Experimental|Lixivaptan|Capsule, 100mg Lixivaptan or matching placebo once daily.
3216590|NCT01055912|Placebo Comparator|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
3216591|NCT01055925|Active Comparator|MPV|
3216592|NCT01055925|Active Comparator|Aquacel|
3216593|NCT01055938|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3216594|NCT01055938|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3216595|NCT01055951|Experimental|Solo MicroPump|
3216596|NCT01055964|Experimental|Tacrobell|
3216597|NCT01055964|Active Comparator|Prograf|
3216598|NCT01055990|Other|Heathy,aged 18-60 years,|They are healthy, are 18-60 years of age, did not have a history of infection with the 2009 H1N1 virus, and are appropriate to vaccination, without any interdictions. And they guardians confirmed that they understood the study procedures, provided written informed consent, and agreed to comply with the following visit schedule. Woman participants all are not pregnant,with a negative pregnancy test before vaccination.
3260397|NCT01478984|Active Comparator|one staged PCI|the patient randomized to this arms complete the myocardial revascularization in one stage PCI, the investigators treat all lesions.
3216599|NCT01055990|Experimental|clinically critical H1N1 patients|The critical H1N1 patients as recipients whose conditions are confirmed according to current standard for critical H1N1 diagnosis. The study wll research H1N1 viral load in blood of critical H1N1 patients and swab nucleic acid testing parallelity; measure H1N1 viral Load in blood and swabs (adopting Real-time PCR method) of 5 to 10 victims; and the planned blood taking time is the tenth day since the fever begins.
3216600|NCT01056003||all patients admitting endoscopy for EGD|
3216601|NCT01056029|Experimental|G-202|
3216602|NCT01056042|Experimental|A|Intramuscular depot medroxyprogesterone acetate
3216603|NCT01056042|Active Comparator|B|ethinyl estradiol 30 micrograms combined with gestodene 75 micrograms
3216604|NCT01056055||Suture anchor, Bone tunnel|Suture anchor group: patients who underwent the modified Brostrom procedure using suture anchor technique Bone tunnel group: patients who underwent the modified Brostrom procedure using bone tunnel technique
3216605|NCT01056081|Experimental|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
3216606|NCT01056094|Active Comparator|20mg Lutein|Dietary Supplement: 20mg Lutein; daily supplementation 12 week
3216607|NCT01056094|Active Comparator|10mg Lutein|Dietary Supplement: 10mg Lutein; daily supplementation 12 week
3216608|NCT01056094|Placebo Comparator|0mg Lutein|Dietary Supplement: 0mg Lutein; daily supplementation 12 week
3216609|NCT01056120||ENERGY-Population|"Patient population in standard clinical care, according to the instructions for use and the inclusion / exclusion criteria. Registry patients should be enrolled consecutively to represent a typical set of patients at each site.~The registry will collect clinical data from patients that have given their prior written consent. All data will be anonymized prior to data entry."
3216610|NCT01056133|Experimental|Omega-3 capsules-Fish Oil|Omega-3 fatty acids in the form of fish oil capsules (2g/d)
3216611|NCT01056146|Active Comparator|Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
3216612|NCT01056146|Experimental|I-InTERACT|Participants will receive the internet-based parenting skills program.
3216613|NCT01056159|Experimental|Albuterol dry powder inhaler|The participants will receive albuterol delivered with the a DPI (dry powder inhaler) and placebo with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler).
3216614|NCT01056159|Active Comparator|Albuterol HFA MDI|The participants will receive albuterol delivered with an HFA MDI inhaler (hydrofluoroalkane metered dose inhaler) and placebo with albuterol in a DPI (dry powder inhaler).
3216615|NCT01056172|Active Comparator|A. 24 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 24 weeks in patients with RVR.
3216616|NCT01056172|Experimental|B. 16 weeks in RVR patients.|Peginterferon alfa-2a and weight-based ribavirin (800-1200mg/day) for 16 weeks in patients with RVR.
3216617|NCT01056185||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
3216618|NCT01056185||Novel Respiratory Virus-1|MERS-CoV (Middle East Respiratory Syndrome Coronavirus
3216619|NCT01056185||Novel Respiratory Virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
3216620|NCT01056211|Active Comparator|hypopigmented scars treated with laser|patients with hypopigmented scars treated with Starlux 300 Lux 1540nm Fractional laser hand piece
3216621|NCT01056211|Placebo Comparator|hypopigmented scars treated without laser|patients with hypopigmented scars treated without laser
3216622|NCT01056211|Active Comparator|hypertrophic scars treated with laser|
3216623|NCT01056211|Placebo Comparator|hypertrophic scars not treated with laser|
3216624|NCT01056211|Active Comparator|scars due to grafts and reconstructions treated with laser|scars due to grafts and reconstructions in the head and neck region
3216625|NCT01056211|Placebo Comparator|grafts and reconstructions scars not treated with laser|scars due to grafts and reconstructions in the head and neck region
3216626|NCT01056224|Experimental|1.25 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3216627|NCT01056224|Experimental|1.5 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3216628|NCT01056224|Experimental|1.75 ug/kg normo-tensive 20-40 year olds|A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.
3216629|NCT01056224|Experimental|1 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
3216630|NCT01056224|Experimental|1.25 ug/kg normo-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.
3216631|NCT01056224|Experimental|1.5 ug/kg normo-tensive 65-75 year olds|"1.5 ug/kg normo-tensive 65-75 year olds~A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old."
3216632|NCT01056224|Experimental|1 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3216633|NCT01056224|Experimental|1.25 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3216634|NCT01056224|Experimental|1.5 ug/kg hyper-tensive 65-75 year olds|A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.
3216635|NCT01056237|Experimental|Multi-target therapy|(Tarcrolimus+mycophenolate mofetil)
3216636|NCT01056237|Active Comparator|Azathioprine|Aza
3216637|NCT01056250|Other|SILS cholangiography|Performing cholangiography in all patients undergoing SILS cholecystectomy.
3216638|NCT01056354||Influenza|Influenza A and subtypes such as H3N2 and 2009 H1N1 or influenza B
3216639|NCT01056354||Novel respiratory virus-1|MERS-CoV (Middle Eastern Respiratory Syndrome Coronavirus)
3216640|NCT01056354||Novel respiratory virus-2|SARS-CoV (Severe Acute Respiratory Syndrome Coronavirus)
3216641|NCT01056393|Experimental|ibalizumab 800mg Q2Weeks|Subject will receive 800mg of ibalizumab every 2 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
3216642|NCT01056393|Experimental|ibalizumab 2000mg Q4Weeks|Subject will receive 2000mg of ibalizumab every 4 weeks administered by intravenous infusion. All patients also will receive optimized background regimen
3216643|NCT01056406|No Intervention|Control Group|Overweight and obese pregnant women who are randomly assigned to the control group will receive the current standard of optimal care in addition to 1 nutrition education session with the study nutritionist (a registered dietitian) at 6-16 weeks gestation.
3216644|NCT01056406|Experimental|Nutrition Education Group|Overweight and obese pregnant women randomly assigned to the nutrition education group, in addition to the current standard of optimal care, will receive twice monthly interaction with the study nutritionist (a registered dietitian) from 6-16 weeks gestation through 6 months postpartum.
3216645|NCT01056419|Active Comparator|Total thyroidectomy|
3216646|NCT01056419|Active Comparator|Anti-thyroid drug|
3216647|NCT01056445|Active Comparator|carotid stenting and hemodynamic instability|27 patients undergone carotid stenting
3216648|NCT01056445|Active Comparator|carotid stenting without hemodynamic instability|no hemodynamic instability after carotid stenting
3216649|NCT01056458|Active Comparator|Acupressure acupressure|
3216650|NCT01056458|Sham Comparator|sham acupressure|
3216651|NCT01056471|Experimental|Low dose autologous mesenchymal cells|The dose of infused cells is 10e6 cells/Kg
3216652|NCT01056471|Experimental|High dose|The dose of infused cells is 4*10e6 cells/Kg
3216653|NCT01056471|No Intervention|Placebo Control|
3216654|NCT01056497|Experimental|alpha lipoic acid|
3216655|NCT01056549|Experimental|exenatide subcutaneous injection|Study A: lipoprotein turnover following subcutaneous exenatide administration, under conditions of pancreatic clamp. Study B: lipoprotein turnover study following subcutaneous placebo administration, under conditions of pancreatic clamp.
3216656|NCT01056575|Experimental|OC000459|
3216657|NCT01056588|Placebo Comparator|Control Condition|In this condition, participants will receive reinforcement for timely breath samples with no contingency for a specific breath CO level.
3216658|NCT01056588|Active Comparator|CO-Contingent|In this condition, participants will receive reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking.
3216659|NCT01056614|Experimental|Treatment (chemotherapy, PBSC transplant)|Patients receive fludarabine phosphate IV over 30 minutes on days -9 to -6, busulfan IV over 3 hours on days -5 to -2, and anti-thymocyte globulin IV over 6 hours on days -3 and -2 and over 4 hours on day -1. Patients undergo allogeneic PBSC transplant on day 0. Patients then receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and taper to day 180 and methotrexate IV on days 1, 3, 6, and 11.
3216660|NCT01056627|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3216661|NCT01056627|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3216662|NCT01056666|Experimental|Conveen optima urisheaths|
3216663|NCT01056666|Placebo Comparator|absorbent protections|The patient use their usual absorbent protection as comparator. All brands are allowed.
3216664|NCT01056679|Experimental|AVD-Rev|Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results
3216665|NCT01056692|Active Comparator|Active compound|OC000459 orally
3216666|NCT01056692|Placebo Comparator|Placebo|Placebo given orally
3216667|NCT01056705|Experimental|Cohort 1: Experiment Infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections;
3216668|NCT01056705|Experimental|Cohort 2: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections;
3216669|NCT01056705|Experimental|Cohort 3: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections;
3216670|NCT01056705|Experimental|Cohort 4: Experiment infants|Biological: Oral Poliomyelitis Vaccine (OPV).3x0.1ml oral;
3216671|NCT01056705|Experimental|Cohort 5: Experiment infants|Biological: Inactivated Poliomyelitis Vaccine (Salk strains). 3x0.5ml intramuscular injections;
3216672|NCT01056731|Experimental|Aliskiren and Aliskiren_HCTZ|aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg 25 mg
3216673|NCT01056744|Active Comparator|DES|Implantation of a XIENCE® V everolimus eluting coronary stent (drug-eluting stent, DES)
3216674|NCT01056744|Active Comparator|BMS/DEB|Implantation of a Coroflex Blue® coronary stent (bare metal stent, BMS) postdilated with a Sequent Please® paclitaxel-eluting balloon (drug-eluting balloon, DEB)
3216675|NCT01056757|Experimental|Ribavirin|
3216676|NCT01056770|Experimental|Vaccinia-naive group|2.5 * 10^5 pfu/dose
3216677|NCT01056783|Experimental|OC000459|OC000459 100mg twice daily
3216678|NCT01056783|Placebo Comparator|Placebo|
3260398|NCT01478984|Active Comparator|multistaged PCI|the patients randomized to this arms in the first stage the investigators treat only the culprit lesion and in second stage the investigators treat the other vessels
3216679|NCT01056796|Experimental|CAR™ 27|Any patient with a diagnosis of colorectal cancer that has been previously radiated to the pelvic area (6-8 weeks prior to surgery) and that is electively scheduled for an open or laparoscopic total mesorectal excision (TME) and low anterior resection surgery (< 10cm from the anal verge) which requires the creation of an anastomosis, will be offered participation in this study.
3216680|NCT01056809|Active Comparator|Traditional strategy|First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
3260399|NCT01478997|Experimental|Flexsure Capsules|Investigational Product
3260400|NCT01478997|Placebo Comparator|Carboxy Methyl Cellulose Capsules|Placebo
3216681|NCT01056809|Active Comparator|Alternative strategy|First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
3216682|NCT01056835|No Intervention|control|
3216683|NCT01056848||CK-LX3401|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia.
3216684|NCT01056848||CK-LX3405|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
3216685|NCT01056848||CK-LX3430|Patients with euvolemic or hypervolemic hyponatremia and who were enrolled in a randomized, blinded, placebo-controlled Phase III lixivaptan study of hyponatremia
3216686|NCT01056861||Cervical dystonia (torticollis)|Subjects meeting the criteria fot torticollis who are receiving botulinum toxin injections.
3216687|NCT01056861||Control|age matched controls with out cervical dystonia (torticollis)
3216688|NCT01056874|Active Comparator|Digoxin|
3216689|NCT01056874|Experimental|Digoxin + Maraviroc|
3216690|NCT01056887||Primary Polydip, D. insipidus|
3216691|NCT01056900||Chondron Implantation|This clinical trial was a follow-up study involving 127 patients from 10 hospitals, for whom autologous chondrocyte transplantation was already performed. All the subjects were investigated as a single group
3216692|NCT01056926|Experimental|Nicotine Patch + Denic Smoking|Subjects will wear a nicotine patch and smoke denic cigarettes for 24 hours prior to scan
3216693|NCT01056926|Experimental|Placebo Patch + Denic Smoking|Subjects will wear a placebo patch and smoke denic cigarettes 24 hours prior to scan
3216694|NCT01056926|Experimental|Nicotine Patch + No Smoking|Subjects will wear a nicotine patch and not smoke for 24 hours prior to scan
3216695|NCT01056926|Experimental|Placebo Patch + No Smoking|Subjects will wear a placebo patch and not smoke for 24 hours prior to scan
3216696|NCT01056939|Active Comparator|NAVA|Children randomised in this arm will be treated with neurally adjusted ventilatory assist
3216697|NCT01056939|Active Comparator|Control|Patients randomized to control group will be treated with pressure controlled ventilation (PC) when they are newborns and older children in this group will be treated with pressure regulated volume controlled (PRVC) ventilation.
3216698|NCT01056952|Experimental|Optiflow then CPAP|Standard low flow oxygen therapy then High flow oxygen nasal therapy (Optiflow)then Continuous positive airway pressure (CPAP)
3216699|NCT01056952|Experimental|CPAP then Optiflow|Standard low flow oxygen therapy then Continuous positive airway pressure (CPAP)then High flow oxygen nasal therapy (Optiflow)
3216700|NCT01056965|Experimental|davunetide (Al-108, NAP) nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with either davunetide 15 mg or placebo. Davunetide and placebo will be administered intranasally with a multi-dispensing, metered nasal spray pump device.
3216701|NCT01056965|Placebo Comparator|Placebo nasal spray|
3216702|NCT01056978||patients|Patients admitted in a palliative care unit
3216703|NCT01056991|Experimental|warming mattress|Patient warmed with electric mattress
3216704|NCT01056991|Active Comparator|warming blanket|Forced air warming blanket
3216705|NCT01057004||all patients|chronical heart failure and EF ≤ 40 %
3216706|NCT01057030|Active Comparator|A1 (BMS-708163)|Healthy Japanese Subjects
3216707|NCT01057030|Placebo Comparator|A2 (Placebo)|Healthy Japanese Subjects
3216708|NCT01057030|Active Comparator|B1 (BMS-708163)|Healthy Non-Japanese Subjects
3216709|NCT01057030|Placebo Comparator|B2 (Placebo)|Healthy Non-Japanese Subjects
3216710|NCT01057043|No Intervention|Waiting list|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
3216711|NCT01057043|Experimental|Cupping|In case of acute pain patients may take paracetamol as rescue medication, maximum dosage 2 gram per day.
3216712|NCT01057056|No Intervention|control group|control group - receiving standard treatment
3216713|NCT01057069|Experimental|HRD; 1x ddAC, 2x tCTC|HRD positive tumors; irrespective of response; - a fourth course of AC followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
3216714|NCT01057069|Active Comparator|HRD; 3x CP|HRD tumors; any response to 3x ddAC; 3 courses of CP
3216715|NCT01057069|Active Comparator|non-HRD;3x CP|non-HRD tumors; unfavourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
3216716|NCT01057069|Active Comparator|non-HRD; response; 3x ddAC|non-HRD tumors; favourable response to 3x ddAC; 3 more courses of ddAC
3216717|NCT01057069|Active Comparator|non-HRD; response; 3x CP|non-HRD tumors; favourable response to 3x ddAC; 3 courses of Carboplatin and Paclitaxel
3216718|NCT01057082|Experimental|Juven|Participants in the treatment arm will receive the dietary supplement Juven.
3216719|NCT01057082|Placebo Comparator|Placebo|
3216720|NCT01057108|Active Comparator|ESRD: FOSTRAP Chewing Gum|
3216721|NCT01057108|Active Comparator|CKD: FOSTRAP Chewing Gum|
3216722|NCT01057108|Placebo Comparator|ESRD Matching Placebo|
3216723|NCT01057108|Placebo Comparator|CKD Matching Placebo|
3216724|NCT01057147|Experimental|rebamipide 2% ophthalmic suspension|
3216725|NCT01057147|Placebo Comparator|placebo eye drops|
3216726|NCT01057160|Experimental|intake of rizatriptan 10 mg|
3216727|NCT01057160|Active Comparator|previous used analgesic|
3216728|NCT01057173|Experimental|Transcatheter Aortic Valve Implantation|
3216729|NCT01057173|Active Comparator|Surgical Aortic Valve Replacement|
3216730|NCT01057186||hereditary hypophosphatemia|Norwegian patients with hereditary hypophosphatemia.
3216731|NCT01057186||Hereditary hyperphosphatemia|Norwegian patients with hereditary hyperphosphatemia (hyperphosphatemic familial tumoral calcinosis and hyperphosphatemia hyperostosis syndrome).
3216732|NCT01057212|Experimental|Bevacizumab and Ixabepilone|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks. Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule to the remaining 40 patients.
3216733|NCT01057238|Experimental|Intensive Communication|regular family meeting every 5 days.
3216734|NCT01057238|No Intervention|Control|usual care
3216735|NCT01057264|Experimental|HAI Abraxane + Gemcitabine + Bevacizumab|HAI (hepatic arterial infusions) Abraxane with Gemcitabine + Bevacizumab
3216736|NCT01057316|Experimental|Study Group A|
3216737|NCT01057316|Experimental|Study Group B|
3216738|NCT01057316|Experimental|Study Group C|
3216739|NCT01057329||Anorexia nervosa|36 severe AN patients treated with aripiprazole
3216740|NCT01057329||Anorexia|36 severe anorexia nervosa patients treated with olanzapine
3216741|NCT01057329||Attention Deficit Hyperactivity Disorder|30 ADHD patients treated with atomoxetine
3216742|NCT01057329||Depressive disorder|30 depressed patients treated with duloxetine
3216743|NCT01057342|Experimental|Paclitaxel, Carboplatin, ASA404|
3216744|NCT01057355|Experimental|Cyst ethanol lavage|Subjects receiving the study intervention
3216745|NCT01057368|Active Comparator|Mindfulness Based Stress Reduction|
3216746|NCT01057368|Active Comparator|Health Enhancement Program|
3216747|NCT01057368|No Intervention|Wait List Controls|
3216748|NCT01057368|Active Comparator|Long Term Meditators|
3216749|NCT01057407|Experimental|ASP group|
3216750|NCT01057407|Active Comparator|Sevelamer group|
3216751|NCT01057420|Other|Inhalation of 80% Oxygen|Inhalation of 80% Oxygen by nonrebreathing reservoir face masks for 4 hours
3216752|NCT01057459||Ancillary-Correlative (biomarkers and treatment outcomes)|Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
3216753|NCT01057472||Term born babies|Term born babies
3216754|NCT01057472||Preterm babies ready for discharge|Preterm babies ready for discharge
3216755|NCT01057472||Preterm stable babies 1500 grams|Preterm stable babies 1500 grams
3216756|NCT01057485|Experimental|AF ablation and AV node ablation|Patients will receive the combined procedure of AF ablation as well as AV node ablation
3216757|NCT01057485|Active Comparator|AV node ablation|Patient will receive AV node ablation alone
3216758|NCT01057498|Experimental|1a - RNS60 in Healthy Subjects|Single dose administration of nebulized RNS60 testing for bronchoconstriction in healthy human subjects.
3216759|NCT01057498|Experimental|1b: RNS60 in Mild Asthmatics|Single-dose administration of nebulized RNS60 testing for bronchoconstriction in mild asthmatics.
3216760|NCT01057498|Experimental|2e: RNS60 in mild-to-moderate asthmatics|RNS60 in mild-to-moderate asthmatics who are not currently taking a chronic asthma medication.
3216761|NCT01057511|Active Comparator|progesterone|Each subject in this group will be give progesterone oil 20mg via intramuscular route once a day for 7 days totally
3216762|NCT01057511|Experimental|Crinone 8%|Each subjects in this group will be given Crinone 8% 90mg via vaginal route once a day for 7 days totally.
3216763|NCT01057524|Active Comparator|Usual Airway Clearance Technique|Two self administered treatment sessions a day and two treatments a day assisted by a Physiotherapist both using the patient's usual airway clearance method.
3216764|NCT01057524|Experimental|High Frequency Chest Wall Oscillation (HFCWO)|Two self administered treatments a day using HFCWO and two treatment sessions a day assisted by a Physiotherapist using their 'usual' airway clearance method.
3216765|NCT01057537|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2.
3216766|NCT01057537|Active Comparator|Usual Care|Participants in the usual care arm will take their usual cardiovascular medications. The participants will be seen as needed by their usual doctor between study visits.
3216767|NCT01057550|Active Comparator|Autologous Fascial Sling|Retropubic, bottom up autologous sling
3216768|NCT01057550|Active Comparator|TVT|Standard retropubic TVT
3216769|NCT01057550|Active Comparator|Pelvicol|Retropubic mid urethral sling made from Pelvicol
3216770|NCT01057563|Active Comparator|BMS group|Patients undergoing PCI with BMS implantation
3216771|NCT01057563|Active Comparator|PRE-DEB group|Patients undergoing PCI with BMS implantation after lesion predilation with DEB
3216772|NCT01057563|Active Comparator|POST-DEB group|Patients undergoing PCI with BMS implantation followed by postdilation with DEB
3216773|NCT01057576|Experimental|PMI 5011|An experimental group randomized to PMI 5011
3216774|NCT01057576|Placebo Comparator|Placebo|Placebo
3216775|NCT01057602||Normal community dwelling elders|Individuals age 65 and older who live in the community
3216776|NCT01057615|Experimental|Active Fish Oil + Vitamin C Placebo|Fifteen subjects will take 10 active fish oil capsules per day and 2 vitamin C placebo capsules per day for 3 weeks.
3216777|NCT01057615|Experimental|Fish Oil Placebo + Active Vitamin C|Fifteen subjects will take 10 fish oil placebo capsules per day and 2 active vitamin C capsules per day for 3 weeks.
3216778|NCT01057615|Experimental|Active Fish Oil + Active Vitamin C|Following a 2-week washout period, all subjects from the other two arms (n=30) will take 10 active fish oil capsules per day and 2 active vitamin C capsules per day for 3 weeks.
3216779|NCT01057628|Experimental|ASP1941 group|oral
3216780|NCT01057628|Placebo Comparator|placebo group|oral
3216781|NCT01057641|Experimental|Spacer|"Implantation of a percutaneously implanted interspinous device (spacer)"
3216782|NCT01057641|Other|physiotherapy|The control group will receive at least physiotherapy and physical therapy (e.g. massage and fango). Under inpatient conditions therapy will last for seven days. After discharge physical therapy has to be continued for 5 weeks. A schedule will ensure the consistency of the physical therapy. The inpatient-treatment can be repeated every 6 months if necessary.
3216783|NCT01057654|Experimental|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
3216784|NCT01057654|Active Comparator|Pravastatin|Pravastatin 40 mg per day
3216785|NCT01057667|Experimental|Arm A: With RO5024048|Patients in arm A will receive RO5024048 (1000mg orally twice daily) for 24 weeks in addition to Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily).
3216786|NCT01057667|Active Comparator|Arm B: Standard treatment|Patients in arm B will receive standard treatment with Pegasys (180 micrograms sc weekly) and Copegus (1000mg or 1200mg orally daily) for 48 weeks.
3216787|NCT01057680|Experimental|creatine|This arm will involve creatine supplementation 0.1 g per kg body mass per day while participating in a resistance training program (1 hour per day, 3 days per week).
3216788|NCT01057680|Placebo Comparator|Sugar|This arm will involve placebo (maltodextrin) given every day while the participant does a resistance training program (1 hour per day, 3 days per week).
3216789|NCT01057706|Experimental|9 months of chiropractic care and exercise|chiropractic, exercise
3216790|NCT01057706|Active Comparator|3 months of chiropractic care and exercise|chiropractic, exercise
3216791|NCT01057719|Experimental|Physiotherapy in Spain|Daily inpatient physiotherapy for four weeks in a warm climate
3216792|NCT01057719|Experimental|Physiotherapy in Norway|Daily inpatient physiotherapy for four weeks in a cold climate
3216793|NCT01057732||primary hyperparathyroidism|patients with primary hyperparathyroidism
3216794|NCT01057732||controls|subjects without primary hyperparathyroidism
3216795|NCT01057758|Placebo Comparator|PLACEBO|Half of the patients will be randomized to the placebo
3216796|NCT01057758|Active Comparator|Simvastatin|Half of the subjects will receive the active drug, Simvastatin.
3216797|NCT01057771|Experimental|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
3216798|NCT01057771|Experimental|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
3216799|NCT01057771|No Intervention|Waiting list control|Waiting list control subjects will be treated exactly like those in active intervention groups, but will not receive interventions.
3216800|NCT01057784||Bariatric Surgery Patients|Patients undergoing bariatric surgery.
3216801|NCT01057784||Reproductive-Age Women - Bariatric Surgery Patients|This subgroup of patients will include 10 reproductive-age women.
3216802|NCT01057797|Experimental|Upper Body Strength Training with Self-Efficacy|16 weeks of upper body strength training combined with an exercise-specific self-efficacy enhancing intervention
3216803|NCT01057797|Active Comparator|Upper body strength training|16 weeks of upper body strength training with weekly health education sessions
3216804|NCT01057797|Sham Comparator|Chair exercise|16 wks of gentle chair exercise with weekly health education
3216805|NCT01057823||Inpatient Elders Age 50 and up|The study population is community-dwelling ambulatory patients age 50 or above hospitalized on the University of Chicago general medicine service. Exclusion criteria include: (1) transfer from the ICU or another hospital; (2) cognitively impaired; (3) not ambulatory; (4) residents of a nursing home or skilled nursing facility; (5) on bedrest; (6)documented sleep disorder in their medical history (i.e. obstructive sleep apnea, narcolepsy, etc).
3216806|NCT01057836|Experimental|Neck strength training|
3216807|NCT01057836|Experimental|Neck endurance training|
3216808|NCT01057836|Active Comparator|Stretching|
3216809|NCT01057849|Experimental|Risperidone, Intensive|risperidone and intensive psychosocial intervention
3216810|NCT01057849|Active Comparator|risperidone, basic|risperidone and basic psychosocial support
3216811|NCT01057849|Experimental|olanzapine, intensive|olanzapine and intensive psychosocial intervention
3216812|NCT01057849|Active Comparator|olanzapine, basic|olanzapine and basic psychosocial support
3216813|NCT01057849|Experimental|aripiprazole, intensive|aripiprazole and intensive psychosocial intervention
3216814|NCT01057849|Active Comparator|aripiprazole, basiv|aripiprazole and basic psychosocial support
3216815|NCT01057875|Experimental|coffee with caffeine|
3216816|NCT01057875|Placebo Comparator|decaffeinated coffee|Starbuck's Grande Pike Roast Decaf
3216817|NCT01057914|Experimental|Supplemention|
3216818|NCT01057914|Experimental|Dietary advice|
3216819|NCT01057914|Experimental|Combination treatment|
3216820|NCT01057914|No Intervention|Usual care|
3216821|NCT01057927|Experimental|OC000459|
3216822|NCT01057927|Placebo Comparator|Placebo|
3216823|NCT01057940||PEJ placement|Patients who have failed conventional DPEJ placement and would otherwise require surgical intervention.
3216824|NCT01057953|No Intervention|Patient|Blood sample for patient included
3216825|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel
3216826|NCT01057966|Experimental|ICAPS AREDS Softgel Capsule - Half Strength|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half -strength)
3216827|NCT01057966|Experimental|ICAPS AREDS coated tablets - Full Strength|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets
3216828|NCT01057979|Experimental|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
3216829|NCT01057979|Active Comparator|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
3216830|NCT01058018|Experimental|A - 100 mg per day RVX000222|Arm A: Treatment with RVX000222 at 50 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3216831|NCT01058018|Experimental|B - 200 mg per day RVX000222|Arm B: Treatment with RVX000222 100 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3216832|NCT01058018|Experimental|C - 300 mg per day RVX000222|Arm C: Treatment with RVX000222 150 mg twice daily for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3216833|NCT01058018|Placebo Comparator|D - Placebo|Arm D: Treatment with placebo for 12 weeks, orally with meals in the morning and in the evening, 10 to 12 hours apart.
3216834|NCT01058031|Experimental|Arm 1|MBSR
3216835|NCT01058044|Experimental|adherence assessment group|evaluation of adherence using MEMS
3216836|NCT01058057|Experimental|Atorvastatin|Atorvastatin 80mg seven days pre-treatment before PCI
3216837|NCT01058083|Experimental|BMS-770767 (Treatment A)|
3216838|NCT01058083|Experimental|BMS-770767 (Treatment B)|
3216839|NCT01058083|Experimental|BMS-770767 (Treatment C)|
3216840|NCT01058083|Experimental|BMS-770767 (Treatment D)|
3216841|NCT01058083|Placebo Comparator|Placebo (Treatment E)|
3216842|NCT01058109|Experimental|calcium group|dietary calcium intake of 1500 mg/d
3216843|NCT01058109|Experimental|calcium-rich diet (1500 mg/d)|calcium intake from food
3216844|NCT01058122||Patients on the ward|
3216845|NCT01058161|Other|Suspects or affected by rheumatoid polyarthritis|
3216846|NCT01058161|Other|stiffening spondylitis with axial and peripheral infringement|
3216847|NCT01058161|Other|polyarthralgies with or without arthritis|Affected by connectivity with anti-nuclear antibody positive and / or specific antibodies, suffering of polyarthralgias with or without arthritis
3216848|NCT01058161|Other|Healthy control|
3216849|NCT01058161|Other|not inflammatory control|Presenting a degenerative osteoarthritis of the wrist traumatic comment, noticed radiologically, which will serve as not inflammatory control.
3216850|NCT01058174|Experimental|micafungin|intravenous infusion
3216851|NCT01058174|Active Comparator|standard care|intravenous infusion
3216852|NCT01058187||Control|Marketed cow milk-based infant formula containing DHA and ARA
3216853|NCT01058187||Investigational 1|Cow milk-based infant formula with differing level of ARA from Control formula
3216854|NCT01058187||Investigational 2|Cow milk-based infant formula with a differing level of ARA from Control
3216855|NCT01058200|Active Comparator|vacuum extractor 'iCUP'|new vacuum extractor: sterile disposable plastic cup
3216856|NCT01058200|Sham Comparator|reference vacuum extractor|reference cup of the obstetrical ward: metallic cup
3216857|NCT01058213|Active Comparator|Aerobic training alone|8 weeks of gentle chair (sham) training followed by 8 weeks of interval aerobic training on a stationary bicycle
3216858|NCT01058213|Experimental|Sequential Resistance then Aerobic Training|8 weeks of resistance training of the lower body followed by 8 weeks of interval aerobic training on a stationary bicycle
3216859|NCT01058213|Active Comparator|Concurrent resistance and aerobic training|8 weeks of gentle chair (sham) exercise followed by 8 weeks of concurrent resistance training of the lower body and interval aerobic training on a stationary bicycle
3216860|NCT01058252||Letrozole, recFSH, INVOCell, Monitoring|Infertile couple following MSP with INVO IVF
3216861|NCT01058278|Active Comparator|Prednisone acetate 1%|A topic cortisone-based treatment
3216862|NCT01058278|Active Comparator|diclofenac 0.1%|an non-steroidal anti-inflammatory drug
3216863|NCT01058278|Placebo Comparator|Artificial Tears|Pharmasciences DIN: 02229570
3216864|NCT01058291|Experimental|KW-6500|
3216865|NCT01058291|Placebo Comparator|KW-6500 Placebo|
3216866|NCT01058317|Experimental|Children treated with propranolol|
3216867|NCT01058330|Active Comparator|Plyometric physical training|Individualized plyometric training program to increase strength, coordination, and bone density.
3216868|NCT01058330|No Intervention|Control Group|This group will have no intervention
3216869|NCT01058343|Experimental|IFN-K 1|IFN kinoid dose 1
3216870|NCT01058343|Experimental|IFN-K-2|IFN kinoid dose 2
3216871|NCT01058343|Experimental|IFN-K 3|IFN kinoid dose 3
3216872|NCT01058343|Experimental|IFN-K 4|IFN kinoid dose 4
3216873|NCT01058343|Placebo Comparator|Saline|saline at same dose as IFN K
3216874|NCT01058382||Progesterone Vaginal Suppositories|
3216875|NCT01058382||Intramuscular Progesterone-in-Oil|
3216876|NCT01058408|Experimental|Rad001 with cisplatin|
3216877|NCT01058434|Experimental|TKI258|
3216878|NCT01058447|Experimental|1|
3216879|NCT01058460|No Intervention|cytology|Subjects in the control arm will receive conventional cytology testing and HPV testing at baseline. Follow up management will be based on the cytology result according to current practice.
3216880|NCT01058460|Experimental|HPV-cytology|Subjects in the HPV-cytology arm will receive HPV testing and cytology testing at baseline. Follow up management will be based on both results.
3216881|NCT01058473||Sickle Cell Disease|
3216882|NCT01058486|Experimental|Activity-Self Management|
3216883|NCT01058486|No Intervention|Usual Care|
3216884|NCT01058499|Experimental|MBSR|
3216885|NCT01058512|Experimental|Single|single-arm study
3216886|NCT01058525|Active Comparator|nerve block|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000)
3216887|NCT01058525|Experimental|median nerve block after hydro-dissection|median nerve block (6 ml lidocaine 1.5 % with adrenalin 1:200000) after hydro-dissection (glucose 5% solution)
3216888|NCT01058538|Experimental|L19IL2|
3216889|NCT01058551|Experimental|Reveal XT ILR|Implantable Loop Recorder Insertion
3216890|NCT01058603|Active Comparator|D3|
3216891|NCT01058603|Experimental|D5|
3216892|NCT01058629|Experimental|SynergEyes A2 Hybrid Contact Lens|
3216893|NCT01058681|Other|isocaloric|impacts of isocaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
3216894|NCT01058681|Other|hypercaloric|impacts of hypercaloric nutrition on LH pulsatility in euglycemic and hyperinsulinemic clamps
3216895|NCT01058681|Other|per os and IV glucose during the clamp|impacts of per os glucose on LH pulsatility in euglycemic and hyperinsulinemic clamps
3216896|NCT01058694|Experimental|Weekly SMS, brief message|Weekly SMS received on Monday at 12 noon
3216897|NCT01058694|Active Comparator|Control Group|Receives a phone, but no messages.
3216898|NCT01058694|Experimental|Daily SMS, Brief message|"Receive daily brief message at 12 noon: This is your reminder"
3216899|NCT01058694|Experimental|Daily SMS, Long Message|"Receive a daily long message at 12 noon: This is your reminder + encouragement"
3216900|NCT01058694|Experimental|Weekly SMS, Long Message|"Weekly message sent at 12 noon on Mondays: This is your reminder + encouragement"
3216901|NCT01058720|Experimental|Vitamin D3|Patients would receive 2000 IU of vitamin D3 daily for 12 weeks
3216902|NCT01058733|Other|Internet|New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
3260401|NCT01479023|Experimental|Cohort 1|"64Cu-DOTA-U3-1287 at a radiotracer dosage of 8-15 mCI and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~Patient will have option to continue to Part 2 (extension phase)."
3216903|NCT01058746|Active Comparator|pts undergoing pancreatic resection Restrictive arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from 8am to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. After randomization occurs, those patients randomized to the Restricted Arm will continue to receive Normosol or equivalent solution at 6ml/kg/operative hour.
3216904|NCT01058746|Active Comparator|pts undergoing pancreatic resection Liberal arm|All patients will receive Normosol or equivalent solution, 0.5 ml/kg/fasted hour IV (approximately from midnight to time of induction) during induction of anesthesia. All patients will then receive maintenance fluids consisting of Normosol or equivalent solution at 6 ml/kg/operative hour. Those patients randomized to the Liberal Arm will receive an additional Normosol bolus or equivalent solution equal to (another) 1.5 ml/kg/fasted hour IV (to bring the total to 2 ml/kg/fasted hour) plus an additional bolus of Normosol or equivalent solution 6ml/kg/operative hour to bring the hourly rate to 12ml/kg/operative hour with a maximum of 1000 ml/operative hour.
3216905|NCT01058759|Experimental|Arm B: Enoxaparin|
3216906|NCT01058759|Active Comparator|Arm A: No Enoxaparin|
3260402|NCT01479023|Experimental|Cohort 2|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~9.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3216907|NCT01058772|Experimental|INDUCTION of LABOUR|"At enrollment patients assigned to the induction group will be admitted to the obstetric ward and will undergo induction of labour as described in the intervention section.~Once patient's Bishop score exceeds 7 or regular contractions are diagnosed, patients will be transferred to the delivery ward for artificial rupture of membranes (ARM) or Oxytocin augmentation as indicated."
3216908|NCT01058772|No Intervention|EXPECTANT MANAGEMENT|"Patients enrolled in the conservative management arm will be followed up twice weekly for foetal wellbeing by Non-stress test and Biophysical profile. Patients will be followed up to 41+0 weeks.~Patients, who will not deliver by this gestational age, will be admitted for labour induction (see the above protocol). Induction of labour will be offered when non-reassuring foetal status is suspected. All patients in the conservative arm will undergo foetal weight ultrasound estimation prior to induction. Patients with estimated foetal weight over 4000 gr will be offered a C-section."
3216909|NCT01058785|Experimental|Lucanix|Patients will receive injections of Lucanix for each dose cohort.
3216910|NCT01058824|Active Comparator|Lincomycin - Active Comparative - Hard Gelatin Capsule|
3216911|NCT01058824|Experimental|Lincomycin - Study Drug - Hard Gelatin Capsule|
3216912|NCT01058850|Experimental|Rindopepimut (EGFRvIII Vaccine, CDX-110)|
3216913|NCT01058876|Experimental|Usual Cigarette|African American and White Smokers will smoke their usual cigarette and also undergo an oral pharmacokinetics protocol after administration of 3 mg deuteriumlabeled nicotine and 5 mg deuterium-labeled cotinine.
3216914|NCT01058876|Experimental|Low-yield Cigarette|"African American and White smokers will smoke a commercial cigarette with a machine-determined nicotine yield of approximately 50% of their usual brand."
3216915|NCT01058889|Experimental|Telemedical device|Patient will receive a blood glucose measurement device and a telemedical device to monitor blood glucose measurements.
3216916|NCT01058889|No Intervention|Treatment as usual|
3216917|NCT01058902|Placebo Comparator|Negative control|Not on aspirin pre operatively, but refuse to enter trial or have a contraindication to aspirin
3216918|NCT01058902|Experimental|Aspirin treatment|group randomised to aspirin
3216919|NCT01058902|Experimental|No aspirin treatment|Randomised to no aspirin
3216920|NCT01058902|Active Comparator|Positive control|Already on aspirin. just observational limb
3216921|NCT01058915|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day for one year
3216922|NCT01058915|Active Comparator|Rosuvaststin 40mg|Rosuvastatin 40mg/day
3216923|NCT01058928||Group ID 7.5|Patients with a tracheal tube ID (internal diameter) 7.5 mm
3216924|NCT01058928||Group ID 8.0|Patients with a tracheal tube ID 8.0 mm
3216925|NCT01058967||major trauma victims|Code 3 patients (highest acuity) admitted to hospital via air ambulance service
3216926|NCT01058980|Active Comparator|Dormant PV conduction|"After PVI, dormant conduction will be evaluated using intravenous adenosine. If dormant conduction is present, the patients will be randomized to two parallel groups:~Group 1: No additional ablation~Group 2: Additional ablation until elimination of dormant conduction."
3216927|NCT01058980|Active Comparator|No dormant PV conduction|If no dormant conduction is documented, patients will be selected in a random fashion to be included in a registry (follow-up as planned for group 1 and 2 above). The registry group will allow for further assessment of the role of dormant conduction as a predictor of AF recurrence by comparing the success rate after ablation in patients without dormant conduction with those of Group 1 and 2.
3216928|NCT01059006|Experimental|PresbyLASIK|Male or female patients with presbyopic symptoms who underwent PresbyLASIK.
3216929|NCT01059019|Sham Comparator|Control|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients.
3216930|NCT01059019|Experimental|Treatment|20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day
3216931|NCT01059032|No Intervention|Unenhanced images|
3216932|NCT01059032|Other|Enhanced images|Enhanced images
3216933|NCT01059045|Experimental|Cryocontact therapy|
3216934|NCT01059045|No Intervention|Control|
3216935|NCT01059058|Active Comparator|Test Group A: MI Paste Plus Group|
3216936|NCT01059058|Active Comparator|Test Group B: Fluoride Varnish Group|
3216937|NCT01059058|Placebo Comparator|Control Group|
3216938|NCT01059097|Active Comparator|High volume surgeons|high volume surgeons performed at least 18 PD/year.
3216939|NCT01059097|Active Comparator|Low volume surgeons|low volume surgeons performed less than 18 PD/year.
3216940|NCT01059110|Experimental|Salicylate ointment|Salicylate ointment under occlusion (pomade M.O Cochon®)
3216941|NCT01059110|Experimental|Imiquimod|Imiquimod : Aldara®
3216942|NCT01059110|Experimental|5-fluoro-uracil|5-fluoro-uracil cream : Efudix®
3216943|NCT01059110|Experimental|Cryotherapy|liquid nitrogen : Cryotherapy
3216944|NCT01059123|Experimental|1:Short treatment|amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
3216945|NCT01059123|Active Comparator|2:Usual treatment|amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.
3216946|NCT01059136|Experimental|1:Spironolactone|Aldosterone blockade on top of standard therapy
3216947|NCT01059136|No Intervention|2:Standard therapy|Standard therapy
3216948|NCT01059149|Experimental|receive real rTMS|For real rTMS, pulses will be delivered at a frequency of 5 Hz for 6s with a 54s interval, with an intensity equal of 90% of the motor threshold as established at Baseline. 20-min real stimulation sessions will be administered 5 days a week for a period of 2 weeks
3216949|NCT01059149|Placebo Comparator|sham rTMS|For sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo procedures will be used administered 5 days a week for a period of 2 weeks.
3216950|NCT01059162|Experimental|IOPtiMate|patients will undergo non-penetrating laser assisted filtering surgery by the IOPtiMate (OT-134) system
3216951|NCT01059253|Experimental|Training|15 training sessions
3216952|NCT01059266|Active Comparator|conventional regimen of PURETHAL Grasses|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml in intervals according to registered scheme (week 8, 10, 12, 16)."
3216953|NCT01059266|Experimental|rush regimen of PURETHAL Grasses|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml (week 1, 2, 3)~Maintenance treatment:~3 monthly doses of 0.5 ml (week 7, 11, 15)."
3216954|NCT01059279||FMF patients|15 FMF patients with double mutations MEFV, mail sex, from the age from 18 to 30. treated with colchicine, without attacks not less than 2 months
3216955|NCT01059279||healthy people|Healthy individuals, that participated in the study of Heller Institute of Medical Research.
3216956|NCT01059331|Experimental|Pregabalin|
3216957|NCT01059331|Placebo Comparator|Sugar pill|
3216958|NCT01059370|Experimental|Autonomic dysrefleksia|Autonomic dysreflexia in SCI when emptying bowels or filling bladder
3216959|NCT01059383|Experimental|VECAM 40/300|
3216960|NCT01059383|Active Comparator|Esomeprazole 20 mg|
3216961|NCT01059396|Experimental|Propranolol|
3216962|NCT01059396|Experimental|carvedilol|
3216963|NCT01059396|Placebo Comparator|Placebo|
3216964|NCT01059409|Experimental|Meniscal Allograft|
3216965|NCT01059448|Experimental|210mg AMG 827|AMG 827 210mg at baseline, week 1, week2, and every 2 weeks thereafter
3216966|NCT01059461|Experimental|Cerebrolysin®, neuroregeneration|Injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
3216967|NCT01059474|Experimental|DMPS|We will recruit 10 healthy adult volunteers, over 18 years of age, who eat at least three servings of fish per week (since this diet is associated with detectable levels of mercury in the urine which may rise following chelation). Patients with known allergies to DMPS or sulfa drugs or history of neurologic or renal disease will be excluded. We will also control for number of mercury containing dental amalgams. History will be obtained regarding any potential mercury exposures or recent vaccinations.
3216968|NCT01059487|Other|Traditional Chinese Medicine|Assessing efficacy of treating subjects/patients with Traditional Chinese Medicine (TCM) by administering SF-36v2 and PIQ-6 surveys to subjects/patients to create a baseline and then re-assessing quality of life achieved through TCM treatments by administering follow-up SF-12v2 and PIQ-6 surveys every four weeks
3216969|NCT01059500|Other|Pilot Phase|First 300 patients will be assigned to arm 1 to test the accuracy of the webtool output.
3216970|NCT01059500|Experimental|Webtool output|Phase 2- Intervention, One group will receive the numeric PTP estimate from webtool output, the other groupwill not receive the nemuric PTP estimate
3216971|NCT01059552|Experimental|vorinostat|Dose escalation of vorinostat, cisplatin, pemetrexed and radiation
3216972|NCT01059578|Experimental|Active|GSK206136 once daily
3216973|NCT01059578|Placebo Comparator|Placebo|Placebo once daily
3216974|NCT01059591|Experimental|Active|GSK424887 once daily
3216975|NCT01059591|Placebo Comparator|Placebo|Placebo once daily
3216976|NCT01059604||Pregnant women exposed to sumatriptan, naratriptan, or combo|Women exposed to sumatriptan, naratriptan or the sumatriptan-naproxen combination treatment during pregnancy
3216977|NCT01059656|Experimental|1:Pazopanib|Pazopanib 800mg/j
3216978|NCT01059669||Patients|Patients with suspected Chronic Pancreatitis
3216979|NCT01059669||Control group|Healthy controls
3216980|NCT01059708||CO poisoned children|Children, ages 6-16, who have been poisoned by carbon monoxide
3216981|NCT01059721|Experimental|Soft tissue realignment|group cohort label
3216982|NCT01059747||treatment group|
3216983|NCT01059786|Experimental|Arm 1|Rituximab + Bendamustine at 70 mg/m2 for initial tolerability study (closed)
3216984|NCT01059786|Experimental|Arm 2|Rituximab + bendamustine at 90 mg/m2 for initial tolerability study (closed)
3216985|NCT01059786|Experimental|Arm 3|Rituximab + Bendamustine (at the tolerated dose)
3216986|NCT01059786|Active Comparator|Arm 4|Rituximab + Pentostatin
3216987|NCT01059838|Experimental|single subject|
3216988|NCT01059890|Experimental|Cefotaxime|
3216989|NCT01059890|Experimental|Metrodinazole|
3216990|NCT01059890|Experimental|Ciprofloxacine|
3216991|NCT01059890|Experimental|Fosfocine|
3216992|NCT01059942||Hospitalist physicians/house-staff|Consented Academic Hospitalist and Internal Medicine Residency staff
3216993|NCT01059955|Experimental|Active treatment at day 0 and day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and one at Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
3216994|NCT01059955|Active Comparator|Active Treatment at Day 0, Sham Treatment at Day 7|"Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses. One treatment will be given at Day 0 (baseline) and a sham treatment Day 7.~The three iontophoresis doses are:~Ocular iontophoresis with EGP-437 1.2 mA-min at 0.4 mA~Ocular iontophoresis with EGP-437 2.5 mA-min at 0.8 mA~Ocular iontophoresis with EGP-437 4.5 mA-min at 1.5 mA"
3216995|NCT01059968||adolescent female endurance athletes|High school female cross country runners in San Diego.
3216996|NCT01059981||1|Dialysis patients
3216997|NCT01059981||2|Trauma patients
3216998|NCT01059981||3|Patients with carbon monoxide poisoning
3216999|NCT01060033|Other|Arm 1|"Clinical T1/T2-weighted MRI sequence per standard of care before treatment, during treatment per standard protocol, and at 3 months.~Patients may have one or all of the following sequences in addition to the standard MRI imaging:~MR Spectroscopy~Fat-saturation and Diffusion-Weighted Imaging~Dynamic Contrast Enhancement MRI (MR-DCE)~Diffusion Tensor Imaging (DTI)"
3217000|NCT01060046||Patients with previously implanted biologic mesh|All patients undergoing a repeat operation to repair a recurrent hernia or to revise a surgical site which has been previously repaired using a biologic mesh.
3217001|NCT01060046||Control patients|Any patient undergoing a surgical procedure where fascial biopsy would not compromise the integrity of the procedure.
3217002|NCT01060085||Breast Cancer|Women shown to have DCIS or invasive breast cancer by fine needle aspiration cytology and/or core needle biopsy.
3217003|NCT01060137|Experimental|001|fentanyl matrix Fentanyl transdermal patch 12 - 25mcg/hr can increase with 12 - 25mcg/h based on pain assessment
3217004|NCT01060163|Experimental|group ET|Patients receiving early CABG <=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3217005|NCT01060163|Placebo Comparator|group EP|Patients receiving early CABG <= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
3217006|NCT01060163|Experimental|group LT|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3217007|NCT01060163|Placebo Comparator|group LP|Patients receiving late CABG >7 days of the cessation of clopidogrel, treated with placebo(saline solution)
3217008|NCT01060163|Experimental|group BT|Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
3217009|NCT01060163|Placebo Comparator|group BP|Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)
3217010|NCT01060176|Experimental|High dosage|Tranexamic acid with a loading dose of 30 mg/kg and a maintenance infusion of 20 mg/kg/h
3217011|NCT01060176|Experimental|Medium dosage|Tranexamic acid with a loading dose of 20 mg/kg and a maintenance infusion of 15 mg/kg/h
3217012|NCT01060176|Experimental|Low dosage|Tranexamic acid with a loading dose of 10 mg/kg and a maintenance infusion of 10 mg/kg/h
3217013|NCT01060176|Placebo Comparator|Control|Saline solution
3217014|NCT01060189|Experimental|Ulinastatin|1,000,000 units of ulinastatin in 50ml solution before skin incision; 50ml saline solution after neutralization
3217015|NCT01060189|Experimental|Tranexamic Acid|15mg/kg tranexamic acid in 50ml solution before skin incision; 15mg/kg tranexamic acid in 50ml solution after neutralization
3217016|NCT01060189|Placebo Comparator|Placebo|50ml saline solution before skin incision; 50ml saline solution after neutralization
3217017|NCT01060202||Bortezomib|
3217018|NCT01060215|Active Comparator|Infusion|20cc saline infusion into the knee joint
3217019|NCT01060215|No Intervention|No infusion|
3217020|NCT01060228|Other|001|paliperidone ER 1 tablet of 500 mg once daily on Day 1 and Day 15
3217021|NCT01060228|Other|002|divalproex sodium ER 2 tablets of 500 mg once daily from Days 5 through 18
3217022|NCT01060241|Experimental|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3217023|NCT01060241|No Intervention|Standard Care|This arm will receive standard care which includes self-blood glucose monitoring at least 3 times daily and visit to the endocrinologist at least once every 3 months.
3217024|NCT01060254|Experimental|JNJ-42160443|
3217025|NCT01060254|Placebo Comparator|Placebo|
3217026|NCT01060267|Active Comparator|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
3217027|NCT01060267|No Intervention|Placebo Group endoscopic therapy|Endoscopic therapy of variceal bleeding.
3217028|NCT01060280|Active Comparator|Education group|Routine clinical practice (includes usual physiotherapy)plus education on active management.
3217029|NCT01060280|Active Comparator|Group GDS physiotherapy|Routine clinical practice (except usual physiotherapy, which is substituted for Group GDS)plus education on active management.
3217030|NCT01060280|Active Comparator|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which will be substituted by Group and Individual GDS) plus education on active management.
3217031|NCT01060293|Active Comparator|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
3217032|NCT01060293|Active Comparator|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
3217033|NCT01060293|Active Comparator|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
3217034|NCT01060306||Bare metal stent 1 month|Patients implanted with the bare metal stent Gazelle evaluated for neointimal coverage one month after implantation
3217035|NCT01060306||Biodegradable polymer stent 6 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage after full drug elution and polymer biodegradation (6 months)
3217036|NCT01060306||Biodegradable polymer stent 7 months|Patients implanted with the biodegradable polymer-based Biolimus A9-eluting stent (Biomatrix stent) evaluated for neointimal coverage one month after full drug elution and polymer biodegradation (7 months)
3217037|NCT01060332||diabetics|
3217038|NCT01060358||healthy|Healthy and active men and women between 21 and 45 years old with no history of low back pain or low back injury.
3260403|NCT01479023|Experimental|Cohort 3|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~12.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3217039|NCT01060371||Spinocerebellar Ataxia 1|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3217040|NCT01060371||Spinocerebellar Ataxia 2|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3217041|NCT01060371||Spinocerebellar Ataxia 3|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3217042|NCT01060371||Spinocerebellar Ataxia 6|"If you decide to participate in this study, the following study procedures will be performed:~blood collection for DNA testing, analysis (genetic modifier study) and banking~Medical history~Physical exam~Scale for Assessment and Rating of Ataxia (SARA)~Timed measure of your hand dexterity and walking (25 ft)~Questionnaire about your daily living activities, your physical and mental quality of life and assessment of depression.~Disease stage estimation by the clinician.~Demographics and disease-related information (i.e. age, sex, race, age at disease onset, disease duration)~Review of your medical records"
3217043|NCT01060397|Experimental|Extended Brief Intervention|FRAMES motivational interviewing approach
3217044|NCT01060397|Experimental|Control|Usual care
3217045|NCT01060410||Cyclophosphamide,low dose,continuous|
3217046|NCT01060423|Experimental|hepatic TACE with irinotecan eluting beads and iv cetuximab|Irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX)
3217047|NCT01060423|Active Comparator|iv cetuximab and irinotecan|systemic treatment with intravenous cetuximab and irinotecan
3217048|NCT01060449|Other|LV lead low output|"Low output on left ventricular pacing lead.~Intervention: LV stimulus intensity"
3217049|NCT01060449|Other|LV lead high output|"High output on left ventricular lead~Intervention: LV stimulus intensity"
3217050|NCT01060462||001|Pts. w/ neutropenic fever associated w/ hematologic malignancy Itraconazole 200 mg twice daily for 2 days for a total of 4 doses then 200 mg once daily for 12 days. After 14 days of IV administration itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
3217051|NCT01060475|Experimental|A|Low dose LIM-0705 and tacrolimus.
3217052|NCT01060475|Experimental|B|High dose LIM-0705 and tacrolimus.
3217053|NCT01060475|Experimental|C|Placebo LIM-0705 and tacrolimus.
3217054|NCT01060475|Experimental|D|High dose LIM-0705 and placebo tacrolimus.
3217055|NCT01060488|Active Comparator|Group 1:|
3217056|NCT01060488|Active Comparator|Group 2:|
3217057|NCT01060501|Active Comparator|5-FU|Standard arm Systemic drug administration of 5-FU (intravenous)
3217058|NCT01060501|Experimental|5-FU + folinic acid|Experimental arm Systemic drug administration of 5-FU + folinic acid (intravenous)
3217059|NCT01060501|Experimental|5-FU + Interferon-alpha|Experimental arm Systemic drug administration of 5-FU + interferon-alpha (intravenous)
3217060|NCT01060514|Experimental|Pazopanib + Vinorelbine|
3217061|NCT01060527||IBS-D|
3217062|NCT01060527||IBS-C|
3217063|NCT01060527||Controll|
3217064|NCT01060566|Experimental|VX-770|
3217065|NCT01060566|Experimental|Midazolam|
3217066|NCT01060566|Experimental|Rosiglitazone|
3217067|NCT01060566|Experimental|Fluconazole|
3217068|NCT01060579|Experimental|AR-12286 0.5% ophthalmic solution|
3217069|NCT01060579|Experimental|AR-12286 0.25% Ophthalmic Solution|
3217070|NCT01060579|Experimental|Latanoprost 0.005% ophthalmic solution|
3217071|NCT01060605|Experimental|Rapamycin pre transplant|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
3217072|NCT01060618|Experimental|Maraviroc + Trofile ESTA®|the patients have the Trofile ESTA® test performed and sent for evaluation. Once the results are obtained (about 1 month later), the patients take the medication Maraviroc during ten days. The viral load assessment throughout the Study help to make a prediction to assess if the patients would have a positive response Vs. CCR5 antagonist of a negative response
3217073|NCT01060631||patients with frontal or frontotemporal brain tumor.|
3217074|NCT01060631||patients without supratentorial brain tumor.|
3217075|NCT01060657||conventional (C) group|
3217076|NCT01060657||low dose (L) groups|
3217077|NCT01060683||Group 1: 15 patients|for elective hepatic resection
3217078|NCT01060683||Group 2: 15|for elective hepatic resection
3217079|NCT01060696|Experimental|Hyoscine, Mefenamic acid, Placebo|Blind randomization to three groups. Mefenamic acid group Hyoscine group Placebo group
3217080|NCT01060709||elective colonoscopy and requiring sedation|
3217081|NCT01060722|Experimental|MOD-4023, dose level 1|
3217082|NCT01060722|Experimental|MOD-4023, dose level 2|
3217083|NCT01060722|Experimental|MOD-4023, dose level 3|
3217084|NCT01060735|Experimental|Larger doses of vitamin D supplementation|The subjects enrolled in this arm will be supplemented during the third trimester of pregnancy with 2000IU vitamin D per day
3217085|NCT01060735|No Intervention|Conventional vitamin D supplementation|Regular supplementation during pregnancy with 400IU vitamin D
3217086|NCT01060748|Experimental|ACE527|"First cohort: ACE527 vaccine doses of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis.~Second cohort: ACE527 vaccine dose of 9 x 10E10 cfu on study day 0 and 21 on an outpatient basis."
3217087|NCT01060748|Placebo Comparator|Placebo vaccine|"First cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis.~Second cohort: Placebo vaccine on study day 0 and 21 on an outpatient basis."
3217088|NCT01060761|Active Comparator|Rehabilitation program|Counselling (supportive conversation with patient and their relatives together) Retreat Weekend (patient and their relatives together)
3217089|NCT01060761|No Intervention|Ususal treatment and support|Usual support and treatment at the hospital, no retreat Weekend.
3217090|NCT01060774|Experimental|Bupivacaine|0.5% bupivacaine/1:200,000 epinephrine
3217091|NCT01060774|Experimental|Lidocaine|2% lidocaine/1:200,000 epinephrine
3217092|NCT01060787||Fluocinolone Acetonide 0.59 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 0.59 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
3217093|NCT01060787||Fluocinolone Acetonide 2.1 mg|Participants who have had the fluocinolone acetonide (FA) drug delivery system 2.1 mg surgically implanted in the ocular vitreous chamber of one (1) eye for at least one (1) year.
3217094|NCT01060813|Active Comparator|Exercise + Leucine|Patients will receive leucine 10 g/d po + exercise for 3 months
3217095|NCT01060813|Active Comparator|Leucine without exercise|patients will receive leucine 10 g/d po
3217096|NCT01060826|Experimental|somatostatin, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
3217097|NCT01060826|Placebo Comparator|Placebo, intravenous bolus|A double- blind study designed to evaluate if the treatment with somatostatin in intravenous bolus before starting the ERCP procedure followed by a continuous infusion for 4 hours after endoscopic proof could prevent acute post-ERCP pancreatitis. Patients submitted to ERCP will be randomized in two groups of treatment, one will receive somatostatin and another placebo.
3217098|NCT01060839|Experimental|Single session counseling|
3217099|NCT01060839|No Intervention|Standard of care|
3217100|NCT01060852|Experimental|Media Detective|10-lesson elementary school, substance use prevention program developed based upon the Message Interpretation Processing model designed to increase children's critical thinking skills about media messages and reduce intent to use tobacco and alcohol products.
3217101|NCT01060865|Experimental|Aliskiren|only one arm with the experimental drug [aliskiren]
3217102|NCT01060878|Experimental|Dose I|
3217103|NCT01060878|Experimental|Dose II|
3217104|NCT01060878|Experimental|Dose III|
3217105|NCT01060878|Placebo Comparator|Placebo|
3217106|NCT01060904|Experimental|1|brentuximab vedotin combined with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
3217107|NCT01060904|Experimental|2|brentuximab vedotin combined with AVD (doxorubicin, vinblastine, dacarbazine)
3217108|NCT01060930|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust ~ 300 mcg/m3 - during intermittent exercise
3217109|NCT01060930|Experimental|Air exposure|1 hour exposure to filtered air during intermittent exercise
3217110|NCT01060943|Active Comparator|KOKEN(collagen)|atelocollagen filler
3217111|NCT01060943|Experimental|TheraFill|atelocollagen filler
3217112|NCT01060956|Active Comparator|Reporting on two bacteria in urine culture|The microbiology laboratory will report on the isolation and susceptibilities of two different bacteria in urine culture
3217113|NCT01060956|Placebo Comparator|"reporting mixed growth"|The microbiology laboratory will report on mixed growth in urine culture
3217114|NCT01060969|Active Comparator|Acetazolamide|acetazolamide 125 mg BID
3217115|NCT01060969|Experimental|Acetazolamide and Tadalafil|Intervention arm
3217116|NCT01060982|Experimental|HIFU treatment|
3217117|NCT01060995||SmartConsent|Subjects receiving SmartConsent informed consent
3217118|NCT01060995||Standard consent|Subjects receiving standard consent
3217119|NCT01061021|Experimental|Integrated Intervention|Five small group + 2 individual counseling behavioral intervention to simultaneously address HIV transmission risk reduction and HIV treatment adherence in men and women living with HIV/AIDS.
3217120|NCT01061021|Active Comparator|Comparison Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
3217121|NCT01061060|Experimental|Beraprost group|Prostaglandin I2
3217122|NCT01061060|Placebo Comparator|Placebo group|
3217123|NCT01061073|Experimental|Omexel|
3217124|NCT01061073|Active Comparator|spasfon|
3217125|NCT01061086||1|Patients over 18 years old admitted to the hospital with Acute Coronary Syndrome.
3217126|NCT01061099|Active Comparator|Stratum A|Subjects with a diagnosis of Type II or Type III osteogenesis imperfecta who have previously undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
3217127|NCT01061099|Active Comparator|Stratum B|Subjects with Type II or III osteogenesis imperfecta who have not undergone a bone marrow transplant. Intervention: Mesenchymal Stromal Cells.
3217128|NCT01061112||CYP2C9*1/*1 Genotype|This genotype is considered the wild type genotype. Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
3217129|NCT01061112||CYP2C9*1/*3 Genotype|Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
3217130|NCT01061112||CYP2C9*3/*3 Genotype|Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Flurbiprofen Control - Flurbiprofen Only, Flurbiprofen Inhibition - Flurbiprofen & Fluconazole, Ketoprofen Control - Ketoprofen Only, Ketoprofen Inhibition - Ketoprofen & Fluconazole, Tolbutamide Control - Tolbutamide Only, and Tolbutamide Inhibition - Tolbutamide & Fluconazole.
3217131|NCT01061125||Unblinded|Transtelephonic (TTM) monitoring weekly for 5 months Holter monitor recording at 4 months and at 12 months Implantable Loop Recorder (ILR) weekly reports
3217132|NCT01061125||Blinded|TTM and Holter Monitor conventional follow up Implantable Loop Recorder (ILR) unblinded at 5 months
3217133|NCT01061138||Screening Patients|Female patients scheduled for routine annual screening mammograms
3217134|NCT01061138||Biopsy Patients|Female patients scheduled for routine breast biopsy procedures
3217135|NCT01061164||HIV-infected infants, children, and adolescents|Infants, children, and adolescents with HIV infection who have participated in PACTG 219C and/or select IMPAACT studies.
3217136|NCT01061190|Active Comparator|Propranolol|
3217137|NCT01061190|Placebo Comparator|Placebo|
3217138|NCT01061203|Active Comparator|Grazax|Grazax tablet 75.000 SQ-T. One tablet per day for administration under the tongue.
3217139|NCT01061203|Placebo Comparator|Tablet with no active grass|Tablet with no active grass component. One tablet per day administered under the tongue.
3217140|NCT01061216|Experimental|Intradermal insulin infusion (ID)|
3217141|NCT01061216|Active Comparator|Subcutaneous insulin infusion (SC)|
3217142|NCT01061229|Experimental|Homeopathic drug, potency C12|
3217143|NCT01061229|Placebo Comparator|Placebo|
3217144|NCT01061242|No Intervention|Baseline|Post-Intensive Care Unit (ICU) neurocognitive testing and sleep survey performed on patients exposed to ad-lib Medical ICU environment.
3217145|NCT01061242|Experimental|Sleep Promotion Group|Post-ICU neurocognitive testing and sleep survey performed on patients exposed to interventions in the pre-existing MICU sleep quality improvement project.
3217146|NCT01061268|Experimental|BLINK™ tears|
3217147|NCT01061268|No Intervention|No topical artificial tear|
3217148|NCT01061281|Active Comparator|Tecnis MF IOL|
3217149|NCT01061281|Active Comparator|Crystalens AO IOL|
3217150|NCT01061294|Other|Advanced CustomVue™ iLASIK procedure|
3217151|NCT01061307|Experimental|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
3217152|NCT01061320|Active Comparator|alpha tocopherol|
3217153|NCT01061320|Placebo Comparator|placebo|
3217154|NCT01061346|Experimental|High Fat Diet with Fructose|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
3217155|NCT01061346|Experimental|High Fat Diet with Glucose|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
3217156|NCT01061346|Experimental|Low Fat Diet with Glucose|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein.
3217157|NCT01061372|Placebo Comparator|Placebo|
3217158|NCT01061372|Experimental|Pregabalin 150 mg/day|
3217159|NCT01061372|Experimental|Pregabalin 300 mg/day|
3217160|NCT01061398|Experimental|Cardiac CT Arm|Patients referred for stress imaging due to complaints consistent with possible angina, randomized to receive an additional cardiac CT scan.
3217161|NCT01061398|Active Comparator|No CT Arm|Patients with symptoms consistent with possible angina, randomized to receive the type of stress imaging test ordered by their physician.
3217162|NCT01061411|Experimental|Treatment (sunitinib malate, dalteparin)|Patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in week 6 during course 1. In all subsequent courses, patients receive sunitinib malate PO QD in weeks 1-4 and dalteparin SC QD in weeks 1-6. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3217163|NCT01061424|Active Comparator|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
3217164|NCT01061424|Experimental|community health worker|community health worker provides home visits for education
3217165|NCT01061437|Active Comparator|Arm 1|Standard 14 day, 3-drug regimen
3217166|NCT01061437|Experimental|Arm 2|Concomitant Therapy - 5 day, 4-drug regimen
3217167|NCT01061437|Experimental|Arm 3|Sequential Therapy - 10 day, 4-drug regimen
3217168|NCT01061450|Placebo Comparator|Placebo|Placebo
3217169|NCT01061450|Experimental|Simvastatin|Simvastatin 80 mg/day
3217170|NCT01061463||Exposed group|French coronary interventional cardiologists and cardiologists specializing in cardiac arrhythmias treatments (electrophysiologists), occupationally exposed to X-Rays
3217171|NCT01061463||Unexposed group|French non-interventional cardiologists and non medical workers, not occupationally exposed to X-Rays
3217172|NCT01061489|Experimental|sensory-cognitive training|
3217173|NCT01061489|Experimental|physical fitness|
3217174|NCT01061489|No Intervention|waiting list (control group)|
3217175|NCT01061502|Experimental|Procellera Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 5-7 days, more frequently if needed
3217176|NCT01061502|Active Comparator|Opsite Transparent Adhesive Dressing|Polyurethane film dressing. Dressing changes every 5-7 days, more frequently if needed
3217177|NCT01061541|Experimental|Group A|
3217178|NCT01061541|Active Comparator|Group B|
3217179|NCT01061554|Experimental|Gastric stable emulsion|A gastric stable emulsion vehicle for administration of tri-glyceride based omega-3 oils
3217180|NCT01061554|Active Comparator|Soft gel capsule (TG)|Soft gel capsule for administration of tri-glyceride based omega-3 oils
3217181|NCT01061554|Active Comparator|Soft gel capsules (MPL)|Soft gel capsule for administration of marine phospholipids based omega-3 oils
3217182|NCT01061580|Experimental|CABG plus BMAC Injection|Injection of Bone Marrow Aspirate Concentrate (BMAC) into ischemic myocardium following CABG during the same open procedure
3217183|NCT01061593|Experimental|ATT+Immunoxel|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Immunoxel honey lozenge once per day day
3217184|NCT01061593|Placebo Comparator|ATT+Placebo|TB patients with DS-TB, MDR-TB, XDR-TB or TB-HIV on standard ATT + Placebo lozenge made of corn syrup once/day
3217185|NCT01061645|Experimental|MOC31-PE|
3217186|NCT01061658|Experimental|Vaccine - High dosage|
3217187|NCT01061658|Experimental|Vaccine - Lower dosage|
3217188|NCT01061658|Placebo Comparator|Placebo|
3217189|NCT01061684||NAFLD|pediatric patients with non-alcoholic fatty liver disease (NAFLD).
3217190|NCT01061749|Experimental|Treatment (selumetinib, cixutumumab)|Patients receive selumetinib PO BID on days 1-28 and cixutumumab IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3217191|NCT01061762|Experimental|Low Literacy Adherence Counseling|3-counseling sessions for medication adherence improvement tailored for people with poor literacy
3217192|NCT01061762|Active Comparator|Standard Adherence Counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
3217193|NCT01061762|Active Comparator|Health Counseling Comparison|3-sessions of health improvement counseling.
3217194|NCT01061788|Experimental|Everolimus, AMG 479, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLC Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
3217195|NCT01061801|Experimental|Emotional expression, patient present|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the presence of the patient (one session).
3217196|NCT01061801|Experimental|Emotional expression, patient absent|Caregivers are asked to talk about their deepest thoughts and feelings regarding the patient's transplant and their role as caregiver, in the absence of the patient (3 sessions).
3217197|NCT01061801|Active Comparator|Comparison|Caregivers are asked to talk about their plans for the upcoming week (time management, sessions 1 and 3) and positive aspects of their life (session 2).
3217198|NCT01061814|Experimental|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) SC daily
3217199|NCT01061814|Placebo Comparator|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) SC daily
3217200|NCT01061827||Dementia|
3217201|NCT01061827||Depression|
3217202|NCT01061827||Control|
3217203|NCT01061840|Experimental|1 x 10 ^7 cells/injection|Vigil™
3217204|NCT01061840|Experimental|2.5 x 10 ^7 cells/injection|Vigil™
3217205|NCT01061840|Experimental|1 x 10^6 or 4 x 10^6 cells/injection|Vigil™
3217206|NCT01061853|Experimental|T|TOPICAL SIROLIMUS AND PETROLATUM IN ORABASE
3217207|NCT01061853|Active Comparator|C|TOPICAL BETAMETHASONE 0.05% in ORABASE AND PHOSAL
3217208|NCT01061905|Experimental|Calorie information only|Posting calorie information of sugar-sweetened and zero-calorie beverages prominently on a poster.
3217209|NCT01061905|Experimental|Exercise Equivalent Information|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
3217210|NCT01061905|Experimental|Calorie and Exercise Equivalent information|Posting of both calorie and exercise equivalent information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
3217211|NCT01061918|Active Comparator|Tecnis MF|
3217212|NCT01061918|Active Comparator|ReSTOR|
3217213|NCT01061931|Active Comparator|Arctic Front® catheter|
3217214|NCT01061931|Active Comparator|HD Mesh Ablator® catheter|
3217215|NCT01061957||Raltegravir patients|HIV patients who initiated raltegravir due to virological failure
3217216|NCT01061957||Haart naive patients|HIV patients initiating HAART for the first time
3217217|NCT01061983|Experimental|Deep Brain Stimulation|Participants will receive deep brain stimulation.
3217218|NCT01061996|Experimental|1|
3217219|NCT01062022|Active Comparator|Control - Standard of Care|Participation in the study will involve your child completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Your child will be asked to complete the questionnaire during the baseline assessment, and at 6 months, 12 months, and 24 months after the original assessment.
3217220|NCT01062022|Active Comparator|FOCUS-CI|Those participants in the FOCUS-CI intervention will be part of a family skill-building/resiliency training program designed to provide information and skills training in a variety of forms, including clinician-led sessions, handouts, on-line training modules, and individual family care management. Study participation will also involve completing a questionnaire about (a) your family's background, descriptive information about people in your family, and previous major life events, (b) his/her current functioning, (c) his/her feelings before, during, and after the combat injury, and (d) his/her current social relationships and adjustment. Questionnaires will be completed during the baseline assessment, and at 6 months, 12 months, and 24 months after the baseline assessment.
3217221|NCT01062035||ACP (advanced colon polyp) Group|Between the ages of 50 and 60 years old and have an ACP (advanced colon polyp)
3217222|NCT01062035||Control Group|Individuals between the ages of 50 and 60 years old who have had a negative screening colonoscopy.
3217223|NCT01062048||All participants|Participants administered Januvia up to 100 mg once daily as monotherapy or combination therapy with a sulfonylurea or with insulin during the re-examination period (up to 6 years)
3217224|NCT01062087||Local anesthetic|Women who received local anesthetic during surgery in addition to general anesthesia
3217225|NCT01062087||No local anesthetic|Women who did not receive any local anesthetic during surgery, but did have general anesthesia
3217226|NCT01062100|Experimental|nuclear breast imaging|nuclear breast imaging using MBI Gamma camera
3217227|NCT01062139|Experimental|Petasites extract, levocetirizine|Cosalin (Petasites hybridus CO2 extract), Xarlin (levocetirizine) combination therapy group
3217228|NCT01062139|Active Comparator|Cosalin (Petasites hybridus CO2 extract)|Cosalin monotherapy
3217229|NCT01062152|Experimental|Revlimid® in Combination with Telintra ®|Lenalidomide (Revlimid®) followed by Telintra® until MDS progression or lack of efficacy.
3217230|NCT01062178|Experimental|comparison to biopsy|Comparing contrast enhanced US with biopsy result
3217231|NCT01062191|Experimental|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Nanoflex Powder Dressing applied to joint
3217232|NCT01062191|Active Comparator|Aquacel AG, typical carboxymethylcellulose dressing|Sodium CMC dressing control applied to joint
3217233|NCT01062243|Experimental|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
3217234|NCT01062282||Group 1|
3217235|NCT01062295|Experimental|Siesta-System|Use of Siesta-System
3217236|NCT01062295|Active Comparator|Standard headrest|Use of standard headrest
3217237|NCT01062321||Hepatitis-E, Pregnant & Non-pregnant|Pregnant,Acute Viral Hepatitis, Fulminant Hepatic Failure
3217238|NCT01062334|Experimental|Microdialysis|
3217239|NCT01062347|Experimental|zinc supplementation (20 mg/d, for 7 d)|
3217240|NCT01062360|Experimental|Arm 1|
3217241|NCT01062360|Active Comparator|Arm 2|
3217242|NCT01062360|Active Comparator|Arm 3|
3217243|NCT01062360|Placebo Comparator|Arm 4|
3217244|NCT01062373|Active Comparator|TG-DHA|TG-DHA: lactating mothers and their newborn with mothers supplemented with Triglyceride enriched in docosahexaenoic acid
3217245|NCT01062373|No Intervention|Control|Control: lactating mothers and their newborn with no supplementation given to the mother
3217246|NCT01062373|Experimental|GPL-DHA|GPL-DHA: lactating mothers and their newborn with mothers supplemented with Glycerophospholipid enriched in docosahexaenoic acid
3217247|NCT01062451|Placebo Comparator|Placebo|
3217248|NCT01062451|Active Comparator|Perindopril|
3217249|NCT01062451|Active Comparator|Candesartan|
3217250|NCT01062477|Experimental|Study Group 1|Participants will receive ACTACEL vaccine at 2, 3, and 4 months of age.
3217251|NCT01062477|Experimental|Study Group 2|Participants will receive ACTACEL vaccine at 3, 4, and 5 months of age.
3217252|NCT01062477|Active Comparator|Study Group 3|Participants will receive Wuhan DTaP and Act-HIB vaccines concomitantly at 3, 4 and 5 months of age.
3217253|NCT01062490|Experimental|Treosulfan|Patients with myelodysplastic syndrome, (MDS) according to WHO classification (< 20 % myeloblasts in peripheral blood or bone marrow at initial diagnosis) indicated for allogeneic transplantation
3217254|NCT01062516|Active Comparator|1|oral esomeprazole 20 mg daily
3217255|NCT01062516|Active Comparator|2|oral famotidine 40mg daily
3217256|NCT01062529|Experimental|somatostatin|
3217257|NCT01062542||Breast Cancer Survivors|
3217258|NCT01062542||Pediatric Cancer Survivors|
3217259|NCT01062542||Control group|
3217260|NCT01062581||Transplant Recipients and Living Donors|"All transplant recipients receiving transplants at the University of Minnesota (kidney, pancreas, liver, heart, lung, islet, intestine). All ages.~All living donors donating an organ at the University of Minnesota (kidney, pancreas, liver, lung) (by law, living donors are required to be at least 18 years old)"
3217261|NCT01062594|Active Comparator|Supervised exercise group|
3217262|NCT01062594|No Intervention|Control group - no exercise|
3217263|NCT01062607||1|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start.
3217264|NCT01062607||2|Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period .
3217265|NCT01062620|Experimental|AXL1717|
3217266|NCT01062633|Experimental|A, observation|dietary supplement
3217267|NCT01062633|Experimental|B|dietary supplement
3217268|NCT01062633|Experimental|C|dietary supplement
3217269|NCT01062646|Experimental|Multimodal music therapy|Multimodal music therapy comprises 16 sessions single music therapy, group music therapy (max. 6 children/group), parent-child sessions, and parent counseling. The manualized treatment integrates music therapy, behavioral interventions, and family-oriented interventions.
3217270|NCT01062646|Active Comparator|community treatment as usual|
3217271|NCT01062659||chronic Hepatitis C|Patients with chronic Hepatitis C (CHC) Genotype 1-4 who are naive to antiviral treatment
3217272|NCT01062685||Shock Cohort|"The SHOCK cohort will meet the American College of Chest physicians/Society of Critical Care Medicine criteria for septic shock, specifically:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Hypotension despite adequate fluid resuscitation:~a. SBP < 90 mm Hg after 20cc/kg crystalloid"
3217273|NCT01062685||Sepsis cohort|"The SEPSIS cohort will to meet:~1) Suspected infection~2) Any two of four criteria of systemic inflammatory response:~a. Temperature > 100.4° or < 96.8° F~b. Heart rate > 90 beats/minute~c. Respiratory rate > 20 breaths/min. or PaCO2 < 32 mm Hg~d. WBC >12,000 or < 4000 cells/µL or > 10% bands~3) Absence of refractory hypotension"
3217274|NCT01062685||Non-Infected controls|The third cohort will be comprised of uninfected ED control patients who met the criteria of no suspected infection, no SIRS criteria met and no evidence of hypoperfusion that are age and sex matched on a 1:1 basis with the shock cohort.
3217275|NCT01062698|Active Comparator|IV thrombolysis + thrombectomy|
3217276|NCT01062698|Active Comparator|IV thrombolysis|
3217277|NCT01062711|Other|Control group 0 g protein|Control group in which a placebo drink containing no protein is given following unilateral knee extension exercise
3217278|NCT01062711|Experimental|10g whey|10g whey protein given following unilateral knee extension exercise
3217279|NCT01062711|Experimental|20g whey|20g whey protein given following unilateral knee extension exercise
3217280|NCT01062711|Experimental|30g whey|30g whey protein given following unilateral knee extension exercise
3217281|NCT01062711|Experimental|40g whey|40g whey protein given following unilateral knee extension exercise
3217282|NCT01062711|Experimental|20g soy|20g soy protein given following unilateral knee extension exercise
3217283|NCT01062711|Experimental|40g soy|40g soy protein given following unilateral knee extension exercise
3217284|NCT01062724|No Intervention|Trophamine|This group of neonates will be receive the Trophamine amino acids solution from Pisa laboratories as an active comparator with Primene. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
3217285|NCT01062724|Experimental|Primene 10% from Baxter|This group of neonates will be receive the Primene amino acids solution (10 %) from Baxter laboratories as other active comparator with Trophamine. The infants in this group will receive, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat or daily enteral intake (ml/kg/d). Besides, the intake of breast milk or formula will be record, during the first 28 days of total parenteral nutrition.
3217286|NCT01062737|Experimental|ASU (Avocado Soybean Unsaponifiable)|
3217287|NCT01062750|Other|adipose tissue derived stromal cells|
3217288|NCT01062776|Placebo Comparator|5 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
3217289|NCT01062776|Placebo Comparator|10 ml/kg of fluid, no dehydration|Volunteers receive an intravenous infusion of acetated Ringers solution over 15 min without preceding deliberate dehydration with furosemide.
3217290|NCT01062776|Experimental|5 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 5 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
3217291|NCT01062776|Experimental|10 ml/kg of fluid, dehydration|Volunteers receive an intravenous infusion of 10 ml/kg acetated Ringers solution over 15 min after being dehydrated with furosemide.
3217292|NCT01062789|Other|Use of an optical breath-hold control device|This is a feasibility study that will use this new device in place of a different bellows-based breath-hold control device for a series patients undergoing CT-guided lung biopsy. The new belt will be used in all patients in our study.
3217293|NCT01062802|Placebo Comparator|Placebo|
3217294|NCT01062802|Active Comparator|Statin group|
3217295|NCT01062815|Experimental|Cycling Parenteral Nutrition|Infants in the intervention cycling group will receive infusion of carbohydrate/amino acids and intralipid over a 20-hour period. During the 4-hour window period, infants in this group will receive dextrose solution only at the same rate calculated for the carbohydrate/amino acid infusion.
3217296|NCT01062815|Active Comparator|Continuous Parenteral Nutrition|Infants in this control group will receive infusion of carbohydrates/amino acids and intralipids continuously, over 24 hours.
3217297|NCT01062828||Gestational age < 32 weeks|Premature infants with gestational age between <32 weeks regardless of birth weight
3217298|NCT01062854|Experimental|Earplugs|Subjects randomized to this arm of the study will wear earplugs during their baseline sleep study (polysomnogram).
3217299|NCT01062854|No Intervention|Comparison group|Subjects randomized to the comparison arm will not wear earplugs during their baseline sleep study.
3217300|NCT01062867|Experimental|ORG25435|Infusion of intravenous anaesthetic agent to induce anaesthesia
3217301|NCT01062906|Placebo Comparator|Control|The control group receives intravenous fentanyl at the induction of anesthesia followed by a continuous infusion of lidocaine during the surgery.
3217302|NCT01062906|Active Comparator|Lidocaine|The Lidocaine group will receive lidocaine as bolus at the induction of anesthesia followed by a continuous infusion of lidocaine until the end of surgery
3217303|NCT01062919|Experimental|Epidural analgesia group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
3217304|NCT01062919|Experimental|Wound Group|patients in the epidural analgesia group will receive ropivacaine 0.2% through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
3217305|NCT01062932|Placebo Comparator|Placebo|
3217306|NCT01062932|Active Comparator|Cycloserine|
3217307|NCT01062945|Placebo Comparator|Placebo|
3217308|NCT01062945|Active Comparator|Doxazosin|
3217309|NCT01062958||Arm #1 (Test group)|50 subjects administered Neevo® or Neevo®DHA daily
3217310|NCT01062958||Arm #2 (Control group)|50 subjects administered a prenatal vitamin daily
3217311|NCT01062984|Active Comparator|Continuous Venovenous Hemofiltration|
3217312|NCT01062984|Active Comparator|Continuous Venovenouos Hemodialysis|
3217313|NCT01063010|Placebo Comparator|Placebo|Placebo IV for 90 minutes (+ 15 minutes)
3217314|NCT01063010|Experimental|Bevicizumab|IV infusion over 90 minutes
3217315|NCT01063023|Active Comparator|Arm A - Ortho Tri-Cyclen®|1 to 28 days
3217316|NCT01063023|Active Comparator|Arm B - Ortho Tri-Cyclen®|29 to 56 days
3217317|NCT01063023|Active Comparator|Arm C - Ortho Tri-Cyclen® + BMS-650032|"Ortho Tri-Cyclen®: 57 to 77 days~BMS-650032: 68 to 77 days"
3217318|NCT01063088|Experimental|Vaccination|Single 0.5 mL intramuscular injection of PreFluCel 2009/2010
3217319|NCT01063101|Experimental|BAX 513|Capsule - one of 5 dose levels (per randomization) - BID (= twice a day)
3217320|NCT01063101|Placebo Comparator|Capsule (cellulose)|Capsule - one of 5 dose levels (per randomization) - BID
3217321|NCT01063114|Experimental|Proton Beam Radiation|Proton Beam Radiation
3217322|NCT01063127||1|group A: 10 morbidly obese subjects who will undergo gastric banding will be studied basally, 1 week after low-calorie diet and 1 week after operation.
3217323|NCT01063127||2|group B: 10 morbidly obese subjects who will undergo gastric bypass will be studied basally, 1 week after low-calorie diet and 1 week after operation.
3217324|NCT01063140||RabAvert|
3217325|NCT01063140||Imovax|
3217326|NCT01063179|Experimental|Arm A: VMPT|Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
3217327|NCT01063179|Active Comparator|VMP|"Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).~No maintenance is scheduled."
3217328|NCT01063192|Active Comparator|Gemcitabine|Arm 1: Gemcitabine alone
3217329|NCT01063192|Active Comparator|GOFL|Arm 2: GOFL (Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
3217330|NCT01063205|Placebo Comparator|Placebo|
3217331|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 1800 mg|
3217332|NCT01063205|Active Comparator|N-Acetylcysteine (NAC) 3600 mg|
3217333|NCT01063218|Other|Emollient|Only one arm: Emollient (Cetaphil Advanced) to be applied twice a day
3217334|NCT01063231|Experimental|1|Subjects that are indicated for colonoscopy, who are suspected or known to suffer from large bowel diseases.
3217335|NCT01063244|Active Comparator|FoleyBalloon|foley balloon placed in the cervix
3217336|NCT01063244|Active Comparator|foley balloon with weight|foley balloon with weight attached
3217337|NCT01063257|Experimental|Cohort A|Clofarabine treatment at D1-D5
3217338|NCT01063257|Experimental|Cohort B|Clofarabine treatment at D1, D3, D5, D8, D10
3217339|NCT01063270|Active Comparator|Antibiotics|
3217340|NCT01063270|Active Comparator|Antibiotics and Laser treatment|
3217341|NCT01063309||Autosomal recessive CGD|Participants must have autosomal recessive CGD (p47phox, p67phox, or p22phox deficiency) as demonstrated by DHR or genetic screening.
3217342|NCT01063309||CGD carrier|Participants with confirmed as X-linked CGD carriers as demonstrated by DHR or genetic screening.
3217343|NCT01063309||Healthy Volunteer|Healthy volunteers over the age of 18, both male and female. That have not been diagnosed with CGD, Inflammatory Bowel Disease, or another primary disease of the immune system.
3217344|NCT01063309||IFN-gamma treated CGD|Participants with CGD the have been treated with Interferon gamma.
3217345|NCT01063309||Inflammatory bowel disease|Participants with Inflammatory Bowel Disease with a well-recognized granulomatous inflammation, but normal phagocyte function and ROS production. They have not been diagnosed with CGD.
3217346|NCT01063309||Other immune system disorders|Participants with other disorders such as Chediak-Higashi Syndrome, Leukocyte Adhesion Deficiency, myeloperoxidase deficiency, Hyper- IgE (Job's) Syndrome, IRAK4-deficiency, and NEMO-deficiency
3217347|NCT01063309||X-linked Chronic Granulomatous Disease (CGD)|Participants diagnosed with X-linked CGD confirmed by DHR.
3217348|NCT01063361|Experimental|Low glycemic Index Diet|Low glycemic Index Diet, emphasizing pulses
3217349|NCT01063361|Active Comparator|High Cereal Fibre Diet|
3217350|NCT01063374|Active Comparator|low glycemic index, diabetic diet|low glycemic index, diabetic diet
3217351|NCT01063374|Active Comparator|high cereal fibre, diabetic diet|high cereal fibre, diabetic diet
3217352|NCT01063387|No Intervention|Sema4c positive +Common iliac lymph nodes control|"Sema4c Positive & Radical hysterectomy +Pelvic Radiotherapy "
3217353|NCT01063387|Active Comparator|Sema4c positive +Common iliac lymph nodes Experimental|"Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
3217354|NCT01063387|No Intervention|Sema4c Positive + PAN positive control arm|"Sema4c Positive &  Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation) "
3217355|NCT01063387|Experimental|Sema4c positive+ PAN positive Experimental|Sema4c Positive & Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation+ supraclavicular lymph nodes irradiation) '
3217356|NCT01063400||Activity monitoring|
3217357|NCT01063413||Coleman Afterschool Program|Children enrolled in a community center-based after-school program.
3217358|NCT01063413||YMCA Fun Company|Children enrolled in a school-based after-school program.
3217359|NCT01063426|Experimental|Atorvastatin + enoxaparine arm|High dose atorvastatin arm before index surgery+ conventional enoxaparin
3217360|NCT01063426|Active Comparator|Conventional Enoxaprin|Conventional Enoxaparin before 12hr and on 1-7th day after index surgery
3217361|NCT01063439|Experimental|BuEAM: Experimental|BuEAM: Experimental Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day Intervention: Drug: Busulfan, etoposide, cytarabine, and melphalan
3217362|NCT01063452|Experimental|Truvalve|Atkinson Product Design urinary slide valve on the catheter
3217363|NCT01063452|Active Comparator|Control|Drainage bag on the catheter
3217364|NCT01063465|Experimental|Early weightbearing|
3217365|NCT01063465|Experimental|Control group|
3217366|NCT01063478|Experimental|RAD001, Chemotherapy, Radiation|RAD001 + Chemotherapy and Radiation
3217367|NCT01063491|Experimental|Early graft angiography after coronary artery bypass surgery|Treatment of any bypass graft abnormalities that are discovered will be performed if needed
3217368|NCT01063491|No Intervention|No early angiography after coronary artery bypass surgery|
3217369|NCT01063504|Active Comparator|Teriparatide 20 microgram daily for 2 months|
3217370|NCT01063504|Placebo Comparator|Placebo|
3217371|NCT01063530|Experimental|Diammine Silver Fluoride|Application fo diammine silver fluoride in cervical lesions
3217372|NCT01063530|Placebo Comparator|Distilled water|Application of distilled water in cervical lesions
3217373|NCT01063543||patients with blood sample|Patients with major orthopedic surgery and prophylactic doses of fondaparinux who have 3 blood sample during their hospitalization to measure anti-Xa activity
3217374|NCT01063556|Experimental|1|
3217375|NCT01063556|Experimental|2|
3217376|NCT01063569|Active Comparator|Oral hydrocortisone|
3217377|NCT01063569|Experimental|Continous subcutaneous hydrocortisone infusion|
3217378|NCT01063582||fighter pilots f-16|This group is made up of pilots from the F-16 Venezuelan military air force stationed in the Base Vicente Landaeta Gil de Barquisimeto, Lara State.
3217379|NCT01063582||aircraft maintenance personnel f-16|Staff responsible for the preparation of aircraft for the flight and maintenance in the hangar at the airbase Vicente Landaeta Gil de Barquisimeto, Lara. Venezuela
3217380|NCT01063608|Experimental|Anti-H1N1v Vaccine|
3217381|NCT01063621|Experimental|KW-6500|
3217382|NCT01063647|Experimental|1|Treosulfan: 10 g/m² i.v. on 3 consecutive days (day -6 to -4)
3217383|NCT01063647|Experimental|2|Treosulfan:12 g/m² i.v. on 3 consecutive days (day -6 to -4)
3217384|NCT01063647|Experimental|3|Treosulfan: 14 g/m² i.v. on 3 consecutive days (day -6 to -4)
3217385|NCT01063660|Experimental|Treosulfan|Patients with acute myeloid leukaemia (AML) according to WHO classification (> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with < 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation
3217386|NCT01063673||Active runners|Observational follow-up study on 39 runners
3217387|NCT01063686|No Intervention|Insemination cervical cap|
3217388|NCT01063699|Experimental|Lap Kasai|Patients in this arm had their necessary Kasai procedure in a laparoscopic way.
3217389|NCT01063725|Experimental|Femarelle|Women will receive Femarelle twice daily for 12 weeks
3217390|NCT01063725|Placebo Comparator|Placebo|Women will take placebo capsules twice daily for 12 weeks
3217391|NCT01063738|Active Comparator|ICU Recovery Manual & placebo supplement|Patients will receive the standard self-directed rehabilitation package and a placebo nutritional supplement
3217392|NCT01063738|Experimental|ICU recovery manual & amino acid (AA) supplement|Patients will receive the standard self-directed rehabilitation package with the essential amino acid supplement
3217393|NCT01063738|Experimental|PEPSE & placebo supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the placebo nutritional supplement
3217394|NCT01063738|Experimental|PEPSE & AA supplement|Patients will receive the standard self-directed rehabilitation package plus PEPSE and the essential amino acid nutritional supplement
3217395|NCT01063751|Other|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell
3217396|NCT01063777|Active Comparator|1|
3217397|NCT01063777|Active Comparator|2|
3217398|NCT01063790|No Intervention|Usual care|Patients undergoing elective inguinal hernia repair attend the pre-admission clinic no later than one week prior to surgery. During this visit they receive one-on-one pre-operative education from a registered nurse. It includes both verbal and written information. Verbal information provided to patients includes procedural information such as the admission process, and post-operative care in the post-anaesthetic care uni and day surgery unit. Post-discharge pain management information is minimal and consists of direction to not wait until the pain is severe before taking prescribed analgesics.
3217399|NCT01063790|Experimental|Individualized Education|
3217400|NCT01063803|Experimental|Arm 1: ATN-103_30mg|
3217401|NCT01063803|Experimental|Arm 2: ATN-103_80 mg|
3217402|NCT01063816|Experimental|Arm 1|
3217403|NCT01063842|Experimental|001|tramadol hydrochloride / acetaminophen and placebo 1 tablet of tramadol/acetaminophen in the morning 1 tablet of placebo in the afternoon and evening for 3 days then 1 tablet of tramadol/acetaminophen in the morning evening and 1 tablet of placebo in the afternoon for 4 days then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
3217404|NCT01063842|Active Comparator|002|tramadol hydrochloride /acetaminophen 1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
3217405|NCT01063894|Experimental|breakfast cereal|breakfast cereal and milk
3217406|NCT01063894|Placebo Comparator|water|water
3217407|NCT01063920|Experimental|LT-NS001|LT-NS001 1200 mg b.i.d. p.o. for 12 weeks
3217408|NCT01063920|Active Comparator|Naprosyn®|Naprosyn® 500 mg b.i.d for 12 weeks
3217409|NCT01063933|Experimental|Cohort I|Cohort I: >/= 12 years to < 18 years. Peramivir administered daily for five days or until the day of hospital discharge, whichever comes first.
3217410|NCT01063933|Experimental|Cohort II|Cohort II: >/= 6 years to < 12 years
3217411|NCT01063933|Experimental|Cohort III|Cohort III: >/= 2 years to < 6 years
3217412|NCT01063933|Experimental|Cohort V|Cohort V: >/= 91 days to < 181 days
3217413|NCT01063933|Experimental|Cohort VII|Cohort VII: birth to < 31 days
3217414|NCT01063933|Experimental|Cohort VI|Cohort VI: >/= 31 days to < 91 days
3217415|NCT01063933|Experimental|Cohort IV|Cohort IV: >/= 181 days to < 2 years
3217416|NCT01063946|Experimental|[14C]-AVE8062|Single, 30 minute, intravenous infusion of 25 mg/m² of [14C]-AVE8062 containing 1.85 MBq (50µCi) at the first cycle, followed by subsequent administrations with non-radiolabelled AVE8062 in combination with cisplatin every 3 weeks, according to the investigator's judgment.
3217417|NCT01063959|Other|Safety|Chart review will evaluate the safety of the two procedures, incidence of complications operatively, hospital stay, and 6-week post-operative periods.
3217418|NCT01063959|Experimental|Weight Loss|Chart review will evaluate weight loss in subjects during the operative, 6-week post-operative, and follow-up of at least 18 months.
3217419|NCT01063959|Other|Insurance versus Private Pay|An insurance company issues an insurance policy to cover specific complications from the gastric bypass or the sleeve gastrectomy surgery which allows the surgeon to offer a fixed price to the patient. Comparison of surgical complications in subjects paying by insurance versus paying personally for the gastric bypass operation.
3217420|NCT01063998||Group 1|Patients demonstrate normal serum creatinine and no radiological evidence of a renal tumor.
3217421|NCT01063998||p 2|Patients diagnosed with renal cancer and normal creatinine.
3217422|NCT01064011|Other|External Ventricular drainage, Intraventricular Thrombolysis|
3217423|NCT01064011|Other|External Ventricular Drainage and Endoscopic Evacuation|
3217424|NCT01064024|Active Comparator|Phenazopyridine Hydrochloride Tablets, USP 200 mg|
3217425|NCT01064024|Placebo Comparator|Placebo|Matching placebo to the phenazopyridine hydrochloride tablets
3217426|NCT01064037|Experimental|Arm 1|
3217427|NCT01064037|Experimental|Arm 2|
3217428|NCT01064037|Experimental|Arm 3|
3217429|NCT01064037|Placebo Comparator|Arm 4|
3217430|NCT01064050|Experimental|trachea-bronchial stent (Novatech)|
3217431|NCT01064050|No Intervention|control|
3217432|NCT01064063|Active Comparator|AGC knee|Patients were randomised to receive an AGC Cruciate Retaining cement knee. This is the control group in the study; the AGC is the gold standard of Biomets' knee products.
3217433|NCT01064063|Experimental|Vanguard CR|Patients were randomised to receive a Vanguard Cruciate Retaining Knee from the Vanguard system which encompasses concepts used in the AGC family of knees. The Vanguard is specifically designed to give greater knees stability through use of more anatomic patello-femoral kinematics.
3217434|NCT01064089|Experimental|HSP990|dose escalation
3217435|NCT01064102|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
3217436|NCT01064102|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
3217437|NCT01064115|Experimental|Cetirizine|Cetirizine Hydrochloride Tablets 10 mg of Dr. Reddys Laboratories Limited
3217438|NCT01064115|Active Comparator|Zyrtec|Zyrtec Tablets 10 mg of Pfizer Labs
3217439|NCT01064128|Active Comparator|conventional laparoscopic hysterectomy|Three or four ports conventional laparoscopic hysterectomy
3217440|NCT01064128|Active Comparator|SPA laparoscopic hysterectomy|Single umbilical incision laparoscopic hysterectomy
3217441|NCT01064141|Experimental|Group 1: Dengue Vaccine Group|Participants will receive CYD Dengue vaccine as Visits 1 and 2.
3217442|NCT01064141|Active Comparator|Group 2: Control Group|Participants will receive Control Vaccines. (Varicella at Visit 1 and Hepatitis A at Visit 2)
3217443|NCT01064141|Experimental|Group 3: Co-administration Group|Participants will receive CYD Dengue vaccine and childhood vaccines at Visit 1 and CYD Dengue vaccine at Visit 2.
3217444|NCT01064141|Experimental|Group 4: Sequential Administration Group|Participants will receive CYD Dengue vaccine and a Placebo vaccine at Visit 1 and CYD Dengue vaccine at Visit 2.
3217445|NCT01064154|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
3217446|NCT01064154|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
3217447|NCT01064180|Experimental|Carvedilol|Carvedilol Tablets 25 mg of Dr Reddys Laboratories Limited
3217448|NCT01064180|Active Comparator|Coreg|Coreg Tablets 25 mg of GlaxoSmithKline
3217449|NCT01064193|Experimental|group 1 : IVF with biopsy|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation plus local injury to the endometrium of patients one menstrual cycle before the IVF
3217450|NCT01064193|Active Comparator|group 2|fresh IVF-embryo transfer treated with long protocol or antagonist protocol for the controlled ovarian hyperstimulation alone
3217451|NCT01064206||Buerger's disease patients|200 thromboangiitis obliterans patients (Buerger's disease or TAO)
3217452|NCT01064206||Control group|200 atheromatous arteritis patients
3217453|NCT01064219|Experimental|intrauterine hCG|intrauterine injection of 100 hCG followed by endometrial biopsy
3217454|NCT01064232|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
3217455|NCT01064232|Active Comparator|Risperdal|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
3217456|NCT01064245|Experimental|Cough Variant Asthma|Those diagnosed with cough variant asthma.
3217457|NCT01064245|Experimental|Asthma|Those with diagnosed asthma.
3217458|NCT01064258|Active Comparator|fixed CPAP|subject will sleep with a fixed CPAP device at minimal pressure
3217459|NCT01064258|Experimental|autoCPAP|the subject will sleep connected to an autoCPAP device
3217460|NCT01064271|Experimental|Risperidone|Risperidone Tablets 1 mg of Dr Reddys Laboratories Limited
3217461|NCT01064271|Active Comparator|Risperdal®|Risperdal® Tablets, 1 mg of Janssen Pharmaceutica Products, L.P
3217462|NCT01064336||Pregnant women on eltrombopag|Any women with eltrombopag exposure during pregnancy that is reported prior to or after knowledge of the pregnancy outcome, substantiated by health care provider, and meeting the enrollment criteria: documentation that eltrombopag is being taken during pregnancy; timing of the prenatal exposure to eltrombopag (i.e. best estimation of which trimester in pregnancy that there was exposure to Eltrombopag for stratification and reporting purposes ); sufficient information to determine whether the pregnancy is being prospectively or retrospectively registered; whether the outcome of pregnancy was known at the time of the report; source of the report (i.e. health care professional, patient); full provider contact information to allow for follow-up (name, address, etc.)
3217463|NCT01064336||Infants|Infants through the first year of life whose mothers were exposed to eltrombopag during pregnancy.
3217464|NCT01064349||Breast cancer patients with brain metastases|Female Erb2+ breast cancer patients with brain metastases diagnosed between January 2006 and December 2008 in 6 Asian countries (Indonesia, Korea, Malaysia, Philippines, Singapore, and Thailand).
3217465|NCT01064375|Experimental|CEA DNA prime (cohort I)|5 patients, tetwtCEA DNA intradermal delivery with electroporation, not previously vaccinated with CEA66 DNA. Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration. One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3217466|NCT01064375|Experimental|CEA DNA boost (cohort II)|10 patients, tetwtCEA DNA intradermal delivery with electroporation, previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3217467|NCT01064375|Experimental|CEA DNA prime + GM-CSF (cohort III)|5 patients, tetwtCEA DNA intradermal delivery with electroporation + GM-CSF, not previously vaccinated with CEA66 DNA.Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration.One dose of Cyclophosphamide (300 mg/m2) will be given i.v. three days before each vaccination with tetwtCEA DNA.
3217468|NCT01064388|Experimental|1|
3217469|NCT01064388|Placebo Comparator|2|
3217470|NCT01064427||Chemotherapy group|Breast cancer patients treated by adjuvant chemotherapy after their surgery. The time points of data collection are before the start of the first, second, fourth and sixth cycle of chemotherapy. If patients are treated by radiotherapy after the chemotherapy, there are 2 measurements points pre- and post radiotherapy.The others measurement points are at 12,18 and 24 months after surgery.
3217471|NCT01064427||No chemotherapy group|Breast cancer patients no treated by adjuvant chemotherapy after their surgery. For patients treated by radiotherapy after surgery, there are 2 measurement points pre- and post radiotherapy. The others measurement points are at 4,6,7,8,12,18 and 24 months after surgery.
3217472|NCT01064440|Experimental|Low Dose VM202|Patients in this group will receive 8mg total of VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
3217473|NCT01064440|Experimental|High Dose VM202|Patients in this treatment group will receive a total of 16mg VM202. Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day42: 4mg of VM202 (16 injections of 0.5ml of VM202)
3217474|NCT01064440|Sham Comparator|Placebo|Patients in this group will receive a total of 8ml normal saline. Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
3217475|NCT01064453||Group 1|
3217476|NCT01064466|Experimental|ETOPOSIDE - Usual|"Etoposide Injection~Combined Chemotherapy~Etoposide Injection + Methotrexate Injection + Topotecan Injection~Usual Approach Group"
3217477|NCT01064466|Experimental|ETOPOSIDE - Study|"Etoposide Capsule~Combined Chemotherapy~Etoposide Capsule + Methotrexate Tablet + HYCAMTIN - Topotecan Capsule~Study Approach Group"
3217478|NCT01064479|Experimental|Arm A (combination chemotherapy and erlotinib hydrochloride)|Patients receive docetaxel IV over 1 hour and cisplatin IV over 2 hours or carboplatin IV over 2 hours on day 1 and erlotinib hydrochloride PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue erlotinib hydrochloride treatment.
3217479|NCT01064479|Active Comparator|Arm B (combination chemotherapy and placebo)|Patients receive docetaxel and cisplatin or carboplatin as in Arm I and placebo PO daily on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression and unacceptable toxicity. Patients achieving complete response, partial response, or stable disease may continue placebo treatment.
3217480|NCT01064492|Experimental|ABC, ACB, BAC, BCA, CAB, and CBA|
3217481|NCT01064505|Experimental|QPI-1007|
3217482|NCT01064518|Active Comparator|Dose A|RT001 Topical Gel
3217483|NCT01064518|Placebo Comparator|Dose B|Placebo Comparator
3217484|NCT01064544|Experimental|Starting with light therapy|Starts with 3 weeks of light therapy, followed by a control period
3217485|NCT01064544|Experimental|Ending with light therapy|Ends with 3 weeks of light therapy after a control period.
3217486|NCT01064583|Experimental|flavanol rich cocoa drink (596mg)|dissolved in water, twice daily intervention
3217487|NCT01064583|Experimental|flavanol poor cocoa drink ( 13mg)|dissolved in water, twice daily intervention
3217488|NCT01064596||blood sample|Patient with 4 blood samples to measure anti-Xa activity
3217489|NCT01064609|Active Comparator|2. Biopsy with cryoprobes|Transbronchial cryobiopsy with a cryoprobe.
3217490|NCT01064609|Active Comparator|2.Biopsy with forceps|Transbronchial lung biopsy with conventional forceps.
3217491|NCT01064635|Active Comparator|Letrozole for 3-2 years|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for 3-2 years. Total duration of early adjuvant endocrine therapy: 5 years
3217492|NCT01064635|Experimental|Letrozole for 5 year|Patients pre-treated with TAM for 2-3 years will receive letrozole 2,5 mg/die for additional 5 years. Total duration of early adjuvant endocrine therapy: 7 years for patients pretreated with 2 years of TAM and 8 years for patients pre-treated with 3 years of TAM
3217493|NCT01064661|Active Comparator|Blend probiotic of L-NCFM and B-LBi07|Blend probiotic pills of L-NCFM and B-LBi07 BID (2x10^10 cfu total bacteria per day)
3217494|NCT01064661|Active Comparator|Single probiotic of L-NCFM alone|Single probiotic pills of L-NCFM alone BID (2x10^10 cfu total bacteria per day)
3217495|NCT01064674||before renal transplantation|Patients with CKD IV° to V° who are actually registering for a renal transplantation in our department.
3217496|NCT01064700|No Intervention|Baseline|1 week period, in which subjects followed usual schedule, though they were asked to maintain a fairly stable sleep schedule. The baseline period was used for comparison with the experimental intervention.
3217497|NCT01064700|Experimental|Experimental Intervention|Randomized exposure to the 4-week experimental treatments.
3217498|NCT01064726|Experimental|Ibuprofen|
3217499|NCT01064726|Experimental|Fluticasone propionate|
3217500|NCT01064726|Placebo Comparator|Placebo|
3217501|NCT01064752||Minocycline|HIV-1 infected, not on anti-retroviral medication
3217502|NCT01064765||Heart failure|Outpatients with heart failure, age 75 or less, left ventricular ejection fraction 40% or less, english speaking with no known dementia
3217503|NCT01064778|Active Comparator|Low GI|
3217504|NCT01064778|Experimental|High GI|
3217505|NCT01064791|Experimental|Arm 1|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
3217506|NCT01064791|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3217507|NCT01064791|Experimental|Arm 3|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
3217508|NCT01064791|Active Comparator|Arm 4|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
3217509|NCT01064804||relative bioavailability|
3217510|NCT01064843||4 Imtec mini-dental implants (MDI)|4 Imtec MDI
3260404|NCT01479023|Experimental|Cohort 3a|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~15.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3217511|NCT01064869|Experimental|Psycho-educational intervention|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
3217512|NCT01064869|No Intervention|usual care|Standard asthma management
3217513|NCT01064895||Active Cohort|Patients receiving the Benephit device and targeted renal therapy.
3217514|NCT01064908||Carotid endarterectomy|Patients who are undergoing elective carotid endarterectomy under local anaesthesia
3217515|NCT01064921|Experimental|Arm I|Patients receive oral vorinostat on days 0-2 and cisplatin IV on days 7, 21 and 35. Patients undergo radiation therapy 5 days a week beginning on day 7. Patients also receive concurrent oral vorinostat along with the radiotherapy to be given 3 days per week (Monday, Tuesday, and Wednesday). Optional repeat tumor and normal mucosal biopsies will be performed and blood will be drawn for correlative studies.
3217516|NCT01064934|Experimental|Lipid apheresis|Lipid apheresis
3217517|NCT01064934|Active Comparator|Standard care|Standard care
3217518|NCT01064960|Experimental|Treated leiomyomas|Pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure are treated with the Philips MR-guided HIFU system. Patients must have completed child bearing prior to enrolling in this study.
3217519|NCT01064973|Experimental|STX209|STX209 (arbaclofen)
3217520|NCT01064986|Placebo Comparator|A|IV Endotoxin plus saline vehicle (placebo)
3217521|NCT01064986|Active Comparator|B|IV Endotoxin plus IV hydrocortisone
3217522|NCT01064999|Experimental|High intensity group|(RT 55Gy + CapOx) + a cycle of Xelox + Surgery
3217523|NCT01064999|Active Comparator|Low instensity group|(RT 50Gy + CapOx) + Surgery
3217524|NCT01065012|Experimental|Udenafil 50 mg|50 mg Udenafil
3217525|NCT01065012|Experimental|Udenafil 100 mg|100 mg Udenafil
3217526|NCT01065012|Experimental|Udenafil 150 mg|150 mg Udenafil
3217527|NCT01065012|Placebo Comparator|Placebo|Placebo Tablets matching Udenafil tablets
3217528|NCT01065025|Experimental|4SC-205|
3217529|NCT01065038|Experimental|Anagrelide|
3217530|NCT01065038|Active Comparator|Hydroxyurea|
3217531|NCT01065064|Experimental|RESTOR|Patients with cataract that had phacoemulsification and AcrySof® ReSTOR IOL implantation.
3217532|NCT01065077|Experimental|Arm 1|
3217533|NCT01065077|Experimental|Arm 2|
3217534|NCT01065077|Experimental|Arm 3|
3217535|NCT01065077|Placebo Comparator|Arm 4|
3217536|NCT01065090||training|one group will receive resistance training and one group the normal physiotherapeutic treatment
3217537|NCT01065090||physiotherapy|one group will receive resistance training and one group the normal physiotherapeutic treatment
3217538|NCT01065103|Experimental|FFR measurement|
3217539|NCT01065116|Experimental|AL Blister-pack|
3217540|NCT01065116|Active Comparator|AL unit dose age specific pre-packs|
3217541|NCT01065129|Experimental|Dose Level 1|"AMD3100 320 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3217542|NCT01065129|Experimental|Dose Level 2|"AMD3100 440 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3217543|NCT01065129|Experimental|Dose Level 3|"AMD3100 560 μg/kg SC Days 1-5 of each 28 day cycle.~Azacitidine 75 mg/m2 SC Days 1-5 of each 28 days cycle.~G-CSF 5 μg/k SC Days 1-5 of each 28 days cycle."
3217544|NCT01065129|Experimental|Expanded DLT Cohort|After the MTD is determined, patients will be enrolled at the MTD dose of plerixafor. These patients will not receive G-CSF priming but will be treated with plerixafor and azacitidine for 2 cycles.
3217545|NCT01065155||Median central blood pressure|Median central blood pressure, lower median group 1 and higher group 2.
3217546|NCT01065168||endometrioma|ovarian endometrioma undergoing cystectomy
3217547|NCT01065194|Experimental|Levosimendan|Chronic stable heart failure
3217548|NCT01065194|Placebo Comparator|Placebo|Chronic Stable Heart Failure
3217549|NCT01065207|No Intervention|patient|
3217550|NCT01065220|Experimental|hormone treatment for MtF|"cyproterone acetate~estradiol~alpha-5-reductase-inhibitor"
3217551|NCT01065220|Experimental|hormone treatment for FtM|"testosterone undecanoate~lynestrenol"
3217552|NCT01065233||alcoholic cirrhosis with viral infection|patient with alcoholic cirrhosis with viral infection (300 patients)
3217553|NCT01065233||alcoholic cirrhosis without viral infection|patient with alcoholic cirrhosis without viral infection
3217554|NCT01065246|Experimental|catumaxomab|
3217555|NCT01065259|Experimental|OROS MPH|the group treated by OROS MPH
3217556|NCT01065259|Active Comparator|atomoxetine|the group treated by atomoxetine
3217557|NCT01065259|No Intervention|control|the normal control with no intervention
3217558|NCT01065272|Active Comparator|Ventolin - Dexamethasone group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Dexamethasone is also given daily for 5 days.
3217559|NCT01065272|Placebo Comparator|Ventolin - Placebo group|Ventolin nebulization with normal saline is given at 0,30,60,120 and 180 minutes,then every 2 hourly. Oral Placebo is also given daily for 5 days.
3217560|NCT01065285|Experimental|Evaluation of vaccines against flu|Evaluation of vaccines against flu
3217561|NCT01065298||Group 1:Stem cell Recipient|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4U/Kg for blood glucose control. They will undergo stem cell therapy initialy and G-CSF therapy at 2 months
3217562|NCT01065298||Group-2: Controls|Type 2 Diabetes mellitus patients on full doses of vildagliptin+metformin+pioglitazone and on Insulin >0.4U/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1.
3217563|NCT01065311|Experimental|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of certain aspects of cognitive behavioral therapy for depression (Beck et al., 1979) and components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
3217564|NCT01065311|Active Comparator|CBASP|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions.
3217565|NCT01065311|Active Comparator|Treatment-as-usual|"Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
3217566|NCT01065324||Anally inserted enteroscopy group|Anally inserted enteroscopy group
3217567|NCT01065324||Orally inserted enteroscopy group|Orally inserted enteroscopy group
3217568|NCT01065337|No Intervention|control group|patients received standard of care wound treatment according guideline of the American Diabetes Association (ADA)
3217569|NCT01065337|Active Comparator|bone marrow stem cells intraarterial|bone marrow stem cells administered intraarterial
3217570|NCT01065337|Active Comparator|tissue repair cells intramuscular|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intramuscular
3217571|NCT01065337|Active Comparator|tissue repair cells intraarterial|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells administered intraarterial
3217572|NCT01065337|Active Comparator|bone marrow stem cells intramuscular|bone marrow stem cells administered intramuscular
3217573|NCT01065363|Experimental|Lifestyle conseling|
3217574|NCT01065376|Experimental|on the day of hCG|cabergoline administration for 8 days on the day of hCG.
3217575|NCT01065376|Experimental|on the day after oocyte retrieval|cabergoline administration for 8 days on the day after oocyte retrieval
3217576|NCT01065389|Experimental|Prgressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
3217577|NCT01065389|Active Comparator|Unstructured Resistance Exercise|Unstructured Resistance Exercise thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
3217578|NCT01065402|Placebo Comparator|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
3217579|NCT01065402|Experimental|PPB-R-203-Based Meal|"PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. RS intake is associated with several changes in metabolism which may confer some health benefits.~PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition."
3217580|NCT01065415||control group|routine staging work-up with chest CT, PET/CT, and brain MRI
3217581|NCT01065415||study group|routine staging work-up plus whole body MRI for Coregistered MRI/PET
3217582|NCT01065467|Experimental|Treatment|LBH589
3217583|NCT01065493|Experimental|Software Assisted Lifestyle Counseling|
3217584|NCT01065493|Active Comparator|Lifestyle Counseling|Status quo smoking cessation counseling.
3217585|NCT01065519|Active Comparator|1|drug-eluting stent
3217586|NCT01065519|Active Comparator|2|Biolimus A9-eluting Biomatrix stent
3217587|NCT01065532|Active Comparator|1|SeQuent Please Drug-eluting balloon
3217588|NCT01065532|Active Comparator|2|Xience V Drug-eluting stent
3217589|NCT01065545|Experimental|Clofarabine|
3217590|NCT01065584||Standard immunosuppression|Patients receiving standard immunosuppression after liver transplantation including calcineurininhibitors
3217591|NCT01065584||Immunosuppression without calcineurininhibitors|Patients receiving immunosuppression after liver transplantation not based on calcineurininhibitors
3217592|NCT01065610|Experimental|Oxytocin|Intranasal Oxytocin, 24 IU
3217593|NCT01065610|Placebo Comparator|Placebo|
3217594|NCT01065623|Experimental|Arm 1|
3217595|NCT01065636|Experimental|Diet + Resistance Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised resistance exercise training three times a week
3217596|NCT01065636|Experimental|Diet + Aerobic Exercise Training|Weekly behavioral/diet-induced weight loss plus supervised aerobic exercise training three times a week
3217597|NCT01065636|Experimental|Diet + Combined Aerobic/Resistance Exercise|Weekly behavioral/diet-induced weight loss plus combined supervised resistance exercise training and aerobic exercise training three times a week
3217598|NCT01065636|No Intervention|Control Group (No Diet/No Exercise)|No diet No exercise training
3217599|NCT01065649|Experimental|Nortriptyline|20 NERD patients will be treated with nortriptyline 10 mg a day in the first 7 days and 25 mg a day in the following 14 days
3217600|NCT01065649|Placebo Comparator|Placebo|Placebo arm
3217601|NCT01065662|Experimental|Cediranib and Temsirolimus|Please see interventions section.
3217602|NCT01065688|Active Comparator|Roux-en Y|Roux-en Y reconstruction after distal gastrectomy
3217603|NCT01065688|Experimental|Billroth-I|Billroth-I reconstruction after distal gastrectomy
3217604|NCT01065701|Active Comparator|1mcg/kg|1mcg/kg intranasal dexmedetomidine administered 45 minutes befoe anesthesia induction
3217605|NCT01065701|Active Comparator|2mcg/kg|2mcg/kg intranasal dexmedetomidine given 45 minutes prior to anesthetic induction
3217606|NCT01065727|Experimental|mitoxantrone followed by immunomodulator|
3217607|NCT01065727|Active Comparator|natalizumab|
3217608|NCT01065740|Experimental|patient education|individual and group meetings with explanations about the disease, lifestyle counseling ; coaching by phone at 1 and 4 months; medical consultation at 3 months; physical exercise with coaching
3217609|NCT01065740|No Intervention|Usual care|
3217610|NCT01065753|Experimental|Life-style modification|Life-style modification for 40 study subjects with metabolic syndrome in comparison to 25 non-obesity subjects for control.
3217611|NCT01065792||1|Patients with HIV-1 infection taking Stocrin
3217612|NCT01065805|Experimental|1|18F-FLT PET
3217613|NCT01065831|Experimental|Lifestyle counseling|This MINT-TLC group will be asked to attend 12 weekly counseling meetings focused on weight loss (if overweight), limiting sodium, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained Lay Health Advisors. Participants will attend weekly group classes targeted at lifestyle changes for the first 12 weeks (intensive phase); followed by three individual MINT sessions conducted monthly for the following three months (maintenance phase). The MINT-TLC sessions aim to help participants make useful therapeutic lifestyle changes (TLC) and develop skills to maintain these changes long-term.
3217614|NCT01065831|Placebo Comparator|Health Education Control Condition|Participants randomized to this control condition will receive traditional, group health education classes for 12 weeks delivered by experts on various health topics unrelated to hypertension such as cancer, health insurance, and depression.
3217615|NCT01065857|Experimental|Citrafleet|The day prior to the colonoscopy in two dose times, first at 15:00h and second at 20:00h.
3217616|NCT01065857|Active Comparator|Klean Prep|The day prior to the colonoscopy from 16:00h to 20:00h.
3217617|NCT01065857|Experimental|Citrafleet Exploratory|The day of the colonoscopy in two dose times, first at 06:00h and second at 09:00h.
3217618|NCT01065870|Experimental|Group I|Patients with only venous involvement Treated with 6 cycles og GTX and then surgery
3217619|NCT01065870|Experimental|Group II|Patients with arterial involvement and may have venous involvement with tumor treated with 6 cycles of GTX, thenb GX/RT and then surgery
3217620|NCT01065883|Experimental|community health worker|community health workers will provide education in the home
3217621|NCT01065883|Active Comparator|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
3217622|NCT01065896||Group 1|
3217623|NCT01065909||Diabetes type 2|
3217624|NCT01065909||Chronic Pain|
3217625|NCT01065909||Atrial Fibrillation|
3217626|NCT01065935|Active Comparator|ALN-RSV01|
3217627|NCT01065935|Placebo Comparator|Normal saline|
3217628|NCT01065948|Experimental|Patients|
3217629|NCT01065961|Active Comparator|Decadron|Subject will be given Decadron 0.2mg/kg intraoperatively. This dose will be followed by 4 mg. every 6 hours for the first 24 hours.
3217630|NCT01065961|Placebo Comparator|Saline|subject will be given a blinded dose of placebo saline intraoperatively followed by placebo doses every 6 hours for 24 hours.
3217631|NCT01065974|Active Comparator|Behavior Therapy|"Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring~Stimulus control~Changing eating behaviors~Goal setting~Problem solving~Social support~Cognitive restructuring~Relapse prevention"
3217632|NCT01065974|Experimental|Behavior Therapy + Meal Replacements|The BT +MR condition will implement behavioral treatment strategies in a way that is nearly identical to that of the BT condition. However, participants in this condition also will use MRs during weight loss and weight loss maintenance.
3217633|NCT01065974|Experimental|Nutritrol|"Participants in this condition will be informed about the evidence indicating that the availability, structure and composition of foods they encounter or seek out in their daily lives will play a major role in determining their ability to maintain the weight they lose. We will present the treatment as an opportunity to make numerous changes to their personal food environment involving the variety, energy density, nutritional composition, and portion size of the foods they encounter in every day life.~The Nutritrol condition is comprised of several components:~Food structure~Energy density~Reduce variety of foods high in energy density and increase variety of foods low in energy density~Protein intake~Controlling the personal food environment~Individualized weight loss maintenance prescriptions"
3217634|NCT01065987|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
3217635|NCT01065987|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
3260405|NCT01479023|Experimental|Cohort 4|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~18.0 mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3217636|NCT01066013|Experimental|Prospective Antimicrobial de-escalation arm|Antimicrobial de escalation team will assess therapy and make recommendations to (a) change to antibiotic(s) with narrow spectrum,(b) stop antibiotics, (c) order new cultures/investigations or (d) consult with specialists or ID service for full evaluation (if patient's condition is worsening).
3217637|NCT01066013|No Intervention|Restrospective control arm|The control subjects will be drawn from historic data of patients on the same medical unit(s) and will be matched based on age, antibiotics, sex, and infectious diseases diagnosis.
3217638|NCT01066065||Raltegravir Cohort|Patients taking RAL 400 mg BID with Truvada
3217639|NCT01066065||Darunavir Cohort|Patients taking Darunavir 800 mg QD plus Norvir 100 mg QD with truvada
3217640|NCT01066078||CRT recipients|
3217641|NCT01066091|Placebo Comparator|mashed potatoes|Mashed potatoes is composed of potatoes and Skim milk powder.
3217642|NCT01066091|Experimental|Mashed potatoes + Oleic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 75% of Oleic Acid
3217643|NCT01066091|Experimental|Mashed potatoes + Palmitic Acid|The test meal is mashed potatoes with 1g/Kg of weight of lipids with 39% of saturated fat with 32% of palmitic acid.
3217644|NCT01066130|Experimental|Intensive treatment arm|Every second person with psychosocial problems was randomized into this arm. The intervention consisted of personalized, intensive psychosocial treatment provided by a medical social worker on the basis of the patient's problems for up to 2 years after inclusion.
3217645|NCT01066130|Experimental|Minimal treatment arm|Every second patient with psychosocial problems was assigned to this arm. Patients in this arm received minimal social support by a medical social worker.
3217646|NCT01066130|No Intervention|No need for psychosocial treatment|This arm consisted of individuals who did not need psychosocial treatment or measures. The need for such treatment and measures was determined at baseline for all persons included in the study.
3217647|NCT01066169||Healthy volunteers|Healthy subjects without HIV, vaccinated with Pandemic Influenza A/H1N1
3217648|NCT01066169||HIV-infected patients|HIV-infected patients, vaccinated with Pandemic Influenza A/H1N1
3217649|NCT01066182|Experimental|DHA supplement|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
3217650|NCT01066182|Placebo Comparator|Sunflower oil capsule|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
3217651|NCT01066195|Experimental|gefitinib|
3217652|NCT01066195|Active Comparator|pemetrexed|
3217653|NCT01066208||WG classification|Patients with Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217654|NCT01066208||MPA classification|Patients with microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217655|NCT01066208||CSS classification|Patients with Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217656|NCT01066208||PAN classification|Patients with polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217657|NCT01066208||Control Classification|For each of the diseases being evaluated (WG, MPA, CSS, PAN, GCA, TAK), patients with the other 5 diseases will be the control group. Within these groups, 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217658|NCT01066208||WG diagnostic|Patients with a new presentation of Wegener's granulomatosis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217659|NCT01066208||MPA diagnostic|Patients with a new presentation of microscopic polyangiitis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217660|NCT01066208||CSS diagnostic|Patients with a new presentation of Churg Strauss syndrome. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217661|NCT01066208||PAN diagnostic|Patients with a new presentation of polyarteritis nodosa. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217662|NCT01066208||Control diagnostic|Patients without vasculitis, but presenting with similar features to the 6 different types of vasculitis being studied. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217663|NCT01066208||GCA classification|Patients with giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217664|NCT01066208||TAK classification|Patients with Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Classification criteria.
3217665|NCT01066208||GCA diagnostic|Patients with a new diagnosis of giant cell arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217666|NCT01066208||TAK diagnostic|Patients with a new diagnosis of Takayasu arteritis. 1st half of these patients will be assigned to the development cohort and the second half to the validation cohort. Diagnostic criteria.
3217667|NCT01066221||Clostridium difficile patients|observational study
3217668|NCT01066234|Experimental|concurrent chemoradiotherapy|
3217669|NCT01066234|Active Comparator|chemotherapy only|
3217670|NCT01066247|Active Comparator|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
3217671|NCT01066247|Active Comparator|Morphine|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
3217672|NCT01066260|Experimental|Probiotic|
3217673|NCT01066260|Placebo Comparator|Placebo|
3217674|NCT01066273|Experimental|P-Stim device|Receiving the device that is activated
3217675|NCT01066286||core binding factor positive|core binding factor positive acute myeloid leukemia
3217676|NCT01066299|Experimental|oxitocin nasal spray|oxytocin nasal spray
3217677|NCT01066299|Placebo Comparator|placebo|inactive nasal spray
3217678|NCT01066312||Practitioners|Healthcare practitioners who either use, have used or do not use MMT in practice
3217679|NCT01066312||Testees|Healthy adults with no experience with MMT
3217680|NCT01066325|Experimental|NET|This arm will receive two 20-minutes sessions of NET 1 week apart. NET (Neuro Emotional Technique) is a non-invasive stress reduction technique.
3217681|NCT01066325|Active Comparator|Active Controls|This arm will receive two 20-minute sessions of stretching instructions 1 week apart.
3217682|NCT01066325|No Intervention|Inactive Controls|This arm will receive no intervention and no instructions.
3217683|NCT01066338||Normal karyotype|The patients were diagnosed as acute myeloid leukemia with normal karyotype.
3217684|NCT01066351|Experimental|Erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
3217685|NCT01066351|Placebo Comparator|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
3217686|NCT01066377|Experimental|Prebiotic and probiotic mix|Prebiotic: 8g/day, will be selected on the basis of ability to promote optimal growth and survival of the probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested). Probiotic: 10^8 - 10^9 live bacteria/day, bifidobacterium longum bv. infantis CCUG52486.
3217687|NCT01066377|Placebo Comparator|Maltodextrin/milk powder|
3217688|NCT01066403|Experimental|Pergolide|Patients will be randomly assigned to a sequence of treatments of either pergolide or placebo p.o. under continuous concomitant atypical neuroleptic therapy (stable at least 2 weeks prior trial begin).
3217689|NCT01066416|Placebo Comparator|Medical therapy|Patients undergo surgery 6 months after randomization
3217690|NCT01066416|Experimental|Surgery|Patients undergo surgery at time of randomization
3217691|NCT01066429|No Intervention|Poor prognosis DLBCL|Newly diagnosed patients with DLBCL and an age-adjusted IPI 2-3
3217692|NCT01066442|Experimental|BF2.649 ( Pitolisant)|BF2.649 (5mg, 10 mg, 20 mg) in capsules
3217693|NCT01066442|Placebo Comparator|Placebo|Placebo of BF2.649 (5mg, 10mg, 20mg) in capsules
3217694|NCT01066468|Experimental|Gleevec/Glivec|
3217695|NCT01066481|Experimental|PF-01913539 5 mg three times daily|PF-01913539 5 mg three times daily for 6 months
3217696|NCT01066481|Experimental|PF-01913539 20 mg three times daily|PF-01913539 20 mg three times daily for 6 months
3217697|NCT01066481|Placebo Comparator|Placebo|Placebo three times daily for 6 months
3217698|NCT01066494|Experimental|Single-arm|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
3217699|NCT01066507||Breast cancer|Slides containing breast cancer paraffin embedded tissue sections.
3217700|NCT01066533|Experimental|Mineral Trioxide Aggregate(MTA)|MTA is a proper material for direct pulp capping,treatment of tooth perforations,root end filling.It is a safe and biocompatible material,which can induce cementum formation on root surface.In direct pulp capping, MTA can induce dentinal bridge formation on the expose surface to preserve pulp vitality.Although MTA has superior biocompatibility compared with the conventional materials,it has a delayed setting time, poor handling characteristics and off-white color
3217701|NCT01066533|Experimental|NEC cement|NEC cement is a proper material for direct pulp capping and treatment of tooth perforation. It is a new dental material that combines reasonable biocompatibility of MTA with appropriate setting time,handling characteristics,chemical properties and color.Like MTA, NEC cement can induce dentinal bridge formation in direct pulp capping to preserve pulp vitality.
3217702|NCT01066559|Experimental|High flux polymethylmetacrylate membrane|
3217703|NCT01066559|Active Comparator|Polysulfone membranes|
3217704|NCT01066572|Experimental|Lisinopril|Experimental
3217705|NCT01066572|Placebo Comparator|Placebo|Placebo Comparator
3217706|NCT01066598|Experimental|Rituximab plus prednisone|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d Treat 61 Patients
3217707|NCT01066611|Active Comparator|1|CAL-263
3217708|NCT01066611|Placebo Comparator|2|Placebo
3217709|NCT01066650|Active Comparator|Endeavor Resolute|
3217710|NCT01066650|Active Comparator|Xience V|
3217711|NCT01066663|Experimental|Pyrimethamine|Single daily oral 50 mg dose.
3217712|NCT01066676|Experimental|Dexibuprofen|Dexibuprofen 400 mg powder for oral suspension
3217713|NCT01066676|Active Comparator|Ibuprofen|Ibuprofen 400 mg powder for oral suspension
3217714|NCT01066689|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3217715|NCT01066689|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3217716|NCT01066702|Experimental|NeoCart|Autologous cartilagenous tissue implant
3217717|NCT01066702|Active Comparator|Microfracture|surgical intervention
3217718|NCT01066715|Placebo Comparator|Placebo|
3217719|NCT01066715|Experimental|XOMA 052|
3217720|NCT01066728|Active Comparator|Theophylline|Oral loading dose of 6 mg per kilogram of body weight of theophylline followed by a maintenance dose of 2 mg per kilogram every 8 hours plus room air by nasal prongs at 0.5 l/min for 3 days.
3217721|NCT01066728|Experimental|CO2 inhalation|Equivalent loading and maintenance volume of oral normal saline plus CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
3217722|NCT01066741|Experimental|Homeodent®|Mouthwash with Homeodent® is started on the first day of irradiation, then continued until the end of the irradiation period or until occurrence of grade ≥3 mucositis. In case of grade ≥3 mucositis, patients are instructed to mouthwash with Sodium Bicarbonate solution until complete disappearance of mucositis or until the end of irradiation.
3217723|NCT01066741|Active Comparator|1.4 % Sodium Bicarbonate solution|"Mouthwash with sodium bicarbonate is started on the first day of irradiation, then continued until the end of the irradiation period. In case of grade ≥3 mucositis, mouthwash is continued until complete disappearance of the mucositis or until the end of irradiation.~In both arms, after the end of irradiation, patients can receive treatment with Sodium Bicarbonate solution until complete disappearance of the mucositis."
3217724|NCT01066754|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets of Dr. Reddy's Laboratories Limited
3217725|NCT01066754|Active Comparator|Allegra|Allegra Tablets 180 mg of Aventis Pharmaceuticals Inc.,
3217726|NCT01066767|Experimental|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets Dr. Reddy's Laboratories Limited
3217727|NCT01066767|Active Comparator|Allegra|Allegra Tablets 180 mg Aventis Pharmaceuticals Inc.,
3217728|NCT01066806|Experimental|high calcium diet|
3217729|NCT01066806|Active Comparator|normal calcium diet|
3217730|NCT01066845||Patients prescribed Adcirca|all patients prescribed Adcirca during study period
3217731|NCT01066858||Maternal/infant antepartum exposure|"HIV-infected women exposed to TDF during pregnancy~Infants of HIV-infected women exposed to TDF during pregnancy"
3217732|NCT01066858||Maternal/infant postpartum exposure|"HIV-infected women exposed to TDF while breastfeeding~Infants of HIV-infected women exposed to TDF while breastfeeding"
3217733|NCT01066858||Maternal/infant antepartum no exposure|"HIV-infected women not exposed to TDF during pregnancy~Infants of HIV-infected women not exposed to TDF during pregnancy"
3217734|NCT01066858||Maternal/infant postpartum no exposure|"HIV-infected women not exposed to TDF during breastfeeding~Infants of HIV-infected women not exposed to TDF during breastfeeding"
3217735|NCT01066884|Experimental|1|
3217736|NCT01066910|Experimental|Parent-only|
3217737|NCT01066910|Active Comparator|Parent and child|
3217738|NCT01066949|Active Comparator|Support and discussion|The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials.
3217739|NCT01066949|Experimental|Behavioral Self management|Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they relate to treatment adherence.Session material utilized by group-leaders will be highly structured and detailed across the seven sessions.
3217740|NCT01066962|Active Comparator|darunavir/r + tenofovir/emtricitabine|
3217741|NCT01066962|Experimental|darunavir/r + raltegravir|
3217742|NCT01066975||young and fit|5 healthy subjects, age lower than 30 yrs and high physical fitness
3217743|NCT01066988|Other|Right Eye|ORB Ocular Emulsion or SootheXP
3217744|NCT01066988|Other|Left Eye|ORB Ocular Emulsion or SootheXP
3217745|NCT01067001||2 Way Crossover|2 Way Crossover bioequivalence study
3217746|NCT01067001||Subjects will be randomly divided in to 2 groups.|A total of 18 normal, healthy, adult, human subjects will be enrolled in the study.
3217747|NCT01067014||iO-Flex|
3217748|NCT01067053|Experimental|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
3217749|NCT01067066|Experimental|TPI 287 + Temodar|Starting dose of TPI 287 90 mg/m^2 IV on Days 1, 8, 15 + Temozolomide (Temodar) PO at 85 mg/m^2 on Days 1-5.
3217750|NCT01067079||Arm 1|
3217751|NCT01067092|Experimental|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
3217752|NCT01067092|Active Comparator|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
3217753|NCT01067118|Active Comparator|Humalog U-100 Insulin|
3217754|NCT01067118|Experimental|LINjeta U-100|
3217755|NCT01067131|Experimental|PEV7C1, intravaginal|Vaccine containing virosomes intravaginally applied
3217756|NCT01067131|Placebo Comparator|PEV7C9, placebo, intravaginal|Placebo vaccine (excipient only) intravaginally applied
3217757|NCT01067131|Experimental|PEV7B2, intramuscular low dose|Intramuscular vaccine low dose of antigen
3217758|NCT01067131|Experimental|PEV7B1, intramuscular high dose|Intramuscular vaccine, high dose of antigen
3217759|NCT01067157|Other|A|"Other = Lifestyle intervention~A: Medical examination before and after inpatient therapy (clinic staff), questionnaires.~Further medical examination and questionnaires after 6 months, 1, 2, 5 and 10 years at home by pediatrics or general practitioner.~The lifestyle intervention includes an age-specific diet (1200-1800 kcal/d), 11 h/wk physical activity (walking, swimming, sports) and behavioural therapy."
3217760|NCT01067170|Experimental|Pneumatic compression stockings|
3217761|NCT01067183|Experimental|breathing and biofeedback device|This group of physicians were trained in the use of the relaxation breathing technique and the biofeedback device, and then used this portable stress reduction tool on a daily basis with twice weekly visits with the research team. After the 28 day RCT, they were invited to continue to use the device at their discretion during a trial extension from day 28-56 to see if any effect measured was maintained.
3217762|NCT01067183|No Intervention|control arm|This group did not undergo training in the breathing technique and use of the PSMD during the RTC trial day 0-28, but were visited twice weekly by the research team to collect outcome data. During the trial extension Day 28-56, this group did undergo a 1 hr training session with the PSMD and invited to use it at their discretion over the 28 days. Effectiveness outcome data (day 28-56) was collected at day 56.
3217763|NCT01067209||Diabetic/Obese Gastric bypass patients|Subjects with obesity including those with known diabetes or those with a high likelihood of diabetes who will undergo gastric bypass surgery.
3217764|NCT01067222|Experimental|BF2.649|
3217765|NCT01067222|Active Comparator|Modafinil|
3217766|NCT01067222|Placebo Comparator|Placebo|
3217767|NCT01067235|Experimental|BF2.649 + Modafinil placebo|
3217768|NCT01067235|Experimental|BF2.649 + Modafinil|
3217769|NCT01067248||COPD, osteoporosis|The subjects are divided into 6 groups of 20 subjects each, I: COPD patients with osteoporosis based on T-score and without vertebral fractures, II: COPD patients with osteoporosis based on T-score and vertebral fractures, III: COPD patients with vertebral fractures and without osteoporosis based on T-score, IV: COPD patients without osteoporosis based on T-score and without vertebral fractures, V: healthy controls with osteoporosis based on T-score and without vertebral fractures, VI: healthy controls without osteoporosis based on T-score and without vertebral fractures.
3217770|NCT01067261|Experimental|TMNS and pelvic floor muscle training|This group will receive both the normal pelvic floor muscle training and the TMNS vibration therapy following their radical prostatectomy. Treatment with TMNS will start before the surgery and continue 6 weeks after the surgery.
3217771|NCT01067261|Active Comparator|Pelvic floor muscle training only|This group will receive the normal pelvic floor muscle training after prostatectomy only.
3217772|NCT01067274|Experimental|R1 Arm A : ATRA|"Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum~All-trans retinoic acid (ATRA): 45mg/m2/day in two divided doses from D8 to D28"
3217773|NCT01067274|No Intervention|R1 Arm B : no ATRA|Idarubicin: 9 mg/m2/d D1 to D4 Cytarabine : 200 mg/m2/d Continuous IV from D1 to D7 Peg-filgrastim : 6 mg SC D9 or filgrastim 5ug/kg/d SC or lenograstim 263ug/d IV 30mn, both from D9 to myeloid recovery(PMN >1G/l over 2 days at minimum
3217774|NCT01067274|Experimental|R2 Arm 1A : AZACITIDINE and ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5 All-trans retinoic acid (ATRA): 45mg/m2/d in two divided doses from D8 to D21
3217775|NCT01067274|Experimental|R2 Arm 1B : AZACITIDINE and No ATRA|Azacitidine: 75 mg/m2/12h SC from D1 to D5 Idarubicine: 9 mg/m2/d IV on D5
3217776|NCT01067274|Experimental|R2 Arm 2A : ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5 All-trans retinoic acid (ATRA): 45mg/ m2/d in two divided doses from D8 to D21
3217777|NCT01067274|Experimental|R2 Arm 2B : no ATRA|Idarubicine : 9 mg/m2/d IV on D1 Cytarabine : 60 mg/m2/12h SC from D1 to D5
3217778|NCT01067287|Active Comparator|Group 1|Monoclonal antibody CT-011 will be given 1-3 months following autologous transplant. 3 doses will be given at 6 week intervals.
3217779|NCT01067287|Active Comparator|Group 2|Vaccination with DC/myeloma fusion cells will be given 1-3 months following autologous transplant. Vaccination will be given at 6 weeks intervals. The monoclonal antibody CT-011 will be given 1 week following each vaccination. 3 doses of CT-011 will be given at 6 week intervals.
3217780|NCT01067300|Active Comparator|Double unit unrelated cord blood transplantation|Transplantation of unrelated cord blood units is done at least 24 hours after last chemotherapy and carried out during the same day. The unit presenting the best degree of HLA compatibility with the patient will be transfused in first. If the 2 units have the same degree of HLA compatibility with the recipient, the unit with the higher cell dose will be transfused in first. A 2 hours time interval between the 2 transfusions will be respected.
3217781|NCT01067300|Active Comparator|single unit unrelated cord blood transplantation|Transplantation of a single unrelated cord blood unit at least 24 hours after last chemotherapy
3217782|NCT01067313|Experimental|Dialyzer Ultraflux EMiC2|Dialyzer Ultraflux EMiC2 used in Continuous Hemodialysis
3217783|NCT01067313|Active Comparator|Dialyzer Ultraflux AV1000S|Dialyzer Ultraflux AV1000S used in continuous Hemofiltration
3217784|NCT01067365|Experimental|12.5 mg Androxal|12.5 mg Androxal daily
3217785|NCT01067365|Experimental|25 mg Androxal|25 mg Androxal daily
3217786|NCT01067378|Active Comparator|Expert instructor debriefing|Expert instructor debriefing
3217787|NCT01067378|Experimental|Peer-led debriefing|Peer-led debriefing
3217788|NCT01067391|Active Comparator|tadalafil 20 mg|Oral study medication to be administered once to each participant
3217789|NCT01067391|Placebo Comparator|placebo|oral study medication to be administered once to each study participant
3217790|NCT01067404||2008-09 study TIV recipients|Infants and toddlers who participated in earlier clinical trial (TITRE) to evaluate dosing (0.25mL versus 0.5mL) of trivalent influenza vaccine (TIV)
3217791|NCT01067417|Active Comparator|Hydroxychloroquine|
3217792|NCT01067417|Placebo Comparator|Placebo|
3217793|NCT01067430|Active Comparator|Etoricoxib 90 mg|Subject will take Etoricoxib 90 mg for 14 days
3217794|NCT01067430|Active Comparator|Diclofenac|Film coated tablet 50 mgs given three times a day for 14 days
3217795|NCT01067443|Experimental|Amb+SSG|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
3217796|NCT01067443|Experimental|Amb+Milt|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
3217797|NCT01067443|Experimental|Milt|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
3217798|NCT01067482||Glaucoma patients|
3217799|NCT01067482||Glaucoma suspect group|
3217800|NCT01067482||Normal population|
3217801|NCT01067495|Experimental|Exercise|
3217802|NCT01067547|Experimental|iron sulfate|Oral iron sulfate 300mg tid
3217803|NCT01067547|Active Comparator|intravenous iron sulfate|intravenous iron sulfate 300 mg
3217804|NCT01067599|Active Comparator|Low nicotine|Conventional smokeless tobacco product with 1) NNN plus NNK of <2 μg/gram and nicotine levels of >5 mg/g wet weight
3217805|NCT01067599|Active Comparator|Medium nicotine|Conventional smokeless tobacco product with ) NNN plus NNK of <2 μg/gram and nicotine levels of 3-5 mg/g wet weight.
3217806|NCT01067599|Active Comparator|High nicotine|Conventional smokeless tobacco product with NNN plus NNK of <2 μg/gram and nicotine levels of <3 mg/g wet weight
3217807|NCT01067625|Experimental|TOGA subjects|
3217808|NCT01067638|Experimental|tranexamic acid|Tranexamic Acid on Postoperative Blood loss and Coagulation in Patients with Preoperative Anemia Undergoing Off-Pump Coronary Artery Bypass Graft
3217809|NCT01067651|Active Comparator|Plaster of Paris (POP)|
3217810|NCT01067651|Active Comparator|semi-rigid fiberglass softcast (SRF, 3M Scotchcast)|
3217811|NCT01067664||Patients undergoing IVF with rFSH and GnRH antagonists|
3217812|NCT01067677|Experimental|Metoclopramide|rescue emetic therapy
3217813|NCT01067677|Experimental|Ondansetron|Rescue emetic therapy
3217814|NCT01067677|Experimental|Diphenhydramine|Rescue emetic therapy
3217815|NCT01067677|Placebo Comparator|Saline|Placebo
3217816|NCT01067703|Active Comparator|RIPC|
3217817|NCT01067703|Sham Comparator|CONTROL|
3217818|NCT01067742||Subjects with Mucolipidosis Type IV|
3217819|NCT01067755||Bronchoscopy, lung neoplasm|Patients who have been recommended for bronchoscopy for the purpose of obtaining a biopsy sample of a central or peripheral pulmonary lesion, diagnosing mediastinal or hilar lymphadenopathy or for lung fiducial placement.
3217820|NCT01067794||pemetrexed + platinum|Patients with pemetrexed + platinum doublet, with or without additional targeted agents
3217821|NCT01067794||gemcitabine + platinum|Patients with gemcitabine + platinum doublet, with or without additional targeted agents
3217822|NCT01067794||taxanes + platinum|Patients with taxanes + platinum doublet, with or without additional targeted agents
3217823|NCT01067794||vinorelbine + platinum|Patients with vinorelbine + platinum doublet, with or without additional targeted agents
3217824|NCT01067794||others + platinum|Patients with other platinum-based doublet, with or without additional targeted agents
3217825|NCT01067807|Experimental|Proellex Formulation 1|25 mg Proellex Gelucire and PEG (original formulation)
3217826|NCT01067807|Experimental|25 mg Proellex Formulation 2|25 mg Proellex coated with MCC
3217827|NCT01067807|Experimental|25 mg Proellex Formulation 3|25 mg Proellex blended with MCC
3217828|NCT01067807|Experimental|50 mg Proellex Formulation 3|50 mg Proellex blended with MCC
3217829|NCT01067820|Experimental|RVX000222, 200 mg daily|
3217830|NCT01067820|Placebo Comparator|Placebo|
3217831|NCT01067833|Placebo Comparator|Placebo|Placebo
3217832|NCT01067833|Experimental|Dose 1|K201
3217833|NCT01067833|Experimental|Dose 2|K201
3217834|NCT01067833|Experimental|Dose 3|K201
3217835|NCT01067859|Experimental|Arm 1|
3217836|NCT01067859|Experimental|Arm 2|
3217837|NCT01067859|Placebo Comparator|Arm 3|
3217838|NCT01067898|Experimental|200 000 IU vitamin D3 every three months|
3217839|NCT01067898|Experimental|100 000 IU vitamin D3 every three months|
3217840|NCT01067898|Placebo Comparator|placebo every three months|
3217841|NCT01067911|Active Comparator|1|In this study subjects will consume test meals containing vegetable oils (soy) and butter
3217842|NCT01067911|Active Comparator|2|In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
3217843|NCT01067911|Active Comparator|3|In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
3217844|NCT01067911|Active Comparator|4|In this study subjects will consume test meals containing vegetable oils (canola) and butter
3217845|NCT01067924|Experimental|Motivational interviewing|
3217846|NCT01067924|Active Comparator|Standard of care|
3217847|NCT01067950|Experimental|Isolated Pancreas Transplant|
3217848|NCT01067950|Active Comparator|Intensive Insulin Therapy|
3217849|NCT01067963|Experimental|Behavioral-education/counseling|"Computer assisted education and telephone counseling using motivational interviewing.~Computer assisted education and motivational interviewing"
3217850|NCT01067963|Placebo Comparator|Group talks/social chat|Group session talks on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
3217851|NCT01067989|Experimental|intervention|same treatment for all patients
3217852|NCT01068002||Control, normotensive, pregnancy|Control, normotensive, pregnancy
3217853|NCT01068002||hypertension, pregnancy, no treatment|hypertension, pregnancy, no treatment
3217854|NCT01068002||hypertension, pregnancy, drug treatment|hypertension, pregnancy, drug treatment
3217855|NCT01068015|Experimental|Intervention|This arm receives free circumcision service, POL intervention, intensive HIV counseling and intensive condom promotion.
3217856|NCT01068015|No Intervention|usual|This arm receives no extra HIV prevention services.
3217857|NCT01068028|Placebo Comparator|Placebo for ORM-12741|
3217858|NCT01068028|Experimental|ORM-12741|
3217859|NCT01068041|Placebo Comparator|A|Placebo
3217860|NCT01068041|Active Comparator|B|250mg active ingredient
3217861|NCT01068041|Active Comparator|C|500mg active ingredient
3217862|NCT01068041|Active Comparator|D|1000mg active ingredient
3217863|NCT01068054|Active Comparator|tacrolimus|Tacrolimus arm: active 0.1% tacrolimus eye ointment BID + placebo eye drops QID
3217864|NCT01068054|Active Comparator|cyclosporine|2% cyclosporine eye drops apply QID + placebo eye ointment apply bid
3217865|NCT01068067|Experimental|pharmacogenetics plus SchE guided dosing|
3217866|NCT01068067|Active Comparator|standard dosing|
3217867|NCT01068080||Myocardial fatty acid metabolism, Insulin resistance|"Myocardial fatty acid metabolism was evaluated by myocardial fatty acid imaging using BMIPP SPECT.~Insulin resistance was evaluated by HOMA-IR."
3217868|NCT01068106|Active Comparator|BPLES|Biodegradable polymer limus-eluting stents
3217869|NCT01068106|Active Comparator|PPLES|Permanent polymer limus-eluting stent
3217870|NCT01068119|Experimental|Same-day discharge|Same-day discharge following PCI
3217871|NCT01068132|Experimental|1|Cetuximab+FOLFIRI: cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1, followed after 1 hour by FOLFIRI: irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
3217872|NCT01068145|Experimental|Very low dose SCH 527123|
3217873|NCT01068145|Experimental|Low dose SCH 527123|
3217874|NCT01068145|Experimental|Medium dose SCH 527123|
3217875|NCT01068145|Experimental|High dose SCH 527123|
3217876|NCT01068145|Placebo Comparator|Placebo to match SCH 527123|
3217877|NCT01068145|Experimental|Low dose SCH 527123 (Part 2)|
3217878|NCT01068145|Experimental|Medium dose SCH 527123 (Part 2)|
3217879|NCT01068145|Experimental|High dose SCH 527123 (Part 2)|
3217880|NCT01068145|Placebo Comparator|Placebo (Part 2)|
3217881|NCT01068171|Active Comparator|shoe, plain dressing|post-op shoe with plain occlusive dressing
3217882|NCT01068171|Active Comparator|shoe, collagen|post-op shoe with collagen dressing
3217883|NCT01068171|Active Comparator|boot, plain dressing|air boot with occlusive dressing
3217884|NCT01068171|Active Comparator|boot, collagen|air boot with collagen dressing
3217885|NCT01068171|Active Comparator|monitored air boot, plain dressing|air boot with retention strap to monitor whether boot is removed with occlusive dressing
3217886|NCT01068171|Active Comparator|monitored boot with collagen|air boot with retention strap to monitor whether boot is removed with collagen dressing
3217887|NCT01068184|Experimental|1|
3217888|NCT01068184|Placebo Comparator|2|
3217889|NCT01068197|Experimental|Low glycemic load dietary plan|"The subjects and their parents will be given instructions, and specific examples, to lower the glycemic load of their diets by replacing high-GI sources of carbohydrates with low-GI food sources, replacing energy from carbohydrate with energy from protein and fat, and attempt to balance meals and snacks with low-GI carbohydrate, proteins and low-fat food sources. The objective will be to achieve macronutrient composition for the low-GL diet of 45-50% low-GI carbohydrates, 20-25% protein, and 30-35% fat. All subjects will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized low-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
3217890|NCT01068197|Active Comparator|Low fat diet|"For the low fat diet, subjects and their parents will be given instructions, and specific examples, to lower the fat content of their diet. The composition of the low-fat diet will be targeted to achieve 55-60% carbohydrates (with no discrimination by their glycemic index), 15-20% protein and 25-30% fat. All recruited children will receive sessions on behavior modification, increasing physical activity and reducing sedentary behavior.~At 3 months, subjects will be admitted to the GCRC for a 24 hour period for a meal study. They will be given standardized high-glycemic load diet for dinner, breakfast and lunch, followed by an ad lib snack platter. Their subjective, hormonal and metabolic responses will be serially measured."
3217891|NCT01068210|Experimental|Aerobic Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level. The exercise program will consist of three supervised sessions per week. During each session, the participant will cycle on a stationary bicycle at moderate intensity for approximately 30-60 minutes.
3217892|NCT01068210|Experimental|Resistance Training|A customized and supervised resistance exercise training program that will last 4 months (16 weeks). Resistance training will be performed on stationary weight machines, modification in equipment may be made by Exercise Physiologist. Patients will be progressively trained to perform two to three sets of 75-85% of maximal strength The participant will be trained to perform different resistance exercise, alternating between lower and upper body muscle groups. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-60 minutes.
3217893|NCT01068210|Experimental|Combined Aerobic and Resistance Training|A customized and supervised endurance exercise training program that will last 4 months (16 weeks). The regimen will be tailored to the individual fitness level, and will be a combination of Arm A and Arm B, described above. At each session, the participant will complete aerobic training on a stationary bicycle and also resistance training using stationary weight machines. The exercise program will consist of three supervised sessions per week. Each session will last approximately 30-90 minutes.
3217894|NCT01068210|Active Comparator|Progressive Stretching Group (Attention-Control)|A customized and supervised progressive stretching program that will last 4 months (16 weeks). The progressive stretching program will consist of a series of stretching exercises alternating between lower and upper body muscle groups/joints. This program will consist of three exercise sessions a week. Each session will last approximately 30-60 minutes.
3217895|NCT01068223|Experimental|001|A:JNJ-39758979/Placebo #1 Single oral dose of JNJ-39758979 600 mg and Placebo
3217896|NCT01068223|Placebo Comparator|002|B: JNJ-39758979 Matching Placebo /Placebo #2 A single dose of 2 different Placebos JNJ-39758979 Matching Placebo and Placebo #2
3217897|NCT01068223|Active Comparator|003|C:Cetirizine/JNJ-39758979 Matching Placebo Single oral dose of 10mg cetirizine and JNJ-39758979 Matching Placebo
3217898|NCT01068236|Experimental|Healthy lifestyle intervention|lifestyle/weight-loss intervention for overweight (95th - 99th percentile) female adolescents (13-15 years of age at study entry) to a usual-care control condition. The intervention will be 20-sessions and combines group visits, individual telephone coaching calls, and tailored pediatric primary care providers (PCP) visits.
3217899|NCT01068236|No Intervention|Usual care|In the usual care control condition adolescents and their family will receive individualized feedback from the assessments as well as handouts outlining healthy means of maintaining / reducing weight for adolescents through improving nutrition and physical activity. In addition, these participants will be encouraged to seek any appropriate health care/education services available through Kaiser Permanente or in the community.
3217900|NCT01068249|Experimental|Letrozole + RAD001|Letrozole and RAD001 (Everolimus)
3217901|NCT01068275|Active Comparator|Lumbar plexus catheter|
3217902|NCT01068275|Active Comparator|femoral nerve catheter|
3217903|NCT01068275|Active Comparator|single-shot femoral block|
3217904|NCT01068288|Experimental|Expectant Management|Expectant Management
3217905|NCT01068288|Experimental|Operative management|Operative management
3217906|NCT01068301|Other|Second Allogeneic Transplant Procedure Recipient|"Participants with Acute Lymphoblastic Leukemia (ALL); Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myeloid Leukemia (CML); Juvenile Myelomonocytic Leukemia (JMML); Non-Hodgkin lymphoma (NHL) with evidence of bone marrow disease, receiving a second allogeneic transplant procedure.~Intervention: Plerixafor"
3217907|NCT01068314|Experimental|Repetitive handgrip exercise|After baseline testing and randomization, subjects in this group are instructed to perform the intervention: daily repetitive handgrip exercise with upper arm compression band. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
3217908|NCT01068314|No Intervention|No arm exercise|Time control. Subjects do usual activities without any exercise intervention. Brachial artery endothelial function and venous compliance are tested at baseline and 6 weeks.
3217909|NCT01068327|Experimental|Treatment (SRT, radiosensitizer, and chemotherapy)|See Detailed Description
3217910|NCT01068340||SBO Patients|Patients who develop small bowel obstruction requiring or not surgical intervention
3217911|NCT01068340||No SBO Patients|Patients who do not develop small bowel obstruction
3217912|NCT01068353|Placebo Comparator|Placebo|
3217913|NCT01068353|Experimental|Etanercept|
3217914|NCT01068379|Experimental|Cryopexy|the cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
3217915|NCT01068379|Experimental|laser photocoagulation 4 weeks after|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
3217916|NCT01068392|Experimental|OXP|Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2HR D1 Prednisolone 100mg/Day D1-D5 Every 3 weeks Maximum 6 cycles of treatment will be given for this study. Subjects will be treated for at least 1 cycle and to a maximum of 6 cycles unless there is documented disease progression, unacceptable adverse events or withdrawal of consent.
3217917|NCT01068405|Experimental|Methotrexate|Patients with digital arthritis receiving methotrexate treatment at 10mg/week during 12 months
3217918|NCT01068405|Placebo Comparator|Placebo|Patients with digital arthritis receiving placebo at 10mg/week during 12 months
3217919|NCT01068431|Active Comparator|trico bandage|Leg lymphedema stage 2-3
3217920|NCT01068431|Experimental|juxta fit compression device|leg lymphedema stage 2/3
3217921|NCT01068444|Experimental|Pioglitazone|Pioglitazone 30 mg/day for 6 months and 3 months of follow-up period after treatment
3217922|NCT01068444|Placebo Comparator|Placebo|Placebo 30 mg/day for 6 months and 3 months of follow-up period after treatment
3217923|NCT01068457||PTPS|Patients with pain after VATS
3217924|NCT01068457||Pain free|Patients reporting no pain late after VAT
3217925|NCT01068470||patients with melanoma or kidney cancer|
3217926|NCT01068483|Experimental|BKM120|Dose escalation followed by dose expansion
3217927|NCT01068522|Experimental|ICP monitoring|Care based upon intracranial pressure.
3217928|NCT01068522|Active Comparator|Usual Care|Treatment based on clinical and imaging without intracranial pressure monitoring.
3217929|NCT01068535||Women with Metabolic Syndrome|"Pre-menopausal women with Metabolic Syndrome~Age 35-50 and any 3 of the following:~Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL < 50mg/dL, Fasting glucose ≥ 100mg/dL but <126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure."
3217930|NCT01068535||Non-Metabolic Syndrome (healthy) women|"Non-Metabolic syndrome pre-menopausal women age 35-50~Body Mass Index ≤ 25~Regular menstrual cycles (occur every 24-35 days)~Fasting glucose < 100mg/dL~HDL-C ≥ 50mg/dL~Waist measurement ≤ 35 inches~Fasting triglycerides < 150mg/dL"
3217931|NCT01068561|Experimental|Test group|open-label study of retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200.
3217932|NCT01068574||Single Observational Cohort|
3217933|NCT01068587|Active Comparator|Erlotinib|
3217934|NCT01068587|Active Comparator|Foretinib plus Erlotinib|
3217935|NCT01068613|Experimental|QAX028 high dose|
3217936|NCT01068613|Experimental|QAX028 low dose|
3217937|NCT01068613|Active Comparator|Tiotropium|
3217938|NCT01068613|Placebo Comparator|Placebo|
3217939|NCT01068639||A|
3217940|NCT01068704|Active Comparator|BMS-690514 + Letrozole|
3217941|NCT01068704|Active Comparator|Lapatinib + Letrozole|
3217942|NCT01068756|Other|Dapagliflozin/Rifampin|
3217943|NCT01068782|Experimental|Arm 1|
3217944|NCT01068782|Experimental|Arm 2|
3217945|NCT01068782|Experimental|Arm 3|
3217946|NCT01068782|Experimental|Arm 4|
3217947|NCT01068795|No Intervention|enoxaparin fixed|enoxaparin dosage will be fixed during pregnancy
3217948|NCT01068795|Experimental|enoxaparin adjusted|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
3217949|NCT01068808||Nonallergic rhinitis|Nonallergic rhinitis (negative skin prick test)
3217950|NCT01068834||KIF6 tested|Recruited subjects, completing a valid KIF6 test with results
3217951|NCT01068834||KIF6 test naïve|Database matched cohort not receiving a KIF6 test
3217952|NCT01068847|Experimental|1|Receives 2-4 of the drugs listed under Intervention
3217953|NCT01068886|No Intervention|no stent|no stent through pancreatic anastomosis
3217954|NCT01068886|Experimental|stent|stent through pancreatic anastomosis
3217955|NCT01068899||Children|healthy children
3217956|NCT01068899||Adult|healthy adults
3217957|NCT01068925|Experimental|ARM 1|"Arm 1:~GSK1349572 QD for 5 days (Treatment A)."
3217958|NCT01068925|Experimental|ARM 2|ARM 2: TPV/RTV 500/200mg BID (Treatment B).
3217959|NCT01068925|Experimental|ARM 3|ARM 3: GSK1349572 50mg QD and TPV/RTV 500/200mg BID (Treatment C).
3217960|NCT01068938||open angle glaucoma, glaucoma suspects|risk of progression, Latanoprost monotherapy
3217961|NCT01068951|Active Comparator|Mesenchymal stem cells|Comparison of active treatment with autologous mesenchymal stem cells (in addition to standard treatment) to standard treatment of patients newly diagnosed with type 1 diabetes mellitus.
3217962|NCT01068951|No Intervention|Control|
3217963|NCT01068977|Experimental|Stage I|
3217964|NCT01068977|Experimental|Stage II|
3217965|NCT01068977|Experimental|Stage III|
3217966|NCT01069016|Experimental|Sacral nerve modulation first|"Sacral nerve modulation is applied before the pudendal nerve stimulation. There is no wash-out period (pause) between the two treatments."
3217967|NCT01069016|Experimental|Pudendal nerve stimulation first|"Pudendal nerve stimulation is applied before the sacral nerve modulation. There is no wash-out period (pause) between the two treatments."
3217968|NCT01069029||Combined surgery|Patient which underwent combined surgery of MH and cataract extraction
3217969|NCT01069029||Successive surgery|Patients which underwent the two successive procedures
3217970|NCT01069042|Active Comparator|preserved LVEF under ACEi treatment|preserved LVEF under ACEi treatment
3217971|NCT01069042|Experimental|Poor LVEF group|Poor LVEF under ACEi treatment
3217972|NCT01069055|Placebo Comparator|Placebo Control|Group I (Placebo Control) 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
3217973|NCT01069055|Active Comparator|Lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
3217974|NCT01069055|Active Comparator|Paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
3217975|NCT01069081|Active Comparator|arm A|docetaxel and cisplatin chemotherapy
3217976|NCT01069081|Experimental|arm B|docetaxel and cisplatin chemotherapy combined with PPI 160mg per day.
3217977|NCT01069081|Experimental|arm C|docetaxel and cisplatin chemotherapy combined with PPI 200mg per day.
3217978|NCT01069094|Experimental|progenta 12.5 mg|Progenta (CDB-4124) 12.5 mg capsule
3217979|NCT01069094|Experimental|progenta 25 mg|Progenta (CDB-4124) 25 mg capsule
3217980|NCT01069094|Experimental|progenta 50 mg|Progenta (CDB-4124) 50 mg capsule
3217981|NCT01069094|Active Comparator|Lucron Depot|Lucron Depot, Leuprolide acetate for depot suspension
3217982|NCT01069094|Placebo Comparator|placebo|Placebo capsule
3217983|NCT01069107|Active Comparator|Consume of health services|One year follow-up of patients randomized to two different levels of health care
3217984|NCT01069133|Experimental|Rifaximin|
3217985|NCT01069146|Experimental|Mild therapeutic hypothermia|Sepsis treatment according to standard guidelines plus mild therapeutic hypothermia
3217986|NCT01069146|No Intervention|Control|Sepsis treatment according to standard guidelines
3260406|NCT01479023|Experimental|Cohort 5|"64Cu-DOTA-U3-1287 at the radiotracer dosage defined by Cohort 1 and ≤ 0.2 mg of DOTA-U3-1287 on Day 1.~TBD (to be determined) mg/kg unlabeled U3-1287 followed by a second dose of ≤ 0.2 mg 64Cu-DOTA-U3-1287 on Day 8.~Patient will have option to continue to Part 2 (extension phase)."
3217987|NCT01069159|Active Comparator|Propranolol|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive propranolol.
3217988|NCT01069159|Placebo Comparator|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
3217989|NCT01069198|Experimental|Intervention group|
3217990|NCT01069198|Placebo Comparator|Non-intervention group|Non-intervention group will receive placebo following the same schedule as intervention group.
3217991|NCT01069211||ER expression : Low|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 3 or 4 point of total Allred score.
3217992|NCT01069211||ER expression : Intermediate|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 5 or 6 point of total Allred score.
3217993|NCT01069211||ER expression : High|Patients were postmenopausal women with hormone receptor positive breast cancer. All patients should be 7 or 8 point of total Allred score.
3217994|NCT01069224||RC tear|This study will include a consecutive series of patients who met the study inclusion criteria. Study group patients will be diagnosed RC tear on clinical examination and imaging findings (US and MRI) that will be verified at arthroscopy in order to complete the enrollment.
3217995|NCT01069224||Control group|Control group will include patients suffering from shoulder instability that scheduled for elective surgical repair.
3217996|NCT01069237||OPTI-FREE Replenish|Multi-Purpose Solution for soft contact lenses
3217997|NCT01069237||Clear Care|Lens Care Solution for contact lenses
3217998|NCT01069250||Brain injury|Patients after traumatic brain injury or spontaneous intracranial bleeding
3217999|NCT01069263|Active Comparator|Intravesical DMSO instillation|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
3218000|NCT01069263|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
3218001|NCT01069276||Patients with clinical signs of stroke|Patients with clinical signs of stroke
3218002|NCT01069302|Active Comparator|High loading and high maintenance|Clopidogrel loading 600mg and maintenance 150mg for 7days
3218003|NCT01069302|Active Comparator|High loading and low maintenance|Clopidogrel loading 600mg and maintenance 75mg for 7days
3218004|NCT01069302|Active Comparator|Low loading and high maintenance|Clopidogrel loading 300mg and maintenance 150mg for 7days
3218005|NCT01069302|Active Comparator|Low loading and low maintenance|Clopidogrel loading 300mg and maintenance 75mg for 7days
3218006|NCT01069328|Experimental|Arm 1|
3218007|NCT01069328|Experimental|Arm 2|
3218008|NCT01069328|Experimental|Arm 3|
3218009|NCT01069328|Experimental|Arm 4|
3218010|NCT01069328|Experimental|Arm 5|
3218011|NCT01069328|Experimental|Arm 6|
3218012|NCT01069367|Experimental|Arm:1|
3218013|NCT01069393|Active Comparator|Standard DAFNE|Usual DAFNE course taught over 5 consecutive days in one week
3218014|NCT01069393|Experimental|DAFNE 5x1 day|DAFNE course taught 1 day a week for 5 consecutive weeks
3218015|NCT01069406||presence of uterine artery notch|patients with uterine artery notch during the 2nd and 3rd trimester
3218016|NCT01069432||Patients with CLL|Patients undergoing routine blood draws as part of their ongoing follow-up care for CLL at the Norris Cotton Cancer Center of DHMC.
3218017|NCT01069432||Normal Volunteers|Normal volunteers who have no history of active or prior hematologic malignancy.
3218018|NCT01069445|Active Comparator|Diet advices|will receive the Optimal Diet for Elderly
3218019|NCT01069445|Experimental|Diet advices + VSL-3|will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
3218020|NCT01069445|Experimental|Diet advices + 5203-L|will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
3218021|NCT01069445|Experimental|Diet advices + Argan oil|will receive the Optimal Diet for Elderly + Argan oil
3218022|NCT01069458|Experimental|The High Protein Diet Group|The high protein diet (25% energy from protein, 55% energy from fat, 20% energy from carbohydrate) will be hypo-caloric and achieved by restricting the amount of sugar containing foods and drinks, reducing the intake of bread, rice, pasta, fruits and fruit-juices and increasing the intake of vegetables (instead of bread, rice, pasta and potatoes) and increasing the amounts of protein (from chicken, fish, and meat) and fat from oil and dressings for lunch and dinner and by choosing nuts and protein-rich yoghurts, egg, cheese, chicken wings, shellfish, fish and fish products as snacks.
3218023|NCT01069458|Active Comparator|The Low Fat Diet Group|The low fat diet (30% energy from fat, 20% energy from protein, 50% energy percent from carbohydrate) will be hypo-caloric and achieved by choosing low-fat diary and meat products, restricting amounts of visible fat and fatty snacks and increasing intake of whole meal bread, muesli, brown rice, whole meal pasta in the main meals and by choosing yoghurt with muesli, oat porridge with milk, fruits and hard bread with jam and soft gout-cheese as snacks.
3218024|NCT01069471|Experimental|HHD O1-EPA plus adjuvant|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
3218025|NCT01069471|Experimental|HHD O1-EPA|10 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
3218026|NCT01069471|Experimental|LHD O1-EPA adjuvanted|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA adjuvanted to aluminium hydroxide
3218027|NCT01069471|Experimental|LHD O1-EPA|2 ug of Shigella dysenteriae polysaccharide O1 conjugated to EPA
3218028|NCT01069497|Experimental|Intervention Nursing Homes|Comprising 24 nursing homes implementing a specific infection prevention program
3218029|NCT01069497|No Intervention|Usual care Nursing Homes|
3218030|NCT01069536|Active Comparator|2 minutes bolus infusion|
3218031|NCT01069536|Active Comparator|15 minutes slow infusion|
3218032|NCT01069549||subjects with diabetic nephropathy.|"Subjects with Type 2 Diabetes. Duration of diabetes should be more than or equal to 5 years. Age between 30 and 85 years. Diabetic nephropathy as defined by ADA.~Subject must be of north Indian origin.~Type 1 diabetes and kidney disease other than diabetes nephropathy are excluded form the study."
3218033|NCT01069549||Subjects without Diabetic nephropathy.|This group of subject with similar characteristics as group 1 without any evidence of nephropathy.
3218034|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (1mg), CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218035|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (2mg), CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218036|NCT01069575|Experimental|URLC10-CDCA1-KIF20A 3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted URLC10 peptide (3mg), CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218037|NCT01069588||Calaxo|Received Calaxo screw
3218038|NCT01069588||Milagro|Received a Milagro screw
3218039|NCT01069601|Experimental|transplanted adults|male and female adults who have previously undergone solid organ transplantation or allogeneic or autologous BMT
3218040|NCT01069614|Experimental|Skin stretching device|Skin stretching device
3260407|NCT01479023|Experimental|Part 2 (extension phase)|Loading dose of 18.0 mg/kg unlabeled U3-1287 followed by 9.0 mg/kg unlabeled U3-1287 every 3 weeks.
3218041|NCT01069640|Experimental|URLC10-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218042|NCT01069640|Experimental|URLC10-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218043|NCT01069640|Experimental|URLC10-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*0201 or HLA-A*0206-restricted URLC10 peptide (3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218044|NCT01069653|Experimental|CDCA1-KIF20A-1mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (1mg) and KIF20A peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218045|NCT01069653|Experimental|CDCA1-KIF20A-2mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (2mg) and KIF20A peptide(2mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218046|NCT01069653|Experimental|CDCA1-KIF20A-3mg|Patients will be vaccinated once a week for four weeks of a treatment cycle. On each vaccination day, the HLA-A*2402-restricted CDCA1 peptide (3mg) and KIF20A peptide(3mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3218047|NCT01069692|Placebo Comparator|Arm 1|Placebo
3218048|NCT01069692|Experimental|Arm 3|
3218049|NCT01069692|Experimental|Arm 2|
3218050|NCT01069692|Experimental|arm 4|SBR759A
3218051|NCT01069692|Experimental|arm 5|
3218052|NCT01069718||Clinical Group|In the Clinical group bottle feedings will be attempted by the bedside nurses, using techniques suggested in the feeding plan. The Infant Feeding Specialist will observe at least one feeding per day to assure that the feeding plan is being adhered to. If, in the judgment of the person feeding the infant, the infant is unable to complete the bottle feeding, the remaining volume will be given via an indwelling gavage tube. During all gavage feedings, both total and partial, infants will be offered a pacifier to suck on.
3218053|NCT01069718||NTrainer Group|"In the NTrainer group, three feedings per day will be given via gavage tube while the infant is receiving NTrainer stimulation. The stimulation will be done by alternating 3 minute epochs of NTrainer stimulation with 3 minutes of sucking on a regular pacifier, up to a total time of 30 minutes.~Every other day, 15 minutes prior to a feeding that is not one of the study sessions, each infant's suck strength and coordination will be measured using the NTrainer device in its NeoSuck RT Assessment mode.~On the day after the study intervention period is completed each infant will be assessed by an investigator unaware of the infant's study group assignment."
3218054|NCT01069731||Infants born at 30 to 36 weeks gestation|Infants will be considered eligible if they are born at 30 to 36 weeks gestation and have no exclusion criteria.
3218055|NCT01069744||Control Group|Control group When neonates are considered ready for oral feedings these feedings will be started with the standard oral feeding protocol for the NICU but without the NTrainer stimulation regimen described previously.
3218056|NCT01069744||NTrainer System|NTrainer Experimental Group When neonates are considered ready for oral feedings these feedings will be started simultaneously with the NTrainer therapy. Control and experimental interventions will not be initiated until the infant is in an optimal behavioral state, i.e., drowsy to quiet alert (NIDCAP state 3 or 4). Preterm infants in the experimental group will receive alternating 3-minute epochs of patterned oral somatosensory stimulation and null conditions using the NTrainer© during the tube (gavage) feeding session up to 4 times per day.
3218057|NCT01069757|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
3218058|NCT01069783|Experimental|A3309 low dose|
3218059|NCT01069783|Experimental|A3309 high dose|
3218060|NCT01069783|Placebo Comparator|Placebo|
3218061|NCT01069796|Experimental|Association bevacizumab paclitaxel capecitabine breast cancer|"bevacizumab 10 mg/kg in IV, D1 and D15~paclitaxel 80mg/m2 in IV, D1 to D8 and D15~capecitabine 1600mg/m2/D, per os, D1 to D5, Weeks 1,2 and 3"
3218062|NCT01069809|Experimental|AGS-004|HIV-1 Immune Therapy
3218063|NCT01069809|Placebo Comparator|Inactive Injection|Inactive Placebo Injection
3218064|NCT01069822|Experimental|1|midazolam + AZD6765 IV solution
3218065|NCT01069822|Active Comparator|2|
3218066|NCT01069835||1|Non-small cell lung cancer patients
3218067|NCT01069848|Experimental|Vedera KXS|
3218068|NCT01069874|Placebo Comparator|Miglyol oil|Miglyol oil will be administered in 2-monthly oral bolus doses over a period of one year
3218069|NCT01069874|Active Comparator|Vigantol oil|Vigantol oil will be administered in 2-monthly oral bolus doses over a period of one year
3218070|NCT01069887||adult with hematological malignancies|
3218071|NCT01069887||pediatrics with hematological malignancies|
3218072|NCT01069887||pediatrics receiving stem cell transplant|
3218073|NCT01069887||adult receiving stem cell transplant|
3218074|NCT01069913|Active Comparator|BG00012|BG00012 Standard Formulation
3218075|NCT01069913|Active Comparator|BG00012 API|BG00012 API
3218076|NCT01069952|Experimental|Active DBS|Participants will receive deep brain stimulation.
3218077|NCT01069965|Experimental|6. BGP-15|400 mg BGP-15 + Placebo
3218078|NCT01069965|Experimental|5. BGP-15|200 mg BGP-15 BID
3218079|NCT01069965|Experimental|4. BGP-15|200 mg BGP-15 + Placebo
3218080|NCT01069965|Experimental|3. BGP-15|Two 50 mg BGP-15 capsules by mouth in the morning; and two 50 mg BGP-15 capsules by mouth in the evening
3218081|NCT01069965|Experimental|2. BGP-15|100 mg BGP-15 + placebo
3218082|NCT01069965|Experimental|1. Placebo|Placebo BID
3218083|NCT01069991|Experimental|Patient education group|Patient education program delivered to high school students with persistent asthma.
3218084|NCT01069991|Experimental|Wait list control group|Control students received no intervention until the one year follow up period was completed.
3218085|NCT01070004|Experimental|Blue light|Exposure to 460-nm monochromatic light (blue light)
3218086|NCT01070004|Experimental|Physical activity|15 minutes of physical activity at a low intensity
3218087|NCT01070017|Experimental|Intervention: DOT-HAART|Intervention group will receive community-based monthly adherence visits, standard care, and DOT-HAART.
3218088|NCT01070017|No Intervention|No DOT-HAART|Control group receives community-based monthly adherence visits and standard care, but no DOT-HAART.
3218089|NCT01070056|Active Comparator|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
3218090|NCT01070056|Experimental|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension (HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
3218091|NCT01070069|Active Comparator|Standard EVAR (IntuiTrak)|EVAR using standard vascular exposure for access
3218092|NCT01070069|Experimental|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
3218093|NCT01070069|Experimental|PEVAR (ProstarXL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
3218094|NCT01070082||Adult ICU patients undergoing procedure|
3260408|NCT01479036|Active Comparator|docetaxel and epirubicin|DE chemotherapy alone
3218095|NCT01070108|Active Comparator|Set 1|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
3218096|NCT01070108|Active Comparator|set 2|2nd set received ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
3218097|NCT01070108|Active Comparator|set 3|3rd set one group had ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
3218098|NCT01070121||RA patients/participants|
3218099|NCT01070134|Experimental|Mindfulness-based Behavioural Therapy (MIBT)|
3218100|NCT01070134|Active Comparator|PT (psychodynamic therapy)|
3218101|NCT01070147|Experimental|Control|The control group will receive a paper-based printed asthma guideline.
3218102|NCT01070160||A|Women with PCOS initiating Metformin and exposure to vaginal progesterone for 6-8 days prior ro Endometrium Biopsy
3218103|NCT01070160||B|Women with PCOS not planning initiating Metformin and exposure to vaginal progesterone for 6-8 days prior to Endometrium Biopsy
3218104|NCT01070160||Women with PCOS who previously initiated metformin|Women with PCOS who initiated metformin at least 3 months prior to enrollment who have completed a 6-10 day course of progesterone
3218105|NCT01070186|Experimental|Treatment|See intervention descriptions
3218106|NCT01070199|Experimental|liquid to liquid,|
3218107|NCT01070199|Experimental|liquid to solid,|
3218108|NCT01070199|Experimental|solid to liquid|
3218109|NCT01070199|Experimental|solid to solid|
3218110|NCT01070212|Experimental|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218111|NCT01070212|Experimental|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218112|NCT01070212|Experimental|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
3218113|NCT01070225|Experimental|Hydrocortisone and Propranolol|Participant administered 10 or 20mg propranolol orally. Participants meeting the parameters are randomised to receive 400mg Hydrocortisone intravenously. Participant then receives Histamine PC10 challenge, Administered 5mg Salbutamol via nebuliser, administered 500mcg Ipratropium Bromide via nebuliser; visit end
3218114|NCT01070225|Placebo Comparator|Placebo and propranolol|identical to other arm but participant receive placebo injection as opposed to hydrocortisone
3218115|NCT01070251|Active Comparator|Existing state-sponsored PA program|standard children-focused gym lessons approach
3218116|NCT01070251|Active Comparator|Participatory intervention plus state-sponsored PA program|Participatory parent-focused intervention over nine months in addition to state-sponsored PA program
3218117|NCT01070264|Experimental|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
3218118|NCT01070277|Placebo Comparator|Placebo arm|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
3218119|NCT01070277|Experimental|Tinidazole and Albendazole treatment|Tinidazole 1 gram BID for 2 days followed by Albendazole 400mg BID for 7 days
3218120|NCT01070290|Experimental|1|ARQ 197
3218121|NCT01070290|Active Comparator|2|Investigator's choice of oxaliplatin, capecitabine or irinotecan
3260409|NCT01479036|Experimental|docetaxel and epirubicin plus endostatin|chemotherapy plus endostatin
3260410|NCT01479049|Experimental|MP group|Hearts are arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L) during cardiac surgery.
3218122|NCT01070342||Chidren ages 6 to 18|Children ages 6 to 18 years will be available for participation in this multicenter study. Subjects will be enrolled from community based general pediatric clinics and other well-child care areas within participating hospitals and clinics of the four participating sites. Enrollment will continue until a total of 85 subjects from each age category (6-<12 years and ≥12- <18 years) successfully complete the study.
3218123|NCT01070355|Placebo Comparator|Placebo|2 capsules twice daily
3218124|NCT01070355|Active Comparator|Eicosapentaenoic acid free fatty acid|2g daily (2 x 500mg capsules twice daily)
3218125|NCT01070368|Experimental|Food challenge, skin test|Skin test by two extract commercial, and in-house extract. and open challenge with wheat (except in patient with history of wheat anaphylaxis: assume as challenge positive)
3218126|NCT01070407|Experimental|Arm A, group 1|4 volunteers
3218127|NCT01070407|Experimental|Arm A, group 2|4 volunteers
3218128|NCT01070407|Experimental|Arm A, group 3|5 volunteers
3218129|NCT01070407|Experimental|Arm B, group 5|4 volunteers
3218130|NCT01070407|Experimental|Arm B, group 6|4 volunteers
3218131|NCT01070407|Experimental|Arm B, group 7|5 volunteers
3218132|NCT01070407|Experimental|Arm C, group 9|5 volunteers
3218133|NCT01070407|Experimental|Arm C, group 10|5 volunteers
3218134|NCT01070407|Experimental|Arm C, group 11|4 volunteers
3218135|NCT01070420|Active Comparator|FFR via central venous line|
3218136|NCT01070420|Experimental|FFR via peripheral vein|
3218137|NCT01070433|Experimental|MEBO Wound Ointment (MEBO)|Topical application twice a day
3218138|NCT01070433|Active Comparator|Standard of Care|Topical application twice a day
3218139|NCT01070446|Experimental|1|This study involves children with CF who will take a water soluble vitamin supplement of choline bitartrate, 2 gm per day with meals.
3218140|NCT01070459|Placebo Comparator|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
3218141|NCT01070459|Experimental|Aerobic exercise group|The patients continues their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heart rate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week training programme 4 information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
3218142|NCT01070459|Experimental|Follow-up first aerobic exercise group|
3218143|NCT01070459|Placebo Comparator|Follow-up control group|
3218144|NCT01070459|Experimental|Follow-up second aerobic exercise group|
3218145|NCT01070485|Experimental|Radium-223 dichloride (Xofigo, BAY 88-8223)|Patients were to receive 4 intravenous administrations of Radium-223 at a dose of 50 kBq/kg body weight (b.w) at intervals of 4 weeks. Radium-223 was given as add-on therapy to existing bisphosphonate therapy.
3218146|NCT01070498|Experimental|Trichuris suis ova (TSO)|
3218147|NCT01070511|Experimental|Tadalafil|
3218148|NCT01070511|Placebo Comparator|Placebo|
3218149|NCT01070524|Experimental|CHF 5188 pMDI|
3218150|NCT01070524|Active Comparator|Budesonide extrafine pMDI|
3218151|NCT01070524|Active Comparator|Seretide(r) Evohaler(r)|
3218152|NCT01070563||Usual|CT angiography is performed 6 hours after the clinical diagnosis of brain death.
3218153|NCT01070563||TCD|When the diagnosis of brain death is made, TCD is performed and then every 2 hours until the flow patterns compatible with brain death are found. Then a CT angiography is performed.
3218154|NCT01070576||normal fracture healing|group in which normal fracture healing has occured
3218155|NCT01070576||atrophic|patients in which an atrophic non-union occured
3218156|NCT01070576||hypertrophic|patients in which a hypertrophic non-union occured
3218157|NCT01070589||Group 1: Obese|BMI>30
3218158|NCT01070589||Group 2: control|Group 2:Normal weight (BMI <25). age and gender matched.
3218159|NCT01070602|Experimental|anterior corneal incision|
3218160|NCT01070628|Experimental|Stalevo (levodopa/carbidopa/entacapone)|"125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.~150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively."
3218161|NCT01070628|Active Comparator|Sinemet (levodopa/carbidopa)|150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively
3218162|NCT01070641|Active Comparator|Carvedilol|Each patient will receive Carvedilol 12.5mg QD
3218163|NCT01070641|Active Comparator|Esophageal Variceal Band Ligation|Each patient will undergo for serial esophageal variceal band ligations after 3 weeks of last session till the eradication of varices
3218164|NCT01070654|Experimental|40/30 Recruitment Manoeuvre|Patients with respiratory failure that will be first ventilated for 30 minutes according to standardized baseline protective ventilation and after that will receive the recruitment manoeuvre
3218165|NCT01070667|Experimental|Dronedarone|Patients will receive 400 mg of dronedarone per day for 3 months.
3218166|NCT01070667|Placebo Comparator|Placebo|Patients will receive a placebo tablet once per day for 3 months. AF burden and other parameters described will be monitored from the participants permanent pacemaker. Participants will also be asked to fill out symptom diaries and questionaires.
3218167|NCT01070680|Active Comparator|dexmedetomidine|sedative medicine
3218168|NCT01070680|Placebo Comparator|sodium chloride 0,9%|
3218169|NCT01070706|Experimental|Paclitaxel, Gemcitabine, Sunitinib|Paclitaxel, Gemcitabine, Sunitinib
3218170|NCT01070719||Relapsing form of MS treated with natalizumab|Only patients diagnosed with a relapsing form of Multiple Sclerosis (MS) and who are being treated with Tysabri (natalizumab) will be included in this Phase IV observational study.
3218171|NCT01070732|Experimental|Paracetamol|All patients will receive one single dose of 1000mg paracetamol.
3218172|NCT01070745|Experimental|Indomethacin for resistant PDA|Treatment with second course of indomethacin
3218173|NCT01070745|Experimental|Ibuprofen for resistant PDA|Ibuprofen as second course of therapy
3218174|NCT01070797|Experimental|Group A|Group A is for CMV seropositive donors.
3218175|NCT01070797|Experimental|Group B|Group B is for CMV seronegative donors.
3218176|NCT01070823||Relapsing Multiple Sclerosis|Participants receiving or considering treatment with Tysabri® (natalizumab).
3218177|NCT01070836||natalizumab|US participants with relapsing MS receiving commercial natalizumab
3218178|NCT01070849|Active Comparator|a) educational booklet|
3218179|NCT01070849|Active Comparator|b) IRENA|
3218180|NCT01070849|Experimental|c) RÜCKGEWINN|
3218181|NCT01070862|Experimental|thalidomide + dexamethasone|Thalidomide 200 mg/d at bedtime + Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
3218182|NCT01070862|Active Comparator|Vincristin, Adriamycin, Dexamethasone|
3218183|NCT01070862|Experimental|thalidomide, melphalan, endoxan, dexamethasone|
3218184|NCT01070862|Active Comparator|melphalan, endoxan, dexamethasone (MCDex)|
3218185|NCT01070862|Experimental|Thalidomide, Dexamethasone|
3218186|NCT01070862|No Intervention|watch and wait|
3218187|NCT01070875|Active Comparator|UFH 5000 U three times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous three times a day.
3218188|NCT01070875|Active Comparator|UFH 5000 U two times per day|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
3218189|NCT01070901||Organ transplant recipients|
3218190|NCT01070927|Experimental|cohort 1|
3218191|NCT01070927|Experimental|cohort 2|
3218192|NCT01070940|Placebo Comparator|Isotonic saline infusion|
3218193|NCT01070940|Active Comparator|Intravenous L-NMMA dose 2|
3218194|NCT01070940|Active Comparator|Intravenous L-NMMA dose 3|
3218195|NCT01070940|Active Comparator|Intravenous L-NMMA dose 1|
3218196|NCT01071005|Experimental|Test|Lorelin Depot - Bergamo
3218197|NCT01071005|Active Comparator|comparator|Lupron Depot® - Abbott
3218198|NCT01071018|Experimental|QOD Schedule|QOD Schedule, MK2206 every other day
3218199|NCT01071018|Experimental|QW Schedule|QW Schedule, MK2206 once weekly
3218200|NCT01071031|Experimental|Group 1|Low Dose HIV-v with water for injection
3218201|NCT01071031|Experimental|Group 2|Low Dose HIV-v with adjuvant
3218202|NCT01071031|Experimental|Group 3|High Dose HIV-v with water for injection
3218203|NCT01071031|Experimental|Group 4|High Dose HIV-v with adjuvant
3218204|NCT01071031|Placebo Comparator|Group 5|Control group: adjuvant only or water for injection only
3218205|NCT01071057|Active Comparator|Naloxone/morphine|Naloxone (12 µg/ml) mixed in a single infusion with morphine (1 mg/ml). The study solutions will be prepared by a pharmacist and diluted in saline to produce equal volumes to ensure proper blinding.
3218206|NCT01071057|Placebo Comparator|saline/morphine|Patients will be randomly assigned to one of two groups (Naloxone/morphine or saline/morphine) using computer-generated random numbers. On arrival to the PACU patients will be started on IV PCA and randomized study drug
3218207|NCT01071109|Experimental|Therapeutic Massage|
3218208|NCT01071109|No Intervention|No therapeutic massage|
3218209|NCT01071122|Experimental|Arm 1|
3218210|NCT01071122|Active Comparator|Arm 2|
3218211|NCT01071122|Active Comparator|Arm 3|
3218212|NCT01071135|Experimental|Quetiapine XR|
3260411|NCT01479049|Active Comparator|HP group|Hearts were arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L) during cardiac operation
3218213|NCT01071148||Subgroup 1: Age < 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
3218214|NCT01071148||Subgroup 2: 42 > Age ≥ 35 years|Subjects who have experienced infertility and justifying IVF/ET treatment will be administered either Gonal-f or Pergoveris or Gonal-f and Luveris as per the discretion of the investigator.
3218215|NCT01071161|Experimental|Azithromycin|
3218216|NCT01071161|Placebo Comparator|Placebo|
3218217|NCT01071174|Placebo Comparator|Placebo Ring|Vaginal Ring containing no drug substance
3218218|NCT01071174|Experimental|Dapivirine Ring|Dapivirine Vaginal Ring 25mg
3218219|NCT01071187|Experimental|Varenicline|Treatment with varenicline with 0,5mg daily on day 1-3, 1mg daily on day 4-7 and 2mg daily on day 8-84.
3218220|NCT01071187|Placebo Comparator|Placebo|
3218221|NCT01071226|Experimental|Stratum 1|Patients receiving an unrelated donor or partially matched related donor.
3218222|NCT01071226|Experimental|Stratum 2|For the patient's whose donors are haploidentical or a 2 antigen mismatched where one of the mismatches includes DRB1
3218223|NCT01071239|Experimental|Bone marrow processing|Bone Marrow processing using the CliniMACs device
3218224|NCT01071265|Placebo Comparator|Sham RIPC|Inflation of thigh pneumatic tourniquet to <15 mmHg
3218225|NCT01071265|Active Comparator|Active RIPC|300 mmHg inflation of thigh pneumatic tourniquet for three cycles of 5 minutes each with 5 minutes of no inflation between cycles.
3218226|NCT01071291|Experimental|Arm A|Arm A will receive a Niaspan treatment in Period 1 and Placebo treatment in Period 2
3218227|NCT01071291|Experimental|Arm B|Arm B will receive a Placebo treatment in Period 1 and Niaspan treatment in Period 2
3218228|NCT01071304|Experimental|All Participants|In Part 1, all participants received a single oral dose of 2 mg midazolam on Day -2. On Days 1-5, all participants received daily single oral doses of ridaforolimus 40 mg ( 4 x 10 mg tablets). On Day 5, all participants received a single oral dose of 2 mg midazolam coadministered with the dose of ridaforolimus. Participants had the option to continue into Part 2 of this study.
3218229|NCT01071369|Active Comparator|Xylocaine|0.5% Xylocaine
3218230|NCT01071369|Active Comparator|Xylocaine and Celestone|0.5% Xylocaine with 6 mg of non-particulate Celestone.
3218231|NCT01071408|Experimental|Stroke Prevention Program + Usual Care|Stroke Prevention Care Program + Usual Care. The Stroke prevention care program is in addition, not a substitute for usual care. Persons randomized to this arm are eligible to all care, including care by stroke specialists, while enrolled in the intervention.
3218232|NCT01071408|No Intervention|Usual care|
3218233|NCT01071421||Control Group (B): Other Infections|Other infections admitted to the hospital
3218234|NCT01071421||Community Acquired Pneumonia (Group A)|Patients admitted to hospital with Community Acquired Pneumonia defined by respiratory symptoms, fever and lung infiltrates
3260412|NCT01479062|Experimental|participation in Alive-PD|Alive-PD lifestyle intervention with multi-channel delivery
3260413|NCT01479062|Placebo Comparator|Control|Usual care
3218235|NCT01071447|Active Comparator|Rheumatologist-led clinic|Rheumatologist-led clinic: The subjects are seeing a rheumatologist after six months and after 12-months of intervention and have the possibility to contact the rheumatology clinic
3218236|NCT01071447|Experimental|Nurse-led clinic|The subjects are seeing a rheumatology nurse after six months and a rheumatologist after 12 months of intervention and have the possibility to contact the rheumatology nurse during the intervention.
3218237|NCT01071460|Other|SFA Stenting|
3218238|NCT01071473|Other|Exercise Group|Survivors of childhood cancer treated with anthracyclines and known to have cardiomyopathy will participate in a 12 week exercise intervention.
3218239|NCT01071499|Active Comparator|1|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3218240|NCT01071499|Active Comparator|2|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3218241|NCT01071499|Active Comparator|3|Subjects recruited will be block assigned to one of the three doses of morphine. Sampling will be done for 4 hrs to determine the key pharmacokinetic parameters.
3218242|NCT01071525|Active Comparator|Niacin|Hypercholesterolemic patients with high-density lipoprotein (HDL) less than 40 mg% will receive Niacin\Laropiprant.
3218243|NCT01071525|No Intervention|Control|Maching subjects will receive no medication, Blood tests will be drawn for laboratory tests.
3260414|NCT01479075|Experimental|intranasal insulin in patients|intranasal insulin is applied to diabetic patients under fasting conditions
3260415|NCT01479075|Experimental|intransal insulin in study participants|intranasal insulin is applied to healthy patients under fasting conditions
3260416|NCT01479075|Placebo Comparator|placebo in patients|placebo spray is applied intranasally in type 2 diabetes patients under fasting conditions
3260417|NCT01479075|Experimental|placebo in study participants|placebo spray is applied intranasally in healthy participants under fasting conditions
3218244|NCT01071551|Experimental|Lifestyle and health promotion|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
3218245|NCT01071551|Active Comparator|Physical activity only|Children allocated to this group will attend physical activity classes only.
3218246|NCT01071564|Experimental|Treatment (RO4929097 and vismodegib)|Patients receive gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO on day 1 or days -2, -1, and 1 of course 1 and days 1-3 and 8-10 of course 2 and all subsequent courses. Patients also receive vismodegib PO QD beginning day 8 of course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3218249|NCT01071629|Active Comparator|Combined interval and strength training|CHF Pts randomly designed at the combined interval and strength training group
3218250|NCT01071629|Active Comparator|Aerobic interval training|CHF Patients that randomly designed to participate at the interval training group
3218251|NCT01071642|No Intervention|continue ace-i and arb's versus dicontinue|
3218252|NCT01071642|Active Comparator|group b|
3218253|NCT01071642|Active Comparator|group c|
3218254|NCT01071655|Experimental|2|"Patients with zero favorable genotype: BVZ + XELIRI.~Patients with one favorable genotype: TS 3'UTR +6bp/+6bp and ERCC1-118 T/T: BVZ + XELOX or TS 3'UTR +6bp/-6bp and ERCC1-118 C/T ó C/C: BVZ + FUIRI.~Patients with two favorable genotypes : BVZ + FUOX."
3218255|NCT01071655|Active Comparator|1|BVZ + XELOX
3218256|NCT01071668||GEM-2 Cohort|Women who have a low risk pregnancy before onset of labor. Patients included in the study who will be hospitalized with spontaneous labor at term with intact membranes or preterm labor will be included in the study group. Patients with premature rupture of membranes or induction of labor will be analyzed separately.
3218257|NCT01071681||Group 1|
3218258|NCT01071694||Group 1|
3218259|NCT01071707||Confirmed Diagnosis of IPF|Subjects in this cohort will continue beyond the screening visit(s) for longitudinal follow up visits for a minimum of 48 weeks and maximum of 80 weeks.
3218260|NCT01071707||No diagnosis of IPF|Subjects that complete screening visits and do not obtain a confirmed diagnosis of IPF will conclude the study at screening, at the time point where IPF is ruled out as a diagnosis.
3218261|NCT01071720|Other|CKD-501 1mg (fed-fasted group)|CKD-501 1mg should be administered following a high-fat, high-caloric diet(fed condition) in one period and on an empty stomach(fasting condition) in the other period.
3218262|NCT01071720|Other|CKD-501 1mg (fasted-fed group)|CKD-501 1mg should be administered on an empty stomach(fasting condition) in one period and following a high-fat, high-caloric diet(fed condition) in the other period.
3218263|NCT01071733||ultrasound wrist|
3218264|NCT01071733||ultrasound finger|
3218265|NCT01071733||ultrasound ankle|
3218266|NCT01071746||Acute decompensation of cirrhosis|acute decompensation of liver function occuring secondary to precipitating events such as sepsis, GI bleed.
3218267|NCT01071759||pregnancy|
3218268|NCT01071772|Experimental|euglycemia|
3218269|NCT01071772|Experimental|hyperglycemia|
3218270|NCT01071785|No Intervention|usual diet|no dietary or drug intervention. Patients followed their usual diet.
3218271|NCT01071785|Experimental|guar gum|guar gum
3218272|NCT01071811|No Intervention|Control group|Participants assigned to the control group received a leaflet from the National Board of Health in Denmark recommending all adults to be physical active for 30 minutes each day of moderate intensity.
3218273|NCT01071811|Experimental|Pedometer group|Received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program, a handout with a summary of the pedometer program, and a calendar for registration of daily steps.
3218274|NCT01071824|Active Comparator|Transverse coloplasty pouch (Short limb)|The short limb is the standard technique of transverse coloplasty pouch.
3218275|NCT01071824|Experimental|Transverse coloplasty pouch (Long limb)|The long limb relates to straight coloanal anastomosis.
3218276|NCT01071837|Active Comparator|Re-Irradiation|33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)
3218277|NCT01071837|Experimental|Re-Irradiation + APG101|66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion
3218278|NCT01071850|Experimental|ASP1941 lowest dose|oral tablet
3218279|NCT01071850|Experimental|ASP1941 low dose|oral tablet
3218280|NCT01071850|Experimental|ASP1941 high dose|oral tablet
3218281|NCT01071850|Experimental|ASP1941 highest dose|oral tablet
3218282|NCT01071850|Active Comparator|Metformin|oral tablet
3218283|NCT01071850|Placebo Comparator|Placebo|oral tablet
3218284|NCT01071863||Rheumatoid Arthritis (RA) Patient Group|Patients with RA who have been refered for biological drug treatment
3218285|NCT01071863||Control Group|20 people of same age and sex as the RA patient cohort
3218286|NCT01071876|Experimental|BF2.649|BF2.649 capsules dosed at 5mg, 10 mg, 20mg
3218287|NCT01071876|Placebo Comparator|Placebo|Capsules of Placebo containing lactose with low, medium and high dosage
3218288|NCT01071889|Other|Brotizolam|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo
3218289|NCT01071889|Other|Zolpidem|Treatment response will be evaluated for each treatment arm. Good Response (GR) - is considered as an improvement of 30% in efficacy parameters of Flumazenil treatment in comparison to placebo.
3218290|NCT01071902|Experimental|Moxidex|Moxidex otic solution
3218291|NCT01071902|Active Comparator|Moxifloxacin|Moxifloxacin otic solution
3218292|NCT01071902|Placebo Comparator|Vehicle|Vehicle
3218293|NCT01071928|Experimental|Docetaxel and ASA404 in Combination|
3260418|NCT01479075|Experimental|taNVS|Transcutanoues auricular vagus nerve stimulation is applied for 14 min in the external ear in healthy participants
3218294|NCT01071967|Experimental|Community-based nurse care management|Participants randomized to receive the intervention worked with a nurse care manager who provided them with a comprehensive set of geriatric and chronic disease preventive services.
3218295|NCT01071967|No Intervention|Usual care|Participants randomized to the control group received usual care without the involvement of a nurse care manager.
3218296|NCT01071980|Active Comparator|Specific resistance training|3 x 20 min a week of specific resistance training for 20 weeks
3218297|NCT01071980|No Intervention|Control|Control group
3218298|NCT01072019|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
3218299|NCT01072019|Active Comparator|MRI generated patient specific custom cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
3218300|NCT01072045|Active Comparator|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
3218301|NCT01072045|Active Comparator|Prednisone|Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
3218302|NCT01072058|Other|TNF blockers|
3218303|NCT01072071|No Intervention|Control group|Patients will be receiving standard of care ICU treatment of their underlying disease according to internationally accepted guidelines and recommendations.
3260419|NCT01479075|Placebo Comparator|Sham stimulation|Sham stimulation in the ear lobe is applied for 14 min in healthy participants
3218304|NCT01072071|Experimental|Furosemide group|patients will be receiving standard of care ICU treatment of their underlying condition according to international guidelines and recommendations. In addition, furosemide will be administered in continuous infusion as per protocol in order to achieve a preset target diuresis that is adjusted according to haemodynamic tolerance.
3218305|NCT01072084||Patients with food allergy|
3218306|NCT01072084||Healthy subjects|
3218307|NCT01072097|Active Comparator|Atorvastatin|6 months atorvastatin 20mg/day treatment
3218308|NCT01072097|Placebo Comparator|Placebo|6 months placebo treatment
3218309|NCT01072110||Group 1: Patients with diarrhea undergoing endoscopy|Standard video colonoscope.
3218310|NCT01072110||Group 2: Patients with diarrhea undergoing endoscopy.|Confocal laser endomicroscopy (CLE).
3218311|NCT01072162|Experimental|Arm B|25 mg powder for oral suspension single dose fasted.
3218312|NCT01072162|Experimental|Arm C|25 mg powder for oral suspension administered with a meal
3218313|NCT01072162|Experimental|Arm D|25 mg powder for oral suspension administered 2 hours prior to meal
3218314|NCT01072162|Experimental|Arm E|25 mg powder for oral suspension administered 2 hours after to meal
3218315|NCT01072162|Other|Arm A|Commercially available eltrombopag 25 mg tablet
3218316|NCT01072175|Experimental|Arm Part A|Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
3218317|NCT01072175|Experimental|Arm Part B|GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
3218318|NCT01072175|Experimental|Arm Part C|GSK2118436 + GSK1120212 cohort expansion for safety and efficacy
3218319|NCT01072214|Experimental|1.6 mg|The actual dosage is 10 mg/ml (GW786034) given 4 times a day for a maximum daily dosage of 1.6mg
3218320|NCT01072214|Experimental|TBD COHORT 2|Dose escalation amount to be determined (TBD) after results from Cohort 1 analyzed
3218321|NCT01072214|Placebo Comparator|Placebo|Subjects will receive placebo (drops without drug).
3218322|NCT01072214|Experimental|TBD COHORT 3|Dose escalation amount to be determined (TBD) after results from Cohort 2 analyzed
3218323|NCT01072227||Single Group|
3218324|NCT01072240||Cohort|
3218325|NCT01072253||eye amputated|lost an eye
3218326|NCT01072266|Experimental|INCB028060|Subjects will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group of patients may be enrolled and receive study drug. The initial cohort will be treated with 10 mg QD. The second cohort will be treated with 20 mg QD. The third cohort will be treated with 50 mg QD. Subsequent cohorts will be treated with two times the dose of the prior cohort to a limited toxicity level.
3218327|NCT01072279|Experimental|Burundi: T24|
3218328|NCT01072279|Experimental|Burundi: TNFP|
3218329|NCT01072279|Experimental|Burundi: T18|
3218330|NCT01072279|No Intervention|Burundi: Control|
3218331|NCT01072279|Experimental|Guatemala: PROCOMIDA|
3218332|NCT01072279|Experimental|Guatemala: no family ration|
3218333|NCT01072279|Experimental|Guatemala: LNS|
3218334|NCT01072279|Experimental|Guatemala: Sprinkles|
3218335|NCT01072279|Experimental|Guatemala: reduced family ration|
3218336|NCT01072279|No Intervention|Guatemala: control|
3218337|NCT01072292|Experimental|CBT-I|CBT-I
3218338|NCT01072292|Active Comparator|Wellness Education|Wellness Education
3218339|NCT01072305|Experimental|Intermittent pneumatic compression (IPC)|IPC from induction of general anesthesia to completion of skin closure.
3218340|NCT01072305|Placebo Comparator|control|IPC - placebo from induction of general anesthesia to closure of the skin
3218341|NCT01072318|Experimental|Letrozole, DFS|Efficacy evaluation of extended letrozole after 5 year fareston use
3218342|NCT01072370|Active Comparator|Treatment Group 1|
3218343|NCT01072370|Sham Comparator|Treatment Group 2|
3218344|NCT01072383|Experimental|BT061|receiving BT061 (active compound)
3218345|NCT01072383|Placebo Comparator|Placebo|receiving a placebo
3218346|NCT01072422|Experimental|counseling based on answers in TTQ|40 participating primary health care nurses will be randomly assigned to this arm. Each nurse will identify 5 consecutive patients with COPD who smoke (n = 200 total patients). The nurses will ask the patients to fill in the assessment protocol, TTQ. The nurses will then provide an intervention to each patient in the form of individual treatment on the basis of that patient's answers to the TTQ.
3218347|NCT01072435|Active Comparator|patient-controlled sedation|PCS
3218348|NCT01072435|Active Comparator|target-controlled infusion|TCI
3218349|NCT01072461|Active Comparator|Train Paretic Hand and Arm Separate|Eight three hour training sessions of robotically facilitated hand and arm training in complex virtual environments, using activities that train the fingers in isolation and other activities that train the arm in isolation.
3218350|NCT01072461|Experimental|Train Paretic Hand and Arm Together|
3218351|NCT01072461|Experimental|Train Both Hands Together in VE|
3218352|NCT01072474|Experimental|Capnography|Arm with capnographic monitoring
3218353|NCT01072474|Placebo Comparator|Standard|Standard monitoring.
3218354|NCT01072487|Experimental|Capnography|Arm with capnographic monitoring
3218355|NCT01072487|No Intervention|Standard|Standard monitoring.
3218356|NCT01072513|Other|Semen analysis|Analysis of semen before and after proton radiation therapy.
3218357|NCT01072552||Treated|Palivizumab treated
3218358|NCT01072552||Untreated|Palivizumab untreated
3218359|NCT01072565|Active Comparator|SMBG Only|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be blinded (neither you nor the study doctor will be able to see the CGM measurements until your final study visit). Only your SMBG measurements will be considered to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of less than 7%.
3218360|NCT01072565|Active Comparator|SMBG and CGM|You will measure your blood glucose 4 times daily by finger sticks using a blood glucose meter and you will also wear a CGM device. The CGM measurements will be downloaded at each study visit and will be considered along with your SMBG measurements to help manage your diabetes. Your medications will be changed or adjusted based on your HbA1c and/or glucose readings with a goal to achieve an HbA1c level of 7%.
3218361|NCT01072578|Experimental|1|
3218362|NCT01072578|Experimental|2|
3218363|NCT01072591|Experimental|1|
3218364|NCT01072591|Placebo Comparator|2|
3218365|NCT01072604|Experimental|Arm 1|
3218366|NCT01072604|Experimental|Arm 2|
3218367|NCT01072604|Active Comparator|Arm 3|
3218368|NCT01072604|Active Comparator|Arm 4|
3218369|NCT01072682|Experimental|SCD|Selective Cytopheretic Device
3218370|NCT01072695|Experimental|Arm 1|
3218371|NCT01072695|Experimental|Arm 2|
3218372|NCT01072695|Experimental|Arm 3|
3218373|NCT01072721|Other|Fibrosis group|a single arm with the two interventions (elastometry and biopsy)
3218374|NCT01072734|Experimental|Vaccine group|single group: all included patients will receive the vaccine
3218375|NCT01072747|Experimental|heparin of bovine origin|Laboratory Bergamo Ltda. 5.000UI/mL bottle with 5mL
3218376|NCT01072747|Active Comparator|heparin of porcine origin|APP Pharmaceuticals
3218377|NCT01072760|Experimental|K wire|
3218378|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 1|Participants will receive the TetraVax-DV admixture 1 vaccine.
3218379|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 2|Participants will receive the TetraVax-DV admixture 2 vaccine.
3218380|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 3|Participants will receive the TetraVax-DV admixture 3 vaccine.
3218381|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 4|Participants will receive the TetraVax-DV admixture 4 vaccine.
3218382|NCT01072786|Placebo Comparator|Placebo|Participants will receive the placebo.
3218383|NCT01072786|Experimental|TetraVax-DV Vaccine-Admixture 5|Participants will receive the TetraVax-DV admixture 5 vaccine.
3218384|NCT01072799|Experimental|Low dose H1N1|
3218385|NCT01072799|Experimental|Mid dose H1N1|
3218386|NCT01072799|Experimental|High dose H1N1|
3218387|NCT01072799|Placebo Comparator|Placebo|
3218388|NCT01072812|Experimental|Posiphen® tartrate capsules|
3218389|NCT01072825||transgender people starting hormone treatment|
3218390|NCT01072838|Other|Dose Escalation|
3218391|NCT01072851|Experimental|Multimedia educational tool|Multimedia education tool - A culturally competent video explaining the importance of and the process of colorectal cancer screening
3218392|NCT01072851|Experimental|Print educational tool|Print media - A culturally competent printed brochure explaining the importance of and the process of colorectal cancer screening
3218393|NCT01072851|Active Comparator|No intervention|Usual and customary waiting room process - Usual and customary office waiting period with access to standard nationally generated colorectal cancer screening informational material in the waiting room and/or exam room.
3218394|NCT01072864|Experimental|5 g of walnuts|
3218395|NCT01072864|Experimental|20 g of walnuts|
3218396|NCT01072864|Experimental|30 g of walnuts|
3218397|NCT01072864|Experimental|40 g of walnuts|
3218398|NCT01072890|Experimental|Temsirolimus and Pazopanib|
3218399|NCT01072903||IBS|Subjects with IBS
3218400|NCT01072903||Healthy|Healthy Controls
3218401|NCT01072916||IBS|Subjects with IBS-D
3218402|NCT01072916||Healthy|Healthy Subjects
3218403|NCT01072942|Experimental|Arm 1|
3218404|NCT01072942|Placebo Comparator|Arm 2|
3218405|NCT01072955|Experimental|heparin of bovine origin|5.000UI/mL bottle with 5mL
3218406|NCT01072955|Active Comparator|heparin of porcine origin|5000 USP Heparin Units / mL vial with 10 mL vial
3218407|NCT01072968|Experimental|BF2.649|BF2.649 capsules dosed at 5 mg, 10 mg, 20 mg
3218408|NCT01072968|Placebo Comparator|Placebo|Capsules of placebo containing lactose with low, medium and high dosage
3218409|NCT01072981|Experimental|HyperAcute-Pancreas Immunotherapy + Standard of Care|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation + HyperAcute Immunotherapy
3218410|NCT01072981|Active Comparator|Standard of Care alone|*Adjuvant Standard of Care Treatment (SOC) consisting of gemcitabine with or without 5FU chemoradiation Alone
3218411|NCT01073007|Experimental|Simvastatin|Simvastatin 40 mg daily for 3 months.
3218412|NCT01073007|Placebo Comparator|Placebo|
3218413|NCT01073033|Experimental|oral supplement1|Oral supplement for pregnant and lactating mothers
3218414|NCT01073033|Active Comparator|oral supplement 2|Oral supplement for pregnant and lactating mothers
3218415|NCT01073033|No Intervention|Reference|No oral supplementation during pregnancy and lactating.
3218416|NCT01073046||Place Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is placed (Rusch® distributed by Teleflex Medical Srl)
3218417|NCT01073046||No Naso-Gastric/Jejunal Tube Group|In this group a silastic naso-gastric/jejunal tube is not placed
3218418|NCT01073059|Experimental|Valproic acid|
3218419|NCT01073072|Experimental|Tutomesh|Technique of abdominal wall reconstruction strengthened by Tutomesh®
3218420|NCT01073072|Active Comparator|conventional repair|Conventional technique to repair incisional or abdominal wall hernias
3218421|NCT01073085|Experimental|Web-based coaching|"Those in the coaching arm will benefit from e-mails with advice, information, support for smoking cessation. These mails will be adapted to their personal profile."
3218422|NCT01073085|Active Comparator|Self-help guide|"Those in the active comparator arm will be allowed to download a self-help guide with step-by-step advice for smoking cessation."
3218423|NCT01073111|Active Comparator|zotarolimus-eluting stents (ENDEAVOR®)|
3218424|NCT01073111|Active Comparator|sirolimus-eluting stents (CYPHER SELECT® PLUS)|
3218425|NCT01073111|Active Comparator|everolimus-eluting stents (PROMUS®)|
3218426|NCT01073124|Active Comparator|Normal Saline|Normal Saline injected intraarticularly into the knee joint
3218427|NCT01073124|Experimental|Dilute Methylene Blue Dye|1 ml methylene blue dye per 500 ml normal saline injected intraarticularly into the knee
3218428|NCT01073137||Diabetic Subjects|
3218429|NCT01073137||Non diabetic subjects|
3218430|NCT01073176|Experimental|TEAMS|TEAMS has been designed to promote executive skills, memory and fine motor control, and includes game-like activities that allow for increases in task complexity.
3218431|NCT01073189|Experimental|Intra-Renal Fenoldopam|Intra-Renal Fenoldopam: Patients randomized to this wing will undergo placement of Angiodynamics Benefit catheter and receive intra-renal infusion of fenoldopm mesylate
3218432|NCT01073189|Active Comparator|Diuretic Control|Patients in the control group will be randomized to receive intra-venous diuretics as a comparator control
3218433|NCT01073202|Active Comparator|ursodeoxycholic acid|
3218434|NCT01073202|Placebo Comparator|identical-appearing placebo|
3218435|NCT01073215|Active Comparator|Group Condition|
3218436|NCT01073215|Experimental|Self-Guided Condition|
3218437|NCT01073228|Active Comparator|EVP-6124 0.3 mg|one 0.3 mg capsule every day for 183 days
3218438|NCT01073228|Active Comparator|EVP-6124 1 mg|one 1 mg capsule every day for 183 days
3218439|NCT01073228|Active Comparator|EVP-6124 2 mg|one 2 mg capsule every day for 183 days
3218440|NCT01073228|Placebo Comparator|Placebo|Placebo every day for 183 days
3218441|NCT01073241|Active Comparator|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP.
3218442|NCT01073241|Experimental|ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
3218443|NCT01073280||undeterminated neurological disease, cerebral endoscopy|patients without neurological diagnosis that require cerebral , meningeal diagnosis
3218444|NCT01073306|Experimental|Dengue Virus Subtype 2 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 2.
3218445|NCT01073306|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
3218446|NCT01073319|Placebo Comparator|Placebo|Matching oral placebo capsule as control.
3218447|NCT01073319|Active Comparator|Rivastigmine 3 mg|
3218448|NCT01073319|Active Comparator|Rivastigmine 6 mg|
3218449|NCT01073332|Placebo Comparator|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
3218450|NCT01073332|Experimental|Arginine antioxidant supplements|Dietary Supplement: Niteworks
3218451|NCT01073345||Major hepatic resection|Patients undergoing resection of > 2 liver segments
3218452|NCT01073345||Minor hepatic resection|Patients undergoing resection of </= 2 liver segments
3218453|NCT01073345||Control group|Patients undergoing exploratory laparotomy for hepatobiliary disease without resection (e.g. due to inoperable disease)
3218454|NCT01073358|No Intervention|Group A: No routine hilar lymphadenectomy|Resection of colorectal liver metastases without routine hilar lymphadenectomy
3218455|NCT01073358|Experimental|Group B: Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases.
3218456|NCT01073371|Active Comparator|liposome-encapsulated 3% prilocaine|
3218457|NCT01073371|Active Comparator|3% plain prilocaine|
3218458|NCT01073371|Active Comparator|3% prilocaine with 0,03IU/mL felypressin|
3218459|NCT01073384|Experimental|BDP 3 mg|1 mg TID
3218460|NCT01073384|Experimental|BDP 6 mg|2 mg TID
3218461|NCT01073384|Experimental|BDP 9 mg|3 mg TID
3218462|NCT01073384|Experimental|BDP 12 mg|4 mg TID
3218463|NCT01073397|Experimental|Behavioral|Weekly Integral Yoga sessions lasting 90 minutes for 10 weeks with home practice.
3218464|NCT01073397|Active Comparator|Health and Wellness Classes|Weekly classes on health and wellness lasting 90 minutes for 10 weeks, with additional home practice
3218465|NCT01073397|No Intervention|Waitlist|This group receives usual care for 10 weeks and is then randomized to one of the study arms.
3218466|NCT01073410||Healthy, non-asthmatic controls|People who are non-asthmatic and non-smokers.
3218467|NCT01073410||Asthmatics|People who have been diagnosed with asthma.
3218468|NCT01073423|Experimental|Yoga|
3218469|NCT01073423|Active Comparator|Music Therapy|
3218470|NCT01073436||Discontinuation|Subjects who agree to discontinue their tyrosine kinase inhibitor(TKI)therapy, namely,imatinib mesylate, dasatinib, or nilotinib,and then followed to see if they can maintain a durable remission.
3218471|NCT01073488|Experimental|EMONC: Community mobilization, HBLSS and Facility Improvement|The intervention group received training in community mobilization activities, Home Based Life Saving Skills (HBLSS) and facility improvement.
3218472|NCT01073488|No Intervention|Control|The control group did not receive an intervention, but collected outcome data through a baseline maternal/newborn birth registry.
3218473|NCT01073501|Placebo Comparator|Placebo|Placebo versus pregabalin
3218474|NCT01073501|Experimental|Pregabalin|Placebo versus pregabalin
3218475|NCT01073527|Active Comparator|Hypertonic saline-salbutamol combination|NaCl 5% - 4cc (with standard treatment - salbutamol 0.5cc)
3218476|NCT01073527|Placebo Comparator|normal saline-salbutamol combination|Standard treatment normal saline 4cc with salbutamol 0.5cc
3218477|NCT01073540|Experimental|Arm 1|
3218478|NCT01073540|Active Comparator|Arm 2|
3218479|NCT01073553|Experimental|Arm 1|
3218480|NCT01073553|Active Comparator|Arm 2|
3218481|NCT01073579||Sabril®|All patients in the U.S. who are prescribed Sabril must participate in this patient registry in order to receive Sabril.
3218482|NCT01073592||CNV patiens|
3218483|NCT01073644||Sunitinb malate|
3218484|NCT01073670|Active Comparator|Acetaminophen|Participants received a loading dose of acetaminophen (2600 mg) at induction followed by 1300 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3218485|NCT01073670|Experimental|Indomethacin|Participants were given 100 mg of indomethacin at induction and then 50 mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3218486|NCT01073670|Experimental|Combination|Participants were given a loading dose of 1300 mg of acetaminophen and 50 mg of Indomethacin followed by 650mg of acetaminophen and 25 mg of indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
3218487|NCT01073683|Experimental|larynx preservation|Decision between surgery and Chemo-rt according to response to initial induction chemotherapy
3218488|NCT01073696|Active Comparator|granisetron IV|
3218489|NCT01073696|Experimental|granisetron patch|
3218490|NCT01073709|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3218491|NCT01073709|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
3218492|NCT01073722|Active Comparator|Left double lumen tube|Traditionally, single lung ventilation is obtained with a double lumen tube (DLT). In our institution a polyvinyl DLT (Broncho-cath, Mallinckrodt,) without carinal hook, is used. This type of tube exists of a tube with two lumen with two distal cuffs. One lumen (called the bronchial lumen) extends some distance further, has a slight curvature and has a small blue cuff. The other lumen (called the tracheal lumen) has a larger cuff. A DLT tube exists in four sizes and one can choose in a left or a right configuration. Almost always, we use a left sided DLT. A DLT has a much larger diameter than a standard single lumen endotracheal tube
3218493|NCT01073722|Active Comparator|EZ-blocker|The EZ-blocker (EZB) is a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. It is intended for use in combination with a standard single lumen tube. After the EZB is advanced trough the distal end of the single lumen tube, both extensions spread out and find their way in the left and right main stem bronchi. The place where the two extensions are attached to the shaft now rests on the carina. Fiber optic bronchoscopy should be used for proper positioning. After placement of the EZB, one of the cuffs can be inflated to obtain lung separation under direct visual inspection with fiber optic bronchoscopy.
3218494|NCT01073735||Cancer Survivors|Examine the construct validity, short-term stability, internal consistency and item-response performance of a health-related needs assessment self-report instrument for adult childhood cancer survivors.
3218495|NCT01073748|Active Comparator|asthmatic subjects|Asthmatic children will be randomly exposed to paracetamol and placebo consecutively and their lung functions will be blindly compared.
3218496|NCT01073748|Other|Healthy children|Children with no asthma as control group.
3218497|NCT01073761|Experimental|Everybody|All Subjects will receive the same intervention
3218498|NCT01073774|Experimental|Side by Side|
3218499|NCT01073774|Active Comparator|couples control condition|
3218500|NCT01073787|Active Comparator|Normal saline|
3218501|NCT01073787|Experimental|Normal saline and possible medication|
3218502|NCT01073800|Active Comparator|atorvastatin 80 mg|active treatment
3218503|NCT01073800|Placebo Comparator|placebo|
3218504|NCT01073813|Active Comparator|Minocycline 100mg|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
3218505|NCT01073813|No Intervention|No treatment|Patients are in one of three strata (currently on Glatiramer acetate (GA), Interferon beta (IFN), or neither disease modifying therapy (DMT). There will be a minimum of 12 patients per strata. Patients will be randomized within each strata in a 2:1 fashion to receive either Minocycline 100mg twice daily or no treatment.
3218506|NCT01073826|Active Comparator|Tocilizumab|Infusion of Tocilizumab and sport intervention
3218507|NCT01073826|Active Comparator|Sitagliptin|Intake of Sitagliptin and sport intervention
3218508|NCT01073826|Placebo Comparator|Placebo|Intake of placebo and sport intervention
3218509|NCT01073839|Experimental|Cisplatin plus Gemcitabine|Patients after resection of cholangiocellular carcinoma will be allocated to treatment with cisplatin plus gemcitabine.
3218510|NCT01073852|Placebo Comparator|Placebo|Patients will be taking placebo medication throughout study.
3218511|NCT01073852|Active Comparator|Hydroxychloroquine|Patients will be taking hydroxychloroquine throughout study.
3218512|NCT01073891|Active Comparator|Arm 1|
3218513|NCT01073891|Experimental|Arm 2|
3218514|NCT01073891|Experimental|Arm 3|
3218515|NCT01073904|Experimental|Arm 1|
3218516|NCT01073904|Active Comparator|Arm 2|
3218517|NCT01073917|Other|Spontaneous Breathing|Patients will be breathing spontaneously during anesthesia
3218518|NCT01073917|Other|Pressure controlled ventilation|Patients in the PPV group will be ventilated by pressure control (tidal volume 8-10 ml/kg, frequency 10-14, I:E 1:1, no PEEP, target CO2 4.5 kPa).
3218519|NCT01073917|Other|Pressure Support Ventilation|The patients in the PSV group will breathing spontaneously on the ventilator with assistance by inspiratory support pressure. The support pressure will be adjusted to achieve a tidal volume of 8-10 ml/kg.
3218520|NCT01073956|Placebo Comparator|Inactive electrotherapy|Inactive electrotherapy is applied to the painful points
3218521|NCT01073956|Active Comparator|Ultrasound|Ultrasound electrotherapy is applied to the painful points
3218522|NCT01073956|Active Comparator|Monopolar radiofrequency|Monopolar radiofrequency electrotherapy is applied to the painful points
3218523|NCT01073969|Placebo Comparator|Control cereal|grain-based ready to eat cereal that does not contain active wheat bran extract
3218524|NCT01073969|Active Comparator|low dose|grain-based ready to eat cereal containing a low dose of wheat bran extract
3218525|NCT01073969|Active Comparator|High dose|grain-based ready to eat cereal that contains a high dose of wheat bran extract
3218526|NCT01073982|Placebo Comparator|cherry flavored fruit drink|
3218527|NCT01073982|Experimental|tart cherry juice|
3218528|NCT01073995|Active Comparator|Kenalog and Sensorcaine|"The following drugs will be administered during a one time injection of the appropriate spinal level based off clinical and radiographic information:~Intervention:~Kenalog 40 mg/ml and Sensorcaine 0.25% 1cc"
3218529|NCT01073995|Placebo Comparator|Saline|Saline injections will be used to mimic the Steroid dose
3218530|NCT01074021|Experimental|Nimotuzumab plus chemoradiotherapy|
3218531|NCT01074021|Placebo Comparator|placebo plus chemoradiotherapy|
3218532|NCT01074060|Experimental|Arm I|"MOBILIZATION: Patients receive cyclophosphamide IV. Patients also receive filgrastim subcutaneously (SC) daily beginning approximately 24 hours later.~TREATMENT/APHERESIS: Beginning 10 days after cyclophosphamide, patients receive plerixafor IV over 30 minutes followed by filgrastim SC on each day of apheresis."
3218533|NCT01074073|Other|Lithium/Lurasidone|Schizophrenia Patients
3218534|NCT01074086|Experimental|RAD 001|RAD 001 in day 1 and day 7 from 10 mg to 50 mg
3218535|NCT01074112||Abdominal Trauma|Patients with mechanism of injury that could produce abdominal bleeding
3218536|NCT01074112||Female Abdominal Pain|Female patients of child bearing age complaining of abdominal pain
3218537|NCT01074112||Difficult Vascular Access|Patients whom vascular access is needed but difficult
3218538|NCT01074112||Abdominal Aortic Anuerysm|Patients who complain of or are suspected of having an abdominal aortic aneurysm
3218539|NCT01074112||Pulseless Electrical Activity|Patients whom are in cardiac arrest and no pulse can be determined yet they show an electrical rhythm on the monitor
3218540|NCT01074112||Kidney Stones (Hydronephrosis)|Patients who complain of flank pain
3218541|NCT01074112||Plueral Effusion|Patients with a history of renal or hepatic problems and complain of difficulty breathing of an unknown etiology
3218542|NCT01074112||ETT placement|field intubated patients who need another means of verifying tube placement
3218543|NCT01074112||Transcutaneous Pacing|Patients who are being externally paced and need a method of determining mechanical capture
3218544|NCT01074112||Paramedic Discretion|Patients in whom the paramedic feels that an ultrasound study would provide useful data in their treatment
3218545|NCT01074138|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
3218546|NCT01074151||Pregnant patients exposed to Cymbalta|Pregnant patients exposed to Cymbalta (duloxetine) at any time during pregnancy, beginning on or after the first day of the last menstrual period
3218547|NCT01074190|Experimental|Group 1|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg followed by a patient controlled epidural analgesia (PCEA) maintenance infusion of bupivacaine 1mg/mL
3218548|NCT01074190|Experimental|Group 2|spinal fentanyl 15 micrograms plus bupivacaine 2.5 mg spinal followed by a PCEA infusion of fentanyl 1 micrograms/mL plus bupivacaine 0.8 mg/mL
3218549|NCT01074190|Active Comparator|Group 3|spinal fentanyl 15 micrograms plus bupivacaine 2.5mg followed by a PCEA infusion of fentanyl 2 micrograms/mL plus bupivacaine 0.625 mg/mL
3218550|NCT01074203|Experimental|Nitazoxanide arm|All patients will receive nitazoxanide
3218551|NCT01074294|Placebo Comparator|Sugar pill|
3218552|NCT01074294|Experimental|OPC-34712|
3218553|NCT01074320||Breast cancer patients on AIs|Breast cancer patients beginning Aromatase Inhibitor therapy
3218554|NCT01074359|Experimental|A0001|A0001 (0.75 g BID)
3218555|NCT01074359|Placebo Comparator|Placebo|Placebo
3218556|NCT01074372|Experimental|Cohort 1|Dose 1 versus placebo
3218557|NCT01074372|Experimental|Cohort 2|Dose 2 versus placebo
3218558|NCT01074372|Experimental|Cohort 3|Dose 3 versus placebo
3218559|NCT01074372|Experimental|Cohort 4|Dose 4 versus placebo
3218560|NCT01074385|Other|Immediate Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions, about a week apart. Subjects will then be asked to complete a questionnaire 1-2 weeks after completing therapy sessions and one month after completing therapy sessions.
3218561|NCT01074385|Other|Wait List Dignity Therapy|At registration, subjects will be mailed a questionnaire. The subject will then receive two separate dignity therapy sessions; the first session will take place about 6 weeks after registration, with the second session occurring 1-3 weeks after the first. Subjects will then be asked to complete a questionnaire about one month after completing therapy sessions.
3218562|NCT01074411|Experimental|Treatment (bortezomib, carboplatin)|Patients receive bortezomib IP and carboplatin IP on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3218563|NCT01074476|Experimental|1|Glucosamine sulphate tablets
3218564|NCT01074476|Placebo Comparator|2|Placebo tablets
3218565|NCT01074528|Experimental|mindfulness based stress reduction|8-week mindfulness based stress reduction program
3218566|NCT01074528|No Intervention|control group|patients who have to wait before entering the MBSR program or who do not want to follow this program
3218567|NCT01074541|Active Comparator|Group 1|UV intensity 10 MIN
3218568|NCT01074541|Active Comparator|Group 2|UV intensity 5 MIN
3218569|NCT01074541|Active Comparator|Group 3|UV intensity 1 MIN
3218570|NCT01074541|Active Comparator|Group 4|UV intensity 20 MIN
3218571|NCT01074567|Experimental|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
3218572|NCT01074580||Deterioration, Crohn's disease|Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors
3218573|NCT01074593|Experimental|Test|Bergamo - Interferon beta-1a
3218574|NCT01074593|Active Comparator|Comparator - Merck Serono|Merck Serono - Interferon beta-1a
3218575|NCT01074606|Experimental|Toric|AcrySof Toric Intraocular Lens (IOL)
3218576|NCT01074619|Experimental|1|Memantine
3218577|NCT01074619|Placebo Comparator|2|Placebo
3218578|NCT01074645|No Intervention|Placebo|Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
3218579|NCT01074645|Active Comparator|Tenofovir disoproxil fumarate (TDF)|Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF
3218580|NCT01074671|Other|No control arm|There is no control arm as part of the study design.
3218581|NCT01074697|Active Comparator|Fosaprepitant dimeglumine|
3218582|NCT01074697|Placebo Comparator|Saline water|
3218583|NCT01074710|Experimental|C13-URA|administered C13-URA 50, 100, 200mg in same subjects
3218584|NCT01074710|Placebo Comparator|Placebo|2 same subjects
3218585|NCT01074723|Experimental|b-cryptoxanthin|
3218586|NCT01074723|Experimental|phytosterols|
3218587|NCT01074723|Experimental|b-cryptoxanthin plus phytosterols|
3218588|NCT01074749|Active Comparator|Optisense lead|Patients with an Accent pacemaker and an OptiSense atrial lead
3218589|NCT01074749|Active Comparator|Tendril lead|Patients with an Accent pacemaker and a Tendril atrial lead
3218590|NCT01074762|No Intervention|Routine general practice care|In the comparison group, doctors were free to choose any treatment and change it over time. The study coordinating centre did not contact comparison practices after the end of recruitment (late 1991) until 1995.
3218591|NCT01074775|Experimental|Challenge group|Recipients of three challenge infections with oral M bovis
3218592|NCT01074788|Experimental|mind body intervention group|
3218593|NCT01074801|Active Comparator|Closed-loop|Subcutaneous insulin delivery to be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
3218594|NCT01074801|Active Comparator|Control arm|Subcutaneous insulin delivery to be administered according the standard insulin pump settings
3218595|NCT01074827|Experimental|Treadmill group|Specific gait training on treadmill
3218596|NCT01074827|Experimental|Strength training group|Eight weeks of intensive strength training
3218597|NCT01074840|Active Comparator|Peanut|Peanut flour will be given in increasing amounts.
3218598|NCT01074840|No Intervention|Control|Subjects will be enrolled who meet the inclusion/exclusion criteria and followed as matched controls. These subjects will not receive any treatment.
3218599|NCT01074853|Experimental|Propranolol|Chronic dose escalation of propranolol over period of 6 to 8 weeks.
3218600|NCT01074853|Placebo Comparator|Placebo|Matched placebo used for dose escalation period of 6 to 8 weeks
3218601|NCT01074866|No Intervention|Pressure support|Non invasive ventilation under pressure support (PS)
3218602|NCT01074866|Active Comparator|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally Adjusted ventilatory Assist
3218603|NCT01074879|Experimental|Whey protein|20 g whey protein + 20 g carbohydrates
3218604|NCT01074879|Experimental|Milk protein|20 g milk protein + 20 g carbohydrates
3218605|NCT01074879|Active Comparator|Carbohydrates|40 g carbohydrates
3218606|NCT01074892|Active Comparator|MPA 10 mg per oral cyclic for 6 months|The peroral treatment is used 10 days each month
3218607|NCT01074892|Active Comparator|MPA 10 mg per os continuous 6 months|Per oral MPA 10 mg is taken daily for 6 months
3218608|NCT01074892|Active Comparator|LNG-IUD for 6 months|Levonorgestrel impregnated IUD is inserted into the uterine cavity and kept in situ for 6 months
3218609|NCT01074905|Active Comparator|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
3218610|NCT01074905|Active Comparator|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
3218611|NCT01074905|Experimental|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
3218612|NCT01074918|Experimental|Potassium Magnesium Citrate|
3218613|NCT01074918|Active Comparator|Potassium Chloride|
3218614|NCT01074957|Active Comparator|Incentive Spirometry|Incentive Spirometry group (IS) was oriented to take a deep breathing through Voldyne 5000TM (Sherwood Medical; St Loius, MO, USA) from Functional Residual Capacity (FRC) to Total Lung Capacity (TLC).
3218615|NCT01074957|Active Comparator|Exercise group|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
3218616|NCT01074957|Active Comparator|Breath-Stacking|Breath-Stacking group (BS) performed successive inspiratory efforts using a facial mask adapted to an unidirectional valve
3218617|NCT01074970|Active Comparator|Arm A: Cisplatin Monotherapy|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
3218618|NCT01074970|Active Comparator|Arm B: Combination Therapy|"Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles~Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles"
3218619|NCT01074983||Written standard of care|
3218620|NCT01074983||Usual practice pattern|
3218621|NCT01074996|Active Comparator|S-1,|Subjects will receive S-1 until progression
3218622|NCT01074996|Experimental|S-1 plus Leucovorin|patients will receive S-1 plus Leucovorin until progression
3218623|NCT01075022|Experimental|Vitamin D|
3218624|NCT01075022|Placebo Comparator|Placebo|
3218625|NCT01075035||Normal Healthy Controls|Individuals with no history of Traumatic Brain Injury.
3218626|NCT01075035||Civilian TBI|Civilians who have had a Traumatic Brain Injury
3218627|NCT01075035||Military TBI|Combat military veterans who have had a Traumatic Brain Injury
3218628|NCT01075061|Other|healthy volunteers|healthy volunteers
3218629|NCT01075061|Other|Kallmann|Kallmann syndrome patients
3218630|NCT01075061|Other|Congenital Mirror Movement|patients with CMM
3218631|NCT01075113|Experimental|Arm A|Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort A has only one dose level: sorafenib 400 mg orally twice a day with vorinostat 300 mg orally. Cohort A was modified to include 2 dose levels: Dose level A1 (sorafenib 400 mg orally twice a day and vorinostat 200 mg orally once a day) and dose level A-1 (sorafenib 400 mg orally twice a day with vorinostat 100 mg orally once a day). The starting dose upon reopening after approval of this version will be dose level A-1a. Dose level A1 will only be used if dose level A-1a is not tolerable.
3218632|NCT01075113|Experimental|Arm B CLOSED|Reduced Dose 200mg Sorafenib + Vorinostat. Patients receive sorafenib tosylate PO BID continuously and vorinostat PO QD, for 5 days each week. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Cohort B has 2 dose levels starting at the second dose level (sorafenib 200 mg orally twice a day with vorinostat 400 mg orally). Cohort B has been closed. Cohort B was intended to evaluate the possibility of dose intensification of vorinostat when patients were unable to tolerate standard dose sorafenib, and required dose-reduced sorafenib. The patients accrued to date in Cohort B were unable to tolerate therapy, and it has been determined that dose intensification of vorinostat is not possible, despite reducing the dose of sorafenib.
3218633|NCT01075139|Experimental|Brief Motivational Intervention|Subjects in this condition met one-on-one with a counselor for 30 minutes. Subjects received personalized feedback regarding their current physical activity levels and fruit/vegetable intake. Counselors used a motivational interviewing style to try to help resolve ambivalence about changing their current behaviors.
3218634|NCT01075139|Active Comparator|Educational information|Subjects in this condition received general educational information about the benefits associated with physical activity and fruit/vegetable intake.
3218635|NCT01075165|Experimental|Silicone Spray|Apply spray silicone
3218636|NCT01075165|Placebo Comparator|Saline Spray|Apply Saline Spray
3218637|NCT01075230|Active Comparator|Standard TKA|
3218638|NCT01075230|Active Comparator|Standard TKA with PRP|
3218639|NCT01075269||Conventional open thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3218640|NCT01075269||Robotic thyroidectomy group|All patients were told about the operative techniques involved in conventional open and robotic thyroidectomy, and patients subsequently chose their preferred surgical procedure, voluntarily agreed to participate in our study, and provided written informed consent.
3218641|NCT01075295|Experimental|Lifestyle Intervention|
3218642|NCT01075295|Active Comparator|TAU|
3218643|NCT01075308|Experimental|SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
3218644|NCT01075334|Experimental|Porimore arm|Infertile men will receive 'Porimore' tablets for a period of time in which three intrauterine insemination cycles will be performed.
3218645|NCT01075334|Active Comparator|Folate and Zinc|
3218646|NCT01075386||Grade 2|Patients with Endometrial cancer of Grade 1 differentiation
3218647|NCT01075386||Benign|Patients without endometrial cancer
3218648|NCT01075386||Grade 1|Patients with Endometrial cancer of Grade 2 differentiation
3218649|NCT01075386||Grade 3|Patients with Endometrial cancer of Grade 3 differentiation
3218650|NCT01075425|Experimental|Arm I|Patients receive belinostat IV over 30 minutes on days 1-5 and 8-12 and bortezomib IV on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3218651|NCT01075464|Experimental|A|
3218652|NCT01075464|Experimental|B|
3218653|NCT01075477||Cohort|
3218654|NCT01075490|Placebo Comparator|prematurely born, bupivacaine, placebo|
3218655|NCT01075490|Experimental|prematurely born, bupivacaine, clonidine|
3218656|NCT01075490|Placebo Comparator|term neonate, bupivacaine, placebo|
3218657|NCT01075490|Experimental|term neonate, bupivacaine, clonidine|
3218658|NCT01075503|Experimental|retrograde infraclavicular|Patients were received retrograde infraclavicular brachial plexus block.
3218659|NCT01075503|Active Comparator|interscalene|Patients were received interscalene brachial plexus block.
3218660|NCT01075503|Active Comparator|supraclavicular|Patients were received supraclavicular brachial plexus block.
3218661|NCT01075529|No Intervention|fluoxetine|
3218662|NCT01075542|Experimental|Toric intraocular lens|Bilateral Toric intraocular lens implantation in cataract surgery
3218663|NCT01075542|Other|Monofocal intraocular lens|Bilateral Monofocal intraocular lens implantation in cataract surgery
3218664|NCT01075555|Active Comparator|sorafenib|sorafenib
3218665|NCT01075555|Experimental|sorafenib + pravastatine|sorafenib + pravastatine
3218666|NCT01075581|Active Comparator|Topical administration|An an intranasal injection of saline will be used as control, and thereafter cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
3218667|NCT01075581|Experimental|Intranasal injection|An intranasal injection of 8 mL epinephrine 1:100,000 will be performed as traditionally practiced in ESS. Thereafter, cotton pledgets soaked in 1 mL epinephrine 1:1,000 will be placed in the nasal cavity during surgery when necessary.
3218668|NCT01075594||1|Patients with dyslipidemia on lipid lowering therapy
3218669|NCT01075620|Experimental|PFC sigma RP|Posterior stabilized rotating platform knee (press Fit Condylar Sigma rotating-platform, Depuy, Warsaw, Indiana)
3218670|NCT01075620|Active Comparator|LCS RP|non posterior stabilized Low Contact Stress Rotating-Platform; Depuy, Warsaw, Indiana
3218671|NCT01075633|Experimental|Fecal occult blood testing|Immunochemical fecal occult blood test Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
3218672|NCT01075633|Active Comparator|Colonoscopy|Colonoscopy with sedation.
3218673|NCT01075659|Experimental|LHN1548|Two single doses of an experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3218674|NCT01075659|Active Comparator|2019706|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3218675|NCT01075659|Active Comparator|2020005|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
3218676|NCT01075672|Experimental|Cognitive Behavioral Therapy|
3218677|NCT01075672|Experimental|Behavioral Medicine with Cognitive Behavioral Therapy|Participants enrolled in this arm of this study will be treated by the behavioral medicine interns with cognitive behavioral therapy focused on both their general health concerns and mental health concerns.
3218678|NCT01075698|Active Comparator|Non-ARB group|
3218679|NCT01075698|Active Comparator|ARB group|
3218680|NCT01075711||NIS in-house doctors|This group will be assigned to general physicians, practicing doctors and interns (in-house doctors) with an observation period of 3 months. Three subjects are expected per in-house doctor therefore altogether, 1000 in-house doctors will be obtained or appointed for the observation study.
3218681|NCT01075711||NIS specialists|This group will be assigned to specialists (rheumatologist) with an observation period of 9 months. Ten subjects per rheumatologist are expected therefore altogether, 500 rheumatologists will be obtained or appointed for the observation study.
3218682|NCT01075724|Active Comparator|Forced air|Forced Air Warming
3218683|NCT01075724|Experimental|Resistive HotDog Warming|Warming by resistive Warming
3218684|NCT01075737||Subjects with Multiple Sclerosis|Subjects with diagnosed MS according to the revised Mc Donald criteria 2005; aged >21 years.
3218685|NCT01075737||Caregivers|Caregivers (aged >21 years) for MS subjects.
3218686|NCT01075750||Normal Saline|Patients receiving Normal Saline during and after the renal transplantation.
3218687|NCT01075750||Elomel Isoton|Patients receiving Elomel Isoton during and after renal transplantation
3218688|NCT01075776|Experimental|CNP|Infusion of CNP prior to IR injury
3218689|NCT01075776|Placebo Comparator|Saline|Effect of saline infusion prior to IR injury
3218690|NCT01075789|Placebo Comparator|Placebo|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this placebo arm or the treatment arm in a 1:1 ratio. The placebo for swallowing is a viscous, coloured, sucrose-flavoured gel designed to match the appearance of the treatment lignocaine gel to be swallowed by the treatment arm, and normal saline will be delivered to the nasal turbinates and nasopharynx in a similar way to atomised xylocaine in the treatment arm.
3218691|NCT01075789|Active Comparator|Lignocaine|This arm will include children aged 6 years of age and older seen at the Royal Children's Hospital who are having an NGT inserted for a clinical indication and who have never experienced an NGT insertion before. These children will be randomised to be in this treatment placebo arm or the treatment arm in a 1:1 ratio. The children in the treatment arm will receive xylocaine viscous 2% to swallow, and atomised 10% xylocaine to the nasal turbinates and nasopharynx.
3218692|NCT01075789|Active Comparator|Pre/post intervention evaluation group|This is a contemporaneous arm of children aged 6 years of age and older requiring nasogastric intubation for a clinical reason, who have previously had a nasogastric tube inserted. These children will be ask to rate by recall their previous NGT intubation on a VAS pain scale, and then will perform a post-procedure VAS pain assessment.
3218693|NCT01075802|Experimental|Tamoxifen|Dose escalation of tamoxifen in patients with low endoxifen levels
3218694|NCT01075867||Control group|Before ELIPS implementation 12 months follow-up
3218695|NCT01075867||Treatment group|After ELIPS implementation 12 months follow-up
3218696|NCT01075893||Adenomatous polyp|Patients who have begun the polyp-cancer sequence (ie. are in polyp surveillance after excision of a prior adenomatous polyp) will be used to test those patients at higher risk of colorectal.
3218697|NCT01075893||Patients at normal risk of cancer|Patients found to have endoscopically and histological normal mucosa.
3218698|NCT01075893||Ulcerative colitis|Patients who are under surveillance for known ulcerative colitis will be used to test those patients at higher risk of colorectal.
3218699|NCT01075906|Experimental|Colchicine|Colchicine Sprinkle Capsules, 0.3 mg - dose administered according to age range on Day 1
3218700|NCT01075906|Experimental|colchicine at steady state|colchicine sprinkle capsules 0.3 mg - dose administered according to age range on Day 15 following once daily dosing of colchicine on Days 2 - 14
3218701|NCT01075919|Active Comparator|DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA
3218702|NCT01075919|Active Comparator|EPA-rich fish oil|1 g EPA-rich fish oil containing 300 mg EPA + 200 mg DHA
3218703|NCT01075919|Placebo Comparator|Placebo|1 g Olive oil
3218704|NCT01075932|Active Comparator|1 g DHA-rich fish oil|1 g DHA-rich fish oil containing 450 mg DHA + 90 mg EPA plus 1 g olive oil
3218705|NCT01075932|Active Comparator|2 g DHA-rich fish oil|2 g DHA-rich fish oil containing 900 mg DHA + 180 mg EPA
3218706|NCT01075932|Placebo Comparator|Placebo|2 g olive oil
3218707|NCT01075945|Experimental|Dihydroartemisinin- piperaquine|orally tablets
3218708|NCT01075945|Active Comparator|artemether- lumefantrine|oral tablets
3218709|NCT01075997|Experimental|A cell phone tips|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone. The group will be asked to check blood sugar on a schedule determined by their providers. The group will have blood sugars downloaded from from the glucometer by their providers at every visit and reviewed. The group will have the A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
3218710|NCT01075997|Active Comparator|B no cell phone tips|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by their provider. The groups will have blood sugars downloaded from from the glucometer by their provider at every visit and reviewed. The group will have A1c measured. Also it will have this test repeated about every 3 months. They will continue to have monitored their A1c at 24, 38 and 52 weeks of the study.
3218711|NCT01076062|No Intervention|Expectant management (EM) arm|Standard of care: routine clinic appointments until they deliver, fetal heart rate and contraction monitoring during their 41st week if not delivered. Also if they have not gone into labor the subjects will be scheduled for an induction by 42 weeks.
3218712|NCT01076062|Experimental|Induction of Labor (IOL) arm|Elective induction of labor at 39 weeks.
3218713|NCT01076101||Sisters who have a diagnosis of SLE|Sisters who have a diagnosis of SLE
3218714|NCT01076101||Unaffected Sisters|Sisters of SLE patients who do not have a diagnosis of SLE
3218715|NCT01076114||Control|Patients with no evidence of glaucoma or as a suspect with normal intraocular pressure, normal cup to disc ratio with no other ocular pathology and a normal ophthalmic exam.
3218716|NCT01076114||Glaucoma Suspect|Patients with abnormal cup to disc ratio or increased intraocular pressure (>21mm/Hg) with an otherwise normal ophthalmic exam.
3218717|NCT01076127|Experimental|Ketllebell group|Basic ketllebell training 3 x 20 min a week for 8 weeks
3218718|NCT01076127|Sham Comparator|Control group|Control group. Receives a health examination before and after the intervention period, and are advised to stay active.
3218719|NCT01076140|Active Comparator|Nebivolol|Nebivolol 5 mg daily for 2 weeks, then 5 or 10 mg daily for 2 weeks
3218720|NCT01076140|Active Comparator|Lisinopril|20 mg once daily for 2 weeks, then 20 or 40 mg once daily for 2 weeks
3218721|NCT01076218||Diabetes|Patients with type 1 diabetes requiring multiple daily insulin injections or using insulin pumps
3218722|NCT01076257|Experimental|Constraint-induced Movement Therapy|
3218723|NCT01076257|Other|Transditional rehabilitation|
3218724|NCT01076309||Tamsulosin|Patients taking tamsulosin
3218725|NCT01076309||Non-tamsulosin|Patients not taking tamsulosin.
3218726|NCT01076322|Experimental|Treatment-A sequence|Meptin® Swinghaler / Ventolin® MDI
3218727|NCT01076322|Experimental|Treatment-B sequence|Ventolin® MDI / Meptin® Swinghaler
3218728|NCT01076387|Active Comparator|open radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
3218729|NCT01076387|Active Comparator|robotic-assisted radical cystectomy|This is a prospective, randomized study designed to compare two techniques of radical cystectomy with PLND (open and robotic) for bladder cancer.
3218730|NCT01076413|Experimental|skill-based exercise|2 times per week for 12 weeks. warm-up, stretching, strengthening, and skill-based exercises. Pre-gait and gait activities including stepping patterns and walking patterns and treadmill training at various walking speeds
3218731|NCT01076413|Active Comparator|aerobic exercise training|warm-up, strengthening and aerobic conditioning (treadmill walking)
3218732|NCT01076426|Experimental|Probiotics|probiotics treatment
3218733|NCT01076426|Placebo Comparator|Placebo|
3218734|NCT01076439|Active Comparator|Olopatadine Nasal Spray (Patanase)|
3218735|NCT01076439|Active Comparator|Fluticasone Furoate Nasal Spray (Veramyst)|
3218736|NCT01076439|Placebo Comparator|Saline Nasal Spray (Placebo)|
3218737|NCT01076465|Experimental|Lifestyle counselling|Educational intervention, monitoring of clinical status, monitoring of treatment adherence
3218738|NCT01076465|Active Comparator|Comparator|Usual care
3218739|NCT01076478|Placebo Comparator|Arm 1|2 tablets BID
3218740|NCT01076478|Experimental|Arm 2|100 mg Cilostazol (2 tablets BID)
3218741|NCT01076478|Experimental|Arm 3|200 mg Cilostazol (2 Tablets BID)
3218742|NCT01076530|Experimental|Arm I|Patients receive oral vorinostat and oral temozolomide once daily on days 1-5. Courses repeat every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3218743|NCT01076556|Experimental|Treatment (rituximab, cyclophosphamide, alvocidib)|Patients receive rituximab IV over 4 hours on days 1 (days 1-3 in course 1), cyclophosphamide IV over 30-60 minutes on days 1-3, and alvocidib IV over 4.5 hours on days 1 and 8 (day 8 only in course 1).
3218744|NCT01076569||Ancillary-Correlative (molecular analysis)|Banked bone marrow samples from diagnosis and remission are used to develop a detailed molecular map of pediatric high-risk acute myeloid leukemia. Analysis includes genome SNP genotyping, expression, and methylation profiling.
3218745|NCT01076582|Experimental|Arm 1|
3218746|NCT01076582|Active Comparator|Arm 2|
3218747|NCT01076595||Group 1|
3218748|NCT01076621||A|
3218749|NCT01076634|Experimental|IDeg 100 U/mL|
3218750|NCT01076634|Experimental|IDeg 200 U/mL|
3218751|NCT01076673|Experimental|PBSC and Hyaluronic Acid|Peripheral blood stem cells and hyaluronic acid injections
3218752|NCT01076673|Active Comparator|Hyaluronic Acid|Hyaluronic Acid
3218753|NCT01076699|Active Comparator|Group taking 0.075 mg RVX-100|This group is taking 0.075 mg RVX-100
3218754|NCT01076699|Active Comparator|Group taking 0.125 mg RVX-100|This group is taking 0.125 mg RVX-100
3218755|NCT01076699|Active Comparator|0.250 mg RVX-100|This group is taking 0.250 mg RVX-100
3218756|NCT01076699|Placebo Comparator|placebo|This group is taking a placebo
3218757|NCT01076712|Experimental|Physiotherapy Interventions|Physiotherapy Interventions including strengthening exercise, balance training, gait training with visual cue, gait training with treadmill.
3218758|NCT01076712|Other|Education|Education
3218759|NCT01076725|Active Comparator|Standard technique group|In the standard technique group(n = 63), the PLMA was inserted by index finger insertion technique.
3218760|NCT01076725|Experimental|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
3218761|NCT01076738||single group study|
3218762|NCT01076751||CRPC patients|
3218763|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.100 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban (0.080 mg/kg bolus followed by 0.100 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
3218764|NCT01076764|Experimental|Otamixaban - 0.080 mg/kg bolus + 0.140 mg/kg/h infusion|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Otamixaban 0.080 mg/kg bolus followed by 0.140 mg/kg/h infusion)~Drug B: Placebo (for UFH)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Placebo (for Eptifibatide)"
3218765|NCT01076764|Active Comparator|UFH + Eptifibatide|"From randomization until the end of the PCI or, if no PCI, up to Day 4 or hospital discharge whichever comes first:~Drug A: Placebo (for Otamixaban)~Drug B: UFH (60 IU/kg bolus followed by 12 IU/kg/h infusion)~From PCI (downstream use) until 18-24 hour post PCI or hospital discharge whichever comes first:~Drug C: Eptifibatide (180 mcg/kg bolus followed by 2 mcg/kg/min infusion)"
3218766|NCT01076777|Experimental|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
3218767|NCT01076777|Active Comparator|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
3218768|NCT01076790|Active Comparator|Dexmedetomidine|Analgo-sedative, adjuvant of propofol anesthesia
3218769|NCT01076803|Experimental|Lanreotide (acetate)|
3218770|NCT01076829|Active Comparator|Spice patty|hamburger meat cooked with spice mixture
3218771|NCT01076829|Placebo Comparator|salt patty|Subjects consume salt containing hamburger meat
3218772|NCT01076842|Active Comparator|A Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
3218773|NCT01076842|Active Comparator|B Exenatide|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
3218774|NCT01076842|Active Comparator|C Levemir+Exenatide|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
3218775|NCT01076855||Elderly with mild dementia|>70 years old and presence of a carer
3218776|NCT01076868|Experimental|Primaquine|Primaquine 14 days
3218777|NCT01076881|Experimental|combined aerobic and resistance training|
3218778|NCT01076881|Active Comparator|resistance training alone|
3218779|NCT01076894|Active Comparator|epidural anesthesia|
3218780|NCT01076894|Active Comparator|intercostal anesthesia|
3218781|NCT01076907|Experimental|Warm water loading of sigmoid colon|Warm water loading of sigmoid colon and irrigation when spasms occur.
3218782|NCT01076907|Placebo Comparator|Control|No water loading, only air and waiting for spasms to subside.
3218783|NCT01076920|Experimental|Intervention arm|
3218784|NCT01076933|Experimental|rTMS|rTMS sessions
3218785|NCT01076933|Sham Comparator|control|sham rTMS (control)
3218786|NCT01076946||TLVBS|patients with transient left ventricular ballooning
3218787|NCT01076998|Experimental|Lubricant eye drop|Lubricant eye drop
3218788|NCT01076998|Active Comparator|Refresh PM Ointment|Refresh PM Ointment
3218789|NCT01077011|Experimental|Lubricant eye drop|Lubricant eye drop
3218790|NCT01077011|Active Comparator|GenTeal Gel|GenTeal Gel
3218791|NCT01077037|Experimental|Decision Aid|Receives Decision Aid
3218792|NCT01077037|No Intervention|Control|Patient receives usual care.
3218793|NCT01077089||Transported TBI patients|Traumatically brain injured patients undergoing in-hospital transport.
3218794|NCT01077102|Experimental|Eccentric exercise training|
3218795|NCT01077102|Active Comparator|Concentric exercise training|
3218796|NCT01077115|Experimental|Laparoscopic cholecystectomy|
3218797|NCT01077115|Active Comparator|Open cholecystectomy|
3218798|NCT01077167|Experimental|1|
3218799|NCT01077180|Experimental|Rheos Device|
3218800|NCT01077180|Active Comparator|Medical Management|
3218801|NCT01077206|Active Comparator|Simvastatin 80mg|
3218802|NCT01077206|Active Comparator|Simvastatin 40mg|
3218803|NCT01077232||Psoriasis Patients|Patients with moderate to severe plaque psoriasis
3218804|NCT01077245|Experimental|MIYA-BM|MIYA-BM Fine Granules (CBM588)
3218805|NCT01077245|Placebo Comparator|Placebo|Placebo Fine Granules (without CBM588)
3218806|NCT01077297|Experimental|Tezosentan|
3218807|NCT01077336||Hospitalized patients with candidemia|
3218808|NCT01077349|Experimental|high volume hemofiltration|
3218809|NCT01077349|Active Comparator|standard care|
3218810|NCT01077388|Experimental|Dietician electronic counseling|This arm will receive care and supportive emails and phone calls from a study dietician for about 6 months. We will also provide a blood pressure monitor, a pedometer, and a scale with instructions for using them at home.
3218811|NCT01077388|No Intervention|Self Care|This arm will continue to get care as usual from their regular doctor. They will also get a blood pressure monitor and a scale at the end of the study.
3218812|NCT01077427|Active Comparator|Gemcitabine + Capecitabine|
3218813|NCT01077427|Experimental|Gemcitabine + Cisplatin + regional hyperthermia|
3218814|NCT01077440||Men - age 18+|
3218815|NCT01077453|Experimental|Arm I (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO thrice weekly for 6 months.
3218816|NCT01077453|Experimental|Arm II (1.0 mg letrozole)|Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.
3218817|NCT01077453|Experimental|Arm III (0.25 mg letrozole)|Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.
3218818|NCT01077453|Experimental|Arm IV (2.5 mg letrozole)|Patients receive 2.5 mg of letrozole PO once daily for 6 months.
3218819|NCT01077466|Experimental|Natalizumab|24 patients: 12 with secondary progressive multiple sclerosis 12 with primary progressive multiple sclerosis
3218820|NCT01077479|Experimental|Metformin|
3218821|NCT01077492||Suspected mediastianl lymph nodes|Patients with (suspected) lung cancer requiring MLN staging after CT-PET during routine work-up according to existing staging guidelines.
3218822|NCT01077505|Experimental|albiglutide|albiglutide 50mg weekly
3218823|NCT01077531|Active Comparator|Otelixizumab|Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
3218824|NCT01077531|Placebo Comparator|Placebo|Matching placebo for intravenous infusion
3218825|NCT01077557||No HIV infection|Subjects without HIV infection (Group 1) are adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. A 3:1 match of subjects without HIV infection to a subject with HIV infection will occur. Each member of the comparator group without HIV infection will be matched on gender, month/year of IHCIS enrolment, and duration of enrollment to the respective study subject with HIV infection.
3218826|NCT01077557||HIV infection with no antiretroviral (ARV) drug exposure|HIV infection with no ARV drug exposure (Group 2) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have no pharmacy dispensing for ARV drugs.
3218827|NCT01077557||HIV infection with ARV drug exposure|HIV infection with ARV drug exposure (Group 3) represents adults, 18 years of age and older, continuously enrolled for at least 12 months in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database, a health insurance claims database, during the interval between January 1, 1997 and March 31, 2008, and with continuous eligibility for pharmacy benefits. HIV exposure will be identified by ICD-9-CM code 042 or v08 in one or more diagnostic fields. This group will have at least one pharmacy dispensing for an HIV antiretroviral drug.
3218828|NCT01077570||Repaglinide|
3218829|NCT01077609||Allergic rhinitis (AR) & Flixonase|Patients initiating treatment for allergic rhinitis on intranasal fluticasone propionate
3218830|NCT01077609||AR & prescription for intranasal steroid other than Flixonase|Random sample of patients initiating treatment for allergic rhinitis with an intranasal steroid other than Flixonase
3218831|NCT01077635||HIV-1 infected children aged 6 ≤ 18 years|HIV-1 infected children aged 6 ≤ 18 years currently or having ever been exposed to FPV/RTV; this is the indicated group for the licensed dose in the paediatric population.
3218832|NCT01077648||Women diagnosed with advanced breast cancer|Women diagnosed with advanced breast cancer during January 1, 1995-December 31, 2007 and treated as part of the Henry Ford Health System
3218833|NCT01077661||Patients administrated Nebivolol|There is only one group. This group includes patients administrated Nebivolol
3218834|NCT01077674||Entropy - BIS|Patients undergoing surgery in sevoflurane anaesthesia.
3218835|NCT01077700|Experimental|ABT-288 Dose 1|low dose of ABT-288
3218836|NCT01077700|Experimental|ABT-288 Dose 2|high dose of ABT-288
3218837|NCT01077700|Placebo Comparator|Sugar Pill|inactive substance
3218838|NCT01077726|Experimental|1|
3218839|NCT01077752|Experimental|1|Patients with continuous ropivacaine preperitoneal infusion
3218840|NCT01077752|Active Comparator|2|Patients with intravenous lidocaine infusion
3218841|NCT01077752|Placebo Comparator|3|Patients without local anesthetics
3218842|NCT01077765|Experimental|treatment|treatment
3218843|NCT01077791|Experimental|original cognitive therapy|
3218844|NCT01077791|No Intervention|no intervention|
3218845|NCT01077843||Exposure|Ankylosing spondylitis patients currently exposed to anti-inflammatory treatments
3218846|NCT01077843||Non-exposure|Ankylosing spondylitis patients not currently exposed to anti-inflammatory treatments
3218847|NCT01077882|Placebo Comparator|current therapy|
3218848|NCT01077882|Experimental|current therapy with educational program|
3218849|NCT01077895|Experimental|CVVH with fluid removal|
3218850|NCT01077895|Active Comparator|CVVH without fluid removal|
3218851|NCT01077908|Experimental|ACT plus standard therapy|Adoptive Cellular Therapy (ACT) prepared using Multimer or Gamma Catch Selection in combination with standard best available antiviral drug therapy
3218852|NCT01077908|Active Comparator|Best available antiviral drug therapy|
3218853|NCT01077934||Injured Extremity without compartment syndrome|
3218854|NCT01077934||Injured extremity with compartment syndrome|
3218855|NCT01077947|Active Comparator|Functional anesthetic discography|"The patients disc levels for surgical treatment will be based exclusively on their Functional anesthetic discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~Patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery by research personnel. Patients will be asked to complete questionnaires before their discography and at every follow-up visit."
3218856|NCT01077947|Active Comparator|Provocative Discography|"The patients disc levels for surgical treatment will be based exclusively on their Provocative Discography results. The discography will be performed at a maximum of two disc levels. Discs showing the following MRI findings will be considered for discography:~Loss of disc signal intensity on T-2 weighted sagittal MR images.~Loss of disc height on sagittal MR images.~The control disc, in the case provocative discography group must appear normal on the MRI - must have preserved disc height and central disc signal intensity on T-2 weighted images. The provocative discography will be performed using the standard IASP criteria. The patients will be followed-up at 3 weeks, 3 months, 6 months and 1 year after the surgery."
3218857|NCT01077999|Active Comparator|Carboplatin + paclitaxel + radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
3218858|NCT01077999|Experimental|Carboplatin+ paclitaxel+ panitumumab+ radiotherapy|Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
3218859|NCT01078012|Active Comparator|Trained counselling|Comparison of outcomes before intervention vs. 2 months after
3218860|NCT01078025||transvaginal hybrid cholecystectomy|
3218861|NCT01078025||laparoscopic cholecystectomy|
3218862|NCT01078038|Active Comparator|Cypher|Sirolimus-eluting stent
3218863|NCT01078038|Active Comparator|Xience V|Everolimus-eluting stent
3218864|NCT01078051|Active Comparator|Optimal medical therapy|optimal medical therapy
3218865|NCT01078051|Active Comparator|drug-eluting stent|Cypher, xience, Endeavor, Taxus
3218866|NCT01078064||Study group|Patients with symptoms suggesting gastroesophageal reflux and referred to perform an impedance study.
3218867|NCT01078129|Active Comparator|behavior therapy - CRT|behavior program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions) by means REHACOM® software
3218868|NCT01078129|Sham Comparator|non-CRT|no intervention
3218869|NCT01078142|Experimental|Single arm|Bendamustin, Rituximab, Temsirolimus
3218870|NCT01078181|Active Comparator|banded gastric bypass|Banded gastric bypass (circular anastomosis 21mm) using the A.M.I. B-Band (Soft Gastric Bypass Band)
3218871|NCT01078181|Active Comparator|non-banded gastric bypass|non-banded gastric bypass (circular anastomosis 21mm)
3218872|NCT01078194||Weight regain / weight loss failure|Weight regain of more than 10 kg from or weight loss of less than 50% EWL 18 months after lap. gastric bypass
3218873|NCT01078272|Experimental|Remote Ischemic Preconditioning (RIPC)|Randomized subjects who are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
3218874|NCT01078272|Placebo Comparator|Sham Remote Ischemic Preconditioning|Patients who prior to stenting have the RIPC blood pressure cuff placed but not inflated for 3 5 minute episodes with 5 minute rest periods.
3218875|NCT01078285||Control|
3218876|NCT01078285||Intervention Arm|
3218877|NCT01078311||HCC patients on Sorafenib|
3218878|NCT01078324||Ischemic colitis|Ischemic colitis, Diverticulosis
3218879|NCT01078428|Active Comparator|Silicone gel|Gel containing silicone gel
3218880|NCT01078428|Placebo Comparator|Vaseline|Gel containing petrolatum gel
3218881|NCT01078480|Experimental|Arm sling treatment|Displaced midshaft fracture of the collar bone treated with an arm sling
3218882|NCT01078480|Experimental|Operation|Displaced midshaft fracture of the collar bone treated with operation using a pre contoured titanium plate and screws.
3218883|NCT01078506||Hong Kong Chinese|Without a history of known intracranial pathologies.
3218884|NCT01078519|No Intervention|Massages baths|doulas, massages and baths
3218885|NCT01078519|Active Comparator|Combined spinal-epidural anesthesia|local anesthetics in low doses with opioids
3218886|NCT01078532|Experimental|SMART PHR|Patients receive the active PHR
3218887|NCT01078532|Other|Passive PHR|Usual PHR Care
3218888|NCT01078597||Patients with early Rheumatoid Arthritis|Patients , aged 18 years or over, diagnosed with Rheumatoid Arthritis, with evidence of disease activity within the last year.
3218889|NCT01078610||Psoriatic arthritis patients|
3218890|NCT01078636||EMCI (only cohort recruiting in this study)|Newly recruited early amnestic Mild Cognitive Impairment patients; estimated enrollment 200
3218891|NCT01078636||LMCI (not recruiting in this study)|Late Mild Cognitive Impairment patients; approximately 400 LMCI participants anticipated to follow from the original ADNI study
3218892|NCT01078636||CN (not recruiting in this study)|Cognitively Normal patients; approximately 200 CN participants anticipated to follow from the original ADNI study
3218893|NCT01078649|Experimental|Debio 1143 (AT-406)|Open label study. All patients participating in the study will receive Debio 1143 (AT-406).
3218894|NCT01078701|Experimental|GHB11L1|Dose levels: 6.0 log10 TCID50/volunteer, 6.5 log10 TCID50/volunteer and 7.0 log10 TCID50/volunteer
3218895|NCT01078701|Placebo Comparator|SPGN buffer|SPGN buffer administration by liquid nasal spray
3218896|NCT01078714|Experimental|Bumetanide|
3218897|NCT01078714|Placebo Comparator|Control|
3218898|NCT01078740||Non-CF subjects|Rectal tissue obtained from study subjects without cystic fibrosis (CF) as part of scheduled colonoscopy/biopsies performed for clinical care
3218899|NCT01078740||CF subjects|"Rectal tissue obtained from study subjects with cystic fibrosis (CF) in one of three ways:~Rectal biopsy as part of scheduled colonoscopy/biopsies performed for clinical care~Sigmoidoscopy/biopsy added onto a scheduled, unrelated procedure or surgery performed under general anesthesia~Sigmoidoscopy/biopsy performed for the sole purpose of obtaining rectal tissue for the current study"
3218900|NCT01078766|Experimental|CIMT+HABIT|"Form of summer camp, for six hours per day for 10 consecutive work days."
3218901|NCT01078779|Experimental|Chloroquine|
3218902|NCT01078779|Placebo Comparator|Placebo|
3218903|NCT01078792||COPD exacerbation|Patients admitted to hospital with COPD exacerbation
3218904|NCT01078818|Experimental|IV trivalent saccharose hydroxide ferrous|
3218905|NCT01078818|Active Comparator|Oral ferrous fumarate|
3218906|NCT01078818|Placebo Comparator|Oral and intravenous Placebo|
3218907|NCT01078831||ARDS / ALI patients|
3218908|NCT01078870|Experimental|A|
3218909|NCT01078870|Experimental|B|
3218910|NCT01078870|Experimental|C|
3218911|NCT01078883||Lung cancer|Patients with primary stage IIIb and IV lung cancer
3218912|NCT01078948|Experimental|Active 2mA tDCS|The stimulator will be used to deliver anodal stimulation to the left prefrontal cortex and cathodal stimulation to the right prefrontal cortex. The placement of the anode is proposed to enhance activity in the left frontal cortex; the cathode aims to reduce activity in the right prefrontal cortex.
3218913|NCT01078948|Sham Comparator|Sham tDCS|The system setup is identical to that of active tDCS; however, the stimulator will be turned off after 30 seconds.
3218914|NCT01078961|Experimental|Dose Escalation|
3218915|NCT01078987|Active Comparator|Group 1|One to three 5-day course of plasma exchange (plasmapheresis)
3218916|NCT01078987|Active Comparator|Group 2|One to three 5-day course of plasma exchange (plasmapheresis)
3218917|NCT01078987|No Intervention|Group 3|No intervention taken
3218918|NCT01078987|Active Comparator|Group 4|One to three 5-day course of plasma exchange (plasmapheresis)
3218919|NCT01079000|Active Comparator|Control - usual care (UC)|Usual care after an ED visit for asthma will include the provision of discharge instructions/plan, and action plan, and verbal instructions for follow-up with their PCP, and a faxed copy of the ED chart to the patient's PCP.
3218920|NCT01079000|Experimental|Opinion leader (OL) guidance to patients' PCPs|In addition to UC, OL guidance will be provided to the patients' PCP. A letter signed by an influential, respected, and local clinical leader (Respirologist) will encourage follow-up within two weeks and provide management suggestions.
3218921|NCT01079000|Experimental|Care manager education to patients|In addition to UC and OL guidance provided to the patients' PCP, care manager self-management education will be provided to patients. A care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged.
3218922|NCT01079013|Experimental|treosulfan|
3218923|NCT01079052|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3218924|NCT01079052|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
3218925|NCT01079065|Experimental|Test|Famotidine Tablets, USP 20 mg of OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3218926|NCT01079065|Active Comparator|Reference|Pepcid® AC Acid reducer famotidine tablets 20 mg of Johnson & Johnson. Merck Consumer Pharmaceutical Co. Fort Washington, PA 19034 USA
3218927|NCT01079078|Experimental|Test|Acetaminophen extended release gelcaps 650 mg of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3218928|NCT01079078|Active Comparator|Reference|Tylenol® Arthritis Pain caplets 650 mg (containing acetaminophen 650 mg)of McNeil Consumer & Specialty Pharmaceuticals, Division of MCNEIL-PPC, Inc. Fort Washington, PA 19034 USA
3218929|NCT01079091|Experimental|ADVOS (Hepa Wash)|"Treatment with the liver support system Hepa Wash"
3218930|NCT01079104|Active Comparator|Control|Standard Medical Therapy
3218931|NCT01079104|Experimental|Hepa Wash|"Treatment with the liver support system Hepa Wash"
3218932|NCT01079117|Active Comparator|Sevre-Long™|slow release oral morphine
3218933|NCT01079117|Active Comparator|Methadone|Methodone
3218934|NCT01079169|Experimental|Cranberry capsule|
3218935|NCT01079169|Placebo Comparator|Placebo capsule|
3218936|NCT01079208|Placebo Comparator|standard starter infant formula|standard starter infant formula
3218937|NCT01079208|Experimental|test starter formula|test infant formula
3218938|NCT01079208|Experimental|test starter formula with synbiotics|starter formula with synbiotics and adapted protein levels
3218939|NCT01079221|Experimental|Knee extensor exercise training|High intensity aerobic knee-extensor exercise training
3218940|NCT01079247|Active Comparator|Liberal|Maintain hemoglobin at 10-11 g/dL
3218941|NCT01079247|Active Comparator|Restrictive|Maintain hemoglobin at 7-8 g/dL
3218942|NCT01079260|Active Comparator|Standard ONS|
3218943|NCT01079260|Experimental|High Energy, Low volume ONS|High energy, low volume ONS
3218944|NCT01079273|Active Comparator|Vaccine|All Subjects enrolled in this study will receive the study vaccine (single-arm)
3218945|NCT01079286|Experimental|nelfinavir and temsirolimus|dose escalation
3218946|NCT01079312|Active Comparator|Propofol infusion|Anaesthesiologist's managed intravenous infusion of propofol 10mg/ml
3218947|NCT01079312|Active Comparator|Patient-controlled sedation|self-administration of propofol and remifentanil mixture during ERCP
3218948|NCT01079325|Experimental|SB-509|
3218949|NCT01079325|Placebo Comparator|Placebo|Saline
3218950|NCT01079338|Experimental|caffeine|
3218951|NCT01079364|Experimental|Insulin glargine + Insulin glulisine|Daily injection of insulin glargine plus one injection of mealtime insulin glulisine at the main meal
3218952|NCT01079364|Active Comparator|Premixed insulin|twice daily premixed insulin (before breakfast and evening meal).
3218953|NCT01079377||Adolescent Surgical Candidates|Adolescents at the Center for Adolescent Bariatric Surgery, Columbia University Medical Center
3218954|NCT01079377||Obese Treatment-Seeking Adolescents|Obese Treatment-Seeking Adolescents, Maxcor Program for Overweight Education and Reduction (POWER) Program
3218955|NCT01079377||Normal-Weight Adolescents|Normal-Weight Adolescents
3218956|NCT01079416||Capsule endoscopy|Study device
3218957|NCT01079416||Esophagogastroduodenoscopy|Gold standard
3218958|NCT01079429||MGUS or SMM|Patients with Monoclonal gammopathy of undetermined significance or smoldering myeloma
3218959|NCT01079442|Active Comparator|Treatment arm: coffee|coffee administration
3218960|NCT01079442|Placebo Comparator|Water arm|The control drink consists of 100 ml warm water
3218961|NCT01079455|Active Comparator|HA|Coxarthrosis
3218962|NCT01079455|Active Comparator|Corticosterone|Coxarthrosis
3218963|NCT01079455|Placebo Comparator|Bupivacaine|Coxarthrosis
3218964|NCT01079468||Total Hip Arthroplasty|
3218965|NCT01079468||Total Hip Resurfacing Arthroplasty|
3218966|NCT01079481|Experimental|taxol plus everolimus|
3218967|NCT01079494|Active Comparator|intervention group|physician-pharmacist teamwork
3218968|NCT01079494|No Intervention|control|physician only team
3218969|NCT01079507||adult acute lymphoblastic leukemia|Patients were diagnosed as adult acute lymphoblastic leukemia.
3218970|NCT01079533|Active Comparator|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
3218971|NCT01079533|Experimental|Minimal Cue and TLC|Participants randomized to the experimental arm will receive a minimal cue after completing the baseline survey. A follow up survey will be sent 9 months after completion of the minimal cue to assess whether the participant received CRCS. If the participant has not had CRCS they will receive a more intensive telephone linked communication intervention. A second follow up will be sent 9 months after the TLC is delivered to assess final screening status.
3218972|NCT01079546||Sq.CC of head and neck TASMC|
3218973|NCT01079546||hadassa Jerusalem|
3218974|NCT01079546||sheba hospital|
3218975|NCT01079546||rambam Haifa|
3218976|NCT01079546||belinson Petah Tikva|
3218977|NCT01079546||Nazeret|
3218978|NCT01079546||soroka beer sheva|
3218979|NCT01079559|Active Comparator|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery. All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
3218980|NCT01079559|Experimental|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
3218981|NCT01079572|Experimental|web-based|The patient will undergo xrays at the closest PACs enabled imaging centre and will login and answer questions online. The surgeon will review the images and patient responses and determine whether the patient needs to be seen more urgently or a per routine.
3218982|NCT01079572|Active Comparator|in-person|Patients will attend their follow-up appointments in-person as per usual
3218983|NCT01079624|Experimental|GIP two doses and GLP-1 one dose|Intervention with infusion of GIP or GLP-1 intravenously
3218984|NCT01079624|Placebo Comparator|Saline infusion|Control
3218985|NCT01079637|Experimental|Midfoot Fusion Bolt|
3218986|NCT01079637|Experimental|Cast treatment|
3218987|NCT01079650||children suffering from abdominal or testicle pain|
3218988|NCT01079676|Experimental|Filgrastim|
3218989|NCT01079676|Active Comparator|Granulokine|
3218990|NCT01079715|Experimental|Propranolol|Oral Propranolol administration is the experimental arm of this study
3218991|NCT01079715|No Intervention|Control|Control arm is treated following the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group
3218993|NCT01079754|Experimental|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
3218994|NCT01079754|Active Comparator|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
3218995|NCT01079767|Other|Temsirolimus|Temsirolimus
3218996|NCT01079780|Experimental|Arm I|Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride over 60-90 minutes on day 1.
3218997|NCT01079780|Experimental|Arm II|Patients receive ramucirumab IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm I.
3218998|NCT01079793|Experimental|ixabepilone|Adjuvant therapy
3218999|NCT01079819|Active Comparator|A1 (BMS-708163)|
3219000|NCT01079819|Placebo Comparator|A2 (Placebo)|
3219001|NCT01079819|Active Comparator|B1 (BMS-708163)|
3219002|NCT01079819|Placebo Comparator|B2 (Placebo)|
3219003|NCT01079845|Experimental|Low-glycemic Load Diet|
3219004|NCT01079845|Active Comparator|Low-fat Diet|
3219005|NCT01079858|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
3219006|NCT01079871|Experimental|FID 114657 (ORB Preserved Ocular Emulsion)|ORB Preserved Ocular Emulsion dosed as needed throughout the day (PRN)
3219007|NCT01079897|Active Comparator|Atopiclair|
3219008|NCT01079897|Experimental|EHK02-01|Ectoine containing cream
3219009|NCT01079910|Experimental|Experimental toothpaste|0.1% isopropylmethylphenol and 1150ppm fluoride
3219010|NCT01079910|Other|Marketed toothpaste|NaF/Silica toothpaste containing 1150ppm fluoride
3219011|NCT01079923|Active Comparator|Single High Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects .
3219012|NCT01079923|Active Comparator|Daily Dose Supplementation|Age 18 to 40 years, non-pregnant, non-lactating, female subjects.
3219013|NCT01080066||Non-Interventional Study|
3219014|NCT01080079|Active Comparator|Group A -Terbinafine HCl|Terbinafine HCl
3219015|NCT01080079|Active Comparator|Group B - Terbinafine HCl|Terbinafine HCl
3219016|NCT01080079|Active Comparator|Group C - Terbinafine HCl|Terbinafine HCl
3219017|NCT01080079|Active Comparator|Group D Terbinafine HCl|Terbinafine HCl
3219018|NCT01080079|Active Comparator|Group E|Terbinafine HCl
3219019|NCT01080079|Placebo Comparator|Group F - Placebo|Placebo application
3219020|NCT01080092|Experimental|breathing technique group|technique as a stress management technique, reinforced by biofeedback
3219021|NCT01080092|Placebo Comparator|no breathing technique|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
3219022|NCT01080105|Experimental|AIM + surveillance|Participants will receive access to the AIM website and calls from a motivational coach for 12 weeks plus an additional year of surveillance and optional coach support.
3219023|NCT01080105|Experimental|AIM intervention|Participants will receive access to the AIM web based intervention and calls from a motivational coach for 12 weeks
3219024|NCT01080105|Active Comparator|Educational website|Participants will be given access to a static website with depression prevention related materials and handouts.
3219025|NCT01080144|Experimental|Critical Flicker Frequency|Critical Flicker Frequency Procedure
3219026|NCT01080157||Volunteers 18+, at risk for diabetes|
3219027|NCT01080170||Anastrazole|Newly diagnosed, non-metastatic, hormone-receptor positive breast cancer patients, who have undergone lumpectomy, have been advised to not require chemotherapy, but will need to undergo radiation therapy and will be initiating therapy with anastrazole.
3219028|NCT01080170||Control group - 2|Healthy controls.
3219029|NCT01080183|Experimental|Feedback form|patients receive feedback regarding their prms in addition to doctor receiving report
3219030|NCT01080183|No Intervention|usual care|patients do not receive feedback form prior to the encounter, clinicians continue to receive patient reported measures prior to the appointment
3219031|NCT01080222|Experimental|Treatment Arm A|Treatment Arm A was discontinued as a result of patients meeting a pre-defined stopping rule related to viral breakthrough during the first four weeks of dosing.
3219032|NCT01080222|Experimental|Treatment Arm B|Treatment Arm B was discontinued as a result of patients meeting a pre-defined stopping rule relating to viral breakthrough.
3219033|NCT01080222|Experimental|Treatment Arm C|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
3219034|NCT01080222|Experimental|Treatment Arm D|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 12 weeks for a total treatment duration of 24 weeks.~Enrollment for this arm is complete. No additional subjects will be recruited."
3219035|NCT01080222|Experimental|Treatment Arm E|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
3219036|NCT01080222|Experimental|Treatment Arm F|"Subjects who meet pre-specified viral response criteria will stop their assigned treatment at 12 weeks.~Subjects who do not meet the pre-specified viral response criteria will receive peginterferon alfa-2a and ribavirin for an additional 24 weeks for a total treatment duration of 36 weeks."
3219037|NCT01080235|Active Comparator|1|Control. Forty-two residency programs randomly assigned and stratified according to size, affiliation, geographic location, and presence of geriatrics fellowship. Twenty-one in the control arm. This group will use PIM as a data collection tool during baseline and follow-up time (i.e. audit of 50-75 charts, survey from 50-75 patients, and one system survey). They will not see the summary results of the data collected; they will not be required to complete a quality improvement plan based on the summary data. Local researchers will collect the data. Individual trainees will not do data collection or audits. At both baseline and follow-up, trainees will complete pre and post test surveys of 1) geriatric and 2) quality improvement knowledge, skills, and attitudes.
3219038|NCT01080235|Other|2|There are 21 residency programs in intervention arm who will 1) use PIM as a data collection tool (local researchers will audit 50-75 charts, survey 50-75 patients, and complete one system survey); 2) Each trainee will audit of up to five patient charts; collect 5 patient surveys; and complete the system survey as a group; 3) Summary data from these data streams will be reviewed by group; then they will design and implement a quality improvement plan; 4) At follow-up, local researchers will re-audit same 50-75 charts, collect surveys from same 50-75 patients, and complete one system survey. At baseline and follow-up, trainees and faculty will complete surveys of geriatric and quality improvement knowledge, skills, and attitudes.
3219039|NCT01080274||positive ergometry|positive ergometry as specified by a cardiologist on site.
3219040|NCT01080274||negative ergometry.|negative ergometry as specified by cardiologist on site.
3219041|NCT01080274||patients with positive stress test|100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
3219042|NCT01080287||Migraineurs with & w/out auras having orthostatic intolerance|Subjects between ages 18 and 65, having ICHD-II classification of migraine with or without aura, having symptoms of orthostatic intolerance
3219043|NCT01080287||Migraineurs with or without auras|Subjects between ages 18 and 65 having ICHD-II classification of migraine with or without auras
3219044|NCT01080313||Patients with head and neck cancer|
3219045|NCT01080339||Physical Activity and Nutrition|Supervised physical activity in the form of novel gaming and exercise equipment several times per week for 12 weeks will be provided in addition to weekly nutrition education sessions.
3219046|NCT01080339||Nutrition Education Only|Children in this group will receive weekly group nutrition sessions, identical to those provided for the Physical Activity + Nutrition group
3219047|NCT01080352|Experimental|Vitamin C treatment|"Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c.~5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20."
3219048|NCT01080365|Experimental|1|Commercial Tablet
3219049|NCT01080365|Experimental|2|Clinical Tablet
3219050|NCT01080378|Other|Higher Birth Weight|3447g to 3879g
3219051|NCT01080378|Other|Lower Birth Weight|2624g to 2964g
3219052|NCT01080378|Other|Normal Birth Weight|2965g to 3446g
3219053|NCT01080404|Experimental|Bariatric surgery (overall study)|A prospective follow-up study is to estimate the prevalence of OSA and associated metabolic abnormalities in Finnish morbidly obese subjects and to evaluate the effects of bariatric surgery on OSA and associated metabolic abnormalities. The study is conducted in seven hospitals in Finland and 300 patients are planned to be recruited in the study.
3219054|NCT01080404|Experimental|Bariatric surgery (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 (15/center) patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
3219055|NCT01080404|Active Comparator|CPAP (randomised substudy)|As a substudy of a larger trial, a randomized study on the effects of bariatric surgery compared to CPAP treatment will be performed in obese (BMI 35-45) patients with OSA. The included 100 patients are randomised to two groups: surgical intervention group (50) and CPAP group (50). Patients in the surgical intervention group undergo standardised surgical treatment (laparoscopic gastric bypass), including general health information, such as avoidance of smoking, alcohol drinking, and importance of healthy nutrition and regular exercise. The CPAP group will be assigned to CPAP treatment and they also receive the general health information.
3219056|NCT01080417|Active Comparator|Cellcept® 250 mg Capsule|
3219057|NCT01080417|Experimental|Mycophenolate Mofetil Capsule 250 mg|
3219058|NCT01080443|Active Comparator|Cellcept® 250 mg Capsule|
3219059|NCT01080443|Experimental|Mycophenolate Mofetil Capsule 250 mg|
3219060|NCT01080456|Active Comparator|Prograf® Capsule 1 mg|
3219061|NCT01080456|Experimental|Tacrolimus Capsule 1 mg|
3219062|NCT01080469|Active Comparator|Prograf® Capsule 1 mg|
3219063|NCT01080469|Experimental|Tacrolimus Capsule 1 mg|
3219064|NCT01080482|Active Comparator|Prograf® Capsule 5 mg|
3219065|NCT01080482|Experimental|Tacrolimus Capsule 5 mg|
3219066|NCT01080495|Other|TEE (transesophageal echcardiography)|all patients get TEE and all parameters (radial strain, fractional shortening and fractional area change) are evaluated
3219067|NCT01080508||10 Asa I & II patients|
3219068|NCT01080521||Observational (cognitive function during chemotherapy)|Patients receive standard chemotherapy. Treatment repeats for 6 courses. Patients complete neurocognitive evaluations (Patient Assessment and Own Functioning scale and HeadMinder Custom Research Tool) and quality-of-life assessments (Hospital Anxiety and Depression Scale, FACT-O, and FACT/GOG-Ntx subscale) at baseline, before the fourth course of chemotherapy, at 3 weeks after the sixth course of chemotherapy, and at 6 months after the sixth course of chemotherapy.
3219069|NCT01080534|Active Comparator|Prograf® Capsule 5 mg|
3219070|NCT01080534|Experimental|Tacrolimus Capsule 5 mg|
3219071|NCT01080547|Active Comparator|Conventional Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
3219072|NCT01080547|Active Comparator|FTMD Treatment （Laparoscopic）|Randomized group of patients receiving laparoscopic colectomy with Fast Track Multi-Displine（FTMD）treatment and XELOX chemotherapy.
3219073|NCT01080547|Active Comparator|Conventional Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with conventional perioperative treatment and mFolfox6 chemotherapy.
3219074|NCT01080547|Active Comparator|FTMD Treatment（Open Surgery）|Randomized group of patients receiving open colectomy with Fast Track Multi-Displine（FTMD） treatment and XELOX chemotherapy.
3219075|NCT01080560|Active Comparator|NEORAL® Capsule 100 mg|
3219076|NCT01080560|Experimental|Cyclosporine 100 mg Capsule|
3219077|NCT01080586|Active Comparator|NEORAL® Capsule 100 mg|
3219078|NCT01080586|Experimental|Cyclosporine 100 mg Capsule|
3219079|NCT01080599|Experimental|conventional pubic approach|
3219080|NCT01080599|Experimental|inguinal approach|
3219081|NCT01080612|Experimental|330 mg pregabalin controlled release: 400 to 500 calories|
3219082|NCT01080612|Experimental|330 mg pregabalin controlled release: 600 to 750 calories|
3219083|NCT01080612|Experimental|330 mg pregabalin controlled release: 800 to 1000 calories|
3219084|NCT01080612|Other|300 mg pregabalin immediate release|
3219085|NCT01080638|Experimental|Abciximab IC bolus|After CAG, For patients with undergoing percutaneous coronary intervention, intracoronary only or intravenous bolus abciximab(0.25mg/kg body weight) administration with intravenous bolus group has subsequent 12-hours continuous infusion at a dose 0.125ug/kg per minute (maximum: 10ug/min)
3219086|NCT01080638|Active Comparator|Abciximab IV bolus and 12hr continuous|
3219087|NCT01080651|Active Comparator|CYP2C19 extensive metabolizer|
3219088|NCT01080651|Active Comparator|CYP2C19 poor metabolizer|
3219089|NCT01080664|Experimental|Regimen 1|Regimen 1: AS703569 administered on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
3219090|NCT01080664|Experimental|Regimen 2|Regimen 2: AS703569 administered on Days 1, 2, 3, 4, 5, 6 of a 21-day cycle
3219091|NCT01080690|Active Comparator|EGD|In this arm EGD will be performed before EUS
3219092|NCT01080690|Active Comparator|EUS|In this arm, EUS will be performed before EGD.
3219093|NCT01080703|Experimental|Lower extremity strengthening|
3219094|NCT01080781||Group 1|normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
3219095|NCT01080781||Group 2|high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)
3219096|NCT01080820|Placebo Comparator|Placebo + Viread|
3219097|NCT01080820|Active Comparator|Viread|
3219098|NCT01080820|Experimental|CMX157 + Viread|
3219099|NCT01080833|Active Comparator|ERCP mechanical simulator practice|Trainees who are offered ERCP Mechanical Simulator (EMS) training in addition to routine training (study group)
3219100|NCT01080833|No Intervention|No ERCP mechanical simulator practice|Trainees undergoing routine ERCP training only (control group).
3219101|NCT01080846|Experimental|600 mcg of sublingual misoprostol|
3219102|NCT01080859||BAS|Patient's receiving BAS
3219103|NCT01080859||EES|Patients receiving EES
3219104|NCT01080872||Titanium-NO coated stent|Patients receiving titanium-nitride-oxide coated stents during the intervention.
3219105|NCT01080872||Everolimus eluting stent|Patients receiving everolimus eluting stents during the intervention.
3219106|NCT01080885|Experimental|Busy Bodies/Better Bites|Healthy Eating/Physical Activity Intervention
3219107|NCT01080885|Active Comparator|Healthy Spots/Safe Tots|Injury Prevention and Safety Intervention
3219108|NCT01080898||DMLA patients|patients > 50 years with suspicion of choroidal neo-vessels complicating age related macular degeneration (DMLA)
3219109|NCT01080911|Experimental|spinal morphine 0.05 mg|spinal morphine 0.05 mg plus 0.5% heavy marcaine 3.5 ml
3219110|NCT01080911|Active Comparator|spinal morphine 0.1 mg|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
3219111|NCT01080924|Experimental|Low frequency ultrasound spectroscopy|Low frequency ultrasound spectroscopy after broncholysis
3219112|NCT01080937||Patient with acute heart failure|Hospitalized patient, whatever the mode of initial admission with acute heart failure
3219113|NCT01080950||fever zinc vit. d|patients with fever but without sepsis
3219114|NCT01080950||sepsis zinc vit. d|patients with sepsis
3219115|NCT01080963|Active Comparator|Daptomycin|
3219116|NCT01080963|Active Comparator|Cefuroxime|
3219117|NCT01080989|Other|health screening and clinical diagnosis and treatment for p|The study project can be divided into two parts: (1) health screening for the community and (2) clinical diagnosis and treatment for patients at National Referral Hospital (NRH) in Solomon islands.
3219118|NCT01081002|Active Comparator|Anesthesia (=A) with lidocaine 10%|3 min before sedation 4 puffs of terbutaline diluted lidocaine solution (Xylocaine ® 10% spray, Astra Zeneca, London, UK) will be sprayed on the pharynx
3219119|NCT01081002|Placebo Comparator|A with diluted gentian root solution|3 min before sedation 4 puffs of highly diluted gentian solution will be sprayed on the pharynx
3219120|NCT01081028||Group One: Patients enrolled between Sep2009 and Nov2011|Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011.
3219121|NCT01081028||Group Two: Patients enrolled between Dec2012 and mid-2016|Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016
3219122|NCT01081054|Other|Ambulatory Treatment|Patients are treated ambulatory with oral antibiotic for 10 days; for the first five days these patients are contacted by telephone daily to progress oral intake.
3219123|NCT01081054|Active Comparator|Hospital treatment|Patients are hospitalized and treated with antibiotic, for the first days by endovenous antibiotic and with diet progression orally.
3219124|NCT01081067||Control|Routine cow milk-based infant formula
3219125|NCT01081067||Investigational|Cow milk-based infant formula containing probiotics
3219126|NCT01081093|Experimental|Biventricular pacing|
3219127|NCT01081106|Other|Low-Level Laser Therapy|
3219128|NCT01081119|Experimental|Project CHOICE|Middle school receives Project CHOICE
3219129|NCT01081119|No Intervention|No Project CHOICE|Middle school does not receive Project CHOICE
3219130|NCT01081158|Experimental|Treatment-naïve 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days."
3219131|NCT01081158|Experimental|Treatment-experienced: 800 mg TID|"Period 1: SCH 900518 (800 mg TID) or placebo for 7 days~Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days"
3219132|NCT01081158|Experimental|Treatment-naïve: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
3219133|NCT01081158|Experimental|Treatment-experienced: 400 mg + RTV BID|"Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.~Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days."
3219134|NCT01081184||primary Sjögren syndrome|
3219135|NCT01081184||Healthy volunteers|
3219136|NCT01081223|Experimental|TVI-Brain-1|Biological/Vaccine: Cancer vaccine plus immune adjuvant, plus activated white blood cells
3219137|NCT01081236||Compensated liver cirrhosis|
3219138|NCT01081236||Decompensated liver cirrhosis|
3219139|NCT01081275|Active Comparator|CI Therapy|CI therapy involves repetitive practice with the more-affected hand on typical daily living activities (such as stacking objects, pouring, moving objects) for 3.5 hours per day, along with physical restraint of the better hand to keep it from assisting, and home practice exercises.
3219140|NCT01081275|Active Comparator|CAM treatments|CAM treatments are holistic physical treatments designed to work on the entire body to improve quality of life and overall health. This study will use yoga, relaxation exercises, aquatherapy (pool therapy), and massage.
3219141|NCT01081288|Active Comparator|Women aged 47-49 invited for breast screening|
3219142|NCT01081288|Active Comparator|Women aged 71-73 invited for breast screening|
3219143|NCT01081314|Experimental|Standard DBT + PTSD Protocol|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team) plus a modified version of Prolonged Exposure therapy for PTSD.
3219144|NCT01081314|Active Comparator|Standard DBT|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
3219145|NCT01081327||Patients receiving Warfarin|
3219146|NCT01081340|Experimental|Social network building intervention|Healthy lifestyle intervention focused on building reciprocal social ties between the intervention group members
3219147|NCT01081340|Active Comparator|Home visit|Home visits focused on preventable infant injuries
3219148|NCT01081353|Experimental|Arm 1|
3219149|NCT01081353|Active Comparator|Arm 2|
3219150|NCT01081353|Active Comparator|Arm 3|
3219151|NCT01081353|Active Comparator|Arm 4|
3219152|NCT01081379||pre-conception immunity|pre-conception immunity- pregnant women with CMV seropositive
3219153|NCT01081379||primary CMV infection|primary CMV infection- pregnant women with primary CMV infection (defined as CMV IgG sero-conversion, the presence of low avidity IgG antibodies or the presence of IgM with no previous IgG antibodies).
3219154|NCT01081392|Experimental|LPS sequence 1|Nebulizers A then B then C
3219155|NCT01081392|Experimental|LPS sequence 2|Nebulizers B then C then A
3219156|NCT01081392|Experimental|LPS sequence 3|Nebulizers C then A then B
3219157|NCT01081392|Experimental|LPS sequence 4|Nebulizers A then C then B
3219158|NCT01081392|Experimental|LPS sequence 5|Nebulizers C then B then A
3219159|NCT01081392|Experimental|LPS sequence 6|Nebulizers B then A then C
3219160|NCT01081405|Experimental|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
3219161|NCT01081418|Experimental|Standard care|Standard care comprised a treatment network consisting of open and closed inpatient wards, day-clinics, an outpatient centre, and eight private psychiatrists. Each patient was treated by a private psychiatrist or by a psychiatrist in the outpatient centre. Home visits were possible, but office visits were the general rule. Patients were allowed to use all treatment offers in the outpatient centre. Outside office hours, patients could refer themselves to the psychiatric hospital. Psychosocial treatments as supportive therapy, psychoeducation, psychotherapy, and family intervention were provided infrequently and in a less intensive and unsystematic way, and only in the minority of cases. This 'standard of care' definition is in accordance with other studies.
3219162|NCT01081431|Experimental|Lenalidomide|
3219163|NCT01081444|Active Comparator|1|Active rTMS
3219164|NCT01081444|Placebo Comparator|2|sham rTMS
3219165|NCT01081457|Active Comparator|ON|Stimulator switched ON
3219166|NCT01081457|Sham Comparator|OFF|Stimulator switched OFF
3219167|NCT01081483|Active Comparator|ABT-072 Tablet|ABT-072 50 mg Tablet, every day (QD), single ascending doses, groups 1-3
3219168|NCT01081483|Placebo Comparator|Placebo|Placebo Tablet, QD, single doses, groups 1-3
3219169|NCT01081535|Experimental|ketorolac|
3219170|NCT01081535|Experimental|fentanyl|
3219171|NCT01081548|Experimental|Generic|
3219172|NCT01081548|Active Comparator|Lipitor|
3219173|NCT01081561|Active Comparator|Cross-linking|Corneal collagen cross-linking with riboflavin and UVA light
3219174|NCT01081561|Active Comparator|Cross-linking plus INTACS|Corneal collagen cross-linking with riboflavin and UVA light plus INTACS
3219175|NCT01081574|Experimental|10 mg Bilastine once daily for 7 days|10 mg Bilastine dispersible oral tablet
3219176|NCT01081587|Experimental|Nutritional Support Team|
3219177|NCT01081587|Active Comparator|Usual care|
3219178|NCT01081600||AUY922|Patients with HER2 positive breast cancer which has become trastuzumab resistent.
3219179|NCT01081613||AUY922|Patients with estrogen receptor (ER) positive, hormone therapy refractory breast cancer.
3219180|NCT01081639|Experimental|Gonal-f|
3219181|NCT01081639|Active Comparator|Puregon|
3219182|NCT01081652|Experimental|Crinone 8% group|Female subjects undergoing IVF/ET treated with Crinone 8% intravaginally
3219183|NCT01081652|Active Comparator|Intramuscular progesterone group|Female subjects undergoing IVF/ET treated with 60 mg progesterone intramuscularly once daily
3219184|NCT01081691|Experimental|001|CNTO 5825 0.1 mg/kg single dose Intravenously (IV) or matching placebo
3219185|NCT01081691|Experimental|002|CNTO 5825 0.3 mg/kg single dose IV or matching placebo
3219186|NCT01081691|Experimental|003|CNTO 5825 1 mg/kg single dose IV or matching placebo
3219187|NCT01081691|Experimental|004|CNTO 5825 3 mg/kg single dose IV or matching placebo
3219188|NCT01081691|Experimental|005|CNTO 5825 10 mg/kg single dose IV or matching placebo
3219189|NCT01081691|Experimental|006|CNTO 5825 For atopic patient:10 mg/kg single IV dose or matching placebo
3219190|NCT01081691|Experimental|007|CNTO 5825 For atopic patient: 3 mg/kg single dose SC or matching placebo
3219191|NCT01081704|Experimental|001|ustekinumab Single dose of 45 mg subcutaneous injection
3219192|NCT01081704|Experimental|002|ustekinumab Single dose of 90 mg subcutaneous injection
3219193|NCT01081717||001|golimumab as prescribed
3219194|NCT01081717||002|anti-TNF biologics as prescribed
3219195|NCT01081717||003|non-anti-TNF biologics as prescribed
3219196|NCT01081717||004|systemic non-biological treatments as prescribed
3219197|NCT01081717||005|general population non-treated cohort
3219198|NCT01081730||001|ustekinumab as prescribed
3219199|NCT01081730||002|anti-TNF biologics as prescribed
3219200|NCT01081730||003|non-anti-TNF biologics as prescribed
3219201|NCT01081730||004|systemic non-biological treatments as prescribed
3219202|NCT01081730||005|general population non-treated cohort
3219203|NCT01081743|Experimental|Social worker|
3219204|NCT01081743|No Intervention|Control|Control group is followed-up as usually (usual care)
3219205|NCT01081756|Experimental|Subjects treated with r-hCG|Subjects treated with r-hCG
3219206|NCT01081756|Active Comparator|Subjects treated with urinary hCG|Subjects treated with urinary hCG
3219207|NCT01081782|Experimental|E1|
3219208|NCT01081782|Experimental|E2|
3219209|NCT01081782|Experimental|E3|
3219210|NCT01081782|Placebo Comparator|P|
3219211|NCT01081808|Other|Armed Activated T Cells|Activated T Cells (ATC) armed with the bispecific antibody OKT3 x Cetuximab (EGFRBi). ATC will be expanded for 14 days from a leukapheresis product, armed with EGFRBi, cryopreserved and infused in 8 divided doses. Patients will also receive low dose subcutaneous IL-2(3000,000 IU/m2/day) and GM-CSF (250ug/m2 twice per week)
3219212|NCT01081821|Experimental|001|single dose NJ-39758979/ matching placebo Single oral dose of JNJ-39758979 (either 50 100 300 600mg) or Placebo
3219213|NCT01081821|Experimental|002|multi-dose JNJ-39758979 /matching placebo JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
3219214|NCT01081847|Active Comparator|Group A|Montanide ISA 720 Dose by peptide 50ug
3219215|NCT01081847|Active Comparator|Group B|Montanide ISA 51 Dose by peptide 50ug
3219216|NCT01081847|Active Comparator|Group C|Montanide ISA 720 Dose by peptide 100ug
3219217|NCT01081847|Active Comparator|Group D|Montanide ISA 51 Dose by peptide 100ug
3219218|NCT01081847|Placebo Comparator|Group E|Control Group. no peptide. Isotonic saline solution
3219219|NCT01081860||Carpal tunnel syndrome|Patients with carpal tunnel syndrome
3219220|NCT01081860||Trigger finger|Patients with trigger fingers
3219221|NCT01081860||Dupuytren Contracture|Patients with Dupuytren
3219222|NCT01081860||Trauma to the hand|Patients with an acute trauma to the hand
3219223|NCT01081899|Experimental|The LCP-I Program.|The Italian version of the Liverpool Care Pathways version 11 for hospital) Programme.
3219224|NCT01081899|No Intervention|standard healthcare practices|No specific interventions are planned in the control wards.
3219225|NCT01081925||Congestive heart failure|Patients suffering from sudden worsening of congestive heart failure
3219226|NCT01081938|Experimental|1|Insulin Glargine + Insulin Glulisine
3219227|NCT01081938|Active Comparator|2|Insulin Glulisine
3219228|NCT01081964|Active Comparator|Levofloxacin 500mg|Levofloxacin 500mg once daily for 7 days
3219229|NCT01081964|Experimental|Zabofloxacin 5 days|Zabofloxacin 400mg for 5 days
3219230|NCT01081964|Experimental|Zabofloxacin 3 days|Zabofloxacin 400mg for 3 days
3219231|NCT01081977|Active Comparator|Early Cord Clamping Group|Early Cord Clamping Group (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate).
3219232|NCT01081977|Experimental|Delayed Cord Clapming Group|Delayed Umbilical Cord Clamping Group (Clamping of Umbilical Cord within 2 minutes of shoulder delivery of neonate).
3219233|NCT01081990|Placebo Comparator|Placebo Pill|
3219234|NCT01081990|Experimental|Flexeril|
3219235|NCT01082003|Other|Permanent Implant|Trental and Vitamin E for 6 months
3219236|NCT01082003|Other|Tissue Expander|Trental and Vitamin E for 6 months
3219237|NCT01082016|No Intervention|Control|Monitor sleep in ICU without attempts at promotion
3219238|NCT01082016|Experimental|Sleep promotion|Measure sleep in ICU with sleep promotion program in effect
3219239|NCT01082029|Experimental|Lansoprazole|
3219240|NCT01082029|Placebo Comparator|Placebo|
3219241|NCT01082042||Standard Care|Individuals who attended the local falls group
3219242|NCT01082042||Intervention group|Individuals who undertook the 12 week exercise (Nintendo WiiFit) intervention
3219243|NCT01082055||Currently receiving antiarrythmic drugs|
3219244|NCT01082068|Experimental|Arm 1|XL147 (SAR245408) + letrozole
3219245|NCT01082068|Experimental|Arm 2|XL765 + letrozole
3219246|NCT01082094|Experimental|ACRX-100|"Cohort 1 = Low dose~Cohort 2 = Middle dose~Cohort 3 = High Dose"
3219247|NCT01082107|Other|Solar disinfection of drinking water|
3219248|NCT01082120|Experimental|1|AZD1656 day 1-5, AZD1656 + Pioglitazone day 6-10, Pioglitazone day 11-15
3219249|NCT01082120|Experimental|2|Pioglitazone day 1-5, AZD1656 + Pioglitazone day 6-10, AZD1656 day 11-15
3219250|NCT01082146|Experimental|Lurasidone|LURASIDONE 40mg
3219251|NCT01082172|Experimental|Thoracic Stent Graft|Thoracic Stent Graft implanted device
3219252|NCT01082185|Other|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
3219253|NCT01082224|Experimental|Waitlisted with HCC-Exception Points|Participants undergo CT and MRI every 90 days for the trial with iodinated contrast dye and motexafin gadolinium, during liver transplant wait listing. Possible Eovist-enhanced MRI substudy participation
3219254|NCT01082237|Active Comparator|escitalopram|All subjects will receive escitalopram (ESC), brand name Lexapro (Forest Laboratories, Inc., New York) throughout the study. Dosing will start at 5 mg/d, be titrated to 10 mg after 4 days, and continue at 10 mg/d thereafter; an additional dose titration to 20 mg will be pursued at week 8 for those not significantly better (<50% improvement on IDS-30 at week 8 visit) and as tolerated.
3219255|NCT01082250|Other|Reference Formulation|Dosed 12.5% drugload 3X40mg
3219256|NCT01082250|Other|Test Formulation|25% Drugload 1X120mg
3219257|NCT01082263|Other|Midazolam/Lurasidone|Schizophrenia patient
3219258|NCT01082276|Other|Rifampin/Lurasidone|Healthy Normal Subject
3219259|NCT01082302|Active Comparator|oral intake of green tea beverage|Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
3219260|NCT01082302|Experimental|Polyphenon E 15% ointment|3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
3219261|NCT01082341|Experimental|Fy(+)|14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites
3219262|NCT01082341|Active Comparator|Fy(+) control|Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites.
3219263|NCT01082341|Active Comparator|Fy(-)|Six Fy(-) volunteers will be exposed to infective mosquito bites.
3219264|NCT01082393|Active Comparator|topical tacrolimus|
3219265|NCT01082393|Active Comparator|topical pimecrolimus|
3219266|NCT01082393|Active Comparator|local steroids|
3219267|NCT01082393|Placebo Comparator|cold cream|
3219268|NCT01082406|Experimental|Trial part 1|
3219269|NCT01082406|Experimental|Trial part 2|
3219270|NCT01082419|Other|Group A|healthy volunteers
3219271|NCT01082419|Other|Group B|patients with supposed disease free liver (normal hepatic and pancreatic biochemistry)
3219272|NCT01082419|Other|Group D|patients with cirrhosis
3219273|NCT01082419|Other|Group E|patients with liver tumour and surgery indication
3219274|NCT01082419|Other|Group F|patients with reversible liver diseases and with acute left cardiac insufficiency
3219275|NCT01082419|Other|Group C|patients with non cirrhotic hepatopathy
3219276|NCT01082419|Other|Group G|patients with reversible liver diseases and with biliary cholestasis
3219277|NCT01082445|Experimental|N-acetylcysteine|50 patients that receive 600 mg of acetylcysteine for 3 times a day.
3219278|NCT01082445|Placebo Comparator|Placebo|50 subjects taking placebo pills 3 times a day
3219279|NCT01082471|Experimental|M6G|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
3219280|NCT01082471|Active Comparator|Morphine|An initial slow bolus injection up to 60 min prior to end of surgery. If required, two additional slow bolus injections to achieve baseline pain relief. Continuing on PCA for a minimum of 24 hours.
3219281|NCT01082484|Experimental|Treprostinil|Treprostinil iontophoresis (250, 25 and 2.5 microM)
3219282|NCT01082484|Experimental|Iloprost|Iloprost iontophoresis (200, 20 and 2 microM)
3219283|NCT01082484|Placebo Comparator|NaCl 0.9%|
3219284|NCT01082497|Experimental|Mindfulness|
3219285|NCT01082497|Active Comparator|Education|8 - weekly workshops on affect consciousness for all staff
3219286|NCT01082510|Active Comparator|BCG maintenance therapy|
3219287|NCT01082510|Experimental|UFT maintenance therapy|
3219288|NCT01082523|Active Comparator|Text message reminders|
3219289|NCT01082523|No Intervention|Control|
3219290|NCT01082536||One ventricle pts, bypass, perfusion|1. Single ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
3219291|NCT01082536||One ventricle pts, bypass only|Single ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion
3219292|NCT01082536||One ventricle pts, no bypass/perfusion|Single ventricle patients who undergo surgery, but do not undergo cardiopulmonary bypass or selective cerebral perfusion.
3219293|NCT01082536||Two ventricle pts, bypass, perfusion|Two ventricle patients who undergo cardiopulmonary bypass and selective cerebral perfusion.
3219294|NCT01082536||Two ventricle pts, bypass only|Two ventricle patients who undergo cardiopulmonary bypass but not selective cerebral perfusion.
3219295|NCT01082536||Two ventricle pts, no bypass/perfusion|Two ventricle patients who do not undergo cardiopulmonary bypass or selective cerebral perfusion.
3219296|NCT01082549|Active Comparator|gemcitabine/carboplatin|
3219297|NCT01082549|Experimental|gemcitabine/carboplatin plus Iniparib|
3219298|NCT01082562|Experimental|Arm 1 - BMS-844421|
3219299|NCT01082562|Placebo Comparator|Arm 2 - 0.9% sodium chloride injection solution|
3219300|NCT01082562|Experimental|Arm 3 - BMS-844421|
3219301|NCT01082562|Placebo Comparator|Arm 4 - 0.9% sodium chloride injection solution|
3219302|NCT01082562|Experimental|Arm 5 - BMS-844421|
3219303|NCT01082562|Placebo Comparator|Arm 6 - 0.9% sodium chloride injection solution|
3219304|NCT01082562|Experimental|Arm 7 - BMS-844421|
3219305|NCT01082562|Placebo Comparator|Arm 8 - 0.9% sodium chloride injection solution|
3219306|NCT01082562|Experimental|Arm 9 - BMS-844421|
3219307|NCT01082562|Placebo Comparator|Arm 10 - 0.9% sodium chloride injection solution|
3219308|NCT01082562|Experimental|Arm 11 - BMS-844421|
3219309|NCT01082562|Placebo Comparator|Arm 12 - 0.9% sodium chloride injection solution|
3219310|NCT01082562|Experimental|Arm 13 - BMS-844421|
3219311|NCT01082562|Placebo Comparator|Arm 14 - 0.9% sodium chloride injection solution|
3219312|NCT01082562|Experimental|Arm 15 - BMS-844421|
3219313|NCT01082562|Placebo Comparator|Arm 16 - 0.9% sodium chloride injection solution|
3219314|NCT01082601||Optimal Medical therapy|Subjects with Class I,IIor III congestive heart failure on optimal medical therapy. Planned catheter ablation for paroxysmal or persistent atrial fibrillation. Paroxysmal AF defined as recurrent AF(2 or more episodes in one month) that terminate within seven days. Persistent AF defined as sustained beyond seven days, or lasting less than seven days but requiring pharmacologic or electrical cardioversion.
3219315|NCT01082627|Experimental|Somatostatin+common daily practice|
3219316|NCT01082627|Placebo Comparator|common daily practice|
3219317|NCT01082653|Experimental|Safety|infusion of autologous bone marrow-derived stem cells
3219318|NCT01082666|Experimental|Continuous control|Continuous control of cuff pressure using a pneumatic device
3219319|NCT01082666|Active Comparator|Manual control|Manual control of cuff pressure is a routine practice in ICU patients
3219320|NCT01082679|Other|methadone via specialty care|
3219321|NCT01082679|Other|Suboxone via specialty care|
3219322|NCT01082679|Other|Suboxone via primary care|
3219323|NCT01082692|Experimental|3mg DNA/dose|Subjects will receive a 4 dose series of PENNVAX-B containing 3mg of DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8 and Week 16.
3219324|NCT01082705|Active Comparator|Artemether-lumefantrine|Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
3219325|NCT01082705|Experimental|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine administered once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
3219326|NCT01082718|Experimental|Pregnant women|Pregnant women with P. falciparum malaria
3219327|NCT01082718|Active Comparator|Non pregnant women|Non pregnant women with P. falciparum malaria
3219328|NCT01082731|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
3219329|NCT01082731|Active Comparator|Artemether- Lumefantrine|Artemether-Lumefantrine: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
3219330|NCT01082744|Active Comparator|Continuous paravertebral block with ropivacaine|
3219331|NCT01082744|Experimental|Continuous paravertebral block with ropivacaine and sufentanil|
3219332|NCT01082770|Active Comparator|TEGO|TEGO needle free access devices will be used in patients randomised to this arm
3219333|NCT01082770|Placebo Comparator|Control|Patients will continue to receive current standard of practice, ie a 'bung' cap at the end of the hemodialysis line
3219334|NCT01082783||patients with acute media infarct|
3219335|NCT01082783||controls with cardiovascular risks|
3219336|NCT01082796|Other|CYP2C19 EMs group|cyp2c19*1/*1 carriers
3219337|NCT01082796|Other|CYP2C19 PMs group|cyp2c19*2/*2 or *2/*3
3219338|NCT01082809|No Intervention|Sunitinib|Sunitinib, 37.5 mg orally once daily continuously, comprising a 4-week cycle
3219339|NCT01082822|Sham Comparator|standard of care|In the first step, the patient was periodontally treated until the inflammation was eliminated through control of bacterial biofilm and oral hygiene for about 6 months. Then the rigid fixed appliances were placed on the diseased teeth, reverse beveled open-flap surgery was performed in the buccal and palatal maxillary sides of the periodontitis-caught teeth to allow granulation tissue debridement and proper root preparation. The roots were completely scaled, and 17%EDTA was applied for 2 minutes to demineralize the root surfaces and bone wall defects, the flap was sutured.
3219340|NCT01082822|Experimental|PDLSC cell sheet transplantion|Periodontal ligament stem cell derived cell sheet or pellet with carrier such as Bioss was implanted into periodontal defect area at post surgical treatment.
3219341|NCT01082822|Experimental|the bio-ss implantation|implantation of Bioss at post surgical treatment
3219342|NCT01082835||the group of Jiangzhuo Qinggan prescription|
3219343|NCT01082835||the group of irbesartan|
3219344|NCT01082848|Experimental|aripiprazole|
3219345|NCT01082848|Placebo Comparator|placebo|
3219346|NCT01082861|Experimental|HPV&HBV vaccin|HPV&HBV vaccin
3219347|NCT01082861|Experimental|HPV vaccination|HPV vaccination
3219348|NCT01082861|Experimental|HBV vaccination|HBV vaccination
3219349|NCT01082887|Experimental|TIL-Ad-INFg|
3219350|NCT01082900|Experimental|Prophylactic CPAP intervention|Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the DR via T piece (Neopuff)
3219351|NCT01082900|Active Comparator|No Intervention|Provision of standard care in the Delivery Room
3219352|NCT01082913|Experimental|Sacral Surface Electrical (SSE)|
3219353|NCT01082913|No Intervention|control|
3219354|NCT01082926|Experimental|Arm I|Patients receive intratumoral GRm13Z40-2 therapeutic allogeneic lymphocytes over 10 minutes on days 1 and 3 and intratumoral aldesleukin over 3 hours on days 2-5 (days 1-5 in week 2). Treatment repeats every week for 2 courses in the absence of disease progression or unacceptable toxicity.
3219355|NCT01082978|Experimental|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
3219356|NCT01082978|Experimental|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
3219357|NCT01082978|No Intervention|Usual standard of care|Patients randomized to this arm of the trial will not be given a Portable Health File. This arm is the concurrent control comparator arm.
3219358|NCT01082991|Other|prevention|
3219359|NCT01083004|Active Comparator|Indocyanine green arm|
3219360|NCT01083004|Active Comparator|Brilliant blue|
3219361|NCT01083017||chlorthalidone|
3219362|NCT01083017||motivational invervention|motivational interview(s) vs. repeated calls vs. no particular intervention
3219363|NCT01083017||standardized anti-hypertensive treatment|
3219364|NCT01083030|Placebo Comparator|Conventional PTA|Angioplasty of SFA with uncoated balloon catheters
3219365|NCT01083030|Active Comparator|Drug coated balloon|Angioplasty of SFA with paclitaxel-coated balloon catheters
3219366|NCT01083043||Type 2 Diabetes Mellitus|
3219367|NCT01083056||Epimacular Gliosis Without Macular Hole|
3219368|NCT01083056||Epimacular Gliosis With Macular Hole|
3219369|NCT01083069||COOL|Patients after therapy with mild hypothermia
3219370|NCT01083069||UnCool|Patients without therapy with mild hypothermia due to non-operational cooling-devices
3219371|NCT01083095|Active Comparator|3 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
3219372|NCT01083095|Active Comparator|6 +/- 1 bite|Volunteers were exposed to mosquito biting for 10 min
3219373|NCT01083095|Active Comparator|9 +/- 1 bite|Volunteers were exposed to mosquito biting for 15 min
3219374|NCT01083108|Active Comparator|Non-surgical Arm|Low-calorie Diet
3219375|NCT01083108|Experimental|Surgical Arm|Roux-en-Y Gastric Bypass
3219376|NCT01083134||percentage of stenosis|
3219377|NCT01083147||Dry AMD|subjects diagnosed as intermediate AMD in at least one eye
3219378|NCT01083212|Experimental|1|Gemfibrozil day 1-5 + AZD1656 day 4, 1 week without, Placebo day 1-5 + AZD1656 day 4
3219379|NCT01083212|Experimental|2|Placebo day 1-5 + AZD1656 day 4, 1 week without, Gemfibrozil day 1-5 + AZD1656 day 4
3219380|NCT01083225|Experimental|Client feedback|
3219381|NCT01083225|Active Comparator|Treatment as usual|
3219382|NCT01083238|Experimental|1|AZD5069 following a 10-hour fast
3219383|NCT01083238|Experimental|2|AZD5069 30 minutes after the start of a high fat meal
3219384|NCT01083251|Experimental|Peg + Vitamin D|Treatment arm with vitamin D will be treated first with vitamin D supplement for 3 months before the initiation of antiviral therapy. Vitamin D levels will be measures at baseline and three months after. The serum vitamin D-25-OH levels should be > 32 ng/ml before the initiation of antiviral treatment). HBV DNA levels will be also measure at baseline and after 3 months of mono therapy with vitamin D
3219385|NCT01083251|Active Comparator|Peginterferon|
3219386|NCT01083251|Active Comparator|Sebivo|Nucleotide Analog Telbivudine 600 mg daily
3219387|NCT01083251|Active Comparator|entecavir + vitamin d|baraclude 1 mg x1/ day + vitamin d
3219388|NCT01083264|Experimental|Arm 1|
3219389|NCT01083264|Experimental|Arm 2|
3219390|NCT01083264|Experimental|Arm 3|
3219391|NCT01083277|Experimental|variable ventilation|A novel means of conducting mechanical ventilation that involves an approximately 40% variation in tidal volume around a set mean tidal volume
3219392|NCT01083277|Other|conventional ventilation|This is the control arm of the study, in which tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
3219393|NCT01083290|Experimental|Order of strenghts; 25 mg, 50 mg, 100 mg|
3219394|NCT01083290|Experimental|Order of strenghts; 50 mg, 100 mg, 25 mg|
3219395|NCT01083290|Experimental|Order of strenghts; 100 mg, 25 mg, 50 mg|
3219396|NCT01083303|Experimental|weaning at 1500 g|weaning infants from an incubator at 1500 g
3219397|NCT01083303|Active Comparator|weaning at 1600 g|weaning infants from an incubator at 1600 g
3219398|NCT01083329|Placebo Comparator|placebo|for 16 weeks
3219399|NCT01083329|Active Comparator|nicotinic acid|"for 16 weeks :~week 1 = 375 mg per day,~week 2 = 500 mg per day,~week 3 = 750 mg per day,~week 4 = 1000 mg per day,~week 5 = 1500 mg per day,~weeks 6 to 16 = 2000 mg per day."
3219400|NCT01083355||Mechanical ventilation|Critical care patients
3219401|NCT01083381|Active Comparator|treatment group|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months. MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months.
3219402|NCT01083381|Placebo Comparator|Control group|Receives the same dosage of Risperidone. Placebo is given to this group in same form and appearance as MS14 in the other arm of the study.
3219403|NCT01083394|Active Comparator|conventional PTA|In stent restenosis is treated with PTA using a conventional balloon.
3219404|NCT01083394|Experimental|PTA with PEB|In stent restenosis is treated with PTA using a paclitaxel eluting balloon.
3219405|NCT01083407|Experimental|0.12% Chlorhexidie Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
3219406|NCT01083407|Placebo Comparator|Toothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
3219407|NCT01083420|Active Comparator|Dexamethasone|Dexamethasone 0.01% mouthwash
3219408|NCT01083420|Experimental|Minocycline|Minocycline 0.2% mouthwash
3219409|NCT01083433|No Intervention|Standard Diabetes Care|Patients will attend diabetes clinic as usual, once every 3 months.
3219410|NCT01083433|Experimental|Intensive Diabetes Clinic|Patients will attend diabetes clinic on a monthly basis for 4 months in a row. Each patient will have a 30 minute visit with a physician, 30 minutes dedicated to diabetes education, and 45 minutes with a child psychologist.
3219411|NCT01083433|Experimental|Intensive Diabetes Clinic plus CGM|Patients in this group will include all procedures as listed for group 2 (intensive diabetes clinic) in addition to wearing a continuous glucose monitor for 3-5 days each month. Patients will also have an additional 30 minutes with a psychology graduate student dedicated to adherence with the CGM.
3219412|NCT01083446|Active Comparator|A|Nutritional intervention, standard Israeli breakfast
3219413|NCT01083446|Active Comparator|B|Nutritional Intervention, fast
3219414|NCT01083459||PCV13 immunized|Children who receive the 13-valent pneumococcal conjugate vaccine
3219415|NCT01083459||PCV13 unimmunized|PCV13 unimmunized Household members of PCV13 immunized children
3219416|NCT01083498|Experimental|Ablative fractional laser|"In each patient, a square test region of 5-10 cm2 was treated with ablative fractional laser in three sessions in combination with intermittent topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream) to prevent laser-induced postinflammatory hyperpigmentation.~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
3219417|NCT01083498|No Intervention|Control|"In each patient, a square test region of 5-10 cm2 was treated with topical bleaching with triple topical therapy (hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% cream)alone (to allow comparison of the regions).~Note: this study had a split-lesion design. In each patient, two test regions were randomized to receive either ablative fractional laser therapy or no treatment."
3219418|NCT01083511||Symptomatic|Individuals with signs and symptoms of a respiratory tract infection where it is suspected that such signs and symptoms are caused by a respiratory virus infection.
3219419|NCT01083524|Experimental|Group 1|Dichloroacetate Sodium 3.0 mg/kg, BID
3219420|NCT01083524|Experimental|Group 2|Dichloroacetate Sodium 6.25 mg/kg, BID
3219421|NCT01083524|Experimental|Group 3|Dichloroacetate Sodium 12.5 mg po bid
3219422|NCT01083537|Experimental|Cisplatin|"Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
3219423|NCT01083537|Experimental|Paclitaxel|"Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
3219424|NCT01083550|Experimental|DA intervention|Decision aid exposure + usual care
3219425|NCT01083550|No Intervention|Control|Usual care
3219426|NCT01083563||RA inadequate response to methotrexate|Individuals with rheumatoid arthritis who have had an inadequate response to methotrexate and will be starting on an anti-TNF agent.
3219427|NCT01083563||RA inadequate response to anti-TNF.|Individuals with rheumatoid arthritis who have had an inadequate response to an anti-TNF and will be be given a rituximab infusion.
3219428|NCT01083589|Experimental|Imatinib Mesylate + Docetaxel|Imatinib Mesylate (Gleevec) Oral 400 mg daily + Docetaxel (Taxotere) 60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
3219429|NCT01083615|Experimental|Custirsen|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of custirsen will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly custirsen infusions (640 mg total dose) on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
3219430|NCT01083615|Placebo Comparator|Placebo|"Study treatment starts with a Loading Dose Period (1 week) during which 3 infusions of placebo (isotonic, 0.9% sodium chloride) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel (75 mg/m2 total dose) or cabazitaxel (25 mg/m2 total dose) on a 21-day cycle with weekly placebo infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.~Participants will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol."
3219431|NCT01083719|Experimental|FDG-PET|A comparison of FDG-PET versus MRI based target volume delineation in glioblastoma and the role of FDG-PET/CT in the alteration of MRI based target volumes.
3219432|NCT01083745||IVF patients - 1|Poor responders
3219433|NCT01083745||IVF patients - 2|Good responders
3219434|NCT01083784|Experimental|Prophylactic group|the group that used prophylactic anticonvulsants (valproate, clonazepam)
3219435|NCT01083784|No Intervention|Control group|control group
3219436|NCT01083797|Other|dexmedetomidine, chloral hydrate|sedation with dexmedetomidine or chloral hydrate on separate occasions in the same patients
3219437|NCT01083823|Active Comparator|Self-reported mood swings|Participants who self-identify as experiencing severe mood swings that interfere with life.
3219438|NCT01083823|Active Comparator|Healthy|Participants who self-identify as not experiencing mood swings in the past or at present and who deny past / present problems with substance use.
3219439|NCT01083862|Experimental|Educational Intervention - Video & Text|"Educational Intervention - Video & Text describing Living with Coronary Artery Disease."
3219440|NCT01083862|Active Comparator|Educational Intervention - Text Only|"Educational Intervention - Text Only describing Living with Coronary Artery Disease."
3219441|NCT01083875|Experimental|0.5% amlexanox oral rinse|Patients treated with an oral rinse containing the active 0.5% amlexanox
3219442|NCT01083875|Placebo Comparator|Vehicle|Patients treated with an oral rinse containing no active
3219443|NCT01083888|Experimental|1 group|Participants received a single oral dose of ASP1517 on Days 1 and 8
3219444|NCT01083914||OPCAB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3219445|NCT01083914||CPB|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3219446|NCT01083914||MECC|Those who have CABG surgery off pump Those who have CABG surgery using conventional cardiopulmonary bypass Those who have CABG surgery using a minimal extracorporeal circulation system
3219447|NCT01083927|Active Comparator|Rotational Narrow Strip Graft|Technique of surgery
3219448|NCT01083927|Active Comparator|Full Graft|Surgical technique
3219449|NCT01083940|Experimental|Reminders to providers|
3219450|NCT01083940|No Intervention|usual care|
3219451|NCT01083953|Experimental|Sevoflurane|1 arm will receive sevoflurane at varying concentrations at which extubation is attempted according to the Dixon up and down method
3219452|NCT01083953|Experimental|Desflurane|1 arm will receive desflurane at varying end tidal concentration at which extubation will be attempted according to Dixon up and down method
3219453|NCT01083966|Experimental|Avastin|IA Avastin
3219454|NCT01083992|Other|Galvus + vitamin D|Galvus in combination with vitamin D
3219455|NCT01083992|Other|Galvus|vitagliptin as monotherapy
3219456|NCT01084031|Experimental|propofol|
3219457|NCT01084044|Experimental|ulinastatin|
3219458|NCT01084044|Active Comparator|saline solution|
3219459|NCT01084044|Placebo Comparator|Sugar pill|
3219460|NCT01084057|Experimental|Arm I (Cohort A)|Patients receive oral vorinostat once daily on days 1-14 and ixabepilone IV over 3 hours on day 2. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3219461|NCT01084057|Experimental|Arm II (Cohort B)|Patients receive oral vorinostat once daily on days 1-7 and 15-21. Patients also receive ixabepilone IV over 3 hours on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3219462|NCT01084070|Experimental|Early oral feeding|
3219463|NCT01084070|Active Comparator|Traditional Care|
3219464|NCT01084096|Active Comparator|Intervention|Eligible women at high risk for preterm birth will be identified and four 6 mg doses of dexamethasone will be administered before delivery.
3219465|NCT01084096|No Intervention|Control|Control arm will not receive a specific intervention for comparison.
3219466|NCT01084109|Active Comparator|1|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
3219467|NCT01084109|Active Comparator|2|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
3219468|NCT01084161|Experimental|N1539 5 mg|
3219469|NCT01084161|Experimental|N1539 7.5 mg|
3219470|NCT01084161|Experimental|N1539 15 mg|
3219471|NCT01084161|Experimental|N1539 30 mg|
3219472|NCT01084161|Experimental|N1539 60 mg|
3219473|NCT01084161|Placebo Comparator|Placebo|
3219474|NCT01084161|Active Comparator|morphine|
3219475|NCT01084187|Active Comparator|vardenafil on demand|four sexual attempts with 20 mg vardenafil during next four weeks
3219476|NCT01084187|Placebo Comparator|placebo|placebo of vardenafil during four weeks
3219477|NCT01084187|Active Comparator|daily vardenafil|10 mg of vardenafil each day during four weeks
3219478|NCT01084200|Experimental|Propofol|anesthesia maintenance with propofol and remifentanil
3219479|NCT01084200|Experimental|Sevoflurane|Sevoflurane and Remifentanil for anesthesia maintenance
3219480|NCT01084200|Experimental|Sevoflurane+Propofol|Sevoflurane+Propofol for anesthesia maintenance
3219481|NCT01084213|Active Comparator|IPTp with SP|Study women will receive at least two doses of SP during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
3219482|NCT01084213|Experimental|IST using RDTs|Scheduled intermittent screening using rapid diagnostic tests and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester.
3219483|NCT01084226|Active Comparator|Sterol|Additional plant sterols incorporated in the rye bread
3219484|NCT01084226|Placebo Comparator|control|No added plant sterol in the identical-looking rye bread
3219485|NCT01084291|Experimental|DEN1 Vaccine|Participants will receive a single dose of investigational vaccine for dengue virus subtype 1.
3219486|NCT01084291|Placebo Comparator|Placebo|Participants will receive a single dose of placebo vaccine.
3219487|NCT01084304||Active|Use of ovulation tests to aid conception
3219488|NCT01084304||Control|No ovulation tests to aid conception
3219489|NCT01084317||asthmatic children|patients under 18 age, with newly diagnosed asthma
3219490|NCT01084330|Experimental|AUY922|
3219491|NCT01084330|Active Comparator|Docetaxel or Irinotecan|
3219492|NCT01084343|Active Comparator|Panel 1|Subjects in this panel receive the low dose of vaccine (10 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
3219493|NCT01084343|Active Comparator|Panel 2|Subjects in this panel receive the high dose of vaccine (50 microgram of peptides). Twelve subjects are included in this panel, 8 of them receive the active vaccine and 4 receive the carrier only (placebo).
3219494|NCT01084356||hand|patients admitted for Tc MDP for evaluation of carpal/metacarpal and finger bone lesions
3219495|NCT01084356||thyroid|patients admitted for Tc thyroid scan
3219496|NCT01084356||parathyroid|patients investigated for parathyroid adenoma
3219497|NCT01084356||sentinel node|patients who are due to sentinel node biopsy
3219498|NCT01084369|Experimental|Testosterone, Vardenafil|All patients will receive Testosterone (n=40) of these (10 patients) will also receive Vardenafil
3219499|NCT01084395|Experimental|Adolescent Safer Sex Intervention|
3219500|NCT01084395|Experimental|Parent Safer Sex Intervention|
3219501|NCT01084395|Other|Adolescent Health Promotion Control|
3219502|NCT01084395|Other|Parent Health Promotion Control|
3219503|NCT01084408|Active Comparator|Sequent®Please|
3219504|NCT01084408|Active Comparator|Taxus™Liberté™|
3219505|NCT01084421|Experimental|Computer based intervention|Participants receive content about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general.
3219506|NCT01084421|No Intervention|Wait list control group|Participants will receive the computer based intervention at 3 months follow-up
3219507|NCT01084434|Experimental|Probiotic group|Group of 25 volunteers consuming probiotic product once a day for 7 weeks
3219508|NCT01084434|Experimental|Prebiotic group|Group of 25 volunteers consuming prebiotic product once a day for 7 weeks
3219509|NCT01084434|Experimental|Synbiotic group|Group of 25 volunteers consuming synbiotic product once a day for 7 weeks.
3219510|NCT01084434|Placebo Comparator|Placebo group|Group of 25 volunteers consuming placebo product once a day for 7 weeks
3219511|NCT01084447|Placebo Comparator|control group|In placebo muscular training group the respiratory exercise was used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA) no load.
3219512|NCT01084447|Active Comparator|trained group|In trained group the respiratory exercise used a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)the load was initially set at 40% of the maximal inspiratory pressure.
3219513|NCT01084460||EUS-suspected gastric GISTs|In this retrospective study, 50 patients with EUS-suspected gastric GISTs, less than 3 cm were enrolled and had EUS follow-up at least two times over a period of more than 24 months.
3219514|NCT01084473|Experimental|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
3219515|NCT01084473|Active Comparator|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
3219516|NCT01084473|Placebo Comparator|Placebo|The study subjects will be given a saline infusion.
3219517|NCT01084486|Experimental|Metformin, Adiponectine, Arterial Compliance|
3219518|NCT01084512||Healthy group|control subjects
3219519|NCT01084512||Paraplegic group|Paraplegic subjects
3219520|NCT01084512||Tetraplegic group|tetraplegic subjects
3219521|NCT01084525|Experimental|OTO-104 (steroid) 3 mg|
3219522|NCT01084525|Placebo Comparator|Placebo|
3219523|NCT01084525|Experimental|OTO-104 (steroid) 12 mg|The start of 12 mg dose cohort is contingent on safety data from 3 mg dose cohort.
3219524|NCT01084564||1|moderate to severe uncontrolled asthma
3219525|NCT01084577|Active Comparator|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
3219526|NCT01084577|Active Comparator|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
3219527|NCT01084590|Experimental|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
3219528|NCT01084590|Active Comparator|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
3219529|NCT01084616||Vaginal Dryness|
3219530|NCT01084616||Non-vaginal dryness|
3219533|NCT01084642||survey|Participants will be asked to complete a survey as a one time assessment.
3219534|NCT01084681|Active Comparator|SILK Artery Reconstruction Device|One arm will receive only the commercially available SILK Artery Reconstruction Device [flow diverter] (no intracranial coils are to be used in association with the SILK device).
3219535|NCT01084681|Active Comparator|Coils|The other arm will be treated with commercially available intracranial coils: the coils can be used with eventual balloon remodeling and/or stents when necessary.
3219536|NCT01084746|Active Comparator|PC-based tailored intervention|
3219537|NCT01084746|Active Comparator|Printed educational materials|
3219538|NCT01084746|No Intervention|No patient intervention|Patients will not receive a patient-directed intervention.
3219539|NCT01084811||chronic rhinosinusitis with nasal polyps|
3219540|NCT01084811||chronic rhinosinusitis without nasal polyps|
3219541|NCT01084811||Control group|
3219542|NCT01084824|Active Comparator|Liquid nitrogen and canthardin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterwards.
3219543|NCT01084824|Placebo Comparator|Liquid nitrogen and placebo|Liquid nitrogen applied to wart(s) then placebo vehicle afterwards.
3219544|NCT01084850||Diabetes Type II|Patients with type 2 Diabetes Mellitus
3219545|NCT01084850||Control|Patients with no diabetes
3219546|NCT01084863|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
3219547|NCT01084863|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
3219548|NCT01084876|Active Comparator|CT-P6 & Paclitaxel|CT-P6 + Paclitaxel
3219549|NCT01084876|Active Comparator|Herceptin & Paclitaxel|Trastuzumab + Paclitaxel
3219550|NCT01084889||symptomatic genital descensus|"Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.~Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally."
3219551|NCT01084902|Experimental|latnoprost|once daily
3219552|NCT01084902|Active Comparator|Brinzolamide|two times daily
3219553|NCT01084915||SAGB VC group|Retrospectively patients with a SAGB-VC gastric band are inventorized. They will also be interviewed and BAROS scores will be taken.
3219554|NCT01084928|Experimental|Intervention Arm (Diet and Exercise)|The lifestyle intervention will include a 16-week intervention period, followed by an 8 week, less intensive maintenance period.
3219555|NCT01084941|Experimental|Lifestyle intervention|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
3219556|NCT01084941|Active Comparator|Standard of care group|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
3219557|NCT01084967||Healthy lean control group|"The healthy lean controls consisted of age-, sex- and geography-matched young volunteers, or golden standard lean controls from China Cardiometabolic Disease and Cancer Cohort Study (4C Study).~Healthy volunteers:~BMI:18.5-22.9kg/m2;~Age:14-30 years old;~To be proved normal by the examinations of liver and kidney function,blood lipids profile,FBG, PBG, fasting insulin and HbA1c.~Controls from 4C Study:~17.0≤BMI≤23.0kg/m2 and waist circumference <85cm for males and <80cm for females;~1.8≤LDL-c≤3.4mmol/l;~FBG<6.1, PBG<7.8;~HOMA-IR<2.5;~BP <140/90mmHg;~eGFR>60mL/(min·1.73 m2), ALT<40IU/L, AST<40IU/L;~Excluding the history of hyperthyroidism, digestive system diseases, malignant tumors, infectious diseases (hepatitis B) and other systemic wasting diseases; Severe dysfunction of heart, lung and kidney;~Not using antihypertensive, hypoglycemic and lipid-lowering drugs；~No history of smoking."
3219558|NCT01084967||obesity group|"BMI ≥30kg/m2;~Age:14-30 years old; obesity group 4000, lean healthy control group 4000"
3219559|NCT01084980|Experimental|Tacrolimus|
3219560|NCT01084993|Active Comparator|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
3219561|NCT01084993|Active Comparator|Heparin|70 U/kg or standard practice
3219562|NCT01085019|Experimental|Dietary supplement: Cinnamon|
3219563|NCT01085019|Experimental|Dietary supplement: Oregano|
3219564|NCT01085019|Experimental|Dietary supplement: Ginger|
3219565|NCT01085019|Experimental|Dietary supplement: Rosemary|
3219566|NCT01085019|Experimental|Dietary supplement: Black pepper|
3219567|NCT01085019|Placebo Comparator|Dietary supplement: Placebo|
3219568|NCT01085032|Experimental|Arm A|Behavioral Counseling and Nicotine Patch
3219569|NCT01085032|Placebo Comparator|Arm B|Behavioral counseling and placebo patch
3219570|NCT01085058|Experimental|A: lenograstim|total group
3219571|NCT01085071|Active Comparator|Normal-high potassium (NHP)|A potassium target of 4.5 mmol/L.
3219572|NCT01085071|Active Comparator|Normal-low potassium (NLP)|A potassium target of 4.0 mmol/L.
3219573|NCT01085084|Experimental|Laquinimod 0.5 mg arm|laquinimod 0.5 mg + placebo
3219574|NCT01085084|Experimental|Laquinimod 1 mg|laquinimod 1 mg
3219575|NCT01085084|Placebo Comparator|Placebo|placebo
3219576|NCT01085097|Experimental|laquinimod 0.5 mg + prednisolone/prednisone|laquinimod 0.5 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
3219577|NCT01085097|Experimental|laquinimod 1 mg + prednisolone/prednisone|laquinimod 1 mg + Mycophenolate Mofetil (MMF) + prednisolone/prednisone
3219578|NCT01085097|Placebo Comparator|placebo + prednisolone/prednisone|Mycophenolate Mofetil (MMF) + prednisolone/prednisone+ placebo
3219579|NCT01085110||Persistent Pain patients|Patients with persistent postherniotomy pain after laparoscopic operation and pain related impaired daily function
3219580|NCT01085123|Experimental|1|PET 1: baseline, PET 2: 10 mg Zomig® Rapimelt, PET 3: 5 mg ZOMIG® Rapimelt, PET 4 2.5 mg ZOMIG® Rapimelt
3219581|NCT01085149|Experimental|study group|simvastatin will be inserted to sockets
3219582|NCT01085149|No Intervention|control|sockets will be left to healing without material in socket
3219583|NCT01085175|Experimental|Cohort 1|Low risk Heart Failure patients
3219584|NCT01085175|Experimental|Cohort 2|High risk Heart Failure patients with history of Implantable Cardioverter-Defibrillator firing
3219585|NCT01085188|Experimental|Assertive Continuing Care (ACC)|Behavioral intervention comprised of the community reinforcement approach plus case management delivered in home and other community settings to youth and their caregivers.
3219586|NCT01085188|Experimental|Contingency Management (CM)|Using a prize drawing system (no, low, medium and large value prizes) with adolescents could earn escalating prize drawing opportunities by completing verifiable pro-social activities and providing negative urine test and breath alcohol test results.
3219587|NCT01085188|Experimental|ACC + CM|This arm is the combination of arms 1 and 2.
3219588|NCT01085188|Active Comparator|Usual Continuing Care (UCC)|UCC consists of a discharge recommendation to seek aftercare services at nearest treatment provider to where the patient lived. This service primarily consisted of outpatient group counseling.
3219589|NCT01085227||Patients carrier of a LRRK2 mutation|
3219590|NCT01085227||Asymptomatic relatives of LRRK2 patients|
3219591|NCT01085240|Other|Start Later|The participants receive the Mission Possible intervention but it is delayed by 3 months.
3219592|NCT01085240|Experimental|Start Now|The participants start the Mission Possible program right away.
3219593|NCT01085253||Parkinson|"without gait impairment~with gait and/or balance impairment~with sleep disorders (RBD)~abnormalities of the brainstem and basal ganglia will be studied in relation with parkinsonism, gait and presence of RBD"
3219594|NCT01085253||PSP|supranuclear palsy patients study the abnormalities with the brainstem and basal ganglia and relation with the observed neurological signs (eye movements, balance, neuropsychological assessment and parkinsonism)
3219595|NCT01085253||controls|age matched controls
3219596|NCT01085266|Experimental|Dimebon (latrepirdine)|Patients receive dimebon 10mg orally 3 times per day for 1 week and 20 mg orally 3 times per day thereafter.
3219597|NCT01085279|Experimental|Non-ablative fractional laser|"In each patient, one side of the face was treated with non-ablative fractional laser in four-five sessions.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
3219598|NCT01085279|Active Comparator|Triple topical therapy|"In each patient, one side of the face was treated with triple topical therapy (Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1%) during 15 weeks.~Note: this study had a split-face design. In each patient, each side of the face was randomized to receive either non-ablative fractional laser therapy or triple topical therapy."
3219599|NCT01085292|Experimental|Group A|
3219600|NCT01085292|Experimental|Group B - D|
3219601|NCT01085305|Experimental|PCIT|Provision of Parent-Child Interaction Therapy
3219602|NCT01085305|Active Comparator|TAU|Treatment as usual from other therapists in the same clinics
3219603|NCT01085370|No Intervention|Control Group|standard medical care only
3219604|NCT01085370|Experimental|Intervention group|2 sessions with early psychological interventions
3219605|NCT01085409||Tinnitus|Patients with tinnitus
3219606|NCT01085409||Artery disease|Subjects with mobility constraints as a results of severe artery disease which in some cases led to leg amputation.
3219607|NCT01085409||Anxiety|Subjects with anxiety complaints
3219608|NCT01085409||Controls|Healthy controls
3219609|NCT01085422|Experimental|Arm A|
3219610|NCT01085435||S-ICD System Commercial Patients|Patients implanted with a CE marked S-ICD System, not participating in Cameron Health's Investigational Device Exemption (IDE) Clinical Study.
3219611|NCT01085448|Other|Low back pain|Individuals with current low back pain.
3219612|NCT01085474||1|1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
3219613|NCT01085474||2|Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)
3219614|NCT01085487||Group 1|
3219615|NCT01085487||Group 2|
3219616|NCT01085487||Group 3|
3219617|NCT01085526|Active Comparator|alutard phl prat. treatment group|18 subjects receiving active treatment: basophil activity, plasma cells and immunoglobulins measured
3219618|NCT01085526|No Intervention|control group|control
3219619|NCT01085526|Active Comparator|alutard phl.prat., treatment group2|basophil activity, basophil biology measured
3219620|NCT01085552|Other|1|Group A consists of 11 Caucasian male subjects Group B consists of 12 Japanese male subjects
3219621|NCT01085565|Experimental|Exablate treatment|
3219622|NCT01085578|Placebo Comparator|Cohort1|CG400549/placebo
3219623|NCT01085578|Placebo Comparator|Cohort2|CG400549/placebo
3219624|NCT01085578|Other|Cohort3|CG400549
3219625|NCT01085604||Low back pain|Individuals with current low back pain attributed to poor trunk neuromuscular control (clinical instability).
3219626|NCT01085617|Active Comparator|B1 - Standard therapy|Standard chemotherapy for precursor B-cell ALL
3219627|NCT01085617|Experimental|B2 - Rituximab|Standard chemotherapy for precursor B-cell ALL plus weekly rituximab infusions during phase 1 induction
3219628|NCT01085617|Active Comparator|T1 - Standard therapy|Standard chemotherapy for T-cell ALL
3219629|NCT01085617|Experimental|T2 - Nelarabine|Standard chemotherapy for T-cell ALL plus an additional course of treatment with nelarabine following phase 2 induction
3219630|NCT01085617|Active Comparator|P1 - standard palifermin|6 doses of palifermin before/after myeloablative stem cell transplant (randomisation closed due to lack of clinical relevance in 2016)
3219631|NCT01085617|Experimental|P2 - collapsed palifermin|1 x large dose of palifermin before myeloablative stem cell transplant and 3 low doses after transplant (randomisation closed due to lack of clinical relevance in 2016)
3219632|NCT01085656|Experimental|OXi4503|Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
3219633|NCT01085669||VEPTR patients|Children treated with VEPTR Implants for severe spinal or thoracic deformities
3219634|NCT01085695|Experimental|1|
3219635|NCT01085695|Experimental|2|
3219636|NCT01085695|Experimental|3|
3219637|NCT01085695|Active Comparator|4|
3219638|NCT01085708|Experimental|1|
3219639|NCT01085708|Experimental|2|
3219640|NCT01085708|Experimental|3|
3219641|NCT01085708|Active Comparator|4|
3219642|NCT01085721|Experimental|Dexchlorpheniramine pseudoephedrine guaifenesin|
3219643|NCT01085721|Active Comparator|Dexchlorpheniramine|
3219644|NCT01085747||Plastic stent|
3219645|NCT01085747||Covered SEMS|
3219646|NCT01085773|No Intervention|Standard written information on exercise|The Control group got the diabetes outpatients clinics standard written information on exercise as a part of the treatment for Type 2 Diabetes and were, like other Type 2 Diabetes patients in the clinic, advised at inclusion to be physically active.
3219647|NCT01085773|Experimental|Exercise on Prescription|In Denmark, Exercise on Prescription have focused on individual behavioral change and an exercise program for 16 weeks. The physical training consisted of both aerobic and strength training and took place in supervised groups
3219648|NCT01085773|Experimental|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
3219649|NCT01085799|Experimental|Health Education Intervention|Groups of schools receiving the health education intervention
3219650|NCT01085799|No Intervention|Control Schools - Regular curriculum|Groups of schools not receiving the health education intervention
3219651|NCT01085838|Experimental|Cohort 1|The first cohort of 5 patients will start with a dosage of 100 mg erlotinib daily
3219652|NCT01085838|Experimental|Cohort 2|The second cohort of patients will receive 150 mg of erlotinib daily
3219653|NCT01085838|Experimental|Cohort 3|The third cohort of five patients will be enrolled to receive 300 mg of erlotinib daily
3219654|NCT01085851|Experimental|Dexchlorpheniramine 1% lotion|
3219655|NCT01085851|Active Comparator|Dexchlorpheniramine 1% cream|
3219656|NCT01085864||Patients with lung nodules on CT scan.|Patients with lung nodules on CT scan.
3219657|NCT01085877|Active Comparator|Trial part 1|
3219658|NCT01085877|Experimental|Trial part 2|
3219659|NCT01085890|Experimental|Motivational interviewing group|The participants in this arm had 2 group seminars with information on hypertension and related lifestyle factors. They participated in 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
3219660|NCT01085890|No Intervention|Treatment as usual|Participants in this group received treatment as usual for their high blood pressure, but no informational seminars and no extra visits with motivational interviewing and blood pressure measurement.
3219661|NCT01085929|Active Comparator|Incision and Drainage|Abscess underwent incision and drainage
3219662|NCT01085929|Active Comparator|Ultrasound guided needle aspiration|Ultrasound was used to identify the abscess location. A needle was introduced into the abscess cavity and aspiration of the contents were attempted.
3219663|NCT01085942||Asymptomatic rotator cuff tear|Subjects identified with an asymptomatic rotator cuff tear
3219664|NCT01085955||Acute Peripartum|pregnant women who have recently given birth and diagnosed with peripartum cardiomyopathy
3219665|NCT01085955||Healthy Peripartum|Healthy pregnant women who have recently given birth, used as controls
3219666|NCT01085955||Healthy, non-pregnant women|Healthy non-pregnant women without cardiac disease, used as controls
3219667|NCT01085955||New Non-ischemic CMP|Women 18-60 years old who have been diagnosed with non-ishemic cardiomyopathy within the last 6 months and have an ejection fraction less than OR equal to 45% by echocardiogram.
3219668|NCT01085981|Active Comparator|GRAS ingredients cream|"The study will be placebo controlled double blind study which will require two office visits after informed consent and sensitivity testing done with the study cream on the day of recruitment.~On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit Then placebo or active cream will be applied and the pt restudied. the same process is repeated another day with the second arm cream."
3219669|NCT01085981|Placebo Comparator|placebo cream then doppler study|
3219670|NCT01085994||Procalcitonin-guided group|
3219671|NCT01085994||Routine practice group|
3219672|NCT01086007||Pain patients|Patients with pain related sexual dysfunction after laparoscopic inguinal hernia repair
3219673|NCT01086007||Non-pain patients|Patients with no pain related sexual dysfunction after laparoscopic inguinal hernia repair
3219674|NCT01086020|Active Comparator|atorvastatin|patients will be treated with atorvastatin 10mg/d after randomization, and continued for two years
3219675|NCT01086020|Experimental|atorvastatin and ezetimibe|patients will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d after randomization, and continued for two years
3219676|NCT01086046|Active Comparator|Heparin|Heparin injection 10 IU/kg/hr within 24h
3219677|NCT01086046|Experimental|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days"
3219678|NCT01086059||Cohort 1 - Exposure cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have used adalimumab in the first trimester of pregnancy for any length of time from the date of conception.
3219679|NCT01086059||Cohort 2 - Matched Diseased Comparison Cohort|Pregnant women with a current diagnosis of RA, JRA, or Crohn's disease who have not used adalimumab or any TNF antagonist in pregnancy.
3219680|NCT01086059||Cohort 3-Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used adalimumab or any TNF antagonist at any time in pregnancy nor have they been exposed to any known human teratogen during pregnancy.
3219681|NCT01086059||Cohort 4 - Registry Group|Pregnant women who have used adalimumab for any length of time following the first day of the last menstrual period until the end of pregnancy who do not meet Cohort 1 inclusionary criteria.
3219682|NCT01086072||Myocardial Infarction - STEMI|
3219683|NCT01086072||Myocardial Infarction - NSTEMI|
3219684|NCT01086085|Experimental|A|
3219685|NCT01086085|Experimental|B|
3219686|NCT01086085|Experimental|C|
3219687|NCT01086085|Experimental|D|
3219688|NCT01086098||All paced patients|
3219689|NCT01086111||PMSF|type 2 diabetes patient receiving a protein sparing diet
3219690|NCT01086111||sleeve gastrectomy|type 2 diabetes patient receiving a gastric bypass
3219691|NCT01086111||RYGBP|type 2 diabetes patient receiving a gastric bypass
3219692|NCT01086124||Echocardiography 1 month|Patients will all have an echocardiography 1 month post myocardial infarction and 3 months post myocardial infarction
3219693|NCT01086163||Omacor dose titration|"Stable documented coronary artery disease proven by angiography treated with statin and aspirin. In order to achieve homogeneity within this population, the following additional inclusion criteria will apply:~survived first-time AMI more than 12 months ago~stable medical treatment during the last 3 months (except removal of Plavix)~Ethnicity: Caucasians~Males, 50 - 60 yrs~non-diabetics~excluded are those who eat more than one meal of fish / week~excluded are those who take omega-3 supplements of any sorts"
3219694|NCT01086176||Patient-control|
3219695|NCT01086202||Tornier Reversed Shoulder Arthroplasty Medial Offset|
3219696|NCT01086202||Lateral offset arthroplasty|
3219697|NCT01086241|Active Comparator|A: routine 2D mammogram|Subject receives regular 2D mammogram.
3219698|NCT01086241|Active Comparator|B: Routine Mammogram + tomosynthesis|Routine Mammogram and tomosynthesis
3219699|NCT01086254|Experimental|Iniparib/ Gemcitabine/ Cisplatin|"Iniparib, 5.6 mg/kg, 60-min IV infusion twice weekly (days 1, 4, 8, and 11). Infusion starts after completion of GC regimen administration.~Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion."
3219700|NCT01086254|Active Comparator|Gemcitabine/ Cisplatin|Gemcitabine, 1250 mg/m2, 30-min IV infusion on day 1 and day 8 and cisplatin 75mg/m², 3- to 4-hour IV infusion on day 1 of each 3-week cycle after the end of gemcitabine infusion.
3219701|NCT01086267|Experimental|BMS-908662 (A1)|Phase 1
3219702|NCT01086267|Experimental|Cetuximab (A1)|Phase 1
3219703|NCT01086267|Experimental|BMS-908662 (B1)|Phase 2
3219704|NCT01086267|Experimental|BMS-908662 + Cetuximab (B2)|Phase 2
3219705|NCT01086280||Patients exposed to Saxagliptin|
3219706|NCT01086280||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3219707|NCT01086293||Patients exposed to Saxagliptin|
3219708|NCT01086293||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3219709|NCT01086306||Patients exposed to Saxagliptin|
3219710|NCT01086306||Patients exposed to oral antidiabetic drugs (not Saxagliptin)|
3219711|NCT01086319||Patients exposed to saxagliptin|
3219712|NCT01086319||Patients exposed to oral antidiabetic drugs (not saxagliptin)|
3219713|NCT01086332|Experimental|phase 1/2|An escalating study of gemcitabine when combined with 1250 mg of nelfinavir twice daily. Dose of gemcitabine is increased for new subjects based on the experiences and tolerance of prior subjects. When the maximum tolerated dose is identified, a recommended phase 2 dose will be assigned and further subjects will receive that dose.
3219714|NCT01086345|Experimental|Arm I|Patients receive bevacizumab IV over 30 minutes on days 1 and 15. Patients also receive irinotecan hydrochloride IV on days 1 and 15 beginning in course 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
3219715|NCT01086371|Experimental|RAS walking|Subjects will walk while listening to music 20 minutes per day every day during the study period.
3219716|NCT01086371|Active Comparator|RAS no walking|Subjects will be listening to music but not performing walking exercise, for 20 minutes per day every day during the study period.
3219717|NCT01086371|Active Comparator|Walking no RAS|Subjects will be walking without listening to music for 20 minutes per day every day during the study period
3219718|NCT01086397||1|
3219719|NCT01086436|Experimental|Rotavirus Group|Subjects will receive Rotarix™
3219720|NCT01086436|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3219721|NCT01086449|Experimental|Group A|
3219722|NCT01086462|Experimental|GSK2239633|Single dose infusion of study drug over 15 minutes
3219723|NCT01086488|Experimental|Nasopharyngeal Carcinoma|A: Experimental B: Active Comparator
3219724|NCT01086514|Experimental|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|In this study we will perform Dual Energy Contrast Enhanced Digital Mammography (DE CEDM) on patients with newly diagnosed breast cancer using a dedicated research system, derived from a standard digital mammography unit and review workstation (Senographe DS and SenoAdvantage) modified to deliver the required dual energy paired exposures and visualization of combined images.
3219725|NCT01086527|Experimental|SLCO2B1{NM_007256.2}:c.[935G>A] + [=]|Individuals in this group will be homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].
3219726|NCT01086553|Experimental|A|9mg budesonide OD
3219727|NCT01086553|Active Comparator|B|3mg budesonide TID
3219728|NCT01086566|Experimental|Multiple Boost Group-15 mcg|25 healthy adults who have previously received both Clade 1 and Clade 3 vaccines as a participant in study DMID 05-0043 will receive a single dose of 15 mcg of A/Indonesia/5/05.
3219729|NCT01086566|Experimental|Primed Group-15 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 15 mcg of A/Indonesia/5/05.
3219730|NCT01086566|Experimental|Unprimed Group-90 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 90 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
3219731|NCT01086566|Experimental|Unprimed Group-15 mcg|15 healthy adults with no previous receipt of H5N1 vaccine at any dose will receive 2 doses of 15 mcg of A/Indonesia/5/05 vaccine separated by 28 days.
3219732|NCT01086566|Experimental|Primed Group-90 mcg|30 healthy adults who have previously received H5N1 vaccine at any dose will receive a single dose of 90 mcg of A/Indonesia/5/05.
3219733|NCT01086579|Experimental|Treatment Arm (IN.PACT Falcon Drug Eluting Balloon)|IN.PACT Falcon™ paclitaxel drug-eluting balloon (DEB) dilatation and provisional spot bare metal stenting (Bare Metal Stent).
3219734|NCT01086579|Active Comparator|Control Arm PES|Control Arm: paclitaxel-eluting stent (PES) implantation as per standard practice.
3219735|NCT01086592|Active Comparator|Control|
3219736|NCT01086592|Experimental|Strengthening exercise|Strong progressive strengthening exercises of lower limbs.
3219737|NCT01086592|Experimental|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
3219738|NCT01086592|Experimental|Electrotherapy+weights|
3219739|NCT01086657|Experimental|Group 1|Inactivated H5N1 Vaccine at Enrollment and inactivated H5N1 Vaccine at Week 24
3219740|NCT01086657|Experimental|Group 2|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 4
3219741|NCT01086657|Experimental|Group 3|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 8
3219742|NCT01086657|Experimental|Group 4|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 12
3219743|NCT01086657|Experimental|Group 5|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 16
3219744|NCT01086657|Experimental|Group 6|H5 DNA Vaccine at Enrollment and Inactivated H5N1 Vaccine at Week 24
3219745|NCT01086683|Experimental|Intervention group|
3219746|NCT01086683|No Intervention|Control group|Wait list control group: The control group received usual care including clinical control visits but no systematic rehabilitation activities.
3219747|NCT01086696|Experimental|1|subjects with tumor types typically treatedwith taxanes
3219748|NCT01086696|Experimental|2|subjects with tumor types typically treatedwith taxanes
3219749|NCT01086722|Experimental|"karolinska cocktail"|The karolinska cocktail contains dextromethorphan, caffeine, losartan and omeprazol
3219750|NCT01086735|Experimental|donor lymphocyte infusion|Donor T-cell transduction
3219751|NCT01086748|Experimental|160 mg LY2140023|80 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks.
3219752|NCT01086748|Active Comparator|4 mg Risperidone|2 mg risperidone administered orally, BID for up to 7 weeks.
3219753|NCT01086748|Placebo Comparator|Placebo|Placebo administered orally, BID for up to 7 weeks.
3219754|NCT01086748|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, BID for up to 7 weeks.
3219755|NCT01086774|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3219756|NCT01086787||Non heart failure patients|Patients without heart failure undergoing open chest surgery
3219757|NCT01086787||Orthopedic patients|Patients without heart failure undergoing orthopedic surgery
3219758|NCT01086787||Heart failure patients|Patients with heart failure undergoing open chest surgery.
3219759|NCT01086800|Other|HLSE plus PAP|
3219760|NCT01086800|Other|HLSE plus Oxygen|
3219761|NCT01086800|Other|Healthy Lifestyles and Sleep Education|
3219762|NCT01086813|Experimental|1|
3219763|NCT01086826|Active Comparator|RT+CDDP/5-FU|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy."
3219764|NCT01086826|Experimental|RT+CETUXIMAB|"RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
3219765|NCT01086826|Active Comparator|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):~DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RT:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU 800 mg/m2/day for 4 will be administered as continuos iv infusion"
3219766|NCT01086826|Experimental|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"DOCETAXEL:~75 mg/m², 1 hour IV infusion, Day and every 3 weeks~CISPLATIN:~80mg/m², intravenous infusion over 30-minute to 3 hours,Day 1 immediately after docetaxel administration and then every 3 weeks 5-FU 800 mg/m²/day, 24 hour continous infusion over 4 days, Day 1 after the end of cisplatin infusion, and every 3 weeks.~RADIOTHRAPY:~Tumor: 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Lymph nodes: at least 50 Gy (2 Gy x1/day, 5 days per week for 6 weeks)~CETUXIMAB:~Cetuximab 400 mg/m2 as first dose, 7 days before the beginning of radiotherapy as 120 minutes IV infusion. Subsequent doses of 250 mg/ m2 will be administered as 60 minutes IV infusion, weekly, for 7 times."
3219767|NCT01086839|Experimental|sodium chloride 6%|"Cross-Over! experimental (days 1 - 28), then Wash-Out (28 days),then placebo comparator (days 57 - 85)."
3219768|NCT01086839|Placebo Comparator|sodium chloride 0,9%|"Cross-Over! placebo comparator (days 1 - 28), then Wash-Out (28 days),then experimental (days 57 - 85)."
3219769|NCT01086865|Active Comparator|Petivit BC|
3219770|NCT01086865|Experimental|Apetiviton BC|
3219771|NCT01086878|Experimental|Cotrimoxazole|
3219772|NCT01086891|Experimental|1|Patients with chronic obstructive pulmonary disease who show arterial oxygen desaturation to effort.
3219773|NCT01086891|Experimental|2|Patients with interstitial lung disease who show arterial oxygen desaturation to effort
3219774|NCT01086917|Experimental|Group 1|to receive a dose of 2,500 PfSPZ Challenge
3219775|NCT01086917|Experimental|Group 2|to receive a dose of 10,000 PfSPZ Challenge
3219776|NCT01086917|Experimental|Group 3|to receive a dose of 25,000 PfSPZ Challenge
3219777|NCT01086930|Experimental|Intervention Group|"In addition to standard care participants in Group A will receive:~• One hour of extra hand training five times per week for 8 weeks using the ReJoyce Workstation.~The training will be supervised by a therapist and provided to the target hand. The hand exercises will be incorporated into computer games and will involve the following tasks using different manipulanda:~reaching~grasping~manipulating~pulling~rotating~releasing"
3219778|NCT01086930|Other|Standard Care Group|Participants in the control group will not receive any training on the instrumented workstation or electrical stimulation to the hand or upper limb. They will however continue to receive standard care as well as three 15-minute specific hand activity sessions per week specifically devoted to the practice of hand activities in a one-to-one format with a therapist (as per the treatment received by the experimental group).
3219779|NCT01086943|Experimental|device arm|
3219780|NCT01086982|Experimental|Octreotide acetate LAR 30 MG|Test
3219781|NCT01086982|Active Comparator|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|
3219782|NCT01087008|Experimental|Zoledronate acid|
3219783|NCT01087008|Other|No treatment control|
3219784|NCT01087021|Experimental|cabazitaxel|"At every cycle (every 3 weeks), on Day 1, patients will receive cabazitaxel, administered by intravenous (IV) infusion over 1 hour, at 25 mg/m2.~An IV premedication regimen composed of up to 4 treatments (antihistamine, corticosteroids, H2 antagonist other than cimetidine at all cycles, plus palonosetron at cycle 1) will be administered before cabazitaxel infusion."
3219785|NCT01087034||Milwaukee brace|Children with an infantile scoliosis requiring Milwaukee bracing
3219786|NCT01087034||Cheneaux brace|Children with an infantile scoliosis requiring Cheaneaux bracing
3219787|NCT01087047||Physiological modifications|Pregnant women who attend the routine ultrasound control in our institution before 14 weeks of pregnancy
3219788|NCT01087047||MRI and acoustic|Women undergoing an MRI for obstetrical purpose
3219789|NCT01087060||cysts surgically removed|
3219790|NCT01087060||cysts under surveillance|
3219791|NCT01087073|Experimental|Patient Activation|Patient knowledge in diabetes self-management behaviors and clinical measures (HbA1c, LDL, HDL, BMI, BP) are tracked at baseline, 10-weeks (post-program), 3 months (post-program) and 6 months (post-program).
3219792|NCT01087073|Experimental|Provider Training Evaluation|Pre-post surveys are conducted at each training session to assess overall satisfaction with the curriculum, knowledge of SDM, and understanding of techniques to promote its use in the healthcare setting.
3219793|NCT01087073|Experimental|Quality Improvement Evaluation|We measure quality improvement efforts through biannual staff experience surveys and one-on-one provider and clinic staff interviews.
3219794|NCT01087073|Experimental|Community Outreach Evaluation|"Pre-post surveys will be disseminated at nutrition tours (Save-A-Lot, Walgreens, 61st Street Farmers Market) to assess change in knowledge of healthy eating behaviors and proper nutrition. Surveys will also assess participant satisfaction of the tours.~Interviews will also be performed with community stakeholders to assess the costs/benefits of the collaboration and overall feedback on involvement."
3219795|NCT01087073|No Intervention|Global Evaluation of the Intervention|A chart review will be performed in order to evaluate our intervention to improve diabetes processes of care and clinical outcomes among our target population. Chart abstractions will be performed on medical records obtained from our six intervention clinics. In addition, chart abstractions from two University of Illinois at Chicago clinics and three FQHCs located on the West Side of Chicago will serve as control data.100 charts will be randomly selected from each clinic per year of the intervention. The chart review will contain charts from adult diabetes patients over a seven year period that matches the duration of the Improving Diabetes project.
3219796|NCT01087086|Experimental|Crononutrition|"Dietary pattern:~Personalized diet~Caloric restriction (-30% Total energy intake)~High adherence to the Mediterranean Diet~Macronutrient distribution (30% Protein, 40% Carbohydrates and 30% Fat)~Low glycemic index/load~Increased antioxidant capacity of the diet"
3219797|NCT01087086|Placebo Comparator|American Heart Association|"Dietary pattern:~Personalized diet~Caloric diet (-30% Total energy intake)~Macronutrients distribution according to the American Heart Association (AHA) guidelines"
3219798|NCT01087099|Experimental|Albendazole|Treatment with albendazole
3219799|NCT01087112|Active Comparator|Child Health Centre care|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Additional treatment was initiated in 1/3 of the cases. This was registered at the end-point interview.
3219800|NCT01087112|Experimental|Mother-Infant Psychoanalytic tmt|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief that the infant understands verbal communication. The analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
3219801|NCT01087125||Pregnant RA patients with abatacept exposure during pregnancy|
3219802|NCT01087138|Experimental|Exercise|exercise class 3x's/week
3219803|NCT01087138|Experimental|exercise and calcium intake|exercise class 3x's/week and 1500mg calcium/day
3219804|NCT01087138|No Intervention|usual exercise and calcium|usual exercise and calcium intake
3219805|NCT01087151|Active Comparator|A|
3219806|NCT01087151|Experimental|B|
3219807|NCT01087151|Experimental|C|
3219808|NCT01087164|Experimental|Compliance|Parents will be randomized to receive high or no compliance condition where those in the experimental group will be asked about whether or not they will protect their daughter from cervical cancer or for males, their son from genital warts.
3219809|NCT01087164|Experimental|Message sidedness|Parents will be given either a one-sided verbal message or a two-sided verbal message about the HPV vaccine.
3219810|NCT01087177|Experimental|Exposure to Pedialink CEASE Trained Site|Parents at a practice where the clinicians were trained to address tobacco use through the Pedialink CEASE module.
3219811|NCT01087190|Experimental|INH treatment group|"randomly allocated to INH treatment group in renal transplant recipients with ELISPOT (+)~INH 300 mg po qd for 9 months"
3219812|NCT01087190|No Intervention|Control group|"randomly allocated to control group in renal transplant recipients with ELISPOT (+)~no treatment"
3219813|NCT01087190|No Intervention|Observation group|"allocated to observation group in renal transplant recipients with ELISPOT (-)~no treatment"
3219814|NCT01087203|Experimental|Tanezumab|
3219815|NCT01087203|Placebo Comparator|Placebo|
3219816|NCT01087216|Active Comparator|Group Laser = Arm As A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
3219817|NCT01087216|Placebo Comparator|Bras B : the control group|patient to accept habitual treatment of corticoid
3219818|NCT01087229|Experimental|equimolar oxygen-nitrous oxide mixture|"equimolar oxygen-nitrous oxide mixture~Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture."
3219819|NCT01087229|Placebo Comparator|Placebo|Patients randomized to this arm will have the placebo.
3219820|NCT01087242|Placebo Comparator|controlled group|Tang-min Lin analogue 6g,tid,po
3219821|NCT01087242|Experimental|Tang-min Lin pill|Tang-min Lin pills 6g,tid,po
3219822|NCT01087255|No Intervention|Usual Care|Usual care patients will have outpatient care and monitoring procedures, as determined by them and their health care providers.
3219823|NCT01087255|Experimental|Electronic Pillbox Monitoring System|Usual care plus receive use of the wireless electronic pillbox and medication monitoring system
3219828|NCT01087346|Active Comparator|Control|Information about child health
3219829|NCT01087346|Experimental|Family Environment Information|Information about family environment factors in children's obesity risk
3219830|NCT01087346|Experimental|Gene times Family Environment Information|Information about interactions between genetic and family environment factors in children's obesity risk
3219831|NCT01087346|Experimental|Genetic Information|Information about genetic factors in child obesity risk
3219832|NCT01087359|Active Comparator|LPS + melatonin night|
3219833|NCT01087359|Placebo Comparator|LPS + placebo night|
3219834|NCT01087359|Active Comparator|LPS + melatonin day|
3219835|NCT01087359|Placebo Comparator|LPS + placebo day|
3219836|NCT01087359|Experimental|LPS night|
3219837|NCT01087359|Experimental|LPS day|
3219838|NCT01087385||Troponin T elevation|
3219839|NCT01087385||No troponin T elevation|
3219840|NCT01087398|Experimental|Intervention|
3219841|NCT01087411|Experimental|Motivational Interviewing and omega 3|This arm is the group that receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
3219842|NCT01087411|Experimental|Motivational interviewing and placebo|This arm is the group that receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
3219843|NCT01087411|Experimental|Control and omega 3|This arm is the group that does not receives the intervention program and eats fish liver oil capsules. Represents 25 % of all participants.
3219844|NCT01087411|Placebo Comparator|Control and placebo|This arm is the group that does not receives the intervention program and eats placebo oil capsules. Represents 25 % of all participants.
3219845|NCT01087424|Experimental|R mini CHOP|Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
3219846|NCT01087437|Experimental|gastrolith calcium treatment|
3219847|NCT01087450||Stage1|1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
3219848|NCT01087450||Stage 2 Randomized, blinded trial|Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment
3219849|NCT01087463|Experimental|single arm|In this single arm study, the Quantum nailing system will be used in all patients.
3219850|NCT01087476|Experimental|doxycycline hyclate|Patients will be randomly assigned to receive either a sub-microbial dose of doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
3219851|NCT01087515|Other|Blood donation|
3219852|NCT01087554|Experimental|Arm A: Vorinostat + Sirolimus|"Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
3219853|NCT01087554|Experimental|Arm B: Vorinostat + Everolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
3219854|NCT01087554|Experimental|Arm C: Vorinostat + Temsirolimus|"Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28.~Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
3219855|NCT01087567|Experimental|Intensive insulin regimen|A weight based, basal bolus will be given for 12 weeks.
3219856|NCT01087567|Active Comparator|Routine Care|Routine Care patients receive oral medications based upon the 2009 ADA treatment recommendations: Metformin, Glimepiride, Pioglitazone.
3219857|NCT01087580|Experimental|Chemotherapy alone, no radiation therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days~B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel"
3219858|NCT01087580|Experimental|Chemotherapy with Radiation Therapy|"A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel~GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
3219859|NCT01087593|Experimental|Treatment with transdermal 17β-estradiol|
3219860|NCT01087593|Placebo Comparator|Control|
3219861|NCT01087619|No Intervention|Follow-up|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are followed only
3219862|NCT01087619|Experimental|Surgery|Patients diagnosed biochemically and clinically with primary hyperparathyroidism who are treated with parathyroid surgery
3219863|NCT01087632|Experimental|Armolipid Plus|Armolipid Plus is an association of berberine 500 mg, red yeast rice titled in 3 mg monacolin K,- policosanol 10 mg,coenzyme Q10 2 mg,astaxanthin 0,5 mg,folic acid 0,2 mg
3219864|NCT01087632|Placebo Comparator|Placebo|Placebo matching Armolipid plus
3219865|NCT01087645|Experimental|Trial part 1|
3219866|NCT01087645|Experimental|Trial part 2|
3219867|NCT01087658|Experimental|Glutamine and calcium magnesium|"Glutamine 10g p.o. 3-times a day beginning at day -2 for 7 consecutive days during each chemotherapy cycle. 1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
3219868|NCT01087658|Active Comparator|Calcium magnesium|"1g of calcium and 1g of magnesium i.v. over 30 minutes just before the chemotherapy and repeated at the same dose after the completion of the oxaliplatine infusion.~All patients will receive an oxaliplatin based chemotherapy with XELOX, FOLFOX-4 or mFOLFOX-6."
3219869|NCT01087671|Other|Open-lable study with one arm|
3219870|NCT01087684|Active Comparator|Argon laser trabeculoplasty|Patients received standard argon laser treatment
3219871|NCT01087684|Active Comparator|Selective laser trabeculoplasty|Patients received a standard selective laser treatment
3219872|NCT01087697|Experimental|Implanted with NUC|Patients who have been implanted with the Neo-Urinary Conduit
3219873|NCT01087710|Experimental|novel nutritional formula|
3219874|NCT01087710|Active Comparator|Control nutritional product|1 8oz serving per day for 12 weeks
3219875|NCT01087749|Experimental|Chronic Kidney Disease|Propranolol, Losartan, and Eprosartan will be administered to patients who have been diagnosed with Chronic Kidney disease and have a glomerular filtration rate (GFR) below 40ml/min.
3219876|NCT01087749|Experimental|Healthy Volunteers|Propranolol, Losartan, and Eprosartan will be administered to healthy volunteers without chronic kidney disease.
3219877|NCT01087840|Experimental|Raltegravir, NPEP|"Drug: Raltegravir Tablet 400mg taken orally, twice daily with or without food for 28 days along with Truvada 1 tablet taken orally daily for 28 days.~Arms: Raltegravir/Truvada"
3219878|NCT01087853|Active Comparator|Phase A1: Plasmalyte|Plasmalyte
3219879|NCT01087853|Active Comparator|Phase A2: 0.9% Saline|0.9% Saline
3219880|NCT01087853|Active Comparator|Phase B1: PlasmaVolume|PlasmaVolume
3219881|NCT01087853|Active Comparator|Phase B2: Voluven|Voluven
3219882|NCT01087866|Experimental|Metformin|
3219883|NCT01087866|Active Comparator|Insulin|
3219884|NCT01087879|Active Comparator|Oral contraceptive pill|9 weeks treatment with contraceptive pill.
3219885|NCT01087879|Active Comparator|Contraception vaginal ring|9 weeks treatment with vaginal ring.
3219886|NCT01087879|Active Comparator|Transdermal contraceptive patch|9 weeks treatment with a transdermal contraceptive patch.
3219887|NCT01087892|Active Comparator|Dietary supplement Probiotic drink|"Double blind~Probiotic containing the live strain 100g/day orally, twice daily for the duration of the course of antibiotics plus seven days"
3219888|NCT01087892|Placebo Comparator|Dietary supplement probiotic placebo drink|"Double blind~'placebo' is actually a control product~Placebo drink contains no strain 100gs orally, twice daily for the duration of the course of antibiotics plus seven days"
3219889|NCT01087983|Experimental|Lapatinib + Sirolimus|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Sirolimus starting oral dose 1 mg daily.
3219890|NCT01087983|Experimental|Lapatinib + Metformin|Lapatinib starting oral dose of 500 mg daily for 21 day cycle. Metformin Starting oral dose 1000 mg daily.
3219891|NCT01088009|Experimental|early add-on|
3219892|NCT01088009|Active Comparator|SOC|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
3219893|NCT01088009|Other|De-novo combination|patients in this arm will receive oral lamivudine 100mg and adefovir 10mg for 104 weeks
3219894|NCT01088022|Experimental|Aprepitant, Palonosetron, dexametasone|
3219895|NCT01088022|Placebo Comparator|Placebo, Palonosetron, Dexamethasone|
3219896|NCT01088035|Experimental|Carboplatin|
3219897|NCT01088061||lean women with PCOS|
3219898|NCT01088061||Obese women with PCOS|
3219899|NCT01088061||lean control women|
3219900|NCT01088061||Obese control women|
3219901|NCT01088074|Active Comparator|Histoacryl Tissue Adhesive|Histoacryl Blue (HAB) Tissue Adhesive (n-butyl-2 cyanoacrylate; B. Braun Corp., Melsungen, Germany). Histocryl is a FDA-approved sterile liquid skin adhesive that has been utilized as a substitute for sutures for wound closure for approximately 40 years.
3219902|NCT01088074|Active Comparator|Dermabond|Dermabond High Viscosity Tissue Adhesive (2-ocytl cyanoacrylate; Ethicon, Somerville, NJ). Dermabond is also a FDA-approved liquid bonding agent that has been utilized for wound closure for approximately 10 years and proven as effective as sutures.
3219903|NCT01088074|Active Comparator|Staples|Visistat 35W Stapler (Teleflex Corp, Limerick, PA). The FDA-approved Weck staple system with stainless steel staples has been proven over years of use and remains the standard accepted closure approach due to speed of insertion as well as removal.
3219904|NCT01088074|Active Comparator|Running Subcuticular with Monocryl|Monocryl 4-0 Suture (Ethicon, Somerville, NJ). Monocryl is an FDA-approved absorbable, synthetic, suture indicated for soft tissue approximation.
3219905|NCT01088087|Placebo Comparator|Colostrum|
3219906|NCT01088087|No Intervention|Sugar pill|
3219907|NCT01088100||Patients with POCD - cases|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
3219908|NCT01088100||Patients without POCD - controls|Out of the 976 patients included in the ISPOCD2 study (Abildstrom H, Christiansen M et al. Apolipoprotein E genotype and cognitive dysfunction after noncardiac surgery. Anesthesiology 2004;101:855-61) the 93 patients with POCD whose blood samples are stored will be included together with 2x93 controls (without POCD), who will be matched by type of surgery, age, education, ASA-score and sex.
3219909|NCT01088113||Tai Chi|Healthy subjects with Tai Chi practice
3219910|NCT01088113||Qigong|Healthy subjects with Qigong practice
3219911|NCT01088126|Active Comparator|Focal ablation|PV isolation + CFAE-targeted focal ablation
3219912|NCT01088126|Active Comparator|Linear ablation|PV isolation + CFAE-guided linear ablation
3219913|NCT01088139|No Intervention|Control|
3219914|NCT01088139|Experimental|Nutritional Supplementation|
3219915|NCT01088152|Active Comparator|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for celiac disease in primary care
3219916|NCT01088152|Experimental|Celiac School|Structured education using problem-based learning at 10 sessions
3219917|NCT01088165|Experimental|Adalimumab treatment group|
3219918|NCT01088165|Active Comparator|Fumaric acid esters treatment group|
3219919|NCT01088178|Experimental|Immediate Postplacental|Within 10 minutes from delivery of placenta
3219920|NCT01088178|Experimental|Early Postpartum|After 10 minutes from delivery of placenta but within 48hrs from delivery
3219921|NCT01088178|Experimental|Interval|After 6 weeks postpartum
3219922|NCT01088191|Active Comparator|Hyaluronan Alone|Hyaluronan Alone
3219923|NCT01088191|Experimental|MSB-CAR001|Single Dose of MSB-CAR001 Combined With Hyaluronan
3219924|NCT01088204|Active Comparator|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
3219925|NCT01088204|Experimental|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
3219926|NCT01088230|Experimental|Botox®|this group will receive an injection of botox in the wrist flexors and forearm pronators
3219927|NCT01088230|Placebo Comparator|Saline|This group will receive an injection of saline solution in the same muscle groups as the treatment group (wrist flexors and pronators).
3219928|NCT01088256|Active Comparator|etoricoxib, peripheral hyperalgesia|14 patient with neuropathic pain and peripheral hyperalgesia get etoricoxib 90mg for 8 days
3219929|NCT01088256|Active Comparator|etoricoxib, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get etoricoxib 90mg for 8 days
3219930|NCT01088256|Placebo Comparator|placebo, peripheral hyperalgesia|14 patients with neuropathic pain with peripheral hyperalgesia get placebo for 8 days
3219931|NCT01088256|Placebo Comparator|placebo, no peripheral hyperalgesia|14 patients with neuropathic pain without peripheral hyperalgesia get placebo for 8 days
3219932|NCT01088269||AF|Hypertensive patients in AF
3219933|NCT01088269||Non-AF|Hypertensive Patients
3219934|NCT01088282|Active Comparator|Implantation of difractive multifocal IOL|
3219935|NCT01088282|Sham Comparator|Implantation of monofocal IOL|
3219936|NCT01088308|Experimental|Single Arm|All Patients underwent Intervention.
3219937|NCT01088321||Patients initiating abatacept|
3219938|NCT01088321||Patients initiating other biologic disease-modifying drugs|
3219939|NCT01088321||Pts initiate non-biologic disease-modify anti-rheumatic drugs|
3219940|NCT01088334||IVTE, follow-up|no malignancy at basal screening, no extensive screening
3219941|NCT01088334||IVTE, screening|No malignancy at basal screening, screening by means of CT-Chest/abdomen and mammography in women
3219942|NCT01088347|Experimental|Advanced cervical cancer patients|
3219943|NCT01088360||Patients with rheumatoid arthritis initiating abatacept|
3219944|NCT01088360||Pts with RA initiating other biologic disease-modifying drugs|
3219945|NCT01088360||Pts w/ RA non-biologic disease-modifying anti-rheumatic drugs|
3219946|NCT01088373|Experimental|Azacitidine, Lenalidomide|
3219947|NCT01088386||Patients|All patients who will be receiving Zyprexa Relprevv must be enrolled into the Zyprexa Relprevv Patient Care Program
3219948|NCT01088425||Spontaneous|Mothers with children conceived after spontaneous cycle
3219949|NCT01088425||Vitrificatíon|Mothers with children conceived after vitrification cycle
3219950|NCT01088425||slow- rate freezing|Mothers with children conceived after slow- rate freezing cycle
3219951|NCT01088477||Breast cancer patients with acquired anti-hormonal resistance|
3219952|NCT01088490||critically ill|Critically ill patients admitted to ICU
3219953|NCT01088516|Experimental|Aluvia-based HAART|Study regimen: ZDV/3TC (combivir) + 2 Aluvia Tabs all PO BID to start at 14-30 weeks gestational age (GA) and continue through labor and as long as the mother breastfeeds
3219954|NCT01088542|No Intervention|No intervention|Communities in the no intervention arm received no intervention from the project and continued to implement prevention services as usual.
3219955|NCT01088542|Experimental|Communities That Care Intervention|Communities randomly assigned to the experimental condition received 5 years of training and technical assistance (from 2003 to 2008) to implement the Communities That Care (CTC) prevention system in their communities. They also received 5 years of funding to support a full-time community coordinator and 4 years of seed money to implement tested and effective prevention programs selected as a result of their CTC process.
3219956|NCT01088555|Active Comparator|Control group|Healthy subjects with no history of kidney stones, heart liver or kidney disease, not pregnant /lactating.
3219957|NCT01088555|Active Comparator|Stone formers|History of calcium containing kidney stones, hypercalciuria on previous urine tests, no heart /liver / kidney disease, not pregnant/lactating
3219958|NCT01088568|Experimental|TICL group|
3219959|NCT01088568|Active Comparator|LASIK group|
3219960|NCT01088581|No Intervention|Observation group|No adjuvant chemotherapy after resection
3219961|NCT01088581|Active Comparator|Adjuvant group|Adjuvant chemotherapy after resection
3219962|NCT01088594|Experimental|1|pioglitazone 45 mg
3219963|NCT01088594|Experimental|2|Rosiglitazone 8 mg
3219964|NCT01088594|Placebo Comparator|3|Placebo
3219965|NCT01088607|Experimental|UDCA Withdrawal and Reinstitution|Each study subject will undergo serial UDCA withdrawal and reinstitution.
3219966|NCT01088620|Experimental|Panitumumab plus pemetrexed and cisplatin (PemCisP)|
3219967|NCT01088620|Active Comparator|Pemetrexed and cisplatin (PemCis)|
3219968|NCT01088633|Other|Exhaled particle analysis|
3219969|NCT01088659|Experimental|1|
3219970|NCT01088659|Experimental|2|
3219971|NCT01088685|Experimental|Experimental Blister Patch|Experimental Hydrogel Blister patch
3219972|NCT01088685|Active Comparator|Marketed Pflaster|Scholls Blasen Pflaster
3219973|NCT01088724|Experimental|chemotherapy|
3219974|NCT01088750|Other|surgery alone|watch and wait strategy after complete resection of localised (e.g. Stage IA) nodular lymphocyte-predominant HL
3219975|NCT01088750|Experimental|CVP Chemotherapy|3 cycles of intensity-reduced, anthracycline-free chemotherapy (Cyclophosphamide, vinblastine and prednisone)
3219976|NCT01088763|Experimental|Arm I|"GROUP A: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~GROUP B: Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-5, 8-12, 15-19, and 22-26. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients may also receive concurrent oral dexamethasone twice daily on the days of gamma-secretase inhibitor RO4929097 administration.~Once the MTD or recommended phase II dose of RO4929097 plus dexamethasone in children with solid tumors, including CNS tumors, or lymphoma has been identified, this dose is used for patients with relapsed-refractory T-ALL (phase 2 portion of the study) to evaluate RO4929097 in combination with dexamethasone using one of the studied schedules."
3219977|NCT01088776|Experimental|Supplement|
3219978|NCT01088776|Placebo Comparator|Control|
3219979|NCT01088789|Other|Arm A|Vaccine only.
3219980|NCT01088789|Other|Arm B|Arm B receives vaccine as well as a single dose of intravenous cyclophosphamide.
3219981|NCT01088789|Other|Arm C|In addition to Vaccine Arm C receives a daily dose of metronomic cyclophosphamide orally.
3219982|NCT01088802|Experimental|Dose de-escalating radiation therapy with chemotherapy|This protocol combines selective radiation therapy dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks) in patients with HPV-associated cancers of the oropharynx
3219983|NCT01088815|Experimental|Gemcitabine, nab-paclitaxel, GDC-0449|Gemcitabine and nab-Paclitaxel in combination with GDC-0449 (Vismodegib)
3219984|NCT01088828||Group A|"Foetuses with clubfoot identified in utero (n=15). Of these:~around 10 will be born with clubfoot and will form most of Group B,~around 5 will be born without clubfoot and will form part of group C."
3219985|NCT01088828||Group B|Neonates affected by clubfoot (n=10)
3219986|NCT01088828||Group C|Control group of unaffected neonates (n=10)
3219987|NCT01088828||Group D|Young adults having completed treatment (n=5)
3219988|NCT01088828||Group E|Control group of young unaffected adults (n=5)
3219989|NCT01088841|Active Comparator|75 g glucose + 150 ppm lactisole|
3219990|NCT01088841|Active Comparator|75 g glucose + 300 ppm lactisole|
3219991|NCT01088841|Active Comparator|75 g glucose + 450 ppm lactisole|
3219992|NCT01088841|Placebo Comparator|75 g glucose|
3219993|NCT01088854|Experimental|positive airway pressure|
3219994|NCT01088867|Other|Acupuncture|14 weeks of electroacupuncture therapy.
3219995|NCT01088880|Experimental|Canakinumab|
3219996|NCT01088893|No Intervention|observation|
3219997|NCT01088893|Experimental|Everolimus|
3219998|NCT01088906|Experimental|1 ARM|pemetrexed 500 mg/m2 IV + cisplatin 75 mg/m2 every 21 days
3219999|NCT01088919|Experimental|Dosing Regimen 1|
3220000|NCT01088919|Experimental|Dosing Regimen 2|
3220001|NCT01088919|Experimental|Dosing Regimen 3|
3220002|NCT01088919|Experimental|Dosing Regimen 4|
3220003|NCT01088932|Experimental|SRX246|SRX246
3220004|NCT01088932|Placebo Comparator|Placebo|placebo
3220005|NCT01088945|Experimental|Enhanced Discharge Process|Caregivers of these infants will receive individual coaching in order to enhance their understanding of their infant's problems and enhance their knowledge and skills to care for their fragile infants.
3220006|NCT01088945|Active Comparator|Standard Discharge Process|These infants will receive the hospital's current standard of care for the discharge of fragile infants from the NICU.
3220007|NCT01088958|Experimental|Micronutrient Sprinkles|Sales of Sprinkles in these groups of villages by community vendors
3220008|NCT01088971|Active Comparator|Duolac 7S|
3220009|NCT01088971|Placebo Comparator|starch capsule|
3220010|NCT01089010|Experimental|Treatment Sequence 1|Treatment sequence 1 consisted of three dosing periods in which patients received single oral doses of placebo, 250 mg, and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220011|NCT01089010|Experimental|Treatment Sequence 2|Treatment sequence 2 consisted of three dosing periods in which patients received single oral doses of placebo, 500 mg, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220012|NCT01089010|Experimental|Treatment Sequence 3|Treatment sequence 3 consisted of three dosing periods in which patients received single oral doses of 250 mg, placebo and 500 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220013|NCT01089010|Experimental|Treatment Sequence 4|Treatment sequence 4 consisted of three dosing periods in which patients received single oral doses of 250 mg, 500 mg and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220014|NCT01089010|Experimental|Treatment Sequence 5|Treatment sequence 5 consisted of three dosing periods in which patients received single oral doses of 500 mg, placebo, and 250 mg of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220015|NCT01089010|Experimental|Treatment Sequence 6|Treatment sequence6 consisted of three dosing periods in which patients received single oral doses of 500 mg, 250 mg, and placebo of CK-2017357, in that order, with approximately one week between each dose. Each patient acted as their own control, as all doses were represented in each treatment sequence.
3220016|NCT01089036||survival|ECMO survival patients
3220017|NCT01089036||ECMO non-survival|ECMO non-survivals
3220018|NCT01089049|Experimental|Pre-Menopausal|
3220019|NCT01089049|Experimental|Post-Menopausal|
3220020|NCT01089075|Placebo Comparator|placebo/20 mg hydrocortisone|Order of study treatment: 7 days placebo followed by 7 days 20 mg hydrocortisone
3220021|NCT01089075|Active Comparator|20 mg hydrocortisone/placebo|Order of study treatment: 7 days 20 mg hydrocortisone followed by 7 days placebo
3220022|NCT01089101|Experimental|Treatment (selumetinib)|Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities.
3220023|NCT01089140|Experimental|. Tranexamic acid low dose 10 mg/kg|
3220024|NCT01089140|Experimental|Tranexamic acid 100mg/kg|
3220025|NCT01089140|Placebo Comparator|Saline Placebo|
3220026|NCT01089166|Experimental|Torrent's Metformin tablets 500 mg|
3220027|NCT01089166|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3220028|NCT01089179|Experimental|Torrent's Metformin tablets 500 mg|
3220029|NCT01089179|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3220030|NCT01089192|Experimental|Torrent's Metformin tablets 750 mg|
3220031|NCT01089192|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA)|
3220032|NCT01089205|Experimental|Torrent's Metformin tablets 750 mg|
3220033|NCT01089205|Active Comparator|Glucophage XR® of Bristol- Myers Squibb Company, USA|
3220034|NCT01089218|No Intervention|control|control without intervention
3220035|NCT01089218|Active Comparator|Amoxicillin/clavulanate|
3220036|NCT01089244||Group A|"Patients with a suspected WHO II low grade glioma, disease progression within~1 year"
3220037|NCT01089244||Group B|Patients with a suspected WHO II low grade glioma, progression free within 1 year
3220038|NCT01089283||LRRK2 mutation|Parkinson patients that carry mutation on LRRK2 gene
3220039|NCT01089283||GBA mutation|Parkinson patients that carry mutation on GBA gene
3220040|NCT01089283||no mutation|Parkinson patients that don't carry mutation on LRRK2 or GBA genes
3220041|NCT01089283||healthy|Healthy volunteers
3220042|NCT01089296|Other|Individually customized physiotherapy|The intervention involves handling the infant and changing its position. It focuses on improving symmetry, muscle balance and movement in infants. The parent who is with the infant during the admission period will carry out the daily intervention after being taught by the physiotherapist.
3220043|NCT01089296|No Intervention|Control|Ordinary follow up in the Neonatal Intensive Care Unit (NICU).
3220044|NCT01089309|Experimental|Aldosteron blokade, Arterial stiffness, Glucose homeostasis|
3220045|NCT01089322|Experimental|Stantardized treament|oral and inhaled corticosteroid plus LABA
3220046|NCT01089335||Papillary thyroid cancer|Patients with preoperatively diagnosed highly differentiated papillary thyroid cancer
3220047|NCT01089335||Tumour of uncertain malignant potential|Thyroid tumours with preoperative cytology indicating follicular neoplasia, or on cytology suspected but not proven malignancy
3220048|NCT01089348|Experimental|Lactofiltrum|
3220049|NCT01089348|Active Comparator|Control|
3220050|NCT01089374|Other|Partial breast radiation after lumpectomy|Radiation per NSABP B-39/R0413 protocol.
3220051|NCT01089387|Experimental|injection of bone marrow cells|
3220052|NCT01089400||Influenza A/H1N1 patients|
3220053|NCT01089400||Non influenza A/H1N1 patients|
3220054|NCT01089426|Other|Historical controls|A subset of patients previously seen, who have had at least 2 consecutive direct bilirubin levels > 2 mg/dL, who depended on parenteral nutrition for at least 90 days after surgical therapy for congenital or acquired intestinal diseases
3220055|NCT01089426|Experimental|Omegaven™|
3220056|NCT01089439|Active Comparator|1: INOMAX|"Nitric oxide by inhalation INOMAX:~active arm treated with nitric oxide"
3220057|NCT01089439|Placebo Comparator|2: Placebo|placebo arm treated with placebo at the same conditions
3220058|NCT01089452|Active Comparator|Perindopril monotherapy|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
3220059|NCT01089452|Active Comparator|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
3220060|NCT01089452|Experimental|Olmesartan/amlodipine FDC|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
3220061|NCT01089530|No Intervention|Standard care|
3220062|NCT01089621|Experimental|Duloxetine|
3220063|NCT01089660|Experimental|Study Group 1|Swine-origin A/H1N1 Vaccine Low-dose
3220064|NCT01089660|Experimental|Study Group 2|Swine-origin A/H1N1 Vaccine High-dose
3220065|NCT01089673||no treatment|retrospective data analysis
3220066|NCT01089686|Active Comparator|Venoplasty (treatment)|Patients will be randomized to treatment or non-treatment arm with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the treatment arm of the study will receive venoplasty at the time of the diagnostic venogram.
3220067|NCT01089686|Sham Comparator|Sham procedure (non-treatment)|Patients will be randomized to treatment or non-treatment with a 2:1 ratio. Patients who meet the inclusion/exclusion criteria and who are randomized to the non-treatment arm of the study will receive the diagnostic venogram only.
3220068|NCT01089699|Active Comparator|Professionally-led online support|Members assigned to 10-week online support group with a professional counsellor.
3220069|NCT01089699|Active Comparator|Peer-led online support|
3220070|NCT01089699|Active Comparator|self-study materials|
3220071|NCT01089712||Patients undergoing cardiac surgery|The patient population for this study consists of all patients undergoing cardiac surgical interventions. All patients who meet the eligibility criteria may be included in the study regardless of gender, race or ethnicity.
3220072|NCT01089738|Experimental|Dosing|Ascending Doses
3220073|NCT01089764|Experimental|Couplelinks.ca Intervention|Intervention arm - Couple participates in the Couplelinks.ca program.
3220074|NCT01089764|No Intervention|No Intervention|Couple is waitlisted for participation in the Couplelinks.ca program.
3220075|NCT01089790|Experimental|1|
3220076|NCT01089790|Active Comparator|2|
3220077|NCT01089803||Patients Treated with Laryngectomy|Patients initially treated with laryngectomy and followed for 12 months after receiving this treatment.
3220078|NCT01089803||Patients Treated with Chemoradiation|Patients treated initially with chemoradiation and followed for 12 months after receiving treatment.
3220079|NCT01089816||All|Anyone presenting with influenza-like-illness
3220080|NCT01089829||CKD Stage 4|eGFR <30
3220081|NCT01089829||CKD Stage 5|Receiving Haemodialysis or Peritoneal dialysis therapy
3220082|NCT01089842|Experimental|Health coaching|
3220083|NCT01089842|No Intervention|Control|
3220084|NCT01089855|Experimental|Carbamazepine|
3220085|NCT01089868||Group A|Patients who suffer from a suspected GBM and will undergo a microsurgical procedure for diagnosis verification. MRI and Positron Emission Tomography (PET) scans are scheduled prior to microsurgery, post microsurgery and after having completed radiochemotherapy and an additional scan after TMZ chemotherapy.
3220086|NCT01089868||Group B|Patients enrolled in Group B suffer from a suspected GBM which cannot be accessed microsurgically either due to a an eloquent location of the tumor, or patient's refusal to undergo surgery. In these patients, diagnosis will be obtained by means of stereotactic surgery. After an initial PET and MRI scan prior to biopsy, patients will be monitored by post radiochemotherapy as well as post 3-months chemotherapy MRI/PET scans.
3220087|NCT01089881||Group 1|patients with BPH
3220088|NCT01089881||Group 2|patients with newly diagnosed prostate cancer
3220089|NCT01089881||Group 3|patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.
3220090|NCT01089894||18F-FLT 1|18F-FLT in differentiating benign from malignant pulmonary nodules
3220091|NCT01089894||18F-FLT 2|18F-FLT in evaluating therapeutic response of platinum-based chemotherapy (The chemotherapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
3220092|NCT01089894||18F-FLT 3|18F-FLT in evaluating therapeutic response of EGFR tyrosin kinase inhibitors (The target therapeutic drugs used in the study are all approved by the Department of Health, Taiwan.)
3220093|NCT01089920|Experimental|High dose coffee|High dose of polyphenols from soluble coffee
3220094|NCT01089920|Experimental|Medium dose coffee|Medium dose of polyphenols from soluble coffee
3220095|NCT01089920|Experimental|Low dose coffee|Low dose of polyphenols from soluble coffee
3220096|NCT01089920|Experimental|High dose green tea|High dose of green tea polyphenols from infusion
3220097|NCT01089920|Experimental|Medium dose green tea infusion|Medium dose of green polyphenols from infusion
3220098|NCT01089920|Experimental|Low dose green tea infusion|low dose of polyphenols from an infusion of green tea
3220099|NCT01089933|Experimental|Thoracic PVB + multimodal anesthesia|Thoracic PVB + multimodal anesthesia
3220100|NCT01089933|Active Comparator|Local anesthetic + multi-modal analgesia|Local anesthetic + multi-modal analgesia
3220101|NCT01089959|Other|Esomeprazole|Effect of PPI esomeprazole on acid reflux & related arousals during sleep in patients with GERD.
3220102|NCT01089972||20 gauge group|
3220103|NCT01089972||22 gauge group|
3220104|NCT01089985|Experimental|Serum eye drops|Patient's autologous serum is diluted in saline solution
3220105|NCT01089998|Experimental|Arm 1|
3220106|NCT01089998|Experimental|Arm 2|
3220107|NCT01089998|Experimental|Arm 3|
3220108|NCT01089998|Experimental|Arm 4|
3220109|NCT01090024|Experimental|BI 671800 AM and PM|Patients receiving two capsules twice daily
3220110|NCT01090024|Experimental|BI 671800 AM|Patients receiving four capsules in the morning
3220111|NCT01090024|Experimental|BI 671800 PM|Patients receiving four capsules in the evening
3220112|NCT01090024|Placebo Comparator|Placebo|Patients receiving four capsules twice a day
3220113|NCT01090037|Experimental|TRK-100STP|
3220114|NCT01090037|Placebo Comparator|Placebo|
3220115|NCT01090089|Experimental|Lenalidomid, PBSCT|A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
3220116|NCT01090089|Active Comparator|Lenalidomid|A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
3220117|NCT01090128|Experimental|All patients|All participants enrolled.
3220119|NCT01090167|Experimental|Clofarabine|
3220120|NCT01090193|Other|obstructive jaundice|
3220121|NCT01090206|Other|Hemophilia, Vitamin D deficiency|"Hemophilia, Rickets - Vitamin D per endocrine consult~Hemophilia, Vitamin D deficient - Vitamin D 2000 units daily plus calcium~Hemophilia, Normal Vitamin D - no intervention - observation only"
3220122|NCT01090219|Experimental|two differents meshes|Heavy-weight versus low-weight polypropylene meshes
3220123|NCT01090232|Experimental|chronic HEV infection|in kidney-transplant recipients with chronic HEV infection
3220124|NCT01090232|Active Comparator|control|the host responses in kidney-transplant recipients without viral infection (controls)
3220125|NCT01090245|Active Comparator|Attendance Information Group|Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program.
3220126|NCT01090245|Experimental|Attendance Incentive Group|Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program.
3220127|NCT01090258|Experimental|Automated settings|Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
3220128|NCT01090258|Active Comparator|protocolized settings|Ventilator settings performed by the local respiratory therapists according to the local protocols
3220129|NCT01090271|Experimental|Eccentric training|
3220130|NCT01090284||Heavy weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene heavy weight mesh.
3220131|NCT01090284||Light weight mesh|This cohort includes patients undergoing inguinal hernioplasty with polypropylene light weight mesh.
3220132|NCT01090297|Active Comparator|Fixed pressure|
3220133|NCT01090297|Active Comparator|Auto-adjusting pressure|
3220134|NCT01090336||Clopidogrel group|At the discretion of the attending cardiologist patients are treated with clopidogrel (600mg loading and 75mg daily dose)
3220135|NCT01090336||Prasugrel group|At the discretion of the attending cardiologist patients are treated with prasugrel (60mg loading and 10mg daily dose)
3220136|NCT01090349|Experimental|Direct Alerts ON|Direct Alerts in implantable device were turned on
3220137|NCT01090349|Active Comparator|Direct Alerts OFF|Direct Alerts in implantable device were turned off
3220138|NCT01090362||Cohort 1|Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.
3220139|NCT01090362||Cohort 2|Cohort completed with 11,351 patients enrolled from 30 countries
3220140|NCT01090362||Cohort 3|Cohort 3 completed with 11,139 patients enrolled globally from 32 countries
3220141|NCT01090362||Cohort 4|Cohort 4 completed with 11,2780 patients enrolled from 35 countries.
3220142|NCT01090362||Cohort 5|Final cohort completed with 12,186 patients enrolled.
3220143|NCT01090375|Experimental|Exercise|
3220144|NCT01090375|Placebo Comparator|Non Exercise|
3220145|NCT01090388||1|Participants voluntarily completed a telephone interview using a questionnaire compiled using validated, patient-centered measures of cancer outcomes and psychosocial status.
3220146|NCT01090401|Experimental|Patients with Linox smart S DX lead|
3220147|NCT01090440|Experimental|Three-way cross- over|Three regimens will be administered in this study: A: GSK1144814 Tablet (100mg) Fasted State; B: GSK1144814 Tablet (200mg) Fasted State and C: GSK 1144814 Tablet (100mg) Fed State (FDA high fat breakfast).
3220148|NCT01090505|Experimental|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2|Drug: Neoadjuvant chemotherapy(S-1+Oxaliplatin) followed by D2 gastrectomy
3220149|NCT01090505|No Intervention|surgery|Procedure/Surgery: Gastrectomy with D2 dissection
3220150|NCT01090518|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
3220151|NCT01090518|Placebo Comparator|Prolonged Exposure therapy with placebo|
3220152|NCT01090557||RSV positive subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are positive for RSV by Direct Fluorescent Antibody technique and/or viral culture
3220153|NCT01090557||RSV negative subjects|Subjects admitted to the hospital with Lower respiratory tract Viral infection symptoms from which nasopharyngeal mucous samples are negative for RSV by Direct Fluorescent Antibody technique and/or viral culture (usually positive for influenza A & B, parainfluenza, human metapneumovirus or adenovirus)
3220154|NCT01090557||Control group|Children with same age range, ethnic background, and gender distribution as the study group coming for evaluation in the outpatient setting without evidence of viral infection
3220155|NCT01090570|Experimental|PLX3397 25 mg|
3220156|NCT01090570|Experimental|PLX3397 50 mg|
3220157|NCT01090570|Experimental|PLX3397 100 mg|
3220158|NCT01090570|Experimental|PLX3397 200 mg|
3220159|NCT01090570|Experimental|PLX3397 300 mg|
3220160|NCT01090570|Placebo Comparator|Placebo|
3220161|NCT01090583||Cesarean Delivery Patients|
3220162|NCT01090596|Active Comparator|Naproxen-Treated|
3220163|NCT01090596|Placebo Comparator|placebo|
3220164|NCT01090609|Experimental|Stent implantation|Cronus Stent implantation
3220165|NCT01090622|Placebo Comparator|Matching Placebo|
3220166|NCT01090622|Experimental|XPF-001|
3220167|NCT01090648|Experimental|001|etravirine One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
3220168|NCT01090661|Experimental|mipomersen IV (supra-therapeutic dose)|200 mg of mipomersen IV / placebo SC
3220169|NCT01090661|Experimental|mipomersen SC (therapeutic dose)|200 mg of mipomersen SC / placebo IV
3220170|NCT01090661|Active Comparator|moxifloxacin IV|400 mg of moxifloxacin IV / placebo SC
3220171|NCT01090661|Placebo Comparator|placebo|Placebo IV / placebo SC
3220172|NCT01090674||1|Patients with amyotrophic lateral sclerosis.
3220173|NCT01090687||Group I Microcalcifications|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary findings based on microcalcifications will be recruited to have a breast CT scan.
3220174|NCT01090687||Group II Soft tissue findings|After classification as BI-RADS 4/5, approximately 75 to 100 subjects with primary soft tissue findings, with or without associated microcalcifications, will be recruited to have a breast CT scan.
3220175|NCT01090700|Experimental|001|TMC435 TMC435 150 mg daily for 7 days
3220176|NCT01090700|Other|002|Escitalopram Escitalopram 10 mg daily for 7 days
3220177|NCT01090700|Experimental|003|TMC435 + Escitalopram TMC435 150 mg + escitalopram 10 mg daily for 7 days
3220178|NCT01090713|Active Comparator|Lisdexamfetamine|drug
3220179|NCT01090713|Placebo Comparator|Placebo|Placebo comparator
3220180|NCT01090726|Experimental|Storz videolaryngoscope|Macintosh overview followed by Airtraq overview followed by Storz videolaryngoscope overview and intubation.
3220181|NCT01090726|Active Comparator|Airtraq|Macintosh overview followed by Storz videolaryngoscope overview followed by Airtraq overview and intubation.
3220182|NCT01090778|Other|Norditropin SimpleXx sc bolus injection|Single sc bolus injection of 3 mg growth hormone without interval exercise
3220183|NCT01090778|Other|Norditropin SimpleXx single sc injection|Single sc bolus injection of 3 mg growth hormone with interval exercise
3220184|NCT01090778|Other|Norditropin SimpleXx contin. sc infusion|Continuous sc infusion of 3 mg growth hormone without interval exercise
3220185|NCT01090778|Other|Norditropin SimpleXx cont. sc infusion|Continuous sc infusion of 3 mg growth hormone with interval exercise
3220186|NCT01090804|Experimental|breathing exercise|BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
3220187|NCT01090817|Experimental|Mesenchymal stromal cells|Mesenchymal stromal cells administered weekly for 4 weeks
3220188|NCT01090830|Experimental|Belinostat|This is a one arm, open label study of the investigational medication Belinostat.
3220189|NCT01090856|No Intervention|No pre-dilation side branch|
3220190|NCT01090856|Active Comparator|Pre-dilation side branch|
3220191|NCT01090869|Active Comparator|Physical training, unchanged diet|Daily endurance training equivalent to 600 kcal/day and unchanged habitual diet
3220192|NCT01090869|Active Comparator|Physical training, increased diet|Daily endurance training equivalent to 600 kcal/day, and increased diet by 600 kcal/day.
3220193|NCT01090869|Active Comparator|Diet, unchanged physical activity|Energy-reduced diet by 600 kcal/day, and unchanged sedentary lifestyle
3220194|NCT01090869|No Intervention|Control|Unchanged sedentary lifestyle and diet
3220195|NCT01090882|Sham Comparator|Control|Sham wash, sham injection
3220196|NCT01090882|Experimental|Subperitoneal injection|Local anaesthetic injection to diaphragm with sham wash over liver and gall bladder
3220197|NCT01090882|Active Comparator|Topical LA|Local anaesthetic washed over gall bladder and liver. Sham injection of diaphragm
3220198|NCT01090895|Active Comparator|Vitamin C|Vitamin C infusion
3220199|NCT01090895|Placebo Comparator|Placebo|Saline solution
3220200|NCT01090908||Ages 6-11 years|
3220201|NCT01090908||Ages 12-17 years|
3220202|NCT01090934|Experimental|high resolution EEG|
3220203|NCT01090934|Active Comparator|Stereo Electroencephalography|
3220204|NCT01090947||Patients referred to CAG.|Sequential design with ProtoCAD and CAG
3220205|NCT01090960|Experimental|A|
3220206|NCT01090986||1|Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV. Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
3220207|NCT01090999|No Intervention|1|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The No Intervention group will undergo a standard, minimal monitoring program."
3220208|NCT01090999|Active Comparator|2|"All patients will receive an initial in-hospital rehabilitation program which includes: Education, Physiotherapy, lower and upper extremities training and respiratory muscles training. Following completion of this program, patients will undergo concealed randomization to one of two maintenance strategies.~The active comparator group will undergo an intensive maintenance program after the initial in-hospital rehabilitation program."
3220209|NCT01091012|Other|Sildenafil 20mg oral|
3220210|NCT01091012|Other|Sildenafil 10mg intravenous|
3220211|NCT01091025|Other|CF patients without known diagnose of CFRD|There is only one arm. All patients in the study had the same procedures (ie. an OGTT). Investigators used the screening criteria in parallel to this.
3220212|NCT01091038|Placebo Comparator|Routine Care|Usual care of patients in the ambulatory setting
3220213|NCT01091038|Experimental|Basic Clinical Decision Support|Providers use basic clinical decision support
3220214|NCT01091051|Active Comparator|Ustekinumab|Ustekinumab S/C 45mg or 90mg depending on patient's weight or placebo injection. 10 with PPPP and 10 with PPP will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
3220215|NCT01091051|Placebo Comparator|Placebo|Placebo S/C (Sodium Chloride). 10 with PPPP and 10 with PPP will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
3220216|NCT01091064|Experimental|Early depart|Patients who will be liberated at triage with mild acute viral bronchiolitis
3220217|NCT01091064|No Intervention|Medical visit group|Patients with acute viral bronchiolitis who will wait to be seen by the physician
3220218|NCT01091077|Placebo Comparator|Naringenin|Single dose of naringenin, compared to placebo in the same individual.
3220219|NCT01091090|Experimental|Cognitive behavioral|Subjects with receive a cognitive behavioral intervention for smoking cessation
3220220|NCT01091090|Active Comparator|Control|Treatment as usual
3220221|NCT01091129|Experimental|Treatment|Treatment with the miraDry System in both axilla
3220222|NCT01091142|Experimental|NP001|
3220223|NCT01091142|Placebo Comparator|Placebo|
3220224|NCT01091181|Active Comparator|high incision group|hysterotomy at cesarean performed 2 cm above plica vesicouterina
3220225|NCT01091181|Active Comparator|low incision group|hysterotomy at cesarean performed 2 cm below plica vesicouterina
3220226|NCT01091194|Other|Exercise|Interval-based aerobic exercise
3220227|NCT01091194|No Intervention|Control|No intervention other than regular follow up hospital visits
3220228|NCT01091207|Experimental|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
3220229|NCT01091220|Placebo Comparator|Placebo|0.9% saline
3220230|NCT01091220|Experimental|Certolizumab pegol|Certolizumab pegol 400 mg
3220231|NCT01091233||Paracentesis|Paracentesis as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
3220232|NCT01091272|Experimental|Cohort 1|Single dose 3 period interleaved cross-over with placebo substitution
3220233|NCT01091272|Experimental|Cohort 2|Single dose 4 period interleaved cross-over, placebo substitution, with food effect
3220234|NCT01091272|Experimental|Cohort 3|Single dose 4 period cross-over, placebo insertion, with food effect
3220235|NCT01091272|Experimental|Optional Cohort 4|Single dose 3 period cross-over with placebo substitution
3220236|NCT01091285|Active Comparator|Single Balloon Catheter|Cervix Ripening is achieved by a single balloon catheter. Further induction by cytotec or/amniotomy and pitocin
3220237|NCT01091285|Active Comparator|Double balloon catheter|Cervix Ripening is achieved by a double balloon catheter. Further induction by cytotec or/amniotomy and pitocin
3220238|NCT01091298|Experimental|Group 1|
3220239|NCT01091298|Placebo Comparator|Group 2|
3220240|NCT01091324|Active Comparator|Dextromethorphan|
3220241|NCT01091324|Active Comparator|Silymarin|
3220242|NCT01091324|Placebo Comparator|sugar pill|
3220243|NCT01091337|Experimental|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
3220244|NCT01091337|Active Comparator|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
3220245|NCT01091350|Active Comparator|Diprifusor group|Propofol was infused via Diprifusor TCI (Target-controlled infusion)
3220246|NCT01091350|Experimental|Orchestra group|Propofol was infused via Orchestra TCI
3220247|NCT01091376|Experimental|Concomitant Erlotinib and radiotherapy|Patients received Erlotinib and radiation therapy.
3220248|NCT01091389|Experimental|GP ablation|Thoracoscopic PV isolation with GP ablation
3220249|NCT01091389|Experimental|No GP ablation|Thoracoscopic PV isolation with no GP ablation
3220250|NCT01091402||chronic urticaria|
3220251|NCT01091402||asthma|
3220252|NCT01091402||seasonal allergic rhinitis|
3220253|NCT01091402||normal controls|
3220254|NCT01091415|Experimental|calcium phosphate bone cement|one arm; volar locking plate alone the other arm; calcium phosphate bone cement as well as volar locking plate
3220255|NCT01091441||Patients with heart failure|Patients hospitalized for acute heart failure
3220256|NCT01091467||Patients with HF|Each patient seen in hospital emergency or for congestive heart failure and with an ejection fraction above 45%
3220257|NCT01091480||Patients with HCM|Patients ≥ 15 years with HCM(sarcomere of origin or not) defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
3220258|NCT01091493|No Intervention|Non-Antibiotic|Patients will not receive antibiotics, although the study is double-blind.
3220259|NCT01091493|Active Comparator|Antibiotic|Patients will receive in a masked way, moxifloxacin.
3220260|NCT01091506|Experimental|L-methylfolate|L-methylfolate 15mg (a medical food)
3220261|NCT01091506|Placebo Comparator|Placebo|Placebo
3220262|NCT01091532|Experimental|Cohort 1|Subjects will be assigned to receive either UK-396,082 or placebo
3220263|NCT01091532|Experimental|Cohort 2|Subjects will be assigned to receive either UK-396,082 or placebo
3220264|NCT01091532|Experimental|Cohort 3|Subjects will be assigned to receive either UK-396,082 or placebo
3220265|NCT01091532|Experimental|Cohort 4|Subjects will be assigned to receive either UK-396,082 or placebo
3220266|NCT01091545|Other|FFDM+DBT|Single-armed study. Women are their own controls with paired images of digital mammography and breast tomosynthesis.
3220267|NCT01091558||Colonoscopy|Healthy volunteer who is having a screening colonoscopy
3220268|NCT01091558||Ulcerative Colitis|Patients with confirmed ulcerative colitis who are scheduled for endoscopy for medical reasons.
3220269|NCT01091571|Placebo Comparator|Endotoxemia placebo|Endotoxin combined with placebo
3220270|NCT01091571|Experimental|Endotoxemia Dipyridamole|Endotoxin combined with Dipyridamol treatment
3220271|NCT01091584|Active Comparator|intervention group|The intervention is to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse.
3220272|NCT01091584|No Intervention|control group|usual care
3220273|NCT01091597|Active Comparator|usual ablation|Wide-area circumferential ablation of the pulmonary veins
3220274|NCT01091597|Experimental|Box isolation of the pulmonary veins|Single Box lesion set encompassing all four pulmonary veins and the posterior wall of the left atrium.
3220275|NCT01091610||1|all emergency medical staff having suffered an accident during work
3220276|NCT01091610||2|non emergency medical personnel having suffered an injury due to a medical mission, e.g. transported patient having suffered additional injury due to an ambulance accident or collision of an ambulance with another vehicle.
3220277|NCT01091623|Active Comparator|strength training|
3220278|NCT01091623|Active Comparator|endurance training|
3220279|NCT01091623|Active Comparator|combined training|
3220280|NCT01091636|Experimental|HIPEC|Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Ovarian Cancer after primary cytoreductive surgery or interval cytoreductive surgery
3220281|NCT01091636|No Intervention|No HIPEC|Primary cytoreductive surgery or interval cytoreductive surgery
3220282|NCT01091649|Active Comparator|A|Low dose ABT-450 capsule and ritonavir capsules (reference).
3220283|NCT01091649|Active Comparator|B|Low dose ABT-450 SDD Tablet Form 1 and ritonavir capsules (test 1)
3220284|NCT01091649|Active Comparator|C|Low dose ABT-450 SDD Tablet Form 2 and ritonavir capsules (test 2).
3220285|NCT01091649|Active Comparator|D|High dose ABT-450 capsule and ritonavir capsules (reference).
3220286|NCT01091649|Active Comparator|E|High dose ABT-450 SDD Tablet Form 1 or 2 and ritonavir capsule (test)
3220287|NCT01091688|Experimental|Just-in-Time intervention|"The infants and physicians in the experimental group will receive the Just-in-Time intervention sheets at the time of discharge."
3220288|NCT01091688|No Intervention|Routine discharge care|The infants and physicians in the routine discharge care arm will receive the same information and details as is per normal routine in the nursery.
3220289|NCT01091701|Experimental|Ex vivo cultured adult allogenic MSCs|
3220290|NCT01091701|Placebo Comparator|Plasmalyte-A|
3220291|NCT01091714|Active Comparator|PRN Dry Eye Omega Benefits|4 capsules per day = 2240 mg Omega-3s
3220292|NCT01091714|Active Comparator|Nature's Made|2 capsules per day = 2400mg Omega-3s
3220293|NCT01091714|Active Comparator|Thera Tears|4 capsules per day = 2332mg Omega-3s
3220294|NCT01091727|Experimental|Botulinum toxin A|Botulinum toxin A 300U diluted with sterile saline (1 ml per injection site) and injected into 30 sites of the bladder, sparing the trigone.
3220295|NCT01091727|Placebo Comparator|Placebo|Sterile saline 30 cc injected into 30 sites in the bladder, sparing the trigone.
3220296|NCT01091740|Experimental|ZES resolute (Endeavor Resolute)|
3220297|NCT01091740|Active Comparator|EES (Xience)|
3220298|NCT01091753|Placebo Comparator|morning administration group|
3220299|NCT01091753|Experimental|nocturnal administration group|
3220300|NCT01091766|Active Comparator|bupivacaine|test solution consists of bupivacaine 0.125%
3220301|NCT01091766|Active Comparator|bupivacaine+epinephrine|test solution consists of bupivacaine 0.125% with epinephrine 1:200000
3220302|NCT01091766|Active Comparator|epinephrine|test solution consists of epinephrine 1:200000
3220303|NCT01091779||Hypertensive and normotensive|
3220304|NCT01091792|Experimental|Bevacizumab|Bevacizumab + temozolomide + radiotherapy followed by adjuvant bevacizumab + temozolomide
3220305|NCT01091818|Active Comparator|midazolam|
3220306|NCT01091818|Experimental|dexmedetomidin|
3220307|NCT01091831|Active Comparator|CRD|Oral therapy with Cyclophosphamide, Lenalidomide and Dexamethasone.
3220308|NCT01091831|Active Comparator|MEL200|High dose Melphalan therapy (200 mg/m2) followed by stem cell support for 2 cycles every 4 months (for 1 cycle if at least VGPR was achieved after the 1st MEL200)
3220309|NCT01091844|Active Comparator|Spontaneous Fill Technique|"We allow the bladder to spontaneously fill, then allow the patient to void and afterward catheterize the patient to check a postvoid residual (spontaneous fill technique)."
3220310|NCT01091844|Active Comparator|Retrograde Fill Technique|"We assess bladder emptying by filling the bladder retrograde through the catheter already in place with 300 mL of saline and then removing the catheter and allowing the patient to void (retrograde-fill technique). We will determine postvoid residual indirectly by subtracting voided volume from the 300 mL infused volume. No catheterization will be performed with this technique unless they void less than 200 mL."
3220311|NCT01091857|Experimental|Exercise intervention (STRIDE)|
3220312|NCT01091857|Active Comparator|Health and Wellness Control|
3220313|NCT01091870|Placebo Comparator|Placebo: soluble blue pigment|Soluble blue pigment for placebo controlling.
3220314|NCT01091870|Experimental|Sildenafil, 75mg daily|Sildenafil citrate, 75 mg daily divided in 3 doses. From third to 14th day after subarachnoid hemorrhage.
3220315|NCT01091870|Experimental|Sildenafil, 150 mg daily|Sildenafil citrate, 150 mg daily divided in 3 doses from third to 14th day after subarachnoid hemorrhage.
3220316|NCT01091883|Experimental|Exablate treatment|Exablate 2000
3220317|NCT01091883|Active Comparator|Radiation|External Beam Radiation
3220318|NCT01091896|No Intervention|1 - no bevacizumab|Patients will not receive bevacizumab before nor during vitrectomy
3220319|NCT01091896|Experimental|2- bevacizumab before vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
3220320|NCT01091896|Experimental|3- bevacizumab after vitrectomy|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
3220321|NCT01091909|Experimental|post-extraction wound healing|53 individuals with diabetes and 29 controls, without diabetes, were followed for 60 days after dental extractions, and were examined after 3, 7, 21, and 60 postoperative days.
3220322|NCT01091922|Placebo Comparator|Low Flavanol|Low flavanol drink containing 23 mg of total flavanols. Macro- and micro-nutrient matched with active comparator
3220323|NCT01091922|Active Comparator|High Flavanols|High Flavanol drink containing 495 mg of total flavanols
3220324|NCT01091935||Lidocaine|"Adults >18 yrs , attending St Joseph's Health Care Pain Clinic with a diagnosis of chronic neuropathic pain who are being treated with an lidocaine infusion of 5 mg/kg over 45 minutes~Consecutive patients from two time periods:~June 15 to August 21, 2009~October 15-Dec 22,2009"
3220325|NCT01091961|Active Comparator|Continuing ACEi/ARB|Patients in this group will continue to take their chronic ACEi/ARB medications up to and including the day of surgery.
3220326|NCT01091961|Active Comparator|Holding ACEi/ARB|Patients in this arm will hold their chronic ACEi/ARB medication at least 24 hours prior to surgery.
3220327|NCT01091987|Experimental|Non-pharmacological approach of insomnia|Non-pharmacological approach of insomnia based on cognitive-behavioural techniques (education on sleep, sleep hygiene, stimulus control, cognitive techniques)
3220328|NCT01092000||Faculty/Staff|
3220329|NCT01092000||Graduate Students|
3220330|NCT01092000||Undergraduate Students|
3220331|NCT01092013|Active Comparator|Operating room training|
3220332|NCT01092013|Active Comparator|Skills lab training|
3220333|NCT01092026|Experimental|cord blood transplant|Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
3220334|NCT01092039|Experimental|XIGO pill|Oral Xigo tablet
3220335|NCT01092039|Placebo Comparator|Placebo|Oral placebo tablet
3220336|NCT01092052|Experimental|1|
3220337|NCT01092065|Experimental|AFQ056 100 mg (Bid)|
3220338|NCT01092065|Placebo Comparator|Placebo|
3220339|NCT01092078|Experimental|Motivational Interviewing|Individuals in the motivational interviewing (MINT) arm of the study will receive telephone-based lifestyle interviewing for 6-months. Counseling will be aimed at modifying diet and/or physical activity behaviors associated with decreasing blood pressure.
3220340|NCT01092078|Experimental|Patient Navigation|Participants in the patient navigation arm will receive patient navigation for colonoscopy.
3220341|NCT01092078|Experimental|PLUS|Both patient navigation for colorectal cancer screening and motivational interviewing for blood pressure control
3220342|NCT01092091|Experimental|PEG-BCT-100|Pegylated Recombinant Human Arginase I
3220343|NCT01092104|Experimental|TBR-652 25 mg QD|TBR 25 mg QD for 10 days
3220344|NCT01092104|Placebo Comparator|Placebo|Matching Placebo QD for 10 days
3220345|NCT01092104|Experimental|TBR-652 50 mg QD|TBR-652 50 mg QD for 10 days
3220346|NCT01092104|Experimental|TBR-652 75 mg QD|TBR-652 75 mg QD for 10 days
3220347|NCT01092104|Experimental|TBR-652 100 mg QD|TBR-652 100 mg QD for 10 days
3220348|NCT01092104|Experimental|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
3220350|NCT01092130|Experimental|Vitamin D|Patients were randomized by an automated computer system to 2000 IU oral cholecalciferol once daily or control (i.e. no extra medication), in a 1:1 ratio for a period of six weeks. Blood was collected in a sitting position on visits 2-4 and patients were asked to collect 24h urine samples prior to visits 2 and 4. Heart failure medication was maintained unchanged throughout the trial. Changes in diuretic dose were permitted if necessary to treat decompensation or renal dysfunction.
3220351|NCT01092143|Experimental|BI671800 (low dose)|Patients receive BI671800 (low dose) capsules twice daily
3220352|NCT01092143|Active Comparator|Fluticasone|Patients inhale from Fluticasone MDI twice daily
3220353|NCT01092143|Placebo Comparator|placebo|Patients receive placebo capsules twice daily
3220354|NCT01092143|Experimental|BI671800 (medium dose)|Patients receive BI671800 (medium dose) capsules twice daily
3220355|NCT01092143|Experimental|BI671800 (high dose)|Patients receive BI671800 (high dose) capsules twice daily
3220356|NCT01092156|Active Comparator|Education on Infant-led latching|
3220357|NCT01092156|No Intervention|Standard education|
3220358|NCT01092169||Sickle cell beta|
3220359|NCT01092221|Experimental|Allopurinol|
3220360|NCT01092221|Placebo Comparator|Placebo|
3220361|NCT01092234|Active Comparator|Traditional ward|
3220362|NCT01092234|Experimental|Observational unit|Organizational change. Innovative organization of in-hospital care
3220363|NCT01092247|Placebo Comparator|Standard diet: Nutritional support|
3220364|NCT01092247|Experimental|Nutritional intervention: Ketogenic diet.|
3220365|NCT01092273||Bimatoprost versus Travoprost|
3220366|NCT01092286|Experimental|neuromuscular warm-up|coaches in this arm use the prescribed warm-up before team practices
3220367|NCT01092286|No Intervention|no warm-up|coaches use their usual warm-up before team practices
3220368|NCT01092299|Experimental|Cohort 1 (2 arms)|Period 1: randomized to either fasting IR or ER1. Period 2: Cross-over to either IR or ER1. Period 3: ER1 in fed conditions.
3220369|NCT01092299|Experimental|Cohort 2 (2 arms)|Period 1: randomized to either fasting IR or ER2. Period 2: Cross-over to either IR or ER2. Period 3: ER2 in fed conditions.
3220370|NCT01092299|Experimental|Cohort 3( 2 arms)|Period 1: randomized to either fasting IR or ER3. Period 2: Cross-over to either IR or ER3. Period 3: ER3 in fed conditions.
3220371|NCT01092299|Experimental|Cohort 4 (2 arms)|Period 1: randomized to either fasting IR or MR4. Period 2: Cross-over to either IR or MR4. Period 3: MR4 in fed conditions.
3220372|NCT01092299|Experimental|Part 2: Extended/Modified release|Extended/Modified release capsule to be determined
3220373|NCT01092299|Placebo Comparator|Part 2: Placebo|
3220374|NCT01092312|Experimental|Signature Knee Guide|Vanguard Knee System with Signature Knee Guide
3220375|NCT01092312|Active Comparator|Conventional Approach|Vanguard Complete Knee System with Conventional Approach
3220376|NCT01092325|Experimental|Cohort 1 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
3220377|NCT01092325|Placebo Comparator|Cohort 1 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
3220378|NCT01092325|Experimental|Cohort 2 CXL-1020|An intravenous infusion of CXL-1020 administered for a total of 4 hours over a total of 3 occasions separated by at least one week. Each of the 3 doses of CXL-1020 are different, starting with the lowest dose and increasing to the highest dose.
3220379|NCT01092325|Placebo Comparator|Cohort 2 Placebo|A 4 hour infusion of Placebo administered one time randomly among the 3 active doses of CXL-1020 in cohort 1
3220380|NCT01092325|Active Comparator|Echo Cohort A CXL-1020|A 4 hour infusion of a fixed dose of CXL-1020 which was studied in Cohort 1 or Cohort 2 which is expected to be well tolerated and have hemodynamic effect
3220381|NCT01092325|Active Comparator|Echo Cohort B CXL-1020|CXL-1020 administered at a fixed rate for the initial 2 hours and at a higher fixed rate for the last 2 hours of a 4 hour infusion at doses which were studied in Cohort 1 or Cohort 2 and expected to be well tolerated and have hemodynamic effects
3220382|NCT01092351|Experimental|Nitrofurantoin|Adult patients with a microbiologically confirmed uncomplicated urinary tract infection
3220383|NCT01092377|Experimental|DHA/EPA capsules and iron tablet|
3220384|NCT01092377|Experimental|DHA/EPA and placebo tablet|
3220385|NCT01092377|Placebo Comparator|placebo capsules & placebo tablet|
3220386|NCT01092377|Experimental|iron tablet and placebo capsules|
3220387|NCT01092390|Experimental|Lovaza|4 grams per day
3220388|NCT01092403|Experimental|ASM-024|ASM-024 once daily by inhalation
3220389|NCT01092403|Placebo Comparator|Placebo|Placebo once daily by inhalation
3220390|NCT01092429||one,two,and three vessels disease; mortality|
3220391|NCT01092455||Citrasate and heparin reduction|Sequential hemodialysis treatment study in which all enrollees move through four (4) separate treatment phases. Results from the separate phases will be compared to standard bicarbonate dialysis with standard does of heparin.
3220392|NCT01092468|Placebo Comparator|Diathermy|Perforator flap elevation using conventional diathermy technique
3220393|NCT01092468|Active Comparator|Harmonic Scalpel|Perforator flap elevation using Harmonic Scalpel
3220394|NCT01092481|Active Comparator|FOLFOX_12 or CAPOX_8|6 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
3220395|NCT01092481|Experimental|FOLFOX_6 or CAPOX_4|3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX
3220396|NCT01092494||OC use|OC use after postoperative gonadotropin-releasing hormone agonist treatment
3220397|NCT01092494||OC non-use|Only postoperative gonadotropin-releasing hormone agonist treatment
3220398|NCT01092520|Experimental|Gabapentin|
3220399|NCT01092533|Experimental|Mycophenolate sodium + Prednisolone|Mycophenolate sodium 1440 mg/day Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
3220400|NCT01092533|Active Comparator|Prednisolone|Prednisolone: initial dose 1 mg/kg/day, maintenance dose 5 mg/day
3220401|NCT01092572|Experimental|Simvastatin 40 mg/d|simvastatin 40 mg per day taken orally
3220402|NCT01092572|Placebo Comparator|Sugar pill|
3220403|NCT01092611|Other|Group A|Subjects who were administered the GSK HIV vaccine 732462 in primary studies and who accepted to participate in this study
3220404|NCT01092611|Other|Group B|Subjects who were administered placebo in primary studies and who accepted to participate in this study
3220405|NCT01092624|Experimental|Pessary and solifenacin|
3220406|NCT01092624|Placebo Comparator|Pessary and placebo|
3220407|NCT01092650|Active Comparator|Smoked|Deuterated Phenanthrene spiked in a study cigarette
3220408|NCT01092650|Experimental|Oral|Deuterated phenanthrene in an oral dose
3220409|NCT01092689|Experimental|PhIP|Prior to surgery, consented subjects will ingest a capsule containing [14C]PhIP. This amount of [14C]PhIP (84 micrograms PhIP; 15.6 micro-curies) is equivalent to that in 2 very well done grilled/barbecued chicken breasts (Sinha 1995); the amount of radioactivity is equivalent to the dose received in a commercial airline flying at 30,000 ft. for 5 h (HPS 2007) or to the amount received during a typical chest x-ray.
3220410|NCT01092715|Experimental|Mobilization|Spinal mobilization and exercises
3220411|NCT01092715|Active Comparator|Massage|Neck massage and exercises
3220412|NCT01092741|Experimental|Gleevec|Gleevec 400 mg by mouth (P.O.) twice daily = 800 mg total daily dose
3220413|NCT01092754|Other|A: Other|
3220414|NCT01092754|Other|B: Other|
3220415|NCT01092793|Active Comparator|Krill|
3220416|NCT01092793|Active Comparator|Fish oil|
3220417|NCT01092793|No Intervention|Control|
3220418|NCT01092806|Active Comparator|Prograf|Patients are treated until steady-state conditions with Prograf and then investigated with clamp
3220419|NCT01092806|Experimental|Advagraf|The patients are treated with Advagraf until steady-state conditions and then investigated with clamp
3220420|NCT01092819||acute ischemic stroke|Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with an imaging-defined large cerebral vessel occlusion.
3220421|NCT01092845|Experimental|PF-04457845 followed by placebo|
3220422|NCT01092845|Experimental|Placebo followed by PF-04457845|
3220423|NCT01092858|Experimental|Arm 1|
3220424|NCT01092858|Placebo Comparator|Arm 2|
3220425|NCT01092884|Active Comparator|Polypodium leucotomos|Subjects randomized to this arm will receive oral supplementation with Polypodium leucotomos extract
3220426|NCT01092884|Placebo Comparator|Sugar pill|Subjects randomized to this arm will receive oral supplementation with placebo
3220427|NCT01092897||Subjects with PAH treated with Imatinib|
3220428|NCT01092962|Experimental|Mycophenolate mofetil|Mycophenolate mofetil
3220429|NCT01092962|Active Comparator|Cyclophosphamide|Cumulative dose of 148mg/kg of cyclophosphamide in 84 days (2mg/kg/day during 12 weeks)
3220430|NCT01092975|Experimental|1.25 mg phenylephrine|
3220431|NCT01092975|Experimental|2.5 mg phenylephrine|
3220432|NCT01092975|Experimental|5.0 mg phenylephrine|
3220433|NCT01092975|Experimental|10.0 mg phenylephrine|
3220434|NCT01092975|Experimental|20.0 mg phenylephrine|
3220435|NCT01092975|Experimental|40.0 mg phenylephrine|
3220436|NCT01092975|Experimental|60.0 mg phenylephrine|
3220437|NCT01092975|Experimental|80.0 mg phenylephrine|
3220438|NCT01092988|Experimental|Exablate 2100|MR Guided Focused Ultrasound treatment
3220439|NCT01093001|Active Comparator|Lead size|The pacemaker lead will be < or = to 7Fr. The ICD lead will be 9 Fr.
3220440|NCT01093001|Active Comparator|RV Lead position|50 patients will be randomized to RV apex lead placement.
3220441|NCT01093001|Active Comparator|Mid-Septum Lead position|50 patients will be randomized to RV mid-septum lead placement.
3220442|NCT01093001|Active Comparator|CS lead position|50 patients will have lead placed in the CS
3220443|NCT01093040|Experimental|Cohort 1|CAT-354 will be administered by SC injection
3220444|NCT01093040|Experimental|Cohort 2|CAT-354 will be administered by SC injection
3220445|NCT01093040|Experimental|Cohort 3|CAT-354 will be administered by SC injection
3220446|NCT01093053|Experimental|Mind-Body Skills Groups|
3220447|NCT01093053|Active Comparator|Standard Treatment|
3220449|NCT01093079||Laparoscopic partial nephrectomy|
3220450|NCT01093079||Open Partial nephrectomy|
3220451|NCT01093092|Experimental|Treatment (calcitriol, cisplatin, gemcitabine hydrochloride)|Patients receive calcitriol PO on days 1, 2, 8, 9, 15 and 16; cisplatin IV over 2 hours on day 2; and gemcitabine hydrochloride IV over 30 minutes on days 2, 9, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3220452|NCT01093118|Experimental|TMI-358|Active treatment
3220453|NCT01093118|Placebo Comparator|MMI-467|
3220454|NCT01093131|Active Comparator|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
3220455|NCT01093131|Active Comparator|Intravenous hydration and sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
3220456|NCT01093131|Active Comparator|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
3220457|NCT01093131|Active Comparator|Oral hydration and oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
3220458|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 40 units|
3220459|NCT01093157|Active Comparator|ACTH (HP Acthar gel) 80 units|
3220460|NCT01093170|Experimental|RNA-144101|
3220461|NCT01093196|Active Comparator|Rd|Induction treatment with oral Lenalidomide and low dose dexamethasone followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
3220462|NCT01093196|Experimental|MPR|Induction treatment with oral Lenalidomide, Prednisone and Melphalan followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone
3220463|NCT01093196|Experimental|CPR|Induction treatment with oral Lenalidomide, Cyclophosphamide and Prednisone for followed by maintenance therapy with Lenalidomide alone or Lenalidomide and Prednisone.
3220464|NCT01093209|Sham Comparator|Conventional Laser Therapy|
3220465|NCT01093209|Active Comparator|Interferential Laser Therapy|
3220466|NCT01093248||Heroin-addicted Patients|Heroin-addicted outpatient department (OPD) patients who seek help for methadone maintenance treatment
3220467|NCT01093261|Experimental|Hydrocortisone and fludrocortisone|Patients with glucocorticoid insufficiency
3220468|NCT01093261|Placebo Comparator|Placebo|Patients with glucocorticoid insufficiency
3220469|NCT01093261|No Intervention|Controlled|Adapted glucocorticoid function
3220470|NCT01093274|Active Comparator|Polyethylene glycol|Preparation with Polyethylene Glycol and bisacodyl
3220471|NCT01093274|Experimental|Picolax|Preparation with Sodium Picosulphate and Bisacodyl.
3220472|NCT01093300|Experimental|Paclitaxel-eluting balloon catheter|Paclitaxel-eluting balloon catheter use for treatment of ISR lesion
3220473|NCT01093300|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent use for treatment of ISR lesion
3220474|NCT01093313|Experimental|Attention training|
3220475|NCT01093313|Active Comparator|Cognitive therapy|
3220479|NCT01093339||No treatment|Subjects w/ condition and subjects w/o condition of GERD (gastroesophageal reflux disease)
3220480|NCT01093352|No Intervention|Standard|Standard expose and bond.
3220481|NCT01093352|Experimental|Alveolar-decortication|Following surgical exposure of the impacted canine, additional perforations will be made in the surrounding cortical bone prior to wound closure.
3220482|NCT01093365|Experimental|Schizophrenia|To measure the effects of varenicline on cognition of smokers with schizophrenia.
3220483|NCT01093378||Fertile group|fertile group
3220484|NCT01093378||Infertility group|Fertility troubles
3220485|NCT01093391|Placebo Comparator|BARE METAL STENT|BARE METAL STENT - STENT CRONUS
3220486|NCT01093391|Experimental|DRUG ELUTING STENT|STENT INSPIRON WITH SIROLIMUS
3220487|NCT01093404|Experimental|Thrombus aspiration|Thrombus aspiration is then followed by standard balloon angioplasty (PCI).
3220488|NCT01093404|Active Comparator|Standard balloon angioplasty (PCI)|
3220489|NCT01093430|Experimental|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
3220490|NCT01093430|Active Comparator|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
3220491|NCT01093443|Placebo Comparator|A|Patients undergo a standard treatment with a classical GnRH antagonist protocol.
3220492|NCT01093443|Active Comparator|B|Before undergoing a standard protocol for ovarian stimulation, patients in this group receive a pretreatment with GnRH antagonists during 3 consecutive days
3220493|NCT01093456||chronic kidney disease|ESKD patients treated with peritoneal dialysis
3220494|NCT01093456||Healthy volunteers|healthy volunteers, aged 18 years and above
3220495|NCT01093495|Experimental|CPAP group|Subjects in this group will continue receiving CPAP until no oxygen requirement for 24 hours, then will be weaned off CPAP completely as long as they tolerate. CPAP will be re-instituted if subjects meet failing criteria. Another trial off CPAP will start 24 hours after failure and/or after being on 21% for 24 hours. CPAP will be weaned off directly to room air at all times.
3220496|NCT01093495|Experimental|Nasal Cannula Group|Subjects will be weaned from CPAP (when FiO2 <0.30) to Nasal cannula (2 L/min) with whatever FiO2 they need until they are off oxygen and NC completely. However, if these infants fail on NC they will be put back to nCPAP. Infants will then be maintained on CPAP until stable on CPAP-30% for 24 hours. Infants will be tried for another weaning using NC. So, infants assigned to NC will be weaned only through NC. CPAP will be used only for stabilization in between trials if needed.
3220497|NCT01093547|Active Comparator|Dianeal only|Patients in Dianeal during the daily exchanges and randomised to Dianeal during the long-dwell exchange
3220498|NCT01093547|Active Comparator|Dianeal; Extraneal long-dwell exchange|Patients in Dianeal during the daily exchanges and randomised to Extraneal during the long-dwell exchange
3220499|NCT01093560|Experimental|young women with MetS|"Saturated fat (control)~n-3 Polyunsaturated fat (experimental)~monounsaturated fat"
3220500|NCT01093612|Experimental|Arm I|PART ONE: Patients are randomized to 1 of 3 dose levels. Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab. PART TWO: Patients undergo a PET scan 24-48 hours after injection of copper Cu 64-DOTA-trastuzumab.
3220501|NCT01093638|Experimental|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with premature infant formula
3220502|NCT01093638|Placebo Comparator|Oral Formulation of Placebo|Oral formulation of placebo fed concomitantly with premature infant formula
3220503|NCT01093664|Experimental|AFFITOPE AD02|
3220504|NCT01093677|Experimental|A|750 mg of LIM-0705 BID for 14 days. Up to 20 subjects.
3220505|NCT01093677|Placebo Comparator|B|Placebo BID for 14 days. Up to 10 subjects.
3220506|NCT01093703|No Intervention|Conventional Therapy|In the conventional therapy group, no medication changes other than the ones needed to achieve target awake average SBP will be undertaken. Time at which patients are taking their BP medications will be recorded.
3220507|NCT01093703|Active Comparator|Intensive Therapy|In the intensive therapy group, BP medications will be adjusted to both control awake average systolic BP to target and to cover the overnight period in an attempt to control nocturnal hypertension.
3220508|NCT01093716|Experimental|rTMS|Compare the change in craving parameters following high frequency rTMS stimulation of right and left DLPFC in patients with alcohol dependence
3220509|NCT01093729|Experimental|Cohort1|HM11260C 0.5mcg/kg or Placebo
3220510|NCT01093729|Experimental|Cohort2|HM11260C 2mcg/kg or Placebo
3220511|NCT01093729|Experimental|Cohort3|HM11260C 4mcg/kg or Placebo
3220512|NCT01093729|Experimental|Cohort4|HM11260C 8mcg/kg or Placebo
3220513|NCT01093729|Experimental|Cohort5|HM11260C 14mcg/kg or Placebo
3220514|NCT01093742|Experimental|cohort 1|HM10560A 0.089 mg/kg or Placebo
3220515|NCT01093742|Experimental|cohort 2|HM10560A 0.179 mg/kg or Placebo
3220516|NCT01093742|Experimental|cohort 3|HM10560A 0.357 mg/kg or Placebo
3220517|NCT01093742|Experimental|cohort 4|HM10560A 0.714 mg/kg or Placebo
3220518|NCT01093781|Experimental|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
3220519|NCT01093807|Placebo Comparator|Placebo|
3220520|NCT01093807|Experimental|Lercanidipine 10 mg|
3220521|NCT01093807|Experimental|Lercanidipine 20 mg|
3220522|NCT01093807|Experimental|Enalapril 10 mg|
3220523|NCT01093807|Experimental|Enalapril 20 mg|
3220524|NCT01093807|Experimental|Lercanidipine 10 mg/Enalapril 10 mg|
3220525|NCT01093807|Experimental|Lercanidipine 10mg/Enalapril 20 mg|
3220526|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril 10 mg|
3220527|NCT01093807|Experimental|Lercanidipine 20mg/Enalapril20mg|
3220528|NCT01093820|Experimental|Epopoetinum beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
3220529|NCT01093833|Experimental|Continuous Glucose Monitoring|Each subject will participate in one experimental intervention. Blood glucose will be measured with the BD continuous glucose monitor (BD CGM), with the Medtronic Guardian CGM and the YSI Glucose Analyzer as controls for 12-14 hours.
3220530|NCT01093859|Experimental|PRX-105 Infusion|
3220531|NCT01093898||No intervention|
3220532|NCT01093911|Experimental|CDP7657|CDP7657 in dose escalating cohorts
3220533|NCT01093911|Placebo Comparator|Placebo|
3220534|NCT01093924|No Intervention|self-guided weight loss maintenance|15-month self-guided weight loss maintenance group will receive monthly reminders to maintain their weight loss and newsletters that contain health information.
3220535|NCT01093924|Experimental|DVD group|15-month weight loss maintenance intervention deliver via DVD.
3220536|NCT01093924|Experimental|face-to-face group|15-month weight loss/weight loss maintenance intervention delivered in a group setting
3220537|NCT01093950||PROSPECTIVE BODY CONTOURING SUBJECTS|"It is anticipated that the participants will undergo body contouring procedures including lipoplasty [internal fat suction removal], abdominoplasty [surgical removal of lower abdominal skin and fat], breast reduction [surgical removal of breast skin, fat, and breast tissue to reduce breast size], breast augmentation [surgical breast enlargement], thigh lift [surgical removal of upper thigh tissue], and brachioplasty [surgical removal of upper arm tissue].~These procedures will be evaluated by pre- and post-operative digital scans, analog measurements, and clinical examinations and photographs."
3220538|NCT01093963|Active Comparator|Lisdexamfetamine|Drug
3220539|NCT01093963|Placebo Comparator|Placebo|Drug
3220540|NCT01093989|Placebo Comparator|Immediate iron|Iron-deficient children will be randomized to receive iron concurrently with anti-malarial treatment or one month later (delayed iron group).
3220541|NCT01093989|Active Comparator|Delayed iron|
3220542|NCT01094002|Experimental|Occupational therapy intervention (OTI)|198 subjects. The OTI schedule consisted of a daily 45-minute session, Monday through Friday, for the duration of hospitalisation. Activities were carried out in a structured manner and varied according to need and day of admission. On the first day, the patient's needs were analysed, including the need for iatrogenic prevention, retraining in basic and instrumental activities of daily living, technical aids, instruct the primary caregiver in patient mobilisation techniques, and social and occupational motivation. All OTI participants received an average of 5 sessions during hospitalisation.
3220543|NCT01094002|No Intervention|Conventional treatment model group|202 subjects. All subjects received medical treatment, nursing care, physical therapy, and social assistance in accordance with the usual practice of the geriatrics unit.
3220544|NCT01094015|Active Comparator|Lidocaine-Prilocaine cream|
3220545|NCT01094015|Placebo Comparator|placebo|
3220546|NCT01094028|Experimental|Saline group|Only 30 mL of saline was injected directly in the umbilical vein after clamping. The injection was performed with a 30-mL syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute and at the end of the injection, the solution was milked toward the cord insertion.
3220547|NCT01094041|Experimental|Gluten free diet|
3220548|NCT01094041|Experimental|Gluten rich diet|
3220549|NCT01094054|Active Comparator|Dietary and lifestyle modification|Patients in this arm will eat meals that are identical in size and caloric composition to those consumed by participants in the other arm who undergo adjustable gastric banding
3220550|NCT01094054|Experimental|Adjustable gastric banding|Subjects will undergo gastric banding as per clinical practice
3220551|NCT01094067|Experimental|1|Placebo at visit 1, tezosentan at visit 2
3220552|NCT01094067|Experimental|2|Tezosentan at visit 1, placebo at visit 2
3220553|NCT01094080|Active Comparator|standard infant formula|infants are fed a commercial formula during the first 4 month of life, according to protocol
3220554|NCT01094080|Experimental|modified infant formula|infants are fed a modified infant formula (modified protein content and fatty acid pattern) during the first 4 month of life, according to protocol
3220555|NCT01094080|Other|breast milk|infants are breast fed
3220556|NCT01094093|Experimental|Part B|Four dose levels of AMG 139 administered as a single dose SC or IV in subjects with moderate-severe psoriasis (Part B).
3220557|NCT01094093|Experimental|Part A|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers.
3220558|NCT01094132|Other|Review by colposcopy + multispectral digital colposcopy|All patients belong under this arm, as all will be reviewed by both conventional colposcopy and by Multispectral Digital Colposcopy (MDC). The nature of these techniques are explained below.
3220559|NCT01094145|Sham Comparator|Placebo|Stimulator setting is OFF
3220560|NCT01094145|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
3220561|NCT01094158|Experimental|high dose|Aramchol 300 mg daily (high dose)
3220562|NCT01094158|Experimental|low dose|100 mg daily (low dose)
3220563|NCT01094158|Placebo Comparator|Placebo|Placebo and two doses will be compared. The Aramchol: placebo ratio is of 2:1.
3220564|NCT01094197||Transfused microchimeric subject|Former trauma patient who underwent blood transfusion and has recent evidence of long-term transfusion-associated microchimerism
3220565|NCT01094210||G1|500 ppm F Test Toothpaste
3220566|NCT01094210||G2|1100 ppm F Control Toothpaste
3220567|NCT01094223|Experimental|Mindfulness|
3220568|NCT01094223|Active Comparator|Health Education|
3220569|NCT01094236|Experimental|Supervisor Treatment Group|Supervisors watched the CD intervention
3220570|NCT01094236|Experimental|Administrators - Treatment|School administrators got access to the intervention binder with CD's, workbook and worksheets
3220571|NCT01094236|Experimental|Students|3rd grade students at participating study schools
3220572|NCT01094236|Experimental|Supervisor Control Group|Supervisors watched a video on playground equipment safety
3220573|NCT01094236|Experimental|Administrators - Control|Administrators did not have access to any treatment materials.
3220574|NCT01094236|Experimental|School Staff|School staff surveyed at staff meetings
3220575|NCT01094249|Experimental|001|divalproex sodium ER/paliperidone ER Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
3220576|NCT01094262|Experimental|JNJ-42160443 (lower dose)|
3220577|NCT01094262|Experimental|JNJ-42160443 (higher dose)|
3220578|NCT01094262|Active Comparator|Oxycodone CR (standard pain medication)|
3220579|NCT01094262|Placebo Comparator|Placebo|
3220580|NCT01094275||wild / normal type allele of CYP2C gene|clopidogrel 75 mg alone.
3220581|NCT01094275||wild / normal type allele of CYP2C|clopidogrel 75 mg + omeprazole 20 mg.
3220582|NCT01094275||Loss of Haplotype CYP2C19|clopidogrel 75mg alone
3220583|NCT01094275||Loss of function haplotype of CYP2C|clopidogrel 75mg + omerprazole 20mg.
3220584|NCT01094314|Active Comparator|sequential medium|
3220585|NCT01094314|Active Comparator|single medium|
3220586|NCT01094340|Other|Thalidoide|CSF
3220587|NCT01094353|Active Comparator|Mini-sling|The minisling Ophira™ is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
3220588|NCT01094353|Active Comparator|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
3220589|NCT01094366|Sham Comparator|No Paracervical Block for Pain Control|Subject will not receive a paracervical block during the procedure
3220590|NCT01094366|Active Comparator|Paracervical Block for Pain Control|Subject will receive a paracervical block during the procedure.
3220591|NCT01094379|Active Comparator|Standard lap chole|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
3220592|NCT01094379|Active Comparator|Single incision lap chole|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
3220593|NCT01094392||treatment every 6th week during 6 months|
3220594|NCT01094392||treatment every 2nd week during 6 months|
3220595|NCT01094405|Experimental|EBV Vaccine|
3220596|NCT01094418||IGT group|IGT diagnosed by endocrinologist
3220597|NCT01094418||DM group|DM diagnosed by endocrinologist and whose primary NCS screening shows SNAP amplitudes of sural and superficial peroneal nerves greater than 10mA DM patients with no previous diagnosis of peripheral polyneuropathy
3220598|NCT01094418||Normal healthy participants|Normal health participants with no previous history of DM, IGT, thyroid disorder, hypercholesterolemia, or other condition associated with peripheral polyneuropathy
3220599|NCT01094444|Experimental|Vitamin K3-lotion|A lotion containing 1.5 mM Vitamin K3.
3220600|NCT01094444|No Intervention|B|Standard lotion without Vitamin K3
3220601|NCT01094457|Active Comparator|standard group|patients in this group received standard dual antiplatelet therapy, i.e. aspirin 300mg/d and clopidogrel 75mg/d
3220602|NCT01094457|Experimental|intensive group|patients in this group received intensive antiplatelet therapy and the regimen can be adjusted according to results of platelet aggregation function test by LTA
3220603|NCT01094483|Experimental|1|PN400 + ASA
3220604|NCT01094483|Placebo Comparator|2|Placebo + ASA
3220605|NCT01094496|Experimental|CDX-1307 Vaccine Regimen|Chemotherapy with CDX-1307 vaccine regimen (neoadjuvant phase), followed by bladder removal surgery (cystectomy). CDX-1307 vaccine regimen will continue to be given for up-to 1 year post-surgery (adjuvant/long-term follow-up phase).
3220606|NCT01094509|Experimental|Tai Chi|Tai Chi exercises
3220607|NCT01094509|Experimental|Guided autobiography|Autobiographical writing during class sessions and at home
3220608|NCT01094509|Experimental|Qigong|Qigong exercises (exploratory, not part of the original protocol, added to gain experience with this intervention)
3220609|NCT01094509|Active Comparator|Successful aging|Seminars on the theme of successful aging
3220610|NCT01094509|Experimental|Combination|Combination of Tai Chi exercises and autobiographical writing
3220611|NCT01094509|Placebo Comparator|Comparison|No assigned experimental activity (exploratory, not part of the original protocol, added to gain experience with a placebo comparator)
3220612|NCT01094535|Experimental|Secretin|One-arm (open label): Synthetic Human Secretin. Patients will undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations.
3220613|NCT01094587|Active Comparator|Sutured closure|
3220614|NCT01094587|Active Comparator|Sutureless closure|
3220615|NCT01094600|Experimental|Secretin|Single arm (open label).
3220616|NCT01094613|Experimental|Delayed Release 6MP|"6 Mercaptopurine delayed release oral tablet for targeted ileal delivery, to be administered once nightly before bedtime, for 12 weeks.~The dose is 2 x 40 mg DR-6MP (total dose, 80 mg DR-6MP)."
3220617|NCT01094613|Active Comparator|Purinethol|6 Mercaptopurine Tablet (50 mg) administered orally, at doses of 1-1.5 mg/kg body weight, daily for 12 weeks. Individual patient doses range from 50 mg to 150 mg, including 75, 100 and 125 mg daily, as per patient weight at baseline, and then are up-titrated to clinical efficacy at two week intervals, as needed. Doses may be down-titrated as well if occurrences of AE's warrant dose reduction.
3220618|NCT01094626|Experimental|Experimental|Fifteen subjects will be randomly selected to undergo S-MRI prior to surgery. These subjects would receive Secretin, administered by IV bolus injection over 1 minute followed by a 30 second saline flush.
3220619|NCT01094626|No Intervention|Controls|Fifteen subjects will be selected as controls, undergoing MRI without secretin-enhancement and matched for age, sex, race and tumor-type.
3220620|NCT01094639|Placebo Comparator|Supragingival prophylaxis|Plaque removal
3220621|NCT01094639|Active Comparator|Scaling root planing|SRP+oral hygiene
3220622|NCT01094652|Experimental|Whole grain diet|Participants in this group will be given whole grain snacks on school days and food packages consisting of whole grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
3220623|NCT01094652|Active Comparator|Refined grain diet|Participants in this group will be given refined grain snacks on school days and food packages consisting of refined grain breads, breakfast cereals, rice, snack foods, and pasta to replace their typical grains consumed at home.
3220624|NCT01094665|Experimental|Focal Laser Thermal Therapy|Thermal therapy delivered to lesion visible on MRI.
3220625|NCT01094678|Experimental|Stent|
3220626|NCT01094691|Experimental|Renal Allograft Biopsy|Urine left over from clinic visits is analyzed for 'Haufen' by negative staining electron microscopy as a marker of intra-renal polyomavirus nephropathy. Correlate Haufen, urine, and plasma data with the clinical presentation and with renal biopsy findings. Patients with PVN will be approached for study participation in which their routine samples will be monitored until urine is negative for 'Haufen', and a study protocol biopsy will be obtained for confirmation.
3220627|NCT01094756|Active Comparator|Obese group - Group 1|If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
3220628|NCT01094756|No Intervention|Lean group - Group 2|If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
3220629|NCT01094769|Experimental|Moxonidine|
3220630|NCT01094769|Placebo Comparator|Placebo|
3220631|NCT01094795||Patients initiating abatacept|
3220632|NCT01094795||Patients receiving other biologic disease-modifying drugs|
3220633|NCT01094795||Patients with early rheumatoid arthritis (RA)|
3220634|NCT01094795||Patients with prevalent RA identified by hospitalization|
3220635|NCT01094795||General population|
3220636|NCT01094821|Experimental|3 mg ATI-7505|3 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3220637|NCT01094821|Placebo Comparator|Placebo|Placebo capsule three times daily for 9 days followed by transit scintigraphy
3220638|NCT01094821|Experimental|10 mg ATI-7505|10 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3220639|NCT01094821|Experimental|20 mg ATI-7505|20 mg ATI-7505 three times daily for 9 days followed by transit scintigraphy
3220640|NCT01094834|Experimental|DWP05195|
3220641|NCT01094847|Experimental|Treatment A|DWJ1252 given by oral administration under fasting conditions
3220642|NCT01094847|Active Comparator|Treatment B|DWJ1252 given by oral administration, 30 minutes after a meal
3220643|NCT01094847|No Intervention|Treatment C|mosapride by oral administration 30 minutes before meals
3220644|NCT01094860|Experimental|Continuous Infusion Nelarabine|Starting dose 200 mg/m2 x 5 days
3220645|NCT01094873|Experimental|Arm A, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 14 and 1 dose Ad6NSmut 5 x 10^8vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
3220646|NCT01094873|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 14 and 1 dose Ad6NSmut 5 x 10^9vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 2"
3220647|NCT01094873|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
3220648|NCT01094873|Experimental|Arm A, group 4|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 2 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 12, after starting PEG-IFN and ribavirin therapy.~Patients: 6"
3220649|NCT01094873|Experimental|Arm A, group 5|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 14 and 18, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 28, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
3220650|NCT01094873|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at weeks 2 and 6, and 1 dose Ad6NSmut 2.5 x 10^10vp at week 16, after starting PEG-IFN and ribavirin therapy.~Patients: 4"
3220651|NCT01094873|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^8vp at week 4 and 1 dose Ad6NSmut 5 x 10^8vp at week 14.~Patients: 2"
3220652|NCT01094873|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; Ad6NSmut. Administration schedule: 1 dose AdCh3NSmut 5 x 10^9vp at week 4 and 1 dose Ad6NSmut 5 x 10^9vp at week 14.~Patients: 2"
3220653|NCT01094873|Experimental|Arm B, group 3|"Interventions: AdCh3NSmut; Ad6NSmut.~1 dose AdCh3NSmut 2.5 x 10^10vp at week 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 14.~Patients: 4"
3220654|NCT01094899|Experimental|Type 1 Diabetics without Neuropathy|Adult male with type 1 diabetes and without peripherical neuropathy
3220655|NCT01094899|Experimental|Type 2 Diabetics without Neuropathy|Adult male with type 2 diabetes and without peripherical neuropathy
3220656|NCT01094899|Experimental|Type 1 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
3220657|NCT01094899|Experimental|Type 2 Diabetics with Neuropathy|Adult male with type 1 diabetes and with peripherical neuropathy
3220658|NCT01094925|Placebo Comparator|Placebo|
3220659|NCT01094925|Active Comparator|Gabapentin 300mg|
3220660|NCT01094925|Active Comparator|Gabapentin 600mg|
3220661|NCT01094938||Repair|
3220662|NCT01094951|Other|ENGAGE|"In stage 1, study investigators will train Neighborhood House caseworkers to screen their clients for depressive symptoms.~In stage 2, study investigators will train Neighborhood House caseworkers to use the ENGAGE intervention in referring their clients to mental health services"
3220663|NCT01094977|Experimental|Low Dose|TXA 10mg/kg bolus before incision and 5 mg/kg infusion until skin closure
3220664|NCT01094977|Experimental|High Dose|TXA 100 mg/kg bolus before incision and 10 mg/kg infusion until skin closure
3220665|NCT01094977|Placebo Comparator|Placebo|Normal saline 10 ml before skin incision and infusion according to weight until skin closure
3220666|NCT01095016|Experimental|Meptin swinghaler|
3220667|NCT01095016|Active Comparator|Berotec|
3220668|NCT01095029|Experimental|Off/Off|Pacemaker status: Bilateral Off for four weeks before first PET scann.
3220669|NCT01095029|Experimental|On/On|Pacemaker status: Bilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
3220670|NCT01095029|Experimental|On/Off|Pacemaker status: Unilateral On. PET scan one hour after activation and after four weeks continuous stimulation.
3220671|NCT01095042|Experimental|Control group|30 Asymptomatic Healthy Volunteers Intervention : Observation of emotional behavior in asymptomatic healthy volunteers subjected to stress.
3220672|NCT01095042|Experimental|Experimental group|"Persons reached by digestive pathologies (SII or IBD). Group SII : 30 patients Group IBD: 60 patients (30 patients RCH and 30 patients CD)~Intervention : Observation of emotional behavior in person affected by digestive pathologies subjected to stress."
3220673|NCT01095055|Experimental|Group 1|AdCh63 AMA1
3220674|NCT01095055|Experimental|Group 2|AdCh63 AMA1 followed by MVA AMA1
3220675|NCT01095068|Experimental|physical exercise|Physical exercise
3220676|NCT01095081||Group 1|
3220677|NCT01095107|Other|Control Arm = Decreased Energy Density|Decreased energy density = 35-50 grams of fat per day between meals and snacks
3220678|NCT01095107|Other|Treatment Arm = Increased Energy Density|increased increased energy density : Intake > 50 grams of fat per day between meals and snacks
3220679|NCT01095133|Experimental|Amiloride|
3220680|NCT01095133|Placebo Comparator|Placebo|
3220681|NCT01095159|Active Comparator|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
3220682|NCT01095159|Active Comparator|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
3220683|NCT01095172|Experimental|Rituximab|"Rituximab 375mg/m2~Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone"
3220684|NCT01095172|Active Comparator|Control group|Low dose tacrolimus with mycophenylate mofetil and continued prednisolone
3220685|NCT01095185|Experimental|Standard therapy + Simvastatin|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)~Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)"
3220686|NCT01095185|Placebo Comparator|Standard therapy + placebo|"Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).~Placebo"
3220687|NCT01095198|Active Comparator|2nd Reminder Letter|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be be mailed a standard second reminder letter
3220688|NCT01095198|Experimental|Offer of Vaginal Self Collection|50% of study participants who are overdue for Pap testing and do not respond to initial reminder letter will be selected to be mailed a second reminder letter and offer of vaginal self collection
3220689|NCT01095211|Active Comparator|B-Vitamins|folic acid, cobalamin, vitamin B6
3220690|NCT01095211|Placebo Comparator|placebo|none of the vitamins (99.5% mannitol)
3220691|NCT01095224|Experimental|rAd35 Env A and rAd5 Env A|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env A vaccine at Month 3.
3220692|NCT01095224|Experimental|rAd35 Env A and rAd5 Env B|Participants will receive the rAd35 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
3220693|NCT01095224|Experimental|rAd35 Env A and rAd35 Env A|Participants will receive the rAd35 Env A vaccine at baseline and at Month 3.
3220694|NCT01095224|Experimental|rAd5 Env A and rAd5 Env A|Participants will receive the rAd5 Env A vaccine at baseline and at Month 3.
3220695|NCT01095224|Experimental|rAd5 Env A and rAd5 Env B|Participants will receive the rAd5 Env A vaccine at baseline and the rAd5 Env B vaccine at Month 3.
3220696|NCT01095263|Experimental|Sham then Stimulation|
3220697|NCT01095263|Experimental|Stimulation then Sham|
3220698|NCT01095276|Placebo Comparator|Nebulized saline|patients on mechanical ventilation who were randomized to receive a placebo comparator (vehicle solution for dornase alpha)
3220699|NCT01095276|Active Comparator|dornase alpha|patients on mechanical ventilation who were randomly assigned to receive dornase alpha by in-line nebulization
3220700|NCT01095289||Total Laryngectomized|
3220701|NCT01095302|Experimental|Ombrabulin/ docetaxel/cisplatin|AVE8062 combined with docetaxel and cisplatin will be administered once in every 3 weeks, with 30-minute intravenous infusion
3220702|NCT01095315|No Intervention|standard|parturients were placed back to the supine position immediately after spinal injection following standard protocol of spinal anesthesia
3220703|NCT01095315|Experimental|lateral|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
3220704|NCT01095328|Experimental|intervention|Screening for Q-fever during pregnancy
3220705|NCT01095328|No Intervention|control|No screening for Q-fever during pregnancy
3220706|NCT01095341||THP|THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism
3220707|NCT01095341||Other causes|patients with hyperthyroidism not caused by parathyroidectomy
3220708|NCT01095354||Asthma Patients|Spirometry. Bronchodilator with Salbutamol. Induced sputum in > 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
3220709|NCT01095367|Active Comparator|Seprafilm™|Subject will have 3 sheets of Seprafilm™ placed in her abdominal cavity (in the pelvis, upper abdomen and below the incision) at the end of debulking surgery. At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
3220710|NCT01095367|No Intervention|No Seprafilm™|Subject will undergo debulking surgery without Seprafilm™ placement (standard care). At 7-21 days after surgery the subject will receive a contrast dye, Iohexol (Omnipaque™), into her intraperitoneal port. The subject will then undergo 3 abdominal X-rays, to assess the extent of abdominal adhesions.
3220711|NCT01095380|Active Comparator|Treadmill training - manual assist (TM)|Participants in the TM group received partial body weight support unilateral or bilateral manual assistance from a trainer for stepping
3220712|NCT01095380|Active Comparator|Treadmill training - electrical stimulation (TS)|Participants in the TS group received partial body weight support and bilateral functional electrical stimulation to assist stepping
3220713|NCT01095380|Active Comparator|Overground Training (OG)|Training over ground with body weight support and electrical stimulation for dorsiflex assistance
3220714|NCT01095380|Active Comparator|Treadmill training - locomat robot (LR)|Treadmill training with partical body weight support and assistance of a robotic gait orthosis for stepping
3220715|NCT01095393||Certolizumab pegol (CZP)|Patients with RA receiving treatment with certolizumab pegol (CZP; Cimzia®)
3220716|NCT01095393||Non-biologic DMARD|Subjects with RA receiving treatment with non-biologic DMARD
3220717|NCT01095406|Active Comparator|S1 ventilation|Mechanical ventilation with S1 the thrid hour of ventilation
3220718|NCT01095406|No Intervention|Servo i ventilation|1 hour ventilation in pressure support mode with Servo i
3220719|NCT01095419|No Intervention|Control|Patients were seated in a chair for the same period then those from MT group, but did not receive intervention
3220720|NCT01095419|Experimental|Massage Therapy|Patients in the postoperative period of coronary artery bypass graft surgery, which receive intervention for 3 consecutive days
3220721|NCT01095432||Main Study Group|All subjects who are undergoing a standard of care colonoscopy for flexible sigmoidoscopy and have a history of UC and agree to participate will be in the main study group.
3220722|NCT01095445|No Intervention|Standard of care treatment|Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
3220723|NCT01095445|Active Comparator|Extended therapy|Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.
3220724|NCT01095458|Experimental|Phone based weight management group|Group based weight management program delivered via conference calls
3220725|NCT01095458|Experimental|Clinic based weight management group|Traditional clinical based group weight management program
3220726|NCT01095471|Experimental|PCV13|Initial vaccination with PCV13
3220727|NCT01095471|Experimental|PCV7|Initial intervention with PCV7
3220728|NCT01095484||Rotigotine|Patients who have a documented medical necessity to receive treatment with rotigotine treatment in accordance with standard medical practice.
3220729|NCT01095549|Placebo Comparator|Control group|HD patients who will not receive far infrared therapy in this study.
3220730|NCT01095549|Experimental|Far infrared therapy|In this study, a WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt<mw>/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on maintenance HD.
3220731|NCT01095562|Experimental|ABT-126 Dose 1|
3220732|NCT01095562|Experimental|ABT-126 Dose 2|
3220733|NCT01095562|Placebo Comparator|Sugar Pill|
3220734|NCT01095575|Active Comparator|group 1|NS preoperatively and MO postoperatively
3220735|NCT01095575|Active Comparator|group 2|MO preoperatively and NS postoperatively
3220736|NCT01095588|Experimental|Avanafil|
3220737|NCT01095588|Placebo Comparator|Placebo|
3220738|NCT01095601|Other|Treatment A|2x100 mg Formulation II avanafil tablet, fasted
3220739|NCT01095601|Other|Treatment B|2x100 mg Formulation II avanafil tablet, fed
3220740|NCT01095601|Other|Treatment C|2x100 mg Formulation I avanafil tablet, fasted
3220741|NCT01095601|Other|Treatment D|1x50 mg Formulation II avanafil tablet, fasted
3220742|NCT01095614||12 women with oral contraception|
3220743|NCT01095614||12 women without any contraception|
3220744|NCT01095627|Other|Metacholine Challenge|Exhaled breath analysis following metacholine challenge
3220745|NCT01095640|Experimental|adapalene 0.3% topical gel (Actavis Mid-Atlaqntic LLC)|
3220746|NCT01095640|Active Comparator|Differin® (adapalene 0.3% topical gel)|
3220747|NCT01095640|Placebo Comparator|Vehicle Control|
3220748|NCT01095679|Experimental|Baclofen|
3220749|NCT01095679|Placebo Comparator|Placebo|Placebo
3220750|NCT01095692|Active Comparator|only surgery|
3220751|NCT01095692|Experimental|surgery + TOT|
3220752|NCT01095705|Active Comparator|Conventional procedure|Local anaesthesia (Lidocaïne)
3220753|NCT01095705|Experimental|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) and Hypnosis
3220754|NCT01095718|Experimental|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
3220755|NCT01095718|Active Comparator|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step.Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance. Then the therapist asks immediately to the patient to do the steps."
3220756|NCT01095718|Active Comparator|Trial and Error|"Trial and Error refers to the regular unstructured learning and is considered as control condition.~Here the patient is encouraged to complete the task. When there is mistake, the therapist corrects it. Verbal cues will only be provided if the patient is unable to find and complete the correct next step or commit mistakes. The therapist use general instruction: Here is task, I will ask you to actions, followed by specific instruction, and I will help you after you have tried."
3220757|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
3220758|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade I-III|Good Grade (Hunt Hess I-III), n=15
3220759|NCT01095731|Experimental|Tiopronin, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
3220760|NCT01095731|Placebo Comparator|Sugar Pill, Hunt Hess Grade IV-V|Poor Grade (Hunt Hess IV-V), n=15
3220761|NCT01095744||EOAD typical AD|this cohort is constituted with early onset typical AD.
3220762|NCT01095744||LOAD typical|this group is constituted with late onset typical AD
3220763|NCT01095744||atypical AD|this group is constituted with atypical form of focal cortical atrophy, like posterior cortical atrophy and logopenic progressive aphasia.
3220764|NCT01095744||young controls|under 65
3220765|NCT01095744||old controls|over 65
3220766|NCT01095770|Active Comparator|Ablation Frontiers Ablation|This group will undergo AF ablation using Ablation Frontiers Technology.
3220767|NCT01095770|Active Comparator|LASSO ablation|This group will undergo atrial fibrillation ablation with traditional LASSO technology
3220768|NCT01095770|Active Comparator|Reveal XT monitoring|This group will be monitored pre and post ablation using a Reveal XT implantable loop recorder.
3220769|NCT01095770|Active Comparator|Permanent Pacemaker - dual chamber|This group will be monitored pre and post ablation with a dual chamber permanent pacemaker
3220770|NCT01095783|Experimental|Physiotherapeutic intervention|
3220771|NCT01095783|Other|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
3220772|NCT01095809|Experimental|bevacizumab|intravitreous bevacizumab 2,5 mg at baseline, week 4 and 8. reinjection is required.
3220773|NCT01095809|Experimental|triamcinolone acetonide|intravitreous triamcinolone 2 mg, frequency: 3 months
3220774|NCT01095822|Active Comparator|Aliskiren|25 patients with recently diagnosed hypertension and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
3220775|NCT01095822|Experimental|Aliskiren + Valsartan|25 patients with recently diagnosed hypertension, and mild to moderate type 2 diabetes will constitute the proposed study population. The diagnosis of diabetes will be made based on the American Diabetes Association criteria, such as random plasma glucose >200 mg/dL with or without symptoms of hyperglycemia (polydipsia, polyuria, polyphagia) and weight loss, or fasting plasma glucose > 126 mg/dL, to be determined at least twice. Patients will qualify if they are insulin-free, treated with an oral antiglycemic agent,(metformin only) and/or managed on diet alone for no less than 30 days and have adequate glucose control at the time of their Screening Visit.
3220776|NCT01095848|Experimental|0.25ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
3220777|NCT01095848|Experimental|1ml dose DPX-0907|On each vaccination day the lyophilized antigen/adjuvant/liposome complex is re-suspended in the oil (Montanide 1SA51 VG) before injection. The vaccine is not an emulsion.
3220778|NCT01095861|Experimental|FlexTip ETT|FlexTip ETT
3220779|NCT01095861|Placebo Comparator|Control|Standard Flexible ETT Mallinckrodt Hi-Lo cuffed tracheal tube Catalog # 86114 Mallinckrodt, ST. Louis, MO, 63134
3220780|NCT01095900||LIS group)|
3220781|NCT01095900||BT group|
3220782|NCT01095913|Experimental|IC-Green Injections|ICG Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
3220783|NCT01095926|Experimental|Doxorubicin|
3220784|NCT01095939|Placebo Comparator|Control Arm|
3220785|NCT01095939|Experimental|Benazepril|
3220786|NCT01095952|Experimental|AVNS ON|Consulta downloaded with AVNS to provide high frequency bursting during fastly conducted AF. AVNS will be programmed on for five months. The feasibility and safety of the AVNS algorithm to reduce inappropriate shocks will be monitored.
3220787|NCT01095965|Experimental|Lifestyle education|Nutrition education comprised of 4 components: Curriculum (8 weeks), follow-up meetings (4 monthly plus 2-bimonthly), education materials for use at home and vegetable gardening demonstrations.
3220788|NCT01095991|Experimental|1|AZD1656, day 1-5, AZD1656 + Sitagliptin day 6-10, Sitagliptin day 11-15.
3220789|NCT01095991|Experimental|2|Sitagliptin day 1-5, AZD1656 + Sitagliptin day 6-10, AZD1656 day 11-15.
3220790|NCT01096004|Experimental|1|
3220791|NCT01096004|Placebo Comparator|2|
3220792|NCT01096030|Experimental|Regorafenib|
3220793|NCT01096043|Placebo Comparator|Placebo|Each Strata of the study will have a placebo control. In strata A, the chance of getting active drug is 4 out of 5, in Strata B the chance of getting active drug is 3 ot of 4, and in Strata C, the chance of getting active Drug is 4 out of 5. In the event that a patient is allocated to receive placebo, the treatment may be stopped if the patient's condition fails to improve or worsens during the placebo infusion.
3220794|NCT01096043|Experimental|Strata 1 CXL-1020|Patients assigned to CXL-1020 in strata one will have their dose increased from the initial dose 2 times during the study period. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3220795|NCT01096043|Experimental|Strata 2 CXL-1020|In strata 2, patients who are assigned to active treatment will receive one of up to 3 possible fixed dose levels of CXL-1020 for a period of 6 hours. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3220796|NCT01096043|Experimental|Strata 3 CXL-1020|In strata 3, patients assigned to receive CXL-1020 will receive a fixed dose of CXL-1020 for 6 hours, and then the dose may be increased or decreased, based on the investigators assessment of the patient. The treatment may be stopped if the patient's condition fails to improve or worsens during the infusion.
3220797|NCT01096069||Rituximab|Rheumatoid arthritis patients undergoing treatment with rituximab.
3220798|NCT01096082|Placebo Comparator|Placebo|
3220799|NCT01096082|Experimental|Lithium Carbonate|
3220800|NCT01096095|Placebo Comparator|Placebo|Placebo
3220801|NCT01096095|Experimental|Sodium phenylbutyrate|Active drug
3220802|NCT01096108|Experimental|Standard Contest|Smoking abstinence, 1 prize award (month 1)
3220803|NCT01096108|Experimental|Standard Contest plus MAPS|Smoking abstinence, 1 prize award (month 1) plus motivational and problem-solving counseling (MAPS - Counseling phone calls); 20 weeks.
3220804|NCT01096108|Experimental|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
3220805|NCT01096108|Experimental|Extended Contests plus MAPS|Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.
3220806|NCT01096121|Placebo Comparator|2|
3220807|NCT01096121|Experimental|1|Enalapril
3220808|NCT01096134|Experimental|HPV Vaccine|Eligible girls were offered 3 doses of the HPV vaccine
3220809|NCT01096147|Active Comparator|SCS|patients receiving SCS for chronic leg and/or back pain.
3220810|NCT01096212|Experimental|generic sevoflurane|
3220811|NCT01096212|Active Comparator|origianl sevoflurane|
3220812|NCT01096225||vaccinated group|
3220813|NCT01096251|Experimental|CBT|CBT group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of CBT) plus 8 outpatient telephone-based sessions of CBT-oriented psychological support and monitoring with the same CBT inpatient psychotherapists.
3220814|NCT01096251|Experimental|BST|BST group: in-hospital treatment (diet, physical activity, dietitian counseling, 8 sessions of BST) plus 8 outpatient telephone-based sessions of BST-oriented psychological support and monitoring with the same BST inpatient psychotherapists.
3220815|NCT01096264|Other|Healthy volunteer|"Healthy volunteer undergoing two imagery evaluation :~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
3220816|NCT01096264|Other|vEDS patients|"vEDS patients undergoing two imagery evaluations:~SSI technique for local PWV and arterial stiffness evaluation~SphygmoCor® for aortic PWV."
3220817|NCT01096277|Active Comparator|Sitagliptin|100 mg sitagliptin per day for 2 weeks
3220818|NCT01096277|Placebo Comparator|Placebo|1 placebo tablet per day for 2 weeks
3220819|NCT01096277|No Intervention|Healthy Control|Healthy control subjects
3220820|NCT01096303||COPD tobacco and/or marihuana users|COPD patients with history of tobacco and/or marihuana smoking.
3220821|NCT01096329|Active Comparator|Cohort 2|Testosterone Spray (5%) vs Intrinsa® Patch
3220822|NCT01096329|Active Comparator|Cohort 3|Testosterone Spray (1%) vs Intrinsa® Patch
3220823|NCT01096329|Active Comparator|Cohort 1|Testosterone Spray (5%) vs Testosterone Spray (1%)
3220824|NCT01096355|Experimental|Group A|"Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3 and 8-10.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220825|NCT01096355|Experimental|Group B|"Patients receive oral RO4929097 once daily on days 1-7.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220826|NCT01096355|Experimental|Group C|"Patients receive oral RO4929097 once daily on days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220827|NCT01096355|Experimental|Group D|"Patients receive oral RO4929097 once daily on days 1, 8, and 15.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220828|NCT01096355|Experimental|Group E|"Patients receive oral RO4929097 once daily on days 1, 4, 8, 11, 15, and 18.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220829|NCT01096355|Experimental|Group F|"Patients receive oral RO4929097 once daily days 1-5, 8-12, and 15-19.~Treatment in all groups repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsies at baseline and between days 15 and 22 in the first course of treatment. Plasma samples are collected periodically for pharmacokinetic, pharmacodynamic, and pharmacogenomic analysis and to assess levels of adipsin and markers of angiogenesis."
3220830|NCT01096368|Experimental|Arm I (radiotherapy, chemotherapy)|Patients receive vincristine IV over 1 minute on days 1 and 8 of cycles 1 and 2, carboplatin IV over 15-60 minutes on day 1 of cycles 1 and 2, and cyclophosphamide IV over 30-60 minutes on days 1-2 of cycle 1 only. Patients also receive etoposide IV over 60-120 minutes on days 1-3 of cycle 2 only. Cycle 1 continues for 3 weeks and cycle 2 continues for 4 weeks in the absence of disease progression or unacceptable toxicity.
3220831|NCT01096368|Experimental|Arm II (radiotherapy, chemotherapy)|Patients undergo conformal radiotherapy over 6-7 weeks. Patients then receive vincristine IV on days 1, 8, and 15 of cycles 1-3 only, etoposide IV over 60-120 minutes on days 1-3, cisplatin IV over 1-8 hours on day 1, and cyclophosphamide IV over 30-60 minutes on days 2-3. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
3220832|NCT01096368|Active Comparator|Arm III (radiotherapy, observation)|Patients undergo conformal radiotherapy over 6-7 weeks and then undergo observation.
3220833|NCT01096381||Will receive bevacizumab|
3220834|NCT01096381||Will not receive bevacizumab|
3220835|NCT01096394||Ovarian cancer|Patients with presumed Stage III-IV ovarian, primary fallopian tube, or primary peritoneal papillary serous carcinoma.
3220836|NCT01096407||Paclitaxel-Induced Myalgias/Arthralgias|
3220837|NCT01096420|Experimental|acupuncture|
3220838|NCT01096420|Active Comparator|topiramate|
3220839|NCT01096433|Experimental|CPAP|The subjects introduced with CPAP treatment
3220840|NCT01096472|Experimental|LAS41003|Once daily
3220841|NCT01096472|Active Comparator|LAS189962|Once daily
3220842|NCT01096472|Active Comparator|LAS189961|Once daily
3220843|NCT01096485|Experimental|Arm 1|
3220844|NCT01096485|Active Comparator|Arm 2|
3220845|NCT01096498|Experimental|Arm 1|
3220846|NCT01096498|Active Comparator|Arm 2|
3220847|NCT01096511||Group 1|
3220848|NCT01096524|Other|Control group standard physiotherapy|Standard pathway of care pre-and post-TKA without using NMES.
3220849|NCT01096524|Experimental|Kneehab|Kneehab on the quadriceps of the affected leg, 20 minutes, twice per day, 5 days per week over 12-week intervention (6 weeks pre-op, 6 weeks post op).
3220850|NCT01096537||Young workers|"Exposed young workers graduated in sectors at risk of occupational asthma (bakery, pastry-making or hairdressing)~Non-exposed young workers graduated in sectors without specific occupational exposure as the sale or the food sectors."
3220851|NCT01096563|Experimental|1|AZD9164
3220852|NCT01096563|Placebo Comparator|2|
3220853|NCT01096576|Experimental|A|
3220854|NCT01096576|Placebo Comparator|B|
3220855|NCT01096602|Experimental|Group 1|DC AML Fusion Vaccine
3220856|NCT01096615|Active Comparator|Tested product: Lactobacillus paracasei LP-33|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table
3220857|NCT01096615|Placebo Comparator|Comparative product : placebo|Each patient will be randomly assigned to either tested product or comparative product (placebo) in accordance with a randomisation table .
3220858|NCT01096628|Experimental|Chiropractic + Exercise|
3220859|NCT01096628|Active Comparator|Exercise|
3220860|NCT01096641|Other|Fatigued patients: Immediate start CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients. At the end of the therapy, after 6 months, a second assessment will take place.This assessment will include the same measurements as at baseline.
3220861|NCT01096641|Other|fatigues patients: delayed CBT (after 6 months)|The fatigued patients on the waiting list will start with CBT after 6 months
3220862|NCT01096641|No Intervention|non-fatiqued controls|Non-fatigued control group. This group is not included in the randomization.
3220863|NCT01096654|Active Comparator|CT-scan|In this group treatment will be based on the outcome of the CT-scan only. Patients will be treated by adrenalectomy (Adx) if an unilateral lesion is visible on the CT-scan and the contralateral gland is normal. If bilateral lesions, bilateral enlargement or symmetric normal adrenal glands are present patients will be treated by the mineralocorticoid receptor antagonist (MRA)
3220864|NCT01096654|Active Comparator|Adrenal Vein Sampling|"This group will be treated according to the results of the adrenal vein sampling only. Adrenal vein sampling will be performed under the continuous infusion of ACTH (adrenocorticotropic hormone). A cortisol ratio ≥ 3 between the adrenal vein and the inferior vena cava is set as the criterium for successful cannulation. The criterium for lateralization is a aldosterone/cortisol ratio ≥ 4 between the adrenal veins and a lower aldosterone/cortisol ratio in the contralateral adrenal vein than in the inferior vena cava.~If AVS fails patients will be treated according to the CT-findings as described in the group with CT-scan only. Patients with a successful AVS will be treated by Adrenalectomy if unilateral production of aldosterone is shown. If no unilateral aldosterone production is present, i.e. the aldosterone/cortisol ratio is less than 4, patients will be treated by MRA."
3220865|NCT01096693|Placebo Comparator|Saline Placebo|In this arm, the response in forearm blood flow to incremental doses of Urocortins 2, 3 and Substance P will be studied co infused with saline placebo.
3220866|NCT01096693|Active Comparator|Response to Urocortin infusion in presence of Astressin 2B|This arm studies the response to intra arterial infusion of incremental doses of Urocortins 2, 3 and Substance P in the presence or absence of a selective antagonist - Astressin 2B.
3220867|NCT01096706|Experimental|Nitric Oxide Clamp|Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
3220868|NCT01096706|Placebo Comparator|Saline Placebo|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
3220869|NCT01096706|Experimental|Fluconazole|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
3220870|NCT01096706|Experimental|Aspirin|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
3220871|NCT01096706|Experimental|Combined|Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.
3220872|NCT01096719|Experimental|Energy Density|
3220873|NCT01096719|Active Comparator|Lifestyle Treatment|
3220874|NCT01096719|Experimental|Energy Density + Lifestyle Treatment|
3220875|NCT01096732|Experimental|GDC-0449|Study drug.
3220876|NCT01096745|Experimental|Gemcitabine/Cisplatin|
3220877|NCT01096745|Experimental|S-1/Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
3220878|NCT01096758||PKU patients|
3220879|NCT01096758||healthy controls|
3220880|NCT01096797|Experimental|Children undergoing adenotonsillectomy|Children between 2-6 years old undergoing elective adenoidectomy with or without tonsillectomy from the ENT Service of the San Gerardo Hospital.
3220881|NCT01096836|Experimental|Diet counseling|Outcomes of the study may enhance diet counseling
3220882|NCT01096836|Experimental|exercise training|
3220883|NCT01096862|Experimental|Group 1|lowest dose
3220884|NCT01096862|Experimental|Group 2|low dose
3220885|NCT01096862|Experimental|Group 3|high dose
3220886|NCT01096862|Experimental|Group 4|highest dose
3220887|NCT01096862|Experimental|Group 5|medium dose
3220888|NCT01096862|Placebo Comparator|Placebo|Matching placebo
3220889|NCT01096888|No Intervention|Standard WIC care|Patients randomized to this group will receive standard WIC care and an information packet surround healthy eating and activity topics.
3220890|NCT01096888|Active Comparator|Enhanced WIC weight loss program|Participants randomized into this condition will receive standard WIC care, but will also receive weight loss classes provided through the internet. Topics will cover behavioral weight loss topics, based off the protocols of the Look AHEAD program.
3220891|NCT01096901|Active Comparator|Comprehensive behavioral weight loss|The group will be implemented to induce a 6% weight loss over 3 months. The lessons will follow protocols from the Look AHEAD trial and Diabetes Prevention Program. This behavioral program has been shown to promote long-term weight loss and a reduction in diabetes and cardiovascular risk factors, and is based on the social cognitive theory.
3220892|NCT01096901|No Intervention|Education and Support Control group|Participants in this group will receive support and education about healthy eating and activity with lessons based on the Look AHEAD support and education control condition. Participants will attend monthly closed group meetings and meetings will be designed to promote retention but not weight loss.
3220893|NCT01096914|Active Comparator|Radiofrequency|patients treated with percutaneous radiofrequency ablation
3220894|NCT01096914|Active Comparator|laser|Patients treated with percutaneous laser ablation
3220895|NCT01096927|Experimental|Non operative Treatment group|Patients with Lower Abdominal and suspected Acute Appendicitis, treated non-operatively with 7 days antibiotic therapy (Amoxicillin and Clavulanic Acid)
3220896|NCT01096940|Experimental|1|AZD1656
3220897|NCT01096940|Experimental|2|Simvastatin
3220898|NCT01096940|Experimental|3|AZD1656 + simvastatin
3220899|NCT01096953|Active Comparator|Telepsychiatry|Psychiatry provided over telehealth network
3220900|NCT01096953|Active Comparator|Face-to-face care|Psychiatry provided in person
3220901|NCT01096966|Experimental|Bupivacaine TTS|
3220902|NCT01096966|Placebo Comparator|Placebo patch|
3220903|NCT01096979|Experimental|LIPO-102, High|LIPO-102, High
3220904|NCT01096979|Experimental|LIPO-102, Low|LIPO-102, Low
3220905|NCT01096979|Experimental|Placebo|Pbo
3220906|NCT01097018|Active Comparator|Perifosine + Capecitabine|Perifosine 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
3220907|NCT01097018|Placebo Comparator|Placebo + Capecitabine|Placebo 1 tablet daily + Capecitabine BID days 1 - 14 every 21 days
3220908|NCT01097031||Continuous Infusion|
3220909|NCT01097031||Intermittent Infusion|
3220910|NCT01097031||Infusion Continuous|
3220911|NCT01097070|Experimental|Bevirimat 200 mg twice daily, 15 days|
3220912|NCT01097070|Experimental|Bevirimat 300 mg once daily, 15 days|
3220913|NCT01097070|Experimental|Bevirimat 400 mg once daily, 15 days|
3220914|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at middle dose|
3220915|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 1 at low dose|
3220916|NCT01097096|Placebo Comparator|Placebo + Adjuvant 1 at middle dose|
3220917|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at middle dose|
3220918|NCT01097096|Active Comparator|CAD106 150μg + Adjuvant 2 at low dose|
3220919|NCT01097096|Placebo Comparator|Placebo + Adjuvant 2 at middle dose|
3220920|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at middle dose|
3220921|NCT01097096|Active Comparator|CAD106 450μg + either Adjuvant 1 or 2 at low dose|
3220922|NCT01097096|Placebo Comparator|Placebo + either Adjuvant 1 or 2 at middle dose|
3220923|NCT01097122|Experimental|Healthy young adult subjects|Forearm vibration will be applied in healthy young adult subjects
3220924|NCT01097135|No Intervention|Standard surgical skin preparation|
3220925|NCT01097135|Active Comparator|Standard Surgical Skin Preparation with Duraprep|standard surgical skin prep
3220926|NCT01097148|Active Comparator|Atracurium, TBW|Dose of atracurium 0.5 mg/kg based on total body weight
3220927|NCT01097148|Active Comparator|Atracurium IBW|dose 0.5 mg/kg based on ideal body weight
3220928|NCT01097161|Experimental|Speech treatment on prosodic basis|Patients receive 20 therapy sessions over a course of 3 months, with one double session per week.
3220929|NCT01097174||CyPass Micro-stent|Patients in whom CyPass Micro-stent implantation was attempted.
3220930|NCT01097200|Other|Elevate meshes|The use of Elevate (American Systems trade mark) meshes for the treatment of pelvic prolapse.
3220931|NCT01097200|Other|Sacrocolpopexy|Sacrocolpopexy for the correction of the prolapse
3220932|NCT01097226|Experimental|Apple flavanols|
3220933|NCT01097239|Experimental|High Intensity Focused Ultrasound|Transrectal High Intensity Focused Ultrasound (HIFU) treatment of the PelvicTumour
3220934|NCT01097252|Active Comparator|weekly cisplatin|Weekly cisplatin 40mg/m2 during radiation therapy
3220935|NCT01097252|Experimental|tri-weekly cisplatin|cisplatin 75mg/m2 three cycles, every 3 weeks
3220936|NCT01097278|Experimental|Arm I|Participants receive oral cholecalciferol once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
3220937|NCT01097278|Active Comparator|Arm II|Participants receive oral placebo once weekly and oral vitamin D once daily. Treatment repeats for 12 months in the absence of evidence of cancer or unacceptable toxicity.
3220938|NCT01097356|No Intervention|common care|HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear
3220939|NCT01097356|Experimental|probiotic drinkers|HPV+, LSIL patients who will drink the study drink for 6 months
3220940|NCT01097369||Anti-rasburicase antibodies|
3220941|NCT01097382|Experimental|AMBIEN CR|AMBIEN CR 12.5 mg once daily immediately before bedtime or in elderly/hepatically impaired patients: 6.25 mg once daily immediately before bedtime
3220942|NCT01097408|Experimental|AZD7295|
3220943|NCT01097408|Placebo Comparator|Matched placebo|
3220944|NCT01097434|Active Comparator|Arm 1|Biodegradable polymer limus-eluting stents
3220945|NCT01097434|Active Comparator|Arm 2|Permanent polymer limus-eluting stent
3220946|NCT01097447||Ciprofloxicine or Vigamox or other|up to qid till epithelialized.
3220947|NCT01097447||Topical Nonsteroidal (Acular, Acuvail, Voltaren Xibrom|up to qid for up to 5-10 days postop
3220948|NCT01097447||Topical steroid (FML, Pred Forte, Flarex|qid for up to 8 weeks
3220949|NCT01097473|Active Comparator|Exercise training|Subjects participate in a once weekly supervised exercise training group, duration of 60 min.
3220950|NCT01097473|No Intervention|Control|Control group receives no intervention
3220951|NCT01097486|Active Comparator|Allograft|Cervical Spinal Fusion with Allograft
3220952|NCT01097486|Experimental|NeoFuse|Cervical Spinal Fusion with NeoFuse
3220953|NCT01097499|Active Comparator|LED application|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
3220954|NCT01097499|No Intervention|No LED application|These patients will receive conventional dental implant treatment without the application of the LED therapy.
3220955|NCT01097512|Experimental|Regimen 1: AS703569/gemcitabine|Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle
3220956|NCT01097512|Experimental|Regimen 2: AS703569/gemcitabine|AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle
3220957|NCT01097525|Active Comparator|Wavefront guided (WFG) PRK|
3220958|NCT01097525|Active Comparator|WFG LASIK|
3220959|NCT01097525|Active Comparator|Wavefront optimized (WFO) PRK|
3220960|NCT01097525|Active Comparator|WFO LASIK|
3220961|NCT01097538|Active Comparator|Body-weight supported treadmill training|Supported treadmill walking
3220962|NCT01097538|Experimental|Total body recumbent stepper training|Recumbent stepper exercise training
3220963|NCT01097551||Patients with type 1 diabetes|Diabetes duration >= 5 years, age >= 18 and <= 60 years old, patients with no visible diabetic retinopathy, and no arterial hypertension
3220964|NCT01097551||Healthy subjects|Sex and age-matched control healthy subjects
3220965|NCT01097564||COL4A1 genetic testing|COL4A1 genetic testing
3220966|NCT01097590|Experimental|Active TLA Gut™ column|The active column contain an engineered protein with the ability to specifically bind the inflammatory cells.
3220967|NCT01097590|Placebo Comparator|Placebo TLA Gut™column|The placebo column is identical to the active column except it does not contain the engineered protein that specifically bind the inflammatory cells.
3220968|NCT01097681|Experimental|Normal renal function group|oral
3220969|NCT01097681|Experimental|Mild renal impairment group|oral
3220970|NCT01097681|Experimental|Moderate renal impairment group|oral
3220971|NCT01097720||LTG-exposed|Children exposed to LTG during pregnancy.
3220972|NCT01097720||VPA-exposed|Children exposed to VPA during pregnancy.
3220973|NCT01097720||CBZ-exposed|Children exposed to CBZ during pregnancy.
3220974|NCT01097733||Pre-procedural cardiac CT|CRT patients will undergo pre-procedural cardiac CT to assess for dyssynchrony, scar, and coronary venous anatomy. The CT venogram will be randomize to pre-knowledge to implanting physician or blinded. The CT dyssynchrony and scar assessment will remain blinded to caregivers and patients.
3220975|NCT01097759||LigaSure|LigaSure is a vascular sealing device that can seal the hemorrhoidal plexus during hemorrhoidectomy (surgery)
3220976|NCT01097759||Stapler|Circular stapler that removes excess loose tissue above the anus and interrupts the blood supply during hemorrhoidal surgery
3220977|NCT01097772|Other|Ovation Abdominal Stent Graft System|Implant of Ovation Abdominal Stent Graft System
3220978|NCT01097798|Experimental|Aliviador|
3220979|NCT01097798|Active Comparator|Gelol|
3220980|NCT01097811|Active Comparator|Erythromycin|
3220981|NCT01097811|Active Comparator|Neomycin|
3220982|NCT01097837||Epilepsy|Cohort is comprised of women with epilepsy between 18 and 47.
3220983|NCT01097850|Other|Right|Application of henna paste to right hand/foot plus CeraVe moisturizer
3220984|NCT01097850|Other|Left|Application of henna paste to the left hand/foot plus CeraVe moisturizer
3220985|NCT01097876|Experimental|Active PF-04447943|
3220986|NCT01097876|Placebo Comparator|Placebo PF-04447943|
3220987|NCT01097889|Active Comparator|Treatment Group 1|
3220988|NCT01097889|Experimental|Treatment Group 2|
3220989|NCT01097902|Active Comparator|Ibuprophen 800 mg|Oral ibuprofen 800 mg, administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
3220990|NCT01097902|Placebo Comparator|Placebo|Oral placebo administered 24 hours after exposure to UV radiation for the creation of an inflamed lesion, and 2 hours prior to site evaluation.
3220991|NCT01097928||Patients undergoing Pulmonary Embolectomy|
3220992|NCT01097941|Active Comparator|LAIV/LAIV|
3220993|NCT01097941|Active Comparator|IIV/IIV|
3220994|NCT01097941|Active Comparator|IIV/LAIV|
3220995|NCT01097967|Active Comparator|CPAP in sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3220996|NCT01097967|No Intervention|no CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3220997|NCT01097967|Active Comparator|CPAP in non sleepy patients with SDB|SDB defined as AHI >=20 Sleepy defined as Epworth Sleepiness Score >=10
3220998|NCT01097980|Experimental|Trazodone|Trazodone versus placebo in a randomized, double-blind manner
3220999|NCT01097980|Placebo Comparator|Placebo|Patients received placebo
3221000|NCT01097993|Experimental|1 = Tested product|
3221001|NCT01097993|Active Comparator|2 = Control product|
3221002|NCT01098019|Experimental|Xeomin|Each bottle of Xeomin will be reconstituted with 2 mL of NaCl 0.9 which will give a final concentration of 5 U of botulinum toxin A per 0.1 mL. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum total dose of 200 units (4mL).
3221003|NCT01098019|Placebo Comparator|Placebo|Patients will receive 0.9% mL NaCl alone. The area affected will be injected with 0.1 mL at each 1-2 square cm for a maximum volume of 4 mL.
3221004|NCT01098045||HIV-infection with fat redistribution (lipoatrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-24 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~No evidence of fat redistribution rated by the investigator."
3221005|NCT01098045||Healthy controls|"No history of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 18-29.9 kg/m2"
3221006|NCT01098045||HIV-infected with fat redistribution (lipohypertrophy)|"Evidence of HIV infection~Age ≥ 20 and ≤ 60 years of age~BMI measurement between 25-29.9 kg/m2~HIV positive, on a stable HAART treatment regimen (including an NRTI) for > 12 months~Evidence of significant fat redistribution rated by the investigator, including 1) significant fat atrophy of the face, arms or legs, and 2) significant increase in fat accumulation of the neck."
3221007|NCT01098045||Dicer Cohort|30 men [HV-infected with fat redistribution (n = 10), HIV-infected without fat redistribution (n=10), and healthy controls (n= 10)] will be recruited for this group.
3221008|NCT01098058|Experimental|CBT plus treatment as usual|
3221009|NCT01098058|Active Comparator|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
3221010|NCT01098084|Experimental|Decitabine|
3221011|NCT01098123||Diet counseling, nutritional index|Lightweight as athletes with weight limit
3221012|NCT01098123||nutritional index|Heavyweight athletes without weight limit
3221013|NCT01098136|Active Comparator|Chiropractic treatment|Management for one-sided pelvic pain, as decided by the chiropractor
3221014|NCT01098136|Active Comparator|Conventional health care|Conventional health care for one-sided pelvic pain
3221015|NCT01098136|Active Comparator|Conventional and alternative treatment|Treament of pregnant women with other pelvic pain syndromes.
3221016|NCT01098149|Active Comparator|AFB stand alone|Patients are switched in AFB treatment, without blood volume control.
3221017|NCT01098149|Active Comparator|BD and BVC|Patients are switched into bicarbonate dialysis with Blood Volume Control
3221018|NCT01098175||Control group|open surgery with exposure of the surgical wound to the air.
3221019|NCT01098175||Full peritoneal conditioning|Full peritoneum cavity conditioning will be performed as follows. A continuous flow of less than 0.5 l/min of gas will be instilled in the lowest part of the operating wound. As gas premixed bottles with CO2+ 4% of oxygen and 10% of N2O will be used. This gas will be humidified and at 31-32 °C to be achieved by a commercial humidifier (Fisher and Paykel) programmed in order to maintain 100% relative humidity at 31-32°C upon entrance of the peritoneal cavity.
3221020|NCT01098227||RSV positive subjects|Subjects admitted to Winthrop University Hospital with lower viral respiratory infection and RSV positive status by DFA and/or Viral culture
3221021|NCT01098227||RSV negative subjects|Subjects admitted to Winthrop University Hospital with a lower viral respiratory infection and RSV status negative by DFA and viral culture. these subjects may be positive for other viruses detected by DFA or viral culture (Adenovirus, Influenza A or B, Metapneumovirus or parainfluenza) or not
3221022|NCT01098227||Control group|Children in the same age range without respiratory conditions and who are well enough to perform the test from the out patient setting
3221023|NCT01098292||Healthy Control|"Healthy Control participants do not suffer from any Urological Chronic Pelvic Pain Syndromes or from the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
3221024|NCT01098292||Positive Control|"Positive Control participants do not suffer from any Urological Pelvic Pain Syndromes like Interstitial Cystitis and/or Chronic Prostatitis. However Positive Controls have a history of one of the following conditions:~Fibromyalgia, Irritable Bowel Syndrome, Chronic Fatigue Syndrome"
3221025|NCT01098357|Experimental|Biochaperone PDGF-BB low dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
3221026|NCT01098357|Experimental|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB is a new formulation of the B isoform dimer of recombinant human Platelet-Derived Growth Factor (rhPDGF-BB) containing the new excipient Biochaperone, a dextran modified polymer. The finished product is a sterile multi-dose spray vial.
3221027|NCT01098357|Active Comparator|Regranex|Becaplermin gel (Regranex® Gel 0.01%, Systagenix, formerly and Johnson & Johnson) is a topical gel of rhPDGF-BB conditioned in a gel tube.
3221028|NCT01098357|Experimental|Very Low Dose BioChaperone PDGF-BB|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
3221029|NCT01098383|Placebo Comparator|Placebo for AChEI and Choline|
3221030|NCT01098383|Experimental|AChEI and Choline|Acetyl-choline Esterase Inhibitor and Choline supplements
3221031|NCT01098409|Experimental|sodium nitrite 24 hours before|
3221032|NCT01098409|Experimental|sodium nitrite during surgery|
3221033|NCT01098409|Placebo Comparator|0.9% sodium chloride|
3221034|NCT01098435|Experimental|RDC-0313 (ALKS 33)|2-capsules taken orally
3221035|NCT01098435|Placebo Comparator|Placebo|2-capsules taken orally
3221036|NCT01098448|Active Comparator|Scaling and root planing|scaling and root planing as a solo therapy
3221037|NCT01098448|Experimental|Periodontal surgery|
3221038|NCT01098448|Experimental|systemic antibiotics|
3221039|NCT01098448|Experimental|Local delivery of tetracycline|
3221040|NCT01098448|Experimental|local antibiotic and systemic antibiotics|
3221041|NCT01098448|Experimental|local antibiotics and surgery|
3221042|NCT01098448|Experimental|systemic antibiotics and surgery|
3221043|NCT01098448|Experimental|local and systemic antibiotics and surgery|
3221044|NCT01098513|Experimental|Part A|Subjects will be randomized in a three-way crossover design to receive a single dose of each of three different tablet formulations of GSK1349572 50 mg (2 tablets). Formulation AP, AW and AX.
3221045|NCT01098513|Experimental|Part B|A total of 18 subjects who complete Part A will return for Part B. Subjects from Part A will be asked to participate on a first come first served basis until there are 18 subjects, at which time enrolment to Part B will be closed. Part B will be a three way crossover design using either formulation AW or AX depending upon the results from Part A. Subjects will receive a single dose of 50 mg GSK1349572 with either a low fat, moderate fat or high fat meal in each period.
3221046|NCT01098526|Experimental|Cohort 1|Subjects will receive a single dose of GSK1349572 100 mg in Period 1 followed by a washout of at least 6 days. Subjects will then receive GSK1349572 50 mg once a day for 5 days in Period 2. Period 3 will begin immediately after Period 2. In Period 3 subjects will receive GSK1349572 50 mg once a day in the morning and Efavirenz 600 mg once a day at bedtime for 14 days. There will be a screening visit up to 30 days before Period 1 and a follow up visit 7-14 days after the end of Period 3.
3221047|NCT01098552||High-risk radical prostatectomy patients|
3221048|NCT01098552||Primary external beam radiotherapy patients|
3221049|NCT01098552||Primary prostate brachytherapy patients|
3221050|NCT01098552||Hormone refractory prostate cancer patients|
3221051|NCT01098552||Active Surveillance|
3221052|NCT01098552||Prostate biopsy patients|
3221053|NCT01098565|Experimental|Study device arm|
3221054|NCT01098591||Myocardial infarction|Patients with post-myocardial infarction receiving cell therapy either intracoronarily or intramyocardial
3221055|NCT01098591||Ischemic cardiomyopathy|Patients with ischemic cardiomyopathy treated with cell therapy either intracoronarily or intramyocardial
3221056|NCT01098604|Active Comparator|32mm ceramic head group|patients performed with THA using 32mm ceramic head
3221057|NCT01098604|Active Comparator|28mm ceramic head group|patients performed with THA using 28mm ceramic head
3221058|NCT01098617||hemorrhage|The patients who had bleeding induced by endoscopic sphincterotomy
3221059|NCT01098630||Group I (limited participation)|Patients do not complete any questionnaires at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
3221060|NCT01098630||Group II (full participation)|Patients complete the Patient Registration Survey and Patient Questionnaire at baseline. At baseline, patients' medical record information is collected; sites complete the Functional Comorbidity Index; and physicians, nurses, and study coordinators complete the follow-up questionnaire. Staff complete the treatment review form after treatment or 7 months after study registration.
3221061|NCT01098656|Experimental|lenalidomide|
3221062|NCT01098656|No Intervention|Observation|
3221063|NCT01098695|Experimental|EcoFIT offered|
3221064|NCT01098695|No Intervention|No Feedback or services offered|
3221065|NCT01098721|Placebo Comparator|Group 1|A placebo cream applied topically twice daily (BID)by each of 20 patients, once in the morning and once in the evening for 12 weeks.
3221066|NCT01098721|Active Comparator|Group 2|A 1.0% WBI-1001 cream applied topically twice daily (BID) by each of 40 patients, once in the morning and once in the evening for 12 weeks.
3221067|NCT01098734|Placebo Comparator|Group 1|0%; vehicle cream
3221068|NCT01098734|Active Comparator|Group 2|0.5% WBI-1001 cream
3221069|NCT01098734|Active Comparator|Group 3|1.0% WBI-1001 cream
3221070|NCT01098760|Experimental|Arm 1|
3221071|NCT01098773||patients requiring ventilation|
3221072|NCT01098773||patients who weaned permanently|
3221073|NCT01098786||Healthy|
3221074|NCT01098799||Control|Healthy controls
3221075|NCT01098799||Chronic kidney disease-1|Chronic kidney disease not taking dialysis treatment
3221076|NCT01098799||Kidney Transplant|Kidney transplants
3221077|NCT01098825||District VI AAP clinicians|
3221078|NCT01098838|Experimental|Weekly dosing of LCL161|by mouth (oral)
3221079|NCT01098838|Experimental|Comparison of LCL161|tablet versus liquid
3221080|NCT01098838|Experimental|Twice daily dosing of LCL161|by mouth for 4 days followed by a 3-day rest period every week
3221081|NCT01098877|Placebo Comparator|Placebo|
3221082|NCT01098877|Experimental|Cohort 1, 1mg|
3221083|NCT01098877|Experimental|Cohort 1, 3mg|
3221084|NCT01098877|Experimental|Cohort 1, 10mg|
3221085|NCT01098877|Experimental|Cohort 2, 30mg|
3221086|NCT01098877|Experimental|Cohort 2, 100mg|
3221087|NCT01098877|Experimental|Cohort 2, 300mg|
3221088|NCT01098877|Experimental|Cohort 3, 600mg|
3221089|NCT01098877|Experimental|Cohort 3, 900mg|
3221090|NCT01098877|Experimental|Cohort 3, up to 900mg (fed)|
3221091|NCT01098877|Placebo Comparator|Cohort 3, placebo (fed)|
3221092|NCT01098890|Placebo Comparator|Placebo|Placebo will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
3221093|NCT01098890|Active Comparator|tPA (tissue plaminogen activator)|Intraventricular TPA will be administered every 12 hours for a total five doses. Patients will be followed for a total of 6 months.
3221094|NCT01098903||Sunitinib|Patients with a malignancy treated with sunitinib
3221095|NCT01098916|Experimental|X-rays at home|Home hospitalized elderly patients undergo X-rays at home
3221096|NCT01098916|Active Comparator|Hospital X-rays|Home hospitalized elderly patients undergo X-rays examinations in hospital
3221097|NCT01098929||Congenital Diaphragmatic Hernia (CDH)|Individuals affected with congenital diaphragmatic hernia (CDH)
3221098|NCT01098929||Unaffected|Healthy family members of individuals affected with congenital diaphragmatic hernia (CDH)
3221099|NCT01098942||Surgical|Roux-en-Y gastric bypass surgery
3221100|NCT01098942||Non-surgical|Non-surgical lifestyle weight management
3221101|NCT01098955|Experimental|ACT Group 1|Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
3221102|NCT01098955|Experimental|MBC Group 2|Motivational and Behavioral Counseling (MBC). Varenicline 2 mg daily for 12 weeks.
3221103|NCT01098968|No Intervention|Normal PE|2 Physical Education sessions / week
3221104|NCT01098968|Experimental|PE Volume|4 Physical Education sessions/week (increased volume)
3221105|NCT01098968|Experimental|PE Volume + Intensity|4 Physical Education sessions/week of high intensity (increased volume and intensity)
3221106|NCT01098981|Experimental|Target group|A combined treatment with transcranial US and systemic tPA
3221107|NCT01098981|Active Comparator|Control group|Systemic tPA alone
3221108|NCT01098994|Other|Haptoglobin 1/1|Individuals with type 1 diabetes and the Haptoglobin 1/1 phenotype
3221109|NCT01098994|Other|Haptoglobin 2/1|Individuals with type 1 diabetes and the Haptoglobin 2/1 phenotype
3221110|NCT01098994|Other|Haptoglobin 2/2|Individuals with type 1 diabetes and the Haptoglobin 2/2 phenotype
3221111|NCT01099007|Active Comparator|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
3221112|NCT01099007|Experimental|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
3221113|NCT01099033||Hiatal/Paraesophageal hernia patients|patients with hiatal or paraesophageal hernias
3221114|NCT01099033||control group|patients without hiatal or paraesophageal hernias who are undergoing crural dissection for heller myotomy, or who are undergoing gastric bypass surgery
3221115|NCT01099046|No Intervention|medication only|medication = anti-diuretics
3221116|NCT01099046|Active Comparator|medication + water intake|anti-diuretics + water intake (at least 2.0 litters per day)
3221117|NCT01099046|Active Comparator|medication + tympanic tubing|anti-diuretics + tympanic tubing (under local anesthesia)
3221118|NCT01099046|Active Comparator|medication + regular sleep|anti-diuretics + regular sleep (regular sleep program under dark everynight)
3221119|NCT01099059|Active Comparator|Ritalin|receive ritalin depending on weight
3221120|NCT01099059|Experimental|Amantadine|100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
3221121|NCT01099072|Active Comparator|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
3221122|NCT01099072|Experimental|methylphenidate+carnitine|
3221123|NCT01099085|Active Comparator|XP/simvastatin|Capecitabine/cisplatin + simvastatin
3221124|NCT01099085|Placebo Comparator|XP/placebo|Capecitabine/cisplatin + placebo
3221125|NCT01099098||Patients with TB sequelae|
3221126|NCT01099098||People without TB sequelae|
3221127|NCT01099124|Experimental|M2ES combined with chemotherapy|
3221128|NCT01099137|Experimental|Vildagliptin|Vildagliptin will be added to uncontrolled diabetic patients with sulphonylurea and metformin
3221129|NCT01099137|Active Comparator|Sulphonylurea dose-up|Sulphonylurea dose will be increased to uncontrolled diabetic patients with sulphonylurea and metformin
3221130|NCT01099150|Experimental|42 healthy volunteers - crossover|"Acute consumption of three interventions (60 g dark chocolate enriched in flavan-3-ols, 60 g standard dark chocolate, or 60 g white chocolate) on three separate days (at least 2 weeks apart) in random order.~Post-prandial measurements at t = 0 h, t = 2 h and t = 6 h."
3221131|NCT01099163|Experimental|3g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, 100 IU vitamin E
3221132|NCT01099163|Active Comparator|3 g CLA|3 g CLA (50:50%) AND other diabetes medication currently prescribed to participant, vitamin E placebo
3221133|NCT01099163|No Intervention|3 g MCT + vit E placebo|3 g MCT AND other diabetes medication currently prescribed to participant, 100 IU vitamin E placebo
3221134|NCT01099176|Experimental|Atorvastatin|10mg of Atorvastatin
3221135|NCT01099176|Experimental|Fenofibrate|267mg of Fenofibrate
3221136|NCT01099176|Experimental|Fenofibrate and atorvastatin|10mg of Atorvastatin and 267mg of fenofibrate
3221137|NCT01099176|Placebo Comparator|Therapeutic Lifestyle Change|Placebo and Therapeutic Lifestyle Change
3221138|NCT01099189||Observed cohort|All patients recruited. Observed for clinical outcomes
3221139|NCT01099228|Active Comparator|131-I MIBG and 111I-n pentetreotide|131-I MIBG and 111I-n pentetreotide
3221140|NCT01099228|Active Comparator|131-I MIBG and In-111 DOTATATE|131-I MIBG and In-111 DOTATATE
3221141|NCT01099280|Experimental|oxytocin group|2 milliunits/min and doubled every 30 minutes to a maximum of 32 milliunits/min or until four contractions in 10 minutes was achieved
3221142|NCT01099280|Experimental|dinoprostone and oxytocin|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
3221143|NCT01099293||Cirrhosis, w/o hepatic encephalopathy|Patients with liver cirrhosis without hepatic encephalopathy by clinical (West-Haven), neurophysiological tests (PHES) nor Critical Flicker Frequency evidence.
3221144|NCT01099293||Cirrhosis-minimal hepatic encephalopathy|Patients with cirrhosis, without clinical evidence of hepatic encephalopathy (West Haven 0) and with positive tests for both, PHES and CFF.
3221145|NCT01099293||Cirrhosis, Hepatic encephalopathy I|Patients with cirrhosis and clinical evidence of hepatic encephalopathy with a West Haven score of I.
3221146|NCT01099293||Control|Healthy subjects willing to participate in the study
3221147|NCT01099306|Active Comparator|intervention|pharmacist-physician collaborative approach to manage Metabolic syndrome
3221148|NCT01099306|No Intervention|control|physician only team to manage Metabolic syndrome
3221149|NCT01099319|Experimental|Renalof|
3221150|NCT01099319|Placebo Comparator|Placebo|
3221151|NCT01099332|Active Comparator|Gastro-retentive zinc cysteine tablet|Once daily administration by mouth of a gastro-retentive, sustained-release preparation of zinc cysteine with excipients, all G.R.A.S., with adequate water.
3221152|NCT01099332|Placebo Comparator|Identical appearance of placebo with active comparator|Once daily administration of placebo of identical physical appearance to that of active comparator with similar amount of water.
3221153|NCT01099345||Group 1 - OAB with DO+|Subjects that DO+ nocturia
3221154|NCT01099345||Group 2- OAB with DO-|Subjects that DO- nocturia
3221155|NCT01099371|Experimental|exercise|
3221156|NCT01099384|Active Comparator|Behavioral: written self-help materials|Behavioral: written self-help materials
3221157|NCT01099384|Experimental|Group behavioral counseling|Group behavioral counseling, weekend program
3221158|NCT01099410||Group 1|volunteer subjects
3221159|NCT01099423|Active Comparator|Immediate nephrectomy|Surgery followed by Sunitinib
3221160|NCT01099423|Experimental|Deferred nephrectomy|Sunitinib (3 cycles) followed by surgery followed by Sunitinib
3221161|NCT01099436|Experimental|TAC + Zoledronic acid|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC) and zoledronic acid (Zometa)
3221162|NCT01099436|Active Comparator|TAC|six cycles of docetaxel (Taxotere®), Adriamycin® (endoxan) and Cyclofosfamide (TAC)
3221163|NCT01099462||Children with fever|
3221164|NCT01099488|Other|All subjects|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received a GSK2231392A vaccine, were enrolled for blood withdrawal to support the development of CD8+ T cell immunological detection assays.
3221165|NCT01099501|Active Comparator|Oxepa|Oxepa (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
3221166|NCT01099501|Active Comparator|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
3221167|NCT01099514|Experimental|Nilotinib|Nilotinib 400 mg (2 capsules) PO BID q 28 days
3221168|NCT01099527|Experimental|Everolimus|"Everolimus (RAD001) dose escalation of capecitabine, everolimus~Capecitabine dose escalation of capecitabine, everolimus"
3221169|NCT01099540|Experimental|Pazopanib|
3221170|NCT01099553|Other|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Boston Medical Center
3221171|NCT01099553|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions asking them to watch an educational video on the Center for Digestive Disorders website
3221172|NCT01099566|Experimental|Prasugrel|
3221173|NCT01099566|Placebo Comparator|pills consisting of lactose-starch|
3221174|NCT01099605|Placebo Comparator|Pump device|One arm will have continuous subcutaneous infusion of normal saline.
3221175|NCT01099605|Active Comparator|Bupivacaine|will receive continuous infusion of bupivacaine
3221176|NCT01099644|Experimental|131 I-8H9|This is a phase I study of 131I-8H9 for patients with DSRCT and other 8H9-reactive solid tumors metastatic to the peritoneum.
3221177|NCT01099657|Experimental|Virtual Reality Hypnosis|Virtual Reality Hypnosis for chronic pain
3221178|NCT01099657|Experimental|Virtual Reality Distraction|Virtual Reality Distraction for Chronic Pain
3221179|NCT01099670|Experimental|7.5 mg NRL001|Nine subjects will receive 7.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3221180|NCT01099670|Experimental|10 mg NRL001|Nine subjects will receive 10 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3221181|NCT01099670|Experimental|12.5 mg NRL001|Nine subjects will receive 12.5 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3221182|NCT01099670|Experimental|15 mg NRL001|Nine subjects will receive 15 mg NRL001 in a 2 g suppository; three will receive matching placebo.
3221183|NCT01099683|Experimental|NRL001|All subjects will receive 10 mg NRL001 in a 2 g rectal suppository
3221184|NCT01099683|Placebo Comparator|Placebo|All subjects will receive placebo
3221185|NCT01099696|Experimental|B. infantis 35624|B. infantis 35624 in white capsules
3221186|NCT01099696|Placebo Comparator|placebo|white placebo capsules (inert)
3221187|NCT01099722|Active Comparator|Inhaler|
3221188|NCT01099722|Active Comparator|inhaler|Symbicort
3221189|NCT01099735||CPAP, Manometry|Patients undergoing Manometry before weight loss surgery
3221190|NCT01099748|Active Comparator|Methadone|Dose of methadone must not change from 1 week prior to study start and through the duration of the study.
3221191|NCT01099748|Experimental|Lersivirine + Methadone|
3221192|NCT01099787||FAP IBS|
3221193|NCT01099800||Mexican/Mexican American families|Parents and children who self-identify as being of Mexican heritage whether US-born or Mexican-born
3221194|NCT01099800||Puerto Rican families|Parents and children who self-identify as Puerto Rican whether US-born or island-born.
3221195|NCT01099813||Inpatients assessed for critical care|Patients admitted to Critical Care Units participating in the ICNARC CMP programme who have been assessed at any time on a ward prior to ICU admission by a critical care decision maker (e.g. the CCOT or any member of the medical staff on duty for the unit)
3221196|NCT01099826|Experimental|lifestyle counseling tailored|
3221197|NCT01099826|Experimental|lifestyle counseling motivational|
3221198|NCT01099826|No Intervention|control|
3221199|NCT01099839|Experimental|one group|"Subjects will receive ASP1941 alone, Miglitol alone and ASP1941 + Miglitol in different order."
3221200|NCT01099878|Active Comparator|Cycling Exercise with Functional Electrical Stimulation|Cycling Exercise with Functional Electrical Stimulation
3221201|NCT01099878|Placebo Comparator|Cycling Exercise|Cycling Exercise
3221202|NCT01099891|Experimental|EGF|
3221203|NCT01099891|Placebo Comparator|Placebo|
3221204|NCT01099904|Experimental|1|Normal Renal Function
3221205|NCT01099904|Experimental|2|Mild Renal Impairment
3221206|NCT01099904|Experimental|3|Moderate Renal Impairment
3221207|NCT01099930|Active Comparator|Non-randomized control group|Patients meeting inclusion/exclusion criteria not consenting to treatment will be requested to consent to control group and followed while receiving standard of care.
3221208|NCT01099930|Experimental|Stem Cell Transplantation|Patients will undergo stem cell transplantation for the treatment of Multiple Sclerosis
3221209|NCT01099943|Experimental|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
3221210|NCT01099943|No Intervention|No education, no implemented decision support tools|Clinics randomized to the control will not participate in the education intervention and implementation of decision support tools.
3221211|NCT01099956||diabetes group|
3221212|NCT01099956||control group|
3221213|NCT01099982||Advanced Heart Failure Therapy Group|Patients diagnosed with end stage heart failure undergoing either VAD implantation or heart transplantation.
3221214|NCT01099982||Normal Hearts Group|Control samples will be obtained from individuals undergoing other types of cardiac surgery during which it is routine to discard some tissue intraoperatively.
3221215|NCT01099995|Active Comparator|One HBO session|hyperbaric oxygen therapy one dive at 2 absolute atmosphere (1-hour plateau) - oxygen was delivered via a full face mask - followed by 4 hours of normobaric oxygen therapy
3221216|NCT01099995|Experimental|2 HBO sessions|Two sessions of hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) with oxygen delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
3221217|NCT01100008|Experimental|Magnetic resonance imaging|
3221218|NCT01100021|Experimental|tamsulosin + avanafil|
3221219|NCT01100021|Experimental|Doxazosin + avanafil|
3221220|NCT01100047|Experimental|1|
3221221|NCT01100047|Placebo Comparator|2|
3221222|NCT01100060|Experimental|Group 1|Co-administer the test chloroquine (CQ) formulation (620 mg CQ base) plus microsphere azithromycin (AZ) (2000 mg) on Day 1.
3221223|NCT01100060|Active Comparator|Group 2|Co-administer the individual tablets of CQ 2 x 500 mg (600 mg CQ base) tablets plus AZ IR 4 x 500 mg tablets on Day 1.
3221224|NCT01100099|Experimental|Gluten challenge.|Diagnosis of celiac disease. Before and after a gluten challenge small bowel biopsies will be taken, and blood samples will be drawn for tetramer staining of gluten specific T cells.
3221225|NCT01100125|Experimental|sitagliptin|
3221226|NCT01100125|Active Comparator|insulin dose increase|
3221227|NCT01100151|Experimental|RDC-1036 (ALKS 37)|Capsules for oral administration
3221228|NCT01100151|Placebo Comparator|Placebo|Capsules for oral administration
3221229|NCT01100164|Experimental|eszopiclone 3 mg|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
3221230|NCT01100164|Active Comparator|zopiclone 7,5mg|Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
3221231|NCT01100177|Experimental|Sunitinib plus radiothery|"Sunitinib at doses of 37.5mg/m2/daily in a continuous dosing during 8 weeks.~After evaluation of efficacy, they will receive Sunitinib 37.5 mg/d and treatment with Radiation therapy (total dose 60 Gy).~After radiation therapy, Sunitinib al 37.5 mg/d will be continued until progression."
3221232|NCT01100190|Experimental|NUVANCE Facial Rejuvenation System|
3221233|NCT01100203|Active Comparator|Treatment|
3221234|NCT01100203|No Intervention|Control|
3221235|NCT01100216|Active Comparator|Nicotine Lozenge|4 mg nicotine lozenge (LOZ
3221236|NCT01100216|Active Comparator|Camel Snus Frost|
3221237|NCT01100216|Active Comparator|Stonewall Spearment Tablet|
3221238|NCT01100216|Active Comparator|Skoal Wintergreen|
3221239|NCT01100281||PSP (Progressive supranuclear palsy)|
3221240|NCT01100281||FTD (Frontotemporal lobar degenerative)|
3221241|NCT01100281||Alzheimer's disease|
3221242|NCT01100294|Experimental|Vaccination with Fluval P|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant. Dose: 0.25 ml (total 3 μg HA), single dose.
3221243|NCT01100385|Placebo Comparator|Healthy (placebo)|
3221244|NCT01100385|Active Comparator|Healthy (Ateronon)|
3221245|NCT01100385|Placebo Comparator|Cardiovascular Group (placebo)|
3221246|NCT01100385|Active Comparator|Cardiovascular Group (Ateronon)|
3221247|NCT01100398||NAFLD/NASH prevalence|Any subject between the ages of 18-70 without known fatty liver disease who meet inclusion criteria
3221248|NCT01100411|Active Comparator|Air Optix Aqua|Contact lens material: Lotrafilcon A
3221249|NCT01100411|Active Comparator|Biofinity|Contact lens material: Comfilcon A
3221250|NCT01100411|Active Comparator|Proclear|Contact lens material: Omafilcon A
3221251|NCT01100411|Active Comparator|Acuvue Oasys|Contact lens material: Senofilcon A
3221252|NCT01100411|Active Comparator|Acuvue 2|Contact lens material: Etafilcon A
3221253|NCT01100411|Active Comparator|Purevision|Contact lens material: Balafilcon A
3221254|NCT01100424|Experimental|Contact lens wearers|Contact lens wearers experienced three currently available contact lens/contact lens care combinations in randomized order: balafilcon A + Optifree RepleniSH, balafilcon A + ReNu MultiPlus, and balafilcon A + Unisol 4 saline.
3221255|NCT01100424|No Intervention|Non-lens wearers|Non-lens wearers completed one study visit and served as the control group.
3221256|NCT01100450|Experimental|Resistance Training|
3221257|NCT01100463|Placebo Comparator|Placebo Lotion|
3221258|NCT01100463|Experimental|0.1% Uracil|
3221259|NCT01100489|Experimental|Arm I|Patients undergo breast-conserving surgery consisting of partial mastectomies followed by external beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
3221260|NCT01100515|Experimental|Experimental arm|Hyperbaric oxygen therapy at 2 absolute atmosphere (1-hour plateau) followed by 4 hours of normobaric oxygen therapy
3221261|NCT01100515|Active Comparator|Control|6 hours course of normobaric oxygen therapy via a face full mask
3221262|NCT01100541|Experimental|Polymeric plate characteristics|Evaluation, in the volunteers viewpoint, of the polymeric plate characteristics.
3221263|NCT01100554|Experimental|all patients|
3221264|NCT01100580|Active Comparator|water therapy|"The term water therapy refers to an abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer)."
3221265|NCT01100580|Experimental|low salt diet + water therapy|low salt diet refers to a salt intake of 4 g/day
3221266|NCT01100593|Active Comparator|1.75 inch catheter length|Length of catheter to be used
3221267|NCT01100593|Active Comparator|2.5 inch catheter length|length of catheter to be used
3221268|NCT01100619|Experimental|All subjects|All subjects will receive daily XL184, and two single doses of rosiglitazone, 3 weeks apart
3221269|NCT01100632|Experimental|Treatment|Treatment with the combination of Panax ginseng, vitamins and minerals
3221270|NCT01100632|Placebo Comparator|Placebo|Placebo.
3221271|NCT01100645|Experimental|Test|Sominex ® (Passiflora incarnata L. 50 mg, Valeriana officinalis L. 40 mg and Crataegus oxyacantha L. 30 mg)
3221272|NCT01100645|Placebo Comparator|Placebo|Excipient
3221273|NCT01100671||Healthy patients|
3221274|NCT01100684|Experimental|Treatment|0.5 mg asimadoline bid
3221275|NCT01100684|Placebo Comparator|Placebo|Placebo
3221276|NCT01100697||thoracal lesion|spinal lesion at thoracal level detected at prenatal ultrasound exam
3221277|NCT01100697||lumbar lesion|spinal lesion at lumbar level detected at prenatal ultrasound exam
3221278|NCT01100697||sacral lesion|spinal lesion at sacral level detected at prenatal ultrasound exam
3221279|NCT01100710||healthy volunteers|
3221280|NCT01100736|Experimental|Bosentan|Bosentan 125mg twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of bosentan therapy
3221281|NCT01100736|Experimental|Sitaxsentan|Sitaxsentan 100mg once daily + placebo tablet will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of sitaxsentan therapy
3221282|NCT01100736|Placebo Comparator|Placebo|Placebo tablet twice daily will be taken for 7 days, before ET-1 plasma sample taken. ET-3 infusion (5mins) and associated forearm blood flow study (60 mins) will also occur after 7 days of placebo therapy
3221283|NCT01100775|Experimental|Galantamine, then Placebo|Participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing.
3221284|NCT01100775|Experimental|Placebo, then Galantamine|Participants took lead-in 3 days of 4mg/ twice a day of placebo followed by 8 mg on the 4th day, the day of testing. Then, after a period of at least one month, participants took lead-in 3 days of 4mg/ twice a day of galantamine followed by 8 mg on the 4th day, the day of testing.
3221285|NCT01100788|Placebo Comparator|Placebo|No treatment
3221286|NCT01100788|Experimental|scFOS 5 g|5 g scFOS
3221287|NCT01100788|Experimental|scFOS 8 g|8 g scFOS
3221288|NCT01100801|Experimental|TS-1 with cisplatin|"Chemotherapy injection (60mg/m2 cisplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
3221289|NCT01100801|Experimental|TS-1 with oxaliplatin|"Chemotherapy injection (100mg/m2 oxaliplatin) will be given on day 1.~14 days of Oral TS-1 (40mg/m²) will be prescribed. Subjects will take it after breakfast and evening meal on Day 1-14 of a 3-weekly treatment cycle. Each cycle is about 21 days."
3221290|NCT01100827||EGFR mutation status in patients|
3221291|NCT01100866|Active Comparator|Group 1|POMELLA™ 2 x 500mg capsule once daily
3221292|NCT01100866|Placebo Comparator|Group 2|POMELLA™ placebo
3221293|NCT01100879|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 3 (week 2).
3221294|NCT01100879|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
3221295|NCT01100892|No Intervention|Control group|Observation only. Does not receive once-daily insulin detemir.
3221296|NCT01100892|Experimental|Once-daily insulin detemir|Once-daily insulin detemir
3221297|NCT01100918|Active Comparator|1: Dyssynchrony positive|
3221298|NCT01100918|Active Comparator|2a: Dyssynchrony negative|
3221299|NCT01100918|Active Comparator|2b: Dyssynchrony negative|
3221300|NCT01100957|Active Comparator|Conventional flexible videoscope for intubation|
3221301|NCT01100957|Experimental|Single-patient flexible endoscope|Single-patient flexible video-endoscope used for tracheal intubation in this intervention-arm
3221302|NCT01100970||Unipolar electric needle|
3221303|NCT01100970||Bipolar electric needle|
3221304|NCT01100970||Control|Infants who were born in a vaginal birth
3221305|NCT01100996|No Intervention|fasted control|Volunteers are fasted for 10 hours and subjected to experimental endotoxemia
3221306|NCT01100996|Placebo Comparator|control feeding|Volunteers are fed a control nutrition starting 1 hour prior to LPS administration until 6 hours after LPS
3221307|NCT01100996|Active Comparator|enriched feeding|volunteers receive the investigational feeding starting 1 hour prior to LPS administration until 6 hours after LPS
3221308|NCT01101009|Active Comparator|Perindopril+amlodipine|
3221309|NCT01101009|Active Comparator|Olmesartan/amlodipine|
3221310|NCT01101048|Placebo Comparator|A|Two (2) women in each of cohorts 1 and 4, and two (2) men in cohort 2 will receive placebo every 2 weeks for a total of 6 doses. Two (2) women in each of cohorts 3 and 5, and two (2) men in cohort 6 will receive placebo every 4 weeks for a total of 3 doses. Six (6) women in cohort 7 will receive placebo every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of placebo; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
3221311|NCT01101048|Active Comparator|B|Six (6) women in each of cohorts 1 and 4, and six (6) men in cohort 2 will receive AMG 167 every 2 weeks for a total of 6 doses. Six (6) women in each of cohorts 3 and 5, and six (6) men in cohort 6 will receive AMG 167 every 4 weeks for a total of 3 doses. Eighteen (18) women in cohort 7 will receive AMG 167 every 2 weeks for a total of 12 doses. In addition, subjects in cohorts 4 have the option to receive an additional 6 doses of AMG 167; subjects in cohorts 5 and 6 have the option to receive an additional 3 doses. Subjects in cohort 7 have the option to transition to 6 months of alendronate treatment.
3221312|NCT01101074||6-23 months|
3221313|NCT01101074||2-8 years|
3221314|NCT01101074||9-17 years|
3221315|NCT01101074||18-44 years|
3221316|NCT01101074||45-60 years|
3221317|NCT01101074||>60 years|
3221318|NCT01101087|Experimental|Taurolock|
3221319|NCT01101087|Placebo Comparator|Placebo|
3221320|NCT01101113|Experimental|Cinacalcet|stepwise dose of cinacalcet + regular medical medication including vit D
3221321|NCT01101113|Active Comparator|Control|conventional treatment for secondary HPT including vit D and phosphate binder
3221322|NCT01101126|Experimental|Disease Management|Comprehensive care delivered by designated nurses and pulmonologists, in collaboration with the primary practitioners and other healthcare professionals in the community
3221323|NCT01101126|Active Comparator|Unual care|Care delivered by the primary practitioner with the advice of a consultant pulmonologist
3221324|NCT01101139|Experimental|Experimental|Single injection of Sugammadex 0.25 mg/kg
3221325|NCT01101139|Placebo Comparator|Placebo comparator|Single injection of Saline 0.9%
3221326|NCT01101152|Experimental|Female|
3221327|NCT01101152|Experimental|Male|
3221328|NCT01101204|Active Comparator|M1000 S10 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 10mg
3221329|NCT01101204|Active Comparator|M1000 S10 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 10mg
3221330|NCT01101204|Active Comparator|M1000 S40 F100|metformin 1000mg, fenofibrate 100mg and simvastatin 40mg
3221331|NCT01101204|Active Comparator|M1000 S40 F267|metformin 1000mg, fenofibrate 267mg and simvastatin 40mg
3221332|NCT01101204|Active Comparator|M2500 S10 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 10mg
3221333|NCT01101204|Active Comparator|M2500 S10 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 10mg
3221334|NCT01101204|Active Comparator|M2500 S40 F267|metformin 2500mg, fenofibrate 267mg and simvastatin 40mg
3221335|NCT01101204|Active Comparator|M2500 S40 F100|metformin 2500mg, fenofibrate 100mg and simvastatin 40mg
3221336|NCT01101204|Placebo Comparator|Therapeutic Lifestyle Change|Only therapeutic lifestyle change
3221337|NCT01101217|Placebo Comparator|placebo|placebo for 6 weeks
3221338|NCT01101217|Active Comparator|zinc|zinc sulfate 220 mg per day orally for 6 weeks
3221339|NCT01101230|Experimental|Almond|
3221340|NCT01101230|Placebo Comparator|Muffin|
3221341|NCT01101243|Active Comparator|Group 1|Body surface area: 88 %
3221342|NCT01101243|Active Comparator|Group 2|Body surface area: 22 %
3221343|NCT01101243|Active Comparator|Group 3|Body surface area: 88 %
3221344|NCT01101243|Active Comparator|Group 4|Body surface area: 88 %
3221345|NCT01101243|No Intervention|Group 5|Body surface area: 0 %
3221346|NCT01101256||Fondaparinux Prophylaxis group|
3221347|NCT01101256||Fondaparinux Therapy group|
3221348|NCT01101269|Experimental|Subjects with diabetic nephropathy|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
3221349|NCT01101269|Active Comparator|Healthy volunteers|Renal blood flow (RBF) will be measured using contrast enhanced ultrasound (CEU) and urine protein will be measured both on and off angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
3221350|NCT01101282|No Intervention|'Usual care'|"Participants will receive 'usual medical care' consisting of the following:~Medical management: Bronchodilators, corticosteroids, antibiotics and supplemental oxygen will be provided (where appropriate) in accordance with Australian and New Zealand COPD management guidelines (COPDX guidelines).~Non-invasive ventilation: if clinically indicated and prescribed in accordance with standardised hospital guidelines.~Physical rehabilitation: Participants will be assessed by a physiotherapist and prescribed appropriate exercises to facilitate a safe and timely discharge. Participants will perform physical rehabilitation according to a standardised protocol with an aim of maximising physical function at discharge.~Other allied health (e.g. occupational therapy, speech pathology, dietician) assessments and interventions, as required."
3221351|NCT01101282|Experimental|'Usual care' plus PEP mask therapy|"This will comprise:~'Usual care'~PEP mask therapy"
3221352|NCT01101347|Experimental|Aneurysm-Embolization System|
3221353|NCT01101360|Active Comparator|Matrix RF followed by Pulse Dye Laser|
3221354|NCT01101373||1|All subjects who received BAC for treatment resistant depression between 2000 and 2009
3221355|NCT01101386||Voriconazole|Pharmacokinetic Monitoring
3221356|NCT01101399|Active Comparator|Ferric carboxymaltose|Subjects will receive a total dose of 1,000 mg iron as FCM on the day of the next scheduled chemotherapy cycle after randomisation or continuous chemotherapy. In subjects with weight ≤66 kg, the first dose iron will be 500 mg; the second dose (500 mg) will be administered on the visit 4 (week 2).
3221357|NCT01101399|No Intervention|Local standard of care.|Subjects will be treated according to the local institutional practice.
3221358|NCT01101412|Experimental|Arm I: Antimicrobial Solution|Antimicrobial solution into central or peripheral venous catheter (CVC or PVC) once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
3221359|NCT01101412|Active Comparator|Arm II: Saline Solution|Saline solution into CVC or PVC once daily for 90 days. Catheter dwell time is 1-24 hours. The catheter is then flushed through before any drug infusion or blood aspiration.
3221360|NCT01101438|Experimental|Arm I|Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
3221361|NCT01101438|Placebo Comparator|Arm II|Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in receptor positive (ER and/or PgR positive) subjects in the absence of disease progression or unacceptable toxicity.
3221362|NCT01101451|Active Comparator|Arm I (EBRT, IMRT)|Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5.5 weeks.
3221363|NCT01101451|Experimental|Arm II (cisplatin, EBRT, IMRT)|Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3221364|NCT01101503|Experimental|Intensive multifactorial group|Intensive multifactorial therapy group receive intensive blood glucose, blood pressure and blood lipids control.
3221365|NCT01101503|Experimental|conventional multifactorial therapy group|Conventional multifactorial therapy group receive conventional blood glucose, blood lipids and blood lipids control to the local targets.
3221366|NCT01101529|Placebo Comparator|Standard antiemetic therapy plus placebo|Standard anti-emetic prophylaxis consisting of 1/dexamethasone 6 mg daily during the chemotherapy days and 2/tropisetron (Navoban)5 mg daily during chemotherapy and 2 days after
3221367|NCT01101529|Experimental|aprepitant (Emend)|Aprepitant given orally 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after as an addition to standard antiemetic therapy as in the placebo arm.
3221368|NCT01101555|Experimental|COHORT 1: CUMULATIVE DOSE 1.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 3 days, dose 0.3, 0.5, 0.7, four patients in cohort, one of which is on placebo, escalation increment N/A
3221369|NCT01101555|Experimental|COHORT 2: CUMULATIVE DOSE 3.5MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.5, 0.7, 1.0, 1.0 four patients in cohort, one of which is on placebo, escalation increment 2.3 fold.
3221370|NCT01101555|Experimental|COHORT 3: CUMULATIVE DOSE 6.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 7 days, dose 0.3, 0.7, 5 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.7 fold.
3221371|NCT01101555|Experimental|COHORT 4: CUMULATIVE DOSE 8.0MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 0.3, 0.7, 1.0, 2 x 3.0 four patients in cohort, one of which is on placebo, escalation increment 1.33 fold.
3221372|NCT01101555|Experimental|COHORT 5: CUMULATIVE DOSE 10MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 10 days, dose 10 x 1.0 four patients in cohort, one of which is on placebo, escalation increment 1.25 fold.
3221373|NCT01101555|Experimental|COHORT 6: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 15 days, dose 15 x 1.0 six patients in cohort, one of which is on placebo, escalation increment 1.5 fold.
3221374|NCT01101555|Experimental|COHORT 7: CUMULATIVE DOSE 15MG, ADMINISTERED SUBCUTANEOUSLY|Duration of treatment 5 days, dose 5 x 3.0 six patients in cohort, one of which is on placebo, escalation increment N/A
3221375|NCT01101568|Experimental|Single Sequence|Simvastatin will be administered on Day 1 and Day 10. Rosuvastatin will be administered on Day 3 and Day 12. GSK1292263 will be administered on Days 6 to 14.
3221376|NCT01101581|Experimental|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab and 90Y-Epratuzumab Tetraxetan target different b-cells. Veltuzumab will be administered in all 4 weekly study drug treatments. 90Y-Epratuzumab Tetraxetan will be administered only on days 8 & 15. The dose of veltuzumab remains the same for all patients.
3221377|NCT01101581|Experimental|90Y-epratuzumab tetraxetan|90Y-epratuzumab tetraxetan will be administered 6 mCi/m2 on days 8 and 15.
3221378|NCT01101594|Experimental|hLL1-DOX|4 Different dose levels of hLL1-DOX will be studied in groups of 3-6 patients. Once an optimal dose has been found, up to additional 30 patients will be studied at that dose level.
3221379|NCT01101607|Active Comparator|Pediatric Emergency Physician|Patients randomized to Pediatric Emergency Physician Group will have their fracture reduced by a Pediatric Emergency Physician
3221380|NCT01101607|Active Comparator|Orthopaedic physician|Patients to be randomized to Orthopaedic physician Group will have their fracture reduced by an Orthopaedic Physician
3221381|NCT01101620|Active Comparator|Levosimendan|
3221382|NCT01101620|Placebo Comparator|Placebo|
3221383|NCT01101633|Active Comparator|1|500 ml beverage containing alginate (3%)
3221384|NCT01101633|Active Comparator|2|330 ml beverage containing alginate (3%)
3221385|NCT01101633|Placebo Comparator|3|500 ml beverage without alginate (placebo)
3221386|NCT01101633|Placebo Comparator|4|330 ml beverage without alginate (placebo)
3221387|NCT01101646|Experimental|001|rabeprazole sodium four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
3221388|NCT01101646|Experimental|002|rabeprazole sodium two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
3221389|NCT01101646|Experimental|003|rabeprazole sodium four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
3221390|NCT01101659|Experimental|001|JNJ-40411813 500 mg as 20 mL of oral suspension single dose
3221391|NCT01101659|Placebo Comparator|002|Placebo 20 mL of oral suspension single dose
3221392|NCT01101659|Other|003|ketamine Ketanest S. vials of 20 ml with 5 mg/ml diluted with saline to 0.02 mg Ketamine per mL and per kg bodyweight of the volunteer
3221393|NCT01101659|Other|004|normal saline infusion 0.5 mL /min over 90 minutes
3221394|NCT01101672|Experimental|Single-port laparoscopic colectomy|
3221395|NCT01101672|Active Comparator|Conventinal laparoscopic colectomy|
3221396|NCT01101685|Active Comparator|Escitalopram|7 days dosing at 10mg per day
3221397|NCT01101685|Placebo Comparator|Placebo|7 days dosing at 10mg daily
3221398|NCT01101698|Active Comparator|Vitamin K2, calcification score changes, vitamin D|90 μg vitamin K2+10μg cholecalciferol
3221399|NCT01101698|Active Comparator|Vitamin D, calcium score changes|10μg cholecalciferol (vitamin D)
3221400|NCT01101711||Patients with subarachnoid hemorrhage|
3221401|NCT01101724|No Intervention|Standard of Care|In this group, the treating attending physician will be free to make rest recommendations as they see fit. An internal survey of physician practice found that the vast majority of physicians instruct patients rest for 1-2 days, then to return to school and physical activity after the patient's symptoms have resolved. The amount of rest will vary from patients to patient based on variation in symptom resolution and patient compliance. This advice is consistent with best practices outlined by the CDC.
3221402|NCT01101724|Experimental|Intervention|Mandated Rest.
3221403|NCT01101737|No Intervention|Usual care|Patients not invited to the nurse-led clinic will continue with usual GP care
3221404|NCT01101737|Experimental|Nurse-led blood pressure clinic|Patients randomly allocated to the intervention will be invited to a specialist nurse-led blood pressure clinic.
3221405|NCT01101763||All Subjects|Healthy males
3221406|NCT01101789|Active Comparator|triclosan|triclosan-coated sutures
3221407|NCT01101789|Placebo Comparator|control|sutures without triclosan-coating
3221408|NCT01101802|Active Comparator|Mycophenolate mofetil|Patients were given 1gm bd mycophenolate mofetil for 8 weeks
3221409|NCT01101802|Placebo Comparator|Sugar pill|
3221410|NCT01101815|Active Comparator|Oral Naltrexone + ART|Naltrexone (oral). 50 mg maintenance daily for 48 weeks, plus group drug counseling manual driven, N= 100
3221411|NCT01101815|Active Comparator|Naltrexone Implant + ART|Naltrexone Implant + ART. Monthly maintenance for 48 Weeks plus, group drug counseling manual driven, N=100
3221412|NCT01101893|Experimental|Period 1|In period 1 all subjects will receive Raltegravir 400mg q12h from Day 1 to Day 5
3221413|NCT01101893|Experimental|Period 2|In period 2 all subjects will receive GSK2248761 200mg q24h from Day 1 to Day 5.
3221414|NCT01101893|Experimental|Period 3|Day 1 of Period 3 will be the day after Day 5 of Period 2. Subjects will receive GSK2248761 200mg q24h + raltegravir 400mg q12h from Day 1 to Day 5.
3221415|NCT01101906|Experimental|Arm A: OSI-906|150 mg BID
3221416|NCT01101906|Placebo Comparator|Arm B: Placebo|Placebo BID
3221417|NCT01101919|Experimental|CP-690,550 Dose Group|
3221418|NCT01101932|Experimental|(Part 1) PF-04308515|
3221419|NCT01101932|Placebo Comparator|(Part 1) Solution Placebo|
3221420|NCT01101932|Experimental|(Part 2) PF-04308515 Tablet|
3221421|NCT01101984|Experimental|DE-089|DE-089 ophthalmic solution
3221422|NCT01101984|Active Comparator|HA|0.1% sodium hyaluronate ophthalmic solution
3221423|NCT01102010|Experimental|Blood transfusion|"Restrictive strategy: Blood transfusion when hemoglobin is less than 6 mmol/l (9.7 g/dl)~Liberal strategy: Blood transfusion when hemoglobin is less than 7 mmol/l (11.3 g/dl)"
3221424|NCT01102023|Experimental|solar salt based-diet|
3221425|NCT01102036|Placebo Comparator|Yoghurt without probiotics|Yoghurt without probiotic bacteria
3221426|NCT01102036|Active Comparator|Cultura yoghurt|Cultura yoghurt with L casei F19, acidophilus La5 adn B lactis Bb 12
3221427|NCT01102049|Experimental|self-administered food intake|self-administered food intake according to dietary protocol
3221428|NCT01102062|Experimental|Orange Juice|1 glass (=200mL) of orange juice
3221429|NCT01102075|Experimental|Electroacupuncture|The Electroacupuncture therapy protocol included a total of 12 acupuncture points at the CV12,CV6, bilateral ST25, SP15, SP14,LI4, LI11, ST36, ST44. All acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Abdominal acupuncture points were inserted horizontally 6~6.5cm in depth and the others were inserted vertically 2~2.5cm in depth until patient can feel De-Qi. All acupuncture points were stimulated electrically with a frequency of 24 Hz an intensity of 0.27-1.3mA(tolerable strength) with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks by practitioner who had had 6 years of acupuncture training and 3 more years of clinical experience.
3221430|NCT01102075|Sham Comparator|Sham electroacupuncture procedure|The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
3221431|NCT01102075|No Intervention|Waiting list|No treatment was done for waiting group, but could receive same treatments as Electroacupuncture group after the end of trial.
3221432|NCT01102088|Experimental|Radiation + Chemotherapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions.~Chemotherapy Administration: Schedule of chemotherapy, and modifications of chemotherapy drugs during chemoradiation treatment will be at the discretion of the treating medical oncologist per their standard of practice and with consideration to standard chemotherapy drugs in the treatment of esophageal cancer."
3221433|NCT01102114|Placebo Comparator|Placebo Vaccine|
3221434|NCT01102114|Experimental|NicVAX Vaccine|
3221435|NCT01102127||Goiter|Patients with nodular goiter
3221436|NCT01102153||Coolgard|invasive cooling
3221437|NCT01102153||ArcticSun|non-invasive (surface) cooling
3221438|NCT01102179||Chronic kidney disease|"All patients with stage 2-5 (pre-dialysis) chronic kidney disease~One-time blood draw (10 ml)"
3221439|NCT01102192||Myasthenia gravis with thymoma|Myasthenia gravis with thymoma
3221440|NCT01102192||Myasthenia gravis without thymoma|Myasthenia gravis without thymoma
3221441|NCT01102192||Thymoma without Myasthenia gravis|Thymoma without Myasthenia gravis
3221442|NCT01102192||cardiac, or thyroid surgery|cardiac, or thyroid surgery
3221443|NCT01102205||healthy|
3221444|NCT01102205||euthyroid hashimoto|
3221445|NCT01102205||hypothyroid hashimoto|
3221446|NCT01102244|Experimental|Tobradex ST|tobramycin 0.3%, dexamethasone 0.05%
3221447|NCT01102244|Active Comparator|Azasite|azithromycin 1%
3221448|NCT01102283||Stent Group|
3221449|NCT01102296|Active Comparator|male homosexuals|HIV-uninfected male homosexuals will be provided 2 doses of HAV vaccine, which will be administered at baseline and 6th month of follow-up.
3221450|NCT01102296|Active Comparator|HIV-infected male homosexuals, group1|HIV-infected male homosexuals will be provided 3 doses of HAV vaccine, which will be administered at baseline, 1st, and 6th month of follow-up.
3221451|NCT01102296|Active Comparator|HIV-infected male homosexuals, group 2|HIV-infected male homosexuals will be provided 2 doses of hepatitis A vaccine, which will be administered at baseline and 6th month of follow-up.
3221452|NCT01102309|Experimental|Experimental Group (EG)|Group assigned to robot plus conventional therapy
3221453|NCT01102309|Active Comparator|Control Group (CG)|Group assigned to conventional therapy only
3221454|NCT01102322||1|
3221455|NCT01102335|Experimental|Telbivudine|
3221456|NCT01102335|Active Comparator|TACE only|
3221457|NCT01102348|Experimental|PEP-uP Protocol (after)|PEP-uP protocol and treatment algorithm implemented for all patients in ICU.
3221458|NCT01102348|No Intervention|Standard feeding protocol (before)|Enteral feeds are guided by a standard feeding protocol specified by pre-printed ICU admission orders. The admitting physician has the option of initiating the enteral feeding protocol or keeping the patient nil per os (NPO).
3221459|NCT01102361|Experimental|Transperineal Biopsy|Biopsy of the prostate using transperineal approach
3221460|NCT01102387|Experimental|LAS41003|
3221461|NCT01102387|Active Comparator|LAS189962|
3221462|NCT01102387|Active Comparator|LAS189961|
3221463|NCT01102400|Experimental|1|
3221464|NCT01102439|Active Comparator|Standard dose clopidogrel|300 mg Loading x 1 day, 75 mg/d x 13 days
3221465|NCT01102439|Experimental|Double dose clopidogrel|600 mg Loading x 1 day, 150 mg/d x 6 days, 75 mg/d x 7 days
3221466|NCT01102439|Active Comparator|Standard dose aspirin|Aspirin 81mg/d x 14 days
3221467|NCT01102439|Experimental|High dose aspirin|Aspirin 325 mg/d x 14 days
3221468|NCT01102452|Placebo Comparator|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
3221469|NCT01102452|Experimental|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
3221470|NCT01102504|Experimental|Tomato extract (Ateronon)|Supplementation of tomato extract containing 28 mg/day for 12 months in addition to routine treatment.
3221471|NCT01102504|Placebo Comparator|Placebo|Placebo
3221472|NCT01102517|Experimental|VATS group|video-assisted thoracoscopic surgery
3221473|NCT01102517|Other|axillary thoracotomy|Control group
3221474|NCT01102543||Premature babies < 28 GA|
3221475|NCT01102543||Premature babies > 28 & < 32 weeks GA|
3221476|NCT01102556||Surgery Patients/High-risk Patients|Patients who have undergone surgery for pancreatic cancer or pre-neoplastic lesions of the pancreas will be accrued to the study. In addition, patients who are determined to be at high-risk for pancreatic cancer (with a significant family history) will also be recruited for study enrollment.
3221477|NCT01102569||Pancreatic cancer and Ashkenazi decent|Patients with pancreatic cancer will be asked to join the study if they identify themselves as being of Ashkenazi descent, as well as patients at a high-risk of pancreas cancer based on family history, and will be followed from the time of diagnosis.
3221478|NCT01102595|Experimental|1: Temozolomide plus Radiation|"Group 1:~Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy).~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
3221479|NCT01102595|Experimental|2: Temozolomide plus Radiation plus Bevacizumab|"Neoadjuvant phase: Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles + bevacizumab 10 mg/kg every 15 days.~Adjuvant phase: Temozolomide 75 mg/m2/d x 42-49 days with standard radiation therapy (60 Gy) + bevacizumab 10 mg/kg every 15 days.~Maintenance phase: Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
3221480|NCT01102608|Experimental|1|
3221481|NCT01102621||case-control, head and neck cancer with radiotherapy|The group of exposed individuals had to be patients with disease-free survival interval of at least two years subsequent to treatment for head and neck cancer by means of radiotherapy alone or in combination, in which the auditory system was included in the field of irradiation.
3221482|NCT01102621||case-control, head an neck cancer without radiotherapy|The group of non-exposed individuals (control group) had to be patients who had not undergone oncological treatment that put their hearing at risk and who were age-matched (2 years). This group was formed by individuals who had had pelvic tumors or skin tumors and who had only undergone local surgery to remove their tumors, and by female volunteers from the hospital. All of these individuals were asked whether they would be willing to participate in a study, without knowing in advance whether they had any previous hearing problems or complaints.
3221483|NCT01102634|Experimental|Acu-TENS|Application of TENS over acupuncture points
3221484|NCT01102634|Placebo Comparator|Placebo-TENS|Application of Acu-TENS but with no electricity
3221485|NCT01102647|Experimental|Phytosterol ester|Plant sterol compared with placebo
3221486|NCT01102660|Other|Treatment Sequence 1|
3221487|NCT01102660|Other|Treatment Sequence 2|
3221488|NCT01102660|Other|Treatment Sequence 3|
3221489|NCT01102660|Other|Treatment Sequence 4|
3221490|NCT01102673|Experimental|PF-04991532|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
3221491|NCT01102673|Placebo Comparator|Placebo|This will be a crossover study with 2 cohorts and an interleaving design with placebo substitution. The study will be conducted over 4 treatment periods in Cohort 1 (n=9) and over 3 treatment periods in Cohort 2 (n=9). Six subjects will be allocated to receive PF-04991532 and three subjects will be allocated to receive placebo treatment during each dosing period, except for the 4th period of Cohort 1. The 4th period of Cohort 1 will be dedicated to assess the effect of food on PF-04991532 PK parameters at one of the doses previously tested in Cohort 1; hence all 9 subjects will be dosed with PF-04991532 in an open-label fashion. A washout period of at least 7 days will occur between each dose.
3221492|NCT01102686|Experimental|Pyrimethamine|
3221493|NCT01102699|Experimental|Filgrastim, G-CSF|Single s.c. dose of G-CSF (300 microg)
3221494|NCT01102712|Experimental|BTVA|
3221495|NCT01102725||Colorectal Surgery|Subject who are undergoing a colon or rectal resection
3221496|NCT01102751||Vitamin D deficient females|(n =18, mean age 29.1±9.9 yrs)
3221497|NCT01102751||vitamin D sufficient healthy females|(control group; n = 19, mean age 28.5±5.2 yrs)
3221498|NCT01102751||genetically-determined hypophosphatemic rahitis|(n=13, mean age 26.5±15.1 yrs)
3221499|NCT01102816|Experimental|Individualized acupuncture|
3221500|NCT01102816|No Intervention|Routine care|
3221501|NCT01102868|Sham Comparator|Needle in acupuncture point Li11|Acupuncture needle in the acupuncture point Li11
3221502|NCT01102868|Experimental|IMS of musculus pronator teres|Acupuncture needle in musculus pronator teres
3221503|NCT01102881|Placebo Comparator|No fiber|No fiber added to muffins or cereal
3221504|NCT01102881|Experimental|Fiber made from corn starch|Muffins and cereal made with novel corn fiber
3221505|NCT01102881|Experimental|Glucose polymer fiber|Muffins and cereal made from glucose polymer fiber
3221506|NCT01102907||Liquid Meal|
3221507|NCT01102907||Solid Meal|
3221508|NCT01102920|Experimental|Tailored behavioural treatment and CPAP|Tailored behavioural treatment targeting physical activity and eating habits.
3221509|NCT01102920|Active Comparator|CPAP-treatment|CPAP-treatment as usual. Advice about benefits of physical activity and weight loss.
3221510|NCT01102933||Unselected post-myocard infarct patients|Patients diagnosed with MI at Uppsala University Hospital
3221511|NCT01102946|Experimental|PRP plus ranibizumab|Patients will be submitted to panretinal photocoagulation plus intravitreal injections of ranibizumab
3221512|NCT01102946|Active Comparator|PRP|Patients will only be submitted to panretinal photocoagulation
3221513|NCT01102959|Experimental|Photographic Material|Photographic Educational Material on Carbohydrate Counting
3221514|NCT01102985|Experimental|aerobic resistance|12 month aerobic resistance exercise at a fitness center
3221515|NCT01102985|Active Comparator|home based physical activity|national recommendations for physical activity for adults
3221516|NCT01102998||Brain Tumor Survivors|Brain tumor survivors ages 8 to 18 years who are at least 5 years post diagnosis and at least 2 years post active therapy or observation and their parents/guardians will be approached to participate during clinic visits.
3221517|NCT01103011|Experimental|ND0611 dose 1, ND0611 dose 2, placebo|
3221518|NCT01103024|Experimental|AIN457 300mg s.c every 2 weeks|
3221519|NCT01103024|Experimental|AIN457 300mg s.c every 4 weeks|
3221520|NCT01103024|Experimental|AIN457 150mg s.c every 4 weeks|
3221521|NCT01103024|Placebo Comparator|Placebo s.c every 2 weeks|
3221522|NCT01103037|Experimental|QAV680|
3221523|NCT01103037|Placebo Comparator|QAV680 Placebo|
3221524|NCT01103050|Active Comparator|QAV680 + Cetirizine Placebo|
3221525|NCT01103050|Experimental|QAV680 + Cetirizine|
3221526|NCT01103050|Active Comparator|Cetirizine + QAV680 Placebo|
3221527|NCT01103050|Placebo Comparator|QAV680 Placebo + Cetirizine Placebo|
3221528|NCT01103076|Active Comparator|Polyamide 210 H|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
3221529|NCT01103076|Experimental|HCO 1100|Chronic HD patients will be treated in random order with either polyamide or HCO membranes (Polyflux 210 H or HCO 1100) for one month (12 HD sessions) before the crossover.
3221530|NCT01103102|Active Comparator|Lowest Dose|
3221531|NCT01103102|Active Comparator|Intermediate Dose|
3221532|NCT01103102|Active Comparator|Highest Dose|
3221533|NCT01103102|Placebo Comparator|Placebo Control|
3221534|NCT01103115|Placebo Comparator|Placebo|Subjects in this group will take the placebo tablets
3221535|NCT01103115|Active Comparator|Ca600mg+VitD400IU|subjects receive a daily dose of 600 mg elemental calcium and 400 IU vitamin D3
3221536|NCT01103115|Active Comparator|Ca600mg+VitD800IU|subjects receive a daily dose of 600 mg elemental calcium and 800 IU vitamin D3
3221537|NCT01103154|Active Comparator|Carvedilol|carvedilol 6.25mg per day
3221538|NCT01103154|Active Comparator|N+I|nadolol 40mg per day, ISMN 10 mg per day
3221539|NCT01103193|Active Comparator|remifentanil injected|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
3221540|NCT01103193|Active Comparator|sevoflurane in step up concentration|a mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
3221541|NCT01103206|Experimental|Control group|Parathyroid hormone suppression tests using successively (each test will be separate for a two week period) an intravenous calcium loading or cinacalcet will be performed in a group of 12 healthy volunteers.
3221542|NCT01103206|Experimental|Primary hyperparathyroidism dose I|Parathyroid hormone suppression test using the first dose of cinacalcet in patients with primary hyperparathyroidism.
3221543|NCT01103206|Experimental|Primary hyperparathyroidism dose II|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
3221544|NCT01103219|Placebo Comparator|Control|Participants in this group will receive nutrition from birth and during the hospital stay until discharge according to the routines of the participating institutions.
3221545|NCT01103219|Active Comparator|Intervention|The participants in this group will receive increased supply of energy, protein, vitamin A, docosahexaenoic acid, and arachidonic acid from birth and during the hospital stay until discharge.
3221546|NCT01103258|Active Comparator|high ligation and stripping|surgery consisting of high ligation in combination with long saphenous stripping
3221547|NCT01103258|Active Comparator|duplex guided foam sclerotherapy|duplex guided foam sclerotherapy
3221548|NCT01103297|Other|Variable Angle Distal Radius Plate|
3221549|NCT01103310|Experimental|Arm 1|Cancer patients, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, PET/CT
3221550|NCT01103310|Experimental|Arm 2|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY94-9392 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY94-9392 in blood
3221551|NCT01103336|Experimental|Nicorandil in saline|
3221552|NCT01103336|Placebo Comparator|saline|
3221553|NCT01103349|Experimental|BI671800|Patients receive BI671800 capsules twice daily
3221554|NCT01103349|Active Comparator|Montelukast|Patients receive Montelukast encapsulated tablets once daily
3221555|NCT01103349|Placebo Comparator|Placebo|Patients receive placebo capsules and/or encapsulated placebo tablets
3221556|NCT01103375|Experimental|Treatment (enzyme inhibitor, immunotherapy)|Patients receive isotretinoin PO QD on days 1-21 and erlotinib hydrochloride PO QD on days 1-28.
3221557|NCT01103388|Experimental|Rituximab|
3221558|NCT01103388|No Intervention|No Rituximbab|
3221559|NCT01103401|Active Comparator|Tobramycin/Dexamethasone|
3221560|NCT01103401|Active Comparator|Tobramycin/Dexamethasone plus Ketorolac tromethamine|
3221561|NCT01103427|Active Comparator|Internet-based coaching .|"Arm 1. Those in the active comparator arm will benefit from automated internet-based coaching. The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
3221562|NCT01103427|Experimental|SMS based coaching|"Arm 2. The subjects will receive automated coachingby SMS.The subjects will be recruited from the general population reporting not to be associated with the University Hospital of North Norway and randomized to arm 1 or 2."
3221563|NCT01103427|Experimental|SMS coaching UNN recruited|Arm 3.The subjects will be recruited from those reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4.
3221564|NCT01103427|Experimental|Craving/Panic function. UNN recruited|"Arm 4. The subjects will in addition to the automated coachingby SMS get a SMS panic/craving function. The subjects will be recruited from subjects reporting to be associated with the University Hospital of North Norway and randomized to arm 3 or 4."
3221565|NCT01103453|Experimental|Intervention Group|Study group are persons diagnosed as suffering from Mild Cognitive Impairment will undergo a series of 9 sessions on a computer program of a virtual supermarket to improve their Executive and IADL functions.
3221566|NCT01103518|Experimental|Combination 1|Ethinyl Estradiol + Cyproterone acetate
3221567|NCT01103518|Active Comparator|Combination 2|Ethinyl Estradiol + Cyproterone acetate
3221568|NCT01103531|Experimental|Exercise Group|Participants in this group will be scheduled for 24 exercise training sessions over an 8-week period (three times weekly) and will be supervised by a certified exercise physiologist.
3221569|NCT01103531|Active Comparator|Education Group|Participants in this group will meet with a counselor who will present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
3221570|NCT01103544||Patients with advanced / metastatic TCCU after CDDP-failure|
3221571|NCT01103570|Experimental|group 1 cholecystocholangiography|cholangiography via gall bladder
3221572|NCT01103570|Experimental|group2 cystic duct cholangiography|cystic duct cholangiography
3221573|NCT01103583|Experimental|Hydroxyurea|
3221574|NCT01103583|Placebo Comparator|Placebo|
3221575|NCT01103596||HIV-infected patients, 1st wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
3221576|NCT01103596||HIV-infected patients, 2nd wave|HIV-infected ARV-experienced patients treated by a combination including Kaletra
3221577|NCT01103609|Experimental|1|twice daily on Day 1 to Day 10, with Warfarin on Day 4
3221578|NCT01103609|Placebo Comparator|2|twice daily on Day 1 to Day 10, with Warfarin on Day 4
3221579|NCT01103622|Experimental|1|twice daily Day 1 to Day 7; digoxin on day 4
3221580|NCT01103622|Placebo Comparator|2|twice daily Day 1 to Day 7; digoxin on day 4.
3221581|NCT01103635|Experimental|Arm I|Patients receive tremelimumab over 1 hour on day 1 and CD40 agonist monoclonal antibody CP-870,893 IV over 30 minutes on days 2, 22, 43, and 64. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3221582|NCT01103648|Active Comparator|Simvastatin arm|A subset of individuals started the study period taking monotherapy with simvastatin. After a 12-week period, ezetimibe was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
3221583|NCT01103648|Active Comparator|Ezetimibe arm|A subset of individuals started the study period taking monotherapy with ezetimibe. After a 12-week period, simvastin was combined to the initial monotherapy for more 12 weeks (combination period = experimental).
3221584|NCT01103648|Experimental|Simvastatin-Ezetimibe arm|To each subset of individuals which started the study period taking monotherapy with simvastatin or ezetimibe (active comparators), the other drug (ezetimibe or simvastatin, respectively) was combined for more 12 weeks (combination period = experimental arm).
3221585|NCT01103661|Other|Numeris-AF Guided Coagulation System|
3221586|NCT01103674|Other|Numeris-AF Guided Coagulation System|
3221587|NCT01103687|Experimental|Ad26.ENVA.01 (rAd26)|Participants will receive the Ad26.ENVA.01 (rAd26) vaccine at baseline.
3221588|NCT01103687|Placebo Comparator|Placebo Vaccine|Participants will receive the placebo vaccine at baseline.
3221589|NCT01103726|Experimental|Stage 1|
3221590|NCT01103726|Experimental|Stage 2|
3221591|NCT01103739|Experimental|cohort 1|
3221592|NCT01103739|Experimental|cohort 2|
3221593|NCT01103752||Surgery|This group (n=220) consist of patients undergoing hip or knee replacement in a fast-track setup and they are tested 3 times for postoperative cognitive dysfunction.
3221594|NCT01103765|Placebo Comparator|classic strategy|after drug-eluting stent(DES) deployment perform of Intravascular ultrasound analysis without post-dilatation
3221595|NCT01103765|Active Comparator|post-dilatation strategy|After drug-eluting stent (DES) deployment IVUS analysis and systematic post-dilatation with noncompliant balloon 0.25mm larger than stent balloon. After post dilatation new IVUS analysis.
3221596|NCT01103791|Experimental|Cohort 1|Docetaxel-PNP 20mg/m2
3221597|NCT01103791|Experimental|Cohort 2|Docetaxel-PNP 35mg/m2
3221598|NCT01103791|Experimental|Cohort 3|Docetaxel-PNP 45mg/m2
3221599|NCT01103791|Experimental|Cohort 4|Docetaxel-PNP 60mg/m2
3221600|NCT01103791|Experimental|Cohort 5|Docetaxel-PNP 75mg/m2
3221601|NCT01103791|Experimental|Cohort 6|Docetaxel-PNP 90mg/m2
3221602|NCT01103817|No Intervention|Vitamin D Sufficient|"Sufficient is defined as a 25 OH vitamin D level >50 nmol/l measured at baseline. No clinical intervention will be assigned to this group.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
3221603|NCT01103817|Experimental|Vitamin D Deficient|"Deficient is defined as a 25 OH vitamin D level ≤ 37.5 nmol/l. This group will receive Vitamin D.~Subjects will have fasting bloodwork done. Other study measurements to be taken include: height and weight, stage of puberty, blood pressure, vitamin D and calcium intake information, diabetes risk information, demographic information and spot urine sample.~We will also do a non-invasive test called a PAT or 'peripheral arterial tonometry' to look at the health of your blood vessels."
3221604|NCT01103830|Experimental|Group 1|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/low-Kcal meal."
3221605|NCT01103830|Active Comparator|Group 2|"4 tablets of Riamet® on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.~Administration of Riamet® will be in fed condition following a high-fat/low-Kcal meal."
3221606|NCT01103830|Other|Group 3|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fed condition, following a high-fat/low-Kcal meal~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
3221607|NCT01103830|Experimental|Group 4|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fed condition following a high-fat/high-Kcal meal."
3221608|NCT01103830|Experimental|Group 5|"3 or 4 tablets of Eurartesim™, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.~Administration of Eurartesim will be in fasting condition."
3221609|NCT01103830|Other|Group 6|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~Administration will be in the morning, in fasting condition.~1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning."
3221610|NCT01103843|Active Comparator|Maintenance Dose Arm|Open label clopidogrel 75 mg daily or prasugrel 10 mg daily
3221611|NCT01103843|Active Comparator|Loading Dose Arm|Clopidogrel 600 mg or Prasugrel 60 mg at time of PCI.
3221612|NCT01103856|Experimental|Patient Mentor Intervention|The patient mentor intervention from TSHC has been adapted to the inpatient setting. Participants randomized to that arm will receive 2 sessions with a patient mentor during their hospitalization, as well as 5 phone call sessions over the 10 weeks after discharge and a brief meeting between the subject and the mentor when the subject attends their first outpatient visit at TSHC after discharge.
3221613|NCT01103856|Placebo Comparator|HIV transmission risk reduction|Participants randomized to the control arm will receive an attention control intervention delivered by a patient educator who is not an HIV patient mentor. We will use a modified version of the RESPECT intervention for our attention control group. Similar to the active intervention, these patients will receive 2 sessions in the hospital and 5 phone calls over 10 weeks after discharge.
3221614|NCT01103908||Pediatric cardiac output (CO) after CPB|Cardiac output measurements made in pediatric patients after cardiopulmonary bypass.
3221615|NCT01103921|Other|Glucose|
3221616|NCT01103921|Other|Fructose|
3221617|NCT01103921|Other|High-Fructose Corn Syrup|
3221618|NCT01103921|Other|Aspartame|No sugar
3221619|NCT01103947|Active Comparator|EcoAnesthesia Mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. This group will receive the EcoAnesthesia Mask first."
3221620|NCT01103947|Active Comparator|Standard mask first|"Both the standard adult facemask (Portex Adult, USA) and the new facemask (EcoAnesthesia Mask, Intersurgical, Inc., Liverpool, NY, USA) will be tested in each patient for three minutes. The order of usage of each mask will be randomly assigned to each patient. Patients in this arm will receive the standard mask first."
3221621|NCT01103986|No Intervention|Control Group|
3221622|NCT01103986|Experimental|motivational/ health literacy education|
3221623|NCT01104012||All patients|Allergy patients, asthma and rhinitis
3221624|NCT01104038|Active Comparator|Nutrition Education/Lifestyle Counseling|Children in this group will receive weekly group nutrition sessions , 30 minutes per week for 12 weeks, identical to those provided for the EXCEL intervention group and delivered by a registered dietician.
3221625|NCT01104038|Experimental|EXCEL|The EXCEL arm is the experimental arm of the study. Participants in this arm will receive supervised physical activity in the form of novel gaming (technology-mediated physical activity, 60 minutes per session, three times per week , for 12 weeks and 12 weeks of group nutrition education sessions.
3221626|NCT01104051||Radiofrequency Ablation|The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
3221627|NCT01104051||Sham|subjects to be blinded,to receive sham procedure; The treatment to be used in this trial is radiofrequency nerve ablation of lateral branches from S1 - S4 using radiofrequency treatments; Simplicity lll Electrode, a single RF electrode with a single percutaneous entry point.
3221628|NCT01104064|Experimental|Real rTMS combined with CIT|
3221629|NCT01104064|Sham Comparator|Sham rTMS combined with CIT|
3221630|NCT01104129||Control Group|Individual who has not had pancreatic cancer/IPMN; surgical resection for lesion of pancreas; history of colorectal, gastric cancer, esophageal, or head-and-neck cancer; administration of chemotherapy less than 1 week prior to enrollment; or an endoscopic procedure conducted less than 1 week prior to enrollment.
3221631|NCT01104129||Diagnosis of Pancreatic Cancer/IPMN|Patients diagnosed with Pancreatic Cancer/Intraductal Papillary Mucinous Neoplasm who are scheduled for surgical resection.
3221632|NCT01104142||MDI|Subject on multiple Daily Injections
3221633|NCT01104142||CSII|Subjects on Continuous Subcutaneous Insulin Infusion
3221634|NCT01104168||Nursing home residents with diabetes|
3221635|NCT01104181|Experimental|swab and brush or swab and swab|we will determine which collection method is superior
3221636|NCT01104194|Experimental|Fish-oil|
3221637|NCT01104194|Placebo Comparator|Placebo|Olive oil capsules, identical in appearance to fish oil capsules
3221644|NCT01104233||The soft spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with soft spreading (using LAP Protector).
3221645|NCT01104233||The rigid spreading|Patients with lung cancer underwent Video-assisted Thoracoscopic Surgery (VATS) with rigid spreading.
3221646|NCT01104259|Experimental|Treatment (veliparib with cisplatin and vinorelbine tartrate)|Patients receive veliparib PO BID on days 1-14 (days 0-13 of course 1 only). Patients also receive cisplatin IV over 1 hour on day 1 and vinorelbine ditartrate IV over 10-20 minutes on days 1 and 8. Treatment repeats every 21 days for 6-10 courses in the absence of disease progression or unacceptable toxicity. Treatment with veliparib alone may continue in the absence of disease progression or unacceptable toxicity.
3221647|NCT01104272|Experimental|Energy Level 1|Subcutaneous Adipose Tissue Treated With Energy Level 1.
3221648|NCT01104298|Active Comparator|Arm A|"Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
3221649|NCT01104298|Experimental|Arm B|"Trabectedin Presentation: vials with trabectedin 1 mg and sucrose 400 mg. Pharmaceutical form: A white or whitish lyophilized powder as concentrate for solution for injection.~Route of administration: for intravenous use after reconstitution and further dilution.~Classic Doxorubicin (Adriamycin - Doxorubicin hydrochloride) Presentation: Solution with 10, 20, or 50 mg Doxorubicin Hydrochloride. Excipients: hydrochloric acid and sodium chloride 0.9%, q.s. 25 ml.~Pharmaceutical form: concentrate for solution for infusion. Route of administration: Intravenous"
3221650|NCT01104337|Experimental|Paracetamol 2g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 2g/d
3221651|NCT01104337|Experimental|Paracetamol 3g/d|18 patients on stable warfarin therapy received a 10-day regimen of paracetamol 3g/d
3221652|NCT01104337|Placebo Comparator|Placebo|9 patients on stable warfarin therapy received a 10-day regimen of placebo
3221653|NCT01104350|Experimental|Radiotherapy and Concurrent Gemcitabine Chemotherapy|This is a Phase I dose-escalation study examining the safety and tolerability of intensity modulated external radiation therapy using image-guidance in combination with gemcitabine chemotherapy as an alternative to radical cystectomy.
3221654|NCT01104363|Experimental|Snow white Plaster 2|Test
3221655|NCT01104363|Active Comparator|Primopattern LC gel + PVS|Control
3221656|NCT01104428|Placebo Comparator|placebo|
3221657|NCT01104428|Experimental|"Drug:ziying"|
3221658|NCT01104467|Experimental|Desmoteplase 70 µg/kg|
3221659|NCT01104467|Experimental|Desmoteplase 90 µg/kg|
3221660|NCT01104467|Placebo Comparator|Placebo|
3221661|NCT01104506|Active Comparator|Painless plexus|Patient with a painless avulsion of brachial plexus
3221662|NCT01104506|Active Comparator|Healthy|Healthy volunteers
3221663|NCT01104506|Experimental|Painful plexus|Patient with a painful avulsion of brachial plexus
3221664|NCT01104519|Experimental|1|Niaspan - Placebo
3221665|NCT01104519|Experimental|2|Placebo - Niaspan
3221666|NCT01104532|Experimental|Dosing Regimen 1|
3221667|NCT01104532|Experimental|Dosing Regimen 2|
3221668|NCT01104532|Experimental|Dosing Regimen 3|
3221669|NCT01104532|Experimental|Dosing Regimen 4|
3221670|NCT01104571|Other|Part 1: Control|No peri-operative therapy given
3221671|NCT01104571|Experimental|Part 1: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
3221672|NCT01104571|Experimental|Part 1: lapatinib|Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery
3221673|NCT01104571|Other|Part 2: Control|No peri-operative therapy
3221674|NCT01104571|Experimental|Part 2: Trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery.
3221675|NCT01104571|Experimental|Part 2: lapatinib-trastuzumab combination|Lapatinib 1000mg/day p.o. continuously for 28 days, in combination with trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery. Both drugs should start 11 days (+2 or -1 day) before the scheduled surgery.
3221676|NCT01104610|Active Comparator|NIV-PSV without Target Volume|Pressure Support Non Invasive Ventilation without Target Volume
3221677|NCT01104610|Active Comparator|NIV-PSV with Target Volume|Non Invasive Pressure Support Ventilation with Target Volume set
3221678|NCT01104610|Active Comparator|NIV-CPAP|Pressure Support Ventilation in CPAP mode
3221679|NCT01104623||ADHD - Patients|Adults (18-50 years old). All eligible subjects will experience the voice recording procedure followed by the assessment of adult ADHD diagnostics. The diagnostic guidelines for ADHD in adulthood will be accomplished as outlined by expert consensus of the German Society for Psychiatry, Psychotherapy and Neurology, with a semi-structured clinical interview following the DSM-IV-TR criteria and the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002) to assess the severity of ADHD-Symptoms. Childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002). To strengthen the validity of the ADHD diagnosis the reported symptoms were corroborated by second party reports.
3221680|NCT01104623||Healthy Controls|Adults(18-50 years old). All eligible subjects will experience the voice recording procedure followed by the ADHD-Checklist (ADHD-CL) for DSM-IV (Hesslinger et al., 2002. To assess the severity of Non-ADHD, the absence of childhood ADHD symptoms will be rated retrospectively amongst others by using the short version (WURS-k) of the Wender Utah Rating Scale (Ward et al., 1993), German version (Retz-Junginger et al., 2002).
3221681|NCT01104649|Experimental|Riluzole|Riluzole 50 mg is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
3221682|NCT01104649|Placebo Comparator|Placebo comparator|Placebo is administered orally every 12 hours for 12 months (a 2:1 ratio for SCA/FA in the stratified randomization procedure)
3221683|NCT01104675|Experimental|ENMD-2076 treatment|
3221684|NCT01104714||All patients|As the trial progresses, patients will be classified as either chemotherapy responders or non-responders.
3221685|NCT01104727|Active Comparator|Multi port|4-Ports Cholecystectomy (4PC): a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
3221686|NCT01104727|Active Comparator|Single port|"Single-Port Cholecystectomy (SPC): a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
3221687|NCT01104753||Non-interventional post-authorisation safety study|
3221688|NCT01104805|Experimental|Therapeutic Education System (TES)|Participants randomized to this arm will replace approximately 2 hours of Standard Treatment with the Therapeutic Education System (TES) (comprised of a web-based version of the Community Reinforcement Approach and contingency management).
3221689|NCT01104805|Other|Treatment-as-Usual (TAU)|Participants randomized to TAU will receive standard treatment offered and prescribed, as usual, in the outpatient substance abuse treatment program.
3221690|NCT01104831|Placebo Comparator|21 degree Cooling|Room temperature water circulated through cryotherapy sleeve.
3221691|NCT01104831|Active Comparator|10 degree cooling|Cooled water circulated through a cryotherapy sleeve.
3221692|NCT01104844|Active Comparator|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug
3221693|NCT01104844|Active Comparator|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.
3221694|NCT01104844|Active Comparator|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
3221695|NCT01104844|Active Comparator|ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
3221696|NCT01104844|Active Comparator|Ibuprofen high dose|Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug
3221697|NCT01104844|Placebo Comparator|placebo|2 Placebo tablets
3221698|NCT01104844|Experimental|Full Dose Strength|Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets
3221699|NCT01104857|Experimental|Diaphragm muscle biopsy|Patients admitted to the ICU meeting severe sepsis / septic shock criteria
3221700|NCT01104857|Active Comparator|Elective laparotomy|
3221701|NCT01104883|Experimental|Adductor-Canal-Blockade|Adductor-Canal-Blockade with ropivacaine
3221702|NCT01104883|Placebo Comparator|Adductor-Canal-blockade with saline|Adductor-Canal-blockade with isotonic saline
3221703|NCT01104896|Active Comparator|Nicotine|One or two 15mg nicotine patch(es) applied from 6am to 10pm according to the patients tobacco dependence measured by the Fagerström scale.
3221704|NCT01104896|Placebo Comparator|Placebo|One or two patch(es) with placebo
3221705|NCT01104909|Active Comparator|Clinical dry weight|Group which the dry weight will be assessed based on clinical examination.
3221706|NCT01104909|Active Comparator|Bioimpedance|Group which the dry weight will be assessed by bioimpedance data.
3221707|NCT01104935|Experimental|trastuzumab monotherapy|"H group (trastuzumab monotherapy group)~Trastuzumab: 1-year treatment~Loading dose, 8 mg/kg; from 2nd dose, 6 mg/kg; iv inj, qw, 18 times"
3221708|NCT01104935|Active Comparator|trastuzumab and chemotherapy|"H+CT group (combination therapy of trastuzumab and chemotherapy)~Chemotherapy: 12 to 24 weeks~Select chemotherapy from certain regimens (PTX, DTX, TC, AC, EC, FEC, CMF and TCb (CBDCA)) based on decision of a physician or a patient. Initiate administration of trastuzumab after completion of chemotherapy as a sequential combination. However, concomitant administration is allowed when combining trastuzumab with PTX, DTX and CMF. In cases of TCb (CBDCA), trastuzumab is used concomitant administration."
3221709|NCT01104948|Experimental|DA-8031|
3221710|NCT01104948|Placebo Comparator|Placebo|
3221711|NCT01104961|Experimental|Contact Lens Packaging Solution #1|Test solution - contact lens packaging solution
3221712|NCT01104961|Experimental|Contact lens packaging solution #2|Test solution - contact lens packaging solution
3221713|NCT01104961|Placebo Comparator|Balanced salt solution|Control solution
3221714|NCT01104987||alendronate|A cross sectional study assessing the prevalence of osteoporosis and vertebral fractures in AS has been conducted during the spring in 2009. Patients with osteoporosis that fulfilled the inclusion criteria and did not have any exclusion criteria for the present trial were asked to join this study.
3221715|NCT01105013|Experimental|tonaftato|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
3221716|NCT01105026|Experimental|bioactive glass|
3221717|NCT01105039||lap. hernia repair|undergoing laparoscopic groin hernia repair
3221718|NCT01105052|Active Comparator|Bibliotherapy|A group receiving a self-help book to work on for six weeks with no therapist support.
3221719|NCT01105052|Experimental|Bibliotherapy with support|A group receiving a self-help book to work on for six weeks, together with brief weekly telephone calls (<15 minutes) from a therapist.
3221720|NCT01105052|No Intervention|Wait-list control group|This group receives no intervention until about five months after the two treatment groups, when participants in this group receive the self-help book without therapist support.
3221721|NCT01105078|Other|Flow rate|Comparison between a flow rate of 2.5/l/min/m2 versus 3.0/l/min/m2
3221722|NCT01105104|Other|MedMinder System|
3221723|NCT01105104|Other|MedMinder System - deactivated|
3221724|NCT01105143|Active Comparator|lifestyle intervention|Multimodal lifestyle intervention to reduce body weight
3221725|NCT01105143|Placebo Comparator|placebo|placebo
3221726|NCT01105156||Gastric Band Patients|
3221727|NCT01105169|Active Comparator|GG genotype and magnesium treatment|Participants who have the GG genotype will be assigned to magnesium glycinate.
3221728|NCT01105169|Placebo Comparator|GG genotype and placebo|Participants who have the GG genotype will be assigned to placebo group
3221729|NCT01105169|Active Comparator|GA/AA genotype and magnesium treatment|Participants who have the GA/AA genotype will be assigned to magnesium glycinate
3221730|NCT01105169|Placebo Comparator|GA/AA genotype and Placebo|Participants who have the GA/AA genotype will be assigned to placebo group
3221731|NCT01105182||Radiofrequency Ablation|
3221732|NCT01105195|Active Comparator|DuraPrep|
3221733|NCT01105195|Active Comparator|ChloraPrep|
3221734|NCT01105208|Experimental|Arm 1|
3221735|NCT01105208|Active Comparator|Arm 2|
3221736|NCT01105221|Experimental|Acupuncture|
3221737|NCT01105221|Active Comparator|Artificial tear drop|
3221738|NCT01105234|Experimental|Calcipotriol ointment|
3221739|NCT01105260||control|group with classical rehabilitation program
3221740|NCT01105260||training|group with an 8 weeks interval training program on wheelchair independence
3221741|NCT01105273|Experimental|HAPLO|
3221742|NCT01105286|Experimental|Calcipotriol ointment|
3221743|NCT01105338|Active Comparator|Green tea drink|Green tea drink
3221744|NCT01105338|Active Comparator|Green tea capsules|Green tea capsules
3221745|NCT01105338|Placebo Comparator|Green tea placebo capsules|Green tea placebo capsules
3221746|NCT01105338|Active Comparator|Lycopene capsules|Lycopene capsules
3221747|NCT01105338|Placebo Comparator|Lycopene placebo capsules|Lycopene placebo capsules
3221748|NCT01105338|Active Comparator|Tomato rich diet|Tomato rich diet
3221749|NCT01105351|Active Comparator|folic acid plus B6 and B12|folic 400 µg plus vitamin B12 plus B6
3221750|NCT01105351|Placebo Comparator|Folic acid|folic acid alone
3221751|NCT01105390|Experimental|Treatment (rilotumumab, cisplatin, pemetrexed disodium)|Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3 weeks, as maintenance therapy in the absence of disease progression.
3221752|NCT01105403|Experimental|CD34+ mobilisation for transplantation|
3221753|NCT01105416|Placebo Comparator|Enhanced Standard Care (ESC)|Standard emergency department care plus informational brochures
3221754|NCT01105416|Experimental|Brief Prevention Intervention (BPI)|Brief Prevention Intervention in the Pediatric ED
3221755|NCT01105429|Active Comparator|BMS-820132 (0.3 mg) or Placebo|
3221756|NCT01105429|Active Comparator|BMS-820132 (1.0 mg) or Placebo|
3221757|NCT01105429|Active Comparator|BMS-820132 (3 mg) or Placebo|
3221758|NCT01105429|Active Comparator|BMS-820132 (10 mg) or Placebo|
3221759|NCT01105429|Active Comparator|BMS-820132 (30 mg) or Placebo|
3221760|NCT01105429|Active Comparator|BMS-820132 (75 mg) or Placebo|
3221761|NCT01105429|Active Comparator|BMS-820132 (150 mg) or Placebo|
3221762|NCT01105429|Active Comparator|BMS-820132 (300 mg) or Placebo|
3221763|NCT01105429|Active Comparator|BMS-820132 (TBD) or Placebo|
3221764|NCT01105442||Bupivacaine|Patients who received bupivacaine + sufentanil
3221765|NCT01105442||Levobupivacaine|Patients who received levobupivacaine and morphine on demand
3221766|NCT01105455|Placebo Comparator|High fiber|High fiber carbohydrate foods with a high / medium glycemic index. Whole wheat bread and/or brown rice are provided to subjects if they wish. Subjects are provided with a list of other recommended carbohydrate foods.
3221767|NCT01105455|Active Comparator|Low GI|Carbohydrate foods with a low glycemic index. Low GI rice and whole grain bread provided to subjects if they wish. Subjects are provided with a list of recommended foods.
3221768|NCT01105468||Mamma Carcinoma, no treatment|
3221769|NCT01105468||Mamma Carcinoma, treatment|
3221770|NCT01105468||No Mamma Carcinoma diagnosed by X-ray|
3221771|NCT01105481|Experimental|amisulpride add-on|
3221772|NCT01105481|Placebo Comparator|placebo add-on|
3221773|NCT01105507|Experimental|canakinumab arm|
3221774|NCT01105520||intralspinal processes|Patients with intralspinal processes
3221775|NCT01105546|Experimental|prophylaxis|prophylaxis with recombinant activated FVII 90 µg/kg/day i.v.
3221776|NCT01105546|Active Comparator|on demand treatment|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
3221777|NCT01105559||Group 1|Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.
3221778|NCT01105559||Group 2|Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.
3221779|NCT01105559||Group 3|Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.
3221780|NCT01105572|Experimental|Intel Home Health Guide|Participants in the intervention group will receive the use of the Intel Healthguide, an Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback when transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager. Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
3221781|NCT01105572|No Intervention|Case Management Only|All participants in the comparison group, are identified for outreach and assistance by a nurse case manager. Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care. Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes.
3221782|NCT01105585|Experimental|ZCB00 IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens (IOL) randomly assigned to one eye, with AcrySof Natural IQ (SN60WF) IOL in the fellow eye for contralateral implantation
3221783|NCT01105585|Active Comparator|SN60WF IOL|AcrySof Natural IQ (SN60WF) intraocular lens (IOL) randomly assigned to one eye, with Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens in the fellow eye for contralateral implantation
3221784|NCT01105598|Experimental|Cohort 1|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3221785|NCT01105598|Experimental|Cohort 2|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3221786|NCT01105598|Experimental|Cohort 3|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3221787|NCT01105598|Experimental|Cohort 4|Subjects (6 active/2 placebo) with mild dyslipidemia in Phase 1 Unit
3221788|NCT01105598|Experimental|Cohort 5|Free-living subjects (18 active/6 placebo) with mild dyslipidemia
3221789|NCT01105611|Experimental|Raltegravir|Raltegravir in combination with Tenofovir/Emtricitabine
3221790|NCT01105611|Active Comparator|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily with Ritonavir 100mg orally once daily; together with combination of Tenofovir/Emtricitabine
3221791|NCT01105624|Experimental|azithromycin ophthalmic solution, 1%|
3221792|NCT01105624|Experimental|rewetting drops|
3221793|NCT01105637|Other|Exercise|
3221794|NCT01105663||Sedated, Intubated, Morphine|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
3221795|NCT01105663||Sedated, Intubated, Midazolam|Subjects will receive morphine/midazolam as part of clinical care. Pharmacokinetic and pharmacogenetic sampling and pharmacodynamic monitoring will occur as indicated. Pharmacokinetic samples will be assayed in the laboratory of the Division of Clinical Pharmacology and Therapeutics. Pharmacogenetic samples will be assayed in the laboratory of the Center for Applied Genomics at CHOP.
3221796|NCT01105676|Experimental|single group single arm study|Open no masking is used. All involved know the identity of the intervention assignment
3221797|NCT01105715||Rheumatoid Arthritis (RA) Case Subjects|"Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA~Have currently active disease as assessed by Clinical Disease Activity Index (CDAI) score of >10~Have > or = 3 swollen joints"
3221798|NCT01105715||Control Subjects|"Age, sex, and 5-year age categories matched to cases~No historical diagnosis of RA and other primary autoimmune or inflammatory disorders"
3221799|NCT01105728|Experimental|Study arm|Endoscopic resection
3221800|NCT01105741||Active Crohn's disease - single arm|Active Crohn's disease, a decision is made to start treatment with adalimumab.
3221801|NCT01105780|Experimental|001|JNJ-41443532 250mg tablet once daily for 1 day
3221802|NCT01105780|Placebo Comparator|002|Placebo Matching placebo
3221803|NCT01105806||cardiopulmonary resuscitation (CPR) video|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative script in advance directive (AD) completion over a 1 month time frame post intervention.
3221804|NCT01105806||cardiopulmonary resuscitation (CPR) narrative script|This pilot study involves a two-arm parallel design comparing the effectiveness of a CPR video versus a CPR narrative in advance directive (AD) completion over a 1 month timeframe post intervention.
3221805|NCT01105819|Other|Standard oral care with chlorhexidine|The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed
3221806|NCT01105819|Active Comparator|Lactobacillus plantarum 299|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
3221807|NCT01105832|Experimental|Proximal humeral fracture - intervention|20 patients will be randomized to 20 micrograms daily of Teriparatide (Forsteo)
3221808|NCT01105832|No Intervention|Proximal humeral fracture|20 patients will receive standard treatment (physiotherapy)
3221809|NCT01105858||Volunteers|Adult volunteers &amp; family members recruited from the Phoenix metropolitan area
3221810|NCT01105871|Active Comparator|naloxone|4 mg in 10 ml saline iv bolus
3221811|NCT01105871|Placebo Comparator|saline placebo|10 ml of normal saline iv bolus
3221812|NCT01105884|Active Comparator|Group 1|
3221813|NCT01105884|Active Comparator|Group 2|
3221814|NCT01105884|Active Comparator|Group 3|
3221815|NCT01105884|Active Comparator|Group 4|
3221816|NCT01105884|Active Comparator|Group 5|
3221817|NCT01105897||Surgically treated endometriosis patients|Women scheduled for operation on suspected endometriosis in two study hospitals specialized in the surgical treatment of endometriosis between January 2005 - December 2007 (Päijät-Häme Central Hospital) and January 2008 - December 2008 (Helsinki University Hospital).
3221818|NCT01105910|Experimental|Systane Ultra|Systane Ultra Lubricant Eye Drops
3221819|NCT01105910|Active Comparator|Sensitive Eyes|Sensitive Eyes Eye Drops (Bausch & Lomb)
3221820|NCT01105923|Experimental|Receive CDS intervention|Providers in clinics that will receive the CDS alert, as their clinic was randomized into our study.
3221821|NCT01105923|No Intervention|No CDS intervention|
3221822|NCT01105949|Other|Marketed nasal strip|Marketed nasal strip
3221823|NCT01105949|Experimental|NexGen JB Organic PET/PE|NexGen JB Organic PET/PE, prototype nasal dilator strip
3221824|NCT01105949|Experimental|NexGen AB 2R11|NexGen AB 2R11
3221825|NCT01106001|Active Comparator|Levobupivacaine|Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children
3221826|NCT01106001|Placebo Comparator|Saline|Saline (also saline solution) is a general term referring to a sterile solution of sodium chloride (NaCl, more commonly known as salt) in water but is only sterile when it is placed intravenously, otherwise, a saline solution is a salt water solution.
3221827|NCT01106053|Experimental|Pramipexole|Open-label trial of pramipexole.
3221828|NCT01106066|Experimental|S-1/oxaliplatin/RT|Radiotherapy + 4 dose levels of oxaliplatin/S-1
3221829|NCT01106079|Experimental|Intensive management|
3221830|NCT01106079|Active Comparator|Standard management|
3221831|NCT01106105||control (Body Mass Index < 25)|
3221832|NCT01106105||Obese (Body Mass Index > 35)|
3221833|NCT01106118||Group 1|
3221834|NCT01106131|Experimental|CKD-501 0.5mg|
3221835|NCT01106131|Active Comparator|Pioglitazone 15mg|
3221836|NCT01106144||Acute myeloid leukemia|
3221837|NCT01106170|Experimental|Arm 1|Participants will consume 330 mg of Provex CV supplement, by mouth, per day, for 4 weeks followed by 4 weeks of 330 mg of placebo (cornstarch)
3221838|NCT01106170|Experimental|Arm 2|Participants will consume 330 mg placebo (cornstarch), by mouth, per day for 4 weeks followed by 4 weeks of 330 mg of ProvexCV for 4 weeks.
3221839|NCT01106183|Active Comparator|Transfer Factor|Transfer factor supplement; 2 capsules per day
3221840|NCT01106183|Placebo Comparator|Sugar pill|
3221841|NCT01106196||MI plus respiratory illness|Patients with an incident myocardial infarction who also have a record of a visit to primary care with a respiratory tract infection
3221842|NCT01106209||Prematurely born infants in the NICU|Preterm infant patients delivered at UUMC and hospitalized in the NICU who are ≤1500 grams or <30 weeks gestational age at birth
3221843|NCT01106209||Healthy term infants|Term infants delivered at UUMC without complication, either via cesarean section or vaginal delivery
3221844|NCT01106209||Infants having surgery at <1 year old|Infants admitted to the PCMC same-day surgery unit in preparation for elective surgery within the first year of life
3221845|NCT01106235|Experimental|Treatment (immunostimulant, autologous lymphocytes, and chemo)|Patients receive cyclophosphamide IV on days -3 and -2 followed by an infusion of IL-21 modulated, MART-1 specific CD8+ cytotoxic T lymphocytes over 30-60 minutes on day 0. Beginning within 24 hours of T cell infusion, patients receive low-dose aldesleukin SC BID for 14 days in the absence of disease progression or unacceptable toxicity.
3221846|NCT01106261|Experimental|Pulmonary metastasectomy|Pulmonary metastasectomy
3221847|NCT01106261|Active Comparator|Active monitoring|Active monitoring
3221848|NCT01106300||Multi-organ failure|Sedated ventilated patients in multi-organ failure
3221849|NCT01106300||Single-organ failure|Sedated ventilated patients in single organ failure
3221850|NCT01106339||A|Patients with somatoform disorders due to DSM-IV
3221851|NCT01106365|Experimental|prefrontal cortex (PFC)|rTMS with the H-coil to the prefrontal cortex (PFC)
3221852|NCT01106365|Active Comparator|motor cortex|rTMS with the H-coil to the motor cortex
3221853|NCT01106365|Sham Comparator|sham treatment|sham treatment
3221854|NCT01106378||NEVO™ Sirolimus-eluting Coronary Stent System.|Subjects treated during routine clinical practice with the NEVO™ Sirolimus-eluting Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease.
3221855|NCT01106378||CYPHER Select® Plus Coronary Stent|Subjects treated during routine clinical practice with the CYPHER Select® Plus Coronary Stent System and diagnosed with acute STEMI for primary intervention and/or diabetes mellitus and/or multi vessel disease
3221856|NCT01106417|Experimental|NeoFuse|"Anterior Cervical Discectomy and Fusion with NeoFuse.~NeoFuseTM is constituted of STRO-3 immunological selected allogeneic MPCs, which are derived from adult bone marrow mononucleated cells that are culture-expanded and subsequently cryopreserved.~The allogeneic MPCs are formulated in concentrations of nucleated cells in a 5 mL volume and are cryopreserved in 7.5% dimethyl sulfoxide (DMSO)/50% Alpha Modified Eagle's Medium (MEM) and 42.5% ProFreeze®. The final formulation consists of 0.15mL (approximately 10 million MPCs) of thawed NeoFuse™ thawed NeoFuseTM combined with the amount of MasterGraftTM Matrix to fill the PEEK cage per ACDF level."
3221857|NCT01106417|Active Comparator|MasterGraft Granules|"Anterior Cervical Discectomy and Fusion with MasterGraft Granules~MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process"
3221858|NCT01106443|Active Comparator|Total Thyroidectomy - CLND|Total thyroidectomy without central lymph node dissection.
3221859|NCT01106443|Experimental|Total Thyroidectomy +CLND|Total thyroidectomy with central lymph node dissection.
3221860|NCT01106443|Experimental|Hemi-thyroidectomy + CLND|Hemi-thyroidectomy with central lymph node dissection.
3221861|NCT01106443|Active Comparator|Hemi-thyroidectomy - CLND|Hemi-thyroidectomy without central lymph node dissection.
3221862|NCT01106469|Experimental|001|JNJ-41443532 25mg tablet once daily
3221863|NCT01106469|Experimental|002|JNJ-41443532 100mg tablet once daily
3221864|NCT01106469|Experimental|003|JNJ-41443532 250mg tablet once daily
3221865|NCT01106469|Experimental|004|JNJ-41443532 500mg once daily (with 250mg tablets)
3221866|NCT01106469|Experimental|005|JNJ-41443532 1000mg once daily (with 250mg tablets)
3221867|NCT01106469|Experimental|006|JNJ-41443532 1500mg once daily (with 250mg tablets)
3221868|NCT01106469|Placebo Comparator|007|Placebo Matching placebo
3221869|NCT01106482|Active Comparator|Arm 1|
3221870|NCT01106482|Active Comparator|Arm 2|
3221871|NCT01106482|Active Comparator|Arm 3|
3221872|NCT01106482|Active Comparator|Arm 4|
3221873|NCT01106495|Experimental|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive therapy for the treatment of patients with coronary artery disease.The systolic deflation/diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. Patients with subclinical atherosclerosis whose serum LDL high than 160mg/ml receive EECP 1- hour session every working day over a 7 week period. Simvastatin is used to decrease cholesterol level for 7 weeks.
3221874|NCT01106495|Active Comparator|Control|Subjects whose LDL higher than 160 mg/dl with subclinical atherosclerosis. Simvastatin is used to decrease cholesterol level for 7 weeks.
3221875|NCT01106508|Experimental|LEQ506|
3221876|NCT01106521|Experimental|PBSI|PBSI is a form of accelerated partial breast irradiation involving the insertion of 103-palladium stranded seeds under ultra-sound guidance and light sedation after CT planning in lieu of whole breast adjuvant radiotherapy.
3221877|NCT01106547|Experimental|Methylprednisolone|
3221878|NCT01106547|Placebo Comparator|placebo/sodium chloride|
3221879|NCT01106560|Active Comparator|Anterior Approach Group|(AMIS)
3221880|NCT01106560|Active Comparator|Posterior Approach Group|(Posterior)
3221881|NCT01106599|Experimental|A|
3221882|NCT01106612|Experimental|Initial coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
3221883|NCT01106612|Active Comparator|Initial nuclear stress test|Stress radionuclide myocardial perfusion imaging
3221884|NCT01106638|Experimental|Intensive behavioral intervention|Eight session, behavioral intervention targeting HIV-infected smokers
3221885|NCT01106638|Active Comparator|Standard care|Advice to quit, smoking cessation brochure, offer of nicotine patch
3221886|NCT01106664|Placebo Comparator|P|
3221887|NCT01106664|Experimental|E|
3221888|NCT01106703|Experimental|PG102 group|
3221889|NCT01106703|Placebo Comparator|placebo group|
3221890|NCT01106716|Placebo Comparator|A1: Placebo|Placebo
3221891|NCT01106716|Experimental|A2: KAI-1678|Experimental
3221892|NCT01106716|Active Comparator|A3: Lidocaine|Lidocaine
3221893|NCT01106729|Other|Cyanidin 3 glucoside|
3221894|NCT01106742|Experimental|AndoSan, UC|AndoSan as a supplement to 10 UC patents
3221895|NCT01106742|Experimental|AndoSan, CD|AndoSan as a supplement to 10 CD patients.
3221896|NCT01106755|Experimental|hemiparetic gait|gait training on ground level
3221897|NCT01106768||test cohort|Evaluation of oral health needs of children with attention deficit disorder with or without hyperactivity
3221898|NCT01106768||not disorder cohort|children without attention deficit disorder
3221899|NCT01106781||1|Patients in this group should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation.
3221900|NCT01106807|Experimental|CD07223 1.5% gel|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
3221901|NCT01106807|Experimental|CD07223 0.5% gel|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks and Epiduo vehicle gel on the other half-face
3221902|NCT01106807|Active Comparator|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters of Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel on one half-face and 500 microliters of the Epiduo vehicle gel on the other half-face in the morning and in the afternoon, 500 microliters of Epiduo vehicle gel on both half-faces
3221903|NCT01106820|Active Comparator|Resistance training|
3221904|NCT01106820|Active Comparator|Relaxation training|
3221905|NCT01106872|Experimental|Treatment|Bevacizumab Combined with Gemcitabine, Docetaxel and Valproic Acid in Advanced Sarcoma
3221906|NCT01106885|No Intervention|Enhanced Usual Care|"Adult patients with diabetes and depression.~Report screening results~Notify PCP of screening results (optional per patient)~PCP referrals~Educational materials regarding diabetes, physical activity, and depression"
3221907|NCT01106885|Experimental|Staged Care Management|Adult patients with diabetes and depression
3221908|NCT01106924|Experimental|Probiotic|daily probiotic consumption
3221909|NCT01106924|Placebo Comparator|Placebo|daily placebo consumption
3221910|NCT01106937||Patients with low Factor XIII|Postoperative occurence of pulmonary embolism in patients scheduled to undergo a neurosurgical procedure with laboratory-confirmed low levels of Factor XIII
3221911|NCT01106963||Tibial shaft fractures|Patients had tibial shaft fractures in the last 3 years. All were treated with intramedullary (IM) reamed nails with 2 or 3 interlocking screws.
3221912|NCT01106989|Experimental|Heated lidocaine/tetracaine patch|Active
3221913|NCT01107002|Experimental|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
3221914|NCT01107028||Rehab|Subjects randomized to the Rehab group will have data collected at baseline and then within one week enroll in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
3221915|NCT01107028||Wait|Subjects randomized to the Wait group will have data collected at baseline and wait eight weeks before enrolling in a pulmonary rehabilitation program. Data will again be collected within one week of completing pulmonary rehabilitation and again six months later.
3221916|NCT01107041|Experimental|Mobilyze!|
3221917|NCT01107054|Experimental|PF-00610355 450 µg|An orally inhaled dose of PF-00610355 450 µg
3221918|NCT01107054|Experimental|PF-00610355 1200 µg|An orally inhaled dose of PF-00610355 1200 µg
3221919|NCT01107054|Active Comparator|moxifloxacin 400 mg|A single oral dose of moxifloxacin 400 mg on Day 4.
3221920|NCT01107054|Placebo Comparator|placebo|A single oral dose of non-matched placebo on Day 4.
3221921|NCT01107067|Experimental|testosterone replacement therapy|
3221922|NCT01107080||Degradation|30 mastectomy, partial mastectomy, and mammoplasty samples will be analyzed to define the effective post-excision time window in which the device must be used before the results can no longer be evaluated. The mammoplasty specimens are necessary to assess normal tissue outcomes.
3221923|NCT01107080||Reproducibility|25 Partial Mastectomy cases will be analyzed to distinguish between different implementation methods of the technology.
3221924|NCT01107093|Placebo Comparator|Placebo|
3221925|NCT01107093|Active Comparator|CDB-2914|
3221926|NCT01107106||Adolescents|250 postmenarcheal adolescent girls
3221927|NCT01107106||Adults|250 adult women
3221928|NCT01107119|Experimental|Integrated care pathway|"program for~communication and information flow aimed at collaboration between hospitals, general practitioners and home care services~systematic patient follow-up in home care services by using checklists"
3221929|NCT01107119|Active Comparator|usual care|usual care
3221930|NCT01107132||Diabetic Retinopathy|T2DM Patient suffering from Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR) and Diabetic Macular Edema (DME)
3221931|NCT01107145|Experimental|Mefloquine- Artesunate|Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
3221932|NCT01107145|Experimental|Artemether-Lumefantrine|Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
3221933|NCT01107145|Active Comparator|Chloroquine|Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
3221934|NCT01107158||Group 1|Control group: these patients have mechanical dystocia; cholesterol metabolism factors are a priori not involved.
3221935|NCT01107158||Group 2|These patients have uterine dystocia
3221936|NCT01107171|Placebo Comparator|placebo|Tang-min Lin pills analogue
3221937|NCT01107171|Experimental|Tang-min-ling pills high dosage|Tang-min-ling pills, high dosage, 12g, tid po
3221938|NCT01107171|Experimental|Tang-min-ling pills low dosage|low dosage group:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
3221939|NCT01107184|Experimental|Preconditioning|The remote ischemic stimulus will be applied after induction of anaesthesia, but before cardiopulmonary bypass.
3221940|NCT01107184|Experimental|Postconditioning|The remote ischemic stimulus during cardiopulmonary bypass.
3221941|NCT01107184|Experimental|Pre and postconditioning|The remote ischemic stimulus will be applied twice, after induction of anaesthesia and during cardiopulmonary bypass.
3221942|NCT01107184|Sham Comparator|Control|
3221943|NCT01107210||stroke patients|50 patients recruited in the stroke rehabilitation unit in the University Hospital, Leuven, Belgium will be included
3221944|NCT01107223|Experimental|Training to antibiotic prescription|Physicians randomized in the education group attended a two days seminar focussed on evidence-based guidelines on antibiotic use in respiratory tract infections.
3221945|NCT01107223|Placebo Comparator|control|
3221946|NCT01107236|Experimental|IW-6118|
3221947|NCT01107236|Placebo Comparator|Placebo|
3221948|NCT01107236|Active Comparator|Naproxen Sodium|
3221949|NCT01107249|Other|BS Ultraflex or Wallstent stents|All subjects receive a stent of surgeons choice from selected stents.
3221950|NCT01107262||Poultry exposed adults|This seroepidemiological study proposes to compare adults with occupational exposure to poultry with non-poultry exposed adult controls for evidence of previous infections with AI viruses.In this study, any person with occupational exposure to poultry i.e. works in poultry production facility or raises a smaller number of poultry on his/her farm will be considered exposed. The questionnaire used in this study will capture poultry exposure data through a group of variables assessing type of occupational setting, length of time of exposure, flock size, type of work performed, and personal protective equipment (PPE) used.
3221951|NCT01107262||Poultry Non-exposed Adult Controls|Controls, adults who were never exposed to poultry, will be enrolled from urban areas such as the capital Beirut. Controls will be invited to volunteer by word of mouth at public/community sites.
3221952|NCT01107275|Experimental|2 primary ID doses|two doses of rabies vaccines given intradermally on days 0 and 28
3221953|NCT01107275|Experimental|3 primary ID doses|three doses of rabies vaccines given intradermally on days 0, 7, and 28
3221954|NCT01107288|Experimental|Intervention group|Randomized to receive the intervention first
3221955|NCT01107288|Other|Delayed intervention control group|Randomized to wait-list control first
3221956|NCT01107314||trauma patient|SBP less than 90mmHg
3221957|NCT01107340|Other|AMIStem Hip System|Patients who comply with the protocol and received an AMIStem femoral component.
3221958|NCT01107431|Active Comparator|Sucrose with Dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
3221959|NCT01107431|Active Comparator|Sucrose without Dietary Supplement|Consumed 70 grams of sucrose without simultaneously taking the dietary supplement
3221960|NCT01107470||Group A1|Age 18-34y (with short protocol)
3221961|NCT01107470||Group A2|age 35-42y ( with short protocol)
3221962|NCT01107470||Group B1|age 18-34y ( with long protocol)
3221963|NCT01107470||Group B2|age 35-42y ( with long protocol)
3221964|NCT01107483||AC group|asymptomatic carriers
3221965|NCT01107483||CH group|patients with chronic hepatitis
3221966|NCT01107483||HC group|patients with hepatic cirrhosis
3221967|NCT01107483||ACLF group|patients with acute on chronic liver failure
3221968|NCT01107483||healthy control|healthy volunteers
3221969|NCT01107496|Experimental|SPN-812|viloxazine, oral, 300mg, tid, 6 weeks
3221970|NCT01107496|Placebo Comparator|Placebo|placebo, oral, tid, 6weeks
3221971|NCT01107509|Experimental|Neo-adjuvant everolimus|
3221972|NCT01107522|Experimental|Arm A|Single Agent CTO
3221973|NCT01107522|Experimental|Arm B|Combination CTO and Temodar®
3221974|NCT01107522|Experimental|Arm C|Combination CTO, Temodar®, Radiation therapy
3221975|NCT01107548|Experimental|Evidence-based treatment, lifestyle counseling|
3221976|NCT01107561|Experimental|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire.
3221977|NCT01107561|Active Comparator|Surgical airway approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
3221978|NCT01107574|Experimental|Gabapentin and Osteopathic Manipulative Medicine|6 weeks of both Gabapentin 900 mg HS given orally was accompanied with Osteopathic Manipulative Medicine treatment 30 minutes weekly to the tender points of the musculoskeletal system of each patient for 6 weeks.
3221979|NCT01107574|Experimental|Gabapentin|Gabapentin was given orally at 900 mg at HS weekly for 6 weeks.
3221980|NCT01107574|Experimental|Osteopathic Manipulative Medicine|6 weeks of Osteopathic Manipulative Medicine Treatment was applied to the patients tender points in the musculoskeletal system weekly by a 30 minute treatment.
3221981|NCT01107587|Experimental|HRV group|Subjects will receive GSK Biologicals' human rotavirus vaccine 444563.
3221982|NCT01107587|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3221983|NCT01107600|Experimental|Nobel Active®|Immediate implant and socket preservation
3221984|NCT01107613|Experimental|Intervention Arm|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
3221985|NCT01107613|No Intervention|Control/Standard Care|All patients will receive prednisone X 10 days and antibiotics X 5 days. This group will receive educational handouts on AECOPD.
3221986|NCT01107639|Experimental|Additional immunotherapy (cetuximab)|All patients in the experimental arm will be given additional immunotherapy (cetuximab) during cycles 1 and 2, during RT and after surgery.
3221987|NCT01107639|Active Comparator|Without additional immunotherapy|Standard therapy without immunotherapy (cetuximab).
3221988|NCT01107678|Experimental|YMCA PAN|YMCA PAN (Physical activity and nutrition)- Consists of organized physical activity and controlled serving sizes of healthy low fat snacks
3221989|NCT01107678|Experimental|YMCA Standard CAre|YMCA standard care - Follow the standard care of the YMCA after school Y-Care program for physical activity and nutrition
3221990|NCT01107691|Experimental|Resistance training|1 set of progressive resistance training per session
3221991|NCT01107691|Experimental|3 sets per session|3 sets of progressive resistance training per session
3221992|NCT01107691|No Intervention|Control|Non exercise control group
3221993|NCT01107704|Experimental|Family Support Intervention|
3221994|NCT01107704|No Intervention|Control Group|
3221995|NCT01107717|Experimental|Triple Therapy|initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed
3221996|NCT01107717|Active Comparator|conventional therapy|sequential addition of metformin, glyburide and basal insulin
3221997|NCT01107756|Experimental|TAXOTERE (Docetaxel) + GRANOGYTE 34 (Lenograstim)|Taxotere (Docetaxel) is given as background treatment and should be administered by the treating physician in accordance with the prescribing information outlined in the package insert + Granocyte 34 (lenograstim)
3221998|NCT01107769||VISIONAIRE™|Total knee arthroplasty with VISIONAIRE™ patient-matched cutting blocks
3221999|NCT01107769||Standard Instrumentation|Total knee arthroplasty with standard instrumentation
3222000|NCT01107782|Experimental|sildenafil|
3222001|NCT01107782|Placebo Comparator|Placebo control|
3222002|NCT01107808|No Intervention|Control|The adolescents randomized to Standard of care group will receive the medical and behavioral counseling regarding their obesity as a patient of the Children's Center for Weight Management (CCWM). They will not receive any pharmacological treatment for their vitamin D deficiency or insulin resistance. Calcium and vitamin D dietary intake will be determined using a specific food frequency questionnaire at each study visit for all groups. This will be used to determine effect of nutrition counseling.
3222003|NCT01107808|Experimental|Calcium and Vit D|The participants in the vitamin D/calcium group will receive standard of care through the CCWM along with the addition of treatment with ergocalciferol (vitamin D2) and calcium carbonate for their vitamin D deficiency. The vitamin D treatment will be 50,000 IU orally weekly for 8 weeks. This treatment regimen for vitamin D deficiency has been found to be safe to children and adolescents. 32 33The dose of calcium supplementation will be calcium carbonate orally 1200mg daily. This is the daily recommended intake of calcium for adolescents
3222004|NCT01107808|Experimental|Metformin/ Vit D|The participants randomized into the vitamin D/calcium/Metformin treatment group will receive standard of care through the CCWM in addition to treatment for their Vitamin D deficiency with the same doses of ergocalciferol (vitamin D2) and calcium carbonate as previously outlined. Additionally, these participants will receive Metformin ER to treat insulin resistance. The Metformin ER will be started at 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks).
3222005|NCT01107821|Experimental|Engenex™-pump|Negative Pressure Wound Therapy with the Engenex™-pump and Bio-Dome™ Dressing
3222006|NCT01107860||Group I|
3222007|NCT01107860||Group II|
3222008|NCT01107873||duplex ultrasonography|conduct duplex ultrasonography after caudal block with sevoflurane anaesthesia in children
3222009|NCT01107938|Experimental|10 mg ilaprazole|
3222010|NCT01107938|Experimental|15 mg ilaprazole|
3222011|NCT01107938|Active Comparator|40 mg esomeprazole|
3222012|NCT01107951|Other|Rituximab -dexamethasone|only one arm receive four doses weekly rituximab and four dosis daily dexamethasona
3222013|NCT01107977|Experimental|Iyengar yoga|
3222014|NCT01107977|No Intervention|Waitlist control|
3222015|NCT01107990||Single right ventricles|
3222016|NCT01107990||Single left ventricles|
3222017|NCT01108029|Active Comparator|memantine|memantine 20 mg/day (2 tablets 1 time a day in the morning)
3222018|NCT01108029|Placebo Comparator|placebo|2 tablets (1 time a day in the morning) during 3 months
3222019|NCT01108042|Experimental|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out.
3222020|NCT01108055|Experimental|pazopanib + paclitaxel|"Cycle of 28 days. Pazopanib: 800mg daily~Cycle of 28 days Paclitaxel: 80mg/m2 on days 1,8 and 15"
3222021|NCT01108107|Other|Chemotherapy only|Chemotherapy only, if mutations in KRAS, BRAF or PIK3CA gene
3222022|NCT01108107|Other|Chemotherapy + biological treatment|Addition of biological treatment, if no mutations in KRAS, BRAF, and PIK3CA genes.
3222023|NCT01108120|Experimental|continuous intra-femoral thrombolysis group|Continuous intra-femoral injection urokinase was taken by a mini-pump in 100 diabetic foot ulcers (Wegnar 2 ~ 4 stage) for 7 - 9 days.Then they receive conventional therapy. The healing rate of foot ulcers is observed during hospitalization period. At 1, 4 and 8 year during follow up, the recurrence rate of diabetic foot ulcers are observed.
3222024|NCT01108120|Experimental|conventional therapy group|Conventional therapy group receives an intravenous injection of prostaglandin E1 20 ug per day. The follow up was taken for 8 years.
3222025|NCT01108133|Experimental|Hydrocortisone, fMRI, Intrusions|10 mg Hydrocortisone are administered one hour before the fMRI experiment. We use the script-driven imagery paradigm to induce intrusive memories during fMRI scanning.
3222026|NCT01108133|Experimental|Dexamethasone, fMRI, Intrusions|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment. (DEX-Test). We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning.
3222027|NCT01108133|Experimental|Placebo, fMRI, Intrusions|Placebo is administered one hour before the fMRI experiment. We use the script-driven imaging paradigm to induce intrusive memories during fMRI-scanning in patients with posttraumatic stress disorder.
3222028|NCT01108146|Experimental|Arm 1|"Drug: Hydrocortisone 10 mg~Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo-1 week hydrocortisone 10 mg/d -1 week placebo - 1 week hydrocortisone 30 mg/d"
3222029|NCT01108146|Experimental|Arm 2|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
3222030|NCT01108172|Active Comparator|Usual Care|
3222031|NCT01108172|Experimental|Virtual Ward|
3222032|NCT01108198|Active Comparator|mometasone furoate cream|The study patient consecutive patients who were referred to outpatient clinic of Pediatric surgery for surgical treatment of non-retractable foreskin. The study patients were randomized to have either mometasone cream or placebo
3222033|NCT01108198|Placebo Comparator|moisturizer|
3222034|NCT01108211|Experimental|Treatment Group|This group will receive Vibration Therapy.
3222035|NCT01108211|No Intervention|Observation Group|This group does not receive Vibration Therapy
3222036|NCT01108224|Experimental|Psychosocial support|
3222037|NCT01108224|No Intervention|Control group|
3222038|NCT01108250|Experimental|polypoidal choroidal vasculopathy|patients with polypoidal choroidal vasculopathy
3222039|NCT01108250|Active Comparator|control|control group with no polypoidal choroidal vasculopathy
3222040|NCT01108289|Experimental|Oxytocin in Uniject|Community Health Officers will provide 10 IU Oxytocin in Uniject device IM immediately after delivery of baby
3222041|NCT01108289|No Intervention|PPH Treatment Only|Community Health Officers will be able to treat for PPH only, not provide Oxytocin in Uniject
3222042|NCT01108302|No Intervention|PPH Treatment only|Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject
3222043|NCT01108302|Experimental|Oxytocin in Uniject|Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery
3222044|NCT01108315|Experimental|Intervention|The participant used the web and/or phone-based PRO reporting symptoms to enter symptoms twice a week at minimum.
3222045|NCT01108315|No Intervention|Usual Care|The participants on this arm do not record their symptoms. They report symptoms as they would under usual care.
3222046|NCT01108328|Experimental|PolyGlycopleX (PGX)|5 grams of PGX 3 times per day with each main meal (breakfast, lunch and dinner)
3222047|NCT01108328|Placebo Comparator|Rice flour|5 grams of rice flour 3 times per day at each main meal (breakfast, lunch and dinner)
3222048|NCT01108354||ADHD patients|10 male adult ADHD patients and 10 female adult ADHD patients
3222049|NCT01108354||healthy controls|20 age- and sex-matched healthy volunteers
3222050|NCT01108380|Experimental|1. CD34|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasmapheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~CD 34 cells will be selected by CliniMACS (Miltenyi Biotec, Bergisch- Gladbach, Germany) (at least 1x10(7) of CD 34 cell)~In same day, right portal vein embolization with infusion of CD 34 cells into left portal vein will be performed."
3222051|NCT01108380|Active Comparator|2. Mononucelar cell|"4 days injection of G-CSF (10μg/kg, Subcutaneous infusion)~On 5th day, plasma pheresis will be performed to select mononuclear cells. (at least 4x10(9) of mononuclear cells)~In same day, right portal vein embolization with infusion of mononuclear cells into left portal vein will be performed."
3222052|NCT01108380|Other|3. Control|Without infusion of G-CSF, patients will be performed just right portal vein embolization
3222053|NCT01108393|Experimental|Agomelatine A|
3222054|NCT01108393|Placebo Comparator|Placebo|
3222055|NCT01108419|Active Comparator|1 = Test Product normal dose|Fermented dairy product containing probiotics - normal dose
3222056|NCT01108419|Active Comparator|2 = Test Product high dose|Fermented dairy product containing probiotics - high dose
3222057|NCT01108419|Sham Comparator|3 = Control Product normal dose|Non-fermented dairy product - normal dose
3222058|NCT01108419|Sham Comparator|4 = Control Product high dose|Non-fermented dairy product - high dose
3222059|NCT01108432|Experimental|Electronic Referrals|Dental practices randomized to the experimental group will have options on how to refer patients to the tobacco cessation website.
3222060|NCT01108432|No Intervention|Routine Referral|Dental practices in this arm will refer patients to the Decide2Quit website by using an information prescription.
3222061|NCT01108484|Experimental|Supervised exercise|Cardiorespiratory and resistance training
3222062|NCT01108484|Experimental|Exercise + diet counseling|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food)
3222063|NCT01108484|Experimental|Exercise + diet counseling + psycho support|Cardiorespiratory and resistance training + Diet counseling to improve food intake(more fruit and vegetable and less fat food) + Weekly sessions to modify the behaviour
3222064|NCT01108484|No Intervention|Control|They will keep their usual way of life
3222065|NCT01108536|Experimental|adaptive trans-tibial socket|subjects are fitted with experimental sockets.
3222066|NCT01108562|Placebo Comparator|Control Group|Patients will receive a Dilaudid PCA in combination with a placebo infusion of normal saline.
3222067|NCT01108562|Experimental|Lidocaine Group|Patients will be receive a Dilaudid PCA in combination with a continuous Lidocaine infusion.
3222068|NCT01108575|Experimental|Inspiratory muscle strength training|
3222069|NCT01108575|Sham Comparator|Sham Inspiratory muscle strength training|
3222070|NCT01108588|Experimental|Sequence 1|Aspirin - Clopidogrel - Placebo
3222071|NCT01108588|Experimental|Sequence 2|Clopidogrel - Placebo - Aspirin
3222072|NCT01108588|Experimental|Sequence 3|Placebo - Aspirin - Clopidogrel
3222073|NCT01108588|Experimental|Sequence 4|Aspirin - Placebo - Clopidogrel
3222074|NCT01108588|Experimental|Sequence 5|Clopidogrel - Aspirin - Placebo
3222075|NCT01108588|Experimental|Sequence 6|Placebo - Clopidogrel - Aspirin
3222076|NCT01108601|Other|Ringer's Lactate|Each patient will act as their own control with one ear receiving treatment, and the contralateral ear acting as control.
3222077|NCT01108614|Experimental|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
3222078|NCT01108614|No Intervention|Usual|Routine HIV prevention, including health education, counseling and testing, condom promotion.
3222079|NCT01108627|Active Comparator|corticosteroid + long acting beta agonist; steroids|
3222080|NCT01108627|Placebo Comparator|placebo + corticosteroid + long acting beta agonist; steroids|
3222081|NCT01108640||Elective surgical patients|
3222082|NCT01108640||Massive resuscitation patients|
3222083|NCT01108640||surgical patients on pressors|
3222084|NCT01108653|Other|Group 1: Usual care sick-leave management|
3222085|NCT01108653|Other|Group 2: Structuralised sick-leave program|
3222086|NCT01108679||Buprenorphine|Opioid-dependent drug users who are initiating buprenorphine treatment at the Albert Einstein College of Medicine Division of Substance Abuse (DoSA) or at Montefiore's Comprehensive Health Care Center (CHCC).
3222087|NCT01108692|Experimental|Active|Patients will be followed by telecardiology.
3222088|NCT01108692|Active Comparator|Control|Patients will be followed in the conventional manner. They will be equipped with telecardiology but data will not be used for patient surveillance.
3222089|NCT01108705|Experimental|Brivanib|
3222090|NCT01108705|Placebo Comparator|Placebo|
3222091|NCT01108744|Active Comparator|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
3222092|NCT01108744|Active Comparator|Mannitol|20% mannitol, dosed by patient's ideal body weight
3222093|NCT01108770||HED affected males|
3222094|NCT01108770||Unaffected male controls|
3222095|NCT01108783|Experimental|Bilastine|
3222096|NCT01108783|Active Comparator|Desloratadine|
3222097|NCT01108783|Placebo Comparator|Placebo|
3222098|NCT01108848||Berinert|Patients requiring treatment with Berinert®
3222099|NCT01108861|Experimental|Endoprosthesis|GORE VIABAHN® Endoprosthesis
3222100|NCT01108861|Active Comparator|Plain old balloon angioplasty|Plain old balloon angioplasty
3222101|NCT01108900||Patients with erectile dysfunction (ED)|100 ED patients in the study that were switched to sildenafil after a previous treatment with udenafil proved ineffective and/or was poorly tolerated
3222102|NCT01108913|Active Comparator|Bimosiamose|
3222103|NCT01108913|Placebo Comparator|Placebo|
3222104|NCT01108926|Experimental|All Subjects|All Subjects will receive the same intervention
3222105|NCT01108939|Experimental|Antimalarial treatment|
3222106|NCT01108939|Sham Comparator|Observation|
3222107|NCT01108965||Extraventricular Drainage|Includes hydrocephalus patients that are in recovery from shunt explanation.
3222108|NCT01108978|Placebo Comparator|Placebo|
3222109|NCT01108978|Active Comparator|Dehypotin|
3222110|NCT01108991|Active Comparator|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
3222111|NCT01108991|Experimental|Physical activity self-management|Cognitive behavioral counseling to increase lifestyle physical activity delivered over five months plus six weeks of COPD self-management education and usual care
3222112|NCT01109017||Norditropin®|
3222113|NCT01109030|Active Comparator|Pioglitazone+Citalopram+Chlordiazepoxide|Pioglitazone 15 mg Q12h will be given to the patients in active comparator group for 6 weeks. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.Chlordiazepoxide 10 mg/day for first three weeks
3222114|NCT01109030|Placebo Comparator|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks."
3222115|NCT01109082||Adolescents with idiopathic scoliosis|Adolescents with idiopathic scoliosis
3222116|NCT01109095|Experimental|HER.CAR CMV-specific CTLs|Subject will be assigned a dose level at study entry.
3222117|NCT01109121|Active Comparator|Allopurinol|Allopurinol
3222118|NCT01109121|Experimental|Combination 400|Tranilast and Allopurinol
3222119|NCT01109121|Experimental|Combination 600|Tranilast and Allopurinol
3222120|NCT01109134|Experimental|Tirofiban intracoronary bolus-only|Tirofiban bolus administered via intracoronary route at the time of primary PCI with no additional peri/postprocedural maintenance infusion
3222121|NCT01109134|Active Comparator|Tirofiban intravenous bolus+infusion|Tirofiban bolus administered intravenously before PCI, followed by periprocedural maintenance infusion
3222122|NCT01109160|Experimental|Azithromycin|Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).
3222123|NCT01109186||kidney-transplanted patients|
3222124|NCT01109199|Experimental|PolyGlycopleX (PGX)|
3222125|NCT01109199|Placebo Comparator|Rice Flour|
3222126|NCT01109212|Experimental|Bindarit|Patients treated with bindarit 2x300 mg bid plus irbesartan 2x150 mg once a day for 12 weeks
3222127|NCT01109212|Placebo Comparator|Placebo|patients treated with placebo 2 tablets bid plus irbesartan 2x150 mg once a day for 12 weeks
3222128|NCT01109225|Experimental|Myocardial infarction|"All patients. Patients hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days.~Intervention:~blood sample~MRI~echocardiography~urine sample~pulmonary echography~vascular check~renal echography"
3222129|NCT01109238||Process Feasibility|
3222130|NCT01109251|Other|Intervention group|Group of patients presenting a non controlled AHT or a masked AHT, benefiting from an optimised caring at visit 0.
3222131|NCT01109251|Other|Control group|Patients presenting a non controlled AHT(persistent AHT, AHT necessiting an adaptation of the treatment by the generalist) with information of the generalist on the necessity of obtaining the tensional control according the HAS recommendations
3222132|NCT01109264|Experimental|Bendamustine Hydrochloride|
3222133|NCT01109264|Active Comparator|Chlorambucil|
3222134|NCT01109277||Healthy term and late-preterm neonates|
3222135|NCT01109290||HED children|
3222136|NCT01109290||HED adults|
3222137|NCT01109290||Control children|
3222138|NCT01109290||Control adults|
3222139|NCT01109303|Active Comparator|TightRope System|Patients are operated on using the TightRope implant by Arthrex.
3222140|NCT01109303|Active Comparator|Screw fixation implant|Patients are operated on using the rigid four-cortices 3,5 mm screw fixation by Synthes.
3222141|NCT01109329|Experimental|HMPV challenge virus|Participants will receive the HMPV challenge virus.
3222142|NCT01109342||Vaccine Recipients|Participants received HIV preventive vaccine VRC-HIV ADV014-00-VP in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
3222143|NCT01109342||Placebo Recipients|Participants received a placebo vaccine in previous trials RV 156A/WRAIR 1078A or RV 172/WRAIR 1218.
3222144|NCT01109407||patients with MGUS or SMM|patients with either Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM)
3222145|NCT01109446|Experimental|Platelet Rich Plasma|
3222146|NCT01109446|Sham Comparator|Isotonoic Saline Solution|
3222147|NCT01109446|Active Comparator|Steroid (Triamcinolonacetonid)|
3222148|NCT01109459|Experimental|Pediatric vision screening|intervention
3222149|NCT01109459|Active Comparator|Pediatric blood pressure screening|control
3222150|NCT01109459|No Intervention|Primary care providers observation only|Observational
3222151|NCT01109472|Experimental|Patient Tailored Magazine|Patient responses from computer assisted telephone interviews will be used to develop a patient tailored educational magazine.
3222152|NCT01109485|Experimental|Olopatadine|Olopatadine hydrochloride ophthalmic solution 0.1%
3222153|NCT01109498|Experimental|Dose cohort 3 x 10^11gc/kg|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
3222154|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
3222155|NCT01109498|Experimental|Alipogene Tiparvovec, Human LPL [S447X], 1xE12 gc/kg|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections with immunosuppressants
3222156|NCT01109511|Active Comparator|oxycodone+naloxone|
3222157|NCT01109511|Active Comparator|Control|Oxycodone alone without naloxone
3222158|NCT01109537||RLS Diagnosis|
3222159|NCT01109537||Healthy Controls|
3222160|NCT01109550||with biliary candidiasis|Patients with positive fungal cultures of bile samples.
3222161|NCT01109550||without biliary candidiasis|Patients with negative fungal cultures of bile samples.
3222162|NCT01109563|Active Comparator|Computer Check-In Control|The Computer Check-In gives the participant contact with the research therapist, an assessment of marijuana use and the current impact of use, and a reminder about optional support sessions.
3222163|NCT01109563|Experimental|Marijuana Check-Ins|The MCI, a MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
3222164|NCT01109589||Children aged 0-2 yrs|
3222165|NCT01109589||Women aged 15-60 yrs|
3222166|NCT01109615|Experimental|Chemotherapy|
3222167|NCT01109628|Experimental|Protein drink|
3222168|NCT01109628|Placebo Comparator|Placebo drink|
3222169|NCT01109667||oral anticoagulant|Patients receiving and not receiving oral anticoagulant therapy.
3222170|NCT01109667||INR Level|Group I: Patients not receiving OAT, Group II: Patients under OAT and INR values in good therapeutic range and Group III: Patients under OAT and INR values over the therapeutic range.
3222171|NCT01109680|Experimental|14 C labelled Neramexane, capsule|
3222172|NCT01109693|Active Comparator|Continue sertraline|Continue sertraline at the dosage at 3 weeks
3222173|NCT01109693|Active Comparator|Augment with mirtazapine|Add mirtazapine to sertraline
3222174|NCT01109693|Active Comparator|Switch to mirtazapine|Stop sertraline and switch to mirtazapine
3222175|NCT01109706||patient treated by statines|
3222176|NCT01109706||patient without normolipidemic treatment|
3222177|NCT01109732|Experimental|Systematic physical training|Hospital-based SET two days per week for 12 weeks and one home-based exercise session every week. The group-based SET was based on The Norwegian Ullevaal Model, a modified cardiac rehabilitation program, and was slightly adjusted to be applicable to this patient group. Each SET session lasted for 60 minutes and consisted of warm-up exercises, three high-intensity, two moderate-intensity and cool-down exercises, including stretching. The exercises were generally simple aerobic dance movements and walking and involved the use of both upper and lower extremities. The warm-up exercises included large muscle movements that were repeated later in the higher-intensity intervals, but with greater force and a larger range of movement.
3222178|NCT01109732|No Intervention|Treatment as of today|The control group did not receive any additional follow-up regarding exercise at discharge beyond the general advice about the importance of exercise that is routinely provided at the hospital.
3222179|NCT01109745|No Intervention|usual primary care|Number of participating children: 85
3222180|NCT01109745|Experimental|PELICAN Primary care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 85 children
3222181|NCT01109745|No Intervention|usual secondary care|number of participating children: 50
3222182|NCT01109745|Experimental|PELICAN Secondary Care|Intervention arm: the integration of the output of the Pelican instrument (i.e., individualised HRQL information) in daily care to guide disease management for children with asthma treated in primary care. Number of participants: 50 children
3222183|NCT01109758|Experimental|1|
3222184|NCT01109771|Active Comparator|absorbable fixation left side|
3222185|NCT01109771|Active Comparator|absorbable fixation right side|
3222186|NCT01109784|Experimental|prasugrel|prasugrel per os 10mg/day
3222187|NCT01109784|Active Comparator|clopidogrel|clopidogrel per os 150mg/day
3222188|NCT01109797|Experimental|Transition Social Behavioral Intervention|
3222189|NCT01109797|Experimental|Diabetes Transition Clinic|
3222190|NCT01109810||IVIg and SCIg therapy|
3222191|NCT01109823|Active Comparator|patients with normal renal function|Patients with normal renal function hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
3222192|NCT01109823|Active Comparator|patients with hyperfiltration|Patients with hyperfiltration hospitalized at the Department Intensive Care Unit who are being treated with levofloxacin I.V. (500mg, twice daily) for an infection.
3222193|NCT01109836|Experimental|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
3222194|NCT01109836|No Intervention|Control|Standard stroke care
3222195|NCT01109862|Experimental|THA|Total hip arthroplasty
3222196|NCT01109862|Active Comparator|HAP|Bipolar Hemiarthroplasty
3222197|NCT01109888|Active Comparator|Cetrotide|
3222198|NCT01109901|Other|anterior submuscular transposition|it is kind of surgical method
3222199|NCT01109901|Other|Anterior subcutaneous transposition|it is kind of surgical method
3222200|NCT01109914|Experimental|Renal transplant recipients (MMF)|"Renal transplant recipients using prednisolone and mycophenolate mofetil (MMF) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
3222201|NCT01109914|Experimental|Renal transplant recipients (CNI)|"Renal transplant recipients using prednisolone and a calcineurin inhibitor (cyclosporine or tacrolimus) but no other immunosuppressive drug.~Intervention: vaccination with Dukoral"
3222202|NCT01109914|Experimental|Healthy volunteers|"Healthy volunteers (partners, brothers or sisters of the renal transplant recipients).~Intervention: vaccination with Dukoral"
3222203|NCT01109927|Experimental|Insulin treatment|Insulin given as soon as possible after diagnosis
3222204|NCT01109927|No Intervention|Conventional treatment|Diet, oral hypoglycemic agents and insulin first when clinically needed
3222205|NCT01109953||Breath-Hold PET/CT image|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both.
3222206|NCT01109966|Active Comparator|Amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
3222207|NCT01109966|Active Comparator|New amino acid based formula|"Patients will be randomised to one of two arms:~Group I: receiving a new amino-acid based formula Group II: receiving a standard AAF formula"
3222208|NCT01110018|Active Comparator|Period 1|20μg intravenous infusion administered over 30 minutes
3222209|NCT01110018|Active Comparator|Period 2|1000μg Oral dose
3222210|NCT01110018|Active Comparator|Period 3|50μg Intravenous infusion administered over 30 minutes
3222211|NCT01110018|Active Comparator|Period 4|1000μg Inhaled dose
3222212|NCT01110018|Active Comparator|Period 5|100μg Intravenous infusion administered over 30 minutes
3222213|NCT01110031|Experimental|Treatment|Six months treatmet with ofatumumab will be given to subjects with chronic lymphocytic leukemia.
3222214|NCT01110044|Experimental|Group A|Subjects will be administered 251154 vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
3222215|NCT01110044|Active Comparator|Group B|Subjects will be administered no vaccine at birth, Infanrix hexa™ at 2, 4, 6 and 12-18 months of age, Synflorix™ at 2, 4, 6 and 12-18 months of age, Rotarix™ at 2 and 4 months of age.
3222216|NCT01110057|Experimental|Active|GW856553
3222217|NCT01110057|Placebo Comparator|Placebo|Placebo
3222218|NCT01110070|Experimental|ChonDux plus microfracture|
3222219|NCT01110070|Active Comparator|Microfracture|
3222220|NCT01110083|Experimental|Arm 1|
3222221|NCT01110096|Experimental|Group A - family camp|Obese families participate in a two week camp with two years follow-up.
3222222|NCT01110096|Other|Group B - family lifestyle school|Families participate in a four day practical course about lifestyle.
3222223|NCT01110109||Continuous Suctioning|Anesthesia staff will suction secretions continuously at 20 mmHg with a safety stop of 5 seconds every 30 minutes.
3222224|NCT01110109||Intermittent Suctioning|Anesthesia staff will suction secretions intermittently using an intermittent suction regulator. The regulator will be set to suction at 100-150 mmHg. The regulator has a preset cycle of intermittent suctioning for 15 seconds with an 8 second pause.
3222225|NCT01110148|Experimental|Video-based informed consent|patients receiving informed consent through video format
3222226|NCT01110148|Active Comparator|traditional informed consent|patients receiving traditional informed consent from the physicians.
3222227|NCT01110161||Visceral fat mass|The study population will include Chinese adult men and women, over the age of 18 years. All subjects will be recruited at Fudan University. Subjects will represent a wide range of BMI values (18.5 - 40 kg/m2).
3222228|NCT01110213|Experimental|Physical activity|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging leisure time physical activity. Content was based on goal setting theory and decisional balance.
3222229|NCT01110213|Experimental|Fruit and vegetable|Participants received individual tailored telephone counseling and group-tailored newsletters encouraging fruit and vegetable intake. Content was based on goal setting theory and decisional balance.
3222230|NCT01110226|Experimental|Period 1: KML001 15mg plus Cisplatin 75mg/m2|KML001 15 mg orally daily days 1-14 with cisplatin IV on day1
3222231|NCT01110226|Experimental|Period 2: KML001 17.5mg plus Cisplatin 75mg/m2|KML001 17.5 mg orally daily days 1-14 with cisplatin IV on day1
3222232|NCT01110226|Experimental|Period 3: KML001 20mg plus Cisplatin 75mg/m2|KML001 20 mg orally daily days 1-14 with cisplatin IV on day1
3222233|NCT01110265|Placebo Comparator|placebo training|
3222234|NCT01110265|Experimental|attention training|
3222235|NCT01110278||Urge Incontinent Women|Women with documented urge/urgency incontinence with established care at the Oregon Health and Science University.
3222236|NCT01110278||Control Women|Women with no urge/urgency incontinence with established care at the Oregon Health and Science University.
3222237|NCT01110291||Breast cancer|Twenty patients with verified high risk breast cancer will be included in the study.
3222238|NCT01110304|Active Comparator|Conservative treatment|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed.
3222239|NCT01110304|Active Comparator|Surgical treatment|Patients will undergo surgery to treat their AC joint dislocation.
3222240|NCT01110317|Experimental|001|paliperidone palmitate 100 mg Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1 8 36 and 64.
3222241|NCT01110343|Active Comparator|mindfulness intervention group|Mindfulness intervention is a formatted curriculum based on Mindfulness based stress reduction techniques which have proven effective in reducing stress related to pain, everyday living and medical and psychiatric disorders.
3222242|NCT01110343|Active Comparator|conventional parent support group|a 6 week behavioral program, with weekly 1.5 hour sessions with a trained parent mentor, 3 monthly booster sessions and follow-up.
3222243|NCT01110356|Experimental|Ferinject|
3222244|NCT01110356|Placebo Comparator|Saline|
3222245|NCT01110369|Experimental|Resistance exercise training and protein drink|
3222246|NCT01110369|Placebo Comparator|Resistance exercise training and placebo drink|
3222247|NCT01110447|Experimental|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
3222248|NCT01110447|Placebo Comparator|Placebo|Placebo sachets contain corn starch
3222249|NCT01110473|Experimental|Monotherapy, once daily|
3222250|NCT01110473|Experimental|Monotherapy, twice daily|
3222251|NCT01110473|Experimental|Combination with Azacitidine|
3222252|NCT01110473|Experimental|IV monotherapy, once daily|
3222253|NCT01110486|Experimental|Monotherapy, once daily|
3222254|NCT01110486|Experimental|Combination with carboplatin|
3222255|NCT01110486|Experimental|Combination with docetaxel|
3222256|NCT01110486|Experimental|Monotherapy, twice daily|
3222257|NCT01110486|Experimental|IV Monotherapy, once daily|
3222258|NCT01110512|Experimental|Flavonid|
3222259|NCT01110512|Active Comparator|Daflon|
3222260|NCT01110525|Experimental|1|AZD1981 + Oral contraceptive
3222261|NCT01110525|Placebo Comparator|2|Placebo + Oral contraceptive
3222262|NCT01110551|Experimental|Group 2: low dose ; ID|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo intradermally on Days 0 and 90.
3222263|NCT01110551|Experimental|Group 1: low dose; SC|D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, D4: 2 x 10^5 or placebo subcutaneously on Days 0 and 90.
3222264|NCT01110551|Experimental|Group 4: high dose; ID|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo intradermally on Days 0 and 90.
3222265|NCT01110551|Experimental|Group 3: high dose; SC|D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, D4: 3 x 10^5 or placebo subcutaneously on Days 0 and 90.
3222266|NCT01110564||1|COPD patients
3222267|NCT01110577||Traveling cohort|Overweight patients with or without type 2 diabetes or pre-diabetes
3222268|NCT01110590|Experimental|Arm 1|
3222269|NCT01110590|Experimental|Arm 2|
3222270|NCT01110590|Experimental|Arm 3|
3222271|NCT01110590|Placebo Comparator|Arm 4|
3222272|NCT01110603|Experimental|MK-4827 + carboplatin|
3222273|NCT01110603|Experimental|MK-4827 + carboplatin/paclitaxel|
3222274|NCT01110603|Experimental|MK-4827 + carboplatin/liposomal doxorubicin|
3222275|NCT01110616|Experimental|Sequence 1|MK3134-Lorazepam-Placebo-MK3134-Lorazepam
3222276|NCT01110616|Experimental|Sequence 2|MK3134-Lorazepam-Placebo-Lorazepam-MK3134
3222277|NCT01110616|Experimental|Sequence 3|MK3134-Placebo-Lorazepam-MK3134-Lorazepam
3222278|NCT01110616|Experimental|Sequence 4|MK3134-Placebo-Lorazepam-Lorazepam-MK3134
3222279|NCT01110616|Experimental|Sequence 5|Lorazepam-Placebo-MK3134-MK3134-Lorazepam
3222280|NCT01110616|Experimental|Sequence 6|Lorazepam-Placebo-MK3134-Lorazepam-MK3134
3222281|NCT01110616|Experimental|Sequence 7|Lorazepam-MK3134-Placebo-MK3134-Lorazepam
3222282|NCT01110616|Experimental|Sequence 8|Lorazepam-MK3134-Placebo-Lorazepam-MK3134
3222283|NCT01110616|Experimental|Sequence 9|Placebo-MK3134-Lorazepam-MK3134-Lorazepam
3222284|NCT01110616|Experimental|Sequence 10|Placebo-MK3134-Lorazepam-Lorazepam-MK3134
3222285|NCT01110616|Experimental|Sequence 11|Placebo-Lorazepam-MK3134-MK3134-Lorazepam
3222286|NCT01110616|Experimental|Sequence 12|Placebo-Lorazepam-MK3134-Lorazepam-MK3134
3222287|NCT01110629|Experimental|Arm 1|
3222288|NCT01110629|Placebo Comparator|Arm 2|
3222289|NCT01110642|Experimental|Lovastatin solution|All patients will receive lovastatin solution
3222290|NCT01110655|Experimental|Intravenous hypertonic saline|
3222291|NCT01110655|Experimental|Oral hypertonic saline|
3222292|NCT01110668|Experimental|Nilotinib|
3222293|NCT01110720|Experimental|Davunetide 30 mg BID|
3222294|NCT01110720|Placebo Comparator|Placebo|
3222295|NCT01110746|Experimental|Formulation A|Single Injection
3222296|NCT01110746|Experimental|Formulation B|Single Injection
3222297|NCT01110759||Under Local Infiltration|
3222298|NCT01110759||Under Peripheral Nerve Block|
3222299|NCT01110772|Experimental|2-octyl cyanoacrylate|As recommended, povidone iodine is used for skin antisepsis. After drying, a layer of cyanoacrylate is applied on the skin surface with the purpose of immobilizing skin bacteria.
3222300|NCT01110772|Active Comparator|iodine povacrylex in isopropyl alcohol|Iodine povacrylex in isopropyl alcohol (Duraprep 3M) This is considered a standard of care in our hospital as many other institutions. It's efficacy and safety have been demonstrated.
3222301|NCT01110811|Active Comparator|TIF procedure|Transoral Incisionless Fundoplication (TIF)
3222302|NCT01110811|Sham Comparator|Sham procedure|The intervention on the Sham procedure consisted of an upper gastrointestinal endoscopy, or EGD.(esophagogastricduodenoscopy).
3222303|NCT01110824|Experimental|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
3222304|NCT01110824|No Intervention|Control|Control arm without intervention
3222305|NCT01110837|Active Comparator|Allergen|
3222306|NCT01110837|Placebo Comparator|Placebo|
3222307|NCT01110850||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3222308|NCT01110863||Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia
3222309|NCT01110889|Experimental|AGO178C 0.5 mg /day|
3222310|NCT01110889|Experimental|AGO178C 1 mg / day|
3222311|NCT01110889|Placebo Comparator|Placebo|
3222312|NCT01110902|Experimental|AGO178C 0.5 mg /day|
3222313|NCT01110902|Experimental|AGO178C 1 mg / day|
3222314|NCT01110902|Placebo Comparator|Placebo|
3222315|NCT01110928||Norditropin®|
3222316|NCT01110941|Experimental|SOL|single arm
3222317|NCT01110954|Active Comparator|PD L 506 2nd dose|Different dosage
3222318|NCT01110954|Experimental|PD L 506|
3222319|NCT01110980|Experimental|Swallowing therapy|Swallowing therapy in combination with individual dietary counselling
3222320|NCT01110980|Active Comparator|Individual dietary counselling|Swallowing therapy only on indication. (usual care)
3222321|NCT01111019|Experimental|r-hGH (Saizen®)|
3222322|NCT01111032||Treadmill test|
3222323|NCT01111045|Active Comparator|Arm 1|0.03 mg/ml BMP-7, single intraarticular knee injection
3222324|NCT01111045|Active Comparator|Arm 2|0.1 mg/ml BMP-7, single intraarticular knee injection
3222325|NCT01111045|Active Comparator|Arm 3|0.3 mg/ml BMP-7, single intraarticular knee injection
3222326|NCT01111045|Placebo Comparator|Arm 4|1 ml placebo, single intraarticular knee injection (control)
3222327|NCT01111071||STEMI|patients with discharge diagnosis of ST elevation myocardial infarction
3222328|NCT01111071||nSTEMI|patients with discharge diagnosis of non ST elevation myocardial infarction
3222329|NCT01111071||unstable angina|patients with discharge diagnosis of unstable angina
3222330|NCT01111097|Active Comparator|Cohort 1|Subjects are given a dose of Dichloroacetate 4mg/kg twice a day for 30 days
3222331|NCT01111097|Active Comparator|Cohort 2|Subjects are given a dose of Dichloroacetate 12.5mg/kg twice a day for 30 days
3222332|NCT01111136|Experimental|stress intervention|Stress intervention.
3222333|NCT01111188|Experimental|all subjects|Subjects will receive PD 0332991 plus bortezomib. The dose of each agent will be dependent on the time point the subject enters the trial.
3222334|NCT01111201||questionnaires|There will be four versions of the questionnaire, each slightly modified to be more specific toward the treatment paradigms in the respective target patient population (Breast Cancer/ Lymphoma/Autologous Bone Marrow Transplant/ Allogeneic Bone Marrow Transplant). All questionnaire versions will consist of seven sections.
3222335|NCT01111214||group 1|Hospitalized children ≤14 years of age with invasive pneumococcal disease
3222336|NCT01111253|Active Comparator|Conservative strategy with antibiotics|"Hospital admission~Intravenous fluids and at least 48 hours of intravenous antibiotics and subsequently switch to oral antibiotics if tolerated (otherwise continuation i.v.) to complete a full 10-day treatment duration~Adequate pain relief~Oral intake as tolerated~Daily monitoring"
3222337|NCT01111253|No Intervention|Liberal strategy without antibiotics|"Admission only if discharge criteria are not met~No initial antibiotics~Intravenous fluids only for those not tolerating oral liquids~Adequate pain relief~Oral intake as tolerated~Daily monitoring when admitted to the hospital~Self-monitoring at home (Patient diary with temperature and VAS pain score until full recovery)"
3222338|NCT01111279|Placebo Comparator|Placebo|
3222339|NCT01111279|Experimental|gpASIT+TM|
3222340|NCT01111279|Experimental|gpASIT+TM/adjuvant|
3222341|NCT01111344|Experimental|Glizigen + Viusid|
3222342|NCT01111344|Placebo Comparator|Placebo|
3222343|NCT01111396||Patient with ALL under chemotherapy|This group consists of patients with initial diagnosis of acute lymphatic leukemia (ALL), who are enrolled into the GMALL 2003 chemotherapy study. There is no change of the initial GMALL 2003 treatment protocol for the present study.
3222344|NCT01111409|Experimental|VFIX|
3222345|NCT01111422|No Intervention|Control|Age and sex matched peritoneal dialysis patients
3222346|NCT01111422|Experimental|N-acetylcysteine|N-acetylcysteine in stable peritoneal dialysis patients
3222347|NCT01111435||Individuals with Multiple Sclerosis|
3222348|NCT01111448|Experimental|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle
3222349|NCT01111487|Active Comparator|Group I|This group will use a pressure level of 10 cmH2O.
3222350|NCT01111487|Active Comparator|Group II|This group will use a pressure level of 15 cmH2O.
3222351|NCT01111500|Active Comparator|external rotation immobilization|Patient will wear an external rotation brace to immobilize the injured arm.
3222352|NCT01111500|Active Comparator|internal rotation immobilization|Patient will wear an internal rotation brace to immobilize the injured arm.
3222353|NCT01111513|Active Comparator|Continuous femoral block|Patients receive a continuous femoral block for 48 hours and they have patient controlled analgesics.
3222354|NCT01111513|Active Comparator|Single dose femoral block|Patients receive a single dose femoral block and have patient controlled analgesics.
3222355|NCT01111513|Active Comparator|Patient controlled analgesics|Patients do not receive a femoral block. They only have patient controlled analgesics.
3222359|NCT01111578||New enteral feeding tube|
3222360|NCT01111591|No Intervention|2. Bile duct cancer - control|Bile duct cancer patients do not administration of COX inhibitor
3222361|NCT01111591|Experimental|3. Pancreas cancer - experimental|Pancreas cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
3222362|NCT01111591|No Intervention|4. Pancreas cancer - control|Pancreas cancer patients do not administration of COX inhibitor
3222363|NCT01111591|Experimental|Bile duct cancer - experimental|Bile duct cancer patients take a COX2 inhibitor 200mg every 12hours for 6 months
3222364|NCT01111617|Experimental|Real-Time fMRI|Real-Time fMRI
3222365|NCT01111630|Experimental|once weekly|
3222366|NCT01111630|Active Comparator|three times weekly|
3222367|NCT01111643||I|
3222368|NCT01111656|Active Comparator|1|Interferon beta-1b 250ug subcutaneously every other day
3222369|NCT01111656|Experimental|2|Interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
3222370|NCT01111669|Experimental|Tranexamic Acid|Patients in the tranexamic acid (TA) group will receive a bolus of TA, prepared according to patient weight (15mg / kg loading dose). The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation for the duration of the operation.
3222371|NCT01111669|Placebo Comparator|Normal Saline|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution as the intervention group. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of normal saline for the duration of the operation.
3222372|NCT01111682|Active Comparator|Mannitol|0.9% normal saline infusion and boluses of mannitol
3222373|NCT01111682|Active Comparator|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
3222374|NCT01111695|Experimental|Honey and ionic silver dressing|
3222375|NCT01111708|Experimental|Close Rectal-Ileo Pouch Anal Anastomosis|
3222376|NCT01111708|Active Comparator|Conventional Ileo Pouch Anal Anastomosis|
3222377|NCT01111708|Active Comparator|Ileo Neo Rectal Anastomosis|
3222378|NCT01111721|Experimental|Project POWER Intervention Group|Intervention group participants will attend the Project POWER intervention sessions, complete a pre-intervention assessment and participate in 3, 6, and 12 month follow-up interviews when they will be asked to provide urine specimens for STI testing. The intervention consists of eight bi-weekly, 1.5 hour sessions. Intervention group participants will also attend one booster group session four weeks after the intervention before being released. Intervention participants will receive booster phone calls from a nurse-interventionist at 2, 6, and 10 weeks after release from prison. Booster phone calls will reinforce intervention content and support participant efforts to reduce risky sex behaviors and make healthy choices.
3222379|NCT01111721|Active Comparator|NC DOC Standard of Care for STIs|Control group participants will receive the North Carolina Department of Correction standard of care for Sexually Transmitted Infections, complete one interview in prison and participate in 3, 6, and 12 month follow up interviews when they will be asked to provide urine specimens for STI testing.
3222380|NCT01111734|Experimental|Treatment Group|The study consists of eight weeks of open label N-Acetylcysteine. All eligible study subjects will be treated with 600mg of N-Acetylcysteine twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks. weeks. Subjects will be seen every two weeks during the 8-week study. Efficacy and safety assessments will be performed at each visit.
3222381|NCT01111734|Experimental|Control|40 healthy age-matched peers with undergo the same baseline testing as the NAC subjects as well as baseline fMRI. They will not engage in any follow up visits.
3222382|NCT01111747|Experimental|PRP|In this group PRP will be used in the patellar tendon donor site.
3222383|NCT01111747|Sham Comparator|Control|In this group PRP will not be aded to the patellar tendon donor site
3222384|NCT01111773|Experimental|Heated Lidocaine and Tetracaine Patch|
3222385|NCT01111799|Experimental|Clomiphene citrate + IUI + endometrial biopsy|Clomiphene citrate + IUI + endometrial biopsy
3222386|NCT01111799|No Intervention|Clomiphene citrate + IUI|
3222387|NCT01111799|Experimental|gonadotrophines + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
3222388|NCT01111799|No Intervention|gonadotrophines + IUI|
3222389|NCT01111799|Experimental|natural cycle + IUI + endometrail biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
3222390|NCT01111799|No Intervention|natural cycle + IUI|
3222391|NCT01111812||weight measurements|This study include 1000 weight measurements of children and adolescence, boys and girls, ages 5-18, that taking pat in a multi-disciplinary intervention program for treatment of the overweight and obese in Meir medical center.
3222392|NCT01111864|Experimental|MixMe powder (iron & micronutrients)|
3222393|NCT01111864|Placebo Comparator|MixMe powder (micronutrients, no iron)|
3222394|NCT01111864|Experimental|Sprinkles (iron and micronutrients)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Iron 12.5 mg; Zinc 5 mg
3222395|NCT01111864|Placebo Comparator|Sprinkles (micronutrients, no iron)|Vitamin A 300 µg; Vitamin C 30 mg; Folic Acid 160 µg; Zinc 5 mg
3222396|NCT01111890|Experimental|Azarga|Azarga (brinzolamide 1% / timolol 0.5%)
3222397|NCT01111890|Active Comparator|Cosopt|Cosopt (dorzolamide 2% / timolol 0.5%)
3222398|NCT01111903|Experimental|lenalidomide|Phase II: lenalidomide 20 mg/day in continuous regimen. Phase I: lenalidomide 25 mg/day 21 days/28 + carboplatin AUC 5 + caelyx 30 mg/m2
3222399|NCT01111929|Active Comparator|Counseling for LAM|"Will receive proper postpartum counseling for LAM by trained research nurse. This is in addition to, adequate contraceptive counseling including information about LAM and its prerequisites.~Women that choose to use LAM will be advised to return to our contraception outpatient clinic to have a long term method of contraception as soon as any of the requirements of LAM expires."
3222400|NCT01111929|Experimental|Counseling for LAM+ LNG-EC|LAM counseling and contraceptive counseling +two 0.75 mg Levonorgestrel EC pills
3222401|NCT01111942|Active Comparator|radiation and weekly carboplatin|
3222402|NCT01111942|Other|conservation surgery|
3222403|NCT01111955|Active Comparator|BMS-823778 (2 mg)|+ metformin
3222404|NCT01111955|Active Comparator|BMS-823778 (10 mg)|+ metformin
3222405|NCT01111955|Active Comparator|BMS-823778 (20 mg)|+ metformin
3222406|NCT01111955|Placebo Comparator|Placebo|+ metformin
3222407|NCT01111968|Experimental|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
3222408|NCT01111968|Experimental|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
3222409|NCT01111968|Experimental|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
3222410|NCT01111968|Experimental|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
3222411|NCT01111968|Experimental|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
3222412|NCT01111968|Experimental|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
3222413|NCT01111968|Experimental|pandemic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
3222414|NCT01111968|Experimental|pandemic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
3222415|NCT01111968|Experimental|pandemic vaccine 13|15µg of A/H1N1 with no adjuvant
3222416|NCT01111968|Placebo Comparator|placebo group 14|placebo
3222417|NCT01112007||prehypertension|Subjects with prehypertension, that is, individuals with systolic blood pressure in the range of 120-139 mmHg or diastolic BP between 80-89 mmHg.
3222418|NCT01112020|Experimental|CHG Catheter Dressing Patch|
3222419|NCT01112020|Active Comparator|Biopatch|Biopatch Protective Disk with CHG
3222420|NCT01112020|Active Comparator|Tegaderm CHG|Tegaderm CHG IV Securement Dressing
3222421|NCT01112033||chronic HCV infection|The study was performed on therapeutically naïve patients with chronic HCV infection. Patients with positivity of anti-HCV antibodies, and detectable HCV RNA in serum for at least 6 months, were included in the study.
3222422|NCT01112046|Experimental|Endoscopic submucosal dissection|
3222423|NCT01112046|Active Comparator|Laparoscopic resection|
3222424|NCT01112072|Active Comparator|Intacs combined with CXL|Intacs placement followed by collagen crosslinking with UV light and riboflavin
3222425|NCT01112072|Active Comparator|Intacs followed by CXL|Intacs placement, to be followed by corneal collagen crosslinking with UV light and riboflavin 3 months later
3222426|NCT01112085|Experimental|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
3222427|NCT01112085|Experimental|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
3222428|NCT01112098|Experimental|Educational Pamphlet and letter|Letter invites patient to self-schedule a DXA; educational pamphlet includes information about DXA scans
3222429|NCT01112111||75 PCOS Patients - step up regime|Group A will be comprised of 75 patients and these will receive a low dose step stimulation regime
3222430|NCT01112111||75 PCOS patients -step down regime|Group B will be comprised of 75 patients who will receive a step down regime of stimulation
3222431|NCT01112111||75 PCOS patients - sequential regime|Group C will be comprised of 75 patients who will be treated using a sequential stimulation regime
3222432|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (600 mg, bolus)|
3222433|NCT01112137|Experimental|Hypertensive individuals: clopidogrel (75 mg daily)|
3222434|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (600 mg, bolus)|
3222435|NCT01112137|Active Comparator|Normotensive individuals: clopidogrel (75 mg, daily)|
3222436|NCT01112150|Active Comparator|Pumping group|Patients in this arm will get a pumping session 2-3 times a day .
3222437|NCT01112150|Active Comparator|No pumping|These patients will not receive pumping but only classical treatment clinically indicated (diuretics, oxygen, Digoxin, Nitrates, ACE inhibitors etc, as necessary)
3222438|NCT01112163|Experimental|Enhanced external counter pulsation|One session of enhanced external counter pulsation (60 minutes)
3222439|NCT01112189|Experimental|Patients with stem cells|Patients that receive the stem cells treatment
3222440|NCT01112189|Active Comparator|Compressed sleeve treatment|Patients that will receive the compressed sleeve treatment
3222441|NCT01112215|Active Comparator|azathioprine|
3222442|NCT01112215|Active Comparator|Enteric-coated Mycophenolate Sodium|
3222443|NCT01112254|Experimental|MRI±biopsy|a MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm from the initial lesion), not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI ± biopsy results.
3222444|NCT01112254|No Intervention|Standard care|The patients will be operated without additional exams
3222445|NCT01112280|Experimental|cap-assisted chromoendoscopy|To the tip of the colonoscope, transparent cap is fitted and applied. In addition, panchromoendoscopy using indigocarmine solution is preformed in this group.
3222446|NCT01112280|No Intervention|Standard colonoscopy|Neither transparent cap nor chromoendoscopy is applied in this group and standard colonoscopy is performed.
3222447|NCT01112306|Experimental|1|ACT-293987, twice daily
3222448|NCT01112319|Experimental|Elf_care|The trial group will receive with Elf_Care unit (Hot-Cold & Electrotherapy) during physiotherapy treatment ( 28 minutes twice a week)
3222449|NCT01112319|Active Comparator|control group|The control group will receive before physiotherapy COLD HOT or Electrotherapy treatment depends on the patient and physiotherapy prefer.
3222450|NCT01112371|Experimental|Contractubex|
3222451|NCT01112371|No Intervention|Non treatment|
3222452|NCT01112384|Experimental|SB939|
3222453|NCT01112397|Experimental|1|AZD1480 until Maximum Tolerated Dose (MTD) is reached
3222454|NCT01112397|Experimental|2|AZD1480 dose expansion of MTD
3222455|NCT01112423|Experimental|BMS-823778 (2 mg)|
3222456|NCT01112423|Experimental|BMS-823778 (10 mg)|
3222457|NCT01112423|Experimental|BMS-823778 (20 mg)|
3222458|NCT01112423|Placebo Comparator|Placebo|
3222459|NCT01112436|Placebo Comparator|control group (group C)|control group will receive no medication preoperatively and during operation
3222460|NCT01112436|Active Comparator|periarticular injecion group (group I)|patients in Group I will receive oral oxycodone SR 10 mg and celecoxib 200 mg 1 hour preoperatively with sips of water, and receive periarticular injection of combination of ropivacaine 15 mg, morphine 10 mg, ketorolac 30 mg epinephrine 0.3 mg and cefmetazole 1000mg during operation.
3222461|NCT01112449|Experimental|Low dose selenized-yeast|200 µg/day of selenized-yeast (SY)
3222462|NCT01112449|Experimental|selenomethionine|The second group will receive 200 µg/day of selenomethionine (SM)
3222463|NCT01112449|Placebo Comparator|Placebo|no active medication.
3222464|NCT01112449|Experimental|High dose selenized-yeast|The fourth group will receive 285 µg/day of selenized-yeast (SY).
3222465|NCT01112462|Experimental|Tablet|Paracetamol 500 mg/Phenylephrine 5 mg tablet
3222466|NCT01112462|Active Comparator|Sachet|Paracetamol 1000 mg/Phenylephrine 10 mg sachet
3222467|NCT01112488|No Intervention|Control|usual care
3222468|NCT01112488|Experimental|multidisciplinary intervention|Patient engagement Programme
3222469|NCT01112527|Experimental|Arm A|Patients with Glioblastoma that has returned or grown after chemotherapy or radiation treatment and who will be having a standard operation to remove the tumor.
3222470|NCT01112527|Experimental|Arm B|Participants with glioblastoma at first recurrence who are not surgical candidates and who have not had prior anti-VEGF therapy.
3222471|NCT01112527|Experimental|Arm C|Participants with glioblastoma who are not surgical candidates and who are at first recurrence from a therapeutic regimen containing bevacizumab.
3222472|NCT01112540|Placebo Comparator|Placebo Group|
3222473|NCT01112540|Experimental|Morphine|
3222474|NCT01112553||Treximet|All migraine subjects will receive Treximet during a migraine episode at Visit 2.
3222475|NCT01112605||otherwise healthy persons|healthy persons, no major trauma or surgery of ankle or calves, no bone or muscle disease, age 18-60
3222476|NCT01112631||Stage II patients post surgery|Stage II patients treated with surgery alone
3222477|NCT01112631||Stage III patients post surgery|Stage III patients treated with surgery and PORT
3222478|NCT01112644|Experimental|OXN PR|Different daily doses; intake every 12 hours
3222479|NCT01112644|Placebo Comparator|PLA|Different daily doses; intake every 12 hours
3222480|NCT01112709|Experimental|SCT|This arm is a long-term, Social Cognitive Theory (SCT)-based intervention, emphasizing self-regulation and other SCT strategies to optimize training, with faded contact.
3222481|NCT01112709|Active Comparator|Control|"This arm will be the control condition; a Standard intervention with minimal contact."
3222482|NCT01112722|Active Comparator|Apitox, purified honeybee toxin, injections|active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'
3222483|NCT01112722|Placebo Comparator|histamine injection|the histamine injection produces a similar local effect of pain and erythema as the active drug
3222484|NCT01112761|Experimental|Healthy Subjects|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
3222485|NCT01112761|Experimental|Athletes with history of concussion|Each subject will undergo each of the three conditions (active anodal tDCS, cathodal tDCS and sham tDCS), but the order in which they do so will be randomized.
3222486|NCT01112774|Experimental|tDCS/Spinal cord injury|Subjects will be randomized to receive 10 sessions of either active or sham tDCS. Stimulation will be given on consecutive days (Monday- Friday) at 2 mA over the primary motor cortex area.
3222487|NCT01112774|Experimental|tDCS/Healthy subjects|Subjects will receive 2 sessions of stimulation: one active and one sham tDCS on two separate visits. The order in which they receive the stimulation will be randomized. Stimulation parameters will be at 2 mA for a total of 20 minutes.
3222488|NCT01112787|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene Foam 0.1%,
3222489|NCT01112787|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam.
3222490|NCT01112787|Active Comparator|Sodium Laural Sulfate|Subjects will be exposed to patches containing Sodium Laural Sulfate.
3222491|NCT01112787|Placebo Comparator|Distilled Water|Subjects will be exposed to patches containing Distilled Water.
3222492|NCT01112800||Participants|Previously untreated patients referred to St. Jude Children's Research Hospital (SJCRH) between the ages of 0 and 21 years with a diagnosis of osteosarcoma, ESFT, rhabdomyosarcoma and intermediate and high-risk non-rhabdomyosarcoma soft tissue sarcomas whose planned treatment includes administration of a cumulative anthracycline dose ≥ 375 mg/m2.
3222493|NCT01112813|Experimental|Lithium|Lithium Carbonate, 0.4-0.8 mmol/L for 2 months
3222494|NCT01112826|Experimental|Capecitabine|Capecitabine 650 mg/m2 bid
3222495|NCT01112826|No Intervention|Standard treatment|Treatment according to National Comprehensive Cancer Network (NCCN) guideline.
3222496|NCT01112839|Active Comparator|Less Intensive Group|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
3222497|NCT01112839|Experimental|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
3222498|NCT01112852|Active Comparator|EVL + vasoconstrictor|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
3222499|NCT01112852|Experimental|EVL + PPI|Pantoloc 40 mg intravenously per day was instituted on enrollment and continued for 5
3222500|NCT01112878|Placebo Comparator|Sugar Pill|"Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3222501|NCT01112878|Active Comparator|Clonidine|"Dosage: 0.2 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3222502|NCT01112878|Active Comparator|Gabapentin|"Dosage: 600 mg~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
3222503|NCT01112891|Experimental|1|
3222504|NCT01112891|Experimental|2|
3222505|NCT01112891|Experimental|3|
3222506|NCT01112943|Experimental|Acupuncture|Acupuncture on predefined points once a week for 20 minutes over the seven week pulmonary rehabilitation course
3222507|NCT01112943|Active Comparator|Pulmonary Rehabilitation|A seven week exercise and educational class run twice a week using international guidelines.
3222508|NCT01112943|No Intervention|Control|Three assessments over the same time frame of three months but without intervention
3222509|NCT01112956||STD clinic patients|Patients attending sexually transmitted Disease clinics. If the initial testing result reported to the patient is confirmed by the Western Blot test, no follow-up specimens will be collected. If the initial testing result reported to the patient is different from the result by the Western Blot test, patients will be asked to provide a follow-up specimen 3-4 months after initial testing.
3222510|NCT01112956||Pregnant women|Women recruited from prenatal clinic. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
3222511|NCT01112956||Men who have Sex with men (MSM)|Men recruited from a clinic for MSM with high risk for HIV infection. A follow-up visit may or may not needed depending on results from the initial test and Western blot test.
3222512|NCT01112969|Experimental|Internet-based supportive coaching OSCAR|Arm 1: Internet-based supportive coaching OSCAR
3222513|NCT01112969|Other|Waiting list control group (treatment as usual, TAU)|
3222514|NCT01112995|Experimental|Probiotic|subjects will be given a pill formulation of a probiotic Lactobacillus rhamnosus to be taken once a day.
3222515|NCT01112995|Placebo Comparator|Sugar pill|placebo identical to the active product will be given
3222516|NCT01113021|Experimental|LLLT and Physical Strength training in Humans|
3222517|NCT01113034|Active Comparator|DAS181 Dry Powder 10 mg qd x 3 days|
3222518|NCT01113034|Placebo Comparator|Lactose Placebo|
3222519|NCT01113047|Experimental|Non responder Olmesartan/Amlodipine|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
3222520|NCT01113060||CAD patients|Representative sample of coronary artery disease patients receiving aspirin therapy for secondary prevention
3222521|NCT01113073|Experimental|Elective open heart surgery|Patients who had undergone elective open heart surgery
3222522|NCT01113086|Experimental|Left active anodal DLPFC|We will place the anodal electrode on the left dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
3222523|NCT01113086|Experimental|Right active anodal DLPFC|We will place the anodal electrode on the right dorsolateral prefrontal cortex. Stimulation will be given at 2 mA for a total of 20 mins for 10 consecutive sessions (Monday through Friday).
3222524|NCT01113086|Placebo Comparator|Sham tDCS|Sham tDCS: For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds.
3222525|NCT01113086|Other|Open-Label Arm|In addition to this study we will have an open label arm in which subjects who received sham stimulation through the course of the study will have the opportunity to receive active stimulation free of charge. The same parameters and identical procedures as is done in the original study will be used. Data will be collected as an open label, which will therefore provide additional information. Data obtained from this open label portion of the study will be kept separate.
3222526|NCT01113099|Experimental|Academic detailing of physicians|
3222527|NCT01113099|No Intervention|Usual care|
3222528|NCT01113112||Biobehavioral factors|Those with biobehavioral factors that contribute to a permissive local environment for macrophage-tumor interactions that enhance tumor growth in ovarian cancer
3222529|NCT01113125|Experimental|Fucicort|
3222530|NCT01113125|Placebo Comparator|Fucidin|
3222531|NCT01113138|No Intervention|Baseline|
3222532|NCT01113138|Active Comparator|Mablet|
3222533|NCT01113138|Active Comparator|Magnesium sulfate|
3222534|NCT01113151|No Intervention|Washout|
3222535|NCT01113151|Active Comparator|Mablet|
3222536|NCT01113151|Placebo Comparator|Placebo|
3222537|NCT01113164|Experimental|Ondansetron, Placebo, Sertraline|LL-carriers receiving ondansetron compared to either placebo or sertraline, will result in a significant reduction in alcohol consumption.
3222538|NCT01113164|Experimental|Sertraline, Placebo, Ondansetron|SL and SS-carriers receiving sertraline compared to either placebo or ondansetron, will result in a significant reduction in alcohol consumption.
3222539|NCT01113177||Distraction splint therapy|All JIA patients with asymmetric mandibular growth due to unilateral TMJ arthritis are offered non-surgical functional orthodontic splint therapy with a distraction splint. Mandibular growth is thereafter evaluated in the affected side compared with the mandibular growth in the healthy side of the same individual.
3222540|NCT01113190|Active Comparator|CBI in ED with AMET at 3 months|computer-delivered brief intervention (CBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3222541|NCT01113190|Active Comparator|CBI in ED with EUC at 3 months|computer-delivered brief intervention (CBI) at baseline with enhanced usual care-EUC at 3 months
3222542|NCT01113190|Active Comparator|IBI in ED with AMET at 3 months|intervener-delivered brief intervention (IBI) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3222543|NCT01113190|Active Comparator|IBI in ED with EUC at 3 months|intervener-delivered brief intervention (IBI) at baseline with enhanced usual care-EUC at 3 months
3222544|NCT01113190|Active Comparator|EUC in ED with AMET at 3 months|enhanced usual care (EUC) at baseline with adapted motivational enhancement therapy-AMET at 3 months
3222545|NCT01113190|Active Comparator|EUC in ED with EUC at 3 months|enhanced usual care (EUC) at baseline with EUC at 3 months
3222546|NCT01113203|Experimental|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
3222547|NCT01113229|Experimental|Misoprostol|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two misoprostol tablets taken orally (400µg) following cord clamp
3222548|NCT01113229|Placebo Comparator|PLACEBO|10 UI of oxytocin IV during delivery of the anterior shoulder of the newborn and two placebo tablets taken orally following cord clamp.
3222549|NCT01113242||A:|Patients with idiopathic PD and with MMSE < à 26
3222550|NCT01113242||B:|Patients with idiopathic PD and with MMSE ≥ à 26
3222551|NCT01113255|Active Comparator|CHRONIC REPIRATORY FAILURE|
3222552|NCT01113255|Active Comparator|ACUTE RESPIRATORY FAILURE|
3222553|NCT01113268|Other|1:cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
3222554|NCT01113281|Experimental|VPM1002 in three dosages|
3222555|NCT01113281|Active Comparator|BCG|
3222556|NCT01113294|Experimental|ablation|
3222557|NCT01113307||Hard to heal wounds|
3222558|NCT01113320|Placebo Comparator|Placebo|
3222559|NCT01113320|Active Comparator|Safinamide|
3222560|NCT01113333|Experimental|SAR113945|SAR113945, single dose according to dose escalation design
3222561|NCT01113333|Placebo Comparator|Placebo|0.9% saline solution, single dose
3222562|NCT01113346|Experimental|Filtrum-STI|
3222563|NCT01113346|Placebo Comparator|Placebo|
3222564|NCT01113359||study group|hypertensive patients
3222565|NCT01113359||control group|healthy volunteer
3222566|NCT01113372|Experimental|Clopidogrel 3 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 3 months.
3222567|NCT01113372|Active Comparator|Clopidogrel 12 months|Regime of dual antiplatelet therapy (DAPT) including aspirin+clopidogrel for 12 months.
3222568|NCT01113411|Active Comparator|Intensive Rehabilitation|
3222569|NCT01113411|Active Comparator|Standard Rehabilitation|
3222570|NCT01113424|Experimental|NRT-2|2 mg single-dose of a new NRT product
3222571|NCT01113424|Active Comparator|GUM-2|2 mg single-dose of a marketed nicotine gum
3222572|NCT01113424|Experimental|NRT-4|4 mg single-dose of a new NRT product
3222573|NCT01113424|Active Comparator|GUM-4|4 mg single-dose of marketed nicotine gum
3222574|NCT01113437|Experimental|Omalizumab|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
3222575|NCT01113437|Placebo Comparator|Placebo|There are 2 arms of the study; patients in one arm receiving omalizumab and in the other arm receiving placebo.
3222576|NCT01113476|Experimental|Nab-paclitaxel, Gemcitabine + Bevacizumab|Starting doses of Nab-paclitaxel 50 mg/m^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m^2
3222577|NCT01113489|Experimental|beclomethasone dipropionate suspension for nebulization|
3222578|NCT01113489|Placebo Comparator|placebo|
3222579|NCT01113515|Placebo Comparator|Placebo|Placebo gel
3222580|NCT01113515|Experimental|Galnobax 20% QD|Esmolol Hydrochloride (Galnobax) 20% gel once daily
3222581|NCT01113515|Experimental|Galnobax 20% BID|Esmolol Hydrochloride (Galnobax) 20% gel twice daily
3222582|NCT01113515|Experimental|Galnobax 14% BID|Esmolol Hydrochloride (Galnobax) 14% gel twice daily
3222583|NCT01113528|Experimental|Regenerative therapy|
3222584|NCT01113528|Placebo Comparator|Sugar pill|
3222585|NCT01113554|Experimental|Arm I|Patients attend exercise therapy sessions over 1 hour 3 times a week for 6 months. Exercise therapy sessions are comprised of a 10 minute warm-up of light stretching and aerobic type exercise (walking, cycling), 30 minutes of endurance type exercise (cycle, walking), and 20 minutes of resistance training exercise.
3222586|NCT01113567|Placebo Comparator|Diet and lactose-free milk|Lactose-free milk
3222587|NCT01113567|Active Comparator|Diet and whole milk|Whole milk with lactose
3222588|NCT01113593|Experimental|1|
3222589|NCT01113593|Experimental|2|
3222590|NCT01113593|Experimental|3|
3222591|NCT01113593|Experimental|4|
3222592|NCT01113593|Experimental|5|
3222593|NCT01113606|Active Comparator|Obagi Nu-Derm System (ONDS)|
3222594|NCT01113606|Active Comparator|Standard of Care|
3222595|NCT01113619|Experimental|RP-G28|Study Drug RP-G28
3222596|NCT01113619|Placebo Comparator|Placebo|Study Drug Placebo
3222597|NCT01113645||Cerebral perfusion evaluation|All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores. Hemodynamic monitoring by CT perfusion scan, as well as by trans-cranial Doppler.
3222598|NCT01113658|Experimental|SNaP|SNaP disposable, mechanically powered Negative Pressure Wound Therapy System
3222599|NCT01113671|Placebo Comparator|Placebo|
3222600|NCT01113671|Experimental|d-alpha-tocopheryl acetate|
3222601|NCT01113697||Clinical Investigator Collaborative (CIC) Asthma study cohort|Participants will be healthy volunteer research subjects with allergic asthma who will have an allergen inhalation challenge at CIC sites across Canada.
3222602|NCT01113697||Western Red Cedar Asthma study cohort|Participants will be volunteer research subjects with Western Red Cedar asthma, who will have a plicatic acid inhalation challenge at The Lung Centre at Vancouver General Hospital.
3222603|NCT01113697||Environmental Exposure Unit (EEU), Kingston General Hospital|Subjects will be over 19 years of age so that they qualify for studies involving allergen challenge.
3222604|NCT01113736|Experimental|Human Peritoneal Membrane: AlloMEM™|For use as a homologous tissue where native peritoneum is absent or traumatized. By decreasing adhesions and providing a peritoneal remodeling capacity, both the time needed for ileostomy closure and the risk of enterotomy or seromyotomy would be reduced. The combination could lead to decreased complication rates and therefore decreased morbidity for the surgical patients requiring an ileostomy.
3222605|NCT01113762|Experimental|resurfacing|a hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint
3222606|NCT01113762|Experimental|large head THA|a standard stemmed THA but with a large metal head, and a metal-metal articulation
3222607|NCT01113762|Active Comparator|28 mm ceramics-polyethylene|a standard 28 mm head uncemented THA
3222608|NCT01113762|Active Comparator|28 mm metal-polyethylene THA|a standard stemmed uncemented THA
3222609|NCT01113775||presence of right ventricle dysfunction|
3222610|NCT01113775||absence of right ventricle dysfunction|
3222611|NCT01113788||imaging|imaging with usual catheter/fluoroscopy, no cartosound
3222612|NCT01113827|Active Comparator|150mg olive extract|
3222613|NCT01113827|Active Comparator|50mg olive extract|
3222614|NCT01113827|Placebo Comparator|Placebo control|
3222615|NCT01113840|Placebo Comparator|Control|Control group continues with their daily activity as they were prior to randomization. Receive bi-weekly follow-up phone calls to assess health status and encourage adherence with protocol.
3222616|NCT01113840|Active Comparator|Exercise|Exercise classes three times per week in a controlled, supervised environment.
3222617|NCT01113866||heart failure|
3222618|NCT01113905||Radiation Only|
3222619|NCT01113905||Radiation and Chemotherapy|
3222620|NCT01113918||Obsity PCOS Women|"Polycystic ovary syndrome (PCOS) was diagnosed according to the European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM) case definition which requires presentation of signs and/or symptoms of a minimum of 2 of the following 3 criteria: polycystic ovary morphology (PCOM), oligomenorrhea or amenorrhea (Oligo-An), androgen excess (HA).~Body mass index (BMI) was defined as body weight in kilograms divided by body height in meters squared (kg/m2). Obesity was defined as BMI≥25 kg/m2, according to the Asia-Pacific definition."
3222621|NCT01113918||Non-obesity PCOS Women|The subjects BMI were less than ≥25 kg/m2 and out of criteria of PCOS by European Society for Human Reproduction (ESHRE)/American Society of Reproductive Medicine (ASRM).
3222622|NCT01113944|Active Comparator|Program 1|Program 1
3222623|NCT01113944|Active Comparator|Program 2|Program 2
3222624|NCT01113957|Experimental|Arm A|ABT-888 in combination with temozolomide
3222625|NCT01113957|Active Comparator|Arm B|pegylated liposomal doxorubicin alone
3222626|NCT01113970|Experimental|Single Arm|open label, single arm, unblinded
3222627|NCT01113996|No Intervention|Standard treatment - usual care|
3222628|NCT01113996|Experimental|Protein supplementation|
3222629|NCT01113996|Experimental|Protein supplementation and strength training|
3222630|NCT01114009|Experimental|Lung recruitment maneuver|The maneuver briefly increases the alveolar pressure to open recruitable lung (50 cmH2O), sustained with adequate positive end-expiratory pressure(PEEP) after lung recruitment, to avoid derecruitment.
3222631|NCT01114009|Active Comparator|Lung protective strategy|Lung protective strategy group received lung protective strategy without recruitment maneuver
3222632|NCT01114022|Active Comparator|Active comparator|cylindrical PVC cuff
3222633|NCT01114022|Experimental|Experimental 1|cylindrical polyurethane cuff
3222634|NCT01114022|Experimental|Experimental 2|conic PVC cuff
3222635|NCT01114022|Experimental|Experimental 3|conic polyurethane cuff
3222636|NCT01114035|Experimental|Patients|intestinal epithelial dysplasia
3222637|NCT01114035|Other|Control|Children without intestinal epithelial dysplasia
3222638|NCT01114061|Experimental|InsuPatch|The arm with the treatment: using the insupatch device to heat the insulin infusion site.
3222639|NCT01114074||Factor XII deficiency|Patients deficient in coagulation factor XII
3222640|NCT01114074||Factor XI Deficiency|Patients deficient in coagulation factor XI
3222641|NCT01114074||Prekallikrein deficiency|Patients deficient in prekallikrein
3222642|NCT01114074||HMWK deficiency|Patients deficient in high molecular weight kininogen (HMWK)
3222643|NCT01114074||Control group|Healthy controls
3222644|NCT01114087|Experimental|1|Patients presenting with chronic myeloid leukaemia or malignant GIST and receiving for the first time a treatment by imatinib, a tyrosin-kinase inhibitor, preceded or not by hydroxyurea therapy for less than one month.
3222645|NCT01114100|Active Comparator|sertraline, panic education|treatment with sertraline after panic education
3222646|NCT01114100|Placebo Comparator|placebo after panic education|treatment with placebo after panic education
3222647|NCT01114100|No Intervention|care as usual|patient received no diagnosis an no panic education, they had a 24 weeks follow up with a visit at 12 weeks and 24 weeks to evaluate their complaints
3222648|NCT01114113|Active Comparator|non-trigger meal|"Measurement of intestinal transport eating a non-trigger meal."
3222649|NCT01114113|Active Comparator|"trigger meal baseline"|"Measurement of intestinal transport after eating a trigger meal."
3222650|NCT01114113|Placebo Comparator|"trigger meal with placebo"|Measurement of intestinal transport with blinded placebo
3222651|NCT01114113|Active Comparator|"trigger meal with enzymes (blinded)"|Measurement of intestinal transport with blinded active enzyme capsule
3222652|NCT01114126|Experimental|Neu-P11 2mg|
3222653|NCT01114126|Experimental|Neu-P11 5 mg|
3222654|NCT01114126|Experimental|Neu-p11 20 mg|
3222655|NCT01114126|Experimental|Neu-P11 50 mg|
3222656|NCT01114126|Placebo Comparator|Placebo|
3222657|NCT01114152|Experimental|1|Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8)
3222658|NCT01114152|Placebo Comparator|2|placebo given (2 subjects in each dose group)
3222659|NCT01114165|Experimental|SeptiFast Test|Pathogen detection by SeptiFast Test as an adjunct to traditional microbiological assessments including blood culture
3222660|NCT01114165|Active Comparator|Only Conventional Diagnostics|Pathogen detection only by conventional microbiological assessments, e.g. blood culture
3222661|NCT01114178||claudicants|patients referred for a treadmill test
3222662|NCT01114191|Experimental|Arm 1|
3222663|NCT01114230|Experimental|Dose Level 1|
3222664|NCT01114230|Experimental|Dose Level 2|
3222665|NCT01114230|Experimental|Dose Level 3|
3222666|NCT01114230|Experimental|Dose Level 4|
3222667|NCT01114230|Experimental|Dose Level 5|
3222668|NCT01114230|Experimental|Dose Level 6|
3222669|NCT01114230|Experimental|Dose Level 7|
3222670|NCT01114230|Experimental|Dose Level 8|
3222671|NCT01114230|Experimental|Dose Level 9|
3222672|NCT01114256||Fine needle aspiration (FNA) biopsies|Fine needle aspiration biopsies (FNA) will be performed prior to and 0 to 336 hours after the therapeutic monoclonal antibody infusion.
3222673|NCT01114282|Experimental|VELCADE with pralatrexate|Pralatrexate,10 mg/m2, IV bolus on days 1, 8, and 15 VELCADE,1.3 mg/m2, IV bolus on days 1, 8, and 15
3222674|NCT01114295|Experimental|Overt Obscure Gastrointestinal Bleeders|The only cohort in this study are those patients identified as having overt, obscure gastrointestinal bleeding who will then undergo CE or CTE.
3222675|NCT01114308|Experimental|Probuphine|Patients are first inducted on SL BPN then switched to 4 buprenorphine implants
3222676|NCT01114308|Placebo Comparator|placebo implant|patients are first inducted on SL BPN then switched to 4 placebo implants
3222677|NCT01114308|Active Comparator|sublingual buprenorphine|patients are inducted on SL BPN, then continue on SL BPN
3222678|NCT01114347|Experimental|Cranberry|Patients randomized to this arm will recieve one gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water.
3222679|NCT01114347|Placebo Comparator|Placebo|The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
3222680|NCT01114386||COPD patients, CHF patients|COPD and CHF patients with smoking history (> 10 pack/years), male and female, older than 50 years, referred to Hospital for dyspnea and chronic cough.
3222681|NCT01114399|Experimental|Standard Broccoli|Standard Broccoli
3222682|NCT01114399|Experimental|High Glucosinolate Broccoli|High Glucosinolate Broccoli
3222683|NCT01114399|Experimental|Peas|Peas
3222684|NCT01114412||Patients|Patients with overactive bladder syndrome
3222685|NCT01114412||Healthy volunteers|Healthy volunteers
3222686|NCT01114451|Experimental|Early Staple Removal|Skin staple removal on post-operative day #3
3222687|NCT01114451|Experimental|Delayed Staple Removal|Skin staple removal on post-operative day 7-10
3222688|NCT01114464||young women with breast cancer|
3222689|NCT01114490|Experimental|Part 1 - Group 1|Moderate Hepatic Patients
3222690|NCT01114490|Experimental|Part 1 - Group 2|Healthy Subjects
3222691|NCT01114490|Experimental|Part 2 - Group 1|Mild Hepatic Patients
3222692|NCT01114490|Experimental|Part 2 - Group 2|Healthy Subjects
3222693|NCT01114542|Experimental|IDeg 0.4 U/kg|
3222694|NCT01114542|Experimental|IDeg 0.6 U/kg|
3222695|NCT01114542|Experimental|IDeg 0.8 U/kg|
3222696|NCT01114542|Active Comparator|IGlar 0.4 U/kg|
3222697|NCT01114542|Active Comparator|IGlar 0.6 U/kg|
3222698|NCT01114542|Active Comparator|IGlar 0.8 U/kg|
3222699|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→osmotic capsule (OC) fast→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 6 hours (EP-Osmotic Capsule-Fast) and C) a single dose of 10 mg extemporaneously prepared osmotic capsule with target release rate of approximately 14 hours (EP-Osmotic Capsule-Slow). Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222700|NCT01114568|Experimental|Ertugliflozin 10 mg: tablet→OC slow→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222701|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→tablet→OC slow|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222702|NCT01114568|Experimental|Ertugliflozin 10 mg: OC fast→OC slow→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222703|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→tablet→OC fast|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222704|NCT01114568|Experimental|Ertugliflozin 10 mg: OC slow→OC fast→tablet|The three treatments are A) a single dose of 10 mg administered as 2x5 mg material sparing formulation tablets B) a single dose of 10 mg EP-Osmotic Capsule-Fast and C) a single dose of 10 mg EP-Osmotic Capsule-Slow. Treatment are administered on Day 1, Hour 0 of each dosing period with a minimum of 7-days wash-out between treatments A, B, and C.
3222705|NCT01114594||PKD|Patients with Autosomal Dominant Polycystic Kidney Disease
3222706|NCT01114594||non-PKD CKD|Patients with non-Polycystic Chronic Kidney Disease
3222707|NCT01114607|Experimental|Treatment sequence ABCDE|Eligible subjects will be randomized in sequence ABCDE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3222708|NCT01114607|Experimental|Treatment sequence ABDEC|Eligible subjects will be randomized in sequence ABDEC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3222709|NCT01114607|Experimental|Treatment sequence ABECD|Eligible subjects will be randomized in sequence ABECD and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3222710|NCT01114607|Experimental|Treatment sequence ABCED|Eligible subjects will be randomized in sequence ABCED and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= a film coated tablet of GSK1605786 GSK formulation 500 mg once daily and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3222711|NCT01114607|Experimental|Treatment sequence ABDCE|Eligible subjects will be randomized in sequence ABDCE and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3222712|NCT01114607|Experimental|Treatment sequence ABEDC|Eligible subjects will be randomized in sequence ABEDC and will receive: A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3222713|NCT01114607|Experimental|Treatment sequence BACDE|Eligible subjects will be randomized in sequence BACDE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3222714|NCT01114607|Experimental|Treatment sequence BADEC|Eligible subjects will be randomized in sequence BADEC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3222715|NCT01114607|Experimental|Treatment sequence BAECD|Eligible subjects will be randomized in sequence BAECD and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3222716|NCT01114607|Experimental|Treatment sequence BACED|Eligible subjects will be randomized in sequence BACED and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, and D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily.
3222717|NCT01114607|Experimental|Treatment sequence BADCE|Eligible subjects will be randomized in sequence BADCE and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily, and E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily.
3222718|NCT01114607|Experimental|Treatment sequence BAEDC|Eligible subjects will be randomized in sequence BAEDC and will receive: B= two capsules of GSK1605786 GSK formulation 250 milligrams once daily, A= two capsules of GSK1605786 ChemoCentryx formulation 250 milligrams once daily, E= film coated tablet of GSK1605786 GSK formulation 500 mg once daily, D= two capsules of GSK1605786 GSK modified-process formulation 250 milligrams once daily, and C= two capsules of GSK1605786 GSK direct-fill formulation 250 milligrams once daily.
3222719|NCT01114659||Women with PCOS|
3222720|NCT01114659||Normal Control|
3222721|NCT01114685|Active Comparator|Effects of taking AlgaeCal-1|Following a bone health plan with Algae-cal-1 supplement
3222722|NCT01114685|Active Comparator|Effects of taking AlgaeCal-2|Following a bone-health plan while consuming AlgaeCal 2
3222723|NCT01114698|Experimental|JNJ26489112|
3222724|NCT01114698|Active Comparator|Venlafaxine XR|
3222725|NCT01114698|Placebo Comparator|Placebo|
3222726|NCT01114711||Frovatriptan|All subjects will be taking Frovatriptan tablets within 48 hours prior to the scan session (Visit 2).
3222727|NCT01114750|Active Comparator|Oral Insulin in Dextran Matrix|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
3222728|NCT01114750|Placebo Comparator|Placebo|A group consisting of male healthy volunteers will be given placebo and one single dose of insulin in dextran matrix, for estimation of post-dose relative bioavailability.
3222729|NCT01114763||Metabolic syndrome|40 men with metabolic syndrome
3222730|NCT01114763||Control|40 physically active men
3222731|NCT01114776||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
3222732|NCT01114776||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3222733|NCT01114776||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3222734|NCT01114776||Controls|
3222735|NCT01114802|Experimental|Project Onward website + social network|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
3222736|NCT01114802|Active Comparator|Project Onward website|This arm has the website which includes 8 weeks of Internet-based cognitive behavioral therapy.
3222737|NCT01114841|Experimental|Tazarotene Foam|Subjects will be exposed to patches containing Tazarotene foam 0.1%
3222738|NCT01114841|Placebo Comparator|Vehicle Foam|Subjects will be exposed to patches containing Vehicle Foam
3222739|NCT01114854|Other|Topiramate IR followed by Topiramate ER|Dosing with IR followed by dosing with ER
3222740|NCT01114932||BMI-I|Patients with BMI values between 18.5-24.9
3222741|NCT01114932||BMI-II|Patients with BMI values between 25-29.9
3222742|NCT01114932||BMI-III|Patients with BMI values between 30-49.9
3222743|NCT01114958|Experimental|IA Cisplatin / IV Thiosulfate|Single-arm study
3222744|NCT01114984||10% after breast biopsy|Incidence Post-operative pain after breast surgery.
3222745|NCT01114984||20% after lumpectomy|Incidence Post-operative pain after breast surgery
3222746|NCT01114984||30% after simple mastectomy|Incidence Post-operative pain after breast surgery
3222747|NCT01114984||50% after mastectomy with reconstruction|Incidence Post-operative pain after breast surgery
3222748|NCT01114984||50% after radical mastectomy|Incidence Post-operative pain after breast surgery
3222749|NCT01114984||50% after radi mastectomy+reconstruction|Incidence Post-operative pain after breast surgery after radical mastectomy with reconstruction
3222750|NCT01114984||40% after cosmetic augmentation|Incidence Post-operative pain after breast surgery
3222751|NCT01114984||40% after breast reduction|Incidence Post-operative pain after breast surgery
3222752|NCT01115010|Experimental|Stiffening wire only if difficulty|Colonoscopy is performed with the unassisted colonoscope. The stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying.
3222753|NCT01115010|Experimental|Stiffening wire #1 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #1 is introduced on entry of the tip of the colonoscope into the transverse colon.
3222754|NCT01115010|Experimental|Stiffening wire #2 transverse colon|Colonoscopy is started with the unassisted colonoscope. Stiffening wire #2 is introduced on entry of the tip of the colonoscope into the transverse colon.
3222755|NCT01115023|Experimental|iron group|This group received an iron cooking pot for daily household cooking as an intervention
3222756|NCT01115023|No Intervention|Aluminium group|the subjects in this group were asked to continue cooking in the aluminium pot and not to cook in the iron pot if they possessed one.
3222757|NCT01115036|Experimental|panobinostat|
3222758|NCT01115049|Experimental|Experimental mouthwash|The experimental mouthwash (Buccagel®, Curaden Healthcare, Saronno, Italy) was made up of: purified water, dicaprylyl-ether, coco-caprylate caprate, xylitol, glyceryl-stearate, ceteareth-20, ceteareth-12, cetyl-palmitate, cetearyl-alcohol, chlorobutanol, aroma, hexetidine, methylparaben, propylparaben, sodium saccharin, citric acid and colorant C.I. 16255.
3222759|NCT01115049|Active Comparator|Chlorexidine-based mouthwash|A conventional commercial mouthwash (Curasept® ADS 0.20%, Curaden Healthcare, Saronno, Italy) made up of: water, xylitol, propylenglycol, Peg-40 of hydrogenated ricin oil, ascorbic acid, chlorhexidine digluconate, aroma, poloxamer 407, sodium metabisulfite, sodium citrate and colorant C.I. 42090.
3222760|NCT01115062|Experimental|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg)
3222761|NCT01115062|Experimental|LMX-4 Cream|LMX-4 (liposomal lidocaine 4%) cream
3222762|NCT01115062|Placebo Comparator|Placebo Patch|Placebo Patch
3222763|NCT01115075|Experimental|Dietitian|Recruitment of dietitians and senior level or graduate level dietetics students who are not restrained eaters. This group is skilled in identifying and accurately recording food than individuals not trained in dietetics.
3222764|NCT01115088|Experimental|Aspartame|Food or beverages containing Aspartame in comparison to Stevia or Sucrose
3222765|NCT01115088|Experimental|Sucrose|Food or beverages containing Sucrose in comparison to Aspartame or Stevia
3222766|NCT01115088|Experimental|Stevia|Food or beverages containing Stevia in comparison to Aspartame or Sucrose
3222767|NCT01115114|Placebo Comparator|Treatment as Usual (TAU)|Study Intervention 1 Treatment as usual (TAU) will be psychiatry follow-up at local Community Mental Health Clinic at least every 3 months.
3222768|NCT01115114|Active Comparator|IMBED|Study Intervention 2 A Primary Care Provider (PCP) will be located within the community mental health clinic one day weekly to specifically run a Metabolic Syndrome Clinic.
3222769|NCT01115114|Active Comparator|Liaison|Study Intervention 3 A Medical Case Manager(MCM) will be assigned to a patient who is identified on the basis of routine screening to need medical follow-up for metabolic syndrome.
3222770|NCT01115127|Active Comparator|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
3222771|NCT01115127|Active Comparator|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
3222772|NCT01115127|Active Comparator|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
3222773|NCT01115140|Active Comparator|Group A1|metformin plus placebo
3222774|NCT01115140|Experimental|Group A2|metformin plus folic acid
3222775|NCT01115140|Active Comparator|Group A3|placebo plus folic acid
3222776|NCT01115140|Placebo Comparator|Group A4|placebo cp, 2 cps daily
3222777|NCT01115140|No Intervention|Group B|observation
3222778|NCT01115153|Experimental|Antibiotic prophylaxis|Rate of Wound infection in patients with gangrenous appendicitis with single doses of antibiotic (before surgery)
3222779|NCT01115153|Active Comparator|Antibiotic treatment, wound infection|Rate of Wound infection in patients with gangrenous appendicitis with five days antibiotic therapy (after surgery)
3222780|NCT01115179|Active Comparator|Propofol|Propofol anesthesia
3222781|NCT01115179|Active Comparator|Control|Anesthesia with isoflurane alone
3222782|NCT01115179|Active Comparator|Solvent|Anesthesia with isoflurane together with the solvent of propofol (intralipid)
3222783|NCT01115192|Experimental|Group A|Patients with chronic blepharitis, that will be treated with blephacura
3222784|NCT01115192|Experimental|Group B|Patients with chronic blepharitis that will be treated with diluted baby shampoo
3222785|NCT01115205|Experimental|Supervised walking groups|Patients included in walking groups, under the supervision of a qualified personal trainer.
3222786|NCT01115205|Active Comparator|Controls|Patients receiving the standard counselling procedures of the Verona Diabetic Clinic.
3222787|NCT01115218||Glaucoma patients|
3222788|NCT01115257|Other|group 1|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with vitrectomy
3222789|NCT01115257|Other|panretinalphotocoagulation (group 2)|90 eyes of 90 patients, with severe PDR, some with tractional retinal detachment (TRD) not involving the macula were included in the study and treated with panretinalphotocoagulation
3222790|NCT01115270||Hydrocephalus Patients|Those patients diagnosed with Normal Pressure Hydrocephalus.
3222791|NCT01115270||Normal Participants|Individuals who are not diagnosed with Normal Pressure Hydrocephalus.
3222792|NCT01115296|Active Comparator|'L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.
3222793|NCT01115296|Placebo Comparator|Placebo|Placebo
3222794|NCT01115322|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
3222795|NCT01115322|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
3222796|NCT01115322|Experimental|Tazarotene Foam with UVA , UVB, and visible light irradiation|Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation
3222797|NCT01115322|Placebo Comparator|Vehicle Foam without irradiation|Subjects will be exposed to Vehicle Foam Patch without irradiation
3222798|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
3222799|NCT01115322|Placebo Comparator|Vehicle Foam with UVA and UVB and visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
3222800|NCT01115322|Sham Comparator|No Treatment without irradiation|Subjects will be exposed to a Blank Patch without irradiation
3222801|NCT01115322|Sham Comparator|No Treatment with UVA and UVB irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB irradiation
3222802|NCT01115322|Sham Comparator|No Treatment with UVA and UVB and visible light irradiation|Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation
3222803|NCT01115335|Active Comparator|Gomco|NMC performed using a Gomco clamp
3222804|NCT01115335|Active Comparator|Mogen clamp|NMC performed using a Mogen clamp
3222805|NCT01115335|Active Comparator|Plastibell|NMC performed using a Plastibell device
3222806|NCT01115361|Experimental|PPFP in child immunization|Women attending immunization services for their infant will receive educational brochures, group education and individual counseling on the benefits of the health timing and spacing of births,, pregnancy risk and return to fertility during the extended postpartum period (12 months), and referral to family planning services for those who are interested.
3222807|NCT01115361|No Intervention|Control - Standard of care|The control arm will receive standard of care infant immunization services.
3222808|NCT01115374|Active Comparator|manual lymphatic drainage|Application of manual lymphatic drainage
3222809|NCT01115374|Experimental|low frequency sound waves|Application of low frequency sound waves
3222810|NCT01115387||ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who have at least one parent with age related maculopathy.~These individuals with ARM-affected parents and relatives have a substantially higher risk (6-12 fold) of developing ARM than the general population. They will be followed prospectively with fundus photography every two years and questionnaires (distributed over six month intervals) to assess external risks for ARM development in order to investigate genotype-phenotype correlations of early onset clinical features of ARM."
3222811|NCT01115387||Partners/Spouses of ARM at risk individuals|"A group of 1,500 participants (from 49 to 65 years old) who are the spouses/partners of individuals with ARM affected parents.~We will invite the partners or spouses to participate in order to compare their risk of developing ARM with those individuals with an increased risk of ARM based on a positive family history."
3222812|NCT01115387||ARM affected individuals and relatives.|"Individuals who have experienced vision loss from ARM and have at least one brother or sister who also has experienced vision loss from ARM can participate in the study. They also need to have at least one adult child (from 49 to 65 years old) who wishes to participate in this study.~We will allow for additional recruitment to compensate for additional family members (such as parents, aunts and uncles) who wish to participate as well as to address potential drop out and those who may be deemed ineligible based on review of their medical and/or eye records. As many as 4000 individuals in this group will be allowed to enroll."
3222813|NCT01115413||young maternal age|maternal age of < 18 years
3222814|NCT01115413||adult maternal age|maternal age >/= 18 years
3222815|NCT01115426|Other|anti-angiotensin II drugs|Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
3222816|NCT01115439||falciparum malaria|Febrile children (above six months of age) and non-pregnant adults with confirmed uncomplicated P. falciparum infection
3222817|NCT01115465|Other|Macroplastique|Macroplastique will be used for the treatment in an open-label, five year, post-market study
3222818|NCT01115478|Active Comparator|Vitamin A|
3222819|NCT01115478|Active Comparator|Zinc|
3222820|NCT01115478|Active Comparator|Vitamin A + Zinc|
3222821|NCT01115478|Placebo Comparator|Placebo|
3222822|NCT01115504|Experimental|Thiamine|Thiamine tablets of 300mg are prescribed for 1 months
3222823|NCT01115504|Placebo Comparator|Plascebo|Tablets of 300mg placebo are prescribed for 1 months
3222824|NCT01115530|No Intervention|1|Control inpatient GEM rehabilitation and continue twice weekly low level walking/stretching to control for time/interaction with intervention/exercise groups
3222825|NCT01115530|Experimental|2|Resistance exercise (2x/week)
3222826|NCT01115530|Experimental|3|Nutritional (amino acid metabolite) supplement twice daily
3222827|NCT01115530|Experimental|4|Resistance exercise (2x/week) and nutritional (amino acid metabolite) supplement twice daily
3222828|NCT01115543|Active Comparator|calcitriol|The subjects were randomized to receive calcitriol in a dose-escalating fashion for up to 24 weeks.
3222829|NCT01115543|Experimental|alfacalcidol|
3222830|NCT01115595|Active Comparator|Intervention|injection by Mite extract with standard allergic medication (oral antihistamine and/or topical nasal steroid)
3222831|NCT01115595|Other|Control Group|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid
3222832|NCT01115608|Experimental|Pharmacist follow-up|"The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of consultation. Written information concerning drugs used will be supplied."
3222833|NCT01115608|No Intervention|Control group|The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.
3222834|NCT01115621|Active Comparator|Glutenfree diet|Glutenfree diet during the first year of life
3222835|NCT01115621|No Intervention|Control - normal diet|
3222836|NCT01115634|Experimental|Fibroblast|Injection of autologous cultured fibroblast
3222837|NCT01115647|Experimental|Ready-to-Use Therapeutic Foood (RUSF)|"Caretakers will receive weekly RUSF, 350g, and will be advised to feed it(50 g d-1 or 3 tablespoons/day) in one meal or on demand. These are pre-defined quantities. However, minimum quantities required for a timely (≤15 days) recovery from moderate malnutrition will be determined during the pilot phase.~Besides supplementary food, parents will be provided with the usual nutrition counsels prevailing currently in the health services.Children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
3222838|NCT01115647|Active Comparator|CSB++|"Caretakers will receive weekly CSB++ (450g) rations. Parents will be advised to feed the CSB++ (65g d-1 diluted in 370 g water) in one meal or on demand. These are pre-defined quantities. However, minimum quantities of CSB++ required for a timely (≤15 days) recovery from moderate malnutrition in the area will be determined during the pilot phase. Besides supplementary foods, parents will be provided with the usual nutrition counsels prevailing currently in the health services, i.e. to keep on breastfeeding, to increase diet diversity and to feed frequent snacks.~Feeding practices will be also assessed, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members."
3222839|NCT01115647|Active Comparator|Children Centered Counseling (CCC)|"The counsellor will spend 1 hour daily (during the 3 first days and then weekly) within the household for identifying enhancing and blocking factors and adapt consequently the treatment strategies in agreement with the caretakers.~As in the other study arms, children will be home-visited once a week by assessors for anthropometry, 24-hours recall of dietary and breastfeeding intake, and morbidity signs. Feeding practices will be also assessed in each arm, and the changes between baseline and intervention periods evaluated. Compliance will be evaluated by interviewing family members.There will be no dietary supplements intervention, outside normal practices in Burkina."
3222840|NCT01115686|Active Comparator|Branched-chain aminoacids|Branched-chain aminoacids are natural constituents of the food. Branched-chain aminoacids will be orally administered in the form of capsules.
3222841|NCT01115686|Placebo Comparator|placebo|The placebo will be orally administered in the form of capsules
3222842|NCT01115712|Active Comparator|Pioglitazone 30 mg|Pioglitazone 30 mg
3222843|NCT01115712|Placebo Comparator|Placebo|Placebo
3222844|NCT01115725||Gonal-f® prefilled pen|
3222845|NCT01115751|Experimental|LY2780301|"Part A: daily dosing~Part B (if determined as needed by pharmacokinetic, pharmacodynamic, and safety data): twice daily dosing~Part C: Dose and frequency as determined by Parts A and B of the study."
3222846|NCT01115777||Pediatric patients treated with radiotherapy|
3222847|NCT01115790|Experimental|Prexasertib|
3222848|NCT01115842|Experimental|Vitamin D|The patients will be given Vitamin D - 4000IU per day for 5 days (Day 1 through 5)
3222849|NCT01115842|No Intervention|control|
3222850|NCT01115868|Experimental|Group 2 - 2 doses of Prevascar and placebo|
3222851|NCT01115868|Experimental|Group 1 - 2 doses of Prevascar and placebo|
3222852|NCT01115868|Experimental|Group 3 - 2 doses of Prevascar and placebo|
3222853|NCT01115868|Experimental|Group 4 - 2 doses of Prevascar and placebo|
3222854|NCT01115894|Experimental|active medication + psychotherapy|
3222855|NCT01115894|Experimental|placebo + psychotherapy|
3222856|NCT01115894|Experimental|active medication+brief supportive counseling|
3222857|NCT01115894|Experimental|placebo + brief supportive counseling|
3222858|NCT01115907|Experimental|Freedom SOLO stentless valve implant|Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.
3222859|NCT01115920|Experimental|Arm 1|Cohort 1, Dose 0.010 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3222860|NCT01115920|Experimental|Arm 2|Cohort 2, Dose 0.025 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3222861|NCT01115920|Experimental|Arm 3|Cohort 3, Dose 0.050 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3222862|NCT01115920|Experimental|Arm 4|Cohort 4, Dose 0.100 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3222863|NCT01115920|Experimental|Arm 5|Cohort 5, Dose 0.250 mg/kg/hr Active (6), Placebo (2), Total Subjects (8)
3222864|NCT01115946|Experimental|single-add first group|single administration first, then concomitant administration
3222865|NCT01115946|Experimental|combi-add first group|concomitant administration first, then single administration
3222866|NCT01115959|Active Comparator|valproic acid|Valproic acid given orally 400mg twice daily
3222867|NCT01115959|Placebo Comparator|placebo|Placebo twice daily for one month
3222868|NCT01115972|Experimental|single-add first group|single administration first, then concomitant administration
3222869|NCT01115972|Experimental|combi-add first group|concomitant administration first, then single administration
3222870|NCT01115985|Experimental|single-add first group|single administration first, then concomitant administration
3222871|NCT01115985|Experimental|combi-add first group|concomitant administration first, then single administration
3222872|NCT01116011|Experimental|AZD7268|
3222873|NCT01116011|Placebo Comparator|Placebo|
3222874|NCT01116050|Placebo Comparator|Placebo|
3222875|NCT01116050|Experimental|MISOPROSTOL|
3222876|NCT01116063|Experimental|Single arm open label|All patients will receive the study drugs and will be evaluated
3222877|NCT01116076|Experimental|DECISION+ Program|Exposure to the Decision+ Program
3222878|NCT01116076|No Intervention|Control|Usual Care
3222879|NCT01116089|Active Comparator|PARI LC® PLUS nebulizer|
3222880|NCT01116089|Active Comparator|PARI eFlow® rapid electronic nebulizer|
3222881|NCT01116115|Active Comparator|Standard vegetable oil based formula|
3222882|NCT01116115|Active Comparator|InFat™ based infant formula|
3222883|NCT01116115|No Intervention|Breast-fed|
3222884|NCT01116128|Experimental|D-MP|
3222885|NCT01116141|Active Comparator|Methotrexate (MTX) + Folic Acid|20 mg MTX weekly + 1 mg folic acid daily
3222886|NCT01116141|Experimental|0.3 mg CH-4051|0.3 mg CH-4051 daily
3222887|NCT01116141|Experimental|1.0 mg CH-4051|1.0 mg CH-4051 daily
3222888|NCT01116141|Experimental|3.0 mg CH-4051|3.0 mg CH-4051 daily
3222889|NCT01116141|Experimental|3.0 mg CH-4051 + folic acid|3.0 mg CH-4051 + 1.0 mg folic acid daily
3222890|NCT01116154|Experimental|Arm I|Patients receive oral vorinostat twice daily on days 1-14 and oral lenalidomide once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3222891|NCT01116167|Experimental|Letrozole -Berberine|
3222892|NCT01116167|Active Comparator|Letrozole|
3222893|NCT01116167|Active Comparator|Berberine|
3222894|NCT01116180|Active Comparator|Candesartan|
3222895|NCT01116180|Placebo Comparator|Placebo|
3222896|NCT01116206|Experimental|Prucalopride|prucalopride 2- milligram (mg), orally once daily for 12 weeks
3222897|NCT01116206|Placebo Comparator|Placebo|Matching placebo, orally once daily for 12 weeks
3222898|NCT01116219|Active Comparator|Stratum mut EGFR|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~Erlotinib 150 mg p.o. daily until progression."
3222899|NCT01116219|Active Comparator|Stratum wtEGFR|"Cohort 1:~Induction chemotherapy with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression.~Cohort 2:~Induction chemotherapy with~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression.~Followed by maintenance therapy in patients without disease progression with~o Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
3222900|NCT01116245|Experimental|Low Dose|5x10^7 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3222901|NCT01116245|Experimental|Middle Dose|3.3x10^8 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3222902|NCT01116245|Experimental|High Dose|1x10^9 cfu x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3222903|NCT01116245|Placebo Comparator|Placebo|normal saline x 3 intravenous infusions at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
3222904|NCT01116258|Experimental|1|
3222905|NCT01116258|Placebo Comparator|2|
3222906|NCT01116271|Experimental|1|Selumetinib (AZD6244) in combination with irinotecan
3222907|NCT01116284|Experimental|Revision of gastric bypass|A laparoscopic plication of the gastrojejunostomy will be performed after three 5-mm trocars are placed in the upper abdomen. Then using Ethibond suture, laparoscopic plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period with an expected discharge from the hospital within 24 hours.
3222908|NCT01116297|Experimental|Imaging with S-FLARE imaging system|3 patients to be imaged by S-FLARE imaging system.
3222909|NCT01116310|Experimental|Fitogyn|4 weeks with placebo followed by 16 weeks with Fitogyn, both taking two capsules per day during the breakfast.
3222910|NCT01116310|Placebo Comparator|Placebo|20 weeks with placebo, taking two capsules per day during the breakfast.
3222911|NCT01116336|Experimental|Erlotinib and Green Tea Polyphenon E|Patients will receive erlotinib, at pre-defined dose level, with polyphenon E.
3222912|NCT01116349|Active Comparator|Surgical treatment|Patients included in the surgical group will have surgery to treat the fracture.
3222913|NCT01116349|Active Comparator|Conservative treatment group|Patients included in the conservative group will be taken to a plaster room where a Hanging Support System(HSS) brace will be installed by a qualified technician.
3222914|NCT01116362|Other|secondary repair|secondary closure beyond the first week.the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
3222915|NCT01116362|Other|primary repair|during first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
3222916|NCT01116375||Obese children with OSA|To determine whether, in obese children with moderate-severe OSA who are prescribed PAP therapy, increased hours of PAP usage per night over a one-year period is associated with a greater improvement in HOMA-IR
3222917|NCT01116388|Other|test product|product free of gluten and casein
3222918|NCT01116388|Other|control product|product containing gluten and milk protein
3222919|NCT01116453|Experimental|Acupuncture|
3222920|NCT01116453|Active Comparator|Usual Care|usual care followed by delayed acupuncture
3222921|NCT01116479|Active Comparator|Haemoglobin (<6.0 mmol/l)|Blood transfusion thresholds:Haemoglobin < 6.0 mmol/l (9.9 g/dL)
3222922|NCT01116479|Experimental|Haemoglobin (< normal range)|Blood transfusion threshold: Haemoglobin < 7.1 mmol/l (11.7 g/dL) for female and 8.1 mmol/l (13.4 g/dL) for males
3222923|NCT01116492|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
3222924|NCT01116492|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
3222925|NCT01116505|No Intervention|gluten-containing diet|
3222926|NCT01116505|Active Comparator|Active comparator, gluten-free diet|
3222927|NCT01116518|Active Comparator|physiotherapy|
3222928|NCT01116518|Active Comparator|acromioplasty|
3222929|NCT01116518|Active Comparator|acromioplasty and rotator cuff reconstruction|
3222930|NCT01116531|Active Comparator|Duloxetine and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
3222931|NCT01116531|Active Comparator|Pregabalin and tramadol|To ascertain the double-blinding of subjects and investigators, duloxetine and pregabalin will be administered as 2 similar capsules twice a day. Each of these capsules will contain either 30mg of duloxetine, 75 mg of pregabalin or placebo. Capsules will be prepared at the hospital pharmacy.
3222932|NCT01116557|Other|THERMOCOOL® group|Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
3222933|NCT01116557|Active Comparator|PVAC® group|Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®
3375835|NCT03722017|No Intervention|Control--usual care|"Medication History: All participants / surrogates will receive a structured interview and chart review by the study Pharmacist or Nurse Practitioner at enrollment to determine:~Medications: Medications will include ANY medication with the potential for continuation at the time of hospital discharge to include pre-hospital medications, [OTC medications] and active in-hospital medications. Pre-hospital [and OTC] medications will be confirmed by Veteran/surrogate interview and pharmacy refills. If a Veteran is admitted from SNF (short-term stay), the investigators will request a copy of the Medication Administration Record (MAR) for the past 30 days. Current medications will be defined as those taken within 30 days prior to the index (enrollment) hospitalization event."
3222934|NCT01116570|Experimental|Physical training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. As a result, lower limb muscles will be mainly solicited. These muscles are heterogeneous in terms of deficiency, but this latter is compatible with cycling. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. Over a 2 to 4 weeks initial period, the program will be conducted in the laboratory or at home under the supervision of a coach. Then a systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
3222935|NCT01116570|Other|control|None intervention
3222936|NCT01116583|Active Comparator|Gabapentin|Gabapentin group
3222937|NCT01116583|Placebo Comparator|Placebo|Placebo group
3222938|NCT01116622|Experimental|Daily oral erlotinib and bexarotene capusles|Open label dose-ranging trial
3222939|NCT01116635|Experimental|50mg dose loading per vial of doxorubicin|
3222940|NCT01116635|Experimental|75mg dose loading per vial of doxorubicin|
3222941|NCT01116674||Glycemic Control|Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of > 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is > 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
3222942|NCT01116713|Active Comparator|Dexamethasone group|This group of patients received intravenous dexamethasone (8 mg) 60 minutes before skin incision.
3222943|NCT01116713|Placebo Comparator|Placebo group|Patients of these group received homologated placebo 60 minutes before skin incision.
3222944|NCT01116726|Experimental|Motivational interviewing and enhanced community services|Motivational interviewing sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries, provided shortly after childbirth, and at 6, 12, and 18 months. Enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ECC through public service announcements and brochures.
3222945|NCT01116726|Active Comparator|Enhanced community services|Enhanced community services will involve development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
3222946|NCT01116752|Active Comparator|Strict control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive strict glycemic control (80-140 mg/dL)
3222947|NCT01116752|Active Comparator|Conservative control|Children requiring intensive care and mechanical ventilation and/or vasopressor/inotropic support who develop critical illness hyperglycemia (persistent BG values if >140 mg/dL) will be randomized to have their glucose levels managed with insulin infusions and receive conservative control (190-220 mg/dL).
3222948|NCT01116765|Experimental|experimental group|Infants in the experimental group receive an oral stimulation program consisting of stimulation of the oral structures during 10 consecutive days
3222949|NCT01116765|Other|control group|Infant in the control group receive no stimulation only non nutritive sucking during feeding
3222950|NCT01116778|Experimental|eN-Lac® Capsules|
3222951|NCT01116778|Other|Placebo Capsules|
3222952|NCT01116791|Experimental|CRS+HIPC|Patients with biliary, gastric, or pancreatic carcinoma and metastatic or recurrent disease confined to the abdominal compartment
3222953|NCT01116804|Other|inoperable liver cancer patients|
3222954|NCT01116817|Experimental|LPV/r monotherapy 400/100 mg twice daily, orally administered|LPV/r monotherapy 400/100 mg twice daily, orally administered
3222955|NCT01116817|Active Comparator|Lumbar puncture|LPV/r 400/100 mg twice daily + 2 NRTI, orally administered.
3222956|NCT01116830|Placebo Comparator|Placebo|
3222957|NCT01116830|Experimental|RO4917838|
3222958|NCT01116843|Experimental|PF-00299804|Patient will receive PF-00299804 pre-operatively at a dose of 45 mg once daily orally for 7-11 days depending on surgery schedule.
3222959|NCT01116843|Placebo Comparator|Placebo arm|Patient will receive matching Placebo for 7-11 days depending on surgery schedule.
3222960|NCT01116856|Experimental|Nutrition|This groups will follow a diet.
3222961|NCT01116856|Experimental|Nutrition + resistance training|In this group, nutrition and resistance training will be combined.
3222962|NCT01116856|Experimental|Nutrition + aerobic training|In this group nutrition and aerobic training will be combined.
3222963|NCT01116856|Experimental|Nutrition + mixed training|In this group the nutrition will be combined with 50% of resistance training plus 50% of aerobic training.
3222964|NCT01116869||MBC patients|300 MBC patients, each of whom will provide a series of at least 3 blood draws (baseline, 3-4 weeks and 6-8 weeks after the initiation of the systemic therapy) for CTC analysis, will be enrolled. All MBC patients will be followed for a maximum of 36 months for disease progression and survival.
3222965|NCT01116869||Benign disease volunteers|100 Benign disease volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
3222966|NCT01116869||Healthy volunteers|100 Healthy volunteers whom will donate blood 1 time for CTC analysis, will be enrolled as controls.
3222967|NCT01116908|No Intervention|Control|
3222968|NCT01116908|Active Comparator|LifeStraw Family|
3222969|NCT01116947|Active Comparator|Intervention Arm|1. Treatment Arm (CASES) will receive high protein meals during thrice weekly hemodialysis in-center (each meal includes ~50 g of protein, ~850 Cal, and phos/protein ratio <10 mg/g) PLUS dietary counseling to continue similar high protein intake with low phosphorus to protein ratio and to avoid foods with high preservative content. Fosrenol 1.0 to 1.5 g per meal will be prescribed (use of pill crusher will be recommended) and will be titrated based on bi-weekly phosphorus levels.
3222970|NCT01116947|Active Comparator|Control Arm (CONTROLS)|2. Control Arm (CONTROLS) will receive salad boxes in-center (no protein, low calorie) and routine dietary counseling and will continue pre-existing phosphorus binder regimen.
3222971|NCT01116960||Faculty; MD|Full time Faculty members working with the Department
3222972|NCT01116960||CRNAs|Full time CRNAs working within the department
3222973|NCT01116960||Residents|Residents working within the department
3222974|NCT01116973|Other|CICC comparison with PICC|All patients will be having CVP reading taken from the CICC
3222975|NCT01116973|Other|PICC group|The transition to the PICC, a 5.0-French, 18-gauge double lumen PICC (BARD, Power PICC Solo Catheter with Tip Location Stylet; Salt Lake City, UT) will be inserted
3222976|NCT01116999|Experimental|Tracheal intubation|
3222977|NCT01117025|Active Comparator|Circumferential PVI|
3222978|NCT01117025|Active Comparator|Circumferential PVI+renal denervation|
3222979|NCT01117038|Experimental|enalapril and avanafil|
3222980|NCT01117038|Experimental|amlodipine and avanafil|
3222981|NCT01117064|Active Comparator|NMTD adjustment testing|We will determine effective NMTD device settings for reducing AHI.
3222982|NCT01117064|Active Comparator|CPAP vs NMTD device|We will randomly assign previously titrated CPAP vs. NMTD to each subject then compare the resultant AHI between the two devices.
3222983|NCT01117064|Active Comparator|NMTD efficacy and tolerability|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
3222984|NCT01117116|Active Comparator|fluticasone propionate and salmeterol|
3222985|NCT01117116|Active Comparator|budesonide and formoterol|
3222986|NCT01117129|Experimental|A|
3222987|NCT01117129|Placebo Comparator|B|
3222988|NCT01117142||CLL/SLL|Chronic lymphocytic leukemia/small lymphocytic lymphoma
3222989|NCT01117142||Healthy Volunteers|Healthy Volunteers
3222990|NCT01117142||MBL|Monoclonal B-cell lymphocytosis
3222991|NCT01117142||MCL|Mantle Cell Lymphoma
3222992|NCT01117194|Experimental|shoulder training, rehabilitation robot|
3222993|NCT01117194|No Intervention|control group|
3222994|NCT01117220|Placebo Comparator|2|
3222995|NCT01117220|Active Comparator|1|
3222996|NCT01117233|Experimental|Single IV Dose 1|
3222997|NCT01117233|Experimental|Single IV Dose 2|
3222998|NCT01117233|Experimental|Single IV Dose 3|
3222999|NCT01117233|Experimental|Single IV Dose 4|
3223000|NCT01117233|Experimental|Single IV Dose 5|
3223001|NCT01117246|Experimental|Treated bone metastasis|Patients with bone metastasis causing pain.
3223002|NCT01117272||PCOS group|Who met the 2003 Rotterdam criteria.
3223003|NCT01117272||Mild hyperprolactinaemia group|Who were diagnosed with prolactin levels above the upper limit of normal (24.29 ng/ml) and under 100 ng/ml.
3223004|NCT01117272||Control group|Without PCOS and with normal prolactin levels.
3223005|NCT01117285|Active Comparator|3-day post-graduate course|3-day post-graduate course on the use of the COTiD program in clinical practice
3223006|NCT01117285|Experimental|Combined implementation strategy|The combined implementation strategy
3223007|NCT01117298|Experimental|Tadalafil|
3223008|NCT01117298|Placebo Comparator|Placebo|
3223009|NCT01117363|Experimental|Rye porrige breakfast|
3223010|NCT01117363|Active Comparator|Refined wheat reference bread breakfast|
3223011|NCT01117376|Active Comparator|Erythromycin|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
3223012|NCT01117376|Active Comparator|Methylnaltrexone|21 patients admitted in ICU with intolerance to enteral feeding defined as more than 250 ml of gastric residual volume (GRV) found by aspiration technique.
3223013|NCT01117389||Mothers of Childhood cancer survivors|Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the After Completion of Therapy (ACT) clinic at SJCRH. Mothers or female primary caregivers of active patients (aged 9-17) and young adult female patients aged 18-26 in the ACT clinic surviving childhood cancer will be asked to complete a questionnaire which queries sociodemographic, medical, and psychological variables which may relate to HPV vaccination.
3223014|NCT01117389||Acquaintance control Group|"Mothers or female primary caregivers ( with daughters aged 9-17) and young adult females aged 18-26 referred for study participation by participants from the ACT clinic. Participants have daughters aged 9-17 years or young adult females aged 18-26 at the time of study enrollment For those acquaintance controls electing to complete the paper-and-pencil questionnaire, the study team will send it to them in the mail along with a pre-addressed, stamped, return envelope. For those electing to complete the on-line questionnaire, the participant's email address will be collected and a secured link to our on-line questionnaire will be sent to them in an email.~A supplemental community control sample (meeting the inclusion and exclusion criteria outlined above) will also be utilized via the subject pool in the Department of Psychology at The University of Memphis."
3223015|NCT01117415||Gall Bladder Surgery|Who have symptomatic cholelithiasis and wish to undergo laparoscopic cholecystectomy for treatment.
3223016|NCT01117441|Active Comparator|R1 control arm|see detailed protocol description
3223017|NCT01117441|Experimental|R1 experimental arm|see detailed protocol description
3223018|NCT01117441|Active Comparator|R2 control arm|see detailed protocol description
3223019|NCT01117441|Experimental|R2 experimental arm|see detailed protocol description
3223020|NCT01117441|Active Comparator|R-HR control arm|see detailed protocol description
3223021|NCT01117441|Experimental|R-HR experimental arm|see detailed protocol description
3223022|NCT01117467|Experimental|Solo|Students will perform their simulation scenario solo and receive feedback within the group
3223023|NCT01117467|Experimental|Paired|Students will be paired with one of their peers for this simulation scenario
3223024|NCT01117493|Other|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
3223025|NCT01117493|Experimental|Expert Patient Programme|Receives a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
3223026|NCT01117519|Active Comparator|unbalanced infusion solution|
3223027|NCT01117519|Active Comparator|balanced infusion solution compound|
3223028|NCT01117532|Experimental|EFT|Four 90 minute group EFT classes
3223029|NCT01117532|No Intervention|No Treatment|
3223030|NCT01117545|Experimental|EFT|Six sessions of EFT (Emotional Freedom Techniques)
3223031|NCT01117545|No Intervention|Wait List|One month wait period
3223032|NCT01117571||open label|iUni® Unicompartmental Knee Resurfacing Device
3223033|NCT01117584|Experimental|ASP1941 lowest dose|oral tablet
3223034|NCT01117584|Experimental|ASP1941 low dose|oral tablet
3223035|NCT01117584|Experimental|ASP1941 high dose|oral tablet
3223036|NCT01117584|Experimental|ASP1941 highest dose|oral tablet
3223037|NCT01117584|Placebo Comparator|Placebo|oral tablet
3223038|NCT01117597|Active Comparator|low RF exposure level|Intervention with low RF exposure level SAR 1.5 W/kg
3223039|NCT01117597|Sham Comparator|sham RF exposure|Intervention with sham RF exposure
3223040|NCT01117597|Active Comparator|high RF exposure level|intervention with high RF exposure level SAR 6W/kg
3223041|NCT01117610|Active Comparator|epidural injection (group I)|patients in Group I will receive epidural injection of 0.1% ropivacaine 10 ml before skin incision.
3223042|NCT01117610|Placebo Comparator|epidural injection group (group C)|control group will receive no medication preoperatively and during operation
3223043|NCT01117636|Experimental|Arm 1|
3223044|NCT01117636|Active Comparator|Arm 2|
3223045|NCT01117636|Placebo Comparator|Arm 3|
3223046|NCT01117649|Experimental|1|hyper-oncotic colloid
3223047|NCT01117649|Active Comparator|2|iso-oncotic colloid
3223048|NCT01117649|Active Comparator|3|crystalloid
3223049|NCT01117662|Experimental|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
3223050|NCT01117662|Placebo Comparator|Control|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
3223051|NCT01117675|Other|Arm I|Arm I: HIV-infected patients controlled through Virtual Hospital
3223052|NCT01117675|Other|Arm II|Arm II: HIV-infected patients controlled through Standard Care
3223053|NCT01117688|Active Comparator|B - without SGW|Ureteroscopy without SGW in place.
3223054|NCT01117688|Active Comparator|A - with SGW|Ureteroscopy with SGW in place.
3223055|NCT01117701|Experimental|A - with SGW|Measurement of the forces needed to passage the ureteroscope in the ureter with a SGW in place.
3223056|NCT01117701|Experimental|B - without SGW|Measurement of the forces needed to passage the ureteroscope in the ureter without a SGW in place.
3223057|NCT01117714|Active Comparator|EUS/EBUS with FNA|EUS/EBUS staging will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. If present and accessible, at least one lymph node from each accessible station will be aspirated with a separate fine needle using routine FNA and cytological techniques. If multiple lymph nodes are present in a single station, the largest lymph node from that location will be sampled. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the staging procedures will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
3223058|NCT01117714|Active Comparator|Surgical Mediastinoscopy|Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
3223059|NCT01117740||Thoracoscopy Group|
3223060|NCT01117740||Indwelling Pleural Catheters|
3223061|NCT01117753|Experimental|OPT-A|OPT-A is an outpatient family-based treatment for co-occurring substance use and internalizing disorders
3223062|NCT01117753|Active Comparator|Treatment as Usual|Treatment as usual in a community based mental health center
3223063|NCT01117779||Kidney lesions amenable to cryoablation|Kidney lesions treated with cryoablation.
3223064|NCT01117805|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based telephone counseling intervention designed for African American women with asthma.
3223065|NCT01117805|No Intervention|usual care|Usual care at the University of Michigan Health System is based on the guidelines as recommended by the National Asthma Education and Prevention Program Expert Panel Report 3 (NAEPP-EPR3): Diagnosis and Treatment of Asthma and is coordinated so that all patients receive the same action plan, educational materials and instructions in use of devices.
3223066|NCT01117818|Active Comparator|A: AFFITOPE AD02|
3223067|NCT01117818|Active Comparator|B: AFFITOPE AD02|
3223068|NCT01117818|Active Comparator|C: AFFITOPE AD02|
3223069|NCT01117818|Active Comparator|D: Placebo control|
3223070|NCT01117844|Experimental|Proton radiation|
3223071|NCT01117896|Experimental|Adult vs Pedi manikin CC quality|"The primary objective is to determine whether chest compression deterioration occurs at the same rate in pediatric and adult manikins. The primary endpoint will be the difference in mean number of effective compressions per minute in each manikin at times 1, 2, 5 and 10 minutes.~Another objective is to identify the correlation between the anaerobic threshold and the deterioration of compressions in each manikin. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each manikin."
3223072|NCT01117896|Experimental|Stepstool use|A third main objective is to determine the effect of the stepstool use on the quality of chest compressions and metabolic demand. The endpoint will be the difference between mean time to ineffective compressions (defined as 10 consecutive compressions that fail to meet AHA guidelines for depth and rate) and mean time to anaerobic threshold in each experimental group.
3223073|NCT01117909|Sham Comparator|"Laying of hands plus standard therapy"|Subjects will lie on their back as if they were receiving the joint mobilization treatment and the therapist will place their hands in a position as if to perform the mobilization but no movement will occur. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
3223074|NCT01117909|Experimental|Standard therapy with joint mobilization|This group will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session, in addition to standard therapy. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression
3223075|NCT01117922|Experimental|Intervention|After consent, subjects will be assigned to either a usual care group (no intervention) or an intervention group (targeted interconceptional interventions).
3223076|NCT01117922|Other|Usual Care Group|This group will receive usual care.
3223077|NCT01117935|Experimental|Arm I|Patients undergo hypofractionated intensity modulated radiotherapy once daily, 5 days a week, for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with intermediate- and high-risk disease may also receive concurrent and adjuvant or long-term androgen deprivation therapy for up to 36 months.
3223078|NCT01117961|No Intervention|control|
3223079|NCT01117961|Experimental|Intervention|Lifestyle intervention delivered during pregnancy
3223080|NCT01117974|Experimental|Liposuction|
3223081|NCT01118000|Experimental|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
3223082|NCT01118078||Biomarker (DNA methylation, gene expression, RT-PCR)|Archived tumor tissue samples are analyzed for DNA copy number determination, gene expression analysis, DNA methylation, and genomic re-sequencing by microarray analysis-based methods, including PCR analysis, DNA methylation analysis-specific RT-PCR, and quantitative RT-PCR (reverse transcriptase-polymerase chain reaction)
3223083|NCT01118104|Other|Pulmonary vocational rehabilitation|
3223084|NCT01118130||Case|MS patients experiencing an adverse drug reaction to an MS immunomodulatory therapy
3223085|NCT01118130||Control|MS patients not experiencing an adverse drug reaction to an MS immunomodulatory therapy
3223086|NCT01118156||Mental Health Clinicians|MH Clinicians at the Denver and Grand Junction VA Medical Centers
3223087|NCT01118169||Veterans|
3223088|NCT01118182||Traumatic Brain Injury (TBI)|Veterans with a positive history of TBI
3223089|NCT01118182||No Traumatic Brain Injury (TBI)|Veterans with a negative history of TBI
3223090|NCT01118195||TBI and Suicidal Behavior|
3223091|NCT01118195||TBI and No Suicidal Behavior|
3223092|NCT01118208|Experimental|Blister Packaging|Patients will receive all prescription medications on blister pack cards.
3223093|NCT01118208|Active Comparator|Dispense as Usual|Patients will receive all prescription medications in standard pill bottles.
3223094|NCT01118234|Experimental|Rituximab|Treatment with Rituximab 375 mg/m² every 3 months for 24 months
3223095|NCT01118234|No Intervention|Observation|Observation for 24 months
3223096|NCT01118247|Experimental|pure Ti|Cup and stem partly coated with pure titanium
3223097|NCT01118247|Active Comparator|pure Ti and HA|Cup and stem partly coated with pure titanium, and fully coated with HA.
3223098|NCT01118260|Active Comparator|TIVA|Total intravenous anaesthesia (TIVA) with propofol and remifentanil
3223099|NCT01118260|Active Comparator|Spinal|Spinal anaesthesia with bupivacaine and fentanyl
3223100|NCT01118286||Group 1|
3223101|NCT01118364|Experimental|cigarette with cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)"
3223102|NCT01118364|Other|cigarette without cannabis|"a cigarette tobacco trade mark Drum"
3223103|NCT01118390|Experimental|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
3223104|NCT01118390|Active Comparator|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
3223105|NCT01118403|Experimental|Sultamicillin, Antibiotic Prophylaxis|Sultamicillin, Antibiotic Prophylaxis
3223106|NCT01118403|Placebo Comparator|Placebo|Physiologic Sodium Chloride Solution
3223107|NCT01118416|Experimental|intervention condition|Participants randomized to the intervention condition will undergo 4 one-hour sessions of motivational interviewing (MI), during which their sexual risk taking and substance use patterns will be discussed with a trained counselor with the goal of reducing instances of unprotected anal sex and substance use.
3223108|NCT01118416|Active Comparator|Education condition|Participants randomized to the education condition will undergo 4 one-hour sessions during which they will view video segments and discuss sexual risk taking and substance use with a health educator, with the goal of reducing instances of unprotected anal sex and substance use by making informed decisions.
3223109|NCT01118429|Experimental|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
3223110|NCT01118429|Placebo Comparator|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
3223111|NCT01118481||Pressure and flow velocity|
3223112|NCT01118481||Pressure only|
3223113|NCT01118494||CKD patients|People who have been diagnosed with CKD，and been in the stage of 3 or 4.
3223114|NCT01118507||TRISOMY|mothers of a trisomic fetus 21
3223115|NCT01118507||NORMAL KARYOTYPE|mothers of DISOMIQUE foetus 21
3223116|NCT01118533|Experimental|metallic blades|laryngoscope blade material
3223117|NCT01118533|Active Comparator|plastic laryngoscope blades|Laryngoscope Blade Material
3223118|NCT01118546||controls 2|patient without CAD, not on aspirin and without history of hypersensitivity
3223119|NCT01118546||case of hypersensitivity|patient with CAD on aspirin, with a history of hypersensitivity
3223120|NCT01118546||controls 1|patient with CAD on aspirin, without history of hypersensitivity
3223121|NCT01118559|Experimental|fast-fed sequence group|drug is administered in a fasted condition first, and fed-condition study follows
3223122|NCT01118559|Experimental|fed-fast sequence group|drug is administered in a fed condition first, and fasted-condition study follows
3223123|NCT01118572|Experimental|YM177 group|
3223124|NCT01118572|Active Comparator|etodolac group|
3223125|NCT01118572|Placebo Comparator|placebo group|
3223126|NCT01118585|Other|TIF Procedure|Intervention: Transoral incisionless fundoplication procedure using the EsophyX device. During general anesthesia the EsophyX device is introduced trans orally into the stomach and used to created a 270 degree, 3cm in length, wrap at the distal end of the esophagus to treat GERD.. .
3223127|NCT01118598|Placebo Comparator|placebo arm|this group will receive placebo as per protocol
3223128|NCT01118598|Active Comparator|tredaptive|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
3223129|NCT01118637|Experimental|Immediate|Assigned immediately after baseline assessment to receive step 1 treatment (web-based self-help)
3223130|NCT01118637|No Intervention|Wait list|Assigned to wait list for 10 weeks before receiving step 1 treatment.
3223131|NCT01118676|Experimental|Cilengitide with standard radiochemotherapy|Cilengitide (4 dose levels are defined :12, 18, 27 et 40 mg /hour) concomitant with radiotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction) and cisplatin and vinorelbine based chemotherapy.
3223132|NCT01118689|Experimental|MLN0128|
3223133|NCT01118702|Active Comparator|001|Concerta one 54mg tablet once
3223134|NCT01118702|Active Comparator|002|Ritalin-SR 3-20mg tablets once
3223135|NCT01118702|Active Comparator|003|Novo-Methylphenidate ER-C one 54mg tablet once
3223136|NCT01118754|Experimental|DE-101 ophthalmic suspension high dose|
3223137|NCT01118754|Experimental|DE-101 ophthalmic suspension low dose|
3223138|NCT01118754|Placebo Comparator|DE-101 ophthalmic suspension vehicle|
3223139|NCT01118793||double dosing of Clopidogrel|
3223140|NCT01118806||medical residents, vit d|vitamin
3223141|NCT01118806||levels of vitamin d|resident
3223142|NCT01118819|Experimental|Clostridium novyi-NT spores|
3223143|NCT01118858||Case|Pediatric patients who have a primary diagnosis of ADHD, combined type, hyperactive impulsive, or inattentive type (ADD).
3223144|NCT01118858||Control|Healthy subjects: Age and gender matched subjects who do not meet any of the exclusion criteria
3223145|NCT01118871|Active Comparator|Standard of care|
3223146|NCT01118871|Experimental|NRTI sparing arm|
3223147|NCT01118884|Experimental|sedation|20 healthy uncooperative children aged 36-96 months were examined in a cross-over study design , each patient served as his/her own control. Each patient was assigned randomly to received 1 of 2 drug regimens for initial sedation session and the other regimen administered at second session which was one week later.
3223148|NCT01118897|Experimental|Neoadjuvant chemoradiation|All patients will receive concurrent chemoradiation. Chemotherapy will consist of Inj. Gemcitabine 300mg/mt2 weekly throughout the course of Radiotherapy. Radiotherapy will be delivered using Tomotherapy to a dose of 57Gy/25# over 5 weeks
3223149|NCT01118910|Experimental|Vusion ointment|
3223150|NCT01118923|No Intervention|Washout|
3223151|NCT01118923|Active Comparator|Mablet|
3223152|NCT01118923|Placebo Comparator|Placebo|
3223153|NCT01118936|No Intervention|Washout|
3223154|NCT01118936|Active Comparator|Mablet|
3223155|NCT01118936|Placebo Comparator|Placebo|
3223156|NCT01119014|Experimental|Aripirazole|
3223157|NCT01119014|Experimental|Quetiapine prolong|
3223158|NCT01119027||Surgeons|Surgeons and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience. .
3223159|NCT01119027||Trainee Surgeons|Surgeon and trainee surgeons attending laparoscopic colorectal training courses will be recruited to study using different training models to compare each model and correlate outcomes with each model to pre-course experience.
3223160|NCT01119053|Sham Comparator|Arm I|In this branch of study, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
3223161|NCT01119053|Experimental|Arm II|Within this space of time, study participants obtain the VNS therapy at once.
3223162|NCT01119066|Experimental|Total Body Irradiation, Thiotepa and Cyclophosphamide|Hyperfractionated total body irradiation to a dose of 1375-1500 cGy (depending on age, stage of disease and requirement of general anesthesia) with lung shielding) Thiotepa (5 mg/kg/day x 2 or 10 mg/kg/day x 1) Cyclophosphamide (60 mg/kg/day x 2) (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated)
3223163|NCT01119066|Experimental|Busulfan, Melphalan and Fludarabine|Busulfan (0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified according to pharmacokinetics Melphalan (70mg/m2/day x 2 ) Fludarabine (25mg/m2/ day x 5)
3223164|NCT01119066|Experimental|Clofarabine, Melphalan and Thiotepa|Clofarabine (20mg/m2/ day x 5) (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval), Melphalan (70 mg/m2/day x 2) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
3223165|NCT01119066|Experimental|Melphalan, Fludarabine and Thiotepa|Melphalan (70 mg/m2/day x 2) Fludarabine (25mg/m2/ day x 5 ) Thiotepa (5 mg/kg/day x 2 or 10mg/kg/day x1)
3223166|NCT01119079|Placebo Comparator|Standard labor epidural protocol|Standard labor epidural protocol
3223167|NCT01119079|Experimental|10ml Normal Saline prior to lidocaine|
3223168|NCT01119092|Sham Comparator|Sham intervention plus standard treatment|"This group will receive a laying of hands treatment in addition to standard treatment. The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between."
3223169|NCT01119092|No Intervention|Control Group|This group will be individuals who suffer from the same injury but will be instructed to stretch at home 5 days a week for 2 weeks.
3223170|NCT01119092|Experimental|Grade IV AP joint mobilization plus standard treatment|This group will receive 3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
3223171|NCT01119144|Experimental|Polycaprolactone / Tricalcium Phosphate|Polycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
3223172|NCT01119144|Active Comparator|Control|Control group with titanium mesh
3223173|NCT01119157|Experimental|humoral and cellular immune response|
3223174|NCT01119157|Experimental|reactogenicity|
3223175|NCT01119170|Placebo Comparator|control starter formula|
3223176|NCT01119170|Experimental|D-lactate probiotics|
3223177|NCT01119183|No Intervention|1|
3223178|NCT01119183|Active Comparator|2|
3223179|NCT01119183|Experimental|3|
3223180|NCT01119196|No Intervention|glucose-based dialysate|most frequently used Standard of Care (SOC) dialysate
3223181|NCT01119196|Other|Icodextrin dialysate|alternate SOC dialysate
3223182|NCT01119209|Active Comparator|Ropivacaine|
3223183|NCT01119209|Placebo Comparator|Saline|
3223184|NCT01119235|Active Comparator|Cohort 1: PF-04531083|
3223185|NCT01119235|Active Comparator|Cohort 2: PF-04531083|
3223186|NCT01119261|Active Comparator|Non-genotype-guided dosing algorithm|
3223187|NCT01119261|Experimental|Genotype-guided dosing algorithm|
3223188|NCT01119274|Active Comparator|Non-genotype-guided dosing algorithm|
3223189|NCT01119274|Experimental|Genotype-guided dosing algorithm|
3223190|NCT01119300|Active Comparator|Standard care|Standard care
3223191|NCT01119300|Experimental|Genotype-guided dosing algorithm|Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days.
3223192|NCT01119313|Experimental|LAS 41002|
3223193|NCT01119313|Active Comparator|Active|
3223194|NCT01119326|Placebo Comparator|Placebo|Placebo procedure
3223195|NCT01119326|Experimental|Autologous Fat Transfer (AFT) group|Subjects will be registered in the context of either the Early AFT subgroup, or the Delayed AFT subgroup based on the timing of their wound closure: early AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 2-4 weeks of definitive closure (STSG) or healing (secondary closure) and the delayed AFT subgroup will contain subjects who are medically stable such that study sites are amenable to AFT within 6 months or more of definitive closure (STSG) or healing (secondary closure
3223196|NCT01119339|Experimental|LAS 41004 dosage 1|
3223197|NCT01119339|Experimental|LAS 41004 dosage 2|
3223198|NCT01119339|Experimental|LAS 41004 dosage 3|
3223199|NCT01119339|Experimental|LAS 41004 dosage 4|
3223200|NCT01119339|Experimental|LAS 41004 dosage 5|
3223201|NCT01119339|Experimental|LAS 41004 dosage 6|
3223202|NCT01119339|Placebo Comparator|Placebo|
3223203|NCT01119339|Active Comparator|Reference|
3223204|NCT01119352|Experimental|1|
3223205|NCT01119352|Placebo Comparator|2|
3223206|NCT01119365|Experimental|Light|Bright light
3223207|NCT01119378|Experimental|Post Menopausal|post menopausal women between the ages 50-70 yrs.
3223208|NCT01119391||Patients undergoing IVF|Women undergoing an in vitro fertilization cycle
3223209|NCT01119404||Metabolic Syndrome|120 men with metabolic syndrome
3223210|NCT01119404||Coronary Heart Disease (CHD)|120 men with angiographically verified CHD
3223211|NCT01119404||Control|80 physically active men
3223212|NCT01119417|Experimental|BQ123|endothelin blocker
3223213|NCT01119417|Placebo Comparator|Saline|IV saline
3223214|NCT01119430|Placebo Comparator|Fluoxetine plus placebo|
3223215|NCT01119430|Active Comparator|Fluoxetine plus DU125530|
3223216|NCT01119469|Experimental|Cognitive Therapy (CT)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include psychoeducation, attention training, cognitive restructuring, behavioral experiments, imagery rescripting and relapse prevention.
3223217|NCT01119469|Experimental|Exposure Therapy (ET)|There will be 12 50-minute individual sessions conducted at weekly intervals. Booster sessions will be conducted one, three and six months after treatment. Sessions include change of safety behavior, exposition (in sensu and in vivo), and response prevention.
3223218|NCT01119469|No Intervention|Waiting List (WL)|12 weeks waiting time
3223219|NCT01119482|Other|Vaccination|Healthy volunteers before and after vaccination
3223220|NCT01119521|Experimental|Group A: INH; BCG|6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI) (completed within no more than 7 months) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination.
3223221|NCT01119521|Experimental|Group B: observation; BCG; observation; INH|7 months of observation (run in period) followed by intradermal Bacillus Calmette-Guérin (BCG) revaccination followed after 6 months of observation by 6 months of Isoniazid (INH) treatment for latent tuberculosis infection (LTBI).
3223222|NCT01119534|Experimental|Transpulmin|Suppository composed by guaiacol, eucalyptol, menthol and camphor
3223223|NCT01119534|Active Comparator|Comparator 1|Suppository composed by guaiacol
3223224|NCT01119534|Active Comparator|Comparator 2|Syrup composed by guaifenesin
3223225|NCT01119547|Experimental|Home exercise|The patients is training at home during 6 v. with an individual exercise program.
3223226|NCT01119547|Experimental|Exercise in group|The patients is doing their individual exercise program in a group.
3223227|NCT01119560||Ancillary-Correlative (Questionnaire, saliva & tissue sample)|The biologic mother of the patient is asked to complete a Diet History Questionnaire about diet during pregnancy, and information on demographics, lifestyle factors, medication used during pregnancy, history of breast feeding, and family history of cancer or birth defects. Parents are given ORAgene saliva collection kits for self-collection. Saliva bio-specimen samples are collected from both biologic parents and the patient. Tissue samples previously stored in a tissue bank are obtained for deceased patients, if available. DNA is extracted from samples, amplified and analyzed using real-time PCR quantitation assay, and genotyped using single nucleotide polymorphisms.
3223228|NCT01119599|Experimental|Treatment (RO4929097, surgery, radiation therapy)|See Detailed Description.
3223229|NCT01119612|Active Comparator|Iron|
3223230|NCT01119612|Placebo Comparator|Placebo|
3223231|NCT01119638|Active Comparator|Escitalopram Drug|"Drug:~Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion."
3223232|NCT01119638|Active Comparator|Risperidone Drug|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
3223233|NCT01119651|Experimental|Tazarotene Foam without irradiation|Subjects will be exposed to Tazarotene Foam Patch without irradiation
3223234|NCT01119651|Experimental|Tazarotene Foam with UVA and UVB irradiation|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation
3223235|NCT01119651|Experimental|Tazarotene Foam & UVA/UVB/visible light|Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB and visible light irradiation
3223236|NCT01119651|Placebo Comparator|Vehicle Foam without irradiation,|Subjects will be exposed to Vehicle Foam Patch without irradiation
3223237|NCT01119651|Placebo Comparator|Vehicle Foam with UVA and UVB irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation
3223238|NCT01119651|Placebo Comparator|Vehicle Foam with UVA & UVB visible light irradiation|Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation
3223239|NCT01119651|Sham Comparator|Blank patch without irradiation|Subjects will be exposed to blank patch without irradiation,
3223240|NCT01119651|Sham Comparator|Blank patch with UVA and UVB irradiation|Subjects will be exposed to blank patch with UVA and UVB irradiation
3223241|NCT01119651|Sham Comparator|Blank Patch with UVA & UVB visible light irradiation|Subjects will be exposed to Blank Patch with UVA and UVB and visible light irradiation
3223242|NCT01119664|Experimental|No prior chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously untreated with chemotherapy
3223243|NCT01119664|Experimental|Patients with prior Pemetrexed-based chemotherapy|Intrapleural SCH 721015 (Ad.hIFN-α2b) instilled over 2-5 minutes on Days 1 and 4. Chemotherapy administered for 4 to 6 cycles Subjects with malignant pleural mesothelioma who have been previously treated with chemotherapy
3223244|NCT01119677|Experimental|Group 1|No dose titration
3223245|NCT01119677|Experimental|Group 2|Fast dose titration
3223246|NCT01119677|Experimental|Group 3|Slow dose titration
3223247|NCT01119690|Active Comparator|Rapeseed oil|
3223248|NCT01119690|Active Comparator|Milk fat|
3223249|NCT01119729||HIV-infected Outpatients|
3223250|NCT01119742|Experimental|Butenafine Hydrochloride 1% A|1
3223251|NCT01119742|Experimental|Butenafine Hydrochloride 1% B|2
3223252|NCT01119742|Active Comparator|Butenafine Hydrochloride 1%|3
3223253|NCT01119742|Placebo Comparator|Vehicle A|4
3223254|NCT01119742|Placebo Comparator|Vehicle B|5
3223255|NCT01119781|Experimental|peginterferon beta-1a|Single dose of peginterferon beta-1a at either 63 or 125 mcg in renal impaired Participants and healthy volunteers
3223256|NCT01119807|Experimental|IV|
3223257|NCT01119807|Experimental|Humeral IO|
3223258|NCT01119807|Active Comparator|Tibial IO|
3223259|NCT01119820|Experimental|Tissue Donation|This study will involve females over 18 who are scheduled to undergo elective surgery. These patients will be screened for participation in this study, which will only involve the collection of discarded tissue.
3223260|NCT01119833|Experimental|GMI-1070|
3223261|NCT01119833|Placebo Comparator|Placebo|
3223262|NCT01119872|Other|Compliance-guided PEEP group|Positive End-Expiratory Pressure(PEEP) level was set daily, according to the method described by Suter in 1978. Static compliance (Cst) was calculated at different levels of PEEP at a constant tidal ventilation of 6-8 ml/kg of predicted body weight. Cst was determined by dividing tidal volume by the difference between the pressure at the end of inflation hold and the PEEP. The maximum value of Cst in individual patients was considered as the best PEEP.
3223263|NCT01119872|Other|FiO2-driven-PEEP group|"PEEP was set based on the patient fraction of inspired oxygen (FiO2) according to the Positive End-Expiratory Pressure(PEEP) strategy reported in 2000:Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network."
3223264|NCT01119885||001|fentanyl matrix Knee osteoarthritis starting with 12mcg/h (flexible dose)
3223265|NCT01119885||002|fentanyl matrix Hip osteoarthritis starting with 12mcg/h (flexible dose)
3223266|NCT01119924|Active Comparator|Mirtazapine|Mirtazapine 15mg/day or placebo once a day on the fist week, then 30 mg/day or placebo once a day, and then for 7 consecutive weeks
3223267|NCT01119924|Placebo Comparator|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
3223268|NCT01119976|Experimental|Group A|Reduced calorie diet and exercise plan that changes with phases of the menstrual cycle
3223269|NCT01119976|Active Comparator|Group B|Different reduced calorie diet and exercise plan based on MyPyramid.gov website
3223270|NCT01119989|No Intervention|weight maintenance diet|
3223271|NCT01119989|Placebo Comparator|weight maintenance + fructose|
3223272|NCT01119989|Experimental|weight maintenance diet + fructose and amino-acid|
3223273|NCT01120002|Placebo Comparator|Placebo pill|
3223274|NCT01120002|Active Comparator|Tamibarotene|
3223275|NCT01120015|Experimental|Diacerein|diacerein 50mg oD first month, 50 mg BD next 2 months
3223276|NCT01120041|Experimental|Prenatal MI - Postpartum MI|Motivational interviewing counseling given during the prenatal and postpartum phases
3223277|NCT01120041|Experimental|Prenatal MI - Postpartum Health Ed|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
3223278|NCT01120041|Experimental|Prenatal Health Ed - Postpartum MI|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
3223279|NCT01120041|Placebo Comparator|Prenatal Health Ed/Postpartum Health Ed|Traditional health education given during the prenatal phase and the postpartum phase
3223280|NCT01120080|Placebo Comparator|Practical Counseling|
3223281|NCT01120080|Active Comparator|Alcohol Intervention Counseling|
3223282|NCT01120106|Active Comparator|levosimendan|levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
3223283|NCT01120106|Placebo Comparator|placebo|saline infusion
3223284|NCT01120119|Experimental|Calcitriol|
3223285|NCT01120119|Placebo Comparator|placebo|
3223286|NCT01120132|Experimental|Cyclosporine low dose , Prednisolone Acetate|Administration of a solution of Cyclosporine (low dose) and a suspension of Prednisolone Acetate
3223287|NCT01120132|Experimental|Cyclosporine high dose, Prednisolone Acetate|Administration of a solution of Cyclosporine (high dose) and a suspension of Prednisolone Acetate
3223288|NCT01120132|Experimental|Cyclosporine high dose|Administration of a solution of Cyclosporine (high dose) and Placebo
3223289|NCT01120132|Experimental|Cyclosporine low dose|Administration of a solution of Cyclosporine (low dose) and Placebo
3223290|NCT01120132|Active Comparator|Prednisolone Acetate|Administration of a suspension of Prednisolone Acetate and Placebo
3223291|NCT01120132|Placebo Comparator|Placebo|Administration of Placebo
3223292|NCT01120145||Therapeutic efficacy study|Asymptomatic parasitemic pregnant women at 16-26 weeks of gestation will be enrolled into the study and followed weekly for 42 days after the receipt of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy to assess the clearance of parasitemia.
3223293|NCT01120145||Birth outcomes study|Women presenting for delivery will be enrolled and assessed for a history of sulphadoxine-pyrimethamine intermittent preventive treatment in pregnancy and evidence of malaria infection by placental histology, maternal peripheral parasitemia, maternal anemia and infant cord blood parasitemia.
3223294|NCT01120145||Characterizing molecular markers of SP resistance|Parasitemic outpatients attending the health facility will be tested for parasite molecular markers of sulphadoxine-pyrimethamine resistance.
3223295|NCT01120158|Experimental|1|Paclitaxel/Bevacizumab
3223296|NCT01120171|Experimental|1|Cyclofosfamide/Liposomal-encapsulated doxorubicin
3223297|NCT01120301|Experimental|Transcranial Laser Therapy|
3223298|NCT01120301|Sham Comparator|Sham control procedure|
3223299|NCT01120314|Experimental|Severe renal impairment population|
3223300|NCT01120314|Experimental|Moderate renal impairment population|
3223301|NCT01120314|Experimental|Mild renal impairment population|
3223302|NCT01120314|Experimental|Healthy population|Healthy matched subjects
3223303|NCT01120327|Experimental|Amlodipine|Amlodipine
3223304|NCT01120327|Placebo Comparator|Placebo|Placebo
3223305|NCT01120340|Active Comparator|mesalamine|Posology: mesalamine: 1,6 g/die for ten days every month for 24 months
3223306|NCT01120340|Placebo Comparator|placebo|
3223307|NCT01120353||Cancer survivors|Survivors of cancer, diagnosed under 21 years of age, between 1970 and 1999 This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, for an increased risk of late-occurring events associated with excess mortality and morbidity.
3223308|NCT01120353||Sibling Controls|A group of sibling controls will be identified to provide: (1) the ability to make direct comparisons with the survivors, (2) data on outcomes in a non-cancer population, and (3) additional comparison group to determine consistency of findings between data sources.
3223309|NCT01120366|Active Comparator|SWITCH|Tocilizumab monotherapy
3223310|NCT01120366|Active Comparator|ADD-ON|Tocilizumab plus methotrexate combination
3223311|NCT01120392|Experimental|Treatment group - Nintendo wii.|
3223312|NCT01120392|Active Comparator|conventional - Physical Therapy|
3223313|NCT01120418|Experimental|Besifloxacin Ophthalmic Suspension 0.6%|Topical ocular administration three times daily (TID) for 5 days
3223314|NCT01120431|Active Comparator|Oral rehydration therapy|
3223315|NCT01120431|Experimental|hylenex-facilitated SC hydration|
3223316|NCT01120444|Active Comparator|Subcutaneous delivery of insulin|A bolus dose of insulin will be given subcutaneously just prior to a standardized meal.
3223317|NCT01120444|Experimental|Intradermal delivery of insulin|A bolus dose of insulin will be given intradermally just prior to a standardized meal
3223318|NCT01120457|Experimental|Arm 1: Dose Escalation and Expansion cohort (AML Patients)|"Dose Escalation: BMS-936564 0.3-10 mg/kg solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)~Dose Expansion: BMS-936564 maximum tolerated dose (MTD) based on dose escalation, solution, Intravenous, Single 60 minute infusion as monotherapy 7 days/cycle 1 and with chemotherapy for subsequent cycles (28 days/cycle)"
3223319|NCT01120457|Experimental|Arm 2: Dose Expansion cohort (DLBCL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3223320|NCT01120457|Experimental|Arm 3: Dose Expansion cohort (CLL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3223321|NCT01120457|Experimental|Arm 4: Dose Expansion cohort (FL Patient)|BMS-936564 MTD based on Arm 1, weekly 60 minute infusion in cycle 1 (up to 56 days) and with chemotherapy for subsequent cycles (28 days/cycle)
3223322|NCT01120470|Experimental|OGX-427 and Prednisone|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427
3223323|NCT01120470|Active Comparator|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization"
3223324|NCT01120496|Experimental|hypertonic saline|hypertonic saline (HS)
3223325|NCT01120496|Placebo Comparator|normal saline (NS)|normal saline (NS)
3223326|NCT01120509|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3223327|NCT01120522|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3223328|NCT01120535|Experimental|Crux Vena Cava Filter System|Subjects at risk for Pulmonary Embolism
3223329|NCT01120548|Experimental|Rehabilitation + Ventilation Group|Patient Heart Failure with sleep disordered breathing who follows ventilation therapy and physical training.
3223330|NCT01120548|No Intervention|Rehabilitation Only Group|
3223331|NCT01120574|No Intervention|1|Oxygen therapy group.
3223332|NCT01120574|Active Comparator|2|Home mechanical ventilation plus oxygen therapy group.
3223333|NCT01120613|Experimental|chronotherapy|Patients identified with Nocturnal Hypertension, will have one of the blood pressure medications switched from daytime dosing to nighttime dosing
3223334|NCT01120652|Experimental|Mind-Body Skills Training|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices.
3223335|NCT01120652|Active Comparator|Supportive Counseling|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice.
3223336|NCT01120665|Experimental|PLACEBO-CONTROL|PLACEBO + CONTROL TO EXERCISE
3223337|NCT01120665|Experimental|ESTROGEN THERAPY + CONTROL|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + CONTROL TO EXERCISE
3223338|NCT01120665|Experimental|PLACEBO+AEROBIC TRAINING|PLACEBO + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
3223339|NCT01120665|Experimental|ESTROGEN THERAPY + AEROBIC TRAINING|ESTROGEN THERAPY (estradiol valerate 1 mg/dia orally) + AEROBIC TRAINING (cicle-ergometer, 50 minutes, 3x week)
3223340|NCT01120678||Neonates assessed for sepsis.|
3223341|NCT01120730|Active Comparator|HES|Fluid resuscitation with HES
3223342|NCT01120730|Placebo Comparator|ringers lactat|Standard treatment
3223343|NCT01120769|Active Comparator|Acetaminophen|
3223344|NCT01120769|Placebo Comparator|Placebo|
3223345|NCT01120795|Experimental|pegylated interferon and ribavirin|Anti hepatitis C agents
3223346|NCT01120821|Experimental|Study drug|Gleevec treatment
3223347|NCT01120847||Veterans with PTSD|No intervention; this is an observational study.
3223348|NCT01120847||Control group w/out PTSD|No intervention; this is an observational study.
3223349|NCT01120873|Experimental|Metamin 3D|A randomized, double-blinded and placebo-controlled study
3223350|NCT01120912|Experimental|Oral insulin and placebo|
3223351|NCT01120925|Experimental|MNC|Bone marrow derived MNC
3223352|NCT01120925|Experimental|CD133|CD133 derived from Bone marrow
3223353|NCT01120925|Placebo Comparator|Control|Normal saline with 5% Human Serum Albumin
3223354|NCT01120964|Experimental|Intravenous L-Citrulline|
3223355|NCT01120964|Placebo Comparator|Placebo of Intravenous L-Citrulline|
3223356|NCT01120977||Male|
3223357|NCT01120977||Female|
3223358|NCT01121003|Other|Low fructose diet/no exercise|
3223359|NCT01121003|Experimental|high fructose diet/no exercise|
3223360|NCT01121003|Experimental|high fructose diet+exercise|
3223361|NCT01121016|Active Comparator|combination therapy|combination therapy with inhaled budesonide and oral montelukast
3223362|NCT01121016|Placebo Comparator|monotherapy|monotherapy with inhaled budesonide and placebo of montelukast
3223363|NCT01121029|Experimental|Hematopoietic stem cells|
3223364|NCT01121042|Active Comparator|Ondansetron|Ondansetron oral capsule 8mg daily
3223365|NCT01121042|Placebo Comparator|Placebo|Placebo (100% lactose) matched oral capsule
3223366|NCT01121055|Placebo Comparator|Control|Placebo 1T by mouth (po) at night one day before FB and placebo 1T po 30min before the FB
3223367|NCT01121055|Experimental|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
3223368|NCT01121068||Health care workers|
3223369|NCT01121081|Placebo Comparator|Placebo|sugar pills
3223370|NCT01121081|Experimental|Dunaliella|drug
3223371|NCT01121107|Experimental|Left Atrial Pressure Monitoring System|Left Atrial Pressure (LAP) Monitoring System
3223372|NCT01121107|Active Comparator|Patient Advisor Module|Patient Advisory Module
3223373|NCT01121120|Experimental|TXA127|300mcg/kg/day administered subcutaneously up to 28 days
3223374|NCT01121120|Placebo Comparator|Placebo|300mcg/kg/day administered subcutaneously up to 28 days
3223375|NCT01121133|Experimental|Arm A (navitoclax and rifampin)|
3223376|NCT01121159||Preoperatively preformed orbital plates|Reconstruction with MatrixMIDFACE Preformed Orbital Plate (Synthes) or Custom-made orbital implant
3223377|NCT01121159||Non-preformed orbital plates|Reconstruction with Orbital Floor Mesh Plate or SynPOR Titanium Reinforced Fan Sheet (both Synthes)
3223378|NCT01121198|Experimental|ASP1941 single arm|
3223379|NCT01121198|Experimental|ASP1941 repeated arm|
3223380|NCT01121198|Placebo Comparator|placebo single arm|
3223381|NCT01121198|Placebo Comparator|placebo repeated arm|
3223382|NCT01121237||CKD5, renal anaemia, haemodialysis|CKD5, renal anaemia, haemodialysis receiving recombinant human erythropoietin alfa (biosimilar)
3223383|NCT01121276|Experimental|NN1218, formulation A|
3223384|NCT01121276|Experimental|NN1218, formulation B|
3223385|NCT01121276|Experimental|NN1218, formulation C|
3223386|NCT01121276|Experimental|NN1218, formulation D|
3223387|NCT01121276|Active Comparator|insulin aspart|
3223388|NCT01121289|Experimental|NN1218, formulation A|
3223389|NCT01121289|Experimental|NN1218, formulation B|
3223390|NCT01121289|Experimental|NN1218, formulation B (high)|
3223391|NCT01121289|Experimental|NN1218, formulation C|
3223392|NCT01121289|Experimental|NN1218, formulation D|
3223393|NCT01121289|Active Comparator|insulin aspart|
3223394|NCT01121302|Experimental|1|dose escalating
3223395|NCT01121302|Placebo Comparator|2|placebo
3223396|NCT01121315||1|Diabetes type II patients, according to medical records, prescriptions or lab results, followed for >6 months after diagnosis.
3223397|NCT01121328|Experimental|Autologous cord blood transfusion|Collected cord blood at birth will be transfused for the preterm neonate
3223398|NCT01121341|Experimental|EVOH|Procedure: Endoscopic vein with an open CO2 system harvesting
3223399|NCT01121341|Active Comparator|OVH|Procedure: Conventional vein harvesting
3223400|NCT01121354|Experimental|Cefazolin 2g (Test)|
3223401|NCT01121354|Active Comparator|Cefazolin 1.5g (Control)|
3223402|NCT01121367||Emphysema-alone|
3223403|NCT01121367||CPFE group|
3223404|NCT01121367||IPF-alone|
3223405|NCT01121367||smokers|
3223406|NCT01121367||nonsmokers|
3223407|NCT01121380|Experimental|Cohort A - 10 mg|
3223408|NCT01121380|Experimental|Cohort B - 20 mg|
3223409|NCT01121380|Experimental|Cohort C - 40 mg|
3223410|NCT01121380|Experimental|Cohort D - 80 mg|
3223411|NCT01121380|Experimental|Cohort E - X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3223412|NCT01121380|Experimental|Cohort F - 2X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3223413|NCT01121380|Experimental|Cohort G - 4X mg|Part 2, multiple dose. X shall be determined using the results of part 1.
3223414|NCT01121380|Placebo Comparator|Placebo|In each cohort there is a placebo arm
3223415|NCT01121419||Neuroblastoma|
3223416|NCT01121432||Mediastinal lymphadenopathy|
3223417|NCT01121445|No Intervention|CPAP with heated humidification|Standard of care
3223418|NCT01121471|Placebo Comparator|Safflower Oil|8.0 g/day safflower oil
3223419|NCT01121471|Experimental|CLA 6.4g/day|Conjugated linoleic acid at a dose of 6.4g/day in a supplement with a total of 8.0g oil
3223420|NCT01121497|Experimental|Physostigmine|Colonoscopy sedation with or without physostigmine
3223421|NCT01121523|Experimental|Cue-directed tactile stimulation|
3223422|NCT01121523|Active Comparator|Control group|
3223423|NCT01121588|Experimental|Crizotinib|
3223424|NCT01121601|Experimental|Group COSEAL|
3223425|NCT01121601|Active Comparator|Reference group|
3223426|NCT01121614|Experimental|LOTUS|LOTUS ultrasonic instrument
3223427|NCT01121614|Experimental|Ethicon Harmonic Scalpel|Ultrasonic instrument
3223428|NCT01121614|Experimental|LigaSure|Bipolar feedback vessel sealing device
3223429|NCT01121627|Experimental|Computerized cognitive training|A 12 week computerized cognitive training
3223430|NCT01121640|Other|CA125 every screen, HE4 at confirmatory screen.|CA125 will be used at every screen. Women with a parametric empirical Bayes (PEB) longitudinal algorithm score above the 90th percentile will be asked to return for early recall screening. Women with a PEB score above the 95th percentile will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
3223431|NCT01121640|Other|CA125 and HE4 at every screen.|CA125 and HE4 will both be used at every screen. Women with a PEB score above the 95th percentile on either CA125 or HE4 will be referred for confirmatory measurements of CA125 and HE4. If confirmatory test results are higher than expected, a transvaginal ultrasound will be performed.
3223432|NCT01121679||Patients aged 80 years and older|Patients aged 80 years and older and hospitalized in a cardiology department
3223433|NCT01121692|Experimental|VCT/Women's CoOp|
3223434|NCT01121692|Experimental|Women's CoOp/Men's CoOp|
3223435|NCT01121692|Experimental|Couples CoOp|
3223436|NCT01121705|No Intervention|A1. standard duration|Patients were randomly assigned in a 1:1 ratio to two treatment arms. In the standard treatment group (A1), patients were treated for 24 weeks irrespective of the HCV RNA status at week 4 with Peg-interferon alfa-2b at a dose of 1.5 mcg per kilogram of body weight weekly in combination with oral ribavirin administered at a dose of 1000 mg/day for patients with a weight <75 kg or 1200 mg/day for those with a weight of ≥75 kg. Patients enrolled in Arm A1 will be treated for standard 24 weeks duration of treatment with standard dosages of PegInterferon alpha 2b and weight-based dosages of ribavirin.
3223437|NCT01121705|Experimental|B 1 I or II|In the variable treatment group, patients with a virologic response at week 4 will receive treatment for 12 weeks and those without a virologic response at 4 weeks treatment for 36 weeks. Patients without RVR will be treated for 24 or 36 weeks and labelled (B1I) or (B1II, respectively Intervention: different durations of treatment for patients without RVR
3223438|NCT01121718|Experimental|ICG Intervention|Intraoperative NIR fluorescence imaging was performed after injection of 1.0 ml of 100 µM, 250 µM or 500 µM of ICG:HSA in four quadrants around the primary lesion. (The intervention to be administered is the ICG.)
3223439|NCT01121731|Experimental|Interferon α-5|
3223440|NCT01121731|Experimental|Interferon α-5 plus Interferon α-2b|
3223441|NCT01121731|Active Comparator|Interferon α-2b (INTRON® A)|
3223442|NCT01121770|Experimental|Arixtra|
3223443|NCT01121783|Active Comparator|Lactisole-Glucose|
3223444|NCT01121783|Active Comparator|Lactisole-water|
3223445|NCT01121783|Placebo Comparator|Water-Glcuose|
3223446|NCT01121783|Placebo Comparator|Water-Water|
3223447|NCT01121796|Active Comparator|Vitamin D|
3223448|NCT01121796|Placebo Comparator|Placebo|
3223449|NCT01121796|Active Comparator|Unique vehicle for Vitamin D supplementation|
3223450|NCT01121809|Other|Raltegravir|Raltegravir 400 mg bid
3223451|NCT01121809|Other|Etravirine|Etravirine 200 mg bid
3223452|NCT01121822|Experimental|Group 1|Participants at age 18 to 59 years
3223453|NCT01121822|Experimental|Group 2|Participants at age 60 years or older
3223454|NCT01121835|Experimental|Insulin glargine|"Administered once a day in the evening, at the same time every day. The starting daily dose is 0.2 U/Kg of body weight or 12 U, at the investigator's decision.~Insulin glulisine is administered for patients of the insulin glargine group requiring insulin glulisine at week 12 (visit 11).~Insulin glulisine is administered prior (10-15 min) to the main meal of the day, which is the meal with highest Post-Prandial Plasma Glucose (PPPG) on the 3 profiles performed before week 12.~Starting dose is of 4 units per day."
3223455|NCT01121835|Experimental|Premixed insulin|administered once a day (in the evening at dinner) or twice a day (in the morning before breakfast and in the evening at dinner). Starting daily dose will be 6 U at breakfast and 6 U at dinner, if administered twice a day or 12 U at dinner if administered once a day
3223456|NCT01121848|Active Comparator|5-FU & LV|"Day 1: LV 400 mg/m2 (given as a 2-hour infusion)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours.~This chemotherapy regimen will be administered each two weeks."
3223457|NCT01121848|Experimental|XELOX or modified FOLFOX-6|"XELOX:~Day 1: Oxaliplatin 130 mg/m2 (2 hours infusion)~This chemotherapy regimen will be administered each two weeks.~OR modified FOLFOX-6:~Day 1: Oxaliplatin 85 mg/m2 (given as a 2-hour infusion)~Day 1: LV 400 mg/m2 (given as a 2-hour infusion simultaneous to oxaliplatin)~Day 1 and 2: 5-FU given as a bolus IV 400 mg/m2 dose on Day 1 followed by 2400 mg/m2 continuous infusion over 46 hours (Day 1 and 2)~This chemotherapy regimen will be administered each two weeks."
3223458|NCT01121874|Active Comparator|LRTI|These patients will undergo ligament reconstruction with tendon interposition (LRTI) surgery. They will serve as a control group, against which to compare the investigational surgical technique.
3223459|NCT01121874|Experimental|Suture fixation system|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system.
3223460|NCT01121874|Experimental|Suture fixation system + 2 week immobilization|CMC arthroplasty which reconstructs palmar oblique ligament using a suture fixation system, and with a decreased immobilization time from 6 to 2 weeks post-surgery.
3223461|NCT01121887|Active Comparator|Standard treatment|
3223462|NCT01121887|Experimental|Motivational Interviewing|
3223463|NCT01121952|Placebo Comparator|Placebo|Single high-velocity, low-amplitude (HVLA) thrust manipulation towards Tibia, not affecting the dysfunctional talo-crural joint
3223464|NCT01121952|Experimental|Treatment|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation on dysfunctional talo-crural joint
3223465|NCT01121965|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs
3223466|NCT01121965|Experimental|Early vitrectomy|Pars plana vitrectomy with ILM peeling would be employed when visual symptoms occur.
3223467|NCT01121978|No Intervention|Conservative treatment group|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole or vision deterioration occurs
3223468|NCT01121978|Experimental|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
3223469|NCT01122004|Active Comparator|Gabapentin|
3223470|NCT01122004|Active Comparator|Pregabalin|
3223471|NCT01122017|Experimental|Medial Opening-Wedge Osteotomy|Medial Opening-Wedge Osteotomy (MOWO) is an approach for the correction of malalignment of the knee
3223472|NCT01122043||Endoglide|Patients with moderate degrees of corneal decompensation from a variety of disorders which require DSAEK corneal transplantation surgery, with or without concurrent cataract surgery, to restore visual acuity.
3223473|NCT01122056|Active Comparator|A = Active group|Patients will receive interactive exercise training session from an experienced multiple sclerosis
3223474|NCT01122056|No Intervention|B = Control group (Placebo Comparator)|Patients will receive general advice about benefits/side effects of physical activity in multiple sclerosis.
3223475|NCT01122069||Contrast echocardiography|110 patients with acute non-ST elevation myocardial infarct were examined with contrast echocardiography prior to coronary angiography.
3223476|NCT01122095||Psoriasis|Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
3223477|NCT01122095||Control patient|Age matched, without psoriasis or significant inflammatory disease
3223478|NCT01122121|Experimental|Combined Radiotherapy and Hormone Therapy|Leuprorelin 11.25 milligram (mg) sustained release (SR), injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin. Radiotherapy 70 +/- 4 Gray (Gy) in 35 fractions at a rate of 5 fractions of 2 Gy per week up to 3 years. An interval of a maximum of 2 weeks is authorized between radiation of the pelvis with 50 Gy (±4) (5 weeks) and radiation of the prostate with an additional 20 Gy.
3223479|NCT01122121|Active Comparator|Hormone Therapy alone|Leuprorelin 11.25 mg SR, injection, subcutaneously, once every 3 months up to 3 years and flutamide 250 mg, tablet, orally, thrice daily for 30 days from the first dose of leuprorelin.
3223480|NCT01122134||20 adults with severe malaria|20 adult patients admitted with severe malaria
3223481|NCT01122147|Active Comparator|chamomilla tincture mouthwash|Chamomile comprises bisaboloids, matricine and chamazulene, flavonoids, and cumarins having therapeutical anti-inflammatory, analgesic, musculotropic, and spasmolytic action
3223482|NCT01122147|Placebo Comparator|placebo mouth wash|placebo mouthwash is produced with the same taste and smell for using in placebo/ control group.
3223483|NCT01122186|Experimental|Intervention Condition|Eight sessions of Motivational Interviewing and Cognitive Behavioral Skills Training, adapted to target both MA use and medication adherence, as well as sexual risk behaviors and polydrug use.
3223484|NCT01122186|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition. The content will be as follows: 3 sessions focusing on medication adherence; 3 sessions focusing on the dangers of methamphetamine use; 1 session addressing sexual risk; and 1 session addressing poly-substance use.
3223485|NCT01122199|Experimental|Open Label|RAD001+ AMG479
3223486|NCT01122225||Septic shock|
3223487|NCT01122251|Experimental|Lercanidpine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
3223488|NCT01122251|Active Comparator|Lercanidipine or Valsartan|L10, L20, V80, V160
3223489|NCT01122251|Placebo Comparator|Placebo|Placebo comparators of Lercanidipine and Valsartan
3223490|NCT01122290||negative emotion|Children experienced induction of mild negative emotion through a jigsaw with a missing piece (negative emotion group)
3223491|NCT01122290||neutral emotion|Vs. Same task with No missing piece (neutral emotion).
3223492|NCT01122303||SJS|Stevens-Johnson syndrome patients with dry eye
3223493|NCT01122303||Control|Non-autoimmune dry eye patients
3223494|NCT01122329|Placebo Comparator|inactive food packet|
3223495|NCT01122329|Active Comparator|Axona®|
3223496|NCT01122342|Experimental|Vaginal Testosterone|Daily application of vaginal testosterone for 28 days.
3223497|NCT01122355|Active Comparator|niacin arm|
3223498|NCT01122355|Active Comparator|fenofibrate arm|
3223499|NCT01122368|Experimental|1 Micafungin|IV
3223500|NCT01122368|Placebo Comparator|2 Placebo|IV
3223501|NCT01122407|Experimental|trimethaphan|Trimethaphan infusion doses of 4 mg/min
3223502|NCT01122407|Experimental|Trimethaphan plus L-NMMA|Trimethaphan infusion 4 mg/min L-NMMA (L-NG-monomethyl Arginine citrate) infusion 250 mpg/kg/min A small group of arm 1 will receive both drugs.
3223503|NCT01122420|Experimental|Goal-Setting Tool|
3223504|NCT01122420|Active Comparator|Health Web Sites|
3223505|NCT01122433|Experimental|C-MAC|After a maximum of three failed intubation attempts using direct laryngoscope the C-MAC video laryngoscope is used as an emergency airway device.
3223506|NCT01122459|Active Comparator|Hartmanns|These patients will receive Hartmanns during anaesthesia
3223507|NCT01122459|Active Comparator|Voluven 6%|
3223508|NCT01122472|Experimental|Lenalidomide|Lenalidomide daily for 3 weeks every 4 weeks for 24 months
3223509|NCT01122472|Placebo Comparator|Placebo|Placebo daily for 3 weeks every 4 weeks for 24 months
3223510|NCT01122485|Experimental|Low dose group|two tablets per dose (one tablet of investigational drug and one tablet of placebo)
3223511|NCT01122485|Experimental|High dose group|two tablets per dose (two tablets of investigational drug)
3223512|NCT01122485|Placebo Comparator|Control group|two tablets per dose (two tablets of placebo)
3223513|NCT01122498|Experimental|1|
3223514|NCT01122498|Experimental|2|
3223515|NCT01122498|Experimental|3|
3223516|NCT01122524||Chromosomal Abnormality|Fetus affected by chromosomal abnormality
3223517|NCT01122524||No Chromosomal Abnormality|Fetus not affected by chromosomal abnormality
3223518|NCT01122589|Experimental|Motivation Interviewing/CBT|
3223519|NCT01122589|Active Comparator|Control|Receive a smoking cessation pamphlet and watch a series of six weekly 30-45 minutes general wellness videos.
3223520|NCT01122602|Experimental|Arm 1|
3223521|NCT01122602|Active Comparator|Arm 2|
3223522|NCT01122602|Placebo Comparator|Arm 3|
3223523|NCT01122615|Experimental|Sunitinib + Temsirolimus|Sunitinib 12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle. Temsirolimus 6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
3223524|NCT01122628||DVR-A|Patients with a distal radial fracture treated with a DVR-A locking plate
3223525|NCT01122641|Placebo Comparator|Placebo|
3223526|NCT01122641|Experimental|Vildagliptin|Vildagliptin 50mg bid
3223527|NCT01122654||Control|
3223528|NCT01122654||Experimental 1|
3223529|NCT01122654||Experimental 2|
3223530|NCT01122667|Experimental|Part 1 - Panel A|Subjects with severe renal impairment
3223531|NCT01122667|Experimental|Part 1 - Panel B|Healthy matched control subjects
3223532|NCT01122667|Experimental|Part 2 - Panel C|Subjects with moderate renal impairment
3223533|NCT01122667|Experimental|Part 2 - Panel D|Healthy matched control subjects
3223534|NCT01122667|Experimental|Part 2 - Panel E|Subjects with mild renal impairment
3223535|NCT01122667|Experimental|Part 2 - Panel F|Healthy matched control subjects
3223536|NCT01122693|Active Comparator|standard 2D ultrasound images|
3223537|NCT01122693|Experimental|high-quality 2D ultrasound images|
3223538|NCT01122693|Active Comparator|nerve stimulation techniques|
3223539|NCT01122706|Experimental|Taiji|35 healthy participants will regularly during 12 weeks attend Taiji training classes twice a week for one hour. (Sept. 6th till Nov. 25th 2010).
3223540|NCT01122706|No Intervention|waiting list control group|35 healthy participants are not allowed to attend any Taiji training during the intervention period (Sept. 6th till Nov. 25th 2010).
3223541|NCT01122732||US Group|Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.
3223542|NCT01122732||NS Group|Catheter will be placed using nerve stimulation guidance
3223543|NCT01122745||Catheter Group|Patient will have continuous interscalene block for pain relief placed preoperatively. They will go home with the portable pump. Pain score will be tracked via phone and compared with the control or single short group.
3223544|NCT01122745||Single shot group|Patient will have single shot interscalene block and will go home. Pain will be tracked using phone. Pain will be compared with the catheter group.
3223545|NCT01122758||COPD cohort|"Inclusion criteria:~Patients ≥ 35 years.~Diagnosis of COPD (GOLD PBD FEV1/FVC ratio <0.70).~Being in a stable phase of disease (8 weeks without exacerbation).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Recent exacerbation (<8 weeks).~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
3223546|NCT01122758||Control cohort|"Inclusion criteria:~Patients ≥ 35 years.~Absence of diagnosis of COPD (GOLD PBD FEV1/FVC ratio >=0.70).~Cummulative smoking ≥ 10 pack-years.~Absence of asthma or other chronic respiratory disease that justify the ventilatory disorder (although a history of asthma is not an exclusion criteria);~Absence of malignancy or very serious comorbidities that would prevent study completion.~Exclusion criteria:~Patients <35 years.~Not giving written informed consent.~Presence of asthma or other chronic respiratory disease justifying the ventilatory disorder,~Diffuse bronchiectasis not associated with COPD.~Presence of malignancy or very serious comorbidities that would prevent study completion.~Difficulty to perform appropriate follow-up."
3223547|NCT01122771|Active Comparator|Ambisome|15mg Ambisome on days 1,3 and 5
3223548|NCT01122771|Experimental|Ambisome + Miltefosine|Ambisome 5mg + miltefosine 10 days
3223549|NCT01122771|Experimental|Ambisome +paromomycin|AmBisome IV infusion (single dose, day 1) + Paromomycin base 11mg/kg/day IM (Gland Pharma, India) for 10 days (days 2-11)
3223550|NCT01122771|Experimental|Miltefosine + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
3223551|NCT01122784|Active Comparator|Group 1|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 182
3223552|NCT01122784|Active Comparator|Group 2|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 182
3223553|NCT01122784|Active Comparator|Group 3|160 Volunteers will be vaccinated with 80 mcg rF1V vaccine with adjuvant at Study Days 0, 56 and 121
3223554|NCT01122784|Active Comparator|Group 4|40 Volunteers will be vaccinated with 80 mcg rF1V vaccine without adjuvant at Study Days 0, 56 and 121
3223555|NCT01122797||Alcoholic liver disease|Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
3223556|NCT01122797||Controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.
3223557|NCT01122823|Experimental|On-line workshop|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
3223558|NCT01122836|Experimental|Massage Dose 1|This arm receives weekly 60-minute massage for 4 weeks after a 4-week period of no treatment.
3223559|NCT01122836|Experimental|Massage - Dose 2|This arm receives weekly 60-minute massage for 4 weeks.
3223560|NCT01122836|Experimental|Massage - Dose 3|This arm receives 2 weekly 30-minute massage for 4 weeks.
3223561|NCT01122836|Experimental|Massage - Dose 4|This arm receives 2 weekly 60-minute massages for 4 weeks.
3223562|NCT01122836|Experimental|Massage - Dose 5|This arm receives 3 weekly 30-minute massages for 4 weeks.
3223563|NCT01122836|Experimental|Massage - Dose 6|This arm receives 3 weekly 60-minute massages for 4 weeks.
3223564|NCT01122875|Experimental|A|
3223565|NCT01122888|Experimental|Arm I (course 1)|Patients receive cilengitide IV over 1 hour twice weekly for 2 weeks.
3223566|NCT01122888|Other|Arm II (course 1)|Patients do not receive treatment and undergo a 2-week rest period.
3223567|NCT01122940|Active Comparator|Epamin: McNeil LA LLC|
3223568|NCT01122940|Experimental|Phenytoin: Laboratorios Pfizer SA DE CV|
3223569|NCT01122953|Experimental|Phenytoin|
3223570|NCT01122953|Active Comparator|Epamin|
3223571|NCT01122966|Other|trabeculectomy|Subjects who have trabeculectomies with intraocular bevacizumab injection
3223572|NCT01122979|Experimental|group 1: insulin glargine + insulin glulisine|insulin glargine once daily + glulisine at meal times
3223573|NCT01122979|Active Comparator|group 2 NPH insulin + regular insulin|NPH insulin (isophane insulin) (2 or more divided doses) + regular insulin at meal times
3223574|NCT01123005|Experimental|Carbogen arm|
3223575|NCT01123005|Experimental|DCA arm|
3223576|NCT01123018||Older Adults|Persons over age 60 Participants will complete the Memtrax memory screening test
3223577|NCT01123031|Active Comparator|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
3223578|NCT01123031|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
3223579|NCT01123044|Experimental|corneal stem cell transplant|
3223580|NCT01123044|No Intervention|conservative medical therapy|
3223581|NCT01123096||Stress Urinary Incontinence|Patients with the primary complaint of stress incontinence with minimal or no urge incontinence symptoms. They must be able to read English as the study involves use of validated questionnaires which have only been validated in English.
3223582|NCT01123109|Other|nulliparous females|nulliparous women over the age of 18
3223583|NCT01123122|Active Comparator|Strict glucose control|
3223584|NCT01123122|No Intervention|Standard glucose control|
3223585|NCT01123135|Active Comparator|Vaginal ERT|Vaginal ERT cream 1 gm at bed time 3 times a week
3223586|NCT01123135|Placebo Comparator|Placebo|1gm of placebo at bed time 3 times a week
3223587|NCT01123174|Experimental|ALGOS group|Algorithm of case management over the 6 months following the suicidal gesture (systematic telephone contact, postcards and crisis card)
3223588|NCT01123174|No Intervention|Control group|Treatment as usual (referral back to the general practitioner)
3223589|NCT01123187|Experimental|islet transplantation|Islet transplantation
3223590|NCT01123226|Experimental|Diversified HVLA spinal manipulation|
3223591|NCT01123226|Active Comparator|Trigger point pressure release|
3223592|NCT01123239|Experimental|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches who have been trained to promote patient participation in the medical visit. The coaches, who themselves have diabetes, meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making."
3223593|NCT01123239|Active Comparator|Standard Diabetes Education|Patients receive one-on-one diabetes education sessions before each medical visit. These sessions are purely informational, and do not include the specific patient activation components of the coached care intervention.
3223594|NCT01123252|Active Comparator|Seasonal Affective Rhinitis Group 1|Active Comparator Group
3223595|NCT01123252|Placebo Comparator|Seasonal Affective Rhinitis Group 2|Placebo Group
3223596|NCT01123265||Anti-TNF|
3223597|NCT01123265||Methotrexate|
3223598|NCT01123278|Experimental|Testosterone gel|Testosterone transdermal gel 50 mg/day
3223599|NCT01123278|Placebo Comparator|Placebo gel|Placebo gel
3223600|NCT01123291|Active Comparator|routine follow-up coronary angiography|routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
3223601|NCT01123291|Active Comparator|clinical follow-up|no routine follow-up coronary angiography at 8-12 after discharge for percutaneous coronary intervention
3223602|NCT01123304|Experimental|MORAb 028|
3223603|NCT01123317|Experimental|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
3223604|NCT01123330|Experimental|Motivational Interviewing plus DVD|Caregivers watched a 15-minute educational video designed for the project emphasizing the importance of good oral health in children, and how the caregiver can keep children free from tooth decay. The MI interviewer engaged the parent in a discussion of their thoughts and concerns regarding their child's oral health and what changes they wished to make regarding monitoring their child's oral health. Feedback from the child's dental exam was also reviewed. MI+DVD caregivers received a brochure displaying a photo of their child and for those who chose to set specific goals for their child's oral health, those goals were listed on the brochure. Caregivers choosing not to set specific goals were offered a list of 10 project recommendations regarding dietary intake, oral hygiene, and dental check-ups. The session ended with a dialogue regarding possible barriers to implementing the personal plan and how the caregiver planned to overcome those barriers.
3223605|NCT01123330|Active Comparator|DVD only|Caregivers watched the same educational video. At the end of the video, caregivers were given a glossy-printed brochure displaying the project developed recommendations as well as the child's photograph. The brochure was not re-mailed, as it was for the MI+DVD group and caregivers in this condition did not receive any feedback from the dental examination regarding their child's oral health status.
3223606|NCT01123343|Active Comparator|LRI Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for LRI.
3223607|NCT01123343|Active Comparator|Capsulorhexis Templates|To evaluate the ability of the TRUEVISION 3D VISUALIZATION AND GUIDANCE SYSTEM FOR MICROSURGERY to provide the ophthalmic surgeon appropriate alignment, orientation and sizing information during cataract or refractive lens exchange surgery compared to the current standard of care (manual markings or heuristic techniques) for Capsulorhexis.
3223608|NCT01123408|Experimental|clozapine|During the first 6 weeks clozapine was gradually increased to 500 mg/day and then continued. For the next period, it could vary from 200-800 mg/day;
3223609|NCT01123408|Experimental|Olanzapine|During the first 6 weeks olanzapine was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks olanzapine could vary from 10 to 30 mg/day
3223610|NCT01123408|Active Comparator|Haloperidol|During the first 6 weeks haloperidol was increased to 20 mg and remained fixed for until the end of six week. During the last 6 weeks the dose could vary from 10 to 30 mg/day
3223611|NCT01123421||With osteoporotic fracture|Approximately 100 postmenopausal women that have been enrolled in a population-based case-control study that have experienced a clinically-diagnosed fracture of thoracolumbar spine or distal forearm due to minimal or moderate trauma based on review on their inpatient and outpatient medical records will be enrolled.
3223612|NCT01123421||Without osteoporotic fracture|Approximately 100 control women will have no history of a prior spine, hip, or wrist fracture.
3223613|NCT01123434||1|Localised with one of any high recurrence risk factors, or locally advanced Chinese prostate cancer patients confirmed histologically through radical prostatectomy either with laparoscopy or laparotomy within 1 month after surgery. Before the patient recruitment, the investigator has decided to prescribe immediate postoperative adjuvant hormonal treatment to the patient according to the Chinese routine practice.
3223614|NCT01123447|Active Comparator|Surgery|Isolated ulnar shaft fractures will be treated with open reduction and internal fixation using a limited contact dynamic compression (LC-DC) plate with screws. These will remain at the fracture site for the lifetime of the patient.
3223615|NCT01123447|Active Comparator|Short arm cast|Those individuals randomized to the non-operative treatment group will be treated with a closed reduction and short-arm (below-elbow) cast.
3223616|NCT01123473|Experimental|Lapatinib|Chemotherapy + lapatinib
3223617|NCT01123473|Placebo Comparator|Placebo|Chemotherapy + placebo
3223618|NCT01123486|Experimental|hydromorphone|open label single arm pharmacokinetic-pharmacodynamic study
3223620|NCT01123525|Experimental|Adenosine cardioplegia|Adenosine cardioplegia
3223621|NCT01123525|Active Comparator|Control|Standard hyperkalemic cardioplegia
3223622|NCT01123538|Other|Natural progesterone|Combined menopausal treatment containing natural progesterone
3223623|NCT01123538|Active Comparator|Chlormadinone acetate|Combined menopausal treatment containing chlormadinone acetate
3223624|NCT01123551|Experimental|Nebulized Morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
3223625|NCT01123551|Active Comparator|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
3223626|NCT01123564|Experimental|Lucentis (ranibizumab)|
3223627|NCT01123564|Active Comparator|Laser|
3223628|NCT01123577|Experimental|Intervention|
3223629|NCT01123577|No Intervention|Control|Participants receive usual care by providers.
3223630|NCT01123590||Thymoma|Patients with thymoma
3223631|NCT01123590||Control|Normal controls
3223632|NCT01123616|Active Comparator|non-triclosan-coated|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3223633|NCT01123616|Active Comparator|triclosan coated suture|Two arms are separeted by computer randomization at abdomial wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3223634|NCT01123668||ADHD and non-ADHD Smokers|Those that are defined as regular smokers (10 cigarettes/day or Carbon Monoxide reading of 10 ppm). The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3223635|NCT01123681||Ventilator associated pneumonia|
3223636|NCT01123681||No pneumonia|
3223637|NCT01123694||Xeroderma Pigmentosum patients|Xeroderma Pigmentosum patients who attend Camp Sundown, a camp for children with this condition.
3223639|NCT01123759|Active Comparator|Tilapia|Subjects are fed 6 oz tilapia once a week for 3 months
3223640|NCT01123759|Active Comparator|Salmon|Subjects fed 6 oz salmon once a week for 3 months
3223641|NCT01123772|Placebo Comparator|Control|Vehicle control
3223642|NCT01123772|Experimental|INO-8875|Active drug
3223643|NCT01123785|Placebo Comparator|Control|Matched vehicle-control
3223644|NCT01123785|Experimental|INO-8875|Adenosine agonist eye drop
3223645|NCT01123798||Stable controls|Uninjured soldiers to provide normative data for stable physiological status
3223646|NCT01123798||Critical controls|"Critically injured soldiers with no lower extremity traumatic injuries (excepting skin abrasions and small/superficial fragmentation wounds) to provide normative data for the shock physiological status."
3223647|NCT01123798||Lower extremity trauma|Soldiers with severe traumatic lower extremity injuries in stable and shock physiologic status. This is the investigational cohort.
3223648|NCT01123811|Experimental|Cetuximab IF|Treatment with combination of Cetuximab and Irinotecan 5-FU
3223649|NCT01123824|Experimental|Sequence clopidogrel 300/75 mg - 600/150 mg|"Period 1:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Period 2:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
3223650|NCT01123824|Experimental|Sequence clopidogrel 600/150 mg - 300/75 mg|"Period 1:~Day 1: clopidogrel, 600 mg loading dose~Day 2 to Day 5: clopidogrel, 150 mg, once daily~Period 2:~Day 1: clopidogrel, 300 mg loading dose + placebo~Day 2 to Day 5: clopidogrel, 75 mg + placebo, once daily~Each intake is at around 8:00 AM fasted for at least 10 hours"
3223651|NCT01123837|Active Comparator|D5LR|In the treatment group, a 250cc bolus over 2 hrs of D5LR will be initiated prior to the end of surgery and continued in PACU.Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning
3223652|NCT01123837|Active Comparator|lactated ringers|In the control group, a 250cc bolus over 2 hrs of LR will be initiated prior to the end of surgery and continued in PACU. Blood glucose will be measured at 3 different timepoints using a point of care testing device (Accu-Chek). We will be measuring changes in blood glucose levels associated with PONV and the type and number of rescue medicines given at 30, 60, and 120 minutes after anesthesia and the first postoperative morning.
3223653|NCT01123863||Patient Group|"This study will administer Brigance Preschool Screen -II to 3 year old children with SCD followed at St. Jude Children's Research Hospital~Intervention: Brigance Preschool Screen -II"
3223654|NCT01123863||control group|"The control group will consist of 3-year-old children attending day care in the Memphis area and serve as a population that come from a similar socioeconomic background as the SCD patient population.~Intervention: Brigance Preschool Screen -II"
3223655|NCT01123876|Experimental|Veliparib and FOLFIRI|Veliparib in combination with FOLFIRI regimen.
3223656|NCT01123902|Experimental|hand-held fan|
3223657|NCT01123902|Placebo Comparator|wristband|
3223658|NCT01123915|Experimental|Opal-HIV-Gag(c)|Opal-HIV-Gag(c) administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
3223659|NCT01123915|Placebo Comparator|Diluent|Administered ex vivo to separated white blood cells on 4 occasions at 4 weekly intervals.
3223660|NCT01123954|Other|Arm 1|
3223661|NCT01123967|Experimental|PRO+NRT+TC|Proactive outreach (mailed invitation letter followed by telephone outreach) combined with free nicotine replacement therapy (NRT) and telephone counseling (PRO+NRT+TC)to usual care (UC)
3223662|NCT01123967|Active Comparator|Usual Care (UC)|Usual (standard) care - Smoking cessation products: patch, gum, lozenge, inhaler and nasal spray
3223663|NCT01123993|No Intervention|Lifestyle counselling|
3223664|NCT01124019||Random Sample|A random sample of 600 women undergoing screening mammography
3223665|NCT01124019||BIRADS score of 4|An additional 600 women determined to have a Breast Imaging Reporting and Data System (BIRADS) score of 4 as determined by final mammogram results.
3223666|NCT01124032|Experimental|ADHD adults|
3223667|NCT01124032|Experimental|healthy adults|
3223668|NCT01124058|Experimental|Loading|1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose
3223669|NCT01124058|Active Comparator|Maintenance|Re-start same dose as previously stable on
3223670|NCT01124071|Active Comparator|Korean Diet|Provision of 2 Korean meals per day, 6 days per week
3223671|NCT01124071|Active Comparator|Western Diet|Lifestyle counseling, dietary advice, grocery vouchers
3223672|NCT01124084||Health Care Providers|
3223673|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
3223674|NCT01124110|Experimental|Tobacco Tactics Intervention|This intervention contains a website, medications, and nurse counseling.
3223675|NCT01124123|Experimental|Bilastine 20 mg|Single dose 20 mg bilastine oral tablet. Test drug
3223676|NCT01124123|Active Comparator|Bilastine 10 mg|Single dose 10 mg Bilastine endovenous. Control drug
3223677|NCT01124136|Experimental|Neurostimulation + Medication management|Investigational nerve stimulator device implanted to heart plus standard medication therapy.
3223678|NCT01124136|Other|Standard of Care (Control)|Standard of Care treatment is medication management only. Heart failure medications control symptoms and comorbidities, i.e. blood thinners, lipid lowering, and diuretics, and manage heart function, i.e. heart rhythm, rate, and pumping strength.
3223679|NCT01124201|Experimental|Stabilization group|In the Segmental Stabilization group exercises focused on the transversus abdominis and lumbar multifidus muscles.
3223680|NCT01124201|Experimental|Strengthening group|In the Superficial Strengthening group, exercises focused on the rectus abdominis, abdominus obliquus internus, abdominus obliquus externus and erector spinae muscles.
3223681|NCT01124201|Experimental|Stretching group|Stretching group: erector spinae, posterior connective tissues and ischiotibials muscles
3223682|NCT01124214|No Intervention|High Resolution endoscopy (HRE)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN
3223683|NCT01124214|Active Comparator|Endomicroscopy (EM)|Standard of care, high resolution endoscopy surveillance/ evaluation of BE and or IEN and endomicroscopy esophageal evaluation
3223684|NCT01124227|Sham Comparator|Standard Care|
3223685|NCT01124227|Active Comparator|2 Icodextrin PD changes / day|
3223686|NCT01124227|Active Comparator|1 Icodextrin PD change/day|
3223687|NCT01124253|Experimental|NP plus recombinant human endostatin|
3223688|NCT01124253|No Intervention|vinorelbine plus cisplatin|
3223689|NCT01124266|Experimental|endoscopist only|
3223690|NCT01124266|Experimental|nurse participation|
3223691|NCT01124279|Experimental|AMG 853|
3223692|NCT01124318|Active Comparator|Lactofiltrum|
3223693|NCT01124318|Placebo Comparator|Placebo|
3223694|NCT01124331|Experimental|High Oxygen saturation|Higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
3223695|NCT01124331|Active Comparator|Lower oxygen saturation|Lower (SpO2 85-89%) functional oxygen saturation target range from birth, or soon thereafter, for durations as specified in each trial protocol.
3223696|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 mg)|Panel 1: Healthy Male Subjects
3223697|NCT01124344|Active Comparator|Placebo or BMS-866949 (10 mg)|Panel 2: Healthy Male Subjects
3223698|NCT01124344|Active Comparator|Placebo or BMS-866949 (30 mg)|Panel 3: Healthy Male Subjects
3223699|NCT01124344|Active Comparator|Placebo or BMS-866949 (45 mg)|Panel 4: Healthy Male Subjects
3223700|NCT01124344|Active Comparator|Placebo or BMS-866949 (60 mg)|Panel 5: Healthy Male Subjects
3223701|NCT01124344|Active Comparator|Placebo or BMS-866949 (90 mg)|Panel 6: Healthy Male Subjects
3223702|NCT01124344|Active Comparator|Placebo or BMS-866949 (3 - 60 mg)|Panel 7: Females
3223703|NCT01124357|Active Comparator|novasure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
3223704|NCT01124357|Other|thermachoice|ThermachoiceTM III thermal balloon ablation
3223705|NCT01124383|Active Comparator|General anesthesia|
3223706|NCT01124383|Active Comparator|Local anesthesia with sedation|
3223707|NCT01124396||30 ug|30 ug
3223708|NCT01124396||60 ug|60 ug
3223709|NCT01124396||Placebo|Placebo
3223710|NCT01124409|Active Comparator|3DCRT with EPID|this patients randomised to this arm will be planned by 3DCRT and during treatment setup error will be identified and corrected by weekly EPID if error >3mm.Weekly CBCT will be done for this arm to note the setup error but will not be corrected.
3223711|NCT01124409|Active Comparator|IGRT with CBCT|The patients randomised to this arm will be planned by 3DCRT and set up error during RT will be verified by CBCT and error corrected if >3mm.Weekly EPID will be done for setup error documentation but no correction based on EPID in this arm.
3223712|NCT01124461||Brain Tumor|Brain neoplasms, malignant
3223713|NCT01124474|No Intervention|Standard fluid management|Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
3223714|NCT01124474|Other|Vigileo model number MHM1|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
3223715|NCT01124487|Experimental|palm olein|
3223716|NCT01124487|Experimental|olive oil|
3223717|NCT01124487|Experimental|lard|
3223718|NCT01124500|Experimental|methylphenidate via transdermal patch compared to placebo|The proposed study is a within-subject, cross-over, randomized and double-blinded pilot trial, designed to evaluate the efficacy and feasibility of sustained-release, long-acting methylphenidate via transdermal patch compared to placebo in fatigued patients with Head and Neck malignancies
3223719|NCT01124513|Active Comparator|Digital Camera|Digital camera images will be taken of a a 2cm^2 area of sun protected skin.
3223720|NCT01124513|Active Comparator|Spectrophotometer|The probe of the protable reflectance spectrophotometer is lightly applied to the sufance of the skin and a reading is taken.
3223721|NCT01124513|Active Comparator|Videodermoscopy|The instrument is put in contact with sun protected skin and an image is taken of a 2 cm^2 area.
3223722|NCT01124526|Experimental|Rituximab, Fludarabine, ciclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2)"
3223723|NCT01124539|Experimental|AR-67|
3223724|NCT01124552|Experimental|RT001 Botulinum toxin Type A (Dose A)|RT001 (Botulinum toxin Type A)
3223725|NCT01124552|Experimental|RT001 Botulinum toxin type A (Dose B)|RT001 (Botulinum Toxin Type A)
3223726|NCT01124552|Other|Dose C|Vehicle Control
3223727|NCT01124552|Placebo Comparator|Dose D|Placebo
3223728|NCT01124565|Experimental|RT001|RT001 (Botulinum Toxin Type A) Topical Gel
3223729|NCT01124578||Control|Existing used daily change-out device
3223730|NCT01124578||Egret|Extended Use Catheter w/BIOSAFE
3223731|NCT01124591|Experimental|Treatment|Assessment and brief intervention
3223732|NCT01124630|Experimental|CS-1008 with FOLFIRI|Experimental drug CS-1008 in combination with FOLFIRI
3223733|NCT01124656|Experimental|Pioglitazone-Azilsartan QD|(Dependent on glycosylated hemoglobin level at screening)
3223734|NCT01124708|Placebo Comparator|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
3223735|NCT01124708|Active Comparator|TC-5619|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, one capsule once daily p.o.
3223736|NCT01124721|Experimental|Cogmed cognitive training|Computerized working memory, attention and cognitive tasks
3223737|NCT01124721|Active Comparator|Active placebo|Cognitive training, however the training does not increase in difficulty, or does so to a minimal degree.
3223738|NCT01124747|Experimental|ASP1585 and 14C-Labeled ASP1585|
3223739|NCT01124760|Experimental|1|AZD9742
3223740|NCT01124773||Previous HT use and cognition|Women who were aged 50-54 at the time of randomization into the WHI hormone trials.
3223741|NCT01124799|Experimental|001|TMC435 one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening for 9 days
3223742|NCT01124799|Placebo Comparator|002|Placebo placebo dose in the morning at noon and in the evening for 9 days
3223743|NCT01124799|Active Comparator|003|Ciprofloxacin one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg for 9 days
3223744|NCT01124812|Experimental|131I-L19SIP|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy: Treatment dose of 131I-L19SIP RIT is titrated in cohorts of 3 patients.
3223745|NCT01124825|Active Comparator|IGel|Subjects will receive an IGel(TM) airway induction and maintenance of positive pressure ventilation
3223746|NCT01124825|Active Comparator|King Airway|Subject will receive a KING-LTS-D(TM) for induction and maintenance of positive pressure ventilation
3223747|NCT01124851|Experimental|Arm 1|ABT-652 Dose 1 vs placebo capsules administered orally once daily for 7 days
3223748|NCT01124851|Experimental|Arm 2|ABT-652 Dose 2 vs placebo capsules administered orally once daily for 7 days
3223749|NCT01124851|Experimental|Arm 3|ABT-652 Dose 3 vs placebo capsules administered orally once daily for 7 days
3223750|NCT01124877|Other|Open|
3223751|NCT01124890|Placebo Comparator|Conservative|no transfer for early percutaneous coronary intervention after thrombolysis
3223752|NCT01124890|Active Comparator|early PCI|transfer for early percutaneous coronary intervention after thrombolysis
3223753|NCT01124903|Experimental|Dehydration|Multiple measures of hydration status were made when subjects were normally hydrated (euhydrated) and when dehydrated. The diagnostic usefulness of the measures was determined.
3223754|NCT01124929|Active Comparator|Arm 1: Category I treatment for 6 months|Anti-tuberculosis drugs
3223755|NCT01124929|Active Comparator|Arm 2: Category I treatment for 9 months|Anti-tuberculosis drugs,
3223756|NCT01124942|Experimental|MGuard|MGuard net protective stent, investigational device
3223757|NCT01124942|Active Comparator|BMS plus thrombectomy|Bare-metal stent plus manual thrombectomy device
3223758|NCT01124968|Experimental|eConsulta|Those patients who are offered to use the eConsulta, a web where they can virtually consult with their primary care doctor or nurse.
3223759|NCT01124981|Placebo Comparator|Albumin|
3223760|NCT01124981|Experimental|Haemocomplettan® P|
3223761|NCT01124994|Active Comparator|Mucosectomy|Patients in this arm are undergoing mucosctomy after previous confocal laser endomicroscopy.
3223762|NCT01125007|Active Comparator|toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
3223763|NCT01125007|Experimental|medium toothbrush|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
3223764|NCT01125020|Active Comparator|gemcitabine and oxaliplatin|
3223765|NCT01125020|Active Comparator|doxorubicin, 5-Fu and cisplatin|
3223766|NCT01125033|Experimental|Vitamin C & Vitamin E.|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
3223767|NCT01125033|Experimental|Vitamin C & Placebo|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
3223768|NCT01125033|Experimental|Vitamin E & Placebo|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
3223769|NCT01125033|Placebo Comparator|Double Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
3223770|NCT01125059|Active Comparator|Methadone Group|0.2 mg/kg IV methadone
3223771|NCT01125059|Placebo Comparator|Placebo Group|5 mL saline bolus
3223772|NCT01125072||entire cohort|patients presenting to the emergency department with chest pain and being admitted to rule out acute coronary syndrome
3223773|NCT01125085|Other|131I-L19SIP RIT in Combination with WBRT|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
3223774|NCT01125111||robotic surgery group|
3223775|NCT01125111||laparoscopic surgery group|
3223776|NCT01125124|Active Comparator|Silver Nitrate 1|Patients submitted to pleurodesis via pleural catheter using 30ml of 0.5% silver nitrate solution.
3223777|NCT01125124|Experimental|Silver Nitrate 2|Patients submitted to instilation of 30ml 0.3% silver nitrate solution via pleural catheter.
3223778|NCT01125124|Experimental|Silver Nitrate 3|Patients submitted to instilation of 60ml 0.3% silver nitrate solution via pleural catheter.
3223779|NCT01125137|Experimental|Biopsy|
3223780|NCT01125215|Placebo Comparator|Placebo|Matched gel base of capsaicin nanoparticle
3223781|NCT01125215|Experimental|Capsaicin|0.075% capsaicin nanoparticle gel
3223785|NCT01125241|Experimental|Wuling capsule|
3223786|NCT01125241|Placebo Comparator|Placebo|
3223787|NCT01125254|Experimental|Amlodipine|amlodipine 5mg qd
3223788|NCT01125254|Placebo Comparator|Controls|placebo
3223789|NCT01125267|Experimental|multifamily group-adherence|multifamily group treatment with a focus on improving adherence to antipsychotic medication
3223790|NCT01125267|Active Comparator|multifamily group-standard|multifamily group focused on problems identified by group participants
3223791|NCT01125267|No Intervention|treatment as usual|
3223792|NCT01125280|Experimental|SBO score application|Acute strangulated SBO patients will receive a severity score at emergency admission. According to the score, they will be managed either conservatively or surgically. During surgery, the need of small bowel resection will be evaluated. The endpoint will be to correlate the type and success of treatment with the score in order to validate this new tool in SBO assessment.
3223793|NCT01125319|Other|patients Hemophagocytic lymphohisticytosis group|
3223794|NCT01125319|Other|group control patient|
3223795|NCT01125319|Other|healthy control group|
3223796|NCT01125332|Placebo Comparator|group gel KY|
3223797|NCT01125332|Experimental|group gel lidocaine|
3223798|NCT01125345|Experimental|Hydrophobic IOL|The single piece Acrysof hydrophobic IOL model- SN60WF
3223799|NCT01125345|Active Comparator|Hydrophilic IOL|Rayner Intraocular Lenses Ltd., England, Model C-flex 570C
3223800|NCT01125345|Active Comparator|Hydrophillic IOL|Bausch and Lomb ltd, model Akreos Adapt
3223801|NCT01125371|Experimental|Computerized Brief Alcohol Intervention + IVR|Computer-delivered brief alcohol intervention (CBI) with booster phone calls delivered by IVR+ text messages (TM)
3223802|NCT01125371|Active Comparator|Computerized Brief Alcohol Intervention|Computerized Brief Alcohol Intervention only (CBI)
3223803|NCT01125371|Placebo Comparator|Attention Control|Attention control
3223804|NCT01125384|No Intervention|nurse swabbing|
3223805|NCT01125384|Experimental|"accurate swabbing by a physician"|
3223806|NCT01125397|Experimental|Behavioral Intervention|
3223807|NCT01125397|No Intervention|Control|These participants will be randomized to receive no behavioral intervention prior to bariatric surgery.
3223808|NCT01125410|Experimental|Dequalinium chloride 10mg|
3223809|NCT01125410|Active Comparator|clindamycin vaginal cream 2%|
3223810|NCT01125423|Active Comparator|Subjects with Fibromyalgia|Subjects with Fibromyalgia have skin biopsies taken from the dominant trapezius and palm. Subjects will receive an eight week supply of milnacipran to be titrated 12.5 mg x one day, 12.5 mg twice a day x 2 days, 25mg twice daily for 4 days, then 50mg twice a day x 7 weeks.
3223811|NCT01125423|Other|Control subjects without Fibromyalgia|Subjects without Fibromyalgia have skin biopsies taken from the dominant trapezius and palm.
3223812|NCT01125436|Experimental|Cholecalciferol|Nutritional supplement
3223813|NCT01125436|Placebo Comparator|placebo|
3223814|NCT01125449|Other|Intravenous IVC Intervention|Intravenous ascorbic acid, 1.5g/kg at an infusion rate not to exceed 250mg/min.
3223815|NCT01125462||Subjects previously treated with Gonal-f|Subjects who had undergone at least one treatment cycle with Gonal-f powder and solvent for solution for injection within the past 12 months (equivalent to 75 IU/ml, 450 IU/0.75ml or 1050 IU/1.75 ml)
3223816|NCT01125462||Subjects previously treated with urine-derived FSH|Subjects which had undergone at least one treatment cycle with urine-derived FSH therapy with vials within the past 12 months
3223817|NCT01125488|Experimental|LNG-IUS|LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
3223818|NCT01125488|Active Comparator|GnRH agonist|The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
3223819|NCT01125501|Active Comparator|Protandim|one capsule a day for 30 days of protandim given, followed by a wash out period.
3223820|NCT01125501|Placebo Comparator|Placebo|one capsule a day for 30 days will be given followed by a washout period.
3223821|NCT01125527|Active Comparator|Arm 1|
3223822|NCT01125527|Active Comparator|Arm 2|
3223823|NCT01125553|Experimental|IDegAsp B|
3223824|NCT01125553|Experimental|IDegAsp F|
3223825|NCT01125579||Children aged 6-12|"Children suffering from nervous restlessness, e.g. in agitated depression (ICD 10, F3 and DSM IV affective disorders), aged 6-12 years"
3223826|NCT01125592|Experimental|Footbath|Participants in this arm of the study will receive 4 30 minutes ionic footbath sessions, one each week for 4 weeks.
3223827|NCT01125618|Experimental|MVP village|Wealth stratified and randomly selected households residing in a village exposed to the Millennium Villages Project intervention (or health and development intervention package)
3223828|NCT01125618|Active Comparator|Comparison village|Villages receiving routine services through established programs
3223829|NCT01125631|Experimental|PF-04360365 8.5 mg/kg|
3223830|NCT01125631|Placebo Comparator|Placebo|
3223831|NCT01125644|Experimental|Single Arm|"Patients are males and females between 18 and 75 years of age with proven fungal etiology confirmed by mycological culture test and by hystopathological exam (patients with definite diagnosis), or patients with fungal infection of which is difficult to determine the etiological agent but with diagnosis of deep mycosis based on blood testing for fungal infection and/or clinical radiological examination, and/or endoscopic clinical examination, clinical symptomatology (patients with clinical diagnosis)."
3223832|NCT01125657|Experimental|formualation-A to -B sequence group|
3223833|NCT01125657|Experimental|formulation-B to -A sequence group|
3223834|NCT01125670|Experimental|fast-fed sequence group|
3223835|NCT01125670|Experimental|fed-fast sequence group|
3223836|NCT01125683|Experimental|1|2,5 mg once daily
3223837|NCT01125683|Active Comparator|2|single dose of 5 mg
3223838|NCT01125683|Placebo Comparator|3|
3223839|NCT01125683|Experimental|4|60 mg once daily
3223840|NCT01125683|Experimental|5|60 mg three times daily
3223841|NCT01125696|Active Comparator|Standard of Care|
3223842|NCT01125696|Experimental|Tenofovir|
3223843|NCT01125735|Experimental|MIST Therapy|MIST Therapy is a low energy, low intensity ultrasound delivered through a saline mist to the wound bed.
3223844|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
3223845|NCT01125761|Experimental|dexamethasone 0.5 mg and 1.0 mg clemastine cream|
3223846|NCT01125761|Active Comparator|dexamethasone 0,5 mg cream|
3223847|NCT01125787|Experimental|ofatumumab + bendamustine|
3223848|NCT01125839||Spondylitis|Patients who checked spine MRI for back pain
3223849|NCT01125852|Active Comparator|Intervention group|Patients in this group are treated with usual therapeutic endoscopy including endoscopic combination therapy and 72 hours intravenous proton pump inhibitor. Within 24 hours from the therapeutic endoscopy they receive supplementary angiographic embolization.
3223850|NCT01125852|Active Comparator|Control group|Patients in this arm receive standard treatment including therapeutic endoscopy with endoscopic combination therapy followed by 72 hours intravenous proton pump inhibitor.
3223851|NCT01125865|Active Comparator|SEMS|Self-expandable metallic stent will be inserted for the malignant hilar obstruction.
3223852|NCT01125865|Active Comparator|DLS|DoubleLayer plastic stent (Olympus) will be inserted for malignant hilar obstruction.
3223853|NCT01125878|Active Comparator|Starch Composite B|fiber mixture
3223854|NCT01125878|Active Comparator|Starch Composite C|fiber mixture
3223855|NCT01125878|Active Comparator|Starch Composite D|fiber mixture
3223856|NCT01125878|Placebo Comparator|Placebo|Placebo
3223857|NCT01125891|Experimental|gemcitabine and ON 01910.Na|
3223858|NCT01125904|Experimental|crizotinib|
3223859|NCT01125943|Experimental|Acetylcholine|Intra-arterial infusion of acetylcholine in two increasing dosages during 5 minutes each during the intra-arterial infusion of bevacizumab
3223860|NCT01125943|Experimental|Nitroprusside|Infusion of two increasing dosages of nitroprusside during 5 minutes each during the continuous infusion of bevacizumab
3223861|NCT01125956|No Intervention|Control|This group will receive usual diabetes care through their primary care clinicians.
3223862|NCT01125956|Experimental|Peer counseling|A peer counselor will be assigned to each participant who currently has good diabetes control but had poor control in the past 3 years.
3223863|NCT01125956|Experimental|Financial incentives|Patient participants in the financial incentive arm will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
3223864|NCT01125969|Active Comparator|Control|
3223865|NCT01125969|Experimental|Incentive|
3223866|NCT01125969|Experimental|Peer Mentoring|
3223867|NCT01125969|Experimental|Incentives and Peer Mentoring|
3223868|NCT01125982|Active Comparator|Desflurane|Patients will receive Desflurane to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
3223869|NCT01125982|Active Comparator|Propofol|Patients will receive Propofol to provide sleep during anaesthesia for laparoscopic cholecystectomy. Analgesia will be provided by remifentanil.
3223870|NCT01125995|Active Comparator|late CCRT|radiotherapy start on day one of the third cycle of chemotherapy
3223871|NCT01125995|Experimental|Early CCRT|Radiotherapy start on day 1 of 1st cycle of chemotherapy
3223872|NCT01126008|Experimental|weekly docetaxel and cisplatin|
3223873|NCT01126021|Active Comparator|Control|Given access to mental exercises but receives no rewards for use.
3223874|NCT01126021|Experimental|Atomistic|Each individual is awarded for his or her individual participation
3223875|NCT01126021|Experimental|Altruistic|Participants are paired and rewarded according to the other individual's participation.
3223876|NCT01126021|Experimental|Team-based|Teams compete against each other and receive rewards according to relative participation.
3223877|NCT01126034|Experimental|intervention|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
3223878|NCT01126034|No Intervention|non-intervention|No intervention letters were sent to subjects in this arm
3223879|NCT01126047|Other|PFT's, eCO, and pulse oximetry|All subjects in the study will undergo complete pulmonary function testing (spirometry, blood collection for carboxyhemoglobin, diffusing capacity); exhaled carbon-monoxide testing, and pulse oximetry.
3223880|NCT01126073|Placebo Comparator|placebo|
3223881|NCT01126073|Active Comparator|Niacin/Laropiprant 2000mg/40 mg|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will be randomized in the ratio 1:1 to either receive ER niacin/laropiprant or placebo in addition to the statin therapy. Patients in the ER niacin/laropiprant group will receive 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
3223882|NCT01126086|Experimental|Mild impairment|Patients with mild hepatic impairment
3223883|NCT01126086|Experimental|Moderate impairment|Patients with moderate impairment
3223884|NCT01126086|Experimental|Healthy subjects|Matched healthy subjects
3223885|NCT01126112|Experimental|Panitumumab|Panitumumab: 6 mg/Kg Q2W Treatment cycles repeated every 14 days. Subjects will be evaluated for tumour response every 3 cycles (6 wks ± 1 wk) the first 24 weeks and every 8 weeks ± 2 weeks thereafter (per the revised-RECIST 1.1 guideline) until PD or withdrawal from the trial.
3223886|NCT01126125|Experimental|Iodized oil to mother|400 mg iodine as iodized oil to breastfeeding mother
3223887|NCT01126125|Active Comparator|Iodized oil to infant|100 mg of iodine as iodized oil to infant
3223888|NCT01126138|Other|Arm A|Vinorelbine plus Capecitabine
3223889|NCT01126138|Other|Arm B|Docetaxel plus Capecitabine
3223890|NCT01126151|Experimental|parent handbook|parent handbook to increase the quantity and quality of communications about alcohol
3223891|NCT01126151|Experimental|parent handbook with boosters|boosters are given to parents at three times (move in, visit weekend; student visits home)
3223892|NCT01126151|Experimental|parent handbook delay|parent handbook is delayed and given after semester has begun
3223893|NCT01126164|Experimental|parent handbook|parent handbook
3223894|NCT01126164|Experimental|peer basics|peer delivered basics
3223895|NCT01126164|Experimental|parent handbook and peer basics|parent handbook and peer basics
3223896|NCT01126177|Placebo Comparator|Placebo|Placebo once daily for 14 days
3223897|NCT01126177|Experimental|SNG001|
3223898|NCT01126190|Experimental|Neugranin|
3223899|NCT01126190|Active Comparator|Pegfilgrastim|
3223900|NCT01126203|Experimental|selective laser trabeculoplasty (SLT)|
3223901|NCT01126203|Experimental|Argon laser trabeculoplasty (ALT)|
3223902|NCT01126216|Experimental|Reduced RT + Pacitaxel/Cisplatin|63,6 Gy accelerated hyperfractionated radiotherapy with Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32, followed by a salvage operation or neck dissection if there is persisting tumor
3223903|NCT01126216|Active Comparator|Standard RT + 5-Fluorouracil/Cisplatin|70,6 Gy accelerated hyperfractionated radiotherapy with 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33, followed by a salvage operation or neck dissection if there is persisting tumor
3223904|NCT01126229|Placebo Comparator|Placebo|Dietary Supplement: placebo
3223905|NCT01126229|Experimental|300 mg/d Resveratrol|Dietary Supplement: 300 mg/d Resveratrol
3223906|NCT01126229|Experimental|1000 mg/d Resveratrol|Dietary Supplement: 1000 mg/d Resveratrol
3223907|NCT01126242|Experimental|tape|Group I will be treated with non-elastic adhesive tape around the affected ankle, applied by the 'van Unen-technique'. This technique is an alternative for the 'Coumans- technique'. The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity. Taping is a treatment that involves no loss of time, requires no crutches and is not attended with any ultimate impairment of function.
3223908|NCT01126242|Active Comparator|Lace-up brace|The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
3223909|NCT01126242|Active Comparator|Semi rigid brace|A semi-rigid brace, the M-step® from Medi®, will be applied. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
3223910|NCT01126255|Active Comparator|1|Clobetasol propionate 0.05%, topical application, once daily about 2 g, during 12 weeks
3223911|NCT01126255|Experimental|2|Progesterone 8%, topical application, once daily about 2 g, during 12 weeks
3223912|NCT01126281|Experimental|Floseal use|
3223913|NCT01126294|Experimental|Melatonin 5 mg|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
3223914|NCT01126294|Experimental|Melatonin 10 mg|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
3223915|NCT01126294|Placebo Comparator|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
3223916|NCT01126307|Active Comparator|verapamil|verapamil 80mg tid
3223917|NCT01126307|Placebo Comparator|placebo sugar pill|placebo tid
3223918|NCT01126320|Experimental|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
3223919|NCT01126320|Active Comparator|Control|routine mechanical ventilator
3223920|NCT01126333||Long term Sirolimus or Tacrolimus|"Ths study cohort will consist of participants who successfully completed two years of the original Spare the Nephron (STN) study, a two year prospective multi-center study where participants were assigned to receive either center-specific CNI regimen (assigned at the time of transplantation) or were switched to replace the CNI with Sirolimus therapy.~In this current long-term follow-up study, we will approach patients who previously enrolled in the STN study and offer them the opportunity to enroll to be followed-up for another 3 years. There will be no change in immunosuppression unless clinically indicated. The majority of effort is standard care with every 6 month follow-up appointments.Participants will be required to consent to participate in the three year extension study."
3223921|NCT01126346|Experimental|Arm I|Patients and their caregiver(s) receive a hyperthermic intraperitoneal chemotherapy (HIPEC) orientation with a Survivorship Navigator (SN) over 90 minutes following their initial surgical consult. Patients then receive telephone calls over 20-30 minutes from the SN once weekly for 3 weeks prior to HIPEC. After HIPEC, patients meet with the SN for 20-30 minutes to discuss adjustments and adaptation to the surgery and hospitalization 3-4 days post-HIPEC, biweekly for two weeks and weekly thereafter until hospital discharge. After hospital discharge, patients receive telephone calls from the SN twice monthly for 1 month.
3223922|NCT01126385||Transpedicular stabilization|Patients undergoing transpedicular stabilization of the spine
3223923|NCT01126398||Ankle / dist. tibia fracture fixation|
3223924|NCT01126411|No Intervention|control|control group / no immunoadsorption
3223925|NCT01126411|Active Comparator|immunoadsorption|immunoadsorption
3223926|NCT01126450|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-28 and cetuximab IV once weekly over 1-2 hours on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3223927|NCT01126463|Experimental|Rhenium Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
3223928|NCT01126476|Active Comparator|small volume strata|12 in small volume strata
3223929|NCT01126476|Active Comparator|large volume strata|12 in large volume strata
3223930|NCT01126502|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive alvespimycin hydrochloride IV over 60 minutes on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3223931|NCT01126515||Hyperbaric oxygen|In this open-label feasibility study, all subjects will receive 60 hyperbaric oxygen sessions (100% oxygen, 1.5 atmospheres absolute (atm abs), for 60 minutes), delivered daily, five days per week.
3223932|NCT01126528|Experimental|Vitamin D3|Vitamin D3 (cholecalciferol)
3223933|NCT01126528|Placebo Comparator|Control|Placebo control group
3223934|NCT01126554||Critically ill patients|
3223935|NCT01126567||High Sampling Rate|Samples will be obtained at a high rate
3223936|NCT01126567||Low Sampling Rate|Samples will be obtained at a low rate
3223937|NCT01126606|Experimental|Group 1|Dermacyd Silver Frutal followed by Dermacyd Silver Frutal+PH_DESYLSTY_FR followed by wash out followed by Glycerine Vegetal Soap Granado Traditional
3223938|NCT01126606|Experimental|Group 2|Glycerine Vegetal Soap Granado Traditional followed by wash out followed by Dermacyd Silver Floral followed by Dermacyd Silver Floral + PH_DESYLSTY_FR
3223939|NCT01126632||Cap Assisted Colonoscopy|Patients receiving colonoscopies where scope is fitted with cap
3223940|NCT01126632||Standard Colonoscopy|Patients receiving standard colonoscopy without the cap on the scope
3223941|NCT01126645|Other|local ablation group|Local ablation group: Potentially curative treatment of early HCC includes surgical resection and local ablation (RFA, PEI, BT). Recurrence rates after such approaches are reported to amount to 50% at 3 years and 70% at 5 years. Tumor recurrence may be either due to de novo development of new primary tumors or due to intrahepatic (unrecognized) metastases. Prevention of recurrence after local ablation is an important strategy to improve overall survival. So far, adjuvant chemoembolization and chemotherapy have not proven to be effective in preventing recurrences. There is, however, a strong rationale to assume that sorafenib will be of value in the adjuvant treatment of HCC as sorafenib has a dual mechanism of action (inhibition of tumor proliferation and antiangiogenesis) and has proven efficacy in HCC.
3223942|NCT01126645|Active Comparator|palliative treatment group|"Radioembolization has been reported to be effective in patients with unresectable HCC with preserved liver function from a number of trials. Successful downstaging of disease rendering patients eligible for potentially curative therapies, and even histologically confirmed complete responses of unresectable HCC, have repeatedly been reported providing the rationale to evaluate SIRT+sorafenib in comparison to sorafenib alone.~The impact of cirrhosis as a concomitant disease in most patients with HCC is that it limits the ability of many patients to tolerate chemotherapy and is an independent cause of death in HCC patients. Thus, the historical difficulty in demonstrating an effect of therapy on survival in patients with advanced-stage, unresectable HCC (the majority). A new therapy that is effective in controlling hepatic disease, is less toxic than traditional chemotherapy, and improves the quality of life for patients in the advanced stages of HCC could represent an alternative."
3223943|NCT01126658||All subjects act as their own contral|
3223944|NCT01126684|Active Comparator|Atorvastatin|
3223945|NCT01126684|Placebo Comparator|Placebo|
3223946|NCT01126697|No Intervention|Enhanced standard of care|
3223947|NCT01126697|Active Comparator|Lisinopril|
3223948|NCT01126697|Active Comparator|Coenzyme Q10|
3223949|NCT01126697|Active Comparator|Coenzyme Q10 and Lisinopril|
3223950|NCT01126736|Experimental|Low Dose E7389 in Combination with Pemetrexed|
3223951|NCT01126736|Active Comparator|Pemetrexed|
3223952|NCT01126736|Experimental|High Dose E7389 in Cominbation with Pemetrexed|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
3223953|NCT01126749|Experimental|E7389 in combination with gemcitabine plus cisplatin|
3223954|NCT01126749|Experimental|gemcitabine plus cisplatin|
3223955|NCT01126762|Experimental|Dietary advice and grocery store card|Dietary advice to consume low mercury, high DHA fish plus a grocery store gift card to support the purchase of fish
3223956|NCT01126762|Experimental|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
3223957|NCT01126762|Placebo Comparator|Control|General dietary advice not focused on fish intake
3223958|NCT01126775||group non-high-risk|
3223959|NCT01126775||group high risk|
3223960|NCT01126788||PADnet + testing|
3223961|NCT01126788||Parks Flo-lab Test|
3223962|NCT01126814|Experimental|one|
3223963|NCT01126827|Active Comparator|Supportive Psychotherapy|
3223964|NCT01126827|Active Comparator|Mindfulness-Based Cognitive Behavioral Therapy|
3223965|NCT01126840||Questionnaire + Telephone Interview|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete. The phone interview should take 30-45 minutes to complete.
3223966|NCT01126853|Experimental|Vaccination|Receipt of up to 3 series of double dose combination hepatitis A/B vaccine (Twinrix)
3223967|NCT01126866|Experimental|preoperative chemotherapy|
3223968|NCT01126892|Experimental|Nilotinib|
3223969|NCT01126918|Active Comparator|Brochure Condition|Participants in this condition receive an educational brochure about healthy body image via post-mail.
3223970|NCT01126918|Experimental|Group Condition|Participants in this condition attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
3223971|NCT01126944|Experimental|system heart mate II|left ventricular assist device
3223972|NCT01126944|No Intervention|normal medical care|Optimal medical treatment for heart failure according to international guidelines
3223973|NCT01126970|Placebo Comparator|Placebos.|Velneperit Placebo q.d.+ Orlistat Placebo t.i.d.
3223974|NCT01126970|Experimental|Velneperit 400 mg|Velneperit 400 mg q.d.
3223975|NCT01126970|Active Comparator|Orlistat 120 mg|Orlistat 120 mg t.i.d.
3223976|NCT01126970|Experimental|Velneperit 400 mg + Orlistat 120 mg|Velneperit 400 mg q.d.and Orlistat 120 mg t.i.d
3223977|NCT01126983|Experimental|Non-Suture|No suture will be used to secure the leads. Benzoin and Steri-Strips will be used like in the other two arms.
3223978|NCT01126996||MenC vaccinated healthy children|Children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
3223979|NCT01127009|Experimental|Arm I|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11; and mitoxantrone IV, etoposide IV over 1 hour, and intermediate-dose cytarabine IV over 6 hours on days 1-6. Treatment continues in the absence of disease progression or unacceptable toxicity.
3223980|NCT01127022|Active Comparator|480 mg/d choline intake|480 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [100 mg choline/d]
3223981|NCT01127022|Experimental|930 mg/d choline intake|930 mg/d choline derived from the diet [380 mg choline/d] plus supplemental choline chloride [550 mg choline/d]
3223982|NCT01127035|Experimental|SLIT|sublingual immunotherapy biologically standardized
3223983|NCT01127035|Placebo Comparator|placebo|same preparation of SLIT without the allergen
3223984|NCT01127048|Experimental|Prospan Hustenzäpfchen|
3223985|NCT01127048|Placebo Comparator|Placebo|
3223986|NCT01127074|Experimental|KS24.22-vaccination|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated. KS24.22 cells were adjusted to 10E7/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
3223987|NCT01127100|Experimental|Transdermal fentany matrix|Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
3223988|NCT01127100|Active Comparator|gabapentin|Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.
3223989|NCT01127113|Active Comparator|SPIO-labelled mononuclear cells|
3223990|NCT01127113|Placebo Comparator|Unlabelled mononuclear cells|
3223991|NCT01127113|Active Comparator|SPIO alone|
3223992|NCT01127126|Active Comparator|Bryophyllum|muscle relaxing substance
3223993|NCT01127126|Placebo Comparator|Placebo|control group postmenopausal women suffering from overactive bladder
3223994|NCT01127152|Active Comparator|Automatic relays|Automatic relays of noradrenalin using intensive basis.
3223995|NCT01127152|Active Comparator|Manual relays|Relays of noradrenalin using manual method
3223996|NCT01127178|Experimental|E7016 + TMZ|
3223997|NCT01127191||Military|
3223998|NCT01127204|Active Comparator|arm 1 (reference strategy)|AZT-3TC-LPV/r twice a day
3223999|NCT01127204|Experimental|arm 2 (simplification strategy)|ABC-3TC-EFV once a day
3224000|NCT01127217|Experimental|amlodipine/losartan|
3224001|NCT01127217|Active Comparator|amlodipine|
3224002|NCT01127230||Liposuction patients|Patients who already opted and are scheduled for liposuction.
3224003|NCT01127243|Active Comparator|inpatient LSH|LSH means laparoscopic supracervical hysterectomy
3224004|NCT01127243|Experimental|Day-case LSH|LSH means laparoscopic supracervical hysterectomy
3224005|NCT01127269|Experimental|Insulin Glargine|"Patients will receive insulin glargine titrated based on standard of care as recommended by the ADA/EASD Consensus Algorithm. Step 1: insulin glargine initiation regimen for insulin naive patients/ Switch to insulin glargine for patient already treated with basal insulin.~Step 2: the insulin dosage of patients will be titrated according to the ADA/EASD Consensus Algorithm."
3224006|NCT01127282|Experimental|Vitamin|Vitamin(vitamin A 15mg,C 500mg,E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
3224007|NCT01127282|Placebo Comparator|Control|Placebo(digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
3224008|NCT01127295|Other|Tamoxifen, Anastrozole, letrozole, Exemestane|Current hormonotherapy treatment in hormono dependent breast cancer
3224009|NCT01127308|Experimental|[14C]Ertugliflozin|Single dose - oral dosing suspension
3224010|NCT01127334||Systolic Heart Failure, Dyssynchrony, CRT-D|Patients with systolic heart failure and dyssynchrony that have a CRT-D that have not been optimized in the past 3 months.
3224011|NCT01127360|Experimental|Bevacizumab|Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
3224012|NCT01127360|Active Comparator|Ranibizumab|Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
3224013|NCT01127386|Experimental|fix dose lenalidomide 25mg, basic cachexia management|dose reduction according to toxicity possible
3224014|NCT01127386|Experimental|CRP-response guided lenalidomide, basic cachexia management|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
3224015|NCT01127386|Experimental|placebo|to generate data about basic cachexia management, no direct comparator for treatment arms efficacy
3224016|NCT01127399||Bariatric, nonasthma|Participants that will have had a bariatric surgery but do not have asthma.
3224017|NCT01127399||Bariatric, asthma|Participants that will have had a bariatric surgery and have been physician diagnosed with asthma prior to the surgery.
3224018|NCT01127399||Control, nonasthma|Healthy participants that who will not be getting a bariatric surgery and who do not have asthma.
3224019|NCT01127399||Control, asthma|Healthy participants that will not be having a bariatric surgery but do have asthma.
3224020|NCT01127412|Active Comparator|Physical activity stimulating program|Advices to stimulate motor activity and motor development at the age of two weeks, two months, four months, eight months and eleven months
3224021|NCT01127412|No Intervention|Control|
3224022|NCT01127425|Active Comparator|1|Intervention: Surgery: laparoscopic sigmoid resection without fast track postoperative care
3224023|NCT01127425|Active Comparator|2|Intervention: Surgery: conventional (open) sigmoid resection without fast track postoperative care
3224024|NCT01127451|Experimental|Denileukin diftitox|12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)
3224025|NCT01127464|Experimental|.3 dose level of DCVax -001|.3 dose level of DCVax plus fixed dose of 1.6 ml Poly ICLC
3224026|NCT01127464|Experimental|1 mg dose level of DCVax -001|1 mg dose level of DCVax -001 plus 1.6 ml of poly ICLC
3224027|NCT01127464|Experimental|3 mg dose level of DCVax-001|3 mg dose level of DCVax-001 plus poly ICLC
3224028|NCT01127464|Placebo Comparator|Placebo|sterile saline
3224029|NCT01127464|Experimental|poly-ICLC alone|1.6 mg of poly-ICLC alone
3224030|NCT01127477|Experimental|1|
3224031|NCT01127529||Subjects with severe congenital protein C deficiency|Registry subjects will be identified by working with Hemophilia Treatment Centers and Thrombosis Centers known to have subjects with severe congenital protein C deficiency, as well as by working with centers that use Ceprotin in emergency care situations.
3224032|NCT01127542|Experimental|Lenalidomide for early stage poor prognosis CLL|
3224033|NCT01127568|Experimental|Propranolol|Propranolol is a beta-blocker (blocking beta- adrenergic receptors) that reduces sympathetic activity. It is a well-known drug typically prescribed to individuals suffering from hypertension, tachycardia, cardiac arrhythmia, tremors, thyroid disease, or migraine.
3224034|NCT01127568|Placebo Comparator|Placebo|The placebo is an inactive capsule that will have no medication effect, but looks exactly like the medication.
3224035|NCT01127620|Experimental|Bilastine|20 mg encapsulated tablets
3224036|NCT01127620|Active Comparator|Cetirizine|10 mg encapsulated tablets
3224037|NCT01127620|Placebo Comparator|Placebo|Encapsulated tablets
3224038|NCT01127672|Active Comparator|control|corticosteroid injection into the origin of the plantar fascia
3224039|NCT01127672|Active Comparator|experimental|platelet rich plasma injection into the origin of the plantar fascia
3224040|NCT01127724|Experimental|group 1- 1000 mcg|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months
3224041|NCT01127724|Experimental|Group 2- 100 mcg|Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months
3224042|NCT01127724|Experimental|group 3- 2000 mcg|Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
3224043|NCT01127750|Experimental|FTY720|
3224044|NCT01127776|Experimental|Apos System|
3224045|NCT01127776|Placebo Comparator|CONTROL|
3224046|NCT01127789|Experimental|non-invasive brain stimulation|
3224047|NCT01127828|Active Comparator|Probiotic yoghurt (Cultura)|Cultura yoghurt containing: L bulgaricus, S thermophilus
3224048|NCT01127828|Placebo Comparator|Yoghurt with no probiotic|
3224049|NCT01127841|Experimental|Rituximab and Bendamustine|
3224050|NCT01127854||Cases|
3224051|NCT01127854||Controls|
3224052|NCT01127880|Active Comparator|Ancef 1 gm or Clindamycin 300 mg|Group A will receive Ancef 1gm or Clindamycin 300mg if penicillin or bet-lactam allergy exists
3224053|NCT01127880|Placebo Comparator|Placebo|Group B will receive .9% Normal Saline as a placebo.
3224054|NCT01127906|Other|Randomized cross-over sequence|Randomized unbalanced sequence of incomplete block design with replicates within sequence
3224055|NCT01127919||Low Commitment|Group 1 participants will take a 1-credit hour course that involves exercise training only.
3224056|NCT01127919||High Commitment|Group 2 participants will take a 3-credit hour course that involves exercise training plus an online cognitive component that provides information on fitness and health topics and includes quizzes and other written course work
3224057|NCT01127919||Non-Exercise|Group 3 participants will take the cognitive component of the formal course but will not partake in the formalized exercise program for a period of 35 weeks.
3224058|NCT01127932|Experimental|CBT for suicide|
3224059|NCT01127932|Active Comparator|Enhanced care control group|This group is designed to be an active control which provides detailed information about substance use, suicide risk, and depression without providing any CBT or other specific therapy.
3224060|NCT01127945|Experimental|atorvastatin 80mg|
3224061|NCT01127945|Active Comparator|conventional therapy (for heart failure)|
3224062|NCT01127958|Active Comparator|SeQuent Please|PCI with drug-eluting balloon
3224063|NCT01127958|Active Comparator|Xience Prime|PCI with a drug-eluting stent
3224064|NCT01127984|Experimental|treatment with tissucol|patients treated with tissucol, local application in the pocket of PM / ICD
3224065|NCT01127984|Active Comparator|vacuum drainage system|patients treated with application of vacuum drainage system.
3224066|NCT01127997||study A|post-breakfast meal tolerance test + post-lunch meal tolerance test
3224067|NCT01127997||study B|fasting + post-lunch meal tolerance test
3224068|NCT01128010||alcoholic liver disease|alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
3224069|NCT01128010||controls|Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination
3224070|NCT01128023||PET Rb-82 perfusion imaging|Patients diagnosed with or suspected coronary artery disease requiring evaluation and/or risk stratification will undergo PET Rb-82 perfusion imaging.
3224071|NCT01128023||SPECT perfusion imaging|Patients diagnosed with or suspected coronary artery disease who have undergone SPECT myocardial perfusion imaging.
3224072|NCT01128036||CHF, cardomyopathy|Patients with signs of poor peripheral perfusion due to cardiomyopathy or congestive heart failure
3224073|NCT01128075||naïve subjects|Cohort of RMS patients who initiate disease modifying treatment with Rebif®
3224074|NCT01128075||non-naïve subjects|Cohort of RMS patients who initiate treatment with Rebif® after having failed therapy with other disease modifying drugs on the basis of lack of efficacy, compliance, safety, tolerability or convenience, as per clinical judgment of study investigator
3224075|NCT01128088||PCA and Volulyte|
3224076|NCT01128088||PCA and Hartmann's|
3224077|NCT01128088||Spinal and Volulyte|
3224078|NCT01128088||Spinal and Hartmann's|
3224079|NCT01128101|Experimental|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
3224080|NCT01128127|Experimental|Multifaceted intervention 1|psycho-educational workshop + audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
3224081|NCT01128127|Experimental|Multifaceted intervention 2|audit-feedback + computer-based clinical decision support system (CCDSS) + usual intervention
3224082|NCT01128127|Active Comparator|Control|usual intervention
3224083|NCT01128140|Experimental|Motivational Enhancement Therapy|
3224084|NCT01128140|Active Comparator|Education|
3224085|NCT01128166||Patients implanted with a CRT-D (Cardiac Resynch. Therapy)|
3224086|NCT01128205||Diagnosed for 6 months or more|
3224087|NCT01128218|Experimental|Tumor fluorescence|A single arm in this open-label study where all patients are treated with the study drug - 5-aminolevulinic acid. Areas of the brain that are fluorescent and areas that are not fluorescent are evaluated for presence of tumor cells
3224088|NCT01128257||1|
3224089|NCT01128257||2|
3224090|NCT01128283||Sepsis|Patients with severe sepsis
3224091|NCT01128283||Non-infected|ICU patients without evidence of infection
3224092|NCT01128309|Experimental|Stress Reduction Intervention|Stress Reduction Intervention
3224093|NCT01128309|Active Comparator|Active Control Condition|
3224094|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 40mg|
3224095|NCT01128322|Experimental|S-Amlodipine 2.5mg + Telmisartan 80mg|
3224096|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 40mg|
3224097|NCT01128322|Experimental|S-Amlodipine 5mg + Telmisartan 80mg|
3224098|NCT01128322|Active Comparator|S-Amlodipine 2.5mg|
3224099|NCT01128322|Active Comparator|S-Amlodipine 5mg|
3224100|NCT01128322|Active Comparator|Telmisartan 40mg|
3224101|NCT01128322|Active Comparator|Telmisartan 80mg|
3224102|NCT01128322|Placebo Comparator|Placebo|
3224103|NCT01128335|Active Comparator|Arm 1|MMF(1000mg bid) + tacrolimus + standard of care medications
3224104|NCT01128335|Experimental|Arm 2|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3224105|NCT01128335|Experimental|Arm 3|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
3224106|NCT01128335|Experimental|Arm 4|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
3224107|NCT01128348|Experimental|patient advocate|"Patient advocate works with patient before, during, and after a visit to asthma doctor.~Patient receives video of asthma education materials"
3224108|NCT01128348|Active Comparator|asthma education|Patient receives video of asthma education materials
3224109|NCT01128374|Experimental|intervention|Therapy
3224110|NCT01128439||1|
3224111|NCT01128452|Placebo Comparator|Placebo|Placebo
3224112|NCT01128452|Experimental|EVT 101|EVT 101
3224113|NCT01128478|Other|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
3224114|NCT01128478|No Intervention|Nil-per-mouth regimen|Conventional management
3224115|NCT01128517|Experimental|Bahavioral|Education about complementary food given to mothers
3224116|NCT01128530|Experimental|JNJ-32729463|JNJ-32729463 250 mg tablet and matching linezolid placebo twice daily
3224117|NCT01128530|Active Comparator|linezolid|linezolid 600 mg tablet and matching JNJ-32729463 placebo twice daily
3224118|NCT01128556|Experimental|Bepreve|topical ocular treatment as indicated
3224119|NCT01128582|Active Comparator|Rozerem|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
3224120|NCT01128582|Placebo Comparator|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology
3224121|NCT01128608|Active Comparator|Control Group - Healthy Subjects|Healthy volunteers with normal EGD.
3224122|NCT01128608|Active Comparator|NERD Group|Subjects with NERD. Heartburn symp x2 wk for 3 months. Normal EGD and abnormal 24 hour pH.
3224123|NCT01128634|Other|GSK573719|GSK573719
3224124|NCT01128634|Other|GSK573719/GW642444|GSK573719/GW642444
3224125|NCT01128660||RSD-citizens|Residents of Southern Denmark, who filed more than 9 prescriptions during 2009.
3224126|NCT01128673||Body Cooled|Infants undergoing total body cooling for HIE
3224127|NCT01128673||HIE,Selective Head Cooled|Infants undergoing head cooling for HIE
3224128|NCT01128686||CHB patients who started LAM as an initial antiviral treatment|CHB patients who started LAM as an initial antiviral treatment at least 5 years prior to this investigation
3224129|NCT01128699|Experimental|ISA+AVI|injection of intraoperative subconjunctival Avastin as an adjunct to Ahmed valve implant
3224130|NCT01128699|Active Comparator|AVI|Ahmed valve implant
3224131|NCT01128712|Other|Group 1|Pregabalin (150mg/day)
3224132|NCT01128712|Other|Group 2|Pregabalin (450mg/day)
3224133|NCT01128725|Other|Group Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
3224134|NCT01128751|Active Comparator|Embol-X|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
3224135|NCT01128751|Active Comparator|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
3224136|NCT01128751|No Intervention|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
3224137|NCT01128764|Experimental|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
3224138|NCT01128764|Active Comparator|CBT for depression|CBT for depression only
3224139|NCT01128777|Experimental|Cognitive behavioral group therapy|Cognitive behavioral group therapy for adolescents and a parallel group for parents
3224140|NCT01128777|Active Comparator|Nondirective supportive group therapy|Nondirective supportive group therapy for adolescents and a parallel group for parents
3224141|NCT01128790|Experimental|remote ischemic preconditioning|4 cycles of 5 mins upper limb ischemia induced by blood pressure cuff inflation 20mmHg above systolic blood pressure
3224142|NCT01128790|Sham Comparator|Sham control|4 x 5 mins of upper limb blood pressure cuff inflation to 10mmHg (non-occlusive)
3224143|NCT01128816|No Intervention|Standard HF therapy|Subjects will receive optimal standard therapy for heart failure conforming to national guidelines as determined by the referring cardiologist
3224144|NCT01128816|Active Comparator|Standard therapy for HF + ASV|Subjects will receive treatment with Adaptive Servo Ventilation in addition to optimal standard therapy for heart failure conforming to national guidelines, as determined by the referring cardiologist
3224145|NCT01128855|Experimental|Cohort 1|3 mg/kg GSK2402968 / placebo
3224146|NCT01128855|Experimental|Cohort 2|6 mg/kg GSK2402968 / placebo
3224147|NCT01128855|Experimental|Cohort 3|9 mg/kg GSK2402968 / placebo
3224148|NCT01128855|Experimental|Cohort 4|12 mg/kg GSK2402968 / placebo
3224149|NCT01128868|Active Comparator|Proximal femur locking plate|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with a Proximal Femur Locking Compression Plate (PF-LCP, PF-LCP Hook Plate, PeriLoc)
3224150|NCT01128868|Other|Trochanteric nail|Treatment of reverse oblique intertrochanteric or subtrochanteric fractures with Trochanteric Nails (PFNA, TFN, GN)
3224151|NCT01128881|Experimental|IMMUNINE|
3224152|NCT01128907||1|Hematological neutropenic patients at high risk of Invasive Aspergillosis with persistent fever and an opportunist infection suspicion.
3224153|NCT01128907||2|Patients without hematological illness and without Invasive Aspergillosis suspicion.
3224154|NCT01128920|Experimental|Skin and Needle Hygiene Intervention|
3224155|NCT01128920|Experimental|Assessment-Only Condition|
3224156|NCT01128933|Experimental|Hypertensive patients|Hypertensive patients with at least moderate renal artery stenosis
3224157|NCT01128985|Experimental|001|Canagliflozin 50 mg 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
3224158|NCT01128985|Experimental|002|Canagliflozin 100 mg 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
3224159|NCT01128985|Experimental|003|Canagliflozin 300 mg 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
3224160|NCT01128985|Placebo Comparator|004|Placebo matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
3224161|NCT01128998|Experimental|S-1 and Sorafenib|
3224162|NCT01129037|Other|Goal directed fluid management|
3224163|NCT01129050|Experimental|Low-dose Flaxseed Oil|2.2 g ALA (alpha-linolenic acid) per day
3224164|NCT01129050|Experimental|High-dose Flaxseed Oil|6.6 g ALA (alpha-linolenic acid) per day
3224165|NCT01129050|Experimental|Low-dose Fish Oil|1.2 g EPA+DHA (700 mg EPA and 500 mg DHA) per day
3224166|NCT01129050|Experimental|High-dose Fish Oil|3.6 g EPA+DHA (2.1 g EPA and 1.5 g DHA) per day
3224167|NCT01129050|Placebo Comparator|Placebo|4 g or 6 g soybean oil per day
3224168|NCT01129063|Experimental|Sequence clopidogrel 75 / 75 / 300 mg|"Period 1: clopidogrel 75 mg single dose~Period 2: clopidogrel 75 mg single dose~Period 3: clopidogrel 300 mg single dose~Each intake is at around 8:00 AM under fasted conditions."
3224169|NCT01129089|Experimental|LNS-PLW|There will be 48 pregnant or lactating women (PLW) in this arm. They will be randomized to receive cumin flavored LNS-PLW or LNS-PLW with no added flavor on day 2. On day 3, the PLW getting a test-dose of cumin flavored LNS-PLW on day 2 will receive LNS-PLW with no added flavor and the PLW getting a test-dose of LNS-PLW with no added flavor on day 2 will receive cumin flavored LNS-PLW.
3224170|NCT01129089|Experimental|LNS-Child|There will be 48 infant and young children(IYC) in this arm. They will be randomized to receive cardamom flavored LNS-Child or LNS-Child with no added flavor on day 2. On day 3, the IYC getting a test-dose of LNS-Child with no added flavor on day 2 will receive cardamom flavored LNS-Child and the IYC getting a test-dose of cardamom flavored LNS-Child on day 2 will receive LNS-Child with no added flavor.
3224171|NCT01129089|Experimental|MNP-Child|There will be 48 infant and young children(IYC) in this arm. They will receive MNP on day 2 and day 3.
3224172|NCT01129154|Experimental|panitumumab|Patients will receive six infusions of panitumumab every 2 weeks for the first cycle.
3224173|NCT01129180|Experimental|Arm I|Patients receive bortezomib IV on days 4, 8, 11, and 15 and azacitidine SC on days 1-5. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity. Attempt to collect Correlative studies will be made.
3224174|NCT01129193|Experimental|Arm I (Hematologic Malignancies)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
3224175|NCT01129193|Experimental|Arm II (Solid Tumors)|Patients will receive orally administered AR-42 three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
3224176|NCT01129219|Experimental|Usual care|Subjects in the control group were asked to maintain their current lifestyle. No restrictions were placed on their exercise activities.
3224177|NCT01129232|Experimental|GAD-alum|GAD-alum administered at 0 and 1 months after inclusion
3224178|NCT01129232|Placebo Comparator|Placebo|
3224179|NCT01129258|Experimental|PF-04991532|
3224180|NCT01129258|Placebo Comparator|Placebo|
3224181|NCT01129271|Experimental|Group clopidogrel fed - fasting|"Period 1:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily"
3224182|NCT01129271|Placebo Comparator|Group placebo fed - fasting|"Period 1:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily~Period 2:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo under fasted conditions, once daily"
3224183|NCT01129271|Experimental|Group clopidogrel fasting - fed|"Period 1:~Day 1: clopidogrel 300 mg loading dose under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg/day under fasted conditions, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose with high fat breakfast~Day 2 to Day 5: clopidogrel 75 mg/day with standard breakfast, once daily"
3224184|NCT01129271|Placebo Comparator|group placebo fasting -fed|"Period 1:~Day 1: placebo loading dose under fasted conditions~Day 2 to Day 5: placebo in fasted conditions, once daily~Period 2:~Day 1: placebo loading dose with high fat breakfast~Day 2 to Day 5: placebo with standard breakfast, once daily"
3224185|NCT01129297||BMI ≥ 35 kg/m2 and diabetes|BMI (Body Mass Index) ≥ 35 kg/m2 and diabetes defined by a fasting blood glucose ≥ 7 mmol/l and/or ≥ to 11.1 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3224186|NCT01129297||BMI ≥ 35 kg/m2 with intolerance glucose|BMI (Body Mass Index) ≥ 35 kg/m2 with intolerance glucose defined by a fasting blood glucose> 6 mmol/L and <7 mmol/l and / or> 7.8 mmol/l and <11.1 mmol/l , 120 minutes after ingestion of glucose (oral glucose tolerance test)
3224187|NCT01129297||BMI ≥ 35 kg/m2 without diabetes|BMI (Body Mass Index)≥ 35 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3224188|NCT01129297||BMI <27 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3224189|NCT01129297||27 < BMI < 35 kg/m2 without diabetes|BMI (Body Mass Index) <27 kg/m2 without diabetes defined by a blood glucose ≤ 6 mmol/L and / or ≤ 7.8 mmol/l, 120 minutes after ingestion of glucose (oral glucose tolerance test)
3224190|NCT01129323|Experimental|Reduced-Intensity Preparative Regimen for Allogeneic SCT|Patient in this arm will receive maximally tolerated (reduced) doses of cytotoxic therapy with the goals of suppressing the immune system, and ablate host hematopoiesis to ensure engraftment of the donor's hematopoietic system.
3224191|NCT01129349|Experimental|Oprozomib|Phase I, Dose Escalation, Single Arm, Open Label
3224192|NCT01129362||Group 1|Participants that only received Pentacel® vaccine.
3224193|NCT01129362||Group 2|Participants that only received a single brand of pertussis vaccine other than Pentacel® vaccine.
3224194|NCT01129362||Group 3|Participants that received more than one brand of Pertussis vaccine or one or more doses of an unknown brand.
3224195|NCT01129375|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3224196|NCT01129375|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3224197|NCT01129375|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions"
3224198|NCT01129375|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
3224199|NCT01129388|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
3224200|NCT01129388|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg in the evening 2 hours after dinner, once daily~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily"
3224201|NCT01129388|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mgin the evening 2 hours after dinner, once daily~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose in the morning under fasted conditions~Day 2 to Day 5: clopidogrel 75 mg in the morning under fasted conditions, once daily"
3224202|NCT01129388|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily in the evening 2 hours after dinner~Day 1: placebo loading dose in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner~Day 2 to Day 5: placebo in the morning under fasted conditions + omeprazole 80 mg in the evening 2 hours after dinner, once daily~Period 2:~Day 1: placebo loading dose in the morning under fasted conditions~Day 2 to Day 5: placebo in the morning under fasted conditions, once daily"
3224203|NCT01129401|Other|Stonewall Project Participants|
3224204|NCT01129414|Experimental|Group clopidogrel - clopidogrel + omeprazole|"Period 1:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3224205|NCT01129414|Placebo Comparator|Group placebo - placebo + omeprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions"
3224206|NCT01129414|Experimental|Group clopidogrel + omeprazole - clopidogrel|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: clopidogrel 600 mg loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 150 mg + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 600 mg loading dose~Day 2 to Day 5: clopidogrel 150 mg, once daily~Each intake is under fasted conditions"
3224207|NCT01129414|Placebo Comparator|Group placebo + omeprazole placebo|"Period 1:~Day -5 to Day -1: omeprazole 80 mg, once daily~Day 1: placebo loading dose + omeprazole 80 mg concomitantly~Day 2 to Day 5: placebo + omeprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions"
3224208|NCT01129427|Experimental|Group clopidogrel - clopidogrel + pantoprazole|"Period 1:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
3224209|NCT01129427|Placebo Comparator|Group placebo - placebo + pantoprazole|"Period 1:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Period 2:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Each intake is under fasted conditions."
3224210|NCT01129427|Experimental|Group clopidogrel + pantoprazole - clopidogrel|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: clopidogrel 300 mg loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: clopidogrel 75 mg + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: clopidogrel 300 mg loading dose~Day 2 to Day 5: clopidogrel 75 mg, once daily~Each intake is under fasted conditions."
3224211|NCT01129427|Placebo Comparator|Group placebo + pantoprazole placebo|"Period 1:~Day -7 to Day -1: pantoprazole 80 mg, once daily~Day 1: placebo loading dose + pantoprazole 80 mg concomitantly~Day 2 to Day 5: placebo + pantoprazole 80 mg concomitantly, once daily~Period 2:~Day 1: placebo loading dose~Day 2 to Day 5: placebo, once daily~Each intake is under fasted conditions."
3224212|NCT01129453|Experimental|Vaccine-recipients|
3224213|NCT01129453|Placebo Comparator|Placebo|
3224214|NCT01129466|Active Comparator|Supplement A followed by supplement B|
3224215|NCT01129466|Active Comparator|Supplement B followed by Supplement A|
3224216|NCT01129479|Active Comparator|Galantamine|
3224217|NCT01129479|Placebo Comparator|Placebo|
3224218|NCT01129492|Placebo Comparator|Sham Laser|Ten applications of placebo were performed (twice a week) with the same method and Laser equipment, which has a placebo function available with a red ordinary light indistinguishable of the Laser light.
3224219|NCT01129492|Active Comparator|Active Laser|Ten applications of low-level Laser therapy (twice a week) were performed with a continuous wave diode laser device (830nm, beam area of 0.2827cm2), using the punctual method, continuous emission mode, output power of de 50 mW and fluence of 70J/cm2.
3224220|NCT01129518|Experimental|Two Dose MenC Group|Two doses of MenC-CRM197 priming at 3 and 4 months of age.
3224221|NCT01129518|Experimental|Single Dose MenC-CRM197 Group|One dose of MenC-CRM197 priming at 3 months of age.
3224222|NCT01129518|Experimental|Single Dose MenC-TT Group|Single dose MenC-TT priming at 3 months of age
3224223|NCT01129518|Experimental|Control Group|Zero dose MenC priming
3224224|NCT01129544|Experimental|Gene Transfer|open label single arm study
3224225|NCT01129570|Experimental|Siliphos - dose escalation|
3224226|NCT01129596||1|
3224227|NCT01129635|Experimental|CRT Candidate|"Patients with NYHA Class III or IV heart failure; EF ≤ 30% and QRS duration ≥ 120 ms, who are scheduled for CRT surgery.~Intervention: Cardiac Resynchronization Therapy (CRT) implantation"
3224228|NCT01129648|Placebo Comparator|BCX4208 placebo + Allopurinol placebo|Administered daily for 21 days.
3224229|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 100mg|Administered daily for 21 days.
3224230|NCT01129648|Active Comparator|BCX4208 placebo + Allopurinol 200 mg|Administered daily for 21 days.
3224231|NCT01129648|Active Comparator|BCX4208 Placebo + Allopurinol 300 mg|Administered daily for 21 days.
3224232|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol Placebo|Administered daily for 21 days.
3224233|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 100 mg|Administered daily for 21 days.
3224234|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 200 mg|Administered daily for 21 days.
3224235|NCT01129648|Experimental|BCX4208 20 mg + Allopurinol 300 mg|Administered daily for 21 days.
3224236|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol placebo|Administered daily for 21 days.
3224237|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 100 mg|Administered daily for 21 days.
3224238|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 200 mg|Administered daily for 21 days.
3224239|NCT01129648|Experimental|BCX4208 40 mg + Allopurinol 300 mg|Administered daily for 21 days.
3224240|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol Placebo|Administered daily for 21 days.
3224241|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 100 mg|Administered daily for 21 days.
3224242|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 200 mg|Administered daily for 21 days.
3224243|NCT01129648|Experimental|BCX4208 80 mg + Allopurinol 300 mg|Administered daily for 21 days.
3224244|NCT01129661|Placebo Comparator|normal saline (0.9%)|
3224245|NCT01129661|Experimental|CSL112|
3224246|NCT01129674|Active Comparator|Standard of Care|
3224247|NCT01129674|Experimental|LY2140023|"20mg, 40mg or 80mg~After 104 weeks, patients have the option to continue on treatment until the end of the study"
3224248|NCT01129687||ANSRS group|Patients qualifying for the study.
3224249|NCT01129700|Experimental|short-course CRT-5FU|
3224250|NCT01129713|Active Comparator|Nexium|Comparing 40 mg.once daily in healing erosive esophagitis.
3224251|NCT01129713|Active Comparator|Secretol|Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
3224252|NCT01129726|Experimental|Intubation|Transillumination-guided Fiberoptic Intubation
3224253|NCT01129739|Experimental|Human umbilical cord-derived MSCs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle
3224254|NCT01129739|Active Comparator|cyclosporine A (CsA)|CsA at a dose of 5 mg CsA/kg
3224255|NCT01129752||children at risk for depression|children at familial risk for depression
3224256|NCT01129791|Experimental|Raw Milk first|Organic raw cow's milk
3224257|NCT01129791|Placebo Comparator|Pasteurized milk first|Organic pasteurized cow's milk
3224258|NCT01129791|Placebo Comparator|Non-Dairy Milk first|Unflavored soy milk
3224259|NCT01129817|Experimental|Cognitive Functional Therapy|
3224260|NCT01129817|Active Comparator|Manual Therapy and Exercise|
3224261|NCT01129830|Other|Dehydroepiandrosterone|infertile women with low anti mullerian hormone levels
3224262|NCT01129843|Experimental|Directly observed home based daily iron therapy|Village volunteers will provide directly observed home based daily iron supplementation( ferrous sulphate) to enrolled anemic women in the experimental arm
3224263|NCT01129843|Active Comparator|Clinic driven unsupervised daily iron therapy|In the control group of villages, clinic driven unsupervised iron ( ferrous sulphate) supplementation will be offered on monthly basis to anemic women for 3 months
3224264|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, Low Dose|Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA
3224265|NCT01129856|Active Comparator|Ocular Iontophoresis EGP-437, High Dose|Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA
3224266|NCT01129856|Placebo Comparator|Ocular Iontophoresis Placebo|Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA
3224267|NCT01129895|Experimental|Health promotion|5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
3224268|NCT01129895|No Intervention|Promoting Health|No intervention follow-up only
3224269|NCT01129934|Experimental|Morphine-Promethazine|Pain relief by administration of morphine-promethazine combination
3224270|NCT01129934|Active Comparator|morphine|pain relief by administration of morphine
3224271|NCT01129947|Experimental|DHEA|
3224272|NCT01129986|Experimental|Dermastream|
3224273|NCT01129999|Experimental|Cognitive-Behavioral Therapy|
3224274|NCT01129999|Experimental|Hypnotherapy|
3224275|NCT01130012|Other|Lifestyle, follow-up, early care, standard care high/low risk|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
3224276|NCT01130012|Other|Close follow-up|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
3224277|NCT01130025|Experimental|Innohep®|Long-term treatment with Innohep® only.
3224278|NCT01130025|Active Comparator|Warfarin|Oral treatment with warfarin in combination with overlapping initial (5 to 10 days) treatment with Innohep®.
3224279|NCT01130038||Children with DCD and Typical Development|
3224280|NCT01130038||Children with DCD|2 groups Children with DCD and Typical Development
3224281|NCT01130064|Experimental|QAX576|QAX576
3224282|NCT01130064|Placebo Comparator|Placebo|Placebo
3224283|NCT01130077|Experimental|HLA Restricted glioma antigen peptides plus Poly ICLC|All subjects will receive vaccine plus Poly ICLC will receive 9 injections ( once every 3 weeks)
3224284|NCT01130129|Experimental|Ex-vivo treatment of platelets|Ex-vivo treatment of platelets
3224285|NCT01130142|Active Comparator|Arm 1 (Phase 2)|IPI-926 in combination with gemcitabine
3224286|NCT01130142|Placebo Comparator|Arm 2 (Phase 2)|Placebo in combination with gemcitabine
3224287|NCT01130155||Mwanza Region|Households, and patients presenting at public health facilities in Mwanza Region
3224288|NCT01130155||Mbeya Region|Households, and patients presenting at public health facilities in Mbeya Region
3224289|NCT01130155||Mtwara Region|Households, and patients presenting at public health facilities in Mtwara Region
3224290|NCT01130181|Experimental|Cholecalciferol|
3224291|NCT01130181|Placebo Comparator|Placebo|
3224292|NCT01130194|Experimental|Experimental|C-MOPP-R chemotherapy, 6 cycles Peripheral blood stem cell mobilization Radioimmunotherapy Autologous Hematopoietic Stem Cell Transplantation
3224293|NCT01130220||Brain Tumor Patient|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
3224294|NCT01130220||Health Care Provider|"A one-time focus group will be held in a quiet room for approximately 30-60 minutes until a saturation of themes has been identified."
3224295|NCT01130233|Experimental|robotic|robotic assisted rectal resection
3224296|NCT01130233|Active Comparator|laparoscopic|laparoscopic rectal resection
3224297|NCT01130246|Experimental|A-002 500 mg|Once daily oral administration
3224298|NCT01130246|Placebo Comparator|Matched Placebo|Once daily oral administration
3224299|NCT01130285||Non-Lung Cancer, Heavy Smoker|Subjects will be ≥ 50 years of age and have a ≥ 20 pack year smoking history and will be either healthy volunteers or individuals undergoing diagnostic bronchoscopy, with absence of lung cancer documented at the time of enrollment.
3224300|NCT01130298|Experimental|1|
3224301|NCT01130311|Experimental|Cholecalciferol (Vitamin D)|Intramuscular injection of VITAMIN D, 600,000 UNITS WILL BE GIVEN TO THE TEST SUBJECTS AT WEEK 0 and at week 4 OF the TRIAL
3224302|NCT01130311|Placebo Comparator|SALINE, INTRAMUSCULAR INJECTION|NORMAL SALINE INJECTION WILL BE GIVEN TO THE CONTROL SUBJECTS at week 0 and week 4 of the trial
3224303|NCT01130324||VIBATIV treated pregnant women|Women treated with telavancin (any dose or duration) during pregnancy.
3224304|NCT01130363||Fundic Gland Polyps on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have also been prescribed and regularly take a proton pump inhibitor.
3224305|NCT01130363||Fundic Gland Polyp not on PPI|Patients found to have fundic gland polyps on endoscopic evaluation that have not been prescribed a proton pump inhibitor.
3224306|NCT01130363||Group 3 (Control Group)|Individuals who are prescribed proton pump inhibitor but are not found to have fundic gland polyps on endoscopic evaluation.
3224307|NCT01130376|Experimental|Vaccine and cytokines|"Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection."
3224308|NCT01130376|Active Comparator|Vaccine alone|"Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0."
3224309|NCT01130376|Active Comparator|Cytokines alone|"Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC."
3224310|NCT01130402||Neck masses|Patients with previously untreated neck masses
3224311|NCT01130415||Patients treated with sacral neuromodulation|
3224312|NCT01130428|Experimental|Intervention group|As a mechanical intervention, we will use a vibration platform to administer mechanical stimulation to the forearm of subjects (see Figure 1). All subjects will participate in a single experiment during which they will receive the mechanical intervention a fixed dose of; the duration of an experiment is approximately three hours.
3224313|NCT01130441||self-harming group|
3224314|NCT01130441||non-self-harming group -control group|
3224315|NCT01130454|Active Comparator|SCIO Test Group|
3224316|NCT01130454|Placebo Comparator|SCIO Placebo Group|
3224317|NCT01130467||Normal control|
3224318|NCT01130467||pure ADHD|
3224319|NCT01130467||ADHD with comorbidity|
3224320|NCT01130480|Experimental|A|
3224321|NCT01130506|Experimental|Treatment (decitabine, vorinostat, cytarabine)|"INDUCTION THERAPY: Patients receive decitabine IV over 1 hour on days 1-10; vorinostat PO on days 5-10; and high-dose cytarabine IV over 2 hours on days 12, 14, and 16 in the absence of disease progression or unacceptable toxicity. Patients who achieve CR proceed to maintenance therapy. Patients who achieve CR with incomplete blood count recovery undergo bone marrow aspiration and biopsy at count recovery or day 42 before proceeding to maintenance therapy.~MAINTENANCE THERAPY: Patients receive decitabine IV over 1 hour on days 1-5 and vorinostat PO on days 5-10. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity."
3224323|NCT01130558|Active Comparator|Ordering template and education|Internal medical residents who were asked to use the insulin order template and received education about basal-bolus insulin ordering.
3224324|NCT01130558|Active Comparator|Education|Internal medical residents who received education about basal-bolus insulin ordering.
3224325|NCT01130571||Non-Small Cell Lung Cancer|
3224326|NCT01130584||Cancer patient|
3224327|NCT01130636|Experimental|Tamiflu|Lactating women (up to 20 subjects) who present with clinical symptoms indicative of influenza will be recruited (a maximum of 6 months period of recruitment) to receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules, provided free of charges for the study) at a standard dose of 75 mg twice daily. These subjects will have a 12 hour pharmacokinetic plasma, urine and breast milk study undertaken after the steady state in oseltamivir concentrations (both active and inactive metabolites will be measured) is reached in blood, i.e. after three days after treatment.
3224328|NCT01130649||Epilepsy patients, electronic diary|Cohort of epilepsy patient using an electronic diary system to record all seizures, side effects, and medication compliance
3224329|NCT01130649||Epilpesy patient, no electronic diary|Group of epilepsy patients who are followed using the standard of care, which is a paper diary and routine outpatient follow up visits
3224330|NCT01130662|Experimental|Decitabine Midostaurin combination|
3224331|NCT01130675|Active Comparator|eight ounces of caffeinated coffee for breakfast and lunch|
3224332|NCT01130675|No Intervention|standard care|
3224333|NCT01130688|Experimental|single arm of experimental drug combination|
3224334|NCT01130714|Experimental|Resistance training|Group assigned to complete resistance training during duration of chemotherapy.
3224335|NCT01130714|No Intervention|Control|Usual care.
3224336|NCT01130727|Active Comparator|green tea extract|
3224337|NCT01130727|Active Comparator|Cocoa extract rich in polyphenols|
3224338|NCT01130727|Placebo Comparator|placebo|
3224339|NCT01130727|Placebo Comparator|cocoa extract with low polyphenol|
3224340|NCT01130766|Experimental|stereotactic radiosurgery (SRS)|
3224341|NCT01130766|No Intervention|observation|
3224342|NCT01130779|Experimental|tarceva|continuation of tarceva
3224343|NCT01130792|Experimental|Lactobacillus GG|LGG once daily for 4 weeks
3224344|NCT01130792|Placebo Comparator|Inulin|
3224345|NCT01130805|Experimental|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
3224346|NCT01130818|Experimental|1|single ascending doses
3224347|NCT01130818|Placebo Comparator|2|single dose placebo
3224348|NCT01130818|Experimental|3|single dose, oral solution, 50 mg
3224349|NCT01130818|Experimental|4|single dose, capsules (fasting)
3224350|NCT01130818|Experimental|5|single dose, capsules (fed)
3224351|NCT01130870|Active Comparator|Sensory threshold - Amplitude|Stimulation amplitude set at sensory threshold.
3224352|NCT01130870|Experimental|25% below sensory threshold - Amplitude|Stimulation amplitude 75% of sensory threshold.
3224353|NCT01130870|Experimental|50% below sensory threshold - Amplitude|Stimulation with amplitude set 50% below sensory threshold
3224354|NCT01130909|Experimental|AZD6765 75 mg|
3224355|NCT01130909|Experimental|AZD6765 150 mg|
3224356|NCT01130909|Active Comparator|Ketamine 0.5 mg/kg|
3224357|NCT01130909|Placebo Comparator|125 mL sterile NaCl 0.9%|
3224358|NCT01130922|Experimental|Moxifloxacin IV|
3224359|NCT01130922|Active Comparator|Moxifloxacin oral|
3224360|NCT01130935||1|
3224361|NCT01130987|Experimental|Comprehensive Handoff Program|Introduction of Computerized tool plus team training
3224362|NCT01131000|Experimental|Ibuprofen|
3224363|NCT01131000|Placebo Comparator|Saline|Normal Saline
3224364|NCT01131013|Experimental|Treatment Sequence 1|Dosing Period 1 - Placebo; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - 500 mg CK-2017357
3224365|NCT01131013|Experimental|Treatment Sequence 2|Dosing Period 1 - Placebo; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - 375 mg CK-2017357
3224366|NCT01131013|Experimental|Treatment Sequence 3|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 500 mg CK-2017357
3224367|NCT01131013|Experimental|Treatment Sequence 4|Dosing Period 1 - 375 mg CK-2017357; Dosing Period 2 - 500 mg CK-2017357; Dosing Period 3 - Placebo
3224368|NCT01131013|Experimental|Treatment Sequence 5|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - Placebo; Dosing Period 3 - 375 mg CK-2017357
3224369|NCT01131013|Experimental|Treatment Sequence 6|Dosing Period 1 - 500 mg CK-2017357; Dosing Period 2 - 375 mg CK-2017357; Dosing Period 3 - Placebo
3224370|NCT01131039|Experimental|Single|
3224371|NCT01131091|Other|Group A|Subjects with end stage renal disease (ESRD) who are receiving hemodialysis treatment
3224372|NCT01131091|Other|Group B|Subjects with severe renal impairment
3224373|NCT01131091|Other|Group C|Subjects with moderate renal impairment
3224374|NCT01131091|Other|Group D|Subjects with mild renal impairment
3224375|NCT01131091|Other|Group E|Healthy subjects
3224376|NCT01131117||Pregnant women|
3224377|NCT01131143|Experimental|Treatment Group 1|Patients will receive a pre-visit, post-referral and post-contact phone call using providers voice
3224378|NCT01131143|Experimental|Treatment Group 2|Patients will receive a previsit, post-referral and post-contact call using a generic voice
3224379|NCT01131143|No Intervention|Treatment Group 3|Patients will be provided usual care with no additional phone calls.
3224380|NCT01131195|Active Comparator|Arm A: bevacizumab and paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle. Both medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug is given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion.
3224381|NCT01131195|Active Comparator|Arm B: bevacizumab, cyclophosphamide and capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily. All three medications are given until PD, unacceptable adverse event, or consent withdrawal. If an unacceptable adverse event to any of the drugs in this treatment arm occurs the remaining tolerated drug(s) is (are) given until PD, consent withdrawal, or unacceptable adverse event according to local investigators opinion
3224382|NCT01131234|Experimental|Treatment (cediranib maleate and RO4929097)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17 (days 1-3, 8-10, 15-17 22-24, 29-31, and 36-38 of course 1 only) and cediranib maleate PO QD on days 1-21 (days 22-42 course 1 only). Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity
3224383|NCT01131247|Experimental|ofatumumab + bendamustine|
3224384|NCT01131273|Active Comparator|Methadone maintenance for 12 weeks|Methadone maintenance for 12 weeks as compared to 12 weeks maintenance on Suboxone.
3224385|NCT01131273|Active Comparator|buprenorphine-naloxone (Suboxone)|12 weeks of maintenance on buprenorphine-naloxone (Suboxone) at daily doses ranging from 8 to 32 mg with counseling
3224386|NCT01131364|Experimental|F16IL2 in combination with doxorubicin|
3224387|NCT01131377|Experimental|Acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
3224388|NCT01131377|Placebo Comparator|Placebo|This group will be managed with general metabolic alkalosis treatment such as electrolyte correction, hydration except acetazolamide.
3224389|NCT01131403||BW= using baby wipes and CW= using cotton wool|
3224390|NCT01131403||wet wipe, cotton wool|Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.
3224391|NCT01131416|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3224392|NCT01131416|No Intervention|Conventional|Conventional postoperative feeding schedule
3224393|NCT01131429|Experimental|first-line erlotinib|erlotinib in first-line treatment and docetaxel/cisplatin in second-line treatment
3224394|NCT01131429|Active Comparator|second-line erlotinib|docetaxel/cisplatin in first-line treatment and erlotinib in second-line treatment
3224395|NCT01131442||The patient group|
3224396|NCT01131442||healthy control group|
3224397|NCT01131468|Experimental|N-acetylcysteine|N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
3224398|NCT01131468|No Intervention|Controls|Vancomycine and/or amikacin alone
3224399|NCT01131481|Other|AcrySof MA50BM,AVS Model X-60|AcrySof MA50BM, AVS Model X-60
3224400|NCT01131533|Experimental|Erythropoietin|patients with chronic macular edema associated with diabetic retinopathy
3224401|NCT01131546|Experimental|Levamlodipine besylate (2.5mg)|
3224402|NCT01131546|Experimental|Levamlodipine besylate (5mg)|
3224403|NCT01131546|Active Comparator|Amlodipine maleate (5mg)|
3224404|NCT01131559|Active Comparator|Lisdexamfetamine|Drug
3224405|NCT01131559|Placebo Comparator|Placebo|Drug
3224406|NCT01131572|Other|N-acetylcysteine|open label treatment. Each subject receives N-acetylcysteine.
3224407|NCT01131611|Experimental|CBPT intervention|Standard PT treatment + CBPT
3224408|NCT01131611|Placebo Comparator|Control-Attention|Standard PT treatment + weekly phone calls
3224409|NCT01131624|Active Comparator|Ferric carboxymaltose|"Subjects with bw ≥66 kg will receive an infusion of 1,000 mg iron as FCM and after 1 week a further 500 mg iron as FCM, depending on Hb at screening.~subjects with bw <66 kg, 2-3 infusions of 500 mg iron as FCM will be administered within 2 weeks from baseline, depending on Hb at screening"
3224410|NCT01131624|Active Comparator|Oral Iron|Oral Iron oral iron preparation will be provided at 200 mg iron per day in a convenient dosage schedule.
3224411|NCT01131637|Experimental|rhNRG-1|recombinant human neuregulin-1
3224412|NCT01131637|Placebo Comparator|placebo|placebo
3224413|NCT01131650||diabetic retinopathy|
3224414|NCT01131650||diabetica retinopathy prevalence|
3224415|NCT01131702|Experimental|Ranitidine Tablets, 300 mg|Ranitidine Tablets, 300 mg of Dr. Reddy's Laboratories Limited
3224416|NCT01131702|Active Comparator|Zantac Tablets, 300 mg|
3224417|NCT01131715||Study group|Patients who are included in the pharmacist follow-up procedure
3224418|NCT01131728|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
3224419|NCT01131728|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
3224420|NCT01131741|Experimental|Epinephrine|
3224421|NCT01131741|Placebo Comparator|Control|
3224422|NCT01131754|Experimental|Heparin sol 100U/L|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
3224423|NCT01131754|Active Comparator|saline|peripheral venous catheter flushing with 3 mL of normal saline from mono-use vials (prepared by the hospital pharmacy) at the end of each drug infusion. Independently of the number of drug infusions, all patients will receive at least two catheter flushes every day.
3224424|NCT01131767|Experimental|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg ER Tablets of Dr. Reddy's Laboratories.
3224425|NCT01131767|Active Comparator|Aleve Cold and Sinus|Aleve Cold and Sinus(Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets).
3224426|NCT01131780|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
3224427|NCT01131780|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
3224428|NCT01131793|Experimental|RF Guidewire|
3224429|NCT01131806|Active Comparator|MD Flu/Sal|fluticasone125 mcg/ salmeterol 25 mcg 2puffs (medium dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
3224430|NCT01131806|Experimental|HD Flu/Sal|fluticasone 250 mcg/salmeterol 25 mcg 2puffs (high dose group) inhaled twice daily; salbutamol evohaler allowed from 100 to 400 mcg for inhalation as needed basis.
3224431|NCT01131819|Other|1|The novel intervention we propose to use, the Wii Fit, will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects in the study.
3224432|NCT01131832|Experimental|Plant sterol|Plant sterol supplementation, 2 grams per day of plant sterols in a margarine
3224433|NCT01131845|Experimental|Treprostinil diethanolamine|
3224434|NCT01131858|Placebo Comparator|Placebo|Placebo
3224435|NCT01131858|Active Comparator|Vitamin D|Vigantol (cholecalciferol) 4000 IE/day
3224436|NCT01131871|Active Comparator|Standard Behavioral Weight Loss Intervention|
3224437|NCT01131871|Experimental|Enhanced Weight Loss Intervention|
3224438|NCT01131897|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
3224439|NCT01131897|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
3224440|NCT01131910|Experimental|Vaccination against TBE|"Less than 60 years old: Two doses of TBE- vaccine separated by a month and a third dose 12 months after the first dose~60 years and above: Three doses, given at 0+1+3 months and a 4 th dose 12 months after the first dose"
3224441|NCT01131923|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
3224442|NCT01131923|Active Comparator|Norvasc Tablets, 10 mg|
3224443|NCT01131936|Experimental|Amlodipine Tablets, 10 mg|Amlodipine Tablets, 10 mg of Dr. Reddy's Laboratories Limited
3224444|NCT01131936|Active Comparator|Norvasc Tablets, 10 mg|
3224445|NCT01131949|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
3224446|NCT01131949|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
3224447|NCT01131962|Active Comparator|band ligation group|this group will have immediate control of the hematemesis by endoscopic band ligation.
3224448|NCT01131962|Active Comparator|sclerotherapy group|This group will have immediate control of hematemesis by endoscopic sclerotherapy
3224449|NCT01131975|Experimental|Lamotrigine (chewable, dispersible)|Lamotrigine Tablets (chewable, dispersible),25 mg of Dr. Reddy's Laboratories Limited
3224450|NCT01131975|Active Comparator|Lamictal|Lamictal Tablets 25 mg of Glaxo SmithKline
3224451|NCT01131988|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
3224452|NCT01131988|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
3224453|NCT01132027|Experimental|Tacrolimus|Tacrolimus Capsules, 5 mg of Dr.Reddy's Laboratories Limited
3224454|NCT01132027|Active Comparator|Prograf Capsules|Prograf Capsules of Astellas Pharma US, Inc.,
3224455|NCT01132040|Experimental|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories
3224456|NCT01132040|Active Comparator|Mysoline|Mysoline Tablets of Yamanouchi Pharma Technologies Inc,
3224457|NCT01132053||PML|These are subjects who have confirmed PML.
3224458|NCT01132053||Control|These are subjects who do not have PML. They may be healthy or immune compromised due to Cancer, Transplant, or HIV.
3224459|NCT01132066|Experimental|tDCS|tDCS will provide an increase in cortical excitability. Patients will be randomized to receive tDCS or sham stimulation.
3224460|NCT01132066|Placebo Comparator|sham|Sham stimulation will provide identical subjective sensation as anodal tDCS.
3224461|NCT01132079|Experimental|Pimecrolimus cream treatment|
3224462|NCT01132079|Active Comparator|Betamethasone valerate cream treatment|
3224463|NCT01132092||Normal hearing (experimental 1)|76 Normal hearing subjects, male and female, adults, , evaluated by new device
3224464|NCT01132092||Normal hearing (experimental 2)|15 Normal hearing subjects, male and female, adults, , evaluated by new device
3224465|NCT01132092||Hearing loss (experimental 3)|15 hearing loss subjects, male and female, adults, evaluated by new device
3224466|NCT01132092||Gold standard 1|15 Normal hearing subjects, male and female, adults, evaluated by gold standard device
3224467|NCT01132092||Gold Standard 2|15 hearing loss subjects, male and female, adults, evaluated by gold standard device
3224468|NCT01132105||Normal subjects|Adults normal hearing and vestibular function subjects
3224469|NCT01132131|Active Comparator|Delegation form|
3224470|NCT01132131|Active Comparator|Regular doctor's consultation|
3224471|NCT01132157|Experimental|Propofol group|
3224472|NCT01132157|Active Comparator|Desflurane group|
3224473|NCT01132170|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
3224474|NCT01132170|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
3224475|NCT01132183|Experimental|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
3224476|NCT01132183|Active Comparator|Depakote Sprinkle|Depakote Sprinkle 125 mg capsules of Abbott Laboratories, USA
3224477|NCT01132196|Experimental|Divalproex Sodium DR Tablets 500 mg|Divalproex Sodium DR Tablets 500 mg of Dr. Reddy's Laboratories Limited
3224478|NCT01132196|Active Comparator|Depakote DR 500 mg Tablets|Depakote DR 500 mg Tablets of Abbott Laboratories PR Ltd.,
3224479|NCT01132209|Active Comparator|Large tissue bites|As control the conventional large bites technique (mass closure) will be applied in with bites widths of 1 cm and inter-suture spacing of 1 cm with the use of PDS plus ll 1-0 double loop suture material with a 48 mm needle.
3224480|NCT01132209|Experimental|small tissue bites|In the other group of 288 patients the small bites technique will be applied with bite widths of 0,5 cm and inter suture spacing of 0,5 cm with the use of PDS plus ll 2-0 single suture material with a 31 mm needle placed in the linea alba. In the small bites technique, twice as many stitches will be placed per sutured cm, with a smaller needle and thinner suture material.
3224481|NCT01132222|Experimental|Ibuprofen + Psuedoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine HCL 30 mg Tablets
3224482|NCT01132222|Active Comparator|Advil® Cold and Sinus|Advil® Cold and Sinus Tablets of Wyeth Consumer Healthcare
3224483|NCT01132248|Experimental|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
3224484|NCT01132248|Placebo Comparator|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
3224485|NCT01132261|Active Comparator|1|brain preservation diet
3224486|NCT01132261|No Intervention|2|
3224487|NCT01132274|Active Comparator|Conventional catheter ablation|Radiofrequency catheter ablation through fluoroscopic guidance
3224488|NCT01132274|Experimental|Non-fluoroscopic catheter ablation|Radiofrequency catheter ablation guided by the EnSite NavX (St.Jude Medical, St Paul, MN, USA) mapping-system
3224489|NCT01132287|Experimental|1 FID 112903|FID 112903
3224490|NCT01132287|No Intervention|No Intervention|
3224491|NCT01132300|Experimental|Treatment|
3224492|NCT01132339||Enhanced MR (case group)|those with an exposure to gadolinium-based contrast agent
3224493|NCT01132339||Unenhanced MR (control group)|those without an exposure to gadolinium-based contrast agent
3224494|NCT01132339||Unenhanced CT (control group)|those without an exposure to iodine-containing contrast agent
3224495|NCT01132339||Enhanced CT (case group)|those with an exposure to iodine-containing contrast agent
3224496|NCT01132352|Experimental|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
3224497|NCT01132352|Active Comparator|Keppra®|Keppra® 750 mg Tablets of UCB Pharma Inc.,
3224498|NCT01132365||knee arthroplasty|
3224499|NCT01132391|Experimental|1|Endoanal application
3224500|NCT01132391|Experimental|2|Perianal application
3224501|NCT01132404|Experimental|TAK-448 Dose 1|
3224502|NCT01132404|Experimental|TAK-448 Dose 2|
3224503|NCT01132404|Active Comparator|Leuprorelin|
3224504|NCT01132417||Multidrug resistant (MDR)bacterial strains|
3224505|NCT01132430|Placebo Comparator|Usual care|Standard medical care within 4-6 week period
3224506|NCT01132430|Experimental|Motivational interviewing|Brief MI sessions within 4-6 week period
3224507|NCT01132443|Experimental|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF)
3224508|NCT01132443|Active Comparator|Duac/ formulation 1|Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved
3224509|NCT01132443|Active Comparator|Duac/ formulation 2|Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF
3224510|NCT01132456|Experimental|Different patient subset|Patients with dual vessel treatment where each vessel has a lesion with length ≤ 27 mm and reference vessel diameters between 2.25 mm and 4.0 mm.
3224511|NCT01132456|Experimental|38 mm Cohort|Patients with at least one lesion amenable to treatment with a 38 mm length Endeavor Resolute stent. Patients may have one or two lesions, if the two lesions are located in separate target vessels.
3224512|NCT01132469|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
3224513|NCT01132521|Experimental|ulinastatin group|Regular treatments plus ulinastatin. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
3224514|NCT01132521|Placebo Comparator|placebo group|Regular treatment plus placebo. Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
3224515|NCT01132534||SE then AFI/NBI|Patients will be randomised to be examined by standard videoendoscopy (SE) then combined AFI/NBI during the esophagogastroduodenoscopy (EGD) examination at same setting.
3224516|NCT01132534||AFI/NBI then SE|Patients will be randomised to be examined by combined AFI/NBI then standard videoendoscopy (SE) during the EGD examination at same setting.
3224517|NCT01132573|Experimental|Treatment (entinostat and clofarabine)|"Patients receive entinostat PO on days 1 and 8 and clofarabine IV over 2 hours on days 3-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity (only for patients >= 60 years of age with newly diagnosed ALL or ABL who are unable or unwilling to tolerate standard multi-agent chemotherapy and patients with relapsed or refractory ALL or ABL).~Patients 40-59 years of age with newly diagnosed ALL receive standard multi-agent induction chemotherapy beginning on day 11. Patients >= 21 years of age in their first relapse with sensitive disease begin initiation of allogeneic transplant after one course of entinostat and clofarabine."
3224518|NCT01132586|Experimental|Treatment (lenalidomide, cytarabine, idarubicin)|"INDUCTION:~COHORT I: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 96 hours on days 5-8, and idarubicin IV over 1 hour on days 5-7.~COHORT II: Patients receive lenalidomide PO QD on days 1-21, cytarabine IV continuously over 24 hours on days 5-11, and idarubicin as above.~Patients with residual disease on day 18 undergo a second course of induction therapy.~CONSOLIDATION:~COHORT I: Patients receive lenalidomide PO QD on days 1-14, idarubicin IV over 1 hour on days 5-6, cytarabine IV continuously on days 5-7. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.~COHORT II: Patients 2 receive 4 courses of consolidation therapy comprising lenalidomide PO QD on days 1-14 and cytarabine IV every 12 hours on days 5, 7, and 9. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3224519|NCT01132625|Experimental|AUY922|
3224520|NCT01132638|Active Comparator|Magnesium Pantoprazole|
3224521|NCT01132638|Active Comparator|Magnesium Esomeprazole|
3224522|NCT01132677|Active Comparator|Hyaluronic Acid (HA) Injection|Patients allocated to the HA group will receive a single IA injection Hylan G-F 20 Synvisc One™ (1 injection of 6cc's). All injections will be administered as outlined on the company label. Aspiration of the knee will not be performed.
3224523|NCT01132677|Active Comparator|Corticosteroid Injection|Patients allocated to the corticosteroid injection will receive a single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label. Aspiration of the knee will not be performed.
3224524|NCT01132703|Placebo Comparator|Matching Placebo|Matching placebo (glyburide excipients without active) is administered as a bolus followed by continuous infusion for 72 hours.
3224525|NCT01132703|Experimental|Glyburide for Injection: Dose 1|Glyburide is administered as a bolus followed by a infusion for 72 hours
3224526|NCT01132703|Experimental|Glyburide for Injection: Dose 2|Glyburide is administered as a bolus followed by a infusion for 72 hours
3224527|NCT01132703|Experimental|Glyburide for Injection: Dose 3|Glyburide is administered as a bolus followed by a infusion for 72 hours.
3224528|NCT01132742||hospitalised children|
3224529|NCT01132768|Active Comparator|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily.
3224530|NCT01132768|Experimental|Olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily.
3224531|NCT01132781|Placebo Comparator|Placebo|200mg twice daily of placebo drug
3224532|NCT01132781|Active Comparator|200mg theophylline|200mg twice daily of slow release theophylline
3224533|NCT01132794|Placebo Comparator|Placebo|Intranasal nasal saline
3224534|NCT01132794|Active Comparator|Dexmedetomidine|Intranasal dexmedetomidine
3224547|NCT01132950|Active Comparator|Didactic Educational Counseling|
3224548|NCT01132950|Experimental|Motivation Interviewing|Participant will receive two sessions of personalized motivational interviewing.
3224549|NCT01132963|Experimental|Outdoor Shoes|Patient will be asked to do balance tests while wearing outdoor shoes.
3224550|NCT01132963|Active Comparator|Pillow Paws Slippers|Patient will be asked to complete balance tests while wearing standard hospital issue 'Pillow Paw' slippers on their feet
3224551|NCT01132976|Active Comparator|Goal-based motivational interview|Participants randomised to this group will receive the goal based motivational interview - Personal Concerns Inventory (PCI) in addition to treatment as usual.
3224552|NCT01132976|Other|Treatment as usual|Participants randomly allocated to this group will receive treatment as usual only, ie no specific motivational intervention.
3224553|NCT01133002||VTE management registry|Patients receiving enoxaparin, with or without oral anticoagulation, within Day 0-10 after diagnosis of VTE
3224554|NCT01133015|Experimental|Intermediate lesion|Intermediate lesion will be evaluated by both IVUS and FFR
3224555|NCT01133028|Experimental|Combined|This represents a combination of the tolerance training and behavioral management interventions together.
3224556|NCT01133028|Active Comparator|Behavioral management|This represents the behavioral contingency management intervention only.
3224557|NCT01133041|Experimental|NBI observation|
3224558|NCT01133041|Experimental|i-Scan observation|
3224559|NCT01133054|Experimental|low FFR|FFR<0.75
3224560|NCT01133054|No Intervention|high FFR|FFR > 0.75
3224561|NCT01133080|Experimental|Minocycline|
3224562|NCT01133080|Placebo Comparator|Placebo|
3224563|NCT01133106|Experimental|In-person behavioral intervention|behavioral counseling plus antidepressant treatment prescribed by participant's own provider; consisted of orientation session plus 6 counseling sessions in person with a psychosocial nurse practitioner
3224564|NCT01133106|Experimental|Telephone behavioral intervention|This arm is identical to the in-person Arm except that the intervention is delivered by telephone instead of in-person.
3224565|NCT01133106|Active Comparator|Standard care|participants have orientation to the study with the same written materials given those in the experimental arms. Keep a medication log and keep appointments with their own post-stroke provider
3224566|NCT01133119|Active Comparator|Treatment Group 1|
3224567|NCT01133119|Experimental|Treatment Group 2|
3224568|NCT01133132|Placebo Comparator|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
3224569|NCT01133132|Experimental|Intervention|For those subjects randomized to the Survivorship CHESS condition they will receive a smartphone and access to a web based information system that provides access to clinical information about colon cancer treatment, survivorship, exercise planning and tracking functions to allow these subjects to monitor their self defined exercise goals and objectives.
3224570|NCT01133145|Experimental|vascularized transplantation|allogeneic vascularized knee transplantation
3224571|NCT01133197||controls|No hand arthritis
3224572|NCT01133197||CMC Arthritis|Patients with arthritis
3224573|NCT01133210|Experimental|Maraviroc|Subjects will receive 12 weeks of treatment with maraviroc (300 mg po bid).
3224574|NCT01133210|Placebo Comparator|Placebo|Subjects will receive 12 weeks of treatment with placebo
3224575|NCT01133223|Active Comparator|Thrombectomy|
3224576|NCT01133223|Active Comparator|Usual Care|
3224577|NCT01133236|Experimental|Salt and Fluid|Intervention: Fluid 800 Ml and Salt 2 g per day Control: FLuid and Salt Free
3224578|NCT01133249||Total hip|all consented patients receiving total hip arthroplasty
3224579|NCT01133301|Active Comparator|Naltrexone-Placebo|In the first three weeks of the study, 50 mg Naltrexone will be administrated, the following three three weeks placebo will be administrated.
3224580|NCT01133301|Placebo Comparator|Placebo-Naltrexone|The first three weeks, placebo will be administrated, the following three weeks 50 mg Naltrexone will be administrated.
3224581|NCT01133327|Experimental|Adapt Carotid Stent System|Intervention with Adapt Carotid Stent System with the FilterWire EZ System
3224582|NCT01133353|Experimental|Tetrabenazine MR|
3224583|NCT01133353|Placebo Comparator|Placebo|
3224584|NCT01133366|Active Comparator|warfarin alone|
3224585|NCT01133366|Experimental|warfarin with mipomersen|
3224586|NCT01133431|Experimental|CKD-501 + Glimepiride -> CKD-501 placebo + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
3224587|NCT01133431|Experimental|CKD-501 placebo + Glimepiride -> CKD-501 + Glimepiride|This study is randomized, single-blinded, two-period, 2 treatments, crossover design to assess the pharmacokinetics interaction between CKD-501 and sulfonylurea.
3224588|NCT01133444|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
3224589|NCT01133444|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
3224590|NCT01133457|Experimental|Finasteride|Finasteride tablets 1 mg of Dr. Reddy's
3224591|NCT01133457|Active Comparator|Propecia|Propecia 1 mgTablets of Merck & Co.,
3224592|NCT01133470|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
3224593|NCT01133470|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
3224594|NCT01133483|Experimental|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories
3224595|NCT01133483|Active Comparator|Allegra-D 24 hour ER Tablets|Allegra-D 24 hour ER Tablets of Aventis Pharmaceuticals INC., USA.
3224596|NCT01133496|Experimental|Alendronate Sodium|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's
3224597|NCT01133496|Active Comparator|Fosamax|Fosamax Tablets 70 mg of Merck & Company. Inc., USA.
3224598|NCT01133509|Other|gardisil|gardisil
3224599|NCT01133535||Pancreatitis, acute, recurrent|Patients with acute recurrent pancreatitis where the cause is unknown
3224600|NCT01133548|Experimental|1|Testosterone Gel 1.62%
3224601|NCT01133561|Active Comparator|actozone A|Pioglitazone 30 mg tablets daily
3224602|NCT01133561|Placebo Comparator|actozone B|placebo
3224603|NCT01133574|Experimental|A1|Part A, Parallel design Arm 1
3224604|NCT01133574|Experimental|A2|Part A, Parallel design Arm 2
3224605|NCT01133574|Experimental|A3|Part A, Parallel design Arm 3
3224606|NCT01133574|Experimental|A4|Part A, Parallel design Arm 4
3224607|NCT01133574|Experimental|A5|Part A, Parallel design Arm 5
3224608|NCT01133574|Experimental|A6|Part A, Parallel design Arm 6
3224609|NCT01133574|Experimental|A7|Part A, Parallel design Arm 7
3224610|NCT01133574|Experimental|A8|Part A, Parallel design Arm 8
3224611|NCT01133574|Placebo Comparator|A9|Part A, Parallel design Arm 9
3224612|NCT01133574|Experimental|B1-1|Part B, Cross-over design, Arm 1
3224613|NCT01133574|Experimental|B1-2|Part B, Cross-over design, Arm 2
3224614|NCT01133574|Experimental|B2-1|Part B, Cross-over design, Arm 3
3224615|NCT01133574|Experimental|B2-2|Part B, Cross-over design, Arm 4
3224616|NCT01133574|Placebo Comparator|B3|Part B, Cross-over design, Arm 5
3224617|NCT01133587|Experimental|admissions contract|"contract regarding patient-guided admissions"
3224618|NCT01133587|Active Comparator|wait list control|1 year on waiting list
3224619|NCT01133600|Active Comparator|daptomycin|Dosed at 6mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if creatinine clearance (CrCl)is <30ml/min.
3224620|NCT01133600|Active Comparator|vancomycin|Dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
3224621|NCT01133613|Experimental|Cohort 1|0.03 mg/ml BMP-7 or placebo via intraarticular knee injection
3224622|NCT01133613|Experimental|Cohort 2|0.1 mg/ml BMP-7 or placebo via intraarticular knee injection
3224623|NCT01133613|Experimental|Cohort 3|0.3 mg/ml BMP-7 or placebo via intraarticular knee injection
3224624|NCT01133652|Active Comparator|VeinViewer|The Veinviewer machine will be used to guide intravenous access.
3224625|NCT01133652|Active Comparator|Ultrasound|The Ultrasound will be used to guide intravenous access.
3224626|NCT01133652|Active Comparator|Conventional IV placement|IV will be placed using conventional technique
3224627|NCT01133691||healthy children aged 6 - 12 years|
3224628|NCT01133717||Control without Sleep Apnea|
3224629|NCT01133717||Subjects with Sleep Apnea|
3224630|NCT01133730|Experimental|Active treatment group|Ultrasound-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
3224631|NCT01133730|Placebo Comparator|Placebo arm|Ultrasound-guided TFP block with 20ml of 5% dextrose solution
3224632|NCT01133743|Experimental|Lenalidomide and Dexamethasone|Lenalidomide target dose of 25 mg PO OD continuously (28-day cycle) using an initial dose escalation period. Oral dexamethasone 12 mg daily on days 1-7, 14 and 21 of each cycle.
3224633|NCT01133769||Surgical vs Non surgical|This is an open, prospective, randomized, dual arm, parallel group clinical study of open reduction and internal fixation (ORIF) or intramedullary nail (IMN) versus non operative treatment for clavicle fracture in polytrauma patients with associated chest injury, with or without additional injuries to the head, abdomen, pelvis and extremities.
3224634|NCT01133782|Experimental|Rapid result|Result of diagnostic PCR panel provided the following day
3224635|NCT01133782|No Intervention|Delayed result|Result of dagnostic PCR panel provided within 10+/-2 days at follow-up visit.
3224636|NCT01133795|Experimental|Midodrine, Albumin|Midodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
3224637|NCT01133834||patients with meningococcemia|Patients with meningococcemia admitted at the Intensive Care Unit
3224638|NCT01133873|Experimental|1|
3224639|NCT01133873|Placebo Comparator|2|
3224640|NCT01133886|Experimental|Decitabine|
3224641|NCT01133899|Experimental|GAA-2|2.4 grams of guanidinoacetic acid
3224642|NCT01133899|Experimental|GAA-1|1.2 grams of guanidinoacetic acid
3224643|NCT01133899|Experimental|GAA-4|4.8 grams of guanidinoacetic acid
3224644|NCT01133899|Placebo Comparator|PLACEBO|cellulose
3224645|NCT01133912|Experimental|paclitaxel, gemcitabine, lapatinib|paclitaxel 80mg/m2 D1, D8 gemcitabine 1000mg/m2 D1, D8, every 3 weeks, 6 cycle lapatinib(Tykerb®)1000mg every day
3224646|NCT01133925|Active Comparator|ODESSA|ODESSA trial (NCT 00693030)Patients were randomized (2:2:2:1) to receive multiple TAXUS Libertè™ vs Cypher Select™ vs Endeavor™ vs Libertè BM stents, in overlap. At 6-months follow-up coronary angiography (QCA), IVUS and Optical Coherence Tomography assessments were made. Data reported in J. Am. Coll. Cardiol. Intv. 2010;3;531-539. DOI 10.1016/j.jcin.2010.02.008.
3224647|NCT01133925|Experimental|Resolute Sprint arm|Zotarolimus Eluting stents (Resolute Sprint) implanted in overlap to treat long coronary lesions
3224648|NCT01133938||Closed reduction < 12 months of age|
3224649|NCT01133938||Open reduction < 12 months of age|
3224650|NCT01133938||Open reduction with concomitant osteotomies > 12 months fo age|
3224651|NCT01133951|Experimental|OAC triple therapy|
3224652|NCT01133951|Placebo Comparator|Placebo|
3224653|NCT01133964|Experimental|milk|skim milk
3224654|NCT01133964|Experimental|casein drink|
3224655|NCT01133964|Experimental|whey drink|
3224656|NCT01133964|Sham Comparator|water|
3224657|NCT01133990|Active Comparator|FOLIRI|
3224658|NCT01133990|Experimental|E7820|FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820
3224659|NCT01133990|Experimental|FOLFIRI plus Bevacizumab|
3224660|NCT01134029|No Intervention|Enhanced Usual Care|Control Group
3224661|NCT01134029|Experimental|Stepped Care|Intervention
3224662|NCT01134094|Active Comparator|Non-Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
3224663|NCT01134094|Active Comparator|Operative|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
3224664|NCT01134120|Experimental|LY2784544|
3224665|NCT01134146|Experimental|Intensity Modulated Radiation Therapy (IMRT)|Intensity Modulated Radiation Therapy (IMRT) Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
3224666|NCT01134159||Xience V|Those who have only received a Xience V stent
3224667|NCT01134159||Taxus Liberte|Those who have received only a Taxus Liberte stent
3224668|NCT01134172||Breast cancer survivors|Women being treated for stage I-III breast cancer who were employed prior to this diagnosis will be recruited in their physicians' offices.
3224669|NCT01134172||Comparison group|Peer controls will be nominated by participants in the breast cancer survivor group or recruited by community outreach and matched for age, language, and ethnicity. This cohort is no longer recruiting.
3224670|NCT01134185|Active Comparator|Group I|Moderate hepatic impairment (grade B)
3224671|NCT01134185|Active Comparator|Group II|Severe hepatic impairment (grade C)
3224672|NCT01134185|Active Comparator|Group III|healthy subjects
3224673|NCT01134211|Other|nelfilcon A / filcon II 3|Nelfilcon A contact lenses worn first, with filcon II 3 contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
3224674|NCT01134211|Other|filcon II 3 / nelfilcon A|Filcon II 3 contact lenses worn first, with nelfilcon A contact lenses worn second. Both products worn in both eyes on a daily wear, daily disposable basis for one week each.
3224675|NCT01134224|Experimental|NN5401 - low dose|
3224676|NCT01134224|Experimental|NN5401 - medium dose|
3224677|NCT01134224|Experimental|NN5401 - high dose|
3224678|NCT01134224|Active Comparator|biphasic insulin aspart 30 - low dose|
3224679|NCT01134224|Active Comparator|biphasic insulin aspart 30 - medium dose|
3224680|NCT01134224|Active Comparator|biphasic insulin aspart 30 - high dose|
3224681|NCT01134237|Active Comparator|Urokinase|arm of interest
3224682|NCT01134237|Placebo Comparator|Control|Normal saline as a placebo for control arm
3224683|NCT01134250|Experimental|F16IL2 in combination with paclitaxel|
3224684|NCT01134289|Active Comparator|lumbar sympathetic block|Unilateral lumbar sympathetic blockade using chirocaine
3224685|NCT01134289|No Intervention|contralateral side|
3224686|NCT01134302|Active Comparator|Arm 1|Hybrid Management
3224687|NCT01134302|Active Comparator|Arm 2|Norwood Management
3224688|NCT01134341|Experimental|Bexarotene (Targretin) & Pralatrexate (Folotyn)|"Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration.~Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned."
3224689|NCT01134354||TEFTOM|Patient outcome measure
3224690|NCT01134367||1|Patients with GERD
3224691|NCT01134380||[*1] Genotype - Good responders to Clopidogrel|This group of patients is defined thanks to the DNA extracted from their saliva: [*1] genotype patients are good responders to clopidogrel
3224692|NCT01134380||[*2] genotype with adapted thienopyridine treatment|This group of patients is defined thanks to the DNA extracted from their saliva: [*2] genotype patients are bad responders to clopidogrel and their thienopyridine treatment has been adapted
3224693|NCT01134406|Experimental|Hydros Joint Therapy|Experimental viscosupplement.
3224694|NCT01134406|Experimental|Hydros-TA Joint Therapy|Experimental viscosupplement.
3224695|NCT01134406|Active Comparator|Synvisc-One|Commercial control.
3224696|NCT01134419|Experimental|Computerized Handoff Tool plus training|Computerized handoff tool implemented together with team training for residents
3224697|NCT01134419|Active Comparator|Team training only|No computerized tool
3224698|NCT01134432|Experimental|Prednisolone + Rituximab|
3224699|NCT01134432|Active Comparator|Prednisolone|
3224700|NCT01134445|Other|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
3224701|NCT01134458|No Intervention|Control|Receive primary care and management of CVD according to the discretion of their primary care provider. They will also receive generic educational information concerning CVD at baseline and at study end (at their request). We will collect outcomes at baseline and 3-months.
3224702|NCT01134458|Experimental|Web-based Intervention|Given current risk assessment for CVD based on Health Dialog Cardiac Risk Calculator, recommendations for behavior change, and Health Dialog's Living with Coronary Heart Disease. Can change initial patient risk information provided by the Risk Calculator during the initial visit, noting what they are will work on during the study. Sent monthly email reminders to log onto the system to choose that months' behavioral modules. Given a choice of at least 2 health behavior modules per month (smoking cessation, exercise, diet, and weight) to improve their CVD risk. Information on risk, CVD knowledge, medication management and side effects will be provided to all participants. It will also provide tailored information to help the individual initiate and maintain these behaviors.
3224703|NCT01134471|No Intervention|Control|
3224704|NCT01134471|Active Comparator|Bonewax|Patients treated with the hemostatic bonewax
3224705|NCT01134471|Active Comparator|Ostene|Patients treated with the hemostatic Ostene
3224706|NCT01134484|Experimental|VTD|
3224707|NCT01134484|Active Comparator|TD|
3224708|NCT01134497|Active Comparator|Arm A (control): carboplatin + placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle.
3224709|NCT01134497|Experimental|Arm B: carboplatin + ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
3224710|NCT01134523|Active Comparator|Group A: EC-T regimen|
3224711|NCT01134523|Experimental|Group B: ET regimen|
3224712|NCT01134536|Experimental|Tapentadol Oral Solution (OS)|
3224713|NCT01134588|Active Comparator|Reference group|This group will fill out paper questionnaires.
3224714|NCT01134588|Experimental|Experimental group|This group will fill out touch-screen questionnaires.
3224715|NCT01134653|Experimental|Jump stretch|Distraction with early mobilization
3224716|NCT01134653|Active Comparator|RICE|Subject receive standard ankle sprain treatment of Rest Ice compression and elevation for one week. This is followed by traditional strength and range of motion therapy. The subject does not receive distraction treatments.
3224717|NCT01134679|Experimental|Phone calls|Disease management with close patient follow-up, using phone calls.
3224718|NCT01134692|Placebo Comparator|Propranolol + Placebo|
3224719|NCT01134692|Active Comparator|Propranolol + Norfloxacin|drug
3224720|NCT01134692|Experimental|Propranolol + Probiotic|VSL#3
3224721|NCT01134718|Experimental|001|TMC435 (F021) one morning dose of 150 mg
3224722|NCT01134718|Experimental|002|TMC435 (G006) one morning dose of 150 mg
3224723|NCT01134718|Experimental|003|TMC435 (G007) one morning dose of 150 mg
3224724|NCT01134744||Chest trauma|chest x-ray applied for patients with chest trauma and the manifestations compared with clinical examination
3224725|NCT01134757|Other|house dust mite and alternaria allergy|As the intervention patients with house dust mite or alternaria allergy will undergo a bronchial allergen challenge with mite or alternaria extract. The early asthmatic response (EAR) and the late asthmatic response (LAR) will be measured before and after one year of allergen specific immunotherapy. Except of the challenge no further interventions are planned.
3224726|NCT01134770||Prenatal Cocaine|Use of cocaine at anytime during pregnancy. Subjects may also have used other drugs in combination with Cocaine
3224727|NCT01134770||Prenatal Nicotine-Alcohol-Marijuana|Subjects may have used any of these drugs during pregnancy, alone or in combination. This group has not used cocaine during pregnancy.
3224728|NCT01134770||Drug-Free Pregnancy|"Subjects did not use any of the following drugs during pregnancy:~cocaine, nicotine, alcohol, marijuana."
3224729|NCT01134809||Major abdominal surgery|Patients having major abdominal surgery
3224730|NCT01134822||Idiopathic pulmonary fibrosis (IPF)|
3224731|NCT01134835|Experimental|IMP Pioglitazone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
3224732|NCT01134835|Placebo Comparator|Placebo|Placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
3224733|NCT01134848|Active Comparator|Morphine-neostigmine|
3224734|NCT01134848|Active Comparator|Secretin|
3224735|NCT01134861|Active Comparator|Arm 1: Sequential ChemoRT|Vinblastine 6 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 50
3224736|NCT01134861|Experimental|Arm 2: Concurrent STD RT|Vinblastine 5 mg/m2 i.v. bolus weekly first 5 weeks Cisplatin 100 mg/m2 i.v. over 30-60 minutes, days 1 & 29 RT: 63 GY/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1
3224737|NCT01134861|Experimental|Arm 3: Concurrent HFX RT|Oral VP-16 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40 (76 mg/day if BSA < 1.7m2) Cisplatin 50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36 RT: 69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1
3224738|NCT01134874|Experimental|Standard weight loss intervention|
3224739|NCT01134874|Experimental|Standard weight loss intervention plus technology|
3224740|NCT01134874|Experimental|Technology only|
3224741|NCT01134926|No Intervention|intra-uterine residua. expectant management|The patients in this arm will not get any treatment and be followed up by US examinations
3224742|NCT01134926|Experimental|Intra-uterine residua. misoprostol|The patients in this arm will be treated with misoprostol at the recruitment day. If there will be sonographic evidence of intra-uterine residua the day after, they'll gat another dose.
3224743|NCT01134965|Experimental|Digoxin plus Flibanserin|Flibanserin 100 mg tablets once daily for 7 days plus Digoxin 0.5 mg (2 tables of 0.25 mg) as single dose
3224744|NCT01134965|Experimental|Digoxin|Digoxin 0.5 mg as single dose
3224745|NCT01134978|Experimental|Practice Schedules|Subjects are randomly assigned to either a blocked or random practice schedule when learning three 3-D computer mazes. A blocked practice schedule is created when the tasks to be learned are presented in a predictable order, while a random practice schedule has tasks presented in a nonsequential, unpredictable order. Neural activity and behavioral measures will differ for the two practice schedules. For memory and transfer, it is predicted that random practice will be better than blocked practice.
3224746|NCT01134991|Placebo Comparator|Topical Minocycline Foam FXFM244 Placebo|Minocycline Foam FXFM244 Placebo
3224747|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 1%|Minocycline Foam FXFM244, 1%
3224748|NCT01134991|Experimental|Topical Minocycline Foam FXFM244, 4%|Minocycline Foam FXFM244, 4%
3224749|NCT01135004||Pneumothorax patients|Primary spontaneous pneumothorax patients undergoing thoracoscopic bullectomy
3224750|NCT01135030|Active Comparator|Posterior referencing|
3224751|NCT01135030|Active Comparator|Anterior referencing|
3224752|NCT01135043|Experimental|education|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
3224753|NCT01135043|Placebo Comparator|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure.
3224754|NCT01135056|Active Comparator|Sorafenib, Multikinase Inhibitor, Tablet|"Sorafenib tosylate:~Sorafenib is a multikinase inhibitor that decreases tumor cell proliferation.~Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR- ß). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of the human hepatocellular carcinoma and renal cell carcinoma, and several other human tumor xenografts in immunocompromised mice. A reduction in tumor angiogenesis and increases in tumor apoptosis was seen in models of human hepatocellular and renal cell carcinoma. Additionally a reduction in tumor cell signaling was seen in a model of human hepatocellular carcinoma."
3224755|NCT01135056|Active Comparator|SIR-Spheres, Microspheres, Device|"SIR-Spheres:~SIR-Spheres consist of biocompatible resin microspheres containing yttrium-90, with a size between 20 and 60 microns in diameter. Yttrium-90 is a high-energy pure beta-emitting isotope with no primary gamma emission. The half life of yttrium-90 is 64.1 hours. In clinical use which requires the isotope to decay to infinity, 94% of the radiation is delivered in 11 days leaving only background radiation with no therapeutic value.~SIR-Spheres is implanted into hepatic tumours by delivery via either the common hepatic artery or the right or left hepatic artery using a catheter or implanted port . Once SIR-Spheres is implanted into the liver, it is not metabolised or excreted and it stays permanently in the liver."
3224756|NCT01135082|Other|1|Receive valent pneumococcal conjugated vaccine in HIV - infected children
3224757|NCT01135082|Other|2|Receive valent pneumococcal conjugated vaccine in HIV negative children
3224758|NCT01135108|Placebo Comparator|A1: Placebo|Placebo
3224759|NCT01135108|Experimental|A2: KAI-1678|Experimental
3224760|NCT01135121||Weaning failure|
3224761|NCT01135121||Weaning succes|
3224762|NCT01135147|Experimental|Diet|Patients treated with diet and physical therapy for the entire 6 months of the study
3224763|NCT01135147|Active Comparator|Surgery|Patients undergoing adenotonsillectomy at some point of the study period
3224764|NCT01135160||TKA/THA|All patients receiving TKA/THA meeting inclusion but not exclusion criteria
3224765|NCT01135173|Active Comparator|Arm A|Motivational and educational intervention, delivered by a trained physician from the SCTS plus written self-help materials.
3224766|NCT01135173|Experimental|Arm B|"Behavioral counseling intervention conducted by a trained physician at the SCTS cessation clinic. Subjects complete homework before the session to facilitate this process. Subjects are asked to identify high-risk situations and difficulties in previous cessation attempts and are walked through a series of suggestions in the event of a slip. Three brief (approximately 10 minute) phone calls are provided to subjects during the 90 day follow-up period. These calls are used to identify early relapse, encourage participants, and provide support. In addition, they are used to review materials and information provided during the sessions."
3224767|NCT01135212|Active Comparator|Fimasartan 60mg|Take one tablet of Fimasartan 60mg once a day in the morning
3224768|NCT01135212|Active Comparator|Fimasartan 120mg|Take one tablet of Fimasartan 120mg once a day in the morning
3224769|NCT01135212|Active Comparator|Candesartan 8mg|Take one tablet of Candesartan 8mg once a day in the morning
3224770|NCT01135225|Active Comparator|PROMUS(TM) Element(TM) Coronary Stent|PROMUS(TM) Element(TM) Everolimus-Eluting Coronary Stent System
3224771|NCT01135225|Experimental|Evolution Coronary Stent A|Evolution Everolimus-Eluting Monorail Coronary Stent System
3224772|NCT01135225|Experimental|Evolution Coronary Stent B|Evolution Everolimus-Eluting Monorail Coronary Stent System
3224773|NCT01135251|Experimental|dimiracetam|Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
3224774|NCT01135251|Placebo Comparator|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
3224775|NCT01135264|Active Comparator|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
3224776|NCT01135264|Experimental|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
3224777|NCT01135277||Sepsis|Patients who have been diagnosed with Sepsis within 24 hours of admission
3224778|NCT01135277||Non-Septic|Patients who have not been diagnosed with sepsis within 24 hours of admission
3224779|NCT01135290|Other|B|
3224780|NCT01135290|Active Comparator|A|
3224781|NCT01135303|Experimental|VistaO2 device|This device combines the transcutaneous oxyhemoglobin saturation (allowing to compute the oxyhemoglobin desaturation index), the slow variations in heart rate and an index of nocturnal respiratory events calculated by analyzing the movements of the chest performed by chest impedance variations.
3224782|NCT01135342|Experimental|Diet & Exercise plus Sleep Intervention|Diet and exercise instruction to promote weight loss plus cognitive behavioral therapy for insomnia.
3224783|NCT01135342|Sham Comparator|Diet & Exercise plus Passion and Balance|Diet and exercise instruction to promote weight loss plus sessions that are of general interest, but unrelated to diet, exercise, or sleep.
3224784|NCT01135407||group #1|Parkinson's disease patients at a disease's stage characterized by motor complications
3224785|NCT01135407||group #2|Parkinson's disease patients treated by subthalamic nucleus deep brain stimulation.
3224786|NCT01135407||group #3|healthy controls
3224787|NCT01135433|Experimental|ASP group|ASP1941 and metformin
3224788|NCT01135433|Placebo Comparator|Placebo group|placebo and metformin
3224789|NCT01135446|Experimental|dapagliflozin (0.001 mg)|Cohort 1
3224790|NCT01135446|Experimental|dapagliflozin (0.01 mg)|Cohort 2
3224791|NCT01135446|Experimental|dapagliflozin (0.1 mg)|Cohort 3
3224792|NCT01135446|Experimental|dapagliflozin (0.3 mg)|Cohort 4
3224793|NCT01135446|Experimental|dapagliflozin (1 mg)|Cohort 5
3224794|NCT01135446|Experimental|dapagliflozin (2.5 mg)|Cohort 6
3224795|NCT01135459|Experimental|CEP-33457|200 mcg of CEP-33457
3224796|NCT01135459|Placebo Comparator|Placebo|
3224797|NCT01135472|Experimental|Nexium|ARM 1: NEXIUM 40MG ONCE DAILY, ARM 2: NEXIUM 40MG TWICE DAILY, ARM 3: NEXIUM 80MG TWICE DAILY
3224798|NCT01135485||Study group I|Study group I will include children who have undergone stage I palliation employing allograft material for left ventricular outflow tract reconstruction at CHOP during infancy (<1 year of age). Stage I palliation is defined as an operation in which augmentation of the native ascending aorta and aortic arch is performed to bypass atresia or critical obstruction of the left heart structures.
3224799|NCT01135485||Study Group II|Study group II who have undergone stage II palliation in which allograft material is used, but have not undergone antecedent stage I palliation. Stage II palliation is defined as a superior cavopulmonary anastomosis in which the superior vena cava is anastomosed to the ipsilateral pulmonary artery via either the bidirectional Glenn or hemi-Fontan procedures.
3224800|NCT01135485||Control Group|The control group who have undergone palliative or corrective surgery for congenital heart disease during infancy (<1 year of age) not requiring allograft material.
3224801|NCT01135550|Active Comparator|Standard Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
3224802|NCT01135550|Active Comparator|Control Arm|"Subjects scheduled to undergo radiation therapy are enrolled before the therapy is started. Once radiation therapy begins they will complete a daily diary about any headaches or nausea/vomiting they experience.~If they experience increased headache or vomiting they will be randomized to receive either a high or a low dose of dexamethasone, to control these symptoms."
3224803|NCT01135563|Experimental|Vinblastine and Sirolimus|The standard 3+3 Phase 1 trial design will be used for the conduct of this study. Three to six patients can be concurrently enrolled onto a dose level. Accrual is suspended when a cohort of three has been enrolled until toxicity data for that cohort have been reported, or when the study endpoints have been met.
3224804|NCT01135576|Placebo Comparator|Placebo juices|Consumption of non-iron fortified fruit juices as part of the usual diet
3224805|NCT01135576|Experimental|Iron fortified fruit juices|Consumption of iron fortified fruit juices as part of the usual diet
3224806|NCT01135589|Experimental|HSCT|
3224807|NCT01135602|Experimental|Topiramate|1 group
3224808|NCT01135615|Other|Sevelamer|
3224809|NCT01135615|Other|calcium acetate|
3224810|NCT01135628|Active Comparator|MHE and diet plus lactobacillus reuteri|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and lactobacillus reuteri.
3224811|NCT01135628|Active Comparator|MHE and diet|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods.
3224812|NCT01135628|Active Comparator|MHE and diet plus nitazoxanide|Patients with minimal hepatic encephalopathy managed with diet consisting in hyperproteic and fiber-rich foods and nitazoxanide.
3224813|NCT01135641|Experimental|Rituximab, ciclosporine and corticosteroids|As soon as the diagnosis of chronic GVHD requiring systemic immunosuppressive therapy is confirmed, patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.Rituximab should be administered within 14 days of starting prednisone. Follow-up dates for response assessment and laboratory tests relate to the date of Rituximab infusion.Patients having a partial response after the 1st cycle of Rituximab will be eligible to receive a second cycle of 4 infusions during 4 weeks. A delay of 8 weeks (from the first infusion of Rituximab) will be observed between the two cycles of Rituximab therapy.Patients who relapse after an initial treatment with one cycle of 4 infusions of Rituximab will be eligible to receive a second cycle of Rituximab therapy.
3224814|NCT01135654|Experimental|Non-Physician Provider|
3224815|NCT01135654|No Intervention|Control|
3224816|NCT01135654|Active Comparator|Primary Care Provider|In clinics randomized to this arm, we will train (and provide technical assistance to) Primary Care providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment.
3224817|NCT01135667|Active Comparator|clopidogrel|clopidogrel 150 mg once daily for 30 days (and then 75 mg for additional 11 months - not study related)
3224818|NCT01135667|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 30 days (and then clopidogrel 75 mg once daily for additional 11 months - not study related)
3224819|NCT01135680|Placebo Comparator|Arm 1|"Cohort A: 9 mL HPN-100 or placebo~Cohort B: 12 mL HPN-100 placebo"
3224820|NCT01135680|Placebo Comparator|Arm 2|"This study requires 4 periods. In each of the periods you will receive one of the dose groups listed below. At the completion of the study you will have participated in all 4 dose groups. The order in which you participate in each dose group will be randomly assigned.~Dose Group A: 9 mL placebo via oral syringe 3 times daily for 3 days~Dose Group B: single oral dose of 400 mg moxifloxacin on study Day 3~Dose Group C: 6 mL HPN-100 and 3 mL placebo via oral syringe 3 times daily for 3 days~Dose Group D: 9 mL HPN-100 via oral syringe 3 times daily for 3 days"
3224821|NCT01135706||Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram with a diagnosis of Pulmonary Hypertension
3224822|NCT01135706||Non Pulmonary Hypertension|Patients having a right heart catheterization and CT pulmonary angiogram without a diagnosis of Pulmonary Hypertension.
3224823|NCT01135732||study group-previous sphincterotomy|
3224824|NCT01135732||control group-not previous sphincterotomy|
3224825|NCT01135745|Experimental|Deep Brain Stimulation Therapy for OCD|Reclaim® DBS Therapy uses thin wires to deliver electric current (stimulation) to a very specific target in the brain. These wires are implanted surgically. They are attached to internal neurostimulators implanted under the skin of the chest below the collarbone, similar to cardiac pacemakers, or in the abdominal wall. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
3224826|NCT01135758|Experimental|ketamine 0.5 mg/kg i.v.|Single administration of ketamine 0.5 mg/kg i.v.
3224827|NCT01135784|Active Comparator|MIGRA-ZEN RELIEF PLUS|Active treatment
3224828|NCT01135784|Placebo Comparator|Placebo for Migra zen plus|Placebo
3224829|NCT01135797||Patients from phase I-II studies|
3224830|NCT01135836|Experimental|pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
3224831|NCT01135836|Experimental|intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity
3224832|NCT01135836|Placebo Comparator|Control group|CO2 was removed by passive exsufflation through the port site.
3224833|NCT01135862|Experimental|platelet administered|patients will receive 6 packs of platelets
3224834|NCT01135862|No Intervention|no platelets administered|patients will not receive platelets
3224835|NCT01135875||GBM Patients|GBM Patients with a histologically confirmed or suspected diagnosis of glioblastoma multiforme.
3224836|NCT01135875||Normal Controls|Normal Controls will be adult volunteers who identify themselves as not having been diagnosed with a glioblastoma multiforme.
3224837|NCT01135888||HED children|
3224838|NCT01135888||HED adolescents|
3224839|NCT01135888||Control children|
3224840|NCT01135888||Control adolescents|
3224841|NCT01135901|Experimental|group programme|Group based behaviour change programme
3224842|NCT01135927|Experimental|A|
3224843|NCT01135927|Active Comparator|B|
3224844|NCT01135940|Experimental|1|2-octylcyanoacrylate (Dermabond) closure
3224845|NCT01135940|Active Comparator|2|Standard staple closure
3224846|NCT01135953|Experimental|ARM 1 - CONTROL|Subject given tDCS every day of the week (5 sessions) at 2 mA.
3224847|NCT01135953|Experimental|Arm 2 - INCREASING|Subjects given increasing intensity during tDCS across the week (Monday 1mA, Tuesday 1.5mA, Wednesday 1.5 mA, Thursday 2 mA, Friday 2mA).
3224848|NCT01135953|Experimental|ARM 3 - CYCLOSERINE|D-cycloserine (100 mg) given on the Monday and Thursday sessions, administering tDCS at 2 mA.
3224849|NCT01135966|Active Comparator|Conventional training|
3224850|NCT01135966|Experimental|Whole body vibration training|
3224851|NCT01135979||Arterio-venous fistulae creation|
3224852|NCT01136005|Experimental|dexpanthenol 5% cream|dexpanthenol 5% cream
3224853|NCT01136005|Active Comparator|cetomacrogol cream|a vehicle
3224854|NCT01136018||intentional lateral caudal approach|
3224855|NCT01136031|Experimental|Paclitaxel and irinotecan|
3224856|NCT01136057||Influenza A Exposure|Participants will include people who have recovered from influenza, received a seasonal influenza vaccine, or have both recovered from influenza and received a seasonal influenza vaccine.
3224857|NCT01136070||Burn Trauma Patients|
3224858|NCT01136083|Experimental|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
3224859|NCT01136083|Active Comparator|Control group|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
3224860|NCT01136096|Experimental|Lifestyle counseling|To promote participants' exercise behaviors with individualized home-based exercise program was designed based on the Health Belief Model and Transtheoretical Model
3224861|NCT01136096|Other|Control|Received oral instruction and written general education information without individualized exercise program
3224862|NCT01136109||Bedside ultrasound only|Bedside ultrasound to determine the dimensions of the inferior vena cava
3224863|NCT01136109||Ultrasound with ventilator changes|Bedside ultrasound to determine the dimensions of the inferior vena cava pre and post ventilator changes.
3224864|NCT01136122|Active Comparator|CPAP Arm|Receive effective CPAP treatment for one month
3224865|NCT01136122|No Intervention|Control Arm|Receive no treatment for one month
3224866|NCT01136135||CARDIAC MRI|
3224867|NCT01136148|Experimental|A Medical and Mental Health Unit|A specialist unit for cognitively impaired older patients admitted as a medical emergency to the acute hospital.
3224868|NCT01136148|Active Comparator|Standard care wards|The standard care provided by the acute hospital for cognitively impaired older patients admitted as a medical emergency.
3224869|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV -|n=12
3224870|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV -|n=12
3224871|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV -|n=12
3224872|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV -|n=12
3224873|NCT01136161|Experimental|RUTI 5 micrograms of FCMtb in HIV +|n=12
3224874|NCT01136161|Experimental|RUTI 25 micrograms of FCMtb in HIV +|n=12
3224875|NCT01136161|Experimental|RUTI 50 micrograms of FCMtb in HIV +|n=12
3224876|NCT01136161|Placebo Comparator|RUTI Matching Placebo in HIV +|n=12
3224877|NCT01136187|Experimental|Radial approach|Primary percutaneous coronary intervention from the radial approach
3224878|NCT01136187|Active Comparator|Femoral approach|Primary percutaneous coronary intervention from the femoral approach
3224879|NCT01136200|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
3224880|NCT01136200|No Intervention|Control|Patients not receiving infectious disease specialist advice
3224881|NCT01136213||Multiple system atrophy|
3224882|NCT01136213||Idiopathic Parkinson Disease|
3224883|NCT01136213||Volunteers without neuropsychiatric disorder (Control)|
3224884|NCT01136239|Placebo Comparator|Placebo|Placebo (600mg twice daily)
3224885|NCT01136239|Active Comparator|N-acetylcysteine|N-acetylcysteine (600mg twice daily)
3224886|NCT01136252|Experimental|Adalimumab|
3224887|NCT01136278|Experimental|clonidine, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3224888|NCT01136304||Adults with Type 1 Gaucher disease (GD1)|Adults with GD1 who are cared for at one of the participating research sites whether treatment naive or treated in past or currently with imiglucerase enzyme replacement treatment.
3224889|NCT01136317|Experimental|Omeprazole|
3224890|NCT01136317|Experimental|Rabeprazole|
3224891|NCT01136317|Placebo Comparator|Placebo|
3224892|NCT01136343|Experimental|lifestyle modified project|education, counseling
3224893|NCT01136343|No Intervention|control|waiting list control
3224894|NCT01136369||OSNA Breast Cancer System|
3224895|NCT01136395|Active Comparator|LD kidney transplantation, ABOi|Living donor (LD) kidney transplantation, ABO incompatible (ABOi); Immunosuppressive treatment: Tacrolimus (Tacr)/ Mycophenolate sodium (MPS), Basiliximab induction, Rtx induction
3224896|NCT01136395|Active Comparator|LD kidney transplantation, ABOc|Living donor (LD) kidney transplantation, ABO compatible (ABOc); Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
3224897|NCT01136395|Active Comparator|DD kidney transplantation|Deceased donor (DD) kidney transplantation, ABO compatible; Immunosuppressive treatment: Tacr/MPS, Basiliximab induction
3224898|NCT01136421|Active Comparator|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
3224899|NCT01136421|Experimental|Magnesium sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
3224900|NCT01136447|Placebo Comparator|Neurostimulation|Block catheter will be introduced using neurostimulation
3224901|NCT01136447|Active Comparator|Ultrasound|Block catheter will be introduced using ultrasound
3224902|NCT01136460||Primary congenital glaucoma|Primary congenital glaucoma patients and their immediate relatives
3224903|NCT01136473||congenital cataract or aphakic glaucoma|children with congenital cataract or aphakic glaucoma
3224904|NCT01136499|Experimental|LBH PANOBINOSTAT|40 mg 3 days per week
3224905|NCT01136512||metformin use|Patients with type 2 diabetes treated with metformin
3224906|NCT01136512||no metformin use|Patients with type 2 diabetes who are not being treated with metformin
3224907|NCT01136525|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
3224908|NCT01136525|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
3224909|NCT01136538|Experimental|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
3224910|NCT01136538|Active Comparator|Valtrex (R)|Valtrex (R) (Valacyclovir Hydrochloride) CAPLETS 1 gram of GlaxoSmithkline
3224911|NCT01136551|Active Comparator|IR formulation|Healthy volunteers will receive imediate release formulation of Huperzine A (0.4mg)
3224912|NCT01136551|Experimental|CR 1|"CR formulation~Healthy volunteers will receive controlled release formulation 1 of Huperzine A (0.4mg)"
3224913|NCT01136551|Experimental|CR 2|"CR formulation~Same volunteers will receive controlled release formulation 2 of Huperzine A (0.4mg)"
3224914|NCT01136564|Active Comparator|Paricalcitol|
3224915|NCT01136564|Placebo Comparator|Placebo|
3224916|NCT01136577|Experimental|LEDDYBLOO®|LEDDYBLOO® phototherapy device equipped with 20 at 30 blue and white LEDs
3224917|NCT01136577|Experimental|Double BILITRON®|Double BILITRON® phototherapy corresponding to two small ramps associated together each one equipped of 5 blue LEDS
3224918|NCT01136577|Experimental|Futura®|Future phototherapy device equipped with 8 fluorescent tubes
3224919|NCT01136590|Experimental|tranexamic acid|tranexamic acid will be administered as a bolus (10-mg/kg dose ) or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery
3224920|NCT01136590|Placebo Comparator|placebo|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
3224921|NCT01136603|Experimental|TIGR Mesh|Experimental - TIGR Mesh
3224922|NCT01136603|Active Comparator|Control|Control group - Non absorbable Polypropylene mesh
3224923|NCT01136616||Nasal Fracture|"67 patients admitted for facial fractures and who undergo routine CT scans of the face are to be studied. CT scans are evaluated to assess the position, comminution and displacement of the 5 said buttresses.~The buttresses are graded Grade 1 Simple fracture without displacement Grade 2 Simple fracture with displacement Grade 3 Comminuted fracture without displacement Grade 4 Comminuted fracture with minimal displacement Grade 5 Comminuted fractured with displacement~The septum is graded from Grade 0 Septum is straight Grade 1 Septum is deviated by less than 1 half the distance from the midline to the nasal turbinate Grade 2 Septum is deviated by more than 1 half the distance from the midline to the nasal turbinate Grade 3 Septum is almost touching the nasal turbinate"
3224924|NCT01136629||Subjects with hyper-pigmented spots|Subjects age 21 to 80 year old, who have elected to undergo a plastic surgery will be enrolled. Subjects will be from Chinese, Malay, Indian or Caucasian ancestry. Subjects will be female or male with a hyper-pigmented spots.
3224925|NCT01136694||RA patients who are new bDMARD users|
3224926|NCT01136694||RA patients who are existing DMARD users|
3224927|NCT01136707||Patients with rheumatoid arthritis new to Orencia|
3224928|NCT01136720||patients injected with the Halifax produced 18-FDG|
3224929|NCT01136759|Placebo Comparator|Pregnancy cohort, placebo|Pregnant women will receive placebo gel.
3224930|NCT01136759|Experimental|Lactation cohort, tenofovir gel|Lactating mothers will receive tenofovir gel.
3224931|NCT01136759|Experimental|Pregnancy cohort, tenofovir gel|Pregnant women will receive tenofovir gel.
3224932|NCT01136824||Sarcoma Subjects|Soft tissue sarcoma patients treated with the adjuvant and neoadjuvant chemotherapy protocol of doxorubicin plus ifosfamide (AI)
3224933|NCT01136837||fragmented QRS positive|fQRS at 48 hours after Primary PCI
3224934|NCT01136850|Active Comparator|SP, chloroquine treatment; bed net|Treatment course of sulphadoxine pyrimethamine and chloroquine on enrolment. Long lasting insecticide treated bed net
3224935|NCT01136850|Experimental|3 x SP plus azithromycin; bed nets|Three x monthly courses of azithromycin and sulphadoxine pyrimethamine plus long lasting insecticide treated bed net.
3224936|NCT01136863|Active Comparator|felodipine group, active, pill|felodipine and HCTZ treatment group
3224937|NCT01136863|Placebo Comparator|placebo, no treatment, pill|placebo and HCTZ group
3224938|NCT01136889|Active Comparator|PFMT plus routine pessary management|"Women allocated to the intervention group will be invited to attend 5 out-patient appointments over a 16 week period with a trained specialist women's health physiotherapist at the study centre. Women will be taught how to contract the muscles, and also how to contract and hold prior to an event that increases intra-abdominal pressure (the Knack). Tailored advice will be given on ways of reducing intra-abdominal pressure, e.g. advice on weight loss, chronic cough, heavy lifting and general exercise. A prolapse specific Lifestyle Advice sheet will also be given to the women by the physiotherapist."
3224939|NCT01136889|Active Comparator|Lifestyle|Women allocated to the control group will be sent a Lifestyle Advice Leaflet only. They will have no planned intervention after their pessary is fitted, other than routine pessary management according to local protocols. The Lifestyle Advice Leaflet gives instructions on seeking advice, where appropriate, about weight loss, constipation, and avoidance of heavy lifting, coughing and high impact exercise, with a view to minimising increases in intra-abdominal pressure which may cause the prolapse to worsen.
3224940|NCT01136902||Type 2 DM|This group includes subjects diagnosed with type 2 diabetes mellitus with none or minimal diabetic retinopathy.
3224941|NCT01136928|Experimental|American ginseng and efavirenz|This is a sequential study. Healthy volunteers will receive efavirenz alone for 14 days followed by efavirenz plus American ginseng for an additional 14 days.
3224942|NCT01136941|Experimental|Treatment|Research participants will be administered Zileuton according to the dose escalation/de-escalation schema provided in the protocol.
3224943|NCT01136967|Experimental|Cohort 1 (V600E BRAF negative)|Cohort 1 (V600E BRAF negative) enrolled participants not harboring the V600E BRAF mutation with disease progression following up to 2 prior systemic anticancer regimens (excluding anti-VEGF) for unresectable Stage III or Stage IV melanoma.
3224944|NCT01136967|Experimental|Cohort 2 (V600E BRAF positive)|Cohort 2 (V600E BRAF positive) enrolled participants harboring the activating BRAF mutations (mainly the V600E mutation) with disease progression following BRAF V600E-targeted therapy.
3224945|NCT01136980|Placebo Comparator|Sham placebo procedure|Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
3224946|NCT01136980|Active Comparator|TIF Transoral Fundoplication|Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.
3224947|NCT01136993||All bi-directional telestroke consultations|
3224948|NCT01137019|Active Comparator|Biolimus-eluting stent|
3224949|NCT01137019|Active Comparator|Everolimus-eluting stent|
3224950|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen|35 healthy volunteers
3224951|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen|35 healthy volunteers
3224952|NCT01137045|Active Comparator|SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
3224953|NCT01137045|Active Comparator|VERORAB with modified TRC-ID regimen plus ERIG|35 WHO category III patients
3224954|NCT01137045|Active Comparator|SPEEDA with ESSEN IM regimen plus ERIG|35 healthy volunteers
3224955|NCT01137045|Active Comparator|TRCS SPEEDA with modified TRC-ID regimen plus ERIG|35 healthy volunteers
3224956|NCT01137058|Experimental|U-healthcare|glucose meter and U-healthcare
3224957|NCT01137058|Active Comparator|SMBG group|Diabetic patients who do self monitoring of blood glucose only were categorized into self monitoring of blood glucose (SMBG) group.
3224958|NCT01137058|No Intervention|control|conventional treatment
3224959|NCT01137084|Active Comparator|a steroid immunosuppression protocol|
3224960|NCT01137084|Active Comparator|a steroid-free immunosuppression protocol|without steroid
3224961|NCT01137097|Active Comparator|Lateral sentinel group|Lateral sentinel lymph node biopsy with radioisotope
3224962|NCT01137097|No Intervention|No intervention for lateral neck|No lateral sentinel lymph node biopsy with radioisotope
3224963|NCT01137123|Active Comparator|standard two field +follow-up|
3224964|NCT01137123|Experimental|standard two field +adjuvant chemotherapy|
3224965|NCT01137123|Experimental|total two field+follow-up|
3224966|NCT01137123|Experimental|total two field+adjuvant chemotherapy|
3224967|NCT01137123|Experimental|three field+follow-up|
3224968|NCT01137123|Experimental|three field+adjuvant chemotherapy|
3224969|NCT01137136||SMAC (SMc AI user Cohort)|All patients who took the AI (Aromatase inhibitor)will be enrolled
3224970|NCT01137149|Active Comparator|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
3224971|NCT01137149|Experimental|Behavioral Acitivation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
3224972|NCT01137188|Experimental|Intervention group|Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks
3224973|NCT01137188|No Intervention|No intervention|Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion
3224974|NCT01137201|Experimental|Mesenteric defects sutured|Closure of the mesenteric defects using running, non-absorbable suture
3224975|NCT01137201|No Intervention|Mesenteric defects not sutured|Non-closure of the mesenteric defects
3224976|NCT01137214|Active Comparator|CPAP|Continuous Positive Airway Pressure
3224977|NCT01137214|Active Comparator|Adaptive Servo-Ventilator|Non-invasive positive pressure ventilator that applies a constant expiratory pressure, as well as a variable inspiratory pressure.
3224978|NCT01137227||Description|"2137 studies retrieved in 8 databases (Biomed Central, CINAHL, EMBASE, ERIC, PsycInfo, PUBMED, SCOPUS, SPORTDiscus and uploaded in EndNote Web®.~332 studies were excluded as duplicates by EndNote Web®.~1805 titles and abstracts were assessed independently by two researchers (PG/AM): 1541 studies excluded.~264 studies referred for full-text assessment by two independent investigators (PG/AM)~225 studies were excluded according to the eligibility criteria (in case of discrepancies in the assessment of the researchers, studies were reviewed in duplicate)~39 Studies assessed for quality using STROBE~13 Studies were included in the descriptive synthesis"
3224979|NCT01137240||Children with mitochondrial disorders|suffering from gastrointestinal dysfunction
3224980|NCT01137253|Experimental|Trimethaphan|Response to intrabrachial vasodilators during autonomic withdrawal
3224981|NCT01137253|Placebo Comparator|Placebo|Response to intrabrachial vasodilators during saline intravenous (IV) infusion
3224982|NCT01137266|Active Comparator|skin resistence|1) the location with the lowest resistance
3224983|NCT01137266|Active Comparator|irradiation|2) the site that causes an irradiation sensation
3224984|NCT01137266|Active Comparator|random|3) a random stimulation site.
3224985|NCT01137318|Experimental|Cognitive remediation and Behavioral Intervention|
3224986|NCT01137318|Placebo Comparator|Low Level Cognitive Remediation and Behavioral Parent Traning|
3224987|NCT01137331|Experimental|K301|K301 applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
3224988|NCT01137331|Placebo Comparator|Placebo|Placebo applied topically to the affected area of the scalp once daily during the 4 weeks. Treatment is to be applied before bedtime and can be washed out with the patient's normal shampoo in the morning.
3224989|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum WCFS1)|
3224990|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum NIZO3400)|
3224991|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L. plantarum NIZO2877)|
3224992|NCT01137357|Experimental|Yoghurt with Lactobacillus strain (L.plantarum CBS125632)|
3224993|NCT01137357|Active Comparator|Yoghurt with Lactobacillus casei Shirota|
3224994|NCT01137357|Placebo Comparator|Placebo Yoghurt|
3224995|NCT01137383|Experimental|Treatment group|
3224996|NCT01137409||Suspected or Diagnosed with Coronary artery disease|All patients with suspected or previously diagnosed coronary artery disease
3224997|NCT01137448|Experimental|Weight Loss|Subjects will be enrolled in a weight loss program and will receive weight loss and nutritional counseling.
3224998|NCT01137461|Other|abdominal ultrasound|traditional technique
3224999|NCT01137461|Other|transvaginal ultrasound|new technique
3225000|NCT01137487|Other|residual gastric volume|
3225001|NCT01137487|Other|residual gastric volume not monitored|
3225002|NCT01137513||Chest Pain|Acute Myocardial ischemia
3225003|NCT01137526|Experimental|ABT-384 Dose 1|
3225004|NCT01137526|Experimental|ABT-384 Dose 2|
3225005|NCT01137526|Active Comparator|donepezil|
3225006|NCT01137526|Placebo Comparator|placebo|
3225007|NCT01137552|Experimental|A|Dose Escalation
3225008|NCT01137552|Experimental|B|Dose Expansion
3225009|NCT01137565|Experimental|AMG 853|
3225010|NCT01137565|Placebo Comparator|Placebo|
3225011|NCT01137591|Experimental|APAP and NAC combination|N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill
3225012|NCT01137591|Placebo Comparator|APAP and Placebo combination|N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill
3225013|NCT01137630|Experimental|K40a|K40a is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3225014|NCT01137630|Experimental|K40b|K40b is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3225015|NCT01137630|Placebo Comparator|Placebo|Placebo is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week. Approximately one tablespoon of the respective formulation is to be applied before bed and to be washed out with the patient's normal shampoo in the morning.
3225016|NCT01137656|Other|Acetylcholine and Blood|This is single arm study. Acetylcholine and blood is infused in brachial artery of non-dominant arm. Blood flow
3225017|NCT01137669|Placebo Comparator|Placebo|10 subjects to receive placebo subcutaneously.
3225018|NCT01137669|Experimental|ZOSTAVAX®|30 subjects to receive 0.65 mL ZOSTAVAX® subcutaneously.
3225019|NCT01137695|Active Comparator|Symlin Naive, Usual Dose|Symlin 120 mcg three times daily in patients not previously treated with pramlintide before the study.
3225020|NCT01137695|Experimental|Symlin Naive, Dose Escalation|Escalation of pramlintide dose to 360 mcg three times daily in patients not taking pramlintide prior to study.
3225021|NCT01137695|Active Comparator|Symlin treated, Usual Dose|pramlintide 120 mcg three times daily in patients who have been treated with pramlintide 120 mcg prior to the trial.
3225022|NCT01137695|Experimental|Symlin Treated, Dose Escalation|pramlintide 360 mcg three times daily in patients previously treated with 120 mcg prior to the study.
3225023|NCT01137708|Experimental|Treatment Sequence 1|
3225024|NCT01137708|Experimental|Treatment Sequence 2|
3225025|NCT01137721||Pre-Hydroxyurea - subjects with SCD|Patients with a diagnosis of HbSS (sickle cell anemia) or HbS/ß0-thalassemia (beta thalassemia) who will be treated with hydroxyurea therapy.
3225026|NCT01137721||Sibling control|Sibling control with no diagnosis of HbSS or HbS/ß0-thalassemia.
3225027|NCT01137721||Observational - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia.
3225028|NCT01137721||Pre-transfusion - subjects with SCD|Patients with a diagnosis of HbSS or HbS/ß0-thalassemia who will be treated with transfusion therapy.
3225029|NCT01137734|Experimental|Valtech Cardinal Mitral Annuloplasty Ring|All subjects enrolled in the study are implanted with the Valtech Cardinal Mitral Annuloplasty ring.
3225030|NCT01137747|Experimental|Dose Level 0 (starting dose)|"Carfilzomib - 20 mg/m2 days 1 and 2, 27 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 36 mg/m2 for all subsequent doses. If DLT occurs while receiving 36 mg/m2, the dose may be reduced to 27 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3225031|NCT01137747|Experimental|Dose Level +1|"Carfilzomib - 20 mg/m2 days 1 and 2, 36 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 45 mg/m2 for all subsequent doses. If DLT occurs while receiving 45 mg/m2, the dose may be reduced to 36 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3225032|NCT01137747|Experimental|Dose Level +2|"Carfilzomib - 20 mg/m2 days 1 and 2, 45 mg/m2 for days 8 and 9 of cycle 1 only and, if days 8 and 9 are tolerated, may be increased to 56 mg/m2 for all subsequent doses. If DLT occurs while receiving 56 mg/m2, the dose may be reduced to 45 mg/m2.~Dosing schedule is days 1, 2, 8, 9, 15, 16, 22, and 23 with no rest period during the 28 day cycle. Dose will be given IV over 30 minutes.~2 cycles of treatment will be given. If the patient enters at leat a partial remission, then treatment may be extended up to 4 additional cycles."
3225033|NCT01137760|Placebo Comparator|Sugar pill|
3225034|NCT01137760|Experimental|Galactooligosaccharide 2.5 g|
3225035|NCT01137760|Experimental|Galactooligosaccharide 5.0 g|
3225036|NCT01137799|Experimental|001|JNJ-39393406 10mg nanosuspension (sort of liquid formulation) once daily (single dose)
3225037|NCT01137799|Experimental|002|JNJ-39393406 30mg nanosuspension (sort of liquid formulation) once daily (single dose)
3225038|NCT01137799|Experimental|003|JNJ-39393406 50mg nanosuspension (sort of liquid formulation) once daily (single dose)
3225039|NCT01137799|Experimental|004|JNJ-39393406 100mg nanosuspension (sort of liquid formulation) once daily (single dose)
3225040|NCT01137799|Experimental|005|JNJ-39393406 200mg nanosuspension (sort of liquid formulation) once daily (single dose)
3225041|NCT01137799|Placebo Comparator|006|placebo Once daily (single dose)
3225042|NCT01137838||Patients with RA and new to abatacept|
3225043|NCT01137838||Patients with RA and new to infliximab|
3225044|NCT01137838||Patients with RA and new to etanercept|
3225045|NCT01137838||Patients with RA and new to adalimumab|
3225046|NCT01137851||New to bDMARD|New to bDMARD RA patients with high and low cost share who continue or discontinue treatment
3225047|NCT01137864|Experimental|Infectious disease specialist advice|Patients receiving the intervention (infectious disease specialist advice)
3225048|NCT01137864|No Intervention|Control|Patients not receiving infectious disease specialist advice
3225049|NCT01137877|Active Comparator|Infant Formula #1|Milk-based Infant Formula Powder
3225050|NCT01137877|Experimental|Investigational Infant Formula #1|Investigational Milk-based Infant Formula Powder
3225051|NCT01137877|Experimental|Investigational Infant Formula #2|Investigational Milk based infant formula powder
3225052|NCT01137877|Active Comparator|Human Milk|Reference group
3225053|NCT01137903|Other|Patients undergoing medical treatment|"Antibiotic treatment within 90 days with:~Ciprofloxacin Amoxicillin /Clavulanic acid. Trimethoprim /Sulfamethoxazole."
3225054|NCT01137903|Other|Patients undergoing surgical treatment|Conservative surgical Minor amputation 7 days antibiotic after surgical
3225055|NCT01137916|Experimental|drug|Imatinib 800 mg
3225056|NCT01137929||With APN, With VUR, With Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and a renal scar on follow-up DMSA renal scan.
3225057|NCT01137929||With APN, With VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will also have VUR by VCUG and NO renal scar on follow-up DMSA renal scan.
3225058|NCT01137929||With APN, without VUR, with Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan but who will NOT have VUR by VCUG; however they will have a renal scar on follow-up DMSA renal scan.
3225059|NCT01137929||With APN, Without VUR, Without Renal Scar|This group of children who present with a febrile UTI will be found to have APN on DMSA renal scan and will NOT have VUR by VCUG, NOR will they have a renal scar on follow-up DMSA renal scan.
3225060|NCT01137929||Without APN, With VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also have VUR by VCUG. They will not undergo a second DMSA scan since the first one is normal.
3225061|NCT01137929||Without APN, Without VUR|This group of children who present with a febrile UTI will be found NOT to have APN on DMSA renal scan and will also NOT have VUR by VCUG, NOR a renal scar on follow-up DMSA renal scan.
3225062|NCT01137942||H. pylori eradication failure|Those who eradicated Helicobacter pylori with appropriate antibiotic therapy and those who did not.
3225063|NCT01137955|Experimental|Rifaximin|Antibiotic
3225064|NCT01137955|Placebo Comparator|Placebo|
3225065|NCT01137968|Experimental|imetelstat plus standard of care|imetelstat plus standard of care (bevacizumab or observation)
3225066|NCT01137968|Other|Standard of care|Bevacizumab or observation
3225067|NCT01137981||Pregnant, HIV Positive Women|Any pregnant, HIV positive woman exposed to antiretroviral drugs during pregnancy.
3225068|NCT01137994|Experimental|Lapatinib plus Chemotherapy|Lapatinib (1250mg once daily) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
3225069|NCT01137994|Experimental|Trastuzumab plus Chemotherapy|Trastuzumab (either 6mg/kg q3-weekly or 2mg/kg weekly) in combination with chemotherapy (docetaxel, paclitaxel or vinorelbine) selected at the discretion of the investigator
3225072|NCT01138033|Experimental|Part 1|Part 1 - dose escalation; starting dose 80 mg BID
3225073|NCT01138033|Experimental|Part 2|Part 2 - Dose expansion phase of the study at the maximum tolerated dose and schedule identified in Part 1 in patients with tumors known to over express FAK
3225074|NCT01138033|Experimental|Part 3|Part 3 - Characterize the biologically active dose range by analysis of PD markers in skin, hair and in tumor tissue in subjects with solid tumors amendable to biopsy and know to over express FAK
3225075|NCT01138033|Experimental|Part 4|Part 4 - Explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM).
3225076|NCT01138033|Experimental|Part 5|Part 5 will investigate the time course, the extent of an apparent change in the PK of GSK2256098 following repeated dosing, and screen for potential CYP3A induction as a possible mechanism of reduced systemic exposure of GSK2256098 at Day 15 and later time points.
3225077|NCT01138059||Acute ischemic stroke patients with unclear onset|
3225078|NCT01138072|Experimental|Treatment A|Simvastatin 20mg (single dose) Day 1
3225079|NCT01138072|Experimental|Treatment B|Atorvastain 20 mg (single dose) Day 3
3225080|NCT01138072|Experimental|Treatment C|Rosuvastatin 10mg (single dose) Day 7
3225081|NCT01138072|Experimental|Treatment X|GSK2248761 200mg single dose Day 10-14, Day 16-17, Day 19-21, Day 23-24
3225082|NCT01138072|Experimental|Treatment D|GSK2248761 200mg + simvastatin 20 mg Day 15
3225083|NCT01138072|Experimental|Treatment E|GSK2248761 200mg + atorvastatin 20 mg Day 18
3225084|NCT01138072|Experimental|Treatment F|GSK2248761 200mg + rosuvastatin 20 mg Day 22
3225085|NCT01138085|Experimental|Dose Escalation|Dose escalation will proceed until unacceptable toxicity is observed. Dose escalation decisions will take into account all available data, including PK data and the safety profile of prior cohorts and will occur following review of these data by the investigator(s), GSK medical monitor, pharmacokineticist, and statistician.
3259017|NCT01466686|Experimental|Temozolomide with Low Dose Fractionated Radiation Therapy|"All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.~All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide."
3225086|NCT01138085|Experimental|Expansion Cohorts|"Enrollment into expansion cohort(s) in Part 2A may begin once a recommended dosing regimen(s) is identified in Part 1A utilizing a once daily continuous dosing schedule for both GSK1120212 and GSK2141795. Enrolment to cohorts utilizing this daily dosing schedule may proceed in parallel with enrolment in Part 1B. Expansion cohort(s) will preferentially enroll subjects with treatment-refractory, measurable and biopsiable triple negative breast cancer or BRAF- wild type melanoma. Subjects selected for enrollment into Part 2A or Part 2B will be tested for PTEN deficiency and must agree to provide paired tumor biopsies (at baseline and once while on- treatment). An additional tumor biopsy at the time of disease progression should also be collected if feasible.~In Part 2A and Part 2B, up to 35 additional subjects per tumor type and schedule (i.e., a total of up to 70 subjects per schedule tested) may be enrolled in a two-stage design to better characterize safety, PK and PD."
3225087|NCT01138137|Experimental|All subjects|
3225088|NCT01138163|Experimental|Docetaxel plus bavituximab 1 mg/kg|
3225089|NCT01138163|Experimental|Docetaxel plus bavituximab 3 mg/kg|
3225090|NCT01138163|Placebo Comparator|Docetaxel plus placebo|
3225091|NCT01138176|No Intervention|Standard care|
3225092|NCT01138176|Experimental|Cooling|Reduction of rectal temperature to 33.5 C for 72 hours
3225093|NCT01138202|Experimental|1|boosted LPV/r 400/100 mg BID + 2 NRTI
3225094|NCT01138202|Experimental|2|boosted LPV/r 600/150 mg BID + 2 NRTI
3225095|NCT01138215|Experimental|1|Receive 1 course of VZV vaccine : 2 doses of vaccines with 3 months apart.
3225096|NCT01138228||Normal vision|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
3225097|NCT01138228||Vein Imaging Device|This within-subjects design is counter balanced for order. Each operator sees the subject's arm either initially with the normal eye or with the device, then repeats with the second condition (i.e., device or normal vision).
3225098|NCT01138241||1|ARV experience (TDF based HAART)
3225099|NCT01138241||2|ARV experience (non TDF based ART)
3225100|NCT01138241||3|ARV Naive
3225101|NCT01138254|No Intervention|control group|ESRD patients will not receive FIR therapy in this study.
3225102|NCT01138254|Experimental|Far infrared therapy|Patients will receive far infrared therapy 40 minutes three times weekly (TIW) for 6 months.
3225103|NCT01138280|Experimental|Heat disinfection|Experimental arm: Heat disinfection link to RO water treatment system and piping system to dialysis machine
3225104|NCT01138280|No Intervention|Conventional RO water treatment|Placebo arm: conventional chemical disinfection link to RO water treatment system.
3225105|NCT01138293|Experimental|motion sensor integrated in a mobile phone|A motion sensor integrated in a mobile phone. The system analyses kind, intensity and duration of physical activity and eating habits.
3225106|NCT01138345||Treatment w/Surgery|Breast Cancer survivors treated with surgery with or without radiation.
3225107|NCT01138345||Treatment w/endocrine therapy|Breast Cancer survivors treated with surgery with or without radiation plus endocrine therapy.
3225108|NCT01138345||Treatment w/ chemotherapy|Breast Cancer survivors treated with surgery with or without radiation and chemotherapy with or without endocrine therapy.
3225109|NCT01138371||Familial hypercholesterolemia|"Heterozygous FH with documented CAD and LDL-C ≥ 200 mg/dL (Documented CAD may be represented as: Lesion(s) on coronary angiography, history of myocardial infarction, CABG, PTCA, progressive angina demonstrated by stress testing, history of other revascularization procedure)~Homozygous FH and LDL-C > 500 mg/dL~Heterozygous FH and LDL-C ≥ 300 mg/dL~On stable LDL apheresis therapy for at least 6 months"
3225110|NCT01138384|Experimental|Foretinib and Lapatinib|Patients will receive foretinib as a continuous oral dose, and lapatinib as a continuous oral dose. Lapatinib will commence on Day1, Cycle 1 and foretinib will commence on Day 3, Cycle 1.
3225111|NCT01138397|Experimental|Group 1|Participants at 18 to 59 years of age
3225112|NCT01138397|Experimental|Group 2|Participants at 60 years of age or older
3225113|NCT01138410|Experimental|SCIB1|
3225114|NCT01138423|Experimental|Aliskiren|
3225115|NCT01138423|Experimental|Moxonidine|
3225116|NCT01138423|Experimental|Hydrochlorothiazide|
3225117|NCT01138423|Placebo Comparator|Placebo|
3225118|NCT01138436|Experimental|MEBO Wound Ointment (MEBO)|Topical application once a day
3225119|NCT01138436|Active Comparator|Standard of Care|Application of Profore multilayer compression bandage system
3225120|NCT01138449|Experimental|Vitamin A|Vitamin A capsules have retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil
3225121|NCT01138449|Placebo Comparator|Placebo|Placebo capsules contain minute amounts of vitamin E in soybean oil
3225122|NCT01138462|No Intervention|Standard Precautions|control arm, standards precautions for all residents living in the nursing home of control arm, including MRSA carriers
3225123|NCT01138462|Other|Intervention|Intervention arm, standards precautions for all residents living in nursing homes of intervention arm, and topical decolonization for MRSA carriers, including environmental disinfection
3225124|NCT01138488|Experimental|NN5401|
3225125|NCT01138527||Biopsy-proven prostate cancer|Patients with biopsy-proven prostate cancer, planned for radical prostatectomy
3225126|NCT01138540|Active Comparator|Semirecumbent position|Semirecumbent position of patients on mechanical ventilation in the bed of the ICU
3225127|NCT01138540|Experimental|lateral-Trendelenburg position|lateral-Trendelenburg position of patients on mechanical ventilation in the bed of the ICU
3225128|NCT01138553|Experimental|Mifepristone|
3225129|NCT01138566||ESBL- and/or AmpC-(+) or (-)|
3225130|NCT01138579|Experimental|1|
3225131|NCT01138592||Primary Care Patients|Any patient undergoing a telemedicine evaluation involving auscultation of the heart and lungs.
3225132|NCT01138605|Experimental|005|Darunavir 400 mg tablet intake of 2 tablets once daily in combination with ritonavir
3225133|NCT01138605|Experimental|006|Ritonavir Liquid formulation 80 mg/ml taken in combination with Darunavir
3225134|NCT01138605|Experimental|007|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3225135|NCT01138605|Experimental|008|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3225136|NCT01138605|Experimental|001|Darunavir Oral suspension 100 mg/ml 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
3225137|NCT01138605|Experimental|002|Darunavir 375 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 20 and 30 kg
3225138|NCT01138605|Experimental|003|Darunavir 450 mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight between 30 and 40 kg
3225139|NCT01138605|Experimental|004|Darunavir 600mg composed via oral solution or various tablets twice daily in combination with ritonavir for body weight as of 40 kg
3225140|NCT01138605|Experimental|009|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
3225141|NCT01138618||CHEMPAQ-venous-CHEMPAQ-venous|The two arms only differ in order of kind of blood samples.
3225142|NCT01138618||Venous-CHEMPAQ-Venous-CHEMPAQ|The two arms only differ in order of kind of blood samples.
3225143|NCT01138631|Active Comparator|Embryoscope|
3225144|NCT01138631|No Intervention|Conventional incubator|
3225145|NCT01138670||Cardiac device group|
3225146|NCT01138683|Active Comparator|ultrafiltration group|
3225147|NCT01138683|Active Comparator|diuretics group|
3225148|NCT01138696||Stryker Dacron synthetic graft|
3225149|NCT01138696||Trevira synthetic graft|
3225150|NCT01138709|Experimental|Convexity/Vitala|For all enrolled Subjects, STAGE 1 (Days 1 - 14 equals Convex Product Wear Period followed by, for those who successfully complete Stage I, weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 15 to 21), followed by 8 hours of daily wear time per week (Day 22 to 28), followed by 12 hours of daily wear time (Days 29 to 43).
3225151|NCT01138748|Experimental|Radiation therapy|
3225152|NCT01138761|No Intervention|Physician/resident instruction|This arm is standard of care instruction given to parents/caregivers of children with atopic dermatitis by the dermatologist and/or dermatology resident during a patient visit.
3225153|NCT01138761|Active Comparator|Nurse instruction|Following the usual standard of care instruction by physician/resident (which both the treatment group and the non-treatment group will receive); the dermatology nurse will give enhanced instruction about skin care and medications to the caregivers/parents who were randomized to the treatment group.
3225154|NCT01138774|Placebo Comparator|Control group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + placebos supplements
3225155|NCT01138774|Experimental|EPA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA (1.3 g/day, 3 capsules of 433 mg/day) supplement (EPA Group).
3225156|NCT01138774|Experimental|Lipoic acid group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + LA (300 mg/day, 3 capsules of 100 mg/day) supplement (LA Group)
3225157|NCT01138774|Experimental|EPA+LA group|Dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline + EPA/LA (1.3 g /day and 300 mg/day respectively).
3225158|NCT01138787|Active Comparator|Reference spread|"2250 mg PS (as PSE) in spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3225159|NCT01138787|Placebo Comparator|Placebo spread|"regular light margarine (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3225160|NCT01138787|Experimental|Test spread|"2250 mg PS in innovatively processed spread (30 g)~50 mg labeled D7-cholesterol,~30 mg 3,4-13C-cholesterol, iv dosed at same time."
3225161|NCT01138813||1|Male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade II or higher
3225162|NCT01138839|Placebo Comparator|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery.
3225163|NCT01138839|Experimental|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
3225164|NCT01138852|Experimental|ampicillin-sulbactam|This is the drug used to prevent post-cesarean infection
3225165|NCT01138852|Active Comparator|cefuroxime|This drug was compared to ampicillin sulbactam for prevention of infection
3225166|NCT01138865|Other|1|Device: AutoSet Spirit--Wash--Modified-AutoSet Spirit 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
3225167|NCT01138865|Other|2|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
3225168|NCT01138878||Patient pre-study group|A set of all 16-65 yr olds (not know already to be HIV-positive) accessing the healthcare setting prior to the introduction of the HIV testing pilot programme
3225169|NCT01138878||Staff pre-study group|A set of staff working within the healthcare setting prior to the introduction of the HIV screening programme
3225170|NCT01138878||Patient intra-study group|A set of patients, aged 16-65 and known not to be HIV-positive, who access the healthcare setting during the HIV testing pilot programme
3225171|NCT01138878||Post-study staff group|A set of staff who worked within the healthcare setting for the duration of the HIV testing pilot programme
3225172|NCT01138891||Removed breast implants for any reason|
3225173|NCT01138904|Active Comparator|IROX arm: FOLFIRI -> FOLFOX|"IROX arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
3225174|NCT01138904|Active Comparator|OXIR arm: FOLFIRI -> FOLFOX|"OXIR arm: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr"
3225175|NCT01138930|Experimental|Berberine|
3225176|NCT01138930|Placebo Comparator|Placebo|
3225177|NCT01138943|Active Comparator|Chlorhexidine alcohol-base mouthrinse|
3225178|NCT01138943|Experimental|non alcohol chlorhexidine mouthrinse|
3225179|NCT01138956|Experimental|Group 1|Pentavalent antimonial, 20mg/kg/day, 28 days, IV, plus N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po.
3225180|NCT01138956|Active Comparator|Group 2|Pentavalent antimonial, 20mg/kg/day, 28 days
3225181|NCT01138982|Experimental|Mentoring program|Mentor and mentee meet at least every second week, for 2-4 h on every occasion, during 1 year (i.e., for a minimum of two school semesters). Meetings take place outside school and work hours, and the pairs choose activities of their own preferences. No monetary incentives exist, and the mentors are laymen volunteers. The program objective is to establish a safe and supportive relationship, by which the youth is assumed to benefit in social, emotional, and academic development, and as a consequence, be less prone to use alcohol and drugs.
3225182|NCT01138982|No Intervention|Control group|No intervention provided, only brief phone calls to control for attention bias
3225183|NCT01139034|Experimental|shoulder FES treatment|
3225184|NCT01139060|Experimental|Intervention Group|18-month organized treatment program focused on outreach and engagement for chronic or recurrent depression
3225185|NCT01139060|No Intervention|Usual Care|
3225186|NCT01139086||Cardiovascular disease|Diagnosis of cardiomyopathy or ischemic heart disease without heart failure
3225187|NCT01139086||Chronic heart failure|Diagnosis of cardiomyopathy or ischemic heart disease LVEF <40%
3225188|NCT01139086||Control|Age and body built matched with chronic heart failure group
3225189|NCT01139099|Other|Arm|There is no arm in this study.
3225190|NCT01139138|Experimental|Panitumumab + Irinotecan + Everolimus|
3225191|NCT01139151|Experimental|Group 1 - 3 Day Thiarabine|Thiarabine 3 days in a row in each cycle.
3225192|NCT01139151|Experimental|Group 2 - 5 Day Thiarabine|Thiarabine 5 days a row in each cycle.
3225193|NCT01139177|Experimental|Stent placement|
3225194|NCT01139203|Active Comparator|lamivudine|
3225195|NCT01139203|Active Comparator|lamivudine and adefovir|
3225196|NCT01139203|Active Comparator|entecavir|
3225197|NCT01139216|Experimental|Daikenchuto (TU-100) 7.5g/day|Daikenchuto (TU-100) 2.5g TID (7.5g/day)
3225198|NCT01139216|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID (15g/day)
3225199|NCT01139216|Placebo Comparator|Placebo|Placebo TID
3225200|NCT01139229|Other|HE group|
3225201|NCT01139229|Other|HS group|
3225202|NCT01139229|Other|SA group|
3225203|NCT01139242|Other|Body & Soul nutritional intervention|This is a standardized intervention to increase fruit and vegetable consumption among church members through pastoral and peer counseling and church activities/menus.
3225204|NCT01139242|Experimental|Newsletters/peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening among church members out-of-date according to screening guidelines. For those up-to-date, promotion is of increased physical activity.
3225205|NCT01139255|Experimental|Podcasting + mobile media|
3225206|NCT01139255|Active Comparator|Podcasting|
3225207|NCT01139281|Active Comparator|Study Group|The Study Group(SG) received Ginkgo biloba extract(GBE761)(240mg/day)plus cisplatin(CDDP)
3225208|NCT01139281|Placebo Comparator|Control Group(CG)|The Control Group received Placebo plus CDDP
3225209|NCT01139346|Experimental|oral darinaparsin|open label, single arm, dose escalation
3225210|NCT01139359|Experimental|Single Arm, darinaparsin and CHOP|open label, single arm, unblinded
3225211|NCT01139372|Experimental|FID 115958D|Lubricant eye drop
3225212|NCT01139385||clipless|laparoscopic cholecystectomy performed by harmonic scalpel with closure and division of the cystic duct only by the device
3225213|NCT01139385||traditional|laparoscopic cholecystectomy performed by harmonic scalpel with closure of the cystic duct only by titanium clip
3225214|NCT01139424|Experimental|open label treatment arm|endoscopic suturing
3225215|NCT01139437|Experimental|Adults|Adults ages 18 to 49 years of age. Open label.
3225216|NCT01139437|Experimental|Seropositive children - vaccine|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving the HPIV2 vaccine.
3225217|NCT01139437|Experimental|Seronegative infants and children - low dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of the HPIV2 vaccine.
3225218|NCT01139437|Experimental|Seronegative infants and children - standard dose vaccine|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of the HPIV2 vaccine.
3225219|NCT01139437|Placebo Comparator|Seropositive children - placebo|Children ages 15 to 59 months of age who already have HPIV2 antibodies receiving a placebo.
3225220|NCT01139437|Placebo Comparator|Seronegative infants and children - low dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a low dose of placebo.
3225221|NCT01139437|Placebo Comparator|Seronegative infants and children - standard dose placebo|Infants and children ages 6 to 59 months of age who do not have HPIV2 antibodies receiving a standard dose of placebo.
3225222|NCT01139463||Antipsychotic treatment|Patients were not taking any medications - apart from the prescribed antipsychotic - for a period of 1 month prior to the study with psychotic relapse or newly diagnosed psychotic disorder were recruited from psychiatric inpatient and outpatient clinics of the Split Clinical Hospital.
3225223|NCT01139489|Active Comparator|procalcitonin-guidance|A daily advise to continue or stop antibiotics based on the measurement of the biomarker procalcitonin
3225224|NCT01139489|No Intervention|standard-of-care|standard-of-care treatment of ICU infections based upon consensus guidelines and expert opinion
3225225|NCT01139502|Active Comparator|Work rehab with cognitive therapy|Work rehabilitation based on the cognitive therapeutical model
3225226|NCT01139502|Active Comparator|Work rehab with cognitive training|Work rehabilitation with the addition of weekly training of concentration, memory, and executive function
3225227|NCT01139528|Active Comparator|Operative treatment|Closed reduction of the fracture and osteosynthesis with 2-3 intramedullary K-wires (Bouquet method), cast treatment for 7-10 days followed by 5 weeks of buddy-strapping before removal of the K-pins
3225228|NCT01139528|No Intervention|Conservative treatment|No attempt of reduction of the fracture, 7-10 days of cast treatment followed by 5 weeks of buddy-strapping
3225229|NCT01139541|No Intervention|Control|Participants in the control condition will be asked to refrain from using the WalkStations during the study period.
3225230|NCT01139541|Experimental|Individual|In the individual condition, participants will not be part of a team. They will receive weekly email feedback on their Walkstation performance (e.g. number of time slots they signed up for, and number of times they showed up for the time slot.)
3225231|NCT01139541|Experimental|Pairs|In the pair condition, participants will be randomly assigned to a partner. They will receive the same feedback as those in the individual condition, for both themselves AND their partner.
3225232|NCT01139541|Experimental|Groups|In the group condition, participants will be randomly assigned to a group of 5 people. They will receive the same feedback as those in the individual condition, for both themselves AND each member of their group.
3225233|NCT01139567||Standard Care Group|Subjects who will undergo only standard wound care management.
3225234|NCT01139567||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
3225235|NCT01139593||morning dose|women undergoing IVF/ICSi taking their gonadotropin dose in the am
3225236|NCT01139593||evening dose|Women undergoing IVF/ICSI taking their gonadotropin in the evening
3225237|NCT01139606|Experimental|Vibration trainig|
3225238|NCT01139619||1|Inoperable non small cell lung cancer patients. Diagnosed between 2010-05-31 and 2009-06-01.
3225239|NCT01139645|Experimental|Proton Pump Inhibitors|patients were started on Proton Pump inhibitors for 3 months (the whole duration of the study)
3225240|NCT01139645|No Intervention|No Proton Pump Inhibitors|patients are not taking any Proton Pump Inhibitor, and they are matched by age to patients in the experimental group.
3225241|NCT01139684|Experimental|Exercise|
3225242|NCT01139697||Patients with systolic heart failure|Patients with systolic heart failure defined as ejection fraction <45%
3225243|NCT01139723|Experimental|A|
3225244|NCT01139723|Experimental|B|
3225245|NCT01139736|Experimental|Probiotics|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks. VSL#3 was selected for use in this study because (a) it contains three different Bifidobacteria strains (in addition to lactobacilli and streptococci) and the limited evidence available Bifidobacteria as the most effective probiotics in IBS .
3225246|NCT01139749|Active Comparator|Oral isotretinoin|Subjects from treatment arm will be treated with low-dose oral isotretinoin - 20 mg a day, every other day, for six months
3225247|NCT01139749|Active Comparator|salicylic acid and ciclopirox olamine|Subjects from comparison arm will be treated with topical salicylic acid and ciclopirox olamine shampoo
3225248|NCT01139788|Experimental|LY2624587|
3225249|NCT01139827||normal|normal group has no diabetes.
3225250|NCT01139827||IGT|IGT group has impaired fasting glucose or impaired glucose tolerance.
3225251|NCT01139840|Active Comparator|vitamin D2|
3225252|NCT01139840|Active Comparator|vitamin D3|
3225253|NCT01139853|Active Comparator|Nasogastric Tube|10 French Nasogastric Tube inserted before surgery
3225254|NCT01139853|No Intervention|No Nasogastric Tube|
3225255|NCT01139866||Group 1: SABER™-Bupivacaine|Received 5.0 mL SABER™-Bupivacaine in previous C803-017 trial
3225256|NCT01139866||Group 2: SABER™-Placebo|Received 5.0 mL SABER™-Placebo in previous C803-017 trial
3225257|NCT01139892||Surgical management|Surgical clipping will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, bypasses, and other flow-redirecting treatments that do not directly clip the aneurysm will not be included.
3225258|NCT01139892||Endovascular management|Endovascular treatment will be performed within 6 weeks of randomization, according to standards of practice, and under general anaesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling or stents, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
3225259|NCT01139905|Other|1|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour
3225260|NCT01139918||Cohort A|40 patients with moderate psoriatic arthritis and moderate psoriasis
3225261|NCT01139918||Cohort B|40 patients with mild psoriatic arthritis and moderate psoriasis
3225262|NCT01139918||Cohort C|40 patients with moderate psoriatic arthritis and mild psoriasis
3225263|NCT01139944||Group 1|Archived tumor and intrathoracic lymph node tissue samples are analyzed for aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by methylation-specific PCR. Analyses are then compared with the preliminary data from the Johns Hopkins institutional study.
3225264|NCT01139957||Ancillary-correlative|Patients complete the Health Update Questionnaire annually for up to 5 years. The questionnaire focuses specifically on cancer risk, incidence, and mortality. Patients also receive ongoing communication (e.g., periodic newsletters, copies of study-related publications, etc.) to keep them informed regarding study-related research results, new research findings, new research opportunities for which patients may be eligible, and evolving clinical recommendations regarding hereditary breast/ovarian cancer.
3225265|NCT01140009|Placebo Comparator|Group 1|FLuviral 2010/11Tri-valent Seasonal Influenza Vaccine (TIV)1st; saline placebo 10 days later
3225266|NCT01140009|Placebo Comparator|Group 2|Saline placebo 1st; Fluviral 2010/11 Tri-valent Seasonal Influenza Vaccine (TIV)10 days later
3225267|NCT01140022||Female Patients 18-25 yo|Female patients aged 18-25 who have come to one of the ED or urgent care sites for care, regardless of the presence of CT symptoms.
3225268|NCT01140035|Experimental|Intensive insulin therapy|"Intensive insulin therapy with goal of glucose < 150 mg/dl~Control group with standard insulin therapy with goal of glucose 180 mg/dl"
3225269|NCT01140074|Experimental|Zinc sulfate|Children in active treatment group will be given zinc sulfate 10-20 mg per day orally plus probiotics
3225270|NCT01140074|Placebo Comparator|Placebo|Children will be given placebo plus probiotics
3225271|NCT01140087|Experimental|Interventional|Face Transplantation
3225272|NCT01140100|Active Comparator|propofol-propofol|
3225273|NCT01140100|Experimental|thiopental-propofol|
3225274|NCT01140113|No Intervention|Placebo|this group had undergone to routine coronary artery bypass graft surgery
3225275|NCT01140113|Experimental|Modified Ultrafiltration|patients after weaning from bypass were submitted to ultrafiltration
3225276|NCT01140126|Experimental|Antibody (UB-421)|
3225277|NCT01140139|Experimental|HIV DNA + Hydroxyurea|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption. The patients also received 500 mg of hydroxyurea daily.
3225278|NCT01140139|Experimental|HIV DNA|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
3225279|NCT01140139|Placebo Comparator|Placebo|PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
3225280|NCT01140152||No rejection|Intestinal transplant recipients with no evidence of biopsy proven rejection
3225281|NCT01140152||Rejection|Intestinal transplant recipients who had evidence of biopsy proven rejection
3225282|NCT01140165|Active Comparator|butter|Danish butter
3225283|NCT01140165|Experimental|cheese|
3225284|NCT01140178|Experimental|HPPH|a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.
3225285|NCT01140204|Placebo Comparator|Placebo control|Contrast medium without Paclitaxel
3225286|NCT01140204|Active Comparator|Iopromide Paclitaxel 0.85 mg|Iopromide Paclitaxel 0.85 mg
3225287|NCT01140204|Active Comparator|Iopromide Paclitaxel 4.27 mg|Iopromide Paclitaxel 4.27 mg
3225288|NCT01140204|Active Comparator|Iopromide Paclitaxel 8.54 mg|Iopromide Paclitaxel 8.54 mg
3225289|NCT01140204|Active Comparator|Iopromide Paclitaxel 17.08 mg|Iopromide Paclitaxel 17.08 mg
3225290|NCT01140217|Experimental|Active treatment|Norethindrone Acetate Transdermal Delivery System
3225291|NCT01140243|Experimental|test product|Dietary supplement
3225292|NCT01140243|Active Comparator|standart|Dietary supplement
3225293|NCT01140256||SGA infants|SGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
3225294|NCT01140256||AGA|AGA infants were recruited at birth and zinc stable isotope was administered at birth and at 6 months of age .This was a longitudinal study whereby the growth trajectory and zinc pools were measured.
3225295|NCT01140256||SGA infant|Infants who were born small for gestational age were recruited and zinc stable isotopes were administered at birth and at 6 months.
3225296|NCT01140269|No Intervention|No PCR testing|Control patients will not have PCR testing. This group will have routine testing and treatment as defined by the standard of care.
3225297|NCT01140269|Experimental|PCR testing|PCR will be used in parallel with routine laboratory tests such as culture. Treatment for PCR results will be based on the standard of care. Treatment of the patient will be dependent on the physician's clinical judgment based on existing clinical information including PCR, microbiology, patient physical presentation, and other laboratory results.
3225298|NCT01140282|Active Comparator|Arm I (Control)|Patients refrain from increasing physical activity levels for 16 weeks.
3225299|NCT01140282|Experimental|Arm II (Exercise)|Patients participate in supervised exercise sessions over 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30-45 minutes once weekly for 16 weeks.
3225300|NCT01140308|Placebo Comparator|Sugar Pill|Simvastatin 20mg + Placebo
3225301|NCT01140308|Active Comparator|Co Q10|Simvastatin 20mg + CoQ10
3225302|NCT01140321|Experimental|Neridronato|Thalassemia Major or Severe Thalassemia Intermedia
3225303|NCT01140321|No Intervention|Placebo|Thalassemia Major or Severe Thalassemia Intermedia
3225304|NCT01140334|Experimental|Reinforced On-Site Integrated Care (ROIC)|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. In addition, they will be able to earn a voucher incentive for each week of psychiatric compliance.
3225305|NCT01140334|Active Comparator|Standard On-Site Integrated Care (SOIC).|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week.
3225306|NCT01140373|Experimental|autologous T cells & cyclophosphamide.|This is a phase I dose escalation study to assess the safety and tolerability using increasing doses of engineered autologous T cells targeted to Prostate-Specific Membrane Antigen (PSMA) administered one day after pretreatment with cyclophosphamide.
3225307|NCT01140386||hospital pediatric patients 1/1/2000-12/31/2008 documented VTE|Age <18 Hospitalized for greater than or equal to 24 hours VTE documented during hospital admission
3225308|NCT01140399|Active Comparator|Infusional drug treatment|Diuretics or diuretics plus fixed low dose dopamine infusion
3225309|NCT01140399|Experimental|Ultrafiltration|Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion
3225310|NCT01140412|Experimental|Cohort 1|Twice daily regimen
3225311|NCT01140412|Experimental|Cohort 2|Once daily regimen
3225312|NCT01140425|Experimental|PF-00232798 supratherapeutic dose|PF-00232798 supratherapeutic dose
3225313|NCT01140425|Experimental|PF-00232798 therapeutic dose|PF-00232798 therapeutic dose
3225314|NCT01140425|Placebo Comparator|Placebo for PF-00232798|Placebo for PF-00232798
3225315|NCT01140425|Active Comparator|Moxifloxacin|Moxifloxacin
3225316|NCT01140438|Active Comparator|Metformin + NPH Insulin|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization insulin treatment will be added in the form of injections of NPH insulin in the evenings.
3225317|NCT01140438|Active Comparator|Metformin + sitagliptin +/-repaglinid|Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is > 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
3225318|NCT01140451|Experimental|Ataluren/Ataluren|Participants who received double-blind ataluren during Study 009 will continue to receive open-label ataluren 3 times per day TID: 10 milligram (mg)/kilogram (kg) of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
3225319|NCT01140451|Experimental|Placebo/Ataluren|Participants who received double-blind placebo during Study 009 will receive open-label ataluren TID: 10 mg/kg of body weight with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner (total dose 40 mg/kg/day), for up to 96 weeks. Participants will be followed for 4 weeks after treatment.
3225320|NCT01140464|Active Comparator|Enhanced Usual Care|Usual care treatment of depression in primary care settings. Usual care considered enhanced as patients and their parents were given screening results and encouraged to seek care from their primary care doctor and behavioral health services.
3225321|NCT01140464|Active Comparator|Collaborative Care|Collaborative care intervention for depression. Involves care management, evidence based treatments in primary care setting, symptom monitoring and stepped care design
3225322|NCT01140490|No Intervention|Sub-total Parathyroidectomy|
3225323|NCT01140516|Active Comparator|Trimethoprim|Prophylactic Antibiotics
3225324|NCT01140516|Placebo Comparator|Simple syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
3225325|NCT01140529|Experimental|Dexmedetomidine|
3225326|NCT01140529|Active Comparator|Haloperidol|
3225327|NCT01140529|Placebo Comparator|Placebo|
3225328|NCT01140542|Active Comparator|Roflumilast|500µg, once daily
3225329|NCT01140542|Placebo Comparator|Placebo|
3225330|NCT01140555|Experimental|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
3225331|NCT01140581|Experimental|Group A|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks followed by dronedarone 400 mg twice daily for 8 weeks
3225332|NCT01140581|Experimental|Group B|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Two weeks wash-out followed by dronedarone 400 mg twice daily for 6 weeks
3225333|NCT01140581|Experimental|Group C|Amiodarone 600 mg daily for 1 week then 400 mg daily for 1 week then 200 mg daily for 2 weeks. Four weeks wash-out followed by dronedarone 400 mg twice daily for 4 weeks
3225334|NCT01140607|Experimental|Cohort 1: normal hepatic function: cabazitaxel|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3225335|NCT01140607|Experimental|Cohort 2: mild hepatic impairment : cabazitaxel|"cabazitaxel 20mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3225336|NCT01140607|Experimental|Cohort 3: moderate hepatic impairment: cabazitaxel|"cabazitaxel 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3225337|NCT01140607|Experimental|Cohort 4: severe hepatic impairment: cabazitaxel|"cabazitaxel 5 mg/m^2 or 10mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks)."
3225338|NCT01140607|Experimental|Cohort 5: normal hepatic function: cabazitaxel and midazolam|"cabazitaxel 25mg/m^2~IV infusion of Cabazitaxel is given over 1 hour on Day 1 of each cycle (every 3 weeks).~Midazolam is given orally in single dosing on day -1 and day 1 (crossover)"
3225339|NCT01140620|Experimental|ketamine and risperidone|Oral risperidone pretreatment and intravenous ketamine infusion
3225340|NCT01140620|Active Comparator|ketamine and placebo|Oral placebo risperidone pretreatment and intravenous ketamine infusion
3225341|NCT01140620|Active Comparator|saline and risperidone|Oral risperidone pretreatment and intravenous saline infusion
3225342|NCT01140620|Placebo Comparator|saline and placebo|Oral placebo risperidone pretreatment and intravenous saline infusion
3225343|NCT01140620|No Intervention|Patients with Schizophrenia|Patients with schizophrenia will not receive study drug and will not undergo randomisation.
3225344|NCT01140659|Other|Objective measurement of sweat|"We selected 40 patients from February 2007 to May 2009. All participants were randomized into two groups of 20 patients (G3 and G4) and underwent the sympathectomy, being followed for 12 months. We used an objective method for measuring sweat, checking the TEWL (transepidermal water loss) measured by the VapoMeter, and evaluated the quality of life before and after the operation. Also studied were: incidence and intensity of the compensatory hyperhidrosis."
3225345|NCT01140672|Experimental|Cohort 1 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
3225346|NCT01140672|Experimental|Cohort 2 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 3 mg per day for 14 days. (2 placebo: 8 active)
3225347|NCT01140672|Experimental|Cohort 3 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 30 mg per day for 14 days. (2 placebo: 8 active)
3225348|NCT01140672|Experimental|Cohort 4 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 100 mg per day for 14 days. (2 placebo: 8 active)
3225349|NCT01140672|Experimental|Cohort 5 (N=10)|Placebo-controlled, multiple doses of PF-04634817 at 300 mg per day for 14 days. (2 placebo: 8 active)
3225350|NCT01140672|Experimental|Cohort 6 (N=10) Optional cohort|Placebo-controlled, multiple doses of PF-04634817 up to 300 mg per day for 14 days. (2 placebo: 8 active)
3225351|NCT01140698||Term and preterm newborn infants|5 infants of each gestational age of 24-42 weeks
3225352|NCT01140711|Experimental|Gastric bypass|Patients submitted to gastric bypass for treatment of morbid obesity
3225353|NCT01140711|Experimental|Sleeve gastrectomy|Patients submitted to sleeve gastrectomy for treatment of morbid obesity
3225354|NCT01140737|Experimental|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily.
3225355|NCT01140763||Sysmex's 5-blade cutter.|
3225356|NCT01140776||OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
3225357|NCT01140789||Crohn's disease patients|Diagnosis of Crohn's disease by endoscopy, radiology and histology
3225358|NCT01140789||Ulcerative colitis patients|Diagnosis of ulcerative colitis defined by endoscopy, radiology and histology
3225359|NCT01140789||Non-IBD patients|Ethically, sex and aged-matched controls attending clinics or endoscopy for functional upper gastrointestinal diseases or screening colonoscopy.
3225360|NCT01140802||IBD patients|Crohn's disease or ulcerative colitis patients
3225361|NCT01140802||Healthy controls (non-IBD)|Patients comprise ethnicity - matched patients undergoing colonoscopy for polyp or colorectal cancer screening, or rectal bleeding
3225362|NCT01140802||Relatives of IBD patients|They will be a first degree relative of a IBD patient.
3225363|NCT01140828|Active Comparator|Rabeprazole|Rabeprazole
3225364|NCT01140828|Placebo Comparator|Rabeprazole Placebo|Rabeprazole Placebo
3225365|NCT01140841||Fipamezole ODT|
3225366|NCT01140841||Placebo|
3225367|NCT01140854||Hypertension (case)|Elderly patients 60 years old or older undergoing simple lumbar spine surgery under general anesthesia will receive neurologic/neuropsychometric examinations.
3225368|NCT01140854||Normotension (control)|Middle-aged patients (40-60 years) undergoing simple lumbar spine surgery under general anesthesia as controls to compare their performance to those patients >60 years - will also receive neurologic/neuropsychometric examinations.
3225369|NCT01140893|Experimental|exenatide|55 subjects
3225370|NCT01140893|Placebo Comparator|Placebo|55 subjects
3225371|NCT01140932|Experimental|Intervention|Medical and behavioural intervention
3225372|NCT01140945||Males attending in vitro fertilization clinic|
3225373|NCT01140971|Active Comparator|Misoprostol|Use 25 micrograms vaginal every 6 hours (max dosis 200 micrograms in 48 hours)
3225374|NCT01140971|Active Comparator|Foley|Foley catheter number 14 or 16 was installed intracervical for no more than 48 hours.
3225375|NCT01140984|Experimental|treatment|
3225376|NCT01140997|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per Week, with Ribavirin 1000-1200mg/d
3225377|NCT01140997|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per Week, with Ribavirin 1000-1200mg/d
3225378|NCT01140997|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per Week, with Ribavirin 1000-1200mg/d
3225379|NCT01140997|Active Comparator|Group 4|Pegasys 180mcg per Week, with Ribavirin 1000-1200mg/d
3225380|NCT01141010|Sham Comparator|Plain language|Conventional plain language will be given without any psychological intervention
3225381|NCT01141010|Active Comparator|Pre-psycho-language|Prior surgery psychological linguistic intervention
3225382|NCT01141010|Active Comparator|Intra-psycho-language|Intraoperative psychological linguistic intervention
3225383|NCT01141010|Active Comparator|Post-psycho-language|Postoperative psychological linguistic intervention
3225384|NCT01141010|Active Comparator|Combined language|Psychological linguistic intervention will be given in a combination of pre-, intra- and post-operatively
3225385|NCT01141023|Experimental|Datscan SPECT Imaging|Subjects will b injected with 3-5 mCi of dopamine transporter. Within a 4 hour (+/- 30 minutes) window following the injection, subjects will undergo SPECT imaging on the camera.
3225386|NCT01141036|Active Comparator|propofol|propofol
3225387|NCT01141036|Active Comparator|Midazolam|Midazolam
3225388|NCT01141062|Experimental|Treated leiomyomas|Philips MR-guided HIFU
3225389|NCT01141088|Experimental|Bilateral stent-in-stent insertion|The passage of the bilateral metal stent across the stricture, stent-in-stent method.
3225390|NCT01141088|Active Comparator|Bilateral side-by-side insertion|The passage of the bilateral metal stent across the stricture, side-by-side method.
3225391|NCT01141101||MRSA-exposed|The MRSA-exposed group will include 100 MRSA-colonized mothers and their babies
3225392|NCT01141101||MRSA-unexposed|The MRSA-unexposed group will include 100 MRSA-negative mothers and their babies.
3225393|NCT01141114|Experimental|Use of a Patient Navigator|
3225394|NCT01141114|Other|Usual Care|No Intervention - usual care
3225395|NCT01141127|Active Comparator|INTERMITENT ADMINISTRATION|Administration of 10 mg/kg of Tranexamic Acid at the beginning ,the middle and at the end of the intervention
3225396|NCT01141127|Experimental|continuous administration of Tranexamic Acid|Administration of 10 mg /Kg of Tranexamic Acid at the beginning in the priming pump and continuous infusion of 1 mg/KG of Tranexamic Acid until the end of the intervention
3225397|NCT01141140|Other|M-NO-NR|Men (M) non-obese (NO) and non-restrained (NR).
3225398|NCT01141140|Other|M-NO-R|Men (M) non-obese (NO) and restrained (R).
3225399|NCT01141140|Other|M-O-NR|Men (M) overweight or obese (O) and non-restrained (NR).
3225400|NCT01141140|Other|M-O-R|Men (M) overweight or obese (O) and restrained (R).
3225401|NCT01141140|Other|W-NO-NR|Women (W) non-obese (NO) and non-restrained (NR).
3225402|NCT01141140|Other|W-NO-R|Women (W) non-obese (NO) and restrained (R).
3225403|NCT01141140|Other|W-O-NR|Women (W) overweight or obese (O) and non-restrained (NR).
3225404|NCT01141140|Other|W-O-R|Women (W) overweight or obese (O) and restrained (R).
3225405|NCT01141153|Experimental|Oral anticoagulation plus dual antiplatelet therapy|
3225406|NCT01141153|Active Comparator|Dual antiplatelet therapy|
3225407|NCT01141166|Experimental|nutritional and physical rehabilitation plan|
3225408|NCT01141179|Experimental|LEO 27847|
3225409|NCT01141192|Active Comparator|Vitamin D3 supplement|60,000 IU vitamin D3 oral supplement provided every four weeks at weeks 0, 4, 8, and 12 in the form of one 50,000 and two 5,000 IU vitamin D3 supplements in gelcap form.
3225410|NCT01141192|Placebo Comparator|Sugar Pill|Inactive placebo tablets identical in appearance to the active comparator provided every four weeks at weeks 0,4,8,and 12.
3225411|NCT01141218||Never-smokers with lung cancer|
3225412|NCT01141244|Experimental|Treatment (temsirolimus, irinotecan, temozolomide)|Patients receive temsirolimus IV over 30 minutes on days 1 and 8 or on days 1, 8, and 15 and temozolomide PO and irinotecan hydrochloride PO on days 1-5. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
3225413|NCT01141257|Experimental|Angiocal®|Angiocal®
3225414|NCT01141270|Experimental|AFOLIA|225 IU sc
3225415|NCT01141270|Active Comparator|Gonal-f|225 IU sc
3225416|NCT01141296|Active Comparator|Fenofibrate|
3225417|NCT01141296|Placebo Comparator|sugar pill|
3225418|NCT01141309|Experimental|sorafenib with everolimus|This is a two-stage phase II study combining sorafenib with everolimus in patients with thyroid cancer.
3225419|NCT01141322|Experimental|UDCA treatment|Patients with drug-induced liver injury will be randomly allocated to UDCA treatment group: oral intake ursodeoxycholic acid (UDCA) 13-15 mg/kg BW/day into 3 divided doses after meal till the endpoint or the 8th week. UDCA is 100 mg per tab.
3225420|NCT01141322|Placebo Comparator|Placebo|Patients with drug-induced liver injury will be randomly allocated to placebo group. The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
3225421|NCT01141335|Experimental|PTFE mesh|A Lichtenstein tension-free hernioplasty is performed using PTFE mesh
3225422|NCT01141335|Active Comparator|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using polypropylene mesh
3225423|NCT01141348|Experimental|Special Intervention|
3225424|NCT01141348|Experimental|Delayed Intervention|
3225425|NCT01141361||Peripheral arterial disease patients|Patients with a peripheral arterial disease, defined by an ankle to brachial index below 0.90
3225426|NCT01141387||Patients at the intervention sites|The intervention sites will receive the results of the patient-reported depression severity collected during the phone interviews on a monthly basis. The patients in the intervention arm will be interviewed by phone once per month for 6 months.
3225427|NCT01141387||Patients at the usual care sites|The usual care sites will receive the results of the patient-reported depression severity at the end of the study. Patients in the usual care arm will be interviewed at 3 months and 6 months post study enrollment.
3225428|NCT01141400||depression & initial prescription for an antidepressant|A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
3225429|NCT01141413||RA patients using Remicade®|
3225430|NCT01141413||RA patients using Orencia®|
3225431|NCT01141426|Active Comparator|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
3225432|NCT01141426|Experimental|Intensive Short-Term Dynamic Psychotherapy (ISTDP) Group|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
3225433|NCT01141439||IPDI HFA-BDP MDI|Patients who commenced inhaled corticosteroid therapy as HFA-BDP via MDI
3225434|NCT01141439||IPDI FP MDI|Patients who commenced inhaled corticosteroid therapy as FP via MDI
3225435|NCT01141439||IPDA FP MDI|Patients who had a step up in inhaled corticosteroid therapy as FP via MDI
3225436|NCT01141439||IPDA HFA-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as HFA-BDP via MDI
3225437|NCT01141439||IPDI CFC-BDP MDI|Patients who commenced inhaled corticosteroid therapy as CFC-BDP via MDI
3225438|NCT01141439||IPDA CFC-BDP MDI|Patients who had a step up in inhaled corticosteroid therapy as CFC-BDP via MDI
3225439|NCT01141452||IPDA FP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as fluticasone via metered dose inhaler
3225440|NCT01141452||IPDA HFA-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as extra-fine hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
3225441|NCT01141452||IPDA CFC-BDP MDI|Patients who were on inhaled corticosteroid therapy as part of their baseline therapy (any ICS therapy) who, at an index prescription date, stepped-up ICS dose as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
3225442|NCT01141452||IPDI CFC-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as chlorofluorocarbon beclomethasone dipropionate via metered dose inhaler
3225443|NCT01141452||IPDI HFA-BDP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
3225444|NCT01141452||IPDI FP MDI|Patients who were not receiving inhaled corticosteroid therapy as part of their baseline therapy but who, at an index prescription date, initiated ICS as fluticasone propionate via metered dose inhaler
3225445|NCT01141465||IPDA FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at ≥twice the equivalent BDP-equivalent dose
3225446|NCT01141465||IPDA FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at ≥twice the equivalent BDP-equivalent dose
3225447|NCT01141465||IPDI FP/SAL DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL DPI at equivalent BDP-equivalent dose
3225448|NCT01141465||IPDI BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at equivalent BDP-equivalent dose
3225449|NCT01141465||IPDI FP/SAL MDI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as FP/SAL MDI at equivalent BDP-equivalent dose
3225450|NCT01141465||IPDA BUD/FOR DPI|Patients who were on inhaled corticosteroid therapy during the baseline year (any ICS therapy) who, at an index prescription date, initiated combination therapy as BUD/FOR DPI at ≥twice the equivalent BDP-equivalent dose
3225451|NCT01141504|Placebo Comparator|Placebo|Oral placebo capsules similar in color and size to the intervention
3225452|NCT01141504|Active Comparator|PeakATP 250|Oral supplement capsules containing 250 mg/day of PeakATP
3225453|NCT01141504|Active Comparator|PeakATP 400|Oral supplement capsules containing 400 mg/day of PeakATP
3225454|NCT01141504|Active Comparator|PeakATP 400 plus proprietary blend|Oral supplement capsules containing 400 mg/day of PeakATP plus a proprietary blend
3225455|NCT01141530||Tissue Bank Samples|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study. All samples studied will be obtained through the UAMS Tissue Bank.
3225456|NCT01141543||cohort 1|Patients in Cohort 1 will be followed with daily Flowcytometric studies to quantify CXCR4 positive cells.The samples will be obtained before the following doses of FLUDARABINE and BUSULFAN. Eighteen hrs (range 18 -20 hrs) after start of the last dose of FUDARABINE andBUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR
3225457|NCT01141543||Cohort 2|Patients in Cohort 2 will receive the second dose of PLERIXAFOR 24 hrs after the first dose. A PB sample for a CBS and Flowcytometry will be drawn prior to the dose. Nine hrs later a further study sample for Flowcytometry will be obtained prior to administration of the second dose of FLUARABINE and BUSULFAN. Flowcytometric studies will be repeated on day 3 and 4. Eighteen hrs (range 18 - 20 hrs) after start of the last dose of FLUDARABINE and BUSULFAN and before the first dose of TBI a PB sample as well as bone marrow aspirate and biopsy will be obtained to repeat the studies as conducted prior to the first dose of PLERIXAFOR.
3225458|NCT01141543||cohort 3|Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN
3225459|NCT01141543||Cohort 4|Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN
3225460|NCT01141556|Placebo Comparator|Placebo|Placebo (NaCl) i.v. intraoperatively, followed by an daily bolus of Placebo (NaCl) i.v. until discharge from ICU (no longer than 13 days)
3225461|NCT01141556|Active Comparator|Selenase|Selenase Bolus 4000 microgram i.v. intraoperatively, followed by an daily bolus of Selenase 1000 microgram i.v. until discharge from ICU (no longer than 13 days)
3225462|NCT01141699||female|Women who live in the Shuang Ho Region of Taipei City. Women can read and write chinese language.
3225463|NCT01141738|Experimental|Caregiver Problem-Solving Intervention|The experimental treatment will provide structured information, guided problem-solving, and training in skills for coping with stress and emotional responses (e.g., relaxation, cognitive reframing, changing negative problem orientation, PS skills).
3225464|NCT01141738|Other|Wait List Control|WLC subjects will be offered an intervention after the 6 month assessment. Both groups will receive standard services provided by the rehabilitation team to CGs of stroke survivors.
3225465|NCT01141764|Experimental|Study Group|"In our study, patients will be scanned with their DBS electrodes turned on and off.~Participation involves undergoing 2 separate PET scans on 2 separate days. The MRI and neuropsychological tests will either be performed on the same day as one of the PET scans or on a separate day.~Procedures performed in this study are not part of the standard management of epilepsy."
3225466|NCT01141777|Active Comparator|Spirulina platensis|
3225467|NCT01141777|Placebo Comparator|Soya bean|
3225468|NCT01141790|Placebo Comparator|Silence|"The control group listened silence and was evaluated the same things."
3225469|NCT01141803|No Intervention|control|
3225470|NCT01141803|Active Comparator|Apples|
3225471|NCT01141803|Active Comparator|Apple pomace|
3225473|NCT01141842|Experimental|lung cancer|breath samples of patients with confirmed lung cancer
3225474|NCT01141842|Active Comparator|underlying lung disease|patients with underlying lung disease and impairment in lung function
3225475|NCT01141842|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
3259018|NCT01466712|Experimental|Tiotropium+formoterol/beclomethasone|run-in of 4 weeks with thiotropium cross-over after first treatment period of 4 weeks
3225476|NCT01141855|Experimental|Champix plus counselling|varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration). In combination with Quit SA (5A) telephone counselling service
3225477|NCT01141855|Active Comparator|counselling alone|5A counselling via Quit SA (quitline) telephone counselling service. (maximum 8 phone calls per subject within a 3 month period).
3225478|NCT01141868|Experimental|Internet Intervention|
3225479|NCT01141868|Experimental|Delayed Intervention|Receive access to the online Internet intervention after completing post-assessments.
3225480|NCT01141881|Experimental|TPA,IVB,F/U|
3225481|NCT01141894|Active Comparator|Routine fluid treatment|Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
3225482|NCT01141894|Experimental|Goal directed haemodynamic treatment|Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
3225483|NCT01141920|Active Comparator|3-month counseling induction: routine care|Participants assigned to this condition will receive routine stepped-care treatment at ATS. Participants will begin in Step 2 (one counseling session per week), and be advanced to higher intensity care based on missed counseling sessions and drug-positive urine samples. Participants advanced to Step 3 will be scheduled to attend 2 group counseling sessions per week (in addition to individual counseling), and those advanced to Step 4 will be scheduled to attend 8 group counseling sessions per week (in addition to individual counseling). Time of methadone dosing will be based on step of care.
3225484|NCT01141920|Experimental|3-month counseling induction: low threshold|Participants assigned to this treatment arm will receive low threshold counseling. These participants will be scheduled to attend one counseling session per month with their individual counselor for the first 3-months. Participants can attend more counseling sessions if they desire, and they can meet with program supervisors to address crisis situations. They can receive methadone dosing any time during the clinic hours (7:30 am-1:15 pm and 4:00 pm - 6:00 pm)
3225485|NCT01141933|Other|Usual care|Subjects in this group receive the usual treatment only.
3225486|NCT01141933|Experimental|Individual intervention|Consisting in a 12 weekly sessions with a therapist. Each session lasts 1 hour.
3225487|NCT01141933|Experimental|Group intervention|Consisting in a 12 weekly sessions with two therapists. Number of subjects in each group is from 5 to 10. Each session lasts 2 hours.
3259019|NCT01466712|Sham Comparator|tiotropium+placebo|cross-over cfr arm1
3225488|NCT01141972|Active Comparator|Supplement|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency
3225489|NCT01141972|Placebo Comparator|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
3225490|NCT01141985|Other|Treated|This is a single arm study.
3225491|NCT01141998|Placebo Comparator|Placebo|
3225492|NCT01141998|Active Comparator|Vitamin D administered orally|
3225493|NCT01141998|Experimental|Vitamin D administered via UVB|
3225494|NCT01142011|Experimental|Belimumab|"The first cycle of Belimumab is a loading cycle of 3 doses over 28 days (days 1, 15, 29).~After the first cycle, additional cycles of belimumab will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles)."
3225495|NCT01142024|Placebo Comparator|saline|saline hydration
3225496|NCT01142024|Experimental|Glutathione|
3225497|NCT01142037|Experimental|Furanocoumarin|Includes participants first refraining from eating foods with furanocoumarins for one week, followed by 2 weeks of increasing furanocoumarin consumption. Participants will be asked to consume cooked parsnips and parsley.
3225498|NCT01142063||Treatment A (Reference fasted)|Treatment A (Reference fasted): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fasted condition.
3225499|NCT01142063||Treatment B (Test fasted)|Treatment B (Test fasted): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fasted condition.
3225500|NCT01142063||Treatment C (Reference fed)|Treatment C (Reference fed): A 40 mg tablet strength neratinib administered as a single dose of 6 x 40 mg under fed condition.
3225501|NCT01142063||Treatment D (Test fed)|Treatment D (Test fed): A 240 mg tablet strength neratinib administered as a single dose of 1 x 240 mg under fed condition.
3225502|NCT01142076|Placebo Comparator|placebo|Dose treatment group, 10%
3225503|NCT01142076|Active Comparator|Xinju Xiaogao Prescription|treatment group
3225504|NCT01142102|Experimental|Arm 1|Radiation Therapy
3225505|NCT01142141|Other|Manual therapy, kinesiotherapy|
3225506|NCT01142154|Experimental|oral, liquid solution|
3225507|NCT01142167|Active Comparator|Standard Colonoscopy|Colonoscopy with standard instrument
3225508|NCT01142167|Experimental|Ultra-thin colonoscopy|New prototype scope
3225509|NCT01142180|Active Comparator|TAE group|Patients will be undergone TAE after endoscopic hemostasis.
3225510|NCT01142180|Active Comparator|No TAE group|No TAE procedure will be performed after endoscopic treatment.
3225511|NCT01142206|Active Comparator|Physical Activity|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week.
3225512|NCT01142206|Experimental|Physical Activity & TV Watching|A standard behavioral weight loss intervention with a physical activity prescription of 200 minutes of moderate intensity physical activity per week and an additional prescription of reducing TV watching to 10 hours per week or less.
3225513|NCT01142219|Experimental|L-arginine|0.1g/kg/day for 6 months
3225514|NCT01142245|Active Comparator|oral esomeprazole|"Esomeprazole placebo IV loading bolus~Esomeprazole placebo intravenous infusion for 72 hours~Oral Esomeprazole: 80 mg/Day on Day 1, 2 and Day 3, and the drug will be given as 40 mg q12h."
3225515|NCT01142245|Active Comparator|Intravenous Esomeprazole|"Esomeprazole IV loading bolus 80mg~• Esomeprazole intravenous infusion 8mg/hr for 72 hours"
3225516|NCT01142258|Experimental|Trazodone|Study group will receive trazodone 50mg
3225517|NCT01142258|Placebo Comparator|Placebo|Inert pill
3225518|NCT01142271|Experimental|Billroth-I|Patients in this group should be underwent gastroduodenostomy as reconstruction procedure after standard distal subtotal gastrectomy with lymph node dissection.
3225519|NCT01142271|Experimental|Roux en Y|Patients in this group should be underwent jejunojejunostomy and gastrojejunostomy as reconstruction procedure after standard distal gastrectomy.
3225520|NCT01142284|Placebo Comparator|Placebo|Placebo
3225521|NCT01142284|Experimental|Cilostazol|cilostazol
3225522|NCT01142284|Experimental|Probucol|probucol
3225523|NCT01142284|Experimental|Cilostazol + Probucol|cilostazol and probucol
3225524|NCT01142349|Experimental|Lifestyles A|Cognitive Behavioral Therapy for Pain and Insomnia
3225525|NCT01142349|Experimental|Lifestyle B|Cognitive Behavioral Therapy for Pain
3225526|NCT01142349|Active Comparator|Lifestyles C|Osteoarthritis Education
3225527|NCT01142362|Experimental|0.6mg of DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 0.6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3225528|NCT01142362|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 2mg of DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3225529|NCT01142362|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400X containing 6 mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3259020|NCT01466725|Experimental|Cohort 1|25 mg daily for 4 weeks (8 active/2 control)
3225530|NCT01142401|Experimental|Arm A (fulvestrant)|Patients receive fulvestrant IM on day 1 (days -14, 1, and 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm C.
3225531|NCT01142401|Experimental|Arm B (fulvestrant, bortezomib)|Patients receive fulvestrant as in arm A and bortezomib IV on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3225532|NCT01142401|Experimental|Arm C (fulvestrant, bortezomib)|Patients receive fulvestrant IV on day 1 and bortezomib IM on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3225533|NCT01142427||Ancillary-Correlative (classification)|Patients undergo blood sample collection and bone marrow biopsies at baseline and during and after induction therapy for immunophenotyping for ALL confirmation and classification, DNA ploidy, genomic variation, and cytogenetic (BCR-ABL, trisomies 4+10, and molecular testing for translocations) analysis by flow cytometry and FISH. Immunophenotype results obtained on this study are used to determine patient's assignment to specific clinical-trial treatments. Some samples (leukemic and germline) may be banked for current and/or future analyses.
3225534|NCT01142440|Experimental|behavioral intervention|
3225535|NCT01142440|No Intervention|convention dental treatment|
3225536|NCT01142479|Placebo Comparator|herbal A|dilute of (TPE-1) decoction.
3225537|NCT01142479|Experimental|herbal B|TPE-1 decoction (100 ml)
3225538|NCT01142505|Placebo Comparator|Placebo|Patients in the placebo arm will be given an inactive version of the investigational medical product formed of the excipient mannitol (which is coated with the active drug montelukast in the active comparator arm)
3225539|NCT01142505|Active Comparator|Montelukast|Patients in the active arm will be given an active version of the investigational medical product formed of the inactive excipient mannitol with a coating of active drug montelukast.
3225540|NCT01142531||COPD|COPD patients aged 40 or more, with a smoking history of > 10 PY and a post-bronchodilator FEV1/VC < 0.7 will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5y.
3225541|NCT01142544||Pediatric ALIEN|All children from 1 month to 18 years old meeting the American-European Consensus Conference definition of acute lung injury
3225542|NCT01142570|Active Comparator|Group 1|Patients will be receive caloric support as dictated by Hariss-Benedict Formula (Group 1)
3225543|NCT01142570|Active Comparator|Group 2|Patients will be receive caloric support as dictated by Indirect Calorimetry (Group 2)
3225544|NCT01142570|Active Comparator|Group 1A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the first(Group 1A)group will receive caloric support calculated by the HARISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight."
3225545|NCT01142570|Active Comparator|Group 2A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight."
3225546|NCT01142570|Active Comparator|Group 3A|"After seven days of hospitalization and study enrollment patients who have not been weaned from ventilator, will be divided into three groups.~Patients in the third group will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight."
3225547|NCT01142609|Experimental|Internet (eGetgoing)|Subjects will assigned to use an accredited web-based platform (eGetgoingTM, CRC Health Group, Inc.) to deliver routine substance abuse counseling.
3225548|NCT01142609|No Intervention|Routine on-site|Subjects will attend routine face-to-face individual counseling sessions.
3225549|NCT01142622|Experimental|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
3225550|NCT01142622|Active Comparator|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity before surgery
3225551|NCT01142687|Active Comparator|dihydrocapsiate 3 mg|• Group 1: 1 Dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner
3225552|NCT01142687|Active Comparator|dihydrocapsiate 9 mg|• Group 2: 3 Dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
3225553|NCT01142687|Placebo Comparator|Placebo capsule|• Group 3: 3 placebo capsules three times per day within 30 minutes before breakfast, lunch and dinner
3225554|NCT01142700|Experimental|BMS-824393 (10mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3225555|NCT01142700|Experimental|BMS-824393 (30 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3225556|NCT01142700|Experimental|BMS-824393 (100 mg)|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3225557|NCT01142700|Placebo Comparator|Placebo|"Plus Peginterferon Alfa-2a and Ribavirin~Day 1 - Week 12"
3225558|NCT01142700|Other|Peginterferon alfa-2a plus Ribavirin|Weeks 13 - 48
3225559|NCT01142739||Parkinson's Disease patient|levodopa-treated parkinson's disease (PD) patients
3225560|NCT01142739||Non Parkinson's disease controls|Non Parkinson's disease controls
3225561|NCT01142752||Control|Control group of women with uneventful pregnancy
3225562|NCT01142752||Population at risk with preterm birth|Women medically considered at risk for PTB and actually delivering preterm
3225563|NCT01142752||Population at risk without preterm birth|Women medically considered at risk for PTB but with uneventful pregnancy
3225564|NCT01142765|Experimental|Group 1|1 dose of AdCh63 MSP1 and 1 dose MVA MSP1 followed by sporozoite challenge
3225565|NCT01142765|Experimental|Group 2|1 dose of AdCh63 AMA1 and 1 dose MVA AMA1 followed by sporozoite challenge
3225566|NCT01142765|Experimental|Group 3|1 dose of AdCh63 AMA1 and 1 dose AdCh63 MSP1 co-administered into separate arms followed by 1 dose of MVA AMA1 and 1 dose MVA MSP1 co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
3225567|NCT01142765|Experimental|Group 4|1 dose of AdCh63 MSP1 and 1 dose AdCh63 ME-TRAP co-administered into separate arms followed by 1 dose of MVA MSP1 and 1 dose MVA ME-TRAP co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge
3225568|NCT01142765|Other|Group 5|Non-vaccinated controls for sporozoite challenge
3225569|NCT01142778|Experimental|Trastuzumab, Docetaxel, and Bevacizumab|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel along with bevacizumab in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the bevacizumab infusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3225570|NCT01142778|Active Comparator|Trastuzumab and Docetaxel|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of <70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3225571|NCT01142778|Active Comparator|Trastuzumab and Docetaxel (Standard Regimen)|Participants will receive 2 cycles of trastuzumab and docetaxel once every 3 weeks. Then, participants with a response of >/=70% will receive trastuzumab and docetaxel in Cycles 3 to 6. All participants will receive trastuzumab alone in Cycle 7, and will undergo surgery after Cycle 7 and between 4 and 6 weeks after the study treatment perfusion in Cycle 6. After surgery, all participants will receive a further 11 cycles of trastuzumab plus radiotherapy with or without hormonal therapy as per site's standard practice, and will be followed for up to 5 years from start of neoadjuvant treatment.
3225572|NCT01142804|Experimental|Enhanced Usual Care Group|Participants received weekly emailed tips of the week to provide support for walking.
3225573|NCT01142804|Experimental|WalkLink Group|Participants received weekly emailed tips of the week, plus evidence-based online fitness walking program.
3225574|NCT01142804|Experimental|WalkLink+ Group|Participants received weekly emailed tips, plus evidence-based online fitness walking program, plus online/in-person social network intervention.
3225575|NCT01142817||HIV Postive Women|Women living with HIV who meet study eligibility criteria
3225576|NCT01142817||Healthy Control Subjects|Women without HIV who meet study eligibility criteria
3225577|NCT01142882|Active Comparator|Traditional Prevention|educator-delivered, small-group HIV & disease prevention education
3225578|NCT01142882|Experimental|Web-based Prevention|self-directed, interactive & customized web-based HIV & disease prevention education
3225579|NCT01142921|Active Comparator|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
3225580|NCT01142921|Experimental|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
3225581|NCT01142934|Other|TegaDerm CHG|TegaDerm CHG is the interventional arm to be compared with the control group in which the dressing is TegaDerm (without CHG).
3225582|NCT01142960|Active Comparator|Placebo|Starch
3225583|NCT01142960|Experimental|Lycium Barbarum|Lycium Barbarum supplement
3225584|NCT01142986|Experimental|Low Threshold Stepped Care (LTSC)|Subjects in this condition will receive low intensity care during the first 3-months (13 weeks) of study participation, and usual counseling care during the final 3-months (13 weeks) of participation.
3225585|NCT01142986|Experimental|Voucher-Based Stepped Care (VBSC)|Subjects in this condition will receive usual counseling care during the entire 6 months of study participation. They will receive voucher reinforcement, and will have the opportunity to earn voucher incentives during the first 3-months of care (13 weeks).
3225586|NCT01142986|No Intervention|Routine Stepped-Care (RSC)|Subjects in this condition will receive usual counseling care during the entire 6-month study (26 weeks).
3225587|NCT01142999|Active Comparator|Intervention (moisturizer group)|One group will be instructed to use a choice of 3 FDA-approved moisturizers and soap substitutes on their newborn infants.
3225588|NCT01142999|Active Comparator|Control group (no moisturizers)|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
3225589|NCT01143012|Active Comparator|Group eczema education session|One group will attend a group eczema education session. All subjects will answer quality of life questions two times.
3225590|NCT01143012|Active Comparator|Control group|The other group will not attend the group eczema education session. Both groups will be asked quality of life questions two times.
3225591|NCT01143025|Active Comparator|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
3225592|NCT01143025|Experimental|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
3225593|NCT01143025|Experimental|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
3225594|NCT01143064|Active Comparator|Progesterone|
3225595|NCT01143064|Placebo Comparator|Lipid emulsion without progestrone|
3225596|NCT01143103|Experimental|Respiratory therapy with cough assist|
3225597|NCT01143103|Active Comparator|Usual respiratory therapy|
3225598|NCT01143129|Experimental|dexamethasone|Single dose of dexamethasone (1 mg/kg) at the start of the cardiac surgical procedure
3225599|NCT01143129|Placebo Comparator|Placebo|
3225600|NCT01143194|Experimental|oréVida™ 60mg/day|
3225601|NCT01143194|Experimental|oréVida™ 120mg/day (1)|
3225602|NCT01143194|Experimental|oréVida™ 120mg/day (2)|
3225603|NCT01143194|Placebo Comparator|Placebo|
3225604|NCT01143220||ICD / CRT-D patient|Patients implanted with a single or dual chamber ICD or CRT-D device approved in Japan capable of using the IBP feature.
3225605|NCT01143233|Active Comparator|control formula group|infants are fed a commercial, hydrolysed formula during the first 4 month of life, according to protocol
3225606|NCT01143233|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula with different protein content during the first 4 month of life, according to protocol
3225607|NCT01143233|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula with different protein content with pro- and prebiotics during the first 4 month of life, according to protocol
3225608|NCT01143233|Experimental|intervention formula 3 group|infants are fed hydrolyzed instant formula with different protein content with pro- and prebiotics during the first 4 months of life, according to protocol
3225609|NCT01143233|No Intervention|Reference group|infants are breast fed
3225610|NCT01143246|Experimental|Terlipressin|intravenous terlipressin (1 mg) every 6 hours with concomitant albumin
3225611|NCT01143246|Placebo Comparator|Placebo|lyophilized mannitol
3225612|NCT01143285|Experimental|I - Early and active nutritional support.|During the initial consultation, the dietician will answer the questions of the patient and their family. Patients will be seen regularly in follow-up for weight measurement, serum albumin assay, a 1 or 3 day food record and an evaluation of appetite level. Nutritional counselling is then adjusted accordingly and:Balanced meals are continued if weight is stable and appetite is undiminished.Protein and energy fortification is recommended if weight loss is observed or if food intake decreases between 2 consultations leading to total food intake of less than 50% of required food intake. When a patient presents with signs of malnutrition according to the criteria set out by the Authority for Health, oral nutritional support (ONS) is set up, in agreement with the department head. Two 200ml bottles of Fortimel Extra are to be taken every day. If this ONS strategy is insufficient to improve the patient's nutritional status, artificial nutrition should be discussed.
3225613|NCT01143285|No Intervention|II - No nutritional support|Should malnutrition develop in a group II patient, ONS will be ordered. It will consist of two 200ml Fortimel Extra* bottles per day in addition to regular meals. Ideally, the ONS should be taken as a snack outside of meal times so as to not spoil the appetite. If this ONS is insufficient to improve the nutritional status of the patient, artificial nutrition (either enteral or parenteral) will be discussed.
3225614|NCT01143298|Experimental|LEO 27847 oral solution 0.1 mg|LEO 27847 oral solution 0.1 mg
3225615|NCT01143298|Experimental|LEO 27847 tablet 0.10 mg|LEO 27847 tablet 0.10 mg
3225616|NCT01143298|Experimental|LEO 27847 tablet 0.01 mg|LEO 27847 tablet 0.01 mg
3225617|NCT01143311|Other|ARM A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
3225618|NCT01143350|Experimental|EHPAD Training and Stimulation|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
3225619|NCT01143350|Placebo Comparator|2- EHPAD control|EHPAD of the reference group, will have their habitual functioning
3225620|NCT01143363|Placebo Comparator|Resting - control|No exercise
3225621|NCT01143363|Experimental|Moderate intensity exercise|Moderate intensity exercise (continuous) 1h after breakfast
3225622|NCT01143363|Experimental|High intensity intermittent training|High intensity intermittent training 1h after breakfast
3225623|NCT01143363|Experimental|Short sprint|Short sprint 1h after breakfast
3225624|NCT01143376|Active Comparator|Moderate intensity exercise|Moderate intensity exercise
3225625|NCT01143376|Experimental|High Intensity training|High Intensity intermittent training
3225626|NCT01143376|Experimental|Short springs|short springs training
3225627|NCT01143441|Experimental|Cohort A|Long-Term daclizumab cohort
3225628|NCT01143441|Experimental|Cohort B|New Treatment Cohort
3225629|NCT01143441|No Intervention|Cohort C|MS Controls
3225643|NCT01143493||Carrier - Other|
3225644|NCT01143493||Carrier hGR N363S Heterozygote|
3225645|NCT01143493||Carrier hGR N363S Homozygote|
3225646|NCT01143493||Carrier hGR9B A3669G Heterozygote|
3225647|NCT01143493||Carrier hGR9B A3669G Homozygote|
3225648|NCT01143493||Control|
3225656|NCT01143545|Experimental|1|Allogeneic tumor cell vaccine + chemotherapy
3225657|NCT01143584|Experimental|Rapid escalation|Weekly escalation of cabergoline dose in macroprolactinomas Start with 1 mg/week. increase by 1mg/wk every week till 4 weeks. after 4 weeks Cabergoline dose would be increased @1mg/wk every 4 weekly till normalization of prolactin and >50% decrease in tumor volume from baseline.
3225658|NCT01143584|Active Comparator|Conventional escalation|"Conventional escalation of cabergoline~In the Conventional escalation group schedule of cabergoline dosing will be 0.5 mg once a week for 4 weeks. Cabergoline will be incrementally dose adjusted on the basis of individual Prolactin values till amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or till primary endpoint."
3225659|NCT01143597|Active Comparator|Somatosensory stimulation (SS)|Participants in the SS group receive median nerve electrical stimulation applied to the skin of the wrists.
3225660|NCT01143597|Active Comparator|Massed practice + somatosensory stimulation (MP+SS)|Participants in the MP+SS group receive a combined intervention consisting of SS and a skill-based exercise protocol
3225661|NCT01143597|Active Comparator|Conventional resistance training (CRT)|Participants in the CRT group will participate in a weight-based exercise program
3225662|NCT01143623|Active Comparator|Probiotic|
3225663|NCT01143623|Active Comparator|Probiotic-2|
3225664|NCT01143623|Placebo Comparator|Placebo|
3225665|NCT01143662|Experimental|Group 1|Ypeginterferon alfa-2b 90mcg per week
3225666|NCT01143662|Experimental|Group 2|Ypeginterferon alfa-2b 135mcg per week
3225667|NCT01143662|Experimental|Group 3|Ypeginterferon alfa-2b 180mcg per week
3225668|NCT01143662|Active Comparator|Group 4|Pegasys 180mcg per week
3225669|NCT01143740|Experimental|Single Arm|
3225670|NCT01143753|Experimental|RO5212054: Continuous Dosing Cohort|Participants will receive RO5212054 in escalating dose levels.
3225671|NCT01143753|Experimental|RO5212054: New Formulation (F05) Bridging Cohort|Participants will receive RO5212054 as a single dose of new formulation (F05-150 mg film-coated tablet with different ratios of ingredients than F03 to increase bioavailability) and a single dose of current clinical Formulation (F03-150 mg film-coated tablet) in a cross-over manner. Participants will be alternately assigned to receive either F05 or F03 as their first dose, followed by the opposite Formulation as their second dose. Dose of RO5212054 will be decided based on the results of continuous dosing cohort.
3225673|NCT01143805|Experimental|Treatment A: Tasocitinib 10 mg oral tablet|
3225674|NCT01143805|Experimental|Treatment B: Tasocitinib 10 mg IV Infusion|
3225675|NCT01143831|Experimental|All study participants|Three blood collections, one at baseline, one two weeks later, and the final blood collection 4 weeks from baseline, after taking Vitamin K orally for 14 days.
3225676|NCT01143844||Exposed females, ages 11-40|"Prior exposure to alkylating agent chemotherapy and/or radiation therapy~At least 1 year from completion of chemotherapy and/or radiation therapy~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition (other than cancer) known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3259021|NCT01466725|Experimental|Cohort 2|50 mg once daily for 4 weeks (8 active/2 control)
3259022|NCT01466725|Experimental|Cohort 3|100 mg daily for 6 weeks (8 active/2 control)
3259023|NCT01466725|Experimental|Cohort 4|100 mg twice daily for 6 weeks (8 active/2 control)
3225677|NCT01143844||Unexposed females, ages 40-50|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3225678|NCT01143844||Unexposed females, ages 11-35|"Never exposed to chemotherapy or radiation therapy~Regular menstrual cycle (every 21-35 days)~Uterus and at least one ovary are present~Not pregnant or breastfeeding in the past 3 months~Not taking any hormones or oral contraceptives for at least 4 weeks prior to study visits~No medical condition known to be associated with premature ovarian failure (such as Turner's Syndrome or Fragile X) or ovulatory dysfunction (such as thyroid disease, congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and polycystic ovary syndrome)."
3225679|NCT01143857|Active Comparator|Varenicline|
3225680|NCT01143857|Placebo Comparator|Placebo|
3225681|NCT01143909|Experimental|No FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to omitting transfusion of fresh frozen plasma before they undergo an intervention.
3225682|NCT01143909|No Intervention|FFP transfusion prior to intervention|Patients with a coagulopathy (INR 1,5-3,0), who are randomized to transfusion of fresh frozen plasma before they undergo an intervention. This is considered standard care.
3225683|NCT01143922||Patients with gastrointestinal tract malignancies|All patients with GI tract malignancies undergoing surgery will be subjected to intraoperative ultrasound
3225684|NCT01143935||Live patients|All patients undergoing CT scans of the abdomen for non hepatobiliary conditions
3225685|NCT01143935||Autopsy cases|All autopsy cases with no liver disease or trauma.
3225686|NCT01143948|Active Comparator|15 patient sliding scale regular insulin|
3225687|NCT01143948|Active Comparator|15 patient BBI NPH plus regular insulin|
3225688|NCT01143948|Active Comparator|15 patients BBI Glargine plus Glulisine|
3225689|NCT01143961|Experimental|NBL with one-way valve|NBL performed with one-way valve in ventilator circuit during procedure
3225690|NCT01143961|No Intervention|Standard NBL|Performance of standard NBL with recording of changes in regional ventilation by electrical impedance tomography
3225691|NCT01143974|Experimental|PC Regimen|
3225692|NCT01143987|Experimental|Cinacalcet|Oral cinacalcet
3225693|NCT01144000|Experimental|Daptomycin|High dose Daptomycin in hip, knee and shoulder prosthesis infections
3225694|NCT01144065||Patient with acute MI|Patients with acute MI ( elevated cardiac enzymes + chest pain or typical ECG changes)admitted to the cardiology department at Meir Medical Center
3225695|NCT01144065||Patient with prior cardiovascular disease and/or diabetes|These patients do not have acute coronary syndrome or stroke. Prior cardiovascular disease (CVD) is defined as a history of hospital admission due to acute coronary artery occlusion, percutaneous coronary interventions (PCI), coronary artery bypass grafting, any aortic or peripheral vascular disease that was either symptomatic or required intervention, ischemic or hemorrhagic stroke or transient ischemic attack.
3225696|NCT01144065||Patients without prior cardiovascular disease or diabetes|These patients do not have acute coronary syndrome or stroke Prior cardiovascular disease (CVD) or diabetes
3225697|NCT01144078|Experimental|High Intensity Interval Exercise|This arms receives the High Intensity Interval Exercise intervention
3225698|NCT01144078|Experimental|Traditional Intensity Exercise|This arms receives the Traditional Intensity Exercise intervention
3225699|NCT01144091|Experimental|pentoxyphylline cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
3225700|NCT01144091|Placebo Comparator|placebo cardio|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo coronary angiography
3225701|NCT01144091|Experimental|radiology pentoxyphylline|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
3225702|NCT01144091|Placebo Comparator|radiology placebo|Patients with chronic renal failure (CRF) and/or diabetes mellitus (DM) who are about to go to undergo computed tomography with contrast
3225703|NCT01144104|Experimental|Public Service Announcements|Demographically targeted public service announcement
3225704|NCT01144104|Experimental|Interactive Multi-Media Computer Program|Personally tailored information about seeking care for depression based on respondent characteristics
3225705|NCT01144104|Active Comparator|Attention Control Video|Two-minute video focusing on common sleep disorders.
3225706|NCT01144117|Experimental|Erythropoietin|Erythropoietin treated patients contra placebo.
3225707|NCT01144169|Experimental|Hydroxychloroquine (HC)|HC orally for 14 days prior to nephrectomy
3225708|NCT01144221|Experimental|Stem cell treatment|Patients treated via stem cell injection
3225709|NCT01144234|Experimental|Invitation letter to male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
3225710|NCT01144234|Placebo Comparator|Information letter|In this arm the pregnant women got an information letter about antenatal care.
3225711|NCT01144247|Experimental|alloreactive CTL arm|
3225712|NCT01144260|Experimental|Bafetinib|
3225713|NCT01144273|Active Comparator|0.5% Ropivacaine|group receiving TAP block (0.5% ropivacaine at TAP plane)
3225714|NCT01144273|Placebo Comparator|normal saline|group receiving placebo (saline) at TAP plane
3225715|NCT01144312|Experimental|pharmacokinetics of fentanyl|
3225716|NCT01144351|Experimental|ELND002|ELND002 sc injection
3225717|NCT01144351|Placebo Comparator|Placebo|placebo injection
3225718|NCT01144390|Experimental|CBT plus MMT|cognitive behavioral therapy for heroin addicts with methadone maintenance treatment
3259024|NCT01466738|Experimental|HRV-16 (100 TCID50)|
3225719|NCT01144390|Active Comparator|methadone maintenance treatment|methadone maintenance treatment for heroin addicts
3225720|NCT01144429|Active Comparator|100 DPP/mL|Concentration of solution fo s.c. injection: 100 DPP/mL
3225721|NCT01144429|Active Comparator|1000 DPP/mL|Concentration of solution fo s.c. injection: 1000 DPP/mL
3225722|NCT01144429|Active Comparator|5000 DPP/mL|Concentration of solution fo s.c. injection: 5000 DPP/mL
3225723|NCT01144429|Active Comparator|10000 DPP/mL|Concentration of solution fo s.c. injection: 10000 DPP/mL
3225724|NCT01144468||MAP3 Participants|study participants in the MAP.3 study are randomly assigned to either placebo or 25 mg exemestane daily for 5 years. Allocation is blinded. We are following 354 of these study participants and are blinded to treatment allocation.
3225725|NCT01144481||breast cancer with metastasis|female breast cancer patients with metastases to any site
3225726|NCT01144507||Group A|Approximately 60 subjects with a heterogeneous echo pattern of the liver on abdominal ultrasound (HTG US).
3225727|NCT01144507||Group B|Approximately 680 subjects with a normal echo pattern on abdominal ultrasound (NL US). Of these subjects, approximately 110 will be matched 1:1 with Group A participants and followed for the duration of the study. The remaining unmatched subjects will not be followed beyond their initial visit.
3225728|NCT01144507||Group C|An estimated 30 subjects with cirrhosis pattern on abdominal ultrasound. These subjects will be followed in the study.
3225729|NCT01144507||Group D|An estimated 30 subjects with diffusely homogeneous echogenic pattern at screening ultrasound will be followed in the study.
3225730|NCT01144533|Placebo Comparator|Isotonic saline|
3225731|NCT01144533|Experimental|Steroid|
3225732|NCT01144533|Experimental|Hyaluronate|
3225733|NCT01144533|Experimental|Steroid + Hyaluronate|
3225734|NCT01144546|Experimental|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before anesthesia induction
3225735|NCT01144559|Active Comparator|Continuous Infusion|Each subject will have one lower extremity (Right or Left) randomized to receive a perineural catheter with a continuous infusion of local anesthetic and then the outcomes will be measured.
3225736|NCT01144559|Active Comparator|Bolus Administration|The opposite lower extremity (right or left) will be randomized to receive a perineural catheter with the local anesthetic being delivered via a bolus as opposed to continuous as is the case with their other extremity. The outcome measures will then be assessed as described.
3225737|NCT01144572||1|Chinese postmenopausal HR(+) EBC patients during adjuvant Aromatase Inhibitors(AIs) treatment
3225738|NCT01144585|Experimental|RIPC|those who receive RIPC and RIPoC before and after CPB
3225739|NCT01144585|Placebo Comparator|Control|this group have same pneumatic cuff around their arm, but it is not inflated.
3225740|NCT01144611|Active Comparator|bIAP|intravenous as a bolus of bIAP (alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
3225741|NCT01144611|Placebo Comparator|placebo|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
3225742|NCT01144650|Placebo Comparator|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
3225743|NCT01144650|Experimental|Dapsone|Patients will receive either a single total dose of 250 mg IV and oral dosage
3225744|NCT01144676|Experimental|Group A1: Dapivirine Vaginal Ring|
3225745|NCT01144676|Placebo Comparator|Group A2: Placebo Vaginal Ring|
3225746|NCT01144676|Experimental|Group B1: Dapivirine Vaginal Ring|
3225747|NCT01144676|Placebo Comparator|Group B2: Placebo Vaginal Ring|
3225748|NCT01144689|Experimental|Mindfulness Training|
3225749|NCT01144689|Active Comparator|Smoking Cessation Therapy|
3225750|NCT01144702|Experimental|artesunate & mefloquine combination|ASMQ will be administered to individuals with uncomplicated malaria by P. falciparum according to the dose regimen for age and weight, standardized (Farmanguinhos, Ministry of Health). For patients in the range of 5 to <18kg (6 months to 5 years old), will be offered treatment in the pediatric presentation of Artesunate+Mefloquine 25 +50 mg (5 to <9 kg = 1 tablet once daily for 3 days, 9 to <18 kg = 2 tablets once daily for 3 days). To study subject aged 18 or more kilos (six years or more years old) will be given the combination of Artesunate + Mefloquine presentation ASMQ 100 +200 mg (18 to 29 kg = 1 tablet once daily for 3 days, 30 kg or more = 2 tablets once daily for 3 days). Clinically and biochemically monitoring will be done for 42 days.
3225751|NCT01144728|Experimental|Single arm Glimepiride+metformin|Start and titration based on FBG and tolerance. Titration should be achieved within maximum 4 weeks.
3259025|NCT01466738|Experimental|HRV-16 (1000 TCID50)|
3259026|NCT01466777|Active Comparator|traditional laparoscopic surgery type|
3259027|NCT01466777|Experimental|Robotic assisted operation type|
3225752|NCT01144741||Freeman-Sheldon syndrome Classic Type|"Patients who have all features required by the Stevenson criteria, including: very small mouth (microstomia); whistling-face appearance (pursed lips); H or V shaped chin dimple; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping."
3225753|NCT01144741||Freeman-Sheldon syndrome Craniofacial Type|"Patients who have only the face and skull physical findings required by the Stevenson criteria, including: very small mouth (microstomia), whistling-face appearance (pursed lips), H or V shaped chin dimple, very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases)."
3225754|NCT01144741||Freeman-Sheldon syndrome Mixed Type|Patients who have the face and skull physical findings required by the Stevenson criteria and some but not all required joint problems.
3225755|NCT01144741||Sheldon-Hall syndrome|Patients who have all features required by the Stevenson criteria, including: small mouth (not microstomia); neck webbing (pterygium colli); small but prominent chin; very obvious down-slanting crease from the nostril to the corners of the mouth (nasolabial creases); and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3225756|NCT01144741||Distal Arthrogryposis Type 1|Patients with features consistent with this diagnosis, including restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3225757|NCT01144741||Distal Arthrogryposis Type 3|Patients with features consistent with this diagnosis, including: gap in the roof of the mouth (cleft palate); drooping eyelid (blepharoptosis); and backbones curve problems; and restricted movement in joints (contractures) of two or more body areas, often hands and feet, with fingers and toes frequently overlapping.
3225758|NCT01144767|Experimental|Computer-generated advisor|Participants receive sessions with a computer-generated adviser who will provide tailored advice and encouragement to engage in physical activity.
3225759|NCT01144767|Active Comparator|Comparison control condition|Participants will receive live, group sessions on health topics unrelated to physical activity.
3225760|NCT01144806|Active Comparator|Group 1|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
3225761|NCT01144806|Active Comparator|Group 2|Ready to use therapeutic food (RUTF / PlumpyNut)will be provided to parent/care givers of children with severe malnutrition in enrolled in this group
3225762|NCT01144819||STEMI|Patients with STEMI according to ESC STEMI guidelines: Age above 18 years and able to give written, informed consent to participation in the project.
3225763|NCT01144832|Placebo Comparator|placebo capsule|
3225764|NCT01144832|Active Comparator|ebastine|
3225765|NCT01144845||Thoracic surgical patients|Patients with pulmonary malignancies
3225766|NCT01144858||patients with persistent atrial fibrillation ablation|
3225767|NCT01144871||Male Parent/Guardians|Male Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
3225768|NCT01144871||Female Parent/Guardian|Female Parent/Guardian of Adolescent 12-17 yo. Health care members of either San Francisco General Hospital or Kaiser Permanente Northern California.
3225769|NCT01144884|Other|Single arm trial|"Education:To standardize, treatment education will consist of counsel to stay active. Details will be given to subjects verbally & reinforced in the home booklet.~Posture:Facilitation of proper posture has been show to increase recruitment of the lumbar multifidus & deep neck flexors. Instruction will be given verbally & in writing.~Stretching:Stretching exercises will be targeted to address these common impairments. Patients will be introduced to proper stretching procedures. Each stretch will be held for 30s & repeated two times,each side as applicable. The following stretches will be performed:~Upper trap Anterior/medial Scalene Suboccipital Pectoralis~Muscular Performance: Muscle performance will be trained incorporating components of strength, endurance and motor control. Each of the exercises listed below are outlined based on progressions.~Isometric Cervical Extension Craniocervical flexion Seated Row Seated T Palms Up Seated Side Arm Raises"
3225770|NCT01144897|Experimental|PET Acetate Imaging with Docetaxel|"PET-acetate as an intermediate endpoint in the assessment of response of patients undergoing docetaxel for hormone refractory prostate cancer (HRPC).~Subjects will be treated with docetaxel, 75 mg/m2 every 21 days until disease progression or unacceptable toxicity occurs. Subjects will have two PET acetate scans - one prior to beginning chemotherapy and one approximately 8-9 weeks after chemotherapy has begun."
3225771|NCT01144910||BHR non-atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
3225772|NCT01144910||BHR atopy|Patients from the outpatient Department of Allergy, Pneumology and Cystic fibrosis, children's hospital, Goethe-University, Frankfurt, Germany. Over a time-span of 5 years the investigators will explore the lung function and the bronchial hyperresponsiveness. Bronchial methacholine challenges will be performed at baseline and after 1, 3 and 5 years.
3225773|NCT01144923|Active Comparator|Conservative treatment|Pharmacotherapy with nortriptyline and/ or gabapentin, physical therapy (e.g. range of motion, therapeutic massage, strengthening exercises), and possibly others (e.g. acupuncture)
3225774|NCT01144923|Experimental|Epidural Steroids|A series of up to 3 epidural steroid injections (ESI)with depo-methylprednisolone
3225775|NCT01144923|Experimental|Combination Treatment|These patients will receive both treatments. They can have up to 3 epidural steroid injections (ESI) with depo-methylprednisolone, and conservative treatment (i.e. pharmacotherapy with nortriptyline and/ or gabapentin, and physical therapy)
3225776|NCT01144936|Experimental|Panel 1: VX-985 Dose 1|
3225777|NCT01144936|Experimental|Panel 2: VX-985 Dose 2|
3225778|NCT01144936|Experimental|Panel 3: VX-985 Dose 3|
3225779|NCT01144962|Sham Comparator|Control group|Patients in the control group will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
3225780|NCT01144962|Active Comparator|Cohort 1|10x10^6 MSC
3225781|NCT01144962|Active Comparator|Cohort 2|30x10^6 MSC
3225782|NCT01144962|Active Comparator|Cohort 3|90x10^6 MSC
3225783|NCT01144975|Active Comparator|XOMA 052|
3225784|NCT01144975|Placebo Comparator|Placebo|
3225785|NCT01145014|Experimental|BI 660848 2 mg|oral drinking solution
3225786|NCT01145014|Experimental|BI 660848 10 mg|oral drinking solution
3225787|NCT01145014|Experimental|BI 660848 20 mg|oral drinking solution
3225788|NCT01145014|Experimental|BI 660848 50 mg|oral drinking solution
3225789|NCT01145014|Experimental|BI 660848 100 mg|oral drinking solution
3225790|NCT01145014|Experimental|BI 660848 150 mg|oral drinking solution
3225791|NCT01145014|Experimental|BI 660848 200 mg|oral drinking solution
3225792|NCT01145014|Experimental|BI 660848 400 mg|oral drinking solution
3225793|NCT01145014|Experimental|BI 660848 600 mg|oral drinking solution
3225794|NCT01145014|Experimental|BI 660848 10,0 mg|immediate release tablet
3225795|NCT01145014|Experimental|BI 660848 50,0 mg|immediate release tablet
3225796|NCT01145014|Experimental|Placebo|matching placebo (oral drinking solution and IR tablets)
3225797|NCT01145027|No Intervention|Control group|
3225798|NCT01145027|Experimental|Sensorial Stimulus|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste, in order to trigger the cephalic phase of insulin secretion
3225799|NCT01145040||Partition 1|Overt primary hypothyroidism
3225800|NCT01145040||Partition 2|"Hypothyroidism with full dose levothyroxine substitution therapy (more than 1.75 µg per kg of body mass)"
3225801|NCT01145040||Partition 3|Overt primary hyperthyroidism
3225802|NCT01145079|Experimental|Endeavor arm|
3225803|NCT01145079|Active Comparator|Endeavor resolute arm|
3225804|NCT01145079|Active Comparator|Xience arm|
3225805|NCT01145079|Active Comparator|Cypher arm|
3225806|NCT01145131|Experimental|Beef steak|
3225807|NCT01145131|Experimental|Minced beef|
3225808|NCT01145144|Experimental|DHEA supplementation|DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
3225809|NCT01145144|No Intervention|only induction of ovulation by same long protocol without DHEA|
3225810|NCT01145157|Experimental|Signature Knee Guide|Total Knee Arthroplasty using the Signature Knee Guide with the Vanguard Knee System
3225811|NCT01145157|Active Comparator|Conventional Instrumentation|Total Knee Arthroplasty will be performed using Conventional Instrumentation with the Vanguard Knee System
3225812|NCT01145157|Active Comparator|Computer Assisted Navigation|Total Knee Arthroplasty will be performed using Computer Assisted Navigation with the Vanguard Knee System
3225813|NCT01145170|Experimental|Nimotuzumab|The study consists of a single treatment group, which will receive the first-line therapy for the disease. The therapy is the standard radiotherapy and a dose of the investigational product (nimotuzumab) at 150 mg/m2.
3225816|NCT01145235||Females previously treated with Macrolane in their breasts.|
3225817|NCT01145248|Experimental|Malignant biliary disease|
3225818|NCT01145248|Experimental|Benign biliary disease|
3225819|NCT01145261||Anxiety|Children with anxiety disorders
3225820|NCT01145261||healthy controls|children without anxiety disorders
3225821|NCT01145313||Patients diagnosed with Major Depressive Disorder|Patients diagnosed with MDD who are treated with antidepressants and subsequently augment with atypical antipsychotic therapy.
3225822|NCT01145326|Sham Comparator|Control|Sham-Functional microneedles (no actual microneedles) application, prior to 4% lidocaine gel (LG4) placement.
3225823|NCT01145326|Experimental|Microneedle|Functional microarray (FMA) (microneedles) application, prior to 4% lidocaine gel (LG4) placement.
3225824|NCT01145339|Experimental|Lactase EUF|1 chewable tablet of the test drug 30 minutes before the standard lactose dose (25 g).
3225825|NCT01145339|Active Comparator|Lactase Ref|1 chewable tablet of the comparative drug 30 minutes before the standard lactose dose (25 g).
3225826|NCT01145365|Active Comparator|Combination Therapy Group|Patients in this arm will have surgically established drainage of their Crohns perianal fistulas and/or abscesses (exam under anesthesia (EUA)) done BEFORE beginning medical therapy with Cimzia.
3225827|NCT01145365|No Intervention|Control Group|Patients in this group will begin medical therapy with Cimzia regardless of status of surgically established drainage.
3225828|NCT01145404|Experimental|Arm A: Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
3225829|NCT01145404|Experimental|Arm B|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
3225830|NCT01145430|Experimental|Treatment (veliparib and liposomal doxorubicin hydrochloride)|Patients receive veliparib PO BID on days 1-14 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3225831|NCT01145443||Continuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when a single intensivist was the sole attending physician of record for intervals of 2 weeks (or 1/2 month).
3225832|NCT01145443||Discontinuous intensivist staffing model|These are the patients admitted to participating Intensive Care Units during the 3 month phases of the study when, for intervals of 2 weeks (or 1/2 month), there was a single intensivist who was the primary attending of record during Mondays-Fridays, but cross-covering colleagues took over that role during the weekends.
3225833|NCT01145456|Experimental|Treatment (RO4929097 and gemcitabine hydrochloride)|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, 15-17, and 22-24 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3225834|NCT01145534|Active Comparator|Glibenclamide|Patients used 5 mg glibenclamide daily for 60 days
3225835|NCT01145534|Experimental|Experimental|Patients ingested the infusion of Cissus verticillata L. prepared as 1 g in 150 mL of hot water for 10 min. This was done daily for 60 days
3225836|NCT01145573|Placebo Comparator|Placebo|Inactive pill taken daily
3225837|NCT01145573|Active Comparator|Calcium|1000mg of calcium taken daily
3225838|NCT01145586|Experimental|Lactase EUF|1 oral tablet of the test drug before breakfast, lunch and dinner for 42 consecutive days
3225839|NCT01145586|Active Comparator|Lactase Ref|1 oral tablet of the comparative drug before breakfast, lunch and dinner for 42 consecutive days
3225840|NCT01145599||Type-2 diabetes, NPDR|Type-2 diabetic patients with NPDR.
3225841|NCT01145612|Experimental|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
3225842|NCT01145612|Experimental|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
3225843|NCT01145664|Active Comparator|Western therapy|
3225844|NCT01145664|Experimental|Herbal concentrate-granules plus western therapy|
3225845|NCT01145664|Experimental|Reduning Injection plus western therapy|
3225846|NCT01145677|Experimental|Topiramate|
3225847|NCT01145690||Internet-based CBT|All participants in this cohort received Internet-based CBT for social anxiety disorder in 2005. All participants were Swedish adults with a DSM-IV diagnosis of social anxiety disorder.
3225848|NCT01145703|Active Comparator|RDA Vitamin D|
3225849|NCT01145703|Experimental|Vit D repletion + 6M Supplementation|
3225850|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +AEX|
3225851|NCT01145703|Experimental|Vit D repletion + 6M Supplementation +RT|
3225852|NCT01145716|Other|Surgical exploration|Descriptive
3225853|NCT01145729|Active Comparator|Biomarker feedback|Biomarkers of tobacco exposure (laboratory values) delivered to health care provider
3225854|NCT01145729|Placebo Comparator|Usual care (general counseling)|Brochure about pesticides, lead, SHS
3225855|NCT01145742|Experimental|self-management support and BP telemonitoring|collaborative intervention involving home BP monitoring, home behavior change counseling to enhance self management, and intensification of treatment by primary care doctors
3225856|NCT01145742|No Intervention|usual care|usual primary care management of BP. lipids, and glucose
3225857|NCT01145768|Experimental|1|Each cohort will have 9 volunteers that will receive TC-5214
3225858|NCT01145768|Placebo Comparator|2|Each cohort will have 3 volunteers that will receive placebo
3225859|NCT01145781|Active Comparator|Single-freeze cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw.
3225860|NCT01145781|Active Comparator|Double-freeze cryotherapy|Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
3225861|NCT01145807|Placebo Comparator|Placebo|non Transfersome® placebo
3225862|NCT01145807|Sham Comparator|Transfersome® vehicle|Transfersome® vehicle
3225863|NCT01145807|Experimental|TDT 067|TDT 067
3225864|NCT01145820|Experimental|Juice Plus|
3225865|NCT01145820|Placebo Comparator|Placebo|
3225866|NCT01145846|Experimental|Arm I (AI regimen)|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Idarubicin 12 mg/m2/day iv daily for 3 days (D 1-3)
3225867|NCT01145859|Experimental|Arm 1|
3225868|NCT01145872|Experimental|Mindfulness Based Cognitive Therapy|
3225869|NCT01145872|Active Comparator|Health Enhancement Program|
3225870|NCT01145911||Glaucoma patients|Glaucoma patients
3225871|NCT01145924|Active Comparator|EBUS TBNF|single arm trial, patients with enlarged mediastinal nodes will be examine
3225872|NCT01145937|Experimental|PET|"Partial endothelial trepanation in addition to anterior lamellar keratoplasty.~The endothelium en Descemet are paracentrally and circular loosened, but some tissue bridges are left in place. This 'island' is able to mould to the healthy donor curvature."
3225873|NCT01145937|Active Comparator|DALK|Conventional DALK grafting procedure where the Big Bubble technique is used according to Anwar et al.
3225874|NCT01145950|Experimental|Group 1|
3225875|NCT01145950|Experimental|Group 2|
3225876|NCT01145963|Experimental|experimental pasta B|Past B
3225877|NCT01145963|Experimental|experimental pasta C|Pasta C
3225878|NCT01145963|Placebo Comparator|Control pasta|Control
3225879|NCT01145976|Active Comparator|CY-ATG(Arm1)|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
3225880|NCT01145976|Experimental|Flu-ATG(Arm2)|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
3225881|NCT01145989|Experimental|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
3225882|NCT01146002|Other|Guanfacine treated.|Single arm - all patients treated with study drug. Comparison is against pre-treatment performance.
3225883|NCT01146015|Experimental|1|
3225884|NCT01146028|Experimental|Tizanidine HCl 4 mg|Tizanidine HCl Tablets 4 mg, Dr.Reddy's Laboratories Limited
3225885|NCT01146028|Active Comparator|Zanaflex|Zanaflex 4 mg Tablets
3225886|NCT01146041|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
3225887|NCT01146041|Active Comparator|exelon|Exelon 1.5 mg capsules of Novartis
3225888|NCT01146067|Experimental|Rivastigmine|Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited
3225889|NCT01146067|Active Comparator|Exelon|Exelon 1.5 mg capsules of Novartis
3225890|NCT01146080|Experimental|Promus Element|21 consecutive patients with Promus Element implanted to treat coronary artery lesion
3225891|NCT01146080|Active Comparator|Promus|21 consecutive patients with Promus stent implanted to treat coronary artery lesions
3225892|NCT01146093|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
3225893|NCT01146093|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
3225894|NCT01146106|Experimental|Pravastatin Sodium Tablets 80 mg|Dr.Reddy's Laboratories Limited
3225895|NCT01146106|Active Comparator|Pravachol 80 mg Tablets|Bristol Myers Squibb
3225896|NCT01146119|Experimental|Multimeric-001, Adjuvanted|64 subjects received 2 injections of Adjuvanted Multimeric-001, 500 mcg with an interval of 21 days and then 60 days later were further immunized with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
3225897|NCT01146119|Active Comparator|PBS and TIV 15%|32 subjects received 2 injections of PBS (Phosphate Buffered Saline) with an interval of 21 days and then were further immunized 60 days later with a 15% dose of commercial seasonal trivalent vaccine (season 2011).
3225898|NCT01146119|Placebo Comparator|Placebo, Adjuvanted|32 subjects received Adjuvanted PBS (Placebo) with an interval of 21 days.
3225899|NCT01146119|Experimental|Co-administration M-001 and TIV 15%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 15%.
3225900|NCT01146119|Experimental|Co administration of M-001 and TIV 50%|24 subjects received 2 injections on the same day, one injection containing Adjuvanted Multimeric-001 500 mcg and the other containing TIV 50%.
3225901|NCT01146119|Active Comparator|Co administration of PBS and TIV 50%|24 subjects received 2 injections on the same day, one injection containing PBS and the other containing TIV 50%.
3225902|NCT01146132|Other|Luxembourg diet + wine|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
3225903|NCT01146132|Other|conventional + wine|conventional Diet with red wine
3225904|NCT01146132|Other|conventional|conventional diet without wine
3225905|NCT01146132|Other|Luxembourg diet|Luxembourg variant of the mediterranean Diet, physical activity with wine consumption
3225906|NCT01146145|Experimental|treatment|intravenous morphine titration combined to ketamine
3225907|NCT01146145|Placebo Comparator|placebo|morphine titration alone
3225908|NCT01146158|Experimental|surgery Axillary dissection|surgery Axillary dissection
3225909|NCT01146171|Experimental|BMS-844203 (CT-322)|
3225910|NCT01146184|Experimental|Single-Incision Cholecystectomy|Extracting the gallbladder laparoscopically is made difficult through a single incision.
3225911|NCT01146197|Experimental|Amiloride, Indometacin, Eplerenone|Amiloride, indometacin(+Omeprazole), Eplerenone
3225912|NCT01146197|Experimental|Amiloride, Eplerenone, indometacin|Amiloride, Eplerenone, indometacin (+Omeprazole)
3225913|NCT01146197|Experimental|Eplerenone, Amiloride, indometacin|Eplerenone, Amiloride, indometacin (+Omeprazole)
3225914|NCT01146197|Experimental|Eplerenone, Indometacin, Amiloride|Eplerenone, Indometacin, Amiloride
3225915|NCT01146197|Experimental|Indometacin, Eplerenone, Amiloride|Indometacin, Eplerenone, Amiloride
3225916|NCT01146197|Experimental|Indometacin, Amiloride, Eplerenone|Indometacin, Amiloride, Eplerenone
3225917|NCT01146210||Ancillary-correlative|Previously collected cryopreserved cells are analyzed via western blot to identify patients with Fanconi anemia.
3225918|NCT01146223||Basic science (correlative studies)|Patient mRNA samples from diagnosis are analyzed via quantitative PCR to measure WT1 and VEGF-1 expression.
3225919|NCT01146236|Active Comparator|Sutures|Orthopedic surgical wound closed with sutures
3225920|NCT01146236|Active Comparator|Staples|Orthopedic surgical wound closed with metallic staples
3225921|NCT01146249||1: healthy subject|
3225922|NCT01146249||3: post stroke patients|
3225923|NCT01146249||2: vestibular patients|Vestibular patients with a unique history of peripheric vestibular disorder
3225924|NCT01146249||4: ataxic patients|Patient with proprioception disorder related to peripheral neuropathy
3225925|NCT01146249||5: Old fallers|Old subjects with a history of falls (one or more during the last year)
3225926|NCT01146301|Active Comparator|300 mg Loading dose clopidogrel|
3225927|NCT01146301|Experimental|600 mg Loading dose of clopidogrel|
3225928|NCT01146314|Experimental|Lifestyle intervention|A 6-month 14 session lifestyle intervention led by a psychologist and a dietitian for 90 minutes group sessions. Intervention sessions were help weekly, biweekly, and monthly over the course of 6 months.
3225929|NCT01146327|Experimental|PF-04620110|
3225930|NCT01146327|Placebo Comparator|Placebo Comparator|
3225931|NCT01146340|Experimental|SBRT|SBRT 40 Gy in 5 fractions over 29 days delivered using step and shoot IGRT
3225932|NCT01146353||CRRT Patients receiving Peramivir|"Eligible patients are male or female patients ≥18 years of age who are hospitalized, undergoing CVVH or CVVHD, and receiving peramivir.~Eligible patients will additionally have the following: blood flow rate will be required to be ≥100 mL/ min with an ultrafiltrate +/- dialysis flow rate greater than or equal to 3000mL/hr, and the continuous renal replacement therapy must be scheduled to run for the full duration of the dosing interval (full 24 hours).~Written informed consent in a form approved by the Northwestern University and the Midwestern University Institutional Review Boards will be granted by the patient."
3225933|NCT01146392||1|Primary care patients with COPD diagnosis
3225934|NCT01146431||Hemodynamic parameters|Hemodynamic parameters will be used as a guide for anesthesia.
3225935|NCT01146431||BIS|Bispectral Index (BIS) will be used as a guide for anesthesia.
3225936|NCT01146444|Experimental|sunscreens with a low, medium, high SPF|sunscreens with a low, medium, and high SPF. UVA and UVB irradiation
3225937|NCT01146444|Experimental|vehicle|Intra-individual application of vehicle in random order; UVA and UVB irradiation
3225938|NCT01146470|Experimental|RGC 200 mg|
3225939|NCT01146470|Experimental|RGC 400 mg|
3225940|NCT01146470|Placebo Comparator|Placebo|
3225941|NCT01146483|Active Comparator|Pantoprazole|two-arm study: 2-period, 2-sequence, cross-over study.Volunteers will be administered either sequence 1 or sequence 2 randomly.
3225942|NCT01146483|Placebo Comparator|Placebo|
3225943|NCT01146509|Experimental|1|
3225944|NCT01146522|Experimental|LCQ908|
3225945|NCT01146522|Placebo Comparator|Placebo|
3225946|NCT01146535|Experimental|Interferon-alpha|"Interferon-alpha~150 IU lozenges bid for 5 days"
3225947|NCT01146535|Placebo Comparator|maltose|"maltose~200 mg maltose lozenges bid for 5 days"
3225948|NCT01146548|Experimental|the fluoxetine group|Multiple System Atrophy's patients with fluoxétine
3225949|NCT01146548|Placebo Comparator|the placebo group|Multiple System Atrophy's patients with placebo
3225950|NCT01146574|Experimental|0.1mg/kg Sotatercept|Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio
3225951|NCT01146574|Experimental|0.3mg/kg Sotatercept|Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days
3225952|NCT01146574|Experimental|0.5mg/kg Sotatercept|Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days
3225953|NCT01146574|Experimental|0.7mg/kg Sotatercept|Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days
3225954|NCT01146574|Placebo Comparator|Placebo|The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.
3225955|NCT01146587|Experimental|GangTrainer GT1|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
3225956|NCT01146587|Experimental|Lokomat|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
3225957|NCT01146587|Active Comparator|Conventional Physiotherapy|First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
3225958|NCT01146626|Active Comparator|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
3225959|NCT01146626|Experimental|Peg+ Ribavirine|Peg+ Ribavirine
3225960|NCT01146639|Experimental|MDCT and additional DynaCT|
3225961|NCT01146652|Experimental|Extension study|Sarilumab (SAR153191), Disease Modifying Anti-Rheumatic Drug (DMARD) therapy as required in the initial protocol.
3225962|NCT01146678|Experimental|Lantus(insulin glargine)/lixisenatide on-site mix|Single dose injection of an on site mix of Lantus U100 and lixisenatide (800µg/mL in Lantus U100) at one peri-umbilical site under fasting conditions
3225963|NCT01146678|Active Comparator|lixisenatide + Lantus (insulin glargine)|Single dose, separate injection simultaneous injections of Lantus U100 and lixisenatide (100µg/mL) at opposite peri-umbilical sites within 1 minute under fasting conditions
3225964|NCT01146691||Standard staffing model|All patients in participating ICUs during the blocks of time when a single intensivist staffs a participating ICU for a 7 day period. The intensivist will be present during daytime hours, and takes call from home afterwards.
3225965|NCT01146691||24-7 shiftwork staffing model|All patients in participating ICUs during the blocks of time when the 24-7 in-hospital intensivist coverage model is in place. This model is enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am. Call rooms will be provided to allow the night shift intensivist to sleep, if the workload permits.
3225966|NCT01146717|Experimental|Exercise|
3225967|NCT01146717|Placebo Comparator|Control group|
3225968|NCT01146730|Experimental|Workcoping and IPS|CBT based counseling and supported employment
3225969|NCT01146730|Active Comparator|Ordinary care by GP or NAV|Ordinary care by GP or The Norwegian Labour and Welfare Administration (NAV)
3225970|NCT01146743|Active Comparator|EUS-guided|EUS-guided gallbladder drainage in acute cholecystitis with high risk patients
3225971|NCT01146743|Active Comparator|percutaneous transhepatic|percutaneous transhepatic gallbladder drainage in acute cholecystitis with high risk patients
3225972|NCT01146756|Experimental|AZD6244 & Thoracic Radiotherapy|AZD6244 in combination with thoracic radiotherapy (RT)- the aim is to determine the recommended phase II dose (RP2D).
3225973|NCT01146769|Experimental|Pelvic floor exercise|
3225974|NCT01146769|No Intervention|Control|
3225975|NCT01146821|No Intervention|Standard care|Standard care
3225976|NCT01146821|Active Comparator|standard care + 0.20gm/kg fish oil|standard care + 0.20gm/kg fish oil
3225977|NCT01146821|Active Comparator|standard care + 0.50 gm/kg fish oil|standard care + 0.50 gm/kg fish oil
3225978|NCT01146847|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish tight glycaemic control
3225979|NCT01146886|Experimental|BI 135585|1 single dose per subject as oral solution in Part 1, or 3 single doses per subject as oral solution and 2 different tablet formulations in Part 2
3225980|NCT01146886|Placebo Comparator|Placebo to BI 135585|1 single dose per subject as oral solution in Part 1
3225981|NCT01146899|Experimental|Provider Alert|Provider receives alert for patient visit
3225982|NCT01146899|No Intervention|No Alert|No alert provided
3225983|NCT01146925|Experimental|CRMD-001-Deferiprone|
3225984|NCT01146925|Placebo Comparator|Placebo|
3225985|NCT01146938|Experimental|hepatic impairment patients|Hepatic impairment patients group Child-Pugh score A or Child-Pugh score B (not Child-Pugh score C)
3225986|NCT01146938|Active Comparator|Healthy volunteers|healthy volunteers group
3225987|NCT01146964|Experimental|Phacoemulsification, Safety, Efficacy|
3225988|NCT01146964|Experimental|MSSICS, Safety, Efficacy|
3225989|NCT01146977|Experimental|Autologous HCT|"5.1.3. After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~5.1.3.1. If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
3225990|NCT01146977|Active Comparator|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
3225991|NCT01146990||Infants Born to Mothers in the 17P-ES-003 Study|Infants Born to Mothers Who Participated in the 17P-ES-003 Study and whose mothers consented for them to be followed for this study.
3225992|NCT01147003|Experimental|BGG492 low dose|
3225993|NCT01147003|Placebo Comparator|Placebo|
3225994|NCT01147003|Experimental|BGG492 high dose|
3225995|NCT01147016|Experimental|HER2Bi-armed activated T cells + Neoadjuvant Chemotherapy|"HER2Bi-armed activated T cells - Total of 4 of the T cell infusions IV over a period of 1 month~Cyclophosphamide, doxorubicin hydrochloride, paclitaxel -As prescribed by physician, standard of care."
3225996|NCT01147081|Experimental|Arm 1|
3225997|NCT01147120|Active Comparator|Progressive Muscle Relaxation|
3225998|NCT01147120|Active Comparator|Clinical Massage Therapy|
3225999|NCT01147133|Experimental|Original|Treatment phase with the original formulation of clopidogrel
3226000|NCT01147133|Active Comparator|Generic|Treatment phase with the generic clopidogrel
3226001|NCT01147159|Other|Skin Prick Test|
3226002|NCT01147185|Other|Intensive training|Locomotor training using a robotic device of at least 50 minutes
3226003|NCT01147185|Active Comparator|Standard training|Locomotor training using a robotic device of maximally 25 minutes
3226004|NCT01147198|Active Comparator|Ready to Use Supplementary Food|Ready to Use Supplementary Food treatment
3226005|NCT01147198|Active Comparator|Premix|Premix Corn Soy Blend-oil treatment
3226006|NCT01147211|Experimental|MK2206 in combination with Gefitinib|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
3226007|NCT01147224||ATEM|A prospective one-arm non-interventional study with asthma patients treated with Alvesco.
3226008|NCT01147237|Experimental|Single arm study|
3226009|NCT01147263||Patients diagnosed with Fibromyalgia|
3226010|NCT01147276|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
3226011|NCT01147289|Experimental|dexalgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose for 3 days, at least
3226012|NCT01147289|Active Comparator|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose for at least 3 days.
3226013|NCT01147315|Experimental|Hybrid bone substitution|Hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow
3226014|NCT01147328||1|Patients who did not have their data accessed in the VHR by a provider within 6 months after they consented will be part of the control group
3226015|NCT01147328||2|Patients who had their data accessed in the VHR by a provider within 6 months after they consented will be part of the intervention group
3226016|NCT01147354|Experimental|experimental group|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
3226017|NCT01147354|Placebo Comparator|control group|The patients in this arm took one placebo capsule daily for 12 weeks.
3226018|NCT01147367|No Intervention|Control|no physical activity intervention
3226019|NCT01147367|Experimental|Exercise intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
3226020|NCT01147419|Experimental|bypass|Patients presenting with long occlusion of the superficial femoral artery enrolled in bypass arm will undergo suprageniculate femoropopliteal bypass surgery to bypass the occluded superficial femoral artery. And the graft will be artificial blood vessel.
3226021|NCT01147419|Experimental|stent|
3226022|NCT01147432|Experimental|PF-04427429|
3226023|NCT01147432|Placebo Comparator|Placebo|
3226024|NCT01147432|Active Comparator|EMLA|
3226025|NCT01147445|Experimental|Cohort 1: 5 mcg dmLT|6 subjects to receive 5 micrograms (mcg) of dmLT vaccine.
3226026|NCT01147445|Experimental|Cohort 4: 100 mcg dmLT|6 subjects to receive 100 mcg of dmLT vaccine.
3226027|NCT01147445|Experimental|Cohort 2: 25 mcg dmLT|6 subjects to receive 25 mcg of dmLT vaccine.
3226028|NCT01147445|Experimental|Cohort 3: 50 mcg dmLT|6 subjects to receive 50 mcg of dmLT vaccine.
3226029|NCT01147445|Experimental|Cohort 5: 50 mcg or 100 mcg dmLT|12 subjects randomized, double-blinded, to receive either 50 mcg or 100 mcg of dmLT vaccine.
3226030|NCT01147484|Experimental|Foretinib|
3226031|NCT01147510|Active Comparator|Monotherapy of medium dose ICS|
3226032|NCT01147510|Experimental|Combination of low ICS and montelukast|
3226033|NCT01147523|Experimental|Vitamin E|Vitamin E, capsules 400 mg daily, for 52 weeks
3226034|NCT01147549|Experimental|1|[C14]AZD9668
3226035|NCT01147562|Other|Lung Cancer Patients|Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
3226036|NCT01147575|Active Comparator|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
3226037|NCT01147575|Placebo Comparator|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
3226038|NCT01147588|Experimental|1|lansoprazole 60 mg + clopidogrel 300 mg/ 75 mg
3226039|NCT01147588|Experimental|2|omeprazole 80 mg + clopidogrel 300/75 mg
3226040|NCT01147588|Experimental|3|esomeprazole 40 mg + clopidogrel 300/75 mg
3226041|NCT01147588|Experimental|4|clopidogrel 300/75 mg alone
3226042|NCT01147614|Active Comparator|specialty mental health care referral|
3226043|NCT01147614|Experimental|Brief Cognitive Behavioral Therapy|
3226044|NCT01147666|Experimental|Population A; Experimental Drug|Patients responding normally to current treatment
3226045|NCT01147666|Active Comparator|Population A; Active Comparator|Patients responding normally to current treatment
3226046|NCT01147666|Experimental|Population B; Experimental Drug|Patients not responding well to current treatment
3226047|NCT01147666|Active Comparator|Population B; Active Comparator|Patients not responding well to current treatment
3226048|NCT01147666|Placebo Comparator|Population B; Placebo Comparator|Patients not responding well to current treatment
3226049|NCT01147679||bvFTD|This group will include 33 patients who have been diagnosed with behavioral variant frontotemporal dementia by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
3226050|NCT01147679||Alzheimer's disease|This group will include 33 patients who have been diagnosed with clinically probable Alzheimer's disease by Dr. Mario Mendez. Patients diagnosed elsewhere must have a secondary evaluation at the UCLA FTD Clinic to confirm their diagnosis before study enrollment.
3226051|NCT01147679||Controls|33 health individuals without clinically significant cognitive impairments will be enrolled in this study.
3226052|NCT01147692|Experimental|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
3226053|NCT01147705|Active Comparator|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks.
3226054|NCT01147705|Placebo Comparator|Placebo|Same number of tablets and appearance as active drug.
3226055|NCT01147718|Experimental|digoxin plus albiglutide|A single dose of 0.5mg digoxin administered on Day 1 followed by 5 weekly subcutaneous injections of albiglutide, followed by a further single dose of 0.5mg digoxin on Day 38.
3226056|NCT01147731|Experimental|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
3226057|NCT01147757|Placebo Comparator|saline|Group S (n = 15): saline
3226058|NCT01147757|Experimental|remifentanil 0.3 mcg/kg/min|Group 0.3 (n = 15): remifentanil 0.3 mcg/kg/min
3226059|NCT01147757|Experimental|remifentanil 0.6 mcg/kg/min|Group 0.6 (n = 15): remifentanil 0.6 mcg/kg/min
3226060|NCT01147757|Experimental|remifentanil 0.9 mcg/kg/min|Group 0.9 (n = 15): remifentanil 0.9 mcg/kg/min
3226061|NCT01147770|Experimental|stop progesterone|
3226062|NCT01147783||SimBaby|
3226063|NCT01147783||Infants (1-12 mo)|
3226064|NCT01147796|Active Comparator|Thrombus|patients with positive TEE (thrombus)
3226065|NCT01147796|Placebo Comparator|No thrombus|patients with negative TEE (no thrombus)
3226066|NCT01147835|Placebo Comparator|Placebo Lollipop|The placebo group will ingest the same herbal lollipop formula without the active ingredient.
3226067|NCT01147835|Experimental|Chinese Licorice Root|The experimental group will ingest the herbal lollipop formula with the active ingredient.
3226068|NCT01147861|Placebo Comparator|Placebo|Subjects will receive 2 placebo tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3226069|NCT01147861|Other|5mg BID|Subjects will receive 1 x 5mg tablet and 1 placebo tablet in the morning, and 1 x 5mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
3226070|NCT01147861|Other|10mg QD|Subjects will receive 2 x 5mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3226071|NCT01147861|Other|25mg BID|Subjects will receive 1 x 25mg tablet and 1 placebo tablet in the morning, and 1 x 25mg tablet and 1 placebo tablet in the evening on Day 1 and Day 2.
3226072|NCT01147861|Other|50mg QD|Subjects will receive 2 x 25mg tablets in the morning and 2 placebo tablets in the evening on Day 1 and Day 2.
3226073|NCT01147887|Experimental|001|Drug combination/ 26489112 On Day 1 and on Day 19 a single oral dose of a drug combination consisting of midazolam (2 mg/mL liquid) tolbutamide (a 500 mg tablet) and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21 a single oral dose of two 26489112 tablets will be taken.
3226074|NCT01147913|Experimental|Positive Interpretation Training|Four sessions of positive information-processing training for interpretation of ambiguous scenarios relevant to themes of depression.
3226075|NCT01147913|Sham Comparator|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
3226076|NCT01147939|Experimental|Elacytarabine|
3226077|NCT01147939|Active Comparator|Investigator's Choice|
3226078|NCT01147952|Experimental|12 week exercise training|
3226079|NCT01147952|No Intervention|Conventional Care|
3226080|NCT01147965|Experimental|Ad5 CEA Vaccine|Single arm dose escalation study
3226081|NCT01147978|Experimental|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
3226082|NCT01147978|No Intervention|Usual Procedure|Usual discharge procedure from the ICU
3226083|NCT01148030||Single|3M Skin and Nasal Antiseptic
3226084|NCT01148043|Placebo Comparator|Placebo|
3226085|NCT01148043|Experimental|Hydroxychloroquine|
3226086|NCT01148069|Experimental|Surgery combined with IMRT-IGRT|
3226087|NCT01148095|Experimental|1|AZD2516 (dose escalating)
3226088|NCT01148095|Placebo Comparator|2|Placebo
3226089|NCT01148108|Experimental|Mantle Cell Lymphoma|Patients with relapsed or refractory mantle cell lymphoma
3226090|NCT01148108|Experimental|Diffuse Large B Cell Lymphoma|Patients with relapsed or refractory diffuse large B cell lymphoma
3226091|NCT01148108|Experimental|Multiple Myeloma|Patients with relapsed or refractory multiple myeloma
3226092|NCT01148134||Bcr-Abl positive ALL|
3226093|NCT01148134||Bcr-Abl negative ALL|
3226094|NCT01148147|Placebo Comparator|Placebo|Intracoronary Placebo administration
3226095|NCT01148147|Active Comparator|Adenosine|Intracoronary adenosine administration
3226096|NCT01148160||1|Patients with hematologic malignancies who were given voriconazole to treat invasive (pulmonary) aspergillosis at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3226097|NCT01148173|Experimental|Systemic and intrathecal chemotherapy|
3226098|NCT01148186|Experimental|Educational intervention|Administration of an educational intervention to inform patients of the risks and safe alternatives to their current potentially inappropriate medication. The textual content of this knowledge transfer tool will be divided into three parts: a) presentation of the evidence-based risks associated with the targeted potentially inappropriate medication (e.g. benzodiazepines); b) presentation of evidence-based equally or more effective therapeutic substitutes for the medical condition (e.g. insomnia and anxiety); and c) presentation of evidence based tapering recommendations where applicable.
3226099|NCT01148186|No Intervention|Wait-list group|
3226100|NCT01148199|Active Comparator|Multiple plastic stents|Multiple plastic stents placement after sphincterotomy and stricutre dilation. ERCP repeated every 3 - 4 months during 1-year
3226101|NCT01148199|Experimental|Self-expandable metalic stent|Self-expandable metalic stent after sphincterotomy. Stent removal scheduled for 6 months
3226102|NCT01148238||Diabetes type 1 older than 10 years|Blood samples will be taken from 10 patients with diabetes type 1 older than 10 years and 10 healthy age-and sexmatched controls.
3226103|NCT01148238||Newly diagnosed type 1 diabetes|Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes and 10 healthy age-and sexmatched controls.
3226104|NCT01148238||LADA|Blood samples will be taken from 10 patients with LADA and 10 healthy age-and sexmatched controls.
3226105|NCT01148264|Experimental|olanzapine|
3226106|NCT01148264|Active Comparator|metoclopramide|
3226107|NCT01148277|Active Comparator|Propofol and Remifentanyl|Propofol, colonoscopies, liver diseases, cirrhosis
3226108|NCT01148277|Active Comparator|midazolam and fentanyl|midazolam and fentanyl, colonoscopies, liver diseases
3226109|NCT01148277|Experimental|control midazolam anf fentanyl|midazolam anf fentanyl
3226110|NCT01148290|Active Comparator|Tension free vaginal tape|
3226111|NCT01148290|Experimental|Bulking agent injection|
3226112|NCT01148303|Experimental|Etoricoxib First|This arm will receive etoricoxib for six days, followed by placebo for eight days.
3226113|NCT01148303|Experimental|Etoricoxib Second|This arm will get placebo for eight days before beginning their fast, followed by etoricoxib for six days.
3226114|NCT01148316|Active Comparator|Fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
3226115|NCT01148316|Active Comparator|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
3226116|NCT01148329||Single arm observational study|To evaluate real world clinical outcomes data for the PROMUS™ Element™ Coronary Stent System in unselected patients in routine clinical practice
3226117|NCT01148368|Experimental|renal impairment patients|renal impairment patients who eGFR is lower than 30 ml/min/1.73m^2 without hemodialysis
3226118|NCT01148368|Active Comparator|healthy volunteers|healthy volunteers group
3226124|NCT01148394|No Intervention|Traditional|Involves traditional management of patients with preoperative mechanical bowel preparation, no preoperative education, nasogastric tube, delayed feeding and mobilisation, use of drains
3226125|NCT01148394|Active Comparator|Multimodal rehabilitation|Involves preoperative patient education, no preoperative mechanical bowel preparation, no nasogastric tube, early oral feeding and mobilisation, physiotherapy
3226126|NCT01148433||TESTIM® - drug given by prescription|Male patients with Hypogonadism
3226127|NCT01148446|Experimental|R-CHOP|R-CHOP (every 21 days) for six courses Cyclophosphamide: 750 mg/m2, IV, day 1 Doxorubicin: 50 mg/m2, IV, day 1 Vincristine: 1.4 (max 2) mg/m2, IV, day 1 Prednisone: 75 mg/m2, IV, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
3226128|NCT01148446|Experimental|R-mini-CEOP|R-miniCEOP (every 21 days)for six courses Cyclophosphamide: 50 mg/m2, IV, day 1 Epirubicin: 50 mg/m2, IV, day 1 Vinblastine: 5 mg/m2, IV, day 1 Prednisone: 60 mg/m2, IV/PO, days 1-5 Rituximab: 375 mg/m2, IV, day 1 G-CSF: 300 µg tota, SC; days 7-11
3226129|NCT01148472|Experimental|Escitalopram|
3226130|NCT01148472|Active Comparator|Duloxetine|
3226131|NCT01148498|Experimental|Group 1|Older adults with mild Dementia Alzheimer's Type (DAT)
3226132|NCT01148498|Experimental|Group 2|Older adult controls with possible Alzheimer's Disease Pathology
3226133|NCT01148498|Experimental|Group 3|Older adult controls with no evidence of Alzheimer's Disease
3226134|NCT01148498|Experimental|Group 4|Younger subjects who are assumed to have no cognitive impairment
3226135|NCT01148550||Group 1|Mitochondrial Hepatopathy Disease Group
3226136|NCT01148550||Group 2|Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1 Subjects with Suspected Mitochondrial Hepatopathy who do not meet the enrollment criteria for Group 1
3226137|NCT01148576|Other|control group|patients only with chronic hepatitis B
3226138|NCT01148576|Active Comparator|model group|patients with chronic hepatitis B and hepatic steatosis
3226139|NCT01148576|Experimental|Essentiale group|patients with chronic hepatitis B and hepatic steatosis
3226140|NCT01148576|Experimental|treatment group 2|patients with chronic hepatitis B and hepatic steatosis
3226141|NCT01148602|No Intervention|'Off Clock'|"Stopwatch timers will NOT be used for off clock weeks, so patients presenting with hyperacute stroke will be managed normally without the visual timer."
3226142|NCT01148602|Active Comparator|"'On Clock"|"LED stopwatch-clock timers will be posted for all patients presenting during ON clock weeks. All patients presenting with hyperacute stroke will be managed normally with the addition of a visual stopwatch timer."
3226143|NCT01148615|Experimental|Aflibercept/ docetaxel|"Patients with advanced cancer will receive different doses of aflibercept in combination with approved dose of docetaxel.~Aflibercept 4 or 6mg/kg over 1 hour IV immediately followed by Docetaxel 75mg/m2 IV over 1 hour on Day 1, every 3 weeks"
3226144|NCT01148628|Experimental|RAD 001 in combination with CaelyxTM|"RAD001 will be given p.o. at increasing doses (no intra-patient)and CaelyxTM will be administered i.v. at a fixed dose.~At each dose level 3 to 6 patients will be entered, according to toxicities observed; the first 3 patients can be treated simultaneously; subsequent patients can be treated after the first 3 have been observed for at least one cycle (4 weeks).~The dose escalation process will be discontinued once the MTD has been achieved and the RD will be evaluated in a subsequent expansion part of the study."
3226145|NCT01148641||LNS-regular|Lipid-based nutrient supplement, regular (peanut) flavor
3226146|NCT01148641||LNS-cinnamon|Lipid-based nutrient supplement, cinnamon flavor
3226147|NCT01148654||1- Preterm Labor 22.0-33.6 weeks gestational age|Pregnant women between 22.0 and 33.6 weeks gestational age presenting to the Hospital of the University of Pennsylvania (HUP) complaining of Preterm labor (PTL), preterm premature rupture of membranes (PPROM), or cervical insufficiency (CI).
3226148|NCT01148654||2- Preterm birth 34-36.6 weeks gestational age|Pregnant women delivering at the University of Pennsylvania between 34.0 and 36.6 weeks gestational age
3226149|NCT01148667|Active Comparator|Infants drink formula added with LGG|Infants have been randomized (1:1) to get casein hydrolysate with or without LGG
3226150|NCT01148667|Placebo Comparator|Infants drink casein hydrolysate without LGG|Infants get extensively hydrolysed casein formula
3226151|NCT01148680|Experimental|immediate registration on islet graft list|"group 1 'immediate registration on infusion waiting list' : patients who will be immediately registrated on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
3226152|NCT01148680|Active Comparator|delayed registration on islet graft list|"group 2 'delayed registration on infusion waiting list' : patients who will be registrated 6 months later on islet cell infusion waiting list after randomization.~Intervention : Procedure/surgery (islet graft)"
3226153|NCT01148706|Experimental|ActiSight Needle Guidance System|
3226154|NCT01148719|Active Comparator|Index group|Patients in the index group receive the diagnostic triage instrument. This includes echocardiographic, electrocardiographic and spirometric measurements and blood testing.
3226155|NCT01148719|No Intervention|Control|Participants receive care as usual.
3226156|NCT01148732||Patient needed intubation in emergency department|
3226157|NCT01148758|Experimental|Single Arm|
3226158|NCT01148784|Active Comparator|Quadrupled Hamstring Allograft|
3226159|NCT01148784|Active Comparator|Doubled Tibialis Anterior Allograft|
3226160|NCT01148797|Experimental|Canakinumab|
3226161|NCT01148823|Experimental|Postoperative day 1|Dressing was removed on the first postoperative day
3226162|NCT01148823|Experimental|Postoperative day 6|Dressing was removed on the 6th postoperative day
3226163|NCT01148849|Experimental|MGAH22|Anti-HER2 monoclonal antibody (margetuximab)
3226164|NCT01148888|Experimental|Magnesium Sulfate|The study will be conducted in the 45 minute interval between the completion of spinal instrumentation and the completion of skin closure. Once the spinal instrumentation is complete and the integrity of the spinal cord pathways is confirmed using SEPs and MEPs, magnesium will be administered for the remainder of surgery.
3226165|NCT01148901|Experimental|Remicade|Infliximab 5 mg/kg was administered as specified in the Summary of Product Characteristics for patients with ankylosing spondylitis
3226166|NCT01148914||Baseline level of biomarkers|
3226167|NCT01148927||Adult acute lymphoblastic leukemia patients|
3226168|NCT01148953|Active Comparator|ALN-TTR01|
3226169|NCT01148953|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3226170|NCT01148966|Experimental|Treatment (photodynamic therapy)|Patients receive aminolevulinic acid PO 4 hours before undergoing surgery.
3226171|NCT01148992|Active Comparator|Lofexidine|
3226172|NCT01148992|Placebo Comparator|Placebo|
3226173|NCT01149005|Experimental|insulin|patients who will get insulin with main meals during Intravenous (IV) antibiotic therapy due to pulmonary exacerbation
3226174|NCT01149018|Experimental|Tetrahydrocannabinol|
3226175|NCT01149018|Placebo Comparator|Placebo|
3226176|NCT01149031|Active Comparator|low level laser therapy, using a probe|"The treatment will be done by using a LLL-probe touching several areas of the vulvar vestibule, according to the selected protocol.~Every patient will be treated twice weekly for 6 weeks."
3226177|NCT01149031|Placebo Comparator|Placebo|The patients will be treated with placebo-probe, according to the same protocol
3226178|NCT01149044|Active Comparator|Upfront Thrombectomy followed by PCI|Upfront manual aspiration thrombectomy followed by PCI
3226179|NCT01149044|Active Comparator|PCI Alone|PCI without upfront manual aspiration thrombectomy
3226180|NCT01149083|Experimental|Arm I (veliparib)|Patients receive veliparib PO BID on days 1-21.
3226181|NCT01149083|Experimental|Arm II (veliparib, carboplatin)|Patients receive carboplatin IV over 30 minutes on day 1 and veliparib as in Arm I.
3226182|NCT01149109|Experimental|lomustine (CCNU) + temozolomide (TMZ) and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) Six 42-day courses of oral CCNU 100 mg/m2 (day 1) and oral TMZ 100 mg/m2 (day 2-6), first CCNU application during the first week of RT CCNU/TMZ and radiotherapy start 2-5 weeks after diagnosis (day of surgery for glioblastoma (GBM)). In courses 2-6, TMZ dose are adjusted according to the hematotoxicity observed in the previous course and can be increased stepwise up to 200 mg/m2/day
3226183|NCT01149109|Active Comparator|temozolomide and radiotherapy|60 Gy standard radiotherapy (RT, 30 x 2 Gy) and concomitant TMZ therapy (daily TMZ 75 mg/m2) starting with the first day of radiotherapy Six 28-day courses of TMZ (day 1-5) starting 4 weeks after completion of radiotherapy. In the first course TMZ is given at a dose of 150 mg/m2/day, in case no toxicity is observed, the 2nd course is applied at a daily dose of 200 mg/m2
3226184|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin with Erlotinib|
3226185|NCT01149122|Active Comparator|Gemcitabine/Oxaliplatin without Erlotinib|
3226186|NCT01149135|Active Comparator|Standard light treatment|standard light treatment 5000K; 10 000 lux
3226187|NCT01149135|Experimental|blue enriched light|Blue enriched light with a low intensity (750 lux)
3226188|NCT01149161|Active Comparator|C group|Routine central neck dissection
3226189|NCT01149161|No Intervention|N group|No central neck node dissection
3226190|NCT01149174|No Intervention|transurethral resection alone|Patients with non-muscle invasive bladder cancer who underwent transurethral resection alone;
3226191|NCT01149174|Active Comparator|intravesical mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent one intravesical instillation of mitomycin-C immediately after transurethral resection
3226192|NCT01149174|Experimental|electromotive mitomycin-C|Patients with non-muscle invasive bladder cancer who underwent single immediate intravesical instillation of electromotive mitomycin-C immediately before transurethral resection
3226193|NCT01149187||IGRA in solitary pulmonary nodules|Inpatients who undergo percutaneous needle biopsy for diagnosis of pulmonary nodules in Seoul National University hospital for six months are going to be included. Patients who are not tolerable for PCNB or do not agree the enrollment of study will be excluded.
3226194|NCT01149200|Experimental|TC-6499|
3226195|NCT01149200|Placebo Comparator|Placebo|
3226196|NCT01149213|Experimental|Transcranial Direct Current Stimulation|"In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.~The patient will receive tDCS every other week during the first three months, then once a month during the next three months."
3226197|NCT01149226|Placebo Comparator|placebo control|
3226198|NCT01149226|Experimental|oral medication chloral hydrate|
3226199|NCT01149252|Placebo Comparator|Psoralait|
3226200|NCT01149265|Experimental|Online support group|
3226201|NCT01149265|Active Comparator|Expressive writing|
3226202|NCT01149278|Active Comparator|high pressure|
3226203|NCT01149278|Placebo Comparator|normal pressure|
3226204|NCT01149291||End stage renal disease patients|
3226205|NCT01149304|Experimental|Group A|Medication group with patients receiving the study medication according to the study protocol for 8 weeks after HDR brachytherapy.
3226206|NCT01149304|No Intervention|Group B|Comparison group with patients receiving the standard therapy of HDR brachytherapy without the study specific medication.
3226207|NCT01149317|Experimental|Acupuncture|Weekly acupuncture treatment for up to 14 weeks
3226208|NCT01149330|Experimental|Adapalene-BPO Gel|
3226209|NCT01149356|Experimental|Arm I|Patients receive oral exemestane once daily on days 1-21 and oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3226210|NCT01149356|Active Comparator|Arm II|Patients receive exemestane as in arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3226211|NCT01149382||islet cell transplant recipients|
3226212|NCT01149395|Experimental|Dexlansoprazole|
3226213|NCT01149408|Experimental|All patients|All participants enrolled.
3226214|NCT01149499|Experimental|Valacyclovir|Test 1000 mg Valacyclovir Tablet
3226215|NCT01149499|Active Comparator|Valtrex|Reference Listed 1000 mg Valtrex Tablet
3226216|NCT01149525|Experimental|1|oral solution of L-Carnitine, 4g per day
3226217|NCT01149525|Placebo Comparator|2|Similar oral solution without L-Carnitine
3226218|NCT01149551||Group 1|
3226219|NCT01149564|Placebo Comparator|IV ibuprofen|The first dose of either oral or IV ibuprofen will be given at the time the patient is randomized.The subsequent doses of indometacin or ibuprofen are also determined according to the echocardiographic PDA flow patterns at intervals of once every 24 hours from the last dose. The dosage of both oral ibuprofen (Ibuprofen suspension, 20 mg/ml, Yung Shing Co., Taiwan) and IV ibuprofen (PedeaR 20 mg/ml, developed by Orphan Europe and approved by the EMEA) are an initial dose of 10 mg/kg and then 5 mg/kg at 24-hour intervals as indicated by PDA flow pattern.
3226220|NCT01149564|Active Comparator|Oral ibuprofen|
3226221|NCT01149577|Experimental|Schizophrenia patients|The study population of 25 schizophrenia patients constituted the active arm of the study.
3226222|NCT01149590|Experimental|CT Calcium Score & Coronary Angiography|CT Scan
3226223|NCT01149590|No Intervention|No CT Scan|No CT Scan
3226224|NCT01149603|Experimental|Implantation of the HeartMate II VAD|Consenting patients who meet the study inclusion and exclusion criteria will be implanted with a HeartMate II ventricular assist device.
3226225|NCT01149629|Active Comparator|Fed Dosing|Subjects fed a high calorie, high fat meal prior to receiving 3 x 100mg capsules
3226226|NCT01149629|Active Comparator|Fasted Dosing|Subjects fasted prior to receiving 3 x 100mg capsules
3226227|NCT01149629|Active Comparator|Bioequivalence|Subjects fasted prior to receiving 1x 300mg capsule
3226228|NCT01149629|Active Comparator|TID Dosing|Droxidopa 300 mg given TID
3226229|NCT01149642|Experimental|Oral immunomodulatory solution|The oral supplement is a 74g sachet containing 302 kcal and 16.7g proteins as well as immunonutrients such as L-Arginine, ARN and omega-3.
3226230|NCT01149642|Placebo Comparator|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
3226231|NCT01149668|Experimental|PCI-24781|
3226232|NCT01149694|Other|Cohort 1|
3226233|NCT01149694|Other|Cohort 2|
3226234|NCT01149694|Other|Cohort 3|
3226235|NCT01149694|Other|Cohort 4|
3226236|NCT01149707|Experimental|PUR 0110 Rectal Enema 250 mg|Active treatment
3226237|NCT01149707|Experimental|PUR 0110 Rectal Enema 500 mg|Active treatment
3226238|NCT01149707|Experimental|PUR 0110 Rectal Enema 1000 mg|Active treatment
3226239|NCT01149707|Placebo Comparator|Placebo Enema|Placebo comparator
3226240|NCT01149720|Experimental|ARQ 197 Capsule, oral|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
3226241|NCT01149720|Experimental|ARQ 197 Tablet, oral|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
3226242|NCT01149720|Experimental|ARQ 197 Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
3226243|NCT01149746|Experimental|Tamsulosin|0.4 mg Capsule
3226244|NCT01149746|Active Comparator|Flomax®|0.4 mg Capsule
3226245|NCT01149798|Experimental|Abraxane and Cisplatin combination|Abraxane and Cisplatin combination
3226246|NCT01149811||Fipamezole ODT Cohort 1|
3226247|NCT01149811||Fipamezole ODT Cohort 2|
3226248|NCT01149824|Other|Dose Escalating|
3226249|NCT01149837||residual blood donor samples|Protocol describes testing an HTLV-I/II antibody reactive population from this cohort using the InnoLIA HTLV I/II Score line immunoassay
3226250|NCT01149850|Experimental|Arm I|Patients receive bevacizumab IV over 30-90 minutes every 2 weeks and oral temozolomide on days 1-5. Treatment repeats every 28 days for 24 courses in the absence of disease progression or unacceptable toxicity.
3226251|NCT01149889|Experimental|active stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
3226252|NCT01149928||C/S delivered, wet lung|
3226253|NCT01149928||C/S delivered, healthy infants|
3226254|NCT01149941|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
3226255|NCT01149941|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
3226256|NCT01149954|Experimental|Ibuprofen|Ibuprofen 200 mg gel Capsules of Dr. Reddy's laboratories Limited
3226257|NCT01149954|Active Comparator|Advil|Advil liquigels 200 mg gel capsules of Wyeth Consumer Healthcare
3226258|NCT01149967|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
3226259|NCT01149967|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
3226260|NCT01149980|Experimental|Citalopram|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's
3226261|NCT01149980|Active Comparator|Celexa|Celexa 40 mg Tablets of Forest Labs
3226262|NCT01149993|Experimental|pre-transplant immunosuppression|subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.
3226263|NCT01149993|Experimental|pre-transplant induction|subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.
3226264|NCT01149993|Active Comparator|standard of care|subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital
3226265|NCT01150006||Healthy male participants|
3226266|NCT01150019||Obese Group|
3226267|NCT01150019||Non Obese Group|
3226268|NCT01150032||Osteopenic women|Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)
3226269|NCT01150071||Children born extremely preterm|national cohort of children born before 28 weeks' gestational age or with a birthweight less than 1000 g. 365 eligible survivors
3226270|NCT01150084|Experimental|lunchtime walking|
3226271|NCT01150084|Other|waiting-list control|
3226272|NCT01150136||1|Children with proven CF and known genotype, age 0-17 yr
3226273|NCT01150149|No Intervention|1|
3226274|NCT01150149|Experimental|2|No face touch
3226275|NCT01150149|Experimental|3|Surgical face mask
3226276|NCT01150149|Experimental|4|Surgical face mask + no face touch
3226277|NCT01150162|Experimental|Mucosta and Omeprazole|
3226278|NCT01150162|Active Comparator|Omeperazole|
3226279|NCT01150175|Experimental|Autologous bone marrow cells|
3226280|NCT01150175|Placebo Comparator|Plasma|
3226281|NCT01150188|Active Comparator|Amino acids|Amino acid supplementation between meals for eight weeks
3226282|NCT01150188|Placebo Comparator|Placebo|Supplementation of placebo (inert components) between meals for eight weeks
3226283|NCT01150201|Experimental|Aliskiren|Aliskiren
3226284|NCT01150201|Active Comparator|Losartan|ARB
3226285|NCT01150214||DE-MRI|All patients will undergo Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI)to quantify the degree of atrial structural remodeling or fibrosis pre-ablation and DE-MRI will be obtained at 3, 6, and 12 months follow-up to detect and quantify ablation-related scar formation.
3226286|NCT01150240||Primary Immunodeficiency Disease|Patients with primary Immunodeficiency disease (PID)
3226287|NCT01150253|Experimental|probiotic fermented milk|
3226288|NCT01150253|Placebo Comparator|placebo|
3226289|NCT01150266|Experimental|Alteplase|Alteplase 0.9mg/kg (maximum 90mg), 10% IV bolus over 1 minute and the remainder over one hour infusion in patients with ischemic stroke after awaking.
3226290|NCT01150292|Experimental|DHA - Sunflower oil|400 mg DHA supplementation by day for 2 weeks then placebo for 2 weeks after a wash out period of 6 to 9 weeks
3226291|NCT01150292|Experimental|Sunflower oil - DHA|Placebo during 2 weeks then 400 mg DHA supplementation by day for 2 weeks after a wash out period for 6 to 9 weeks
3226292|NCT01150305||1|Patient presenting familial dominant non syndromic hearing loss starting between 4 and 40 years old, over 2 generations
3226293|NCT01150305||2|Healthy volunteer from the same families
3226294|NCT01150318|Experimental|1|Patients treated by 131 iodine for thyroid cancer
3226295|NCT01150331|Experimental|Clonazepam + levetiracetam|Clonazepam IV 1 mg+ levetiracetam IV 2500 mg
3226296|NCT01150331|Active Comparator|Clonazepam + placebo|Clonazepam IV 1 mg + placebo levetiracetam IV
3226297|NCT01150344|Active Comparator|Malarone|"Malarone (atovaquone + proguanil combination):~patients treated with Malarone®"
3226298|NCT01150344|Active Comparator|Riamet|"RIAMET (artemether + LUMEFANTRIN combination):~patients treated with Riamet®"
3226299|NCT01150370|Experimental|Males undergoing circumcision|
3226300|NCT01150383|Active Comparator|group RO (Room air / Oxygen)|RO (Room air / Oxygen): First 6 weeks of exercise training under normoxic conditions (Room air), followed by 6 weeks of exercise training with oxygen supplementation.
3226301|NCT01150383|Active Comparator|group OR (Oxygen / Room air)|OR (Oxygen / Room air): First 6 weeks of exercise training with oxygen supplementation, followed by 6 weeks of exercise training under normoxic conditions (room air).
3226302|NCT01150422|No Intervention|Standard of care for post medical abortion follow-up|Standard of care includes a routine hospital visit two weeks after mifepristone administration. At the hospital visit, the woman will undergo a bimanual and vaginal ultrasound examination. In the event the woman fails to return for the follow-up visit, each hospital will follow their standard procedure for contacting women who fail to attend their follow-up visit, i.e. three efforts to contact the woman. Form 2a will document the results of any clinical examinations, any additional medical abortion-related care given and the abortion outcome. At the follow-up visit, women will also be asked about the acceptability of current medical abortion follow-up procedures and their future preferences.
3226303|NCT01150422|Active Comparator|Alternative follow-up|"At their first clinic visit, women will be asked to provide their phone number for contact purposes. Women will also be asked to complete a semi-quantitative pregnancy test in the clinic and the results of the test will be noted on a study form. After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist.~Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned date two weeks after mifepristone administration. The checklist will indicate that if the woman answers yes to any of the questions, then she should return to the clinic for a follow-up visit. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests."
3226304|NCT01150435||Maintenance Medication D, S- Methadon|
3226305|NCT01150435||Maintenance Medication S- Methadon|
3226306|NCT01150435||Buprenorphine|
3226307|NCT01150435||Buprenorphine+ Naloxone|
3226308|NCT01150448|Experimental|001|Paliperidone palmitate Treatment A All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
3226309|NCT01150448|Experimental|002|Paliperidone palmitate Treatment B Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq patients who do not wish to have multiple blood samples collected will also be assigned to Treatment B
3226310|NCT01150487|Experimental|Sensitized Renal Allograft Recipients|Patients who have antibodies against their donors in their blood.
3226311|NCT01150513|Active Comparator|EC-T|
3226312|NCT01150513|Experimental|TP|
3226313|NCT01150526|Placebo Comparator|Placebo|Oral Placebo capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3226314|NCT01150526|Experimental|CaHMB Pre|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3226315|NCT01150526|Experimental|CaHMB Pre and Post|Oral CaHMB capsule and one placebo gel dosage given 30 min prior to the acute exercise session. A CaHMB capsule and placebo gel dosage are are then administered 3 times daily during the remainder of the study.
3226316|NCT01150526|Experimental|HMB Free Acid Gel Pre|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and placebo gel dosage are then administered 3 times daily during the remainder of the study.
3226317|NCT01150526|Experimental|HMB Free Acid Gel Pre and Post|Oral placebo capsule and one HMB free acid gel dosage given 30 min prior to the acute exercise session. A placebo capsule and HMB free acid gel dosage are then administered 3 times daily during the remainder of the study.
3226318|NCT01150539|Experimental|Overweight/obese women with PCOS|10 overweight/obese women with polycystic ovary syndrome
3226319|NCT01150552||Poultry exposed individuals|Any individual who had an occupational contact with poultry in the previous five years will be considered exposed. Individuals working on poultry farms, poultry wet markets, or keeping limited numbers of poultry in their backyard, are considered exposed.
3226320|NCT01150552||Non-poultry exposed adult controls|Unexposed individuals must have no occupational exposure to poultry in their lifetime and must also not be exposed to poultry purchased from live bird markets.
3226321|NCT01150565|Experimental|LiRIS low dose|The first dose group of approximately 10 patients receive low dose LiRIS on Day 1 to Day 14.
3226322|NCT01150565|Experimental|LiRIS high dose|The second dose group of approximately 10 patients receive high dose LiRIS on Day 1 to Day 14.
3226323|NCT01150578||Lexi-Echo pilot|Appropriate patients at University of Arizona Medical Center stress imaging laboratory who have a routine regadenoson SPECT nuclear scan will have simultaneous cardiac echo images obtained.
3226324|NCT01150604|Experimental|Self-help course|
3226325|NCT01150617|Active Comparator|long-acting insulin plus analogues|three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening.
3226326|NCT01150617|Active Comparator|long-acting insulin and oral agents|treatment will be once-daily long-acting insulin and oral antidiabetic agents
3226327|NCT01150630|Experimental|adjuvant PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 6 months
3226328|NCT01150630|Experimental|perioperative PEXG|cisplatin and epirubicin at 30 mg/mq, gemcitabine at 800 mg/mq and capecitabine at 1250 mg/mq/day per os for 14 days every 14 days for 3 months before surgery and 3 months after surgery
3226329|NCT01150630|Active Comparator|Adjuvant Gemcitabine|Adjuvant Gemcitabine at 1000 mg/mq for 3 weeks every 4 weeks for 6 months
3226330|NCT01150669||Observational|Cryopreserved specimens are studied in vitro with lestaurtinib with or without chemotherapy agents. Samples are analyzed for FLT3 protein expression and/or activation; sensitivity to lestaurtinib with or without chemotherapy agents; and activation of STAT, AKT, and RAS-MAPK and other pathways by western blot. The most effective treatment from this study is then validated in vivo in a NOD/SCID xenograft model.
3226331|NCT01150695|Experimental|Group A (DVC-LVS)|Single dose of the Dynport Vaccine Company Live Vaccine Strain (DVC-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
3226332|NCT01150695|Experimental|Group B (USAMRIID-LVS)|Single dose of the United States Army Medical Research Institute of Infectious Diseases Live Vaccine Strain (USAMRIID-LVS) product in one arm and normal saline (NS) control in the other arm on Day 0.
3226338|NCT01150747||Risk of positive chlamydia|"current, untreated endocervical C. trachomatis infection~mucopurulent cervicitis on pelvic examination~Sexual contact with a male partner recently diagnosed with C. trachomatis, and/or non-gonococcal urethritis"
3226339|NCT01150786|Experimental|selenium|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
3226340|NCT01150786|Placebo Comparator|placebo capsule|The patients in this arm took one placebo capsule daily for 12 weeks.
3226341|NCT01150812|Experimental|1|
3226342|NCT01150825||STEMI|Patients with ST segment elevation myocardial infarction, verified by elevated troponin levels
3226343|NCT01150825||NSTEMI|Patients with non-ST segment elevation myocardial infarction, verified by elevated levels of troponin
3226344|NCT01150851|Active Comparator|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
3226345|NCT01150851|Active Comparator|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
3226346|NCT01150851|Active Comparator|caloric restriction and aerobic exercise|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration, and supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
3226347|NCT01150851|No Intervention|usual diet and usual activity|usual diet and usual activity
3226348|NCT01150864|Active Comparator|Passive Humidifier|The Passive Humidifier (HME)will changed every 24 hours
3226349|NCT01150864|Active Comparator|Active-Passive humidifier|The Active-Passive Humidifier will be changed every 24 hours
3226350|NCT01150864|Active Comparator|Hot Water Humidifier|Hot water humidifier will be set at 36-37 °C
3226351|NCT01150877|Experimental|Experimental Dietary Supplement (e.g., vitamins, minerals)|Experimental arm is supplemented with high-dose of vitamin D.
3226352|NCT01150877|No Intervention|No Intervention|
3226357|NCT01150916|Active Comparator|Heart failure|Patients must fulfill Framingham and/or Boston criteria for heart failure and have systolic or diastolic disfunction in rest echocardiography.
3226358|NCT01150916|Active Comparator|Liver Cirrhosis|Patients must have a biopsy proven diagnosis of liver cirrhosis or the diagnosis established on clinical basis in cases of known etiology of liver disease, peripheral signs of chronic liver disease, esophageal varices at endoscopy and an imaging method with evidence of cirrhosis.
3226359|NCT01150916|Active Comparator|Other causes of ascites|Patients must fulfill stringent diagnostic criteria for the cause of ascites, by clinical criteria, laboratory and imaging tests and histology when appropriate.
3226360|NCT01150916|Active Comparator|Concurrent heart failure and cirrhosis|Patients must fulfill the aforementioned criteria for both conditions.
3226361|NCT01150929|Active Comparator|Fixed bearing|One of the 2 used implants.
3226362|NCT01150929|Active Comparator|Rotating platform|One of the 2 used implants.
3226363|NCT01150942|Experimental|vero cell-derived JE vaccine|vero cell-derived vaccine group
3226364|NCT01150942|Active Comparator|Mouse brain-derived JE vaccine|Mouse brain-derived JE vaccine group
3226365|NCT01150955|Active Comparator|Resveratrol|Dietary supplement of resveratrol 500 mg three times a day over five weeks.
3226366|NCT01150955|Placebo Comparator|Placebo|
3226367|NCT01150968|Experimental|Internal Medicine Residents|All UCSf Internal Medicine residents for 2009-2010
3226368|NCT01150994|No Intervention|Treatment as Usual|
3226369|NCT01150994|No Intervention|Screening Alone|Enhanced screening among ED patients
3226370|NCT01150994|Experimental|Safety Assessment and Follow-up Telephone Intervention|SAFTI: Safety Assessment in the ED combine with a Follow-up Telephone Intervention.
3226371|NCT01151007||Patients with colorectal carcinoma|Patient with colorectal carcinoma operated in Martinique between January 1st, 2007 and December 31st, 2009
3226372|NCT01151033|Experimental|stent implantation|ProNOVA XR Polymer Free Drug Eluting Stent implantation - single arm
3226373|NCT01151059|Other|Group 1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3226374|NCT01151072|Experimental|IDeg i.m. thigh|
3226375|NCT01151072|Experimental|IDeg i.v.|
3226376|NCT01151072|Experimental|IDeg s.c. abdomen|
3226377|NCT01151072|Experimental|IDeg s.c. deltoid|
3226378|NCT01151072|Experimental|IDeg s.c. thigh|
3226379|NCT01151124|Experimental|CTX0E03 DP|human neural stem cell product, once only injection, increasing doses
3226380|NCT01151176|Active Comparator|Insulin|Intensive Insulin Therapy
3226381|NCT01151176|Other|Regular Insulin|Sub Cutaneous Regular Insulin
3226382|NCT01151202|Experimental|AG NPP709 syrup|AG NPP709 contains Ivy leaf extract and coptis rhizoma extract
3226383|NCT01151202|Active Comparator|Ivy leaf extract syrup|
3226384|NCT01151228|Placebo Comparator|Zero volume|Patients will not ingest any apple juice prior to the second ultrasound.
3226385|NCT01151228|Experimental|50 mL|Patients will ingest 50 mL apple juice prior to the second ultrasound.
3226386|NCT01151228|Experimental|100 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
3226387|NCT01151228|Experimental|200 mL|Patients will ingest 100 mL apple juice prior to the second ultrasound.
3226388|NCT01151228|Experimental|300 mL|Patients will ingest 300 mL apple juice prior to the second ultrasound.
3226389|NCT01151228|Experimental|400 mL|Patients will ingest 400 mL apple juice prior to the second ultrasound.
3226390|NCT01151241|Experimental|Early discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
3226391|NCT01151241|Active Comparator|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
3226392|NCT01151254|Active Comparator|PA-Intravenous Sedation|Propofol based total intravenous anesthesia and postoperative sedation
3226393|NCT01151254|Active Comparator|Volatile sedation|Total inhalational anesthesia and postoperative sedation with the AnaConda device
3226394|NCT01151267|Other|Control Arm|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
3226395|NCT01151267|Active Comparator|HSH Group|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
3226396|NCT01151306|Placebo Comparator|Lactose tablet|
3226397|NCT01151306|Active Comparator|Simvastatin 20mg|
3226398|NCT01151319|Experimental|Stage 1.|The first stage will start from a low and well tolerated, but likely less immunogenic dose of ChAdV63.HIVconsv (n=2).
3226399|NCT01151319|Experimental|Stage 2|The highest dose of ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0 and 8, respectively (n=8). Followed up at 6,12 and 24 months after last vaccination.
3226400|NCT01151319|Experimental|Stage 3|Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
3226401|NCT01151319|Experimental|Stage 4|Three doses of pSG2.HIVconsv DNA followed by boost with MVA.HIVconsv followed by boost with high dose ChAdV63.HIVconsv at weeks at week 0,4,8,12 and 16, respectively (n=8).
3226402|NCT01151319|Placebo Comparator|Stage 2 Placebo|Time-course matched to vaccinations (n=2)
3226403|NCT01151319|Placebo Comparator|Stage 3 placebo|Time-course matched to vaccinations (n=2)
3226404|NCT01151319|Placebo Comparator|Stage 4 placebo|Time-course matched to vaccinations (n=2)
3226405|NCT01151384|Experimental|LE-DT|
3226406|NCT01151397|Active Comparator|Peg + Vitamin D + Ribavirin|Peg + Vitamin D + Ribavirin for 3 months
3226407|NCT01151397|Active Comparator|Peg + Ribavirin|Peg + Ribavirin for 6 months
3226408|NCT01151488|Experimental|Resistance Training|16 weeks of moderate intensity resistance training, 3x/week
3226409|NCT01151501|Experimental|noninvasive positive pressure ventilation|
3226410|NCT01151514||nrHA-AKI patients|Patients with hospital-acquired acute kidney injury not referred to the nephrologists
3226411|NCT01151514||lrHA-AKI patients|Patients with hospital-acquired acute kidney injury whao are late referred to the nephrologists
3226412|NCT01151527||Sporadic (idiopathic) or familial interstitial pneumonia|We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
3226413|NCT01151566||Renal Compromise|Those referred for CT scan with identified renal compromise necessitating use of no contrast agent
3226414|NCT01151566||Sensitivity to CT Contrast Agents|Those referred for CT scan with prior demonstration of contrast sensitivity requiring use of no contrast
3226415|NCT01151605|Experimental|obese|20 obese subjects
3226416|NCT01151605|Active Comparator|lean|20 lean subjects
3226417|NCT01151605|Experimental|type 2 diabetes|20 type 2 diabetes
3226418|NCT01151631|Active Comparator|100% occipital nerve stimulation|Stimulation frequency and pulse width will be uniformly held constant at 60 Hz and pulse width at 450 ms. The perception and discomfort amplitude will be defined by increasing the stimulation amplitude in steps of 0.1 V. The amplitude at which the patient starts feeling paraesthesis is called the perception threshold. The threshold at which the patient does not want the voltage to be increased any further because of painful sensations is designated the discomfort threshold. 100% stimulation is defined as stimulation at 90% of the range between perception and discomfort thresholds.
3226419|NCT01151631|Sham Comparator|30% occipital nerve stimulation|30% stimulation means a stimulation level at 30% of the range between perception threshold and 100% stimulation level
3226420|NCT01151644|Active Comparator|VACCINATION OF PATIENTS|
3226421|NCT01151644|Active Comparator|VACCINATION OF HEALTHY CONTROLS|
3226422|NCT01151657|Placebo Comparator|Placebo|Capsules containing maltodextrin.
3226423|NCT01151657|Experimental|Probiotics|Probiotics containing the 3 strains: Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12 in the dose of 2 x 109 - 10 x 109 CFU/capsule. The patients are to take 2x2 capsules a day.
3226424|NCT01151670|Experimental|Arm I|Pioglitazone 22.5 mg once daily by mouth
3226425|NCT01151670|Experimental|Arm 2|Pioglitazone 45 mg once daily by mouth
3226426|NCT01151683|Active Comparator|Magnesium|Magnesium chelate 600 mg per day
3226427|NCT01151683|Placebo Comparator|Placebo|Placebo 4 capsules per day
3226428|NCT01151696|Experimental|hydroxyzine|Patients will receive intravenous hydroxyzine 1mg/kg at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
3226429|NCT01151696|Placebo Comparator|Placebo|Patients will receive intravenous placebo at the beginning of the morphine titration protocol, and intravenous morphine 0.15 mg/kg then 0.05 mg/kg if necessary, every 5 minutes.
3226430|NCT01151709||physicians|primary care practitioners, both family practice and internal medicine physicians from a random sample of providers nationwide
3226431|NCT01151722|No Intervention|no injection|no bevacizumab
3226432|NCT01151722|Experimental|experimental 2|bevacizumab before vitrectomy
3226433|NCT01151722|Experimental|experimental 3|bevacizumab after vitrectomy
3226434|NCT01151735|Active Comparator|C-1-esterase inhibitor 1000 units|1000 units of C-1-esterase inhibitor given at time of prodromal symptoms
3226435|NCT01151735|Active Comparator|1500 units of C-1-esterase inhibitor|treatment with 1500 units of C-1-esterase inhibitor IV at the time of prodromal symptoms to decrease risk of exacerbation of HAE
3226436|NCT01151735|Placebo Comparator|placebo injection|placebo injection given for prodromal symptoms as double blinded therapy
3226437|NCT01151787|Active Comparator|cyclobenzaprine hydrochloride|
3226438|NCT01151787|Placebo Comparator|placebo|
3226439|NCT01151800|Experimental|IVR group|
3226440|NCT01151800|No Intervention|Usual care|
3226441|NCT01151839|Active Comparator|Surgery Alone|
3226442|NCT01151839|Active Comparator|Neoadjuvant chemoradiation followed by surgery|
3259028|NCT01466803|Active Comparator|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
3259029|NCT01466803|Placebo Comparator|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
3259030|NCT01466816|Experimental|Saturated fatty acid test meal|
3226443|NCT01151865|Active Comparator|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
3226444|NCT01151865|Placebo Comparator|Saline placebo|An identical syringe to that in the intervention arm, but which does not contain dexmedetomidine, will be provided. The initial rate of infusion and subsequent adjustments will be the same as in the dexmedetomidine group.
3226445|NCT01151878|Experimental|Glucomannan|glucomannan preparation in sachets: 1 saschet of 1.26g 2 times per day (daily dosage 2,52g); duration of intervention: 4 weeks
3226446|NCT01151878|Placebo Comparator|Placebo|maltodextrin prepared in sachets (1,3 g per sachet); 2 sachets per day; duration of intervention: 4 weeks
3226447|NCT01151891||Diabetics|Diabetics in the parish of St. James, Jamaica
3226448|NCT01151917||Bilio-pancreatic diversion|Each subject is own control
3226449|NCT01151943|Experimental|Transversus Abdominis Plane (TAP) Block|Patients will receive a bilateral transversus abdominis plane block
3226450|NCT01151943|Active Comparator|Incisional Infiltration of Local Anesthetic|Patients will receive an incisional infiltration with local anesthetic (continuous administration of levobupivacaïne during 48 hours)
3226451|NCT01151956||actinic keratosis patients|patients who see their non-hospital based dermatologist, because of multiple actinic keratoses and who are then routinely treated with topical 5% Imiquimod
3226452|NCT01151969|Experimental|New multicomponent intervention|
3226453|NCT01151969|No Intervention|Usual Care|
3259031|NCT01466816|Experimental|Monounsaturated fatty acid meal|
3259032|NCT01466816|Experimental|Polyunsaturated fatty acid meal|
3259033|NCT01466829|Placebo Comparator|Control|Control patients treated with placebo.
3259034|NCT01466829|Active Comparator|Intervention|Daily injection with Parathyroid hormone
3259035|NCT01466842|Other|Catheter ablation|
3259036|NCT01466842|No Intervention|Antiarrhythmic drugs|Three months before starting antiarrhythmic drugs, a subcutaneous loop recorder will be implanted.
3226454|NCT01151982|Experimental|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
3226455|NCT01151982|No Intervention|Usual Care|The kind of care that general practitioners usually provide when not knowing the level and risk profile of depression of the patients
3226456|NCT01151995||Remote plus on-site|Subjects will have remote source document verification performed 2-4 weeks prior to study monitors scheduled visit and any variables that were not able to be verified remotely will be verified on-site.
3226457|NCT01151995||On-site monitoring|Traditional source document verification will be performed when study monitor is on site
3226458|NCT01152008||healthy volunteers|
3226459|NCT01152034|Experimental|Psychoeducation group therapy|The structured group program comprised of an initial block of 12 weekly sessions with three additional monthly booster sessions, designed to support participants in the application of knowledge and skills to everyday life situations. All participants also received standard psychiatric care as well.
3259037|NCT01466855|Experimental|Treatment of Retinoblastoma|Study of Intra-Ophthalmic Artery Topotecan infusion for the Treatment of Retinoblastoma.
3259038|NCT01466868|Experimental|MK2206|Treatment is started the day after registration (day 1)until progression according to Cheson international response criteria or documented toxicity.
3226460|NCT01152034|Placebo Comparator|Treat as Usual|Patients who were assigned to the control group received standard psychiatric care and standard pharmacological treatment without group-based psychosocial intervention. Weekly phone calls to the control group over the initial 12 weeks were controlled for any extra contact time with researchers outside of the structured intervention group.
3226461|NCT01152047|Experimental|oxytocin, satiety|Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
3226462|NCT01152060||prednisone|
3226463|NCT01152060||prednisone and anti-virus|
3226464|NCT01152073|Placebo Comparator|Placebo|Study participants whose drink formulation contains no active ingredients but will appear and taste similar to the two other formulations. This will form the control formulation
3226465|NCT01152073|Active Comparator|Second Formulation|Study participants' drink formulation will include Red Yeast Rice 600mg, Niacin 12.5mg, Phytosterol esters 650mg, L-Carnitine 150mg, vitamin C 500mg, and Co-Q-10 25mg.
3226466|NCT01152073|Active Comparator|Third Formulation|The third formulation will be identical to the second, but without the Red Yeast Rice.
3226467|NCT01152086|Active Comparator|Hiking first|This group first starts with mountain hiking over 9 weeks followed by a 9 weeks control period.
3226468|NCT01152086|Active Comparator|Control first|This group first starts with the control period (9 weeks) followed by the 9 weeks mountain hiking intervention.
3226469|NCT01152099|Active Comparator|GroupA|"Ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. Multilayer bandage is applied daily during the first four weeks.~The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
3259039|NCT01466894|Experimental|IMM 124-E high dose|IMM 124-E 3600 mg per day
3259040|NCT01466894|Experimental|IMM 124-E low dose|IMM 124-E 1800 mg per day
3259041|NCT01466894|Placebo Comparator|Placebo|Placebo tablets
3226470|NCT01152099|Experimental|GroupB|"Ambulatory treatment is carried out during one month. Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
3226471|NCT01152125|Experimental|Autologous bone marrow stem cells|
3226472|NCT01152138|Active Comparator|Open Cell Stent|Open cell stent (Driver™ or Integrity™,Medtronic), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
3226473|NCT01152138|Active Comparator|Closed Cell Stent|Closed cell stent (Presillion Plus™, Cordis), routinely employed during percutaneous coronary interventions for ST elevation acute myocardial infarction
3226474|NCT01152151|Active Comparator|Postal reminders|Postal reminders
3226475|NCT01152151|Active Comparator|Electronic reminders|Electronic reminders
3226476|NCT01152164||rectal cancer patients|
3226477|NCT01152177|Active Comparator|Electronic reminders|Electronic reminders
3226478|NCT01152177|No Intervention|Usual care|usual care
3226479|NCT01152203|Experimental|Bendamustine + Bevacizumab|Bendamustine starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle. Bevacizumab 10 mg/kg by vein on Days 1 & 15 of every 28 day cycle.
3226480|NCT01152216|Experimental|Dimebon|
3226481|NCT01152229||nuisance bleeding|
3226482|NCT01152229||alarming bleeding|
3226483|NCT01152229||maintenance therapy|
3226484|NCT01152242|Active Comparator|Part 1|Part I of the trial
3226485|NCT01152242|Active Comparator|Part 2|Part II of the trial
3226486|NCT01152255|Experimental|Panel A - MK6186 40 mg|MK6186 40 mg
3226487|NCT01152255|Placebo Comparator|Panel A - Placebo|placebo
3226488|NCT01152255|Experimental|Panel B - MK6186 150 mg|MK6186 150 mg
3226489|NCT01152255|Placebo Comparator|Panel B - Placebo|placebo
3226490|NCT01152255|Experimental|Panel C - MK6186 <=150 mg|MK6186 <=150 mg
3226491|NCT01152255|Placebo Comparator|Panel C - Placebo|placebo
3226492|NCT01152255|Experimental|Panel D - MK6186 <=150 mg|MK6186 <=150 mg
3226493|NCT01152255|Placebo Comparator|Panel D - Placebo|placebo
3226494|NCT01152268||Adolescent Male Participants|"Self-report questionnaire data will be collected one time, between Days 1-7 post initiation of cancer therapy(e.g. Days 2-8 of being on-treatment for cancer) among eligible participants and their families who enroll on the study. Patients who agree to participate will be asked to complete a battery of paper and pencil questionnaires (which will also be available on-line if preferred) that assess risk/protective factors for sperm banking. When the banking recommendation is Yes or further assessment required, the profiling and referral tool will be given to the family and instructions for completion will be provided. The tool will include a list of key items which will be based on the most influential barriers to banking sperm."
3226495|NCT01152281|Active Comparator|Maximal Control|Basic awareness messages with stories of people living with AIDS
3226496|NCT01152281|Experimental|Instrumental|Instrumental messages with stories of people living with HIV
3226497|NCT01152281|Experimental|Empowering|Empowering messages with stories of people living with HIV
3226498|NCT01152281|Experimental|Instrumental and Empowering|Instrumental and empowering messages with stories of people living with HIV
3226499|NCT01152281|Active Comparator|Minimal Control|Basic awareness messages with stories of people who are not infected with HIV
3226500|NCT01152320|No Intervention|Standard of Care|
3226501|NCT01152320|Experimental|Intervention|Spirometry Fundamentals™ CD training program
3226502|NCT01152333|Active Comparator|Exendin (9-39) Acetate|Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
3226503|NCT01152333|Placebo Comparator|Saline|Saline 0.9% will be used as the control infusion.
3226504|NCT01152346|Other|ARM 1|Sequence- Azacitidine followed by Vidaza®
3226505|NCT01152346|Other|ARM 2|Sequence-Vidaza® followed by Azacitidine
3226506|NCT01152372|Other|Arm 1|Beta cell function by frequently sampled intravenous glucose tolerance test
3226507|NCT01152372|Other|Arm 2|Modified glucose disposal test assessment of insulin sensitivity, endogenous glucose production and insulin secretion
3226508|NCT01152372|Other|Arm 3|Endogenous glucose production and insulin sensitivity by isotope dilution and isoglycemic, heperinsulinemic clamp
3226509|NCT01152398|Experimental|MVA-BN-HER2|
3226510|NCT01152411|Experimental|Autologous bone marrow stem cells|
3226511|NCT01152424||Acute eosinophilic pneumonia|
3226512|NCT01152424||Community acquired pneumonia|
3226513|NCT01152476|Active Comparator|group SR|
3226514|NCT01152476|Active Comparator|group S|
3226515|NCT01152489|No Intervention|Standard Care|Immunizations are given with standard care of no pain control
3226516|NCT01152489|Active Comparator|Experimental|Vibrating device with cold pack held to arm proximal to injections within the same dermatome; caretakers offered and instructed in use of distraction cards.
3226517|NCT01152489|Sham Comparator|Sham Device|The device without batteries or cold pack held to arm proximal to injections. No formal distraction.
3226518|NCT01152541|Active Comparator|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
3226519|NCT01152541|Active Comparator|Riboflavin/dextran|Administration of Riboflavin/dextran every 2 minutes for the duration of UV exposure.
3226520|NCT01152567||ACE|Patients treated for hypertension with ACEs without CVD
3226521|NCT01152567||Candesartan|Patients treated for hypertension with candesartan without CVD
3226522|NCT01152593|Experimental|Intranasal Mupirocin|
3226523|NCT01152606||Cohort|
3226524|NCT01152619|Experimental|1|
3226525|NCT01152619|Experimental|2|
3226526|NCT01152619|Placebo Comparator|3|
3226527|NCT01152619|Placebo Comparator|4|
3226528|NCT01152632|Experimental|specific points of Bladder meridian and Shanjiao meridian|In traditional Chinese acupuncture theory, Bladder meridian and Shanjiao meridian have been considered as the main pathological meridian location of migraine. Meanwhile, specific points on both meridians have been used widely in its treatment for a long time.
3226529|NCT01152632|Experimental|non-specific points of Bladder meridian and Shanjiao meridian|Non-specific points of Shaoyang meridians are also used in cure of migraine. It is conventionally thought to be less effective using non-specific points than specific ones.
3226530|NCT01152632|Active Comparator|specific points of Stomach meridian|Specific points of Stomache meridian for migraine were searched in Chinese ancient data. And this group is set to compare with specific points of Shaoyang meridians for their possible different brain networks.
3226531|NCT01152632|Placebo Comparator|non-acupoints|Three non-acupoints were chosen,two of which were located on the arm and one one the leg.
3226532|NCT01152632|No Intervention|waiting list|
3226533|NCT01152645|Experimental|ARQ 197|
3226534|NCT01152658|Placebo Comparator|Nacl Injection|"Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).~NACL0.9% solution will be then injected to the control group in sterile conditions under ultrasound control~double blind procedure~."
3226535|NCT01152658|Experimental|PRGF|1. Blood samples (4 test tubes) will be extracted from control groups and 8 test tubes for the trial group. The blood of the trial group will be centrifuged and the platelet fraction extracted and counted (only 4 test tubes).2. The enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control.
3226536|NCT01152671|Experimental|Arm 1|
3226537|NCT01152671|Placebo Comparator|Arm 2|
3226538|NCT01152684||HIV-Positive Latinos living in San Diego or Tijuana|This is an exploratory study of Latinos living with HIV in the San Diego-Tijuana US-Mexico border region.
3226539|NCT01152723|Experimental|UNG-GA|New NRT product
3226540|NCT01152723|Experimental|UNG-GB|New NRT product
3226541|NCT01152723|Active Comparator|Nicorette® Gum|Nicorette® Gum
3226542|NCT01152736|Experimental|NSC018|Nicotine
3226543|NCT01152736|Active Comparator|Nicotine Gum|Nicorette® Gum
3226544|NCT01152749|Experimental|UNG-GC-2|2 mg experimental NRT product
3226545|NCT01152749|Experimental|UNG-GC-4|4 mg experimental NRT product
3226546|NCT01152749|Active Comparator|Nicorette® Gum-2|2 mg Nicorette® Gum
3226547|NCT01152749|Active Comparator|Nicorette® Gum-4|4 mg Nicorette® Gum
3226548|NCT01152762|Experimental|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy is the intervention in all selected patients
3226549|NCT01152775|Placebo Comparator|No Media|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
3226550|NCT01152775|Experimental|Yes Media Newly Diagnosed Breast Cancer Pts|Sixty participants will be randomized into one of two cohorts: 1. No media 2. Yes media
3226551|NCT01152801|Experimental|RAD001|
3226552|NCT01152827|Experimental|RAD001|RAD001 10 mg daily po medication
3226553|NCT01152840|Experimental|RAD001|RAD001 daily po medication
3226554|NCT01152853|Experimental|single arm|PF00299804 treatment arm
3226555|NCT01152879||Home Parenteral Nutrition|Patients receiving home parenteral nutrition
3226556|NCT01152905||Air/TIVA group|The patients received during the anesthesia a mixture of air with 30% oxygen All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
3226557|NCT01152905||Nitrous oxide/TIVA group|The patients received nitrous oxide with 30% oxygen.All patients received total intravenous anesthesia (TIVA) using target controlled infusion of propofol and remifentanil.
3226558|NCT01152918|Experimental|Linkage-to-Care Component: Financial Incentive (FI)|HIV test sites will provide financial incentives to encourage linkage to HIV care.
3226559|NCT01152918|Active Comparator|Linkage-to-Care Component: Standard of Care (SOC)|HIV test sites will provide the standard-of-care to their patients for linkage to HIV care.
3226560|NCT01152918|Experimental|Viral Suppression Component: FI|HIV care sites will provide financial incentives to encourage viral load suppression.
3226561|NCT01152918|Active Comparator|Viral Suppression Component: SOC|HIV care sites will provide the standard-of-care to their patients for viral load suppression.
3226562|NCT01152918|Experimental|Prevention for Positives Component: Counseling and SOC|Participants will take part in a computerized HIV risk reduction counseling program and receive SOC for HIV infection.
3226563|NCT01152918|Active Comparator|Prevention for Positives Component: SOC|Participants will receive SOC for HIV infection.
3226564|NCT01152931|Active Comparator|COHORT A= Amodiaquine + Artesunate|Amodiaquine will be administered orally at 10mg/kg daily for 3days. Artesunate 50mg will be administered orally daily for 3days.For subjects >6months< 1 years 4mg/kg daily for 3 days
3226565|NCT01152931|Active Comparator|cohort B= Lumefantrine +Artemether|Artemether 20mg/Lumefantrine 120mg fixed combination administered daily for 3 days
3226566|NCT01152931|Experimental|cohort C = Artesunate + vitamin A|Artesunate 50mg daily for 4days. if >6 months< 1 year 4mg/kg daily for 4days + Vitamin A 5000IU daily for 4days if < 1 year and 10,000IU daily for 4days if > 1 year respectively
3226567|NCT01152931|Experimental|Artesunate, vitamin E oral administration|Artesunate 50mg daily for 4 days.if >6 months< 1 year 4mg/kg daily for 4 days + vitamin E 100mg daily administered orally to the experimental group 4 days.
3226568|NCT01152931|Experimental|cohort E will be given Artesunate and Zinc orally|cohort E will be given Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + zinc gluconate 50mg orally daily for 4 days. if < 1 year 25 mg daily for 4 days
3226569|NCT01152931|Experimental|cohort F= Artesunate and selenium will be given orally|Artesunate 50mg daily for 4 days. if > 6 months< 1 year 4mg/kg daily for 4 days + selenium 100ug daily for 4 days. if < 1 year 50ug daily for 4 days.
3226570|NCT01152931|Experimental|cohort G = Amodiaqiune and Vitamin A will be given orally|Amodiaquine 10mg/kg daily for 3 days + vitamin A 5000iu daily for 4 days if < 1 year. 10,000 IU daily for 4 days if > 1 year.
3226571|NCT01152931|Experimental|cohort H = amodiaquine and vitamin E administerd orally|Amodiaquine 10mg/kg daily for 4 days + vitamin E 100 mg daily for 4 days
3226572|NCT01152931|Experimental|cohort I = Amodiaquine and Zinc will be given orally|Amodiaquine 10mg/kg daily for 4 days + zinc 50mg daily 4 days. if < 1 year 25 mg daily for 4 days.
3226573|NCT01152931|Experimental|Cohort J = amodiaquine and selenium will be given orally|Amodiaquine 10mg/kg daily for 4 days + selenium 100ug daily for 4 days if > 1 year. 50ug daily for 4 days if < 1 year.
3226574|NCT01152931|Experimental|K= Artesunate+ vitamin A + vitamin E|Tab Artesunate 50mg orally dly x 4 days + Vitamin A, 5000IU orally, dly x 4 days if ≤ 1yr. 10,000IU orally dly x 4days if > 1 yr + vitamin E 100 mg orally dly for 4 days
3226575|NCT01152931|Experimental|L = Artesunate+ Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
3226576|NCT01152931|Experimental|M = Artesunate+ Vitamin A + selenium|Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
3226577|NCT01152931|Experimental|N = Artesunate + Vitamin E + Zinc|Artesunate 50mg daily for 4 days. vitamin E 100mg daily for 4 days. Zinc 50 mg daily for 4 days if > 1 year. 25 mg daily for 4 days if < 1 year.
3226578|NCT01152931|Experimental|O = Artesunate+ Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
3226579|NCT01152957|Experimental|Community Health Worker Model|Care, Attention, Resources, Information, Nutrition and Optimism Project (CARIÑO Project) will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
3226580|NCT01152957|Active Comparator|Enhanced Usual Care|Usual Care and mailing of 4 health education brochures over the year.
3226581|NCT01152970||drug-using youth with violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for an acute violent injury
3226582|NCT01152970||drug-using youth with non-violent injury|Youth(ages 14-24) who report illicit drug use and who present to an urban ED for non-violence related care
3226584|NCT01153048|Experimental|Specific education intervention with peer educators|
3226585|NCT01153048|No Intervention|General education session in the health structure|
3226586|NCT01153061|Experimental|Fistula closure with occluder|Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder.
3226587|NCT01153074|Experimental|Occluder|The patients with bronchopleural fistulas treated with bronchoscopic deployment of the cardiac septal defects occluder.
3226588|NCT01153100|No Intervention|Standard insulin drip therapy|Standard insulin drip therapy
3226589|NCT01153100|Active Comparator|Insulin drip and glargine|Insulin drip and glargine 0.25 units per kg body weight
3226590|NCT01153113|Experimental|Treatment Arm A|• 5x106 cells per infusion administered ID
3226591|NCT01153113|Experimental|Treatment Arm B|• 1x107 cells per infusion administered ID (Treatment arm B).
3226592|NCT01153126|No Intervention|No Intervention: Usual Care|A group receiving usual care plus 5 reliable websites
3226593|NCT01153126|Experimental|Intervention|A group using the Comprehensive Health Enhancement Support System (CHESS.)
3226594|NCT01153139|Experimental|bilateral theta burst stimulation to the DLPFC|intermittent TBS (iTBS) to the left DLPFC continuous TBS (cTBS) to the right DLPFC
3226595|NCT01153139|Placebo Comparator|Sham stimulation|Sham stimulation with a 45° tilted coil
3226596|NCT01153165|Experimental|Citalopram|Participants will be commenced on Citalopram 20mgs daily
3226597|NCT01153165|Placebo Comparator|Control|Control group - will receive a matched placebo
3226598|NCT01153191|Experimental|Pressurized irrigation|first group-After closure of patients abdominal wall fascia, Hydrostatic irrigation with 3 liters of normal saline with Simpulse Solo irrigation system (Davol) at less than 15PSI will be applied to subcutaneous tissues prior to closure
3226599|NCT01153191|Experimental|Sub Q Antibiotic|second group of patients will receive 2mg/lg of gentamicin in 20 ml of sterile saline injected into the superficial tissues above the ABD wall fascia prior to initial incision
3226600|NCT01153204|Experimental|Group Psychotherapy (GP)|Time-limited group psychotherapy is a technique based on psychodrama, an in-depth method of group psychotherapy. Active methods are used to enable past, present, and future life events to be explored. Sexual issues and their possible solutions are enacted rather than simply discussed. Time-limited group psychotherapy focuses on a central or core issue or a circumscribed area of conflict (psychogenic erectile dysfunction) as the only or major object of intervention efforts.
3226601|NCT01153204|Active Comparator|Sildenafil|Participants took sildenafil citrate 50 mg as needed for sexual activity (on demand), no more than once daily, according to psychiatric prescription. Sildenafil citrate was taken with a glass of water on an empty stomach (at least 2 hours after eating). Participants met with a psychiatrist every month for 30-minutes to report adverse effects and to obtain the following month's dosage of four pills.
3226602|NCT01153204|Active Comparator|Group Psychotherapy (GP) plus Sildenafil|The same as above.
3226603|NCT01153217|Experimental|Abacavir|Switch from tenofovir to abacavir
3226604|NCT01153217|No Intervention|tenofovir|Follow same ART regimen
3226605|NCT01153230||poisoned patient|after patients died the pathological findings evaluated with autopsy
3226606|NCT01153243|Active Comparator|Ergocalciferol|The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)
3226607|NCT01153243|Placebo Comparator|Placebo pill|The investigators will give intervention group 12 weeks of placebo pill (in pill every week)
3226608|NCT01153256|Experimental|group M|
3226609|NCT01153256|Placebo Comparator|Group R-0.6|
3226610|NCT01153256|Placebo Comparator|Group R-0.9|
3226611|NCT01153295|Experimental|Positive diagnosis|The diagnosis of IBS is based on the international ROME III criteria, few blod tests, and abscence of danger signals
3226612|NCT01153295|Active Comparator|Diagnosis of exclusion|The diagnosis of IBS is based on normal extended blood tests, screening for celiac sprue and lactose intolerance, stool for ova and parasites and endoscopy with biopsy
3226613|NCT01153308||Bariatric Surgery Patients|Bariatric Surgery patients at UMass Memorial Medical Center
3226614|NCT01153334|Experimental|Early intensive rosuvastatin therapy|
3226615|NCT01153334|Placebo Comparator|Conventional statin therapy|
3226616|NCT01153360|Experimental|T3|triiodothyronine
3226617|NCT01153360|Active Comparator|cyanocobalamin|vitamin B12
3226618|NCT01153373|Placebo Comparator|Minimal Intervention Control|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only. The reports will not be printed or dynamic referrals generated, and all patients will receive treatment-as-usual by their ED providers."
3226619|NCT01153373|Active Comparator|DARSSA Intervention|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
3226620|NCT01153386|Experimental|0.5 mg treprostinil diethanolamine|0.5 mg treprostinil diethanolamine
3226621|NCT01153386|Experimental|2.5 mg treprostinil diethanolamine|2.5 mg treprostinil diethanolamine
3226622|NCT01153386|Experimental|1 mg treprostinil diethanolamine|1 mg treprostinil diethanolamine
3226623|NCT01153399||1|Patients with Non Small Cell Lung Cancer, visiting hospital oncology clinics
3226624|NCT01153412|No Intervention|Control Group|Control group no intervention
3226625|NCT01153412|Experimental|Osteopathic Manipulative Treatment|Osteopathic Manipulative medicine group
3226626|NCT01153438||Gastric bypass, Gastric banding|
3226627|NCT01153451|No Intervention|Usual Care|Responsible inpatient and ambulatory physicians assigned to usual care will not receive any email(s) of patients' test results generated from the notification system.
3226628|NCT01153451|Other|Email Notification|Responsible inpatient and ambulatory physicians will receive automated email(s) of patients' tests results finalized post-discharge generated from the notification system. Finalized results will be batched such that no provider will receive more than one email per day.
3226629|NCT01153464|No Intervention|Treatment As Usual|In this arm, participants are not provided any intervention through the study, they are just followed for research purposes at 3m, 6m, 9m, and 12m post baseline as the comparison group.
3226630|NCT01153464|Experimental|Recovery Support Counseling|This group is eligible to receive the telephone based recovery support counseling from paraprofessionals based out of the City of Philadelphia's Department of Behavioral Health.
3226631|NCT01153477|No Intervention|TAU|This group is the control group by which we are comparing our intervention. This group will not receive an intervention from us but will continue to be treated at the Intensive Outpatient facility from which we recruited them.
3226632|NCT01153477|Experimental|Counseling (TMAC-E)|This telephone based intervention includes six factors to improve our extended treatment model: Incentive component; Patient choice; Provision of cell phones to those who need them; Social support and community resources; Positive recovery factors; and Outreach following dropout.
3226633|NCT01153490|Placebo Comparator|Placebo|
3226634|NCT01153490|Active Comparator|Quetiapine ER|
3226635|NCT01153529||Group 1|OEF/OIF Veterans
3226636|NCT01153542|Experimental|VX-770|
3226637|NCT01153542|Experimental|desipramine|
3259042|NCT01466907|Active Comparator|Intervention group|Control of secondary prevention at three months and one year after stroke and referral to physician if medical interventions are needed. Assessment of functional status and self-reports on health outcome. Supportive counselling provided.
3226638|NCT01153555||Intermediate coronary lesions|"Diagnostic device: FFR~Diagnostic device: IVUS RF~At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol."
3226639|NCT01153568|Placebo Comparator|Placebo|placebo
3226640|NCT01153568|Experimental|Vitamin D 3|Vitamin D3 will be available in doses of 60, 90, 120, and 150 µg
3226641|NCT01153594|Experimental|Recovery Management Checkups (RMC)|Participants in the RMC group are interviewed quarterly. When they were found to be in need of treatment, the participant was transferred from the interviewer to a linkage manager to receive the intervention (described next). They were also able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
3226642|NCT01153594|No Intervention|Control Group|Participants in the control group are interviewed quarterly. While they do not receive any active intervention from the research team, they are able to re-enter treatment on their own and naturally cycle through multiple periods of substance use, treatment, incarceration and recovery.
3226643|NCT01153607|Experimental|Arm 1|
3226644|NCT01153607|Experimental|Arm 2|
3226645|NCT01153607|Experimental|Arm 3|
3226646|NCT01153646|Experimental|Cohort 1: 1x10e9 and Cohort 2: 1x10e10 T cells per infusion|Group of patients receiving genetically modified T-cells
3226647|NCT01153659|Experimental|1|
3226648|NCT01153659|Active Comparator|2|
3226649|NCT01153659|Active Comparator|3|
3226650|NCT01153737|Experimental|manual therapy|
3226651|NCT01153737|Active Comparator|TENS|Electric Nerve Stimulation (TENS)
3226652|NCT01153750|Experimental|Glivec and 5-Fluorouracil/Leucovorin|"All patients will receive Glivec® 600 mg once daily without dose escalation. Glivec® will be given on day -4, -3, -2, -1, 1, 2, 3 and 4. There will be no day 0. Patients will also receive 5-FU (2000mg/qm 24hc.i. d1 + d2) and leucovorin (200mg/qm 2h-infusion) qd15."
3226653|NCT01153776|Experimental|64-slice CT angiography|64-slice CT angiography
3226654|NCT01153789|Experimental|Patients orthoptic rehabilitation|Children with vertigo-headache and vergence disorders
3226655|NCT01153789|Other|Control Orthoptic diagnostic|Healthy controls
3226656|NCT01153802|Experimental|Healthy Male Volunteers|All the 12 subjects enrolled in the study were exposed to at least one dose of GSK1360707 15 mg, 30 mg, 60 mg, 90 mg, 120 mg and 150 mg. All the subjects completed the study. The initial dose, given in the study as a single-dose was 15 mg GSK1360707. The remaining subjects were dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose did not exceed 150 mg per day, the maximum total dose given in the FTIH study.
3226657|NCT01153828||(1) Age <9 months|Age at time of prescription was <9 months
3226658|NCT01153828||(2) 9 months to 6 years|Age at time of prescription was 9 months to 6 years
3226659|NCT01153828||(3) 7 years to 18 years|Age at time of prescription was 7 years to 18 years
3226660|NCT01153828||(4) 19 to 65 years|Age at time of prescription was 19 to 65 years
3226661|NCT01153828||(5) 66 years and older|Age at time of prescription was 66 years and older
3226662|NCT01153854|Experimental|ORS-Raceca In hospital Group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
3226663|NCT01153854|Placebo Comparator|ORS-Placebo in hospital group|This group included 135 dehydrated patients which need an oral rehydration therapy in hospital and were assigned to received oral rehydration solution and placebo in double blind assigned.
3226664|NCT01153854|Placebo Comparator|ORS-Placebo ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and placebo in double blind assigned and ambulatory (in home) bases.
3226665|NCT01153854|Experimental|ORS-Raceca ambulatory group|This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
3226666|NCT01153867|Experimental|Schema Focused Therapy|Participants will receive Schema Focused Therapy
3226667|NCT01153880||Age <9 months definitive|Age at time of prescription was <9 months
3226668|NCT01153880||Age <9 months uncertain|Age at time of prescription was uncertain for <9 months
3226669|NCT01153880||9 months to 6 years|Age at time of prescription was 9 months to 6 years
3226670|NCT01153880||7 to 18 years|Age at time of prescription was 7 to 18 years
3226671|NCT01153880||19 to 65 years|Age at time of prescription was 19 to 65 years
3226672|NCT01153880||66 years and older|Age at time of prescription was 66 years and older
3226673|NCT01153906||Exposed cohort|Females 9-25 years of age, who received at least one dose of Cervarix® as part of their routine health care.
3226674|NCT01153906||Unexposed cohort|Females 9-25 years of age, who did not receive Cervarix®
3226675|NCT01153919|Active Comparator|Arm I|Patients receive romiplostim subcutaneously once weekly for 8 weeks in the absence of disease progression or unacceptable toxicity.
3226676|NCT01153919|Placebo Comparator|Arm II|Patients receive placebo subcutaneously once weekly for 8 weeks. Patients failing to achieve a platelet count of &gt; 100,000/L cross over to arm I.
3226677|NCT01153932|Experimental|Continuous regimen; 6mg/kg once weekly|Once Weekly
3226678|NCT01153932|Experimental|Intermittent regimen; 6mg/kg twice weekly|Twice weekly on 1st, 3rd and 5th weeks, once weekly on 2nd, 4th and 6th weeks, and no active drug on 7th to 10th week of each 10 week cycle
3226679|NCT01153945||Hypothyroid|
3226680|NCT01153945||Non hypothyroid|
3226681|NCT01153945||Healthy subjects|
3226682|NCT01153997|Experimental|A|
3226683|NCT01153997|Experimental|B|
3226684|NCT01153997|Placebo Comparator|C|
3226685|NCT01153997|Placebo Comparator|D|
3226686|NCT01154023|Experimental|stimulus control therapy|Focuses on strengthening the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, and developing a consistent sleep-wake pattern
3226687|NCT01154023|Experimental|sleep restriction therapy|Sleep restriction therapy consolidates sleep by restricting the amount of time spent in bed and limiting sleep to a specific time period .
3226688|NCT01154023|Experimental|multi-component intervention|Combines stimulus control and sleep restriction: strengthen the bed and bedroom as cues for sleepiness and sleep, weaken them as cues for arousal, develop a consistent sleep-wake pattern, consolidate sleep by restricting the amount of time spent in bed and limit sleep to a specific time period
3226689|NCT01154049|Experimental|single arm|3 doses of the vaccine, on days 0, 30 and 60.
3226690|NCT01154062|Experimental|low dose|Pazopanib tablet
3226691|NCT01154114|Experimental|moderate hepatic impaired subjects|Male and female subjects with moderate hepatic impairment defined by a Child-Pugh score of 7-9 will be included. The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.
3226692|NCT01154114|Experimental|normal healthy volunteers|Healthy male and female subjects will be included and will be matched as closely as possible to the group of moderate hepatic impairment subjects for gender, age and body mass index. Each subject will receive daily 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets for 10 consecutive days.
3226693|NCT01154179|No Intervention|Normocaloric feeding|This control group will receive energy and protein intakes as recommended by the use of Schofield equations, as is current practice (100% of requirements)
3226694|NCT01154205||Patients post implantation of ICD or CRTD|
3226695|NCT01154244||Drug naive type II DM|Newly diagnosed type II Diabetes Mellitus
3226696|NCT01154257|Experimental|Cleaning teeth with toothbrush|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a toothbrush
3226697|NCT01154257|Experimental|Cleaning teeth with foam swab|Following randomisation one side of the mouth (split mouth study) will be assigned to cleaning teeth with a faom swab
3226698|NCT01154270|Experimental|IMRT + C12-boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
3226699|NCT01154309|Experimental|1|Clients are invited to attend 18 group CBT sessions
3226700|NCT01154309|No Intervention|2|Clients receive usual care
3226701|NCT01154348|Experimental|Washout period, S-707106 tablet|14-day washout of metformin, followed by S-707106 once daily for 14 days under fed conditions
3226702|NCT01154348|Placebo Comparator|Washout, placebo|14-day washout of metformin followed by placebo for S-707106 once daily for 14 days under fed conditions
3226703|NCT01154348|Experimental|Maintenance, S-707106 tablet plus metformin|14-day maintenance of metformin, followed by S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
3226704|NCT01154348|Placebo Comparator|Maintenance, placebo plus metformin|14-day maintenance of metformin, followed by placebo for S-707106 once daily plus open-label metformin twice daily for 14 days under fed conditions
3226705|NCT01154361|Experimental|Arm A|
3226706|NCT01154361|Active Comparator|Arm B|
3226707|NCT01154374|Experimental|MEBO Wound Ointment|Topical application twice daily
3226708|NCT01154374|Active Comparator|Standard of Care (sterile saline moistened gauze)|Topical application twice daily
3226709|NCT01154387|Active Comparator|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3226710|NCT01154387|Experimental|TOL101 (Dose A)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3226711|NCT01154387|Experimental|TOL101 (Dose B)|TOL101 induction as part of an immunosuppressive regimen that includes steroids, MMF, and tacrolimus.
3226712|NCT01154400|Experimental|Casein protein hydrolysates|15 g casein protein hydrolysates and 15 g maltodextrin
3226713|NCT01154400|Experimental|Whey protein hydrolysates|15 g whey protein hydrolysates and 15 g maltodextrin
3226714|NCT01154400|Experimental|Casein protein hydrolysates + LEU|15 g casein protein hydrolysates + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
3226715|NCT01154400|Experimental|Whey protein hydrolysates + LEU|15 g whey protein hydrolysates + 1.5 g LEU (40% of EAA content) + 15 g maltodextrin
3226716|NCT01154413|Experimental|Intensive education of the doctor/nursing team on the protocol|
3226717|NCT01154413|No Intervention|Without intervention in the team|
3226718|NCT01154426|Experimental|Treatment (gemcitabine hydrochloride and ABT-888)|Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease progression or unacceptable toxicity.
3226719|NCT01154439|Experimental|Everolimus|Everolimus mice-regimen
3226720|NCT01154465|Active Comparator|Anatomical guidance puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The preparation of the CVC installation will follow the procedures for disinfection, for skin preparation of the operator, for installation of sterile fields and for local anaesthesia.~The veins will be tracked by simple palpation of the carotid pulse.~The puncture will be made following:~The anterior Boulanger's incision for the internal jugular vein;~When venous aspiration is obtained, the catheter is assembled according to the Seldinger method."
3226721|NCT01154465|Experimental|US-guided puncture|"The patient is placed supine (with a slight neck extension for jugular punctures).~The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed. A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein pathway;"
3226722|NCT01154478|Experimental|B group|Diet rich in omega-3 fatty acids
3226723|NCT01154478|Experimental|C group|Diet rich in polyphenols
3226724|NCT01154478|Experimental|D group|Diet rich in polyphenols and in omega-3 fatty acids
3226725|NCT01154478|Placebo Comparator|A group (control group)|diet with low content of omega-3 fatty acids and polyphenols
3226726|NCT01154491|Placebo Comparator|Placebo|Two placebos: placebo for ferric carboxymaltose and placebo for erythropoietin
3226727|NCT01154491|Experimental|FE|Ferric carboxymaltose and placebo for erythropoietin
3226728|NCT01154491|Experimental|EPOFE|Ferric carboxymaltose and erythropoietin
3226729|NCT01154504|Other|clinical treatment|"Patients with previous diagnosis of decompensated III and IV Heart Failure will be included. The clinical treatment will be optimized.~Clinical assessment, Adrenomedullin, Angiotensin II, Brain Natriuretic Peptide, oxydative stress, sympathetic nervous system activity will be evaluated at the beginning, at discharge and 90 days after randomization(plus or minus3)."
3226730|NCT01154504|Experimental|ultrafiltration|"ultrafiltration will be done on decompensated patients III and IV acute heart failure on Intensive Care Unit. This patients will have biochemical analysis, adrenomedullin, angiotensin II,Brain Natriuretic Peptide, oxydative stress measurements,sympathetic nervous system activity evaluated and clinical outcome analyzed at the beginning,at discharge and 90 days after randomization(plus or minus 3).~Diuretic will be withdrawn during ultrafiltration."
3226731|NCT01154504|Experimental|isovolumetric hemofiltration|Patients randomized to this group will have isovolumetric hemofiltration on Intensive Care Unit. They will have biochemical analysis, Adrenomedullin plasmatic level, Brain Natriuretic Peptide Level, Angiotensin II level, Oxydative stress measurement,sympathetic nervous system, and clinical outcome evaluated at the study beginning,at discharge and 90 days after randomization(plus or minus 3).
3226732|NCT01154530|Active Comparator|Chlorhexidine mouthwash|Participants randomized to chlorhexidine mouthwash prior to gastroscopy
3226733|NCT01154530|No Intervention|No mouthwash|Mouthwash is not performed prior to gastroscopy as is the standard today.
3226734|NCT01154543||HIV positive, gential HSV,Famvir™ 500mg bd, suppressive|
3226735|NCT01154556||HIV1 positive, NNRTI exposure and failure|
3226736|NCT01154569|Active Comparator|Post Roux-en-Y gastric bypass|Post-bypass receiving a single dose of azithromycin
3226737|NCT01154569|Active Comparator|Controls|BMI and sex matched. Have not undergone surgery
3226738|NCT01154582|Experimental|Egg|
3226739|NCT01154582|Experimental|Cottage cheese|
3226740|NCT01154595|Active Comparator|Food-for-Training component|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
3226741|NCT01154595|Experimental|Food-for-Training + RUF (Plumpy Doz(r))|"Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.~In addition, a blanket supplementation with 47g RUF (Plumpy Doz(r)) per day per child is provided."
3226742|NCT01154608|Experimental|pancreatic enzymes|
3226743|NCT01154608|Placebo Comparator|control|
3226744|NCT01154621|Experimental|1|Single dose of 750mg of intravenous AZD9742 in healthy elderly volunteers
3226745|NCT01154621|Placebo Comparator|2|Sterile 5% dextrose solution
3226746|NCT01154647|Experimental|selective serotonin reuptake inhibitor|intravenous, acute, 20mg/ml
3226747|NCT01154647|Placebo Comparator|1 ml 0.9 % NaCl|
3226748|NCT01154660|Experimental|Neutral|
3226749|NCT01154660|Active Comparator|Trendelenberg|
3226750|NCT01154712|Active Comparator|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
3226751|NCT01154712|Sham Comparator|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
3226752|NCT01154725|Other|Habitual stoma care|habitual patient education
3226753|NCT01154725|Experimental|Patient education and rehabilitation|patient education and rehabilitation
3226754|NCT01154738|Experimental|Lidocaine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Lidocaine
3226755|NCT01154738|Placebo Comparator|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
3226756|NCT01154764|Experimental|CG100649|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
3226757|NCT01154764|Experimental|CG100649 and ketoconazole|study drug CG100649 (1 mg x 6 capsules) will be administered alone on Day 1, or the combination of CG100649 (1 mg x 6 capsules) and Dongkwang ketoconazole tablets (200 mg x 2 tablets) will be administered together on Day 1, followed by additional Dongkwang ketoconazole tablets (200 mg x 2 tablets) which will be administered once a day for 4 days (Days 2-5), for a total of 5 days.
3226758|NCT01154790|Experimental|CG100649|By the amount of doses, the groups are classified
3226759|NCT01154790|Active Comparator|Naproxen|By the amount of doses, the groups are classified
3226760|NCT01154790|Placebo Comparator|Placebo|By the amount of doses, the groups are classified
3226761|NCT01154803|Experimental|Ready to Use Therapeutic Food (RUTF)|500 kcal /day for 2 weeks
3226762|NCT01154803|Experimental|Micronutrient Powder (MNP)|2 x 1 g sachets micronutrients /day for 2 weeks
3226763|NCT01154803|No Intervention|no supplement|no supplementation
3226764|NCT01154829|Active Comparator|first choice treatment|Treatment with amisulpride
3226765|NCT01154829|Active Comparator|second choice treatment|treatment with aripiprazole
3226766|NCT01154842||Hemodialysis|Adult hemodialysis patients (age>18 years)
3226767|NCT01154855||Periodontitis|"Patients with severe periodontal disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning~1 per patient at 2nd visit lasting approximately 1 hour."
3226768|NCT01154855||Healthy patients|"Patients without periodontal (gum) disease Intervention (Procedure/surgery): Prophylaxis; Gross debridement for diseased patients~Other Names:~Teeth cleaning"
3226769|NCT01154868|Other|Healos|
3226770|NCT01154881|Experimental|IDeg 100U/mL 0.4U/kg|
3226771|NCT01154881|Experimental|IDeg 100U/mL 0.6U/kg|
3226772|NCT01154881|Experimental|IDeg 100U/mL 0.8U/kg|
3226773|NCT01154881|Experimental|IDeg 200U/mL 0.6U/kg|
3226774|NCT01154894|Experimental|Placebo-controlled trial|
3226775|NCT01154907||Girls ages 10-12|"In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
3226776|NCT01154907||Young adult women|"In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.~Praziquantel was administered at 40mg/kg in annual mass-treatment"
3226777|NCT01154920|Experimental|PCC Group + RT|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT)
3226778|NCT01154920|Experimental|PCC Group + RT + Chemotherapy|Group A: Paclitaxel, Carboplatin and Cetuximab (PCC) Induction + Radiation (RT) + Chemotherapy
3226779|NCT01154920|Experimental|C-TPF Group + RT|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT)
3226780|NCT01154920|Experimental|C-TPF Group + RT + Chemotherapy|Group B: Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) Induction + Radiation (RT) + Chemotherapy
3226781|NCT01154933|Experimental|exenatide 5 mcg|exenatide 5 mcg
3226782|NCT01154933|Experimental|exenatide 10 mcg|exenatide 10 mcg
3226783|NCT01154933|Placebo Comparator|placebo|placebo
3226784|NCT01154946||DAC group|patients who show detrusor after-contraction during voiding cystometrography (CMG)
3226785|NCT01154959|Experimental|Regimen 1|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 3 months (3RHZEM)
3226786|NCT01154959|Experimental|Regimen 2|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin daily for 2 months (2 RHZEM daily / 2 RHM daily)
3226787|NCT01154959|Experimental|Regimen 3|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2RHM thrice weekly)
3226788|NCT01154959|Experimental|Regimen 4|Rifampicin, isoniazid, pyrazinamide, ethambutol and moxifloxacin daily for 2 months followed by rifampicin, isoniazid, ethambutol and moxifloxacin thrice weekly for 2 months (2 RHZEM daily / 2 RHEM thrice weekly)
3226789|NCT01154959|Active Comparator|Control Regimen|Rifampicin, isoniazid, pyrazinamide and ethambutol thrice weekly for 2 months followed by rifampicin and isoniazid thrice weekly for 4 months (2 RHZE thrice weekly / 4 RH thrice weekly)
3226790|NCT01154972|Experimental|Single arm study - Sentinel Node Localisation|
3226791|NCT01154998||Cases|
3226792|NCT01154998||Controls|
3226793|NCT01155037|Experimental|3.75 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
3226794|NCT01155037|Experimental|7.5 µg of the vaccine on days 0 and 21|Patients infected with HIV will receive 7.5µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
3226795|NCT01155037|Active Comparator|3.75 µg of the vaccine on day 0|The volunteers in the control group will receive a single application of 3.75 µg dose of the vaccine.
3226796|NCT01155076|Experimental|Vitality product|Proprietary blend of ginseng, cordyceps, and pomegranate
3226797|NCT01155076|Placebo Comparator|Placebo|Placebo
3226798|NCT01155115|Experimental|Primary Ciliary Dyskinesia (PCD) Patients|
3226799|NCT01155115|Experimental|Cystic Fibrosis (CF) Patients|
3226800|NCT01155128|Experimental|Lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
3226801|NCT01155128|Placebo Comparator|lifestyle interventions|After recruitment of the participants and consented to participate those deemed eligible for inclusion completed baseline surveys will be randomly assigned to an intervention group and another control group that will receive the usual care
3226802|NCT01155206|Experimental|high glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a dose that has been shown to achieve high physiological plasma levels. The IV glucagon will be administered at a rate of 3ng/kg/min.
3226803|NCT01155206|Experimental|low glucagon|For one of the two studies to be performed in random order, the subject will receive an infusion of glucagon at a low rate that is designed to mimic basal plasma glucagon concentration. The IV glucagon will be administered at a rate of 0.65ng/kg/min.
3226804|NCT01155232||Forteo (teriparatide)|postmenopausal women and men with osteoporosis Teriparatide is marketed as Forteo by Eli Lilly Teriparatide is not supplied (observational study)
3226805|NCT01155232||Forteo (teriparatide) in AFF|women who have experienced an atypical femur fracture (AFF) Teriparatide is not supplied (observational study)
3226806|NCT01155245||Forteo (teriparatide)|postmenopausal women with osteoporosis
3226807|NCT01155245||Forteo (teriparatide) with AFF|Women with atypical femur fractures
3226808|NCT01155258|Experimental|Arm I|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22 and vinorelbine ditartrate IV over 5-10 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3226809|NCT01155271|Active Comparator|ERGO|General endurance training on cycloergometer
3226810|NCT01155271|Active Comparator|ERGONIV/ ERGOSPIRO|General endurance training on cycloergometer using ventilatory assistance (ERGONIV) or additional respiratory muscle training (ERGOSPIRO)
3226811|NCT01155297|Sham Comparator|Control Group|At the control group, with 34 subjects, will be performed stretching and metabolic exercises. This group will make the assessments before and the reassessments after the end of the program.
3226812|NCT01155297|Active Comparator|Training group|At the training group, with 34 subjects, will be performed stretching, physical training and resistance. This group will make the assessments before and the reassessments after the end of the program.
3226813|NCT01155310|Experimental|Helium/Oxygen|Helium/Oxygen 78%/22% will be administered for a maximum of 72 hours.
3226814|NCT01155310|Active Comparator|Air/Oxygen|Air/Oxygen will be administered for a maximum of 72 hours.
3226815|NCT01155349|Experimental|InSight Brain Fitness|
3226816|NCT01155349|Placebo Comparator|No contact-control|
3226817|NCT01155362|Experimental|1 unit Human Placenta-Derived Cells PDA001|1 unit PDA001 in 240 millilters (mL) infused intravenously in one arm on Day 0 and Day 7.
3226818|NCT01155362|Experimental|4 units Human Placenta-Derived Cells PDA001|4 units PDA001 in 240 mL infused intravenously in one arm on Day 0 and Day 7.
3226819|NCT01155362|Placebo Comparator|vehicle control|4 units placebo in 240 mL infused intravenously in one arm on Day 0 and Day 7.
3226820|NCT01155362|Experimental|8 units Human Placenta-Derived Cells PDA001|4 units PDA-001 in 240 mL infused intravenously in each arm on Day 0 and Day 7 or 8 units PDA-001 in 240 mL infused intravenously in one arm on Day 0 and Day 7
3226821|NCT01155401||1|Patients with acute upper gastrointestinal bleeding
3226822|NCT01155414|Experimental|Investigational infant formula A|Investigational Protein Hydrolysate formula
3226823|NCT01155414|Active Comparator|Hydrolysate based Infant Formula|
3226824|NCT01155414|Experimental|Investigational Infant Formula B|Investigational Protein Hydrolysate Formula
3226825|NCT01155427||entecavir|Patients initiating special antiviral treatments for CHB
3226826|NCT01155427||tenofovir|Patients initiating special antiviral treatments for CHB
3226827|NCT01155427||lamivudine|Patients initiating special antiviral treatments for CHB
3226828|NCT01155427||telbivudine|Patients initiating special antiviral treatments for CHB
3226829|NCT01155427||adefovir|Patients initiating special antiviral treatments for CHB
3226830|NCT01155440|Experimental|LIDOCAINE group|Beside general anesthesia, patients will receive intravenous lidocaine bolus 1.5 mg/kg just prior induction and an infusion of lidocaine 2mg/kg/h will be started and maintained during the whole surgical procedure. Entering the recovery room, this infusion will be decreased at the rate of 1mg/kg/hour for the 48 first hours
3226831|NCT01155440|Active Comparator|Epidural group|Beside general anesthesia, patient will receive epidural freezing medication for 48 hours.
3226832|NCT01155453|Experimental|BKM120 + GSK1120212 DE|Dose Escalation
3226833|NCT01155453|Experimental|BKM120 + GSK1120212 NSCLC patients|Advanced RAS or BRAF mutant NSCLC patients
3226834|NCT01155453|Experimental|BKM120 + GSK1120212 ovarian cancer patients|Advanced RAS or BRAF mutant ovarian cancer patients
3226835|NCT01155453|Experimental|BKM120 + GSK1120212 pancreatic cancer patients|Advanced RAS or BRAF mutant pancreatic cancer patients
3226836|NCT01155492||Subjects with Parkinson's disease|Male and female subjects with clinically diagnosed Parkinson's disease, Stage I-IV.
3226837|NCT01155492||Control subjects|Age- and gender-matched subjects who do not have Parkinson's disease
3226838|NCT01155492||Multiple system atrophy.|Men and women with clinically diagnosed multiple system atrophy.
3226839|NCT01155505|Experimental|CC-5013 in combination with Paclitaxel|"Cohorts of 3 evaluable patients will initially be entered within each dose level, sequentially. In each dose level the second and third patient will enter 2 weeks after the first one. The second and third patient may be treated simultaneously, except if a DLT is reported in the first patient, in which case the second and third patient should be treated sequentially, at least one week apart.~Dose escalation will be done when all the patients included in each DL will finish the first treatment cycle. Three additional patients will be sequentially entered (separated by one week each other) if one DLT is observed in cycle 1 among the first 3 patients entered within a dose level. If a DLT is observed in a second patient at this dose level, no further dose escalation will be allowed and the dose level will be considered the MTD.~Once the RD (one level below the MTD) has been defined, additional patients (up to 12) will be treated in order to confirm the safety profile of the combination."
3226840|NCT01155544|Active Comparator|Aripiprazole|
3226841|NCT01155544|Placebo Comparator|Placebo|
3226842|NCT01155557|Active Comparator|Specific Strength Training|10 weeks of specific strength training of neck and shoulder muscles using elastic resistance.
3226843|NCT01155557|Active Comparator|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
3226844|NCT01155596|No Intervention|Control group|Base on positive pressure ventilation with intubation and mechanical ventilator, weaning processes will undergo by Pulmonologists.
3226845|NCT01155596|Experimental|Experimental group|Experimental group is weaning with the support of negative pressure ventilator.
3226846|NCT01155609|Experimental|Supportive care (oral complications management)|Patients receive L-Lysine PO QD until completion of radiotherapy and resolution of mucositis in the absence of disease progression or unacceptable toxicity.
3226847|NCT01155622|Active Comparator|32º Celsius|Endovascular Cooling was set at a target temperature of 32°C
3226848|NCT01155622|Active Comparator|34º Celsius|Endovascular Cooling was set at a target temperature of 32°C
3226849|NCT01155635|Active Comparator|Beta-blocker|Use of Carvedilol with any dose
3226850|NCT01155635|Active Comparator|Non Beta-blocker|No use of Carvedilol
3226851|NCT01155648|Experimental|PSV group.|Chest wall compression plus increase of 10 cmH2O of PSV.
3226852|NCT01155648|Active Comparator|chest wall compression group|Chest wall compression
3226853|NCT01155674||Sepsis patients|Patients presenting sepsis
3226854|NCT01155674||SIRS patients|Patients presenting with the systemic inflammatory response syndrome
3226855|NCT01155674||Healthy subjects|Healthy blood donors
3226856|NCT01155687||Psychosocial counseling|the group received annualized treatment of psychosocial counseling
3226857|NCT01155687||Medication|this group received medical treatment by the local medical doctor
3226858|NCT01155700|Experimental|Omalizumab|Omalizumab treatment
3226859|NCT01155713|Experimental|Arm 1 - TKI258 - bioavailability|
3226860|NCT01155713|Experimental|TKI258 - food effect|
3226861|NCT01155739||procalcitonine monitoring|PCT group: antibiotic use is tailored by serum procalcitonin values, determined every 48houres.
3226862|NCT01155739||control group|control group: antibiotic use and length of treatment as defined by guidelines
3226863|NCT01155752|Experimental|PULMOZYME|active drug
3226864|NCT01155752|Placebo Comparator|placebo|cross over to placebo
3226865|NCT01155765|Experimental|Prasugrel|Prasugrel per os 10 mg/day
3226866|NCT01155765|Active Comparator|Clopidogrel|Clopidogrel per os 150 mg/day
3226867|NCT01155791|Experimental|combination sodium selenite and docetaxel|
3226868|NCT01155804|Other|Exercice|
3226869|NCT01155804|Other|non-exercice|
3226870|NCT01155817|Experimental|Nilotinib|
3226871|NCT01155843||Asthmatic, chronic stress|
3226872|NCT01155843||Asthmatic, non-stress|
3226873|NCT01155856|Experimental|telemedicine|Within 24 hours after admission for exacerbation of COPD, patients in the intervention group are sent home for further treatment (telemedicine based) instead of the conventional treatment at the hospital. Patients in the intervention group will receive the same treatment as the control group and have daily contact with the physician/nurse at the hospital through a videoconference system.
3226874|NCT01155856|No Intervention|control|The control group will receive usual care and treatment at the hospital until discharge(typically between 5-7 days).
3226875|NCT01155882||Whipple Surgery at the Splenic Artery|Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
3226876|NCT01155895|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
3226877|NCT01155895|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
3226878|NCT01155908|Experimental|Amlodipine Besylate/Benazepril Hydrochloride|10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited
3226879|NCT01155908|Active Comparator|Lotrel|Lotrel® (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis
3226880|NCT01155921|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
3226881|NCT01155921|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
3226882|NCT01155934|Experimental|Risperidone Orally Disintegrating|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
3226883|NCT01155934|Active Comparator|Risperdal M-TAB|(Risperdal M-TAB) 1 mg risperidone orally disintegrating tablets Janssen Pharmaceutica Products
3226884|NCT01155947|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
3226885|NCT01155947|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
3226886|NCT01155960|Active Comparator|Arimidex|Arimidex® Tablets 1 mg
3226887|NCT01155960|Experimental|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
3226888|NCT01155973|Experimental|EDUCORE intervention|Use of low risk SCORE table. Use of visual impact images. Handing the patient a pamphlet (advice on how to maintain cardiovascular health plus the low risk SCORE table with the patient's current score marked).
3226889|NCT01155973|Active Comparator|control group|Use of low risk SCORE table; verbally informing the patient of his/her CVR. Giving advice/verbal information on risk factors.
3226890|NCT01155986|Placebo Comparator|Placebo Plaster|Active Comparator
3226891|NCT01155986|Active Comparator|Lidocaine Plaster|
3226892|NCT01156025|Experimental|GV550|(Ganciclovir 1.5 mg/g ophtalmic gel)
3226893|NCT01156025|Placebo Comparator|Placebo|Placebo ophtalmic gel
3226894|NCT01156038|Experimental|Atopy patch test|Atopy patches were applied on healthy volunteer's back for 48 hrs then the patches were removed. Reaction was evaluated 48 and 72 hrs after applying atopy patch test
3226895|NCT01156064||Case (subjects with digestive diseases)|The investigators cases are subjects with confirmed digestive diseases.
3226896|NCT01156064||Control|Healthy individuals aged between 18 and 90 years who are asymptomatic for digestive diseases.
3226897|NCT01156077|Experimental|oral TR-701 FA|Single oral dose of 200 mg TR-701
3226898|NCT01156077|Experimental|IV TR-701 FA|Single IV infusion of 200 mg TR-701 FA
3226899|NCT01156090||Vectibix|patients who received at least one treatment of Vectibix
3226900|NCT01156103|Experimental|SCORES|America SCORES, Bay Area, after-school program
3226901|NCT01156103|No Intervention|Usual care|Standard after-school programming
3226902|NCT01156129|Active Comparator|Arm A: Standard therapy (use of medications)|stool softener
3226903|NCT01156129|Experimental|Arm B: Acupressure bracelets|device - Biobands
3226904|NCT01156129|Experimental|Arm C|Sugar free gum
3226905|NCT01156155||Participants with Rheumatoid Arthritis|Rheumatoid arthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination Bilateral digital xray of hands
3226906|NCT01156155||Osteoarthritis|Osteoarthritis patients Digital xray of jaw and teeth Blood draw questionnaires Periodontal Examination
3226907|NCT01156181|Experimental|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
3226908|NCT01156181|Active Comparator|Control|Embryo transfer without any intervention
3226909|NCT01156194|Active Comparator|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
3226910|NCT01156194|Active Comparator|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
3226911|NCT01156194|Placebo Comparator|Placebo|globules identical to true comparators
3226912|NCT01156207|Experimental|Aliskiren|
3226913|NCT01156207|Placebo Comparator|placebo|
3226914|NCT01156220|Experimental|female|"The healthy female volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2."
3226915|NCT01156220|Experimental|male|"The healthy male volunteers receive furosemide and aminohippurate sodium PAH as single dose randomised on day 1 or day 2"
3226916|NCT01156233|Experimental|Cuff palpation technique|Cuff palpation by the investigator's finger.
3226917|NCT01156233|Experimental|Withdrawing tube technique|Identification of the tube by withdrawing until good quality breath sounds
3226918|NCT01156246|Experimental|1|Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, fasting conditions day 1, visit 3.
3226919|NCT01156246|Experimental|2|Dapagliflozin/metformin tablet, fasting conditions day 1, visit 2, 7-14 days wash-out, Dapagliflozin/metformin tablet, high fat, high calorie breakfast day 1, visit 3.
3226920|NCT01156259|Experimental|30 Gy|
3226921|NCT01156259|Active Comparator|40 Gy|
3226922|NCT01156272||Replacement aortic heart valve|ATS 3f® Aortic Bioprosthesis, Model 1000, Size 19mm
3226923|NCT01156285||AAU|patient with acute attack of anterior uveitis
3226924|NCT01156298||Cohort 1|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Cohort 1 patients will have annual EDSS, self-report EDSS, medication review and relapse recalculation. SF-36 and SDMT assessments will be performed at years 1 and 5 during routine office visits. A MRI will be performed each patient's 15 year anniversary date.
3226925|NCT01156298||Cohort 2|Patients were diagnosed upon entry into CHAMPS with CIS demyelinating event with MRI lesions consistent with MS. Patients are eligible regardless of whether they have converted to Clinically Definite Multiple Sclerosis (CDMS) or not. Patients will be waiving written informed consent and asked to provide concomitant medication, self-reported EDSS, and SF-36 only.
3226926|NCT01156324|Placebo Comparator|Control|Participants of the routine care control group will each receive a $50 gift certificate at the end of each IVF cycle for which they completed the questionnaires.
3226927|NCT01156324|Experimental|Online Stress Management Group (Upliv)|Personalized online stress management program consisting of weekly sessions which each include relaxation exercises, stress management strategies, and lifestyle modification advice. Participants in Upliv will also be given a set of personal care products as part of the program.
3226928|NCT01156337||low sodium diet 80 mmol/day|
3226929|NCT01156337||moderate sodium intake 120 mmol/day|
3226930|NCT01156389|Active Comparator|Ritonavir plus Pyramax arm|Subjects in arm A will take 7 days of ritonavir followed by 3 days of ritonavir plus Pyramax followed by 7 days of ritonavir followed by 33 days follow-up period (40 days since last Pyramax dosing) and a study completion evaluation.
3226931|NCT01156389|Active Comparator|Pyramax arm|Subjects in arm B will take a three day treatment course of Pyramax, followed by a follow up period of 40 days since last Pyramax dosing and a study completion evaluation.
3226932|NCT01156402|Experimental|Active Intervention: Obesity Prevention|
3226933|NCT01156402|Experimental|Alternative Intervention/control: Oral Health|
3226934|NCT01156415|Experimental|Agomelatine (AGO178) 0.5 mg|
3226935|NCT01156415|Experimental|Agomelatine (AGO178) 1 mg|
3226936|NCT01156428||Control Subjects (normal volunteers)|"Control kidney specimens will be obtained from donor transplant kidneys or nephrectomy specimens performed on patients undergoing nephrectomy for the clinical indication of an identified renal mass.~In the case of donor transplant kidneys, the renal biopsy will be conducted during the act of living donor nephrectomy and transplantation.~In the case of renal mass nephrectomies, representative normal tissue will be obtained from the nephrectomized kidney at a site distant from the renal mass."
3226937|NCT01156428||Renal Disease Subjects|Patients who require a renal biopsy based upon clinical indications such as proteinuria, hematuria, acute renal failure (ARF) of unclear etiology, chronic kidney disease of unclear etiology, nephrotic syndrome, nephritic syndrome, suspected lupus nephritis or any other medically warranted indication for a biopsy.
3226938|NCT01156441|Experimental|surgical mitral valve repair|Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree. Mitral valve repair will be performed with mitral valve annuloplasty via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia.
3226939|NCT01156441|No Intervention|control: medical management|Clinical observation will be continued without surgery. Non-invasive transesophageal echocardiography will be performed on all study volunteers to determine if the individual has mitral regurgitation and, if so, to what degree.
3226940|NCT01156454||Surgery followed by x-ray assessment|After nodes are removed they are taken to radiology to be x-rayed
3226941|NCT01156467|Active Comparator|Control|Infants randomised to this arm will receive a regular nasogastric tube, and the ventilatory care is given as routinely is done.
3226942|NCT01156467|Active Comparator|NAVA|Infants randomised to this arm will receive and Edi-catheter as an oro-/nasogastric tube and the Edi-signal will be monitored and when possible NAVA-ventilation used.
3226943|NCT01156493|Experimental|Protein Hydrolyzed Formula|Infants assigned to this group will receive HP formula when breast milk not available or indicated to receive formula by the attending physician
3226944|NCT01156493|No Intervention|Control|Infants in this group will receive standard prematrue formula when no breast milk available or indicated by the attending physician
3226945|NCT01156519|Other|Salivary cortisol|
3226946|NCT01156545|Experimental|Treatment arm|BIBW 2992 plus simvastatin arm
3226947|NCT01156545|Active Comparator|control arm|BIBW 2992 arm
3226948|NCT01156584|Experimental|Single arm|Toca 511 vector/ Toca FC prodrug
3259043|NCT01466907|Other|Control group|Standard care with no outlined follow-up until one year after stroke. Control of secondary prevention after one year after stroke and referral to physician if medical interventions are needed. Follow-up one year after stroke according to the same protocol as the intervention group.
3259044|NCT01466933|Experimental|Community-based|Community trained peer educator delivers parenting sessions to mothers in the village on a monthly basis
3226949|NCT01156610|Experimental|Integrated Cessation Counseling|"IVR System: IVR will be used for two purposes: (1) to facilitate access to treatment for low-SES and minority smokers and (2) perform six-month outcome assessment.~Tobacco Treatment Specialist Calls: A tobacco treatment specialist will make four attempts to contact the patient by phone within 14 days. On contacting the patient, the specialist will screen the patient for readiness to quit, provide brief (10 to 15 minutes) counseling tailored to the patient's readiness to quit, and provide information and support for use of medications that could be or were prescribed and about relevant community resources.~NRT: Patients who do not have a contraindication and smoke > 10 cigarettes per day, will be offered a free 6-week kit of generic nicotine patches (2 weeks of 21 mg patches, 2 weeks of 14 mg patches, and 2 weeks of 7 mg patches). Individuals who smoke 5-10 cigarettes/day will be offered a 6-week course, starting with the 14 mg patch. Those with a contraindication will not get NRT."
3259045|NCT01466933|Active Comparator|Government-based|Government community health workers, trained, deliver the intervention to mothers in the village
3259046|NCT01466933|No Intervention|Control|Mothers receive the standard care which is a visit from the health worker
3226950|NCT01156610|Active Comparator|Usual Care|"IVR Call: Similar to the initial IVR call for the intervention arms, the initial control arm call will confirm the participant's identify and provide a brief description of the study (obtaining information about health behaviors), with the opportunity for the individual to accept or decline participation. Following this introduction, the IVR script will confirm smoking status. The phone script will collect specific information about current smoking (cigarettes/day), prior quit attempts, and motivation to quit during the next month. No further contact will be made with patients in the control clinics until the outcome assessment call. In the control practices, the IVR machine will also generate a text note documenting the information obtained for the patients' EHR for use by the patient's health care providers as part of their visit-based best practices."
3226951|NCT01156623|Experimental|With EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, further EBUS-TBNA will be arranged if patients agreed it.
3226952|NCT01156623|No Intervention|Without EBUS-TBNA group|The patients enrolled in present study are those with non-small lung cancer and receive contrast-enhanced computed tomography (CT) and Positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (FDG) examination. In this group, no EBUS-TBNA will be arranged if patients refused it despite we advised it.
3226953|NCT01156636|Active Comparator|Sildenafil|
3226954|NCT01156636|Placebo Comparator|Placebo|
3226955|NCT01156649|Sham Comparator|Sham PAP therapy|Sham PAP will be used with 30 children, and consists of continuous sub-therapeutic levels of air pressure (approximately 1 cm of water) that are delivered through the nasal interface device.
3226956|NCT01156649|Active Comparator|Treatment group|30 children will receive active treatment PAP, which consists of automatically adjusted air pressures that are delivered through the nasal interface device at levels which effectively treats the obstructive events.
3226957|NCT01156662|Active Comparator|No aspiration|
3226958|NCT01156662|Active Comparator|Thrombus aspiration|
3226959|NCT01156688|Active Comparator|Sublingual Misoprostol|
3226960|NCT01156688|Active Comparator|Buccal misoprostol|
3226961|NCT01156727||SURVEY: 6 months post-deployment|Michigan Army National Guard soldiers 6 months post deployment between August 2011 and December 2013
3226962|NCT01156727||SURVEY: 12 months post-deployment|Michigan Army National Guard soldiers 12 months post deployment between August 2011 and December 2013.
3226963|NCT01156727||INTERVIEWS|Michigan Army National Guard soldiers 12-24 months post deployment between October 2011-April 2014. Also key stakeholders from the B2B program.
3226964|NCT01156740|Active Comparator|Intramuscular benzathine Penicillin G|A single dose of intramuscularly administered intramuscular benzathine penicillin G (IM BPG). The dosing was as follows: IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg
3226965|NCT01156740|Active Comparator|Amoxicillin|A 10-day once daily dose of Amoxicillin was given in an oral form. The first dose was given at the time of randomization, and parents were instructed on giving the remaining doses. Dosing was as follows: 750 mg/QD
3226966|NCT01156753|Experimental|CDX-011|
3226967|NCT01156753|Active Comparator|"Investigator's Choice chemotherapy"|
3226968|NCT01156779|Experimental|DA-3091|SR-exenatide
3226969|NCT01156779|Placebo Comparator|Placebo of DA-3091|Placebo
3226970|NCT01156818||Children|Age 8-21 years
3226971|NCT01156818||Adult|Age 21-80 years
3226972|NCT01156857|Experimental|A|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
3226973|NCT01156857|Experimental|B|Drug: PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets).
3226974|NCT01156870|Experimental|SAR566658|SAR566658 will be administered by intravenous (IV) infusion according to three different schedules
3226975|NCT01156896|Experimental|Iron intervention|"All study subjects with malaria and all control subjects will receive an iron intervention (supplement or fortification dose of iron).~Control subjects will be studied on only one occasion.~Study subjects with malaria will receive the same iron intervention two weeks later, after the malarial episode has been successfully treated."
3226976|NCT01156909|Experimental|Rituximab|Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
3226977|NCT01156922|Experimental|Rituximab|Rituximab induction two infusions (500 mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.
3226978|NCT01156935|Experimental|Laugh yoga|experimental laugh yoga
3226979|NCT01156948|Active Comparator|vaginal misoprostol|vaginal misoprostol was administered to this group of nulliparous women
3226980|NCT01156948|Experimental|oral misoprostol|oral misoprostol
3226981|NCT01156961|Experimental|Single Arm|
3226982|NCT01156974|Experimental|care guide|patients receive education about care goals and work with a care guide to achieve goals
3226983|NCT01156974|Active Comparator|no care guide|patients receive education about care goals and usual care to achieve goals
3226984|NCT01157000|Experimental|001|Canagliflozin On Day 1 all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
3226985|NCT01157013|Experimental|Advanced Hepatocellular Carcinoma|Hepatocellular carcinoma patients not candidates to local and/or curative treatment and an expected overall survival of at least three months and who are susceptible of receiving sorafenib therapy.
3226986|NCT01157026|Experimental|Tocotrienol Rich Fraction plus Tamoxifen|
3226987|NCT01157026|Active Comparator|Placebo plus tamoxifen|
3226988|NCT01157039|Experimental|Dietary Supplement|Arm A: At cycle 2, patients will be randomized to receive for 6 days- Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3
3226989|NCT01157039|Experimental|Dietary supplement|Arm B: At cycle 2, patients will be randomized to receive for 6 days: Glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3.
3226990|NCT01157052|Active Comparator|Ca2+/Mg2+ pre & post cycle 1|Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1
3226991|NCT01157052|Active Comparator|Ca2+/Mg2+pre & post cycle 2|Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
3226992|NCT01157091|Experimental|Arm I|Patients receive oral pazopanib hydrochloride once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3226993|NCT01157104|Experimental|IDX320 + PBO → IDX320 + IDX184|400 mg IDX320 and IDX184 matching placebo (PBO) once daily for 7 days; followed by 400 mg IDX320 and 100 mg IDX184 once daily for 7 days
3226994|NCT01157104|Experimental|IDX184 + PBO → IDX184 + IDX320|100 mg IDX184 and IDX320 matching PBO for 7 days; followed by 100 mg IDX184 and 400 mg IDX320 for 7 days
3226995|NCT01157104|Placebo Comparator|IDX320 PBO + IDX184 PBO|IDX320 matching PBO + IDX184 matching PBO for 14 days
3226996|NCT01157130|Experimental|Intervention Group|Each patient will have a weekly goal of 2000 calories burned and 18 MET-hours of exercise which can be achieved in 4 to 7 hours of physical activity per week. Resistance training, using weight machines and aerobic training using treadmills, elliptical trainers and stationary bicycles, will be utilized in the intervention group.
3226997|NCT01157130|No Intervention|Control Group|The control group will receive basic information on physical activity but not be instructed.
3226998|NCT01157143|Experimental|NV1FGF 500 μg|8 intramuscular injections for a total of 500 μg administered in one single administration 3 to 8 days before major amputation
3226999|NCT01157143|Experimental|NV1FGF 2000 μg|8 intramuscular injections for a total of 2000 μg administered in one single administration 3 to 8 days before major amputation
3227000|NCT01157143|Experimental|NV1FGF 4000 μg|8 intramuscular injections for a total of 4000 μg administered in one single administration 3 to 8 days before major amputation
3227001|NCT01157195|Active Comparator|CI therapy|
3227002|NCT01157195|Experimental|Tele-AutoCITE|AutoCITE stands for Automated Constraint Induced Therapy Extender.
3227003|NCT01157208|Experimental|Diet A|This diet is high in omega-3 fatty acids, low in trans fatty acids, and low in omega-6 fatty acids. Subjects are encouraged to eat fatty fish daily (e.g., salmon), to limit vegetable oil intake, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include salmon-salad sandwiches, hummus with olive oil, other bean dips and bean dishes, frozen and canned fish, and blueberry-flax muffins.
3227004|NCT01157208|Experimental|Diet B|This diet is low in trans fatty acids and low in omega-6 fatty acids. Subjects are encouraged to to limit vegetable oil intake, to replace meats and eggs with beans and lean fish/shellfish, and to eat fruits, vegetables and whole grains. Specifically formulated and other provided foods for this group will include hummus with olive oil, other bean dips and bean dishes, lean fish and shellfish,and blueberry muffins.
3227005|NCT01157221|Experimental|intervention group|intervention group: end-range mobilization/scapular mobilization treatment approach group
3227006|NCT01157221|Active Comparator|control|
3227007|NCT01157221|Sham Comparator|control-criteria group|
3227008|NCT01157247|Other|Group SNI|Insertion of spinal needle with introducer
3227009|NCT01157247|Other|Group SNI+LA|Local infiltration of lidocaine was applied three minutes after insertion of spinal needle with introducer
3227010|NCT01157247|Other|Group SNI+F|Intravenous fentanyl was applied 3 min before insertion of spinal needle with introducer
3227011|NCT01157247|Other|Group SN|Spinal puncture was performed only with spinal needle without introducer, local anesthetic infiltration or intravenous fentanyl before spinal puncture.
3227012|NCT01157260|Experimental|AST-120|AST-120 administration 2g three times a day
3227013|NCT01157260|No Intervention|Control|Control Chronic Kidney disease stage 3,4
3227014|NCT01157273||High Anxiety (HA) group|13 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores above 41 in STAI-Trait
3227015|NCT01157273||Low Anxiety (LA) group|11 participants of both genders, 19-42 years old, with no history of psychiatric disorders and scores below 41 in STAI-Trait
3227016|NCT01157286||level of apnea|patients will be separated depending on the iah(apnea hypopnea index) in mild, moderate and severe
3227017|NCT01157299||Hemodynamic instability|Hypotension and/or evidence of end-organ hypoperfusion
3227018|NCT01157299||Hemodynamic stability|"Normotension and end-organ normoperfusion along with~Vasopressor, vasodilator or inotropic therapy~Edema and/or evidence of hypervolemia"
3227019|NCT01157299||"Hemodinamically normal"|"Normotension and end-organ normoperfusion along with~Non vasopressor, vasodilator or inotropic therapy~Normohydration state~Non Systemic Inflammatory Response Syndrome~Spontaneous breathing and PEEP, or CPAP, equal or less than 5 cm H2O"
3227020|NCT01157312|Experimental|minimal stimulation protocol|5 days of CC (100mg/day) from day 3 followed by 150 IU of highly purified uFSH on cycle day 9 for three treatment cycles
3227021|NCT01157312|Active Comparator|clomiphene citrate(CC)|5 days of CC (100mg/day) from cycle day 3 for three treatment cycles.
3227022|NCT01157325|Active Comparator|Non-neuraxial analgesia|Parturients will not receive neuraxial analgesia
3227023|NCT01157325|Active Comparator|Neuraxial analgesia|Parturients will receive neuraxial analgesia
3227024|NCT01157338|Active Comparator|diagnostic cardiac catheterization|patients with diagnostic cardiac catheterization
3227025|NCT01157338|Active Comparator|therapeutic cardiac catheterization|patient with angioplasty
3227026|NCT01157390|Experimental|Infant formula|The infants will be fed with Wondersun infant formula with high proportion of palmitic acid at the sn-2 position
3227027|NCT01157390|Active Comparator|Breast feeding|Complete breast feed within the first 3 month
3227028|NCT01157403|Experimental|mesenchymal stem cells|To study the safety and efficacy of autologous transplantation of bone marrow mesenchymal stem cells in treatment of newly diagnosed patients with T1DM.
3227029|NCT01157442|Experimental|cell phone sms messages|The experimental arm will receive the cell phone SMS text messaging intervention.
3227030|NCT01157442|No Intervention|Control|The control group will receive the standard of care but no SMS text messages.
3227031|NCT01157468||Cases|"The Case group is constituted with patients with Systemic Lupus Erythematosus from Martinique, divided en 2:~30 patients with a quiescent lupus~30 patients with an active lupus"
3227032|NCT01157468||Controles|"The Control group is constituted by people coming to give blood to the French Blood Establishment of Martinique."
3227033|NCT01157481|Experimental|Conventional therapy plus nifedipine|
3227034|NCT01157481|Active Comparator|Conventional therapy|
3227035|NCT01157494||children with hemiplegia|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
3227036|NCT01157507|Active Comparator|Botulinum A toxin|Botulinum A toxin intravesical injection.
3227037|NCT01157507|Sham Comparator|Bladder overdistension|Standard treatment: bladder overdistension
3227038|NCT01157507|Placebo Comparator|Placebo|
3227039|NCT01157520||Cesarean|Women scheduled for elective Cesarean section under spinal anesthesia
3227040|NCT01157546|Placebo Comparator|Control|group A (control) will receive a bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side) via both TAP catheters.The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
3227041|NCT01157546|Experimental|TAP|group B (TAP) will receive a bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side) via TAP catheters. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
3227042|NCT01157572|Active Comparator|Metoprolol|
3227043|NCT01157572|Placebo Comparator|Placebo|
3227044|NCT01157585|Other|drug|
3227045|NCT01157598|Active Comparator|BIS group|
3227046|NCT01157598|Placebo Comparator|non BIS group|
3227047|NCT01157611|Active Comparator|Mentoring program group|type 1 diabetes patients participating in online base mentoring program
3227048|NCT01157611|No Intervention|Control group|type 1 diabetes patients receiving regular clinic visits
3227049|NCT01157624|Active Comparator|oxygen|
3227050|NCT01157624|Placebo Comparator|air supplement|
3227051|NCT01157650|Experimental|Autologous mesenchymal stem cells|Fistulizing Crohn's disease
3227052|NCT01157663|Experimental|Adapted Balance Training group|
3227053|NCT01157663|Active Comparator|Standard Balance training group|Balance training with unipedal standing during 8 weeks
3227054|NCT01157689||Coartem, chloroquine, quinine|All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.
3227055|NCT01157702|Experimental|Vaccine|Vaccination with one dose (0.5 mL) of inactivated influenza vaccine
3259047|NCT01466946||semi-structured interviews|A qualitative study of MSKCC lung cancer patients of Hispanic/Latino descent by collecting retrospective patient narratives to understand the processes that led them to seek medical help when they did, their experiences in seeking and receiving medical guidance, as well as their decisions regarding lung cancer treatment. In addition, we will explore how these patients' representations of lung cancer with its associated risk factors and symptoms affected their treatment decisions.
3227056|NCT01157715|Experimental|0.5 mg cohort|patients will receive monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
3259048|NCT01466959|Active Comparator|AD- acetic acid dialysate|AD is a standard bicarbonate based dialysate with a small amount of acetic acid which is the standard of care for dialysis.
3259049|NCT01466959|Experimental|CD - citrasate dialysate|Dialysis with a citric acid based dialyasate.
3227057|NCT01157715|Experimental|2.0 mg cohort|patients will receive monthly intravitreal injections of 2.0 mg KH902 for 3 times in the study eye;following the initial 3-month fixed-dosing phase of the trial, patients will be randomized in a 1:1 ratio into one of two groups as follows: i. q1m group: patients will continue to receive monthly intravitreal injections of KH902 at the same dose received during the fixed dosing phase; ii. prn group: patients will continue to receive injection of KH902 at the same dose received during the fixed dosing phase, on an as needed (PRN) dosing schedule based upon the physician assessment of the need for re-treatment in accordance with pre-specified criteria .
3227058|NCT01157728||Relapsing Multiple Sclerosis patients|
3227059|NCT01157728||healthy volunteer|
3227060|NCT01157741|No Intervention|Standard Practice (H-C)|1) Hospital control group (Group H-C): children assigned to this group received the standard hospital-based, outpatient treatment package, which consisted of fortnightly follow-up for growth monitoring, health and nutrition education, and micronutrient supplementation.
3227061|NCT01157741|Experimental|C-C|Community-based follow-up (Group C-C): the standard community-based follow-up package was identical to the one provided to the hospital-based control group, except that the follow-up visits took place at the nearest CNFU rather than the HNFU.
3227062|NCT01157741|Experimental|C-SF|Community-based follow-up plus supplementary food (Group C-SF): children assigned to this group received the same treatment package as those in Group C-C, except that supplementary food (SF) packets and preparation instructions were also provided at the time of each follow-up clinic visit for consumption at home in addition to the children's usual meals.
3227063|NCT01157741|Experimental|C-PS|Community-based follow-up plus psychosocial stimulation (Group C-PS): children assigned to this group received the same treatment package as those in Group C-C, except that they were also provided with psychosocial stimulation (PS).
3227064|NCT01157741|Experimental|C-SF+PS|Community-based follow-up plus SF and PS (Group C-SF+PS): children assigned to this group received the same treatment package as those in the Group C-C, except that they were also provided with both SF and PS, as described above.
3227065|NCT01157754|Experimental|OCP+GnRH antagonist|Microgynon 14 to 21 tablets starting COH on day 5 post pill, rFSH + GnRH antagonist
3227066|NCT01157754|Active Comparator|long GnRH agonist|daily triptorelin starting day 21st of previous cycle
3227067|NCT01157767||breast pts who have undergone surgery|This will be a feasibility study designed to evaluate the compliance of an at-home, directed exercise program and its influence on physical measures during post-operative adjuvant chemotherapy and radiation (if applicable).
3259050|NCT01466998|Experimental|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3227068|NCT01157780|Experimental|fish oil|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
3227069|NCT01157780|No Intervention|standard of care|When a subject develops PNALD (three consecutive direct bilirubin concentrations > 2 mg/dL), and is able to tolerate at least trophic feeds (1 mL Q12h), the subject will be randomized to either the control group (our current hospital practice including advancement of enteral feeding, ursodiol, and cyclic PN, but not ω3PUFA) or the active treatment group (current hospital practice plus the addition of enteral ω3PUFA supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period). All patients will be started at 1 g/kg/day with a maximum dose of 4 g/day.
3227070|NCT01157793|Experimental|Group 1|
3227071|NCT01157793|Experimental|Group 2|
3227072|NCT01157806|Experimental|radiochemotherapy instead of surgery|
3227073|NCT01157819|Active Comparator|Ciloxan Ear Drops|Ciloxan (Alcon, Inc.) Sterile Ophthalmic and Ear Drops
3227074|NCT01157819|Experimental|Foam Otic Cipro|Patients randomized to this study arm will receive the experimental product
3227075|NCT01157858|Active Comparator|Everolimus + octreotide LAR|Octreotide LAR combined with everolimus
3227076|NCT01157858|Active Comparator|Octreotide LAR|Octreotide LAR monotherapy
3227077|NCT01157871|Experimental|placebo|4 administrations at 2-week interval of placebo solution
3227078|NCT01157871|Experimental|NV1FGF 16 mg|4 administrations at 2-week interval of 4mg at each administration
3227079|NCT01157871|Experimental|NV1FGF 32 mg|4 administrations at 2-week interval of 8mg at each administration
3227080|NCT01157884||Kidney Transplantation|
3227081|NCT01157923|Experimental|intervantion group|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
3227082|NCT01157923|No Intervention|control group|Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
3227083|NCT01157936|Active Comparator|Allopurinol treatment|
3227084|NCT01157936|Placebo Comparator|Placebo|
3227085|NCT01157949|Active Comparator|Study withdrawn|Study withdrawn
3227086|NCT01157949|Placebo Comparator|Withdrawn|Study withdrawn
3227087|NCT01157962|Experimental|Group A Sentinel lymphadenectomy|In group A exclusively sentinel lymphadenectomy is performed
3227088|NCT01157962|Active Comparator|Group B radical pelvine lymphadenectomy|in group B radical systematic pelvic lymphadenectomy is done. In patients with tumor free lymph nodes either radical hysterectomy or, in women seeking parenthood, radical trachelectomy is performed. If lymph nodes are tumor-involved systematic pelvic and paraaortic lymphadenectomy followed by primary chemoradiation is recommended.
3227089|NCT01157975|Experimental|Pioglitazone|
3227090|NCT01157975|Experimental|Prednisone|
3227091|NCT01157988|Experimental|ibritumomab tuixetan, response, toxicity|
3227092|NCT01158001|Experimental|Psychotherapy via telemedicine|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in a novel format - interacting with a therapist via videoconferencing.
3227093|NCT01158001|Active Comparator|Face-to-face (in person) psychotherapy|In this arm, veterans received standard psychotherapy (prolonged exposure therapy) in the traditional format - in person with a therapist.
3227094|NCT01158014|Experimental|Fibrin Glue, surgery|Conjunctival autograft will be glued using fibrin glue to pterygia bed after removal
3227095|NCT01158014|Active Comparator|Control|Conjunctival autograft will be sutured using 10/0 vicryl sutures to pterygia bed after removal
3227096|NCT01158027||children|
3227097|NCT01158040||Insulin pump|Women suffering from pregestational diabetes mellitus and being treated with insulin pump during pregnancy and delivery
3227098|NCT01158040||IV insulin|Women suffering from pregestational diabetes mellitus and being treated with insulin sub-cutan (SC) during pregnancy and IV insulin during delivery
3227099|NCT01158040||Healthy|Healthy women accepted for delivery in our institute
3227100|NCT01158066|No Intervention|CT cardiac|the patient will undergo cardiac CT
3227101|NCT01158092|Active Comparator|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
3227102|NCT01158092|Active Comparator|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
3227103|NCT01158105|Experimental|Bortezomib|1.6 mg/m2 intravenous infusion will be administered on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles. Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles. This maintenance dose will be administered on days 1 and 15.
3227104|NCT01158131|Experimental|Lifestyle Intervention group|Participants in this group will take part in the lifestyle intervention.
3227105|NCT01158131|No Intervention|Post-gestational diabetes mellitus (GDM) Follow-up Group|Participants in this group will not take part in the intervention.
3227106|NCT01158144|Experimental|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
3227107|NCT01158144|Active Comparator|Conctrol|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
3227108|NCT01158170|Experimental|prophylactic cranial irradiation|Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.
3227109|NCT01158170|Active Comparator|Conctrol|Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity
3227110|NCT01158183||Group 1|No intervention
3227111|NCT01158196|Experimental|infra-red diode laser|one session, one dose
3227112|NCT01158209||Assessed cohort|Subjects attending out-patient health services for gynaecological examination.
3227113|NCT01158235|Experimental|LTX-109 (Lytixar)|Ascending dose study. Start enrollment to group 1: 1% LTX-109/placebo, then group 2: 2%LTX-109/placebo and finally group 3: 5%LTX-109/placebo dosed in each nostril TID for 3 consecutive days.
3227114|NCT01158274|Experimental|Treatment|Patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3227115|NCT01158287|Experimental|Sorafenib 400mg bd, p.o, continuously|
3227116|NCT01158313||Thickener|"Patients with history of swallowing difficulties associated with aging and/or neurological diseases including patients with:~neurodegenerative diseases.~non-progressive neurological diseases including stroke.~older patients including nursing home patients."
3227117|NCT01158326|Active Comparator|Resfenol Solution oral|Acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride active drug
3227118|NCT01158326|Placebo Comparator|Placebo|Placebo oral solution
3227119|NCT01158339|Active Comparator|Arm 1: CBGT|Cognitive Behavioural Group Therapy (CBGT)
3227120|NCT01158339|Experimental|Arm 2: CBGT-ISE|Cognitive Behavioural Group Therapy, with in-Session Exposure (CBGT-ISE).
3227121|NCT01158352|Experimental|Nutritional supplemntation formula|Nutritional supplementation standardized formula (powder added to liquids or food) containing 25% of recommended DRI for calories, high protein (20% of calories) and multi vitamins and mineral(25%-100% of DRI for recommended daily allowance or adequate intake)
3227122|NCT01158352|Placebo Comparator|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
3227123|NCT01158365|Experimental|Dermacyd (different fragrances)|Day 1 until 30: Investigational Product (Dermacyd) Day 31 until 37: wash-out Day 38 until 67: Glycerine Vegetal Soap Granado Traditional
3227124|NCT01158365|Active Comparator|Glycerine Vegetal Soap Granado Traditional|Day 1 until 30: Glycerine Vegetal Soap Granado Traditional Day 31 until 37: wash-out Day 38 until 67: Investigational Product (Dermacyd)
3227125|NCT01158391|Experimental|NTrainer® Intervention|NTrainer® Intervention - Infants in the experimental group will receive the NTrainer System patterned synthetic orocutaneous stimulation during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
3227126|NCT01158391|Sham Comparator|Control Intervention|Control Intervention - Infants in the Control group will be provided orocutaneous stimulation with a 'quiet pacifier' during the first 30 minutes of a tube (gavage) feeding session. The intervention may be provided up to 4 times daily to achieve an average of 30 sessions distributed over a two week period.
3227127|NCT01158417|Placebo Comparator|Placebo|Placebo tablets
3227128|NCT01158417|Experimental|Resveratrol 40 mg oral three times a day|Resveratrol
3227129|NCT01158417|Experimental|resveratrol 500 mg oral once daily.|Resveratrol
3227130|NCT01158430|Experimental|ACT group therapy|"Third generation cognitive behavioral therapy~Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours"
3227131|NCT01158430|No Intervention|Control|Control group assigned to wait list (treatment as usual). After 9 months they are offered ACT group therapy, but not as part of the research project.
3227132|NCT01158443|Experimental|Behavioral activation therapy|The Behavioral Activation Program for Energy and Productivity (BA-PEP) is a manualized, 8-session intervention, scheduled to coincide with maintenance armodafinil treatment. It is a structured counseling program with homework, short-term activities and goals, and includes problem-solving, identification of barriers and strategies for their resolution, with an ongoing focus on achieving employment or training.
3227133|NCT01158443|Placebo Comparator|supportive counseling (SC)|Supportive counseling is designed to create an empathic, accepting environment, to direct attention to the patient's feelings and to facilitate acceptance of affective experience using supportive statements, reflective listening and empathic communications.
3227134|NCT01158456||African Americans|Subjects will be classified as African American if they report themselves, biological parents and both sets of biological grandparents as African American or African descent.
3227135|NCT01158456||European American|Subjects will be classified as European American if they report themselves, biological parents and both sets of biological grandparents as European American or European descent.
3227136|NCT01158482||IVC Filter Placement or Removal|Patients undergoing IVC filter placement and/or IVC filter removal at Stanford Medical Center.
3227137|NCT01158508|Experimental|Remote Ischemic Preconditioning|Patients with aneurysmal subarachnoid hemorrhage, after aneurysm treatment, will be given prophylactic remote ischemic preconditioning by transient lower limb ischemia.
3227138|NCT01158560|Experimental|Vitamin D and gargling|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and asked to gargle with tap water twice daily
3227139|NCT01158560|Experimental|Vitamin D and general health advice|Participants will be given a weekly dose of 10,000 IU of vitamin D3 (oral capsule) and will receive general health advice in place of gargling advice
3227140|NCT01158560|Placebo Comparator|Placebo and general health advice|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be given general health advice in place of gargling advice.
3227141|NCT01158560|Placebo Comparator|Placebo and gargling|Participants will be given an aesthetically matched placebo capsule to take once weekly and will be asked to gargle with tap water twice daily
3227142|NCT01158586|Experimental|Levobupivacaine|patient control epidural analgeisa using 0.2% levobupivacaine with 2ug/ml fentanyl
3227143|NCT01158586|Active Comparator|Ropivacaine|patient controlled epidural analgesia using 0.2% ropivacaine with 2ug/ml fentanyl
3227144|NCT01158599|Other|IXIARO 0,5 ml|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
3227145|NCT01158612|Experimental|Growth hormone|The effect of Growth hormone on the collagen synthesis rate
3227146|NCT01158612|Placebo Comparator|Saline|
3227147|NCT01158625|No Intervention|Morning dosing of antihypertensive drugs|
3227148|NCT01158625|Active Comparator|Nighttime dosing of antihypertensive drugs|
3227149|NCT01158638|No Intervention|Usual Care|Usual Care
3227150|NCT01158638|Active Comparator|10,000 Steps Group|Each participant randomized to this study arm will receive a pedometer and a generic recommendation to accumulate 10,000 Steps per Day.
3227151|NCT01158638|Experimental|Web Mediated Step Group|Participants randomized to this study arm receive an introduction to the study website. Each person utilizes the website to track their daily physical activity steps. Goals are given on a weekly basis to increase steps by 10% per day per week over baseline values. The website channels each participant through a series of motivational messages designed to increase compliance with recommended physical activity targets
3227152|NCT01158664|Experimental|0.6 mm tread pitch implant|
3227153|NCT01158664|Experimental|0.1 mm tread pitch implant|
3227154|NCT01158690|Experimental|resource card group|The intervention group will receive an envelope with a gift voucher and a resource card (wallet size card with on the one side safety measures and on the other side contact details of resources for violence).
3227155|NCT01158690|Active Comparator|control group|The control group will receive the same envelop with a gift voucher and a letter of thanks.
3227156|NCT01158729|Experimental|ATIII experimental group|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive Antithrombin (Recombinant) prior to initiation of bypass
3227157|NCT01158729|Placebo Comparator|Placebo Controls|30 neonates (4-30 days of age) undergoing surgery requiring cardiopulmonary bypass will receive placebo prior to initiation of bypass
3227158|NCT01158742||1|Caucasians who donated a kidney at Mayo Clinic in Rochester, Minnesota (MN)
3227159|NCT01158742||2|Caucasians who donated a kidney at the University of Minnesota
3227160|NCT01158742||3|African-Americans who donated a kidney at the University of Alabama
3227161|NCT01158755|Active Comparator|Standard dose rifampisin|"Subjects in this arm receive 450 mg rifampicin orally.~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
3227162|NCT01158755|Experimental|High dose rifampisin|"Subjects in this arm receive 600 mg Rifampisin i.v. for 14 days, and the dosage will be switched to 450 mg Rifampisin p.o afterwards until completion of TB medication (in accordance with National TB Program)~In accordance with national TB treatment standard that encourages the use of 4 drugs, all subjects -both in active comparator and experimental arm- will also receive isoniazide 300 mg p.o. and pyrazinamide 1500 mg p.o.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
3227163|NCT01158768||Violence, Comorbidity|
3227164|NCT01158781|Experimental|gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition
3227165|NCT01158794||Study participants|Participants with sickle cell disease and transfusional iron-overload, and non-sickle cell disease (thalassemia major, cancer patients, etc.) and iron overload. Participants with iron overload, defined as too much iron in the body as a consequence of too many blood transfusions.
3227166|NCT01158807||HHT- Brain Arteriovenous Malformation|"Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and~Presence of Brain Arteriovenous Malformation"
3227167|NCT01158807||HHT -NO BAVM|1. Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT
3227168|NCT01158833||spastic diplegia due to Cerebral Palsy|
3227169|NCT01158846|Active Comparator|prasugrel/bivalirudin|60 mg loading dose of prasugrel will be followed by maintenance dose of 10mg (or 5mg according to body weight and age). During primary PCI, Bivalirudin will be used as anticoagulant (bolus plus infusion), on a weight-adjusted dose.
3227170|NCT01158846|Active Comparator|clopidogrel/abciximab|600mg loading dose of clopidogrel will be followed by 75mg maintenance dose. During primary PCI abciximab (bolus plus infusion) will be used as anticoagulant.
3227171|NCT01158859|Experimental|Pregabalin|
3227172|NCT01158859|Placebo Comparator|Placebo|
3227173|NCT01158898|Active Comparator|TPI ASM8 low dose|
3227174|NCT01158898|Active Comparator|TPI ASM8 high dose|
3227175|NCT01158898|Placebo Comparator|Placebo|
3227176|NCT01158911||non-diabetic Chronic Kidney disease|
3227177|NCT01158937|Experimental|Extended Meropenem Infusion|Meropenem Infusion over 3 hours
3227178|NCT01158937|Experimental|Bolus Meropenem Infusion|Meropenem infusion over 30 minutes
3227179|NCT01158989||Critically ill|Critically ill subjects were intubated, mechanically ventilated and sedated
3227180|NCT01158989||Ambulatory Group|Subjects were scheduled for an outpatient procedure but were otherwise healthy
3227181|NCT01159002||Critically ill ICU patients|ICU patients with brain injuries who will be receiving a feeding tube.
3227182|NCT01159028|Experimental|BP1001|Subjects are treated with open-label study drug (BP1001) in a dose-escalation model.
3227183|NCT01159028|Experimental|BP1001 in combination with LDAC|AML subjects are treated with open-label escalating study drug (BP1001) in combination with low dose ara-C (LDAC)
3227184|NCT01159041|Experimental|Family Focused Treatment (FFT)|15 session family-based treatment emphasizing improving relationship skills to combat depression symptoms and support recovery.
3227185|NCT01159041|Active Comparator|Individual Treatment (IP)|15 session individually-based treatment to assist children in understanding the causes of their symptoms.
3227186|NCT01159080|Active Comparator|routine dose tacrolimus and less myfortic|
3227187|NCT01159080|Experimental|reduced dose tacrolimus and conventional myfortic|
3227188|NCT01159093|Experimental|Family Decision Support|Families will receive informational vaccine reminder telephone calls.
3227189|NCT01159093|Experimental|Clinical Decision Support|In this treatment arm, clinicians receive the decision support at the point of care within an electronic health record.
3227190|NCT01159093|Experimental|Family DS+ Clinician DS|Families will receive informational vaccine reminder calls and their clinicians will receive electronic health record-based decision support for immunizations.
3227191|NCT01159093|Other|Control|This group will receive regular primary care with no decision support.
3227192|NCT01159119|Experimental|EUR-1066-A|Treatment with Eur-1006-A.
3227193|NCT01159119|Experimental|EUR-1066-B|Treatment with Eur-1066-B
3227194|NCT01159119|Active Comparator|Zenpep|Control Group: Consist of treatment with Zenpep
3227195|NCT01159132|Active Comparator|1|RAL 400 mg OD
3227196|NCT01159132|Active Comparator|2|RAL 800 mg OD
3227197|NCT01159145|Experimental|D961H 10 mg capsule|2 way crossover
3227198|NCT01159145|Experimental|Omeprazole 10 mg tablet|2 way crossover
3227199|NCT01159158|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
3227200|NCT01159158|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
3227201|NCT01159197|Experimental|cognitive behaviorial therapy|
3227202|NCT01159223|Experimental|1|ATV/r 200 mg/100 mg OD
3227203|NCT01159223|Experimental|2|ATV/r 300 mg/100 mg OD
3227204|NCT01159236|Experimental|Group 1: ER-Positive|"Participants with Estrogen Receptor (ER)-Positive breast cancers receive Standard T/FAC or T/FEC chemotherapy before surgery.~T/FAC or T/FEC: Combination chemotherapy with sequential paclitaxel (80 mg/m2) weekly x 12 weeks followed by 5-fluorouracil (500 mg/m2), cyclophosphamide (500 mg/m2) and doxorubicin (50 mg/m2) or epirubicin (100 mg/m2) (FAC or FEC) once every 3 weeks for 4 treatments."
3227205|NCT01159236|Experimental|Group 2: ER-Negative|Participants with ER-negative cancers (randomized between Group 2 & Group 3), Standard T/FAC or T/FEC chemotherapy before surgery.
3227206|NCT01159236|Experimental|Group 3: ER-Negative + Bevacizumab|Participants with ER-negative cancers (randomized between Group 2 & Group 3), T/FEC chemotherapy combined with 10 mg Bevacizumab every 2 weeks during first 3 treatments before surgery.
3227207|NCT01159249|Other|Open Met add-on vildagliptin|
3227208|NCT01159249|Other|Open TZD add-on vildagliptin|
3227209|NCT01159249|Other|Open α-GI add-on vildagliptin|
3227210|NCT01159249|Other|Glinides add-on vildagliptin|
3227211|NCT01159275|Other|1|First Generic LPV/r 200/50 mg BID, then cross over to Pediatric Aluvia 200/50 mg BID
3227212|NCT01159275|Other|2|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
3227213|NCT01159301|Experimental|Treatment (entinostat, sorafenib tosylate)|Patients receive oral entinostat once daily on days 1 and 15 and oral sorafenib tosylate twice daily on days 1-28 (days 15-28 only of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3227214|NCT01159314|Experimental|Arm A - Baerveldt 250 mm2|Patients receiving Baerveldt 250 mm2
3227215|NCT01159314|Experimental|Arm B - Baerveldt 350 mm2|Patients receiving Baerveldt 350 mm2
3227216|NCT01159327|Experimental|Arm A|Sorafenib maintenance arm
3227217|NCT01159327|No Intervention|Arm B|observation arm
3227218|NCT01159353|Experimental|insulin glulisine + insulin aspart|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
3227219|NCT01159353|Experimental|insulin aspart + insulin glulisine|insulin glulisine (1 day) + wash-out (7 days) + insulin aspart (1 day)
3227220|NCT01159366|Active Comparator|occluded culprit artery|An occluded lesion was defined as a lesion with 100% stenosis or TIMI-flow grade 0 or 1.
3227221|NCT01159366|Active Comparator|non-occluded culprit artery|A non-occluded lesion was defined as a lesion without 100% stenosis or TIMI-flow grade 0 or 1.
3227222|NCT01159379|Experimental|ertapenem, tolerance tests|Patients with IgE-mediated allergy to beta-lactams
3227223|NCT01159392||Brain injury plus acute lung injury|Patients with severe brain injury (Glasgow coma score<13) with acute lung injury (PaO2/FiO2 <300 mmHg)
3227224|NCT01159405|Experimental|99mTc-GP|99mTc-GP with SPECT/CT imaging & whole body scan.
3227225|NCT01159418|Experimental|Panobinostat (LBH589), Carboplatin and Paclitaxel|
3227226|NCT01159457|Active Comparator|1|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Sci-B-Vac vaccination series
3227227|NCT01159457|Active Comparator|2|celiac patients who did not respond to initial hepatitis B vaccine series , will receive Engerix 3-dose vaccination series
3227228|NCT01159470||bacterial infection|children with fever due to bacterial infection
3227229|NCT01159470||viral infection|children with fever due to viral infection
3227230|NCT01159483|Experimental|Cohort A|"Period 1: Participants received 0.01 milligrams (mg) of PF-04958242 or matching placebo, once, orally.~Period 2: Participants received 0.03 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 0.1 mg of PF-04958242 or matching placebo, once, orally."
3227231|NCT01159483|Experimental|Cohort B|"Period 1: Participants received 0.3 mg of PF-04958242 or matching placebo, once, orally (fasted).~Period 2: Participants received 0.6 mg of PF-04958242 or matching placebo, once, orally.~Period 3: Participants received 1.0 mg of PF-04958242 or matching placebo, once, orally (fed)."
3227232|NCT01159496|Experimental|Active|
3227233|NCT01159496|Placebo Comparator|Placebo|
3227234|NCT01159509||Infants ages -13 years that had HPS in infancy|
3227235|NCT01159522|Experimental|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
3227236|NCT01159548|No Intervention|Saline|
3227237|NCT01159548|Other|Promethazine 6.25 mg|
3227238|NCT01159548|Other|Promethazine 3 mg|
3227239|NCT01159561|Experimental|Vaccinated|Western Equine Encephalitis Vaccine, Inactivated, TSI-GSD 210, Lot 3-1-92, administered in 0.5 mL doses subcutaneously in the upper outer aspect of the triceps in a 3-dose primary series (Days 0, 7, and 28) with a mandatory boost (Day 180)
3227240|NCT01159587||Group 1|
3227241|NCT01159587||Group 2|
3227242|NCT01159613||Non Responders|Non Responders
3227243|NCT01159613||RESPONDERS|
3227244|NCT01159626|Experimental|Single dose|
3227245|NCT01159626|Experimental|Multiple dose|
3227246|NCT01159639|No Intervention|aspirin low responders monotherapy|patients with inappropriate response to aspirin assessed by multiple electrode aggregometry
3227247|NCT01159639|Active Comparator|aspirin low responders dual antiplatelet therapy|patients with inappropriate response to aspirin 300 mg therapy after CABG, randomized to receive clopidogrel 75 mg in addition to aspirin
3227248|NCT01159652|Placebo Comparator|Bedtime Placebo|
3227249|NCT01159652|Placebo Comparator|Middle of the Night Placebo|
3227250|NCT01159652|Experimental|Zolpidem|
3227251|NCT01159652|Experimental|Zaleplon|
3227252|NCT01159678|Experimental|online psychoeducation|
3227253|NCT01159704|Experimental|Network plus HIV Counseling&Education|"Social network peer education model plus HIV testing and counseling; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
3227254|NCT01159704|Active Comparator|HIV Counseling and Education (C&E) only|"HIV testing and counseling C&E; the C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
3227255|NCT01159730|Experimental|Multiple doses of VB-201|
3227256|NCT01159730|Placebo Comparator|Placebo|
3227257|NCT01159756|Experimental|Travacom|Travacom ophthalmic solution
3227258|NCT01159782|Other|Asthma, Healthy|Asthmatics or Healthy Volunteers
3227259|NCT01159808|Experimental|INX-08189|
3227260|NCT01159808|Placebo Comparator|Placebo|
3227261|NCT01159821|Experimental|001|31001074/paroxetine 1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
3227262|NCT01159834||Gardasil, HPV infection|
3227263|NCT01159847|Experimental|Sitagliptin|Patients will receive insulin therapy with sitagliptin.
3227264|NCT01159847|Active Comparator|Insulin|Patients will receive insulin therapy without sitagliptin.
3227265|NCT01159860|Active Comparator|Cryosurgery|One lesion on the patients' trunk or proximal extremities will be treated with cryosurgery.
3227266|NCT01159860|Active Comparator|Curettage|One lesion on one side of the patients' trunk or proximal extremities will be treated by curettage.
3227267|NCT01159873|Experimental|CEP-37251|
3227268|NCT01159873|Placebo Comparator|Placebo|
3227269|NCT01159886|Active Comparator|left lateral|After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus position. Then terminal ileal intubation will be attempted.
3227270|NCT01159886|Active Comparator|supine|After confirmation of cecal intubation, patient will undergo randomization to the supine position. Then terminal ileal intubation will be attempted.
3227271|NCT01159925||Possible hepatitis A Cohort|Children with an acute disease characterized by discrete onset of symptoms and jaundice
3227272|NCT01159925||Probable hepatitis A Cohort|Children with an increase in serum levels of transaminase 2.5 times higher than the maximum limit of the normal interval
3227273|NCT01159925||Confirmed hepatitis A Cohort|Children presenting a positive result for Immunoglobulin M for hepatitis A virus
3227274|NCT01159951||Hepatitis Cohort|Subjects suffering with hepatitis
3227275|NCT01159964|Experimental|Cohort 1|Subjects will receive investigational dose-level A (different from dose-levels B and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3227276|NCT01159964|Experimental|Cohort 2|Subjects will receive investigational dose-level B (different from dose-levels A and C). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3227277|NCT01159964|Experimental|Cohort 3|Subjects will receive investigational dose-level C (different from dose-levels A and B). All patients are to receive 13 injections of the immunotherapeutic GSK2302032A
3227278|NCT01159977|Experimental|Facilitated small group|Facilitated small groups.
3227279|NCT01159977|Active Comparator|Unstructured protected time|Same time provided as for facilitated small groups, but without structure.
3227280|NCT01159977|Placebo Comparator|Usual practice|No protected time.
3227281|NCT01159990|Experimental|Recombinant adenovirus serotype 5 (rAd5) Gag/Pol Env A/B/C|Participants will receive one intramuscular injection of rAd5 Gag/Pol Env A/B/C.
3227282|NCT01159990|Active Comparator|rAd5 gag/pol|Participants will receive one intramuscular injection of rAd5 gag/pol.
3227283|NCT01160003|Experimental|Treatment Period 1|5mg of GW870086X or placebo will be given once daily for 14 days.
3227284|NCT01160003|Experimental|Treatment Period 2|GW870086X (5mg or 8.75mg) or placebo will be given once daily for 14 days. In a randomised dose escalating manor following on from treatment period 1.
3227285|NCT01160003|Experimental|Treatment Period 3|8.75mg of GW870086X or placebo will be given once daily for 14 days.
3227286|NCT01160029|Experimental|Nateglinide|Nateglinide Tablets 120 mg of Dr. Reddys Laboratories Limited
3227287|NCT01160029|Active Comparator|Starlix|Starlix Tablets 120 mg of Novartis
3227288|NCT01160042|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
3227289|NCT01160042|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
3227290|NCT01160055||Cohort A|Subjects with a new episode of Acute Otitis Media (<3 days of onset) who have not yet received antibiotic therapy for the episode.
3227291|NCT01160055||Cohort B|Subjects who have had a diagnosis of Acute Otitis Media within 2-3 days prior to study enrolment and received antibiotic therapy, but remain symptomatic.
3227292|NCT01160068|Experimental|Metformin|Metformin Hydrochloride 1000 mg tablets of Dr. Reddy's Laboratories Limited
3227293|NCT01160068|Active Comparator|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
3227294|NCT01160081||National Health and Nutrition Survey 2006 (ENSANUT 2006)|
3227295|NCT01160094||Patients|ErbB2+ metastatic breast cancer patients
3227296|NCT01160107|Experimental|RP followed MPR|
3227297|NCT01160120|Other|1|Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.
3227298|NCT01160133|Experimental|Systane|Systane Lubricant Eye Drops
3227299|NCT01160133|Experimental|Refresh Tears|Refresh Tears Lubricant Eye Drops
3227300|NCT01160146||Lifestyle counseling|"Clinicians provide lifestyle management counseling regarding healthful lifestyle behaviors and daily physical activity.~Logging foods for accountability and counting calories~Close attention to portion control and appropriate serving sizes of foods consumed~Consumption of appropriate calorie and sugar free beverages~Good meal distribution and avoidance of meal skipping~Balance of food groups using the MyPlate concept (USDA Choose My Plate)-inclusion of all food groups with emphasis on fruits, vegetables, whole grains, low-fat dairy products and lean meat/fish/poultry~Increasing physical activity with reasonable, sustainable exercise or activity. Working toward a goal of at least 30 minutes, 5 days per week"
3227301|NCT01160159||Thrombophilia|
3227302|NCT01160159||Healthy volunteers|
3227303|NCT01160172|Experimental|Group A|
3227304|NCT01160172|Experimental|Group B|
3227305|NCT01160172|Experimental|Group C|
3227306|NCT01160172|Experimental|Group D|
3227307|NCT01160172|Placebo Comparator|Group E|
3227308|NCT01160172|Placebo Comparator|Group F|
3227309|NCT01160185||cisplatin|
3227310|NCT01160185||cisplatin + topotecan|
3227311|NCT01160185||cisplatin + paclitaxel|
3227312|NCT01160224|Active Comparator|GW766944|This is the active drug (GW766944)
3227313|NCT01160224|Placebo Comparator|Placebo|Placebo Arm.
3227314|NCT01160263|Other|patients without stiffness|
3227315|NCT01160263|Other|patients with pyramidal stiffness|
3227316|NCT01160263|Other|patients with mixed stiffness|
3227317|NCT01160276|Active Comparator|Cyclosporine|The first group is composed of 14 renal graft recipients under cyclosporine
3227318|NCT01160276|Active Comparator|Tacrolimus|The second group is composed of 14 renal graft recipients under tacrolimus
3227319|NCT01160302|Experimental|Microgranular Curcumin|Consume 4g microgranular curcumin (Curcumin C3 Complex) twice per day
3227320|NCT01160315|Experimental|Arm A (GnRha arm)|IM injection of Triptorelin -Decapeptyl PR 11.25mg- (every 3 months) and Norethisterone acetate- Primolut-Nor 5 mg- per os continuously until the end of the chemotherapy
3227321|NCT01160315|Active Comparator|Arm B (control Arm)|Norethisterone acetate alone, 5mg par day, (ARM B) until the end of the chemotherapy.
3227322|NCT01160328|No Intervention|Control Group|Participants in this group will not receive any treatment.
3227323|NCT01160328|Experimental|Lupron Group|Participants in this group will receive leuprolide acetate (Lupron) treatment for 7 weeks resulting in temporary decreases in testosterone levels.
3227324|NCT01160328|Other|Lupron & Testosterone Group|Participants in this group will receive 7 weeks of leuprolide acetate (Lupron) treatment with testosterone gel (Androgel).
3227325|NCT01160341|Experimental|Testosteron, secondary hypogonadism|
3227326|NCT01160367|Active Comparator|standard of care health decision making|Patient-family dyads will receive the standard of care for support of patient and family members health care decision making during a clinic appointment.
3227327|NCT01160367|Experimental|TAILORED intervention|Patients and family members who receive the TAILORED Decision Making Intervention
3227328|NCT01160393|Other|Miniaturized bypass system|Miniaturized bypass system and the incidence of atrial fibrillation after cardiac surgery
3227329|NCT01160406||ischemic stroke, no atrial fibrillation|Patients who have suffered ischemic stroke or transient ischemic attack without known atrial fibrillation
3227330|NCT01160419|Other|FLOT|Docetaxel, Oxaliplatin, Folinic acid, 5-FU, q 2 weeks, application of 6 cycles
3227331|NCT01160432|Experimental|Methadone naloxone combination product 2/0,04 mg/ml|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml
3227332|NCT01160432|Active Comparator|Methadone 2 mg/ml|Normal treatment except the dilution of methadone solution (5 mg/ml → 2 mg/ml).
3227333|NCT01160471||Healthy Volunteers|Adult men and women without a clinical diagnosis of heart failure
3227334|NCT01160471||Patients|Adult men and women with a clinical diagnosis of heart failure
3227335|NCT01160510||Women undergoing mammography|women undergoing mammography at the UVM Breast Cancer Surveillance Consortium site
3227336|NCT01160549||Cases|Women living in rural environments
3227337|NCT01160549||Controls|Women living in more urban environments
3227338|NCT01160588||Sertraline treatment|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and sertraline treatment.
3227339|NCT01160588||Healthy Controls|Healthy control participants will undergo MRI scanning and EEG's.
3227340|NCT01160588||Cognitive Behavioral Therapy|Participants with Generalized Anxiety Disorder, and/or Social Anxiety Disorder, and/or Separation Anxiety Disorder will undergo MRI scanning, EEG's, and talk therapy (CBT).
3227341|NCT01160601|Experimental|paclitaxel/carboplatin plus bavituximab|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles, in combination with 3 mg/kg bavituximab administered weekly.
3227342|NCT01160601|Active Comparator|paclitaxel/carboplatin|Patients will receive paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
3227343|NCT01160627|Active Comparator|Standard treatment|Hydration
3227344|NCT01160627|Active Comparator|Combined Acetylcystein and Sodium Bicarbonat|
3227345|NCT01160627|Active Comparator|Sodium Bicarbonate|
3227346|NCT01160627|Active Comparator|Acetylcystein for 2 days|Standard treatment + acetylcystein for 2 days
3227347|NCT01160653|Experimental|1|Gait training and Cognitive Training
3227348|NCT01160653|No Intervention|2|Able Bodied
3227349|NCT01160666|Experimental|1: Belilumab|
3227350|NCT01160692|Experimental|Arm 1|
3227351|NCT01160692|Placebo Comparator|Arm 2|
3227352|NCT01160718|Active Comparator|Arm A: Fulvestrant / AZD6244|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid
3227353|NCT01160718|Placebo Comparator|Arm B: Fulvestrant / Placebo|Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)
3227354|NCT01160731|Experimental|Cisplatin, Etoposide & Panobinostat|
3227355|NCT01160757|Other|ultrasound|
3227356|NCT01160796|Experimental|Lcr35®|
3227357|NCT01160796|Placebo Comparator|placebo|
3227358|NCT01160809|Experimental|Mosquito repellent and LLINs group vs. LLINs group only|This study is based on two population groups: 1) a group of households that use LLINs alone (control) and 2) a group of households that use both mosquito repellent and LLINs (repellent group).
3227359|NCT01160835|Experimental|Quadriceps-sparing total knee arthroplasty|Quadriceps-sparing arthrotomy with side-cutting instruments
3227360|NCT01160835|Active Comparator|Medial parapatellar total knee arthroplasty|Medial parapatellar arthrotomy with front-cutting instruments
3227361|NCT01160861|Experimental|A|
3227362|NCT01160861|Experimental|B|
3227363|NCT01160861|Experimental|C|
3227364|NCT01160874|Experimental|TDA/H|
3227365|NCT01160874|Other|Sleep apnea patient|
3227366|NCT01160874|Other|Healthy volunteer|
3227367|NCT01160887||Patients with diabetic peripheral neuropathy|
3227368|NCT01160887||Healthy matched controls|
3227369|NCT01160900|Experimental|multivessel revascularization|Complete Revascularization : the Infarcted related artery was opened followed by dilatation of other significantly narrowed arteries during the same procedure
3227370|NCT01160913|Active Comparator|Continuous wound infusion above the fascia|
3227371|NCT01160913|Active Comparator|Continuous wound infusion below the fascia|
3227372|NCT01160926|Experimental|AZD6244 + capecitabine + radiotherapy|10 days single-agent dosing AZD6244 Then 35 days dosing of AZD6244 in combination with standard chemoradiotherapy
3227373|NCT01160926|Experimental|Cediranib + capecitabine + radiotherapy|10 days single agent dosing with Cediranib (AZD2171) then 35 days dosing of AZD2171 in combination with standard chemoradiotherapy
3227374|NCT01160952|Other|long-term group|long-term group refers to prophylaxis by using itraconazole for up to 90 days
3227375|NCT01160952|Other|short term group|short term group refers to prophylaxis by itraconazole for 30 days
3227376|NCT01160965|Active Comparator|0.5% levobupivacaine|Participants given 15mls of 0.5% levobupivacaine as the solution for their epidural top-up
3227377|NCT01160965|Active Comparator|0.75% Rpoivacaine|Participants given 15mls of 0.75% ropivacaine as the solution for their epidural top-up.
3227378|NCT01160978|Active Comparator|Simvastatin 80 mg group|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
3227379|NCT01160978|Experimental|Control Rx|The transplant recipients who have received an organ from non-treated donors.
3227380|NCT01160991|Active Comparator|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
3227381|NCT01160991|Experimental|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
3227382|NCT01160991|Placebo Comparator|Placebo|Placebo capsules are given at 8:00 a.m. Procedures are performed as described above.
3227383|NCT01161004|Experimental|Sugammadex - Nacl 9/00|"Sugammadex - Nacl 9/00:~Patients will first receive sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive Nacl 9/00 5 minutes after the first bolus of sugammadex.~The study is finished 5 minutes after this second injection and care is let to the choice of the anesthesiologist in charge."
3227384|NCT01161004|Experimental|Nacl 9/00 - sugammadex|"Nacl 9/00 - Sugammadex :~Patients wil first receive Nacl 9/00. In case of complete reversal of myorelaxation, total intravenous anesthesia is stopped and patients are allowed to awake.~In the adverse case, patients wil receive sugammadex 5 minutes after the first bolus of Nacl 9/00.~Sugammadex is given as: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~The study is finished 5 minutes after the injection of sugammadex and care is let to the choice of the anesthesiologist in charge."
3227385|NCT01161017|Active Comparator|1 Amitriptyline.|Amitriptyline
3227386|NCT01161017|Active Comparator|2 Topiramate|Topiramate
3227387|NCT01161030|Experimental|almonds|1-oz raw almonds: 173 kcal, 4.6 g carbohydrate, 14.6 g fat
3227388|NCT01161030|Placebo Comparator|Control|cheese stick
3227389|NCT01161056||Healthy Control Group|
3227390|NCT01161069|Active Comparator|PF-03049423|Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers
3227391|NCT01161069|Placebo Comparator|Drug|Placebo in oral solution, given once daily for 14 days
3227392|NCT01161082|Experimental|Group 1 with atorvastatin|Dose 1 versus placebo
3227393|NCT01161082|Experimental|Group 2 with atorvastatin|Dose 1 versus placebo
3227394|NCT01161082|Experimental|Group 3 with atorvastatin|Dose 2 versus placebo
3227395|NCT01161082|Experimental|Group 4 with atorvastatin|Dose 2 versus placebo
3227396|NCT01161082|Experimental|Group 5 with atorvastatin|Dose 3 versus placebo
3227397|NCT01161082|Experimental|Group 6 with atorvastatin|Dose 3 versus placebo
3227398|NCT01161082|Experimental|Group 7 without atorvastatin|Dose 3 versus placebo
3227399|NCT01161082|Experimental|Group 8 with atorvastatin|Dose4 versus placebo
3227400|NCT01161095|Experimental|Immediate|LNG-IUS insertion within the timeframe of delivery of the placenta to 72 hours postpartum
3227401|NCT01161095|Active Comparator|Interval|LNG-IUS insertion after 6 weeks postpartum
3227402|NCT01161108|Active Comparator|Group A: Fast Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
3227403|NCT01161108|Active Comparator|Group B: Timed Release Melatonin|"Subjects will be randomized to one of the two treatment arms and to the order of study medication v.s. placebo.~The subject will undergo the assigned treatment for 7 weeks (3 weeks of study drug, a one week wash-out and 3 weeks of placebo, or vice versa)."
3227404|NCT01161134|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
3227405|NCT01161134|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
3227406|NCT01161147|Experimental|Meloxicam|Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited
3227407|NCT01161147|Active Comparator|Mobic|Mobic Tablets 15 mg of Boehringer Ingelheim Pharmaceuticals Inc
3227408|NCT01161186|Experimental|Nab-paclitaxel,Gemcitabine, and Capecitabine|
3227409|NCT01161199||Untreated non-controllers|
3227410|NCT01161199||Elite controllers|
3227411|NCT01161199||HAART-suppressed|
3227412|NCT01161212|Other|Control group|
3227413|NCT01161212|Other|Intervention group|
3227414|NCT01161238||Lower-limb amputee|Subjects with at least one lower limb amputated at the trans-tibial level
3227415|NCT01161251||Atrial fibrillation patients|Non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
3227416|NCT01161264|Experimental|18-60 YOA|
3227417|NCT01161264|Experimental|≥ 60 YOA|
3227418|NCT01161277|Active Comparator|aripiprazole|
3227419|NCT01161277|Active Comparator|haloperidol|
3227420|NCT01161277|Placebo Comparator|suger pill|
3227421|NCT01161316|Active Comparator|Control|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
3227422|NCT01161316|Experimental|Experimental|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
3227423|NCT01161355|Experimental|AZD9668|Tablets and intravenous (IV) dose
3227424|NCT01161368|Experimental|lapatinib, vinorelbine|"Drug: Lapatinib, Vinorelbine Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
3227425|NCT01161381||Normal|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) < 5.
3227426|NCT01161381||OSAHS patients|Subjects that underwent night polysomnography with an observed Apnea-Hypopnea Index (AHI) > 5.
3227427|NCT01161394|Experimental|Pioglitazone 15mg|8 patient will receive this drug
3227428|NCT01161394|Experimental|pioglitazone 30mg|8 patients will get this drug
3227429|NCT01161394|Placebo Comparator|Placebo|8 patient will get this drug
3227430|NCT01161433|Experimental|Intervention|Virtually delivered spirometry quality improvement program
3227431|NCT01161433|No Intervention|Standard of Care|
3227432|NCT01161459|Experimental|Tripterygium wilfordii|120mg/d for 6 months,then decrease to 60mg/d by 30mg/d every month for 12 months
3227433|NCT01161459|Active Comparator|FK506|
3227434|NCT01161485|Active Comparator|HIV Testing and Counseling|HIV Testing and Counseling
3227435|NCT01161485|Active Comparator|Contingency Management (CM)|Contingency management is based on Skinner's principles of operant conditioning in behavioral psychology, dating back to the 1930s (Skinner 1938). The basis of this model is that behavior is learned and reinforced by environmental contingencies that reward or punish.
3227436|NCT01161485|Experimental|CM with Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community.
3227437|NCT01161511|Experimental|1|XmAb5574
3227438|NCT01161550|Experimental|Arm 1|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 25 mg PO BID Days 7-20"
3227439|NCT01161550|Experimental|Arm 2|"GCSF 300 mcg SC Days 1-6~Cladribine 5 mg/m2 IV Days 2-6~Cytarabine 2 mg/m2 IV Days 2-6~ATRA 15 mg/m2 PO QD Days 7-20~Midostaurin 50 mg PO BID Days 7-20"
3227440|NCT01161576|Experimental|Group A|The first dose cohort consists of 6 subjects who received AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies (gc) total dose. This is equal to 900,000,000,000 molecules of the drug.
3227441|NCT01161576|Experimental|Group B|The second dose cohort consists of 10 subjects, who will receive AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (gc) total dose. This is equal to 285,000,000,000 molecules of the drug.
3227442|NCT01161602|Experimental|0.2mg Pumosetrag|
3227443|NCT01161602|Experimental|0.5mg Pumosetrag|
3227444|NCT01161602|Experimental|0.8mg Pumosetrag|
3227445|NCT01161602|Placebo Comparator|Placebo|
3227446|NCT01161615|Placebo Comparator|Placebo|Therapy with placebo
3227447|NCT01161615|Experimental|MRX-7EAT|Therapy with experimental drug
3227448|NCT01161693|No Intervention|Standard pillow under head|Control (C) - Standard pillow under head (figure 1) as is the usual practice at BC Women's Hospital
3227449|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP|TROOP® elevation pillow (designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table)
3227450|NCT01161693|Active Comparator|Troop Elevation Pillow in horizontal position-HERP-H|Operating table tilted in Trendelenberg position so angle of Troop pillow is parallel to floor (figure 3) until establishment of adequate block and then the bed levelled to horizontal i.e. to the same position as group (HERP) (figure 2)
3227451|NCT01161706|No Intervention|Control|0 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3227452|NCT01161706|Experimental|8 fluid ounces vegetable juice|8 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3227453|NCT01161706|Experimental|16 fluid ounces vegetable juice|16 fluid ounces vegetable juice plus dietary education on the DASH (Dietary Approaches to Stop Hypertension) diet
3227454|NCT01161719|Experimental|Videoconference|Parent training through videoconference
3227455|NCT01161719|Active Comparator|Control|Parent training through face to face conference
3227456|NCT01161732|No Intervention|Conventional treatment|In the conventional treatment group, indications for aortic valve replacement surgery are development of symptoms, reduced left ventricular systolic function and an increase in aortic jet velocity > 0.5 m/sec during follow-up.
3227457|NCT01161732|Active Comparator|Early Surgery|Early surgery is performed within 2 months of randomization.
3227458|NCT01161758|Active Comparator|Passive cervical mobilisation|Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
3227459|NCT01161758|Placebo Comparator|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique.
3227460|NCT01161758|No Intervention|Non-contact control|Non-contact control, which involved the subject resting in the treatment position without any physical contact between the researcher and the subject.
3227461|NCT01161784|Placebo Comparator|Nutrient drink|
3227462|NCT01161784|Experimental|Probiotics|
3227463|NCT01161810||Post-Burn Rehabilitation|Patients with an acute burn injury who are admitted to the hospital with anticipated length of stay of 5 days or greater
3227464|NCT01161823||Nebivolol|2,5mg or maximum 5mg per day
3227465|NCT01161823||Menoflavon|2 times 1 pill at 40mg Isoflavone per day
3227466|NCT01161836|Experimental|iniparib|"Segment 1: 400 mg [14C]-iniparib single administration~Segment 2: Iniparib, 5.6mg/kg, extension treatment with or without additional chemotherapy"
3227467|NCT01161901||blood sample|
3227468|NCT01161914|Active Comparator|Cerezyme®|60 U/kg infusion (every 2 weeks for 24 weeks)
3227469|NCT01161914|Experimental|ISU302|60 U/kg infusion (every 2 weeks for 24 weeks)
3227470|NCT01161927|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
3227471|NCT01161927|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
3227472|NCT01161940|Experimental|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
3227473|NCT01161940|Active Comparator|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
3227474|NCT01161966|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
3227475|NCT01161966|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
3227476|NCT01161979|Experimental|Zonisamide|Zonisamide Capsules 100 mg of Dr.Reddy's laboratories Limited
3227477|NCT01161979|Active Comparator|Zonegran|Zonegran Capsules 100 mg of EISAI INC
3227478|NCT01162018|Experimental|Acupuncture Arm|
3227479|NCT01162018|Sham Comparator|Sham Acupuncture|Sham Acupuncture
3227480|NCT01162044|No Intervention|No intervention|Subjects will be assessed, but no active intervention given
3227481|NCT01162044|Experimental|Computer game|Subjects will play with computer game while in the Emergency Room
3227482|NCT01162070|Active Comparator|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
3227483|NCT01162070|Experimental|Experimental strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
3227484|NCT01162083||Mitral Valve disease|Patients with mitral valve disease, deemed suitable and ready for elective valve repair or replacement. No significant arrhythmias, other valvular disease or LV dysfunction present. We shall also be recruiting patients undergoing a Mitraclip procedure.
3227485|NCT01162083||COPD|Patients with isolated chronic obstructive pulmonary disease and no cardiac disease.
3227486|NCT01162083||Mixed Lesions|Patients with proven limitation from both cardiac and respiratory disease.
3227487|NCT01162083||CRT|Patients with symptomatic heart failure who have responded to cardiac resynchronisation therapy (biventricular pacemaker).
3227488|NCT01162083||Cardiomyopathy|Heart Failure of primarily myopathic origin, without rhythm disturbance, ongoing ischaemia or significant valvular disease.
3227489|NCT01162109|Placebo Comparator|Severe sepsis without zinc|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
3227490|NCT01162109|Experimental|Zinc in severe sepsis|Mechanically ventilated patients with severe sepsis will be randomized to receive IV zinc or placebo
3227491|NCT01162109|Experimental|Healthy Volunteers receiving zinc|Cohort of healthy volunteers will receive a single dose of 500 mcg/kg IBW IV zinc and pharmacokinetics will be measured for 8 hours. PK in sepsis patients and healthy volunteers will be compared.
3227492|NCT01162148|Experimental|1|conventional
3227493|NCT01162148|Experimental|2|sham IMT
3227494|NCT01162148|Experimental|3|Conventional plus threshold IMT
3227495|NCT01162148|Experimental|4|threshold IMT alone
3227496|NCT01162161||hydrostatic pulmonary edema|patients with a pulmonary edema caused by chronic heart failure
3227497|NCT01162161||toxic pulmonary edema|patients with a pulmonary edema preceded by pneumonia
3227498|NCT01162161||control group|not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure)
3227499|NCT01162174|Experimental|100 mg of Oligonol|
3227500|NCT01162174|Experimental|200 mg of Oligonol|
3227501|NCT01162174|Placebo Comparator|0 mg of Oligonol|
3227502|NCT01162200|Other|Stereotactic Body Radiation Therapy|SBRT dose per fraction
3227503|NCT01162213|Experimental|100 mg of Lychee fruit extract|
3227504|NCT01162213|Experimental|200 mg of Lychee fruit extract|
3227505|NCT01162213|Experimental|600 mg of Lychee fruit extract|
3227506|NCT01162213|Experimental|2000 mg of Lychee fruit extract|
3227507|NCT01162226|Experimental|training program|
3227508|NCT01162252|Active Comparator|Mindfulness-Based Stress Reduction|
3227509|NCT01162252|Active Comparator|Living Well|
3227510|NCT01162265||Contacts|Contacts of active cases of tuberculosis
3227511|NCT01162265||new entrants|new entrants from high incidence (>40/100000) countries.
3227512|NCT01162278|Other|single fraction|Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 35Gy in one fraction. Subsequent cohorts of patients will receive an additional 5Gy per treatment to a maximum planned dose of 50Gy in one fraction.
3227513|NCT01162291||movement|healthy subjects, randomised to do flexion and extension movements with their left and right elbow joint after intramuscular application of NaCl 2ml in the right musculus biceps brachii, and 1ml in the left musculus biceps brachii
3227514|NCT01162291||rest|healthy subjects are randomised to rest after intramuscular application of NaCl 1ml in the left and 2ml in the right musculus biceps brachii
3227515|NCT01162330||Babies referred for further hearing tests|Babies referred for further hearing tests after their neonatal hearing screening tests
3227516|NCT01162369||Group 1 - Non-Delirius Patients|
3227517|NCT01162369||Group 2 - Delirious Patients|
3227518|NCT01162395|Experimental|A|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
3227519|NCT01162434||Patients|Up to 8 patients who have received Deep Brain Stimulation for Treatment Resistant Depression at Frenchay Hospital (UK) will be recruited.
3227520|NCT01162434||Healthy volunteers|Up to 16 healthy volunteers, matched to the DBS patients on age, sex, handedness, and education, will be recruited.
3227521|NCT01162447||PCO|Healthy control subjects and patients with polycystic ovarian syndrome will be recruited for the study.
3227522|NCT01162460|Active Comparator|Carbamazepine controlled release|
3227523|NCT01162460|Experimental|Eslicarbazepine acetate|
3227524|NCT01162512|Experimental|Physical Activity|Participants will receive 7 weeks of weekly news letters and phone calls. The news letters and phone calls will include information about physical activity and ways to increase physical activity levels. This is in addition the standard medical care.
3227525|NCT01162512|No Intervention|Standard Medical Care|Participants will receive standard medical care
3227526|NCT01162525|Experimental|pTNS treatment|
3227527|NCT01162564||NG-TSM|Patients receiving NG-TSM to repair an abdominal incisional/ventral hernia
3227528|NCT01162577|Experimental|Intervetion|The intervention group received the 5 standard tobacco calls plus 3 weight calls with a weight coach to address weight concerns related to quitting smoking
3227529|NCT01162577|No Intervention|Control|Participants in this arm received only the 5 standard tobacco calls
3227530|NCT01162590|Experimental|Rotarix Group|Subjects will receive Rotarix™.
3227531|NCT01162590|Placebo Comparator|Placebo Group|Subjects will receive placebo.
3227532|NCT01162603|Experimental|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means of Goldmann and Perkins applanation tonometry.
3227533|NCT01162603|Active Comparator|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution will be given once a day at the evening,in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. IOP values after three months of treatment will be evaluated throughout the 24-hour by the means Goldmann and Perkins applanation tonometry.
3227534|NCT01162616|Other|Iron absorption|
3227535|NCT01162629||Osteon|Patients requiring dental implants with deficient alveolar bone height
3227536|NCT01162642|Experimental|Green Tea|4 cups daily of green tea for 6 weeks
3227537|NCT01162642|Placebo Comparator|No Green Tea|4 cups daily of placebo tea for 6 weeks
3227538|NCT01162655|Experimental|Telehealth|Complete CBT group via telehealth
3227539|NCT01162655|Experimental|Internet|Complete Internet-based CBT program
3227540|NCT01162681|Experimental|A-623 high dose weekly|
3227541|NCT01162681|Experimental|A-623 low dose weekly|
3227542|NCT01162681|Experimental|A-623 high dose every 4 weeks|
3227543|NCT01162681|Placebo Comparator|Placebo|
3227544|NCT01162694|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3227545|NCT01162694|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the uploaded data and receive feedback from their endocrinologist every 2 weeks.
3227546|NCT01162707|Experimental|Pressure Measurement System|CardioMEMS HF Pressure Measurement System
3227547|NCT01162720|Experimental|Short duration tourniquet|Patients allocated to this group will have the pneumatic tourniquet applied to the index limb for approximately 20-30 minutes during cement fixation of the prosthesis.
3227548|NCT01162720|Active Comparator|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied from commencement of surgery and removed just prior to skin closure.
3259051|NCT01466998|Active Comparator|Music Therapy|Participant will use an identical appearing device, programmed to play quiet, relaxing non-rhythmic music while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
3259052|NCT01467011||Cases|de novo liver transplant recipients receiving Enteric-coated Mycophenolate Sodium
3227549|NCT01162746|Experimental|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
3227550|NCT01162746|Active Comparator|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
3227551|NCT01162759|No Intervention|Usual Care|The control group receiving usual care
3227552|NCT01162759|Experimental|Home Blood Pressure Monitoring Group|Intervention group
3227553|NCT01162772||Female Diabetics|female, 25-75 years old, no pregnancy, with/out Hormone replacement therapy T2DM, HbA1c > 7% with metformin mono-therapy
3227554|NCT01162772||Male diabetics|25-75 years, T2DM, HbA1c > 7% with metformin mono-therapy
3227555|NCT01162785|Experimental|First Dose SCH 721015|Part1: 2 Instillations of intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume
3227556|NCT01162785|Experimental|Second Dose SCH 721015|Part 2: Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration of SCH 721015 with Syn3 on same Day 1 and Day 4 regimen at same dose level.
3227557|NCT01162798|Active Comparator|Control|commercially available formula
3227558|NCT01162798|Experimental|Test|test formula
3227559|NCT01162811|No Intervention|Control group|The control group receives conventional care and treatment
3227560|NCT01162811|Experimental|Intervention group|the intervention group receives visualization and relaxation exercises together with structured behavioural attention
3227561|NCT01162824|Other|No endothelial dysfunction|
3227562|NCT01162824|Other|Endothelial Dysfunction|Definition of abnormal epicardial and microvascular vasoreactivity Abnormal epicardial vasoreactivity is defined as a reduction of the baseline coronary diameter ≥75% after glyceryltrinitrate i.c. together with a reproduction of the angina symptoms reported by the patient and/or ischemic ECG-changes. Abnormal microvascular vasoreactivity is defined as the reproduction of the angina symptoms together with ischaemic ECG-changes, but without changes in epicardial vasomotion.
3227563|NCT01162837|Other|All subjects|All subjects are enrolled in this arm and will use the BEAM device on one side of the face and the other side of the face will be the control
3227564|NCT01162850|Active Comparator|Polypodium Leucotomos|Oral Polypodium Leucotomos twice daily plus sunscreen SPF 45 for 12 weeks.
3227565|NCT01162850|Placebo Comparator|Placebo|Oral Placebo twice daily plus sunscreen SPF 45 for 12 weeks.
3227566|NCT01162876|Experimental|saxagliptin|5 mg daily for 14days
3227567|NCT01162889|Placebo Comparator|Placebo - SC injection|
3227568|NCT01162889|Experimental|Drug dose level 1 - SC injection|
3227569|NCT01162889|Experimental|Drug dose level 2 - SC injection|
3227570|NCT01162889|Experimental|Drug dose level 3- SC injection|
3227571|NCT01162889|Experimental|Drug dose level 4 - SC injection|
3227572|NCT01162889|Experimental|Drug dose level 5 - SC injection|
3227573|NCT01162889|Experimental|Drug dose level 6 - IV Infusion|
3227574|NCT01162889|Experimental|Drug dose level 7 - IV Infusion|
3227575|NCT01162889|Experimental|Drug dose level 8 - IV infusion|
3227576|NCT01162889|Placebo Comparator|Placebo - IV infusion|
3227577|NCT01162889|Experimental|Drug dose level 9 - IV infusion|
3227578|NCT01162902|Experimental|Diltiazem treated group|Diltiazem 180mg treated group
3227579|NCT01162902|Active Comparator|Bisoprolol treated group|Bisoprolol 5mg treated group
3227580|NCT01162902|Active Comparator|Candesartan treated group|Candesartan 32mg treated group
3227581|NCT01162915|Experimental|Safety|Infusion of autologous bone marrow-derived mesenchymal stem cells.
3227582|NCT01162928|Experimental|1|3-chamber-bag combined with Oxepa
3227583|NCT01162928|Active Comparator|2|3-chamber-bag combined with Pulmocare
3227584|NCT01162941|Experimental|Steroid dependant ITP|more than 10 mg of prednisolone per day is required to maintain a platelet count above 20X109/L (minimum follow up duration: 3 months after diagnosis)
3227585|NCT01162954|Experimental|DA-6034|
3227586|NCT01162954|Placebo Comparator|Placebo|
3227587|NCT01162967|Active Comparator|Benznidazole|
3227588|NCT01162967|Experimental|Posaconazole, low dose|
3227589|NCT01162967|Experimental|Posaconazole, high dose|
3227590|NCT01162993|Experimental|Spinal Cord Stimulation|Spinal cord stimulation
3227591|NCT01162993|No Intervention|Treatment as usual|Treatment as usual
3227592|NCT01163006|Experimental|polydextrose|
3227593|NCT01163006|Experimental|soluble glucofibre|
3227594|NCT01163006|Placebo Comparator|isocaloric dietary control|
3227595|NCT01163006|Placebo Comparator|full caloric control|
3227596|NCT01163019||Chest pain|Patients who present to the emergency department with a chief complaint of chest pain and have a moderate pre-test probability for an acute coronary syndrome
3227597|NCT01163045|Experimental|neuromonitoring and neurostimulation|
3227598|NCT01163045|Experimental|neurostimulation of recurrent laryngeal nerve|
3227599|NCT01163071|Experimental|ABI-011|
3227600|NCT01163188||Proband|Very low birth weight children (< 32 weeks of gestation) and/ or Very preterm children (< 1500 g birthweight) of the Bavarian Longitudinal Study
3227601|NCT01163188||Controls|Term born children of the Bavarian Longitudinal Study
3227602|NCT01163201|Experimental|Treg Plus CD3+Teff Treatment|Includes dose adjustment of T regulatory (Treg) and CD3+ T effector (CD3+ Teff) cells in recipients of double UCB transplantation
3227603|NCT01163227|Placebo Comparator|Placebo|
3227604|NCT01163227|Experimental|AQW051 Dose 1|
3227605|NCT01163227|Experimental|AQW051 Dose 2|
3227606|NCT01163227|Experimental|AQW051 Dose 3|
3227607|NCT01163240||pediatric|
3227608|NCT01163305||metastatic colorectal cancer|
3227609|NCT01163331|Experimental|Singing Therapy Group|Singing Therapy Group
3227610|NCT01163344||Dance Therapy Group|This will group will undergo dance therapy once a week for a series of 8 weeks.
3227611|NCT01163344||Physical Therapy Group|This group will undergo physical therapy sessions once a week for a series of 8 weeks
3227612|NCT01163357|Experimental|Group I (bortezomib, fludarabine phosphate, TMI, melphalan)|Patients receive fludarabine phosphate IV on days -9 to -5 and melphalan IV on day -4. Patients also undergo TMI BID on days -9 to -7. If no DLT is observed in the first cohort, bortezomib IV will be added on days -6 and -3 for subsequent cohorts.
3227613|NCT01163357|Experimental|Group II (bortezomib, fludarabine phosphate, melphalan|Patients receive fludarabine phosphate IV and melphalan IV as in Stratum I. Patients also receive bortezomib IV on days -6, -3, 1, and 4.
3227614|NCT01163370|Placebo Comparator|control and exercise|this is trained and receives placebo
3227615|NCT01163370|Experimental|creatine|this is non-exercise trained and receives creatine supplementation
3227616|NCT01163370|Experimental|exercise and creatine|this is exercised trained and receives creatine supplementation
3227617|NCT01163370|Placebo Comparator|placebo|this only receives placebo (dextrose)
3227618|NCT01163396|Experimental|FOLFOXIRI plus bevacizumab|BEVACIZUMAB 5 mg/Kg i.v. followed by IRINOTECAN 165 mg/sqm i.v. over 1 hr followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hr concomitantly with l-LV 200 mg/sqm over 2 hrs followed by 5FU 3.200 mg/sqm c.i. over 48 hrs starting on day 1. Cycles repeated every 2 weeks
3227619|NCT01163409|Experimental|acupuncture|will be made with classic acupuncture needling in traditional points, surpassing the skin
3227620|NCT01163409|Experimental|sham acupuncture|sham acupuncture will be done through a needle and a plastic device attached to skin in traditional acupuncture points.
3227621|NCT01163409|Experimental|exercise training resistance and aerobic|Aerobic exercise for 1 hour and resistance exercises for major muscle groups.
3227622|NCT01163409|No Intervention|healthy lifestyle|Group 4 - will be the control group who receive follow-up and recommendation for physical activity, but without any intervention supervised.
3227623|NCT01163422|Active Comparator|Immediate RVRT|RVRT switched on immediately after pacemaker implant
3227624|NCT01163422|Placebo Comparator|Delayed RVRT|RVRT switched on 4 weeks after pacemaker implant
3227625|NCT01163435|Experimental|high dose dual therapy|group A1 and A2 - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
3227626|NCT01163435|Experimental|sequential therapy|group B1 and B2 - sequential therapy (rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days)
3227627|NCT01163435|Active Comparator|clarithromycin-based triple therapy|group C1 - clarithromycin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days)
3227628|NCT01163435|Active Comparator|levofloxacin-based triple therapy|group C2 - levofloxacin-based triple therapy (rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days)
3227629|NCT01163448|Experimental|High-Dose Single-Fraction Image-Guided Radiotherapy|This will assess the feasibility and safety of this approach in men at high-risk for extraprostatic prostate cancer undergoing RP. This initial trial has been designed in a manner intended to emphasize patient comfort and safety.
3227630|NCT01163487|Experimental|Dichloroacetate (DCA)|25 mg/kg/day, 37.5 mg/kg, or 50 mg/kg/day oral DCA.
3227631|NCT01163500|Placebo Comparator|Pill|
3227632|NCT01163500|Experimental|Coenzyme Q10|
3227633|NCT01163513||White population|
3227634|NCT01163513||Indian|
3227635|NCT01163513||Pakistani|
3227636|NCT01163513||Bangladeshi|
3227637|NCT01163513||Other|other South Asian
3227638|NCT01163526||neuroendocrine metastases|15 patients with neuroendocrine metastases
3227639|NCT01163526||colon cancer metastases|15 patients with colon cancer metastases
3227640|NCT01163526||HCC treated with cyberknife radiation and chemotherapy|15 patients with HCC treated with cyberknife radiation and chemotherapy
3227641|NCT01163526||HCC treated with Sirsphere embolization and chemotherapy|15 patients with HCC treated with Sirsphere embolization and chemotherapy
3227642|NCT01163552|Experimental|Surgical Debulking and Intrathoracic Hyperthermic Chemotherapy|Patients in this trial will undergo surgical debulking followed by intrathoracic hyperthermic chemotherapy perfusion.
3227643|NCT01163565|Active Comparator|Ligasure device|
3227644|NCT01163565|No Intervention|Hand ties|
3227645|NCT01163591||Case|Patients with overt diabetic nephropathy as evidenced by ACR greater than or equal to 30mg/mmol on urinalysis and eGFR greater than or equal to 15ml/min/1.73m2 and less than 60ml/min/1.73m2
3227646|NCT01163591||Control|Patients without diabetic nephropathy as defined by the absence of albuminuria (defined by a random spot urinary ACR <2.5 mg/mmol in women or ACR<3.5 mg/mmol in men)and eGFR greater or equal to 90 ml/min/1.73m2
3227647|NCT01163630|Experimental|1|esomeprazole 20mg/ASA 81 mg FDC after a 10-hour fast
3227648|NCT01163630|Experimental|2|esomeprazole 20mg/ASA 81 mg FDC 30 minutes after start of a high-fat, high-calorie breakfast
3227649|NCT01163669||kidney transplant recipients|
3227650|NCT01163682|Active Comparator|Electro-acupuncture|45 minute sessions scheduled once a week for 12 weeks.
3227651|NCT01163682|Sham Comparator|Sham acupuncture|45 minute sessions scheduled once a week for 12 weeks
3227652|NCT01163708|Active Comparator|Navigation alone|Navigation system alone vs Prophecy technique with Navigation system validation
3227653|NCT01163708|Experimental|Prophecy and Navigation validation|
3227654|NCT01163734|Experimental|Ranolazine|
3227655|NCT01163734|Placebo Comparator|Saline 0.9%|Saline 0.9% and placebo tablet
3227656|NCT01163799|Experimental|Alefacept (ASP0485)|Safety and efficacy of alefacept in combination with alemtuzumab induction and calcineurin inhibitor (CNI) and corticosteroid withdrawal.
3227657|NCT01163812|Experimental|Laparoscopic D2 gastrectomy|
3227658|NCT01163825|Experimental|Nerve Growth Factor|Dose 1
3227659|NCT01163825|Experimental|Nerve Growth Factor 2|Dose 2
3227660|NCT01163838|Placebo Comparator|Placebo|
3227661|NCT01163838|Experimental|RN316: 1 mg/kg every 2 weeks|
3227662|NCT01163838|Experimental|RN316: 2 mg/kg every 4 weeks|
3227663|NCT01163838|Experimental|RN316: 4 mg/kg every 4 weeks|
3227664|NCT01163838|Experimental|RN316: 4 mg/kg every 8 weeks|
3227665|NCT01163838|Experimental|RN316: 8 mg/kg every 8 weeks|
3227666|NCT01163838|Experimental|RN316: 12 mg/kg every 8 weeks|
3227667|NCT01163864|Experimental|affect regulation training|
3227668|NCT01163864|Active Comparator|health and lifestyle|
3227669|NCT01163877|Other|Symptomatic malaria infection|
3227670|NCT01163877|Other|Asymptomatic malaria infection|
3227671|NCT01163877|Other|Hookworm infection|
3227672|NCT01163877|Other|Schistosoma haematobium infection|
3227673|NCT01163890|Experimental|WHI|
3227674|NCT01163890|Active Comparator|Usual Care|
3227675|NCT01163903|Experimental|Pantoprazole and doxorubicin|
3227676|NCT01163929|Experimental|paclitaxel, trastuzumab and everolimus|
3227677|NCT01163942|Active Comparator|No G-CSF, No 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
3227678|NCT01163942|Active Comparator|No G-CSF, yes 2nd ATG|Patients randomised not to receive G-CSF (alongside ATG and CSA) but they do receive early retreatment in case of no response.
3227679|NCT01163942|Active Comparator|Yes G-CSF, No 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to not receive early retreatment in case of no response.
3227680|NCT01163942|Active Comparator|Yes G-CSF, Yes 2nd ATG|Patients randomised to receive G-CSF (alongside ATG and CSA) and to receive early retreatment in case of no response.
3227681|NCT01163968|Experimental|Weight reduction program|MOMENTUM intervention
3227682|NCT01163981|No Intervention|Blind cannulation|Cannulation without guidance
3227683|NCT01163981|Experimental|Ultrasound guided cannulation|Ultrasound guided cannulation
3227684|NCT01163994|Active Comparator|MEM-ceftriaxone|
3227685|NCT01163994|Active Comparator|MEM-doxycycline|
3227686|NCT01163994|No Intervention|controls|
3227687|NCT01163994|Active Comparator|EM-doxycycline|
3227688|NCT01164020|Placebo Comparator|placebo control|this only receives placebo (dextrose)
3227689|NCT01164020|Experimental|placebo and exercise|this is trained and receives placebo
3227690|NCT01164020|Experimental|creatine supplementation|this is non-exercise trained and receives creatine supplementation
3227691|NCT01164020|Experimental|Creatine and Exercise|this is exercised trained and receives creatine supplementation
3227692|NCT01164033|Active Comparator|A|
3227693|NCT01164033|Experimental|B|
3227694|NCT01164033|Experimental|C|
3227695|NCT01164033|Experimental|D|
3227696|NCT01164046|Active Comparator|vitamin K antagonists|
3227697|NCT01164046|Active Comparator|Low molecular weight heparin|
3227698|NCT01164059|Experimental|atypical antipsychotics|Olanzapine, Quetiapine, or Aripiprazole
3227699|NCT01164059|Active Comparator|typical antipsychotics|Haloperidol or Flupentixol
3227700|NCT01164072||HIGH NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with 7.2 mg nicotine cartridges (high nicotine group).
3227701|NCT01164085|Experimental|Ketorolac|4mg intravitreal injection of ketorolac
3227702|NCT01164111|Experimental|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise. Frequency: 2 times/week
3227703|NCT01164111|No Intervention|Control|Standard preoperative track.: No training intervention. Standard preoperative information.
3227704|NCT01164124|Experimental|Probiotic supplementation|500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
3227705|NCT01164124|Placebo Comparator|Routine feedings|
3259053|NCT01467024||EIA Negative|Blood donor specimens that tested non-reactive by previously licensed HTLV screening assay.
3227706|NCT01164150|Experimental|Arm B|Radiation: 45 Gy / 25 fractions pelvic radiotherapy using intensity modulated radiotherapy (IMRT) followed by 11 Gy / 2 fractions vaginal vault brachytherapy
3227707|NCT01164150|Other|Arm A Control|Radiation: 45 Gy/25 fraction external beam pelvic radiotherapy delivered using a 3-dimensional planned technique followed by 11 Gy / 2 fractions vaginal vault brachytherapy
3227708|NCT01164163|Experimental|Treatment (Ruxolitinib)|
3227709|NCT01164176|Experimental|RAD001 group|
3227710|NCT01164189|Other|Temozolomide|Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles
3227711|NCT01164189|Experimental|Temozolomide + Bevacizumab|"TMZ: Administered orally on day 1-5, 150-200 mg/m(2), repeated every 4 weeks, up to 12 cycles~Beva: 10 mg/kg bw IV in 90 minutes on day 1 and 14, 4 week cycles."
3227712|NCT01164202|Placebo Comparator|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
3227713|NCT01164202|Experimental|Sunitinib|sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year
3227714|NCT01164215|Experimental|mFOLFOX6|"Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)"
3227719|NCT01164280|Experimental|Pulse Rate Change|Patients are subjected to different pulse rate settings of their neurostimulator. The effect of pulse rate changes on clinical outcome is measured.
3227720|NCT01164293|Experimental|Atopy patch test|Atopy patches were applied on food allergy patient's back for 48 hrs then the patches were removed. Reaction was evaluated at 48 and 72 hrs after applying atopy patch test
3227721|NCT01164306|Experimental|LifeSkills training|
3227722|NCT01164306|Active Comparator|Healthy Lifestyle Behaviors|
3227723|NCT01164319|Active Comparator|Group 1 (no early recurrence)|Patients without atrial fibrillation recurrences through the implantable cardiac monitors during the 3 months post-ablation period.
3227724|NCT01164319|Active Comparator|Group 2 (early AF recurrence)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period.
3227725|NCT01164319|Active Comparator|Group 3 (early recurrence-no reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 would not receive reablation.
3227726|NCT01164319|Active Comparator|Group 4 (early recurrence-early reablation)|Patients with AF recurrences documented by the ICM during the 3 months post-ablation period from Group 2 will receive early reablation based on data stored by implanted monitor.
3227727|NCT01164332|Other|Method A|First experimental detection method
3227728|NCT01164332|Other|Method B|Second experimental detection method
3227729|NCT01164345|Experimental|MOZOBIL|treatment with mozobil for autologous stem cell collection
3227730|NCT01164358||study arm I|"patients who have been enrolled in the previous study Intrastromal Correction of Ametropia by Femtosecond Laser (study ISCAF), study arm 1, Presbyopia sub-group: treatment pattern 5-Rings"
3227731|NCT01164358||study arm II|"patients who have been enrolled in the previous study Intrastromal Presbyopia Correction by Means of Femtosecond Laser (study # 0905)"
3227732|NCT01164371||Initial presentation of coronary disease - Stable angina|Patients whose initial symptomatic presentation of coronary disease is stable angina (either diagnosis or symptoms)
3227733|NCT01164371||Initial presentation of coronary disease - ACS|Patients whose initial symptomatic presentation of coronary disease is acute coronary syndrome (ST-elevation myocardial infarction [STEMI], non-STEMI [nSTEMI] or unstable angina) without prior stable angina or symptoms of stable angina
3227734|NCT01164371||Initial presentation of coronary disease - Coronary death|Patients whose initial symptomatic manifestation of coronary disease is coronary death with no prior diagnosis of stable angina (or symptoms of stable angina) or diagnosis of acute coronary syndrome
3227735|NCT01164371||Initial presentation of coronary disease - None|Patients without symptomatic presentation of coronary disease, either alive or dead from non-coronary cause
3227736|NCT01164397||Dislipidemic Population|People with high levels of total cholesterol, LDL, C-HDL and triglycerides
3227737|NCT01164410||Pediatric Colonoscopy|Patients undergoing colonoscopy in the Department of Pediatric Gastroenterology at the Cleveland Clinic Children's Hospital in Cleveland, Ohio.
3227738|NCT01164423|Experimental|1|Space TGC system with incorporated eMPC advised insulin infusion to establish glycaemic control
3227739|NCT01164449|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
3227740|NCT01164462|Other|A 2|During the normal opening hours of five testing centers, clients with a rapid finger-stick blood specimen test
3227741|NCT01164462|Other|B group|During evenings and week-ends (i.e. when the centers are closed) only community based with rapid HIV testing
3227742|NCT01164462|Other|A1 group|During the normal opening hours of five testing centers, clients with a conventional test.
3227743|NCT01164488|Experimental|1|
3227744|NCT01164514|Active Comparator|Group 1 - vaccine alone|8 subjects to receive vaccine (10 mcg) alone on Days 0, 29 and 59.
3227745|NCT01164514|Experimental|Group 3 - vaccine + CPG 7909 (250 mcg)|8 subjects to receive vaccine (10 mcg) with 250 mcg of adjuvant on Days 0, 29 and 59.
3227746|NCT01164514|Experimental|Group 2 - vaccine + CPG 7909 (500 mcg)|8 subjects to receive vaccine (10 mcg) with 500 mcg of adjuvant on Days 0, 29 and 59.
3227747|NCT01164514|Placebo Comparator|Group 4 - Placebo|4 subjects to receive normal saline (placebo) on Days 0, 29 and 59.
3227748|NCT01164540|Experimental|1|Oral Treatment
3227749|NCT01164540|Placebo Comparator|2|Oral treatment
3227750|NCT01164553|Experimental|Group 2, 0.5 mL TIV|Naive cohort participants (n=180) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=40) will receive 0.5 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose.
3227751|NCT01164553|Active Comparator|Group 1, 0.25 mL TIV|Naive cohort participants (n=90) receive 0.25 mLTrivalent Inactivated Vaccine (TIV) in two intramuscular doses 28-42 days apart. Fully Primed cohort participants (previously vaccinated) (n=20) will receive 0.25 mL Trivalent Inactivated Influenza Vaccine (TIV) in one intramuscular dose
3227752|NCT01164566|Experimental|Arm I|Patients undergo transnasal esophagoscopy at baseline and 3 months following completion of radiation therapy and/or chemotherapy.
3227753|NCT01164592|Active Comparator|Therapy with adaptive servo ventilation|optimal medical therapy + adaptive servoventilation
3227754|NCT01164592|No Intervention|Optimal medical therapy according to guidelines|optimal medical therapy
3227755|NCT01164618|Experimental|Group 1|The subjects in this arm will begin on the daily remote ischemic preconditioning (RIPC) protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily exercise.
3227756|NCT01164618|Experimental|Group 2|The subjects in this arm will begin on the exercise protocol for 10 days. After a 21 day washout period they will then crossover to 10 days of daily remote ischemic preconditioning (RIPC).
3227757|NCT01164631|Experimental|Orthodontic treatment|Snoring patients enrolling for tonsil surgery with maxillary constriction, and/or jaw retrognathism
3227758|NCT01164631|No Intervention|Control Group|Patients enrolled for tonsils surgery
3227759|NCT01164657|Experimental|study group|Randomized to give birth on a birthing seat
3227760|NCT01164657|No Intervention|control group|Randomized to birth in any other position except the birthing seat
3227761|NCT01164670||Men|Men over 70 years old.
3227762|NCT01164670||Women|Women over 70 years old.
3227763|NCT01164683|Experimental|Arm 1|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
3227764|NCT01164683|Active Comparator|Arm 2|Usual care
3227765|NCT01164696||Group 1|
3227766|NCT01164709|Experimental|bortezomib + nelfinavir|escalation 3 by 3 cohorts
3227767|NCT01164735||Correlative studies|Archived tumor tissue samples are analyzed for topoisomerase 2-alpha gene alteration and expression and chromosome 17 polysomy by FISH and IHC. Clinical information associated with each endometrial carcinoma sample (e.g., age, race/ethnicity, cell type, histologic grade, disease stage, and regimen type) is also collected.
3227768|NCT01164748||Sentinel Node Biopsy|All women who has Sentinel Node Biopsy as their primary treatment of the axilla
3227769|NCT01164748||Axillary Lymph Node Dissection|All women who had Axillary Lymph Node Dissection as primary axillary treatment
3227770|NCT01164761|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
3227771|NCT01164761|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
3227772|NCT01164774|Experimental|Ramipril|Ramipril 10 mg capsules of Dr. Reddy's Laboratories Limited
3227773|NCT01164774|Active Comparator|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
3227774|NCT01164787|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
3227775|NCT01164787|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
3227776|NCT01164800|Experimental|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
3227777|NCT01164800|Active Comparator|Mavik®|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
3227778|NCT01164813|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
3227779|NCT01164813|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
3227780|NCT01164826|Experimental|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
3227781|NCT01164826|Active Comparator|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
3227782|NCT01164852|No Intervention|Expectant management|Expectant management: refers to pregnancy prolongation during which time women and fetuses are carefully monitored for indications for delivery.
3227783|NCT01164852|Active Comparator|Interventionist management|Interventionist management: in which blood pressure is stabilized, corticosteroids are given for acceleration of fetal maturity and delivery is planned within 48-72 hours.
3227784|NCT01164878||Before|ELBW infants before change of feeding policy
3227785|NCT01164878||After|ELBW infants after change of feeding policy
3227786|NCT01164904|Experimental|Experimental|Ten escalating dose levels of AMG 181 administered as a single dose SC or IV in healthy volunteers and SC in subjects with mild-to-moderate ulcerative colitis.
3227787|NCT01164917|Active Comparator|AMG811|All will receive AMG 811, either on Day 1 or Day 85
3227788|NCT01164917|Placebo Comparator|AMG811 Placebo|All will receive placebo, either on Day 1 or Day 85
3227789|NCT01164930|Experimental|Acceptance and Commitment Therapy group|8-week ACT group
3227790|NCT01164930|No Intervention|Wait-list control group|Participants will be offered treatment following wait-list data collection
3227791|NCT01164943|Active Comparator|Human FSH|
3227792|NCT01164943|Active Comparator|Recombinant FSH|
3227793|NCT01164969||H. pylori eradication failure|People who are not able to eradicate H. pylori although the appropriate antibiotic therapy taken.
3227795|NCT01165034|No Intervention|Usual care|Best usual practice including general respiratory specialist and primary care
3227796|NCT01165034|Experimental|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
3227797|NCT01165060|Experimental|Bezafibrate|All patients in the trial will use bezafibrate 400 mg once daily until week 12, and subsequently use 800 mg onde daily until week 24.
3227798|NCT01165073|Experimental|Naso-gastric tube feeding|
3227799|NCT01165073|Active Comparator|Oral feeding|
3227800|NCT01165099|Experimental|manual acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were manually manipulated during this time. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
3259054|NCT01467024||EIA Repeat Reactive|Blood donor specimens that tested repeat reactive by previously licensed HTLV screening assay, but are unconfirmed.
3227801|NCT01165099|Experimental|electro acupuncture|Sterile needles were inserted intramuscularly to a depth of 15-20mm until an unusual (De-Qi) sensation developed and remained inserted for 30-60 minutes and were either electronically simulated withm2 Hz pulses of 0.5 msec duration for 30 minutes sufficient to cause non-painful muscle contractions. The following bilateral acupoints on the hands and feet at Hegu (LI 4), Sanyinjiao (Sp 6) Kunlun (BL 60) and Zhiyin (BL 67)were used.
3259055|NCT01467024||Known Positive|Blood donor specimens that tested repeat reactive with a licensed HTLV screening assay and have been confirmed through additional, unlicensed supplemental testing.
3259056|NCT01467050|Active Comparator|Application of STOPP/START criteria|
3259057|NCT01467050|No Intervention|Control|
3227802|NCT01165099|Sham Comparator|Sham manual or electro acupuncture|Sterile needles were inserted adjacent to the specific acupuncture sites identified for the manual and electro groups to a depth of 1-1.5mm only and insufficient to provoke an unusual sensation and left in position for a 30-60 minutes. Those randomised to 'sham-manual' received no stimulation and those randomised to 'sham-electro' were connected to the electrical stimulator but the current not activated.
3227803|NCT01165099|No Intervention|control group|Following randomisation to be control group, no specific treatment was organised at this time.
3227804|NCT01165125|Other|FF/GW642444 and keto|Ketoconazole (400mcg) administered on Days 1-11, with co-administration of fFF / GW642444 (200mcg/25mcg) on Days 5-11
3227805|NCT01165125|Other|Ketoconazole Placebo to match & FF/GW642444|ketoconazole placebo to match administered on days 1-11. FF/GW642444 (200mcg/25mcg) co-administered on Days 5-11
3227806|NCT01165151|Experimental|Small group|10-member groups
3227807|NCT01165151|Active Comparator|Large group|30-member groups
3227808|NCT01165164|Experimental|FID 115958D|Lubricant eye drop
3227809|NCT01165190||Pioglitazone group|
3227810|NCT01165255||Infants born to women who were exposed to antidepressants|Women ages 12 through 49 (as of delivery date) who were dispensed an antidepressant between 01 January 1995 and 30 September 2004 from the original Bupropion study.
3227811|NCT01165268|Active Comparator|Dapagliflozin (T2DM)|
3227812|NCT01165268|Active Comparator|Dapagliflozin (Healthy Subjects)|
3227813|NCT01165294|Experimental|001|ketamine An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
3227814|NCT01165294|Experimental|002|Placebo An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
3227815|NCT01165333|Experimental|Dose escalation|In the first part of the trial, a dose-ranging study in ca. 18-21 patients will be done. A standard dose escalation strategy will be used including 3 to 6 patients at each dose level, the first cohort of patients being treated at dose level one Interventions : Cilengitide dose escalation ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
3227816|NCT01165333|Experimental|Cohort extension|An additional 20 patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations Interventions : Cilengitide ; Concomitant radiotherapy ; Pharmacokinetic ; Pharmacogenetic
3227817|NCT01165346|Experimental|Stereotaxic radiation by CyberKnife|Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days
3227818|NCT01165359|Experimental|Part A: ITX 5061|Participants will receive ITX 5061 once a day for 3 days.
3227819|NCT01165359|Placebo Comparator|Part A: Placebo|Participants will receive placebo once a day for 3 days.
3227820|NCT01165359|Experimental|Part B: ITX 5061|Participants will receive ITX 5061 once a day for 14 days.
3227821|NCT01165359|Placebo Comparator|Part B: Placebo|Participants will receive placebo once a day for 14 days.
3227822|NCT01165359|Experimental|Part C: ITX 5061|Participants will receive ITX 5061 once a day for 28 days.
3227823|NCT01165359|Placebo Comparator|Part C: Placebo|Participants will receive placebo once a day for 28 days.
3227824|NCT01165372|Experimental|Artesunate 2mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 2mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
3227825|NCT01165372|Experimental|Artesunate 4mg|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with artesunate 4mg/kg/day for 3 days and followed by DHA-PPQ treatment at doses according to National guidelines for 3 days.
3227826|NCT01165372|Experimental|DHA-piperaquine|People with uncomplicated malaria who meet the study inclusion criteria will be enrolled, screened, randomized and treated on site with dihydroartemisinin-piperaquine once daily according to weight for 3 days.
3227827|NCT01165385|Experimental|Pazopanib and Cisplatin|"Steady state period:Pazopanib will be given 8 days prior to cisplatin~Then pazopanib will be given 400 mg, 600 mg or 800 mg/day, daily and cisplatin 60, 75 or 100 mg/m2 , day 1 - 3 weekly, depending of the dose level"
3227828|NCT01165398||Residents, PAs, mid level providers|Lehigh Valley Health Network residents, physician assistants, and mid level providers who place central lines and attend the central lines simulation course
3227829|NCT01165411||Patients with CVCs and PICC lines placed|This group will have either Standard of Care (control) or Process Improvement infection control changes administered.
3227830|NCT01165437||Suspected Arterial Disease|Patients with known or suspected arterial disease and patients screened using AHA/ACC criteria for P.A.D.
3227831|NCT01165463|Experimental|Clinic-based SOPT basic training|Clinic-based SOPT basic training for 10 hours.
3227832|NCT01165463|Experimental|Home-based SOPT basic training|Home-based SOPT basic training for 10 hours.
3227833|NCT01165463|Active Comparator|Crossword Puzzles Training|Crossword puzzles training for 10 hours in our lab.
3227834|NCT01165463|Experimental|SOPT basic and SOPT booster-training|Clinic-based SOPT basic training and SOPT booster training.
3227835|NCT01165476|Active Comparator|manufacturer #1|treprostinil diethanolamine from manufacturer #1
3227836|NCT01165476|Experimental|manufacturer #2|treprostinil diethanolamine from manufacturer #2
3227837|NCT01165489||Laryngomalacia|Patients with Laryngomalacia
3227838|NCT01165489||Control Group|Patients without Laryngomalacia
3227839|NCT01165502|Experimental|CM3.1-AC100|Compound CM3.1-AC100 s.c.
3227840|NCT01165502|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
3227841|NCT01165515||Healthy young females|20 healthy females, aged between 18 and 35 years
3227842|NCT01165515||Healthy young males|20 healthy males, aged between 18 and 35 years
3227843|NCT01165515||Healthy elderly smokers|20 healthy smokers, aged between 45 and 75 years
3227844|NCT01165515||Healthy elderly non-smokers|20 healthy non-smokers, aged between 45 and 75 years
3227845|NCT01165515||Healthy young female smokers|20 healthy female smokers, aged between 18 and 35 years
3227846|NCT01165515||Healthy young male smokers|20 healthy male smokers, aged between 18 and 35 years
3227847|NCT01165515||Healthy postmenopausal women|20 healthy postmenopausal women
3227848|NCT01165515||Female CMP Patients|20 female patients suffering from cardiomyopathy (ischemic or dilating)
3227849|NCT01165515||Male CMP Patients|20 male patients suffering from cardiomyopathy (ischemic or dilating)
3227850|NCT01165515||Female CHD patients|30 female patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
3227851|NCT01165515||Male CHD Patients|30 male patients suffering from cardiac heart disease, before aorto-coronary bypass surgery (and after)
3227852|NCT01165515||male athlets|20 male athlets
3227853|NCT01165515||female athlets|20 female athlets
3227854|NCT01165528|Active Comparator|Adaptive support ventilation in ARDS|patients of ARDS will be randomized to this arm to receive mechanical ventilation as per ASV protocol
3227855|NCT01165528|Active Comparator|conventional ventilation strategy in ARDS|
3227856|NCT01165567|Experimental|sarpogrelate 300 mg per day|Patients in the sarpogrelate group receive sarpogrelate 300 mg per day for 24 hours before exposure to contrast agent.
3227857|NCT01165567|No Intervention|No sarpogrelate medication|
3227858|NCT01165580|Experimental|Single Arm|
3227859|NCT01165593||Patients with atrial fibrillation|Patients with atrial fibrillation who have received a cardiac CT scan as part of normal care prior to catheter-based treatment of atrial fibrillation.
3227860|NCT01165606|Experimental|Physiotherpy|
3227861|NCT01165619||Hypothalamic Amenorrhea|This group is for pre-menopausal women between the aged 18-40 who have been previously diagnosed with Hypothalamic Amenorrhea. They can be currently diagnosed or may have recovered.
3227862|NCT01165619||Healthy Adult Men|This group is men over the age of 18 who do not have any history of reproductive disorders or chronic disease.
3227863|NCT01165619||Healthy Adult Women|This group is pre-menopausal, regularly menstruating women ages 18-40 who do not have a history of reproductive disorders or chronic disease.
3227864|NCT01165619||Idiopathic Hypogonadotropic Hypogonadism|This group is for adult men and women over the age of 18 who have been diagnosed with Idiopathic Hypogonadotropic Hypogonadism with or without anosmia.
3227865|NCT01165632|Experimental|Arm I|Beginning at no more than 1 week before biopsy or resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.
3227866|NCT01165645|Experimental|Arm I|Patients receive oral lopinavir and ritonavir twice daily for 28 days in the absence of disease progression or unacceptable toxicity.
3227867|NCT01165645|No Intervention|Arm II|Patients receive no therapy.
3227868|NCT01165658|Experimental|Proton Therapy|The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.
3227869|NCT01165671|Experimental|Experimental Arm|Carbon Ion Radiotherapy to the Macroscopic Tumor 6 x 3 Gy E up to 18 Gy E
3227870|NCT01165671|Active Comparator|Standard Arm|Proton Radiotherapy to the Macroscopic Tumor 5 x 2 Gy E up to 10 Gy E (Standard dose) applied after 48-52 Gy photon radiotherapy
3227871|NCT01165697||Fabry disease biomarker|Neuro-retinal fluorescein angiography (NRFA) exam will be administered once every 6 months for up to 3 years.
3227872|NCT01165710||001|Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
3227873|NCT01165723|Experimental|IV Dose 1: experimental|
3227874|NCT01165723|Experimental|IV Dose 2: experimental|
3227875|NCT01165736|Active Comparator|Intravenous: PF-05186462|
3227876|NCT01165736|Active Comparator|Oral: PF-05186462|
3227877|NCT01165736|Active Comparator|Intravenous: PF-05089771|
3227878|NCT01165736|Active Comparator|Oral: PF-05089771|
3227879|NCT01165736|Active Comparator|Intravenous: PF-05150122|
3227880|NCT01165736|Active Comparator|Oral: PF-05150122|
3227881|NCT01165736|Active Comparator|Intravenous: PF-05241328|
3227882|NCT01165736|Active Comparator|Oral: PF-05241328|
3227883|NCT01165762|Experimental|Immune Tolerance, Kidney transplantation|Induction of immune tolerance in Haplotype matched living donor kidney transplantation.
3227884|NCT01165788||autologous BMT recipients|Lymphoma patients who received an autologous BMT as adults
3227885|NCT01165801|No Intervention|Control Group (CO)|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
3227886|NCT01165814|Active Comparator|Tramadol at fixed intervals|
3227887|NCT01165814|Active Comparator|Tramadol on request|
3227888|NCT01165814|Active Comparator|Naproxen at fixed intervals|
3227889|NCT01165814|Active Comparator|Naproxen on request|
3227890|NCT01165827||Patients with aortic valve procedures|"All consecutive patients from participating hospitals with aortic valve defects who have received one of the following therapies:~surgical aortic valve replacement,~percutaneous transvascular (retrograde) aortic valve implantation~percutaneous transapical aortic valve implantation as principal indication. If the aortic valve insufficiency is concurrent with combination procedures (e.g. coronary artery bypass graft, mitral valve surgery) the aortic valve stenosis must fulfil only the criteria for indication according to the German National guidelines (see: detailed study description)."
3227891|NCT01165853|Other|Glucose|
3227892|NCT01165853|Other|Fructose|
3227893|NCT01165866|Active Comparator|Treatment 1.|Metoclopramide 0.3 mg/kg max 10 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline as a single intravenous dose. Complete blood count,serum electrolytes,renal function,HCO3 level will be requested.Oral fluid will be started thereafter and increased gradually until patient discharge.
3227894|NCT01165866|Other|Treatment2.|Ondansetron 0.15 mg/kg max 4 mg in burette and mixed with normal saline to make up 50 cc of medication and normal saline to be given over 10 minutes,then patient will be kept NPO for one hour after completion of the anti emetic infusion and last episode of vomiting . Oral fluid will be started thereafter and increased gradually until fully tolerated and the patient is ready for discharge
3227895|NCT01165918||Donated embryos|
3227896|NCT01165931|Experimental|Arm 1|
3227897|NCT01165944|No Intervention|Standard diabetes therapy|Standard diabetes therapy with either oral agents or insulin injections
3227898|NCT01165944|Active Comparator|Oral diabetic agents and pramlintide|
3227899|NCT01165944|Active Comparator|Insulin injection with pramlintide|
3227900|NCT01165957||Mobile bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is designed to slide or rotate on the metal baseplate.
3227901|NCT01165957||Fixed bearings|Tibial polyethylene inserts retrieved from total knee replacements where the insert is locked to the metal baseplate.
3227902|NCT01165970|Active Comparator|Glandosane|After in situ exposition the enamel and dentin samples will demineralize with Glandosane.
3227903|NCT01165970|Experimental|Saliva natura|After in situ exposition the enamel and dentin samples will remineralize with Saliva natura
3227904|NCT01166022|Experimental|Exercise|Muscle strengthening program using weights and resistance bands in combination with a home based cycle ergometry program. The home-based exercise program will be performed up to 5 times weekly.
3227905|NCT01166022|No Intervention|Typical Activity|Subjects in this group will be asked to maintain their typical daily activity. Those assigned to this arm will be given the opportunity to join the intervention arm seven months after their screening visit.
3227906|NCT01166048|Placebo Comparator|Milk powder pill|Patients will receive 2 placebo pills per day for a period of 4 weeks.
3227907|NCT01166048|Experimental|Duloxetine|In the experimental arm of the study patients will receive duloxetine, which will be titrated up to a dosage of 120mg over a period of two weeks and continued at this dosage for two weeks.
3227908|NCT01166061|Experimental|Cohort 1|Subjects to receive either active or placebo
3227909|NCT01166061|Experimental|Cohort 2|Subjects to receive either active or placebo comparator
3227910|NCT01166061|Experimental|Cohort 3|Subjects to receive either active or placebo comparator
3227911|NCT01166061|Experimental|Cohort 4|Subjects to receive either active or placebo comparator
3227912|NCT01166061|Experimental|Cohort 5|Subjects to receive either active or placebo comparator
3227913|NCT01166074||SCIG|
3227914|NCT01166087|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
3227915|NCT01166087|Active Comparator|Prozac ® weekly|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
3227916|NCT01166100|Experimental|Fluoxetine Hydrochloride|Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories Limited
3227917|NCT01166100|Active Comparator|Prozac ® weekly TM|Prozac ® weekly 90 mg delayed release capsules of Eli Lilly and company
3227918|NCT01166113|Experimental|PCP|
3227919|NCT01166165|Active Comparator|Cholecalciferol|
3227920|NCT01166165|Placebo Comparator|Placebo|
3227921|NCT01166191|Experimental|SCLC|
3227922|NCT01166204|Experimental|Single group|
3227923|NCT01166217|Experimental|ABCE, ACBD, BACD, BCAE, CABE and CBAD|
3227924|NCT01166243|Experimental|Fibrin Pad|Biologic
3227925|NCT01166243|Other|Standard of Care|Procedure
3227926|NCT01166256|Experimental|High-flow nasal cannula|In this arm,patients with acute hypoxemic respiratory failure were treated with high-flow nasal cannula system(Optiflow, Fisher & Paykel, Auckland, New Zealand) to achieve SpO2 >92% or PaO2 >65 mmHg.
3227927|NCT01166256|Active Comparator|Non-invasive ventilation|In this arm, patients with acute hypoxemic respiratory failure is treated with the bi-level positive airways pressure mode (BiPAP Vision, Respironics Inc., Murrysville, PA) S/T mode to achieve SpO2 >92% or PaO2 >65 mmHg.
3227928|NCT01166269|Experimental|Grass-Allergen x 6|This arm will receive 6 injections of allergen.
3227929|NCT01166269|Active Comparator|grass-allergen x 3 and placebo x 3|this arm will receive 3 injections of allergen, and 3 injections of placebo.
3227930|NCT01166269|Placebo Comparator|placebo x 6|this arm will receive 6 injections of placebo.
3227931|NCT01166308|Experimental|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I Part of the Trial
3227932|NCT01166308|Active Comparator|Standard Treatment: Fractionated Stereotacitc Radiotherapy|Standard Precision Radiotherapy performed as Fractionated Stereotactic Radiotherapy (FSRT) up to 36 Gy in single dosis of 2 Gy
3227933|NCT01166321|Experimental|Carbon Ion Radiotherapy Boost|Carbon Ion Boost to the Macroscopic Tumor visible on contrast-enhanced MR-Imaging
3227934|NCT01166334|Active Comparator|WebQuit study group|Intervention arm 1 (identity and description withheld to protect integrity of study)
3227935|NCT01166334|Active Comparator|WebQuit control group|Intervention arm 2 (identity and description withheld to protect integrity of study)
3227936|NCT01166360||Patients 2009|Patients undergoing cardiac surgery in 2009
3227937|NCT01166360||Patients 2008|Patients undergoing cardiac surgery in 2008
3227938|NCT01166399||Primiparous women with an obstetric anal sphincter tear|Subjects in this trial will be primiparous women who underwent anal sphincter repair at the time of a singleton vaginal delivery. Sphincter tears will be clinically characterized at the time of delivery as <50% tear through the anal sphincter (modified WHO 3a), >50% (modified WHO 3b), or complete tear through the anal sphincter (4th degree). Subjects in this study will not have receive study interventions.
3227939|NCT01166412|Active Comparator|Dose level AG1000-6.5|
3227940|NCT01166412|Active Comparator|Dose level AG1000-12.5|
3227941|NCT01166425|Active Comparator|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID (three times a day) at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID (two times a day) the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose.
3227942|NCT01166425|Placebo Comparator|placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
3227943|NCT01166451|Experimental|Low-iron|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age.
3227944|NCT01166451|Experimental|High-iron|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age.
3227945|NCT01166464|Experimental|Text Messaging|A text message-based intervention for smoking cessation
3227946|NCT01166464|Placebo Comparator|Control|Individuals in this group will receive generic (non-smoking related) text messages on the same schedule as the intervention arm. This provides a control for staff/program contact time and participant burden.
3227947|NCT01166477|Active Comparator|Triple therapy|The patients who would be allocated to this arm will continue with their triple therapy treatment, based on any protease inhibitor boosted with ritonavir
3227948|NCT01166477|Experimental|Monotherapy|Those patients allocated to this arm will start to take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
3227949|NCT01166490|Experimental|1|ASG-5ME
3227950|NCT01166503||Early Surgery|This group will be made up of subjects whose parents choose to have them undergo corrective surgery at or before age 11 months.
3227951|NCT01166503||Standard Surgery|This group will be made up of subjects who present after age 11 months or whose parents choose to have them undergo corrective surgery between 11-18 months.
3227952|NCT01166516|Other|Treatment with HUD IBV Valve System|Treatment with HUD IBV Valve System in Post-Approval Study
3227953|NCT01166529|Experimental|EUS-CPN|
3227954|NCT01166542|Active Comparator|REOLYSIN, paclitaxel, carboplatin|
3227955|NCT01166542|Placebo Comparator|placebo, paclitaxel, carboplatin|
3227956|NCT01166555|Experimental|1|
3227957|NCT01166594|Experimental|Bevacizumab|Tested Drug
3227958|NCT01166594|Placebo Comparator|Control|Control - BSS
3227959|NCT01166620||Patients with rheumatoid arthritis new to abatacept.|
3227960|NCT01166620||Patients with rheumatoid arthritis new to etanercept|
3227961|NCT01166620||Patients with rheumatoid arthritis new to adalimumab|
3227962|NCT01166620||Patients with rheumatoid arthritis new to infliximab|
3227963|NCT01166633|Experimental|Pitavastatin 2 mg|
3227964|NCT01166633|Active Comparator|Atorvastatin 10mg|
3227965|NCT01166685|Active Comparator|Everolimus-eluting stent|A Xience Prime stent (Everolimus-eluting stent) is implanted in significant coronary lesions.
3227966|NCT01166685|Active Comparator|Bare-metal stent|Implantation of a bare-metal stent
3227967|NCT01166685|Experimental|Biodegradable Polymer-DES|Implantation of a Biodegradable Polymer-DES
3227968|NCT01166698|Experimental|AZD9819|Inhaled suspension
3227969|NCT01166698|Placebo Comparator|Placebo|Inhaled suspension
3227970|NCT01166711|Experimental|Bare Metal Stent (BMS) followed by Drug Eluting Balloon (DEB)|
3227971|NCT01166711|Active Comparator|Drug Eluting Stent (DES)|
3227972|NCT01166737|No Intervention|Control Arm - Chemotherapy only|Chemotherapy for platinum-sensitive Ovarian Cancer can be selected on investigators choice
3227973|NCT01166737|Experimental|Procedure/Surgery|Maximum effort cytoreductive surgery
3227974|NCT01166776||Umbilical cord|To isolate Umbilical cord Wharton's jelly matrix to be used as a scaffold for tissue regenerative applications, including avascular necrosis.
3227975|NCT01166789|Active Comparator|Lubiprostone|Lubiprostone 48ug taken daily for 14 days.
3227976|NCT01166789|Placebo Comparator|Placebo|2 capsules containing a substance with no active ingredient taken daily for 14 days.
3227977|NCT01166815|Active Comparator|Zinc supplemented|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
3227978|NCT01166815|Placebo Comparator|Placebo|"Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. Bulk boxes will identify the products as A and B."
3227979|NCT01166828|Experimental|1|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
3227980|NCT01166828|Active Comparator|2|TAC participants will have six phone contacts every other week for three months.
3227981|NCT01166841|Experimental|PSVC line clamped|Clamping of the percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
3227982|NCT01166841|No Intervention|Unclamped PSVC|Unclamped percutaneously placed superior vena cava line placed for minimally invasive mitral valve repair/replacement.
3227983|NCT01166854||Muscle weakness|Diffuse Optical Spectroscopy
3227984|NCT01166867||Infant Development|Photo-plethysmography monitoring
3227985|NCT01166880||Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
3227986|NCT01166893||Burn wound|Modulated Imaging and Laser Speckle Imaging
3227987|NCT01166919|Experimental|Medical Tool|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
3227988|NCT01166932|Active Comparator|amoxicillin/clavulanic acid|patients who received amoxicillin/clavulanic acid
3227989|NCT01166932|Active Comparator|ceftriaxone/oxacillin|
3227990|NCT01167010|Experimental|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a day for 12 weeks.
3227991|NCT01167010|Active Comparator|Foraseq|Foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
3227992|NCT01167010|Active Comparator|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
3227993|NCT01167036|Experimental|FascialEdge tool|A massage tool used to loosen adhesions in the superficial fascia
3227994|NCT01167036|Placebo Comparator|Placebo|Detuned electric point stimulation over the upper trapezius trigger point
3227995|NCT01167049|Experimental|CAPECITABINE|"Single arm:~Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; repeat three cycles (approximately 3- months);"
3227996|NCT01167062|Placebo Comparator|Placebo|
3227997|NCT01167062|Experimental|Tamsulosin Hydrochloride OCAS 0.4 mg|
3227998|NCT01167075|Active Comparator|Fresubin Original|
3227999|NCT01167075|Experimental|Intestamin plus Fresubin Original|
3228000|NCT01167088|Experimental|Mitoquinone mesylate tablets (MitoQ)|
3228001|NCT01167088|Placebo Comparator|Matching placebo tablet|
3228002|NCT01167101|Other|Pantoprazole|controls Pantoprazole 40mg qd for 28days
3228003|NCT01167101|Active Comparator|Pantoprazole + Rebamipde|Pantoprazole 40mg qd + Rebamipide 100mg Tid for 28days
3228004|NCT01167114|Experimental|STA-9090|All subjects receive STA-9090
3228005|NCT01167127|No Intervention|Tablet|OXN tablet, oral BID, flexible dose design
3228006|NCT01167166|Experimental|rigosertib|Patients will receive 2400 mg dose of rigosertib as a intravenous continuous infusion over 24 hours for 72 to 120 consecutive hours every 2 weeks for the first 4 weeks then will receive oral rigosertib at a 560 mg twice-daily dose as capsules taken continuously.
3228007|NCT01167218||verify now assay|subjects who have Myelodysplastic syndrome, immune thrombocytopenia, and myeloproliferative disorders with platelet disorders
3228008|NCT01167231||Group 1|
3228009|NCT01167244|Experimental|BMS-690514|
3228010|NCT01167270|Active Comparator|Parenting Insight|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
3228011|NCT01167270|Placebo Comparator|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the AAP guidelines and the Academy's guide for health supervision, Bright Futures
3228012|NCT01167283|Active Comparator|Electrostimulation|Neuromuscular electrical stimulation
3228013|NCT01167283|Sham Comparator|Sham stimulation|Sham stimulation
3228014|NCT01167296|Active Comparator|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.removed uterine stent was sent for bacterial culture too.
3228015|NCT01167296|Experimental|without Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
3228016|NCT01167309|Active Comparator|Part 1 SAD|four diffferent doses
3228017|NCT01167309|Placebo Comparator|Part 2a MAD|three doses
3228018|NCT01167309|Active Comparator|Part 2b|0.24 mg LEO 27847
3228019|NCT01167309|Active Comparator|Part 2c|0.24 mg LEO 27847
3228020|NCT01167309|Placebo Comparator|Parat 2a MAD|one dose
3228021|NCT01167322|Experimental|NPC-07|Single administration of NPC-07 at a dose of 20mg/kg body weight
3228022|NCT01167335|Experimental|BGG492|
3228023|NCT01167335|Placebo Comparator|Placebo|
3228024|NCT01167361||Children with upper or lower respiratory infections|Respiratory Virus infections in children who are symptomatic with either an Upper Respiratory Tract Infections and/or Lower Respiratory Tract Infections is determined by using a novel highly sensitive and rapid assay for RV detection. An aliquot from the leftover sample remaining after clinical diagnostic testing will be used for FilmArrayTM analysis. Specimens collected will include nasopharyngeal washes, nasopharyngeal swabs, tracheal aspirates and bronchoalveolar lavage as ordered by the treating physician. Diagnostic studies on this specimen will be performed as ordered and the results will be available to the treating physicians after reporting.
3228025|NCT01167374|Experimental|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
3228026|NCT01167387|Experimental|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
3228027|NCT01167387|Placebo Comparator|water|The control group will receive plain water with the same volume and timing of treatment.
3228028|NCT01167400|Experimental|Cybercycling|cybercycling for 3 months
3228029|NCT01167400|Active Comparator|Traditional Stationary Biking|Traditional exercise on a stationary bike for 3 months.
3228030|NCT01167413||FIbromyalgia Patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR criteria
3228031|NCT01167439|No Intervention|Mild dysphagia|
3228032|NCT01167439|Active Comparator|Severe dysphagia|
3228033|NCT01167478|Experimental|Caffeine|
3228034|NCT01167491|Other|Disease group|Physiopathology
3228035|NCT01167517|Experimental|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge.
3228036|NCT01167517|Placebo Comparator|Instructions in print format|Breast milk expression instructions provided in print format at the time of hospital discharge.
3228037|NCT01167543||Pediatric patients with symptoms or diagnosis of GER|
3228038|NCT01167543||Control group of pediatric subjects with no symptoms of GER.|
3228039|NCT01167556|Experimental|Family Motivational Intervention|An intervention provided to parents consisting of 6 sessions of training in Interactions Skills and 6 sessions training in Motivational Interviewing.
3228040|NCT01167556|Active Comparator|Routine care for parents|Routine care for parents consisting of 2 sessions psycho-education and individual support
3228041|NCT01167647||bronchoscopy patients|
3228042|NCT01167660||Healthy newborn babies|Healthy newborn babies immediately after birth.
3228043|NCT01167660||Sick newborn babies|Sick newborn babies whose medical condition indicates performing coagulation tests.
3228044|NCT01167673|Active Comparator|treatment with study drug|patients receiving study drug for 4 weeks. 3 capsules a day of coltect
3228045|NCT01167673|Placebo Comparator|placebo|patients receiving similar capsules but no active ingredients
3228046|NCT01167686|Experimental|Food supplement|Half of the subjects participating in the trial (91) will recieve four tablets of the food supplement (Gardemont Goldrain Plus) three times a day for seven consecutive days from inclusion.
3228047|NCT01167725|Active Comparator|Arm I|Patients receive standard systemic therapy, at the discretion of patients' oncologist, comprising combinations of fluorouracil, leucovorin calcium, irinotecan hydrochloride, oxaliplatin, and/or capecitabine (including FOLFOX4, mFOLFOX6, CapeOx, or FOLFIRI), bevacizumab, or cetuximab. Treatment repeats in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may crossover to arm II.
3228048|NCT01167725|Experimental|Arm II|Patients undergo cytoreduction surgery and hyperthermic intraperitoneal mitomycin C over 45-90 minutes. Beginning 8 weeks after surgery, patients receive standard systemic therapy as in arm I. Treatment with systemic therapy repeats for 6 courses in the absence of disease progression or unacceptable toxicity.
3228049|NCT01167738|Experimental|PEXG regimen + metformin|cisplatin and epirubicin at 30 mg/mq on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15, Metformin at 2 g days 1-28
3228050|NCT01167738|Active Comparator|PEXG regimen|cisplatin and epirubicin at 30 mg/mQ on days 1 and 15, capecitabine at 1250 mg/mq days 1-28, gemcitabine at 800 mg/mq on days 1 and 15
3228051|NCT01167751|Experimental|MNC implantation|Implantation of BM derived MNC
3228052|NCT01167751|Experimental|AC 133 implantation|Implantation of BM derived AC 133
3228053|NCT01167751|Placebo Comparator|Control|Injection of cell carrier
3228054|NCT01167764|Active Comparator|tranexamic acid|tranexamic acid 250mg po 3 times/day for 1 months
3228055|NCT01167764|Placebo Comparator|placebo|placebo po 3 times/day for 1 months
3228056|NCT01167777||male/female|Symtomatic and asymptomatic males and females attending STD, family planning, public health and women's health clinics, or other applicable centers, who are being screened for CT or GC.
3228057|NCT01167803|Active Comparator|Reference - desflurane|The patients in this group will undergo anesthesia using remifentanil associated with desflurane.
3228058|NCT01167803|Experimental|Experimental - xenon|The patients in this group will undergo anesthesia using remifentanil associated with xenon
3228059|NCT01167816|Experimental|azacitabine|
3228060|NCT01167855|Experimental|Intervention|"Telemedicine asthma education sessions~Asthma health assessment via telemonitoring~Provider treatment prompts~School absenteeism~Prescription filling profile"
3228061|NCT01167868|Experimental|FosD|Four sequential cohorts of Japanese subjects are planned with doses ranging from 50mg once daily to a maximum of 200mg twice daily. One cohort of White subjects is also planned to receive the same dose regimen as the third dose level in Japanese subjects
3228062|NCT01167868|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3228063|NCT01167894|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
3228064|NCT01167894|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
3228065|NCT01167920|Active Comparator|Virtual Hypertension Clinic Group|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals till the end of the study.
3228066|NCT01167920|No Intervention|Usual Care Group|The Usual Care Group (UCG) patients will be told their BP is not in control and encouraged to work with their physician to improve it. There will be no further structured intervention during the rest of the study.
3228067|NCT01167933|Experimental|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd.
3228068|NCT01167933|Active Comparator|Zocor|Zocor® 80 mg tablets of Merck & Co. Inc., USA
3228069|NCT01167946|Experimental|Group A|will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks
3228070|NCT01167946|Active Comparator|Group B|will receive 2 consecutive daily pulses every 3 weeks for 24 weeks
3228071|NCT01167946|Active Comparator|Group C|will receive 3 consecutive daily pulses every 3 weeks for 24 weeks.
3228072|NCT01167959||obesity diabetes, surgical and dietary|
3228073|NCT01167972||1|
3228074|NCT01167985|Experimental|Root canal sealer group+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3228075|NCT01167985|Experimental|Provisional restoration material+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3228076|NCT01167985|Experimental|Experimental- Different root canal sealer+ IABN|Device: alkylated polyethylenimine nanoparticles antibacterial evaluation
3228077|NCT01168011|Experimental|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day every day of 21-day cycles.
3228078|NCT01168037||Open repair|Open Surgical Repair (aortic replacement with revascularization of visceral arteries)
3228079|NCT01168037||Endovascular (Windows 1)|Endovascular therapy branched or fenestrated stent-graft
3228080|NCT01168037||Endovascular (Windows 3)|Endovascular therapy branched or fenestrated stent-graft (vascutek anaconda)
3228081|NCT01168050|Experimental|Nilotinib|
3228082|NCT01168063|Experimental|Helicobacter pilory triple treatment|Triple treatment on this arm is based on results of molecular detection of resistance to antibiotics
3228083|NCT01168063|Active Comparator|Helicobacter pilori standard recommended treatment|H.Pylori Eradication rate with empirical treatment
3228084|NCT01168128|Experimental|Tailored Action Plan|A Tailored Action Plan is an intervention selected to overcome barriers identified before the design and delivery of the intervention.
3228085|NCT01168154|Active Comparator|Lactobacillus Reuterii|
3228086|NCT01168154|Placebo Comparator|Placebo|
3228087|NCT01168167||raltegravir-based cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus raltegravir (n=10 patients) will be offered to participate in this observation arm, but only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
3228088|NCT01168167||standard of care-cART|Patients who begin cART in regular clinical routine with 2N(t)RTI plus either a boosted protease inhibitor or efavirenz (n=10 patients) at standard doses will be offered to participate in this observation arm. They will be offered to participate in this trial only if no other antiretroviral drugs and no concomitant drugs with relevant impact on antiretroviral's pharmacokinetics are administered. At time of study inclusion, patients should be characterised by a HIV-1 RNA load of >5,000 copies/mL and CD4-cell count of >200/µL within 12 weeks before cART initiation.
3228089|NCT01168180|Experimental|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
3228090|NCT01168180|Active Comparator|Ultrasound therapy and hot pack|The participants will receive thirty minutes session of Ultrasound therapy and hot pack for 9 sessions over a period of 3 weeks
3228091|NCT01168193|Other|Patients that underwent surgery|Single arm
3228092|NCT01168206|Placebo Comparator|Placebo|
3228093|NCT01168206|Experimental|TK3|1 capsule, 3 times per day.
3228094|NCT01168245|Experimental|NICE-System NeuroAD|Treatment Group
3228095|NCT01168245|Sham Comparator|Sham-TMS|Control Group
3228100|NCT01168297||Maycoba residents|Pima and non-Pima Mexicans from the village of Maycoba
3228101|NCT01168310|Experimental|1|
3228102|NCT01168310|Experimental|2|
3228103|NCT01168310|Experimental|3|
3228104|NCT01168310|Experimental|4|
3228105|NCT01168310|Experimental|5|
3228106|NCT01168310|Active Comparator|6|
3228107|NCT01168310|Placebo Comparator|7|
3228108|NCT01168323|Experimental|Spaced education clinicians - cohort 1|Spaced education clinicians receive four isomorphic cycles of 9 spaced education emails over 36-weeks (0-2 emails per week). Each email contained one question-explanation.
3228109|NCT01168323|No Intervention|Control clinicians - cohort 2|Control clinicians received no intervention
3228110|NCT01168336|Experimental|betahistine|Betahistine 24 mg tablets
3228111|NCT01168336|Experimental|betahistine XR|betahistine 32 mg tablets
3228112|NCT01168336|Placebo Comparator|placebo|
3228113|NCT01168362||High risk group|positive cardiovascular risk group
3228114|NCT01168362||Low risk group|negative cardiovascular risk group
3228115|NCT01168375|Active Comparator|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
3228116|NCT01168375|Active Comparator|conventional therapy plus umbilical cord serum eye drop|
3228117|NCT01168388||Movement disorder|
3228118|NCT01168414|Active Comparator|Ganfort|Fixed combination of Bimatoprost and Timolol
3228119|NCT01168414|Active Comparator|Duotrav|Fixed combination of Travoprost and Timolol
3228120|NCT01168453||neutral head position|supine with neutral head position
3228121|NCT01168453||head rotation|supine with 30° head rotation
3228122|NCT01168466|No Intervention|Neurofeedback|Waitlist control group.
3228123|NCT01168466|Experimental|QEEG-based Neurofeedback Training|A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
3228124|NCT01168479|Active Comparator|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
3228125|NCT01168479|Experimental|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
3228126|NCT01168492|Experimental|ketamine|group with triple sedation (ketamine, midazolam, meperidine)
3228127|NCT01168492|Placebo Comparator|placebo|group with conventional sedation and placebo ( midazolam, meperidine and placebo)
3228128|NCT01168505|No Intervention|no iron supplentation|
3228129|NCT01168505|Experimental|iron supplement|
3228130|NCT01168531|Placebo Comparator|placebo arm|
3228131|NCT01168531|Active Comparator|pregabalin arm|
3228132|NCT01168531|Experimental|dexamethasone with pregabalin arm|
3228133|NCT01168544|Experimental|loading dose and 50.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25 (OH)D level + 50.000 IU vit D3/month consolidation
3228134|NCT01168544|Experimental|Loading dose and 25.000 IU vit D3/month|Loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
3228135|NCT01168544|Active Comparator|800 IU vit D3/dag|800 IU vit D3/dag
3228136|NCT01168557|Experimental|Stress-Echo and EIT|Patients who routinely undergo stress-echocardiography will additionally be measured by EIT using a rubber belt, which will be placed around their chest
3228137|NCT01168570||SAA monitored group|FMF-Amyloidosis patients receiving colchicine with a purpose to normalize SAA levels
3228138|NCT01168570||Historical control group|FMF-Amyloidosis patients receiving colchicine at a dose determined to stop FMF attacks. obtained from the Fibrillex study
3228139|NCT01168583||Positive Fluid Balance of 2000ml|
3228140|NCT01168583||Negative Fluid Balance of 2000ml|
3228141|NCT01168609||patients with acute myocardial infarction|Acute myocardial infarction (AMI) was defined using the European Society of Cardiology / American College of Cardiology guidelines. Myocardial infarction was detected by the presence of at least two of the following criteria: chest pain lasting more than 30 minutes, typical electrocardiographic changes, and elevated creatinine kinase-MB fraction. Consecutive patients 18 years of age or older who presented within 12 hours after the onset of symptoms were considered for enrollment. Patients who had ST-segment elevation of 1 mm or more in two or more contiguous leads were classified as ST-segment elevation MI.
3228142|NCT01168635|Experimental|Intervention|Virtually-delivered spirometry quality improvement program
3228143|NCT01168635|No Intervention|Standard of Care|
3228144|NCT01168648|Experimental|Yoga as stress management|The intervention consists of following a program of yoga at least three times a week for three months. The yoga program has been designed to reduce stress.
3228145|NCT01168648|Active Comparator|Control group|The group rests without using any specific program for relaxation at least three times a week for three months.
3228146|NCT01168648|Other|Yoga as stress management fewer tests|Eight persons participated in the same intervention as the experimental arm but did not undergo the full range of tests because they did not meet all the inclusion criteria for the study, most commonly because of medication use or body mass index.
3228147|NCT01168661|No Intervention|Control arm|Participants in this arm will be recruited from the group who applied to participate in the study and fulfilled the inclusion criteria but for various reasons (such as time constraints) could not participate.
3228148|NCT01168661|Active Comparator|Cognitive psychotherapy arm|In this arm, participants will attend a group meeting to practice cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
3228149|NCT01168661|Active Comparator|Mindfulness based cog psychotherapy arm|In this arm, participants will attend a group meeting to practice mindfulness based cognitive psychotherapy once a week. They will also practice on their own >= 4 times a week.
3228150|NCT01168661|Active Comparator|Yoga treatment group|Persons in this arm will practice yoga >= 5 time each week (2 times in a supervised group and the other times on their own).
3228151|NCT01168700|Placebo Comparator|Placebo|Placebo 1.2 g per day for 12 weeks, followed by a second treatment period with aged garlic extract during 12 more weeks.
3228152|NCT01168700|Experimental|Aged garlic extract (Kyolic ®)|Aged garlic extract, 1.2 g per day for 12 weeks, followed by a second treatment period with placebo during 12 more weeks.
3228153|NCT01168713|Active Comparator|Levofloxacin|
3228154|NCT01168713|Experimental|CEM-101|
3228155|NCT01168739|Experimental|Quercetin|not necessary, contained in protocol
3228156|NCT01168739|Placebo Comparator|Placebo|not necessary, contained in protocol
3228157|NCT01168752|Experimental|schedule A|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as an every-other-day schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
3228158|NCT01168752|Experimental|schedule B|"Debio 0932 will be administered orally to sequential escalating dose cohorts, as a daily schedule.~Each dose level (DL) for each schedule will be determined according to the maximum grade of treatment-related AEs observed during the first 30 days treatment period (DLT period) in the previous DL.~Dose-escalation could be undertaken only after a minimum of 3 (or 6 in case of DLT) patients have been followed up and evaluated for at least 1 DLT period."
3228159|NCT01168765|Experimental|Intervention group|This is the promotora plus group that will receive the TSSC newsletter and exposure to the media campaign but will also receive monthly visits by promotoras/lay health workers who will review the monthly newsletter with participants, emphasize role model stories, and discuss physical activity and healthful food choices using motivational interviewing strategies.
3228160|NCT01168765|Other|Control group|TSSC Media Campaign only participants who will receive a newsletter and the same exposure to the media campaign intervention as other community members not enrolled in the behavioral intervention.
3228161|NCT01168778|No Intervention|Control|
3228162|NCT01168778|Experimental|Intervention|
3228163|NCT01168791|Experimental|doxorubicin plus palifosfamide-tris|
3228164|NCT01168791|Active Comparator|doxorubicin plus placebo|
3228165|NCT01168804|Experimental|single arm bendamustine bortezomib dexamethasone|single arm combination regimen: bendamustine - bortezomib- dexamethasone
3228166|NCT01168817|Experimental|Arm 1|
3228167|NCT01168817|Active Comparator|Arm 2|
3228168|NCT01168817|Placebo Comparator|Arm 3|
3228169|NCT01168830|Experimental|Investigational device|
3228170|NCT01168843||normal pregnant|
3228171|NCT01168869||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3228172|NCT01168895|Experimental|Arm 1|
3228173|NCT01168895|Experimental|Arm 2|
3228174|NCT01168921|Experimental|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle.
3228175|NCT01168947|Experimental|5% dextrose|5% dextrose rinsing fluid
3228176|NCT01168960|Other|Cognitive Behavioral Treatment|A single intervention study
3228177|NCT01169012|Other|Single Arm Trial|Single Arm Trial
3259058|NCT01467089||schizophrenia|"Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.~Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures."
3259059|NCT01467102||Patients|> 18 years of age
3228178|NCT01169025|Experimental|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
3228179|NCT01169025|Active Comparator|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
3228180|NCT01169051||Thoracic sugery statins|
3228181|NCT01169051||Thoracic surgery non-statins|
3228182|NCT01169077|Experimental|Group I: 0.25 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 0.25 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3228183|NCT01169077|Experimental|Group II: 1.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 1.0 mg, on Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3228184|NCT01169077|Experimental|Group III: 4.0 mg EP-1300|Ten subjects will receive 3 immunizations of EP1300, 4.0 mg, Day 0, Day 28 and Day 56. Three control subjects in this group will receive placebo injections at the same timepoints.
3228185|NCT01169090|Experimental|SK-0403 100 mg QD|
3228186|NCT01169090|Experimental|SK-0403 200 mg QD|
3228187|NCT01169090|Experimental|SK-0403 400 mg QD|
3228188|NCT01169090|Experimental|SK-0403 200 mg BID|
3228189|NCT01169090|Sham Comparator|Placebo|
3228190|NCT01169090|Active Comparator|Sitagliptin 100 mg QD|
3228191|NCT01169129|Active Comparator|surgery+whole-brain irradiation|brain metastases is resected and the patient is submitted to whole-brain irradiation
3228192|NCT01169129|Active Comparator|whole-brain irradiation+radiosurgery|patients will be submitted to whole-brain irradiation and after, they will be submitted to radiosurgery.
3228193|NCT01169142|Active Comparator|Immediate Vitamin D3|Will start Vitamin D3 immediately
3228194|NCT01169142|Active Comparator|Three month delay|Half the subjects will be delayed three months (but evaluated) before getting Vitamin D3. (If the level is very low they will start immediately)
3259060|NCT01467115|Experimental|Treatment|Treatment with induction chemotherapy followed by radiation and cetuximab.
3259061|NCT01467128|Active Comparator|Structured expert pharmacist review|
3259062|NCT01467128|No Intervention|Normal pharmaceutical care in hospital|
3228195|NCT01169155|Active Comparator|Study 3. Adults 20-49 Years of Age|"Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in a linked study, Study 3, with adult participants 20-49 years of age to ensure that the alarms tested will also work for adults in this age group.~This arm will use the alarm signal identified in Study 2 that is significantly associated with Electroencephalography (EEG)-defined awakening and successful completion of simulated escape behaviors by children after awakening from slow wave sleep. A lower frequency tone smoke alarm will evaluate the influence of alarm signal frequency on awakening. A conventional residential tone smoke alarm will be used as a reference stimulus. Both a male and a female voice will be used as alarm stimuli. Note that these will be strangers' voices, and not a mother's voice."
3259063|NCT01467141|Experimental|IAsp|
3259064|NCT01467141|Active Comparator|HI|
3259065|NCT01467154||Control group|
3259066|NCT01467154||NAC group|
3259067|NCT01467167||Baseline|Baseline group in which patients are anesthetized without the use of Smart Pilot View, according to common practice.
3259068|NCT01467167||Smart Pilot View Group|Study group in which patients are anesthetized with the use of Smart Pilot View.
3259069|NCT01467180|Experimental|HCO CVVHD|treatment of rhabdomyolysis pts with septeX dialyzer
3259070|NCT01467180|Active Comparator|HF CVVH|treatment of rhabdomyolysis pts with standard high flux dialyzer
3259071|NCT01467193||1|Endurance trained athletes: minimal >50 mlO2/KG body weight
3259072|NCT01467193||2|Sedentary healthy control subjects: age, BMI, Gender and waist matched (to the growth hormone deficient patients)
3259073|NCT01467193||3|GHD patients without a GH substitution therapy in the last 6 months
3228196|NCT01169155|Active Comparator|Study 4. Older Adults 60-84 Years of Age|Study 4 of this project will take the voice alarm script in Study 2 and compare it with a low-frequency 520 Hz square wave tone smoke alarm in awakening older adults 60-84 years of age from slow wave sleep and prompting their performance of a simulated escape procedure. Note that this will necessarily be a female stranger's voice, and not a mother's voice, in this older age group. As in Studies 1 and 2, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 4. In order to maintain the same experimental design across these studies, a fourth alarm type will be introduced. This fourth alarm will be a hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm, i.e., the stimulus will begin with the 520 Hz square wave tone in a T-3 pattern followed by the voice script, with this stimulus being repeated until the subject completes the escape procedure.
3259074|NCT01467206|Experimental|Long term follow up program|
3259075|NCT01467206|Active Comparator|Standard care|
3259076|NCT01467219|Experimental|PET Probe|"Patients will receive an IV injection of approximately 5 MBq/kg body weight of 18F-FDG (Fludeoxyglucose) (up to 550 MBq). Following injection, patients will undergo CT and PET scans. Intraoperatively, a hand held gamma counter will be used to identify hot lymph nodes."
3259077|NCT01467232|Experimental|Autologous CD133+ Stem Cells|Autologous CD133+ stem cells
3259078|NCT01467232|Placebo Comparator|Saline solution containing autologous plasma|Saline solution containing autologous plasma without CD133+ (indistinguishable from the autologous CD133+ stem cells)
3228197|NCT01169155|Active Comparator|Study 1. Maternal Voice Smoke Alarm Characteristics|"Study 1. Identification of Specific Maternal Voice Smoke Alarm Characteristics Associated With Awakening and Escaping.~Using a randomized, non-blinded, repeated measures, clinical intervention design, Study 1 will identify the critical elements (i.e., use of child's first name and/or behavior commands in message content) in the maternal voice signal that are significantly associated with EEG-defined awakening (and completion of simulated escape behaviors by children after awakening from S4). A conventional residential tone smoke alarm meeting current NFPA 72 National Fire Alarm Code will be used as a reference stimulus to allow comparison of responses to the voice alarm stimuli with responses to a conventional residential tone alarm stimulus."
3259079|NCT01467245|Experimental|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
3259080|NCT01467245|Experimental|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
3259081|NCT01467258|Experimental|Amantadine|Single dose
3259082|NCT01467284|Experimental|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
3259083|NCT01467284|Active Comparator|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
3259084|NCT01467297|Experimental|ceftidoren|ceftidoren 200 mg bid for 5 days
3259085|NCT01467297|Active Comparator|levofloxacin|levofloxacin 500 mg once daily for 7 days
3259086|NCT01467310|Experimental|GSK1120212|
3228198|NCT01169155|Active Comparator|Study 2. Mother's Versus Stranger's Voice Alarms & Alarm Freq.|"Study 2. Comparison of Mother's Versus Stranger's Voice Smoke Alarms and Alarm Frequency.~Study 2 will take the voice alarm script that was the most successful in Study 1 in awakening and prompting children to perform the simulated escape behaviors, and will compare mother's voice to a female stranger's voice using this script. This will determine whether mother's voice is a critical factor for success of the voice smoke alarm. In addition, a Temporal-Three (T-3) pattern smoke alarm with dominant tones in lower frequency ranges similar to the human voice range will be included as a stimulus in Study 2 to evaluate the influence of alarm signal frequency on EEG-defined awakening (as well as completion of simulated escape behaviors by children after awakening from S4). As in Study 1, a conventional residential tone smoke alarm will be used as a reference stimulus in Study 2. This conventional residential tone alarm has a higher frequency signal than the other T-3 tone alarm."
3228199|NCT01169155|Active Comparator|Study 5. Male Voice and Hybrid Tone/Voice Alarm for Children|Study 5. Children 5-12 Years of Age (Testing Male Voice and Hybrid Tone/Voice Alarm) Using a randomized, non-blinded, repeated measures, clinical intervention design, our two working hypotheses as stated in Specific Aims 1 and 2 will be tested in Study 5 among children 5-12 years of age using the following 4 alarm stimuli: female stranger's voice, male stranger's voice, hybrid of the low-frequency 520 Hz square wave tone smoke alarm and the voice alarm (from Study 4), and conventional high frequency tone residential alarm. This study arm will allow comparison of a male versus female voice and also evaluate the hybrid low frequency tone/voice alarm among children 5-12 years of age. The same protocol will be used for children in this study arm as was used in Studies 1 and 2.
3228200|NCT01169181|Active Comparator|AMES therapy with rTMS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+rTMS, followed by an EMG test. During the hand-opening phase of the AMES therapy, the subjects assigned to the AMES+rTMS treatment group will be subjected to trains of TMS pulses.
3228201|NCT01169181|Active Comparator|AMES therapy with tDCS|Each subject will participate in 30 therapy sessions over a 10- to 15-week period. A session will last 90 to 120 minutes, which includes 20 minutes of AMES+tDCS, followed by an EMG test. A constant current will be applied throughout the entire 20-minute therapy session with the AMES device.
3228202|NCT01169194||Affected|Patients with IBD
3228203|NCT01169194||Unaffected|Individuals who do not have IBD
3228204|NCT01169207||Unaffected|Individuals who do not have IBD
3228205|NCT01169207||Affected|Individuals with IBD
3228206|NCT01169220|Experimental|Split prep|
3228207|NCT01169220|Active Comparator|Whole prep|
3228208|NCT01169233|Other|Shorter Wavelength (green)|
3228209|NCT01169233|Other|Intermediate Wavelength (white w/ green filter)|
3228210|NCT01169233|Other|Longer Wavelength (red)|Placebo
3228211|NCT01169246||Paradym VR, DR and CRT models|
3228212|NCT01169272|Experimental|CRT-SonR 9770|Active implantable defibrillator with ability to cardiac resynchronization therapy
3228213|NCT01169298|Experimental|Lenalidomide|Lenalidomide: 25mg daily on day1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort) or 35 mg daily of each 28 days (3rd cohort)
3228214|NCT01169324|Experimental|DBS on|baseline settings
3228215|NCT01169324|No Intervention|DBS off|DBS off
3228216|NCT01169389|Active Comparator|Durolane|
3228217|NCT01169389|Placebo Comparator|Bupivacaine|
3228218|NCT01169402|Experimental|Fluconazole|
3228219|NCT01169415|Experimental|Protracted (30 days), Dexamethasone|Participants will receive a protracted course (30 days) of dexamethasone after surgery.
3259087|NCT01467323|Experimental|A|
3259088|NCT01467323|Active Comparator|B|
3228220|NCT01169415|Experimental|Abbreviated (14 days), dexamethasone|Participants will receive an abbreviated (14 days) course of dexamethasone after surgery.
3228221|NCT01169428|Active Comparator|Standard Behavioral Weight-Loss Maintenence|"Attention/Education/Support Control~Group designed to control for educational content as well as multiple nonspecific treatment factors (e.g., support, time invested, leader attention, positive expectancy)"
3228222|NCT01169428|Active Comparator|Behavioral: Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss.
3228223|NCT01169454||Monitor then drain|Subjects who are treated with intermittent CSF drainage
3228224|NCT01169454||Drain then monitor|Subjects who are treated with continuous CSF drainage at set pressure thresholds
3228225|NCT01169480|Experimental|Massage Giver|Participants in the experimental group will be asked to give one 50-minute Swedish massage to another volunteer.
3228226|NCT01169480|No Intervention|Passive Controls|Participants in this arm will wait in a classroom (as usual) and do nothing out of their ordinary routines.
3228227|NCT01169506|Experimental|COPD patients and healthy individuals|
3228228|NCT01169545||Cancer patients over the age of 18|Cancer patients over the age of 18 who are receiving active treatment.
3228229|NCT01169571||Group I - No loading dose|No loading dose to be administered during the loading-dose paradigms
3228230|NCT01169571||Group II - Loading dose over 10 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 10 minutes during the loading-dose paradigms
3228231|NCT01169571||Group III - Loading dose over 20 minutes|Loading dose dexmedetomidine 1 mcg/kg administered over 20 minutes during the loading-dose paradigms
3228232|NCT01169584|Experimental|Single Arm - JX-594|Intratumoral injection of JX-594
3228233|NCT01169623|Experimental|Educational Intervention|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
3228234|NCT01169623|Placebo Comparator|CONTROL|55 of head nurses who will not participate in educational intervention will be considered as a control arm
3228235|NCT01169662|Active Comparator|Vegetable/ Fruit juice|450ml active product, 45 ml no added sugar squash (for flavour)
3228236|NCT01169662|Placebo Comparator|Placebo juice|
3228237|NCT01169714|Experimental|Dosing Healthy Adult|Ascending Doses in Healthy Adult Volunteers
3228238|NCT01169714|Experimental|Dosing Healthy Elderly|Dosing in Healthy Elderly volunteers
3228239|NCT01169740||Neonatal jaundice|Infants born between July 1st 2010 and July 31st 2010 and admitted to normal newborn nursery
3228240|NCT01169792||Breast cancer patients|Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
3228241|NCT01169805|Experimental|ONSERAN|
3228242|NCT01169805|Experimental|NASEA|
3228243|NCT01169805|Experimental|ALOXI|
3228244|NCT01169805|Placebo Comparator|normal saline|
3228245|NCT01169818|Experimental|Intervention group|Initiation on a fixed dose of insulin glargine, then subjects will self-adjusted their basal insulin dose every 3 days
3228246|NCT01169818|Active Comparator|Usual standard of care group|Initiation on a fixed dose of insulin glargine, then basal insulin dose is adjusted at each visit by a physician
3228247|NCT01169831|Experimental|Sedentary Older Adults|
3228248|NCT01169831|Experimental|Older Endurance Athletes|
3228249|NCT01169857|Experimental|Velcade Therapy|
3228250|NCT01169870|Experimental|Genexol-PM|Genexol-PM 300mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 1 hour on day 1, every 3 week cycle.
3228251|NCT01169870|Active Comparator|Paclitaxel|Paclitaxel 175mg/m2, diluted with 500ml of 5% dextrose or normal saline, intravenous infusion over 3 hour on day 1, every 3 week cycle.
3228252|NCT01169883|Active Comparator|Attention Control Group|1) Doctor Asthma Messages delivered over a 10 week time period; 2) Asthma Supervision; and 3) Music Tracks.
3228253|NCT01169883|Experimental|Intervention Group|1) Coping Peer Support delivered over a 10 week time period; 2) Coping Peer Asthma Messages delivered over a 10 week time period; 3) Asthma Supervision; and 4) Music Tracks.
3228254|NCT01169909|Experimental|Ranibizumab treatment|Patients will receive a sub-tenons injection of Ranibizumab 0.5mg, to be repeated twice with 30 day intervals between each dose.
3228255|NCT01169922|Experimental|SEXUAL PLUS ALCOHOL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction as well as alcohol risk reduction.
3228256|NCT01169922|Active Comparator|INFORMATION-ONLY SEXUAL RISK REDUCTION|Intervention contains information geared toward sexual risk reduction only.
3228257|NCT01169935|Experimental|Administration of Intra-dermal SPIO|MRI scanning before and after intra-dermal injection of SPIO.
3228258|NCT01169935|Experimental|Mantoux, Venesection, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by venesection.
3228259|NCT01169935|Experimental|Mantoux, Apheresis, Labelled cells|Mantoux test then MRI scanning before and after administration of iron-labelled cells obtained by apheresis.
3228260|NCT01169935|Experimental|Mantoux, Administration of Endorem|Mantoux test then MRI scanning before and after administration of Endorem.
3228261|NCT01169935|Experimental|Mantoux only|Mantoux test then serial MRI scanning.
3228262|NCT01169948||Patients awaiting cardiac surgery|
3228263|NCT01169974||healthy volunteers|
3228264|NCT01170013|Experimental|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
3228265|NCT01170013|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
3228266|NCT01170026|Experimental|Family Check-up/Individual MI|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use plus 2 session Individual Motivational Intervention for the adolescent
3228267|NCT01170026|Active Comparator|Psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors especially substance use
3228268|NCT01170078|Experimental|Arm A: Epoetin Hospira administered IV for three doses|
3228269|NCT01170078|Active Comparator|Arm B: Epogen administered IV for three doses|
3228270|NCT01170130|Experimental|Lidmyd|The same group is used for the first and the second part of the experiment. Initially the patients will be given topical cyclopentolate 1% and Phenylephrine 10% and the pupil diameter will be recorded. In the second part of the experiment lidocaine 1% will be introduced intracamerally and the pupil size will be recorded again. The 2 measurements will be statistically compared/evaluated.
3228271|NCT01170143|Active Comparator|Trastuzumab QW|Arm A: Trastuzumab 2mg/kg, d1; qw (loading dose 4mg/kg wk1) Paclitaxel 80mg/m2,. d1; qw Carboplatin AUC 2 d1, qw
3228272|NCT01170143|Active Comparator|Trastuzumab Q3W|Arm B: Trastuzumab 6mg/kg, d1(loading dose 8mg/kg wk1) Paclitaxel 175mg/m2,. d1, q3w; Carboplatin AUC 6 ,. d1,q3w
3228273|NCT01170169|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's laboratories limited
3228274|NCT01170169|Active Comparator|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
3228275|NCT01170182|Experimental|Omeprazole|Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
3228276|NCT01170182|Active Comparator|Prilosec|Prilosec® 40 mg Merck & Co. Inc
3228277|NCT01170234||Eosinophilic esophagitis (EoE)|Treatment-naïve EoE patients, age 7 -65
3228278|NCT01170260|Active Comparator|Info-only sexual risk reduction|Corresponding intervention gives information only on STDs/HIV
3228279|NCT01170260|Experimental|Sex plus alcohol risk reduction|Corresponding intervention gives info focusing on sex and alcohol risk reduction only
3228280|NCT01170260|Experimental|Sex + alcohol + marijuana risk reduction|Corresponding intervention gives info on sex, alcohol, and marijuana risk reduction
3228281|NCT01170286|Experimental|DBV712 Viaskin|The experimental arm is composed of subjects treated with whole peanut extract on an epicutaneous delivery system (Viaskin patch)
3228282|NCT01170286|Placebo Comparator|Placebo Viaskin|The placebo arm is composed of subjects treated with a placebo formulation on an epicutaneous delivery system (Viaskin patch)
3228283|NCT01170312|Active Comparator|Autologous conditioned plasma|
3228284|NCT01170312|Placebo Comparator|Normal saline|
3228285|NCT01170325|Experimental|Group A|
3228286|NCT01170325|Placebo Comparator|Group B|
3228287|NCT01170338|Experimental|active Chantix|active drug to help smoking cessation
3228288|NCT01170338|Placebo Comparator|sugar pill|
3228289|NCT01170351|Active Comparator|Group-A|Treatment-naive AIH patients consenting to participate
3228290|NCT01170351|Experimental|Group-B|Treatment-naive AIH patients consenting to participate. This group will receive Cyclosporine-A according to a set protocol.
3228291|NCT01170377||Mental Retardation|Patients receiving valproate or not
3228292|NCT01170403||NGT/IFG/DM, MeS/no-MeS|NGT: normal glucose tolerance IFG: impaired glucose tolerance DM : diabetes mellitus MeS: metabolic syndrome no-MeS: no metabolic syndrome
3228293|NCT01170416||12-Lead Body Surface Mapping - Focal VT .|Body surface mapping (BSM) will be completed in patients with a defined focal VT site during the EP study.
3228294|NCT01170416||12-Lead BSPM - Scar related VT, exit not identified|Body surface mapping will be competed on patients with scar related VT where the exit cannot be identified
3228295|NCT01170416||12-Lead BSPM - Scar related VT exit identified|Body surface mapping will be competed on patients with scar related VT where the exit is identified
3228296|NCT01170416||12-Lead BSPM - Supraventricular tachycardia|Body surface mapping will be completed on patients requiring an EP study for the treatment of symptoms related to supraventricular tachycardia
3228297|NCT01170429|Experimental|I. Procaterol Hydrochloride|Meptin (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
3228298|NCT01170429|Placebo Comparator|II. Procaterol hydrochloride placebo|Meptin placebo (Procaterol hydrochloride) Tablets, 25µg twice daily orally plus inhaled budesonide 200µg twice daily for eight weeks;
3228299|NCT01170442|Experimental|vitamin D3 2000 IU|
3228300|NCT01170442|Experimental|vitamin D3 5000 IU|
3228301|NCT01170442|Placebo Comparator|Placebo|
3228302|NCT01170455|Experimental|Blind Intubation Device|
3228303|NCT01170455|Active Comparator|Direct laryngoscope|
3228304|NCT01170468|Experimental|Vitamin D3|Vitamin D3 5000 IU daily
3228305|NCT01170468|Placebo Comparator|Placebo|Placebo daily
3228306|NCT01170481||papilloedema without glaucoma|
3228307|NCT01170481||papilloedema with glaucoma|
3228308|NCT01170481||glaucoma without papilloedema|
3228309|NCT01170494|Active Comparator|D2 2000 IU daily|
3228310|NCT01170494|Active Comparator|D3 2000 IU daily|
3228311|NCT01170494|Active Comparator|D2 1000 IU + D3 1000 IU daily|
3228312|NCT01170494|Active Comparator|D2 25000 IU Q2wk|
3228313|NCT01170494|Active Comparator|D3 25000 IU Q2wk|
3228314|NCT01170494|Active Comparator|D2 50000 IU Q4wk|
3228315|NCT01170494|Active Comparator|D3 50000 IU Q4wk|
3321452|NCT02018978|Experimental|CTHP|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
3321453|NCT02018978|No Intervention|Standard of Care|This arm will receive standard of care HIV-related services, including clinic-based voluntary counseling and testing and referrals to HIV care and treatment government-run facilities.
3321454|NCT02018991|Active Comparator|Everolimus-Eluting-Stent (EES)|Patients treated with EES
3321455|NCT02018991|Active Comparator|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
3321456|NCT02018991|Active Comparator|Biolimus-Eluting-Stent (BES)|Patients treated with BES
3321459|NCT02019017|Experimental|Botulinum Toxin Type A 25 IU|The first five patients will be injected 25 IU of Botulinum Toxin Type A
3321460|NCT02019017|Experimental|Botulinum Toxin Type A 50 IU|the next five patients will receive 50 IU of Botulinum Toxin Type A
3321461|NCT02019030||BPH on anticoagulation|Patients with Benign Prostatic Hyperplasia (BPH) undergoing Transurethral Vaporization of Prostate and are on anticoagulant medication
3321462|NCT02019043|Experimental|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count.
3228316|NCT01170494|Placebo Comparator|placebo daily|
3228317|NCT01170507|Active Comparator|vitamin D3 1000 IU|
3228318|NCT01170507|Active Comparator|Vitamin D3 3000 IU|
3228319|NCT01170507|Active Comparator|Vitamin D3 5000 IU|
3228320|NCT01170507|Placebo Comparator|Placebo|
3228321|NCT01170520|Experimental|rTMS|
3228322|NCT01170559|Experimental|Group 1: ILR Group|Group allocated to receiving an ILR in the A&E department.
3228323|NCT01170559|No Intervention|Group 2: Conventional|Group randomised to conventional lines of investigation
3321463|NCT02019043|No Intervention|Current care practice|The control condition will remain the current care practice, which is generally opportunistic screening or diagnostic testing for those presenting with signs/symptoms or who report sexual risk behaviour.
3321464|NCT02019056|Placebo Comparator|Placebo|enteric coated capsule
3321465|NCT02019056|Experimental|MG 500mg|Metadoxine + garlic oil
3321466|NCT02019056|Experimental|MG 1000mg|Metadoxine + garlic oil
3321467|NCT02019056|Sham Comparator|Metadoxine 500mg|enteric coated capsule
3321468|NCT02019082|Active Comparator|electrical stimulation|electrical stimulation group, group who received direct current ES at sensory threshold intensity for 1 h/day, 3 days/week, for 4 weeks (12 sessions)
3321469|NCT02019082|Placebo Comparator|placebo|In the placebo group, the treatment procedure was the same as that the ES group, but the current intensity was zero.
3321470|NCT02019095||Acute Respiratory Failure - Bronchoalveolar lavage|Intensive care unit patients with acute respiratory failure due to ventilator-associated pneumonia or the acute respiratory distress syndrome. Bronchoalveolar lavage (BAL) fluid will be obtained on days 1 and 5 post-enrollment for the determination of biochemical markers, and microbiological studies.
3321471|NCT02019134|Active Comparator|usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
3321472|NCT02019134|Experimental|relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
3321473|NCT02019147||Term Hypoxic Ischaemic Encephalopathy|Term Hypoxic Ischaemic Encephalopathy (HIE)
3321474|NCT02019147||Healthy Term Neonates|Controls
3321475|NCT02019160|Experimental|Silver nitrate|Biannual application of 25% AgNO3 solution followed by 5% NaF varnish.
3321476|NCT02019160|Active Comparator|Silver diamine fluoride|Biannual application of 38% SDF solution followed by placebo varnish.
3228324|NCT01170572||Long bone fracture|Patients presenting to accident and emergency during the study period with long bone or clavicle fracture
3228325|NCT01170585|Placebo Comparator|Placebo|randomised to placebo.
3228326|NCT01170585|Active Comparator|Active|randomised to rosuvastatin.
3228327|NCT01170611|Experimental|AAISAFER alone - AAISAFER+PREVENTIVE ALGORITHM - DDD|
3228328|NCT01170637|Active Comparator|Ibuprofen 200 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
3228329|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg|Oral administration as a fixed dose combination tablet (RhinAdvil(R))
3228330|NCT01170637|Active Comparator|Ibuprofen 200 mg BI|Oral administration as a fixed dose combination tablet (BI product)
3228331|NCT01170637|Active Comparator|Pseudoephedrine-HCl 30 mg BI|Oral administration as a fixed dose combination tablet (BI product)
3228332|NCT01170650|Experimental|Arm A|EC145 + Pegylated Liposomal Doxorubicin (PLD)
3228333|NCT01170650|Active Comparator|Arm B|placebo + Pegylated Liposomal Doxorubicin (PLD)
3228334|NCT01170676|Experimental|Puff City GA|Puff City is an NHLBI-funded (C. Joseph, PI; Henry Ford Health System, Detroit, MI), web-based intervention that targets three key asthma management issues in youth: 1) smoking reduction or cessation in those who are smokers, 2) improving adherence to asthma controller medication use, and 3) improving compliance of carrying a rescue inhaler at all times for use at the first sign of asthma symptoms. Puff City Ga. is a replication study in the rural southeastern United States that adds biological assessments in addition to self-report data.
3228335|NCT01170676|Active Comparator|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
3228336|NCT01170689||Inpatient schizophrenia or schizoaffective disorder|
3228341|NCT01170728||Virtue® Male Sling|Device: Coloplast Virtue® Male Sling
3228342|NCT01170741|No Intervention|Delayed Control Condition|Participants assigned to the delayed treatment control condition will be offered biological testing and the tailored cue-card intervention upon completion of their 3- month follow-up interview. Use of a delayed treatment control group design will permit us to separate intervention effects on HIV risk behaviors from the general effects of participating in the study and completing a detailed HIV risk assessment.
3228343|NCT01170767|Experimental|Avastin|intravitreal injection of bevacizumab
3228344|NCT01170767|Active Comparator|Lucentis|intravitreal injection of ranibizumab
3228345|NCT01170780|Placebo Comparator|Placebo|Saline
3228346|NCT01170780|Active Comparator|Dexamethasone|Corticosteroid (Fortecontin 8 mg)
3228347|NCT01170793|No Intervention|2|no educative telephone coaching (ETC)
3228348|NCT01170793|Experimental|1|with educative telephone coaching (ETC)
3228349|NCT01170806|Active Comparator|Orlistat (Lipiblock) treatment|Lipiblock is a new Orlistat formulation, produce by Germed Pharma, Brazil. Capsule 120mg
3228350|NCT01170806|Active Comparator|Orlistat (Xenical) treatment|Xenical is a innovator Orlistat formulation, produced by Roche
3228351|NCT01170819|Active Comparator|Dinoprostone Vaginal Insert|
3228352|NCT01170819|Experimental|Double Balloon Catheter|
3228353|NCT01170845|Placebo Comparator|Control group|Patients in the control group received saline for 7 days starting at the beginning of surgery
3228354|NCT01170845|Active Comparator|S group|Patients in the S group received sivelestat sodium hydrate at a dosage 4.8mg/kg/day for 7 days starting at the beginning of surgery
3228355|NCT01170858|Experimental|Icodextrin group|7.5% icodextrin dialysis solution
3228356|NCT01170858|Active Comparator|glucose solution group|2.5% or 4.25% glucose dialysis solution
3228357|NCT01170871|Experimental|Experimental|Escalating doses of Ixabepilone and Pemetrexed
3228358|NCT01170897|Other|Maximally Tolerated Dose|To identify the maximally tolerated dose (MTD) of PEGPH20.
3228359|NCT01170910|Other|Static incubation|If conservation in static incubation (group 1) is chosen by random selection, the transplant should be carried out while keeping the cold ischemic time (CIT) as short as possible (preferably less than 18 hours). Keep in mind that for reasons of homogeneity for result analysis and for conservation quality, it is recommended that kidneys in group 1 be conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution.
3228360|NCT01170910|Experimental|Pulsatile perfusion|If conservation in a pulsatile perfusion machine (group 2) is chosen by random selection, the kidney will be placed in the perfusion machine within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
3228361|NCT01170923|Experimental|FDG-PET guided|Chemotherapy regimen will be changed depending on metabolic response.
3228362|NCT01170923|Active Comparator|CT guided|Chemotherapy regimen will be changed depending on CT findings (RECIST).
3228363|NCT01170936|Experimental|Canakinumab|
3228364|NCT01170975|Other|Treatment sequence 1|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
3321477|NCT02019173|Experimental|Boot camp balance training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
3321478|NCT02019186|Experimental|Vitamin C and E|6 weeks of daily treatment with Vitamin C and E
3321479|NCT02019212||MPI Perfusion Imaging|Clinical patients who have undergone myocardial perfusion imaging with 99mTc
3321480|NCT02019225|Experimental|Dialysis session of at least 4.25 hours|Dialysis facilities randomized to the Intervention arm will adopt an approach of recommending that all patients who are initiating treatment with maintenance hemodialysis have a treatment session duration of at least 4.25 hours.
3321481|NCT02019225|No Intervention|Usual care|There will be no trial-driven approach to dialysis session duration in the Usual Care arm.
3321482|NCT02019238|Placebo Comparator|Group 1-Standard PVI ablation|Pulmonary Vein Isolation procedure combined with ablation of documented non-PV triggers of AF
3321483|NCT02019238|Active Comparator|Group 2-PVI with empiric ablation|Pulmonary Vein Isolation procedure combined with empiric ablation of common sites of non-PV triggers of AF and locations that may sustain AF sources on long term arrhythmia control
3228365|NCT01170975|Other|Treatment sequence 2|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
3228366|NCT01170988|Other|surgical procedure|T-graft bypass or conventional bypass
3321484|NCT02019251|Experimental|Post single or double lung transplant|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using Disposable Face mask and a standard Douglas Bag system.
3321485|NCT02019290|Experimental|bitopertin-Midazolam|
3321486|NCT02019303|Other|Abnormal lymph nodes|There is only one arm to this study and includes all eligible and consented patients with abnormal axillary lymph node on ultrasound.
3321487|NCT02019316|Experimental|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
3321488|NCT02019316|Placebo Comparator|Isoenergetic Control|Participants will orally ingest 500ml of Isoenergetic Control (0.18 calories/kg body weight) 2 times separated by 60 minutes.
3321489|NCT02019329|Placebo Comparator|Placebo + risperidone|
3321490|NCT02019329|Experimental|RO5545965 + risperidone|
3321491|NCT02019342||Post-quality improvement cohort|Patient cohort after FACE quality improvement initiative is implemented
3321492|NCT02019342||Pre-quality improvement cohort|Patient cohort prior to implementation of FACE quality improvement initiative
3321493|NCT02019355|Experimental|calcipotriol plus 5-fluorouracil|calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
3321494|NCT02019355|Active Comparator|5-fluorouracil plus vaseline|5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days.
3321495|NCT02019368|Placebo Comparator|Placebo|Smoker subjects take 6 capsules once a day for 4 weeks.
3321496|NCT02019368|Experimental|Aged garlic extract|Smoker subjects take 1.5 g of aged garlic extract in 6 capsules once a day for 4 weeks.
3321497|NCT02019368|No Intervention|Non-smoker|Oxidative status in non-smoker
3321498|NCT02019381|Other|Endocrine Society UL Dosage Vitamin D|Participants will be randomly assigned vitamin D + calcium dose based on Endocrine Society Upper limit guidelines. And given 10,000IU Vitamin D + 1200mg Calcium (600IU Placebo Vitamin D, in addition to two calcium tablets of 600mg) each to be taken per day.
3321499|NCT02019381|Other|Institute of Medicine Dosage Vitamin D|Participants will be randomly assigned Vitamin D dose based on IOM guidelines; calcium dose will be as per IOM upper limits. And will receive 600 IU Vitamin D + 1,200 mg of calcium tablets to be taken per day.
3321500|NCT02019394|Experimental|Lu AE58054|
3321501|NCT02019407|Experimental|CTI group|CTI(Cavo-Tricuspid Isthmus)
3321502|NCT02019407|Placebo Comparator|Non CTI group|Non CTI (Cavo-Tricuspid Isthmus)
3321503|NCT02019433||Structan®|
3321504|NCT02019446|Experimental|Laser Treatment|Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
3321505|NCT02019446|Active Comparator|Standard Treatment (control group)|Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
3321506|NCT02019459|Active Comparator|0.8 mg nicotine with 10.5 mg tar|SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine yield with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)
3321507|NCT02019459|Experimental|0.03 mg nicotine with 9 mg tar|SPECTRUM Cigarette: 0.03 mg (± 0.02) nicotine yield with 9 mg (± 1.5) tar
3321508|NCT02019485|Experimental|Treatment Sequence AB|Participants will receive single dose of new tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF) tablet and later, participants will receive single dose of current tapentadol prolonged-release formulation 2 (PR2) tablet without food. Administration of the study medications will be separated by a washout period (no treatment) of 7 to 14 days.
3228367|NCT01171014|Experimental|High dose probiotic|Bifidobacterium lactis HN019, 10 billion cfu/day
3228368|NCT01171014|Experimental|Low dose probiotic|Bifidobacterium lactis HN019, 1 billion cfu/day
3228369|NCT01171014|Placebo Comparator|Placebo|Placebo
3228370|NCT01171027|Experimental|NOTES(R) Cholecystectomy|Natural Orifice Translumenal Endoscopic Surgery techniques
3228371|NCT01171027|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
3228372|NCT01171040||Consecutive patients received echocardiographic examinations|Consecutive patients received echocardiography are willing to participate in this study.
3228373|NCT01171053|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
3228374|NCT01171053|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support
3228375|NCT01171066|Experimental|Tasman CPAP|
3228376|NCT01171079|Experimental|Interceed|
3228377|NCT01171092|Experimental|bortezomib and G-CSF|
3321509|NCT02019485|Experimental|Treatment Sequence BA|Participants will receive single dose of current tapentadol PR2 tablet and later, participants will receive single dose of new tapentadol ER TRF tablet without food. Administration of the study medication will be separated by a washout period of 7 to 14 days.
3321510|NCT02019498|Experimental|relaxation|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
3228378|NCT01171105|Experimental|1|AZD5213 (dose escalating)
3228379|NCT01171105|Placebo Comparator|2|Placebo
3228380|NCT01171131||Chronic TBI Patients - Non-penetrating|"Chronic TBI patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
3228381|NCT01171131||Chronic TBI Patients - Blast|"Chronic TBI Blast injury patients should have a history of head trauma manifesting in one or more of the following:~Loss of consciousness~Post-traumatic amnesia~Focal neurologic deficits, seizure~Persistent symptoms of increased arousal (e.g. difficulty falling or staying asleep, anger and hypervigilance)~Impairment in social, occupational, or other important areas of functioning (e.g. problems with work and relationships.) Patients will be excluded from the study if we are unable to obtain informed consent and if they are non-communicative (i.e. in a vegetative state)."
3321511|NCT02019498|Active Comparator|Usual care waiting list|Patients allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
3321512|NCT02019511||High dose Steroid|"Patients scheduled for primary unilateral elective TKA Age >17 years~none of the following contraindications for Methylprednisolone:~Allergy against Methylprednisolone.~Currently in systemic treatment with glucocorticoid~Current gastric ulcer~Insulin dependent diabetes mellitus~Citizens without Danish social security number are not eligible for this study as follow-up is not possible."
3321513|NCT02019511||Historical cohort|"Patients having primary unilateral elective TKA before initiation of Methylprednisolone as standard treatment~age >17 years, Danish social security number~and none of the following at time of surgery:~systemic treatment with glucocorticoid defined as: regular prescriptions on glucocorticoid within 2 months prior to surgery.~gastric ulcer defined as: prescriptions on drugs used in triple therapy for Helicobacter Pylori infection or prescriptions on antiacids/proton pump inhibitors beginning 1 month before surgery~Insulin dependent diabetes mellitus defined as: any prescriptions on insulin within 6 months prior to surgery"
3321514|NCT02019511||Procedures without Steroid|Patients scheduled for primary unilateral elective TKA and age >17 years but who did not receive high dose Methylprednisolone regardless of reason.
3321515|NCT02019524|Experimental|E39 peptide vaccine|Patients receive 6 monthly injections of E39 peptide + GM-CSF. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3321516|NCT02019524|Experimental|E39 vaccine then J65 vaccine|Patients receive 3 inoculations with the E39 vaccine followed by 3 inoculations with the J65 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3321517|NCT02019524|Experimental|J65 vaccine then E39 vaccine|Patients receive 3 inoculations with the J65 vaccine followed by 3 inoculations with the E39 vaccine. Immunologic data is assessed at 1 month and 6 months (+/- 2 weeks) after the primary vaccine series (PVS), specifically ex vivo immunologic recognition of E39 and J65 is assessed by clonal expansion using a dextramer assay and the in vivo response is assessed by delayed type hypersensitivity. The 6-month post-PVS immunologic data is then used to assess each patient for significant residual immunity. Patients are then sorted into two groups: those with SRI and those without. Patients within each group will be randomized to receive 1 booster inoculation of the J65 vaccine or the E39 vaccine. Patients return to the clinic within 1-2 weeks of their 6-month post-PVS visit to receive their booster inoculation.
3321518|NCT02019537|Active Comparator|Steroid group|Triamcinolone injection group
3228382|NCT01171131||Healthy Volunteers|"Healthy volunteers include gender, age and race matched volunteers able to provide informed consent who have,~No significant medical history~Take no medications (other than birth control pills)~Fever free~No history of head trauma or recent injury/infection~No history of neurological or psychiatric disorders or alcohol or drug dependency."
3228383|NCT01171144||Gastroenteritis Group|All children suffering with gastroenteritis
3228384|NCT01171157||Group 1|Subjects with influenza like illness
3228385|NCT01171170|Active Comparator|carboplatin-paclitaxel-bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin area under the curve (AUC) 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
3228386|NCT01171170|Experimental|standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
3228387|NCT01171209|Experimental|IFN-alfa|One single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c.
3228388|NCT01171209|Experimental|Interferon-beta|One single injection of IFN-beta followed by blood test for MxA9.12 hours after injection
3321519|NCT02019537|Experimental|PRP group|Allogeneic PRP injection group
3321520|NCT02019576|Other|Stereotactic radiotherapy (SRT)|Stereotactic radiotherapy will be administered for up to five areas of metastatic sites showing oligo-progression within the same time period. During the Sunitinib break period, stereotactic radiotherapy will be delivered in a single fraction or up to a maximum of eight fractions. The number of fractions will depend on how many sites are being irradiated.
3321521|NCT02019589|Active Comparator|Progesterone 225 mg/day|Progesterone + Placebo
3321522|NCT02019589|Active Comparator|Progesterone, 300 mg/ day|Progesterone + Placebo
3321523|NCT02019589|Placebo Comparator|Placebo|Placebo
3228389|NCT01171222||veteran soccer players from Saarland County, Germany|
3228390|NCT01171248||type 1 diabetes|
3228391|NCT01171248||non-diabetics|
3259089|NCT01467336|Other|Passive group|Rehabilitation program is immediate. Active range of motion rehabilitation is started at the sixth week.
3259090|NCT01467336|Other|Immobilization group|No passive Rehabilitation program is started. An active protocol is started after the sixth week
3321524|NCT02019615|Active Comparator|anodal stimulation|Patients received anodal tDCS (on the left dorsolateral prefrontal cortex) every day for 5 days (tDCS of 2mA during 20minutes). A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session to assess the potential long term effects of the tDCS.
3321525|NCT02019615|Sham Comparator|sham stimulation|Patients received sham tDCS (5 secondes of stimulation) every day for 5 days. A CRS-R is performed at baseline (before the first stimulation) and after each tDCS. A final CRS-R is performed one week after the end of the session.
3321526|NCT02019628|Experimental|BRM4 at a dosage level of 1 gram/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 1 gram/day.
3321527|NCT02019628|Experimental|BRM4 at a dosage level of 3 grams/day|60-day trial of Rice Bran Arabinoxylan Compound (RBAC) at a dosage level of 3 grams/day.
3321530|NCT02019732||Study Group|Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.
3321531|NCT02019745||LAIV (FluMist)|All subjects will receive a 0.2 mL dose of LAIV (FluMist) once during the study.
3321532|NCT02019784|Active Comparator|Rifaximin-α|Rifaximin-α (TARGAXAN TM, manufactured by Alfa-Wasserman, Bologna, Italy) tablets - 550mg twice daily for 90 days
3321533|NCT02019784|Placebo Comparator|Placebo|Placebo tablets - 550mg twice daily for 90 days
3321534|NCT02019797|Experimental|Desflurane|Desflurane inhalation at 1-2 MAC during surgery.
3321535|NCT02019797|Active Comparator|Propofol|5-8 mg/kg/hr infusion during surgery.
3321536|NCT02019810|Active Comparator|Noradrenaline alone|Treatment for 30 minutes with noradrenaline alone
3321537|NCT02019810|Experimental|Noradrenaline + dobutamine|Treatment with noradrenaline and dobutamine for 30 minutes
3321538|NCT02019823|Active Comparator|Enhanced usual care|"In addition to usual care participants will receive the pre-randomisation Welcome to the *StAR Study SMS-text, post-randomisation they will received a Happy Birthday SMS-text on their date of birth and up to six additional SMS-text messages containing study specific information and thanking the participant for taking part in the study. Participants in the Enhanced Usual Care group will receive no more than one study specific SMS-text every two months."
3321539|NCT02019823|Experimental|Informational SMS-text|"In addition to enhanced usual care, participants allocated to the informational SMS-text support group will receive a series of text-messages covering the following areas:~I. Medication pick-up reminders send 48 hours before scheduled medication pick-up date a) Participants who fail to pick-up medication within 3 days of scheduled pick-up date will be sent one further reminder SMS-text~II. III. Clinic appointment reminder 48 hours before scheduled follow-up appointment~a) Participants who fail to attend clinic appointment will be sent an additional SMS-text checking they are alright and inviting them to rebook their appointment via the clinic IV. Messages which support medication adherence (focused on organisation, memory, and habit) or provide hypertension related health information"
3321540|NCT02019823|Experimental|Interactive SMS-text|"In addition to enhanced usual care and informational SMS-text messages, SMS-text messages sent to participants in the interactive SMS-text group will contain a prompt to respond which will guide participants to additional SMS-text based resources."
3321541|NCT02019836||sepsis group, control group|Sepsis group; infants with the diagnosis of high probable sepsis Control group; infants without sepsis
3321542|NCT02019849||Plasmafit® Total Hip Arthroplasty|
3321543|NCT02019862||TRJ®|
3321544|NCT02019875|Placebo Comparator|Water|200 mL of water once a day for 14 days
3259091|NCT01467336|Other|Delayed group|Rehabilitation program is delayed to the third week. Active range of motion rehabilitation is started at the sixth week.
3321545|NCT02019875|Active Comparator|Rifampin|Rifampin 600 mg once a day for 14 days
3321546|NCT02019875|Active Comparator|Grapefruit Juice|200 mL of grapefruit juice once a day for 14 days
3321547|NCT02019875|Active Comparator|Grapefruit Juice Plus Rifampin|200 mL of grapefruit juice once a day for 8 days plus rifampin 600 mg once a day for 14 days
3321548|NCT02019875|Active Comparator|Clarithromycin|Clarithromycin 250 mg twice a day for 14 days
3321549|NCT02019875|Active Comparator|Clarithromycin Plus Rifampin|Clarithromycin 250 mg twice a day for 14 days plus rifampin 600 mg once a day for 14 days
3321550|NCT02019901|No Intervention|Regular care|"The control-group is treated according to care as usual with visits to physician every 6th month."
3321551|NCT02019901|Experimental|Nurse-led clinic|Nurse-led visits every 6th week, with structured person-centered care and evaluation of disease activity. If disease remission is not reached, pharmacological treatment including both short-term (intra-articular and oral steroids) and long-term alterations (DMARDs and biologics) is modified according to a predefined algorithm.
3321552|NCT02019914||PTSD and OSA|Veterans diagnosed with Post Traumatic Stress Disorder (PTSD) and Obstructive Sleep Apnea (OSA), interested in a trial of CPAP therapy.
3321553|NCT02019953|Other|Yoga 3 times per week|Yoga participation 3 x per week for 24 weeks; 48 week follow-up.
3321554|NCT02019953|Other|Yoga 2 times per week|Yoga participation 2 x per week for 24 weeks; 48 week follow-up
3321555|NCT02019953|Other|Yoga 1 time per week|Yoga participation 1 x per week for 24 weeks; 48 week follow-up
3321556|NCT02019953|Other|Walking 3 times per week|Walking 3x per week for 24 weeks; 48 week follow-up
3321557|NCT02019953|Other|Healthy Lifestyles Education|Healthy Lifestyles Education Participation 1 x per week for 24 weeks; 48 week follow-up
3321558|NCT02019966||TDF monotherapy|"TDF monotherapy - treated by tenofovir alone~patients with CHB receiving rescue TDF (300mg once daily) monotherapy"
3321559|NCT02019966||TDF-based combination therapy|"TDF-based combination therapy - treated by tenofovir based combination therapy.~patients with CHB receiving rescue TDF-based combination therapy (TDF 300mg once daily with any other nucleoside analogue such as lamivudine 100mg, telbivudine 600mg, or entecavir 1.0 mg once daily)."
3321560|NCT02019992||sepsis|sepsis defined as suspected infection and systemic inflammatory response
3321561|NCT02019992||severe sepsis|sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension
3321562|NCT02019992||control group|control defined as non-infected patients without systemic inflammatory response.
3321563|NCT02020005|Experimental|non-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321564|NCT02020005|Experimental|non-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321565|NCT02020005|Experimental|mint-flavored 2mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321566|NCT02020005|Experimental|mint-flavored 4mg nicotine gum|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321567|NCT02020005|Experimental|non-flavored nicotine inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321568|NCT02020005|Experimental|mint-flavored inhaler|All subjects will test six different nicotine replacement products over the course of the 2-week product sampling phase. The six nicotine replacement products being tested are non-flavored 2mg nicotine gum, non-flavored 4mg nicotine gum, mint-flavored 2mg nicotine gum, mint-flavored 4mg nicotine gum, non-flavored nicotine inhaler and mint-flavored inhaler. The order in which the subjects test these products will be randomized and subjects will be blinded to the nicotine content of the product but will be instructed about the flavor of the product.
3321569|NCT02020044|Other|Endothelial Keratoplasty|Descemet membrane endothelial keratoplasty DMEK Ultra-thin Descemet stripping automated endothelial keratoplasty Ultra-thin DSAEK
3321570|NCT02020057|Active Comparator|Conventional|knee receiving Total knee arthroplasty with conventional polyethylene inserts
3321571|NCT02020057|Experimental|Prolong|knee receiving total knee arthroplasty with highly cross linked polyethylene insert
3228392|NCT01171261|Experimental|Jackie Chan Studio Fitness|The Jackie Chan Studio Fitness (J-MAT) cartridge includes four types of activities that use a four panel floor mat made of flexible material that functions as the wireless interface game controller. The celebrity actor and choreographer Jackie Chan is the avatar character in the game that demonstrates and guides users in four types of aerobic and anaerobic game modes.
3228393|NCT01171261|Experimental|XaviX Tennis|XaviX Tennis simulates tennis using a tennis racket controller and an infrared sensor to detect speed and timing of the player's swing of the racquet. The Tennis cartridge includes three playing modes. In Tournament Tour players select from eight different characters with different skills and play opponents in a bracketed tournament. In Exhibition mode players choose a computer opponent or play a tennis match with a friend. The Training Games mode includes a) Serving, b) Target Challenge, c) Serve & Finish, and d) Rally Time.
3228394|NCT01171261|Experimental|XaviX Bowling|XaviX Bowling uses a wireless bowling ball game controller to simulate bowling. The cartridge includes three modes. In Regular Game up to four people can select from 8 preset bowlers with different characteristics. In Tournament Mode up to eight people can play. Challenge Games consists of three games called Against the Clock, Moving Pins, and Panel Crusher.
3228395|NCT01171261|Experimental|XaviX Boxing|XaviX Boxing uses boxing gloves as the game controller and allows players to box against five different computer opponents in Championship and Exhibition modes and to practice boxing skills in Exercise mode. Exercise mode includes Punch Fast, Panel Toucher, Punch the Red Ball, and Combination Training.
3228396|NCT01171274|Active Comparator|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
3228397|NCT01171274|Active Comparator|Exercise information|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
3228398|NCT01171287|Experimental|Aircast Walker|Automobile driving with an Aircast Walker applied to each participant's right lower extremity
3321572|NCT02020070|Experimental|Ipilimumab & Degarelix With Radical Prostatectomy|"Week 1: Degarelix SQ injection (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose) and Ipilimumab at 3 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ (except patients who have already received hormonal therapy per standard of care and are not yet due for their next dose)~Week 11, 14, 17 or after sufficient wound healing and recovery post RP:~Ipilimumab 3 mg/kg IV Follow-up Twelve week intervals until Week 87."
3321573|NCT02020070|Experimental|Ipilimumab & Degarelix With Prior With Radical Prostatectomy|Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
3321574|NCT02020096|Experimental|U+N group|Ultrasound and nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic block
3321575|NCT02020096|Active Comparator|N group|Nerve stimulator guided lumbar plexus block combined with nerve stimulator guided sciatic nerve block
3321576|NCT02020109||Patients with Chronic Lymphatic Leukemia|Patients with Chronic Lymphatic Leukemia treated with splenic irradiation
3321577|NCT02020122|Active Comparator|Duloxetine|DUL 60mg x once a day x 2 days. This arm will also take 2 non-active placebo x once a day x 2 days
3321578|NCT02020122|Active Comparator|Pregabalin|PGB 150mg x twice a day x 2 days
3321579|NCT02020122|Placebo Comparator|Placebo|Non active placebo x twice a day x 2 days
3321580|NCT02020161|Experimental|ATRA-Idarubicin|
3321581|NCT02020187|Experimental|Exercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
3321582|NCT02020187|No Intervention|Controls|Controls with diagnosed congenital myopathy. Subjects are tested two times on a cycle ergometer. There will be ten weeks between the tests. In between tests the subjects are living life as usual without any interventions.
3321583|NCT02020200|Experimental|MPH or Placebo|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
3321584|NCT02020213|Other|Posaconazole, salvage|Posaconazole, per oral , 400 mg, bid , 8 weeks.
3321585|NCT02020226|Experimental|TH-302|480 mg/m2 by IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle
3321586|NCT02020239|Experimental|Prescribed exercise|Participants will be asked to choose one activity and stick to it for the duration of the intervention. Participants will be able to choose between brisk walking/slow jogging or cycling. The intervention will require the completion of 30 minutes of chosen activity on 5 days of the week, which will be recorded in a physical activity diary.
3321587|NCT02020239|Experimental|Points-based physical activity|Participants will be asked to achieve a pre-set, individualised points target for physical activity each week. Points are acquired through the completion of a minimum 10 minutes of activity, choosing from the extensive list of activities provided; for example, 10 minutes of jogging achieves 4.5 points, whereas 10 minutes of washing a car achieves 1.5 points. The target will be 35-40 points per week, which equates to approximately 6 points per day. Any combination of activity, duration and frequency can be selected.
3321588|NCT02020239|No Intervention|Waiting list control|Participants will be asked to maintain their normal activities and diet. They will be added to a waiting list to receive either exercise intervention after completing the 24-week trial period, so that they do not miss out on the opportunity to receive the exercise intervention.
3321589|NCT02020265|Experimental|NF group|This group will train modulation of the amygdala EEG fingerprint by EEG neurofeedback.
3228399|NCT01171287|Experimental|Walking cast|Automobile driving with a walking cast applied to each participant's right lower extremity
3321590|NCT02020265|Sham Comparator|Sham NF|This group preform the same procedure as the NF group only reviving sham feedback
3321591|NCT02020265|Active Comparator|A\T NF|This group will train modulation of A\T ratio by EEG neurofeedback
3228400|NCT01171287|Active Comparator|Running shoe|Automobile driving with a running shoe applied to each participant's right lower extremity
3228401|NCT01171313|Experimental|Treatment sequence 1|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3228402|NCT01171313|Experimental|Treatment sequence 2|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3228403|NCT01171313|Experimental|Treatment sequence 3|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3228404|NCT01171313|Experimental|Treatment sequence 4|Subjects will receive XP21279 and carbidopa, Sinemet, placebo for XP21279 and carbidopa, placebo for Sinemet in a randomized sequence.
3228405|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 4%|Minocycline Foam FXFM244 - 4%
3228406|NCT01171326|Experimental|Topical Minocycline Foam FXFM244 - 1%|Minocycline Foam FXFM244 - 1%
3321592|NCT02020291|Experimental|Foxy-5|Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly on Monday, Wednesday and Friday for three weeks.
3321593|NCT02020317|Active Comparator|computer-based reminders and alerts|Behavioral: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts (decision support in potassium-inc. drug-drug-interactions)
3321594|NCT02020317|No Intervention|no computer-based reminders or alerts|Behavioral: no display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
3321595|NCT02020330|Active Comparator|AL3days|Artemether-lumefantrine 3 days
3321596|NCT02020330|Experimental|AL5days|Artemether-lumefantrine 5 days
3321597|NCT02020343||Healthy|Not insulin resistant
3321598|NCT02020343||Insulin resistant|Insulin resistant by IVGTT
3321599|NCT02020343||Type 2 diabetics|Type 2 diabetics
3321600|NCT02020356|Experimental|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
3321601|NCT02020356|Placebo Comparator|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
3321602|NCT02020382|Other|Crohn adult colic|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3321603|NCT02020382|Other|RCH adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3228407|NCT01171339|No Intervention|Control|"Usual care in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
3321604|NCT02020382|Other|Witnesses healthy adults|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3321605|NCT02020382|Other|Witnesses adults with non-IBD inflammation|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3321606|NCT02020382|Other|Children with colitis|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3321607|NCT02020382|Other|Witnesses healthy children|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
3321608|NCT02020395|Placebo Comparator|Test meal (500 kcal)_normal weight|ham sandwich chocolate cream orange juice
3321609|NCT02020395|Active Comparator|Test meal (500 kcal)_obese weight|ham sandwich chocolate cream orange juice
3321610|NCT02020421|Experimental|rTMS|Participants will receive real rTMS and sham tDCS
3321611|NCT02020421|Experimental|tDCS|Participants will receive real tDCS and sham rTMS
3321612|NCT02020421|Sham Comparator|Sham|Participants will receive both sham rTMS and sham tDCS
3321613|NCT02020434|Experimental|Single dose of RPX7009 and RPX2014|Single dose of combination RPX7009 and RPX2014
3321614|NCT02020460|Active Comparator|Subdural trial lead|SCS trial lead in the subdural space.
3321615|NCT02020460|Active Comparator|Epidural trial lead|SCS trial lead in the epidural space.
3321616|NCT02020473||WLS group|patients with informed consents for withholding/withdrawing life support
3321617|NCT02020473||non-WLS group|patients without informed consents for withholding/withdrawing life support
3321618|NCT02020486|Experimental|Group A|Experimental
3321619|NCT02020486|Experimental|Group B|Days 1-14: Multiple oral dose of 2 mg perampanel (one 2 mg tablet) Days 15-28: Multiple oral dose of 4 mg perampanel (two 2 mg tablets) Days 29-42: Multiple oral dose of 6 mg perampanel (three 2 mg tablets)
3321620|NCT02020499||Acromegalic patients|Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)
3321621|NCT02020525|Experimental|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
3321622|NCT02020525|Active Comparator|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
3321623|NCT02020538|Placebo Comparator|Chloride-rich IV fluid|The chloride-rich strategy will include 0.9% saline as the perioperative crystalloid of choice with 4% albumin as the perioperative colloid of choice.
3321624|NCT02020538|Active Comparator|Chloride-poor IV fluid|A low-chloride strategy of perioperative IV fluid will include PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice with 20% albumin as the colloid of choice.
3321625|NCT02020551|Placebo Comparator|saline spray application|Placebo group
3321626|NCT02020551|Experimental|lidocaine spray application|2 puff lidocaine spray applicated before IUD insertion
3321627|NCT02020564|Experimental|Treatment Group|Computerized exercised will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3321628|NCT02020564|Placebo Comparator|Placebo control group|Computerized exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3321629|NCT02020603|Active Comparator|APC group|epinephrine injection plus argon plasma coagulation
3321630|NCT02020603|Active Comparator|Forceps group|epinephrine injection plus soft coagulation using hemostatic forceps
3321631|NCT02020629|Experimental|Lixisenatide|Lixisenatide 20µg daily
3228408|NCT01171339|Experimental|Intervention arm|"Intervention: Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
3228409|NCT01171352||ICU Dialysis Patients|Any patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
3228410|NCT01171365|Active Comparator|Ciclesonide|Ciclesonide 320 microgrammes twice daily
3228411|NCT01171365|Placebo Comparator|Placebo|Placebo 2 inhalations twice daily
3228412|NCT01171378|Other|Ofatumumab|Single arm study
3228413|NCT01171391|Experimental|VA106483 1mg|
3228414|NCT01171391|Experimental|VA106483 2mg|
3228415|NCT01171391|Experimental|VA106483 4mg|
3228416|NCT01171391|Placebo Comparator|Sugar pill|
3321632|NCT02020642|Experimental|Intervention Group|A baseline polysomnography (PSG) is performed at inclusion (before renal transplantation, Tx), followed by a post-Tx PSG 6 months after transplantation
3321633|NCT02020642|No Intervention|Control Group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already transplanted
3228417|NCT01171404||1|Patients, older than 18, hospitalized within 24 hours of onset of symptoms and diagnosed with UA, STEMI or NSTEMI
3228418|NCT01171417||Cohort 1|1st-line Faslodex 500 mg
3228419|NCT01171417||Cohort 2|2nd-line Faslodex 500 mg
3228420|NCT01171417||Cohort 3|3rd- line Faslodex 500 mg
3228421|NCT01171417||Cohort 4|patients on exemestane
3228422|NCT01171430|Experimental|MRI WHOLE BODY|
3228423|NCT01171456|Placebo Comparator|Metformin Placebo|
3228424|NCT01171456|Active Comparator|Metformin|
3228425|NCT01171469|Experimental|Dose Level 3|15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3321634|NCT02020655||10 healthy volunteers|Shear- force model
3321635|NCT02020668|Experimental|Physiotherapy|Physiotherapy included joint protection strategies, performance of therapeutic exercises and patient education.
3321636|NCT02020668|Other|Wait list control|Wait list control received standard care and were invited to join the physiotherapy once intervention period is finished.
3321637|NCT02020681|Experimental|Curodont Repair|Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
3321638|NCT02020681|Placebo Comparator|Placebo|Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.
3321639|NCT02020694|Experimental|Vitamin D and Diet|"Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.~Hypocaloric diet"
3321640|NCT02020694|Placebo Comparator|Placebo & Diet|"Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.~Hypocaloric diet"
3321641|NCT02020707|Experimental|Treatment (AB-complex)|Patients receive nab-paclitaxel/bevacizumab-complex IV over 30-60 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3321642|NCT02020720|Experimental|Diagnostic (18F-DOPA-PET)|Within 1 week of biopsy or resection, patients undergo 18F-DOPA PET/CT scan and pMRI and DTI at baseline. Patients then undergo stereotactic craniotomy or image-guided biopsy.
3321643|NCT02020733|Other|balloon catheter|
3321644|NCT02020733|Other|metal cannula|
3321645|NCT02020746|Active Comparator|EscharEx|Enzymatic debridement
3321646|NCT02020746|Placebo Comparator|Gel Vehicle|Control arm
3321647|NCT02020759||Patient on ECMO|Neurological monitoring with transcranial Doppler ultrasound
3321648|NCT02020759||Healthy subjects|Neurological monitoring with transcranial Doppler ultrasound
3321649|NCT02020759||ICU patients|Neurological monitoring with transcranial Doppler ultrasound
3321650|NCT02020772|Experimental|coordinating primary health care 1|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
3321651|NCT02020772|Active Comparator|usual primary health care 1|usual care of musculoskeletal pain in general practice
3321652|NCT02020772|Experimental|coordinating primary health care 2|musculoskeletal pain care by a coordinating team of one general practitioner and two physical therapists
3321653|NCT02020772|Active Comparator|usual primary health care 2|usual care of musculoskeletal pain in general practice
3321654|NCT02020798|Placebo Comparator|Nutrient formulations without active ingredient|4 nutrient formulations without active ingredient and variable level of available placebo ingredient
3321655|NCT02020798|Experimental|Nutrient formulation with active ingredien|4 nutrient formulations with increasing amount of active ingredient
3321656|NCT02020811|Experimental|sentinel arm|all patients will be recieving Iv therapy by using the sentinel controller, a device that is mounted on the IV administration set.
3321657|NCT02020824|Active Comparator|Exposure without control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments without control.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
3321658|NCT02020824|Experimental|Exposure with control|"Exposure to anxiogenous environments: 20 acrophobic patients will be exposed during 8 sessions to anxiogenous environments with the ability to control and secure these.~Imagery with functional MRI initial. Imagery with functional MRI final. Imagery with PET-scanner initial. Imagery with PET-scanner final."
3321659|NCT02020824|Other|Healthy volunteers|"20 healthy volunteers will be submitted to the same initial measurements in order to explore potential differences between them and the patients.~Imagery with functional MRI initial. Imagery with PET-scanner initial."
3321660|NCT02020850||Toe-Brachial and Ankle-Brachial Index|toe systolic blood pressure, ankle systolic blood pressure, brachial systolic blood pressure test
3321661|NCT02020876||Practicing urologic surgeons|Performing at least 60 radical prostate surgeries annually
3228426|NCT01171469|Experimental|Dose Level 2|10 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3228427|NCT01171469|Experimental|Dose Level 1|5 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
3228428|NCT01171482|Experimental|The FM group|Patients in the FM group will be administered 5-FU plus mitomycin
3228429|NCT01171482|Active Comparator|The sorafenib group|Patients in the sorafenib group will be administered sorafenib
3228430|NCT01171495|Experimental|Ensure Plus + Multivitamin/Counselling|
3228431|NCT01171495|Active Comparator|Multivitamin/Counselling|
3228432|NCT01171508||Breast cancer patients|12 breast cancer patients aged 30-70 years undergoing a lumpectomy at Herlev Hospital. ASA score I-III.
3228433|NCT01171560|Active Comparator|EZ Blocker|Patients assigned to the EZ group will be intubated using a conventional tube in an adequate size as it is standard of care and single lung ventilation will be provided using the EZ-Blocker.
3228434|NCT01171560|Active Comparator|Double lumen tube|"The patients assigned to the double lume tube group will be intubated using the double lume tube in an adequate size as it is standard of care."
3228435|NCT01171573||Myositis Patients|Cases with myositis PM DM IBM Venepuncture
3228436|NCT01171573||Healthy controls|Control
3228437|NCT01171586|Experimental|SMS Only|"The SMS only group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The SMS only group will also receive a brief printed or web based outline on weight loss resources and information."
3228438|NCT01171586|Experimental|SMS + Phone Counseling|"This group will receive hints, tips, strategies, and questions related to weight loss behaviors, physical activity, nutrition, and motivation. The messages will be pushed to participants (i.e. no response needed) and pulled from participants (i.e. response is needed). The group will also receive monthly counseling calls from a Health Coach to discuss barriers and solutions and will receive a brief printed or web based outline on weight loss resources and information."
3228439|NCT01171586|No Intervention|Control|The Control group will receive a binder with an attractive set of Standard Print Materials related to weight loss that is comparable to what one would receive from community resources such as libraries, magazines and national non-profit or governmental organizations such as 5-A Day, American Heart Association and the like.
3228440|NCT01171638||Critical Controls|"Critically injured patients with NO severe traumatic lower extremity injuries to provide normative data for the critically injured physiological status upon arrival at study site"
3321662|NCT02020915||Patients with chronic anal fissure|Patients are included who had previous treatment with diltiazem or glycerol-nitrate and botox injections
3321663|NCT02020928|Experimental|Low level laser therapy|The Low level laser therapy application is performed from the first day of conditioning of the patient until the second day after bone marrow transplantation (D + 2). The patients are divided into two groups. The first will contain the patients who will receive the red laser light, whereas the second will cover patients who receive sham or placebo controlled - the device is triggered, but not deliver the laser light.
3321664|NCT02020928|Sham Comparator|sham|patients will receive sham Low level laser therapy - the device is triggered, but not deliver the laser light
3321665|NCT02020954||Dystrophinopathy|Patients with mutations in the DMD gene and Becker muscular dystrophy and/or dilated cardiomyopathy
3321666|NCT02020980||Post-stroke lower limb spasticity patients|
3321667|NCT02020993||Respiratory distress group|Newborns with respiratory distress will constitute the study group. All patients will be evaluated by Urine NT-proBNP and echocardiography on postnatal days 1-2 and 5-7.
3321668|NCT02020993||Control Group|Newborns without any respiratory and cardiac diseases will constitute the control group, and will be evaluated by urine Nt-proBNP and echocardiography on postnatal days 1-2 and 5-7.
3321669|NCT02021006|Active Comparator|ANTIBIOTIC PROPHYLAXIS|"Children in this arm will take antibiotic prophylaxis for 2 years. Patients in this arm will do clinical/instrumental follow-up for 5 years.~The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~Amoxicillin-Potassium Clavulanate Combination 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
3321670|NCT02021006|Experimental|NO PROPHYLAXIS|Children in this arm will not take antibiotic prophylaxis. Patients in this arm will do clinical/instrumental follow-up for 5 years
3321671|NCT02021019|Experimental|Renal Denervation|Renal denervation using a catheter-based Radio-frequency approach
3321672|NCT02021019|No Intervention|Usual Care|Usual care
3321673|NCT02021032|Experimental|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
3321674|NCT02021045||Patient on Hemodialysis|Renal hemodialysis
3321675|NCT02021045||Patient in a hemodialysis-free interval|No Renal hemodialysis
3321676|NCT02021058|Experimental|Experimental Formula|Experimental Formula
3321677|NCT02021058|Other|Standard Formula|Standard Control formula
3321678|NCT02021084|Placebo Comparator|placebo, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
3321679|NCT02021084|Active Comparator|probiotic, response, adverse effect|children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children hospital Israel Haifa that are being treated with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with no interventions and will be required to record all there FMF episodes and their GIT adverse effect, in the second period the patients will be randomly divided into two groups patients that will received placebo arm one and patients that will receive probiotics arm two.
3321680|NCT02021097|Experimental|LNG100 mcg/EE20 mcg|
3321681|NCT02021097|Active Comparator|LNG 150mcg/ EE 30mcg|
3321682|NCT02021110|No Intervention|Control group|This group will receive standard care (no treatment)
3321683|NCT02021110|Experimental|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
3321684|NCT02021123|Experimental|Anidulafungin 100 mg single dose|100 mg single dose anidulafungin pre-surgery (gastric bypass)
3321685|NCT02021136|Experimental|Rebel reliever|Rebel Reliever(R) knee brace + usual antalgic treatment + physical exercises recommendations.
3321686|NCT02021136|Active Comparator|Control|usual antalgic treatment + physical exercises recommendations.
3228441|NCT01171638||Investigational cohort|"Soldiers with severe traumatic lower extremity injuries in stable or critical physiological status presenting to a participating study site within 12 hours of their injury, to provide data on the acute post-injury phase. This cohort will be made up of:~Patients meeting inclusion criteria for investigational cohort, who have UNILATERAL severe lower extremity injuries~Patients meeting inclusion criteria for investigational cohort, who have BILATERAL severe lower extremity injuries.~Patients meeting inclusion criteria for investigational cohort, who have been clinically diagnosed by the treating provider using that treating providers standards for diagnosing ACS and the patient in addition to be diagnosed with ACS undergoes four-compartment leg fasciotomy."
3228442|NCT01171651|Experimental|JX-594 followed by sorafenib|1e9 pfu (plaque-forming units) total JX-594 dose on each of up to four (4) JX-594 treatment days. Sorafenib is initiated after 3 JX-594 treatments and briefly interrupted if an optional 4th JX-594 treatment is given.
3228443|NCT01171664|Placebo Comparator|Placebo|Placebo containing no active pharmaceutical ingredients
3228444|NCT01171664|Experimental|STAHIST|STAHIST tablet for the symptomatic treatment of Seasonal Allergic Rhinitis
3321687|NCT02021149|Other|Psychotherapy and Questionnaire Group|Participants in this arm will have their regular psychotherapy sessions with their psychotherapist and will, prior to each session, fill out study related questionnaires.
3321688|NCT02021149|Experimental|High intensity whole-body infrared heating and Psychotherapy.|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3228445|NCT01171703|Experimental|bypass|femoral-popliteal bypass
3228446|NCT01171703|Experimental|stent|
3228447|NCT01171716|Other|Dietary Protein Intake|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
3228448|NCT01171742|Experimental|IHIO|Intermittent hepatic inflow occlusion (IHIO) by clamping of the portal triad, minimizes blood loss and operation time during liver resection. In addition, ischemic preconditioning with IHIO has been reported to have protective effects in patients undergoing liver resection. IHIO'll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
3228449|NCT01171742|Sham Comparator|Control|The donor liver parenchyma'll be transected without IHIO.
3321689|NCT02021149|Sham Comparator|Low intensity whole-body infrared heating and Psychotherapy|Subjects will have weekly psychotherapy sessions and fill out study questionnaires. The participant's 4th psychotherapy session will be conducted while the patient undergoes WBH-control where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
3321690|NCT02021162||Gilenya|MS patients taking Gilenya
3321691|NCT02021162||Healthy Controls|Healthy controls age and gender matched to MS patients taking Gilenya
3321692|NCT02021175|Experimental|Tailored CBME Therapy via Technology|6 weeks of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
3321693|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 weeks of a standard smoking cessation approach
3321694|NCT02021188||Carotid artery disease|Participants with symptomatic or asymptomatic carotid artery plaques
3321695|NCT02021188||Coronary artery disease|Participants with stable coronary artery disease or recent acute coronary syndrome
3321696|NCT02021201|Experimental|1|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
3321697|NCT02021201|Experimental|2|Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
3321698|NCT02021214|Experimental|Methylphenidate/Placebo|40 mg Methylphenidate, per os, single dose Placebo, single dose
3321699|NCT02021227|No Intervention|Standard group|
3321700|NCT02021227|Other|Chair sitting group|
3321701|NCT02021240|Active Comparator|Ketamine|Single dose of intravenous ketamine 0.5mg/kg before incision
3321702|NCT02021240|Active Comparator|Dexamethasone|Single dose of intravenous dexamethasone 8mg before incision
3321703|NCT02021240|Placebo Comparator|Normal saline|Single dose of intravenous normal saline before incision
3321704|NCT02021253|Placebo Comparator|Placebo of Probiotics|"Placebo: Composition: Each capsule contains 560 mg:~459 mg of corn starch~6 mg of magnesium stearate~Dosage: 2 capsules / day, in the morning at sunrise, one at bedtime.~Methods of administration: Oral.~Duration of treatment: 14 days"
3321705|NCT02021253|Active Comparator|Probiotics- Lactibiane Tolerance|"Active substance mixture of lactic 10% Bifidobacterium lactis LA 303, 10% Lactobacillus acidophilus LA 201, LA 40% Lactobacillus plantarum 301, 20% Lactobacillus salivarius LA 302, LA 20% Bifidobacterium lactis 304 Dosage: 10 X 10^9 probiotic / capsule~Composition: One capsule of 560 mg contains Lactibiane tolerance:~345 mg of corn starch~114 mg premix lactic~6 mg of magnesium stearate Excipients: magnesium stearate~Method of administration: Oral~Dosage: 2 capsules per day for 14 days in two doses: one capsule at sunrise, one capsule at bedtime;"
3321706|NCT02021279|Experimental|MatriStem Pelvic Floor Matrix|surgical mesh device
3321707|NCT02021279|Active Comparator|Native Tissue Repair|suture repair
3321708|NCT02021305||Patients|60 children with a recorded episode of acute Urinary Track infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
3321709|NCT02021305||Controls|100 children with no history of Urinary Track Infection who attended 4th Department of Pediatrics of Medical School of Aristotle University of Thessaloniki.
3321710|NCT02021344|No Intervention|Pure control|Practice as usual (no MHFA) in all residences on these campuses.
3321711|NCT02021344|Experimental|Intervention residence on mixed campus|Mental Health First Aid delivered to these residences, but not all other residences at the same campus.
3321712|NCT02021344|Experimental|Pure intervention residence|Mental Health First Aid delivered to this residence and all other residences at the same campus
3321713|NCT02021344|No Intervention|Control at mixed campus|Practice as usual (no MHFA) at this residence, but some other residences at same campus are in experimental condition (MHFA).
3321714|NCT02021357|Experimental|Hyperboloid associated with the exercise of proprioceptive|The proprioceptive treatment protocol if run in the use of exercises with hyperboloid based on studies of Biasotto-Gonzalez (2005), for each exercise will be held 6 sets of 6 reps. Between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain, and after that period you will be asked to volunteer the proprioceptive exercise of ´ ´ tongue on the hard palate ´ ´ Biasotto-Gonzalez-based (2005), which consists of the language supported in the hard palate, you must open and close the mouth, having as the principle language as a physical reference.
3321715|NCT02021357|Active Comparator|Hyperboloid|"The proprioceptive treatment protocol if run in the use of the hyperboloid, based on studies of Biasotto-Gonzalez (2005), but without the proprioceptive exercise of language in ´ ´ hard palate ´ ´.~For each exercise will be held 6 series of 6 repetitions, and between exercises, 1 minute will be established for rest of the volunteer, in order to avoid muscle fatigue and possible exacerbation of pain."
3321716|NCT02021357|No Intervention|Control|The individuals in control group did not receive any type of intervention, being offered proprioceptive treatment after the study period.
3321717|NCT02021370|Experimental|BAY85-3934 (25mg OD)|25 mg once daily (OD) of BAY85-3934 Morning: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo Evening: 3 tablets matching placebo
3321718|NCT02021370|Experimental|BAY85-3934 (50mg OD)|50 mg OD of BAY85-3934 Morning: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo Evening: 3 tablets matching placebo
3321719|NCT02021370|Experimental|BAY85-3934 (75mg OD)|75 mg OD of BAY85-3934 Morning: 3 tablets BAY85-3934 25 mg Evening: 3 tablets matching placebo
3321720|NCT02021370|Experimental|BAY85-3934 (25mg BID)|25 mg twice daily (BID) of BAY85-3934 Morning and evening: 1 tablet BAY85-3934 25 mg and 2 tablets matching placebo
3321721|NCT02021370|Experimental|BAY85-3934 (50mg BID)|50 mg BID of BAY85-3934 Morning and evening: 2 tablets BAY85-3934 25 mg and 1 tablet matching placebo
3321722|NCT02021370|Placebo Comparator|Placebo BID|Placebo BID Morning and evening: 3 tablets of placebo matching BAY85-3934 25 mg
3228450|NCT01171755|Experimental|Gemcitabine, Ts-1|Gemcitabine : 1000/m2 will be administered on days 1 and 8 at every 3 weeks . TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
3228451|NCT01171768||patients with hemoptysis within 2 weeks|
3228452|NCT01171768||patients without hemoptysis within 2 years|
3228453|NCT01171781|Active Comparator|3 weekly CDDP based CCRT|radiation (conventioal or IMRT) with 3 cycles of 3-weekly cisplatin
3228454|NCT01171781|Experimental|weekly cisplatin based CCRT|radiation (conventional or IMRT) with 7 cycles of weekly cisplatin therapy
3228455|NCT01171807|Active Comparator|Dexamethasone 21-phosphate encapsulated into red cells|
3228456|NCT01171807|Sham Comparator|Placebo|
3321723|NCT02021383|Experimental|Contest Plus|The Contest Plus group were eligible to receive the financial incentives for weight loss maintenance at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance. In addition to the financial incentives, participants in this group had bi-weekly in person meetings with a Registered Dietician during phase 2 (week 16-24) of the trial. They also received an in home scale to monitor weight daily.
3321724|NCT02021383|No Intervention|Control|The Control condition did not receive any intervention and were not eligible to win the lottery based incentive. Participants completed follow surveys (weeks 16, 20 and 24) and received remuneration for completing surveys and in person weigh in.
3228457|NCT01171833|Experimental|Group A(Sevoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3228458|NCT01171833|Experimental|Group B(Desflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3228459|NCT01171833|Experimental|Group C(Isoflurane)|"Twelve patients will be enrolled in this group. They will be divided into subgroups with ventilatory settings.~Each subgroup has 4 patients.~A8: tidal volume(8 ml/kg) and respiratory rate(10 /min) A10: tidal volume(10 ml/kg) and respiratory rate(10 /min) A12: tidal volume(12 ml/kg) and respiratory rate(10 /min)"
3228460|NCT01171846|Active Comparator|Physiotherapy|
3228461|NCT01171846|No Intervention|Control|Women allocated to the Control group will only receive, by post, the same Lifestyle Advice Sheet as the intervention group.
3228462|NCT01171859|Experimental|Doxycycline + Tauroursodeoxycholic acid|
3228463|NCT01171872||Unaffected|Individuals who do not have IBD
3228464|NCT01171872||Affected|Individuals who have IBD
3228465|NCT01171885|Placebo Comparator|Placebo|Bilateral superficial cervical block.
3228466|NCT01171885|Experimental|Ropivacaine 0.25%|Bilateral superficial cervical block
3228467|NCT01171885|Experimental|Ropivacaine 0.5%|Bilateral superficial cervical block.
3228468|NCT01171937|Active Comparator|Open-Label Risperidone|Risperidone oral solution (1mg/mL) qd for 8 weeks.
3228469|NCT01171937|Placebo Comparator|Placebo|Placebo
3228470|NCT01171950|Other|All Patients|All patients meeting the patient selection criteria will be treated with the CentriMag device.
3228471|NCT01172002|Experimental|leflunomide group|
3228472|NCT01172002|Active Comparator|Azathioprine group|
3228473|NCT01172015|Experimental|PTI patients|Study NK cells functions, phenotypic changes and transcripts from ITP patients
3321725|NCT02021383|Experimental|Contest Only|The Contest only group were eligible to receive the financial incentives for weight loss maintenance for maintaining weight lost at three monthly follow ups; weeks 16, 20 and 24. Eligible participants completed online surveys and in person weigh ins verifying weight maintenance.
3321726|NCT02021396|Experimental|Embolization|this arm of the study was interventional (embolization) with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180) read by 2 expert radiologists blinded to the study arm
3321727|NCT02021396|No Intervention|Surveillance|this arm of the study was non-interventional (surveillance), with CT scans at inclusion (D0, to validate the inclusion criteria), at one month (D30-validating the primary endpoint) and at 6 months (D180 ) read by 2 expert radiologists blinded to the study arm
3321728|NCT02021409|Experimental|BAY85-3934 (25mg)|Fixed starting dose of 25 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's hemoglobin (Hb) response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3321729|NCT02021409|Experimental|BAY85-3934 (50mg)|Fixed starting dose of 50 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3321730|NCT02021409|Experimental|BAY85-3934 (75mg)|Fixed starting doses of 75 mg of BAY85-3934 oral tablet (once daily dose) titrated at the scheduled dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
3321731|NCT02021409|Active Comparator|Darbepoetin alfa|Darbepoetin (intravenous or subcutaneous) will be administered according to the local label and titrated at the scheduled dose control visits. Titration will be based on the subject's Hb response and tolerability of the prior dose.
3321732|NCT02021422|Other|Anakinra with Modified Folfirinox|"8-weeks of anakinra and modified FOLFIRINOX regimen (refer to Appendix 9 for regimen) as follows~Kineret (anakinra) Dosage Route Administration 100 mg SC Every Other Day~Modified FOLFIRINOX Drug Dose Administration Oxaliplatin 85 mg/m2 2-4 hours Irinotecan 180 mg/m2 90 minutes fluorouracil 2400 mg/m2 48 hours"
3321733|NCT02021435|Experimental|Salt Substitute|salt substitute
3321734|NCT02021435|No Intervention|Control|Participants continue to buy salt at their own expense
3321735|NCT02021448|Other|Obesity: BMI > 30 kg/m2|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS) Polygraphy/Polysomnography, Blood sampling, EKG, Lung function testing, Arterial blood gases, Thoracic radiography, Six-minute walk test, Respiratory questionnaires
3321736|NCT02021474|Experimental|Histamine Dihydrochloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
3321737|NCT02021474|Placebo Comparator|Evan's solution = phenol 0.4%, isotonic sodium chloride|Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.
3321738|NCT02021500||Patients previously enrolled in study CA046|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
3321739|NCT02021513|Experimental|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
3321740|NCT02021513|Placebo Comparator|Placebo|Olive Oil
3321741|NCT02021526|Experimental|No Dietary Therapy|Patients currently on no dietary therapy will receive triheptanoin (C7 oil), dosed at 1 g/kg body weight and divided into 4 doses daily, administered for 6 months
3321742|NCT02021526|Experimental|Ketogenic Diet|Patients on ketogenic diet will receive triheptanoin (C7 oil) in place of their usual fat intake, at a dose sufficient to maintain their ketogenic diet ratio (based on patient weight and current ratio). Patients will receive triheptanoin for 6 months.
3228474|NCT01172015|Other|healthy volunteers|Study NK cells functions, phenotypic changes and transcripts from healthy volunteers
3228475|NCT01172028|Experimental|Alimta and Taxotere|Alimta and Taxotere given in combination with dose modifications.
3228476|NCT01172054|Experimental|VAX128|Novel H1N1 Influenza vaccine
3228477|NCT01172054|Placebo Comparator|Placebo|one IM injection
3228478|NCT01172080|No Intervention|control|Participants in this group are monitored for adherence to colonoscopy recommendations.
3228479|NCT01172080|Experimental|intervention|Participants to receive a protocol of reminder letters and a phone call regarding due follow up colonoscopy
3228480|NCT01172106|Placebo Comparator|Encouragement on drug compliance|The intervention for the placebo comparator will be encouragement on drug compliance
3228481|NCT01172106|Experimental|Family psychoeducation|The experimental group will receive weekly sessions of psychoeducation for 12 weeks in addition to receiving drug compliance encouragement
3228482|NCT01172119|Experimental|BioFreedom Standard Dose|
3228483|NCT01172119|Experimental|BioFreedom Low Dose|
3321743|NCT02021539||The study population|"The study population consists of pregnant women presenting between the 24th and 34th week of pregnancy, with uterine contractions associated with cervical changes objectified by ultrasound examination of the cervix (5-25mm) who consult for obstetric emergencies (both single or multiple pregnancies can be included).~Intervention : Cervical ultrasound +elastography 1 Intervention : Vaginal fibronectin measurement Intervention : Tocolytic treatment for 2 hours Intervention : Cervical ultrasound +elastography 2"
3321744|NCT02021552||trauma patients|trauma patients 18 years or older requiring treatment in the ICU >24 hours. All subjects will undergo blood sampling.
3321745|NCT02021578|Experimental|Family Cognitive Behavioral Prevention|A family cognitive behavioral program for parents and children. Parents learn parenting skills and cognitive behavioral techniques for managing depression. Children learn coping skills.
3321746|NCT02021578|Active Comparator|Written Information|Families receive written materials about depression and the effects of parental depression on children.
3228484|NCT01172119|Active Comparator|Taxus Liberte drug eluting stents|
3321747|NCT02021591|No Intervention|Control|Control Arm: Study participants attending one of the 4 control arm centers will receive usual diabetes education provided by staff at the site; be provided with free test strips for their blood glucose meters during the 4-week intervention period; given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
3321748|NCT02021591|Experimental|Intervention|Intervention: Mobile Diabetes Detective (MoDD) Study participants attending one of the 4 Intervention sites will receive usual diabetes education provided by staff at the site and be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
3321749|NCT02021604|Experimental|Pancreatic Imaging with Fluorodopa F 18|
3321750|NCT02021617|No Intervention|Intraosseous Access|This study will evaluate the proximal humerus and proximal tibia IO infusion sites for infusion flow rates attainable at specified infusion pressures. We will evaluate the IO infusion pathway to determine the mean time from IO contrast injection at the proximal humerus and proximal tibia sites to delivery to central circulation. This study will provide additional data regarding the relationship between IO and IV blood when used for routine laboratory analysis, adding to the current sample size. Lastly, this study will provide data to determine the average time from IO needle insertion to access of the IO space for immediate drug administration, and the average time from IO needle insertion to the ability to infuse fluids in the conscious subject. Intraosseous access.
3321751|NCT02021630||Patient|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3321752|NCT02021630||Spouse/Partner|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3321753|NCT02021630||Child(ren)|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
3228485|NCT01172158||Forgotten ureteral stents|
3228486|NCT01172171|Active Comparator|Melatonin|The randomized patients will receive 10 ml 0,1 mg/ml melatonin intracoronarily and 49 mg intravenously.
3228487|NCT01172171|Placebo Comparator|Isotonic saline|The randomized patients will receive 10 ml isotonic saline (NaCl)and 490 ml intravenously.
3228488|NCT01172210||Bulimia Nervosa|
3228489|NCT01172210||Bulimia Nervosa w/ Alcohol Use Disorder|
3228490|NCT01172210||Healthy Controls|
3228491|NCT01172223|Experimental|LAPADO|Non-pegylated liposomal doxorubicin (NPLD; Myocet, 60 mg/m2 i.v. day 1 q3 weeks), Paclitaxel (175 mg/m2 i.v. day 1 q3 weeks), and Lapatinib (GW572016, Tykerb, 750-1500 mg/d orally daily until the day of the definitive surgery)
3228492|NCT01172236|Experimental|Lactoferrin|
3228493|NCT01172249|Experimental|Glucosamine-Chondroitin Mantecorp|1 capsule three times daily before meals (drug test - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Mantecorp)
3228494|NCT01172249|Active Comparator|Condroflex|1 capsule three times daily before meals (reference medication - glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg - Condroflex ®).
3228495|NCT01172262||Bothered Tinnitus|Either responds with a Global Tinnitus Scale of Moderately or Severely Bothered. Score >30 on the Tinnitus Handicap Index (THI).
3228496|NCT01172301|Experimental|Oral EAA vs total AA supplement|
3321754|NCT02021682||Amyloid positive (Amyloidosis)|Amyloidosis defined by positive Positive emission tomography (PET)/Pittsburg Compound B (PIB) score, or low CSF Aβ42 concentration.
3321755|NCT02021682||Amyloid negative (Control)|Amyloid negative defined by negative Positive emission tomography (PET)/Pittsburg Compound B (PIB) score or high/normal CSF Aβ42 concentration .
3228497|NCT01172314|Experimental|EAA+LEU vs total AA|
3228498|NCT01172314|Experimental|Total AA vs EAA+LEU|
3228499|NCT01172327|Experimental|Multicomponent exercise|This arm is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks.
3321756|NCT02021695||Group I: Non-diabetic controls|"Group I: Non-diabetic controls Good overall health without history of Type II diabetes. Normal fasting glucose level (<100 mg/dL) and HbA1C < 5.7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
3321757|NCT02021695||Group II: Diabetic with HbA1C<7%|"Group II:~HbA1C<7%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
3321758|NCT02021695||Group III: Good controlled diabetics with 7 % <HbA1C < 10%|"Group III Good controlled diabetics with 7 % <HbA1C < 10%~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
3228500|NCT01172327|Active Comparator|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks.
3228501|NCT01172340|Experimental|Behavioral and support intervention|one individual counseling session with diet and exercise recommendations plus 16 weeks of group sessions, plus 8 weeks of phone followup
3228502|NCT01172340|Placebo Comparator|wait-listed control group|Controls receive individual counseling session and recommendations, mailed health information, and after post-test measures are offered an abbreviated group-based intervention
3228503|NCT01172379|Experimental|Experimental 1|
3228504|NCT01172379|Experimental|Experimental 2|
3228505|NCT01172379|Experimental|Experimental 3|
3228506|NCT01172379|Placebo Comparator|Placebo Comparator|
3321759|NCT02021695||Group IV: Poorly controlled diabetics with HbA1C > 10%.|"Group IV:~Poorly controlled diabetics with HbA1C > 10%.~Also:~Must provide informed consent~Males or Females aged 30 years or older to minimize the potential confounding of other forms of diabetes mellitus~In patients with diabetes, no concomitant diseases except for micro- and macrovascular complications of diabetes (nephropathy, retinopathy, peripheral arterial disease, coronary artery disease, neuropathy) or symptoms of the metabolic syndrome (hypertension, dyslipidemia and obesity)~Not taking any chronic medications (except of the diabetes and cardiovascular related drugs)."
3321760|NCT02021708||Non-smoker|This group will include individuals without any history of lung disease, including asthma, and without recurrent or acute pulmonary disease. Individuals must also have smoked less than 100 cigarettes and/or less than 10 shisha pipes in their lifetime.
3321761|NCT02021708||Shisha smoker|This group will include individuals who have a shisha smoking history of more than 5 pipe-years and must currently smoke more than 5 pipes per week. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
3321762|NCT02021708||Cigarette smoker|This group will include individuals who have a cigarette smoking history that will be confirmed by urine testing. Individuals must not show any signs of acute lung infection or have medical history of significant illness or other significant medical issues.
3321763|NCT02021721||Cohort|Subjects who fulfill the inclusion criteria will be pre-identified by consultation with their attending physicians and by thorough review of the literature to establish that the disease is indeed genetic and unsolved.
3321764|NCT02021747||Individuals with TB|"Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3321765|NCT02021747||Smokers|"Active smoker as evidenced by self report and urine nicotine >30 ng/mL and urine cotinine >50 ng/mL~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3321766|NCT02021747||Non-smokers|"Never smokers is defined as someone who has smoked < 100 cigarettes per lifetime and whose urine nicotine <2 ng/mL and urine cotinine <5 ng/mL, at entry into the study~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3321767|NCT02021747||Individuals with COPD|"All study subjects should meet the Lung Disease protocol criteria for having COPD may be of any stage (GOLD I - IV), be ambulatory and have no evidence of respiratory failure~Diagnosis of pulmonary tuberculosis without extra-pulmonary TB, confirmed by at least one of the following:~Symptoms consistent with TB~Chest X-rays and or chest CT consistent with TB~Positive PPD test~Positive sputum test"
3321768|NCT02021760|Active Comparator|Remote Ischemic per-postconditioning|Remote conditioning is induced by inflation of a blood pressure cuff around the left thigh to 200 mmHg or 20 mmHg above systolic blood pressure (if >180 mmHg) for 5 min followed by deflation for 5 min. At least one of these conditioning cycles is performed before PCI is initiated. If time allows, cycles of remote conditioning (5 min leg ischemia and 5 min reperfusion) are repeated until PCI is performed. Following reperfusion, defined as first balloon inflation, four additional cycles of remote conditioning will be performed.
3228507|NCT01172392|Experimental|PegIFN + Nucleosidic or Nucleotidic Analog|
3228508|NCT01172392|Active Comparator|Nucleosidic or Nucleotidic Analog|
3228509|NCT01172405|Experimental|Ibuprofen + Caffeine|72 patients treated with one or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
3228510|NCT01172405|Active Comparator|Ibuprofen|72 patients treated with one or two tablets of ibuprofen 400 mg when presenting headache.
3228511|NCT01172431|Experimental|Indapamide|Indapamide SR 1.5mg qd
3228512|NCT01172431|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
3228513|NCT01172444|Experimental|Test|Sandoz Mesalamine 1 g Suppository
3228514|NCT01172444|Active Comparator|Reference|Canasa 1 g Suppository
3228515|NCT01172444|Placebo Comparator|Placebo|Sandoz 1 g Placebo Suppository
3228516|NCT01172457|Active Comparator|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
3228517|NCT01172457|Placebo Comparator|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
3228518|NCT01172483|Experimental|multimodal community program|multimodal community program of exercise and education
3228519|NCT01172483|Active Comparator|active control|general practice in primary care and education of chronic disorders
3228520|NCT01172496|Experimental|1 mg tablet; 1mg solution|
3228521|NCT01172496|Experimental|1mg solution; 1mg tablet|
3321769|NCT02021760|Sham Comparator|Sham|"The sham procedures include application of the cuff around the thigh but it is not inflated.~Otheriwize normal primary PCI."
3321770|NCT02021786|Experimental|Mobile phone based intervention|The intervention in the present study is a web- and mobile phone based intervention aiming to develop healthy lifestyle behaviors regarding physical activity and dietary habits in 4-year-olds. The intervention will be delivered to the parents and it is available to the parents during six months.
3321771|NCT02021786|No Intervention|Control|The control group receive a pamphlet on healthy eating and physical activity in pre-school children based on the existing guidelines. The information is similar to what parents receive from the Swedish child healthcare system
3321772|NCT02021799|No Intervention|Undernourished Pregnant Women|Pregnant women who are classified as undernourished
3321773|NCT02021799|No Intervention|Nourished Pregnant Women|Pregnant women who are classified as healthy
3321774|NCT02021799|No Intervention|Overweight/obese Pregnant women|Pregnant women who are classified as obese or overweight
3228522|NCT01172509|Placebo Comparator|sugar pill|placebo administered under double blind conditions
3228523|NCT01172509|Experimental|3 mg of R-baclofen|3 mg of R-Baclofen administered double blind
3228524|NCT01172509|Experimental|10 mg of R-baclofen|10 mg of R-baclofen administered double-blind
3228525|NCT01172509|Experimental|25 mg of R-baclofen|25 mg of R-baclofen administered double blind
3228526|NCT01172509|Placebo Comparator|second sugar pill|the second placebo administered double blind
3228527|NCT01172548|Experimental|imatinib mesylate|
3228528|NCT01172561|Active Comparator|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
3321775|NCT02021799|Experimental|Undernourished + Yogurt Pregnant Women|Pregnant women who are undernourished and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
3321776|NCT02021799|Experimental|Nourished + Yogurt Pregnant Women|Pregnant women who are healthy and selected to receive Moringa and Lactobacillus rhamnosus GR-1 probiotic yogurt. Yogurt contained 4.3 grams of Moringa and 10^8 CFU/mL of Lactobacillus rhamnosus GR-1 as well as Streptococcus thermophilus and Lactobacillus bulgaricus starter cultures.
3321777|NCT02021825|Other|MITO, annual relapse rate, safety|For refractory NMO patients aged 18-55, the initial dose 12 mg/m2 mitoxantrone was administered over a five day course every 3 months for 2 years (a total of eight courses). The initial dose was reduced to 9 mg/m2 if the preinfusion white-blood-cell count was 3.0-3.99 ×109/L,and to 6 mg/m2 if the white-blood-cell count was 2.0-2.99 ×109/L. No infusion if the white-blood-cell count was less than 2.0×109/L. The initial dose was reduced to 10 mg/m2 for nonhaematological toxic effects of WHO grade 2-3. Subsequent dose after 3 month was reduced to 10 mg/m2 for infections that occurred within 3 weeks of a previous infusion accompanied by a white-blood-cell count below 2×109/L, or to 8 mg/m2 for infections accompanied by white-blood-cell count of less than 1×109/L.
3321778|NCT02021838||California|Lethality Assessment Program
3321779|NCT02021838||North Carolina|Lethality Assessment Program
3321780|NCT02021838||Ohio|Domestic Violence High Risk Team
3321781|NCT02021838||Illinois|Lethality Assessment Program
3321782|NCT02021838||Michigan|Lethality Assessment Program
3321783|NCT02021838||Tennessee|Lethality Assessment Program
3321784|NCT02021851|Active Comparator|Group DA: Dexamethasone and aprepitant|Group DA: Dexamethasone: 8 mg (intravenous), Aprepitant: 40 mg (oral)
3321785|NCT02021851|Placebo Comparator|Group DO: Dexamethasone and ondansetron|Group DO: Dexamethasone: 8 mg (intravenous), Ondansetron: 4 mg (intravenous)
3321786|NCT02021864|Experimental|vitamin D3, prenatal multivitamin|vitamin D3 50,000 unit/week for 8 weeks, daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
3321787|NCT02021864|Active Comparator|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
3321788|NCT02021877||TBI subjects|Unselected adult patients with acute TBI from the Emergency Departments of the recruiting hospitals
3321789|NCT02021877||Control subjects|Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries)
3321790|NCT02021890|Experimental|ballroom and Latin dance program|two-hour dancing session twice a week
3321791|NCT02021890|Active Comparator|Self-selected physical activity|self-selected program of physical activity
3321792|NCT02021903|Experimental|HGPO + Placebo|V1: HGPO 75 mg + meal and V2: Placebo 75 mg + meal
3228529|NCT01172561|Experimental|Lay Health Advisor Intervention|The Lay Health Advisor education intervention - The intervention consisted of an intensive, reinforced, one on one, interactive ed. program (an initial meeting, then 2 calls and a series of 4 postcards mailed at regular intervals and a 2nd visit. Woman were enrolled for about 12 to 14 months.
3228530|NCT01172574|Experimental|Motor control exercise|Subjects of the exercise group underwent a 3-month (13-week) treatment program directed on 3-weekly 1-hr one-to-one sessions by the researcher who had experience in the specific exercise treatment of the spinal region. During the next 3 months, the subjects were urged to perform the exercises alone at home at least once a day, and compliance was monitored by the activity quota chart given to them at the beginning of each study-month.
3228531|NCT01172574|No Intervention|Control group|The control group underwent treatment throughout a 6-month period, directed by each patient's medical practitioner. This consisted of the patients carrying out regular weekly general exercises (walking and swimming). Three of them regularly attended other treatment providers involving group general exercise programs. Two patients received the application of local pain-relieving methods such as heat, massage, laser and ultrasound and one did nothing except for receiving osteoporotic medication.
3321793|NCT02021903|Placebo Comparator|Placebo + HGPO|V1: Placebo 75 mg + meal and V2: HGPO 75 mg + meal
3321794|NCT02021968|Experimental|TetraVax-DV-TV003 vaccine|Participants in this arm will receive a single injection of the TetraVax-DV-TV003 vaccine on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
3321795|NCT02021968|Placebo Comparator|Placebo|Participants in this arm will receive a single injection of placebo on Day 0 (study entry). On Day 180, participants will receive a single injection of the attenuated rDEN2∆30-7169 virus.
3321796|NCT02021981||Observational Group 1|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321797|NCT02021981||Observation Group 2|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321798|NCT02021981||Observation Group 3|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3228532|NCT01172587|Experimental|Lifestyle Counseling|Couples receive behavioral couples therapy for parental drug use.
3228533|NCT01172613||healthy subjects no symptoms|
3228534|NCT01172613||allergic rhinitis patient|
3228535|NCT01172626||epileptic patients|epileptic patients receiving treatment with continuous Sodium Valproate
3228536|NCT01172652|Experimental|ziprasidone|
3228537|NCT01172652|Placebo Comparator|Placebo|
3228538|NCT01172691|Experimental|Placebo and Study|
3228539|NCT01172704|Active Comparator|Care as Usual|Participants randomized to CAU receive the standard care given to patients of the Boston Medical Center who are interested in learning more about HIV/AIDS. Included in this care would be referrals for HIV counseling and testing.
3228540|NCT01172704|Experimental|Skills Building - Motivational Interviewing|Participants randomized to SB-MI will receive three individual sessions and a booster. Content of the sessions are as follows; Session 1: Risk Behavior Feedback & Building Motivation; Session 2: Building Motivation & Skill Selection and Practice; Session 3: Developing Change Plan & Skill Practice and Booster Session(s): Review Change Plan Implementation, Maintaining Motivation & Skill Practice.
3228541|NCT01172717|Experimental|Panitumumab|Single arm study
3228542|NCT01172730||Ultrasound scanning|
3228543|NCT01172743||Diabetes|Individuals with diabetes that fit eligibility criteria.
3228544|NCT01172743||Normal Control|Individuals without history of diabetes.
3228545|NCT01172756|Experimental|Arm 1|
3228546|NCT01172756|Experimental|Arm 2|
3228547|NCT01172756|Experimental|Arm 3|
3228548|NCT01172756|Placebo Comparator|Arm 4|
3228549|NCT01172769|Experimental|Temsirolimus|
3228550|NCT01172782|Placebo Comparator|control group|control group (CG) received 6 mg of hyperbaric bupivacaine and 0.05 mL of saline.
3228551|NCT01172782|Active Comparator|2.5 ug hydromorphone recieved group|the 2.5 μg hydromorphone group (2.5HG) received 1.2 (6 mg) mL of 0.5% hyperbaric bupivacaine and 2.5 μg of hydromorphone in 0.05 mL of saline
3228552|NCT01172782|Active Comparator|5 μg hydromorphone group|5 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 5 μg of hydromorphone in 0.05 mL of saline
3228553|NCT01172782|Active Comparator|the 10 μg hydromorpnone group|the 10 μg hydromorphone group received 1.2 mL of 0.5% hyperbaric bupivacaine and 10 μg of hydromorphone in 0.05 mL of saline.
3228554|NCT01172795||healthy controls|
3228555|NCT01172795||chronic whiplash patients|
3228556|NCT01172795||Fibromyalgia patients|
3228557|NCT01172834|Experimental|Lifestyle counseling|
3228558|NCT01172860|Experimental|EndoVe treatment|Use of the EndoVe device to safely and effectively ablate rectal tumor tissue
3228559|NCT01172899|Experimental|Laparoscopic adjustable gastric band|
3228560|NCT01172899|Active Comparator|Control group|
3228561|NCT01172925|Experimental|Tiotropium|Inhaler
3228562|NCT01172925|Placebo Comparator|Placebo|Inhaler
3228563|NCT01172951|Active Comparator|OGTT-OGTT-Physical tests|2 successive Oral Glucose Tolerance Tests followed by a physical tests session
3228564|NCT01172951|Active Comparator|OLTT-OLTT-Physical tests|2 successive Oral Lipid Tolerance Tests followed by a physical test session
3228565|NCT01172951|Active Comparator|OGTT-OLTT-Physical tests|Oral glucose tolerance test followed by an oral lipid tolerance test (or vice-versa) followed by a physical tests session
3228566|NCT01172964|Experimental|Arm I|Patients undergo debulking craniotomy and receive injections of HB1.F3.CD neural stem cells directly into brain tissue on day 0. Patients then receive oral 5-fluorocytosine every 6 hours on days 4-10 in the absence of disease progression or unacceptable toxicity.
3228567|NCT01172977||HbA1c ≤ 7|Stroke patients with mild diabetes mellitus HbA1c ≤ 7
3228568|NCT01172977||HbA1c ≥ 7,5|Stroke patients with severe diabetes mellitus HbA1c ≥ 7,5
3228569|NCT01172990|Experimental|Conventional Group|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- Percutaneous Coronary Intervention PCI between 24 to 48 hours from randomisation according to local policy and guidelines
3228570|NCT01172990|Active Comparator|Immediate Invasive Group|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting Percutaneous Coronary Intervention(PCI) will be performed according to local policy and guidelines
3228571|NCT01173042|Placebo Comparator|Control|Shake containing heavy whipping cream, glucose and chocolate syrup
3228572|NCT01173042|Experimental|Peanut|Shake containing control (whipping cream, glucose and chocolate syrup) + 3oz of peanuts
3321799|NCT02021981||Observation Group 4|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321800|NCT02021981||Observation Group 5|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321801|NCT02021981||Observation Group 6|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321802|NCT02021981||Observation Group 7|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321803|NCT02021981||Observation Group 8|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321804|NCT02021981||Observation Group 9|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321805|NCT02021981||Observation Group 10|Coach care teams in the practice site on how to implement evidence-based enhancements in hypertension care delivery processes, using established quality improvement principles and methods. In one year, figure out the best way to help different types of ambulatory clinical practices achieve improved blood pressure control.
3321806|NCT02021994||Arm Automatic Electronic BPM|
3321807|NCT02021994||mercury sphygmomanometer|
3228573|NCT01173042|Experimental|Oil blend|Shake containing control (heavy whipping cream, glucose and chocolate syrup) + oil blend (equivalent to fatty acids provided in 3oz peanuts)
3228574|NCT01173081|Experimental|Teriparatide|Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
3228575|NCT01173081|Placebo Comparator|Placebo Control|Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.
3228576|NCT01173094|Experimental|PTA|The patients with short-obstruction in the below-knee artery will be included in this group.
3228577|NCT01173094|Experimental|bypass|The patients with long-obstruction in the below-knee artery will be included in this group.
3321808|NCT02022046||2/study, control|Study group: children aged<18 years with chronic kidney disease Control group: children aged<18 years without chronic kidney disease Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
3321809|NCT02022059|Experimental|Lidocaine|patient nécessitant une SNG pour nutrition entérale bénéficiant d'une pré-médication par vaporisateur de lidocaïne lors de l'insertion (group A = lidcoaine)
3321810|NCT02022059|Placebo Comparator|Placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion (group B)
3321811|NCT02022072|Other|measure of assisted vital capacity by mechanical insufflation|measure of assisted vital capacity by a mechanical insufflation/exsufflation
3321812|NCT02022124|Experimental|microcrystalline cellulose (open-label inert substance)|3-week course of non-deceptive placebo using placebo pills plus the usual regime that the patients had been prescribed at the time of intake.
3321813|NCT02022124|No Intervention|Usual care treatment|This arm will entail a 3-week course of the stable treatment the patient is following at time of intake.
3321814|NCT02022137|Experimental|Red cereal bar|It includes the intervention of the red cereal bar for the designation of the group.
3321815|NCT02022137|Placebo Comparator|Green cereal bar|It includes the intervention of the green cereal bar for the designation of the group.
3321816|NCT02022137|Active Comparator|White cereal bar|It includes the intervention of the white cereal bar for the designation of the group.
3321817|NCT02022150||Body composition in paracentesis|Taking blood samples and bioelectrical impedance, Psychometric Hepatic Encephalopathy Score (PHES) and Critical Flicker Frequency (CFF) before and after paracentesis.
3321818|NCT02022163|Experimental|Low dose of H7 VLP vaccine + Alhydrogel|Biological: Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3321819|NCT02022163|Experimental|Med dose of H7 VLP vaccine + Alhydrogel|Biological: Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3321820|NCT02022163|Experimental|High dose of H7 VLP vaccine + Alhydrogel|Biological: High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
3321821|NCT02022163|Experimental|High dose of H7 VLP vaccine|Biological: High dose of H7 VLP vaccine, 2 doses given 21 days apart
3321822|NCT02022163|Placebo Comparator|Placebo|Placebo, 2 doses given 21 days apart
3321823|NCT02022176|Active Comparator|Sodium nitrate|0.1 mmol NaNO3 / kg bodyweight / day for three days.
3321824|NCT02022176|Placebo Comparator|Sodium Chloride|0.1 mmol NaCl / kg bodyweight / day for three days.
3321825|NCT02022176|Active Comparator|Sodium nitrite infusion|Sodium nitrite (NaNO2) at a rate of 1, 10 and 100 nmol kg-1 min-1 (10 minutes per dose) was infused intravenously.
3321826|NCT02022176|Placebo Comparator|Saline infusion|Saline at a rate corresponding to 1, 10 and 100 nmol NaCl kg-1 min-1 (10 minutes per dose) was infused intravenously.
3321827|NCT02022189||Dent Disease patients|Patients with diagnosed Dent Disease
3321828|NCT02022215|Experimental|ME1111 Solution, Low strength|
3321829|NCT02022215|Experimental|ME1111 Solution, High strength|
3321830|NCT02022215|Placebo Comparator|Matching Vehicle Solution|
3321831|NCT02022228|Experimental|0.2mg triptorelin and 500 IU hCG|Patients were triggered with 0.2mg triptorelin and 500 IU hCG
3321832|NCT02022228|Experimental|0.2mg triptorelin and 1000 IU hCG|Patients were triggered with 0.2mg triptorelin and 1000 IU hCG
3321833|NCT02022241|Experimental|Repeated GnRHa|Patients were triggered with repeated GnRHa
3321834|NCT02022254|Experimental|Semaglutide administrations|
3321835|NCT02022267||study group|Patients with a minimum age of three years from our prospective, consecutive database of patients with clubfoot treated with the Ponseti method beginning in 2002 are considered for this study. Patients with unilateral or bilateral idiopathic clubfoot are included. Patients with clubfoot associated with syndromes or neurological diseases, with mild clubfoot that required fewer than three casts for initial correction, who first presented at an age older than three months, who were living outside of the country, and who were initially treated elsewhere with more than three casts are excluded.
3321836|NCT02022267||control group|healthy children of employees of our hospital
3321837|NCT02022280|Experimental|Proton Pump Inhibitor|Lansoprazole (Prevacid)
3321838|NCT02022280|Placebo Comparator|Vitamin pill|
3321839|NCT02022293|Active Comparator|Atorvastatin|Patients will take atorvastatin 20mg per night, totally 2 years.
3321840|NCT02022293|Placebo Comparator|Placebo|Patients will take placebo once per night for 2 years. The appearance and dosage of placebo will be the same as atorvastatin.
3321841|NCT02022306|Placebo Comparator|SAD TD-6450|Single ascending dose (Part A)
3321842|NCT02022306|Placebo Comparator|MAD TD-6450|Multiple ascending dose (Part B)
3321843|NCT02022306|Active Comparator|Food effect of TD-6450|Food effect will be assessed in Part A (SAD) of this study.
3321844|NCT02022319|Other|Shear Wave Elastography|All included patients undergo a supplementary Shear Wave Elastographic scan
3321845|NCT02022345|Active Comparator|PCI at pilot hospitals|Percutaneous Coronary Interventions performed at pilot hospitals which do not have onsite cardiac surgery.
3321846|NCT02022345|Active Comparator|PCI at non-pilot hospitals|Percutaneous Coronary Intervention performed at non-pilot hospitals which have onsite cardiac surgery or perform only primary PCIs for STEMI patients.
3228578|NCT01173107|Experimental|MDRD eGFR 10~50 ml/min/1.73m2|
3228579|NCT01173172|Experimental|BNCT, recurrent head and neck cancer|Single arm treated by BNCT only
3228580|NCT01173198|Active Comparator|WAVEFRONT GUIDED LASIK|
3228581|NCT01173198|Active Comparator|WAVEFRONT OPTIMIZED|
3228582|NCT01173224|Experimental|Cohort 2: 20 mg 10 days|Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg).
3321847|NCT02022358|Active Comparator|M|"Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy ."
3321848|NCT02022358|Experimental|GluM|"Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy"
3321849|NCT02022371|Experimental|Targeted biopsy|Snap frozen targeted biopsies of the prostate for genomic analysis
3321850|NCT02022384||study patients|Blood sample and life quality questionnaires
3321851|NCT02022397||difficult intubation|general population necessitating tracheal intubation for general anesthesia
3321852|NCT02022410||CAS after primary and revision TKA|CAS and RAPT
3228583|NCT01173224|Experimental|Cohort 3: 30 mg 1 day|Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
3228584|NCT01173224|Experimental|Cohort 1: 20 mg, 1 day|Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg).
3321857|NCT02022436|Active Comparator|contrast ultrasound for patients with AAA|Contrast ultrasound
3321858|NCT02022436|Active Comparator|contrast ultrasound for patients without arterial disease|contrast enhanced ultrasound
3228585|NCT01173237|Active Comparator|Tracheal intubation|Endotracheal tube is a airway device used for ventilation or surfactant administration, in preterm babies with SDR surfactant deficiency.
3228586|NCT01173237|Experimental|Proseal laryngeal mask airway|Laryngeal mask airway is a airway device used for ventilation with self-inflating bag or flow-inflating bag. In this study it will be used for surfactant administration, in preterm babies with SDR surfactant deficiency.
3228587|NCT01173250|Active Comparator|stapled ileoanal pouch without diverting ileostomy|
3321859|NCT02022449|No Intervention|Control|participants only complete assessments
3228588|NCT01173250|Placebo Comparator|stapled ileoanal pouch with diverting ileostomy|
3228589|NCT01173263|Active Comparator|BIS 70|BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
3228590|NCT01173263|Active Comparator|BIS 50|BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)
3321860|NCT02022449|Experimental|Stress management|Cognitive Behavioral Stress management Coping enhancement strategies Progressive muscle relaxation Guided imagery relaxation skills Deep breathing relaxation skills Social support
3321861|NCT02022462|Experimental|Health Navigation|Up to 151 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (6 month waitlist with treatment as usual) or immediate intervention with the Bridge. Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
3321862|NCT02022462|Other|Waitlist Control|Up to 146 participants with SMI in the El Camino clinic, operated by Pacific Clinics, will be recruited to participate in a 12 month study of Bridge navigation. Participants will be randomly assigned to either waitlist control (n = 73, 6 month waitlist with treatment as usual then they will receive the intervention) or immediate intervention with the Bridge (n = 73). Participants in the immediate treatment group will complete three assessments (baseline, 6 months, and 12 months) and, after 6 months, one interview about their health, healthcare, and navigation experiences. Participants in the waitlist control group will complete three assessments (baseline, 6 month, 12 months) and one interview about their health, health care, and their experiences using health navigation after 12 months.
3321863|NCT02022475|Active Comparator|Cholecalciferol|100 000 units vitamin D3 single dose
3321864|NCT02022475|Placebo Comparator|Placebo|similar appearance
3321865|NCT02022488|Active Comparator|midazolam and alfentanil|Midazolam 0.5mg/kg (oral) Alfentanil 10 microgram/kg (oral)
3321866|NCT02022488|Active Comparator|midazolam and ketamine|Midazolam 0.5mg/kg (oral) Ketamine 2mg/kg (intranasal)
3321867|NCT02022488|Placebo Comparator|midazolam|Midazolam 0.5mg/kg
3321868|NCT02022501|Experimental|Low Dose DE-120|Single 20 µL intravitreal injection of Low Dose DE-120 injectable solution
3321869|NCT02022501|Experimental|Medium Dose DE-120|Single 20 µL intravitreal injection of Medium Dose DE-120 injectable solution
3228591|NCT01173263|Active Comparator|BIS 35|BIS levels of 35 will be targeted (low frequency EEG activity)
3228592|NCT01173289|Experimental|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning :~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
3228593|NCT01173302|Experimental|Post vaccination|All the subjects had been vaccinated with antirabies vaccine.
3228594|NCT01173315|Experimental|Group MV|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg
3228595|NCT01173315|Experimental|Group MVB|Group MVB: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg)plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg)
3321870|NCT02022501|Experimental|High Dose DE-120|Single 20 µL intravitreal injection of High Dose DE-120 injectable solution
3321871|NCT02022514|Experimental|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
3321872|NCT02022514|Active Comparator|Conventional medical treatment|Conventional medical treatment
3321873|NCT02022527|Experimental|Combination|Warfarin tablets adjusted according to international normalized ratio (INR) (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and oral 75 mg Acetyl Salicylic Acid tablets daily long life.
3321874|NCT02022527|Active Comparator|Warfarin|Warfarin tablets adjusted according to INR (2 for Aortic Valve Replacement & 2.5-3 for Mitral Valve Replacement, 2.5-3.5 for Double Valve Replacement) and placebo long life.
3321875|NCT02022540|Experimental|Stage 1 - Group 1|Patients randomized to Group 1 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3321876|NCT02022540|Experimental|Stage 1 - Group 2|Patients randomized to Group 2 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3321877|NCT02022540|Experimental|Stage 1- Group 3|Patients randomized to Group 3 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3321878|NCT02022540|Experimental|Stage 1- Group 4|Patients randomized to Group 4 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3321879|NCT02022540|Experimental|Stage 1 - Group 5|Patients randomized to Group 5 will receive PAN-90806 Ophthalmic Solution daily for 8 weeks.
3321880|NCT02022540|Experimental|Stage 2|Patients enrolled in Stage 2 will receive an intravitreal injection of ranibizumab and then 7-9 days later begin daily dosing with PAN-90806 Ophthalmic Solution for 12 weeks
3228596|NCT01173315|Placebo Comparator|Group P|Group P: starch (placebo
3228597|NCT01173328|Experimental|Pursed-lip Breathing|
3321881|NCT02022553|Experimental|rectal cancer, surgery|
3321882|NCT02022553|Active Comparator|rectal cancer, RACHEL, surgery|
3321883|NCT02022566||Supported self-management of osteoarthrits program|
3321884|NCT02022579|Experimental|DCE-MRI and DWI|Single arm study, diagnosis defined as BIRADS 3, 4, or 5 lesion(s) based on DCE-MRI only with DWI collected in tandem as standard practice.
3321885|NCT02022592|Experimental|Lormetazepam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Sedalam®).
3321886|NCT02022592|Active Comparator|Midazolam|The patient is treated on ICU not longer than 2 days. Dosage requirements according to Summary of product characteristics (Midazolam-ratiopharm®, Midazolam-hameln®).
3321887|NCT02022605|Experimental|Hands-on EMS training group|
3321888|NCT02022605|Active Comparator|Standard training group|
3321891|NCT02022644|Experimental|Group 1 - 20 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 20 mg/ml, Infusion time: 6-24 hours, no more than 48
3321892|NCT02022644|Experimental|Group 2 - 40 mg|Tumor diameter: 2 cm,Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321893|NCT02022644|Experimental|Group 3 - 140 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 140 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321894|NCT02022644|Experimental|Group 4 - 340 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 340 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321895|NCT02022644|Experimental|Group 5 - 40 mg|Tumor diameter: 1 cm, Tumor volume: ~0.5cm3, Infusion Volume: 2-3 ml, Irinotecan conc.: 40 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321896|NCT02022644|Experimental|Group 6 - 80 mg|Tumor diameter: 2 cm, Tumor volume: ~4.1cm3, Infusion Volume: 3-4 ml, Irinotecan conc.: 80 mg/ml, Infusion Time: 6-24 hours, no more than 48
3228598|NCT01173341||Subgroup 2|Subgroup2 represents will undergo trastuzumab therapy only
3228599|NCT01173341||Subgroup 1|Subgroup 1 are anthracycline only treated patients.
3228600|NCT01173341||Subgroup 3|Subgroup 3 are patients that will undergo trastuzumab therapy with anthracyclines.
3228601|NCT01173354|Experimental|COPD patients only|Free balanced amino acid mixture or free essential amino acid mixture
3228602|NCT01173367|Active Comparator|Aggressive Fever Treatment|
3321897|NCT02022644|Experimental|Group 7 - 280 mg|Tumor diameter: 3 cm, Tumor volume: ~14cm3, Infusion Volume: 6-7 ml, Irinotecan conc.: 280 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321898|NCT02022644|Experimental|Group 8 - 680 mg|Tumor diameter: 4 cm, Tumor volume: ~34cm3, Infusion Volume: ≤17 ml, Irinotecan conc.: 680 mg/ml, Infusion Time: 6-24 hours, no more than 48
3321899|NCT02022683|Experimental|Endoscopic Lung Volume Reduction|Patients are implanted with Zephyr Valves
3321900|NCT02022683|No Intervention|Standard of Care|Patients are given Standard Medical Care
3321901|NCT02022709|Active Comparator|Selective Serotonin Reuptake Inhibitor|In this group,routine treatment strategies will be used for patients. Any one of the SSRIs including fluoxetine, citalopram, paroxetine, sertraline, fluvoxamine ,which are approved in the treatment of OCD by SFDA, may be used for patients who are randomized to this treatment arm. The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
3321902|NCT02022709|Active Comparator|Exposure and Response Prevention|Exposure and Response Prevention Structured protocol described by Foa et al., 2012 Patients will attend eight 1-h sessions,once a week. Benzodiazepine will be used when necessary.
3321903|NCT02022722|Active Comparator|Pelvic Rehabilitation|Pelvic Rehabilitation will be conduction on weekly basis for a total of 6 weeks
3321904|NCT02022722|Active Comparator|Trigger Point Injections|Trigger point injections will be administered on weekly basis for a total of 6 weeks
3321905|NCT02022761|Experimental|40 mg Laninamivir octanoate|Dry Powder Inhaler
3321906|NCT02022761|Experimental|80 mg Laninamivir octanoate|Dry Powder Inhaler
3321907|NCT02022761|Placebo Comparator|Matching placebo|Dry Powder Inhaler
3321908|NCT02022787||Renal cell carcinoma|Patients with renal cell carcinoma scheduled for partial or radical nephrectomy
3321909|NCT02022800|Other|PET 18FDOPA|PET 18FDOPA
3321910|NCT02022813|No Intervention|Enteral nutrition only|Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
3321911|NCT02022813|Experimental|Supplemental parenteral nutrition|"Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.~Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4."
3228603|NCT01173367|Active Comparator|Permissive Fever Treatment|
3228604|NCT01173380|Sham Comparator|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
3228605|NCT01173380|Active Comparator|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
3321912|NCT02022852|Active Comparator|Concurrent chemoradiotherapy|Capecitabine neoadjuvant concurrent radiochemotherapy and XELOX adjuvant therapy
3321913|NCT02022852|Experimental|Sequential therapy|XELOX/capecitabine/XELOX neoadjuvant chemo-chemoradio-chemo sequential therapy and XELOX adjuvant therapy
3321914|NCT02022865||periodontitis patients|according to american academy of periodontology classification of periodontal diagnosis.
3321915|NCT02022865||healthy periodontium|according to american academy of periodontology classification of periodontal diagnosis.
3321916|NCT02022878||Attempted PCI of CTO|Attempted PCI of CTO with preprocedural coronary CTA scan
3321917|NCT02022891||systematic psychological care|Systematic psychological treatment plan added to medical care for children with SCD. Bio-psychosocial paradigm applied at pediatric consultations.
3321918|NCT02022891||Control|medical care only at routine pediatric consultations for SCD. Psychological support provided only when the pediatrician consider it appropriate.
3321919|NCT02022904|Experimental|Metastatic prostate cancer|Near infrared (NIR) emissive nanotechnology
3321920|NCT02022917|Experimental|Epithelial Ovarian Cancer|Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab 21 day cycles of carboplatin, paclitaxel, and bevacizumab
3321921|NCT02022930|Experimental|Hydros|Hydros Joint Therapy
3321922|NCT02022930|Experimental|Hydros-TA|Hydros-TA Joint Therapy
3321923|NCT02022930|Active Comparator|Triamcinolone acetonide|Triamcinolone acetonide
3321924|NCT02022956|Experimental|Open-Label Lorcaserin (BELVIQ)|
3321925|NCT02022982|Experimental|Palbociclib and PD-0325901|"Palbociclib by mouth once a day, every day for 3 weeks every 4 in each cycle.~PD-0325901 by mouth twice a day, every day for 3 weeks every 4 in each cycle. ."
3321926|NCT02022995||Patients with cetuximab treatment|Patients with cetuximab treatment
3321927|NCT02022995||Patients without cetuximab treatment|Patients without cetuximab treatment
3321928|NCT02023008|Experimental|Supportive care (internet-based integral yoga intervention)|Participants undergo 12 sessions of cancer-adapted integral yoga classes using an internet-based videoconferencing platform. Integral yoga includes postures, deep relaxation, breathing practices and meditation to create a profound experience of peace and well-being. Participants take part in study classes from home (or other location that is convenient for the participant and that allows them to access the internet-based classes) with two-way interaction with group instructors and members alike over 75 minutes twice weekly for 6 weeks during radiation therapy. Participants are encouraged to complete additional yoga practice sessions outside of the twice weekly study sessions.
3321929|NCT02023021|Experimental|nab-paclitaxel + gemcitabine|nab-paclitaxel at 100 mg/m^2 on days 1, 8, and 15; gemcitabine at 1000 mg/m^2 on days 1, 8, and 15
3321930|NCT02023034|Experimental|Virtual exercises|"All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers, the period instrument used was the video game with the Nintendo ® Wii Balance Board ® platform."
3321931|NCT02023034|Sham Comparator|Control|"Traditional exercises. All patients underwent 12 sessions, twice a week for a period of 06 weeks. The exercises were performed in the on dopaminergic medication, supervised by the researchers."
3321932|NCT02023047|Experimental|Once daily|Nifedipine 12 mg Once daily
3228606|NCT01173393|No Intervention|Standard Treatment|"For patients randomised to hospital cooling:~LMA/ Intubation and ventilation with 100% oxygen~Measure temperature using tympanic probe and record~Insert IV line and administer drugs as per protocol~Fluid challenge with standard temperature saline only as per current guideline (suspected hypovolemia)~Post resuscitation: midazolam 1-5 mg only to maintain LMA/ intubation as needed.~Pancuronium 8 mg only if intubation unable to be maintained with midazolam.~After arrival at the Emergency Department, all patients receive standard care."
3228607|NCT01173406|Sham Comparator|Standard care (SC)|Standard care
3228608|NCT01173406|Active Comparator|Extended education (ME+SC)|Motivational enhancement education + Standard care
3228609|NCT01173419|Active Comparator|VenaCure EVLT NeverTouch|
3228610|NCT01173419|Active Comparator|RF ClosureFAST|
3228611|NCT01173432|Active Comparator|continuous positive airway pressure|using continuous positive airway pressure (CPAP) device during sleep, for the study period (4 weeks)
3321933|NCT02023047|Experimental|Twice Daily|Nifedipine 12 mg twice daily
3321934|NCT02023073||Healthy volunteers|
3321935|NCT02023086||FABRY group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~OSOME (oxygen flow at the optic nerve head measurement)~Tropicamide"
3321936|NCT02023086||CONTROL group|"contrast sensitivity measurement~slit lamp assessment and intra-ocular pressure measurement~ocular coherence tomography at the optic nerve head~visual field testing~oxygen flow at the optic nerve head measurement (OSOME)~Under tropicamide"
3321937|NCT02023138|Active Comparator|Focus group|
3321938|NCT02023138|Experimental|Wiki|
3228612|NCT01173432|No Intervention|control|observation for the study period (4 weeks, no CPAP)
3321939|NCT02023164|Experimental|Test Drug|10 mg/mL, 1 mL
3321940|NCT02023164|Active Comparator|Control|50 mg/mL, 1 mL
3321941|NCT02023177||Phase angle|Phase angle obtained from bioelectrical impedance
3228613|NCT01173458||Blood Draw|"Approximately 1 and one-half teaspoons of blood will be drawn at times specified.~one sample prior to treatment initiation~one sample after completion of treatment~one sample every 6 to 8 weeks during follow up visits~one sample at the time of Relapse"
3228614|NCT01173484||Vomiting-predominant idiopathic gastroparesis|Vomiting with retching and nausea are the most bothersome symptoms
3321942|NCT02023190||Nutritional assessment|Nutritional assessment will be performed by bioelectrical impedance vector analysis
3228615|NCT01173484||Dyspepsia-predominant idiopathic gastroparesis|Unpleasant or troublesome sensation (discomfort or pain) centered in the upper abdomen is the most bothersome symptom; this sensation may be characterized by or associated with upper abdominal fullness, fullness after small meals, bloating, or nausea
3228616|NCT01173484||Regurgitation-predominant idiopathic gastroparesis|Effortless regurgitation of acid or undigested food or heartburn is the most bothersome symptom
3228617|NCT01173497|Experimental|INIPARIB, irinotecan|
3321943|NCT02023203|Experimental|LP PTFE|Placement of Large Pore PTFE mesh for inguinal hernia treatment
3228618|NCT01173510|Experimental|Raltegravir plus tenofovir/emtricitabine|
3321944|NCT02023203|Active Comparator|SP-PPL|Placement of Small Pore polypropylene mesh for inguinal hernia treatment
3228619|NCT01173510|Active Comparator|Efavirenz/Emtricitabine/Tenofovir|
3228620|NCT01173536|Active Comparator|A|
3228621|NCT01173536|Active Comparator|B|
3228622|NCT01173536|Experimental|C|
3321945|NCT02023229|Experimental|Diet plus branched chain aminoacids|High-fiber high-protein diet Oral supplement : branched chain aminoacids
3321946|NCT02023229|Active Comparator|Diet|High-fiber high-protein diet
3321947|NCT02023255|Experimental|Part A: Cohort 1|8 participants will be included in this cohort. 6 participants will receive a single dose of 50 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3321948|NCT02023255|Experimental|Part A: Cohort 2|8 participants will be included in this cohort. 6 participants will receive a single dose of 150 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3321949|NCT02023255|Experimental|Part A: Cohort 3|8 participants will be included in this cohort. 6 participants will receive a single dose of 450 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3321950|NCT02023255|Experimental|Part A: Cohort 4|8 participants will be included in this cohort. 6 participants will receive a single dose of 1,350 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3321951|NCT02023255|Experimental|Part A: Cohort 5|8 participants will be included in this cohort. 6 participants will receive a single dose of 2,700 mg JNJ-39393406 and 2 participants will receive placebo for 7 consecutive days.
3321952|NCT02023255|Experimental|Part B: Cohort A|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the pharmacokinetic (PK) data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3321953|NCT02023255|Experimental|Part B: Cohort B|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3321954|NCT02023255|Experimental|Part B: Cohort C|16 participants will be included in this cohort. 12 participants will receive a single dose of JNJ-39393406 selected based on the PK data from Part A of the study and 4 participants will receive placebo for 13 consecutive days.
3321955|NCT02023281|No Intervention|Control Group|Control group will serve as a wait list and not be exposed to the intervention.
3321956|NCT02023281|Experimental|Experimental Group|The experimental group will engage in a mild-moderate level of structured and clinically supervised exercise program for approx. 30-45 mins 2-3 days per week for 12 weeks
3321957|NCT02023294|Active Comparator|Lap|Patients candidate to bariatric surgery undergoing Conventional laparoscopic Sleeve Gastrectomy
3321958|NCT02023294|Experimental|SILS|Patients candidate to bariatric surgery undergoing Single Incision Laparoscopic Sleeve Gastrectomy supported by Endograb
3321959|NCT02023307|Experimental|Rhytidectomy with Covidien|25 patients receiving a mid-face lift in short-flap rhytidectomy
3321960|NCT02023320|Experimental|Low dose of blueberry dry powder|0.5 g blueberry dry powder, twice a day for 12 weeks
3228623|NCT01173549|Experimental|001|no intervention Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
3228624|NCT01173549|Experimental|002|Canagliflozin/Placebo Placebo/Canagliflozin Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
3228625|NCT01173562|Experimental|Mebendazole|
3228626|NCT01173575||Bacterial Infection|All Patients with bacterial infection receiving fosfomycin may be included
3228627|NCT01173588|Experimental|Yogurt+fiber+probiotic|Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
3228628|NCT01173588|Placebo Comparator|regular yogurt|yogurt YR had no additional fiber or bifidobacterium
3228629|NCT01173614||Normal subjects|Subjects with two normal eyes.
3228630|NCT01173627|Experimental|A - Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche
3321961|NCT02023320|Experimental|High dose of blueberry dry powder|5.0 g blueberry dry powder, twice a day for 12 weeks
3321962|NCT02023333|Experimental|Regorafenib|This is an open-label, phase II study of regorafenib for patients with metastatic colorectal carcinoma. The treatment will be repeated every week for three weeks on and one week off. Patients will be evaluated for response after every 2 cycles (8 weeks).
3321963|NCT02023346||Malignant Glioma patients|This is a cross-sectional study of patients with MG who are admitted to the inpatient Neurology service at MSKCC. We anticipate that participants will be accrued over approximately 18-24 months. All patients with MG admitted to Neurology, will be screened for eligibility and willingness to participate in the study.
3228631|NCT01173627|Active Comparator|B - Actiq 400 mcg|Actiq 400 mcg
3228632|NCT01173640|Experimental|Midazolam Alone|Baseline pharmacokinetics. On Study Visit Day 1, subjects will receive a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3228633|NCT01173640|Experimental|Single dose resveratrol|On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3228634|NCT01173640|Experimental|Multiple dose resveratrol|Between Study Visit Days 8 and 15, subjects will take a 1 g dose of resveratrol daily. On Study Visit Day 15, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
3228635|NCT01173666|Placebo Comparator|Drug therapy|Patients will be treated by standard medical therapy.
3228636|NCT01173666|Experimental|Drug therapy + stenting angioplasty|Patients will be treated by standard medical therapy + stenting angioplasty of renal artery.
3228637|NCT01173705||Normal weight: abdominal surgery|Lean individuals undergoing elective abdominal surgery
3321964|NCT02023359||Treatment|Everolimus and exemestane
3321965|NCT02023372|Other|NuCel with Autograft|NuCel will be used with local autograft during surgical treatment of one, two or three level degenerative disease of the lumbar spine
3321966|NCT02023385|Experimental|LLLT group|Subjects in the Low Level Laser Therapy (LLLT) group will be treated with the BTL-9000 LLLT
3228638|NCT01173705||Obese: abdominal or bariatic surgery|Obese subjects undergoing elective abdominal or bariatric surgery
3228639|NCT01173731|Experimental|AFQ056|
3228640|NCT01173744|Experimental|Gamma-3 Nail|
3228641|NCT01173744|Active Comparator|DHS|
3228642|NCT01173757|Experimental|PF-04995274|
3228643|NCT01173770|Experimental|Cohort 1: ADC3680B vs. Placebo|
3228644|NCT01173770|Experimental|Cohort 2: ADC3680B vs. Placebo|
3228645|NCT01173770|Experimental|Cohort 3: ADC3680B vs Placebo|
3228646|NCT01173770|Experimental|Cohort 4: ADC3680B vs. Placebo|
3228647|NCT01173770|Experimental|Cohort 5: ADC3680B vs. Placebo|
3228648|NCT01173770|Experimental|Cohort 6: ADC3680B|
3228649|NCT01173796|Experimental|PMFL ablation|Radio-frequency catheter ablation of the mitral isthmus only
3228650|NCT01173796|Experimental|Repeat PVAI and triggers ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
3321967|NCT02023385|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 LLLT
3321968|NCT02023398|Experimental|HFT group|Subjects in the High Frequency Therapy (HFT) group will be treated with the BTL-9000 HFT
3321969|NCT02023398|Placebo Comparator|Placebo group|Subjects in the Placebo group with be treated with the sham BTL-9000 HFT
3321970|NCT02023424|Experimental|Copaxone|Glatiramer Acetate (Copaxone® , Teva Pharmaceutical Industries Ltd.) 20 mg daily or in an interval determined in the Dose Setting period. Administration will be subcutaneous to various areas on the body: back of the upper arms (2 areas), front and outside of thighs (2 areas), upper buttocks/rear hips (2 areas), and stomach (the abdomen).
3321971|NCT02023437|Experimental|Experimental: Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
3321972|NCT02023437|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
3321973|NCT02023450|Experimental|micro/low dose saquinavir and ritonavir|To determine if micro dose and low dose SQV+RIT mediates parameters of chronic inflammation in patients with IPAH.
3321974|NCT02023450|Experimental|standard dose saquinavir and ritonavir|To determine if short-term use of SQV+RIT reduces parameters of chronic inflammation and PA pressure of IPAH based on echocardiographic parameters. Safety issue also evaluated at the same time.
3321975|NCT02023463|Experimental|Treatment (enzalutamide, radiation therapy, hormone therapy)|Patients receive enzalutamide PO QD for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate SC or leuprolide acetate IM or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH therapy, patients undergo either IMRT or VMAT daily five days a week for 8 weeks.
3228651|NCT01173809|Active Comparator|Control|Patient will continue taking Amiodarone before, during and after catheter ablation (8 weeks post-ablation).
3228652|NCT01173809|Active Comparator|Study|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
3321976|NCT02023476|Experimental|wide tourniquet|(Zimmer A.T.S.®3000 ) wide tourniquet MRI intervention
3321977|NCT02023476|Active Comparator|narrow tourniquet|HemaClear ™ tourniquet MRI intervention
3321978|NCT02023489|Other|Type 2 Diabetes Mellitus|
3321979|NCT02023489|Other|Insulin sensitive volunteers|
3321980|NCT02023489|Other|prediabetic subjects|
3321981|NCT02023489|Other|familiar hypocalciuric hypercalcemic patients|
3321982|NCT02023489|Other|Type 1 diabetes mellitus|
3321983|NCT02023502||stress urinary incontinence|Patients presenting with stress urinary incontinence according to the inclusion and exclusion criteria
3321984|NCT02023502||healthy controls|healthy women with the same inclusion and exclusion criteria as the case group, except for stress urinary incontinence
3321985|NCT02023541|Other|Resectable disease|Patients with resectable disease will undergo treatment with proton beam therapy.
3321986|NCT02023541|Other|Unresectable disease|Patients with unresectable disease will undergo treatment with proton beam therapy.
3321987|NCT02023554|Experimental|Theophylline with azithromycin|steady-state plasma concentration of theophylline in the presence of azithromycin
3321988|NCT02023554|Active Comparator|Theophylline alone|steady-state plasma concentration of theophylline alone
3321989|NCT02023567|Experimental|MDD group|Drugs: SSRIs fluoxertine hydrochloride (20- 60m/day),paroxetine hydrochloride (20- 60m/day),sertraline hydrochloride (50- 200m/day),citalopram (20-60m/day), escitalopram (10-20mg/day),fluvoxamine (50-300mg/day)
3321990|NCT02023567|No Intervention|Healthy controls|This group just receive baseline evaluation and did not receive any intervention.
3321991|NCT02023580|Experimental|Intervention|The Video Treatment arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. Between baseline and 3-month follow-up, men will view 6 video vignettes (participants will receive a link to view a video vignette once a week for 6 weeks). Based on our team's experience of attenuated intervention effects at 6 months, men will receive 4 video boosters, spaced 1 week apart, after the 6-month assessment survey. Spacing the dose over time can improve critical thinking. The additional videos will be a continuation of the dramatic series plus additional video scenes on disclosure and serodiscordant partnerships.
3321992|NCT02023580|Active Comparator|Control|The video control arm will complete baseline, 3-, 6-, 9-, and 12-month online survey assessments. The control arm will receive the same number (and timing of) video clips as the intervention arm, but from a non-theoretically driven gay-oriented show with videos that are similar in length in order to preserve dosing equality across both arms. As the video treatment arm will be provided efficacious theory-driven videos, investigators expect to find a significant decrease in sexual risk behaviors in the intervention arm, compared to the control arm. Should this occur by month 6, with agreement from the data safety monitoring board (DSMB), investigators will provide the control arm with the video treatments.
3321993|NCT02023593|Experimental|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
3321994|NCT02023606|Experimental|SPN-810M|Single dose of 20 mL solution containing 50 mg of SPN-810M and no less than 8.5 MBq (225 µCi) carbon-14 (14C)-SPN-810M, and no more than 11.3 MBq (305 µCi) [14C] SPN-810M.
3321995|NCT02023619||Keratoconus|Eyes with confirmed keratoconus diagnosis
3321996|NCT02023619||Astigmatism >2.0 D|Healthy eyes with astigmatism >2.0 D
3321997|NCT02023632|Experimental|Similar-Age-Same-Gender (SASG)|Participants in this trial arm will be of similar age (65+) and of the same gender (i.e., separate groups for male older adults and female older adults).
3321998|NCT02023632|Active Comparator|Similar-Age-Mixed-Gender (SAMG)|This group will include participants of both genders who are similar aged (65+).
3321999|NCT02023632|Sham Comparator|Mixed-Age-Mixed-Gender (MASG)|This group is used as the 'standard' group based exercise course; including those of mixed age and mixed gender.
3322000|NCT02023645|Experimental|Active supplement|10 mg lutein + 2 mg zeaxanthin
3228653|NCT01173822|Experimental|Treatment group|Ultra filtration of residual blood.
3322001|NCT02023645|Placebo Comparator|inert placebo|placebo for comparison
3322002|NCT02023658|Experimental|Systems analysis and improvement|pMTCT systems analysis and improvement
3322003|NCT02023658|No Intervention|Control|No systems analysis and improvement intervention for prevention of mother to child HIV transmission services in place.
3322004|NCT02023684|Placebo Comparator|control|Irrigation will be carried out with saline
3322005|NCT02023684|Active Comparator|Lidocaine|Irrigation will be carried out with Lidocaine
3322006|NCT02023684|Active Comparator|Ropivacaine|Irrigation will be carried out with Ropivacaine
3322007|NCT02023710|Experimental|BEV plus Chemotherapy|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; Bevacizumab 5mg/kg, d1、15; 28 days a cycle
3322008|NCT02023710|Active Comparator|Chemotherapy alone|Paclitaxel 175mg/m2, d1; Carboplatin AUC=5, d1; 28 days a cycle
3322009|NCT02023723|Experimental|Energy Drink|16oz original flavor energy drink consume 2 -16oz energy drinks within 60 minutes
3322010|NCT02023723|Active Comparator|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
3322011|NCT02023736|Active Comparator|Treatment as Usual|Patients in the Treatment as Usual condition receive the same psychotherapy treatment as they would were they not enrolled in the study.
3322012|NCT02023736|Experimental|Treatment as Usual with the STIC (TAU + STIC)|Patients in the TAU + STIC condition receive the treatment that they normally would from their therapist, but with the addition of the STIC measurement and feedback system.
3322013|NCT02023749|Active Comparator|Nut group|Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
3322014|NCT02023749|No Intervention|Control group|Control group maintained their usual diet without nut supplement
3228654|NCT01173822|No Intervention|Control|The current practice in our institution was to displace all the remaining volume in the CPB circuit into a transfer pack by displacing the remaining blood in the CPB circuit with additional Lactated Ringers solution. This transfer pack is then given to the anesthetist for reinfusion into the patient.
3228655|NCT01173861|Experimental|Physical activity counseling|Group receives face-to-face physical activity counseling.
3228656|NCT01173861|Active Comparator|Manual|Group receives physical activity manual.
3228657|NCT01173887|Active Comparator|mLSG15|
3228658|NCT01173887|Experimental|mLSG15 + KW-0761|
3228659|NCT01173900|Other|Class-based delivery|All girls attending standard 6 in schools selected for class-based vaccine delivery
3228660|NCT01173900|Other|Age-based delivery|All girls born in 1998 attending schools selected for age-based delivery
3228661|NCT01173913|Experimental|ModraDoc001 10 mg capsules|The optimal dose weekly bi-daily oral docetaxel - ModraDoc001 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
3228662|NCT01173913|Experimental|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|Both new oral dosage forms, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets will be investigated to see whether these new formulations have comparable pharmacokinetic characteristics, in terms of systemic exposure to docetaxel, as ModraDoc001 10 mg capsule.
3228663|NCT01173913|Experimental|ModraDoc006 10 mg tablet|The optimal dose weekly bi-daily oral docetaxel - ModraDoc006 10 mg in combination with ritonavir will be determined with a classical dose escalation design. Approximately 24 patients will be enrolled depending on required number of dose levels before MTD is reached.
3228664|NCT01173926|Experimental|IAsp|
3322015|NCT02023775||Patients implanted with Medtronic Melody valve|All patients that received a valve implantation were included in the registry.
3322016|NCT02023788||Pneumostem®|"Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg~Intervention: Biological: Pneumostem®"
3228665|NCT01173926|Experimental|IDeg|
3322017|NCT02023814||Study group|All patients who underwent stem cell mobilization after chemotherapy and G-CSF at our institution between 2002 and 2013
3322018|NCT02023827|Experimental|RAYS intervention|In addition to standard care, participants receive three monthly online RAYS sessions, each followed by a one-on-one discussion with the probation officer
3322019|NCT02023827|No Intervention|Standard care|Participants receive standard care from the probation officer
3322020|NCT02023840|Active Comparator|ultrasonics and erythritol, metronidazole gel|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of metronidazole gel
3322021|NCT02023840|Placebo Comparator|ultrasonics and erythritol, placebo|Scaling and root planing with ultrasonics and erythritol air powder will be followed by application of placebo
3322022|NCT02023853|Experimental|ultrasonic, erythritol, metronidazole gel|
3322023|NCT02023892|Experimental|atorvastatin|atorvastatin 20mg tablet, single dose of 80mg by mouth
3322024|NCT02023892|Placebo Comparator|placebo|placebo 20mg tablet, single dose of 80mg by mouth
3322025|NCT02023931|Experimental|Broccoli Sprout Extract Drink|Three different regimens of BSE delivery will be evaluated in each participant, with participants serving as their own controls. Each regimen will involve a 3 day exposure, with daily collection of buccal cell scrapings. Between regimens, a minimum 3 day (72 hour) washout period will occur.
3322026|NCT02023957|Experimental|Interactive computer-assisted screening|Eligible patients completed the interactive computer-assisted screening (iCAS) tool in English or Spanish before seeing the consenting clinician. Participating patients then received the iCAS generated tailored recommendation sheet. Participating clinicians received the iCAS generated risk report.
3322027|NCT02023957|No Intervention|Usual Care|Eligible patients randomized to the control group completed their standard visit to the participating clinician. There was no pre-visit health risk screening. There were no tailored reports for the patients or clinicians.
3322028|NCT02023970|Other|Phase A: Diagnostic Study|Objective: to assess the differential immune response in patients with or without SVD (given the low rate of SVD) a matched cases-controls study allows a powerful statistical analysis avoiding main confounding factors for a first discovery of a SVD-specific immune response. Results will be validated in prospective Phase B.
3322029|NCT02023970|Other|Phase B1 (Prospective Study): Cohort of prevalent patients|This cohort is specifically designed to study the kinetics of the immune response before and after implantation of an aortic BHV. Eight of the most frequently implanted BHV worldwide will be assessed:
3322030|NCT02023970|Other|Phase B2 (Prospective Study): Cohort of incident patients|Due to the low incidence of SVD during the first 4 post-operative years, a second cohort will be constituted by patients undergone biological aortic valve replacement at least 5 years before. The objective of this second cohort is to cover a period of time where risk of SVD occurrence is potentially high.
3322032|NCT02024009|Experimental|Arm A|"12 weeks (3 cycles) of induction Gemcitabine and Nab-paclitaxel (GEMABX) chemotherapy then 1 cycle of GEMABX* whilst radiotherapy (RT) planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 50.4 Grays (Gy) in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3228666|NCT01173926|Experimental|IDegAsp|
3322033|NCT02024009|Experimental|Arm B|"12 weeks (3 cycles) of induction GEMABX chemotherapy then 1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 50.4Gy in 28#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3322034|NCT02024009|Experimental|Arm C|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + Nelfinavir** + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15"
3322035|NCT02024009|Experimental|Arm D|"12 weeks (3 cycles) of induction GEMABX chemotherapy then~1 cycle of GEMABX* whilst RT planned then capecitabine (830mg/m2 oral bd) + 60Gy in 30#~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3322036|NCT02024009|Experimental|Arm E|"6 cycles of GEMABX*~*1 cycle GEMABX = 28 day cycle of intravenous Abraxane 125mg/m2 followed by gemcitabine 1000mg/m2 on day 1, 8 and 15."
3228667|NCT01173939|Active Comparator|Active comparator: Standard Pravastatin Group|
3228668|NCT01173939|Active Comparator|Intensive Rosuvastatin Group|
3228669|NCT01173965|Active Comparator|Endometrial ablation with microwaves|Endometrial ablation with the use of MEA(microwaves endometrial ablation device)
3322037|NCT02024022|Active Comparator|Standard approach|"patients will be randomized to one of the 2 currently used bowel preparation regimens in our clinic:~4L split polyethylene glycol solution~split magnesium citrate/sodium picosulphate preparation regimen"
3322038|NCT02024022|Experimental|Individualized approach|patients will receive either the 4L split polyethylene glycol bowel prep regimen or the sodium picosulphate/magnesium citrate split prep regimen according to personal characteristics assessed using a self-administered questionnaire (including bowel habits, the preference for large-volume preparation and education level)
3322039|NCT02024035||Tomotherapy|
3322040|NCT02024035||Arc'therapy Vmat|
3322041|NCT02024035||Arctherapy Rapid'Arc|
3322042|NCT02024048||Pregnant|OCT
3322043|NCT02024048||Control|OCT
3322044|NCT02024061|Experimental|Peer support|"The intervention will be similar with the exception that in the experimental group during the interventions (Interactive Sessions, Physical activity sessions and holiday camps), the presence of peers is predominant, indispensable and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
3322045|NCT02024061|Active Comparator|Regular treatment|"The intervention will be similar with the exception that in the experimental group during the interventions (IS, PA sessions and holiday camps), the presence of peers is predominant, indispensible and motivational in the context and the dynamics of development of activities.~A team composed by a paediatrician and five exercise physiologists will conduct the delivery of the intervention. They all have previous training in adolescent obesity, resulting from their involvement in the adolescent obesity consult at the Hospital of Santa Maria."
3322046|NCT02024074|Other|Sestamibi(Tc- MBI) scan of the breast|
3322047|NCT02024113||Lung cancer|"Subjects with lung cancer detected by a computed tomography (CT)-scan and referred to a positron emission tomography (PET)/CT-scan are included. The diagnosis of lung cancer is confirmed by means of an pathological biopsy or by a medical doctor specialized in oncology with respect to radiological or clinical data.~Intervention: a fasted venous blood sample is taken before PET-scan"
3322048|NCT02024113||Control subjects|"The control group consists of subjects who were referred to the department Nuclear Medicine for an examination of the heart. This control group represents the average population, consists of healthy subjects and patients with non-cancer diseases and who did not undergo a PET/CT-scan.~Intervention: fasted venous blood sample"
3322049|NCT02024126|Experimental|High dosage exercise therapy|The high-dosage exercise treatment will be conducted under supervision of experienced physiotherapists, and it follows an exercise protocol previously described as Medical Exercise Therapy, MET. The regimen contains different semi-global and local exercises for the knee. To be able to reach a high number of repetitions despite ongoing pain, the principle of de-loading (reducing weight) will be applied. The use of de-loading allows high number of repetitions nearly or entirely pain free. Later, as the patient improves and tolerates increased loading, the exercises are adapted to be more functional, using closed chain exercises without de-loading the body. Each of the exercises will be performed in 3 sets of 30 repetitions with 30-60s rest in between. Global exercises using a stationary bike will be performed three times during one treatment-session; first 20 minutes as global pain modulation, ten minutes in the middle of the treatment, and then ten minutes at the end of the treatment.
3228670|NCT01173965|Active Comparator|Endometrial ablation with bipolar diathermy|Endometrial ablation with Novasure(bipolar impedence control system)
3228671|NCT01173978|Experimental|No intervention|Each participant is examined during a normal, active lifestyle, without any intervention: The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
3228672|NCT01173978|Experimental|Intervention|Each participant is examined during a 12 days intervention.The examinations include an OGTT, a glucagon test, three hyperglycemic clamps with infusion of a)GLP-1; b)GIP; c)Nacl
3228673|NCT01173991|Experimental|Carbohydrate counting|This group received carbohydrate counting training
3228674|NCT01173991|No Intervention|Controls|This group received standard education
3228675|NCT01174017|Active Comparator|Standard loose Iodine 125 seeds|Prostate brachytherapy implant to be performed with standard format loose Iodine 125 seeds
3228676|NCT01174017|Experimental|AnchorSeed Iodine 125 implant|Prostate brachytherapy implant to be performed with a new design of Iodine 125 seed that has a coating to increase adherence to tissue
3228677|NCT01174056|Experimental|Pioglitazone+zileuton placebo|Pioglitazone 45 mg qD for 2 weeks plus Sugar pill q6hr for 5 days
3228678|NCT01174056|Experimental|Zileuton+pioglitazone placebo|Sugar pill qD for 2 weeks plus Zileuton 600 mg q6hr for 5 days
3228679|NCT01174056|Sham Comparator|Pioglitazone placebo+zileuton placebo|Sugar pill qD for 2 weeks plus Sugar pill q6hr for 5 days
3322050|NCT02024126|Active Comparator|Lower dosage exercise therapy|Patients in the comparison-/control group will perform six exercises, of which, five will be in 2 sets of 10 repetitions combining local and semi-global exercises, again using the principle of de-loading. The five semi-global and local exercises are the same as performed in the MET-group, and the regimen will be supervised in the same manner as for the MET-group. The therapy starts with 10 minutes using a stationary bike, and the same principles will be applied as for the MET-group regarding grading and follow-up with exercises and adjusting the exercises so that they are performed close to pain-free.
3322051|NCT02024139|Experimental|Chewing Sugarless Gum and Mouthwash|Patients are asked to chew sugarless gum 3 times per day in addition to using a fluoridated mouthwash 3 times per day
3322052|NCT02024139|Placebo Comparator|Using fluoridated mouthwash|Using Mouthwash: Patients are asked to use a fluoridated mouthwash 3 times per day as a placebo
3322053|NCT02024152|Experimental|JDP-205 IV high dose|
3322054|NCT02024152|Experimental|JDP-205 IV low dose|
3228680|NCT01174069|Experimental|NOTES cholecystectomy|
3228681|NCT01174095||Follow-up Group|"Subjects who received AdGVVEGF121cDNA in either IRB protocol #0794-894 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease or IRB protocol #0297-693 entitled Phase I Study of Direct Administration of a Replication Deficient Adenovirus Vector (AdGVVEGF121.10) Containing the VEGF121 cDNA to the Ischemic Myocardium of Individuals with Diffuse Coronary Artery Disease Via Minimally Invasive Surgery."
3228686|NCT01174134|Placebo Comparator|Milk-based beverage w/out DHA|
3322055|NCT02024152|Experimental|JDP-205 IM high dose|
3322056|NCT02024152|Active Comparator|Control|
3322057|NCT02024178|Experimental|Ultrasound Imaging|Men already electing to undergo radical prostatectomy will undergo transrectal ultrasound procedure at induction of anesthesia prior to their surgery procedure.
3228687|NCT01174134|Experimental|Milk-based beverage with DHA|
3228688|NCT01174134|Experimental|Milk-based beverage containing DHA at a higher level|
3322058|NCT02024191|Experimental|Glutamine|The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.
3322059|NCT02024191|No Intervention|Observation|The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..
3322060|NCT02024217|Experimental|chemoradiotherapy, S1, oxaliplatin|chemoradiotherapy is given before surgical therapy,S1(Tegafur，Gimeracil and Oteracil Potassium Capsules) is given during radiation therapy and neoadjuvant chemotherapy, oxaliplatin is given during neoadjuvant chemotherapy.
3322061|NCT02024230||Warfarin|The dose of warfarin can be controlled so that the PT-INR value will be 2.0-3.0 in those aged under 70 years and 1.6-2.6 in those aged 70 years or more.
3322062|NCT02024230||Rivaroxaban|A dose of 15 mg of rivaroxaban is orally administered to adults once a day. The dose can be reduced to 10 mg in patients with renal insufficiency (creatinine clearance: 30-49 mL/minute), patients at a high risk of hemorrhage (HAS-BLED score), old patients aged 75 years or more, and low body weight patients.
3322063|NCT02024243||miR210 and Punch Tissue Biopsy|Patients visiting the Indiana University Health Comprehensive Wound Center, with a chronic venous leg ulcer(s), who qualify based on the study inclusion and exclusion criteria, will be involved in a 14-week (98 days) longitudinal observational study. All subjects in this arm will have wound measurements, photographs for digital planimetry to measure wound area, and two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) on days day 0, 14, and 28. Biopsies will not be taken if the wound has closed by day 14 or 28. Patient charts will be reviewed 98 days (14 weeks) after enrollment to determine the final status of the wound as healed or not-healed.
3228689|NCT01174147||Hospital Candida Cases|People who developed a positive blood culture for Candida while hospitalized
3228690|NCT01174199|Experimental|Arm I|Patients receive oral vorinostat once daily on days 1-14 and temsirolimus IV on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3228691|NCT01174212|Experimental|Experimental|Patients receiving antibiotics approximately 1 hour prior to incision are considered to be in the experimental group of this study.
3322064|NCT02024256|Active Comparator|Magnesium sulfate|Pads soaked in cold magnesium sulfate solution
3322065|NCT02024256|Sham Comparator|Water|Pads soaked with cold water
3322066|NCT02024269|Experimental|Adipose Stem Cells|
3322067|NCT02024282|Other|usual care|
3228692|NCT01174212|Other|Control|Control group is to receive no antibiotics until the intraoperative cultures have been obtained.
3322068|NCT02024282|Active Comparator|Use of C-reactive protein point of care (CRP POC) test|"CRP analysis will be performed during the consultation in accordance with the manufacturer's instructions.~The CRP point of care test will be performed in case of a positive decision tree (irrespective of the intervention group) and also in case of a negative decision tree by clinicians of intervention group 1 and 2. Because no reliable cut-off points for CRP are known currently (as this is the aim of this study) for acute infections in children in primary care (nor for referral, nor for prescription of antibiotics), clinicians will not be given guidance on the interpretation of the CRP results.~We will not impose restrictions on the clinicians about treatment, other technical investigations nor referrals.~The device distributor will provide technical assistance. All clinicians will be trained in the use of the CRP device prior to the start of the study."
3322069|NCT02024282|Active Comparator|Brief intervention and parent leaflet|
3322070|NCT02024282|Active Comparator|CRP POC test and brief intervention & parent leaflet|Combination of CRP POC test and the brief intervention & parent information leaflet intervention groups (factorial design)
3322071|NCT02024295|Experimental|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
3322072|NCT02024295|Active Comparator|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
3322073|NCT02024308|Experimental|Fludarabine|The patients in experimental arm should receive the consolidation chemotherapy regimen with fludarabine and cytarabine. The dosage of fludarabine is 30mg/m2/d for 5 days intravenously and cytarabine is 1.4g/m2/d for 5 days intravenously.
3322074|NCT02024308|Active Comparator|HD-Arac|The patients in control arm should receive the consolidation chemotherapy regimen with high-dose cytarabine. The dosage of cytarabine is 2000mg/m2/12h for 3 days (1,3,5) intravenously.
3322075|NCT02024321||Tumor patients, TPN, surgery|This work involved prospective study of surgical patients receiving TPN during the calendar year of 2013 at Cancer Hospital.
3322076|NCT02024334|Active Comparator|leflunomide|leflunomide tablet: for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
3322077|NCT02024334|Placebo Comparator|placebo|placebo tablet for patients less than 20 kg: 10 mg every 2 day, for patients 20 - 40 kg: 10 mg daily, for patients more than 40 kg: 20 mg daily.
3322078|NCT02024347||LSSM arm|Intervention: upper endoscopy only performed to patients with high LSM (≥12.0kPa) or SSM (≥41.3kPa) values
3322079|NCT02024347||Control arm|Intervention: upper endoscopy performed to all patients in this group.
3322080|NCT02024360|Experimental|patient navigation|Patient navigator visits home to encourage health eating, active living and parental skill building
3322081|NCT02024373|Experimental|Atorvastatin|atorvastatin：20 mg (every evening orally) for 8 weeks
3322082|NCT02024373|Placebo Comparator|placebo|placebo:20 mg (every evening orally) for 8 weeks
3322083|NCT02024399|Other|Exercise|Strength training x 20 sessions (10 weeks) Aerobic exercise core strengthening Running
3322084|NCT02024412|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
3322085|NCT02024412|Placebo Comparator|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
3228693|NCT01174225|Active Comparator|I|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Flexi T 380(+) IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
3228694|NCT01174225|Active Comparator|II|Participants who elect to have an IUD inserted at the time of abortion will be randomized to either Arm I or Arm II. In this arm participants will receive the Nova T IUD. The participant is counseled that she may leave the device in for up to five years. She will be followed for up to five years to determine expulsion rate, discontinuation rate, pregnancy rate, and overall satisfaction with form of contraception.
3228695|NCT01174225|No Intervention|III|"Participants who elect for forms of contraception other than a copper IUD will chose which form of contraception they would like to use and be put into one of the groups specified below based on her contraceptive choice. These participants will be observed throughout the study for overall satisfaction and repeat pregnancy rate.~Groups - Participants will be in one of the five following groups Group A - Oral contraceptive pill 28day supply provided after abortion Group B - Medroxyprogesterone acetate (Depo-provera)150mg IM provided after abortion, lasts for 3 months Group C - Ethinyl estradiol and etonogestrel (Nuva ring) provided at time of abortion, lasts for 28 days Group D - Condoms provided at time of abortion Group E - Other"
3228696|NCT01174277||Collection of blood sample|Blood draw
3322086|NCT02024425|Active Comparator|Functional bioactive supplement|The functional bioactive supplement is composed of antioxidant extracted from rosemary, oligosaccharides derived from lactulose and bioactive peptides. It will be used for obese and overweight treatment
3322087|NCT02024425|Placebo Comparator|Maltodextrin and saccharose|The control supplement is composed of maltodextrin and saccharose . It has no effect for obese and overweight treatment
3322088|NCT02024438|Other|placebo|arm B: equal saline as placebo ,one hour before chemotherapy(mFOLFOX6) every two weeks until tumor progress or intolerant
3322089|NCT02024438|Experimental|monosialotetrahexosylganglioside Sodium|arm A: monosialotetrahexosylganglioside Sodium Injection, 40mg,one hour before chemotherapy(mFOLFOX6), every two weeks until tumor progress or patients become intolerant
3322090|NCT02024451|Active Comparator|Radial shock wave, Acupuncture|"Radial shock wave: 2 Hz with 2000 shock waves, and the energy level of 0.056mJ/mm2 in the trapezius muscle. It will be done once per week for 3 weeks.~Acupuncture: performed at Fenfchi (GB20) point over upper back. It will be performed once per week for 3 weeks ."
3322091|NCT02024451|No Intervention|radial shock wave& no treatment|No treatment: patients recieved no intervention.
3322092|NCT02024464|Experimental|Hydrus Microstent|Patients randomized to the Hydrus Microstent
3228697|NCT01174290|Experimental|Haloperidol 1mg IV q6h|
3228698|NCT01174290|Placebo Comparator|D5W 0.2mL IV q6h|
3228699|NCT01174303|Experimental|IDegAsp - BIAsp|
3228700|NCT01174303|Experimental|BIAsp - IDegAsp|
3228701|NCT01174316|Experimental|autotitrating NIV|approximately 24 hours using autotitrating non-invasive ventilation for as many hours as possible whilst an inpatient in hospital
3228702|NCT01174316|Active Comparator|Standard non-invasive ventilation|approximately 24 hours using standard non-invasive ventilation for as many hours as possible whilst an inpatient in hospital.
3228703|NCT01174329|Experimental|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"Patient regulated (by a remote control) neuro-electrostimulation by Saliwell Crown"
3228704|NCT01174329|Active Comparator|"Automatic neuro-electrostimulation by Saliwell Crown"|No remote control used
3322093|NCT02024464|Active Comparator|iStent Trabecular Micro Bypass|Patients randomized to the iStent Trabecular Micro Bypass
3322094|NCT02024490||RDS group, non-RDS group|RDS group; infants with clinical, radiological and laboratory findings of RDS non-RDS group; infants without clinical, radiological and laboratory findings of RDS
3322095|NCT02024503||Experimental group|Hospitalized patients with acute stroke.
3322096|NCT02024503||Control group|Healthy Volunteers.
3322097|NCT02024516|Experimental|50 gr concentrated pomegranate juice|
3322098|NCT02024529|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL Intra-articular injection of Ampion
3322099|NCT02024529|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
3322100|NCT02024542||Weight Loss Surgery - Healthy|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients do not have metabolic syndrome.
3322101|NCT02024542||Weight Loss Surgery - Metabolic Syndrome|Patients consented to participate have met the NIH criteria for Bariatric Surgery and have completed the normal pre-operative work up including nutritional counseling, psychological evaluation, and all necessary studies to rule out other co-morbid conditions prior to surgery. Patients have metabolic syndrome.
3322102|NCT02024555|Active Comparator|Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin|Levofloxacin 500mg po QD; Ethambutol 1200mg po QD; Azithromycin 250 mg po QD; Rifampin 600mg po QD or Rifabutin 300mg po QD
3228705|NCT01174355|Experimental|ND0801|
3228706|NCT01174381|Experimental|Lifestyle modification|Lifestyle modification for behavior change related to NCD prevention
3322103|NCT02024555|Placebo Comparator|Placebo|"Riboflavin will be used for rifampin; encapsulated microcrystalline cellulose will be used to replace the levofloxacin, ethambutol and azithromycin.~The pill count will be the same as the comparator regimen."
3322104|NCT02024568|Active Comparator|Pregabalin|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Pregabalin started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 75mg twice daily (morning + evening). Option for dose increase with additional 75mg in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to 50mg doses is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
3322105|NCT02024568|Placebo Comparator|Placebo|"Includes 19 out of 38 subjects reporting athralgia-myalgia in the wake of paclitaxel infusion in the course of breast cancer treatment.~Placebo externally identical to the pregabalin 75mg capsules will be started on the evening before receiving infusion of paclitaxel and 5 day thereafter. Initial dosing of 1 capsule twice daily (morning + evening). Option for dose increase with additional capsule in case of inadequate pain control. A minimal interval of 2 hours is required between doses.~In case of poorly tolerated side effects a reduction to capsules with the appearance of 50mg pregabalin capsules is available.~Access to additional analgesic interventions is open as required for patient wellbeing."
3322106|NCT02024581|Active Comparator|10% East Indian sandalwood oil cream|East Indian sandalwood oil in a cream formulation administered twice a day for ninety (90) days
3322107|NCT02024581|Placebo Comparator|Placebo cream|A scented cream formulation administered twice a day for ninety (90) days
3322108|NCT02024594|Experimental|Nitrous Oxide-Oxygen|Children in this group were sedated by rapid induction method by means of Nitrous Oxide-Oxygen gas.
3228707|NCT01174394|Experimental|DCEAS|"Body electroacupuncture plus dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3322109|NCT02024594|Experimental|cognitive-behavioral therapy|Children in this group were asked to come to playroom before entering operation room. Modeling , Benson relaxation and positive self-talking were instructed to them.
3322110|NCT02024594|No Intervention|control|No intervention
3322111|NCT02024620|Experimental|Behavioral activation plus mobile app|Standard behavioral activation protocol with the addition of the Mood Coach mobile app to replace the paper and pencil forms used in the standard protocol.
3322112|NCT02024620|Active Comparator|Standard behavioral activation|Standard behavioral activation protocol using paper and pencil forms for treatment delivery and homework completion.
3228708|NCT01174394|Placebo Comparator|n-CEA|"Body electroacupuncture plus non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3228709|NCT01174407||cd35|
3228710|NCT01174420|Experimental|ologen Collagen Matrix|
3228711|NCT01174420|Active Comparator|Mitomycin-C (MMC)|
3228712|NCT01174433|Experimental|Tryton bifurcation stent system|
3228713|NCT01174472|Active Comparator|Conventional Balloon Angioplasty (COBA)|Patients with lesions treated with conventional balloon angioplasty
3228714|NCT01174472|Experimental|Drug Eluting Balloon Angioplasty (DEB)|Patients with lesions treated with Drug Balloon Angioplasty
3228715|NCT01174485|Experimental|exercise|exercise plus liposuction
3228716|NCT01174485|No Intervention|sedentary|physical inactivity plus liposuction
3322113|NCT02024633|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
3322114|NCT02024659|Experimental|budesonide|
3322115|NCT02024659|Placebo Comparator|placebo|
3322116|NCT02024672||Immediate postpartum placement of IUD|Women who plan to have an IUD placed at the time of cesarean section or vaginal delivery, or women who have had an IUD placed at the time of cesarean section or vaginal delivery.
3322117|NCT02024685|Active Comparator|Standard patient-physician counseling interaction|The control arm will receive counseling regarding treatment options using standard patient-physician interactions and nomogram-predicted probabilities of treatment outcome for the various treatment options and they will be unaware of the decision analysis recommendation.
3322118|NCT02024685|Experimental|Personalized treatment recommendations|The treatment arm would be provided with a personalized treatment recommendations based on the decision analysis model prior to treatment selection.
3322119|NCT02024737||Moderate-Severe COPD|"Patients with moderate to severe COPD, as defined by GOLD 2-3 (The GOLD classifications are the main method doctors use to describe the severity of COPD.~GOLD is short for the Global Initiative for Chronic Obstructive Lung Disease, a collaboration between the National Institutes of Health and the World Health Organization)"
3228717|NCT01174498|Active Comparator|t-VNS sytem Vagus stimulation|Subjects experience a transcutaneous vagal stimulation by the t-VNS device
3228718|NCT01174498|Sham Comparator|Sham transcutaneous stimulation|Sham stimulation with an attached t-VNS device
3322120|NCT02024763|Experimental|Educational Intervention|Intervention was applied to classroom teachers by the RRIDA Project team. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities were taught in order to be replicated at PE classes to 1st and 2nd grades' children of three exposed schools. Physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models. In each meeting the PE professionals, performed PE classes with the classroom teachers as students, focusing in strategies to keep them in movement for the most of PE class time to stimulate students' joint participation instead of individual participation or games.
3322121|NCT02024763|No Intervention|No Intervention|No educational intervention was taken place in the control schools while the project was running. Afterwards, control schools received training.
3322122|NCT02024776|Active Comparator|Prehabilitation|Prehabilitation program is defined as a tailored physical exercise program to be carried out to a patient on the basis of his/her health condition, social circumstances and adherence profile. The intervention consisted of a standard 4-6 week supervised outpatient program including global endurance exercise training, or educational sessions followed by a self-management program supported by ICT during the follow-up period, or a combination of both.
3322123|NCT02024776|No Intervention|No-intervention|Standard counseling and conventional pre-surgical measures
3322124|NCT02024789|Placebo Comparator|Placebo|
3322125|NCT02024789|Experimental|RG1662 120 mg bid|
3322126|NCT02024789|Experimental|RG1662 240 mg bid|
3322127|NCT02024815|Experimental|External Beam radiotherapy|Single 8 Gy fraction
3322128|NCT02024815|Active Comparator|3 Gy x 10 fractions|External Beam radiotherapy - total dose 30 Gy, 3 Gy per fraction.
3322129|NCT02024828|Experimental|Early/Slow|Infants were offered oral feedings beginning at 32 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
3322130|NCT02024828|Experimental|Early/Fast|Infants were first offered oral feedings beginning at 32 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
3322131|NCT02024828|Experimental|Late/Slow|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 2 oral feedings per day for 3 days (Days 1-3). The number of oral feedings offered per day increased by 1 feeding every other day until day 14 when they were offered 8 oral feedings each day (Days 4-5, 3 oral feeds offered; Days 6-7, 4 oral feeds offered; Days 8-9, 5 oral feeds offered; Days 10-11, 6 oral feeds offered; Days 12-13, 7 oral feeds offered; Day14, 8 oral feeds offered). Any feedings not offered orally were provided by gavage.
3322132|NCT02024828|Experimental|Late/Fast|Infants were offered oral feedings beginning at 34 weeks PMA. They were offered 8 oral feedings every day, at each of 8 scheduled daily feedings.
3228719|NCT01174511|Experimental|A-1 COOL cream|"A research product - A-1 COOL cream contain herbal medicine plants basically :~WATER PETROLATUM~WILD YAM (DIOSCOREA VILLOSA) EXTRACT~SORBITAN SESQUIOLEATE~CALENDULA OFFICINALIS EXTRACT~MINERAL OIL~ARNICA MONTANA EXTRACT~MICROCRYSTALLINE WAX~LICORICE (GLYCYRRHIZA GLABRA) EXTRACT~DECYL OLEATE~DICOCOYL PENTAERYTHRITYL DISTEARYL CITRATE~BEESWAX~ALUMINUM STEARATES"
3228720|NCT01174511|Placebo Comparator|Vaselin ointment|Using the study as placebo.
3228721|NCT01174524|Experimental|gestoden and ethinylestradiol|"Gestoden 60 mcg plus ethinylestradiol 15 mcg, once a day, administered in 24∕4 regimen, for three months.~The use of gestoden and ethinylestradiol can do an improvement of the quality of life before and after the use of the drug.Numerous large clinical trials have shown that this combination is as effective in preventing pregnancies as other oral contraceptives presently on the market. Irregular bleeding and spotting rates appear to be at least as good as older formulations. In general, the incidence of side effects associated with the progestin and estrogen components tends to be low, with very little impact on lipid and carbohydrate metabolism. . For this, the regimen can ameliorate the quality of life of the patients."
3228722|NCT01174563|Experimental|Single Arm|
3228723|NCT01174589|Other|6 weeks of physical training|The 6 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
3322133|NCT02024841|Experimental|Intraperitoneal docetaxel|"Intraperitoneal docetaxel in 1litre normal saline infused over 1 hour on day 1 every 3 weeks:~- Level I: 40mg/m2; Level II: 50mg/m2; Level III: 60mg/m2~Intravenous cisplatin: 60mg/m2 on day 1 every 3 weeks~Oral TS-ONE: 40-60mg twice daily on day 1 -14 every 3 weeks"
3322134|NCT02024854|Experimental|skin-to-skin|immediately after birth the baby is laid on mother's chest for as long as justifiable medically to max 2 hours.
3228724|NCT01174589|Other|12 weeks of physical exercise|The 12 weeks of physical training consists of muscle strength training of both legs, balance and coordination exercises 2 times a week.
3322135|NCT02024854|Active Comparator|standard care|after birth the baby is transferred to the neonatal intensive care unit
3322136|NCT02024880|Experimental|Protective catheter group|Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
3322137|NCT02024880|Active Comparator|Conventional catheter group|Conventional catheter group uses Sydney IVF catheter from Cook.
3322138|NCT02024893||National womens water- polo team|Observational study-members of the national womens waterpolo team participating in formal team training and tournaments for the 2014-2015 season.
3228725|NCT01174602|Experimental|Exposure Therapy for AN (AN-EX/RP)|Exposure Therapy and Ritual Prevention (AN-EX/RP) includes 12 sessions of confronting feared eating situations without the use of anxiety reducing behaviors.
3228726|NCT01174602|Active Comparator|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT)
3228727|NCT01174641|Experimental|TMS intervention|Trans-cranial magnetic stimulation will be applied at a 1Hz rate for 20min over the ipsilesional posterior parietal cortex of patients showing left neglect after a right hemisphere stroke
3322139|NCT02024893||National mens handball team|Observational study-Twenty men , members of the national , over 18 years old handball team preparing for the european championships for summer 2014
3322140|NCT02024893||National womens volleyball team|20 players who are part of the women's national olympic volleyball team
3322141|NCT02024906|Experimental|soy protein isolate (SPI)|25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones
3322142|NCT02024906|Active Comparator|milk protein isolate (MPI)|milk protein isolate (MPI) containing 0 mg/d isoflavones
3228728|NCT01174641|Placebo Comparator|Placebo TMS|1 Hz trans-cranial magnetic stimulation will be applied over the vertex
3228729|NCT01174654|No Intervention|Referral to community resources|
3228730|NCT01174654|Experimental|Contingency Management|
3322143|NCT02024919|Active Comparator|Diltiazem|intracoronary diltiazem 5 milligrams which is diluted with 5 mL of saline
3322144|NCT02024919|Placebo Comparator|Saline|intracoronary saline 5 mL
3322145|NCT02024945||Propiverine|Participants with symptoms of OAB, prescribed propiverine in accordance with the summary of product characteristics (SPC).
3228731|NCT01174667|Experimental|Fascial massage|A specific type of fascial massage to release restricted lumbodorsal fascia.
3322146|NCT02024958||indirect calorimetry measurement|Measurement of energy expenditure in made by indirect calorimetry in patients laying down in a supine position on a bed during ongoing measure by connecting the calorimeter to the endotracheal tube (invasive mechanical ventilation) or to the facemask (non-invasive mechanical ventilation), or by using a transparent canopy in plexiglas to cover the head while room-air flows through and is mixed with the expirate (spontaneous breathing). This mixture of patient breath and room air is finally collected and analyzed by the IC device for O2 and CO2 concentrations, and used to calculate EE. EE is calculated using the modified Weir equation.
3322147|NCT02024984|Experimental|Group A|Luteal Phase Administration of Clomiphene (50mg twice per day for 5 days)
3322148|NCT02024984|Active Comparator|Group B|Follicular Phase Administration of Clomiphene Citrate in PCOS(50mg twice per day for 5 days)
3322149|NCT02024997|Experimental|Abdominal MRI|Subjects will undergo magnetic resonance imaging (MRI) with contrast. Magnetic resonance (MR)_freebreathing scan will be acquired. MR_inspiration scan will be acquired. MR_expiration scan will be acquired.
3322150|NCT02025010|Experimental|abiraterone acetate|"Pre-treatment and progression tumor biopsies.~Four 250 mg tablets (1,000 mg) of abiraterone acetate (AA) taken orally on 28 day cycles.~For participants who experience symptoms of persistent or severe hypertension or hypokalemia, prednisone 5 mg by mouth twice daily.~For participations who tolerate AA monotherapy without the addition of prednisone to manage symptoms of persistent or severe mineralocorticoid excess, prednisone 5 mg by mouth twice daily will be added at PSA progression.~Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess."
3322151|NCT02025023|Active Comparator|Incision and Curettage|A vertical incision over the area of chalazion will be done. Inflammatory material will be removed and the chalazion capsule will be excised.
3322152|NCT02025023|Active Comparator|Injection of Triamcinolone Acetonide|0.1 ml of triamcinolone is injected directly in the chalazion.
3322153|NCT02025023|Active Comparator|Injection of 5-fluorouracil|0.1 ml of 5-fluorouracil is injected directly in the lesion transconjunctivally.
3322154|NCT02025023|Active Comparator|Injection of triamcinolone/5FU mixture|0.1 ml of a 4:1 mixture of 4 parts 5-FU and 1 part triamcinolone is injected in the lesion.
3322155|NCT02025036|Experimental|Capecitabine-oxaliplatin-radiotherapy|"oxaliplatin：65mg/m2，d1，8，22, 29,I.V.or d1, 8, 22, 29, 43, 50, 64, 71,I.V.plus,capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
3322156|NCT02025036|Active Comparator|cisplatin with 5-FU and radiotherapy|"cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85, 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w."
3322157|NCT02025036|Experimental|Capecitabine and radiotherapy|capecitabine: 625mg/m2, bid d1-5; q1w, po,6 weeks or 12 weeks in total, radiotherapy： 50-50.4Gy ，1.8-2 Gy/d，5d/w.
3322158|NCT02025049|Experimental|DP-b99|Intravenous DP-b99, 1.0 mg/kg twice daily for 2 consecutive days
3228732|NCT01174667|No Intervention|No treatment control|Patient will rest quietly without receiving any instruction.
3228733|NCT01174680|Experimental|patients with stable angina pectoris|stable patients, who have been admitted to one of the participating centres for an elective coronary angiography
3228734|NCT01174693|Active Comparator|Clopidogrel|Plavix® 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
3322159|NCT02025049|Placebo Comparator|Placebo|Intravenous placebo (mannitol based, DP-b99 look-alike) twice daily for 2 consecutive days
3322160|NCT02025062|No Intervention|Control|In the control arm, patients are followed-up by the head-and-neck physician, oncologist and radiotherapists and did not benefit of Comprehensive Geriatric Assessment.
3322161|NCT02025062|Experimental|Comprehensive Geriatric Assessment|The CGA (Comprehensive Geriatric Assessment) is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up.
3322162|NCT02025088|Active Comparator|Laser|In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
3322163|NCT02025088|Active Comparator|Microneedling|"In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
3322164|NCT02025101||Slow Coronary Flow|Patients who were hospitalized with anginal pain and with laboratory markers or pathological ECG for ischemia.
3322165|NCT02025114|Experimental|Capsule|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
3228735|NCT01174693|Experimental|Triflusal|Disgre® 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
3228736|NCT01174706|Experimental|Usual care arm|Patients randomized to this group will receive usual care. Usual care at the three study sites varies but will be defined as whatever information is usually given to patients regarding the prescription medication or over the counter medicine they were prescribed at emergency department discharge.
3322166|NCT02025127|Experimental|Trophic feeding|Mechanically ventilated patients with septic shock > 18 years old randomized to this group will receive more than 50 but less than 600 kilocalories of enteral nutrition per day while on vasopressors. This will be started within 24 hours of intensive care unit admission.
3322167|NCT02025127|No Intervention|No Enteral Nutrition|Mechanically ventilated patients with septic shock randomized to this group will receive no enteral nutrition while on vasopressor support.
3322168|NCT02025140|Active Comparator|: This group consisted of 30 patients.|The traditional IANB injection was given according to the standard technique (Evers and Haegerstam 1981). From everyday practice, it is known that the present operator takes approximately 60 to 90 seconds to give a mandibular block
3322169|NCT02025140|Experimental|30 IANB with Computer controlled|The IANB injection was given by a computer- regulated device performed with the STA system. The IANB injection was given according to the manufacturer's instruction (the model was used is the STA Single Tooth Anesthesia System produced by Milestone Scientific, Livingston, NJ).
3322170|NCT02025140|Experimental|consisted of 30 periodontal anesthesia|The interligamental injection was given by computer- regulated device performed with the STA system.
3322171|NCT02025153|Other|Cohort|pain testing. All 444 subjects enrolled in the study. Subjects will receive preoperative physical (tonic heat stimulation, mechanical temporal summation and wound hyperalgesia), psychological (State Trait Anxiety Inventory, Pain Catastrophizing Scale), and genetics test; postoperative pain score assessment at 24, 48 hours; postoperative wound hyperalgesia in open abdominal hysterectomy at 72 hours; and phone survey for CPSP at 4 months.
3322172|NCT02025153|Other|Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
3322173|NCT02025153|Other|No Chronic Post-surgical Pain|pain testing. physical testing, psychological testing, genetics testing and functional brain imaging
3322174|NCT02025166|Active Comparator|Paracetamol|Pain treatment, aniline analgesics
3322175|NCT02025166|Active Comparator|lornoxicam|Pain treatment, nonsteroidal anti-inflammatory (NSAID)
3322176|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with capecitabine|
3228737|NCT01174706|Experimental|Information prescription|Patients randomized to this arm will receive written information from Medline Plus regarding the prescription or over the counter medicine they have been prescribed at ED discharge plus information on their health condition.
3228738|NCT01174706|Experimental|Informationist|Patients in this arm will receive the same information as patients in group 2 but will also be given contact information for a clinical informationist if they have further questions about their prescription medicine or over the counter medicine prescribed at ED discharge.
3228739|NCT01174706|Experimental|practical assistance|Subjects will be offered practical assistance with obtaining prescription such as location of most convenient pharmacy and hours of operation, programs that offer drugs more cheaply, fax prescription from ED to pharmacy
3228740|NCT01174719|Active Comparator|Hydroxyethylstarch|
3322177|NCT02025192|Experimental|Tucatinib (ONT-380) in combination with trastuzumab|
3322178|NCT02025192|Experimental|Tucatinib (ONT-380) combined with capecitabine and trastuzumab|
3228741|NCT01174719|Active Comparator|Humanalbumin|
3228742|NCT01174719|Active Comparator|Ringer lactate|
3322179|NCT02025218|Experimental|Re-administration gefitinib|
3322180|NCT02025231|Experimental|External beam radiotherapy|Hypofractionated external beam radiation delivered in 4 different sequential dose/fractionation groups.
3228743|NCT01174732|Experimental|T1|A006 albuterol inhalation powder, 120 mcg/inhalation, 1 inhalation
3228744|NCT01174732|Experimental|T2|A006 albuterol inhalation powder 180 mcg/ inhalation, 1 inhalation
3228745|NCT01174732|Experimental|T3|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
3228746|NCT01174732|Experimental|T4|A006 albuterol inhalation powder 180 mcg/inhalation, 2 inhalations
3228747|NCT01174732|Placebo Comparator|P|Placebo, 2 inhalations
3228748|NCT01174732|Active Comparator|R1|Proventil 90 mcg/inhalation, 2 inhalations
3228749|NCT01174732|Active Comparator|R2|Proventil 90 mcg/inhalation, 4 inhalations
3228750|NCT01174758||Parkinson's disease|Individuals participating in the study have been diagnosed with idiopathic Parkinson's disease.
3322181|NCT02025244|Active Comparator|Key Hole Biopsy|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
3322182|NCT02025244|Active Comparator|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
3322183|NCT02025257|Experimental|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
3322184|NCT02025257|No Intervention|Control|Patients are asked to live as usual.
3322185|NCT02025270|Other|Laboratory and Clinical|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into rete testis.
3322186|NCT02025283||Group Decompression|Group Decompression: Patients assigned to Group Decompression. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) were advanced inside the trochar needle towards the disc and decompression was performed. After being sure of achieving sufficient decompression inside the disc, the decompression device were removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
3322187|NCT02025283||Group Nucleoplasty|Group Nucleoplasty : Patients assigned to Group Nucleoplasty. After determination of the appropriate space for the approach under fluoroscopy guidance, a 17 gauge trochar needle was advanced posterolaterally up to the center of the disc. Then site verification was done again with water soluble contrast material under floroscopy guidance. Then radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA] were advanced inside the trochar needle towards the disc and nucleoplasty was performed. After being sure of achieving sufficient decompression inside the disc, the nucleoplasty probe was removed under fluoroscopy guidance and the incision site was closed and the patients were recommended to have bedrest for 2 hours.
3322188|NCT02025296|No Intervention|Self-Monitoring of Blood Glucose|measurement of their blood glucose level using a glucometer at least eight times a week
3322189|NCT02025296|Experimental|U-healthcare|individualized multidisciplinary u-healthcare service combined with exercise monitoring and dietary feedback on glucose control
3322190|NCT02025309|Active Comparator|Group Methylprednisolone|Patient in this group received general anaesthesia for surgical procedures. During the anesthesia management methylprednisolone was administered intravenously (1mg/kg) to the patients in this group. Also neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
3322191|NCT02025309|Placebo Comparator|Group Control|Patients who received general anaesthesia and endothracheal entubation but who did not recieved methyprednisone during general anaesthesia were enrolled in the study as control group. Neuromuscular monitorisation was performed to assess the train of four ratio at the end of the procedure, after the reversal of neuromuscular block. All patients were followed during the recovery period from general anaesthesia and the time needed to regain a full neuromuscular recovery was noted. For that, the train of four ratio was followed up and the ratio of 0.9 was recorded.
3322192|NCT02025322|No Intervention|Standard of Care|Between baseline and 4-month follow-up, control group patients will receive current standard of care which includes: (a) two or more HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (b) resource referrals from a Patient Navigator based on the participant's needs (e.g., mental health, substance abuse, social support groups, etc.); and (c) automated medical appointment reminders via phone.
3322193|NCT02025322|Experimental|Peer Mentoring|Between baseline and 4-month follow-up, experiment group patients will be receiving (a) Weekly contacts with their Peer Mentor, with the option of receiving more frequent contact, if needed; and (b) 4 monthly, 1-hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness. In addition, experiment group participants will also be provided with all standard practice services given to control group participants, including: (c) Two more or HIV basics education and medication adherence counseling sessions with their HIV specialty care provider and Patient Navigator; (d) resource referrals from a Patient Navigator based on the participant's needs; and (e) automated medical appointment reminders via phone.
3322194|NCT02025335||high CMV ELISPOT results|high spot counts in ELISPOT
3322195|NCT02025335||low CMV ELISPOT results|low spot counts in ELISPOT
3322196|NCT02025348|Experimental|Treatment A metoprolol 50mg|IntelliCap® capsule Release profile 1 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3322197|NCT02025348|Experimental|Treatment B metoprolol 50mg|IntelliCap® capsule Release profile 2 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3322198|NCT02025348|Experimental|Treatment C metoprolol 50mg|IntelliCap® capsule Release profile 3 filled with metoprolol gastroenteral solution 233 mg/mL (dose 50 mg).
3322199|NCT02025348|Experimental|Treatment D metorpolol 50mg|metoprolol oral solution 1 mg/mL (dose 50 mg).
3322200|NCT02025361|Experimental|intrarectal lidocaine gel|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure % 2 lidocaine hydrochloride gel instilated into the rectum for local anesthesia
3322201|NCT02025361|Experimental|periprostatic nerve blockade|transrectal ultrasound guided prostate biopsy was performed with intrarectal lidocaine gel anesthesia: 10 minutes before the procedure transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction between the prostate base and seminal vesicle.
3322202|NCT02025374|Experimental|Hyperbaric levobupivacaine|Group 2 Hyperbaric levobupivacaine % 0.5 plus fentanyl; 2 ml total intrathecally
3322203|NCT02025374|Active Comparator|Hyperbaric bupivacaine|Group 1 Hyperbaric bupivacaine % 0.5 plus fentanyl 2 ml intrathecally
3322204|NCT02025387|Experimental|Experimental|Patients will receive physical activity feedback and be encouraged to achieve the daily goals of physical activity
3322205|NCT02025387|Sham Comparator|Control|Physical activity will be measured but not be informed to patients. She will receive usual care.
3322206|NCT02025400|Active Comparator|Physical Therapy|This arm will receive the standard of care for orthopedic patients receiving a diagnosis and then a recommendation for outpatient physical therapy referral. They will follow through on the referral and attend physical therapy.
3322207|NCT02025400|Experimental|eRehab|This group will not go to formal therapy but receive Internet delivered patient education and exercise instruction. This group will then perform those exercises at home.
3322208|NCT02025413|Other|Metastatic progressive castration-resistant prostate cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
3322209|NCT02025413|Other|Metastatic progressive breast cancer|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
3322210|NCT02025452|Active Comparator|Rapid diagnostics and probiotic|
3322211|NCT02025452|Placebo Comparator|Rapid diagnostics and placebo|
3322212|NCT02025452|Experimental|Delayed diagnostics and probiotic|
3322213|NCT02025452|Placebo Comparator|Delayed diagnostics and placebo|
3228751|NCT01174771||PSP patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., PSP
3228752|NCT01174771||CBD patients|People that have been clinically diagnosed with atypical parkinsonism, i.e., CBD
3322214|NCT02025465|Experimental|Metoprolol|"Metoprolol 2.5 to 5.0 mg IV bolus over two minutes~Repeat every five minutes up to a total dose of 15 mg as long as tolerated (Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy))~If rate inadequate the physician has option of:~Further doses of metoprolol IV or PO~Intravenous amiodarone~IV diltiazem~Observation"
3322215|NCT02025465|Active Comparator|Diltiazem|"Bolus 0.25 Mg/Kg over two minutes (average adult dose 20 mg).~If after 15 minutes~The first dose is tolerated, and~Ventricular rate is over 100 beats a minute AND~Blood pressure is over 100 mm /Hg systolic (or BP is 90 to 100 mm\Hg systolic and the patient is not dizzy)~Give diltiazem 0.35 Mg/Kg over two minutes (average adult dose 25 mg).~After initial bolus', start infusion 5 to 15 Mg/hour to maintain rate control as long as:~1. BP over 100 mm/Hg or between 90 and 100 mm/Hg and the patient is not dizzy.~If rate inadequate the physician has an option of:~Metoprolol PO (by mouth) or IV (intravenous)~Digoxin PO or IV~Intravenous amiodarone~Observation"
3322216|NCT02025478|Experimental|Enteral Donor Breastmilk|"Donor breast milk will be pasteurized prior to use.~Given orally or by nasogastric (NG) or nasojejunal (NJ) tube.~Feeding will be supervised and will be advanced as quickly as tolerated with a goal of providing 40-50% of nutritional needs from the donor milk.~It is recognized that the volume of enteral feeds will need to be adjusted per patient tolerance."
3322217|NCT02025491|Experimental|Liposomal Amphotericin|Liposomal Amphotericin by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment.
3322218|NCT02025504|Experimental|ColoWrap Intervention Group|Patients randomized to ColoWrap Intervention Group will have the ColoWrap abdominal binder secured firmly around their lower abdomen just prior to colonoscopy.
3322219|NCT02025504|Sham Comparator|Sham Group|Sham Group will also have a ColoWrap binder placed around their lower abdomen, but it will be placed loosely so no appreciable lower abdominal pressure is generated by the device.
3322220|NCT02025517|No Intervention|Without Cognitive Tasks|Gait training on treadmill during 20 minutes.
3322221|NCT02025517|Experimental|Cognitive Tasks|Treadmill training plus cognitive verbal fluency, memory and spatial planning tasks, during 20 minutes.
3322222|NCT02025543||Patient Group|Subjects with known or suspected iron overload will undergo serum ferritin measurement and an MRI scan.
3322223|NCT02025543||Control Group|Subjects with no known history of iron overload or liver disease will undergo an MRI scan.
3322224|NCT02025569|Experimental|Experimental group|Strain counterstrain intervention
3322225|NCT02025569|Sham Comparator|Control Group|Sham Strain Counterstrain intervention
3322226|NCT02025582|Experimental|Kinesio tape|
3322227|NCT02025595||Monozygotic twin pairs|15 monozygotic twin pairs discordant for obesity
3228753|NCT01174771||Age-matched healthy controls|People that have not been diagnosed with any kind of neurologic movement disorder.
3228754|NCT01174797||Patients being evaluated for active ischemia|Subjects with known or suspected CAD who are scheduled to undergo routine exercise MPI or stress echocardiography for the detection of active ischemia are eligible for enrollment.
3228755|NCT01174810|No Intervention|Control|
3228756|NCT01174810|Experimental|Exenatide|
3228757|NCT01174849|Active Comparator|Synflorix|
3322228|NCT02025595||Genetic predisposition for obesity|15 obese and 15 non-obese individuals with a high genotype obesity risk score and 15 obese and 15 non-obese individuals with a low genotype obesity risk score. Genotype obesity risk score will be based on genome wide association single-nucleotide polymorphisms (SNP's) associated with obesity.
3322229|NCT02025608|Experimental|Pramipexole|Pramipexole, 0.25 mg, daily for 4 weeks
3322230|NCT02025608|Placebo Comparator|Placebo|Placebo, daily for 4 weeks
3322231|NCT02025660|Experimental|Mw|
3322232|NCT02025660|Placebo Comparator|Saline; 0.3 ml x three days sc|
3322233|NCT02025673||Healthy Controls|Healthy subjects as control group.
3322234|NCT02025673||Type 2 diabetes|Patients with type 2 diabetes.
3322235|NCT02025673||Gestational diabetes mellitus|Patients with gestational diabetes mellitus.
3322236|NCT02025686|Experimental|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min
3228758|NCT01174849|Active Comparator|Prevenar13|
3228759|NCT01174849|Experimental|COMBO|COMBINATION SCHEDULE of comparator vaccine 1 and comparator vaccine 2 Synflorix at 1,2,4 months then Prevenar13 at 6 months.
3228760|NCT01174862||Aspirin responder|Normal aspirin responsiveness in ASPI test (Multiplate)
3322237|NCT02025699||LRTI|
3322238|NCT02025699||Sepsis|
3322239|NCT02025699||Non-Infectious disease group|
3228761|NCT01174862||Aspirin non-responder|Reduced aspirin responsiveness in ASPI test (Multiplate)
3228762|NCT01174875||Pregnant mothers, infants and children|Women in their early pregnancy who are attending the first trimester antenatal ultrasound scan at the public maternity units at KK Women's and Children's Hospital (KKH) and National University Hospital (NUH). Only women age 18 years and above who are Singapore Citizens or Singapore Permanent Residents. Participants have to intend to eventually deliver in NUH or KKH and to reside in Singapore for the next 5 years. Willingness to donate cord, cord blood and placenta. The fetus should be racially homogenous with both sets of grandparents of the same ethnicity. Babies born from these mothers will be followed up until the child is at least 14 years of age.
3322240|NCT02025712|Experimental|Exemestane plus Everolimus|Exemestane 25 mg daily in combination with Everolimus 10 mg daily until disease progression or intolerable toxicity
3322241|NCT02025738|Active Comparator|MAGNET|magnet application over cardiac device
3322242|NCT02025738|Active Comparator|REPROGRAMING|reprograming of cardiac device by trained technician/electrophysiologist
3228763|NCT01174888|Experimental|GROUP I (Dose levels 1-2):|Patients receive midostaurin orally (PO) twice daily on days 1-14 and bortezomib intravenously (IV) on days 1, 4, 8, and 11. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3228764|NCT01174888|Experimental|GROUP II (Dose levels 3-6)|Patients receive mitoxantrone hydrochloride IV over 10 minutes, etoposide IV over 1 hour, and cytarabine IV over 6 hours on days 1-6. Patients also receive midostaurin PO twice daily on days 8-21 and bortezomib IV on days 8, 11, 15, and 18. Treatment continues in the absence of disease progression or unacceptable toxicity.
3322243|NCT02025738|Active Comparator|NO ACTION|no action is performed if patient meets inclusion criteria
3322244|NCT02025777|Experimental|capsule endoscopy and colonoscopy|
3228765|NCT01174914|Experimental|Naltrexone Low-dose 3mg capsule|Each person in this arm 1 of the study had never received any ARV drugs and in this study received only one Low-Dose Naltrexone 3mg capsule nightly for 9 months (no placebo).
3228766|NCT01174914|Active Comparator|Naltrexone Low Dose + ARVs|In this Arm 3, Patients were on ARV's plus being given Naltrexone Low-Dose (3mg) once daily at bedtime for 9 months.
3228767|NCT01174914|Placebo Comparator|ARV's (continued,standard) plus Placebo|In this arm 2, patients were started or continued on their standard ARV drugs plus placebo capsule once daily at bedtime; in the 2nd and 3rd arms patients did not know whether they were taking Low-Dose Naltrexone or a placebo.
3228768|NCT01174927|Active Comparator|Heroin-dependent patients_1|daily dose of diacetylmorphine (30 mg to 500 mg) in 5 ml
3228769|NCT01174927|Placebo Comparator|Heroin-dependent patients_2|5 ml saline
3322245|NCT02025790|Experimental|Group A - POEM|Per Oral Endoscopic Myotomy for treatment of achalasia
3322246|NCT02025790|Active Comparator|Group B - Dilatation|- Pneumatic dilatation using a balloon for treatment of achalasia.
3322247|NCT02025803|Experimental|TAS-114/capecitabine|See intervention description
3322248|NCT02025842||Chronic hepatitis B patients|Chronic hepatitis B patients treated with nucleoside/nucleotide
3322249|NCT02025842||Compensated cirrhosis patients|Compensated cirrhosis patients treated with nucleoside/nucleotide
3322250|NCT02025855|Experimental|Methadone|Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube.
3322251|NCT02025855|Placebo Comparator|Placebo|This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in.
3322252|NCT02025868|Experimental|Adherence reinforcement before switch to 3rd-line ART|
3322253|NCT02025881|Experimental|Treatment|carboplatin + etoposide then thiotepa then Cyclophosphamide + Busilvex
3322254|NCT02025894||PCVCs|Cohort of cancer patients with indication PCVC under the usual practice
3322255|NCT02025920|Experimental|Salmon Group|Participants will eat 150g salmon for dinner, 3 times per week for 12 weeks
3322256|NCT02025920|Experimental|Cod Group|Participants will eat 150g cod for dinner, 3 times per week for 12 weeks
3322257|NCT02025920|Active Comparator|Meat Group|Participants will eat 150g mixed meat for dinner, 3 times per week for 12 weeks
3322258|NCT02025933||Salmon Group|Participants will eat 75 - 150 grams of salmon for dinner, three times a week for 12 weeks.
3322259|NCT02025933||Cod Group|Participants will eat 75-150 grams of cod for dinner, three times a week for 12 weeks.
3322260|NCT02025933||Meat Group|Participants will eat 75-150 grams of mixed meat for dinner, three times a week for 12 weeks.
3322261|NCT02025946||Total Ankle Arthroplasty|
3322262|NCT02025946||Tibiotalar Arthrodesis|
3322263|NCT02025959|Experimental|Educational Intervention|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders
3322264|NCT02025972|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
3322265|NCT02025998|Experimental|Ibudilast|Ibudilast will be administered for 7 days at the target dose of 50 mg/bid
3322266|NCT02025998|Placebo Comparator|Sugar pill|Placebo pills will be administered for 7 days and taken twice daily
3322267|NCT02026037|Experimental|Experimental|Brief Treatment for Acutely Burned Patients (BTBP)
3322268|NCT02026050|Active Comparator|intraarticular dexamethasone|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2 ml serum phsyologic and after surgery 2 ml 8 mg dexamethasone+ 8 ml serum phsyologic administration for intraarticular
3322269|NCT02026050|Active Comparator|interscalene dexamethasone|interscalene brachial plexus was preoperative performed 30 ml 0.5 % bupivacaine added 2 ml 8mg dexamethasone and after surgery 10 ml serum phsyologic administration for intraarticular
3322270|NCT02026050|Placebo Comparator|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
3322271|NCT02026076|Experimental|manual unloading|All subjects will first undergo a manual unloading test, followed by a single application of mechanical lumbar traction to determine predictive effect
3322272|NCT02026089|No Intervention|Sero-positive for varicella at least 5 years prior|No treatment
3322273|NCT02026089|Active Comparator|Varicella vaccine|One dose varicella vaccine (Varivax).
3322274|NCT02026102|No Intervention|Usual Care|Patients will receive no additional ICD specific information other than what is offered by the clinic consistent with usual care. The control group will be asked where they went for information in the follow-up interviews.
3322275|NCT02026102|Experimental|ICD Decision Aid Toolkit|In the intervention arm, research assistants will provide the patients with the toolkit of decision aids. At that time, participants will have the option of using all of the decision aids or just some of the decision aids. Participants who do not have access to the internet, will be offered a DVD (digital video disc) version of the video and they will be asked if they would like to arrange a visit where they can review the website with the research assistant.
3322276|NCT02026115|Active Comparator|usual hospice care|The usual care group will receive the typical hospice care and interact with PAINReportIt to provide data necessary for the analysis of study aims. They will use the tablet computer at baseline and at the study end and daily between. They also will have access to what looks like PAINUCope, but is really computer games so that they have similar attention with the computer as the experimental group. For ethical purposes, we will provide a PAINReportIt Summary to their hospice nurses to have access to their pain assessment information, something we did not do in previous studies focused on efficacy of the interventions.
3322277|NCT02026115|Experimental|PAINRelieveIt (experimental group)|We will use Nursing Consult LLC's PAINRelieveIt software that includes: (1) PAINReportIt that has screens to collect pain, medications, and misconception data; (2) the intervention for the nurse clinicians, PAINConsultN; and (3) the intervention for the patients and lay caregiver, PAINUCope. This innovative, new program is the first computerized, multi-dimensional, self-report measure of pain with clinician decision support for analgesic prescriptions and multimedia patient education tailored to the patient's misconceptions and pain. Prototype versions of PAINConsultN and PAINUCope were tested in recently completed studies among outpatients with cancer and patients with sickle cell disease in outpatient, emergency and hospital settings.
3322278|NCT02026128||Active Uveitis|Physician-confirmed diagnosis of uveitis of any origin.
3322279|NCT02026154||A, B, C|Group A- 15 patients without symptoms of heart failure - control group Group B- 30 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
3322280|NCT02026167|No Intervention|Usual Care|No intervention, usual care
3322281|NCT02026167|Experimental|Intervention|Collaborative care with Health Care Assistant
3322282|NCT02026180|Active Comparator|Micropuncture Access|Vascular access using micropuncture needle kit
3322283|NCT02026180|Active Comparator|Standard 18G vascular access needle|Vascular access using standard 18G needle
3322284|NCT02026219|Experimental|Clopidogrel|Clopidogrel 600mg loading
3228770|NCT01174940|Experimental|Extracorporeal Photopheresis|Patients will receive 2 ECP treatments on day -10 and day -8 and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
3228771|NCT01174953|Other|Finasteride plus soy|Finasteride and soy
3322285|NCT02026219|Experimental|Ticagrelor|Ticagrelor 180mg loading
3322286|NCT02026232|Active Comparator|hydroxychloroquine|hydroxychloroquine twice daily for 4 weeks
3322287|NCT02026232|Placebo Comparator|Placebo|hydroxychloroquine placebo twice daily for 4 weeks
3322288|NCT02026245|Experimental|5DT electronic data glove|"Using the electronic data gloves to perform a set routine of movements.~Intervention: Data gloves to perform movements"
3322289|NCT02026245|Experimental|Tyndall/UU electronic data glove|"Using the electronic data gloves to perform a set routine of movements~Intervention: Data gloves to perform movements"
3322290|NCT02026271|Experimental|Ad-RTS-hIL-12+veledimex|varying doses of intratumoral Ad-RTS-hIL-12 (INXN-2001) and oral veledimex (activator ligand).
3322291|NCT02026284||Gravid women|A questionnaire was performed to gravid women
3322292|NCT02026310|Experimental|glimepiride|on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.
3322293|NCT02026310|Active Comparator|Metformin and glargine|on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l
3322294|NCT02026323|Experimental|acupuncture|"Normal weight group,the PCOS women with insulin resistance who are normal weight( BMI=18.5-23Kg/m2).The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
3322295|NCT02026323|Experimental|acupuncture 2|"Over weight or obese group ,the PCOS women with insulin resistance who are overweight or obese: BMI >23 Kg/m2.The acupuncture treatment will last for six months, 3 times per week, 30 minutes per treatment."
3228772|NCT01174966||Survivor Nonsurvivor|
3322296|NCT02026336|No Intervention|enose|Electronic nose can discriminate the inflammatory asthma phenotypes, supporting their potential as a non-invasive alternative tool to induced sputum.
3322297|NCT02026349|Active Comparator|favipiravir|
3228773|NCT01174979|Experimental|Caroverin|
3228774|NCT01174979|Placebo Comparator|Placebo|
3228775|NCT01174992|Experimental|Evicel|
3322298|NCT02026349|Placebo Comparator|placebo|
3228776|NCT01174992|Other|Sutures only|
3322299|NCT02026362|Other|The foundation treatment after radical operation or RFA|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
3322300|NCT02026362|Experimental|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens
3322301|NCT02026388||Primary Hyperoxaluria|Diagnosis of Primary Hyperoxaluria, or a family member of someone with this diagnosis.
3322302|NCT02026388||Dent Disease|Diagnosis of Dent Disease, or a family member of someone with this diagnosis.
3322303|NCT02026388||Cystinuria|Diagnosis of Cystinuria, or a family member of someone with this diagnosis.
3322304|NCT02026388||APRT deficiency|Diagnosis of APRT Deficiency, or a family member of someone with this diagnosis.
3322305|NCT02026401|Experimental|NGM282 Dose 1|NGM282 Dose 1
3322306|NCT02026401|Experimental|NGM282 Dose 2|NGM282 Dose 2
3322307|NCT02026401|Placebo Comparator|Placebo|Placebo
3322308|NCT02026414|Experimental|PrimaVie Exercise|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
3228777|NCT01175044|Active Comparator|Betadine Lavage|dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000ml of sterile saline irrigation
3322309|NCT02026427||Drotaverine|40 mg of drotaverine hydrochloride administered intramuscularly just after the proper level of spinal anesthesia was achieved.
3322310|NCT02026427||Control|Without intramuscular administration of drotaverine hydrochloride.
3322311|NCT02026440||Smokers|Those who smoke at least one cigarette a day.
3322312|NCT02026440||Non smokers|Those who have not smoked for at least one week when the sample is collected.
3322313|NCT02026466||CAD with CTO|Subjects will have Coronary Artery Disease with a diagnosed Chronic Total Occlusion: a coronary artery with TIMI flow of zero(no flow) for at least three months.
3322314|NCT02026479|Experimental|regular treatment comparator|Ginaton
3322315|NCT02026479|Experimental|Dexamethasone Phosphate low dose|5mg
3228778|NCT01175044|Placebo Comparator|Saline Lavage|2000 ml sterile saline lavage alone
3228779|NCT01175057||Group A|10 patients who undergo home monitoring with the MeDiNa Homebox for 4 weeks and then 4 weeks without the MeDina Homebox
3322316|NCT02026479|Experimental|Dexamethasone Phosphate high dose|10mg
3228780|NCT01175057||Group B|Group B starts without the MeDiNa Homebox for 4 weeks and then undergo Homemonitoring with the MeDiNa Homebox for 4 weeks.
3228781|NCT01175070|Experimental|Pegaptanib|Participants receiving 6-weekly treatment with pegaptanib sodium (Macugen [TM]) for ischaemic diabetic macular oedema over a 30 week period.
3322317|NCT02026492|Other|40 patients aged 6-18 years|All 40 patients with a diagnosis of asthma are recruited from the outpatients clinic of the department of Pediatric Pneumology and Allergology of the University Hospital Frankfurt. Patients undergo a methacholine challenge and two exercise challenges in a cold chamber and one exercise challenge in room temperature.
3322318|NCT02026492|Other|40 subjects aged 18-45 years|All subjects show bronchial hyperresponsiveness e.g. dyspnea when exercising in cold environment, in their medical history. Subjects undergo a methacholine challenge and exercise challenge in a cold chamber and one exercise challenge in room temperature.
3322319|NCT02026505||Multiple Myeloma, Bortezomib|
3322320|NCT02026518|Experimental|Soy|Group Soy receiving placebo similar to 50000 IU cholecalciferol (includes MCT oil) biweekly for 6 weeks in addition to 40 milligram (2 capsules per day) soy isoflavones capsules for 6 weeks
3322321|NCT02026518|Experimental|Soy- Cholecalciferol|Group Soy- Cholecalciferol receiving Supplement in form of 40 milligrams soy isoflavones (diadzein, genistein, glycitin) per day (2 capsules of 20 milligrams) for 6 weeks in addition to supplement of cholecalciferol (vitamin D3) biweekly for 6 weeks
3322322|NCT02026518|Placebo Comparator|Placebo|Group Placebo receiving Placebo in similar form of cholecalciferol supplement biweekly for 6 weeks in addition to 40 milligrams placebo in similar form of soy isoflavones including starch for 6 weeks
3228782|NCT01175096|Active Comparator|RAD001|2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day Dose level modifications/interruptions must follow guidelines. One treatment cycle consists of 28 days.
3228783|NCT01175109|Experimental|Escalating doses of imatinib and LBH589|"Study will incorporate a 3+3 dose escalation design."
3228784|NCT01175122|Experimental|H2N3 MO 2003/AA ca Vaccine|Participants will receive a nasal spray administration of the H2N3 MO 2003/AA ca vaccine on Day 0 and Day 28.
3322323|NCT02026518|Experimental|Cholecalciferol|Group Cholecalciferol receiving oral Placebo in similar form to soy isoflavones (diadzein, genistein, glycitin) supplement including starch (2 capsules per day) for 6 weeks in addition to 50000 IU cholecalciferol supplement biweekly for 6 weeks
3322324|NCT02026531|Experimental|3-Helium inhalation gas|This is a pilot study. The aim is to recruit 20 patients who will all receive the product under investigation.
3322325|NCT02026544|Experimental|Low Frequency Therapeutic Ultrasound|Low Frequency Therapeutic Ultrasound (LOTUS) applied transcutaneously
3322326|NCT02026570|No Intervention|Control|Persons with unilateral transtibial amputation receiving standard physical therapy.
3322327|NCT02026570|Experimental|Motor Control Internal Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with motor control internal focus of attention instructions.
3322328|NCT02026570|Experimental|Motor Control External Focus|Persons with unilateral transtibial amputation receiving standard physical therapy and additional training with external focus of attention instructions.
3228785|NCT01175161|Experimental|Immediate postpartum IUD insertion|Women assigned to have the IUD placed 10 minutes to 48 hours postpartum
3228786|NCT01175161|Experimental|6 week postpartum IUD insertion|Women who receive the IUD at the traditional time frame.
3228787|NCT01175187||EPIDURAL FEVER|
3322329|NCT02026583|Experimental|Simvastatin|
3228788|NCT01175187||EPIDURAL WITHOUT FEVER|
3322330|NCT02026596||aSAH patients|Patients suffering from aneurysmal subarachnoid haemorrhage
3322331|NCT02026609||TIPS|Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
3322332|NCT02026622|Other|3 groups of subjects|"3 groups: depressive subjects, subjects remitted from depression and control subjects, with the same interventions.~psychometric tests, MRI, transcranial doppler and TPI, explicitative interview"
3322333|NCT02026635||Optivol® Device in CareLink|A single cohort group of heart failure patients with already implanted Optivol® capable devices who are discharged home from the hospital
3322334|NCT02026648||cases with cervical cancer|
3228789|NCT01175187||GROUP 1: EPIDURAL FEVER . GROUP 2 EPIDURAL WITHOUT FEVER|
3228790|NCT01175200|Active Comparator|Prasugrel|
3228791|NCT01175200|Active Comparator|Clopidogrel|
3322335|NCT02026661||those that did not receive ICSI or LAH|
3322336|NCT02026661||those that received ICSI only|
3228792|NCT01175200|Active Comparator|Lansoprazole|proton pump inhibitor
3228793|NCT01175200|Placebo Comparator|Placebo|
3228794|NCT01175239|Experimental|Single infusion of autologous CD34+ cells|
3228795|NCT01175252||Gastroenteritis Cohort|All children suffering with gastroenteritis
3228796|NCT01175265|No Intervention|pulmonary rehabilitation, no breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
3228797|NCT01175265|No Intervention|breathing retraining|Forty COPD patients (23 females) with a mean (SD) age of 66.0 (6.3) years and a FEV1 of 47.1 (18.9) % predicted were randomized to conventional pulmonary rehabilitation (n=20) and conventional pulmonary rehabilitation plus breathing retraining (n=20).
3228798|NCT01175278|No Intervention|Observation Arm|Patients who are asymptomatic (no symptoms) will participate in the observational portion of the study.
3228799|NCT01175278|Experimental|Balloon Kypholasty|
3322337|NCT02026661||those that received LAH only|
3322338|NCT02026661||those that received both ICSI and LAH|
3322339|NCT02026674|Experimental|FloRite|LUTS patients that used FloRite for home urine flow diagnostics.
3228800|NCT01175278|Active Comparator|Control Arm|Non-surgical Management Treatment Group
3228801|NCT01175291|Active Comparator|Arm A - FOLFOX 7 + MK-0646|
3228802|NCT01175291|Placebo Comparator|Arm B - FOLFOX 7 + Placebo|
3228803|NCT01175304||Workers in a Barcelona tertiary hospital|Workers attending annual medical checkups
3228804|NCT01175330|Placebo Comparator|CABG and intralipid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Intralipid Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
3322340|NCT02026700|Experimental|bariederm, barrier cream|one arm study: use of bariederm cream on hands twice daily for 21 days
3322341|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and Prasugrel or|All patients quit smoking for a 2 weeks period
3228805|NCT01175330|Active Comparator|CABG and omega-3 fatty acid infusion|Procedure: CABG surgery and subcutaneous cardiac monitor implantation Drug: Omegaven Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
3228806|NCT01175408|Active Comparator|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
3228807|NCT01175408|Active Comparator|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will send the data to their endocrinologist and receive feedback based on the uploaded glucose data.
3228808|NCT01175408|Active Comparator|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
3228809|NCT01175408|Active Comparator|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
3228810|NCT01175421||Patients undergoing sleep study|
3228811|NCT01175447|Experimental|Chemoradiotherapy with S-1|radiation 54Gy over 30 fractions,and concurrent with s-1 on days 1-14 and 29-42
3228812|NCT01175460|Experimental|Chemoradiotherapy|Thoracic radiation 60Gy over 30 fractions.Concurrently, nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 was given on Days 1-14,repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
3228813|NCT01175486|Experimental|Actos|Actos 30 mg for 6 months
3228814|NCT01175486|Active Comparator|Acarbose|Acarbose 50mg tid for 6 months
3228815|NCT01175512|Active Comparator|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
3228816|NCT01175512|Placebo Comparator|Placebo|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
3228817|NCT01175525|Placebo Comparator|sugar pill|sugar pill dissolved in water to be given 4 times a day 30 minutes prior to meals
3228818|NCT01175525|Active Comparator|Cromolyn|Cromolyn dose of 200mg(dissolved in water) will be given 4 times a day(30 minutes before a meal)
3228819|NCT01175538|Experimental|Lactulose|
3228820|NCT01175551||Group 1|women screened at Penn OB/GYN Associates or Helen O. Dickens Center with a documented singleton pregnancy less than 18 weeks gestational age
3322342|NCT02026713|Experimental|smokers on dual antiplatelet therapy with ASA and ticagrelor|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
3322343|NCT02026713|Active Comparator|smokers on dual antiplatelet therapy with ASA and Clopidogrel|All patients on chronic dual antiplatelet therapy (>1 month) quit smoking for a 2 weeks period
3322344|NCT02026739|Experimental|low supplemental oxygen concentration|The group in which low supplemental oxygen concentration of 40% will be performed during minimally invasive esophagectomy.
3322345|NCT02026739|Active Comparator|high supplemental oxygen concentration (conventional)|The group in which high supplemental oxygen concentration (onventional) of 80% will be performed during minimally invasive esophagectomy.
3322346|NCT02026752||Study Population|
3322347|NCT02026765|Other|Heparin Surface Modified Aspheric Lens|Heparin Surface Modified Aspheric Lens
3322348|NCT02026765|Other|traditional lens|traditional Aspheric lens
3322349|NCT02026778|Experimental|ondansetron-betahistine|ondansetron-betahistine group
3322350|NCT02026778|Placebo Comparator|ondansetron|ondansetron group
3322351|NCT02026791|Experimental|The clinical efficacy of the I-gel|The clinical efficacy of the I-gel
3322352|NCT02026791|Active Comparator|The clinical efficacy Supreme-LMA|The clinical efficacy Supreme-LMA
3322353|NCT02026804||Prenatal mental disorders|
3322354|NCT02026817|Experimental|HCP1201|Participants received a single oral dose of the HCP1201 750/10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3322355|NCT02026817|Active Comparator|Metformin and Rosuvastatin|Participants received a single oral dose of coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3322356|NCT02026830||Diabetic foot infection|Patients with DM (Diabetes Mellitus) presenting with a diabetic foot infection will be enrolled in the current trial to determine the causative microorganisms and their antibiotic sensitivity patterns in diabetic patients with a foot infection in Turkey.
3322357|NCT02026843||Diabetic retinopathy,humor,angiogenic|Samples of aqueous humor was taken before injection and before surgery. The injection include bevacizumab or triamcinolone.
3322358|NCT02026843||Nondiabetic,angiogenic,humor|Aqueous humor was taken before surgery. Surgery include pars plana vitrectomy of macular hole, epiretinal membrane, cataract surgery.
3322359|NCT02026856||Se-OI> 200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
3322360|NCT02026856||Se-OI <200|patients who received form of sodium selenite pentahydrate at 750 mg/day for 6 days immediately after admission to our department (1000 mg of sodium selenite pentahydrate = 333 micrograms of selenium) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
3322361|NCT02026856||Placebo-OI> 200|patients who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was higher than 200
3228821|NCT01175551||Group 2|Nulliparous pregnant women (no previous pregnancy greater than 15 weeks) screened at Penn OB/GYN Associates or Helen O. Dickens Center less than 18 weeks gestational age
3228822|NCT01175564|Experimental|Active|Each cohort will have 9 volunteers that will receive TC-5214
3322362|NCT02026856||Placebo-OI <200|patients who who received continuous saline NaCl 50 ml/day for 6 days as a continuous infusion (excluding additional infusion therapy) and oxygenation index (OI) by PaO2/FiO2 (partial pressure of oxygen in arterial blood/ fraction of inspired oxygen) was lower than 200
3228823|NCT01175564|Placebo Comparator|Placebo|Each cohort will have 3 volunteers that will receive placebo
3228824|NCT01175577|Active Comparator|Supplement 1|
3228825|NCT01175577|Active Comparator|Supplement 2|
3228826|NCT01175577|Active Comparator|Food-based Intervention|
3228827|NCT01175577|Placebo Comparator|Placebo|
3228828|NCT01175603|Experimental|Cognitive behavioral intervention|Women in the intervention condition will receive 6 two-hour intervention sessions delivered weekly in a group format by the Study Clinician. Each session contains didactic instruction on core content, as well as activities and group discussion. One of the strengths of embedding the MB Course within home visiting is our ability to have home visitors reinforce the material presented by the Study Clinician. The 6-week curriculum is divided into three modules: (a) pleasant activities, (b) thoughts, and (c) relationships with others. Each module has two sessions. These sessions map onto core cognitive-behavioral concepts.
3322363|NCT02026869|Active Comparator|Oral metformin|Metformin 850 mg tablets taken by mouth every 12 hours for 6 months
3322364|NCT02026869|Active Comparator|Vaginal metformin|Metformin 850 mg tablets taken vaginally every 12 hours for 6 months
3228829|NCT01175603|No Intervention|Usual home visiting|Women in the control group will receive usual home visiting services and information on postpartum depression.
3228830|NCT01175616|Experimental|Creatine|Open-Label Active Treatment with Creatine 5 grams daily for 8 weeks.
3228831|NCT01175629||Group 1|The Vietnam Era Twin (VET) Registry is a closed cohort composed of 7,369 middle-aged male-male twin pairs both of whom served in the military during the time of the Vietnam conflict (1965-1975). The Registry is a United States Department of Veterans Affairs resource that was originally constructed from military records; the Registry has been in existence for more than 15 years. It is one of the largest national twin registries in the US and currently has subjects living in all 50 states. Initially formed to address questions about the long-term health effects of service in Vietnam the Registry has evolved into a resource for genetic epidemiological studies of mental and physical health conditions. Several waves of mail and telephone surveys have collected a wealth of health-related information on Registry twins. Other data collection efforts have focused on specific sets of twin pairs and conducted detailed clinical or laboratory testing.
3322365|NCT02026882|Other|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
3322366|NCT02026895|Experimental|Patient with infection by Staphylococcus lugdunensis|
3322367|NCT02026908|Experimental|Prostate Artery Embolization|There is only one arm of this study where patients receive Prostate Artery Embolization
3322368|NCT02026921|Experimental|Carboplatin and docetaxel|Intravenous infusion every 3 weeks Carboplatin plus docetaxel
3322369|NCT02026947|Placebo Comparator|Placebo|In both arms, one capsule at the morning for the first week. One capsule at the morning and one at the evening for the weeks 2-12.
3228832|NCT01175642|Experimental|Cognitive remediation|Cognitive remediation
3228833|NCT01175642|Active Comparator|Functional Adaptive Skills Training|Functional and social skills group treatment
3228834|NCT01175642|Active Comparator|Combined Treatment|Combined cognitive remediation and functional adaptive skills training
3228835|NCT01175655|Experimental|MSC|
3228836|NCT01175681|Experimental|treatment|remote ischaemic preconditioning
3228837|NCT01175681|No Intervention|untreated|control
3322370|NCT02026947|Experimental|Sodium benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
3322371|NCT02026960|Experimental|Renal Cell Carcinoma Tumor Tissue|
3322372|NCT02026960|Experimental|Genitourinary tumor tissue (Expansion cohort)|Bladder, prostate or testicular cancer
3322373|NCT02026973|Experimental|IM Placebo/Oral Placebo|IM placebo given once on Day 1; Oral placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3228838|NCT01175694|Active Comparator|Brachytherapy|Interstitial multicatheter brachytherapy
3322374|NCT02026973|Experimental|IM Placebo/PO Anastrozole|IM placebo given once on Day 1; Oral Anastrozole 2.0mg pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3322375|NCT02026973|Experimental|IM Fulvestrant/PO Placebo|IM Fulvestrant 250mg given once on Day 1; Oral Placebo pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3322376|NCT02026973|Experimental|IM Fulvestrant/IM Anastrozole|IM Fulvestrant 250mg given once on Day 1; Oral Anastrozole pills daily x14-18 days. Somatostatin 1mcg/kg/hr will be administered for 2 hours from 8-10AM on the overnight visit.
3322377|NCT02026986|Experimental|sleep deprivation|Ten subjects in the SD group were examined after a SD experiment in which they did not sleep for 24 h.
3228839|NCT01175720|Experimental|test and control|The test and control technique will be tested in a split-mouth design.
3228840|NCT01175733|Experimental|Panitumumab|
3322378|NCT02026986|No Intervention|control|The 10 subjects in the control group were not sleep deprived (had 8 h of sleep).
3322379|NCT02027012|Experimental|Renal denervation with Vessix system|
3322380|NCT02027038|Experimental|Patients with sacroiliac joint pain|Patients suffering from sacroiliac joint pain
3322381|NCT02027038|Active Comparator|Controls|healthy controls
3322382|NCT02027064|Experimental|interferon|
3322383|NCT02027077|Active Comparator|Control group|Control group
3322384|NCT02027077|Active Comparator|Lifestyle counseling|Behavioral intervention group
3228841|NCT01175746|Experimental|nicardipine|
3322385|NCT02027090|Experimental|Higher dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are randomly assigned to higher dose icotinib group to receive icotinib with a dose of 375 mg three times per day, till progressive disease or unaccepted toxicity.
3322386|NCT02027090|Active Comparator|Routine dose icotinib|Patients with stable disease after 8-week routine dose icotinib treatment, are administered with icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity.
3322387|NCT02027103|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3322388|NCT02027103|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3228842|NCT01175746|Active Comparator|remifentanil|
3228843|NCT01175759|Experimental|Healthy control group|
3228844|NCT01175759|Experimental|UPRL|
3228845|NCT01175772|Experimental|Metronomic Chemoterapy|Maintenance Treatment for Ovary Carcinoma by Metronomic Chemotherapy
3259092|NCT01467349||Raltegravir group|"This study will include subjects who received raltegravir and were previously exposed to NRTIs, NNRTIs, PIs, regardless of the stage of HIV disease at the start of the treatment.~A control group will be used for the evaluation of the primary and secondary objectives in comparison to patients treated with raltegravir (study patients). The control group will be constituted by subjects who never received raltegravir, matched (in a ratio 1:3) with the study subjects by gender, age (± 3 years), CD4+ cells counts (± 50 cells) and HCV co-infection status yes/no). For control patients, the last antiretroviral regimen prescribed will be considered."
3259093|NCT01467362|Experimental|V0034CR01B|
3322389|NCT02027116|Experimental|Experimental: 1mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3322390|NCT02027116|Experimental|Experimental: 3mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3322391|NCT02027116|Experimental|Experimental: 6mg of DNA/dose|Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
3322392|NCT02027129|Other|Low frequency HFO/HFO-TGI vs high frequency HFO|Total study population for the testing of the ventilatory strategies
3322393|NCT02027142||Cases|Women referred to two academic centres for the diagnosis and treatment of endometriosis.
3322394|NCT02027142||Controls|Women referred to our Institutions because of routine gynaecologic consultations.
3322395|NCT02027155|Active Comparator|AR09 solution|AR09, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
3322396|NCT02027155|Placebo Comparator|Placebo (for AR09 solution)|Placebo; normal saline
3322397|NCT02027168||CPA treatment|CPA treatment group receives 20 hours of patient centered manual physical therapy
3322398|NCT02027181|Experimental|device FreeO2|Automatic adjustment of oxygen
3322399|NCT02027181|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
3322400|NCT02027194|Experimental|Cure-Allergic Rhinitis Syrup|In syrup form, 20 ml once daily for 4 weeks
3322401|NCT02027194|Active Comparator|Yu-ping-fung San|In syrup form, 20ml once daily for 4 weeks
3322402|NCT02027194|Placebo Comparator|Placebo group|In syrup form (wheat powder with ginger and flavors), 20 ml once daily for 4 weeks
3322403|NCT02027207|Experimental|Shanchol|
3322404|NCT02027207|Placebo Comparator|Placebo|
3322405|NCT02027220|Experimental|G-CSF/Bortez/Cyc/Dex|G-CSF IC on days 0, 1, 7, 8, 14, 15, 21 and 22. Bortezomib IV on days 1, 8, 15 and 22. Cyclophosphamide CIV on days 1, 8, 15 and 22. Dexamethasone IV on days 1, 2, 8, 9, 15, 16, 22 and 23.
3228846|NCT01175785|Experimental|Treatment (chemo, radiation, transplant, GVHD prophylaxis)|Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
3228847|NCT01175837|Experimental|Short-term fasting prior to systemic chemotherapy|"COHORT I: Patients fast 24 hours before day 1 of course 2 of chemotherapy. If fast is well tolerated, patients may escalate fasting by 12 hours for each subsequent course of chemotherapy for up to 3 courses in the absence of unacceptable toxicity.~COHORT II: Patients fast at the longest fasting regimen found to be safe and tolerable in cohort I before day 1 of each course of course of chemotherapy for up to 4 courses in the absence of unacceptable toxicity."
3322406|NCT02027233|Experimental|Nasopharyngeal sample|Rapid completion of nasopharyngeal within 24 hours after hospitalization without exceeding 7 days after the onset
3322407|NCT02027246|Experimental|Stem cell|Autologous bone marrow mononuclear cell transplantation
3322408|NCT02027259|Experimental|Group visits with behavioral activation|Group visits with behavioral activation (BA) will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
3322409|NCT02027259|No Intervention|Standard group visits|Standard group visits will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
3322410|NCT02027285|Experimental|fortified milk|The subjects assumed daily 250 ml of fortified milk for 12 weeks. Then, after a period of wash-out of 12-14 weeks they start to assume placebo milk for 12 weeks.
3322411|NCT02027285|Placebo Comparator|placebo milk|The subjects assumed daily 250 ml of placebo milk. Then, after a period of wash-out of 12-14 weeks they start to assume fortified milk for 12 weeks.
3228848|NCT01175863|Active Comparator|Intravascular ultrasound|
3228849|NCT01175863|Active Comparator|Fractional flow reserve|
3322412|NCT02027298|Experimental|Abatacept|Abatacept by SC injection of 125 mg weekly for 6 months
3322413|NCT02027324|Experimental|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
3322414|NCT02027324|Experimental|Povidone-Iodine group|10% Povidone-iodine applied topically according to manufacturer's instructions
3322415|NCT02027337|No Intervention|Control group|Healthy women that no use combined oral contraceptives
3322416|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz)
3322417|NCT02027337|Experimental|20 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/3 mg drospirenone (Yaz) and antioxidant complex Selmevit
3322418|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin)
3322419|NCT02027337|Experimental|30 mcg EE/3 mg drospirenone and Selmevit|Women that use combined oral contraceptives containing 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin) and antioxidant complex Selmevit
3322420|NCT02027337|Experimental|35 mcg EE/2mg cyproterone|Women that use combined oral contraceptives containing 35 mcg ethinylestradiol/2 mg cyproterone
3322421|NCT02027337|Experimental|35 mcg EE/2 mg cyproterone and Selmevit|Women that use combined oral contraceptives containing 20 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3322422|NCT02027350|Experimental|Pressure-volume relationship|Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration.
3322423|NCT02027363|Experimental|Observation group|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation.
3322424|NCT02027363|Experimental|Capecitabine group|"Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy could continue to receive oral capecitabine as maintenance therapy, capecitabine, 1000mg/m2 bid d1-14, every 3 week.~The maintenance treatment was continued until progression, unacceptable toxicity, or patient withdrawal."
3322425|NCT02027389||control|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2012 - Dec 31, 2012. No rapid testing was performed, and standard bacterial culture and susceptibility testing was done.
3322426|NCT02027389||intervention|Patients with growth of S. aureus from sterile site cultures between Sept 15, 2013 - Dec 31, 2013. Rapid PBP2a testing was performed along with pharmacist notification of service if modification to therapy needed based on rapid test results.
3322427|NCT02027415|Experimental|Beet Orange|Beet juice will be given prior to the first car ride and orange juice will be given prior to the second car ride.
3322428|NCT02027415|Experimental|Orange Beet|Orange juice will be given before the first car ride and beet juice will be given before the second car ride.
3322429|NCT02027441||Home-based Testing|"At enrollment, consenting index participants will provide the study staff with locator information and a complete list of individuals currently living in his/her home who may be eligible for home-based HIV testing intervention (Household Composition form).~The study staff and index participant will schedule a date/time for the study staffto visit the index participant's home. Study staff will also provide the index participant with an information sheet to give to household members.~A study testing team comprised of trained counselors and interviewers will visit the index participant's home on the pre-determined date/time and offer home-based HIV testing to those household members who are present."
3322430|NCT02027454|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1, treatment B in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322431|NCT02027454|Experimental|Sequence 2|Participants in this arm will receive treatment A in period 1, treatment C in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322432|NCT02027454|Experimental|Sequence 3|Participants in this arm will receive treatment B in period 1, treatment A in period 2 and treatment C in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322433|NCT02027454|Experimental|Sequence 4|Participants in this arm will receive treatment B in period 1, treatment C in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322434|NCT02027454|Experimental|Sequence 5|Participants in this arm will receive treatment C in period 1, treatment A in period 2 and treatment B in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322435|NCT02027454|Experimental|Sequence 6|Participants in this arm will receive treatment C in period 1, treatment B in period 2 and treatment A in period 3. Where treatment A= Three doses of GSK1265744 150 mg (5 x 30mg tablets) every 12 hours. B= Three doses of GSK1265744 placebo (5 tablets) every 12 hours. C= A single dose of Moxifloxacin 400mg (one 400mg tablet).
3322436|NCT02027467|Experimental|StemAlive®|Stem Alive® includes ingredients like green tea, ashwagandha. Dose: 3 capsules twice daily to be taken orally for 14 days.
3322437|NCT02027467|Placebo Comparator|Placebo|Matching placebo capsules (for StemAlive®) containing polyethylene glycol, rice powder and magnesium stearate. Dose: 3 capsules twice daily to be taken orally for 14 days.
3322438|NCT02027480||Prospective Cohort|"The study will be a prospective cohort study of HIV-infected adults initiating ART at 4-8 health facilities in Nyanza Province, Kenya. Participants will be asked to take part in four visits over a 12 month period.~At each study visit, participants will be asked questions related to demographic characteristics, medical history, including history of/recent medical conditions, family medical history, TB history and smoking status. Participants will also have their height (at baseline visit only) and weight measured for calculation of BMI and blood pressure reading. Blood and urine specimens will be collected and stored at each study visit for future testing."
3322439|NCT02027493|Active Comparator|Reiferon R weekly plus ribavirin|patients who continued treatment on weekly basis (7-day schedule). This group included patients who were HCV-RNA negative at week 12 and those who had < 1 log decrease in HCV-RNA viremia
3322440|NCT02027493|Active Comparator|Reiferon R (every 5-day) plus ribavirin|patients who continued treatment on a 5-day schedule. This group included patients who had ≥ 1 log decrease in viremia (compared to pre-treatment level) at week 12
3228850|NCT01175876|Experimental|1|Device: RIPC RIPC consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins Procedure: Carotid Artery Stenting
3228851|NCT01175876|Sham Comparator|2|Procedure: Carotid Artery Stenting
3228852|NCT01175889|Experimental|one side ACE blade|
3228853|NCT01175889|Active Comparator|one side scalpel|
3322441|NCT02027519||Home-based Self-testing|"Index participants who have tested positive for HIV will be provided with information regarding the importance of HIV testing for their partners and other household members and the role of home-based self-testing in potentially increasing the number of partners and household members tested for HIV. In addition, index participants will be counseled about ways in which to talk to partners and household members about HIV testing and provided with information sheets that can be distributed within the household. Lastly, index participants will be introduced to a member of the testing team that will present at their home and offer the study intervention."
3322442|NCT02027532|Active Comparator|Cefazolin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
3322443|NCT02027532|Active Comparator|Vancomycin|intravenous, weight-based dose (1gm<80kg, 2gm>80kg), perioperatively
3228854|NCT01175915|Active Comparator|Western therapy|
3228855|NCT01175915|Experimental|Reduning Injection|
3228856|NCT01175915|Experimental|Reduning Injection plus western therapy|
3228857|NCT01175928|Experimental|Peristaltic Pulse PCD|Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
3228858|NCT01175928|Sham Comparator|Sham Device|Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
3322444|NCT02027571|Experimental|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
3228859|NCT01175941|Experimental|NRL001|10 mg NRL001 in a 2 g suppository
3228860|NCT01175941|Placebo Comparator|Placebo|Matched placebo control
3228861|NCT01175954|Experimental|Lacosamide Open-Label|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
3228862|NCT01175993|Active Comparator|Eliptical training|Home base exercise
3228863|NCT01176019|Experimental|Interactive Video|In addition to standard care, the experimental arm will receive an interactive video designed to inform and educate patients about the choices that exist concerning prenatal screening and diagnosis.
3228864|NCT01176019|No Intervention|Control|A control arm will receive standard care, which is the opportunity to meet with a genetic counselor.
3228865|NCT01176045||Pre-surgical treatment|Patients who are pre & post-surgical treated with ocular lubricants.
3228866|NCT01176045||Non-presurgical treatment|Patients who are only post-surgical treated with ocular lubricants
3228867|NCT01176084|Experimental|low carbohydrate diet|
3228868|NCT01176084|Experimental|diet & exercise|
3322445|NCT02027584||parturient|mother who had given birth within 48 hours of clinically indicated blood sampling
3322446|NCT02027584||healthy, non-pregnant, female volunteers|healthy, non-pregnant, female volunteers
3322447|NCT02027584||preterm infant|gestational age at birth < 37 weeks
3322448|NCT02027584||term infant|gestational age at birth >36 weeks
3228869|NCT01176097|Experimental|6 - 8 cohorts|6 patients in each cohort will receive AZD5658
3228870|NCT01176097|Placebo Comparator|6 - 8 cohorts|2 patients in each cohort will receive placebo
3322449|NCT02027597|Experimental|Video Game Treatment|This group received the AOTSM game experience followed by additional oral health information. They did not receive any follow-up treatment after the exhibit.
3322450|NCT02027597|Active Comparator|Control|Instead of playing Attack of the S. Mutans!, children in the control group attended a 90 minute classroom session about virtual reality applications for relieving pain and for therapy. This content was unrelated to oral health.
3322451|NCT02027597|Experimental|Video Game Treatment Plus Follow-Up|Children assigned to the Treatment-Plus conditions not only had the Attack of the S. Mutans video game experience, but also gained access to an educational website that reinforced the exhibit's teachings two months later. These students received a special login and password in the mail and were instructed to visit the site before completing their next questionnaire.
3322452|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-F)|Patients in this arm (ECLA-F) receive the 6-8 session CBT plus care-management intervention, administered in person.
3322453|NCT02027636|Active Comparator|Engagement and Counseling for Latinos (ECLA-T)|Patients in this arm received the 6-8 session CBT intervention via telephone.
3322454|NCT02027636|No Intervention|Usual Care|Patients in this arm receive usual care for depression from their primary care providers, which could include antidepressant prescription or referral to specialty mental health care.
3322455|NCT02027649||Bladder cancer|Patients who suffered a bladder cancer
3228871|NCT01176110|Experimental|thermal management with LMA PerfecTemp™|
3322456|NCT02027649||Control group|Patients with urologic diseases of non tumoral origin
3322457|NCT02027662|Experimental|Osvaren Granules|Osvaren Granules
3322458|NCT02027662|Active Comparator|Osvaren film-coated tablets|Osvaren film-coated tablets
3322459|NCT02027675|Experimental|Meal Exercise Challenge- Order 2|Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.
3322460|NCT02027675|Experimental|Meal Exercise Challenge- Order 1|"Two different meals,an high fat micronutrient poor meal and Mediterranean Meal will be followed by an exercise challenge and performed at different orders accordingly to the cross over design.~Each arm corresponds to a different intervention order."
3322461|NCT02027688|Active Comparator|Every 6 hour Feeding Schedule|Infants in this arm will be offered oral feedings every 6 hours if they are safe and ready to feed by mouth.
3322462|NCT02027688|Active Comparator|Every 3 Hour Oral Feeding|Infants in this arm will be offered oral feedings every 3 hours if they are safe and ready to feed by mouth.
3322463|NCT02027714||Women's Quantitative Survey|"Quantitative surveys will be administered to 200 pregnant and recently postpartum women. Surveys will be conducted in either English or Sesotho depending on the participant's preference. Surveys will be administered by a study-staff member. Survey activities will be conducted in a private space either within or around the clinic building. All study activities will take approximately 1 hour to complete.~The survey is comprised of 62 close-ended questions. Included in this survey are questions related to demographics, sexual behaviors, HIV and various HIV testing services."
3322464|NCT02027714||Women's Focus Group Discussions|"6-8 focus groups of approximately 6-12 pregnant or recently postpartum women will be conducted. Focus group discussions will be organized according to HIV serostatus to allow for open dialogue and participant comfort. All group discussions will be conducted in Sesotho. Each group discussion will be facilitated, preferably, by a female study-staff member. All group discussions will be held in a private space either within a study site or another speciﬁed location within the community. All study activities will take approximately two hours to complete.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding male circumcision will be asked."
3228872|NCT01176110|Active Comparator|no specific thermal management|
3228873|NCT01176123|Active Comparator|CBT-I in person|Cognitive behavioral therapy for insomnia delivered in person
3228874|NCT01176123|Experimental|CBT-I via telephone therapy|Cognitive behavioral therapy for insomnia delivered by telephone
3228875|NCT01176136|Experimental|HOPS Intervention|Middle school age children who receive the Homework, Organization, and Planning Skills (HOPS) intervention.
3228876|NCT01176136|No Intervention|Treatment As Usual|Middle school age children randomly assigned to receive treatment-as-usual services available through the school and community.
3228877|NCT01176149|Experimental|SMBG + intensive education|Patients will receive specific educational interventions to teach them how to perform Self monitoring Blood Glucose (SMBG), how to modify diet and level of physical activity according to blood glucose levels, and the actions to be undertaken in case of abnormal values (hypoglycemia, particularly elevated glucose levels). Patients will be instructed to modify their lifestyle habits (diet, physical activity) in order to reach specific goals (weight reduction, reduction in fat consumption intake, reduction in saturated fat intake, increase in fiber intake, regular physical activity.
3228878|NCT01176149|No Intervention|Usual Care|Usual Care
3228879|NCT01176162||"Group < 28"|• Gestational Age < 28 weeks
3228880|NCT01176162||"Group 28 - < 33"|• Gestational Age : 28 - < 33 weeks
3228881|NCT01176162||"Group 33- < 37"|Gestational Age : 33- < 37 weeks
3228882|NCT01176162||"Group > 37"|Gestational Age > 37 weeks
3228883|NCT01176175|Experimental|50 mg|Progesterone microspheres injectable suspension 50 mg
3322465|NCT02027714||Male Interviews|"30 in-depth individual interviews with men. In-depth semi structured interviews consisting of open-ended questions will be conducted in either English or Sesotho depending on the participant's preference will be conducted. Interview activities will be conducted in a private space either within or around the clinic building.~Topics that will be discussed during these interviews include relationship dynamics between Basotho men and women, knowledge of HIV and various related issues, including HIV testing, HIV treatment and discordancy in HIV status. Additionally, questions about knowledge and attitudes regarding traditional and medical male circumcision will be asked.~Following the completion of the interview, the same facilitator will administer a brief survey to the study participant."
3322466|NCT02027727||No intervention|No intervention- this is an observational study of patients receiving Infliximab.
3322467|NCT02027740|Experimental|almond|almonds are substituted for visible fat and carbohydrates
3322468|NCT02027753|Experimental|Insulin glargine and Oral anti diabetic treatment(s)|"Insulin glargine: Lantus~Add basal insulin: starting with 0.2 U/kg/day or 10 U/day~Adjust insulin glargine dose according to Fasting blood glucose~Oral Anti Diabetic treatment(s): DPP-4 inhibitors and Metformin plus or minus Sulphonylurea - Only Sulphonylurea can either be omitted or reduced at the physician's discretion."
3228884|NCT01176175|Experimental|100 mg|Progesterone microspheres injectable suspension 100 mg
3228885|NCT01176175|Experimental|200 mg|Progesterone microspheres injectable suspension 200 mg
3322469|NCT02027766|Experimental|Stretching|Daily stretching of the calf (dominant side; defined as leg used to kick a ball). 2 stretching exercises are performed daily: 1) stretching of the soleus muscle; 2) stretching of the gastrocnemius muscle.
3322470|NCT02027766|No Intervention|Control|
3322471|NCT02027779|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 additional exposure days.
3322472|NCT02027779|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during additional 50 exposure days.
3322473|NCT02027792|Experimental|Cabbage leaf wraps|Daily application of cabbage leaf wraps over night, 4 weeks application
3228886|NCT01176175|Experimental|300 mg|Progesterone microspheres injectable suspension 300 mg
3228887|NCT01176188|Experimental|Comfort Care|Parental soothing, including tactile and auditory strategies, followed by a quiet period with the application of earmuffs to block auditory stimulation
3228888|NCT01176188|Active Comparator|Usual Care|
3228889|NCT01176201|Experimental|A|400 mg suspension
3322474|NCT02027792|Active Comparator|Diclofenac gel|daily application of diclofenac gel 4 weeks application
3322475|NCT02027792|No Intervention|Usual care|no specific intervention
3322476|NCT02027805|Experimental|T-Guard|Four doses of T-Guard (4 mg/m2), administered at 48-hour intervals as 4 hour infusions.
3322477|NCT02027818|Experimental|Indocyanine Green|study of the correlation between fluorescence and margins of the tumours after iv injection of Indocyanine Green
3322478|NCT02027831|Experimental|Indocyanine Green|Intravenous injection of 0,25 mg/kg Indocyanine Green
3322479|NCT02027857|No Intervention|mannitol empirical therapy|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the empirical therapy by doctors.
3322480|NCT02027857|Experimental|EIT monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of Electrical impedance tomography monitoring.
3322481|NCT02027857|Other|non-invasive ICP monitoring|There would be 20 patients in this group, who would be given mannitol to relieve the brain edema depending on the results of non-invasive intracranial pressure monitoring.
3322482|NCT02027870||EXCEL-II DES|Using EXCEL-II biodegradable polymer sirolimus-eluting stent treating CAD
3322483|NCT02027896|Experimental|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
3322484|NCT02027896|No Intervention|Standard surgical care|Surgical hip fracture repair according to the standard timing.
3322485|NCT02027909||Therapy group one|Lower rate of 60 bpm and out of the box rate response settings of an ADL Rate of 95 bpm and rate profile optimization on with the only change being adjusting the activity threshold from med/low to low.
3322486|NCT02027909||Therapy group two|Rate response programming will be determined by an exercise test consisting of a 2 minute hall walk will be performed at the 2 week follow up and set points will be manually adjusted to achieve an ADL rate of 95 bpm. Rate Profile Optimization will be turned off. Activity threshold is programmed to low.
3322487|NCT02027909||Therapy group three|Lower rate of 60 bpm and the ADL rate based upon 220- age x 55%. Activity threshold is programmed to low. Rate Profile Optimization will be turned ON.
3228890|NCT01176201|Active Comparator|B|5 x 200 mg immediate release capsule
3228891|NCT01176214|Experimental|early tracheostomy|see study description
3228892|NCT01176214|Active Comparator|late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
3228893|NCT01176227|Placebo Comparator|Kyodophilus matching placebo capsules|
3228894|NCT01176227|Active Comparator|Kyodophilus multi strain probiotic capsules|
3228895|NCT01176253||25 newly diagnosed Type 1 diabetics|25 newly diagnosed Type 1 diabetics within onset of symptoms
3228896|NCT01176253||25 healthy volunteers|25 healthy volunteers (age & sex matched)
3259094|NCT01467362|Placebo Comparator|Vehicle cream|
3259095|NCT01467375|Experimental|A|
3259096|NCT01467388||phacic|Study patients who still have their own ocular lens
3259097|NCT01467388||pseudophacic|Study patients who have an intraocular lens after cataract surgery
3259098|NCT01467401|Experimental|A|
3259099|NCT01467401|Active Comparator|B|
3322488|NCT02027922|Experimental|Fluoride varnish Fluor Protector S|Fluoride varnish Fluor Protector S (Ivoclar Vivadent) with 1.5% ammonium fluoride was not scored. The emergence of a new varnish implies the necessity to compare the effectiveness of both agents in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
3322489|NCT02027922|Active Comparator|Duraphat|5% Sodium fluoride varnish Duraphat Colgate implies the necessity to compare the effectiveness with Fluor Protector S in preventing caries in deciduous teeth. All of the elements of a clinical trial and the varnish applications will be performed four times at three-month intervals: examination - 0 (initial score), follow-ups to the initial examination and intervention: 1 - after 3 months, 2 - after 6 months, 3 - after 9 months. Changes in OHI-S, spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs, and their components will be scored at follow-up examinations.
3259100|NCT01467414|Experimental|NN1250|
3259101|NCT01467440||PGA|Patients under glaucoma treatment with prostaglandines
3259102|NCT01467440||NON-PGA|Patient not recieving prostaglandines to treat their glaucoma
3322490|NCT02027922|No Intervention|an oral hygiene tutorial|an oral hygiene tutorial
3322491|NCT02027935|Experimental|Treatment (T cells, chemo, aldesleukin, ipilimumab)|Beginning 48 to 72 hours prior to T cell infusion, patients receive cyclophosphamide IV over 30-60 minutes. Patients then receive autologous CD8+ melanoma-specific T cells IV over 30-60 minutes on day 0, aldesleukin SC BID on days 0-13 and ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 in the absence of disease progression or unacceptable toxicity.
3322493|NCT02027961|Experimental|Cohort A1: Durvalumab (3 mg/kg) + Dabrafenib +Trametinib|Participants will receive intravenous (IV) dose of 3 milligrams per kilogram (mg/kg) durvalumab every 2 weeks (Q2W) from Day 1 up to 12 months along with oral 150 mg dabrafenib capsule twice daily (BID) and oral 2 mg trametinib tablet once daily (QD) until confirmed disease progression (PD), initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 3 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
3322494|NCT02027961|Experimental|Cohort A2: Durvalumab (10 mg/kg) + Dabrafenib +Trametinib|Participants will receive IV dose of 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral doses of dabrafenib 150 mg capsule BID and trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of dabrafenib and trametinib.
3259103|NCT01467518|Other|Period 1|Subjects will be on individualize stable dose of methdaone for 8 days.
3322495|NCT02027961|Experimental|Cohort B: Durvalumab (10 mg/kg) +Trametinib (Concurrent)|Participants will receive concurrent doses of IV 10 mg/kg durvalumab Q2W from Day 1 up to 12 months along with oral dose of trametinib 2 mg tablet QD until confirmed PD, initiation of alternate cancer therapy, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue treatment. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months and continued the treatment of trametinib.
3322496|NCT02027961|Experimental|Cohort C: Durvalumab (10 mg/kg) +Trametinib (Sequential)|Participants will receive sequential doses of oral trametinib tablet 2 mg QD from Day 1 to Day 42 and IV durvalumab 10 mg/kg Q2W starting from Day 29 (Week 5) up to 12 months. Post-durvalumab treatment period, participants who developed PD and meet the criteria for re-administration, will receive durvalumab 10 mg/kg up to an additional 12 months.
3322497|NCT02027974|Active Comparator|Iconacy Hip System|Iconacy hip system prosthesis components
3322498|NCT02027974|Active Comparator|Stryker Accolade Hip System|Stryker Accolade hip system prosthesis components
3322499|NCT02027987|Experimental|valproate acid|The patients began receiving treatment at a dose of 400 mg VPA twice daily on the day after randomization by intravenous drip, with this dose continued for 14 days.The dose was increased to 500 mg twice daily at week 3 and to 400 mg three times daily at week 4 if the DRS score had not improved by at least 2 points from baseline. After the week 4 assessment, the study drug was tapered over a period of 2 to 3 days, with assessment of the patients continued through week 6. Additional procedural details are provided in the study protocol.
3322500|NCT02027987|Placebo Comparator|placebo|
3322501|NCT02028000|Active Comparator|INSORB staples skin closure|Women undergoing cesarean section delivery will have skin closure with INSORB staples.
3322502|NCT02028000|Active Comparator|Monocryl skin closure|Women undergoing cesarean section delivery will have skin closure with Monocryl.
3322503|NCT02028000|Active Comparator|Vicryl skin closure|Women undergoing cesarean section delivery will have Vicryl skin closure
3322504|NCT02028026|Experimental|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
3322505|NCT02028026|Active Comparator|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks.
3322506|NCT02028039|Experimental|IPI-145|IPI-145 given at dose of 75 mg orally twice daily for 4 weeks. Courses repeated about every 4 weeks (range 4-6 weeks).
3322507|NCT02028052|Other|ROSE|In the case of ROSE, sampling frequency will occur similarly, but no additional samples will be taken in the case of provision of a preliminary diagnosis.
3322508|NCT02028052|Other|NO ROSE|In the case of no ROSE, sampling frequency will be predetermined at 4 needle aspirations per site
3228897|NCT01176279|Active Comparator|Manual and automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of TM BD DTXPlus ™), put the needless connector included in the kit to make the extractions of blood. Connect an arterial blood sampling syringe on the proximal 3-way stopcock key. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
3228898|NCT01176279|Experimental|Automated washing of the line|Place in the radial artery the system of invasive monitoring of the blood pressure (BD DTXPlus ™). Insert in line a second 3-way stopcock above the one that has the BD DTXPlus ™; this second 3-way stopcock will be called proximal key. On the distal 3-way stopcock key (the one of BD DTXPlus™), put the needless connector included in the kit to make the extractions of blood. On the proximal 3-way stopcock key put a second identical needless connector: in the intervention group the two 3-way stopcock keys have, each one, a needless connector. With the assembled system, it is necessary to print a curve of invasive determination of the blood pressure.
3228899|NCT01176305||Danish Women 15 to 49 years old.|Free of previous VTE and current use of oral contraceptives.
3228900|NCT01176318|Experimental|erdosteine|standard care plus erdosteine for 10 days
3228901|NCT01176318|Placebo Comparator|placebo|Standard care for exacerbation of COPD plus placebo
3228902|NCT01176331||vitrectomy|
3228903|NCT01176344|Experimental|Vitamin D supplementation|Participants in the intervention arm will receive 50,000 IU (1.25 mg) cholecalciferol capsules given once monthly
3228904|NCT01176344|Placebo Comparator|Placebo|The control arm will receive identical inert placebo capsules given once monthly.
3322509|NCT02028078|Experimental|Insulin human (Actrapid)|At 22:00 subject will receive insulin human (Actrapid) intravenously in order to obtain a steady state of a PG level of 5.5 mmol/L overnight until approximately 08:00 in the morning of day 2. At 8:00 am, in the morning at day 2, human insulin infusion will be increased to 1.5 mU/kg/min for each subject until approx. 12 pm for hypoglycaemia induction.
3322510|NCT02028091||Diabetes mellitus|All patients over 18 years with diagnosed diabetes mellitus type II.
3322511|NCT02028091||Non Diabetic|Patients over 18 years with no known diabetes mellitus or other known/diagnosed vascular diseases.
3322512|NCT02028104|Experimental|stem cells|autologous bone marrow mononuclear cell transplantation
3322513|NCT02028117|Experimental|Enadenotucirev|
3228905|NCT01176357||1|CABG
3322514|NCT02028130|Experimental|LAA electrical isolation + occlusion|Standard persistent AF ablation protocol + LAA electrical isolation + Watchman device implantation to occlude LAA
3322515|NCT02028143|Experimental|Study arm|The study arm group will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
3228906|NCT01176357||2|Valve surgery
3228907|NCT01176370|Experimental|Implantable Counterpulsation Therapy|The study is a single arm study with up to 20 patients enrolled and implanted with implantable counterpulsation. Patients that meet eligibility will be enrolled and implanted into the treatment arm of the study. There is not a control arm in this feasibility study.
3322516|NCT02028143|Active Comparator|Control arm|The control arm group will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
3322517|NCT02028156|Experimental|Partially Hydrolyzed Infant Formula|Fed ad lib.
3322518|NCT02028195|Experimental|Health check|The intervention consists of invitation for a behavioural and clinical examination followed by either (I) referral to a health promoting consultation in general practice (II) targeted behavioural programmes at the local Health Centre or (III ) no need for follow-up.
3322519|NCT02028195|No Intervention|No invitation|The persons randomised to the control arm does not get invitation to a health care examination before time for follow up in the intervention group.
3322520|NCT02028234|Active Comparator|pantoprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3322521|NCT02028234|Active Comparator|Omeprazole|Patients were randomly assigned to omeprazole (20 mg day) or pantoprazole (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3322522|NCT02028260|Active Comparator|Modafinil|Modafinil 200 mg qAM enterally for the duration the patient is confirmed to be in a hypoactive delirium to a maximum of 14 days.
3322523|NCT02028260|Placebo Comparator|Placebo|normal saline
3322524|NCT02028273||Control|Healthy control group. No history of substance abuse or dependence.
3228908|NCT01176383|No Intervention|Control group|The control group will have a standard NHS cessation clinic experience
3228909|NCT01176383|Experimental|Respiragene test and risk score|Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.
3228910|NCT01176396|Active Comparator|Caries prevention active intervention|Patients receive CAMBRA related products like CHX, 5000ppm F-toothpaste etc according to their risk level
3228911|NCT01176396|Placebo Comparator|control treatment|Patients receive treatment according to standard of care
3228912|NCT01176409|Experimental|High dose valacyclovir|Valacyclovir 1g po BID
3228913|NCT01176409|Active Comparator|Low dose valacyclovir|Valacyclovir 500mg po BID
3228914|NCT01176409|Placebo Comparator|Placebo|Inert placebo
3228915|NCT01176422||advanced Myelodysplastic Syndrome or acute myeloid leukemia|advanced MDS and AML with/without associated cytogenetic abnormality
3228916|NCT01176487|Experimental|A|A clinical trial using 3-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer
3228917|NCT01176539||Sleep Clinic|
3228918|NCT01176552|Experimental|Study group: GM-CSF, IFN, IL-2|
3228919|NCT01176578|Experimental|T2DM|Type 2 Diabetes Mellitus
3228920|NCT01176578|Experimental|IGT|Impaired Glucose Tolerance
3228921|NCT01176578|Active Comparator|NGT|Normal Glucose Tolerance
3228922|NCT01176604|Experimental|Treatment (yttrium Y 90 glass microspheres)|Participants receive yttrium Y 90 glass microspheres via a catheter over 5 minutes on day 0. Participants may receive additional treatments at 4-12 week intervals until all tumors in the liver have been treated in the absence of disease progression or unaccepted toxicity.
3228923|NCT01176643|Active Comparator|standard care plus yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
3228924|NCT01176643|No Intervention|Standard care|
3228925|NCT01176656||SU|T2DM patients with a prescription for a sulfonylurea but no insulin
3228926|NCT01176656||Antidiabetic without SU|T2DM patients with an oral antidiabetic drug other than an SU, and no insulin
3228927|NCT01176656||Insulin|T2DM patients using insulin, with or without other oral antidiabetics
3228928|NCT01176669|Experimental|Apatinib|
3322525|NCT02028273||Actively using patients|Participants actively using cocaine.
3228929|NCT01176682||1|Adult patients treated with NSAID therapy for diagnosed OA, RA or AS, and with GI risk factors
3228930|NCT01176695|Experimental|1|fish oil containing lipid emulsion
3228931|NCT01176695|Active Comparator|2|MCT/LCT containing lipid emulsion
3228932|NCT01176708|Experimental|Liver transplanted|10 Liver transplanted patients
3228933|NCT01176708|Experimental|Kidney transplanted|10 kidney transplanted individuals
3228934|NCT01176708|Experimental|Healthy controls|10 healthy controls
3228935|NCT01176721|Active Comparator|t-VNS verum|Active stimulation of the left auricle by t-VNS
3322526|NCT02028273||Abstinent Patients|Participants who have been abstinent from cocaine use for 3-6 months.
3322527|NCT02028286|Experimental|CLS001|CLS001
3322528|NCT02028299|Experimental|2D doppler echo with Definity solution|Study subjects will already be scheduled for right heart catheterization to diagnose pulmonary hypertension. Prior to the catheterization, each subject will have a 2D doppler echocardiogram with Definity solution as well.
3322529|NCT02028312|Active Comparator|Loteprednol etabonate + Restasis|Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days
3322530|NCT02028312|Placebo Comparator|Artificial Tears + Restasis|Artificial Tears, BID 30 days Restasis, BID 45 days
3322531|NCT02028338|Experimental|Dapivirine ring|dapivirine vaginal ring (25 mg)
3228936|NCT01176721|Placebo Comparator|Sham|Sham-simulation of the left auricle by the t-VNS device.
3228937|NCT01176734|Experimental|active t-VNS|active t-VNS
3228938|NCT01176747|Experimental|BDP/formoterol NEXT DPI|Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
3228939|NCT01176760|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
3322532|NCT02028338|Placebo Comparator|Placebo ring|silicone vaginal ring
3322533|NCT02028351||Normal|No Intervention
3322534|NCT02028351||Cataract|No intervention
3322535|NCT02028351||Maculopathy|No Intervention
3322536|NCT02028364|Experimental|Everolimus given in conjunction with exemestane|Everolimus 10mg orally daily given in conjunction with exemestane 25mg orally daily until disease progression or treatment discontinuation for any other reasons.
3322537|NCT02028377|Experimental|Imaging|PET/MRI
3322538|NCT02028390|Experimental|subjects with external wounds|Subjects with external wounds or body surface areas of interest are imaged visually and thermally with the Scout to trace the wound's perimeter visually and measure thermal variation data as described in the primary outcomes, using the ImageReview software.
3228940|NCT01176760|Experimental|Cardia|Truncally vagotomized subjects (due to cardia resection)
3228941|NCT01176760|Experimental|Ctrl|Healthy matched control subjects
3228942|NCT01176799|Active Comparator|Arm A: Control Arm|"Doxorubicin - 60mg/m2 day 1~Cyclophosphamide~-600mg/m2 day1, every 3 weeks x 4 cycles"
3228943|NCT01176799|Experimental|Arm B: Experimental|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
3228944|NCT01176812||Dermal Fillers|Facial Wasting
3228945|NCT01176825|Experimental|CBT|14-week individual cognitive-behavior therapy
3228946|NCT01176825|No Intervention|Treatment As Usual|14-week waitlist control
3228947|NCT01176851|Experimental|Glyco pMDI|Glyco pMDI 100 µg
3228948|NCT01176851|Experimental|Glyco pMDI Charcoal|Glyco pMDI 100 µg + charcoal block
3228949|NCT01176851|Active Comparator|Glyco IV injection|Glyco solution for injection 100 µg
3228950|NCT01176864|Active Comparator|Double-balloon enteroscopy|DBE for suspected or known small-bowel bleeding
3228951|NCT01176864|Active Comparator|Single-balloon enteroscopy|SBE for suspected or known small-bowel bleeding
3228952|NCT01176890|Experimental|Vago|Truncally vagotomized subjects (due to duodenal ulcer operation)
3228953|NCT01176890|Experimental|Cardia|truncally vagotomized subjects (due to esophagus resection)
3228954|NCT01176890|Experimental|Healthy controls|Healthy control subjects
3228955|NCT01176903|Experimental|Glyco SD1|Single administration of Glyco pMDI dose level 1
3228956|NCT01176903|Experimental|Glyco SD2|Single administration of Glyco pMDI dose level 2
3228957|NCT01176903|Experimental|Glyco SD3|Single administration of Glyco pMDI dose level 3
3228958|NCT01176903|Experimental|Glyco SD4|Single administration of Glyco pMDI dose level 4
3228959|NCT01176903|Experimental|Glyco SD5|Single administration of Glyco pMDI dose level 5
3228960|NCT01176903|Placebo Comparator|Placebo SP|Single administration of Placebo pMDI
3322539|NCT02028403|Experimental|Cohort 1A: single dose 0.3 mg/kg BMS-936559|Participants will receive 0.3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3322540|NCT02028403|Placebo Comparator|Cohort 1B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3322541|NCT02028403|Experimental|Cohort 2A: single dose 1 mg/kg BMS-936559|Participants will receive 1 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3228961|NCT01176903|Experimental|Glyco MD1|Multiple administration of Glyco pMDI dose level 1
3228962|NCT01176903|Experimental|Glyco MD2|Multiple administration of Glyco pMDI dose level 2
3228963|NCT01176903|Experimental|Glyco MD3|Multiple administration of Glyco pMDI dose level 3
3228964|NCT01176903|Placebo Comparator|Placebo MP|Multiple administration of placebo pMDI
3228965|NCT01176903|Active Comparator|Tiotropium|Multiple administration of tiotropium
3322542|NCT02028403|Placebo Comparator|Cohort 2B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3322543|NCT02028403|Experimental|Cohort 3A: single dose 3 mg/kg BMS-936559|Participants will receive 3 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3228966|NCT01176929|Experimental|Interventional group|Usual treatment + prevention program of recurrent suicidal acts
3322544|NCT02028403|Placebo Comparator|Cohort 3B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3322545|NCT02028403|Experimental|Cohort 4A: single dose 10 mg/kg BMS-936559|Participants will receive 10 mg/kg of BMS-936559, administered as a single infusion once at study entry.
3322546|NCT02028403|Placebo Comparator|Cohort 4B: single dose placebo for BMS-936559|Participants will receive placebo for BMS-936559, administered as a single infusion once at study entry.
3322547|NCT02028416|Active Comparator|ATG-Fresenius 3 Days|In one group Injection ATG-Fresenius will be given @ 10mg/kg will be given for 3 days along with Capsule Cyclosporin 5mg/kg for 6 months followed by very slow tapering of dose
3322548|NCT02028416|Experimental|ATG-Fresenius 5 Days|In other arm injection ATG will be given @10mg/Kg for 5 days (different dose regimen, according to the randomization) with capsule Cyclosporin@5mg/Kg (same dose) for 6 months followed by very slow tapering. There is a difference of days of treatment received i-e 5 days.
3322549|NCT02028429|Experimental|Intervention 'Sildenafil'.|MHE patient receiving Sildenafil. Intervention: Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
3228967|NCT01176929|Active Comparator|Control group|Usual treatment
3228968|NCT01176942|Experimental|Probiotic|
3322550|NCT02028429|No Intervention|'No sildenafil'|Control Arm: MHE patients not receiving SIldenafil Intervention.Followed up for 4 weeks.
3322551|NCT02028442|Experimental|Enadenotucirev|
3228969|NCT01176942|Placebo Comparator|Placebo|
3228970|NCT01176994|Experimental|Skin lesions|Individuals with skin lesions whose lesions are not sent for histology by dermatologists
3228971|NCT01177020||Placentas after delivery or abortion|
3228972|NCT01177033||Best endovascular treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
3228973|NCT01177033||Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
3228974|NCT01177072|Experimental|Components-Based Interventions (CBI)|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
3322552|NCT02028455|Experimental|Cohort 1|This cohort will determine the maximum tolerated dose of the Patient Derived CD19 specific CAR T cells also expressing an EGFRt and is restricted to patients with a prior history of allo-HCT
3322553|NCT02028455|Experimental|Cohort 2A|This cohort is for patient who have a history of allo-HCT with recurrence of disease post HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1.
3322554|NCT02028455|Experimental|Cohort 2B|This cohort is restricted to patients wtih no prior history of allo-HCT and they will receive the MTD of Patient Derived CD19 specific CAR T cells also expressing an EGFRt determined in cohort 1
3322555|NCT02028468|Active Comparator|Anterolateral Approach|Patient Operated with Watson Jones Approach
3322556|NCT02028468|Active Comparator|Trans-gluteal Approach|Patient operated with Trans-gluteal Hardinge Approach
3322557|NCT02028481|Experimental|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
3228975|NCT01177072|Experimental|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
3228976|NCT01177072|No Intervention|Wait List Control|Eligible clients will not be provided therapy at enrollment. After the study period has completed, control clients will be re-interviewed. Those that remain eligible due to symptom cutoff scores will be offered therapy. In the interim, controls will receive a phone call once a month; those with indications of possible harm to self or others will be referred to a psychiatrist.
3228977|NCT01177085|Experimental|Mushroom|Mushroom enriched weight loss diet. Participants will be given a personalized diet plan, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
3259104|NCT01467518|Other|Period 2|Subjects will be on individualize stable dose of methadone and open label doses of 50mg Dolutegravir (DTG) every 12 hours for 5 days.
3322558|NCT02028494|Experimental|Arm A: Capecitabine 2,000 mg (flat dose)|Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).
3322559|NCT02028494|Active Comparator|Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day|Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
3322560|NCT02028507|Experimental|Palbociclib plus Exemestane or Fulvestrant|"Palbociclib 125 mg orally once daily on Day 1 to Day 21 followed by 7 days off treatment on every 28 days cycles in combination with~Cohort 1: Exemestane 25 mg orally once daily.~Cohort 2: Fulvestrant 500 mg on Days 1 and 15 of Cycle 1, and Day 1 of each subsequent 28 days Cycle."
3322561|NCT02028507|Active Comparator|Capecitabine|Capecitabine, 1,250 mg/m2 twice daily for 2 weeks followed by a 1 week rest period, given as 3 weeks cycles. Capecitabine must be administered at a dose of 1,000 mg/m2 twice daily for 2 weeks followed by a 1 week of rest period, given as 3 weeks cycles, in patients over 70 years of age.
3322562|NCT02028533|Active Comparator|Patients 1|Participants will receive intranasal oxytocin 40 International Units (IU).
3322563|NCT02028533|Placebo Comparator|Patients 2|Participants will receive 40 International Units of intranasal placebo.
3322564|NCT02028546|Experimental|Water|The patients in water group were soaking an arm for 10 minutes with tap water before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.)
3322565|NCT02028546|Experimental|mild cleanser|The patients in mild cleanser group were soaking an arm for 10 minutes with mild cleanser before application of moisturizer. (Excepted the 4th regimen included no bathing, waited for 10 minutes and followed by moisturizer application.) Non soap base cleanser contained Sodium Cocoyl Isethionate was used in this mild cleanser arm.
3322566|NCT02028559|Experimental|Treatment with Ultrasonic Propulsion|Subjects receive treatment with the Propulse 1 device. Intervention consists of the non-invasive application of ultrasound to move stones within the kidney and ureter.
3322567|NCT02028559|No Intervention|Control|Subject follow same protocol as treatment group but do not receive the ultrasonic propulsion intervention.
3322568|NCT02028572||Primary open angle glaucoma|Subjects diagnosed to have primary open angle glaucoma with intraocular pressure > 21 mm Hg and characteristic glaucomatous damage to the optic nerve.
3322569|NCT02028585|Active Comparator|Low-fat milk group|The low-fat milk group was instructed to consume 2 packs of low-fat milk per day (200 mL twice daily) for 6 weeks.
3322570|NCT02028585|No Intervention|Control group|Control group maintained their usual diet without low-fat milk supplement.
3322571|NCT02028598|Experimental|Sequence A|Treatment 1 - Treatment 2 - Treatment 3
3322572|NCT02028598|Experimental|Sequence B|Treatment 1 - Treatment 3 - Treatment 2
3322573|NCT02028598|Experimental|Sequence C|Treatment 2 - Treatment 1 - Treatment 3
3322574|NCT02028598|Experimental|Sequence D|Treatment 2 - Treatment 3 - Treatment 1
3322575|NCT02028598|Experimental|Sequence E|Treatment 3 - Treatment 1 - Treatment 2
3322576|NCT02028598|Experimental|Sequence F|Treatment 3 - Treatment 2 - Treatment 1
3322577|NCT02028624|Experimental|Face-to-face|Patients received face-to-face nutrition counseling.
3322578|NCT02028624|Experimental|Telephone|Patients received telephone nutrition counseling.
3322579|NCT02028624|No Intervention|Minimum Intervention|Patients in this group received no further lifestyle-related counseling and contact until the 6-month evaluation.
3322580|NCT02028637|Experimental|toll like receptor (TLRs)|TLRs are a family of proteins responsible for the recognition of Pathogen-Associated Molecular Patters
3322581|NCT02028650||the first donor|the original donor applicable patients were assigned to receive the first donor's stem cell treatment after G-CSF mobilization or combination chemotherapy
3259105|NCT01467531|Experimental|Cohort 1|Period 1 Treatment A = Dolutegravir 50mg q24h x 5 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 11; Period 3 Dolutegravir 50mg q24h + Rilpivirine q24h x 5 days
3322582|NCT02028650||the second donor|HLA-mismatched, the second donor's stem cell infusion
3322583|NCT02028663|Experimental|CJ-12420 Amg|50 volunteers will be administered CJ-12420 Amg
3322584|NCT02028663|Experimental|CJ-12420 Bmg|50 volunteers will be administered CJ-12420 Bmg
3322585|NCT02028663|Experimental|CJ-12420 Cmg|50 volunteers will be administered CJ-12420 Cmg
3322586|NCT02028663|Active Comparator|Esomeprazole 40mg|50 volunteers will be administered Esomeprazole 40mg
3322587|NCT02028689|Experimental|Lesinurad and Metformin|"Sequence A- Day 1: Metformin 850 mg; Day 5: Lesinurad 400 mg with metformin 850 mg~Sequence B- Day 1: Lesinurad 400 mg with metformin 850 mg; Day 5: Metformin 850 mg"
3322588|NCT02028689|Experimental|Lesinurad and Furosemide|"Sequence C - Day 1: Furosemide 40 mg; Day 5: Lesinurad 400 mg with furosemide 40 mg~Sequence D - Day 1: Lesinurad 400 mg with furosemide 40 mg; Day 5: Furosemide 40 mg"
3322589|NCT02028702|Active Comparator|Red Clover extract|150 ml/d Red Clover extract
3322590|NCT02028702|Placebo Comparator|Placebo|150 ml/d sweetened and coloured water
3322591|NCT02028728||Orsiro|
3322592|NCT02028741|Experimental|symptomatic intervention group|Paitients with mechanical neck pain were treated with transverse vertebral pressures
3322593|NCT02028741|Sham Comparator|aymptomatic non-intervention group|Sham treatment to aymptomatic subjects
3322594|NCT02028793||Pharmacists provide pharmaceutical care|The group is the community pharmacists who attend the protocol to provide home visit to the patients with heavy health expenditure, through pharmaceutical care approach.
3322595|NCT02028806|Experimental|FOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
3322596|NCT02028832|Active Comparator|Usual care|Usual care provided to pediatric inpatients
3322597|NCT02028832|Experimental|PIM consult and service provision|Pediatric integrative medicine service (PIM) through which pediatric inpatients will have the option of supplementing their usual care with acupuncture/acupressure, massage, and/or reiki
3322598|NCT02028845|Active Comparator|Loop guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with loop guidewire.
3322599|NCT02028845|Active Comparator|Straight guidewire|This study has two arms. We will compare the performance of a loop-tipped guidewire with a straight-tipped guidewire in achieving successful deep biliary cannulation with straight guidewire.
3322600|NCT02028897|Active Comparator|Conventional embryo culture|Conventional embryo culture in dishes, in droplets under oil.
3322601|NCT02028897|Experimental|Alternative embryo culture|Embryo culture in system using small enclosed containers
3322602|NCT02028910|Experimental|Ondansetron|"The treatments in the form of cases numbered 1 vial of 50 ml of ondansetron 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions ondansetron syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
3322603|NCT02028910|Placebo Comparator|placebo|"The treatments in the form of cases numbered 1 vial of 50 ml of placebo 0.8 mg / ml oral solution + 5 ml syringe for oral administration.~No special storage conditions placebo syrup.The treatment is administered orally as a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed a maximum dose of 10mg. A second outlet, at the same dose, is restored if the child vomits within 15 minutes after the first administration."
3322604|NCT02028923|Experimental|Morphine gel|morphine 30 mg, quantity of gel per application: 15mg (15ml)
3322605|NCT02028923|Placebo Comparator|Neutral gel|water for injection, quantity of gel per application: 15mg (15ml)
3322606|NCT02028936|Experimental|Grape juice rich in polyphenols|
3322607|NCT02028936|Active Comparator|grape juice not enriched with polyphenols|
3322608|NCT02028949|Experimental|Chemo-lipiodol|
3322609|NCT02028962|Experimental|Lifestyle counseling|The experimental group will receive three letters with advices for smoking cessation-the first letter after the enrolment in the study, the second one one month after the first letter, the third one three months after the first letter
3322610|NCT02028962|No Intervention|Control|
3322611|NCT02028975|Other|Patients with type 2 diabetes|
3322612|NCT02028975|Other|Obese patients without diabetes|
3322613|NCT02028975|Other|Healthy volunteers|
3322614|NCT02028988|Experimental|Enzalutamide with External Beam Radiation|On this study patients will be treated with 6 months of Xtandi (enzalutamide). Approximately one-third of the way through this treatment they will receive EBRT. Starting on Day 1, all patients will ingest enzalutamide 160 mg/day at the same time each day without breaks (except as outlined for toxicity), with or without food, for 6 (28 day +/-3 days) cycles. Dose reduction of enzalutamide to 120 mg/day is allowed with the approval of the Medical Monitor. Patients will be instructed to return all unused capsules at each study visit to assess compliance and will receive study drug every 28 days (+/-3 days) for 6 cycles (24 weeks).
3322615|NCT02029001|Experimental|Arm A: Maintenance treatment|"Patients will continue targeted treatment matching the molecular alterations identified in their tumor~for a maximum of 136 weeks starting from the date of patient's first study drug intake following inclusion or a discontinuation criteria (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) is met for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib.~until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met (unacceptable toxicity, interruption of study drug more than 28 days, documented on-treatment disease progression, patient decision, investigator decision, pregnancy) for durvalumab + tremelimumab"
3322616|NCT02029001|No Intervention|Arm B:Interruption of targeted treatment|"Targeted treatment received during induction period will be discontinued until a first documented off-treatment disease progression occurs. At progression, treatment reintroduction may be proposed to the patient (left at the investigator's appreciation, and upon patient approval).~Treatment may be continued until on-treatment disease progression, unacceptable toxicity or for a maximum of 136 weeks from the date of patient's first study drug intake following inclusion for nilotinib, everolimus, sorafenib, lapatinib, pazopanib, olaparib or until loss of clinical benefit, or until a permanent study drug discontinuation criteria is met for durvalumab + tremelimumab.~If the investigator considers that the treatment cannot be safely reintroduced (regarding patient's condition and/or laboratory results), the patient will be withdrawn from study."
3322617|NCT02029014|Experimental|LAmbre closure system|
3322618|NCT02029027|Experimental|GYNEFFIK(R)|30 min-session of vaginal electro-stimulation by GYNEFFIK thrice a week for 6 months (except during menstrual periods)
3322619|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
3322620|NCT02029053|Other|Single Arm Study|Vaginal Lubrication Ring for Vaginal Dryness
3228978|NCT01177085|Active Comparator|No mushroom diet|Participants will be given a personalized diet plan, without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
3228979|NCT01177111|Experimental|Sunflower seed Oil|
3322621|NCT02029066|Experimental|SR-T100 gel|dosage form: topical gel dosage: 2g of 2.3% SR-T100 frequency: once duration: 24 hours
3322622|NCT02029079|Experimental|E+ drink, enriched with energy and nutrients.|The intervention consists of 300 ml E+ per day for 35 days in addition to a normal food intake. This means 525 kcal, and 22.5 gram protein extra per day for five weeks.
3322623|NCT02029079|No Intervention|Control|Subjects in the control group will be assessed in the same way and same time as the intervention group.
3322624|NCT02029092||Orsiro|
3322625|NCT02029105||Mesothelin, hyaluronan, osteopontin, syndecan|The patients with pleural diseases
3228980|NCT01177111|Active Comparator|Mustard seed oil|
3228981|NCT01177124|Experimental|MBSR 6 Weeks Program|
3228982|NCT01177124|No Intervention|Usual Care (UC)|
3259106|NCT01467531|Experimental|Cohort 2|Period 1 Treatment A = GSK1265744 30mg q24h x 12 days; Period 2 Treatment B = Rilpivirine 25mg q24h x 12; Period 3 GSK1265744 30mg q24h + Rilpivirine q24h x 12 days
3322626|NCT02029118|Experimental|Herbal application on acupoint group|Containing the herbal medicine application on the specific acupoints plus foundation treatment
3228983|NCT01177150|Experimental|001|JNJ-28431754/ Placebo Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses the evening dose will be administered at 10 hours after the morning dose.
3228984|NCT01177150|Experimental|002|JNJ-28431754 Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
3322627|NCT02029118|Placebo Comparator|Placebo application on acupoint|Not containing herbal medicine application on the specific acupoints plus foundation treatment
3322628|NCT02029118|Placebo Comparator|Herbal application on non-acupoint group|Containing the herbal medicine application on the non-acupoints plus foundation treatment
3322629|NCT02029118|Sham Comparator|Placebo application on non-acupoint|Not containing herbal medicine application on the non-acupoints plus foundation treatment
3322630|NCT02029131|Experimental|Exercise|
3322631|NCT02029131|No Intervention|Controls|
3322632|NCT02029157|Experimental|ARQ 197|Daily oral dose
3322633|NCT02029157|Placebo Comparator|Placebo|Daily oral dose
3228985|NCT01177163|Other|001|Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
3228986|NCT01177163|Experimental|002|JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
3322634|NCT02029170|Experimental|Early weightbearing|After operative reduction and fixation of the fractures, patients allocated to the early weightbearing group start weightbearing after stitch out at 2 weeks and the application of a walking cast.
3322635|NCT02029170|Active Comparator|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
3322636|NCT02029183|Experimental|bi-level positive airway pressure|bi-level positive airway pressure for 6 hour per night，total 7 days
3322637|NCT02029209|Experimental|Anlotinib|Anlotinib QD orally and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3322638|NCT02029209|Placebo Comparator|Placebo Capsule|Placebo capsule QD orally and it should be continued until disease progression or patients withdrawal of consent
3322639|NCT02029222||25 NSCLC patients|25 NSCLC patients who received curative radiotherapy. Re-irradiation can either be indicated for primary or secondary cancers in the lung. All patients referred for primary radiotherapy or chemoradiation after curative radiation therapy more or equal to one year ago with overlapping CTV will be included. The organs at risk of the primary tumor are the same organs at risk at the secondary treatment.
3228987|NCT01177163|Experimental|003|JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
3322640|NCT02029248||Children 6-7|Patients who are between 6 and 7 years old
3322641|NCT02029248||Children 8-11|Patients who are between 8 and 11 years old
3322642|NCT02029248||Children 12-16|Patients who are between 12 and 16 years old
3322643|NCT02029248||Patients 17-30|Patients who are between 17 and 30 years old
3228988|NCT01177176|Other|Standard Care|Standard tobacco counseling provided to hospital inpatients as part of routine, clinical-guideline compliant care in the study hospital. No post-discharge treatment is offered in this arm.
3228989|NCT01177176|Experimental|Extended Care Management|In addition to Standard Care, subjects in this arm receive Extended Care Management intervention to facilitate the continued use of smoking cessation treatment (counseling and medication use) after hospital discharge. This consists of 3 months of telephone-based contact after discharge.
3322644|NCT02029287|Experimental|Subjects with CHF follow-up|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up.In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of CHF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of heart failure-related health behaviors.
3322645|NCT02029287|Active Comparator|Subjects with CHF conventional clinic visit|Subjects with standardized treatment according to latest guidelines via conventional visit.
3322646|NCT02029300|Other|Nasal Route|The nasal route will be when the airway is acquired and secured with a fiberoptic bronchoscope through one of the nares.
3322647|NCT02029300|Other|Oral Route|The oral route will be when the airway is acquired and secured with a fiberoptic bronchoscope through the patient's mouth.
3322648|NCT02029313|Experimental|MKT-N2|Montelukast
3322649|NCT02029313|Active Comparator|Singulair|Montelukast sodium
3228990|NCT01177202|Experimental|Group A|HAC1 Dose = 15ug; Alum Dose = 0
3228991|NCT01177202|Experimental|Group B|HAC1 Dose = 15ug; Alum Dose = 0.75mg
3322650|NCT02029339|Experimental|triple-tube group|The patients were treated with continuous topical triple-tube irrigation and suction
3322651|NCT02029339|Active Comparator|SOC group|The patients were treated with standard of care (SOC) without topical irrigation
3322652|NCT02029352|Experimental|Sinecatechins 10%|Patients are instructed to apply a thin layer of the sinecatechins 10% ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
3322653|NCT02029352|Placebo Comparator|Placebo|Patients are instructed to apply a thin layer of the placebo ointment twice daily (morning and evening) in a thin layer to the tumour including 5mm of the surrounding skin. Before applying a new layer patients are advised to wipe off the remnants. Sinecatechins 10% ointment has to be applied for six weeks. Patients are advised to wash their hands after each application to prevent spreading of the ointment.
3322654|NCT02029365|Other|Without eating disorders|Women consulting for infertility but without diagnosis of eating disorder.
3322655|NCT02029365|Other|With Eating disorders|Womenconsulting for infertility for which eating disorder is diagnosed.
3322656|NCT02029378|Experimental|Eculizumab|Eculizumab, 900 mg intravenously once a week
3322657|NCT02029378|Placebo Comparator|Placebo|Matched placebo, intravenously once a week
3322658|NCT02029391|Active Comparator|Myofascial pain syndrome patients|Manual pressure release only
3322659|NCT02029391|Experimental|Myofascial pain syndrome|One session of manual pressure release and kinesio tape
3322660|NCT02029404|Active Comparator|Tibial nerve group|In the TN (tibial nerve ) group probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Identified the tibial nerve we will proceed , previous local anaesthesia, to insert a catheter medially to tibial branch of the sciatic nerve according to in plane approach.
3322661|NCT02029404|Active Comparator|Tibial peroneal nerve group|"In the TPN (tibial -peroneal nerve) group the probe will be placed in popliteal cave to identify the popliteal artery and laterally the tibial nerve. Afterwards, proceeding cranially with the probe according to in plane approach, we will identify the confluence of tibial with peroneal branch and in this point, previous local anaesthesia, we will position the catheter within the confluence of peroneal and tibial nerve."
3322662|NCT02029430|Experimental|aldoxorubicin|Subjects will receive either 100 or 150 mg/m2 (75, and 110 mg/m2 doxorubicin equivalents) by intravenous infusion (IVI) to 10 subjects in each group.
3228992|NCT01177202|Experimental|Group C|HAC1 Dose = 45ug; Alum Dose = 0
3228993|NCT01177202|Experimental|Group D|HAC1 Dose = 45ug; Alum Dose = 0.75mg
3228994|NCT01177202|Experimental|Group E|HAC1 Dose = 90ug; Alum Dose = 0
3228995|NCT01177202|Experimental|Group F|HAC1 Dose = 90ug; Alum Dose = 0.75mg
3228996|NCT01177202|Placebo Comparator|Group G|Saline
3322663|NCT02029443|Experimental|acalabrutinib|
3322664|NCT02029456|Experimental|Low dose prolonged infusion arm|Low dose prolonged infusion of tPA arm (25mg Actilyse in 6 hours)
3322665|NCT02029469|Experimental|HRA Device|Patients who will be treated with Ascension HRA device.
3322666|NCT02029482|Experimental|ACT-128800|ACT-128800 tablets, once daily for 3 days at each dose level: 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg.
3322667|NCT02029482|Placebo Comparator|Placebo|Matching placebo tablets, once daily, for 18 days
3322668|NCT02029508|Active Comparator|Epley maneuver|The group using modified Epley maneuver for PSCC BPPV
3228997|NCT01177202|Active Comparator|Group H|H1N1
3228998|NCT01177215||Digital chest tube|All patients will be treated with the digital chest tube device
3322669|NCT02029508|Active Comparator|Semont maneuver|The group using Semont maneuver for PSCC BPPV
3322670|NCT02029508|Sham Comparator|Sham|The group using Reverse Epley maneuver for PSCC BPPV
3322671|NCT02029534|Active Comparator|Atorvastatin 20 mg|atorvastatin 20 mg daily 2 to 7 days prior to surgery and up to 7 post surgery
3228999|NCT01177241||CLBP|
3229000|NCT01177241||CLBP OU|
3229001|NCT01177306|Experimental|Extended Release Guanfacine|pre and post testing of working memory in subjects whose ADHD has responded to extended release guanfacine. Subjects will be tested before starting study drug and after 6-8 weeks on a stable dose of the study drug.
3322672|NCT02029534|Experimental|Atorvastatin 80 mg|atorvastatin 80 mg daily 2 to 7 days prior to surgery and up to7 days post surgery
3322673|NCT02029547|Experimental|Physician Readers|Physician readers will interpret 60 Amyvid scans using qualitative analysis followed by the use of quantitation. No subjects will be exposed to florbetapir (18F) as part of this study.
3322674|NCT02029573|Experimental|Atorvastatin in Combination With Radiotherapy and Temozolomide|
3322675|NCT02029586|Experimental|MB12066|
3322676|NCT02029586|Placebo Comparator|Placebo|
3322677|NCT02029599|Experimental|High dose group|Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
3322678|NCT02029599|Experimental|Low dose group|"Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.~placebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
3322679|NCT02029599|Placebo Comparator|The placebo group|placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10.
3322680|NCT02029612|Other|Group 1 - Phone Call Support|Smoking cessation telephone hotline phone number provided to participants, along with a 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participant receives 11 phone calls from study staff over a 6-month period. Breath test performed at 3 month and 6 month visit.
3322681|NCT02029612|Other|Group 2 - Text Messaging Support|Participants receive 10 week supply of nicotine patches. Each participant counseled on quitting smoking at baseline. Questionnaires completed at baseline, 3 months, and at 6 months. Participants receive text messages for support about quitting smoking over a 6 month period. Breath test performed at 3 month and 6 month visit.
3322682|NCT02029625|Experimental|NVP-1205|administration of NVP-1205(rosuvastatin+ezetimibe)
3322683|NCT02029625|Active Comparator|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe
3322684|NCT02029651|Experimental|E-glove system|E-glove rehabilitation system for upper extremity
3322685|NCT02029651|Active Comparator|Conventional occupational therapy|conventional occupational therapy
3322686|NCT02029664|Experimental|Visual feedback distortion|Visual distortion increment based on the gait pattern
3229002|NCT01177332|Experimental|Fasted|Two-hour cycling test, fasted condition
3229003|NCT01177332|Other|Glucose-fed|Two-hour cycling test, glucose-fed condition
3229004|NCT01177345||Terminal Disease|Terminal cervical cancer- not treatable
3229005|NCT01177345||Early Disease|Early cervical cancer = meaning treatable with hysterectomy.
3229006|NCT01177345||Advanced Disease|Advanced cervical cancer- treatable with chemotherapy and/or radiation.
3322687|NCT02029690|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol
3322688|NCT02029716|Placebo Comparator|Part A|RTA 408 lotion 0.5%, 1%, and 3% and lotion vehicle applied to skin twice daily for 14 days
3229007|NCT01177358|Experimental|Botulinum Toxin A injection|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 Units (0.1 mL) of Botulinum Toxin A will be injected at three sites along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy."
3229008|NCT01177358|Placebo Comparator|Saline|0.1 mL of normal saline in a placebo vial containing 2 mL of normal saline will be injected along the incision (midline and 1.5 cm lateral to midline) following a thyroidectomy or parathyroidectomy.
3229009|NCT01177371|Experimental|Arm I|"HIGH-DOSE CHEMOTHERAPY: Patients receive oral busulfan every 6 hours on days -8 to -5 and cyclophosphamide IV over 2 hours on days -4 and -3, or -4 to -2.~TRANSPLANTATION: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.~GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine IV over 6 hours on day -1, over 10 hours twice daily on days 0-20, and then orally every 12 hours beginning on day 21 and continuing for 12 months with taper at 9 months. Patients also receive methylprednisolone IV or orally beginning on day 8 and continuing for 7 months with taper at 4 months. Some patients may also receive methotrexate IV on days 1, 3 and 6."
3229010|NCT01177397|Experimental|CC-223|All patients will receive CC-223, but serial patient groups will receive different dose levels in Phase 1. The number of groups will be determined by the number of dose levels required to establish dose-limiting toxicity.
3229011|NCT01177423|Active Comparator|Quicksleeper intraosseous anesthesia|Pulpal and periapical molar and premolar sedation is managed by Quicksleeper intraosseous anesthesia.
3322689|NCT02029716|Experimental|Part B|Up to 3% RTA 408 lotion applied to skin twice daily for 14 days (% concentration to be determined, based on results from Part A, ~100 cm2 surface area)
3322690|NCT02029716|Experimental|Part C|3% RTA 408 lotion applied to skin twice daily for 28 days (~500 cm2 surface area)
3322691|NCT02029729|Experimental|RTA 408 Capsules|RTA 408 capsules, beginning dose 2.5 mg once daily, 28-day cycle, up to 12 cycles. Doses will increase by 100% of previous dose (e.g., 5 mg, 10 mg, 20 mg, etc.) until such time the Protocol Safety Review Committee decreases the escalation rate to 50% of the previous dose (e.g., 20 mg, 30 mg, 45 mg, etc). Dose escalation will continue until Maximum Tolerated Dose is identified.
3322692|NCT02029742|Experimental|Community Health Worker Intervention|Community Health Workers will have scheduled interactions with subjects and will customize text messaging jointly with each youth and parent and initiate text message reminders to both parent and youth for months 4-6.
3322693|NCT02029742|Active Comparator|Education|Those randomized to the Education group will continue usual care, and will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
3322694|NCT02029768||Women with burn injury|
3229012|NCT01177423|Active Comparator|Inferior alveolar nerve block|Pulpal and periapical molar and premolar sedation is managed by inferior alveolar nerve block.
3229013|NCT01177436|Experimental|Patients treated for prostatic pathology|Patients treated for prostatic pathology (benign or malign)in the hospital department.
3322695|NCT02029768||Men with burn injury|
3322696|NCT02029781|Other|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
3229014|NCT01177462||hemineglect stroke patients|Stroke patients with hemineglect
3229015|NCT01177462||Control stroke patients|Stroke patients without hemineglect
3322697|NCT02029794|Experimental|HPV Self-collection|Subjects will self-collect a cervical-vaginal sample. One time use.
3229016|NCT01177462||Normal control|Normal subjects
3322698|NCT02029794|Active Comparator|VIA arm|Standard of care in Uganda is visual inspection with acetic acid (VIA). Women randomized to this arm will undergo the following: Cervix examined by clinician using speculum and light source. Cervix then sprayed with 3-5% acetic acid, and then lesions described one minute after application of acetic acid. VIA negative no acetowhite lesions detected; positive is when dense aceto-white lesions are seen touching squamocolumnar junction
3322699|NCT02029807||Blood donors|Healthy adult volunteers donating blood
3322700|NCT02029820|Active Comparator|RenalGuard|Hydration with the device renalguard
3322701|NCT02029820|No Intervention|Saline|Hydration with saline 1ml/Kg/h for 12h
3322702|NCT02029833|Experimental|Regular Canola Oil|60% oleic acid
3322703|NCT02029833|Experimental|High Oleic Canola Oil|70% oleic acid
3229017|NCT01177475|Active Comparator|natural milk|
3229018|NCT01177475|Experimental|pasteurized milk|
3322704|NCT02029833|Active Comparator|Western Type Diet - Common Dietary Oils|Ghee, Safflower oil, Coconut oil, & flax oil
3322705|NCT02029859|Experimental|Prevalence of obstructive sleep apnea syndrome|"Determine the prevalence of obstructive sleep apnea syndrome (OSA) in late pregnancy in a population of obese patients .~Polygraphic examination between 30 and 36 weeks of amenorhea"
3322706|NCT02029885|Experimental|Investigational Therapy (Surround Sound)|Investigational Therapy using external focused ultrasound
3322707|NCT02029885|Sham Comparator|Sham Control|Blinded Sham Control Arm
3322708|NCT02029898|Active Comparator|Remifentanil|injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute
3229019|NCT01177488|Experimental|BATE-T|Behavioral Activation Therapeutic Exposure done while the patient is at home via videoconferencing technology
3229020|NCT01177488|Active Comparator|BATE-IP|Behavioral Activation Therapeutic Exposure done in the therapist's office
3229021|NCT01177501|Experimental|Topotecan|
3229022|NCT01177514|Experimental|GABAPENTIN|Group of patients treated with oral gabapentin
3322709|NCT02029898|Placebo Comparator|Placebo|injectable solution 0.9% for the end of surgery
3322710|NCT02029924|Experimental|BioChaperone insulin lispro|BioChaperone insulin lispro
3322711|NCT02029924|Active Comparator|Humalog®|Humalog®
3322712|NCT02029937|Experimental|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
3322713|NCT02029937|No Intervention|Standard of care|No invention
3322714|NCT02029950|Experimental|Treatment (combination chemotherapy, pomalidomide)|See Detailed Description
3229023|NCT01177514|Placebo Comparator|PLACEBO|Group given the placebo capsules
3322715|NCT02030028|Other|ACTHAR Gel|Open label Adrenocorticotropic Hormone (ACTH) Gel for 12 weeks, 80u (1mL), given subcutaneously twice each week.
3322716|NCT02030054|Active Comparator|atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3322717|NCT02030054|Active Comparator|rosuvastatin|Patients were randomly assigned to atorvastatin (40 mg day) or rosuvastatin(20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
3322718|NCT02030067|Experimental|RX-3117|All subjects will receive RX-3117.
3322719|NCT02030093||High-frequency telephone-based continuing care|High-frequency telephone-based continuing care
3322720|NCT02030093||Low-frequency telephone-based continuing care|Low-frequency telephone-based continuing care
3322721|NCT02030093||SMS group|SMS group
3322722|NCT02030093||Control group|Control group
3322723|NCT02030106||Prior Preterm Birth Patients|All obstetrical patients eligible for the study that have had a prior preterm birth.
3322724|NCT02030106||Term Birth Patients|All obstetrical patients eligible for the study that have not had a prior preterm birth.
3322725|NCT02030132|Active Comparator|Feedback 50th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3322726|NCT02030132|Experimental|Feedback 75th Percentile|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on all 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3322727|NCT02030132|Experimental|Feedback 50th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the average team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 50th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3229024|NCT01177540|Experimental|Arm A|
3229025|NCT01177540|Experimental|Arm B|
3229026|NCT01177566|Active Comparator|pimecrolimus (Elidel)|pimecrolimus twice daily to a chosen target lesion on one side of body
3229027|NCT01177566|Active Comparator|topical medical device cream (Eletone)|topical medical device cream three times daily to a chosen target lesion on one side of the body
3229028|NCT01177579|No Intervention|Aim 1; Biomarkers|Blood concentrations of copper coenzymes will be monitored for 1 year
3322728|NCT02030132|Experimental|Feedback 75th Percentile + Forgiveness|At the end of each week, participants will be told (by email or text, based on the participant's preference) the team's average daily step count for the previous week based on the best 5 of 7 days. They will also be told the average for the 75th percentile in their arm. If the team's average daily step count (best 5 of 7 days) is ≥ 7000 steps, the team will be eligible for the weekly lottery.
3322729|NCT02030145|Active Comparator|Classic Thoracic Lymphatic Pump|Subjects begin with Classic Thoracic Lymphatic Pump, then crossover to Compressive Thoracic Lymphatic Pump after 4-week washout period.
3229029|NCT01177579|Experimental|Copper supplement Arm|4 mg or 8 mg copper will be compared in a randomized controlled study
3229030|NCT01177579|No Intervention|Normal Controls|Normal subjects will be used to generate reference measures.
3322730|NCT02030145|Experimental|Compressive Thoracic Lymphatic Pump|Subjects begin with Compressive Thoracic Lymphatic Pump, then crossover to Classic Thoracic Lymphatic Pump after 4-week washout period.
3322731|NCT02030158||Early Goal-Directed Therapy (EGDT)|Protocolised resuscitation (termed Early Goal-Directed Therapy - EGDT)
3322732|NCT02030158||Usual resuscitation|Usual resuscitation
3322733|NCT02030171|Active Comparator|PLURIHOC|-Functionnal reeducation : in hospital, intensive, multidisciplinary.
3229031|NCT01177592|Experimental|Guided Therapy|Subjects on chronic clopidogrel therapy (≥ 5 days maintenance or loading within 4 hours of PCI) will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing
3229032|NCT01177592|No Intervention|Standard Therapy|Patients randomized to the control arm will remain on 75mg clopidogrel arm throughout the study.
3322734|NCT02030171|Active Comparator|KIPLURI|-Functionnal reeducation : ambulatory, no intensive multidisciplinary.
3322735|NCT02030171|Active Comparator|KIMONO|-Functionnal reeducation : ambulatory, low-intensity
3322736|NCT02030184|Experimental|Topotecan and Rhenium Re 188 P2045|In the phase II portion of this study, patients will be screened using Technicium Tc99m. Eligible, consented patients will receive Topotecan treatment for three days, at doses of either 1.0 mg/m2 or 1.5 mg/m2. They will then receive a single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
3229033|NCT01177605|Placebo Comparator|Vanilla flavored milk-based beverage containing no prebiotics|Vanilla flavored milk-based beverage containing no prebiotics
3229034|NCT01177605|Experimental|Vanilla flavored milk-based beverage containing prebiotics|Vanilla flavored milk-based beverage containing prebiotics
3229035|NCT01177618||Probands|Severe, early-onset COPD subjects that bring the family into the study
3259107|NCT01467544|No Intervention|wait list control group|After completing time three data collection, wait-listed participants will be provided with the complete tai chi intervention (8 weeks).
3322737|NCT02030197|Active Comparator|CRISP program|educational and socialization program
3322738|NCT02030197|Placebo Comparator|Control Group|no treatment control group
3322739|NCT02030210||cardiologists|
3322740|NCT02030210||study coordinators|
3322741|NCT02030210||registred nurses|
3322742|NCT02030223|Active Comparator|Transversus abdominis plane block with 20 ml ropivacaine 0,75%|Transversus abdominis plane block with 20 ml ropivacaine 0,75%
3322743|NCT02030223|Placebo Comparator|Transversus abdominis plane block with 20 ml saline|Transversus abdominis plane block with 20 ml saline
3322744|NCT02030236|Experimental|Cooling|
3322745|NCT02030249|Experimental|High Protein / Low Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 25% of energy intake, carbohydrate intake is 45% of energy intake, dietary glycaemic index is < 55. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
3322746|NCT02030249|Active Comparator|Moderate Protein / High Glycaemic Index|A 10-month weight maintenance diet, administered from the 2-month to the 12-month time point, where protein intake is 15% of energy intake, carbohydrate intake is 55% of energy intake, dietary glycaemic index is > 65. Please see parent study for further Arm details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
3322747|NCT02030262|Experimental|Air|The participant will undergo epiretinal membrane peeling with fluid-air exchange. The remaining of the surgery is the same in all arms.
3322748|NCT02030262|Active Comparator|Sulfur hexafluoride (SF6)|The participant will undergo epiretinal membrane peeling with fluid-SF6 exchange. The remaining of the surgery will stay the same.
3322749|NCT02030275|Experimental|RXI-109|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
3229036|NCT01177618||Relatives|Relatives of early-onset COPD probands, including first-degree relatives (parents, siblings, and children), second-degree relatives (aunts, uncles, grandparents, half-siblings), spouses, and other affected individuals.
3229037|NCT01177644|Experimental|Active|
3229038|NCT01177657||Gastroenteritis cohort|Children born after 6 March 2006, at least 12 weeks of age and hospitalized for rotavirus severe gastroenteritis
3322750|NCT02030275|Placebo Comparator|Placebo|Treatment with RXI-109 on one side of revised scar and a placebo comparator on the other side. Treatment to begin either immediately or 2 weeks following the scar revision surgery.
3322751|NCT02030301|Experimental|VCL-HB01, 0.25-mL dose|VCL-HB01, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
3322752|NCT02030301|Placebo Comparator|PBS, 0.25-mL dose|PBS, 0.25-mL dose by intramuscular injection once every 28 days for 3 doses
3322753|NCT02030301|Experimental|VCL-HB01, 0.5-mL dose|VCL-HB01, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
3322754|NCT02030301|Placebo Comparator|PBS, 0.5-mL dose|PBS, 0.5-mL dose by intramuscular injection once every 28 days for 3 doses
3322755|NCT02030301|Experimental|VCL-HB01, 1-mL dose|VCL-HB01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3322756|NCT02030301|Experimental|VCL-HM01, 1-mL dose|VCL-HM01, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3322757|NCT02030301|Placebo Comparator|PBS, 1-mL dose|PBS, 1-mL dose by intramuscular injection once every 28 days for 3 doses
3322758|NCT02030314|Experimental|chlorthalidone, resistant high blood pressure|if Furosemide dose is 40 mg per day, start Chlorthalidone 12.5 mg per day if Furosemide dose is 80 mg per day, start Chlorthalidone 25 mg per day
3322759|NCT02030327||No trauma|n=5 patients
3322760|NCT02030327||trauma without organ dysfunction|n=40 patients
3322761|NCT02030327||trauma with organ dysfunction|n=40 patients
3322762|NCT02030340||Testing Lower urinary tract dysfunction|All patients with lower urinary tract dysfunction where urodynamic diagnosis is required according to standards and (international) practice guidelines will have a synchronous double system (combination of air-charged and water filled) urodynamic test.
3322763|NCT02030353|Experimental|Self-regulation plus activity monitoring|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, tailored feedback, and activity monitoring.
3229039|NCT01177657||Hospital control cohort|Children hospitalized for non gastroenteritis causes
3322764|NCT02030353|Experimental|Self-regulation|Participants will receive an individual in-person session, digital smart scale, access to a website to view tracking information, weekly lessons, and tailored feedback.
3322765|NCT02030353|No Intervention|Delayed intervention control|Participants will receive an individual in-person session and a digital smart scale, and a modified version of the self-regulation intervention after the 6-month assessment.
3322766|NCT02030366||TBI patients|
3322767|NCT02030366||Healthy Volunteers|
3322768|NCT02030379|Experimental|Online QPL-CT to Oncologist|Use the online QPL-CT to prioritize their questions and the prioritized list will be conveyed to their oncologist
3322769|NCT02030379|Experimental|Online QPL-CT|Use the online QPL-CT to prioritize their questions.
3322770|NCT02030379|Experimental|Pencil and Paper QPL-CT|Use pencil and paper QPL-CT to prioritize their questions
3322771|NCT02030392|Experimental|Intervention group|"IG participation in the cognitive-behavioral program Stop the pain with Happy Pingu. The program compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each)."
3322772|NCT02030392|Active Comparator|Active control group|CG participation in an information and education control group (physical well-being, health and gastrointestinal tract). The program of the control group compromises six weekly sessions for the children in small groups (90 min each) and 2 sessions for the parents (90 min each).
3322773|NCT02030418|Experimental|Leadless Pacemaker|VVIR pacing
3322774|NCT02030431|Active Comparator|Cancellous screws|Patients in this group are having osteosynthesis with three screws
3322775|NCT02030431|Active Comparator|Dynaloc|Patients in this group are having osteosynthesis with Dynaloc (three screws fixed in a small plate)
3322776|NCT02030444|No Intervention|Standard diagnostic work-up|All patients will undergo todays' standard work-up (examination for diagnosing and staging) of lung cancer. This will be individualized for each patient according to current guidelines.
3322777|NCT02030444|Experimental|Extensive diagnostic work-up|All patients will in addition to standard diagnostic work-up undergo PET-MRI and systematic mediastinal and hilar lymph node mapping using EBUS-TBNA (endobronchial ultrasound transbronchial needle aspiration of lymph nodes).
3229040|NCT01177657||Neighbourhood control cohort|Children without any symptoms of gastroenteritis or severe gastroenteritis
3322778|NCT02030470|Other|fotosan|
3322779|NCT02030483|Experimental|All Subjects|Palbociclib (PD 0332991) will be given at a prespecified dose by cohort orally on days 1-14 of a 28-day cycle. For cycle 1 only, PD 0332991 will start on Day 0. Lenalidomide (Revlimid®) will be given at a prespecified dose by cohort orally on days 8-21 of a 28-day cycle (or days 1-21 as defined by dose cohort level). Dexamethasone (Decadron®) will be given orally at a dose of 20 mg on days 1, 8, 15, and 22 of a 28-day cycle. For cycle 1 only, the dexamethasone will be omitted on Day 1.
3322780|NCT02030496|Active Comparator|Closed reduction and plaster|Closed reduction will be performed and after adequate reduction has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks.
3322781|NCT02030496|Active Comparator|open reduction and internal fixation|The intervention group will be treated with open reduction and internal fixation with a volar locking plate.
3322782|NCT02030509||New diagnosed patients of head and neck cancer|New diagnosed patients of head and neck cancer
3322783|NCT02030509||Old diagnosed head and neck cancer patients|
3322784|NCT02030522|Experimental|Prospective Treatment Cohort of ART|The target population (n=200) of persons treated with the intervention, Accelerated Resolution Therapy, will consist of U.S. service members and veterans who have symptoms indicative of a current diagnosis of PTSD. No age limit or duration of symptoms of PTSD will be imposed for study eligibility, and it is anticipated that most, if not all, of eligible and enrolled participants will have had prior deployments to conflicts dating back to the 1970s, including the Vietnam War, Persian Gulf conflict, and wars in Iraq and Afghanistan. No person will be excluded on the basis of race, ethnicity, gender, or disability.
3322785|NCT02030548||acute CABG|patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy
3322786|NCT02030561|Experimental|Trastuzumab + NK cells|"During cycle 1, Day 1 patient will receive intravenous trastuzumab and subcutaneous IL-2 on day 1, followed by NK cell infusion on day 2, followed by subcutaneous IL-2 for an additional 5 doses three times a week to support NK cell viability and expansion in vivo.~From cycles 2-4, patient will receive trastuzumab monotherapy alone every 21 days, except for patients who achieve objective tumor response after 2 cycles of therapy, who will then receive an additional infusion of NK cells along with trastuzumab during cycle 4 therapy at the same dose and schedule as in cycle 1.~Patients will be taken off study after cycle 4, unless the patient has objective tumor response after 4 cycles of therapy with only stable disease after cycle 2, in which case the patient will be given another 2 cycles of trastuzumab with an additional NK cell infusion during cycle 6 therapy at the same dose and schedule as in cycle 1."
3322787|NCT02030587|Experimental|Radiofrequency Ablation|Radiofrequency Ablation
3229041|NCT01177683|Experimental|Arm 1|Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.
3229042|NCT01177696|Experimental|psychotherapy|"The study aims to evaluate the effectiveness of an intervention of psychotherapy in improving the mental health of caregivers.~This intervention is based on theoretical approaches to care adjusted to cognitive theory, in order to be applied in primary health care centres."
3322788|NCT02030587|Active Comparator|Laparoscopic Adrenalectomy|Laparoscopic Adrenalectomy
3229043|NCT01177696|No Intervention|Control|
3229044|NCT01177748||Patients on the Stroke Unit|
3229045|NCT01177761|Active Comparator|exercise|endurance,balance, power, resistance type exercise
3229046|NCT01177761|No Intervention|sedentary control|Subjects were instructed to do not relevantly change their lifestyle
3229047|NCT01177774||Recent-onset tics that will persist|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who, when reassessed at 1 year after the first tic began (i.e. 6-12 months after study enrollment) will turn out to meet criteria for a chronic tic disorder (including Tourette syndrome). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
3259108|NCT01467544|Experimental|Tai Chi intervention group|This participant group completes the 8-week tai chi group intervention.
3322789|NCT02030613|Other|Single arm: etanercept|Patients treated with etanercept for JIA
3322790|NCT02030626|Experimental|active rTMS or active tDCS or placebo|Active rTMS (10 Hz) of the motor cortex followed by active tDCS (2 mA) of the motor cortex or conversely
3322791|NCT02030626|Placebo Comparator|Sham rTMS followed by tDCS (or conversely)|Placebo rTMD followed by placebo tDCS or conversely
3322792|NCT02030639|Experimental|[14C]-rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
3322793|NCT02030652|Experimental|SNIPPV Group|Synchronized nasal intermittent positive pressure using NAVA ( Intermittent nasal positive pressure positive ventilation.)
3322794|NCT02030652|Active Comparator|CPAP Group|Nasal CPAP group without intermittent ventilation.
3322795|NCT02030665|Active Comparator|Standardized MET plus CB (SMET-CB)|Motivational Enhancement plus Cognitive-Behavioral treatment
3322796|NCT02030665|Experimental|SMET+ CM (SMET-CB-CM)|Motivational Enhancement plus CB treatment plus contingency management
3322797|NCT02030665|Experimental|Individualized Assessment & Treatment (IATP)|Individualized Assessment and Treatment Program; Cognitive-Behavioral Treatment based on in-depth field monitoring of patient behavior
3322798|NCT02030665|Experimental|IATP + CM (IATP-CM).|Individualized Assessment and Treatment plus Contingency Management
3322799|NCT02030678|Experimental|irinotecan Hydrochloride|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
3322800|NCT02030691|Experimental|nCPAP - nHFPV|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
3322801|NCT02030691|Experimental|nHFPV - nCPAP|Eligible patient received after randomization nCPAP or nHFPV for 15 minutes then after the 15 minutes, they received the seconde non invasive device for 15 minutes. Study end 30 minutes after randomization or before if mechanical ventilation is required.
3322802|NCT02030704||Atherosclerotic Plaque|
3229048|NCT01177774||Recent-onset tics that will remit|Children between 5 to 10 years of age with recent-onset tics (first tic occurred within the past 9 months) who will no longer have tics when reassessed 1 year after the first tic began (6 to 12 months after study enrollment). Scheduled follow-up visits will include children over age 10 (initially enrolled at age 5-10).
3229049|NCT01177774||Tic-free control subjects|Children with no current or past tic disorder of similar age, sex and handedness as the children in the recent-onset tics groups.
3322803|NCT02030717|Experimental|Spinal anesthesia|The drugs used in the spinal injection are: 12 mg bupivacain, 160 ug morfin och klonidin( < 60 years 75 ug, 60 - 85 years old 60 ug and older than 85 years 45 ug)
3322804|NCT02030717|Active Comparator|Epidural anesthesia|Epidural anesthesia patients group gets an epidural catheter at level Th 8- 10 with per- and postoperative infusion with a routine mixture of: bupivacain 1 mg/ml, fentanyl 1 ug/ml, and adrenalin 1 ug/ml) until termination.
3322805|NCT02030730|Experimental|Triple P Seminar Series|Intervention parents received the Seminar Series (Selected TripleP); three 90-minute seminars ('The Power of Positive Parenting', 'Raising Confident, Competent Children', and 'Raising Resilient Children'), including 60 minutes of scripted presentation material and 30 minutes question time for discussion. Parents received tip sheets with the material presented at the end of each seminar. The seminars were free of charge. The delivery of each seminar was 2 to 4 weeks apart.
3322806|NCT02030730|No Intervention|Leaflets on child health and development|An attention control group received leaflet information on child health and development provided by the Greek National Health Services of the Ministry of Health. They cover topics such as vaccinations, common childhood illnesses, first aid guide on severe injuries and cuts, and nutrition. The topics did not overlap with the topics of the Seminar Series or the general purpose of the study. Control families received the seminar tip sheets after 6-month follow-up.
3322807|NCT02030743|Active Comparator|Visual training|Training in visual attention
3322808|NCT02030743|Placebo Comparator|Usual activity|Usual activity
3322809|NCT02030756|Active Comparator|Vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
3322810|NCT02030756|Sham Comparator|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
3322811|NCT02030769|Experimental|Pronase|Add pronase 20000 U in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
3322812|NCT02030769|Sham Comparator|control|No pronase in 80ml pretreatment mixture plus 5ml Dimethicone and 1g sodium bicarbonate.
3322813|NCT02030782|Active Comparator|Usual Care|Patients received usual care through primary care, enhanced by provider education regarding depression evaluation and management (1-2 hour training, plus study manual)
3322814|NCT02030782|Experimental|Quality Improvement for Depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
3322815|NCT02030795|Active Comparator|Disconnection group|The single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse.
3322816|NCT02030795|Active Comparator|Bronchial Suction group|The suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
3322817|NCT02030808|Placebo Comparator|Muscle Relaxants (MR) group|Cisatracurium will be administered
3322818|NCT02030808|Active Comparator|Non- Muscle Relaxants (NMR) group|No cisatracurium will be administered
3322819|NCT02030860|Experimental|Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane with preoperatively paricalcitol. Patients randomized to receive paricalcitol pre-operatively will begin treatment with intravenous paricalcitol at 25 μg three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days).
3322820|NCT02030860|Active Comparator|No Pre-operative Paricalcitol|Subject will receive gemcitabine/abraxane without paricalcitol preoperatively.
3322821|NCT02030873|Experimental|Virtual simulation training first|Participants in this arm receive virtual simulation training before dissection training.
3322822|NCT02030873|No Intervention|Dissection training first|Participants in this arm receive dissection training first and then virtual simulation training.
3322823|NCT02030899|Active Comparator|Cage|Cage filled with autologous bone
3322824|NCT02030899|Other|Plate|Plate augmentation after iliac bone graft
3322825|NCT02030912|Active Comparator|3 doses of amoxicillin daily for 7 days|Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
3322826|NCT02030912|Active Comparator|2 doses of minocycline daily for 5 days|Cohort B: 2 doses of minocycline daily for five days (n=14). Follow up 12 months.
3322827|NCT02030912|Placebo Comparator|2 doses of placebo daily for 5 days|Cohort C: 2 doses of placebo daily for five days (n=14). Follow up 12 months.
3322828|NCT02030925|Experimental|IW-3718|Twice a day
3322829|NCT02030925|Placebo Comparator|Matching Placebo|Twice a day
3322831|NCT02030964|Experimental|DFMO, Celecoxib, Cyclophosphamide & Topotecan|Reconstituted DFMO powder by mouth for 14 days and celecoxib capsule by mouth daily in each cycle. Cyclophosphamide and Topotecan IV on days 8-12 in cycle 1 and days 1-5 of cycles 2-17. Patients may continue for up to 17 cycles as long as therapy is tolerated (no DLT) and disease progression does not occur (SD or better). *Cycle 1 will include a 7 day lead-in with DFMO and celecoxib to deplete tumor polyamines.
3322832|NCT02030977|Active Comparator|Resveratrol|"Active Comparator: Resveratrol~1 Resveratrol capsules for 12 weeks"
3322833|NCT02030977|Placebo Comparator|Placebo|one capsule per day
3322834|NCT02030990|Experimental|Mitomycin-C; 3 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 3 week fluorometholone 1% topical steroid taper.
3322835|NCT02030990|Experimental|Mitomycin-C; 1 week FML steroid taper|Mitomycin-C 0.01% will be administered intraoperatively during PRK for 15 seconds. The patient will take a 1 week of fluorometholone 1% topical steroid.
3322836|NCT02030990|Active Comparator|No mitomycin-C; 8 week FML steroid taper|No mitomycin-C will be administered during the procedure. Instead a sham application of salt solution will be given for 15 seconds. The patient will take 8 weeks of topical fluorometholone 1% topical steroid drop taper.
3322837|NCT02031003|Other|Control|Standard infant formula
3322838|NCT02031003|Experimental|Experimental 1|Standard infant formula containing a new fat blend
3322839|NCT02031003|Experimental|Experimental 2|Standard infant formula containing a new fat blend and fiber
3322840|NCT02031003|No Intervention|Human Milk (HM)|Non-randomized Human Milk group
3322841|NCT02031016|Active Comparator|Fentanyl|"fentanyl bolus injections on an as needed base, next to the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
3229050|NCT01177774||Existing TS/CTD|Children with current tics whose first tics were more than 12 months ago (DSM-5 Tourette's Disorder or Persistent [Chronic] Motor or Phonic Tic Disorder), of similar age, sex and handedness as the children in the recent-onset tics groups.
3322842|NCT02031016|Active Comparator|Remifentanil|remifentanil, starting with 0.15 ug/Ideal Body Weight(IBW)(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
3322843|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]FTD|
3322844|NCT02031055|Experimental|TAS-102 with light tracer dose of [14C]TPI|
3322845|NCT02031068|Active Comparator|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms~A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
3229051|NCT01177826||Group 1|Cases
3229052|NCT01177826||Group 2|Controls
3322846|NCT02031068|Experimental|Behavioral:Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program.~A physiotherapist will supervise the rehabilitation."
3322847|NCT02031081|Experimental|Treatment Period 1|A randomized assignment of prucalopride or placebo for a period of 28 days, crossover design
3322848|NCT02031081|Experimental|Treatment Period 2|A randomized assignment of either prucalopride or placebo for a period of 28 days, crossover design. Subjects who received active drug in Treatment Arm 1 will receive placebo and vice versa.
3322849|NCT02031094||Major resection|Patients undergoing resection of >3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
3322850|NCT02031094||Minor resection|Patients undergoing resection of </= 3 segments (resting energy expenditure measured by Sense Wear Armband and indirect calorimetry)
3322851|NCT02031107|Active Comparator|cTBS|A transcranial magnetic stimulator (MagPro X100, Medtronic Functional Diagnostics, Skovlunde, Denmark) will deliver continuous bursts of bipolar magnetic pulses exerting an inhibition on the underlying brain tissue (cTBS). The stimulation coil will be placed over the unaffected primary motor cortex. The stimulation protocol implies 200 bursts, each consisting of three pulses applied at 30 Hz, repeated at inter-burst intervals of 167 ms. Two stimulation trains of 30 s, separated by 15 min, will be applied 3 times per week for 3 weeks and will be immediately followed by physical therapy.
3322852|NCT02031107|Active Comparator|cathodal tDCS|A stimulator (NeuroConn GmbH, Illmenau, Germany) will deliver cathodal transcranial direct current stimulation (tDCS) of the unaffected motor cortex. The anode will be placed over the contralateral supraorbital region. Stimulation will be performed for 25 min, 3 times per week for 3 weeks during upper extremity treatment sessions.
3322853|NCT02031107|Sham Comparator|sham stimulation|This group will receive the same stimulation protocol as used for the active groups except that sham stimuli will be applied. Half of the patients receive sham cTBS, the other half sham tDCS.
3322854|NCT02031172||Subjects with Dry Eye Disease|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3322855|NCT02031172||Subjects with Sjogren's Syndrome|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3229053|NCT01177839||Intussusception cohort|Subjects with Intussusception
3229054|NCT01177852|Experimental|Notuss® syrup|Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
3229055|NCT01177852|Active Comparator|Dropropizine + Pseudoephedrine and brompheniramine|Group 2: combined use of dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate.
3229056|NCT01177891||Subject index|Population of familial cases of POF : 20 families with at least two subjects with POF nonsyndromic
3229057|NCT01177891||Population Index Related topics|Women, healthy women, men are potential carriers
3229058|NCT01177891||Population control|100 Caucasian women with normal cycles until at least the age of 40 years and a proven fertility
3229059|NCT01177904|Active Comparator|Progesterone 5 Weeks|The study group stop receiving P4 on the day of their first US at 5 weeks pregnancy
3229060|NCT01177904|Other|Control Group : P4 8 weeks|Progesterone will be given until 8 weeks of pregnancy
3229061|NCT01177917|Experimental|Cow milk-based infant formula with prebiotic blend|
3322856|NCT02031172||Healthy Controls|Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
3322857|NCT02031185|No Intervention|Wait-list control|No intervention
3322858|NCT02031185|Experimental|FitBit only|Participants will use the FitBit device
3322859|NCT02031185|Experimental|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
3322860|NCT02031198|Experimental|AADvac1|"Patients who have received 6 doses in the previous trial will be administered 1-2 booster doses of AADvac1 (2 if their antibody titers decline below those achieved in the previous trial).~Patients who have received 3 doses in the previous trial will be administered another 3 doses, then vaccinated with booster doses as above."
3322861|NCT02031211|Placebo Comparator|Placebo|0.4 ml/kg of normal saline will be administered subcutaneously.
3322862|NCT02031211|Experimental|Etanercept|Patient will receive 0.4 mg/kg of Etanercept subcutaneously twice weekly.
3322863|NCT02031224|Experimental|Keto-diet (KD)|Patients in the intervention arm (KD group) will receive a vegetarian very low protein diet (0.3 g proteins/kg ideal body weight per day) supplemented with ketoanalogues of essential amino acids (Ketosteril®, Fresenius Kabi, Bad Homburg, Germany), 1 capsule for every 5 kg of ideal dry body weight per day.
3229062|NCT01177917|Placebo Comparator|Marketed Cow milk-based infant formula|
3229063|NCT01177930||Feeding with milk with DHA and ARA|
3229064|NCT01177930||Feeding with milk without DHA and ARA|
3229065|NCT01177982|Active Comparator|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club
3322864|NCT02031224|Active Comparator|Low Protein Diet group (LPD)|"The patients in the control arm (LPD group) will continue their conventional low protein diet, with 0.6 g/kg per day (including high biological value proteins).~The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in both arms."
3322865|NCT02031250|Active Comparator|Control Arm|Standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
3322866|NCT02031250|Experimental|Boost Arm|Boost radiation to hypoperfused volumes in addition to standard chemotherapy (Cisplatin or Carboplatin) and IMRT (Intensity-Modulated Radiation Therapy)
3322867|NCT02031263|Experimental|thermoplasty group|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
3322868|NCT02031289|Active Comparator|Anemia|Hb < 120 g/L in women, Hb < 130 g/L in men Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
3322869|NCT02031289|Active Comparator|Iron deficiency|ferritin < 100 µg/l Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
3322870|NCT02031289|No Intervention|Natural comparison group|Patients without anemia or iron deficiency will be observed and the same postoperative measurements performed
3322871|NCT02031315||Resident of health areas of interest|Residents of 4 health areas will be monitored for sudden unexpected death within 72 months of follow up. Circumstances and past medical conditions will be checked.
3322872|NCT02031328|Experimental|Stereotactic Ablative Radiation|Stereotactic Ablative Radiation 26 Gy in 2 fractions, once weekly to prostate
3322873|NCT02031341||Patients with type 2 diabetes mellitus|
3229066|NCT01177982|Experimental|Reduced RBT (r-RBT)|Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
3229067|NCT01177982|Experimental|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
3229068|NCT01177982|Active Comparator|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club Recovery housing CAP short term housing admission Recovery sponsor
3229069|NCT01177982|Active Comparator|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
3229070|NCT01177982|Active Comparator|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
3322874|NCT02031341||Normoglycemic individuals|Control group
3322875|NCT02031354|Experimental|Lysine Chloride|
3322876|NCT02031367|Active Comparator|Corticosteroid|
3322877|NCT02031367|Experimental|Platelet Rich Plasma|
3322878|NCT02031380|Experimental|Open angle glaucoma - iDropper device|Device
3229071|NCT01177982|Experimental|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
3229072|NCT01177982|Experimental|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
3229073|NCT01177995|Experimental|Social Network|Leaders of labor migrant social networks will be trained to disseminate HIV prevention messages to the members of their social networks. The training will sequentially target ways to increase network members' HIV-related knowledge and norms, attitudes, intentions, and confidence in how to avoid risk. Leaders will be encouraged to have these discussions with network members between and after training sessions.
3229074|NCT01178008|Experimental|Active acupuncture group|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints.
3259109|NCT01467596|Experimental|Elderly population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
3259110|NCT01467596|Active Comparator|Middle aged population|MEAV50, MEAV95 Onset and duration of sensory and motor blockade
3322879|NCT02031393||singelton pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
3322880|NCT02031393||twin pregnancy|will be followed 11-14 weeks and 19-28 weeks of gestation and after birth
3322881|NCT02031406|No Intervention|Usual care|No extra post-discharge pharmacist counseling is explicitly provided to patients, although some patients may receive it depending on their care setting
3322882|NCT02031406|Experimental|Post-discharge pharmacist counseling|Patients will receive post-discharge telephonic pharmacist counseling at around 72 hours after hospital discharge.
3322883|NCT02031419|Experimental|CC-122 + CC-223 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
3322884|NCT02031419|Experimental|CC-122 + CC-292 +/- rituximab|CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days
3322885|NCT02031419|Experimental|CC-292 + CC-223 +/- rituximab|CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days
3322886|NCT02031419|Experimental|CC-122 + rituximab|CC-122 administered orally once daily in combination with Rituximab.
3322887|NCT02031445|Placebo Comparator|Placebo|BID
3322888|NCT02031445|Experimental|MRX-6|BID
3322889|NCT02031497|Experimental|Drink with sweeteners|
3322890|NCT02031497|Active Comparator|Drink without sweeteners|
3322891|NCT02031510|Active Comparator|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
3322892|NCT02031510|Active Comparator|bupivacaine|transversus abdominis plane block with bupivacaine 0.25%
3322893|NCT02031510|Placebo Comparator|placebo|Transversus abdominis block with saline 0.9%
3229075|NCT01178008|Placebo Comparator|Placebo acupuncture group|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
3229076|NCT01178021|Active Comparator|Chloroquine|Standard arm
3229077|NCT01178021|Experimental|Chloroquine/Primaquine|Chloroquine combined with primaquine
3322894|NCT02031523|Active Comparator|Sanjie analgesic capsule|every 4 capsules , 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
3322895|NCT02031523|Placebo Comparator|placebo|every 4 capsules, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.
3322896|NCT02031549||SpermComet Assay|All study subjects will have their surplus sperm analyzed for DNA fragmentation with the SpermComet assay.
3322897|NCT02031562|Active Comparator|Chiropractic|Chiropractic
3322898|NCT02031562|Active Comparator|Physical therapy|Physical therapy
3322899|NCT02031575|Experimental|Basic Treatment|Sends messages to participants about reproductive health.
3229078|NCT01178034|Experimental|pharmacogenetic warfarin dose|Warfarin maintenance dose on the basis of demographic/pharmacogenetic data
3229079|NCT01178047|Active Comparator|Rasagiline|
3229080|NCT01178047|Placebo Comparator|Placebo|
3229081|NCT01178060|Active Comparator|Personalized Risk Information|Patients received personalized stroke and heart attack risk assessment information.
3229082|NCT01178060|Other|Standard Education|Patients received general risk information on heart attack and stroke.
3322900|NCT02031575|Experimental|Interactive Treatment|Sends multiple choice questions and receives texts message responses from participants with incentive for responding correctly
3229083|NCT01178112|Experimental|Trientine + Carboplatin MTD Group|Trientine starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group.
3229084|NCT01178112|Experimental|MTD Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group
3229085|NCT01178112|Experimental|Carboplatin PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
3229086|NCT01178112|Experimental|Trientine PK Expansion Group|Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
3229087|NCT01178151|Experimental|afinitor|10mg afinitor daily orally
3229088|NCT01178164|Experimental|Diagnosis of Fabry disease|
3229089|NCT01178177||SOT recipients|solid organ transplant recipients with invasive pulmonary aspergillosis
3229090|NCT01178177||Hematologic disease|Hematologic disease patients with invasive pulmonary aspergillosis
3229091|NCT01178190||lung cancer|
3229092|NCT01178229|Experimental|Physiotherapy|group of bruxist children that received physiotherapy to change the head posture
3229093|NCT01178229|No Intervention|Control|Group of bruxist children that did not receive treatment
3322901|NCT02031575|Placebo Comparator|Control|Sends messages to students about malaria prevention and control.
3229094|NCT01178242|Experimental|Salivary Gland and Labial Mucous Membrane Transplantation|
3229095|NCT01178255|Experimental|Group 1|
3229096|NCT01178255|Experimental|Group 2|
3229097|NCT01178255|Experimental|Group 3|
3322902|NCT02031588||Ceftriaxone|Patients receiving a C3G (ceftriaxone) during the hospitalization.
3322903|NCT02031588||Ceftriaxone + Fluoroquinolone|ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
3322904|NCT02031588||Fluoroquinolones|fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
3322905|NCT02031588||Reference|"A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation."
3229098|NCT01178255|Experimental|Group 4|
3229099|NCT01178307||Part 1|Patient interview and developmental questionnaires
3322906|NCT02031601|Experimental|Combination therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana] plus Drug: Docetaxel for patients of lung squamous cell carcinoma; Pemetrexed for patients of lung adenocarcinoma plus Drug: Platinum (cisplatin or carboplatin)"
3322907|NCT02031601|Other|TKI alone therapy|"Interventions:~Drug: Erlotinib [Tarceva] or Gefitinib [Iressa] or Icotinib [Conmana]"
3322908|NCT02031614|Experimental|Phlebotomy|Subjects in this arm will undergo phlebotomy of 500 mL of blood.
3229100|NCT01178307||Part 2|Content Expert Panel (doctors, nurses) + Patients and Caregivers Questionnaire Development
3229101|NCT01178307||Part 3|Patient MDASI-GIST Questionnaire
3322909|NCT02031653||Study Group|
3322910|NCT02031666|Active Comparator|Treatment A|15 participants will receive 240-mg dose as Softgel Capsule Formulation of JNJ-56021927.
3322911|NCT02031666|Experimental|Treatment B|15 participants will receive 240-mg dose as Tablet Formulation number 1 of JNJ-56021927.
3322912|NCT02031666|Experimental|Treatment C|15 participants will receive 240-mg dose as Tablet Formulation number 2 of JNJ-56021927.
3322913|NCT02031666|Experimental|Treatment D|15 participants will receive 240-mg dose as Tablet Formulation number 3 of JNJ-56021927.
3322914|NCT02031666|Experimental|Treatment E|15 participants will receive 240-mg dose as Tablet Formulation number 4 of JNJ-56021927.
3229102|NCT01178320||Simvastatin|Participants in the main AIM-HIGH study who are receiving simvastatin.
3229103|NCT01178320||Simvastatin and Extended-Release Niacin|Participants in the main AIM-HIGH study who are receiving simvastatin and extended-release niacin.
3229104|NCT01178346|Experimental|NicVAX|Experimental vaccine
3229105|NCT01178346|Placebo Comparator|Placebo|Placebo vaccine
3229106|NCT01178372|Active Comparator|lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
3229107|NCT01178372|Active Comparator|probiotics|
3229108|NCT01178424|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of mindfulness skills taught in the program.
3229109|NCT01178424|Active Comparator|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
3229110|NCT01178450|Active Comparator|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
3229111|NCT01178450|Experimental|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
3229112|NCT01178463||I. Obstructive Azoospermia|
3229113|NCT01178463||II. Non-Obstructive Azoospermia Patients|
3229114|NCT01178476|Experimental|Hyposafe Hypoglycemia alarm device|EEG based hypoglycemia detection
3229115|NCT01178476|Active Comparator|Regular glucose control|Regular glucose control group
3229116|NCT01178489||Patients undergoing arthroplasty|Patients undergoing primary, unilateral, total hip or knee arthroplasty under spinal anaesthesia
3229117|NCT01178515|Sham Comparator|Full fat milk|Full fat milk contain 3% fat
3229118|NCT01178515|Experimental|Partially defatted milk|Partially defatted milk contains 2% of fat
3229119|NCT01178515|Experimental|Defatted milk|Defatted milk contains 1% fat
3229120|NCT01178554|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
3322915|NCT02031666|Experimental|Treatment F|15 participants will receive 240-mg dose as Tablet Formulation number 5 of JNJ-56021927.
3322916|NCT02031666|Experimental|Treatment G|15 participants will receive 240-mg dose as Tablet Formulation number 6 of JNJ-56021927.
3322917|NCT02031666|Experimental|Treatment H|15 participants will receive 240-mg dose as Tablet Formulation number 7 of JNJ-56021927.
3322918|NCT02031692|Active Comparator|Vitamin D and calcium supplement|
3322919|NCT02031692|No Intervention|Control|
3322920|NCT02031705|Active Comparator|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
3322921|NCT02031705|Placebo Comparator|control group|Control group was performed no additional cavotricuspid isthmus ablation.
3322922|NCT02031718|No Intervention|Online Education|
3322923|NCT02031718|Experimental|Online Education & Virtual Counseling|Online virtual counseling
3322924|NCT02031731|Experimental|4 mg/kg Onartuzumab (MetMAb)|
3322925|NCT02031731|Experimental|15 mg/kg Onartuzumab (MetMAb)|
3322926|NCT02031731|Experimental|30 mg/kg Onartuzumab (MetMAb)|
3229121|NCT01178554|Experimental|Standard Manual Treatment (SMT)|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
3322927|NCT02031744|Placebo Comparator|erlotinib [Tarceva] + placebo|
3322928|NCT02031744|Experimental|erlotinib [Tarceva] + onartuzumab [MetMAb]|
3322929|NCT02031757|Experimental|perturbation training|Standard physiotherapy augmented with perturbation training (BaMPer system).
3322930|NCT02031757|Active Comparator|balance exercise|standard physiotherapy augmented with balance exercises.
3322931|NCT02031783|Experimental|mixture of glucose and fructose|mixture of glucose and fructose
3229122|NCT01178554|Experimental|Modular Maual Treatment (MMT)|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems; Chorpita & Weisz, 2004) to help children with primary problems of anxiety, depression, and conduct.
3322932|NCT02031783|Active Comparator|Glucose|Single glucose
3322933|NCT02031796|Experimental|CAVAREC images|CAVAREC images from x-ray angiography
3322934|NCT02031809||No additional unplanned major surgery|uneventfull intra-operative and postoperative course
3322935|NCT02031809||Additional unplanned major surgery|"Additional per-operative or post-operative unplanned major surgery such as unforeseen pneumonectomy, bilobectomy, lobectomy or additional segmentectomy, repair of major vessels or bronchi, bronchopleural fistula, unplanned surgery to other organs, within 30 days after the primary surgery.~These do not include:~Conversions without additional unplanned major surgery or suddne blood loss less than 500cc~Conversions or additional resection for unforeseen oncologic reasons.~Plasty, repair or sleeve resection of vessels after deliberate resection or transection for oncologic reasons"
3322936|NCT02031822|Active Comparator|US-guided Distal GON Block (Group D)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the superior nuchal line lateral to the external occipital protuberance, close to the occipital artery.
3322937|NCT02031822|Active Comparator|US-guided Proximal GON Block (Group P)|Needle placement for 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg will be performed under US guidance at the level of the bifid C2 spinous process laterally, between the inferior obliquus capitis and semispinalis capitis muscles.
3322938|NCT02031835|Other|BWSTT (3 days a week for maximum of 20 minutes session)|BWSTT (20 minutes of treadmill training (velocity (≥0.1km/h) and body weight support (≤40% of patients weight) according to patients capability and comfort
3322939|NCT02031848|Active Comparator|Healthy Weight Control Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study
3322940|NCT02031848|Active Comparator|Dieting Group|Subjects will complete the Assessments, Diet Intake, and MRI portions of the study and will be given the weight loss and weight maintenance diets, and will attend weekly behavioral meetings
3322941|NCT02031861|Experimental|nifedipine CR tablets (Xin Ran)|Subjects will take a nifedipine controlled-release tablet (30 mg, Xin Ran) orally in every morning for a 12-week treatment period.
3322942|NCT02031861|Active Comparator|nifedipine CR tablets (Adalat)|Subjects will take a nifedipine controlled-release tablet (30 mg, Adalat) orally in every morning for a 12-week treatment period.
3322943|NCT02031874||Miami Cohort|Measured vaccine response to H1N1 in HIV perinatally infected children
3322944|NCT02031887|Experimental|Infant starter formula with synbiotics|Infant starter formula with synbiotics
3229123|NCT01178593|No Intervention|Standard Medical Therapy (SMT)|standard medical treatment (care as usual) with supportive talks
3229124|NCT01178593|Active Comparator|Gut focused hypnotherapy|weekly sessions of gut focused hypnotherapy in groups (10 sessions within 12 weeks)
3229125|NCT01178619||AGA|
3322945|NCT02031887|Active Comparator|Infant formula without synbiotics|Infant formula without synbiotics
3322946|NCT02031900||Undergoing EGD|
3322947|NCT02031913||HBV without FL|Chronic hepatitis B without steatosis
3322948|NCT02031913||HBV with FL|Chronic hepatitis B patients with steatosis
3322949|NCT02031926|Experimental|Positive expiratory pressure|
3322950|NCT02031939|Active Comparator|Standard chemoradiotherapy|Standard chemoradiotherapy (Capecitabine 825mg/m2 combined with radiotherapy )
3322951|NCT02031939|Experimental|induction and gap chemotherapy|induction chemotherapy (Capecitabine 2000mg/m2 +oxaliplatine 130mg/m2) + standard chemoradiotherapy (Capecitabine 2000mg/m2 combined with radiotherapy) + gap chemotherapy (Capecitabine 2000mg/m2 + oxaliplatine 130mg/m2)
3322952|NCT02031952|Experimental|hepatectomy combined lymphadenectomy|hepatectomy combined lymphadenectomy
3322953|NCT02031952|Active Comparator|hepatectomy|hepatectomy alone
3322954|NCT02031965|Experimental|Treatment (oncolytic HSV-1716)|Patients receive oncolytic HSV-1716 IT and peritumorally after undergoing surgical tumor resection. Patients also receive dexamethasone IV prior to and 6 and 12 hours after surgery.
3322955|NCT02031991|Experimental|A = PF-06439535|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3322956|NCT02031991|Active Comparator|B = Bevacizumab-EU|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3322957|NCT02031991|Active Comparator|C = Bevacizumab-US|Intervention Description: Sterile vial 400mg, single-dose 5mg/kg administered as 90-minute infusion on day 1.
3322958|NCT02032004|Experimental|Allogeneic Mesenchymal Precursor Cells|Participants randomly assigned to treatment will undergo a single index cardiac catheterization involving transendocardial delivery of rexlemestrocel-L into the myocardium at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
3322959|NCT02032004|Sham Comparator|Control Treatment|Participants randomly assigned to control treatment will undergo a single cardiac catheterization involving a scripted sham cardiac mapping and cell delivery procedure at a cell injection center by an interventional cardiology team not involved with review or assessment of subsequent study results.
3322960|NCT02032017|Experimental|Percutaneous assisted approach|In this technique, a second small incision (1 cm) at the anterior border of the femur is made. A canulla is placed underneath the muscle and used to pass the reamers in the direction of the acetabulum. There's no need to enlarge the skin incision or to release more muscle insertion to achieve good working access to the acetabulum. Two advantages can be defined: sparing of the gluteus medius muscle and safe access to the acetabulum to obtain perfect positioning of the implants.
3322961|NCT02032017|Active Comparator|Anterolateral approach|A standard transgluteal approach is used. This means a large part of the gluteus medius muscle is released to obtain good access to the acetabulum.
3322962|NCT02032043||Annual MDA treated Group|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
3322963|NCT02032043||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Ivorian Ministry of Health.
3322964|NCT02032056|Experimental|probiotic (10^9 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^9 cfu/day, provided as powder in a sachet which can be added to food or drink.
3322965|NCT02032056|Experimental|probiotic (10^8 cfu/day)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12), 10^8 cfu/day, provided as powder in a sachet which can be added to food or drink.
3322966|NCT02032056|Placebo Comparator|Placebo|provided as powder in a sachet which can be added to food or drink.
3322967|NCT02032069||NHBD|Non Heart Beating Donors
3229126|NCT01178619||symmetrical IUGR|
3229127|NCT01178619||asymmetrical IUGR|
3229128|NCT01178632|Experimental|Passiflora, Anxiety Disorders|1 tablet Passiflora;Crataegus;Salix; PO;BID
3322968|NCT02032069||BDD|Brain death donors
3322969|NCT02032082|No Intervention|Ex vivo without CO|
3322970|NCT02032082|Experimental|EX Vivo with carbone monoxide|During the Ex Vivo Lung Perfusion reconditioning,the lungs will be ventilated wit h Oxygen (21%) and Carbon Monoxide (250ppm).
3322971|NCT02032095|Experimental|GB-0998|
3322972|NCT02032108|Experimental|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
3322973|NCT02032121|Experimental|Intervention procedures|All the procedures will be completed for every subject
3322974|NCT02032134|Other|Patients with severe thrombocytopenia|Intervention Patients with severe thrombocytopenia with an active bleeding, in preparation for surgery, or after chemotherapy (prophylaxis of bleeding),will receive transfusion of Pooled Platelets Cryopreserved In DMSO With a New System
3322975|NCT02032147||NGF group|This group will be treated with NGF 18u daily for 60 days.
3322976|NCT02032147||control group|"this group will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
3322977|NCT02032160|Experimental|Engerix B|Engerix B IM injection - 20ug At 0, 1 and 6 months
3229129|NCT01178632|Active Comparator|Valeriane, Anxiety Disorder|1 tablet Valeriana officinalis, PO, BID
3322978|NCT02032160|Experimental|Fendrix|Fendrix IM injection - 20ug At 0, 1 and 6 months
3322979|NCT02032186|Experimental|Mg++|Magnesium Citrate oral supplementation from early pregnancy; 160 mg twice per day.
3322980|NCT02032186|Placebo Comparator|Placebo|Placebo pills twice per day.
3322981|NCT02032225||CADASIL|patients with CADASIL
3322982|NCT02032251|Experimental|ginger|The patients with infertility that underwent oral administration of ginger.
3322983|NCT02032251|Placebo Comparator|Placebo|The patients with infertility that receive placebo.
3322984|NCT02032264|Experimental|Comprehensive Chromosome Screening|Trophectoderm biopsy will be performed on all blastocysts and CCS via next generation sequencing screening performed on biopsy samples. Patients will proceed with a single or double embryo transfer of the one or two morphologically best euploid embryos
3322985|NCT02032264|Placebo Comparator|No Comprehensive Chromosome Screening|The patients in this group will proceed with a single or double embryo transfer of the one or two morphologically best embryos.
3322986|NCT02032277|Active Comparator|Arm A|Veliparib + carboplatin + paclitaxel followed by doxorubicin/cyclophosphamide (AC)
3322987|NCT02032277|Placebo Comparator|Arm C|Placebo + placebo + paclitaxel followed by AC.
3322988|NCT02032277|Placebo Comparator|Arm B|Placebo + carboplatin + paclitaxel followed by AC
3322989|NCT02032290|Active Comparator|ticagrelor|ticagrelor: loading dose of 180 mg and maintaining dose of 90 mg twice daily in NSTEMI and STEMI (Class I B) patients;
3322990|NCT02032290|Active Comparator|clopidogrel|clopidogrel: loading dose of 600 mg and maintaining dose of 75 mg daily in NSTEMI (Class I B) and STEMI (Class I C) patients.
3322991|NCT02032303|Active Comparator|Ticagrelor|Patient randomized to Ticagrelor
3322992|NCT02032303|Active Comparator|Prasugrel|Patient randomized to Prasugrel
3322993|NCT02032316|Experimental|Interventional|Placement of ureteral stent following post-ureteroscopy
3322994|NCT02032329|Experimental|FastFES|Single Group Study - see Intervention Description
3322995|NCT02032342|Active Comparator|Fuji Uni-blocker|Fuji Uni-blocker for selective lobar deflation
3322996|NCT02032342|Active Comparator|Cohen blocker|Cohen blocker for selective lobar deflation
3322997|NCT02032342|Active Comparator|Arndt® blocker|Arndt® blocker for selective lobar deflation
3322998|NCT02032342|Placebo Comparator|Endobronchial double lumen tube|Endobronchial double lumen tube for one lung ventilation
3322999|NCT02032355||hypotension|
3323000|NCT02032368|Experimental|TACE group|Patients in TACE group receive transarterial chemoembolization (TACE) one month after resection.
3323001|NCT02032368|No Intervention|Control group|Patients in Control group receive no management.
3323002|NCT02032381|Other|allogeneic hematopoietic stem cell|The eligible population for this study will consist of all children under 18 years who received allogeneic hematopoietic stem cell and evaluate of late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
3323003|NCT02032394|Experimental|Chlorhexidine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Chlorhexidine 0.2%, 3 times a day for 10 days.
3323004|NCT02032394|Experimental|Povidone-Iodine|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Povidone-iodine 10%, 3 times a day for 10 days.
3323005|NCT02032394|Active Comparator|Normal saline|Washing of perineal area and proximal first 5 centimeters of catheter from mea, done by 15 ml of Normal saline 0.9%, 3 times a day for 10 days.
3323006|NCT02032446|Experimental|Umbilical Cord Mesenchymal stromal cells (UC-MSC)|"Pentostatin will be given by intravenous infusion at a dose of 1 mg/m2 for 3 consecutive days. Thereafter, three Umbilical Cord Mesenchymal stromal cells (UC-MSC) infusions will be given at weekly interval starting from day 5. We will follow a dose escalating programme with progressively increasing doses of cells until the maximally tolerated dose (MTD) is achieved.~The dose escalating design will be characterised by the administration of 1x106 /kg UC-MSC per dose per three doses for the first three patients (total up to 3x106/kg). The second three patients will receive 2x106/kg UC-MSC per dose per three doses (total up to 6x106/kg). The third three patients will receive 3x106/kg UC-MSC per dose per three doses (total up to 9x106 cells/kg).~Since three dosages of cells are programmed for each group of 3 patients, a minimum of 9 patients should be studied, unless unacceptable acute infusion related toxicity is observed."
3323007|NCT02032459||Minority Women|Study data pulled from already collected data (N=1141 from the Camden Study of low income gravidae and minority gravidae (White, African-American and Hispanic) living in the northeastern United States (New Jersey).
3323008|NCT02032472|No Intervention|Health Center (usual practice)|Controlling arterial pressure in the health center (a common practice is carried out)
3229130|NCT01178645|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
3323009|NCT02032472|Experimental|Collaboration of pharmacies|Pharmacies cooperate in Measurement of Arterial Pressure of patients
3323010|NCT02032485|Experimental|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green in patients with peritoneal carcinomatosis from colorectal cancer before the surgery
3323011|NCT02032498|Experimental|Indocyanine Green|superficial injections of Indocyanine Green in the breast
3229131|NCT01178658|Experimental|BuEAM|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
3229132|NCT01178684||1: HIV-pos on d4T with neuropathy|
3323012|NCT02032511||RAM Cannula Nasal Continuous Positive Airway Pressure|
3229133|NCT01178684||2: HIV-pos on d4T without neuropathy|
3229134|NCT01178684||3: HIV-neg without peripheral neuropathy|
3323013|NCT02032511||Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|
3323014|NCT02032524|Experimental|Avalglucosidase alfa|administered intravenously every 2 weeks
3323015|NCT02032537|Active Comparator|Callmax cream|
3323016|NCT02032537|Placebo Comparator|Placebo|
3323017|NCT02032563|Experimental|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before surgery
3323018|NCT02032576|Experimental|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
3323019|NCT02032589|Experimental|Self-generation treatment|self-generation strategy treatment, embedded within practice of various activities
3323020|NCT02032589|Placebo Comparator|memory training|Treatment consists on traditional memory training
3323021|NCT02032602|Active Comparator|1, CG: Active MTrP|a single session of physical therapy intervention which will be consisted on Deep Dry Needling of the active MTrP most hyperalgesic to palpation of the infraspinatus muscle homolateral to painful shoulder
3323022|NCT02032602|Experimental|2, EG: Active+Latent MTrPs|The same treatment described above for the Control Group, combined with the Deep Dry Needling of the most hyperalgesic latent MTrP, both located in the infraspinatus muscle homolateral to the painful shoulder.
3323023|NCT02032615|Active Comparator|Education plus Gudness Nutritional Bar|Subjects will receive education about anemia and will consume Gudness Nutrition bars for 3 months
3323024|NCT02032615|Placebo Comparator|Education with no nutrition bar|Subjects will receive education about anemia but will not receive nutrition bar
3323025|NCT02032628|Experimental|High Intensity/Longer Duration|Exercise at higher intensity (~75% of VO2max) for 40 minute bouts 4 times per week
3323026|NCT02032628|Experimental|High Intensity/Lower Duration|Exercise at high intensity (~75% of VO2max) for 20 minute bouts 4 times per week
3323027|NCT02032628|Experimental|Lower Intensity/Higher Duration|Exercise at lower intensity (~55% of VO2max) for 40 minute bouts 4 times per week
3323028|NCT02032628|Experimental|Low Intensity/Low Duration|Exercise at lower intensity (~55% of VO2max) for 20 minute bouts 4 times per week
3323029|NCT02032654|Active Comparator|Standard course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Flucloxacillin 500mg capsules, every 6 hours, for 6 days
3323030|NCT02032654|Experimental|Short course|Flucloxacillin (1000mg iv OR, later, 500mg capsules), every 6 hours, for 6 days, followed by: Placebo (for flucloxacillin 500mg) 500mg capsules, every 6 hours, for 6 days
3323031|NCT02032667|Experimental|Multi-player condition|The multi-player condition examines the aspect of online gaming and social interaction with adherence to the exergame.
3323032|NCT02032667|No Intervention|Single-player condition|This arm will look at whether those who play an exergame by themselves or with a computer generated player have the same adherence and use when compared to a multi-player condition.
3323033|NCT02032693|Experimental|Everycell™|Patient will take 1 tablet two times daily of Everycell™ (double-blind) for the 4-week treatment period.
3323034|NCT02032693|Placebo Comparator|Placebo|Patient will take 1 tablet two times daily of the placebo (double-blind) for the 4-week treatment period.
3323035|NCT02032719|Experimental|smartphone assisted lifestyle coaching|6 months of smartphone assisted lifestyle coaching
3323036|NCT02032719|Active Comparator|Lifestyle health coaching|6 months of lifestyle health coaching
3323037|NCT02032732||suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for suspected infection
3323038|NCT02032732||no suspected infection|leukocyte esterase test on fluid removed by intra-articular aspiration for reason other than suspected infection
3323039|NCT02032745||Chemo-insensitive|Non-responders to chemotherapy (Probability for pathological negative nodal status)
3323040|NCT02032745||Chemo-sensitive|Responders to chemotherapy (Probability for pathological negative nodal status)
3323041|NCT02032771|Experimental|M22 IPL and ResurFX|The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
3323042|NCT02032784|Experimental|Octreotide|Octreotide 100mcg subcutaneous every 8 hours for 5 days
3323043|NCT02032784|Other|no octreotide|No Octreotide
3323044|NCT02032797|Experimental|A: 7 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
3323045|NCT02032797|Placebo Comparator|B: 5 days of progesterone|"Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B.~Group A receives 7 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 5 days of micronized progesterone vaginally. On the 7th (group A) or 5th (group B) day of progesterone supplementation, the cryopreserved-thawed day 5 embryo is transferred."
3323048|NCT02032836|Experimental|I-Neb - FOX|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer; followed by single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer in a cross-over fashion. A washout period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks in a cross-over fashion.
3323049|NCT02032836|Experimental|FOX - I-Neb|Part 1: Subjects received single inhalation of 1.25 mcg iloprost using 10 mcg/ml iloprost solution (Ventavis 10) and then 2.5 mcg iloprost using Ventavis 10, both using the FOX nebulizer on Day 1. Part 2: On Day 2, subjects received single inhalation of 5 mcg iloprost using 20 mcg/ml iloprost solution (Ventavis 20) with the FOX nebulizer; followed by single inhalation of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer in a cross-over fashion. A wash-out period of at least 2 hours was maintained between treatments in Part 1 and Part 2. Part 3: Continued on Day 2, and through until Day 30, subjects received multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 20 with the FOX nebulizer for 2 weeks; followed by multiple inhalations (approximately 6 to 9 inhalations per day) of 5 mcg iloprost using Ventavis 10 with the I-Neb nebulizer for 2 weeks in a cross-over fashion.
3323050|NCT02032849|Active Comparator|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
3323051|NCT02032849|Experimental|Manual air-impingement operation|A method which we invented to clear subglottic secretion
3323052|NCT02032862|Experimental|Sage tablets|Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase
3323053|NCT02032862|Placebo Comparator|Placebo|Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase
3323054|NCT02032914||Colonoscopic examination group|The patients diagnosed with cryptogenic pyogenic liver abscess
3229135|NCT01178684||4 HIV-pos on d4T with asymtomatic neuropathy|
3229136|NCT01178697|Active Comparator|Intravitreal triamcinolone|
3323055|NCT02032927|Active Comparator|Codeine/paracetamol|"The combination codeine/paracetamol,30 mg/500 mg,1 tablet every 8 hours, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.~At any stage of the study, patients treated with combination codeine/paracetamol in case of ineffectiveness (NRS> 4) despite maximal dosage (2 tablets every 8 hours) and/or side effect, will be subject to the opioid switch and will start equianalgesic therapy with oxycodone/naloxone combination."
3323056|NCT02032927|Active Comparator|Oxycodone/Naloxone|Combination oxycodone /naloxone, 5 mg/2.5 mg, 1 tablet/day, paracetamol 500 mg if NRS> 4, repeatable up to 3 times per day.
3229137|NCT01178697|Active Comparator|Intravitreal bevasizumab|
3229138|NCT01178710|Experimental|treatment|
3323057|NCT02032940||Standard Sequence Imaging MRI|Patients requiring MRI. All Comers accepting study participation.
3323058|NCT02032940||Additional Pulse Sequence Increased|Patients requiring MRI. All comers accepting study participation and the run of additional pulse sequences during MRI procedure.
3229139|NCT01178710|No Intervention|untreated|control
3229140|NCT01178736||Cancer Screening and Diagnosis|Screening of asymptomatic women for Breast and Cervical cancer in the age group of 35-64 years. Diagnostic assessment of symptomatic women for Ovarian and Endometrial cancer in the age group of 50-64 years.
3229141|NCT01178749||Chronic Hepatitis C Infection|patients Receiving 24-week Interferon-α with Ribavirin Treatments
3229142|NCT01178775|No Intervention|1|control design
3229143|NCT01178775|No Intervention|2|education only group
3229144|NCT01178775|Experimental|3|education and education and walking program design
3229145|NCT01178788|Active Comparator|17 alfa hydroxy Progesterone caproate|Women treated with i.m. 17P injection/weekly (Lentogest, IBSA, Italy)
3229146|NCT01178788|Active Comparator|Micronized Progesterone|micronized P 200 mg per vagina /day (Utrogestan, Besins Healthcare, Belgium)
3229147|NCT01178788|Active Comparator|Control|Routine clinical controls
3229148|NCT01178801||liver cancer|Clinical data of patients with liver cancer
3323059|NCT02032953|Experimental|Insulin, Travasol (35%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid supplementation) given from start of surgery to 6 hours after, at an amount of 35% of patient's energy expenditure as measured before surgery, .
3323060|NCT02032953|Experimental|Insulin, Travasol (20%) postop|Insulin (hyperinsulinemic-normoglycemic clamp) with Travasol (amino acid infusion), given from start of surgery to 6 hours after, at an amount of 20% of patient's energy expenditure as measured before surgery.
3323061|NCT02032953|Placebo Comparator|Insulin, no protein after surgery|Insulin (hyperinsulinemic-normoglycemic clamp, an insulin infusion between 2 and 5 microunits/kg with glucose at a variable rated titrated to maintain normoglycemia, blood glucose 4-6 mmol/L) with no protein supplementation from start of surgery to 6 hours after.
3323062|NCT02032966|Experimental|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
3323063|NCT02032966|Active Comparator|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
3323064|NCT02032966|Other|syndesmotic injury|"Non-randomized / syndesmotic injury: patients who have a positive ligament stress test (signifying a syndesmotic injury) during surgery will require surgical treatment of both the tibia and the fibula and cannot be randomized to either arm (nonsurgical versus surgical). Patients in this arm will still be included in the study for the collection of clinical and functional outcomes."
3323065|NCT02032979|Experimental|FSHD patient|
3323066|NCT02033018|Experimental|Aflibercept injection|Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection
3323067|NCT02033031|Active Comparator|Lucentis|PRN intravitreal injection of Lucentis
3323068|NCT02033031|Active Comparator|Avastin|PRN intravitreal injection of Lucentis
3323069|NCT02033044|Experimental|cognitive remediation|Cognitive remediation programme in order to improve several cognitive domains.
3323070|NCT02033044|Active Comparator|Psychoeducation|Psychoeducation group in order to improve psychosocial functioning of patients.
3323071|NCT02033057|Experimental|Muscular electrostimulation.|The interventions is muscular electrostimulation.
3323072|NCT02033070||Non-Dysplastic IM, LGD, HGD|
3229149|NCT01178840|Other|WC then FC2|The couples will use 4 PATH Woman's Condom then 4 FC2 female condom.
3229150|NCT01178840|Other|FC2 then WC|The couples will use 4 FC2 female condom then 4 PATH Woman's Condom.
3229151|NCT01178866||Clinical course|complicated course group (death within 30 days after surgery or ICU stay > 4 days) and uncomplicated course group (ICU stay ≤ 4 days).
3323073|NCT02033096||Cohort 1: Stannsoporfin 1.5 mg/kg|Cohort 1: Received one 1.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
3323074|NCT02033096||Cohort 2: Stannsoporfin 3.0 mg/kg|Cohort 2: Received one 3.0 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
3323075|NCT02033096||Cohort 3: Stannsoporfin 4.5 mg/kg|Cohort 3: Received one 4.5 mg/kg stannsoporfin injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
3323076|NCT02033096||Cohort 4: Placebo Control|Cohort 4: Received one sterile saline injection (with phototherapy as needed) during participation in an earlier interventional trial (NCT00850993)
3323077|NCT02033109|Experimental|PC-1005|"4.00 g dosed once daily for 3 days (safety run-in)~4.00 g dosed once daily for 14 days (main study)"
3323078|NCT02033109|Placebo Comparator|HEC gel|4.00 g dosed once daily for 14 days (main study only)
3323079|NCT02033122|Active Comparator|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
3323080|NCT02033122|Sham Comparator|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
3323081|NCT02033135|Experimental|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX) plus unsupervised exercise therapy, smoking cessation advice and best medical therapy.
3323082|NCT02033135|Active Comparator|Best medical treatment|Unsupervised exercise therapy, smoking cessation advice and best medical therapy.
3323083|NCT02033148|Experimental|Treatment (icotinib hydrochloride)|Patients receive icotinib hydrochloride PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3323084|NCT02033161|Experimental|Internet-delivered CBT|
3323085|NCT02033187|Experimental|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
3229152|NCT01178879|Experimental|Telehealth consultation|Telehealth nurse consultation plus treatment as usual
3229153|NCT01178879|No Intervention|Conventional|Treatment as usual
3323086|NCT02033187|Active Comparator|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
3323087|NCT02033226|Experimental|Amniotic Membrane|The test site was treated as follows; After placement and proper condensation of natural Hydroxyapatite graft in the defect, AM was cut based on defect anatomy of surgical site and then adapted over the bone graft and alveolar bone extending from base of the flap reflection to the tooth surface.
3323088|NCT02033226|Placebo Comparator|Control group (Hydroxyapatite only)|The control site was treated by graft placement (Hydroxyapatite) only
3323089|NCT02033239|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
3323090|NCT02033239|Active Comparator|NovoRapid®|Each subject will be randomised to a treatment sequence consisting of 8 treatment periods
3323091|NCT02033252|Experimental|Acupuncture|A series of acupuncture sessions within four weeks from the baseline with concurrent conventional medications for asthma
3323092|NCT02033252|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no acupuncture treatments throughout the 4 weeks while receiving other conventional managements for asthma. After 4 weeks, if participants choose to try the acupuncture treatment, the active acupuncture treatment will be provided for 4 weeks (3 sessions/week).
3229154|NCT01178892|Placebo Comparator|Placebo|
3229155|NCT01178892|Experimental|Omega-3|
3323093|NCT02033265||Patients with BMI less than 30 kg/m2|Patients with BMI less than 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC.
3323094|NCT02033265||Patients with BMI 30 or above|Patients with BMI 30 kg/m2 undergoing surgical procedures on upper limb (elbow, forearm and hand) scheduled to receive ultrasound-guided axillary brachial plexus block as their primary anesthetic modality at SJHC
3323095|NCT02033278|Experimental|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
3323096|NCT02033278|Placebo Comparator|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
3323097|NCT02033291||Cortical stroke or primary intracerebral hemorrhage patients:|patients who have a clear clinical presentation of either cortical stroke or primary intracerebral hemorrhage confirmed on brain CT. The patients are eligible when the DCE-MRI scans can be performed within 0-6 weeks of the vascular event and on two subsequent days as the vascular permeability may change significantly on the timescale of weeks.
3323098|NCT02033291||cSVD patients|patients who present with a transient ischemic attack (TIA) and cSVD related abnormalities on brain MRI. TIA patients are defined as patients with stroke like symptoms that last no longer than 24 hours. MRI abnormalities include extended white matter lesions, (asymptomatic) lacunar infarcts, microbleeds and enlarged Virchow-Robin spaces. The patients are eligible when the first DCE-MRI scan can be performed 8-12 weeks after the TIA to avoid the acute phase, and the second MRI-scan within four weeks after the first.
3323099|NCT02033330|Active Comparator|phenolics form orange peel, type 1|1 dose of 500 mg of phenolics from orange peel, orally ingested
3323100|NCT02033330|Active Comparator|phenolics from orange peel, type 2|1 dose of 500 mg of phenolics from orange peel, orally ingested
3323101|NCT02033330|Experimental|phenolics from orange peel, type 3|1 dose of 500 mg of phenolics from orange peel, orally ingested
3323102|NCT02033343|Experimental|Real-time tracking & beam adjustment|Prostate cancer radiotherapy using real-time tracking
3229156|NCT01178892|Experimental|Yoga|
3229157|NCT01178892|Experimental|Exercise|
3229158|NCT01178892|Other|Usual Activity 1|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
3229159|NCT01178892|Other|Usual Activity 2|Usual Activity 1 and Usual Activity 2 arms will be compared to the Yoga and Exercise arms.
3323103|NCT02033356|Experimental|ACB with 30 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3323104|NCT02033356|Experimental|ACB with 25 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3323105|NCT02033356|Experimental|ACB with 20 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3323106|NCT02033356|Experimental|ACB with 15 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3323107|NCT02033356|Experimental|ACB with 10 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3229160|NCT01178905|Other|Mother CMV positive|
3229161|NCT01178918||Healthy volunteers from recipients of H1N1 vaccine|
3229162|NCT01178931|Active Comparator|Oral dydrogesterone|Study group receiving 2x10mg of oral dydrogesterone until a pregnancy test or in the case of pregnancy until 10 week.
3229163|NCT01178931|Active Comparator|Crinone 8% vaginal gel|Control group is receiving vaginal gel, 1x90mg, until a pregnancy test or in the case of pregnancy until 10 week.
3229164|NCT01178957||Type 1 diabetes|
3229165|NCT01178983|Experimental|telebiofeedback|
3229166|NCT01178983|Active Comparator|biofeedback|
3259111|NCT01467622||Study population|Patients undergoing elective pulmonary wedge resection, anatomic segmentectomy, or lobectomy.
3323108|NCT02033356|Experimental|ACB with 5 ml lidocaine 1%|"Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml."
3323109|NCT02033395||Participants exposed to tramautic event|
3323110|NCT02033408|Experimental|Antibiotics in addition to steroids|"methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses and in addition the following antibiotics:~PO Vancomycin 250mg 4 times a day for 3 weeks (children under age 8 125mgX4/d for 3 weeks)~PO Amoxycillin 50mg per Kg divided by 3 (up to 500mg 3 times a day) - for 3 weeks~PO Metronidazole 5mg per Kg 3 times a day (up to 250mg 3 times a day) - for 3 weeks~PO Doxycycline 2mg per kg twice a day (up to 100mg twice a day) - for 3 weeks; OR- For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks"
3323111|NCT02033408|Active Comparator|Steroids only|methylprednisolone-1.5mg/kg up to 60mg daily in two divided doses
3323112|NCT02033408|Other|Open arm|either the antibiotics and/or FMT (fecal microbiome transplant) may be administered in a non-randomized, uncontrolled open-label arm to any resistant IBD patients
3323113|NCT02033421||Pharmacokinetics Beta-lactam antibiotics|Patients with infective endocarditis treated with Beta-lactam antibiotics
3323114|NCT02033434|Experimental|Intranasal Ketamine|All patients
3229167|NCT01178996|Experimental|Thymosin alpha 1|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
3229168|NCT01178996|Placebo Comparator|Placebo|Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).
3229169|NCT01179009|Experimental|ketamine 100-hour infusion|100-hour infusion of ketamine plus a safener (clonidine)
3323115|NCT02033447|Experimental|Magnetic Nanoparticle Injection|Patients undergoing radical cystoprostatectomy or prostatectomy
3323116|NCT02033460|Experimental|Manual therapy, education and Exercise|"The protocol for this group is identical to the previous group with the sole difference that is added an exercise protocol :~In the fifth session we explained the patients to perform :~Five sets of isometric contraction of the deep neck flexors for 8-10 seconds.~Five sets of isometric contraction of the neck extensors for 6-8 seconds~Neural self-mobilization and stretching held for 10 - 12 seconds for the levator scapulae and the trapezius muscle.~In the sixth session the patient repeat all the exercises from the previous session and also with the help of a theraband made :~• Isotonic contraction of the head, performing 3-4 sets of 8-10 repetitions."
3323117|NCT02033460|Active Comparator|Manual Therapy and Education|"The protocol used for therapeutic education consisted of two approaches:~Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective."
3323118|NCT02033460|Active Comparator|Manual Therapy|Manual therapy will consist on Traction oscillatory, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
3323119|NCT02033473|Experimental|Apelin|An apelin clamp in which an apelin infusion will be administered prior to reference clamp
3323120|NCT02033473|Placebo Comparator|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered prior to apelin clamp
3323121|NCT02033486|Experimental|TOBI + DBT|TOBI + DBT of women presenting for breast imaging.
3323122|NCT02033525|Experimental|XCEL-M-ALPHA and standard rehabilitation|Intraarticular administration of XCEL-M-ALPHA followed by standard rehabilitation program
3323123|NCT02033525|Active Comparator|standard rehabilitation|Standard rehabilitation program
3323124|NCT02033538|Experimental|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
3323125|NCT02033551|Experimental|Arm A - Veliparib Monotherapy|Subjects in this arm will be dosed with Veliparib continuous dosing.
3323126|NCT02033551|Experimental|Arm B - Veliparib in Combination with Carboplatin & Paclitaxel|Subjects enrolled will receive Veliparib in combination with Carboplatin and Paclitaxel and have an option to move to Veliparib monotherapy.
3229170|NCT01179009|Experimental|ketamine 40-minute infusion|40-minute ketamine infusion following a 100-hours +/- placebo (saline) infusion. Participants will also receive a safener (clonidine)
3323127|NCT02033551|Experimental|Arm C Veliparib in Combination with Modified FOLFIRI|Subjects will be given Veliparib in combination with modified FOLFIRI. The subject will have the opportunity to receive Veliparib as monotherapy.
3323128|NCT02033564|Active Comparator|Macintosh/Miller Laryngoscope|Macintosh or Miller laryngoscopy blade, preference left up to practitioner conducting intubation. These are the gold standards currently used in laryngoscopy.
3323129|NCT02033564|Active Comparator|Glidescope Laryngoscope|Glidescope video-guided laryngoscopy blade
3323130|NCT02033577|Experimental|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb
3229171|NCT01179009|Experimental|ketamine IM injections|One-2 weeks after the end of the 96-hour ketamine infusion, subjects assigned to the ketamine maintenance arm will return for ketamine maintenance injections (0.5-5 mg/kg, IM).
3229172|NCT01179009|Experimental|lorazepam IM Injections|Subjects randomized to the lorazepam control arm will also return for IM lorazepam maintenance injections 2 mg IM (range 0.5 - 4).
3323131|NCT02033577|Active Comparator|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb
3323132|NCT02033590|Experimental|SERI® Surgical Scaffold|
3229173|NCT01179035|Active Comparator|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
3259112|NCT01467635|Active Comparator|EBUS-TBNA|Sampling using endobronchial ultrasound guided transbronchial needle aspiration
3323133|NCT02033603|Active Comparator|Femoral Nerve Block|Femoral Nerve block performed with 0.5% Ropivacaine 30mls (150mg)
3323134|NCT02033603|Active Comparator|Adductor Canal block|Adductor Canal block performed with 0.5% Ropivacaine 30mls (150mg)
3323137|NCT02033629|Active Comparator|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
3323138|NCT02033629|Active Comparator|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
3323139|NCT02033629|Placebo Comparator|Ce 3 ng/ml|Remifentanil Ce 3 ng/ml
3229174|NCT01179035|Experimental|Transitions Clinic - Parolee Targeted Care|Following randomization, subjects in this arm receive ongoing primary care in a parolee-targeted clinic. Parolee-targeted care includes care from clinicians with a knowledge of the impacts of incarceration on health and experience caring for formerly incarcerated patients, a community health worker that works in medical and social services coordination and chronic disease education, and linkages with community-based organizations serving formerly incarcerated individuals.
3229175|NCT01179061|Experimental|Apelin infusion|6 hour infusion of apelin peptide into circulation
3323140|NCT02033642|Experimental|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to: (1) educate adolescent/young adult participants and their parents in principles of good nutrition and physical activity, and (2) train parents to implement lifestyle changes at home to facilitate weight loss in their child.
3323141|NCT02033642|Experimental|Maintenance|The Maintenance condition in this study is a 12-session intervention designed to extend FBBI and continue to teach adolescent/young adult participants and their parents to continue practicing lifestyle behaviors at home.
3323142|NCT02033655|Experimental|Weight loss high protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60% of animal protein from pork.
3323143|NCT02033655|Active Comparator|Weight loss control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
3323144|NCT02033668|Active Comparator|Arm A|Participants in this arm will receive single 200 milligram (mg) dose of GSK933776 administered by IV infusion
3323145|NCT02033668|Experimental|Arm B|Participants in this arm will receive single 200 mg dose of GSK933776 administered SQ
3323146|NCT02033668|Experimental|Arm C|Participants in this arm will receive 50 mg dose of GSK933776 administered SQ once weekly for 4 weeks (total dose = 200 mg).
3323147|NCT02033668|Experimental|Arm D|Participants in this arm will receive single 200 mg dose of GSK933776 administered IM
3229176|NCT01179061|Placebo Comparator|Placebo|Infusion of saline into systemic circulation
3323148|NCT02033681|Experimental|"One-per-mil Tumescent Solution"|
3323149|NCT02033681|Placebo Comparator|Saline Solution|
3323150|NCT02033707|Experimental|Male volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
3323151|NCT02033707|Experimental|Female volunteers|Hallucinogens and psychoactive substances will be administered via capsule. Results will be compared between male and female participants.
3323152|NCT02033720||Shockable arrest|Initial arrest rhythm shockable. This is either pulseless ventricular tachycardia (pulseless VT) or ventricular fibrillation (VF).
3323153|NCT02033720||Pulseless electrical activity|Initial arrest rhythm is pulseless electrical activity.
3229177|NCT01179074|Active Comparator|Oesophageal stent alone|Patients of inoperable oesophageal cancer in this arm underwent oesophageal stenting with self expandable metal stents
3323154|NCT02033720||Asystole|Initial arrest rhythm is asystole.
3323155|NCT02033733||Adequate cooling time|"Patients that reached target temperature within 4 hours of initiation of the hypothermia protocol will be in the adequate cooling time group."
3323156|NCT02033733||Inadequate cooling time|"Patients that did not reach target temperature within 4 hours of initiation of the hypothermia protocol will be in the inadequate cooling time group."
3323157|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm A|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator while receiving concurrent buprenorphine-naloxone as prescribed
3229178|NCT01179074|Active Comparator|Oesophageal stent followed by EBRT|Patients in this arm underwent oesophageal stenting with self expandable metal stents followed by external beam radiotherapy (30Gy/10#/2weeks)
3229179|NCT01179100|Placebo Comparator|Normal Saline|Normal Saline: Calculated and adjusted to match loading dose and infusion rate of lidocaine equivalent adjusted for weight.
3229180|NCT01179100|Active Comparator|Lidocaine|
3229181|NCT01179126|Experimental|complete multivessel revascularization|
3229182|NCT01179126|Active Comparator|stress echo guided revascularization|
3323158|NCT02033746|Experimental|Transdermal Electroacupuncture - Arm B|week 1-2 real treatment, week 3-6 sham treatment with Han's Acupoint Nerve Stimulator treatment while receiving concurrent buprenorphine-naloxone as prescribed
3323159|NCT02033772||Thoracoscopic surgery|Infants undergoing thoracoscopic surgery.
3323160|NCT02033798|Experimental|Tamsulosin|The dosage form of Tamsulosin is tablet, dosage is 0.2mg, frequency is once daily and duration is 6 months.
3323161|NCT02033824|Other|Group 1 Control|Will receive only traditional craniectomy
3323162|NCT02033824|Experimental|Group 2 Treatment dHACM|Will receive craniectomy, but with the addition of a piece of dHACM placed over any dural defect or dural closure.
3323163|NCT02033863||Cohort A|Varicocele arising from the spermatic vein(s) and pampiniform plexus, with or without concomitant diagnosis of infertility or subfertility
3323164|NCT02033863||Cohort B|Pelvic varices in females for the treatment of pelvic congestion syndrome (e.g., pelvic venous incompetence).
3323165|NCT02033902||Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
3323166|NCT02033915|Experimental|Interactive Discussion Group|The interactive discussion groups were held for six times (8-10 persons for each group). During the 50-60 minutes' discussion, the facilitators guided the participants to discuss a case vignette, focusing on the key issues of hospital suicide prevention, and to enhance their abilities of suicide risk identification and evaluation. Two research team members who served as facilitators led the group in a standardized manner.
3323167|NCT02033928||Arm I: Transplant patients|
3323168|NCT02033928||Arm II: Plasma cell dyscrasia patients|
3323169|NCT02033941|Active Comparator|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
3323170|NCT02033941|Placebo Comparator|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
3323171|NCT02033967|Active Comparator|CVP|Central venous pressure-guided vasodilator-induced hypovolemia
3323172|NCT02033967|Experimental|SVV|stroke volume variation-guided vasodilator-induced hypovolemia
3323173|NCT02033980|Other|colorectal lesions|All lesions will be observed with NBI and removed endoscopically or surgically for histological diagnosis.
3323174|NCT02034032|Active Comparator|Regenexx SD|Regenexx-SD (Same Day) is a bone marrow based injection procedure.
3323175|NCT02034032|Active Comparator|Exercise Therapy|Subjects in the Exercise Therapy group will attend an initial session with a trained Physical Therapist. During that session the physical therapist will instruct the subject in a home exercise program and instructions about activity limitations. The subject's progress will also be followed by the Physical Therapist during the 6 week follow-up visit with further instructions provided.
3229183|NCT01179139|Active Comparator|Healthy Control|
3229184|NCT01179139|Experimental|CRS|
3229185|NCT01179152|Active Comparator|Budicort|75 children will receive treatment with Budicort 200 mcg
3323176|NCT02034045|Active Comparator|Usual Care|Patients randomized to the control group will continue to receive usual care from their Family Health Care Team. Usual care includes physician assessment and treatment and periodic augmentation of care in the community (CCAC or case manager, nurse practitioner) at the discretion of the treating physician.
3323177|NCT02034045|Experimental|Community Paramedicine|The intervention will consist of an initial visit and 3 follow-up visits at 3 month intervals over one year by a paramedic who has received additional training in chronic disease management, in addition to routine usual care and any additional visits prompted by the patient, the paramedic or the Family Health Care Team.
3323178|NCT02034071|Experimental|DCCR Open Label - DCCR Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to continue DCCR, at the same dose as they received on Day 69, in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
3323179|NCT02034071|Experimental|DCCR Open Label - Placebo Double Blind|Patients are initiated on a DCCR dose of about 1.5 mg/kg (maximum starting dose of 145 mg) and are titrated every 14 days through 4 dose levels of DCCR. Patients will be up-titrated at each visit at the discretion of the investigator. Randomized to receive placebo equivalent to the DCCR dose received on Day 69 in the Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension
3323180|NCT02034084|Experimental|Right radial approach|Coronary diagnostic procedures performed through right radial approach
3323181|NCT02034084|Experimental|Left radial approach|Coronary diagnostic procedures performed through left radial approach
3323182|NCT02034097|Experimental|Cohort 1|Subjects with EGFRm NSCLC who have received clinical benefit (CR, PR, SD) for at least 4 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 milligram (mg) erlotinib once daily (OD) and 45 mg foretinib OD as a combination therapy until disease progression
3323183|NCT02034097|Experimental|Cohort 2|Subjects with EGFR/WT NSCLC who have received clinical benefit (CR, PR, SD) for at least 2 months and then progressed on an EGFR-TKI within the last 30 days will receive 150 mg erlotinib OD and 45 mg foretinib OD as a combination therapy until disease progression.
3323184|NCT02034097|Experimental|Cohort 3|Subjects with NSCLC who are predicted to be sensitive to foretinib based on biomarkers identified with preclinical or clinical data will receive 60 mg foretinib OD as a monotherapy until disease progression
3323185|NCT02034110|Experimental|Dabrafenib + Trametinib|Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. Dabrafenib will be administered under fasted conditions, either 1 hour (hr) before or 2 hours (hrs) after a meal with approximately 200 mL of water with an interval of 12 hours. Trametinib will be administered under fasted conditions, either 1 hr before or 2 hrs after a meal with approximately 200 mL of water. Subjects will take their dose of Trametinib concurrently with the morning dose of Dabrafenib. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
3229186|NCT01179152|Active Comparator|Symbicort|75 children will receive treatment with Symbicort 160 mcg
3229187|NCT01179152|No Intervention|counselling|75 children who will not treated as their request but will be folowedup
3229188|NCT01179165||Type 2 diabetes age 40-75|Only one diagnostic/observational group
3229189|NCT01179178||COPD-patients|
3229190|NCT01179178||Older adults (65-81 y)|
3229191|NCT01179204||Patiens operated with TKA|
3229192|NCT01179230||PET SPECT|Subjects will have both types of imaging performed, PET and SPECT
3229193|NCT01179243||intensive care patients|no interventions
3229194|NCT01179256|Experimental|CURCUMIN|oral supplementation of curcumin 2000mg
3229195|NCT01179256|Placebo Comparator|PLACEBO|oral PLACEBO TABLET
3229196|NCT01179269|Experimental|Pazopanib plus Paclitaxel|Pazopanib daily and weekly Paclitaxel IV.
3229197|NCT01179282|Placebo Comparator|PLACEBO|PLACEBO NASAL SPRAY
3229198|NCT01179282|Active Comparator|DUST MITE ALLERGEN|Subjects will use dust mite Dermatophagoides pteronyssinus (Dp) extract or placebo nasal spray at home for 2 weeks, with a 1 month washout period followed by 2 weeks of the other nasal spray.
3229199|NCT01179295|Experimental|Arm 1|
3229200|NCT01179295|Experimental|Arm 2|
3229201|NCT01179295|Experimental|Arm 3|
3229202|NCT01179295|Experimental|Arm 4|
3323186|NCT02034123|Experimental|Dose Escalation Cohort|The safety and PK/PD data will be reviewed prior to the dose decision, and the dose escalation will be guided by the Neuenschwander -continuous reassessment method (N-CRM).The dose escalation will complete when RP2D is determined. The RP2D will be the MTD or a lower dose that provides adequate PK exposure and biologic activity with superior tolerability.
3323187|NCT02034123|Experimental|Dose Expansion Cohort|Once the RP2D has been determined, an expansion cohort of up to 30 subjects will be enrolled in order to better characterize the clinical activity and safety profile of the RP2D
3323188|NCT02034136|Experimental|Ginsenoside|"Ginsenoside :~Intervention : ginsenoside, 3 gram / day, for 28 days in intervention group"
3323189|NCT02034136|Placebo Comparator|Dietary fiber fill|Dietary fiber fill manufactured to mimic Ginsenoside tablet
3323190|NCT02034149|Other|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.We collected information on baseline and follow-up data on biochemical and physiological check-ups, health promotion behavior, dietary intake status, self-efficacy and cost etc. The effectiveness assessments have been set for the baseline, 3rd, 6th, 12th and 18th months.
3229203|NCT01179308|Active Comparator|General-epidural anesthesia|Epidural and general anesthesia
3229204|NCT01179308|Active Comparator|General anesthesia|General anesthesia alone
3323191|NCT02034149|Experimental|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with digital video disc (DVD) courses. We negotiated their behavior change set goals for them etc.With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
3323192|NCT02034149|Experimental|peer-assisted management|The peer-assisted management group received the peer oriented group activities followed, including group discussions to share experience and sports map etc. With one year of intervention period, the 3 groups will be assessed at the 18th months of follow-up next year.
3323193|NCT02034188|Experimental|Umbilical cord mesenchymal stem cells|
3323194|NCT02034201|Active Comparator|Lisdexamfetamine|Lisdexamfetamine will be admistered at 140 mg orally daily through week 6 of the protocol.
3323195|NCT02034201|Placebo Comparator|Placebo|Placebo will be administered orally daily through week 6 of the protocol.
3323196|NCT02034214|Experimental|Full Intervention|Life skills education vocational counseling Economic livelihoods reproductive health services social support
3323197|NCT02034214|Active Comparator|Education and health services alone|Life skills education Reproductive health services
3323198|NCT02034227|Experimental|SG2000 - 15 µg/m2/day|Cohort 1 - will commence at 15 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
3229205|NCT01179321|No Intervention|Control|
3229206|NCT01179321|Experimental|Early nutrition intervention|
3229207|NCT01179360||Imaging group|
3229208|NCT01179373|Active Comparator|TMS, High Frequency|High Frequency TMS with H coil to prefrontal cortex
3323199|NCT02034227|Experimental|SG2000 - 30 µg/m2/day|Cohort 2 - will commence at 30 µg/m2/day intravenous doses of SG2000 until Maximum Tolerated Dose is determined.
3323200|NCT02034253||first episode psychosis|Unmedicated first episode psychosis patients that wish to enroll in a 16 week treatment regimen with the drug Risperidone.
3229209|NCT01179373|Active Comparator|TMS, Low Frequency|Low Frequency TMS to Prefrontal cortex
3229210|NCT01179373|Placebo Comparator|Sham Stimulation|Sham TMS with H Coil on Prefrontal Cortex
3323201|NCT02034253||healthy demographic-matched controls|healthy controls will be matched to patients one to one based on: age, smoking status, parental socio-economic status, and gender. Healthy controls must be free from current or past Axis I mental disorders, 1st degree relative current or past Axis I mental disorders, and any other neurological conditions.
3323202|NCT02034266|Experimental|Omega-3 supplementation|Participants will take an oral 5 mL serving (1 tbsp) of mammalian omega-3 seal oil (375 mg EPA, 280 mg DPA and 510 mg DHA) (Auum Inc., Timmons, On) twice daily. Total daily essential fatty acid load - 2330 mg.
3229211|NCT01179386||methylphenidate|30 adolescents who are treated with Methylphenidate will perform the driving simulator and seat pressure mapping tests, in 2 different days : 1. with their regular methylphenidate medication and 2: without the methylphenidate medication after a 4 days washout period. Results will be recorded and statistical test will be performed.
3229212|NCT01179386||no medication|30 adolescents : control group , not suffering from ADHD and without methylphenidate medication will perform the driving simulator and seat pressure mapping tests. Results will be recorded and statistical test will be performed.
3229213|NCT01179412|Experimental|2% povidone-iodine|
3229214|NCT01179425|Active Comparator|non-marijuana dependent controls|
3229215|NCT01179425|Experimental|Marijuana-dependent subjects|
3229216|NCT01179451||Post streptococcal reactive arthritis (PSRA)|children who were diagnosed with psra at least one year before the study
3229217|NCT01179464|Active Comparator|Aminobiphosphonates|Aminobiphosphonates
3229218|NCT01179464|Experimental|Aminobiphosphonates and Statin|Aminobiphosphonates and Statin
3229219|NCT01179503|Active Comparator|Calcium only|1200 mg Calcium per day
3229220|NCT01179503|Experimental|Vitamin D plus calcium|2000 IU vitamin D plus 1200 mg calcium per day
3229221|NCT01179529|Experimental|Omalizumab|
3229222|NCT01179542||first trimester|first trimester
3229223|NCT01179542||third trimester|third trimester
3229224|NCT01179542||prgnancies complicated with IUGR|prgnancies complicated with IUGR
3229225|NCT01179542||preeclampsia|preeclampsia
3259113|NCT01467635|Experimental|EBUS-TBNB|Sampling using endobronchial ultrasound guided transbronchial forceps biopsy needle.
3259114|NCT01467648|Experimental|0.5 g by 4 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 4 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
3323203|NCT02034279|Experimental|Intravenous infusion of albumin|Treatment arm will receive intravenous albumin on days 1 and 3 plus antibiotics
3323204|NCT02034279|No Intervention|No albumin|Only antibiotics
3323205|NCT02034292|Experimental|10mg MD|APD791 10mg Multiple dose and
3323206|NCT02034292|Experimental|20mg MD|APD791 20mg Multiple dose
3323207|NCT02034292|Experimental|40mg MD|APD791 40mg Multiple dose
3323208|NCT02034292|Experimental|60mg MD|APD791 60mg Multiple dose
3323209|NCT02034292|Placebo Comparator|Placebo MD|Placebo for Multiple dose group
3323210|NCT02034292|Experimental|120mg SD|APD791 120mg Single dose
3323211|NCT02034292|Experimental|240mg SD|APD791 240mg Single dose
3323212|NCT02034292|Experimental|320mg SD|APD791 320mg Single dose
3323213|NCT02034292|Placebo Comparator|Placebo SD|Placebo for Single dose
3323214|NCT02034331|Active Comparator|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
3323215|NCT02034331|Active Comparator|Heat Application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
3323216|NCT02034331|Experimental|Insulin Iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
3323217|NCT02034331|Placebo Comparator|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
3323218|NCT02034344||Group 1: Healthy participants|20 healthy participants will be enrolled.
3323219|NCT02034344||Group 2: DLE/SCLE without SLE|30 participants with Discoid Lupus Erythematosus/Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) without Systemic Lupus Erythematosus (SLE) will be enrolled.
3229226|NCT01179555|Experimental|Pt. 1 Behavioral Activation|"Behavioral Activation (BA) is a behavioral technique to help people overcome avoidant tendencies through goal setting, activity scheduling, and graded task assignment. The key component of BA involves developing an Action Plan, and having the subject document each step of the plan as he or she implements it, reinforcing the steps towards goal attainment. Action Plans are easily applied to diabetes self-care tasks because the latter lend themselves to documentation of simple, step-by-step plans. In this study, a Community Health Educator (CHE) - interventionist will schedule and deliver four 45-60 minute in-home BA sessions within 3 months of randomization (i.e., one session every 2-3 weeks)."
3229227|NCT01179555|Placebo Comparator|Pt. 1 Supportive Therapy|The purpose of Supportive Therapy (ST) is to explore the impact of aging and diabetes on the subject's life. In contrast to the BA intervention, the interventionist does not discuss the importance of dilated eye exams. In subsequent sessions, ST facilitates and deepens knowledge about the subject's life situation in relation to his or her health and other life difficulties. The ST therapist encourages this process and creates an accepting, nondirective, and supportive opportunity for discussion.
3323220|NCT02034344||Group 3: DLE/SCLE with SLE|30 participants with DLE/SCLE with SLE will be enrolled.
3323221|NCT02034357|Other|Neurocognitive function|Neurocognitive function assessment (verbal learning and memory) as measured by CVLT and sleep evaluations in Parkinson's disease patients at baseline, and after 4 months and 1 year of CPAP treatment
3229228|NCT01179581|Experimental|1|single ascending doses
3229229|NCT01179581|Placebo Comparator|2|single dose placebo
3229230|NCT01179581|Experimental|3|multiple dose, 10 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
3323222|NCT02034370||Included patients|All ten patients included in this cohort. Shoulder surgery patients that are getting a nerve block and are at high risk for OSA. They will receive a Lung-function spirometry test and an overnight sleep test.
3323223|NCT02034383|Experimental|Control|Diet will consist of a controlled diet without almonds for 3 weeks.
3323224|NCT02034383|Experimental|Whole Almonds|Diet will consist of a controlled diet with whole almonds for 3 weeks.
3323225|NCT02034383|Experimental|Roasted Whole Almonds|Diet will consist of a controlled diet with roasted whole almonds for 3 weeks.
3323226|NCT02034383|Experimental|Diced Almonds|Diet will consist of a controlled diet with diced almonds for 3 weeks.
3323227|NCT02034383|Experimental|Almond Butter|Diet will consist of a controlled diet with almond butter for 3 weeks.
3323228|NCT02034396|Other|Blood draw|One blood draw at enrollment
3323229|NCT02034422|Experimental|Specific Aim #1|Specific Aim 1: Determine the consequences of oxidative stress on skeletal muscle afferent feedback and muscle blood flow during exercise in hypertension. Hypothesis: Afferent feedback sensitivity, determined by passive leg movement (isolation of mechanoreceptor sensitivity) and post exercise circulatory occlusion (isolation of metaboreceptor sensitivity) will be greater in hypertension leading to the exaggerated EPR. Muscle blood flow, assessed by Doppler ultrasound during multiple exercise intensities, will be impaired in hypertension leading to exercise intolerance. Reductions in oxidative stress, achieved by an oral antioxidant treatment (Vitamins C, E and alpha lipoic acid), will reduce afferent fiber sensitivity and improve muscle blood flow in hypertension. Additionally, venous endothelial cells will express elevated markers of oxidative stress providing novel evidence that the vascular endothelium contributes to the greater oxidative stress in hypertension.
3229231|NCT01179581|Placebo Comparator|4|multiple dose, capsules, 10 days; scheme to match that of Study Arm 3.
3229232|NCT01179594|Placebo Comparator|A|
3323230|NCT02034422|Experimental|Specific Aim #2|Specific Aim 2: Determine the remediable effect of combined antioxidant treatment and exercise rehabilitation in the treatment of hypertension. Hypothesis: Acute antioxidant treatment administered prior to exercise in hypertensive patients will ameliorate the exaggerated EPR resulting in a normal and safe blood pressure response to exercise-based rehabilitation. This two-pronged approach (antioxidants and exercise training) will result in a safely achieved reduction in skeletal muscle afferent feedback facilitating improved exercise tolerance, improved muscle blood flow and ultimately reduced cardiovascular risk in this population.
3323231|NCT02034448||Acute Kidney Injury|CRRT intervention with adult patients with Acute Kidney Injury
3323232|NCT02034461|Experimental|Acute surgical implantation|
3323233|NCT02034461|Experimental|Implantation of a Utah Electrode Array|Arm which has been amputated or has peripheral nerve trauma. Interventions include insertion of the Utah Slanted Electrode Arrays which will interact with nerve endings in order to gain knowledge about nerve stimulation.
3323234|NCT02034487||Boys with delayed puberty|Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.
3323235|NCT02034500|Experimental|S. sonnei 1790GAHB - 0.1 mcg - ID|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 0.1 mcg intradermally (ID)
3323236|NCT02034500|Experimental|S. sonnei 1790GAHB - 1 mcg - ID|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 1 mcg intradermally (ID)
3229233|NCT01179594|Experimental|B|
3229234|NCT01179594|Placebo Comparator|C|
3323237|NCT02034500|Experimental|S. sonnei 1790GAHB - 10 mcg - ID|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 10 mcg intradermally (ID)
3229235|NCT01179594|Experimental|D|
3229236|NCT01179607|Active Comparator|M0002|"Started at 0.3 mg/day and increased every 3 days (to 1, 3 and 6 mg/day)~for hyponatraemic subjects: dose was increased until the evening serum level was between 132 mmol/l and 145 mmol/l;~for normonatraemic subjects the dose was increased until a 500 ml increase in the 24-h urine volume compared with Day-1 was reached.~Once the required response or max dose was achieved, subjects entered a maintenance phase where they remained on the same dose of M0002 or placebo until 15 days."
3229237|NCT01179607|Placebo Comparator|Placebo|
3229238|NCT01179620|Experimental|Certoparin|
3229239|NCT01179633|Active Comparator|Oplon Active Patch|
3229240|NCT01179633|Placebo Comparator|Placebo patch|
3323238|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IN|Subjects enrolled in COHORT A receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intranasally (IN)
3323239|NCT02034500|Experimental|S. sonnei 1790GAHB - 20 mcg - IN|Subjects enrolled in COHORT B receiving 3 injections of S. sonnei 1790GAHB - 20 mcg intranasally (IN)
3323240|NCT02034500|Experimental|S. sonnei 1790GAHB - 80 mcg - IN|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 80 mcg intranasally (IN)
3323241|NCT02034500|Experimental|S. sonnei 1790GAHB - 5 mcg - IM|Subjects enrolled in COHORT C receiving 3 injections of S. sonnei 1790GAHB - 5 mcg intramuscularly (IM)
3323242|NCT02034500|Placebo Comparator|Placebo - ID|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intradermally (ID). These were pooled in one Placebo group in the analyses
3323243|NCT02034500|Placebo Comparator|Placebo - IN|2 subjects enrolled in each COHORT A, B and C receiving 3 injections of Placebo intranasally (IN). These were pooled in one Placebo group in the analyses
3323244|NCT02034500|Placebo Comparator|Placebo - IM|2 subjects enrolled in COHORT C receiving 3 injections of Placebo intramuscularly (IM)
3229241|NCT01179646|Active Comparator|Protonix|Protonix 40 mg DR Tablet
3229242|NCT01179646|Experimental|Pantoprazole|Pantoprazole 40 mg DR Tablet
3323245|NCT02034526|Placebo Comparator|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
3323246|NCT02034526|Experimental|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
3323247|NCT02034539|Experimental|VADOplex treatment|best medical treatment in combination with intermittent pneumatic foot compression by the VADOplex system for 4 - 6 hours/day until total wound closure of the target lesion is achieved with a maximum treatment of 24 weeks
3323248|NCT02034539|No Intervention|conservative treatment|best medical treatment of the target lesion alone
3323249|NCT02034604|Experimental|Naftopidil Group|Naftopidil medication patients
3229243|NCT01179659|Active Comparator|Protonix|Protonix 40 mg DR Tablet (Wyeth Pharmaceuticals)
3229244|NCT01179659|Experimental|Pantoprazole 40 mg DR Tablet|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
3229245|NCT01179698|Other|Stryker navigation system|
3229246|NCT01179711|Other|glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
3229247|NCT01179724|Experimental|high dose proton pump inhibitor|
3229248|NCT01179724|Active Comparator|H2 receptor antagonist|
3229249|NCT01179750|No Intervention|No Ultrasonic Coagulating Shears group|the one arm: operated group without using Ultrasonic coagulation shears during gastrectomy;
3229250|NCT01179750|Experimental|ultrasonic coagulation shears group|the other arm: operated group using ultrasonic coagulation shears during gastrectomy
3229251|NCT01179763||Retinal layer thickness analysis|Optical coherence tomography will be conducted to analyze retinal layer thickness (safe examination)
3323250|NCT02034604|Active Comparator|Tamsulosin Goup|Tamsulosin medication patients
3323251|NCT02034617|No Intervention|Standard care|The family receive standard care when enrolled in the Neonatal intensive care unit
3323252|NCT02034617|Experimental|Observation|The family receive standard care when enrolled in the Neonatal intensive care unit and are also included in an observational program called LiMoNid.
3323253|NCT02034630|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3323254|NCT02034643|Other|patients with single-lumen tube|Patients who required intraoperative TEE and single-lumen tube; balloon pressure adjustment before TEE probe insertion
3323255|NCT02034643|Other|patients with double-lumen tube|Patients who required intraoperative TEE and double-lumen tube; balloon pressure adjustment before TEE probe insertion
3323256|NCT02034656||imatinib resistance|All mutation data from CML and Ph positive ALL patients who developed imatinib resistance during the year 2001-2009
3323257|NCT02034669|Experimental|Treatment with ADSCs transplantation|4 Intervention: laminectomy, intradural space at damage site, intrathecal at lumbar puncture, intravenous
3323258|NCT02034669|No Intervention|Treatment without ADSCs transplantation|Only intervention: laminectomy
3229252|NCT01179776|Experimental|Ilomedin and standard low dose treatment|
3229253|NCT01179776|Placebo Comparator|Placebo|
3229254|NCT01179789|Active Comparator|Optimal Diet|Diet advices will receive the Optimal Diet for Elderly
3229255|NCT01179789|Experimental|VSL#3|Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
3229256|NCT01179789|Experimental|AISA-5203-L|Diet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
3323259|NCT02034682|Experimental|Volulyte 6%|"- Volulyte 6% (HES 130/0.4 in an isotonic composition). In 1000 ml:~Maize starch 60 gr. Molar substitution 0.38-0.45. 130000 Da~Na acetate trihydrate 4.63 gr~Sodium Chloride 6.02 gr~Potassium Chloride 0.3 gr~MgCl 0.3 gr~Sodium hydroxide-hydrochloric acid & H2O"
3323260|NCT02034682|Active Comparator|Geloplasma|"In 1000 ml:~Modified fluid gelatin 30 gr~Sodium Chloride 5.4 gr~Potassium Chloride 0.37 gr~MgCl 0.14 gr~Sodium lactate 3.36 gr"
3323261|NCT02034695||RAMP and Non-RAMP|
3323262|NCT02034721|Experimental|Protein supplementation|60 grams protein before, during, after eccentric exercise
3323263|NCT02034721|Placebo Comparator|Placebo|60 grams placebo before, during, after eccentric exercise
3323264|NCT02034734|Experimental|1: ASP3652|Multiple doses of ASP3652
3323265|NCT02034747|Experimental|Corticosteroid with the 50% reduced dose|oral
3229257|NCT01179789|Experimental|Argan oil|Diet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
3229258|NCT01179802|Experimental|1|single event of a prolonged strenuous endurance exercise (mountain marathon)
3229259|NCT01179815||1|Patients with type 1 or type 2 diabetes mellitus, monogenetic diabetes, pancreatogenic diabetes, drug-induced diabetes, other forms
3229260|NCT01179828|Active Comparator|1|Oxycodone 15mg
3323266|NCT02034747|Active Comparator|Corticosteroid with the maintained dose|oral
3323267|NCT02034760|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3323268|NCT02034760|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3323269|NCT02034760|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
3323270|NCT02034760|Active Comparator|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
3323271|NCT02034760|Placebo Comparator|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
3323272|NCT02034773|Experimental|CC-220 0.3mg x 14 days|
3323273|NCT02034773|Experimental|CC-220 1mg x 28 days|
3323274|NCT02034773|Experimental|CC-220 0.3mg x 28 days|
3323275|NCT02034773|Experimental|CC-220 1mg x a total of 14 days|
3323276|NCT02034773|Experimental|Placebo|
3323277|NCT02034773|Experimental|CC-220 0.3mg (once every 3 days for 14 days)|
3323278|NCT02034773|Experimental|CC-220 1mg (once every 7 days for 28 days)|
3323279|NCT02034773|Experimental|CC-220 1mg (formulated and reference capsules)|
3323280|NCT02034786|Experimental|Test|Adipose tissue collection and Transdermal injection of the filler agent, composed of mesenchymal stem cells derived from the autologous adipose tissue, associated with hyaluronic acid.
3323281|NCT02034786|Active Comparator|Control|Transdermal injection of hyaluronic acid only.
3229261|NCT01179828|Active Comparator|2|Clobazam 20mg
3323282|NCT02034812||Radiation Oncologists|"Radiation oncologists targeted for recruitment into the study must meet the following criteria:~Practicing, board-certified radiation oncologists~Perform consultations on at least 80 patients with prostate cancer annually~Each participant is asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant's opinion is collected based on a random selection of cases."
3323283|NCT02034825||Practicing urologic surgeons|"US board-certified~Practicing urologic surgeons~Performing at least 40 radical prostate surgeries annually~Urologists will be excluded from participating in the study if:~They are unable to identify a the required number of eligible patient cases with available clinical data and tissue specimens;~They have spent less than 3 years in practice or perform less than 40 RP's per year~All participants will be asked to complete a questionnaire based on a random selection of retroactively selected cases."
3323284|NCT02034838|Experimental|atazanavir 300mg boosted with ritonavir 100mg|"Two period drug interaction. Period one: atazanavir 300mg boosted with ritonavir 100 mg once daily as part of current treatment standard of care.~Period two: atazanavir 300 mg boosted with ritonavir 50 mg once daily for study days 2-8 inclusive"
3229262|NCT01179828|Active Comparator|3|Imipramine 75mg
3229263|NCT01179828|Placebo Comparator|4|Tolterodine 1mg
3229264|NCT01179841|Experimental|Playgroup and Parent Training|"One to two-hour individual therapeutic sessions with parent training in the home or clinic, 1x every week over six months;~parent training/enrichment once a week in our clinic for 20 sessions at 1-2 hours;~a playgroup session for 1-2 hours 2x week for 6 months in our clinic and~Community treatment as usual."
3229265|NCT01179841|Active Comparator|Parent Training|"Parent enrichment sessions once a week for 20 sessions (for 1-2 hours)~Community treatment as usual."
3229266|NCT01179854|Experimental|500 mg|Group of active treatment of Remegal 500 mg
3323285|NCT02034851||Dexamethasone|Intervention group
3323286|NCT02034851||Control|Placebo group (physiological saline)
3323287|NCT02034864|Experimental|Osteopathic manipulative treatment|6 sessions of standardized manipulative treatment
3323288|NCT02034864|Sham Comparator|Placebo of osteopathic manipulative treatment|6 sessions of standardized placebo of manipulative treatment
3323289|NCT02034890|Experimental|hyaluronic acid|intravesical instillation of 40 mg of hyaluronic acid at 6 specific time points: 1,2,3 and 4 weeks postoperatively 2 and 3 months postoperatively
3323290|NCT02034890|No Intervention|retrospective control patients|retrospective control patients
3323291|NCT02034903|No Intervention|Standard warming|Feeding warmed in water bath
3323292|NCT02034903|Experimental|Commercial warmer|Feedings warmed with a commercial warmer
3323293|NCT02034929|Active Comparator|Endocuff-assisted colonoscopy|Endocuff-assisted colonoscopy
3229267|NCT01179854|Experimental|Remegal 750 mg|Group of active treatment of Remegal 750 mg
3229268|NCT01179854|Experimental|Remegal 1000 mg|Group of active treatment of Remegal 1000 mg
3323294|NCT02034929|Active Comparator|Standard colonoscopy|Standard Colonoscopy
3323295|NCT02034942|Experimental|Non-sedation|"The experimental group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants will be awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium will be treated with haloperidol."
3323296|NCT02034942|Active Comparator|Sedation with daily wake-up|"The control group will be sedated to Ramsay score 3-4. The first 48 hours the patients will be sedated with propofol, after 48 hours midazolam will be used. During daytime, the patient will be awakened as the intravenous infusion of sedatives will be discontinued. The patient will be considered to be awake when he/she can perform at least three of the following four tasks:~Open the eyes to verbal commands.~Follow the examiner's instructions with the eyes.~Squeeze hands on request.~Stick out the tongue on request.~After a successful wake-up, the infusion of sedative will be resumed, starting on half of the pre-wake-up dose and adjusted to Ramsey score 3-4."
3323297|NCT02034955|Experimental|Post-Operative adaptive radiotherapy|All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
3323298|NCT02034968|Experimental|Nimotuzumab & nab-paclitaxel & cisplatin|"Nimotuzumab: 200mg,IV once a week during chemotherapy.~Nab-paclitaxel: 125mg/m2,(IV over 30 min) (days 1 and 8) on 21 day cycle~Cisplatin: 75mg/m2,IV on 21 day cycle"
3323299|NCT02034981|Experimental|CRIZOTINIB|All eligible patients entering the study will receive oral crizotinib as monotherapy
3323300|NCT02034994|Experimental|Intervention group|Reduction of sugar sweetened beverages. cookies, sedentary activities and increasing physical activity
3323301|NCT02034994|No Intervention|Control group|No intervention
3323302|NCT02035007|Experimental|LV-EF > 50%|PiCCO catheter analysis of patients with coronary heart disease without impaired left ventricular function [LV-EF > 50%]
3323303|NCT02035020|Experimental|Gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
3323304|NCT02035033||low calcium supplement|low calcium supplement
3323305|NCT02035033||Calcium intake 500-1000 mg per day|Calcium intake 500-1000 mg per day
3323306|NCT02035033||Calcium intake above 1000 mg per day|Calcium intake above 1000 mg per day
3323307|NCT02035046|Other|study's population|
3323308|NCT02035059||Women with/without gestational diabetes|Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3323309|NCT02035072|Experimental|Hypofractionated RT + Gem + Oxali|Hypofractionated radiotherapy + Gemcitabine + Oxaliplatin
3323311|NCT02035098|Experimental|The Pac-IFicO programme|The Pac-IFicO programme is a complex interventions aimed at improving the quality of pain managementi in hospitalized patients.
3323312|NCT02035111|Experimental|Tianshu capsule|Four Tianshu capsules (0.34 g per capsule) by oral three times a day for 12 weeks.
3323313|NCT02035111|Placebo Comparator|Sugar pill|Four sugar pills (0.34 g per capsule) by oral three times a day for 12 weeks.
3323314|NCT02035124|Experimental|BKM120 and Cabazitaxel|"BKM 120 orally once daily;~Cabazitaxel 25 mg/m2 IV every 3 weeks"
3229269|NCT01179854|Placebo Comparator|Placebo|Placebo
3229270|NCT01179867|Experimental|Electronic Medication Reconciliation|"Electronic medication reconciliation includes:~Electronic retrieval of the community drug list at admission~Generation of discharge prescription using the discharge reconciliation module at discharge~Transfer of information on discontinued and changed medication to respective dispensing pharmacies and prescribing physicians"
3229271|NCT01179867|No Intervention|Usual practice medication reconciliation|Usual practice in dealing with medication reconciliation. This includes viewing the hospital medications through the hospital electronic pharmacy system, and viewing the community drugs in the patient's chart, if it was collected at admission (not always the case). However not all physicians view the community drugs before writing the discharge prescription. The physician will write a paper discharge prescription to be given to the patient, but communications are generally not made directly to the community pharmacist or previous prescribing physicians.
3229272|NCT01179880|Experimental|1|
3229273|NCT01179880|Placebo Comparator|2|
3229274|NCT01179893|Active Comparator|IVIG|Intravenous Immunoglobulin, 2G/Kg, infused over 2 days in the Medical Day Unit of the University Health Network
3229275|NCT01179893|Experimental|PLEX|Patients received one plasma volume plasma exchanges with 5% albumin replacement fluid. Five plasma exchange procedures occurred every second day with breaks over the weekend allowed. Patients treated in the apheresis units at the University Health Network.
3323318|NCT02035150|Experimental|Oatmeal Breakfast|Participants will consume oatmeal breakfast daily for 4 weeks
3229276|NCT01179906|Experimental|Lifestyle intervention-exercise & diet|Subjects trained for 48 weeks with a personal trainer
3229277|NCT01179932||Anesthesia Record|The nursing and anesthesia records will be examined for accuracy and completeness
3229278|NCT01179945|Experimental|sodium benzoate containing|
3229279|NCT01179945|Active Comparator|non sodium benzoate containing|
3323319|NCT02035150|Experimental|Frosted Flakes|Participants will consume a frosted flakes breakfast daily for 4-weeks
3229280|NCT01179958|Experimental|aerobic training|24 weeks of aerobic training, 4 times/week
3229281|NCT01179958|Placebo Comparator|stretching/toning|stretching/toning condition, 24 weeks to parallel the active intervention group
3323320|NCT02035150|Placebo Comparator|No Breakfast|Participants will consume no breakfast for a 4-week period
3323321|NCT02035163|Active Comparator|Two sites cryoablation group|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
3229282|NCT01179971|Experimental|Fish oil|3g/d
3229283|NCT01179971|Experimental|Gamma-linolenic Acid|3g/d gamma-linolenic acid
3323322|NCT02035163|No Intervention|Control group|No Intervention group
3323323|NCT02035176||Autistic children ages 6-11|Autistic children ages 6-11
3323324|NCT02035176||ADHD children ages 6-11|ADHD children ages 6-11
3323325|NCT02035176||Typical children ages 6-11|Typical children ages 6-11
3323326|NCT02035215|Experimental|Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g|Atorvastatin calcium 20mg, Omega-3-acids ethylesters 90 4g: po, q.d
3323327|NCT02035215|Placebo Comparator|Atorvastatin 20mg, Placebo|Atorvastatin calcium 20mg, Placebo for Omega-3-acids ethylesters 90 4g: po, q.d
3323328|NCT02035228|Experimental|Seated|"Patients breathing will be compared across a series of 9 trials in which unassisted breathing is compared to abdominal stimulation (SecondBreath) assisted breathing at various intensities. Each breathing trial will last for 2 minutes and will be conducted while the patient is seated. The following abdominal stimulation trials were included:~Abdominal Stimulation - low / early Abdominal stimulation - low/late Abdominal Stimulation - low/full Abdominal stimulation - med/early Abdominal stimulation - med/late Abdominal Stimulation - med/full Abdominal Stimulation - high/early Abdominal Stimulation - high/late Abdominal Stimulation - high/full"
3323329|NCT02035228|Experimental|6 minute step test|"Patients will complete a 6 minute step test with and without abdominal stimulation (SecondBreath).~Abdominal Stimulation - high/full"
3229284|NCT01179971|Experimental|Fish oil plus GLA|1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid
3323330|NCT02035241|Experimental|Spices 1|220 ml test drink containing spices 1, acute study / one time administration
3323331|NCT02035241|Experimental|Spices 2|220 ml test drink containing spices 2, acute study / one time administration
3323332|NCT02035241|Experimental|Spices 3|220 ml test drink containing spices 3, acute study / one time administration
3323333|NCT02035241|Experimental|Herbs 1|220 ml test drink containing herbs 1, acute study / one time administration
3323334|NCT02035241|Experimental|Herbs 2|220 ml test drink containing herbs 2, acute study / one time administration
3323335|NCT02035241|Placebo Comparator|Placebo|220 ml control drink, acute study / one time administration
3229285|NCT01179971|Sham Comparator|Olive oil|3 g/d olive oil
3229286|NCT01179997|Active Comparator|Tissue Doppler Imaging (TDI) optimization|Interventricular pacing delay optimized according to Tissue-Doppler echocardiography
3323336|NCT02035254|Experimental|Intervention group|Web-based wellness program
3323337|NCT02035254|Other|Wait control group|Web-based wellness program after 3 month wait.
3323339|NCT02035293|Other|PEP|No drug and no placebo were used in this study. For all the patients who participated at the study PEP, only following exams must be performed: a clinical probability score (revised Geneva score), plasma D-dimer assay and if necessary, a chest multidetector-row CT angiography and venous ultrasound of the lower limbs
3323340|NCT02035306|Experimental|non-invasive Haemaglobin|Measuring haemaglobin using non-invasive co-oximetry device
3229287|NCT01179997|Active Comparator|Electrocardiographic optimization|Interventricular pacing delay optimized according to QRS width observation in the 12-lead surface electrocardiogram
3229288|NCT01180023|Experimental|Sweeping|
3229289|NCT01180023|No Intervention|No sweeping|
3229290|NCT01180062|Active Comparator|Arm 1|Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
3229291|NCT01180062|Active Comparator|Active Comparator - Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
3229292|NCT01180062|Active Comparator|Active Comparator - Arm 3|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
3229293|NCT01180075||TDF/FTC/EFV Intensive Sampling-Group A|Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
3229294|NCT01180075||TDF/FTC/ATV/r Intensive Sampling Group A|Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
3229295|NCT01180075||TDF/FTC/EFV Sparse Sampling Group B|Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
3229296|NCT01180075||TDF/FTC/ATV/r Sparse Sampling Group B|Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
3229297|NCT01180088|Experimental|ANTERIOR APPROACH|SURGICAL TECHNIQUE
3323341|NCT02035319||capillary malformation treated by laser|capillary malformation treated by laser
3229298|NCT01180101|Active Comparator|Lifestyle modification group|This group will undergo supervised exercise training 5 days per week and follow hypocaloric diet for 12 weeks. All exercise training sessions will be supervised by an Exercise Physiologist or Research Nurse, and will be conducted in the Exercise Physiology Laboratory at the CCF CRU. Exercise training will consist of walking, running on a treadmill, and stationary cycling on a cycle ergometer. Each exercise session will include a brief standardized warm-up and cool-down that include a series of stretching exercises.
3323342|NCT02035358|Experimental|HyperAcute®-Renal Immunotherapy|Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization. Once the first three months of immunizations are completed, patients may receive other systemic treatment (non-investigational) while continuing to receive the remaining 6 immunizations.
3323343|NCT02035371|Experimental|FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3323344|NCT02035371|Active Comparator|NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3229299|NCT01180101|Active Comparator|Bariatric Surgery Group|This group will include CKD patients who undergo bariatric surgery.
3323345|NCT02035384||All patients|
3323346|NCT02035397|Experimental|Botulinum toxin A|Botulinum toxin type A injection in muscles of stomach wall
3229300|NCT01180101|No Intervention|CKD Group (control)|This group will not undergo any form of weight loss intervention
3229301|NCT01180114|Experimental|SUUBI-MAKA|Involves creating and broadening asset ownership opportunities and life options for children (ages 12 to 15 years) orphaned due to AIDS in Uganda.
3229302|NCT01180114|Other|Usual Care|No intervention for asset ownership, development of future planning skills, enhancement of mental health and reduction of risk taking behaviors for children orphaned due to AIDS in Uganda.
3229303|NCT01180140|No Intervention|1|without seamguard
3229304|NCT01180140|Experimental|2|with seamguard
3229305|NCT01180153|Experimental|SOX: advanced BTC or ampullary carcinoma|unresectable, metastatic or locally advanced biliary tract or ampullary adenocarcinoma receive SOX regimen
3323347|NCT02035397|Placebo Comparator|Saline solution|Placebo (saline solution) injection first 6 months, then active treatment
3323348|NCT02035410|Active Comparator|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
3323349|NCT02035410|No Intervention|Control group|No intervention group
3323350|NCT02035423|Active Comparator|Male Guidance School|Non-Fortified Milk 120IU Milk 200IU Milk
3323351|NCT02035423|Active Comparator|Female Guidance|Non-fortified Milk 120IU Milk 200IU Milk
3323352|NCT02035423|Active Comparator|Male Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
3229306|NCT01180166|Experimental|nimotuzumab|Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
3229307|NCT01180179|Active Comparator|Lansoprazole 30mg once daily|Lansoprazole 30mg once daily
3323353|NCT02035423|Active Comparator|Female Highschool|Non-Fortified Milk 120IU Milk 200IU Milk
3229308|NCT01180179|Active Comparator|Famotidine 40mg once daily|Famotidine 40mg once daily
3229309|NCT01180192|Experimental|oxygen|
3229310|NCT01180205|Active Comparator|T/A|Telmisartan + Amlopidpine
3229311|NCT01180205|Active Comparator|O/HCT|Olmesartan + Hydrochlorothiazide
3323354|NCT02035436|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
3323355|NCT02035436|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
3323356|NCT02035449||McGrath MAC|McGrath MAC is a videolaryngscope
3323357|NCT02035488|Experimental|Tobramycin|Patients with bronchiectasis
3323358|NCT02035501|Active Comparator|L-Tyrosine|
3323359|NCT02035501|Placebo Comparator|Placebo|
3323360|NCT02035514|Experimental|Arm 1|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on day 0 and placebo on month 6.
3323361|NCT02035514|Experimental|Arm 2|A single infusion of up to 1 million cells per Kg of autologous MSC stem cells vs placebo. The treatment will be on month 6 and placebo on day 0.
3229312|NCT01180231|Active Comparator|Moxonidine|
3229313|NCT01180231|Active Comparator|Diet|
3229314|NCT01180231|Active Comparator|Moxonidine and diet|Subjects will be asked to take moxonidine and follow dietary plan designed by a qualified nutritionist for 6 months.
3229315|NCT01180231|No Intervention|Control|Subjects will not be asked to take any interventions.
3229316|NCT01180270||Cervical dystonia|"patients suffering from cervical dystonia~under routine botulinum toxin treatment"
3229317|NCT01180270||healthy volunteers|control group
3229318|NCT01180283|Experimental|lodenafil carbonate (Helleva®)|
3229319|NCT01180309||lingual frenum alterations|individuals each one with their phonological system complete
3229320|NCT01180322|Active Comparator|Arm A|Standard Therapy
3229321|NCT01180322|Experimental|Arm B|"Investigational Therapy Azacitidine Prior"
3229322|NCT01180322|Experimental|Arm C|"Investigational Therapy Azacitidine Concurrent"
3229323|NCT01180322|Experimental|Arm D|"Investigational Therapy Azacitidine After"
3229324|NCT01180335|Active Comparator|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
3229325|NCT01180335|Experimental|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
3323362|NCT02035527|Experimental|Treatment (sorafenib tosylate, docetaxel, and cisplatin)|Patients receive sorafenib tosylate PO BID on days 1-14 of course 0. Beginning in course 1, patients receive sorafenib tosylate PO BID on days 1-21, docetaxel IV over 1 hour on day 1, and cisplatin IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sorafenib tosylate PO BID in the absence of disease progression or unacceptable toxicity.Correlative studies will be performed and a total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
3323363|NCT02035540||Decellularized human valves|Pulmonary heart valve replacement
3323364|NCT02035566|Experimental|Telehome Care Monitoring + Usual Care|
3323365|NCT02035566|No Intervention|Usual Care|
3323366|NCT02035579|Experimental|Aerobic Training Intervention|Children with PCS who are eligible for the study will be randomized to a progressive, sub-symptom exacerbation, cycling aerobic training intervention or stretching comparison intervention. Children with PCS that meet criteria for the intervention trial will complete a baseline evaluation followed by a one week run-in-period (week 0-1) prior to their first intervention visit. After the initial intervention visit, weekly visits will be completed for at least 6 additional weeks (i.e., at least 6 weeks of aerobic training). An individualized home exercise program 5-6 days per week will also be developed. Children will be provided with a home stationary cycle to complete the home program.
3229326|NCT01180348|Experimental|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
3323367|NCT02035579|Experimental|Stretching Intervention|Children in the stretching intervention will complete a series of full body stretches of the shoulders, arms, chest, back, legs, and feet 5-6 days per week and will return weekly to review the stretching program. The minimum duration of the stretching intervention will also be 6 weeks
3323368|NCT02035592|Active Comparator|Full dose blueberry|"26g of freeze dried blueberry powder; equivalent to 2 portions of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
3323369|NCT02035592|Active Comparator|Half dose blueberry|"26g of freeze dried powder; containing 13g of freeze dried blueberry powder and 13g of placebo comparator material; equivalent to 1 portion of fresh blueberries per day.~Frequency: 26g per day.~Total duration: 6-month."
3229327|NCT01180348|Active Comparator|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
3229328|NCT01180361||Active SLE patients|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Fulfill 1982 ACR revised criteria for SLE. SLE activity status designated using the SLEDAI disease activity index. Patients excluded if previous documentation of a connective tissue disorder other than SLE.
3229329|NCT01180361||Psoriatic arthritis|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Diagnosed according to criteria described by McGonagle et al (McGonagle, D., Conaghan, P.G., and Emery, P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999; 42: 1080-1086.)
3229330|NCT01180361||Normal controls|Age 18-65; female and male. No methotrexate or statin therapy in prior 3 months. Not on biological therapies. Healthy volunteers. Not on corticosteroids.
3229331|NCT01180361||Active RA patients|Age 18-65, male and female, no methotrexate or statin therapy in prior 3 months. Not on biological therapies. satisfy at least 4 of the 7 revised criteria (1987) for the classification of RA
3229332|NCT01180374|Experimental|Active Canabidiol and Active Delta-9-THC|
3229333|NCT01180374|Placebo Comparator|Placebo and Active Delta-9-THC|
3229334|NCT01180374|Experimental|Active Cannabidiol and Placebo|
3323370|NCT02035592|Placebo Comparator|Control|"Matched control powder; matched for appearance, taste and sugar content.~Frequency: 26g per day.~Total duration: 6-month."
3323371|NCT02035605|Active Comparator|ALN-AT3SC|
3323372|NCT02035605|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3229335|NCT01180374|Placebo Comparator|Placebo and Placebo|
3229336|NCT01180413|Experimental|Vasodilatory|Patients in this arm will receive intensive vasodilatory treatment
3323373|NCT02035618|Experimental|Exercises and manual therapy|
3323374|NCT02035618|Active Comparator|Exercises|
3323375|NCT02035631|Experimental|Intervention|Lifestyle intervention combining weight control, diet and physical activity
3323376|NCT02035631|Sham Comparator|Minimal intervention|Minimal diet intervention and minimal physical activity intervention
3323377|NCT02035644|Experimental|Jinlida granules|Jinlida granules, a traditional Chinese medicine, was a herbal formula which was developed under cognition of the theory in the onset of diabetes
3229337|NCT01180426|Experimental|Tosedostat|
3229338|NCT01180452|Other|Single group open label|Prospective Cohort
3323378|NCT02035644|Placebo Comparator|placebo granules|placebo prepared in indistinguishable granules
3229339|NCT01180465|Experimental|LIPO-102 High|
3229340|NCT01180465|Experimental|LIPO-102, Low|
3229341|NCT01180465|Placebo Comparator|LIPO-102; Placebo|
3229342|NCT01180517|Active Comparator|Drug Eluting Balloon|
3229343|NCT01180517|Active Comparator|Plain Old Balloon Angioplasty (POBA)|
3229344|NCT01180530||A|
3229345|NCT01180543|Active Comparator|Active Comparator: Oplon Active Patch|
3229346|NCT01180543|Placebo Comparator|Placebo Comparator: Placebo patch|
3229347|NCT01180556|Experimental|Probiotics supplementation|Supplementation by probiotics for 4 weeks
3229348|NCT01180556|Placebo Comparator|Placebo|Supplementation of placebo for 4 weeks
3229349|NCT01180569|Experimental|lenalidomide|Eligible patients for this clinical trial will be treated for 6 cycles with lenalidomide at 15 mg daily by mouth on Days1-21 of 28 day cycle, preceded by an escalating schema for safety (5mg daily for 2 weeks; 10 mg daily for 2 weeks; and 15 mg daily for 2 weeks) and then a one week rest).
3323379|NCT02035657|Experimental|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
3323380|NCT02035670||tradition diagnostic strategy|According to the current diagnistic procedures of FUO
3323381|NCT02035670||two-step diagnostic strategy|"First step is to differentiate FUO according to the onset of disease and invasive pathogens.~Second step is to further differentiate FUO according to trends of disease and inflammation scores."
3323382|NCT02035683|Other|Advanced NSCLC patients undergoing first-line chemotherapy|single cohort
3323383|NCT02035709|Active Comparator|TCI-PCA|Intravenous Patient-Controlled Analgesia with Target-Controlled Infusion
3323384|NCT02035709|Active Comparator|PCA|Intravenous Patient-Controlled Analgesia
3323385|NCT02035722|No Intervention|Control group|AMD-related information is not given to patients randomized to the control group.
3323386|NCT02035722|Active Comparator|Video materials|Educational materials are presented in through a video (audio and visual)
3323387|NCT02035722|Active Comparator|Print materials|Educational materials are presented in the format of printed brochure (visual)
3323388|NCT02035735|Experimental|Videoendoscopy with WL and NBI|The day before the laryngoscopy under general anesthesia (LGA), two endoscopies by two different physicians were performed for each patients and recorded: the first one with white light (WL) and the second one with NBI (NBI).
3323389|NCT02035761||MSA Case|The screening evaluation will take less than 1 to 2 hours, and is usually conducted over the telephone. The visit for testing will take approximately 3 days, consisting (usually) of a day for clinical examinations and questionnaires and one day each for PET and MRI brain imaging and the third day for PET imaging of the heart and autonomic testing. If some checklists and questionnaires could not be completed conveniently in the time available, they may be finished over the telephone on a later day. At the completion of the 3-day evaluation, subjects are asked to return home and keep a log of their MSA symptoms and medication responses for 2 days. This will complete the active participation of MSA subjects in all aspects of the entire research program. The average time the subjects will be followed could be up to 1 week during which time the subjects are undergoing research related procedures.
3323390|NCT02035774|Active Comparator|LSIB +SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml)
3323391|NCT02035774|Placebo Comparator|LSIB + placebo|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml) + SSNB (4 ml saline)
3323392|NCT02035787|Experimental|Metformin|Metformin, 850 mg. twice daily.
3323393|NCT02035800|Experimental|Adalimumab (humira)|As standard of care.
3229350|NCT01180595|Other|Modular|Trabecular Metal Modular Tibial Total Knee Component
3229351|NCT01180595|Other|Monoblock|Trabecular Metal Monoblock Tibial Total Knee Component
3323394|NCT02035813|Experimental|Ribociclib in combination with standard endocrine therapy|Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and indication for standard endocrine therapy.
3323395|NCT02035813|Experimental|Eriubulin|Patients with hormone-receptor positive, HER2-negative metastatic breast cancer and indication to chemother-apy or patients with triple-negative metastatic breast cancer, both with HER2-negative circulating tumor cells (CTCs).
3323396|NCT02035826|Active Comparator|Arm 1|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 1 ($2.80) $100 $10 $10
3323397|NCT02035826|Active Comparator|Arm 2|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 2 ($1.40) $50 $5 $5
3323398|NCT02035826|Active Comparator|Arm 3|Arm (Expected Value) 2 Digit Match 1st Digit Match 2nd Digit Match Arm 3 ($0.70) $25 $5 $0
3323399|NCT02035826|No Intervention|Arm 4|Control Arm
3323400|NCT02035839|Other|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
3323401|NCT02035839|Other|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
3323402|NCT02035839|Other|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
3229352|NCT01180608|Active Comparator|Pregabalin|
3229353|NCT01180608|Placebo Comparator|placebo + pregabalin|
3229354|NCT01180621|Experimental|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
3229355|NCT01180634|Experimental|1|Inhaled MP-376 (Aeroquin)
3229356|NCT01180634|Placebo Comparator|2|Placebo
3229357|NCT01180673|Experimental|MINT-TLC|
3323403|NCT02035852||Adult Gilomas|
3323404|NCT02035865||Participants from former study 1|Surviving participants from a former study called 'Psykosomale faktorer hos pasienter med hjertesvikt og hos hjertetransplanterte'
3323405|NCT02035865||Participants from former study 2|Surviving participants, included at the Norwegian centre, from a study called 'Scandinavian Heart Transplant Everolimus De Novo Study with Early Calcineurin Inhibitor Avoidance (SCHEDULE)' (NCT01266148)
3323406|NCT02035878|Active Comparator|Probiotics|400mg probiotic capsule taken once daily for ten weeks
3323407|NCT02035878|Placebo Comparator|Placebo (rice flour)|400mg placebo capsule containing rice flour taken once daily for ten weeks
3323408|NCT02035891|Active Comparator|colchicine|0.5mg/d colchicine
3323409|NCT02035891|Placebo Comparator|placebo|appearance is same as colchicine
3323410|NCT02035904|Experimental|Levobupivacaine|Levobupivacaine Patient Controlled Infusion 5 ml 0,25%, lock out 2 hours
3323411|NCT02035904|Placebo Comparator|Saline|patient controlled infusion 5 ml bolus, lock out 2 hours
3323412|NCT02035917|Experimental|Locking plate|
3323413|NCT02035917|Active Comparator|Non-Locking plate|
3323414|NCT02035930|Other|menstrual cycle,dexmedetomidine|
3323415|NCT02035943|Active Comparator|Insulin separated|Seprated infusion of insulin
3323416|NCT02035943|Active Comparator|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
3323417|NCT02035956|Experimental|IVAC MUTANOME RBL001/RBL002|All participants will be treated with the personalized IVAC MUTANOME vaccine with or without prior treatment with RBL001/RBL002 vaccine depending on expression of these two antigens. Vaccines will be administered intra-nodally.
3323418|NCT02035969|No Intervention|Conventional treatment (CT)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling and clinical follow up every three months. The caretaker of the child is responsible that the child will take the drugs and is provided with a pre-packed dosage form for easy remembering
3323419|NCT02035969|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counselling and clinical follow up every three months. In addition adherence support is provided according to the description under intervention.
3323420|NCT02035982|Active Comparator|Cholinesterase Inhibitor|Participants randomized into the cholinesterase inhibitor arm will continue receiving their cholinesterase inhibitor at the same dosage.
3229358|NCT01180673|Active Comparator|Control Condition|
3229359|NCT01180686|Active Comparator|Multiple thrust Impulse instrument|This instrument automatically delivers 12 thrusts at the same intensity over the joint involved.
3323421|NCT02035982|Placebo Comparator|Placebo|Participants randomized into the placebo arm will be tapered off their cholinesterase inhibitor for the first 2 weeks. For the remaining 6 weeks of their study they will be receiving only placebo, and no cholinesterase inhibitor.
3323422|NCT02035995||Healthy volunteers|This group consisted of age matched non-pregnant healthy volunteers
3323423|NCT02035995||Healthy pregnant volunteers|This group consisted of age matched healthy pregnant volunteers
3323424|NCT02036008|Other|Liver MRI with EcGd and with Gdfos|All participants will receive two contrast-enhanced MRI studies of the liver: one with gadofosveset trisodium (Gdfos) and one with gadobutrol (EcGd) at a dose of 0.1 mL/kg body mass up to 10 mL.
3323425|NCT02036021||PRE/non-PRE|children who develop or did not perioperative respiratory events between November 2012 and December 2013
3323426|NCT02036034|Active Comparator|drape with forced air warmer|forced air warmer placed under the chin before draping, inflated after draping completed.
3323427|NCT02036034|Placebo Comparator|drape with warming blanket|warming blanket placed on torso of patient under the drape.
3323428|NCT02036047|Experimental|Exclusive cold polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using an exclusive cold polypectomy snare (Exacto cold snare). The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
3323429|NCT02036047|Active Comparator|regular polypectomy snare|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed using a regular polypectomy snare. The technique is cold snare resection of the polyp without tenting without electrocautery and then suction of the transected polyp into a trap followed by submission to the histological evaluation. The hemostatic clipping is not performed after cold snare polypectomy.
3323430|NCT02036060|Experimental|Arm A|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d
3323431|NCT02036060|Active Comparator|Arm B|docetaxel 75 mg/m2 + prednisone 10 mg/d
3323432|NCT02036073|Experimental|EPO|In EPO group, the EPO was given by 500IU/kg every other day intravenously for 2 weeks. Recombinant human erythropoietin was configured by the hospital pharmacy intravenous Center Configuration, melted configured with saline to 1ml/kg solution. For severe patients, they were started to treat with EPO when their vital signs, blood pressure were stable.
3323433|NCT02036086|Experimental|Vemurafenib, pill, twice daily|Vemurafenib, 960 mg, oral, twice daily plus Cobimetinib, 60 mg, oral, four times daily
3323434|NCT02036099|Experimental|Intervention|Participants in this arm will assess patients using the Driving in Mild Dementia Decision Tool.
3323435|NCT02036099|No Intervention|Control|Participants in this arm will assess patients using their usual care strategies.
3323436|NCT02036112|Experimental|Individual ELAPE|Patients will receive Individual ELAPE technique
3323437|NCT02036112|Experimental|Conventional ELAPE|Patients with advanced lower rectal cancer will receive conventional EALPE technique
3323438|NCT02036125|Experimental|Ultrasound guided injection|Ultrasound guided injection of 40 mg of methylprednisolone
3323439|NCT02036125|Active Comparator|Blind injection|Blind injection of 40 mg of methylprednisolone
3323440|NCT02036138|Active Comparator|Advanced Medical Therapy Patients.|Advanced medical therapy is deﬁned as the use of the latest lifestyle guidelines set forth by the American Diabetes Association to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest FDA approved drug therapy (incretin analogues, insulin sensitizers, etc.)
3323441|NCT02036138|Experimental|Bariatric Surgery Patients - Roux-en-Y gastric by- pass|
3323442|NCT02036138|Experimental|Bariatric Surgery Patients -Laparoscopic sleeve gastrectomy|
3323443|NCT02036151|Experimental|Experimental, control|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
3323444|NCT02036151|Active Comparator|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
3229360|NCT01180686|Active Comparator|Single impulse Activator IV instrument|This is a manual spring loaded device that delivers one thrust to the joint involved
3229361|NCT01180699|Experimental|influenza vaccine - intradermal|intradermal versus intramuscular
3229362|NCT01180699|Active Comparator|influenza vaccine - intramuscular|
3229363|NCT01180712|Active Comparator|Blaeberry concentrated caspule|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a total daily dose of 1.4 grams of mirtoselect (a concentrated blaeberry extract) a day formulated in hard gelatin capsules (0.47 gram per capsule) administered thrice a day for 21 days.~Mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/)"
3229364|NCT01180712|Placebo Comparator|Placebo capsules containing lactose|"30 obese male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given a placebo consisting of lactose formulated in hard gelatin capsules administered thrice a day for 21 days."
3323445|NCT02036164|Active Comparator|Concurrent chemoradiation|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin~- Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy"
3229365|NCT01180738|Active Comparator|Body weight supported treadmill training|
3323446|NCT02036164|Experimental|Concurretn chemoradiation plus adjuvant chemotherapy|"Radiation: Radiation Therapy~External beam pelvic radiotherapy (45-50.4 Gy in 1.8 Gy fractions) delivered by Linear accelerator machine~Vaginal brachytherapy for 4-5 fractions~Chemotherapy: Cisplatin, paclitaxel, carboplatin~Cisplatin 40 mg/m2 i.v., q wk, 6 cycles during radiotherapy~Paclitaxel 175 mg/m2 i.v. q 4 wks, 3 cycles starting 4 week after completion of CCRT~Carboplatin AUC 5 i.v. q 4 wks, 3 cycles given together with paclitaxel"
3323447|NCT02036177|Experimental|SCu300A IUB|
3323448|NCT02036177|Active Comparator|T380A copper IUD|
3229366|NCT01180738|Active Comparator|Overground walking training|
3229367|NCT01180751|Other|[18F]-Fluorodeoxyglucose|Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
3323449|NCT02036190||Control group|Former or current smokers without emphysema
3323450|NCT02036190||Emphysema|Current or former smokers with emphysema
3323451|NCT02036203|Experimental|SCu300A IUB|
3323452|NCT02036203|Active Comparator|TCu380A|
3323453|NCT02036216||Hepatocellular Carcinoma|The mutation will be found in the DNA samples from the plasma and solid tumor tissues in the patients with HCC.
3323454|NCT02036229|Experimental|0.5% ivermectin cream|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
3323455|NCT02036229|Placebo Comparator|vehicle cream|Each participant will be treated with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
3229368|NCT01180764|Experimental|Lovaza|Lovaza 4g po qd
3229369|NCT01180764|Placebo Comparator|Placebo|Matching placebo
3323456|NCT02036242|Experimental|Sole local anesthetic|Epidural analgesia will be given with sole local anesthetic (0.125% ropivacaine) intermittently
3323457|NCT02036242|Active Comparator|Opioid plus local anesthetic|Epidural analgesia will be given with opioid (sufentanil) combined with local anesthetic (0.125% ropivacaine) intermittently
3323458|NCT02036255|Experimental|Taurolidine Urokinase|Taurolock Urokinase is used weekly in this arm substituting the classic Taurolock HEP500
3323459|NCT02036255|Active Comparator|Taurolidine Heparin|Taurolock HEP 500 is used as locking solution after each dialysis session
3229370|NCT01180803|Experimental|oxygen-saving valves|
3323460|NCT02036268|Active Comparator|Standard|Subjects will receive standard ostomy education.
3323461|NCT02036268|Experimental|Pre-Operative Education|In addition to standard ostomy education, subjects will receive additional education pre-operatively.
3323462|NCT02036268|Experimental|Two-week Post Operative Education|In addition to standard ostomy education, subjects will receive additional education two weeks following surgery.
3323463|NCT02036281|Experimental|SP-SAP ARM|The first subject will be enrolled in the 1-mcg SP-SAP cohort. A percutaneous intraspinal catheter will be placed at the L5-S1 interspace and the catheter advanced 4-5 cm into the intrathecal space under fluoroscopic guidance. To confirm location, CSF will be aspirated and radioopaque contrast dye injected. 1-mL study drug will be mixed with 1-mL patient CSF fluid and administered intrathecally via the catheter. The catheter will be flushed with 1 mL bolus of saline. Four hours after injection (+15 min), the catheter will be removed and the exit site treated with Neosporin ointment and sterilely dressed. Subjects will be monitored in the recovery room for 4 hours and in the hospital for 24 hours and discharged home. Patients only receive a single IT dose.
3323464|NCT02036307|Experimental|DHA-enriched|DHA-enriched supplement (DHA 3g + 600 mg EPA in 6 g of fish oil/day)
3323465|NCT02036307|Experimental|EPA-enriched|EPA-enriched supplement (EPA 2.4 g + DHA 600mg in 6 g of fish oil/day)
3323466|NCT02036333||Concussion Group|
3323467|NCT02036333||Control Group|
3323468|NCT02036346|Experimental|Oral rehydration solution|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
3323469|NCT02036346|Experimental|No intervention|Patients who have undergone colorectal resection surgery resulting in an ileostomy creation
3229371|NCT01180803|Active Comparator|continuous oxygen supplementation|
3229372|NCT01180816|Experimental|Temozolomide (Temodar)|
3323470|NCT02036346|Active Comparator|Colorectal resection without an ileostomy|Patients who have undergone colorectal resection surgery without an ileostomy creation
3323471|NCT02036359|Active Comparator|erlotinib|Patients in erlotinib arm will take erlotinib 150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
3229373|NCT01180829|No Intervention|Control condition|No interventions text messages sent
3229374|NCT01180829|Experimental|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking
3229375|NCT01180829|Experimental|Consciousness raising text message|A series of 12 text messages, each of which contains text designed to get the person to think about his or her drinking
3229376|NCT01180842|Other|Alternative Treatment|The CF Patient Population receiving the specific yoga study treatment
3229377|NCT01180855|Placebo Comparator|Placebo|Placebo pills prepared by Takeda Pharmaceutical.
3229378|NCT01180855|Active Comparator|Rozerem|Rozerem 8mg
3229379|NCT01180855|Active Comparator|Rozerem + Multi Component Behavior Therapy|Rozerem 8mg in combination with 4 small group sessions and 2 phone calls of Multi Component Behavior Therapy.
3229380|NCT01180868||patients with cancer|patients with hematological malignancies and solid tumors
3323472|NCT02036359|Active Comparator|Chemotherapy|"Patients in chemotherapy arm will then receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.~Treatment failure will include patients who fail to complete 3 cycles (9 weeks) of study treatments due to disease progression or unacceptable toxicity.~Patients with no disease progression after terminating study treatment will undergo surgical resection and be followed until disease progression is noted, or study end. Survival will be recorded and analyzed.~If progressive disease or unacceptable toxicity occurs during study treatments, patients will be treated at discretion of investigator according to local protocol."
3323473|NCT02036372|Experimental|BR (bolus regimen)|"Day before surgery: half evening dose long acting insulin~Day of surgery:~patients using mealtime and longacting insulin/NPH: withhold mealtime morning dose, stop glucose lowering tablets~patients using only long acting insulin/NPH: half dose of long-acting or NPH insulin, stop glucose lowering tablets~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Give bolus of insulin according to treatment algorithm"
3323474|NCT02036372|Experimental|LG (Liraglutide)|"Day before surgery: half dose of long acting and mealtime insulin from start liraglutide~Day of surgery: withhold own insulin, stop oral glucose lowering tablets~Start with 0.6 mg liraglutide subcutaneously (s.c.) the day prior to surgery at 17.00hr.~In case of nausea graded higher than minimal, the patient will be excluded from the study~Otherwise, treatment will be continued with 1.2 mg liraglutide s.c. per day on the day of surgery at 07.00hr.~Measure glucose every 60 minutes, start 30 min prior to surgery~Adjust according to bolus algorithm of BR group"
3323475|NCT02036372|Active Comparator|GIK (glucose -insulin - potassium) infusion|"Day before surgery: half evening dose long acting insulin~Day of surgery: stop oral glucose lowering tablets and withhold own insulin.~GIK infusion: 500 cc glucose 5% with insulin and 10 mmol KCL per 500 cc. Start at 83 ml/hr.~Calculate the insulin amount in the GIK infusion according to the formula:~I= (PG-7)/(200/W)+8 I=Insulin amount, PG=glucose 30 minutes preoperative, W= body weight in kg~Measure blood glucose every 60 minutes, start 30 min prior to surgery~Adjust glucose > 8 mmol/l according to treatment algorithm"
3229381|NCT01180868||patients with autoimmune dosorders|patients with Rheumatoid arthritis, Crohns's disease, systemic lupus erythematosus.
3229382|NCT01180868||healthy subjects|
3229383|NCT01180881||Proton Radiation Patients at MGH|Pediatric brain and central nervous system (CNS) tumor patients treated with proton beam radiation therapy
3229384|NCT01180907||patients with cancer|
3229385|NCT01180907||patients with autoimmune diseases|
3323476|NCT02036398|Active Comparator|Nephrostomy tube + double J stent|Standard therapy group with nephrostomy tube and double J stent left at the end of the PCNL
3323477|NCT02036398|Experimental|Double J stent without nephrostomy|Double J stent only left at the end of the procedure
3323478|NCT02036437|Experimental|Cases|A dose of 20ug is required obtained by dissolving the 200ug tablet (Misotac® Sigma Pharmaceutical Industries) in 200 ml water (1ug per ml), the solution is shaked well before each administration. The solution will be orally administrated every two hours (max. 12 hrs) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy.
3323479|NCT02036437|Active Comparator|Control|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
3323480|NCT02036450|Experimental|ILR group|Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
3323481|NCT02036450|No Intervention|Control group|Followed according to standard care, i.e. by their general practitioner. Study visits are scheduled at inclusion and after 3 years. Furthermore, the participants are contacted by telephone after 1 and 2 years of follow-up, and endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
3323482|NCT02036463|Active Comparator|Immediate Release Prednisone|During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
3229386|NCT01180907||healthy subjects|
3229387|NCT01180920||Periodontal disease|11 patients with periodontal disease, specifically generalized chronic or aggressive periodontitis will be selected. In general, the disease group will be comprised of subjects that need an open flap procedure.
3229388|NCT01180920||Healthy periodontium|11 patients without periodontal disease will be selected. In general, the healthy group will be comprised of subjects that are requiring a gingivectomy or crown lengthening procedure.
3229389|NCT01180933|Experimental|fish oil|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA and 150 eicosapentaenoic acid per day from gestational week 22 until delivery
3229390|NCT01180933|Experimental|folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 400 µg folate (methyltetrahydrofolate)per day from gestational week 22 until delivery
3229391|NCT01180933|Experimental|fish oil + folate|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women and 500 mg DHA, 150 mg eicosapentaenoic acid and 400 µg MTHF per day from gestational week 22 until delivery
3229392|NCT01180933|Placebo Comparator|placebo|the participating women receive a milk based supplement providing vitamins and mineral as recommended for pregnant women from gestational week 22 until delivery
3229393|NCT01180946|Active Comparator|Ergocalciferol|Weekly ergocalciferol for 16 weeks
3229394|NCT01180946|Placebo Comparator|Placebo|Placebo pill. Note that all subjects in this arm will receive vitamin D repletion at the conclusion of the study.
3323483|NCT02036463|Experimental|Delayed Release Prednisone|During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
3323484|NCT02036463|Placebo Comparator|Placebo-Delayed Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
3323485|NCT02036463|Placebo Comparator|Placebo-Immediate Release Prednisone|During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.
3229395|NCT01180959|Experimental|Erlotinib + Bevacizumab|Erlotinib 150 mg by mouth once a day. Bevacizumab 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes.
3229396|NCT01181024|Experimental|A: HV ascending dose|
3229397|NCT01181024|Experimental|B: HV food effect|
3323486|NCT02036476|Experimental|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
3323487|NCT02036489|Experimental|Induction and consolidation treatment|
3323488|NCT02036528|Experimental|AppliGel-G with oral Ciprofloxacin and Doxycycline|AppliGel-G (Gentamicin Topical Gel) in conjunction with oral Ciprofloxacin and Doxycycline
3323489|NCT02036528|Active Comparator|Oral Ciprofloxacin and Doxycycline only|Ciprofloxacin and Doxycycline
3229398|NCT01181024|Experimental|C: Hepatitis C|
3229399|NCT01181037||100 patients, displaced subcapital fracture, T.A.N nail.|100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
3323490|NCT02036554|Experimental|Tacrolimus plus Everolimus|Low dose Tacrolimus + Everolimus
3323491|NCT02036554|Active Comparator|Tacrolimus plus Mycophenolic acid|standard dose Tacrolimus + Mycophenolic acid
3323492|NCT02036567||surgical patients|no interventions, observational study
3323493|NCT02036567||laboring women|no interventions, observational study
3323494|NCT02036567||volunteers|pain induction by noxious heat stimulation, measurement of pain by device and documentation of pain reported by subjects
3323495|NCT02036593|Experimental|Walk Your Heart to Health intervention|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
3323496|NCT02036593|Other|Walk Your Heart to Health lagged|"Participants were randomized into one of two groups: intervention and lagged intervention. The intervention group completed the 8 week Walk Your Heart to Health intervention, followed by a second wave of data collection for both initial and lagged intevention groups. The lagged intervention group then completed the 8 week Walk Your Heart to Health intervention. Both groups continued walking for another 24 weeks.~Walking group sessions conducted 3 times per week for 32 weeks."
3323497|NCT02036606||mood disorders|Questionary and neuropsychological tasks will be administered
3323498|NCT02036606||control|Questionary and neuropsychological tasks will be administered
3229400|NCT01181037||100 patients, displaced subcapital fracture, Bipolar H.A..|
3229401|NCT01181063|Experimental|400/12 μg D94-2BF (60/40) inhaler|
3229402|NCT01181063|Experimental|320/9 μg D94-2BF (20/80) inhaler|
3323499|NCT02036619||pregnant women without known diabetes|
3229403|NCT01181063|Active Comparator|Symbicort 320/9 μg inhaler|
3229404|NCT01181063|Experimental|320/9 μg D94-2F (60/40) inhaler|
3323500|NCT02036632|Other|Eye Patching|Intervention
3323501|NCT02036658|Active Comparator|Cognitive Behavioral Group Therapy|Cognitive behavioral group therapy (CBGT) will be delivered by two Ph.D. clinical psychologists trained by Dr. Richard Heimberg to implement his CBGT for SAD (Heimberg & Becker, 2002). Groups of six individuals will meet for 12 sessions of 2.5 hours each. The participants will also use selected portions of the client workbook developed by (Hope, Heimberg, & Turk, 2010) to supplement relevant portions of the protocol. The treatment will be comprised of four major components: (1) psychoeducation and orientation to CBGT; (2) cognitive restructuring skills; (3) graduated exposure to feared social situations, within session and as homework; and (4) relapse prevention and termination. Further details of the treatment are available elsewhere (Heimberg & Becker, 2002).
3323502|NCT02036658|Active Comparator|Mindfulness-Based Stress Reduction|MBSR will follow the standard curriculum outline compiled in 1993 by Jon Kabat-Zinn except that the one-day meditation retreat will be converted to four additional weekly group sessions between the standard class 6 and 7 so that there will be 12 weekly 2.5 hour sessions. This will be done to match the CBGT protocol in duration and time. The MBSR intervention will be delivered by a University of Massachusetts Center for Mindfulness certified MBSR instructor with more than 30 years of teaching experience. To support the practice, each participant will be given A Mindfulness-Based Stress Reduction Workbook (Stahl & Goldstein, 2010), which includes descriptions of mindfulness exercises together with pre-recorded audio files to support ongoing practice.
3229405|NCT01181063|Experimental|320/9 μg D94-2BF (60/40) inhaler|
3229406|NCT01181115|Experimental|Active treatment|Interferon treatment for MS
3229407|NCT01181154|Placebo Comparator|equivalent volume total (=1000 ml)|Placebo : equivalent volume total (=1000 ml)
3229408|NCT01181154|Experimental|rituximab (Mabthera®)|rituximab (Mabthera®), 1000 mg at day 1 and day 15
3229409|NCT01181180|Experimental|balance treatment|
3229410|NCT01181206|Active Comparator|Arm 1|
3229411|NCT01181206|Active Comparator|Arm 2|
3229412|NCT01181219|Experimental|CXL without epithelial removal|Application of Riboflavin and the consequent UV-irradiation with intact corneal epithelium
3229413|NCT01181219|Active Comparator|CXL with epithelial removal|Corneal epithelial removal prior to Riboflavin and the consequent UV-irradiation
3229414|NCT01181232|Experimental|MR low-dose group|
3229415|NCT01181232|Experimental|MR high-dose group|
3323503|NCT02036658|No Intervention|Waitlist Control|This will be a delayed treatment arm. Participants randomized to the waitlist control group will be re-randomized after completing the no treatment period of 12 weeks to CBGT or MBSR with equal probability.
3323504|NCT02036671|Experimental|EndoAVF|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
3229416|NCT01181232|Active Comparator|IR group|
3229417|NCT01181245|Experimental|FG-3019|All subjects are treated with FG-3019
3229418|NCT01181284||Lisinopril|Participants will be randomized 2 to 1 to receive drug versus placebo.
3229419|NCT01181297|Experimental|Extensively Hydrolyzed Formula with a Probiotic|Extensively Hydrolyzed Formula with a Probiotic
3229420|NCT01181297|Placebo Comparator|Extensively Hydrolyzed Formula without a Probiotic|
3229421|NCT01181310|Experimental|A, B, D, E, C|Participants received treatment A, B, D, E, C for Periods 1, 2, 3, 4, and 5, respectively.
3229422|NCT01181310|Experimental|B, C, E, A, D|Participants received treatment B, C, E, A, D for Periods 1, 2, 3, 4, and 5, respectively.
3229423|NCT01181310|Experimental|C, D, A, B, E|Participants received treatment C, D, A, B, E for Periods 1, 2, 3, 4, and 5, respectively.
3323505|NCT02036684|No Intervention|Healthy Lifestyle Booklet|Standard care for radical prostatectomy (RP) patients includes the provision of preoperative information from a urology nurse educator. Usual care (UC) participants will be given generic instructions by the research coordinator about pelvic floor muscle exercises (PFMX), mobilization and general timeframes for a return to normal activities. The UC group will receive the same PFMX prescription as the PREHAB (Experimental) group and will receive weekly communication from the research coordinator regarding compliance with the PFMX prescription to provide an attentional-control. These instructions are provided in a healthy lifestyle booklet for men with prostate cancer.
3323506|NCT02036684|Experimental|Prehabilitation (PREHAB)|The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
3323507|NCT02036697|Experimental|Low Dose Spinal|"Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section."
3323508|NCT02036697|Active Comparator|Control Spinal Group|"Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section."
3323509|NCT02036710||Cecum|Food hydrolysate instilled into terminal cecum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
3323510|NCT02036710||Ileum|Food hydrolysate instilled into terminal ileum of patient undergoing open duodenal switch procedure. Blood samples were then obtained at baseline and at 0, 30, 60, 90, and 120 minutes for analysis of circulating GLP-1, PYY, and leptin.
3323511|NCT02036723|Experimental|BCD-021|"BCD-021 is a product code for bevacizumab biosimilar manufactured by CJSC BIOCAD, Russia.~In this arm 72 patients will receive BCD-021 at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months."
3323512|NCT02036723|Active Comparator|Lucentis®|Lucentis® is ranibizumab drug produced by Novartis Pharmaceuticals Canada Inc. In this arm 36 patients will receive Lucentis® at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
3323513|NCT02036736|Experimental|Propofol|Intraoperative anesthetic strategy by Propofol versus Desflurane
3323514|NCT02036736|Experimental|Desflurane|Intraoperative anesthetic strategy by Desflurane versus Propofol
3323515|NCT02036749|Active Comparator|quadratus lumborum block (nerve block)|quadratus lumborum block with ropivacaine
3323516|NCT02036749|Placebo Comparator|sham block|QL block with saline
3323517|NCT02036762|Active Comparator|Treatment Group|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
3323518|NCT02036762|Sham Comparator|Control Group|The control group received stretching exercises in the fist and ankle muscles and treadmill exercises
3323519|NCT02036788||Postsurgical patients sedated and paralized|Patients admitted to ICU after surgery, treated with mechanical ventilation, sedated and paralized
3323520|NCT02036788||Postsurgical patients intubated and breathing spontaneously|
3229424|NCT01181310|Experimental|D, E, B, C, A|Participants received treatment D, E, B, C, A for Periods 1, 2, 3, 4, and 5, respectively.
3229425|NCT01181310|Experimental|E, A, C, D, B|Participants received treatment E, A, C, D, B for Periods 1, 2, 3, 4, and 5, respectively.
3229426|NCT01181310|Experimental|A, C, B, E, D|Participants received treatment A, C, B, E, D for Periods 1, 2, 3, 4, and 5, respectively.
3229427|NCT01181310|Experimental|B, D, C, A, E|Participants received treatment B, D, C, A, E for Periods 1, 2, 3, 4, and 5, respectively.
3229428|NCT01181310|Experimental|C, E, D, B, A|Participants received treatment C, E, D, B, A for Periods 1, 2, 3, 4, and 5, respectively.
3229429|NCT01181310|Experimental|D, A, E, C, B|Participants received treatment D, A, E, C, B for Periods 1, 2, 3, 4, and 5, respectively.
3229430|NCT01181310|Experimental|E, B, A, D, C|Participants received treatment E, B, A, D, C for Periods 1, 2, 3, 4, and 5, respectively.
3229431|NCT01181336|Experimental|Group 2|"FLU-v Low Dose with adjuvant. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
3323521|NCT02036801||ARDS|Patients with ARDS (according to the Berlin Definition criteria) in mechanical ventilation
3323522|NCT02036801||Healthy control|Patients with healthy lung supported with mechanical ventilation for clinical purposes
3323523|NCT02036814|Experimental|Group A who underwent to an inter-relational strategy|Group A who underwent to a health educational orientation program (inter-relational strategy)
3323524|NCT02036814|Experimental|Group B who underwent group orientation by the nurse|
3323525|NCT02036827|Active Comparator|moderate NMB + standard pressure|Investigators will administrate rocuronium until moderate neuromuscular blockade (Train of Four >=1, Post-tetanic count>=8) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
3323526|NCT02036827|Active Comparator|deep NMB + standard pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 14 mmHg.
3229432|NCT01181336|Experimental|Group 3|"FLU-v High Dose with water for injection. FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection.~10 subjects."
3229433|NCT01181336|Experimental|Group 4|High Dose FLU-v with adjuvant FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection. 10 subjects
3229434|NCT01181336|Experimental|Group 1|FLU-v Low Dose with water for injection FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection 10 subjects
3229435|NCT01181336|Placebo Comparator|Control Group|Placebo with adjuvant (4 subjects) or Placebo without adjuvant (4 subjects)
3323527|NCT02036827|Active Comparator|deep NMB + low pressure|Investigators will administrate rocuronium until deep neuromuscular blockade (Train of Four=0, Post-tetanic count<=3) is established. And pneumoperitoneum will be maintained with standard-pressure 8 mmHg.
3323528|NCT02036866|Experimental|Physical Therapy Positive Expectation|The physical therapist will read a script indicating that the intervention is an effective treatment for knee osteoarthritis and is expected to reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS (transcutaneous electrical nerve stimulation) unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
3229436|NCT01181362|Other|Endoscopy|
3229437|NCT01181375|Experimental|Assays on cervical cancer tissue|
3323529|NCT02036866|Experimental|Physical Therapy Neutral Expectation|The physical therapist will read a script indicating that the intervention may or may not be an effective treatment for knee osteoarthritis and may nor may not reduce pain and improve strength. Patients are then instructed on the home exercise program and how to operate the TENS unit. The duration of intervention is 1 week during which patients will wear then wear the TENS unit for 8 hours per day and perform no more than 3 sets of 10 repetitions of the physical therapy exercises daily.
3323530|NCT02036866|Experimental|Control- No Intervention|The patients in the control group will be reminded of their appointment in 1 week and instructed to maintain their usual activity level during that time.
3323531|NCT02036879|No Intervention|Main study|"The main study is an observational study.~All women will be followed for one menstrual cycle (or approximately one month) observationally off of any hormone supplementation. They will have 3 study visits corresponding to their menstrual cycle phases (menses, ovulation, and luteal).~Women participating in the main study may participate in the optional interventional sub-study.~Men participating in this study will be followed for 1 month observationally. They will have 3 study visits that correlate with the female arm of this study."
3229438|NCT01181388|Active Comparator|intra-guide-catheter infusion of tirofiban|
3229439|NCT01181388|Experimental|intra-thrombus-aspiration-catheter infusion of tirofiban|
3229440|NCT01181401|Active Comparator|TPF standard|"TPF version 1 (standard)~Induction chemotherapy:~Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
3323532|NCT02036879|Experimental|Loestrin Optional Substudy|Women participating in the main study may participate in the optional sub-study. Following a negative urine pregnancy test, women will be started on once daily oral Loestrin (1.5 mg norethindrone + 0.03 mg ethyl estradiol). They will be followed for two months on this agent and have 2 additional study visits.
3229441|NCT01181401|Experimental|TPF experimental|"TPF version 2 (experimental)~Induction chemotherapy:~Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles~Antibody therapy with:~cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX~RTX: HART (72 Gy), IMRT or 3D-conformal techniques"
3323533|NCT02036892|Experimental|Lifestyle counseling with smartphones|Lifestyle counseling assisted by smartphones
3229442|NCT01181401|Active Comparator|Standard RCT|"Standard RCT:~HART (72 Gy), IMRT or 3D-conformal techniques~with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5"
3229443|NCT01181414|Experimental|Atrioventricular junction ablation|Atrioventricular junction ablation by using radiofrequency energy.
3323534|NCT02036892|Active Comparator|Lifestyle counseling|Lifestyle counseling
3323535|NCT02036905|Experimental|Cervical and thoracic mobilization|Cervical and thoracic mobilization: described as a repetitive low-velocity oscillatory movement applied to a joint segment. It is graded 1-4 based on the size of the amplitude and where in range it is being applied. The mobilization technique chosen will be based on the examination and clinical reasoning process of the therapist. The cervical and thoracic mobilization will be applied to the most provocative level.
3323536|NCT02036905|Experimental|Cervical and thoracic manipulation|Cervical and thoracic manipulation: is defined as high-velocity low-amplitude thrust at end range of a particular spinal segment. The therapist performs this technique by taking up all available slack at a particular segment and applying a high-velocity thrust through the end-range restriction. The manipulation technique will be chosen based on the examination and clinical reasoning process of the therapist.
3323537|NCT02036918|Active Comparator|Arm A|Pre-treatment control group will be randomized to immediate lymph node biopsy followed by sipuleucel-T immunotherapy.
3323538|NCT02036918|Experimental|Arm B|Post-treatment experimental group will be randomized to immediate sipuleucel-T immunotherapy followed by lymph node biopsy.
3323539|NCT02036931||Metal on Polyethylene articulation|G7 cup with Metal on Polyethylene articulation (MOP)
3323540|NCT02036931||Ceramic on Polyethylene articulation|G7 cup with Ceramic on Polyethylene articulation (COP)
3323541|NCT02036931||Ceramic on Ceramic articulation|G7 cup with Ceramic on Ceramic articulation (COC)
3323542|NCT02036957|Experimental|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. Will be applied twice a day (after showering and at night), massaging the area until completely absorption.
3323543|NCT02036957|Placebo Comparator|PLACEBO ARM|It be applicated in like manner that balm arm
3323544|NCT02036983|Active Comparator|Ultrasound guided bilateral TAP block|Ultrasound guided TAP Block with local anesthetic and dexamethasone.
3323545|NCT02036983|Active Comparator|Instillation of surgical site with local anesthestic.|Instillation of surgical site under direct visualization with local anesthetics and dexamethasone.
3323546|NCT02036983|Placebo Comparator|Control Group|Standard anesthetic technique
3229444|NCT01181414|Active Comparator|Drug control of ventricular rate|Drug control of ventricular rate.
3229445|NCT01181427|Placebo Comparator|Single Ascending Dose (SAD)|Healthy volunteers, receiving single ascending doses of ABT-267 or placebo.
3323547|NCT02037009|No Intervention|Usual surveillance|surveillance performed by a qualified nurse, present in the operating room during the whole anesthesia.
3229446|NCT01181427|Placebo Comparator|Multiple Ascending Dose (MAD)|Healthy volunteers, receiving multiple ascending doses of ABT-267 or placebo, OR, multiple doses of ABT-267 + single dose of a Cytochrome P450 inhibitor or placebo + single dose of a Cytochrome P450 inhibitor.
3229447|NCT01181427|Active Comparator|Food Effect (FE)|Healthy volunteers, receiving ABT-267, multi-dose, food effect.
3229448|NCT01181427|Placebo Comparator|Antiviral Activity|HCV genotype 1-infected treatment naïve subjects receiving multiple ascending doses of ABT-267 or placebo monotherapy for 3 days.
3229449|NCT01181427|No Intervention|Resistance Monitoring|"HCV genotype 1-infected treatment naïve subjects, receiving at least one dose of ABT-267 or placebo in the Antiviral Activity arm, follow-up to monitor resistance developed to ABT-267, no treatment and only blood samples will be collected"
3323548|NCT02037009|Experimental|centralised monitoring surveillance|1 anesthetic nurse is posted at a centralised monitoring station outside of the 3 operating rooms, while another one can intervene inside the 3 operating rooms whenever needed. Interphones allow communication between the monitoring station and the operating rooms.
3323549|NCT02037022|Experimental|Pivotal Response Treatment Package|Pivotal Response Treatment Package (PRT-P)
3229450|NCT01181440|Experimental|Dermagraft(R) and conventional care|
3229451|NCT01181440|Other|Conventional care only|
3229452|NCT01181453|Experimental|Dermagraft(R)|Weekly application of Dermagraft(R) with standard care
3229453|NCT01181453|Other|Standard care only|Weekly application of standard care
3229454|NCT01181505|Experimental|Tolterodine|
3229455|NCT01181544|Experimental|Heparin dose titration|
3323550|NCT02037022|No Intervention|Delayed Treatment Group|Delayed Treatment Group (DTG)
3323551|NCT02037035|Experimental|Healthy|Healthy participants will receive ketamine in the scan
3323552|NCT02037035|Experimental|Depressed|Depressed participants will receive ketamine in the scan
3229456|NCT01181557||rectal cancer with stoma|rectal cancer submitted to rectal anterior resection with stomia (RARS). Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month after stoma reconversion
3323553|NCT02037074|Experimental|Experimental: EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 14
3323554|NCT02037074|Experimental|Experimental: EVP-6308; Arm 2|intermediate dose, Capsule, Once Daily, Day 1 through Day 14
3323555|NCT02037074|Experimental|Experimental: EVP-6308; Arm 3|high dose, Capsule, Once Daily, Day 1 through Day 14
3323556|NCT02037074|Placebo Comparator|Placebo Comparator; Arm 4|Placebo, Capsule, Once Daily, Day 1 through Day 14
3323557|NCT02037087|Experimental|Good household prenatal practice (GHPP)|The GHPP arm receives SMS messages regarding knowledge on nutrition, labor, non-medical pain management, breastfeeding, and depression. This arm also receives messages delivered to the control group.
3229457|NCT01181557||rectal cancer without stoma|rectal cancer submitted to rectal anterior resection (RAR) Differences in QoL between the two groups were analyzed during three time: first preoperative, second postoperative and latter six month later
3323558|NCT02037087|Experimental|Care seeking (CS)|The CS arm receives SMS messages which include danger-sign recognition and reminders for government-subsidized projects. This arm also receives messages delivered to the control group.
3229458|NCT01181557||anterior resection of rectum|patients with rectal cancer submitted to RAR and patients with rectal cancer submitted to RARS
3229459|NCT01181570|Experimental|Adalimumab|
3229460|NCT01181570|Placebo Comparator|Placebo|
3229461|NCT01181583|Experimental|Tailored Internet-delivered CBT|
3229462|NCT01181583|Experimental|Non-tailored Internet-delivered CBT|
3229463|NCT01181583|Active Comparator|Online discussion group|
3229464|NCT01181622|Experimental|denufosol tetrasodium Inhalation Solution|
3229465|NCT01181622|Placebo Comparator|Placebo|
3229466|NCT01181635|Experimental|Psychotherapy|Short-term pychotherapy and/or psychoeduchative courses.
3229467|NCT01181648||oropharynx cancer survivors|This study has two components. First, we will conduct a cross-sectional survey of 200 oropharynx cancer survivors, diagnosed with HPV+ tumors, who are at least 12 months from their last treatment. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis.
3229468|NCT01181661|Experimental|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
3259115|NCT01467648|Experimental|0.5 g by 1 hour infusion|"Blood samples (approximately 2 ml) in group  0.5 g of doripenem with 1 h infusion every 8 h regimen will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
3229469|NCT01181661|Experimental|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
3323559|NCT02037087|Experimental|Full bank of SMS|This arm receives the SMS messages delivered to the GHPP, CS and control group.
3323560|NCT02037087|No Intervention|Control|"Control group receives SMS messages regarding:~Reminders of prenatal visits and certified skilled attendance of labor (status quo);~Fetal development in different gestational stages.~The three experimental groups receive the control messages as well."
3323561|NCT02037100||T2DM|Children 6-20 years old diagnosed with T2DM
3323562|NCT02037100||Obesity|
3323563|NCT02037113||Patient underwent PAD-Stent|Patient who underwent angioplasty and/or atherectomy with stent placement for Femoro-popliteal disease and Intravascular ultrasound was performed after stent deployment.
3323564|NCT02037126|Experimental|Psilocybin administration|Psilocybin will be administered in pill form at a dose of .36 mg/kg. Psilocybin will be administered in one session over the course of 8 hours.
3323565|NCT02037126|Active Comparator|Diphenhydramine administration|Diphenhydramine will be administered in pill form at a dose of 100 mg. Diphenhydramine will be administered in one session over the course of 8 hours.
3229470|NCT01181700|Experimental|Treatment A|
3229471|NCT01181700|Experimental|Treatment B|
3323566|NCT02037139|Active Comparator|Control (screening)|screening only (standard care control)
3323567|NCT02037139|Active Comparator|Educational brochure|Screening + illustrated educational brochure
3323568|NCT02037139|Experimental|Education|Screening + illustrated educational brochure + an in-person educational intervention
3323569|NCT02037152|No Intervention|Waitlist|Participants randomized to this arm are instructed that they will have access to the study intervention after four weeks. Waitlist group participants are prompted to answer weekly questionnaires.
3229472|NCT01181700|Experimental|Treatment C|
3229473|NCT01181700|Active Comparator|Treatment D|
3229474|NCT01181700|Active Comparator|Treatment E|
3229475|NCT01181700|Active Comparator|Treatment F|
3323570|NCT02037152|Experimental|Active treatment|"The active treatment group will be instructed to use the app-guided body scan exercise daily for six days per week over a period of four weeks. The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. Before and after each use of the body scan, users complete a single-item scale measuring pain intensity/distress. Users are prompted to complete all other questionnaires at weekly or four-week intervals. The app includes access to a graphical display showing changes in average pain level. Subjects also have access to a section of frequently asked questions about the practice."
3323571|NCT02037178||The study population|"See inclusion/exclusion criteria.~Intervention: First ultrasound reading~Intervention: Second ultrasound interpretation"
3323572|NCT02037191|Placebo Comparator|ARM A : METHOTREXATE|"Arm A: methotrexate 20 to 25 mg / week for 6 months. Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
3323573|NCT02037191|Placebo Comparator|ARM B : PLACEBO|"Arm B placebo Patients who will experience at least a 25% hair regrowth after the month 5 evaluation will continue methotrexate or placebo from month 6 to the end of the study (month 12).~Non responder patients in both arms A and B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or~methotrexate associated with prednisone 0.3 mg/Kg/day"
3229476|NCT01181700|Active Comparator|Treatment G|
3229477|NCT01181713||No Antibiotic|No prophylactic antibiotic post intravitreal injection
3323574|NCT02037217|Experimental|ExAblate Treatment|
3323575|NCT02037243|Experimental|Water Treatment|Chlorine dispenser promotion and provision
3323576|NCT02037243|Experimental|Hand washing|Hand washing with soapy water promotion
3323577|NCT02037243|Experimental|Standard public health intervention|Health promotion using information about germs and disease
3323578|NCT02037243|Experimental|Disgust and shame intervention|Health promotion using disgust shame
3323579|NCT02037269||All participants|Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)
3323580|NCT02037308|Placebo Comparator|Control white bread|
3323581|NCT02037308|Experimental|Beetroot bread|
3323582|NCT02037334||Pregnancy|
3229478|NCT01181713||Prophylactic Antibiotic|Group treated with 3 day course of prophylactic topic antibiotic, fourth generation fluoroquinolones, after each intravitreal injection
3229479|NCT01181752||Group A|Baseline/control subjects who are only tested on postoperative day 30
3229480|NCT01181752||Group B|Subjects who will be tested on postoperative day 1 and day 30
3229481|NCT01181752||Group C|"Subjects who cannot proficiently administer the medication on postoperative day 1 will be re-classified as Group C subjects"
3229482|NCT01181765|Experimental|Infliximab infusions (5 mg/kg) at weeks 0, 2, 6, 14 and 22|
3229483|NCT01181791|Experimental|probiotic group|Lactobacillus reuteri will be given at a dose of 1x108 colony forming units (CFU)/day
3229484|NCT01181791|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
3229485|NCT01181817|Other|SCS|patients with Failed back Surgery syndrome treated with SCS
3229486|NCT01181830|Active Comparator|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate for 8 weeks
3229487|NCT01181830|Placebo Comparator|placebo|administration of 8.1 mmol bid of placebo for 8 weeks
3229488|NCT01181843||Cesearean sections receiving duramorph|
3229489|NCT01181856|Experimental|Group A|Intramuscular immunisation
3229490|NCT01181856|Experimental|Group B|Intradermal immunisation
3323583|NCT02037360|Active Comparator|Active Comparator App/Training|This is a standard smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. Subjects will be encouraged to set a quit date of 3 weeks, to allow comparison to experimental arm quit date.
3323584|NCT02037360|Experimental|Experimental App/Training|This is a 3-week smartphone-based training program that trains mindfulness for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
3323585|NCT02037373||Octaplas™|Patients treated with Octaplas™ infusion solution for IV administration as prescribed by their treating physician.
3323586|NCT02037373||Plasma|Patients treated with regular plasma (e.g., fresh frozen plasma (FFP) and other FDA and American Association of Blood Banks (AABB) approved plasma products).
3323587|NCT02037386|Experimental|H-side branch stent|H-side branch stent group
3323588|NCT02037399|Experimental|intravenous dexamethasone|To receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD
3323589|NCT02037399|Placebo Comparator|intravenous normal saline|To receive normal saline as placebo intravenous immediately after ESD
3323590|NCT02037412|Experimental|Ticagrelor Arm|Ticagrelor Arm
3323591|NCT02037412|Active Comparator|Clopidogrel Arm|Clopidogrel Arm
3323592|NCT02037451|Experimental|intervention group|intervention group which receive auditory cueing while performing movement
3323593|NCT02037451|No Intervention|Control group|control group which performing movement after listen to required movement rhythm.
3323594|NCT02037464|Experimental|Capsaicin Supplement|
3323595|NCT02037490|Experimental|Grow2Gether Intervention|"Participants in the intervention group will:~Participate in the Grow2Gether intervention~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
3323596|NCT02037490|No Intervention|Control|"Participants in the control group will:~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network."
3323597|NCT02037503|Placebo Comparator|Placebo for drug resistant depression|Patients will be treated for 21 days with daily oral placebo
3323598|NCT02037503|Experimental|Ketamine for suicidal ideation|Patients will be treated for 21 days with daily oral Ketamine
3229491|NCT01181869||Oxygen therapy|Database of patients on oxygen
3323599|NCT02037503|Experimental|Ketamine for drug resistant depression|Patients will be treated for 21 days with daily oral Ketamine
3323600|NCT02037503|Placebo Comparator|Placebo in suicidal ideation|Patients will be treated for 21 days with daily oral placebo
3229492|NCT01181869||ventilation|database of patients on ventilatory support
3229493|NCT01181869||Continuous positive airway pressure|Sleep apnoea patients on CPAP
3229494|NCT01181882|Experimental|Fish Oil and Aspirin|
3323601|NCT02037503|Experimental|Healthy Participants|Healthy participants that underwent a romantic relationship breakup will attend in tow experimental sessions, one with placebo and one with ketamine. Sessions will be separated within the range of 1 to 6 weeks
3323602|NCT02037516|Active Comparator|Control Group|qualitative monitoring of neuromuscular paralysis, standard treatment at this facility
3229495|NCT01181908|Experimental|GSK1144814|Subjects will receive either GSK1144814 or placebo at each treatment arm.
3229496|NCT01181908|Placebo Comparator|placebo|Subjects will receive either GSK1144814 or placebo at each treatment arm.
3229497|NCT01181934|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
3323603|NCT02037516|Active Comparator|Study Group|quantitative monitoring of neuromuscular paralysis as described in (Brull Murphy Anesth Analg 2010;111:129-40) Acceleromyography
3229498|NCT01181934|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
3229499|NCT01181934|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
3229500|NCT01181960||001|Risperidone long acting injectable - New Starts Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
3259116|NCT01467674||Healthy|
3259117|NCT01467674||Chronic Periodontitis|
3323604|NCT02037529|Experimental|Arm A (eribulin mesylate)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3323605|NCT02037529|Experimental|Arm B (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3323606|NCT02037542|Experimental|Diet and Exercise|Prospective, observational, cohort study, with a proposed start date of May 2013 and proposed end date of June 2018. Our goal is to gather data on a total of 200 patients: 100 patients (study group) will be prospectively enrolled, while data on another 100 patients (control) will be accessed through retrospective data collection. Number of patients to be analyzed will depend on enrollment and patient compliance. We would like to enroll the proposed 100 patients in the first 1-3 years of the study (approximately 30 per year).
3323607|NCT02037581|Experimental|Early detection and Integrated Care|"The intervention condition consisted of measures to improve early detection and treatment quality (Integrated Care).~Interventions for the improvement of early detection. The measures for improved early detection aiming at reducing the duration of untreated psychosis included 4-year measures to improve mental health literacy, reduce stigma and improve service utilization.~Measures to improve treatment quality should be achieved through extending the Hamburg model to a cross-age and interdisciplinary Integrated Care model for adolescent and young adult patients with psychotic disorders aged 12-29 years."
3323608|NCT02037581|Other|Standard Care|Historical control group with standard care parallelized regarding age, diagnosis and illness stage, which was treated in the period before the implementation of the intervention conditions. The control group consisted of n=105 patients with early psychosis between the ages of 12 and 29, who had been treated between January 2005 and December 2008. The central differences in comparison with the intervention conditions lie in the lack of measures for the improvement of early detection, the absence of the TACT team, as well as the regular referral to an established psychiatrist with in most cases regular contact frequency.
3323609|NCT02037594|Experimental|Counseling + SOC Adherence|Sexual Health Counseling followed by Standard of Care Adherence Support
3323610|NCT02037594|Experimental|Counseling + Enhanced Adherence|Sexual Health Counseling followed by Enhanced Adherence Intervention
3229501|NCT01181960||002|Risperidone long acting injectable - Continuous Users Patients who have been on Risperidone long acting injectable for at least 6 months before baseline with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
3229502|NCT01181960||003|Paliperidone Palmitate -New and Continuous Users Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
3323611|NCT02037594|Experimental|Information + SOC Adherence|PrEP Information followed by Standard of Care Adherence Support
3323612|NCT02037594|Experimental|Information + Enhanced Adherence|PrEP Information followed by Enhanced Adherence Intervention
3323613|NCT02037620|Experimental|Epidural Stimulation|80 sessions each of epidural spinal cord stimulation for 1) cardiovascular function; 2) voluntary movement; and 3) standing.
3323614|NCT02037633|Active Comparator|Fascia iliaca compartment block|
3323615|NCT02037633|Active Comparator|Fentanyl|
3323616|NCT02037646|Other|Qualitative fecal immunochemical test|"Stool samples will be tested with the qualitative fecal immunochemical test (qFIT), and will be stratified for colonoscopy as follows:~>200 ng/dL - colonoscopy with one month 100-200 ng/dL - colonoscopy as per waiting list <100 ng/dL - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
3323617|NCT02037646|Other|Quantitative fecal immunochemical test|"Stool samples will be tested with the quantitative fecal immunochemical test (FIT), and will be scheduled for colonoscopy as follows:~Positive - colonoscopy as per waiting list Negative - no colonoscopy~Cost analysis, anxiety scores and patient satisfaction scores will be calculated for all patients."
3323618|NCT02037659||Gastric Varices treatment|DermaBond (glue) treatment of Gastric Varices.
3323619|NCT02037672|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3323620|NCT02037672|Active Comparator|metformin and roflumilast|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time roflumilast was initiated at a dose of 500 mg BID per os.
3323621|NCT02037685|Active Comparator|Usual care|Subjects randomized to usual care will receive a brochure once a year on the importance and impact of controlling cardiovascular risk factors, tips to improve statin adherence and smoking cessation strategies and public services. Subjects will also receive a letter every 6 months to remind about study participation along with educational material.
3323622|NCT02037685|Experimental|Motivational Interviewing (MINT)|"The MINT intervention will consist of 6 to 9 telephone encounters between a counselor trained in Motivational interviewing. All subjects in the MINT arm will be contacted every 3 months; however subjects who are not filling medication appropriately will receive additional calls.~Each telephone encounter will last from 20 to 30 minutes and have a patient centered approach having the following basic structure and goals:~Establishing a connection and reinforcing autonomy: .~Empathizing with ambivalence and rolling with resistance.~Coach the subject towards expressions of commitment."
3323623|NCT02037698|Experimental|Pre-PCI CT scan group|Pre-PCI CT scan
3323624|NCT02037698|No Intervention|Control group|Control
3323625|NCT02037711|Active Comparator|Chirocaine group (levobupivacaine )|
3323626|NCT02037711|Sham Comparator|Control group|
3323627|NCT02037724|Other|supplement containing 60 mg iron sulfate|nutrient supplement containing 60 mg of iron as ferous sulfate
3323628|NCT02037724|Experimental|iron rich food supplement (60 mg iron)|contains 60 mg Iron
3323629|NCT02037724|Experimental|iron rich food supplement (10 mg iron)|contains 10 mg of iron
3323630|NCT02037724|Other|supplement containing 10 mg iron sulfate|nutrient supplement containing 10 mg of iron as ferous sulfate
3323631|NCT02037737||RA patients on Abatacept IV|Rheumatoid Arthritis (RA) patients with inadequate response to one or more conventional DMARDs including Methotrexate and treated with Abatacept IV according to routine clinical practice in France
3323632|NCT02037750|Experimental|LINKS|Foster parent and child participate in 16-week intervention
3323633|NCT02037750|No Intervention|Services as Usual|Foster parent and child receive standard services through child welfare system
3323634|NCT02037802|Active Comparator|caudal epidural catheterization group|30 patients received continuous intra and post-operative caudal epidural infusion of bupivacaine 0.125% with fentanyl (2 microgram/ml) over 24 hours
3323635|NCT02037802|Sham Comparator|control group|30 patients didn't receive caudal epidural analgesia
3323636|NCT02037815|Experimental|Mannitol|20% mannitol solution, 125 ml, IV infusion in 15 min
3323637|NCT02037815|Experimental|Hypertonic saline|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min
3323638|NCT02037828||Stable COPD in STEP1|no intervention
3229503|NCT01181960||004|Other Antipsychotics - New Starts Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
3229504|NCT01181973|Active Comparator|Treatment sequence #1|One 1-mL subcutaneous injection at 30 mg/mL in Period 1 and two 1-mL subcutaneous injections at 15 mg/mL each in Period 2
3323639|NCT02037828||Control in STEP 1|no intervention
3323640|NCT02037828||Case group in STEP 2|no intervention
3323641|NCT02037828||Control group in STEP2|no intervention
3323642|NCT02037841|Experimental|Nursing-driven Asthma protocol|Children randomized to the intervention group will have their β2-agonist medication weaned by the nurse, according to the steps outlined in the clinical pathway. The nurse will ensure that the patient's family is booked for asthma teaching, and will also remind the physicians to fill out an asthma action plan on discharge. Detailed information as to when to contact physicians in the event of an acute deterioration of the patient is included in the clinical pathway.
3323643|NCT02037841|No Intervention|Physician-driven asthma management|Patients in the control group will continue receiving the current standard of care, which consists of physicians weaning the β2-agonist medication when called to the bedside by the nurse or when deemed necessary by a physician
3323644|NCT02037854|Placebo Comparator|Placebo|A nutrient formulation without the active ingredient
3229505|NCT01181973|Active Comparator|Treatment sequence #2|Two 1-mL subcutaneous injections at 15 mg/mL each in Period 1 and one 1-mL SC injection at 30 mg/mL in Period 2
3229506|NCT01181999|Experimental|rituximab|
3323645|NCT02037854|Experimental|Nutrient formulation|Nutrient formulations with variable amounts of active ingredients.
3323646|NCT02037867||Patients|"Patients identified with one of the below chronic liver disease risk factors and undergoing community liver disease stratification using fibrosis biomarkers:~Hazardous alcohol use (>14 units per week in females, >21 units per week in males, alcohol AUDIT score >=8 or read code relevant to alcohol abuse on GP system)~Type 2 Diabetes~Obesity~Persistently raised serum ALT level, negative liver serology, and absence of above 2 risk factors"
3323647|NCT02037880||MPS IIIA/B Subjects|Cohort will be followed for one year to assess natural history of the disease.
3323648|NCT02037906|Experimental|Escalating Energy SWL|50 Patients
3323649|NCT02037906|Experimental|Constant Energy SWL|50 Patients
3323650|NCT02037906|Experimental|Reduction Energy SWL|50 Patients
3323651|NCT02037919|Experimental|Immediate Nexplanon Insertion|An etonogestrel rod will be placed within 15 minutes following the abortion procedure.
3323652|NCT02037919|Active Comparator|Post-op Nexplanon Insertion|"Participants in the delayed placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment. At this time an etonogestrel rod will be placed in her arm using standard procedure."
3323653|NCT02037932|Experimental|Balloon Assisted Coiling|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
3323654|NCT02037945|Experimental|pts with brain mets going for surgery|"This study will enroll patients with brain metastases that are evolving after SRS who are scheduled to undergo surgical resection. Eligible patients will undergo an 18F-FCH PET study 1-to-7 days pre-operatively. Although no toxicity has been previously reported following 18F-FCH administration, patients will be contacted 1-3 days after their scan and asked whether they experienced any adverse effects. The patients who have a positive 18F-FCH PET study (in which there is visible focal hot spots (a focus of lesion/normal white matter ratio >1.4) of 18F-FCH) will undergo further evaluation and be administered a second administration oflower activity 18F-FCH at the time of surgery. The purpose of the second 18F-FCH administration in the operating room is to further elucidate the tissue distribution of 18F-FCH radioactivity with respect to the histopathology of the surgically resected tissue."
3323655|NCT02037958|Experimental|Laryngeal Mask Airway-Supreme|Patients who are randomly assigned to receive the LMA-Supreme
3229507|NCT01182012|Experimental|Lifestyle counseling|Adjust drug treatment to control cardiovascular factor risks. A nurse will implement a lifestyle counseling in order to improve compliance of treatment and a healthy lifestyle.
3229508|NCT01182025|Active Comparator|Western therapy|
3323656|NCT02037958|Active Comparator|Endotracheal Tube|Patients who are randomly assigned to receive endotracheal intubation
3323657|NCT02037971|Experimental|Aerobic Exercise|Subjects will follow one defined exercise process, according their cardiopulmonary exercise test, during 16 weeks, two times per a week.
3323658|NCT02037971|Experimental|Control Group|A non-exercise group will receive regular educational information relating to their condition.
3323659|NCT02037997|Experimental|combination with Erlotinib|Erlotinib 150mg qd combination with docetaxel 75mg/m2 or pemetrexed 500mg/m2
3323660|NCT02037997|Active Comparator|sequential chemotherapy for Erlotinib|docetaxel 75mg/m2 or pemetrexed 500mg/m2，after PD，Erlotinib 150mg qd
3323661|NCT02038062|Experimental|Sevoflurane|Sevoflurane Preconditioning
3323662|NCT02038062|No Intervention|No Sevoflurane|No Sevoflurane Preconditioning
3323663|NCT02038088||A|intravenous inhalational anesthesia
3323664|NCT02038088||B|intravenous anesthesia
3323665|NCT02038101|Experimental|Education and Feedback Intervention|"This intervention includes the following components:~Formal Rounds on AUC for TTE:~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
3229509|NCT01182025|Experimental|Xiyanping Injection|
3323666|NCT02038101|No Intervention|Control|Usual echocardiography ordering pratice.
3323667|NCT02038114|Experimental|Instructed to read pamphlets|This group will be instructed to read patient education pamphlets.
3323669|NCT02038192|Experimental|Living with Hope Program|"All participants in this group will receive the Living with Hope Program. It consists of viewing a 15 minute film on hope. Then for 5 minutes at the end of each day to write Stories of the Presentto work on over one month. Stories of the present is a directed journaling activity which includes writing challenges of the day, what was their hope that day and what would be their hope tomorrow."
3229510|NCT01182025|Experimental|Xiyanping Injection with western medicine|
3229511|NCT01182038|Experimental|Birth seat group|Randomized to birth on a midwife designed birth seat
3229512|NCT01182038|No Intervention|Non-birth seat group|Randomized to birth in any other position except on the midwife designed birth seat.
3229513|NCT01182051|Experimental|Cognitive behavioral therapy|Key treatment ingredients in CBT include psychoeducation, trigger identification, progressive muscle relaxation training, cognitive restructuring, problem solving, in vivo exposure, and relapse prevention (see Appendix I for an outline of the treatment manual).
3323670|NCT02038192|Experimental|Stories of the Present|Participants in this group will write Stories of the Present and not see the film.
3323671|NCT02038192|No Intervention|Usual Care|Participants in this group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
3323672|NCT02038231|Experimental|Parenting Mindfully Program|Mindfulness program for parents of adolescents provided for 2 hours once per week for 8 weeks.
3323673|NCT02038231|Active Comparator|Parent Education Program|Group for parents of adolescents providing handouts and brief education to parents on topics of adolescence, family relations, and risk behaviors. Group meets 3 times over the course of 8 weeks for about 15 minutes per meeting.
3323674|NCT02038244|Experimental|Integrative Medicine|
3323675|NCT02038257|Active Comparator|MKTP with CO2 Laser/Collagen Dressing|Each Subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and a collagen dressing for the wound dressing.
3323676|NCT02038257|Active Comparator|MKTP with CO2 laser/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using the carbon dioxide laser for de-epithelialization and vaseline impregnated gauze as the wound dressing.
3229514|NCT01182051|Active Comparator|Relaxation Training|RT will consist of progressive muscle relaxation training, diaphragmatic breathing, and thermal biofeedback.
3323677|NCT02038257|Active Comparator|MKTP with dermabrasion/collagen dressing|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and a collagen dressing for the wound dressing.
3229515|NCT01182064||Non infarct|
3229516|NCT01182064||Posttraumatic acute myocardial infarct without coronary injury|
3229517|NCT01182064||Posttraumatic acute myocardial infarct with coronary injury|
3323678|NCT02038257|Active Comparator|MKTP with dermabrasion/vaseline gauze|Each subject will have a depigmented patch of skin treated with MKTP using dermabrasion for de-epithelialization and vaseline impregnated gauze as a wound dressing.
3323679|NCT02038270||surgical patients|120 Adult patients, that are having a routine surgical procedure.
3323680|NCT02038283||Low-risk Colorectal Polyps|≤2 adenomas or 3-4 adenomas all of which are <1cm
3323681|NCT02038283||High-risk Colorectal Polyps|≥5 adenomas or ≥3 adenomas at least one of which is ≥1cm
3229518|NCT01182077|Experimental|Group 1|ASP015K low dose and midazolam followed by ASP015K high dose and midazolam
3229519|NCT01182077|Experimental|Group 2|ASP015K high dose and midazolam followed by ASP015K low dose and midazolam
3229520|NCT01182090|Active Comparator|Prolapse repair by open approach|Correction of urogenital prolapse by open surgery approach
3229521|NCT01182090|Active Comparator|Prolapse repair by laparoscopic approach|Correction of urogenital prolapse by laparoscopic approach
3229522|NCT01182116|Experimental|J Pouch side to end|Colorectal surgery Function Quality of Life
3323682|NCT02038283||Stage I CRC|at least six months since diagnosis of Stage I CRC
3323683|NCT02038283||Stage II CRC|at least six months since diagnosis of Stage II CRC
3323684|NCT02038283||Stage III CRC|at least six months since diagnosis of Stage III CRC
3323685|NCT02038283||Stage IV CRC|at least six months since diagnosis of Stage IV CRC
3229523|NCT01182129|Active Comparator|Swedish Snus Type 1|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
3229524|NCT01182129|Active Comparator|Swedish Snus Type 2|The subject keeps one pouch of snus still between the upper lip and the gum for 30 minutes. Amount of nicotine extracted, plasma nicotine concentration at 30 minutes (C30), Tmax, Cmax, AUCinf and heart rate for each treatment.
3229525|NCT01182129|Active Comparator|4 mg Nicorette chewing gum|Nicorette is chewed according to instructions in package insert over 30 minutes.
3323686|NCT02038296|Experimental|Group 1|Group 1 received single-drug (doxorubicin)transarterial chemoembolization.
3323687|NCT02038296|Experimental|Group 2|Group 2 received double-drug (doxorubicin and mitomycin C)transarterial chemoembolization
3229526|NCT01182142|Experimental|Capecitabine|All patients will receive capecitabine.
3323688|NCT02038296|Experimental|Group 3|Group 3 were treated with triple-drug (doxorubicin, mitomycin C and gemcitabine)transarterial chemoembolization.
3323689|NCT02038322|No Intervention|The Stork|Device - The Stork - complete kit (Conceptacle and Applicator)
3229527|NCT01182168|Experimental|gemcitabine and cisplatin plus Everolimus|This is a single-institution phase I study of gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001) in patients with advanced urothelial cancer.
3229528|NCT01182220||Ultrasound L5/S1 catheter placement|Pt will have back scanned with Ultrasound and L5/S1 interspace localized for epidural placement.
3323690|NCT02038335||DMPA|Depot medroxyprogesterone acetate
3323691|NCT02038335||NET-EN|Norethisterone enantate
3229529|NCT01182220||Control Group|Patients will have catheter placed after clinically evaluating the back as is done routinely resulting in mid lumbar catheter placement in general.
3229530|NCT01182233|Experimental|Total Skeletal Irradiation|Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
3229531|NCT01182246|Experimental|AXP107-11|
3229532|NCT01182311||Controls|Never received HBV vaccine and never had HBV
3323692|NCT02038335||MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
3323693|NCT02038335||LNG-I|Levonorgestrel subdermal implant
3323694|NCT02038335||ENG-I|Etonogestrel subdermal implant
3323695|NCT02038335||Cu-IUD|Copper IUD
3229533|NCT01182311||HIV vaccinated >= 10 years|Well compensated HIV disease, vaccinated HBV >= 10 years ago
3229534|NCT01182311||Spontaneously recovered >= 10 years|Spintaneously recovered from acute HBV >= 10 years ago
3229535|NCT01182311||Vaccinated >= 20 years|Vaccinated against HBV >= 20 years ago
3229536|NCT01182311||Vaccinated 10 < 15 years|Vaccinated against HBV 10 < 15 years ago
3323696|NCT02038348|Other|PET with 18F-FDOPA|
3323697|NCT02038361|Experimental|blood sample|
3323698|NCT02038374|Experimental|severe asthma atopic|
3323699|NCT02038374|Experimental|asthma non atopic|
3323700|NCT02038387|Experimental|Diet|
3323701|NCT02038400|Experimental|group A|KINETUBE medical Device
3323702|NCT02038400|Active Comparator|group B|insertion of tympanic ventilation tubes (tympanostomy)
3323703|NCT02038413||NSCLC stage I|Consecutive patients were identified from October 2009 onwards in MAASTRO clinic, Maastricht. All patients received respiratory gated CT (4DCT) scans. All were patients referred for primary radiotherapy or chemo radiation.
3323704|NCT02038426|Experimental|the patients with SpA|
3323705|NCT02038426|Experimental|sports subjects|
3323706|NCT02038426|Other|control subjects|
3323707|NCT02038439|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, clinicians will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3323708|NCT02038439|Experimental|Interventions A + B|"See Interventions Description. In this arm, clinicians will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
3323709|NCT02038439|Experimental|Interventions A + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
3323710|NCT02038439|Experimental|Interventions B + C|"See Interventions Description. In this arm, clinicians will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3323711|NCT02038439|Experimental|Intervention A alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
3323712|NCT02038439|Experimental|Intervention B alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
3323713|NCT02038439|Experimental|Intervention C alone|"See Interventions Description. In this arm, clinicians will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
3323714|NCT02038439|No Intervention|No intervention|In this arm, clinicians will be offered non of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
3323715|NCT02038452|Active Comparator|Steroid Injection|Single steroid injection into Carpal Tunnel (as Depo-medrone 20mg)
3323716|NCT02038452|Active Comparator|Wrist Splint|Wrist splint to be worn at night
3323717|NCT02038465|Other|patient|Complete questionary remembering the day
3323718|NCT02038465|Other|healthy volunteers|- Complete questionary, remembering the day
3323719|NCT02038478|Experimental|Transplantation Arm|"Transplantation~One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects."
3323720|NCT02038491||regional anesthesia|patients undergoing regional anesthesia procedures
3323721|NCT02038504||gastrointestinal fistula|
3323722|NCT02038530||No Ultrasound|Low Clinical Pretest Probability and D-dimer < 1000 ug/L; Moderate Clinical Pretest Probability and D-dimer < 500 ug/L
3323723|NCT02038530||Ultrasound Required|Low Clinical Pretest Probability and D-dimer 1000 - 3000 ug/L; Moderate Clinical Pretest Probability and D-dimer 500 - 3000 ug/L; High Clinical Pretest Probability
3323724|NCT02038556|Experimental|cognitive behaviorial therapy for insomnia group program|Behavioral
3323725|NCT02038582|Active Comparator|POC CD4 & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and follow up with clinic accompaniment
3323726|NCT02038582|Active Comparator|POC CD4 & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and lay counselor follow up
3229537|NCT01182311||Vaccinated 15 < 20 years|Vaccinated against HBV 15 < 20 years ago
3229538|NCT01182363|No Intervention|Control|Usual early intervention services
3323727|NCT02038582|Active Comparator|POC CD4 & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to POC CD4 testing and referral to clinic
3323728|NCT02038582|Active Comparator|CD4 Referral & Clinic Accompaniment|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and follow up with clinic accompaniment
3323729|NCT02038582|Active Comparator|CD4 Referral & Lay Counselor|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and lay counselor follow up
3323730|NCT02038582|Active Comparator|CD4 Referral & Clinic Referral|HIV positive persons not on ART at enrollment, randomized to referral for CD4 testing and referral to clinic
3323731|NCT02038582|Active Comparator|Circumcision - SMS Reminder|HIV negative uncircumcised males, randomized to SMS reminder for male circumcision
3323732|NCT02038582|Active Comparator|Circumcision - Lay Counselor|HIV negative uncircumcised males, randomized to lay counselor follow-up for male circumcision
3323733|NCT02038582|Active Comparator|Circumcision - Promotion|HIV negative uncircumcised males, randomized to promotion of male circumcision at the time of HIV testing
3323734|NCT02038582|Active Comparator|POC VL|HIV positive persons on ART, randomized to POC viral load testing
3323735|NCT02038582|Active Comparator|Laboratory based VL assay|HIV positive persons on ART, randomized to laboratory based viral load testing
3323736|NCT02038595|Experimental|Healthy subjects|Healthy subjects (male, female)
3323737|NCT02038608|Experimental|PET|
3323738|NCT02038621|Experimental|A|Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.
3323739|NCT02038621|Placebo Comparator|B|Observation until progression
3323740|NCT02038634|Active Comparator|Unguided injections|Corticosteroid injection (betamethasone) without ultrasound guidance.
3323741|NCT02038634|Active Comparator|Ultrasound-guided injections|Corticosteroid injections (betamethasone) under ultrasound guidance.
3323742|NCT02038660||Patients with coronary artery disease|
3323743|NCT02038673|Experimental|Dose escalation part 0.5 mg QD|Oral
3323744|NCT02038673|Experimental|Dose escalation part 1.0 mg QD|Oral
3323745|NCT02038673|Experimental|Dose escalation part 2.0 mg QD|Oral
3323746|NCT02038673|Experimental|Dose escalation part 2.0 mg BID|Oral
3323747|NCT02038673|Experimental|Dose escalation part 4.0 mg BID|Oral
3323748|NCT02038673|Experimental|Dose escalation part 6.0 mg BID|Oral
3323749|NCT02038673|Experimental|Dose escalation part 10.0 mg BID|Oral
3323750|NCT02038673|Experimental|Dose escalation part 20.0 mg BID|Oral
3323751|NCT02038673|Experimental|Dose escalation part 16.0 mg BID|Oral
3323752|NCT02038673|Experimental|Expansion part Urothelial Carcinoma|Oral
3323753|NCT02038673|Experimental|Expansion part Hepatocellular Carcinoma|Oral
3323754|NCT02038673|Experimental|Expansion part Squamous Cell Lung Carcinoma|Oral
3323755|NCT02038686|Active Comparator|Standard PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A short nail (170-240mm)
3323756|NCT02038686|Active Comparator|Long PFN-A|Patients with unstable proximal femoral fractures treated with PFN-A long nail (300-420mm)
3229539|NCT01182363|Experimental|Problem Solving Education|
3229540|NCT01182389|Active Comparator|robotic VT Ablation|Robotic VT ablation by substrate elimination
3229541|NCT01182389|Active Comparator|Conventional therapy|review of ICD programming to ensure that detection and therapy will occur appropriately.
3323757|NCT02038699|Experimental|ONC201|Oral ONC201 will be administered once every three weeks at various doses.
3323758|NCT02038712|Experimental|Binge eating disorder (BED)|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who meet the current criteria for binge eating disorder (BED) in the fed condition and fasted condition.
3323759|NCT02038712|Experimental|Control|Blood samples, subjective appetite ratings and fMRI scan will be collected in subjects who do not meet the current criteria for BED (Controls) in the fed condition and fasted condition.
3323761|NCT02038738|Experimental|Scan|We will perform 68Ga-DOTATATE PET scans on subjects.
3323762|NCT02038751||Index proband|moderate to severe OSA (AHI>30 or AHI>15 needing CPAP intervention) age 20-99 y/o
3323763|NCT02038751||Index family|first-degree, second-degree, or spouse of index proband age >20 y/o
3323764|NCT02038751||Control proband|friends of index proband, living in the same environment as index proband age > 20 y/o
3323765|NCT02038751||Control family|first-degree, second-degree, or spouse of control proband age >20 y/o
3323766|NCT02038777|Experimental|Monotherapy Cohort|PF-04449913 Monotherapy
3323767|NCT02038777|Experimental|Combination Cohort 1|PF-04449913 in combination with low dose ARA-C (LDAC)
3229542|NCT01182402|Experimental|Electronic compliance monitoring|Suboxone treated patients in Kuopio city area get their unsupervised Suboxone doses in electronic compliance monitoring devices during the 4 month study.
3229543|NCT01182467||Crohn's disease|Patients will receieve Radiation: PET-CT scan
3229544|NCT01182506|Experimental|Breast cancer survivors|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
3229545|NCT01182506|Experimental|Collateral source|Participants from both groups will be asked to complete two follow up neurocognitive assessments face to face at MSKCC. The first will be completed within 1-4 weeks after completing the memory training and the second will take place 3-4 months after completing the memory training. Collateral sources will be contacted at these same points to complete their brief assessments as well to test for maintenance of the treatment effect.
3229546|NCT01182519||Diagnosed with metastatic breast cancer|"The primary objective of this study is to examine the association between urinary PGE-M and the presence or absence of lung metastases in patients with breast cancer. These patients will be subdivided into a set with lung metastases (group 1A; clinically assessed as per guidelines below) versus those with no evidence of lung metastases (group 1B; no known lung metastases). Group #2 (control) will have been treated for early stage breast cancer and will have no known metastases."
3323768|NCT02038777|Experimental|Combination Cohort 2|PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
3323769|NCT02038777|Experimental|Azacitidine Combination Cohort|PF-04449913 in combination with azacitidine
3323770|NCT02038777|Experimental|Continuation Cohort|PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
3323771|NCT02038777|Experimental|Expansion Cohort of LDAC Combination for Efficacy|PF-04449913 in combination with LDAC to evaluate efficacy
3323772|NCT02038803||Adults- Cystic Fibrosis|Adults with cystic fibrosis who have respiratory colonization with Pseudomonas Aeruginosa. The actual study will involve instructing adult patients with CF on the use of a new form of Tobramycin for inhalation (powder) and then assessing this new form of TOBI podhaler vs the old TOBI solution related to patient preference on use, time involved in taking the new medication vs the old, and impact on their pulmonary function and subsequent exacerbation rate plus quality of life.
3323773|NCT02038816|Experimental|Deferasirox + Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles + Deferasirox 10-30 mg/kg/d depending on transfusion needs
3323774|NCT02038816|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 daily X 7 days every 28 days for 6 cycles
3323775|NCT02038842|Experimental|MVA HIV-B and LIPO-5 vaccines|MVA HIV-B primes 0,5 milliliter (mL) Intramuscular at Week 0 and Week 8 LIPO-5 1mL Intramuscular boosts at Week 20 and Week 28
3323776|NCT02038842|Experimental|LIPO-5 and MVA HIV-B vaccines|LIPO-5 primes 1mL intramuscular at Week 0 and Week 8 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
3323777|NCT02038842|Experimental|GTU-MultiHIV B and LIPO-5 vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and LIPO-5 1mL intramuscular boosts at Week 20 and Week 28
3323778|NCT02038842|Experimental|GTU-MultiHIV B and MVA HIV-B vaccines|GTU-MultiHIV B 0,5mL intramuscular via Biojector 2000 and 0,5mL intradermic primes at Week 0, Week 4 and Week 12 and MVA HIV-B 0,5mL intramuscular boosts at Week 20 and Week 28
3229547|NCT01182519||History of early breast cancer|History of early breast cancer and currently no evidence of disease
3323779|NCT02038855|Active Comparator|IIDEA|Patients in the Integrated Intervention for Dual Problems and Early Action (IIDEA) arm will receive the 10 session intervention administered in person and via telephone.
3323780|NCT02038855|No Intervention|Usual Care|Patients in this arm receive usual care for dual-diagnosis symptoms of mental health and substance use. They receive 5 check-in calls from a care manager to assess safety.
3323781|NCT02038868|Experimental|ASP4901 group|After the main enrollment, patients will receive an oral dose of ASP4901 once daily for 4 weeks (double-blind treatment period).
3323782|NCT02038868|Placebo Comparator|Placebo group|After the main enrollment, patients will receive an oral dose of placebo once daily for 4 weeks (double-blind treatment period).
3229548|NCT01182532|Active Comparator|Western therapy|
3323783|NCT02038868|Active Comparator|Tamsulosin group|After the main enrollment, patients will receive an oral dose of tamsulosin once daily for 4 weeks (double-blind treatment period).
3323784|NCT02038972|Experimental|Autologous Stem Cells|A single dose of intravenously administered autologous hUCB will be done. The minimum acceptable dose will be 6x10 6th mononuclear cells/kilogram body weight. The hUCB reanimation, cell processing and product infusion will occur at Florida Hospital for Children and the Florida Hospital Center for Cellular Therapy.
3323785|NCT02038985|Other|+ ICG Dye (Firefly)|Participants will receive ICG Dye
3323786|NCT02038998|Sham Comparator|Static group|Control group. They will receive the standard care provided by the protocols of the ictus unit. They will lay on the Exer-Rest® TL device but the acceleration will NOT be connected.
3323787|NCT02038998|Experimental|Single pGz intervention|In addition to the standard care established in the ictus unit, these patients will receive a single exposure to pGz on the Exer-Rest® TL, for 3 hours, during the first day of their stay in the hospital.
3323788|NCT02038998|Experimental|Multiple pGz interventions|In addition to the standard care, these patients will be exposed to 45 minutes of pGz, on the Exer-Rest® TL, every day during their first week in the Hospital.
3323789|NCT02039011|Active Comparator|Indacaterol|
3323790|NCT02039011|Experimental|Indacaterol & tiotropium|
3323791|NCT02039024|Experimental|18F- DTBZ for Parkinson's Disease|"This study will compare the amyloid deposition of brain by florbetapir F-18 PET imaging and monoaminergic function by18F- DTBZ PET in 10 NC group, 30 PD group, 30 PDD group, 20 AD group. We will also analyze monoaminergic function by18F- DTBZ PET in 30 PDI group.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, healthy subjects, PD, PDD, and AD patients will have 4 visits in this study. PDI patients will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3323792|NCT02039037|Active Comparator|Acupuncture group|This group perform acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
3323793|NCT02039037|Active Comparator|Electroacupuncture group|Electro Group, will be added through the use of electrical stimulation of electroacupuncture using the apparatus Accurate pulse 585 at the same points.
3323794|NCT02039050|Active Comparator|Tiotropium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
3323795|NCT02039050|Experimental|Aclidinium|Participants receive tiotropium for 2 to 3 weeks.Participants then enter a washout period and after the washout period receive the alternative treatment arm.
3323796|NCT02039063|Experimental|1|E6011 2 mg/kg
3323797|NCT02039063|Experimental|2|E6011 5 mg/kg
3323798|NCT02039063|Experimental|3|E6011 10 mg/kg
3323799|NCT02039063|Experimental|4|E6011 15 mg/kg
3323800|NCT02039076|Experimental|avatrombopag|Each subject will receive a single administration during each of the 5 treatment periods as follows: 40 and 60 mg in the fed and fasted state, and 20 mg in the fed state. Subjects will be randomized to one of four dosing sequences.
3323801|NCT02039089|Experimental|1|Part A: dose escalation of E2006 in Japanese subjects from 2.5 mg (1 x 2.5-mg tablet) up to 10 mg (1 x 10-mg tablet) then to 25 mg (2 x 10-mg tablet, 1 x 5-mg tablet).
3323802|NCT02039089|Experimental|2|Part B: E2006 10 mg for White subjects that will be group matched to the Japanese subjects in the 10 mg period in Part A.
3323803|NCT02039089|Placebo Comparator|3|E2006-matched placebo tablets
3323804|NCT02039102||Non-users of hormonal contraceptives|
3229549|NCT01182532|Experimental|TCM treatment|
3229550|NCT01182532|Experimental|Western therapy plus TCM treatment|The combination of both western therapy and TCM treatment.
3229551|NCT01182545|Placebo Comparator|The normoventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a tidal volume (TV) of about 8 mL.kg-1 and respiratory rate (R.R) owas adjusted to maintain an end-tidal CO2 (ETCO2) of 4.6-6 kPa throughout the procedure.
3323805|NCT02039102||Users of hormonal contraceptives|
3323806|NCT02039128|Experimental|Krill oil|1 gram per day in 12 weeks
3323807|NCT02039128|Active Comparator|Fish oil|1 gram per day in 12 weeks
3229552|NCT01182545|Active Comparator|The hyperventilation group|15 minutes prior to CO2 insufflation, the patients' lungs were ventilated with a TV of 8 mL.kg-1 with the adjustment of the R.R to maintain an ETCO2 of 4-4.6 kPa, until the end of anaesthesia.
3229553|NCT01182558|Other|Activation of Hypothenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3229554|NCT01182558|Other|Activation of Thenar Eminence|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3229555|NCT01182558|Other|Activation of Extensor Digitorum Brevis|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various lengths of time (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
3229556|NCT01182558|Placebo Comparator|Maintain Relaxation of the Opposite Side|While the muscle of the right side is activated periodically and the compound muscle action potential is tested frequently, the muscle on the left side is maintained at rest and the compound muscle action potential is tested infrequently.
3229557|NCT01182571||heart transplantation|
3323808|NCT02039128|Placebo Comparator|Placebo|1 gram per day in 12 weeks
3323809|NCT02039141|Experimental|Every Little Step Counts Intervention|Exercise classes (3/week) Lifestyle sessions (1/week)
3323810|NCT02039141|No Intervention|Delayed ELSC Intervention Group|Control group (delayed intervention group)
3229558|NCT01182584||Graves' disease|
3229559|NCT01182584||Healthy volunteers|
3323811|NCT02039154|Experimental|Aerobic and strength training group|
3323812|NCT02039154|Active Comparator|Balance and flexibility group|
3229560|NCT01182597|Active Comparator|IV PPI|Pantoprazole 3.3mg/hr for 72hrs
3323813|NCT02039167|Active Comparator|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
3323814|NCT02039167|No Intervention|OAC with a vitamin K antagonist|Oral anticoagulants (OAC) as Standard of Care (SOC) provided by primary care physician
3323815|NCT02039180|Experimental|AZD3293 oral solution|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3323816|NCT02039180|Experimental|AZD3293 tablet formulation A|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3323817|NCT02039180|Experimental|AZD3293 tablet formulation B|single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
3323818|NCT02039193|Experimental|adherence priming|"To investigate various types of how to conduct a standardized CBT-protocol, all therapists are tutored in peer dyads (tandem peer tutoring). Immediate before sessions 1 to 5, the therapists are required to contact the tandem-partner face-to-face or via self-phone to deliberate the forthcoming session by a 5 to 10 minute brief communication (primings; comparable to Flückiger & Grosse-Holtforth, 2008).~Adherence priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement the disorderspecific interventions that are described in the treatment protocol. These communications are focused on therapists' understanding of patients GAD and the related comorbidities and how these issues can be addressed in the prescriptive treatment protocol."
3323819|NCT02039193|Experimental|resource priming|Resource priming: Immediately before sessions 1 to 5, therapists have a five-minute conversation about how to implement strengths-based micro-interventions in the forthcoming session. Strengths-based micro-interventions addresses therapists explicit focus on patients' preexisting strengths and abilities, subtle changes and improvements during therapy (potential recources) as well as motivational preparedness, readiness and goals (motivational resources; Grawe, 2006; Flückiger, et al., 2010).
3323820|NCT02039193|Experimental|supportive resource priming|Supportive resource priming: The supportive resource priming condition has the very same protocol as the resource priming condition (5 brief tandem peer tutorings). The only difference in the procedure is that the therapists are allowed to integrate a helpful significant person of the patients (such as the partners or the best friends) around session 1 and 7 to encourage and support the patient to realize their treatment plans (active integration of interpersonal resources). However, the integration of a significant other person does not touch the CBT-treatment protocol.
3323821|NCT02039206|Experimental|Treatment|Deep TMS
3323822|NCT02039232|Experimental|CarboFix Pedicle Screw System|
3229561|NCT01182597|Experimental|Oral PPI|Lansoprazole (Takepron OD) 30mg PO q12h
3229562|NCT01182623||In vivo diagnosis|Patients undergoing colonoscopy where one or more polyps up to 10mm in size are found.
3323823|NCT02039245|Experimental|Canagliflozin/Metformin XR|Each patient will receive 2 tablets of CANA/MET XR combination of total dose 300/2000 mg
3323824|NCT02039258|Experimental|Sequence AB|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fasted conditions (treatment A) followed by the same single dose under fed conditions (treatment B).
3323825|NCT02039258|Experimental|Sequence BA|A single dose of CANA/MET XR FDC tablet of 150 mg/1,000 mg under fed conditions (treatment B) followed by the same single dose under fasted conditions (treatment A).
3323826|NCT02039271|No Intervention|Standard of Care|Subjects will receive standard post-operative care after total knee replacment surgery
3323827|NCT02039271|Experimental|Music Therapy|Subjects will receive music therapy in addition to standard post-operative therapy.
3323828|NCT02039284|Experimental|SES group|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.
3229563|NCT01182636|Experimental|Investigational Test Product|Adapalene Topical Gel, 0.1%
3229564|NCT01182636|Active Comparator|Reference Listed Drug|Differin® (adapalene 0.1%) Topical Gel
3323829|NCT02039284|Experimental|VCT group|VCT group received the VCT training in addition to traditional rehabilitation.Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise.
3229565|NCT01182636|Placebo Comparator|Placebo|Gel base only
3229566|NCT01182649|Experimental|EES Group|Patients who received an everolimus eluting stent
3229567|NCT01182649|Active Comparator|SES Gruop|Patients who received a sirolimus eluting stent
3229568|NCT01182662|Experimental|Human umbilical cord-derived MSCs and cyclosporin|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated to apply in trimonthly for 2 cycle and CsA 5mg/kg po for 12 months
3229569|NCT01182662|Active Comparator|cyclosporine A|cyclosporine A at a dose of 5 mg CsA/kg
3229570|NCT01182701|Active Comparator|Behavioral intervention|
3229571|NCT01182701|No Intervention|Education support|
3229572|NCT01182714|Other|removal of catheter|
3229573|NCT01182740||glidescope|
3229574|NCT01182740||storz c-mac|
3229575|NCT01182740||mcgrath vl|
3229576|NCT01182740||ambu pentax aws|
3229577|NCT01182740||macintosh laryngoscope|
3229578|NCT01182740||others|
3259118|NCT01467674||Better Controlled T2DM|
3259119|NCT01467674||Poor Controlled T2DM|
3323830|NCT02039284|Experimental|VRCIT group|VRCIT group received the VRCIT training in addition to traditional rehabilitation.Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day.
3323831|NCT02039284|Active Comparator|traditional rehabilitation group|Shame control group received the shame SES and traditional rehabilitation programs.
3323832|NCT02039297|Other|No Intervention: Baseline arm|Pre and post design (same arm)
3323833|NCT02039310||≥ 65 years / opts for radical cystectomy|
3323834|NCT02039323|Experimental|All Participants|Maraviroc 600 mg + Tenofovir 600 mg
3323835|NCT02039336|Experimental|Dacomitinib + PD-0325901|Dacomitinib: oral tablets PD-0325901: oral capsules
3229579|NCT01182753|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
3229580|NCT01182753|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
3323836|NCT02039362|Other|tenofovir|tenofovir DF one pill (245 mg) per day from week 28 of pregnancy to week 12 after birth
3323837|NCT02039388|Other|High risk patients for breast and/or ovarian cancer|
3323838|NCT02039401|Experimental|VM202|Total dose of 64 mg of VM202 It will be administered over the course of four visits: Day 0, Day 7, Day 14, and Day 21. As in all previous VM202 studies, final dose of VM202 for each target muscle group is divided and administered 2 weeks apart.
3323839|NCT02039440|Other|Single arm|1 blood draw
3323840|NCT02039453|Experimental|Fentanyl arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and fentanyl.
3323841|NCT02039453|Active Comparator|Pethidine arm|The subjects of this arm will consist of the patients who undergo colonoscopy with sedative agents, propofol and pethidine.
3323842|NCT02039466|Active Comparator|volume controlled ventilation|volume controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
3229581|NCT01182766|Experimental|topiramate|topiramate with brief behavioral enhancement therapy
3229582|NCT01182766|Placebo Comparator|Placebo|Placebo with brief behavioral enhancement therapy
3229583|NCT01182779|Experimental|A|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
3323843|NCT02039466|Active Comparator|pressure controlled ventilation|pressure controlled ventilation as a tidal volume of 8 ml/kg (ideal body weight)
3323844|NCT02039479|Placebo Comparator|TAU + Placebo|Treatment as Usual + Placebo
3323845|NCT02039479|Active Comparator|TAU + Lithium|Treatment as Usual + Lithium
3323846|NCT02039492|Experimental|A|Denervation
3323847|NCT02039492|Active Comparator|B|Treatment with aldactone
3323848|NCT02039518|Experimental|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
3229584|NCT01182779|Active Comparator|B|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
3229585|NCT01182792|Experimental|Antioxidant|
3323849|NCT02039518|Other|observation group|observation
3323850|NCT02039531|Experimental|Plasma rich in growth factors (PRGF)|"Patients in this group will receive one cycle of three intra-articular injections of PRGF every 15 days.~Procedure for the application of the treatment:~1. Study Group or PRGF group~Blood sample :~Taken minimum after 4 hours of fasting and drinking only water in order to maintain low levels of glucose.~20 cc of peripheral blood will be taken by sterile systems with Sodium Citrate buffer to avoid hemolysis.~Spinning of the sample:~8 minutes at 1800 rpm .~getting the blood fraction containing the PRGF~activation of PRGF with 50 ul of 10% CaCl2 per ml of plasma.~the application of PRGF should not exceed 90 minutes after the blood sample extraction in order to avoid risk of contamination."
3323851|NCT02039531|Active Comparator|Hyaluronic acid (Durolane®)|Patients in this group will receive a single intra-articular injection at visit 1.
3323852|NCT02039544|Experimental|Xuebi formula|Xuebi formula , one dosage ,every day, treat 6 months.
3323853|NCT02039544|Placebo Comparator|Placebo|placebo,has the same taste and color as Xuebi formula one dosage ,every day, treat 6 months.
3323854|NCT02039557||NiCord®/CordIn™ transplanted|Anyone who signed the consent for this study received a NiCord®/CordIn™ infusion as part of a GC clinical interventional study, and completed the interventional study Day 365 status assessment.
3323855|NCT02039570||haemorrhoids|The cohort contains only patients with symptomatic haemorrhoids - these patients will receive a transvaginal scan to examine their ovarian and internal iliac veins to ascertain whether there is any reflux
3323856|NCT02039583||full cohort|All singleton births in England. See 'statistical analysis' for denominator specification for individual outcomes.
3323857|NCT02039596|Experimental|vegetarian breakfast|Diet: Vegetarian food items
3323858|NCT02039596|Experimental|Swedish Breakfast|Diet: Swedish food items
3323859|NCT02039596|Experimental|English breakfast|Diet: English food items
3323860|NCT02039596|Experimental|Lacto-vegetarian breakfast|Diet: Lacto-vegetarian food items
3323861|NCT02039596|Experimental|Swedish omnivore breakfast|Diet: Swedish breakfast with meat items
3323862|NCT02039609||Omnivores|No intervention, habitual diet
3323863|NCT02039609||Vegetarians|No intervention, habitual diet
3323864|NCT02039609||Vegans|No intervention, habitual diet
3323865|NCT02039609||Vegetarians consuming fish|No intervention, habitual diet
3323866|NCT02039622||Patient under study condition|Patient under study condition
3323867|NCT02039635|Experimental|Korean Red Ginseng|"Patients receive oral Korean Red Ginseng twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Dietary Supplement: Korean Red Ginseng"
3323868|NCT02039635|Placebo Comparator|Placebo|"Patients receive oral placebo twice daily for 16 weeks. Treatment repeats every 4 weeks for 4 courses.~Intervention: Other: Placebo"
3323869|NCT02039648|Active Comparator|Rumex acetosa L. extract|Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days
3323870|NCT02039648|Placebo Comparator|Placebo|Placebo mouthrinse, 10 ml, tid, 3 min, 7 days
3229586|NCT01182792|Placebo Comparator|Control|
3229587|NCT01182818||Observation|all adult patients (18 - 60 years of age) with an acute cerebrovascular event of any etiology
3229588|NCT01182831|Active Comparator|percutaneous fluoro guided celiac plexus neurolysis|
3229589|NCT01182831|Active Comparator|EUS guided neurolysis|
3229590|NCT01182870|Experimental|cholecalciferol|cholecalciferol in doses 800-6000 IU per day
3229591|NCT01182870|Placebo Comparator|placebo|placebo identical looking as cholecalciferol capsules
3229592|NCT01182922|Active Comparator|Doctor's Information Invitation|Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
3229593|NCT01182922|Active Comparator|Gender Preference Invitation|Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
3323871|NCT02039661|Active Comparator|Lidocaine Spray|
3323872|NCT02039661|Placebo Comparator|Placebo|These patients received placebo spray.
3229594|NCT01182922|Active Comparator|Standard Invitation|Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
3229595|NCT01182935||participants in the 4th Tromsø study|
3229596|NCT01182948|Experimental|Aerobic Exercise|The aerobic training group will use cardiovascular training devices.
3229597|NCT01182948|Experimental|Resistance Exercise|The resistance training group will perform exercises on weight machines and free weights.
3229598|NCT01182961|Experimental|Treadmill +virtual reality training|
3323873|NCT02039700|Experimental|Lesinurad and [14C]lesinurad|Single oral dose of lesinurad and single infusion of [14C]lesinurad
3323874|NCT02039713||IRIS DeSyne|DeSyne drug eluting stent group
3323875|NCT02039739||Orsiro™ Drug Eluting Stent|
3323876|NCT02039752||Multivessel|from 1995
3323877|NCT02039765|Experimental|Brimonidine tartrate|One drop of brimonidine tartrate ophthalmic solution 0.025% in each eye once at Visit 2 (Day 1) then four times daily (QID) approximately 4 hours apart at Visit 3 (Day 2) through day 6, and then once at Visit 4 (Day 7).
3229599|NCT01182961|Active Comparator|Treadmill alone|
3229600|NCT01182961|Active Comparator|standard of care exercise group|
3229601|NCT01182974|Active Comparator|paracetamol treatment|
3229602|NCT01182974|Active Comparator|control- dypirone treatment|
3229603|NCT01182987|Active Comparator|Dementia care management|Patients and family caregivers will be offered dementia care management, which includes detailed comprehensive assessment, education, counseling, referrals to community agencies, collaboration with medical providers and frequent telephone follow-up
3229604|NCT01182987|No Intervention|Usual care|Patients and care family care givers will receive usual support and medical care offered by the health plan.
3229605|NCT01183000|Active Comparator|peritoneal closure|
3229606|NCT01183000|No Intervention|Non closure of the peritoneum|
3229607|NCT01183039|Active Comparator|Ventilatory threshold|Training at the ventilatory threshold
3229608|NCT01183039|Active Comparator|Metabolic threshold|Training at the metabolic threshold
3229609|NCT01183052|Other|Training|20 sessions of training
3229610|NCT01183078|Other|Free-hand technique|Free-hand technique utilized to find screw holes.
3229611|NCT01183078|Other|Wand technique|Wand technique is utilized to find screw holes.
3229612|NCT01183091||First AF ablation|Description of the patients experiencing an AF ablation
3229613|NCT01183117|Experimental|SM-01|
3229614|NCT01183117|Active Comparator|PTA|
3229615|NCT01183130|Experimental|Compliance monitoring in real time|Patients get their opioid substitution medications in electronic compliance monitoring devices and send information of their medication intakes with mobile phone to the clinic every day during the two month study period.
3229616|NCT01183130|Active Comparator|Compliance monitoring|Patients get their opioid substitution medications in electronic compliance monitoring devices. Information of their medication intakes will be reviewed during the weekly visits to the clinic.
3229617|NCT01183156|Active Comparator|Re-invitation letter|
3229618|NCT01183156|Active Comparator|Educational Meeting|
3229619|NCT01183182|Experimental|Needle Guidance|Lung biopsies performed with the needle guidance system.
3229620|NCT01183208|Experimental|Cohort 1 active treatment and placebo|Active treatment and placebo
3229621|NCT01183208|Experimental|Cohort 2 - Active treatment and placebo|Active treatment and placebo
3229622|NCT01183208|Experimental|Cohort 3 Active Treatment and placebo|Active treatment and placebo
3229623|NCT01183247|Active Comparator|Rapamycin|Rapamycin-MMF-tacrolimus
3229624|NCT01183247|Active Comparator|Everolimus|Everolimus - tacrolimus - MMF
3229625|NCT01183247|Active Comparator|Prednisone|tacrolimus - MMF -prednisone
3229626|NCT01183273|Active Comparator|Micro-laparoscopic bypass|
3229627|NCT01183273|Active Comparator|Laparoscopic gastric bypass|
3229628|NCT01183286|Active Comparator|CFFONE|
3229629|NCT01183286|Placebo Comparator|CF website|
3229630|NCT01183299|Active Comparator|High salt intake|
3229631|NCT01183299|Placebo Comparator|Low salt intake|
3229632|NCT01183325|Experimental|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
3229633|NCT01183351|Experimental|Psychosocial intervention|This is a single-group pilot-study
3229634|NCT01183364|Experimental|STA-9090 and Docetaxel|STA-9090 (ganetespib) and Docetaxel
3229635|NCT01183377||1|Female athlete Triad syndrom was based on menstrual disorder,Eating Disorder and bone loss
3229636|NCT01183442|Active Comparator|vitamin D (Oleovit®)|vitamin D drops
3229637|NCT01183442|Placebo Comparator|Placebo|placebo drops
3323878|NCT02039791|Experimental|Nimotuzumab plus chemoradiotherapy|
3323879|NCT02039804|Experimental|Hyaluronic acid|Injectable hyaluronic acid.
3323880|NCT02039804|Active Comparator|Corticosteroids|Injectable corticosteroids.
3323881|NCT02039830|Experimental|Group physiotherapy|12 weekly treatment visit + daily home exercise program
3323882|NCT02039830|Active Comparator|Individual one-on-one physiotherapy|12 weekly treatment visit + daily home exercise program
3323883|NCT02039843|Active Comparator|1|Emotional Support Dogs
3323884|NCT02039843|Active Comparator|2|Service Dogs
3323885|NCT02039869|Experimental|Proton Pump Inhibitor|Patients will receive proton pump inhibitor therapy with omeprazole twice daily while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from proton pump inhibitor therapy.
3323886|NCT02039869|Experimental|Sucralfate|Patients will receive sucralfate therapy four times a day while we observe for improvement in reflux symptoms. We will compare the confocal endomicroscopy images in the responders to non-responders at the end of 8 weeks to determine if confocal endomicroscopy can select patient that would benefit most from sucralfate therapy.
3323887|NCT02039882||Controls/Normals|control subjects without known cardiac disease, age ± 5 years and sex matched
3323888|NCT02039882||Acute Coronary Syndrome requiring Percutaneous Intervention|Subjects presenting to ER with Acute chest pain requiring cardiac catheterization
3229638|NCT01183455|Experimental|Aralast NP|Participants will receive Aralast NP (90mg/kg) intravenously once a week for 12 weeks.
3229639|NCT01183455|Placebo Comparator|Placebo|Participants will receive placebo intravenously once a week for 12 weeks.
3323889|NCT02039882||Acute Coronary Syndrome, no intervention|Acute Coronary Syndrome, not requiring Percutaneous intervention
3323890|NCT02039895|Experimental|HITS for CTCL|Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
3323891|NCT02039934|Experimental|high intensity interval training|
3323892|NCT02039960||DAWN cases including all prescription drugs|This group will consist of all DAWN cases where prescription drugs are mentioned.
3323893|NCT02039960||All bupropion cases (including use of other drugs)|This group will consist of all DAWN cases where bupropion is mentioned and is a subset of Group 1.
3323894|NCT02039960||Burpropion Only Cases|This group will consist of all DAWN cases where burpropion is specifically the only drug mentioned within the case report, and is a subset of Group 2.
3323895|NCT02039973|Experimental|Task-sharing approach to group therapy|The intervention will consist of problem-solving therapy as well as cognitive behavioral components. Core problem-solving therapy components will involve lay CBHW facilitated discussions to explore symptoms of depression and how problems are related to depression. Core cognitive behavioral components will include lay CBHW facilitated discussions to explain the purpose of the sessions, as well as effect a number of behavioral changes in participants.
3323896|NCT02039973|Active Comparator|Enhanced standard of care|The control condition will promote an enhanced standard of care. Clinicians and nurses at MCH clinics included in the study will receive a structured one day re-orientation training consistent with the World Health Organization (WHO) mh-GAP guidelines for assessment as well as basic psychosocial and drug treatment of moderate to severe depression in primary care settings. The training will be consistent with the standard of care for mental health among HIV-positive populations as outlined in Tanzanian health policy. In addition, clinical staff will be trained to encourage women to invite their male partners to accompany them at clinic visits, where psycho-education on perinatal depression for couples will be offered for those opting to participate.
3323897|NCT02039986||all subjects|all subjects enrolled in same cohort
3323898|NCT02039999|Experimental|Chronic cough|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
3323899|NCT02039999|Active Comparator|Normal volunteer|"Cough challenges to be administered include:~Nebulised citric acid in serial dilutions Nebulised ATP solution in serial dilutions Nebulised TRPA1 agonist solution in serial dilutions"
3323900|NCT02040012|Active Comparator|AZP-531|subcut administration once or twice daily
3323901|NCT02040012|Placebo Comparator|Mannitol|subcut administration once or twice daily
3323902|NCT02040038|Experimental|LIVE Arm|Participation in 3D virtual environment for DSMT/S for a period of 12 months.
3323903|NCT02040038|Active Comparator|Website|Participation in 2D website for DSMT/S for a period of 12 months.
3323904|NCT02040051|Active Comparator|GROUP A: Sound isolation / Music therapy|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Sound isolation~INTERVENTION: Third hour. Music therapy~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
3323905|NCT02040051|Active Comparator|GROUP B: Music therapy / Sound isolation|"PREINTERVENTION: First hour. The patient will remain under the usual conditions of intensive care unit~INTERVENTION: Second hour. Music therapy~INTERVENTION: Third hour. Sound isolation~POSTINTERVENTION: Fourth hour. The patient will remain under the usual conditions of intensive care unit"
3323906|NCT02040064|Experimental|Treatment|"Cohort 1: Tremelimumab 3 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 3 mg/kg is the MTD)~Cohort 2: Tremelimumab 6 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 6 mg/kg is the MTD)~Cohort 3: Tremelimumab 10 mg/kg every 4 Weeks plus Gefitinib 250 mg/daily, 6 patients (+ 6 patients if 10 mg/kg is the MTD)"
3323907|NCT02040103|Experimental|Intermittent Pneumatic Compression(IPC)|The intervention group will be receiving Intermittent Pneumatic Compression(IPC)
3323908|NCT02040103|No Intervention|No Intermittent Pneumatic Compression|patients will not receive Intermittent Pneumatic Compression
3323909|NCT02040129|Experimental|Acrysof toric IOL|Acrysof Toric intraocular lens in congenital cataract
3323910|NCT02040142|Experimental|HIPEC + Mitomycin C|HIPEC + 40mg of Mitomycin C. Mitomycin C, 30 mg, will be administered into the inflow line of the perfusion circuit once target temperature is reached. At the 60 minute time point of the perfusion, Mitomycin C, 10 mg, will be administered into the inflow line of the perfusion circuit. Once the 90-minute perfusion period has elapsed, the perfusate will be drained into the waste reservoir. The peritoneal cavity will be rinsed/washed-out.
3323911|NCT02040155|Experimental|Real time dosimetric monitoring of brachytherapy.|
3323912|NCT02040168||28 days - 18 yo|Children requiring mechanical ventilation for at least 24h from 28 days to 18 yo
3323913|NCT02040168||18 months - 18 yo|Post traumatic stress disorder evaluation in children requiring mechanical ventilation for at least 24h from 18 month to 18 Years old
3323914|NCT02040194|Experimental|AM-101 injection|AM-101
3323915|NCT02040194|Placebo Comparator|Placebo injection|Placebo
3323916|NCT02040207|Experimental|AM-101 injection|AM-101 gel for intratympanic injection
3323917|NCT02040220||Group 1|Eylea treatment goup
3323918|NCT02040233|Active Comparator|BAY1067197 (10 mg)|
3323919|NCT02040233|Active Comparator|BAY1067197|
3323920|NCT02040233|Placebo Comparator|Placebo (10 mg)|
3323921|NCT02040233|Placebo Comparator|Placebo|
3323922|NCT02040246|Experimental|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
3323923|NCT02040246|Active Comparator|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
3323924|NCT02040272|Experimental|Surgery|(Extended) pleurectomy decortication
3323925|NCT02040272|No Intervention|no surgery|no surgery
3323926|NCT02040285|Active Comparator|Free laxative CTC|
3323927|NCT02040285|Experimental|Low-dose laxative bowel preparation for CTC|
3323928|NCT02040311|Experimental|Topiramate 96 mg daily|
3323929|NCT02040311|Experimental|Topiramate 192 mg daily|
3323930|NCT02040311|Placebo Comparator|placebo|
3323931|NCT02040324|Active Comparator|Endotracheal Intubation|Clinical routine for longer lasting procedures
3259120|NCT01467687|Active Comparator|1|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
3323932|NCT02040324|Experimental|Laryngeal Mask|Laryngeal mask with gastric access and drainage as airway management instead of endotracheal intubation
3323933|NCT02040350|Placebo Comparator|Placebo|Placebo was given to compare the effects
3323934|NCT02040350|Active Comparator|Pralidoxime|Pralidoxime for treating organophosphorous poisoning patients
3323935|NCT02040363|Active Comparator|COPD Patients ~90% VO2max|COPD Patients ~90% VO2max
3323936|NCT02040363|Active Comparator|COPD patients ~60-65% VO2max|COPD patients ~60-65% VO2max
3323937|NCT02040363|Placebo Comparator|healthy volunteers|healthy volunteers
3323938|NCT02040376|Experimental|Group A (Crossover Group 1)|Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo.
3323939|NCT02040376|Experimental|Group B (Crossover Group 2)|Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin.
3323940|NCT02040389|Active Comparator|pictures book + standard education|arm with children undergoing urological procedures and their parents will receive standard preoperative education + pictures book with pictures of surgical wound in different stages of healing
3323941|NCT02040389|Active Comparator|Standard preoperative education|Arm with children undergoing urological procedures and their parents will receive only standard preoperative education
3323942|NCT02040402|Active Comparator|4-Dose Regimen|"3+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 3+1 schedule will be administrated one dose of PCV7 at the age of 2 months old, 4months old and 6 months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
3323943|NCT02040402|Active Comparator|3-Dose Regimen|"2+1 schedule of 7-valent pneumococcal conjugated vaccine:~Infants who are randomized for 2+1 schedule will be administrated with one dose of PCV7 at the age of 2 months old and 4months old. A booster dose will be administrated at the age of 12 months old.~Infants will be followed up for 12-16 months starting from vaccination of first dose. There is no restriction on the use of other medications before or during the follow-up period."
3323944|NCT02040415|Experimental|DW-1030(eperisone HCl)|DW-1030(eperisone HCl) 75mg BID
3323945|NCT02040415|Active Comparator|Myonal Tab.(eperisone HCl)|Myonal Tab.(eperisone HCl) 50mg TID
3323946|NCT02040441|Active Comparator|Spironolactone|High-risk pattern: Spironolactone 25 mg once daily + Standard care
3323947|NCT02040441|Placebo Comparator|Placebo|High-risk pattern: One placebo tablet once daily + Standard care
3323948|NCT02040441|Other|Observational|Low-risk pattern: Standard care
3323949|NCT02040454|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard Therapy - heparin, angioplasty, stent~Paclitaxel - single intravascular dose up to 20 mg"
3323950|NCT02040454|Sham Comparator|Standard Therapy Alone|heparin, angioplasty, stent
3323951|NCT02040480|Experimental|Sequence 1|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
3323952|NCT02040480|Experimental|Sequence 2|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
3323953|NCT02040480|Experimental|Sequence 3|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
3323954|NCT02040480|Experimental|Sequence 4|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
3323955|NCT02040480|Experimental|Sequence 5|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
3323956|NCT02040480|Experimental|Sequence 6|Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
3323957|NCT02040493|Experimental|Intra-operative radiation therapy (IORT)|IORT
3323958|NCT02040506|Experimental|IGN523|IGN523
3323959|NCT02040519|Experimental|Evaluation by voiding diaries|
3323960|NCT02040545||Infertility|Patients undergoing ovulation induction and controlled ovarian hyperstimulation at a participating infertility center
3323961|NCT02040558|Experimental|MNK-010|Subjects will receive 1 dose of MNK-010 followed by a 7-day post dose assessment period per treatment cycle. Dose levels will be based upon the amount of active delivered per square meter of body surface area (mg/m2). Cycles will repeat every 3 weeks (21 days) based on toxicity and response, as determined by a Safety Review Committee (SRC). Subjects will continue treatment with MNK-010 until unacceptable toxicity, documented progression of disease, another criterion for discontinuation is met, or until 4 treatment cycles have been completed.
3229640|NCT01183494|Experimental|UGT1A1*1/*1|Participants with UGT1A1*/*1 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
3323962|NCT02040571|Experimental|Closed Loop|
3323963|NCT02040571|Active Comparator|Open Loop|
3323964|NCT02040584|Experimental|Minimisation of TAC|Treatment with rTAC+EVR+corticosteroids
3323965|NCT02040584|Active Comparator|TAC + MMF + corticosteroids|Treatment with TAC + MMF + corticosteroids
3323966|NCT02040597|Experimental|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations
3323967|NCT02040610|Active Comparator|Low Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
3323968|NCT02040610|Active Comparator|Intermediate Risk Prostate Cancer|Hypofractionated Proton Therapy 62 Gy (RBE) in 20 fractions of 3.1 Gy (RBE) over 4 weeks
3229641|NCT01183494|Experimental|UGT1A1*1/*28|Participants with UGT1A1*1/*28 genotype will receive escalating doses of FOLFIRI (folinic acid+fluorouracil+irinotecan) and bevacizumab. The initial dose of irinotecan will be 260 mg/m2 administered as a 120 min intravenous infusion every two weeks. The dosage of irinotecan will be increased to 310, 370, and 420 mg/m2, and further irinotecan doses will be increased by 14%. 5-FU will be administered as a 400 mg/m2 bolus right after the end of the irinotecan infusion, followed by 2,400 mg/m2 over a 46 h continuous infusion plus LV 200 mg/m2 every two weeks. Bevacizumab will be administered at a dose of 5 mg/kg over 15-30 min IV (after an initial 90 min infusion without a reaction) every two weeks. The first dose will be administrated on day 2 (48 hours after the first irinotecan administration), while the second dose on day 14 (the same day as the second irinotecan administration). No dose escalation will be performed for 5-FU, LV or bevacizumab.
3229642|NCT01183507|Active Comparator|NIA intervention|
3229643|NCT01183507|Experimental|TSE intervention|
3229644|NCT01183520|Active Comparator|90 grams of Salmon|Subjects will consume 90 grams of salmon twice a week for 4 weeks
3229645|NCT01183520|Active Comparator|180 grams of salmon|Subjects will consume 180 grams of salmon twice a week for 4 weeks
3229646|NCT01183520|Active Comparator|270 Grams of Salmon|Subjects will consume 270 grams of salmon twice a week for 4 weeks
3323969|NCT02040636|Experimental|Study Group 1|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) at month 0, Hepatitis B at months 1, 2 and 7.
3323970|NCT02040636|Active Comparator|Study Group 2|Participants randomized to receive Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) + Hepatitis B at month 0, Hepatitis B at months 1 and 6.
3323971|NCT02040649|Experimental|Non-sedation|Non-sedation supplemented with pain management during mechanical ventilation.
3323972|NCT02040649|Active Comparator|Sedation|Current gold standard: Sedation with a daily wake-up trial.
3323973|NCT02040662|Experimental|Continuous Thoracic Paravertebral Block|"continuous thoracic paravertebral blockade 0,08 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
3323974|NCT02040662|Experimental|Continuous Thoracic Epidural Analgesia|"continuous thoracic epidural block 0,06 ml/kg/h with bupivacaine 0,25% + epinephrine 1:200.000~patient-controlled analgesia (morphine), bolus dose 2 mg, lockout time 10 min"
3323975|NCT02040688||Sleep Disorders|7-36 months old children with behavioral insomnia of childhood based on the International Classification of Sleep Disorders (ICSD) criteria will be recruited from the Pediatric Sleep Center at Dana Children's hospital
3323976|NCT02040688||Control|7-36 months old chidren of age who attend well-care clinics in the metropolitan of Tel Aviv for routine periodic medical examination.
3323977|NCT02040688||Feeding disorder|7-36 monthsold children with feeding disorders based on Chatoor criteria will be recruited from the clinic of feeding disorders at Dana Children's Hospital.
3323978|NCT02040701||SDB group|
3229647|NCT01183572|Active Comparator|Folic Acid and Iron|0.4mg of folic acid and 30 mg elemental iron taken daily for 6 months
3323979|NCT02040701||Control group|
3323980|NCT02040714||Nonoperative management between ages 6-8 in early stage|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3229648|NCT01183572|Placebo Comparator|Folic Acid|0.4mg of folic acid taken daily for 6 months
3323981|NCT02040714||Operative management between age 6-8 in early stage|Operative containment treatment (femoral or pelvic osteotomy or Shelf acetabuloplasty) rendered in the early stage of the disease process
3323982|NCT02040714||Nonoperative management between age 8-11 in early stage|Patients who do not undergo some form of containment surgery because of medical, social, or other reasons will receive no surgical treatment.
3323983|NCT02040714||Operative containment with short-term non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11 in developed countries, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 weeks of non-weight bearing on the operated leg."
3323984|NCT02040714||Operative containment with prolonged non-weightbearing in early stage|"As per the current standard practice for patients between age 8-11, all patients will undergo some form of containment surgery (pelvic or femoral osteotomy) in order to better contain the femoral head underneath the acetabulum. Post-operative treatment will include 6 months of non-weight bearing on the operated leg."
3323985|NCT02040714||Operative containment for over 11 age group|Patients presenting over age 11 may receive multiple drilling and be non weight bearing for up to 6 months according to the treating physician's preference. Patients with application of fixator (arthrodiastasis) will be studied in this cohort arm as well, which typically involved 3-4 months followed by 8-12 weeks of non-weight bearing after fixator removal. Other surgical techniques may be included, however these are the most common for this age group.
3323986|NCT02040714||Nonoperative management in over 11 age group|Patients will be non-weight bearing and receive physical therapy according to the physician preferences.
3229649|NCT01183572|Active Comparator|Multivitamins, Folic Acid, and Iron|A multivitamin and micronutrient supplement that constitutes 1 RDA of Vitamins A (2500 IU), B1 (1.4 mg), B2 (1.4 mg), B6 (1.9 mg), B12 (2.6 ug), niacin (18 mg), C (70 mg), E (10 mg), and folic acid (0.4 mg)along with 30 mg of elemental iron taken daily for 6 months.
3229650|NCT01183585|Experimental|1|
3323987|NCT02040714||Nonoperative management in 1-6 age group|The choice of non-osteotomy management without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3323988|NCT02040714||Operative management in 1-6 age group|The choice of osteotomy management with containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3323989|NCT02040714||Late Stage Bracing group|Patients presenting with <= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3323990|NCT02040714||Late Stage Symptomatic treatment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated symptomatically. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3323991|NCT02040714||Late Stage Surgical Containment group|Patients presenting in the late stages of the disease (defined as Waldenstrom stage IIb or IIIa) who are treated with surgical containment. The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
3323992|NCT02040727|Active Comparator|Non-Resistance Trained|No Participation in Resistance Training
3323993|NCT02040727|Experimental|Resistance Trained|Participation in Resistance Training
3323994|NCT02040740||Observation|Healthy early pubertal boys
3323995|NCT02040753||Intensive Lifestyle Intervention|Former participants of intensive lifestyle intervention at Ubberup Folk High School.
3323996|NCT02040818|Experimental|Antibiotic Lock Solution|
3323997|NCT02040818|Active Comparator|Guide-wire Exchange|
3323998|NCT02040831|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
3323999|NCT02040831|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
3324000|NCT02040883|Active Comparator|Control Group|Treated with a stable dose of an AAPD for at least three months before enrollment; Atypical antipsychotic drugs(AAPDs): Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole
3324001|NCT02040883|Experimental|Study Group|Atypical antipsychotic drugs(AAPDs) and Tandospirone ; Atypical antipsychotic drugs(AAPDs) ,treated with a stable dose of an AAPD for at least three months before enrollment; AAPD: Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole; Tandospirone, 30mg per day;
3324002|NCT02040896||Group 1|All consecutive emergency department patients undergoing CT during study hours will be prospectively enrolled, except for those meeting pre-specified exclusion criteria.
3324003|NCT02040909|Experimental|Propofol|A predetermined propofol dose is used in every 5 consecutive patients per age group. Starting dose is 1.0 mg/kg. Dose is increased or decreased with 0.5 mg/kg
3324004|NCT02040922||Post-Campylobacter|Adults with symptoms of intestinal infection who submit a stool sample from which Campylobacter jejuni or coli is cultured
3324005|NCT02040935|Experimental|Trastuzumab|Participants will receive 600 milligrams (mg) trastuzumab SC by SID every 3 weeks (Q3W) for up to a total of 1 year, unless disease recurrence, unacceptable toxicity or participant withdrawal occurs. The first 3 administrations will be done at hospital, after that participants will be permitted to self-administer under the supervision of a healthcare professional (HCP).
3324006|NCT02040948|Experimental|Surgical patients|"Nexfin (Pulse Pressure Variation)~Radical 7 (Pleth Variability Index)~CardioQ (stroke volume)"
3324007|NCT02040961|Experimental|EtView|Use of ETVew double-lumen tube
3324008|NCT02040987|Experimental|AZD3293 dose A|AZD3293 therapeutic dose oral solution (low dose)
3324009|NCT02040987|Experimental|AZD3293 dose B|AZD3293 supratherapeutic dose oral solution (high dose)
3324010|NCT02040987|Placebo Comparator|Placebo|Placebo oral solution
3324011|NCT02040987|Active Comparator|Moxifloxacin|Moxifloxacin tablet
3324012|NCT02041013|No Intervention|No Talking Card|Usual care of asthma by study clinician, including evaluation of asthma using C-ACT and clinical history, treatment using asthma action planning
3324013|NCT02041013|Experimental|Taking Card|Usual care, as in comparison group, plus recordable Talking Card at each visit
3229651|NCT01183598|Experimental|Single Arm|
3324014|NCT02041026|Experimental|probiotic yoghurt|the subject will be given 200ml of yogurt daily for 28 days
3324015|NCT02041039||normal weight|non-smoking, right handed women age 18-40 years BMI between 18-25 kg/m2
3324016|NCT02041039||overweight/obese|non-smoking, right-handed women age 18-40 year BMI 30-50 kg/m2 (maximum weight 350 pounds, shoulder width no greater than 23/5 inches)
3324017|NCT02041052|Active Comparator|Conventional Whipple procedure|Conventional Whipple procedure
3229652|NCT01183611|Experimental|A1|health neonates born to mother with positive for both HBsAg and e antigen
3229653|NCT01183611|Active Comparator|A2|health neonates born to mother with positive for both HBsAg and e antigen
3229654|NCT01183611|Experimental|B1|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
3229655|NCT01183611|Active Comparator|B2|health neonates born to a mother positive for HBsAg, negative for the hepatitis B e antigen
3229656|NCT01183611|Experimental|C1|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3229657|NCT01183611|Active Comparator|C2|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3229658|NCT01183611|Placebo Comparator|C3|health neonates born to mother with negative for the HBsAg and HBeAg and HBeAb and HBcAb
3229659|NCT01183624|Experimental|Experimental Patch|Herbal Patch
3229660|NCT01183624|Placebo Comparator|Control Patch|Placebo Patch
3324018|NCT02041052|Experimental|Subtotal gastrectomy added to whipple procedure.|Subtotal gastrectomy added to Whipple procedure.
3324019|NCT02041065|Experimental|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
3324020|NCT02041065|Active Comparator|CUSA induced dissection|CUSA transection of the liver. Ultrasound based destruction of the liver parenchyma to allow separate ligation of the bile duct and intrahepatic vessels.
3324021|NCT02041078|Placebo Comparator|Extrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA.
3324022|NCT02041078|Experimental|Intrahepatic vein division|Conventional right sided hemihepatectomy with division of the liver parenchyma with CUSA and intrahepatic division of the right hepatic vein.
3324023|NCT02041117|Other|Rosuvastatin|
3324024|NCT02041130|Experimental|Renal Denervation and standard medical management|"Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.~A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes."
3324025|NCT02041130|No Intervention|Contorl and Standard Medical Management|Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
3324026|NCT02041143|Experimental|Milk protein|Study product will provide 25 g of protein to subjects. One single supplement will be taken.
3324027|NCT02041143|Placebo Comparator|Placebo|Placebo (no protein)
3324028|NCT02041156|Experimental|aerobic with resistance training|Regular aerobic activity combined with 3 sessions/week of resistance training totalling 150 minutes per week of physical activity
3324029|NCT02041156|Active Comparator|aerobic with balance training|Regular aerobic activity combined with 3 sessions/week of balance training totalling 150 minutes per week of physical activity
3324030|NCT02041169|Experimental|Subsequent walking performance|Subsequent walking performance
3324031|NCT02041182|Experimental|Intervention Pre-visit Questionnaire|Adolescents receive PVQ that includes questions about youth violence/bullying
3324032|NCT02041182|Active Comparator|Control Pre-visit Questionnaire|Adolescents received PVQ without youth violence/bullying items
3324033|NCT02041195|Active Comparator|RM-493 Once Daily|Once daily in the morning, equivalent PBO in evening.
3324034|NCT02041195|Active Comparator|RM-493 Split Dose|Split dose, one half in the morning and one half in the evening.
3324035|NCT02041195|Placebo Comparator|Placebo|Placebo in the morning, placebo in the evening.
3324036|NCT02041234|Active Comparator|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
3324037|NCT02041234|Active Comparator|Best Medical Treatment|"Anti-diabetic medications provided (Mono- or Combination- therapy):~Incretin analogues: Liraglutide up to 3 mg daily Or DPP-4 Inhibitors: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily Xenical: Up to 120 mg tds SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily Participants will also take lipids & BP medications according to standard of care."
3324038|NCT02041247|Active Comparator|VAC-3S 16µg/administration|VAC-3S 16µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3324039|NCT02041247|Placebo Comparator|VAC-3S Placebo|VAC-3S placebo administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3324040|NCT02041247|Active Comparator|VAC-3S 32 µg/administration|VAC-3S 32µg/ml administered every 4 weeks for 3 months followed by 3 maintenance vaccinations every 12 weeks after the third initial vaccination.
3229661|NCT01183637|Experimental|Treatment|Patients assigned to the treatment arm will receive treatment with the Kensey Nash Corp. Cartilage Repair Device.
3229662|NCT01183637|Active Comparator|Control|Patients assigned to the Control Arm will receive treatment with the standard surgical technique known as microfracture.
3229663|NCT01183663|Experimental|Lenalidomide + Bevacizumab|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Bevacizumab starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
3229664|NCT01183663|Experimental|Lenalidomide + Sorafenib|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Sorafenib starting dose: 200 mg by mouth daily for 28 a day cycle.
3324041|NCT02041247|Active Comparator|VAC-3S 64 µg/administration|VAC-3S 64µg/ml administered every 4 weeks for 3 months without maintenance vaccination.
3324042|NCT02041260|Experimental|Open Label Cabozantimib|
3324043|NCT02041273|Experimental|Palbociclib given to healthy volunteers|
3229665|NCT01183663|Experimental|Lenalidomide + Temsirolimus|Lenalidomide starting dose: 10 mg by mouth daily for 21 days of a 28 day cycle. Temsirolimus starting dose: 15 mg by vein every week for a 28 day cycle.
3229666|NCT01183663|Experimental|Lenalidomide + Oxaliplatin + Leucovorin + 5-fluorouracil|Lenalidomide starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle. Oxaliplatin starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle. Leucovorin 400 mg/m2 by vein on day 1 of a 21 day cycle. 5-fluorouracil 400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
3229667|NCT01183676|Experimental|Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG - Mylan Pharmaceuticals Inc
3324044|NCT02041312||Gastric cancer|No intervention
3324045|NCT02041338|Experimental|Luminal subtype test|Paclitaxel 175mg/m2, every 2 weeks as a cycle for 4-6 cycles
3324046|NCT02041338|Active Comparator|Luminal subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
3324047|NCT02041338|Experimental|Her2 positive subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 with or without trastuzumab every 2 weeks as a cycle for 4-6 cycles
3229668|NCT01183676|Active Comparator|Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
3229669|NCT01183702|Active Comparator|non-LASIK|These participants have NOT had LASIK surgery.
3229670|NCT01183702|Active Comparator|LASIK|These participants have had LASIK surgery.
3229671|NCT01183715|Experimental|Cohort 1|Subjects in Cohort 1 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-05161704 will be administered in Period 4 in the fasted state.
3229672|NCT01183715|Experimental|Cohort 2|Subjects in Cohort 2 will receive 2 single doses of PF-05161704 and 1 placebo dose in random order in Periods 1-3
3229673|NCT01183754||patients receiving drug-eluting stents|
3229674|NCT01183767|Active Comparator|EGCG|Epigallocatechin-Gallate (EGCG)
3229675|NCT01183767|Placebo Comparator|Placebo|
3324048|NCT02041338|Active Comparator|Her2 positive subtype control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 with or without trastuzumab every 3 weeks as a cycle for 4-6 cycles
3229676|NCT01183793|Other|Bras pair|MR-enterography then barium follow through
3229677|NCT01183793|Other|Bras impair|Barium follow-through then MR-enterography
3229678|NCT01183806|Experimental|Rivastigmine and exercise program|Experimental group: Rivastigmine and exercise program: All patients will monthly receive Rivastigmine (Exelon patch). The exercise training program consists of two 40-minute sessions per week for six months and includes aerobic, strength, flexibility and balance training
3324049|NCT02041338|Experimental|Triple negative subtype test|Paclitaxel 175mg/m2 plus carboplatin AUC 4 every 2 weeks as a cycle for 4-6 cycles
3324050|NCT02041338|Active Comparator|Triple negative subypte control|Epirubicin 75mg/m2 plus paclitaxel 175mg/m2 every 3 weeks as a cycle for 4-6 cycles
3324051|NCT02041351|Experimental|docetaxel|measurement evaluation every 2 months tomography of all measurable lesions in millimeters, to assess response rate, partial and complete responses.
3324052|NCT02041364||Control: patients without fatigue|Patients whose scores on the brief fatigue inventory (BFI) (15) won't increase after having received the first cycle of chemotherapy will be considered as controls
3324053|NCT02041364||Patients with fatighe|Patients whose scores on the brief fatigue inventory (BFI) (15) increase after having received the first cycle of chemotherapy will be considered as having manifested fatigue
3324054|NCT02041390|Experimental|SMS group|Patients in SMS group will receive reminding by additional SMS messages monthly after stent implantation.
3324055|NCT02041390|Active Comparator|Conventional reminder group|Patients in control group will not receive additional SMS reminder monthly after stent implantation.
3324056|NCT02041403||Renal resistive Index|
3324057|NCT02041416||Group 1|REDCap and paper pencil
3324058|NCT02041416||Group 2|REDCap twice
3324059|NCT02041416||Group 3|Support Screen and paper pencil
3324060|NCT02041416||Group 4|Support Screen twice
3324061|NCT02041442|Experimental|All subjects|Electrical mapping of the urinary bladder
3324062|NCT02041455|Experimental|Melatonin and Placebo|Melatonin 10mg and placebo, once in the evening, for 6 weeks.
3324063|NCT02041455|Experimental|Amitriptyline and placebo|Amitriptyline 25mg and placebo, once in the evening, for 6 weeks.
3324064|NCT02041455|Active Comparator|Melatonin and Amitriptylin|Melatonin 10mg and Amitriptylin 25mg, once in the evening, for 6 weeks.
3324065|NCT02041468||Pharmacoeconomic main study|Patients from Quebec and Ontario (first or second line treatment)
3324066|NCT02041468||Biomarker sub-study|Patients from Quebec only (first or second line treatment)
3324067|NCT02041481|Experimental|Arm I (continuous MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-14, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3229679|NCT01183806|Active Comparator|Rivastigmine|Control group : Rivastigmine All patients will monthly receive Rivastigmine (Exelon patch)
3324068|NCT02041481|Experimental|Arm II (intermittent MEK inhibitor MEK162, FOLFOX)|Patients receive MEK inhibitor MEK162 PO BID on days 1-5, and leucovorin calcium IV over 2 hours, oxaliplatin IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 6 and 7. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3324069|NCT02041507|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3229680|NCT01183819|Experimental|Space Fortress and Exercise|Participants engage in aerobic exercise 4 times week and Space Fortress sessions 3 times a week for a total of 12 weeks.
3229681|NCT01183819|Active Comparator|Control Games and Exercise|Participants engage in aerobic exercise 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
3324070|NCT02041507|Experimental|Water Immersion method.|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using air insufflation.
3324071|NCT02041507|Experimental|Water Exchange method.|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using air insufflation.
3324072|NCT02041546|Active Comparator|Bolus surfactant|Bolus surfactant 100 mg/kg proctant alfa
3324073|NCT02041546|Active Comparator|Lung lavage with surfactant|Lung lavage with surfactant
3324074|NCT02041559||robot assisted prostatectomy|robot assisted prostatectomy
3229682|NCT01183819|Active Comparator|Control Games and Stretching|Participants engage in stretching/toning exercises 4 times a week and control game sessions 3 times a week for a total of 12 weeks.
3229683|NCT01183832||Concomitant|In this group, anastrazole is concomitant to the radiotherapy
3324075|NCT02041572|Other|Attentional Bias Retraining|Each participant receives 12 sessions. The first three sessions are baseline (assessment only) sessions. The last four sessions must be treatment sessions. The attentional bias intervention starts randomly on sessions 4 - 8, and continues until the end of the 12 sessions.
3324076|NCT02041585||Elder discharge cohort|There will be no intervention in this observational survey research.
3324077|NCT02041598|Experimental|Full CHW Intervention|5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
3324078|NCT02041598|No Intervention|Control: Intro to Diabetes Session Only|One-time, Introduction to Diabetes educational session only
3324079|NCT02041611|Other|Standard Care Pts Eval of T-Cell Immune Status|Pts undergoing standard radiation/TMZ and adjuvant TMZ will have blood collections at 6 different time points throughtout their treatment to evaluate T Cell changes
3324080|NCT02041624||allergic rhino-conjunctivitis|Patient with proven allergic rhino-conjunctivitis due to grass pollen
3229684|NCT01183832||Sequential|In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
3229685|NCT01183845|Experimental|Exam with colon capsule|Colon Capsule Endoscopy
3324081|NCT02041650|Other|Patients with ACS treated medically|
3324082|NCT02041663|Experimental|Population|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
3229686|NCT01183871|Active Comparator|good pulmonary functions (group 1)|FVC and/or FEV1 of 80% of predicted or more
3229687|NCT01183871|Active Comparator|mild pulmonary dysfunction (group 2)|FVC and/or FEV1 of 70%-79% of predicted
3324083|NCT02041676|Experimental|1: chest physiotherapy technique|Chest physiotherapy technique increasing inspiratory flow (IIF) 3 times per day
3324084|NCT02041676|Active Comparator|2: Usual surveillance|Usual surveillance of the non invasive ventilation
3324085|NCT02041689||Participants|"Patients at St. Jude Children's Research Hospital between the ages of 7 and 11 years who have a working diagnosis or initial diagnosis of a bone or soft tissue sarcoma.~Interventions: two unstructured life-story interview sessions, observations, and guided activities."
3229688|NCT01183871|Active Comparator|moderate pulmonary dysfunction (group 3)|FVC and/or FEV1 of 60%-69% of predicted
3229689|NCT01183871|Active Comparator|severe pulmonary dysfunction (group 4)|FVC and/or FEV1 of 50%-59% of predicted
3229690|NCT01183910|Placebo Comparator|Calcium carbonate placebo pill|Placebo medication to treat the appearance of the skin in patients with senile purpura
3229691|NCT01183910|Active Comparator|Nutraceutical|Patients take a novel, natural nutraceutical product to improve the appearance of the skin of patients with senile purpura
3229692|NCT01183936|Active Comparator|2 cm margin of excision|Patients with CMM >2 mm treated with an excision of 2-cm.
3229693|NCT01183936|Active Comparator|4 cm margin of excision|Patients with CMM >2 mm treated with an excision of 4-cm.
3229694|NCT01183949|Experimental|Treatment|Patients will be enrolled into 3 groups which will run sequentially. Groups A and B will receive AT7519M only, whereas Group C will receive AT7519M in combination with Bortezomib.
3324086|NCT02041715|Experimental|TKM-100802 for Injection|
3324087|NCT02041715|Placebo Comparator|Placebo|
3324088|NCT02041741|Active Comparator|Weekly tips|Daily small and concrete happiness tips
3324089|NCT02041741|Active Comparator|Daily Tips|Weekly more in-depth happiness tips involving an active (doing and experiencing) task
3324090|NCT02041741|No Intervention|Wait-List Control|No intervention
3229695|NCT01183962|Other|Vitamin D|Subject receives daily dose of Vitamin D
3229696|NCT01183962|Other|No medicine|Subject does not receive medication
3324091|NCT02041754|Active Comparator|IQP-AK-102|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
3229697|NCT01184001|Experimental|Sequence 1|
3229698|NCT01184001|Experimental|Sequence 2|
3229699|NCT01184027||G-tube/swallowing intervention|patients will receive G-tube/nutritional and swallowing intervention. As per patient needs
3324092|NCT02041754|Placebo Comparator|Placebo|2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water
3324093|NCT02041767|Experimental|group A|One single perfusion of 1g of ertapenem 1 hour prior to prostate surgical resection
3324094|NCT02041767|Experimental|group B|One single perfusion of 1g of ertapenem 12 hour prior to prostate surgical resection
3324095|NCT02041780|Experimental|Shearwave electrography|"Two experimental interventions will be realized in each patient in this population : Shearwave electrography (new diagnostic test of fibrosis) and Fibrotest .~Moreover, liver biopsies, the gold standard for the fibrosis diagnosis is also realized in each patient within usual cares."
3324096|NCT02041793|Active Comparator|Laparoscopic cystogastrostomy|Laparoscopic cystogastrostomy will be performed by using a stapled cystogastrostomy
3324097|NCT02041793|Active Comparator|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance.
3324098|NCT02041819|Experimental|Nimotuzumab nab-paclitaxel cisplatin|"Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22.~Nab-paclitaxel: 125mg/m2,IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
3324099|NCT02041832|Other|Holter monitoring|Screening of patients with older age, arterial hypertension and diabetes for paroxysmal atrial fibrillation by using conventional Holter monitoring
3324100|NCT02041832|Other|Implantable loop recorder|Screening of patients with older age, arterial hypertension and diabetes mellitus for paroxysmal atrial fibrillation by using an implantable loop recorder
3324101|NCT02041845|Active Comparator|A|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
3324102|NCT02041845|Experimental|B|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week
3229700|NCT01184027||G-tube/swallowing counseling|G-tube/ad lib dietary and swallowing counseling. Current standard of care.
3229701|NCT01184027||nutrition/swallowing intervention|Patients will receive active nutrition and swallowing intervention based on patients caloric and swallowing needs.
3229702|NCT01184027||nutrition/swallowing counseling|Patients will have ad lib dietary intake with general nutrition and swallowing counseling.
3229703|NCT01184040|No Intervention|(A) Non-contingent control|Participants assigned to the control condition will be told to wear the pedometer daily and select a twice-weekly meeting schedule with research staff for 12 weeks (study weeks 4-15). On days randomly selected as meeting days, participants will be asked to bring in their pedometers. Participants who attend their scheduled meetings will receive a $5 gift card just for attending and bringing the pedometer, so long as it has registered steps walked in at least the past 4 days. They will be congratulated if they walked 10,000 steps or more on the prior 4 days, and encouraged to walk 10,000 steps or more per day on subsequent days.
3229704|NCT01184040|Experimental|VIP CM|Participants assigned to Increasing Variable Interval Prize (VIP) Reinforcement group will be scheduled for the same study visits as those in the Control group, but will also earn chances to win prizes if they have walked more than 10,000 steps in the past 4 days.
3229705|NCT01184066|Experimental|ACTS Intervention|The intervention arm are the women who received the ACTS Intervention. It is a 45 minute intervention provided by a breast cancer survivor. The intervention includes a discussion of the patient's attitudes towards chemotherapy, communication strategies with providers, the recommended treatment in accordance with tumor size and tumor characteristics
3229706|NCT01184066|Active Comparator|Usual Care|This group receives care as usual.
3229707|NCT01184092|Experimental|Sequence 1|
3229708|NCT01184092|Experimental|Sequence 2|
3229709|NCT01184092|Experimental|Sequence 3|
3229710|NCT01184092|Experimental|Sequence 4|
3324103|NCT02041858|No Intervention|Control|Control arm with organizational-based alarm parameter settings
3324104|NCT02041858|Experimental|Altered Alarm Settings|Altered set of alarm parameter settings.
3324105|NCT02041871|Experimental|Impact control|ORAL IMPACT Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
3324106|NCT02041871|Placebo Comparator|Placebo|Placebo
3324107|NCT02041884|Experimental|iCBT|A skill training internet-based treatment program based on CBT and DBT interventions .
3324108|NCT02041884|Active Comparator|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
3324109|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
3324110|NCT02041897|Other|EUS-FNA, Rate of chang on diagnosis|It is a single arm study. We will conclude by calculating the rate of change of diagnosis before and after getting the results of EUS-FNA.
3324111|NCT02041910|Experimental|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
3324112|NCT02041910|Experimental|Stem Cells Injection|Stem Cell Dose 3-5 Million Autologous MSCs Injected into testis.
3324113|NCT02041936|Experimental|NanoKnife IRE System|
3324114|NCT02041975|Experimental|Prebiotic|Nutriose FB06 14g/day
3324115|NCT02041975|Placebo Comparator|Placebo|Maltodextrin
3324116|NCT02041988||0,2 mg/kg oral morphine|Patients have been assigned to two groups of 20 individuals, they have been premedicated with oral morphine sulfate, 0,2 mg/kg group A, 0,4mg/kg group B.During surgery analgesic administration will be monitored
3324117|NCT02041988||0,4 mg/ kg oral morphine|morphine and analgesic consumption throughout surgery will be monitored
3324118|NCT02042001|Experimental|Immediate Switch|Immediate switch to TDF/FTC/RPV
3324119|NCT02042001|Active Comparator|Deferred Switch|Switch to TDF/FTC/RPV after 24 weeks
3324120|NCT02042027|Active Comparator|Group A|Gamunex-C 50 mg subconjunctival injections, in addition to standard of care treatment (steroids and cyclosporine). One dose of Gamunex-C injection delivered four weeks prior to corneal transplant surgery and one dose at the time of corneal transplantation. Dose to be repeated if recurrence of corneal neovascularization
3324121|NCT02042027|Active Comparator|Group B|Gamunex-C 50 mg subconjunctival injections, one dose injected for patients with active disease from corneal melts (peripheral ulcerative keratitis; Mooren's ulcer), ocular cicatricial pemphigoid, or anterior uveitis refractory to conventional therapy.
3324122|NCT02042053|Experimental|PET/MR|Patients treated with SipT (standard of care) undergo FDG-PET/MRI, NaF-PET/CT and blood drawing at 3 time points: baseline, Day 7 after the last SipT infusion, Week 10 after the last SipT infusion.
3324123|NCT02042066|Experimental|Treated Group|This group will receive actual shockwave treatment
3229711|NCT01184092|Experimental|Sequence 5|
3229712|NCT01184092|Experimental|Sequence 6|
3229713|NCT01184105|Experimental|Cohort 1 (pre)|Active treatment or placebo
3229714|NCT01184105|Experimental|Cohort 2 (post)|Active treatment or placebo
3229715|NCT01184131|Experimental|Mentor Training|The group that is randomized into the intervention group to attend Mentor Training Sessions.
3229716|NCT01184131|No Intervention|No Mentor Training|
3229717|NCT01184144|Experimental|pioglitazone|Pioglitazone study drug
3229718|NCT01184144|No Intervention|No drug|"Placebo like comparitor"
3229719|NCT01184157|Experimental|Home|Home-based STI screening using self-obtained vaginal swabs and postal return of samples.
3324124|NCT02042079|Experimental|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
3324125|NCT02042092|Active Comparator|Color Doppler Ultrasound (CDUS)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by color Doppler ultrasound
3324126|NCT02042092|Active Comparator|Magnetic resonance angiography (MRA)|The aorta, supraaortic large vessels and the temporal arteries of the sLVV patients will be evaluated by Magnetic resonance angiography
3324127|NCT02042118|Experimental|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
3229720|NCT01184157|Active Comparator|Clinic|Receive STI screening in a clinical setting such as a private physician or clinic.
3229721|NCT01184170|Experimental|Metabolically Normal|"Subjects in this group are metabolically normal. They have low liver fat defined as less than five percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
3324128|NCT02042118|Active Comparator|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
3229722|NCT01184170|Experimental|Metabolically Abnormal|"Subjects in this group are metabolically abnormal. They have high liver fat defined as at least ten percent as determined by magnetic resonance spectroscopy.~Intervention: Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits."
3229723|NCT01184183||Accuseal patch|
3229724|NCT01184183||Bovine Pericardial patch|
3229725|NCT01184196|Active Comparator|Arm 1|Subjects randomized to Arm 1 will receive Betadine surgical scrub at the time of primary total knee arthroplasty.
3324129|NCT02042144||Group 1|
3324130|NCT02042157|Experimental|Bidet use|This arm will have a bidet installed in their home bathroom and be instructed how to use it. This arm will use the bidet for usual toileting for a period of two years.
3324131|NCT02042157|Placebo Comparator|Usual Toileting|This group will toilet as usual.
3324132|NCT02042157|Experimental|Caregivers of PT in Arm 1 (bidet use)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to bidet."
3324133|NCT02042157|Placebo Comparator|Caregivers of PT in Arm 2 (usual toileting)|"Participants with functional impairment will be randomized into one of two arms (bidet use or usual toileting). Their caregivers will be enrolled and their randomization is bundled with the study participant who they care for. This arm will care for participants who have been randomized to usual toileting."
3324134|NCT02042170|Experimental|Sr-hGH 0.5 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.5 mg/kg/wk every week himself/herself.
3324135|NCT02042170|Experimental|Sr-hGH 0.7 mg/kg/wk|Patients inject Eutropin plus (Sr-hGH) 0.7 mg/kg/wk every week himself/herself.
3324136|NCT02042170|Active Comparator|Daily hGH 0.37 mg/kg/wk|Patients inject Eutropin (daily hGH) 0.37 mg/kg/wk everyday for the first 6days a week himself/herself.
3324137|NCT02042196|Experimental|Pre or Early perimenopausal 1|"Baseline experiment: Subjects randomized to either 1) KUVAN (10mg/kg body weight) crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: GnRH antagonist with Cetrotide (0.25mg/d) + placebo transdermal patch, then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
3324138|NCT02042196|Experimental|Pre or Early Perimenopausal 2|"Baseline experiment: Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~Hormone modification: Estrogen add-back with Cetrotide + Climara (0.075mg/d), then subjects randomized again to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN"
3229726|NCT01184196|Active Comparator|Arm 2|Subjects in Arm 2 will receive ChloraPrep surgical scrub prior to elective primary total knee arthroplasty.
3229727|NCT01184222|Active Comparator|Arm Active SENGO|The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
3229728|NCT01184222|Placebo Comparator|Arm sham SENGO|The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted.
3229729|NCT01184235||Autism Spectrum Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Autism Spectrum Disorder
3229730|NCT01184235||Attention Deficit Hyperactivity Disorder|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is Attention Deficit Hyperactivity Disorder.
3229731|NCT01184235||Unaffected 1st Degree Relatives|This group will include unaffected, non treated first degree relatives of this study's subjects receiving or anticipating receiving pharmacological intervention.
3324139|NCT02042196|Experimental|Late Perimenopausal and Postmenopausal|"Subjects randomized to either 1) KUVAN crossover to placebo OR 2) placebo crossover to KUVAN~No hormone modification."
3324140|NCT02042222|Active Comparator|Standard Arm|Half of the subjects initiating hydroxyurea will be randomly assigned to the standard treatment arm, consisting of escalation to the maximum tolerated dose (MTD) of hydroxyurea utilizing a previously published algorithm. Hydroxyurea dosing will commence at 20+/-2.5 mg/kg/day, given as a single daily oral dose. All patients will be offered the choice of a liquid formulation of hydroxyurea or hydroxyurea tablets, with the exact dose rounded up or down to the closest practical dose based on the chosen formulation but not differing from the intended dose by more than 2.5 mg/kg. It should take approximately 6 to 12 months for subjects to reach the MTD on this arm.
3324141|NCT02042222|Active Comparator|Alternative Treatment Arm|"Half of the subjects initiating hydroxyurea therapy will be assigned to the alternative treatment arm of the study. In this arm, the predicted hydroxyurea MTD will be calculated for each subject.~As in the dose-escalation arm, the exact dose will be rounded up or down to the closest practical dose based on the chosen formulation of hydroxyurea. Since the most common toxicity associated with hydroxyurea use is excessive myelosuppression, the maximum dose at which a subject in the dose-prediction arm will be started will be 30 mg/kg/day or 2000 mg/day. Patients with a higher predicted MTD will subsequently be escalated to this higher dose after four weeks on therapy if there is no evidence of toxicity."
3324142|NCT02042235|Experimental|Parent-implemented language intervention|In the intervention group, the techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
3324143|NCT02042235|No Intervention|Control group|The control group will benefit from the actual routine care for children with language delay before the age of 3 years. In order to provide them the best routine care, the psychologist will provide some advice to the parents to enhance their child's language (e.g.: using life situations to talk with the child and encourage him/her to talk …).
3324144|NCT02042248|Experimental|Arm A: ART initiated during AHI|Arm A will enroll approximately 6 participants who initiated ART during AHI (acute HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
3229732|NCT01184235||Mood Disorders|This group will include those receiving or anticipating receiving pharmacological intervention whose primary diagnosis is mood disorder.
3324145|NCT02042248|Experimental|Arm B: ART initiated during CHI|Arm B will enroll approximately 6 participants who initiated ART during CHI (chronic HIV infection). The target dose of AGS -004 is delivered in three ID (intradermal) injections of 0.2 mL of AGS-004 (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 is administered every 4 weeks at weeks 0, 4, 8, and 12 for a total of 4 doses.
3229733|NCT01184261|Experimental|Arm I|Patients attend behavioral sessions for smoking and binge drinking cessation over 30 minutes once weekly in weeks 1-6.
3324146|NCT02042287|Experimental|1: Gynofit®|Vaginal lactic acid gel
3324147|NCT02042287|Active Comparator|2: metronidazole|Oral antibiotic
3324148|NCT02042300||IRIS-Xpedition/Alpine/Sierra Cohort|XIENCE Xpedition/Alpine/Sierra
3324149|NCT02042313|Active Comparator|Epidural|Epidural catheters will be applied at the T6-8 level prior to the induction. 6 ml of 2% xylocaine with 1 in 200,000 epinephrine administered before surgery. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be given at a rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.
3324150|NCT02042313|Experimental|combined PVB TAP|"Paravertebral catheterization into the paravertebral region ipsilateral to the VATS incision as described by Murata at the level of T7-8 will be performed. 10 ml of 2% xylocaine with 1 in 200,000 epinephrine to initiate analgesia. During the surgery, 2% xylocaine with 1 in 200,000 epinephrine infusion will be administered at a rate of 2-10 ml/hour adjusted according to patient's blood pressure. After the surgery, 0.125% levobupivacaine with 2.5μg fentanyl and 1 in 400,000 epinephrine will be administered at the rate of 0.10-0.15 ml kg-1 h-1 (0.5 h lock and 2 ml bolus) through a patient-controlled infusion pump.~Ultrasound-guided (USG) subcostal TAP block will be performed at the end of surgery. Fifteen milliliters of 0.5% levobupivacaine with 1 in 400,000 epinephrine will be injected in incremental doses on each side of the abdomen."
3324151|NCT02042326|Experimental|Sirolimus treatment|"Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.~The starting dose will be 2 mg per day, and will be adapted every week for one month.~The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment."
3324152|NCT02042339|Experimental|Hyperbaric oxygen|Problem-wound schedule: 2.4 atmospheres, 100% oxygen for 90 minutes, two 10 - minute breaks (patients breathing pressurized air from the chamber atmosphere)
3324153|NCT02042339|Placebo Comparator|Sham Hyperbaric oxygen|The patients will be transferred into the chamber like the treatment group. Instead of 100% oxygen they will breathe normal air through the tight fitting masks, at an ambient pressure of 1.1 bar. During the two 10 - minute breaks patients will breathe pressurized air from the chamber atmosphere.
3229734|NCT01184261|Experimental|Arm II|Patients attend behavioral sessions for smoking cessation over 30 minutes once weekly in weeks 1-6.
3324154|NCT02042352||pH test|VpH test gloves
3324155|NCT02042365||ERAS (Enhanced recovery after surgery)|This observational study evaluates the feasibility of ERAS pathway in six French departments of surgery located at Clermont-Ferrand, Bordeaux, Montpellier, Amiens, Strasbourg and Aurillac
3324156|NCT02042378|Experimental|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
3229735|NCT01184274|Experimental|SB939|
3229736|NCT01184287|Experimental|ranpirnase|All patients who do not progress after two cycles of pemetrexed-carboplatin will receive the study drug, ranpirnase
3229737|NCT01184300|Experimental|Rapid Genotyping|Patients randomized to the Rapid Genotyping arm will have their CYP2C19*2 carrier status determined at the time of percutaneous coronary intervention with subsequent alteration in anti-platelet therapy for *2 carriers.
3324157|NCT02042391|Experimental|Low-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered low-risk if they reached a complete remission with the first 4 applications of rituximab monotherapy or if they reached a partial remission and had a baseline IPI of 0, 1 or 2. Patients considered low-risk will receive rituximab sc consolidation.
3324158|NCT02042391|Experimental|High risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, patients will be considered high-risk, if the reached a partial remission and were IPI 3, 4 or 5 at time of diagnosis of PTLD, if they show stable disease or if they had progressive disease but are not recipients of heart or lung transplants. Patients considered high-risk will receive four more applications of rituximab sc combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113.
3324159|NCT02042391|Experimental|Very high-risk|All patients will receive rituximab sc on days 1, 8, 15 and 22. Interim staging will be performed around day 50. After interim staging, heart and lung transplant recipients and patients with a combination of organs transplanted including a heart or lung transplant who show disease progression during rituximab monotherapy or at interim staging will be considered very high-risk. Patients considered very high-risk will receive six more applications of rituximab sc combined with alternating chemotherapy with CHOP and DHAOx.
3324160|NCT02042417|Experimental|INRatio2 and CoaguChek|one measuring per tool, in case of error: one repetiton
3324162|NCT02042456||Main Cohort|Subjects enrolled in this group will receive a full field digital mammogram, digital breast tomosynthesis exam and an automated whole breast ultrasound exam as part of their visit.
3324163|NCT02042469||Survey|Cross-sectional survey will be carried out using an interview questionnaire composed of close-ended questions to be completed by trained research coordinator.
3324164|NCT02042482|Experimental|Coenzyme Q10U, L-carnitine|Patients receive combination of coenzyme Q10U 180 milligram and L-carnitine 2000 milligram
3324165|NCT02042495|Experimental|Metformin|"Metformin 500 mg PO TID from time of entry to study until scheduled surgical staging operation.~In cases of unresolving side effects, the metformin will be dose reduced to metformin 500 mg PO BID with evaluation after 1 week followed by withdrawal from the study if side effects persist."
3324166|NCT02042508|Experimental|Paraplegic patients|
3324167|NCT02042521|Experimental|Healthy Smokers (Active then Placebo)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
3324168|NCT02042521|Experimental|Healthy Smokers (Placebo then Active)|"Healthy individuals who smokes at least 20 cigarettes per day~Interventions: Dietary Supplement, Lactose Placebo"
3324169|NCT02042547||Patients about to undergo heart surgery|
3324170|NCT02042560||Patients with ITP|
3324171|NCT02042560||Controls|
3324172|NCT02042573|Other|Depressive patients treated with rTMS|
3324173|NCT02042573|Other|Depressive patients treated with SSRI|
3229738|NCT01184300|No Intervention|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping at the time of percutaneous coronary intervention. All patients will receive clopidogrel 75 mg daily for 1 week. At the end of the 1 week period, their CYP2C19*2 carrier status will be verified.
3229739|NCT01184313||aortic valve surgery|
3229740|NCT01184339||Standard of Care|Current practice methods for the determination of bacteremia, specific to site practice.
3324174|NCT02042573|Other|Controls|
3324175|NCT02042586||Patients|
3324176|NCT02042586||Controls|
3229741|NCT01184339||Gold Standard ID/AST|"Identification of S. aureus: coagulase positive, catalase positive, Staphaurex positive, and PYR negative, if performed).~Determination of MRSA:S. aureus gold standard and </=11mm OXA DD or </=21mm CFX DD.~Determination of MSSA: S. aureus gold standard and >/=13mm OXA DD or >/=22mm CFX DD."
3324177|NCT02042599|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in ICU patients with acute kidney injury
3324178|NCT02042612|Experimental|sevoflurane|Determination of plasmatic concentrations of sevoflurane at different times of a 48h sedation of sevoflurane in obese ICU patients
3324179|NCT02042625|Other|nasopharyngeal|The nasopharyngeal probe will be inserted into the nostril. The nasopharyngeal temperature will initially be recorded 45 minutes after anesthetic induction. The nasopharyngeal probe will then be withdrawn 2 cm and after a 3-minute equilibration period, nasopharyngeal temperatures will again be recorded. The nasopharyngeal probe withdrawal sequence will be repeated, 2 cm at a time, until only 2 cm remains in the nostril. There will be a total of 10 sets of nasopharyngeal temperatures obtained.
3324180|NCT02042638||16 treatment naive Hypogonadotropic hypogonadism patients|Treatment naive 16 patients with idiopathic hypogonadotrophic hypogonadism
3324181|NCT02042651|Experimental|Low intensity extracorporeal shockwave therapy|Active treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
3324182|NCT02042651|Sham Comparator|Sham low intensity extracorporeal shockwave therapy|Sham treatment with low intensity extracorporeal shockwave therapy applied to the perineum.
3324183|NCT02042664|Experimental|treatment BYETTA|
3229742|NCT01184352||PCI patients treated with Glider Device|
3324184|NCT02042664|Active Comparator|metformine|
3229743|NCT01184365|Experimental|EnMP-1|The goal of the EnMP-1 is to enable participants, through a behavioural, psycho-educational intervention, to better manage and understand their fatigue. This program is provided in four, two-hour sessions held weekly.
3324185|NCT02042690|Active Comparator|chemotherapy|"Drugs:~Drug:Methotrexate 1g/m2 d1,IV (in the vein) , used in cycle 1,3,5 Drug:arabinoside 2-3g/m2,q12h, d2-3, IV, used in cycle 1,3,5 Drug:cyclophosphamide:300mg/m2 q12h, d1-3, IV,used in cycle 2,4,6 Drug:Epirubicin 60mg/m2.d，d4,used in cycle 2,4,6 Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6 Drug:dexamethasone 40mg/d，d1-4，d11-14, IV, in cycle 2,4,6 Drug:Methotrexate 20 mg/m2/w,po, during maintenance treatment for 2 years Drug:6-mercaptopurine 60 mg/m2/d，po，d1-d28,during maintenance treatment for 2 years Drug:Vindesin 4mg/d，Predisone:1mg/kg, d1-7, every month during maintenance treatment for 2 years"
3324186|NCT02042690|Experimental|Haplo-identical HSCT|Haplo-identical HSCT Protocol:G, donor treatment with recombinant granulocyte colony-stimulating factor (rhG-CSF); I, intensified immunologic suppression; A, antihuman thymocyte immunoglobulin (ATG) for the prevention of GVHD; C, combination of peripheral blood stem cell transplantation (PBSCT), and bone marrow transplantation (BMT)，named GIAC regimen. Graft versus-host disease(GVHD) prevention regimen: CSA/MMF/MTX, cyclosporine A(CSA) 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HSCt and then gradually tapered. Every 12h, 0.5g mycophenolate mofetil (MMF)(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. Methotrexate (MTX) was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
3324187|NCT02042703||exfoliation syndrome|patients with exfoliation syndrome
3324188|NCT02042703||POAG|patients with primary open angle glaucoma (POAG)
3324189|NCT02042703||cataracts|patients with cataracts
3324190|NCT02042716|Experimental|diagnosis of white matter damage|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
3324191|NCT02042729|Experimental|E2022- Tape Formulation|
3324192|NCT02042729|Placebo Comparator|Matching Placebo E2022|Matching Placebo
3324193|NCT02042729|Active Comparator|E2022- New Formulation|
3324194|NCT02042729|Placebo Comparator|Placebo E2022- New Formulation|Matching Placebo
3229744|NCT01184365|Active Comparator|EnMP-2|The goal of the EnMP-2 is to control for group effects
3229745|NCT01184378|Placebo Comparator|control formula|formula containing only vegetable fats
3229746|NCT01184378|Experimental|new formula|new formula with dairy lipids and soluble milk proteins
3229747|NCT01184391|Experimental|Test: Divalproex Sodium|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
3229748|NCT01184391|Active Comparator|Reference: Depakote Tablets|DEPAKOTE® Tablets, 500 MG Abbott Laboratories
3324195|NCT02042742|Experimental|Antioxidant supplement|Treatment consist of consuming 65g of punicalagin and 3,3g of hydroxytyrosol (plus 331,7g of maltodextrin) three times daily, during 8 weeks.
3324196|NCT02042742|Placebo Comparator|Control supplement|Treatment consist of consuming 400g of maltodextrin three times daily, during 8 weeks.
3324197|NCT02042781|Experimental|PG545|Once weekly, one hour IV infusion of PG545.
3324198|NCT02042807|Placebo Comparator|Placebo|placebo arm
3324199|NCT02042807|Active Comparator|MCS® 15 mg/day|MCS® soft capsule
3324200|NCT02042807|Active Comparator|MCS® 30 mg/day|MCS® soft capsule
3324201|NCT02042820||Dry Eye Disease|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~Tear Break Up Time (TBUT)~Ocular Surface Disease Index (OSDI)~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
3324202|NCT02042820||Control|"Confocal Imaging - In vivo confocal microscopy (IVCM)~Ophthalmic Examination:~TBUT~OSDI~Schirmer's II test~Conjunctival staining with lissamine green~Corneal staining with fluorescein~Conjunctival redness assessment"
3229749|NCT01184404|Experimental|Treatment|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
3229750|NCT01184404|No Intervention|Control|
3229751|NCT01184430|Active Comparator|advanced hemodynamic monitoring|advanced hemodynamic monitoring with pulse contour analysis ( LiDCO rapid) and goal-directed therapy
3229752|NCT01184430|No Intervention|standard monitoring|hemodynamic monitoring based on the standard operating procedures of our clinic
3229753|NCT01184443|Experimental|Olanzapine|Those who choose to take olanzapine as part of their treatment (standard practice plus medication).
3324203|NCT02042833||Cohort|
3324204|NCT02042846|Experimental|SportWelding Fiji Anchor|
3324205|NCT02042885|Experimental|1: Regimen A Escalation|1: OPB-111001, orally, once weekly
3324206|NCT02042885|Experimental|2: Regimen A Extension|2: OPB-111001, orally, once weekly
3229754|NCT01184443|No Intervention|Comparison|Those who choose not to take olanzapine as part of their treatment (standard practice).
3229755|NCT01184469||Fresh embryo transfers|Patients who received fresh blastocyst transfer
3229756|NCT01184469||Thawed embryo transfers|Patients who received transfers of frozen/thawed embryos
3229757|NCT01184482|Experimental|Cetuximab and lapatinib|All patients will receive cetuximab by IB weekly and daily doses of lapatinib orally in 3 week cycles with response assessed every 2 cycles.
3229758|NCT01184495|Experimental|Epoetin Bio-Manguinhos|
3229759|NCT01184495|Active Comparator|EPO-BioSimilar|Subcutaneous administration of EPO-BioSimilar
3229760|NCT01184521||pulse CO-oximeter|
3229761|NCT01184534||Questionnaires + Video|
3229762|NCT01184534||Questionnaires|
3229763|NCT01184547|Experimental|COMBEX|Community Based Exercise Program or exercise group and quality of life Intervention- The community-based exercise program consisted of 12 weeks of exercise with a community-based trainer after hospital discharge.
3229764|NCT01184547|Active Comparator|Standard Of Care|Standard of Care group, group with no exercise and quality of life. Intervention- No exercise training received.
3229765|NCT01184560|Experimental|Sibutramine + Orlistat|"A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence"
3229766|NCT01184560|Placebo Comparator|Sibutramine + Orlistat(Placebo)|"Sibutramine : one of components included into Diet Pills. This reduces appetite, normalizes amount of cholesterol in blood, and reduces abdominal fat.~Orlistat : A lipase inhibitor used for weight loss. Lipase is an enzyme found in the bowel that assists in lipid absorption by the body. Orlistat blocks this enzyme, reducing the amount of fat the body absorbs by about 30%. It is known as a fat blocker. Because more oily fat is left in the bowel to be excreted, Orlistat can cause an oily anal leakage and fecal incontinence."
3229767|NCT01184573||Mild to Moderate CP|Subjects must have a history compatible with chronic pancreatitis.
3324207|NCT02042885|Experimental|3: Regimen B Escalation|3: OPB-111001, orally, 2 - 3 times per week
3324208|NCT02042885|Experimental|4: Regimen B Extension|4: OPB-111001, orally, 2 - 3 times per week
3324209|NCT02042898|Active Comparator|Restrictive transfusion strategy|Restrictive transfusion strategy: patients will receive a red cell transfusion if their hemoglobin is <75 g/L (<7.5 g/dL;<4.7mmol/L) intraoperatively and/or postoperatively
3324210|NCT02042898|Active Comparator|Liberal transfusion strategy|Liberal transfusion strategy: patients will receive a red cell transfusion if their hemoglobin concentration is <95 g/L (<9.5 g/dL<5.9mmol/L) intraoperatively, or postoperatively in the intensive care unit; and/or <85 g/L (< 8.5 g/dL;<5.3mmol/L) on the ward.
3324211|NCT02042937|No Intervention|Control|No intervention
3324212|NCT02042937|Experimental|Exercise|Exercise to improve gluteus maximus recruitment
3229768|NCT01184573||Healthy Controls|Subjects must be in good health of greater than 18 years of age.
3229769|NCT01184586|Active Comparator|Intervention arm - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (STORZ DUOLITH, 1000 impulses, 0.55-0,8mJ/mm2)
3324213|NCT02042963||KNOW-KT|1000 Kidney transplant recipients in Korea
3324214|NCT02042976|Experimental|Mindfulness-based cognitive therapy + pulmonary rehabilitation|An 8-week manual-based programme developed by Segal, Williams and Teasdale (2013) adjusted to the COPD population. The programme is delivered as an add-on to an 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
3324215|NCT02042976|Active Comparator|Pulmonary rehabilitation only|An 8-week standardised rehabilitation programme consisting of physical exercise and COPD-specific patient education.
3324216|NCT02042989|Experimental|MLN9708 and Vorinostat|"Dose Escalation Phase: Starting Dose of MLN9708 3 mg by mouth on day 1, 8 and 15. Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Doses of MLN9708 and Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
3324217|NCT02043002|Experimental|18F-FDG-PET scan|An early evaluation 18F-FDG-PET scan after 7-10 days
3324218|NCT02043028|Experimental|Group 1|"Participants compress the chest of a manikin with kneeling posture using a kneeling stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with standing posture using a step stool during 5 minutes"
3324219|NCT02043028|Experimental|Group 2|"Participants compress the chest of a manikin with a standing posture using a step stool for chest compression posture during 5 minutes~2 weeks later, They perform the chest compression with a kneeling posture using a kneeling stool stool and bed height adjustment during 5 minutes"
3324220|NCT02043041||1 Dried Blood Spot (DBS)|Number of DBS Spots Participants will be asked to fill one spot on a dried blood spot collection card.
3324221|NCT02043041||3 DBS Spots|Number of DBS Spots Participants will be asked to fill three spots on a dried blood spot collection card.
3324222|NCT02043041||5 DBS Sports|Number of DBS Spots Participants will be asked to fill five spots on a dried blood spot collection card.
3324223|NCT02043054|Experimental|Liraglutide|Liraglutide doses will be self-administered by the participant through daily subcutaneous injections. Liraglutide doses will be initiated at 0.6 mg and then increased to 1.2 mg in week two and 1.8mg in week three. The dose will then be maintained at 1.8 mg. Where 1.8 mg doses are not tolerated by the patient, the dose will be lowered to the maximum tolerated dose at the investigators discretion.
3324224|NCT02043054|Active Comparator|Sitagliptin|Sitagliptin doses will be self-administered by the participant orally at 100mg/day throughout the 26 week period of the study. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea)
3324225|NCT02043067||new HIV clinic enrollees|All new enrollees to a Lusaka HIV clinic will receive a full TB work-up.
3324226|NCT02043080|No Intervention|SOC: sputum smear and Chest x-ray|HIV-infected adult and pediatric TB suspects screened for TB according to current standard of care
3324227|NCT02043080|Experimental|Xpert MTB/RIF, sputum, chest xray &TB culture|HIV-infected adult and pediatric TB suspects screened for TB using the Xpert MTB/RIF Tuberculosis diagnostic tool (algorithm) which include chest x-ray, sputum TB culture
3324228|NCT02043093|No Intervention|Waiting|Surveys are administered to school students and staff, but Sources of Strength program is not implemented until the school year following two years of survey participation
3324229|NCT02043093|Experimental|Intervention|School receives Sources of Strength Peer Leader training and implementation for two school years, beginning in fall of enrollment year. Peer leaders are actively implementing program across two school years. Students and school staff participate in surveys across the two implementing school years.
3324230|NCT02043106|Experimental|spinal cord injury|Individuals who have sustained an incomplete spinal cord injury
3324231|NCT02043106|Active Comparator|non-spinal cord injury|Individuals who have not sustained a spinal cord injury
3324232|NCT02043119|Active Comparator|Breastfeeding Clinic|A breastfeeding clinic that mothers can attend with their infants up to one month post delivery.
3324233|NCT02043119|No Intervention|Standard of Care|
3324234|NCT02043158||Ovarian Cancer Survivors|Short-term and long-term ovarian cancer survivors
3324235|NCT02043171|Placebo Comparator|Placebo Exercise|Placebo supplementation group with 3 days per week of exercise
3229770|NCT01184586|Sham Comparator|Control - SHAM ESWT STORZ DUOLITH [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave with modified probe without shockwave transduction (1000 impulses)
3229771|NCT01184612|Active Comparator|(BSF) MI sessions|5 semi-structured manualised MI sessions was conducted by existing prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual.
3324236|NCT02043171|Placebo Comparator|Placebo Non-exercise|Placebo supplementation group without exercise
3324237|NCT02043171|Active Comparator|HMB plus Vitamin D Exercise|HMB plus Vitamin D supplementation group with 3 days per week of exercise
3324238|NCT02043171|Active Comparator|HMB plus Vitamin D Non-exercise|HMB plus Vitamin D supplementation group without exercise
3324239|NCT02043184|Active Comparator|Standard Care 12 weeks|Standard care. Standard supportive care and Toolkit given at 12 weeks.
3324240|NCT02043184|Experimental|Standard Care 8 wks, Daily IVR 4 wks|Interactive Voice Response (IVR) Reminders Daily delivery for the last 4 weeks of the study.
3324241|NCT02043184|Experimental|Daily IVR 8 weeks|Interactive Voice Response (IVR) Reminders daily for the first 8 weeks of the study.
3324242|NCT02043184|Experimental|Daily IVR 4 wk, Every other day IVR 4 wk|Interactive Voice Response (IVR) Reminders daily for the first 4 weeks of the study and every other day for weeks 4-8.
3324243|NCT02043210|Active Comparator|Standard Treatment as Usual|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
3324244|NCT02043210|Experimental|CBT4CBT plus Standard treatment as usual|A computerized program that teaches skills for stopping substance use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
3324245|NCT02043223|Experimental|Early postpartum vitamin A suppl.|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
3324246|NCT02043223|Experimental|Late postpartum vitamin A suppl.|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
3324247|NCT02043223|Experimental|Early & late postpartum vitamin A suppl|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
3324248|NCT02043223|Experimental|No postpartum vitamin A suppl.|Placebo supplementation, both at <3-day and 6-wk postpartum.
3324249|NCT02043236|Active Comparator|Healthy bones pamphlet, letter to GP|Strategy 1: Written educational material to patient and GP
3324250|NCT02043236|Active Comparator|Healthy bones pamphlet, Bone Health Care Coordinator|Strategy 2: Written educational material to patient and counseling from a Bone Health Care Coordinator
3324251|NCT02043236|No Intervention|Usual care|Control group gets usual care from their oncologist.
3229772|NCT01184612|Active Comparator|(BSF+) MI sessions with supervision|5 semi-structured manualised MI sessions was conducted by ordinary prison staff having undergone 3 days of Motivational Interviewing workshop training and 2 days of training with the BSF manual, followed by ongoing Motivational Interviewing training with feedback based on audio taped sessions in peer supervision groups.
3229773|NCT01184612|Active Comparator|(UPI) Usual Planning Interview|5 sessions was conducted by prison staff according to usual working practices, with the exception that content was structured into 5 sessions and audio recorded. The provision of a government decree served as a basis for the intervention, covering planning of prison activities and post release arrangements including strategies for drug use cessation.
3324252|NCT02043249|No Intervention|CORD MILKING|WITHOUT MILKING
3324253|NCT02043262|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to older adults, although there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the older person on a daily basis focusing on self-help.
3324254|NCT02043262|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
3324255|NCT02043275|Experimental|Leg training|Lower body resistance training only
3324256|NCT02043275|Active Comparator|Arm training|Upper body resistance training only
3324257|NCT02043288|Experimental|NC-6004 and Gemcitabine combination|NC-6004 90mg/m2 i.v. on Day 1 and Gemcitabine 1000mg/m2 i.v. on Day 1 and Day 8 respectively
3324258|NCT02043288|Active Comparator|Gemcitabine monotherapy|Gemcitabine 1000mg/m2 i.v. on Day 1 ,8 and 15
3324259|NCT02043314|Active Comparator|Isoniazida-LAQFA®|3 coated tablet of 100mg
3229774|NCT01184625|Experimental|Exercise|
3324260|NCT02043314|Experimental|Isoniazida|coated tablet of 300mg
3324261|NCT02043327||Experienced in Colonoscopy|two tests on two different modalities of colonoscopy simulators
3324262|NCT02043327||Novices in colonoscopy|Two tests on each of trw colonoscopy simulators
3324263|NCT02043340|Experimental|Indocyanine green (ICG)|The study included 30 patients diagnosed with chronic periodontitis. Three sites from three different quadrants were selected and assigned to three groups namely, SRP group - scaling and root planing, LASER group - scaling and root planing with application of 810 nm diode laser and ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
3324264|NCT02043353||Winter Vs. Summer|All children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010
3324265|NCT02043353||Primary snoring|All children that were diagosed with primary snoring at the Tel Aviv Medical center between 2005-2010
3229775|NCT01184625|No Intervention|No intervention|12 weeks of stable physical exercise level.
3324266|NCT02043353||Adenotonsillectomy Vs. Adenoidectomy|All children that underwent adenotonsillectomy or tonsillectomy at the Tel Aviv Medical center between 2005-2008
3324267|NCT02043353||repeated PSG|All children that underwent Adenoidectomy / Adenotonsillectomy and two PSG evaluations at the Tel Aviv Medical center between 2005-2012
3324268|NCT02043392|Experimental|Magnamosis|Create an intestinal anastomosis using the Magnamosis Magnetic Compression Anastomosis (Magnamosis) device to re-establish intestinal continuity that would otherwise be performed using sutures or stapling devices
3324269|NCT02043405|Experimental|Exercise Training and Weight Loss Intervention|Combination weight loss/exercise training, on insulin sensitivity, muscle lipid composition and localization in skeletal muscle.
3324270|NCT02043405|Active Comparator|4 Month Weight Loss Only Intervention|Use exercise training and weight loss as separate interventions in obese subjects with and without pre-diabetes.
3324271|NCT02043418||children VIH+|children infected with HIV
3324272|NCT02043418||Chlidren VIH-|uninfected children born from HIV-positive or HIV-negative mothers
3229776|NCT01184638|No Intervention|Local anesthesia|Patients received local anesthesia without any intervention of general anesthetics
3229777|NCT01184638|Active Comparator|Inhalational anesthesia|Patients received sevoflurane anesthesia during general anesthesia
3324273|NCT02043444|Experimental|secretory azoospermia|110 men with secretory azoospermia will have FDG PET-CT
3324274|NCT02043444|Active Comparator|excretory azoospermia|30 men with secretory azoospermia will have FDG PET-CT
3324275|NCT02043444|Placebo Comparator|normospermia|20 men with secretory azoospermia will have FDG PET-CT
3324276|NCT02043457||Lifestyle intervention|Opt-in intervention to include the following procedures, called 'phenotyping' performed at baseline, after 10-15% weight loss from baseline weight or 6 months (whichever comes first) and at end of 2 years while in weight maintenance: oral glucose tolerance test, mixed meal tolerance test, with fasting leptin, biased and unbiased metabolomic profiling, DNA, RNA, muscle and adipose tissue biopsies: measurement of resting energy expenditure by indirect calorimetry; oxidative capacity (V02 peak/max); body composition by Dual Energy X-ray Absorptiometry (DEXA) or air displacement plethysmograph (Bod Pod); inventories of depression and health related quality of life instruments, measures of impulsivity, measures of hunger and appetite, work performance (including presenteeism and absenteeism) and pain survey.
3324277|NCT02043483||CPAP|Patients with moderate/severe OSAS will be treated with CPAP
3324278|NCT02043483||Control|Patients with snoring will not be subject to treatment with CPAP
3324279|NCT02043496|Experimental|CBT-Guided Self Help|Integrative Cognitive-Affective Therapy CBT-Guided Self Help
3324280|NCT02043496|Experimental|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
3324281|NCT02043522|Experimental|Nuclear Imaging|Planar, conventional SPECT imaging and CZT SPECT imaging will be done. Imaging will begin immediately following radioisotope injection with CZT SPECT imaging for 15 minutes, followed by 1) planar anterior view imaging for 10 minutes, 2) conventional SPECT imaging for 12.5 minutes and 3) CZT SPECT imaging for 12 minutes. A low dose CT transmission scan will be acquired for attenuation correction (GE Infinia Hawkeye) with the initial conventional SPECT imaging and not repeated with subsequent imaging. Participants will undergo repeat imaging at 1, 2, 3 and 4 hours after radiotracer injection with each imaging session to include 1) planar anterior, 2) conventional SPECT and 3) CZT SPECT imaging.
3324282|NCT02043535|Other|Myocardial blood flow quantification|"The RA-MR™ Virtual Sequential Gas Delivery System. : delivery of CO2 in increasing levels.~Rubidium Elution System: delivery of Rb-82 through an automated pump system for myocardial PET perfusion imaging.~Persantine stress myocardial PET perfusion imaging: as a standard for comparison."
3324283|NCT02043561|Sham Comparator|no urge|rectal balloon deflated
3324284|NCT02043561|Experimental|moderate urge|moderate urge induced by rectal balloon
3324285|NCT02043561|Experimental|high urge|high urge induced by rectal balloon
3324286|NCT02043587|Experimental|Chemotherapy for ALL|"Course 1A: DNR 60 mg/m2 IV d1,2,3; VCR 1.4 mg/m2 d1,8,15,22 (cap 2 mg age >50); PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3750 IU/m2; CTX 750 mg/m2 d1,15 age < 40; Prednisone 60 mg/m2 PO d1-28; Liposomal AraC 25 mg IT d1, 15~1B: MTX 220 mg/m2 IV then 60 mg/m2/h for 36h d2-3,d16-17; LCV 50 mg/m2 IV q6h x3 then 10 mg/m2 PO/IV q6h til MTX <0.1 uM; 6-MP 60 mg/m2 PO d2-8, d16-22; PEG-asp 2000 IU/m2 IV d18, age >50 1000 IU/m2, cap 3750 IU/m2~1C: AraC 2 g/m2 IV d1-4; Etoposide 500 mg/m2 IV d1-4~1A-C repeat x1(2A-C) then 3rd Course B (3B)~Maintenance (monthly, 24 mo): Prednisone 60 mg/m2 PO d1-5; VCR 1.4 mg/m2 IV d1 (cap 2 mg age >50); MTX 20 mg/m2 PO wkly; 6-MP 60 mg/m2 PO qd PEG-asp 2000 IU/m2 IV d16, age >50 1000 IU/m2, cap 3,750 IU/m2 (Mo. 1)~Maintenance mo. 1-4: Liposomal AraC 50 mg IT d1~Dasatinib 140 mg PO qd if Ph/BCR-ABL+; Rituximab 375 mg/m2 IV d1,15 of 1A-C, 2A (Pre-B)~1:1 randomization: hydrocortisone v. placebo before PEG-asp 1B, 2B, & Maint."
3324287|NCT02043600|Experimental|Yoga|
3324288|NCT02043600|Active Comparator|Self-care|
3229778|NCT01184638|Active Comparator|Intravenous anesthesia|Patients received intravenous anesthetic (Propofol) during general anesthesia
3229779|NCT01184651||Girls|Girls with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) ages 10-13
3324289|NCT02043613|Active Comparator|Exercise in standard room|"Intervention: Exercise~Patients exercise in standard physical surroundings. The room is marked by years of use. The room is placed in the basement, has artificial lighting, poor acoustics and bare concrete walls."
3324290|NCT02043613|Experimental|Exercise in a contexually enhanced room|"Intervention: Exercise + contextually enhanced physical surroundings~Patients exercise in a contextually enhanced room. The room has both artificial lighting and daylight, view of a recreational park, better acoustics, decorations among other factors, which may cause or enhance the context effect."
3324291|NCT02043613|No Intervention|Waiting list|Patients on waiting list are included, baseline tested and placed on a waiting-list for a 8 week period and tested at 8 weeks follow-up. The group is representative of the natural cause of disease.
3324292|NCT02043626|Experimental|Physical Activity Only|Students in 3 designated study schools will receive educational intervention and increased opportunities for physical activity.
3229780|NCT01184651||Parents|Parent, guardian, or significant caretaker of girls with CAH
3229781|NCT01184664|Experimental|Varenicline + Active Patch|Participants will use varenicline (1mg BD) + an active, 15mg/16hr Nicotine Patch
3229782|NCT01184664|Placebo Comparator|Varenicline + Placebo Patch|Participants will use varenicline (1mg BD) + a Placebo Nicotine Patch
3229783|NCT01184677|Placebo Comparator|Group size 4|
3229784|NCT01184677|Experimental|Group size 3|ProSeal LMA size 3 is inserted to the patients of Group size 3.
3229785|NCT01184690|Active Comparator|Single-operator DBE|Single-operator double-balloon endoscopy
3229786|NCT01184690|Active Comparator|Dual-operator DBE|Dual-operator double-balloon endoscopy
3229787|NCT01184716|Active Comparator|Vitamin D fortified bread and milk|
3324293|NCT02043626|No Intervention|Delayed Interventions Only|Students in 3 designated schools will receive educational interventions on health topics not related to nutrition or physical activity (i.e. peer relations, sleep, dental care, etc.)
3324294|NCT02043626|Experimental|Nutrition and Physical Activity|Students in 3 designated schools will receive nutrition education, nutrition standards for foods sold, and opportunities for physical activity.
3229788|NCT01184716|No Intervention|Non-fortified bread and milk|
3229789|NCT01184729||Spinal Cord Injury|
3324295|NCT02043626|Experimental|Nutrition Only Interventions|Students in 3 designated study schools will receive multiple interventions regarding nutrition education and nutrition standards for foods sold.
3229790|NCT01184768||participants in the 6th tromsø study|
3229791|NCT01184781|Other|A|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
3324296|NCT02043665|Experimental|CVA21/pembrolizumab|CVA21/pembrolizumab
3324297|NCT02043691|Experimental|Cook Custom Aortic Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Cook Custom Aortic Endograft. The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
3324298|NCT02043691|Experimental|Zenith t-Branch Endovascular Graft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the sizing of the the Zenith t-Branch Endovascular Graft. The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
3229792|NCT01184794|Placebo Comparator|Saline|Placebo solution
3229793|NCT01184794|Experimental|levobupivacaine, analgesia|Active drug
3324299|NCT02043691|Experimental|Surgeon-Modified Endograft|Participants will receive the following: Clinical Exam, Blood Tests, CT Scans (with and without contrast) or Ultrasound, Abdominal Device X-ray, and Angiography. These tests will aid in the design of the Surgeon-Modified Endografts. These will be created in the operating room by modifying a commercially-available Cook Alpha Thoracic Endograft or Cook Zenith Infrarenal Aortic Device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
3324300|NCT02043717||CF patients|Both children and adults, with or without vitamin D deficiency.
3324301|NCT02043730|Experimental|nab-paclitaxel and gemcitabine|ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
3324302|NCT02043730|Active Comparator|Gemcitabine|ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
3324303|NCT02043743|Experimental|Laboratory and Clinical|"Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.~Stem Cell Dose:~•3-5 Million Autologous MSCs Injected into Ovarian tissue."
3324304|NCT02043756|Experimental|Mitoxantrone Hydrochloride Liposome|Dose escalation will begin at 6mg/m2 to 16mg/m2,4 weeks apart
3324305|NCT02043756|Active Comparator|Mitoxantrone ,injection|When the dose of experiment drup up 10mg/m2,10mg/m2 of Mitoxantrone as active comparator
3324306|NCT02043769||Prospective Cohort|"The prospective cohort surveillance will be built upon and support the routine clinical care, visit schedule and monitoring system at each study site. Eligible HIV-infected ART naïve children who are accessing care at study sites will be recruited sequentially for study enrollment. Children enrolled in the surveillance study will attend study visits co-scheduled to coincide with routine clinical visits. Study nurses will:~review routinely collected information;~conduct questionnaires with caregiver and child;~conduct additional assessments of child;~contact the caregiver by phone or through home visits for active follow-up for up to 24 months; and~conduct active follow-up including appointment reminders by means of phone calls and defaulter tracking."
3324307|NCT02043795|Other|Treated with BVS|Symptomatic patients would be screened with a duplex ultrasound as per clinical practice prior to intervention. After informed consent for a standard angiography/intervention, the patient will undergo a planned intervention under general or local anaesthesia in an angiographic facility.
3324308|NCT02043821|Other|Placebo|Placebo 1250mg/m2 tablet by mouth every 12 hours for 14 days
3229794|NCT01184807|Other|OPB-51602|
3229795|NCT01184820|Experimental|Arm 1|
3324309|NCT02043821|Experimental|Capecitabine|Capecitabine 1250mg/m2 tablet by mouth every 12 hours for 14 days
3229796|NCT01184820|Experimental|Arm 2|
3229797|NCT01184833||Group 1|
3229798|NCT01184911|Experimental|SP|Asymptomatic parasitemic pregnant women who receive the standard dose of sulfadoxine-pyrimethamine for prevention of placental malaria
3229799|NCT01184924|No Intervention|Control|Usual Care only. Usual care is defined as the care these subjects would like to seek from any health care practitioner or other program they may seek for healthy living. The subjects in this arm will be offered the AF Tai Chi intervention after an 8 week followup data collection
3229800|NCT01184924|Experimental|Tai Chi|Usual care plus Tai Chi. These subjects will be allowed to seek care from any health practitioner or any other programs and will receive the AF Tai Chi program for 8 weeks.
3229801|NCT01184937|Experimental|Patient education program|
3229802|NCT01184937|No Intervention|Standard care|
3229803|NCT01184950|Experimental|Trainer Curriculum|
3229804|NCT01184950|No Intervention|No Curriculum|
3229805|NCT01184963|Other|Controls|Women in reproductive age regular ovulatory cycles
3229806|NCT01184963|Other|PCOS patients|Patients with anovulatory cycles, hyperandrogenism with or without polycystic ovarian appearance
3324310|NCT02043834|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3324311|NCT02043834|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3324312|NCT02043873||25 composite restorations replaced|25 composite replaced with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
3229807|NCT01184976|Experimental|0.6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 0.6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3324313|NCT02043873||25 composite repaired|25 composite repaired with clinically diagnosed secondary caries (Charlie) or undercontoured anatomical form defects (Bravo)
3229808|NCT01184976|Experimental|2mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 2mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3229809|NCT01184976|Experimental|6mg DNA/dose|Subjects will receive a 2 dose series of VGX-3400 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0 and Month 1
3324314|NCT02043886|Active Comparator|Acarbose|Acarbose 50mg by mouth at minute 0 of the Meal Test.
3324315|NCT02043886|Placebo Comparator|Placebo|Placebo 1 tablet at 0 minutes of Meal Test.
3324316|NCT02043912||patients treated with haloperidol|
3324317|NCT02043925||psychiatric patients treated with QT-prolonging drugs|
3324318|NCT02043951||Single Arm: Lutonix Drug Coated Balloon|
3229810|NCT01185002|Experimental|MgC boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered MgC boosts."
3229811|NCT01185002|Experimental|Suprep boosts|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered Suprep boosts"
3229812|NCT01185002|Experimental|Suprep boosts - Reduced dose|"Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects will be administered a reduced dose of Suprep boosts"
3324319|NCT02043964|Experimental|tears and cerebro-spinal fluid sampling|
3229813|NCT01185041|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3324320|NCT02043977|Experimental|propofol infusion|Induction of sleep is accomplished with a bolus of propofol (up to 0.5mg/kg over one minute, concurrently with a constant infusion of propofol starting at 25 ug/kg/min titrated to a maximum of 100ug/kg/min, to maintain the subject at a Modified Ramsay Score of 3-4 for a total of 120 minutes. An additional bolus may be given by the investigator in order to maintain the level of sleep. This procedure will be conducted over 5 consecutive nights.
3324321|NCT02043990|Experimental|Noninvasive NAVA Ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
3324322|NCT02044003|Experimental|Post Angioplasty Dissection Repair|Implant of Innovasc Tack Intravascular Staple System (Tack) to repair post angioplasty dissections
3324323|NCT02044016||Observational study|To compare results of the ATLM with goniometry and Ultrasound measures of the achilles tendon.
3324324|NCT02044029||Age- and gender-matched controls|
3324325|NCT02044029||Patients with spinal muscular atrophy|
3229814|NCT01185041|Experimental|Watermelon|(6g per day)containing L-citrulline/L-arginine (4/2 g)
3229815|NCT01185054|Experimental|Fluids as Tolerated (FAT) Group|The FAT group will receive ½ strength apple juice and will form the experimental group in this study.
3229816|NCT01185054|Active Comparator|Electrolyte Maintenance Solution (EMS)|The EMS group will form the control group as solutions such as Pediatric Electrolyte® are routinely recommended for use in children with gastroenteritis.
3229817|NCT01185067|Active Comparator|grape seed extract capsule|Grape seed extract (MegaNatural BP, Polyphenolics, Inc.) 300 milligram capsules twice daily for six weeks
3229818|NCT01185067|Placebo Comparator|maltodextrin capsule|Maltodextrin capsules (matched for appearance and taste to grape seed extract capsules) twice daily for six weeks
3229819|NCT01185093||Fourth grade students|Each participant will attend two presentations and six hands-on activities led by St. Jude faculty and research staff on topics within their expertise, such as cells and cancer, and healthy living. The pre-test will take place within 7±1 days before the program presentations and before students receive copies of the printed material. Two post-tests will take place. The first post-test will be administered within 7±1 days after the final scheduled program presentation and will be a measure of knowledge acquisition. The second post-test will take place 90±7 days post-intervention and will be a measure of knowledge retention.
3229820|NCT01185119|Active Comparator|GLP-1|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
3229821|NCT01185119|Placebo Comparator|placebo|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
3229822|NCT01185132|Experimental|IMRT|Intensity modulated radiotherapy, 38.5 Gy, 10 fractions over 5 days
3229823|NCT01185132|Active Comparator|3D-CRT|Three dimensional conformal external radiotherapy, 38.5 Gy, 10 fractions over 5 days
3229824|NCT01185145|Experimental|Mammosite|Accelerated Partial Breast Irradiation using Mammosite RTS
3229825|NCT01185145|Experimental|IMRT|Accelerated partial breast irradiation using IMRT planning technique of external beam radiotherapy
3229826|NCT01185158|Experimental|ZD1839 (IRESSA) 250mg|ZD1839(IRESSA) 250mg orally (po) daily
3229827|NCT01185184|Experimental|1|Subjects will receive in random order, the immediate release tablet containing 10 mg of CP-690,550 and two different controlled-release capsules containing 20 mg of CP-690,550.
3229828|NCT01185197|Experimental|Myfortic plus low-dose steroid|Not necessary
3229829|NCT01185197|Active Comparator|Standard-dose steroid|Not necessary
3324326|NCT02044042||HCV pregnant women|HCV chronically infected pregnant women, with a positive HCV RNA during pregnancy
3324327|NCT02044055||Children born to HBV-HDV women|"Children born to HBV-HDV co-infected women will be checked for:~HDV antibodies~if positive, HDV RNA"
3324328|NCT02044068||children born from HIV-HBV women|Studying retrospectively their status for HBs Ag and HBc Ab
3229830|NCT01185210|Placebo Comparator|Placebo|Subjects will receive placebo (mix of sugar and salt).
3229831|NCT01185210|Experimental|Alanine - 12.5|Subjects will receive 12.5 grams of alanine
3229832|NCT01185210|Experimental|Alanine - 25|Subjects will receive 25 grams of alanine.
3229833|NCT01185223|Other|Valganciclovir|
3229834|NCT01185223|Active Comparator|Ganciclovir|
3324329|NCT02044081|Other|Mouth Rinse Administration|Day 0, three consecutive C16G2 or placebo rinse administrations followed by three single C16G2 or placebo rinse administrations. Days 1 to 6 two additional C16G2 or placebo rinse administrations.
3324330|NCT02044081|Other|Dental Tray Gel Administration|Day 0, two C16G2 or placebo gel dental tray applications and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo dental tray applications and two C16G2 or placebo rinse administrations.
3324331|NCT02044081|Other|Electric Toothbrush Gel Application|Day 0, four C16G2 or placebo gel administrations applied with an electric toothbrush and four C16G2 or placebo rinse administrations. Days 1 to 6, two C16G2 or placebo gel administrations applied with a electric toothbrush and two C16G2 or placebo rinse administrations.
3324332|NCT02044081|Other|Manual Toothbrush Gel Application|Day 0, four C16G2 or Placebo gel administrations applied with a manual toothbrush and four C16G2 or Placebo rinse administrations. Days 1 to 6, two C16G2 or Placebo gel administrations applied with a electric toothbrush and two C16G2 or Placebo rinse administrations.
3324333|NCT02044107|Experimental|Co-packaging and counseling messages|"Current standard care at public health center ( zinc ORS for treatment of diarrhea and antibiotics for treatment of of pneumonia).~The intervention consists of health center level co-packaging and visual counseling messages (zinc & ORS packaged at health center for diarrhea, and zinc & antibiotics co-packaged at health center for pneumonia) Co-packaging is done in a plastic bag, which is covered with pre-tested zinc treatment messages - a distinct packaging has been designed for diarrhea and for pneumonia"
3324334|NCT02044107|No Intervention|Control group|Current standard care at public health center (zinc & ORS for treatment of diarrhea and zinc & antibiotics for treatment of of pneumonia).
3324335|NCT02044120|Experimental|niraparib and temozolomide|Niraparib (capsule) and temozolomide (capsule) will be taken together.
3324336|NCT02044120|Experimental|niraparib and irinotecan|Niraparib will be taken orally and irinotecan will be administered intravenously.
3229835|NCT01185236|Experimental|simvastatin/ezetimibe (vytorin) group|vytorin 10/20mg po once daily for 12weeks
3229836|NCT01185236|Active Comparator|atorvastatin group|atorvastatin 20mg po once daily for 12weeks
3229837|NCT01185262|Experimental|Lenalidomida, Rituximab|Phase I: Lenalidomide will be administered from day 1 to 21 of 28 days cycles, escalating doses (from 2,5mg to 25 mg).Rituximab dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
3229838|NCT01185275||Severe Asthma Patients|Severe asthma patients symptomatic despite high dose inhaled corticosteroid and long acting beta-agonist
3229839|NCT01185314|Other|1|EGFR mutation testing
3229840|NCT01185327||Study|Infants to Israeli Ethiopian-origin Mothers
3229841|NCT01185327||Control|Infants to Israeli non-Ethiopian-origin mothers
3229842|NCT01185379|Active Comparator|Efalex Active 50+|
3229843|NCT01185379|Active Comparator|DHA-rich fish oil|
3229844|NCT01185379|Placebo Comparator|Placebo|
3229845|NCT01185405|Experimental|EA group|Voriconazole dosage adjustment according to the each measurements of voriconazole levels from day 1, using NONMEM program
3229846|NCT01185405|Active Comparator|CA group|Voriconazole dosage adjustment according to the levels from day 5, using predefined protocol
3229847|NCT01185418||risperidone|
3229848|NCT01185418||aripiprazole|
3229849|NCT01185418||haloperidol|
3229850|NCT01185418||amisulpride|
3229851|NCT01185418||lactose|
3324337|NCT02044120|Experimental|niraparib, irinotecan and temozolomide|Niraparib and temozolomide will be taken orally. Irinotecan will be administered intravenously.
3324338|NCT02044133|Other|Dosage of vitamine D : inclusion and 6 month|Participant will have one dosage of vitamine D to entrance of prison and one dosage of vitamine D 6 month after entry
3324339|NCT02044133|Other|Dosage of Vitamine D 6 month|Participant will have one dosage of vitamine D 6 month after entry to prison
3229852|NCT01185431|Experimental|Ficus carica (Fig paste)|
3324340|NCT02044146|Experimental|Personalized Therapy|"A point-of-care bedside genetic test for CYP2C19*2 and CYP2C19*3 using a buccal swab will be conducted.2 P2Y12 inhibitory drug therapy will be then be directed based on a risk algorithm (integrating genotyping and clinical variables). Patients with high ischemic risk are defined as having (*2 or *3) and/or diabetes and/or (having age>65 AND BMI>=28). High-risk patients will be switched to prasugrel at 10mg daily, while low ischemic risk patients be kept on clopidogrel 75 daily. For patients >age 75 or wt < 60 kg, prasugrel will be reduced to 5mg daily."
3229853|NCT01185431|Placebo Comparator|Control (Placebo paste)|
3229854|NCT01185444|Experimental|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
3229855|NCT01185444|Active Comparator|Hyalgan|the control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
3229856|NCT01185457||Left interscalene block|Left shoulder surgery under left interscalene block and HRV
3229857|NCT01185457||Right interscalene block|Right shoulder surgery under right interscalene block and HRV
3229858|NCT01185470|Experimental|Subjects with Implantable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo study device implantation .
3229859|NCT01185496||CGM|Blinded/Unblinded CGM wear in adjunct with SMBG meter diabetes management
3229860|NCT01185535|Active Comparator|2 times topical anesthesia for glottis|
3229861|NCT01185535|Active Comparator|3 times topical anesthesia for glottis|
3229862|NCT01185535|Active Comparator|4 times topical anesthesia for glottis|
3229863|NCT01185574|Experimental|Vitamin D supplementation|The study medication (a capsule of 50,000 IU of vitamin D2) will be administered once a week for six months.
3324341|NCT02044146|Active Comparator|Ticagrelor|Patients will be treated with a 90mg twice daily regimen of Ticagrelor
3324342|NCT02044146|Other|Clopidogrel registry arm|A concurrent registry of patients (not randomized) who are receiving clopidogrel only (as decided by treating physician) will be followed as a comparator group.
3324343|NCT02044172|Active Comparator|Radical prostatectomy|Radical prostatectomy
3324344|NCT02044172|Active Comparator|Conformal radiation therapy|Conformal radiation therapy External beam radiation therapy
3229864|NCT01185587||healthy patients with a normal heart|
3229865|NCT01185587||patients with HF without an lCD|
3229866|NCT01185587||patients with HF and an ICD without shock|
3229867|NCT01185587||patients with HF and an ICD with shock|
3229868|NCT01185613|Experimental|Therapy™ Cool Flex Ablation Catheter|
3229869|NCT01185626|No Intervention|Usual care|The gynaecological oncologist (GO) provides care as usual. Currently, hospitals provide follow-up following the Dutch guidelines, meaning that they see their patients on given time points based on the number of years after diagnosis. Most hospitals give their patients leaflets regarding the diagnosis and treatment they receive, however none of them provide personalized information. All information is given during the initial treatment phase, but none of the GOs give additional information during follow-up. None of the GOs is actively screening on psychosocial needs. As this might change in time, we will ask the providers and patients about the type of information they provide, respectively, receive.
3229870|NCT01185626|Experimental|SCP care|After initial treatment, the GO provides the patient with a paper SCP and takes time to discuss all items in the SCP. Each time during follow-up meetings between patient and GO, the patient will receive an updated SCP if applicable. The paper SCP is extracted from the online registration system 'ROGY' (Registrationsystem Oncological GYnaecology) and combines personal patient and disease data with tailored information that is related to the specific situation of this patient. Recurrences, toxicities or additionally involved specialists will be registered in ROGY and automatically updated in the personal SCP.
3229871|NCT01185665|Active Comparator|TENS|FBSS patients treated with TENS
3324345|NCT02044172|Active Comparator|Active monitoring|Active monitoring of prostate specific antigen levels and disease surveillance
3324346|NCT02044185||high dose chemotherapy|group of using myeloablation regimen, autologous stell cell transplantation
3324347|NCT02044185||control group|normal population with health screening
3324348|NCT02044198|Active Comparator|Group 1 - FMP2.1/AS01B vaccine|"FMP2.1/AS01B vaccine administered at days 0, 28 and 56.~Blood-stage controlled human malaria infection (CHMI) at day 70."
3324349|NCT02044198|No Intervention|Group 2 - control|"Group 2 is an infectivity-control group for the malaria infection challenge procedures; these volunteers will not be vaccinated.~Blood-stage controlled human malaria infection (CHMI) at day 70."
3324350|NCT02044211|Active Comparator|Collaborative Care for Heart Failure + Depression|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Counseling for depression~Drug:~Pharmacotherapy for heart failure Pharmacotherapy for depression"
3324351|NCT02044211|Active Comparator|Collaborative Care for Heart Failure Only|"Collaborative care program for heart failure and depression involving a nurse care manager providing counseling and treatment advice via telephone~Interventions:~Behavioral:~Counseling for heart failure self-care Usual care for depression~Drug:~Pharmacotherapy for heart failure~Usual Care for depression"
3324352|NCT02044211|No Intervention|Usual Care for Heart Failure and Depression|Control group will receive their doctors' usual care for heart failure and depression
3324353|NCT02044211|No Intervention|Non-Depressed Comparison Cohort|Control group will receive their doctors' usual care for heart failure
3324354|NCT02044224|Experimental|Dexmedetomidine|Dexmedetomidine infusion during anaesthesia for IRE procedure
3324355|NCT02044237|Experimental|Decoupling|specific technic to reduce hair pulling
3229872|NCT01185665|Placebo Comparator|Sham-TENS|patients treated with Sham-Tens
3229873|NCT01185678||Group1|
3229874|NCT01185730|Experimental|pulmonary hypertension|cohort of patients with pulmonary hypertension
3229875|NCT01185743|Active Comparator|olanzapine|olanzapine
3229876|NCT01185743|Active Comparator|ziprasidone|ziprasidone
3324356|NCT02044237|Active Comparator|progressive muscle relaxation|Progressive relaxation relaxation technic
3324357|NCT02044250|Active Comparator|Clopidogrel|Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
3324358|NCT02044250|Placebo Comparator|Aspirin|Antiplatelet monotherapy : Aspirin 100~200mg P.O. daily
3324359|NCT02044263|Experimental|Internet CBT-i|Participants will be instructed on the use of the internet CBT-i (SHUTi) intervention site, then use the program for six weeks.
3324360|NCT02044263|Active Comparator|face-to-face CBT-i|4 to 8 sessions of face-to-face CBT-i treatment with one of three clinicians (experienced CBT-i psychiatrists)
3324361|NCT02044315|Sham Comparator|Conventional|Conventional ICD programming
3229877|NCT01185743|Placebo Comparator|Sugar pill|Sugar pill
3229878|NCT01185756|Experimental|ICD implantation|"MIBG for diagnostic purpose:~MIBG scintigraphy for diagnostic purpose"
3229879|NCT01185769|Experimental|High fat|500 mg of tocotrienol will be administered at single dose after consumption of high fat diet
3324362|NCT02044315|Experimental|High-zone|High-zone ICD programming
3324363|NCT02044328|Experimental|Icotinib|Patients receive icotinib 125 mg three times daily as adjuvant chemotherapy with for 18 months after surgery.
3324364|NCT02044341|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
3324365|NCT02044341|Placebo Comparator|Glycerin ear drops|"Topical ear drops~The dosing regimen is every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period~Children 2 Months to 12 Years: dispense five drops of study drug into the affected ear canal(s) each hour, as needed for ear pain, or Children 12 years to <19 years: dispense 10 drops of study drug into the affected ear canal(s) each hour, as needed for ear pain."
3324366|NCT02044354|Other|Do/Ca|Arm Do/Ca : Taxotere 75mg/m2/3w x 4 cycles, followed by Jevtana 25mg/m2/3w x 4 cycles
3324367|NCT02044354|Other|Ca/Do|Arm Ca/Do : Jevtana 25mg/m2/3w x 4 cycles, followed by Taxotere 75mg/m2/3w x 4 cycles
3324368|NCT02044406|Experimental|1 BI 1181181 single rising dose part|single rising doses of BI 1181181
3324369|NCT02044406|Experimental|2 BI 1181181 bioavailability part|bioavailability, food effect part of BI 11881181
3324370|NCT02044432|Experimental|Ginger compress|
3324371|NCT02044432|No Intervention|Wait list|
3324372|NCT02044445|Active Comparator|36 h group|Oocyte retrieval will be performed 36 hours after hCG administration
3324373|NCT02044445|Active Comparator|38 h group|Oocyte retrieval will be performed 38 hours after hCG administration
3324374|NCT02044471|Experimental|Intervention|"Our intervention will be ischemic conditioning (IC) remotely applied using a sphygmomanometer. We will use the standard, validated protocol, which is inflation of the sphygmomanometer to 200 mmHg for 5 minutes, then deflation with 5 minutes of reperfusion, repeated for 3 cycles (total 30 minutes). This will be done in the dominant arm, twice daily.~Once patients are discharged home on a stable pharmacotherapy regimen, they will be expected to follow the above intervention for 6 weeks, followed by another 6 weeks in the control (no intervention) phase. Patients will be randomized as to which phase they begin the study."
3324375|NCT02044471|No Intervention|Control|standard care
3324376|NCT02044484|Experimental|Multi-component intervention|"Computer-based intervention (CBI) completed twice (separated by 2-4 months) among patients whose viral load exceeds 1000 copies/mL at time of enrollment.~One-on-one counseling from a project Health Coach (three 1-hour sessions at the clinic and two follow-up phone calls at 1 and 3 months after last session). The counseling is offered to patients who do not show a 1-log reduction in their viral load after the first CBI or whose viral load remains above 200 copies/mL after two administrations of the CBI.~Behavioral screening of patients at HIV primary care visits.~Dissemination of palm cards with empowering messages at HIV primary care visits."
3324377|NCT02044484|No Intervention|Standard of care control|HIV patients will continue to receive existing standard of care practices at the clinic without receiving the multi-component intervention.
3324378|NCT02044497|Experimental|oral oxycodone|An orogastric tube will be placed in the stomach (placement verified by routine accepted clinical guidelines) under anesthesia as is part of standard routine clinical care to remove gastric contents. The same orogastric tube will be used for intragastric liquid oxycodone administration in a dose of 0.1 mg/kg before the surgical incision. This weight-adjusted dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines at Boston Children's Hospital.
3324379|NCT02044523||Hepatis C, Hepatitis B, NAFLD|"All patients enrolled will undergo:~Transient Elastography (Fibroscan)~Acoustic Radiation Force Impulse (ARFI)~Magnetic Resonance Elastography (MRE)"
3324380|NCT02044536||Faculty doctors|Experienced endoscopists (> 6000 cases). no intervention
3324381|NCT02044536||Trainees|Doctors on fellowship who are inexperienced endoscopists (< 4 months of endoscopy training) no intervention
3229880|NCT01185769|Experimental|Low fat|500 mg of tocotrienol will be administered at single dose after consumption of low fat diet
3229881|NCT01185795|Experimental|Cardioviva™ yogurt|
3229882|NCT01185795|Placebo Comparator|Placebo yogurt|
3229883|NCT01185808|Active Comparator|Vitamin D|Vitamin D 5,000IU/day for 6 weeks
3229884|NCT01185808|Placebo Comparator|Placebo|Placebo for 6 weeks.
3229885|NCT01185847|Experimental|A non-squamous|
3229886|NCT01185847|Experimental|A squamous|
3229887|NCT01185847|Active Comparator|B non-squamous|
3229888|NCT01185847|Active Comparator|B squamous|
3229889|NCT01185860|Active Comparator|A|
3229890|NCT01185860|Experimental|B|
3229891|NCT01185860|Placebo Comparator|C|
3229892|NCT01185873|Experimental|1|
3229893|NCT01185899||Suspected ACS patients|Patients presenting with chest pain to the Emergency Department, who are suspected of having ACS, will be asked to participate in the study.
3229894|NCT01185912||Cardiomyocyte apoptosis|Elective aortic valve replacement patience
3229895|NCT01185925|Placebo Comparator|Placebo|Control Group
3229896|NCT01185925|Active Comparator|sildenafil, pde5 inhibitor|treatment group; sildenafil 50 mg three times a day for 1 year
3229897|NCT01185938|Active Comparator|Rosuvastatin|
3229898|NCT01185938|No Intervention|Control|
3229899|NCT01185951|Active Comparator|Achilles tendinopathy|Patients suffering both, insertional and midportion Achilles tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3229900|NCT01185951|Active Comparator|Patella tendinopathy|Patients suffering patella tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3229901|NCT01185951|Active Comparator|Epikondylitis|Patients suffering both, lateral (tennis elbow) or medial (golfers' elbow) elbow tendinopathy seeking medical help. All patients were evaluated with a standardized Power-Doppler ultrasound to detect the level of neovascularisation at the point of pain.
3229902|NCT01185977|Active Comparator|Fluoxetine|1 week single-blinded placebo lead-in and double-blinded FLX treatment for 8 weeks
3229903|NCT01185977|Placebo Comparator|Placebo (PBO)|Placebo treatment for 9 weeks of study
3229904|NCT01185990||Tinnitus subjects|Subjects with chronic, moderate to severe unilateral tinnitus.
3229905|NCT01185990||Healthy control subjects|
3259121|NCT01467687|Active Comparator|2|300 mg capsule of Verelan PM or 300 mg verapamil controlled release capsule given orally with food as a single dose with blood collected at 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 30, 36, 48, 60 and 72 hours.
3259122|NCT01467726|Experimental|Dose regimen 1|Varied doses
3259123|NCT01467726|Experimental|Dose regimen 2|Varied doses
3259124|NCT01467726|Experimental|Placebo|Matching placebo
3229908|NCT01186016|Experimental|Genetic Education Session (GES)|The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment.
3229909|NCT01186016|Active Comparator|Nutrition Education Session (NES)|
3324382|NCT02044549|Active Comparator|carbetocin|single 100 μg IV dose of carbetocin (150 women) after fetal extraction and before placental removal.
3324383|NCT02044549|Active Comparator|Syntometrine|Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.
3324384|NCT02044562|Experimental|nitrate supplementation|Patients will receive 7-day nitrate supplementation at the end of the radiotherapy.
3324385|NCT02044562|Placebo Comparator|Placebo|Patients will receive 7-day placebo supplementation at the end of the radiotherapy
3324386|NCT02044575||Critically ill patients|Intensive care unit patients with refractory septic shock
3324387|NCT02044588||HBsAg negative kidney allograft donor|
3324388|NCT02044588||HBsAg positive kidney allograft donor|HBsAg positive kidney allograft donor
3324389|NCT02044601|Experimental|Chemoradiation + Onartuzumab|"Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
3324390|NCT02044601|Experimental|Chemoradiation + Erlotinib + Onartuzumab|"Participants with EGFR mutation to receive this regimen. Participants with wild-type EGFR mutation to be randomized, and may receive this regimen.~Phase I: Erlotinib 150 mg by mouth every day throughout radiation, except for chemotherapy day. Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle. Paclitaxel 45 mg/m2 by vein once a week throughout radiation for 7 weeks. Carboplatin AUC 2 by vein once a week throughout radiation for 7 weeks. Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.~Phase II: Same regimen as in Phase I, but starting dose of Onartuzumab is maximum tolerated dose from Phase I."
3324391|NCT02044614|Other|icodextrin-based peritoneal dialysis to hemodialysis|12-week course of adjuvant low-frequency icodextrin-based peritoneal dialysis to ongoing thrice-weekly maintenance hemodialysis
3324392|NCT02044627|Experimental|1 dose of [14C-ETC-1002]|
3229910|NCT01186042||Aging in HIV|20-40 years of age or older than 50
3324393|NCT02044640||Appendectomy|Patients undergoing a laporascopic appendectomy
3324394|NCT02044653|Experimental|Group A (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 3ug/kg
3324395|NCT02044653|Experimental|Group B (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
3324396|NCT02044653|Experimental|Group C (Part A)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
3324397|NCT02044653|Experimental|Group D (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 3ug/kg
3229911|NCT01186055||Smoking Cessation Counseling|Individuals will receive individual and group counseling for 8 weeks (6 visits) while they quit smoking.
3229912|NCT01186068|Experimental|V-101 Cream 0.01% Concentration|Low dose
3324398|NCT02044653|Experimental|Group E (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 5ug/kg
3324399|NCT02044653|Experimental|Group F (Part A)|GX-E2 : Subcutaneously injection every 4 weeks (Q4W) at dose 8ug/kg
3229913|NCT01186068|Experimental|V-101 Cream 0.06% Concentration|Mid-dose
3324400|NCT02044653|Experimental|Group G (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 5ug/kg
3324401|NCT02044653|Experimental|Group H (Part B)|GX-E2 : Subcutaneously injection every 2 weeks (Q2W) at dose 8ug/kg
3229914|NCT01186068|Experimental|V-101 Cream 0.1% Concentration|Mid-dose
3324402|NCT02044653|Active Comparator|Group I (Part B)|MIRCERA : Subcutaneously injection every 2 weeks (Q2W) at dose 0.6ug/kg
3324403|NCT02044653|Experimental|Group J (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 5ug/kg
3324404|NCT02044653|Experimental|Group K (Part B)|GX-E2 : Intravenously injection every week (Q1W) at dose 8ug/kg
3324405|NCT02044653|Experimental|Group L (Part B)|GX-E2 : Intravenously injection every 2 weeks (Q2W) at dose 8ug/kg
3324406|NCT02044653|Active Comparator|Group M (Part B)|NESP : Intravenously injection every week (Q1W) at dose 30ug
3324407|NCT02044666|Experimental|Treatment|
3324408|NCT02044679|Experimental|A = Increase water intake 1|+ 1,5 to 2,0 L/day of water
3324409|NCT02044679|Experimental|B = Increase water intake 2|+ 1,0 to 1,5 L/day of water
3324410|NCT02044679|Other|C = no change|No change
3324411|NCT02044705|Experimental|Family group sessions|Active and Healthy Families
3324412|NCT02044705|No Intervention|Wait-list control|Controls may participate in Active and Healthy Families after the study
3324413|NCT02044731|Experimental|Family group sessions|Active and Healthy Families
3324414|NCT02044744|Experimental|Referral|Physical activity referral
3324415|NCT02044744|No Intervention|Wait-list control|Wait-list controls receive no intervention until after they provide follow-up measurements.
3229915|NCT01186068|Experimental|V-101 Cream 0.15% Concentration|High dose
3229916|NCT01186068|Placebo Comparator|Vehicle|Cream without an active ingredient
3229917|NCT01186081|Experimental|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
3324416|NCT02044757|Experimental|SSB withdrawal|
3324417|NCT02044783|Experimental|Behavioral Intervention|Behavioral Counseling Intervention: 6 telephone calls that include physical activity goal-setting, tracking,and problem-solving of barriers
3229918|NCT01186081|Active Comparator|Postoperative chemoradiotherapy|Postoperative chemoradiotherapy with conventional radiation schedule and oral fluoropyrimidine (capecitabine)
3324418|NCT02044783|No Intervention|Usual Care|Monthly mailed print materials on aging topics (that would generally be administered by subjects' primary care clinic). No behavioral counseling.
3324419|NCT02044809|Placebo Comparator|Placebo|
3324420|NCT02044809|Experimental|Cannabidiol 200mg Oral|
3324421|NCT02044809|Experimental|Cannabidiol 400mg Oral|
3324422|NCT02044809|Experimental|Cannabidiol 800mg Oral|
3324423|NCT02044835|Placebo Comparator|OMT controll|placebo 20 ml every time, three times a day, combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
3324424|NCT02044835|Experimental|herbal treatment|Fu-zheng-qu-zhuo oral liquid ( herbal medicine) 20 ml every time, three times a day,combined with optimal medical therapy of internal medicine, including anti-platelet therapy and other protocol-driven medical therapies to control blood pressure and glucose and lipid levels in accordance with guidelines.
3324425|NCT02044861|Experimental|ACT-PFK-158|dose escalation
3324426|NCT02044887|Experimental|INTERVENTION|Participants will receive instructions to do physical activity with an adapted physical activity program. This program will be designed and applied by Primary Health Care professionals in patients with dementia and caregivers.
3324427|NCT02044887|No Intervention|Control|The control group will receive regular care.
3324428|NCT02044913|Experimental|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention aims at supporting the patients in coordinating their aftercare treatment which can help to maintain or even improve longterm treatment outcome.
3324429|NCT02044913|No Intervention|Treatment as usual|After inpatient treatment patients receive treatment as usual within routine care.
3229919|NCT01186094|Active Comparator|Cypher|Sirolimus-eluting stent
3229920|NCT01186094|Active Comparator|Endeavor Resolute|Zotarolimus-eluting Stent
3324430|NCT02044939|Experimental|Pulmonary rehabilitation|Sarcoidosis patients will realize a pulmonary rehabilitation program
3324431|NCT02044939|No Intervention|Controls|Sarcoidosis patients who do not achieve a respiratory rehabilitation program but will have physical activity counseling.
3324432|NCT02044952|Experimental|Mesalazine, Tripterygium glycosides|Mesalazine 4g/d and Tripterygium glycosides 2mg/kg/d for 12 weeks
3324433|NCT02044965|No Intervention|Antibiotic|This group will be prescribed a dose of antibiotics (Septra 2mg/kg)
3324434|NCT02044965|Placebo Comparator|Probiotic plus placebo|Receive probiotic plus an antibiotic placebo
3324435|NCT02044965|Active Comparator|probiotics plus antibiotic|This group will be on a dose of probiotics (2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule) plus a antibiotic (Septra)
3324436|NCT02044978|Active Comparator|Bisphosphonate implant|Dental implant coated with zoledronate Note: Both arms in each patient (2 implants)
3324437|NCT02044978|Placebo Comparator|control|Dental implant without coating Note: Both arms in each patient (2 implants)
3324438|NCT02045004||Surgery Group Sevoflurane|Patients aged ≥ 65 years undergoing major surgical procedures.
3324439|NCT02045004||Control Group|Healthy study participants aged ≥ 65 years (no surgical intervention).
3324440|NCT02045017|Experimental|Pomalidomide and low dose Dexamethasone|Pomalidomide 4mg, and low dose Dexamethasone, starting at 40mgs(≤ 75 years old) or 20 mg/day (> 75 years old)
3324441|NCT02045030|Experimental|aflibercept and FOLFIRI|aflibercept and FOLFIRI
3324442|NCT02045043||Cardiomyopathy patients with ICDs|
3324443|NCT02045056|Experimental|Gemfibrozil|Gemfibrozil 600 mg by mouth twice daily for 48 weeks
3324444|NCT02045056|Placebo Comparator|Sugar pill|Matching placebo capsule by mouth twice daily for 48 weeks
3324445|NCT02045069|Experimental|2 days Ivermectin|Ivermectin 200 - 400 µg/kg once daily for 2 days
3324446|NCT02045069|Experimental|3 days Ivermectin|Ivermectin 200-400 µg/kg once daily for 3 days
3324447|NCT02045069|Placebo Comparator|Placebo|Placebo
3324448|NCT02045082|Experimental|Flocked swab (Copan 519CS01)|Sampling of the cornea by the flocked swab
3324449|NCT02045082|Experimental|Traditionnal fiber swab (Copan 164KS01)|Sampling of the cornea by the traditional finer swab
3324450|NCT02045121|Experimental|Indwelling Pleural Catheter|Day-case IPC insertion. Attendance d10 for drainage, stitch removal and education in catheter care.
3324451|NCT02045121|Active Comparator|Talc Pleurodesis|Hospital admission for chest drain insertion and suction if needed, plus talc pleurodesis by slurry or poudrage if >75% of visceral and parietal pleura in direct contact on chest x-ray.
3324452|NCT02045134|Placebo Comparator|Placebo|Soluble corn flour not rich in anthocyanins
3324453|NCT02045134|Active Comparator|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
3324454|NCT02045147|Experimental|Grp 1 Low Cognition, Low Activation|Group 1: Subjects will receive an 8 week care transition intervention with an Advanced Practice Registered Nurse-Nurse Practitioner (APRN-NP) and Certified Nursing Assistant (CNA). The APRN-NP will guide the care transition intervention. This group will receive the most intense intervention.
3324455|NCT02045147|Experimental|Grp 2 Low Cognition, High Activation|Group 2: Subjects will receive an 8 week care transition intervention with an APRN-NP and CNA. The APRN-NP will guide the care transition intervention. This group will receive an intense intervention.
3324456|NCT02045147|Experimental|Grp 3 Normal Cognition, Low Activation|Group 3: Subjects will receive an 4 week care transition intervention with a Registered Nurse (RN) Coach. This group will be evaluated at four weeks, if the patient activation levels are still low, they will be referred to the 4 week APRN-NP and CNA.
3229921|NCT01186107|Experimental|Endeavor Resolute stent|zotarolimus-eluting stent
3229922|NCT01186107|Active Comparator|Cypher stent|sirolimus-eluting stent
3229923|NCT01186120|Experimental|Biolimus A9-eluting stent|NOBORI stent
3229924|NCT01186120|Active Comparator|Everolimus-eluting stent|PROMUS ELEMENTE stent
3229925|NCT01186133||DESSIAN|consecutive patients receiving CYPHER stent
3324457|NCT02045147|Experimental|Grp 4 Normal Cognition, High Activation|Group 4: Subjects will receive the least intensive intervention delivered by a RN coach.
3324458|NCT02045160||Sulfamethoxazole-trimethoprim treatment|
3324459|NCT02045173|Other|Apneascan TM|autoscoring algorithms of the Apneascan TM compared to the polysomnography or polygraphy
3324460|NCT02045186|Other|Assessment of Oral HPV Infection|Oral HPV infection will be assessed 14 times, once prior to starting CRT, weekly during CRT, and then serially post-treatment: 4-8 weeks, 3 months, 6 months, 12 months, 18 months, 24 months. Patients will provide samples of their saliva and exfoliated epithelial cells at these timepoints. Samples will be collected with supplies provided by and analyzed by OralDNA Labs.
3324461|NCT02045199|Experimental|V0111|
3324462|NCT02045199|Placebo Comparator|Placebo|
3324463|NCT02045225|Experimental|Cognitive behavioural therapy|Reduction of social anxiety & substance use in gay/bi men
3324464|NCT02045251|Experimental|Interventional Arm|This arm will have 100 patients receiving the proposed Pylera based regimen for 10 days.
3324465|NCT02045290|Placebo Comparator|Oral Placebo|"A central pharmacy will compound a placebo to match the metformin tablets.~The placebo product will contain the following components:~Micosolle™, silica based excipient~Silicified Micro Crystalline Cellulose, National Formulary~Safflower Oil, United States Pharmacopeia~K-30 Povidone Powder~Magnesium Stearate, National Formulary (Vegetable source)~Fumed Silica, National Formulary"
3324466|NCT02045290|Experimental|Metformin|Metformin 2000 mg per day
3324467|NCT02045303|Experimental|Ambulatory Wound Clinic|Intervention with contact ultrasound therapy and noncontact ultrasound therapy following the study protocol on subjects receiving care at the wound clinic.
3324468|NCT02045316||Preeclamptic pregnants|pregnants with preeclampsia
3324469|NCT02045316||Normal pregnants|pregnants without obstetric complications
3229926|NCT01186133||K-XIENCE|consecutive patients receiving Xience stent
3229927|NCT01186133||GENOUS|consecutive patients receiving GENOUS stent
3324470|NCT02045329||Staphylococcus aureus nasal carriers|Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus
3324471|NCT02045342|Experimental|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
3324472|NCT02045342|Placebo Comparator|Placebo|Ingest 500ml of placebo prior to metabolic measures.
3229928|NCT01186133||ELEMENT|consecutive patients receiving PROMUS-ELEMENT stent
3229929|NCT01186133||PRIME|consecutive patients receiving XIENCE-PRIME stent
3229930|NCT01186133||NOBORI|consecutive patients receiving NOBORI stent
3229931|NCT01186133||INTEGRITY|consecutive patients receiving RESOLUTE-INTEGRITY stent
3324473|NCT02045355|Experimental|Fish intervention|The patients will receive one portion of salmon (150 g), one portion of cod (150 g), and two portions of sild (50g each) per week.
3324474|NCT02045355|No Intervention|Meat control group|The control food will be pork and chicken (150 g each) and two portions of cooked ham / liver pate for use in cold meals (50 g each).
3324475|NCT02045368|Experimental|Subject Treatment with IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.
3324476|NCT02045381||MRI group|Patient receives one research MRI prior to radiation treatment.
3324477|NCT02045394||Patients presenting with haemoptysis|
3324478|NCT02045420||Normal Participants|"The investigators will use normal age-matched volunteers to compare against the Idiopathic Parkinson's Disease Patients"
3324479|NCT02045420||Idiopathic Parkinson's Disease Patients|The investigators will observe the MR scans to determine the vascular flow, brain lesions and brain iron levels in this group.
3324480|NCT02045446|Active Comparator|Maintenance chemotherapy|FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed
3324481|NCT02045446|Experimental|Stereotactic Body Radiation Therapy|consolidative Stereotactic Body Radiation Therapy (SBRT) plus maintenance chemotherapy
3324482|NCT02045459|Experimental|Exercise Program and Medical Therapy|All subjects randomized to this arm will be given intensive medical therapy including - Isosorbide mononitrate, Lisinopril, Carvedilol, and Simvastatin. After 8 weeks of ONLY medication therapy, the subjects will begin a intensive exercise program. This will be supervised on site at UVA. Also, on days that the subject is not being supervised, they will be required to keep a journal of their exercise at home.
3324483|NCT02045472|Experimental|VIS410|VIS410 administered as a single infusion with ascending dose-escalation ranging from 2 to 50 mg/kg
3324484|NCT02045472|Placebo Comparator|Placebo|Placebo administered as a single infusion
3324485|NCT02045498|Experimental|capnography, feedback, quality of cpr|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
3324486|NCT02045498|No Intervention|conventional cpr|conventional cpr
3324487|NCT02045524|Experimental|Injection location1|Single dose IM injection
3324488|NCT02045524|Experimental|Injection location 2|Single dose IM Injection
3324489|NCT02045537||Fractures|Patients in follow up from 1st Jan 1997 to 1st Jan 2012 with any fracture (pathologic)
3324490|NCT02045550|Placebo Comparator|Placebo Syrup|Placebo Syrup 2.5 ml twice daily for 4 weeks
3229932|NCT01186133||XPEDITION|consecutive patients receiving XIENCE-XPEDITION stent
3229933|NCT01186133||BIOMATRIX|consecutive patients receiving BIOMATRIX stent
3229934|NCT01186133||CILOTAX|consecutive patients receiving CILOTAX stent
3229935|NCT01186133||DEB|consecutive patients receiving Drug eluting balloon
3229936|NCT01186133||DESYNE|consecutive patients receiving DESYNE stent
3229937|NCT01186133||PREMIER|consecutive patients receiving PROMUS-PREMIER stent
3229938|NCT01186133||ORSIRO|consecutive patients receiving ORSIRO stent
3229939|NCT01186133||ONYX|consecutive patients receiving ONYX stent
3229940|NCT01186133||BVS|consecutive patients receiving Bioresorbable Vascular Scaffold
3229941|NCT01186133||BVS AMI|consecutive acute myocardial infarction patients receiving Bioresorbable Vascular Scaffold
3229942|NCT01186133||Ultimaster|consecutive patients receiving Ultimaster stent
3324491|NCT02045550|Active Comparator|Prospan Syrup|Prospan Syrup 2.5 ml twice daily for 4 weeks
3324492|NCT02045563||Patients with type-1 diabetes|
3324493|NCT02045563||Patients with type-2 diabetes|
3229943|NCT01186133||Synergy|consecutive patients receiving Synergy stent
3324494|NCT02045563||Volontaires sains|
3324495|NCT02045576|Experimental|Sleep position trainer|Nightbalance
3229944|NCT01186133||Biofreedom|consecutive patients receiving Biofreedom stent
3324496|NCT02045576|Active Comparator|Oral Appliance Therapy|Somnodent
3324497|NCT02045589|Experimental|Dose Escalation, Combination|Three intratumoral administrations of VCN-01 oncolytic adenovirus every 28 days in combination with Abraxane® and Gemcitabine.
3324498|NCT02045602|Experimental|Part I: Dose Escalation, Single Agent|Single intravenous injection of VCN-01 oncolytic adenovirus
3324499|NCT02045602|Experimental|Part II: Dose Escalation, Combination|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
3324500|NCT02045602|Experimental|"Part III: Dose Escalation, Combination, delayed schedule"|Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
3324501|NCT02045615||Conventional|Conventional technique for Wichita nail extraction
3324502|NCT02045615||New|Proposed technique for Wichita nail extraction
3324503|NCT02045628|Experimental|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
3229945|NCT01186133||Firehawk|consecutive patients receiving Firehawk stent
3229946|NCT01186133||DESyne X2|consecutive patients receiving DESyne X2 stent
3324504|NCT02045628|No Intervention|Control|Those in the control group will receive usual care.
3324505|NCT02045641|No Intervention|current postoperative regimen|The group will follow the current postoperative regimen at the surgical ward; screening for pleural effusions with x-ray and further diagnostic procedures in case of symptoms. Treatment will be entirely in the hands of the clinical personnel.
3324506|NCT02045641|Experimental|pleuracentesis|The group will follow the current postoperative regimen. In addition they will be followed with ultrasound examination, clinical examination, spirometry examination and 6 minute walk test. In case of either a) pleural effusion > 400ml OR b) pleural effusion< 400ml with symptoms in rest or during the walk test, the effusion will be drained and examinations will be repeated. In case of pericardial effusion of predefined size and location, either the surgeon on call or a cardiologist will be consulted.
3324507|NCT02045654||MDS patients|MDS patients who were treated with decitabine
3324508|NCT02045667|Placebo Comparator|Placebo|Placebo tablets three times daily orally
3229947|NCT01186133||Sierra|consecutive patients receiving Sierra stent
3324509|NCT02045667|Active Comparator|Mexiletine|Mexiletine 200mg three times daily orally
3324510|NCT02045680||deep block|deep block
3324511|NCT02045680||non deep block (historical control)|non deep block (historical control)
3229948|NCT01186133||Tansei|consecutive patients receiving Tansei stent
3229949|NCT01186146|Active Comparator|Aspirin|Aspirin monotherapy (stopping clopidogrel at 1 year after DES)
3324512|NCT02045693|Experimental|Part 1: Methadone + DCV 3DAA FDC + BMS-791325|"Methadone 40-120 mg tablet or solution orally once on Day 1~Methadone 40-120 mg tablet or solution orally once daily + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3 direct-acting antiviral (3DAA) fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
3324513|NCT02045693|Active Comparator|Part 2: Buprenorphine/Naloxone + DCV 3DAA FDC + BMS-791325|"Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once on Day 1~Buprenorphine/Naloxone 8/2 - 24/6 mg tablet or sublingual film orally once + DCV 3DAA FDC (Daclatasvir 30 mg/Asunaprevir 200 mg/BMS-791325 75 mg 3DAA fixed dose combination tablet) orally twice daily + BMS-791325 75 mg tablet orally twice daily on Days 2 through 12"
3324514|NCT02045706|Experimental|Community Health Worker Trainings|Trained community health workers (CHW) (one per 25 households), conducted a focus group and four quarterly meetings. CHWs were then responsible for 25 households where they would teach preventive health, track health data for the Ministry, and refer sick cases (700 households total). Staff and volunteers also conducted home visits and handed out printed summaries. We also worked with the local villagers and community health workers to construct 3 protected water sources in the Intervention areas.
3324515|NCT02045706|No Intervention|Control Group|The Control Group was comprised of similar households to the Intervention Group (n = 700). In these villages, however, we did not instill the community health worker program until after the trial was completed.
3229950|NCT01186146|Experimental|Aspirin,Clopidogrel|Aspirin,Clopidogrel Dual antiplatelet therapy (continue aspirin and clopidogrel 1year after DES)
3229951|NCT01186159|Experimental|Normal Saline|
3229952|NCT01186172|Experimental|Ethanol-lock|Treatment with a combination of ethanol-lock and parenteral therapy
3229953|NCT01186172|Active Comparator|Antibiotic lock|Treatment with a combination of antibiotic-lock and parenteral therapy
3229954|NCT01186185|Experimental|Fludrocortisone|
3229955|NCT01186198||MINI TREK RX 1.20 mm Coronary Dilatation Catheter|
3229956|NCT01186211||Patients presenting for elective TKA|Patients will be advised preoperatively about an accelerated path while in hospital that will share many attributes of the standard TOH care map but with several additions, chosen to help reduce pain and hemarthrosis, both felt to be the major impediments to faster recuperation.
3229957|NCT01186237|Experimental|Early urinary catheter removal|
3229958|NCT01186263|Experimental|99mTc- labeled albumin macroaggregates (MAA)|Diagnostic MAA- SPECT- imaging.
3229959|NCT01186263|Experimental|99mTc- labeled albumin microspheres (B20)|Diagnostic B20- SPECT- imaging.
3229960|NCT01186276|Placebo Comparator|Corn Starch|Corn starch will serve as the control arm.
3229961|NCT01186276|Experimental|Fiber|Fiber will serve as the intervention.
3229962|NCT01186289|Experimental|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
3229963|NCT01186289|Placebo Comparator|placebo|
3229964|NCT01186302|Other|Midlevel provider|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
3259125|NCT01467739|Active Comparator|Ambu ® aScope®|
3324516|NCT02045719|Experimental|cat's claw|100 mg dose of a dry extract of U. tomentosa three times per day
3324517|NCT02045745|Experimental|Prolonged postoperative air leaks in risk patients.|Patients with prolonged postoperative air leaks
3324518|NCT02045758|Experimental|TAP20-C|TAP20-C
3324519|NCT02045758|Active Comparator|Fingerstick|Fingerstick
3324520|NCT02045771|Other|Support Group (Control Group)|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
3324521|NCT02045771|Experimental|Behavioral Activation|Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
3324522|NCT02045784|Experimental|Infant formula milk 60 µg iodine/day|Infant formula containing 57 µg/100 g powder, providing approximately 60 µg iodine/day (i.e. 55% of the current AI). Unrestricted consumption during 11 days.
3324523|NCT02045784|Experimental|Infant formula milk 110 µg iodine/day|Infant formula containing 92 µg/100 g powder, providing approximately 110 µg iodine/day (i.e. 100% of the current AI). Unrestricted consumption during 11 days.
3324524|NCT02045784|Experimental|Infant formula 220 µg iodine/day|Infant formula containing 217 µg/100 g powder, providing approximately 220 µg iodine/day (i.e. 200% of the current AI). Unrestricted consumption during 11 days.
3324525|NCT02045784|Other|Breast milk|Unrestricted consumption during 4 days
3324526|NCT02045797|Experimental|Treatment Group A|Subject will receive GSK2140944 750mg IV every 12 hours (q12h; twice daily [BID]) on Day 1 and Day 2. Subject may switch to GSK2140944 1500mg orally (PO) q12h (BID) at investigator's decision or will continue to receive GSK2140944 750mg IV q12h (BID) from Day 3 to Day 10.
3324527|NCT02045797|Experimental|Treatment Group B|Subject will receive GSK2140944 1000mg IV q12h (BID) on Day 1 and Day 2 . Subject may switch to GSK2140944 2000mg PO q12h (BID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q12h (BID) from Day 3 to Day 10.
3324528|NCT02045797|Experimental|Treatment Group C|Subject will receive GSK2140944 1000mg IV q8h (TID) on Day 1 and Day 2. Subject may switch to GSK2140944 2000mg PO q8h (TID) at investigator's decision or will continue to receive GSK2140944 1000mg IV q8h (TID) from Day 3 to Day 10.
3324529|NCT02045810|Active Comparator|Treatment|Patients in group receive Ileoinguinal block before the start of surgery, and an injection of plasebo saline after surgery. Injectate is blinded from caregiver.
3324530|NCT02045810|Placebo Comparator|Control group|Patients receive a plasebo saline injetion at the site of ileoinguinal block prior to surgery and an injectio with local anesthetics after surgery. The treatment group is blinded for caregiver.
3229965|NCT01186302|Other|Physician arm|Patients were assigned to a midlevel provider (arm 1) or to a physician (arm 2) for their abortion.
3324534|NCT02045849|Experimental|Part 1|Subjects will receive either GSK2140944 1500 mg (500 mg x 3) capsules under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fasted conditions or GSK2140944 1500 mg (750 mg x 2) tablets under fed conditions as per the randomization schedule in each of the three periods with a washout period of at least 3 days between the doses. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
3324535|NCT02045849|Experimental|Part 2|Subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) on Day 1 followed by a repeat dose of Itraconazole 200 mg once daily for 6 days from Day 4 to Day 9. On Day 7, subjects will receive a single dose of GSK2140944 1500 mg (tablet or capsule) one hour after the dose of Itraconazole. There will also be a follow-up visit within 5-7 days after the last dose of study drug.
3324536|NCT02045849|Experimental|Part 3|Subjects in Group 1 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fasting and fed conditions in Period I and Period II, respectively. Subjects in Group 2 will receive GSK2140944 1500 mg (750 mg x 2) tablets twice daily from Day 1 to Day 5 under fed and fasting conditions in Period I and Period II, respectively. There will be a washout of at least 7 days between the periods. Subjects will have a follow up visit 5-7 days after the last dose of study drug in both the groups.
3324537|NCT02045888|Experimental|Low Dose ADRC|ADRCs prepared by investigational Celution Device
3324538|NCT02045888|Experimental|High Dose ADRC|ADRCs prepared by investigational Celution Device
3324539|NCT02045888|Placebo Comparator|Placebo|Placebo
3324540|NCT02045914|No Intervention|control group|the patients who have no intervention with calcium ionophore during ICSI cycle
3324541|NCT02045914|Experimental|calcium ionophore|the patients whose oocytes are incubated with calcium ionophore solution during ICSI cycle
3324542|NCT02045927|Active Comparator|Intevention Group|sedation monitoring with RASS score plus sedation monitoring with BIS-Guided monitoring
3324543|NCT02045927|Other|Control Group|sedation monitoring with RASS score
3324544|NCT02045940|Experimental|Cohort 1|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 1=Placebo, dose level (DL) 2, DL3, and DL4. Sequence 2=DL1, placebo, DL2, and DL4. Sequence 3=DL1, DL2, placebo, and DL4. Sequence 4=DL1, DL2, DL3, and placebo
3229966|NCT01186315|Active Comparator|Prolonged Exposure therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
3229967|NCT01186315|Experimental|Exposure therapy + VR/ER|prolonged exposure therapy plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
3324545|NCT02045940|Experimental|Cohort 2|Participants will receive one of the following four treatment sequences in four study period (one treatment per period). Sequence 5=Placebo, DL5, DL6, and DL7. Sequence 6=DL4, placebo, DL6, and DL7. Sequence 7=DL4, DL5, placebo, and DL7. Sequence 8=DL4, DL5, DL6, and placebo
3324546|NCT02045940|Experimental|Cohort 3|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A
3324547|NCT02045940|Experimental|Cohort 4|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohort
3324548|NCT02045940|Experimental|Cohort 5|Participants will receive repeat doses of GSK2881078 or placebo in a 3:1 randomization ratio for 14 days. The dose level will depend upon results from Part A and preceding repeat dose Cohorts
3229968|NCT01186341||Chronic Pain|New or existing patients of the center who are seeking their initial treatment at the Integrative Medicine center for chronic pain (chronic > 3 months) who report their average pain level over the past month to be at least a 4 of 10 on the Visual Analog Scale.
3324549|NCT02045953|Experimental|Sequence 1|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): ABCD, where A= FLIXOTIDE 250 Hydrofluoroalkane (HFA) with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3324550|NCT02045953|Experimental|Sequence 2|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): BDAC, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3324551|NCT02045953|Experimental|Sequence 3|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): CADB, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3324552|NCT02045953|Experimental|Sequence 4|Participant will receive study treatments in following sequence in four treatment periods (one treatment per period): DCBA, where A= FLIXOTIDE 250 HFA with Aerochamber Plus spacer, B= FLIXOTIDE 250 HFA with VENTOLIN Mini-Spacer, C= SERETIDE 250/25 HFA with Aerochamber Plus spacer, D= SERETIDE 250/25 HFA with VENTOLIN Mini-Spacer
3324553|NCT02045966|Experimental|Arm 1: Cocktail + DCV 3DAA FDC + BMS-791325|"Treatment A: Cocktail of CYP and transporter probe substrates orally as a single dose on Day 1~Treatment B: DCV 3DAA FDC tablet administered orally BID on Days 6 to 15~Treatment C: DCV 3DAA FDC tablet administered orally BID on Days 16 to 20, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 16 only~Treatment D: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 21 to 30~Treatment E: DCV 3DAA FDC tablet plus BMS-791325 75-mg single-agent tablet administered orally BID on Days 31 to 35, plus the cocktail of CYP and transporter probe substrates administered orally as a single dose on Day 31 only"
3324554|NCT02045992|Experimental|Caffeine|Caffeine 500mg
3324555|NCT02045992|Placebo Comparator|Placebo|Lactose 500mg
3324556|NCT02046018|Active Comparator|ICCM delivered by VHT|Health Outcomes in Communities where VHT's were trained in ICCM and given drugs.
3229969|NCT01186354|Experimental|Receiving results via web-based program|participants will receive genetic risk results for Type 2 diabetes via a web-based program that they access on their own
3229970|NCT01186367|Experimental|Linear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training, at 60% to 75 % of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at baseline.
3229971|NCT01186367|Experimental|Nonlinear Aerobic Training|The ultimate goal is for participants to complete approximately 130-180 minutes/week of aerobic training at 55% to 100% of the individually determined exercise capacity (VO2peak), for 16 weeks. VO2peak will be determined by the second CPET performed at Baseline and and as well as the CPET performed at Week 8.
3259126|NCT01467739|Active Comparator|a conventional reusable fiberscope.|
3324557|NCT02046018|Active Comparator|ICCM delivered by VHT with cell phone|Health Outcomes in communities with VHT's who were trained in ICCM and given cell phones
3324558|NCT02046018|Active Comparator|Health outcomes in communities with no ICCM|Health outcomes in communities with VHT's who were not trained in ICCM
3324559|NCT02046031|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using Ginkgolides Meglumine Injection, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
3324560|NCT02046044|Experimental|Ivabradine|Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
3324561|NCT02046044|Experimental|Digoxin|Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
3324562|NCT02046083|Experimental|treatment|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
3324563|NCT02046083|Placebo Comparator|placebo|Prospective randomized double blind, placebo controlled, protocol in two phases: 1/ active treatment versus placebo for induction phase; 2/ long versus short maintenance
3324564|NCT02046096|Experimental|Günther Tulip® Vena Cava Filter|Günther Tulip® Vena Cava Filter
3324565|NCT02046096|Experimental|Cook Celect® Vena Cava Filter|Cook Celect® Vena Cava Filter
3229972|NCT01186367|Experimental|Progressive Stretching Group (Attention control)|The ultimate goal for the progressive stretching program is 3 to 4 individual stretching sessions/week for 10 to 50 minutes per session (+/- 10 minutes).
3324566|NCT02046109|Experimental|Repair|Subjects in the Repair group will be given a local anesthetic only if required (i.e. for restorations extending gingivally or on exposed dentin surface) as per usual clinical protocol. The existing restoration will not be removed. The surface of the existing restoration will be roughened with a Brasseler 8856 bur without extending to the surrounding enamel (except is the defect being repaired is adjacent to enamel). No accessory groves/pits for retention will be prepared. To repair the restoration, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
3229973|NCT01186380||TEE Procedure|patients requiring TEE procedure by their physician
3324567|NCT02046109|Active Comparator|Replace|Subjects in the Replace group will be given local anesthetic (an injection of 2% lidocaine with 1:100 000 epinephrine). The type of injection and dosage of anesthetics will be dependent on the tooth being treated, and will follow the usual protocol used in the Dalhousie Dentistry undergraduate clinics. The existing composite restoration will then be removed and the peripheral enamel beveled if not already beveled. To restore the tooth, the surface will be etched using 35% phosphoric acid, and then 3M ESPE Scotchbond Universal Adhesive System followed by 3M ESPE Filtek Supreme Ultra Universal Restorative composite will be used as per the manufacturer's instructions.
3324568|NCT02046161|Experimental|colon cleansing room group|All patients in colon cleansing room group drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
3324569|NCT02046161|Placebo Comparator|standard colon preparation group|All patients in the standard colon preparation groupinitiate the standard colon preparation with PEG-ELS made from two sachets of PEG (Klean-PrepTM, Norgine Ltd. Harefield, Middlesex, United Kingdom) dissolved in 2 L of water at 8:00 AM on the day of colonoscopy.
3324570|NCT02046187|Experimental|Ketogenic Diet|Subjects will adhere to a ketogenic diet prior to the start of and through radiation therapy course until the time of first scan after radiation ends. During radiation course, patients also take temozolomide daily.
3324571|NCT02046213|Experimental|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
3324572|NCT02046239|Other|Staple Group|Staple Group: At the end of the operation, the skin will be closed using stainless steel staples, which is standard clinical practice at St. James's University Hospital. Approximately ten days after the operation, the staples will be manually removed; this is normally performed by the patients GP.
3324573|NCT02046239|Experimental|Suture Group|Suture Group: At the end of the operation, the skin will be closed using absorbable surgical suture. Manual removal of this suture is not required because the thread is self-absorbable.
3324574|NCT02046278|No Intervention|Control arm - Standard of Care|The anastomosis will be created using Standard of Care only
3324575|NCT02046278|Experimental|Device arm - Standard of Care + LifeSeal™ Kit|The anastomosis will be created using SOC + LifeSeal™ Kit
3324576|NCT02046291|Experimental|Romiplostim treatment|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.
3324577|NCT02046304|Experimental|Gemcitabine + Radiation Therapy|Patients receive concurrent chemoradiation (days 1 - 33) consisting of external beam radiotherapy (EBRT) plus gemcitabine, administered in a phase I dose escalation format until MTD is reached. EBRT delivered preoperatively (for patients with measurable disease) or postoperatively (for patients who have undergone pre-referral excisional biopsy) to a dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks. Surgical resection of the post-treatment tumor mass performed 4 to 8 weeks after the final dose of gemcitabine. Gemcitabine administered intravenously (IV) on days 1, 8, 22, 29, 43, and 50, concurrently with radiotherapy. Starting dose of gemcitabine 400 mg/m2 by vein once a week.
3324578|NCT02046330|Experimental|Deep Brain Stimulation|Device implantation (Deep Brain Stimulation Model 3387 Model 3389)
3324579|NCT02046343|Experimental|Physical Activity|Weekly promotora-led group sessions on physical activity (16 weeks) and followed by monthly telephone counseling and newsletters during the 24 week maintenance period. Promotoras will also implement environmental change strategies to increase the number of PA program offerings available to study participants.
3324580|NCT02046343|Placebo Comparator|Community Health and Safety|Weekly promotora-led group sessions on home safety/first aid (16 weeks) followed by and monthly generic health education materials and informational telephone calls during the 24 week maintenance period.
3324581|NCT02046356||Early-Stage HCC|Early-Stage hepatocellular carcinoma From January 2014 to January 2015, a total of 139 patients with early HCC from the First Affiliated Hospital, the Second Affiliated Hospital and the Third Affiliated Hospital of the Third Military Medical University were prospectively recruited according after MESS-RFA
3324582|NCT02046395|Other|Washout Period for 30 days|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure. The goal for their blood pressure will be set at < 140/90 mm/Hg. The washout period will last for four weeks at the end of which the patient will enter the test period.
3324583|NCT02046408|Experimental|Tablet Intervention|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
3324584|NCT02046408|No Intervention|Control|Primary care providers will be randomized into intervention or control conditions. The patients of intervention providers will be given a computer tablet that provides 5A's for smoking cessation counseling. Patients of control providers will not receive a tablet intervention.
3324585|NCT02046421|Experimental|Treatment (mifepristone, carboplatin, gemcitabine)|Patients receive mifepristone PO QD on days 0, 1, 7, and 8, and carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3324586|NCT02046434|Experimental|Parkinson's Diesase|Participant will take Glycerol Phenylbutyrate, participant has Parkinson's Disease
3324587|NCT02046434|Experimental|Control|Participant does not have Parkinson's Disease, Participant will be taking glycerol phenylbutyrate
3324588|NCT02046447||Primary Cervical Dystonia (Trihexyphenidyl)|"These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.~After the above baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional fMRI scan. The subjects will be done with the study after the second MRI scan has been completed."
3324589|NCT02046447||DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
3324590|NCT02046447||Primary Cervical Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
3324591|NCT02046447||DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed; and 6) Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) to assess dystonia severity.
3324592|NCT02046460|Active Comparator|Oral Anticoagulation|Vitamin K-Antagonists, target INR 2.0-3.0
3324593|NCT02046460|Experimental|Antiplatelets|Acetylsalicylic acid, 300mg o.p.d.
3324594|NCT02046473|Other|Volumetric Flow in TIPS|Subjects who have TIPS (transjugular intrahepatic porto-systemic shunts) have measurements taken to determine if someone has increased blood pressure in the portal vein of the liver (portal hypertension). Subjects who have a TIPS receive clinical ultrasounds every 3 months to determine if the TIPS is working properly.
3324595|NCT02046486|Active Comparator|Ticagrelor 180mg whole tablets|Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
3229974|NCT01186393|Experimental|Control|Arm includes dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). Control diet will be prescribed for weight maintenance.
3229975|NCT01186393|Experimental|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
3229976|NCT01186393|Experimental|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on High Glycemic Index foods.
3324596|NCT02046486|Experimental|Ticagrelor 180mg crushed and dispersed|Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position
3324597|NCT02046499|Active Comparator|Oxytocin arm|Oxytocin alone administered which is current standard of care
3324598|NCT02046499|Experimental|Oxytocin + syntometrine|Oxytocin plus syntometrine administered
3324599|NCT02046512|Experimental|Probiotic|Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
3324600|NCT02046512|Placebo Comparator|Sugar Pill|Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis
3324601|NCT02046538|Experimental|Postoperative Chemo WITH Zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy with zaltrap for 3 additional months. Patients may continue zaltrap (without chemotherapy) until disease recurrence or up to an additional 15 months."
3229977|NCT01186432|Experimental|Active|ranibizumab sustained delivery implant
3229978|NCT01186445|Experimental|Morphine chlorhydrate|Intracoronary injection of morphine chlorhydrate during reperfusion
3229979|NCT01186445|Placebo Comparator|Saline solution|Intracoronary injection of saline solution during reperfusion
3229980|NCT01186471|Experimental|001|A643 (nicotine) 1mg oromucosal nicotine spray- three times daily during each treatment period
3229981|NCT01186471|Experimental|002|A643 (nicotine) 2mg oromucosal nicotine spray- three times daily during each treatment period
3324602|NCT02046538|Active Comparator|Postoperative chemo WITHOUT zaltrap|"Subjects will receive 3 months of chemotherapy consisting of either FOLFOX (oxaliplatin, leucovorin, 5-FU) or FOLFIRI (Irinotecan, leucovorin, 5-FU) in the case of liver limited CRC, or FOLFOX (in the case of rectal cancer). Zaltrap will be administered with chemotherapy every 2 weeks for the first 5 out of 6 planned treatment cycles. After a standard 3-4 week recovery period (i.e. 5-6 weeks from the last Zaltrap dose), patients will undergo standard resection. At the time of resection, the tumor will be collected for biomarker discovery.~Following resection, patients will receive chemotherapy (without zaltrap) for 3 additional months."
3324603|NCT02046551|Placebo Comparator|Placebo|placebo
3324604|NCT02046551|Experimental|Atomoxetine|atomoxetine (40 mg/day)
3324605|NCT02046577|Experimental|5600 IU Vitamin D3|Oral 5600 IU Vitamin D3 in liquid weekly during 6 months
3324606|NCT02046577|Experimental|Oral 11200 IU Vitamin D3 weekly|Oral 11200 IU Vitamin D3 in liquid weekly during 6 months
3324607|NCT02046577|Placebo Comparator|Placebo|Oral placebo in liquid weekly during 6 months
3324608|NCT02046590|Active Comparator|Deep Sedation|"Remifentanil 1ng/ml throughout the procedure. Propofol administration starts at an initial (estimated plasma) target concentration of 1,5 microg/ml.~Propofol administration is adjusted to level 1 or 2 on the modified observer's assessment of alertness/sedation scale. The propofol infusion will be increased stepwise by 0,5 microg/ml every 1 minute until loss of consciousness. Propofol is continued while maintaining spontaneous ventilation without assistance and systolic blood pressure ≥ 60 % of baseline systolic blood pressure."
3324609|NCT02046590|Active Comparator|General Anaesthesia|"General anesthesia will be induced with target controlled infusion (TCI) of propofol and remifentanil as in the group deep sedation.~Suxamethonium (succinylcholine) will be used to facilitate intubation. Endotracheal tube balloon pressure will be controlled during the procedure. Ventilation will be assisted using 40% oxygen in air mixture and mechanically controlled using an anaesthetic ventilator."
3324610|NCT02046629|Experimental|teriflunomide dose 1|Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition
3324611|NCT02046642|Active Comparator|Maternal rest in left lateral position|"women in maternal rest in left lateral position group rested in the left lateral position for 15 minutes and then rested in the right lateral position for another 15 minutes."
3324612|NCT02046642|Active Comparator|Maternal rest in right lateral position|"Women in maternal rest in right lateral position group started resting in the right lateral position for 15 minutes and then rested in the left lateral position for another 15 minutes."
3324613|NCT02046655|Experimental|Corifollitropin alfa group|"On day 2 of the cycle, a single subcutaneous (SC) dose of 150 μg Corifollitropin alfa (Elonva) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day flexible initiation by a follicle of 14mm.~A daily dose of recFSH (450 IU/day) will be used from day 8 of stimulation until the day of hCG, if necessary.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
3324614|NCT02046655|Active Comparator|rec FSH group|"On day 2 of the cycle, daily SC dose of min 450 IU recFSH (Puregon) will be administered.~GnRH antagonist (Orgalutran) 0.25 mg/day , flexible initiation by a follicle of 14mm.~Triggering of final oocyte maturation will be performed using 250 μg of rechCG."
3229982|NCT01186471|Placebo Comparator|003|placebo placebo - three times daily during each treatment period
3229983|NCT01186484|Experimental|001|JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
3229984|NCT01186497|Experimental|Treatment sequence AEBDC|
3229985|NCT01186497|Experimental|Treatment sequence BACED|
3229986|NCT01186497|Experimental|Treatment sequence CBDAE|
3229987|NCT01186497|Experimental|Treatment sequence DCEBA|
3229988|NCT01186497|Experimental|Treatment sequence EDACB|
3324615|NCT02046668|Active Comparator|spironolactone|25mg spironolactone daily
3324616|NCT02046668|Placebo Comparator|Placebo|Matched Placebo
3324617|NCT02046681||Acetam, acetam + codeine, Ibuprofen, Oxycodone|monitoring side effects of pain medication prescribed in patients over 65 acetaminophen 1000 mg tabs po q6h acetaminophen + codeine 500 mg tabs po q6h ibuprofen 200 mg tabs po q8h oxycodone 5 mg tabs po bid
3229989|NCT01186510|Experimental|Lung perfusion|
3229990|NCT01186510|Active Comparator|no lung perfusion|
3229991|NCT01186523|Experimental|400 kcal of exercise/session|400 kcal of exercise/session
3229992|NCT01186523|Experimental|600 Kcal of exercise/session|600 Kcal of exercise/session
3229993|NCT01186523|Experimental|Control, no exercise|No exercise control group
3229994|NCT01186536|Experimental|Whey protein supplementation|Daily whey protein supplementation
3229995|NCT01186536|Experimental|Soy Protein supplementation|Daily soy protein supplementation
3229996|NCT01186536|Experimental|Placebo|Daily carbohydrate placebo supplementation
3229997|NCT01186549|Active Comparator|ephedrine 30 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3229998|NCT01186549|Active Comparator|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3229999|NCT01186549|Active Comparator|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3259127|NCT01467752|Experimental|MCP joint|reconstruction of metacarpophalangeal (MCP) joint
3324618|NCT02046694|Experimental|Allopurinol|Patients will stop taking their 6-MP and methotrexate at week 0. One week later (week 1), patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks). Dose adjustments of 6-MP and methotrexate will be directed by the guidelines outlined in the study protocol.
3324619|NCT02046707|Experimental|Patients with chronic heart failure|
3324620|NCT02046707|Other|Controls|
3324621|NCT02046720|Experimental|propofol induced sedation|Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
3324622|NCT02046733|Experimental|Nivolumab + Ipilimumab|"- Induction: Nivolumab at a dose of 1 mg/kg i.v. followed (on the same day) by Ipilimumab at a dose of 3 mg/kg i.v. once every 3 weeks, 4 cycles~- Maintenance: Nivolumab 240 mg i.v. once every 2 weeks, for a maximum of 12 months from start of maintenance"
3324623|NCT02046733|No Intervention|Observation|no further treatment; tumour assessment, follow-up documentation and collection of biological material will be done according to the same schedule as Arm 1.
3230000|NCT01186549|Active Comparator|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3324624|NCT02046746|Experimental|Oral Nutritional Supplement (ONS)|1-2 serving per day of a renal specific oral nutritional supplement
3324625|NCT02046759|Experimental|Pharmacist-Intervention|
3324626|NCT02046759|Active Comparator|Routine Care|
3324627|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% saline
3324628|NCT02046798|Experimental|14C labeled ASP3652|
3230001|NCT01186549|Placebo Comparator|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
3230002|NCT01186575|Experimental|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
3230003|NCT01186575|No Intervention|Usual Care|Usual care after adult male circumcision (no text messages)
3230004|NCT01186588|Experimental|001|Canagliflozin One 300-mg dose of canagliflozin on Day 1
3230005|NCT01186601|Experimental|Arm 1|
3230006|NCT01186614|Experimental|Novel treatment paradigm|treatment protocol including - mechanical CPR, therapeutic hypothermia, ECMO, coronary intervention
3230007|NCT01186640|Experimental|FCM-A followed by A-maintenance|First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
3230008|NCT01186653|Experimental|Symbicort|Symbicort® (budesonide / formoterol, 400 micrograms/9 micrograms one puff bd, dose as per NICE guidelines
3230009|NCT01186653|Active Comparator|Seretide|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
3230010|NCT01186666|Experimental|Non ST-elevation acute coronary syndrome|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
3324629|NCT02046811|Experimental|Patient activation and education|Patient activation and education (PAE)
3324630|NCT02046811|Experimental|PAE plus physician activation|PAE plus physician activation (PAE + MD)
3324631|NCT02046811|Experimental|PAE, MD, plus teledermoscopy|PAE physician activation, plus teledermoscopy (PAE +MD +TD)
3324632|NCT02046824|Experimental|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the Xtra Sorin cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3324633|NCT02046824|Experimental|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the C.A.T.S. cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3324634|NCT02046824|Experimental|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, and when the patients has been allocated to the CardioPAT cellsaver group, the washing process will be started. Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
3259128|NCT01467765|Active Comparator|Elemental diet|
3259129|NCT01467765|Placebo Comparator|Liquid nutrient|
3324635|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
3230011|NCT01186666|Experimental|Stable coronary artery disease|"Coronary intervention using IVUS-VH & FDG PET-MDCT:~All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers."
3324636|NCT02046837|Experimental|Supervised 1:1 exercise|This intervention arm will include 3 one-on-one, supervised sessions per week for 6 months with a certified exercise specialist. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
3324637|NCT02046837|Experimental|Supervised group exercise|This intervention arm will include 3 group, supervised sessions per week for 6 months with a certified exercise specialist. Supervised sessions will be delivered in a group format with 4-8 participants per group. Flexibility training will include stretching for 5-10 minutes at the beginning and end of each session. Aerobic training will involve 30 minutes of low-impact step aerobics. Resistance training will be conducted using resistance bands, a stability ball, and an exercise mat with 8 prescribed exercises that target the major muscle groups. Participants will be encouraged to perform exercises independently on additional days, for a total of 4-5 days per week of exercise.
3230012|NCT01186679|Experimental|Intralesional|"Surgical transplantation into the lesion site in chronic patients~Direct intrathecal implantation in acute and subacute patients"
3324638|NCT02046837|Experimental|Home-based exercise|The same protocol and training frequency as the supervised programs described above will be followed. However, all exercises will be completed independently by participants. Specific exercises in the aerobic program may be modified to accommodate patient preference (same target heart rate range as supervised groups). Participants will be supported with smartphone technology and remote 'health coaches' during the intervention phase. This will help to ensure participant adherence, appropriate progression, and safety.
3324639|NCT02046850|Experimental|selumetinib 75mg.|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule
3324640|NCT02046850|Other|rifampicin 600mg.|Volunteers will receive rifampicin 600mg administered by mouth, as a capsule
3324641|NCT02046850|Experimental|selumetinib 75mg and rifampicin 600mg|Volunteers will receive selumetinib 75mg and rifampicin 600mg, by mouth, as a capsule
3324642|NCT02046876|Experimental|Multimodal Physiotherapy Program for Chronic Neck Pain Suffers|
3324643|NCT02046889|Experimental|Intervention group|The intervention group or experimental group will receive the bicycle training intervention during the first year of the study. The intervention is a 5 day/75 minutes per day bicycle training intervention which used specialized instruction and adapted equipment to teach independent bicycle riding skills to youth aged 9-18 years with autism spectrum disorder and Down syndrome.
3230013|NCT01186679|Experimental|intrathecal|direct into the CSF through lumbar puncture
3230014|NCT01186718||Control Group|Control group = functional symmetric cervical motion.
3324644|NCT02046889|No Intervention|Control group|The control group will not receive the intervention during the first year of the study. Instead, this group will receive a delayed intervention during the second year of the study, after pre-post effects have been evaluated.
3324645|NCT02046915|Experimental|Pomalidomide, Dexamethasone, Cyclophosphamide|"Pomalidomide administered orally at the starting dose of 4 mg/day on Days 1-21 of a 28-day cycle~Low-dose Dexamethasone administered orally at the starting dose of 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15, and 22 of a 28-day cycle~Cyclophosphamide administered intravenously 500 mg/m² on Days 1 and 15 of a 28-day cycle"
3324646|NCT02046928|Experimental|A6|A6 is administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
3324647|NCT02046954||Study group|Patients monitored with hemodynamically focussed transesophageal echocardiography (placement within 12 hours of ICU admission)
3324648|NCT02046954||Control Group|Patients receiving conventional monitoring (e.g. transpulmonary thermodilution)
3324649|NCT02046967|Active Comparator|Endovenous laser ablation|Endovenous laser ablation with 940 nm bare fiber.
3324650|NCT02046967|Active Comparator|Endovenous steam ablation|Endovenous steam ablation with steam vein sclerosis system.
3324651|NCT02047006|Experimental|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Rivaroxaban is given as a single oral dose of 10 mg immediately after three subsequent dialysis sessions. Patients remain in the hospital from the intake of the first dose until 48 hours after the intake of the third dose.~Effect of dialysis on levels of rivaroxaban:~Rivaroxaban is given as a single oral dose of 10 mg in the morning when dialysis is scheduled in the afternoon, or the previous evening when dialysis is scheduled in the morning. The interval between the two doses was at least 48 hours. Dialysis is scheduled 6 to 8 hours after the intake of rivaroxaban."
3324652|NCT02047019|Active Comparator|Candesartan|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan 16 mg, Placebo combination A, Placebo combination B)
3324653|NCT02047019|Experimental|Nifedipine/Candesartan-30/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination A, Combination nifedipine / candesartan 30/16 mg)
3324654|NCT02047019|Experimental|Nifedipine/Candesartan-60/16|Treatment with 1 capsule and 2 tablets once daily in the morning for 8 weeks (Candesartan placebo, Placebo combination B, Combination nifedipine / candesartan 60/16 mg)
3324655|NCT02047058||high-risk|high-risk is determined by the evaluation of the biomarkers of Q cell.
3324656|NCT02047071|No Intervention|Standard Care|Conservative treatment. This group will be receive standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
3230015|NCT01186718||Experimental subject group|Experimental subject group = asymmetric cervical motion
3230016|NCT01186731|Experimental|Liposome Entrapped Docetaxel (LE-DT)|
3230017|NCT01186757|Active Comparator|PF-03715455 1.6mg BID|
3230018|NCT01186757|Active Comparator|PF-03715455 4 mg BID|
3324657|NCT02047071|Experimental|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
3324658|NCT02047084||Theraskin, Apligraf|Theraskin used every other week x 4 Apligraf used weekly x 8
3324659|NCT02047084||Venous leg ulcers|Theraskin and Apligraft
3324660|NCT02047123|Experimental|Raw Flaxseed|For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of raw flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
3324661|NCT02047136|Experimental|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
3324662|NCT02047136|Active Comparator|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
3324663|NCT02047149|Experimental|Zileuton/Dasatinib|zileuton/dasatinib: This is a traditional phase I design. Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
3324664|NCT02047162|Experimental|Bismuth subsalicylate|Bismuth subsalicylate, 262 mg/chewable tablet, 2 tablets every hour as needed up to 16 tablets per 24 hours, for up to 48 hours.
3324665|NCT02047162|Placebo Comparator|Placebo|Placebo chewable tablets, 2 every hour as needed up to 16 tablets per 24 h, for up to 48 h.
3324666|NCT02047175|Experimental|A(Telmisartan/S-Amlodipine)|"A(Telmisartan/S-Amlodipine)~: Telmisartan/S-Amlodipine 40/2.5mg 2T for 9days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 5days"
3324667|NCT02047175|Experimental|B(Rosuvastatin)|"B(Rosuvastatin)~: Rosuvastatin 20mg 1T for 5days and Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T for 9days"
3324668|NCT02047201|Experimental|Experimental|Induction chemotherapy (Docetaxel, Cisplatin and Fluorouracil) following radiochemotherapy (IMRT using PET/CT images after IC for treatment planning + cisplatin iv 40 mg/m2 weekly).
3324669|NCT02047214|Experimental|TPI 287 + bevacizumab|All subjects will be administered TPI 287 as an IV infusion (1-hour target duration) once every 3 weeks (Days 1 and 22) and bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29) of a 42-day cycle. The dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6 subjects, while the dose of bevacizumab remains constant (10 mg/kg). The planned dose escalation levels are 140, 160, 170, and 180 mg/m2; subsequent dose levels will be increased in increments of 10 mg/m2. If dose de-escalation below the starting dose level of 140 mg/m2 is required, dose levels of 130 and 120 mg/m2 will be used. Once the MTD is identified, 6 additional subjects will be enrolled at the MTD to better characterize the toxicity profile at this level. Subjects may continue on treatment unless they meet one or more of the discontinuation criteria outlined in the protocol.
3324670|NCT02047266|Experimental|MICS CABG|"Minimally invasive cardiac surgery coronary artery bypass grafting (complete multivessel minimally invasive off-pump revascularization via left minithoracotomy), which is performed with a help of Octopus® Nuvo, Starfish® Non-Sternotomy, ThoraTrak®, Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(MICS CABG group, n=50)"
3324671|NCT02047266|Active Comparator|OPCABG|"Off-pump coronary artery bypass grafting treatment which is performed with a help of Starfish®, Octopus®, Clearview® blower, ClearView® Shunt.~(OPCABG group, n=50)"
3324672|NCT02047266|Active Comparator|ONCABG|On-pump coronary artery bypass grafting treatment (ONCABG group, n=50)
3230019|NCT01186757|Active Comparator|PF-03715455 10 mg BID|
3230020|NCT01186757|Placebo Comparator|Placebo|
3230021|NCT01186783|No Intervention|standard treatment|All patients receive established medical therapy according to current guidelines and therapeutic standards.
3230022|NCT01186783|Active Comparator|ivabradine (add-on)|Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
3230023|NCT01186822|Experimental|Lung Flute for BHT|The Lung Flute arm participants were instructed to blow twice in to the Lung Flute device vigorously enough to make the reed oscillate, followed by 5 normal breaths. This was repeated 10 times, followed by 3 huff coughs to complete 1 cycle. Two such cycles were recommended twice a day. One of these cycles was performed under supervision of the study personnel at the time of enrollment and at each subsequent study visit. Baseline COPD medication regimen was continued in all participants, although the primary physicians of the participants could make medically necessary changes. Chest physical therapy, additional breathing exercises and formal pulmonary rehabilitation programs were not prescribed to any of the participants during the study.
3230024|NCT01186822|No Intervention|No intervenstion|No intervention. Same population.
3230025|NCT01186835|Experimental|Combination Botulinum Toxin A and Hyaluronic Acid|One side of face treated with the combination of Botulinum Toxin A and Hyaluronic Acid injections.
3230026|NCT01186835|Active Comparator|Botulinum Toxin A alone|Other side of face treated with =Botulinum Toxin A injection alone.
3230027|NCT01186861|Experimental|Arm A: OSI-906 plus erlotinib|OSI-906 150 mg twice daily (BID) starting on Day 1; erlotinib 150 mg once daily (QD) starting on Day 1
3230028|NCT01186861|Placebo Comparator|Arm B: placebo plus erlotinib|placebo BID starting on Day 1: erlotinib 150 mg QD starting on Day 1
3230029|NCT01186887|Placebo Comparator|Celecoxib|
3230030|NCT01186887|Placebo Comparator|Placebo|
3230031|NCT01186900|Experimental|Ultrasound-guided needle aspiration|One arm is ultrasound-guided needle aspiration, the other active comparison is traditional open incision and drainage of skin abscess
3230032|NCT01186900|Active Comparator|open incision and drainage|
3259130|NCT01467778|Active Comparator|ELAPR001|Tropoelastin 0.1ml SC implant
3230033|NCT01186913||Stratum A: Typical SCID +HCT|"Stratum A: Typical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with typical (formerly referred to as classic) SCID + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
3324673|NCT02047279|Active Comparator|MVS + maze|"Procedure: Maze procedure, mitral valve surgery~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed."
3230034|NCT01186913||Stratum B: Atypical SCID +HCT|"Stratum B: Atypical Severe Combined Immunodeficiency (SCID) treated with HCT therapy.~Participants with leaky SCID, Omenn syndrome, or Reticular Dysgenesis (RS) + allogeneic hematopoietic stem cell transplantation (HCT) therapy according to standard of care, per local protocol."
3259131|NCT01467778|Active Comparator|ELAPR002|Tropoelastin 0.1ml SC implant
3324674|NCT02047279|Experimental|MVS + maze + LA reduction|"Procedure: maze procedure, mitral valve surgery, left atrial reduction~The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp.~The left atrial appendage was excluded in all cases. For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.~The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape."
3324675|NCT02047292|Active Comparator|THA28|THA Corail PinnacleCoC28
3324676|NCT02047292|Active Comparator|THA36|THA Corail DeltaMotion36
3324677|NCT02047292|Active Comparator|THA40|THA Corail DeltaMotion40
3324678|NCT02047331|Active Comparator|group PI|group PI were performed periarticular drug injection during surgery.
3324679|NCT02047331|Active Comparator|group FI|group FI were performed fascia iliaca block before surgery
3324680|NCT02047357|Experimental|Intervention Arm|Learning Through Play Plus
3259132|NCT01467778|Active Comparator|ELAPR003|Tropoelastin 0.1ml SC implant
3324681|NCT02047357|No Intervention|Control|This arm will receive no intervention
3324682|NCT02047370|Experimental|Diaphragm stretching|30 Patients with asthma are included in this group. They will receive a diaphragm stretching technique
3324683|NCT02047370|Placebo Comparator|Placebo group|Ultrasound disconnected in same position and with the same duration.
3324684|NCT02047383||respiratory infection|Hospitalized patients with a respiratory infection
3324685|NCT02047396||Myocardial Infarction subjects|Subjects with first Myocardial Infarction presenting to one of the Mayo Clinic Hospitals in Rochester, Minnesota.
3324686|NCT02047422|Experimental|Add furosemide/no spironolactone|
3324687|NCT02047422|Experimental|Add metolazone/no spironolactone|
3324688|NCT02047422|Experimental|Add furosemid/spironolactone|
3324689|NCT02047422|Experimental|Add metolazone/spironolactone|
3324690|NCT02047435|Experimental|Information, event and workshops at a cartoon museum|
3324691|NCT02047435|Active Comparator|Information and event at a cartoon museum|
3324692|NCT02047448|No Intervention|Control Group|The control group will receive the current standard of care including medication reconciliation during hospitalization performed by a nurse or physician and education about discharge medications provided by the inpatient nurse. There will not be a pharmacist discharge care plan developed for this group. The patients will not be required to choose a participating community pharmacist and no counseling and education appointments will be scheduled. Any medication-related problems identified by the pharmacists and will be communicated as appropriate and resolved as is the standard of care. Any other interaction between the patient and their pharmacist will be according to the current standard of care.
3324693|NCT02047448|Experimental|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
3324694|NCT02047474|Experimental|Treatment (mFOLFIRINOX)|"NEOADJUVANT THERAPY: Patients receive mFOLFIRINOX comprising oxaliplatin IV over 2 hours, levoleucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV continuously for 46 hours on day 1. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Beginning 3-8 weeks after completion of neoadjuvant therapy patients undergo surgical resection.~ADJUVANT THERARPY: Beginning within 12 weeks after surgery, patients receive mFOLFIRINOX as in neoadjuvant therapy. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
3324695|NCT02047526||1|
3324696|NCT02047539|Experimental|1000 mg/day aspirin|1000 mg/day aspirin
3324697|NCT02047539|Placebo Comparator|sugar pill|sugar pill
3324698|NCT02047552|Active Comparator|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
3324699|NCT02047552|Active Comparator|Oxandrolone|Oxandrolone 10 mg PO q12 hours will be dosed for seven days.
3324700|NCT02047552|Experimental|Iron sucrose + oxandrolone|Combination goal-directed iron sucrose (as described in the iron sucrose only arm) and oxandrolone (as described in the oxandrolone only arm) for seven days.
3259133|NCT01467778|Placebo Comparator|Saline|Normal Saline 0.9%
3259134|NCT01467791||Patients|All patients with sarcoidosis associated pulmonary hypertension
3324701|NCT02047552|Placebo Comparator|IV iron placebo and Oxandrolone placebo|100 mL normal saline in place of iron and similar color and size sugar pill for Oxandrolone placebo
3324702|NCT02047565|Experimental|Part 1 - 60mg edoxaban|Treatment A: single oral dose of 60 mg edoxaban (1 × 60 mg tablet)
3230035|NCT01186913||Stratum C:SCID +Non-HCT|"Stratum C: Severe Combined Immunodeficiency (SCID) who receive alternative therapy per standard of care, non-standard care and/or investigational. This stratum includes:~Adenosine Deaminase-Deficient SCID (ADA Deficient SCID) with intention to treat with Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT)~ADA Deficient SCID with intention to treat with gene therapy~X-linked SCID (XSCID) with intention to treat with gene therapy~Any individual with SCID previously treated with a thymus transplant (includes intention to treat with HCT, as well as PEG-ADA ERT or gene therapy)"
3230036|NCT01186926|Experimental|HGNS Treatment|
3230037|NCT01186952|No Intervention|Optimized usual care|participants will attend one visit with the dietician (30mn) and the physical activity specialist (30mn) when they will be given Canadian guidelines pamphlets for physical activity and food consumption. They will also receive a phone call once a month to discuss about issues in guidelines following.
3230038|NCT01186952|Active Comparator|Diet intervention alone|Participants will attend one visit with the physical activity specialist (30mn) when they will receive the physical activity guidelines. Monthly phone call will be make to discuss about issues in physical activity guidelines following.These individuals will also be enrolled in a supervised caloric restriction program. They will have to visit the dietician once a week for the first months and then twice a month for 3 months. The diet intervention will focus on a low fat diet. At each session participants will be weighed and taken the blood pressure.
3324703|NCT02047565|Experimental|Part 1 - 180mg edoxaban|Treatment B: single oral dose of 180 mg edoxaban (3 × 60 mg tablet)
3230039|NCT01186952|Active Comparator|diet intervention and exercise program|"Participants will attend diet intervention as described for group 2. They will also follow a supervised exercise program three days per week for 4 months. The exercise training is an interval high intensity aerobic (85-90% heart rate reserve) program with resistance exercises (15RM, 2-3 repetitions). Each session will last one hour. At the end of month 1, 2, and 3, all participants will receive the SWA armband for 7 days to record physical activity and estimate energy expenditure.~At the end of Month 4, all participants will attend a study visit for repeat baseline testing."
3324704|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 50 IU/kg Beriplex P/N|Dose cohort 1: 60 mg edoxaban + 50 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3324705|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 20 IU/kg Beriplex P/N|Dose cohort 2: 60 mg edoxaban + 25 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3324706|NCT02047565|Experimental|Part 2 - 60mg edoxaban and 10 IU/kg Beriplex P/N|Dose cohort 3: 60 mg edoxaban + 10 IU/kg Beriplex P/N in 1 period and placebo (0.9% Sodium Chloride Injection, USP), in the other period
3324707|NCT02047578|Experimental|Busulfan|Drug: Busulfan First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3324708|NCT02047591||Relaxing-touch method|
3324709|NCT02047591||Usual care|
3324710|NCT02047617|Active Comparator|the standard physiotherapy group|Physiotherapy rehabilitation techniques used in the management of this group include passive range of motion, active range of motion/bed exercises, sitting at edge of bed, sitting in armchair, active transfer from the bed to chair. Mobilization and rehabilitation program is progressively introduced after clinical stabilization with a goal of progressing to ambulation and pulmonary rehabilitation.
3324711|NCT02047617|Experimental|standing table group|The same program as standard physiotherapy group is applied, with daily sessions of standing table in supplement. Standing table was performed on a motorized tilt table (ref: table de verticalisation, Franco&fils). The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform, at 10° intervals from 30° to 80°.
3324712|NCT02047630|Experimental|Generic latanoprost|1 eye drop hs
3324713|NCT02047630|Active Comparator|Brand-name latanoprost|1 eye drop hs
3324714|NCT02047656|Placebo Comparator|Placebo to LFF269 (Part 1)|Placebo to LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
3324715|NCT02047656|Experimental|LFF269 (Part 1)|LFF269 twice daily (b.i.d) for 10 days in healthy volunteers
3324716|NCT02047656|Experimental|LFF269 (Part 2)|LFF269 twice daily (b.i.d) for 5 days in patients with hypertension
3324717|NCT02047669|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
3324718|NCT02047669|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
3324719|NCT02047682|Experimental|Biopsychosocial|Biopsychosocial intervention with Individually tailored physical exercises and stress management
3324720|NCT02047682|Active Comparator|Reference|"Reference group receiving usual care in terms of standard workplace ergonomics and physical exercises"
3324721|NCT02047695||Migraine with aura|Participants with migraine with aura (cases), their co-twins, and unrelated migraine-free twins (controls)
3324722|NCT02047721|Experimental|Physical Intervention|A supervised exercise program
3324723|NCT02047721|Experimental|Nutritional Intervention|A supervised diet program
3324724|NCT02047760||MS patients|All MS sub-types
3324725|NCT02047760||Controls|sex- and age-matched controls
3324726|NCT02047773|Placebo Comparator|14 days Duration|14 days of antibiotics regardless of bacterial load.
3324727|NCT02047773|Active Comparator|Bacterial load guided duration|Antibiotics stopped early on day 8 or day 11 if the bacterial load when checked on day 7 and day 10 is less than 10^6cfu/ml.
3324728|NCT02047786||General Hospital Patients|Those patients undergoing appendicectomy in a general (non-specialised) surgical centre.
3324729|NCT02047786||Paediatric Hospital Patients|Those patients undergoing appendicectomy in specialised paediatric centres.
3324730|NCT02047799|Active Comparator|Calcitriol|A daily dose of 1000 IU of cholecalciferol (administered as 1 capsule of 25 μg each)
3324731|NCT02047799|Placebo Comparator|Control|A daily dose of placebo (administered as 1 capsule )
3324732|NCT02047812||High volume hospitals|The hospitals in the upper tertile for procedural volume
3324733|NCT02047812||Medium volume hospitals|The hospitals in the middle tertile for procedural volume
3324734|NCT02047812||Low volume hospitals|The hospitals in the lowest tertile for procedural volume.
3324735|NCT02047825|Experimental|Experimental group|The patients included in this group will receive an intensive intervention based on upper limbs intervention with exercises added to the usual treatment they receive.
3324736|NCT02047825|Active Comparator|Control group|Patients with multiple sclerosis not included in the intensive intervention. They receive the usual treatment of occupational and physical therapy.
3324737|NCT02047838||Cases.|Patients with recurrent unilateral endometrioma who were previously operated for the same condition.
3230040|NCT01186991|Experimental|Onartuzumab + Bevacizumab + Paclitaxel|Participants will receive treatment with onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable drug-related toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3324738|NCT02047838||Controls.|Patients previously operated for unilateral endometrioma without recurrence.
3324739|NCT02047851|Active Comparator|Acupuncture in active points|Patients in this group will receive real acupuncture
3324740|NCT02047851|Sham Comparator|Acupuncture in non-active points|Patients in this group will receive acupuncture, but in non-active points
3324741|NCT02047851|No Intervention|No treatment, just observation|Patients in this group will receive no treatment and will only be observed.
3324742|NCT02047864|Experimental|Creatine monohydrate|Creatine monohydrate to be given during a resistance training program
3324743|NCT02047864|Placebo Comparator|Sugar pill|Placebo to be given during a resistance training program
3324744|NCT02047877||Respiratory Illness|Previously healthy patients admitted with acute respiratory illness who are then intubated requiring mechanical ventilator support. Endotracheally intubated patients of age 37 weeks gestation through 17 years with an acute respiratory illness in the absence of existing cardiopulmonary disease, tracheostomy, or immunocompromised condition. Tracheal aspirates (TA), bronchial fluid (nb-BALF), and blood are collected within 48-hours following endotracheal intubation. All three samples are collected again at two additional time points following intubation: between days 3-4 and between days 5-7, so long as the patient remains endotracheally intubated.
3324745|NCT02047890|Experimental|BAY1000394|Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
3324746|NCT02047916||Normal Neonates > 33 weeks gestation|"Neonates >33 weeks gestational age~Postnatal age <72 hours;~Parental informed consent;~Inpatient at the Royal Sussex County Hospital (RCSH): either receiving special care on the Trevor Mann Baby Unit (TMBU) or normal care on the postnatal ward"
3324747|NCT02047942|Active Comparator|Center-based cardiac rehabilitation|Patients randomized to the center-based training group will continue their training sessions at the outpatient clinics of UZ Leuven under direct supervision of physical therapists
3230041|NCT01186991|Experimental|Onartuzumab + Placebo + Paclitaxel|Participants will receive treatment with onartuzumab, placebo matching to bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3230042|NCT01186991|Active Comparator|Placebo + Bevacizumab + Paclitaxel|Participants will receive treatment with placebo matching to onartuzumab, bevacizumab, and paclitaxel, which may continue until disease progression, unacceptable toxicity, investigator decision, death, or completion of study, whichever occurs first (up to approximately 5 years).
3324748|NCT02047942|Experimental|Home-based training with telemonitoring guidance|Patients will receive an patient-tailored exercise prescription and will be asked to perform the exercise sessions in their home environment wearing heart rate monitors. Training data will be accessed by the research group on weekly basis in order to keep a record of frequency; duration and intensity of the sessions. Feedback will be given weekly to every patient.
3324749|NCT02047942|No Intervention|Control|
3230043|NCT01187056|Experimental|Training, decision making|General practitioners receive training in shared decision-making and risk communication, and use their newly acquired skills in real-life consultations with 7 patients with high cholesterol.
3324750|NCT02047968|Experimental|wake therapy, light therapy and sleep time stabilisation|Wake therapy/sleep deprivation: Patients are awake for 36 hours three times in one week with a normal night of sleep between. Light therapy for 30 minutes daily in the entire study period. Sleep time stabilisation which involves psychoeducation regarding sleep hygiene and keeping the day-night cycle constant.
3324751|NCT02047968|No Intervention|treatment as usual|
3324752|NCT02047994|Experimental|Group 1:Triple therapy|Among those assigned to Group 1, participants who are Helicobacter pylori positive will receive Triple therapy and/or upper endoscopy. Participants with serological evidence of atrophic gastritis will undergo upper endoscopy and further endoscopic follow-up. H. pylori positive individuals will be offered Helicobacter pylori eradication as appropriate, independently of the pepsinogen results. From subjects in this group, breath samples will also be collected for volatile markers study. In addition, fecal occult blood test (FOBT) will be offered to this group as a benefit to participate in the study.
3324753|NCT02047994|No Intervention|Group 2:No intervention|Those who assigned to Group 2 will receive no intervention and will be offered FOBT as a benefit of study participation. Any participants who show positive FOBT will be referred to colonoscopy. This will be the benefit to this group together with initial medical evaluation at the time of inclusion. During the follow-up period this group will be offered to consult a specialist when required due to clinical symptoms.
3324754|NCT02048007|Active Comparator|Biannual mass oral azithromycin|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years~Morbidity monitoring:~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community.~Anthropometry for all children aged 1 to 60 months per community.~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint."
3324755|NCT02048007|Placebo Comparator|Biannual mass oral placebo|"Comparison of childhood infectious and nutritional morbidity in communities randomized to azithromycin versus communities randomized to placebo.~Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years~Collect swabs (nasopharyngeal, nasal, conjunctival), blood samples, (thick/thin blood smears, hemoglobin, dried blood spots), and stool samples from 40 randomly selected children aged 1 month to 60 months per community; collect swabs (nasopharyngeal) from 40 randomly selected children aged 7-12 years per community~Anthropometry for all children aged 1 to 60 months per community~Collect nasopharyngeal swabs from all children aged 1-60 months who are seen at a local health clinic and have a respiratory complaint"
3230044|NCT01187056|Active Comparator|Training, usual practice|The control group GPs will receive 2 hours of training in the primary care guideline for prevention of cardiovascular disease
3230045|NCT01187069|Experimental|Training course for practice nurses in autonomy support|
3230046|NCT01187069|No Intervention|Control|Control practices were randomly drawn from among intervention practice applicants and were informed by mail about their status as control practice.
3324756|NCT02048020|Experimental|Treatment (paclitaxel, carboplatin, IMRT)|"INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity."
3324757|NCT02048033|Active Comparator|Arm with Apollo Endosurgery OverStitch technical|
3324758|NCT02048033|Placebo Comparator|Arm without Apollo Endosurgery OverStitch technical|
3324759|NCT02048046||ECMO|
3324760|NCT02048059|Experimental|ANG1005|Participants received ANG1005 intravenously (IV) at a dose of 600 mg/m^2 on Day 1 of each 21-day cycle. ANG1005 will be administered for up to a maximum of one year, or until disease progression or adverse events (AE) that are not tolerated.
3324761|NCT02048085|Experimental|Ticagrelor|Ticagrelor Arm will be dosed with a loading dose of 180 mg followed by maintenance dose of 90 mg BID until discharge or up to 8 days.
3324762|NCT02048085|Active Comparator|Clopidogrel|Clopidogrel arm will be dose with a loading dose of 300 mg followed by maintenance dose of 75 mg everyday until discharge or up to 8 days.
3324763|NCT02048098|Active Comparator|Buccal misoprostol|400 µg buccal misoprostol per 3 hours
3324764|NCT02048098|Active Comparator|vaginal misoprostol|400 µg vaginal misoprostol per 3 hours
3324765|NCT02048111|Experimental|IB1001|
3324766|NCT02048124|Active Comparator|25g standard needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
3324767|NCT02048124|Experimental|25d ProCor needle|"EUS-FNA passes will be performed without stylet. One needle pass is defined as 5 strokes in 4 different areas of the lesion. The material from the needle passes will be expressed into formalin to look for core samples. Material from the next needle passes will be expressed onto slides for cytological analysis. Ease of puncture will be scored qualitatively as poor (scored 1), good (scored 2) or excellent (scored 3)."
3324768|NCT02048137|Active Comparator|Active transcranial direct current stimulation|
3324769|NCT02048137|Sham Comparator|Sham transcranial direct current stimulation|
3324770|NCT02048150|Experimental|Diagnostic (MDX1201-A488, IOOI, RALP)|Patients receive anti-PSMA monoclonal antibody MDX1201-A488 IV over 30 minutes on day 1 and undergo IOOI during RALP on day 3.
3324771|NCT02048163||Short infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a 30 minute period. An equal volume of normal saline will be infused at the same time over four hours.
3324772|NCT02048163||Prolonged infusion meropenem|Meropenem 20 mg/ml IV will be administered at a dose of 40 mg/kg (maximum 2,000 mg) every eight hours for 12 doses and will be infused over a four hour period. An equal volume of normal saline will be infused at the same time over 30 minutes.
3324773|NCT02048176||Posterior Fossa Mutism|Patients with Posterior Fossa Mutism
3324774|NCT02048176||Non Posterior Fossa Mutism|Patients that did not develop Mutism
3230047|NCT01187082|Experimental|bladdertraining group|Cognitive training in groups at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
3230048|NCT01187082|Active Comparator|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
3324775|NCT02048189|Other|Intensified multiple injections|
3324776|NCT02048189|Other|Pumps|
3324777|NCT02048202||premature neonate|premature neonate
3324778|NCT02048215|Active Comparator|Ephedrine + Caffeine + diet|Ephedrine 20 mg + Caffeine 200 mg capsule t.i.d. for one month plus hypocaloric diet
3324779|NCT02048215|Placebo Comparator|Placebo + diet|Similarly-looking placebo capsule t.i.d. for one month plus hypocaloric diet
3324780|NCT02048228|Experimental|genotyping guided therapy|Patients randomized to the genotyping guided therapy arm will have their CYP2C19*2 carrier status determined at the time before antiplatelet therapy with subsequent alteration in antiplatelet therapy for *2 carriers.CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers will be given 75 mg clopidogrel daily.
3230049|NCT01187108|Placebo Comparator|Placebo pills|
3230050|NCT01187108|Active Comparator|Acetazolamide alone|
3230051|NCT01187108|Active Comparator|N-acetylcysteine alone|
3324781|NCT02048228|Active Comparator|Standard Therapy|Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
3324782|NCT02048254|Experimental|brachytherapy|Iodine-125 radioactive seeds permanent interstitial implantation brachytherapy
3230052|NCT01187108|Active Comparator|Combination of N-acetylcysteine and acetazolamide|
3324783|NCT02048254|Active Comparator|IMRT|IMRT (intensity-modulated radiation therapy), 6 Millivolt (MV)-x fractionated irradiation, 1 time/day, 5 times a week, till the end. Add up to 33 times.
3230053|NCT01187121||Experimental|Those persons randomized to the Decide Your Time program.
3230054|NCT01187121||Standard Pracitice|Those persons randomized to the standard probationary practice condition.
3324784|NCT02048267||Alcoholic|
3230055|NCT01187134|Active Comparator|Intervention group|
3230056|NCT01187134|No Intervention|Conventional CME|Hospitals receive conventional continuing medical education in lecture style twice a year. They receive current publications and recommendations for national and international meetings regarding diagnosis and therapy of sepsis.
3230057|NCT01187147|Experimental|Green Tea|Recruited subjects will be asked to take green tea capsules for 3 months and then stopped for another 3 months.
3324785|NCT02048267||Non alcoholic|
3324786|NCT02048280|Experimental|Intubated|NAVA level from 0.1 to 3
3324787|NCT02048293|Active Comparator|Group O|Remifentanyl innovative molecule = Ultiva®
3324788|NCT02048293|Active Comparator|Group A|Remifentanyl comparator A = Remifentanil Laboratorios Chalver de Colombia S.A.
3230058|NCT01187160|Experimental|Transoral robotic surgery (TORS)|da Vinci® Robotic Surgical System
3230059|NCT01187186|Experimental|Moderate Hepatic Impairment|Subjects with Moderate Hepatic Impairment
3230060|NCT01187186|Experimental|Normal Hepatic Function|Subjects with Normal Hepatic Function
3324789|NCT02048293|Active Comparator|Group B|Remifentanyl comparator B = Fada Remifentanilo
3324790|NCT02048306|Experimental|Family-based PR group|
3324791|NCT02048306|Active Comparator|Conventional PR group|
3324792|NCT02048319|Experimental|Experimental: Pasireotide LAR 60 mg|The subjects will be randomized (1:1) into two groups. Both groups will undergo aspiration sclerotherapy following the standard procedure. The intervention group will additionally receive two injections of 60 mg pasireotide long-acting release (LAR) intramuscularly: the first injection 14 days before and the second injection 14 days after the intervention.
3324793|NCT02048319|Placebo Comparator|Placebo|Patients in the placebo arm will receive two injections of saline solution corresponding to the scheme of the intervention group.
3230061|NCT01187199|Experimental|Carboplatin Group|Carboplatin: Starting dose AUC 2 by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3324794|NCT02048332|Experimental|Viral Specific VST Infusion|Viral reactivation or infection. VST Reinfusion required.
3324795|NCT02048345|Experimental|Suspension, fasted state|Suspension Noxafil will be administered in the fasted state to the volunteers.
3324796|NCT02048345|Experimental|Suspension, with sugar (delay gastric emptying)|Suspension will be co-administered with glucose to delay the gastric emptying time
3324797|NCT02048345|Experimental|Solution, fasted state|A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.
3324798|NCT02048345|Experimental|Solution, with sugar (delaying gastric emptying)|A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.
3324799|NCT02048358|Experimental|2B3-201 150mg|2B3-201 150mg, once, IV infusion in 1000ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1000ml 5% dextrose/ Placebo, once, IV infusion 1000ml 5% dextrose
3230062|NCT01187199|Experimental|Paclitaxel Group|Paclitaxel: Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3230063|NCT01187199|Experimental|Sorafenib Group|Sorafenib: Starting dose 200 mg by mouth daily for a 21 day cycle. Temsirolimus: Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle. Bevacizumab: Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
3324800|NCT02048358|Experimental|2B3-201 300mg|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose/ Methylprednisolone hemisuccinate 300mg, once, IV infusion in 1500ml 5% dextrose/ Placebo, once, IV infusion 1500ml 5% dextrose
3230064|NCT01187212|Active Comparator|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day (D) 1
3230065|NCT01187212|Experimental|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
3230066|NCT01187225|Active Comparator|Fibrinogen concentrate|
3324801|NCT02048358|Experimental|2B3-201 450mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 2500ml 5% dextrose/ Placebo, once, IV infusion 2500ml 5% dextrose
3324802|NCT02048358|Experimental|450mg 2B3-201|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
3324803|NCT02048358|Experimental|300mg 2B3-201|2B3-201 300mg, once, IV infusion in 1500ml 5% dextrose
3324804|NCT02048358|Experimental|2B3-201 450mg male volunteers|2B3-201 450mg, once, IV infusion in 1500ml 5% dextrose
3324805|NCT02048358|Experimental|2B3-201 300mg or 450mg female volunteers|2B3-201 300mg or 450mg, once, IV infusion in 1500 or 2500ml 5% dextrose/ Methylprednisolone hemisuccinate 1000mg, once, IV infusion in 1500 or 2500ml 5% dextrose
3324806|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 450 mg|2B3-201 450mg, once, IV infusion in 2500ml 5% dextrose
3324807|NCT02048358|Experimental|Relapsing MS patients; 2B3-201 dose tbd|2B3-201 (dose to be determined), once, IV infusion in 5% dextrose
3324808|NCT02048371|Active Comparator|Cohort A: Liposarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
3324809|NCT02048371|Placebo Comparator|Cohort A: Liposarcoma, Placebo|"21 days on and 7 days off~Placebo"
3324810|NCT02048371|Active Comparator|Cohort B: Osteosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
3324811|NCT02048371|Placebo Comparator|Cohort B: Osteosarcoma, placebo|"21 days on and 7 days off~Placebo"
3230067|NCT01187225|Active Comparator|Cryoprecipitate|
3324812|NCT02048371|Active Comparator|Cohort C: Ewing sarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
3324813|NCT02048371|Active Comparator|Cohort D: Rhabdomyosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
3324814|NCT02048371|Active Comparator|Cohort E: Mesenchymal Chondrosarcoma|"Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off~Regorafenib"
3324815|NCT02048384|Experimental|A - metformin alone|metformin alone Arm A patients will receive metformin 850mg orally twice a day on a 28 day cycle.
3324816|NCT02048384|Active Comparator|B - metformin + rapamycin|metformin + rapamycin Arm B patients will receive 850mg orally twice a day and rapamycin 4mg orally once a day on a 28 day cycle.
3324817|NCT02048397|Other|Pulmonary Rehabilitation (PRP)|Pulmonary Rehabilitation (PRP)
3324818|NCT02048397|Other|Pulmonary Rehabilitation plus oral nutritional supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate (HMB)
3324819|NCT02048410|Active Comparator|diet plus Lactobacillus paracasei B21060|low saturated fats diet plus the symbiotic (2.5×109cfu, bid)
3324820|NCT02048410|Placebo Comparator|low saturated fats diet|low saturated fats diet
3324821|NCT02048423|Experimental|Ketamine|Drug
3324822|NCT02048436||male female 18-45 years range of body types|18 male female subject mix that are 18-45 years of age and selected to represent a range of body types of varying physiques and body mass indexes
3324823|NCT02048462||Cyclists|
3324824|NCT02048475|No Intervention|desflurane|inhalation concentration
3324825|NCT02048488|Experimental|Experimental Drug TSR-011|Experimental Drug TSR-011
3230068|NCT01187238|No Intervention|Arm1-radical radiotherapy alone group|Arm1-radical radiotherapy alone group, the eligibility patients will received radical intensity-modulated radiotherapy alone
3230069|NCT01187238|Experimental|Arm2-concurrent chemoradiotherapy group|Arm2-concurrent chemoradiotherapy group, the eligibility patients will received radiotherapy the same as radical radiotherapy arm,and also will received the concurrent chemotherapy wiht the regimen consist of cisplatin 40mg/m2, weekly for 7weeks.
3324826|NCT02048501|Other|Weight Regain|The weight regain group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and regained at least 15% of the post-operative nadir weight.
3324827|NCT02048501|Other|Sustained Weight Loss (SWL)|The sustained weight loss group will include 20 subjects who underwent Roux-en-Y gastric bypass (RYGB) with a follow up of at least 2 years and have experienced excess weight loss (EWL) of at least 50% at 12 (+ 2) months post-operatively and have regained less than 15% of the post-operative nadir weight.
3324828|NCT02048514|Experimental|Nellix Aneurysm Sealing|The Nellix® EndoVascular Aneurysm Sealing System
3324829|NCT02048527|Active Comparator|Global|In vitro embryo culture in single-step medium (Global)
3324830|NCT02048527|Active Comparator|Origio|In vitro embryo culture in sequential media (Origio)
3324831|NCT02048540|Experimental|bevacizumab plus DOF|patients receive bev +DOF pre and post surgery up to total 6 cycles
3324832|NCT02048540|Active Comparator|DOF|patients receive DOF pre and post surgery up to total 6 cycles
3324833|NCT02048553|Experimental|Tablet-guided|Guide-assisted ventriculostomy.
3230070|NCT01187251||Group 1 - mp3 users|Subjects who have been using mp3 players for at least 1 hour per day for at least 1 year
3230071|NCT01187251||Group 2 - mp3 non-users|Subjects who does not listen regularly to mp3 music
3324834|NCT02048553|Experimental|Freehand|standard ventriculostomy.
3324835|NCT02048566|Experimental|hTEEPM|Group hTEE protocolled monitoring (hTEEPM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration (see below) and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3324836|NCT02048566|Experimental|hTEESM|Group hTEE standard monitoring (hTEESM) will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management in which case an hTEE assessment has to be performed. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3324837|NCT02048566|Active Comparator|ControlPM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3230072|NCT01187264|Active Comparator|methotrexate 10 mg|oral methotrexate 10 mg once weekly
3230073|NCT01187264|Active Comparator|methotrexate 25mg|oral methotrexate 25 mg once weekly
3230074|NCT01187277|Experimental|Group A|Group A = conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
3230075|NCT01187277|Active Comparator|Group B|Group B = conventional therapy plus robot-assisted means: 30 min individual physiotherapy plus 20 min robot-assisted gait training and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
3230076|NCT01187290|No Intervention|neoadjuvant chemotherapy|Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
3230077|NCT01187290|Experimental|neoadjuvant chemoradiotherapy|Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
3230078|NCT01187316|Experimental|TENS|
3230079|NCT01187316|Active Comparator|Massage therapy and muscle stretching|
3324838|NCT02048566|Active Comparator|ControlSM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h after study inclusion. A follow up assessment is defined as any assessment that leads to significant changes in hemodynamic management. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
3324839|NCT02048579|No Intervention|Treatment as Usual|
3324840|NCT02048579|Experimental|Behavior Therap + Motivational Interviewing|Supporting Teens' Academic Needs Daily Therapy program delivered to parents and teens
3324841|NCT02048592|Active Comparator|Impact-Nutridrink|The first arm will be given immunonutrition -Impact- for 8 weeks, afterwards the patients will return to their previous nutrition support for another 8 weeks. We expect the improvement of oxidative stress parameters after 8 weeks of immunonutriton and return to baseline values when immunonutrition is stopped
3324842|NCT02048592|Active Comparator|Nutridrink-Impact|The second group will be given their previous nutrition support (Nutridrink) for 8 weeks, afterwards the patients will be switched to immunonutrition- Impact- for another 8 weeks. In this group of patients we do not expect any change of oxidative stress parameters after the first 8 weeks. The improvement is expected at the end of the second half of study.
3324843|NCT02048605|Experimental|Psycho-social (CBT) based training|Psycho-social Training in Neurological Diseases - Parkinson's Disease ( Training according to Ellgring et al., 2006)
3324844|NCT02048605|Placebo Comparator|Unspecific group training|"Health Enhancement Program~The validation of an active control intervention for Mindfulness Based Stress Reduction (MBSR) (MacCoon et al., 2012)"
3324845|NCT02048618|Experimental|GLPG0634 200 mg QD|2 tablets of 100 mg GLPG0634 in the morning
3230080|NCT01187342||Non-striatal lesion group|acute ischemic Stroke in MCA territory of 10-100 cm³ with sparing of striatocapsular structures
3230081|NCT01187342||Striatal lesion group|acute ischemic stroke in MCA/AchA territory with involvement of at least 125 mm³ of striatocapsular structures
3324846|NCT02048618|Experimental|GLPG0634 100 mg QD|1 tablet of 100 mg GLPG0634 and 1 placebo tablet in the morning
3230082|NCT01187368|Experimental|Evaheart LVAS (EVA2)|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.
3230083|NCT01187368|Active Comparator|HeartMate 3|The objective of the study is to evaluate the safety and effectiveness of the EVA2 by demonstrating non-inferiority to commercially approved LVADs when used for the treatment of refractory NYHA Class IV heart failure.
3230084|NCT01187420||EEG and Cerebral Vasospasm|Cerebral Vasospasm and role of BIS vista monitor in Subarachnoid Hemorrhage (SAH) patients
3324847|NCT02048618|Placebo Comparator|Placebo QD|2 placebo tablets in the morning
3324848|NCT02048631||Oral Cancer Patients underwent Free Flap Reconstruction|
3230085|NCT01187459|Experimental|10 ug/day|
3230086|NCT01187459|Experimental|50 ug/day|
3230087|NCT01187472||Treated subjects|Subjects treated on a previous study of locally advanced head and neck cancer
3230088|NCT01187485|Experimental|Androderm® 2.5mg|Study subjects will be randomized to one of the study arms: 2.5 mg of Androderm®.
3324849|NCT02048644|Placebo Comparator|placebo inhaler|matched placebo inhaler, to be taken 2 puffs, twice a day for 28 days
3230089|NCT01187485|Experimental|Androderm® 5.0 mg|Study subjects will be randomized to one of the study arms: 5.0 mg of Androderm®.
3324850|NCT02048644|Experimental|fostair|fostair 100mcg/6mcg 2pufss, twice a day.
3230090|NCT01187485|Experimental|Androderm® 7.5mg|Study subjects will be randomized to one of the study arms: 7.5 mg of Androderm®.
3230091|NCT01187537|Experimental|Continuous Femoral Nerve Block|
3230092|NCT01187537|Active Comparator|Single-Inj Nerve Block with IV PCA|
3230093|NCT01187537|Active Comparator|IV PCA|
3230094|NCT01187576|Experimental|Intervention|Multi-professional team intervention with PAR, lifestyle brochure
3230095|NCT01187576|Active Comparator|Conventional treatment|Ordinary recommendations on health behaviours, lifestyle brochure
3230096|NCT01187576|No Intervention|retrospective med history comparison|Treatment as usual (retrospective data collection)
3230097|NCT01187589|Experimental|Pulsehaler|Fully operational Pulsehaler, with protocol enabled
3230098|NCT01187589|Active Comparator|Nebulizer|Deactivated Pulsehaler (protocol disabled), so only the nebulizer is active
3230099|NCT01187602||Women at average risk for ovarian cancer|Women at average risk for ovarian cancer (no first degree relatives with breast or ovarian cancer) undergoing gynecologic evaluation at UVA for non-malignant or routine indications.
3230100|NCT01187602||Women with ovarian cancer|Women with known or suspected ovarian cancer who are undergoing evaluation and/or treatment at UVA Cancer Center
3230101|NCT01187602||Increased risk for ovarian cancer|Women at increased risk of ovarian cancer based on family history, personal history, or genetic factors defined as either BRCA1 or BRCA2 mutations who still retain both fallopian tubes and both ovaries.
3230102|NCT01187615|Experimental|Arm 1|
3230103|NCT01187615|Experimental|Arm 2|
3230104|NCT01187628|Experimental|Arm 1|
3230105|NCT01187641||colon cancer|patients undergoing treatment for colon cancer
3230106|NCT01187654|Experimental|AC133 recipients|intra coronary injection of bone marrow derived AC133+ cells
3230107|NCT01187654|Experimental|MNC recipients|intra coronary injection of bone marrow derived MNC
3230108|NCT01187654|Active Comparator|control|injection of autologous serum
3230109|NCT01187667||Haloperidol prevention group|ICU patients with a high risk for delirium who are treated with haloperidol for preventive reason.
3230110|NCT01187667||Control group|Historical cohort group of patients (2008-2009)with a determined risk of 50% or more for delirium who were not treated with haloperidol for preventive reason.
3230111|NCT01187680|Experimental|Spraygel|
3230112|NCT01187680|Active Comparator|Control|
3230113|NCT01187693|Other|Shoe lift|
3324851|NCT02048657|Experimental|Foley group|The Foley Airway Stylet Tool was used to guide ProSeal LMA insertion
3324852|NCT02048657|Experimental|I-Tool group|the ProSeal LMA was inserted with a standard introducer-tool
3324853|NCT02048683|Experimental|burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
3324854|NCT02048683|Other|non burn ICU patients|Determination of plasmatic concentrations of sevoflurane at different times of a short term sedation of sevoflurane in burn versus non burn ICU patients
3324855|NCT02048696|Experimental|Exercise training|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
3324856|NCT02048696|No Intervention|control|Individuals in this group are offered current ACC/AHA recommendations on physical activity in patients post-myocardial infarction.
3324857|NCT02048709|Experimental|GDC-0919 Dose Escalation|GDC-0919 to be given on an outpatient basis as a single agent. Starting dose of GDC-0919 will be 50 mg by mouth every 12 hour. Patients will receive the study drug daily for 21 days followed by 7 days off for a cycle length of 28 days; or on 28 consecutive days of a 28-day cycle
3324858|NCT02048748|Experimental|Telemonitoring|Device: Weight and blood pressure device Device: Home telemonitoring device
3324859|NCT02048748|No Intervention|Control|Usual care
3230114|NCT01187706||gynecological cancer survivors|"Criteria for including: (1)Been diagnosed as cervical cancer, ovarian cancer or endometrial cancer, and has completed six months after the relevant treatment. (2)Age from 20 - 70 years old. (3) Agreed to participate in this study.~Criteria for exclusion: Combined with other non-gynecologic cancer (cervical cancer, ovarian cancer or endometrial cancer) patients."
3230115|NCT01187706||healthy controls|Criteria for including: (1)Not those who suffer from cancer.(2)20-70 years old.(3)Agreed to participate in this study.Criteria for exclusion:Had undergone gynecologic surgical removal of ovaries or uterus were.
3324860|NCT02048761|Placebo Comparator|Placebo Group|After debridement, placebo gel was applied into the periodontal pockets with a syringe and a blunt canula.
3324861|NCT02048761|Active Comparator|1% Metformin|After debridement, 1% Metformin gel was applied into the periodontal pockets with a syringe and a blunt canula.
3324862|NCT02048774|Active Comparator|High Social Position|The investigators will randomly assign a participant to a higher social position.
3230116|NCT01187719|No Intervention|Control|ARV prophylaxis for PMTCT follows national guidelines.
3324863|NCT02048774|Experimental|Low Social Position|The investigators will randomly assign a participant to a lower social position.
3324864|NCT02048787|Experimental|Moderate renal impairment group|Subjects with moderate renal impairment defined as eGFR of 30-59 mL/min/1.73m2 at screening can be enrolled in this group
3324865|NCT02048787|Experimental|Severe renal impairment group|Subjects with severe renal impairment defined as eGFR of 15-29 mL/min/1.73m2 at screening can be enrolled in this group
3324866|NCT02048787|Experimental|Matching healthy control group|Subjects with normal renal function defined as eGFR ≥ 90 mL/min/1.73m2 at screening and matching to the renal impaired subject based on gender, race, age, and weight can be enrolled in this group.
3324867|NCT02048800||Treosulfan PK|Children with indication to HSCT receiving Treosulfan
3324870|NCT02048839||Radiel Intervention group and their children|Participated the Radiel- intervention study (2008-2011) in the Intervention group: Lifestyle counselling during and after pregnancy (up to 1 year post partum)
3324871|NCT02048839||Radiel Control Group with their children|Control group in the Radiel- intervention study.
3230117|NCT01187719|Experimental|phenytoin interaction|ARV prophylaxis for PMTCT follows national guidelines + start phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
3230118|NCT01187732|Experimental|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
3324872|NCT02048852|Experimental|Reduced Nicotine Content -Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarettes (NRC 200-Reduced Nicotine Content cigarette) which contain 0.07mg nicotine yield without menthol.
3324873|NCT02048852|Experimental|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced Nicotine Research Cigarettes which contain 0.07mg nicotine yield with Menthol
3324874|NCT02048852|Active Comparator|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette. No research cigarettes used.
3324875|NCT02048852|Experimental|Conventional Nicotine Content- Non Menthol|Switch from own brand of cigarette to SPECTRUM research cigarette (NRC-600 Conventional Nicotine )which contains conventional nicotine yield.
3324876|NCT02048865|Active Comparator|Apixaban|2.5 mg BID for 6 months
3230119|NCT01187732|Active Comparator|Traditional soap and water bath|The control intervention is the traditional bathing assistance as performed in care dependent patients by using tap water, a bowl, towels, washcloths and soap.
3230120|NCT01187745||suspect kidney stones|Patients presenting with flank abdominal pain
3324877|NCT02048865|Placebo Comparator|Placebo drug|2.5 mg BID for 6 months
3324878|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
3324879|NCT02048917|Experimental|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
3324880|NCT02048917|Experimental|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
3324881|NCT02048917|Experimental|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
3324882|NCT02048917|Experimental|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
3230121|NCT01187758|Experimental|Educational intervention|Multifacet educational intervention that includes workshops, seminars and focus group meetings
3230122|NCT01187758|No Intervention|Control - no intervention|This group did not have any intervention, but their population was screened for carriage of antibiotic resistant bacteria
3230123|NCT01187784|Active Comparator|CBT|Coping Cat cognitive-behavioral therapy protocol
3324883|NCT02048917|Experimental|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
3324884|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
3324885|NCT02048917|Experimental|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
3324886|NCT02048917|Experimental|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
3324887|NCT02048917|Experimental|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
3324888|NCT02048917|Experimental|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
3324889|NCT02048917|Experimental|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
3324890|NCT02048930||Initiation cohort|Receive their first prescription for ICS therapy as one of the study drugs
3324891|NCT02048930||Step-up cohort|Receive a prescription for one of the study drugs at a dose ≥50% that of their prescribed ICS dose during baseline.
3324892|NCT02048930||Switch cohort|switch from BUD DPI (other) to BUD EH or continue on BUD DPI (other) with no change in ICS dose
3324893|NCT02048943|Experimental|Treatment (dovitinib, gemcitabine, nab-paclitaxel)|Patients receive dovitinib lactate PO QD 5 days per week, paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324894|NCT02048956|Experimental|Hydrotherapy intervention|30 people will be recruited in order to the inclusion criteria for the study and they will receive an hydrotherapy intervention.
3324895|NCT02048956|Active Comparator|Control group|30 people will be recruited and included in this control group. The are not going to receive hydrotherapy treatment, only the treatment they receive as usual.
3324896|NCT02048969|Experimental|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of flumazenil will be administered to the patient at a rate of 0.1 mg flumazenil per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
3324897|NCT02048969|Placebo Comparator|Saline|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
3324898|NCT02048982|Experimental|Guideline and Cost|The Choosing Wisely guideline and the cost of the test at our institution: $60.35 for a basic metabolic panel.
3230124|NCT01187784|No Intervention|Waitlist Control|Treatment as usual
3230125|NCT01187797|Experimental|Intervention|
3324899|NCT02048982|Placebo Comparator|Guideline|"The Choosing Wisely guideline: Don't perform blood chemistry panels in asymptomatic, healthy adults."
3324900|NCT02048982|Active Comparator|Guideline and Victim|The Choosing Wisely Guideline and a clinical scenario with a patient as an identifiable victim who suffered harm from having an unnecessary test done
3230126|NCT01187810|Experimental|Combination of Fenretinide, Cytarabine, and Methotrexate|IV for 7 days for each 21 day cycle
3230127|NCT01187823|Active Comparator|Nocturnal oxygen therapy|
3230128|NCT01187823|Active Comparator|Adaptive servo ventilation|Bipap® auto SV Advanced
3230129|NCT01187836|Experimental|TRV120027|
3230130|NCT01187836|Placebo Comparator|Placebo|
3230131|NCT01187849|Active Comparator|Metformin|
3230132|NCT01187849|Placebo Comparator|Placebo|
3324901|NCT02048982|Experimental|Guideline, Cost, and Victim|The Choosing Wisely guideline and a clinical scenario with a physician as an identifiable victim who suffered harm when he ordered an unnecessary test.
3324902|NCT02048995||Bipolar Depressed|Bipolar Depressed - are participants with Bipolar Disorder Type I or II and a current episode of major depression which is confirmed on the SCID interview
3230133|NCT01187862|Other|Basel cocktail|
3324903|NCT02048995||Healthy Comparator|Healthy Comparator - are participants without mental disorders, alcohol or substance disorders confirmed by the SCID-interview
3324904|NCT02049008|Experimental|Photodynamic Therapy|
3324905|NCT02049008|Sham Comparator|Sham Photodynamic Therapy|
3324906|NCT02049021|Experimental|Electroconvulsive Therapy|Patients in use of clozapine randomized to receive ECT treatment
3324907|NCT02049021|Sham Comparator|SHAM ECT|Patients receiving clozapine randomized to sham ECT (placebo)
3230134|NCT01187875|Placebo Comparator|Control|Dextrin Control
3230135|NCT01187875|Experimental|Hi-maize resistant starch 9g|Hi-maize resistant starch 9g
3230136|NCT01187875|Experimental|Novalose 330 resistant starch 9g|Novalose 330 resistant starch 9g
3230137|NCT01187875|Experimental|4.5g Hi-maize and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330
3230138|NCT01187888|Active Comparator|Rasagiline|
3230139|NCT01187888|Placebo Comparator|Sugar pill|
3230140|NCT01187927||Female subjects|Subjects received Cervarix® as per routine practice
3230141|NCT01187940|Experimental|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
3230142|NCT01187940|No Intervention|Placebo|Will receive managment as usual from their local educational and NHS services
3230143|NCT01187966|Placebo Comparator|Placebo|Drug: Placebo
3230144|NCT01187966|Experimental|High Dose (100mg/day)|
3230145|NCT01187966|Experimental|Low dose (50mg/day)|
3324908|NCT02049034|Placebo Comparator|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
3324909|NCT02049034|Experimental|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
3324910|NCT02049047|Experimental|Everolimus|oral everolimus
3324911|NCT02049060|Experimental|Tivantinib+carboplatino+pemetrexed|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
3324912|NCT02049073|Experimental|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
3324913|NCT02049073|Experimental|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
3324914|NCT02049073|No Intervention|Control|no medication
3324915|NCT02049086|Experimental|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
3230146|NCT01187979|Active Comparator|Control|All eligibly enrolled learners in the intervention schools will receive a prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education. No cash incentives will be paid for meeting milestones
3230147|NCT01187979|Experimental|Cash incentive|All eligibly enrolled learners in the intervention schools will receive a cash incentivised prevention program delivered by MIET Africa and the KwaZulu-Natal Department of Education
3324916|NCT02049086|Active Comparator|Pain Module Only|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
3324917|NCT02049086|No Intervention|No Additional Referral|No intervention.
3230148|NCT01187992|Experimental|Full-dose atorovastatin (80 mg/d)|For patients randomised to this arm, atorvastatin in the fixed dose of 80 mg/ day was started immediately after randomisation.
3230149|NCT01187992|No Intervention|Conventional medical treatment|For patients randomised to this arm, adherence to the National Cholesterol Education Program, Adult Treatment Panel III guidelines was required. In particular, in these patients,atorvastatin was started at the initial dosage of 20 mg/day immediately after randomisation. Subsequently, atorvastatin dosage was titrated in order to attain low-density lipoprotein cholesterol (LDL-C) levels <100 mg/dL (2.5 mmol/L).
3230150|NCT01188005|Experimental|OSAS patients|This arm includes the OSAS diagnosed cohort that has been planned to undergo four polysomnographic studies. One standard, one with oxygen supplementation, one with n-CPAP device and one post antioxidants administration
3324918|NCT02049112|Experimental|Salivary equivalent|Single dose stick without any active substance
3324919|NCT02049112|Sham Comparator|Aequasyal|Multidose moisturizing oral spray without any active substance
3324920|NCT02049112|Sham Comparator|Biotene|Multidose moisturizing oral spray without any active substance
3324921|NCT02049125||No AKI|Patients with cirrhosis admitted to hospital with bacterial infection with initial serum creatinine below 1.5mg/dL.
3324922|NCT02049125||AKI and Infection|Patients with cirrhosis admitted to hospital with bacterial infection and initial serum creatinine above 1.5mg/dL.
3324923|NCT02049125||AKI with No Infection|Patients with cirrhosis admitted to hospital with initial serum creatinine above 1.5mg/dL without bacterial infection.
3324924|NCT02049138|Experimental|Open-label extension|All subjects will start treatment with ABT-494.
3324925|NCT02049164|Experimental|AR08 0.5 mg/day|AR08 QD oral dosing for 14 weeks
3324926|NCT02049164|Experimental|AR08 1.0 mg/day|AR08 QD oral dosing for 14 weeks
3230151|NCT01188005|No Intervention|Control Group|This group is scheduled to undergo a plain polysomnographic study, whilst plasma cytokine levels will be measured. It will comprise of healthy, non-OSAS volunteers.
3324927|NCT02049164|Experimental|AR08 2.0 mg/day|AR08 QD oral dosing for 14 weeks
3324928|NCT02049164|Placebo Comparator|Placebo|Placebo QD oral dosing for 14 weeks
3324929|NCT02049177||Head and Neck Cancer Cases|Cases of Head and Neck Cancer identified in North West England in 2002/2003. Observational study - no intervention other than usual care.
3324930|NCT02049190|Experimental|onapristone 10 mg BID|onapristone 10 mg BID extended-release tablets
3324931|NCT02049190|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
3324932|NCT02049190|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
3230152|NCT01188018|Active Comparator|Brief Advice|
3230153|NCT01188018|Experimental|Motivational Interviewing|
3324933|NCT02049190|Experimental|onapristone 40 mg BID|onapristone 40 mg BID extended-release tablets
3324934|NCT02049190|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release
3324935|NCT02049190|Experimental|onapristone 30 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 30 mg BID + abiraterone 1000 mg
3324936|NCT02049190|Experimental|onapristone 50 mg BID + abiraterone 1000 mg|Expansion cohort: onapristone 50 mg BID + abiraterone 1000 mg
3324937|NCT02049190|Experimental|Expansion cohort: onapristone 50 mg BID|Expansion cohort: onapristone 50 mg BID
3324938|NCT02049203|Placebo Comparator|Placebo|Placebo gel capsule, dosage matches number of Ataciguat capsules for each respective dose, capsules taken once daily with breakfast for 14 consecutive days.
3230154|NCT01188018|Active Comparator|Health Education|
3230155|NCT01188031|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
3324939|NCT02049203|Active Comparator|Ataciguat|Ataciguat, orally administered gel capsule, 50, 100, or 200 mg, once per day with breakfast for 14 consecutive days
3324940|NCT02049216|Sham Comparator|Sham tape|"Fixomull tape only~Single piece of 10cm wide, 32cm long applied from inferior to tibial tuberosity, over patella and onto quadriceps muscle. Corners rounded. Tape to be applied with the knee in 90 degrees flexion.~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
3324941|NCT02049216|Experimental|Flexible tape|"Flexible tape (rocktape brand) applied as follows:~First piece of tape 10 cm wide and 32cm long (length of a standard goniometer). Split down centre 18cm from 1 end. Second piece of tape 5cm wide and 14cm long.~Tape applied in 90 degrees knee flexion Applied with no tension in proximal and distal ends. 30% tension to un-split portion placed over quads. 50% tension to split portion placed either side of patella and crossing over at tibial tuberosity Additional piece of 5cm wide flexible tape applied with 80% tension over patella tendon, with no tension in 3cm from ends All tape corners rounded~Participants in both groups will also be prescribed an individualised home exercise program by a physiotherapist."
3324942|NCT02049229|Experimental|OPTIMAX stent|Patients randomised to receive titanium-nitride-oxide coated OPTIMAX-stent
3324943|NCT02049229|Active Comparator|SYNERGY stent|Patients randomised to receive everolimus-eluting, biabsorabble polymer coated stent
3324944|NCT02049242|Active Comparator|Triple tourniquet|
3324945|NCT02049242|Active Comparator|Single tourniquet|
3324946|NCT02049255|Placebo Comparator|Marcaine|Rachianesthesia with marcaine or chloroprocaine
3324947|NCT02049255|Active Comparator|Chloroprocaine|Rachianesthesia with marcaine or chloroprocaine
3324948|NCT02049268|Experimental|Nicotine + Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3324949|NCT02049268|Experimental|Placebo Nicotine + Alcohol|A placebo nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (placebo nicotine) measurements will be made, then participants will drink an alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3324950|NCT02049268|Experimental|Nicotine + Placebo Alcohol|A nicotine patch will be applied to the subject. After a 3-4 hour uptake period, subjects will undergo a single MRI session. Baseline (nicotine only) measurements will be made, then participants will drink a placebo alcoholic beverage. Post-alcohol measurements will be made after a 20 minute uptake period.
3324951|NCT02049281|Experimental|Vintafolide|Participants receive vintafolide intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
3324952|NCT02049294|Active Comparator|Omalizumab (Xolair)|Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.
3324953|NCT02049294|Placebo Comparator|Placebo (Normal Saline)|0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab
3324954|NCT02049320||Remifentanil|Patients sedated using Remifentanil
3230156|NCT01188031|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
3230157|NCT01188044||Study group|Healthy children
3230158|NCT01188057|Experimental|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG, single dose
3230159|NCT01188057|Active Comparator|NIRAVAM TM|NIRAVAM TM 2 mg orally disintegrating tablets, single dose
3230160|NCT01188070|Sham Comparator|Usual Care Attention Control|Provision of printed educational material and attendance at one group session. This session will focus on nutrition education and flexibility and stretching.
3230161|NCT01188070|Experimental|Psychoeducation plus exercise|Psychoeducation intervention plus an individualized exercise program which will include monitored, individually-prescribed aerobic and resistance exercise.
3230162|NCT01188070|Active Comparator|Psychoeducation|Psychoeducational program to involve group sessions over consecutive weeks. The sessions will use the principles of adult learning, emphasizing active learning, group exercises and discussion, and coaching as well as brief talks to provide content. The curriculum will focus on the strengthening of caregiver self-efficacy through enhancement of knowledge and understanding, the acquisition, strengthening, and practice of caregiving skills, and the development of a more clinical or strategic outlook on the caregiving role.
3230163|NCT01188083|Experimental|Fructose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
3230164|NCT01188083|Experimental|Glucose Drink|Subject will drink 3-8oz drinks per day for 4 weeks
3230165|NCT01188096|Experimental|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
3324955|NCT02049333|Active Comparator|Phacoemulsification|Cataract extraction alone
3324956|NCT02049333|Experimental|Phacoemulsification with Endoscopic Cycloplasty (ECPL)|Cataract extraction combined with endoscopic cycloplasty
3324957|NCT02049346|Active Comparator|Epoetin alpha or beta (Epoetin group)|Patients in that arm were continued on the previous same dose and route of administration of Epoetin alpha/ beta (Epoetin group).
3324958|NCT02049346|Active Comparator|Darbepoetin alpha|subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol.
3324959|NCT02049346|Experimental|Methoxy polyethylene glycol-epoetin beta|Patients in that arm received Intravenous Methoxy polyethylene glycol-epoetin beta monthly.
3230166|NCT01188122|Experimental|AnapnoGuard|
3230167|NCT01188135|Experimental|Interactive Voice messaging|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed"
3324960|NCT02049359|No Intervention|Control group|Care as usual; no bidirectional texting
3324961|NCT02049359|Experimental|Texting|Bidirectional texting weekly for 12 weeks
3324962|NCT02049398||Oral microbiome cohort|a cohort of 40 adults willing to provide oral samples approximately every two months forone year
3324963|NCT02049411|Experimental|Ketamine group|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
3230168|NCT01188135|No Intervention|Usual care arm|usual care treatment with no interactive phone reminder calls phone
3324964|NCT02049411|Sham Comparator|physiological solution|Control group: only physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
3324965|NCT02049424||transplanted patients|T-repleted haploidentical transplanted patients in Italy
3230169|NCT01188135|Experimental|IVR messaging w/ Psycho-ed. materials|"Participants will receive three kinds of interventions calls from the IVR phone system. (1) The first call is to orient the participant to the IVR system, ask permission to leave detailed messages in the future, and to encourage adherence in this initial period of great risk for premature discontinuation. (2) The Refill Reminder Call is to remind patients that a refill their antidepressant medications and occurs approximately 6 days before the prior dispense of medication is due to run out. (3) The Tardy Refill Call is made to participants for whom EMR records indicate that a scheduled refill was missed. In addition, participants will receive educational material about antidepressant medication."
3230170|NCT01188148|Active Comparator|VPA & Placebo|VPA & Placebo
3324966|NCT02049489|Experimental|ICT-121 DC vaccine|Autologous dendritic cells pulsed with peptide antigens
3324967|NCT02049515|Experimental|IPI-145|IPI-145 is administered orally and supplied as 5 mg and 25 mg formulated capsules.
3324968|NCT02049515|Active Comparator|Ofatumumab|Ofatumumab is administered as an intravenous (IV) infusion and is supplied in single-use vials at two strengths, 100 mg/5mL and 1000 mg/50 mL
3324969|NCT02049528|Experimental|3 mg CC-122 reference capsule formulation|3 mg CC-122 reference capsule given by mouth with 240 mL of room temp tap water
3324970|NCT02049528|Experimental|3 mg CC-122 test capsule formulation|3 mg CC-122 test capsule give by mouth with 240 mL of room temp tap water
3324971|NCT02049528|Experimental|3 mg CC-122 test capsule + high fat meal|3 mg CC-122 test capsule given by mouth with 240 mL of room temp tap water approximately 5 minutes after eating a high-fat meal
3230171|NCT01188148|Experimental|VPA & memantine|
3230172|NCT01188161||Normal subjects|Volunteers without a history of dizzyness or vertigo
3230173|NCT01188174|Experimental|Clofarabine|
3230174|NCT01188187|Experimental|Custirsen, Docetaxel, Prednisone|"Three doses of 640 mg custirsen administered intravenously (IV) as a loading dose between Days -9 to -1. Custirsen, 640 mg, given IV weekly on Days 1, 8, and 15 of each 21-day cycle. Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
3259135|NCT01467804|Experimental|Chinese medicine|There are 90 patients with mild to moderate depress in JWXY group, who take the JWXY capsule, and placebo of Sertraline, for 2 months
3324972|NCT02049541|Experimental|Treatment (PI3K inhibitor BKM120, rituximab)|Patients receive BKM120 PO daily and rituximab IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with asymptomatic progression may continue treatment for up to 12 months. Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline. Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission.
3324973|NCT02049554|No Intervention|Usual Care|
3324974|NCT02049554|Experimental|Preconception Care Screener Group|Women's Health Screener and Clinician discussion
3324975|NCT02049567|Experimental|FluidVision|FluidVision AIOL implanted in the capsular bag of the eye during cataract surgery
3324976|NCT02049580|Experimental|RIC regimen|Thiotepa, Fludarabine, Cyclophosphamide pre- and post- transplantation.
3324977|NCT02049593|Experimental|Arm A (PARP inhibitor BMN-673, temozolomide)|Patients receive PARP inhibitor BMN-673 PO QD on days 1-28 and temozolomide PO daily on days1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324978|NCT02049593|Experimental|Arm B (PARP inhibitor BMN-673, irinotecan hydrochloride)|Patients receive PARP inhibitor BNM-673 as in Arm A and irinotecan hydrochloride IV on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3324979|NCT02049606|Experimental|LAYLA|Drug : LAYLA tablet/bid
3324980|NCT02049606|Active Comparator|CENATONE|Drug : CENATONE tablet/qd
3324981|NCT02049619|No Intervention|Control|Following endotracheal intubation, no pharyngeal pack was inserted into the hypopharynx.
3324982|NCT02049619|Experimental|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
3324983|NCT02049632|Experimental|Omission of axillary clearance|No axillary lymph node dissection after sentinel node biopsy and sentinel node micrometastases
3324984|NCT02049645||faculty staff and their adult family members|faculties and their adult family members of the Third Xiang-Ya Hospital
3324985|NCT02049658||Healthy volunteers|Healthy volunteers measured by currently used healthy screening procedures
3324986|NCT02049658||Suspected breast cancer subjects|Suspected breast cancer subjects without pathological examination yet but will have it soon
3324987|NCT02049658||Suspected lung cancer subjects|Suspected lung cancer subjects without pathological examination yet but will have it soon
3324988|NCT02049658||Suspected neurological tumor subjects|Suspected neurological tumor subjects without pathological examination yet but will have it soon
3324989|NCT02049658||Suspected patients with gynecological tumor|Suspected subjects with gynecological tumors without pathological examination yet but will have it soon
3324990|NCT02049671||Growth Hormone Therapy|
3324991|NCT02049671||Control Group|
3324992|NCT02049684||Surgery|
3324993|NCT02049684||Physiotherapy|
3324994|NCT02049697|Experimental|14C-JNJ-39823277|
3324995|NCT02049710|Active Comparator|Sexual Behavior Intervention|
3324996|NCT02049710|Active Comparator|Driving behavior intervention|
3324997|NCT02049723||Patients with GERD|The knowledge level on GERD among Korean patients with gastroesophageal disease was evaluated by the method of multicenter survey
3324998|NCT02049736|Experimental|Telbivudine|
3324999|NCT02049762|Active Comparator|P2Y12 inhibitors and aspirin|ACS patients on novel P2Y12 inhibitors and aspirin
3325000|NCT02049762|Placebo Comparator|P2Y12 inhibitors and placebo|ACS patients on novel P2Y12 inhibitors and placebo
3325001|NCT02049775|Experimental|NBI|
3230175|NCT01188187|Active Comparator|Docetaxel, Prednisone|"Docetaxel (75 mg/M^2 via intravenous injection) on Day 1 of every 21 days plus prednisone (5 mg tablets taken by mouth) twice each day and dexamethasone (8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration).~Treatment continues for 10 cycles or until unacceptable toxicity or disease progression."
3325002|NCT02049788|Active Comparator|low calorie/fat diet|The low calorie/fat diet group, obese children aged 9-16, received conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
3325003|NCT02049788|Experimental|Low glycaemic index diet|Low glycaemic index diet group, obese children of both sexes aged 9-16, received experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
3325004|NCT02049801|Experimental|Treatment (MEK inhibitor, MEK162, idarubicin, cytarabine)|"INDUCTION THERAPY: Patients receive MEK inhibitor MEK162 PO BID on days -4 to -1 and days 5-18, cytarabine IV continuously over 24 hours on days 1-4, and idarubicin IV over 1 hour on days 1-3. Patients may receive a second course of induction at the discretion of the principal investigator.~POST-REMISSION THERAPY: Patients receive cytarabine IV continuously over 24 hours on days 1-3, idarubicin IV over 1 hour on days 1 and 2, and MEK inhibitor MEK 162 PO BID on days 4-17. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3325005|NCT02049827|Experimental|Renal transplant|
3325006|NCT02049840|Experimental|Altis Single Incision Sling System|Altis Single Incision Sling System
3325007|NCT02049853|No Intervention|default group|"Patients with the randomization result default group receive standard diagnostics"
3325008|NCT02049853|Active Comparator|POCT group|"patients with the randomization result POCT group receive a NTproBNP measurement with point of care device Cobash232 in the ambulance vehicle"
3325009|NCT02049879|Experimental|Injection|Corticosteroids injection
3325010|NCT02049892||Metal Ion|
3325011|NCT02049905|Experimental|Aldoxorubicin|Aldoxorubicin is administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously on Day 1 every 21-day cycles until tumor progression or unacceptable toxicity occurs.
3325012|NCT02049905|Active Comparator|Investigator's Choice of Treatment|"These treatments include:~Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;~Pazopanib, 800 mg orally each day until tumor progression or unacceptable toxicity occurs;~Gemcitabine, 900 mg/m2 by IVI over 90 minutes on Days 1 and 8, plus docetaxel, 100 mg/m2 by IVI over 1 hour on Day 8 of a 28 day cycle until tumor progression or unacceptable toxicity occurs;~Doxorubicin, 75 mg/m2 by IVI over 5 to 30 minutes every 21 days for a maximum cumulative dose of 550 mg/m2 or unacceptable toxicity occurs; or~Ifosfamide 2.0 g/m2 administered over 2 to 4 hours on Days 1-4 of a 21 day cycle + mesna per standard site administration regimen until tumor progression or unacceptable toxicity occurs."
3325013|NCT02049970|Experimental|dexmedetomidine and bupivacaine|Bupivacaine 50 mg and dexmedetomidine 1 microgram/kg
3325014|NCT02049970|Experimental|Bupivacaine and placebo|Bupivacaine 100 mg and SF 10 ml
3325015|NCT02049983|Experimental|Use of Levita Magnetics Grasper|
3325016|NCT02049996||Robotic-assisted prolapse repair|Subjects already scheduled for robotic-assisted prolapse repair in conjunction with vaginal hysterectomy
3325017|NCT02049996||Vaginal prolapse repair|Subjects already scheduled for vaginal prolapse repair in conjunction with vaginal hysterectomy.
3230176|NCT01188200|Experimental|Nutritional Formula #M979|nutritional formula
3230177|NCT01188200|Active Comparator|Regular standard meal|standard meal
3325018|NCT02050009|Experimental|Treatment (metformin hydrochloride, carboplatin, paclitaxel)|Patients receive metformin hydrochloride BID on days 1-21, paclitaxel IV over 3 hours on day 1, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3325019|NCT02050022||Exacerbation|Patients experiencing acute exacerbation of COPD.
3325020|NCT02050022||Non-Exacerbation|COPD patients not experiencing acute exacerbation of COPD.
3325021|NCT02050035|Experimental|CKD Aerobic Exercise Training|Chronic Kidney Disease participants randomly allocated to the CKD Exercise arm will receive 12 weeks of Aerobic Exercise Training three times per week.
3230178|NCT01188213|Experimental|Purified MSM|
3325022|NCT02050035|No Intervention|CKD Control|Chronic Kidney Disease participants allocated to the the CKD Control arm will receive their standard routine care over a 12 week period.
3325023|NCT02050035|No Intervention|Healthy Control|Healthy participants will act as comparators, they will undergo baseline testing only and will not receive an intervention.
3325024|NCT02050061|Experimental|compression stocking|compression stocking (SIGVARISTM), daily for 3 months
3230179|NCT01188239||HIGH 6wks LOW 6wks NICOTINE|"Well characterized group of 100 regular smokers experimenting the E-Cigarette loaded with ORIGINAL 7.4 mg nicotine cartridges for 6 weeks followed by CATEGORIA 5.2 mg nicotine cartridges for a further 6 weeks (high and low nicotine group)."
3230180|NCT01188252|Experimental|Roniciclib|
3230181|NCT01188265|Experimental|Valproate & dextromethorphan 30 mg|Valproate and dextromethorphan 30 mg per day
3230182|NCT01188265|Experimental|VPA & dextromethorphan 60 mg|VPA & dextromethorphan 60 mg per day
3230183|NCT01188265|Active Comparator|VPA & Placebo|VPA & placebo
3230184|NCT01188278||Patients in CP-CML treated with 2G TKI|Patients in CP-CML treated with 2G TKI (nilotinib or dasatinib) post imatinib failure
3230185|NCT01188291||Sleep Apnea / Hypopnea syndrome|Study group composed of patients with Obstructive Sleep Apnea / Hypopnea syndrome
3230186|NCT01188304|Experimental|1|
3230187|NCT01188304|Placebo Comparator|2|
3230188|NCT01188317|Experimental|1|
3230189|NCT01188317|Placebo Comparator|2|
3230190|NCT01188330|Experimental|WITH Comprehensive Geriatric assessment|Conventional haematological management of patients and Comprehensive Geriatric assessment (CGA) at diagnosis followed by interventions according to disabilities detected and planned monthly follow up by a nurse practitioner during 6 months.
3230191|NCT01188330|Active Comparator|Conventional|Conventional haematological management of patients
3230192|NCT01188382||Healthy elderly|Healthy elderly 60-82 years; Normal MRI; No psychiatric or neurological disorder and without signs of advanced atherosclerotic disease
3230193|NCT01188395||subtypes of bipolar disorders|Bipolar I Disorder with alcoholism Bipolar I Disorder without alcoholism Bipolar II Disorder with alcoholism Bipolar II Disorder without alcoholism
3230194|NCT01188408|Experimental|Liposome Entrapped Docetaxel (LE-DT)|Disease status and tumor responses/progression is assessed in accordance to the RECIST guideline
3230195|NCT01188434|Experimental|Integrated Behavioral Treatment|Combined substance abuse, parenting skills, and basic needs intervention
3230196|NCT01188434|Active Comparator|casework treatment as usual|services as usual as referred by child welfare
3325025|NCT02050061|No Intervention|standard medical therapy|Usual care
3325026|NCT02050074|Experimental|Colesevelam|
3325027|NCT02050074|Experimental|Metformin|
3325028|NCT02050074|Experimental|Placebo|
3325029|NCT02050074|Experimental|Colesevelam + exendin (9-39)|
3325030|NCT02050074|Experimental|Metformin + exendin (9-39)|
3325031|NCT02050074|Experimental|Placebo + + exendin (9-39)|
3325032|NCT02050087|Active Comparator|3 weeks with simple sling|Early motion after arthroscopic rotator cuff repair.
3325033|NCT02050087|Active Comparator|6 weeks with neutral brace|Delayed motion after arthroscopic rotator cuff repair.
3325034|NCT02050100||Lung Cancer|Early-late stage primary lung cancer
3325035|NCT02050100||Lung Neoplasm|Benign non-calcified pulmonary nodules
3325036|NCT02050113|Experimental|Endovascular repair|Endovascular repair of Complex Aortic Aneurysm using a physician modified stent graft. custom made device or arch branch device.
3325037|NCT02050126|Experimental|Scar Revision|Caesarean Scar Revision using Lumenis UltraPulse Encore.
3230197|NCT01188473|Experimental|NPPV plus standard of care|NPPV initiated early and for a prolonged period of time in addition to standard of care in the management of children admitted to the hospital with status asthmaticus
3325038|NCT02050139|Experimental|L-cysteine (Biocysan®)|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
3325039|NCT02050139|Placebo Comparator|Placebo|Study subjects will take one tablet of L-cysteine or placebo every morning four times a week and two tablets of L-cysteine or placebo three times a week during the whole study period
3325040|NCT02050152|Placebo Comparator|0% nitrous oxide|Explicit and implicit memory will be tested in 0% nitrous oxide
3325041|NCT02050152|Active Comparator|30% nitrous oxide|Explicit and Implicit memory in 30% nitrous oxide
3325042|NCT02050152|Active Comparator|60% nitrous oxide|Explicit and Implicit memory with 60% nitrous oxide
3325043|NCT02050165|Experimental|KIND Bar|Daily inclusion of KIND Bars with almonds as a primary ingredient as part of the participant's usual diet, with diet counseling to adjust for the calories from the KIND Bars. KIND Bars that we will use in the study will include: Dark Chocolate Chili Almond; Cranberry Almond; Almond Walnut Macadamia; Pomegranate Blueberry Pistachio; Nut Delight; Fruit and Nut Delight; Almond and Apricot; Blueberry Pecan and Fiber.
3325044|NCT02050165|Experimental|Typical American Snack|Daily inclusion of conventional snacks (as part of the participant's usual diet, with diet counseling to adjust for the calories from the snacks. The snacks will consist of cookies considered to be conventional snack foods that are nutrient-dilute (i.e. relatively low in nutrients) and energy-dense (i.e., relatively high in kcal). Examples of conventional snack foods will include: Nabisco Snackwell Creme Sandwich 1.7 oz pack, Nabisco Newtons Fig 2 oz pack, Nabisco Cips Ahoy! Chocolate Chip 1.4 oz pack, and Nabisco Oreo Double Stuff Chocolate 1.3 oz pack.
3325045|NCT02050178|Experimental|Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine|
3230198|NCT01188473|No Intervention|Control: standard of care alone|standard of care in the management of children admitted to the hospital with status asthmaticus
3230199|NCT01188486|Experimental|pulmonary interstitial lymphography|stereotactic body radiation therapy & pulmonary interstitial lymphography
3230200|NCT01188512|Experimental|BPZE1 - Low dose|1,000 colony forming units (cfu) of BPZE1
3230201|NCT01188512|Experimental|BPZE1- middle dose|100,000 colony forming units (cfu) of BPZE1
3230202|NCT01188512|Experimental|BPZE1 - High dose|10,000,000 colony forming units (cfu) of BPZE1
3230203|NCT01188512|Placebo Comparator|Placebo|Formulation buffer
3230204|NCT01188590||Patients undergoing heart surgery|
3325046|NCT02050191|No Intervention|program feasibility|
3230205|NCT01188629|Placebo Comparator|Safety Training|
3230206|NCT01188629|Experimental|Personal Health Partner and Counseling (PHP+C)|
3230207|NCT01188707|Experimental|Belinostat, Erlotinib, NSCLC|
3230208|NCT01188720|No Intervention|Baseline|Assessment only baseline
3230209|NCT01188720|Experimental|Acute exercise|Exercise immediately before sexual activity, three times per week.
3230210|NCT01188720|Active Comparator|General exercise|Exercise not immediately before sexual activity, three times per week.
3230211|NCT01188733|Experimental|Sandostatin LAR 10mg|Sandostatin LAR ( long-acting octreotide) administered every 28 days in a dose of 10mg
3230212|NCT01188733|Experimental|Sandostatin LAR 30mg|Comparison of drug doses
3230213|NCT01188733|Placebo Comparator|Saline|Saline control
3230214|NCT01188746|Experimental|Questionnaire or interview|A pre-experimental design was chosen to examine changes in QoL following a palliative intervention.
3230215|NCT01188759|Experimental|Voriconazole and Anidulafungin Combination|Subjects in the combination arm will receive voriconazole and anidulafungin in combination for 2-4 weeks followed by voriconazole monotherapy to complete 6-12 weeks of therapy.
3230216|NCT01188759|Active Comparator|Voriconazole Monotherapy|Subjects in the monotherapy arm will receive voriconazole monotherapy for 6-12 weeks of therapy.
3325047|NCT02050204|Experimental|LEEF Industry only: Intervention|"Customized to the Leef (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
3230217|NCT01188785|Experimental|1 arm|SOC + siG12D LODER
3230218|NCT01188824|Active Comparator|Cilostazol|Pletaal® (Cilostazol) 100 mg, bid p.o.
3325048|NCT02050204|No Intervention|LEEF Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
3325049|NCT02050204|Experimental|TOMO Industry only: Intervention|"Customized to the Tomo (alias) workplace: A 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors."
3325050|NCT02050204|No Intervention|TOMO Industry only: Usual Practice|"Continued work conditions and practice as Usual Practice in that workplace"
3325051|NCT02050217|Experimental|Noninvasive ventilation|Neurally Adjusted Ventilatory Assist versus Pressure Support flow triggered delivered by helmet
3325052|NCT02050230|Active Comparator|Fresh blood transfusion|One unit of blood stored for less than 14 days
3325053|NCT02050230|Experimental|Standard issue blood transfusion|One unit of blood stored under standard conditions
3325054|NCT02050243|Experimental|5ALA|All included patients will receive 20mg/kg of 5ALA (oral suspension) about 3 hours prior to surgery
3325055|NCT02050256|Other|general practioner|
3325056|NCT02050269|Experimental|Iohexol|injection of 5 ml of iohexol
3325057|NCT02050282|No Intervention|Business as usual|Triage and treatment based on routine clinical assessment as usual
3325058|NCT02050282|Experimental|Supplementary NT-proBNP measurement|Triage and treatment based on routine clinical assessment supplemented with measurement of NT-proBNP
3325059|NCT02050295|Experimental|Nerve block washout|Patients will receive a washout infusion of saline through their perineural catheter to reverse their motor block while maintaining the sensory block.
3325060|NCT02050295|Sham Comparator|Sham washout|Patients will receive an infusion of saline run just enough to maintain catheter patency.
3325065|NCT02050360|Experimental|Sildenafil 80 mg|Sildenafil 80 mg
3325066|NCT02050360|Experimental|Sildenafil 40 mg|Sildenafil 40 mg
3325067|NCT02050360|Placebo Comparator|Placebo|placebo
3325068|NCT02050386||Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds.
3325069|NCT02050386||Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds.
3325070|NCT02050399|Active Comparator|Healthy subjects|15 men, 45 and 65 years old. After initial evaluation, clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise protocol will be performed.
3325071|NCT02050399|Experimental|Coronary disease with Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease and type 2 diabetes will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood), clinical autonomic tests and isometric exercise protocol will be performed.
3230219|NCT01188824|Placebo Comparator|placebo|"Placebo~1 tablet, bid p.o."
3230220|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy|
3230221|NCT01188837|Active Comparator|Full Kinetic Chain Rehabilitation|
3230222|NCT01188837|Active Comparator|Full Kinetic Chain Manipulative Therapy with Rehabilitation|
3325072|NCT02050399|Experimental|Coronary disease without Type 2 Diabetes|15 men, 45-65 years old, with coronary artery disease will perform clinical exercise testing, cardiopulmonary exercise testing, carotid ultrasound, laboratory tests (biochemical blood) and isometric exercise will be performed.
3325073|NCT02050412|Other|Cat fur scratch test|
3325074|NCT02050425|Active Comparator|Therapeutic CPAP|Patients continue therapeutic continuous positive airway pressure (CPAP).
3325075|NCT02050425|Placebo Comparator|Subtherapeutic CPAP|Placebo-CPAP device delivering subtherapeutic pressure for two weeks.
3325076|NCT02050438||Knee Osteoarthritis patients with prostesis treatment|Patients operated previously of Knee Osteoarthritis with different prostesis designs according the Hospital guide
3325077|NCT02050451|Experimental|Nutrition Intervention|Ensure Plus®, consumed orally twice daily for 2 weeks before and 4 weeks after surgery
3325078|NCT02050451|Active Comparator|Control|Over the counter daily multivitamin for 2 weeks before and 4 weeks after surgery
3325079|NCT02050464||Healthy controls|Healthy controls
3325080|NCT02050464||Alzheimer's disease|Patients with mild Alzheimer's disease
3325081|NCT02050464||Vascular dementia|Patients with vascular dementia
3325082|NCT02050464||Fronto-temporal dementia|Patients with fronto-temporal dementia
3325083|NCT02050464||Mild cognitive impairment|Patients with mild cognitive impairment
3325084|NCT02050477|Experimental|Laparoscopic Vertical Gastroplasty|
3325085|NCT02050490||Before group, no diary|
3325086|NCT02050490||After group, with symptom diary|
3325087|NCT02050503||intranasal transmucosal fentanyl pectin|intranasal transmucosal fentanyl in pectin (100, 200, 400 or 800 microg) intranasal route titration phase 7 days treatment phase until completing treatment of 12 consecutive episodes of breakthrough pain
3325088|NCT02050516|Active Comparator|single embryo culture|single embryo culture in single drops inside micro-well group culture dish
3325089|NCT02050516|Experimental|group embryo culture|group embryo culture in a single drop inside micro-well group culture dish
3325090|NCT02050529|Experimental|Labetalol|This group (Group A; Labetalol) receiveD intravenous(IV) labetalol manufactured by Zafa pharmaceutical, 50mg/10 ml ampoule) bolus doses administered over 2 minutes, at 10 minutes interval. Initially dose of 20 mg wAS administered, and if required repeated in increments of 40 mg,80 mg,80 mg,80 mg every 10 minutes till SBP became <160 and DBP <110 mm Hg, upto a maximum cululative dose of 300mg(total 5 bolus doses).During this time pulse and blood pressure were checked every 10 minutes.
3325091|NCT02050529|Active Comparator|Hydralazine|This group (Hydralazine;Group B) received intravenous Hydralazine and served control. Bolus doses of 5 mg administered over 2 minutes, at 20 minutes interval. Pulse and blood pressure were checked every 10 minutes interval. If SBP threshold of 160 mm Hg or DBP 110 mm Hg was still reached after 20 minutes, then second bolus was repeated. Similarly if after 20 minutes SBP was still ≥160 or DBP ≥110 mm Hg, then third dose was given. If SBP or DBP thresholds were still exceeded after 20 minutes then similarly 4th and 5th dose of 5 mg were given. Failure to reduce SBP<160 or DBP<110 after consecutive maximum 5 boluses(total 25 mg) was labeled as severe persistent hypertension.
3325092|NCT02050542|Other|Targeted biopsies guided by a fusion of MRI and ultrasound|After the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
3325093|NCT02050542|Other|Systematic biopsies|The patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
3325094|NCT02050555|Placebo Comparator|Koji-extracted beverage|100ml/day for 12 weeks
3325095|NCT02050555|Experimental|Koji-extracted beverage fermented with LP28|100ml/day for 12 weeks. 1x10^11 cells (LP28)/day
3325096|NCT02050568||Anterior genital prolapse|Women with anterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
3325097|NCT02050568||Posterior genital prolapse|Women with posterior genital prolapse ≥ grade 2, who are awaiting genital prolapse surgery.
3325098|NCT02050594||Melanoma patients on Ipilimumab|All unresectable, recurrent or metastatic melanoma patients
3325099|NCT02050607|No Intervention|Control group|Control group
3230223|NCT01188850|Experimental|6mg of DNA/dose|Subjects who have previously received a 3 dose series of VGX-3100 containing either 0.6, 2 or 6mg DNA/dose will receive a fourth dose of VGX-3100 containing 6mg of DNA/dose administered via IM injection + electroporation at Day 0
3230224|NCT01188863|Experimental|Solid Oral Dose - 150 mg tablets|
3325100|NCT02050607|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation from healthy lean donors
3325101|NCT02050633||Severe cranial trauma|This is a cohort of adult patients who have suffered a severe TBI between 1 July 2005 and 1 May 2007.
3325102|NCT02050646|Experimental|Low salt/ Liberal salt Diet|Cross-over trial of liberal salt and low salt diet.
3325103|NCT02050646|Experimental|Liberal salt/Low salt diet|Cross-over trial of low salt and liberal salt diet
3230225|NCT01188863|Experimental|Solid Oral Dose - 50 mg tablets|
3230226|NCT01188863|Experimental|Liquid Oral Dose|
3230227|NCT01188902|Experimental|walnut|western type diet with 48 g walnut per day
3230228|NCT01188902|No Intervention|control|
3230229|NCT01188915|Experimental|intensive screening|annual breast cancer detection based on mammography, echography and RMI.
3325104|NCT02050672|Active Comparator|untreated|Semen was prepared with routinely used media
3325105|NCT02050672|Experimental|myo-inositol|"routinely used semen preparation media have been enriched with myo-inositol 2mg/ml.~in particular the stock solution was prepared in order to add 15microliters per ml of medium"
3325106|NCT02050685||All patients for PSG at SLBO|All patients incoming in the sleep study centre for a PSG. At the arrival the screening score will be recorder. AHI will be recorded next morning after analysis of the PSG.
3325107|NCT02050698|Active Comparator|short leg walking cast|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed protected weightbearing in a short leg walking cast
3325108|NCT02050698|Experimental|hard-soled shoe|After 1 weeks of immobilization in a short leg posterior splint, patient is allowed tolerable weightbearing in a hard-soled shoe
3325109|NCT02050711|Other|Usual care|Patients will receive usual care from their general practitioners/pulmonologists.
3325110|NCT02050711|Experimental|Pulmonary rehabilitation|Patients will enrol in a 12-week PR program consisting on exercise training (3 times a week) and psychoeducation (once a week).
3325111|NCT02050724|Experimental|CT guided labelling|CT guided radioactive labelling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
3325112|NCT02050724|Experimental|Electromagnetic bronchoscopic labelling|Electromagnetic guided bronchoscopic labeling of pulmonary nodules followed by handheld-SPECT guided thoracoscopic surgery.
3325113|NCT02050737||A - due for adjuvant chemotherapy|Stage II/III colorectal cancer resectable disease due for adjuvant chemotherapy
3325114|NCT02050737||B - for observation only|Stage II colorectal cancer with resectable disease for observation only
3325115|NCT02050750||TAILORx ICORG 06-31|Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
3230230|NCT01188941|No Intervention|Standard of Care|
3230231|NCT01188941|Experimental|Assigned a Health System Navigator|
3230232|NCT01188954|Active Comparator|Doxycycline|Doxycyline, family of tetracycline antibiotics, used to scleroses the lymphatic vessels that may have transected during dissection.
3230233|NCT01188954|Placebo Comparator|Normal Saline/Water|The standard care is wetting and suctioning fluids followed with suturing of the groin.
3230234|NCT01188980||NoBE (control)|
3230235|NCT01188980||BE without dysplasia|
3230236|NCT01188980||BE with dysplasia|
3230237|NCT01188993|Active Comparator|septic shock TPT then TEE|Group 1: Each patient will be assessed by both the transpulmonary thermodilution technique and transesophageal echocardiography (TEE)..
3230238|NCT01188993|Active Comparator|septic shock TEE then TPT|Goup 2: Each patient will be assessed by both transesophageal echocardiography (TEE) and the transpulmonary thermodilution technique.
3230239|NCT01189006|Experimental|dextromethorphan|Research clinical trial of double-blind, stratified randomized, parallel group, double-centre study
3230240|NCT01189019|Experimental|Group 1 - 2mg ranibizumab monthly|2mg ranibizumab monthly
3325116|NCT02050763|Experimental|Intervention arm|Intervention arm clusters (n=4) received an IPV prevention intervention (the Safe Homes and Respect for Everyone (SHARE) Project), enhanced HIV testing and treatment and routine HIV services.
3325117|NCT02050763|No Intervention|Control arm|Control arm clusters (n=7) received standard of care HIV services alone.
3325118|NCT02050776|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
3325119|NCT02050789|No Intervention|Usual Care Arm|Programs will continue adhering to current ACGME requirements.
3325120|NCT02050789|Experimental|Intervention Arm|The intent of the intervention arm is to allow flexibility in surgical resident duty hours and improve continuity of care.
3325121|NCT02050802|Experimental|Treatment sequence BCAD|Subjects received study medication in the sequence BCAD. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325122|NCT02050802|Experimental|Treatment sequence ABDC|Subjects received study medication in the sequence ABDC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325123|NCT02050802|Experimental|Treatment sequence DACB|Subjects received study medication in the sequence DACB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325124|NCT02050802|Experimental|Treatment sequence CDBA|Subjects received study medication in the sequence CDBA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325125|NCT02050802|Experimental|Treatment sequence DBAC|Subjects received study medication in the sequence DBAC. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325126|NCT02050802|Experimental|Treatment sequence ADCB|Subjects received study medication in the sequence ADCB. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325127|NCT02050802|Experimental|Treatment sequence CABD|Subjects received study medication in the sequence CABD . Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3325128|NCT02050802|Experimental|Treatment sequence BCDA|Subjects received study medication in the sequence BCDA. Treatment A: moxifloxacin positive control (3 placebo tablets once daily on Days 1-7, and on Day 8 moxifloxacin 400 mg tablet and 2 macitentan-matching placebo tablets). Treatment B: macitentan 10 mg (1 macitentan 10 mg tablet and 2 placebo tablets once daily on Days 1-8). Treatment C: macitentan 30 mg (3 macitentan 10 mg tablets once daily on Days 1-8). Treatment D: placebo (3 placebo tablets on Days 1-8). There was a wash-out period of at least 10 days between the last study drug administration of the previous treatment and the first study drug administration of the following treatment.
3230241|NCT01189019|Active Comparator|Group 2 - 2mg x 3 then PRN|
3230242|NCT01189045|Experimental|Aerobic Program|The Aerobic Program will be the Experimental arm of this trial, where a structured, progressive aerobic exercise will be conducted in a class format
3230243|NCT01189045|Active Comparator|Balance and Flexibility Program|The Balance and Flexibility Program will be a non-aerobic intervention that will act as an Active Comparator. Stretching, balance exercises, yoga- or Tai Chi-style classes will be conducted.
3230244|NCT01189058|Experimental|rTMS and CIMT|This group will receive both rTMS and CIMT.
3230245|NCT01189058|Experimental|rTMS and no CIMT|This group will receive rTMS only.
3230246|NCT01189058|Experimental|Sham and CIMT|This group will receive CIMT and sham rTMS.
3230247|NCT01189058|No Intervention|Sham and no CIMT|This group will receive sham rTMS and no CIMT.
3325129|NCT02050815|Experimental|MEK162|A minimum of 24 subjects (6 subjects per group) will be enrolled. Enrollment into Group 1 (control group with normal hepatic function) should be similar to the enrollment into Group 2, 3 and 4 with respect to age, gender, and body weight. Enrollment into Group 1 will remain open until the enrollment into the mild, moderate, and severe impairment groups are complete with matching controls for comparison. Serum level of total bilirubin and AST will be used to determine which group the hepatic impaired patient will be allocated l. Dosing of the different treatment groups will be staggered. Initially, 6 subjects in Group 1 (normal hepatic function) and 6 subjects in Group 2 will receive a single oral dose of MEK162 on Day 1.
3325130|NCT02050828|Experimental|AKB-9778 15 mg BID monotherapy|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus monthly sham intravitreal injection for 3 months.
3325131|NCT02050828|Experimental|AKB-9778 15 mg BID + ranibizumab 0.3 mg|Subcutaneous AKB-9778 15 mg BID (total daily dose of 30 mg/day) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
3325132|NCT02050828|Active Comparator|ranibizumab 0.3 mg monotherapy|Placebo subcutaneous injection (BID) plus ranibizumab 0.3 mg monthly intravitreal injection for 3 months.
3325133|NCT02050854||Observation|Subjects with Bipolar 1 Disorder or Schizophrenia who have a history of suboptimal adherence and are currently on treatment with oral aripiprazole
3325134|NCT02050880||Normal eyes|Eyes without pathology.
3325135|NCT02050880||Glaucoma|Eyes with Glaucoma.
3325136|NCT02050880||Retinal|Eyes with Retinal Disease.
3230248|NCT01189084||Observational immunotherapy follow-up|
3325137|NCT02050880||Corneal|Eyes with corneal disease including a kerato-refractive group.
3325138|NCT02050893|Experimental|Midazolam|Midazolam infused at a 0.03mg/kg loading dose ,and 0.02-0.1mg/kg.h maintenance dose to achieve Ramsay score of 4
3325139|NCT02050893|Experimental|Propofol|Propofol infuse at a loading dose of 0.5mg/kg，and 0.5-2.0mg/kg.h maintenance dose to achieve Ramsay score of 4
3325140|NCT02050906|Experimental|Arm I (diet and exercise intervention)|"EXERCISE COMPONENT: Patients undergo 1 hour of monitored intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.~BEHAVIORAL ACTIVITY COUNSELING: Patients undergo behavioral activity counseling in small group sessions over 20 minutes once weekly during months 1-2 and individualized activity counseling via telephone calls over 20 minutes every 2 weeks for 3 months. Counseling will include questionnaire administration.~BEHAVIORAL DIETARY INTERVENTION: Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3."
3325141|NCT02050906|Active Comparator|Arm II (standard of care)|TELEPHONE BASED COUNSELING: Patients receive standard care and educational literature describing the American Institute of Cancer Research dietary and physical activity guidelines. Patients also receive phone calls over 20 minutes every 2 weeks for 3 months focusing on routine prostate cancer self-management. After 3 months, patients have the option to undergo 2 supervised exercise training and dietary counseling sessions. All patients will complete a comprehensive exercise and quality-of-life assessment at baseline, month 2 and month 3.
3325142|NCT02050932|Experimental|Iron absorption assessement|"60 mg Fe as FeSO4 with stable isotopic labels participants will receive at different times of the day (total of three dosages) and follow a standardized diet scheme.~Subjects will act as their own controls during the study"
3325143|NCT02050945|Experimental|Patients with COPD|Patients with COPD are to be trained 3 times a week for 8 weeks
3325144|NCT02050945|Active Comparator|Control patients with COPD|Control patients with COPD are to be trained 3 times a week for 8 weeks
3325145|NCT02050958|Experimental|OXP001|OXP001
3325146|NCT02050958|Active Comparator|Ibuprofen|Brufen
3325147|NCT02050971|Active Comparator|Autologous cord blood transfusion|Treatment Group 1 Interventions: collected autologous whole cord blood at birth will be transfused for the preterm neonate
3325148|NCT02050971|Sham Comparator|Standard treatment for neonatal anemia|Treatment Group 2 Interventions: transfusion of allogeneic whole peripheral blood or any of its components at a time of anemia of prematurity development
3325149|NCT02050997||B|Unresectable or metastatic PDAC patients who will receive standard treatment of CT +/- radiotherapy
3325150|NCT02050997||A|Resectable PDAC patients who will receive standard treatment of CT +/- radiotherapy
3325151|NCT02051010||Metastatic Breast Cancer|
3325152|NCT02051023|Experimental|FML 0.1% eyedrops|FML (fluorometholone) 0.1% eyedrops 4 times a day in both eyes for 22 days
3325153|NCT02051023|Active Comparator|Liquifilm artificial tears eyedrops|Topical application 4 times a day in both eyes for 22 days
3325154|NCT02051036|Experimental|Moxibustion|A series of moxibustion sessions within four weeks from the baseline with concurrent conventional medications for BPH.
3325155|NCT02051036|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 4 weeks while receiving other conventional managements for BPH. After 4 weeks, if participants choose to try the moxibustion treatment, the active acupuncture treatment will be provided for 4 weeks (2 sessions/week).
3325156|NCT02051049||Inborn errors of liver metabolism|
3325157|NCT02051062|Experimental|One 5 mL blood sample will be collected|A single 5 mL blood sample will be collected from pediatric patients treated with BAT®. The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
3230249|NCT01189097|Experimental|dextromethorphan|
3230250|NCT01189149|Experimental|IV fluids|Infants will get IV fluids whem indicated until able to tolerate full oral feedings
3230251|NCT01189149|Experimental|Oro/naso gastric tube feeding|Infants will get oro/naso gastric tube feeding whem indicated until able to tolerate full oral feedings
3230252|NCT01189162|Experimental|NIMV- nasal respiratory support|Infants with RDS will be treateg with nasal intermittent mandatory ventilation
3230253|NCT01189162|Experimental|HFNC- nasal respiratory support with HFNC|Infants with RDS will be treated with nasal respiratory support with high flow nasal canulla
3230254|NCT01189175|Experimental|BI 113823|single oral dose per subject
3325158|NCT02051075|Active Comparator|PXN only|Sperm activation with PXN before ICSI
3325159|NCT02051075|Experimental|PXN activation and oocyte activation|Sperm activation with PXN and oocyte activation
3325160|NCT02051088|Experimental|Revascularization with drug eluting technology|Revascularization with drug eluting technology
3325161|NCT02051088|Active Comparator|Revascularization without drug elution|Revascularization without drug elution technology
3230255|NCT01189175|Experimental|BI 113823 + Ketokonazole|after wash-out 5 days ketokonazole with BI 113823 on day 3
3230256|NCT01189188|Experimental|With ultrasound guidance|In this group of patients, ultrasound guidance will be used when drawing blood from the radial artery.
3230257|NCT01189188|Active Comparator|Without ultrasound guidance|In this group of patients, no ultrasound guidance will be used when drawing blood from the radial artery.
3325162|NCT02051101|Other|Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
3325163|NCT02051127|Experimental|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
3325164|NCT02051127|No Intervention|Control|Instructed to continue with their sedentary behavior for another 6 months.
3325165|NCT02051140|Experimental|Strawberry|Participants randomized into this arm of the study consume freeze-dried strawberry.
3325166|NCT02051140|Placebo Comparator|Placebo|Participants randomized into this arm of the study consume a strawberry placebo.
3325167|NCT02051153|Experimental|Placebo|"Placebo: study participants received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.~Other Names: Placebo."
3325168|NCT02051153|Experimental|Modafinil|"Study participants received, in a double blind fashion, either a single dose (200 mg) of modafinil or a placebo pill identical to the drug.~Other Names:~Provigil"
3325169|NCT02051179||Replacement amalgam|Replacement The clinicians totally removed and replaced the defective restorations. After completing the cavity preparations, the tooth was restored with a new AM (Original D). Bonding agents and/or liners underneath the amalgam restorations were not used in this trial. Rubber dam isolation was used for all restorative treatments. .
3325170|NCT02051179||Repair Amalgam|The clinicians (PV and CM) used Carbide burs (330-010 Komet, Brasseler GmbH Co. Postfach 160.32631, Lemgo, Germany) to explore the defective margin, carious lesion or anatomic form of the restorations. Part of the restorative material adjacent to the defect was removed as an exploratory proceedure thus allowing a proper evaluation and subsequent diagnosis of the extent of the defect. Provided that the defect was limited and localized, the clinician then removed any defective tooth tissue. Mechanical retention was employed inside the existing AM restoration. Rubber dam isolation was used for this procedure. Repair of the restorations was carried out with a dispersed-phased amalgam (Original D, Wyckle Research Inc, Carson City, NV, USA).
3325171|NCT02051192|Experimental|Parent-Led Exposure Therapy (PLET)|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
3325172|NCT02051192|Active Comparator|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
3325175|NCT02051231|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with oxytocin.
3230258|NCT01189214|Experimental|Memantine|
3230259|NCT01189253|Active Comparator|Doxorubicin 75 mg/m² every 3 weeks|Doxorubicin administered on day 1 every 3 weeks for a maximum of 6 cycles
3230260|NCT01189253|Experimental|Trabectedin IV 3 hours|Trabectedin administered on day 1 every 3 weeks at the dose of 1.3 mg/m² until progression
3325176|NCT02051231|Experimental|Oxytocin|Samples from each patient will be exposed to oxytocin and then allowed to rest for 30, 60 or 90 minutes.
3325177|NCT02051244||Subjective memory loss|Subjects who report memory loss, that may or may not be confirmed by an informant, but have normal cognitive tests ( MMSE scores of 27 or above out of 30. SLUMS scores of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education).
3325178|NCT02051244||Mild Cognitive Impairment|Subjects with Mild Cognitive Impairment - defined as being problems with memory, language or another essential cognitive ability that are severe enough to show up on cognitive tests but not to interfere with daily life. MMSE score of 23-27 out of 30. SLUMS score of 16-19 for subjects with less than 8 years of education or 20-26 for those who have 12 or more years of education.
3230261|NCT01189253|Experimental|Trabectedin IV 24 hours every 3 weeks|Trabectedin administered on day 1 every 3 weeks at the dose of 1.5 mg/m² over 24 hours until progression
3230262|NCT01189305|Experimental|Behavioral Couples Therapy|
3230263|NCT01189305|Experimental|Individual Drug Counseling|
3325179|NCT02051244||Control|Subject who do not report memory loss and have normal cognitive tests. MMSE of 27 or above out of 30. SLUMS score of 20-30 for subjects with less than 8 years of education or 27-30 for those who have 12 or more years of education.
3230264|NCT01189318|Experimental|Seroquel XR|Patients with MDD receives Seroquel XR.
3230265|NCT01189318|No Intervention|healthy control|
3230266|NCT01189331|No Intervention|CT and FFR|
3230267|NCT01189344|Experimental|Not surgical group|The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.
3230268|NCT01189344|Experimental|Surgical group|The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
3230269|NCT01189357||failed meniscal transplantation|
3325180|NCT02051257|Experimental|Arm 1 (autologous TCM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TCM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
3325181|NCT02051257|Experimental|Arm 2 (autologous TN/MEM-enriched T cells)|Patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells IV over 10 minutes on day 2 or 3 following HSCT.
3325182|NCT02051270||Elders|Older people living in nursing homes will undergo a descriptive study.
3325183|NCT02051283||patients with HCC eligible for RFA|patients with HCC eligible for RFA
3230270|NCT01189383|Experimental|IL15-DC Vaccine|Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12.At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
3230271|NCT01189396|Experimental|T|Four doses of A006 taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
3325186|NCT02051322|Experimental|Jet Nebulizer|Nebulization with a jet nebulizer and a classic mask
3325187|NCT02051322|Experimental|Trunk Mask Nebulizer|Nebulization with a je nebulizer and a trunk mask
3325188|NCT02051322|Experimental|Aerobika Nebulizer|Nebulization with an Aerobika
3325189|NCT02051348|Placebo Comparator|Placebo|Placebo - 2 doses per day for 4 weeks
3230272|NCT01189396|Active Comparator|R|Four doses of Proventil-HFA taken in 30 minute intervals. Doses will have an escalating number of inhalations (2, 2, 4, and 8 inhalations). Total cumulative Albuterol dose at 90 minutes is 1440 mcg.
3230273|NCT01189396|Placebo Comparator|P|Four doses of Placebo DPI taken in 30 minute intervals. Doses will have an escalating number of inhalations (1, 1, 2, and 4 inhalations). Total cumulative Albuterol dose at 90 minutes is 0 mcg.
3325190|NCT02051348|Active Comparator|Pylopass|Probiotic - 2 doses per day for 4 weeks
3230274|NCT01189422|Experimental|Segment 1: 3 Arms|
3325191|NCT02051361||Clopidogrel treated patients|Patients pre and post operatively following stent implantation treated with clopidogrel and aspirin
3325192|NCT02051374|Active Comparator|Decompression alone|Posterior approach with decompression will be performed. The decompression will be done after microsurgical principles, and the midline structures will be preserved. The surgeons will either use microscope or magnifying glasses.
3230275|NCT01189422|Experimental|Segment 2: 4 Arms|
3325193|NCT02051374|Active Comparator|Decompression followed by fusion with instrumentation|Posterior approach with decompression will be performed, followed by posterolateral pedicle screw fixation with or without an additional cage. The surgeons will either use microscope or magnifying glasses.
3325194|NCT02051387|Active Comparator|Cannabidiol|Cannabidiol capsule, 200 mg single dose
3230276|NCT01189448|Active Comparator|Pyrimethamine/Sulfadiazine|Women who are enrolled and randomised in Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
3325195|NCT02051387|Experimental|Cannabidiol CR|Cannabidiol tablet, various dosages
3325196|NCT02051387|Experimental|Amisulpride and Cannabidiol CR|Interaction between Amisulpride and Cannabidiol CR
3325197|NCT02051387|Experimental|Olanzapine and Cannabidiol CR|Interaction between Olanzapine and Cannabidiol CR
3230277|NCT01189448|Active Comparator|Spiramycine|Spiramycin group : spiramycin 1g tid orally
3230278|NCT01189513|Experimental|SCH 900105|10 mg/kg intravenous Days 1, 8 and 15 of 30 day cycle.
3325198|NCT02051387|Experimental|Quetiapine and Cannabidiol CR|Interaction between Quetiapine and Cannabidiol CR
3325199|NCT02051387|Experimental|Risperidone and Cannabidiol CR|Interaction between Risperidone and Cannabidiol CR
3230279|NCT01189526|Experimental|IVRI|IVRI : intravitreal ranibizumab (0.5mg) injection
3230280|NCT01189526|Active Comparator|Laser|Laser : macular laser photocoagulation
3230281|NCT01189552|Active Comparator|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). LETS ACT is based on the belief that the best way to improve mood, remain sober, and to make long-term life changes is by changing and increasing one's activity level. It has been modified to accommodate the needs of a substance using population currently receiving inpatient substance use treatment. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
3259136|NCT01467804|Active Comparator|westen medicine|There are 90 patients with mild to moderate depress in westen medicine group, who take Sertraline, and placebo of the JWXY capsule, for 2 months
3259137|NCT01467817|Experimental|Lifestyle Intervention|This arm will test the combination of 6 months of structured lifestyle intervention incorporating education, exercise, diet, and behavioral support.
3325200|NCT02051387|Placebo Comparator|Cannabidiol CR and Placebo|Cannabidiol CR levels without interaction with antipsychotics
3325201|NCT02051400|Experimental|Intubation with the McGrath® MAC video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3325202|NCT02051400|Experimental|Intubation with the GlidesScope® Ranger video laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3325203|NCT02051400|Experimental|Intubation with Macintosh laryngoscope|Participants perform five intubation attempts using the airway manikin with the normal airway setting. After completing the normal airway session, the participants performed another five attempts with the neck immobilization setting using a neck collar.
3325204|NCT02051413|Other|Venlafaxine extended release|Venlafaxine extended-release, flexible dose
3230282|NCT01189552|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Treatment is provided over a 4-week period and is provided in small group format, with each group consisting of 3-5 patients.
3230283|NCT01189565||Joint Replacement Patients|
3230284|NCT01189578||Recreational cocaine users|Individuals who have used cocaine in the past 3 months, but do not meet DSM-IV-TR diagnostic criteria for Cocaine Dependence.
3230285|NCT01189591|Experimental|Sleep deprivation|Slow-wave sleep deprivation for one night as an experimental treatment for major depressive disorder
3325205|NCT02051439|Other|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava before balloon assisted Valsava. The second group performed balloon assisted Valsava before conventional Valsava for venous reflux examination by duplex scan.
3325206|NCT02051465|Experimental|LumenR Retractor|Endoscopic removal of polyp using modified overtube LumenR Retractor
3230286|NCT01189643|Experimental|Chemotherapy|This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
3230287|NCT01189656|Experimental|Vaccine+Lamivudine group|Subjects assigned into the experimental and the controlled groups with randomization and double-blindness by a ratio of 2:1
3325207|NCT02051465|Active Comparator|Removal without overtube|Endoscopic removal of polyp without overtube
3325208|NCT02051478|Experimental|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied.
3325209|NCT02051478|Active Comparator|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
3325210|NCT02051491|Active Comparator|BP-NCPAP|Nasal BP-NCPAP will be delivered using the Infant Flow® SiPAP™ and either nasal prongs or mask interface. A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with transcutaneous carbon dioxide (TcCO2) monitor data (if available). Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm water (H2O) and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on fraction of inspired oxygen (FiO2) requirements.
3325211|NCT02051491|Experimental|NIHFV|NIHFV will be provided using the Drager VN500, using either nasal prong or mask interfaces.A blood gas (arterial if an arterial line exists, or a capillary sample) will be drawn at the time of NCPAP failure (time 0) unless one was done within 1 hour preceding the randomization. The blood gas will then be repeated at 1 hour and recorded along with TcCO2 monitor data (if available). Initial settings for NIHFV arm will be MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
3325212|NCT02051504||Type 1 diabetes, HbA1c <7%|"Patients with Type 1 diabetes and adequate glycemic control: HbA1c <7% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3230288|NCT01189656|Placebo Comparator|Placebo+Lamivudine group|
3230289|NCT01189669|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
3325213|NCT02051504||Type 1 diabetes, HbA1c >8%|"Patients with Type 1 diabetes and inadequate glycemic control: HbA1c >8% at the entrance in the study.~Intervention:~Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3230290|NCT01189669|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
3230291|NCT01189669|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
3230292|NCT01189682|Active Comparator|Tegaderm HP|
3230293|NCT01189682|Placebo Comparator|Tegaderm|
3230294|NCT01189682|Active Comparator|Tegaderm CHG|
3230295|NCT01189695|Experimental|Boosted lopinavir monotherapy|
3230296|NCT01189695|Active Comparator|boosted lopinavir + optimized background regimens (OBRs)|
3230297|NCT01189708|Experimental|Mesh implantation|Ultrapro® Mesh implantation
3230298|NCT01189708|Active Comparator|Standard wound closure without a mesh|Standard wound closure
3230299|NCT01189721|Active Comparator|sevoflurane|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
3230300|NCT01189721|Experimental|propofol|Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
3230301|NCT01189734|Placebo Comparator|laparoscopic common bile duct exploration|
3230302|NCT01189734|Active Comparator|laparoscopic cholecystectomy with intraoperative ES|
3230303|NCT01189773|Experimental|1|Ibuprofen given orally (10 mg/kg, max = 600 mg) and codeine given orally (1 mg/kg, max = 60 mg).
3325214|NCT02051504||Healthy controls, Groupe 1|"Healthy controls for patients with Type 1 diabetes and adequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3325215|NCT02051504||Healthy controls, Group 2|"Healthy controls for patients with Type 1 diabetes and inadequate glycemic control matched on age, sex, body composition and physical activity level.~Intervention:~Oral Glucose Tolerance Test Incremental maximal exercise Near-Infra Red-Spectroscopy at vastus lateralis and pre-frontal cortex (during exercise) Gas exchanges (VO2, VCO2) during exercise Combined DLCO/DLNO (at rest) Venous and arterialised blood sampling (rest and exercise) Muscle biopsy at the vastus lateralis (rest) Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires Accelerometry over one week Dual energy X-ray Absorptiometry"
3325216|NCT02051517||Vitrectomy|Subjects expected to have normal vitreous, undergoing vitrectomy surgery for medically indicated reasons.
3325217|NCT02051530|Experimental|tryptophan depletion first day|tryptophan depletion on the first day. on the other day participants receive placebo.
3325218|NCT02051530|Experimental|tryptophan depletion on day 2|tryptophan depletion on the second day. on the first day participants receive placebo.
3325219|NCT02051543|Experimental|Brief Behavioral Treatment of Insomnia-Military Version|
3230304|NCT01189773|Placebo Comparator|2|Ibuprofen given orally (10 mg/kg, max = 600 mg) and placebo given orally ( identical in taste color to codeine preparation).
3230305|NCT01189786|Experimental|Cohort 2: CD34+ cells as a top off|"Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a topoff without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse."
3325220|NCT02051556|Experimental|Best Side Improvement|Physical Therapy BSI (Best Side Improvement), aimed to potentiate the less affected body side.
3325221|NCT02051556|Experimental|Worse side improvement|Physical Therapy WSI (Worst Side Improvement), aimed to potentiate the most affected body side.
3325222|NCT02051556|Active Comparator|Standard treatment|Physical Therapy ST (Standard Treatment), aimed to potentiate both sides equally.
3325223|NCT02051569|Experimental|Tryptophan first|Tryptophan is given for the first 14 days, 6 times 500mg per day. Placebo is given 6 times per day for the second 14 days.
3325224|NCT02051569|Experimental|Tryptophan second|Placebo is given 6 times per day for the first 14 days. Tryptophan is given for the second 14 days, 6 times 500mg per day.
3325225|NCT02051582||Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
3230306|NCT01189786|Experimental|Cohort 1: CD34+ Cells for transplant|Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
3325226|NCT02051582||Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
3325227|NCT02051608|Experimental|Gantenerumab|Participants will receive gantenerumab as subcutaneous (SC) injection every 4 weeks (Q4W)
3325228|NCT02051608|Placebo Comparator|Placebo|Participants will receive placebo as SC injection Q4W
3325229|NCT02051621|Active Comparator|Cavo-tricuspid-isthmus-ablation|Ablation of atrial flutter
3325230|NCT02051621|Active Comparator|Pulmonary vein isolation|pulmonary vein isolation
3325231|NCT02051621|Active Comparator|Antiarrhythmic drug|"Medical treatment of atrial flutter with either class I antiarrhythmics (flecainide (Tambocor ®) 100 mg twice daily or propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily~cardioversion as needed"
3325232|NCT02051634|Active Comparator|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
3325233|NCT02051634|Placebo Comparator|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
3325234|NCT02051660|Experimental|Manualized CALM Intervention|
3325235|NCT02051660|Active Comparator|Non-manualized supportive intervention|
3325236|NCT02051699||One-leg standing view|
3325237|NCT02051699||both-leg standing view|
3325238|NCT02051712|No Intervention|Usual care|Usual car accruing to guidelines
3325239|NCT02051712|Experimental|Individualized training|Individualized exercise training program in addition to usual care
3325240|NCT02051712|Experimental|Individualized training plus adherence measures|Individualized exercise training plus measures to increase adherence
3325241|NCT02051725|Experimental|Active life-style intervention|"The active life-style intervention is designed as 12-week structured and progressive heavy-resistance power training combined with recommended everyday physical activity."
3325242|NCT02051725|No Intervention|Control|The control group is offered to enroll in the same active life-style intervention after the end of the 12-week control period. During the control period this group is asked to maintain the habitual life style.
3325243|NCT02051738|Experimental|Treatment Sequence AB|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fasted condition (Treatment A) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fed condition (Treatment B).
3325244|NCT02051738|Experimental|Treatment Sequence BA|A single 500 mg dose of mebendazole fast-disintegrating chewable tablet will be administrated under fed condition (Treatment B) in Treatment Period 1; In Treatment Period 2, the same medication will be administrated under fasted condition (Treatment A).
3325245|NCT02051751|Experimental|BYL719 and paclitaxel|All patients enrolled in the study will receive BYL719 once daily plus weekly paclitaxel
3325246|NCT02051777|Other|ONS 1 and DA|Oral Nutritional Supplement 1 and Dietary Advice
3325247|NCT02051777|Other|ONS 2 and DA|Oral Nutritional Supplement 2 and Dietary Advice
3230307|NCT01189799|Experimental|Motivational Therapy Aftercare|
3230308|NCT01189799|Other|Dual Recovery Anonymous|Aftercare Treatment as Usual
3230309|NCT01189825|Experimental|Exercise|
3230310|NCT01189838||Low Cyr61|Low Cyr61 immunohistochemical stain in patients' TCC tumor
3325248|NCT02051777|Other|DA Alone|Dietary Advice Alone
3325249|NCT02051803|Experimental|Distress Tolerance Treatment for Weight Concern (DT-W)|DT-W is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes distress tolerance intervention for weight concern plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3325250|NCT02051803|Active Comparator|Health Education (HE)|HE is delivered over a 9 week period with 1 1-hr individual session during week 1, 8 weekly 1.5-hr group counseling sessions during weeks 2-9, and 1 20-minute individual telephone session during week 4. Session content includes smoking health education program plus standard behavioral smoking cessation treatment. Participants also receive 8 weeks of nicotine patch.
3325251|NCT02051829||All patients|Comparison of the four screening score
3325252|NCT02051842|Experimental|Metadoxine|Metadoxine 500 mg tablets by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
3325253|NCT02051842|Placebo Comparator|Placebo tablet|Placebo tablet (for Metadoxine) by mouth every 12 hours for 6 months and metformin 500 mg tablets by mouth every 8 hours for 6 months
3325254|NCT02051868|Active Comparator|Arm A|Cisplatin and 5-Fluorouracil
3325255|NCT02051868|Experimental|Arm B|Carboplatin plus Paclitaxel
3325256|NCT02051881|Other|Biopsies|Intestinal biopsies were taken in patients who underwent endoscopy.
3325257|NCT02051894||HIE Group|
3325258|NCT02051907|Experimental|KAM1403 Gel|A group treated with KAM1403 for the study period.
3325259|NCT02051907|Sham Comparator|Aloevera Gel|A group treated with Aloevera Gel for the study period
3325260|NCT02051933|Experimental|Botox|See Botox intervention description
3325261|NCT02051933|Placebo Comparator|Placebo|See Placebo Intervention Description
3325262|NCT02051946|Active Comparator|Retroject device only|The first 5 patients enrolled will serve as controls and will have the device alone placed on the eye (without an injection of ethacrynic acid).
3325263|NCT02051946|Experimental|Retroject injection with ethacrynic acid injection|The next 3 patients, after the first 5 controls, will have the device placed on the eye with a subsequent injection of ethacrynic acid into the episcleral vein.
3325264|NCT02051946|Experimental|randomization to ethacrynic acid or balanced salt solution|The last 12 patients will all have the device placed on their eye. They will then be randomized in a 2:1 ratio to receive either an injection of ethacrynic acid or balanced salt solution.
3325265|NCT02051959|Active Comparator|Crossover 1a: anodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3325266|NCT02051959|Active Comparator|Crossover 1b: sham + anodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA anodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3325267|NCT02051959|Active Comparator|Crossover 2a: cathodal stimulation of M1 + sham|"6 amputees will undergo 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area followed by 8 sham treatments.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3325268|NCT02051959|Active Comparator|Crossover 2b: sham + cathodal stimulation of M1|"6 amputees will undergo 8 sham treatments followed by 8 active treatments of 20 min 2mA cathodal stimulation of M1 localized to the contralateral amputation area.~Total duration and frequency of treatments: 8 weeks, 2 sessions per week.~Each session will last approximately one hour which will consist of:~EEG and pain measurements~20 minutes of stimulation~EEG and pain measurements after completion of stimulation"
3325269|NCT02051972||Indicated for a VVI(R) pacemaker|
3325270|NCT02051985|Experimental|Aerobic exercise training|
3325271|NCT02051985|Active Comparator|Standard physical therapy|
3325272|NCT02052024|Active Comparator|Botox|Treatment group will receive 100 units of BOTOX and will receive 1-3 injections per muscle at each visit.
3325273|NCT02052024|Active Comparator|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and will receive 1-3 injections per muscle at each visit.
3230311|NCT01189838||High Cyr61|High Cyr61 immunohistochemical stain in patients' TCC tumor
3230312|NCT01189851|Other|IORT|Treated with Intraoperative Radiation Therapy
3325274|NCT02052037|Experimental|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
3325275|NCT02052037|Experimental|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained."
3325276|NCT02052050|Experimental|core stability|Stabilized muscle program will consist of two months of individual physical training that it will be conducted 3 times/week for 90 min each. A correct progression to improve stabilization of deep abdominal muscles will be made.
3325277|NCT02052050|No Intervention|control group|usual care
3325278|NCT02052063|Experimental|Surgery|Patient who undergone stapled transanal rectal resection for rectocele. Anal compliance will be evaluated before and starting the surgery using endoflip system
3325279|NCT02052076|Experimental|Irregular meal pattern|Participants will be asked to consume a standard diet, spread over a different number of meals/snacks per day, for a 2week intervention period. Number of meals will range from 3 to 9 per day.
3325280|NCT02052076|Placebo Comparator|Regular Meal Pattern|Participants will be asked to consume a standard diet, spread over 6 of meals/snacks every day, for a 2week intervention period.
3325281|NCT02052089|Active Comparator|Physiotherapy|patients were educated to do stretching and eccentric strengthening exercise of wrist extensor muscles
3325282|NCT02052089|Experimental|extracorporeal shockwave therapy|patients were treated with 3 sessions of high-energy shock wave therapy ESWT (Evotron, Switech medical, Kreuzlingen, CH) in 2 weeks interval. Total energy flux density ranged from 0.1 to 0.14 mJ/mm2 (1500 impulses). Shockwave was targeted over lateral epicondyle where maximum tenderness was located.
3325283|NCT02052089|Experimental|Prolotherapy|injection of 20% dextrose (3cc mixed with 0.3cc of lidocaine) to ECRB tendon was done under ultrasound guidance
3325284|NCT02052089|Experimental|Platelet-rich plasma|3 cc of PRP (Harvest SmartPReP 2 APC 30 Process Kit, Harvest Technologies, Plymouth, MA) was injected into ECRB tendon under ultrasound guidance
3325285|NCT02052102|Active Comparator|No prior therapy, DIBH irradiation|Cohort 1 - No prior anthracycline-based chemotherapy or herceptin, deep inspiration breath hold breast radiation therapy
3325286|NCT02052102|Active Comparator|No prior therapy, FB technique|Cohort II - no prior Anthracycline based chemotherapy or Herceptin and (ii) to receive FB RT (not able to hold breath for at least 20 seconds or does not have a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
3325287|NCT02052102|Active Comparator|Prior therapy, DIBH irradiation|Cohort III - Prior Anthracycline-based chemotherapy or Herceptin, and (ii) eligible to receive DIBH RT. (Patient has a minimum of 1.0 cm of heart on at least 3 slices (3mm slices) on the FB scan)
3325288|NCT02052115|Other|Exercise and weight loss|12 month exercise and weight loss intervention
3325289|NCT02052128|Experimental|onapristone 10 mg BID mg|onapristone 10 mg BID extended-release tablets
3325290|NCT02052128|Experimental|onapristone 20 mg BID|onapristone 20 mg BID extended-release tablets
3325291|NCT02052128|Experimental|onapristone 30 mg BID|onapristone 30 mg BID extended-release tablets
3325292|NCT02052128|Experimental|onapristone 40 mg BID mg|onapristone 40 mg BID mg extended-release tablets
3325293|NCT02052128|Experimental|onapristone 50 mg BID|onapristone 50 mg BID extended-release tablets
3325294|NCT02052128|Experimental|onapristone 100 mg QD|onapristone 100 mg QD immediate-release tablets
3325295|NCT02052154|Experimental|Prime-boost pneumococcal immunization|
3325296|NCT02052167|Experimental|Methotrexate|
3325297|NCT02052180|Experimental|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
3325298|NCT02052180|Active Comparator|Control|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
3230313|NCT01189864||Ciprofloxicin or Vigamox or other.|
3325299|NCT02052193|Experimental|Dabrafenib|Dabrafenib 150mg BID orally
3325300|NCT02052193|Active Comparator|Vemurafenib|Vemurafenib 960mg orally BID
3325301|NCT02052206|Experimental|Computer-assisted 3D planning|Realization of the fracture reconstruction according to the computer-assisted 3D preoperative plan
3325302|NCT02052219|Experimental|Blisibimod|
3325303|NCT02052219|Placebo Comparator|Placebo|
3325304|NCT02052232|Active Comparator|Control|Control protein powder sachet
3325305|NCT02052232|Experimental|Experimental|Experimental protein powder sachet
3325306|NCT02052245||Subject delivering preterm baby|
3325307|NCT02052245||Subject delivering term baby|
3325308|NCT02052258|Experimental|oxytocin|
3325309|NCT02052271|Experimental|Essential tremor|cerebellar stimulation
3325310|NCT02052271|Placebo Comparator|Placebo arm|placebo stimulation
3325311|NCT02052284|No Intervention|Control|The control group will receive standard skin care of the NICU, which does not include specific measures to modulate skin-barrier function.The current practice at GWUH NICU is that nurses clean the bodies of newborns less than 1000 grams using a piece of damp cloth with warm water. This is performed at birth and consequently every other days.
3325312|NCT02052284|Experimental|Water wash|The study group will undergo a protocol of sterile water application in addition to routine skin care of the NICU. The study group will receive more frequent and standardized applications. A commercially sterile water bottle (Enfamil® Water) will be kept inside the isolette, to be maintained at isolette temperature, and will be changed on a daily basis. Nurses use sterile gloves as a routine for care of ELBW infants. A 2 inches x 2 inches sterile gauze will be soaked in sterile water and gently applied to all skin of the baby excluding umbilical cord and IV lines sites. This procedure will be repeated every 4 hours with routine patient care for the first 1 week of life.
3325313|NCT02052297|Other|Part A|In Part A, up to 6 healthy subjects will be enrolled in order to determine the human radiodosimetry following administration of the PET radioligand.
3325314|NCT02052297|Other|Part B|In Part B, up to 8 healthy subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in healthy subjects.
3325315|NCT02052297|Other|Part C|In Part C, up to 20 IPF subjects will be recruited to provide sufficient PET data to quantify the uptake and distribution of GSK2634673F in IPF subjects and, if appropriate, potentially quantify the test/re-test variability.
3325316|NCT02052323|Experimental|artesunate/mefloquine (AS/MQ)|The antimalarial drug regimen being evaluated is: artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours; plus mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours; plus primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours
3325317|NCT02052336|Experimental|CJ-12420 200 mg + Clarithromycin 500mg|CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days
3325318|NCT02052336|Active Comparator|CJ-12420 200mg|CJ-12420 200mg QD for 5 days
3325319|NCT02052336|Active Comparator|Clarithromycin 500mg|Clarithromycin 500mg BID for 5 days
3230314|NCT01189864||Nonsteroidal (Acular, Voltaren Xibrom, etc)|
3230315|NCT01189864||Steroid (FML, Pred Forte, Flarex, etc.)|
3230316|NCT01189877|Experimental|pO2 measurements|In patients meeting eligibility requirements outlined below, comparisons will be made between direct pO2 measurements using a tissue hypoximeter and IHC-assessed expression of hypoxia related proteins (HIF-1α, VEGF, CA IX and GLUT-1) in both normal and tumor tissue.
3230317|NCT01189916|Experimental|Transrectal NOTES appendectomy|These patients will undergo an experimental surgical procedure that uses flexible endoscopic instruments (i.e., inserted through the rectum).
3325320|NCT02052349|Experimental|Arm 1: ABT-333|A single centre, open-label, 4-treatment, 3-period, 4-sequence incomplete randomised, single dose crossover study in healthy subjects.
3325321|NCT02052362|Experimental|Group 1 - Regimen A|8 Subjects in Group I - Regimen A: ABT-450/r/ABT-267
3325322|NCT02052362|Experimental|Group 2 - Regimen B|8 Subjects in Group II - Regimen B: ABT-450/r/ABT-267
3325323|NCT02052375|Experimental|ASP2408 low dosing frequency|
3230318|NCT01189929|Experimental|Gemcitabine and demcizumab With or Without Abraxane®|Gemcitabine and demcizumab With or Without Abraxane®
3230319|NCT01189955|Active Comparator|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
3325324|NCT02052375|Experimental|ASP2408 high dosing frequency|
3325325|NCT02052375|Experimental|Placebo low dosing frequency|
3230320|NCT01189955|Active Comparator|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
3230321|NCT01189968|Experimental|Carboplatin and Pemetrexed plus demcizumab|Carboplatin and Pemetrexed plus demcizumab
3230322|NCT01189968|Experimental|Pemetrexed plus demcizumab|Pemetrexed plus demcizumab
3325326|NCT02052375|Experimental|Placebo high dosing frequency|
3325327|NCT02052388|Experimental|Low Single Dose Brilacidin|0.6mg/kg Brilacidin IV (single dose)
3325328|NCT02052388|Experimental|High Single Dose Brilacidin|0.8mg/kg Brilacidin IV (single dose)
3325329|NCT02052388|Experimental|3-Day Regimen Brilacidin|0.6mg/kg Brilacidin IV on Day 1, followed by 0.3mg/kg Brilacidin IV on Days 2 & 3
3230323|NCT01189981|Experimental|eHealth intervention|Standard lifestyle counseling. Short Message Service (SMS) encouragements for physical activity,
3230324|NCT01189981|Active Comparator|Lifestyle counseling|Standard lifestyle counseling. No Short Message Service (SMS) encouragements for physical activity.
3230325|NCT01189994|Experimental|Acupuncture|Patients will receive acupuncture treatment in addition to standard care, coming to twelve weekly acupuncture sessions
3325330|NCT02052388|Active Comparator|Standard dosing regimen Daptomycin|4mg/kg Daptomycin IV daily for 7 Days
3325331|NCT02052401|Experimental|Occupational Therapy Intervention|Post Discharge Domiciliary Intervention by Occupational Therapy (OT)
3325332|NCT02052401|No Intervention|Usual follow-up|Usual follow-up of post discharge elderly patients, including pharmacological, and non-pharmacological care.
3325333|NCT02052427|Experimental|ADRCs|"Adipose-Derived Regenerative Cells (ADRCs) processed by the Celution System:~0.8 x 10^6 cells/kg body weight (not to exceed 80.0 x 10^6 cells)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
3325334|NCT02052427|Placebo Comparator|Placebo|"Placebo - Physiological Solution~Inactive substance (Lactated Ringers + autologous blood)~Delivered via the MYOSTAR™ Injection Catheter in 15 intramyocardial injections"
3325335|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, Caucasian, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
3325336|NCT02052479|Other|Polycystic Ovary Synrome, PCOS, African-American, No treatment|Frequently Sampled Intravenous Glucose Tolerance Test with minimal model analysis (MINMOD FSIVGTT)
3325337|NCT02052492|Experimental|Cohort A: EF-022 100 ng once weekly|Intra-Muscular injections of EF-022 100 ng once weekly for a period of 8 weeks
3325338|NCT02052492|Experimental|Cohort B: EF-022 500 ng once weekly|Intra-Muscular injections of EF-022 500 ng once weekly for a period of 8 weeks
3325339|NCT02052492|Experimental|Cohort C: EF-022 1000 ng once weekly|Intra-Muscular injections of EF-022 1000 ng once weekly for a period of 8 weeks
3325340|NCT02052492|Experimental|Expanded Cohort|the expanded cohort, 24 Patients will be allocated to receive either 100ng, 500ng or 1000ng weekly treatment as detailed below: The first 18 patients will be assigned to alternating doses of either 100ng or 500ng in a sequential manner (each patient will be assigned to a single dose). A decision regarding adding a 1000ng dose cohort vs. continuing with the 100ng and 500ng doses will be based on a discussion of the interim analysis results.
3325341|NCT02052505|No Intervention|Usual care|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions.
3325342|NCT02052505|Experimental|Medication review|The patients will receive the usual care when admitted. This includes an examination by a physician, a medication review and the physician will prescribe medications for the patients as well as other necessary interventions. Following this (usual care) a trained nurse will perform a medication review and discuss the observations with a physician.
3325343|NCT02052518|Experimental|Enhanced NFN Home Program|Education and Skill set training with materials to implement the behaviors recommended. Using a motivational interviewing framework, intervention participants will receive dietary and activity counseling, develop a Family Wellness Plan and will be linked to community resources.
3325344|NCT02052518|Placebo Comparator|Nurturing Family Network Home Visitation|Mothers will receive the standard of care from the Nurturing Families Network Home Visitation program
3325345|NCT02052531|Experimental|PAC-14028 cream 0.3%|PAC-14028 cream 0.3%, twice daily for 28 days
3325346|NCT02052531|Experimental|PAC-14028 cream 1.0%|PAC-14028 cream 1.0%, twice daily for 28days
3325347|NCT02052531|Placebo Comparator|Vehicle|Vehicle, twice daily for 28days
3325348|NCT02052570||Children post-HSCT|Children post-HSCT age 10-16 yrs of age who had allogeneic transplant who are within 5 years of transplant and returned to school in past 12-24 months after previously attending school pre-transplant
3325349|NCT02052570||Parents of children post-HSCT|Parents of children post-HSCT (children in focus group) will participate in focus group with other parents to discuss the challenges and successes of their child returning to school following HSCT.
3325350|NCT02052570||Teachers of children post-HSCT|Teachers of children post- HSCT (children in focus group) will participate in focus group with other teachers to discuss the challenges and successes of children returning to school post HSCT
3325351|NCT02052570||PBMT provider of child post-HSCT|PBMT provider of child-post HSCT (child in focus group) will participate in in focus group with other PBMT providers to discuss the successes and challenges of coordinating school reentry in child post-HSCT
3325352|NCT02052583|Experimental|34°C|therapeutic hypothermia at 34 ° C
3325353|NCT02052583|Experimental|32°C|therapeutic hypothermia at 32 ° C
3325354|NCT02052609|Experimental|KHK4827 140mg SC|
3325355|NCT02052609|Experimental|KHK4827 210mg SC|
3325356|NCT02052648|Experimental|Phase 1b Cohort 1|"Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle.~Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity."
3325357|NCT02052648|Experimental|Cohort 2a|Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
3325358|NCT02052648|Experimental|Cohort 2b|"Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab.~Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg."
3325359|NCT02052648|Experimental|Cohort 2c|Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
3325360|NCT02052674|Experimental|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
3325361|NCT02052674|Active Comparator|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
3230326|NCT01189994|Active Comparator|Orientation|Patients will receive standard care only, coming to three monthly orientation sessions
3325362|NCT02052687|Experimental|Part 1: LFX453/placebo|once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
3325363|NCT02052687|Experimental|Part 2 groupA: LFX453/placebo|once daily: LFX453 cream 1 / Placebo 1
3230327|NCT01190033|Active Comparator|Neurolysis|In this intervention the neurotome will be connected
3230328|NCT01190033|Placebo Comparator|Neurotome OFF|neurotome not raised
3325364|NCT02052687|Experimental|Part 2 groupB: LFX453/placebo|once daily: LFX453 cream 2 / Placebo 2
3325365|NCT02052687|Experimental|Part 2 groupC: LFX453/LFX453|once daily: LFX453 cream 1 / LFX453 cream 2
3230329|NCT01190046|Other|Resistance exercise training|Exercise is being used as an experimental tool to determine if remediation of muscle disuse counteracts cellular/molecular defects in muscle structure/function.
3230330|NCT01190059|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the ex vivo lung perfusion system with Steen Solution™ .
3230331|NCT01190111|Experimental|CYT107 (r-hIL-7)|
3230332|NCT01190137|Active Comparator|400 IU Vitamin D3|
3230333|NCT01190137|Experimental|400 IU Vitamin D2|
3230334|NCT01190163|Experimental|A|
3230335|NCT01190163|Active Comparator|B|
3230336|NCT01190202|Experimental|Overall Study Group (Survey 1)|Subjects at least 6 months of age at the time of Survey 1, conducted at Year 1 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
3259138|NCT01467817|Placebo Comparator|Exercise Control|This arm will test the benefits of exercise alone while controlling for investigator contact.
3230337|NCT01190202|Experimental|Overall Study Group (Survey 2)|Subjects at least 6 months of age at the time of Survey 2, conducted at Year 2 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
3230338|NCT01190202|Experimental|Overall Study Group (Survey 3)|Subjects at least 6 months of age at the time of Survey 3, conducted at Year 3 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
3325366|NCT02052687|Other|Part 2 groupD: Imiquimod|once daily: imiquimod cream
3325367|NCT02052687|Experimental|Part 3: LFX453/placebo|twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2
3325368|NCT02052713|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 2 orally once daily under fasted condition.
3325369|NCT02052713|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fasted condition.[dutasteride 0.5 mg and tamsulosin HCl 0.4 mg) in period 2 orally once daily under fasted condition.
3325370|NCT02052726|Experimental|Arm Label: Month 0, 1 and 3 Schedule|
3325371|NCT02052726|Experimental|Day 1, 8, and 30 Schedule|
3325372|NCT02052739|Experimental|active drug|SAGE-547
3325373|NCT02052765|Experimental|ajmaline test|All patients underwent ajmaline test for ST shift recording
3325377|NCT02052791|Experimental|nusinersen|
3230339|NCT01190202|Experimental|Overall Study Group (Survey 4)|Subjects at least 6 months of age at the time of Survey 4, conducted at Year 4 of the 4 annual cross sectional surveys performed preferably at peak transmission (end of rainy season), infected with P. falciparum parasite. Infection determined using a blood smear slide and determined using microscopy. Subjects were enrolled from the catchment areas of study 110021 (NCT00866619) but those who previously participated in study 110021 were excluded from this epidemiological study.
3230340|NCT01190241|Experimental|Targeted treatment|Targeted treatment with desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib
3230341|NCT01190280||AC - operation|Patients admitted with acute cholecystitis randomized to operation
3230342|NCT01190280||AC - observation|Patients admitted with acute cholecystitis randomized to observation
3325378|NCT02052817|Active Comparator|Control|Debridement and standard of care in off-loading on control patients
3325379|NCT02052817|Experimental|Toad Brace|Debridement and fitting of Toad Brace
3230343|NCT01190280||SGBS - operation|Patients admitted with uncomplicated gallstone disease randomized to operation
3230344|NCT01190280||SGBS - observation|Patients admitted with uncomplicated gallstone disease randomized to observation
3325380|NCT02052830|Experimental|Wise Guys|A sexual health and male responsibility program for adolescent males
3230345|NCT01190280||1983 - stones|Patients that in 1983 were diagnosed with gallstones in a population screening
3230346|NCT01190280||1983 - operation|Patients that were operated for gallstone disease at Haukeland University Hospital, Bergen, Norway, in 1983
3230347|NCT01190280||1983 - controls|Patients that were shown not to have gallstones in a 1983 population screening
3325381|NCT02052830|No Intervention|Control|Business as usual sexual education in schools
3325382|NCT02052843|Experimental|Steps to Success|Steps to Success enhanced home visits-including instruction for both young mothers and fathers on contraception, comprehensive sex education, and the importance of adequate birth spacing, and accompanied by group sessions on adulthood preparation topics.
3230348|NCT01190280||Gallstone patients|Patients with symptoms from gallstone disease
3230349|NCT01190293|Experimental|All subjects|All Subjects will receive the same intervention.
3325383|NCT02052843|Active Comparator|Traditional Healthy Families|Traditional Healthy Families home visits which cover topics of parenting and child development
3230350|NCT01190319|Placebo Comparator|Placebo Beverage|The placebo beverage is matched in energy, macronutrient composition and sensory properties to the active beverage, but is devoid of strawberry polyphenols.
3230351|NCT01190319|Experimental|Strawberry Beverage|The strawberry beverage is matched in energy, macronutrient composition and sensory properties to the placebo beverage, but contains strawberry polyphenols.
3230352|NCT01190332|Placebo Comparator|conventional technique of ERCP|
3230353|NCT01190332|Active Comparator|Rendezvous technique|
3230354|NCT01190345|Experimental|WITH bevacizumab|"bevacizumab 15 mg/kg on day 1 of each cycle : 4 cycles of 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
3259139|NCT01467830|Experimental|absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using absorbable sutures.
3325384|NCT02052856||ACL Surgery|All English speaking patients 16 years and older having anterior cruciate ligament (ACL) surgery without any other surgery to knee or contralateral knee.
3325385|NCT02052869|Other|esophagus intubation|all patients will be intubated in the trachea first, with subsequent intubation in the esophagus. measurements will be performed on both tubes in a blinded manner.
3230355|NCT01190345|Active Comparator|without bevacizumab|"4 cycles 5-fluorouracil 500 mg/m² IV + epirubicin 100 mg/m² IV + cyclophosphamide 500 mg/m² IV of (FEC100) every 21 days and 4 cycles of docetaxel 100 mg/m² IV every 21 days.~Patients with HER2+ disease will receive trastuzumab (8 mg/kg (IV then 6 mg/kg, every 21 days), which will be started with docetaxel and administered for a total duration of 54 weeks, 18 injections."
3230356|NCT01190358|Placebo Comparator|Placebo|Sugar pill
3230357|NCT01190358|Active Comparator|Grape seed extract|300mg of grape seed extract.
3325386|NCT02052882|Experimental|Romiplostim|"All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy.~Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel."
3325387|NCT02052908|Experimental|Arm I (high-dose naproxen)|Patients receive high-dose naproxen PO QD for 6 months.
3325388|NCT02052908|Experimental|Arm II (low-dose naproxen, placebo)|Patients receive low-dose naproxen PO QD and placebo PO QD for 6 months.
3325389|NCT02052908|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO QD for 6 months.
3325390|NCT02052921|Active Comparator|Rectal resection|Surgical rectal resection
3325391|NCT02052921|Experimental|Observation|Conservative approach
3325392|NCT02052934|Experimental|Cohort 1|Three sublingual (SL) doses of dMLT, 1 microgram (mcg), on Days 1, 15 and 29, 8 subjects
3325393|NCT02052934|Experimental|Cohort 2|Three SL doses of dMLT, 5 mcg, on Days 1, 15 and 29, 8 subjects
3325394|NCT02052934|Experimental|Cohort 3|Three SL doses of dMLT, 25 mcg, on Days 1, 15 and 29, 11 subjects
3325395|NCT02052934|Experimental|Cohort 4|Three SL doses of dMLT, 50 mcg, on Days 1, 15 and 29, 11 subjects
3325396|NCT02052934|Experimental|Cohort 5a|Three SL doses of dMLT,25 mcg on Days 1, 15 and 29, 13 subjects.
3325397|NCT02052934|Experimental|Cohort 5b|Three oral doses of dMLT, 25 mcg on Days 1, 15and 29, 13 subjects
3325398|NCT02052947|Other|SPEC-DaTscan|SPEC-DaTscan
3325399|NCT02052973|Experimental|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
3325400|NCT02052986|Experimental|Vascazen|Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks.
3325401|NCT02052999|Experimental|PAC-14028 cream 1%|PAC-14028 cream 1%, twice daily for 8 weeks
3230358|NCT01190371|Other|Artesunate|Confirmation of artemisinin tolerance
3325402|NCT02052999|Active Comparator|Rozex gel 0.75%|Rozex gel 0.75%, twice daily for 8 weeks
3325403|NCT02052999|Placebo Comparator|Vehicle|Vehicle, twice daily for 8 weeks
3325404|NCT02053012||PVT-192|
3325405|NCT02053025|Active Comparator|mycoprotein|3 levels of mycoprotein will be consumed
3325406|NCT02053025|Active Comparator|control protein|3 levels of a control protein will be consumed
3230359|NCT01190384|Experimental|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
3230360|NCT01190384|Active Comparator|Couscous plus Fiber|Soup with added fiber; has a low ORAC value. Subject serving is isocaloric to the experimental Bean soup.
3230361|NCT01190384|Active Comparator|Couscous plus Grape Seed Extract|Control for ORAC value of the Bean soup; for examining the effect of fiber in the bean soup.
3325407|NCT02053038|Experimental|iFR|Treatment guided by iFR
3325408|NCT02053038|Active Comparator|FFR|Treatment guided by FFR
3325409|NCT02053051|Experimental|MDI of insulin & ABC4D|Advanced Bolus Calculator for Type Diabetes (ABC4D)
3325410|NCT02053051|Active Comparator|MDI of insulin|Multiple daily injections(MDI) of insulin
3325411|NCT02053064|Experimental|SAF-301|
3325412|NCT02053090|Active Comparator|Group Education with Stretching|"Group Education with Stretching will receive 10 small group educational classes at the Oregon Health & Science University (OHSU), based on the book Fibromyalgia (Biographies of Disease). Each chapter of Fibromyalgia covers different aspects of the disease and its treatment including global, economic, and risk statistics; a timeline of key events in the study of fibromyalgia; common symptoms and diagnostic indicators; natural history of fibromyalgia; pharmacologic and non-pharmacologic treatments; associated disorders and syndromes; and impact of fibromyalgia at home, in the workplace and in society at large. Participants will be informed that they should not start additional treatments until the end of the study and complementary and alternative treatments won't be covered until the last session. Participants will also receive a digital video disk (DVD) covering stretching appropriate for fibromyalgia patients and will be asked to incorporate the DVD over the next 10 weeks."
3325413|NCT02053090|Experimental|Group Acupuncture|20 treatments in 10 weeks will include individualized acupuncture in a group setting, dietary and lifestyle recommendations each based on the Traditional Chinese Medicine diagnosis (zhang fu) at the time of the visit.
3325414|NCT02053103|Experimental|PF-05175157|
3325415|NCT02053103|Placebo Comparator|Placebo|
3325416|NCT02053116|Experimental|PF-05175157|
3325417|NCT02053116|Placebo Comparator|Placebo|
3230362|NCT01190397|Experimental|Blephasteam Arm|
3230363|NCT01190397|Active Comparator|warm and moist compresses arm|
3230364|NCT01190423|Experimental|Family Based therapy for young adults|
3325418|NCT02053129|Other|HIV negative pregnant women|Pregnant women who are HIV negative attending their first ANC visit
3325419|NCT02053129|Other|HIV positive pregnant women|Pregnant women who are HIV positive accessing antenatal care.
3325420|NCT02053142|Experimental|Part 1 PK|400mg dose of acyclovir taken orally, followed by 2 ml blood plasma collection at 1,2,4,6 and 8 hours.
3325421|NCT02053142|Active Comparator|Acyclovir|400 mg Acyclovir three times daily for 5 days
3325422|NCT02053142|Placebo Comparator|Placebo|Placebo three times daily for 5 days
3325423|NCT02053155|Experimental|computer based patient education|The patients will complete a pre module and post module set of questions to determine whether their knowledge about peri operative smoking cessation increase smoking has changed. According to their willingness and eligibility, pharmacotherapy will be given.
3325424|NCT02053181|Experimental|Cadazolid|Single oral dose of 3000 mg.
3325425|NCT02053194|Experimental|Pharmacist-led educational intervention|Participants will receive an educational brochure on an inappropriate prescription they are currently taking from their pharmacists. Participants' physicians will receive an evidence-based pharmaceutical opinion for the same medication.
3325426|NCT02053194|No Intervention|Control|Participants in the control group will be wait-listed and observed for 6 months prior to receiving the intervention.
3325427|NCT02053207|Experimental|Cog-Train Intervention|
3325428|NCT02053220|Experimental|Intra-tumoural cohort|
3325429|NCT02053220|Experimental|Intra-venous cohort|
3325430|NCT02053233|Experimental|Walkbot group|The Walkbot group received conventional physical therapy (session I for 40 min/day) companied with Walkbot training (session II for 30 min/day) 5 days a week for 4 weeks, 40 session in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks.
3325431|NCT02053233|Placebo Comparator|control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
3325432|NCT02053246|Experimental|Nebivolol|Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
3325433|NCT02053272|Active Comparator|2 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 2 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3325434|NCT02053272|Active Comparator|5 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 5 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3325435|NCT02053272|Active Comparator|15 mg GWP42004 bid|Licaps® size double zero (Size 00) hard gelatin capsules containing 15 mg GWP42004 dissolved in excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3325436|NCT02053272|Placebo Comparator|Placebo|Licaps® size double zero (Size 00) hard gelatin capsules containing excipients Macrogolglycerol Ricinoleate and Oleoyl macrogol-6-glycerides. One capsule taken twice daily for 12 weeks.
3325437|NCT02053298|Experimental|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
3325438|NCT02053311|Active Comparator|Arm A: Orteronel|300mg orteronel twice daily and best supportive care until disease progression
3325439|NCT02053311|Active Comparator|Arm B: Placebo|Placebo twice daily and best supportive care until disease progression
3325440|NCT02053324|Experimental|AvidinOX/ST2210|AvidinOX/ST2210 - vial containing 22.5 mg AvidinOX + vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to 15 % of the lesion volume followed by intravenous infusion of 177Lu-ST2210 Diagnostic dose : 10 ml, 250 MBq±10%177Lu, approximately 1 mg ST2210, 100 mg/mL ascorbic acid, followed by intravenous infusion of a therapeutic dose: 25 ml, escalating 177Lu dose starting at 5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210, 100 mg/ml ascorbic acid
3325441|NCT02053337|Experimental|Self adhesive foam dressing|Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
3325442|NCT02053337|Active Comparator|Comparator self adhesive foam dressing|Non Sponsor manufactured self adhesive foam dressing. Use of CE marked dressing according to instructions for use and study protocol.
3325443|NCT02053350|Experimental|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days.
3325444|NCT02053363|Experimental|High Dose/Study Group|Tranexamic Acid (Cyklokapron) Loading Dose 50mg/kg given over 15 minutes, followed by 5mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
3230365|NCT01190488|Experimental|Intervention - Decision Aid|In addition to usual care, patients assigned to the intervention group will also be asked to view and/or read the EOL-PtDA during their hospitalization. The EOL-PtDA can be utilized anytime in the course of their hospitalization (all hospital rooms at UCH have a DVD player). This could be before, during, or after the palliative care team consultation.
3230366|NCT01190488|Active Comparator|Active comparison|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
3230367|NCT01190501|Experimental|complier device|
3230368|NCT01190540|Active Comparator|OSS Phase 1|Thirty-six sites will receive the On Site Support service (OSS) activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 1
3325445|NCT02053363|Active Comparator|Standard of Care/Control|Tranexamic Acid (Cyklokapron) Loading Dose 10mg/kg given over 15 minutes, followed by 1mg/kg/hr via continuous infusion. The loading dose will be given to coincide with incision. The continuous infusion will be stopped at the conclusion of fascial layer closure.
3230369|NCT01190540|Active Comparator|OSS Phase 2|Thirty-six sites will receive the OSS activities for nine to 15 months; 18 will be randomly assigned to receive the OSS in phase 2 that will serve as a control group in phase 1 and receive OSS nine months later.
3230370|NCT01190553|Experimental|Treatment|IV amantadine treatment
3230371|NCT01190592|Experimental|Milk|
3230372|NCT01190592|Experimental|Juice|
3230373|NCT01190592|Placebo Comparator|Water|
3230374|NCT01190631|Experimental|Acrysof IQ (SN60WF) IOL|AcrySof IQ SN60WF intraocular lens (IOL) implanted in one eye only during cataract surgery.
3230375|NCT01190644|Experimental|ACE 011 (Sotatercept)|35mg dose of ACE 011 will be given by subcutaneous injection on Day 1. Up to two additional doses of ACE 011 will be given every 42 days during the treatment period (Day 43 and Day 85)
3325446|NCT02053389|Experimental|DVD Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) AND the DVD decision aid (Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer), which provides instruction and recommendations on how to participate in shared decision making with one's physician."
3325447|NCT02053389|Active Comparator|Written Decision Aid|"Eligible participants receive the written decision aid (Making the Choice: Deciding What to Do About Early Stage Prostate Cancer) alone."
3325448|NCT02053402|Placebo Comparator|Placebo|Placebo to be given daily for six months
3230376|NCT01190657|Experimental|Selbex 50mg (14 days)|
3230377|NCT01190657|Experimental|Selbex 50mg (56 days)|
3325449|NCT02053402|Active Comparator|Vitamin D|1200 IU of vitamin D, daily for six months
3325450|NCT02053415|Experimental|Krill oil low dose|3 capsules krill oil per day, for 28 days
3325451|NCT02053415|Experimental|Krill oil high dose|9 capsules krill oil per day, for 28 days
3325452|NCT02053428|Active Comparator|Gastrostomy - pull technique|Percutaneous image-guided gastrostomy using large-bore mushroom-retained catheters via the pull technique
3325453|NCT02053428|Active Comparator|Gastrostomy - push technique|Percutaneous image-guided gastrostomy using small-bore cope loop catheters via the push technique
3325454|NCT02053454|Active Comparator|patisiran (ALN-TTR02)|
3325455|NCT02053454|Active Comparator|Sterile Normal Saline (0.9% NaCl)|
3325456|NCT02053467|Experimental|eConsult|Physicians randomized to the intervention will have access to the Champlain BASE eConsult service right away (pending completion of an orientation session)
3325457|NCT02053467|No Intervention|Control|Physicians randomized to the control group will use their standard referral practices for one year after randomization and only then will be given the option to use eConsult.
3325458|NCT02053480||Pyruvate Kinase Deficiency|Patients of all ages with Pyruvate Kinase Deficiency
3325459|NCT02053506|Experimental|Immune-enhancing nutritional beverage|This group will consume an immune-enhancing beverage and additional protein (1.2-1.5 grams•kg-1 body weight•day-1 versus the RDA of 0.8 grams•kg-1 body weight•day-1) during and after the period of sleep restriction to determine if this nutritional approach attenuate the loss of immune responsiveness.
3325460|NCT02053506|Experimental|Probiotics (BB-12)|This group will consume probiotics (BBB12) during and after the period of sleep restriction to determine if nutritional approaches attenuate the loss of immune responsiveness. Consistent with the control group, this group will consume the RDA for protein (0.8 grams•kg-1 body weight•day-1) and placebo beverage (no immune-enhancing vitamins/minerals).
3325461|NCT02053519|Active Comparator|Vigantol Oil, (Vitamin D3)|Oral Vigantol Oil 5 mls, (100 000 iu of Vitamin D). First dose at randomisation, 7 -28 days prior to commencing standard Hepatitis C treatment for Hepatitis C Genotypes 1 or 3 . Thereafter monthly with concurrent Hepatitis C treatment.
3325462|NCT02053519|Placebo Comparator|MyGliol Oil|Matched placebo. Subjects randomised to this arm will take 5 mls of active Placebo, (Mygliol oil), 7 - 28 days prior to commencing active Hepatitis C treatment and thereafter 5 mls monthly concurrent with Hepatitis C treatment for the duration of the study
3325463|NCT02053532||Positron emission tomography/magnetic resonance imaging|
3325464|NCT02053545|Experimental|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Clofarabine, Melphalan,Thiotepa, Cyclophosphamide, Mesna, Tacrolimus and mycophenolate mofetil (MMF)~Stratum 2 (Myeloid in remission): Busulfan, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Fractionated total body irradiation (fTBI), Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Tacrolimus, MMF"
3325465|NCT02053558|Placebo Comparator|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
3325466|NCT02053558|Active Comparator|TAP BLOCK with ropivacaine|TAP block will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
3325467|NCT02053571|Experimental|TIPS with 3D overlay|
3325469|NCT02053597|Experimental|doxorubicin and paclitaxel|All patients will receive four cycles of doxorubicin (A) (50 mg/m2) and paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
3325470|NCT02053636|Experimental|lucitanib|"Hard gelatine capsules of 2,5, 5 and 10 mg or film coated tablets of 5 and 7,5 mg.~5 to 10 mg orally on a daily basis until unacceptable toxicity according to the investigator, disease progression or withdrawal of consent"
3230378|NCT01190670|Experimental|Part 1, Group 1|ASP015K, low dose followed by high dose, with oral tacrolimus
3230379|NCT01190670|Experimental|Part 1, Group 2|ASP015K, high dose followed by low dose, with oral tacrolimus
3230380|NCT01190670|Experimental|Part 2|ASP015K high dose with intravenous tacrolimus
3230381|NCT01190683|Active Comparator|cholecalciferol|cholecalciferol 60,000IU/week for first eight weeks followed by 60,000 IU every 15 days for four months along with calcium placebo
3325471|NCT02053649|Active Comparator|Usual Care|Usual Care will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
3325472|NCT02053649|Experimental|Triple Chronotherapy + Usual Care|triple chronotherapy (TC) will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
3230382|NCT01190683|Active Comparator|Calcium carbonate|two tablets of calcium carbonate daily equivalent to 1 gm of elemental calcium for six months along with vitamin D placebo
3230383|NCT01190683|Active Comparator|oral calcium and cholecalciferol|60,000 IU of cholecalciferol every week for ist eight week and then 60,000IU every 15 days for next four months along with 1 gm of elemental calcium ever day for six months
3230384|NCT01190683|Placebo Comparator|lactose|identical placebos
3230385|NCT01190696|Other|hip spica casting|Patients in the spica cast group treated with skeletal traction and spica cast applied for them
3325473|NCT02053662||Bladder Cancer Patients|Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
3325474|NCT02053675|Other|Vasopressin|
3230386|NCT01190696|Other|titanium elasting nailing|For patients in the Titanium Elasting Nailing group, the nail applied retrogradely in femoral shaft fracture
3230387|NCT01190709|Other|unreamed Intramedullary Nailing|tibial fracture fixed with unreamed Intramedullary Nailing
3325475|NCT02053688|Active Comparator|Astigmatic Correction Lens|Nexis ACCL lenses vs commercial Toric Lenses
3325476|NCT02053688|Active Comparator|Toric Soft Contact Lenses|commercial toric soft contact lenses
3325477|NCT02053714|Other|Self-management and education group|Self-management and education group - 8 weeks of group-based information and activities designed to improve diabetes self-management
3325478|NCT02053727|Active Comparator|Abatacept Arm|This arm of study subjects will receive 125 mg subcutaneous abatacept during the 24 week double blind period.
3325479|NCT02053727|Placebo Comparator|Placebo Arm|This arm of study patients will receive matching placebo injections during the 24 week double blind period.
3230388|NCT01190709|Other|Dynamic Compression Plate|tibial fracture fixed with Dynamic Compression Plate
3230389|NCT01190722|Experimental|etoricoxib|active study drug, coxib
3230390|NCT01190722|Active Comparator|diclofenac|active traditional NSAID control
3230391|NCT01190735|Experimental|Caffeine|Each patient will take pills twice per day containing 100-200 mg of caffeine (as synthetic caffeine alkaloid). Patients will be instructed to take whatever caffeine-containing beverages they are accustomed to taking, without changing their habitual schedule (note that all will be taking <200 mg per day). Caffeine intake will be assessed at each visit. Patients will continue their usual PD medications, without change in dose or timing for the entire duration of the study. Medication will be provided in pre-packaged dosettes.
3325480|NCT02053740|Experimental|R-S-Y-R-T|We added R-S-Y-R-T (500 mg 3 times per day) for 6 months
3325481|NCT02053740|Other|Routine western medicine|We kept routine western medicine only (as control group)
3325482|NCT02053766|Active Comparator|Sevoflurane|In the Operating Room (OR) after applying routine monitors, anesthesia will be induced with a mask using Sevoflurane up to 8%. Sevoflurane will be used for maintenance for the rest of the procedure with dosage between 1.5% and 4%. Vitals will be monitored. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Sevoflurane will be turned off at the end of procedure.
3325483|NCT02053766|Active Comparator|Dexmedetomidine (Precedex®)|These subjects will receive Dexmedetomidine intravenously. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Precedex 1mcg/ kg will be given over 10 minutes. Infusion will be started using Precedex 1mcg/ kg/ hr and can be increased or decreased as needed. Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Precedex infusion will be stopped at the end of the procedure.
3325484|NCT02053766|Active Comparator|Propofol|These subjects will receive propofol for anesthesia maintenance. In the OR routine monitors will be placed. Vitals will be monitored. A loading dose of Propofol 2mg/ kg will be given over 2 minutes. Infusion will be started using Propofol 50 mcg/ kg/min and can be increased or decreased as needed (range 50-300mcg/kg/min). Fentanyl will be used as needed. Rocuronium will be used as needed for muscle relaxation. At the end of the procedure twitches will be evaluated and muscle relaxation will be reversed. Propofol infusion will be stopped at the end of the procedure.
3325485|NCT02053779|Experimental|GnRH-agonist|Experimental Arm: Triptorelin 0.1 mg
3325486|NCT02053779|No Intervention|Control Arm|Control Arm: No intervention
3325487|NCT02053805|Other|screening tests|The screening will include: DRE, PSA , a multiparametric prostate MRI and a trans-rectal ultra-sound guided prostate biopsy/ MRI-US fusion , IPSS questionnaire, trans-rectal US assessment of prostate size, urine flow and residual.
3325488|NCT02053818|Active Comparator|Remifentanil|Remifentanil the basic opioid drug in anesthesia
3325489|NCT02053818|Active Comparator|Sufentanil|Sufentanil the basic opioid drug in anesthesia
3325490|NCT02053844|Experimental|lottery and enhanced promotion of tool|tool users in the intervention arm will be eligible to enter a monthly lottery to win one of two monthly drawings of a $500 gift card, and will receive enhanced promotion of the tool (mailed promotion, promotional message on the member web portal, and promotion through employers to employees)
3325491|NCT02053844|No Intervention|usual promotion of the tool|Routine promotion of the tool through newsletter and on health plan web site
3325492|NCT02053857|Active Comparator|RUTF|Standard RUTF at a dose of 175 kcal/kg/d
3325493|NCT02053857|Experimental|RUTF-P|RUTF fortified with polyunsaturated fatty acids (PUFA) at a dose of 175 kcal/kg/d
3325494|NCT02053870|Experimental|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
3325495|NCT02053870|Active Comparator|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
3325496|NCT02053883|Placebo Comparator|Placebo|Fibrin sealant only.
3230392|NCT01190748|Experimental|A|Galantamine 4 mg Tablet, single dose
3230393|NCT01190748|Active Comparator|B|Reminyl 4 mg Tablet, single dose
3230394|NCT01190761|Experimental|A|Galantamine 4 mg Tablet, single dose
3230395|NCT01190761|Active Comparator|B|Reminyl 4 mg Tablet, single dose
3230396|NCT01190774|Experimental|Dentist behaviour|Patient completes the MDAS which is handed to receptionist who then gives the information to the dentist with patient knowledge
3230397|NCT01190774|Experimental|Dentist behaviour and patient expectancy|Patient completes the MDAS and hands to the dentist
3325497|NCT02053883|Experimental|Cethrin (BA-210) - Low Dose|Low dose of Cethrin in a fibrin sealant.
3325498|NCT02053883|Experimental|Cethrin (BA-210) - High Dose|High dose of Cethrin in a fibrin sealant.
3325499|NCT02053896||ISU302|15~60U/kg (once every 2 weeks for 6 months)
3325500|NCT02053909|Active Comparator|Aspirin|One aspirin 81 mg capsule 2 times per day
3325501|NCT02053909|Active Comparator|Ticagrelor|One ticagrelor 90 mg capsule 2 times per day
3325502|NCT02053922|Active Comparator|Syntocinon|Drug is given just after delivery of the neonate during cesarean section.
3325503|NCT02053922|Active Comparator|Carbetocin|Drug is given just after delivery of the neonate during cesarean section.
3325504|NCT02053922|Active Comparator|Misoprostol|Drug is given just after delivery of the neonate during cesarean section.
3325505|NCT02053935|Other|Dopamine|All patients will receive the same intervention.
3325506|NCT02053948|Experimental|Pursestring Wound Closure group|use Pursestring Wound Closure technique to close the stoma
3325507|NCT02053948|Experimental|Gunsight Skin Incision and Closure group|use Gunsight Skin Incision and Closure Technique to close the stoma
3230398|NCT01190787|Experimental|VMP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3325508|NCT02053961|Active Comparator|1Hz dTMS Real|This group will receive dTMS real treatment of 1Hz
3325509|NCT02053961|Sham Comparator|1HZ dTMS SHAM|This group will receive 1HZ dTMS SHAM treatment
3325510|NCT02053974|Active Comparator|Spironolactone|patients who randomized to spironolactone administered arm
3325511|NCT02053974|Placebo Comparator|Placebo|Patients who randomized to placebo administered arm
3325512|NCT02053987|Experimental|Stroke rehabilitation|
3325513|NCT02053987|No Intervention|Control Group|This group will undergo rehabilitation as per the current stroke rehabilitation pathway.
3325514|NCT02054000|Active Comparator|Tirofiban group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary tirofiban (25 µgr/kg) was administered via the guiding catheter to the infarct related artery
3325515|NCT02054000|Placebo Comparator|Placebo group|If thrombolysis in myocardial infarction flow <3 in spite of performed treatments, patients were considered as no-reflow and randomized to tirofiban or placebo group. Intracoronary serum physiologic as placebo was administered via the guiding catheter to the infarct related artery
3325516|NCT02054013|Experimental|Prostatic artery embolization|Prostatic artery embolization (PAE) has been suggested as a minimal invasive alternative procedure with rapid recovery and low morbidity
3325517|NCT02054013|Other|Conventional monopolar transurethral prostatectomy|Standard treatment
3325518|NCT02054026|Experimental|Reducing the Risk|An eight-lesson (approximately eight-hour) version of Reducing the Risk
3325519|NCT02054026|No Intervention|Control|
3325520|NCT02054039|Experimental|Incentive spirometry (IS)|Group I
3325521|NCT02054039|Active Comparator|Breath stacking (BS)|Group II
3325522|NCT02054052|Experimental|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating maliganant pleural or percardial effusion
3325523|NCT02054065|No Intervention|Control|Normal care conditions, no computer-based physician alert.
3325524|NCT02054065|Experimental|CAUTI Decision Support|Decision support aimed at preventing Catheter Associated Urinary Tract Infections (CAUTIs)
3325525|NCT02054078|Experimental|Bevacizumab|Bevacizumab200mg by intrapleural administration
3325526|NCT02054078|Active Comparator|Pulvis talci|Pulvis talci 4g by intrapleural administration
3325527|NCT02054091|No Intervention|Control group|Infants are fed according to the standard feeding practices at each hospital. At FWCH & SBMCH babies are fed infant formula supplemented to mother's own milk (if avaible), and at RH, babies are fed donor milk supplemented to Mother'w own milk (if avaible).
3325528|NCT02054091|Experimental|Colostrum group|Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH & SBMCH.
3325529|NCT02054104|Experimental|1/Vaccine plus chemotherapy|H1299 cell lysates with iscomatrix vaccine with metronomic chemotherapy
3325530|NCT02054104|Experimental|2/Vaccine alone|H1299 cell lysates with iscomatrix adjuvant vaccine
3325531|NCT02054117||Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
3325532|NCT02054143|Experimental|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) after the intubation occured until the patient was extubated.
3325533|NCT02054169||pre-test group|All patients aged 65 or older presenting to the ED during the pre-test period
3325534|NCT02054169||post-test period|All patients aged 65 or older presenting to the ED in the post-test period
3325535|NCT02054182|Active Comparator|Vitamin D|Vitamin D 2 500 IU daily from enrolment until hospital discharge
3325536|NCT02054182|Placebo Comparator|Placebo|Placebo
3325537|NCT02054195|Experimental|IUD new technique|Training
3325538|NCT02054195|Experimental|No Training|No Training
3325539|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs)- low dose|human umbilical cord blood derived mesenchymal stem cells Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
3325540|NCT02054208|Experimental|NEUROSTEM (hUCB-MSCs) - high dose|human umbilical cord blood derived mesenchymal stem cells High dose: 3 x 10^7 cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
3325541|NCT02054208|Placebo Comparator|Placebo|normal saline 2mL, doses separated by 4 weeks for a total of 3 doses
3325542|NCT02054221|Other|extended myectomy + MVreplacement|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy with full isscheniem subvalvular apparatus and mitral valve replacement.~Evaluation results will be made myoectomy as TEE and direct tensiometer."
3325543|NCT02054221|Other|extended myectomy + MVrepair|"Procedure: extended myoectomy, mitral valve surgery~Will be included in a group of 41 patients with obstructive hypertrophic cardiomyopathy and severe mitral insufficiency. Intraoperatively for all patients will be executed TEE to calculate the volume of excision. All patients will be performed extended myoectomy which supplemented resection and release of the papillary muscles and the mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.~Evaluation results will be made myoectomy as TEE and direct tensiometer ."
3230399|NCT01190787|Experimental|VCP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3230400|NCT01190787|Experimental|VP|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
3230401|NCT01190826|Experimental|ASM-024 10 mg|ASM-024 administered once by inhalation at a target dose of 10 mg
3325544|NCT02054247|Experimental|ultrasound|ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2
3230402|NCT01190826|Experimental|ASM-024 100 mg|ASM-024 administered once at a target dose of 100 mg
3230403|NCT01190826|Placebo Comparator|Placebo|Placebo administered once by inhalation
3325545|NCT02054247|Experimental|pulsed ultrasound|pulsed ultrasound : a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4
3325546|NCT02054247|Placebo Comparator|placebo ultrasound|placebo ultrasound : same ultrasound device as described above seemed to be working but without delivering any output
3325547|NCT02054260|Experimental|Surgicel add therapy|
3325548|NCT02054286|Experimental|Group 1: THV01 (5.10E+6 TU) or Placebo|5.10E+6 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+6 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3325549|NCT02054286|Experimental|Group 2: THV01 (5.10E+7 TU) or Placebo|5.10E+7 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+7 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3230404|NCT01190852|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
3230405|NCT01190852|Active Comparator|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
3325550|NCT02054286|Experimental|Group 3: THV01 (5.10E+8 TU) or Placebo|5.10E+8 TU (transducing unit) of THV01-1 (Week 0) OR matching placebo; 5.10E+8 TU (transducing unit) of THV01-2 (Week 8) OR matching placebo
3325551|NCT02054299|Experimental|Drug application|6 treatment periods. On each period one of the following interventions
3325552|NCT02054312|Experimental|Family Based Interpersonal Psychotherapy (FB-IPT)|Family Based Interpersonal Psychotherapy for Depressed Preadolescents (FB-IPT) is a promising psychosocial treatment for preadolescent depression. It is conceptually rooted in an interpersonal model of depression that focuses on how stress in interpersonal relationships is often related to the onset or maintenance of depressive symptoms. In keeping with adult and adolescent models of IPT, FB-IPT focuses on improving the interpersonal functioning of individuals as a means to improve their depressive symptoms. FB-IPT addresses two domains of interpersonal impairment in depressed preadolescents, parent-child conflict and interpersonal avoidance, and focuses on family relationships, the primary context for children's social and emotional development.
3325553|NCT02054312|Active Comparator|Client Centered Therapy (CCT)|Child Centered Therapy (CCT), a supportive and nondirective treatment that closely approximates the standard of care for pediatric depression in community mental health. CCT is a manualized treatment for children between the ages of 8-14 based on a Rogerian counseling model. In that model, changes in children's mood and behavior are initiated through their experience of a therapeutic relationship marked by unconditional positive regard, empathic understanding, and therapeutic genuineness.
3325554|NCT02054364|Experimental|FBT and CRT|Family-Based Treatment combined with Cognitive Remediation Therapy (15 sessions of each)
3325555|NCT02054364|Experimental|FBT and art therapy|Family-Based Treatment combined with art therapy (15 sessions of each)
3325556|NCT02054377|Experimental|Group A (face to face tai chi)|"8 x 1 hour taught individual classes of Tai Chi over 3 months provided by a Tai Chi instructor at the participant's home/convenient location. These focus on 8 core postures. This is in addition to participant's usual routine care. A DVD and booklet to aid home practise will be provided.~Daily home Tai Chi practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
3325557|NCT02054377|Active Comparator|Group 2 (online tai chi)|"3 months usual routine care.~8 x 1 hour taught individual classes of Tai Chi over 3 months provided over the internet by a Tai Chi instructor. A DVD and booklet to aid home practise will be provided.~Daily Tai Chi home practise for 6 months (home practice encouraged for 5 to 10mins 5 times a week).~At the end of the 9 months, local Tai Chi classes can be recommended if requested."
3325558|NCT02054403||angle closure|
3325559|NCT02054416|Active Comparator|Art Assist Device|The ArtAssist© (model AA1000) device is made by ACI Medical located in San Marcos, CA (http://acimedical.com/) and is cleared per FDA under K942530.The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
3325560|NCT02054416|Sham Comparator|Sham Device|"Sham devices look identical to the actual ArtAssist© devices, but provide low-pressure and differ only in number-coded tubing. The study sham intervention will consist of one hour of IPC with the sham ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the sham device has an internal device that stores the usage data) to evaluate subject compliance."
3230406|NCT01190852|Active Comparator|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
3230407|NCT01190904||Coronary Artery Disease (≥50%) with or without PCI|We propose to investigate four specific aims using 1,143 diabetic men who have CAD (≥50%) lesion in at least one major epicardial vessel with or without PCI.
3230408|NCT01190917|Active Comparator|Cognitive Behavioral Therapy Group|
3325561|NCT02054429|Experimental|Insulin|IIT arm subjects will receive an insulin aspart infusion at a minimal rate of 2 units/hr while maintaining blood glucose between 90-120mg/dl for 48 hrs
3325562|NCT02054429|No Intervention|Standard glycemic control|standard of care if not randomized to Insulin
3325563|NCT02054442|Experimental|Arm A: MTX in combination with cetuximab|"The dosage of cetuximab will be i.v. 400 mg/m2 over a period of 2h for the first infusion, followed by infusions of 250 mg/m2 over 1 hour once weekly. Cetuximab will be dissolved in 500 ml NaCl 0.9%.~Premedication: H1-receptor antagonist and dexamethasone.~The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
3325564|NCT02054442|Active Comparator|Arm B: MTX|"The dosage of MTX (Methotrexate) will be i.v. 40 mg/m2 once weekly, administered within 5-10 minutes. MTX will be dissolved in 50 ml NaCl 0.9%.~Premedication: ondansetron 8 mg.~Treatment will be continued until progressive disease, unacceptable toxicity or refusal by patient."
3325565|NCT02054455|Placebo Comparator|PPI and placebo|Patients will receive PPI and placebo for 3 days/week for 6 months
3325566|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for 6 months
3325567|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 1|Patients will receive placebo 3 days/week for the first three months and Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the following three months
3325568|NCT02054455|Active Comparator|PPI and Lactobacillus paracasei F19 cross-over 2|Patients will receive Lactobacillus paracasei F19 in a dose of 25x10E9 live bacterial cells for 3 days/week for the first three months and placebo 3 days/week for the following three months
3325569|NCT02054468|Active Comparator|Single-shot-Propofol & Remifentanil|Induction group: A single-shot propofol induction dose with remifentanil infusion followed by injection of rocuronium (for doses, please see interventions). Airway: tracheal intubation
3325570|NCT02054468|Experimental|30min infusion Propofol & Remifentanil|Maintenance group: 30min of total intravenous anesthesia (TIVA) with propofol and remifentanil before rocuronium (for doses, please see interventions) is administered. Airway: tracheal intubation/laryngeal mask
3230409|NCT01190917|Active Comparator|Social Play Group|
3230410|NCT01190943||Ancillary-Correlative (biomarker sampling and analysis)|Archived tumor tissue and peripheral blood DNA specimens are analyzed for DNA copy number profiling, gene expression profiling, DNA methylation profiling, microRNA profiling, and genomic resequencing. Clinical data including demographics; date of diagnosis, surgery, chemotherapy, recurrence, progression, and death; imaging; toxicity; and pathologic data elements associated with the specimens are also collected and analyzed.
3325571|NCT02054494||HIV patients with high CD4+ cell counts|HIV Infection, Chronic high CD4+ cell counts (>500 /μl), No known cardiac disease
3325572|NCT02054494||HIV patients with low CD4+ cell counts|HIV Infection, Chronic low CD4+ cell counts (<200 /μl), No known cardiac disease
3325573|NCT02054494||Control Group|No known cardiac disease.
3325574|NCT02054507|No Intervention|Former premature infants|Cognitive and executive evaluation by Wechsler IV tests
3230411|NCT01190982|Experimental|LEP-ETU|All patient will have baseline to confirm disease status. The disease progression/response is assessed inaccordance to the RECIST guidelines
3259140|NCT01467830|Other|non absorbable sutures|patients attributed to that arm, undergoing surgery of Open Inguinal Hernia Repair With Mesh Fixation using non absorbable sutures,this is the method being considered the standard of care thus far.
3325575|NCT02054533||IBD patients|patients with IBD undergoing intra-abdominal surgery
3325576|NCT02054559|Active Comparator|Total 6 cycles of R-CHOP|
3325577|NCT02054559|Experimental|Total 3 cycles of R-CHOP + RT|Total 3 cycles of R-CHOP followed by radiotherapy (involved field or involved site radiotherapy, 30-50 Gy/ 15-25 fractions)
3325578|NCT02054585|Active Comparator|NaCl %0.9|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
3325579|NCT02054585|Experimental|NaCl 0.9% +5% dextrose|"Children will be included in each group in a randomized way using SAS program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% glucose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
3325580|NCT02054598|No Intervention|Control group|Usual care.
3325581|NCT02054598|Experimental|Intervention group|Decision aid and navigation
3325582|NCT02054611|Active Comparator|Educational Module First|Respondents will complete the online educational module first, followed by the evaluation
3325583|NCT02054611|Placebo Comparator|Evaluation First|Respondents will complete the the evaluation first, followed by the online educational module
3325584|NCT02054624|Active Comparator|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by one-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
3259141|NCT01467843|Active Comparator|Cognitive Behavioral Therapy|Participants randomized to the CBT intervention will attend eight weekly 2 hour sessions.
3230412|NCT01190995|Experimental|Sucrose|The enrolled neonates will be administered a sterile solution of 24 % sucrose orally for a period of 7 days from enrollment The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure.
3325585|NCT02054624|Active Comparator|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by conference telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive two phone calls per month from their group leader for the first 6 months, and one phone call per month for the next 6 months."
3325586|NCT02054624|Active Comparator|Health Education Control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 participants will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help them maintain lost weight."
3325587|NCT02054637|Experimental|Lanreotide|Lanreotide autogel 120mg injection every 4 weeks (every patient will receive 3 injections)
3325588|NCT02054650|Experimental|Osteopathic Manual Treatment (OMT)|The OMT protocol will be delivered following an examination for somatic dysfunction at each treatment session. The protocol will target the thoracic, lumbosacral, iliac, and pubic regions using the following techniques: high-velocity, low-amplitude thrusts; moderate-velocity, moderate-amplitude thrusts; soft tissue including stretching, kneading, and pressure; myofascial stretching and release; counterstrain; muscle energy; and other optional techniques as time permits and indicated. The intervention will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
3325589|NCT02054650|Sham Comparator|Sham OMT|Sham OMT will involve hand contact, active and passive range of motion, and sham techniques that simulate OMT (including optional OMT techniques), but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force. Sham OMT will be delivered at weeks 0, 1, 2, 4, 6 and 8. Week 12 is a data collection visit with no intervention.
3325590|NCT02054663|Experimental|Bolus|Patients randomized to this arm will receive a 600mg bolus dose of clopidogrel at the time of switching from ticagrelor to clopidogrel, followed by 75mg daily.
3325591|NCT02054663|Experimental|no bolus|Individuals randomized to this arm will receive 75mg of clopidogrel at the time of the transition followed by a daily dose of 75mg orally.
3325592|NCT02054676|Experimental|Classification assessment.|Random group of the partially edentulous individuals will be assessed according to prepared classification evaluation protocol during dental implant treatment period. Cone-beam computed tomography preoperative evaluation will be made during preoperative stage. Intraoperative edentulous jaw segment parameters evaluation, endosseous dental implant placement parameters assessment during intraoperative stage will be made. Dental implant position evaluation during early postoperative stage will be made. Medications will be prescribed. Late postoperative soft tissue evaluation of edentulous jaw segment will be made during final crown placement. Cone-beam computed tomography analysis results will be compared with subsequent stages assessment results to evaluate reliability of the classification.
3325593|NCT02054689|Other|Fractionated Stereotactic Radiosurgery|24 to 36 Gy in 3 fractions (8-12 Gy/fx).
3325594|NCT02054728|Experimental|RHC and IMT|
3325595|NCT02054741|Experimental|Arm I (GA intervention)|Patients complete a geriatric assessment. Patients and physicians are provided with the geriatric assessment information and recommendations.
3325596|NCT02054741|No Intervention|Arm II (usual care)|Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams.
3325597|NCT02054767|Experimental|lidocaine|injections of 3.6 mL of 2% lidocaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3325598|NCT02054767|Experimental|mepivacaine|injections of 3.6 mL of 2% mepivacaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3325599|NCT02054767|Experimental|articaine|injections of 3.6 mL of 4% articaine with 1:100,000 epinephrine Intervention: inferior alveolar nerve block injection
3230413|NCT01190995|Placebo Comparator|Placebo|The enrolled neonates will be administered double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
3230414|NCT01191021|Other|Propofol|Volunteers will receive propofol anesthesia on the study day.
3230415|NCT01191060|Experimental|lenalidomide, bortezomib with ASCT|"RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)~Autologous stem cell transplant:~Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)"
3325600|NCT02054780|Active Comparator|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling (PC) was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH. PC is considered an enhanced model of a Psychosocial Support program for OVC."
3325601|NCT02054780|Experimental|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for more overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Recent trials have provided direct evidence that CBT may be effective in HIV prevention. TF-CBT has eight components including: Psychoeducation, Relaxation, Affective Modulation, Cognitive Coping, Trauma Narrative, In-vivo Exposure (if needed), Conjoint parent-child session, and Enhancing Safety Skills. This cognitive behavioral therapy teaches skills such as how to think about situations differently in order to feel better. It also includes helping a child face the fear and anxiety of the traumatic situations, rather than avoid them. Based on earlier pilot projects, the MoH has endorsed TF-CBT in Zambia.
3325602|NCT02054806|Experimental|Pembrolizumab|Participants receive pembrolizumab 10 mg/kg, intravenously (IV), on Day 1 of every 2-week dosing cycle for up to 24 months
3325603|NCT02054819|Other|Single arm study|"Induction chemotherapy and concurrent radiation to primary tumor Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions~Consolidation Radiation: therapy to metastatic sites At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites."
3325604|NCT02054832||Glycosade|A prospective cohort design will be used to assess the impact on sleep and continue to monitor safety of Glycosade.
3230416|NCT01191060|Experimental|lenalidomide, bortezomib without ASCT|RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
3230417|NCT01191112|Experimental|Peptide Based enteral formula|
3230418|NCT01191125|Experimental|medical food with AN777|
3325605|NCT02054845|Experimental|Body awareness therapy|The experimental treatment: BEWARE
3325606|NCT02054845|Active Comparator|Treatment as Usual|The new treatment is compared to this arm: Physical therapy
3230419|NCT01191125|Active Comparator|oral nutritional formula|
3230420|NCT01191138|Other|Infracolic Anastamosis|The gastrojejunal anastamosis is done in the infracolic compartment
3230421|NCT01191138|Other|Supracolic Anastamosis|The gastrojejunal anastamosis is done in the supracolic compartment
3230422|NCT01191151||Orthopedic injury, osteoarthritis|All eligible patients receiving orthopedic, sports medicine, arthroscopy and related surgery or nonoperative treatment
3230423|NCT01191164|Experimental|Study Arm|
3230424|NCT01191177|Experimental|Lovaza group|Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
3230425|NCT01191177|Placebo Comparator|Placebo group|Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
3325607|NCT02054858|Experimental|RIPC|Preconditioning will be performed in the same manner as several previous trials. Immediately prior to having the CT scan a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
3325608|NCT02054858|No Intervention|Control|Patients randomised to this group will receive routine care associated with undergoing a CT scan.
3230426|NCT01191203|Active Comparator|Depo Medroxyprogesterone Acetate|
3230427|NCT01191203|Active Comparator|Copper IUD (CuT360)|
3230428|NCT01191216|Experimental|Arm I|Patients receive oral 1-methyl-d-tryptophan twice daily on days 1-21 and docetaxel IV over 1 hour on day 1 (in course one patients receive 1-methyl-d-tryptophan once daily on days 1 and 3-21).
3230429|NCT01191229|No Intervention|Tecnis One-Piece MF IOL|It is planned that about 25 people who are at least 18 years old who are scheduled to have the Tecnis One-Piece Multifocal Intraocular Lenses placed into their eyes after cataract surgery
3230430|NCT01191229|No Intervention|Crystalens AO|It is planned that about 25 people who are at least 18 years old and have been implanted with Crystalens AO
3230431|NCT01191281|Experimental|Diet/nutrition counsel+food aid|Intervention. Patients enrolled in the intervention group will receive a multi-component intervention that includes dietary and nutritional counseling and food assistance (food aid basket)
3230432|NCT01191281|Active Comparator|dietary/nutritional counseling|Patients enrolled in the comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
3230433|NCT01191294|Experimental|Medical Students|3rd year medical students during their primary care clerkship
3230434|NCT01191307||Shunt Implant|hydropcephalus cohort
3230435|NCT01191307||Cochlear Implant|hearing impaired cohort
3230436|NCT01191307||Spinal Cord Stiumulation|spinal cord injury cohort
3230437|NCT01191307||Vagus Nerve Stimulation|epilepsy cohort
3230438|NCT01191307||Deep Brain Stimulation|dystonia cohort
3230439|NCT01191346||3T MRI|Patients receiving 3T MRI
3230440|NCT01191359|Active Comparator|sublingual administration|oral immunotherapy with drops applied once daily by single dose containers (200 STU per dose)
3230441|NCT01191359|Active Comparator|vestibular administration|oral immunotherapy with drops applied by single dose containers (200 STU per dose)
3325609|NCT02054871|Experimental|EGFR 30-60|"Experimental: RIPC Remote preconditioning Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles."
3325610|NCT02054871|Experimental|EGFR 60-90|Experimental: RIPC Remote preconditioning. EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Preconditioning will be performed in the same manner as several previous trials. Immediately prior to angiography a CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
3325611|NCT02054871|No Intervention|EGRF 30-60|"No Intervention: Remote preconditioning control Calculated EGFR based on MDRD. Patients receive intravenous fluids preprocedure as additional renal protection.~Patients randomised to this group will receive routine care."
3325612|NCT02054871|No Intervention|EGRF 60-90|No Intervention: Remote preconditioning control EGFR calculated using MDRD equation. Oral hydration pre-procedural as reno-protective measure. Patients randomised to this group will receive routine care.
3325613|NCT02054884|Experimental|Arm A: F16IL2 in combination with paclitaxel|
3325614|NCT02054884|Experimental|Arm B: Paclitaxel|
3325615|NCT02054923|Experimental|Routine video recording group|Intervention: Procedure: Implementation of routine videorecording of colonoscopy withdrawal
3230442|NCT01191372|Placebo Comparator|saline for injection|
3325616|NCT02054923|Active Comparator|Control group|Intervention: Behavioral: No routine videorecording (on demand videorecording possible)
3325617|NCT02054936|Active Comparator|Rivaroxaban (Xarelto)|Rivaroxaban dosing will be 10mg once daily beginning on postoperative day 1 for a duration of 30 days.
3325618|NCT02054936|Active Comparator|Warfarin (Coumadin)|Warfarin dosing will be titrated to achieve an INR of 2-3 and dosing will begin on postoperative day 1 for a duration of 30 days.
3325619|NCT02054949|Experimental|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
3325620|NCT02054962||Elderly|The investigators intend to asses the effect of fear of movement, PTSD symptoms, and physical activity on persistent pain and functional decline.
3325621|NCT02054975|Experimental|vitamin D2 + vitamin D3|Vitamin D2 50,000 IU each week x 4 + vitamin D3 4,000 IU each day for 3 months
3325622|NCT02054975|Active Comparator|Vitamin D lower dose|800 IU vitamin D3 by mouth each day for 3 months
3325623|NCT02054988|Experimental|caffeine|"three cups of coffee will be administered for 10 days (on chronic phase) and two cups of coffee will be consecutively administered for acute evaluation."
3325624|NCT02054988|Active Comparator|not caffeine|not caffeine will be administered for the duration of the study
3325625|NCT02055014|Active Comparator|Liraglutide alone|Liraglutide 1.8mg once daily subcutaneous injection
3230443|NCT01191372|Experimental|ARC19499 Low Dose|
3230444|NCT01191372|Experimental|ARC19499 Mid Dose|
3325626|NCT02055014|Experimental|Endobarrier alone|Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy
3325627|NCT02055014|Experimental|Endobarrier and Liraglutide|Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection
3325628|NCT02055027||Adherent Patients|Comparison between groups
3325629|NCT02055027||Non-adherent patients|Comparison between groups
3325630|NCT02055066|Experimental|Arm 1|ARGX-111 0.3 mg/kg
3325631|NCT02055066|Experimental|Arm 2|ARGX-111 1.0 mg/kg
3325632|NCT02055066|Experimental|Arm 3|ARGX-111 3.0 mg/kg
3325633|NCT02055066|Experimental|Arm 4|ARGX-111 10 mg/kg
3325634|NCT02055079|Experimental|Sirolimus|Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months.
3230445|NCT01191372|Experimental|ARC19499 High Dose|
3230446|NCT01191385||Group 1|
3230447|NCT01191424|Experimental|CHF1535 NEXT DPI|Male and female adolescents and adult patients (≥ 12 years old) treated with CHF1535 NEXT DPI
3325635|NCT02055079|Placebo Comparator|Placebo|Fixed oral dose of placebo (blinded) once weekly for 24 months.
3325636|NCT02055092||YOD-FTD|Young onset dementia - frontotemporal dementia, 38 persons with their respective family members.
3325637|NCT02055092||YOD-AD|Young onset dementia - Alzheimer's disease, 50 persons with their respective family members.
3325638|NCT02055092||LOD|Late onset dementia >= 70 years of age; Control group of 100 persons with dementia (mostly AD and AD/vascular) and their respective family members. Data already collected in a previous study.
3325639|NCT02055105|Other|miRNA|
3325640|NCT02055131|Placebo Comparator|aspirn fixed dose|patients of this arm will receive 100 mg of aspirin daily.over the period of follow up we will detect all thromboembolic events.
3325641|NCT02055131|Placebo Comparator|aspirin dose titrated with PFA-100|patients of this arm will receive 100 mg of aspirin daily.this dose will be multiplied whenever the PFA-100 is not suitable.once the time of occlusion is correct ,we will keep the same dose of aspirin and continue monitoring the PFA-100 durin the follow up period.
3325642|NCT02055131|No Intervention|placebo arm|in this group of patients we will just supervise thromboembolic events of the vascular access.
3325643|NCT02055144||Non squamous histology|patients with advanced, non-squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and pemetrexed. Maintenance with pemetrexed is allowed.
3325644|NCT02055144||Squamous histology|patients with advanced squamous non-small cell lung cancer treated with cisplatin (or carboplatin) and gemcitabine
3325645|NCT02055170|Experimental|finasteride|finasteride 5mg po od from study entry to date of surgery
3325646|NCT02055183||Participants treated with BAT®|Any patient of any age with a confirmed or suspected exposure to botulinum toxin who were treated with BAT®.
3325647|NCT02055196|Experimental|Treatment (neuronal stem cells, irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells via intracerebral catheter on day 1 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Patients also receive irinotecan hydrochloride IV over 90 minutes on day 3 of week 1; weeks 1 and 3, weeks 1, 2, and 3; or weeks 1, 2, 3, and 4. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3325653|NCT02055261|Other|OFF PPN DBS-ON PPN DBS|Patients randomly allocated to the order OFF Low frequency DBS of the pedunculopontine nucleus then ON Low frequency DBS of the pedunculopontine nucleus
3325654|NCT02055261|Other|ON PPN DBS - OFF PPN DBS|Patients randomly allocated to the order ON Low frequency DBS of the pedunculopontine nucleus then OFF Low frequency DBS of the pedunculopontine nucleus
3325655|NCT02055274|Experimental|LY03003|4 Stable doses of LY03003 14, 28, 42 and 56 mg
3230448|NCT01191424|Active Comparator|Free combination BDP and FF|Male and female adolescents and adult patients (≥ 12 years old) treated with a free combination of licenced BDP and FF
3230449|NCT01191450|Active Comparator|Higroton®|Chlorthalidone 25mg - one oral tablet a day in the morning
3325656|NCT02055274|Active Comparator|Neupro|Neupro patch 2 mg/24 hours in the first week, and then be titrated to 4, 6 and 8 mg/24 hours at weekly intervals
3325657|NCT02055274|Active Comparator|Neupro PK|Neupro patch 2 mg/24hr in the first week then titrated to 4 and 6mg/24hr
3325658|NCT02055287|Experimental|LY03004- 12.5|LY03004 dosage strength at 12.5mg
3325659|NCT02055287|Experimental|LY03004 - 25|LY03004 Dose Strength 25mg
3325660|NCT02055287|Experimental|LY03004- 37.5|LY03004 Dose Strength 37.5mg
3325661|NCT02055287|Experimental|LY03004 - 50|LY03004 Dose Strength 50mg
3325662|NCT02055300|Experimental|LY03005 - 20|LY03005 Dose Strength 20mg
3230450|NCT01191450|Experimental|Diupress®|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning
3325663|NCT02055300|Experimental|LY03005 - 40|LY03005 Dose Strength 40mg
3325664|NCT02055300|Experimental|LY03005- 80|LY03005 Dose Strength 80mg
3325665|NCT02055300|Experimental|LY03005 - 120|LY03005 Dose Strength 120mg
3325666|NCT02055300|Experimental|LY03005 - 160|LY03005 Dose Strength 160 mg
3230451|NCT01191463|Experimental|Mung Bean Meals and Guava fruit|Subject in this group will receive, a lunch meal based on 50g of Mung beans together with a local, Vitamin C rich fruit (Guava)
3230452|NCT01191463|Active Comparator|Mung Bean|Subjects in this group will receive a lunch meal based on 50g mung beans but without any vitamin C source.
3325667|NCT02055300|Experimental|LY03005 - 200|LY03005 Dose Strength 200mg
3230453|NCT01191463|No Intervention|School feeding program|Subjects in this arm, will receive the regular school feeding program as provided by the school authorities
3325668|NCT02055300|Experimental|LY03005 - 120 - Fed|LY03005 120mg under Fed Conditions
3325669|NCT02055300|Active Comparator|Pristiq|Pristiq - 50mg
3325670|NCT02055300|Placebo Comparator|Placebo|Placebo
3325671|NCT02055326|Experimental|Yoga|One-hour sessions of twice weekly yoga for 8 weeks.
3325672|NCT02055326|Active Comparator|Health & Wellness|8 week program of health & wellness classes, materials and handouts. Topics included healthy eating, cancer prevention and cardiovascular disease prevention.
3325673|NCT02055339|Experimental|Fisher & Paykel heated humidified high flow nasal cannula|For neonates randomized to HHHFNC, they will be placed on a flow rate equivalent to the pressures of nCPAP they were originally receiving based on a published chart, or stay on the same flow rate prior to randomization. When it is time for oral feeds, the Registered Nurse (RN) will turn the dial of the high flow circuit down to 2 lpm. The baby will then proceed to feed for up to one hour, and afterwards, will be turned back up to the flow rate they were on prior to feeds.
3325674|NCT02055339|Active Comparator|InfantFlow/RAM nasal continuous positive airway pressure|Neonates randomized to the nCPAP arm will remain on the nCPAP pressures they were on before recruitment into the study or match the flow rate they were receiving on high flow based on a published chart. The nCPAP circuit will only be removed when it is time for oral feeds. The respiratory therapist (RT) will exchange the circuit for a low flow nasal cannula which will be set at the flow that is optimal for the baby's gestational age saturations. The baby will then proceed to feed for up to one hour, and afterwards, will be changed back to the nCPAP circuit.
3325675|NCT02055378|Experimental|auricular acupoint stimulation|Five auricular acupoints were selected for taping stimulation by using a 1-mm alloy ball by fingers three times a day, each time for five minutes over the five selected acupoints. Topical 0.125% atropine was given nightly.
3230454|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in high risk patients|
3230455|NCT01191489|Active Comparator|Non-invasive mechanical ventilation in High Risk Patients|
3230456|NCT01191489|Experimental|High Flow Conditioned Oxygen Therapy in Low Risk Patients|
3325676|NCT02055378|Active Comparator|Atropine|topical 0.125% atropine was given nightly during the study period.
3325677|NCT02055391|Active Comparator|Behavioral Weight Loss|State of the art behavioral weight loss treatment
3325678|NCT02055391|Experimental|Enhanced Behavioral Weight Loss|Combines behavioral weight loss skills with skills specifically targeting emotional eating.
3325679|NCT02055417|Experimental|Personal Approaches to Treatment Choices for HIV|PATCH is a brief intervention designed to support participants' decision-making processes and enhance intrinsic motivation to initiate ART.
3325680|NCT02055417|Active Comparator|Stress Reduction Skills Program|SRSP includes training in stress reduction skills such as relaxation, problem solving, and expressing negative feelings.
3230457|NCT01191489|Active Comparator|Conventional Oxygen Therapy in Low Risk Patients|
3325681|NCT02055443||Holter monitor group|12-lead holter monitor application
3325682|NCT02055456|Experimental|Nandrolone Decanoate|Nandrolone Decanoate intramuscularly administered, every two weeks, 5 mg/kg/dose
3230458|NCT01191502||TECNIS MULTIFOCAL (TMF) INTRAOCULAR LENS|
3230459|NCT01191502||CRYSTALENS HD (CHD) INTRAOCULAR LENS|
3325683|NCT02055482|Experimental|BAY85-3934|
3325684|NCT02055482|Active Comparator|Darbepoetin|
3325685|NCT02055508|Experimental|Exercise Intervention Program (EIP)|"Inpatient periods: The combined resistance and endurance program consist of free weight and rubber band training for major upper and lower body muscle groups respectively of cycling/walking on an ergometer/treadmill 3x/week.~Outpatient periods (3x/week at least two/one supervised training sessions): Supervised training sessions in the local outpatient training center will comprise of resistance exercise on machines and endurance training on an ergometer/treadmill. For non-supervised training session during the outpatient period participants will receive an exercise manual for individualized home-based exercising.~In weekly phone calls, the advanced practice nurse will review adherence to the intervention and identify problems. Furthermore, the patients will also be asked the same questions as in the CMPC group."
3325686|NCT02055508|Active Comparator|Care-Management-Phone-Calls (CMPC)|"Patients in this arm will receive a weekly care-management-phone-call (CMPC), performed by an advanced practice nurse (APN). The CMPCs are based on a structured questionnaire, reflecting pain, shortness of breath, disturbed sleep, exhaustion and distress and potentially treatment related side effects (e.g. infections, polyneuropathy, etc.). In case of demanding management of symptoms or complaints (e.g. uncontrolled pain or breathlessness) the treating physician is contacted by the APN to facilitate improvement."
3230460|NCT01191515||Near visual outcomes with Monofocal IOL|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
3230461|NCT01191515||Intermediate Visual outcomes|Evaluation of intermediate visual outcomes of patients undergoing routine cataract surgery with phacoemulsification and monofocal IOl placement in the capsular bag in at least one eye.
3325687|NCT02055534|Experimental|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the Amyloidosis Center
3325688|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the Amyloidosis Center
3230462|NCT01191554|Experimental|High dosage|A loading dose of 30 mg/kg and a maintenance infusion of 16 mg/kg through out the operation, and 2 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
3325689|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and matching placebo (PBO) in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325690|NCT02055547|Experimental|Part 1 - Panel A - PBO > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325691|NCT02055547|Experimental|Part 1 - Panel A - MK-8521 100μg > MK-8521 300μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg in the first treatment period, and MK-8521 300μg in the second treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325692|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > PBO > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, PBO in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3230463|NCT01191554|Experimental|Low dosage|A loading dose of 10 mg/kg and a maintenance infusion of 1 mg/kg through out the operation, and 1 mg/kg into the cardiopulmonary bypass (CPB) prime volume.
3230464|NCT01191567|Active Comparator|Conventional treatment|
3230465|NCT01191567|Experimental|VAC treatment|
3230466|NCT01191580|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy is a brief, manualized therapy that has shown efficacy in treating major depression in several controlled trials including a large trial for depressed HIV-infected individuals and other randomized trials in depressed individuals with other comorbid medical illnesses. Research shows that Interpersonal Psychotherapy improves social skills and functioning. Interpersonal Psychotherapy has shown remarkable flexibility and efficacy across age ranges, cultures, formats, and modes of delivery. We recently obtained promising pilot data in a small open trial on the acceptability and efficacy of individual IPT for depressed breast cancer patients of diverse ethnic background, socioeconomic status, and cancer progression stage.
3230467|NCT01191580|Experimental|Problem-Solving Therapy|Problem-Solving Therapy is a brief, manualized form of cognitive-behavioral therapy (CBT) that has been adapted to treat depression in cancer patients, and has shown highly promising results.
3230468|NCT01191580|Active Comparator|Brief Supportive Psychotherapy|Brief Supportive Psychotherapy, a relatively unstructured psychotherapy commonly used in clinical practice, focuses on the patient's affect. It builds a strong therapeutic alliance through careful, empathic listening and validating and encouraging toleration of the patient's emotions. It has shown promising results in depressed individuals with cancer and other medical illnesses.
3230469|NCT01191593|Experimental|Adductor-Canal-Blockade with ropivacaine|
3230470|NCT01191593|Placebo Comparator|Adductor-Canal-blockade with saline|
3230471|NCT01191606|Active Comparator|Group A|the exchange of ventilatory mode from volume controlled ventilation to pressure controlled ventilation
3230472|NCT01191606|Active Comparator|Group B|the exchange of ventilatory mode from pressure controlled ventilation to volume controlled ventilation
3230473|NCT01191619|Experimental|McIvor group|groups in which proseal laryngeal mask airway is inserted with McIvor retractor.
3230474|NCT01191632|Active Comparator|Radiation 0,5Gy|"Radiation: one time Radiation with an intensity of 0.5 Gy Group A~Beginning on a weekday 48 hours before surgery"
3230475|NCT01191632|Active Comparator|No radiation|Control group with 0Gy radiation
3325693|NCT02055547|Experimental|Part 1- Panel B- MK-8521 150μg > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325694|NCT02055547|Experimental|Part 1 - Panel B - MK-8521 150μg > MK-8521 200μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 150μg in the first treatment period, MK-8521 200μg in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325695|NCT02055547|Experimental|Part 1 - Panel B - PBO > MK-8521 200μg > MK-8521 175μg|Healthy male participants of 18 to 45 years of age received PBO in the first treatment period, MK-8521 200μg in the second treatment period, and MK-8521 175μg in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3230476|NCT01191632|Active Comparator|Radiation 2Gy|"Radiation: one time Radiation with an intensity of~2.0 Gy Group B~Beginning on a weekday 48 hours before surgery"
3230477|NCT01191632|Active Comparator|Radiation 5Gy|"Radiation: one time Radiation with an intensity of~5 Gy Group C Beginning on a weekday 48 hours before surgery"
3325696|NCT02055547|Experimental|Part 2 - Panel C - MK-8521 50μg > MK-8521 72μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 50μg Days 1 to 5 and MK-8521 72μg Days 6 to 10 in a single treatment period.
3325697|NCT02055547|Experimental|Part 2 - Panel D - MK-8521 100μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 100μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
3230478|NCT01191645|Experimental|Primperan|
3230479|NCT01191645|Active Comparator|Naloxon|
3230480|NCT01191645|Placebo Comparator|Natriumklorid|
3230481|NCT01191645|Experimental|Ultiva|
3230482|NCT01191684|Experimental|Treatment (vaccine therapy)|Patients receive MVAp53 subcutaneously on days 0, 21, and 42 in the absence of unacceptable toxicity.
3325698|NCT02055547|Experimental|Part 2 - Panel E - MK-8521 125μg > MK-8521 150μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg Days 1 to 5 and MK-8521 150μg Days 6 to 10 in a single treatment period.
3325699|NCT02055547|Experimental|Part 2 - Panel F - MK-8521 72μg > MK-8521 125μg|Obese male participants of 45 to 65 years of age received a single dose of MK-8521 72μg Days 1 to 7 and MK-8521 125μg Days 8 to 14 in a single treatment period.
3325700|NCT02055547|Placebo Comparator|Part 2 - Panels C+D+E - Pooled Placebo|Healthy male participants of 18 to 45 years of age received PBO once daily for 10 days.
3325701|NCT02055547|Placebo Comparator|Part 2 - Panel F - Placebo|Obese male participants of 45 to 65 years of age received a single dose of PBO Days 1 to 14.
3325702|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > MK-8521 35μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, MK-8521 35μg (low dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325703|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > PBO > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, PBO MK-8521 in the second treatment period, and 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3230483|NCT01191697|Experimental|Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine|"Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine for patients with HER2-positive metastatic esophagogastric cancer. Each cycle is 21 days.~Cycle 1, Day 1 Trastuzumab (loading dose) 4mg/kg IV~Cycle 2, Day 1 and all Subsequent Cycles Bevacizumab (7.5mg/kg) IV Trastuzumab (6mg/kg) IV Oxaliplatin (130mg/m2) IV Capecitabine (1200mg/m2) PO (taken Days 1-14 of each cycle)~Patients remained on treatment until disease progression, intercurrent illness that prevented further administration of treatment, unacceptable adverse events, participant decision to withdraw consent or general or specific changes in the participant's condition that rendered the participant unacceptable for further treatment."
3230484|NCT01191710|Experimental|Antagonist group|Antagonist protocol for IVF
3325704|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 125μg > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 125μg (high dose) in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325705|NCT02055547|Experimental|Part 3 - Panel H - PBO > MK- 8521 35μg > MK-8521 125μg|Healthy male participants of 18 to 45 years of age received a single dose of PBO in the first treatment period, MK- 8521 35μg (low dose) in the second treatment period, and MK-8521 125μg (high dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325706|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 125μg > PBO > MK-8521 35μg|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 125μg (high dose) in the first treatment period, PBO in the second treatment period, and MK-8521 35μg (low dose) in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325707|NCT02055547|Experimental|Part 3 - Panel H - MK-8521 35μg > MK-8521 125μg > PBO|Healthy male participants of 18 to 45 years of age received a single dose of MK-8521 35μg (low dose) in the first treatment period, MK-8521 125μg (high dose) in the second treatment period, and PBO in the third treatment period. There was a minimum of a 7-day washout period between treatment periods.
3325708|NCT02055560||PK-Guided Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was monitored and optimized using PK-guided dose adjustment.
3230485|NCT01191710|Active Comparator|Agonist group|Long Agonist protocol for IVF
3230486|NCT01191775|Experimental|PNT2258|PNT2258 is composed of PNT100, a 24-mer oligonucleotide, the active drug substance encapsulated in a liposome.
3325709|NCT02055560||BSA Cohort|CRC patients who were treated with 5-FU containing therapy regimen where 5-FU dosing was done according to body surface area (BSA) and no PK monitoring was performed.
3230487|NCT01191814|Active Comparator|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
3325710|NCT02055573|Experimental|Ready To Learn|1) The Ready to Learn (RTL) arm will receive a DVD in both Spanish and English and a bilingual booklet (both produced by Parents' action for Children) addressing the benefits of reading, talking and playing with young children, as well as a new children's board book.
3325711|NCT02055573|Experimental|All Babies Cry|2) The All Babies Cry (ABC) arm will receive a DVD in both, Spanish and English and a bilingual booklet (both produced by VIDA Health Communications, INC) explaining crying as part of normal infant behavior, highlighting signs of parental distress and providing strategies to sooth parents and their children
3325712|NCT02055586||Diagnostic (FLT-PET/MRI)|Patients undergo FLT-PET/MRI twice at baseline and once within 4 weeks after start of treatment.
3325713|NCT02055625|Experimental|Mesenchymal stromal cell treatment|Biological: Mesenchymal stromal cells
3325714|NCT02055651||Bayer Sao Paulo employees|Workers from Bayer in site Socorro who participate in the trial
3325715|NCT02055664|Experimental|treatment|
3325716|NCT02055664|Placebo Comparator|control|
3325717|NCT02055690|Experimental|Phase Ib/II: Fosbretabulin & Pazopanib|"Phase Ib:~Fosbretabulin and Pazopanib in combination. Fosbreatabulin dose will be in the range of 45mg/m2- 60 mg/m2 delivered by infusion every week for 3 weeks of a 4 week cycle until disease progression. Pazopanib will be either 600 mg or 800mg taken orally each day of 28 day cycle until disease progression.~The phase II dose of both drugs will be determined by the Phase Ib component which is a dose finding exercise.~Phase II:~Fosbretabulin and Pazopanib in combination. Fosbretabulin 54mg/m2 delivered by infusion every week for 3 weeks of a 4 week for 28 day cycle until disease progression. Pazopanib 600mg taken orally each day for 28 day cycle until disease progression"
3230488|NCT01191814|Active Comparator|Plastic Stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a plastic stent
3230490|NCT01191866||Diabetes mellitus|All children and adolescents with type 1 diabetes mellitus attending Assaf Harofeh Pediatric Diabetes Clinic
3325718|NCT02055690|Active Comparator|Phase II: Pazopanib|Pazopanib 800mg taken orally each day of 28 day cycle until disease progression
3325719|NCT02055703|Experimental|E2609|Experimental drug for Parts A, B, and C
3325720|NCT02055703|Active Comparator|itraconazole|Comparator drug for Part A1
3325721|NCT02055703|Active Comparator|rifampin|Comparator drug for Part A2
3325722|NCT02055703|Active Comparator|digoxin|Comparator drug for Part B
3230491|NCT01191879||acute MI group|Patients presenting with acute ST elevation myocardial infarction, admitted to the intensive cardiac care unit and that are planned for emergency primary PCI
3230492|NCT01191879||Controls|Patients undergoing a non-invasive evaluation of possible myocardial ischemia.
3325723|NCT02055703|Active Comparator|donepezil|Comparator drug for Part C
3325724|NCT02055716|Placebo Comparator|alpha-cyclodextrin|A placebo comparator composed of the same acid resistant HPMC capsules filled with 300mg of alpha cyclodextrin
3325725|NCT02055716|Experimental|Sulforadex|100mg or 300mg size 00 acid resistant HPMC capsules
3325726|NCT02055729||The study population|"The proposed study is a prospective, single-center pilot study lasting 28 days. Our goal is to study the temporal evolution of the bacterial communities present in the skin and digestive flora (stool) of spinal cord injured persons having one or more sacral bedsores. The study timespan can include treatment initiation, notably of antibiotics. Urinalysis for studying urinary flora will simultaneously occur.~For a description of the study population, see the inclusion/exclusion criteria.~Intervention: Superficial bedsore sample Intervention: 3mm tissue punch biopsy Intervention: Stool sample Intervention: Urine sample"
3325727|NCT02055742||Specimen Collection|
3325728|NCT02055794|Active Comparator|Suturing of the perineal skin|Suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3325729|NCT02055794|Active Comparator|No suturing of the perineal skin|No suturing of the perineal skin after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3230493|NCT01191892|Placebo Comparator|Placebo|Carboplatin, Gemcitabine and Placebo
3230494|NCT01191892|Experimental|vandetanib|Carboplatin, Gemcitabine and vandetanib
3325730|NCT02055794|Active Comparator|Closing perineal skin with surgical glue|Closure of the perineal skin with n-Butyl 2-cyanoacrylate (Indermil®) surgical glue after deep vaginal and perineal tissues are closed using a continuous 3-0 Vicryl suture.
3325731|NCT02055807|Experimental|PEEP and recruitment maneuvers|A PEEP of 7 cm H2O will be applied starting after intubation until the end of surgery. Recruitment maneuvers (continuous positive pressure of 30 cm H20 for 30 seconds) will be initiated following intubation and repeated every 30 minutes during surgery and immediately prior to extubation. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
3325732|NCT02055807|Active Comparator|ZEEP (Zero end-expiratory pressure)|No PEEP nor recruitment maneuvers will be used during surgery. Lung ultrasound examinations will be performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis.
3325733|NCT02055833|Experimental|Intensive nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy) + n-3 polyunsaturated fatty acids-enriched oral nutritional supplements (1-2 bottles/day)
3325734|NCT02055833|Active Comparator|Nutritional counseling|Nutritional counseling (follow-up visits once a week for 6 weeks [during radiotherapy] and at 1 month and at 3 months since the end of radiotherapy)
3325735|NCT02055846|Experimental|prostate cancer|Realisation of blood sample, urinary sample and tumor biopsy
3325736|NCT02055859|Other|single session radiosurgery|single session radiosurgery (gold standard)
3325737|NCT02055859|Experimental|multisession radiosurgery|multisession radiosurgery (3 fraction)
3325738|NCT02055872|Experimental|Intravenous albumin|Administration of 25% albumin by intravenous infusion, twice daily for a total of 72 hours (6 treatments)
3230495|NCT01191905|Experimental|High dose CRRT|Clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
3325739|NCT02055872|Placebo Comparator|Normal saline|Administration of 100 mL normal saline by intravenous infusion, twice daily, for 72 hours (6 treatments)
3325740|NCT02055885||Positive responders|Positive responders (R+): patients exhibiting an increase in the 6WT distance ≥ 10% and/or a decrease in dyspnea ≥ 10% (i.e., ≥ 1 point on the visual analogue scale).
3325741|NCT02055885||negative responders|Negative responders(R-): patients exhibiting a decrease in the distance ≥ 10% and/or an increase in dyspnea ≥ 10%.
3325742|NCT02055911|Experimental|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
3325743|NCT02055924|Experimental|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
3325744|NCT02055937|Experimental|immediate implant breast reconstruction|immediate implant breast reconstruction
3325745|NCT02055950||Kidney perfused by pulsatile machine|
3230496|NCT01191905|Active Comparator|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
3230497|NCT01191918|Experimental|donepezil|donepezil plus Lithium
3230498|NCT01191918|Placebo Comparator|Control|Placebo plus Lithium
3230499|NCT01191931||prostate cancer|Patients with histologically proven prostate cancer (positive biopsy) and who are planned to undergo radical prostatectomy.
3325746|NCT02055950||Kidney stored in refrigerated solution|
3325747|NCT02055963|Experimental|Minocycline|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Minocycline100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
3230500|NCT01191957|Active Comparator|I. V. Busulphan plus Cyclophosphamide|Conventional conditioning regimen with intravenous (i.v.) Busulphan (Busilvex), 12.8 mg/kg followed by Cyclophosphamide, 120 mg/kg iv.
3325748|NCT02055963|Placebo Comparator|Placebo|"Participants take study medication twice daily, starting 2 days prior to surgery, and continue for 3 weeks postsurgery. The final day of study medication will be the 21st day after surgery.~Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery).~Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21."
3325749|NCT02055989|Experimental|Dose-escalated radiotherapy level 1|
3325750|NCT02055989|Experimental|Sequential dose-escalated radiotherapy level 2|
3325751|NCT02056002|Active Comparator|Usual Care|"Standard CPAP educational training~Educational Brochures~Educational DVD videos mailed to participant"
3325752|NCT02056002|Experimental|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~-Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
3325753|NCT02056015|Experimental|[68Ga]MLN6907|
3325754|NCT02056028||Bile leak after hepatic resection|
3230501|NCT01191957|Experimental|I. V. Busulphan plus Fludarabine|Reduced toxicity conditioning regimen with intravenous (i.v.)Busulphan (Busilvex), 12.8 mg/kg plus Fludarabine, 4 x 40 mg/m².
3230502|NCT01191970||Epidural recipients|Subjects who received epidural analgesia during labor
3325755|NCT02056041||Hepatectomy for HCC|Patients submitted to surgery for HCC
3325763|NCT02056067|Experimental|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
3325764|NCT02056067|Active Comparator|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
3230503|NCT01191970||Non-epidural recipients|Subjects who did not receive epidural analgesia during labor
3230504|NCT01191983|Experimental|Methoxy polyethylene glycol-epoetin beta|Participants will receive 1.2 mcg/kg methoxy polyethylene glycol-epoetin beta given in monthly doses at each visit. Dose will be measured on the basis of the participants Hb level during the study period. The dose administration will be the nearest possible dose using the prefilled syringes containing 50, 75 and 100 mcg/kg Q4W.
3230505|NCT01191996|Experimental|MIS416|MIS416, immunomodulating microparticle, given intravenously weekly
3230506|NCT01192009|Experimental|Immobilization and Leucine|
3325765|NCT02056093|Experimental|Intubated patients|Intubated patients: The three modes (PSV, PAV, NAVA) will be applied in random order to each mechanically ventilated patient included in the study.
3325766|NCT02056106|Active Comparator|Clinical acumen|Depression diagnosis and antidepressant treatment provided based on clinical acumen of primary care providers trained to provide depression care.
3325767|NCT02056106|Active Comparator|Protocolized Arm|Structured, algorithm-based protocol that guides depression diagnosis and antidepressant treatment
3230507|NCT01192009|Placebo Comparator|Immobilization and Placebo|
3230508|NCT01192035|Active Comparator|NNRTI|
3230509|NCT01192035|Active Comparator|Protease inhibitor|
3325768|NCT02056119|Active Comparator|Jet Nebulizer Arm|"The Jet Nebulizer Protocol:~Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
3230510|NCT01192048||Study Subjects|Individuals with Congenital Heart Disease and family members with or without Congenital Heart Disease. A blood sample collection will be required for all study participants.
3230511|NCT01192061||Normal tension glaucoma group|
3230512|NCT01192061||Control group|
3230513|NCT01192074||Ultrasound of the spine|Pregnant women receiving labor epidural analgesia or spinal anesthesia for cesarean delivery
3325769|NCT02056119|Experimental|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
3325770|NCT02056145|Placebo Comparator|Group 1|Group 1 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.9% saline solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 30 ml saline solution 0.9%.
3325771|NCT02056145|Active Comparator|Group 2|Group 2 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.9% saline solution for lateral femoral cutaneous block, for a total of 20 cc 0.25% bupivacaine solution en 10 cc saline solution 0.9%.
3325772|NCT02056145|Active Comparator|Group 3|Group 3 consented subjects who will receive for their hip surgery procedures general anesthesia (sevoflurane) with single shot femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 cc of 0.25% bupivacaine solution for the femoral block and 10 cc of 0.25% bupivacaine solution for lateral femoral cutaneous block, for a total of 30 cc of 0.25% bupivacaine solution.
3325773|NCT02056158||HIV Negative Early COPD Smokers|HIV Negative Early COPD Smokers
3325774|NCT02056158||HIV Negative COPD Smokers|HIV Negative COPD Smokers
3325775|NCT02056158||HIV Negative Nonsmokers|HIV Negative Nonsmokers
3325776|NCT02056158||HIV Negative Smokers|HIV Negative Smokers
3325777|NCT02056158||HIV Positive Smokers|HIV Positive Smokers
3325778|NCT02056158||HIV Positive Nonsmokers|HIV Positive Nonsmokers
3325779|NCT02056158||HIV Positive COPD Smokers|HIV Positive COPD Smokers
3230514|NCT01192087|Experimental|Cetuximab arm|patients receive weekly cetuximab in combination with IMRT and carbon ion boost
3230515|NCT01192113|Experimental|Group A: Diabetic Peripheral Neuropathy (IV)|
3230516|NCT01192113|Experimental|Group B: Diabetic Peripheral Neuropathy (IM)|
3230517|NCT01192113|Experimental|Group C: Idiopathic Peripheral Neuropathy|
3230518|NCT01192113|Experimental|Group D: Nutritional & Metabolic Peripheral Neuropathy|
3230519|NCT01192113|Experimental|Group E: Compression Peripheral Neuropathy|
3325780|NCT02056158||HIV Positive Early COPD Smokers|HIV Positive Early COPD Smokers
3230520|NCT01192165|Experimental|Treatment Group 1|Trametinib plus Docetaxel
3230521|NCT01192165|Experimental|Treatment Group 2|Trametinib plus Erlotinib
3230522|NCT01192165|Experimental|Treatment Group 3|Trametinib plus Pemetrexed
3230523|NCT01192165|Experimental|Treatment Group 4|Trametinib plus Pemetrexed and Carboplatin
3230524|NCT01192165|Experimental|Treatment Group 5|Trametinib plus nab-Paclitaxel
3230525|NCT01192165|Experimental|Treatment Group 6|Trametinib plus Pemetrexed and Cisplatin
3230526|NCT01192217|Active Comparator|VATS group|
3230527|NCT01192217|Active Comparator|Mini-thoracotomy group|
3230528|NCT01192269|Experimental|Docosahexaenoic Acid Supplement|"DHA supplement: Experimental~1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric)."
3230529|NCT01192308|Experimental|40mg QD dose intervention|40mg QD dose intervention during 4 weeks in patients with CYP2D6 variant allele or using CYP2D6 inhibitor.
3230530|NCT01192321|Experimental|Toric T3 - T9|Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
3230531|NCT01192321|Active Comparator|Monofocal|Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.
3325781|NCT02056184|Active Comparator|Adalimumab, masked ultrasound|Adalimumab and blinded ultrasound.
3325782|NCT02056184|Experimental|Adalimumab, unmasked ultrasound|Adalimumab and open ultrasound.
3325783|NCT02056197|Placebo Comparator|Placebo|Shortwave 30 minutes.
3325784|NCT02056197|Active Comparator|Stable|Stable surface exercises
3325785|NCT02056197|Experimental|Unstable|Unstable surface exercises
3325786|NCT02056210|Experimental|Stem cell mobilization in diabetic patients|Injection of Mozobil (Plerixafor / AMD3100) in diabetic patients
3325787|NCT02056210|Experimental|Stem cell mobilization in non diabetic subjects|Injection of Mozobil (Plerixafor / AMD3100) in non diabetic subjects
3325788|NCT02056223|Experimental|paracetamol|Boluses of intravenous paracetamol at 15 mg/Kg four time a day for three consecutive days.
3325789|NCT02056223|Active Comparator|Intravenous ibuprofen|Standard boluses of ibuprofen at 10-5-5-mg/Kg/dose once a day for three consecutive days.
3325790|NCT02056236|Experimental|Anti-epileptic drugs|"Step 1. Lorazepam 4 mg iv (initial dosage) titrated up to a maximum of 12 mg/24 hours OR midazolam 10 mg (initial dosage) up to 60 mg/24 hours (in steps of 5 mg/5 minutes) PLUS Fenytoine bolus i.v. 15-20 mg/kg in 30 minutes, followed by 150 mg 2 dd 1, adapted based on serum levels.~Step 2. Propofol infusion with a maximum of 8 mg/kg/hour PLUS A second anti-epileptic drug in addition to fenytoin: Option 1: levetiracetam bolus 1500 mg, followed by 1000 mg 2 dd 1 intravenously or Option 2: valproic acid bolus 10-20 mg/kg in 30 min, followed by15 mg/kg/day in 2 dosages intravenously.~Step 3. Thiopental, initial dosage 12,5 mg/kg/hr for the first 6 hours followed by 5 mg/kg/hr for 6 hours. After these loading dosages treatment should be guided by the EEG pattern."
3325791|NCT02056236|Active Comparator|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma in both treatment arms. Reasons for withdrawal of treatment will be documented."
3325792|NCT02056249||Healthy, lean subjects|Volunteers without anemia (hematocrit), diabetes (A1c), use of illicit drugs and antidepressants, or any other major health issues.
3325793|NCT02056262||3 to 16 years of age|"Volunteers of 3 to 16 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
3325794|NCT02056262||17 - 45 years of age|"Volunteers of 17 to 45 years of age, coming in to the hospital for a dental consultation. See inclusion/exclusion criteria.~Intervention: Dental cavity evaluation Intervention: Saliva sampling Intervention: Plaque sampling"
3325795|NCT02056275|Experimental|ONS + dietary counseling|ONS/day + dietary counseling
3325796|NCT02056275|Active Comparator|Dietary counseling|Dietary counseling
3325797|NCT02056314|Active Comparator|brochure|The participants will be given a brochure that describes problem gambling and recommends methods of staying in control of gambling such as coping skills.
3325798|NCT02056314|Experimental|electronic tutorial|The participants will be given an electronic tutorial that will explain how to stay in control of their gambling including information about coping skills, warning signs, and information about myths related to gambling.
3325799|NCT02056327||Oral appliance with monitoring suite|Subjects will sleep with a standard oral appliance with the newly developed monitoring suite embedded within it for 1-2 nights while being monitored with standard in lab polysomnography or home sleep testing.
3325800|NCT02056353|Active Comparator|Nurse-directed|Blood glucose control guided by paper protocol
3325801|NCT02056353|Experimental|LOGIC-Insulin|Blood glucose control guided by the LOGIC-Insulin algorithm
3325802|NCT02056366|Active Comparator|α-lipoic acid|α-lipoic acid PO medication, 600mg per day, for 6weeks α-lipoic acid PO medication, 1200mg per day, for 6weeks
3325803|NCT02056366|No Intervention|No treatment group|No Intervention
3325804|NCT02056379|Active Comparator|Budesonide|2 mg of nebulized budesonide at 12/12 hours and 8 cc of intravenous normal saline.
3230532|NCT01192360|Experimental|Cardiac Patients|In addition to the routine clinical MRI, we will conduct the DCE MR perfusion imaging research component. For this, we will measure native pre-contrast T1 and then inject a tight bolus of gadolinium (0.1mmol/kg) while acquiring high temporal resolution T1-weighted 3D contrast dynamics information over the whole thorax while the patient is holding his / her breath. Overall, the research component will prolong the clinical study by approximately 5 minutes.
3230533|NCT01192360|Experimental|Pulmonary Patients|Patients in this group will receive a full cardiac and pulmonary MRI assessment, with the DCE pulmonary perfusion scan added as described above. Overall, the investigation will take approximately 45 minutes
3230534|NCT01192373|Experimental|High circulating free fatty acids|using Heparin af intralipid infusion for 8 hours
3230535|NCT01192373|Active Comparator|Low circulation free fatty acids|using hyperinsulinaemic euglycemic clamp for 8 hours
3325805|NCT02056379|Active Comparator|Dexamethasone|This group will receive 0,15 mg/kg/dose of intravenous dexamethasone at 6/6 hours and 8 cc of nebulized normal saline at 12/12 hours.
3325806|NCT02056405|Placebo Comparator|Placebo|Placebo arm: intake of placebo (Lactose). 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
3325807|NCT02056405|Active Comparator|Mosapride|Mosapride arm: intake of active drug (Mosapride). 15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
3325808|NCT02056418|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
3325809|NCT02056418|Experimental|Corticosteroid|The patients receive treatment of corticosteroid only.
3325810|NCT02056418|No Intervention|Healthy control|healthy people applied with normal diet.
3325811|NCT02056444|Experimental|Topical tranexamic acid (TXA)|Single dose 1.5 grams topical TXA infiltrated into the surgical field at time of arthrotomy closure.
3325812|NCT02056444|Active Comparator|Intravenous TXA|Single 20 mg/kg dose of intravenous TXA administered prior to skin incision.
3325813|NCT02056457|Experimental|Responsible fatherhood or healthy marriage|
3325814|NCT02056457|Experimental|Control|
3325815|NCT02056470|Experimental|Freedom Total Knee Replacement|Freedom Total Knee
3325816|NCT02056483|Experimental|Screening-based nurse navigation|Based on systematic screening for psychological and physical symptoms as well as health behavior a nurse navigator will refer to and monitor use of appropriate rehabilitation programs
3325817|NCT02056483|No Intervention|Usual care|Usual care
3325818|NCT02056496|Experimental|Pomegranate extract|The same group will consume the two types of pomegranate extract (crossover study).
3325819|NCT02056509||Out of hospital cardiac arrest|Out of hospital cardiac arrest of non-traumatic cause
3325820|NCT02056509||Unexpected in-hospital cardiac arrest|Unexpected cardiac arrest during emergency department stay
3325821|NCT02056522||Suspicious skin lesions.|No intervention is administered.
3325822|NCT02056535|No Intervention|Screened Only|Screened only and met criteria for eligibility for study
3325823|NCT02056535|No Intervention|Screened and Assessed|Screened as eligible for the study and received baseline assessment
3325824|NCT02056535|Active Comparator|Intervention|Screened eligible, received baseline assessment and intervention
3325825|NCT02056561||TIVA (group T n: 15)|Group T were given propofol infusions of 12 mg/kg/hr for the first 10 minutes, 9 mg/kg/hr for the second 10 minutes and 6 mg/kg/hr after that. Patients were ventilated with 50% air and 50% O2 mix at 6 L/min flow.
3325826|NCT02056561||Sevoflurane (group S n: 15)|Group S were ventilated with 2% sevoflurane, 50% air and 50% O2 mix at 6 L/min flow.
3325827|NCT02056561||Desflurane (group D n: 15)|Group D cases were given 6% desflurane 50% air and 50% O2 mix at 6 L/min flow.
3325828|NCT02056574|Experimental|NA-1|20 amino acid peptide that consists of a 9 amino acid domain that inhibits PSD-95 and an 11 amino acid domain that enables the peptide to cross the blood-brain barrier. Single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion.
3325829|NCT02056574|Placebo Comparator|Placebo|Single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion.
3325830|NCT02056587|Experimental|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
3325831|NCT02056600|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
3325832|NCT02056600|Experimental|C|Combination of gemigliptin50mg/metformin HCl sustained release 1000mg
3230536|NCT01192438|Experimental|Procedure/surgery|
3230537|NCT01192464|Experimental|autologous CAR.CD30 EBV specific-CTLs|"Group One Dose (CTLs CAR.CD30) at Day 0: 2x10^7 cells/m2~Group Two Dose (CTLs CAR.CD30) at Day 0: 5x10^7 cells/m2~Group Three Dose (CTLs CAR.CD30) at Day 0: 1x10^8 cells/m2"
3325833|NCT02056665|Experimental|MINOCYCLINE 8 weeks|"Duration of treatment: 8 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
3230538|NCT01192477|Experimental|Ozone 0.1 ppm|
3230539|NCT01192477|Experimental|Ozone 0.2 ppm|
3230540|NCT01192477|Sham Comparator|Filtered air|
3230541|NCT01192490|Experimental|Lidocaine Arm|This arm will receive intracervical and cervical lidocaine prior to placement of a Mirena.
3230542|NCT01192490|Placebo Comparator|Lubricant|Subjects in this arm will receive KY gel intracervically and on the cervix prior to placement of a Mirena.
3230543|NCT01192503|Active Comparator|rasagiline|
3230544|NCT01192503|Placebo Comparator|placebo (sugar pill)|
3230545|NCT01192529|Experimental|Experimental Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of Supressi nutritional supplement"
3325834|NCT02056665|Placebo Comparator|PLACEBO 8 weeks|Pill manufactured to mimic Minocycline 50 mg capsule
3325835|NCT02056665|Experimental|MINOCYCLINE 16 weeks|"Duration of treatment: 16 weeks~Patients <35 kg. 100 mg / day. Administered at a dose of one capsule of 50 mg breakfast and dinner.~Patients 35 - 50 kg. 150 mg / day. Administered at a dose of 2 capsules of 50 mg breakfast and 1 capsule of 50mg dinner.~Patients > 50 kg. 200 mg / day. Administered at a dose of two capsules of 50 mg of breakfast and dinner."
3230546|NCT01192529|Active Comparator|Control Group|"In addition to their daily diet, patients of this group will receive 400 ml per day of T-Diet plus High Protein product"
3230547|NCT01192555|Experimental|Treatment Plan|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells) and Cytoxan (Cyclophosphamide)
3230549|NCT01192581|No Intervention|control|routine treatment for brain hypoperfusion
3230550|NCT01192581|Experimental|Vuloven1|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
3230551|NCT01192581|Experimental|Vuloven2|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
3230552|NCT01192581|Experimental|Vuloven3|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
3230553|NCT01192594|Experimental|MAPP Trained Case Managers|Consumers assigned to case managers who receive training in the Milestones of Adjustment Post-Psychosis Recovery Model
3230554|NCT01192594|Active Comparator|Non-MAPP trained case managers|Consumers of case managers not trained in the Milestones of Adjustment Post-Psychosis Recovery Model
3325836|NCT02056678|Active Comparator|IV acetaminophen, OSA, laparoscopic cholecystectomy|IV acetaminophen 1000mg to be administered to obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy
3325837|NCT02056678|No Intervention|OSA, laparoscopic cholecystectomy, narcotics|No IV acetaminophen in obese patients at risk of obstructive sleep apnea intraoperatively during laparoscopic cholecystectomy; patients will receive other modalities for pain control primarily including IV narcotics
3325838|NCT02056691|Experimental|Exercise programme|Exercise programme Muscle biopsies
3325839|NCT02056704|No Intervention|Angiography|Evaluation by angiography only.
3325840|NCT02056704|Experimental|Angiography with IVUS|Evaluation with angiography and intravascular ultrasound.
3325841|NCT02056717|Experimental|Dexamethasone group|
3325842|NCT02056717|Placebo Comparator|Control group|
3325843|NCT02056730|Experimental|Regpara|calcium sensing receptor agonist
3325844|NCT02056743|Experimental|Fermented-red ginseng|"At period 1, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered fermented-red ginseng. At period 2, the fermented-red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
3325845|NCT02056743|Experimental|Red ginseng|"At period 1, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the first day. At second day, they administered Fexofenadine 30mg under fasting conditions.~During 4~17th days they administered red ginseng. At period 2, the red ginseng group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions on the 15th day. At 16th day, they administered Fexofenadine 30mg under fasting conditions."
3325846|NCT02056756|Experimental|CBD|
3230555|NCT01192646|Active Comparator|Home based life saving skills training|Home based life saving skills will done in one the study group and in the control group no training will be done
3230556|NCT01192646|No Intervention|NO HBLSS|No intervention will be given to the control clusters
3325847|NCT02056769|Experimental|CT Perfusion|All patients enrolled in the study
3325848|NCT02056782|Experimental|PGX-ODSH-2013-AML-1|See Intervention Description
3325849|NCT02056795|Experimental|Electroacupuncture|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
3325850|NCT02056795|Sham Comparator|Control|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
3325851|NCT02056808|Experimental|SMT C1100|Patients will be studied in 3 groups (Groups A to C), with each group consisting of 4 patients aged between 5 to 11 years. It is planned that doses for Groups A to C will be administered in an escalating manner after safety review for each dose group.
3325852|NCT02056847|Active Comparator|Pitavastatin calcium 4mg|Pitavastatin calcium (LIVALO®) 4mg, once a day
3230557|NCT01192659||Patients treated with saxagliptin or placebo|Patients will be treated with saxagliptin or placebo, on top of whatever baseline treatment for diabetes the patient is already receiving.
3325853|NCT02056847|Active Comparator|Pitavastatin calcium 2mg|Pitavastatin calcium (LIVALO®) 2mg, once a day
3325854|NCT02056860||Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
3325855|NCT02056860||Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
3325856|NCT02056860||Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz 2 .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
3325857|NCT02056860||Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
3230558|NCT01192659||Patients currently or previously on treatment|Patients currently or previously on (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics are excluded.
3230559|NCT01192672|Experimental|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
3230560|NCT01192672|Active Comparator|Control Writing|The participants were instructed to write for 30-minute intervals for 4 consecutive days about all of the actions they performed that day for a 24 hour period. The subjects were asked not to write about their feelings or thoughts related to these actions.
3325858|NCT02056860||Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
3230561|NCT01192672|No Intervention|Usual Care|Subjects in this group did not receive an intervention. They filled out measures at baseline, 1 month, and 3 month follow-up time periods.
3259142|NCT01467843|Active Comparator|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR arm will attend eight weekly 2 hour MBSR sessions.
3259143|NCT01467843|No Intervention|Usual Care|Participants randomized to Usual Care will continue to receive care for their low back pain as prescribed by his/her Primary Care Physician.
3259144|NCT01467856||chronic tetraplegia|
3325860|NCT02056886|Experimental|OSNA|"Intra operative sentinel lymph-node sampling. In this experimental arm, the molecular biology technique is only used through the OSNA technique (One Step Nuclear Acid analysis), and no other classical pathology's diagnosis method such as formalin fixation, then parraffin embedding before slices cutting, hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy is immediately decided if a tumor invasion is detected within the sentinel LN material."
3230562|NCT01192685|Other|Depressed outpatients treated with TMS|This a 12- week study (1-4 week screening, 6 weeks treatment, 2 weeks follow-up) outpatient open label clinical trial. Twenty-five subjects diagnosed with depression with a Montgomery Asberg Depression Rating Scale (MADRAS) score of 26 or higher, will be enrolled into this trial, up to fifty subjects will be consented. Transcranial Magnetic Stimulation (TMS) will be administered to subjects 5 days a week for 6 weeks. Near infrared spectroscopy (NIRS), a spectroscopic method that uses the near infrared region of the electromagnetic spectrum (from about 700 nm to 2500 nm), will be used to assess blood flow in the brain.
3230563|NCT01192711|Experimental|insulin + DID|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections per day of insulin glulisine associated with basal insulin glargine; the DID will be used to estimate the CHO content of the food intended to eat. Insulin doses in this group will be adjusted based on DID calculations and pre-meal BG values.
3230564|NCT01192711|No Intervention|insulin + usual care|Three prandial (before or at the end of meal administration, based on doctor counselling and patient decision) injections of insulin glulisine associated with basal insulin glargine. Insulin doses in group B will be adjusted based on SMBG values reviewed during the doctor office visit.
3325861|NCT02056886|Other|PATHOLOGICAL ANALYSIS|"No intra operative examination is performed in this arm, but the final pathological examination:~In this arm, the classical pathology's diagnosis method is starting with a formalin fixation of suspected invaded lymph-nodes sampling at least 24Hrs; then parraffin embedding before slices cutting; then hematoxylin-eosin-safran staining or any other immunohistochemical stainings.~According to the results of the staging procedure, the treatment in this arm is decided in conformity with local and national updated guidelines in breast cancer treatments.~SLN detection +/- complementary axillary lymphadenectomy: is decided in a second surgical step when the pathologic analysis has detected a tumor invasion"
3325862|NCT02056886|Other|EXTEMPORANEOUS|"Intra-operative pathological frozen sections of sentinel LN samples are coloured and examined immediately by the pathologist, allowing an immediate result at the disposal of the surgeon who can decide to complete by an axillary LN dissection or not.~Then the remaining material will be prepared similarly as in the pathological classical method (Arm B), ie formalin fixation, then parraffin embedding, then slices cutting, then HES staining or ImmunoHistochemistry for a final diagnosis.~SLN detection +/- complementary axillary lymphadenectomy: is decided immediately when the tumor invasion is detected in the sentinel LN material."
3325863|NCT02056899|Experimental|Gabapentin|
3325864|NCT02056912|Other|Lipodystrophie Héréditaire|
3325865|NCT02056925|Experimental|Experimental|
3325866|NCT02056938|Experimental|ATG|"The first infusion of Thymoglobuline® begins before the kidney reperfusion. In case of a patient with a functional arteriovenous fistula or a high-flow venous catheter, the infusion of Thymoglobuline® can begin just after the randomization pre operatively. When the patient has no available arteriovenous fistula for the Thymoglobuline® infusion, it is necessary to install a high-flow vein (central vein) by the anesthesiologist, and to begin the perfusion as soon as possible intra-operatively before the reperfusion of the kidney. The dose of Thymoglobuline® per infusion is 1.5mg/kg. The duration of each infusion is between 6 to 24 hours.~The total duration of the Thymoglobuline® administration is 4 days (starting at and including the first day of the surgery)."
3325867|NCT02056938|Active Comparator|Basiliximab|The first infusion of Simulect® begins within the two hours before the surgery. There is no need of central venous catheter or arteriovenous fistula to infuse the Simulect®. The duration of the infusion is 30 minutes. Each dose of Simulect® is 20 mg. The first infusion of Simulect® is displayed on Day 0 (within the two hours before the surgery) and the second infusion 3 days afterward (Day 4).
3325868|NCT02056951|Active Comparator|Multidisciplinary rehabilitation|The central objective of inpatient multidisciplinary orthopedic rehabilitation (MOR) is to improve functional health with the main focus on restoring and improving work ability. A MOR lasts on average 23 days with a total extent of therapy of 48 hours on average. MOR is provided by a multiprofessional team consisting of physicians, psychologists, sport therapists, physiotherapists, occupational therapists, masseurs, social workers, dieticians and nurses. The interventions are carried out mainly in open groups.
3325869|NCT02056951|Experimental|Interprofessional rehabilitation|The central objective of the interprofessional rehabilitation (PASTOR) is the development of active self-management of chronic non-specific low back pain. PASTOR is matched to the MOR with respect to the total duration and total extent of therapy, the included professions and the interventions dimensions (physical, psychological). The differences between PASTOR and MOR are characterized by, a) an integrative combination of profession related modules within a comprehensive and consistent treatment approach, b) an interprofessional and collaborative teamwork based on profession related modules, c) the use of standardized methods, media and materials by all professions in the therapeutic team d) a highly structured and detailed manual for the entire treatment process. The interventions are carried in fixed groups with eight to twelve participants.
3325870|NCT02056964||Post-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain after implementation of the HEART Pathway decision aid.
3325871|NCT02056964||Pre-HEART Pathway Implementation|Data will be collected on patients presenting to the Emergency Department (ED) with chest pain prior to Implementation of the HEART Pathway decision aid.
3230565|NCT01192724|Active Comparator|Triple antiplatelet therapy (TAPT) group|3-month use of cilostazol in addition to dual antiplatelet agent
3230566|NCT01192724|Active Comparator|Dual antiplatelet therapy (DAPT) group|Aspirin and clopidogrel (dual antiplatelet therapy, DAPT) for 1 year
3230567|NCT01192763|Experimental|Arm I|Patients receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10 in the absence of disease progression or unacceptable toxicity. Beginning 7 days after completion of gamma-secretase inhibitor RO4929097, patients undergo complete resection comprising pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy based on the anatomic location of the cancer. Tumor tissue from biopsy and surgery and blood samples are collected periodically for pharmacodynamic studies.
3230568|NCT01192789|Other|Intervention|Severe Pneumonia Treatment by LHWs with Amoxicillin at 90mg/kg/day for severe pneumonia
3230569|NCT01192789|Other|Control|LHWs refer the severe pneumonia case to local health facility or private practitioner.
3230570|NCT01192802|Active Comparator|1 dose, Albendazole , tablet|
3325872|NCT02056977|Experimental|Titration|Individualized PEEP titration by EIT
3325873|NCT02056977|Active Comparator|Control|PEEP stablished according to the routines at the institution (PEEP table according to the P/F ratio)
3325874|NCT02056990||training advise|
3325875|NCT02057003||DAA-based therapy against HCV|HIV/HCV-coinfected patients who start therapy against HCV including one or more DAA
3325876|NCT02057029|Other|BCI Assay Results|The Breast Cancer Index (BCI) is a novel gene expression-based prognostic predictor for ER positive cancers and is provided through a CLIA certified commercial laboratory. It is an RT-PCR assay that can be performed on formalin fixed paraffin embedded sections of archived tissues. Participants will work in concert with a physician to determine future treatment options based on BCI results.
3325877|NCT02057055|Experimental|Soap 300000027003|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
3325878|NCT02057055|Experimental|Soap 300000029240|Subjects will apply this soap to one of their arms daily in the shower for 3 weeks
3325879|NCT02057094|Placebo Comparator|Control|Dining facility recovery feeding only, no supplemental protein consumed (an isoenergetic, carbohydrate supplement will be consumed by those assigned to the Control group)
3325880|NCT02057094|Active Comparator|Protein|"Consume dining facility food with:~2, 20 g whey protein supplements daily (for ~27 days)~1, 40 g casein protein supplement daily (for ~27 days)"
3325881|NCT02057094|Active Comparator|High-Protein|"Consume dining facility food with:~2, 40 g whey protein supplements daily (~27 days)~1, 50 g casein protein supplement daily (~27 days)"
3325882|NCT02057107|Other|SBRT + Cetuximab + Docetaxel followed by Cetuximab + Docetaxel|Previously Treated With Cetuximab - Group A No Previous Cetuximab - Group C
3325883|NCT02057107|Other|SBRT + Cetuximab followed by Cetuximab|Previously Treated with Cetuximab - Group B No Previous Cetuximab - Group D
3325884|NCT02057120|Active Comparator|Grupo A (Kinesio Taping)|Will be held the application of Kinesio Taping (Tex Gold) in the region of the rectus femoris dominant lower limb by a physical therapist trained in the technique (KT1 KT2 and) and with experience in this type of application to be designed without knowing in which group fits this patient. In the sequence, the athlete will be oriented to remain at rest for 30 min to get a better grip on the tape and one of the first tests and rest, only after this period will conduct a new evaluation of jump tests (single leg Hop test and Triple Hop Test) and, finally, a new test of strength in the isokinetic dinamomêtro in conjunction with the electromyographic assessment.
3230571|NCT01192802|Active Comparator|2 doses, albendazole, tablet|1 tablet of 400 mg of albendazole per day for two consecutive days
3230572|NCT01192802|Active Comparator|3 doses albendazole, 400mg, tablet|
3230573|NCT01192841|No Intervention|White coat group|Participants continued their regular practice of wearing their physician white coat.
3230574|NCT01192841|Experimental|Uniform group|Participants were given a clean uniform (scrubs) at the beginning of the day.
3230575|NCT01192854|Experimental|1|
3230576|NCT01192854|Active Comparator|2|
3230577|NCT01192867|Experimental|RO4917838 20 milligrams (mg)|Participants, on stable antipsychotics, will receive RO4917838 orally at 20 mg once daily (QD) up to 56 weeks followed by an optional treatment extension for up to 3 years.
3325885|NCT02057120|Placebo Comparator|Placebo Taping|The volunteer will receive a Placebo application tape, being in this case the physical therapist will apply a strip of Kinesio Taping perpendicular to the muscle fibers of the rectus femoris of the dominant member of the individual.
3325886|NCT02057133|Experimental|LY2835219 + Letrozole|LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.
3325887|NCT02057133|Experimental|LY2835219 + Anastrozole|LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.
3325888|NCT02057133|Experimental|LY2835219 + Tamoxifen|LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.
3230578|NCT01192867|Experimental|RO4917838 10 mg|Participants, on stable antipsychotics, will receive RO4917838 orally at 10 mg QD up to 56 weeks followed by an optional treatment extension for up to 3 years.
3230579|NCT01192867|Placebo Comparator|Placebo|Participants, on stable antipsychotics, will receive RO4917838 matching placebo orally QD up to 56 weeks.
3230580|NCT01192880|Experimental|Bitopertin 10 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 10 milligrams (mg) tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 10 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50 percent (%) of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3259145|NCT01467908|Experimental|Vegetative state|Patients with the diagnosis of the vegetative state
3259146|NCT01467921|Active Comparator|LV5FU2|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2
3325889|NCT02057133|Experimental|LY2835219 + Exemestane|LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.
3325890|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Escalation|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
3325891|NCT02057133|Experimental|LY2835219 + Exemestane + Everolimus Dose Expansion|LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.
3325892|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Escalation|LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.
3325893|NCT02057133|Experimental|LY2835219+ Trastuzumab Dose Expansion|LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.
3325894|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Escalation|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).
3325895|NCT02057133|Experimental|LY3023414 + LY2835219 + Fulvestrant Dose Expansion|LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.
3325896|NCT02057133|Experimental|LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation|LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
3230581|NCT01192880|Experimental|Bitopertin 20 mg + Antipsychotics|Treatment Period 1: Participants will receive bitopertin 20 mg tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin 20 mg tablet orally once daily for 28 weeks (up to Study Week 52). After Week 52 there will be a 4-week washout period for at least 50% of participants (up to Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and continue to receive bitopertin 20 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3259147|NCT01467921|Experimental|FOLFOX|leucovorin 200 mg/m2 and 5-fluorouracil 400 mg/m2 intravenously on day 1, followed by a 46-h protracted infusion of 5-fluorouracil 2,400 mg/m2 oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
3325897|NCT02057133|Experimental|LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion|"Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.~Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally."
3325898|NCT02057133|Experimental|LY2835219 + Endocrine Therapy|LY2835219 administered orally. Ongoing endocrine therapy administered orally.
3325899|NCT02057146|Experimental|Mother-baby endoscopy|Spyglass mother-baby endoscopy in conjunction with ERCP
3325900|NCT02057159|Experimental|NeuroVax|NeuroVax
3325901|NCT02057159|Placebo Comparator|IFA Placebo|IFA Placebo
3325902|NCT02057172|Experimental|HM11260C (0.3 mg)|Weekly administration of 0.3 mg of HMC11260C by subcutaneous injection for 12 weeks
3325903|NCT02057172|Experimental|HM11260C (1 mg)|Weekly administration of 1 mg of HM11260C by subcutaneous injection for 12 weeks
3325904|NCT02057172|Experimental|HM11260C (2 mg)|Weekly administration of 2 mg of HM11260C by subcutaneous injection for 12 weeks
3325905|NCT02057172|Experimental|HM11260C (3 mg)|Weekly administration of 3 mg of HM11260C by subcutaneous injection for 12 weeks
3325906|NCT02057172|Experimental|HM11260C (4 mg)|Weekly administration of 4 mg of HM11260C by subcutaneous injection for 12 weeks
3325907|NCT02057172|Placebo Comparator|Placebo|Weekly administration of placebo by subcutaneous injection for 12 weeks
3325908|NCT02057172|Active Comparator|Liraglutide|Liraglutide will be administered daily, at doses of 0.6 mg to 1.8 mg.
3325909|NCT02057185||Study population|"Patients diagnosed with Chronic Myeloid Leukaemia, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndromes (low risk), Chronic Thrombocytopenia or Hodgkin Disease in complete remission, who have signed written informed consent according to ICH/EU/GCP and Italian laws, aged between 15 and 74 years old.~The study excludes non Italian speaking patients or unable to fully understand the study's forms."
3325910|NCT02057211|Placebo Comparator|sham transplantation of mesenchymal stem cells|control arm with sham transplantation
3325911|NCT02057211|Active Comparator|autologous mesenchymal stem cell transplantation|Active arm with transplantation of cells
3325912|NCT02057224|Experimental|Single arm|15 clinical patients undergoing renal denervation
3325913|NCT02057263|Experimental|Alendronate and Hepatitis B Vaccine|Participants in the experimental arm will receive 4 alendronate doses during their Hepatitis B vaccination course.
3325914|NCT02057263|Experimental|Sugar Pill and Hepatitis B Vaccine|Participants in the experimental arm will receive placebo doses during their Hepatitis B vaccination course.
3325915|NCT02057289|Experimental|Micafungin|"Subjects will be administered 5 mg/kg of micafungin intravenously as a ONE TIME dose.~For patients undergoing Hematopoietic Stem Cell Transplant (HSCT), Micafungin will be given on during rest days (i.e. days when no chemotherapy is administered) and blood for pharmacokinetic measurements will be drawn over next 96 hours.~Following this, further anti-fungal coverage will be at the discretion of the patient's attending physician. (I.e. other antifungal agent(s) or Micafungin at a standard clinical dose; repeat doses of 5mg/kg will NOT be administered.)"
3325916|NCT02057302|Placebo Comparator|Group B|There are 538 patients recruited in this group. Patients in this group will take 2 capsules of placebo every time, twice every day, respectively after breakfast and supper.
3325917|NCT02057302|Experimental|Group A|There are 1614 patients recruited in this group. Patients in this group will take 2 capsules of Xuezhikang every time, twice every day, respectively after breakfast and supper.
3325918|NCT02057315|Experimental|ELS-M11|Topical 5% ELS-M11 (3 g)
3325919|NCT02057315|Placebo Comparator|Placebo|A matching formulation with no active ingredient
3325920|NCT02057328|Active Comparator|NEBIVOLOL|Patients of the group of nebivolol will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients still classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range 12,5 mg hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
3325921|NCT02057328|Active Comparator|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisarta daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM (24h SBP/DBP < 130/80 mm Hg) will continue on the same medication scheme. Patients classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. The same procedure will be repeated at the end of the 6th month from the beginning of the study. Patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
3325922|NCT02057341|Experimental|ARRY-371797 (Dose 1)|
3325923|NCT02057341|Experimental|ARRY-371797 (Dose 2)|
3325924|NCT02057354|Active Comparator|Healthy Sedentary Young Adults|Participants 18-35 years of age will be randomized to either aerobic or non-aerobic exercise training.
3325925|NCT02057354|Experimental|Healthy Sedentary Older Adults|Participants 55-85 years of age will be randomized to either aerobic or non-aerobic exercise training.
3325926|NCT02057367|Experimental|Scalp block with 0.5% plain marcaine|Anterior scalp block with 0.5% plain Marcaine 20 ml.
3325927|NCT02057367|Placebo Comparator|Scalp block with 0.9% normal saline|Anterior scalp block with 0.9% normal saline 20 ml.
3325928|NCT02057380|Experimental|Arm A: High dose linsitinib twice daily monotherapy|Arm A includes subjects from Protocol OSI-906-301
3325929|NCT02057380|Experimental|Arm B: High dose linsitinib BID plus high dose erlotinib QD|Arm B includes subjects from Protocol OSI-906-205
3325930|NCT02057380|Experimental|Arm C: High dose erlotinib monotherapy once daily|Arm C includes subjects from Protocol OSI-906-205 and OSI-906-207
3325931|NCT02057380|Experimental|Arm D: High dose linsitinib BID plus weekly paclitaxel|Arm D includes subjects from Protocol OSI-906-202
3325932|NCT02057380|Experimental|Arm E: Highest dose linsitinib intermittent once daily|Arm E includes subjects from Protocol OSI-906-202, linsitinib on Days 1-3 of each week plus weekly paclitaxel
3325933|NCT02057380|Experimental|Arm F: Paclitaxel alone weekly|Arm F includes subjects from Protocol OSI-906-202
3325934|NCT02057380|Experimental|Arm G: Lowest dose linsitinib twice daily + low dose erlotinib|Arm G includes subjects from Protocol OSI-906-103
3325935|NCT02057380|Experimental|Arm H: high dose linsitinib twice daily|includes subjects from protocols SARC 022/CTEP 8945, linsitinib x28 days (each cycle)
3325936|NCT02057380|Experimental|Arm I: highest dose linsitinib once daily|includes subjects from EuroSARC protocol, linsitinib on Days 1-3; Days 8-10 and Days 15-17
3230582|NCT01192880|Placebo Comparator|Placebo|Treatment Period 1: Participants will receive bitopertin matching placebo tablet orally once daily for 24 weeks. Treatment Period 2: Participants will receive bitopertin matching placebo tablet orally once daily for 32 weeks (up to Study Week 56). Long-Term Extension: After Week 56, participants will enter the long term extension period and will be switched to (in blinded manner) bitopertin 10 mg tablet orally once daily up to 3 years. In addition, throughout the study, participants will continue their same stable antipsychotic treatment as they were receiving prior to entry in the study.
3230583|NCT01192893||OPUS|OPUS is a prospective study of postmenopausal women recruited in the general population between April 1999 and April 2001 from five European centers (Aberdeen (UK), Berlin (Germany), Kiel (Germany), Paris (Hospital Cochin, France), and Sheffield (UK)). Investigations were approved at each institution according to the Declaration of Helsinki. Written consent was obtained from all subjects. Each center recruited approximately 500 postmenopausal women comprising 100 individuals in each 5-yr age band between 55 and 79. Ninety-nine percent of subjects were of white ethnicity.
3230584|NCT01192906|Experimental|1|
3230585|NCT01192906|Experimental|2|
3325937|NCT02057380|Experimental|Arm J: Low dose linsitinib 2x daily+bortezomib & dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3325938|NCT02057380|Experimental|Arm K: med. dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3325939|NCT02057380|Experimental|Arm L: high dose linsitinib 2x daily+bortezomib&dexamethasone|includes subjects from protocol MM-001; Days 1, 4, 8 & 11 (cycles 1-8) and Days 1, 8, 15 & 22 (cycles 9+)
3230586|NCT01192906|Placebo Comparator|3|
3230587|NCT01192919||Patients with lung cancer|Patients with lung cancer requiring therapy
3230588|NCT01192932||COPD|COPD patients aged 40 or more, with a smoking history of > 10 pack-years, a post-bronchodilator FEV1/VC < 0.7 and an optimal treatment according to GOLD guidelines will be included. Exclusion criteria are: COPD exacerbation or respiratory infection in the 4 weeks before the begin of the study, concomitant pulmonary disease (tuberculosis, significant bronchiectasis, lung cancer), pulmonary resection, active malignancy or malignancy of any organ system within the past 5 years.
3230589|NCT01192971|Experimental|A 850|Arm 850: Experimental apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patient withdrawal of consent
3230590|NCT01192971|Experimental|B750|B750: apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3230591|NCT01192984|Experimental|KW-0761|
3230592|NCT01192997|Active Comparator|Menveo-Meningitec|Subjects who were primed with Meningitec who will receive Novartis Menveo
3325940|NCT02057419||Contraceptive Method|"Protocol 1: 3-month use period for each of 3 contraceptive methods, randomly ordered. intravaginal ring, oral contraceptive pill, spermicide+condom; dosage and frequency as instructed...~Protocol 2: 3-month use period for 1st randomly assigned contraceptive method. At end of use period, user chooses to continue on 1st method or to switch to 2nd randomly assigned method for remaining 3-month use-period."
3325941|NCT02057419||Sexual Lubricant Method|3-month use period for each of 3 sexual lubricant methods, randomly ordered. gel formulation, film formulation, insert formulation; dosage and frequency as instructed
3325942|NCT02057432|Experimental|Intra-operative MRI|Images will be obtained both before and after intravenous bolus injection with subsequent dynamic imaging. Dynamic contrast enhancement maps will be created for evaluation of residual tumor. Images will be reformatted into three orthogonal planes as well as into a 3D model for surgical orientation. All imaging protocols using contrast, contrast enhancement maps and reformatting, as described above, which will be applied to the intra-operative MRI performed in the AMIGO suite are consistent with the standard MRI breast imaging at Brigham and Women's Hospital.
3325943|NCT02057445|Experimental|Recipient|EBV+ patients will receive 3rd party LMP-CTLs for treatment of EBV infection and/or disease
3325944|NCT02057445|Other|Donor|Healthy donors who are EBV+ will be asked to donate 60-120 ml of peripheral blood for development of cell lines to be stored for cell line bank.
3325945|NCT02057471|Experimental|Intravenous Ferric Carboxymaltose|All recruited patients will be allocated to this treatment. 1 gram of Ferric carboxymaltose (FERINJECT) to be given at recruitment
3325946|NCT02057484||Organ transplant patients treated with Advagraf|To evaluate long-term graft survival in patients treated with Advagraf
3325947|NCT02057497||Healthy volunteers|Considered generally healthy based on medical history and physical examination as per discretion of the investigator
3325948|NCT02057497||Type 1 Diabetes|T1DM diagnosed clinically prior to start of trial examinations
3325949|NCT02057497||Type 2 Diabetes|T2DM diagnosis prior to the start of trial examinations
3325950|NCT02057510||Patients receiving head and neck RT|No intervention
3230593|NCT01192997|Active Comparator|MenACWY-TT-Meningitec|Subjects who were primed with Meningitec who will receive GSK MenACWY-TT
3230594|NCT01192997|Active Comparator|Menveo-Menjugate|Subjects who were primed with Menjugate who will receive Novartis Menveo
3230595|NCT01192997|Active Comparator|MenACWY-TT-Menjugate|Subjects who were primed with Menjugate who will receive GSK MenACWY-TT vaccine.
3230596|NCT01192997|Active Comparator|Menveo-NeisVac-C|Subjects who were primed with NeisVac-C who will receive Novartis Menveo
3230597|NCT01192997|Active Comparator|MenACWY-TT-NeisVac-C|Subjects who were primed with NeisVac-C who will receive GSK MenACWY-TT vaccine
3325951|NCT02057536|Experimental|Arm A|8 week directed exercise program
3325952|NCT02057536|Active Comparator|Arm B|No directed exercise other than patients normal level of activity
3325953|NCT02057562||Routine colonoscopy|Patients receiving routine colonoscopy (for a multitude of indications) at the study centers are eligible for participation
3230598|NCT01193023|Active Comparator|Pressure support|"in this arm, pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS)~with ETS +10%~with ETS -10%"
3325954|NCT02057588|Other|LV Paced sites|LV pacing sites : Patients will be paced from various left ventricular origin, defined by their 3D localization.
3325955|NCT02057601|Experimental|Infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0ml and will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
3325956|NCT02057601|No Intervention|Non infiltration group|The patients in this group will receive spinal anaesthesia with intrathecal bupivacaine 0.5% 2.0 ml.
3325957|NCT02057627|Experimental|Perinatal Dyadic Psychotherapy|The Perinatal Dyadic Psychotherapy intervention consists of 8 home-based, nurse-delivered mother-infant sessions consisting of (a) a supportive, relationship-based, mother-infant psychotherapeutic component, and (b) a developmentally based infant-oriented component focused on promoting positive mother-infant interactions. The 8 sessions take place over three months with weekly 4 sessions (weeks 1 through 4) followed by 4 every other week sessions (weeks 5 through 8)
3325958|NCT02057627|Placebo Comparator|Standard care plus depression monitoring|Standard care plus depression monitoring by phone on a schedule comparable to the intervention groups' home visits. Eight phone calls will take place over three months with weekly 4 calls (weeks 1 through 4) followed by 4 every other week calls (weeks 5 through 8). Phone monitoring will include administration of the Edinburgh Postnatal Depression Scale.
3325959|NCT02057653||Before GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record prior to the start of the training curriculum.
3325960|NCT02057653||After GDFM Training|Approximate 300 patients' medical record information will be extracted from the UC Irvine Medical Center electronic medical record after the training program took place
3325961|NCT02057679|Active Comparator|Group A (Amoxicillin Clavulanic)|Intake of active drug (Amoxicillin Clavulanic). 3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
3325962|NCT02057679|Placebo Comparator|Placebo|Intake of placebo (Lactose). 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
3325963|NCT02057731||Ia carriers|Carriers of GSD type Ia will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3325964|NCT02057731||Ib carriers|Carriers of GSD type Ib will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3325965|NCT02057731||III carriers|Carriers of GSD type III will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3325966|NCT02057731||0, VI, IX carriers|Carriers of GSD types 0, VI, and IX will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to determine their specific mutation. A questionnaire will also be filled out.
3230599|NCT01193023|Experimental|NAVA|Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.
3230600|NCT01193036||Interview|
3230601|NCT01193036||Symptom Inventory Assessment|
3230602|NCT01193062|Experimental|Cohort 1|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
3325967|NCT02057731||Noncarriers|Noncarriers of any type of GSD will have their blood and urine tested to measure markers of GSD. Their saliva will be tested to ensure their noncarrier status. A questionnaire will also be filled out.
3325968|NCT02057744||Robotic-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive robotic-guided spinal fixation surgery.
3325969|NCT02057744||Freehand image-guided|Adult patients (21 years or older) undergoing short (4 or less consecutive vertebrae) thoracic, lumbar or lumbosacral percutaneous/minimally invasive image-guided freehand or navigated spinal fixation surgery.
3325970|NCT02057770|Experimental|Treatment (preparative regimen, transplant, cyclophosphamide)|"BUSULFAN AND FLUDARABINE BASED PREPARATIVE REGIMEN: Patients receive busulfan IV over 3 hours on days -7 to -4, fludarabine phosphate IV over 30-60 minutes on days -6 to -2, and cyclophosphamide IV over 60 minutes on days -3 and -2.~OR~FLUDARABINE AND TBI BASED PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30-60 minutes on days -6 to -4 and undergo TBI twice daily on days -3 to 0.~AND~DONOR CELL INFUSION: Patients undergo HLA-matched sibling stem cell transplant, HLA-matched unrelated, or HLA-haploidentical transplant on day 0.~AND~POST-TRANSPLANT CYCLOPHOSPHAMIDE: Patients receive cyclophosphamide IV over 90 minutes on days 3 and 4."
3325971|NCT02057770|Experimental|CRS preventive regimen|The final ~15 people enrolled who will be recipients of haploidentical transplants will receive tocilizumab IV over 60 minutes 6-12 hours prior to the start of the donor cell infusion.
3325972|NCT02057783|Experimental|Physical activity|Obstructive sleep apnea and resistant hypertension controlled + physical activity
3230603|NCT01193062|Experimental|Cohort 2|Subjects will be receive single oral doses of PF-04995274 not exceeding 15mg or a placebo
3230604|NCT01193075||CMT1B|Families/patients with genetically confirmed CMT1B
3325973|NCT02057783|No Intervention|Control Group|Obstructive sleep apnea and resistant hypertension controlled
3325974|NCT02057796|Experimental|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"Arm1 Extensive TB screening:~In this arm, point-of-care tests for TB will be used at randomization (in all patients) and at each scheduled or unscheduled follow-up visit (in patients with signs or symptoms suggestive of TB and no clear alternative diagnosis); TB treatment will only be prescribed to patients with a diagnosis of TB"
3325975|NCT02057796|Experimental|Rifampin, isoniazid, pyrazinamide, ethambutol|"Arm 2: Systematic Empiric treatment (Rifampicin,isoniazid, pyrazinamide, ethambutol) ART~In this arm, all patients will start a systematic 6-month TB treatment at randomization. TB screening tests will not systematically be used neither at randomization nor while patients are on TB treatment."
3325976|NCT02057809||Parent-child dyad|Children with Developmental Disabilities and their parents
3325977|NCT02057809||Therapits|Therapists experienced in serving children with developmental disabilities
3325978|NCT02057822||vernal keratoconjunctivitis|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjonctivitis and in control subjects
3325979|NCT02057822||healthy children|The main objective of our study was to compare the concentration of 40 cytokines in vernal keratoconjunctivitis and in control subjects
3325980|NCT02057848|Active Comparator|low amount of carbohydrates|2 x 10 g carbohydrates (muesli bars)
3325981|NCT02057848|Active Comparator|high amount of carbohydrates|2 x 20 g carbohydrates (muesli bars)
3325982|NCT02057848|Other|Rapid-acting carbohydrates|30 g rapidly absorbable carboh. + 20 g muesli bar
3325983|NCT02057861||non-diabetic|non-diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded.
3325984|NCT02057861||diabetic|Diabetic group; 2 mg/kg sugammadex iv, postoperatively Extubation times were recorded
3230605|NCT01193075||CMT2A|Families/patients with genetically confirmed CMT2A
3230606|NCT01193075||CMT4A|Families/patients with genetically confirmed CMT4A
3230607|NCT01193075||CMT4C|Families/patients with genetically confirmed CMT4C
3230608|NCT01193075||All other CMT|Families/patients with all other forms of CMT or CMT that has not yet been genetically identified
3230609|NCT01193088||CMT1A|Families/people with genetically defined CMT1A
3230610|NCT01193088||Genetically undefined CMT|Families/people with genetically undefined CMT with common causes ruled out.
3230611|NCT01193140|Experimental|Arm A|
3325985|NCT02057887|Experimental|Cohort1|HM10660A SC once weekly
3325986|NCT02057887|Experimental|Cohort2|HM10660A SC once every 2 weeks
3325987|NCT02057887|Experimental|Cohort3|HM10660A SC once every 4 weeks
3325988|NCT02057887|Active Comparator|Cohort4|180 mcg Pegasys SC once weekly
3325989|NCT02057900|Experimental|Human embryonic stem cell|Patients with ischemic heart failure receiving a fibrin gel embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors in addition to coronary artery bypass grafting and/or a mitral valve procedure.
3325990|NCT02057913|Experimental|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
3325991|NCT02057926|Experimental|Tetracycline, Without Tetracycline|The study consist in two groups: test group (membrane treated with tetracycline) and control group (membrane no treated with tetracycline).
3230612|NCT01193166|Experimental|001|paliperidone palmitate 78 117 156 or 234 mg monthly injection for 12 months
3230613|NCT01193166|Active Comparator|002|olanzapine flexible dosing as prescribed by the study doctor for 12 months
3230614|NCT01193166|Active Comparator|003|paliperidone flexible dosing as prescribed by the study doctor for 12 months
3230615|NCT01193166|Active Comparator|004|aripiprazole flexible dosing as prescribed by the study doctor for 12 months
3230616|NCT01193166|Active Comparator|005|haloperidole flexible dosing as prescribed by the study doctor for 12 months
3230617|NCT01193166|Active Comparator|006|perphenazine flexible dosing as prescribed by the study doctor for 12 months
3230618|NCT01193166|Active Comparator|007|quetiapine flexible dosing as prescribed by the study doctor for 12 months
3325992|NCT02057965|Active Comparator|Mesenchymal Stromal Cells + Everolimus|"Intervention: two doses of autologous bone marrow (BM) derived Mesenchymal Stromal Cells IV, 7 days apart, 6 and 7 weeks after transplantation in combination with Certican® (1.5mg/day). Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight.~At the time of the second MSC infusion tacrolimus will be withdrawn in 2 weeks (after 1 week dose of tacrolimus wil be halved, after 2 weeks stopped)"
3325993|NCT02057965|No Intervention|Everolimus + Tacrolimus|Patients in the control group will receive Certican® (1.5 mg b.i.d.) and standard dose tacrolimus (through levels 6-8 ng/ml after 6 weeks).
3230619|NCT01193166|Active Comparator|008|risperidone flexible dosing as prescribed by the study doctor for 12 months
3230620|NCT01193179|Experimental|OPC-262|
3325994|NCT02057978||EXCEL DES|Use EXCEL DES implatationas as control group,Implant DES for CAD cases
3325995|NCT02057978||EXCEL-II DES|EXCEL-II DES implantation as control group,Implant DES for CAD cases
3325996|NCT02057991|No Intervention|Group I (standard of care)|Patients and caregivers receive standard of care.
3325997|NCT02057991|Experimental|Group II (educational video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
3325998|NCT02057991|Experimental|Group III (educational video, mindfulness exercise video)|Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.
3325999|NCT02058004|Experimental|Cricoid pressure|Patients randomized to receive cricoid pressure during endotracheal intubation.
3326000|NCT02058004|No Intervention|No cricoid pressure|Patients randomized to receive no cricoid pressure during endotracheal intubation.
3230621|NCT01193192||Arm #1 (Test Group)|100 subject administered Neevo® or NeevoDHA® daily
3326001|NCT02058017|Experimental|Part I & Part II|"Part I - This is a lead-in dose-finding, open-label, non-randomised arm of the study: Using a starting dose of 10mg per week, an accelerated dose titration escalation followed by a 3+3 design will be employed until MTD and recommended weekly dose are determined.~Part II - This is a single-centre, open-label non-randomised phase II study evaluating OPB-51602 in stage III-IVB NPC conducted in the window period prior to definitive chemoradiotherapy. Eligible patients will receive OPB-51602 on a weekly basis (Day 1, 8, 15) at the recommended dose determined in part I for a total of 15 days prior to definitive chemoradiotherapy."
3230622|NCT01193192||Arm #2 (Control group)|100 subject administered a prenatal vitamin daily
3230623|NCT01193205|Experimental|20 weeks skills group|Participants receive 20 weeks of Dialectical Behaviour Therapy Skills training, covering 5 modules: mindfulness, interpersonal effectiveness, emotional regulation, distress tolerance, dialectics.
3230624|NCT01193205|No Intervention|Waitlist|Participants on the waitlist condition will be assessed at baseline and symptoms monitored at 10 weeks, 20 weeks and 8 months following baseline assessment. They will then be offered the active treatment.
3326002|NCT02058030|Other|3cm head elevation|Insertion of ProSeal laryngeal mask airway
3326003|NCT02058030|Active Comparator|6cm head elevation|Insertion of ProSeal laryngeal mask airway
3230625|NCT01193231||Acuvail 0.45%|Each subject will be randomized to the eye that they will use Acuvail in for 3 days after PRK
3230626|NCT01193231||Systane Ultra Preservative Free Tears|Each subject's contralateral eye (other eye) will use Sytane for 3 days after PRK surgery.
3230627|NCT01193270|Experimental|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate (Aquasol E®) 50 IU/kg.
3230628|NCT01193270|Placebo Comparator|Placebo|Sterile water in volume equal to that of the comparator drug.
3230629|NCT01193296|Experimental|Vildagliptin|
3230630|NCT01193296|Active Comparator|Sitagliptin|
3230631|NCT01193361|Experimental|Arm 1 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
3230632|NCT01193361|Experimental|Arm 2 - BMS-791325 plus peg-interferon alfa-2a and ribavirin|
3230633|NCT01193361|Placebo Comparator|Arm 3 - Placebo plus peg-interferon alfa-2a and ribavirin|
3326004|NCT02058056|Experimental|Experimental: HA-PCI treatment|Irradiation HA-PCI concomitant to the second cycle of CHT and to tRT for patients with LD SCLC
3326005|NCT02058082|Active Comparator|ejaculated sperm|Intracytoplasmic sperm injection (ICSI) cycles using ejaculated sperm
3326006|NCT02058082|Active Comparator|testicular extracted sperm|Intracytoplasmic sperm injection (ICSI) cycles using testicular extracted sperm
3326007|NCT02058121|Experimental|Acceptance and Commitment Therapy|
3230634|NCT01193374|Experimental|Parent/child tailored mailed materials|Family provided newsletters tailored to issues and readiness to change. Family receives educational nutrition DVD, pedometers for family activities and child nutrition/physical activity games
3230635|NCT01193374|Active Comparator|Basic information at single time|Family provided with high quality booklet from American Dietetic Association providing the same information that intervention arm received but not tailored.
3230636|NCT01193387|Experimental|IDeg (M) IM1|
3230637|NCT01193387|Experimental|IDeg (M) IM2|
3230638|NCT01193400|Experimental|Clofarabine-Cytarabine|Induction therapy with a combination of clofarabine and low-dose cytarabine followed by consolidation therapy with clofarabine and low-dose cytarabine
3230639|NCT01193413||Non-infected necrosis group|There is no necrosis infection in severe acute pancreatitis.
3230640|NCT01193413||Single drainage group|The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
3230641|NCT01193413||Combined surgery group|If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
3230642|NCT01193426||Cirrhosis patient|All consecutive patients with cirrhosis admitted to the five participating center Patients were hospitalized or treated in an ambulatory setting for treatment of ascites or complications of cirrhosis. Ascitic fluid was obtained by paracentesis according to the usual clinical management for these patients.
3230643|NCT01193439||Patients with high risk|
3230644|NCT01193439||Patients in normal conditions|
3326008|NCT02058121|Active Comparator|Treatment as usual|
3326009|NCT02058134|No Intervention|Control group|
3230645|NCT01193452|Experimental|S-1/LV|S-1 combined with Leucovorin
3230646|NCT01193452|Active Comparator|sLV5FU2|5-FU/LV infusion
3326010|NCT02058134|Experimental|Interventional group|For patients in the interventional group we use a CardioPAT cell saver intra- and postoperatively.
3326011|NCT02058173|Experimental|chloroquine|150 mg chloroquine and lacebo , one tablet daily for 2 month
3230647|NCT01193465|Experimental|humidity|
3326012|NCT02058173|Experimental|placebo|150 mg chloroquine and lacebo , one tablet daily for 2 month
3326013|NCT02058186|Active Comparator|Atopic dermatitis patients: Active|Atopic dermatitis patients: age 1-18 years old
3326014|NCT02058186|Placebo Comparator|Atopic dermatitis patients: Placebo|Atopic dermatitis patients: age 1-18 years old
3326015|NCT02058199|Experimental|normal subjects|A single dose of 10 mg of rivaroxaban will be administered
3326016|NCT02058199|Experimental|Obese non bypassed|A single dose of rivaroxaban will be administered
3326017|NCT02058199|Experimental|obese bypassed|A single dose of rivaroxaban will be administered
3230648|NCT01193478|Active Comparator|Cohort 1|GS-5885 (3 mg), once daily or matching placebo, once daily
3326018|NCT02058199|Experimental|pre and post bypassed subject|A single dose of rivaroxaban will be administered prior to gastric bypass. Subjects will be restudied 12 to 24 weeks following bypass
3326019|NCT02058212|Placebo Comparator|no antioxidant , ROS , pregnancy outcome|no anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) will be given to endometriotic women undergoing IVF
3326020|NCT02058212|Active Comparator|antioxidant , ROS , pregnancy outcome|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium)
3326021|NCT02058225||Infant Group 1|This group consist of healthy, full-term babies whose mothers have no known medical conditions or complications during pregnancy.
3326022|NCT02058238||Arm 1: Robotic-guided, Open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3326023|NCT02058238||Arm 2: control-arm - non-robotic, open approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3326024|NCT02058238||Arm 3: robotic-guided, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3230649|NCT01193478|Active Comparator|Cohort 2|GS-5885 (10 mg), once daily or matching placebo, once daily
3230650|NCT01193478|Active Comparator|Cohort 3|GS-5885 (30 mg), once daily or matching placebo, once daily
3326025|NCT02058238||Arm 4: control-arm - freehand, MIS approach|Adult patients (age> 21 years) undergoing long (>4 consecutive vertebrae) open instrumentation, correction and fusion surgery in the thoracic, lumbar or sacral spine for a kypho/scoliotic curve, sagittal or coronal imbalance or a combination of these.
3326026|NCT02058264|Experimental|Low Strength BBI-4000 and Vehicle|
3326027|NCT02058264|Experimental|High Strength BBI-4000 and Vehicle|
3230651|NCT01193478|Active Comparator|Cohort 4|GS-5885 ( up to 90 mg), once daily or matching placebo, once daily
3326028|NCT02058277|Other|Healthy volunteers|Healthy volunteers taking a single dose of bosutinib and a single dose of bosutinib plus aprepitant in random order
3326029|NCT02058303|Experimental|Exparel forearm block|Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
3326030|NCT02058303|Active Comparator|Bupivacaine supraclavicular block|Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.
3326031|NCT02058316||Patients at risk for IPA|
3326032|NCT02058329|No Intervention|No intervention|Standard of care with no home visit
3326033|NCT02058329|Experimental|Home Visit|After the post hip-fracture patient is discharged to home, there will be home visits by a geriatric fellow assess overall function and response to treatment/s by depression screen, FIM scores, and environmental risk assessment
3326034|NCT02058342|Experimental|Active Play at Home Intervention|Participant parents in the intervention arm will receive: 1) Active Play at Home curriculum and equipment, 2) Training session on Active Play at Home curriculum, 3) counseling on physical activity scheduling, identification of barriers, motivational strategies, 4) phone calls to check on compliance and issues with doing the program at home
3326035|NCT02058342|No Intervention|Wait-listed control|Participants will attend the baseline visit to do baseline measurements but will not receive any materials related to the Active Play at Home curriculum and will also not be contacted by phone during the control 24 weeks. After they serve as control group, they will be provided with the opportunity to receive the intervention.
3326036|NCT02058355|Experimental|Personalized Normative Feedback|This group receive the complete Personalized Normative Feedback (with normative information and a list of consequences)
3326037|NCT02058355|Experimental|Normative Feedback|This group receive a feedback only with normative informations (without a list of consequences)
3326038|NCT02058355|Experimental|Consequences List Feedback|This group receive a list of consequences without normative informations
3326039|NCT02058381|Experimental|Group 1 (alpelisib)|Alpelisib plus Tamoxifen and Goserelin (Group 1)
3230652|NCT01193478|Active Comparator|Cohort 5|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
3230653|NCT01193478|Active Comparator|Cohort 6 (optional)|GS-5885 (up to 90 mg), once daily or matching placebo, once daily
3230654|NCT01193491|Experimental|IPI-493|
3259148|NCT01467986|Active Comparator|Irinotecan, Temozolomide|Patients randomized to the control arm receive irinotecan (I) and temozolomide (T) alone.
3326040|NCT02058381|Experimental|Group 2 (buparlisib)|Buparlisib plus Tamoxifen and Goserelin (Group 2)
3326041|NCT02058394||Cataract Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
3326042|NCT02058407|Experimental|Cohort 1- Part A|This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
3326043|NCT02058407|Experimental|Cohort 2- Part A|This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
3230655|NCT01193504|Active Comparator|Pred Forte|Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
3230656|NCT01193504|Active Comparator|Lotemax|patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.
3230657|NCT01193543|Experimental|calanus oil|calanus oil 1 gram twice daily
3230658|NCT01193543|Placebo Comparator|olive oil|olive oil 1 gram twice daily
3326044|NCT02058407|Experimental|Cohort 3- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
3326045|NCT02058407|Experimental|Cohort 4- Part B|It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.
3326046|NCT02058420|No Intervention|Placebo group|No active dose of tocotrienols
3326047|NCT02058420|Active Comparator|Low tocotrienols group|Low dose of tocotrienols
3326048|NCT02058420|Active Comparator|High tocotrienols group|High dose of tocotrienol
3230659|NCT01193569||Standard of Care|Standard of Care for stroke except mechanical therapy
3326049|NCT02058433|Experimental|pharmacokinetics group|Based on pharmacokinetics. Observe safety and efficacy. In first cycle a fixed Paclitaxel dose depends on BSA. In subsequent cycles the dosage of Paclitaxel will be adjusted depending on pharmacokinetics follow up .
3230660|NCT01193595|Experimental|AVE8062/ bevacizumab|The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
3230661|NCT01193621|Active Comparator|haloperidol|"0.5, 1, 3 mg of haloperidol will be administered orally every 24 hours for 7 days to 4 healthy subjects in each dose level (a total of 12 subjects).~Dose groups are as follows; D2-receptor occupancy study Group Single Oral Dose No. of subjects~0.5 mg 4~1 mg 4~5 mg 4"
3326050|NCT02058433|Active Comparator|Body surface area(BSA) group|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
3326051|NCT02058446|Experimental|Study group|Amlodipine/Valsartan Single-Pill Combination
3326052|NCT02058459|Active Comparator|Targeted Lung Denervation|active targeted lung denervation
3326053|NCT02058459|Sham Comparator|Sham-Control|non-active targeted lung denervation
3326054|NCT02058472|Experimental|G3041|Amlodipine orotate 10mg/Olmesartan medoxomil 40mg
3326055|NCT02058472|Active Comparator|SEVIKAR®|Amlodipine besylate 10mg/Olmesartan medoxomil 40mg
3326056|NCT02058485|Active Comparator|Group HD|Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
3326057|NCT02058485|Sham Comparator|Group ND|Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
3326058|NCT02058485|Active Comparator|Group HM|Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
3326059|NCT02058485|Sham Comparator|Group NM|Midazolam was administered 0.025 mg. kg-1 in normotensive patient.
3326060|NCT02058524|Experimental|fecal microbiota transplantation|
3326061|NCT02058550|No Intervention|Arm I (no intervention)|Patients receive no additional reminders.
3326062|NCT02058550|Experimental|Arm II (email survey)|Patients receive a reminder email survey every 2 weeks for 1 year after completing radiation.
3326063|NCT02058550|Experimental|Arm III (email surveys and phone calls)|Patients receive a reminder email survey as in Arm I and 4 additional phone calls at 4-8 weeks, 3-5 months, 7-8 months, and 10-11 months during their first year of follow-up.
3326064|NCT02058576|Experimental|Sequence AB|Subjects will receive Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 1 and Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination) in period 2 orally once daily under fed condition.
3326065|NCT02058576|Experimental|Sequence BA|Subjects will be randomized to receive Treatment B (combination of second generation dutasteride 0.5 mg and tamsulosin HCl 0.4 mg combination) in period 1 and Treatment A (commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg) in period 2 orally once daily under fed condition.
3326066|NCT02058602|Experimental|Arm 1|This is a clinical study to characterise the lung function, airway morphometry, pharyngometry and inhalation profiles in patients with mild to severe Idiopathic Pulmonary Fibrosis (IPF) over a period of up to 6 months. Approximately 30 subjects will be enrolled so that at least 20 subjects complete all critical assessments.
3326067|NCT02058615|Experimental|Male Spouse Transition Toolkit|All participants in this group will be given access to the Male Spouse Transition Toolkit (MaTT). MaTT is a website based application that is designed to help male spouses of women with breast cancer to increase their awareness of the transitions and experiences they have as a husband and caregiver as well as to stay organized and seek help and resources as needed. To do so it consists of six sections: about me; common changes to expect; frequently asked questions; resources; calendar; and, important health information. These sections contain activities and exercises, as well as fillable templates (i.e., resources, calendar) that users can download at their convenience, from their home computer, tablet, or smart phone. They will be asked to use the MaTT for one month.
3326068|NCT02058615|No Intervention|Usual Care|Participants in this group will not receive access to the Male Spouse Transition Toolkit, and thus will not receive an intervention. Data collection for outcome variables will be the same as the participants in the experimental arm.
3326069|NCT02058641|Experimental|Part A|Part A will consist of 2 sessions. In Session 1, 3 blisters will be induced by a challenging agent (cantharidin solution 0.2 %, with 5 microliter administered topically) in T2DM subjects on Day 1. Blisters will be harvested 48 (+/-2) hour (hr) post induction. In Session 2, the same subjects will be administered darapladib EC tablet 160 mg orally, once daily for 11 days. On Day 10, 3 blisters will be induced by cantharidin. Blisters will be harvested 48 (+/-2) hr post induction.
3230662|NCT01193634|Experimental|Paradym RF ICD|Active implantable defibrillators range
3230663|NCT01193699|Experimental|P1101|
3326070|NCT02058641|Experimental|Part B|In Part B, healthy subjects will be enrolled and will follow the same dosing procedure as in Part A. The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A.
3326071|NCT02058654|Experimental|Creatine Group|Whey protein (30 g) and creatine supplement (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
3326072|NCT02058654|Placebo Comparator|Placebo Group|Whey protein (30 g) and bulking agent powder (5 g) shaken with 250-300 ml water in a blender bottle, and the full shake to be taken twice a day for 14 days.
3326073|NCT02058667|Experimental|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
3230664|NCT01193712|Other|on-table non-responder|patients who do not show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
3230665|NCT01193712|No Intervention|on-table responders|patients who do show an improvement of more than or equal to 15% in LV dP/dtmax measured immediately after implantation of a cardiac resynchronization therapy device
3230666|NCT01193725|Active Comparator|Prolonged Exposure Therapy (PE)|The PE protocol is based on manualized procedures, which are derived from the theory that effective treatment for PTSD requires that the underlying pathological fear structure be activated and paired with new information that is incompatible with the fear structure. PE involves imaginal exposure and in vivo exposure as the two primary strategies to elicit repeated confrontation of feared but objectively safe thoughts, feelings, situations and events.
3326074|NCT02058680|Experimental|PSA/IL-2/GM-CSF vaccine|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
3326075|NCT02058693|Placebo Comparator|Placebo Group|"Phase I (3 weeks) placebo adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
3230667|NCT01193725|Experimental|Virtual Reality Exposure Therapy (VRET)|The VRET protocol follows the same procedures as the PE protocol with the primary exception being that all instances of imaginal exposure will be augmented by immersion into Virtual Iraq environments, thus creating a situation known as immersive exposure.
3230668|NCT01193725|Placebo Comparator|Waitlist|The waitlist (WL) participants will be asked to refrain from psychotherapy during the 5 weeks of study participation.
3230669|NCT01193738|Active Comparator|active osteopathic compression|osteopathic compression of Pterygopalatine node
3230670|NCT01193738|Placebo Comparator|placebo osteopathic compression|placebo osteopathic compression
3230671|NCT01193751||asphyxiated newborns > 37 weeks of gestation|
3230672|NCT01193764|Experimental|cocoa|unsweetened 100% cocoa (Ghirardelli)
3230673|NCT01193764|Placebo Comparator|placebo|hydrolyzed gelatin powder (Gelita)
3230674|NCT01193777|Placebo Comparator|Saline|
3230675|NCT01193777|Experimental|L-Carnitine|
3230676|NCT01193790|Experimental|Coblation|
3326076|NCT02058693|Active Comparator|MSA group|"mixed salts amphetamine, adjunctive to Anti-Depressant Therapy (ADT). The total daily dosing of the concurrent ADT will be as follow: escitalopram 10-40 mg; Fluoxetine 20-80 mg; paroxetine CR 25-100 mg (paroxetine 20-80 mg may be substituted if paroxetine CR is not available); sertraline 100-400 mg; venlaflaxine XR 150-600 mg; desvenlafaxine 50-200 mg; citalopram 20-80 mg; or duloxetine 60-180 mg; buproprion 150-450 mg; mirtazapine 15-45 mg, tricyclics (standard dosing, individually per label instructions).~Phase II (3 weeks) mixed salts amphetamine adjunctive to ADT"
3326077|NCT02058706|Experimental|Arm A (enzalutamide and LHRH analogue therapy)|Patients receive enzalutamide orally PO QD and undergo orchiectomy or receive LHRH analogue therapy (leuprolide acetate, goserelin acetate, or any other FDA approved preparation). Treatment continues in the absence of disease progression or unacceptable toxicity.
3326078|NCT02058706|Active Comparator|Arm B (bicalutamide and LHRH analogue therapy)|Patients receive bicalutamide PO QD and undergo orchiectomy or receive LHRH analogue therapy as in Arm A. Treatment continues in the absence of disease progression or unacceptable toxicity.
3326079|NCT02058719||Cohort A1|HIV positive smokers
3326080|NCT02058719||Cohort A2|HIV positive non-smokers
3326081|NCT02058719||Cohort A3|HIV negative smokers
3326082|NCT02058719||Cohort A4|HIV negative non-smokers
3230677|NCT01193803||Spondylodiscitis control group|Patients needing vertebral biopsy looking for tumoral etiology
3230678|NCT01193803||Prosthetic Joint Infection control group|Patients with primary prosthetic arthrosis surgery
3230679|NCT01193803||Septic arthritis control group|Arthrosic patients needing evacuating articular punction with leucocytes infiltration less than 1000 /mm3
3230680|NCT01193803||Spondylodiscitis case group|Patients suspected of Discitis and/or Vertebral Osteomyelitis is defined by the need of spinal biopsy in infectious context.
3230681|NCT01193803||Prosthetic Joint Infection case group|Patients suspected of Prosthetic Joint Infection defined by the need of surgical revision for diagnostic or therapeutic aiming in infectious context.
3230682|NCT01193803||Septic arthritis case group|Patients suspected of Septic arthritis without prosthesis were defined by the need of synovial punction and/or biopsy
3326083|NCT02058719||Cohort B1|HIV positive with COPD
3326084|NCT02058719||Cohort B2|HIV positive without COPD (non-COPD)
3326085|NCT02058719||Cohort B3|HIV negative with COPD
3326086|NCT02058732|Active Comparator|ALS patients receivng stem cells|Amyotrophic lateral sclerosis(ALS)subjects, who will be receiving stem cells, will undergo a brief clinical evaluation and questionnaire that will last approximately 20 to 30 min. Subjects will be asked to undergo magnetic resonance imaging(MRI)scans of the cervical spine and brain that will last approximately 60 minutes.
3326087|NCT02058732|Active Comparator|ALS patients not receiving stem cells|Amyotrophic lateral sclerosis(ALS)patient who will not be receiving stem cells, will have an MRI that lasts approximately 60 minutes. This MRI will be repeated at three different time points. Subjects will have an initial MRI, then another at both 6 and 12 months after the initial magnetic resonance imaging(MRI)scan. Subjects will also complete a clinical examination which will take approximately 30 minutes for each MRI. The follow-up magnetic resonance imaging(MRI)scans done for ALS patients who do not receive stem cells are part of routine clinical studies and therefore subjects will not be billed.
3326088|NCT02058745|Active Comparator|CAU+ (Enhanced Care as Usual)|CAU+ (Enhanced Care as Usual) is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page for the 10 month duration of the study.
3326089|NCT02058745|Experimental|CAU+ and SmartCare|CAU+ (Enhanced Care as Usual) for eight weeks, followed by eight weeks of SmartCare. SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management.
3326090|NCT02058745|Experimental|CAU+ and Beating the Blues and SmartCare|CAU+ (Enhanced Care as Usual) and Beating the Blues concurrently for eight weeks, followed by SmartCare for eight weeks. Beating the Blues is an established, web-based, self-directed, cognitive behavioral therapy for managing depressive symptoms.
3230683|NCT01193816|Experimental|loxapine|loxapine
3230684|NCT01193816|Placebo Comparator|Placebo|Placebo
3230685|NCT01193829||NSCLC patients|
3326091|NCT02058758||Healthy Volunteers|Device: Magnetic Resonance Imaging
3326092|NCT02058758||Breast Cancer Patients|Device: Magnetic Resonance Imaging
3326093|NCT02058771||Ischaemic cardiomyopathy|Patients with ischaemic cardiomyopathy attending for ICD implantation
3230686|NCT01193881|Experimental|Treatment (erlotinib, RO4929097)|Patients receive erlotinib hydrochloride PO QD on days 1-21 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3230687|NCT01193894|Experimental|Profermin|
3230688|NCT01193894|Active Comparator|Fresubin|
3230689|NCT01193946||Single-arm design|There is currently considerable debate regarding the accuracy of the estimated average requirement (EAR) and the recommended dietary allowance (RDA) for older people. Very limited data obtained from older individuals are available to support the assumption that age does not affect protein requirement. Existing method like nitrogen balance has inherent limitations that diminish it from being considered a reference method. Indicator amino acid oxidation technique is emerging as an alternative method to measure dietary protein requirement. It is more accurate and less demanding. The current study will be the first time this technique is used with elderly adults and will provide an important foundation for geriatric nutrition research
3230690|NCT01193985|Experimental|Intervention|
3230691|NCT01193998|Active Comparator|Clinician exposed to Model result|
3230692|NCT01193998|Experimental|Clinician blinded to Model result|
3230693|NCT01194024||Intubated within 24hrs of admission|All patients that are admitted to a participating burn center and intubated within 24 hours
3230694|NCT01194037|Experimental|Hanferon (low dose) sc weekly + RBV oral daily|
3230695|NCT01194037|Experimental|Hanferon (high dose) sc weekly + RBV oral daily|
3230696|NCT01194037|Active Comparator|Pegasys 180 ug sc weekly + RBV oral daily|
3326094|NCT02058784|Experimental|Single-dose food effect in nonsmokers|Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.
3326095|NCT02058784|Experimental|Single-dose food effect in smokers|Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.
3326096|NCT02058797|Experimental|Coherence Therapy|Individual treatment with Coherence Therapy: three one-hour sessions + one booster session.
3326097|NCT02058797|Active Comparator|Cognitive Behavioral Therapy|Individual treatment with Cognitive Behavioral Therapy: three one-hour sessions + one booster session.
3326098|NCT02058810|Other|Conventional nasal Oxygen|Conventional nasal Oxygen as needed
3326099|NCT02058810|Other|Nasal high flow|Nasal high flow therapy with FiO2 40% and flow of 40l/min for at least 48h
3326100|NCT02058823|Placebo Comparator|Arm 1: Real hypoxia and ¨Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 2.
3326101|NCT02058823|Placebo Comparator|Arm 2: Hypoxia placebo and Placebo|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the hypoxia placebo and the placebo during the first two weeks and, after the wash-out, receive the treatment of the arm 1.
3326102|NCT02058823|Active Comparator|Arm 3: Hypoxia and Valsartan|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the Valsartan during the first two weeks and, after the wash-out, receive the treatment of the arm 4.
3326103|NCT02058823|Active Comparator|Arm 4: Hypoxia and Amlodipine|This arm last 4 weeks with 2 periods of 2 weeks separated by a 6 weeks wash-out. The subjects of this arm receive the real hypoxia and the amlodipine during the first two weeks and, after the wash-out, receive the treatment of the arm 3.
3326104|NCT02058875|Experimental|Treatment Group|Maximization of mycophenolicacid (MPA) derivative (to a total daily dosage of 1440mg of Myfortic®) and reduction of cyclosporine dosage (as defined by C2 monitoring) in 50 stable renal transplant patients previously on immunosuppressive therapy with cyclosporine, an MPA derivative and prednisone.
3326105|NCT02058875|Active Comparator|Control Group|25 patients continued on an mycophenolicacid (MPA) derivative, cyclosporine and prednisone.
3326106|NCT02058875|No Intervention|Observation Group|25 patients continued on an mycophenolic acid (MPA) derivative, tacrolimus, and prednisone will be followed during the same recruitment period as an additional comparison, as this is the other Calcineurin Inhibitor (CNI), which is used in kidney transplantation.
3326107|NCT02058901|Experimental|Sunitinib high dose, weekly schedule|Initial dose of sunitinib is set at 200 mg once weekly. Three patients are treated at the current dose level. If at least 2 patients are observed to have Dose Limiting Toxicity (DLT), the prior dose level is defined as the Maximum Tolerated Dose (MTD) (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort of 3 patients. If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level. If none of these show DLT, the dose level is escalated for the next cohort of 3 patients; otherwise, the prior dose level is defined as the MTD (unless only 3 patients have been treated at that level, in which case it is the tentative MTD). A tentative MTD becomes final when a total of 6 patients are treated with less than 2 showing DLT
3326108|NCT02058901|Experimental|Sunitinib high dose, biweekly schedule|When the final MTD is reached for the cohort of patients treated once weekly and depending on the toxicities developed and defining MTD, enrollment of patients in the once every 2 weeks escalation cohort will begin, with the initial dose set at the MTD dose of the once weekly schedule, escalating again at 100 mg increments per dose level.
3326109|NCT02058914|Experimental|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage (sweetened with 50 g fructose and 15 g glucose)
3326110|NCT02058914|Active Comparator|High Glucose sweetened beverage|HG-sweetened beverage (sweetened with 50 g glucose and 15 g fructose)
3326111|NCT02058927||HIV-1 infected children|HIV-1-infected children initiating ART
3230697|NCT01194050||Cohort|
3230698|NCT01194063|Experimental|Omegaven|Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs
3230699|NCT01194076|Experimental|5day intensive treatment|
3230700|NCT01194102|Experimental|Stroke Community Wellness Program|"Participants with stroke will attend a 12 week Community Wellness Program. The program consists of a Community Based Exercise Program at the YMCA (2x 1 hour exercise sessions per week with specially trained fitness instructors). They will also attend a 1 hour long Living with Stroke education session one time per week and an independent exercise session in the fitness centre one time per week."
3326112|NCT02058927||HIV-1 uninfected children|control group of HIV-1 uninfected children matched by age
3326113|NCT02058927||HIV-1 infected children revaccinated|nested study of revaccination against measles virus of HIV-1-infected children receiving ART who lack protective antibody titers
3326114|NCT02058953||Craniotomy scheduled|"Patients who have scheduled craniotomy with melanoma brain metastases will have the following specimens collected:~CNS tumor specimens, specifically the remaining portion from the resected melanoma CNS metastasis~the remaining portion from the adjacent normal CNS tissue. No additional normal brain tissue will be collected for research purposes only, however the routinely collect peritumoral tissue will be retained.~melanoma specimens from other extracranial, clinically palpable metastatic sites.~CSF taken at around the time of the craniotomy procedure~peripheral blood prior to craniotomy."
3326115|NCT02058953||Collection for non-craniotomy|"For those eligible patients who are not having a craniotomy:~collection of CSF will be performed by lumbar puncture or from the patient's Ommaya reservoir, if present.~collection of peripheral blood.~NOTE: Only patients who have no absolute contraindications or up to two relative contraindications will be considered for lumbar puncture"
3326116|NCT02058979|Active Comparator|BOLUS INFUSION|Bolus infusion of antibiotics
3326117|NCT02058979|Experimental|CONTINUOUS INFUSION|Continuous infusion of antibiotics by way of infusion pump
3230701|NCT01194102|Active Comparator|Regular YMCA membership|"The control group will have access to YMCA facilities to use at their discretion but will not attend the Community Based Exercise Program for stroke survivors or the Living with Stroke education program. YMCA staff working with the control group will not receive specialized training in exercise and education for stroke survivors but will be trained on important safety precautions and contraindications to exercise after stroke."
3230702|NCT01194115|Experimental|Cephalexin and metronidazole|500 mg cephalexin per oral every 8 hours for total of 6 doses; 500 mg metronidazole per oral every 8 hours for total of 6 doses
3230703|NCT01194115|Placebo Comparator|Placebo/standard of care|Placebo pills per oral every 8 hours for total of 6 doses
3230704|NCT01194128|Experimental|Psychoeducatioinal Support|The intervention is comprised of three modules (see Table 6), each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
3230705|NCT01194128|Active Comparator|INformation only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. This packet will contain several fact sheets from a nationally-recognized expert source in caregiving (the Family Caregiver Alliance's National Center on Caregiving) and a national information and advocacy group (the National Citizens' Coalition for Nursing Home Reform). The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition."
3230706|NCT01194141|Experimental|Exercise training|Aerobic exercise training 45-60 min/3x/week/12 weeks
3326118|NCT02059018|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions over two examination days
3326119|NCT02059018|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions over two examination days
3326120|NCT02059031|Experimental|Part A|In Part A, subjects will be randomized to receive two new formulations of GSK1265744 30 mg (New formulation 1 -micronized [B], New formulation 2un-micronized [C]) and the sodium salt reference formulation 30 mg (Reference formulation [A]) in one of six sequences; ABC, BCA, CAB, BAC, ACB, CBA in three treatment periods under fasting condition.
3326121|NCT02059031|Experimental|Part B|Fifteen eligible subjects completing the Part A of the study will enter in to Part B where they will receive either formulation B or C. The selected drug (B or C) will be administered under fed (moderate fat meal) condition in the fourth treatment period.
3326122|NCT02059044|Experimental|ISTOP-ADE|Interactive Voice Response System + Pharmacist
3326123|NCT02059044|No Intervention|Routine care|Routine care
3326124|NCT02059083|Active Comparator|Cognitive behavioral therapy (CBT) alone|
3326125|NCT02059083|Experimental|Cognitive behavioral therapy plus HRV biofeedback|
3326126|NCT02059096|Experimental|Repetitive transcranial magnetic stimulation (rTMS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation
3326127|NCT02059096|Other|Theta-Burst Stimulation (pcTBS)|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
3326128|NCT02059096|Other|repetitive Transcranial Magnetic Stimulation (rTMS)placebo|The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.
3326129|NCT02059109|Experimental|Single|Staff will work alone to assemble the Belmont Rapid Infuser
3326130|NCT02059109|Experimental|Pair|Staff will work in pairs to assemble the Belmont Rapid Infuser
3326131|NCT02059200|Experimental|MBCL + TAU|This cohort receives the Mindfulness Based Compassionate Living program in addition to treatment as usual.
3326132|NCT02059200|No Intervention|TAU|This cohort receives treatment as usual of any nature, e.g. psychotherapy, antidepressant medication etc.
3230707|NCT01194167|Experimental|Eltrombopag|Eltrombopag 75 mg per day. Possible escalation to 150 mg per day after day 15 lab results. Possible escalation to 300 mg per day after day 29 lab results.
3230708|NCT01194180|Experimental|Group A|"BCG-naive subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
3230709|NCT01194180|Experimental|Group B|"BCG-naïve subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
3230710|NCT01194180|Experimental|Group C|"BCG-experienced subjects receiving intradermal challenge injection of BCG and challenge site punch biopsy"
3230711|NCT01194180|Experimental|Group D|"BCG-experienced subjects receiving intradermal injection of MVA85A followed by intradermal challenge injection of BCG and challenge site punch biopsy"
3230712|NCT01194193|Experimental|1|
3230713|NCT01194206|Experimental|Arm I|Patients undergo 3 fractions of stereotactic body radiation therapy in 3 fractions delivered within 14 days in the absence of disease progression or unacceptable toxicity.
3326133|NCT02059226|Experimental|Internet-based CBT|Internet-based cognitive behavioural therapy
3326134|NCT02059226|Active Comparator|Internet-based resource page|Static webpage
3326135|NCT02059252|Experimental|SmartMatrix scaffold|SmartMatrix dermal replacement scaffold
3326136|NCT02059304|Other|Preterm Delivery|Preterm Delivery: Births before the completion of 37 weeks' of gestation.
3326137|NCT02059304|Other|Term Delivery|Term Delivery: Births after the completion of 37 weeks' of gestation.
3326138|NCT02059317||Group 1|"Six groups are created in order to randomized the order of interventions. In group 1, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Rotation in a transverse plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326139|NCT02059317||Group 2|"Six groups are created in order to randomized the order of interventions. In group 2, the order of interventions is as follows:~Flexion-extension in the sagittal plane~Complex movement in three dimensions~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326140|NCT02059317||Group 3|"Six groups are created in order to randomized the order of interventions. In group 3, the order of interventions is as follows:~Rotation in a transverse plane~Flexion-extension in the sagittal plane~Complex movement in three dimensions~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326141|NCT02059317||Group 4|"Six groups are created in order to randomized the order of interventions. In group 4, the order of interventions is as follows:~Rotation in a transverse plane~Complex movement in three dimensions~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326142|NCT02059317||Group 5|"Six groups are created in order to randomized the order of interventions. In group 5, the order of interventions is as follows:~Complex movement in three dimensions~Flexion-extension in the sagittal plane~Rotation in a transverse plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326143|NCT02059317||Group 6|"Six groups are created in order to randomized the order of interventions. In group 6, the order of interventions is as follows:~Complex movement in three dimensions~Rotation in a transverse plane~Flexion-extension in the sagittal plane~2 minutes of rest and walking occurs between interventions. The above-mentioned exercises (1, 2 & 3) are performed on day 0, day 7 and week 6 for patients, and only on day 0 for healthy volunteers."
3326144|NCT02059330|Experimental|Healthy Subjects of Japanese Descent|Enrolled Japanese subjects will receive four palbociclib single doses of differing dose amounts in fixed sequence over four treatment periods.
3326145|NCT02059330|Experimental|Healthy Non-Asian Subjects|Enrolled healthy non-Asian subjects will receive a single 125mg oral dose of palbociclib in a single treatment period.
3326146|NCT02059343||age less than or equal to 2 years|
3230714|NCT01194232|Experimental|Sildenafil|15 subjects will receive 8 week course of Sildenafil administered at a dose of 20 mg per dose three times per day.
3230715|NCT01194284||High-grade osteosarcoma patients|
3326147|NCT02059356||Non-cirrhotic patients with cognitive impairment|
3326148|NCT02059369|Active Comparator|CFAE ablation|Intervention: Complex fractionated atrial electrograms (CFAE) Ablation
3326149|NCT02059369|Active Comparator|CFAE + Lines|CFAE Ablation followed by linear lesions (anterior and Roof line)
3326150|NCT02059382|Active Comparator|Control|ChiRunning training Weekly training log Blinded accelerometer
3326151|NCT02059382|Experimental|Technology support for behavior change|ChiRunning training unblinded accelerometer tracking structured exercise using mobile app participation in online social network participation in study website
3326152|NCT02059421|Experimental|Johrei Therapy|"3 sessions per week lasting 30 minutes.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
3326153|NCT02059421|Active Comparator|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"1 session per week for a total of 6 weeks with the option of 2 additional sessions.~Daily report of bedtime and wake time.~Baseline:~Polysomnography~Actigraphy~Questionnaires~Blood draw~Urine collection~2 weeks:~Questionnaires~Actigraphy download~Sleep log reconciliation~6 weeks:~Polysomnography~Actigraphy download~sleep log reconciliation~Questionnaires~Blood draw~Urine collection"
3326154|NCT02059447|Experimental|Mindfulness Based Cognitive Therapy|An 8 week course of Mindfulness Based Cognitive therapy
3326155|NCT02059447|Active Comparator|Relaxation Therapy|An 8 week course of Relaxation Therapy.
3326156|NCT02059460|Experimental|Terlipressin group|Terlipressin group, Terlipressin (Glypressin®, Rentschler biotechnology Gmbh, Erwin, Germany) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
3230716|NCT01194310||phaco alone|patients w/ diagnosis of open angle glaucoma underwent phaco alone
3230717|NCT01194310||phaco-ELT|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus ELT
3230718|NCT01194310||phaco-Trabectome|patients w/ diagnosis of open angle glaucoma underwent combined phaco plus Trabectome
3230719|NCT01194323||Controls|No complaints or history of heartburn or acid regurgitation; no erosion at EGD; and normal pH monitoring
3230720|NCT01194323||GERD Cases|Patients with esophageal erosion at EGD and abnormal pH monitoring.
3230721|NCT01194336||Huperzine A: 100 ug|
3230722|NCT01194336||Huperzine A: 200 ug|
3230723|NCT01194336||Donepezil: 2.5 mg|
3230724|NCT01194336||Donepezil: 5 mg|
3230725|NCT01194336||Galantamine: 4 mg|
3230726|NCT01194336||Galantamine: 8 mg|
3230727|NCT01194336||Placebo|
3230728|NCT01194362||45 specimens collected from BAV patients|
3230729|NCT01194362||45 specimens collected from TAV patients|
3230730|NCT01194362||15 specimens collected from CABG pts|
3230731|NCT01194375|Experimental|Low Strength IDP-107|
3230732|NCT01194375|Experimental|High Strength IDP-107|
3230733|NCT01194375|Placebo Comparator|Placebo|
3230734|NCT01194388||MicroFx™ PGLA Treated Subjects|
3230735|NCT01194401||Cohort|
3230736|NCT01194492|Other|Albumin kinetics|
3230737|NCT01194505|Active Comparator|ACL, sciatic, femoral, obturator|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
3326157|NCT02059460|Placebo Comparator|Control group|
3230738|NCT01194505|Active Comparator|ACL, sciatic nerve block, posterior lumbar plexus block|ACL reconstruction surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
3230739|NCT01194518|Experimental|Lifestyle Intervention Program|
3230740|NCT01194544||population undergoing EGD in health examination.|
3326158|NCT02059473|Experimental|Physiotherapy & Surgery|Mini-open rotator cuff repair
3326159|NCT02059473|Active Comparator|Physiotherapy|Structured physiotherapy
3326160|NCT02059486|Experimental|Teen Choice|The curriculum provides comprehensive sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress. The curriculum can be delivered in different formats that range in length from 6 to 12 weeks.
3326161|NCT02059486|No Intervention|Control|Business as usual school health curriuclum
3230741|NCT01194557|Active Comparator|rapid diagnostic test|Treatment and diagnosis of malaria in drugs hops using rapid diagnostic tests
3230742|NCT01194557|No Intervention|Presumptive malaria treatment|Presumptive treatment for malaria in drug shops
3230743|NCT01194583||NO NICOTINE|Well characterized group of 100 regular smokers experimenting the E-Cigarette without nicotine cartridges (NO nicotine group).
3326162|NCT02059499|Experimental|Arm A (imiquimod)|Patients apply imiquimod intra-anally QD for 16 weeks.
3326163|NCT02059499|Experimental|Arm B (fluorouracil)|Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
3326164|NCT02059499|No Intervention|Arm C (observation)|Patients receive no treatment. Patients who still have HSIL at week 20 and who agree to randomization may cross-over to Arm A or B.
3326165|NCT02059525||syphilis infected|all patients with a new diagnosis of syphilis, receiving treatment at the Institute of Tropical Medicine
3326166|NCT02059538|Other|Group 1|Metabolic syndrome
3230744|NCT01194596|Experimental|Spirometry and lifestyle counseling|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
3230745|NCT01194596|No Intervention|Lifestyle counseling|No intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
3230746|NCT01194609|Experimental|Low dose radiation, Immune cell therapy|Combination treatment of low-dose radiation 20cGy every 3 weeks three times and autologous immune cell therapy 2 consecutive weeks 3 times every 3 weeks
3230747|NCT01194622|Experimental|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
3230748|NCT01194622|Active Comparator|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
3230749|NCT01194622|Active Comparator|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
3326167|NCT02059538|Other|Group 2|Severly obese patients
3326168|NCT02059538|Other|Group 3|Type-2 diabetics patients
3326169|NCT02059538|Other|Group 4|Patients with first recent (< 2 weeks) acute coronary syndrome (ACS)
3326170|NCT02059538|Other|Group 5|Patients with stable chronic coronary artery disease without heart failure
3326171|NCT02059538|Other|Group 6|Patients with ischemic systolic heart failure (CHF)
3326172|NCT02059538|Other|Group 7|Patients with non-ischemic chronic heart failure
3326173|NCT02059538|Other|Group 8|Healthy volunteers
3326174|NCT02059551|Experimental|Intervention|"In case of positive D-dimer testing or in patients with a high clinical probability of PE, these patients have MRI protocol combined with venous ultrasonography of the legs. MRI includes 2 different sequences: Unenhanced steady-state-free precession sequences (SSFP) sequences and angiography sequences. (please see \\\intervention section\\\ for more details). MRI readings will be performed centrally by two independent readers blinded to the results of diagnostic reference standard. Venous ultrasonography of the legs will be interpreted locally."
3326175|NCT02059564|Experimental|Cohort A|The weekly treatment of the 6 mg HM11260C or placebo will be maintained
3326176|NCT02059564|Experimental|Cohort B|The monthly treatment with 4 mg HM11260C or placebo will be up titrated to 16 mg
3326177|NCT02059564|Experimental|Cohort C|The daily treatment with 0.6 mg Victoza will be up titrated to 1.2 mg
3326178|NCT02059577|Experimental|Treatment Group|This group received a combination of nutritional treatments, added sequentially, including vitamins/minerals, essential fatty acids, Epsom salt baths, carnitine, digestive enzymes, and healthy, gluten-free, casein-free diets.
3326179|NCT02059577|No Intervention|Non-Treatment Group|This group did not have any significant changes in their treatments for 12 months
3326180|NCT02059590|Experimental|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|single dose
3326181|NCT02059603|Experimental|Electroacupuncture|Bilateral acupoints relevant to the treatment of abdominal pain, abdominal distension, and constipation, including Zusanli (stomach meridian ST-36), Sanyinjiao (spleen meridian SP-6), Hegu (large intestine meridian LI-4), and Zhigou (triple energizer meridian TE-6), will be used. Electric stimulation at a frequency of 50 Hz will be employed to the acupuncture needles.
3326182|NCT02059603|Active Comparator|Fast-track program|The design of this program is based on the consensus between our surgeons, anesthetists, physiotherapists, dietitians, and nurses, who have reviewed the relevant literature and made appropriate adjustments to suit the local situation.
3326183|NCT02059616|Experimental|AML 5mg|Amlodipine 5 mg, once a day for 8 weeks
3326184|NCT02059616|Experimental|AML 10mg|Amlodipine 10 mg, once a day for 8 weeks
3326185|NCT02059616|Experimental|CC 8mg|Candesartan Cilexetil 8 mg, once a day for 8 weeks
3326186|NCT02059616|Experimental|CC 16mg|Candesartan Cilexetil 16 mg, once a day for 8 weeks
3230750|NCT01194648|Other|High Intensity Focused Ultrasound|HIFU, the Intervention
3326187|NCT02059616|Experimental|AML 5mg/CC 8mg|Amlodipine 5 mg and Candesartan 8 mg, once a day for 8 weeks
3326188|NCT02059616|Experimental|AML 5mg/CC16mg|Amlodipine 5 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
3326189|NCT02059616|Experimental|AML 10mg/CC 8mg|Amlodipine 10 mg and Candesartan Cilexetil 8 mg, once a day for 8 weeks
3326190|NCT02059616|Experimental|AML 10mg/CC 16mg|Amlodipine 10 mg and Candesartan Cilexetil 16 mg, once a day for 8 weeks
3326191|NCT02059629||Group A: Eluna pacemaker family|Patients with standard indication for pacemaker therapy or Cardiac Resynchronization Therapy (CRT), who will be implanted with a pacemaker or CRT device of the Eluna pacemaker family. Single-, Dual- and Tripple-chamber pacemakers are applicable.
3326192|NCT02059629||Group B: Sentus BP lead|Heart failure patients with indication for Cardiac Resynchronization Therapy (CRT) therapy, who will be implanted with the left ventricular Sentus BP lead. Patients can receive either CRT pacemaker or CRT-D (CRT with defibrillator function).
3326193|NCT02059655|Placebo Comparator|Eye drop solution|Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
3326194|NCT02059655|Active Comparator|Bimatoprost|1 drop daily of Bimatoprost 0.03%. Patients will receive 1 dose daily over 3 month period followed by 2 months washout period. Subsequently patient will cross over to the opposite treatment and continue further treatment for 3 month period.
3230751|NCT01194700|Experimental|Evohaler|
3230752|NCT01194700|Experimental|Volumatic spacer|
3326195|NCT02059681|Experimental|Autologous bone marrow derived-CD133+ cells|CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.
3326196|NCT02059694|Experimental|Hyaluronidase|"Dilutions (Blocks):~0.5 mL of lidocaine 2% with epinephrine 1:100,000 and 0.5 mL of marcaine 0.75% and 1 mL (150 U) of rHuPH20 for a total of 75 U/ml"
3326197|NCT02059694|Other|Comparitor|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20
3326198|NCT02059707|Experimental|LAA exclusion procedure|LAA exclusion with the LARIAT RS Suture Delivery Device
3326199|NCT02059720|Active Comparator|auto|patients receive autologous SCT
3326200|NCT02059720|Active Comparator|haplo|patients receive haplo-SCT
3326201|NCT02059733|Experimental|18F-DTBZ for Parkinson's Disease and parkinsonism|"This study will compare the brain uptake of 18F- DTBZ in 20 patients with PD, 20 patients with MSA, 20 patients with PSP, 20 patients with CBS, and 20 patients with VaP, 20 patients with ET, and 10 patients with DT.~Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3326202|NCT02059746||Vaginal birth|"Patients in the group give birth vaginally.~Intervention: Questionnaires sent by mail"
3326203|NCT02059746||Cesaren section|"Patients in this group give birth via cesarean section.~Intervention: Questionnaires sent by mail"
3326204|NCT02059759|Placebo Comparator|Placebo|"Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: Placebo"
3326205|NCT02059759|Experimental|1.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 1.0 MIU IL-2 per day"
3326206|NCT02059759|Experimental|2.0 IL-2|"Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).~Intervention: 2.0 MIU IL-2 per day"
3326207|NCT02059772|Experimental|Control Group|Standard therapy of diabetic macular edema with Lucentis (ranibizumab) according to SmPC
3326208|NCT02059772|Experimental|Treatment Group|Combination of standard therapy of Lucentis (ranibizumab) according to SmPC and micropulse diode laser treatment
3326209|NCT02059785|Experimental|Pinocembrin for Injection|40mg /60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
3326210|NCT02059785|Placebo Comparator|placebo|60mg in 100ml of a solution of 0.9 percent saline,iv.drip bid,14day
3326211|NCT02059798||Decompression of cervical myelopathy|JOA (Japanese Orthopaedic Association) Scores for cervical myelopathy Compliance Rigidity activity unit
3326212|NCT02059811|Experimental|DASH Diet|"All participants will be provided a control diet for a 7-day run-in period followed by the DASH dietary intervention for a 14-day intervention period. Participants will consume the largest meal of the day in a supervised setting at the study center and all other meals and snacks will be provided in to-go packages. Weight will be held constant by measuring participant weight daily and adjusting caloric content of meals. Adherence will be monitor by review of daily food diaries."
3230753|NCT01194700|Experimental|Aerochamber Plus|
3230754|NCT01194700|Experimental|Synchro-Breathe|
3230755|NCT01194713|Active Comparator|Sleep deprivation|"13 subjects will undergo full sleep deprivation~these subjects are blind to allocation ntil they enter the study center"
3230756|NCT01194713|No Intervention|Control night|control night of unrestricted sleep in 13 other subjects
3326213|NCT02059824|Experimental|Eyelid|The selection of the laterality of the eyelid will be randomized
3230757|NCT01194765|Experimental|Cognitive Behavioural Therapy|
3230758|NCT01194765|No Intervention|Waiting List|
3230759|NCT01194778|Placebo Comparator|placebo|The participants of the placebo group will receive daily 1 placebo sachet containing only sucrose
3230760|NCT01194778|Active Comparator|vitamin K1|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K1.
3230761|NCT01194778|Active Comparator|vitamin K2 - 15 µg|The participants of this group will receive daily 1 sachet containing 15 µg vitamin K2
3230762|NCT01194778|Active Comparator|vitamin K2 - 30 µg|The participants of this group will receive daily 1 sachet containing 30 µg vitamin K2
3230763|NCT01194778|Active Comparator|vitamin K2 - 45 µg|The participants of this group will receive daily 1 sachet containing 45 µg vitamin K2.
3230764|NCT01194791|Experimental|Lenalidomide, Cyclophosphamide and Dexamenthasone|
3230765|NCT01194817|Other|Cemented fixation|Nexgen High-Flexion Knee Replacement System using Cemented Fixation
3326214|NCT02059837||Pterygium,recurrent|Consecutively recorded photographs of recurrent pterygium excision and following grafting were analyzed.
3326215|NCT02059850|Experimental|Treatment (cyclophosphamide, NY-ESO-1 specific T cells)|Patients receive cyclophosphamide IV on days -3 and -2 and NY-ESO-1 specific T cells IV over 60 minutes on day 0. Patients may receive additional infusions at the discretion of the PI.
3326216|NCT02059863|Experimental|SPRING intervention clusters|"SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision~PLUS access to routine maternal and child health services"
3326217|NCT02059863|No Intervention|Control clusters|access to routine maternal and child health services
3326218|NCT02059876|Experimental|carboplatin and paclitaxel ± trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer.
3326219|NCT02059889|Experimental|Diagnostic (diffusion-weighted MRI, 4D CT, FDG-PET)|Patients undergo 15 imaging studies: 5 chest CT scans, 5 chest MRI scans, 5 PET scans. Each scan will be obtained before treatment begins, weeks 2 and 4 during radiation therapy, 3 months and 1 year following radiation therapy. THe chest CT obtained pre-treatment, at 3 months post treatment and 1 year post treatment are considered routine and would be obtained regardless of study participation. The pre-treatment PET scan is also considered routine. All other scans are being done for the purposes of this research.
3326220|NCT02059915|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3326221|NCT02059915|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3326222|NCT02059915|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3230766|NCT01194817|Other|Cementless fixation|Nexgen High-Flexion Knee Replacement System using Cementless Fixation
3230767|NCT01194843|Experimental|Ropivacaine|Ropivacaine administration by local per and post surgery infiltration
3230768|NCT01194843|Active Comparator|Physiological serum|Administration of physiological serum by local per and post surgery infiltration
3326223|NCT02059915|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3326224|NCT02059954|Active Comparator|Vaginal hysterectomy|Vaginal hysterectomy
3326225|NCT02059954|Active Comparator|Total laparoscopic hysterectomy|Laparoscopic hysterectomy
3230769|NCT01194882|Experimental|Insuman Implantable|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
3230770|NCT01194882|Active Comparator|Insuplant|Starting dose regimen is the same as the one administered to the patient prior randomization, then the insulin odse is established by the investigator on a patient basis in respect to the American Diabetes Association guidelines.
3326226|NCT02059967|Experimental|Treatment (IGART using ABC, SIVAB, paclitaxel, carboplatin)|Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
3326227|NCT02060006|Placebo Comparator|Placebo 7.5 mg daily for 8 weeks|Placebo 7.5 mg once-daily First 8 weeks of ART Only Control arm
3326228|NCT02060006|Experimental|Meloxicam 7.5 mg once-daily|Meloxicam 7.5mg once-daily for 8 weeks
3230771|NCT01194895|Experimental|protective ventilation|
3230772|NCT01194895|Active Comparator|conventional ventilation|
3326229|NCT02060019|Experimental|exforge 10/160mg(amlodipine 10mg, valsartan160mg)|1 tablet daily for 10days
3326230|NCT02060019|Experimental|crestor 20mg(rosuvastatin 20mg)|1 tablet daily for 7days
3326231|NCT02060032|Active Comparator|Atorvastatin|1.2% atorvastatin local drug delivery
3326232|NCT02060032|Sham Comparator|Simvastatin|1.2% simvastatin local drug delivery
3326233|NCT02060032|Placebo Comparator|Placebo|Placebo local drug delivery
3230773|NCT01194934|Experimental|Group A|Group A: 2.0 mg/kg NOX-A12 IV every day for 5 days
3230774|NCT01194934|Experimental|Group B|Group B: 4.0 mg/kg NOX-A12 IV every day for 5 days
3230775|NCT01194934|Active Comparator|Group C|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group C: 5 µg/kg filgrastim SC every day for 5 days"
3230776|NCT01194934|Experimental|Group D|"The treatment groups will enter the study sequentially. The decision on starting groups C and D will be made after groups A and B have been completed and data are available.~Group D: Safe and efficacious dose of NOX-A12 IV in combination with filgrastim SC for 5 days"
3230777|NCT01194947||Study participants|patients 18 or older presenting to the Sheba Medical Center pigmented lesion clinic for skin cancer surveillance. Patients routinely undergo total skin examination that includes clinical and dermoscopic evaluation of skin lesions. Patients also routinely undergo annual total body digital photography that allows identification of new or changing lesions.
3230778|NCT01194960|Active Comparator|Docetaxel Alone|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
3230779|NCT01194960|Experimental|TroVax plus Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
3230780|NCT01194986|Experimental|Pilot panel|[11C]AZ12807110 distribution and kinetics
3230781|NCT01194986|Experimental|Main panel|Histamine receptor occupancy reached by AZD5213
3230782|NCT01195012|Other|wait-list control arm|Participants wait-listed to start the behavioral obesity treatment program (Helping HAND) after time two data collection (7 months after baseline).
3326234|NCT02060045|Experimental|bundle implementation|The measures were a specific training program, aspiration of subglottic secretions (ASS), introduction of an inclinometer to improve the semirecumbent position, and reinforcement of oral care with chlorhexidine.
3326235|NCT02060071|Other|Aortic setnsosi|blood test
3230783|NCT01195012|Experimental|Intervention arm|see intervention description
3230784|NCT01195051|Experimental|Electronic medication reconciliation|Providers have access to a new, computer-based application to facilitate documentation and prescribing of outpatient medications in the inpatient setting.
3326236|NCT02060071|Other|controls|blood test
3326237|NCT02060084|Experimental|a control group|a control group : the same dose of luke warm water
3326238|NCT02060084|Experimental|treatment group|treatment group: viable Bifidobacterium 0.5 bid po
3326239|NCT02060097|Active Comparator|Cocoa flavanol beverage|flavanol 320mg/day
3326240|NCT02060097|Placebo Comparator|Placebo beverage|no flavanol
3326241|NCT02060110||MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study
3326242|NCT02060110||MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study
3326243|NCT02060123|Experimental|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
3326244|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
3326245|NCT02060136||Study group|Men presenting to the urology clinic with lower urinary tract symptoms
3326246|NCT02060149|Sham Comparator|no nebulization|Antibiotics protocol is C/S plus minocycline. That is Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral,q12h).No nebulization will given to these patients.
3326247|NCT02060149|Active Comparator|nebulization with pH 7.4 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.4 solution(Each time the volume of aerosol solution is 5ml, q8h).
3326248|NCT02060149|Experimental|nebulization with pH 7.8 solution|Patients will received the same antibiotics protocol with C/S plus minocycline and nebulization with pH 7.8 solution(Each time the volume of aerosol solution is 5ml, q8h).
3326249|NCT02060175|Experimental|1 CILOTAX arm|Cilotax drug-eluting stents implantation
3326250|NCT02060175|Active Comparator|2 DESyne arm|DESyne drug-eluting stents implantation
3326251|NCT02060188|Experimental|Nivolumab Monotherapy|Nivolumab administered as IV infusion at a dose of 3mg/kg every 2 weeks until disease progression
3326252|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi)|"Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3 week (wk) for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~Dose Escalation Phase: (Complete)~Dose Level (DL) 1: Nivo 0.3mg/Kg with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~DL 1: Nivo 1mg/Kg IV with Ipi 1 mg/Kg IV every 3 wk for 4 doses followed by Nivo 3mg/Kg IV every 2wk until progression~DL 2a: Nivo 1mg/Kg IV with Ipi 3 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression~DL 2b: Nivo 3mg/Kg IV with Ipi 1 mg/Kg IV every 3wk for 4 doses followed by Nivo 3mg/Kg IV every 2 wk until progression"
3326253|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) Cohort C3|Nivo IV dosed every 2wk with Ipi IV dosed every 6wk.
3326254|NCT02060188|Experimental|Nivolumab (Nivo) + Ipilimumab (Ipi) + Cobimetinib Cohort C4|Nivo IV dosed every 2wk, with Ipi IV dosed every 6wk, combined with Cobimetinib dosed orally once daily 21 days on/7 days off.
3326255|NCT02060188|Experimental|Nivolumab (Nivo) + BMS-986016 Cohort C5|Nivo IV dosed every 2wk with BMS-986016 dosed every 2 wk
3326256|NCT02060188|Experimental|Nivolumab (Nivo) + Daratumumab Cohort C6|Daratumumab IV dosed weekly for week 1-8; then every 2 wks from Week 9-24; then every 4 wks on week 25; with Nivo dosed every 2 wks starting at week 3 and every 4 wks starting at week 25
3326257|NCT02060201|Other|Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting|Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods
3326258|NCT02060201|Other|Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3326259|NCT02060201|Other|Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed|Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3326260|NCT02060201|Other|Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting|Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods
3230785|NCT01195051|No Intervention|Control|
3230786|NCT01195064||COPD+ OSAS- patients|Patients with chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
3230787|NCT01195064||COPD- OSAS+ patients|Patients with obstructive sleep apnea syndrome (OSAS) and without chronic obstructive pulmonary disease (COPD), before planned cardiovascular surgery
3230788|NCT01195064||COPD+ OSAS+ patients|Patients with chronic obstructive pulmonary disease (COPD) and with obstructive sleep apnea syndrome (OSAS), with planned cardiovascular surgery
3230789|NCT01195064||COPD- OSAS- patients|Patients without chronic obstructive pulmonary disease (COPD) and without obstructive sleep apnea syndrome (OSAS), before planned cardiovascular surgery
3230790|NCT01195077|Experimental|Seaweed, Spirulina, Seaweed + Spirulina|"Randomized to:~Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day."
3230791|NCT01195129|Other|MicroVention Hydrogel Coils|FDA approved and in common use for cerebral aneurysm treatment.
3230792|NCT01195129|Active Comparator|Non-hydrogel coils|Cerecyte or bare platinum coils (FDA approved and in common use for treatment of cerebral aneurysm).
3230793|NCT01195142||PCOS-CSAT|Women with PCOS
3230794|NCT01195142||Control-CSAT|Control population consisting of women without PCOS, matched for age and BMI with the PCOS cohort
3230795|NCT01195155|Active Comparator|LC n-3 PUFA|Supplementation with 4 x 1g fish oil capsules (Seven Seas, Ireland) containing 1.9g combined EPA and DHA daily for 6 weeks.
3230796|NCT01195155|Placebo Comparator|Placebo (olive oil) supplement|4 x 1g olive oil capsules (Millas Inc) were given daily for 6 weeks.
3326261|NCT02060201|Other|Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3326262|NCT02060201|Other|Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed|Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods
3326263|NCT02060227|Active Comparator|Arthroscopic Bankart repair|After the diagnostic arthroscopy is completed, any other pathology is documented. At least 3 anchors will be used for the bankart repair for repair of the labrum with an inferior to superior capsular shift. The suture anchors used will be at the discretion of the surgeon but will be of the screw-in variety. The sutures are passed through the labrum, and the labrum is tied to the glenoid rim after the bone is prepared in the standard fashion. The surgical times will be recorded on standardized forms.
3230797|NCT01195155|No Intervention|Wash out period|A 6 week wash out period separated the LC n-3 PUFA and the Placebo (olive oil) arms. During this period the subjects took no supplements. This arm was designed to minimise a cross-over effect.
3326264|NCT02060227|Active Comparator|Open Latarjet procedure|A deltopectoral approach is used. The coracoacromial ligament (CAL) is exposed and incised 1 cm from its coracoid attachment. Harvesting of a 2.5- to 3-cm coracoid graft allows use of 2 screws for fixation to the glenoid neck through a subscapularis-splitting approach. The stump of the CAL is repaired to the capsule with the arm positioned in neutral. The graft is placed in a extra-articular fashion with capsular closure to the native glenoid rim.
3230798|NCT01195168||PCOS cohort|Women with PCOS as diagnosed by the NIH criteria
3230799|NCT01195168||Control cohort|Women without PCOS
3326265|NCT02060240|Experimental|High Activity Group|Subject randomized to High Activity group will have 36, one hour training sessions over 12 weeks.
3326266|NCT02060240|No Intervention|Standard of Care Group|The standard of care group will maintain their baseline level of activity for 12 weeks
3326267|NCT02060253|Experimental|ganetespib, paclitaxel, and trastuzumab with pertuzumab|Patients receive trastuzumab intravenously (IV) over 30 minutes on days 1, 8, 15, and 22, pertuzumab IV over 30 minutes every 3 weeks (only in Part II of the study, starting day 1), paclitaxel IV over 1 hour on days 1, 8, 15, and 22, and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. The MTD for ganetespib in combination with paclitaxel and trastuzumab is 150 mg/m2.
3326268|NCT02060266|Experimental|Semaglutide|
3326269|NCT02060279|Experimental|Lifestyle intervention and carotenoid supplement|
3230800|NCT01195181|Active Comparator|peginterferon alfa-2a plus ribavirin|patients will receive a fixed dose of 180ug/week of peginterferon alfa-2a plus ribavirin at 15mg/kg/daily.
3230801|NCT01195181|Active Comparator|peginterferon alfa-2b plus ribavirin|patients will receive a weight adjusted dose (1,5ug/kg) from 50 to 150ug/week of peginterferon alfa-2b (standard dose) or a lower dose (1,0ug/kg) at physician discretion (randomization list available only for 100 cases) plus ribavirin at 15mg/kg/daily.
3230802|NCT01195194|Experimental|A- negative pre-transplant ELISPOT|Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml (immunoassay) in the first 3 months, followed by trough levels of 5-10 ng/ml.
3230803|NCT01195194|Experimental|B- Positive pre-transplant ELISPOT|Tacrolimus 0.1 mg/kg/12h starting as soon as treatment allocation arrives to obtain targeting troughs levels of 8-15 ng/ml the first 3 months, followed by trough levels of 5-10 ng/ml until the end of the study.
3326270|NCT02060279|Experimental|Lifestyle intervention and placebo|
3326271|NCT02060292||COPD|Stable, Non hypoxaemic, without history of vascular disease
3326272|NCT02060292||Healthy smokers|Age matched, smokers without COPD
3326273|NCT02060305|Experimental|Bevacizumab|Bevacizumab intra-articular injection; dose 20mg~40mg every 28 days for 4 times
3326274|NCT02060318||Infliximab|35 Crohn patients about to start Infliximab treatment, gives as i.v. injection of 5 mg/kg at baseline, after 2 weeks, 6 weeks, and then every 8th week.
3230804|NCT01195207|Experimental|001|CNTO 3157 or placebo 0.003 mg/kg CNTO 3157 or placebo infusion
3230805|NCT01195207|Experimental|002|CNTO 3157 or placebo 0.01 mg/kg CNTO 3157 or placebo infusion
3230806|NCT01195207|Experimental|003|CNTO 3157 or placebo 0.03 mg/kg CNTO 3157 or placebo infusion
3230807|NCT01195207|Experimental|004|CNTO 3157 or placebo 0.1 mg/kg CNTO 3157 or placebo infusion
3230808|NCT01195207|Experimental|005|CNTO 3157 or placebo 0.3 mg/kg CNTO 3157 or placebo infusion
3230809|NCT01195207|Experimental|006|CNTO 3157 or placebo 1 mg/kg CNTO 3157 or placebo infusion
3230810|NCT01195207|Experimental|007|CNTO 3157 or placebo 3 mg/kg CNTO 3157 or placebo infusion
3230811|NCT01195207|Experimental|008|CNTO 3157 or placebo 10 mg/kg CNTO 3157 or placebo infusion
3326275|NCT02060318||Healthy controls|12 healthy controls without Crohn's Disease.
3326276|NCT02060331||Pelvic Organ Prolapse with Nocturia|Pelvic Organ Prolapse with Nocturia
3326277|NCT02060344||Hispanic/Latinos residing in the US|The cohort consists of over 16,400 persons of Hispanic/Latino origin, ages 18-74, specifically Cuban, Puerto Rican, Mexican, and Central/South American, to be recruited through four Field Centers affiliated with San Diego State University, Northwestern University in Chicago, Albert Einstein College of Medicine in the Bronx area of New York, and the University of Miami.
3326278|NCT02060357|Active Comparator|Resolute Integrity Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
3326279|NCT02060357|Active Comparator|Promus Stent|Patients will be randomised in a 1:1 ratio to receive two different types of DES
3326280|NCT02060396|Experimental|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
3326281|NCT02060409||spliceosome|patient who have available data for spliceosome mutation status
3326282|NCT02060422|Placebo Comparator|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
3326283|NCT02060422|Experimental|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
3326284|NCT02060435||EBER+ AMC|EBV+DLBCL patients in Asan Medical Center
3326285|NCT02060435||EBER+ SMC|EBV+DLBCL patients in Samsung Medical Center
3326286|NCT02060435||EBER- SMC|EBV-DLBCL patients in Samsung Medical Center
3326287|NCT02060448|Experimental|2wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal self-injurious thoughts and behaviors, or SITBs, (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
3230812|NCT01195220|Active Comparator|HIV-T|"Group 1, the control, will be the current standard of care, consenting video and testing for HIV alone (HIV-T).~This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test"
3230813|NCT01195220|Experimental|STI/HIV-T|"Group 2 will add routine STI testing for CT and GC, (STI/HIV-T).~This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED."
3326288|NCT02060448|Experimental|2wk baseline + reappraisal (+ awareness)|"Participants will first undergo a two-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs and behaviors (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
3326289|NCT02060448|Experimental|4wk baseline + awareness (+ reappraisal)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after emotion awareness training will go straight to a four-week follow-up, and not receive cognitive reappraisal. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after emotion awareness training will return to a two-week baseline phase before receiving cognitive reappraisal, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after emotion awareness training will immediately receive cognitive reappraisal and then enter a four-week follow-up."
3326290|NCT02060448|Experimental|4wk baseline + reappraisal + (awareness)|"Participants in this arm will first undergo a four-week baseline phase. Participants who evidence a significant decrease in non-suicidal SITBs (i.e., responders) after cognitive reappraisal will go straight to a four-week follow-up, and not receive emotion awareness training. Participants who evidence a less than satisfactory response in non-suicidal SITBs (i.e., partial responders) after cognitive reappraisal will return to a two-week baseline phase before receiving emotion awareness training, and then enter a four-week follow-up. Participants who evidence little to no response in non-suicidal SITBs (i.e., non-responders) after cognitive reappraisal will immediately receive emotion awareness training and then enter a four-week follow-up."
3326291|NCT02060474|Experimental|AHDS patients|all AHDS recruited for this study will be located in the experimental arm and will receive the investigational medicinal product Triac. The Triac dose will be individually titrated to the optimal dose level.
3326292|NCT02060487|Experimental|Low dose|
3326293|NCT02060487|Experimental|Medium dose|
3326294|NCT02060487|Experimental|High dose|
3326295|NCT02060500|Experimental|Cardiaplication|
3326296|NCT02060552|Placebo Comparator|Febuxostat|Febuxostat 40mg once a day
3326297|NCT02060552|Experimental|Febuxostat plus diacerein|Febuxostat 40mg once a day plus diacerein 50mg twice a day
3326298|NCT02060552|Experimental|Febuxostat plus Colchicine|Febuxostat 40mg once a day plus Colchicine 0.5mg twice a day
3326299|NCT02060565||Chronic liver disease|all patients with chronic liver disease followed using non-invasive methods
3326300|NCT02060578|Other|Intervention|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
3326301|NCT02060591|Active Comparator|Exparel|
3326302|NCT02060591|Active Comparator|Marcaine|
3326303|NCT02060604|Experimental|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID
3326304|NCT02060604|Active Comparator|Ranibizumab Alone|3 monthly ranibizumab, then as needed
3326305|NCT02060617|Experimental|Impairment-Based Group|The impairment-based intervention will be a multi-modal treatment approach utilizing manual therapy of the thoracolumbosacral spine and hips as well as motor control exercises. Patient education will also be provided.
3326306|NCT02060617|Active Comparator|Classification-Based Group|Patients in this group will be categorized into subgroups according to the Treatment-Based Classification (TBC) Algorithm and treated accordingly. Patient education will also be provided.
3326307|NCT02060630|Other|Available vein, open surg. revasc.|Subjects with an available SSGSV cohort randomized to open surgical revascularization
3326308|NCT02060630|Other|Available vein, endovasc. revasc.|Subjects with an available SSGSV cohort randomized to endovascular revascularization
3326309|NCT02060630|Other|Alternative conduit, open surg. revasc.|Subjects with an alternative conduit cohort randomized to open surgical revascularization
3326310|NCT02060630|Other|Alternative conduit, endovasc. revasc.|Subjects with an alternative conduit cohort randomized to endovascular revascularization
3326311|NCT02060643||Cross-sectional hemi-neck RT|
3326312|NCT02060656|Active Comparator|Control: R-GEM-P|Rituximab,Gemcitabine, Methylprednisolone,Cisplatin.
3326313|NCT02060656|Experimental|Experimental: LR-GEM|Lenalidomide, Rituximab, Gemcitabine, Methylprednisolone
3326314|NCT02060669|Experimental|Arm 1|xeloda maintaenance
3326315|NCT02060669|No Intervention|Arm 2|best supprotive care
3326316|NCT02060682||Navvus Catheter FFR|The Navvus Catheter is a rapid exchange microcatheter with a pressure sensor at the distal tip that measures Fractional Flow Reserve measurements to guide PCI treatment strategy.
3326317|NCT02060708|Other|Real HD-tDCS first, Sham HD-tDCS second|Real HD-tDCS will be applied in the first session Sham HD-tDCS will be applied in the second session (at least one week after the first session)
3326318|NCT02060708|Other|Sham HD-tDCS first, Real HD-tDCS second|Sham HD-tDCS will be applied in the first session Real HD-tDCS will be applied in the second session (at least one week after the first session)
3326319|NCT02060734|Experimental|lidocaine|The treatment group will receive a 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point. Three to five points injection.
3326320|NCT02060734|Active Comparator|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
3326321|NCT02060747|Experimental|Coordinator-based post fracture program|The intervention arm deals with the intervention of a nurse trained in the management of osteoporosis fractures assisted by a clinical research technician who will manage the logistics and reglementary aspects of the study (patient enrollment, quality and study proceedings).
3326322|NCT02060747|No Intervention|standard care|
3326323|NCT02060760||UTROPIA study cohort|At least two cTnI data points available (including baseline) with blood samples available for hs-cTnI testing. No intervention.
3326324|NCT02060786|Active Comparator|original Clopidogrel Bisulfate (Plavix®)|original Clopidogrel Bisulfate (Plavix®) 600mg loading
3326325|NCT02060786|Experimental|generic Clopidogrel Bisulfate (Plavitor®)|generic Clopidogrel Bisulfate (Plavitor®) 600mg loading
3326326|NCT02060812|Experimental|Group I, SSNB & ANB|21 patients were randomly allocated into group I, and received suprascapular nerve block (SSNB) and axillary nerve block (ANB) both with 10mL ropivacaine.
3326327|NCT02060812|Placebo Comparator|Group II, SSNB alone|The other 21 patients were allocated into group II, and received suprascapular nerve block (SSNB) with 10mL ropivacaine and axillary nerve block (ANB) with placebo (10mL normal saline).
3326328|NCT02060825||Regional saturation monitor|Patients undergoing surgical repair of hypoplastic left heart syndrome.
3326329|NCT02060851|Experimental|Vifor and EPO|intravenous iron and EPO
3326330|NCT02060851|Placebo Comparator|control|no intravenous iron or EPO
3326331|NCT02060851|Experimental|Vifor|intravenous iton but no EPO
3326332|NCT02060864|Placebo Comparator|Placebo|2 Placebo pills
3259149|NCT01467986|Experimental|Rapamycin, Dasatinib, Temozolomide, Irinotecan|Patients with rNB receive on the study arm the experimental combination of rapamycin (R)- mTOR Inhibitor, dasatinib (D)- protein kinase inhibitor irinotecan (I)- cytostatic topoisomerase-I-inhibitor and temozolomide (T)- Antineoplastic agent
3326333|NCT02060864|Experimental|AN-PEP 80.000 PPI|1 pill AN-PEP 80.000 PPI and 1 pill Placebo.
3326334|NCT02060864|Experimental|AN-PEP 160.000 PPI|2 pills AN-PEP 80.000 PPI
3326335|NCT02060877||patients suspected of having lung cancer|observational study, there is no study intervention, only patient questionnaires
3326336|NCT02060916|Experimental|PAZ320|Patients will all take part in the control arm of the study and then be crossed over into treatment with PAZ320 at two different dosages.
3326337|NCT02060929|Experimental|Sequence 1|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal (through nose) device with a nasal guide on Day 1 of period 1 as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
3326338|NCT02060929|Experimental|Sequence 2|Participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device without a nasal guide on Day 1 of period 1 as treatment regimen B at time 0 and repeated twice every 5 minutes (total dose: 84 mg). There will be a washout period of 5-10 days between the treatment regimens. On Day 1 of period 2, participants will self administer 1 spray of esketamine solution to each nostril using a intranasal device with a nasal guide as treatment regimen A at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
3326339|NCT02060942||Coronary artery bypass grafting|Post Anaesthetic Care Unit (PACU) patients treated with coronary artery bypass grafting (CABG) are highly eligible for this study. These are patients with an indication for fast track treatment (PACU) post-cardiac surgery with a good left ventricular ejection fraction without significant co-morbidity. The final decision for PACU-classification is taken by the responsible anaesthesiologist and intensivist in close collaboration with the cardiothoracic surgeon performing the operation, as well as the cardiologist.
3326340|NCT02060955|Experimental|Alecsat|"The experimental product is an autologous product based on the individual patients blood. Blood donation are performed in study weeks 0, 6, 11, 23 and 43.~The patient receives treatment as bolus injection at study weeks 4, 9, 14, 26 and 46."
3326341|NCT02060955|Active Comparator|bevacizumab/irinotecan|Patients allocated to the comparator arm will be treated in accordance with standard practice in Denmark for relapsed glioblastoma multiforme, up to 16 treatment cycles with 4 weeks duration
3326342|NCT02060968||IRIS PREMIER Cohort|Promus PREMIER
3326343|NCT02060981|Active Comparator|Interview only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
3326344|NCT02060981|Placebo Comparator|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey. These patients will be asked to review the brochure, complete the survey, and mail it back to the research team using a self-addressed stamped envelope.
3326345|NCT02060981|Experimental|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension, and to provide feedback regarding a new tool for helping patients learn more about their medications. Interview plus patients' index date for follow-up is the date of the scheduled interview.
3326346|NCT02060994||37-38 weeks|"Children who were born by elective Cesarean section after 37-38 gestational weeks.~Intervention: No intervention."
3326347|NCT02060994||39 week or more|Children who were born by elective Cesarean section after 39 gestational weeks or more Intervention: No intervention.
3326348|NCT02061007|Experimental|Scans, Surgery and Follow-up|Pre-surgery scans, surgical resection and post-surgery follow-up. All patients will receive a fluorodeoxyglucose (FDG)-PET scan as part of standard of care. This scan must be completed within 28 days of surgery for the patient to be eligible. All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered. Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
3326349|NCT02061020|Experimental|Sequence 1|"THC containing cigarettes 10mg~THC containing cigarettes 30mg~Placebo"
3326350|NCT02061020|Experimental|Sequence 2|"THC containing cigarettes 30mg~Placebo~THC containing cigarettes 10mg"
3326351|NCT02061020|Experimental|Sequence 3|"Placebo~THC containing cigarettes 10mg~THC containing cigarettes 30mg"
3326352|NCT02061046||On CPAP therapy|OSA patients assessed before and after 8 weeks of CPAP therapy
3326353|NCT02061059|Other|group 1|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements.~group is assigned to standard: wears shoes produced with standard procedure"
3326354|NCT02061059|Other|group 2|"group is assigned to block 1: shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
3230814|NCT01195220|Experimental|STI/HIV-Plus|"Group 3, in addition to combined STI/HIV testing, will add a behavioral video encouraging safer sex, which is chosen for participants based on their answers to a brief measure on stage of change (STI/HIV-PLUS).~This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes"
3230815|NCT01195233|Other|bioxtra spray and mouth rinse|Drug: BioXtra spray or mouth rinse Patients had been xerostomia due to radiation of head and neck were selected for the study. Gender, age, medical history, VAS, dichotomous questionnaire of xerostomia , and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received BioXtra spray and second group used BioXtra mouth rinse for 2 weeks and then 1 weeks wash -out period and for other 2 weeks drugs is switched . Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and 35 days after first visit.
3326355|NCT02061059|Other|group 3|"group is assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to standard: wears shoes produced with standard procedure"
3326356|NCT02061059|Other|group 4|"group assigned to block 2: shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements~group is assigned to with measurements: wears shoes produced with plantar pressure measurements"
3326357|NCT02061072||Population pharmacokinetic estimation|Patients with severe or moderate hemophilia A or B, providing sparse data for population PK estimation
3326358|NCT02061085|Experimental|monotherapy treatment with Eribulin|Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days
3326359|NCT02061098|Experimental|Pomegranate extract|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
3326360|NCT02061098|Placebo Comparator|Placebo|"Crossover and dose-response: Both groups A and B will consume pomegranate extract and placebo. Both groups will also consume two doses of pomegranate extract and placebo.~Group A will consume 1 daily capsule of pomegranate extract and group B will consume 1 daily capsule of placebo for 3 weeks. After a wash-out period of 3 weeks, group A will consume 1 daily capsule of placebo and group B will consume 1 daily capsule of pomegranate extract for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of pomegranate extract for 3 weeks and group B will consume 4 daily capsules of placebo for 3 weeks. After a washout period of 3 weeks, group A will consume 4 daily capsules of placebo for 3 weeks and group B will consume 4 daily capsules of pomegranate for 3 weeks."
3326361|NCT02061111||Subclinical thyroid disease|26 pregnant women with subclinical hypothyroidism and/orTPO-antibodies, and their offspring.
3326362|NCT02061111||Healthy controls|51 pregnant women without thyroid disease or any other metabolic disorders, and their offspring.
3326363|NCT02061124|Active Comparator|T2DM, sevelamer|Patients with type 2 diabetes treated with sevelamer
3326364|NCT02061124|Placebo Comparator|T2DM, placebo|Patients with type 2 diabetes treated with placebo
3326365|NCT02061124|Active Comparator|Healthy subjects, sevelamer|Healthy subjects treated with sevelamer
3326366|NCT02061124|Placebo Comparator|Healthy subjects, placebo|Healthy subjects treated with placebo
3326367|NCT02061137|Experimental|Rett syndrome, fingolimod (FTY720)|0.5 or 0.25mg Fingolimod daily
3230816|NCT01195246|Experimental|HEPLISAV|0.5 mL HEPLISAV
3230817|NCT01195246|Active Comparator|Engerix-B|2.0 mL Engerix-B
3326368|NCT02061150||Asymptomatic newborns that had sepsis workup|Evaluation of medical records of asymptomatic newborns that had sepsis workup in the first 48 hours of life.
3230818|NCT01195246|Active Comparator|Fendrix|0.5 mL Fendrix
3230819|NCT01195259||metformin|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
3230820|NCT01195259||rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
3230821|NCT01195285|Active Comparator|Single-Incision Laparoscopic Cholecsytectomy (SILS)|
3326369|NCT02061163|Experimental|Subjects with Crohn's disease|Contrast Enhanced Ultrasound Optison
3326370|NCT02061176|Experimental|Transanal Haemorrhoidal Dearterialization|Patients randomised to Transanal Haemorrhoidal Dearterialization.
3326371|NCT02061176|Active Comparator|Open Haemorrhoidectomy|Patients randomised to Open Haemorrhoidectomy
3326372|NCT02061189|Experimental|Swimming pool training group|"10 patients will be selected to perform a 6 months training in a swimming pool, from M12 to M18 or M18 to M24 or M24 to M36, in defined and reproducible conditions.~M0, M6, M12 and M18 or M0, M6, M12, M18 and M24 or M0, M6, M12, M18, M24 and M30 assessments: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis.~M12 to M18 or M18 to M24 or M24 to M30: Physical exercise in a swimming pool (3 times per week).~M24 or M30 or M36: Medical examination + MFM + Hammersmith scale + Non-invasive motor capacity analysis."
3326373|NCT02061189|No Intervention|Control group|"20 patients with same assessments at M0, M6, M12 and M18, but:~without swimming pool training.~without M24 assessment."
3326374|NCT02061215||recipients aged 20-40|CMV viral load
3326375|NCT02061215||recipients older than 60|CMV viral load
3326376|NCT02061228|No Intervention|Control arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle.
3326377|NCT02061228|Experimental|Induced endometrial injury arm|Women undergoing exogenous gonadotropin ovarian stimulation for ART in an antagonist downregulated cycle. Additionally, they will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France).
3326378|NCT02061241||Patients|All included patients, having CRT implant procedure Will have both Pacing in vein at site of latest mechanical activation and Pacing in other suitable vein.
3326379|NCT02061254|Experimental|3 groups of subjects|"3 groups:~group of 48 healthy volunteers (matched with venous insufficiency patients)~group of 48 patients with venous insufficiency (16 with stage 1/2, 16 with stage 3/4, 16 with stage 5/6)~group of 40 patients with unilateral lymphedema (20 on upper limb (10 early stage, 10 severe stage), and 20 on lower limb (10 early stage, 10 severe stage))~Each group have the same interventions: physical examination, measures by cutometer, high resolution ultrasonography, elastography 30 persons will have a skin biopsy (15 healthy volunteers and 15 patients with venous insufficiency) For patients with lymphedema, all measures will be performed on lymphedema limb and on controlateral healthy limb"
3230822|NCT01195285|Active Comparator|Traditional Laparoscopic Cholecystectomy (TLC)|
3230823|NCT01195311|Experimental|INCB024360|
3326380|NCT02061267|Experimental|Niacin Control|The subjects will receive a vitamin B3 supplement (2 g)
3230824|NCT01195324|Experimental|001|Canagliflozin/Warfarin Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6 followed 14 days later by Treatment B: Tablets oral warfarin 30 mg single dose on Day 1
3230825|NCT01195324|Experimental|002|Canagliflozin/Warfarin Treatment B: Tablets oral warfarin 30 mg single dose on Day 1 followed 14 days later by Treatment A: Tablets oral canagliflozin 300 mg once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg single dose on Day 6
3326381|NCT02061267|Experimental|Niacin + SAT|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
3326382|NCT02061267|Experimental|Niacin + ROO|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
3230826|NCT01195337||Study Group|Newsletters, Physical Activity (PA) Prescription Plan, Pedometer
3230827|NCT01195350||stroke|
3326383|NCT02061267|Experimental|Niacin + O3|The subjects will receive a vitamin B3 supplement (2 g) and a test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
3326384|NCT02061293|Experimental|Psilocybin|Psilocybin 25 mg/70 kg PO administered at week 4, 25-40 mg/70 kg PO administered at week 8. Psilocybin 25-40 mg/70 kg administered at 38 weeks.
3326385|NCT02061293|Active Comparator|Diphenhydramine|Diphenhydramine 50 mg PO administered at week 4, 50-100 mg PO administered at week 8. Psilocybin 25 mg/70 kg administered at 38 weeks.
3326386|NCT02061306||Infants with a first-degree relative with celiac disease|Infants who have a first-degree relative diagnosed with celiac disease.
3230828|NCT01195376|Experimental|BEZ235 Dose Escalation once daily|oral BEZ235 once daily (q.d.)
3230829|NCT01195376|Experimental|BEZ Dose escalation twice daily|oral BEZ235 twice daily (b.i.d.)
3230830|NCT01195389|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
3230831|NCT01195389|Placebo Comparator|Placebo treatment|
3326387|NCT02061319|Experimental|Nordic Walking Group|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
3326388|NCT02061319|No Intervention|Standard Exercise Therapy|Individuals assigned to standard exercise therapy will attend on-site exercise classes twice weekly for 12 weeks. Each on-site class will be one hour in duration and consist of: a 15-minute chair-based warm-up that includes 6-8 upper and lower body resistance training exercises using either hand-held weights or therabands at an intensity of 50-60% of 1- RM with the patient completing one set of 10-12 repetitions progressing to 15 repetitions before increasing the intensity by 5-10%; 10-15 minutes of walking for the first 3 weeks, progressing to 30 minutes of continuous walking for the remaining 9 weeks; and 15 minutes of cool down exercises. A strength training program will be provided to participants and they will be encouraged to do one additional strength training session at home. Participants will also be instructed to complete additional walking sessions at home so that they can accumulate a total of 200-400 minutes of exercise per week.
3326389|NCT02061332|Experimental|Intranodal Vaccine|An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.
3326390|NCT02061332|Experimental|Intralesional Vaccine|The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.
3326391|NCT02061332|Experimental|Intranodal + Intralesional Vaccine|You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.
3326392|NCT02061345||MCI|Prostate cancer patients having mild cognitive impairment (MCI) attributable to ADT with LHRHa
3326393|NCT02061345||Control|Prostate cancer patients on ADT with LHRHa not having mild cognitive impairment
3230832|NCT01195402|No Intervention|Control|Subjects do not receive any kind of active intervention.
3230833|NCT01195402|Active Comparator|pulmonary outpatient rehabilitation|Subjects participate in an outpatient pulmonary rehabilitation program
3230834|NCT01195428|Active Comparator|Simvastatin|Simvastatin 40 mg daily.
3230835|NCT01195428|Placebo Comparator|Placebo|Placebo
3230836|NCT01195454|Experimental|Insulin glargine / New insulin glargine formulation|"Period 1: Insulin glargine~Period 2: New insulin glargine formulation~Period 3: New insulin glargine formulation~Period 4: New insulin glargine formulation~Duration of treatment: 1 day at each period"
3230837|NCT01195480|Experimental|Prophylaxis arm|Patients who have relapsed in the bone marrow after previous myeloablative HSCT and achieve remission after chemotherapy will be treated prophylactically with CD19-specific gene-engineered T cells after a second HSCT with reduced intensity conditioning.
3230838|NCT01195480|Experimental|Pre-emptive arm|In this arm, patients identified at high (> 50%) risk of relapse will be eligible for generation of donor-derived EBV CTL immediately prior to HSCT. These patients will be monitored for evidence of MRD in regular bone marrow aspirates for the first year post-HSCT. MRD positivity post-HSCT is highly predictive of subsequent relapse. In those patients who become MRD+ in the marrow at a level of minimum 5 x 10-4, cryopreserved CTL that have been transduced with a retroviral vector carrying the CD19-zeta transgene will be thawed and administered to the patient pre-emptively.
3230839|NCT01195493|Experimental|test mouthrinse|
3230840|NCT01195493|Active Comparator|control group|
3230841|NCT01195519||peritoneal dialysis and hemodialysis patients|peritoneal dialysis and hemodialysis patients
3230842|NCT01195532||Gliclazide/2|60 mg*1 for T 30 mg*2 For R
3230843|NCT01195532||Reference and test drug|Reference: 30 mg *2 Test: 60 mg *1
3230844|NCT01195558||Blind with sleep problems|Blind individuals with no light perception and with sleep-related problems who may suffer from Non-24
3230845|NCT01195571|No Intervention|vaccine administration|Each subject will receive on of four chimera CMV vaccines
3230846|NCT01195610|Experimental|New Nordic Diet|New Nordic Diet
3230847|NCT01195610|Experimental|Average Danish Diet|Average Danish Diet
3230848|NCT01195649||Group 1|
3230849|NCT01195688|Experimental|BI 638683|1 single dose per subject as oral solution
3230850|NCT01195688|Placebo Comparator|Placebo solution|1 single dose per subject as oral solution
3230851|NCT01195714|Experimental|Ofatumumab|
3230852|NCT01195727|Experimental|Group 5A - Apixaban (Low Dose)|"Group 5: 12 years to <18 years;~0.66 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
3230853|NCT01195727|Experimental|Group 5B - Apixaban (High Dose)|"Group 5: 12 years to <18 years;~1.32 mg/m² Oral solution, Oral, Twice A Day (BID), 10 days"
3230854|NCT01195740|Experimental|Attachment Based Family Therapy|
3230855|NCT01195740|Active Comparator|Enhanced Usual Care|
3230856|NCT01195753|Experimental|Liver Cell Infusion|
3230857|NCT01195766|Experimental|Ofatumumab|Ofatumumab in addition to ESHAP therapy
3259150|NCT01468025|Active Comparator|Theramine and naproxen|Patients in this group were randomly given active Theramine and active naproxen.
3326394|NCT02061371|Experimental|virtual therapy|Group 1 (G1) included 20 patients who will carry out the virtual therapy.
3326395|NCT02061371|Experimental|conventional physiotherapy|Group 2 (G2) included 20 patients who hold conventional physiotherapy.
3326396|NCT02061410|Experimental|Neuromuscular Electrical Stimulation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
3326398|NCT02061449|Experimental|Initiating therapy with Romidepsin (Arm A)|Patients who are starting therapy with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
3326399|NCT02061449|Experimental|treatment with Romidepsin with SD or PR (Arm B)|Patients with stable disease on the treatment with Romidepsin (intravenously on days 1, 8, and 15 of every 21-day cycle or alternate schedule per treating physician) also receive focal lesional radiation on days 1,3, and 5 without (level 1) or with (level 2) Poly ICLC (subcutaneously on days 1, 3, and 5) on the first cycle.
3326400|NCT02061462|No Intervention|Standard Group|Recipients of lungs procured from brain dead donors.
3230858|NCT01195792|Experimental|2 mg GSK1521498|Approximately 20 subjects will be randomised to receive 2 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
3230859|NCT01195792|Experimental|5 mg GSK1521498|Approximately 20 subjects will be randomised to receive 5 mg GSK1521498. The drug is being developed for the treatment of obesity due to excessive consumption of high calorie foods
3230860|NCT01195792|Placebo Comparator|Placebo|Approximately 20 subjects will be randomised to receive matching placebo.
3326401|NCT02061462|Active Comparator|EVLP-DCD Group|Recipients of lungs procured from DCD donors, reconditioned/evaluated by EVLP
3326402|NCT02061475|Active Comparator|Lidocaine Patches|
3326403|NCT02061475|Placebo Comparator|Placebo Patches|
3326404|NCT02061488|Active Comparator|open-loop night|
3326405|NCT02061488|Experimental|closed-loop night|
3326406|NCT02061501|Active Comparator|Speech therapy|Speech therapy (30 min per week) alone for the 6 first months. Then speech therapy (30 min per week) and optometric therapy (30 min per week) for the 6 last months.
3326407|NCT02061501|Experimental|Speech therapy and optometric therapy|Speech therapy (30 min per week) and optometric therapy (30 min per week) for 12 months.
3326408|NCT02061514|Experimental|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
3326409|NCT02061514|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
3326410|NCT02061527|Experimental|Breast reconstruction with ADM|Implant based Breast Reconstruction with ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implants. Patients in group B with ADM and partial submuscular coverage.
3326411|NCT02061527|Active Comparator|Breast reconstruction without ADM|Breast reconstruction without ADM. Both arms will undergo skin or nipple sparing mastectomy and immediate breast reconstruction with implant. Patients in group B will be reconstructed with implant and total submuscular coverage.
3326412|NCT02061553|Sham Comparator|Motivation|1 in person session focused on importance of motivation followed by 8 wk SMS messages with self-selected motivational statements.
3230861|NCT01195805|Active Comparator|Amiloride|
3230862|NCT01195805|Active Comparator|Spironolactone|
3230863|NCT01195805|Placebo Comparator|Placebo|1 tablet twice a day for 28 days
3230864|NCT01195818|Experimental|RAS Inhibitors|RAS Inhibitors
3230865|NCT01195974|Experimental|Period 1|YASMIN + 200 mg GSK2248761 or Placebo
3326413|NCT02061553|Active Comparator|Intention|1 session of Behavioral Activation followed by 8 wk SMS messages in the form of BA- based implementation intentions.
3326414|NCT02061553|Experimental|BA-Tech|6 in person and 2 phone sessions of Behavioral Activation with EMA-based activity monitoring and SMS-assisted scheduling of value-based activities.
3326415|NCT02061566||Acute kidney injury|Acute kidney injury in ICU
3230866|NCT01195974|Experimental|Period 2|YASMIN + 200 mg GSK2248761 or Placebo
3230867|NCT01195974|Other|Run In Period|YASMIN
3326416|NCT02061566||Non acute kidney injury|Non acute kidney injury
3326417|NCT02061579|Experimental|Once-Weekly Structured Contact|Participants in the Once Weekly Structured Contact group will take part in an 6-month exercise intervention and attend one structured group exercise session per week. They will engage in aerobic and resistance training for approximately 80 minutes per exercise session. Additionally, they will attend three exercise evaluations and six study visits.
3230868|NCT01195987||Hepatitis C with Arthritis|
3230869|NCT01195987||Hepatitis C without Arthritis|
3230870|NCT01196000|Active Comparator|Arm I|Patients undergo standard conventional laparoscopic resection.
3230871|NCT01196000|Experimental|Arm II|Patients undergo robotic-assisted laparoscopic resection.
3230872|NCT01196013|Experimental|Clofarabine|
3230873|NCT01196039|Experimental|A|
3230874|NCT01196039|Placebo Comparator|B|
3230875|NCT01196065|Experimental|Single Arm|
3230876|NCT01196130||Biomarker Assessment|Leftover sample of tumor tissue from a previous procedure used for biomarker testing. Blood drawn for biomarker testing, to check for levels of cytokines, and to check the circulating tumor cells (CTCs). Cancer Symptom Questionnaire completion about cancer symptoms.
3230877|NCT01196169|Experimental|Daptomycin|Half of patients anticipated to be enrolled will receive daptomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
3230878|NCT01196169|Active Comparator|Vancomycin|Half of patients anticipated to be enrolled will receive vancomycin in antimicrobial prophylaxis prior to their prosthetic joint surgery.
3326418|NCT02061579|Experimental|Thrice-Weekly Structured Contact|Participants in the Thrice-Weekly Structured Contact group will take part in an 6-month exercise intervention and attend three structured group exercise sessions per week. In total, they will engage in aerobic and resistance training sessions for approximately 200 minutes per week. Additionally, they will attend three exercise evaluations and six study visits.
3326419|NCT02061579|No Intervention|Usual Care|Participants in the Usual Care group will not take part in an 6-month exercise intervention. They will continue to seek regular care from their primary care providers and attend six study visits.
3326420|NCT02061605|Experimental|Laser Tissue Welding Device|"The laser tissue welding device is intended for use in patients requiring laparoscopic surgery requiring hemostasis and sealing of the resected kidney after partial nephrectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.~The device's intended use is to seal the kidney surface using a laser to weld human albumin based biomaterials after surgical removal of kidney tumors during a laparoscopic partial nephrectomy."
3326421|NCT02061618|No Intervention|Usual Care|
3326422|NCT02061618|Experimental|Bollywood Dance Exercise|Participants in the Bollywood Dance Exercise group will take part in an 8-week dance intervention. The dance classes will take place 2 times per week, approximately 60 minutes per class, for 8 weeks total.
3326423|NCT02061631|Experimental|Docetaxel, Cisplatin|"Induction:One-hour intravenous infusion of docetaxel at 75 mg/m2 followed by a 30 minute intravenous infusion of cisplatin at 75 mg/m2. All patients to be pre-medicated with oral dexamethasone at 8 mg twice daily for 3 days, commencing one day before docetaxel infusion. All patients will be premedicated with intravenous dexamethasone 20 mg to be administered before cisplatin infusion. Docetaxel and cisplatin treatments to be repeated every 21 days for three cycles.~Chemoradiotherapy (CRT): Cisplatin to be administered by 30 minutes intravenous infusion at a dose of 30 mg/m2 weekly starting concomitantly with conventional radiotherapy for a period of 6 weeks. Intravenous cisplatin to be continued for four weeks.~Radiotherapy: Gross disease dose will be 60 Gy/30 fractions and sub clinical dose 45-50 Gy/30 fractions."
3326424|NCT02061644|Experimental|Spinal|Spinal anesthesia for surgical procedure will be applied to the patients. Intraocular pressures will be measured before and after the procedure.
3326425|NCT02061657|Experimental|Myomectomy, rectal Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation.
3326426|NCT02061657|Active Comparator|Myomectomy, Placebo|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
3230879|NCT01196195|Experimental|QD kaletra|Once daily kaletra
3230880|NCT01196195|Active Comparator|BID kaletra|twice daily dose of kaletra
3326427|NCT02061670|Experimental|Ragweed-SPIRE 1|Ragweed-SPIRE regimen 1 given 2 weeks apart
3326428|NCT02061670|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
3326429|NCT02061670|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3326430|NCT02061709|Experimental|Ragweed-SPIRE 1|Ragweed SPIRE regimen 1 given 2 weeks apart
3326431|NCT02061709|Experimental|Ragweed-SPIRE 2|Ragweed-SPIRE regimen 2 given 2 weeks apart
3326432|NCT02061709|Experimental|Ragweed-SPIRE 3|Ragweed-SPIRE regimen 3 given 2 weeks apart
3326433|NCT02061709|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3326434|NCT02061722|Experimental|PET Imaging with [18F]MNI-659|"All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).~The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
3326435|NCT02061735||oral propranolol|Dosage of 1 mg/kg per day divided 2 times daily. Blood pressure, heart rate and oxygen saturation are monitored after propranolol initiation. Treatment is continued with a gradual increase to 2 mg/kg per day divided 2 times daily. Treatment is continued until the hemangioma no longer changes in the characteristics judged by the physicians, including, color, size, temperature and deformability.
3326436|NCT02061735||timolol maleate 0.5% gel|One drop of of timolol maleate 0.5% gel is topically applied and massaged into the hemangioma twice per day . This dosage provides an estimated 0.5 mg of timolol per day. The treatment is continued until it is considered to be no longer effective as judged by the physicians.
3230881|NCT01196221||Patients with 30 to 70% carotid artery stenosis|
3230882|NCT01196234|Experimental|Paclitaxel/Carboplatin/Gefitinib|Paclitaxel/Carboplatin/Gefitinib
3230883|NCT01196234|Active Comparator|Paclitaxel/Carboplatin|Paclitaxel/Carboplatin
3230884|NCT01196260|Experimental|5-fluorouracil plus oxaliplatin|patients will be randomized assigned to receive 5-fluorouracil plus oxaliplatin
3230885|NCT01196273||Regional Ruhrgebiets Cohort|
3230886|NCT01196286|Experimental|MFG and CR|Subjects provided with both multifamily psychoeducation (MFG) and cognitive remediation (CR)
3230887|NCT01196286|Active Comparator|MFG|Subjects provided with only multifamily group psychoeducation (MFG)
3230888|NCT01196299||Severe Traumatic Brain Injury Group|The severe traumatic brain injury group are patients admitted to the study with an admission GCS between 3 and 8.
3230889|NCT01196299||Moderate Head Injury Group|The moderate head injury group are patients admitted to the study with an admission GCS from 9 to 12.
3230890|NCT01196299||Mild Head Injury Group|The mild head injury group are patients admitted to the study with an admission GCS from 13 to 15.
3230891|NCT01196299||Healthy Volunteer Group|Healthy volunteers will be selected to match the age distribution of the TBI groups. They must be absent of any abnormal radiological findings.
3230892|NCT01196325||Laser Group|Patients who are clinically indicated for the laser treatment
3230893|NCT01196325||Anti-VEGF Group (Bevacizumab)|Patients who are clinically indicated for the intravitreal injection of Bevacizumab
3230894|NCT01196325||Anti-VEGF Group (Ranibizumab)|Patients who are clinically indicated for intravitreal injection of Ranibizumab
3230895|NCT01196325||Age-matched controls|Group of non-diabetic participants who will be age and gender matched
3230896|NCT01196338|Active Comparator|Non-weightbearing no ROM|"Patients will be placed in a back slab post-op and will remain non-weight bearing with crutches with no range of motion for a total of 6 weeks.~After 6 weeks post-op, they will be placed in a boot orthosis and permitted to weight-bear as tolerated."
3230897|NCT01196338|Experimental|Early weight-bearing and ROM|"Patients will be placed in a back slab post-operatively. At 2 weeks post op they will have the back slab removed and placed in a boot orthosis. At this time they will be permitted to weight-bear as tolerated and perform limited ankle range of motion exercises.~After 6 weeks post op they will start to wean from the boot orthosis."
3326437|NCT02061735||No treatment, observation only|No oral or topical treatment will be given as recommended by the treating physicians and elected by the parents. Patients will be evaluated periodically to determine what changes in treatment are warranted. If this occurs, the patients will be included in the appropriate study group.
3326438|NCT02061761|Experimental|Part A - relatlimab (Dose escalation)|
3326439|NCT02061761|Experimental|Part C - relatlimab + nivolumab (Dose escalation)|
3326440|NCT02061761|Experimental|Part B - relatlimab (Cohort expansion)|
3326441|NCT02061761|Experimental|Part D - relatlimab + nivolumab (Cohort expansion)|
3326442|NCT02061787||cardiopulmonary exercise testing|cardiopulmonary exercise testing
3230898|NCT01196351|Experimental|Sedentary activity, noncaloric beverage|
3326443|NCT02061800|Active Comparator|Full intensity with TBI|Patients will start their pre-conditioning regimen on 8 days before scheduled transplant. Fractionated total body irradiation (TBI) will be administered twice daily on the 6th, 7th, and 8th before transplant. Patients will receive Thiotepa on the 4th and 5th day before transplant, Cyclophosphamide on the 2nd and 3rd day before transplant, and Alemtuzumab on the 1st-5th day(s) before transplant. Then the stem cell infusion will be performed (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after transplant, and methylprednisolone will start on day -5.
3230899|NCT01196351|Experimental|Sedentary activity, glucose beverage|
3326444|NCT02061800|Experimental|Full intensity without TBI|Patients will start their pre-conditioning regimen 9 days before their scheduled transplant. Patients will receive busulfan twice daily on the 5th-8th day before transplant, and Melphalan on the 2nd-4th days before transplant and Alemtuzumab on the 1st-5th day before transplant. Subjects will then undergo with their stem cell infusion (allogeneic family member or ≥ 8/10 HLA matched adult unrelated donor peripheral blood stem cell transplantation with CD34 Selection using CliniMACS CD34+ Reagent System) and GVHD prophylaxis will consist of tacrolimus only. Tacrolimus administration will begin on the day after their transplant, and methylprednisolone will start on day -5.
3326445|NCT02061800|Experimental|Reduced intensity|Patients will begin tacrolimus 8 days pre-transplant, and then will receive alemtuzumab on the 3rd-7th day pre-transplant; busulfan twice daily on the 5th-8th day pre-transplant; and fludarabine on the 2nd-7th day pre-transplant. Methylprednisolone will start on day -7.The stem cell infusion will be performed (with CD34 Selection using CliniMACS CD34+ Reagent System). GVHD prophylaxis will consist of tacrolimus or sirolimus. For patients with a history of hepatic toxicity and/or high-risk for veno-occlusive disease or other liver toxicity post stem cell transplant, melphalan at 70 mg/m2 will be substituted for Busulfan, followed by fludarabine on the 2nd-7th day before transplant and alemtuzumab on the 3rd-7th day before transplant.
3326446|NCT02061839|Experimental|Teinted sunscream|UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
3326447|NCT02061839|Active Comparator|Regular sunscream|UVA and UVB protection
3326448|NCT02061852|Active Comparator|Physiotherapy|Traditional techniques
3326449|NCT02061852|Experimental|simeox|Medical device
3326450|NCT02061865|Experimental|Cohorts 1 - 4|Participants in cohort 1 will receive REGN2176-3 dosing regimen 1. Participants in cohort 2 will receive REGN2176-3 dosing regimen 2. Participants in cohort 3 will receive REGN2176-3 dosing regimen 3. Participants in cohort 4 will receive REGN2176-3 dosing regimen 4.
3326451|NCT02061878|Experimental|Bexarotene|The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
3326452|NCT02061878|Placebo Comparator|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
3326453|NCT02061891|Active Comparator|Deferred invasive evaluation|Deferred invasive coronary evaluation and revascularization (PCI/CABG) within 72 hours from time of clinical diagnosis (CONTROL group)
3326454|NCT02061891|Experimental|Very early invasive evaluation|Acute invasive coronary evaluation within 12 hours from time of diagnosis - INTERVENTION group
3326455|NCT02061904|Other|Bone Mineral Density|"Bone mineral density measurement with intervention DEXA at the bone impaction graft site:~DEXA: dual energy X-ray absorptiometry"
3326456|NCT02061904|Other|Hip function|"Hip Function/mobility development:~Harris Hip Score"
3326457|NCT02061904|Other|pain experience|Pain experiences after surgery in the hip joint VAS-pain
3326458|NCT02061904|Other|General Patients Health condition|"Patients health condition monitoring: intervention SF12:~Short Form Health Survey 12"
3230900|NCT01196351|Experimental|Exercise activity, noncaloric beverage|
3326459|NCT02061904|Other|Intervention Satisfaction|Patients satisfaction development after the intervention VAS-satisfaction
3326460|NCT02061917|Experimental|Tobacco-Heating Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette
3326461|NCT02061917|Experimental|Snus (Smokeless Tobacco)|A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)
3326462|NCT02061917|Experimental|Tobacco-Burning Cigarette|A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette
3230901|NCT01196351|Experimental|Exercise activity, glucose beverage|
3230902|NCT01196364|Experimental|Sedentary activity, noncaloric beverage|
3230903|NCT01196364|Experimental|Sedentary activity, glucose beverage|
3230904|NCT01196364|Experimental|Exercise activity, noncaloric beverage|
3230905|NCT01196364|Experimental|Exercise activity, glucose beverage|
3230906|NCT01196468||Anal/cervical dyplasia|Any patient presenting for care with any degree of anal or cervical dysplasia
3326463|NCT02061930||single crowns supported by implants|single crowns supported by implants placed in the anterior maxilla region, periodontally healthy
3230907|NCT01196468||STI|Any patient presenting for care with any non-HIV sexually transmitted infection
3326464|NCT02061956||HCC received TACE|Patients with HCC in cancer center, Sun Yat-sen University received TACE between 2011.01-2011.12
3326465|NCT02061982|Experimental|Caffeine|Instant coffee with or without caffeine will be provided
3326466|NCT02061982|Placebo Comparator|Coffee without caffeine|Coffee without caffeine
3326467|NCT02061995|Experimental|PREOB® Intravenous Infusion|
3326468|NCT02062034|Experimental|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
3326469|NCT02062034|Experimental|Combined antioxidant therapy|(1mg copper + 20mg zinc + 180mg vitamin C + 30mg vitamin E + 1mg zeaxanthin + 4mg astaxanthin + 10mg lutein) daily of oral antioxidant combined therapy for 24 weeks
3326470|NCT02062034|Placebo Comparator|Placebo|Placebo. 100mg daily oral intake for 24 weeks
3326471|NCT02062047|Experimental|FMSRP+CLX|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of chlorhexidine 2% gel, rinsing chlorhexidine 0.12% solution during 60 days
3326472|NCT02062047|Placebo Comparator|FMSRP + placebo group|Full-mouth scaling and root planing in a maximum of 24 hours, application and irrigation of placebo, rinsing placebo solution during 60 days
3326473|NCT02062047|Active Comparator|PMSRP group|Partial-mouth scaling and root planing in 4-6 sessions in a maximum of 2 weeks
3230908|NCT01196468||Lymphoma|Any patient presenting for care with malignant lymphoma of any histological type
3230909|NCT01196468||Seborrhoeic dermatitis/exanthema|Any patient presenting for care with seborrhoeic dermatitis/exanthema
3326474|NCT02062060|Active Comparator|Abametapir Lotion 0.74% w/w|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
3326475|NCT02062060|Placebo Comparator|Vehicle Lotion|Single topical treatment administered to scalp and hair for 10 minutes. Applied at home by subject/caregiver.
3326476|NCT02062073|Active Comparator|Abametapir Lotion 0.74%|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3326477|NCT02062073|Placebo Comparator|Vehicle Lotion|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3326478|NCT02062073|Other|0.1% sodium lauryl sulfate|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3326479|NCT02062073|Other|Saline 0.9%|Concurrent control 0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions 3 times weekly for 3 weeks, following with rest period and a challenge.
3326480|NCT02062086|Other|Population 1|"(Community-dwelling older adults) will participate in the study for approximately 65 days.~Population 1 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~The estimation of muscle mass will be made on 2 separate occasions in the community-dwelling elderly population in order to assess reproducibility of the method when tested approximately 60 days apart."
3326481|NCT02062086|Other|Population 2|"(Hip-fracture patients) will participate in the study for approximately 35 days during their in-hospital period, followed by 30 during their post-discharge period, so for a total period of at least 65 days.~Population 2 will absorb deuterated creatine 30 mg, a non-radioactive, stable isotope of creatine, for the estimation of muscle mass in humans.~In the hip fracture population, estimation of muscle mass by the D3 creatine method will be performed on up to 3 separate occasions to assess whether the method is sensitive enough to detect decreases in muscle mass that may occur during the recovery period after hip fracture."
3326482|NCT02062099|Experimental|Memory complaint /MCI/ mild to moderate MA|Memory complaint (without cognitive decline): 12 patients/ Mild Cognitive Impairment: 12 patients/ Mild to moderate Alzheimer Disease: 12 patients
3326483|NCT02062112|No Intervention|Unflavored group|The patient will mix 1 gallon of polyethylene glycol with water and drink as directed by his/her endoscopist. No flavoring will be added.
3326484|NCT02062112|Active Comparator|Flavored group|The patient will mix 1 gallon of polyethylene glycol with water, add flavoring to the entire solution and drink at the time specified by his/her endoscopist.
3326485|NCT02062112|Active Comparator|Liberal group|The patient will mix 1 gallon of polyethylene glycol with water. Fill 2 cups with the solution. The patient will add flavoring to one cup and drink both the flavored and unflavored solutions in the cups. The patient will then determine how he/she wants to drink the rest of the bowel preparation laxatives based on their taste preference and drink at the time specified by his/her endoscopist.
3326486|NCT02062138|Active Comparator|continuous passive motion (CPM)|
3326487|NCT02062138|Experimental|controlled active motion (CAM I)|
3326488|NCT02062138|Experimental|controlled active motion (CAM II)|
3326489|NCT02062164||bariatric surgery group|subjects who participate in the overall project and undergo bariatric surgery
3326490|NCT02062164||conservative care group|subjects who participate in the overall project and do not undergo bariatric surgery
3326491|NCT02062190|Active Comparator|resveratrol|
3326492|NCT02062190|Placebo Comparator|corn starch|"(10 patients) 100mg 2x/day~1 month"
3326493|NCT02062203|Experimental|AKB-6548 (therapeutic dose)|
3326494|NCT02062203|Experimental|AKB-6548 (supratherapeutic dose)|
3326495|NCT02062203|Placebo Comparator|Placebo|
3326496|NCT02062203|Active Comparator|Moxifloxacin|
3326497|NCT02062216||STEMI|Patients with ST-elevation myocardial infarction (STEMI) with angiographic evidence of massive thrombosis in the culprit artery undergoing primary percutaneous coronary intervention (PCI)
3326498|NCT02062216||STABLE ANGINA|Patients with coronary artery disease in stable conditions scheduled to undergo elective percutaneous coronary intervention and patients with Class I indication to elective percutaneous coronary intervention
3326499|NCT02062229||Halthy controls|Subjects not affected by any disease and with normal seminal fluid characteristics
3326500|NCT02062229||Oligospermia|Infertile subjects with oligospermia
3326501|NCT02062229||Varicocele|Infertile subjects with varicocele
3326502|NCT02062229||Asthenospermia|Infertile subjects with asthenospermia
3326503|NCT02062242|Experimental|Transvaginal electrical stimulation|Patients treated with transvaginal electrical stimulation.
3326504|NCT02062242|Experimental|Palpation|Patients treated with vaginal palpation.
3326505|NCT02062242|Experimental|Palpation with posterior pelvic tilt|Patients treated with vaginal palpation associated with posterior pelvic tilt and contraction of accessory muscles.
3326506|NCT02062242|Experimental|Control group|Patients receive verbal instructions related to the pelvic floor and its contraction.
3326507|NCT02062255|Active Comparator|Aspirin|Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day.
3326508|NCT02062255|Active Comparator|Omega-3 Free Fatty Acids|Three hundred thirty-six gelatin coated 450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner).
3326509|NCT02062255|Active Comparator|Aspirin & Omega-3 FFAs|Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily.
3326510|NCT02062268||Urban area in South Jiangsu Province|health education & law enforcement
3230910|NCT01196468||Thromobocytopaenia/Leucopaenia, or hypergammaglobulinaemia|Any patient presenting for care with unexplained thromobocytopaenia/leucopaenia of more than four weeks duration, or with hypergammaglobulinaemia
3230911|NCT01196481|Experimental|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD + VSL#3
3230912|NCT01196481|Active Comparator|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation
3230913|NCT01196494|Experimental|intraoperative colon lavage|
3230914|NCT01196494|Active Comparator|stent and deferred surgery|
3230915|NCT01196507|Experimental|Carvedilol|Tablet Carvedilol 12.5 mg BD or maximum tolerated dose
3326511|NCT02062268||urban area in Middle Jiangsu Province|health education & law enforcement
3326512|NCT02062268||urban area in North Jiangsu Province|health education & law enforcement
3326513|NCT02062268||rural area in South Jiangsu Province|health education & law enforcement
3326514|NCT02062268||rural area in North Jiangsu Province|health education & law enforcement
3326515|NCT02062281|Active Comparator|23-valent Pneumococcal Polysaccharide vaccine|"0.5ml 23-valent pneumococcal Polysaccharide vaccine made by Chengdu Institute of Biological Products Co.,Ltd.~lot number: 20130106-1, duration:JAN,17,2015."
3326516|NCT02062281|Active Comparator|Trivalent Influenza Vaccine|"0.5ml trivalent influenza vaccine made by Shanghai Institute of Biological Products Co.,Ltd.~lot number:20130713, duration:Jul,1,2014."
3326517|NCT02062281|Experimental|23vPPV+TIV|
3326518|NCT02062307||control patients|BMI and age matched healthy male subjects
3326519|NCT02062307||hypogonadism patients|unconfounded group of patients with hypogonadism
3326520|NCT02062320||PRE-PCAPS|Parturients who underwent delivery by Caesarean Section in the period October 2009 - September 2010
3326521|NCT02062320||POST-PCAPS|Parturients who underwent delivery by Caesarean Section in the period November 2010 - October 2011.
3326522|NCT02062333|Active Comparator|dexmedetomidine|0,4-0,8 µg./kg./h dexmedetomidine
3326523|NCT02062333|Active Comparator|esmolol|100- 300 µg./kg./min esmolol
3326524|NCT02062346|Placebo Comparator|Placebo|Saline placebo
3326525|NCT02062346|Experimental|BQ123|Intravenous infusion of BQ123 1000nmol/min for 15min
3230916|NCT01196507|Placebo Comparator|Placebo|Placebo tablets 2 to 4 BD
3230917|NCT01196520||BL Cases|Children from East Africa diagnosed with BL
3326526|NCT02062346|Experimental|BQ123/788|Intravenous infusion of BQ123 1000nmol/min and BQ788 300nmol/min
3326527|NCT02062346|No Intervention|Assessment of forearm vascular function|Response of forearm blood flow to endothelium-dependent and endothelium-independent vasodilators
3326528|NCT02062372|Experimental|Biopsy|Subjects will receive a 7 T MRI and one additional biopsy to their standard diagnostic biopsies
3326529|NCT02062411|Experimental|CBT with booster sessions|Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol.
3326530|NCT02062411|Active Comparator|CBT only|Participants will only receive 12 cognitive-behavioral therapy sessions weekly.
3326531|NCT02062411|No Intervention|waiting|Participations will not be treated with CBT and keep waiting for 12 weeks for comparison.
3326532|NCT02062424|Active Comparator|DIPI: Danish national dietary guidelines|The subjects will receive dietary advice according to the current national dietary guidelines
3326533|NCT02062424|Active Comparator|DIPI: Specific IHD dietary guideline|The subjects will receive dietary advice, according to the specific ischemic heart disease dietary guidelines.
3326534|NCT02062424|No Intervention|Normal dietary habits|The Subjects will be instructed to follow their normal dietary habits
3326535|NCT02062476|Experimental|Treatment with Lactobacillus GG|extensively hydrolyzed casein formula containing LGG
3326536|NCT02062476|No Intervention|Children at diagnosis|
3326537|NCT02062489|Active Comparator|Tamoxifen|20mg(2#)/day, PO, daily, five years
3326538|NCT02062489|Placebo Comparator|Placebo|2#/day, PO, daily, five years
3326539|NCT02062515|Experimental|Icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
3326540|NCT02062528|Experimental|omega-3 fatty acids|3 capsules each day during 8 weeks
3326541|NCT02062528|Placebo Comparator|placebo|3 capsules each day during 8 weeks
3326542|NCT02062541|Experimental|Funct. assessment+fast rehabilitation|Funct. assessment+fast rehabilitation
3326543|NCT02062541|Experimental|Funct. assessment+usual rehabilitation|Funct. assessment+usual rehabilitation
3326544|NCT02062541|Experimental|usual assessment+fast rehabilitation|usual assessment+fast rehabilitation
3326545|NCT02062541|No Intervention|usual assessment+usual rehabilitation|usual assessment+usual rehabilitation
3326546|NCT02062567||Acute Achilles tendon rupture|
3326547|NCT02062619|Experimental|Real tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~2mA anodal direct current stimulation applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
3230918|NCT01196520||HCII Controls|Matched controls from the local health clinics
3230919|NCT01196520||Population Controls|Matched controls from the geographic region
3230920|NCT01196546|Experimental|Vildagliptin/metformin|
3230921|NCT01196559|Experimental|Vinorelbine and Gemcitabine|Vinorelbine 25 ㎎/㎡ and Gemcibine1000㎎/㎡ D1, D8 every 3weeks
3230922|NCT01196572|Experimental|Laser IU|Urethral stricture incised by Holmium laser
3326548|NCT02062619|Sham Comparator|Sham tDCS|"Transcranial direct current stimulation (tDCS) administered concurrently with computer-based behavioural word reading therapy.~Sham tDCS (periodical fade-in and fade-out stimulation routine) applied to the left inferior frontal gyrus (IFG) for first 20 minutes of therapy."
3326549|NCT02062671|Experimental|immediate renal denervation|immediate renal denervation
3326550|NCT02062671|Active Comparator|delayed renal denervation|delayed renal denervation
3326551|NCT02062684|Experimental|Blisibimod|Blisibimod administered subcutaneously
3230923|NCT01196572|Active Comparator|Cold knife IU|Urethral stricture incised by knife
3326552|NCT02062684|Placebo Comparator|Placebo|Placebo administered subcutaneously
3326553|NCT02062697|Other|Ovarian Epithelial Cancer|"Lavage of the Cavum uteri and proximal fallopian tubes~Liquid-PAP (Papanicolaou) smear"
3326554|NCT02062723||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
3326555|NCT02062736||pts addicted to heroin in MMT|patients addicted to heroin who have undertaken methadone maintenance treatment
3326556|NCT02062749|Experimental|Hyperthermic Intraperitoneal Chemotherapy|After cytoreductive surgery and lysis of adhesions, two large bore catheters are placed in the peritoneal cavity through the incision. Thirty minutes before HIPEC is begun, body temperature is cooled to 35°C. ). The catheters are connected to a perfusion circuit. Heated Oxaliplatin is added to the perfusate administered over 90 minutes. The starting dose of Oxaliplatin is 175 mg/m2.
3230924|NCT01196585|Experimental|Patients under CT- guided pleural biopsy|Arm A: Patients who go under CT-guided pleural needle biopsy for pleural diseases
3230925|NCT01196585|Experimental|Patients under ultrasonography guided needle biopsy|Arm B: Patients who go under ultrasonography guided cutting needle pleural biopsy for pleural diseases
3230926|NCT01196598|Active Comparator|PFMT group|Women who undergo to three months of a pelvic floor muscle training program.
3230927|NCT01196598|Active Comparator|HE + PFM group|Women who undergo to three months of a hypopressive exercises plus pelvic floor muscle contraction program.
3230928|NCT01196598|Active Comparator|HE group|Women who undergo to three months of a hypopressive exercises program.
3326557|NCT02062762|Experimental|Online-MBSR|8 week mindfulness based stress reduction online
3326558|NCT02062762|Active Comparator|Expressive Writing Online|Online distributed expressive writing intervention as active control
3326559|NCT02062775|Active Comparator|Self-Fixating Hernia Mesh|Self-fixating polyester mesh will be used for laparoscopic inguinal hernia repair.
3326560|NCT02062775|Placebo Comparator|Non-Fixating Hernia Mesh|Non-fixating polyester mesh will be used for laparoscopic hernia repair.
3326561|NCT02062788|Experimental|ORS group|Oral rehydration solution (ORS) treated group
3326562|NCT02062788|No Intervention|Non-ORS group|Oral rehydration solution (ORS) untreated group
3326563|NCT02062827|Experimental|Group A single dose of HSV-1 (M032)|single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
3326564|NCT02062840|Experimental|High intensity whole-body infrared heating and Neuroimaging|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3326565|NCT02062840|Sham Comparator|Low intensity whole-body infrared heating and|Subjects will have an fMRI the morning of their WBH session and and fill out study questionnaires. Following the fMRI session, the participant will undergo the WBH-control intervention where subjects will be induced to levels of heat that causes only a minor increase in body temperature.
3230929|NCT01196598|Active Comparator|Control|Women who undergo to a session for lifestyle advice.
3326566|NCT02062853|Experimental|Video Group|Subjects view educational video on the use of cream medication for the treatment of actinic keratoses.
3326567|NCT02062853|Active Comparator|Verbal Group|Subjects are given verbal instructions on the use of cream medication for the treatment of actinic keratoses.
3230930|NCT01196611|Experimental|Function Voice Exercises|Behavioral: Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
3326568|NCT02062866|Active Comparator|Purse-String|Surgical wounds are healed via suturing.
3326569|NCT02062866|Active Comparator|Second Intent|Surgical wounds are allowed to heal without sutures.
3326570|NCT02062892|Experimental|Everolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
3230931|NCT01196611|Experimental|Voice amplification|Behavioral: Voice amplification Patients will use VA over a course of 6 weeks.
3230932|NCT01196624|Active Comparator|TMS TO RT DLPF WITH EXPOSURE|TMS TO RIGHT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
3230933|NCT01196624|Active Comparator|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO RIGHT DLPF BRAIN AREA WITHOUT EXPOSURE
3230934|NCT01196624|Active Comparator|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE|TMS TO LEFT PREFRONTAL DORSOLATERAL BRAIN AREA WITH EXPOSURE
3230935|NCT01196624|Active Comparator|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE|TMS TO LEFT DLPF BRAIN AREA WITHOUT EXPOSURE
3230936|NCT01196637||Thoracic outlet syndrome|These patients have documented thoracic outlet syndrome
3230937|NCT01196637||Normal Subjects|These patients have no thoracic outlet syndrome
3230938|NCT01196650|Active Comparator|1|IN 10 003 formulation A
3326571|NCT02062892|Active Comparator|Sirolimus / Tacrolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
3326572|NCT02062918|No Intervention|Control group|Patients in the control group did not use an abdominal belt.
3326573|NCT02062918|Experimental|Experimental group|Patients were instructed in how to use the abdominal belt for activities of physical effort that exacerbated lumbar pain as well as during moments of pain, and not to use it during rest. They should record the number of hours of belt use per day on spreadsheets distributed for this purpose.
3326574|NCT02062931|Experimental|Stem Cell Preparation and Injection|"Stem Cell Preparation and Injection:~Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared and suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
3326575|NCT02062944|Experimental|Single-arm study Sirolimus Withdrawal|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
3230939|NCT01196650|Active Comparator|2|IN 10 003 formulation B
3326576|NCT02062970|Experimental|septic shock patients suffering|blood sample done in a population whom suffer of septic shock
3326577|NCT02062983||Herceptin|The study will be carried in prospective manner enrolling all patients diagnosed with breast cancer and over expressed human epidermal growth factor receptor 2 (HER2) and they are requiring Trastuzumab Neu adjuvant/ adjuvant /metastatic therapy as per standard care.
3326578|NCT02062996|Experimental|ENT - full strength|Full strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
3326579|NCT02062996|Experimental|ENT - 1/2 strength|½ strength oxymetazoline pledgets packed in the nose (total volume 20 ml).
3326580|NCT02062996|Experimental|DENTAL - Full strength 1.0 mL|Full strength oxymetazoline 1.0 mL to each naris (total =1000 mcg).
3326581|NCT02062996|Experimental|DENTAL - Full strength 0.5 mL|Full strength oxymetazoline 0.5 mL to each naris (total = 500 mcg).
3326582|NCT02062996|Experimental|DENTAL - ½ strength 0.5 mL|½ strength oxymetazoline 0.5 mL to each naris (total = 250 mcg).
3326583|NCT02063009||patients scheduled for oncologic high-risk surgery|
3326584|NCT02063022|Active Comparator|Standard treatment (as per ISG SSG III protocol)|"Standard treatment for non metastatic Ewing's Sarcoma (as defined by the ISG/SSG III protocol).~It is based on a 6 drugs pre-local treatment (Vincristin, dactinomycin, cyclophosphamide,ifosfamide,etoposide and doxorubicin) followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response"
3230940|NCT01196650|Placebo Comparator|3|Placebo capsules
3326585|NCT02063022|Experimental|Intensified treatment|Dose intense treatment for non metastatic Ewing's Sarcoma It is based on a 3 drug pre-local treatment (Vincristin, ifosfamide and doxorubicin)followed by local treatment (surgery and/or radiotherapy)and by a maintenance treatment based on induction response
3230941|NCT01196676|Experimental|1|AZD4451
3230942|NCT01196676|Placebo Comparator|2|Placebo
3230943|NCT01196689|Experimental|1|AZD1981 100 mg twice daily for 6 ½ days
3326586|NCT02063048|No Intervention|Usual Care for Weight Loss|Patients randomized to this arm will not receive text messages or any other weight-loss support besides usual care provided at Denver Health. They will receive a weight loss educational packet and be asked to follow up with their primary care provider to further discuss their efforts at weight loss with additional follow-up as directed by their provider. They will be contacted periodically to be weighed. Providers will not be made aware that their patients are participating in the study's control arm.
3326587|NCT02063048|Experimental|Text Message Based Weight Loss Support|Patients will receive the same weight loss educational packet as those randomized to usual care. Patients will be assisted in choosing a self-management goal related to exercise and to eating behaviors. They will receive text messages at a frequency up to 1x daily; input from focus groups will guide text message frequency.
3230944|NCT01196702||CVID|Patients with common variable immunodeficiency
3230945|NCT01196702||CVID and granulomatous disease|Patients with CVID complicated with granulomatous inflammation
3230946|NCT01196702||CVID and bronchiectasis|Patients with CVID complicated by bronchiectasis
3230947|NCT01196702||Control on Immunoglobulin|Patients on immunoglobulin long-term who do not have an immunodeficiency
3230948|NCT01196702||Control bronchiectasis|Controls with bronchiectasis not caused by a known immunodeficiency
3230949|NCT01196702||Control with granulomatous disease|Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
3230950|NCT01196702||Healthy Controls|
3230951|NCT01196715|Active Comparator|Darbepoetin Alfa|
3230952|NCT01196715|Active Comparator|G-CSF|
3230953|NCT01196715|Active Comparator|Best Supportive Care|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl
3230954|NCT01196728|Experimental|CM3.1-AC100 dose A|Compound CM3.1-AC100 s.c.
3230955|NCT01196728|Experimental|CM3.1-AC100 dose B|Compound CM3.1-AC100 s.c.
3230956|NCT01196728|Experimental|CM3.1-AC100 dose C|Compound CM3.1-AC100 s.c.
3230957|NCT01196728|Placebo Comparator|Placebo|Placebo for compound CM3.1-AC100 s.c.
3230958|NCT01196754|Other|sevoflurane|
3230959|NCT01196767|Experimental|ropivacaine|
3230960|NCT01196767|Other|normal saline|
3230961|NCT01196780||Cohort|
3326588|NCT02063061|Sham Comparator|Sham treatment|Subject will answer standardized questionnaires. Sham treatment arm will receive initially 5 sham series and after they answer standardized questionnaires they will receive 5 series of active treatment. Afterwards patients will answer standardized questionnaires again.
3326589|NCT02063061|Active Comparator|ESWT treatment|Subject will answer standardized questionnaires. Subjects will receive 10 treatments with ESWT. Afterwards patients will answer standardized questionnaires again.
3326590|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 100mg|
3326591|NCT02063100|Experimental|Shenyankangfu tablets and Losartan potassium 50mg|
3326592|NCT02063100|Experimental|Losartan potassium 50mg|
3326593|NCT02063100|Experimental|Shenyankangfu tablets|
3326594|NCT02063100|Experimental|Losartan potassium 100mg|
3326595|NCT02063113|No Intervention|NA/NA|
3326596|NCT02063126|Active Comparator|ReConnect|CFS patients who were randomized to measure the effect of oral ReConnect supplementation (NADH: 20 mg/day, Coenzyme Q10: 200 mg/day; 4 tablets/day) on the maximum HR during 8-weeks in term.
3326597|NCT02063126|Placebo Comparator|Placebo|CFS patients who were randomized to measure the effect of oral Placebo supplementation ( phosphoserine and vitamin C, 4 tablets/day) on the maximum HR during 8-weeks in term.
3326598|NCT02063139|Experimental|Flutiform 50/5 ug (2 puffs bid) pMDI|Flutiform 50/5 ug (2 puffs bid) pMDI
3326599|NCT02063139|Active Comparator|Fluticasone 50 ug (2puffs bid) pMDI|Fluticasone 50 ug (2puffs bid) pMDI
3326600|NCT02063139|Other|Beclometasone Autohaler 50 ug (2 puffs bid)|Active control
3326601|NCT02063152||Entire Taiwan women|
3230962|NCT01196832||Chronic obstructive pulmonary disease patients|"COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux.~Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis."
3230963|NCT01196832||Control group|Subjects without any history of lung disease and with normal lung function testing
3230964|NCT01196845|Other|obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3230965|NCT01196845|Other|obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3326602|NCT02063191||Atrial Fibrillation|Patients with atrial fibrillation during the EP study
3326603|NCT02063191||Bundle Branch Block|Patient with bundle branch block during the course of the EP study
3230966|NCT01196845|Other|non-obese + cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3230967|NCT01196845|Other|non-obese + Sham cPAP|Patients with sleep apnea syndrome will be first randomised in 2 arms according to their obesity. They will be secondly randomised in 2 arms receiving either cPAP treatment or Sham cPAP.
3230968|NCT01196884||Asymptomatic ITP patients|
3230969|NCT01196884||ITP patients treated with Rituximab|
3230970|NCT01196884||ITP patients treated with steroids|
3230971|NCT01196897|Experimental|Implantable device|WATCHMAN LAA Closure Technology (Gen 4.0)
3230972|NCT01196910|Active Comparator|Stimulation over the left dorsolateral prefrontal cortex|Group A (fifteen subjects) - treatment by HLPFC coil high-frequency stimulation over the left dorsolateral prefrontal cortex (DLPFC).
3326604|NCT02063204|Experimental|HV selumetinib Stage 1|Healthy volunteer (HV)group to receive selumetinib 50mg (2x25mg) orally
3326605|NCT02063204|Experimental|ESRD selumetinib Stage 1|End stage renal disease (ESRD)patients to recieve selumetinib 50mg (2x25mg) orally
3326606|NCT02063204|Experimental|Selumetinib stage 2|If deemed necessary patients with mild and/or moderate and/or severe renal impairment will recieve selumetinib 50mg(2x25mg) orally
3326607|NCT02063243|Other|keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
3326608|NCT02063256|Active Comparator|7 NUTS a day|the patients allocated to this arm will be instructed to supplement their diet with 7 nuts a day (whole shelled weight around 75 grams)
3326609|NCT02063256|Experimental|Diet modification|the patients allocated to this arm will be instructed to modify their diet allowing more intake of PUFA rich food avoiding saturated fat rich food
3326610|NCT02063269|Experimental|Rivastigmine|Rivastigmine
3326611|NCT02063282||Clostridium difficile carriers|
3326612|NCT02063282||Clostridium difficile non carriers|
3326613|NCT02063295|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.
3326614|NCT02063295|Experimental|ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3326615|NCT02063308|Experimental|Oxaloacetate (OAA)|100 mg OAA to be taken twice daily over the course of a month
3326616|NCT02063334|Active Comparator|Vitamin D3|2000 micrograms of vitamin D3 in two doses during one day
3326617|NCT02063334|Placebo Comparator|Placebo|Placebo in two doses during one day
3326618|NCT02063347||Coronary artery disease|With coronary artery disease
3326619|NCT02063347||No coronary artery disease|Without coronary artery disease
3326620|NCT02063360|Experimental|Cohort 1: BMS-663068+DRV/RTV|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg orally orally twice daily on days 7-16
3326621|NCT02063360|Experimental|Cohort 2: BMS-663068+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet ETR 200mg orally orally twice daily on days 7-16
3326622|NCT02063360|Experimental|Cohort 3: BMS-663068+DRV/RTV+ETR|Extended release tablet BMS-663068 600mg orally twice daily on days 1-4 and 17-26. Tablet DRV 600mg / RTV 100mg and ETR 200mg orally orally twice daily on days 7-16
3326623|NCT02063373|Experimental|biomechanis knee OA and HA injection|Weekly intra- articular Hyaluronic acid injection (20 MG/ 2 ML) into both knees for five weeks
3326624|NCT02063386|Experimental|AZD1722|Single oral dose 15 mg of [14C]AZD1722
3326625|NCT02063412||XELOX|Capecitabine (Xeloda) 1000mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
3326626|NCT02063412||XP|Cisplatin (CDDP) 80 mg/m2 iv over 3 hrs d1 Capecitabine (Xeloda) 1000 mg/m2 po bid d1-14, Q3w
3326627|NCT02063412||FOLFOX|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and d2 5-FU 400mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d1 and d2 Q2w
3326628|NCT02063412||FP|Cisplatin (CDDP) 100 mg/m2 iv d1 5-FU 1000 mg/m2/d civi d1-5, Q4w
3230973|NCT01196910|Active Comparator|stimulation over the right DLPFC|Group B (fifteen subjects) - Treatment by HLPFC coil high-frequency stimulation over the right DLPFC.
3230974|NCT01196910|Placebo Comparator|Treatment with HLPFC coil simulator mode|Group C (fifteen subjects) - Treatment with HLPFC coil simulator mode (sham).
3230975|NCT01196949|Active Comparator|Manipulative and Rehabilitative Therapy|
3230976|NCT01196949|Active Comparator|Rehabilitative Therapy|
3326629|NCT02063425|Active Comparator|Fluoxetine|
3326630|NCT02063425|Placebo Comparator|Placebo|
3326631|NCT02063438|Active Comparator|Pericostal Suture Technique|A #2 Vicryl suture is placed along the superior aspect of the rib above the specific thoracic interspace. This suture is then passed below the inferior rib along the superior aspect of the next rib below. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
3326632|NCT02063438|Active Comparator|Intracostal Suture Technique|A handheld drill is used to drill holes in the rib below the specific thoracic interspace. A #2 Vicryl suture is passed through each of the holes and then passed along the superior aspect of the rib above the specific thoracic interspace. These sutures are then tied to approximate the ribs leaving enough room for the tip of a finger.
3326633|NCT02063451|Other|Obese, Weight Loss, Very Low Calorie Diet|Obese individuals will a Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA) for 3-6 months until individually targeted weight loss determined by a clinician is reached. Typically, individuals consume 850-1000 kilocalories per day.
3230977|NCT01196962|Experimental|Internal jugular vein|
3326634|NCT02063451|No Intervention|Lean, baseline measure|MOR binding will be observed in lean individuals at one timepoint. Lean individuals will not receive any intervention.
3326635|NCT02063477|Placebo Comparator|Product one|150 mg (maltodextrin)/day (75 mg maltodextrin included in 280 mg/gelule; 2 times/day: morning and evening) of Placebo plus Dietary Approaches to Stop Hypertension (DASH)
3326636|NCT02063477|Active Comparator|Product two|150 mg Oligopin/day (75mg Oligopin included in 280mg/gelule; 2 times/day: morning and evening) of Oligopin® plus Dietary Approaches to Stop Hypertension (DASH)
3326637|NCT02063490|Experimental|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
3326638|NCT02063490|No Intervention|Control arm|Standard care
3326639|NCT02063503|Experimental|Motor control therapy|physiotherapy
3326640|NCT02063503|Experimental|Isometric training therapy|physiotherapy
3326641|NCT02063503|Experimental|Combination therapy|physiotherapy
3326642|NCT02063529|Experimental|A (FOLFOXIRI + Cetuximab)|FOLFOXIRI + Cetuximab
3326643|NCT02063529|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
3326644|NCT02063555|Experimental|DAR-901|"Intradermal administration at 0, 2 and 4 months~Three dose groups in dose escalation: 0.1 mg, 0.3 mg and 1.0 mg, all constituted in 0.1 mL"
3326645|NCT02063555|Active Comparator|BCG|Intradermal injection of 0.1 mL saline at 0 mos, 2 mos, intradermal injection of 0.1 mL BCG at 4 mos
3326646|NCT02063555|Placebo Comparator|Sterile saline|Intradermal injection of 0.1 mL sterile saline at 0, 2 and 4 mos
3230978|NCT01197001|Experimental|Amlodipine plus Losartan|
3326647|NCT02063568|Active Comparator|Low dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 0.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
3326648|NCT02063568|Active Comparator|High dose oxytocin infusion|oxytocin will be administered as an intravenous infusion at a rate of 1.33 units/min starting after fetal delivery upon umbilical cord clamping and continuing for a total of 30 minutes
3326649|NCT02063581|Experimental|Sequence 1: Tablet followed by Capsule|
3230979|NCT01197001|Active Comparator|Amlodipine, Losartan|
3326650|NCT02063581|Experimental|Sequence 2: Capsule followed by Tablet|
3326651|NCT02063594|Placebo Comparator|Saline Placebo|2 of 8 subjects in each dose cohort will receive normal saline as a single intravenous infusion
3230980|NCT01197014|Experimental|Amlodipine plus Losartan|
3230981|NCT01197014|Active Comparator|Amlodipine, Losartan|
3230982|NCT01197027|Experimental|Enhanced counseling|5 intensive counseling sessions following acute HIV infection
3230983|NCT01197027|Active Comparator|Standard counseling|Standard HIV counseling following acute HIV infection
3230984|NCT01197040|Experimental|B-Experimental|Experimental
3230985|NCT01197040|Active Comparator|A-Active Comparator|Active Comparator
3230986|NCT01197053|Experimental|100 mcg DBV712 (active)|100 mcg DBV712 administered epicutaneously every 24 hours.
3230987|NCT01197053|Placebo Comparator|Placebo|Placebo will be administered epicutaneously every 24 hours
3230988|NCT01197066|Other|Certolizumab Pegol|Single Arm
3230989|NCT01197079||MSM|Young men (under 26 years of age) who have sex with men
3326652|NCT02063594|Experimental|NCTX|6 of 8 subjects in each dose cohort will receive NCTX (PEGylated Liposomal Iodixanol Injection) as a single intravenous infusion
3326653|NCT02063607|Active Comparator|Peginterferon alfa 2a|Peginterferon alfa 2a 180 mcg
3326654|NCT02063607|Experimental|Peginterferon Lambda|Peginterferon Lambda 60,120,180 and 240 mcg
3326655|NCT02063620|Active Comparator|ketamine HCL|%0.5 Lidocaine+Ketamine HCL 0.8 mg/kg, total 40ml, single dose administration, 30 minute duration, total 200mg lidocaine
3326656|NCT02063620|No Intervention|lidocaine+ serum physiologic|% 0.5 lidocaine+ serum physiologic, total 40ml, total 200 mg lidocaine, 30 minute duration, single dose administration,
3326657|NCT02063646|Placebo Comparator|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
3326658|NCT02063646|Experimental|Polyphenol-rich extract|"The test product is a food supplement named Neurophenol. It is presented as a hard-shell capsule containing polyphenol-rich extracts.~Dose: 2 capsules per day, one capsule at least 1 hour after breakfast and one capsule at least one hour after dinner, with a glass of water."
3230990|NCT01197079||Parents|Parents of Boys aged 9 to 18 years
3230991|NCT01197092|Active Comparator|Verum|
3230992|NCT01197092|Experimental|Control|
3230993|NCT01197105|Experimental|Aroeira|
3230994|NCT01197118|Active Comparator|2|chemotherapy alone following radical resection
3326663|NCT02063711|Experimental|Yoga Intervention|A 1-hour yoga session will take place with guided instruction provided by a registered yoga instructor. The class includes a warm up period of 5 minutes, which includes sitting with the eyes closed and slowly breathing through the nose. After which the participant will perform a series of yoga postures in coordination with her breathing for approximately 45 minutes. The last 10 minutes of class will encompass a semi-recumbent relaxation period. This is a one time intervention.
3326664|NCT02063711|No Intervention|Control group|In order to control for 1 hour worth of time, the participants in the control group will be given a 1 hour Power Point presentation on the benefits of exercise and yoga during pregnancy.
3326665|NCT02063750|Experimental|Strengthening group|This group perform muscle strengthening exercises using a Swiss ball of 65 cm diameter.
3326666|NCT02063750|Active Comparator|Stretching group|Performed stretching exercises
3326667|NCT02063776||Children on HDF|
3326668|NCT02063776||Children on conventional HD|
3230995|NCT01197118|Experimental|1|sequence chemoradiotherapy following radical resection
3326669|NCT02063789|Experimental|Human immunoglobulin intravenous|Human immunoglobulin intravenous; GC5107A (IV-Globulin SN Inj. 10%); Day 1: GC5107A, 1g/kg, intravenous Day 2: GC5107A, 1g/kg, intravenous; Starting infusion rate: 0.01mg/kg/min (1mg/kg/min) for first 15 minutes, and then 2-fold increase every 30 minutes by maximum 0.08ml/kg/min (8mg/kg/min). Dosing modification is allowed due to tolerance.
3326670|NCT02063802|Active Comparator|metformin and healthy habits program|1 gr per day. (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
3230996|NCT01197131||autistic boys|Boys with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician
3230997|NCT01197131||autistic girls|Girls with autism spectrum disorder, age 5-15 years, diagnosis meets DSM-IV criteria ascertained by ADI-R or ADOS schedule or specialised paediatrician.
3326671|NCT02063802|Experimental|Conjugated Linoleic Acid and healthy habits|Total dose: 3gr per day (500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner by mouth for four months.
3230998|NCT01197131||control boys|"Healthy boys, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger-Syndrome (MBAS)."
3230999|NCT01197131||control girls|"Healthy girls, age 5-15 years, mental status assessed by Marburger Beurteilungsskala zum Asperger Syndrome (MBAS)."
3231000|NCT01197144|Active Comparator|Adalimumab|Treatment with adalimumab 40 mg sc eow for 4 weeks
3231001|NCT01197144|Placebo Comparator|Placebo|Treatment with placebo s c eow for 4 weeks
3231002|NCT01197144|No Intervention|Healthy Controls|"Healthy volunteers, age ≥18. Will perform all the same pain assessments, blood sampling and baseline fMRI as RA patients~Exclusion criteria:~For fMRI - left handedness and all forms of metallic implants.~Fulfilling ACR criteria for fibromyalgia.~Severe ischemic heart disease.~Concurrent treatment for depression/anxiety with antidepressant drugs.~Concurrent neurological disease.~Other reason as evaluated by the P.I."
3231003|NCT01197157|Placebo Comparator|placebo|"• Group A: comprises 100 chronic hepatitis patients who will receive placebo twice daily orally with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
3231004|NCT01197157|Experimental|Nitazoxanide|"• Group B: comprises 100 CHC patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.~All patients in this group will have an HCV RNA within 3 months before initiation of therapy, in addition to ALT levels, CBC and other routine liver function tests."
3231005|NCT01197170|Experimental|Anastrozole|1 mg PO (by mouth) daily for 28 days.
3231006|NCT01197170|Experimental|Anastrozole + Bevacizumab|Anastrozole 1 mg PO daily and Bevacizumab starting dose 10 mg IV Day 1 of 21 day cycle. Expansion group added when MTD dose of Anastrozole + Bevacizumab found.
3231007|NCT01197170|Experimental|Anastrozole + Everolimus|Anastrozole 1 mg PO daily and Everolimus starting dose 5 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Everolimus found.
3231008|NCT01197170|Experimental|Anastrozole + Sorafenib|Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
3231009|NCT01197170|Experimental|Anastrozole + Erlotinib|Anastrozole 1 mg PO daily and Erlotinib starting dose 75 mg PO daily for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Erlotinib found.
3231010|NCT01197196|Experimental|Behavioral weight loss|
3231011|NCT01197196|Active Comparator|Migraine Education|
3326672|NCT02063802|Placebo Comparator|Placebo and healthy habits program|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months.
3326673|NCT02063815|Active Comparator|glass ionomer based fissure sealant|fissure sealant application
3326674|NCT02063815|Active Comparator|resin based fissure sealant|fissure sealant application
3231012|NCT01197209|Experimental|Ad-REIC/Dkk-3 Arm|Active arm on Ad-REIC/Dkk-3
3231013|NCT01197222|Active Comparator|EndoClear used|The EndoClear device is used during a laparoscopic abdominal surgery.
3231014|NCT01197222|No Intervention|Control|EndoClear Lens Cleaning Device not used during a laparoscopic abdominal surgery.
3231015|NCT01197235|Experimental|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
3231016|NCT01197235|Placebo Comparator|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
3231017|NCT01197248|Active Comparator|Cystocele Plication|Placement of sutures over the pubocervical fascia during cystocele repair.
3326675|NCT02063841|Active Comparator|sterile identical sham drape|Sham drape and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
3326676|NCT02063841|Experimental|lead-free protective drape containing bismuth and antimony|lead-free protective drape containing bismuth and antimony (RADPAD®) hung around the fluoroscopy image intensifier to prevent scatter radiation, and conventional protection (wearing a lead apron and thyroid shield as well as suspension of a standard lead skirt over the X-ray source).
3231018|NCT01197248|Experimental|No Plication|Avoid sutures over pubocervical fascia during cystocele repair
3231019|NCT01197261|Active Comparator|OXN PR|Oxycodone Naloxone tablets
3326677|NCT02063893||non-vaccine|
3326678|NCT02063893||giving low vaccine|
3231020|NCT01197261|Placebo Comparator|PLA|
3231021|NCT01197274||Mite-sensitized person|
3231022|NCT01197287|Experimental|QAK423A Arm A|
3231023|NCT01197287|Experimental|QAK423A Arm B|
3326679|NCT02063893||giving middle vaccine|
3326680|NCT02063893||giving high vaccine|
3326681|NCT02063906||Breast cancer stage I-III|who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008.
3326682|NCT02063919||endomicroscopy|
3326683|NCT02063932||endomicroscopy|
3326684|NCT02063945|Active Comparator|Methylphenidate|"Participants in this arm will be given either Concerta - a long acting (12 hours) Methylphenidate pill - once daily, in the morning (starting dose 1 mg/kg, max dose 2 mg/kg), or Ritalin LA - a long acting (10 hours) Methylphenidate pill - once daily, in the morning (starting dose 0.6 mg/kg, max dose 1.5 mg/kg) for children who can not swallow pills."
3326685|NCT02063945|Active Comparator|Risperidone|Participants in this arm will be given a low dose of Risperidone. Starting dose will be 0.5 mg/d, max dose will be 2 mg/d.
3326686|NCT02063958|Experimental|SNX-5422|Open-label administration of SNX-5422 capsules dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period. Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. Dose escalation will not exceed a dose of 100 mg/m2 SNX-5422 qod even if the MTD has not been identified. Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.
3326687|NCT02063971|Experimental|Skin aging|Anti-age product will be applied once a day, in the evening, on half face and neck for an uninterrupted period of 12 weeks and the placebo cream in the morning with the same modalities. On the contralateral face side (right or left side according to a previous randomisation list), the volunteers will apply the placebo cream twice a day
3231024|NCT01197287|Experimental|QAK423A Arm C|
3231025|NCT01197313|Experimental|Exercise|
3326688|NCT02063997|Experimental|Arhalofenate 600 mg|
3326689|NCT02063997|Experimental|Arhalofenate 800 mg|
3231026|NCT01197339|Experimental|treatment|
3231027|NCT01197339|Sham Comparator|Controls|
3231028|NCT01197352|Experimental|Text message queries with feedback|Weekly prompted queries about drinking behavior with personalized feedback.
3231029|NCT01197352|Active Comparator|Text message queries|Weekly prompted queries about drinking behavior
3231030|NCT01197352|No Intervention|Control|Weekly text reminders to complete final (12 week) instruments
3231031|NCT01197365|Experimental|STUDY GROUP|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
3231032|NCT01197365|Other|CONTROL GROUP|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
3231033|NCT01197391|Experimental|Cohort 1|Dose 1 versus placebo
3231034|NCT01197391|Experimental|Cohort 2|Dose 2 versus placebo
3231035|NCT01197404|Active Comparator|General Health Promotion|
3231036|NCT01197404|Experimental|Affect Management|
3231037|NCT01197443|Experimental|Parent-only Group|Treatment will be administered to parents of the overweight child. Parent-only group treatment will include all of the same skills and techniques to promote weight loss, but the information will be delivered only to the parent. Participation of the children assigned to the parent-only treatment arm will be limited to the baseline and follow-up assessments.
3326690|NCT02063997|Active Comparator|Allopurinol 300 mg; colchicine 0.6 mg|
3326691|NCT02063997|Active Comparator|Allopurinol 300 mg|
3326692|NCT02063997|Placebo Comparator|Placebo|
3326693|NCT02064010|Experimental|SNC-102, low dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
3326694|NCT02064010|Experimental|SNC-102, high dose|SNC-102 (Acamprosate calcium) tablet 4 week duration dosing
3326695|NCT02064010|Placebo Comparator|Placebo|Placebo tablet 4 week duration dosing
3326696|NCT02064023|Experimental|insulin pump|subjects will use an insulin pump for the duration of the pregnancy. The intervention is that they will control their diabetes using an insulin pump
3326697|NCT02064023|Active Comparator|Multiple Daily Insulin injections|subjects will continue their usual insulin treatment with multiple daily injections of sc insulin
3326698|NCT02064036|Experimental|Single|Neoadjuvant Androgen Blockade (Casodex) Followed by: Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade (Casodex and Leuprolide) to Whole Pelvis, Prostate, and Seminal VesiclesFollowed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance Followed by: Adjuvant Androgen Blockade (Casodex)
3326699|NCT02064049|Experimental|Hepatitis C treatment|All prisoners (in participating correctional centres) with hepatitis c, as identified during the hepatitis C surveillance phase of the study will be offered treatment for hepatitis C. The treatment course is sofosbuvir/velpatasvir 400/100mg for 12 weeks (1 tablet once daily).
3326700|NCT02064062|Experimental|Autologous Mesenchymal Stem Cells|
3326701|NCT02064075|Active Comparator|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day.
3326702|NCT02064075|Active Comparator|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day.
3326703|NCT02064088|Experimental|Small volume|Local analgesia by one injection of 0,2 ml/kg of 0,2% lévobupivacaine
3231038|NCT01197443|Active Comparator|Parent + child Group|The treatment for participants in the parent + child arm will be administered in two separate groups, one for the parents and one for the child.
3231039|NCT01197469|Placebo Comparator|Placebo|Placebo
3231040|NCT01197469|Active Comparator|Tadalafil|
3231041|NCT01197599||Spinal Cord Injury|
3326704|NCT02064088|Experimental|High volume|Local analgesia by one injection of 0,4 ml/kg of 0,1% lévobupivacaine
3326705|NCT02064101||Adolescent idiopathic scoliosis|Patients with adolescent idiopathic scoliosis undergoing spinal fusion
3326706|NCT02064114|Active Comparator|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
3326707|NCT02064114|Active Comparator|control group|conventional treatment, followed for a period of 3,6 and 12 months after the procedure.
3326708|NCT02064127||Patients with abdominal pain|Adult patients admitted to the Emergency Department with a main complaint of abdominal pain
3326709|NCT02064140|Experimental|Neuromuscular blocking agent|
3326710|NCT02064153|Active Comparator|Cool dialysate|Recruited study subject undergoes cool dialysate (35.5ºC) session.
3231042|NCT01197599||Able-Bodied Control|
3231043|NCT01197625|Experimental|DC-vaccine|
3231044|NCT01197664|Experimental|Arm I (paricalcitol and chemoradiotherapy)|Patients receive paricalcitol PO daily. Patients also receive standard care chemoradiotherapy with fluorouracil PO.
3231045|NCT01197664|Active Comparator|Arm II (chemoradiotherapy)|Patients receive standard care chemoradiotherapy as in Arm I.
3231046|NCT01197729||STEMI|(ST-Elevation myocardial infarction)
3231047|NCT01197729||NSTEMI|Non-ST-Elevation myocardial infarction
3326711|NCT02064153|Active Comparator|Warm dialysate|Recruited study subject undergoes warm dialysate (37ºC) session.
3326712|NCT02064192||ICD Group (n=1500)|First ICD device implantation (after baseline assessments) is not part of this observational study and is carried out in the responsibility of the treating physician, all ICD-devices will undergo unique standard programming to ensure comparability of ICD shock events between patients.
3326713|NCT02064192||Control Group (n=750)|Patients who fulfill inclusion criteria but do not receive an ICD device will be followed as part of the Control Group
3231048|NCT01197768|Experimental|Nutrition Intervention|The intervention group will receive a full nutrition assessment and a nutrition intervention.
3231049|NCT01197768|No Intervention|Control|This group will receive the nutrition assessment but no intervention from a Registered Dietician. If participant appears to be in danger due to BMI or Caloric intake status, their primary care physician will be notified.
3326714|NCT02064218||Hypertensive patients|Hypertensive patients naive to hypertensive treatment
3326715|NCT02064218||healthy subjects|healthy subjects
3326716|NCT02064244||Acute renal failure in ICU|Ultrasound for measurement of Inferior Vena Cava size
3326717|NCT02064257|Experimental|Intervention group|Participants will be included in all pre-intervention and post-assessment measures. Participants will receive the Listening Project Protocol intervention. The duration of the intervention is approximately 45 minutes per day, for 5 consecutive days.
3326718|NCT02064257|No Intervention|Assessment-only group|The assessment-only group will participate in all pre- and post-intervention assessments, but will not receive the Listening Project Protocol.
3326719|NCT02064283|Experimental|Diffusion MRI Assessment|Men with newly diagnosed metastatic disease initiating therapy with androgen deprivation, or men with hormone refractory prostate cancer initiating treatment with chemotherapy, will be assessed by diffusion MRI (Magnetic Resonance Imaging) at baseline, 2 weeks and again at 9-12 weeks.
3326720|NCT02064296|No Intervention|Controls|Healthy pain free controls will be recruited for comparison with fibromyalgia patients.
3326721|NCT02064296|Active Comparator|Non-Traditional Acupuncture|40 fibromyalgia patients will be randomized to non-traditional laser acupuncture (Vita Laser 650, Lhasa OMS). They will receive 2 treatments per week for 4 weeks.
3326722|NCT02064296|Active Comparator|Traditional Acupuncture|40 fibromyalgia patients will be randomized to receive electro acupuncture (AS Super 4 digital needle stimulator, Harmony Medical Co) . They will receive 2 treatments per week for 4 weeks.
3326723|NCT02064309|Experimental|Human islets in Beta-Air device|
3326724|NCT02064322||SImmetry Implant|Subjects who are indicated for the SImmetry Device according to the approved product labeling and inclusion/exclusion criteria will receive a SImmetry implant.
3326725|NCT02064335|Experimental|Intervention group|"Physical activity coaching: Participants will be coached by a professional physical activity coach through individual and group sessions.~Intake: This talk (1 hour) is the start of the coaching. A physical activity plan will be set up, according to the needs and possibilities of the participant. Activities in leisure time and daily physical activity will be included.~Group sessions: During 5 weeks and one time a week, the subjects will take part in the exercise lessons. About 5 subjects will be in one group and all sessions are supervised by a professional physical activity coach. Activities are walking, Nordic walking and conditional fitness.~Evaluation: After the 5 weeks of group sessions, an evaluation moment will take place between each participant and the physical activity coach. The physical activity plan will be refined."
3326726|NCT02064335|No Intervention|Control group|The control group will operate as a waiting group. It means that in the first 6 months of the project, the subjects of the control group will only be measured and will not receive any intervention.
3326727|NCT02064348|Experimental|Arm 1: semaglutide + moxifloxacin placebo|Subjects will receive a single dose of moxifloxacin placebo both before the start of semaglutide treatment and at the end of the semaglutide treatment.
3326728|NCT02064348|Active Comparator|Arm 2A:|"Semaglutide placebo + moxifloxacin/moxifloxacin placebo:~Subjects will receive moxifloxacin before the start of semaglutide placebo treatment and moxifloxacin placebo at the end of the semaglutide placebo treatment."
3326729|NCT02064348|Experimental|Arm 2B:|"Semaglutide placebo + moxifloxacin placebo/moxifloxacin:~Subjects will receive moxifloxacin placebo before the start of semaglutide placebo treatment and moxifloxacin at the end of the semaglutide placebo treatment."
3326730|NCT02064361|Experimental|High intensity exercise|A dive to 18 meters sea water for a duration of 41 minutes preceded by high intensity cycling
3326731|NCT02064374|Experimental|Cohort 1|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin immediate release (IR) 500 mg q12h following a moderate fat meal for 5 days (Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q24h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
3326732|NCT02064374|Experimental|Cohort 2|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive Metformin IR 500 mg q12h following a moderate fat meal (Day 1-5 of Period 1), followed by Metformin IR 500 mg q12h plus DTG 50 mg q12h following a moderate fat meal for 7 days (Days 1-7 of Period 2), followed by Metformin IR 500 mg q12h following a moderate fat meal (Days 1-10 of period 3).
3326733|NCT02064387|Experimental|Schedule 1 Part 1|Participants will receive GSK2857916 intravenously over 60 minutes (one dose) every 3 weeks (21 day cycle) for a maximum of 16 cycles.
3326734|NCT02064387|Experimental|Schedule 2 Part 1|Participants may receive GSK2857916 intravenously over 60 minutes (one dose) once weekly for three consecutive weeks followed by 1 week of rest (28 day cycle) for a maximum of 16 cycles.
3326735|NCT02064387|Experimental|Schedule 1 Part 2|Participants will receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for up to 16 cycles.
3326736|NCT02064387|Experimental|Schedule 2 Part 2|Participants may receive the dose and schedule of GSK2857916 evaluated in Part 1 that is selected for further evaluation in Part 2 for a maximum of 16 cycles.
3326737|NCT02064400||Observational study group|Musculoskeletal ultrasound (all patients) and semi-structured patient interview (anticipated maximum 15 patients)
3326738|NCT02064413|Experimental|ESS310|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
3326739|NCT02064426|Experimental|Molidustat (BAY85-3934)|
3326740|NCT02064426|Active Comparator|Epoetin alfa/beta|
3326741|NCT02064452|Experimental|Triple P Online System|The Triple P Online System (TPOS) is an interactive, video-driven online parenting support website, delivered with 3 different levels of intensity, depending on severity of children's behavior problems. In this arm, pediatric clinics are randomized to receive training in child disruptive behavior disorders, Triple P principles and target parenting strategies, the Triple P Online System, effectively referring eligible families to TPOS, and supporting their use of the program. Referred parents in this condition receive access to TPOS immediately.
3326742|NCT02064452|Placebo Comparator|Enhanced Usual Community Care-Waitlist|In this arm, pediatric clinics are randomized to receive access for their parents and practitioners to a referral website designed to assist parents of children with disruptive behavior disorders in accessing appropriate community resources; on the website, community resources for treatment of child disruptive behavior disorders (mental health services, parenting services) are described and can be searched by location, cost, and acceptance of Medicare. Parents in this condition receive access to the Triple P Online System (TPOS) after completion of their 1-year follow-up assessment. Pediatricians receive free training in TPOS at the end of their waiting period.
3231050|NCT01197781|Experimental|Period 1|
3326743|NCT02064465|Experimental|Lamotrigine Dispersable/Chewable|lamotrigine dispersible/chewable tablet 100mg
3326744|NCT02064465|Experimental|Lamotrigine Compressed|lamotrigine compressed tablet 100mg
3326745|NCT02064478||Tissue preservation|Ponto implant installed using a tissue preservation surgical technique
3326746|NCT02064478||Tissue reduction|Ponto implant installed using a classical technique with skin thinning
3326747|NCT02064491|Experimental|Erlotinib and Chemotherapy|Intercalated erlotinib in combination with chemotherapy for four to six cycles followed by continuous erlotinib maintenance
3326748|NCT02064491|Active Comparator|Chemotherapy|Chemotherapy for four to six cycles
3326749|NCT02064504|Experimental|Sequence 1|Participants will receive the study treatment in the following order: ABFCED in each period (one per period). Where A=GSK961081 administered from DISKUS, B=GSK961081 Single strip (SS) administered from DPI, C=GSK961081 Dual Strip (DS) administered from DPI with a filled (lactose) second strip (DS configuration), D=GSK961081/fluticasone furoate (GSK961081/FF) administered from DPI (GSK961081 higher dose), E=FF DS administered from DPI with a filled (lactose) second strip (dual strip configuration), F=GSK961081/FF administered from DPI (GSK961081 lower dose).
3231051|NCT01197781|Experimental|Period 2|
3231052|NCT01197807|Active Comparator|Bulb suctioning|Bulb suctioning of mouth and nose immediately after delivery
3231053|NCT01197807|Active Comparator|Wiping|Gentle wiping of mouth then nose with soft cloth
3231054|NCT01197820|Experimental|Arm 1|30 patients with liver tumour and 15 patients with kidney tumour will be enrolled.
3326750|NCT02064504|Experimental|Sequence 2|Participants will receive the study treatment in the following order: BCADFE in each period (one per period)
3326751|NCT02064504|Experimental|Sequence 3|Participants will receive the study treatment in the following order: CDBEAF in each period (one per period)
3326752|NCT02064504|Experimental|Sequence 4|Participants will receive the study treatment in the following order: DECFBA in each period (one per period)
3231055|NCT01197846|Experimental|Quetiapine|Quetiapine 300 mg or 600 mg
3231056|NCT01197846|Placebo Comparator|Placebo|
3326753|NCT02064504|Experimental|Sequence 5|Participants will receive the study treatment in the following order: EFDACB in each period (one per period)
3326754|NCT02064504|Experimental|Sequence 6|Participants will receive the study treatment in the following order: FAEBDC in each period (one per period)
3326755|NCT02064517|Placebo Comparator|Conventional technique|Apical MTA barrier
3326756|NCT02064517|Experimental|Revascularisation pulpaire|hydroxide of calcium
3326757|NCT02064530|Active Comparator|bupivacaine|0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on TAP block
3326758|NCT02064530|Active Comparator|dexmedetomidine|100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on TAP block
3326759|NCT02064530|Sham Comparator|serum phsyologic|0,9% 21 ml serum physiologic
3326760|NCT02064543||ADPM and GAITRite|mobility assessments (ADPM, GAITRite) measuring gait parameters
3326761|NCT02064556|Experimental|A(Amlodipine 10mg)|Amlodipine 10mg 1T, PO, QD for 9days
3326762|NCT02064556|Experimental|B(Amlodipine 10mg/Candesartan 32mg)|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
3326763|NCT02064569|Experimental|GS010|
3231057|NCT01197859|Active Comparator|Contamac 74% silicone hydrogel contact lens|Definitive Contact Lens
3231058|NCT01197859|Placebo Comparator|Cooper Vision Biofinity|Biofinity Contact Lens
3326764|NCT02064595|Other|Intramedullary nail|Fractures treated with intramedullary reamed nail
3326765|NCT02064595|Active Comparator|External fixator|Tibial fractures treated with biplanar external fixation
3326766|NCT02064608|Experimental|AZD2014|This is a single arm study whereby a cohort of 20 patients with early high risk prostate cancer will be treated with a 15-day course of AZD2014 (mTOR inhibitor) treatment prior to radical prostatectomy.
3326767|NCT02064621|Experimental|C(Candesartan 32mg)|Candesartan 32mg 1T, PO, QD for 9days
3326768|NCT02064621|Experimental|B(Candesartan 32mg/Amlodipine 10mg)|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
3326769|NCT02064634||Shinbaro (only)|
3326770|NCT02064634||Celecoxib (only)|
3326771|NCT02064634||Shinbaro + NSAIDs|
3326772|NCT02064634||Shinbaro + Celecoxib|
3326773|NCT02064647|Experimental|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool, uses a formula based on the patients Insulin Sensitivity Factor (ISF) to allow adjustments to meal time insulin boluses, based on CGM trend arrows.
3231059|NCT01197885|Experimental|IMAB362|Two different doses (antibody / body surface area) of IMAB362 will be administered sequentially.
3231060|NCT01197924||healthy volonteer children|paired for the sex and the age
3231061|NCT01197924||older children followed for a médulloblastome cérébelleux|children followed for a médulloblastome treaty by surgery, radiotherapy and chemotherapy
3231062|NCT01197950|Active Comparator|Manual Acupuncture|Manual stimulation
3231063|NCT01197950|Experimental|Electro Acupuncture|Electrical and manual stimulation
3231064|NCT01197950|No Intervention|Standard care|No acupunture
3326774|NCT02064647|Active Comparator|10/20% bolus adjustment|10-20% increase/decrease of the total original recommended bolus dose (10% for one arrow up or down, and 20% for two arrows up or down), with the original bolus dose calculated by the pump calculator (i.e. Bolus Wizard).
3326775|NCT02064647|No Intervention|No adjustment/ignore trend arrows|Subjects will ignore the CGM trend arrows, meal time bolus insulin as per Bolus Wizard
3326776|NCT02064660|Experimental|single arm|A series of acupressure sessions within six months from the baseline
3326777|NCT02064673|Active Comparator|Curcumin|Curcumin 500 mg orally twice a day
3326778|NCT02064673|Placebo Comparator|sugar pill|placebo orally twice a day
3326779|NCT02064686|No Intervention|TAE|
3326780|NCT02064699||CMV infection|Renal transplant recipient immunized against the Cytomegalovirus
3326781|NCT02064712|Active Comparator|Low CPAP Wean|NCPAP weaned to 5cm H2O for minimum of 24h, and if the neonate remains clinically stable as defined, wean in 1cm increments to 3cm H2O for minimum of 24h, at which time move to room air or 1L/min nasal cannula if supplemental O2 is required.
3326782|NCT02064712|Active Comparator|High CPAP Wean|NCPAP weaned to 5cm H2O for a minimum of 24h, and if the neonate remains clinically stable, move to room air or 1L/min nasal cannula if supplemental O2 is required.
3326783|NCT02064725|Experimental|Sodium cridanimod|Sodium cridanimod in combination with megestrol acetate or medroxyprogesterone acetate. Treatment period is 12 months; patients will be followed for another 12 month period or to disease progression whichever occurs first.
3326784|NCT02064738|No Intervention|Normal diet|Two weeks of unaltered diet
3326785|NCT02064738|Experimental|Low omega-6/high omega-3 diet|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams
3326786|NCT02064751|Experimental|MultiPoint Pacing|CRT with MultiPoint Pacing
3326789|NCT02064777|Experimental|Tacrolimus|
3326790|NCT02064790||Group G - receiving gabapentin|Receiving gabapentin as standard of care. No intervention
3326791|NCT02064790||Group P - receiving pregabalin|Receiving pregabalin as standard of care No intervention
3326792|NCT02064790||Group Z - no neuropathic agent|Receiving only conservative treatment No drug treatment No intervention
3326795|NCT02064829|Active Comparator|Reference Drug - Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1
3326796|NCT02064829|Experimental|Test Drug - IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1
3326797|NCT02064842|Experimental|TMC647055 150 mg or placebo + ritonavir (RTV)|Participants in Part 1 will receive a single oral dose of 150 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3326798|NCT02064842|Experimental|TMC647055 450 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 450 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3326799|NCT02064842|Experimental|TMC647055 600 mg or placebo + RTV|Participants in Part 1 will receive a single oral dose of 600 mg of TMC647055 or placebo with 30 mg of RTV on Day 1.
3326800|NCT02064842|Experimental|Sequence 1 (Treatment A-B-C)|Participants in Part 2 will receive Treatment ABC in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3326801|NCT02064842|Experimental|Sequence 2 (Treatment B-C-A)|Participants in Part 2 will receive Treatment BCA in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3326802|NCT02064842|Experimental|Sequence 3 (Treatment C-A-B)|Participants in Part 2 will receive Treatment CAB in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3231065|NCT01197963|Other|Surgical treatment|Surgical treatment of one arm of the patient population.
3231066|NCT01197963|Other|Medically controlled group|Managed by endocrinologists using current medical therapy such as pills, injections and life style medication.
3231067|NCT01197976|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
3231068|NCT01197976|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
3326803|NCT02064842|Experimental|Sequence 4 (Treatment A-C-B)|Participants in Part 2 will receive Treatment ACB in the following sequence - Treatment A: TMC435 150 mg once daily on Days 1 to 7; Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3231069|NCT01197989|Experimental|TEPSO socks|This arm include all patients sides (left or right) treated with TEPSO socks.
3231070|NCT01197989|Placebo Comparator|Standard socks|This arm include all patients sides (left or right) treated with standard cotton socks.
3326804|NCT02064842|Experimental|Sequence 5 (Treatment B-A-C)|Participants in Part 2 will receive Treatment BAC in the following sequence - Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment A: TMC435 150 mg once daily on Days 1 to 7; and Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3326805|NCT02064842|Experimental|Sequence 6 (Treatment C-B-A)|Participants in Part 2 will receive Treatment CBA in the following sequence - Treatment C: TMC435 100 mg once daily + TMC647055 600 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; Treatment B: TMC435 75 mg once daily + TMC647055 450 mg once daily in combination with RTV 30 mg once daily on Days 1 to 7; and Treatment A: TMC435 150 mg once daily on Days 1 to 7 with a washout period of 7 days between consecutive treatment sessions in each individual participant.
3326806|NCT02064881|Experimental|metformin glycinate|"620mg tablets of metformin glycinate: 1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1240mg every 12 hours."
3326807|NCT02064881|Active Comparator|metformin hydrochloride|"500mg tablets of metformin hydrochloride:1 tablet by mouth at night for 3 days, 1 tablet in the morning and evening for 3 days, 1 tablet in the morning and 2 tablets in the evening for 3 days and 2 tablets in the evening and 2 tablets in the morning until the end of the study.~Total study dose: 1000mg every 12 hours."
3326808|NCT02064933||Retrospective Cohort (Longitudinal Analysis)|Participants with WAS treated at consortium centers since 1990 who have received transplant (Stratum A) or gene therapy (Stratum B)
3326809|NCT02064933||Prospective Cohort (Longitudinal Analysis)|Participants treated at consortium centers since 1990 who will receive transplant (Stratum A) or gene therapy (Stratum B)
3326810|NCT02064933||Cross-Sectional Cohort (Cross-sectional Analysis)|Living participants with WAS who have received transplant (Stratum A) or gene therapy (Stratum B) at Consortium Centers 1990-Present And >= 2 Years Post-Transplant
3326811|NCT02064946|Active Comparator|Vitamin D3|Vitamin D3 50,000 IU: Patients will be assigned to receive weekly high-dose vitamin D (50,000 IU/week) along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium) and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
3326812|NCT02064946|Placebo Comparator|Control|Control: Patients will be assigned to receive a weekly vitamin D placebo along with a daily multivitamin (600 IU/day vitamin D + 210 mg/day calcium)and calcium supplements (1,000 mg/day calcium) for a period of 24 weeks.
3326813|NCT02064972||Patients undergoing allo-HSCT, who manifest GvHD.|Patients undergoing allo-HSCT, that manifest GvHD. Patients undergoing allo-HSCT will have CEC count performed at the following timepoints: T1 (baseline), T2 (pre-transplant), T3 (engraftment), T4 (GvHD onset) and T5 (post-GvHD). All patients will also be checked for CEC at day + 28.
3259151|NCT01468025|Active Comparator|Theramine and placebo|Patients in this group were randomly given active Theramine with placebo representing naproxen.
3231071|NCT01198015||Rett syndrome girls|The study population (identical to the population in the preliminary research project) consists of a well-defined group of thirteen Dutch RTT girls with complete clinical, molecular, neurophysiological and metabolic work-up.
3231072|NCT01198054|Experimental|Lenalidomine|Post-induction lenalidomide in patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5 (-5)
3231073|NCT01198067|Experimental|Treatment (pomalidomide)|Patients receive pomalidomide PO on days 1-28 or 1-21. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
3231074|NCT01198080|Experimental|femoral osteonecrosis patients|patientswith femoral head osteonecrosis
3231075|NCT01198119|Experimental|Patient with oral cavity cancer|Patient treated by surgery for the oral cavity cancer
3231076|NCT01198171||Basic science (DNA analysis)|DNA from archived frozen normal tissue samples is genotyped for the ancestry informative markers. Clinicopathological and demographic characteristics associated with each sample are also collected.
3231077|NCT01198184|Experimental|Treatment (temsirolimus and RO4929097)|Patients receive temsirolimus IV over 30 minutes on day -6 (course 1 only). Patients then receive temsirolimus IV or PO on days 1, 8, and 15 and gamma-secretase/Notch signalling pathway inhibitor RO4929097 PO once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3231078|NCT01198210|Placebo Comparator|saline|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3231079|NCT01198210|Active Comparator|ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3326814|NCT02064998|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
3326815|NCT02064998|Experimental|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
3326816|NCT02064998|No Intervention|Control Study 1|Waitlist control group that is given access to the Promillekoll and PartyPlanner apps after a 12-week wait.
3326817|NCT02064998|Experimental|Crossover group 1: TeleCoach - Control|Six-week access to the TeleCoach app, with exercises and vignettes for reducing or abstaining from alcohol consumption, followed by a 6-week period with no access to the app.
3326818|NCT02064998|Experimental|Crossover group 2: Control - TeleCoach|Initially a 6 week no-app control period, followed by 6-week access to the TeleCoach app, offering exercises and vignettes for reducing or abstaining from alcohol consumption.
3259152|NCT01468025|Active Comparator|Naproxen and placebo|Patients in this group were randomly given active naproxen and placebo to represent Theramine.
3326819|NCT02065011|Other|Long-term follow up|Long-term follow up of patients who received SAR421869 in a previous study TDU13600
3326820|NCT02065024|Active Comparator|b-cryptoxanthin plus phytosterols|Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols
3326821|NCT02065024|Placebo Comparator|control|Fruit and milk based beverage not enriched
3326822|NCT02065037|Experimental|Warmed Carbon Dioxide Insufflation|warmed carbon dioxide insufflation used in colonoscopy
3326823|NCT02065037|Active Comparator|Room Temperature Air Insufflation|room temperature air insufflation used in colonoscopy
3326824|NCT02065050|No Intervention|Usual Care|Individuals in the usual care arm will not receive frequent contact by the study team. Individuals will be seen by a study team clinician 1 year after discharge to review diabetes management and obtain pertinent study related data.
3326825|NCT02065050|Experimental|Continued care|team-based care: Individuals in the continued care arm will be frequently contacted by the study team (consisting of endocrinologists, nurse practitioners, and health coaches) over the course of one year post-discharge. The team will monitor blood sugars and other health data, altering management as needed.
3326826|NCT02065063|Experimental|Part 1|Part 1 is a dose finding phase in which subjects will be initially administered 75 milligram (mg) of palbociclib (21 days on/7 days off) and 1.5 mg of trametinib (once daily continuous dosing) in each 28-day cycle. Dose escalations will continue based on predefined parameters until the RCR is identified. The RCR will not exceed the maximum tolerated dose (MTD).
3259153|NCT01468038|Active Comparator|Active trazodone and placebo|trazodone 50mg with Sentra PM-like placebo
3326827|NCT02065063|Experimental|Part 2|Once the MTD and schedule have been determined, two expansion cohorts of up to 20 subjects each will be enrolled. The cohorts will enroll subjects with BRAF-WT (wild type) cutaneous melanoma that are either NRAS-WT or NRAS-MUT (mutated). Subjects will be dosed at or below the RCR to determine the inhibition of selected tumor biomarkers at each dose level.
3326828|NCT02065063|Experimental|Part 3|Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
3326829|NCT02065076|Active Comparator|Sodium Polystyrene Sulfonate|30 g sodium polystyrene sulfonate powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
3326830|NCT02065076|Placebo Comparator|Lactose with carob gum|30 g placebo powder, mixed with water qs ad 150 ml, taken PO once daily for seven days
3326831|NCT02065089|Experimental|playing the ipad quiz game|There will only be one arm--any patient who consents to participate in the intervention (playing the ipad quiz game)
3326832|NCT02065115|Experimental|Cryotherapy|Cryotherapy: 12 ounces of crushed ice place in a plastic bag applied to the radial artery puncture area for 3 minutes
3326833|NCT02065115|No Intervention|Control|Cryotherapy is not applied to the radial artery puncture area
3326834|NCT02065128||Healthy Volunteers|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
3326835|NCT02065128||Irritable Larynx Syndrome Patients|Capsaicin cough challenge test. The ILS participants will be asked to attend two study visits at the pulmonary function laboratory at SMH; one before behavioural therapy and one after. The healthy volunteers will be asked to attend one study visit. At each of these study visits, the ILS participants will complete the Leicester Cough Questionnaire (LCQ) (Appendix B) and the Dyspnea Index (DI) Questionnaire (Appendix C). The LCQ is a valid assessment tool for evaluating the impact of cough on QoL.19 The DI is a short, validated questionnaire used to quantify a patient's symptoms of dyspnea.20 Following completion of the questionnaires, participants will complete a capsaicin cough challenge test, which is discussed in the following section.
3326836|NCT02065141|Other|Healthy|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed.~study day: stable isotope infusions with blood draws, sip feed"
3326837|NCT02065141|Other|Chronic Obstructive Pulmonary Disorder|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
3326838|NCT02065141|Other|Chronic Heart Failure|"screening visit: body weight and composition by DXA, height, and vital signs will be assessed. Subjects may sign a medical release form to obtain medical information about them that will help determine study eligibility or can be used for later coding.~study day: stable isotope infusions with blood draws, sip feed"
3326839|NCT02065154|Experimental|Treatment|Cyclophosphamide (Cytoxan)
3326840|NCT02065167|Experimental|Cultured autologous Mesenchymal Cells|"Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.~20x106 cells per cc in a single administration of 7cc"
3326841|NCT02065180|Experimental|commercially available nutrition supplement|this group receives a commercially available nutritional supplement for a period of 2 months
3231080|NCT01198210|Active Comparator|dexamethasone|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3231081|NCT01198210|Active Comparator|dexamethasone-ketamine|One hundred sixtyAmerican Society of Anesthesiologists (ASA) I-II children 3-12 were randomized four groups of 40 each. Group P received a local peritonsillar infiltration of 2 ml saline, group D dexamethsone (0.2 mg/kg)) , group K ketamine (0.5 mg/kg) and group KD combination of ketamine0.5mg/kg-dexamethasone 0.2mg/kg. All medications were 2 ml in volume which was applied 1 ml per tonsil 3 min prior to tonsillectomy( all four groups).
3231082|NCT01198223|Other|drug: garlic extract, nystatin|Drug: garlic extract 40mg/dl or nystatin suspension 100000 iu/ml tid for one month Patients had been clinically with denture stomatitis and confirmed by oral medicine specialist were selected for the study. Gender, age, medical history, erythema types, size, and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received garlic extract and second group used nystatin suspension for 1 month. Each patients was examined at the beginning of the therapy ,and then every 1 weeks up to 1 months .
3326842|NCT02065180|Placebo Comparator|control group|this group receives a placebo for a period of 2 months
3326843|NCT02065193||Beijing group|
3326844|NCT02065193||Guangdong group|
3231083|NCT01198249|Experimental|amlodipine monotherapy|
3231084|NCT01198249|Experimental|losartan monotherapy|
3231085|NCT01198249|Experimental|HCTZ|
3326845|NCT02065193||Shenzhen group|
3326846|NCT02065193||Shanxi group|
3326847|NCT02065193||Liaoning group|
3326848|NCT02065193||Jilin group|
3326849|NCT02065193||Heilongjiang group|
3326850|NCT02065193||Jiangsu group|
3326851|NCT02065193||Zhejiang group|
3326852|NCT02065193||Fujian group|
3326853|NCT02065193||Henan group|
3326854|NCT02065193||Hubei group|
3326855|NCT02065193||Hunan group|
3326856|NCT02065193||'Shanxi group|
3326857|NCT02065219|Experimental|Bupivacaine|injection, 25 mg, once, 5 min
3326858|NCT02065219|Placebo Comparator|Placebo|injection, 10 ml 0.9% sodium chloride, once, 5 min
3326859|NCT02065232||Tilmanocept|Patients will receive technetium-labeled tilmanocept, which is FDA approved for sentinel lymph node mapping in breast cancer.
3326860|NCT02065232||Sulfur Colloid|Patients will receive technetium-labeled sulfur colloid, which is FDA approved for sentinel lymph node mapping in breast cancer.
3326861|NCT02065258|Active Comparator|Breathing Exercise|It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions and will be part of the routine of breathing exercises the following exercises: I) Kapalabhati ; II) Uddhiyana ;III) Surya Bedhana
3326862|NCT02065258|Active Comparator|Aerobic Exercise|Exercise will be performed on a treadmill, with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957).Aerobic training sessions that will consist in 40 minutes divided in 5 minutes of warm-up, 35 minutes of aerobic training and 5 minutes of cool down. Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. The program will be performed twice a week, for 3 months.
3326863|NCT02065271|Experimental|herbal supplements|500mg, 3 per day, 4weeks
3326864|NCT02065271|Placebo Comparator|placebo|500mg, 3 per day, 4 weeks
3326868|NCT02065297||Horton's disease|
3326869|NCT02065297||Infectious disease|
3326870|NCT02065297||Neoplasia|
3326871|NCT02065297||Control|
3326872|NCT02065310|No Intervention|Diabetes, Non-diabetes|
3326873|NCT02065323|Active Comparator|ADT alone|Standard androgen deprivation therapy (LHRH analogue or orchiectomy)
3326874|NCT02065323|Experimental|ADT plus Dovitinib|"Standard androgen deprivation therapy (LHRH analogue or orchiectomy)~Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons."
3326875|NCT02065349|Placebo Comparator|Placebo|oral
3326876|NCT02065349|Active Comparator|ASP8477|oral
3326877|NCT02065362|Experimental|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f|DNR.NPC-specific T cells or DNR.NPC-specific T cells + c/f
3326878|NCT02065375|Experimental|RTA 408 0.5% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 0.5% or Placebo) in the study eye for 14 days
3326879|NCT02065375|Experimental|RTA 408 1.0% Ophthalmic Suspension or Placebo|Patients will be randomized to twice-daily dosing of ophthalmic suspension (RTA 408 1.0% or Placebo) in the study eye for 14 days
3326880|NCT02065388|Active Comparator|Standard of care dosing for warfarin|Loading dose (5mg) of warfarin for the first 3 days of treatment. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3326881|NCT02065388|Experimental|Genotype-guided dosingTaiwan algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3326882|NCT02065388|Experimental|Genotype-guided dosing IWPC algorithm for warfarin|Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the IWPC algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
3326883|NCT02065401|Experimental|Deferitazole (disodium salt, granule)|
3326884|NCT02065401|Experimental|Deferitazole (disodium salt, tablet)|
3326885|NCT02065401|Experimental|Deferitazole (magnesium hydroxide salt)|
3326886|NCT02065414|Placebo Comparator|Neg Control Mouth Rinse W002194-0221-P|"Mouth rinse containing 5% Hydroalcohol~Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse W002194-0221-P for 30 seconds and spit it out."
3326887|NCT02065414|Experimental|Experimental: Mouth Rinse 19668-012|Listerine Advance Gum Defense Twice each day, brush in usual manner with a fluoride-containing dentifrice, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
3326888|NCT02065414|Active Comparator|Active Comparator Mouth Rinse 5000347078873|"Mouth rinse containing Chlorhexidine Corsodyl ®Mouthwash~Twice each day, brush in usual manner with a fluoride-containing dentifrice, in the usual manner, rinse mouth with water, wait 5 minutes after brushing and then rinse with 10 ml of mouth rinse 5000347078873for 60 seconds and spit it out - do not swallow."
3326889|NCT02065427|Experimental|Social support|"Social support intervention~Intervention is performed by the health professionals working at the primary health care team responsible for the patient, and consisits of the following components:~a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support."
3326890|NCT02065427|No Intervention|Usual home health care|Caregivers and dependent patients: usual home health care, consisting of bimonthly scheduled visits, follow-up as needed, and additional attention upon request
3326891|NCT02065440|Active Comparator|Ebastine/Pseudoephedrine|administration of ebastine/pseudoephedrine 1cap/day for 1 week.
3326892|NCT02065440|Placebo Comparator|placebo|administration of placebo pill 1 cap/day for 1week
3326893|NCT02065466|Experimental|Combination|nab-paclitaxel and temozolomide combined with full dose of bevacizumab
3326894|NCT02065492|Experimental|Standard Chelation & Amlodipine|"This arm will receive both chelation and amlodipine.~Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day.~Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist."
3326895|NCT02065492|Active Comparator|Standard Chelation|"Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone.~The dosage will depend on individual requirement, as determined by the treating hematologist.~This will serve as the control arm of the study without any additional intervention."
3231086|NCT01198249|Experimental|mlodipine and Losartan and HCTZ|
3231087|NCT01198288|Active Comparator|Standard Care|"Drugs for COPD (as prescribed), oxygen therapy if needed*, check-up by the general practitioner and/or respirologist as usual.~Educational leaflet regarding optimization of oxygen therapy and drugs; Benefits of physical activity and proposal of a programme of exercise training; Energy conservation techniques; Nutritional counselling; Activity of daily Living (ADL) diary; Prevention and management of acute exacerbation~Monthly phone call with the aim of verifying:~the patients' clinical conditions;~the patient's adherence to the pharmacological treatments prescribed~the patient's compliance in filling out the clinical diary and the ADL diary"
3231088|NCT01198288|Experimental|domiciliary rehabilitation|"Same as the standard care group plus 10 (ten) home-based visits supervised by a specifically trained respiratory therapist (education+exercise training) Autonomous home-based programme: The patients will be given instructions and training in order to continue the exercise training programme on the days the respiratory therapist is not visiting them.~Counselling addressed at the outdoor activities."
3326896|NCT02065505|Experimental|Pilates Group Solo|participate in this group 30 individuals who will be treated with the Pilates Method performing the exercises on the ground, using the Swiss ball and elastic bands. The exercises will aim to lengthen the musculature that are shortened due to the characteristic postural pattern of pathology (major and minor pectoral, shoulder adductors, biceps, wrist flexors, trunk side chain); strengthen the musculature that provide postural support (abdominal, middle trapezius, rhomboids, gluteus maximus, erector spinae and latissimus dorsi) and the upper limb musculature important for activities of daily living (triceps, biceps, internal rotators, external rotators and abductors of the shoulder).
3326897|NCT02065505|Experimental|Water Pilates Group|participate in this group 30 individuals who will be treated with the Pilates method, but doing the exercises in the therapy pool, with the aid of floats and weights. The protocol of stretches and exercises will work the same muscle groups than the G1, keeping the same decubitus whenever possible. The adaptations to the exercises are justified by the physical principles of water, which at one point may act for or against the activity being performed.
3326898|NCT02065531|Experimental|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
3231089|NCT01198314|Experimental|LT, withdrawal of immunosuppression|
3326899|NCT02065531|Active Comparator|Mobilization with impulse technique|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
3326900|NCT02065544|Experimental|behavioral weight loss and exercise|weight loss and exercise lifestyle intervention over a 6 month period
3231090|NCT01198314|Active Comparator|LT, maintenance of immunosuppression|
3231091|NCT01198340|Active Comparator|With basal local anesthetics|
3326901|NCT02065583||GI abdominal surgery patients|Patients recovering from gastrointestinal abdominal surgery.
3326902|NCT02065596|Experimental|Immunomodulation with Fludarabine prior to HSCT|Fludarabine given beginning at 25mgm/m2 three times per day. Patients may be escalated up to 25mgm/m2 five times per day depending on dose-limiting toxicity
3326903|NCT02065609|Experimental|Cohort 1|89Zr-Trastuzumab Human Dosimetry and Safety
3326904|NCT02065609|Experimental|Cohort 2: Lesion Detection and Safety|HER2 Positive Lesion Detection and Safety
3231092|NCT01198340|Experimental|Without basal local anesthetics|
3231093|NCT01198353|Experimental|Ziprasidone|During the 12-week study period, patients were prescribed ziprasidone at 20 to 160 mg/day flexibly based on their effectiveness and tolerability. Fifty to one hundred percent of the past antipsychotic dose was maintained in the first week; during next 3 weeks, flexible dosing of 0-100% was used; then, ziprasidone was discontinued. This study included four visits: baseline, week 4, week 8, and week 12. Concomitant benzodiazepines (oral formula or injection) were allowed up to a dose of 4 mg of lorazepam-equivalents per day for anxiety and agitation.
3231094|NCT01198379|Experimental|Aspirin|
3326905|NCT02065635|Experimental|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
3231095|NCT01198379|Placebo Comparator|Sugar pills|Hemodialysis (HD) patients receive placebo not containing aspirin in this study.
3231096|NCT01198392|Experimental|S-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
3231097|NCT01198392|Active Comparator|5-Fu plus cisplatin|5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
3231098|NCT01198405|Experimental|Enhanced External Counterpulsation|Treatment of Enhanced External Counterpulsation (EECP) with a prespecified protocol on top of guideline-driven standard medical therapy.
3326906|NCT02065635|Active Comparator|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
3326907|NCT02065648||Syngo NATIVE MRA|All consenting participants will receive an additional non-contrast Syngo NATIVE MRA sequence prior to contrast injection their standard of care MRA.
3326908|NCT02065700|Experimental|Filgotinib 200 mg once daily|Filgotinib 200 mg (2 x 100 mg) once daily (morning)
3326909|NCT02065700|Experimental|Filgotinib 100 mg twice daily|Filgotinib 100 mg twice daily (morning and evening)
3326910|NCT02065726|Experimental|Whey protein|Nutritional counseling + 20 g (2 x 10 g) of whey proteins (Prother® - Spepharm Italy)
3326911|NCT02065726|Active Comparator|Nutritional counseling|Nutritional counseling
3231099|NCT01198405|Active Comparator|Control|Guideline-driven standard medical therapy.
3231100|NCT01198418|Experimental|Internet-based counseling|Completes surveys monthly about their sexual and drug use behaviors as well as receives information designed to help reduce the chances of getting an STI.
3231101|NCT01198418|No Intervention|Survey Alone|Completes surveys monthly about their sexual and drug use behaviors
3231102|NCT01198431|Experimental|Sleep restriction|Each participant will be engaged in three consecutive nights of 4 hours of sleep per night (from 3.00 a.m. to 7.00 a.m.)
3326912|NCT02065739|Experimental|Period 1|Participants will receive a single 30-mg dose of JNJ-42165279 on Day 1.
3326913|NCT02065739|Experimental|Period 2|Participants will receive itraconazole 200 mg once a day from Day 4 to Day 10. A single oral 30-mg dose of JNJ-42165279 will be administered on Day 8 along with the dose of 200 mg itraconazole.
3326914|NCT02065752|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3326915|NCT02065752|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3326916|NCT02065752|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3326917|NCT02065778|Experimental|Stem Cells|autologous bone marrow mononuclear cell transplantation
3326918|NCT02065804|Experimental|Active drug|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
3326919|NCT02065804|Placebo Comparator|Placebo|10 ml of normal saline deposited by ultra-sound guidance around the spermatic cord
3326920|NCT02065817|Experimental|Tracer|
3326921|NCT02065830|Experimental|Robot Safety and Efficacy|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
3326922|NCT02065843|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
3326923|NCT02065843|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.
3326924|NCT02065843|Active Comparator|Passiflora incarnata|100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.
3231103|NCT01198431|Placebo Comparator|Normal sleep duration|Each participant will be engaged in three consecutive nights of 9 hours of sleep per night (from 10.00 p.m. to 7.00 a.m.)
3231104|NCT01198444||Group 1|
3231105|NCT01198457||Group 1|
3231106|NCT01198483|Active Comparator|Micro|Microincision cataract surgery
3231107|NCT01198483|Active Comparator|Small|Smallincision cataract surgery
3231108|NCT01198496|Experimental|Blood pressure|"The incidence of recurrent stroke will be lower in a strict BP control group having lower BP target: less than 120/80 mmHg* than in a standard BP control group having BP target less than 140/90 mmHg or less than 130/80 mmHg for current DM/CKD/old MI in patients with hypertension.~This study uses BP target: less than 120/80 mmHg that is sat up for this study rather than the BP target recommended in the Guidelines for the management of hypertension, Japanese Society of Hypertension 2009.~BP management is strongly recommended in patients with hypertension, DM, and/or CKD for prevention of recurrent stroke in the Japanese guidelines for the management of stroke 2009."
3326925|NCT02065843|Active Comparator|midazolam|15 mg midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.
3326926|NCT02065856|Experimental|AVANZ Salsola kali|Subcutaneous immunotherapy
3326927|NCT02065869|Experimental|BPX-501 T cells and rimiducid|"TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).~Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
3326928|NCT02065882|Experimental|BT524|Single intravenous infusion of a fixed dose of 70 mg BT524 per kilogram body weight (BW)
3326929|NCT02065921||COPD patients|establishing COPD cohort database to allow high quality research on diagnosis, treatment, complication and progression of COPD on long-term course.
3326930|NCT02065947|Active Comparator|general anesthesia|fentanyl 0,05 - 0.1 mg/h, propofol 150 - 200 mg, atracurium
3231109|NCT01198522|Other|Therapy of L19IL2 and Gemcitabine|Dose escalation study. Part A) Gemcitabine dose escalation. Part B) L19IL2 dose escalation.
3231110|NCT01198535|Experimental|Arm A (RO4929097, cetuximab)|Patients in Arm A will receive cetuximab at the standard dose: 400 mg/m2 IV loading dose on Day 1 followed by cetuximab 250 mg/m2 IV weekly. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
3326931|NCT02065947|Experimental|paravertebral block|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
3326932|NCT02065960|Experimental|Stereotactic body radiotherapy (SBRT)|Radiotherapy with SBRT to a dose of 40 Gy in 5 fractions delivered every other day over a period of 10-12 days, followed by breast conserving surgery.
3326933|NCT02065973|Active Comparator|Cohort 1 (Low Dose)|The group will receive the lowest dose of the vaccine
3326934|NCT02065973|Active Comparator|Cohort 2 (Mid Dose)|The Group will receive the middle dose of the vaccine
3326935|NCT02065973|Active Comparator|Cohort 3 (High Dose)|The Group will receive the highest dose of vaccine to be tested
3231111|NCT01198535|Experimental|Arm B (RO4929097, cetuximab)|Patients in Arm B will receive cetuximab 200 mg/m2 IV weekly without a loading dose. The RO4929097 will be dose escalated starting at 20 mg given daily 3 days on, 4 days off, weekly. The dose levels of RO4929097 to be explored will be 20 mg, 30 mg, 45 mg, 90 mg, 140 mg given days 1-3 weekly. No intrapatient dose escalation will be allowed.
3231112|NCT01198561||repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
3326936|NCT02065986|Experimental|Arm A: Immediate offer of Truvada-PrEP|Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
3326937|NCT02065986|Other|Arm B: Deferred (12m) offer of Truvada-PrEP|Access to Truvada from 12 months after enrolment
3326938|NCT02066012||group DIOS|group DIOS composed of subjects with dysmetabolic hepatosiderosis
3326939|NCT02066012||group M|group M composed of subjects with metabolic syndrom without iron overload
3326940|NCT02066012||group T|group T composed of lean subjects
3326941|NCT02066025||group_0|Women with negative mammography (BIRADS 1-2), as negative controls.
3326942|NCT02066025||group_1|Women with positive biopsy for (ID, IL, DCIS) as patients.
3326943|NCT02066025||group_2|Women with positive mammography (BIRADS 3-4-5-6), and a negative biopsy diagnosis for breast cancer (ID, IL, DCIS) will be enrolled as benign (ADH, ALH, LCIS, fibroadenoma, fibrocystic changes (including sclerosing adenosis), Benign papillaoma, normal breast) as benigns.
3231113|NCT01198613|Placebo Comparator|Placebo|
3231114|NCT01198613|Experimental|ToleroMune Ragweed Regimen 1|
3231115|NCT01198613|Experimental|ToleroMune Ragweed Regimen 2|
3231116|NCT01198613|Experimental|ToleroMune Ragweed Regimen 3|
3326944|NCT02066038|Experimental|A|Pemetrexed 500mg/m2+Carboplatin area under curve(AUC)=5, every 3 weeks, maximum 4 cycles, Erlotinib 150mg/d every cycle d2-15, and Erlotinib 150mg/d from the last cycle until disease progression
3326945|NCT02066064|Experimental|Group A|Subjects will undergo complete standard colonoscopy, followed by G-EYE(TM) Colonoscopy
3326946|NCT02066064|Active Comparator|Group B|Subject will undergo G-EYE(TM) colonoscopy followed by standard colonoscopy
3326947|NCT02066077|Experimental|Bilateral temporal and propofol|During the MECT treatment, electrodes are placed at bilateral temporal, with propofol 2mg/kg to Induce anesthesia.
3326948|NCT02066077|Experimental|Bilateral temporal and etomidate|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3326949|NCT02066077|Experimental|The right temporal and propofol|During the MECT treatment, electrodes are placed at the right temporal, with propofol 2mg/kg to Induce anesthesia.
3326950|NCT02066077|Experimental|The right temporal and etomidate|During the MECT treatment, electrodes are placed at the right temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3326951|NCT02066077|Experimental|Bilateral frontal and propofol|During the MECT treatment, electrodes are placed at bilateral frontal, with propofol 2mg/kg to Induce anesthesia.
3326952|NCT02066077|Experimental|Bilateral frontal and etomidate|During the MECT treatment, electrodes are placed at bilateral frontal, with etomidate 0.3mg/kg to Induce anesthesia.
3326953|NCT02066077|Active Comparator|Standard-therapy Group|During the MECT treatment, electrodes are placed at bilateral temporal, with etomidate 0.3mg/kg to Induce anesthesia.
3326954|NCT02066090|Experimental|Real acupuncture|manual acupuncture + electroacupuncture, twice a week, for 6 weeks
3326955|NCT02066090|Sham Comparator|Sham acupuncture|sham acupuncture + placebo acupuncture without electrical stimulation, twice a week, for 6 weeks
3326956|NCT02066103|Experimental|Treatment|
3326957|NCT02066116|Experimental|Kinect-based Rehabilitation|
3326958|NCT02066116|Active Comparator|Self-exercises education|
3326959|NCT02066142|Active Comparator|Tomosynthesis|Tomosynthesis will be compared to Ultrasound
3326960|NCT02066142|Other|Ultrasound|Ultrasound (sensitivity and specificity) will be compared to Tomosynthesis
3231117|NCT01198613|Experimental|ToleroMune Ragweed Regimen 4|
3326961|NCT02066155|Experimental|Parish nurse|On-going support provided by parish nurse
3326962|NCT02066155|Experimental|Peer support|On-going support provided by a person with diabetes
3326963|NCT02066155|No Intervention|Control group|No on-going support provided
3326964|NCT02066194|Active Comparator|Electroacupuncture|Patients randomized to the experimental group will receive EA at acupoints relevant to the treatment of abdominal pain and anxiety. Selection of these acupoints is based on a consensus between the acupuncturist of the study (Leung WW) and several professors of the Diploma Course of Clinical Acupuncture of the School of Professional and Continuing Education, University of Hong Kong.
3326965|NCT02066194|Placebo Comparator|Sham Acupuncture|Patients randomized to the control group will receive Sham acupuncture with sterile blunt-tip needles
3231118|NCT01198626|Experimental|JNJ-32729463|
3326966|NCT02066207|Experimental|Fenofibrate|Subjects received Fenofibrate
3326967|NCT02066207|Experimental|Atorvastatin|Subjects received Atorvastatin
3326968|NCT02066207|Experimental|Fenofibrate and Atorvastatin|Subjects received Fenofibrate and Atorvastatin
3326969|NCT02066220|Experimental|PNET 5 MB-LR (low-risk)|Radiotherapy and reduced-intensity maintenance chemotherapy. Total treatment duration is 39 weeks.
3326970|NCT02066220|Experimental|PNET 5 MB-SR (standard-risk)|"Radiotherapy with carboplatin or radiotherapy without carboplatin and maintenance chemotherapy.~Total treatment duration is 48 weeks."
3231119|NCT01198626|Active Comparator|moxifloxacin|
3231120|NCT01198626|Experimental|JNJ-32729463 Open-Label|subjects with suspected or confirmed S. aureus CABP may be entered into an open-label JNJ 32729463 treatment group at selected study sites
3326971|NCT02066246|Sham Comparator|Olympus UHI-3|patients are treated with the Olympus UHI-3-CO2-insufflation and trocar system
3326972|NCT02066246|Active Comparator|AirSeal|patients are treated with the AirSeal-CO2-insufflator and trocar-system
3231121|NCT01198639|Active Comparator|manual administration of iv anesthetics|
3326973|NCT02066259||healthy_0|healthy, people with normal (negative) colonoscopy results.
3326974|NCT02066259||patient_1|people with biopsy/surgery verified carcinoma of the colon, either an Adenocarcinoma, or carcinoma in situ
3231122|NCT01198639|Experimental|closed-loop administration of iv anesthetics|
3231123|NCT01198652||Belfort-Dildy Obstetric Tamponade Tx|Patients treated with Belfort-Dildy Obstetric Tamponade System are eligible for inclusion in the cohort.
3231124|NCT01198665|Experimental|RAD001-CHOP|Prospective multicenter open-label phase I/II study Phase I: RAD001 2.5 - 10 mg PO daily D1-14 + CHOP every 3 weeks Phase II: Determined dosage of RAD001 + CHOP every 3 weeks Treatment will be continued until planned 6 cycles or disease progression
3231125|NCT01198704||HCC patients|Patients notified on the national waiting list for hepatic transplant
3231126|NCT01198782|Experimental|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
3231127|NCT01198821|Experimental|Oral sodium bicarbonate and Gemcitabine|
3231128|NCT01198834|Placebo Comparator|Placebo Patch|Treatment with Placebo Patch
3231129|NCT01198834|Experimental|MRX-7EAT Patch|Treatment with MRX-7EAT Patch
3231130|NCT01198834|Experimental|Lidocaine Patch|Treatment with Lidocaine Patch
3326975|NCT02066259||benign_2|people with biopsy verified benign polyps of the colon one of the following - Villus adenoma, Tubular adenoma, Low grade dysplasia, Intermediate grade dysplasia, High grade dysplasia, Severe dysplasia
3326976|NCT02066272||IBD patients|IBD patients who start or re-start anti-TNF therapy
3231131|NCT01198834|Experimental|Etodolac Patch|Treatment with Etodolac Patch
3231132|NCT01198847|Active Comparator|Low intensity arm|Written information about a healthy lifestyle
3326977|NCT02066285|Experimental|Pazopanib|Single arm of pazopanib 800 mg (2x400 mg or 4x200 mg) given as a single agent once daily continuously.
3326978|NCT02066337|Placebo Comparator|placebo gel|scaling and root planing with placebo gel
3231133|NCT01198847|Experimental|High intensity arm|Lifestyle support (PA, sleep, food intake) using MI
3231134|NCT01198886|Placebo Comparator|Successful Aging Program|
3231135|NCT01198886|Experimental|Exercise-Nutrition Program|
3231136|NCT01198899||left ventricular hypertrophy|Patients with left ventricular hypertrophy will be used.
3231137|NCT01198912|Placebo Comparator|placebo|
3231138|NCT01198912|Experimental|doxycycline 100 mg|
3326979|NCT02066337|Active Comparator|Ozonated olive oil gel|scaling and root planing with Ozonated olive oil gel
3326980|NCT02066350|Experimental|Single pancreas transplantation|This is an explorative analysis to assess the impact of establishing normoglycemia in previously hyperglycemic patients, without using antidiabetic drugs, by investigating patients before and after single pancreas transplantation. Active patients on the waiting list for single pancreas transplantation will be investigated while on the waiting list and subsequently 8 weeks and 1 year after transplantation if they have a functioning pancreas graft. A control group of healthy volunteers (non-diabetic, non-transplanted), frequency-matched for age and gender with regards to the pancreas transplanted patients, will be investigated once.
3326981|NCT02066363|Active Comparator|Best nutritional Care|Best supportive nutritional care and dietician advise
3326982|NCT02066363|Experimental|Parenteral nutrition|Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.
3326983|NCT02066428|Experimental|AERAS-404(50mcg H4/0nmol IC31) or Placebo|1 dose
3326984|NCT02066428|Experimental|AERAS404 (50mcgH4/100nmol IC31) or Placebo|1 dose
3326985|NCT02066428|Experimental|AERAS404 (50mcgH4/0nmol IC31) or Placebo|2 dose
3326986|NCT02066428|Experimental|AERAS404 (150mcgH4/0nmol IC31) or Placebo|1 dose
3326987|NCT02066428|Experimental|AERAS404 (50mcgH4/5000nmol IC31) or Placebo|1 dose
3326988|NCT02066428|Experimental|AERAS404 (50mcgH4/500nmol IC31) or Placebo|2 dose
3326989|NCT02066428|Experimental|AERAS404|2 dose placebo
3326990|NCT02066428|Experimental|AERAS404 (50mcg H4/100nmol IC31) or Placebo|2 dose
3326991|NCT02066441|Experimental|Bio-D-Mulsion Forte®|Bio-D-Mulsion Forte® at a dosage level of 2 drops (4,000 IU) once daily for the 6-month treatment period.
3231139|NCT01198925|Active Comparator|extended infusion|
3231140|NCT01198925|Experimental|continuous infusion|
3231141|NCT01198938|Active Comparator|Melatonin|
3326992|NCT02066441|Placebo Comparator|Placebo|Placebo a dosage level of 2 drops once daily for the 6-month treatment period.
3326993|NCT02066454|Experimental|Apixaban|oral direct anti-Xa anticoagulant
3231142|NCT01198964||Epileptic Patients|The population of patients with medically refractory epilepsy will already have been recommended clinically for electrode grid placement on the brain and high-level stimulation to map brain function.
3326994|NCT02066480||women between 50 and 80 years hospitalized in CHD Vendée|
3231143|NCT01198990|Experimental|Group 1|"Subjects in will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.~eating/physical activity/positive affect/self-affirmation group."
3231144|NCT01198990|Experimental|Group 2|"Subjects will be randomized to the small change eating strategy and a physical activity goal.~eating/physical activity group. No intervention, just the eating strategy and physical activity components."
3231145|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (8hrs)|
3231146|NCT01199029|Experimental|(Part 1) 10 mg PF-04308515 (12hrs)|
3231147|NCT01199029|Active Comparator|(Part 1) 5 mg Prednisone|
3231148|NCT01199029|Experimental|(Part 2) X mg PF-04308515|
3231149|NCT01199029|Experimental|(Part 2) Y mg PF-04308515|
3231150|NCT01199029|Active Comparator|(Part 2) 5 mg Prednisone|
3231151|NCT01199029|Active Comparator|(Part 2) 20 mg Prednisone|
3231152|NCT01199081|Experimental|Group A|"Dronedarone 400 mg twice daily for 8 weeks starting from randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3231153|NCT01199081|Experimental|Group B|"Dronedarone 400 mg twice daily for 6 weeks starting 2 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3326995|NCT02066493||conservative management|neither surgical nor endovascular management
3326996|NCT02066493||endovascular management|endovascular management
3326997|NCT02066493||surgical management|surgical management
3326998|NCT02066506|Sham Comparator|asymptomatic group|patients with systemic right ventricle who are asymptomatic,
3326999|NCT02066506|Sham Comparator|symptomatic group|symptomatic group : patients with systemic right ventricle and heart failure signs and/or decrease exercise performance
3327000|NCT02066506|Sham Comparator|control|healthy subject matched with patients of asymptomatic group
3327001|NCT02066519|Experimental|Physical exercise arm|Arm with physical exercise on rowing machine between M3 and M6
3327002|NCT02066519|No Intervention|Control arm|Arm with standard medical care without additional physical exercise
3327003|NCT02066532|Experimental|Ruxolitinib/Trastuzumab|Jakafi (Ruxolitinib) and Trastuzumab (Herceptin) - 21 day cycle until disease progression
3327004|NCT02066545|Placebo Comparator|Vehicle Gel|
3327005|NCT02066545|Experimental|CLS001 topical gel 1%|Topical application once daily
3327006|NCT02066545|Experimental|CLS001 topical gel 1.75%|Topical application once daily
3327007|NCT02066545|Experimental|CLS001 topical gel 2.5%|Topical application once daily
3231154|NCT01199081|Experimental|Group C|"Dronedarone 400 mg twice daily for 4 weeks starting 4 weeks after randomization.~The last 2 months regimen of Amiodarone 200 mg/day is continued until randomization."
3327008|NCT02066558|Active Comparator|carbon monoxide|Inhalation of carbon monoxide up to a carboxyhemoglobin concentration of 12% and 22%.
3327009|NCT02066558|Placebo Comparator|placebo|Atmospheric air
3327010|NCT02066571|Other|droxidopa, then sugar pill|Droxidopa will be titrated over a 2-week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks. Then, the subject will start sugar pills.
3327011|NCT02066571|Other|sugar pill, then droxidopa|Subject will be be on sugar pill for 5 weeks (4 weeks of placebo treatment and one week of wash-out or sugar pills). Then, droxidopa will be titrated over 2 week period up to 300 mg twice daily (600 mg total daily dose). Subjects will be titrated to highest tolerated dose and will continue on that dose for two weeks.
3327012|NCT02066584||Universal IVF Medium|An oocyte culture medium containing 5.55 Mm glucose (Origio, Medi-Cult)
3231155|NCT01199094||Patients with mutation in the Lrp5 gene|Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype
3231156|NCT01199107|Experimental|Prolonged Exposure + Exercise|
3327013|NCT02066584||ISM1 Medium|An oocyte culture medium containing 1mM glucose ((Origio, MediCult)
3327014|NCT02066584||P1 Medium|An oocyte culture medium containing no glucose (Irvine)
3327015|NCT02066584||ECM Medium|An oocyte culture medium containing 0.5mM glucose (Irvine)
3327016|NCT02066597|Experimental|Intervention|
3327017|NCT02066610|Experimental|PN selenium and formula sodium selenate|Parenteral nutrition (PN) with selenium and sodium selenate supplementation of infant formula
3327018|NCT02066610|Experimental|PN selenium and formula sodium selenite|Parenteral nutrition (PN) with selenium and sodium selenite supplementation of infant formula
3327019|NCT02066610|Experimental|PN without selenium and formula sodium selenate|Parenteral nutrition (PN) without selenium and sodium selenate supplementation of infant formula
3327020|NCT02066610|Experimental|PN without selenium and formula sodium selenite|Parenteral nutrition (PN) without selenium and sodium selenite supplementation of infant formula
3231157|NCT01199107|Active Comparator|Prolonged Exposure + Wellness Intervention|
3231158|NCT01199120|Experimental|Omega 3|
3327021|NCT02066623||Implantation of ABSORB Scaffold|Patients suffering from coronary artery stenosis with an indication for implantation of ABSORB scaffold
3231159|NCT01199133|Active Comparator|Dpte and Dfar Allergen Extract|
3231160|NCT01199133|Placebo Comparator|Placebo tablets|
3231161|NCT01199159|Active Comparator|preoperative misoprostol|400mcg misoprostol given preoperatively
3231162|NCT01199159|Placebo Comparator|Placebo|
3231163|NCT01199172|No Intervention|Control|
3231164|NCT01199172|Experimental|voice hygiene|Subjects will receive training in voice hygiene
3327024|NCT02066649|Active Comparator|Carvedilol|Initiating patient on carvedilol after diagnosis of varices made on endoscopy
3327025|NCT02066649|Active Comparator|Variceal Band Ligation|performing variceal band ligation during endoscopy on patient after diagnosis of esophageal varices made on endoscopy
3327026|NCT02066649|Active Comparator|Combination Group (Carvedilol + Variceal band ligation)|once patient has confirmed large esophageal varices on endoscopy, he/she will be started on carvedilol (post-procedure) in addition to having variceal band ligation performed during endoscopy
3327027|NCT02066662|Experimental|Rivaroxaban|Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing
3327028|NCT02066662|Active Comparator|Marcumar|Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
3327029|NCT02066675|Experimental|Trabectedin|Trabectedin administered at the dose of 1.5 mg/mq-1.3 mg/mq a 24-hour continuous infusion via a central venous access, every 3 weeks
3231165|NCT01199172|Experimental|VH + VP|
3231166|NCT01199185|Active Comparator|Tobacco Quitline Group|
3231167|NCT01199185|Experimental|Tobacco Quitline plus Interactive Technology Group|
3231168|NCT01199211||Exercise training, women, marathon.|Other: prospective study with no intervention
3231169|NCT01199224|Experimental|Arm A|
3231170|NCT01199224|Experimental|Arm B|
3231171|NCT01199224|Experimental|Arm C|
3231172|NCT01199224|Experimental|Arm D|
3231173|NCT01199250||Basic science (biomarker analysis)|Previously collected samples are analyzed for biomarker and other laboratory analyses.
3231174|NCT01199276|Experimental|Xenon|60%(1MAC)in oxygen (FiO2 = 0.35-0.45)
3231175|NCT01199276|Active Comparator|Sevoflurane|1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air
3231177|NCT01199315|Experimental|1|Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.
3231178|NCT01199315|Placebo Comparator|2|Oral capsule. Dose single and followed by 5-day repeated dosing.
3231179|NCT01199328|Active Comparator|1|Aspirin 81 mg
3231180|NCT01199328|Active Comparator|2|Esomeprazole 20mg/aspirin 81mg
3231181|NCT01199341|Experimental|Treatment A|AZD1981, low dose, + Warfarin
3231182|NCT01199341|Experimental|Treatment B|AZD1981, high dose, + Warfarin
3231183|NCT01199367|Experimental|Dose escallation|
3231184|NCT01199406|Placebo Comparator|normal saline|80 mL 0.9% NaCl
3231185|NCT01199406|Experimental|Levobupivacaine|80mL 0.125% levobupivacaine
3231186|NCT01199419||PCI|
3231187|NCT01199419||CABG|
3231188|NCT01199432|Experimental|Group B(CEF)|
3231189|NCT01199432|Experimental|Group A(CEFci)|
3231190|NCT01199432|Active Comparator|Group C(EC)|
3231191|NCT01199445|Experimental|triple fortified extruded rice|
3327030|NCT02066688|Experimental|FA|Patients receive oral folic acid pill 1 mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (FA Arm).
3327031|NCT02066688|Experimental|FA+Ca|Patients receive oral folic acid pill 1 mg+ calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects(FA+Ca arm).
3327032|NCT02066688|Experimental|Ca|Patients receive oral calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects (Ca Arm).
3327033|NCT02066688|Placebo Comparator|blank control group|Patients receive oral placebo once daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
3327034|NCT02066701||Endoscopy Barrett's|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
3327035|NCT02066701||Endoscopy control|Patients undergoing clinically indicated upper endoscopy will be invited to participate. Patients who are known to have Barrett's Esophagus as well as patient who do not will be approached for enrollment
3327036|NCT02066714||Healthy Cohort|These children will be recruited from district 8, Ho Chi Minh City where most HFMD admissions to the Hospital for Tropical Diseases occur. We wil recruit healthy children from three kindergartens and ask for volunteers from participants enrolled in an Oxford University Clinical Research Unit Dengue birth cohort study (OXTREC approval 02-09) in District 8, HCMC. This birth cohort is an observational study.
3327037|NCT02066714||Hand Foot and Mouth Disease|The Vietnamese Ministry of Health has a clinical grading system. Grade 1 disease is uncomplicated and are not admitted to hospital. Grade 2 and above are admitted to hospital with clinical features of neurological or systemic involvement. Grade 2 is split into Grade 2a and 2b depending if neurological manifestations such as myoclonus have been witnessed by the parents or by a health professional. In total, it is anticipated that 125 Grade 2a and 125 Grade 2b and 100 more severe Grade 3 and 4 will be recruited over one year. A subset who agree for brain magnetic resonance imaging (MRI) will also have a scan done during their hospital admission.
3327038|NCT02066753|Active Comparator|24 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 24 hours after reaching the target temperature between 32-34°C.
3327039|NCT02066753|Experimental|48 hours mild therapeutic hypothermia|The patient will be treated with mild therapeutic hypothermia for 48 hours after reaching the target temperature between 32-34°C.
3327040|NCT02066766||Subjects with diabetes mellitus (type 2)|
3327041|NCT02066805||Cohort 1|
3327042|NCT02066818|Active Comparator|Lidocaine Injection|Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
3327043|NCT02066818|Experimental|Lidocaine/tetracaine patch|Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
3327044|NCT02066831|Experimental|Telemedical Coaching|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal, which can be monitored by the participant and the coach. Health coaches which will have close phone contact to patients, supporting them to reduce weight and increase physical activity. In the first 12 weeks, patients will follow a formula diet (Almased) to achieve an initial weight reduction.
3327045|NCT02066831|Active Comparator|Telemedicine|Patients will receive telemedical devices i.e. for the measurement of blood glucose, weight and physical activity. These devices will transfer the data to a data collector with a SIM card which sends the data to a data portal which can be monitored by the participant.
3327046|NCT02066844|Active Comparator|Standard Manual Needle Injection|2cc of Celestone and 5cc of Lidocaine will be administered by the nurse or surgeon
3327047|NCT02066844|Experimental|Navigator Injection|2cc of Celestone and 5cc of Lidocaine will be administered using the Navigator by the nurse or surgeon
3231192|NCT01199445|Other|regular meal|regular vitamin A meal
3231193|NCT01199458|Active Comparator|opioid|Preoxygenation for 5 min. Injection of opioid (alfentanil 20 mikrogr/kg iv) after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
3231194|NCT01199458|Placebo Comparator|placebo|Preoxygenation for 5 min. Injection of saline iv. after 2 min:Injection of induction drug(propofol 2-2.5mg/kg) after anesthesia induction: Application of cricoid pressure for 15 sec.
3231195|NCT01199497|Experimental|Group 1|Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
3231196|NCT01199497|Placebo Comparator|Group 2|Placebo
3231197|NCT01199510|Experimental|Standard of Care plus FID 112903|SYSTANE® ULTRA Lubricant Eye Drops dosed 4 times daily
3231198|NCT01199510|Active Comparator|Standard of Care only|Post Cataract Standard of Care Regimen
3231199|NCT01199523|Placebo Comparator|Placebo|
3231200|NCT01199523|Experimental|mirabegron high dose|
3231201|NCT01199523|Experimental|mirabegron medium dose|
3231202|NCT01199523|Experimental|mirabegron low dose|
3231203|NCT01199523|Active Comparator|moxifloxacin|
3231204|NCT01199536||1|patients with Helicobacter-positive duodenal ulcer
3231205|NCT01199549||Lycopene group|Mixed age and gender group of healthy volunteers for testing bio-availability of Lycopene containing supplement
3231206|NCT01199549||Resveratrol group|Mixed age and gender group of healthy volunteers for testing bio-availability of Resveratrol containing supplement
3231207|NCT01199549||Laflavon group|Mixed age and gender group of healthy volunteers for testing bio-availability of Soy Isoflavones containing supplement
3259154|NCT01468038|Active Comparator|placebo and active Sentra PM|Trazodone-like placebo and Sentra PM
3231208|NCT01199562||Arm I|Patients receive standard antiviral infection prophylaxis and management comprising ganciclovir, valganciclovir, or foscarnet sodium for 2 weeks or until the plasma CMV DNA Q-PCR is negative. Patients may receive additional courses based on subsequent CMV reactivations.
3327048|NCT02066870|Experimental|Icotinib and arsenic trioxide|"Icotinib is administered 125 mg three times per day, until disease progression or untolerated toxicity.~Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
3327049|NCT02066909|Experimental|Cohort 1|Dosing in healthy Western subjects.
3327050|NCT02066909|Experimental|Cohort 2|Dosing in healthy Western subjects.
3327051|NCT02066909|Experimental|Cohort 3|Dosing in healthy Western subjects.
3327052|NCT02066909|Experimental|Cohort 4|Dosing in healthy Western subjects.
3327053|NCT02066909|Experimental|Cohort 5|Dosing in healthy Western subjects.
3327054|NCT02066909|Experimental|Cohort 6|Dosing in healthy Western subjects.
3327055|NCT02066909|Experimental|Cohort 7|Dosing in healthy Western subjects.
3231209|NCT01199588|Experimental|Nexagon® High Dose|Weekly applications of Nexagon® high dose in addition to compression dressings.
3231210|NCT01199588|Placebo Comparator|Nexagon® Vehicle|Weekly applications of Nexagon® Vehicle in addition to compression dressings.
3327056|NCT02066909|Experimental|Optional Cohort 8|Dosing in healthy Western subjects. Cohort may not be conducted.
3327057|NCT02066909|Experimental|Cohort 9|Dosing in healthy Japanese subjects.
3327058|NCT02066935||kidney transplant patient|Kidney transplanted patients for at least one year
3327059|NCT02066948|Active Comparator|Skew meal pattern w/ wt loss&exercise|Skew meal pattern w/ wt loss&exercise e
3327060|NCT02066948|Active Comparator|even meal pattern w/ wt loss&exercise|even meal pattern w/ wt loss&exercise
3327061|NCT02066961||Cohort 1|Subjects with biochemical failure experience after primary treatment and have high-risk disease
3327062|NCT02066961||Cohort 2|Subjects with a medical diagnosis of castration-resistant prostate cancer
3231211|NCT01199588|No Intervention|No Investigational Product|Weekly application of compression dressings.
3327063|NCT02066961||Cohort 3|Subjects with an initial diagnosis of metastatic prostate cancer
3327064|NCT02066974||Hepatoma, Circulating tumor genome|Hepatoma requiring radiotherapy
3327065|NCT02066987|Experimental|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
3327066|NCT02066987|Experimental|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
3327067|NCT02066987|Active Comparator|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
3327068|NCT02067013|Active Comparator|Ranibizumab|Subjects undergoing surgery for neovascular glaucoma, diabetic retinopathy, or tractional Retinal Detachment due to AMD will receive one intravitreal injection of ranibizumab within 2 weeks of their surgery. Vitreous and aqueous humor samples will be collected during the surgery. Serum samples may be collected before, during, or after surgery.
3327069|NCT02067013|Placebo Comparator|Control|Subjects undergoing surgery for ERM or macular hole will NOT receive an injection of ranibizumab, but will have vitreous, and aqueous humor samples collected during surgery (no serum collection).
3231212|NCT01199588|Experimental|Nexagon® Low Dose|Weekly applications of Nexagon® low dose in addition to compression dressings.
3231213|NCT01199614|Experimental|open-label PTH(1-84)|open-label PTH(1-84) / variable dosing: 25mcg every other day, 25mcg every day, 50mcg every day, 75mcg every day, 100mcg every day
3327070|NCT02067026|Experimental|Aleurone supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Aleurone/day. One bread bun (35 g) contains 4.8 g Aleurone; one biscuit (15 g) contains 4 g Aleurone; 36 g of RTE cereals contain 9 g Aleurone.
3327071|NCT02067026|Placebo Comparator|Hemicellulose supplementation|The study supplementation will be introduced in the daily diet according to the participant preference to a total of 27g of Hemicellulose/day. One bread bun (35 g) contains 4.8 g Hemicellulose; one biscuit (15 g) contains 4 g Hemicellulose; 36 g of RTE cereals contain 9 g Hemicellulose. Placebo products contain the same levels of cellulose in place of aleurone's dietary fiber content.
3327072|NCT02067052||Advanced vulvar cancer|Patients with advanced-stage tumors.
3327073|NCT02067052||Early-stage vulvar cancer|Patients with early-stage tumors
3327074|NCT02067065|Experimental|Non-anesthesiologist propofol sedation|Bolus propofol sedation by non-anesthesiologist
3327075|NCT02067065|Active Comparator|Anesthesiologist administered propofol|Propofol sedation administered by an anesthesiologist
3327076|NCT02067078|Experimental|Combined saphenous nerve and obturator nerve block|
3327077|NCT02067078|Experimental|Saphenous nerve block|
3231214|NCT01199627|Experimental|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
3259155|NCT01468038|Active Comparator|Sentra PM and trazodone|Active Sentra PM and active trazodone
3327078|NCT02067078|Active Comparator|Local infiltration analgesia|
3327079|NCT02067091|Active Comparator|BVS|Implantation of bioresorbable vascular scaffold in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
3327080|NCT02067091|Active Comparator|DES|Implantation of drug eluting stent in coronary artery by direct stenting after thrombus aspiration by percutaneous coronary intervention
3327081|NCT02067117|Experimental|influenza split vaccine|
3327082|NCT02067130|Other|Fibroscan|Subjects enrolled will undergo Fibroscan. It is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Fibroscan reading will be collected at the Gastroenterologist's (Dr. Ko) outpatient clinic (Pacific Gastroenterology Associates) where a qualified research nurse/assistant will perform the scan under supervision of the physician. Anticipated timing of this procedure will be October to December 2013
3231215|NCT01199627|Experimental|B|"Group B: 1st dose: 10mg/kg of TXA (tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
3327083|NCT02067143|Experimental|Study population|In this phase II multicentric trial, eligible patients with Ph- ALL/LL will receive homogeneous supportive care and chemotherapy and will be homogeneously analyzed for response at prefixed timepoints from induction day 1. For risk-/MRD-oriented therapy, CR patients will be stratified by risk class according to diagnostic characteristics, MRD study and CT/PET (LL only) results during early consolidation.
3327084|NCT02067156|Experimental|G-202 (Mipsagargin)|G-202 (Mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
3327085|NCT02067169||CMV infection|allograft recipient with active CMV infection
3327086|NCT02067182|Experimental|Oral Anticoagulation with Dabigatran|"The recommended daily dose of Pradaxa is 300 mg taken as one 150 mg capsule twice daily.~For the following patients the recommended daily dose of Pradaxa is 220 mg taken as one 110 mg capsule twice daily:~Patients aged 75 years or above~Cr-Cl 30-50 ml/min~Patients who receive concomitant verapamil~For the following groups, the daily dose of Pradaxa of 300 mg or 220 mg should be selected based on an individual assessment of the thromboembolic risk and the risk of bleeding:~Patients with moderate renal impairment~Patients with gastritis, esophagitis or gastroesophageal reflux~Other patients at increased risk of bleeding"
3231216|NCT01199627|Placebo Comparator|C|Placebo
3231217|NCT01199640|Experimental|MLN1202|
3231218|NCT01199653|Active Comparator|Non-operative treatment|Non-operative (conservative) treatment of the clavicle fracture
3231219|NCT01199653|Active Comparator|Operative treatment|Operative stabilization (i.e. ORIF) of the fracture with a plate and screws.
3231220|NCT01199666|Experimental|Text message reminders|
3231221|NCT01199666|Active Comparator|standard of care for MMR, letter reminder for Hep A|MMR: automated phone call appointment reminder Hep A: recall letter, automated phone call appointment reminder
3231222|NCT01199679|Experimental|Endoscopic Mucosal Resection (EMR) Group|
3231223|NCT01199679|Experimental|Banding Group|
3231224|NCT01199692||Age|
3231225|NCT01199692||Gender|
3327087|NCT02067182|No Intervention|No Oral Anticoagulation|
3327088|NCT02067195|Active Comparator|Guideline Hydration|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
3327089|NCT02067195|Active Comparator|Adequate Hydration|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
3327090|NCT02067208|No Intervention|Waitlist Control|A waitlist control condition, where the participant receives no insole for 3 months. During this 3 month period, the participant will continue to be monitored for outcome variables.
3231226|NCT01199692||Ethnicity|
3327091|NCT02067208|Experimental|Experimental wedged insole|Either a medially wedged or laterally wedged footwear insole (whichever reduces knee joint mechanical loading more, as determined from subject-specific biomechanical tests), constructed using a 3D printer will be inserted into each participant's shoe. The participant will be asked to utilize this insole as much as possible throughout the day over the course of 3 months.
3231227|NCT01199692||Body Mass Distribution|
3231228|NCT01199692||Dietary Habits|
3231229|NCT01199692||Exercise Habits|
3231230|NCT01199692||Medication Requirements|
3231231|NCT01199692||Disease State Burden|
3231232|NCT01199718|Experimental|CX-4945|CX-4945 oral formulation
3231233|NCT01199757||FF|Cohort of patients receiving fluticasome furoate
3231234|NCT01199757||MF|cohort of patients on mometasone furoate
3231235|NCT01199757||FP|cohort of patients receiving fluticasone propionate
3231236|NCT01199770|Experimental|experimental pasta B, small|small portion experimental pasta B
3231237|NCT01199770|Experimental|experimental pasta C, small portion|small portion experimental pasta C
3231238|NCT01199770|Placebo Comparator|Control pasta, small|small portion Control pasta
3231239|NCT01199770|Other|No Load|Only water
3231240|NCT01199770|Active Comparator|Control pasta, medium|medium portion Control pasta
3231241|NCT01199770|Experimental|experimental pasta B, medium portion|medium portion experimental pasta B
3231242|NCT01199770|Experimental|experimental pasta C, medium portion|medium portion experimental pasta B
3231243|NCT01199783|Experimental|Daptomycin|Infusion of Daptomycin (6 mg/kg bodyweight) once daily
3231244|NCT01199783|Active Comparator|Vancomycin|Vancomycin once daily (effective blood-plasma concentration of 15 mg/l)
3231245|NCT01199809|Experimental|1|
3231246|NCT01199809|Placebo Comparator|2|
3231247|NCT01199835|Experimental|high calcium|Dietary intake of calcium ~ 1500 mg/ d, including ~1200 mg/d from dairy products
3327092|NCT02067221|Active Comparator|RIRS (retrograde intrarenal surgery)|Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
3327093|NCT02067221|Experimental|MPCNL (mini-perc)|"A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.~Patients will be randomized and assigned to each group at the ratio 1:1"
3327094|NCT02067234|Active Comparator|Routine Care/Education|Patient will be assessed by MD and provided education by nurse
3327095|NCT02067234|Experimental|Psychoeducation/Coping Prevention|Patient will be assessed by MD and will meet with psychologist to obtain psychoeducation about coping, behavioral strategies, and sleep hygiene
3327096|NCT02067247|Experimental|SOS forearm test|BeamMed Speed-of-Sound bone strength test at forearm
3327097|NCT02067260|Active Comparator|X5 HairLaser|
3231248|NCT01199835|Active Comparator|Low calcium|Low dietary intake of calcium, i.e. ~ <600 mg/d, including 0-1 portion of dairy products
3231249|NCT01199874|Active Comparator|Primary 1: Rotavirus vaccine 6 and 10 weeks|EPI vaccines + rotavirus vaccine at 6 and 10 weeks
3231250|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 6, 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks
3327098|NCT02067260|Sham Comparator|X5 HairLaser Sham Device|
3327099|NCT02067299|Experimental|Cohort A|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of placebo (Period 1), JNJ-42847922 10 mg (Period 2), JNJ-42847922 20 mg (Period 3), and JNJ-42847922 40 mg (Period 4). Each treatment period and each subsequent treatment period will be separated by 1 week.
3327100|NCT02067299|Experimental|Cohort B|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 10 mg (Period 1), JNJ-42847922 40 mg (Period 2), placebo (Period 3), and JNJ-42847922 20 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
3327101|NCT02067299|Experimental|Cohort C|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 20 mg (Period 1), placebo (Period 2), JNJ-42847922 40 mg (Period 3), and JNJ-42847922 10 mg (Period 4). Each subsequent treatment period will be separated by 1 week.
3327102|NCT02067299|Experimental|Cohort D|5 participants will be included in this cohort. Participants will receive the study medications in the sequence of JNJ-42847922 40 mg (Period 1), JNJ-42847922 20 mg (Period 2), JNJ-42847922 10 mg (Period 3), and placebo (Period 4). Each subsequent treatment period will be separated by 1 week.
3231251|NCT01199874|Experimental|Primary 1: Rotavirus vaccine 10 and 14 weeks|EPI vaccines + rotavirus vaccine at 10 and 14 weeks
3231252|NCT01199874|Experimental|Primary 2: Rotavirus vaccine withholding breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks withholding breastfeeding
3231253|NCT01199874|Experimental|Primary 2: Rotavirus vaccine with immediate breast feeding|EPI vaccines + rotavirus vaccine at 6, 10 and 14 weeks with immediate breastfeeding
3231254|NCT01199874|No Intervention|Baseline seroconversion for rotavirus|EPI vaccines
3231255|NCT01199887|Experimental|IW001|Three dose cohorts, 0.1 mg, 0.5 mg, 1.0 mg
3327103|NCT02067312|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the trapezius muscle
3327104|NCT02067312|Sham Comparator|Sham Microwave diathermy|The participants will receive a thirty minutes session of Sham microwave diathermy onto the trapezius muscle
3327105|NCT02067325|Experimental|Thai massage|The participants will receive thirty minutes session of Thai massage onto the trapezius muscle for 1 sessions
3327106|NCT02067325|Sham Comparator|Sham Microwave diathermy|The participants will receive thirty minutes session of Sham Microwave diathermy onto the trapezius muscle for 1 sessions
3327107|NCT02067338|Placebo Comparator|normal saline|During posterior lumbar spinal surgery,one group of patient received normal saline soaked collagen sponge.
3327108|NCT02067338|Active Comparator|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery ,Another group of patients received 1 mg morphine-soaked in epidural oxidized cellulose.
3327109|NCT02067351|Experimental|Mindfulness Intervention|Mindfulness intervention
3327110|NCT02067364|Other|Fit & function test|CRT ShuntCheck sensors will be applied over the shunts of asymptomatic hydrocephalus patients. The device will be activated, cooling the skin under the sensor. Patients will change positions during the one hour procedure and data will be recorded. Data will be analyzed offline to identify product performance issues due to motion.
3327111|NCT02067377|Placebo Comparator|inactive powder substance|inactive powder substance by mouth twice a day for 6 months
3327112|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medical food|SBI medical food 5 gr powder substance by mouth twice a day for 6 months
3327113|NCT02067377|Experimental|serum bovine immunoglobulin (SBI) medicalfood|SBI medical food 10 gr powder substance by mouth twice a day for 6 months
3231256|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT|
3231257|NCT01199900|Experimental|(Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT|
3231258|NCT01199900|Active Comparator|(Part 1) 5 mg Prednisone|5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
3327114|NCT02067390||Vancomycin|Vancomycin
3231259|NCT01199900|Experimental|(Part 2) 3 mg PF-04171327|
3231260|NCT01199900|Experimental|(Part 2) 10 mg PF-04171327|
3231261|NCT01199900|Active Comparator|(Part 2) 5 mg Prednisone|
3231262|NCT01199900|Active Comparator|(Part 2) 20 mg Prednisone|
3231263|NCT01199913||desflurane and sevoflurane|Subjects will be randomized to either desflurane or sevoflurane. They will be given the Mini Mental State exam at 1, 6 and 24 hours after the end of anesthesia.
3231264|NCT01199978|Other|Fractionated Proton Radiation|Single arm study, delivering fractionated radiation with a technique (proton therapy) that may be associated with reduced side effects
3231265|NCT01199991||Normative database|
3259156|NCT01468038|Placebo Comparator|placebo trazodone and placebo Sentra PM|trazadone-like placebo and Sentra PM-like placebo
3327115|NCT02067390||Linezolid|Linezolid
3327116|NCT02067403|Experimental|Eadi optimized pressure-support|
3327117|NCT02067416|Active Comparator|taxane-based chemotherapy|physician choice: taxane-based chemotherapy to include Paclitaxel, Docetaxel, Abraxane or Ixabepilone given as standard of care
3327118|NCT02067416|Active Comparator|anthacycline based chemotherapy|Physician choice: anthracycline based chemotherapy including Adriamycin, Epirubicin give as standard of care
3327119|NCT02067429|Experimental|Toric Intraocular lens|Toric intraocular lens implantation during standard cataract surgery
3231266|NCT01200004|Experimental|Azacitidine + Lenalidomide|Azacitidine 75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle. Lenalidomide starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
3231267|NCT01200004|Experimental|Azacitidine + Lenalidomide + Grifola Frondosa|Once Lenalidomide MTD identified in combination with azacitidine, Grifola frondosa added. Cycle 1, azacitidine on day 1, lenalidomide on day 2 and Grifola frondosa on day 3. Azacitidine daily for 5 days every 28 days while lenalidomide and Grifola frondosa on days 1-21 of subsequent cycles.
3327120|NCT02067429|Experimental|Limbal Relaxing Incisions|Limbal relaxing incisions during standard cataract surgery
3327121|NCT02067442|Active Comparator|oral acetaminophen|Patients in this arm of the study will receive oral acetaminophen and an IV placebo
3327122|NCT02067442|Active Comparator|intravenous acetaminophen|Patients in this arm of the study will receive IV acetaminophen and an oral placebo
3327123|NCT02067455|Other|LVAD patients|
3327124|NCT02067481|Experimental|Single-arm weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (AP) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment.
3231268|NCT01200004|Experimental|Expansion Group A|Azacitidine + Lenalidomide MTD, then 2 weeks later Grifola frondosa
3231269|NCT01200004|Experimental|Expansion Group B|Azacitidine + Grifola Frondosa, then 2 weeks later Lenalidomide
3327125|NCT02067494|Experimental|Myofascial Soft Tissue Release|"Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.~Myofascial release assisted the paravertebral fascia."
3327126|NCT02067494|Active Comparator|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
3327127|NCT02067507|No Intervention|Control|"LACDPH Site: CDC-developed small media in preferred language~AltaMed Health Services Corporation Site: Usual care - Standing order for the HPV vaccine; required web-based training module for medical assistants and nurses containing basic information on HPV, the HPV vaccine, and standing order implementation~Northeast Valley Health Corporation Site: Usual care"
3231270|NCT01200043|Experimental|fructose restriction|Isocaloric fructose restricted diet for 10 days
3231271|NCT01200056|Active Comparator|Atorvastatin 10mg low dose|Atorvastatin 10mg daily for 6 months and compared to atorvastatin 40mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
3231272|NCT01200056|Active Comparator|Atorvastatin 40mg moderate dose|Atorvastatin 40mg daily for 6 months and compared to atorvastatin 10mg daily in the other arm. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes would be monitored and compared.
3231273|NCT01200082||Healthy Controls|Male or female, age 19-65, no apparent signs of hepatobiliary diseases
3231274|NCT01200082||Patients with hepatobiliary diseases|Male or female, age 19-65, visiting the UNMC hepatology clinic for treatment from hepatobiliary diseases
3231275|NCT01200108|Experimental|Budesonide high dose via AKITA (1mg/2ml)|
3327128|NCT02067507|Experimental|Tailored education and referral|LACDPH Site: Tailored education and referral intervention administered at LACDPH Site
3327129|NCT02067507|Experimental|Staff training and patient reminders|Staff training and patient reminders administered at AltaMed Health Services Corporation Site
3327130|NCT02067507|Experimental|Clinic-level reminder systems|Clinic-level reminders administered at Northeast Valley Health Corporation Site
3231276|NCT01200108|Experimental|Budesonide low dose via AKITA (0.5mg/2ml)|
3231277|NCT01200108|Active Comparator|Budesonide high dose via conventional nebulizer (1mg/2ml)|
3231278|NCT01200108|No Intervention|Placebo via AKITA|
3327131|NCT02067520|Other|IT hydromorphone dose|dose response study
3327132|NCT02067546|Experimental|Experimental toilet seat|Experimental toilet seat for 1 month
3327133|NCT02067546|Sham Comparator|Standard toilet seat|Standard toilet seat for 1 month
3231279|NCT01200121|Experimental|Arm A Bevacizumab|48 patients randomized into arm A will receive repeated intra¬peritoneal application of Bevacizumab
3327134|NCT02067559|Experimental|ICU Diaries|A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Instructions will be provided to the patient's family at the time of randomization and will be available at the bedside for reference. Staff instructions will be posted at charting area for staff. During the patient's stay in ICU, the diary will never leave the unit. Under no circumstances will any part of an ICU diary be duplicated. Research staff will take a photograph of the patient after consent is obtained and the photograph will be mounted on the first page of the diary. Photographs will be taken with a Polaroid camera; therefore there will be no other record of the photograph.
3231280|NCT01200121|Placebo Comparator|Arm B Placebo|26 patients randomized into arm B will receive repeated intra¬peritoneal application of Placebo
3231281|NCT01200134|Experimental|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
3231282|NCT01200147|Active Comparator|Biopsy Arm|
3231283|NCT01200147|Active Comparator|Dilation Arm|
3231284|NCT01200173|Active Comparator|1 = Tested product|
3231285|NCT01200173|Sham Comparator|2 = Control product|
3231286|NCT01200186||Group 1|
3231287|NCT01200186||Group 2|
3231288|NCT01200199||Varicose veins|
3231289|NCT01200212|Experimental|A|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22 + 1800 mg/m2 Capecitabine day 1-14 q22
3231290|NCT01200212|Active Comparator|B|A Taxane (80mg/m2 Paclitaxel weekly or 75mg/m2 Docetaxel day1 q22) + 15mg/kg Bevacizumab day1 q22
3231291|NCT01200225||Cohort|
3231292|NCT01200251|Experimental|Bimatoprost treated eyelid|one eyelid of the patient was randomized to the treatment arm and given the gel to use
3231293|NCT01200251|No Intervention|control arm - no gel|the other fellow eyelid of the patient did not receive any treatment until month 4 and the patient crossed over to treating both eyelids
3327135|NCT02067559|Experimental|Psychoeducation|The research nurse will provide a psychoeducational brochure to study participants at ICU discharge (if cognitive capacity is established) or 30 days after ICU discharge. If participants are not well enough 30 days post-discharge, they will be assessed every two weeks by research staff until the brochure is given to them. The brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions. The document will also be mailed to the participant's follow-up physician.
3327136|NCT02067559|Experimental|ICU Diary plus Psychoeducation|Participants will receive both ICU diary and psychoeducation interventions, with both documents provided at ICU-discharge, or 30 days post-discharge as above.
3327137|NCT02067559|No Intervention|Treatment as Usual|No additional intervention to usual ICU care will be given.
3327138|NCT02067572|Experimental|Salvia|Salvia mouthwash used 4 times per day for 4 days
3327139|NCT02067572|Active Comparator|Saline|Saline mouthwash used 4 times per day for 4 days.
3327140|NCT02067598|Experimental|Scapular exercise|The participants will receive thirty minutes session of scapular exercise for 12 sessions
3327141|NCT02067598|No Intervention|Control|
3327142|NCT02067624|Experimental|Thai massage|The participants will receive a thirty minutes session of Thai massage onto the wrist extensor groups muscle for 9 sessions
3327143|NCT02067624|Sham Comparator|Sham Ultrasound therapy|The participants will receive a thirty minutes session of sham ultrasound therapy onto the wrist extensor groups muscle for 9 sessions
3327144|NCT02067637||Exposed|Individuals with one of the following cancer diagnoses: breast, leukemia, lymphoma, and/or any gynecologic cancer.
3327145|NCT02067637||Unexposed|Healthy controls
3231294|NCT01200264|Experimental|apremilast for all subjects|
3327146|NCT02067689|Experimental|Hemisphere Stimulation|Participants will receive 1mA vs. 2mA transcranial direct current stimulation of a) right and b) left brain structures (1x1 stimulation), and sham/placebo stimulation. A subset of participants will undergo right and left brain stimulation, but all will undergo sham stimulation.
3327147|NCT02067689|Experimental|Temporal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the temporal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left structures using 4x1 stimulation (e.g., 1mA left temporal, 1mA right temporal, sham; 2mA left temporal, 2mA right temporal, sham).
3327148|NCT02067689|Experimental|Frontal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the frontal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left frontal structures using 4x1 stimulation (e.g., 1mA left frontal, 1mA right frontal, sham; 2mA left frontal, 2mA right frontal, sham).
3231295|NCT01200277|Experimental|vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3231296|NCT01200277|Sham Comparator|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
3231297|NCT01200303|Active Comparator|non-cathartic CTC and OC|This is a single arm, open label, prospective test comparison of non-cathartic, CAD-assisted CTC to segmentally unblinded optical colonoscopy (OC). All study subjects receive both tests, starting with CTC, followed by OC within 5 weeks. CTC results are recorded and revealed to endoscopist on a segment-by-segment basis after initial (blinded) OC evaluation; endoscopist can double check / confirm lesion presence after unblinding and this second read serves as reference standard.
3231298|NCT01200316|Experimental|Standard of Care Group|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
3231299|NCT01200316|Experimental|Rocking Motion Group|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
3231300|NCT01200381|Active Comparator|Group A|Automatic anonymous ICD/CRTD follow up (quarterly remote follow ups)
3231301|NCT01200381|Active Comparator|Group B1|Personal ICD/CRTD follow up (phone calls + quarterly remote follow ups)
3231302|NCT01200381|Active Comparator|Group B2|Personal ICD/CRTD follow up (Quarterly visits)
3231303|NCT01200420|Experimental|miravirsen|Dose escalation study with review of safety data following each cohort.
3231304|NCT01200420|Placebo Comparator|saline|Dose escalation study with review of safety data following each cohort.
3231305|NCT01200446|Placebo Comparator|Placebo Docosahexaenoic Acid (DHA)|Eight subjects will take 8 placebo DHA capsules per day for 3 weeks.
3231306|NCT01200446|Experimental|Active Docosahexaenoic Acid (DHA)|Eight subjects will take 8 active DHA capsules per day for 3 weeks.
3327149|NCT02067689|Experimental|Parietal Lobe Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the parietal lobes at 1 mA vs. 2 mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left parietal lobes using 4x1 stimulation (e.g., 1mA left parietal lobes, 1mA right parietal lobes, sham; 2mA parietal lobes, 2mA right parietal lobes, sham).
3327150|NCT02067689|Experimental|Supplementary Motor Stimulation|A group of participants will undergo 1x1 transcranial direct current stimulation of the Supplementary Motor Area at 1mA vs. 2mA vs. sham stimulation. A second group of participants will undergo 1mA or 2mA stimulation, and sham, in right vs. left Supplementary Motor Area using 4x1 stimulation (e.g., 1mA left Supplementary Motor Area, 1mA right Supplementary Motor Area, sham; 2mA left Supplementary Motor Area, 2mA right Supplementary Motor Area, sham).
3231307|NCT01200459|Experimental|Social/Mobile Intervention|Theory-based intervention to promote weight loss utilizing web, mobile phone and social media.
3327151|NCT02067689|Experimental|Brain Structure Interactions Group|This cohort will evaluate the interaction between frontal, parietal, temporal, and SMA regions in cognitive function. To accomplish this goal will require evaluation of change in cognitive and neurocognitive performance following transcranial direct current stimulation of different brain regions within the same subjects. For example, we will evaluate the contribution of frontal, SMA, and parietal regions by asking participants to undergo stimulation sessions at each of these sites, in addition to a sham session.
3327152|NCT02067702||Limb Cooling Assessment of ET Control|Healthy, volunteers with no known dermatological lesions, sensitivity to cold, or peripheral vascular disease.
3327153|NCT02067702||Limb Cooling Assessment of ET Experimental|Patients with known essential tremor for at least a year, and +2 or worse action or kinetic tremor of one or both upper limbs involving at least the forearm and/or hand.
3327154|NCT02067715|Experimental|Sealed bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide. However, a customized tray will be placed over the bleaching agent during entire permanence of peroxide (45 minutes).
3327155|NCT02067715|Active Comparator|Conventional Bleaching Protocol|The 35% hydrogen peroxide gel will be mixed and applied over the buccal surfaces of teeth. The bleaching agent will remain for 45-min application without replacement of peroxide.
3327156|NCT02067741|Experimental|Stratum A - HER2neg BC RD - CR1447|Stratum A - patients with endocrine responsive-HER2neg BC
3327157|NCT02067741|Experimental|Stratum B - ARpos B - CR1447|Stratum B - patients with triple-negative and confirmed ARpos BC
3327158|NCT02067754||metastatic Cancer|metastatic gastrointestinal cancer, genitourinary cancer , rare cancer with treated any anti-cancer therapy
3327159|NCT02067767|Experimental|Abacavir/Lamivudine/Dolutegravir|Patients switched from their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG.
3327160|NCT02067780|Experimental|The intervention (CRP-guided) group|500 mg (one tablet) of oral levofloxacin daily of levofloxacin for 7 days unless the serum CRP decrease by at least 50% from baseline value. Measurements of serum CRP were done at ED admission, at day-2, day-4 and day-6 and made available to the attending physicians.
3327161|NCT02067780|Experimental|The standard care (control) group|500 mg of levofloxacin per day for the first two days. Thereafter, oral tablet of placebo was prescribed according to CRP values as in CRP guided group to keep the blindness of the study.
3327162|NCT02067793|Placebo Comparator|Placebo|Placebo
3327163|NCT02067793|Experimental|NRX-1074 1 mg|NRX-1074 1 mg, intravenous
3327164|NCT02067793|Experimental|NRX-1074 5 mg|NRX-1074 5 mg, intravenous
3327165|NCT02067793|Experimental|NRX-1074 10 mg|NRX-1074 10 mg, intravenous
3327166|NCT02067819|Experimental|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
3327167|NCT02067819|Placebo Comparator|Placebo Oral Orthotic Treatment|Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study.
3327168|NCT02067845|Other|Pre-post test design|
3231308|NCT01200459|No Intervention|Control|"Participants randomized to this group will have access to usual care health information via the SMART study website. This arm will be compared to our intervention group."
3327169|NCT02067871|Experimental|Electrical stimulation|"18-32 min of pulsed current.~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated."
3327170|NCT02067871|Experimental|Laser Therapy|"λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point~six points at the knee joint"
3327171|NCT02067871|Experimental|Combined Treatment|"Electrical Stimulation:~18-32 min of pulsed current,~stimulation frequency of 80Hz (hertz).~pulse duration of 200μs (microseconds).~stimulation intensity fixed near to maximal tolerated.~and~Laser Therapy:~λ = 810 nm (nanometers)~continuous wave~200 mW (milliwatts) output power~low-level laser therapy dose of 4-6J (Joules) per point.~six points at the knee joint."
3327172|NCT02067884|Experimental|Diagnostic (CEUS, SWE)|Patients undergo dynamic contrast-enhanced ultrasound imaging and shear wave elastography at baseline, 2-3 weeks after initiation of chemotherapy, and before surgery.
3327173|NCT02067897||Vandenbos procedure (skinfold excision)|Participants in this cohort will undergo with Vandenbos procedure (skinfold excision) for one or more ingrown toenails. This surgery will be formed as an day procedure under general anesthetic.
3327174|NCT02067910|Active Comparator|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept during 48 weeks
3231309|NCT01200472|Experimental|Apremilast capsules|Apremilast in 10 mg capsules
3231310|NCT01200472|Placebo Comparator|Placebo|
3231311|NCT01200537|Active Comparator|Estradiol Patch|This group of patients will receive estradiol patches prior to the IVF cycle.
3327175|NCT02067910|Placebo Comparator|Placebo|First phase: Weekly subcutaneous administration of placebo during 24 weeks. Second phase: Weekly subcutaneous administration of 125 mg Abatacept during 24 weeks.
3327176|NCT02067923||Anti-CD3 mAb Plus Diabetes Standard of Care Group|This group of individuals received treatment in the original AbATE study.
3327177|NCT02067923||Diabetes Standard of Care Group|During the original AbATE study these individuals received standard care.
3327178|NCT02067936|Active Comparator|Group A propofol + remifentanil|Propofol highest dose, remifentanil lowest dose, TOL 90% according to Bouillon model
3327179|NCT02067936|Active Comparator|Group B propofol + remifentanil|Propofol intermediate high, remifentanil intermediate low, TOL90% according to the Bouillon Model
3327180|NCT02067936|Active Comparator|Group C propofol + remifentanil|propofol intermediate low+ remifentanil intermediate high: TOL 90% according to the Bouillon interaction model
3327181|NCT02067936|Active Comparator|group D propofol + remifentanil|propofol lowest dose+ remifentanil highest dose: TOL 90% according to the Bouillon model
3327182|NCT02067949|No Intervention|broad spectrum AB +fluids|Control group :50 patients will be treated according to SURVIVING SEPSIS CAMPAIGN BUNDLES
3327183|NCT02067949|Active Comparator|simvastatin|50 patients will be treated according SSCG plus simvastatin as single oral tablet 40 mg / day begin with inclusion in the study and continue until hospital discharge .If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube. (White R, Bradnam V, 2013)
3327184|NCT02067962|Other|Juvenile idiopathic arthritis.|Blood sample
3327185|NCT02067988|Experimental|Treatment arm|Holmium-166 microspheres hepatic radioembolization, adjuvant to systemic 177Lu-dotatate.
3327186|NCT02068001||RYGB|Food preference assessment in 100 patients at different timepoints, in a subset of 30 participants, also brain reward response to food cues will be assessed.
3327187|NCT02068040|Experimental|CocoaVia capsules|From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin
3231312|NCT01200537|Active Comparator|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
3231313|NCT01200550||1|
3231314|NCT01200563|Active Comparator|Group 1|Subjects assigned to receive MIST Therapy will be treated 3 times per week. The duration of each MIST treatment will be dependent on the wound's area measured at baseline and at each weekly assessment.
3231315|NCT01200563|Active Comparator|Group 2|Subjects assigned to receive Negative Pressure Wound Therapy will be treated with the Vacuum Assisted Closure system. For administration of this study treatment, e.g., treatment cycle, target pressure and dressing changes, the manufacturer's recommended guidelines will be followed.
3327188|NCT02068053|Experimental|Arm A - BMS-986020|600 mg (approximately 80 micro Curie) of [14C] BMS-986020 Single Dose for 1 Day (Day 1) orally
3327189|NCT02068079|Other|Vemurafenib and Trientine|
3327190|NCT02068092|Experimental|Hydroxytyrosol|Hydroxytyrosol 25 mg orally once daily for 1 year.
3327191|NCT02068105|Experimental|ALKS 5461-A|
3327192|NCT02068105|Experimental|ALKS 5461-B|
3327193|NCT02068105|Experimental|ALKS 5461 Dose 1|
3327194|NCT02068105|Experimental|ALKS 5461 Dose 2|
3327195|NCT02068105|Experimental|ALKS 5461 Dose 3|
3327196|NCT02068105|Placebo Comparator|Placebo|
3327197|NCT02068131|Experimental|Novaferon+ xeloda|"Capecitabine for 2 weeks straight (Days 1-14) followed by 1 week without capecitabine (Days 15-21).~Recombinant anti-tumor and anti-virus protein for injection(Novaferon), three times per week."
3327198|NCT02068144|Experimental|Cranberry Extract|Cranberry Extract in a 15.2oz beverage daily for 8 weeks
3231316|NCT01200563|Active Comparator|Group 3|Subjects assigned to this group will receive MIST Therapy treatments and Negative Pressure Wound Therapy.
3231317|NCT01200576||1|healthy volunteers
3231318|NCT01200615|Other|Explanation about common side effects|50 patients started on SSRI's will be updated about its common side effects
3231319|NCT01200615|Other|Explaning side effects and the nocebo effect|subjects started on SSRI's will be updated about its common side effects and the nocebo effect
3327199|NCT02068144|Placebo Comparator|Placebo|Placebo 15.2oz beverage daily for 8 weeks
3231320|NCT01200615|Other|explanation about the nocebo effect|3. 50 patients started on SSRI's will receive an explenation on the nocebo effect, but will not be updated about common side-effects. Nonetheless, they will be informed of severe side-effects.
3231321|NCT01200628||Road traffic accident victims|Cohort of patients hospitalized in surgical department after a motor vehicle accident less than 2 weeks
3231322|NCT01200641|Active Comparator|melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3327200|NCT02068170||patients treated with a potentional QT-prolonging drug|
3327201|NCT02068183||World Trade Center exposed group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the World Trade Center exposed group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
3327202|NCT02068183||Unexposed comparison group|After informed consent, anthropometric and blood pressure/brachial artery distensibility assessments; physical examination and environmental and respiratory history questionnaire completion; heart rate variability measurement; and spirometry/IOS will be performed on the unexposed comparison group. A research assistant well trained in pediatric phlebotomy will collect 23 mL of fasting blood. Spirometry and IOS, diet diary collection, lung volumes by plethysmography, and arterial wall stiffness.
3327203|NCT02068196|Experimental|Ipilimumab|Ipilimumab 3mg/kg
3327204|NCT02068209|Active Comparator|Tramadol|Patients will receive Tramadol 50mg 1 hour before outpatient hysteroscopy
3327205|NCT02068209|Placebo Comparator|Placebo|Patients will receive a placebo 1 hour before the procedure.
3327206|NCT02068235|Experimental|Pilot Phase|Subjects will receive a single intravenous (i.v.) dose of 5 mg ponesimod dissolved in 50 mL sterile 0.9% sodium chloride (NaCl) solution as a 3-hour infusion in the fasted state in the morning (infusion rate: 0.028 mg/min).
3327207|NCT02068235|Experimental|Treatment A/Treatment B|"Subjects will receive Treatment A followed by Treatment B.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
3231323|NCT01200641|Active Comparator|gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3231324|NCT01200641|Placebo Comparator|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
3327208|NCT02068235|Experimental|Treatment B/Treatment A|"Subjects will receive Treatment B followed by Treatment A.~Treatment A: a single i.v. dose of ponesimod administered in the fasted state in the morning.~Treatment B: a single oral dose of ponesimod (10 mg) administered as 1 tablet in the fasted state in the morning.~There will be a washout period between doses of 12-15 days."
3327209|NCT02068261|Experimental|Cogmed working memory training|30-40 minutes of Cogmed computerized working memory training 3-5 days a week for 5-8 weeks. Every training session consists of a set of visual- and verbal working memory tasks that are trained on during the session.
3231325|NCT01200654|Experimental|MRSA Infections|Methicillin-Resistant Staphylococcus aureus Infections
3327210|NCT02068261|Active Comparator|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment. After a 8 week period participants in this arm well be offered Cogmed working memory training.
3231327|NCT01200693|Active Comparator|ZES|Patients with coronary bifurcation lesions treated by Zotarolimus eluting stent
3327211|NCT02068274||chronic pain|CO2 monitoring in chronic pain patients who treated with opioids.
3327212|NCT02068287|Experimental|ESMOLOL|Resuscitated, hyperkinetic septic shock patients are treated with esmolol in order to reduce heart rate of 20% during 6 hours. During the intervention period, multimodal macro and micro hemodynamic data are recorded.
3327213|NCT02068313||Single cohort|
3327214|NCT02068326|Experimental|Mentalization Based Treatment|"the experimental intervention is a year-long manualized program that comprises four components:~Five individual case-formulation sessions,~MBT-I, an introductory pedagogical program for patients (three weekly sessions)~MBT-G, MBT-program in groups (37 weekly sessions)~MBT-P, a psychoeducation program for the patients' parents or parents substitutes (six sessions)."
3327215|NCT02068326|Active Comparator|Treatment As Usual|Participants randomized to the control group will receive Treatment As Usual (TAU). TAU is defined as comprising at least 12 monthly individual supportive sessions provided by non-MBT trained mental health professionals in the Department of Child and Adolescent Psychiatry in Region Zealand. Additional supportive sessions or other types of intervention may be offered to the patients according to the needs of the patients as evaluated by mental health professionals responsible for his/hers treatment. Hence, TAU may vary considerably in number and type of intervention across clinics and patients. All mental health services delivered during the treatment period to patients in the TAU group will be monitored and registered.
3327216|NCT02068339|Placebo Comparator|Placebo|Placebo Comparator / Tid (total 0mg)
3327217|NCT02068339|Experimental|Oltipraz 1|Total 90mg, by mouth, tid
3231328|NCT01200693|Active Comparator|SES|Patients with coronary bifurcation lesions treated by Sirolimus eluting stent
3231329|NCT01200693|Active Comparator|EES|Patients with coronary bifurcation lesions treated by Everolimus eluting stent
3231330|NCT01200706|Active Comparator|Amoxicillin given twice a day|
3231331|NCT01200706|Active Comparator|Amoxicillin given three times a day|
3231332|NCT01200719|Experimental|tACS group|
3231333|NCT01200719|No Intervention|Control group|Patients in the control group followed exactly the same protocol but without receiving the transcranial alternating current stimulation .
3327218|NCT02068339|Experimental|Oltipraz 2|Total 120mg, by mouth, tid
3327219|NCT02068365|Other|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
3327220|NCT02068378|Experimental|CMPE Optical Sensor Device|Single arm study
3327221|NCT02068391|Experimental|Exercise|This group will perform the 'Exercise Program' for months 0 to 6, and will be unsupervised for months 7 to 12.
3327222|NCT02068391|Active Comparator|Stretching|This group will perform the 'Stretching Program' for months 0 to 6, and the 'Exercise Program' for months 7 to 12.
3327223|NCT02068404|Other|Nifedipine|
3327224|NCT02068417|Active Comparator|Shock wave treatment|Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
3327225|NCT02068417|Placebo Comparator|Placebo Shock wave treatment|Shock waves are prohibited to enter the body by placebo stand-off.
3231334|NCT01200732|Active Comparator|Tadalafil|
3231335|NCT01200732|Placebo Comparator|placebo|
3231336|NCT01200745|Active Comparator|capsaicin patch|
3231337|NCT01200745|Placebo Comparator|Hydrogel patch|
3231338|NCT01200784|Experimental|250 mg/d modified release Nicotinamide|
3231339|NCT01200784|Experimental|500 mg/d modified release Nicotinamide|
3231340|NCT01200784|Experimental|750 mg/d modified release Nicotinamide|
3231341|NCT01200784|Experimental|1000 mg/d modified release Nicotinamide|
3231342|NCT01200784|Active Comparator|1000 mg/d immidiate release Nicotinamide|
3231343|NCT01200849|Experimental|Enhanced Label|Subjects in this arm will receive their prescriptions labeled with our enhanced, patient-friendly label.
3231344|NCT01200849|No Intervention|Standard Label|Subjects in this arm will receive their prescriptions labeled with a standard label.
3327226|NCT02068430|Experimental|Riboflavin 0.1% & UV-X™ Illumination System|UV-X Cross linking: After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber. When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture.
3327227|NCT02068456||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved Korean label.
3327228|NCT02068482|Active Comparator|1a USDD|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
3327229|NCT02068482|No Intervention|1b USDD|Patients control, no drug
3327230|NCT02068482|No Intervention|Control group|Control Group, no disease, no drug
3231345|NCT01200862|Experimental|BGS649 (Part 1)|BGS649 1mg and 0.1mg in hard gelatin capsules. In part 1 there was individualised dosing to titrate the subject's testosterone into the normal range. If the dose was lower than 0.1mg then specific instructions for dilution of an oral solution of BGS649 were provided.
3231346|NCT01200862|Placebo Comparator|Placebo to BGS649 (Part 2)|Matching placebo to BGS649 (0.3 and 0.1mg). 0.3mg placebo capsule given on Day 1 and 0.1mg placebo capsule on other treatment visits (week 1 to 11).
3231347|NCT01200862|Experimental|BGS649 (Part 2)|0.3 or 0.1mg hard gelatin capsules of BGS649 given orally. 0.3mg on Day 1 and 0.1 on all other treatment visits (week 1 to 11).
3231348|NCT01200901|Experimental|Melancolic depression patients|Patients with major depression will be recruited for the 8-week clinical trial of quetiapine XR 100 - 300 mg (flexible dosing).
3231349|NCT01200914|Active Comparator|'PTA without use of the GORE VIABAHN'|Subjects randomized to 'PTA alone without use of the GORE VIABAHN' will receive the standard of care treatment which is Percutaneous Transluminal Angioplasty without the use of the 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
3327231|NCT02068521|Experimental|Treatment naive subjects with GHD|Up to 100 new treatment naïve subjects with GHD will receive somavaratan 3.5mg/kg twice monthly.
3327232|NCT02068521|Experimental|Subjects who have completed a somavaratan study|All subjects after participation in (12VR2) or participation in the 14VR4 protocols have the option to receive somavaratan 3.5mg/kg twice monthly.
3327233|NCT02068534||survivors from charcoal-burning suicide|survivors from charcoal-burning suicide and at least above 20 years old.
3327234|NCT02068560|Experimental|dDAVP infusion|During the 9 hour study period, the subjects will receive three doses of dDAVP infusion (0.0003micrg/kg, 0.0005micrg/kg, 0.004micrg/kg).
3327235|NCT02068573|Active Comparator|Ventilation|Increased ventilation in the childs bedroom to at least 2-3 air changes pr hour.
3327236|NCT02068573|Placebo Comparator|Placebo ventilation|Ventilation system that recirculates the air in the childs bedroom
3231350|NCT01200914|Experimental|PTA with covered stent|Subjects randomized to PTA with covered stent will receive Percutaneous Transluminal Angioplasty followed by the delivery of a 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' .
3327237|NCT02068586|Experimental|Sunitinib|Patients receive sunitinib malate PO daily for 6 months in the absence of disease progression or unacceptable toxicity
3327238|NCT02068586|Experimental|Valproic acid|Patients receive valproic acid PO daily for 6 months in the absence of disease progression or unacceptable toxicity
3327239|NCT02068612|Experimental|MICT + IT|Moderate Intensity Continuous Training+Interval Training
3327240|NCT02068612|Active Comparator|LICT|Low Intensity Continuous Training
3231351|NCT01200940|Experimental|Phase I - Low-dose sweetener|68 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3231352|NCT01200940|Experimental|Phase I - Medium-dose sweetener|170 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3231353|NCT01200940|Placebo Comparator|Phase I Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3231354|NCT01200940|Experimental|Phase I- High-dose sweetener|250 mg sucralose dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test.
3231355|NCT01200940|Placebo Comparator|Phase II - Control Condition|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3327241|NCT02068625|Experimental|Treatment|Patients getting perioperative oral treatment with rasagiline (1mg daily) for 7 days
3327242|NCT02068625|Placebo Comparator|Control|Patients getting perioperative oral treatment with placebo for 7 days
3231356|NCT01200940|Experimental|Phase II - Diet Soda 1|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3231357|NCT01200940|Experimental|Phase II - Diet Soda 2|less than or equal to 5 mg/kg sucralose, less than or equal to 50 mg/kg aspartame, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3327243|NCT02068638|Experimental|IHE first, CONT second, CSII and MDI therapy|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
3231358|NCT01200940|Experimental|Phase II - Water with sucralose and acesulfame-potassium|less than or equal to 5mg/kg sucralose, less than or equal to 15 mg/kg acesulfame-potassium dissolved in 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
3231363|NCT01200979||pregnant flu vaccinated|pregnant women that choose to receive the seasonal flu vaccine
3327244|NCT02068638|Experimental|CONT first, IHE second,CSII and MDI therapy|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
3327245|NCT02068638|Experimental|GLU first, GLUFRU second, CSII and MDI therapy|GLU: ingestion of a 6% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
3231364|NCT01200979||pregnant non-flu vaccinated|pregnant women that do not receive the flu vaccine
3231365|NCT01201005|Active Comparator|Hydroxycobalamin|"Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma) is given as a singel intramuscular injection.~The syringe is covered so it is impossible to see whether it contains any substance"
3231366|NCT01201005|Sham Comparator|needle injection|"The controls receive an intramuscular injection: which is merely an introduction of the needle into the muscle whithout any injection. The syringe is covered so it is not possible to see whether the syringe contains any substance"
3231367|NCT01201018|Experimental|Oshadi DR|
3327246|NCT02068638|Experimental|GLU-FRU first, GLU second, CSII therapy|GLU-FRU : ingestion of a 20% carbohydrate solution (consisting of 100 g glucose + 100 g fructose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): ingestion of a 10% carbohydrate solution (consisting of 100 g glucose dissolved in 1000 ml tap water) over a continuous moderate exercise of 90 minutes. CSII = continuous subcutaneous insulin infusion. MDI=multiple daily injections.
3327247|NCT02068651|Experimental|Advance care planning programme|Participants in the experimental group will receive a structured advance care planning programme, namely Let Me Talk, delivered by a trained nurse facilitator. The programme will be conducted on individual basis through three one-hour home visits, once weekly. Family carers of the participants will be invited to all sessions.
3327248|NCT02068651|No Intervention|Usual care|Participants in the control group will receive three weekly home visits with basic health assessment and education provided by the trained nurse facilitator. If they request advance care planning information or assistance, an advance directive form, which is available on the Internet for public access, will be provided to them for their information.
3327249|NCT02068664||Observational|prism adaptation treatment
3327250|NCT02068677|Other|sympathetic response|This group will be composed of subjects who experience a heart rate and/or Blood Pressure change during injection.
3327251|NCT02068677|Other|no sympathetic response|This group will be made up of subjects that do not experience a vital sign change with injection for CPN.
3327252|NCT02068690|Experimental|BI 425809 single rising dose|BI 425809 powder for oral solution (PfOS) in single rising doses
3231368|NCT01201044|Experimental|Gemcitabine, Nedaplatin,BAI plus 3DCRT|"Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year.."
3231369|NCT01201044|Other|Gemcitabine, Nedaplatin, IV Plus 3DCRT|"Gemcitabine 100mg/m2, D1 & D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month.~for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin.~then patient will be followed for 1 year."
3231370|NCT01201070|No Intervention|control group|
3231371|NCT01201070|No Intervention|no treatment|
3231372|NCT01201070|Active Comparator|TREATMENT WITH ANTITHROMBIN|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
3231373|NCT01201083||HIV-|This study measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 105 HIV- recently tested men who have sex with men (MSM) and followed them for a year.
3231374|NCT01201083||HIV+ Acutely Infected|This study enrolled and followed 125 acutely infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
3259157|NCT01468051|Experimental|40 μg (2 ml) four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
3259158|NCT01468051|Experimental|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
3259159|NCT01468064|Experimental|BMSCs group|
3259160|NCT01468064|Experimental|EPCs group|
3259161|NCT01468064|Placebo Comparator|Control group|
3231375|NCT01201083||HIV+ Chronically Infected|This study enrolled and followed 91chronicially infected HIV+ men. It measured how transmission risks and partnership dynamics change over time among recently HIV-infected individuals and their partners comparing their behavioral patterns with those with chronic HIV infection, no HIV infection, and HIV negative testers. Of special focus was the role of drug use, especially methamphetamine, in affecting behaviors over time, and how partnership dynamics interact with drug use to allow for HIV transmission. The study compared behaviors of recently HIV infected men to those with long-term HIV infection and no HIV infection. We looked at how different types of sex partners affected one's drug use and consequently HIV transmission risks including having a prevalent sexually transmitted infection (STI). The study enrolled 321 recently tested men who have sex with men (MSM) and followed them for a year.
3231376|NCT01201096||peptide radioreceptor therapy and liver transplantation|
3231377|NCT01201109||Diabetics|Diabetic patients operated for carpal tunnel syndrome
3327253|NCT02068690|Experimental|BI 425809 Crossover|Bioavailability of BI 425809 PfOS
3231378|NCT01201109||Non-diabetics|Non-diabetic patients operated for carpal tunnel syndrome
3327254|NCT02068703|Active Comparator|Intervention|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools (face mask, ear plugs and white noise machine) to improve sleep.
3327255|NCT02068703|Placebo Comparator|Inert Control|Same 10 min time exposure and tool delivery to subjects in this arm WITHOUT demonstration.
3327256|NCT02068716||Adults with HAIs|"Adult cardiac surgery patients who develop infections in hospitals within 30 days post surgery.~We will exclude patients presenting with endocarditis."
3327257|NCT02068742|Experimental|General Anesthesia patients battery neuropsychological tests|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
3327258|NCT02068742|Active Comparator|Regular recovery patients|Mini Mental State Examination, Geriatric Index of Comorbidity, Geriatric Depression Scale, Trail Making Test B-A, Digit Span, Digit Symbol Substitution Test Application of the scores will be on the day 0 (the day after the hospital admission), day 2 and day 4 (days after the hospital admission).
3327259|NCT02068755||Cardiac surgery|Patients who have undergone cardiac surgery
3327260|NCT02068781|Active Comparator|Start with low-sodium diet|One week of low-sodium diet, followed by a two-week wash-out period and subsequently, another week of high-sodium diet
3327261|NCT02068781|Active Comparator|Start with high-sodium diet|One week of high-sodium diet, followed by a two-week wash-out period and subsequently, another week of low-sodium diet
3327262|NCT02068794|Experimental|Treatment (MV-NIS infected mesenchymal stem cells)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IP over 30 minutes on day 1 of cycle 1 and MV-NIS infected MSC (if MSC are not available, MV-NIS may be given alone) IP over 30 minutes of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3327263|NCT02068807|Active Comparator|Lutein drops|oral administration of 0.28 mg of lutein in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
3231379|NCT01201122|Experimental|Weight based Mesalamine: Once daily|
3327264|NCT02068807|Placebo Comparator|Glucose drops|oral administration of 0.28 mg of vehicle (0.5 mL of 5% glucose solution) in two doses: within 6 hours (hrs) after birth and at 36 hrs of life
3327265|NCT02068833||Gastrectomy|Subjects in this group will undergo a gastrectomy only.
3327266|NCT02068833||BPD-DS|Subjects in this group will undergo a BPD-DS surgery.
3327267|NCT02068859|Experimental|Diclofenac Cream 8%|Diclofenac Cream 8% applied 3-4 times daily for 6 weeks.
3231380|NCT01201122|Experimental|Weight based Mesalamine: Twice daily|
3231381|NCT01201135||Sickle cell disease|
3231382|NCT01201135||hereditary spherocytosis.|
3231383|NCT01201148|Experimental|Oscillating or intermittent tDCS|
3231384|NCT01201161|Experimental|RANI/PPV|Preoperative intravitreal ranibizumab and pars plana vitrectomy
3231385|NCT01201161|Placebo Comparator|PPV|Sham injection and pars plana vitrectomy
3231386|NCT01201174|No Intervention|Patients with Hereditary Spherocytosis|All patients should have clinical and laboratory findings, consistent with mild to severe HS, diagnosed on the basis of spherocyte morphology, elevated MCHC (33-38 g/dl), with a mean value of (35.47 g/dl), increased osmotic fragility , splenomegaly and non-immune mediated hemolysis.
3327268|NCT02068859|Active Comparator|Control|Diclofenac Gel 1% applied 3-4 times daily fr 6 weeks
3327269|NCT02068872|Experimental|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
3327270|NCT02068898|Experimental|XS003 Dose-level 1|Capsule formulation
3327271|NCT02068898|Experimental|XS003 Dose-level 2|Capsule formulation
3327272|NCT02068898|Experimental|XS003 Dose-level 3|Capsule formulation
3327273|NCT02068898|Experimental|Tasigna|Marketed capsule
3231387|NCT01201187|Experimental|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
3231388|NCT01201187|Placebo Comparator|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
3231389|NCT01201200||Group 1 - Obstructive Sleep Apnea (OSA)|Fifty-six patients with Obstructive Sleep Apnea
3327274|NCT02068911||Monitoring of ETCO2 and PTCO2|All neuromuscular patients
3231390|NCT01201200||Group 2 - Non-OSA Controls|Fifty individuals without OSA with similar age, gender and body mass index (BMI)
3231391|NCT01201200||Group 3 - Treatment|Fifteen patients with moderate and severe sleep apnea from group 1 underwent treatment with continuous positive airway pressure
3231392|NCT01201200||Group 4 - Placebo|Fifteen patients with moderate/severe sleep apnea underwent to placebo
3327275|NCT02068924|Experimental|slow freezing|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
3327276|NCT02068924|Other|vitrification|Therefore, the aim of our study is to analyze whether extended culture of Day-2 top embryos to blastocyst-stage may improve the cumulative delivery rate in an in vitro fertilization program with Single Embryo Transfer policy in a prospective and randomized study integrating the transfer of fresh and frozen/thawed embryos using a slow freezing versus vitrification procedure.
3231393|NCT01201213|Active Comparator|Extradural bupivacaine|Local anesthetic
3231394|NCT01201213|Active Comparator|Extradural levobupivacaine|local anaesthetic
3231395|NCT01201213|Active Comparator|Extradural ropivacaine|local anaesthetic
3327277|NCT02068937|Active Comparator|Control Group|In the control group, patients just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline. The patients do not receive phone calls neither advising on non-pharmacological treatment; The medication is adjusted by the doctor during the initial evaluation of study baseline.
3327278|NCT02068937|Experimental|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day.
3327279|NCT02068950|Other|Progressive resistance training|12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand).
3231396|NCT01201213|Active Comparator|Intrathecal bupivacaine|local anaesthetic
3327280|NCT02068963||Study Population|
3327281|NCT02068976||Women with Primary Ovarian Insufficiency|
3327282|NCT02068989||Stress Hyperglycemic Group|Repeat HbA1C in 1 year
3327283|NCT02068989||Euglycemic Group|Repeat HbA1C in 1 year
3327284|NCT02069002|Experimental|Cognitive-Behavioral Therapy (CBT)|"There will be ten (10) manualized session, fist 90 minutes and nine (9) 45-minute individual sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after the treatment. Sessions include psychoeducation about indoor air related symptoms and personal health behavior factors integrated on patients individual symptomatology, cognitive restructuring, behavioral experiments of patients health promoting behavior, imagery rescripting and relapse prevention.~Intervention: Behavioral: Psychotherapy (CBT)"
3231397|NCT01201213|Active Comparator|Intrathecal levobupivacaine|local anaesthetic
3327285|NCT02069002|Experimental|Applied relaxation group therapy|"There will be seven (7) manualized session, first 120 minutes and six (6) 90-minute group sessions conducted at weekly intervals, last two sessions 2 weeks intervals. One booster session will be conducted three months after treatment. Sessions include information about indoor air related symptoms, behavioral training and experiments focusing on applied relaxation technique and relapse prevention.~Intervention: Behavioral: group therapy (ART)~NB: The Applied Relaxation group Therapy won´t be carried out due to slow and prolonged recruiting process (A steering group agreement 4/2015 and the Ethics Committee approval 5/2015 for the change of the study plan)."
3327286|NCT02069002|Experimental|Information session (psychoeducation)|"There will be one (1) manualized 90-minute individual session. The session includes information about indoor air related symptoms and factors affecting individual health behavior.~Intervention: Information session (psychoeducation)"
3327287|NCT02069028||Low intensity intervention|human oriented interventions with less consideration to the system based act including, but not limited to, education, training, sepsis profile and posters with protocol algorithms.
3327288|NCT02069028||Intermediate intensity intervention|interventions that lie in between human oriented and system oriented Including, but not limited to, sepsis protocols, daily audits, feedback and clinical pathway
3231398|NCT01201213|Active Comparator|Intrathecal ropivacaine|local anesthetic
3231399|NCT01201226|No Intervention|Patients|Perimenopausal women, who will undergo oelvic organ surgery, and will allow harvest of about half an oary for the study purpose
3327289|NCT02069028||High intensity intervention|system based interventions with less involvement of human effect including, but not limited to, electronic alert systems and sepsis response team.
3327290|NCT02069054||Asthma|Patients with mild to moderate asthma diagnosed in accordance with GINA
3327291|NCT02069054||COPD|Patients with mild to moderate COPD diagnosed in accordance with GOLD
3327292|NCT02069054||Control|Healthy subjects
3327293|NCT02069067||Advanced cancer patients with pain|
3327294|NCT02069080|Experimental|1|All subjects are administered the study drug
3327295|NCT02069106|Experimental|Pro-Omega LDL|3 capsules 1000 mg BID for 8 weeks
3327296|NCT02069106|Placebo Comparator|Placebo|3 capsules BID for 8 weeks
3231400|NCT01201239|Experimental|raltegravir|HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance are to accept Ral plus OBT.
3231401|NCT01201252||Acute gastroenteritis Group|Suspected/confirmed cases of rotavirus gastroenteritis in children < 5 years of age
3231402|NCT01201278|Experimental|Nasal insulin 8 IU|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
3231403|NCT01201278|Experimental|Nasal insulin 16 IU|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
3231404|NCT01201278|Active Comparator|Subcutaneous insulin lispro 8 U|Subcutaneous insulin lispro (Humalog®) 8 U
3231405|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.4|Fraction of inspired normobaric oxygen of 0.4 (low oxygen group)
3327297|NCT02069132||Warfarin in elderly with comorbidity|Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement
3327298|NCT02069145|Experimental|Drug: OMP-54F28, with Sorafenib|
3327299|NCT02069158|Experimental|PF-05212384, Carboplatin, Paclitaxel|starting dose of PF-05212384: 95 mg iv weekly Dose of Carboplatin: 5 AUC every 28 days Dose of Paclitaxel: 80 mg/m2 on days 1, 8 and 15
3327300|NCT02069171||early ovarian cancer group|
3327301|NCT02069171||locally advanced cervical cancer group|
3327302|NCT02069171||primary endometrial cancer group|
3327303|NCT02069197|Active Comparator|Ketogenic diet, lifestyle counseling|ketogenic diet consisted of 3:1[fat]:[protein+carbohydrate] weight ratio with 1600kcal restriction.
3327304|NCT02069197|Active Comparator|Orlistat, Lifestyle counseling|Orlistat 120 mg TID, standardized diet and lifestyle-modification counseling based on the LEARN (Life, Exercise, Attitudes, Relationships,and Nutrition) program with recommended caloric goal of 1600 kcal/day.
3327305|NCT02069197|Active Comparator|Standartized diet, Lifestyle counseling|Standardized diet and lifestyle-modification counseling based on the LEARN (Lifestyle, Exercise, Attitudes, Relationship, Nutrition) program with recommended caloric goal of 1600kcal/day.
3231406|NCT01201291|Active Comparator|Fraction of inspired oxygen of 0.7|Fraction of inspired normobaric oxygen of 0.7 (high oxygen group)
3231407|NCT01201304|Experimental|Interoceptive exposure|Repeated trials of voluntary hyperventilation intended to reduce fears of arousal-related body sensations.
3327306|NCT02069210||Blood transfusion|Patients receive blood transfusion during operation
3327307|NCT02069223|Active Comparator|Gastrectomy|Subjects in this group will undergo a gastrectomy as their first surgery with a BPD-DS 1-year later.
3327308|NCT02069223|Active Comparator|BPD-DS|Subjects in this group will undergo a BPD-DS as their first surgery with a gastrectomy 1-year later.
3327309|NCT02069223|Active Comparator|Gastrectomy+BPD-DS|Subjects in this group will undergo a gastrectomy AND a BPD-DS concomitantly. They will then be closely monitored for the remainder of the study.
3327310|NCT02069236|No Intervention|G6PD Testing|All subjects receive G6PD test
3327311|NCT02069249|Experimental|Healthy Nutrition Intervention|Healthy Nutrition Intervention (HNI)
3327312|NCT02069249|Experimental|Healthy Sleep Intervention|Healthy Sleep Intervention (HSI)
3327313|NCT02069249|No Intervention|Waiting list control|Waiting list control group
3327314|NCT02069262|Experimental|angiography combination laparoscopy|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence. Those who developed rebleeding during the observation would be crossed over to the other investigation modality. Patients with negative findings on the initial assigned investigation but who developed rebleeding would undergo further investigation to localize the site of bleeding.
3327315|NCT02069262|Placebo Comparator|angiography alone|All patients were randomized to receive either mesenteric angiography alone or angiography combination laparoscopy in a 1:1 ratio. Randomization was performed computer-generated list using a randomly permuted block design. To ensure concealed randomization, the randomization code was put in opaque envelope and kept by researchers not performing angiography or angiography combination laparoscopy. Both patients and investigators were unaware of the randomization sequence.
3327316|NCT02069275|Experimental|Immediate mobilization|Immediate mobilization after coronary angiography or percutaneous coronary intervention
3231408|NCT01201304|Placebo Comparator|Expressive writing|Expectancy control intervention.
3231409|NCT01201330||ONJ sufferers|history of jaw osteonecrosis
3327317|NCT02069275|Active Comparator|Two hours bedrest|Bedrest two hours after coronary angiography or percutaneous coronary intervention
3327318|NCT02069288|Experimental|1|Fludrocortisone
3327319|NCT02069288|Placebo Comparator|2|Placebo
3327320|NCT02069301|Experimental|Integrated Depression/Microfinance Group|LIFE-DM is a Depression and Microfinance integrated program using behavior activation and problem solving therapy applied to both depression and livelihood. Livelihood support include microfinance loans, personal finance, and income-generation skills.
3327321|NCT02069301|Other|Treatment as Usual|Currently treatment as usual in this province includes national guidelines for antidepressant care for depression and referral for microfinance/livelihood programs
3327322|NCT02069314|Experimental|Whey protein supplementation|50 grams of whey blended into frozen drink
3327323|NCT02069314|Experimental|Carbohydrate supplementation|50 grams of polycose blended into frozen drink
3327324|NCT02069340|Experimental|Arm I (zoledronic acid over 15 minutes)|Patients receive zoledronic acid IV over 15 minutes on day 1.
3327325|NCT02069340|Experimental|Arm II (zoledronic acid over 30 minutes)|Patients receive zoledronic acid IV over 30 minutes on day 1.
3327326|NCT02069366|Placebo Comparator|Placebo|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
3327327|NCT02069366|Active Comparator|Dronabinol|"In a randomized, double-blind, placebo-controlled, between-subjects design, we will administer a one-time oral dose of dronabinol (7.5mg) or placebo (PBO) approximately two hours prior to fMRI scanning and task performance in 40 patients with PTSD, 40 trauma-exposed controls without PTSD (TEC), and 40 non-exposed healthy controls (HC).~Within each of the three groups half of the participants will receive dronabinol and the other half will received placebo to create the following 6 groups:~PTSD-dronabinol (20)~PTSD-placebo (20)~TEC-dronabinol (20)~TEC-placebo (20)~HC-dronabinol (20)~HC-placebo (20)"
3231410|NCT01201330||Bisphosphonate exposure|patients with exposure to bisphosphonates
3231411|NCT01201369|Active Comparator|Cypher™ Stent|Participants in the Cypher arm will be randomised to receive a Cypher™ (Cordis, Miami Lake, USA) coronary stent
3327328|NCT02069405|Experimental|Music Group plus normal standard of care|Patients will listen to music prior and during the scan
3327329|NCT02069405|No Intervention|Control Group - Normal standard of care|
3231412|NCT01201369|Active Comparator|Xience™ Stent|Patients in the Xience™ arm will receive a Xience™ Stent(Abbott Vascular, Santa Clara, USA.
3231413|NCT01201382|Experimental|IPT-AST|Interpersonal Psychotherapy-Adolescent Skills Training
3231414|NCT01201382|Active Comparator|Group Counseling|Group Counseling
3327330|NCT02069418|Experimental|Experimental arm|All patients will be in the same arm. Patients are going to have two 18F-FLT-TEP and two 18F-FDG-TEP : the first ones during the two weeks before the beginning of erlotinib and the second ones will occur during the second week after the initiation of erlotinib. The order of TEP is not definite : 18F-FLT-TEP may be planned first or reciprocally. A period of 48 hours must separate two TEP.
3327331|NCT02069431|Experimental|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
3231415|NCT01201395||Dental caries assessment|
3231416|NCT01201408||Dental Caries assessment|
3231417|NCT01201434|Experimental|Probiotics, Treatment, Food Additive|
3231418|NCT01201447||Questionable occlusal lesions|
3231419|NCT01201460||Glucose testing|Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health.
3231420|NCT01201473||Measure impact of research participation|
3231421|NCT01201499|Active Comparator|Intrathecal morphine|A single shot of intrathecal morphine given before the induction of general anesthesia. Followed by postoperative IV patient-controlled morphine analgesia.
3327332|NCT02069431|Placebo Comparator|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
3327333|NCT02069444||Truview EVO2 laryngoscope|patients intubated withTruview EVO2 laryngoscope
3327334|NCT02069444||Macintosh laryngoscope|patients intubated with Macintosh laryngoscope
3327335|NCT02069470|Experimental|Continuing Medical Education|Continuing Medical Education
3231422|NCT01201499|Active Comparator|Continuous IV remifentanil|Continuous administration of IV remifentanil during surgery, supported by a single bolus of IV morphine at the end of surgery. Followed by postoperative IV patient-controlled morphine analgesia.
3231423|NCT01201512||Temporomandibular disorders|
3231424|NCT01201525|Experimental|Surgical scar - part 1|Surgical scar - part 1
3327336|NCT02069470|No Intervention|Usual care|Usual care
3327337|NCT02069483|Active Comparator|Motivational Interviewing|Subjects will engage in motivational interviewing and come up with messages to motivate quitting during the activity.
3327338|NCT02069483|Active Comparator|Tailored Feedback|Subjects will use reasons for quitting that they provided during the phone baseline for the text messages and audio recordings.
3327339|NCT02069496||Subjects who receive Arepanrix®|Subjects who receive Arepanrix® as per routine practice
3327340|NCT02069509||Control research participants|diagnosis of FRDA genetically excluded
3327341|NCT02069509||FRDA patients|with genetically confirmed diagnosis of FRDA
3327342|NCT02069522|Active Comparator|Standard Milk-based Formula Containing Carotenoid|milk-based ready to feed infant formula
3327343|NCT02069522|Experimental|Investigational Milk-based Formula Containing Carotenoid|investigational milk-based ready to feed infant formula
3327344|NCT02069535|Experimental|AVANZ Cupressus|AVANZ Cupressus
3327345|NCT02069548||Cervical dystonia|
3327346|NCT02069548||matched controlled subjects|matched in age (+/- 5 years) and gender
3327347|NCT02069561|Experimental|Eicosapentaenoic Acid|Subjects with long-standing ulcerative colitis and meeting the inclusion criteria will receive 2 g/day of Eicosapentaenoic Acid as a supplement for 90 days
3327348|NCT02069561|No Intervention|Normal controls|Five patients undergoing screening colonoscopy and polypectomy using biopsy forceps. Six biopsies of healthy mucosa will be collected at the time of colonoscopy. Faeces, urine and blood samples will be collected prior to performing colonoscopy. The samples will serve as healthy reference for the basic studies.
3327349|NCT02069574|Experimental|severe periodontitis group|non-surgical periodontal therapy
3327350|NCT02069574|Experimental|Moderate periodontitis group|non-surgical periodontal therapy
3327351|NCT02069574|No Intervention|healthy control|No treatment
3327352|NCT02069587|Experimental|Pomegranate|The women in this group will drink pomegranate juice
3327353|NCT02069600|Active Comparator|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure is a device that apply a positive pressure in the airway to avoid its collapse during sleep during three months in this study
3327354|NCT02069600|No Intervention|No intervention|No intervention. No placebo is used. Control group without CPAP treatment during three months
3327355|NCT02069613||Mild traumatic brain injury (mTBI)|Patients admitted to Huntington Memorial Hospital (HMH), Pasadena CA, Emergency Department (ED) diagnosed with mTBI by history (alteration of consciousness, post-traumatic amnesia, loss of consciousness) and normal brain computed tomography (CT).
3231425|NCT01201525|Placebo Comparator|Surgical scar - part 2|Surgical scar - part 2
3231426|NCT01201538|Experimental|Single arm|
3231427|NCT01201551|Active Comparator|healthy subjects without PVD|healthy subjects without primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
3231428|NCT01201551|Active Comparator|healthy subjects with PVD|healthy subjects with primary vascular dysregulation Intervention: Brimonidine, Latanoprost and Placebo
3231429|NCT01201564|Active Comparator|intraperitoneal onlay mesh repair|
3231430|NCT01201564|Active Comparator|sublay mesh repair|
3231431|NCT01201577|Active Comparator|Placebo/Probiotic|
3231432|NCT01201577|Active Comparator|Placebo/Prebiotic|
3231433|NCT01201577|Active Comparator|Prebiotic/Probiotic|
3231434|NCT01201577|Placebo Comparator|Placebo/Placebo|
3231435|NCT01201590|Experimental|High Flavanol Cocoa|609mg cocoa flavanols per 24g serving
3231436|NCT01201590|Placebo Comparator|Low flavanol cocoa|13mg cocoa flavanols per 24g serving
3231437|NCT01201603|Experimental|Orange Juice|Orange Juice reconstituted from frozen concerntrate
3231438|NCT01201603|Placebo Comparator|Orange drink|Sugars matched orange drink
3231439|NCT01201616|Experimental|High fat, low carbohydrate diet|Fats intake 55% , Protein 17% and carbohydrate 28% of total energy
3231440|NCT01201616|Active Comparator|Low fat, high carbohydrate diet|Fat intake 20%, Protein 17% and carbohydrate 63% of total energy intake
3327356|NCT02069613||Control|Patients admitted to HMH ED for minor extremity trauma (sprains) and no evidence of mTBI
3327357|NCT02069626|Active Comparator|No wait|Usage of linear stapler without waiting of compression time
3327358|NCT02069626|Active Comparator|20 second wait|Usage of linear stapler with 20 second compression time
3327359|NCT02069626|Active Comparator|60 second wait|Usage of linear stapler with 60 second compression time
3327360|NCT02069639||no treatment|
3327361|NCT02069665|Experimental|Injection, medications and application|"Intravenous injection: Xiyanping injection, produced by Jiangxi Qing Feng Pharmaceutical Co., Ltd;~Medications: according to TCM syndrome differentiations;~Wind-heat blocking lungs pattern (feng re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Zhi Ke San (herbal powder to relieve cough)~Phlegm-heat blocking lungs pattern (tan re bi fei zheng): Xiaoer Qingfei Heji (mixture), and Hua Tan San (herbal powder to remove phlegm)~External application: Fuxiong San"
3327362|NCT02069665|Active Comparator|Injection and medications|"Intravenous injection: Ribavirin Injection;~Medications: symptomatic therapies~Guaifenesin Syrup, for removing phlegm, relieving gasp-cough;~Ibuprofen Suspension, and salbutamol in case of different symptoms"
3327363|NCT02069691|Experimental|virtual reality-cycling training system|
3327364|NCT02069717||Not applicable-observational study|Not applicable-observational study
3327365|NCT02069743|Experimental|Intervention|The intervention group will use the study's mobile application during the 8-week study.
3327366|NCT02069743|No Intervention|Control|The control group will not use the study's mobile application during the study.
3327367|NCT02069756||Duchenne and Becker Muscular Dystrophy|Patients with Duchenne or Becker Muscular Dystrophy, as well as carrier females.
3327368|NCT02069769|Experimental|communication with oncology team|oncology team will be prompted to contact family caregiver and/or patient twice weekly while the patient is receiving hospice care.
3327369|NCT02069782|Experimental|Home visiting|Home visiting programs in the United States grew from three major approaches that first became prominent in the 1960s: visits by public health nurses to promote infant and child health in disadvantaged families, Head Start home visiting to promote school readiness in hard-to-reach families, and home-based family support to promote positive parenting and prevent child abuse in high-risk families. All of these approaches sought to foster early childhood health and development by intervening in the home to support and improve socialization, health, and education practices.Today, home visiting is seen as a particularly important strategy for high-risk families who may be difficult to engage in other services.
3327370|NCT02069795|Experimental|Voice recording|Subjects voices were recorded as they spoke specific words
3327371|NCT02069808|Experimental|Group B: Follistim and Menopur|"Group B: N=25 subjects~Cycle day 2 start Follistim 200 U/day up to 11 days duration.~Cycle day 2 start Menopur (menotropins) 75 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
3327372|NCT02069808|Active Comparator|Group A: Follistim only|"Group A: N=25 subjects~Cycle day 2 start Follistim 250 U/day up to 11 days duration.~Add GnRH antagonist Ganirelix 250 µg/day starting 5 days before GnRH agonist trigger.~GnRH agonist Leuprolide Acetate (Lupron) 1 mg subcutaneous injection 36 hours prior to egg collection.~Transvaginal ultrasound guided needle aspiration of oocytes 36 hours after Lupron trigger."
3327373|NCT02069821|Experimental|Group A|single administration : amlodipine/valsartan 10/160mg, qd, 10days(oral)
3327374|NCT02069821|Experimental|Group B|single administration : atorvastatin 40mg, qd, 7days(oral)
3231441|NCT01201642|Experimental|Prednisolone|Prednisolone as 5 mg tablets will be given within 72 h after onset of Bell's palsy as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
3231442|NCT01201642|Experimental|Acute stage acupuncture|Accept acupuncture therapy within 10days after onset of Bell's palsy, do not accept prednisolone therapy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints within 72 h after onset of Bell's palsy. Yifeng (TE17), Hegu (LI4) are punctured 0.5-1.0 cun, the others are punctured 0.1-0.3 cun. and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
3231443|NCT01201642|Experimental|Prednisolone + acute stage acupuncture|Accept prednisolone and acupuncture therapy within 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Acute stage acupuncture.
3327375|NCT02069834|Experimental|Arm 1 (intervention)|Dolutegravir 50 mg/d + Rilpivirine 25 mg/d qd orally (intake during a meal)
3327376|NCT02069834|Active Comparator|Arm 2 (control)|Continuation of existing HAART at the time of randomization
3327377|NCT02069860|Experimental|Access for heamodialysis treatment|The Bone Anchored Port System (BAP) will be implanted in the mastoid bone behind the ear, connected with a double lumen central venous catheter inserted in the jugular vein, and will be used in conjunction with an adapter as a permanent vascular access for hemodialysis treatment
3327378|NCT02069873|Experimental|16-Week Group Treatment|The 16-week treatment group will contain 3 blocks of treatment (exposure, cognitive, skills) with order randomized within the treatment. The first and last group session are considered inactive treatment sessions. The group treatment will be provided weekly.
3327379|NCT02069873|No Intervention|Wait List Control|The Wait List Control group will receive minimal attention, as they will meet bi-monthly for supportive sessions with the study psychologist. The study psychologist will not introduce any active treatment in the individual sessions.
3327380|NCT02069886|Experimental|deferasirox|single arm. all patients will receive deferasirox
3327381|NCT02069899|Other|NI-0501 only in case is requested|NI-0501, in the event that, upon request of the treating physician, NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous protocol, patients will continue receiving NI-0501 in the context of this study.
3327382|NCT02069912|Experimental|Collaborative depression care|All enrolled patients will receive collaborative depression care management.
3327383|NCT02069925|Experimental|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
3327384|NCT02069925|Active Comparator|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
3231444|NCT01201642|Experimental|Resting stage acupuncture|Accepted acupuncture therapy after 10 days of the onset of Bell's palsy. The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. Penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints 7 d after enrolment. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
3231445|NCT01201642|Experimental|Prednisolone + resting stage acupuncture|Accept prednisolone and acupuncture therapy more than 10days after onset of Bwll's palsy. Prednisolone used as same as the Arm of Prednisolone. The acupuncture points used as same as the Arm of Resting stage acupuncture.
3231446|NCT01201642|Other|Other treatment|Do not accept neither prednisolone nor acupuncture therapy. The therapy accepted is different from the five Arms Previously.
3231447|NCT01201668||Persistent Tooth Pain|
3231448|NCT01201681||Post-operativeTooth Pain|
3231449|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Group|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
3231450|NCT01201694|Experimental|Surface-Controlled Water Soluble Curcumin Expansion|Following finding of MTD surface-controlled water soluble curcumin, escalating dose levels
3231451|NCT01201707|Experimental|Treatment of CCSVI with Angioplasty|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will be treated with angioplasty.
3231452|NCT01201707|Sham Comparator|Observation of CCSVI|At the time of venography, these patients will have had a significant lesion (blockage) in the internal jugular and/or the azygos vein that will not be treated with angioplasty. These patients will be observed after treatment and compared to those patients who received treatment.
3231453|NCT01201720|Other|Albumin|Albumin solution for infusion 5%. dosage: 43,5 millimole intravenouse use , 6 plasma exchange with albumin in 11 days and administration of polyclonal gamma globulin.6 sessions
3327385|NCT02069938||Healthy Subjects|Noninvasive Brain Computer Interface Control
3327386|NCT02069951|Experimental|Practice two procedures on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises.~Participants randomised to the intervention group will practice two procedures on a simulator. First a procedural module A (a laparoscopic appendectomy) to a predefined proficiency level. Upon reaching proficiency for procedural module A the participants will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
3327387|NCT02069951|No Intervention|Practice one procedure on a simulator|"All participants start by practicing a series of six basic skills modules until they reach a predefined proficiency level for each module. For all of the basic skills exercises proficiency is reached when the participants have passed the proficiency level for all exercises. Each exercise has to be passed twice within five consecutive attempts.~Participants randomised to the control group will practice procedural module B (a laparoscopic salpingectomy) to a predefined proficiency level."
3327388|NCT02069964||Prospective hemi-neck RT|
3327389|NCT02069977|Experimental|Aripiprazole|"Dose level: 2, 5, 10, 15 mg/day~Starting dose: 2 mg/day~Dose increment: The dose should be gradually increased according to the investigator's judgment of subject's response.~Target dose: 5-15 mg/day~Maximum dose: 15 mg/day~Flexibly dosed (2 to 15 mg/day) aripiprazole (oral tablet or solution) is taken once in a day at the same time without regarding to meals"
3327390|NCT02069990|Active Comparator|30000 IU cholecalcipherol once a week|30000 IU cholecalcipherol once a week oral
3327391|NCT02069990|Experimental|7000 IU cholecalcipherol once a week|7000 IU cholecalcipherol once a week oral
3327392|NCT02069990|Experimental|30000IU cholecalcipherol once a month|30000IU cholecalcipherol once a month oral
3327393|NCT02069990|Active Comparator|1000 IU cholecalciferol once a day|1000 IU cholecalciferol once a day
3327394|NCT02070003|Experimental|Motivational Interviewing and Physician Guided Opioid Weaning|Patients will go through motivational interviewing with the study physician via phone once a week for 7 weeks, and once a month up to a year as applicable, until patient completes the protocol.
3327395|NCT02070003|No Intervention|Usual Care|
3231454|NCT01201733|Experimental|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
3231455|NCT01201733|Active Comparator|Ultrasound therapy and hot pack|The participants will receive a thirty minutes session of Ultrasound therapy and hot pack
3327396|NCT02070016|Experimental|TMS Parameter Condition 1 first|Application of Transcranial Magnetic Stimulation
3327397|NCT02070016|Experimental|TMS Parameter Condition 2 First|Application of Transcranial Magnetic Stimulation
3327398|NCT02070029|Experimental|Acupuncture|"Acupuncture Therapy~- twice weekly sessions for 5 weeks: 1st session 60 minutes with remaining 9 session approximately 45 minutes each. Physical exam at 1st session includes evaluation of peripheral pulses, head, neck, throat/tongue. No pelvic exam required."
3231456|NCT01201746|Experimental|Periodontal Therapy|Scaling Root planing and oral hygiene instructions
3231457|NCT01201746|Placebo Comparator|Delayed treatment|Scaling Root planing and oral hygiene instructions
3231458|NCT01201824|Other|1|
3231459|NCT01201837|Placebo Comparator|Placebo|
3327399|NCT02070042|Experimental|Omega- 3 Fatty Acid|The patient will receive oxybutynin 5 mg twice daily (BID). The patients in the study group will receive a 0.9 gm capsule of Omega-3 BID. The amount of medication was chosen based on dosage used in prior studies and the current FDA recommendations to not exceed 2gm/day of omega-3 in dietary supplementation.
3327400|NCT02070042|Placebo Comparator|Placebo|Seagate® Extra Virgin Olive oil capsules
3327401|NCT02070055||No treatment|No treatment
3327402|NCT02070068|Experimental|Group 1|ICG administered 10 minutes prior to time of visualization
3327403|NCT02070068|Experimental|Group 2|ICG administered 45 min prior to time of visualization
3327404|NCT02070081|Experimental|Surgery|
3327405|NCT02070107|Other|no arms|no arms, sponsor withdrew
3327406|NCT02070120|Experimental|Chemoresection|4 once weekly outpatient intravesical instillations 40mg Mitomycin C
3327407|NCT02070120|Other|Surgical Management|Surgical management according to local practice
3327408|NCT02070133|Experimental|Simvastatin|Patients with COPD will receive simvastatin 40 mg once a day for 12 weeks
3231460|NCT01201837|Experimental|Low Dose|CER-001 Low Dose
3231461|NCT01201837|Experimental|Mid Dose|CER-001 Mid Dose
3327409|NCT02070133|Placebo Comparator|Placebo|Patients with COPD will receive placebo once a day during 12 weeks
3327410|NCT02070159|Active Comparator|Clopidogrel 600 mg|Patients administer conventional loading dose of clopidogrel 600 mg as active comparators.
3231462|NCT01201837|Experimental|High Dose|CER-001 High Dose
3231463|NCT01201902|Experimental|Group 1 : Low dose with adjuvant|Group 1: 18 ~ 64 years old subjects
3231464|NCT01201902|Experimental|Group 1: High dose with adjuvant|Group 1: 18 ~ 64 years old subjects
3327411|NCT02070159|Experimental|Prasugrel 30 mg|Patients administer lower loading dose of prasugrel 30 mg.
3327412|NCT02070159|Active Comparator|Prasugrel 60 mg|Patients administer conventional loading dose of prasugrel 60 mg as active comparators.
3327413|NCT02070172||Cervicogenic Headache Group|This group of subjects is considered the symptomatic group. No intervention was provided in this study so there are no intervention groups.
3231465|NCT01201902|Active Comparator|Group1 : Plain vaccine|Group 1: 18 ~ 64 years old subjects
3231466|NCT01201902|Experimental|Group 2 : Low dose with adjuvant|Group 2: greater than or equal to 65 years of age
3327414|NCT02070172||Healthy, Asymptomatic Group|Subjects in this group had no headache symptoms. Their neck motion was compared to subjects in the headache group. No intervention was provided to subjects in either group for this study.
3327415|NCT02070185|Experimental|2 exposures|During the conditioning period, the children of this group was exposed only twice to the beverages
3231467|NCT01201902|Experimental|Group 2 : high dose with adjuvant|Group 2: greater than or equal to 65 years of age
3231468|NCT01201928||Technosphere Insulin Inhalation Powder|
3327416|NCT02070185|Experimental|7 exposures|During the conditioning period, children of this group were exposed exposed 7 times to the beverages
3327417|NCT02070198|Experimental|Long acting FSH and GnrH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
3327418|NCT02070198|Experimental|daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
3327419|NCT02070198|Experimental|Triptorelin and recombinant FSH|Women in triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day until the day of HCG administration.
3327420|NCT02070211|Experimental|omega-3 PUFAs in add on to standard care|omega-3 PUFA supplementation as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
3231469|NCT01201928||Comparator|Based on parent trial
3231470|NCT01201941||Intervention group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will have access to the e-Chasqui system."
3231471|NCT01201941||Simultaneous/historical control group|"During the first part of the study, the intervention group will not have access to the e-Chasqui system.~During the second part of the study, the intervention group will not have access to the e-Chasqui system."
3231472|NCT01201954|Active Comparator|sucrose|0,5 ml/kg of sucrose administered 2 minutes prior the procedure
3231473|NCT01201954|Placebo Comparator|sterile water|0,5 ml/kg of sterile water administered 2 minutes prior the procedure
3231474|NCT01201980||1|Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
3231475|NCT01202006|Experimental|Intervention|General practitioners of patients in the intervention group will receive detailed instructions on uptitration of ACE-inhibitors and beta-blockers before the inclusion of participants.
3231476|NCT01202006|No Intervention|Control|Patients in the control group receive care-as-usual. Their general practitioner will not be trained in applying the uptitration protocol.
3231477|NCT01202019|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
3231478|NCT01202019|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
3231479|NCT01202045||systemic sclerosis patients|Every patient will have a rest echocardiography, a stress echocardiography, a right heart catheterization, a blood specimen, and a pulmonary function test.
3231480|NCT01202058|Experimental|NEVO™ SES|"Design Protocol Am3.0 - safety follow-up:~The study population consists of 103 subjects with atherosclerotic coronary artery disease treated with the NEVO™ SES. Candidates for the initial NEVO II Study must have met ALL inclusion criteria and NO exclusion criteria.~Design Original Protocol~Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System."
3231481|NCT01202058|Active Comparator|XIENCE V®/XIENCE PRIME™/PROMUS®|Subjects randomized to treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System
3327421|NCT02070211|Placebo Comparator|Placebo in add on to standard care|Placebo made by paraffin oil (not absorbed by the gastrointestinal tract) as an adjunct to non-neuroleptic, standard therapy in individuals with 22q11DS and UHR criteria for psychosis
3327422|NCT02070224|Other|Knee osteoarthritis|
3327423|NCT02070250|Experimental|From Cancer to Health (C2H-D)|Individuals participating in the From Cancer to Health (C2H-D) Stress Management Psychological Intervention
3327424|NCT02070289|Experimental|Group 1: Cohort 1|
3231482|NCT01202084|Experimental|Formoterol/Fluticasone Eurofarma|formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks
3231483|NCT01202084|Active Comparator|Foraseq®|formoterol + budedonide (12/400 mcg) twice a day per 12 weeks
3231484|NCT01202084|Active Comparator|Fluticasone|fluticasone (500 mcg) twice a day per 12 weeks
3231485|NCT01202097|Experimental|Salmeterol/Fluticasone|
3231486|NCT01202097|Active Comparator|Seretide|
3327425|NCT02070289|Experimental|Group 1: Cohort 2|
3327426|NCT02070289|Experimental|Group 1: Cohort 3|
3231487|NCT01202136||Pancreatic cysts|patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts
3231488|NCT01202149|Active Comparator|Elidel Right Side, Hylatopic Plus Left Side|Elidel applied topically on Right Side of body twice a day and Hylatopic plus emollient foam applied topically on Left Side of body three times a day
3231489|NCT01202149|Active Comparator|Elidel Left Side Hylatopic Plus Right Side|Elidel applied topically on Left Side of body twice a day and Hylatopic plus emollient foam applied topically on Right Side of body three times a day
3231490|NCT01202201||Study Cohort|Subjects hospitalized with acute gastroenteritis or rotavirus gastroenteritis
3231491|NCT01202214|Experimental|Active drug|
3231492|NCT01202214|Placebo Comparator|Placebo|
3327427|NCT02070289|Experimental|Group 2: Cohort 4|
3327428|NCT02070289|Experimental|Group 1 or 2: Cohort 5|
3327429|NCT02070289|Experimental|Group 1 or 2: Cohort 6|
3327430|NCT02070328||Radiation therapy Registry|Cancer patients who have received proton therapy
3327431|NCT02070341|Experimental|Split dose PEG|Patients randomized to the Polyethylene Glycol (PEG) group will be instructed to ingest 2L of bowel preparation the night before their colonoscopy (starting at 7PM), as well as 1.5-2L of carbohydrate-electrolyte rehydration solution. The following day they will be instructed to ingest the remaining 2L of bowel preparation and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy.
3231493|NCT01202240|Experimental|Tasocitinib (CP-690,550) plus Ketoconazole|
3231494|NCT01202266|Experimental|5 mg PF-05161704 or Placebo|
3231495|NCT01202266|Experimental|15 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3231496|NCT01202266|Experimental|50 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3231497|NCT01202266|Experimental|150 mg PF-05161704 or Placebo|Planned dose: may be modified based on emerging PK and safety data.
3231498|NCT01202266|Experimental|xx mg PF-05161704 or Placebo|Planned dose and dosing regimen will be determined based on emerging PK and safety data.
3231499|NCT01202266|Experimental|xxx mg PF-05161704 or Placebo|Dose will be determined based on data from previous 5 arms.
3231500|NCT01202266|Experimental|yy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 6 arms
3231501|NCT01202266|Experimental|yyy mg PF-05161704 or Placebo|Dose will be determined based on data from previous 7 arms.
3327432|NCT02070341|Experimental|Split dose Picosalax|Patients randomized to the Picosalax (P/MC) group will be instructed to mix one sachet in 150mL of water and ingest the entire mixture at 7PM the night before their colonoscopy. In addition, they will be instructed to ingest 1.5-2L of carbohydrate-electrolyte rehydration solution after they consume the P/MC sachet. The following day they will mix the second sachet in 150mL of water and must finish ingesting the entire preparation at least 4 hours prior to the scheduled colonoscopy. They will also be instructed to drink additional carbohydrate-electrolyte rehydration solution after they ingest the P/MC sachet.
3327433|NCT02070354||Group 1|New clinic visit in GI Nutrition (prior to bariatric surgery).
3327434|NCT02070354||Group 2|1 month prior to bariatric surgery
3327435|NCT02070354||Group 3|6 months after bariatric surgery
3327436|NCT02070354||Group 4|12 months after bariatric surgery
3327437|NCT02070354||Group 5|24 months after bariatric surgery
3327438|NCT02070354||Group 6|≥ 36 months after bariatric surgery
3327439|NCT02070367|Experimental|Somatosensory rehabilitation|Weekly sessions with a certified (RSDC) somatosensory therapist using distal vibro-tactile counter-stimulation to anatomically related territories of the area of allodynia. Participants will also be provided with a structured home exercise program.
3327440|NCT02070367|Active Comparator|Usual treatment|Treatment as usual for condition Physiotherapy sessions
3231502|NCT01202292|Experimental|Lifestyle counseling|
3327441|NCT02070393|Experimental|Radiation Treatment using Protons|14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
3231503|NCT01202305||HIV negative|
3327442|NCT02070406|Experimental|Treatment (gene-modified T-cells, vaccine therapy, ipilimumab)|"CONDITIONING CHEMOTHERAPY REGIMEN: Patients receive cyclophosphamide IV on days -5 and -4 and fludarabine phosphate IV over 30 minutes daily on days -4 to -1.~NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV on day 0.~IPILIMUMAB ADMINISTRATION: Patients receive ipilimumab IV over 90 minutes before the NY-ESO-1 TCR PBMC infusion on day 0 or after the infusion on day 1. Treatment repeats every 3 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity.~NY-ESO-1(157-165) PEPTIDE PULSED DC ADMINISTRATION: Patients receive NY-ESO-1(157-165) peptide pulsed DC vaccine ID on days 1, 14, and 30.~LOW DOSE IL-2 ADMINISTRATION: Patients receive aldesleukin (IL-2) SC BID on days 1-14."
3231504|NCT01202305||HIV positive|
3231505|NCT01202331|No Intervention|J|Stop Annual Treatment
3327443|NCT02070419|Active Comparator|Arm I (TACE)|Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
3327444|NCT02070419|Experimental|Arm II (TACE+SBRT)|Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
3327445|NCT02070432|Experimental|LUZ11 PDT|"Study consists of two phases, in each participant:~Dose-finding phase with sequential periods in which single-ascending doses of LUZ11 will be titrated up to a dose that shows to be effective following photoirradiation of small spots of tumor surface.~Final PDT session with the previously identified individual effective dose."
3327446|NCT02070445||Patients undergoing CABG|Patients will have no ventilation during CABG. There will be non-invasive assessments of the lung using ultrasound at different times during the perioperative period.The first assessment will be conducted before anesthesia induction (i.e. patients will be awake). A second assessment will be conducted after anesthesiology induction, but before the beginning of surgery. A third assessment will be conducted at the end of the surgery in the operating room. And two subsequent assessments will be conducted in ICU before and after extubation.
3327447|NCT02070458|Experimental|Treatment (ixazomib, MEC)|Patients receive ixazomib PO on days 1, 4, 8, and 11; they receive mitoxantrone hydrochloride IV, etoposide IV over 1 hour; the receive intermediate-dose cytarabine IV over 6 hours on days 1-6.
3327448|NCT02070471|Experimental|LC28-0126 Dose A|LC28-0126 Dose A
3327449|NCT02070471|Experimental|LC28-0126 Dose B|LC28-0126 Dose B
3327450|NCT02070471|Experimental|LC28-0126 Dose C|LC28-0126 Dose C
3327451|NCT02070471|Placebo Comparator|Placebo|Placebo
3327452|NCT02070497|Experimental|case management_new|The patients with new-diagnosed lung cancer and accepting case management
3327453|NCT02070497|Experimental|case management_old|the patients with non-new-diagnosed lung cancer and with accepting case management
3327454|NCT02070497|No Intervention|control group|The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management
3327455|NCT02070510|Experimental|Victim and perpetrator compounds|Subjects receive two different victim compounds (lisinopril and warfarin) and two different perpetrator compounds (placebo semaglutide with carrier and oral semaglutide). Each dosing occasion is separated by a 7-day wash-out period.
3327456|NCT02070523|Experimental|PLD-contained VDCLD regimen|PLD 36 mg/m2 ivdrip over 60 minutes( d1、15),VCR 1.4mg/m iv(d1，8，15，22), CTX 800 mg/m2 ivdrip( d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip (d1～28).
3327457|NCT02070523|Active Comparator|DNR-contained VDCLD regimen|DNR 45 mg/m2 ivdrip over 60 minutes(d1～3),VCR 1.4mg/m2 iv(d1，d8，d15，d22), CTX 800 mg/m2 ivdrip(d1), L-asp 6000u/m2 ivdrip(d19～28),Dex10mg ivdrip(d1～28).
3231506|NCT01202331|No Intervention|K|Stop Biannual Treatment
3327458|NCT02070536||ARDS (Acute Respiratory Distress Syndrome)|
3327459|NCT02070549|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3327460|NCT02070562||Community Group|Chinese lactating mothers from community maternal & child healthcare centre
3327461|NCT02070562||VIP Group|Chinese lactating mothers from VIP clinics (maternal care center)
3327462|NCT02070575||Pts with prostate cancer|This study is planned to determine the kallikrein panel of 200 patients presenting with biochemical recurrence (PSA ≥ 0.05ng/ml) after radical prostatectomy prior to any additional therapy or minimum post 1 year additional therapy.
3327463|NCT02070614||rs2242480 wild-type homozygote|*1/*1 Grouped by rs2242480 polymorphism genotyping
3327464|NCT02070614||rs2242480 mutant heterozygote|*1/*1G Grouped by rs2242480 polymorphism genotyping
3327465|NCT02070614||rs2242480 mutant homozygote|*1G/*1G Grouped by rs2242480 polymorphism genotyping
3231507|NCT01202331|Other|L|Continue Annual Treatment
3231508|NCT01202331|Other|M|Continue Biannual Treatment
3327466|NCT02070627|Experimental|NIRF-C and IOC|Each enrolled subject will undergo injection with indocyanine green (ICG), intraoperative near infrared fluorescence cholangiography (NIRF-C) and standard of care intraoperative cholangiography.
3231509|NCT01202331|Experimental|N|Targeted Treatment by Age
3231510|NCT01202331|Experimental|O|Targeted Treatment by Clinical Exam
3327467|NCT02070653|Active Comparator|Ticagrelor|Ticagrelor 90 mg tablets twice daily for 12 months.
3231511|NCT01202344|Other|Restenosis|Patients who have restinosis immediately following angioplasty.
3231512|NCT01202344|Other|No Restenosis|Patients who do not have restinosis immediately following angioplasty.
3231513|NCT01202357|Experimental|Case Management (1 year)|
3231514|NCT01202357|No Intervention|Standard Care (1 year)|
3231515|NCT01202370|Experimental|AR-67|Phase 1 study
3231516|NCT01202383|Active Comparator|NADCC tablets|
3231517|NCT01202383|Placebo Comparator|Placebo tablets|
3231518|NCT01202396||ulcerative colitis patients with a pouch|"ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis~comparing patients with versus those without pouchitis~no intervention"
3231519|NCT01202422|Experimental|Pregabalin controlled release, 165 mg|
3231520|NCT01202422|Experimental|Pregabalin controlled release, 330 mg|
3231521|NCT01202422|Other|Pregabalin immediate release, 150 mg|Reference Treatment
3327468|NCT02070653|Placebo Comparator|Placebo|Ticagrelor-placebo tablets twice daily for 12 months.
3327469|NCT02070666|Experimental|Protective ventilation arm|"Low tidal volumes (from 4 to 6 milliliters(mL)/kilogram (kg) of predicted body weight (PBW)~Plateau pressure less than 25 centimeter of water (cmH2O)~Minimum PEEP of 5 cmH2O."
3327470|NCT02070666|Active Comparator|Control group|"Traditional-sized tidal volumes (from 8 to 10 mL/kg PBW)~Plateau pressure less than 25 cmH2O~Minimum PEEP of 5 cmH2O."
3327471|NCT02070679|Placebo Comparator|Placebo|
3327472|NCT02070679|Active Comparator|Vit-E|600 IU on 12 hours before angiography and 400 IU on 2 hours before angiography
3327473|NCT02070705|Experimental|Arm I (High-risk for familial/hereditary pancreatic cancer)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) yearly for a minimum of 3 scans.
3231522|NCT01202435|Experimental|Pregabalin controlled release, 82.5 mg|
3231523|NCT01202435|Other|Pregabalin immediate release, 25 mg|Reference Treatment
3327474|NCT02070705|Experimental|Arm II (IPMN)|Patients undergo DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) prior to surgery for resection of IPMN.
3327475|NCT02070705|Experimental|Arm III (Pancreatic cancer)|Patients who undergo chemotherapy prior to resection will have 2 DCE MRI scans; one study scan prior to undergoing neoadjuvant therapy, as well as one study scan following neoadjuvant therapy as part of their pre-operative work up in addition to the standard imaging studies. For patients that do not require chemotherapy treatment prior to resection they will have just one DCE MRI scan prior to surgical resection
3231524|NCT01202448|Active Comparator|DLBCL with risk factor|Patients have any of risk factors for secondary CNS involvement
3231525|NCT01202474|Experimental|insulin glulisine and insulin glargine|insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)
3327476|NCT02070705|Active Comparator|Arm IV (Healthy volunteers)|Patients undergo a single DCE MRI (Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Ferumoxytol) examination.
3327477|NCT02070718|Placebo Comparator|Placebo|Cornstarch, National Formulary
3327478|NCT02070718|Experimental|Standard Dose Kappa Agonist|Pentazocine/Naloxone 50/0.5 mg
3327479|NCT02070718|Experimental|Half Dose Kappa Agonist|Pentazocine/Naloxone 25/0.25 mg
3327480|NCT02070731|No Intervention|unprotected TAVI|standard unprotected Transcatheter Aortic Valve Implantation
3327481|NCT02070731|Experimental|TAVI with the TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
3327482|NCT02070770|Experimental|Very low calorie diet|
3327483|NCT02070770|Active Comparator|Standard weight loss diet|
3327484|NCT02070783|Experimental|ARA290|11-amino acid, linear peptide ARA290; intravenous injection with 2 mg ARA290 (single dosage).
3327485|NCT02070783|Placebo Comparator|Placebo|saline (NaCl 0.9%)
3327486|NCT02070796|Experimental|Treatment A - B|Single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours.
3327487|NCT02070796|Active Comparator|Treatment B - A|Single application of the reference transdermal patch (Treatment B, Rotigotine PR2.1.1) for 24 hours, followed by a Wash-Out Period of 7 days and a single application of the test transdermal patch (Treatment A, Rotigotine PR2.2.1) for 24 hours.
3327488|NCT02070809|Experimental|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
3327489|NCT02070809|Active Comparator|split-thickness skin graft method|This method is traditional split-thickness skin graft
3327490|NCT02070822||TACE patients, for HCC|unresectable HCC patients
3327491|NCT02070835|Experimental|ReCell®|ReCell® with skin graft
3327492|NCT02070835|Active Comparator|skin graft|split-thickness skin graft as control group
3327493|NCT02070848||Concentric vs eccentric|One arm study in which each subject will act as his own control.
3327494|NCT02070861|Experimental|Comparing cardiac output changes|"Explore the relationship between changes in cardiac output measured with eosophagal Doppler, the volume-clamp-method and exhaled CO2 during ventricular pacing and passive leg raise.~Measurements with the volume-clamp-method were aborted due to technological difficulties."
3231526|NCT01202487|Experimental|Pre-treatment with LET|Pre-treatment with Lidocaine Epinephrine Tetracaine solution at least 45 minutes prior to laceration repair with tissue adhesive
3231527|NCT01202487|Placebo Comparator|Pre-treatment with Placebo|Pre-treatment with Placebo solution at least 45 minutes prior to laceration repair with tissue adhesive
3327495|NCT02070874|Experimental|telehealth enhanced pain management|video-case conferences for providers PainTracker for patients
3327496|NCT02070874|No Intervention|usual care|usual care
3327497|NCT02070887||Entacapone|
3327498|NCT02070887||No Entacapone|
3231528|NCT01202500|Other|12 months|
3231529|NCT01202500|Experimental|3 months|
3231530|NCT01202513|Experimental|Bimatoprost application|
3231531|NCT01202526||RYGB patients with type 2 diabetes|Morbid obese patients with type 2 diabetes undergoing gastric bypass surgery
3327499|NCT02070900|No Intervention|Standard of Care|Sites implementing Option B+ for pregnant and lactating women according to the standard of care prescribed by the Ministry of health and Child Care national guidelines
3327500|NCT02070900|Experimental|POC Plus|Sites implementing Option B+ according to the standard of care prescribed by the Ministry of Health and Child Care, as well as programmatic mentoring and POC CD4 machines
3327501|NCT02070926||Perform coronary CT angiography|
3327502|NCT02070926||Do not perform coronary CT angiography|
3327503|NCT02070939|Experimental|SAD cohorts 1-7 Experimental Arm|
3327504|NCT02070939|Placebo Comparator|SAD Cohorts 1-7 Placebo Arm|
3327505|NCT02070939|Experimental|MAD cohorts 2-6 Experimental Arm|
3327506|NCT02070939|Placebo Comparator|MAD cohorts 2-6 Placebo Arm|
3327507|NCT02070939|Experimental|Japanese MAD cohort 7 Experimental arm|
3327508|NCT02070939|Placebo Comparator|Japanese MAD cohort 7 Placebo Arm|
3327509|NCT02070952|Experimental|CyberKnife|CyberKnife Stereotactic Ablative Body Radiation Therapy
3327510|NCT02071004|Other|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
3327511|NCT02071004|Experimental|DS-1040b|IV of 6 mg given once over 30 minutes
3231532|NCT01202526||RYGB patients without type 2 diabetes|Morbid obese patients with normal glucose tolerance undergoing gastric bypass surgery
3231533|NCT01202552|Experimental|group 1|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
3327512|NCT02071030|Other|CBCT|Cone Beam CT
3327513|NCT02071030|Other|Panoramic radiograph|
3231534|NCT01202552|Experimental|group 2|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site
3231535|NCT01202552|Experimental|group 3|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
3327514|NCT02071043|Experimental|XELOX|"XELOX: Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
3327515|NCT02071056||history of visceral cancer|
3231536|NCT01202604||Outpatients with bipolar disorder I or II (as per DSM-IV)|The percentage of patients who experience a relapse episode during the first 9 months after a mood event (manic or depressive).
3231537|NCT01202617||Schizophrenic outpatients between 18 & 70 years of age|
3231538|NCT01202630|Experimental|Probiotic|BIO-K+ CL1285
3327516|NCT02071069|Experimental|maintenance therapy|"Initially, all subjects received 8 cycles of Cetuximab (400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks)plus FOLFIRI (irinotecan 180 mg/m2 IV on day 1 , leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks) .~After 8 cycles or severe toxicity, patients received maintenance therapy comprising Cetuximab (250mg/m2 every week or 500mg/m2 every 2 weeks) and either irinotecan( 180 mg/m2 IV every 2 weeks) or fluorouracil arm( leucovorin 400mg/m2 on day 1 , fluorouracil 400mg/m2 on day 1 and fluorouracil 2400mg/m2 civ46h every 2 weeks ). In cases of unacceptable toxicity, only the related medication was stopped"
3327517|NCT02071121|Placebo Comparator|Placebo|Fasted participants will receive a single oral dose of placebo to BIIB061.
3327518|NCT02071121|Experimental|BIIB061 3 mg|Fasted participants will receive a single oral dose of BIIB061 3 mg.
3327519|NCT02071121|Experimental|BIIB061 10 mg|Fasted participants will receive a single oral dose of BIIB061 10 mg followed by a tracer amount of 14C-BIIB061 (at ≤ 500 nCi/participant; approximately 4 μg of BIIB061), administered by manual slow intravenous push injection at 4 hours postdose.
3327520|NCT02071121|Experimental|BIIB061 30 mg|Fasted participants will receive a single oral dose of BIIB061 30 mg. Following a washout period, participants will receive the same dose of BIIB061 after a high-fat, high-calorie meal (fed state).
3327521|NCT02071121|Experimental|BIIB061 60 mg|Fasted participants will receive a single oral dose of BIIB061 60 mg.
3327522|NCT02071121|Experimental|BIIB061 100 mg|Fasted participants will receive a single oral dose of BIIB061 100 mg.
3327523|NCT02071147|Other|Standard clinical intervention|Patients reviewed at 6 weeks (+/- 1 week) as is our normal practice and recalled for a further evaluation if deemed appropriate. Patients will be instructed to visit their optometrist once their eye has fully recovered from the operation for provision of glasses.
3327524|NCT02071147|Other|No Clinical Follow up|No routine follow-up appointment is made. Patients will be instructed to visit their optometrist between 6-8 weeks post-operative for review of the patient's glasses.
3327525|NCT02071160|No Intervention|Healthy Control|A group of healthy control without any history suggestive of perinatal asphyxia or other diseases, are enrolled to compare different laboratory measurements
3327526|NCT02071160|No Intervention|Hypothermia Group|HIE infants who will not receive melatonin and only receive routine cooling protocol.
3327527|NCT02071160|Experimental|Melatonin/ hypothermia group|HIE infants who will receive melatonin in addition to the routine cooling protocol
3327528|NCT02071186|Experimental|Virtual Reality training|Subjects will be asked to walk on a treadmill while negotiating virtual obstacles. The VR system includes a camera based motion capture and a computer generated simulation. The camera is used to capture the movement of the participant's feet. These images are then transferred to the computer simulation and projected to the patient on a screen. The speed, orientation, size, frequency of appearance and shape of the targets are manipulated to increase task difficulty. The Virtual environment imposes a cognitive load requiring attention and response selection as well as processing of rich visual stimuli involving several perceptual processes. The system provides visual and auditory feedback of task performance to enhance motor learning.
3327529|NCT02071186|Experimental|Computerized Cognitive Remediation|"The AttenGo program will be used for neuro-cognitive remediation aimed at enhancing attention, concentration, working memory, and executive function. The program has shown to be effective in improving attention and executive function in children with ADHD. The training is composed of cognitive exercises that challenge subjects with problem solving, information processing, response inhibition and dividing attention. The users receive immediate feedback from the system when losing focus. The program is adaptive and progresses according to the subjects abilities."
3327530|NCT02071186|Active Comparator|Control group|Subjects in this group will be assessed based on the study protocol but will receive no treatment other than their standard of care which could include pharmacological or/ and non-pharmacological treatment.
3327531|NCT02071199|Experimental|Low dose 0.3X ACCS|20 microliters of 0.3X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3327532|NCT02071199|Experimental|High dose 1X ACCS|20 microliters of 1X ACCS per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3327533|NCT02071199|Placebo Comparator|Normal saline|20 microliters of saline placebo per tooth is applied directly excluding third molars by dental professional daily Monday through Friday for two weeks
3327534|NCT02071212|Active Comparator|Clopidogrel|Loading dose 600 mg .Mainatinance dose 75 mg QD
3327535|NCT02071212|Experimental|Ticagrelor|Loading dose 180 mg . Maintenance 90 mg BID
3231539|NCT01202630|Placebo Comparator|Placebo|Placebo
3327536|NCT02071238|Experimental|Pamphlet|Patient group that will receive a written pamphlet outlining the risks of surgery as discussed in consultation.
3327537|NCT02071238|No Intervention|No pamphlet, individual|Patient group that will not receive a written pamphlet outlining the risks of surgery as discussed in consultation.
3327538|NCT02071238|Experimental|Group Consultation|Patient group that will receive informed consent discussion in a group-format.
3327539|NCT02071251|Experimental|Prospective intervention|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
3231540|NCT01202669||Epilepsy patients, EMU stay|
3231541|NCT01202695|Experimental|AVP-21D9|
3231542|NCT01202695|Placebo Comparator|Placebo|
3231543|NCT01202734|Experimental|001|Methylphenidate HCl Period 1: One tablet oral 36 mg once daily single-dose on Day 1 Period 2: Three tablets oral 18 mg once daily single-dose on Day 1 Period 3: Two tablets oral 36 mg once daily single-dose on Day 1. (Each treatment period will be separated by 3-7 days)
3327540|NCT02071264|Other|HIV/STI intervention|This study implements a socio-behavioral intervention in Metro Manila, the Philippines, using a community-based participatory approach with 1-2 psychosocial and health education training workshops for the establishment managers and their workers, including street sex workers, focusing on HIV/AIDS risk reduction information, condom use, and condom negotiation skill-building. Participants participate in dream-building activities to explore personal goals and goals for their organization of peers. The interventions are directed at organizational behavior change and social influence modeling through training peers and managers. The participants receive information on STIs along with standard care, held on a day convenient to the participants and at a neutral location.
3327541|NCT02071277|Experimental|Pressure targeted modes|
3327542|NCT02071303|Active Comparator|Tramadol|Women will receive Tramadol 100mg 1 hour before the procedure.
3327543|NCT02071303|Active Comparator|Celecoxib|Women will receive Celecoxib 200mg 1 hour before the procedure.
3327544|NCT02071303|Placebo Comparator|Placebo|Women will receive a placebo 1 hour before the procedure.
3327545|NCT02071316|Active Comparator|Treatment group, hexacapron , esomeprazole|Treatment group - receive I.V. esomeprazole 80 mg and 8mg/h continuously with concurrent hexacapron I.V. every 6 hours until 72 hours and then continue oral treatment 6 g /day for 7 days.
3327546|NCT02071316|Placebo Comparator|Standard of care group, esomeprazole|* Standard of care group - receive I.V. esomeprazole 80 mg once then 8mg/h continuously
3327547|NCT02071329|Experimental|Vaccine FP-01.1|Vaccine FP-01.1
3231544|NCT01202786||miRview mets Disclosed|Patients of group 1 will be submitted to the standard conventional work-up (see below) as well as miRview™ mets assay. Their physician will treat the patient based upon both results
3231545|NCT01202786||Control|Patients of group 2 will be submitted to the standard conventional work-up. miRview™ mets assay will be performed but will remain blinded for both the patient and referring physician. Treatment will be decided based on standard work-up results
3231546|NCT01202799|Experimental|Treatment A|2% w/w diclofenac sodium topical gel
3327548|NCT02071329|Placebo Comparator|Placebo|Placebo
3231547|NCT01202799|Active Comparator|Treatment B|
3327549|NCT02071342||acute coronary syndrome|patients with acute myocardial infarction who are undergoing coronary angioplasty. MACE at 30 days and 1 year will be assessed . The acute recoil after implantation of bioabsorbable stents will also be assessed
3327550|NCT02071355|Experimental|Group 1|Participants will receive 100 mg TMC435 once daily for 7 days.
3327551|NCT02071355|Experimental|Group 2|Participants will receive 150 mg TMC435 once daily for 7 days.
3327552|NCT02071368|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 2 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3327553|NCT02071368|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]) formulation 1, under fed conditions.
3231548|NCT01202799|Active Comparator|Treatment C|
3231549|NCT01202812|Experimental|LOVAZA|
3231550|NCT01202812|Placebo Comparator|Placebo capsule|
3231551|NCT01202825|Experimental|001|
3231552|NCT01202825|Placebo Comparator|008|
3231553|NCT01202825|Placebo Comparator|002|
3231554|NCT01202825|Experimental|009|
3231555|NCT01202825|Experimental|003|
3231556|NCT01202825|Placebo Comparator|004|
3231557|NCT01202825|Experimental|005|
3231558|NCT01202825|Experimental|010|
3327554|NCT02071368|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC (2 x [150 mg/500 mg]), formulation 2, under fed conditions.
3327555|NCT02071381|Experimental|A|only DW330SR 45mg
3327556|NCT02071381|Experimental|B|only DW1030 75mg
3327557|NCT02071381|Experimental|C|DW330SR 45mg and DW1030 75mg
3327558|NCT02071394|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
3327559|NCT02071394|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
3327560|NCT02071407|Placebo Comparator|N1(traditional treatment group)|Patients in group N1 are treated with basic therapeutic measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
3327561|NCT02071407|Experimental|N2(midazolam group)|Patients in group N2 was treated with intravenous infusion of midazolam on the basis of basic treatment measures which include reducing intracranial pressure with mannitol, hemostasis, acid inhibition, anti-infection, nutrition support and control of blood glucose, blood pressure and body temprature.
3327562|NCT02071433|Experimental|Saphenous nerve blockade|Experimental treatment 15 mL of levobupivacaine 0.5%
3327563|NCT02071433|Active Comparator|Femoral nerve blockade|Standard treatment 15 mL of levobupivacaine 0.5%
3231559|NCT01202825|Placebo Comparator|006|
3231560|NCT01202825|Experimental|007|
3327564|NCT02071459|Experimental|L-Threo DOPS|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with L-Threo DOPS
3327565|NCT02071459|Placebo Comparator|placebo|patients with Multiple System Atrophy (MSA) after 12 weeks to continued therapy with placebo
3231561|NCT01202838||Composite Implant|Subject receiving composite implant
3231562|NCT01202851|Experimental|Relaxation Group 1|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3327566|NCT02071472|Experimental|DP medication reconciliation|medication reconciliation by a pharmacist using an electronic pharmaceutical record associated to the anesthesiologist consultation for planned surgery patients.
3327567|NCT02071472|No Intervention|control|conventional anesthesiologist consultation for planned surgery patients
3327568|NCT02071485||No treatment|Subjects in this study will receive no treatment and rather will only be trained in using the motor imagination-based BCI system
3327569|NCT02071498|Experimental|Pillbox app named ALICE|pillbox app for elderly patients taking multiple medications. App was used during three months
3327570|NCT02071498|Active Comparator|oral and written information|oral and written information regarding the main risks related to their medications and the most common errors of patients
3327571|NCT02071511|Active Comparator|control group|Ablation of ventricular arrhythmias
3327572|NCT02071511|Sham Comparator|intervention group|Ablation of ventricular arrhythmias + renal denervation
3327573|NCT02071524|Active Comparator|Cristalloid|group cristalloid (ringer lactate)
3327574|NCT02071524|Active Comparator|colloids|colloid: cristalloid in according to cardiac output
3327575|NCT02071537|Experimental|Chloroquine with Carboplatin/Gemcitabine|Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
3327576|NCT02071550||zero PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
3327577|NCT02071550||10 CM H2O PEEP|Patients undergoing laparoscopic cholecystectomy and monitorized with FORESIGHT,INVOS monitor
3327578|NCT02071563|Active Comparator|CSB14|Isocaloric amount and cost-effectiveness of CSB14 (with whey protein concentrate and enhanced micronutrient profile), prepared with fortified vegetable oil (FVO).
3327579|NCT02071563|Active Comparator|RUSF1|Isocaloric amount and cost-effectiveness of Ready-to Use Supplementary Food 1(RUSF1), USAID's Lipid-Based Nutrient Supplement (LNS) product
3327580|NCT02071563|Active Comparator|SC+|Isocaloric amount and cost-effectiveness of Supercereal Plus (SC+), the FBF used by WFP, which has an enhanced nutrient profile, dairy ingredient (non-fat dry milk), and oil already embedded into the flour
3327581|NCT02071563|No Intervention|CSB+|Isocaloric amount and cost-effectiveness of Supercereal/CSB+ prepared with FVO.
3327582|NCT02071576|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes
3327583|NCT02071589|Experimental|Nifedipine oral solution|Nifedipine 5 mg/mL oral solution, 6 mL (30 mg of Nifedipine) at single dose
3327584|NCT02071589|Active Comparator|Nifedipine soft gelatine capsules|Nifedipine soft gelatine capsules x3 (total 30 mg Nifedipine) at a single dose
3327585|NCT02071602|Placebo Comparator|Placebo|Placebo infused for up to 72 hours IV
3327586|NCT02071602|Active Comparator|CD-NP 5 ng/kg/min|CD-NP 5 ng/kg/min infused for up to 72 hours IV
3327587|NCT02071602|Placebo Comparator|CD-NP 10 ng/kg/min|CD-NP 10 ng/kg/min infused for up to 72 hours IV
3327588|NCT02071615|Experimental|Methylphenidate and placebo|Placebo or Methylphenidate 20 mg tablet given once by mouth
3327589|NCT02071615|Experimental|modafinil and placebo|placebo or modafinil 200mg tablet given once by mouth
3327590|NCT02071615|Experimental|caffein and placebo|placebo or caffein 200mg tablet given once by mouth
3327591|NCT02071641|Experimental|Sunitinib|Patients will be treated in repeated 6-week cycles with 50 mg sunitinib orally daily for 4 weeks followed by 2 weeks off.
3327592|NCT02071654|Experimental|Venus P-valve transcatheter implantation|Single arm of percutaneous implantation of Venus-P valve for treating RVOT stenosis
3327593|NCT02071667||Subjects who require sinus surgery|
3327594|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|123I-mIBG administration followed by nuclear imaging pre-ablation and post-ablation
3327595|NCT02071719||Sunitinib|
3327596|NCT02071719||Sorafenib|
3327597|NCT02071719||Everolimus|
3327598|NCT02071719||Pazopanib|
3327599|NCT02071719||Axitinib|
3327600|NCT02071732|Active Comparator|Real rTMS|Real rTMS is real continuous theta burst stimulation.
3327601|NCT02071732|Sham Comparator|Sham rTMS|Sham rTMS is sham continuous theta burst stimulation.
3327602|NCT02071745||Navigation|
3327603|NCT02071758|Experimental|20 mcg LEISH-F3 + 5 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and low dose of SLA-SE adjuvant.
3327604|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of GLA-SE adjuvant.
3327605|NCT02071758|Experimental|5 mcg LEISH-F3 + 10 mcg GLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + GLA-SE at Days 0, 28, and 56. Low dose of antigen and high dose of GLA-SE adjuvant.
3327606|NCT02071758|Experimental|20 mcg LEISH-F3 + 10 mcg SLA-SE Vaccine|Three intramuscular injections of LEISH-F3 + SLA-SE at Days 0, 28, and 56. High dose of antigen and high dose of SLA-SE adjuvant.
3327607|NCT02071797|Active Comparator|Arm A - Blanketroll lll|Cutaneous Cooling Blanket, Blanketroll lll, applied to cool patient to 32C. Standard care
3327608|NCT02071797|Active Comparator|Arm B - RhinoChill|Intra nasal cooling system, RhinoChill, to cool patient to 32C - Standard care
3231563|NCT01202851|Experimental|Relaxation Group 2|Simple stretching exercises, specific breathing skills, and guided relaxation for 3 sessions, 3 times a week for 6 weeks. Each session should last about 60 minutes. Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3231564|NCT01202851|Other|Waitlist Control Group (WLC)|Participants in this group given the option to take part in one of the two forms of relaxation (off study) after they finish their last questionnaire packet. 4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
3231565|NCT01202864||Cases|3000 Cases
3231566|NCT01202864||Controls|3000 Controls
3231567|NCT01202890|Experimental|Arm 1|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
3231568|NCT01202916||Congenital Heart Disease|
3327609|NCT02071836|Experimental|Right Turns web application|Right Turns web application
3327610|NCT02071836|Active Comparator|Treatment as usual|Treatment as usual
3327611|NCT02071862|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
3327612|NCT02071862|Experimental|Pac-CB|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity
3327613|NCT02071862|Experimental|CBE|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity
3327614|NCT02071862|Experimental|CB-Erl|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity
3231569|NCT01202916||Healthy children|
3327615|NCT02071862|Experimental|CBD|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity
3327616|NCT02071862|Experimental|CB-Cabo|CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity
3327617|NCT02071875||Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording
3327618|NCT02071888|Experimental|CB-839|CB-839 is administered as oral capsules three times daily (TID) or twice daily with food (BIDf) in 21-day cycles until disease progression or unacceptable toxicity
3327619|NCT02071888|Experimental|CB-839 and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with dexamethasone until disease progression or unacceptable toxicity
3327620|NCT02071888|Experimental|CB-839, pomalidomide, and low dose dexamethasone|CB-839 is administered as oral capsules twice daily with food (BIDf) in 28 day cycles in combination with pomalidomide and dexamethasone until disease progression or unacceptable toxicity
3327621|NCT02071927|Experimental|CB-839|CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity
3327622|NCT02071927|Experimental|CB-Aza|CB-839 administered as oral capsules twice daily (BID) in combination with azacitidine in 28-day cycles until disease progression or unacceptable toxicity
3327623|NCT02071940|Experimental|PLX3397|Patients will be given PLX3397 1000mg/day as monotherapy. Patients will remain on treatment as long as they are deriving benefit. This is a single cohort study and so there is no comparator arm - all patients receive the same treatment.
3327624|NCT02071953|Experimental|Adhesive without acid pretreatment|Experimental adhesive w/out phosphoric acid in post. rest.
3327625|NCT02071953|Active Comparator|Adhesive with acid pretreatment|Experimental adhesive with phosphoric acid in post. rest.
3327626|NCT02071966|Active Comparator|Ticagrelor|Ticagrelor: oral, 180 mg once for the first dose then 90 mg twice a day
3327627|NCT02071966|Active Comparator|Clopidogrel|Clopidogrel: oral, 300 or 600 mg once for the first dose, 75 mg once a day
3327628|NCT02071979|Experimental|Autologous PRP Gel|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. The application of topical PRP gel may be used in chronic wounds possessing an open, moist wound bed according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical application) data.
3327629|NCT02071979|Experimental|Autologous PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Autologous PRP Injections may be used where chronic wounds possess a raised, hyperproliferative wound margin and/or plaque, according to following treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare Autologous PRP for injections. For data analysis, the data from these patients will be classified as PRP Treatment Group (Direct Injection) data.
3231570|NCT01202929||Type I achalasia|classic achalasia: complete esophageal motor failure
3231571|NCT01202929||Type II achalasia|compression achalasia: simultaneous panesophageal pressurization with aperistalsis
3231572|NCT01202929||Type III achalasia|spastic achalasia with aperistalsis: 100% spasm
3327630|NCT02071979|Experimental|Autologous PRP Gel plus PRP Injections|The method of application for PRP treatment will be decided by the clinician in accordance with the appearance of the wound bed. Some wounds may be suitable for both Autologous PRP Gel plus PRP Injections. Autologous PRP injections into, or to the periphery of, a moist wound bed in which no scarification or raised wound margin is apparent (where autologous PRP Gel can also be used) may further augment wound healing by addressing wound healing in multiple areas, following the treatment schedule: Baseline/Week 0, Week 1, Week 2, Week 3, Week 7, and Week 11. The Arteriocyte Magellan® System (510(k) cleared) will be used to prepare the autologous PRP gel. For data analysis, the data from these patients will be classified as PRP Treatment Group (Topical and Direct) data.
3327631|NCT02071979|No Intervention|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices. For data analysis, the data from these patients will be classified as Control (Standard of Care) Group data
3327632|NCT02072005||Regular cigarette smokers|
3327633|NCT02072018|Active Comparator|H-100|H-100, gel, daily, 6 months
3327634|NCT02072018|Placebo Comparator|Placebo|Placebo gel, daily, three months then switch to H-100 for three months
3327635|NCT02072031|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3327636|NCT02072031|Active Comparator|Sunitinib maleate|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3327637|NCT02072044|Experimental|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3327638|NCT02072057|Experimental|Ruxolitinib|Interventional arm
3327639|NCT02072070|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
3327640|NCT02072070|Placebo Comparator|Placebo|Single intra-articular injection to the damaged knee joint
3327641|NCT02072083|Active Comparator|dexmedetomidine|intranasal 1mcg/kg
3327642|NCT02072083|Active Comparator|ketamine|intranasal 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
3231573|NCT01202942|Experimental|Quest|Participants smoke Quest cigarettes level 1 for 10 days, followed by level 2 for 10 days, and finally by level 3 for 10 days.
3231574|NCT01202942|No Intervention|Preferred brand|Participants smoke their preferred brand of cigarettes for the duration of the study.
3327643|NCT02072109||Bolus feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
3327644|NCT02072109||Continuous feeding|Preterm infants born in Meir Medical Center and being treated in the Neonatal Intensive Care Unit
3327645|NCT02072122||women during fertility treatment|
3231575|NCT01202981||Group 1|Patients who had cataract surgery by the Investigators between July 1, 2007 and June 30, 2008.
3327646|NCT02072135|Experimental|Exparel|Exparel 266mg
3327647|NCT02072148|Experimental|Low Risk Group I|"Group I:~Complete resection (margins: tonsil >1mm, tongue >3mm, pT1-2, pN0-2B),~No LVI, no PNI, <3 positive nodes.~No ECS, No matted or Level >III,"
3327648|NCT02072148|Experimental|Intermediate Risk Group II|"Group II~Complete resection (margins: tonsil <1mm, tongue <1mm, pT1-2, pN0-2B),~+LVI, +PNI, <3 positive nodes. ≤1mm ECS."
3327649|NCT02072148|Experimental|High Risk Group IIIA|"3+ nodes, no ECS > 1mm~Contralateral or supraclavicular nodes"
3327650|NCT02072148|Experimental|High Risk Group IIIB|"Incomplete surgical resection with + surgical margins~≥ 1 mm ECS~Matted nodes"
3327651|NCT02072161|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
3327652|NCT02072161|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
3327653|NCT02072161|Placebo Comparator|Placebo|Orally, once daily in morning
3327654|NCT02072187|Experimental|Active|"The vitamin D formula that will be used is Bio-D Mulsion 1000, produced by Biotics Research Corporation. This formula contains: Vitamin D (cholecalciferol), water and acacia gum and sesame oil.~Participants will be provided with a dose of vitamin D at each visit beginning at the Baseline visit. The weekly dose of vitamin D will be 28 000IU (the equivalent of 4000IU daily) for a period of eight weeks. If baseline or week 4 serum vitamin D levels are measured as >100nmol/L, the dose will be reduced to 14 000IU (the equivalent of 2000IU daily). The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
3327655|NCT02072187|Placebo Comparator|Placebo|"The placebo formula, also produced by Biotics Research Corporation, will contain all of the non-medicinal ingredients but no vitamin D. It will be identical in appearance and taste.~Participants will be provided with a dose of the placebo at each visit beginning at the Baseline visit. The weekly dose will be 28 drops or 14 drops if serum Vitamin D levels are >100nmol/L. The dose will be dispensed, using the bottle dropper, onto a disposable plastic spoon which the participant will insert into their mouth."
3327656|NCT02072213|Experimental|GL2702 GLARS-NF1 , fasted|Tamsulsoin 0.4mg
3327657|NCT02072213|Active Comparator|Omix Ocas® , fasted|Tamsulsoin 0.4mg
3327658|NCT02072213|Experimental|GL2702 GLARS-NF1, after meal|Tamsulsoin 0.4mg
3327659|NCT02072213|Active Comparator|Omix Ocas®, after meal|Tamsulsoin 0.4mg
3327660|NCT02072239|Experimental|Device Applied|All participants will be treated with the Angioshield
3231576|NCT01202981||Group 2|Patients who had cataract surgery by the Investigators between July 1, 2008 and July 1, 2009.
3231577|NCT01203007|Experimental|Tailored diet|Tailored diet according to demonstrated food sensitivity
3327661|NCT02072252|Experimental|App teaching cognitive behavioral skills|"App teaching cognitive behavioral skills. This mobile phone application (app) teaches cognitive behavioral techniques to help participants manage their mood, for example by providing information, interactive tools and tips, and a mood tracker. A coach will support participants as they use the app via phone calls and email contacts."
3231578|NCT01203007|Experimental|Low-antigen content (LAC) diet|Low-antigen content diet
3231579|NCT01203020|Experimental|Allogeneic hematopoietic progenitor cell transplant|Intravenous busulfex 130mg/m2 on days -6 to -3 before transplant
3327662|NCT02072252|No Intervention|Wait-list with referrals|10-week wait-list control condition in which participants will be provided with and encouraged to use mental health referrals to resources in the community. After the 10-week waiting period, control group participants will have the option to receive the mobile phone application and coaching.
3327663|NCT02072265||Port-A implantation and chemotherapy|Patients scheduled for Port-A implantation and subsequent chemotherapy
3327664|NCT02072265||Port-A infection|Patients receiving Port-A removal due to infection
3327665|NCT02072278|Experimental|Vortioxetine 10 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3327666|NCT02072278|Experimental|Vortioxetine 20 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3327667|NCT02072278|Active Comparator|Escitalopram 15 mg|encapsulated tablets; 3 daily doses in each treatment period; orally
3327668|NCT02072278|Placebo Comparator|Placebo|capsules; 3 daily doses in each treatment period; orally
3327669|NCT02072291|Experimental|Nifedipine|Nifedipine 5mg single dose
3327670|NCT02072291|Placebo Comparator|Placebo|
3327671|NCT02072304|Experimental|web-based CBT|Web-based CBT group : The intervention is made up of 8 internet modules based on behavioral activation, cognitive behavioral therapy
3327672|NCT02072304|Active Comparator|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks
3327673|NCT02072317|Experimental|Paclitaxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
3327674|NCT02072317|Active Comparator|taxol|taxol 135 mg/m2, every three weeks for a cycle
3327675|NCT02072330|Active Comparator|TAK-536CCB 20 mg/5 mg ＋Placebo (dual therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide (HCTZ) placebo for 10 weeks
3327676|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 6.25 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo (triple therapy) for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 6.25 mg for the remaining 8 weeks.
3327677|NCT02072330|Experimental|TAK-536CCB 20 mg/5 mg ＋HCTZ 12.5 mg (triple therapy)|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide placebo for the first 2 weeks of the treatment period and TAK-536CCB 20 mg/5 mg and HCTZ 12.5 mg (triple therapy) for the remaining 8 weeks.
3327678|NCT02072330|Active Comparator|Placebo ＋HCTZ 6.25 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
3327679|NCT02072330|Active Comparator|Placebo ＋Hydrochlorothiazide 12.5 mg (HCTZ monotherapy)|TAK-536CCB placebo and Hydrochlorothiazide 12.5 mg (HCTZ monotherapy) for 10 weeks from the start of the treatment period.
3327680|NCT02072343|Experimental|Mainstream capnometer|
3327681|NCT02072343|Experimental|Microstream capnograph|
3231580|NCT01203033||AML patients|newly diagnosed or relapsed AML patients
3231581|NCT01203085||Pediatric patients|All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.
3231582|NCT01203111|Experimental|Intensive insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: + insulin glulisine if HbA1c ≥7% at week 12 (end of treatment period 1)
3231583|NCT01203111|Experimental|insulin regimen|Treatment Period 1: Insulin glargine + metformin + other OGLDs, if any Treatment period 2: no change, if HbA1c <7% at week 12 (end of treatment period 1)
3327682|NCT02072356|Experimental|Treatment (yttrium Y 90 glass microspheres)|Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
3327683|NCT02072369|Experimental|VAEDA Glove|Voice And EMG-Driven Actuated glove used during hand occupational therapy training
3327684|NCT02072369|Active Comparator|No-glove|hand occupational therapy sessions without assistive device
3327685|NCT02072382|Experimental|Metformin|Metformin 850 mg twice a day for eight weeks versus Placebo
3327686|NCT02072395|Experimental|Band/Plication|Treatment -- band/plication
3327687|NCT02072408|Experimental|polypoidal choroidal vasculopathy without polyp|
3327688|NCT02072447|Experimental|Microdose|
3231584|NCT01203124|Placebo Comparator|1|Placebo given once daily on 7 days
3231585|NCT01203124|Experimental|2|Active treatment at Day 1 and Day 7. Placebo on Day 2, 3, 4, 5 and 6
3327689|NCT02072460|Experimental|vestibular signals determination|vestibular signals determination by electromyography and electroencephalography associated to approaches from psychophysics
3327690|NCT02072473||Unsuccessful right-sided AVNRT ablation|Patients with unsuccessful right-sided slow pathway ablation attempt, will be candidates for Coronary sinus / left-sided slow pathway ablation.
3327691|NCT02072486|Experimental|Treatment (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
3327692|NCT02072499|Experimental|KTP Green Light Prostatectomy|Device
3231586|NCT01203124|Experimental|3|Active treatment at Day 1, 4 and 7. Placebo on Day 2, 3, 5 and 6.
3231587|NCT01203124|Experimental|4|Active treatment at Day 1, 3, 5 and 7. Placebo on Day 2, 4 and 6.
3231588|NCT01203124|Experimental|5|Active treatment once daily on 7 days
3231589|NCT01203137||tricuspid regurgitation, severe|To be included in the present study, the following 3 criteria for severe TR should be met based on the preoperative echocardiography: (1) TR jet > 30% of right atrial area, (2) inadequate cusp coaptation, and (3) systolic flow reversal in the hepatic vein.
3327693|NCT02072499|Active Comparator|Open prostatectomy|Surgical procedure
3327694|NCT02072512|Active Comparator|Fulvestrant|Goserelin plus High Dose Fulvestrant
3327695|NCT02072512|Active Comparator|Anastrozole|Goserelin plus Anastrozole
3327696|NCT02072525|Experimental|Mtdap1 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3327697|NCT02072525|Experimental|Mtdap2 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3327698|NCT02072525|Experimental|Mtdap3 Group|Subjects will receive concomitant doses of Menveo and Boostrix.
3327699|NCT02072525|Experimental|Pneum1 Group|Subjects will receive a dose of Pneumovax 23.
3327700|NCT02072525|Experimental|Pneum2 Group|Subjects will receive a dose of Pneumovax 23.
3327701|NCT02072525|Experimental|Pneum 3 Group|Subjects will receive a dose of Pneumovax 23.
3327702|NCT02072525|Experimental|Prev1 Group|Subjects will receive a dose of Prevnar 13.
3231590|NCT01203150|Experimental|Supplement|Participants randomized to the 'supplement' arm will consume a blended drink containing 48g of ionexchange, hydrolyzed vanilla-flavored whey protein (Whey to Go, Solgar Vitamin and Herb, Leonia, NJ; 3g CH2O, < 3g Total Fat). The drink will be given in split doses immediately before and after each training session, which represents a timing schedule that best stimulates muscle anabolism in persons undergoing exercise training.
3231591|NCT01203150|Placebo Comparator|Placebo|As ingestion of the protein supplement is critically influenced by time of administration, participants assigned to the 'placebo' study arm will consume the identical supplement and dose on days during which training is not performed. This strategy will allow the groups to be isocaloric and equal in protein supplementation.
3231592|NCT01203163||PDT with porfimer sodium|
3231593|NCT01203176|Active Comparator|Post-menopausal symptomatic women|
3327703|NCT02072525|Experimental|Prev2 Group|Subjects will receive a dose of Prevnar 13.
3327704|NCT02072525|Experimental|Prev3 Group|Subjects will receive a dose of Prevnar 13.
3327705|NCT02072538||Pre-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
3327706|NCT02072538||Post-discharge stress testing|Stress-testing (e.g. treadmill exercise test, stress-echochardiography)
3327707|NCT02072551||Adult with neonatal diabetes|Adult with neonatal diabetes (before 1 year ) and need for insulin
3327708|NCT02072551||non diabetic adults with a relative with neonatal diabetes|
3327709|NCT02072564||Couples with indication for IVF|Couples with primary or secondary infertility with indication of IVF
3327710|NCT02072577|Experimental|Knowledge|Educational video.
3327711|NCT02072603|Experimental|Intervention Hospitals|HITSystem implementation at hospital and its affiliated laboratory
3327712|NCT02072603|Active Comparator|Control Hospitals|Existing standard of EID care
3327713|NCT02072616|Experimental|Sample for Circulating Tumoral Cells|Sampling of Circulating Tumoral Cells will be done after Pancreatic adenocarcinoma diagnosis
3231594|NCT01203176|Experimental|Post-menopausal asymptomatic women|
3231595|NCT01203202|Placebo Comparator|PED 0|placebo
3327714|NCT02072629|Experimental|Training of VHVs in iCCM|In these villages VHVs will be provided with iCCM training and equipped to support iCCM in their villages
3327715|NCT02072642|Active Comparator|Active light therapy (10,000 lux)|Light therapy: DayVia lamp 10000 lux
3327716|NCT02072642|Placebo Comparator|Placebo light therapy (70 lux)|Placebo light therapy
3231596|NCT01203202|Experimental|PED 1|PED-1 (clomipramine 15mg)
3231597|NCT01203202|Experimental|PED-2|PED-2 (Clomipramine 30mg)
3327717|NCT02072655|No Intervention|without socio-asthetic care|
3327718|NCT02072655|Experimental|with socio-aesthetic cares|
3327719|NCT02072681||Mild and Rapidly Improving Ischemic Stroke|"Patients 18 years or older with mild or rapidly improving acute ischemic stroke defined clinically. .Absence of non-ischemic conditions neuro-imaging (i.e. absence of hemorrhage or a mass on brain imaging that arrived to the hospital within 4.5 hours after the onset of stroke symptoms.~All participants will have two follow up telephone calls: One at approximately 30 days after the stroke and one at approximately 90 days after the stroke to ask questions about how well participant can carry out usual duties after the stroke, how much assistance do he/she needs to perform your daily activities and how good or bad would he/she considers current health to be."
3327720|NCT02072694|Experimental|75 grams of glucose plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 75 grams of glucose plus water solution (meal challenge) and in another time to only water."
3327721|NCT02072694|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 75 grams of glucose plus water solution (meal challenge)."
3327722|NCT02072707|Active Comparator|Epicardial VT ablation|Patients will underwent combined epicardial and endocardial mapping and ablation
3231598|NCT01203215|Experimental|JumpStart|
3231599|NCT01203215|Experimental|Choose to Move|
3231600|NCT01203215|Active Comparator|Wellness|
3231601|NCT01203228|Active Comparator|A|Myeloablative conditioning
3231602|NCT01203228|Experimental|B|Reduced Intensity Conditioning
3231603|NCT01203241|Active Comparator|Conventional ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
3231604|NCT01203241|Active Comparator|Conventional ablation plus left atrial roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
3231605|NCT01203254|Placebo Comparator|Placebo|
3231606|NCT01203254|Active Comparator|Cholestagel|
3231607|NCT01203267|Experimental|paclitaxel plus carboplatin (PCb) Arm|4 cycles of neoadjuvant paclitaxel plus carboplatin
3231608|NCT01203280|Experimental|balance, neck isometric strength and range of motion|
3231609|NCT01203293|Experimental|Cognitive Behavior Therapy|
3231610|NCT01203293|Active Comparator|Treatment as usual|
3231611|NCT01203306|Experimental|Drugs: bevacizumab + octreotide LAR + capecitabine|bevacizumab + octreotide + metronomic capecitabine
3231612|NCT01203332||Alternative Venue Testing (AVT)|Participants recruited for testing through the AVT recruitment method.
3327723|NCT02072707|Active Comparator|Endocardial VT Ablation|Patients will underwent endocardial only VT mapping and ablation
3327724|NCT02072720|No Intervention|on-treatment tumor biopsie|patients will undergo an pre-treatment and on-treatment tumor biopsy, to measure VEGF expression, and identify the time point of induction of VEGF expression.
3327725|NCT02072720|Experimental|bevacizumab|These patients will receive bevacizumab once a week during their chemoradiation, starting at the identified time point of enhanced VEGF expression. These patients will also undergo and pre-treatment tumor biopsy and 1 tumor biopsy 1 week after the start of bevacizumab treatment.
3327726|NCT02072733|Other|geriatric assessment|"The intervention is individual and based on the Comprehensive Geriatric assessment (CGA) : collection of information on comorbidity, polypharmacy, physical, psychological and cognitive functions, nutrition as well as social status and support.~The results of the CGA, the eventual medical changes and recommendations regarding e.g. initiation of nutritional supplementation, home-care referral or referral to e.g. physiotherapist will be forwarded to the general practitioner and to the oncologist in charge of the treatment"
3327727|NCT02072746|Active Comparator|Zinc|zinc sulfate 220 mg daily
3327728|NCT02072746|Placebo Comparator|Placebo|Placebo study for comparison
3327729|NCT02072759|Experimental|Carnitine supplement|Carnitine supplement
3327730|NCT02072759|Placebo Comparator|Placebo|Placebo supplement
3327731|NCT02072759|No Intervention|Healthy control|Healthy control group
3327732|NCT02072772|Experimental|Positively Smoke Free group treatment|"Eight 90 minute group sessions (6-8 HIV-infected smokers per group) led by a pair of trained group leaders: a professional with psychology or social work training and a peer HIV-infected ex-smoker with tobacco treatment training.~All subjects will be offered a 3 month supply of nicotine patches"
3327733|NCT02072772|Active Comparator|Standard care|Brief (<5 minutes) advice to quit Offer of nicotine patches Self-help brochure
3231613|NCT01203332||SSNIT - Index Recruiter|Participants recruited for HIV testing and to bring members of their social and sexual network to the study.
3231614|NCT01203332||SSNIT - Network Member|Participants recruited by someone in their social or sexual network to participate in the study, including HIV testing.
3327734|NCT02072785|Experimental|Vincristine Sulfate Liposome|"Vincristine Sulfate For Injection simulation agent 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection: 1.4mg/m2, (2mg, maximum dose), iv, d1, d8, d15, d22.~Duration between these two agents should be more than 2.5h, and saline should be avoided for flushing before Vincristine Sulfate Liposome For Injection."
3327735|NCT02072785|Active Comparator|Vincristine Sulfate|"Vincristine Sulfate For Injection 1.4mg/m2,(2mg, maximum dose), iv, d1, d8, d15, d22. Vincristine Sulfate Liposome For Injection simulation agent: 1.4mg/m2,(2mg, maximum dose), iv, d1, 8, 15, 22.~Duration between these two agents should be more than 2.5h, and saline should not be used for flushing before Vincristine Sulfate Liposome For Injection simulation agent."
3231615|NCT01203345|Active Comparator|Immune globulin|Lyophilized human immune globulin product
3231616|NCT01203345|Placebo Comparator|Albumin solution|
3231617|NCT01203358|Active Comparator|Surfactant 1|Exosurf Neonatal (Burroughs Wellcome Co.)
3327736|NCT02072798|Active Comparator|preoperative antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
3327737|NCT02072798|Active Comparator|postoperative antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
3327738|NCT02072811|Other|Induction, DAC|"The first stage of treatment.~First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy)."
3327739|NCT02072811|Other|II early induction, CLAG|"Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.~Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day"
3327740|NCT02072811|Other|Consolidation, I HAM cycle|"I induction cycle starts after complete remission (CR).~- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):~If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation~- After I consolidation, patients from Adverse risk group (ELN prognostic system):~If compatible donor is present - immediate qualification for allogeneic HSCT.~- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor"
3327741|NCT02072811|Other|II Consolidation HiDAraC|"Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.~Patients form Very adverse risk receive Maintenance treatment:~Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.~Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification)."
3327742|NCT02072811|Other|Consolidation, III HiDAraC cycle|"Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).~Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol."
3327743|NCT02072850||Myocardial infarction|Patients presenting with acute-ST elevation myocardial infarction referred for emergency invasive management by primary or rescue percutaneous coronary intervention.
3231618|NCT01203358|Active Comparator|Surfactant 2|Survanta (Ross Laboratories)
3231619|NCT01203371|Experimental|Naftopidil|0,25 mg (2 weeks) and 0,50 mg (10 weeks)
3231620|NCT01203371|Active Comparator|Tamsusolin|0,4 mg/day
3231621|NCT01203384|Experimental|CHF5074 1x|oral tablet, multidose
3231622|NCT01203384|Experimental|CHF5074 2x|oral tablet, multidose
3231623|NCT01203384|Experimental|CHF5074 3x|oral tablet, multidose
3231624|NCT01203384|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3231625|NCT01203397|Active Comparator|GROUP 2|
3231626|NCT01203397|Experimental|GROUP 1|
3327744|NCT02072863|Experimental|Oprozomib with Melphalan and Prednisone (OMP)|"Subjects will receive oprozomib administered orally.~The combination of oprozomib, melphalan, and prednisone (OMP) will be administered until progression of disease, unacceptable toxicity, discontinuation of study treatment for reasons other than progression or toxicity, or a maximum of 9 cycles (54 weeks), whichever occurs first."
3327745|NCT02072876||Asymptomatic ICAD on MRI Absent|Those who test negative on QVSFS, Questionnaire to Verify Stroke Free Status, and do not have ICAD on MRI. They are clinically and biologically free of disease.
3327746|NCT02072876||Asymptomatic ICAD Present on MRI|Those who are negative for Stroke Symptoms on QVSFS, Questionnaire to Verify Stroke Free Status, yet have evidence of ICAD on MRI
3327747|NCT02072889|Experimental|Neck Angle Measures|Subjects will position his/her neck in order to measure distance between the internal jugular and the carotid artery to determine if there is a maximal distance to target prior to cannulation
3231627|NCT01203410||Cohort 1|Term infants >2500g birthweight.
3327748|NCT02072902||diabetes free|No intervention
3327749|NCT02072902||Diabetes prevalent|The exposure is diabetes morbidity present at study entery
3327750|NCT02072902||Diabetes incidence|The exposure is diabetes incidence during study follow up
3327751|NCT02072915|Experimental|Suction|Suction will be applied to patients undergoing EUS-FNA
3327752|NCT02072915|No Intervention|Without suction|No suction will be applied to patients undergoing EUS-FNA
3327753|NCT02072954|Experimental|Asenapine Sublingual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for a period of 7 days
3327754|NCT02072954|Active Comparator|Saphris Subligual Tablets|Asenapine Sublingual Tablets, 10 mg. Twice daily for 2 periods of 7 days each.
3327755|NCT02072967||Ribomustin and rituximab|
3327756|NCT02072993|Experimental|AZD1979|Single ascending doses of oral solution AZD1979
3327757|NCT02072993|Placebo Comparator|Placebo|Placebo to match single ascending doses of oral solution AZD1979
3327758|NCT02073006|Active Comparator|Natural Fibre Supplement|2 doses per day for 4 weeks
3327759|NCT02073006|Placebo Comparator|Placebo|2 doses per day for 4 weeks
3327760|NCT02073019|Experimental|Cohort A|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3327761|NCT02073019|Experimental|Cohort B|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3231628|NCT01203436|Experimental|Supplemental Oxygen|Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.
3231629|NCT01203436|Active Comparator|Conventional Oxygen|Conventional oxygenation at a pulse oximetry target of 89% to 94%.
3231630|NCT01203462|Experimental|Bifidobacterium supplemented yogurt|Bifidobacterium supplemented (minimum dosage of 1E+10cfu/serving) vanilla flavored yogurt containing starter cultures: Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
3231631|NCT01203462|Placebo Comparator|Placebo Yogurt|Vanilla flavored yogurt containing starter cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. Bulgaricus
3327762|NCT02073019|Experimental|Cohort C|Each subject will receive a BL-8040 or Placebo on in a randomized double-blind fashion
3327763|NCT02073032||Head -Neck cancer patients, no intervention|
3231632|NCT01203488|Experimental|Experimental|Vitamin A group.
3231633|NCT01203488|Sham Comparator|Control|Sham procedure Control group.
3231634|NCT01203514|Experimental|Trial 1 Experimental|Infants 401-1,000g birthweight
3231635|NCT01203514|Sham Comparator|Trial 1: Sham Comparator|Infants 401-1,000g birthweight
3231636|NCT01203514|Experimental|Trial 2: Experimental|Infants 1,001-1,250g birth weight
3231637|NCT01203514|Sham Comparator|Trial 2: Sham Comparator|Infants 1,001-1,250g birth weight
3231638|NCT01203527||Tamiflu use during first trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
3327764|NCT02073045|Experimental|Supportive care (lymphedema education)|In an educational intervention, participants complete a five question lymphedema survey, designed by the Occupational Therapy staff, as an instrument to assess a patient's knowledge of lymphedema signs/symptoms before surgery. An OT, PT, and/or CLT provide written handouts to participants on the pathophysiology, signs, symptoms, and treatment of lymphedema. Participants repeat the survey at 3 months post-surgery. BUE circumferential measurements are also collected before surgery and at 3 months post-surgery.
3327765|NCT02073071||Preterm/low birth weight infants|Preterm infant formula per standard of care
3231639|NCT01203527||Tamiflu use during second trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the second trimester of their pregnancy.
3327766|NCT02073084|Other|Sequence A|Sequence A
3327767|NCT02073084|Other|Sequence B|Sequence B
3327768|NCT02073084|Other|Sequence C|Sequence C
3327769|NCT02073084|Other|Sequence D|Sequence D
3231640|NCT01203527||Tamiflu use during third trimester|This group will consist of twenty-five pregnant women who are being treated with Oseltamivir for clinical indications during the first trimester of their pregnancy.
3231641|NCT01203527||Tamiflu use in non-pregnant women|This group will consist of twenty-five non-pregnant healthy female volunteers who are being treated with Oseltamivir.
3231642|NCT01203540|Experimental|Naaga in ABAK system|
3231643|NCT01203540|Placebo Comparator|Saline solution|
3231644|NCT01203553||Control Group|The main operation will be performed as planned. For the closure of the abdominal wall, a standard technique will be applied using a running suture of PDS 1 loop. The distance of the sutures to the fascial border is 1cm and the distance between two stitches is not more than 1cm. The total length of suture is at least 4 times the total length of the abdominal incision
3259162|NCT01468090||Disease course|562 patients diagnosed with Crohn's disease (209), ulcerative colitis (326) or indeterminant colitis (27) in the period of 1st of January 2003 to 31st of December 2004 in Copenhagen City and County (an area covering 23% of the Danish population).
3231645|NCT01203553||Treatment Group|The main operation will be performed as planned. Prior to the closure of the abdominal wall a mesh will be implanted in a standardized fashion: A Dynamesh IPOM mesh will be used for the present study. The mesh has a width of 15cm and is tailored to overlap lateral and cranial boarders at least 5cm. The mesh will be placed intra-abdominally and fixed using intra-abdominal stitches using Prolene 2/0 in all four corners. After the initial fixation of the mesh in all quadrants, the boarders of the mesh will be adapted using Prolene 2/0 running sutures. The fixation aims to prevent any intestinal structures to herniate onto the mesh. Afterwards, the abdominal wall is closed as described in the control group.
3327770|NCT02073097|Experimental|rituximab, combination chemotherapy, carfilzomib|"Participants receive (every 21 day cycle):~Rituximab IV over at least 90 minutes on day 2~Carfilzomib IV over 30 minutes on days 1, and 2~Cyclophosphamide IV over 30-60 minutes on day 3~Doxorubicin hydrochloride IV over 3-5 minutes on day 3~Vincristine sulfate IV over 1 minute on day 3~Prednisone PO on days 3-7 any time~Pegfilgrastim day 4~Acyclovir 2x per day from cycle 1, 6 months after completion of cycle 6~Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity."
3327771|NCT02073110||≥ 18 years, solid enhancing renal mass suspected for RCC|
3327772|NCT02073123|Experimental|Indoximod + Ipilimumab|"Indoximod will be administered at 1200mg BID by mouth.~Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.~Indoximod and ipilimumab will be dosed concurrently. Indoximod will be dosed twice daily on all days of each 21 day cycles (segment 1). Ipilimumab will be dosed on the 1st day of each 21 day cycle for the first 4 cycles. Indoximod dosing will continue after all 4 doses of ipilimumab are administered (segment 2, 28-day cycles).~Patients will continue until they experience disease progression or limiting toxicity."
3231646|NCT01203566|Active Comparator|Conventional 3-port laparoscopic appendectomy|Laparoscopic appendectomy will be performed with the standard 3-port technique. The laparoscope is introduced via a 10mm subumbilical port. Dissection will be performed with a 5mm LLQ port and a 5mm RLQ port. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
3231647|NCT01203566|Active Comparator|LESS appendectomy|Two 5 mm ports and a 10mm port will be inserted through a 13mm transumbilical incision. Exploratory laparoscopy was first carried out to locate the appendix and to rule out other pathologies. Retraction of the appendix would be performed with a flexible curved forceps. The mesoappendix will be divided with the ultrasonic dissector (Sonosurg, Olympus surgical, Tokyo, Japan). The appendix will be ligated between two polydioxanone suture loops. The specimen will be delivered within a plastic bag via the subumbilical port. Purulent fluid will be irrigated and suctioned from the subhepatic space, right lower quadrant and the pelvis if present. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O absorbable subcuticular sutures. A pelvic drain (12Fr) will be inserted in cases of abscesses or gangrene.
3231648|NCT01203592|Experimental|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
3231649|NCT01203605||In-patient adult non-cardiac surgery|Consecutive patients admitted to participating centres undergoing elective and non-elective non-cardiac surgery commencing during the seven day study period with a planned overnight stay. All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible.
3327773|NCT02073123|Experimental|Indoximod + Pembrolizumab|"Indoximod will be administered at 1200mg BID by mouth.~Pembrolizumab administered intravenously at 2 mg/kg every three weeks."
3327774|NCT02073123|Experimental|Indoximod + Nivolumab|"Indoximod will be administered at 1200mg BID by mouth.~Nivolumab administered intravenously at 240 mg every 2 weeks."
3327775|NCT02073136|Experimental|Phosphate modified diet|
3231650|NCT01203631|Experimental|NNC 0142-0000-0002|
3231651|NCT01203631|Placebo Comparator|Placebo|
3327776|NCT02073149|Active Comparator|Low-dose iron as NaFeEDTA|Daily point-of-care fortification of (complementary) foods with 3 mg iron as NaFeEDTA.
3327777|NCT02073149|Active Comparator|Conventional dose iron as ferrous salt|Daily point-of-care fortification of (complementary) foods with 12.5 mg iron as encapsulated ferrous fumarate.
3327778|NCT02073149|Placebo Comparator|Placebo|Daily point-of-care fortification of (complementary) foods with placebo.
3327779|NCT02073175|Experimental|Postpartum with crying spells-Full dose|"Healthy women who are within the first 18 months postpartum and have crying spells but do not have major depression. The effect of the dietary supplement in reducing sadness in this group will be assessed.~Intervention: Full dose dietary supplement Motherwell"
3327780|NCT02073175|Experimental|Day-5 postpartum - Full dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the dietary supplement consumption is being done after delivery and during postpartum.~Intervention: Full dose dietary supplement Motherwell"
3231652|NCT01203657|Experimental|Tai Chi|Tai Chi instruction, 2x week in a community senior center setting
3231653|NCT01203657|No Intervention|Wait List Control|This is a wait list control group. There is no active or placebo intervention.
3231654|NCT01203670|Experimental|Soft capsules of Phytalgic|Phytalgic is a food supplement. Its galenic form is soft capsule.
3231655|NCT01203683|Experimental|Active Computer-Based Program|Putatively therapeutic computer program.
3231656|NCT01203683|Placebo Comparator|Placebo computer-based program|Inert computer program.
3231657|NCT01203696|Active Comparator|non-amlodipine|For patient with suboptimal angina control: anti-anginal agent excluding calcium channel blocker
3231658|NCT01203696|Active Comparator|non - amlodipine|For patient with suboptimal BP control: anti-hypertensive agent excluding calcium channel blocker
3231659|NCT01203709|Experimental|Combination treatment|treatment arm
3327781|NCT02073175|Experimental|Day-5 postpartum - Half dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Half dose dietary supplement Motherwell"
3327782|NCT02073175|Experimental|Day-5 postpartum - Quarter dose|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving the proposed dietary supplement consumption, is being done after delivery and during postpartum.~Intervention: Quarter dose dietary supplement Motherwell"
3327783|NCT02073175|Other|Day-5 postpartum - Control|"Healthy women on day-5 postpartum. This group is recruited during pregnancy but the main study day, involving a control supplement consumption, is being done after delivery and during postpartum.~Intervention: Control protein to compare with Motherwell"
3327784|NCT02073188|Experimental|iBGStar (Group A)|Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager Application (App) uploaded on iPhone for all duration of the study (6 months of experimental phase plus 6-months of observational phase). In the first 3 months, the patients in Group A will send their glycemic test values and notes by mail to the physician through Diabetes Manager App every 2 weeks. Afterwards until the visit V2 (six months), the patients in Group A will send their glycemic test values and notes by mail monthly. 9 reports in total.
3231660|NCT01203722|Active Comparator|REGIMEN B|"Pre-BMT :~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy total body irradiation (TBI) administered in a single fraction~Day 0: Allogeneic blood or marrow transplantation (BMT)~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5: Sirolimus loading dose 6 mg PO once~Day 5 thru Day 35: Mycophenolate Mofetil (MMF) 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
3231661|NCT01203722|Active Comparator|REGIMEN C|"Pre-BMT:~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy TBI administered in a single fraction~Day 0: BMT~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD"
3259163|NCT01468103|Experimental|PACS|primary angle closure suspects
3327785|NCT02073188|Active Comparator|Traditional Glucometer (Group B)|Self-Monitoring Blood Glucose will be managed with a traditional glucometer according to usual care for the first 6 months (experimental phase). In the 6 months post-trial follow-up (observational phase), Self-Monitoring Blood Glucose will be managed with iBGStar and iBGStar Diabetes Manager App.
3327786|NCT02073201||High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3327787|NCT02073201||Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3327788|NCT02073201||Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
3327789|NCT02073214|Experimental|Probiotic|"Single dose of probiotic, was administered enterally twice daily with food (in the morning and in the evening). The first dose of probiotic was administered within the first 48 hours after birth. The probiotic administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the probiotic. If the probiotic was discontinued for more than 7 days, the patient was withdrawn from the study."
3327790|NCT02073214|Placebo Comparator|Placebo|"Single dose of placebo was administered enterally twice daily with food (in the morning and in the evening). The first dose of placebo was administered within the first 48 hours after birth. The placebo administration was continued for 6 weeks or until hospital discharge (whichever was earlier).~Discontinuation of the enteral nutrition was equivalent with discontinuation of the administration of the placebo. If the placebo was discontinued for more than 7 days, the patient was withdrawn from the study."
3327791|NCT02073227|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
3327792|NCT02073227|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3327793|NCT02073227|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3327794|NCT02073240||Enhanced TB IC Package|"Facilities randomized to the intervention group will receive the following:~Skills-based training for TB IC focal points~Audits and Feedback of performance data~TB IC collaborative (including mentoring)~Checklists"
3327795|NCT02073240||Usual Care Group|Usual Care group will receive available TB IC training/education alone.
3327796|NCT02073253|No Intervention|Without performing any operation (Phase Control)|
3327797|NCT02073253|Experimental|With ventilatory support through NIV (NIV Phase)|
3327798|NCT02073266|Active Comparator|SF6 vitrectomy|The first group included 31 patients who had undergone MH surgery using SF6 gas and who were advised to stay in face-down position for 7 days postoperatively (SF6 group). Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
3259164|NCT01468103|Experimental|PAC|primary angle closure
3259165|NCT01468116||RYGB patients with type 2 diabetes|Morbidly obese patients with type 2 diabetes undergoing gastric bypass surgery
3231662|NCT01203722|Active Comparator|REGIMEN B2|"Pre-PBSCT:~Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV~Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV~Day -1: 400 cGy TBI administered in a single fraction~Day 0: Peripheral Blood Stem Cell Transplant (PBSCT)~Post-Transplantation Immunosuppression Consisting of:~Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV~Day 5: Sirolimus loading dose 6 mg PO once~Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)~Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
3231663|NCT01203735|Other|Valproic acid, Chemoradiotherapy|
3327799|NCT02073266|Active Comparator|C3F8 vitrectomy|The second group included 28 patients who had undergone MH surgery with C3F8 gas and who were advised to maintain a face-down position for 14 days. Patients in both groups underwent 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8. The internal limiting membrane was coloured with trypan blue or indocyanine green in equal proportion in both groups.
3327800|NCT02073292|Experimental|c-RFA|cooled radiofrequency ablation
3327801|NCT02073292|Active Comparator|t-RFA|thermal radiofrequency ablation
3327802|NCT02073305||No sleep apnea|Subjects with no or light sleep apnea (AHI < 15/h)
3327803|NCT02073305||Sleep Apnea - untreated|"Subjects with moderate to severe sleep apnea (AHI ≥15/h) and no specific treatment.~Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol."
3327804|NCT02073305||Sleep Apnea - treated|Subjects with treated moderate to severe sleep apnea (AHI ≥15/h). Decision to treat or not sleep apnea is left to the treating physician, independently of the study protocol.
3327805|NCT02073318|Experimental|Balance training|
3231664|NCT01203748|Experimental|PVI + Lines Ablation|
3231665|NCT01203748|Active Comparator|PVI Ablation|
3327806|NCT02073318|Active Comparator|Control|Control group received 4 weeks upper extremities exercise in sitting position
3327807|NCT02073344|Experimental|Intevention group|A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG 6 months after the beginning of a renal replacement therapy
3327808|NCT02073344|Experimental|Control group|No intervention A baseline polysomnography (PSG) is performed at inclusion, followed by a follow-up PSG at 6 months if the patient is not already on renal replacement therapy
3327809|NCT02073357|Experimental|Light general anaesthesia (BIS = 50)|Light general anaesthesia
3327810|NCT02073357|Experimental|deep general anaesthesia (BIS = 35)|deep general anaesthesia
3231666|NCT01203748|Experimental|PVI + CFE|
3231667|NCT01203761||Preoperative patients|ENT surgical patients, approximately 1 day before their procedure undertaken
3327811|NCT02073370||health subjects; outpatients aged over 65|The research subjects will be culled from outpatients aged over 65 at NTUH; 1000 Taiwanese subjects aged 20-40 equally divided in both genders will be recruited in order to establish the norm of Taiwanese's skeletal muscle index.
3327812|NCT02073383|Experimental|Around Artery|"Intervention Name: Axillary brachial plexus block~Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 ."
3231668|NCT01203761||Postoperative patients|ENT surgical patients during their postoperative hospitalization
3231669|NCT01203761||Family members|Family members of ENT surgical patients, during the perioperative period
3231670|NCT01203813|Experimental|Physician Intervention|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
3327813|NCT02073383|Experimental|Two injections|Group 2: 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position .
3327814|NCT02073383|Active Comparator|Perineural|Group Perineural : 10 ml of bupivacaine 0.375 % will be injected around the median, ulnar and radial nerves .
3231671|NCT01203813|No Intervention|Physician Control|Physicians randomized to the control arm will continue to manage their patients with chronic kidney disease according to routine primary care standards.
3231672|NCT01203839|Experimental|Radiation treatment|This is a Phase II single-arm study of PBI with external-beam radiation therapy in which a group of select women with early-stage invasive and noninvasive breast cancer will be given radiation to the partial breast.
3327815|NCT02073396||Patients|Patients diagnosed with coronary disease or atrial fibrillation. All the patients will undergo Global Thrombosis Test.
3327816|NCT02073409||CF patients|Male and female subjects with CF age 6 years and older who have a positive sputum culture for NTM.
3327817|NCT02073422||Non-ST elevation myocardial infarction|Natural history study of non-ST elevation myocardial infarction and coronary physiology
3327818|NCT02073474||Sativex® users|UK: All patients and who are prescribed Sativex®. Germany and Sweden: Patients who are prescribed Sativex® from selected specialist neurology centres.
3327819|NCT02073500||Observational study|Patients diagnosed with PSM undergoing CRS with HIPEC.
3231673|NCT01203891||Healthy brain subjects|The study seeks to recruit 100 normal, healthy brain subjects between ages 10 and 90 for SPECT brain imaging.
3231674|NCT01203904||Pulmicort|
3327820|NCT02073513|Experimental|kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied which controled the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
3327821|NCT02073513|Experimental|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
3327822|NCT02073513|No Intervention|Control Group (CG)|No application.
3327823|NCT02073526||Anti-TNF|Inflammatory bowel patients age 18 and over treated with anti-TNF agents
3327824|NCT02073539|Experimental|chest compression with 5cm feedback|We will feedback by one accelerometer (U-cpr). U-cpr is android based smartphone application.
3327825|NCT02073539|Experimental|chest compression with 6cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
3327826|NCT02073539|Experimental|chest compression with 7cm feedback|We will feedback by one accelerometer(U-cpr). U-cpr is android based smartphone application.
3231675|NCT01203943|Experimental|Cohort 1|• Cohort 1: CC-930 50 mg PO daily (two 25 mg capsules once per day PO) beginning on Day 1 in the AM.
3327827|NCT02073552|Active Comparator|High volume|"Two 5 mg bisacodyl tablets It is a stimulant laxative with local action.~Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate."
3327828|NCT02073552|Experimental|Low volume|"Two 5 mg bisacodyl tablets, taken in the same way as for the high volume group.~Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid."
3231676|NCT01203943|Experimental|Cohort 2|• Cohort 2: CC-930 100 mg PO daily (one 100 mg capsule once per day PO) beginning on Day 1 in the AM
3231677|NCT01203943|Experimental|Cohort 3|• Cohort 3: CC-930 100 mg twice daily approximately 12 hours apart (one 100 mg capsule twice per day PO) beginning on Day 1.
3327829|NCT02073578|Other|Treatment|Peroral Endoscopic Myotomy (POEM)
3327830|NCT02073591||Ceradan Regimen|Ceradan Cream and Ceradan Wash
3327831|NCT02073604|Other|Healthy volunteers|Healthy volunteers
3327832|NCT02073604|Other|Congenital mirror movements|Patients presenting with congenital mirror movements
3231678|NCT01203943|Placebo Comparator|Placebo|Placebo
3231679|NCT01203969|Experimental|Single port laparoscopic surgery|
3231680|NCT01203969|Active Comparator|Conventional laparoscopic surgery|
3231681|NCT01203982|Active Comparator|Rosuvastatin 5mg|Rosuvastatin 5mg/day
3231682|NCT01203982|Active Comparator|Rosuvastatin 40mg|Rosuvastatin 40mg/day
3327833|NCT02073617|Experimental|Real-time 3-dimensional DynaCT|Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
3327834|NCT02073630|Other|Healthy subjects|healthy subjects will receive either sham or active cerebellar stimulation
3327835|NCT02073630|Other|Dystonia|dystonic patients will receive either sham or active cerebellar stimulation
3327836|NCT02073669|Other|Second generation immigrants from high TB incidence countries|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
3327837|NCT02073669|Other|Native Israelis|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA).
3327838|NCT02073695|Other|Neutral Rotation Brace|Neutral Rotation Brace
3327839|NCT02073695|Other|Standard polysling (Current practice)|Standard polysling (Current practice)
3327840|NCT02073721|Experimental|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.
3327841|NCT02073721|Active Comparator|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor
3327842|NCT02073734|Experimental|Dexamethasone|Dexamethasone
3327843|NCT02073734|Placebo Comparator|Placebo|Sterile normal saline solution
3327844|NCT02073760||Infection Prevention Experts|Adult caregivers of cardiac surgery patients (e.g. surgeons, nurses, infection preventionists) and administrators
3231683|NCT01203995|No Intervention|Usual Care|
3327845|NCT02073773|Experimental|Virtual Reality based therapy, levodopa|"The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
3327846|NCT02073773|Active Comparator|occupational therapy, levodopa|"The control group will receive and additional half an hour per working day of standard occupational therapy.~Patients will receive a single dose of 100mg levodopa in combination with benserazide 2-3 hours before each additional Occupational therapy session or VR therapy session depending on the assigned group."
3231684|NCT01203995|Experimental|brief nutrition education|
3231685|NCT01203995|Active Comparator|In Center training|
3327847|NCT02073786|Active Comparator|Lightwand|Conventional lightwand intubation will performe for intubation
3231686|NCT01203995|Experimental|Video Conference training|
3231687|NCT01204008|Experimental|CS|conservative discectomy
3231688|NCT01204008|Active Comparator|AS|
3231689|NCT01204021|Experimental|Tai Chi Chih|12 weeks of physical exercise in the form of Tai Chi Chih
3231690|NCT01204021|Active Comparator|Stress Education Control|Stress management education
3231691|NCT01204034|Other|Inuvair|
3231692|NCT01204060|Active Comparator|Nasal allergen challenge|
3231693|NCT01204060|Placebo Comparator|Nasal placebo challenge|
3231694|NCT01204073|Experimental|TAK-441|
3231695|NCT01204086|Experimental|venlafaxine|
3231696|NCT01204086|Experimental|fluoxetine|
3327848|NCT02073786|Experimental|Optiscope|Rigid video stylet, manufactural named Optiscope, will perform for intubation
3327849|NCT02073799||Photoselective vaporization of the prostate|Patients who underwent photoselective vaporization of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
3327850|NCT02073799||Holmium laser enucleation of the prostate|Patients who underwent holmium laser enucleation of the prostate for prostatic hyperplasia and in whom 12-months follow-up data were available
3327851|NCT02073812|Experimental|Multiple dose of Carbavance (RPX7009/RPX2014)|Multiple dose of Carbavance
3327852|NCT02073825|Experimental|Web Brief Intervention (WBI)|4-session WBI
3327853|NCT02073825|No Intervention|Delayed-WBI|4-session WBI after follow-up
3327854|NCT02073838|Experimental|Ribavirin, vismodegib, decitabine|Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
3327855|NCT02073838|Experimental|Ribavirin, vismodegib|Ribavirin 1400mg BID, vismodegib 150mg QD
3327856|NCT02073851|Experimental|TriGuard™HDH|Patients undergoing TAVR will be treated wIth experimental device TriGuard™HDH
3327857|NCT02073877||Controls - Holgers 0 & 1|
3231697|NCT01204099|Active Comparator|Docetaxel (NSCLC)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3231698|NCT01204099|Experimental|PX-866 (NSCLC)|Oral PX-866 administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3231699|NCT01204099|Active Comparator|Docetaxel (SCCHN)|IV docetaxel administered once every three weeks as per standard of care. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3231700|NCT01204099|Experimental|PX-866 (SCCHN)|Oral PX-866, administered daily at the RD in combination with IV docetaxel administered once every three weeks on a 21 day cycle. Treatment continues until disease progression, unacceptable toxicity or withdrawal of consent.
3231701|NCT01204112|Experimental|Tasocitinib (CP-690,550) plus Rifampin|
3327858|NCT02073877||Cases - Holgers >1 (active peri-implant dermatitis)|
3327859|NCT02073890||traumatic subarachnoid haemorrhage|
3327860|NCT02073903||LEP inpatients and their providers|This is a feasibility project with the goal of improving communication between limited English proficiency (LEP )inpatients and their providers. Quantitative data will be obtained via two surveys: a patient survey to assess patients' feedback on the effectiveness of the communication during their hospital stay and their understanding of their medical care, and a provider survey to assess the handset's impact on the effectiveness of the communication. From this data we will be able to assess patient and provider communication effectiveness with both the current various practices at MSKCC and the new intervention.
3327861|NCT02073916|Experimental|T-DM1 + Lapatinib + Abraxane|T-DM1 with Laptinib followed by Abraxane
3327862|NCT02073955||Pakistani adults|"Men and women aged 40 and above, residing in Ibrahim Hyderi (periurban Pakistani community)~Consenting to Interview about stroke symptoms"
3327863|NCT02073981||Parkinson Disease|
3327864|NCT02073994|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or Investigator discretion.
3327865|NCT02074007|Active Comparator|AR01 - Topical Otic Solution|"Topical ear drops~The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period"
3327866|NCT02074007|Placebo Comparator|Placebo Comparator|"Topical ear drops~Glycerin ear drops-The dosing regimen is 5-10 drops every hour as needed for ear pain, not to exceed 10 mL of solution per ear in a 24-hour period."
3327867|NCT02074020|Experimental|Blisibimod|
3327868|NCT02074020|Placebo Comparator|Placebo|
3327869|NCT02074033||antibiotics for pneumonia|We will be examined whether the antibiotic prescribed following the orientation of literature, considering the dose, interval between doses, dose adjustment for renal failure infusion time, treatment time and conduct after the culture results (deescalation, escalation or maintenance of antimicrobial initially prescribed )
3327870|NCT02074046|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3327871|NCT02074046|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3327872|NCT02074046|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3327873|NCT02074046|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3327874|NCT02074072|Experimental|Direct laryngoscope|Macintosh laryngoscope
3327875|NCT02074072|Experimental|Videolaryngoscope-1|Glidescope
3327876|NCT02074072|Experimental|Videolaryngoscope-2|Airwayscope
3327877|NCT02074098|Experimental|a 65 cm bed height|1) Bed height : approximately 65cm (Lowest)
3327878|NCT02074098|Experimental|a 95cm bed height|2) Bed height : approximately 95cm (highest)
3327879|NCT02074111||Intracranial atherosclerotic stroke|
3327880|NCT02074111||Moyamoya disease|
3327881|NCT02074111||Healthy controls|
3327882|NCT02074124||Adenosine Vasodilation test|Group scanned with CT perfusion during adenosine vasodilation test.
3327883|NCT02074124||Reference group|Group scanned twice without adenosine vasodilation test for a reference. No randomization.
3327884|NCT02074137|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
3327885|NCT02074150|Experimental|Biceps Brachii|"Biceps Brachii (elbow flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327886|NCT02074150|Experimental|Flexor Carpi Radialis|"Flexor Carpi Radialis (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327887|NCT02074150|Experimental|Flexor carpi ulnaris|"Flexor carpi ulnaris (wrist flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327888|NCT02074150|Experimental|Flexor digitorum profundus|"Flexor digitorum profundus (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327889|NCT02074150|Experimental|Flexor digitorum sublimis|"Flexor digitorum sublimis (finger flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327890|NCT02074150|Experimental|Adductor pollicis|"Adductor pollicis (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327891|NCT02074150|Experimental|Flexor pollicis longus|"Flexor pollicis longus (thumb flexors)~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327892|NCT02074150|Experimental|Change from Baseline in Elbow Ashworth|"Change from Baseline in Elbow Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3327893|NCT02074150|Experimental|Change from Baseline in Wrist Ashworth|"Change from Baseline in Wrist Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3327894|NCT02074150|Experimental|Change from Baseline in Finger Ashworth|"Change from Baseline in Finger Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3327895|NCT02074150|Experimental|Change from Baseline in Thumb Ashworth|"Change from Baseline in Thumb Ashworth Scale as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. Ashworth score (the force required to move an extremity around a joint):~0 = No increase in muscle tone (none)~= Slight increase~= Moderate increase~= Considerable increase~= Limb rigid (very severe)."
3327896|NCT02074150|Experimental|Change from Baseline in PGAS|Change from Baseline in PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
3327897|NCT02074150|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30
3327898|NCT02074150|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327899|NCT02074150|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327900|NCT02074150|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327901|NCT02074150|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327902|NCT02074150|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327903|NCT02074150|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327904|NCT02074150|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327905|NCT02074150|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327906|NCT02074150|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327907|NCT02074150|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327908|NCT02074163|Experimental|Glabella|"Glabella~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327909|NCT02074163|Experimental|Frontal|"Frontal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327910|NCT02074163|Experimental|Temporal|"Temporal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327911|NCT02074163|Experimental|Occipital|"Occipital~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3259166|NCT01468116||RYGB patients without type 2 diabetes|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
3231702|NCT01204125|Experimental|SAR240550 twice weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 5.6mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions twice weekly (day 1 and day 4; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
3327912|NCT02074163|Experimental|Paraspinal|"Paraspinal~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327913|NCT02074163|Experimental|Trapezius|"Trapezius~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327914|NCT02074163|Experimental|Change in frequency of headache days|Change in frequency of headache days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3327915|NCT02074163|Experimental|Change in hrs of HA on HA days|Change in hrs of HA on HA days as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3327916|NCT02074163|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327917|NCT02074163|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3231703|NCT01204125|Experimental|SAR240550 weekly/ paclitaxel weekly|SAR240550 will be administered at the dose of 11.2 mg/kg as a 60-min intravenous (IV) infusion. Patients will receive SAR240550 infusions once weekly (day 1; total dose of 11.2mg/kg per week) and paclitaxel weekly as a 60-min IV infusion (day 1; dose of 80mg/m2).
3231704|NCT01204125|Active Comparator|Paclitaxel alone|Paclitaxel will be administered at the dose of 80mg/m2 as a 60-min IV infusion. Patients will receive weekly (day 1) paclitaxel infusions.
3231705|NCT01204138|Placebo Comparator|placebo|Patient randomized to one of two arms, either placebo, or Apremilast
3231706|NCT01204138|Active Comparator|Apremilast|Patients randomized to either placebo or apremilast
3327918|NCT02074163|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327919|NCT02074163|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327920|NCT02074163|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327921|NCT02074163|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327922|NCT02074163|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327923|NCT02074163|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327924|NCT02074163|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327925|NCT02074163|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327926|NCT02074163|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327927|NCT02074189|Active Comparator|Adjuvant Chemotherapy|Adjuvant Chemotherapy(Gemcitabine, Cisplatin):Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
3327928|NCT02074189|No Intervention|Control|No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
3327929|NCT02074202|Experimental|FCH PET/CT scan results|PET/CT scan results with FCH intravenous injection
3231707|NCT01204151|Experimental|Math intervention|
3231708|NCT01204164|Experimental|TG02 in AL|Single agent TG02 citrate in acute leukemia patients
3327930|NCT02074202|Active Comparator|FDG PET/CT scan|PET/CT scan results with FDG intravenous injection
3327931|NCT02074215|Experimental|Aerobic exercises|90-minute exercise sessions per week for 12 weeks
3327932|NCT02074215|Active Comparator|Stretch exercise|90-minute exercise sessions per week for 12 weeks
3231709|NCT01204164|Experimental|TG02 in MM|Single Agent TG02 citrate in multiple myeloma patients
3231710|NCT01204164|Experimental|TG02 + CFZ in MM|TG02 in combination with carfilzomib and dexamethasone in multiple myeloma patients
3327933|NCT02074228|Experimental|Methylphenidate|Methylphenidate (Concerta) 18mg or 36mg 1# qd, 12 weeks
3327934|NCT02074241||Positive Expression|Expression analysis:Positive expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51,SNF5, etc) in bladder cancer specimens.
3327935|NCT02074241||Negative Expression|Expression analysis:Negative expression of DNA repair-related genes(XPC, XPF, Brca1, Rad51, SNF5,etc) in bladder cancer specimens.
3327936|NCT02074267|Experimental|Carbatin|Carbatin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
3231711|NCT01204164|Experimental|TG02 + CFZ + DEX in CFZ refractory MM|TG02 in combination with carfilzomib and dexamethasone in carfilzomib refractory multiple myeloma patients
3231712|NCT01204177|Experimental|Arm 1|
3231713|NCT01204190|Experimental|Arm 1|
3231714|NCT01204190|Experimental|Arm 2|
3231715|NCT01204190|Experimental|Arm 3|
3231716|NCT01204216|Active Comparator|Aim 1|Subjects in this arm will be 10 people without diabetes as well as 10 people with diabetes and stable glycemic control. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
3327937|NCT02074267|Active Comparator|Neurontin|Neurontin is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days
3327938|NCT02074280|Experimental|high dose of rifaximin|rifaximin 600 mg, bid, orally, 2 weeks and conventional treatment
3327939|NCT02074280|Experimental|low dose of rifaximin|rifaximin 400 mg bid,orally, 2 weeks
3327940|NCT02074280|No Intervention|control|conventional treatment
3327941|NCT02074293|Experimental|Splenius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327942|NCT02074293|Experimental|Scalene|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327943|NCT02074293|Experimental|Sterno-cleido-mastoid|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327944|NCT02074293|Experimental|Levator Scapulae|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327945|NCT02074293|Experimental|Semispinalis|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327946|NCT02074293|Experimental|Trapezius|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327947|NCT02074293|Experimental|Longissimus|"Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9ccNS intramuscularly for 30 patients, and subdermally with ASIS Device for 30 patients."
3327948|NCT02074293|Experimental|Change from Baseline in Pain Frequency|Change from Baseline in Pain Frequency as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30.
3327949|NCT02074293|Experimental|Change from Baseline in Pain Intensity|Change from Baseline in Pain Intensity as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The severity on scales of 0(no pain) to 4(constant or extremely severe intensity).
3231717|NCT01204216|Active Comparator|Aim 2|For Aim 2, 10 additional subjects with diabetes in poor glycemic control will be studied initially and then again in improved glycemic control after at least 8 months (with up to 5 additional subjects entered as needed to ensure 10 completed paired studies) to assess the potential role of MRBC variation in the discordances seen between HbA1c and blood glucose testing. Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
3327950|NCT02074293|Experimental|Change from Baseline in CDSS|Change from Baseline in CDSS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The CDSS or Cervical Dystonia Severity Scale quantifies the severity of abnormal head positioning and was newly devised for this study. CDSS allots 1 point for each 5 degrees (or part thereof) of head deviation in each of the three planes of head movement (range of scores up to theoretical maximum of 54).
3327951|NCT02074293|Experimental|Percent of Patients with Improved PGAS|Percent of Patients with Improved PGAS as Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, and Efficacy of Botox intramuscularly at Week 30 vs.Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, and Efficacy of Botox subdermally at Week 30. The Physician Global Assessment Scale or PGAS is a 9 category scale scoring the physician's evaluation of the patients' status compared to baseline, ranging from -4 to +4 (very marked worsening to complete improvement), with 0 indicating no change from baseline and +1 slight improvement.
3231718|NCT01204229|Experimental|MCID|
3231719|NCT01204229|Experimental|BMI|
3231720|NCT01204242|Placebo Comparator|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
3231721|NCT01204242|Experimental|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
3231722|NCT01204268|No Intervention|Propofol group|Patients will receive the total intravenous anesthesia with propofol infusion during the surgery.
3231723|NCT01204268|Active Comparator|Sevo-C group|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
3231724|NCT01204268|Experimental|Sevo-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
3231725|NCT01204281|Experimental|High assistance PAV+|Ventilatory support performed by PAV at 80% assistance (PB 840-plus) FiO2 and PEEP according to routine practice
3231726|NCT01204281|Active Comparator|Assist-control ventilation|Tidal volume, FiO2 and PEEP set according to routine practice
3327952|NCT02074293|Experimental|Adverse Reactions with Facial paresis|Facial paresis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327953|NCT02074293|Experimental|Adverse Reactions with Eyelid ptosis|Eyelid ptosis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327954|NCT02074293|Experimental|Adverse Reactions with Bronchitis|Bronchitis as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327955|NCT02074293|Experimental|Adverse Reactions with Neck pain|Neck pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327956|NCT02074293|Experimental|Adverse Reactions with Muscle stiffness|Musculoskeletal stiffness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327957|NCT02074293|Experimental|Adverse Reactions with Muscular weakness|Muscular weakness as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327958|NCT02074293|Experimental|Adverse Reactions with Myalgia|Myalgia as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3231727|NCT01204307|Experimental|docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
3231728|NCT01204307|Active Comparator|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
3231729|NCT01204320|Experimental|Paclitaxel-coated Balloon|Paclitaxel-coated Balloon Angioplasty
3327959|NCT02074293|Experimental|Adverse Reactions with Muscle pain|Musculoskeletal pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327960|NCT02074293|Experimental|Adverse Reactions with Muscle spasms|Muscle spasms as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327961|NCT02074293|Experimental|Adverse Reactions Injection site pain|Injection site pain as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327962|NCT02074293|Experimental|Adverse Reactions with Hypertension|Hypertension as Adverse Reactions of Botox intramuscularly vs.Adverse Reactions of Botox subdermally at Week 30.
3327963|NCT02074306|Experimental|UROSHIELD®|Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
3231730|NCT01204320|Active Comparator|Paclitaxel-eluting Stent|Paclitaxel-eluting Stent Implantation
3231731|NCT01204333|Experimental|Endovascular thrombolysis|
3327964|NCT02074306|Sham Comparator|SHAM UROSHIELD®|same as abouve but with Sham device.
3327965|NCT02074319|Placebo Comparator|Placebo|Matching placebo for methotrexate
3327966|NCT02074319|Experimental|Methotrexate|Methotrexate 10 mg once a week orally
3327967|NCT02074332|Experimental|Intervention|Physical activity guidance Health education
3327968|NCT02074332|No Intervention|Control|Receive no intervention
3327969|NCT02074397|Experimental|Distant extrafascial injection|Injection away from the brachial plexus with the needle tip positioned in the middle scalene muscle
3231732|NCT01204333|Active Comparator|Standard treatment|
3231733|NCT01204346|Experimental|MBT group|mentalization based treatment program
3231734|NCT01204346|Active Comparator|Treatment as usual group|treatment as usual group
3231735|NCT01204359|No Intervention|follow-up|
3231736|NCT01204372|Experimental|Treatment|Gemcitabine - Trastuzumab - Erlotinib
3231737|NCT01204385||Study Group|
3327970|NCT02074397|Active Comparator|Subfascial injection|Injection within the brachial plexus, with the needle tip positioned between C5 and C6
3327971|NCT02074410|Experimental|OMS643762 Low Dose without food|Orally administering OMS643762 low dose daily without food for 28 days
3327972|NCT02074410|Experimental|OMS643762 Medium Dose without food|Orally administering OMS643762 medium dose daily without food for 28 days
3327973|NCT02074410|Experimental|OMS643762 Medium Dose with food|Orally administering OMS643762 Medium dose daily with food for 28 days
3327974|NCT02074410|Placebo Comparator|Placebo|Orally administering placebo daily for 28 days
3327975|NCT02074423|Experimental|MealShape cinnamon extract|Intake of 2 capsules of 500 mg MealShape 30 minutes before consumption of a standard meal (white bread)
3327976|NCT02074423|Placebo Comparator|Placebo|Intake of 2 capsules of 500 mg placebo, composed of 20% microcrystalline cellulose and 80% dicalcium phosphate, 30 minutes before consumption of a standard meal (white bread)
3327977|NCT02074436|Experimental|Prophylactic EACA|Prophylactic EACA 1000 mg PO twice daily if platelets < 20 x 10⁹/L
3327978|NCT02074436|Active Comparator|Platelet transfusion|Platelet transfusion if platelet count is < 20 x 10⁹/L in the outpatient or < 10 x 10⁹/L in the inpatient setting
3327979|NCT02074475||Control group|The control group of three sites for larger Adequacy of Anaesthesia study. Total 150 patients
3231738|NCT01204437|Active Comparator|EC standard chemotherapy 4 cycles|
3231739|NCT01204437|Active Comparator|CMF standard chemotherapy 6 cycles|
3231740|NCT01204437|Experimental|Nab-Paclitaxel + Capecitabine 6 cycles|6 cycles of weekly nab-Paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
3327980|NCT02074488|Experimental|Fall Prevention Exercises|Participant provided with Balancing Act exercise curriculum for completion at least fifteen minutes three times a week over a six month period.
3327981|NCT02074488|Other|Informational brochure|Participant receives an informational brochure and orientation to brochure contents.
3327982|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge; (iii) using telephone support, counselling caregivers on 3rd, 6th, 8th and 10th weeks post discharge. It aims at facilitating the caregivers 'adjustment to stroke demands, increasing knowledge and practical skills to support their decision-making."
3327983|NCT02074540||Diabetes Type II Patients|
3231741|NCT01204450|Other|Single Arm Temsirolimus + Valproic Acid|"Drug: temsirolimus 60-230mg/m2 weekly during each 28 day course, for up to 12 courses~Drug: valproic acid (VPA) All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses"
3231742|NCT01204476|Experimental|Treatment (cixutumumab, octreotide acetate, everolimus)|Patients receive cixutumumab IV over 60-90 minutes and octreotide acetate IM on day 1 and everolimus PO QD on days 1-21. Treatment repeats every 21 days for up to 18 courses in the absence of disease progression or unacceptable toxicity.
3327984|NCT02074566|Other|2 times 1|PVI will be performed using a cryoballoon ablation application time of 2 times 1 minute
3327985|NCT02074566|Other|2 times 2|PVI will be performed using a cryoballoon ablation application time of 2 times 2 minutes
3327986|NCT02074566|Other|2 times 3|PVI will be performed using a cryoballoon ablation application time of 2 times 3 minutes
3327987|NCT02074579|Experimental|TU-100|15g TU-100 (oral, daily) for 4 consecutive weeks (administered as 5g three times daily)
3327988|NCT02074579|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
3327989|NCT02074592|Experimental|1|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
3327990|NCT02074592|Active Comparator|2|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
3327991|NCT02074605||Observation|Patients with melanoma who qualify for interferon treatment, but choose not to receive it.
3327992|NCT02074605||Interferon alpha|Patients who receive high dose interferon alpha for 4 weeks
3327993|NCT02074618|Experimental|Physical Exercise|The program of physical exercise was a resistance and aerobic training, initiated at low intensity and with a slow progressing according to the patient's tolerance. In aerobic exercise, for greater effectiveness of the training, the literature recommends moderate intensity, which corresponds with 50 to 70% of the maximum heart rate. Patients were instructed to keep the most constant as possible the speed during exercise on treadmill or cycle ergometer. For muscle strengthening exercises, the number of repetitions varied from 1 to 4 sets of 10 to 15 repetitions.
3231743|NCT01204489|Experimental|Intensified dietary counseling|The dietary intervention consists of tailored dietary counseling, information leaflets and self-evaluation cards given to the families.
3231744|NCT01204489|Active Comparator|Normal dietary counseling|Public health nurses continue their usual dietary counseling.
3327994|NCT02074631|Active Comparator|Control group|Subjects will receive a standard recommended dose of calcium and vitamin D.
3327995|NCT02074631|Experimental|Pamidronate Group|Subjects randomized to pamidronate treatment will receive infusions approximately 100, 180, and 270 days after HCT along with calcium and vitamin D.
3231745|NCT01204502|Experimental|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
3327996|NCT02074644|Experimental|Prostatic Arterial Embolization|Selective catheterization of the prostatic arteries followed by slow injection of Bead Block 300-500 or PVA 100+200 micra particles under fluoroscopic control.
3231746|NCT01204515||Girls with IBS|Girls ages 7-12 years who meet Rome III criteria for IBS
3231747|NCT01204515||Healthy Girls (controls)|Girls ages 7-12 years who are otherwise healthy and have no complaints of stomach pain
3327997|NCT02074644|Sham Comparator|Sham procedure|Selective catheterization of the prostatic arteries followed by removal of the catheter with no particles injected.
3327998|NCT02074657|Experimental|Activated natural killer cells|
3327999|NCT02074670|Experimental|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
3328000|NCT02074683|Active Comparator|YEAR A PATHWAY|"Operative Procedure will occur after screening visit.~Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Follow-up visits:~Post op Visit 1 (2 weeks +/- 5 days)~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month) CROSSOVER to YEAR B PathWay~Post op study visit 6 (18 months)~Post op study visit 7 (24 months)"
3231748|NCT01204528|Active Comparator|Paricalcitol 2 microgram/d|
3231749|NCT01204528|Active Comparator|Paricalcitol 1 microgram/d|
3328001|NCT02074683|Active Comparator|Year B Pathway|"Observational visits at 6 and 12 months with fat grafting procedures during year 2.~Study visit 1 (month 6)~Study Visit 2 (month 12)~Collection of subject's medication profile, vital signs (Temp, HR, Resp, BP), and weight to calculate BMI,~Limited physical exam with a foot exam completed by the PI and /or the Coinvestigator~Adverse Event Reporting~Ultrasound~Pedobarograph~2D Photographs~Foot Pain Assessment Questionnaire~Medical chart review including review of records from SOC podiatrists~Operative Visit Followed by Post op study visits 2-5 as described in Year A Pathway"
3231750|NCT01204528|Placebo Comparator|Placebo|
3231751|NCT01204541||AMD|
3231752|NCT01204541||Young normals|
3231753|NCT01204541||Older normals|
3231754|NCT01204567|Active Comparator|Training follow-up after discharge|Aerobic training Home-program
3231755|NCT01204580|Experimental|Amaryl-M (Glimepiride + Metformin)|"Glimepiride 1 mg and metformin 250 mg are the active ingredients of Amaryl-M 1/250 mg film coated tablets.~Starting dosage is 1 tablet per day, then dosage titration will be based on the result of patient FBG test."
3328002|NCT02074722||Healthy Subjects|Healthy Subjects
3328003|NCT02074748||Bunion|Patients being treated for foot bunion with surgery.
3328004|NCT02074748||Controls (normal foot)|Participants in this group will not undergo surgery.
3328005|NCT02074761||SImmetry Implant|Subjects who are indicated for the SImmetry device and meet the inclusion/exclusion criteria will receive a SImmetry implant.
3328006|NCT02074774|Experimental|IntellO2|Automated control of FiO2
3328007|NCT02074774|Active Comparator|Manual|Manual control of FiO2
3328008|NCT02074787||Adult burn injuries|Adult patients with burns injuries attending the regional burns unit at Chelsea & Westminster hospital between 48 and 72 hours post burn will be invited to take part in the study at the time of presentation to the unit.
3328009|NCT02074800|Experimental|Part 1|Participants will receive either 1.4 or 2.8 mg/kg of either Sp2/0-derived CNTO 328 or CHO-derived CNTO 328 or placebo.
3328010|NCT02074800|Experimental|Part 2|Participants will receive 1.4 mg/kg of either Sp2/0-derived or CHO-derived CNTO 328.
3328011|NCT02074813|No Intervention|Standard|conventional pulmonary rehabilitation
3328012|NCT02074813|Experimental|Inspiratory muscle training|Inspiratory muscle training associated with a conventional pulmonary rehabilitation
3328013|NCT02074826||Atrial fibrillation|"Genotyping of the AF associated variants~Measurement of the amount of left atrial fibrosis"
3328014|NCT02074839|Experimental|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle.
3328015|NCT02074852||Immediate catheter removal|The catheter was removed immediately after the CS
3328016|NCT02074852||Delayed catheter removal|The catheter was removed 12 hours postoperatively
3328017|NCT02074865||newborns|
3328018|NCT02074878|Experimental|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200mg, twice daily and Sunitinib 25.0mg once daily
3328019|NCT02074878|Experimental|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
3231756|NCT01204593|Experimental|Insulin glargine + insulin glulisine|"Insulin glargine dosage will be individually titrated once a week to obtain FPG 80-120 mg/dL (4.5-6.7 mmol/L).~Insulin glulisine dosage will be individually titrated once a week to obtain a 2-hour postprandial plasma glucose (PPG) < 180 mg/dL (<10.0 mmol/L) and ideally around 140 mg/dL."
3231757|NCT01204606|Experimental|MMA group|
3328020|NCT02074878|Experimental|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
3231758|NCT01204606|Placebo Comparator|Control group|
3231759|NCT01204619|No Intervention|Conventional training group|in-center conventional training programs + two home visits
3328021|NCT02074891||Persons prescribed PrEP|adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.
3328022|NCT02074917|Experimental|AM anatomical ACL reconstruction|Femoral and tibial tunnels performed in anteromedial footprint of ACL reconstruction
3328023|NCT02074917|Experimental|CENTRAL anatomical ACL reconstruction|Femoral and tibial tunnels performed in the center of ACL footprint
3328024|NCT02074930|Other|Single Arm|
3328025|NCT02074943|Experimental|PRP/Saline|Same patient will be injected with PRP and normal saline. Each one will be inject on half head.
3328026|NCT02074956|Experimental|Cohort 1 AERAS-404|"H4 Antigen at 5 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3328027|NCT02074956|Experimental|Cohort 2 AERAS-404|"H4 Antigen at 15 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3328028|NCT02074956|Experimental|Cohort 3 AERAS-404|"H4 Antigen at 50 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3328029|NCT02074956|Experimental|Cohort 4 AERAS-404|"H4 Antigen at 150 ug IC31 Adjuvant 500 nmol~2 doses at Study days 0 and 56"
3328030|NCT02074956|Experimental|Cohort 5 AERAS-404|"H4 Antigen at 5 ug or 15 ug IC31 Adjuvant 100 nmol Placebo - sterile buffer~2 doses at Study days 0 and 56"
3328031|NCT02074969|Active Comparator|Gamma Nail 3|Gamma Nail 3 Stryker.
3328032|NCT02074969|Active Comparator|PFNA|PFNA Antirotation Synthes
3328033|NCT02075034|Experimental|560 mg morning/280 mg afternoon|Two 280 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule of rigosertib will be taken in the afternoon.
3328034|NCT02075034|Experimental|420 mg morning and afternon|One 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the morning and one 280 mg capsule and two 70 mg capsules of rigosertib will be taken in the afternoon.
3328035|NCT02075034|Experimental|280 mg TID|One 280 mg capsule of rigosertib will be taken in the morning, one 280 mg capsule of rigosertib will be taken at mid-day, and one 280 mg capsule of rigosertib will be taken in the afternoon.
3328036|NCT02075060|Experimental|IPOI|One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),
3328037|NCT02075060|Active Comparator|IPOP|One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).
3328038|NCT02075086|Experimental|Chemotherapy treatment|Chemotherapy treatment with Xelox or Xeliri and bevacizumab
3328039|NCT02075099|Experimental|Isotonic drink|"Predonation hydratation with 500 ml of isotonic drink, to drinking in immediate predonation.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3231760|NCT01204619|Experimental|Intensive training group|in-center conventional training programs + an extra structured patient home visits repeatedly and regularly
3328040|NCT02075099|Experimental|mineral water|"Predonation hydratation with 500 ml of mineral water to drinking in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3328041|NCT02075099|Active Comparator|Advices|"Advices of drinking water or fruit juice glass(es) in immediate predonation whole blood.~(The half of included donors will do tensing exercises during the blood whole donation and the other half will do no tensing exercises)"
3328042|NCT02075112|Experimental|Soy isoflavone|Study treatment: Soy isoflavone in combination with radiation therapy & cisplatin
3328043|NCT02075138||Grass-Induced Rhinoconjunctivitis Subjects|
3328044|NCT02075151|Other|Bronchial Thermoplasty|Bronchial thermoplasty
3231761|NCT01204645||Acute Coronary Syndrome (ACS)|Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
3231762|NCT01204645||Follow up|Patients included at 6 or 12 months follow-up visit after an acute coronary event.
3328045|NCT02075164|Experimental|Fructose|Volunteers will be challenged with oral 150g Fructose per day for 56 days.
3328046|NCT02075164|Experimental|Glucose|Volunteers will be challenged with oral 167g Fructose per day for 56 days.
3328047|NCT02075164|No Intervention|NAFLD|Patients with confirmed simple fatty liver will be compared at baseline with other arms.
3328048|NCT02075164|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
3328049|NCT02075190|Experimental|Treatment Group|Participants randomized to receive remediation training intervention delivered online (60 days of online training)
3328050|NCT02075190|Active Comparator|Control Group|Participants randomized to receive online gaming intervention (60 days of online play)
3328051|NCT02075216|Experimental|Myoblasts Preparation|"Myoblast Preparation, Myoblast Transplantation & Neonatal Cystourethroscope Injection~Approximately 8 to 10 gm muscle will be obtained from the rectus abdominis. Patient muscle fibers will be isolated using the fiber explant technique described by Rosenblatt et al, with some modifications. Culture conditions will be mainly adapted from Rando and Blau.~After 22 days of culture myoblasts will be harvested by trypsinization and incubated in serum-free medium during the last 2 hours before injection. Immediately before injection the cell pellet will be resuspended in autologous serum and/ or platelet rich plasma (PRP)."
3328052|NCT02075229||Group A|45 participants with AzBio baseline sentence scores between 41 - 50%
3328053|NCT02075229||Group B|45 participants with AzBio baseline sentence scores between 51 - 60%.
3328054|NCT02075242|Active Comparator|tacrolimus|Control group: Tacrolimus + Corticosteroid (dual oral therapy)
3328055|NCT02075242|Experimental|Mycophenolate Mofetil|Tacrolimus + Mycophenolate Mofetil+Corticosteroid (triple oral therapy)
3328056|NCT02075268|Other|10 mg, 30 mg|To compare PKPD of prasugrel 10 or 30 mg, 4 subjects will be given 10 mg of prasugrel (one tablet of 10 mg of Effient) on day 1 as a single oral dose and another 4 subjects will be given 30 mg of prasugrel (3 tablets of 10 mg of Effient) on day 1 as a single oral dose.
3328057|NCT02075281|Experimental|HM11260C|HM11260C 4 mg weekly sc injection
3328058|NCT02075281|Placebo Comparator|Placebo|Placebo weekly sc injection
3328059|NCT02075281|Experimental|HM11260C 6 mg/week|HM11260C 6 mg weekly sc injection
3328060|NCT02075281|Experimental|HM11260C 6 mg/biweekly|HM11260C 6 mg biweekly sc injection
3328061|NCT02075281|Experimental|HM11260C 8 mg/biweekly|HM11260C 8 mg biweekly sc injection
3328062|NCT02075294||youth|"<45years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3328063|NCT02075294||middle age|"≥45years and<65years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3328064|NCT02075294||elderly|"≥65 years~Adefovir dipivoxil or Entecavir~Participants who received 10mg ADV more than 3 years or switch to other agent due to Renal dysfunction will be recruited.~Participants who received 0.5mg ETV more than 3 years will be recruited."
3328065|NCT02075307|Experimental|Blueberry Powder|The intervention group will receive the Blueberry freeze-dried powder equivalent to 1 cup of whole Blueberries twice a day for 8 weeks (i.e. 2 cups/day).
3328066|NCT02075307|Placebo Comparator|Placebo Powder|The placebo group will receive placebo powder in the same amounts for the same duration.
3328067|NCT02075333|Active Comparator|Sucrose (50g)|A 381g blackcurrant drink (cordial and water) providing 50g of sucrose
3328068|NCT02075333|Placebo Comparator|Sucralose (0.92 g sugars)|A 381g blackcurrant drink (cordial and water) providing 0.92g of natural sugars
3328069|NCT02075359||Preschoolers|Preschoolers, ages 3 to 5
3328070|NCT02075372||Data registration of CTO-PCI patients|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will register data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry.
3328071|NCT02075385|Experimental|Speech pathology therapy|Pre, during and pos-treatment swallowing exercises.
3328072|NCT02075385|No Intervention|Control group|These patients will not receive speech pathology therapy.
3328073|NCT02075424|Experimental|salivery sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call For each participant, a serie of control-samples will be taken during a day off and during a security break."
3231763|NCT01204645||Coronary|Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
3231764|NCT01204684|Experimental|Tumor Lysate-pulsed DC vaccination|Cohort #1 will receive autologous tumor lysate-pulsed DC vaccination together with a placebo cream or intramuscular injection of saline.
3231765|NCT01204684|Experimental|Tumor lysate-pulsed DC vaccination+0.2% resiquimod.|Cohort #2 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant 0.2% resiquimod.
3328074|NCT02075437|Experimental|Functional Abdominal Pain (FAP)|To access (FAP) subjects will participate in: 10 therapy sessions; and the following treatments: 1) identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis: 2) adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children; and 3) incorporate caregivers as role models and facilitators based on attachment research.
3231766|NCT01204684|Experimental|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC.|Cohort #3 will receive autologous tumor lysate-pulsed DC vaccination together with adjuvant poly ICLC (TLR3 agonist).
3328075|NCT02075450|No Intervention|Arm 1|Practice CPRcard lights not visible, Practice Just in Time Video - not provided to study participants, CPRcard lights not visible during study scenario
3328076|NCT02075450|Experimental|Arm 2|Practice CPRcard light- not visible, Practice CPR Just in Time Video- not provided, CPRcard light visible during study scenario.
3328077|NCT02075450|Experimental|Arm 3|Practice CPRcard light- visible, Practice Just in Time Video- watched by study participant, CPRcard light- not visible during study scenario.
3328078|NCT02075450|Experimental|Arm # 4|Practice CPRcard visible and the study participants watch the Just in Time Video,CPRcard light visible during study scenario
3328079|NCT02075489|Experimental|Acupressure|This group of patients will serve as the experimental group and receive acupressure treatment in addition to routine clinical care. Acupressure will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
3328080|NCT02075489|Active Comparator|Reiki|This group of participants will serve as control group and receive Reiki treatment in addition to routine clinical care. Reiki will be provided 40 mins/day, 2 days/week for 6 weeks (total of 12 sessions).
3328081|NCT02075502|Experimental|Exercise therapy|Claudication, no peripheral revasc
3328082|NCT02075502|Placebo Comparator|Exercise advice|Claudication, no peripheral revasc
3328083|NCT02075502|Experimental|lower extremity ET, exercise therapy|
3328084|NCT02075502|Placebo Comparator|lower extremity ET, exercise advice|
3328085|NCT02075502|Experimental|Peripheral open intervention, exercise therapy|
3328086|NCT02075502|Placebo Comparator|Peripheral open intervention, exercise advice|
3328087|NCT02075528|Experimental|Paliperidone Extended Release (ER)|The participants were assigned to receive a fixed dosage of 9 mg/d of paliperidone ER for the first 2 weeks. The paliperidone ER dosage was adjusted flexibly after 2 weeks according to the clinical judgment of the physicians in charge.
3328088|NCT02075567|Experimental|Therapy adaption T1DM|
3328089|NCT02075580|Experimental|psychological support|Arm A will undergo psychological support and standard care prior and post TIVAD (Totally Implantable Venous Access Devices) insertion Arm B will undergo standard care prior and post TIVAD insertion
3328090|NCT02075580|No Intervention|standard care|this arm does not receive psychological support before and after Totally Implantable Venous Access Devices positioning
3231767|NCT01204723|Experimental|Behavioral Condition 1|Nicotine patch (21 mg) plus placebo oral cannabis (0 mg; 3 times a day on days 2-4, given once on day 5)
3231768|NCT01204723|Experimental|Behavioral Condition 2|Placebo nicotine patch (0 mg) plus oral cannabis (10 mg, 3 times each day, days 2-4, day 5 given once)
3231769|NCT01204723|Experimental|Behavioral Condition 3|Placebo nicotine patch (0 mg) plus placebo oral cannabis (0 mg, 3 times each day days 2-4, day 5 given once)
3231770|NCT01204749|Experimental|AMG 386|Arm A: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 15mg/kg IV QW
3231771|NCT01204749|Placebo Comparator|AMG 386 Placebo|Arm B: Paclitaxel 80mg/m2 IV QW and Blinded AMG 386 Placebo IV QW
3231772|NCT01204762|Experimental|Part A Arm 1: pegIFN (180 μg)|
3231773|NCT01204762|Active Comparator|Part A Arm 2: pegIFNα-2a|
3231774|NCT01204762|Experimental|Part B: pegIFN lambda + Entecavir|
3328091|NCT02075593|Experimental|DTG/ABC/3TC|All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
3328092|NCT02075619|Experimental|Sequence 1|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 Fixed dose combination (FDC) formulation-1 tablet in Period 2 and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3231775|NCT01204801|Experimental|Thermochemotherapy|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy.
3231776|NCT01204801|Active Comparator|Chemotherapy (control)|Preoperative Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs
3328093|NCT02075619|Experimental|Sequence 2|Four subjects (2 Chinese and 2 Caucasian) will receive one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2 and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3328094|NCT02075619|Experimental|Sequence 3|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1, one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-2 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3328095|NCT02075619|Experimental|Sequence 4|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-1 tablet in Period 1; one GSK3074477 FDC formulation-2 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3231777|NCT01204827|Experimental|CHBV Sebivo|
3231778|NCT01204840|Active Comparator|Group A - Control group|"Group A (n=10; control group) will receive the patch protocol consisting of the 100ug estrogen patch (Estradot), a Gonadotropin Releasing Hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), and gonadotropin stimulation with 412 IU of recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris)."
3231779|NCT01204840|Experimental|Group B - treatment group|"Group B will consist of 30 subjects. In addition to the same hormone stimulation patch protocol as Group A, subjects will be treated with growth hormone 10 IU (3.33mg) per day by subcutaneous injection starting day 1 of the last menstrual period in the month prior to gonadotropin stimulation, and will continue daily until the day of human chorionic gonadotropin (hCG) injection."
3328096|NCT02075619|Experimental|Sequence 5|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 2; and one GSK3074477 FDC formulation-1 tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3328097|NCT02075619|Experimental|Sequence 6|Four subjects (2 Chinese and 2 Caucasian) will receive one GSK3074477 FDC formulation-2 tablet in Period 1; one GSK3074477 FDC formulation-1 tablet in Period 2; and one amlodipine 10mg tablet and one rosuvastatin 20mg tablet in Period 3; all treatments will be administered orally in fasted state. The three treatment periods will be separated by a washout period of between 12-17 days.
3328098|NCT02075645|Other|team training|"Intervention: team training course. A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
3328099|NCT02075671|Experimental|Levulan and Blu-U Light|Entire face treated with 20% Aminolevulinic Acid (Levulan) and Blu-U light
3231780|NCT01204866|Experimental|Stage I|Three (3) healthy male or female volunteers aged 18-59 years, not previously exposed to Valortim and who do not have pre-existing allergies
3231781|NCT01204866|Experimental|Stage II|Up to 4 healthy male or female volunteers aged 18-59 previously exposed to intravenous (IV) Valortim in PharmAthene Study #0036-08-05
3328100|NCT02075671|Sham Comparator|Vehicle and Blu-U Light|Entire face treated with vehicle substance only and Blu-U light
3328101|NCT02075671|Placebo Comparator|Vehicle Only|Entire face treated with vehicle substance only
3328102|NCT02075684|Other|In-office, Percutaneous Renal Biopsy|
3328103|NCT02075697||New drugs|Cohort exposed to biologic therapy, apremilast or fumarates
3328104|NCT02075697||Classic systemic therapy|Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).
3328105|NCT02075710|Experimental|High sugar/meal feed|Diet high in simple sugar fed as two large meals daily
3328106|NCT02075710|Experimental|High sugar/nibble|Diet high in simple sugar fed as 8 small meals daily
3328107|NCT02075710|Experimental|High fat/meal feed|Diet high in fat fed as two large meals daily
3328108|NCT02075710|Experimental|High fat/nibble|Diet high in fat fed as 8 small meals daily
3328109|NCT02075710|Experimental|High sugar/3 meals a day|Diet high in simple sugar fed as 3 meals a day
3328110|NCT02075710|Experimental|High fat/ 3 meals a day|Diet high in fat fed as 3 meals a day
3328111|NCT02075723|Experimental|Overfeeding + sleep restriction|overfeeding condition (130 % of energy requirements ) + 6 days of sleep restriction (4 hours per night)
3328112|NCT02075723|Experimental|Overfeeding + normal sleep duration|overfeeding condition (130 % of energy requirements ) + 6 days of normal sleep duration (8 hours per night)
3328113|NCT02075736|Experimental|KTP laser|device
3328114|NCT02075736|Active Comparator|TUR-P|device
3328115|NCT02075749|Active Comparator|triamcinolone acetonide mucoadhesive|30 patients received triamcinolone acetonide mucoadhesive films
3328116|NCT02075749|Experimental|Licorice|30 patients received licorice mucoadhesive films
3328117|NCT02075749|Placebo Comparator|Mucoadhesive film|30 patients received mucoadhesive films without any drug ingredients
3328118|NCT02075762|Active Comparator|Transbronchial biopsy|S-TBBx will be performed using standard biopsy forceps (Boston Scientific, Natick, MA) - 2.0mm diameter.
3328119|NCT02075762|Active Comparator|Cryoprobe biopsy|C-TBBx will be performed using the cryoprobe (ERBE, Tubingen, Germany) -1.9 mm diameter, 78cm in length. This cryoprobe is routinely used in the bronchoscopy suite for carcinoma-TBBX; therefore it is a technique already employed by the interventional pulmonologists who are familiar with its use.
3328120|NCT02075762|Active Comparator|VATS biopsy|Once the biopsies are obtained by the interventional pulmonologist, the thoracic surgeon will perform VATS biopsy. Following their procedure, subjects will be monitored in the post-anesthesia care unit as per standard of care. As part of their ongoing follow-up care, all subjects will be monitored for any adverse events that may have resulted from either the surgical or bronchoscopic procedure, specifically bleeding or pneumothorax.
3231782|NCT01204879|Active Comparator|CM for general activities|Standard care plus individual contingency management session for general activities
3231783|NCT01204879|Experimental|CM for exercise-related activities|Standard care plus individual contingency management session for physical activities
3231784|NCT01204892|Active Comparator|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
3328121|NCT02075775||MOON Shoulder Instability|Patients indicated for Shoulder Instability surgery
3328122|NCT02075788|Placebo Comparator|Commercial white bread|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3328123|NCT02075788|Experimental|Millet based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3328124|NCT02075788|Active Comparator|Corn based products (porridge etc.)|All product servings will provide 50 g of available carbohydrate and will be consumed by participants within 10 minutes.
3328125|NCT02075801||Defective amalgam restorations|"Treatment Groups:~A. Sealing of amalgam margin defects: Defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Sealant, 3MESPE)was applied over the defective area. The sealant was polymerized with a photo curing unit (Curing-Light 2500, 3MESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B. Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr, Orange, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C. Control Group: The defective restorations did not receive any treatment."
3328126|NCT02075827|Active Comparator|Problem-solving video game|Playing the video game 'Little Big Planet'
3328127|NCT02075827|Experimental|Competitive video game|Playing the video game 'Call of Duty'
3328128|NCT02075853||Bovine Xenograft|Patients in this group received a bovine xenograft in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so no future patients will receive the bovine xenograft during the procedure.
3231785|NCT01204892|Active Comparator|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
3328129|NCT02075853||Iliac Crest Allograft|Patients in this group received an iliac crest cadaver allograft (bicortical or tricortical) in their Evans calcaneal lengthening procedure. Up until April 2014, patients were randomized into receiving the bovine graft or allograft. However, the bovine xenograft will no longer be manufactured, so all future patients will receive the allograft during the procedure.
3328130|NCT02075879|Experimental|Nurse-led interviewing|Participants in experimental arm received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. They were additionally instructed to start walking or brisk walking at low duration and gradually progress to a maximum of 30 minutes daily per week. To facilitate exercise progression, the nurse case managers discussed exercise benefits, explored exercise barriers and developed mutual goals with patients. The nurse motivated them and checked the exercise behaviors to ensure adherence to the recommended exercise regime. The nurse case managers interviewed the patients weekly for six weeks and biweekly for another six weeks.
3328131|NCT02075879|Active Comparator|Brief group exercise|Participants received the in-center exercise training (20 minutes) before hemodialysis sessions weekly for 6 weeks and were instructed to perform exercise at home. The in-center training was conducted by the researcher with a group of four-to six participants focusing on flexibility and strengthening exercise only.
3328132|NCT02075892|Active Comparator|Mushroom Blend|4 grams daily; oral; 7 and 21 days
3328133|NCT02075892|Placebo Comparator|Placebo|4 grams maltodextrin, oral, 7 and 21 days
3328134|NCT02075905||Barrett's Esophagus-Low Grade Dysplasia|Subjects enrolled who have Barrett's Esophagus with low grade dysplasia. No research intervention is administered.
3231786|NCT01204931||Gastroesophageal Reflux Disease (GERD) Cases|"Erosive disease - presence of esophageal mucosal injuries documented endoscopically.~Non-erosive disease - normal esophagogastroduodenoscopy with symptoms"
3231787|NCT01204931||Control Group|normal subjects without symptoms of gastroesophageal reflux disease (GERD)
3328135|NCT02075905||Barrett's Esophagus-no dysplasia|Subjects enrolled with Barrett's Esophagus and no dysplasia. No research intervention is administered.
3328136|NCT02075931|Experimental|Physical Activity Feedback|The physical activity feedback intervention will involve real-time physical activity monitoring using a device to provide activity feedback directly to patients in combination with patient group meetings held monthly during the 12 week intervention for the purposes of mutual support in attaining physical activity goals.
3328137|NCT02075931|Active Comparator|Control|The control represents the current standard of care post total knee arthroplasty.
3328138|NCT02075944|Experimental|High intensity aerobic exercise|30 minutes of high intensity aerobic exercise 3 times a weeks for 9 weeks - incorporation interval training
3328139|NCT02075944|Experimental|Low intensity aerobic exercise|30 minutes of low intensity aerobic exercise 3 times a weeks for 9 weeks
3328140|NCT02075944|No Intervention|Control|No intervention. Participants are told not to make any changes in their everyday life
3328141|NCT02075970|Experimental|Epoetin Alpha study 1|"Epoetin Alpha Tthe number of separate doses (per kg) to be given over 4 weeks by day of age will not exceed 10. These will be administered as follows: day of life (DOL) 2 (1200 U), DOL 4 (600 U), DOL 5 (600 U), DOL 6 (600U), DOL 7 (600 U), DOL 9 (600 U), DOL 14 (600 U), DOL 15 (600 U), DOL 16 (1200 U), and DOL 28 (600 U). The greatest dose in any 1 wk period is 3600 U.~Infant study 1 Drug Intervention: all infants will be treated with Epoetin Alpha during the first four weeks of life to provide data for determining: 1) the PK/PD model determined optimized Epoetin Alpha dosing schedule; and 2) clinical and laboratory covariates predictive of which infants are good and poor Epoetin Alpha responder."
3328142|NCT02075970|Placebo Comparator|Epoetin Alpha study 2|"Epoetin Alpha dosing schedule will be determined based on the results of Infant Study 1.~Infant Study 2 is a randomized, masked study to test the hypothesis that optimized Epoetin Alpha treatment of VLBW infants predicted to be good responders will result in the elimination of RBCTx relative to poor responders.~Infant Study 2 in Years 4 and 5 will make use of the knowledge acquired in Infant Study 1 to test the central hypothesis that RBCTX can be eliminated in the majority of good Epoetin Alpha responders by optimal administration of Epoetin Alpha, but only marginal reductions in RBCTx will occur in the poor Epoetin Alpha responders."
3328143|NCT02075970|Experimental|Biotinylated red blood cells|Individual fetal RBC lifespans will be determined by administering biotinylated red blood cells, both autologous and allogeneic, simultaneously. Left over red blood cells are examined to determine red cell survival.
3328144|NCT02075983|Experimental|Group 3 (IM+EP)|Group 3 will receive 12.0mg of vaccine over 12 weeks administered with EP using the Trigid Ichor device. We expect to see the greatest proportion of individuals making T cell and antigen specific antibody responses responses in this group. Depending on the magnitude of the effects, the differences between group 3 and the other groups may be statistically significant.
3328145|NCT02075983|Experimental|Group 2 (IM+TC)|Group 2 will also receive 13.2mg of vaccine over 12 weeks, with 12.0mg given IM and 1.2mg TC. We are interested in the impact of TC relative to ID vaccination on the ratio between HIV-specific T-cell responses, and whether or not CD8+ Tcells are favoured by this route.
3328146|NCT02075983|Active Comparator|Group 1 (IM+ID)|"Group 1 will serve as the reference arm and this group will receive a total dose of 13.2mg vaccine over 12 weeks with 12.0mg given IM and 1.2mg ID. This is 7.2mg more than has been given previously to healthy individuals and 6.2 mg more than given to those HIV-infected but similar doses of HIV DNA vaccines have been given in other trials with no serious consequences."
3328147|NCT02075996||Pomalidomide following lenalidomide|75 patients with pomalidomide directly following lenalidomide treatment
3328148|NCT02075996||Pomalidomide following other therapy|75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.
3328149|NCT02076048||Previous LCPUFA Supplementation|Children between the ages of 7 and 10 that were previously enrolled in a study of supplemented LCPUFA formula.
3328150|NCT02076061||GOLD stage I|
3328151|NCT02076061||GOLD Stage II|
3328152|NCT02076061||GOLD Stage III|
3328153|NCT02076061||GOLD Stage IV|
3231788|NCT01204957|Experimental|Arm 1 Seaweed and Soy Protein|Arm 1 5 g/d Seaweed for 6 wk, then 5 g/d Seaweed and Soy Protein for 1 wk
3328154|NCT02076061||Smokers/ex-smokers w/o COPD|
3231789|NCT01204957|Experimental|Arm 2 Placebo and soy protein|Arm 2 5 g/d Placebo for 6 wk, then 5 g/d Placebo and Soy Protein for 1 wk
3231790|NCT01204970||COPD|COPD Gold class 1-4
3328155|NCT02076061||non-Smokers w/o COPD|
3328156|NCT02076087||Normal Weight (BMI: 18.5-24.9 kg/m²)|Liposuction/lipectomy
3328157|NCT02076087||Overweight (BMI: 25.0-29.9 kg/m²)|Liposuction/lipectomy
3328158|NCT02076087||Obese (BMI: >30.0kg/m²)|Liposuction/lipectomy
3231791|NCT01204970||Transplant|Lung transplant recipients
3328159|NCT02076126||Gastric aspirate|L/S ratio on the gastric aspirates are retrospectively compared with the possible development of RDS
3328160|NCT02076126||Hypopharyngeal secretion|L/S ratio on the hypopharyngeal secretions are retrospectively compared with the possible development of RDS
3231792|NCT01204970||Control|Patients with normal spirometric data
3328161|NCT02076139|Experimental|Nyaditum resae® 10e4|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e4 Colony-forming units (CFUs) of Nyaditum resae®.
3328162|NCT02076139|Experimental|Nyaditum resae® 10e5|The subjects will receive 1 drinkable vial (4mL) per day during 14 days. Each vial contains 10e5 CFUs of Nyaditum resae®.
3328163|NCT02076139|Placebo Comparator|Placebo|The subjects will receive 1 drinkable vial (4mL) of distilled water per day during 14 days.
3328164|NCT02076178|Experimental|Arm 1|Participants will receive daily oral 744 (30 mg tablets) for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of 800 mg of 744 LA at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
3328165|NCT02076178|Experimental|Arm 2|Participants will receive daily oral matching placebo for 4 weeks, followed by a one week washout period followed by intra-muscular (IM) injections of saline at three time points at 12 week intervals as: Week 5, Week 17, and Week 29
3328166|NCT02076191|Experimental|Myeloproliferative neoplasms|In phase I, increasing doses of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days. An initial dose of ruxolitinib of 10 mg orally twice daily is anticipated with planned, dose escalations of 15 mg orally twice daily, 25 mg orally twice daily and 50 mg orally twice daily. The dose can also be de-escalated to 5mg orally twice daily if dose limiting toxicities (DLTs) are observed at the initial 10mg dose. Patients will receive ruxolitinib as a single agent for the first 7 days followed by the administration of decitabine on day 8 for a total of 5 consecutive days. Patients will continue ruxolitinib at the assigned dose through the first cycle and may reduce the dose for specified toxicity beginning with the second cycle. Patients in Phase II will start at the recommended phase II dose (RPTD) of ruxolitinib in combination with decitabine at a dose of 20 mg/m2 daily intravenously over 5 days.
3328167|NCT02076204|Experimental|Home visiting|Home visiting group: Women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group. Home visiting for low-income, pregnant women - whereby individualized in-home services (including direct education, assessments, and referrals to community resources) are provided to families - has been identified by the Strong Start initiative as one promising method for reaching women who are vulnerable to poor birth outcomes.
3328168|NCT02076204|No Intervention|Non-Home Visiting|Control group: As described above, women will be randomized so that 60 percent can receive home visiting services and 40 percent are in the control group.The home visiting program will provide control group families with referrals to other appropriate services in the community.
3328169|NCT02076217||unprotected intercourse 6-14 days prior to contraception|Women who initiate highly effective reversible contraception within 6-14 days of unprotected intercourse.
3328170|NCT02076230|Experimental|[14C] TH-302 (Label 1)|
3328171|NCT02076230|Experimental|[14C] TH-302 (Label 2)|
3328172|NCT02076256|No Intervention|Control Group|
3328173|NCT02076256|Experimental|The helping relationships intervention program|The helping relationships intervention program will be implemented on the experimental group. And the control group will be provided with routine nursing care. Data will be collected at baseline, the sixth and the ninth month of the third year of study. Data will be analyzed using generalized estimating equation measures to evaluate the effect of the intervention program.
3328174|NCT02076269|Other|Arm 1|Subjects will receive no treatment in this study. Each subject will attend the clinic on 2 occasions, initially for a screening visit and then for further assessments (Visit 1). Subjects will remain in the study for maximum 33 days from the screening visit to follow up.
3328175|NCT02076282||Healthy volunteers 1 MRI scan|"Healthy volunteers, recruited at the UMC Utrecht, older than 18, who do not meet the exclusion criteria of the department of Radiology.~Healthy volunteers will receive 1 MRI scan without contrast agent."
3328176|NCT02076282||Patients with stage III NSCLC, 1 MRI scan|"Patients with histopathologically or cytologically proven stage III NSCLC (excluding T4N0), older than 18, with a recent (≤ 21 days) GFR value available~Patients will receive 1 MRI scan with contrast agent."
3328177|NCT02076295||Parkinson's disease subjects|
3328178|NCT02076295||Normal control subjects|
3231793|NCT01204983||Observational|"This is a quality improvement project to evaluate the current standard of care of nutritional management for very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.~There is no randomization, there are no control subjects, and therefore there is no probability of group assignment."
3328179|NCT02076308|Experimental|Electroacupuncture|Electroacupuncture and physical therapy
3328180|NCT02076308|Sham Comparator|Sham-electroacupuncture|Sham-electroacupuncture and physical therapy
3328181|NCT02076347|Experimental|Office visit-based intervention|
3328182|NCT02076347|Experimental|Electronic message-based intervention|
3328183|NCT02076360|Experimental|Preop Video|This arm will watch an instructional video in addition to their normal preoperative visit with the physician.
3328184|NCT02076360|No Intervention|No video|This arm will receive only the normal preoperative visit with the physician without the additional video
3328185|NCT02076373|Experimental|recombinant human Erythropoietin (Epo)|"Epo 2000 U in normal saline per ml/kg of body weight 5 times intravenously, total dosage 10000 U per 5ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
3231794|NCT01204996|Experimental|1|CNTO888 + docetaxel 15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
3231795|NCT01204996|Experimental|2|CNTO888 + gemcitabine 15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
3231796|NCT01204996|Experimental|3|CNTO888 + Paclitaxel and carboplatin 15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
3231797|NCT01204996|Experimental|4|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
3231798|NCT01205009|Active Comparator|Ovitrelle supplemantation|The women will be given 250 mcg of Ovitrelle prior to their IVF cycle
3231799|NCT01205009|No Intervention|no Ovitrelle supplementation|
3328186|NCT02076373|Placebo Comparator|Control|"Placebo 1 ml normal saline/kg of body weight 5 times intravenously, total dosage 5 ml/kg.~In detail: For loading 3 times beginning at day 5 of life (± 2 days), followed at 24 hours and 48 hours later. For maintenance 2 times, at day 10 and day 17 after the first study medication."
3328187|NCT02076386||Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
3328188|NCT02076438|Placebo Comparator|Placebo|Placebo capsules
3328189|NCT02076438|Experimental|Probiotics|Lactobacillus Rhamnosus GG 10 billion cfu BID
3328190|NCT02076451|Experimental|2 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3231800|NCT01205022|Experimental|Arm I|Patients receive irinotecan hydrochloride IV over 90 minutes, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46-48 hours, and bevacizumab IV over 30-90 minutes once every 2 weeks. Patients also receive yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A IV over 25 minutes once in weeks 3 and 9.Treatment continues in the absence of disease progression or unacceptable toxicity.
3231801|NCT01205048|Experimental|Emervel Classic Lidocaine|Emervel Classic Lidocaine injected into left nasolabial fold. Juvederm® Ultra injected into right nasolabial fold.
3328191|NCT02076451|Experimental|8 mg/kg DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3328192|NCT02076451|Experimental|16 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3328193|NCT02076451|Experimental|24 mg/kg of DS-8273a|2 mg/kg, 8 mg/kg, 16 mg/kg, and 24 mg/kg of DS-8273a; DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks).
3231802|NCT01205048|Active Comparator|Juvederm® Ultra|Juvederm® Ultra injected into left nasolabial fold. Emervel Classic Lidocaine injected into right nasolabial fold.
3231803|NCT01205061|Experimental|Emervel Deep Lidocaine|Emervel Deep Lidocaine injected into left nasolabial fold. Juvederm® Ultra Plus injected into right nasolabial fold.
3328194|NCT02076464|Experimental|StudentBodies - Eating Disorders|Participants will participate in the StudentBodies - Eating Disorders program
3328195|NCT02076464|No Intervention|Usual Care|Participants will be referred to treatment per protocol at students' corresponding college's mental health services center
3328196|NCT02076477|Experimental|Arm A|"Patients receive concurrent chemoradiotherapy at first。Patients also receive chemotherapy every 3-4 weeks for two cycles after concurrent chemoradiotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
3231804|NCT01205061|Active Comparator|Juvederm® Ultra Plus|Juvederm® Ultra Plus injected into left nasolabial fold. Emervel Deep Lidocaine injected into the right nasolabial fold.
3231805|NCT01205074|Experimental|Repeatability|
3328197|NCT02076477|Active Comparator|Arm B|"Patients receive neoadjuvant chemotherapy every 3-4 weeks for two cycles at first.Patients then receive concurrent chemoradiotherapy after neoadjuvant chemotherapy.~chemotherapy：（1） squamous cell carcinoma：Docetaxel 60mg/m2 d1+Cisplatin 25mg/m2 d1-3.（2）non squamous cell carcinoma： pemetrexed 500mg/m2 d1+Cisplatin 25mg/m2 d1-3."
3231806|NCT01205074|Experimental|COPD|
3231807|NCT01205074|Experimental|Smokers|
3231808|NCT01205074|Experimental|CYP450 1A2 Inhibitors|
3328198|NCT02076490|Experimental|Software Supported Mirror Therapy|First experimental condition Physical/Occupational Therapy
3328199|NCT02076490|Experimental|Traditional mirror therapy|Second experimental condition Physical/Occupational Therapy
3328200|NCT02076490|Active Comparator|Sensomotor exercises without mirror|Control condition Physical/Occupational Therapy
3328201|NCT02076503|Experimental|PET-MR 18F-FACBC|
3328202|NCT02076516|Experimental|Drug-eluting stent: CORACTO®|Single arrm
3231809|NCT01205074|Experimental|Cirrhosis Beta Blockers|
3231810|NCT01205074|Experimental|Alcohol|
3231811|NCT01205087|Placebo Comparator|Placebo|
3328203|NCT02076529|Experimental|Ramosetron 0.6mg|Ramosetron 0.6mg intravenous injection 30min before chemotherapy
3328204|NCT02076529|Experimental|Ramosetron 0.45mg|Ramosetron 0.45mg intravenous injection 30min before chemotherapy
3328205|NCT02076529|Active Comparator|Ramosetron 0.3mg|Ramosetron 0.3mg intravenous injection 30 min before chemotherapy
3328206|NCT02076542|Experimental|Education - Diabetes and Sports|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Sports"
3328207|NCT02076542|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3328208|NCT02076555|Experimental|Education - Diabetes and Social Issues|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Social Issues"
3328209|NCT02076555|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3328210|NCT02076568|Experimental|Education - Diabetes and Partnership|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Partnership"
3328211|NCT02076568|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3328212|NCT02076581||Stroke|Ten individuals with chronic stroke and limb spasticity will be recruited.
3328213|NCT02076581||Dystonia|Ten individuals with dystonic limbs and no spasticity will be recruited.
3328214|NCT02076581||Cerebral Palsy|Ten individuals with Cerebral palsy with the potential for a mix of dystonic and spastic abnormal tone in their affected limbs will be recruited.
3328215|NCT02076581||Neurologically normal|Thirty individuals without neurological injury that are age matched to the rest of the study population will be recruited.
3328216|NCT02076594|Experimental|Docetaxel & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Docetaxel (35 mg/ m2, intravenous at days 1 and 8 by 1-hour infusion)and Oxaliplatin (80 mg/ m2, intravenous at day 1 by 2-hour infusion) and Capecitabine (750 mg/ m2, oral tablets of 500 and 150 mg, x2 daily for 2 weeks)
3328217|NCT02076594|Experimental|Epirubicin & Oxaliplatin & Capecitabine|Patients will receive cycles every 3 weeks of Epirubicin (50 mg/ m2, intravenous on day 1 by 2-hour infusion)and Oxaliplatin (130 mg/ m2, intravenous on day 1 by 2-hour infusion) and Capecitabine (625 mg/ m2,oral tablets of 500 and 150 mg, x2 daily for 3 weeks)
3231812|NCT01205087|Active Comparator|OKT3 - 0.2|
3231813|NCT01205087|Active Comparator|OKT3 - 1|
3231814|NCT01205087|Active Comparator|OKT3 - 5|
3231815|NCT01205100|Active Comparator|Biofeedback|Patients will be taught to control abdominal and diaphragmatic muscles by bio-feedback using EMG recordings.
3231816|NCT01205100|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
3231817|NCT01205139|Experimental|001|TMC435 150 mg capsule once daily for 11 days
3231818|NCT01205139|Experimental|002|TMC278 25 mg tablet once daily for 11 days
3231819|NCT01205139|Experimental|003|TMC435 + TMC278 150 mg TMC435 capsule + 25 mg TMC278 tablet once daily for 11 days
3231820|NCT01205139|Experimental|004|TMC435 150 mg capsule once daily for 7 days
3328218|NCT02076607||Conservative Treatment|Eleven patients underwent conservative treatment with Brace.
3328219|NCT02076607||Surgical Treatment|Fourteen patients who underwent surgical treatment (arthrodesis).
3328220|NCT02076620|Experimental|L19TNFα + doxorubicin|"Only one arm is specified. Patients will be treated in three cohorts with 3 different dosages of L19TNFα in combination with 60 mg/m2 of doxorubicin, according to the following study design:~cohort 1 --> 10.4 μg/kg L19TNFα + doxorubicin; cohort 2 --> 13 μg/kg L19TNFα + doxorubicin; cohort 3 --> 17 μg/kg L19TNFα + doxorubicin."
3328221|NCT02076633|Experimental|L19IL2 + L19TNF|One arm, intratumoral injections of 10 Mio IU of L19IL2 and 312 μg L19TNF. Weekly administration for all combined leasions
3231821|NCT01205139|Experimental|005|TDF 300 mg tablet once daily for 7 days
3328222|NCT02076646|Experimental|Ph I: L19IL2 + DTIC|"Cohorts of 3-6 patients will receive escalating doses of L19-IL2 until MTD is reached.~L19-IL2 will be administered on days 1, 8 & 15 of each 21-day-cycle. Dacarbazine will be given at a fixed dose on day 1 of each 21-day cycle, 30 minutes after the end of the L19-IL2 infusion."
3328223|NCT02076646|Experimental|Ph II - ARM 1: L19IL2 at RD + DTIC|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 1 will receive L19IL2 at the RD + DTIC at a fixed dose.
3231822|NCT01205139|Experimental|006|TMC435 + TDF 150 mg TMC435 capsule + 300 mg TDF tablet once daily for 7 days
3231823|NCT01205178|Active Comparator|Tafenoquine|Tafenoquine, TQ is an 8-aminoquinoline (8-AQ) antimalarial drug being developed for the radical cure of acute P. vivax malaria. Chloroquine will be given for the first 3 days in second and third part of this study to treat Malaria.
3231824|NCT01205178|Active Comparator|Chloroquine|Dose for first 3 days for Part B & C of the study
3231825|NCT01205178|Active Comparator|Primaquine|once daily for first 14 days
3231826|NCT01205191|Experimental|CBT-ubiquitous|
3231827|NCT01205191|Placebo Comparator|CBT-placebo|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management
3231828|NCT01205191|Active Comparator|CBT-TAU|Cognitive behavioural Therapy provided 'As Usual'
3231829|NCT01205204|Active Comparator|BF25 (Control)|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
3231830|NCT01205204|Experimental|BC15(Study 1)|GROUP BC15 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
3231831|NCT01205204|Experimental|BC30(Study 2)|GROUP BC30 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
3328224|NCT02076646|Active Comparator|Ph II - ARM 2: DTIC monotherapy|During the phase II part of this study, 60 patients with Stage IV M1a and M1b melanoma will be randomized in a 1:1 ratio: 30 patients assigned to Arm 2 will receive DTIC at a fixed dose as monotherapy.
3328225|NCT02076659|Experimental|F8IL10 + MTX|"Ten cohorts of 3-6 RA patients will be treated at increasing doses per cohort of F8IL10 plus fixed doses of MTX and folic acid.~An additional 12 patients will be randomized (6+6) in a double blind, placebo controlled cohort with F8IL10 given at RD and placebo. In both arms, MTX will be administered as concomitant medication.~In all coohorts a stable dose of folic acid (5 mg) will be administered on Day 2."
3328226|NCT02076672|Experimental|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
3328227|NCT02076685|Experimental|isoniazid rechalleng|When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.
3328228|NCT02076698|Experimental|AN-DBS|Deep Brain Stimulation of the Anterior Nucleus of the thalamus
3328229|NCT02076698|Active Comparator|Usual treatment|Usual treatment of epilepsy including vagus nerve stimulation (VNS)
3231832|NCT01205204|Experimental|BC60 (Study 3)|GROUP BC60 In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
3231833|NCT01205217|Experimental|Arm A|"Lapatinib in combination with epirubicin and cyclophosphamide followed by paclitaxel and lapatinib.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Lapatinib 1000 mg orally once daily continuously Loperamide as required for the proactive management of diarrhoea"
3328230|NCT02076711|Active Comparator|Active|Metoprololsuccinate
3328231|NCT02076711|Placebo Comparator|Placebo|Placebo
3328232|NCT02076724|Experimental|Biological mesh (Strattice Firm)|Strattice Firm is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
3328233|NCT02076724|Experimental|Synthetic mesh (Prolene)|Prolene mesh is inserted using inlay technique as reinforcement of the abdominal wall where the anterior rectus fascia has been excised.
3231834|NCT01205217|Active Comparator|Arm B|"Epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab.~Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days~Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week"
3231835|NCT01205243||ZIAGEN®|Patients administrated ZIAGEN® at the site
3231836|NCT01205256|Experimental|Methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
3328234|NCT02076737|Experimental|VEO|
3328235|NCT02076750|Experimental|Vitamin D3 (cholecalciferol) 10,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 10,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 50,000 IU weekly for patients weighing 50 kg or greater.
3328236|NCT02076750|Active Comparator|Vitamin D3 (cholecalciferol) 5,000 IU per 10 kg body weight|Vitamin D3 (cholecalciferol) will be administered orally at a dose of 5,000 IU per 10 kg body weight weekly for 6 consecutive weeks. The maximum dose will be 25,000 IU weekly for patients weighing 50 kg or greater.
3328237|NCT02076763||Acute intermittent porphyria|Patient diagnosed of AIP (by clinical, biochemical data and genetic confirmation of porphobilinogen deaminase (PBGD) gene mutation). The patient must have a severe AIP condition, with at least two hospitalizations during the previous year due to acute attacks (clinical manifestations of acute porphyria), or at least four hospitalizations during the previous year due to the requirement of hospital treatment administration (including day-hospital and home hospital program).
3328238|NCT02076789||ICD generator replacement|Patients with standard indications to ICD generator replacement
3231837|NCT01205282|Experimental|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). There will be 14 weeks of active treatment.
3231838|NCT01205282|Placebo Comparator|Placebo|
3328239|NCT02076802||lifestyle counseling|physical exercises
3328240|NCT02076815|Experimental|Anagrelide retard|Anagrelide Retard prolonged-release formulation
3328241|NCT02076815|Active Comparator|Thromboreductin|Anagrelide immediate release formulation
3328242|NCT02076828|Experimental|Fe-OH-PM (Santafer® sp.)(Group II)|The patients in Group II were treated with Fe-OH-PM (Santafer® sp.), 6 mg/kg/day orally.
3231839|NCT01205295||Mental disorders|Preoperative and postoperative screening of mental disorders and efficacy of treatment in hip and shoulder patient.
3328243|NCT02076828|Experimental|Fe-Zn (Ferro Zinc® sp.)(Group III)|The patients in Group III were treated with Fe-Zn (Ferro Zinc® sp.), 6 mg/kg/day orally
3328244|NCT02076828|Experimental|Fe-S (Ferro Sanol® sp.)(Group I)|The patients in Group I were treated with Ferro Sanol® sp., 6 mg/kg/day orally
3328245|NCT02076841||interferon beta-1a|30 μg intramuscularly once a week using an injection device (Avonex Pen).
3328246|NCT02076854|Experimental|Text-Message Intervention|Participants will undergo four weeks (in a randomized order) of receiving personalized motivational text-messages while receiving CBT for their eating disorder.
3328247|NCT02076854|No Intervention|No Text Message Phase|Participants will receive 4 randomized weeks of not receiving text messages while receiving CBT for their eating disorder.
3328248|NCT02076867|Experimental|Intensive Short Term Dynamic Psychotherapy (ISTDP)|
3231840|NCT01205308|Active Comparator|Stanol ester spread|Vegetable oil based margarine with stanol ester enrichment
3231841|NCT01205308|Placebo Comparator|control spread|Vegetable oil based margarine without stanol ester enrichment
3231842|NCT01205321|Experimental|Arm 1|
3231843|NCT01205321|Experimental|Arm 2|
3231844|NCT01205334|Experimental|Autologous CMV-specific CTL|"The patient will receive one of the following doses:~1.5x10^7 cells/m2~4.5x10^7 cells/m2~1.5x10^8 cells/m2"
3231845|NCT01205347|Experimental|Simvastatin 80mg|Simvastatin 80mg once a day
3231846|NCT01205347|Active Comparator|Simvastatin 10mg|Simvastatin 10mg once a day
3231847|NCT01205360|Active Comparator|Bupivacaine-Fentanyl (3-15)|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
3231848|NCT01205360|Experimental|Bupivacaine-Fentanyl (4-20)|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
3231849|NCT01205360|Experimental|Bupivacaine-Fentanyl (6-30)|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
3231850|NCT01205373|Experimental|BI 671800 high dose|Oral drinking solution
3231851|NCT01205386||CROSSER|
3231852|NCT01205412||Assessed Cohort|Subjects attending out-patient health services for routine cervical screening or presenting for post-natal check up
3231853|NCT01205425|Experimental|CT|Procedure of stent implantation will be planed on the basis of both angiography and computed tomography results.
3231854|NCT01205425|Active Comparator|Angio|Procedure of stent implantation will be planned only on the basis of diagnostic coronary angiography.
3231855|NCT01205464|Active Comparator|Doxycycline|Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.
3328249|NCT02076867|Active Comparator|Medical Care As Usual (MCAU)|
3328250|NCT02076880|Experimental|Arm with caloric restriction|"Patients in this arm will have, during 7 days before surgery, a caloric restriction of 1000 kcal per day compared to the usual food intake. They will be hospitalized during this period.~Intervention: caloric restriction"
3328251|NCT02076880|Experimental|Arm without caloric restriction|"Patients in this arm will not have a caloric restriction before surgery.~Intervention: No caloric restriction"
3328252|NCT02076893|Active Comparator|Tramadol/gabapentin/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled gabapentin 3 mg/kg [max 150 mg] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
3328253|NCT02076893|Placebo Comparator|Tramadol/placebo/ibuprofen|(A) Scheduled tramadol 1mg/kg Q6h [max. 50mg] for 5 days; plus tramadol 1mg/kg Q6h PRN [max. 50mg] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg [max. 500 mg] Q6h PRN
3328254|NCT02076906|Experimental|MR-HIFU|Magnetic Resonance High Intensity Focused Ultrasound (MR-HIFU) ablative therapy for children with recurrent or relapsed solid tumors.
3328255|NCT02076932|Active Comparator|Premenopausal women|The premenopausal women will be attending Spinning classes.
3328256|NCT02076932|Experimental|Postmenopausal Women|The postmenopausal women will be attending Spinning classes.
3328257|NCT02076945|Active Comparator|Healthy patients|Patients without diabetes and without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
3231856|NCT01205464|Placebo Comparator|Sugar pill|Capsule Placebo, 200 mg, once daily, for 21 days.
3231857|NCT01205477|Experimental|Methylprednisolone|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
3231858|NCT01205477|Placebo Comparator|Placebo|Infiltration of 1 mL of xylocaine
3328258|NCT02076945|Experimental|Diabetic patients without neuropathy|Patients with diabetes but without peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus <19.01 mm2)
3328259|NCT02076945|Experimental|Diabetic patients with neuropathy|Patients with diabetes and with peripheral neuropathy (based on the cross sectional area of the posterior tibial nerve 3 cm above the medial malleolus > 19.01 mm2)
3328260|NCT02076958|Active Comparator|Traditional/classroom|Community health advisors trained using traditional/classroom methods and provided with technical assistance/support as needed
3328261|NCT02076958|Experimental|Technology|Community health advisors trained using technology/online methods and provided minimal technical assistance/support
3328262|NCT02076984|Other|Group A|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by titanium tacks
3231859|NCT01205516|Experimental|Methadone|
3231860|NCT01205516|Active Comparator|Controlled Release Morphine|Controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
3231861|NCT01205542|Experimental|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
3231862|NCT01205542|Active Comparator|Reference|Health check and advice to continue ordinary physical activity
3328263|NCT02076984|Other|Group B|laparoscopic incisional or ventral hernia repair use of lightweight polypropylene mesh fixed by U shaped absorbable tacks
3328264|NCT02077010|Experimental|Inhaled nebulized milrinone|Inhaled nebulized milrinone 60mg/4ml every 8 hours using a jet nebulizer
3328265|NCT02077023||Asymptomatic Carotid Artery Disease, AF|
3328266|NCT02077036|Experimental|Active medical device|
3328267|NCT02077036|Placebo Comparator|Inactive medical device|
3328268|NCT02077049|Experimental|serious games self-training program|Serious games are played, using Kinect® and Fit Bit®. This program is performed during the 10 days of the intervention on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
3328269|NCT02077049|Active Comparator|Conventional self-training program|conventional physical exercises are performed during the 10 days of the intervention, on a self-training basis and 2 specific time-slot (2x30 min) per day are allocated for this program.
3328270|NCT02077062||study (hepatectomy) group|patients undergoing hepatectomy for malignant neoplasm
3328271|NCT02077062||control (non hepatectomy) group|patients undergoing intestinal resections (not incluiding hepatectomy) for malignant neoplasm
3328272|NCT02077075|Active Comparator|Web-based weight loss program|Subjects will have access to a web-based weight loss program for an 8-week period.
3231863|NCT01205555|No Intervention|ultrasound alone group|Patients in the control group will have a standard ultrasound monitoring with HCG administered when the leading follicle reaches 18 mm, and IUI 36 h afterward.
3231864|NCT01205555|Experimental|LH testing combined with ultrasound monitoring|
3231865|NCT01205594|Experimental|ITPR device|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
3231866|NCT01205607|Experimental|ITPR -9 & then -5 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
3231867|NCT01205607|Experimental|ITPR -5 & then _9 mm HG|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
3231868|NCT01205620|Experimental|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
3231869|NCT01205620|No Intervention|No intervention|No intervention will be performed in this control group
3328273|NCT02077075|Experimental|On-line health coaching in addition to web-based program|Subjects will have access to the web-based wellness program and will also receive weekly personalized health coaching emails.
3328274|NCT02077088|Experimental|Galactooligosaccharides|addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula
3328275|NCT02077088|No Intervention|Only HA formula|only standard HA starter formula
3328276|NCT02077101|Other|Quantitative study group|Patients complete questionnaires validated and published in the literature: Brief IPQ R and HIV PROQOL [28, 29]. The questionnaire RAVVIH therapeutic vaccine has been designed from the literature review and advice of the Scientific Council in particular Dr. Pierre Verger social scientist vaccination and experts on the perception of patients. It was tested on a sample of 15 PWLHA
3328277|NCT02077101|Other|Qualitative study group|"An interview guide was developed from the literature and expert community. Data will be collected through qualitative interviews with a psychologist trained to conduct interviews. Volunteers will be recruited according to the different categories of people representative of the HIV population in France.~These interviews will be conducted at the Foch Hospital. The physician investigator propose participation in the investigation and agree on a day appointment with the psychologist. Consent will be collected at that time after reading the prospectus . All interviews will be recorded orally with the agreement of the participants , and transcribed in full . They will be completely anonymous .~The average length of the interviews will be 45-60 minutes. Textual data from these interviews will be analysis."
3231870|NCT01205633||CNS draining vein abnormalities|
3328278|NCT02077114|Experimental|Ipilimumab|Patient who according to standard criteria are candidates to treatment with Ipilimumab
3328279|NCT02077114|Experimental|Vemurafenib|Patients who according to standard criteria are candidates to treatment with Vemurafenib
3328280|NCT02077153|Experimental|Group Reminescence|In the experimental condition, everything begins ensuring the participants that all the memories shared will not be spread out of the group. Every session will deal with a theme, recalling specific autobiographic experiences; they will be suggested following a chronological order. Participants are encouraged to bring photos or objects related to past themes: at the end of each meeting the theme of the following is revealed. The researchers can also bring materials as cues for reminiscence.
3328281|NCT02077153|Active Comparator|Group discussion|In the control condition, every meeting will offer topics for discussion taken from newspaper and newscasts: personal opinions are promoted, and links with the daily life of participants are welcome (everyday activities, personal preferences). The main goal is to stimulate the social interaction and the communication, without dealing with personal events from the past nor private memories.
3328282|NCT02077166|Experimental|Phase 1: Dose Level -1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328283|NCT02077166|Experimental|Phase 1: Dose Level 1|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328284|NCT02077166|Experimental|Phase 1: Dose Level 1+|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328285|NCT02077166|Experimental|Phase 1: Dose Level 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328286|NCT02077166|Experimental|2Phase 1: Dose Level 3|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328287|NCT02077166|Experimental|Phase 2|Ibrutinib PO+ Lenalidomide (PO) + Rituximab (IV)
3328288|NCT02077179|No Intervention|Standard of Care|Participants in this arm will receive care as per the usual standards from Kingston General Hospital and their primary care provider.
3328289|NCT02077179|Experimental|HIP Program|Participants in this arm will follow the HIP Program in addition to their usual care from Kingston General Hospital and their primary care provider.
3328290|NCT02077192|Experimental|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
3328291|NCT02077205|Experimental|Manualised Cognitive Behavioral Therapy|Manualised Cognitive Behavioral Therapy in a Routine Care Setting
3328292|NCT02077218|Experimental|Diagnostic (CT and blood biomarkers)|Patients undergo cardiac CT and collection of blood samples for analysis of hs-CRP via quantitative immunoturbidimetry and Lp-PLA2 via ELISA.
3328293|NCT02077231|Experimental|vitamin A palmitate eye gel|0.1% vitamin A palmitate; Sinqi, Shenyang, China
3328294|NCT02077231|Experimental|carbomer eye gel|0.2% Carbomer 940; Bausch & Lomb, Aschheim, Germany
3328295|NCT02077244|Experimental|Follow up talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Nurse led follow up talks at the ward and one and two months later.
3328296|NCT02077244|No Intervention|No talks|Patients with a score like or above 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual
3231871|NCT01205672|Experimental|Metformin|Metformin 850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
3231872|NCT01205698|Placebo Comparator|Group 1 - Control A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3231873|NCT01205698|Experimental|Group 2 - Experimental A|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3231874|NCT01205698|Placebo Comparator|Group 3 - Control B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3231875|NCT01205698|Experimental|Group 4 - Experimental B|Vanilla milk-based beverage containing varying levels of lactose, sucrose, and fructose
3231876|NCT01205724|Experimental|A|
3231877|NCT01205724|Experimental|B|
3231878|NCT01205724|Experimental|C|
3231879|NCT01205737|Experimental|TL011|
3231880|NCT01205737|Active Comparator|MabThera®|
3231881|NCT01205750|Experimental|Glucose clamp|
3231882|NCT01205789||Universal Registry|Subjects who are either not eligible for randomization or for other reasons are not randomized will be consented for the Universal Registry
3231883|NCT01205802|Active Comparator|PTFE group|MHV reconstruction with ringed Goretex
3231884|NCT01205802|Placebo Comparator|Homograft group|MHV reconstruction with homograft
3231885|NCT01205841|Experimental|Adults|Patients from 16 years of age onwards
3231886|NCT01205841|Experimental|Children|Patients aged 5 to 15 years
3231887|NCT01205854|No Intervention|Conventional clinical and laboratory assessment|
3231888|NCT01205854|Experimental|Conventional assessment plus ultrasonography|
3231889|NCT01205867|Experimental|1|AZD8848 given to BChE deficient subjects and age & gender matched control subjects
3231890|NCT01205880|Active Comparator|vectical ointment and clobex spray|patients were assigned to apply vectical ointment first then clobex spray on one target lesion and also apply clobex spray first then vectical ointment on a different target lesion on the opposite side of the body.
3231891|NCT01205893|Experimental|Reducer|Implant Reducer
3231892|NCT01205893|Sham Comparator|Control|No treatment
3328297|NCT02077244|No Intervention|Observation group|Patients with a score below 25 on Post traumatic stress scale-10 Intensive Care Screen after discharge from the ICU. Care as usual.
3328298|NCT02077257|Other|Rosuvastatin 20mg|Rosuvastatin 20 mg/d
3328299|NCT02077257|Other|Rosuvastatin 10mg|Rosuvastatin 10 mg/d
3231893|NCT01205906|Experimental|Internet-based guided self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
3259167|NCT01468116||Cholecystectomy patients without type 2 diabetes|Patients with normal glucose tolerance undergoing laparoscopically cholecystectomy
3328300|NCT02077270|Experimental|electroacupuncture|patients in whom precolonoscopic electroacupuncture is preformed
3328301|NCT02077270|Placebo Comparator|Sham electroacupuncture|sham electroacupuncture
3328302|NCT02077270|Sham Comparator|No intervantion|no intervantion
3328303|NCT02077283||Healthy people|This group contains healthy people only whose liver function and B ultrasound are normal.
3328304|NCT02077283||"group of liver depression and spleen deficiency pattern"|"In this group, patients are considered to be the pattern of liver depression and spleen deficiency. They mainly have the symptoms of loose stool, depression, fat tongue with white coating and teeth marks and soft or string pulse."
3328305|NCT02077283||"group of damp-heat in the interior pattern."|In this group ,NAFLD patients have symptoms with dry mouth, bitter mouth, heavy feeling in legs, yellow urine, reddish tongue with thick yellowish coating and slippery pulse.
3328306|NCT02077296||Preoperative chemoradiotherapy|The group consists of patients aged ≥18 with a pathohistological diagnosis of locally advanced rectal adenocarcinoma (<15 cm from the anal verge). They are found eligible for preoperative chemoradiotherapy (chemotherapy: oral capecitabine / radiotherapy: 45-50 Gy in total; fractions of 1.8-2 Gy) and surgery (stage 2 or 3 rectal cancer).
3328307|NCT02077309|Active Comparator|Linagliptin|Patients will receive 5 mg linagliptin once daily for a period of 6 months.
3328308|NCT02077309|Placebo Comparator|Placebo|Patients will take placebo tablets once daily for a period of 6 months.
3259168|NCT01468129|Active Comparator|Cell Saver|
3328309|NCT02077322|Experimental|Silastic Spacer|This study arm receives the experimental treatment, a Silastic spacer.
3328310|NCT02077322|Active Comparator|Merocel Spacer|Merocel spacers are actively being used as the standard of care.
3328311|NCT02077335|Experimental|HDR brachytherapy monotherapy|Radiation therapy: Treatment with 2 separate HDR brachytherapy implants, each with one fraction of 13.5 Gray (Gy) with an interval of 7-14 days between treatments.
3328312|NCT02077348|No Intervention|Insulin|"good glycemic control: 50 % of the subject's basal insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) and on the study-day. Basal period from 7.00 am to 12.00pm. The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3328313|NCT02077348|Experimental|Insulin withdrawal|"10 % of the individual subject's regular insulin dosage will be given as a continuous IV administration of insuman rapid overnight (hospitalized and fasting from 10 p.m.) Basal period from 7.00 am to 12.00 pm (without insulin). The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3328314|NCT02077348|Experimental|Norditropin (Growth Hormone)|"Same amount of insulin administered on the control day (good glycemic control) overnight and on the study day (hospitalized and fasting from 10 p.m.). On the study day, a bolus injection of 0,4 mg of growth hormone (Norditropin) will be administered at 7.05 am. Basal period from 7.00 am to 12.00 pm (good glycemic control).The subject will undergo a hyperinsulinemic euglycemic clamp from 12.00 pm to 2.30 pm.~Three muscle- and three fat-biopsies will be obtained. A palmitic-acid tracer, a glucose tracer, urea tracer, tyrosine- and phenylalanine- tracers will be given."
3328315|NCT02077361|Experimental|Open Label|"Patients will receive a subretinal injection of 0.10 ml of the rAAV2.REP1 vector drug substance. It is a colourless opalescent frozen liquid with no visible particles. Each patient will be given a one-time dose in one eye.~It is the same vector used in the United Kingdom Phase I/II trial logged at: http://clinicaltrials.gov/ct2/show/NCT01461213."
3259169|NCT01468129|No Intervention|Non Cell Saver|
3259170|NCT01468155|Active Comparator|Dabigatran|Dabigatran will be compared to historical data using other OAC methods for Pulmonary Vein Ablation
3328316|NCT02077387|Experimental|CHild Inhibitory Control Play (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
3328317|NCT02077387|Active Comparator|Attention control|Children will receive information regarding other healthy behaviors: brushing teeth, sunscreen use, being physically active
3328318|NCT02077400|No Intervention|no antibiotic|
3328319|NCT02077400|Active Comparator|Cephazolin|cefazoline
3259171|NCT01468168|Experimental|DE-101 Ophthalmic Suspension High Dose|
3259172|NCT01468168|Experimental|DE-101 Ophthalmic Suspension Low Dose|
3328320|NCT02077413|Active Comparator|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
3231894|NCT01205906|Experimental|Cognitive-behavior group therapy|This well-established, cognitive-behavior group therapy was developed by Hiller and Haerkötter (2005) and consists of 10 weekly group sessions of 90 minutes. The strictly manualized program includes the following components focusing on the special needs of chronic tinnitus patients: Education, relaxation techniques, cognitive restructuring, the role of attentional processes for tinnitus perception, analysis of avoidance behaviors, tinnitus and the health care system as well as relapse prevention. For each session participants receive written materials, exercises and homework assignments to enhance understanding and to transfer the new information into the daily routine.
3328321|NCT02077413|Experimental|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
3328322|NCT02077413|Active Comparator|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
3328323|NCT02077413|Experimental|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
3328324|NCT02077426|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises
3328325|NCT02077439|Experimental|Hand Robotic Training|Hand Robotic Training
3328326|NCT02077439|Experimental|Hand and Arm Robotic Training|Hand and Arm Robotic Training
3328327|NCT02077439|Active Comparator|Conventional therapy|Conventional therapy
3328328|NCT02077452|Experimental|HMS5552 dose 1|HMS5552 25~400mg. Oral administration, twice per day.
3328329|NCT02077452|Experimental|HMS5552 dose 2|HMS5552 25~400mg. Oral administration, twice per day.
3328330|NCT02077452|Experimental|HMS5552 dose 3|HMS5552 25~400mg. Oral administration, twice per day.
3328331|NCT02077452|Experimental|HMS5552 dose 4|HMS5552 25~400mg. Oral administration, once per day.
3231895|NCT01205906|Active Comparator|Discussion forum group|To the participants of the control group the group therapy or the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
3231896|NCT01205919|Experimental|Internet-based self-help|This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
3231897|NCT01205919|Active Comparator|Discussion forum group|To the participants of the control group the internet-based self-help after waiting time of 10 weeks is offered. During the waiting period participants receive access to a tinnitus online discussion forum.
3231898|NCT01205932|Experimental|Arm 1|
3231899|NCT01205932|Experimental|Arm 2|
3231900|NCT01205932|Experimental|Arm 3|
3231901|NCT01205932|Active Comparator|Arm 4|
3231902|NCT01205958|Active Comparator|medication(Zaltoprofen)|
3328332|NCT02077452|Experimental|HMS5552 dose 5|HMS5552 25~400mg. Oral administration, twice per day.
3328333|NCT02077478|Experimental|MCI|manually controlled infusion will be used
3328334|NCT02077478|Experimental|TCI|Target Controlled Infusion will be used
3328335|NCT02077491|Active Comparator|Intervention|High-protein diet and resistance training
3328336|NCT02077491|No Intervention|Control|The control group recieves standard care during the study.
3328337|NCT02077504|Experimental|CONDUCTOME|MEG and MRI
3328338|NCT02077517|Active Comparator|hand sewn anastomosis|Patients with hand sewn anastomosis during Roux en Y Gastric bypass performing
3328339|NCT02077517|Active Comparator|stapled anastomosis|Patients with stapled anastomosis during Roux en Y Gastric Bypass performing
3328340|NCT02077543|Experimental|ProTool|Device: Brain Tissue Imprint - Medical Device (ProTool)
3328341|NCT02077556|Experimental|Everolimus|Everolimus/Tacrolimus/Methylprednisolone & Prednisolone
3231903|NCT01205958|Active Comparator|Acupuncture|
3328342|NCT02077556|Active Comparator|Mycophenolate mofetil|Mycophenolate mofetil/Tacrolimus/ Methylprednisolone & Prednisolone
3231904|NCT01205958|Active Comparator|Zalprofen plus Acupuncture|
3231905|NCT01205971|Experimental|Motivational Interviewing|Motivational Interviewing to reduce caregiver risk factors for early childhood caries in their children is delivered by Dental Health Advocates (trained public housing residents) in combination with fluoride varnish applications, oral health assessments and referrals for children.
3231906|NCT01205971|Active Comparator|Dental Preventive Services|Fluoride varnish applications, written oral health educational materials regarding early childhood caries prevention, oral health assessments and referrals.
3231907|NCT01205984|Active Comparator|oral methylprednisolone|
3231908|NCT01205984|Placebo Comparator|placebo|
3259173|NCT01468168|Placebo Comparator|DE-101 Ophthalmic Suspension Vehicle|
3259174|NCT01468194|Experimental|Breathing procedure 1|"Walking with breathing procedure 1."
3328343|NCT02077569|Experimental|AZD5363 480mg|STAGE 1 ONLY AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3328344|NCT02077569|Placebo Comparator|Placebo|STAGE 1 ONLY Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3328345|NCT02077569|Experimental|AZD360mg|STAGE 2 AZD5363 360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3328346|NCT02077569|Experimental|AZD5363 240mg|STAGE 2 AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule
3328347|NCT02077595|Active Comparator|120Hz alternating current stimulation group|
3328348|NCT02077595|Active Comparator|5Hz alternating current stimulation group|
3328349|NCT02077595|Sham Comparator|sham alternating current stimulation group|
3328350|NCT02077608||Hyaluronan enriched transfer media|Embryos are incubated at least 10 minutes in hyaluronan enriched embryo transfer media before transfer
3328351|NCT02077608||Control group|Embryos are incubated in embryo transfer media containing low concentration of hyaluronan for at least 10 minutes before transfer
3328352|NCT02077621|Experimental|PG2|"Treatment Group:~PG2 (500 mg in 500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
3328353|NCT02077621|Placebo Comparator|Placebo|"Control group:~Placebo (500 ml saline), 1 dose a day before surgery and 1 dose a day for 3 days after surgery"
3328354|NCT02077634|Active Comparator|abiraterone acetate + prednisone + LHRH-therapy|Patients randomized to this group will continue their LHRH-therapy.
3231909|NCT01205997|Active Comparator|fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3231910|NCT01205997|Placebo Comparator|placebo|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3328355|NCT02077634|Active Comparator|abiraterone acetate + prednisone|Patients randomized to this group will stop LHRH-therapy.
3328356|NCT02077647||Conservative|Conservative treatment of osteoarthritis of the knee
3231911|NCT01205997|Active Comparator|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
3328357|NCT02077660|Placebo Comparator|4 daily placebo tea bags for 12 weeks|"All subjects will undergo a 12 weeks supplemented with four daily placebo maltodextrin tea-bags. The subjects will be instructed than to brew the placebo sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Placebo period)."
3328358|NCT02077660|Experimental|Four green tea bags per day for 12 weeks|After the placebo period, all subjects will undergo a 12 weeks supplemented with four daily green tea bags. The subjects will be instructed than to brew the green tea sachets for five minute in 240 mL boiling water without stirring and to drink 4 cups per day for 12 weeks period (Green tea period).
3328359|NCT02077673||open surgery|25 patients undergoing open gastroesophageal resection
3328360|NCT02077673||robotic-assissted surgery|25 patients under-going robotic-assisted gastroesophageal surgery
3328361|NCT02077686|Experimental|Education - Diabetes and Travel|"Patients randomized to this arm, will participate immediately in the education module Diabetes and Travel"
3328362|NCT02077686|No Intervention|Waiting-list control group|Patients in the control group will get the education with the education module after completion of the 6-month follow-up
3328363|NCT02077699|Experimental|1|Treatment with Lactobacillus casei DG (24 billion of live cells per pill) 2 pills b.i.d. for 4 weeks
3328364|NCT02077712|Active Comparator|Dexmedetomidine 1 ug/kg|1 ug/kg of intranasal dexmedetomidine
3328365|NCT02077712|Active Comparator|Dexmedetomidine 2 ug/kg|2 ug/kg of intranasal dexmedetomidine
3328366|NCT02077725||Interdisciplinary polypharmacy clinic|Patients will be seen in the interdisciplinary polypharmacy clinic for a complete comprehensive medication review
3328367|NCT02077738|Experimental|HFCWO|HFCWO for 15 min twice a day
3328368|NCT02077738|Placebo Comparator|placebo|not to receive high-frequency chest wall oscillation (HFCWO)
3328369|NCT02077751|Experimental|Biotin labelled RBCs|Subjects receive biotin labelled autologous red blood cells.
3328370|NCT02077764||Controls, healthy individuals|controls
3328371|NCT02077764||Heart transplanted patients|Patients
3328372|NCT02077777|Experimental|5-ASA|Mesalazine 800 mg orally t.i.d for 3 months
3328373|NCT02077777|No Intervention|No treatment|no treatment
3328374|NCT02077790|No Intervention|Substantial Equivalence|The CASIA Cornea/Anterior Segment OCT SS-1000 was used on all subjects for this study.
3328375|NCT02077803|Experimental|Treatment A|Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 100 mg, and 4 tablets of metformin extended release (MET XR), 500 mg, administered together under fed conditions.
3328376|NCT02077803|Experimental|Treatment B|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 1, under fed conditions.
3328377|NCT02077803|Experimental|Treatment C|Each participant will receive a single dose of 2 tablets of CANA/MET XR FDC, formulation 2, under fed conditions.
3328378|NCT02077816||Central venous catheter|Inpatients with CVC for medical care.
3328379|NCT02077829|Other|IMR therapists, IMR patients|"30 voluntary therapists from 9 mental health services will be trained and coached in IMR.~40 patients from the 9 mental health services will receive Illness Management and Recovery from the therapists in training."
3328380|NCT02077842|Experimental|Nasal CPAP|The experimental group will receive nasal continuous positive airway pressure at 10cmH20 for one hour in the Post Anesthetic Care Unit.
3328381|NCT02077842|Active Comparator|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
3328382|NCT02077855||Toddlers fractures|
3328383|NCT02077868|Other|Control Arm A|Patients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
3328384|NCT02077868|Experimental|Treatment Arm B|MGN1703 treatment as maintenance therapy
3328385|NCT02077881|Experimental|Indoximod and Gemcitabine + Nab-paclitaxel|"Phase 1 portion:~Participants to receive indoximod (600mg, 100mg, or 1200mg according to their assigned dose cohort) PO BID for 28 days concurrently with IV Nab-paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 weekly for 3 weeks with one week rest. Each cycle is 28 days. Patients will continue until they experience disease progression or significant toxicity.~Phase 2 portion:~Once a RP2D is determined, treatment will commence with oral indoximod concurrent with the first backbone chemotherapy cycle.Patients will receive gemcitabine plus nab-paclitaxel on a standard 4 week cycle schedule. Oral indoximod will continue throughout."
3231912|NCT01206010|Experimental|Varenicline + Active Tailored Dose|
3231913|NCT01206010|Placebo Comparator|Varenicline + Placebo Tailored Dose|
3231914|NCT01206023||Multiple Sclerosis|Multiple Sclerosis patients
3231915|NCT01206023||Healthy controls|healthy individuals
3328388|NCT02077907|Active Comparator|Super Cereal Plus (SC+)|"800 kcal/d, 215 g/d~Current protocol for treating MAM is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. In Sierra Leone, their FBF standard is Super Cereal Plus."
3328389|NCT02077907|Experimental|Super Cereal (SC) and oil and sugar|"200 g SC and 20 g fortified oil and 15 g sugar, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
3328390|NCT02077907|Experimental|Corn Soy Blend 14 (CSB14) and fortified oil|"978 kcal/day - 150 g CSB14 and 45 g oil, per day~Fortified blended food (FBF) Fortified Oil with Vitamins A & D"
3328391|NCT02077907|Experimental|Plumpy'Sup|"500 kcal/d, 92 g/d~Ready-to-Use Supplementary Food (RUSF)"
3328392|NCT02077920|Experimental|Chlorhexidine before intubation|Group A: Oropharyngeal decontamination with chlorhexidine before intubation, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation, and every 6 hours after intubation.
3328393|NCT02077920|Experimental|Chlorhexidine after intubation|Group B: Oropharyngeal decontamination with chlorhexidine after intubation, n=48. Oral cleansing with chlorhexidine will be performed every 6 hours after endotracheal intubation.
3328394|NCT02077920|Experimental|Subglottic secretion drainage|"Group C: Suctioning of subglottic secretions, n=48. Oral cleansing with chlorhexidine will be performed before endotracheal intubation and every 6 hours after intubation, and fiberoptic bronchoscopy-guided suctioning of subglottic secretions will be performed at 10:00 a.m. every day. The procedure will be as follows:~Routine cleaning of the bronchoscope.~Oral or nasal insertion of the bronchoscope (according to the decision of the attending physician based on the patient's condition). Rinsing of the subglottic region with 5-20 mL of chlorhexidine solution followed by suctioning. The rinsing procedure will be repeated 3-5 times.~Routine cleaning of the bronchoscope. The patient will be monitored during all procedures."
3328395|NCT02077920|Experimental|0.9% sodium chloride injection|Group D: 0.9% sodium chloride injection, n=48. After endotracheal intubation, oral cleansing with normal saline will be performed every 6 hours.
3328396|NCT02077933|Experimental|alpelisib and everolimus|alpelisib and everolimus administered once a day
3328397|NCT02077933|Experimental|alpelisib, everolimus and exemestane|alpelisib, everolimus and exemestane administered once a day
3328398|NCT02077933|Experimental|alpelisib and exemestane|alpelisib and exemestane administered once a day
3328399|NCT02077946||Liraglutide / Sitagliptin|
3328400|NCT02077959|Experimental|Treatment (lenalidomide, pidilizumab)|Patients receive lenalidomide PO daily on days 1-21 and pidilizumab IV over 1-2 hours on day 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3328401|NCT02077972|Experimental|High intensity whole-body infrared heating|The participant will undergo the WBH intervention where subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C.temperature.
3328402|NCT02077985|No Intervention|Regular Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Regular dental environment no sensory characteristics of the dental environment are altered, the cleaning is conducted as per usual.
3231916|NCT01206049|Experimental|Combination chemotherapy + panitumumab|
3231917|NCT01206049|Experimental|Combination chemotherapy + bevacizumab|
3231918|NCT01206075|Other|Mozobil + G-CSF - 001|Up to four patients (splenectomized and non-splenectomized) previously mobilized with G-CSF (previous study), who failed to yield by 2 leukaphereses sufficient CD34+ cells for a future gene therapy procedure, will receive the combination of G-CSF+Mozobil
3328403|NCT02077985|Experimental|Sensory Adapted Dental Environment|There are two dental environments - the regular dental environment and the sensory dental environment; each child will be randomized to which is first. In the Sensory Adapted Dental Environment the sensory characteristics of the dental environment are altered (visual, auditory, tactile adaptations).
3328404|NCT02077998|Experimental|Diagnostic (carbon C 14 oxaliplatin and oxaliplatin)|"PHASE 0: Patients receive carbon C 14 oxaliplatin IV over 2 minutes on day 1.~PHASE II: Patients receive oxaliplatin IV over 2 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity."
3328405|NCT02078011|Experimental|HIFU treatment|The high intensity focused ultrasound (HIFU) will be administered to the targeted site to create heat and cause the cells to die
3328406|NCT02078024|Active Comparator|Annual Ivermectin|Ivermectin 200 µg/kg body weight given orally at 0, 12 and 24 months
3328407|NCT02078024|Experimental|Biannual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg (regardless of weight) given at 0, 6, 12, 18, and 24 months.
3328408|NCT02078024|Experimental|Annual IVM 200 µg/kg plus ALB 800 mg|IVM 200 µg/kg plus ALB 800 mg given at 0, 12 and 24 months; vitamin pills at given at 6 and 18 months.
3328409|NCT02078024|Experimental|Biannual IVM 200 µg/kg|IVM 200 µg/kg given 0, 6, 12, 18, and 24 months.
3328410|NCT02078024|Experimental|IVM 200 µg/kg plus ALB 400 mg|IVM 200 µg/kg plus ALB 400 mg given at 0, 6, 12, 18, and 24 months.
3231919|NCT01206075|Other|Mozobil|Sixteen or more patients (non-splenectomized and splenectomized) who were not previously mobilized will receive Mozobil alone.
3231920|NCT01206075|Other|Mozobil + G-CSF - 002|Patients who, in this study, fail to mobilize sufficient yields of blood stem cells with Mozobil alone will be invited to be re-mobilized with the combination of Mozobil plus G-CSF.
3328411|NCT02078037|Experimental|Arctic Sun cooling device|The Arctic Sun device pads will be placed on the patient as per manufacturer's instructions. Patients, who cannot tolerate placement of all the pads for any given reason, will still be included in the study if they can maintain normothermia (normal body temperature). The total normothermia time for the study is five days. After 5 days, the attending physician will make clinical decisions based on the patient needs.The temperature goal for this study is 36.5 degree Celsius, but normothermia for the purpose of this study will be defined as a temperature of 35.5 - 37.5 degree Celsius. A thermometer mounted urinary catheter will be used for temperature monitoring and feedback to the Arctic Sun.
3328412|NCT02078037|Active Comparator|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician) initiated at a temperature of 38.5 degrees Celsius
3328413|NCT02078050|Other|Phrenic nerves magnetic stimulations|
3328414|NCT02078063|Experimental|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
3328415|NCT02078063|Placebo Comparator|NaCL|10 ml NaCl 9mg/ml instilled into the uterus through a hydrosonography catheter
3328416|NCT02078076|Experimental|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
3231921|NCT01206088|Experimental|nilotinib|
3231922|NCT01206114||Vaccinated persons|The participants have taken one or more doses of 2009 H1N1 vaccine, either as a monovalent vaccine or as a part of a trivalent seasonal 2010-2011 influenza vaccine
3231923|NCT01206114||Not (yet) vaccinated persons|The participants do not want to take any 2009 H1N1 vaccine or have not received any yet
3231924|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group must be lying down facing up 2 hours postoperatively
3231925|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperatively
3328417|NCT02078089|Other|Oxcarbazepine and Morphine|"Patients must be on stable or increasing doses of greater than or equal to 180 mg of morphine sulfate per day. Morphine is taken orally for 42 days.~In addition to Morphine, patients will also receive oral Oxcarbazepine 150 mg, every 12 hours, for 2 weeks, then increase the dose to 300 mg, every 12 hours, for 2 weeks and then increase the dose to 450 mg, every 12 hours, for the final 2 weeks. Patients will take oral tablets of oxcarbazepine for a total of 42 days."
3328418|NCT02078115||chronic kidney disease, hypertension|20 <= age < 75 years 15 <= estimated glomerular filtration rate (GFR) < 90
3328419|NCT02078128|Experimental|oral beta-glucans|Daily give kg per day to 30 mg of β-glucan (30mg/kg/day), taking to the wound healed.
3328420|NCT02078128|Placebo Comparator|oral sugar powder|control group, daily give and the glucose powder 30 mg per kilogram of body weight (30mg/kg/day) a day, taking to the wound healed.
3328421|NCT02078154||Deep Venous Thrombosis (DVT)|DVT diagnosed by imaging technique with a low or moderate Wells score
3328422|NCT02078206|Experimental|Neurocognitive stimulation|Intervention of experimental group consists in a neurocognitive stimulation treatment. Using kinect technology, patient can interact with a virtual environment where different cognitive tasks have to be resolved.
3328423|NCT02078206|No Intervention|Treatment as usual|
3328424|NCT02078232|Experimental|19G flex needle puncture|puncture of head of pancreas
3231926|NCT01206153|Experimental|metformin|
3328425|NCT02078232|Active Comparator|22G needle puncture|puncture of head of pancreas
3328426|NCT02078245||Familial pancreatic cancer patients|Individual with ten fold higher risk to develop pancreatic cancer.
3231927|NCT01206179|Experimental|non union|Patients with nonunion fracture of long bones
3328427|NCT02078258|Experimental|Attentional bias modification training|"Attention bias modification training (ABMT) is a a variation of attention tasks to modify attentional biases, in which a probe always appears in the location of relatively positive stimuli after the two stimuli, one neutral and one emotional, were simultaneously presented.~Participants complete 8 sessions (320 trials each with 20 minutes) over two weeks of neutral ABMT to shift attention toward neutral, in which a probe appeared in the location of neutral with 90% probability, and sadness-related with 10% probality. At a 9-week follow-up, participants completed 4 more sessions (480 trials each with 30 minutes)over two weeks of positive ABMT to shift attention toward positive words,in which a probe appeared in the location of 67% positive or 33% neutral."
3328428|NCT02078258|Active Comparator|Placebo control|The placebo ABMT was identical to the active ABMT, but shifted toward neutral (50%) or sad (50%) stimuli equally often (i.e., 50/50 training).
3328429|NCT02078271|Experimental|FBDG group|The group received Food Based Dietary Guidelines for feeding recommendation. Monthly-session with group of mothers involving interactive activities e.g. cooking session, cooking competition and games.
3231928|NCT01206192||Abused Chinese women|
3231929|NCT01206205|Experimental|Lenalidomide, Bortezomib|"3 induction cycles of bortezomib, lenalidomide and dexamethasone (VRD) followed by high dose melphalan and autologous stem cell transplantation.~Two months after haematological recovery, patients will receive 2 consolidation cycles of VRD and maintenance therapy for 1 year with lenalidomide."
3231930|NCT01206218|Active Comparator|Group A|FLOT Regimen
3231931|NCT01206218|Experimental|Group B|FLO Regimen or FLOT Regimen
3231932|NCT01206231||1|Patients with hypercholesterolemia
3231933|NCT01206244||Normal|Normal subjects
3231934|NCT01206244||Dry eye|clinically diagnosed dry eye with aqueous tear deficiency
3231935|NCT01206257||Group 1|
3328430|NCT02078271|Experimental|Stimulation group|The children received psychosocial stimulation from the mothers. Mothers were taught on psychosocial module which was developed using locally existing resources and was directed at improving four aspects of child development, namely gross motoric, fine motor, language and socio-emotional developments.
3328431|NCT02078271|Experimental|Combined (FBDG and Stimulation)|The group received both FBDG and psychosocial stimulation
3328432|NCT02078271|Other|Control|The group received standard health education messages from existing health care system.
3328433|NCT02078297||Scalp psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3231936|NCT01206270|Experimental|Testosterone|Testosterone undecanoate 1000mg injection at baseline (0-week), 6-week, 18-week, 30-week
3231937|NCT01206270|Placebo Comparator|Placebo|Injection 4 ml of castor oil at baseline (week-0), week-6, week-18, week-30
3231938|NCT01206283|Active Comparator|Cerebral perfusion pressure-targeted|15 comatose operated patients after aneurysmal subarachnoid haemorrhage and severe traumatic brain injury respectively were managed postoperatively using cerebral perfusion pressure-targeted therapy according to the American Associations of Neurological Surgeons. Results were categorised into different Glasgow Outcome Scores.
3231939|NCT01206283|Active Comparator|Intracranial pressure-targeted therapy|
3231940|NCT01206309||Controls|Never develop an immune mediated disorder
3231941|NCT01206309||Immune Mediated Disorder|Develop an immune mediated disorder
3231942|NCT01206335|Experimental|OHR/AVR118|Experimental Drug
3328434|NCT02078297||pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3328435|NCT02078297||non-pustular palmo-plantar psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3328436|NCT02078297||elbow psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3328437|NCT02078297||leg psoriasis|Patients have at least one psoriatic lesion on trunk or and psoriasis that is more resistant to treat such as scalp psoriasis, pustular palmo-plantar psoriasis, non-pustular palmo-plantar psoriasis, elbow psoriasis and lower leg psoriasis.
3328438|NCT02078297||Healthy subjects|
3328439|NCT02078310|Experimental|ITI-007 Part 1|Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007
3328440|NCT02078310|Placebo Comparator|Placebo Part 1|Part 1: Healthy geriatric volunteers with placebo given
3328441|NCT02078310|Experimental|ITI-007 Part 2|Part 2: Geriatric patients with dementia with ITI-007 given
3328442|NCT02078310|Placebo Comparator|Placebo Part 2|Part 2: Geriatric patients with dementia with placebo given
3231943|NCT01206348|Experimental|Open Label Combination|Solodyn, Ziana, Triaz FC
3231944|NCT01206361||fixed dose prostaglandin combination|
3328443|NCT02078323|Active Comparator|Linaclotide|Linaclotide 290micrograms q day 30 min before meal for a 10 week period
3328444|NCT02078323|Placebo Comparator|placebo|Placebo q day 30 min before meal for a 10 week period
3231945|NCT01206400||pioglitazone vs placebo|15 patients in pioglitazone group and 15 in placebo group
3231946|NCT01206413|Experimental|LGI|Low glycemic index
3328445|NCT02078336|Experimental|Midazolam|Midazolam Mylan 5 mg/ml solution for injection 15mg Oral use Single dose 45 minutes before dental treatment
3328446|NCT02078336|Active Comparator|Lorazepam / Valium+Akineton+Dehydrobenzperidol+Atropine sulfat|"Lorazepam Mylan 2,5 mg tabletten 2.5mg Oral use Single dose 45 minutes before dental treatment~OR~Valium 10 mg/2 ml solution for injection 10mg Intramuscular use Single dose 45 minutes before dental treatment~+ Akineton 5 mg/ml solution for injection 5mg Intramuscular use Single dose 45 minutes before dental treatment~+ Dehydrobenzperidol 5 mg/2 ml solution for injection 0,000125 ml/cm2 Intramuscular use Single dose 45 minutes before dental treatment~+ Atropine sulfate Sterop 0,25mg/1ml solution for injection 0,25mg Intramuscular use Single dose 45 minutes before dental treatment"
3231947|NCT01206413|Active Comparator|HGI|High glycemic index
3231948|NCT01206413|Experimental|HB|Home-based exercise
3328447|NCT02078349|Experimental|Solid Tumors|"Patients will receive Selinexor once weekly (Schedule 1) or twice weekly (Schedule 2) or three times a week (Schedule 3) orally at a starting dose of 50 mg/m² (Schedule 1) and 40mg/m2 (Schedule 2) and 20mg/m2 (Schedule 3).~One cycle is 28 days for Schedule 1 and Schedule 3 and 21 days for Schedule 2. Treatment will continue until disease progression or the development of unacceptable toxicities."
3328448|NCT02078375|Placebo Comparator|Carbohydrate supplement|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a carbohydrate supplement to take twice daily (once after exercise).
3328449|NCT02078375|Experimental|Protein Supplementation|Participants will be enrolled in a twice weekly resistance exercise program. They will receive a twice daily protein supplement (once after exercise).
3231949|NCT01206413|Active Comparator|CONTROL|Non-exercisers
3231950|NCT01206543|Experimental|Intraoperative imaging|
3231951|NCT01206569|Experimental|advagraf|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
3231952|NCT01206621||ED patients presenting with dyspnea|
3231953|NCT01206634|Experimental|Regenerative injection therapy|
3231954|NCT01206634|Active Comparator|Exercise|
3231955|NCT01206647|No Intervention|Control arm|The patients randomized to the control arm will continue their current therapy, as individually prescribed. Insulin will be administered via subcutaneous injection and OADs (if applicable) will be administered orally, as individually prescribed.
3259175|NCT01468194|Experimental|Breathing procedure 2|"Walking with breathing procedure 2."
3259176|NCT01468194|No Intervention|Control group|Walking without any reglementation of breathing
3328450|NCT02078388||Breast cancer,Doxorubicin|Breast cancer patients who received at least one cycle of doxorubicin-containing adjuvant chemotherapy for treatment of early stage breast cancer at least 12 months ago and who had a pre-doxorubicin echocardiography done at NUHS will be enrolled. Study subjects will donate one sample of blood (20ml) for genetic and biomarker studies related to breast cancer and anthracyclines pharmacodynamics. An echocardiography will be performed to measure left ventricular ejection fraction, and compared with the subject's pre-doxorubicin echocardiography done at NUH. Correlative analysis will be performed between genetic variants and left ventricular ejection change.
3328451|NCT02078401||Neurofibromatosis type 1 children|
3328452|NCT02078414||Ulipristal acetate|Women choosing EllaOne as emergency contraception
3328453|NCT02078414||Copper IUD|Women choosing copper IUD as emergency contraception
3328454|NCT02078440|Other|Bromocriptine mesylate (Cycloset)|Bromocriptine mesylate (Cycloset)
3328455|NCT02078453|Active Comparator|Visual inspection|Dental treatment performed according to the caries diagnosis obtained with visual inspection performed alone
3328456|NCT02078453|Experimental|Radiographic examination|Dental treatment performed according to the caries diagnosis obtained with visual inspection and additional radiographic method.
3328457|NCT02078466|No Intervention|Control group|Usual care
3328458|NCT02078466|Experimental|Assessment of functional ability|Assessment of functional ability and follow-up at home
3328459|NCT02078479|Active Comparator|Real rTMS|The active group received Real rTMS over the hand area of motor cortex (20 Hz, 10 second, 10 trains with inter-train interval 30 second with total pulses 2000, intensity 80% of motor threshold) every day for ten consecutive days (5 days/week).
3328460|NCT02078479|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce the same of subjective sensation of rTMS
3328461|NCT02078505|Experimental|PCOS after diet|Patients after 2 months of diet
3328462|NCT02078505|No Intervention|control|Ovulatory women
3328463|NCT02078518||Multiple Myeloma|Questionnaires will be given to patients for completion.
3328464|NCT02078531||Chemotherapy and anti-hormonal therapy|"cognitive assessment using CANTAB~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
3328465|NCT02078531||chemotherapy only and healthy control group|"cognitive assessment using CANTAB~Imaging to assess the effect of systemic therapy on brain function. Subjects may participate in the first part of the study without undergoing the imaging assessment or may participate in both parts of the study."
3328466|NCT02078544||Gynaecological cancer|
3328467|NCT02078570||Breast Cancer ACR BI-RAD Category 3 or 4 result|
3328468|NCT02078583|Experimental|Remifentanil，midazolam|Remifentanil 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3231956|NCT01206647|Experimental|Saxagliptin & metformin|Saxagliptin and metformin tablets will be administered orally. Pioglitazione (Rescue medication) tablets will be administered orally. Insulin glargine (Rescue medication) will be administered via subcutaneous injection as individually prescribed.
3328469|NCT02078583|Experimental|Fentanyl，midazolam|Fentanyl 1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3328470|NCT02078583|Placebo Comparator|Normal saline|Normal saline1µg/kg/hr intravenous pump and Midazolam loading dose 0.05mg/kg followed by 0.02~0.1mg/kg/h continuous intravenous pump for 7days or extubation
3328471|NCT02078596|Experimental|Divalproex|Divalproex at 10 mgs/lb
3328472|NCT02078596|Placebo Comparator|Sugar Pill|Equivalent 250 mg pills titrated to 10 mgs / lb over six weeks
3328473|NCT02078609|Experimental|LGH447 monotherapy arm|LGH447 monotherapy in patients with AML or MDS
3328474|NCT02078609|Experimental|LGH447 + midostaurin combination arm|LGH447 + midostaurin in patients with AML
3328475|NCT02078622||COPD, Education and Case Management|Respiratory Therapist Education and Case Management
3231957|NCT01206686|Experimental|1 Hour Planning Prompt|
3231958|NCT01206686|Experimental|2 Hour Planning Prompt|
3231959|NCT01206686|Experimental|1 Day Planning Prompt|
3328476|NCT02078635|Experimental|Portfolio Plus Diet|Participants will be advised to follow a low glycemic index dietary portfolio. Specifically, the advice will be to limit saturated fat (to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat and selection of low glycemic index foods; emphasizing current recommendations for fruit and vegetable intakes (5-10 servings/d)
3328477|NCT02078635|Active Comparator|DASH-like (high fibre) diet|The DASH-like dietary advice will emphasize a diet of whole grains, low-fat dairy and current recommendations for fruit and vegetables (5-10 servings/day)
3328478|NCT02078648|Experimental|SL-701; poly-ICLC 1.6mg; bevacizumab|SL-701 emulsion and the adjuvant poly-ICLC will be administered twice weekly for the initial 2 weeks, every 7 days during the subsequent 3 doses, and subsequently every 14 days for the subsequent 9 doses (16 doses total) through Week 22, and every 4 weeks thereafter. Bevacizumab will be administered every 2 weeks, subsequent to the administration of SL-701/poly-ICLC
3328479|NCT02078661|Active Comparator|PG101 0.25%|Topical application of drug
3328480|NCT02078661|Active Comparator|PG101 1.0%|Topical application of drug
3328481|NCT02078661|Placebo Comparator|Placebo|Topical application of placebo
3328482|NCT02078674|Experimental|Group A|Placebo
3328483|NCT02078674|Experimental|Group B|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 and Day 21
3328484|NCT02078674|Experimental|Group C|High dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3328485|NCT02078674|Experimental|Group D|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3328486|NCT02078674|Experimental|Group E|Low dose Monovalent Avian Influenza VLP (H7N9) with Low dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3328487|NCT02078674|Experimental|Group F|High dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3231960|NCT01206686|Experimental|Default Planning Prompt|
3231961|NCT01206686|Active Comparator|Control|
3231962|NCT01206699|Experimental|corticoid|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
3328488|NCT02078674|Experimental|Group G|Intermediate dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3328489|NCT02078674|Experimental|Group H|Low dose Monovalent Avian Influenza VLP (H7N9) with High dose Matrix-M1™ adjuvant; IM; Day 0 and Day 21
3328490|NCT02078687|Active Comparator|Group 1, HM|This group received breastfeeding (human milk, HM) solely throughout the 4 month of intervention. Randomisation for group 1 or group 2. Mothers own milk.
3328491|NCT02078687|Active Comparator|Group 2, HMF|This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
3328492|NCT02078687|Active Comparator|Group 3, PF|This group received preterm formula (PF) throughout the intervention period of 4 month. This group was not randomised for ethical reasons. Enfalac Premature Formula, Mead Johnson Nutritionals
3231963|NCT01206699|Placebo Comparator|physiological solution|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
3231964|NCT01206712||T2DM patients treated with LANTUS + MET|T2DM patients treated with LANTUS + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3328493|NCT02078700|Experimental|early palliative care programme|Patients will be proposed to be followed by the Palliative Care Team
3328494|NCT02078739|Experimental|Yoga Program|Yoga Program twice per week for 8 weeks
3328495|NCT02078739|Active Comparator|Education|Education once per week for 8 weeks
3328496|NCT02078765||hypertension|75 patients with hypertension and chronic kidney disease (CKD stage I-II)
3328497|NCT02078765||healthy subjects|75 healthy subjects
3328498|NCT02078778|Experimental|Treatment|Patients with hypertension and moderate to severe OSA is treated with CPAP for 3 months.
3328499|NCT02078791|Experimental|Botox infiltration|Botox infiltration in cervical region
3328500|NCT02078791|Experimental|Psychology therapy|Problem solving group therapy
3328501|NCT02078791|Experimental|Botox infiltration & psychology therapy|Botox infiltration in cervical region and problem solving group therapy.
3328502|NCT02078804|Experimental|Colonoscopy|20 000 subjects will be invited to an once-only colonoscopy.
3328503|NCT02078804|Experimental|FIT for occult blood|60 000 persons will be invited to take a fecal test for hemoglobin year 1 and year 3. If test-positive, they will be referred to colonoscopy.
3231965|NCT01206712||T2DM patients treated with SU + MET|T2DM patients treated with Sulfonylurea (SU) + Metformin(MET)in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3231966|NCT01206712||T2DM patients treated with DPP-4 + MET|T2DM patients treated with Dipeptidylpeptidase 4 inhibitors (DPP-4) + Metformin(MET) in their routine antidiabetic therapy. These patients do not receive any study specific medication.
3231967|NCT01206712||Healthy subjects|healthy volunteres who do not receive any antidiabetic medication in their routine therapie.
3328504|NCT02078804|No Intervention|Controls|120 000 matched persons will be identified in the Swedish Register of the total population and will be used as controls.
3328505|NCT02078830|Placebo Comparator|3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
3328506|NCT02078830|Experimental|3M™ Tegaderm™ CHG Securement Dressing|- CHG activity at EVD entry site
3328507|NCT02078843|Other|All patients|Subsequent performance of index test and standard test
3328508|NCT02078856|Experimental|A3384 Low dose|Administered twice daily for the duration of the study
3328509|NCT02078856|Experimental|A3384 High dose|Administered twice daily for the duration of the study
3328510|NCT02078856|Placebo Comparator|Placebo|Administered twice daily for the duration of the study
3328511|NCT02078869|Active Comparator|intramuscular Progesterone in oil|50mg of intramuscular Progesterone injection will be administered once daily for 6 days including the day of embryo transfer
3231968|NCT01206725|Other|. Moderate Intensity Exercise Group|Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
3231969|NCT01206725|Other|Aerobic interval training|Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
3328512|NCT02078869|Active Comparator|vaginal progesterone suppositories|200mg of progesterone suppositories will be administered 3 times a day for 6 days including the day of embryo transfer
3231970|NCT01206790|Experimental|Narrative Exposure Therapy (NET)|
3231971|NCT01206790|No Intervention|Waitinglist Control Group|
3328513|NCT02078895|Experimental|Botox|The experimental group will include ureteral stent placement with three peri-ureteral injections of Botox A and fourteen site-specific intradetrusor injections of Botox A.
3328514|NCT02078895|No Intervention|Control|The control group will involve a ureteral stent placement with no injection.
3231972|NCT01206829|Active Comparator|Audiological rehabilitation|16 hours of psychosocial rehabilitation course
3328515|NCT02078908|Active Comparator|40 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
3328516|NCT02078908|Active Comparator|120 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
3328517|NCT02078908|Active Comparator|240 micrograms sodium nitrite|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
3328518|NCT02078908|Placebo Comparator|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
3328519|NCT02078921|Experimental|Treatment|Inorganic Nitrate
3328520|NCT02078921|Placebo Comparator|placebo|Placebo
3328521|NCT02078934|Experimental|Weight Loss|Patients with complex incisional/ventral hernias who are too obese to undergo hernia repair.
3328522|NCT02078973|Active Comparator|15 mg tolvaptan|Oral administration of 15 mg tolvaptan on each examination day.
3328523|NCT02078973|Active Comparator|30 mg tolvaptan|Oral administration of 30 mg tolvaptan on each examination day.
3328524|NCT02078973|Active Comparator|45 mg tolvaptan|Oral administration of 45 mg tolvaptan on each examination day.
3328525|NCT02078973|Placebo Comparator|Placebo|Oral administration of a Unikalk tablet
3328526|NCT02078986|Experimental|Whole Body Electromyostimulation|
3328527|NCT02078986|Experimental|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise 2-3 session/week/14 weeks
3328528|NCT02078999||Control Grup|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3328529|NCT02078999||Patients with pulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3328530|NCT02078999||Patients with extrapulmonary infection|"Daily clinical data collection~Quantitative tracheal aspirates (QTA) every 3 days~Deep freeze serum samples for posterior analysis every day (two aliquots).~In patients with documented pneumonia daily collection of the following variables will continue: CRP, PCT, ABG, mechanical ventilation parameters, ACCP/SCCM consensus conference criteria, simplified CPIS, SOFA."
3328531|NCT02079012|Experimental|Intervention group|"Receives:~An information session~A 10-week walking program (with documents, pedometer and three information sessions about motivation, a healthy diet and smoking cessation)~A physical activity diary (which also functions as a tool to check protocol-compliance)~Measurements"
3328532|NCT02079012|No Intervention|Control group|Only receives measurements.
3328533|NCT02079051|Experimental|High Intensity Weight Loss|High intensity medical weight loss
3328534|NCT02079051|Active Comparator|Moderate Intensity Weight Loss|Moderate intensity weight loss
3328535|NCT02079064|Experimental|Desflurane|Desflurane at 1 MAC and
3328536|NCT02079064|Experimental|propofol|propofol TCI (target controlled infusion) infusion of to keep a target plasma concentration between 2 and 5 µg ml-1
3328537|NCT02079090|Active Comparator|Ketofol|Patient will receive 0.5 mg/kg Ketamine, and 2 minutes later receive 1 mg/kg Propofol.
3328538|NCT02079090|Experimental|Fentofol|Patient will receive 1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol.
3328539|NCT02079103|Experimental|Virtual reality|Virtual reality training using the YouGrabber® for patients with impaired arm motor function after stroke. The YouGrabber exercises focus on intensity, repetitions and motivating tasks and are adapted to the patient's motor abilities.
3231973|NCT01206842|Experimental|social cognition training|
3231974|NCT01206842|No Intervention|treatment as usual|
3328540|NCT02079103|Active Comparator|Conventional arm training|The patients receive supervised self-training exercises with focus on functional tasks adapted to their motor abilities.
3328541|NCT02079116|Experimental|60 grams of fat plus water solution|"In the group with 10 volunteers with obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water.~Also, in the group with 10 volunteers without obesity, some of them are submitted first to the 60 grams of fat plus water solution (meal challenge) and in another time to only water."
3328542|NCT02079116|Placebo Comparator|Pure water.|"In the same group with 10 volunteers with obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge).~Also, in the same group with 10 volunteers without obesity, some of them are submitted first to only water (control) and in another time to the 60 grams of fat plus water solution (meal challenge)."
3231975|NCT01206855|Active Comparator|SOC Treated Side of Incision|One side of the incision will be treated with surgeon's standard postoperative care including cleansing, creams, dressings
3328543|NCT02079142|Experimental|High Intensity Strategy: Train-the-trainer|One therapist from each counseling center randomized to this arm will be selected to become the trainer and will be trained to train their colleagues.
3328544|NCT02079142|Active Comparator|Low Intensity Strategy: Expert Consultation|The IPT expert from Washington University will travel to all counseling centers randomized to this condition and train all participating therapists on site and be available for monthly phone consultation for up to one year following training on site.
3328545|NCT02079155|Active Comparator|Arm I (RALP)|Patients undergo standard RALP.
3328546|NCT02079155|Experimental|Arm II (R-LESS RP)|Patients undergo R-LESS RP.
3328547|NCT02079168|Experimental|Cohort 1|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin at the time of surgery.
3328548|NCT02079168|Experimental|Cohort 2|Treatment with RXI-109 at the site of one excised keloid and a placebo at the site of a second excised keloid. Dosing to begin two weeks after surgery.
3231976|NCT01206855|Active Comparator|MIST Treated Side of Incision|One half of the incision will receive MIST Therapy treatments 3 times per week for 2 weeks
3231977|NCT01206868|Active Comparator|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
3231978|NCT01206868|Sham Comparator|Control|Standard kidney transplantation
3231979|NCT01206933||Detectable HIV RNA and HCV RNA|HIV and HCV co-infected with detectable HIV RNA and HCV RNA
3231980|NCT01206933||Undetectable HIV and Detectable HCV|HIV and HCV infected, HIV RNA Undetectable(treated) and Detectable HCV RNA.
3231981|NCT01206933||Undetectable HIV and HCV|HIV and HCV infected, Undetectable HIV RNA and HCV RNA
3231982|NCT01206933||Undetectable HCV|HCV(mono-infected,) HCV RNA undetectable
3231983|NCT01206933||Detectable HCV RNA|Monoinfected HCV, detectable RNA
3231984|NCT01206933||Detectable HIV RNA|Monoinfected HIV, Detectable RNA
3231985|NCT01206946|Experimental|Antenatal steroids|
3231986|NCT01206946|Placebo Comparator|Normal saline|
3231987|NCT01206959||monitor method|"blood pressure monitor Cuff circumference:22cm-48cm~stethoscopy Cuff circumference: 22cm-48cm"
3231988|NCT01206972|Experimental|Arm 1|
3231989|NCT01206972|Experimental|Arm 2|
3231990|NCT01206972|Experimental|Arm 3|
3328549|NCT02079181|Experimental|Diagnostic (fluorine F 18 d-FMAU PET/CT scan)|Patients receive fluorine F 18 d-FMAU IV followed by PET/CT prior to start of cancer treatment. Patients may undergo 2 additional scans at one week prior to second course of chemotherapy and after completion of cancer treatment depending on cancer type.
3328550|NCT02079194|Experimental|P2Y12 antagonist monotherapy|P2Y12 antagonist monotherapy after 3-month DAPT
3328551|NCT02079194|Experimental|Aspirin + P2Y12 antagonist|Aspirin + P2Y12 antagonist after 3-month DAPT
3328552|NCT02079207|Experimental|NBP606|Participants aged over 50 years are given a 0.5mL dose of 13-valent peumococcal conjugate vaccine administered on day 0.
3328553|NCT02079207|Active Comparator|Prodiax-23|Participants aged over 50 years are given a 0.5mL dose of 23-valent pneumococcal polysaccharide vaccine administered on day 0.
3328554|NCT02079220|Experimental|Arm A|"Arm A (every 2 week schedule) Dosage and dosage regimen for all study periods~Capecitabine: will be administered 1,000 mg/m2 orally twice a day on Days 1 - 7 of each cycle, repeating every 14 days.~Oxaliplatin: will be administered 85 mg/m2 IV on Day 1 of each cycle, repeating every 14 days.~Ziv-aflibercept: will be administered 4 mg/kg IV on Day 1 of each cycle, repeating every 14 days."
3328555|NCT02079220|Experimental|Arm B|"Arm B (every 3 week schedule):~Dosage and dosage regimen for all study periods~Capecitabine: will be administered 850 mg/m2 orally twice a day on Days 1 - 14 of each cycle, repeating every 21 days.~Oxaliplatin: will be administered 130 mg/m2 IV on Day 1 of each cycle, repeating every 21 days.~Ziv-aflibercept: will be administered 6 mg/kg IV on Day 1 of each cycle, repeating every 21 days."
3328556|NCT02079233|Experimental|CLP 15 g QD|Cross-Linked Polyelectrolyte (CLP) study medication delivered immediately before bedtime
3328557|NCT02079233|Experimental|CLP 7.5 g BID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered b.i.d. one hour before breakfast and dinner
3328558|NCT02079233|Experimental|CLP 5 g TID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered t.i.d. one hour before breakfast, lunch and dinner
3328559|NCT02079233|Experimental|CLP 3.75 g QID|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d on hour before breakfast, lunch, dinner and immediately before bedtime
3328560|NCT02079272|Other|Helical tomotherapy for breast cancer|"All women included in REBECCA cohort will be treated with helical tomotherapy for theur breast cancer.~Their cardiac follow-up will be based on echocardiography, CT coronary angiogram and blood samples"
3328561|NCT02079285||EUS-FNA|Any patients who will undergo EUS-FNA for pancreas lesion during the study period
3231991|NCT01206972|Active Comparator|Arm 4|
3231992|NCT01206998|Experimental|Vaginal progesterone gel|
3231993|NCT01206998|Placebo Comparator|Placebo vaginal gel|
3328562|NCT02079298|Active Comparator|1|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated only with fluconazole.
3328563|NCT02079298|Active Comparator|2|Premature newborn infants with Gestational Age 23+0 to 26+6 weeks who are treated with both fluconazole and Ibuprofen.
3328564|NCT02079298|Active Comparator|3|Premature newborn infants with Gestational Age 27+0 to 36+6 who are treated only with ibuprofen.
3328565|NCT02079298|Placebo Comparator|4|Premature newborn infants with Gestational Age 27+0 to 36+6 and fullterm infants who are not treated either with fluconazole or ibuprofen.
3328566|NCT02079324|Experimental|GX-051|GX-051 intratumoral injection
3328567|NCT02079337|Active Comparator|Deep NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during deep neuromuscular blockade and without neuromuscular blockade
3328568|NCT02079337|Placebo Comparator|No NMB|Videorecordings and subjective ratings of intraabdominal surgical conditions during no neuromuscular blockade and during deep neuromuscular blockade.
3328569|NCT02079350||%4 Gelofusine|patients administered %4 Gelofusine during liver transplantation
3328570|NCT02079350||%6 HES|patients administered %6 HES during liver transplantation
3328571|NCT02079363||Patients with pancreatic adenocarcinoma|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
3328572|NCT02079363||Patients with chronic pancreatitis|"Exclusion criteria:~No prior cancer. No anticoagulant treatment."
3328573|NCT02079363||Patients with acute pancreatitis|"Exclusion criteria:~No prior cancer."
3328574|NCT02079363||Patients screened for but not having upper GI cancer|"Exclusion criteria:~No prior cancer."
3328575|NCT02079376|Experimental|Low blood TG patients|subjects with baseline blood triglyceride level ≤ 1.7 mmol/l will have intervention device (DIAMOND Implantable Pulse Generator (IPG)) programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period.
3328576|NCT02079376|Experimental|High blood TG patients treated with blood TG lowering therapy|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive fenofibrate at the dose of 160mg per day
3231994|NCT01207011|Experimental|1 AMR|
3231995|NCT01207011|Active Comparator|2 DOC|
3231996|NCT01207024||knee MRI|knee MRI for all patients undergoing bariatric surgery as usual care
3231997|NCT01207037|Other|Intervention|
3231998|NCT01207050|Experimental|Rozerem (Ramelteon)|The primary drug of interest is a melatonin agonist for the treatment of insomnia.
3231999|NCT01207050|Placebo Comparator|Sugar pill|Control condition.
3232000|NCT01207063|Experimental|Radiotherapy|
3232001|NCT01207076|Experimental|receiving AHN-12 and 90Y-AHN-12|Patients receiving nonradiolabeled cold AHN-12 (.20 mg/kg to 1.0 mg/kg) of at least one dose and up to a total of 3 dosimetry infusions (intervals no sooner than 8 days and up to 21 days).
3232002|NCT01207089|Placebo Comparator|1|
3232003|NCT01207089|Experimental|2|AZD8329
3232004|NCT01207115|Experimental|ABT-652 high dose|ABT-652 capsules- twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm.
3232005|NCT01207115|Experimental|ABT-652 low dose|ABT-652 capsules - twice daily for 8 weeks. The dose ABT-652 will depend on the Arm
3232006|NCT01207115|Active Comparator|Naproxen|Naproxen capsules- twice daily for 8 weeks
3232007|NCT01207115|Placebo Comparator|Placebo|Placebo capsules- twice daily for 8 weeks
3328577|NCT02079376|Placebo Comparator|High blood TG patients|subjects with baseline blood triglyceride level > 1.7 mmol/l will have their device programmed to deliver GCM signal including the setting of automatic eating detection parameters for a 48 weeks period and will receive placebo of fenofibrate administered in the same schedule as the drug.
3328578|NCT02079389|Active Comparator|Lap+Lus|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a LUS examination of the primary tumor, liver and retroperitoneum.~All the included patients are getting a CT scan of the abdomen after 3 months."
3328579|NCT02079389|No Intervention|laparoscopic examination (Lap)|"The included patients randomly assigned either to the department's standard laparoscopic (Lap) surgery or standard laparoscopic surgery (lap) plus a LUS examination.~In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection.~All the included patients are getting a CT scan of the abdomen after 3 months."
3328580|NCT02079402|Active Comparator|Liberal (target-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~Fluid boluses may be given as long as hemodynamic variables improve (dynamic or static variable(s) of choice). A fluid bolus is to be followed by evaluation of effect 30 minutes after the intervention at the latest.~'Variable(s) of choice' refers to the variable(s) used to assess hemodynamic improvement.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
3232008|NCT01207128|Active Comparator|Voriconazole, Micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV) Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
3232009|NCT01207128|No Intervention|Voriconazole+Micafungin or Voriconazole+Placebo|Voriconazole+Micafungin or Voriconazole+Placebo
3328581|NCT02079402|Experimental|Conservative (trigger-guided) fluid resuscitation|"Noradrenaline to MAP >= 65 mmHg.~A fluid bolus of 250-500 ml may be given followed by evaluation of effect 30 minutes after the intervention at the latest if one of the following occurs:~Plasma lactate concentration ≥ 4 mmol/l at point-of-care testing.~Severe hypotension (MAP < 50mmHg).~Mottling beyond edge of kneecap.~Severe oliguria (only in the first 2 hours after randomisation). Severe oliguria defined as urine output ≤ 0.1 ml/kg/hour IBW last hour.~Only isotonic crystalloids are to be given as resuscitation fluid; the type of isotonic crystalloid is free of choice."
3328582|NCT02079428||Systolic heart failure, Diastolic heart failure|
3328583|NCT02079441||Infants, IBD mothers, anti TNF, pregnancy|Infants born to mother with IBD receiving ant- TNF medications during pregnancy
3328584|NCT02079441||infants, IBD mothers, pregnancy, medications|Infants born to mothers with IBD receiving non anti TNF medications during pregnancy
3328585|NCT02079467|Active Comparator|Standard rehabilitation|"Patients randomized to the control group will be managed with hip precautions immediately following surgery. They will weight bear on the operative joint as tolerated after surgery. They will be managed as per usual protocol post total hip arthroplasty. They will be transferred from the operative table with an abduction pillow between their legs and will be asked to keep this pillow between their legs while resting in bed and during sleep throughout their course in hospital. During physiotherapy treatments they will not flex the operative hip beyond 90 degrees, internally or externally rotate the operative hip more than 45 degrees, or actively adduct the operative hip past neutral."
3328586|NCT02079467|Experimental|Unrestricted rehabilitation|Patients randomized to the treatment group will have no restrictions in their post-operative rehabilitation. They will weight bear on the operative joint as tolerated after surgery. They will be asked to participate in activity as their level of comfort permits and will have no positional restrictions while in bed or completing activities of daily living.
3328587|NCT02079480|Experimental|Panel 1: BMS-986090 (0.5 mg) or Placebo|"BMS-986090 0.5 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3328588|NCT02079480|Experimental|Panel 2: BMS-986090 (3 mg) or Placebo|"BMS-986090 3 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3328589|NCT02079480|Experimental|Panel 3: BMS-986090 (10 mg) or Placebo|"BMS-986090 10 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once"
3328590|NCT02079480|Experimental|Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)|"BMS-986090 30 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once"
3232010|NCT01207141||rATG induction|Liver transplant recipients who receive induction with rATG prior to transplantation.
3232011|NCT01207141||no rATG induction|Liver transplant recipients who do not receive rATG induction therapy prior to transplantation.
3328591|NCT02079480|Experimental|Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)|"BMS-986090 100 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
3328592|NCT02079480|Experimental|Panel 6: BMS-986090 (100 mg) or Placebo|"BMS-986090 100 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
3328593|NCT02079480|Experimental|Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)|"BMS-986090 300 mg solution single dose subcutaneously once~OR~Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once~And KLH 1 mg solution single intramuscular dose once"
3328594|NCT02079480|Experimental|Panel 8: BMS-986090 (750 mg) or Placebo|"BMS-986090 750 mg solution single dose intravenously once~OR~Placebo matching with BMS-986090 0 mg solution single dose intravenously once"
3328595|NCT02079480|Experimental|Panel 9: BMS-986090 (150 mg) or Placebo|"BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks~OR~Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks"
3328596|NCT02079493||Total Knee Arthroplasty patients|TKA patients
3328597|NCT02079506|Experimental|Treatment A|
3328598|NCT02079506|Experimental|Treatment B|
3328599|NCT02079545|Experimental|Group 1|18 participants will receive a single intravenous (IV) infusion of 100 mg sirukumab
3328600|NCT02079545|Experimental|Group 2|18 participants will receive a single subcutaneous (SC) injection of 50 mg sirukumab using a Pre-filled Syringe (PFS) fitted with the UltraSafe Passive™ Delivery System (PFS-U)
3328601|NCT02079545|Experimental|Group 3|18 participants will receive a single SC injection of 50 mg sirukumab using the SmartJect™ Autoinjector (PFS-AI)
3328602|NCT02079545|Experimental|Group 4|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-U
3328603|NCT02079545|Experimental|Group 5|42 participants will receive a single SC injection of 100 mg sirukumab using a PFS-AI
3328604|NCT02079558|Experimental|Oxytocin|A single 100 microgram IV dose of carbetocin after operation
3328605|NCT02079558|Experimental|Carbetocin|A standard 30 international units (IU) IV infusion of oxytocin during two hours
3328606|NCT02079571|Experimental|water+ Coconut water|forty subjects
3328607|NCT02079571|Experimental|ginger tea +water|
3328608|NCT02079584||Warfarin|A study group taken from existing anticoagulant clinics treated with warfarin.
3328609|NCT02079584||Rivaroxaban|A group seen in the rivaroxaban clinic under study.
3328610|NCT02079597||Healthy|Healthy individuals no infection
3328611|NCT02079597||SIRS|SIRS patients no included in an interventional study no peroperative infection
3328612|NCT02079623||Pancreatic cancer|Patients with locally advanced pancreatic cancer.
3328613|NCT02079662|Experimental|Arm I (IO interventions)|Patients undergo up to 7 different IO intervention sessions per week during their 6-week course of radiotherapy for between 1 and 3 hours each session, in addition to, up to 6 aerobic training sessions per week and one grocery store trip during the course of the program. IO intervention programs consist of nutritional coaching, behavioral therapy, yoga and meditation practice, resistance training, and a weekly meal sharing and cooking class. Patients then have weekly meetings with the study psychologist on the computer for 6 months, followed by a monthly meeting on the computer from 6-12 months, and 2 hour meetings at all follow-up appointments during the first year after radiotherapy.
3328614|NCT02079662|Active Comparator|Arm II (standard of care)|Patients undergo standard of care.
3328615|NCT02079675|Experimental|SKI3246 Low Dose|Intervention: Drug: SKI3246 Low Dose
3232012|NCT01207154||BIS guidance|Sedation guided according to a predetermined BIS level
3232013|NCT01207154||Clinical sign guided|Sedation guided by clinical signs
3328616|NCT02079675|Experimental|SKI3246 High Dose|Intervention: Drug: SKI3246 High Dose
3328617|NCT02079675|Placebo Comparator|Placebo|Intervention: Drug: Placebo
3328618|NCT02079688|Experimental|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (area 1, area 2).~IMP SB011: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments) daily dosage: Approximately 10 mg hgd40 total dosage: Approximately 145 mg hgd40"
3328619|NCT02079688|Placebo Comparator|Multiple W/O/W formulation, active ingredient-free vehicle|"All patients will perform treatment with formulation SB011 containing 2 % hgd40 and the active ingredient-free vehicle. The comparison of the IMPs will be performed intraindividually.~Comparison and random assignment of treatments to two distinct treatment areas (Area 1, Area 2).~Vehicle: Topical application of approximately 5 mg/cm2 (250 μl) per treatment area (50 cm2) twice daily on 14 consecutive days, one single last application at the site on Day 15 (29 treatments)"
3328620|NCT02079701|Experimental|23-valent pneumococcal vaccine|single dose, 23-valent pneumococcal vaccine, 0.5ml, intramuscular (IM)
3328621|NCT02079701|Placebo Comparator|placebo|0.5 ml injectible saline, IM
3328622|NCT02079714||Questionnaire|All STREAM Study participants will be complete a series of computer adaptive testing (CAT) questions covering all core and exploratory domains, once written informed consent is obtained. Administration of these surveys will follow completion of all other follow-up activities related to the main METRC study in which they were originally enrolled. Identical surveys will be repeated at the 6 month study visit. At the final 12 month study visit, participants will complete the CAT survey for the six core domains, and will also complete a randomly assigned subset of items from the total item bank across these six core domains. At any visit, if the CAT cannot be administered, respondents will instead complete paper surveys of the short form for each domain.
3328623|NCT02079727|Experimental|Condrosulf (Chondroitin 4&6 sulfate)|1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days
3328624|NCT02079727|Placebo Comparator|Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule|1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days
3328625|NCT02079727|Active Comparator|Celebrex 200 mg capsule|1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days
3328626|NCT02079753|Active Comparator|combined system|During the first visit, the technician installed a reservoir of liquid oxygen (Liberator 30, Caire) and a liquid Stroller oxygen pack (Caire) for patients using liquid oxygen, or a VisionAire5 (Airsep) stationary concentrator and an Inogen One G2 portable (Inogen) concentrator for patients using concentrators.
3328627|NCT02079753|Experimental|single system|Inogen One G2 portable concentrator (Inogen)
3232014|NCT01207180|Experimental|Follow-up phone call from Nurse|Patients in this are will receive a phone call follow-up from a nurse 1-3 days after their discharge from the ED.
3232015|NCT01207180|Placebo Comparator|Satisfaction survey|This group of patients will receive a phone call from a student who will conduct a brief satisfaction survey of the patient's experience in the ED.
3232016|NCT01207180|Placebo Comparator|Control group|Patients in this group will receive no phone call at 1-3 days.
3232017|NCT01207193|Experimental|bone cyst|Patients with bone cyst defect are injected with mesenchymal cells.
3232018|NCT01207232|Experimental|Time Plan Condition|A basic reminder mailing prompted each subject to write down a planned date and time for getting their flu shot.
3232019|NCT01207232|Experimental|Date Plan Condition|A basic reminder mailing prompted each subject to write down a planned date for getting their flu shot.
3259177|NCT01468220|Placebo Comparator|normoxic training|6 weeks of endurance training under normoxia
3232020|NCT01207232|Active Comparator|Control Condition|A basic reminder mailing prompted each subject to receive a flu shot.
3232021|NCT01207245|Active Comparator|Morning dose of tobramycin|Administration of tobramycin once daily dose in the morning
3328628|NCT02079766|Experimental|High Risk of CTE|Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)
3328629|NCT02079766|Experimental|Control|Flortaucipir PET scans in former non-contact athletes
3328630|NCT02079779|Experimental|Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of robotic-assisted therapy.
3328631|NCT02079779|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. The 30 patients of this group will receive a supplement of classical rehabilitation.
3328632|NCT02079792|Active Comparator|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
3328633|NCT02079792|Experimental|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards. Subjects will be instructed to administer budesonide 1mg/2cc nebules daily for 12 weeks using the MAD syringe, in the head position to which they were randomized.
3328634|NCT02079818|Experimental|Penumbra Ruby Coil System|
3328635|NCT02079831|Experimental|Higher protein and energy restriction|Participants in this arm will consume 30% of energy as protein with 25% energy restriction.
3328636|NCT02079831|Experimental|Lower protein and energy restriction|Participants in this arm will consume 15% of energy as protein with 25% energy restriction.
3328637|NCT02079857|Experimental|Standard|Fixed protocol
3328638|NCT02079857|Experimental|Individualized|Individualized protocol
3232022|NCT01207245|Active Comparator|Evening tobramycin|Evening dose of tobramycin once daily
3232023|NCT01207258|Experimental|Brief Intervention Group|Participants randomly assigned to this group receive a brief motivational enhancement therapy intervention group and are assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
3232024|NCT01207258|No Intervention|Assessed Control Group|This group does not receive the intervention and is assessed at baseline, weekly for 12 weeks, and at 3, 6 and 12 months.
3328639|NCT02079857|Sham Comparator|Control|Sham acupuncture/Placebo moxa
3328640|NCT02079870|Experimental|Sema|Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing
3232025|NCT01207258|No Intervention|No Contact Control Group|This group does not receive the intervention and is assessed only at 3 months.
3328641|NCT02079870|Placebo Comparator|Placebo|
3328642|NCT02079883||ocriplasmin|
3328643|NCT02079896|Experimental|Single dose cross-over pilot|Single dose of lexaptepid pegol (NOX-H94) cross-over with single dose of placebo
3328644|NCT02079896|Placebo Comparator|Control|Twice weekly doses of placebo, 9 total
3328645|NCT02079896|Experimental|Lexaptepid pegol (NOX-H94)|Twice weekly doses of lexaptepid pegol (NOX-H94), 9 total
3328646|NCT02079922|Experimental|Cohort 1|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3328647|NCT02079922|Experimental|Cohort 2|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3232026|NCT01207271|Experimental|Cognitive Therapy|
3232027|NCT01207271|Experimental|Dynamic Therapy|
3328648|NCT02079922|Experimental|Cohort 3|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3328649|NCT02079922|Experimental|Cohort 4|Single dose level of PF-06678552 or placebo every 12 hours (Q12H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3232028|NCT01207284|Experimental|Physical Therapy|Foot and ankle passive and active stretching, muscle strengthening, proprioception training and gait training.
3232029|NCT01207284|No Intervention|Control|
3232030|NCT01207297|Active Comparator|TAC group|Oral tacrolimus (0.04-0.08 mg/kg/d) and prednisone for 12 months.
3328650|NCT02079922|Experimental|Cohort 5|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3328651|NCT02079922|Experimental|Cohort 6|Single dose level of PF-06678552 or placebo will be provided either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days to investigate the safety, tolerability, and pharmacokinetics.
3328652|NCT02079935|Experimental|Cognitive Behaviour Therapy|Treatment with small groups following a modified protocol first described by Fairburn 2008
3328653|NCT02079935|Experimental|Physical activity and dietary therapy|Treatment with guided physical activity and dietary therapy in small groups
3232031|NCT01207297|Active Comparator|CYC group|Pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day）for 6 months.
3232032|NCT01207310|Experimental|Pager Arm|Participants in the Pager Arm will be provided with alphanumeric pagers and will receive therapeutic messages on these pagers for 3 months in addition to individual smoking cessation counseling and nicotine patches.
3259178|NCT01468220|Active Comparator|hypoxic training|6 weeks of endurance training under hypoxia
3328654|NCT02079948|Active Comparator|Methotrexate + Folic Acid|Participants in the methotrexate condition will consume a dose of 15 mg/week of methotrexate during months 2 - 6. Participants will also consume 1 mg of folic acid/day for six days per week.
3328655|NCT02079948|Placebo Comparator|Placebo + Folic Acid|Participants in the placebo condition will consume microcrystalline cellulose once per week. The number of capsules consumed on this day will match the number of capsules consumed by participants in the methotrexate condition. There are no active ingredients in the placebo capsules.
3328656|NCT02079948|Experimental|Functional MRI Experimental Tasks|15 participants will be randomly assigned to complete the fMRI visits at the baseline and 6 month.
3232033|NCT01207310|Active Comparator|Control Arm|Participants in the Control Arm will receive individual smoking cessation counseling and nicotine patches.
3232034|NCT01207323|Experimental|Dose Escalation (MEHD7945A)|Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W until MTD is reached or up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first. Approximately 5 dose levels between 1 and 30 mg/kg will be evaluated.
3232035|NCT01207323|Experimental|Dose Expansion (MEHD7945A)|Participants will receive IV infusion of MEHD7945A Q2W at or below the MTD (decided from dose escalation part) up to disease progression as determined by the investigator, intolerable toxicity, withdrawal of consent, or death, whichever occurs first.
3328657|NCT02079948|Experimental|Muscle Biopsy|10 participants will be randomly assigned to complete the skeletal muscle tissue sample at the baseline and 6 month visits.
3328658|NCT02079961|Experimental|Micronutrient-fortified yoghurt|"Micronutrient-fortified yoghurt + BCC~All eligible children within the intervention arm will receive one fortified yoghurt per day, every day of the week, if the household satisfied to the contract of reliability in milk supply during the previous week, during the one year duration of the intervention."
3328659|NCT02079961|Active Comparator|Control|"BCC~Children will not receive fortified yoghurt during the duration of the intervention"
3328660|NCT02079974|Experimental|Pravastatin|Pravastatin sodium 20mg PO daily
3328661|NCT02080000|Experimental|Optimised V-V timing delay|V-V timing delay setting on biventricular pacemaker will be optimised guided by size of R-wave on surface ECG
3328662|NCT02080000|Active Comparator|Standard V-V timing delay|Standard settings
3328663|NCT02080013|Sham Comparator|ClosureFast group|Radiofrequency Ablation for the Treatment of Great Saphenous Vein Reflux
3328664|NCT02080013|Sham Comparator|group 1|EVL group Endovenous Laser Ablation for the Treatment of Great Saphenous Vein Reflux
3328665|NCT02080026|Experimental|CPS-immunization|"In this group a total of four CPS-immunizations will be performed, with bites from 15 Plasmodium infected mosquitoes per immunization, over a period of four months, during which volunteers will take chloroquine prophylaxis.~14 weeks after the last immunization, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
3328666|NCT02080026|Other|Control|"This group will take chloroquine prophylaxis during the same period as the immunization group, but will not receive CPS-immunizations.~10 weeks after stopping chloroquine prophylaxis, these volunteers will undergo Controlled Human Malaria Infection (CHMI) by exposure to bites from 5 Plasmodium falciparum sporozoite infected mosquitoes.~If a subject develops a malaria infection he/she will be treated with atovaquone/proguanil (Malarone). At the end of the study any subjects that did not develop a malaria infection will also be treated with atovaquone/proguanil (Malarone)."
3328667|NCT02080039|Experimental|Electrical Stimulation|
3328668|NCT02080052|Experimental|Robot-assisted prostate biopsy|
3328669|NCT02080065||liver transplantation|patients who underwent living donor liver transplantation during between 2007 and 2013
3232036|NCT01207349||close follow-up by nurse|close follow-up by nurse : patients were visited each tree months
3328670|NCT02080078|Experimental|Increasing dose of Theophylline|Patients will be put on the standard dose of 150 mg/day of erlotinib. Patients will be entered into the study on different dose levels of theophylline (100 mg/bid, 150 mg/bid, 200 mg/bid, or 200 mg/tid) for 28 days to find what is the lowest dose that effectively controls the diarrhea caused by erlotinib.
3328671|NCT02080078|Experimental|Increasing dose of erlotinib|Patients will be kept on a specified dose of theophylline while the dose of erlotinib increases in each group of patients enrolled (200 mg/qd, 225 mg/qd, or 250 mg/qd) for 28 days to determine what the maximum dose of erlotinib that can be given with theophylline and maintain a safety profile.
3328672|NCT02080104|Active Comparator|intravenous 10 ıu oxytocin|group which 2 ampul prophylactic oxytocin given for third stage of labour intravenously after vaginal delivery
3328673|NCT02080104|Experimental|intramusculer 10 ıu oxytocin|group which oxytocin administered intramusculary after vaginal delivery
3328674|NCT02080117||patients who underwent kidney transplantation|patients who underwent living or deceased donor kidney transplantation between 2008 and 2013
3328675|NCT02080130|Experimental|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
3328676|NCT02080130|Experimental|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
3328677|NCT02080130|Placebo Comparator|Placebo|Placebo sachet. One sachet orally, BID, for 5 days.
3328678|NCT02080143|Experimental|Air Activated Heat Patch|The experimental air activated heat patch will be worn by the subjects for 8 hours.
3328679|NCT02080143|Active Comparator|Marketed ThermaCare Air Activated Heat Patch|The marketed air activated heat patch will be worn by the subjects for 8 hours.
3328680|NCT02080156|No Intervention|no-CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
3232037|NCT01207349||standard follow up|stantdard follow up at one year
3232038|NCT01207362||Young adult|
3232039|NCT01207362||Older adult|
3232040|NCT01207375|Experimental|experimental group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3232041|NCT01207375|Placebo Comparator|Placebo control group|The placebo control group will receive placebo memory exercises administered on a laptop computer twice a week for five weeks (10 placebo control sessions).
3232042|NCT01207479|Experimental|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
3232043|NCT01207505|Experimental|Enchancing Emotion Regulation|12 week group 3 week modules: 1) Mindfulness 2) Emotion Regulation 3) Distress Tolerance
3232044|NCT01207518|Experimental|Intervention Group|For the intervention group, there will be a Guide facilitator provided by the project team, normally the Project Manager or their delegate. The role of the Guide facilitator will be to provide basic information about the Guide and to facilitate the use of the web-based tools.
3232045|NCT01207518|Active Comparator|Control Group|The Control Group will be asked to provide immunization rates for the base year and two years of the study, and will be asked about their influenza immunization campaign activities to use as a comparator. They will receive the Guide and web-based tools following completion of the study.
3328681|NCT02080156|Experimental|CPAP|CPAP vs. no-CPAP in patients undergoing Coronary Revascularization follow-up for 3 years
3328682|NCT02080169|Experimental|midazolam|Initiative dosage of midazolam is 0.05 mg/kg given intravenously, the maintenance dosage is 0.01-0.05 mg/kg/h, drug dosage is adjusted by target sedation level.
3328683|NCT02080169|Experimental|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min, the maintenance dosage is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level.
3328684|NCT02080169|Experimental|midazolam & dexmedetomidine|"Initiative dosage of midazolam is 0.05 mg/kg given intravenously, The loading dose of dexmedetomidine is 0.5-0.8 μg/kg given intravenously more than 10 min(given or not according to patients' condition),.~The maintenance dosage of midazolam is 0.01-0.05 mg/kg/h, the maintenance dosage of dexmedetomidine is 0.2-0.7 μg/kg/h,the drug dosage is adjusted by target sedation level."
3328685|NCT02080182|Active Comparator|Acetylcysteine|Effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
3328686|NCT02080182|Placebo Comparator|Placebo|Placebo effervescent tablet of acetylcysteine 600 mg dosing according to weight, until 5 days. Dose for patients more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily: more than 30 kg: 1.5 tablet daily 8.5-30 kg: 1 tablet daily less than 8.5 kg: 70 mg/kg
3328687|NCT02080208|Experimental|High Flow Oxygen|Patients receiving oxygen via high flow oxygen therapy (Optiflow)
3328688|NCT02080208|No Intervention|Conventionnal|patients receiving oxygen via conventional way (low flow)
3328689|NCT02080234|Experimental|concurrent chemoradiotherapy with GELOX|"GELOX:~gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days~IFRT~IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.~the first cycle of chemotherapy was initiated on the same day of radiotherapy."
3328690|NCT02080247|Active Comparator|Intervention: Skin care regimen with Calmoseptine ointment|In this arm the patients with IAD will receive treatment with Calmoseptine Ointment for 6 days as a part of a structured skin regimen
3328691|NCT02080247|Active Comparator|Control: Skin care regimen with Destin ointment|In this arm , patient will receive treatment with Destin Maximum Strength 40% Zinc Oxide. Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
3232046|NCT01207531||Survival Group|
3232047|NCT01207531||Death group|
3232048|NCT01207544|Experimental|fitball program|This group will undergo the fitball program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
3232049|NCT01207544|Active Comparator|Task-oriented program|This group will undergo the task-oriented motor training program consisting of a supervised exercise session once per week for 8 weeks, supplemented by home exercises. The exercise session will be conducted by a qualified physiotherapist.
3232050|NCT01207557|Active Comparator|Standard education only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
3232051|NCT01207557|Active Comparator|Standard Education plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials plus the Ottawa Influenza Decision Aid and tested on their confidence with their immunization decision
3232052|NCT01207609|Experimental|Laparoscopic Gastric Plication|Collect data prospectively on the safety and efficacy of the Laparoscopic Gastric Plication operation for 50 patients with Severe or Morbid Obesity
3232053|NCT01207622|Active Comparator|Atomoxetine|
3232054|NCT01207622|Placebo Comparator|Placebo|
3232055|NCT01207635||Breast Cancer Patients|
3232056|NCT01207661|Experimental|Mesenchymal Injection|Intra Articular injection in Patients with osteoarthritis of knee joint
3232057|NCT01207700|Experimental|CHW based intervention post ACS|CHW trained and supervised for intervening upon post ACS patients to improve adherence to evidence based care
3232058|NCT01207700|No Intervention|Standard Care|Patients will be followed upto 12 months without a community health worker intervention as per standard practices of the hospital
3232059|NCT01207739|Active Comparator|Doxycycline|
3232060|NCT01207739|Active Comparator|Clarithromycin and hydroxychloroquine|
3232061|NCT01207739|Placebo Comparator|Placebo|
3232062|NCT01207778||preterm ESA recipients|infants 500-1250 grams who received erythropoietin (400 units/kg 3x/week) or darbepoetin (10 micrograms/kg 1x/week), from the first week of life through 35 weeks corrected gestation
3232063|NCT01207778||preterm controls|preterm infants 500-1250 grams who received placebo (sham dosing), from first week of life through 35 weeks corrected gestation
3232064|NCT01207778||term controls|Term infants with normal delivery
3232065|NCT01207791|Other|Minimal screening only (MSO)|Minimal screening
3232066|NCT01207791|Active Comparator|Screening, assessment, and referral (SAR)|
3232067|NCT01207791|Experimental|Brief intervention plus telephone boosters (BI-B)|
3232068|NCT01207804|Experimental|Device|
3232069|NCT01207817||no condition|no condition - healthy volunteers
3232070|NCT01207830|Experimental|Endo Bypass|Subjects implanted with the investigational ValenTx Endo Bypass System
3232071|NCT01207856|Active Comparator|group A|specific cognitive rehabilitation
3232072|NCT01207856|Active Comparator|Groupe B : non specific rehabilitation|
3232073|NCT01207856|Other|group C|group C for MRI, neuropsychological and ecological assessments
3328692|NCT02080286|Active Comparator|Prism adaptation + anodal tDCS|"Participants will receive 1 milliamp (mA) anodal tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3328693|NCT02080286|Placebo Comparator|Prism Adaptation + Sham tDCS|"Participants will receive Sham tDCS over the left primary motor cortex concurrent with a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3232074|NCT01207869|Experimental|Mesenchymal stem cells|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
3232075|NCT01207869|Placebo Comparator|Control|Normal saline
3328694|NCT02080286|Placebo Comparator|Prism adaptation + no tDCS|"Participants will receive no tDCS at all but will undergo a 20-minute session of prism adaptation.~They will undergo 5 consecutive daily sessions."
3232076|NCT01207895|Experimental|[18F]-FLT PET scans|
3232077|NCT01207921|Experimental|Arm 1|"Lenalidomide 15 mg/day Cycle 1 (28 days).~If no unacceptable side effects Cycle 2 (28 days) will be lenalidomide 20 mg/day.~If no unacceptable side effects Cycles 3 thru 18 (28 days for each cycle) will be lenalidomide 25 mg/day."
3328695|NCT02080299|Active Comparator|Remote ischemic preconditioning (RIPC)|RIPC-protocol before TAVI: after induction of conscious sedation/anesthesia, but prior to TAVI procedure, remote ischemic preconditioning (RIPC) protocol is performed, consisting of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion, followed by a time interval between the end of the last deflation and local groin anaesthesia with subsequent skin puncture of 30 min.
3328696|NCT02080299|Placebo Comparator|Placebo|Placebo protocol before TAVI: After induction of conscious sedation/anesthesia and before TAVI, the cuff is left uninflated for 30 min, followed by a further time interval of 30 min until local groin anaesthesia with subsequent skin puncture.
3328697|NCT02080325|Other|High Protein-Weight loss-Meat/High Protein-Weight loss Soy|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Meat with High Protein-Weight loss-Soy
3328698|NCT02080325|Other|High Protein-Weight loss-Soya/High Protein Weight loss-meat|After 3 Days - Normal Protein Maintenance diet (NP- MTD, 3 days), there is the first arm of the study, Days 14 days- randomised to High Protein-Weight loss-Soy with High Protein-Weight loss-Meat
3328699|NCT02080338|Experimental|0.018 bracket slot system|Participants treated using 0.018-inch orthodontic bracket slot system
3328700|NCT02080338|Active Comparator|0.022 bracket slot system|Participants treated using 0.022-inch orthodontic bracket slot system
3328701|NCT02080351|Experimental|Simple cognitive task|"A memory reactivation cue followed by playing the computer game Tetris"
3328702|NCT02080351|No Intervention|Usual care|Usual care in the emergency department
3328703|NCT02080377|Active Comparator|Current Standard Care|Insulin + Metformin
3328704|NCT02080377|Active Comparator|Treatment|Glibenclamide + Metformin
3328705|NCT02080390||Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
3328706|NCT02080416|Experimental|Nelfinavir|Nelfinavir twice daily on days 1-14 of a 14-day cycle for 4 cycles
3232078|NCT01207947||Group 1|
3232079|NCT01207960|Active Comparator|EMDR|Eye Movement Desensitization and Reprocessing
3328707|NCT02080429|Active Comparator|Immediate Pushing|Patient's will begin to push when they are determined to be completely dilated.
3328708|NCT02080429|Experimental|Passive Descent|Patient's will wait 90 minutes prior to begin pushing
3232080|NCT01207960|No Intervention|WLC|Wait-list control group. EMDR treatment takes place after 4 weeks of no treatment which represents the wait-list comparison interval.
3232081|NCT01207973|Experimental|BI 113823|5 dose-groups of multiple oral doses of BI 113823
3232082|NCT01207986|Other|CT screening|CT interpretations and lung biopsies are guided by a suggested workup algorithm, which is not imposed in each HIV-caring centre
3328709|NCT02080442||Chronic Obstructive Pulmonary Disease|
3328710|NCT02080494|No Intervention|Control|No tranexamic acid given
3328711|NCT02080494|Experimental|Tranexamic Acid|15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose
3328712|NCT02080520|Active Comparator|Nattokinase|Oral nattokinase 2,000 fibrinolytic units daily
3232083|NCT01207999||Group A|Subjects diagnosed with invasive cervical cancer
3328713|NCT02080520|Placebo Comparator|Placebo|Oral placebo matched nattokinase daily
3328714|NCT02080533|Experimental|Single|Slow-paced respiration therapy
3232084|NCT01208012|No Intervention|Metformin|Patients taking Metformin at individual dose
3232085|NCT01208012|Experimental|Metformin and Liraglutide|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks.
3232086|NCT01208025||symptomatic carotid stenosis 30-69%|Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
3232087|NCT01208064|Experimental|Pazopanib|2 weeks at 600mg and then maintenance at 800mg
3232088|NCT01208064|Placebo Comparator|Placebo|placebo match 2 weeks at 600mg and then maintenance at 800mg
3232089|NCT01208077||Acute CHF|"Recurrent or worsening (within 3 days) shortness of breath as the primary presenting ED complaint~Initial treating ED physician impression that the worsening dyspnea is most likely caused by decompensated CHF~Known history of physician diagnosed CHF~Natriuretic peptide (BNP, MR-pro ANP, NT pro BNP) level will be ordered by the treating physician as part of the patient's work up"
3232090|NCT01208077||Acute Stroke Syndrome|"Onset of abnormal neurological symptoms consistent with possible stroke, within the prior 24 hours, as the primary ED complaint~Initial treating ED physician impression that the abnormal neurological symptoms/signs are most likely caused by an acute stroke syndrome~Non contrast head CT will be ordered by the treating physician as part of the patient's work up"
3259180|NCT01468259|Experimental|Normal renal function|16 subjects with normal renal function (eGFR greater than 90 mL/min/1.73m²)
3259181|NCT01468259|Experimental|Mild RD|Eight (8) with mild (60 less than eGFR less than 89 mL/min/1.73m²)
3328715|NCT02080559|Experimental|4CMenB - Test group|Administered at 2, 4 and 12 months of age
3232091|NCT01208077||Acute Systemic Infection|"Any combinations of acute (within 3 days) symptoms and signs that the treating ED physician, after initial history and physical examination, attributes to a systemic infection~Blood cultures and/or a blood lactate will be ordered by the treating physician as part of the patient's work up"
3232092|NCT01208090|Experimental|Investigational drug - Dose 1|
3328716|NCT02080559|Active Comparator|4CMenB - control group|Given at 5, 7 and 13 months of age
3328717|NCT02080572||Parkinson's Disease with DBS|Individuals with Parkinson's disease and deep brain stimulation will be recruited.
3328718|NCT02080585|No Intervention|Control group without advice|Control group receives no intervention or physical activity advice.
3328719|NCT02080585|Experimental|Computer-tailored physical activity advice|Subjects receive computer-tailored physical activity advice.
3232093|NCT01208090|Experimental|Investigational drug - Dose 2|
3232094|NCT01208090|Placebo Comparator|Matching placebo|
3328720|NCT02080598|No Intervention|Controle|The volunteer do not smoke any cigarette during the study period
3328721|NCT02080598|Experimental|smoking|the volunteer smokes 2 cigarettes in 15 minutes
3328722|NCT02080624|Experimental|Rapamycin|Topical rapamycin applied once a day
3328723|NCT02080650|Other|Prostate cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328724|NCT02080650|Other|Renal cell carcinoma|Mesenchymal-marker based ferrofluid (c-MET)
3328725|NCT02080650|Other|Bladder cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328726|NCT02080650|Other|Gastric cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328727|NCT02080650|Other|Colorectal cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328728|NCT02080650|Other|Pancreatic cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328729|NCT02080650|Other|Non-small cell lung cancer|Mesenchymal-marker based ferrofluid (c-MET)
3328730|NCT02080650|Other|Advanced MET amplified solid tumor|Mesenchymal-marker based ferrofluid (c-MET)
3328731|NCT02080663||Proximal row carpectomy|Proximal row carpectomy
3328732|NCT02080689|Other|Salvage setting|The clinical utility of Decipher will be evaluated for patients meeting the inclusion criteria in the salvage setting: post-RP with evidence of PSA rise or BCR (defined as PSA detectable and rising on 2 or more subsequent determinations)
3328733|NCT02080689|Other|Adjuvant setting|The clinical utility of Decipher will be evaluated for patients in the adjuvant setting: within 12 months after surgery (in the absence of detectable PSA rise of BCR)
3328734|NCT02080702||Monosyn|Construction of a gastrointestinal anastomoses
3328735|NCT02080715|Experimental|Tolcapone|Tasmar
3328736|NCT02080728|Experimental|TAP-Bloc|
3328737|NCT02080728|Placebo Comparator|Control|
3328738|NCT02080741|Other|Type A behaviour profile|
3328739|NCT02080741|Other|Type B behaviour profile|
3328740|NCT02080754|Placebo Comparator|sham arm|sham sellick maneuver
3328741|NCT02080754|Experimental|sellick arm|effective sellick maneuver
3328742|NCT02080793|Other|Patients phase pilote|
3328743|NCT02080793|Other|Patients phase réelle|
3328744|NCT02080806|Active Comparator|Mechanical insufflation exsufflation|Application of cough assist machine as part of the regular physiotherapy
3328745|NCT02080845|Placebo Comparator|no caffeine & no theobromine|Drink 1
3328746|NCT02080845|Experimental|no caffeine & low theobromine|Drink 2
3328747|NCT02080845|Experimental|no caffeine & high theobromine|Drink 3
3328748|NCT02080845|Experimental|high caffeine & no theobromine|Drink 4
3328749|NCT02080858|Experimental|Ticagrelor + Apixaban + ASA|180 mg Ticagrelor loading dose + apixaban 2.5 mg bid + 300 mg ASA loading dose (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg + 100 mg ASA od to reach steady state conditions within 4.5 days
3328750|NCT02080858|Active Comparator|Ticagrelor + Apixaban|180mg ticagrelor loading dose + apixaban 2.5 mg bid (day 1) followed by ticagrelor 90 mg bid + apixaban 2.5 mg to reach steady state conditions within 4.5 days
3328751|NCT02080884||CLL patients on Mabthera (rituximab)|
3328752|NCT02080897||Palliative Surgery Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt to proceed with palliative surgical treatment
3232095|NCT01208116||Subgroups|According to the demographic features, subjects may be divided into some subgroups.
3232096|NCT01208129|Experimental|Active drug|
3232097|NCT01208129|Placebo Comparator|Vehicle alone|
3232098|NCT01208142|Active Comparator|Standard of care|25 Control subjects will only receive SOC (a weekly standardized physical therapy and daily wear of an AFO).
3328753|NCT02080897||Non-surgical Group|Patients who present to clinic with soft tissue sarcoma with metastatic lung disease who opt not to pursue palliative surgery
3328754|NCT02080910|Experimental|Psychoeducational program|Psychoeducational program consisted of (1) two inpatient sessions of face-to-face education on stroke and its caregiving; (2) six biweekly problem-solving training via telephone contacts after the discharge of stroke survivors
3328755|NCT02080910|No Intervention|Usual care|
3328756|NCT02080923|Experimental|Brief Motivational Interview|Health-related counseling that takes place in as little as one hour or up to a few sessions.
3328757|NCT02080923|No Intervention|Standard Care|Participant will receive information about dating abuse in a handout and referrals to a national domestic violence hotline.
3328758|NCT02080949|Experimental|HSRT - 4fx x 5 Gy|It'll be recruited 3 patients to the initial regimen of four fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered that the study was initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with the next dose level.
3328759|NCT02080962|Experimental|30 Gy in 5 fractions of 6 Gy|tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89
3232099|NCT01208142|Experimental|Dynasplint|25 Patients will receive the standard of care as well as an Ankle Flexion Dynasplint
3328760|NCT02080962|Experimental|40 Gy in 10 fractions of 4 Gy|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
3328761|NCT02080975|Experimental|Data Collection During Atrial Flutter Ablation|
3328762|NCT02080988||Silent aspirators|Stroke patients with dysphagia with severe aspiration
3328763|NCT02080988||Non aspirating, no dysphagia group|Stroke patients with no dysphagia and no evidence of aspiration
3232100|NCT01208155|Experimental|1|Fostamatinib 50 mg tablet x 2
3328764|NCT02081027|Experimental|Riluzole|The maximum dose of riluzole to be used in this study is 200 mg per day divided BID
3328765|NCT02081027|Placebo Comparator|Placebo|Placebo will be administered in the same manner as the riluzole group, in order to maintain subject assignment throughout the study.
3328766|NCT02081040||Infratentorial dysphagia patients|Infratentorial brain lesion patients with confirmed evidence of dysphagia
3328767|NCT02081040||Supratentorial dysphagia patients|Supratentorial brain lesions\ patients with confirmed evidence of dysphagia
3328768|NCT02081040||Brain lesion patients without dysphagia|Brain lesion patients with no evidence of dysphagia
3232101|NCT01208155|Experimental|2|Fostamatinib 100 mg tablet (batch 1)
3232102|NCT01208155|Experimental|3|Fostamatinib 100 mg tablet (batch 2)
3328769|NCT02081053|Other|RF Ablation and Vertebral Augmentation|
3328770|NCT02081066|Other|patients with cardiovascular risk factors|
3328771|NCT02081092||Pulmonary Alveolar Proteinosis (PAP)|Patients diagnosis with Pulmonary Alveolar Proteinosis.
3328772|NCT02081105|Other|PEEP 5|level of PEEP of 5 cm H2O randomly applied to the patient
3328773|NCT02081105|Other|PEEP 15|level of PEEP of 15 cm H2O randomly applied to the patient
3328774|NCT02081118|Experimental|HM11260C (8 mg)|Monthly administration of 8 mg of HMC11260C by subcutaneous injection for 16 weeks
3328775|NCT02081118|Experimental|HM11260C (12 mg)|Monthly administration of 12 mg of HMC11260C by subcutaneous injection for 16 weeks
3328776|NCT02081118|Experimental|HM11260C (16 mg)|Monthly administration of 16 mg of HMC11260C by subcutaneous injection for 16 weeks
3328777|NCT02081118|Placebo Comparator|Placebo|Monthly administration of placebo by subcutaneous injection for 16 weeks
3328778|NCT02081131|Active Comparator|Laparoscopic Surgery|patients will be randomized to laparoscopic pancreatoduodenectomy group
3328779|NCT02081131|Active Comparator|Open Surgery|Patients will be randomized to Open pancreatoduodenectomy
3232103|NCT01208155|Experimental|4|Fostamatinib 100 mg tablet (batch 4)
3232104|NCT01208168|Experimental|Active drug|
3328780|NCT02081144|No Intervention|Control Condition|Control or Standard Care condition. No intervention will be provided.
3328781|NCT02081144|Experimental|Texting + NRT Condition|Enrollment in NCI's Smokefree TXT Program 4 weeks of Nicotine Replacement Patches 4 weeks of Nicotine Replacement Gum Faxed Referral CT Smokers Quitline
3328782|NCT02081170|Experimental|autologous platelet concentrate|
3328783|NCT02081209|Experimental|Fat Reduction|
3328784|NCT02081222||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease in 2013 at Samsung Medical Center
3328785|NCT02081235||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease during 2012 in Samsung Medical Center
3328786|NCT02081261||Coronary artery bypass surgery|patients who underwent coronary artery bypass surgery between 2010 and 2012 in Samsung Medical Center
3328787|NCT02081274||patients who underwent surgery for congenital heart disease|patients who underwent surgery for congenital heart disease between 2009 and 2013 in Samsung Medical Center
3232105|NCT01208168|Placebo Comparator|Vehicle alone|
3232106|NCT01208194|Experimental|MGN1703|Study medication
3232107|NCT01208194|Placebo Comparator|Placebo|
3232108|NCT01208259|Experimental|Binge Eating Disorder/Therapy|
3232109|NCT01208272|Experimental|Binge Eating Disorder/Therapy|
3232110|NCT01208285|Experimental|Group A|approximately 12 male and female subjects with moderate hepatic impairment
3232111|NCT01208285|Experimental|Group B|approximately 12 healthy male and female subjects
3232112|NCT01208298|Experimental|# 1727|Cold sore Patch
3232113|NCT01208311||Patients with Hepatitis C Cirrhosis|Patients with Hepatitis C Cirrhosis
3232114|NCT01208350|Experimental|1|
3232115|NCT01208350|Experimental|2|
3232116|NCT01208350|Active Comparator|3|
3232117|NCT01208363|No Intervention|Unfortified Toubani|Children in the school will receive, 3 times per week 66g of raw unfortified (no added Fe) cowpea in form of Toubani (a cowpea based snack).
3232118|NCT01208363|Active Comparator|Fortified Cowpea|Study subjects will receive 3 times per week, as part of the school feeding programme 66g of raw fortified cowpea (with added 10mg Fe as NaFeEDTA)in form of Toubani (a cowpea based snack).
3232119|NCT01208376||unexplained chronic ALT elevation|Case patients: HIV-infected, unexplained chronic alanine aminotransferase (ALT) elevation
3232120|NCT01208376||always normal ALT|Control patients: HIV-infected, always normal ALT values
3232121|NCT01208389|Experimental|voretigene neparvovec-rzyl (AAV2-hRPE65v2)|Administration of study agent (AAV2-hRPE65v2) to the previously, uninjected contralateral eye:
3328788|NCT02081287|Active Comparator|Lamotrigine|As adjunct to lithium therapy
3328789|NCT02081287|Experimental|IP6|As adjunct to lithium therapy
3328790|NCT02081300|Experimental|Oral testosterone undecanoate, LPCN 1021|Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
3328791|NCT02081300|Other|Topical testosterone gel 1.62 %|Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28
3328792|NCT02081313|Active Comparator|Netherton syndrome|Patients with Netherton syndrome
3328793|NCT02081313|Active Comparator|Healthy controls|healthy controls
3328794|NCT02081326|Experimental|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
3328795|NCT02081326|Placebo Comparator|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
3328796|NCT02081339||Macular diseases|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
3328797|NCT02081352|Active Comparator|DermaPure™|DermaPure™ in combination with standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
3328798|NCT02081352|Sham Comparator|Standard care|Standard care comprising surgical debridement, covered by a non-adherent silicone wound contact layer, a wound cavity filler (if required), a secondary foam wound dressing and appropriate off-loading footwear.
3328799|NCT02081391|Experimental|Tapentadol immediate-release (IR)|"In the first 24 hours, tapentadol oral solution at a dose of 1.25 mg/kg body weight was given every 4 hours (±15 min) to participants aged 6 months to less than 18 years (maximum individual dose of tapentadol was 100 mg). Participants from 30 days to less than 6 months were dosed with 0.5 mg/kg body weight every 4 hours. Participants from birth to less than 30 days of age were dosed with 0.1 mg/kg body weight every 4 hours.~After 24 hours and up to 72 hours, the dose could be reduced based on the investigator's judgment."
3328800|NCT02081391|Placebo Comparator|Placebo|Matching placebo oral solution was administered every 4 hours (±15 min) up to 72 hours.
3232122|NCT01208428|Active Comparator|Conventional cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy for the treatment of major depression
3232123|NCT01208428|Experimental|Religious cognitive behavioral therapy|Subjects randomized to this arm will receive conventional cognitive behavioral therapy, but their religious beliefs will be utilized as a resource in the therapy
3328801|NCT02081404|Active Comparator|Esomeprazole|proton pump inhibitor
3328802|NCT02081404|Placebo Comparator|Placebo|placebo
3328803|NCT02081430|Experimental|CT Manipulation|Prone cervicothoracic manipulation
3328804|NCT02081430|Active Comparator|Upper trapezius stretch|Passive sustained stretch to upper trapezius muscle
3328805|NCT02081430|No Intervention|Control|8 Minute wait
3328806|NCT02081469|Other|Arm A:TDF for extend 24 weeks|Arm A:Continue TDF 300mg daily for extend 24 weeks after completion of chemotherapy
3328807|NCT02081469|Other|Arm B: TDF for extend 48 weeks|Arm B: Continue TDF 300mg daily for extend 48 weeks after completion of chemotherapy.
3328808|NCT02081482|Experimental|subjects with refractory chronic cluster headache|Adult subjects with refractory chronic cluster headache and ONS indication
3232124|NCT01208441|Experimental|Arm I|"Patients receive oral letrozole once daily on days 1-21. Beginning in course 2, patients also receive oral RO4929097 on days 1-3, 8-10, and 15-18. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~Beginning 1 week after completion of neoadjuvant therapy, patients undergo surgery or tumor biopsy. Patients continue to receive oral letrozole once daily during surgery and for an additional 4 weeks."
3232125|NCT01208454|Experimental|Treatment (isotretinoin and vorinostat)|"Patients receive isotretinoin PO BID on days 1-14, PO suspension* of vorinostat QD on days 1-4 of course 1, and capsules of vorinostat PO QD on days 1-4 and 8-11 of course 2 and subsequent courses. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~EXPANSION COHORT 1 (=< 21 years of age): Once the MTD has been determined, patients are treated at that dose level as above.~EXPANSION COHORT 2 (22-30 years of age): Patients receive isotretinoin as above and vorinostat at the MTD on days 1-3 and 8-10."
3328809|NCT02081495|Experimental|Sequence AB|Twenty-one participants will receive DOXIL/CAELYX reference product in Cycle 1 and DOXIL/CAELYX test product in Cycle 2. Each cycle will be separated by 28 days.
3328810|NCT02081495|Experimental|Sequence BA|Twenty-one participants will receive DOXIL/CAELYX test product in Cycle 1 and DOXIL/CAELYX reference product in Cycle 2. Each cycle will be separated by 28 days.
3328811|NCT02081508|Experimental|Unfilled interference|Interference onset: delayed test at 540000 ms
3328812|NCT02081508|Experimental|Early interference|Interference onset: delayed test at 0 ms
3328813|NCT02081508|Experimental|Mid interference|Interference onset: delayed test at 360000 ms
3328814|NCT02081508|Experimental|Late interference|Interference onset: delayed test at 180000 ms
3328815|NCT02081521|Experimental|Community behaviour change campaign|Participants will be exposed to the community behaviour change intervention.
3328816|NCT02081521|No Intervention|No community behaviour change campaign|No community intervention will take place in the control arm, although exposure to some intervention messaging (radio adverts) may take place.
3328817|NCT02081547||IPC status|presence of cancer cells.
3328818|NCT02081560|Other|colistin pharmacokinetics|Intravenous colistin 9 million units loading dose and 3 million units q8h maintenance dose as long as treatment of infection is required
3328819|NCT02081612|Active Comparator|Nutrition Education|Educational weight management group sessions alone
3328820|NCT02081612|Active Comparator|Nutrition Education Plus Acupuncture|Educational weight management group sessions in addition to weight loss acupuncture
3328821|NCT02081625|Experimental|NS-065/NCNP-01|
3328822|NCT02081651|Experimental|Parmigiano Reggiano cheese|Children treated Parmigiano Reggiano cheese for 12 months
3328823|NCT02081651|No Intervention|Control subjects|Children with cow's milk allergy not assuming Parmigiano Reggiano cheese
3328824|NCT02081664|Other|Lifestyle intervention|life-style oriented group program together with an individualized treatment program using therapies out of the spectrum of Complementary and Alternative Medicine (CAM)
3328825|NCT02081703|Experimental|AYX1 Injection 660 mg / 6 mL|Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3328826|NCT02081703|Placebo Comparator|Placebo Injection 6 mL|Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3259182|NCT01468259|Experimental|Moderate RD|Eight with moderate (30 less than eGFR less than 59 mL/min/1.73m²),
3328827|NCT02081703|Experimental|AYX1 Injection 1100 mg / 10 mL|Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3328828|NCT02081703|Placebo Comparator|Placebo Injection 10 mL|Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery
3232126|NCT01208467||Basic science (DNA analysis)|DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
3232127|NCT01208493|Experimental|high protein preterm infant formula|preterm infant formula with high protein levels
3328829|NCT02081716||high CMV ELISPOT results|high spot counts in ELISPOT
3328830|NCT02081716||low CMV ELISPOT results|low spot counts in ELISPOT
3328831|NCT02081729||high VZV ELISPOT results|high spot counts in ELISPOT
3328832|NCT02081729||low VZV ELISPOT results|low spot counts in ELISPOT
3328833|NCT02081755|Experimental|Everolimus and Tacrolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) Tacrolimus Dosing: 0.05 mg/kg BID
3328834|NCT02081755|Active Comparator|Tacrolimus and Myfortic or CellCept or Imuran|Myfortic: 360 mg to 1080 mg BID OR CellCept: 500 mg to 1500 mg BID OR Imuran: 0.5mk/kg to 2mg/kg QD AND Tacrolimus Dosing: 0.05 mg/kg BID
3328835|NCT02081768|Experimental|90yttrium colloid|90 Yttrium colloid will be inserted into the cystic cavity. Based on clinical expertise, the treating neurosurgeon will determine the appropriate surgical procedure for each patient on an individual basis which will be reflected in the surgical consent the patient is presented and signs.
3328836|NCT02081781||Probing, topical anesthesia|Nasolacrimal duct obstruction (NLDO) is a quite common condition among the infants. An imperforate membrane at the distal end of the nasolacrimal duct is the main cause of occlusion. Children with the signs of NLDO presenting with epiphora and/or mucous discharge were included in this study. Intervention with probing under topical anesthesia was performed on the same surgeon. And success rate was evaluated.
3328837|NCT02081794|Experimental|Arm I (Tailored education intervention)|Participants receive a tailored educational intervention on the risk of falls comprising one of four two-minute videos determined by which educational group the participant is placed in: high risk/high perception, high risk/low perception, low risk/high perception, or low risk/low perception. Participants also receive tailored printed educational information concerning hospital falls based on the participants' answers given on the Perceived Risk Survey and are tailored to the participants' perception of falls risk. Participants also complete an investigator-constructed satisfaction survey at 24 and 72 hours post-intervention.
3328838|NCT02081794|Active Comparator|Arm II (standard fall care)|Participants receive standard care by nurses comprising a falls risk assessment and verbal education and receive an educational instruction sheet on falls prevention.
3328839|NCT02081820||aneurysmal subarachnoid hemorrhage|observational, no intervention
3328840|NCT02081833||Reminder group|the reminder group receives every 2 weeks a reminder to fill out the symptom diary (postcard or SMS)
3328841|NCT02081885|Experimental|Tricalcium Phosphate / Chitosan|
3328842|NCT02081885|Active Comparator|Autologous Graft|
3328843|NCT02081898|No Intervention|control group|weight maintenance diet
3328844|NCT02081898|Experimental|low calorie diet (LCD) group|approximate 100 kcal/d calorie deficit
3328845|NCT02081911|Experimental|High volume Adductor canal block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
3232128|NCT01208493|Active Comparator|control preterm formula|
3232129|NCT01208506|Experimental|Dose level 1|
3328846|NCT02081911|Experimental|Low volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
3328847|NCT02081911|Experimental|Femoral nerve block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
3328848|NCT02081924|Active Comparator|Kisspeptin 0.1|Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
3232130|NCT01208506|Experimental|Dose level 2|
3232131|NCT01208506|Experimental|Dose level 3|
3328849|NCT02081924|Placebo Comparator|Saline|Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
3328850|NCT02081924|Active Comparator|Kisspeptin 0.3|Participants will receive kisspeptin hormone at a dose rate of 0.3nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
3232132|NCT01208506|Experimental|Dose level 4|
3232133|NCT01208506|Experimental|Dose level 5|
3232134|NCT01208506|Experimental|Dose level 6|
3328851|NCT02081924|Active Comparator|Kisspeptin 1.0|Participants will receive kisspeptin hormone at a dose rate of 1.0nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.
3328852|NCT02081937|Experimental|Anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on d1-5 in the absence of disease progression or unacceptable toxicity.
3232135|NCT01208506|Experimental|Dose level 7|
3232136|NCT01208506|Experimental|Dose level 8|
3232137|NCT01208519||Case Control Study 1|To define the impact of antibiotics on new acquisition of MRSA and ESBL-producing gram negative bacteria, a matched case-control study will be done (ratio 1:4). The control group will be selected among patients not receiving antibiotics, admitted in the same ward on the day of the corresponding case, with negative cultures at hospital admission. Matching criteria will include: age (±5 years), sex, and total length of hospitalization.
3232138|NCT01208519||Case control study 2|To define individual level of risk related to specific antibiotics, patients acquiring MRSA and ESBL-producing gram negative bacteria will be compared with patients not acquiring antibiotic-resistant strains after starting antibiotic therapy (ratio 1:4). Previously known risk factors or clinically relevant significant variables from the univariate analysis will be considered for inclusion in multivariate logistic regression analysis.
3232139|NCT01208558|Active Comparator|Diet A and physiotherapy|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people, i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid junk food and juice. In order to match carbohydrate intake between the arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end."
3328853|NCT02081976|Active Comparator|Standard Care Group|Dental therapist providing standard periodontal treatment
3328854|NCT02081976|Experimental|Integrated Care Group|a combined treatment approach of Dental Therapist, Dental Hygienist, Cardiologist along with counselor
3328855|NCT02081989|Experimental|Denervation|Renal denervation
3328856|NCT02081989|No Intervention|No intervention|Control group - no intervention
3328857|NCT02082002||MS-Group|MS-Group
3232140|NCT01208558|Active Comparator|Diet B and physiotherapy|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A.~Other Name: Whole grains Behavioral: Physiotherapy Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.~Other Name: Exercise"
3232141|NCT01208558|Active Comparator|Diet A only|"Behavioral: Diet A Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Other Name: No grains"
3328858|NCT02082002||Healthy control|Healthy control
3328859|NCT02082015|Experimental|true coil|Use the true coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
3328860|NCT02082015|Sham Comparator|sham coil|Use the sham coil / Low frequency rTMS / Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: vertical to scalp
3328861|NCT02082028|Experimental|A (BGStar)|Patients will be educated within the context of the SINERGIA educational program to understand how to manage their own diabetes on the basis of their Self Monitoring of Blood Glucose values obtained with BGStar. Patients will be requested two 6-points profiles monthly.
3232142|NCT01208558|Active Comparator|Diet B only|"Behavioral: Diet B Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.~Other Name: Whole grains"
3232143|NCT01208558|No Intervention|Control|Only follow-up. No intervention.
3232144|NCT01208571|Experimental|Lifestyle counseling|
3328862|NCT02082028|Active Comparator|B (traditional approach)|Usual approach for the disease management. Patients in Group B will receive usual education and, at any time during the study duration, if needed, will be instructed on Self Monitoring of Blood Glucose, performed with any glucose meter.
3328863|NCT02082041||Wounds on leg|
3328864|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.36 mg|Pseudoephedrine 120 mg,chlorpheniramine 8 mg, atropine 0.36 mg tablet dosed BID for 7.5 days
3328865|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.24 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg tablets dosed BID for 7.5 days
3328866|NCT02082054|Experimental|PSE 120 mg, CM 8 mg, Atr 0.12 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 dosed BID for 7.5 days
3328867|NCT02082054|Active Comparator|PSE 120 mg, CM 8 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg white, scored, tablets with M27 on scored side and plain on the other side"
3328868|NCT02082054|Experimental|Atropine 0.24 mg|Atropine 0.24 mg tablets dosed BID for 7.5 days
3232145|NCT01208571|No Intervention|Treatment as usual|
3232146|NCT01208584||Chronic posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A, spinal cord injury (SCI) 12-24 months
3232147|NCT01208584||Acute posttraumatic paraplegia|Paraplegic patients (Thoracic level of lesion Th1-Th12), ASIA A,SCI 2-6 months,
3232148|NCT01208584||Myelomeningocele patients|Myelomeningocele patients (congenital paraplegia, thoracic level of lesion Th1-Th12) ASIA A
3232149|NCT01208584||Volunteers|Volunteers without any neurological deficits
3232150|NCT01208623||2D|2D digital venography images alone
3232151|NCT01208623||3D|3D rotational venography
3232152|NCT01208623||Combine|combined MDCT angiography/venography
3232153|NCT01208636||Sun exposed people|Sun exposure >3 hours daily for at least 5 days weekly for the last 3 months.
3232154|NCT01208649|Active Comparator|Exenatide|Drug (including placebo)
3232155|NCT01208649|Placebo Comparator|Placebo|
3232156|NCT01208662|Active Comparator|High Dose Treatment|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Maintenance Lenalidomide.
3328869|NCT02082067|Experimental|Adductor canal|All patients in the arm will receive continuous adductor canal block under ultrasound guidance. 10ml of Ropivacaine 0,75%, BBraun, Germany, will be injected to dilate adductor canal. After catheter insertion 10ml of Ropivacaine 0,75% will be injected.
3328870|NCT02082067|Active Comparator|Femoral|All patients in the arm will receive continuous femoral nerve block under ultrasound guidance. Correct position of catheter will be check with injection of 20ml Ropivacaine 0,75% BBraun, Germany medial to femoral nerve.
3328871|NCT02082067|Placebo Comparator|Controls|No patients of this arm receive continuous nerve block. Intravenous opioids analgesia will be administered.
3328872|NCT02082080|Active Comparator|Obese and overweight children, education|Overweight and obese school children in grades 5 and 6
3328873|NCT02082080|No Intervention|Obese and overweight children|
3328874|NCT02082093|No Intervention|Traditional Care|
3328875|NCT02082093|Experimental|eNephro Application|"Telemedicine system which is a collaborative and expert system, consisting of:~A dynamic shared medical record for the collection of administrative , medical, biological and clinical data for each patient. All health professionals can access the folder and fill in the support. It is the same for patients treated at home.~A secure messaging for communication between health professionals and between patients and health professionals Expert systems analyzing data from each patient A management tool of therapeutic education~These patients have a chronic renal failure moderate to end up being treated by ambulatory dialysis or kidney transplantation. The patients of each population will be randomly assigned in group 1 ie traditional care or in group 2 ie traditional care added by telemedicine system"
3232157|NCT01208662|Experimental|High Dose Treatment with SCT|Lenalidomide, bortezomib, dexamethasone. Stem cell collection. Autologous Stem Cell Transplant. Maintenance Lenalidomide.
3232158|NCT01208675||Mild cognitive impairment|550 patients with mild cognitive impairment or subjective cognitive symptoms at baseline.
3328876|NCT02082106||males/females|Participants should be capable of alpine skiing and cross country skiing.
3328877|NCT02082171|No Intervention|Control group|
3328878|NCT02082171|Experimental|Intervention group|Comprehensive geriatric assessment followed by multi-domain preventive intervention
3328879|NCT02082197|Experimental|ABT-SLV176|ABT-SLV176 administered daily
3328880|NCT02082223|Experimental|Preoperative Rehabilitation|"Patient & caregiver input regarding 'single biggest concern right now' (modified BEACON buttons) will be elicited. Information gathered by the study team which includes a trained nursing coach and the patient/caregiver will together develop an individualized 'toolbox' of possible interventions to improve preoperative quality of life.~Candidate interventions include, but not limited to: Participation in SMART program, caregiver participation in Caregivers study protocol MC1295 (IRB 13-002943), nutritional recommendations (deficiencies, immuno-nutrition), low impact resistance training/tai chi, referral to financial or counseling services, establishment of information sources & plans for concerns not frequently covered in clinical practice such as sleeplessness, spiritual assistance."
3328881|NCT02082236|Active Comparator|Treatment A|Sufenta® IV (50 mcg/mL) 30 mcg infused over 1 minute
3232159|NCT01208675||Healthy elderly subjects|650 elderly subjects, who are cognitively healthy at baseline.
3232160|NCT01208688|Experimental|FES Therapy|FES Therapy
3232161|NCT01208688|Active Comparator|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
3328882|NCT02082236|Experimental|Treatment B|Single dose of SSM 30 mcg
3328883|NCT02082236|Experimental|Treatment C|2 consecutive doses of SSM 15 mcg administered 20 minute apart
3328884|NCT02082236|Experimental|Treatment D|12 consecutive doses of SSM 30 mcg administered 1 hour apart
3328885|NCT02082249|Experimental|ABT-SLV187|up to 6 years
3328886|NCT02082275|Experimental|OB Nest|OB Nest is designed to reduce the number of pre-planned visits with their OB provider and replace the in-clinic visits with a direct and constant support from an assigned nursing team. OB Nest will empower moms-to-be to take ownership of their prenatal care by providing a wealth of resources.
3328887|NCT02082275|No Intervention|Traditional Prenatal care|Traditional prenatal visits in clinic with OB providers.
3328888|NCT02082301||Gestational diabetes|Primary cohort is women with diagnosis of gestational diabetes without evidence of overt diabetes
3328889|NCT02082327|Experimental|0.3 mg/kg|IV infusion of migalastat HCl or placebo
3328890|NCT02082327|Experimental|1 mg/kg|IV infusion of migalastat HCl or placebo
3328891|NCT02082327|Experimental|10 mg/kg|IV infusion of migalastat HCl or placebo
3328892|NCT02082327|Experimental|150 mg IV|150 mg single IV infusion
3328893|NCT02082327|Experimental|150 mg oral|150 mg single oral dose
3232162|NCT01208701|Active Comparator|Atorvastatin|
3232163|NCT01208701|Placebo Comparator|Placebo|
3328894|NCT02082353||Retrospective CGD Cohort|Longitudinal analysis
3328895|NCT02082353||Prospective CGD Cohort|Longitudinal analysis
3328896|NCT02082353||HCT CGD Cohort|Cross-sectional analysis
3328897|NCT02082353||Conventional Non-Transplant CGD Cohort|Longitudinal analysis
3328898|NCT02082366|Active Comparator|conventional irrigated ablation catheter|"TCD testing during procedure from trans-septal puncture until completion using a conventional irrigated ablation catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
3328899|NCT02082366|Active Comparator|nMARQ circumferential irrigated catheter|"TCD testing during procedure from trans-septal puncture until completion using the nMARQ circumferential irrigated catheter.~Intervention: TCD monitoring of microembolic signal during procedure"
3328900|NCT02082379|Active Comparator|Term newborns 1-6 week old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
3328901|NCT02082379|Active Comparator|Infants 6-8 month old|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The interfaces that will be used are: tight mask, the angled PediNeb, the B&B adapter, mask placed at 2 cm from the face, the PediNeb T-piece, and a capped corrugated tubing placed 2 cm away from the face.
3232164|NCT01208714|Active Comparator|revascularization|The patients randomized to this treatment will undergo PTA with stenting of the renal artery.
3232165|NCT01208714|Active Comparator|medical therapy|The patients randomized to this treatment will undergo optimal medical therapy
3232166|NCT01208727|No Intervention|Control|22 controls patients without post conditionment
3232167|NCT01208727|Experimental|Intervention|22 posconditioned patients
3328902|NCT02082405|Experimental|Treatment (bortezomib, cyclophosphamide, dexamethasone)|Patients receive bortezomib SC or IV over 3-5 seconds on days 1, 8, and 15; cyclophosphamide PO QD on days 1-21; and dexamethasone PO on days 1, 8, and 15. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3328903|NCT02082418|Experimental|Healthy|healthy control subjects
3328904|NCT02082418|Experimental|MCI|mild cognitive impariments
3328905|NCT02082418|Experimental|Dementia|established diagnosis of dementia
3328906|NCT02082444|Experimental|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
3328907|NCT02082457|Placebo Comparator|Placebo|Two tablets of YKP10811 placebo are administered orally once a day for 12 weeks.
3328908|NCT02082457|Experimental|YKP10811 10mg|Two tablets of YKP10811 5mg are administered orally once a day for 12 weeks.
3328909|NCT02082457|Experimental|YKP10811 20mg|One tablet of YKP10811 20mg and one tablet of placebo are administered orally once a day for 12 weeks.
3328910|NCT02082457|Experimental|YKP10811 40mg|Two tablets of YKP10811 20mg are administered orally once a day for 12 weeks.
3328911|NCT02082470|Active Comparator|Arm I (standard post-treatment)|Participants receive standard post-treatment care consisting of regular cancer surveillance visits with treating oncologists.
3328912|NCT02082470|Experimental|Arm II (survivorship care planning)|Participants complete survivorship care planning in close collaboration with treating oncologists.
3328913|NCT02082496|Experimental|Control Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
3328914|NCT02082496|Experimental|Case Group|4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
3232168|NCT01208740|Experimental|Metformin|Metformin pre-treatment and co-administration
3232169|NCT01208740|Placebo Comparator|Placebo|Placebo pre-treatment and co-administration
3232170|NCT01208753|Experimental|Aqueous formulations for formulation selection|50 mg once daily for 3 days of two different aqueous suspensions, with four day wash-out between formulation
3232171|NCT01208753|Experimental|GLPG0555 ascending doses|multiple ascending doses for 13 days, ranging from 100 mg once daily upto a maximum to be determined during escalation (given as once or twice daily)
3232172|NCT01208753|Placebo Comparator|3|once or twice daily for 13 days, matching the scheme of the multiple ascending dose.
3232173|NCT01208766|Active Comparator|R1: 4 cycles Bortezomib, Melphalan, Prednisone (VMP)|All patients randomized to VMP treatment, will be treated with Bortezomib, Melphalan, Prednisone(VMP, 4 cycles) and will start intensification with VMP between 4 and 6 weeks after stem cell collection.
3232174|NCT01208766|Experimental|R1: 1 (2) cycle(s) HDM|All patients randomized to intensification with High Dose Melphalan will start intensification with HDM (in hospitals with a policy of double intensification, patients will be randomized between VMP, 1 HDM and 2 HDM) between 4 and 6 weeks after stem cell collection.
3232175|NCT01208766|No Intervention|R2: none|No consolidation, patients will continue to Lenalidomide maintenance.
3232176|NCT01208766|Experimental|R2: 2 cycles of VRD|In patients randomized to consolidation treatment, 2 cycles of Bortezomib, Lenalidomide,Dexamethasone (VRD) will start at 8 weeks after the end of the last course of VMP or HDM.
3328915|NCT02082509||Traumatic Brain Injury (TBI)|Patient who have sustained a TBI over 1 month prior to enrollment, and endorse at least 1 post-concussive symptom at the time of enrollment.
3328916|NCT02082509||Healthy Controls (no TBI)|Subjects who match the TBI group's demographic characteristics, except that they have not sustained a TBI and they are otherwise physically and mentally healthy.
3328917|NCT02082548|Experimental|Intervention|educational intervention arm
3232177|NCT01208779||1|Women with estrogen receptor positive breast cancer already receiving treatment with an aromatase inhibitor (AI) will be enrolled in the study
3328918|NCT02082548|No Intervention|control|Standard of care
3232178|NCT01208792|Experimental|Disease group|Two hundred patients with PAH will be included: 50 patients with idiopathic PAH (iPAH), 20 with PAH associated with HIV infection, 20 with porto-pulmonary hypertension, 20 with PAH secondary to congenital heart disorders, 40 with SSc, 20 with SLE, 20 with MCTD and 10 with a PAH associated with a Sjögren's syndrome. Two hundred patients without PAH will also be included: 80 patients with SSc and 20 in each of the following groups: HIV infection, porto-pulmonary hypertension, SLE, congenital heart disorders, MCTD and with Sjögren's syndrome.
3232179|NCT01208792|Other|Control group 1|Two hundred healthy blood donors age and sex-matched with patients with PAH, will be included as controls.
3232180|NCT01208792|Other|Control group 2|Twenty patients with proximal chronic thromboembolic pulmonary hypertension (CTPH) will also be included in a control arm of the study.
3232181|NCT01208805||Candidates for dorsal column stimulation|
3232182|NCT01208818|Active Comparator|BD|
3232183|NCT01208818|Experimental|C-BD|
3232184|NCT01208818|Experimental|HCO|
3232185|NCT01208818|Active Comparator|Control HD|
3232186|NCT01208831|Experimental|LDE225|
3232187|NCT01208844||Posttraumatic Stress|
3232188|NCT01208844||Depression|
3232189|NCT01208844||Healthy|
3232190|NCT01208883|Experimental|repetitive per-treatment [18F]FDG-PET for treatment adaptation|
3232191|NCT01208896|Experimental|Rituximab|
3232192|NCT01208948|Active Comparator|Alpha lipoic acid 600 mg|
3232193|NCT01208948|Placebo Comparator|placebo pill|
3259183|NCT01468259|Experimental|Severe RD|Eight with severe (15 less than eGFR less than 29 mL/min/1.73m²)
3259184|NCT01468259|Experimental|End Stage Renal Disease|Eight with ESRD (eGFR < 15 mL/min/1.73m² and requiring hemodialysis)
3259185|NCT01468272|Active Comparator|reference treatment|Free combination of Beclomethasone dipropionate DPI and Formoterol fumarate DPI
3328919|NCT02082561|Experimental|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The F-SET protocol is consistent with current CBT protocols for anxiety disorders.
3328920|NCT02082561|No Intervention|Waitlist|The waitlist control condition was comprised of patients randomly assigned to the waitlist condition (WL). Individuals in this condition were reassessed after five weeks and were then offered treatment, but were no longer followed.
3328921|NCT02082574||patients|HIV infected for more than 5 years, aged over 50, treated with ARV
3328922|NCT02082574||control|non HIV (matched for age and gender)
3328923|NCT02082587||QOL Assessment|
3232194|NCT01208974|Experimental|Phase 1 MTD NAC RT|"Participants will undergo a Nipple-Areolar Complex (NAC)-sparing mastectomy with immediate reconstruction and axillary surgery, if indicated, on Week 1. Anytime between Weeks 5-8, participants will undergo a dose-escalation/de-escalation of prophylactic NAC radiation treatment (RT) twice daily (minimum of 4 hours apart) for 5 days. Dose escalation/de-escalation design are as follows:~Dose Level I - 10 fractions of 2.0 Gy for a total of 20 Gy~Dose Level II - 10 fractions of 2.5 Gy for a total of 25 Gy~Dose Level III - 10 fractions of 3.0 Gy for a total of 30 Gy~Dose Level IV - 10 fractions of 3.5 Gy for a total of 35 Gy~Participants will be treated between cohorts of 2-6 patients per dose level starting at dose level II. Dose escalation stops when 2 out of 2-6 participants encounter Dose Limiting Toxicities (DLT).~Standard of care chemotherapy, at treating physician's discretion, can be initiated 2 weeks after RT."
3232195|NCT01208987|Experimental|Intervention (with Medication History)|these patient visits generated a medication history
3328924|NCT02082600|Experimental|Sleep deprivation|Exercise induced-muscle damage protocol followed by 60h of sleep deprivation (two nights) and one night of normal sleep (rebound).
3328925|NCT02082600|Experimental|Normal sleep|Exercise induced-muscle damage protocol followed by 3 nights of normal sleep
3328926|NCT02082613|Experimental|Lord´s procedure|Lord´s procedure for testicular hydrocele, under local anesthesia in a conventional operation room, under sterile conditions
3328927|NCT02082613|Active Comparator|Sclerotherapy|Sclerotherapy with 4 ml of polidocanol 30mg/ml after complete emptying of the hydrocele. With or without local anesthesia, not performed in an operation room.
3328928|NCT02082626|Experimental|Eribulin|All patients will receive the experimental agent eribulin. The dose will increase with subsequent cohorts of patients.
3328929|NCT02082639|Experimental|HPV Group|Subjects will receive two doses of HPV vaccine intramuscularly
3328930|NCT02082639|Experimental|HAV Group|Subjects will receive two doses of HAV vaccine intramuscularly
3328931|NCT02082639|Experimental|HPV+HAV Group|Subjects will receive two doses of both HPV and HAV vaccines intramuscularly
3328932|NCT02082652|Active Comparator|Control group (No ART)|Etonogestrel implant in participants not yet receiving ART (control group)
3328933|NCT02082652|Active Comparator|Nevirapine-based ART group|Etonogestrel implant in participants receiving nevirapine (NVP)-based ART
3328934|NCT02082652|Active Comparator|Efavirenz-based ART group|Etonogestrel implant in participants receiving efavirenz (EFV)-based ART
3328935|NCT02082665|Experimental|Arm 1|On Day 1 subjects will simultaneously receive single dose of Rosuvastatin 10 mg tablet and Midazolam 3 mg syrup administered orally in the morning.
3328936|NCT02082704|Experimental|SE Game on DSME|The intervention cohort will participate in an online team-based game on diabetes self-management education (DSME) and will receive a paper documents on American history,
3328937|NCT02082704|Active Comparator|SE Game on American History|The 'attention control' cohort will participate in an online team-based game on American history and will receive a paper documents on DSME.
3328938|NCT02082730|Active Comparator|Mid treatment Group|Patients who have completed 6 sessions at the Manchester CFS/ME Service for Children & Young People will be recruited. They would have had previous experience of using paper diaries.They will collect activity data using the ASARM system.
3328939|NCT02082730|Experimental|Start of Treatment Group|Newly presented patients, will collect activity data using the ASARM system.
3328940|NCT02082730|No Intervention|Audit group|"To provide comparative baseline data for general treatment response, we will audit pre-treatment and post-treatment clinical data on the regular gold standard clinical measures package, as these are the outcome measures routinely used in the clinic."
3328941|NCT02082743|Experimental|Outdoor activity|Outdoor activity in recess time
3328942|NCT02082743|No Intervention|Control|
3328943|NCT02082756|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
3328944|NCT02082756|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
3328945|NCT02082756|No Intervention|lifestyle counseling|
3328946|NCT02082782|Experimental|irreversible electroporation (IRE)|Single arm study: percutaneous or open irreversible electropration of CRLM
3328947|NCT02082808|Experimental|Sequence 1|Participants will receive the study Treatment A for 5 days (DTG 50mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment B for 5 days (DCV 60mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
3328948|NCT02082808|Experimental|Sequence 2|Participants will receive the study Treatment B for 5 days (DCV 60mg q24h) in Period 1 followed by a washout period (>=7days) and Treatment A for 5 days (DTG 50mg q24h) in Period 2 and Treatment C (DCV 60mg q24h + DTG 50mg q24h) for 5 days in Period 3
3328949|NCT02082834|Experimental|EVAR|
3328950|NCT02082860|Experimental|Cohort A|rAAV2/5-PBGD vector dosage 1
3328951|NCT02082860|Experimental|Cohort B|rAAV2/5-PBGD vector dosage 2
3328952|NCT02082860|Experimental|Cohort C|rAAV2/5-PBGD vector dosage 3
3328953|NCT02082860|Experimental|Cohort D|rAAV2/5-PBGD vector dosage 4
3328954|NCT02082899|Active Comparator|Active Comparator EBI-005 5 mg/mL|Administered 3 times per day
3328955|NCT02082899|Placebo Comparator|Placebo Comparator|Administered 3 times per day
3328956|NCT02082925|Experimental|COPD patient|
3328957|NCT02082938|Experimental|Bracing|Bracing: the patients began four weeks of training the gait with the brace, under the guidance and observation of the physiotherapist belonging to the group of authors of this study.
3328958|NCT02082951|Experimental|Group 2: empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
3328959|NCT02082951|Experimental|Group 1: empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
3328960|NCT02082964|Experimental|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
3328961|NCT02082964|Experimental|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course.
3328962|NCT02082990|Active Comparator|Face-to-Face Brief Intervention Group|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
3328963|NCT02082990|Experimental|Online Brief Intervention Group|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
3328964|NCT02083003|Experimental|Polyamine low-diet|Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
3328965|NCT02083003|Active Comparator|Liberal alimentation|No specific alimentary diet
3328966|NCT02083016|Other|Conventional Mapping|Both pre and post-ablation mapping will be performed firstly by conventional point by point mapping using a Navistar Thermocool catheter, and secondly by multielectrode contact mapping using a Pentaray catheter. In this group, ablation will be guided by conventional mapping.
3328967|NCT02083016|Other|Multielectrode mapping.|Both pre and post-ablation mapping will be performed firstly by multielectrode contact mapping using a Pentaray catheter, and secondly by conventional point by point mapping using a Navistar Thermocool catheter. In this group ablation will be guided by multielectrode contact mapping.
3328968|NCT02083029|Experimental|Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3328969|NCT02083029|Experimental|Non Syncopal Asthmatic|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3328970|NCT02083029|Experimental|Normal Volunteers|All subject undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
3328971|NCT02083055|Experimental|dexmedetomidine|Intraoperative controlled hypotension by dexmedetomidine
3328972|NCT02083055|Active Comparator|nitroglycerin|Intraoperative controlled hypotension by nitroglycerin
3328973|NCT02083068|Experimental|Experimental|10 individuals per sub- group to be immunized with the Vaccine PvCS N+C at month 0 and the Vaccine PvCS N+C+R at months 2 and 6
3328974|NCT02083068|Placebo Comparator|Control|six individuals for each sub- group to be immunized with placebo SSN Montanide ISA-51
3328975|NCT02083081|Experimental|community intervention|Community level intervention (Social marketing campaign delivered to entire village) plus individual peer counseling sessions for enrolled pregnant women
3328976|NCT02083081|No Intervention|usual care|Usual care provided by health aides to pregnant women
3328977|NCT02083120|Experimental|nasal High Flow and Oxygen|overnight nasal High Flow (NHF) therapy+ individually titrated supplemental oxygen (2-6 L/min),total 35 L/min, 4 weeks at home
3328978|NCT02083120|Active Comparator|Long term Oxygen Therapy (LOT)|individually titrated supplemental oxygen (2-6 L/min), 4 weeks at home
3328979|NCT02083133||End Stage Renal Disease|GFR 15 ml/min or less or on Dialysis
3328980|NCT02083133||Chronic Kidney Disease Stage 4|GFR 15-30 ml/min
3328981|NCT02083133||Chronic Kidney Disease Stage -3|GFR 30-60 ml/min
3328982|NCT02083146||Patients with CAD|Acute coronary syndromoe (ACS) patients who were admitted to the coronary care unit.
3328983|NCT02083159||Patients with NAFLD|
3328984|NCT02083172||Hemodynamically stable patients|Hemodynamically stable patients will be defined as patients with normal hemodynamic profile as evidenced by normal age-determined vital signs and normal perfusion.
3328985|NCT02083172||Hemodynamically unstable patients|Hemodynamically unstable patients will be defined as patients who are admitted to the Pediatric Critical Care Unit (PCCU), in whom there is a clinical diagnosis of shock as evidenced by signs and symptoms of hypoperfusion, requiring fluid resuscitation and/or inotropic support.
3328986|NCT02083172||Mechanically ventilated patients|Patients requiring mechanical ventilation
3328987|NCT02083198||High Chloride|Patients receiving .9% sodium choride for resuscitation
3328988|NCT02083198||Low chloride|Patients receiving Plasmalyte for resuscitation
3328989|NCT02083211|Experimental|mAb Nimotuzumab + chemotherapy|
3328990|NCT02083211|Placebo Comparator|placebo + chemotherapy|
3328991|NCT02083224||Cancer patients|
3328992|NCT02083237|Active Comparator|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
3328993|NCT02083237|No Intervention|Waitlist Control|Due to the heavy demand for this clinical program, there is a naturally-occurring waitlist of approximately 3 months. Control participants are assessed during this period.
3328994|NCT02083250|Experimental|Treatment (vorinostat, chemotherapy, SCT)|"CONDITIONING REGIMEN: Patients receive vorinostat PO QD, fludarabine phosphate IV over 1 hour, clofarabine IV over 1 hour, and busulfan IV over 3 hours on days -6 to -3. Patients receiving a transplant from a HLA-matched unrelated donor, receive anti-thymocyte globulin IV over 4 hours on days -3 to -1.~TRANSPLANT: Patients undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0."
3232200|NCT01209013|Experimental|Medlight PDT Balloon|
3328995|NCT02083276|Experimental|Pivmecillinamhydrochlorid|Selexid 400 mg x 3 , 7 days
3328996|NCT02083289|Experimental|Experimental Arm 1|ONO-9054 eye drop solution, 30 µg/mL (0.003%), once daily in both eyes, for 28 days.
3328997|NCT02083289|Active Comparator|Active Comparator Arm 2|Latanoprost eye drop solution, 0.005%, once daily in both eyes for 28 days.
3328998|NCT02083302|Experimental|Treatment1|The Treatment1 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2 and SCREAM Theater Dose 3.
3232201|NCT01209026|Experimental|FF/GW642444M (200/25mcg)|Inhaled fluticasone furoate (200mcg) /GW642444M (25mcg) combination Days 1- 7; placebo tablet taken orally single dose (po SD) on Day 7.
3232202|NCT01209026|Experimental|FF/GW642444M (800/100 mcg)|Inhaled fluticasone furoate (800mcg) /GW642444M (100mcg) combination Days 1- 7; placebo tablet (po SD) on Day 7.
3232203|NCT01209026|Active Comparator|Moxifloxacin|Inhaled placebo on Days 1-7; moxifloxacin (400mg po SD) on Day 7
3232204|NCT01209026|Placebo Comparator|Placebo|Inhaled placebo on Days 1-7; placebo tablet (po SD) on Day 7.
3328999|NCT02083302|Experimental|Treatment2|The Treatment2 group received SCREAM Theater Dose 1, SCREAM Theater Dose 2, SCREAM Theater Dose 3 and SCREAM Theater Dose 4.
3329000|NCT02083302|Other|Control|The control group received SCREAM Theater Dose 1.
3329001|NCT02083315|Experimental|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
3329002|NCT02083315|Experimental|TRV130 3 mg|TRV130 3 mg IV x 1 dose
3329003|NCT02083315|Experimental|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
3329004|NCT02083315|Active Comparator|Morphine|Morphine 10 mg IV x 1 dose
3329005|NCT02083315|Placebo Comparator|Placebo|Dextrose 5% in water IV x 1 dose
3329006|NCT02083328|Active Comparator|Caffeine|Caffeine will be administrated at a dosage of 6mg/kg of body mass. It is ingested once, one hour before the exercise performance test.
3232205|NCT01209039|Experimental|Part A, cohort 1 and 2|Part A, Cohorts 1 and 2, will investigate escalating multiple daily doses of GSK1144814 in 19 subjects
3232206|NCT01209039|Experimental|Part A, cohort 3|Cohort 3 will investigate safety, tolerability and PK of a dose of GSK1144814 over a repeat treatment period of 28 days in 18 subjects and a potential drug drug interaction between GSK1144814 and the CYP3A4 sensitive substrate midazolam (in 15 subjects).
3232207|NCT01209039|Experimental|Part B|Part B will assess NK1 receptor occupancy following repeated administration of GSK1144814 given once daily until steady state is obtained
3329007|NCT02083328|Placebo Comparator|Mannitol (Placebo)|Placebo capsules will be administrated one hour before the exercise performance test. The subject gets exactly the same number of capsules as for the caffeine dosage. Caffeine and placebo capsules look the same.
3329008|NCT02083341|Experimental|Muscle tension dysphonia - treatment|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
3329009|NCT02083341|Sham Comparator|Muscle tension dysphonia - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
3329010|NCT02083341|Experimental|Classically trained singers|external vibration device. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP.
3329011|NCT02083341|Sham Comparator|Classically trained singers - Sham|external vibration device - sham. A prospective, randomized, placebo controlled, single blinded study design will be used to investigate the effects of an external vibration device on voice acoustic parameters and perceptual in MTD patients and singers. The external vibration device to be investigated is the Lelo® Siri vibrator. The external vibration therapy sessions, and pre and post acoustic recordings will be conducted by a SLP. Lelo® Siri vibrator with vibration component removed.
3329012|NCT02083367||Hepatic Encephalopathy Group|Disease Group
3329013|NCT02083367||Control Group|Healthy Group
3232208|NCT01209052|Experimental|COHORT 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 10mg, to 50mg, and 200mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
3259186|NCT01468272|Experimental|CHF 1535 NEXT DPI|CHF 1535 50/6 NEXT DPI
3232209|NCT01209052|Experimental|COHORT 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that two subjects will receive GSK1325756 and at least one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK1325756 from 25mg, to 100mg, and 400mg, will be administered over the 6 week long treatment period allowing adequate washout period between doses.
3329014|NCT02083393||Patients with acute lung injury|Patients with sepsis induced acute lung injury
3329015|NCT02083393||Postsurgery patients|Postsurgery patients without acute lung injury and sepsis
3329016|NCT02083419||LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
3329017|NCT02083432|Active Comparator|5-weeks waiting list control|Half of the participants were randomly assigned to 5-weeks waiting list/Control group.The participants in the waiting list/Control Group are enrolled to the treatment Group (INtervention: 5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV).
3329018|NCT02083432|Experimental|5 session of CBT|Half of the participants were direct enrolled to 5 weeks(5 sessions) of cognitive behaviour therapy (CBT) performed by specially trained dentists. (Intervention: CBT)
3329019|NCT02083445|Placebo Comparator|Control group|Once a week there will be an attendance cognitive session (specific sessions designed to work on aspects related to body perception, movement, space) and the extraction of blood samples will be carried out to determine the progenitor cells on the same day of the active groups.
3329020|NCT02083445|Active Comparator|Exercise group|Patients with past history of TBI will perform exercise sessions two hours three days a week during 12 weeks. The sessions will consist of aerobic, strength, flexibility, proprioception and balance activities and muscle electro-stimulation sessions or cycling sessions.
3329021|NCT02083445|Active Comparator|Muscle electro-stimulation and IHH|Patients with past history of TBI will perform a 12 weeks program: intermittent hypobaric hypoxia (IHH) 2 hours at a simulated altitude of 4500 meters 3 days/week. Muscle electro-stimulation for two periods of 20 minutes during the stay in the hypobaric chamber.
3329022|NCT02083458|Experimental|axillary vein catheterization|Catheterization of the axillary vein based on anatomical landmark.
3329023|NCT02083471|Active Comparator|SOTI|Specific Oral Tolerance Induction with Egg or Cow's milk
3329024|NCT02083471|No Intervention|Food Allergy follow-up|
3329025|NCT02083497|Experimental|No banding|The volunteers who make up this group, held 18 kicks, 9 with the dominant leg and 9 with the non-dominant lower limb, without the intervention of any kind of bandage.
3329026|NCT02083497|Experimental|Group with Rigid Bandage|Volunteers carry out the same protocol described above, however, using rigid bandage. The bandage will be used for tape, Cremer brand and will be applied ankle support member of the individual, in order to limit the movement of the joint inversion.
3329027|NCT02083497|Experimental|Group with elastic bands|The protocol will be maintained, however, a brand elastic bandage Kinesio Sport applied to the lower support member of the individual, also in order to limit the movement of the joint inversion is used.
3329028|NCT02083510|Experimental|Colchicine|Patients will be enrolled with either gout/pericarditis or hypertriglyceridemia, have VAP and Apolipoprotein CIII levels at baseline, administer Colchicine for 6 weeks with reassessment of Apolipoprotein CIII and VAP.
3232210|NCT01209052|Experimental|COHORT 3|Placebo controlled, 14-day, once daily, repeat-dose evaluation with one selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohorts 1 and 2.
3232211|NCT01209052|Experimental|COHORT 4|Placebo controlled, 14-day, once daily, repeat-dose evaluation with a higher selected dose of GSK1325756 in 14 subjects. Dose selection based on review of safety and tolerability data from cohort 3.
3232212|NCT01209065|Experimental|Part A|Approximately 12 subjects will be enrolled. In the first treatment period, all subjects will receive GSK1349572 50 mg every 24 hours for 5 days. In Period 2, subjects will receive GSK1349572 50 mg every 24 hours in combination with fosamprenavir 700 mg plus ritonavir 100 mg every 12 hours for 10 days. Day 1 of Period 2 will be the day after Day 5 of Period 1. Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3232213|NCT01209065|Experimental|Part B|Approximately 15 subjects will be enrolled and receive three single doses of GSK1349572 approximately one week apart. One will be the current tablet formulation containing micronized drug substance and 2 will be new tablet versions, one containing unmicronized drug substance and one containing an intermediate particle size drug substance. Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug.
3232214|NCT01209091||No treatment|
3232215|NCT01209104|Experimental|Cohort 1-PK and and safety of GSK1325756 in subjects 40-64y|This arm assesses the pharmacokinetics and safety of a single oral ose of 100mg of GSK1325756 administered to subjects in the age range 40y-64y when administered in the fasted state, in the presence of a high-fat meal and in the presence of a proton-pump inhibitor.
3232216|NCT01209104|Experimental|Cohort 2- PK and safety of GSK1325756 in subjects aged 65y-80y|This arm assesses the pharmacokinetics and safety of a single dose of 100mg of GSK1325756 administered to a group of subjects in the 64y-80y age range in the fasted state
3232217|NCT01209117|Experimental|Periods 1 - 4|Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
3232218|NCT01209117|Experimental|Period 5|Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
3232219|NCT01209130|Experimental|A|
3232220|NCT01209130|Experimental|B|
3259187|NCT01468285|Experimental|Treatment arm 1: betahistine dihydrochloride|
3329029|NCT02083523|Active Comparator|Motivational Interview|The Motivational Interview, or MI, (15-30 minutes) was provided after initial substance use disorder assessments but prior to treatment admission. I twas facilitated by a computer generated report and included: an orientation to the session, discussion of the participants' strengths, an agenda setting procedure, a review of concerns, and a session summary. Therapists conveyed empathy, used reflective listening, tried to elicit and reinforce change talk elements, and elicited action steps from the participants.
3329030|NCT02083523|Active Comparator|MI with Normative Feedback|The Motivational Interview with Normative Feedback, or MI + NF, condition/intervention included all procedures described for the MI condition. Additionally, in the MI + NF condition/intervention, the participants' days of marijuana and alcohol use were compared to two sets of norms ( age specific or level of care specific) available for treatment attending youth. Therapists used whichever norm provided a greater contrast with participants' use.
3329031|NCT02083536|Experimental|LDFWART + Docetaxel|"This study has 6 treatment cycles given at 3 weeks intervals ± 3 days. A cycle is defined as 1 treatment of morning Docetaxel and afternoon Low Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART). The first day of the first treatment is designated study day 1."
3329032|NCT02083549||Trauma 1 massively transfused|Trauma 1 massively transfused patients are identified as a Trauma level one patient by triage through guidelines from the Kessler Regional Trauma Center Trauma Triage Guidelines.
3329033|NCT02083575|Active Comparator|vitamin c|25 heavily iron-loaded thalassemia patients, receiving adjuvant vitamin c with iron chelator.
3329034|NCT02083575|Other|iron chelator|Included 25 heavily iron-loaded thalassemia patients, not receiving adjuvant vitamin c with iron chelator.
3329035|NCT02083588|Experimental|open - single arm|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
3329036|NCT02083601|Experimental|Psychological Support|The intervention group will participate in the 2-day, in-person Parent Forum and receive monthly phone calls from a mental health professional for 12 months.
3329037|NCT02083601|Other|No Psychological Support|This comparison group will attend the 2-day, in-person Parent Forum but will not receive long-term psychological support.
3329038|NCT02083614|Experimental|clamping|to clamp or release the catheter for 2 days before removal
3329039|NCT02083614|No Intervention|no clamping|
3329040|NCT02083627|Experimental|1:Single rosuvastatin,multiple fidaxomicin,single rosuvastatin|
3329041|NCT02083627|Experimental|2:Multiple fidaxomicin,single rosuvastatin,single rosuvastatin|
3329042|NCT02083640|Other|Treatment A (Reference)|
3329043|NCT02083640|Other|Treatment B (Test)|
3329044|NCT02083640|Other|Treatment C (Test)|
3329045|NCT02083666|Experimental|SOBI002|Single and repeated administration of different doses of test product
3329046|NCT02083666|Placebo Comparator|placebo|Single and repeated administration of placebo comparator
3329047|NCT02083692|Experimental|Metformin|
3232221|NCT01209156|Experimental|Assess [18F] PBR111 and PET imaging|Evaluation of PET imaging with [18F]PBR111 in HV and AD subjects (Proof of Mechanism)
3329048|NCT02083705|Experimental|SI+CC|"Chest compression will be superimposed by sustained inflations during CPR:~CC+SI group Infants randomized in the SI group requiring CC, would receive CC at a rate of 90/min during an SI with a duration of 20sec (CC+SI). After 20 sec the SI will be interrupted for 1 sec and the next SI will be started for another 20sec13. Throughout this time CC is continued until ROSC. Every 45 sec (approximately 2 SIs) the clinical team would assess for changes in heart rate. CC+SI was continued until ROSC."
3329049|NCT02083705|Active Comparator|3:1 CPR|"CPR using 3:1 C:V ratio:~3:1 C:V group Infants randomized into the 3:1 group requiring CC, would received CC using the current 3:1 C:V ratio recommend in the neonatal resuscitation guidelines16. Every 45 sec the clinical team would assess heart rate. 3:1 C:V CPR was continued until ROSC."
3329050|NCT02083718|Experimental|PBSC & MSCs|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week. The vital signs of all patients will be closely monitored during and for 24h after administration.If the NEU and PLT levels do not attain the completely response(CR)standards within 28d, a second course of the same treatment will be given.
3329051|NCT02083731|Experimental|MSCs|MSCs will be used to treat refractory CMV infection or CMV-associated diseases. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg. If anticipates do not attain the complete remission standards within 14d, a second course of the same treatment will be given.
3329052|NCT02083744|Active Comparator|Control Group|Usual care group - patients will receive scales to take home and heart failure literature for self-monitoring of heart failure. Patients will complete final questionnaires
3329053|NCT02083744|Experimental|Psychoeducational Counseling|"1-on-1 psychoeducation session conducted by a bilingual research nurse at the clinic site or in the patient's home. Patients will receive a scale to measure weight, a diary to record weight and symptoms of heart failure, and telephone follow-up from the research nurse to reinforce the content of the education program every other week.~Focus-groups - Perception of the intervention will be assessed with two focus groups."
3232222|NCT01209182|Experimental|Device image reading|Tissue images generated by the device are read by surgeons to determine if the tissue area under test has abnormal component or not. When Images generated by the device are read by surgeons as abnormal an additional margin of tissue is removed. The new margin is also imaged by the device to ensure complete tumor excision.
3232223|NCT01209208|Experimental|A|Budesonide
3232224|NCT01209208|Experimental|B|Mesalazine
3232225|NCT01209208|Placebo Comparator|C|
3329054|NCT02083757||Resp|Fluid responsiveness is defined as a change of stroke volume stroke volume ≥ 10% after 250 ml rapid saline infusion in 10 minutes.
3329055|NCT02083757||Nonresp|Fluid responsiveness is defined as a change of stroke volume stroke volume < 10% after 250 ml rapid saline infusion in 10 minutes.
3329056|NCT02083770|Experimental|Cancer Clinical Trials Education Program|Cancer Clinical Trials Education Program is offered to English- and Spanish-speaking Hispanics in the experimental arm. This program was designed to promote increased clinical trials literacy among Hispanic Americans. Increased clinical trials knowledge and a better understanding of clinical trials is anticipated to create more positive attitudes, and perceptions about clinical trials among Hispanic Americans.
3329057|NCT02083770|Placebo Comparator|Neighborhood Watch Education Program|The Neighborhood Watch Program created by the Bureau of Justice Assistance and the National Crime Prevention Council was selected for inclusion in the control arm of this study. It provided participants with a program of equivalent length and format, as well as an equivalent focus on improving the well-being of Hispanic Americans. It also provided an opportunity to evaluate the impact of the Neighborhood Watch Program.
3232226|NCT01209221|Experimental|1|
3232227|NCT01209221|Experimental|2|
3232228|NCT01209221|Placebo Comparator|3|
3232229|NCT01209221|Placebo Comparator|4|
3329058|NCT02083796|Experimental|Shoulder impingement_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times.
3329059|NCT02083796|Sham Comparator|Shoulder impingement_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
3232230|NCT01209247|Active Comparator|patient treated by fluoroquinolone|patient treated by fluoroquinolone. Nasal, rectal and pharyngeal swabs
3232231|NCT01209247|Placebo Comparator|patient not receiving FQ treatment|reference group of patients not receiving FQ treatment, but hospitalized in the same wards at the same time
3329060|NCT02083796|Active Comparator|Asymptomatic_TSM|For the manipulation intervention, the subjects were in a seated position and a thrust technique was performed. If no cavitation was detected with the manipulation, the thrust was repeated up to 3 times
3329061|NCT02083796|Sham Comparator|Asymptomatic_sham|For the sham intervention, the subjects were positioned in the same seated position with the therapist holding the patient in the same position as for the thrust manipulation. In this position, the therapist applied all the same forces as done for a thrust-manipulation and held that position for a few seconds, but a thrust was not used.
3329062|NCT02083822|Experimental|MRI assessment|
3329063|NCT02083835||post-surgical patients|post-surgical patients > 18 years
3329064|NCT02083835||pediatric patients post-op day 1|pediatric patients > 4 years on post-op day 1 (sub-project QUIPSI - PAIN OUTinfant)
3329065|NCT02083848|Other|7T MRI|All subjects are entered into a single arm.
3329066|NCT02083874|Experimental|CBD|Open label CBD
3329067|NCT02083887|Active Comparator|Group 1: ChAd63 ME-TRAP / MVA ME-TRAP at 16/24 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 infants aged 16 weeks at time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp (virus particles) intramuscular (IM) at 16 weeks and MVA ME-TRAP 1 x 10^8 pfu (plaque forming units) IM at 24 weeks.
3329068|NCT02083887|Active Comparator|Group 2: ChAd63 ME-TRAP / MVA ME-TRAP at 8/16 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 8 weeks at the time of first vaccination vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 8 weeks and MVA ME-TRAP 1 x 10^8 pfu IM at 16 weeks
3329069|NCT02083887|Active Comparator|Group 3: ChAd63 ME-TRAP / MVA ME-TRAP at 1/8 weeks old|ChAd63 ME-TRAP / MVA ME-TRAP. 15 healthy infants aged 1 week will be vaccinated with ChAd63 ME-TRAP 5 x 10^10 vp IM at 1 week and MVA ME-TRAP 1 x 10^8 pfu IM at 8 weeks.
3329070|NCT02083887|No Intervention|Group 4: Control|20 healthy infants aged 16, 8 and 1 weeks will be enrolled into this group. (Five infants will be randomised to each of Groups 1 and 2 respectively while 10 infants aged 1 week will be randomised to Group 3). All twenty infants will receive EPI vaccinations only.
3232232|NCT01209273||APD group|which can be 3 to 5 exchanges daily, and up to 20 liters daily( including up to two daytime exchanges)
3232233|NCT01209273||CAPD group|which can be 1 to 4 exchanges daily and up to 16 liters daily(including up to two daytime exchanges)
3232234|NCT01209312|Experimental|full bolus -20|Will administer full insulin bolus 20 minutes prior to meal
3232235|NCT01209312|Experimental|Full bolus, T0|Will administer full meal bolus at the start of the meal
3329071|NCT02083900|Experimental|Banana Leaf Dressing Group|The Banana Leaf Dressing site will receive a single layer of banana leaf dressing
3329072|NCT02083900|Active Comparator|Hydrocolloid Dressing Arm|The donor under Hydrocolloid dressing was covered with hydrocolloid (DuoDERM CGF).
3329073|NCT02083913|Experimental|Supervised physical activity|
3232236|NCT01209312|Experimental|1/2 bolus, T-20|Will only give half the insulin dose 20 minutes before meal
3232237|NCT01209312|Experimental|1/2 bolus T0|Will give half the amount of insulin at the time of the meal
3232238|NCT01209338|Active Comparator|sensitized group|One arm will be a sensitized group which would have received cancer health awareness sessions and / or screening earlier at least once in the past.
3232239|NCT01209338|No Intervention|non-sensitized group|The second arm will belong to an area which has never been exposed to any form of cancer awareness or screening activities thus this group is a completely non-sensitized group.
3232240|NCT01209351|Placebo Comparator|Placebo|Placebo
3232241|NCT01209351|Experimental|teduglutide|
3232242|NCT01209364|Experimental|Durolane|intraarticular hyaluronic acid
3232243|NCT01209364|Active Comparator|methylprednisolone|intraarticular injection
3232244|NCT01209377|Experimental|standard|EMDR treatment with bilateral stimulation via eye movement
3232245|NCT01209377|Experimental|fixed|EMDR treatment with eyes fixed
3232246|NCT01209377|Experimental|no focus|trauma exposition without external stimulus
3232247|NCT01209390||Osteochondral lesions|Patients with osteochondral lesions in the knee, the ankle, or other joint
3232248|NCT01209403|No Intervention|No treatment|
3232249|NCT01209403|Active Comparator|Glukose-infusion|Glucose-infusion during hemodialysis
3232250|NCT01209403|Active Comparator|Glucose-insulin infusion|Glucose-insulin infusion during hemodialysis
3232251|NCT01209416|Active Comparator|Ghrelin / Acipimox|Ghrelin infusion and tablet acipimox
3329074|NCT02083939||Antibiotic Prophylaxis|This cohort will receive antibiotic prophylaxis prior to the hernia repair
3329075|NCT02083939||No Antibiotic Prophylaxis|This cohort will not receive antibiotic prophylaxis prior to the surgery
3329076|NCT02083952|Experimental|swaddle blanket|
3329077|NCT02083978||Bipolar Diagnosis|Individuals identified as having a Bipolar Diagnosis with a manic episode
3329078|NCT02083978||Control|Individuals identified as not having a major psychiatric diagnosis
3329079|NCT02083991|Experimental|Steroid-free low TAC-arm|"Induction therapy: Thymoglobulin i.v. 2,5 mg/kg day 0 and 1, preceded by methylprednisolone i.v. 250 mg day 0 and 50 mg day 1.~Maintenance therapy: Advagraf(TAC) 0,2 mg/kg p.o. started day1 (target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml; MMF 1g x 2 p.o. (target Area Under Curve, AUC 40-60 mg.h/L); No steroids p.o."
3329080|NCT02083991|Active Comparator|Standard low-TAC arm|"Induction therapy: Simulect i.v. 20 mg day 0 and 4; Steroids i.v. according to local practice.~Maintenance therapy: Advagraf(TAC) p.o. 0,2 mg/(target concentration 5-10 ng/ml, after 3 months 4-7 ng/ml); MMF 1g x 2 p.o. (target AUC 40-60 mg.h/L); Steroids p.o. according to hospital practice (but not less than 5mg daily after 6 months)."
3329081|NCT02084004|Experimental|Bifidobacterium viable pharmaceutics|Bifidobacterium viable pharmaceutics, 2 Capsules, 2/day, 12 weeks
3329082|NCT02084004|Experimental|Berberine Hydrochloride|Berberine Hydrochloride, 0.5g, 2/day, 12 weeks
3329083|NCT02084004|No Intervention|lifestyle counseling|
3329084|NCT02084017|Active Comparator|Current Standard|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing applied under sterile conditions in the operating room following skin closure. Dressing changed post-operative day two and daily thereafter with daily inspection for infection by a physician.
3329085|NCT02084017|Experimental|Negative Pressure Wound Therapy|A negative pressure therapy (Kinetic Concepts, Inc, San Antionio, Tex) device will be applied under sterile conditions post-operatively and placed on suction (125-150 cm H2O). The device will be removed on post-operative day 4-7 depending on day of discharge.
3329086|NCT02084030||Experimental: Patient with POCD|Patients who suffer from POCD after surgery. The mini-mental state examination scale decline more than 1 SD of baseline after surgery.
3329087|NCT02084030||Sham Comparator: patient without POCD|Patients who don't suffer from POCD after surgery. There is no obvious difference between pre-operation and post-operation in mini-mental state examination scale
3329088|NCT02084043|Experimental|Breath-actuated vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with an experimental breath-actuated vibrating mesh nebulizer associated with a single limb circuit ventilator.
3329089|NCT02084043|Experimental|Conventional vibrating mesh nebulizer|500 mg/4 mL of Amikacin solution delivered with a conventional vibrating mesh nebulizer (in continuous mode) associated with a single limb circuit ventilator.
3329090|NCT02084108|No Intervention|Control arm= usual care|Two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the resident assessment instrument-home care (RAI-HC) and identified as frail by pre-defined clinical criteria.
3329091|NCT02084108|Other|Intervention arm|The intervention arm will consist of two clusters of patients over 60 years of age followed by a primary care physician and routinely evaluated by the home nursing service with the RAI-HC and identified as frail by predefined clinical criteria that will receive in addition an in-home multidimensional geriatric assessment, access 24 hours a day, 7 days a week to a call service provided by the Community Geriatrics Unit and coordinated long-term follow-up.
3329092|NCT02084173|Other|MET|Motivational Enhancement Therapy (MET)
3329093|NCT02084173|Other|MET + CRA|Motivational Enhancement Therapy (MET) with subsequent add-on The Community Reinforcement Approach (CRA)
3329094|NCT02084186|Experimental|moxibustion group|herb-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
3329095|NCT02084186|Placebo Comparator|bran-partitioned moxibustion|bran-partitioned moxibustion on bilateral Tianshu (ST25) and Shangjuxu (ST37)
3329096|NCT02084199|Experimental|Part 1 - Severe renal impairment|Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or <15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
3329097|NCT02084199|Experimental|Part 1: Normal renal function|Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
3329098|NCT02084199|Experimental|Part 2 - Mild renal impairment|Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3329099|NCT02084199|Experimental|Part 2 - Moderate renal impairment|Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3329100|NCT02084199|Experimental|Part 2 - Normal renal function|Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
3329101|NCT02084212|Other|Patients about to undergo epiretinal membrane surgery|
3329102|NCT02084225||Course participants|Physicians, nurses and orthopedic officers who staff the emergency intake and orthopedic procedure area of HEAL hospital, Goma DRC, Black Lion Hospital, Addis Ababa and Kindu General Hospital in Kindu DRC. These participants recorded their nerve block intervention over one year for pain management and assessed patient pain level after 10 cc lidocaine.
3329103|NCT02084251|Experimental|Exenatide analogue, Injection|PB-119 will be administered once weekly subcutaneously at dosage of 2μg、5μg、10μg、25μg、50μg、100μg、200μg or 400μg.
3329104|NCT02084264||Arm 1: Robotic-guided, open approach|Robotic-guided, open approach
3329105|NCT02084264||Arm 2: control arm- non-robotic, open approach|control arm- non-robotic, open approach°
3329106|NCT02084277|Experimental|Self-ligating brackets|Several self-ligating brackets are currently FDA-approved but have not been rigorously studied in this malocclusion patient population or in comparison to traditional brackets methods. Unlike conventional brackets, Self-ligating brackets (SLB) are bracket systems, without the wire ligature or elastic ligature, that have a tube-like device build into the bracket to close off the edgewise slot.
3329107|NCT02084277|Placebo Comparator|Conventional brackets|"The conventional brackets (CB) (edgewise appliance) retain the basic principle design of a rectangular wire in a rectangular slot. Archwire are tied to the bracket once placed in the slot with either elastometric ligation ties (O-rings) or steel ligation."
3329108|NCT02084290|Experimental|Shared Decision Making Program|Patients will have access to an educational decision making program and a risk prediction model, this web based program will be sent subjects in the intervention arm upon enrollment, they can access the program as many times as they wish.
3329109|NCT02084290|No Intervention|Control|Subjects enrolled at sites participating as control arms will access the same web-based surveys as the intervention group, and receive the same contacts from the study coordinator as the subjects enrolled at intervention sites.
3329110|NCT02084303|Other|Ferumoxytol MRI|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI.
3329111|NCT02084316|Experimental|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
3329112|NCT02084316|Active Comparator|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
3329113|NCT02084329|Experimental|Weighted Compression Vest|Weighted Compression Vest
3329114|NCT02084329|No Intervention|Control|
3329115|NCT02084342|Placebo Comparator|Group TN|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min, before incision.Then at 1mg/kg/h, IV pump, until the surgery is over.~Normal saline (NS) 100ml IV for 20min, before incision."
3329116|NCT02084342|Experimental|Group TD|"Tranexamic acid and sodium chloride injection at 10mg/kg, IV (in the vein) for 30min,before incision.Then at 1mg/kg/h,IV pump,until the surgery is over.~Desmopressin acetate injection at 0.3μg/kg dissolved in 100ml NS, IV for 20min, before incision."
3329117|NCT02084355|Experimental|opioid rotation|"Patients who are randomized to opioid rotation are treated with strong opioid other than currently used strong opioid (Reduce the dose by 25%-50% to allow for incomplete cross-tolerance between different opioids).~oral oxycodone : convert to oral hydromorphone or fentanyl patch~oral hydromorphone : convert to oral oxycodone or fentanyl patch~fentanyl patch : convert to oral oxycodone or oral hydromorphone"
3329118|NCT02084355|Active Comparator|opioid dose escalation|"Patients who are randomized to opioid dose escalation will be treated cancer pain by escalation dose of same strong opioid.~oral oxycodone : maintain oral oxycodone and titrate the dose~oral hydromorphone : maintain oral hydromorphone and titrate the dose~fentanyl patch : maintain fentanyl patch and titrate the dose"
3329119|NCT02084368|Experimental|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block guided by PNS.
3232252|NCT01209416|Active Comparator|Ghrelin / placebo|Ghrelin infusion and placebo tablets
3232253|NCT01209416|Active Comparator|Placebo / Acipimox|saline infusion and tablet Acipimox
3329120|NCT02084368|Placebo Comparator|combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group.
3232254|NCT01209416|Placebo Comparator|Placebo / placebo|saline infusion and placebo tablets
3232255|NCT01209429|Experimental|42 hour fast/GH infusion|
3329121|NCT02084381|Experimental|MCO-Ci 400|MCO-Ci 400 is the investigational medical product applied in hemodialysis mode
3232256|NCT01209429|Experimental|42 hour fast/Placebo infusion|
3232257|NCT01209429|Experimental|12 hour fast/GH infusion|
3232258|NCT01209429|Placebo Comparator|12 hour fast/Placebo infusion|
3329122|NCT02084381|Active Comparator|Revaclear 400|the standard high flux dialyzer Revaclear 400 is used as an comparator in hemodialysis mode
3329123|NCT02084394||no intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the concommittent ultrasound of the temporal artery. Deemed interventional by JHUIRB but no actual intervention done to subject.
3329124|NCT02084407|Active Comparator|DM1 subject with cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
3232259|NCT01209455|No Intervention|Saline|Volunteers will receive an incremental rising dose infusion of IA NAC (6 doses) together with a co-infusion of normal saline to determine a dose response curve for arterial vasodilatation in the forearm.
3232260|NCT01209455|Active Comparator|Histamine antagonists|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of histamine antagonists (H1 and H2 antagonists) to determine vasodilatation in response to NAC in the presence of histamine antagonists.
3232261|NCT01209455|Active Comparator|Low dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of low dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
3259188|NCT01468285|Placebo Comparator|Treatment arm 2: placebo|
3259189|NCT01468298|Active Comparator|Isostretching|
3259190|NCT01468298|Active Comparator|Global Posture Reeducation|
3329125|NCT02084407|Active Comparator|DM1 subject without cardiopathy|Clinical examination, Skin biopsy, Blood and urine sampling
3232262|NCT01209455|Active Comparator|High dose paracetamol|Subjects will receive an increasing dose infusion of NAC as described in arm 1 but in this arm will receive a co-infusion of higher dose paracetamol to determine whether the vasodilatory response to NAC is inhibited.
3329126|NCT02084407|Active Comparator|Not DM1subject|Clinical examination, Skin biopsy, Blood and urine sampling
3329127|NCT02084420|Experimental|Ilaprazole or Pantoprazole placebo|Ilaprazole 10mg, Pantoprazole 40mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day, PO
3329128|NCT02084420|Active Comparator|Ilaprazole placebo or Pantoprazole|Pantoprazole 40mg, Ilaprazole 10mg, Amoxicillin 1000mg, Clarithromycin 500mg 2 times/day,PO
3329129|NCT02084433|Active Comparator|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
3329130|NCT02084433|Experimental|intraosseous anaesthesia|"intraosseous anaesthesia using a computerized system (Quicksleeper) 1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
3329131|NCT02084446|Active Comparator|Mycophenolate + Low Tacrolimus|"Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1. Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.~Steroids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
3329132|NCT02084446|Experimental|Everolimus + Very Low Tacrolimus|"Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.~Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.~Corticoids: endovenous Methylprednisolone before doses of r-ATG; Prednisone per oral.~Thymoglobulin: all patients will receive induction in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg)."
3329133|NCT02084459|No Intervention|Control|Standard of care
3329134|NCT02084459|Experimental|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
3329135|NCT02084472|Active Comparator|study 1: aqueous cream and baby oil|enrolled patients in this arm use either aqueous cream or baby oil as a soap substitute
3329136|NCT02084472|Active Comparator|study 2: emulsifying ointment and cetomacrogol|patients in this study arm continue to use emulsifying ointment and cetomacrogol as a moisturiser, the current standard of care in our institution
3329137|NCT02084485|Experimental|Arm A|
3329138|NCT02084485|Placebo Comparator|Arm B|
3329139|NCT02084498|Active Comparator|ACC|Training in advanced carbohydrate counting
3329140|NCT02084498|Experimental|ACC + ABC|Training in advanced carbohydrate counting plus the use of an automated bolus calculator.
3329141|NCT02084524|No Intervention|Nutritional evaluation|
3329142|NCT02084537|Active Comparator|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7 French (Fr) double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
3329143|NCT02084537|Active Comparator|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic approach. This includes laparoscopic cystogastrostomy with internal debridement.
3329144|NCT02084550|Active Comparator|Vaminolac|Intravenous Vaminolac during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
3329145|NCT02084550|Placebo Comparator|Saline|Intravenous saline during 3 hours, with an infusion rate of 1,6ml/kilogram bodyweight/h.
3329146|NCT02084563|Other|AML-Intensive Chemotherapy|"Patients with Acute Myeloid Leukemia fit for intensive chemotherapy Patients will receive Induction Chemotherapy, and CR will be evaluated after 28 days.~Patients who achieve CR post-induction chemotherapy will receive post-remission therapy according to risk:~Low risk patients: Consolidation chemotherapy or Autologous stem cell transplantation~Intermediate and high-risk patients: Allogeneic stem cell transplantation Patients who do not achieve CR may receive one second induction cycle, and if CR is achieved may proceed to post-remission therapy as per above. Patients who do not achieve CR after two cycles of induction will be deemed refractory and removed from the study."
3329147|NCT02084563|Other|AML-Non-intensive chemotherapy|"Patients with acute myeloid leukemia not fit for intensive chemotherapy Patients will receive induction chemotherapy with either low dose cytarabine or decitabine. Assignment to each drug will depend on drug availability and physician discretion. No randomization will be done between the drugs.~Cycles will be repeated every 28 days. Patients who achieve CR will continue to post-consolidation therapy with either cytarabine or decitabine, based on the induction therapy received. Patients will receive a maximum of 4 cycles until achieving CR, if no response is seen after 4 cycles patients will be deemed refractory."
3329148|NCT02084563|No Intervention|Chronic Myeloid Disorders|"Patients with Chronic Myeloid Disorders:~Myeloproliferative Neoplasms~Myelodysplastic Syndromes~Myeloproliferative/Myelodysplastic Neoplasms"
3329149|NCT02084576|Experimental|Nepafenac|One drop in the study eye 3 times daily for 30 days
3329150|NCT02084576|Active Comparator|Ketorolac|One drop in the study eye 4 times daily for 30 days
3329151|NCT02084589|Active Comparator|PCEA of continuous background infusion with demand dose|PCEA with background infusion of 5 ml/h and demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
3329152|NCT02084589|Active Comparator|PCEA with demand dose only|PCEA with demand dose of 5 ml with lockout 10 minutes, using ropivacaine 0,15% and fentanyl 2μg/ml.
3329153|NCT02084602|Experimental|Artesunate/mefloquine|Orally administration of artesunate 4mg/Kg by three days Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
3329154|NCT02084615|Experimental|81mg aspirin|This arm will include perioperative 81 mg of aspirin.
3329155|NCT02084615|Experimental|325mg aspirin|Subjects will be taking 325mg of aspirin.
3329156|NCT02084641|Experimental|Insulin resistant and insulin sensitive|Both groups will be given the same intervention and then outcomes compared between groups
3232263|NCT01209468|Active Comparator|oral appliance 2|Patients in treatment arm/group B will have a customized twinblock OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized monobloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the monobloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
3232264|NCT01209468|Experimental|oral appliance 1|Patients in treatment arm/group A will have a customized monobloc OA constructed for them individually. They will undergo an appliance acclimatization period of 4-5 weeks. Three months after baseline assessments - T1 (6 weeks of 'active' treatment), physiological measurements will be evaluated, clinical oral examinations conducted, quality of life and compliance assessed. Following this, a customized twin-bloc OA will be constructed for subjects individually and they will acclimatize to it for 4-5 weeks (so that the mandible is protruded to the maximum position they feel comfortable with when the appliance is worn). Prior to the active treatment phase, patients will not wear the twin-bloc OA for 1 week (washout phase). Three months later - T2 (6 weeks of 'active' treatment), all the previous measurements will be conducted again.
3232265|NCT01209481|Experimental|Nutritional education|
3232266|NCT01209481|No Intervention|control|
3232267|NCT01209494||Invasive EP Study Group|200 patients are studied before clinically indicated (according to AHA/ACC/ESC guidelines) first ICD implantation or ICD exchange. Invasive EP study is performed to test inducibility of malignant arrhythmia. In addition MAP recordings are performed for measurements of restitution properties. Pacing is done for 12-lead ECG and MAP recordings for analysis of BVR and TWA, if applicable.
3232268|NCT01209494||Noninvasive EP Study Group|"The assignment of patients to the invasive and noninvasive EP groups does not occur by randomization or for intervention.~In the noninvasive EP study group, 500 patients with chronically implanted ICD (>3 month after implantation) are investigated using non-invasive EP study via ICD programmer. Programmed electrical stimulation is performed to test for inducibility of malignant arrhythmia. In addition pacing is done for measurements of BVR from the 12-lead ECG."
3232269|NCT01209507||Chemotherapy every 3 weeks|One treatment of chemotherapy every 3 weeks. Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV. The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
3329157|NCT02084654|Active Comparator|exenatide 5 and 10 mcg 2 times a day|Exenatide in addition to weight loss. Starting dose 5 mcg titrate to 10 mcg
3329158|NCT02084654|Placebo Comparator|placebo|placebo in addition to weight loss
3329159|NCT02084680|No Intervention|Control|Control group standard care
3329160|NCT02084680|Experimental|Community Health Workers|individual prenatal education
3329161|NCT02084693||COMPREHENSIVE|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.
3329162|NCT02084719|Experimental|Group A|Patients will be tests with both the standard algorithm and the Oraquick HCV Rapid Antibody Test
3329163|NCT02084719|Active Comparator|Group B|Patients will be tested only with the standard algorithm
3329164|NCT02084732|Experimental|Sorafenib|drug
3329165|NCT02084745|Active Comparator|Simultaneous implantation|Simultaneous implantation of a glaucoma drainage device at the time of Boston keratoprosthesis type 1 surgery
3329166|NCT02084745|Active Comparator|Implantation at post-Kpro at 6 months|Implantation of a glaucoma drainage device 6 months after Boston keratoprosthesis type 1 surgery
3329167|NCT02084758|Active Comparator|Nitrate supplementation|Sodium nitrate solution
3329168|NCT02084758|Placebo Comparator|Placebo supplementation|Sodium chloride solution
3329169|NCT02084771|Experimental|Oral Salt and Water|"Oral Salt and Water Loading:~Participants randomized to this arm of the trial will receive 0.1 g/kg of salt (NaCl) and 12 mL/kg of water. Patients weighing more than 110 kg will receive the same amount as per a 110 kg patient. One third of the oral salt and water will be given before the CT and 2/3 post-CT as in the intravenous saline arm. Specifically, 0.03 g/kg of NaCl and 4 mL/kg of water in the one hour before CT and 0.07 g/kg of NaCl and 8 mL/kg of water taken over 2 hours post-CT. The ingestion of the oral salt and water will be directly observed by the study nurse to ensure adherence to the protocol."
3329170|NCT02084771|Active Comparator|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg give in the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
3329171|NCT02084784|Experimental|Indocyanine green & methylene blue,|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1% Indocyanine green with 1ml of 0.5%
3329172|NCT02084810|Active Comparator|NovoSeven®|
3329173|NCT02084810|Experimental|Eptacog alfa A 6 mg|
3329174|NCT02084823|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329175|NCT02084823|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329176|NCT02084823|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329177|NCT02084823|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329178|NCT02084836||Lean adolescents|
3329179|NCT02084849||Group 1|Group 1 will consist of 300 ADPKD individuals who are early in the course of their disease and demonstrate risk factors for progression to ESRD.
3329180|NCT02084849||Group 2|Group 2 will consist of ADPKD subjects who have progressed to a more advanced stage of their renal disease. There is no limit with regard to the number of subjects to be recruited into this group.
3329181|NCT02084862|Experimental|Ultrasound|Ultrasound guided percutaneous tracheostomy
3329182|NCT02084862|Active Comparator|Bronchoscopy|Bronchoscopy guided percutaneous tracheostomy
3329183|NCT02084875|Experimental|tofacitinib MR 11 mg Fed|tofacitinib modified release (MR) 11 mg tablet administered with food.
3329184|NCT02084875|Experimental|tofacitinib MR 11 mg Fasting|tofacitinib modified release (MR) 11 mg tablet administered without food.
3329185|NCT02084901|Experimental|Orsiro Arm|
3329186|NCT02084901|Active Comparator|BioMatrix or BioMatrix Flex Arm|
3329187|NCT02084914|Experimental|Group A|Endometrial scraching of uterine cavity by pipelle .
3329188|NCT02084914|Active Comparator|Group B|Uterine sound intoduced into uterine cavity without scratch .
3329189|NCT02084927|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
3329190|NCT02084927|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
3329191|NCT02084940||GnRH antagonist depot, Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
3329192|NCT02084953|Experimental|ARM A: BMS-791325|BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days
3329193|NCT02084953|Active Comparator|ARM B: Moxifloxacin|Moxifloxacin 400mg tablet orally once on third day
3329194|NCT02084953|Placebo Comparator|ARM C: Placebo matching BMS-791325|Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days
3329195|NCT02084966|Experimental|OCT Imaging|OCT imaging of the kidneys prior to and following their transplant
3329196|NCT02084979|Experimental|Asynchronous telepsychiatry|Experimental Arm: Asynchronous telepsychiatry evaluation and consultation
3329197|NCT02084979|Active Comparator|Synchronous telepsychiatry|Control Arm: Synchronous telepsychiatry evaluation and consultation
3329198|NCT02084992|Experimental|Expanded technology disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, patients randomized to this arm will be given tablet computers with a web-based heart failure disease management application. Patients will be asked to interact with the system daily with transmission of weight, heart rate, blood pressure and symptom reports to the nurse manager. A nurse manager will check the data daily and contact patients if any parameters exceed pre-specified parameters. Nurse managers will also touch base with the participants at regular intervals as in the control arm. In addition, educational modules will be placed onto individual tablet computers and given to each patient.
3329199|NCT02084992|Active Comparator|telephonic disease management|After an initial visit where the program is introduced and education regarding adherence, methods for self-monitoring and early reporting of changes in status are reviewed, the nurse manager will telephone participants weekly for the first month followed by either every two weeks or monthly calls depending on clinical status with the goal of transitioning all participants to monthly calls. During these phone calls the nurse manager will focus on identifying changes in clinical condition and education reinforcement. Participants will be instructed to check and record their weight, heart rate and blood pressure daily and will be encouraged to call if there are any changes in their clinical status.
3329200|NCT02085005|Experimental|Aflibercept|Intravenous (IV) infusion on Day 1 every 3 weeks, followed by CAPOX (capecitabine by oral administration on Day 1 to Day 14 and oxaliplatin intravenous (IV) infusion on Day 1 every 3 weeks) for the induction treatment period (6 cycles) after which the patient may enter the maintenance period during which the treatment is Aflibercept + Capecitabine
3329201|NCT02085018|Experimental|Omeprazole|Omeprazole 20 milligrams twice a day taken for 90 days
3329202|NCT02085018|Placebo Comparator|Matched placebo|Matched placebo twice a day taken for 90 days
3329203|NCT02085031|Experimental|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed for the patients assigned to this arm.
3329204|NCT02085031|Active Comparator|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed for the patients assigned to this arm.
3329205|NCT02085044|Experimental|12 months RUSF|Children between 6 to 24 months received ready-to-used supplementary food every months during the whole year.
3329206|NCT02085044|Active Comparator|4 months RUSF|children between 6 to 24 months of one zone received a ready-to-used supplement food during the 4 months of the hunger gap period (june to september)
3329207|NCT02085057||anorexia nervosa|Diagnosis of anorexia nervosa
3329208|NCT02085057||obsessive-compulsive disorder|Diagnosis of obsessive-compulsive disorder
3329209|NCT02085057||healthy control|No psychiatric diagnoses
3329210|NCT02085057||sisters|Sisters of those enrolled with a diagnosis of anorexia nervosa
3329211|NCT02085083|Experimental|Regular telephone and email access to an IBD Nurse|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the intervention arm each month. The email will include the following: Brief Questionnaire;The Option For Direct Nurse Contact; Educational modules; MyHealth Passport and a Comprehensive Study Questionnaire.
3329212|NCT02085083|Active Comparator|Minimal Intervention|The IBD pediatric-adult transition nurse will send an email to each individual randomized to the control arm every 3 months. The email will include the following: MyHealth Passport and Study Questionnaire. This intervention is not expected to significantly improve outcomes.
3329213|NCT02085096|Experimental|Problem-Solving Therapy|A problem-solving therapy training program will be provided to the spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
3329214|NCT02085096|Placebo Comparator|Standard Supportive Care|Participants who are randomized to this arm will be encouraged to use whatever supporting care is recommended to them by their health provider.
3329215|NCT02085109|Experimental|High fat meal|A high fat milkshake containing 60.6 grams of fat
3329216|NCT02085109|Placebo Comparator|Low fat meal|A Low fat milkshake containing 10.5 gram of fat
3329217|NCT02085109|Experimental|A Low fat meal containing theobromine|A low fat milkshake containing 10.5 grams of fat supplemented with 850 mg of theobromine
3329218|NCT02085122|Experimental|noninvasive ventilation|
3329219|NCT02085122|No Intervention|Control Group|
3329220|NCT02085187|Experimental|Telemedicine training and counselling|
3232270|NCT01209507||Weekly chemotherapy|Chemotherapy will be given three times in a three week cycle. Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8). Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV. The total dose per cycle will be 20-40 mg approximately for 18 weeks.
3329221|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapular stabilization is not provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
3329222|NCT02085200|Other|Horizontal adduction with scapular stabilization|Scapular stabilization is provided during a manual horizontal adduction stretch of the shoulder. Each stretch is held for 25 seconds and repeated for a total of 3 times.
3329223|NCT02085213|Experimental|Glyceryl Trinitrate|"Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.~Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.~The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given."
3329224|NCT02085213|Placebo Comparator|Placebo|Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
3232271|NCT01209546|Active Comparator|Flutter group|In Flutter group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland).
3232272|NCT01209546|Active Comparator|PEP group|In PEP group the exercise used the Flutter ®VRP1 (VarioRaw SA, Switzerland) without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1.
3329225|NCT02085226|Experimental|Creative Engagement Intervention|Creative Engagement Intervention participants will receive 4-8 art sessions over 3-5 weeks, depending on length of inpatient stay. Sessions will be delivered as 1:1 sessions with the artist lasting up to one hour (depending on patient fatigue levels) and group sessions, with up to 5 participants, lasting up to two hours (depending on patient fatigue levels). Participant with receive one group and one individual session per week of inpatient stay. The sessions will cover 5 activity stages of the intervention, taking the participant through a progressive artwork development process. Participants will explore basic visual art materials and processes and progress to creating artworks with a personal context that they have directed and controlled.
3329226|NCT02085226|Placebo Comparator|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
3329227|NCT02085239|Active Comparator|Lidocaine alone|Lidocaine: 8-10 ml of Lidocaine by subcutaneous injection
3329228|NCT02085239|Experimental|Lidocaine Ropivacaine|"Lidocaine Ropivacaine~8-10 ml of Lidocaine given by subcutaneous injection~8-10 ml of Ropivacaine given by subcutaneous injection"
3329229|NCT02085265|Experimental|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
3232273|NCT01209546|Placebo Comparator|control group|In placebo patients were assessed as pulmonary function, respiratory muscle strength and transport properties of respiratory secretions
3232274|NCT01209546|Sham Comparator|Group Sham|Exercise with Flutter®VRP1 without the ball inside
3232275|NCT01209559||air-Q Intubating Laryngeal Airway|
3232276|NCT01209559||LMA FastrachTM or ILMA|
3232277|NCT01209572|Experimental|calorimetric chamber|
3329230|NCT02085265|Active Comparator|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
3329231|NCT02085278|Experimental|Apollo Group|Apollo Micro catheter device
3232278|NCT01209572|Experimental|Free living conditions|
3232279|NCT01209585||Rheumatoid Arthritis|Subject must have RA with inflamed joint
3232280|NCT01209585||Osteoarthritis|Subjects must have OA of the knee
3232281|NCT01209585||Pseudo gout|Subjects must have peusdo-gout of knee
3232282|NCT01209611|Experimental|Autologous bone marrow mononuclear cells|Patients received autologous MNC transplantation. Bone marrow aspirates are harvested from the anterior iliac crest of the patients under general or local anesthesia. MNCs are isolated by density gradient centrifugation. The cell suspension was adjusted to a final volume of 6-20 ml with saline. The cell suspension was injected into expanded skin intradermally via a 27-gauge needle (approximately 0.5-1×10^6 cells/cm2).
3232283|NCT01209611|Placebo Comparator|Saline|Patient has intradermally and subcutaneously injection of saline.
3232284|NCT01209637|No Intervention|control|standard care of coronary artery diseases incl. recommended home based exercise 3x/week
3232285|NCT01209637|Active Comparator|Exercise training|exercise training for 4 weeks at 70% of ischemia free individual threshold within a rehabilitation care center
3232286|NCT01209637|Active Comparator|intensive exercise training|intensive exercise training incl. interval training
3232287|NCT01209663|Active Comparator|Ward Care|Protocol based discharge to the surgery ward. Observation and treatment is conducted by ward nurses and general surgeons (current treatment).
3232288|NCT01209663|Experimental|Intermediate Care|Observation and treatment in an intermediate care bed in a minimum of 48 hours after randomization. Daily rounds will be carried out by both general surgeons and intensive care physicians.
3232289|NCT01209676|Experimental|IMCgp100|IMCgp100 will be injected cutaneously or subcutaneously into the metastasis, and peritumoral area if applicable
3232290|NCT01209715|Placebo Comparator|Matching Placebo|Participants will be treated with placebo twice a day for 3 weeks.
3232291|NCT01209715|Active Comparator|Fluticasone/salmeterol|Participants will be assigned to inhaled fluticasone/salmeterol twice a day for 3 weeks.
3232292|NCT01209728|Experimental|Primary insomnia patients and healthy subjects|Elderly participants, including primary insomnia patients and healthy subjects
3232293|NCT01209741|Active Comparator|1|MK-0974 12MoRT
3232294|NCT01209741|Active Comparator|2|MK-0974 5Mo5C
3329232|NCT02085291|Experimental|Resp-FL|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one. The target MAP was maintain MAP within 10% of the reference value.
3329233|NCT02085291|Experimental|Resp-NE|In Resp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
3329234|NCT02085291|Experimental|Nonresp-NE|In Nonresp-NE group, norepinephrine was increased to enhance MAP within 10% of the reference value.
3329235|NCT02085304|Experimental|GammaKnife(R) stereotactic radiosurgery|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive a one-day GammaKnife(R) stereotactic radiosurgery procedure and will also take temozolomide (Temodar(R)) chemotherapy daily for six weeks with a one month break before taking temodar for additional 12 monthly cycles.
3329236|NCT02085304|Active Comparator|Standard fractionated radiation therapy|Following surgery for Gross total resection and Gliadel(R) wafers implanted , the patient will receive six weeks of standard fractionated radiation therapy plus daily temozolomide (Temodar(R)) chemotherapy for six weeks. This is followed by a one month break before taking temodar for additional 12 monthly cycles.
3329237|NCT02085317|Other|Lepromatous Patients|Composed of patients with lepromatous Leprosy acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
3329238|NCT02085317|Other|Healthy Patients|Composed of patients without any disease acetylcholine Iontophoresis sodium nitroprusside Iontophoresis
3329239|NCT02085330|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
3329240|NCT02085330|No Intervention|Standard follow up|
3329241|NCT02085343|Experimental|EXP + SBF + AA|Exposure therapy (EXP) with safety behavior fading (SBF) and anti-phobic action (AA)
3329242|NCT02085343|Active Comparator|EXP + SBF|Exposure therapy (EXP) with safety behavior fading (SBF)
3329243|NCT02085343|Active Comparator|EXP|Standard therapist-guided in vivo exposure therapy (EXP)
3329244|NCT02085343|No Intervention|Wait-list control|Subjects assigned to this arm will undergo assessments at Weeks 0, Week 1, and Week 5, but will not receive any interventions.
3329245|NCT02085382|Other|Kangaroo Mother Care Group|"Mothers in the KMC group were oriented in detail about KMC procedure. The mothers provided skin to skin contact using a specially tailored kangaroo tube made of soft flannel cloth. The mothers were encouraged to keep the baby in KMC as long as possible during the day and night for an accumulated time of at least 6 hours per day. The duration of the kangaroo care by each of the mother were recorded and tallied accordingly."
3329246|NCT02085382|Other|Conventional Mother Care|Conventional method of care was the routine care offered in the neonatal unit to low birth weight infants.
3329247|NCT02085395|Experimental|SR-T100 ® Gel|Topical gel containing 2.3% of solamargine in Solanum undatum extract is used once daily with occlusive dressing for 16 weeks.
3329248|NCT02085408|Active Comparator|Arm I (daunorubicin hydrochloride and cytarabine)|See Detailed Description
3232295|NCT01209741|Active Comparator|3|MK-0974 12Mo5C
3329249|NCT02085408|Experimental|Arm II (clofarabine)|See Detailed Description
3329250|NCT02085421|Active Comparator|Active tDCS|The active tDCS will be applied at a current of 1-2mA via two saline soaked electrode sponges (3 cm x 4.5 cm) for the first 20 minutes of each CRT session in the active condition.
3329251|NCT02085421|Sham Comparator|Sham tDCS|In the sham condition, tDCS will be ramped up to 1-2 mA via two saline soaked electrode sponges (3 cm x 4.5 cm) over the first 30 seconds of each CRT session and then turned off.
3329252|NCT02085434|Experimental|FITLINE practice-based referral program|
3329253|NCT02085434|No Intervention|Contemporaneous control|
3232296|NCT01209754||Pregnant Women|Pregnant women exposed to an HIV prevention study agent during pregnancy
3329254|NCT02085486|Experimental|Ultrasound-assisted puncture|Ultrasound-assisted puncture by the nursing staff of patients with difficult AV-shunts.
3232297|NCT01209754||Infant|Infants resulting from pregnancies where there exists maternal HIV prevention agent exposure
3232298|NCT01209793|Experimental|Dose 1|(3:1, active: placebo)
3232299|NCT01209793|Experimental|Dose 2|(3:1, active: placebo)
3232300|NCT01209793|Experimental|Dose 3|(3:1, active: placebo)
3232301|NCT01209793|Experimental|Dose 4|(3:1, active: placebo)
3232302|NCT01209793|Experimental|Dose 5|(3:1, active: placebo)
3232303|NCT01209806|Active Comparator|simethicone|
3232304|NCT01209806|No Intervention|no simethicone|
3232305|NCT01209845|Experimental|Ketamine|Patients were administered a single sub-anaesthetic i.v. bolus of ketamine (0.2 mg/kg over 1-2 min) in the ED, with continuous monitoring of vital signs, adverse events and psychotomimetic side-effects for 4 h post-administration.
3232306|NCT01209858|Experimental|Experimental 1|
3232307|NCT01209858|Experimental|Experimental 2|
3232308|NCT01209871|Experimental|Treatment (vaccine therapy)|Patients receive autologous lymphoma immunoglobulin-derived scFV-chemokine DNA vaccine ID at 0, 4, and 8 weeks.
3329255|NCT02085486|Other|Standard|Classical method wtih inspection and palpation
3329256|NCT02085499|Other|NIMV followed by S-NIMV|During the study infants assigned to this arm will undergo a 2-hour period of non-synchronized NIMV followed by a 2-hour period of Synchronized-NIMV.
3329257|NCT02085499|Other|S-NIMV followed by NIMV|During the study infants assigned to this arm will undergo a 2-hour period of synchronized NIMV followed by a 2-hour period of non-synchronized NIMV.
3329258|NCT02085512|Experimental|Neurocognitive retraining|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
3329259|NCT02085512|Placebo Comparator|Control, Web Based Tasks|Engaging daily, for 30 days in web-based video games or reading tasks that do not specifically engage or train neurocognitive functions.
3329260|NCT02085525|Other|Weekly NP Visits|100 HNC (Head and Neck Cancer) patients seen weekly in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
3329261|NCT02085525|Other|Every Other Week NP Visits|100 HNC (Head and Neck Cancer) patients seen every other week in a Nurse Practitioner (NP) led symptom management clinic for supportive care.
3329262|NCT02085538|Experimental|Normal Renal Function|
3329263|NCT02085538|Experimental|Mild Renal Impairment|
3329264|NCT02085538|Experimental|Moderate Renal Impairment|
3329265|NCT02085538|Experimental|Severe Renal Impairment|
3329266|NCT02085564||GEJ-cancer patients consideres resectable|All patients have biopsy verified GEJ-cancer, and has been considered for intend curative resection by a multidisciplinary panel of specialists.
3329267|NCT02085577|Experimental|Ketamine|"(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
3329268|NCT02085577|Placebo Comparator|Placebo|"Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/h terminated at last suture to the skin.~Morphine. Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 min before expected awakening.~Escape sufentanil. Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.~Morphine. PCA-morphine, bolus 2.5 mg, lock-out-time 5 min. Concentration : Morphine sulphate 1 mg/ml.~Escape morphine. Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.~Ondansetron 2 mg/ml, 4 mg iv in case of moderate to severe nausea, supplemented by 1 mg iv if needed~Paracetamol 1 g orally 1 h preoperatively and every 6 h after extubation time during the first 24 h.~The patients usual daily opioids"
3329269|NCT02085590|Active Comparator|BCG vaccine|BCG vaccine SSI, 0.75mg/ml, injection 0.1 cc intradermal
3329270|NCT02085590|Placebo Comparator|NaCl 0.9%|injection 0.1 cc intradermal
3329271|NCT02085603|Active Comparator|Saracatinib|Saracatinib at a dose of 125mg orally will be administered daily for four weeks.
3329272|NCT02085603|Placebo Comparator|Placebo|Placebo tablet to be orally administered daily for four weeks.
3329273|NCT02085616|Experimental|Proactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the proactive service the callers to the quitline are offered a number of callbacks.
3329274|NCT02085616|Active Comparator|Reactive service|Intervention: Tobacco cessation by telephone support. The structured treatment protocol is a mixture of motivational interviewing (MI), cognitive behaviour therapy, and pharmacological consultation. In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
3329275|NCT02085629|Experimental|M reg treatment|"Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a LD renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus, as detailed below:~Prednisolone~D 0: 500 mg IV~D 1: 125 mg IV~D 2 - 14: 20.0 mg/d (oral)~Wk 3 - 4: 15.0 mg/d~Wk 5 - 8: 10.0 mg/d~Wk 9 - 12: 5.0 mg/d~Wk 13 - 14: 2.5 mg/d~Wk 15 - End: Cessation~MMF (or biologic equiv.)~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 - 36: 1000 mg/d~Wk 37 - 40: 750 mg/d~Wk 41 - 44: 500 mg/d~Wk 45 - 48: 250 mg/d~Wk 49 - End: Cessation NOTE: MMF tapering will only happen if a 36-Wk biopsy shows no signs of subclinical rejection or if there is no evidence of declining renal function or if the clinician has any other concern about dose reduction.~Tacrolimus (or biologic equiv.)~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 - 12: 3-10 ng/ml~Wk 13 - 36: 3-8 ng/ml~Wk 37 - End: 3-6 ng/ml"
3329276|NCT02085642|Experimental|Acupuncture|True acupuncture
3329277|NCT02085642|Sham Comparator|Sham needle|Retractable acupuncture needles will be used. No true transcutaneous needling through the skin
3329278|NCT02085655|Experimental|PEG-ASP+Gemox regimen group|PEG-ASP 2000U/m2 im d1 Gemcitabine 800mg/m2 ivdrip 30min d1，8 Oxaliplatin 100mg/m2 ivdrip d1 Thalidomide 150-200mg po qn d8-21
3329279|NCT02085655|Active Comparator|AspaMetDex regimen group|Pegaspargase 2000U/m2 im， d1 methotrexate 3000m g/m2 civ 6-hour，d1, Calcium folinate 30mg iv q6h x6 Dexamethasone 40 mg ivdrip QD
3329280|NCT02085668|Experimental|Treatment Group|Renal denervation and maintenance of heart failure medications
3329281|NCT02085668|No Intervention|Control Group|Maintenance of heart failure medications with option for cross-over renal denervation treatment after 6-months
3329282|NCT02085681|Experimental|Tele-medicine|Tele-medicine aided retinal imaging and referral to eye hospital
3329283|NCT02085681|Other|Conventional Referral|Patients will be counselled on the importance of eye examination and will be referred to the eye hospital in the conventional manner.
3329284|NCT02085694|Experimental|Lactobacillus brevis CD2 lozenges|
3329285|NCT02085707|Active Comparator|Total hip replacement arthroplasty|59 off 118 patients will be randomized to total hip replacement arthroplasty
3329286|NCT02085707|Active Comparator|Closed reduction and internal fixation|"59 off 118 patients will be randomized to closed reduction and internal fixation.~2 cancellous parallel hip pins"
3329287|NCT02085733||Possible Septic Arhtritis Patients|
3329288|NCT02085759||Normal BMI|Subjects with a BMI range of 18.5 to 24.9 which is defined by the CDC as within normal range.
3329289|NCT02085759||Overweight BMI|Subjects with a BMI of 25.0 to 29.9 are defined by the CDC as being overweight.
3329290|NCT02085759||Obese BMI|Subjects with a BMI of 30.0 and above are defined by the CDC as being obese.
3329291|NCT02085772|Experimental|Patients with pre-conceptional obesity|
3329292|NCT02085798||Group 1|Low or intermediate-1 risk MDS patients according to IPSS
3329293|NCT02085798||Group 2|Intermediate-2 risk MDS patients according to IPSS
3329294|NCT02085798||Group 3|Any risk CMML patients according to CPSS
3329295|NCT02085811||Patients|
3329296|NCT02085824|Experimental|enoxaparin|enoxaparin 40mg 1x1 s.c. daily, once preoperatively and then daily for 28 days
3329297|NCT02085824|Experimental|rivaroxaban|rivaroxaban 10 mg 1x1 p.o. daily for 28 days after the surgery
3329298|NCT02085824|Experimental|dabigatran|dabigatran 110 mg 1x1 p.o. postoperatively and then 1x2 p.o. for 27 days after the surgery
3232309|NCT01209884||Healthy Elderly sub-group|Healthy males between the age of 80-85 years old who have not experienced chronic disease during their lifetime.
3232310|NCT01209897|Active Comparator|Stage of Change|
3232311|NCT01209897|Experimental|Common Sense Model|
3232312|NCT01209897|Active Comparator|Action Model|
3329299|NCT02085837|Experimental|Healthy Transitions Group|"Additional nursing services will be provided to this group in addition to a usual care by Nephrologist.~Daily weight measurement and monitoring~Medication review~Universal dietary education~Focused advanced directive program~Countdown to fistula program"
3329300|NCT02085837|No Intervention|Usual Care Group|Usual care by nephrologist. No additional nursing support services will be provide to this group.
3329301|NCT02085850||Subjects identified in the Tema Eye Survey|Subjects identified in the Tema Eye Survey
3329302|NCT02085876||Patients requiring a liver biopsy|
3329303|NCT02085889||food intolerance|lactose intolerance fructose intolerance neither intolerance
3329304|NCT02085902|No Intervention|standard anesthesia|
3329305|NCT02085902|Experimental|standard anesthesia with ropivacaine|ropivacaine
3329306|NCT02085915|Other|strip Peri Screen|
3329307|NCT02085928||Lateral epicondylitis|Patients with lateral epicondylitis with persistent pain for at least 3 months
3329308|NCT02085941|Experimental|Image-guided cryoablation +/- biopsy|"MRI/PET/CT imaging in the Advanced Multimodality Image Guided Operating (AMIGO) suite used to place cryoablation needle(s) into target lesion (Mean: 3 cryoprobes, Range: 1-10).~MR/PET/CT imaging in the AMIGO suite will monitor two 15-minute freeze cycles separated by a 10 minute thaw period."
3329309|NCT02085967|Experimental|E2006 Part A|E2006 10-mg tablets alone and in combination with rifampin 600 mg or itraconazole 200 mg
3329310|NCT02085967|Experimental|E2006 Part B|E2006 10-mg tablets alone and in combination with midazolam 2 mg plus bupropion 75 mg
3329311|NCT02085993||single arm|single arm study
3329312|NCT02086006|Other|DESolve scaffold|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold. test arm, intervention
3329313|NCT02086019|Other|Conservative Arm- Medical therapy|Medical therapy
3329314|NCT02086019|Other|Invasive Arm-angiogram with PCI or CABG|same medical drug therapy as conservative arm, and angiogram with PCI (percutaneous coronary intervention) or CABG (coronary artery bypass grafting) revascularisation if appropriate
3329315|NCT02086032|Experimental|micronized progesterone|1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.
3329316|NCT02086032|Experimental|dydrogesterone|1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.
3329317|NCT02086045|Other|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|DESolve Scaffold
3329318|NCT02086071|Other|Re biopsies feasibility|the Interest of the study is to evaluate the feasibility of the re biopsy; the re biopsy is done if the patient agrees to perform it.
3329319|NCT02086084|Active Comparator|NIV|Standard application of NIV in hypercapnic respiratory failure as per usual standard of care
3329320|NCT02086084|Experimental|ECCO2R|Addition of ECCO2R to NIV in AECOPD
3232313|NCT01209910|Experimental|free water|The subjects in this arm will be able to drink water followings study rules.
3232314|NCT01209910|No Intervention|Control|These subjects will be observed during the study.
3232315|NCT01209923|Experimental|Body composition testing|Body composition tested using bioelectrical impedance and the DEXA or hydrostatic weighing methods.
3232316|NCT01209936|Experimental|deuterium oxide and BC3|Testing of total body water on the BC3 compared to total body water measured by deuterium oxide.
3329321|NCT02086097|Experimental|dexketoprofen trometamol|Administration of 25mg of Dexketoprofen Trometamol, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3329322|NCT02086097|Active Comparator|IBUPROFEN|Administration of 600mg of Ibuprofen, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3329323|NCT02086097|Placebo Comparator|PLACEBO|4 doses of sugar pills, 1 pill right after clinical procedure, the other 3 every 8 until the 24 hours administration period is completed
3329324|NCT02086123|Active Comparator|Epidural Analgesia|Subjects randomized to this arm will receive Bupivacaine + Fentanyl Epidural Analgesia. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
3329325|NCT02086123|Active Comparator|Parenteral Analgesia (Intravenous)|Subjects randomized to this arm will receive Analgesia with Dilaudid 0.2 -0.4 mg Intravenously (IV) every 3 hours. Subjects on this group could be allowed to receive Toradol Intravenously (IV) + Acetaminophen Orally (PO) if needed.
3329326|NCT02086136||Suspected AD|Consecutive adult patients with suspected AD presenting to Emergency Departments will be enrolled at the time of initial medical evaluation and before the establishment of a final diagnosis.
3329327|NCT02086149|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
3329328|NCT02086149|Active Comparator|Health Education|12-week health education control
3329329|NCT02086188|Experimental|Mirabegron|Mirabegron - 25mg (one tablet) taken by mouth daily with option to up-titrate to 50mg daily (two tablets) taken by mouth daily
3329330|NCT02086188|Placebo Comparator|Placebo|Placebo - one tablet taken by mouth daily and two tablets taken by mouth daily if subject chooses up-titration
3329331|NCT02086201|Active Comparator|Problem Solving Therapy|Problem solving therapy is an evidence based psychotherapy for depression, with 30 years of research supporting its efficacy. PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment.
3329332|NCT02086201|Experimental|Engage|"Engage utilizes reward exposure consisting of the reintroduction of activities that patients once found rewarding and enjoyed, but have abandoned after they developed depression. Engage uses basic problem solving through which patients learn how to form action plans for pursuing rewarding activities of their choice."
3329333|NCT02086214|Experimental|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
3329334|NCT02086214|Placebo Comparator|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
3329335|NCT02086227|Experimental|A Glucagon for Injection, Fresenius Kabi USA|The subjects will be administered the test (A) (Glucagon for Injection, Fresenius Kabi USA)or reference (B) product (GlucaGen® for Injection, Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
3329336|NCT02086227|Active Comparator|B GlucaGen® (Bedford Laboratories)|The subjects will be administered the test (A) Glucagon for Injection, Fresenius Kabi USA; or reference (B) product, GlucaGen® (Bedford Laboratories) according to a two treatments, four periods replicate crossover, randomized design with two sequences (BABA and ABAB, the Left-Right site of injection for each period and treatment will be randomized.
3329337|NCT02086240|Experimental|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity. In a previous study (approved by NRES Committee London-West London, REC ref No. 12/LO/0735), we administered an oral dose of XBD173 (up to 90mg) in 12 subjects. No adverse events due to XBD173 occurred and it was well tolerated.
3329338|NCT02086253|Experimental|BQ-788|Effect of BQ-788 on the magnitude of sustained flow-mediated dilatation
3232317|NCT01209962||Cohort|"The majority of recruited patients will be treated on protocol HUM00004531 A Multi-Institutional Phase II Study of Neoadjuvant Gemcitabine and Oxaliplatin with Radiation Therapy in Patients with Pancreatic Cancer."
3232318|NCT01209975||untreated glaucoma patients|We will evaluate the blood flow before and after Selective Laser Trabeculoplasty in patients with primary open angel glaucoma.
3232319|NCT01209988|Experimental|Tamsulosin 0.4mg|Perioperative tamsulosin 0.4mg daily
3329339|NCT02086253|Experimental|BQ-123|Effect of BQ-123 on the magnitude of sustained flow-mediated dilatation
3329340|NCT02086253|Experimental|BQ-788 + BQ-123|Effect of BQ-788+BQ-123 on the magnitude of sustained flow-mediated dilatation
3329341|NCT02086266|Experimental|PILATES|Weekly Pilates sessions, guided by a specialized physiotherapist. The duration of the treatment was 10 weeks, and each session lasted 45 to 50 minutes. All subjects received instruction to perform specific daily home exercises.
3329342|NCT02086266|Active Comparator|PFMT and AES|For also 10 weeks, the participants went trough anal electrical stimulation associated with Pelvic Floor Muscle Training, supervised by a specialized physiotherapist. All subjects received orientation to perform the same pelvic floor exercises at home.
3329343|NCT02086279|No Intervention|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for surgery are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients enrolled will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between 1 and 4 days of the menstrual cycle will be measured at study entry and at 1, 3 and 6 months after the administration of the first vial of GnRH-a"
3329344|NCT02086292|Experimental|2 milliliter lidocaine|2 ml 1% Lidocaine in one ring finger, 1 ml 2% Lidocaine in the other ring finger
3329345|NCT02086292|Experimental|1 milliliter lidocaine|1 ml 1% Lidocaine in one ring finger, 2 ml 2% Lidocaine in the other ring finger
3329346|NCT02086305|Experimental|Usual Care + Transitional Care Model|Transitional Care, Evidence-based symptom management, Protocol-driven home visit and telephone follow-up, Trained nurse case manager and volunteer partnership
3329347|NCT02086305|Active Comparator|Usual Care|Usual care
3329348|NCT02086318||OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle
3329349|NCT02086344|Experimental|TLH_plus_PBS|TLH plus PBS
3329350|NCT02086344|Active Comparator|TLH _adnexal preservation|Standard TLH without PBS
3329351|NCT02086357||SWUE|
3329352|NCT02086370|Active Comparator|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx
3329353|NCT02086370|Experimental|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal
3232320|NCT01209988|Placebo Comparator|Control|No medication
3232321|NCT01210014|Placebo Comparator|A|Patients with Recurrent aphthous stomatitis
3329354|NCT02086383||Patients with COPD|This is an observational study of patients with chronic obstructive pulmonary disease (COPD) who attend pulmonary rehabilitation, which is the routine standard of care in Guy's and St. Thomas' Hospital, London. It lasts for 14 sessions, twice a week and primarily consists of a supervised exercise program and educational sessions.
3329355|NCT02086396|Experimental|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
3232322|NCT01210014|Active Comparator|B|Patients with Recurrent aphthous stomatitis
3232323|NCT01210040|Active Comparator|Folic Acid|2.8mg of Folic Acid given weekly
3232324|NCT01210040|Experimental|Folic Acid and Iron|2.8mg Folic Acid and 60mg Iron given weekly
3232325|NCT01210053|Experimental|Single arm|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
3232326|NCT01210066|Active Comparator|Pain Challenge|Cold pressor test
3232327|NCT01210066|Active Comparator|Pain + Opioid Challenge|IV fentanyl 1mcg/kg followed by cold pressor test
3329356|NCT02086396|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
3329357|NCT02086409|Experimental|Yogurt supplemented with vitamin D and calcium|20 participants take yogurt supplemented with vitamin D and calcium during 12 weeks
3329358|NCT02086409|Active Comparator|Yogurt not supplemented with vitamin D and calcium|20 participants take yogurt not supplemented with vitamin D and calcium during 12 weeks
3329359|NCT02086422|Active Comparator|ivabradine|Exercise with ivabradine
3232328|NCT01210066|Active Comparator|Opioid Challenge|Administration of fentanyl 1mcg/kg of subject weight
3232329|NCT01210092||Macintosh #3 Laryngoscope|
3329360|NCT02086422|Placebo Comparator|Placebo|Exercise with placebo
3329361|NCT02086435|Experimental|Extracorporeal morcellation|"Extracorporeal morcellation in which patients are treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
3329362|NCT02086435|Active Comparator|Intracorporeal morcellation|Intracorporeal morcellation patients treated with standard intracorporeal morcellation, using reusable electronic device
3329363|NCT02086448|No Intervention|Obese, SDB negative|No intervention, observational comparison group
3329364|NCT02086448|Active Comparator|Obese, SDB postive, CPAP|Therapeutic CPAP
3329365|NCT02086448|Sham Comparator|Obese, SDB postive, sham-CPAP|Sham (non-therapeutic) CPAP
3329366|NCT02086448|Other|Obese, SDB postive, sleep hygiene|Sleep hygiene information and local sleep resources
3329367|NCT02086461|Sham Comparator|15 mm Pyloric balloon dilatation.|During fluoroscopic control the pneumatic balloon is positioned of the pyloric sphincter and maintained there during the entire dilatation.
3329368|NCT02086461|Active Comparator|Pneumatic pyloric dilatation.|Endoscopy and 15 mm balloon dilatation is completed according to the same principle as active comparator arm.
3329369|NCT02086474|Experimental|Hyaluronan|Hyaluronan acid Neovisc : one 6cc (viscosupplement) intra-articular injection
3329370|NCT02086474|Placebo Comparator|Bupivacaine|one Marcain extra-capsular injection
3329371|NCT02086487|Experimental|Nilotinib 300 mg|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg but show sub-optimal response on Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg twice daily and will be assessed for timely.~In the absence of safety concerns, nilotinib could be escalated to 400 mg twice daily if patients had not obtained any of the following milestones:~BCR-ABL1 transcript level ≤ 10% at 3 months;~CCyR at 6 months,~BCR/ABL1 ≤ 1% at 6 months~MMR at 12 months, or~if they showed loss of cytogenetic or molecular response or disease progression at any time. Failure and thus, stopping nilotinib will be considered if any of above milestones happened while on the 400mg twice daily dose."
3329372|NCT02086513|Experimental|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose of 200 mg, 400 mg, 600 mg, or 800 mg depending on the specific cohort. Starting dose 200 mg daily for a 28 day cycle. The DLT period will be for the first 2 cycles of therapy. Each cycle is 28 days in length, making the DLT period of minimum of 56 days.
3329373|NCT02086526|Experimental|Metformin|Metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
3329374|NCT02086526|Other|Delayed Start Metformin|After baseline study visit, this arm will return after three months without metformin for a repeat of the baseline study visit prior to initiating metformin 500 mg. extended release (taken orally) one tablet with evening meal for one week, one tablet with morning and evening meal for one week, and one tablet at all three meals for the next three months.
3329375|NCT02086539|No Intervention|Normal Letter|This arm will receive the recruitment letter in a business sized envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
3329376|NCT02086539|Experimental|Large Envelope|This arm will receive the recruitment letter in an 8.5 x 11 inch envelope. The letter states the participant will receive a $25 check upon enrollment into the study.
3329377|NCT02086539|Experimental|Priority Mail|Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
3329378|NCT02086539|Experimental|Amazon|This arm will receive a recruitment letter with the image of an Amazon gift card and told they will receive the $25 gift card if they enroll in the study.
3232330|NCT01210092||Glidescope|
3232331|NCT01210092||Ambu Pentax AWS|
3232332|NCT01210092||McGrath|
3232333|NCT01210092||Airtraq|
3232334|NCT01210092||Storz C-MAC|
3232335|NCT01210105||Macintosh #3 Laryngoscope|
3232336|NCT01210105||Glidescope|
3232337|NCT01210105||Ambu Pentax AWS|
3232338|NCT01210105||McGrath|
3232339|NCT01210105||Airtraq|
3232340|NCT01210105||Storz C-MAC|
3232341|NCT01210131|Experimental|[18F]HX4|
3232342|NCT01210157||I Ischemic CMP|Patients with impaired ventricular function caused by coronary artery disease.
3232343|NCT01210157||II CMP|Patients with impaired ventricular function which is not caused by coronary artery disease. Subgroups based on etiology (familial cardiomyopathy, toxic cardiomyopathy, etc.)
3232344|NCT01210196||mild affected Fabry patients|
3232345|NCT01210235|Experimental|FLU-FIT Arm|In this arm, eligible patients aged 50-75 will be offered a FIT kit
3232346|NCT01210235|No Intervention|FLU-Only Arm|In this arm, patients will receive flu shots as usual, without the FLU-FIT intervention.
3232347|NCT01210261|Active Comparator|Autoset S8|Single night auto-titrating CPAP treatment using the reference device (Resmed Autoset S8) with polysomnographic monitoring
3329379|NCT02086578|Experimental|Group 1|Physical examination by MD, optional Breast MRI, Breast-Q© at baseline (after permanent implant exchange, physical exam and Breast-Q© may be done after the initiation of IMRT), 12 ± 2 months and 24 ± 2 months post- IMRT. Total length of the follow-up time will be 24 ± 2 months post-IMRT. A subset of 10 left-sided patients will receive 13N-NH3 PET scans within the radiation simulation session. A CT for coronary calcium scoring and a low-dose CT for attenuation correction will also be obtained at this time. Myocardial blood flow will be measured during rest and at peak stress with 13N-NH3 as a perfusion tracer. A follow-up 13N-NH3 PET study with low-dose CT for attenuation correction will be obtained 12-18 months (± 6 months) post-IMRT.
3329380|NCT02086578|Experimental|Group 2|Physical examination by MD, optional Breast MRI, Breast-Q © at baseline (after permanent implant exchange and after IMRT), 18 ± 2 months and 30 ± 2 months post-IMRT, as these patients will undergo exchange of the temporary expander for the permanent implant approximately 4-8 months following the completion of radiation (at the discretion of the treating plastic surgeon). Total length of the follow-up time will be 30 ± 2 months post-IMRT
3329381|NCT02086604|Experimental|Starting Dose (brentuximab vedotin & lenalidomide)|"Brentuximab vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3329382|NCT02086604|Experimental|Dose Level 1 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3329383|NCT02086604|Experimental|Dose Level 2 (brentuximab vedotin & lenalidomide)|"Brentuximab Vedotin 1.2 mg/kg intravenously (IV) on Day 1 of every 21 day cycle.~Lenalidomide 20 mg orally on Days 1-21 of every 21 day cycle."
3329384|NCT02086617|Other|ultrasound of aorta|
3232348|NCT01210261|Experimental|Somnilink SPAP|Single night auto-titrating CPAP treatment using the test device with polysomnographic monitoring
3329385|NCT02086630|Experimental|Intervention|The Heart to Heart (HTH) intervention was a flexible and individualized intervention with the following components: 3 intervention sessions with video-components; patient navigation lasting up to 24 weeks; treatment initiation support groups (up to 5); and inclusion of a Support Partner. This is a behavioral intervention. The intervention uses Motivational Interviewing.
3329386|NCT02086630|No Intervention|Control|Treatment as usual
3329387|NCT02086643|Experimental|Retroclavicular block|Retroclavicular block
3329388|NCT02086656|Experimental|open label|Single arm, open label
3329389|NCT02086669|Experimental|Pneumatic dilatation|Repetitive pneumatic dilatation as the initial treatment followed by repetitive dilatation in case of dysphagia recurrence.
3329390|NCT02086669|Active Comparator|Surgical myotomy|Laparoscopic myotomy and subsequent follow up.
3329391|NCT02086695||Cancer Group|All subjects with cancer who will be treated with anyone of the following chemotherapy drugs; Pazopanib, Sutent or Bevacizumab
3329392|NCT02086721|Experimental|Oligometastatic cancer patients; N=18|
3329393|NCT02086734||mRCC patients assessed with Perfusion CT|Study population consists of patients with metastasized renal cancer eligible for AAT with either Sunitinib (Sutent®), Pazopanib (Votrient ®), Sorafenib (Nexavar®) evaluated with Perfusion-CT
3329394|NCT02086747|Active Comparator|Acetaminophen|Postoperative 72 hours acetaminophen 1 g iv 4 times a day for 72 hours iv
3329395|NCT02086747|Placebo Comparator|isotonic|1 g intravenous %0.9 NaCl four times Daily for 72 hours
3329396|NCT02086760|Experimental|Ultrasonography sensibilized by oral hydratation|Ultrasonography before, 30 min and 90 min following hydratation.
3329397|NCT02086773|Experimental|Low transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 7 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
3329398|NCT02086773|Active Comparator|High transfusion threshold|Patients receive red blood cell transfusions with a transfusion threshold of 8 g/dL hemoglobin (Hb). Transfusions will not be given on schedule but will be given whenever Hb dips below the threshold.
3329399|NCT02086799|Experimental|IV thyroxin|IV thyroxin
3329400|NCT02086799|Placebo Comparator|control IV saline|Placebo
3329401|NCT02086825|Experimental|Rifaximin|
3329402|NCT02086825|Experimental|Lactulose|
3329403|NCT02086838|Active Comparator|Theragran Hematinic, oral iron, 120 mg elemental iron/|pregnant women taking 60 mg elemental iron twice per day (120 mg/day) using iron tablets (Theragran Hematinic)® SmithKline Beecham, Egypt an affiliated co. to GlaxoSmithKline. Adherence to the treatment will be monitored by asking the women to bring back the empty packs and mark the consumption of tablets on calendar.
3329404|NCT02086838|Active Comparator|low molecular weight iron dextran, total dose infusion|Pregnant women taking elemental iron in the form of low molecular weight dextran complex intravenously as a total dose infusion (T.D.I) using iron dextran ampules (Cosmofer)R pharmacosmos Denmark (Inspire Pharma Egypt). Patients selected for parental iron will be admitted as day cases in the hospital in a single visit. The required dose has to be individually adapted according to the total iron deficit which is dependent on the patient's body weight and hemoglobin status. Total iron dose (mg) = weight (kg) X Hemoglobin deficit {target Hemoglobin (g/l)- Actual Hemoglobin (g/l)} X 0.24 + 500 mg.
3329405|NCT02086851|Experimental|Lifestyle Intervention plus Parent Motivational Interviewing|Lifestyle intervention + Parent MI
3329406|NCT02086851|Active Comparator|Lifestyle Intervention alone|lifestyle intervention alone
3232349|NCT01210287|No Intervention|Observation|Observation of the HBV reactivation in HBsAg negative/HBcAg positive patients receiving RCHOP without prophylactic anti-HBV treatment.
3232350|NCT01210313||no treatment|
3232351|NCT01210326|Experimental|aspiration|90 patients with non-obstructive azoospermi undergo testicular sperm aspiration
3232352|NCT01210326|Experimental|extraction|90 patients with non-obstructive azoospermi undergo testicular sperm extraction
3232353|NCT01210339|Experimental|1|Treatment A (Clopidogrel 9 days), at least 14 days wash-out, Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days)
3329407|NCT02086864|No Intervention|Usual care|
3329408|NCT02086864|Active Comparator|Individualized homeopathic medicine treatment|Participant will have a homeopathic consultation and be given a homeopathic medicine. Homeopathic medicines are chosen from those available for sale in Canada.
3329409|NCT02086864|Placebo Comparator|Unmedicated lactose/sucrose pill|Participant will receive a homeopathic consultation and receive an unmedicated lactose/sucrose pill.
3329410|NCT02086877||ICU Survivors who required > 72 hrs mechanical ventilation|No intervention
3329411|NCT02086890|Experimental|Electro-acupuncture|Electro-acupuncture applied to acupoints around the eye and traditional needle acupuncture applied to acupoints throughout the body at 10 half-hour sessions over 2 weeks
3329412|NCT02086890|Sham Comparator|Sham Electro-acupuncture|No electro-acupuncture applied to non-acupoints around the eye and traditional needle acupuncture applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 half-hour sessions over 2 weeks
3232354|NCT01210339|Experimental|2|Treatment B (Clopidogrel 4 days followed by Clopidogrel + Esomeprazole/ASA 5 days), at least 14 days wash-out, Treatment A (Clopidogrel 9 days)
3329413|NCT02086890|Experimental|Laser acupuncture|Laser applied to acupoints throughout the body at 10 sessions each lasting 15 minutes over a 2 week period
3329414|NCT02086890|Sham Comparator|Sham Laser acupuncture|An inactive sham laser (red light only) applied to non-acupoints throughout the body; i.e., to locations not on the acupuncture meridians; at 10 sessions each lasting 15 minutes over a 2 week period
3329415|NCT02086890|Experimental|Transcorneal Electrical Stimulation|Transcorneal Electrical Stimulation at 150% individual phosphene threshold applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
3329416|NCT02086890|Sham Comparator|Sham Transcorneal Electrical Stimulation|Sham Transcorneal Electrical Stimulation at 0% individual phosphene threshold (no stimulation) applied to both eyes using DTL electrodes at 6 weekly 30 minute sessions
3329417|NCT02086903|Experimental|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
3232355|NCT01210365|Experimental|furosemide (40 mg) +amiloride (10 mg)|One group of patients will receive furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow the tablet in whole form on an empty stomach with some liquid.
3329418|NCT02086903|Experimental|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
3329419|NCT02086916||Inpatients who test positive for CDI|Observational study, hence no intervention will be administered
3329420|NCT02086929|Experimental|Trazodone|"300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.~Dosage form: capsule."
3329421|NCT02086929|Active Comparator|Venlafaxine XR|"75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.~Dosage form: capsule."
3329422|NCT02086942|Experimental|modified VCD regimen1|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen1 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.6mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
3329423|NCT02086942|Experimental|modified VCD regimen2|"Induction therapy：modified VCD regimen1 for 4 cycles,28 Days per Cycle.Intensive therapy：modified VCD regimen 2 for 5 cycles.~Maintenance treatment:CP for 12 cycles. Interval between every two cycles for one month.~Interventions:~Drug: Bortezomib 1.3mg/m2 SC,Days 1, 6, 11, 16; Drug:Cyclophosphamide 300mg/m2 VD,Days 1-3; Drug: Dexamethasone 40 mg/d VD,Days 1, 6, 11,16; We undertook a pharmacodynamic substudy at selected sites. Blood samples were collected in cycle 1 on day 1, 6,11,16 before the dose was given and at several time points after dosing. We analysed whole blood samples to measure 20S proteasome chymotryptic activity, with a standard method. Pharmacodynamic parameters were calculated by analysis of percentage inhibition of 20S proteasome activity-time data."
3329424|NCT02086955|No Intervention|Standard care|All participants receive three specially-developed brochures with information regarding the diabetic foot condition. The brochures containes explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home.
3232356|NCT01210365|Active Comparator|Lasix ®|One group of patients will receive Lasix® (furosemide 40 mg). For treatment, the patient will swallow the tablet in whole form on an empty stomach with some liquid.
3232357|NCT01210378|Experimental|Nitroglycerin|
3329425|NCT02086955|Experimental|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention go on for five weeks. During a period of five weeks, the participants are provided with weekly education, skill training, and counseling sessions on foot care.
3329426|NCT02086994|Active Comparator|cabetocin|a single dose of carbetocin (100 μg in 1 mL ampoule, Pabal) given intravenously after delivery of anterior shoulder
3329427|NCT02086994|Active Comparator|misoprostol|misoprostol (600 μg, 3 tables) sublingually after the delivery of the anterior shoulder of the baby.
3329428|NCT02087007|Experimental|group 1|Cilostazol 50mg, Cilostzaol 100mg
3329429|NCT02087007|Placebo Comparator|group 2|placebo
3329430|NCT02087020||Periprosthetic joint infection|Patient treated with 'Debridement, antibiotics and implant retention' for early postoperative periprosthetic joint infection at Danderyd Hospital between 2007-01-01 and 2012-12-01
3329431|NCT02087033|Placebo Comparator|ritmonutra and placebo|ritmonutra 2 tablets/day by mouth for 4 weeks sugar pill manufatured to simulate ritmonutra: 2 tablets/day by mouth for 4 weeks
3232358|NCT01210391|Experimental|New hydrolyzed infant formula|New, extensively hydrolyzed infant formula
3232359|NCT01210391|Active Comparator|Commercially available infant formula|Commercially available, extensively hydrolyzed infant formula.
3232360|NCT01210404|Experimental|1.0|
3329432|NCT02087072||Recently discharged homebound patients|
3329433|NCT02087098||Patients with residual OAB symptoms|Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics
3329434|NCT02087111|Experimental|Treatment|All patients who are fulfil the entry criteria are treated for 24 weeks with 40 Kd Pegylated interferon alfa 2a, Ribavirin and 12 weeks with telaprevir.
3329435|NCT02087124|Experimental|0g whey protein|0g whey protein dissolved in 200 milliliter (mL) water.
3232361|NCT01210417||Trauma victims|All prehospital traumatic patients enrolled by our Helicopter Emergency Medical System (HEMS)
3329436|NCT02087124|Experimental|10g whey protein|10g whey protein dissolved in 200 milliliter (mL) water.
3329437|NCT02087124|Experimental|20g whey protein|20g whey protein dissolved in 200 milliliter (mL) water.
3329438|NCT02087137|Active Comparator|Memory and Aging Program|The Memory and Aging Program intervention consists of five 2-hour sessions conducted over five consecutive weeks. The content of the program includes: (a) the provision of factual information (i.e., about memory, age-related memory changes, lifestyle factors affecting memory, and memory strategies) in an informal lecture format; and (b) memory intervention (i.e., practice and application of several evidence-based memory strategies) in a hands-on interactive format.
3329439|NCT02087137|No Intervention|Wait-list Control|Participants randomized to the wait-list control group will receive no intervention following randomization. They will be offered the intervention immediately following completion of the week 14 outcome testing session.
3329440|NCT02087189||ICD/ CRT-D therapy|
3329441|NCT02087202|Experimental|magnesium|magnesium is added perioperatively to those patients undergoing staged total knee arthroplasty and other surgeries.
3329442|NCT02087202|Experimental|ketamine|ketamine is administered to those patients undergoing stated TKA and other operations.
3329443|NCT02087202|Placebo Comparator|control|normal saline (placebo) is administered to the patients.
3329444|NCT02087215|Active Comparator|boron gel|diabetic foot ulcer care with formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v).
3329445|NCT02087215|Placebo Comparator|control gel|placebo gel containing polymer of carbopol ultrex (1%)
3329446|NCT02087228|Experimental|Hydrothermal ablation|Uterine ablation performed with a device that circulates heated water inside the uterus
3232362|NCT01210430|Active Comparator|Losartan|
3232363|NCT01210430|Active Comparator|Ascorbic Acid (VItamin C)|
3232364|NCT01210430|Placebo Comparator|Normal Saline|
3329447|NCT02087228|Active Comparator|radiofrequency energy|ablation performed with a device that uses radiofrequency energy.
3329448|NCT02087267||1- or 2-level spinal fusion|Patients suffering from symptomatic degenerative disc disease or degenerative spondylolisthesis grade 1 or 2 with chronic low back pain, pain in the leg or buttock, muscle weakness, sensation abnormalities and/or neurogenic claudication requiring 1- or 2-level lumbar or lumbar-sacral spinal fusion.
3232365|NCT01210456|Active Comparator|Physiological Saline and N-Acetylcysteine|
3329449|NCT02087280||Anorexia Nervosa|
3329450|NCT02087280||Healthy controls|
3329451|NCT02087293|Experimental|Intervention group, IVR call, RPh counseling|Group receives interactive voice response automated call asking about side effects of newly prescribed medications; has opportunity to speak with study pharmacist via phone about medication
3329452|NCT02087293|No Intervention|Control|Intervention patients are matched with control patients; control patients have only chart review completed.
3232366|NCT01210456|Active Comparator|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|
3232367|NCT01210469|Experimental|Strengthening Group|Performed balance training with lower limbs muscle strengthening.
3232368|NCT01210469|Experimental|Stretching Group|Performed balance training with stretching
3232369|NCT01210469|No Intervention|Control Group|
3232370|NCT01210482||Temsirolimus|Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)
3232371|NCT01210521|No Intervention|Prior to intervention with Vitamin D|Patients will be analyzed for clinical, serological and immunological parameters before starting the interventional drug, Vitamin D.
3232372|NCT01210521|Active Comparator|Vitamin D Intervention|Patients will be analyzed for clinical, serological and immunological parameters after one month taking Vitamin D.
3232373|NCT01210573||Device adjustment|Advanced or suspected advanced heart failure. Most are anticipated to have severely depressed ejection fraction (<30% and typically <20%), but patients with preserved ejection fraction and either hypertrophy or restrictive cardiomyopathy will also be eligible. Patients pulmonary hypertension, on any therapy (other than diuretics alone), are also felt to be at high risk of developing right heart failure and may also be included. Patients who have already undergone LVAD or cardiac transplant are also considered to have advanced heart failure and are eligible to participate, regardless of the severity of their symptoms at the time of enrollment.
3232374|NCT01210586|Active Comparator|Nicotine Patch|Nicotine Patch for Smoking Cessation
3329453|NCT02087319|Experimental|platelet-rich plasma|hair loss, baldness
3329454|NCT02087332|Experimental|Prolonged release Torasemide (Britomar)|"Prolonged release Torasemide (Britomar) - round, biconvex, white to off-white tablets debossed SN with one side. 1 tablet contains active substance - torasemide 5 or 10 mg and excipients - guar gum, maize starch, anhydrous colloidal silica, magnesium stearate, lactose.~Dosage scheme: per os, once a day, regardless of meals. The common starting dose in CHF - 10-20 mg once a day. If adequate diuretic effect is absent, the dose is increased approximately twofold up to adequate diuretic effect."
3329455|NCT02087332|Active Comparator|Torasemide (Diuver)|Torasemide (Diuver) - white to off-white, round, biconvex tablets. 1 tablet contain active substance - torasemide 5 or 10 mg and excipients - lactose monohydrate, maize starch, sodium glycolate starch, anhydrous colloidal silica, magnesium stearate. Dosage scheme: per os, once a day, after meals. Therapeutic dose - 5 mg a day. If necessary, a dose may be increased up to 20 mg a day, in some cases - up to 40 mg.
3329456|NCT02087345||Dental erosions|
3329457|NCT02087358||Stress and craving|This 3 weeks study examines the correlation between stress and alcohol using an ecological, prospective design. Participants will be given phone calls 4 times a day for 3 weeks, assessing perceived stress and alcohol related craving.
3232375|NCT01210586|Placebo Comparator|Placebo Patch|
3232376|NCT01210599|Experimental|IV infusion of pamidronate vs placebo|
3232377|NCT01210612|Active Comparator|Without Unilateral CAI|
3232378|NCT01210612|Active Comparator|With Unilateral CAI|
3329458|NCT02087371||Included patients|Patients with end-stage liver failure and registered on transplantation list.
3329459|NCT02087384|Experimental|Gardasil|Gardasil
3329460|NCT02087384|Placebo Comparator|Placebo|Intramuscular Saline 0.9% vaccination at 0, 2 and 6 months
3329461|NCT02087397|Experimental|AD-SVF Cell Injection|
3232379|NCT01210638|Active Comparator|Oxymorphone Hydrochloride|Tablet
3329462|NCT02087410||study|patients with polycystic ovary syndrome
3329463|NCT02087410||control|healthy patients serves as control group
3329464|NCT02087436|Active Comparator|Taperloc Complete Standard|Group one will receive a total hip replacement with Taperloc Complete Standard. Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
3329465|NCT02087436|Active Comparator|Taperloc Complete Microplasty|Group one will receive a total hip replacement with Taperloc Complete Microplasty.Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
3329466|NCT02087449||E1-Hip Bearing|E1-Hip Bearing, Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population
3329467|NCT02087462|Experimental|Electroacupuncture (EA)|Use Electroacupuncture only
3329468|NCT02087462|Other|EA + Traction|Use electroacupuncture and traction together
3329469|NCT02087462|Other|EA + Traction + Oral Medication|Combine electroacupuncture, traction and oral medication (Voltaren and Vitamin B1) together for treatment
3329470|NCT02087475|Experimental|Neoadjuvant therapy arm|FOLFIRI * 6 cycles +/- radiotherapy -> surgery -> FOLFIRI * 6 cycles
3329471|NCT02087475|Active Comparator|Adjuvant therapy arm|Surgery -> FOLFIRI * 12 cycles +/- radiotherapy
3329472|NCT02087488|Experimental|auricular acupuncture(AA) & Eszopiclone|The disposable Seirin Pyonex Needle will be chosen as AA material to attach every 3 days for 4 weeks, meanwhile, oral Eszopiclone 1 piece (3mg) will be applied 15 minutes before going to sleep everyday for 4 weeks. The manufacturer of disposable Seirin Pyonex Needles is Seirin Corporation, a Japanese company.
3329473|NCT02087488|Placebo Comparator|placebo AA & Eszopiclone|The disposable Pyonex Zero Needle, a non-invasive material will be chosen as placebo AA, with auricular acupoints have no certain effect on PI. Additionally, 1 piece (3mg) Eszopiclone will be administrated to participants 15 minutes before going to sleep everyday for 4 weeks.
3329474|NCT02087501|Other|HORIZON AAA Stent Graft|All patients will received the HORIZON AAA Stent Graft
3329475|NCT02087527|Experimental|CORTICOSTEROID|In addition to standard care for cellulitis, subject will receive intravenous Dexamethasone (8mg/2ml) 0.15 mg/kg/dose every 6 hours for the first 48 hours
3329476|NCT02087527|Placebo Comparator|NORMAL SALINE|In addition to standard care for cellulitis, subject will receive normal saline solution administered intravenously using the same volume as the active drug group every 6 hours for the first 48 hours
3329477|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
3329478|NCT02087540|Experimental|Telmisartan 80mg & Rosuvastatin 10mg|PO, Once Daily, 8weeks
3329479|NCT02087540|Active Comparator|Telmisartan placebo & Rosuvastatin 20mg|PO, Once Daily, 8 weeks
3329480|NCT02087540|Active Comparator|Telmisartan Placebo & Rosuvastatin 10mg|PO, Once Daily, 8 weeks
3329481|NCT02087540|Active Comparator|Telmisartan 80mg & Rosuvastatin placebo|PO, Once Daily, 8 weeks
3329482|NCT02087540|Placebo Comparator|Telmisartan placebo & Rosuvastatin placebo|PO, Once Daily, 8 weeks
3329483|NCT02087553||Transfused pediatric patients|Children who might receive packed red blood cell (PRBC) transfusion will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Transfusion of red blood cells will be done according to standard of care.
3329484|NCT02087553||Saline/Albumin infusion|Children who might receive albumin or saline for volume resuscitation will be enrolled after obtaining consent from their parents/legal guardians and assent from the patient, if possible. Infusion will be done according to standard of care.
3329485|NCT02087566|Other|Administration of linezolid to 6 healthy volunteers|Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
3329486|NCT02087566|Other|Administration of linezolid to 6 acute renal failure patients|Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
3329487|NCT02087566|Other|Administration of linezolid to 6 ESRD patients|Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of >60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).
3329488|NCT02087579|Experimental|Cohort A: Aripiprazole|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3329489|NCT02087579|Experimental|Cohort B: Olanzapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3329490|NCT02087579|Experimental|Cohort C: Paliperidone|Administration of prolonged-release (extended-release) tablets or long-acting injectables (LAI) will continue at a participant's usual dose and dosing schedule.
3329491|NCT02087579|Experimental|Cohort D: Quetiapine|Administration of oral formulation will continue at a participant's usual dose and dosing schedule.
3329492|NCT02087579|Experimental|Cohort E: Risperidone|Administration of oral formulation or LAI will continue at a participant's usual dose and dosing schedule.
3329493|NCT02087592|No Intervention|Control|Usual standard of care
3232380|NCT01210638|Active Comparator|Opana|Tablet
3232381|NCT01210677|Active Comparator|Prednisone|Prednisone 0.5 mg/Kg per day orally for 3 months
3232382|NCT01210677|Placebo Comparator|Placebo|Matching placebo tablets(s) taken orally per day
3232383|NCT01210742|Experimental|Viscosupplementation with routine management|
3232384|NCT01210742|Active Comparator|Routine management|Routine management for knee OA (NICE guidelines)
3329494|NCT02087592|Experimental|Intervention|Usual standard of care plus structured physical exercise training plus mediterranean-style diet
3329495|NCT02087618|Active Comparator|Kodro+|Will begin Kodro program at baseline
3329496|NCT02087618|Placebo Comparator|Kodro+D|Will begin Kodro program 12-weeks post baseline
3329497|NCT02087631|Experimental|Quetiapine|Extended-release quetiapine fumarate up to 300mg once daily for 4 weeks
3329498|NCT02087644|Experimental|CYT003|Injections of CYT003
3329499|NCT02087644|Placebo Comparator|Placebo|Injections of placebo
3329500|NCT02087657|Experimental|Hyperbaric Oxygen Treatment|Administration of hyperbaric oxygen on the morning of stem cell transplant (Day 0).
3329501|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months.
3329502|NCT02087683|Placebo Comparator|Control Group (Placebo)|Participants in this group will receive a placebo containing gelatin and corn oil per day for 12 months
3329503|NCT02087696|Other|Naive biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received previous biological treatment.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
3329504|NCT02087696|Other|Previous Biological treatment|"Rheumatoid arthritis patients with intolerance or poor compliance or contraindication to methotrexate and who have not received more than two previous biological treatments.~Tocilizumab dose 8mg/kg administered every 4 weeks for 24 weeks"
3329505|NCT02087709|Experimental|Low-calorie diet|The subjects were prescribed a daily energy intake 500 kcal lower than the estimated energy requirement.
3329506|NCT02087722|Experimental|KI1001|
3329507|NCT02087722|Placebo Comparator|Placebo|
3329508|NCT02087735|Experimental|cranberry extract 1|One capsule with a proanthocyanidin standardized cranberry extract of 36 mg and one capsule of placebo cranberry extract.
3329509|NCT02087735|Experimental|cranberry extract 2.|Two capsules with a proanthocyanidin standardized cranberry extract of 36 mg.
3329510|NCT02087735|Placebo Comparator|cranberry extract 3.|Two capsules with a proanthocyanidin standardized cranberry extract of 2 mg.
3329511|NCT02087787|No Intervention|Control|The control group will be provided the standard method, which is providing the Cancer Legal Line (CALL) brochure with a short explanation of the resource.
3329512|NCT02087787|Experimental|Intervention|The intervention group will be provided with a 2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
3232385|NCT01210755|Experimental|Rivaroxaban then Dabigatran|Cross-over study with 15 days between administration of Rivaroxaban and Dabigatran
3232386|NCT01210755|Experimental|Dabigatran then Rivaroxaban|Cross-over study with 15 days between administration of Dabigatran and Rivaroxaban
3232387|NCT01210833|Active Comparator|Healthy participants|Healthy participants aged from 18 to 60 with no history of hand injuries recruited by convenience sampling.
3232388|NCT01210833|Experimental|Hand Injured participants|Participants with hand injuries aged from 18 to 60 recruited from the outpatients attending the occupational therapy clinic.
3329513|NCT02087800||F Phase Lab session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the F phase lab session will be first. Followed by the L phase lab session.
3329514|NCT02087800||L Phase Lab Session|Potential participants will complete an interview over the phone, followed by an in clinic office visit, to assess eligibility. Those who meet eligibility criteria will be invited to attend two four-hour lab sessions. Lab sessions will occur in the F (F phase lab session) and L phases (L phase lab session) of menses. In this arm, the L phase lab session will be first. Followed by the F phase lab session.
3329515|NCT02087813|Experimental|A1AT|Alpha1-antitrypsin 120mg/kg once weekly for a total of 4 doses, to be given intravenously. This will be given in addition to standard of care 3-5 days of 1000mg IV methylprednisolone.
3329516|NCT02087813|Active Comparator|Standard of care|Patients that do not wish to receive study treatment but agree to otherwise follow study protocol will also be enrolled in an observational cohort. They will receive the standard of care 3-5 days 1000mg IV methylprednisolone.
3329517|NCT02087826|Active Comparator|Carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
3329518|NCT02087826|Placebo Comparator|Non-carriers of the SLC16A11 risk allele|"Day 1: Mixed Meal Tolerance Test~Day 3-7: 500mg metformin, twice daily~Day 8: Mixed Meal Tolerance Test in presence of Metformin"
3232389|NCT01210846|Experimental|tivozanib|
3232390|NCT01210859||Ureteral stents Detrusitol treatment Lyfestyle outcome|Ureteral stents Detrusitol treatment Lyfestyle outcome
3329519|NCT02087852||kidney cancer patients receiving care at MSKCC|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire and complete the Epidemiologic Questionnaire (when applicable,), and providing a blood sample and saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3329520|NCT02087852||relatives of patients with kidney cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3232391|NCT01210885|Experimental|Group I: Investigational MenABCWY Formulation 1|
3232392|NCT01210885|Experimental|Group II: Investigational MenABCWY Formulation 2|
3232393|NCT01210885|Experimental|Group III: Investigational MenABCWY Formulation 3|
3232394|NCT01210885|Experimental|Group IV: Investigational MenABCWY Formulation 4|
3329521|NCT02087852||healthy controls who are unrelated & do not have hx of cancer|Participation will consist of completing the Kidney Cancer Questionnaire Family History Questionnaire (when applicable,), and providing a saliva sample for germline DNA. In cases where tissue samples from surgically derived tumor specimens are obtained these will used to determine genetic alterations related to cancer predisposition or pathogenicity.
3329522|NCT02087852||high risk|Participation will consist of completing the Epidemiologic Questionnaire, Family History Questionnaire (if + FH), provide saliva and blood sample , referral for screening evaluation
3329523|NCT02087865|Active Comparator|Donepezil HCL|Participants will receive 5mg of donepezil HCL for 4 weeks and then 10mg of donepezil HCL for 20 weeks.
3329524|NCT02087865|Placebo Comparator|Placebo|Participants will receive placebo for 24 weeks.
3329525|NCT02087865|No Intervention|Control Group|Participants without a family history of AD will undergo the study evaluations but will not receive any study drug
3329526|NCT02087878||Group 1|To collect and store blood and biopsy samples obtained from CD or UC patients exposed to adalimumab and diagnosed with HSTCL for the purpose of identifying potential biomarkers and genetic mutations in patients who develop HSTCL.
3329527|NCT02087891|No Intervention|CTL|Wait-list control, no intervention. Intervention offered after week 16 and outcomes are collected.
3232395|NCT01210885|Active Comparator|Group V: Active comparator investigational MenB|
3232396|NCT01210885|Active Comparator|Group VI: Active comparator MenACWY|
3232397|NCT01210898|Experimental|Group 1|
3329528|NCT02087891|Experimental|Web-based stress management (WSM)|Subjects randomized to this group will receive access to the WSM program to complete on their own time.
3329529|NCT02087891|Experimental|WSMg1|Subjects randomized to this group will receive access to WSM with group support. They will meet once per week for 1 hour. Meeting will be led by one of their peers who is a non-expert facilitator.
3329530|NCT02087891|Experimental|WSMg2|Subjects randomized to this group will receive access to WSM and group support and clinical expert support. They will attend 4 weekly support groups led by a peer non-expert facilitator and 4 weekly support groups led by a clinical psychologist.
3232398|NCT01210898|Experimental|Group 2|
3232399|NCT01210898|Experimental|Group 3|
3232400|NCT01210898|Experimental|Group 4|
3329531|NCT02087917|Placebo Comparator|Placebo|
3329532|NCT02087917|Active Comparator|HS-25 5 MG|
3329533|NCT02087917|Active Comparator|HS-25 10 MG|
3329534|NCT02087917|Active Comparator|HS-25 20 MG|
3329535|NCT02087917|Active Comparator|HS-25 30 MG|
3329536|NCT02087930||Cow milk allergy children|Children affected by Immunoglobulin E medited cow milk allergy
3329537|NCT02087930||healthy control|healthy infants
3329538|NCT02087969|Experimental|Dry Needling|Dry Needling to Triceps Surae
3329539|NCT02087969|Experimental|Stretching|Subjects will be given a home exercise program of stretches which are commonly prescribed to improve ankle dorsiflexion.
3232401|NCT01210898|Experimental|Group 5|
3232402|NCT01210898|Experimental|Group 6|
3232403|NCT01210898|Experimental|Group 7|
3329540|NCT02087982||Seniors|"The study will be based on a 6-months assessment period, with two consecutive monitoring visits on enrollment.~Patient follow-up after 3 months will be conducted by telephone and monitoring after 6 months will be carried out as part of a routine consultation.~Each subject will have a BGA (Brief Geriatric assesment)."
3329541|NCT02088008|Experimental|cilnidipine/valsartan|cilnidipine/valsartan tablet
3329542|NCT02088008|Active Comparator|cilnidipine+valsartan|coadministration of cilnidipine and valsartan
3329543|NCT02088021|Experimental|Portico Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a ALC delivery system
3329544|NCT02088060|Experimental|Cannabidiol|Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks
3329545|NCT02088060|Active Comparator|Olanzapine|Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks
3329546|NCT02088060|Placebo Comparator|Placebo|Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks
3232404|NCT01210898|Experimental|Group 8|
3232405|NCT01210898|Experimental|Group 9|
3232406|NCT01210898|Experimental|Group 10|
3232407|NCT01210898|Experimental|Group 11|
3232408|NCT01210898|Experimental|Group 12|
3232409|NCT01210898|Experimental|Group 13|
3232410|NCT01210911|Experimental|Gemcitabine, erlotinib and metformin|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. Metformin will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
3329547|NCT02088086|Experimental|BMI screening and reporting (Group 1)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will send BMI reports home to parents.
3329548|NCT02088086|Active Comparator|BMI screening only (Group 2)|For three school years, 3rd-8th grade students will have their heights and weights measured once annually. Additionally, 5th-8th grade students will participate in five fitness assessments. Schools will NOT send BMI reports home to parents.
3329549|NCT02088086|No Intervention|No BMI screening or reporting (Group 3)|For two school years, 3rd-8th grade students will NOT have their heights and weights measured at school.
3329550|NCT02088099|Experimental|Complex clinical intervention|
3329551|NCT02088099|Active Comparator|Treatment as usual|
3329552|NCT02088112|Experimental|Escalation|MEDI4736 will be combined with gefitinib to assess safety and tolerability
3329553|NCT02088112|Experimental|Expansion Arm|MEDI4736 will be combined with gefitinib
3329554|NCT02088125|Active Comparator|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
3329555|NCT02088125|Active Comparator|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
3329556|NCT02088138|Experimental|Functional Electrical Stimulation|"Functional Electrical Stimulation~In the intervention group the FES was applied in the medial and lateral vastus of both thighs targeting the movement of knee extension. The application frequency was 15 Hz, lasting 40 minutes, pulse width of 0.5 ms, time ON 5s, time OFF 10s, ramp-up of 0 or 1s, descent ramp 2s and intensity as tolerance patient."
3329557|NCT02088138|Experimental|FES placebo|"Functional Electrical Stimulation placebo~The placebo group received functional electrical stimulation with the same parameters in the intervention group, except that the intensity of stimulation did not lead to visible or palpable contraction."
3329558|NCT02088151|Experimental|Treatment|Patients receive selective retinal pigment epithelium laser treatment
3329559|NCT02088164||Healthy men|Healthy men who received PSA screening
3329560|NCT02088190||Age group 1|Age > 60 years old
3329561|NCT02088190||Age group 2|Age < 60 years old
3329562|NCT02088203|Experimental|Single Dose Sequence 1|Dose 1, Dose 2, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3329563|NCT02088203|Experimental|Single Dose Sequence 2|Dose 1, Dose 0, Dose 2: Each subject will receive a single dose during each of three separate test periods.
3329564|NCT02088203|Experimental|Single Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive a single dose during each of three separate test periods.
3329565|NCT02088203|Experimental|Single Dose Sequence 4|Dose 3, Dose 4, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3329566|NCT02088203|Experimental|Single Dose Sequence 5|Dose 3, Dose 0, Dose 4: Each subject will receive a single dose during each of three separate test periods.
3329567|NCT02088203|Experimental|Single Dose Sequence 6|Dose 0, Dose 3, Dose 4: Each subject will receive a single dose during each of three separate test periods.
3329568|NCT02088203|Experimental|Single Dose Sequence 7|Dose 5, Dose 6, Dose 0: Each subject will receive a single dose during each of three separate test periods.
3329569|NCT02088203|Experimental|Single Dose Sequence 8|Dose 5, Dose 0, Dose 6: Each subject will receive a single dose during each of three separate test periods.
3329570|NCT02088203|Experimental|Single Dose Sequence 9|Dose 0, Dose 5, Dose 6: Each subject will receive a single dose during each of three separate test periods.
3329571|NCT02088203|Experimental|Multiple Dose Sequence 1|Dose 1, Dose 0, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3329572|NCT02088203|Experimental|Multiple Dose Sequence 2|Dose 1, Dose 2, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3329573|NCT02088203|Experimental|Multiple Dose Sequence 3|Dose 0, Dose 1, Dose 2: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3329574|NCT02088203|Experimental|Multiple Dose Sequence 4|Dose 2, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3329575|NCT02088203|Experimental|Multiple Dose Sequence 5|Dose 2, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3232411|NCT01210911|Placebo Comparator|Gemcitabine, erlotinib and placebo|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine. Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food. PLacebo will be administered at a dose of 500 mg twice daily. If well tolerated the dose will be increased to 1000 mg twice daily in the second week.
3329576|NCT02088203|Experimental|Multiple Dose Sequence 6|Dose 0, Dose 2, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3232412|NCT01210924||Pediatric ART patients|
3232413|NCT01210937|Experimental|CEA and TCD monitoring|CEA involves a neck incision and physical removal of the plaque from the inside of the artery.During the surgery, the patient will be monitored by TCD.
3232414|NCT01210950|Experimental|cell and RPR recepients|mesenchymal cells and plasma reach protein are injected to the callus center of short limb
3232415|NCT01210963||SENSIMED Triggerfish|
3232416|NCT01210976|Experimental|levosimendan|
3329577|NCT02088203|Experimental|Multiple Dose Sequence 7|Dose 1, Dose 0, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3232417|NCT01210976|Placebo Comparator|placebo|
3232418|NCT01210989|Active Comparator|Hepaguard|
3329578|NCT02088203|Experimental|Multiple Dose Sequence 8|Dose 1, Dose 6, Dose 0: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3329579|NCT02088203|Experimental|Multiple Dose Sequence 9|Dose 0, Dose 1, Dose 6: Each subject will receive daily doses for 21 consecutive days during each of three separate test periods.
3232419|NCT01210989|Placebo Comparator|Placebo|
3329580|NCT02088242|Placebo Comparator|Placebo|Subjects receiving placebo will be asked to ingest 3 capsules identical in shape, colour and size to the Astaxanthin capsules, and will contain only the inactive ingredients of the same formulation.
3329581|NCT02088242|Experimental|Astaxanthin|Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
3329582|NCT02088255|Active Comparator|Static surface|The subjects will do the walking training with partial body weight support on static surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
3329583|NCT02088255|Active Comparator|dynamic surface|The subjects will do the walking training with partial body weight support on dynamic surface. The will be submitted to three weekly training sessions of approximately 45 minutes each , for six weeks , totaling 18 sessions
3329584|NCT02088268|Experimental|platelet-rich plasma|wound healing
3329585|NCT02088281|Experimental|Indigo naturalis extract in oil ointment|Indigo naturalis extract in oil ointment: each gram of ointment contains 200 μg±20 μg of indirubin.
3329586|NCT02088294|No Intervention|Non-intervention control|No intervention will be delivered.
3329587|NCT02088294|Experimental|Lifestyle Education (LS)|"The lifestyle curriculum will be taught in twice weekly after-school sessions of ~1.25 hours, one physical activity and one nutrition-related, delivered over 12-weeks during the course of a single academic semester. The lifestyle program will utilize the Shape Up curriculum of SOSMentor, a community non-profit collaborator, modified to seamlessly integrate key concepts of the non-diet philosophy of Intuitive Eating. The curriculum fully encompasses health-promoting nutrition and physical activity practices consistent with consensus recommendations ."
3329588|NCT02088294|Experimental|LS + Stress Reduction Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided Imagery (IGI) consisting of standard stress reduction imagery practices, delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures."
3329589|NCT02088294|Experimental|LS + Activity/Eating Guided Imagery|"In addition to the after school lifestyle classes, participants will receive group Interactive Guided ImagerySM (IGI) delivered once weekly for 12 weeks as an after school class of ~1.25 hours. The group IGI will be delivered by certified facilitators in the context of the facilitated group process known as Council, a group communication process used by many indigenous and other cultures. Participants in this arm will receive stress reduction IGI for 4 wks, plus 8 weekly sessions with IGI content designed to promote physical activity and healthy eating."
3329590|NCT02088307|No Intervention|Control|Subjects in the control arm will not receive an intervention.
3329591|NCT02088307|Experimental|CardioLife|The main ingredients in the CardioLife supplements are as follows: garlic, co-enzyme Q10, arjuna, hawthorn, guggul, red yeast rice, policosanol, nattokinase, tumeric/curcumin, ashwangandha, L-carnitine, grape seed extract and vitamin B12.
3329592|NCT02088333|Experimental|mCRC intervention|intervention arm
3329593|NCT02088333|Placebo Comparator|Healthy lifestyles education|tablet-based patient education about healthy lifestyles
3329594|NCT02088346||Teleconsultation|Intravenous thrombolysis guided by telemedicine consultation system based on portable hardwares
3329595|NCT02088346||Historical control|Usual stroke care without the guidance from hub hospital
3329596|NCT02088359||Cycled light|Approximately 12 hours of light on and 12 hours of light off.
3329597|NCT02088359||Near darkness|Continue near darkness
3329598|NCT02088372||Vanguard with E1 PS Bearing|"E1™ Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty.~Vanguard Total Knee System™ The Vanguard™ Knee System was designed to incorporate features from prior designs, including: ACG, Maxim, & Ascent."
3329599|NCT02088398|Experimental|160 mg ACY-1215 CLF (20 mg/mL) fed|• Treatment A: a single dose of 160 mg ACY-1215 CLF (20 mg/mL) in the fed state
3329600|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fed|• Treatment B: a single dose of 120 mg ACY-1215 ALF (10 mg/mL) in the fed state
3329601|NCT02088398|Experimental|120 mg ACY-1215 ALF (10 mg/mL) fasted|• Treatment C: a single dose of 120 mg ACY-1215 ALF (10 mg/mL)
3329602|NCT02088411|Active Comparator|Diclofenac|Subjects assigned to receive 1 tablet of Diclofenac Sodium (50 mg) and two tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
3329603|NCT02088411|Active Comparator|Wobenzym|Subjects assigned to receive 2 tablets of Wobenzym(R) and 1 tablet of an indistinguishable placebo three times daily for a duration of 12 weeks.
3232420|NCT01211002|Active Comparator|radiotherapy combined with EP|the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
3232421|NCT01211002|Experimental|adiotherapy / EP /recombinant human endostatin|recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.
3329604|NCT02088411|Placebo Comparator|Placebo|Subjects assigned to receive three tablets of an indistinguishable placebo three times daily for a duration of 12 weeks.
3329605|NCT02088424||group A|cases with recurrent abortion with insulin resisance
3329606|NCT02088424||GROUP B|cases that are pregnant with no history of recurrent abortion with no insulin resistance
3329607|NCT02088437|Active Comparator|Usual care|usual care physiotherapy - once daily treatment whilst inpatient in acute hospital
3232422|NCT01211015||Control group|healthy control group
3232423|NCT01211015||Disease group|asthma, COPD, ILD, lung malignancy
3232424|NCT01211028|Other|Autologous ASCs|Expanded autologous ASCs (Adipose Stroma/Stem Cells) Intramuscular dose of 100 million expanded cells.
3232425|NCT01211067||Patients age: 15 - 40 years-old|Patients within the 15 to 40 years-old age-group
3232426|NCT01211067||Patients age: 41 to 60 years-old|Patients within the group-age from 41 to 60 years-old
3232427|NCT01211067||Patients age: older than 61 years-old|Patients within the group-age from 61 years-old and older
3232428|NCT01211080||Threatening hemangioma|The group with cosmetically threatening of functionally threatening hemangiomas warranting active treatment according to our usual criteria (location face, hands, feet with a strong growth tendency and below age of 8 months)
3329608|NCT02088437|Experimental|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention
3329609|NCT02088450|Active Comparator|Active treatment|Active treatment with nitrendipine (10-40 mg/day). If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
3329610|NCT02088450|Placebo Comparator|Placebo|Placebo tablets were identical to the study drugs with a similar schedule.
3329611|NCT02088463|Experimental|Mobilization (manual therapy)|Mobilization (manual therapy) posterior- anterior at the L3 for 2 minutes in addition to the traditional treatment in the form of infra-red and ultrasound. The treatment duration for the three groups was 3 times/week for 4 weeks.
3329612|NCT02088463|Placebo Comparator|placebo mobilization|placebo mobilization applied without force application. The treatment duration for the three groups was 3 times/week for 4 weeks
3329613|NCT02088463|Other|Ultrasound and infrared therapy|ultrasound and infrared are a traditional treatment for low back painThe treatment duration for the three groups was 3 times/week for 4 weeks.
3329614|NCT02088476||Candidemia|Candidemia is defined as the presence of growth of any candida species in at least one blood culture obtained by either peripheral venipuncture or through an indwelling central venous catheter.
3329615|NCT02088489|Active Comparator|Atrial flutter, irrigated catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® (Biosense Webster, Diamond Bar, CA) irrigated catheter
3329616|NCT02088489|Experimental|Atrial flutter, porous tip catheter|Patients with isthmus dependent atrial flutter, undergone to catheter ablation with Thermocool® SF(Biosense Webster, Diamond Bar, CA) irrigated catheter
3232429|NCT01211093|Experimental|High frequency whole body vibration|This group will receive a single 10-minute session of WBV therapy. The frequency of the vibration signals will be set at 30Hz.
3329617|NCT02088502|Active Comparator|N-acetylcysteine|Patients in the N-acetylcysteine group receive 600 mg non-effervescent N-acetylcysteine tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
3232430|NCT01211093|Active Comparator|low frequency whole body vibration|This group will receive a single 10-minute session of WBV. The frequency of the vibration signals will be set at 20 Hz.
3232431|NCT01211093|Active Comparator|Control|This group will stand on the same vibration platform for 10 minutes, but no vibration will be given.
3232432|NCT01211119|Experimental|platelet-rich fibrin, PRF|
3232433|NCT01211132|Active Comparator|Cap arm|
3232434|NCT01211132|Active Comparator|Standard arm|
3232435|NCT01211158|Active Comparator|Propofol alone|Patients receiving propofol alone.
3329618|NCT02088502|Active Comparator|Theophylline|Patients in the Theophylline group receive 200 mg Theophylline slow-release tablet plus placebo twice daily from 24 hours before to 48 hours after administration of contrast material.
3329619|NCT02088502|Active Comparator|Theophylline plus N-acetylcysteine|Patients in the Theophylline plus N-acetylcysteine group receive Theophylline slow-release 200 mg tablet plus non-effervescent N-acetylcysteine 600 mg tablet twice daily from 24 hours before to 48 hours after administration of contrast material.
3232436|NCT01211158|Active Comparator|Ketofol|0.375 mg/kg each of ketamine and propofol (mixed in the same syringe) as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
3329620|NCT02088515|Experimental|experimental group|experimental group: Nedaplatin(（80 mg/m2, i.v Day1）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total.
3329621|NCT02088515|Active Comparator|comparative group|comparative group:Cisplatin (（75 mg/m2, i.v Day1 or 25 mg/m2 Day1-3）in combination with Docetaxel（75 mg/m2, i.v Day1）for each cycle, 4 cycles in total
3329622|NCT02088528|Active Comparator|Aurolab glaucoma drainage device|
3329623|NCT02088528|Active Comparator|Trabeculectomy with mitomycin-c|
3329625|NCT02088567|Experimental|dHACM|Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation
3329626|NCT02088567|Other|Control|Total knee arthroplasty, per the usual practice of the physician without application of dHACM.
3329627|NCT02088580|Experimental|Triple Chronotherapy|Total sleep deprivation, Sleep phase advance, and Bright light therapy.
3329628|NCT02088593|Experimental|DAWN simulation|Simulated Dawn Light box
3232437|NCT01211171||Group 1|
3232438|NCT01211210|Active Comparator|A: 5Fu with Radiation|Patients receive fluorouracil IV continuously and undergo radiotherapy once daily 5 days a week for 5-6 weeks.
3232439|NCT01211210|Experimental|B: FOLFOX with radiation|Patients receive FOLFOX for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFOX
3329629|NCT02088593|Active Comparator|Sleep hygiene instructions read aloud|Standard sleep hygiene instructions were read aloud.
3329630|NCT02088619|Experimental|Quality of Life Therapy (QOLT)|Positive emotion-focused cognitive behavioral psychotherapy
3329631|NCT02088619|Active Comparator|Heart Healthy Education (HHE)|Heart healthy education program
3329634|NCT02088645|Experimental|Phase 0: One arm; Phase I: One arm|"Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)~Phase I: expected 12 - 18 patients, intravenous application of max. 6 x 7-8 GBq 177Lu-PP-F11N (increasing number of applications by one in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study."
3329635|NCT02088658|Experimental|Techonology Intensified|Subjects randomized to this group will receive: 1) the FORA system for self-monitoring; 2) weekly telephone-delivered diabetes education/skills training; 3) patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions); and 4) patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools). The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes.
3232440|NCT01211210|Experimental|C: FOLFOX alone|Patients receive FOLFOX for 4 cycles
3232441|NCT01211223|Experimental|Scaling and root planning + placebo + antibiotics|"Scaling and root planning + placebo~Scaling and root planning + metronidazole plus amoxicillin~Metronidazole plus amoxicillin + scaling and root planning"
3232442|NCT01211236|Experimental|Maggot Debridement Therapy|
3232443|NCT01211236|Active Comparator|control|
3232444|NCT01211249|Experimental|GLPG0259 (Part A)|
3232445|NCT01211249|Placebo Comparator|Placebo (Part A)|
3232446|NCT01211249|Experimental|GLPG0259 (Part B)|
3232447|NCT01211249|Placebo Comparator|Placebo (Part B)|
3232448|NCT01211275|Experimental|arm 2|axitinib + cisplatin + premetrexed
3232449|NCT01211275|Active Comparator|arm 1|cisplatin + premetrexed
3329636|NCT02088658|No Intervention|Usual Care|Apart from study visits, patients will be followed by their primary care providers. The provider will be responsible for determining treatment parameters, making changes in the treatment regimen, and determining the timing of follow up visits. Between scheduled office encounters, contact between patient and provider will be patient initiated. The provider may use clinic nurses to follow up on problematic patients or patients with abnormal results. In essence, this group will receive the current standard of care at the study clinics.
3329637|NCT02088671||Anesthesia|"A single study group undergoing general anesthesia procedure to observe post-hoc the effect on the NeuroSENSE monitor readings.~Interventions of interest:~Drug: Propofol induction followed by randomized doses of desflurane; Emergence by stepping down the desflurane ET - See intervention descriptions.~Device: Recording of EEG using NeuroSENSE (blinded to clinicians) - See intervention descriptions.~Other: Data Collection - See intervention descriptions"
3329638|NCT02088684|Experimental|LEE011 + BKM120 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BKM120 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3329639|NCT02088684|Experimental|LEE011 + BYL719 + fulvestrant|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating) BYL719 - daily (dose escalating) fulvestrant - i.m. - 500 mg given on day 1 and day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3329640|NCT02088684|Experimental|LEE011 + fulvestrant|LEE011 - 28 day cycles (3 weeks on, 1 week off) or (continuous daily dosing - dose escalating) fulvestrant - 500 mg i.m. given on Day 1 and Day 15 of Cycle 1, then on Day 1 of each subsequent cycle.
3329641|NCT02088723|Experimental|head of bed elevation|Compare the apnea hypopnea index with the patient in standard polysomnography and in elevated polysomnography (head of bed elevation)
3329642|NCT02088736|Active Comparator|Intravenous and Intraosseous|'IV + IO' Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If IV is unsuccessful, IO will attempt at the Primary site (proximal tibia). If IO is unsuccessful at scene, 2nd attempt can be done in the ambulance. Adrenaline will be delivered as according to protocol.
3329643|NCT02088736|Experimental|Intravenous|Intravenous fluids or medications needed and a peripheral IV given 2 attempts or 90 seconds. If 1st IV is unsuccessful at scene, 2nd IV attempt can be done in the ambulance. Adrenaline will be delivered according to protocol.
3329644|NCT02088749|Experimental|small group treatment|lifestyle intervention for obesity delivered to small groups of approximately 12 participants/group
3329645|NCT02088749|Active Comparator|large group treatment|lifestyle intervention for obesity delivered to a large group of approximately 30 participants
3329646|NCT02088762||1 cm safety margin|1 cm safety margin
3329647|NCT02088762||2 cm safety margin|2 cm safety margin
3329648|NCT02088775|Experimental|Diagnostic: PET scan - CT scan|Patients undergo PET-CT scan before and after standard radioembolization on day 0. A subset of patients undergo PET-CT scan on day 1, 24 hours after the day 0 post-treatment PET-CT.
3329649|NCT02088801|Experimental|Airtraq, blade without channel for tracheal tube|intubation
3232450|NCT01211301|Active Comparator|Food-based, Reduced Energy Diet Plan|
3232451|NCT01211301|Experimental|Medifast 5 & 1 Plan|
3329650|NCT02088801|Experimental|KingVision , blade without channel for tracheal tube|intubation
3329651|NCT02088801|Experimental|A.P. Advance, blade without channel for tracheal tube|intubation
3329652|NCT02088801|Experimental|Macintosh|intubation
3329653|NCT02088814|Experimental|'EPICAP'|Secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
3329654|NCT02088814|No Intervention|Medical treatment as usual|Medical treatment of burn injuries as usual
3232452|NCT01211314|Experimental|lercanidipine-enalapril fixed combination|uncontrolled hypertensive patients will receive fixed combination therapy
3232453|NCT01211327|Experimental|Cyclosporine A|Cyclosporine A (CsA) 2% eye drops
3232454|NCT01211327|Active Comparator|Dexamethasone|Dexamethasone 0,1% eye drops
3329655|NCT02088827|Other|Activity|During a 4 hour Meal Test subjects will cycle for 2 minutes every 20 minutes
3329656|NCT02088827|Other|Inactivity|During a 4 hour Meal Test study subjects will remain inactive (remain lying on a bed)
3329657|NCT02088840||stem cell tranplant|All patients undergoing autologous or allogeneic stem cell tranplant for any underlying disease
3329658|NCT02088853|Experimental|high fat diet|
3329659|NCT02088853|Active Comparator|high carb diet|
3329660|NCT02088866|Experimental|Transdermal Lidocaine|All patients will be in this arm. This arm will be the transdermal lidocaine group.
3329661|NCT02088879|Experimental|Group1|"first : chest compression with kneeling position~second : chst compression with standing position"
3329662|NCT02088879|Experimental|Group2|"first : chest compression with standing position~second : chst compression with kneeling position"
3232455|NCT01211353|Experimental|Personalized Drinking Feedback|Personalized feedback on drinking behaviors
3232456|NCT01211353|Active Comparator|Education-Only|Educational information about alcohol
3232457|NCT01211366|Active Comparator|Conventional Transfusion|Infants will receive PRBCs, crystalloid, and colloid for hemodynamic instability per the usual routine at the discretion of the attending intensive care physician
3329663|NCT02088892|Experimental|Group A|10 BCG-naïve subjects receiving intradermal BCG SSI at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3329664|NCT02088892|Experimental|Group B|10 BCG-naïve subjects receiving BCG Tice at standard dose (2-8 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3329665|NCT02088892|Experimental|Group C|10 BCG-naïve subjects receiving intradermal BCG SSI at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3329666|NCT02088892|Experimental|Group D|10 BCG-naïve subjects receiving intradermal BCG Tice at high dose (6-24 x 10^5 cfu) followed by a punch biopsy at the challenge site 14 days later.
3329667|NCT02088892|Experimental|Group E|8-12 BCG-naïve subjects receiving the optimal strain and dose of intradermal BCG identified from preliminary results obtained from Group A, B, C and D, followed by a punch biopsy at the challenge site 14 days later.
3329668|NCT02088918|Active Comparator|Nateglinide+Metformin|coadministration of nateglinide and metformin
3329669|NCT02088918|Experimental|Nateglinide/Metformin|Nateglinide/Metformin tablet
3329670|NCT02088931|Experimental|Single infusion polyclonal Treg|"3 subjects with inflammation on their 6-month surveillance biopsy following renal transplantation will receive a single infusion of a target of 320 million ex vivo selected and expanded autologous polyclonal Tregs.~After the therapy visit the patient will return for a total of nine (9) more visits for the main part of the study: 1 and 4 days after therapy, then once a week for 4 weeks, and then 3, 6, and 12 months after you get the therapy."
3329671|NCT02088944||exposed to IFX|
3329672|NCT02088970|Active Comparator|antibiotic treatment alone|
3329673|NCT02088970|Experimental|Crosslinking + Antibiotic|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
3329674|NCT02088983|Experimental|CDP-Choline|Single dose of 500 mg, 1000 mg, or 2000 mg given in one of 4 test sessions
3232458|NCT01211366|Experimental|Cell Saver|Infants will receive washed cell-saver RBCs for hemodynamic instability in the first 24 hours post-operative period as long as Hgb is < 13 gm/dL and cell-saver is available.
3232459|NCT01211379|No Intervention|FLU-Only Arm|In this arm, primary care patients who got flu shots were only provided with FOBT if the doctor decided to order it.
3232460|NCT01211379|Experimental|FLU-FOBT Arm|In this arm, patients who came in for primary care got a flu shot and were assessed by nurses for eligibility for colorectal cancer screening. Eligible patients were provided with home FOBT.
3329675|NCT02088983|Placebo Comparator|Placebo (cellulose)|Given randomly in one of the 4 testing sessions as a comparison
3329676|NCT02088996|Active Comparator|IT and LWD on high power|IT and LWD on high power
3232461|NCT01211405|Active Comparator|Low dose MDMA|Participants will receive 30 mg MDMA during each of two blinded experimental sessions.
3232462|NCT01211405|Active Comparator|Medium dose MDMA|Participants will receive 75 mg MDMA on each of two blinded experimental sessions
3329677|NCT02088996|Placebo Comparator|LWD on low power|LWD on low power
3329678|NCT02089009|Other|Group 1 Standard Population|Retinal Imaging, vessel measurements, vessel changes of a population of a female health hospital
3329679|NCT02089009|Other|Group 2 Pregnant Population|Change in vessel diameter at perinatal visits with retinal imaging (Retinal Imaging, vessel measurements, vessel changes)
3329680|NCT02089022|Experimental|Physiotherapy resources|The goal of applying ice and shortwave diathermy to the calf, ankle and sole of the foot was to verify the effect of this resources at the neuromuscular response of the lower limb and postural balance
3329681|NCT02089035|Experimental|MUFA-rich dairy products|"Subjects are asked to exchange habitual dairy products for modified MUFA-rich experimental dairy products for a 12 week period.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
3329682|NCT02089035|Experimental|Conventional dairy products|"Subjects are asked to consume habitual non-modified dairy products for a period of 12 weeks.~Participants will provided with standardised quantities of pasteurised UHT milk, cheese and butter that they will be asked to consume on a daily basis."
3329683|NCT02089048|Experimental|Cohort 1|15 subjects receive 6mg of auranofin once every 24 hours for 7 days
3329684|NCT02089061|Experimental|Cohort 1: Rosuvastatin + BMS-919373|"Rosuvastatin 10 mg tablet orally once for Day 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
3329685|NCT02089061|Experimental|Cohort 2: Atorvastatin + BMS-919373|"Atorvastatin 40 mg tablet once for Days 1 and 5~BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension"
3329686|NCT02089074|Experimental|drug use counselling|Pharmacist conducting drug reconciliation, medication reviews and drug use counselling during hospitalisation. Follow up telephone calls 1 week, 1 month, 2 months and three months after discharge from hospital
3232463|NCT01211405|Experimental|Full dose MDMA|Participants will receive 125 mg MDMA during each of two blinded experimental sessions, followed by a third open label session.
3329687|NCT02089074|No Intervention|Control group|The patients in the control group receive no intervention just treatment and follow up according to national standards
3329688|NCT02089087|Experimental|CFZ533 in healthy volunteers|CFZ533 single dose in healthy volunteers
3329689|NCT02089087|Experimental|CFZ533 in rheumatoid arthritis patients|CFZ533 single dose in rheumatoid arthritis patients
3329690|NCT02089087|Placebo Comparator|Placebo|Placebo single dose
3329691|NCT02089100|Experimental|stereotactic body radiation therapy|The SBRT of all metastases should start in maximum 4 weeks after randomization. Beginning of systemic treatment will take place before 2 and 7 days after SBRT completion. All metastases lesions should be treated every 48h.
3329692|NCT02089100|Active Comparator|no specific treatment|no specific treatment to the oligometastatic sites except for palliation (pain, compression, hemorrhage)
3329693|NCT02089126|Experimental|Gemigliptin/Glimepiride combination|Gemigliptin 50mg qd added to ongoing Glimepiride as fix-dose combination. The subjects will take a total of 2 tablets, Gemigliptin/Glimepiride combination & Placebo for Glimepiride.
3329694|NCT02089126|Placebo Comparator|Placebo|The subjects will take a total of 2 tablets, Placebo for Gemigliptin/Glimepiride combination & Glimepiride.
3329695|NCT02089139|Experimental|DISCOGEL|Percutaneous intradiscal injection of Discogel
3329696|NCT02089139|Active Comparator|conventional treatment|conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to: medications (analgesics, NSAIDs, muscle relaxants), physical therapy, manual techniques, transcutaneous electrical nerve stimulation (TENS), blocks
3329697|NCT02089152|Other|Cluster A|General education for prevention of diabetic complications in year 1, Melioidosis prevention education in years 2, 3 and 4.
3329698|NCT02089152|Other|Cluster B|General education for prevention of diabetic complications in year 1 and 2, Melioidosis prevention education in year 3 and 4.
3329699|NCT02089152|Other|Cluster C|General education for prevention of diabetic complications in year 1, 2 and 3, Melioidosis prevention education in year 4.
3329700|NCT02089165|Experimental|Krill oil|The interventions are administered in the randomized order.
3329701|NCT02089165|Experimental|Krill meal|The interventions are administered in the randomized order.
3329702|NCT02089165|Active Comparator|Fish oil|The interventions are administered in the randomized order.
3329703|NCT02089178|Experimental|intravenous|the total intravenous anesthesia group
3329704|NCT02089178|Active Comparator|inhalation|the inhalation anesthesia group
3329705|NCT02089204||FMISO-PET/CT|18F-MISO PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3329706|NCT02089204||FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3232464|NCT01211418|Experimental|Integrative Meditation|
3329707|NCT02089204||contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy . GTVs were delineated based on fusing diagnostic CT images with simulation CT images.All patients were given concurrent chemoradiotherapy within two weeks of diagnosis. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) IMRT technique in the dose-escalation treatment arms. Concurrent chemotherapy consisted of cisplatin (20mg / m2 ,iv, d1- 4) and docetaxel (75mg / m2, d1, d8) administered on the 1st and 4th week of treatment. All patients received adjuvant chemotherapy that ranged from 2 to 4 cycles.
3329708|NCT02089243|Experimental|Vagus nerve stimulation therapy|Surgical follow-up typically occurred 2 weeks postoperatively and, subsequently, on a variable schedule as indicated. The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes. Retrospective chart review was performed to collect follow-up and outcome data. At the time of last available clinical follow-up, the following data were collected: mean weekly seizure frequency (from seizure logs kept by caretakers or patient or caretaker report averaged of the last 3 months prior to ﬁnal follow-up), complications of VNS therapy, duration of VNS therapy, timing and all subsequent surgical procedures.
3329709|NCT02089243|Experimental|Resective surgery|The type of surgery performed consisted of standard anterior temporal lobectomy, electrocorticography tailored temporal lobectomy, anteromedial temporal lobectomy, transcortical or transsylvian or subtemporal selective amygdalohippocampectomy, temporal lobe disconnection and hippocampal transection.
3329710|NCT02089256|Experimental|Liraglutide|Liraglutide 0.6 mg/day subcutaneously.
3329711|NCT02089269||Cohort 1|1,625 patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention
3329712|NCT02089269||Cohort 2|100 patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention
3329713|NCT02089282||Clavicle fractures|
3329714|NCT02089295|Experimental|Treatment A|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3329715|NCT02089295|Experimental|Treatment B|Single dose of 20 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3232465|NCT01211418|Active Comparator|Nondirective Therapy|
3232466|NCT01211431|Active Comparator|Reference|Intrathécale morphine is used for post-cesarean pain control
3232467|NCT01211431|Experimental|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
3232468|NCT01211444|Experimental|HGNS System|
3232469|NCT01211457|Experimental|Sapacitabine/decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
3232470|NCT01211457|Experimental|sapacitabine/venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
3232471|NCT01211470|Experimental|PMX-30063|3 arms of PMX-300063
3232472|NCT01211470|Active Comparator|Daptomycin.|Daptomycin will be administered according to the approved product monograph information for ABSSSI.
3232473|NCT01211496|Active Comparator|High-speed power training|Volunteers randomized into High-speed power training (HSPT) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
3232474|NCT01211496|Active Comparator|Slow-speed strength training|Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
3232475|NCT01211496|No Intervention|placebo exercise (control group)|Volunteers randomized into the control group (CON) will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
3232476|NCT01211509|Experimental|montelukast sodium|Daily treatment with 10 mg montelukast after diagnosis of fibroproliferative BOS (fBOS) which is the low neutrophilic phenotype within BOS
3232477|NCT01211509|Placebo Comparator|placebo|Lactose monohydricum Ph.Eur.
3232478|NCT01211548||contrast CTA of the CAP|All patients being considered for a complex aortic surgery and undergoing medically indicated contrast enhanced CT aortic angiography of the chest abdomen and pelvis will be includedRaw data from CT coronary angiography will be available from all patients.
3232479|NCT01211561|Experimental|Selenium, selenomethionine|
3232480|NCT01211561|Active Comparator|placebo|
3232481|NCT01211574|Experimental|peer coach|Participants will be coached by a peer between treatment visits.
3232482|NCT01211574|Experimental|mentor|Participants will be coached by a mentor between treatment visits
3329716|NCT02089295|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3329717|NCT02089308|Other|Treatment-Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment -Sequence 1 : Period 1 (test drug) + period 2 (reference)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
3329718|NCT02089308|Other|Treatment-Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treament periods.~Treatment-sequence 2 : Period 1 (reference) + period 2 (test drug)~The duration of each treatment period will be 3 days. Each patch will be applied for 24 hours."
3329719|NCT02089321||Patients with Low Back Pain|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years Currently seeking, but not yet initiated, treatment from a health care professional (PT, MD, DO, DC) for a chief complaint of pain between the level of the twelfth thoracic vertebrae and the coccyx Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~Signs of neurological impairment including diminished myotatic reflex, sensory impairment or strength deficits in a myotomal pattern No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
3329720|NCT02089321||Healthy Controls|"n= 19~Inclusion Criteria:~Between the ages of 18 and 70 years No LBP episodes requiring clinical care by a health professional and/or greater than 3 days absence from work/school/recreation within the previous 5 years Able to transition between standing, sitting, supine, prone and sidelying independently~Exclusion Criteria:~No previous spine or hip surgery Serious spinal or systemic pathology Pregnancy within previous 12 months Inability to understand and follow verbal instructions in English"
3329721|NCT02089373|Experimental|Probe-based confocal laser endomicroscopy|
3329722|NCT02089373|Active Comparator|White light endoscopy|
3232483|NCT01211574|Experimental|Professional|Participants will be coached by an interventionist between treatment visits
3232484|NCT01211587|Experimental|100mg safinamide|Two 50mg tablets of safinamide once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
3232485|NCT01211587|Placebo Comparator|Placebo|Two 50mg tablets of placebo once per day for 12 weeks (weeks 1-12) Open Label part: Two 50mg tablets of safinamide once per day for 12 weeks (week 13-24)
3329723|NCT02089386|Experimental|Tamoxifen|Tamoxifen 20 mg daily for 12 weeks
3329724|NCT02089399|Experimental|Treatment AB|S->S+C
3232486|NCT01211626|Active Comparator|Part A, Group 1 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 200 mg of ANA773 (n=6) or placebo (n=2)
3329725|NCT02089399|Experimental|Treatment C|C
3329726|NCT02089412|Experimental|E2006: fed conditions|E2006 10-mg will be administered as a single dose under fed treatment conditions.
3232487|NCT01211626|Active Comparator|Part A, Group 2 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 400 mg of ANA773 (n=6) or placebo (n=2)
3232488|NCT01211626|Active Comparator|Part A, Group 3 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 800 mg of ANA773 (n=6) or placebo (n=2)
3329727|NCT02089412|Experimental|E2006: fasted conditions|E2006 10-mg will be administered as a single dose under fasted treatment conditions.
3329728|NCT02089425|Placebo Comparator|Placebo|Placebo patch: 0% indomethacin
3329729|NCT02089425|Experimental|K-103-IP|K-103-IP: 0.5% indomethacin
3329730|NCT02089438|Experimental|Saxagliptin|Ssaxagliptin is given before breakfast
3329731|NCT02089438|Experimental|´Sitagliptin|Sitagliptin is given before breakfast
3329732|NCT02089438|Experimental|Vildagliptin|Vildagliptin is given before breakfast
3329733|NCT02089451|Experimental|FIAsp|Each subject will be randomised to a treatment sequence consisting of 5 treatment periods
3329734|NCT02089477|Experimental|Support|"The participants in the intervention group receives the intervention and support consisting of:~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
3329735|NCT02089477|No Intervention|Control group|Patient's in the control group receives the intervention with interval Walking and no other support.
3329736|NCT02089490|Experimental|NEVELIA®|NEVELIA® implantation according to the intended use in the leaflet, prior to autologous skin grafting planned 3 weeks after its application.
3329737|NCT02089503||induction phase + intravitreal inj.|Group of patients who received Lucentis ® with induction phase
3329738|NCT02089503||intravitreal inj. without induction|Group of patients who received Lucentis ® without induction phase
3329739|NCT02089503||intravitreal inj. + monthly follow-up|group of patients who were monthly monitored (+/- 1 week)
3329740|NCT02089503||intravitreal inj. + follow-up :> 1 month|group of patients with Follow up visits intervals> 1 month (+/- 1 week)
3329741|NCT02089503||intravitreal inj +induction+ month. FU|Group of patients who received Lucentis with induction phase and who were monthly monitored (+/- 1 week)
3329742|NCT02089503||date Lucentis® 1st intravitreal Inj.|Group of patients selected in accordance with the date of Lucentis® treatment start.
3329743|NCT02089516||Frail elderly|Measuring movement activity in frail elderly (GFI score ≥ 4) of 75 years and older using DynaPort.
3232489|NCT01211626|Active Comparator|Part A, Group 4 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1200 mg of ANA773 (n=6) or placebo (n=2)
3329744|NCT02089529|Active Comparator|Ibuprofen/Ibumetin|Ibumetin is administrated. Intervention: No information about the effect.
3329745|NCT02089529|Placebo Comparator|Placebo|Placebo is administrated. Intervention: No information about the effect.
3329746|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+positive information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
3329747|NCT02089529|Placebo Comparator|Placebo+positive information|Placebo is administrated. Intervention:The patient receive written information that the capsule is Ibumetin.
3329748|NCT02089529|Active Comparator|Ibuprofen/Ibumetin+neutral information|Ibumetin is administrated. Intervention: The patient receive written information that the capsule is Ibumetin.
3232490|NCT01211626|Active Comparator|Part A, Group 5 Healthy Volunteer|a single oral dose (Period 1) and multiple oral doses every other day (4 administrations) (Period 2) of 1600 mg of ANA773 (n=6) or placebo (n=2)
3232491|NCT01211626|Active Comparator|Part B, Group 6 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 2000 mg of ANA773 (n=6) or placebo (n=2)
3232492|NCT01211626|Active Comparator|Part B, Group 7 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1200 mg of ANA773 (n=6) or placebo (n=2)
3232493|NCT01211626|Active Comparator|Part B, Group 8 HCV Infected Patient|multiple oral doses(14 administrations) every other day of 1600 mg of ANA773 (n=6) or placebo (n=2)
3232494|NCT01211626|Active Comparator|Part B, Group 9 HCV Infected Patient|multiple oral doses(5 administrations) every other day of 2000 mg of ANA773 (n=8) or placebo (n=2)
3232495|NCT01211652||1|
3232496|NCT01211691|Experimental|Phase 1 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects with heme malignancies will be assigned to one of 11 planned KB004 (dose levels (20mg, 40mg, 70mg, 100mg, 140mg, 190mg, 250mg, 330mg)"
3232497|NCT01211691|Experimental|Phase 2 dose levels: KB004|"IV infusion 1x Weekly for a 21 day dosing cycle~Subjects will be assigned to the recommended Phase 2 dose of 250 mg"
3329749|NCT02089529|Placebo Comparator|Placebo+neutral information|Placebo is administrated. Intervention:The patients receive information that the capsule is placebo.
3329750|NCT02089529|No Intervention|Control|Control condition
3329751|NCT02089542|Experimental|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
3329752|NCT02089555||African Americans|This group consists of African American (AA) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)) or the Registry for Remembrance (RfR) (a community of AA individuals who are interested in studies of memory and aging). AA and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
3329753|NCT02089555||Non-Hispanic Whites|This group consists of Non-Hispanic White (NHW) individuals aged 65-80 who are part of the Emory Alzheimer's Disease Research Center (ADRC) (a multi-racial cohort of subjects with normal cognition, Mild Cognitive Impairment (MCI) or mild Alzheimer's Disease (AD)). African American (AA) and Non-Hispanic White (NHW) participants will be frequency-matched for age, gender, and education within each cognitive category (35 with normal cognition, 30 with MCI, and 10 with mild AD for each race).
3329754|NCT02089568|Experimental|Drug: co-amoxiclav|experimental
3329755|NCT02089568|Placebo Comparator|Control|comparator
3329756|NCT02089581|Active Comparator|Drug|MR2XXX
3329757|NCT02089581|Experimental|MRXXX|MRXXX capsule 12 hourly
3329758|NCT02089581|Experimental|MR1XXX|MR1XXX capsule, 12 hourly
3329759|NCT02089581|Experimental|Experimental|Experimental Fed
3329760|NCT02089594|Experimental|Hyperbaric Oxygen Therapy (HBOT)|Hyperbaric Oxygen Therapy at 1.5 ATA (atmospheres absolute). The subjects will receive 40 low pressure HBOT's on a once/day, 5d/week eight week schedule.
3329761|NCT02089594|Experimental|No Hyperbaric Oxygen Treatment (HBOT)|Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
3329762|NCT02089607|Experimental|Thoracoabdominal Aortic Aneurysm Arm|The TAAA study arm will include patients treated by endovascular aortic repair of thoracoabdominal aortic aneurysms (Extent I to IV) using either an off-the-shelf Zenith t-Branch or patient-specific stent-graft with a combination of fenestrations and/or branches. The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.
3232498|NCT01211704|Placebo Comparator|Placebo, Counceling|Placebo
3329763|NCT02089607|Experimental|Aortic Arch Aneurysm Arm|Aortic Arch study arm will include patients with aortic arch aneurysms treated by Patient-specific stent-grafts with one to three inner branches or a scallop. The study will include patients with thoracoabdominal and/or aortic arch aneurysms due to degenerative aneurysms or chronic aortic dissections. The stent-graft design for this study will be individually selected based on anatomy at the discretion of the principal investigator, including an off-the-shelf stent-graft (t-Branch stent-graft) or patient-specific stent-graft with a combination of fenestrations and/or branches.
3232499|NCT01211704|Experimental|Paliperidone Palmitate|Paliperidone Palmitate
3232500|NCT01211717|Experimental|Branched Chained Amino Acids|
3232501|NCT01211717|Placebo Comparator|Cellulose mix|
3232502|NCT01211743|Active Comparator|Lap Group|Patients in this group are operated for uncomplicated cholelithiasis with standard 4 port laparoscopic cholecystectomy
3232503|NCT01211743|Active Comparator|SILS group|Patients in this group are operated for uncomplicated cholelithiasis with Single Incision Laparoscopic Cholecystectomy
3232504|NCT01211782|Experimental|AC-1204|
3232505|NCT01211782|Placebo Comparator|Placebo|
3232506|NCT01211795|Active Comparator|Topical Ketoprofen gel|
3232507|NCT01211795|Placebo Comparator|Placebo gel|
3232508|NCT01211808|Experimental|Treatment A (BMS-914832)|
3232509|NCT01211808|Experimental|Treatment B (BMS-914832 + diltiazem)|
3232510|NCT01211821|Other|metoprolol|Treatment A
3232511|NCT01211821|Experimental|BMS-914392 + metoprolol|Treatment B
3232512|NCT01211834|Experimental|Tocilizumab 8mg/kg+DMARDs|
3232513|NCT01211834|Placebo Comparator|Placebo+DMARDs|
3232514|NCT01211847|Experimental|DCCR|DCCR Treatment with 290 mg Diazoxide Choline
3232515|NCT01211847|Placebo Comparator|Placebo|Placebo matching DCCR
3329764|NCT02089620|Active Comparator|Yasmin|Yasmin is an oral contraceptive pill containing (Disperinone 3mg+Ethinylestradiol 0.3mg) will be administered once daily orally by the woman from day 2 of the cycle for 21 days each month for 3 months in addition to a daily placebo.
3329765|NCT02089620|Active Comparator|Calver|Calver is a calcium supplement drug containing (ca 1000mg+vit D400 I.U) given to the woman continuously for 3 months in addition to placebo for 21 days
3329766|NCT02089620|Placebo Comparator|Placebo|A daily oral placebo will be given to the patients daily for 3 months in addition to a placebo similar to COC for 21 days
3329767|NCT02089633|Experimental|PACOX|Pegylated human arginase (PA) in combination with Capecitabine (C) and Oxaliplatin (OX)
3232516|NCT01211860|Experimental|DCCR Treatment|DCCR Treatment 290 mg diazoxide choline
3232517|NCT01211912|Experimental|Arm 1 (20 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally after a baseline ultrasound and 60 minutes before a repeat ultrasound.
3232518|NCT01211912|Experimental|Arm 2 (34 patients)|Pregnant women will be given a single dose of 1000 mg of acetaminophen orally 30 minutes to 24 hours before a scheduled cesarean section.
3232519|NCT01211925|Experimental|critical ischemia|
3329768|NCT02089672||Atrial flutter patients|Atrial flutter patients undergoing catheter ablation
3329769|NCT02089685|Experimental|Pembrolizumab + PegIFN-2b|Participants in Part A receive pembrolizumab intravenously (IV) at assigned dose every 3 weeks + PegIFN-2b subcutaneously (SC) at assigned dose once a week in each 6-week cycle.
3329770|NCT02089685|Experimental|Pembrolizumab + IPI Q3W|Participants in Parts 1A and 1B receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 1 mg/kg every 3 weeks (Q3W) for a total of two 6-week cycles.
3329771|NCT02089685|Experimental|Pembrolizumab + IPI Q6W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 50 mg every 6 weeks (Q6W) for a maximum of four 6-week cycles.
3329772|NCT02089685|Experimental|Pembrolizumab + IPI Q12W|Participants in Part 1C receive pembrolizumab IV at assigned dose every 3 weeks + IPI IV at 100 mg every 12 weeks (Q12W) for a maximum of eight 6-week cycles.
3329773|NCT02089698|Active Comparator|Reversed tip|Reversed Kelman tip
3329774|NCT02089698|Experimental|Mini-flared|Mini-flared Kelman tip
3329775|NCT02089711||Japanese healthy subjects|subjects with healthy eyes
3329776|NCT02089724||vemurafenib/other BRAF inhibitors|
3329777|NCT02089750|Active Comparator|Orthotics|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
3329778|NCT02089750|Active Comparator|Orthotics Plus Chiropractic Care|Subjects are asked to wear custom-made shoe orthotics for a 12 week study period in addition to receiving Chiropractic Care 1-4 times per week during the first 6 weeks of the 12 week study period.
3232520|NCT01211925|No Intervention|Control|Best medical treatment
3232521|NCT01211938|Active Comparator|single-fraction radiotherapy with concomitant 5FU and Hydrea|six 5-day cycles with a 9-day rest period between each cycle (split course). Each cycle includes : a single-fraction at a dose of 2 Gy per session for 5 sessions, combined with 5FU (800 mg/m2/day) and Hydrea (500 mg x 3/day) over the 5 days of the cycle. The total dose of radiotherapy is therefore 60 Gy delivered over 11 weeks.
3232522|NCT01211938|Experimental|hyperfractionated radiotherapy with concomitant Cetuximab|Bifractionated radiotherapy at a dose of 1.2 Gy per session at a rate of 2 sessions per day, at least 6h apart, 5 days per week over 5 weeks, without a split course, combined with Cetuximab. The total dose of radiotherapy is 60 Gy delivered over 5 weeks. Cetuximab (ErbituxÒ) is to be administered in a 2-hour IV infusion at a dose of 400 mg/m2, 8 days before the start of radiotherapy, then in a 1-hour infusion at a dose of 250 mg/m2 on days 1, 8, 15, 22 and 29 of radiotherapy.
3232523|NCT01211951|Experimental|KCT-0809 ophthalmic solution, low dose|
3329779|NCT02089750|Other|Wait List|The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last six weeks they are fitted for the custom-made shoe orthotics.
3232524|NCT01211951|Experimental|KCT-0809 ophthalmic solution, medium dose|
3329780|NCT02089763|Experimental|PEG-BCT-100|pegylated recombinant human arginase 1
3329782|NCT02089802|Experimental|Normal plasma level patients and low plasma level patients.|"Patients with normal Pazopanib plasma trough levels; normal plasma level patients (NPLP).~Patients with low Pazopanib plasma trough levels, low plasma level patients (LPLP)."
3329783|NCT02089815|Experimental|Home based exercise|simple designed home based exercise program
3329784|NCT02089815|Active Comparator|fall prevention education and counseling|fall prevention education & counseling : home modification, vision screening, avoid sedative drugs use, proper shoes, report dizziness and fall to doctors
3329785|NCT02089828|Experimental|autologous purified CD34+ cell|transplantation of autologous purified CD34+ cell
3329786|NCT02089828|Active Comparator|autologous PB-MNC|transplantation of autologous peripheral blood mononuclear cells
3329787|NCT02089841|Experimental|Artemether/lumefantrine|In this single-arm study, patients will be treated with Artemether/lumefantrine, and the first, third and fifth doses of the drug will be given under the direct observation of the health workers. The patients will be followed-up for 42 days, on day 1, 2, 3, 7, 14, 21, 28 and 42 to assess the efficacy of the drug.
3329788|NCT02089854|Experimental|endocrine therapy|toremifene 60mg PO. per day for premenopausal and perimenopausal patients; anastrozole 1mg PO. per day for postmenopausal patients
3329789|NCT02089854|No Intervention|observation|
3329790|NCT02089867|Experimental|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
3329791|NCT02089867|Experimental|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
3329792|NCT02089867|No Intervention|Control group|No additional therapy, statin maintenance
3329793|NCT02089867|Experimental|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
3329794|NCT02089880|Experimental|C-brace then stance control orthosis|
3329795|NCT02089880|Experimental|Stance control orthosis then C-brace|
3329796|NCT02089893||Healthy subjects|Healthy subjects
3329797|NCT02089906||Chinese Elderly|multi-center cross-sectional study
3329798|NCT02089919|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329799|NCT02089919|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329800|NCT02089919|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329801|NCT02089919|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3329802|NCT02089932|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 1 ml normal saline peri-neurally
3329803|NCT02089932|Experimental|Group B-DEX 25 : Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (25 microgram) Dexmedetomidine peri-neurally
3329804|NCT02089932|Experimental|Group B-DEX 50:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (50 microgram) Dexmedetomidine peri-neurally
3329805|NCT02089932|Experimental|Group B-DEX 75:Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 1 ml (75microgram) Dexmedetomidine peri-neurally
3329806|NCT02089945||transcatheter aortic valve implantation|This study recruits individuals that are undergoing transcatheter aortic valve implantation.
3329807|NCT02089958||Laparoscopic incisional hernia repair|Incisional hernia, LIPOM
3329808|NCT02089971||Young Chinese adults|cross-sectional, observational study of community dwelling young Chinese adults
3329809|NCT02089984|Experimental|Internet-Based Training|On-line tutorial followed by live remote training via videoconferencing
3232525|NCT01211951|Experimental|KCT-0809 ophthalmic solution, high dose|
3232526|NCT01211951|Placebo Comparator|Placebo|
3329810|NCT02090010|Active Comparator|GroupC|Group C means Control group which use Seldinger technique for subclavian catheterization. The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed. After that catheter is passed over the guidewire into the vessel.
3329811|NCT02090010|Experimental|Group MS|Group MS means experimental group which use modified Seldinger technique for subclavian catheterization. The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instatntly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
3329812|NCT02090023||NHIRD obstructive sleep apnea|Secondary database from community-based National Health Insurance Research Database
3329813|NCT02090023||NTUH obstructive sleep apnea cohort|Primary database from enrollment of retrospective NTUH hospital-based cohort
3329814|NCT02090036|Active Comparator|artemether-lumefantrine+placebo|In the artemether-lumefantrine arm, the first dose of artemether-lumefantrine will be administered concomitantly with a single-dose placebo. A volume of normal saline will be measured based on weight bands and then will be given to patients.
3329815|NCT02090036|Experimental|artemether-lumefantrine+primaquine|All the recruited patients will be treated with a six doses, 3 days artemether-lumefantrine treatment regimen. However, patients randomized to the artemether-lumefantrine+primaquine arm will be given 0.25 mg/kg single-dose primaquine concomitantly with artemether-lumefantrine first dose.
3329816|NCT02090049|Experimental|Puravita Breakfast|Puravita Breakfast is a high protein and high fiber soft bread that contains 22% fruit (figs, apricots, raisins and prunes), a selection of cereals: wheat, oat and spelt and no added sugar.
3329817|NCT02090049|Placebo Comparator|Control breakfast|White bread (85g) with jam (10g) and margarine (2g) adjusted for energy, fat, and sugar levels and for energy density.
3329818|NCT02090101|Experimental|ANAKINRA|LV5FU2 + bevacizumab + anakinra
3232527|NCT01211964|Experimental|LEO 22811 oral solution 1.5 mg (fasted state)|
3232528|NCT01211964|Experimental|LEO 22811 single tablet 1.5 mg (fasted state)|
3232529|NCT01211964|Experimental|LEO 22811 single tablet 1.5 (fed state)|
3329819|NCT02090140|Experimental|ADSC Application|Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.
3329820|NCT02090140|Active Comparator|Microfracture Arm|Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.
3329821|NCT02090153|Experimental|S-1 plus LV|All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks.
3329822|NCT02090166|Other|lung cancer diagnosis|"4 arms will be included in the study:~The groups sample size is as follows:~Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects~A blood test will be taken from each patient."
3329823|NCT02090179||MPS IIIB|Those with a definitive diagnosis of MPS IIIB (Sanfilippo B Syndrome).
3329824|NCT02090192|Experimental|WBV training|"Whole-body vibration training was performed on a commercial Galileo machine (Germany). Participants were required to stand on the moveable rectangular platform and positioned their feet at an equal and standardized distance from the axis of rotation so that the vertical vibration amplitude was 1-3 mm. The frequency was set at 6-26 Hz. The vibration protocol consisted of four to five bouts (60 seconds for each bout), and three to five times a week for 12 weeks. The positions taken by the subjects differed according to their function. Participants who could stand independently were instructed to adopt a partial squat position with slight flexion at the hips, knees, and ankle joints to damp the vibrations approximately at the pelvic level."
3329825|NCT02090192|Experimental|WBV+ PRT training|
3329826|NCT02090192|Active Comparator|PRT training|
3329827|NCT02090192|Placebo Comparator|Control group|
3329828|NCT02090205|Placebo Comparator|Non-ventilation during CPB|This group of patients will not be ventilated during the cardio-pulmonary bypass. They will be disconnected from the respirator.
3329829|NCT02090205|Experimental|Ventilation with CPAP|This group will receive a ventilation with CPAP (at least 5 cmH2O) and FiO2 50%-80%
3329830|NCT02090205|Experimental|Ventilation with 5 act/minute|This group will receive 5 respiratory acts/minute. Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
3329831|NCT02090218|Active Comparator|I-Gel|I-Gel supraglottic airway device
3329832|NCT02090218|Active Comparator|LTS, ETI or other airway practice|Laryngeal tube, endotracheal tube or other current airway management practice
3329833|NCT02090231|Experimental|Real 5 Hz rTMS|real 5 Hz rTMS, 10 minutes per day, for 10 weekdays.
3329834|NCT02090231|Sham Comparator|sham 5 Hz rTMS|sham 5Hz rTMS, 10 minutes per day, for 10 weekdays.
3329835|NCT02090244|No Intervention|Control|Standard care postoperatively.
3329836|NCT02090244|Experimental|Teriparatide|One injection daily for 4 weeks
3329837|NCT02090257|Experimental|TRANSIT, behavioral|The intervention group will receive more guidance during their transition from a pediatric center to the adult center
3329838|NCT02090257|No Intervention|Usual Care Group|The usual care group will receive a standard transfer of care from a pediatric center to an adult center.
3329839|NCT02090270||Ischemic stroke|Sudden onset of focal neurologic deficit lasting more than 24 hours, with cerebral hemorrhage ruled out by brain CT, in the absence of obvious causes of embolic stroke.
3329840|NCT02090270||Control|Patients admitted to an internal medicine department for indications other than stroke or acute myocardial ischemia.
3329841|NCT02090296|Placebo Comparator|Sugar water|Placebo arm
3232532|NCT01212029|Experimental|1/All Subjects|Imaging studies related to functional brain activation
3329842|NCT02090296|Active Comparator|Hydroxyurea|Treatment Arm
3329843|NCT02090309|Active Comparator|Hydrocortisone injection|I.V Hydrocortisone 100 mg single bolus.
3329844|NCT02090309|Placebo Comparator|normal saline|I.V normal saline 0.9% a single bolus of 5 ml.
3329845|NCT02090322|Experimental|Bevacizumab|"The treatment for Retinopathy of prematurity is Intravitreal bevacizumab. We want to compare two dosages (0.500 and 0.625mg) and demonstrate that 0.500mg there isn't lower in efficacy than 0.625mg.~When the baby have the diagnosis or Retinopathy of prematurity we are going to inyect the eye that have te problem, then we are going to explore until this illness disappear. It is only one intervention"
3232533|NCT01212120||All patients|All patients
3329846|NCT02090335|Experimental|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
3232534|NCT01212133||A|
3232535|NCT01212146|Experimental|Probiotic-enriched Artichokes|Artichokes containing approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme
3232536|NCT01212146|Active Comparator|Ordinary artichokes|Ordinary artichokes (probiotic free) of identical shape, texture, and appearance of probiotic-enriched artichokes
3329847|NCT02090335|Active Comparator|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
3329848|NCT02090348|Experimental|dimethyl fumarate|DMF at a dose of 120 mg twice a day (BID) for the first 7 days and 240 mg BID for the remainder of study period (up to 12 months)
3329849|NCT02090361|Experimental|skin graft with dermal matrix|Epidermization of the defect by applying a thin layer of autologous epidermis with addition of a dermal matrix
3329850|NCT02090361|Placebo Comparator|skin graft - classic procedure|Epidermization of the defect by applying a thin layer of autologous epidermis
3329851|NCT02090387|Active Comparator|Control ONS|ONS without AN777
3232537|NCT01212198||Korean type 2 diabetic patients|
3232538|NCT01212198||Koreans at high risk for diabetes|
3232539|NCT01212198||Korean gestational diabetic patients|
3232540|NCT01212211|Experimental|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
3232541|NCT01212211|No Intervention|reference|drug treatment of ten patients will remain unchanged during the three months of inclusion
3329852|NCT02090387|Experimental|Investigational ONS|ONS containing AN777
3329853|NCT02090400|Other|Bazedoxifene & Calcium/Vit D|Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)
3329854|NCT02090400|Other|Calcium/Vit D|Calcium 500mg and 400 IU vitamin D (OSTINE )daily.
3329855|NCT02090439|Experimental|standard treatment with Silodosin|Silodosin
3329856|NCT02090439|No Intervention|standard treatment|
3329857|NCT02090452|Experimental|Transmission of vital signs, ecg, chat|Data from patients transported in ambulances with equipment which enables real time transmission of vital signs, ecg and chat from ambulances to the emergency department.
3329858|NCT02090452|No Intervention|No transmission of data|Patient transported with conventional ambulances without the possibility to transmit real time patient related data.
3329859|NCT02090465||all eligible patients|Treatment with Picato according to Summary of Product Characteristics (SmPC)
3329860|NCT02090478|Sham Comparator|No change in dietary sugar levels|Group met with a dietician as often as the control group to discuss diet, but the dietician gave them advice geared toward no change in dietary sugar levels
3329861|NCT02090478|Experimental|Low sugar group|Subjects met with a dietician who discussed diet records. After the first month (baseline, regular diet), the dietician made suggestions geared toward reducing calories from simple sugars by 40%. This will be achieved by replacing sugar calories with complex carbohydrates and fats, while maintaining energy balance (same number of calories as the baseline month).
3329862|NCT02090504|Experimental|Sodium oxybate (SMO)|"Patients randomized to the first arm of the study will receive:~SMO (sodium oxybate 175 mg/ml suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10 (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml);~placebo (tablets): 1 tablet at 8.00 a.m., 1 tablet at 12.00 p.m., 1 tablet at 7.00 p.m. from day 1 to day 10."
3329863|NCT02090504|Active Comparator|Oxazepam|"Patients randomized to the second arm of the study will receive:~OXAZEPAM (tablets): 60mg at 8.00 a.m., 60mg at 12.00 p.m., 90mg at 7.00 p.m. from day 1 to day 5, 30mg at 8.00 a.m., 30mg at 12.00 p.m., 30mg at 7.00 pm, on days 6 and 7, and 15mg at 8.00 a.m., 15mg at 12.00 p.m., 15mg at 7.00 p.m. from day 8 to day 10;~placebo (suspension): 10ml at 8.00 a.m., 10ml at 12.00 p.m., 10ml at 7.00 p.m. from day 1 to day 5, 5ml at 8.00 a.m., 5ml at 12.00 p.m., 5ml at 7.00 pm, on days 6 and 7, and 2.5ml at 8.00 a.m., 2.5 ml at 12.00 p.m., 2.5ml at 7.00 p.m. from day 8 to day 10, (If patient's weight is > 75 kg the dosage will be of 12ml instead of 10 ml, 6ml instead of 5ml, 3 ml instead of 2.5ml)."
3329864|NCT02090517|Active Comparator|Pulsed Dye Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser.
3329865|NCT02090517|Active Comparator|Long Pulsed Alexandrite Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with long pulsed alexandrite laser.
3329866|NCT02090517|Active Comparator|Pulsed Dye Laser Plus Nd:YAG Laser|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with pulsed dye laser plus Nd:YAG laser.
3232542|NCT01212237||fMRI Evaluation|"All patients will undergo the following standard imaging and radiotherapy procedures will be performed for each patient:~Standard MRI for radiotherapy treatment planning which takes about 60 minutes.~Radiotherapy treatment simulation with CT.~Radiotherapy treatment planning~Radiotherapy treatment~Routine follow-up every 3 months after the radiotherapy.~Special Procedures.~The following special imaging and radiotherapy procedures will be performed for each patient:~fMRI (30 minutes)~The 3MS examination, administered every 3 months during routine follow-up for one year after the completion of the radiotherapy."
3232543|NCT01212250|Experimental|Carvedilol|Tablet 6.25 mg BD
3232544|NCT01212250|Placebo Comparator|placebo|Placebo tablets 2 BD
3232545|NCT01212263|Experimental|Clomiphene Citrate plus HP uFSH|Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
3232546|NCT01212263|Active Comparator|Step-up HP uFSH|HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5) IU /day until follicular diameter reaches 18 mm mean diameter
3232547|NCT01212276|Experimental|Cohort 1|MORAb-028 0.1 mg/kg intravenous
3232548|NCT01212276|Experimental|Cohort 2|MORAb-028 0.2 mg/kg intravenous
3232549|NCT01212276|Experimental|Cohort 3|MORAb-028 0.5 mg/kg intravenous
3232550|NCT01212276|Experimental|Cohort 4|MORAb-028 1.0 mg/kg intravenous
3232551|NCT01212289||Primary cardiac surgery|Pediatric patients receiving primary cardiac surgery
3232552|NCT01212289||Reoperation|Pediatric patients receiving cardiac surgery reoperation
3232553|NCT01212315|No Intervention|Control group|Ordinary sutures (Vicryl / Monocryl) is used for wound closure
3329867|NCT02090517|Active Comparator|Electrodesiccation|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will be treated with electrodesiccation.
3329868|NCT02090517|No Intervention|No Treatment|Subjects with multiple nose telangiectasias will be enrolled. One nose telangiectasia (of 5) will receive no treatment.
3232554|NCT01212315|Active Comparator|Group A|Triclosan coated sutures (Vicryl Plus / Monocryl Plus) is used for wound closure
3232555|NCT01212328|Experimental|Care coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
3329869|NCT02090530||Advanced Cancer Patients|Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
3329870|NCT02090543||Group 1|300 AF patients, with at least 3 month of anticoagulation therapy with VKAs (VKA-experienced patients)
3329871|NCT02090543||Group 2|300 AF patients, with at least 3 month of rivaroxaban therapy (rivaroxaban-experienced patients)
3329872|NCT02090556||Cohort 1:|RA patients naive of Abatacept and any other biologic agents
3329873|NCT02090556||Cohort 2:|RA patients naive of Abatacept and who previously failed one or more biologic agents
3329874|NCT02090569|Experimental|Functional micro-Doppler sonography|
3329875|NCT02090582|Other|Structured Palliative Care|
3329876|NCT02090582|Other|Usual Care|
3329877|NCT02090595|Experimental|MBCT-C|Mindfulness-Based Cognitive Therapy for Anxious Children (MBCT-C) is a 12-week manualized group therapy program for children with anxiety disorders. The program involves teaching children to pay attention to anxiety-related thoughts, emotions, and physical sensations with openness and non-judgment.
3329878|NCT02090595|Other|Waitlist Control|Education and Therapy
3232556|NCT01212328|Active Comparator|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
3232557|NCT01212341|Experimental|Singe-dose infusion|Cohort 1: 1x10^6 cells/kg Cohort 2: 1x10^7 cells/kg
3232558|NCT01212341|Experimental|Repeated dose infusion|Cohort 3: 1x10^6 cells/kg Cohort 4: 3x10^6 cells/kg Cohort 5: 1x10^7 cells/kg Cohort 6: 3x10^7 cells/kg
3329879|NCT02090608|Experimental|Paricalcitol|In patients identified by the inclusion criteria, data will be collected at baseline , during administration of oral Paricalcitol (PCT) (after 1, 3 and 6 months), and three months after PCT withdrawal. PCT will administered at dosage of 1 mcg/day; this dosage was chosen as it is not associated with excessive decline of parathyroid hormone (PTH) levels in most patients
3329880|NCT02090621|Experimental|Extracorporeal Photopheresis|Extracorporeal Photopheresis
3329881|NCT02090647|Active Comparator|titanium 1|titanium abutment type 1
3232559|NCT01212354|Experimental|A - experimental|7 weeks Radiotherapy Intervention with with 5x2.3 Gy per week up to a total dose of 80.5 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
3329882|NCT02090647|Active Comparator|titanium 2|titanium abutment type 2
3329883|NCT02090647|Active Comparator|zirconia 1|zirconia abutment type 1
3329884|NCT02090647|Active Comparator|zirconia 2|zirconia abutment type 2
3329885|NCT02090647|Active Comparator|titanium nitrate|titanium nitrate abutment
3329886|NCT02090660|Experimental|VATS wedge lung resection|
3329887|NCT02090673||Group1:Type 2 diabetic patients treated with Exenatide therapy|Korean patients who are at least 18 years old, diagnosed with type 2 diabetes, and are treated with Exenatide in an ambulatory care setting according to the approved label
3232560|NCT01212354|Active Comparator|B - control|7 weeks Radiotherapy Intervention with 5x2.0 Gy per week up to a total dose of 70 Gy and parallel chemotherapy of 20 mg/m²/d Cisplatin in week 1 and 5.
3329888|NCT02090686|Active Comparator|Pulsatile Cupping|
3329889|NCT02090686|Active Comparator|Minimal Cupping|
3329890|NCT02090686|No Intervention|No Intervention|Waiting list
3329891|NCT02090699||Myocardial Iron Overload|chronic blood transfusion related myocardial iron overload
3329892|NCT02090699||Healthy Volunteers|age matched healthy volunteers
3329893|NCT02090712||Reperfusion strategies|Patients submitted to thrombolysis with tenecteplase after acute myocardial infarction will be transferred to a tertiary center and angiography with the intention to treat the culprit artery will be performed in 3 - 48 hours (preferably first 24 hours).
3232561|NCT01212367|Experimental|Dose Level 1|
3232562|NCT01212367|Experimental|Dose Level 2|This is a dose de escalation.
3329894|NCT02090712||Primary PCI|Patients with contra-indication to thrombolytics or able to reach the catheterization laboratory within 90 minutest will be transferred for primary angioplasty, according to current guidelines.
3329895|NCT02090738|Experimental|Arm1|Treatment group
3329896|NCT02090738|Active Comparator|Arm2|Control group
3329897|NCT02090751||No Maculopathy|Aged 50 to 80 with no macular disease
3329898|NCT02090751||Early Maculopathy|Aged 50 to 80 with early AREDS defined 2,3 age related maculopathy
3329899|NCT02090790|Active Comparator|iv dexamethasone|perioperative 2ml 8 mg ıv dexamethasone
3232563|NCT01212380|Experimental|Arm 1|Patients receive carfilzomib IV over 30 minutes once daily on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.Performance of pharmacology, pharmacodynamic and pharmacogenomic studies allow assessment of carfilzomib mechanism of action and also to understand how the variability of these different features correlate with clinical benefit/response and also toxicity.
3329900|NCT02090790|Active Comparator|femoral dexamethasone|femoral block was performed postoperative 30 ml 0,5 % bupivacaine added 2 ml 8 mg dexamethasone
3329901|NCT02090790|Placebo Comparator|serum physiologic|
3329902|NCT02090803||Graft of autologous hematopoietic stem cells|
3329903|NCT02090816||Surgery of liver and lung|Patients carriers of both liver and right lung metastases in the same time
3232564|NCT01212393||Intervention group|reminders
3232565|NCT01212393||current practice group|no intervention
3232566|NCT01212406|Placebo Comparator|Placebo|Olive oil
3232567|NCT01212406|Experimental|Vitamin D|Addition of D-cure (100.000U) to standard care
3329904|NCT02090829|Placebo Comparator|Placebo Group|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
3329905|NCT02090829|Active Comparator|Experimental Group|"Intranasal oxytocin (Trade name: Syntocinon) Pharmacological class: The pharmacologic and clinical properties of Syntocinon are identical with the naturally occurring hormone oxytocin, which is released from the posterior pituitary.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal oxytocin (24 IU) per day for 5 days.~One dose of 24 IU equals 6 spray puffs (3 puffs in each nostril). Oxytocin will be imported from Victoria Pharmacy Zurich- Switzerland."
3329906|NCT02090842|Experimental|Whey protein isolate|Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks.
3329907|NCT02090842|Experimental|Ca-caseinate|Subjects are asked to supplement their habitual diet with 56 g of Ca-caseinate a day for 8 weeks.
3329908|NCT02090842|Other|Maltodextrin|Subjects are asked to supplement their habitual diet with 54 g of maltodextrin a day for 8 weeks.
3329909|NCT02090868||Pre Introduction|Pre tool introduction cohort 22 patient participants who will receive standard care (no patients were recruited)
3329910|NCT02090868||Nurses|12 nurse participants who will take part in 2 focus group interviews and a teaching session (6 nurse participants were recruited)
3329911|NCT02090868||Post Introduction|Pre tool introduction cohort 22 patient participants who's ability to eat and drink orally will be assessed using the Oral Intake Screening Tool (no patient participants were recruited)
3329912|NCT02090881|Experimental|ultrasound scan in ages 2-16 years|Children aged 2-16 years of age with Sickle Cell Disease and under the care of consultant haematologist as part of the NHS screening programme.
3329913|NCT02090907|Experimental|Levothyroxin|In the treatment group, daily doses of 100 mg of Levothyroxine will be administered every morning, half an hour before breakfast.
3329914|NCT02090907|Placebo Comparator|Placebo|In the placebo group treatment regimen and advices are identical to that of the treatment group, except for using a pharmacologically neutral agent, with complete resemblance to the real treatment.
3232568|NCT01212497|Experimental|Mindfulness meditation coaching|Assess effectiveness of using a virtual computer coach to train mindfulness meditation
3232569|NCT01212510|Other|Tumor markers|measurement of tumor markers ( blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA )
3329915|NCT02090920||Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
3329916|NCT02090933|Experimental|Treatment (celecoxib)|Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
3329917|NCT02090946||parental experiences|interviews
3329918|NCT02090972||Patients with fracture|"fracture within the last 14 days~no other fractures within the last 6 month~patients >60 years"
3232570|NCT01212536|No Intervention|Conventional|conventional laryngoscopy for intubation
3232571|NCT01212536|Experimental|Airtraq|laryngoscopy with Airtraq for intubation
3232572|NCT01212549|Active Comparator|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 weeks imiquimod
3232573|NCT01212549|Active Comparator|Cryoimmunotherapy|Cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 5 weeks imiquimod
3232574|NCT01212562||Immunocryosurgery|2 weeks daily imiquimod application prior to a session of cryosurgery and subsequently 3 weeks continued daily imiquimod application
3232575|NCT01212575||300 patients|Female or male aged 18-65 years with a diagnosis of schizophrenia having received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
3329919|NCT02090972||Control Patients|"patients hospitalized for an internal reason~no other fractures within the last 6 month~patients >60 years"
3329920|NCT02090985|Experimental|Lipomodelling|Lipomodelling of peri-stomal skin contour abnormalities
3329923|NCT02091011||Cohort group|Subjects who have been implanted within 30 days with a commercially available Boston Scientific ICD or a CRT-D device
3329924|NCT02091024|Experimental|ECG (Ecklonia cava extract)|ECE 200mg, twice a day
3329925|NCT02091024|Placebo Comparator|Placebo|Placebo 200mg, twice a day
3329926|NCT02091050|Other|HDR Brachytherapy 24Gy (4 x 6Gy)|Vaginal vault brachytherapy, associated or not with external beam radiotherapy.
3329927|NCT02091063|Experimental|Phase Ib: Arm A: ACY-1215 QD|Phase Ib: ACY-1215 160mg PO QD
3329928|NCT02091063|Experimental|Phase Ib: Arm B: ACY-1215 BID|Phase Ib: ACY-1215 160mg PO BID
3329929|NCT02091063|Experimental|Phase II: ACY-1215|Phase I dosing schedule has been determined. 160 mg BID dosing will be administered for Phase II.
3232576|NCT01212601||1|
3232577|NCT01212653|Active Comparator|Golimumab|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
3232578|NCT01212653|Placebo Comparator|Pacebo-controlled|"In this 52-week, randomized, placebo-controlled study, patients will be randomized to receive either Golimumab 50 mg monthly or matching placebo for 12 months using a 1:1 randomization procedure.~The doctors and patients and the nurse who administer the study medication (Golimumab) will be blinded. There will be one unblinded nurse to prepare the study medication."
3329930|NCT02091076|Experimental|Silk with bioactive coated dressing|Silk fibroin coated with bioactive layer, apply once only
3232579|NCT01212666|Experimental|Adductor-Canal-Block, Ropivacain|25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.
3232580|NCT01212666|Placebo Comparator|Adductor Canal Block, Placebo (saline)|25 patients. ACB. 30 mL Saline. Ultrasound-guided application.
3232581|NCT01212679|Experimental|nerve growth factor|Patients who underwent TBI will be chosen to receive NGF randomly.
3232582|NCT01212679|Placebo Comparator|Control|Patients who underwent TBI will be chosen to receive nomral saline randomly.
3232583|NCT01212692|Experimental|Mentally stimulating activities|
3232584|NCT01212692|Active Comparator|Mentally stimulating activities- other|
3232585|NCT01212705|Experimental|ASV|
3232586|NCT01212718|Active Comparator|5-FU|FUFA 5-flurouracil and folinic acid control
3232587|NCT01212718|Active Comparator|Folfiri|5-fluouracil and folinic acid in combination with irinotecan (Folfiri) systemic chemotherapy intensified treatment arm
3232588|NCT01212731||Cohort 1|Subjects with a histological diagnosis of malignancy of the base of skull necessitating irradiation to a minimum of 60 Gy, ECOG PS 0-1 with no evidence of metastatic disease and an estimate life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
3232589|NCT01212731||Cohort 2|Subjects with a histological diagnosis of low grade glioma requiring radiotherapy. ECOG PS 0-1 with no evidence of metastatic disease and an estimated life expectancy of at least 1 year and who is able to provide informed consent. Subjects will undergo standard CT simulation and radiotherapy treatment planning.
3232590|NCT01212783|Active Comparator|Present-Centered Therapy|Mothers will receive 15 weekly sessions of PCT plus two monthly booster sessions following the 15th session.
3232591|NCT01212783|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus two booster sessions scheduled monthly following the 15th session.
3329931|NCT02091076|Active Comparator|Control|Bactigras wound dressing, apply once only
3329932|NCT02091115|Placebo Comparator|Dairy drink|Patients received dairy drink for 60 days and were instructed to consume a glass of 150 mL daily.
3329933|NCT02091115|Active Comparator|Dairy drink with probiotic culture|Patients received dairy drink with probiotic culture for 60 days and were instructed to consume a glass of 150 mL daily.
3329934|NCT02091128||Females with classic galactosemia and POI|
3329935|NCT02091141|Experimental|Trastuzumab Plus Pertuzumab|Participants will receive trastuzumab 8 milligrams per kilogram (mg/kg) intravenous (IV) infusion as loading dose, followed by 6 mg/kg IV infusion every 3 weeks; and pertuzumab 840 mg IV infusion as loading dose, followed by 420 mg IV infusion every 3 weeks. This treatment arm is now closed for screening and enrollment.
3329936|NCT02091141|Experimental|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
3232592|NCT01212809|Active Comparator|Juvéderm Ultra|Juvéderm Ultra injection
3232593|NCT01212809|Active Comparator|Cosmoderm 1|Cosmoderm 1 injection
3232594|NCT01212822|Experimental|Treatment (bevacizumab, FOLFOX)|"NEOADJUVANT THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive FOLFOX chemotherapy comprising oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV continuously over 46 hours on days 1-2. Treatment with bevacizumab repeats every 2 weeks for 4 courses and treatment with FOLFOX repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients then undergo planned surgical resection 4-6 weeks after 6 courses of chemotherapy and at least 8 weeks since the last dose of bevacizumab.~ADJUVANT THERAPY: Beginning 8-10 weeks after surgery, patients receive bevacizumab IV, oxaliplatin IV, leucovorin calcium IV, and fluorouracil IV as in neoadjuvant therapy. Treatment repeats every 2 weeks for 6 courses in the absence of disease progression or unacceptable toxicity."
3329937|NCT02091141|Experimental|Vemurafenib Plus Cobimetinib|Participants will receive vemurafenib 960 mg orally twice daily (BID) in each 28-day cycle; and cobimetinib 60 mg orally once daily for 21 days on and 7 days off in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
3329938|NCT02091141|Experimental|Vismodegib|Participants will receive vismodegib 150 mg orally once daily in each 28-day cycle. This treatment arm is now closed for screening and enrollment.
3329939|NCT02091141|Experimental|Alectinib|Participants will receive alectinib 600 mg orally BID in each 28-day cycle.
3329940|NCT02091141|Experimental|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion every 3 weeks.
3329941|NCT02091154|Experimental|USDA Regulations Only|Implement USDA Regulations in assigned school cafeterias during the intervention period.
3329942|NCT02091154|Experimental|USDA Regulations and Marketing Kit|Implement new USDA regulations in assigned schools along with the Marketing Kit during the intervention period.
3329943|NCT02091154|Experimental|USDA Regulations and SLM|Implement USDA Regulations and Smarter Lunchrooms Makeover in assigned schools during intervention period.
3329944|NCT02091154|No Intervention|Control|Schools assigned to this intervention made no changes to their lunchroom or menus.
3329945|NCT02091180|Experimental|Mannitol|Patients will receive 0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
3329946|NCT02091180|Placebo Comparator|Control|Patients will receive normal saline
3329947|NCT02091193||Placebo to Krill Oil|Group 2 receives supplement B for four weeks, undergoes a two week washout period, and then receives supplement A for another four weeks. Measurements are taken at baseline, after supplement B completion and after supplement A completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 2 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
3329948|NCT02091193||Krill Oil to Placebo|Group 1 receives supplement A for four weeks, undergoes a two week washout period, and then receives supplement B for another four weeks. Measurements are taken at baseline, after supplement A completion and after supplement B completion. Participants are informed which supplement was krill oil and which was placebo following completion of this phase of the study. Group 1 participants are given an option to also take an additional 17 weeks of Krill Oil and return for a follow up evaluating the long term use of krill oil.
3329949|NCT02091219|Experimental|25(OH)D3|20 micrograms/day by mouth for 16 weeks
3329950|NCT02091219|Experimental|Vitamin D3|2,400 IU/day by mouth for 16 weeks
3329952|NCT02091297|Active Comparator|TAP BLOCK|One unique regional technique for lower abdominal surgery, that has been shown effective for Cesarean Section in particular, is the transversus abdominis plane (TAP) block, which blocks T6-L1 sensory nerve branches and provides anesthesia to the anterior abdominal wall. The TAP block has been recommended and shown in case reports, but not clinically studied with trials, for patients on methadone or buprenorphine, to improve post-operative pain control. A long active local anesthetic, called ropivacaine, will be used to provide this anesthesia.
3329953|NCT02091297|Active Comparator|Common Care|Common care refers to the common way pain is treated after Cesarean Section: a long-acting spinal or epidural opioid such as morphine, plus oral and IV opioids and non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
3329954|NCT02091297|Active Comparator|Patient Controlled Epidural Analgesia|For post-Cesarean analgesia, another regional technique that has been employed for superior pain control is continued epidural analgesia with local anesthesia and an opioid, either in addition or instead of long acting neuraxial opioids (Cohen). One study revealed equal analgesic efficiency, higher patient satisfaction scores, and less side effects with patient controlled epidural ropivacaine compared to epidural morphine (Chen). This is an especially attractive option for opioid dependent patients, but like the TAP block, has been not studied whether or not it lessens acute or chronic postoperative cesarean section, in the setting or in the absence of neuraxial opioids.
3232595|NCT01212835|Sham Comparator|no ring|Patients at this group will have RING REMOVED AT THE END OF SURGERY.
3232596|NCT01212835|Active Comparator|RYGBP-Ring|Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.
3329955|NCT02091310|Placebo Comparator|Placebo (Study Part I)|Hard gelatin capsules, oral administration, 5 or 6 capsules per day before breakfast with a glass of water
3329956|NCT02091310|Experimental|GFT505 300 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 5 capsules per day before breakfast with a glass of water
3329957|NCT02091310|Experimental|GFT505 360 mg (Study Part I)|Hard gelatin capsules dosed at 60mg, oral administration, 6 capsules per day before breakfast with a glass of water
3329958|NCT02091310|Placebo Comparator|Placebo (Study Part II)|Hard gelatin capsules, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
3329959|NCT02091310|Experimental|GFT505 120 mg (Study Part II)|Hard gelatin capsules dosed at 60mg, oral administration, 2 capsules per day plus 2 to 4 capsules of placebo per day before breakfast with a glass of water
3329960|NCT02091310|Experimental|GFT505 xx mg (Study Part II)|Supra-therapeutic dose: hard gelatin capsules dosed at 60mg, oral administration, 4 to 6 capsules per day before breakfast with a glass of water
3329961|NCT02091310|Active Comparator|Moxifloxacin 400 mg (Study Part II)|On days 1 to 13, 4 to 6 placebo capsules per day, then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14
3232597|NCT01212848|Experimental|TMS|
3329962|NCT02091323|Experimental|BMI<28kg/m2|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI<28kg/m2 group.
3329963|NCT02091323|Other|control|Indicators monitored preoperatively and at 1,3,6,12 months after surgery in BMI>28kg/m2 group as well.
3329964|NCT02091336|Active Comparator|Glyburide|Glyburide 2,5 mg
3329965|NCT02091336|Active Comparator|Metformin|Metformin 500mg bid
3329966|NCT02091349|Placebo Comparator|Group A- placebo|control- snack bar or muffin containing no fiber
3232598|NCT01212848|Sham Comparator|Sham|
3232599|NCT01212861|Experimental|Suprachoroidal Dissection Instrument|
3329967|NCT02091349|Experimental|Group B- polydextrose|polydextrose- randomly bonded polysaccharide of glucose which is poorly digested in small intestine
3329968|NCT02091349|Experimental|Group C- soluble corn fiber|Soluble corn fiber made from corn starch and contains oligosaccharides with random glyucosyl bonds and may contain minor amounts of monosaccharides
3329969|NCT02091388|Experimental|LY03004 25 mg|5 intramuscular injections 25 mg over 113 days
3329970|NCT02091388|Active Comparator|Risperdal® Consta® 25 mg|5 intramuscular injections 25 mg over 113 days
3329971|NCT02091401|Active Comparator|IV|Women randomized into this treatment group will receive magnesium sulfate via an IV loading dose administered manually by study staff and an IV maintenance regimen.
3329972|NCT02091401|Experimental|Springfusor|Women randomized into this treatment group will receive magnesium sulfate via IV infusion (with the Springfusor® pump).
3329973|NCT02091453|Experimental|attention training acute|20 hours of attention training, APT training, or multiprofessional rehabilitation
3329974|NCT02091453|Experimental|attention training subacute|20 hours of attention training, APT training, or multiprofessional rehabilitation
3329975|NCT02091479|Experimental|UFH Early group|anticoagulant (UFH or LMWH) reintroduction at 48h to 72h after hemorrhage
3329976|NCT02091479|Active Comparator|UFH Late group|anticoagulant (UFH or LMWH) réintroduction 120h to 144h after hemorrhage
3329977|NCT02091492|Active Comparator|Teriparatide|Teriparatide 20µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
3232600|NCT01212913|Experimental|group 1: Basal plus|Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
3232601|NCT01212913|Active Comparator|group 2: Biphasic insulin|Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
3232602|NCT01212926|Experimental|analysis of myocardial deformation in 2D strain|
3232603|NCT01212978|No Intervention|Delayed Intervention|These subjects will neither receive a pedometer or access to the motivational software until completion of the study.
3232604|NCT01212978|Active Comparator|Pedometer only|Participants in the this arm will receive a pedometer with instructions to reach a goal of 10,000 steps/day but will not receive access to the motivational software.
3232605|NCT01212978|Experimental|Pedometer + Motivational Software|In this arm, subjects will receive access to both a pedometer and motivational software
3329978|NCT02091492|Placebo Comparator|Placebo-Teriparatide|Placebo-Teriparatide 20 µg daily subcutaneous injection for 12 weeks after proximal humerus fracture
3329979|NCT02091505|Experimental|Intravitreal injection of Ranibizumab|
3329980|NCT02091518|Experimental|MRI|"Add-On Research Patients will include patients who are scheduled for a routine clinical MRI who meet the eligibility requirements for this protocol. Protocol participation will consist of an add-on research. MRI scan, which will be performed any point during of the routine clinical MRI scan.~Volunteers will be subjects expressing interest in participation and who meet the eligibility requirements for this protocol. No contrast enhanced research MRIs including gadolinium-based or other contrast agents will be performed in volunteers."
3329981|NCT02091544||Lifestyle intervention|lifestyle intervention
3329982|NCT02091557||GnRH-analogue|CA125 levels and VAS pain score changes will be assessed after GnRH-a administration in all patients
3329983|NCT02091570|Placebo Comparator|Nutrition bar|50 g nutrition bar
3329984|NCT02091570|Experimental|Nutrition Bar 1|50 g nutrition bar with additional 2 g of milk-based nutrient
3329985|NCT02091570|Experimental|Nutrition bar 2|50 g nutrition bar with additional 3 g of milk-based nutrient
3329986|NCT02091583|Placebo Comparator|Butter, sunflower and safflower oil|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day)daily for 4 weeks.
3329987|NCT02091583|Active Comparator|High Oleic Canola Oil and DHA (HOCO-DHA)|The oil (50g/day) is given in muffin and cookies made with refined wheat flour (3 g/day) daily for 4 weeks.
3329988|NCT02091583|Active Comparator|Barley Beta-glucan|The Barley beta-glucan (3 g/day) is given in muffin and cookies made with a combination of butter, sunflower and safflower oil (50 g/day) daily for 4 weeks.
3329989|NCT02091583|Active Comparator|HOCO-DHA and Barley beta-glucan|The oil and beta-glucan (50g and 3g/day, respectively) is given in muffin and cookies daily for 4 weeks.
3329990|NCT02091596|Placebo Comparator|PluroGel|PluroGel
3329991|NCT02091596|Experimental|PluroGel N|PluroGel N
3329992|NCT02091609|Experimental|group : implants and oral hygiene|dental floss
3329993|NCT02091609|Experimental|implants and oral hygiene|dental interproximal brush
3329994|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
3329995|NCT02091622|No Intervention|No intervention|No intervention.
3329996|NCT02091635|Active Comparator|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
3329997|NCT02091635|Placebo Comparator|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
3329998|NCT02091648|Experimental|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
3329999|NCT02091648|Active Comparator|Standard Education Intervention|"this group will receive the standard American Lung Association Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute recommendations for asthma education."
3232606|NCT01213004|Experimental|thoracic (study group 1) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
3232607|NCT01213004|Experimental|abdominal (study group 2) malignancies|On the same day as the CBCT scans and treatment session, patients will receive a research-only respiration correlated CT (RCCT scan), for calculating motion-corrected CBCT. The localization accuracy of motion-corrected CBCT using same-day RCCT will be compared to that using the standard RCCT from simulation.
3330000|NCT02091648|No Intervention|No treatment control|"This group will receive no treatment during the course of the study and will have the option to receive the Open Airways program after their participation in the study is complete."
3330001|NCT02091661|Active Comparator|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh.surgery started with dissection of the pelvic lymph nodes. If there were no signs of metastasis in frozen sections, the operation was continued with retropubic radical prostatectomy. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing.The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
3232608|NCT01213017|Experimental|Certolizumab pegol|
3232609|NCT01213030|Active Comparator|10 mCi HX4|Patient will be injected with [F-18] FMISO
3330002|NCT02091661|Active Comparator|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
3330003|NCT02091674|Experimental|Hyaluronic acid|All subjects administered hyaluronic acid
3330004|NCT02091700||Normals|Subjects with normal visual and retinal function will be enrolled
3330005|NCT02091713||Experimental/Functional movement screen|300 subjects from three different combat units will undergo functional movement screening
3330006|NCT02091765|No Intervention|Minimal intervention control group|Women who are assigned to the control group will be contacted by telephone by a member of the study staff to inform them about this allocation. They will receive a booklet per mail that addresses 80 questions about sexuality and cancer. Six weeks later, they will receive an empathetic phone call from one of the sexologists, during which there is also time available to discuss further questions the participants may have concerning sexuality and cancer. The purpose of keeping in contact with the control group, as opposed to a pure waiting list control group, is creating the opportunity to provide some control for a possible attention placebo-effect. The final questionnaire will be completed twenty weeks post study entry, after which women will be given the opportunity to undergo the internet-based cognitive behavioral program.
3330007|NCT02091765|Experimental|Internet-based cognitive behavioral therapy|"Each woman who is allocated to the intervention group is assigned a personal sexologist (therapist) who guides her through the internet-based cognitive behavioral therapy (CBT) program and provides feedback on the homework assignments. The CBT program comprises a maximum of ten treatment modules that can be used in varying order. Each module contains three interventions and a personal evaluation form to report on the intervention. Each intervention comprises the following elements: 1) introduction, 2) psycho-education about symptoms, 3) homework assignments (e.g. relaxation techniques (pelvis); discuss intimacy with partner; sensate focus) and 4) reporting back to the therapist and receiving feedback on the homework assignments. Each week there are two practice sessions of 30 minutes each and one hour per week to report on/evaluate the intervention. The therapy has a mean duration of 20 weeks."
3232610|NCT01213030|Active Comparator|10 mCi FMISO|Patient will be injected with [F-18] HX4
3232611|NCT01213056|Active Comparator|Mindfulness Based Cognitive Therapy * (MBCT)|Mindfulness based cognitive therapy aimed to improve coping with, and managing chronic headache pain.
3330008|NCT02091791|Experimental|LT10|"Long duration (30 minutes) traction sessions of low force (10% of body weight) for 2 weeks (5 sessions/week)."
3330009|NCT02091791|Experimental|LT50|"Long duration (30 minutes) traction sessions of high force (50% of body weight) for 2 weeks (5 sessions/week)."
3330010|NCT02091804|Active Comparator|Wait-List group|Individuals randomized to the control group will receive the intervention program immediately after their 3-month research visit.
3232612|NCT01213056|No Intervention|Delayed Treatment Control * (DT)|
3232613|NCT01213069||all 5000 subjects|this is a purely descriptive study with one group
3232614|NCT01213095|Experimental|Rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
3232615|NCT01213108|Experimental|Örebro prevention program|
3330011|NCT02091804|Experimental|Immediate Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
3330012|NCT02091817|Other|Control group|Control group will be administered oxytocin and placebo, in a double-blind randomized order.
3330013|NCT02091817|Experimental|congenital prosopagnosia|Congenital prosopagnosics will be administered oxytocin and placebo in a double-blind randomized order.
3330014|NCT02091830||Non-surgical treatment|
3232616|NCT01213108|Active Comparator|Control|Business as usual
3232617|NCT01213121|Experimental|bipolar depression|unmedicated patients with bipolar depression receiving quetiapine treatment
3330015|NCT02091843|Experimental|DBS of the Amygdala-30 days|Deep brain stimulation of the amygdala BLn starting at 30 days post-operatively.
3330016|NCT02091843|Experimental|DBS of the Amygdala-90 days|Deep brain stimulation of the amygdala BLn starting at 90 days post-operatively.
3330017|NCT02091895|Experimental|endo group|colon polyp, early colon cancer, colorectal submucosal tumor, ileocecal ulcers
3330018|NCT02091908|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
3330019|NCT02091908|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
3330020|NCT02091908|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
3330021|NCT02091908|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
3330022|NCT02091947|Experimental|experimental group|Real FMS, 5 Hz, 20 minutes per day, for 10 weekdays.
3330023|NCT02091947|Sham Comparator|sham group|sham FMS, 5 Hz, 20 min per day, for 10 weekdays.
3330024|NCT02091973|Experimental|Everolimus|everolimus dosing to tough level 6-10 ng/ml
3330025|NCT02091973|Experimental|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
3330026|NCT02092012|Active Comparator|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anesthesia induction
3330027|NCT02092012|Active Comparator|dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
3330028|NCT02092038|Experimental|Preoperative chemoradiation|Stereotactic biopsy of brain tumor, then partial brain irradiation and temozolomide, followed by craniotomy and tumor resection, followed by temozolomide
3330029|NCT02092051|Experimental|Continuous glucose monitoring|Continuous glucose monitoring with DexCom G4 platina during 6 months
3330030|NCT02092051|No Intervention|Conventional therapy|Conventional therapy during 6 months using only SMBG for glucose monitoring
3330031|NCT02092090|No Intervention|Control|Dietary advice at baseline only
3330032|NCT02092090|Experimental|Dietary sodium reduction|Dietary advice and reduced-sodium added-potassium salt substitute
3330033|NCT02092103|No Intervention|Delayed Clamping|"The American Congress of Obstetricians and Gynecologists (ACOG) recommends delayed cord clamping for preterm infants. Infants randomized to this group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Once infant is delivered designated RN starts timer~Infant warming bag on delivery table~Infant placed into warming bag then wrapped in a towel~Assistant to deliver preps cord clamps~Registered Nurse (RN) notifies provider at 30 seconds~Cord clamped and cut~Infant handed off to waiting staff~Exceptions: Placental separation, cord stops pulsating, need for immediate resuscitation, all would result in clamping prior to 30 seconds"
3232618|NCT01213121|No Intervention|Control|healthy controls matched for age, gender, and body mass index
3330034|NCT02092103|Experimental|Cord Milking|"Infants randomized to the cord milking group will follow the protocol below:~Infant held at or below level of perineum (vaginal delivery) or incision (cesarean delivery)~Infant held and the cord is milked from perineum to infant four times~Assistant to deliver preps cord clamps~Cord clamped and cut~Infant handed off to waiting staff"
3330035|NCT02092129||Acromegaly|Patients with acromegaly who have received surgical treatment
3232619|NCT01213147|Experimental|clomiphene citrate,pregnancy,poor responders|Woman in clomiphene citrate arm are administered 100mg/day oral from day 3 of menstrual cycle until day 7 of cycle
3330036|NCT02092142|Experimental|Vaccinated|The vaccine will be administered subcutaneously in the upper outer aspect of the arm (triceps area) with 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105 (which equals 30 μg)
3330038|NCT02092194|Active Comparator|Standard Dose online HDF|Proposed target convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
3232620|NCT01213147|Active Comparator|buserelin,pregnancy,poor responder|women in control arm are administered Buserelin buserelin 50 µg SC twice a day from cycle day 2 of menstrual cycle
3232621|NCT01213160|Experimental|AZD4547|
3232622|NCT01213186|Experimental|Drug: high dose of MSC treatment|Participants will receive high dose of MSC from Day 0 through the Week 48 study visit. Participants will then be followed until the Week 48 study visit.
3232623|NCT01213186|Experimental|low dose of MSC treatment|Participants will receive a low dose of MSC treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
3330039|NCT02092194|Experimental|High Dose online HDF|Proposed target convection volume; 33-43 L/treatment (140-180 mL/min).
3330040|NCT02092207|Experimental|KL7016 900mg|
3330041|NCT02092207|Placebo Comparator|Placebo|
3330042|NCT02092207|Experimental|KL7016 600mg|
3330043|NCT02092233||Blinded, Prospective Arm|The diagnostic accuracy for lesions from individuals suspected of having a herpes infection will be evaluated in prospectively collected, left-over de-identified, clinical specimens accrued between pre-defined dates.
3330044|NCT02092233||Blinded, Pre-selected Arm|For specimen types that are less common, banked, pre-selected, positive clinical specimens will be tested.
3330045|NCT02092246|Active Comparator|Ultrasound Machine Guided Injection|Use of ultrasound machine guidance in needle placement into the knee joint
3330046|NCT02092246|Active Comparator|Unguided Injection|Needle placement performed without ultrasound machine guidance
3330047|NCT02092272|Experimental|instructional exercise video source|instructional exercise video source
3330048|NCT02092272|No Intervention|Standard Therapy|Standard Therapy
3330049|NCT02092337|Experimental|computer assisted speech training|computer assisted speech training
3330050|NCT02092363|Experimental|Drug: OMP-54F28, Paclitaxel and Carboplatin|
3330051|NCT02092376|Active Comparator|Intervention|The loading dose of 300 000 IU is divided into three doses (100 000 IU) and will be given over the first months. All patients in the intervention group will receive the first loading dose of 100 000 IU at day of discharge. The second (2 weeks) and third (4 weeks postoperative) administration will be given based on the 25-hydroxy vitamin D concentration. After the last respectively third loading dose a maintenance dose of 3420 IU per day should maintain the high 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up visit)
3330052|NCT02092376|Placebo Comparator|Placebo|The placebo loading dose (oil) is divided into three administrations and will be given over the first months. All patients in the placebo group will receive the first placebo loading dose at day of discharge. After the last placebo loading dose a maintenance dose of 3420 IU per day should maintain the 25-hydroxy vitamin D concentration. It should be administered for up to 46 weeks (until follow-up).
3330053|NCT02092402|Placebo Comparator|Fecal transplantation of own stool|Autologous fecal transplantation (own stool)
3330054|NCT02092402|Experimental|Fecal transplantation (stool from donor)|Allogeneic fecal transplantation (from donor)
3330055|NCT02092428|Experimental|Image Quality|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to compare image quality between contrast and non-contrast scans.
3330056|NCT02092428|Experimental|Diagnostic Accuracy|Healthy volunteers and patients will undergo non-contrast MRI or contrast-enhanced MRI to assess the diagnostic accuracy of coronary MRI in detecting CAD as compared to conventional x-ray angiography
3330057|NCT02092454|Experimental|Benzocaine|Topical otic solution, every 1-2 hours, for up to 3 days
3330058|NCT02092454|Placebo Comparator|Placebo|Topical otic solution, every 1-2 hours, for up to 3 days
3330059|NCT02092480|Experimental|Intervention|After baseline data collection, four schools will be randomly assigned to the intervention arm, those receiving the If I Were Jack programme. RSE teachers will deliver the intervention to all participating Year 11 pupils during four weekly lessons of the 'Learning for Life and Work' strand of the Key Stage 4 curriculum.
3330060|NCT02092480|No Intervention|Control|After baseline data collection, three schools will be randomly assigned to the control arm. Participating pupils will not receive the If I Were Jack intervention and will continue with normal RSE practice.
3330061|NCT02092493|No Intervention|Non-ScopeGuide|This arm will have patients undertaking the procedure without ScopeGuide. All outcome measures will be recorded as usual
3330062|NCT02092493|Experimental|ScopeGuide|Patients have their colonoscopy done with ScopeGuide
3232624|NCT01213186|Placebo Comparator|low dose of MSC|Participants will receive a saline placebo treatment from Day 0 through the Week 48 study visit, and then follow-ed up for additional 48 weeks.
3330063|NCT02092506|Active Comparator|triple therapy|10 day triple therapy (PPI, amoxicillin 1g, clarithromycin 500mg twice daily)
3330064|NCT02092506|Active Comparator|Concomitant therapy|10-day concomitant therapy (PPI, amoxicillin 1g, clarithromycin 500mg, metronidazole 400mg twice daily).
3232625|NCT01213212|Experimental|Caloric restriction|Caloric restriction
3232626|NCT01213212|Sham Comparator|"Diet ad libitum"|"Diet ad libitum"
3232627|NCT01213238|Experimental|Oxaliplatin + Capecitabine + Bevacizumab|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle. Bevacizumab 10 mg/kg by vein on day 1 of a 21 day cycle.
3330065|NCT02092506|Active Comparator|sequential therapy|10-day sequential therapy (PPI and amoxicillin 1 g twice daily x 5 days followed by PPI, clarithromycin 500mg, metronidazole 400mg twice daily x 5days)
3330066|NCT02092519|Active Comparator|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport (NA-220H-8022)
3330067|NCT02092519|Active Comparator|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport (NA-230H-8020)
3330068|NCT02092532|Other|Intravitreal Aflibercept Injection|All patients will receive monthly IAI 2.0 mg intravitreally for 3 months (Baseline, Months 1 and 2), followed by mandatory IAI 2.0 mg every 2 months (Months 4, 6, 8 and 10) for 12 months.
3330069|NCT02092545|Other|Ketogenic diet|Weight management on a male population of retired NFL athletes.
3330070|NCT02092558||Female 1|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
3330071|NCT02092558||Male 2|Owing to the absence of an established treatment modality for squamous metaplasia of the urinary bladder in children, we developed our own treatment modalities. Children presenting with recurrent urinary tract infections on medical interview, were subjected to ultrasonography of the urinary system, repeated urinalysis, and urine culture tests. Then, on the basis of antibiogram findings, antibiotic and chemotherapeutic treatment was administered to eliminate the bacteriological factors. Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months.
3330072|NCT02092584|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3330073|NCT02092584|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
3330074|NCT02092597|Active Comparator|GLP-1 agonist|Exenatide 5 ug s.c. bid for the 1st month, 10 ug s.c. bid for the next 2 months
3330075|NCT02092597|Active Comparator|DPP-4 inhibitor|Linagliptin 5 mg tbl qd for 3 months
3232628|NCT01213238|Experimental|Oxaliplatin + Capecitabine|Oxaliplatin 140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle. Capecitabine starting dose of 500 mg/m2 by mouth twice daily, on days 1 -14 of a 21 day cycle.
3232629|NCT01213277|Active Comparator|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
3330076|NCT02092597|Active Comparator|Sulfonylurea derivate|Gliclazid 30 mg tbl qd for 3 months
3330077|NCT02092623|Other|Transvaginal posterior mesh surgery|All study patients undergo transvaginal mesh operation.
3330078|NCT02092636|Experimental|NIR/US Diagnostic Group|These patients will include women who have breast lumps/lesions visible by ultrasound and are prescribed follow up with an ultrasound-guided biopsy at the UCHC Cancer Center for evaluation and diagnosis of actual/suspected breast abnormalities.
3330079|NCT02092636|Experimental|NIR/US Neoadjuvant Chemotherapy Group|These patients will include women who have breast lumps/lesions visible by ultrasound and have been diagnosed with breast cancers and will undergo neoadjuvant chemotherapy. These patients may be identified from the diagnostic group or after initial diagnosis. Patients will only be enrolled to one of the two groups.
3232630|NCT01213277|Active Comparator|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
3232631|NCT01213290|Active Comparator|EUS-FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
3330080|NCT02092636|Other|NIR/US Process Validation Group|This group will contain data from about five women who did not have ultrasound visible lumps on the day of the planned biopsy. Data from the NIR/US scan will be used to validate instrument measurements.
3330081|NCT02092675||COPD patients - frequent exacerbator|COPD patients with 2 and more exacerbation in one year
3330082|NCT02092675||COPD patients - non frequent exacerbator|COPD patients with less than 2 exacerbation during one year
3330083|NCT02092675||control group - healthy smokers|healthy smokers, they do not have COPD
3330084|NCT02092688||Study group|Study group: women between 24 and 36 6/7 weeks of gestation that present with self-reported signs, symptoms or complaints suggestive of preterm labor
3330085|NCT02092688||Control group|Control group: women between 24 and 36 6/7 weeks of gestation without signs or symptoms of PTL
3330086|NCT02092701|Experimental|cholecalciferol|
3330087|NCT02092714||Ancillary-correlative (molecular analysis)|Previously collected tissue samples are analyzed via mutational sequencing and immunohistochemistry.
3330088|NCT02092727|No Intervention|Control|Standard of care arm will receive no specific interventions, but will have access to standard educational materials and quality improvement through End Stage Renal Disease Network 6.
3330089|NCT02092727|Experimental|Behavioral Intervention|A variety of dialysis facility-level, behavioral interventions will be examined.
3330090|NCT02092740||Seminoma|Seminoma
3330091|NCT02092740||Non-Seminoma|Non-Seminoma
3330092|NCT02092753|Placebo Comparator|Standard diet|Standard diet (SD): Nutrition following the standard recommendations of the German society for nutrition
3330093|NCT02092753|Experimental|Ketogenic diet|"Nutritional intervention: Ketogenic diet (KD).~Intervention: Nutritional support (hospital) + self support (outpatient phase) with KD"
3330094|NCT02092753|Experimental|Logi diet|"Nutritional intervention: low glycämic and insulinemic diet (LOGI)~Intervention: Nutritional support (hospital) + self support (outpatient phase) with LOGI"
3330095|NCT02092766|Experimental|IV artesunate|Intravenous artesunate 2.4 mg/kg body weight STAT, then 2.4 mg/kg at 12, 24, 48 and 72 hours (5 doses total)
3330096|NCT02092766|Active Comparator|IV quinine|Intravenous quinine dihydrochloride 20 mg salt/kg body weight loading dose over 4 hours, then 10 mg/kg over 2 hours 8 hourly until 72 hours (9 doses total)
3330097|NCT02092779||Obese patients, no treatment|
3330098|NCT02092792|Experimental|Dose-Escalation Phase|
3330099|NCT02092792|Experimental|Dose-expansion cohort|
3330100|NCT02092805|Sham Comparator|Sham rTMS|Sham-rTMS was applied using the same parameters but with the coil elevated and angled away from the head to reproduce some of subjective sensation of rTMS.
3330101|NCT02092805|Active Comparator|Real rTMS|The active group recieved real-rTMS over the motor cortical area corresponding to the hand of painful side. Each train consist of 2000 pulses at 20 Hz and 80% RMT (total duration 10s). The treatment was repeated every day for 5 consecutive days in week for two weeks (the total number of sessions had be given was 10 sessions).
3330102|NCT02092818||Group 1|Patients who have been prescribed Adempas for a medically appropriate use
3330103|NCT02092831|Experimental|Crossover sequence 1|
3330104|NCT02092831|Experimental|Crossover sequence 2|
3330105|NCT02092831|Experimental|Crossover sequence 3|
3330106|NCT02092831|Experimental|Crossover sequence 4|
3330107|NCT02092844|Experimental|CBT for Menopausal Insomnia (CBTMI)|CBTMI is a combination of Cognitive Behavioral Therapy for Insomnia (CBTI) and Cognitive Behavioral Therapy for Hot Flashes (CBTH).
3330108|NCT02092844|Placebo Comparator|Enhanced Treatment as Usual|In the Enhanced Treatment as Usual/Information Control group, participants continue with clinical care of their choosing, but will be enhanced by the provision of 3 American Academy of Sleep Medicine (AASM) brochures.
3330109|NCT02092870|Experimental|Treatment of Chronic Wound|Patients will receive a single treatment with ASCs in the form of multiple injections of cells within and immediately surrounding the wound. Cells will be delivered using a 1 cc syringe with an appropriate gauge and length needle. Each injection will have a volume less than 250 micro-liters. The number of injections will be determined by the surgeon as a function of total wound volume.
3330110|NCT02092883|Experimental|Infantile Spasms|
3330111|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 2|Study 2: Cognitive performance test
3330112|NCT02092896|Experimental|Liraglutide + Insulin + Study 2|Study 2: Cognitive performance test
3330113|NCT02092896|Experimental|Liraglutide + Insulin + Study 1|Study 1: Gastric emptying test
3330114|NCT02092896|Placebo Comparator|Placebo + Insulin + Study 1|Study 1: Gastric emptying test
3232632|NCT01213290|Active Comparator|EUS-FNA without stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
3232633|NCT01213303||Blood donors|Evaluation of cardiovascular risk factors, oxidative stress and fatty acid metabolism in a cohort of blood donors
3330115|NCT02092922|Experimental|Filanesib|
3330116|NCT02092935|Experimental|SMT19969|200 mg capsule of SMT19969 twice a day for 10 days with alternating 200 mg placebo twice a day
3232634|NCT01213342|Experimental|Treatment Group|This group will receive Omega-3 EFA supplements for 8 weeks. They will take 4 capsules/day.
3330117|NCT02092935|Active Comparator|Vancomycin|125 mg capsule four times a day for 10 days
3330118|NCT02092948|Experimental|All patients|Patients will receive one intravenous dose of 4 mg, 20mg or 40 mg of A11 minibody labeled with 5 mCi (185 MBq) of 124I, followed by [124I] PSCA-Minibody PET/CT imaging of the whole body.
3232635|NCT01213342|Placebo Comparator|Placebo Group|This group will receive placebo supplements for 8 weeks. They will take 4 capsules a day.
3232636|NCT01213355|Experimental|Placebo|placebo, plus scopolamine 0.5 mg
3330119|NCT02092974|Experimental|tDCS + SSRI|
3330120|NCT02092974|Placebo Comparator|tDCS + placebo|
3330121|NCT02092974|Sham Comparator|sham-tDCS + SSRI|
3330122|NCT02092974|Placebo Comparator|sham-DCS + placebo|
3330123|NCT02093000||Bevacizumab|Participants who have received the induction phase of 4-6 cycles of bevacizumab plus platinum doublet chemotherapy will be treated with bevacizumab as maintenance treatment, according to approved label and local reimbursement.
3330124|NCT02093013|Experimental|Integrated care program|
3330125|NCT02093013|No Intervention|Control group|This group kept receiving usual care from their health care professionals.
3330126|NCT02093039|Experimental|Decision aid group|Women allocated to the decision aid group received an invitation to participate in the national breast cancer screening program and the specially-designed decision aid (a leaflet), by mail.
3330127|NCT02093039|No Intervention|Control group|Women in the control group received an invitation and the usual standard information by mail.
3330128|NCT02093052|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up - 10 session intervention to enhance nurturance and following the lead
3330129|NCT02093052|Active Comparator|Developmental Education for Families|Developmental Education for Families - 10 session intervention that targets cognitive development
3330130|NCT02093052|No Intervention|Low-risk|Low-risk comparison group
3330131|NCT02093078||CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
3330132|NCT02093078||Control Arm|
3232637|NCT01213355|Experimental|PF-05212377 5 mg, plus scopolamine 0.5 mg;|
3232638|NCT01213355|Experimental|PF-05212377 20 mg, plus scopolamine 0.5 mg;|
3232639|NCT01213355|Experimental|PF-05212377 60 mg, plus scopolamine 0.5 mg;|
3330133|NCT02093091|Sham Comparator|Vitremer|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer (n = 30). The right molars was always filled by Vitremer. A split-mouth design was used in the present clinical trial. Twenty nine children were involved in the present study and every one had one bilateral identical pair of carious molars except one child that had two identical pairs. This design was performed to enhance the accuracy of the present study.
3232640|NCT01213355|Active Comparator|donepezil 10 mg, plus scopolamine 0.5 mg.|
3232641|NCT01213368|Experimental|dronedarone 300 mg|Dronedarone, 100mg + 200mg tablets twice daily, administered with food.
3232642|NCT01213368|Experimental|dronedarone 400 mg|Dronedarone, 400mg tablets twice daily, administered with food.
3232643|NCT01213368|Experimental|dronedarone 600 mg|Dronedarone, 400mg + 200mg tablets twice daily, administered with food.
3330134|NCT02093091|Active Comparator|Ketac Nano|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano (n=30). The left molars was always restored with Ketac Nano filling material.
3330135|NCT02093117|Experimental|Recruitment maneuver|The recruitment maneuver will involve application of continuous positive airway pressure of 30 cm of water for 30 seconds.
3330136|NCT02093117|Sham Comparator|Sham recruitment maneuver|The sham recruitment maneuver will involve application of continuous positive airway pressure of 5 cm of water for 30 seconds.
3330137|NCT02093130|Experimental|Pomegranate Juice|Eight ounces of 100% Pomegranate Juice daily
3330138|NCT02093130|Placebo Comparator|Placebo|Eight ounces of Placebo juice daily. The Placebo is engineered to look and taste the same as the Pomegranate Juice and contains the same vitamins and minerals as the Pomegranate Juice. Because the Placebo juice does not come from actual pomegranates, it does not contain the polyphenols contained in the Pomegranate Juice.
3232644|NCT01213368|Placebo Comparator|placebo|Matching placebo tablets twice daily, administered with food.
3232645|NCT01213381|Experimental|SAR240550|"single cohort: SAR240550~combination cohort: SAR240550 in combination with Gemcitabine and Carboplatin"
3232646|NCT01213394|Experimental|CellCept optimization|
3232647|NCT01213394|Active Comparator|Control|
3330139|NCT02093143|Experimental|Remifentanil|"The general anesthesia during the diagnostic panendoscopy of the upper airway will associate the target controlled infusion of propofol (pharmacologic model of Schnider et al.) and of remifentanil (pharmacologic model of Minto et al.) in the remifentanil group.~The arm will be randomized prior to the beginning of the surgical procedure and blinded to the investigator and to the practitioner in charge of the patient.~Two milligrams of remifentanil will be diluted in 40 cc of sodium chloride 0,9% in a 50 ml syringe."
3330140|NCT02093143|Placebo Comparator|Placebo|"The general anesthesia during the diagnostic panendoscopy of the upper airway will consist in the target controlled infusion of propofol alone (pharmacologic model of Schnider et al.) in the placebo group.~The placebo is a 40 ml sodium chloride 0,9% solution in a 50 ml syringe. No one can distinguish the syringe of placebo from the syringe of remifentanil."
3330141|NCT02093156||training cohort|the training cohort was used to establish the bowel preparation score (BPS)
3330142|NCT02093156||validation cohort|the validation cohort was used to verify the BPS (bowel preparation score)
3330143|NCT02093169|Experimental|Part A: Lu AF35700|
3330144|NCT02093169|Experimental|Part B: Lu AF35700|
3330145|NCT02093195|Experimental|Bosentan|Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.
3330146|NCT02093195|Active Comparator|Control|Inhaled Symbicort turbuhaler, 320/9μg, bid.
3330147|NCT02093260|Experimental|Vaccine|"Vaccine~Flubio (Influenza HA) vaccine~2 doses for infants and children (6 months - 8 years old)~1 doses for children (9-11 years old)~The vaccine will be given intramuscularly"
3330148|NCT02093273|Active Comparator|tOPV commercial batch (Bio Farma)|tOPV (Bio Farma) one dose correspond to 2 drops (0.1ml)
3330149|NCT02093273|Experimental|tOPV pilot batch|tOPV (Bio Farma), one dose correspond to 2 drops (0.1ml)
3330150|NCT02093286||Pentabio Vaccine|1 dose of Pentabio vaccine, 0.5 ml Will be given intramuscularly
3330151|NCT02093299||Stroke|clopidogrel 75 mg
3330152|NCT02093312|No Intervention|Control group|The control group is not offered any home food-delivery service, but continues with their habitual diet
3330153|NCT02093312|Experimental|Intervention group|The intervention group is offered home food-delivery service
3330154|NCT02093325|Experimental|eltrombpag|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days.
3330155|NCT02093325|Placebo Comparator|Eltrombopag/placebo|Eligible patients will be enrolled randomly in 2:1 ratio to Investigational Drug (Eltrombopag) arm, 50 mg/day, or placebo arm for 7 days
3330156|NCT02093338|Experimental|fermentum 3x|Lactobacillus fermentum CECT5716 at 3x10e9 cfu/day
3330157|NCT02093338|Experimental|fermentum 6x|Lactobacillus fermentum CECT5716 at 6x10e9cfu/day
3330158|NCT02093338|Experimental|fermentum 9x|Lactobacillus fermentum CECT5716 at 9x10e9cfu/day
3330159|NCT02093338|Placebo Comparator|maltodextrin|maltodextrin
3330160|NCT02093377|No Intervention|Control|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology alone
3330161|NCT02093377|Active Comparator|Adaptive servo-ventilation|optimal medical therapy for the management of myocardial infarction according to the current guidelines of the European Society of Cardiology plus treatment of sleep apnea with adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia). Dose: The optimal ASV settings will be determined during 1-2 nights monitored by polygraphy within 5 days after PCI.
3330162|NCT02093403|Experimental|Treatment (decitabine and selinexor)|"INDUCTION: Patients receive decitabine IV over 1 hour on days 1-10 and selinexor PO on days 11, 13, 18, 20, 25 and 27. Treatment repeats every 31 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive decitabine IV over 1 hour on days 1-5 and selinexor PO on days 6, 8, 13, 15, 20 and 22. Courses repeat every 31 days in the absence of disease progression or unacceptable toxicity."
3330163|NCT02093416||Group 1: Control Group|BMI <30 There are 20 controls in this group
3330164|NCT02093416||Group 2|BMI 30-35 There were 12 controls in this class
3330165|NCT02093416||Group 3|BMI 35-40 There were 9 controls in this clas
3330166|NCT02093416||Group 4|BMI >40 There were 9 controls in this class
3330167|NCT02093429|Experimental|INCB047986 4 mg|Participants will receive INCB047986 4 mg once daily for at least 16 weeks.
3330168|NCT02093429|Experimental|INCB047986 6 mg|Participants will receive INCB047986 6 mg once daily for at least 16 weeks.
3330169|NCT02093429|Experimental|INCB047986 10 mg|Participants will receive INCB047986 10 mg once daily for at least 16 weeks.
3330170|NCT02093442|Experimental|Endometrial injury|Women allocated to this group will be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
3232648|NCT01213407|Experimental|Standard therapy plus Trivax|Standard therapy with Surgery, Temozolomide, and Radiotherapy; plus Trivax, 5x10e6 autologous interleukine-12 secreting dendritic cells charged with autologous tumour lysate.
3232649|NCT01213407|Active Comparator|Standard therapy|Surgery, Temozolomide, Radiotherapy
3232650|NCT01213420|Experimental|Aloë Vera FORMULA F-BC-096|
3232651|NCT01213420|Active Comparator|Aloë Vera FORMULA F-BC-096 with modified preservative|
3232652|NCT01213420|Active Comparator|Eucerin Calming cream|
3330171|NCT02093442|No Intervention|Control|Women allocated to this group will NOT be submitted to endometrial injury before undergoing endometrial preparation for embryo transfer.
3330172|NCT02093455|Active Comparator|Chardonnay Seed Flour (CSF)|Prepackaged capsules taken 3 times per day. During the first month, the total dose will be 15 g/d. For months 2-4, the total dose will be 30 g/d.
3232653|NCT01213420|Active Comparator|Nivea Cream|
3232654|NCT01213433|Experimental|Amodiaquine+Artesunate|
3232655|NCT01213446|Experimental|Biostate|
3232656|NCT01213459||Cohort A|Women ≥15 years of age attending out-patient departments for routine cervical screening in the Kingdom of Saudi Arabia.
3232657|NCT01213485||Cohort|
3232658|NCT01213498|Active Comparator|Atorvastatin|
3232659|NCT01213498|Placebo Comparator|Unikalk|
3232660|NCT01213511|Active Comparator|MECC Group|Patients operated for elective coronary artery bypass grafting with the use of minimal extracorporeal circulation.
3232661|NCT01213511|Active Comparator|CECC Group|Group of patients undergoing elective coronary bypass grafting with the use of conventional extracorporeal circulation.
3330173|NCT02093455|Placebo Comparator|Placebo|Pre-packaged capsules taken 3 times per day. For the first month, a total of 15 g/d. During months 2 - 4, a total of 30 g/d.
3330174|NCT02093468|Placebo Comparator|Saline|Saline administered IV for 12 hours
3330175|NCT02093468|Experimental|Lower Dose|MST-188 loading dose 100 mg/kg IV for 1 hour followed by 25 mg/kg/hr for 11 hours
3330176|NCT02093468|Experimental|Higher Dose|MST-188 loading dose 200 mg/kg IV for 1 hour followed by 75 mg/kg/hr for 11 hours
3330177|NCT02093481|Experimental|+ ind. CHO + prim|Test meal: ate intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
3330178|NCT02093481|Experimental|- ind. CHO + prim|Reference:ate no intrinsic indigestible carbohydrates 3 days prior to measurements of variables (priming)
3232662|NCT01213537||Patients undergoing clinically indicated CRT implantation|"Patients may be included in the study if they fulfil the following;~Age ≥18 years old~Fulfil the current guidance for the implantation of a CRT device; optimal medical treatment for heart failure, broad QRS complex on electrocardiogram with or without evidence of cardiac dyssynchrony as appropriate, LVEF <35%, functional impairment as defined by an NYHA class of III-IV~Clinically stable with no unplanned admission to hospital for preceding 4 weeks~No changes in medications for heart failure in preceding 4 weeks~Able to read and understand patient information sheet and give informed consent~Patients must be excluded from the study if they fulfil they the following;~On positive pressure treatment for known sleep disordered breathing at the time of inclusion~Other known condition (untreated) likely to significantly disturb sleep eg. Restless legs syndrome, pain from any cause etc.~Pregnancy"
3232663|NCT01213550|Experimental|Chlorhexidine|
3330179|NCT02093481|Experimental|+ ind. CHO - prim|Test meal: ate intrinsic indigestible carbohydrates 1 day prior to measurements of variables (no priming)
3330180|NCT02093481|Experimental|- ind. CHO - prim|Reference: ate no indigestible carbohydrates the day prior to measurements of variables (no priming).
3330181|NCT02093494|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used to collect the blood culture.
3330182|NCT02093494|Active Comparator|Lab standard practice (LSP)|The ISDD will not be used to collect the blood culture. Standard blood culture specimen collection kits will be utilized.
3330183|NCT02093507|Experimental|parents manipulation|parents manipulation
3330184|NCT02093507|No Intervention|no manipulation|no manipulation
3330185|NCT02093533|Experimental|Eculizumab|Patient Body weight ≥40 kg: initial phase 900 mg weekly x 4 and maintenance phase 1200 mg at week 5; then 1200 mg every 2 weeks Patient Body weight 30 - <40 kg : initial phase 600 mg weekly x 2 and maintenance phase 900 mg at week 3; then 900 mg every 2 weeks
3330186|NCT02093546||Ancillary-correlative (Biospecimen collection)|Patients undergo collection of blood at screening, between days 3 and 5, 28, and 56. Patients also undergo collection of tumor biopsy at screening and day 28.
3330187|NCT02093559|Experimental|Brief Counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
3330188|NCT02093559|No Intervention|Control Group|The control group will have access to brochures and be offered referral to services requested. SFDPH Community Behavioral Health Services (CBHS) provides immediate access to substance abuse treatment in San Francisco, including office- and clinic-based methadone and buprenorphine treatment. Given the pilot nature of this study, the control group will not be a full attention control; we will account for an attention effect due to assessment alone.
3330189|NCT02093572|Experimental|Control|Subjects randomized to this group will consume 3 standard meals/day during the 2 week intervention period of the study.
3330190|NCT02093572|Experimental|Breakfast skipping|Subjects randomized to this group will consume 2 meals/day (omit breakfast - with caloric intake equal to consuming 3 meals/day) during the 2 week intervention period of the study.
3330191|NCT02093585|Experimental|Tenofovir to abacavir|Patients switching from tenofovir (245 mg QD) to abacavir (600 mg QD)
3330192|NCT02093585|Experimental|Abacavir to tenofovir|Patients switching from abacavir (600 mg QD) to tenofovir (245 mg QD)
3232664|NCT01213550|Placebo Comparator|Placebo mouthrinse|
3232665|NCT01213563|Experimental|Actrapid insulin|Intensive glycaemic control Intervention: Actrapid insulin
3330193|NCT02093598|Experimental|Temsirolimus|25 mg administered intravenously, infused over a 30- to 60-minute period once weekly for 28 days (Total doses: 4 doses).
3330194|NCT02093611|Placebo Comparator|Placebo|This arm will serve as the placebo supplementation.
3330195|NCT02093611|Active Comparator|ATP|This arm will serve as the treatment intervention, ATP
3330196|NCT02093637|Placebo Comparator|Placebo acupuncture|Placebo acupuncture up to 5 acupuncture needles* in each ear (up to 10 needles total) at points identified by point-finder to have no electrical conductance) plus usual operative and post-operative care (narcotic and non-narcotic pain medication).
3330197|NCT02093637|Experimental|Battlefield Acupuncture|Usual operative and post-operative care (narcotic and non-narcotic pain medication) plus Battlefield Acupuncture (up to 5 acupuncture needles* in each ear (up to 10 needles total), identified by a point-finder.
3330198|NCT02093637|No Intervention|standard therapy|standard therapy
3330199|NCT02093650|Active Comparator|Black cohosh extract|black cohosh extract 80 mg daily
3330200|NCT02093650|Placebo Comparator|Placebo|Matching placebo
3330201|NCT02093676|Experimental|parents counseling|parents counseling guided by the experiment protocol
3330202|NCT02093715||RSV|Infant with acute bronchiolitis due to RSV
3330203|NCT02093715||Co- Infection|Infant with acute bronchiolitis due to RSV and other respiratory virus
3330204|NCT02093715||Other|Infant with acute bronchiolitis due to non-RSV respiratory virus
3330205|NCT02093715||Unknown|Infant with acute bronchiolitis with negative PCR results for respiratory viruses
3330206|NCT02093715||Control|Healthy infants
3330207|NCT02093728|Experimental|selumetinib; itraconazole; selumetinib + itraconazole|Volunteers will receive selumetinib 25mg alone; itraconazole 200mg pre-dosing; selumetinib 25mg and itraconazole 200mg; all adminstered by mouth as a capsule
3330208|NCT02093728|Experimental|selumetinib; fluconazole; selumetinib + fluconazole|Volunteers will receive selumetinib 25mg alone administered by mouth as a capsule; fluconazole 400mg and fluconazole 200mg pre-dosing, administered by mouth as a tablet; selumetinib 25mg and fluconazole 200mg.
3330209|NCT02093741||ADVATE - 2mL|
3330210|NCT02093767|Active Comparator|7.5g dose Synergy1|7.5 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 3.75 g each which are consumed at breakfast and dinner
3232666|NCT01213563|Active Comparator|Actrapid insulin+Gloucose|conventional glycaemic control Intervention: Actrapid insulin+Glucose
3232667|NCT01213602||Femoral block preoperative|In one group (T1) with performance of femoral block before general anesthesia and administration of bolus of local anesthetic through stimulating catheter (combined anesthesia)
3232668|NCT01213602||Femoral block postoperative|In second group (T2) with a administration of local anesthetic through stimulating femoral catheter until awareness of patient (balanced anesthesia).
3232669|NCT01213615||all patients eligible for implantation of a Hancock II Ultra|
3232670|NCT01213628|Experimental|Standard heating|Standard intraoperative warming measures including heated sheets, heating with forced warmed air, warming of fluids, and insulation of limbs and head.
3232671|NCT01213667|Other|ranibizumab as needed|
3330211|NCT02093767|Active Comparator|15g Synergy1|15 g/day dose of Synergy1 (oligofructose enriched inulin 1:1) for 9 weeks. The daily dose is dispersed in two sachets of 7.5 g each which are consumed at breakfast and dinner
3330212|NCT02093780|Experimental|Alberta Anti-inflammatory Diet|Patients randomized into this group will receive a dietary menu plan that contains anti-inflammatory foods/nutrients that have been shown to be effective in the management of IBD in previous studies. The main aim of this diet will be to increase dietary intakes of prebiotics/probiotics, omega 3 fatty acids, fiber (soluble), antioxidants and decrease dietary intake of red and processed meat.
3330213|NCT02093780|Active Comparator|Canada's Food Guide Diet|"Patients that have been randomized into this group will receive simple dietary recommendations based on the Canada's Food Guide. The details of Canada's Food Guide can be available here:~http://www.hc-sc.gc.ca/fn-an/food-guide-aliment/index-eng.php"
3330214|NCT02093806||CT of the temporal bone|
3330215|NCT02093832||Total hip arthroplasty|
3330216|NCT02093845|Active Comparator|SYNERGY|Coronary implantatation of the SYNERGY everolimus-eluting stent
3330217|NCT02093845|Active Comparator|Biomatrix Neoflex|Coronary implantation of the biolimus-eluting Biomatrix NeoFlex stent
3330218|NCT02093858||olanzapine|15-25mg/day for 24 weeks
3330219|NCT02093871|Experimental|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
3330220|NCT02093884|Experimental|Text Messaging Intervention|Patients in the text messaging group will receive educational and motivational text messages.
3330221|NCT02093884|Active Comparator|Standard Referral|Patients in the standard referral arm will receive paper based information about the Family Planning Clinic.
3330222|NCT02093910|Experimental|Monosialotetrahexosylganglioside|each patient in this arm received velcade+dexamethasone (VD) regimen（bortezomib,1.3mg/㎡，subcutaneously injection，d1,8,15,22；dexamethasone,20mg d1-2, 8-9,15-16,22-23）every 4 weeks; and monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.
3232672|NCT01213680|Active Comparator|1000 mg iron isomaltoside as intravenous infusion|
3232673|NCT01213680|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
3330223|NCT02093936||Healthy non exposed|Healthy patients with no pulmonary symptoms that were not exposed to occupational or environmental exposure
3330224|NCT02093936||Healthy exposed|Healthy patients with no pulmonary symptoms that were exposed to occupational or environmental exposure
3330225|NCT02093936||Non-healthy exposed|Patients with pulmonary symptoms or diseases that were exposed to occupational or environmental exposure
3330226|NCT02093936||Non-healthy non-exposed|Patients with pulmonary symptoms or diseases that were not exposed to occupational or environmental exposure
3330227|NCT02093975|Experimental|Video consultation|Patients in this arm receive video consultation from physician in doctor manned rapid response vehicle.
3330228|NCT02093975|Active Comparator|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician in rapid response vehicle.
3330229|NCT02093988|Experimental|Topical and Intravenous TXA|
3330230|NCT02093988|Active Comparator|Intravenous TXA only|
3330231|NCT02094001|Experimental|Riociguat therapy|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
3330232|NCT02094014||Aphasic/Apraxic Participants|"The aphasic/apraxic participant group will include 30 adults who have had strokes affecting their ability to communicate verbally, broadly classified as aphasic and including individuals with and without apraxia of speech (AOS).~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
3330233|NCT02094014||Neurologically Healthy Participants|"The neurologically healthy participant group will include 15 adults with no history of stroke or developmental speech or language disorder.~Participants will speak under Masked Auditory Feedback, Altered Auditory Feedback, and Normal Auditory Feedback."
3330234|NCT02094027|Experimental|Guided Self Help|Guided Self Help intervention to reduce binge eating
3232674|NCT01213693|Experimental|ICS/LABA group|Patients assigned to this arm will take bid 50/500 mcg fluticasone/salmeterol combination
3232675|NCT01213693|Active Comparator|LABA group|Patients assigned to this arm will take bid 50 mcg salmeterol
3232676|NCT01213719|Experimental|creatine|will receive creatine monohydrate (20g/d) throughout 10 days
3330235|NCT02094027|Placebo Comparator|Treatment As Usual|No intervention for binge eating (treatment as usual in the form of bariatric surgery)
3330236|NCT02094040|Experimental|Follow-up visit|Receive municipality-based follow-up visit including primary physician.
3330237|NCT02094040|No Intervention|Usual care|Does not receive follow-up visit
3330238|NCT02094053|Experimental|E2020 3 mg|3 mg of E2020 (oral) once daily, for 24 weeks
3330239|NCT02094053|Experimental|E2020 5 mg|5 mg of E2020 (oral) once daily, for 24 weeks
3330240|NCT02094053|Placebo Comparator|Placebo|placebo (oral) once daily, for 24 weeks
3330241|NCT02094066|Active Comparator|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
3330242|NCT02094066|Sham Comparator|serum physiologic|preoperative 100 cc serum physiologic
3330243|NCT02094079||L-T4 treated hypothyroid pregnant women|L-T4 treated pregnant women
3330244|NCT02094092|Placebo Comparator|ProTectis drops|Arm A.
3330245|NCT02094092|Placebo Comparator|Placebo drops|Arm B
3330246|NCT02094105|Experimental|screening|endoscopy examination with iodine staining
3330247|NCT02094105|No Intervention|control|1/10 sampling questionnaire interview for control group.
3330248|NCT02094131|Experimental|Cliniflo group (CG)|Training using flow-oriented incentive spirometry Cliniflo
3330249|NCT02094131|Experimental|Voldyne group (VG)|Training using volume-oriented incentive spirometry Voldyne
3330250|NCT02094131|No Intervention|Control group (CONG)|No intervention. Assessment and reassessment after 5 weeks.
3330251|NCT02094144|Other|exercise group (brisk walking program)|The intervention is named brisk walking program. It consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
3330252|NCT02094144|Other|control group (physical activity habits)|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
3330253|NCT02094157|Active Comparator|Bridged regimen|Bridged regimen Warfarin therapy is stopped for 5 days before surgery and restarted in the evening of surgery at double the usual dose for two days. Bridging with low-molecular-weight heparin at therapeutic dose is given for 2½ days before surgery.
3330254|NCT02094157|Experimental|Tapered warfarin regimen|Tapered warfarin regimen Warfarin is given at half the usual maintenance dose for 3-6 days before surgery depending on the INR at the baseline visit. A double dose is given in the evening of surgery. No bridging with LMWH is used.
3330255|NCT02094183|Experimental|GLP-1|GLP-1 and low calorie diet
3330256|NCT02094183|Experimental|Control|low calorie diet
3330257|NCT02094196||Controls, highrisk for AD|Community-based ad-hoc participants, high risk for alcohol dependence, matched to inpatients by sociodemographics
3330258|NCT02094196||Controls, low risk for AD|Community-based ad-hoc participants, low risk for alcohol dependence, matched to inpatients by sociodemographics
3330259|NCT02094196||Alcohol detoxification|Inpatients with alcohol dependence from local psychiatric hospital wards (18-65 years old)
3330260|NCT02094235|Experimental|1|E6005 0.2% ointment applied twice a day to eczema areas
3330261|NCT02094235|Experimental|2|E6005 0.05% ointment applied twice a day to eczema areas
3330262|NCT02094235|Placebo Comparator|3|Placebo ointment applied twice a day to eczema areas
3330263|NCT02094248|Experimental|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
3330264|NCT02094248|Placebo Comparator|control|Normal saline，1ml/day, s.c injection
3330265|NCT02094274|Experimental|LAS40468|Single dose, administered via Genuair® dry powder inhaler (DPI)
3330266|NCT02094274|Active Comparator|Salmeterol/fluticasone propionate|Single dose, Seretide® (salmeterol fluticasone propionate) administered via Accuhaler™
3330267|NCT02094274|Placebo Comparator|Placebo|Single dose administered via Genuair® or Accuhaler™ dry powder inhaler (DPI)
3330268|NCT02094287|Experimental|verum, instruction, conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. One classical conditioning process with saline was applied during the skin prick test procedures.
3232677|NCT01213719|Experimental|betaine|will receive betaine (2g/d) throughout 10 days
3232678|NCT01213719|Placebo Comparator|placebo (dextrose)|will receive dextrose(20g/d)throughout 10 days.
3232679|NCT01213719|Active Comparator|creatine plus betaine|will receive creatine (20g/d) plus betaine (2g/d) throughout 10 days
3330269|NCT02094287|Experimental|verum, instruction, no conditioning|This group received dimetindene and instructions about dimetindene and its effectiveness. No conditioning process were applied
3330270|NCT02094287|Experimental|placebo, instruction, conditioning|This group received a placebo (saline) as intravenously administered substance. But instructions about receiving dimetindene and its effectiveness were given. One classical conditioning process was applied during the skin prick test procedures.
3232680|NCT01213732|Experimental|L19TNFα plus melphalan|Subjects will be sequentially assigned to one of 2 dose levels of L19TNFα: 325 µg or 650 µg. All subjects will receive a single dose of L19TNFα and Melfalan (10mg/ L Limb volume).
3330271|NCT02094287|Experimental|verum, no instruction, no conditioning|Dimetindene was covertly administered (unawareness of treatment). No instruction and no conditioning were given.
3330272|NCT02094313|Experimental|atovastatin|
3330273|NCT02094339|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
3330274|NCT02094339|Active Comparator|Nerve Block|People in this group will receive a postoperative pain management by continuous lumbar plexus block with 0.2% ropivacaine.
3330275|NCT02094339|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
3330276|NCT02094365|Experimental|ALS-008176|ALS-008176 drug substance for oral suspension
3330277|NCT02094365|Placebo Comparator|vehicle alone|Vehicle alone
3330278|NCT02094378|Experimental|Esketamine-Placebo|Participants assigned to treatment sequence 1 will receive 84 mg esketamine intranasally on Day 1 of Period 1 and then receive placebo intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
3330279|NCT02094378|Placebo Comparator|Placebo-Esketamine|Participants assigned to treatment sequence 2 will receive placebo intranasally on Day 1 of Period 1 and then receive 84 mg esketamine intranasally on Day 1 in Period 2. Periods 1 and 2 will be separated by 7 days.
3330280|NCT02094391|Experimental|Ipilimumab|
3330281|NCT02094391|No Intervention|No Ipilimumab|
3330282|NCT02094404||Children at the ED<18yr|
3330283|NCT02094430|Experimental|FGTW|
3330284|NCT02094456|Experimental|Endoscopic clipping of diverticula|Endoscopic clipping of diverticula Follow-up colonoscopy
3330285|NCT02094469|Other|Cilostazol|Cilostazol 50mg and 100mg
3330286|NCT02094482|Other|OSAS Palatal Implant|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate .
3232681|NCT01213745|Experimental|Intervention|
3232682|NCT01213745|Experimental|Attention|
3232683|NCT01213745|Active Comparator|Control|
3330287|NCT02094495||breast cancer group|Taking tamoxifen
3330288|NCT02094521|Experimental|NNC0113-0987|
3330289|NCT02094547|Experimental|New infant formula|New infant formula with key ingredients.
3330290|NCT02094547|Active Comparator|Standard infant formula|Standard infant formula
3330291|NCT02094547|Other|Breastfeeding|Control
3232684|NCT01213758||Liver tumors|Patients where stereotactic body radiation therapy is planned for primary or metastatic liver tumors.
3232685|NCT01213771|No Intervention|Preoperative care 2009|Patients are receiving the usual care
3232686|NCT01213784|Experimental|optimized diabetic control|each participant will be assigned to be optimized in a dedicated diabetic clinic
3330292|NCT02094560|Experimental|Small cell lung cancer|Histologically- or cytologically-confirmed, limited and extensive SCLC disease with progression after first or second line treatment
3330293|NCT02094560|Experimental|Non small cell lung cancer|Histologically- or cytologically-confirmed diagnosis of NSCLC with Stage IIIB or IV after failure of at least two lines of therapy
3330294|NCT02094560|Experimental|biliary tract cancer|Histologically or cytologically confirmed diagnosis of biliary tract cancer progress after first line therapy
3330295|NCT02094599|Experimental|All Enrolled Participants|Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.
3330296|NCT02094625|Experimental|N-Acetylcysteine Intervention|"This is a dose-finding study using a traditional 3+3 dose escalation scheme. Up to 18 subjects (3 dose levels as per below) will be enrolled to determine the maximum tolerated dose (MTD). The MTD is defined as per traditional 3+3 criteria of less than or equal to one dose-limiting toxicity at the dose level. Once the MTD is determined, subjects will be equally distributed at the safe dose levels (less than or equal to the MTD) to determine the optimum dose to achieve NAC levels in the blood necessary for hearing protection.~As of August 2018: The dose-escalation phase was completed and dose-level three was selected for expansion in 9 subjects."
3330297|NCT02094625|No Intervention|Observation only|"Subjects who are ineligible to receive the study drug NAC will have the option to enroll for study assessments only including laboratory testing and hearing assessments identical to the experimental intervention arm. This is a cohort of convenience for which we anticipate up to 36 children will be enrolled over the course of the study."
3330298|NCT02094638||Tanreqing|Inpatient using the Tanreqing Injection
3330299|NCT02094651|Experimental|divalproex sodium|divalproex sodium will be administered in sprinkle capsule formulation, target dose of 30mg/kg, drug will be administered for 12 weeks
3232687|NCT01213784|No Intervention|control|participants will be assigned to follow what ever control they were in before the study and not to change any antidiabetic treatment during the interventions period.
3232688|NCT01213797||Suicide attempter and its entourage|"Suicide attempter and its close relatives (who are living under the same roof)~Comparison of the population of the close relations of committing suicide with the data of the Research Institute and Documentation in Economy of Health (IRDES) on the French population (sample of 20.000 people, representative of 95% of the French households)."
3330300|NCT02094651|Placebo Comparator|Placebo|Blue and white capsules with equivalent amount of lactose spheres/beads inside Placebo will be formulated to look identical to the active medication
3330301|NCT02094690|Active Comparator|Device Hyperboloid|"5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy (RT) and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
3330302|NCT02094690|Active Comparator|Device Therabite|"10 repetitions holding the device Therabite for 30 seconds~5 min of bilateral mastication alternated with the device hyperboloid The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT.~Repeated 4x a day (after breakfast, lunch, dinner and before going to bed)."
3330303|NCT02094690|No Intervention|Control|The control group (GEC) will not receive any of the protocols tested in the study, but together with the other groups, will receive the regular treatment offered by the institution, which is made up of guidance and advice given by the hospital´s nursing team about the radiotherapy treatment. Currently, patients do not receive any information as far as trismus is concerned.
3330304|NCT02094703|Experimental|levofloxacin and solifenacin succinate|Levofloxacin 500 mg tablet and solifenacin succinate 5 mg tablet by mouth once daily for 3 days
3330305|NCT02094703|Active Comparator|levofloxacin and placebo|Levofloxacin 500 mg tablet and placebo (for solifenacin succinate) by mouth once daily for 3 days
3330306|NCT02094729|Experimental|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
3330307|NCT02094729|Experimental|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
3232689|NCT01213849|Experimental|200/100 mcg fluticasone furoate/vilanterol|4 inhalations of 50/25 mcg fluticasone furoate/vilanterol
3232690|NCT01213849|Experimental|400/100 mcg fluticasone furoate/vilanterol|4 inhalations of 100/25 mcg fluticasone furoate/vilanterol
3232691|NCT01213849|Experimental|800/100 mcg fluticasone furoate/vilanterol|4 inhalations of 200/25 mcg fluticasone furoate/vilanterol
3232692|NCT01213862|Experimental|intervention and control|"Group I - Intervention: Routine follow-up in a reference health institution with four home visits and four telephone contacts with specialist nurses.~Group II - Control: Routine follow-up with the health team in the reference institution."
3330308|NCT02094729|Experimental|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
3330309|NCT02094729|Placebo Comparator|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
3232693|NCT01213875|Experimental|Experimental: Intervention and control|"I: Experimental Routine monitoring by health team in the reference institution, four home visits and four telephone contacts with trained nurses.~II: Control Routine monitoring by health team in the reference institution."
3232694|NCT01213875|No Intervention|Control|
3232695|NCT01213888|Experimental|Arm II|
3330310|NCT02094742|Other|all-commers|All patients will undergo a biopsy of their metastatic lesion and have a blood sample taken for molecular screening purposes. No drugs are administered or other interventions are performed.
3330311|NCT02094768|Experimental|Reduced Fat Milk|20 oz. reduced fat (2%) milk per day
3330312|NCT02094768|Experimental|Sugar Sweetened Soda|24oz. soda per day
3330313|NCT02094781|Experimental|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3330314|NCT02094781|Active Comparator|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3330315|NCT02094781|Placebo Comparator|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
3330316|NCT02094794|Experimental|Treatment (TMLI, chemotherapy)|Patients undergo image guided TMLI on days -9 to -5, receive etoposide IV on day -4 and cyclophosphamide IV on day -2, and undergo allogeneic peripheral blood stem cell or bone marrow transplant on day 0.
3330317|NCT02094807|Other|Conservative management|Not operated. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
3330318|NCT02094807|Active Comparator|Operative management|Operative fixation of rib fractures. Thoracic epidural anesthesia will be used togeteher with paracetamol. If not sufficient opioids and NSAID will be added.
3330319|NCT02094820||Single Group Study|Questionnaires
3330320|NCT02094833|Experimental|Group A|Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
3330321|NCT02094833|Active Comparator|Group B|Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
3330322|NCT02094846|Active Comparator|Voice messages|This group receive voice messages to reinforce given information about diet, physical activity, glycemic index
3330323|NCT02094846|Placebo Comparator|Messages|This group received voice messages with fun facts.
3330324|NCT02094859||GlucoClear System|
3330325|NCT02094911|Experimental|Combined lifestyle intervention|Lifestyle counselling (nutrition and physical activity) by dietician and physiotherapist during 10-month intervention period
3330326|NCT02094911|Other|Usual care group|Subjects receive brochures on healthy lifestyle at baseline, and during the 10-month intervention period only usual care as provided by their own general practitioner.
3330327|NCT02094924|Experimental|Sequence 1|Participants in this arm will receive treatment A in period 1 and treatment B in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
3330328|NCT02094924|Experimental|Sequence 2|Participants in this arm will receive treatment B in period 1 and treatment A in period 2. Subjects will receive a single reference FDC tablet of 16mg candesartan cilexetil/12.5mg HCTZ as Treatment A administered orally with 240mL of water and a single 16mg candesartan cilexetil/12.5mg HCTZ FDC tablet (GSK587323) as Treatment B.
3232696|NCT01213888|Placebo Comparator|Arm I. Placebo + Pan-Retinal Photocoagulation|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
3232697|NCT01213901|Experimental|1|"Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.~Injections will be given in a random order and the technician will be blinded to the injection.~Each patient will evaluate the comfort of the injection by completing a visual analog scale."
3330329|NCT02094950|Experimental|Lung Cancer Patient with Dyspnea|
3330330|NCT02094963|Experimental|Ticagrelor|
3330331|NCT02094963|Active Comparator|Clopidogrel|
3330332|NCT02094976|Active Comparator|Group C|Group C means active comparator group which use chest rolls intraoperatively for prone position.
3330333|NCT02094976|Active Comparator|Group W|Group W means experimental group which use Wilson frame intraoperatively for prone position.
3330334|NCT02094976|Experimental|Group J|Group J means experimental group which use Jackson surgical table intraoperatively for prone position.
3330335|NCT02094989||diagnostic|
3330336|NCT02095015||Analysis population|All subjects enrolled in the study who meet the eligibility criteria
3330337|NCT02095028|Experimental|Dietary and lifestyle intervention|Intervention group:Based on standard care,intensive dietary and lifestyle intervention was provided. Initiated from the first trimester to delivery,every 2-4 weeks follow-up
3330338|NCT02095028|No Intervention|Standard care group|Standard care group:Participants received one group session in which prenatal general dietary, nutrition guideline, physical activity and recommendation for gestational weight gain introduced by a registered dietitian in 1.5hours.Participants received their regularly scheduled visits without additional dietary and lifestyle follow-up and guidance.
3330339|NCT02095041||Healthy Term infants|
3232698|NCT01213914|Experimental|High-volume hemofiltration at 70ml/kg/hr|Paired randomization into four groups via central randomization center. Group 1: age 18-65 and <40%TBSA Group 2: age 18-65 and >40%TBSA Group 3: age >65 and <40%TBSA Group 4: age >65 and >40%TBSA
3232699|NCT01213914|Active Comparator|Control group|Contemporary care via consideration of the Burn-Specific Sepsis Bundle adapted form the most recent Surviving Sepsis campaign recommendations and specifically modified to our patient population.
3232700|NCT01213979|Active Comparator|1000 mg iron isomaltoside 1000 as intravenous infusion|
3330340|NCT02095054|Experimental|Regorafenib + Cetuximab|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle. Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group.~Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle. Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group.~Symptom questionnaire completed at each study visit."
3330341|NCT02095067|Experimental|Video consultation|Patients in this arm receive video consultation from physician at the emergency medical dispatch center
3330342|NCT02095067|No Intervention|Telephone consultation|Patients receiving prehospital care by ambulance personnel whom receive telephone consultation/supervision by physician at the emergency medical dispatch center.
3330343|NCT02095080|Experimental|Leucine intake|Dietary supplement: Leucine intake
3232701|NCT01213979|Active Comparator|500 mg iron isomaltoside 1000 as bolus injection|
3330344|NCT02095093|Experimental|Intellijoint HIP|Patient's will have their leg length and hip offset determined intraoperatively using Intellijoint HIP.
3232702|NCT01213992|Active Comparator|Monofer® 500 mg|500 mg iron isomaltoside 1000
3232703|NCT01213992|Active Comparator|Monofer® 1000 mg|1000 mg iron isomaltoside 1000
3232704|NCT01214005|Experimental|schizophrenia|Smokers with schizophrenia or schizoaffective disorder
3330345|NCT02095093|Active Comparator|Outrigger|Control patients will have their leg length and hip offset determined intra-operatively using the standard at Mount Sinai Hospital, which is a pin and outrigger system.
3330346|NCT02095132|Experimental|Treatment (irinotecan hydrochloride, adavosertib)|Patients receive irinotecan hydrochloride PO and adavosertib PO on days 1-5. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity.
3330347|NCT02095171|Experimental|PRX002|
3330348|NCT02095171|Placebo Comparator|Placebo|
3330349|NCT02095184|Active Comparator|Cohort 1: Normal Weight Anastrozole|Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
3330350|NCT02095184|Active Comparator|Cohort 2: Overweight Anastrozole|Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
3330351|NCT02095184|Active Comparator|Cohort 3: Obese|Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
3330352|NCT02095184|Active Comparator|Cohort 4: Normal Weight Letrozole|Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
3330353|NCT02095184|Active Comparator|Cohort 5: Overweight Letrozole|Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
3330354|NCT02095184|Active Comparator|Cohort 6: Obese Letrozole|Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
3330355|NCT02095210|Experimental|[68Ga]ABY-025 PET imaging|Radiolabeled [68Ga]ABY-025
3330356|NCT02095236|Experimental|experimental|Radioopaque fiducial markers or electro-magnetic transponders will be implanted into or in close proximity of the tumor. During a radiotherapy treatment session image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors The data will help to characterize tumor and organ motion during one treatment session which may in fact have impact on dose distribution
3330357|NCT02095249|Other|Pimonidazole|
3330358|NCT02095262|Active Comparator|STAR2|Reactive auditory training
3330359|NCT02095262|Experimental|Treasure Hunter|Interactive auditory training
3330360|NCT02095262|Experimental|Submarine|Interactive auditory training
3330361|NCT02095275||Acute kidney injury|ICU patients with Acute kidney injury
3330362|NCT02095288||Healthy volunteers|Blood draw
3330363|NCT02095301|Experimental|Control plus herbal extract|Control plus herbal extract
3330364|NCT02095301|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
3330365|NCT02095314|Experimental|Pentavalen|Pentabio Vaccine One dose corresponds to 0.5ml The vaccine shall be given intramuscularly
3330366|NCT02095366|Experimental|IN Sufentanil AND IV Placebo|Patient receives silmutaneously intranasal sufentanil spray AND intraveinous placebo administration
3330367|NCT02095366|Active Comparator|IV Morphine AND IN Placebo|Patient receives silmutaneously intraveinous morphine administration AND intranasal placebo spray
3330368|NCT02095379||oligosecretary|Multiple myeloma (MM) characterized by low levels of serum and urine monoclonal (M) protein below thresholds of measurable disease (a serum M protein ≥ 1g/dL, a urine M protein ≥ 200mg/day)
3330369|NCT02095392|Experimental|P1000/Ca0|
3330370|NCT02095392|Experimental|P1000/Ca500|
3330371|NCT02095392|Experimental|P1000/Ca1000|
3330372|NCT02095392|Placebo Comparator|Placebo|
3330373|NCT02095405|Active Comparator|Caffeine arm|"SVT group: Caffeine tablets, 5 mg/kg.~AF group: Caffeinated substances and Dark Chocolate"
3330374|NCT02095405|Placebo Comparator|Placebo arm|"SVT group: Placebo~AF group: Decaffeinated substances and White Chocolate"
3330375|NCT02095418|Experimental|Mycophenolate mofetil, Corticosteroids|"Mycophenolate mofetil: 500-1500mg/day, bid, PO~Corticosteroids: 500mg for the first dosage. It will be tapered at least 5mg for 14days and withdrawn"
3330376|NCT02095418|Active Comparator|Corticosteroids, Mycophenolate mofetil|"Mycophenolate mofetil: 500-1000mg/day, bid, PO~Corticosteroids 500mg for the first dosage. It will be tapered at least 5mg for 3months(± 2 weeks) and withdrawn."
3232705|NCT01214005|Other|non-psychiatric|smokers without psychiatric illness
3232706|NCT01214018||Reference|Nearest relatives of brain-dead patients who donated organs
3330377|NCT02095431||with AKI and without AKI|development of AKI by sCr and by novel biomarkers
3330378|NCT02095444|Experimental|Menstrual blood stem cells|1x10*7 cells/kg, IV(in the vein) twice a week. Number of course for two weeks.
3330379|NCT02095457|Active Comparator|Frequent Monitoring and Feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
3330380|NCT02095457|Sham Comparator|Infrequent monitoring without feedback|In the control arm, patients will infrequently fill short monitoring questionnaires, the results of which are not fed back to their therapists and staff. The frequency of monitoring is between about once a year
3232707|NCT01214018||Opposition|Nearest relatives of brain-dead patients opposed to organ donation
3330381|NCT02095470|Experimental|videolaryngoscope group|video laryngoscopy was done for them
3330382|NCT02095470|Placebo Comparator|traditional laryngoscope|comparison to active group with routine laryngoscope
3330383|NCT02095496|Experimental|Intellivent-ASV|Patients will receive Intellivent-ASV ventilation during 12 hours
3330384|NCT02095496|Active Comparator|Conventional ventilation|Patients will receive pressure support ventilation during 12 hours
3330385|NCT02095509|Active Comparator|Subcutaneous Enoxaparin|Subcutaneous enoxaparin 40 mg every 24 hours for three days
3330386|NCT02095509|Active Comparator|Intravenous Enoxaparin|40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)
3330387|NCT02095522|Experimental|Colchicine|Colchicine 1mg per day for one month
3330388|NCT02095522|Placebo Comparator|Placebo|Placebo 1mg per day
3330389|NCT02095548|Experimental|SM04690, 0.03mg/2mL|Single, intra-articular injection of SM04690, 0.03mg/2mL
3330390|NCT02095548|Experimental|SM04690, 0.07mg/2mL|Single, intra-articular injection of SM04690, 0.07mg/2mL
3232708|NCT01214018||Medical/Legal|Nearest relatives of brain-dead patients for whom organ donation was not an option because of medical or legal reasons
3232709|NCT01214031|Other|Confocal Laser Endomicroscopy Arm|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy.
3330391|NCT02095548|Experimental|SM04690, 0.23mg/2mL|Single, intra-articular injection of SM04690, 0.23mg/2mL
3330392|NCT02095548|Placebo Comparator|Placebo|Single, intra-articular injection of placebo
3330393|NCT02095574|Experimental|[14C]ABT-199|Subjects with relapsed or refractory Non-Hodgkin's Lymphoma
3330394|NCT02095587|Experimental|Mild Hepatic Impairment|
3330395|NCT02095587|Experimental|Moderate Hepatic Impairment|
3232710|NCT01214070|Active Comparator|Arm 1|Group 1 - Combination Treatment
3330396|NCT02095587|Experimental|Healthy Subjects|
3330397|NCT02095587|Experimental|Severe Hepatic Impairment|Optional arm based on results from Arms 1, 2, and 3
3232711|NCT01214070|Active Comparator|Arm 2|Group 2 - Combination Treatment
3232712|NCT01214070|Active Comparator|Arm 3|Group 3 - Combination Treatment
3232713|NCT01214070|Active Comparator|Arm 4|Group 4 - Combination Treatment
3232714|NCT01214070|Active Comparator|Arm 5|Group 5 - Monotherapy Treatment
3232715|NCT01214070|Active Comparator|Arm 6|Group 6 - Monotherapy Treatment
3232716|NCT01214070|Active Comparator|Arm 7|Group 7 - Monotherapy Treatment
3232717|NCT01214096|Placebo Comparator|placebo|
3232718|NCT01214096|Experimental|rhNRG-1|recombinant human neuregulin-1
3232719|NCT01214122|Experimental|Treatment A|AZD9668 - 2 x30mg tablets
3232720|NCT01214122|Experimental|Treatment B|Warfarin - 10 x2.5 mg tablets
3232721|NCT01214135||1|Patients with a diagnosis of schizophrenia who have been hospitalized and received at least one dose of Seroquel XR or Seroquel IR during the study period (1st of July 2009 - 30th of September 2010).
3232722|NCT01214148|Other|ORSIRO|
3232723|NCT01214226|Active Comparator|Pentoxifylline + Prednisolone|"Pentoxifylline 400 mg prolonged-released tablets 3 time a day [1200 mg/day]~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
3232724|NCT01214226|Placebo Comparator|Placebo + Prednisolone|"Placebo prolonged-release tabled 3 time a day~+ Prednisolone 2 ORODISPERSIBLE TABLETS OF 20 MG 1 TIME PER DAY [40 mg/day]"
3232725|NCT01214278|Experimental|Supplement 1|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil uncoated capsules
3232726|NCT01214278|Experimental|Supplement 2|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG)
3232727|NCT01214278|Experimental|Supplement 3|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules
3232728|NCT01214278|Experimental|Supplement 4|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL)
3232729|NCT01214304|Placebo Comparator|Lavender Scent|Patients will receive aromatherapy with a fake lavender scent (placebo) which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
3232730|NCT01214304|Experimental|Essential Lavender Oil|Patients will receive essential Lavender Oil which will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure.
3232731|NCT01214343|Experimental|Sorafenib with Low-dose FP|
3232732|NCT01214343|Active Comparator|Sorafenib|
3232733|NCT01214369|Active Comparator|X-tip intraosseous injection|
3232734|NCT01214369|Active Comparator|PDL injection|
3232735|NCT01214382|Experimental|Sertraline|
3232736|NCT01214408|Experimental|GRP-A|
3232737|NCT01214408|Experimental|GRP-B|
3330398|NCT02095600|Experimental|Radiosurgical thalamotomy|
3330399|NCT02095613|Active Comparator|Corn-soy-blend plus|food A type of ground meal called corn-soy-blend plus
3330400|NCT02095613|Active Comparator|Ready-to-use-supplementary food|food A nutrient dense food comprised of peanuts, oil, multivitamins.
3330401|NCT02095626|Experimental|AP301|Treatment group
3330402|NCT02095626|Placebo Comparator|Saline solution|
3330403|NCT02095639||ECT and Treatment Resistant Depression|Subjects will be those with diagnosis of major depressive disorder that have not responded to many different treatments and who are planning to take electroconvulsive therapy (ECT). This group will receive two [18F]FEPPA PET scans, one baseline and one after an average of 2.5 weeks of ECT treatments.
3330404|NCT02095665|Active Comparator|Narcotic analegesic only|"Drug:~Tylenol #3 1 tablet every six hours as necessary"
3330405|NCT02095665|Active Comparator|Mirabegron and narcotic analgesia|"Drug :~Mirabegron 50 mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
3330406|NCT02095665|Active Comparator|Tamsulosin and narcotic analgesia|"Drug:~Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary"
3330407|NCT02095665|Experimental|Mirabegron, Tamsulosin and narcotic|"Drug:~Mirabegron 50 mg oral daily~Drug:~Tamsulosin 0.4mg oral daily~Drug:~Tylenol #3 1 tablet every six hours as necessary"
3330408|NCT02095704|Experimental|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
3330409|NCT02095704|Experimental|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
3330410|NCT02095717|Experimental|Curcumin|curcumine capsule
3330411|NCT02095717|Placebo Comparator|Placebo|placebo capsule
3232738|NCT01214447||Low - OSND less than 22|
3232739|NCT01214447||Moderate - OSND score 23-27|
3232740|NCT01214447||Normal - OSND score 28-32|
3232741|NCT01214460||All MET calls|We make an Utstein type analyze to all MET calls
3232742|NCT01214460||All EMS calls|We make an Utstein type analyze to all EMS calls during June 2015
3232743|NCT01214460||All patient in the emergency department|We make an Utstein type analyze to all Emergency visits during June 2015
3232744|NCT01214473|Experimental|Probiotic group|Once daily oral administration of a probiotic preparation (1 billion cells of Lactobacillus plantarum and 150 mg of fructooligosaccharides) for one week to newborn infants
3232745|NCT01214473|Placebo Comparator|Placebo|Once daily oral administration of maltodextrin for one week to newborn infants
3232746|NCT01214486|Experimental|Raltegravir|
3232747|NCT01214499|Active Comparator|Treatment Control|Transmyocardial revascularization (TMR) with Holmium YAG (yttrium aluminium garnet) laser, according to habitual clinical practice in the Department of Cardiovascular Surgery.
3330412|NCT02095730|Active Comparator|Epi-On Continuous|Continuous beam of UV light treating cornea with surface epithelium present
3330413|NCT02095730|Active Comparator|Epi-Off Continuous|Continuous beam of UV light treating cornea without surface epithelium present
3330414|NCT02095730|Active Comparator|Epi-On Pulsed|Pulsed beam of UV light treating cornea with surface epithelium present
3330415|NCT02095730|Active Comparator|Epi-Off Pulsed|Pulsed beam of UV light treating cornea without surface epithelium present
3330416|NCT02095743|Experimental|PICC line|Use of a PICC line for chemo administration (PowerPICC SOLO²)
3330417|NCT02095743|Active Comparator|Implanted Port|Use of an implanted port for chemo administration
3330418|NCT02095756|Experimental|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of melasma
3330419|NCT02095782|Experimental|chemotherapy and erlotinib|Intercalated combination of chemotherapy and erlotinib in 1st line setting for patients with advanced stage non-small-cell lung cancer with low abundant activating EGFR mutation
3330420|NCT02095795|Experimental|Technological Rehabilitation|Patients in the experimental group received a multimodal treatment intervention consisting of 60 minutes of conventional treatment according to the Bobath approach (Bobath B. Adult hemiplegia: evaluation and treatment. Oxford: Butterworth-Heineman, 1990) followed by 30 minutes of robotic gait training on the Lokomat robotic system with the supervision of an expert rehabilitator. Patients started the first session with 50% weight unload and 1.5 Km/h gait speed, performances increments are allowed only in the following sessions. Each patient received 20 sessions over a period of 4 weeks (5 sessions per week).
3330421|NCT02095795|Active Comparator|Control Rehabilitation|Patients in the control group received the same number of treatment sessions of a similar duration as those in the experimental group but they received activities of overground walking exercises targeted to improve walking in substitution of the robotic gait trainer.
3330422|NCT02095808|Experimental|Surgery|"The 13C-glucose solution will be given intravenously. It will be started at about the same time as the start of surgery, according to the study guidelines.~The 13C-glucose IV solution will be stopped once the surgeon has removed the tumor tissue."
3232748|NCT01214499|Experimental|Experimental Treatment|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.
3330423|NCT02095821||Humoral rejection, TPE|
3330424|NCT02095834|Experimental|Treatment (dexamethasone, bendamustine, carfilzomib)|Patients receive dexamethasone PO or IV over 20 minutes on days 1, 2, 8, 9, 15, 16, 22, and 23 of courses 1-3; on days 1, 2, 15, and 16 of courses 4-12; and on days 1 and 2 of all subsequent courses. Patients also receive bendamustine hydrochloride IV over 10 minutes on days 1 and 2 of courses 1-3 and on day 1 of all subsequent courses and carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 of courses 1-12 and on days 1, 2, 15, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3232749|NCT01214525||Meatotomy|Toilet trained children scheduled for urethral meatotomy for the treatment of urethral meatal stenosis.
3232750|NCT01214538||Control group - culture negative|50 children with pneumococcal culture-negative Acute Otitis Media
3232751|NCT01214538||study group- culture positive|50 children with pneumococcal culture-positive Acute Otitis Media
3232752|NCT01214564|Experimental|1|Up to three days of treatment
3232753|NCT01214577|Experimental|1|Up to three days of treatment
3232754|NCT01214590|Experimental|VascuActive Treatment|
3232755|NCT01214681|Placebo Comparator|Placebo|
3232756|NCT01214681|Experimental|Hi-maize 260|
3232757|NCT01214681|Experimental|Polydextrose|
3232758|NCT01214681|Active Comparator|Hi-maize 260 and polydextrose|
3232759|NCT01214694|Experimental|Active Comparator: Internet Resources Comparison (IRC)|Participants will receive the Internet resource comparison group treatment
3232760|NCT01214694|Experimental|I-InTERACT|Participants will receive a 24 week, 27 session internet-based parenting skills program
3232761|NCT01214694|Experimental|I-InTERACT Express|Participants will receive an abbreviated 7 week, 14 session version of the I-InTERACT parenting skills program.
3232762|NCT01214707||Exercise protocol|No arms are required for this study as all subjects complete the entire protocol
3232763|NCT01214733|Experimental|1|
3232764|NCT01214746|Placebo Comparator|Placebo|
3232765|NCT01214746|Active Comparator|Atorvastatin|
3232766|NCT01214772|Experimental|heparin,pregnancy,IVF failure|Women in the heparin arm are administered 5000 IU twice a day on the day of embryo transfer
3232767|NCT01214785|Active Comparator|Sanitation intervention|
3232768|NCT01214785|No Intervention|Control|
3232769|NCT01214863||T3|Model SN60T3 assigned by AcrySof Toric calculator
3232770|NCT01214863||T4|Model SN60T4 assigned by AcrySof Toric calculator
3232771|NCT01214863||T5|Model SN60T5 assigned by AcrySof Toric calculator
3232772|NCT01214876||Children 1-5 years old|
3232773|NCT01214876||Children 6-10 years old|
3330425|NCT02095847|Experimental|Hysteroscope Imaging|All patients entered in study will undergo cervical dilation after induction of general anesthesia. Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the High-Resolution Microendoscopy (HRME) camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera. The resectoscope will then be used to remove all tumor as guided through HRME images. The entire imaging and tumor resection process is estimated to take 45 minutes or less.
3330426|NCT02095860|Experimental|Treatment A: DCV 3DAA FDC fasted state|DCV 3 Direct Acting Antiviral (DAA) Fixed Dose Combination (FDC) tablet by mouth once on specified days in fasted state
3330427|NCT02095860|Experimental|Treatment B: DCV 3DAA FDC with high-fat meal|DCV 3DAA FDC tablet by mouth once on specified days with high-fat meal
3330428|NCT02095860|Experimental|Treatment C: DCV 3DAA FDC with light meal|DCV 3DAA FDC tablet by mouth once on specified days with light meal
3232774|NCT01214876||Adults 25 years and above|
3232775|NCT01214889|Experimental|Study Group A|Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.
3330429|NCT02095886|Experimental|Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)|BMS-955176 single dose by mouth as specified
3330430|NCT02095886|Experimental|Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)|BMS-955176 single dose by mouth as specified
3330431|NCT02095886|Experimental|Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)|BMS-955176 single dose by mouth as specified
3330432|NCT02095886|Experimental|Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)|BMS-955176 single dose by mouth as specified
3330433|NCT02095886|Experimental|Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)|BMS-955176 single dose by mouth as specified
3330434|NCT02095886|Experimental|Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)|BMS-955176 single dose by mouth as specified
3330435|NCT02095886|Experimental|Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)|BMS-955176 single dose by mouth as specified
3330436|NCT02095886|Experimental|Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)|BMS-955176 single dose by mouth as specified
3232776|NCT01214889|Active Comparator|Study Group B|Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.
3232777|NCT01214902|Experimental|Experimental CIMT|Two month home program that includes restricting the non hemiplegic hand an hour a day during play
3232778|NCT01214902|Active Comparator|Active Play|Two month home program that includes active use of hemiplegic hand during play one hour a day
3232779|NCT01214928|Active Comparator|Cholecalciferol|Cholecalciferol 50,000IU po once weekly for 12 continuous weeks.
3232780|NCT01214928|Placebo Comparator|Placebo|Matching placebo po once weekly for 12 continuous weeks
3232781|NCT01214941|Placebo Comparator|Placebo|
3232782|NCT01214941|Active Comparator|Ticlopidine|
3232783|NCT01214941|Active Comparator|Ticlopidine and itraconazole|
3232784|NCT01214954|Active Comparator|Control group|Standard rehabilitation
3232785|NCT01214954|Experimental|Resistance training|10 weeks of supervised progressive resistance training initiated within the first week after total hip replacement.
3232786|NCT01214967|Experimental|1|Problem Solving Education, a psycho-educational intervention
3232787|NCT01214967|No Intervention|2|Usual care
3232788|NCT01214993|Experimental|Treatment A|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3232789|NCT01214993|Experimental|Treatment B|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive GSK1349572 50mg (two 25mg tablets) q12h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3232790|NCT01214993|Placebo Comparator|Treatment C|There will be a screening visit within 30 days prior to the first dose of study drug. In this treatment arm, all subjects will receive placebo q24h for 14 days. Subjects will also receive iohexol and PAH infusions on Days -1, 7 and 14. There will be a follow-up visit 7-10 days after the last dose of study medication.
3232791|NCT01215019|Active Comparator|Arm 1|20% Mannitol
3232792|NCT01215019|Active Comparator|Arm 2|3% sodium chloride
3232793|NCT01215045||ReSTOR +4|AcrySof ReSTOR Aspheric +4
3232794|NCT01215058||1|
3232795|NCT01215071|Experimental|limited lymphadenectomy|Fields 5, 7, 9, 11, 13, 14 are removed
3232796|NCT01215071|Experimental|extended lymphadenectomy|Fields 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 are removed
3232797|NCT01215084|Experimental|Chinese Subpopulation: Fampridine-PR 10 mg|Chinese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3232798|NCT01215084|Experimental|Japanese Subpopulation: Fampridine-PR 10mg|Japanese ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3232799|NCT01215084|Experimental|Caucasian Subpopulation: Fampridine-PR 10mg|Caucasian ethnic participants were administered a single dose of Fampridine-PR 10 mgs
3232800|NCT01215136|Active Comparator|Cohort 1|Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance < 60 ml/min AND Karnofsky performance status of 60-70%)
3232801|NCT01215136|Active Comparator|Cohort 2|Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance < 60 ml/min OR Karnofsky performance status of 60-70%)
3330437|NCT02095899|Experimental|Rufinamide|- oral Rufinamide administration as ad-on to Oxycodone
3330438|NCT02095899|Placebo Comparator|Manitol|- oral Placebo administration - as ad-on to Oxycodone
3330439|NCT02095925||cancer patients|Patients with stage III or IV esophageal carcinoma, gastric carcinoma, intestinal carcinoma, pancreatic carcinoma, ovarian cancer, breast carcinoma, prostate cancer, urothelial cell carcinoma or lung carcinoma (small cell or non-small cell) who have started chemotherapy no more than 3 months ago
3330440|NCT02095938|Experimental|Solian|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
3330441|NCT02095964||Cardiac Syndrome X|
3330442|NCT02095964||Control Group|
3330443|NCT02095977|Other|participants|all subjects meeting inclusion and none of exclusion criteria
3330444|NCT02095990|Experimental|Hydroquinone|"Hydroquinone 4% Cream will be applied in one side of the face while the other side of the face receives placebo.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
3330445|NCT02095990|Placebo Comparator|Placebo|"Placebo cream (vehicle of Hydroquinone 4% cream), will be applied in one side of the face, while the other side receives the active treatment.~Half of the patients will receive Hydroquinone on the right side of the face and the other half on the left side.~It will be applied daily, at night, during 8 weeks."
3330446|NCT02096016||Human Papilloma Virus test|"Patients treated with surgery alone for uterine cervical neoplasms attending surveillance at Dept. of Obstetrics and Gynecology, Oncogynecological unit, Aarhus University Hospital from 01.01.14 From 01.01.15 patients will be recruited from Oncogynecologic units at Aalborg University Hospital and Rigshospitalet. Recruitment of patients from these institutions has not been successful and has been closed.~It is expected due to political decisions that the cervical cancer patients from the uptake area of Aalborg University Hospital will be treated at Aarhus University Hospital and they will then be eligible for the study"
3232802|NCT01215149|Experimental|Group A|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 6. Vaccine:Placebo=10:3
3232803|NCT01215149|Experimental|Group B|Ad35-ENVA at Month 0 followed by Ad26.ENVA.01 at Month 6. Vaccine:Placebo=10:3
3330447|NCT02096055|Experimental|Arm I (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine as in Induction therapy. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
3330448|NCT02096055|Experimental|Arm II (CLOSED) (guadecitabine)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-10. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 (days 1-10 of courses 1 and 2). Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
3330449|NCT02096055|Experimental|Arm III (guadecitabine, idarubicin)|"INDUCTION THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on days 1-2. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC on days 1-5 and idarubicin IV over up to 1 hour on day 1. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
3330450|NCT02096055|Experimental|Arm IV (CLOSED) (guadecitabine, cladribine)|"INDUCTION THERPAY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-6 weeks for 2-3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a CR or CRp continue on to Maintenance therapy; patients not achieving CR or CRi but deriving clinical benefit may continue to Maintenance therapy at the discretion of the PI.~MAINTENANCE THERAPY: Patients receive guadecitabine SC and cladribine IV over up to 1 hour on days 1-5. Courses repeat every 4-8 weeks for up to 24 months in the absence of disease progression or unacceptable toxicity."
3330451|NCT02096068|Experimental|Study group|"Application of Dexmedetomidine (Dexdor®) perioperatively for a maximum of 48 hours~Dosing Scheme:~during operation and mechanical ventilation: 0,7μg/kgABW/h; recovery time until extubation: 0,4μg/kgABW/h; after extubation: 0,2-1,4μg/kgABW/h"
3330452|NCT02096068|Placebo Comparator|Control group|Application of placebo for a maximum of 48 hours
3330453|NCT02096068|No Intervention|POCD control group|A non-surgical control group of 15 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. The participants are matched on age, education, and gender to the study patients.
3330454|NCT02096094|Experimental|Chlorhexidine bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes impregnated with 2% chlorhexidine and with shampoo with 0.15% chlorhexidine.
3330455|NCT02096094|Placebo Comparator|Control bath|This arm is composed with 27 healthy volunteers which will perform full body bath with wipes and shampoo without chlorhexidine.
3330456|NCT02096120||All patients|
3330457|NCT02096133|Experimental|Cholecalciferol|Patients receive 1dd 100ug vitamin D3 (drops) for 16 weeks
3330458|NCT02096133|Placebo Comparator|Placebo comparator|placebo drops during 16 weeks
3330459|NCT02096146|Other|TMT Fusion Plate|Patients are treated with TMT Fusion Plate to encourage bony fusion of the 1st TMT joint.
3330460|NCT02096146|Other|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion .
3330461|NCT02096159|Experimental|Antibiotics|trimethoprim-sulfamethoxazole oral suspension, 4 mg/kg (0.5 mL/kg) twice daily for 10 days
3330462|NCT02096159|Placebo Comparator|Placebo|placebo oral suspension, 0.5 mL/kg twice daily for 10 days
3330463|NCT02096185|Experimental|3 dimensional tomosynthesis imaging|Breast specimen to be x-rayed using both conditions 3 dimensional tomosynthesis imaging 2 dimensional conventional digital imaging
3330464|NCT02096185|Experimental|2 dimensional digital imaging|Breast specimens to be x-rayed under both conditions 3 dimensional tomosynthesis imaging 2 dimensional digital imaging
3330465|NCT02096198||Other CERAMAX COC 36mm Acetabular Cup|The CERAMAX COC 36mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The insert is available in several inner diameter sizes, including 36mm; only 36mm inserts will be utilized in this PAS. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper.
3330467|NCT02096224|Experimental|Sevoflurane|Sevoflurane will be administered as the maintenance agent of general anesthesia.
3330468|NCT02096224|Active Comparator|Desflurane|Desflurane will be administered as the maintenance agent of general anesthesia.
3330469|NCT02096237|Experimental|apheresis, IgE adsorber|9 apheresis treatments with the new IgE adsorber in a period of 3 months with 3 cycles of 3 treatments each every month.
3330470|NCT02096237|No Intervention|Conventional drug treatment|Patients treated with conventional asthma treatment as prescribed before study entry. No intervention in prescription
3330471|NCT02096250|Experimental|NaFeEDTA|NaFeEDTA
3330472|NCT02096250|Experimental|Ferrous fumarate|Ferrous fumarate
3330473|NCT02096250|Experimental|NaFeEDTA + ferrous fumarate|NaFeEDTA + ferrous fumarate
3330474|NCT02096289|Experimental|Thioridazine|Up to 3 dose levels of thioridazine will be assessed sequentially: 25 mg Q6H (Level I), 50 mg Q6H (Level II) and 100 mg Q6H (Level III). The duration of thioridazine therapy is for a total of 21 days (Days 1-22 on study). All patients will receive cytarabine 1 g/m2 administered as a 2 hour infusion for 5 consecutive days (Days 6-10 on study).
3330475|NCT02096302|Experimental|Experimental Formula|Infant formula with a novel probiotic CECT7210
3232804|NCT01215149|Experimental|Group C|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=10:3
3232805|NCT01215149|Experimental|Group D|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=10:3
3232806|NCT01215149|Experimental|Group E|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3232807|NCT01215149|Experimental|Group F|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3232808|NCT01215149|Experimental|Group G|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3232809|NCT01215149|Experimental|Group H|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3232810|NCT01215149|Experimental|Group I|Ad26.ENVA.01 at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3330476|NCT02096302|Active Comparator|Standard Formula|Standard infant formula without probiotics
3232811|NCT01215149|Experimental|Group J|Ad35-ENV at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3232812|NCT01215149|Experimental|Group K|Ad26.ENVA.01 at Month 0 followed by Ad26.ENVA.01 at Month 3. Vaccine:Placebo=16:4
3232813|NCT01215149|Experimental|Group L|Ad35-ENV at Month 0 followed by Ad35-ENV at Month 3. Vaccine:Placebo=16:4
3232814|NCT01215162|Experimental|Single arm study|Patients with stage T1/T2No breast cancer receiving breast conserving treatment
3232815|NCT01215201|Other|Scaling and Root Planing Alone|Control group
3232816|NCT01215201|Experimental|Diode Laser plus Scaling and Root Planing|Diode Laser is used in addition to Scaling and root planing procedure.
3232817|NCT01215214|Experimental|midazolam|period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
3232818|NCT01215266|Active Comparator|Sorafenib|
3330477|NCT02096315|Experimental|POL7080|POL7080 administered daily
3330478|NCT02096328|Experimental|POL7080, Anti-pseudomonal antibiotics|POL7080 daily co-administered with standard of care treatment
3330479|NCT02096341|Experimental|RRx-001|RRx-001 will be administered as subcutaneous injections twice weekly for at least 8 weeks. At least three subjects must complete 2 weeks of treatment with RRx-001 at each dose level, before escalation to the next higher RRx-001 dose level; 2 doses-16 and 27 mg/m2- will be tested.
3330480|NCT02096354|Experimental|RRx-001 followed by irinotecan|Once-weekly intravenous RRx-001 at a dose of 4 mg on Days 1, 8, 15, and 22 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
3330481|NCT02096354|Active Comparator|Regorafenib followed by irinotecan|Regorafenib daily on Days 1- 21 of a 4-week cycle. On progression and if eligible, patients will receive irinotecan (with or without bevacizumab)
3330482|NCT02096367|Experimental|Hemiplegia after vascular stroke|"Muscle vibration stimulation~Gait analysis with Gait Rite : quantitative and spatio-temporal gait parameters~Kinematic gait analysis in lower limb measured by optoelectronic system (Optitrack).~Analysis of static posture on force platform~Evaluation of the gait on treadmill during 2 minutes"
3330483|NCT02096380||one cycle induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
3330484|NCT02096380||three cycles induction chemotherapy|"Drug: docetaxel, cisplatin and fluorouracil~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~Other Names:~docetaxel, cisplatin and fluorouracil"
3330485|NCT02096393|Experimental|Patient specific instrumentation|The patient will undergo using patient specific instrumentation
3330486|NCT02096393|Active Comparator|Standard instrumentation|The patient will undergo surgery using standard instrumentation
3330487|NCT02096406|Other|ACE/ARB Continuation|ACE/ARB will be continued up to and including the morning of surgery.
3232819|NCT01215266|Placebo Comparator|Placebo|
3330488|NCT02096406|Other|ACE/ARB withdrawal|ACE/ARB will be discontinued medication 48 hours prior to surgery
3330489|NCT02096419|No Intervention|control group|Patients in this group will receive standard clopidogrel dose
3330490|NCT02096419|Experimental|interventional group|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
3330491|NCT02096432|Experimental|Behavioral: Behavioral Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
3330492|NCT02096432|Other|Usual Community Care|Community standard care as usual
3330493|NCT02096445|Experimental|Robot group|"Receive robot-assisted neurocognitive therapy instead of conventional neurocognitive therapy.~(4 x 45 min/week)"
3232820|NCT01215305||Visiting outpatient departments, if symtoms|patients with upper GI symptoms, visiting the outpatient departments of peripheral hospitals in Greece
3330494|NCT02096445|Active Comparator|Control group|Receive dose-matched conventional neurocognitive therapy
3330495|NCT02096484|Experimental|Metacognitive Therapy|Individuals randomly assigned to the metacognitive therapy group will undergo group metacognitive therapy for generalized anxiety disorder.. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
3330496|NCT02096484|Experimental|Mindfulness Meditation Therapy|Individuals randomly assigned to the mindfulness meditation therapy group will undergo group mindfulness meditation therapy for generalized anxiety disorder. Individuals will undergo 8 sessions of group therapy lasting approximately 90 minutes.
3232821|NCT01215331|Active Comparator|Insulin|Rapid acting insulin and long acting insulin
3232822|NCT01215331|Experimental|Oral Hypoglycemic Agents|Metformin + glyburide + insulin if needed
3232823|NCT01215383||psychiatric patients|20 in patients and outpatients with schizophrenia, schizoaffective and bipolar disorder based on psychiatrist diagnostic evaluation using DSM-IV criteria, before and at least two months after antipsychotic therapy will be enrolled.
3330497|NCT02096497||Vascular pattern 1|
3330498|NCT02096497||Vascular pattern 2|
3330499|NCT02096497||Vascular pattern 3|
3330500|NCT02096497||Vascular pattern 4|
3330501|NCT02096497||Vascular pattern 5|
3232824|NCT01215383||healthy volunteers|"Ten healthy volunteers will be checked as controls:~Employee from the hospital staff with no metabolic disease (Diabetes mellitus, hypertension or dyslipidemia) and non-smokers."
3330502|NCT02096497||Vascular pattern 6|
3330503|NCT02096497||Vascular pattern 7|
3330504|NCT02096497||Vascular pattern 8|
3330505|NCT02096497||Vascular pattern 9|
3330506|NCT02096497||Vascular pattern 10|
3232825|NCT01215396|Placebo Comparator|Carbohydrate Placebo|
3232826|NCT01215396|Active Comparator|Single Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 0.96 g of amino acids."
3330507|NCT02096497||Vascular pattern 11|
3330508|NCT02096510|Experimental|continuous subcutaneous hydrocortisone|continuous subcutaneous hydrocortisone infusion (CSHI), Solu-Cortef ® 50mg/ml infusate
3232827|NCT01215396|Active Comparator|Double Dose|"The Amino Vital Focus Zone is a dietary supplement of amino acid mixture, which also contains some minerals, vitamin C, flavour, and sweetener, and its appearance is clear to slightly opaque powder. The Amino Vital Focus Zone contains the five kind of amino acid (L-Leucine, L-Isoleucine, L-Valine, L-Arginine, and L-Glutamine), Citric acid, Vitamin C, some mineral, and sweetener.~Powdered treatments will be dissolved in water and administered orally. This treatment will contain 1.92 g of amino acids."
3232828|NCT01215409||Group 1|
3232829|NCT01215448|No Intervention|Lifestyle changes|Lifestyle changes(booklet and audio cassette of recommended diet, physical activity and breathing exercises)
3232830|NCT01215448|Experimental|Wheatgrass juice & lifestyle changes|Wheatgrass juice & lifestyle changes
3232831|NCT01215474||NSCLC Stadium III-IV|
3330509|NCT02096510|Active Comparator|cortef tablets|the patient regular treatment by Cortef 5 mg, produced by Nycomed Pharma two times or three times a day.
3330510|NCT02096510|Experimental|ultradian subcutaneous hydrocortisone|ultradian subcutaneous hydrocortisone infusion, Solu-Cortef ® 50mg/ml infusate
3330511|NCT02096523|Experimental|platelet disease|patients with inherited platelet disorders
3330512|NCT02096523|Experimental|Healthy|Healthy family members of patients with inherited platelet disorders
3330513|NCT02096536|Other|Vancomycin|All included patients receive vancomycin for medical reasons. Decision for start of therapy is made by the treating physician.
3330514|NCT02096562|Placebo Comparator|B - No compression stockings|normal therapy - no compression stockings
3330515|NCT02096562|Active Comparator|A - Use of compression stockings|Patients use compression stockings for 10 days after surgery
3330516|NCT02096601|Experimental|ND0612|Levodopa and carbidopa SC solution
3330517|NCT02096601|Active Comparator|Oral levodopa and carbidopa|Oral levodopa and carbidopa
3330518|NCT02096614|Experimental|Low dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone.
3330519|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 1|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone.
3330520|NCT02096614|Experimental|High dose TBI-1201 with pre-treatment 2|TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine.
3330521|NCT02096614|Experimental|TBI-1201 with pre-treatment 1 or 2|Arm1, 2 or 3, which is considered as optimal.
3330522|NCT02096627||conventional|Patients who undergo routine cataract surgery using conventional phacoemulsification technique
3330523|NCT02096627||FLACS|Patients who undergo femtosecond laser assisted cataract surgery
3330524|NCT02096640|Active Comparator|Percutaneous dilatation tracheostomy: Smiths Medical|Type of surgical teqnique for tracheostomy: Percutaneous dilatation tracheostomy. The set for the tracheostomy is bought from Smiths Medical TM.
3330525|NCT02096640|Active Comparator|Open surgery tracheostomy|Type of surgical teqnique for tracheostomy: Open surgical tracheostomy
3330526|NCT02096653|Experimental|X-ray guided intra-articular injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
3330527|NCT02096653|Active Comparator|Landmark-guided SI joint injection|Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
3330529|NCT02096757|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules; 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
3330530|NCT02096757|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day (Nordic Naturals, Watsonville, CA, USA) 2 weeks prior to surgery and continued for 4 weeks after.
3330531|NCT02096783|Active Comparator|Arm I (standard counseling)|Patients receive standard counseling at both the pre-operative and 2-4 week post-operative visit.
3330532|NCT02096783|Experimental|Arm II (standard counseling, scripted intervention)|Patients receive standard counseling at the pre-operative visit and the scripted sexual health intervention at the 2-4 week post-operative visit.
3330533|NCT02096783|Experimental|Arm III (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at the pre-operative visit and standard counseling at the 2-4 week post-operative visit.
3330534|NCT02096783|Experimental|Arm IV (standard counseling, scripted intervention)|Patients receive standard counseling and the scripted sexual health intervention at both the pre-operative and 2-4 week post-operative visit.
3330535|NCT02096796||persons without arm pump|
3330536|NCT02096796||persons with arm pump|
3330537|NCT02096809|Experimental|One week loading of Bone Anchored Hearing Aid (BAHA)|Bone Anchored Hearing Aid (BAHA) loading after one week
3232832|NCT01215487||1 - Chronic Myelogenous Leukemia Patients|Patients will be selected from patients referred to the primary hospital site for treatment and assessment. The patients will be approached by the physicians and or the study research nurse to consider participation in the study. Patients may be selected by participating off-site hospital centres and may be enrolled at those collaborating centres.
3330538|NCT02096822|Active Comparator|non-nutritive sucking alone|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water.
3330539|NCT02096822|Experimental|Facilitated tucking + non-nutritive sucking|After randomization, baby will receive heel stick procedure with non-nutritive sucking and sterile water combined with facilited tucking.
3330540|NCT02096887|Other|Patient Education|Patient Education
3330541|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 4 weeks|
3330542|NCT02096913|Active Comparator|Dolormin® extra (Ibuprofen) 12 weeks|
3330543|NCT02096926|Placebo Comparator|Placebo|placebo
3330544|NCT02096926|Active Comparator|Ibuprofen|400 mg PO
3330545|NCT02096939||Primary aldosteronism|Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists
3330546|NCT02096939||Essential hypertension|Patients with essential hypertension who will be started on antihypertensive medication
3330547|NCT02096965|Experimental|Tolvaptan first, then Placebo|Tolvaptan twice daily in first intervention period and placebo twice daily in second intervention period. (after washout period)
3330548|NCT02096965|Experimental|Placebo first, then Tolvaptan|Placebo twice daily in first intervention period and Tolvaptan twice daily in second intervention period. (after washout period)
3330549|NCT02096978|Experimental|Osteotome preparation|Procedure/Surgery: Preparing the osteotomy to accept a standard implant device
3232833|NCT01215500|Experimental|Radiation therapy|
3330550|NCT02096978|Active Comparator|Drill preparation|Preparing the osteotomy to accept a standard implant device
3330551|NCT02096991|Active Comparator|Glass|consume beverage in glass first and cross over to other interventions
3330552|NCT02096991|Experimental|Can 1|consume one canned beverage and a glass bottled beverage first and cross over to other interventions
3330553|NCT02096991|Experimental|Can 2|Consume two canned beverage first and cross over to other interventions
3330554|NCT02097004|Experimental|Concomitant:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
3330555|NCT02097004|Experimental|Sequential:Pegasys, Euvax B, Baracrude|"Peginterferon alfa-2a: once weekly 180 μg or weight base dose subcutaneous injection for 48 weeks~HBV vaccination (Euvax B Inj): 1.0 mL (20 μg) intramuscular injection at 52, 56, 60 and 76 weeks~Continue Entecavir(0.5mg) for 100 weeks(once daily)"
3330556|NCT02097004|Active Comparator|Control Group|"Continue Entecavir(0.5mg) for 100 weeks(once daily)~After EOS(100W), injection(once weekly) a Peginterferon alfa-2a for 48 weeks"
3330557|NCT02097017|Active Comparator|lidocaine spray group|
3330558|NCT02097017|Placebo Comparator|placebo arm|
3330559|NCT02097043|Experimental|[Group 1] DA-7218|200mg, By mouth or orally (PO) & intravenous(IV) administration
3330560|NCT02097043|Placebo Comparator|[Group 1] Placebo|Placebo, By mouth or orally (PO) & intravenous(IV) administration
3330561|NCT02097043|Experimental|[Group 2] DA-7218|400mg, By mouth or orally (PO) administration
3330562|NCT02097043|Placebo Comparator|[Group 2] Placebo|Placebo, By mouth or orally (PO) administration
3330563|NCT02097043|Experimental|[Group 3] DA-7218|600mg, By mouth or orally (PO) administration
3330564|NCT02097043|Placebo Comparator|[Group 3] Placebo|Placebo, By mouth or orally (PO) administration
3330565|NCT02097069|Other|Subgroup A|folic acid 400 mcg/day
3330566|NCT02097069|Experimental|Subgroup B|myo-inositol 2000 mg twice a day
3330567|NCT02097069|Experimental|Subgroup C|D-chiro-inositol 250 mg twice a day
3232834|NCT01215539|Experimental|Panitumumab,capecitabine,oxaliplatin|"Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg.~Oxaliplatin 130 mg/m2 IV infusion over 2 hours on Day 1 Capecitabine 2000 mg/m2 divided in two doses, orally, on Days 1 - 14"
3330568|NCT02097069|Experimental|Subgroup D|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
3330569|NCT02097082|Experimental|STANZA Drug-eluting Resorbable Scaffold|Treatment of Superficial Femoral Artery (SFA) lesion with resorbable scaffold
3330570|NCT02097095||Vaccine group|TB vaccine GSK 692342 (M72/AS01E) administered on study TB-018
3330571|NCT02097095||Placebo Comparator|Placebo administered on study TB-018
3330575|NCT02097147|Experimental|Vilazodone 20 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 28 days.
3330576|NCT02097147|Experimental|Vilazodone 40 mg|Vilazodone 10 mg once daily for 7 days, followed by vilazodone 20 mg once daily for 7 days, followed by vilazodone 40 mg once daily for 21 days
3330577|NCT02097147|Active Comparator|Paroxetine 20 mg|Paroxetine 10 mg once daily for 7 days, followed by paroxetine 20 mg for 28 days
3330578|NCT02097147|Placebo Comparator|Placebo|Placebo once daily for 35 days
3330579|NCT02097160|Active Comparator|Control Group 1|regular fortified milk + regular cheese/yogurt
3330580|NCT02097160|Experimental|Intervention Group 2|Vitamin D fortified yogurt and cheese; vitamin D dose increment of 252 IU vs grp 1
3330581|NCT02097160|Experimental|Intervention Group 3|Vitamin D fortified yogurt and cheese, vitamin D dose increment of 420 IU vs grp 1
3330582|NCT02097173|Other|SC MTX followed by IM MTX|1 subcutaneous injection of 30 mg methotrexate administered by a prefilled pen (50mg/mL) followed by 1 intramuscular injection of 30 mg methotrexate (comparator) after a wash-out phase of 1 week
3330583|NCT02097173|Other|IM MTX followed by SC MTX|1 intramuscular injection of 30 mg methotrexate (comparator) followed by 1 subcutaneous injection of 30 mg methotrexate by a prefilled pen (50mg/mL) after a wash-out phase of 1 week
3330584|NCT02097186|Experimental|Remote ischaemic preconditioning|Remote ischaemic preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
3330585|NCT02097186|No Intervention|Control to remote preconditioning group|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
3232835|NCT01215552|Experimental|HT-0712|
3232836|NCT01215565|Experimental|patient treated|patient who receive sunitinib
3330586|NCT02097199||Sports group|The cohort will consist of about 55 female and 55 male individuals aged 30-65 years with mostly sedentary work (>6 hours/day) doing no or less physical activity (<30 minutes quick walking/day) who want to engage more in physical activity (at least 150 minutes of at least moderate intensity per week). The gain in workload will be objectified and quantified by performing a bicycle stress test at the beginning of the study and after 8 months of physical engagement.
3330587|NCT02097225|Experimental|Treatment (dabrafenib, trametinib, onalespib)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-28, and onalespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3232837|NCT01215578|Experimental|patient treated|patient who receive sunitinib (SUTENT)
3232838|NCT01215591|Active Comparator|Gradual wean from Nasal CPAP|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
3330588|NCT02097264|Experimental|NNC0109-0012|
3232839|NCT01215591|No Intervention|Sudden wean from Nasal CPAP|Usual practice to wean the preterm neonates from nasal CPAP
3232840|NCT01215617|Experimental|Aerobic Interval Training|Patients randomized to training will meet for supervised aerobic interval training three times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
3232841|NCT01215617|Other|Control|Patients will receive standard medical treatment at the University Hospital lung department.
3232842|NCT01215630||Healthy subjects|Men Women Age; 18-75
3232843|NCT01215656|Experimental|Probiotic|follow on formula with the probiotic Lactobacillus fermentum
3232844|NCT01215656|Active Comparator|Control|follow on formula without probiotics
3232845|NCT01215669|Experimental|Group 1: Adult Intradermal (ID) Vaccine|Participants aged 18 to 59 years will be vaccinated with IDflu™ influenza vaccine
3232846|NCT01215669|Active Comparator|Group 2: Adult Intramuscular (IM) Vaccine|Participants aged 18 to 59 years will be vaccinated with Vaxigrip® Influenza vaccine
3330589|NCT02097264|Active Comparator|Adalimumab|
3330590|NCT02097316|Experimental|JewelPump|JewelPump for the first treatment period followed by the usual pump for the second treatment period
3330591|NCT02097316|Active Comparator|Usual insulin pump|Patients in the arm 2, will have the usual insulin pump for the first treatment period, followed with the second period which they will have the JewelPump.
3330592|NCT02097329|Experimental|Cohort 1: Palbociclib under fed conditions|
3330593|NCT02097329|Experimental|Cohort 2: Palbociclib under fed conditions|
3232847|NCT01215669|Experimental|Group 3: Elderly Intradermal (ID) Vaccine|Participants aged 60 years or older will be vaccinated with IDflu™ Influenza vaccine
3232848|NCT01215669|Active Comparator|Group 4: Elderly Intramuscular (IM) Vaccine|Participants aged 60 years or older will be vaccinated with Vaxigrip® Influenza vaccine
3330594|NCT02097342|Experimental|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
3330595|NCT02097342|Placebo Comparator|Placebo|Tablet Placebo per oral, once daily will be given to 10 patients for 6 months
3330596|NCT02097342|Active Comparator|Voglibose|Tablet Voglibose (0.2mg) per oral, thrice daily (with meals) will be given to 10 patients for 6 months
3330597|NCT02097355|Experimental|TriVox Active|Provider using TriVox for clinical care
3330598|NCT02097355|No Intervention|TriVox Delayed-start|Providers not using TriVox for clinical care
3330599|NCT02097368||neuromuscular patient|Patients affected by neuromuscular pathology will be explored by tongue strength measurement, respiratory function measurement, swallowing tests and Magnetic resonance imaging
3330600|NCT02097381|Other|naïve for cART that met the criteria to start treatment|"patients naïve for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~These patients will be studied for primary and secondary outcomes after a short term antiretroviral therapy."
3232849|NCT01215682|Active Comparator|vit D|
3330601|NCT02097394|Active Comparator|Combizym-treated group|The patients who received polypectomy of colon polyps take the digestion enzyme (Combizym) regularly.
3330602|NCT02097394|Active Comparator|Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take Bifidobacteri regularly
3330603|NCT02097394|Active Comparator|Combizym + Bifidobacteri-treated group|The patients who received polypectomy of colon polyps take drugs (Combizym + Bifidobacteri) regularly
3330604|NCT02097394|No Intervention|control|The patients who received polypectomy of colon polyps take no drugs
3330605|NCT02097407|Experimental|Group D : Dexmedetomidine + propofol group|In Group D, DEX (1 µg kg-1) was intravenously loaded for 10 min before induction of anaesthesia.
3330606|NCT02097407|Placebo Comparator|Group C : Saline + propofol group|In Group C, 0.9% of normal saline (1 µg kg-1) was loaded 10 min before induction of anaeshtesia.
3330607|NCT02097433|Experimental|Dacomitinib|
3330608|NCT02097446|Experimental|GUARDIX-FL|Patients will be treated with 1 or 2 sheet of GUARDIX-FL after ovarian cystectomy(Operative Day).
3330609|NCT02097446|Active Comparator|Interceed|Patients will be treated with 1 or 2 sheet of interceed after ovarian cystectomy(Operative Day).
3330610|NCT02097459|Experimental|Failed group|Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy.
3330611|NCT02097459|Experimental|Succeeded group|Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy.
3330612|NCT02097459|Active Comparator|No chang group|Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy.
3330613|NCT02097498|No Intervention|Simulation only|One group will be randomized to receive simulation training similar to that required for certification. Paramedics in this group will then complete a second simulation scenario
3330614|NCT02097498|Experimental|Directed feedback|One group will review their baseline simulation scenario with a member of the research staff while providing specific feedback for errors made during the first simulation. Paramedics in this group will then complete a second simulation scenario.
3330615|NCT02097498|Experimental|Basic Videolaryngoscopy|One group will review a series of instructional videos related to common airway management errors. Paramedics in this group will then complete a second simulation scenario.
3330616|NCT02097511|Experimental|Sarpogrelate pretreatment and Metoprolol|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days and Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
3232850|NCT01215682|Placebo Comparator|placebo|
3232851|NCT01215708|Active Comparator|Nifedipine|nifedipine retard 20mg daily
3232852|NCT01215708|Active Comparator|tamsulosin|tamsulosin 0,4mg
3232853|NCT01215708|Placebo Comparator|placebo|placebo capsule
3232854|NCT01215747|Experimental|Kiacta (eprodisate disodium)|
3232855|NCT01215747|Placebo Comparator|Placebo|
3330617|NCT02097511|Active Comparator|Sarpogrelate and Metoprolol|Metoprolol Tartrate 100 mg once a day with Sarpogrelate hydrochloride 100 mg three times a day
3232856|NCT01215760|Active Comparator|MIRROR|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
3232857|NCT01215760|Active Comparator|Home program|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
3232858|NCT01215773|Experimental|BI 671800 HEA medium dose|Tablet, oral administration with 240 mL of water for each treatment
3232859|NCT01215773|Experimental|BI 671800 HEA high dose|2 Tablets, oral administration with 240 mL of water for each treatment
3232860|NCT01215773|Placebo Comparator|Placebo|Matching to HEA 200 mg tablets, oral administration
3232861|NCT01215799|Experimental|Bafetinib|
3232862|NCT01215825||HD, LD, NIL|HD: the highest daily dose of steroids receiving more than 60 mg/day LD: the highest daily dose of steroids receiving less or equal to 60 mg/day NIL: no steroid use
3232863|NCT01215864|Experimental|TCD-717|
3232864|NCT01215890|Active Comparator|risedronate plus calcium and viamin D|
3232865|NCT01215890|Placebo Comparator|placebo plus clacium and vitamin D|
3232866|NCT01215903|Experimental|Fish gelatin and omega-3|
3232867|NCT01215903|Experimental|Omega-3|
3232868|NCT01216007|Active Comparator|TIVA|TIVA
3232869|NCT01216007|Active Comparator|Inhalational|Inhalational/volatile general anesthetic
3330618|NCT02097511|Active Comparator|Metoprolol only|Metoprolol Tartrate 100 mg once a day
3232870|NCT01216020|Experimental|cetuximab plus radiotherapy|Cetuximab given one week before radiotherapy (loading dose, 400 mg/m2) plus weekly (250 mg/m2), concomitant with radiotherapy (7O Gy on clinically involved sites).
3232871|NCT01216020|Active Comparator|cisplatin plus radiotherapy|CDDP 40 mg/mq in a single weekly 1-hour infusion concomitant to radiotherapy: (70 Gy to clinically involved sites)
3330619|NCT02097524|Experimental|Sarilumab - dose 1|Single subcutaneous (SC) injection of Sarilumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
3330620|NCT02097524|Experimental|Sarilumab - dose 2|Single SC injection of Sarilumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
3330621|NCT02097524|Active Comparator|Tocilizumab - dose 1|Single intravenous (IV) administration of Tocilizumab, dose 1, plus methotrexate background treatment (dispensed and dosed according to local practice)
3330622|NCT02097524|Active Comparator|Tocilizumab - dose 2|Single IV administration of Tocilizumab, dose 2, plus methotrexate background treatment (dispensed and dosed according to local practice)
3330623|NCT02097550|Experimental|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
3330624|NCT02097550|No Intervention|Standard of care|These patients will receive the standard of care from their physician.
3330625|NCT02097563|Experimental|High Intensity Training|High intensity training: clinician attends a 6-hr live workshop in family-focused treatment techniques, and then, after taking on a case, gets weekly technical consultation sessions (by telephone) in FFT from an expert after every session;
3330626|NCT02097563|Active Comparator|Low Intensity Training|Low Intensity Training: clinician completes online workshop in FFT and then, after taking on a case, gets telephone consultation sessions after every third session.
3330627|NCT02097576|Active Comparator|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
3330628|NCT02097576|Active Comparator|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
3330629|NCT02097589|Experimental|Pneumovax-Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
3330630|NCT02097589|Placebo Comparator|Pneumovax-Placebo|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days. Pneumovax 23 injected once, intramuscularly at Day 7.
3330631|NCT02097615|Experimental|chlorhexidine gluconate|application every 24 hours, six weeks
3330632|NCT02097615|Other|Other: deionized water|application every 24 hours, six weeks
3330633|NCT02097628|Active Comparator|pressure-controlled ventilation|pressure-controlled ventilation: a peak airway pressure that provided a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column, respiratory rate 12-16 times per minute.
3330634|NCT02097628|Experimental|volume-controlled ventilation|volume-controlled ventilation: tidal volume 8-12ml/kg, respiratory rate 12-16 times per minute.
3330635|NCT02097654|Experimental|SENATOR|Physicians attending multi-morbid older patients i.e. with 3 or more chronic medical conditions receive a SENATOR software-generated report with advice details on potentially inappropriate pharmacotherapy and/or potentially inappropriate prescribing omissions.
3330636|NCT02097654|No Intervention|Control|Standard pharmaceutical care as per local practice.
3330637|NCT02097680|Experimental|Letrozole|
3330638|NCT02097680|Placebo Comparator|Placebo comparator|
3330639|NCT02097693||dyston-dyskinetic cerebral palsy|Young patients with dyston-dyskinetic cerebral palsy who receive DBS in the GPi
3232872|NCT01216046|Experimental|Treatment Arm|Subjects randomized to study drug will take VX-809 for 14 days followed by a 14 day washout. Next subjects will take VX-770 for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 for 14 days.
3232873|NCT01216046|Placebo Comparator|Placebo Arm|Subjects randomized to placebo will take VX-809 placebo for 14 days followed by a 14 day washout. Next subjects will take VX-770 placebo for 14 days followed by a 14 day washout. Lastly, subjects will take both VX-809 and VX-770 placebo for 14 days.
3330640|NCT02097706|Active Comparator|NMDA receptor antagonist|20mg/daily for 8 weeks (56 days)
3330641|NCT02097706|Placebo Comparator|Placebo tablet|1 capsule/daily for 8 weeks (56 days)
3232874|NCT01216059|Experimental|Intervention group|Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.
3232875|NCT01216059|No Intervention|Control Group|Subjects will receive a weekly text message reminder about pop-culture, sports or weather.
3232876|NCT01216085|Experimental|imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
3232877|NCT01216098|Experimental|Experimental arm - D|Experimental arm - Women randomized to this arm will receive doula support alongside standard care.
3232878|NCT01216098|No Intervention|No intervention - ND|No intervention - Women randomized to this arm will receive standard care alone.
3330642|NCT02097758|Experimental|transcatheter device closure|Choosing device size using three dimensional image and the formula without sizing balloon
3330643|NCT02097771|Active Comparator|LMA SupremeTM|
3330644|NCT02097771|Sham Comparator|Ambu AuraOnce|
3330645|NCT02097784|Other|cirrhosis with portal hypertension,ascite and acute kidney|
3232879|NCT01216111|Experimental|6 cycles of PC adjuvant chemotherapy|paclitaxel 80 mg/m2 and carboplatin (area under the curve [AUC]= 2) on day 1, 8, 15 every 28 days for six cycles
3232880|NCT01216111|Active Comparator|3 cycles of FEC followed by 3 cycles of Docetaxel|fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 intravenously on day 1 every 21 days for three cycles followed by docetaxel 100 mg/m2 intravenously
3232881|NCT01216137|Experimental|Exercise: Vestibular Rehabilitation|Balance and eye movement training
3330646|NCT02097797|Experimental|Fecal Transplantation|patients receiving the fecal transplant (fecal microbiota from a healthy donor)
3330647|NCT02097797|Sham Comparator|Sham Transplantation|patients receiving the vehicle (Physiological serum)
3330648|NCT02097810|Experimental|Entrectinib (RXDX-101)|Oral entrectinib (RXDX-101)
3330649|NCT02097836|Experimental|Single subject case series|Targeted training, 5-6 days a week for 6 months, minimum of 20 minutes per day
3330650|NCT02097875|Experimental|BLZ-100|A single dose of BLZ-100 (1, 3, 6, 12 or 18 mg) will be administered by intravenous injection approximately 48 hours prior to planned excision of skin tumor.
3330651|NCT02097901|Experimental|Microfracture|Rotator Cuff Repair AND Microfracture at rotatorcuff footprint
3330652|NCT02097901|Active Comparator|NO microfracture|Rotator cuff reinsertion without microfracture
3232882|NCT01216137|Active Comparator|Exercise Control|Bicycle ergometry and stretching
3232883|NCT01216137|No Intervention|Wait-listed Control|Wait-listed Control
3232884|NCT01216150||aspirin|group treated with aspirin alone
3232885|NCT01216150||aspirin clopidogrel|Goup treated with aspirin and clopidogrel
3232886|NCT01216215||Asthmatic sporadic and familial|
3330653|NCT02097914|No Intervention|Control|Participant receives usual care.
3330654|NCT02097914|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and once coaching call.
3232887|NCT01216215||Control subjects spradic and familial|
3232888|NCT01216254|Active Comparator|Classic electrocoagulation|Arm of the study where the classic low-frequency electrocoagulation is used during the operation
3232889|NCT01216254|Experimental|High Frequency electrocoagulation|Arm of the study where the tested high-frequency electrocoagulation is used during the operation
3232890|NCT01216267|Active Comparator|lansoprazole|lansoprazole for 7 days
3232891|NCT01216280|Placebo Comparator|2 x 10 mg placebo capsule|2 x 10 mg placebo capsules, administered orally with water, b.i.d.
3232892|NCT01216280|Experimental|10mg Natura-alpha + 10 mg placebo|10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
3232893|NCT01216280|Experimental|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
3232894|NCT01216293|Experimental|Dexlansoprazole 60 mg QD|
3232895|NCT01216293|Active Comparator|Esomeprazole 40mg QD|
3232896|NCT01216293|Placebo Comparator|Placebo QD|
3330655|NCT02097927|Experimental|High energy, low sensory|Mango-flavour beverage
3330656|NCT02097927|Experimental|Low energy, high sensory|Mango-flavour beverage
3330657|NCT02097927|Experimental|High energy, high sensory beverage|Mango-flavour beverage
3330658|NCT02097940|Active Comparator|treatment|The treatment group performed of proprioceptive exercises with shifts and one-leg jumps.
3330659|NCT02097940|No Intervention|control|The control group remained in soccer training
3330660|NCT02097953|Experimental|Daptomycin and Rifampin|Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on the first study day Drug: Rifampin Rifampin 600 mg capsules will be given orally once daily for 14 days starting on study day 2 Drug: Daptomycin Daptomycin 6 mg/kg will be given by IV infusion on study day 15
3330661|NCT02097979|Experimental|Glaucoma Educational Intervention|
3330662|NCT02097979|No Intervention|Delayed Intervention|
3330663|NCT02098005|Active Comparator|Usual care|usual care evidence-based physiotherapy
3330664|NCT02098005|Experimental|modern neuroscience approach|modern neuroscience approach
3330665|NCT02098018|Active Comparator|Program 1|Program 1
3330666|NCT02098018|Active Comparator|Program 2|Program 2
3330667|NCT02098031|No Intervention|control|
3330668|NCT02098031|Experimental|intervention|Nutritional intervention (nutrition education)
3330669|NCT02098044||Professional footballers|Retired professional footballers
3330670|NCT02098044||Control Population|members of the general public recruited from the east midlands region
3330671|NCT02098057|Placebo Comparator|Placebo|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
3330672|NCT02098057|Active Comparator|Gluten|A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
3330673|NCT02098070||Knee Pain Population|Participants who have responded to the questionnaire with self-reported pain.
3330674|NCT02098070||Non-Knee Pain Population|Participants who have responded to the questionnaire, no self-reported pain.
3330675|NCT02098096|Experimental|Negative Work|Negative work exercise via isokinetic knee extension/flexion will be performed twice per week for 12 weeks.
3232897|NCT01216306|Experimental|Television reduction curriculum|Students are taught the television reduction curriculum during the school day and parents are invited to attend after-school meetings to discuss reducing their children's television viewing.
3232898|NCT01216306|No Intervention|Control|Students will be taught the standard preschool curriculum.
3232899|NCT01216358||Arm 1: Combined contraceptive|Initiating an estrogen/progesterone contraceptive
3232900|NCT01216358||Arm 2: Progesterone only contraceptive|Initiating a progesterone-only contraceptive
3232901|NCT01216358||Arm 3 (control): Non-hormonal contraceptive|Initiating or using non-hormonal contraception or not using contraception
3232902|NCT01216371|Active Comparator|Sunitinib|one year adjuvant treatment with sunitinib
3232903|NCT01216371|Placebo Comparator|Placebo|one year treatment with placebo
3232904|NCT01216384|Experimental|BI 671800 active|SRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose. MRD part: 3 dose groups each consisting of 12 subjects (9 active, 3 placebo), subjects receive single dose followed by multiple doses with a PK sampling interval in between.
3232905|NCT01216384|Placebo Comparator|Placebo|3 subjects will receive placebo in each of the 3 doses in the SRD part and 3 doses in the MRD part
3330676|NCT02098096|Placebo Comparator|Stretching|A home exercise program consisting of stretches for the major lower extremity muscles groups will be performed twice per week for 12 weeks.
3330677|NCT02098122||Tetraplegia|
3330678|NCT02098122||Paraplegia|
3330679|NCT02098135|Experimental|ArmeoSenso|The ArmeoSenso system is an easy to set up and use upper limb rehabilitation system for the home environment. It consists of a motion capture system based on wearable sensors in combination with a personal computer as well as a therapy software that provides an ergonomic user interface, therapy games and automated assessments.
3232906|NCT01216423||Incidence of recent stroke in patients with PFO|
3232907|NCT01216423||Incidence of recent stroke in patients without PFO|
3330680|NCT02098148|Experimental|Xenon/Placebo|Participants in this group will receive three treatments of 25% xenon followed by 3 treatments of placebo (room air).
3232908|NCT01216436|Experimental|Vaccine plus untransfected DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm A), each subject will be coinjected with additional mature autologous dendritic cells that are not transfected with RNA.
3232909|NCT01216436|Experimental|Vaccine plus GITRL RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm B), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding the immune modulator GITR-L.
3232910|NCT01216436|Experimental|Vaccine plus antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm C), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding immune modulator anti-CTLA4 mAb.
3232911|NCT01216436|Experimental|Vaccine plus GITRL/ antiCTLA4 RNA DC|Subjects in all study arms will be vaccinated with mature autologous dendritic cells transfected with a combination of RNAs encoding melanoma tumor associated antigens MART, Tyrosinase, gp100, and MAGE-3. In this Study Arm (Study Arm D), each subject will be coinjected with additional mature autologous dendritic cells transfected with RNA encoding both GITR-L and anti-CTLA4 mAb immune modulators.
3330681|NCT02098148|Experimental|Placebo/Xenon|Participants in this group will receive three treatments of placebo (room air) followed by three treatments of 25% xenon.
3330682|NCT02098174|Experimental|Healthy participants|MP-3180 (1 µmol/kg or 0.372 mg/kg) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes. The iohexol comparator (Omnipaque 300, 5 mL) was then administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
3330683|NCT02098187|Active Comparator|Below target dose MP-3180|0.5 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3330684|NCT02098187|Active Comparator|2 times above target dose MP-3180|2 µmol/kg (0.744 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3330685|NCT02098187|Active Comparator|4 times above target dose MP-3180|4 µmol/kg (1.488 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3330686|NCT02098187|Active Comparator|At target dose MP-3180|1 µmol/kg (0.186 mg/kg) dose of MP-3180 by IV one time over 2 minutes.
3232912|NCT01216449|Experimental|Intravenous Citalopram|
3232913|NCT01216449|Placebo Comparator|Normal Saline|250mL of 0.9% Sodium Chloride Solution
3232914|NCT01216475|Active Comparator|Femtosecond LASIK|2 lasers refractive procedure
3232915|NCT01216475|Experimental|SMILE|Small incision lenticule extraction (SMILE)
3232916|NCT01216488|Active Comparator|40 ml of Xylocaine|
3232917|NCT01216488|Experimental|25 ml of Xylocaine|
3232918|NCT01216527|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Surgery
3232919|NCT01216527|Active Comparator|control group|only Surgery
3232920|NCT01216540||Patients receiving vancomycin|
3330687|NCT02098200|Experimental|Percutaneous treatment of TR by TriCinch|Percutaneous treatment of Tricuspid Regurgitation with TriCinch System
3330688|NCT02098213|Active Comparator|Immediate Spa treatment|Three week course of spa treatment soon after randomization
3330689|NCT02098213|Sham Comparator|Late Spa treatment|Three week course of spa treatment soon after 4,5 months visit
3330690|NCT02098239|Active Comparator|Group A|Jaundiced patients with bilirubin value >80 μmol/L. Received G17DT immediately prior to biliary stenting.
3330691|NCT02098239|Active Comparator|Group B|Patients to be treated following biliary decompression or for immediate treatment if non-jaundiced. Received G17DT 2 weeks after biliary stenting when bilirubin was <40 μmol/L.
3330692|NCT02098252|Active Comparator|Interventional therapy|"Interventional therapies include:~neurosurgery (surgical resection when the lesion is considered by a multidisciplinary team to be safely 'operable'); radiation therapy (when the AVM is smaller than 3 cm, and considered to not be safely 'operable'); radiosurgery, alone or in combination, with or without endovascular procedure; curative embolization (when the lesion is considered curable by embolization).~Patients with AVMs that the multidisciplinary team judges could potentially benefit from endovascular treatment prior to surgical resection or radiation therapy will then also be pre-randomly allocated to embolization or to no embolization."
3330693|NCT02098252|No Intervention|Conservative management (medical management)|The conservative, or medical management arm, involves pharmacological therapy as deemed appropriate for medical symptoms as determined by the treating investigator. Should patients in the conservative management arm develop hemorrhage or infarction related to their AVM, they then potentially become candidates for interventional therapy.
3330694|NCT02098265|Experimental|Experimental Group - Immediate BCI Therapy|EEG - BCI training (closed loop)
3330695|NCT02098265|Experimental|Experimental Group - Delayed BCI Therapy|Scanned and tested 4 times over a 10-week period before EEG-BCI training
3330696|NCT02098265|Experimental|Experimental Group - RecoveriX|Recruited from participants who have completed the study intervention
3330697|NCT02098265|Active Comparator|Control Group 1|48 stroke patients, 48 participants with risk factors for stroke, 48 healthy controls receiving 4-6 training sessions on the EEG-BCI, pre- and post- behavioral testing, and MRI
3330698|NCT02098265|Active Comparator|Control Group 2|24 Stroke Patients with UE impairment receiving standard FES only therapy
3232921|NCT01216553|Active Comparator|hypertonic inhalation + O2|oxygen for 30 minuets after inhalation of 3% saline 4 times daily
3232922|NCT01216553|Active Comparator|Epinephrine & bromhexine nebulized + O2|oxygen for 30 minuets after inhalation of racemic epinephrine with bromhexine 4 times daily
3232923|NCT01216566|Experimental|I. Patients with chronic neck pain|
3232924|NCT01216579|Placebo Comparator|Reference arm|Asthmatic patients managed as per British Thoracic Society guidelines by symptoms and lung function.
3232925|NCT01216579|Active Comparator|Mannitol managed arm|Group of asthmatic patients managed according to their mannitol challenge.
3330699|NCT02098278|Experimental|CAT-2003 or Placebo|All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.
3330700|NCT02098291|Experimental|G17DT|
3232926|NCT01216592||COPD|
3330701|NCT02098317|Experimental|TREATED GROUP|this group will treated with pearls containing DHA plus Vitamin D3 (500 mg and 800 IU, respectively) given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
3330702|NCT02098317|Placebo Comparator|PLACEBO GROUP|this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 24 weeks
3330703|NCT02098330|Active Comparator|: Ginkgo biloba & methylprednisolone|Patients receive Ginkgo biloba & methylprednisolone per oral.
3330704|NCT02098330|Placebo Comparator|Ginkgo biloba|Patients receive Ginkgo biloba per oral.
3232927|NCT01216605|Active Comparator|Oxytocin|
3330705|NCT02098343|Experimental|Phase Ib. APR-246 + Carboplatin/PLD.|Dose escalation of APR-246.
3330706|NCT02098343|Experimental|Phase II: Arm A. APR-246 + Carboplatin/PLD.|Experimental
3330707|NCT02098343|Active Comparator|Phase II: Arm B. Carboplatin/PLD.|Active Comparator
3330708|NCT02098356|Experimental|Low bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
3232928|NCT01216605|Placebo Comparator|Placebo|
3232929|NCT01216618|Experimental|Device|Subject starts with two clamps including device use follows by a clamp without device use
3330709|NCT02098382||Dilapan-S|125 Patients with / without caesarean section in their medical history
3330710|NCT02098408|Experimental|Standard treatment + cognitive remediation|The cognitive remediation therapy targets neurocognition as well as social cognition.
3330711|NCT02098408|Active Comparator|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling
3330712|NCT02098421|No Intervention|Control|No oxytocin while the Foley bulb is in place
3330713|NCT02098421|Experimental|Oxytocin|Use of oxytocin while the Foley bulb is in place
3232930|NCT01216618|No Intervention|Control|Subject starts with clamps without device
3232931|NCT01216644|Experimental|FLOT|Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP
3232932|NCT01216644|Active Comparator|ECF|Epirubicin 50 mg/m2, d1 Cisplatin 60 mg/m², d1 5-FU 200 mg/m², d1-d21 every 3 weeks (q3w) 3 cycles (9 weeks) pre-OP and 3 cycles (9 weeks) post-OP
3232933|NCT01216657|Experimental|sunitinib|50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
3232934|NCT01216696|Experimental|Intervention|"Intervention Details:~Drug: ipilimumab~Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first."
3232935|NCT01216709|Experimental|iron drops|
3232936|NCT01216709|Experimental|iron-fortified formula (2.3 mg iron/L)|
3232937|NCT01216709|Experimental|iron-fortified formula (12.4 mg iron /L)|
3232938|NCT01216722|Experimental|Resistance Strengthening|Body weight antigravity positioning and elastic resistance bands are used to provide resistance for strengthening in supine, sitting, and standing in subjects post liver transplant.
3232939|NCT01216722|No Intervention|Usual Care Control|Subjects perform the usual care of progressive ambulation and increased activity post liver transplant
3232940|NCT01216774|Experimental|Low load + fatigue|
3232941|NCT01216774|Active Comparator|High load|
3232942|NCT01216774|Placebo Comparator|Low load|
3232943|NCT01216787|Experimental|Treatment (gamma-secretase inhibitor RO4929097, surgery)|Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Within 35-56 days after completion of therapy, patients with stable or responsive disease undergo surgery. Patients may continue RO4929097 for 28 days after surgery in the absence of disease progression or unacceptable toxicity.
3232944|NCT01216826|Experimental|Everolimus|
3232945|NCT01216839|Experimental|Everolimus|
3232946|NCT01216865|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
3232947|NCT01216865|Active Comparator|Standard Therapy|Any therapy for diabetic foot which is routinely practiced and accepted in China
3232948|NCT01216891|Experimental|Team-based treatment|
3232949|NCT01216904|Placebo Comparator|Placebo patch|
3232950|NCT01216904|Active Comparator|Nicotine patch|
3232951|NCT01216917||Fitness|
3232952|NCT01216917||Whole-body vibration|
3232953|NCT01216917||Control|
3232954|NCT01216930||All colorectal cancer patients|
3232955|NCT01216956|Experimental|Extended release nicotinic acid|
3232956|NCT01216956|Placebo Comparator|Placebo|
3232957|NCT01216982|Active Comparator|Lovaza, omega-3 fatty acid ethyl ester|
3232958|NCT01216982|Placebo Comparator|Placebo|one gram corn oil in a soft gelatin capsule
3232959|NCT01216995|Active Comparator|Dose A|Dose A
3232960|NCT01216995|Placebo Comparator|Placebo|Placebo
3232961|NCT01217008|Experimental|GRNOPC1|Subjects who receive an injection of GRNOPC1
3232962|NCT01217021|Experimental|Assess [18F] MNI-558 and PET imaging|
3232963|NCT01217034|Experimental|TACE with sorafenib|TACE(on demand) with sorafenib till untreatable progression
3232964|NCT01217034|Active Comparator|TACE alone|TACE(on demand) till unreatable progression
3232965|NCT01217086|Active Comparator|CT-P13|
3232966|NCT01217086|Active Comparator|Remicade|
3232967|NCT01217099|No Intervention|methylprednisolone|methylprednisolone pulse azithromycin
3330714|NCT02098421|Experimental|PROMS Foley and oxytocin|Subjects who are induced due to premature rupture of membranes randomized to use of Foley bulb and oxytocin once the bulb is removed.
3330715|NCT02098421|No Intervention|PROMS no Foley bulb|Subjects who are induced due to premature rupture of membranes randomized to no Foley bulb.
3232968|NCT01217099|No Intervention|azithromycin|azithromycin
3232969|NCT01217138|Other|Original epinephrine autoinjector group|Participants were given original epinephrine autoinjector trainer wrapped by a gray sticky paper.
3232970|NCT01217138|Active Comparator|Modified epinephrine autoinjector group|Participants were given the same epinephrine autoinjector trainer wrapped by a gray sticky paper which was modified by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.
3330716|NCT02098434|Experimental|Montreal Imaging Stress Task|Math task to induce stress response
3330717|NCT02098447|Experimental|auricular vagal nerve stimulation|"Study participants (healthy and diabetics) are treated with auricular vagal nerve stimulation using four needle electrodes connected to an electrical stimulation device (PrimeStim). After an acclimatization phase the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and another 10 minutes paused stimulation. This intervention is repeated on four consecutive days. Needle electrodes stay fixed over the whole study period.~Two different stimulation schemes are tested, each being assessed twice in random order. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
3330718|NCT02098460|Placebo Comparator|Probucol,Cilostazol|Atorvastatin + Probucol-placebo + Cilostazol-placebo
3330719|NCT02098460|Placebo Comparator|Cilostazol|Atorvastatin + Probucol+ Cilostazol-placebo
3330720|NCT02098460|Active Comparator|Probucol, Cilostazol|Atorvastatin + Probucol + Cilostazol
3330721|NCT02098473|Experimental|RPC4046 Low Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
3330722|NCT02098473|Experimental|RPC4046 High Dose|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
3232971|NCT01217151|Sham Comparator|Usual treatment|The hemodynamic management will be performed according to the institution's standard of care, using fluids at the discretion of the anesthesiologist and the ICU specialist.
3232972|NCT01217151|Active Comparator|NICOM|"For volume replacement, crystalloids will be used following the standard procedure according to the anesthesiologist or ICU specialist. Mean arterial pressure and cardiac index will be assessed every 5 minutes, and a volume bolus (250 mL colloid in 10 minutes) will be used to achieve a:~Mean arterial pressure ≥ 65 mmHg (intra and postoperatively), AND~Cardiac index ≥ 2.5 L/min/m2 (intra and postoperatively).~If these cardiovascular parameters are not met after the first colloid infusion, a supplementary bolus will be added. In case of not achieving the target, additional colloid boluses and/or pharmacologic support (norepinephrine in case of persistent hypotension, dobutamine in case of low cardiac output) will be provided according to the protocol"
3232973|NCT01217164|No Intervention|higher protein|
3232974|NCT01217177|Experimental|2.5 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (2.5mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3330723|NCT02098473|Placebo Comparator|Placebo|intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks
3330724|NCT02098486|Active Comparator|Ceftraxone|ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min)
3232975|NCT01217177|Experimental|5.0 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (5.0mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3232976|NCT01217177|Experimental|10 mg everolimus + radiotherapy + cisplatin|patients treated with daily doses of everolimus (10mg) in association with radiotherapy and cisplatin (40 mg/m2 of body surface per week, 5 cycles during radiotherapy)
3232977|NCT01217203|Experimental|IPH2101 and lenalinomide|
3232978|NCT01217216|Active Comparator|Group-based Intervention|We randomly assigned 30 individuals to a group-based intervention to promote weight loss through dietary restriction and physical activity.
3232979|NCT01217216|Active Comparator|Telephone-based Intervention|We randomly assigned 22 individuals to the telephone-based intervention to promote weight loss through dietary restriction and physical activity.
3232980|NCT01217242||Children with cerebral palsy (CP)|ages 2 to < 10 years who are able to walk with or without an assistive device
3232981|NCT01217255||Brazilian Subject's|Subject's will be recruited from the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paolo (HCFMUSP); Universidade Estadual de Campinas (UNICAMP); Universidade Federal de São Paulo (UNIFESP)
3232982|NCT01217255||Canadian Subject's|Recruited from The Hospital for Sick Children
3232983|NCT01217268|Experimental|Training and supervision of staff|Staff members get training in person centered care by supervision using video-conference kit
3232984|NCT01217281|No Intervention|Control|"Full mouth supra-gingival debridement using hand instruments and ultrasonic scalers, in one session. Patient motivation and oral hygiene instructions Review and prophylaxis at 1 month, 3 months and 6 months after initial treatment session.~Full mouth periodontal therapy provided at the end of the 6month period (supra and sub- gingival full mouth scaling)"
3232985|NCT01217281|Active Comparator|Test/ Non-surgical Periodontal Therapy|"Full mouth periodontal therapy (sub and supra- gingival debridement) provided under local anaesthesia in two half-mouth sessions.~Review and prophylaxis 1 month, 3 months and 6 months after the end of the initial therapy."
3232986|NCT01217294|Sham Comparator|spinal morphine, sham block|"Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as specified by the anaesthetist performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham ultrasound guided fascia iliaca plane block with saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
3330725|NCT02098486|Active Comparator|Moxifloxacin|Intravenous moxifloxacin (400 mg/day, infused more than 60 min)
3330726|NCT02098499|Active Comparator|Haloperidol and Diphenhydramine|Haloperidol 5mg IV X1 and Diphenhydramine 25mg IV X1
3330727|NCT02098499|Active Comparator|Metoclopramide and Diphenhydramine|Metoclopramide 10mg IV X1 and Diphenhydramine 25mg IV X1
3330728|NCT02098512|Experimental|Allogeneic Transplant and Immunotherapy|We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma.
3232987|NCT01217294|Active Comparator|ultrasound guided fascia iliaca block|"Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.~Post-operative analgesia with Paracetamol 1g four times daily, and patient controlled analgesia (PCA) with morphine (1mg bolus, 5 minute lockout period)"
3330729|NCT02098525||HIV associated CM patients|The study population is all adult HIV positive patients with CM at Ramathibodi Hospital.
3330730|NCT02098538|Experimental|patients with adenoid cystic carcinoma|This is a single-arm phase II study of patients with progressive, recurrent/metastatic adenoid cystic carcinoma (R/M ACC) treated with regorafenib.
3330731|NCT02098551||Four (4)|"Group 1: Birch pollen-related atopic dermatitis (AD) (n=15) Group 2: Birch pollen allergic patients without AD (n=5) Group 3: Allergic individuals without birch pollen allergy (n=5) Group 4: Non-allergic individuals (n=5)~Patients will be tested by SPT and APT:~SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, and equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~APT: birch pollen extract, rBet v 1, rBet v 1 fragment 1, rBet v 1 fragment 2, equimolar mix of rBet v 1 fragments (160 μg/application); negative control with vaseline"
3232988|NCT01217320|Experimental|creatine supplementation|will receive 5g/d of creatine monohydrate throughout the trial
3232989|NCT01217320|Placebo Comparator|placebo|will receive 5g/d of placebo (dextrose) throughout the trial
3330732|NCT02098564|Active Comparator|strong sense of coherence control group|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3330733|NCT02098564|Experimental|strong sense of coherence intervention|Patients with a strong sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3330734|NCT02098564|Active Comparator|weak sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3330735|NCT02098564|Experimental|weak sense of coherence intervention|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3330736|NCT02098564|Experimental|medium sense of coherence intervention|Patients with a medium sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury and specific meaningful activities which they performed prior to the hand-related injury. This will be performed both in the therapy setting and as a home exercise program.
3330737|NCT02098564|Active Comparator|medium sense of coherence control group|Patients with a weak sense of coherence. Participants will perform joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program.
3330738|NCT02098577||PD patients cross-over treatment|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent cross-over treatment with the ability to walk without any assistance with mini-mental state examination score >26.
3330739|NCT02098577||PD patients stabilometric platform|30 PD patients (according to Gelb et al) in Hoen&Yahr stage 3, underwent stabilometric platform treatment, with the ability to walk without any assistance with mini-mental state examination score >26.
3232990|NCT01217333|Active Comparator|In-person|Participants in this arm have been randomized to receive Consultation Planning in-person
3330740|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF135.C10|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3330741|NCT02098590|Experimental|NF54 CPS-immunization challenged by NF166.C8|Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a heterologous malaria challenge infection by exposure to the bites of 5 NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3232991|NCT01217333|Active Comparator|Telephone|Participants in this arm have been randomized to receive Consultation Planning by telephone.
3232992|NCT01217346||cardiac syndrome X|subjects fulfilling the clinical triad of cardiac syndrome X
3330742|NCT02098590|Other|NF54 CPS-immunization challenged by NF54|[Negative control group, to assess effectiveness of CPS-immunization.] Subjects will receive CPS-immunization by bites from 3 x 15 NF54 P. falciparum infected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a homologous malaria challenge infection by exposure to the bites of 5 NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3330743|NCT02098590|Other|Control group challenged by NF135.C10|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF135.C10 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3232993|NCT01217359|Experimental|Interferon Alfa-2b|Patients will receive a single dose of interferon
3232994|NCT01217372|Experimental|Lemon supplementation YES|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
3330744|NCT02098590|Other|Control group challenged by NF166.C8|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF166.C8 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3330745|NCT02098590|Other|Control group challenged by NF54|[Control group] Subjects will receive bites from 3 x 15 uninfected mosquitoes under chloroquine prophylaxis. After stopping chloroquine subjects will receive a malaria challenge infection by exposure to the bites of NF54 P. falciparum infected mosquitoes. Subjects will be treated with Malarone if they develop a malaria infection or on day 28 after challenge infection.
3232995|NCT01217372|No Intervention|Lemon supplementation NO|No lemon supplementation
3232996|NCT01217450|Experimental|Treatment (selumetinib, cetuximab)|Patients receive oral MEK inhibitor AZD6244 once or twice daily on days 1-28 and cetuximab IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3330746|NCT02098603|No Intervention|Testing Only|
3330747|NCT02098603|Experimental|Testing & Intervention|
3330748|NCT02098616|Experimental|Arm 1|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 8 weeks
3330749|NCT02098616|Experimental|Arm 2|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 6, 8 or 12 weeks
3330750|NCT02098616|Experimental|Arm 3|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 4 weeks
3330751|NCT02098616|Experimental|Arm A|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 8 weeks
3330752|NCT02098616|Experimental|Arm B|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 6, 8 or 12 weeks
3330753|NCT02098616|Experimental|Arm C|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day for 4 weeks
3330754|NCT02098629|Active Comparator|Milrinone+Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
3330755|NCT02098629|Placebo Comparator|Saline infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion.
3330756|NCT02098642||Patients with passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT), including the mobilization of the metatarsophalangeal joint of the hallux
3330757|NCT02098642||No passive joint mobilization|Patients diagnosed with PD according to the Gelb et al in Hoen&Yahr stage 3, with Freezing of Gait and treated with a Multidisciplinary intensive rehabilitation treatment (MIRT)
3330758|NCT02098655||30 patients with PD|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) with PD in stage 3 of H&Y will undergo training of balance using a stabilometric platform
3330759|NCT02098655||12 healthy volunteers|12 healthy volunteers (3 M, 9 F, mean age 66,5 ± 6,0) served as controls will undergo training of balance using a stabilometric platform
3330760|NCT02098668||Normal, pathological cycle, infertility|healthy women PCOS Endometriosis hyperprolactinemia fertility treatment
3330761|NCT02098694|Experimental|Physiotherapy follow-up|Consultation at Physiotherapy-led Outpatient Clinic every 4 month.
3330762|NCT02098694|No Intervention|Usual care|Consultation every 4 months, twice a year by rheumatologist as usual, once a year by nurse.
3330763|NCT02098707||30 Parkinson disease patients|30 patients (12 M, 18 F, mean age 66,8 ± 8,7) diagnosed with PD in stage 3 of Hoen&Yahr (mean Unified Parkinson Disease Rating Scale [UPDRS] III 18.8±10.5) will undergo a balance training using a stabilometric platform.
3330764|NCT02098720|Experimental|Conbercept|Subjects will receive Conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 3 months, the investigator will decide whether repeat injections are needed based on the monthly assessment results.
3232997|NCT01217489||Attendees to symptomatic breast clinic|
3232998|NCT01217502|Experimental|Self management|
3232999|NCT01217528|Active Comparator|Group A|"Group A:~VT zone: 350ms~VF zone: 280ms"
3233000|NCT01217528|Experimental|Group B|"Group B:~VT zone: 320ms~VF zone: 250ms"
3233001|NCT01217541|Other|Education and supervision|Personnel in nursing home units get intervention in form of education and supervision
3233002|NCT01217541|No Intervention|Control|Only registering of patient and personnel data in the beginning and the end of the study without any form of intervention.
3330765|NCT02098759|Experimental|epilepsy early diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
3330766|NCT02098759|Experimental|standard epilepsy diagnosis|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges, and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
3330767|NCT02098772|Experimental|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
3330768|NCT02098772|Active Comparator|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
3330769|NCT02098785|Experimental|Caffeine citrate (Peyona) 400mg|Caffeine Citrate (Peyona) 400mg single dose (20ml oral solution)
3330770|NCT02098798||HD|High Definition Colonoscopy alone
3233003|NCT01217554||age-matched healthy male participants|age-matched healthy male participants without LBP
3233004|NCT01217554||participants with non specific chronic LBP|male participants with non specific chronic LBP
3330771|NCT02098798||HD + iSCAN|HD colonoscopy + iSCAN
3330772|NCT02098798||HD + Dye|High definition colonoscopy + dye spraying chromoendoscopy
3330773|NCT02098811|Experimental|1064nm laser Treatment Before Abdominoplasty|Patient will be treated with 1064nm Laser prior to abdominoplasty
3233005|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery - s.l.|
3233006|NCT01217567|Experimental|Woman with previous ceasarean section - staples left|
3233007|NCT01217567|Experimental|1st c-section, no previous lower abdominal surgery|
3233008|NCT01217567|Experimental|Woman with previous ceasarean section|
3233009|NCT01217580|Experimental|20 ml per side of 0.5% ropivacaine|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.5% ropivacaine will be injected. The procedure will be repeated on the other side.
3233010|NCT01217580|Placebo Comparator|20 ml per side of 0.9% sodium chloride|Ultrasound guided TAP blocks will be performed once patient is in the recovery area. Patients will be placed on their back with their hands resting comfortably above their head. Using an ultrasound guided technique, the ultrasound probe will be positioned on abdominal until the three lateral abdominal wall muscles and TAP are clearly imaged. A two or four inch, 20 gauge needle will be advanced using an in-plane technique. After visual confirmation that the needle tip is in the TAP, 1 ml of preservative free 0.9% sodium chloride will be injected to reconfirm correct placement in the TAP. Then 20 ml of 0.9% preservative free sodium chloride will be injected. The procedure will be repeated on the other side.
3330774|NCT02098811|Experimental|940nm Laser Treatment Before Abdominoplasty|Patient will be treated with 940nm Laser prior to abdominoplasty
3330775|NCT02098824|Active Comparator|Galantamine|Single administration of capsule containing 16 mg Galantamine
3233011|NCT01217593|Experimental|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
3330776|NCT02098824|Placebo Comparator|Placebo|Single oral administration of capsule containing placebo
3330777|NCT02098824|Active Comparator|Methylphenidate|Single administration of capsule containing 10 mg Methylphenidate
3330778|NCT02098837|Active Comparator|Immediate switch|Patients will be randomised to switch from a boosted PI to dolutegravir at baseline.
3330779|NCT02098837|Active Comparator|Deferred switch|Patients will be randomised to switch from a boosted PI to dolutegravir after 48 weeks.
3330782|NCT02098889|Active Comparator|hyoscine-N-butyl bromide|A single dose intravenously(IV) 20ml hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose 20ml IV NaCl) on the active phase of labor
3233012|NCT01217593|Active Comparator|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
3233013|NCT01217619|Experimental|Erlotinib|Single-arm
3233014|NCT01217632|Placebo Comparator|FG-3019 Placebo|Placebo will be administered at 15-45 mg/kg every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
3233015|NCT01217632|Experimental|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
3233016|NCT01217645|Experimental|150 mg [14C] AZD6765|
3233017|NCT01217658|Experimental|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
3233018|NCT01217658|Active Comparator|AAP Education|Those receiving the control group allocation will be counseled in the American Academy of Pediatrics guidelines regarding Infant Colic (AAP Infant Colic counseling).
3233019|NCT01217671|Experimental|Alpha-1 Antitrypsin|
3233020|NCT01217671|Placebo Comparator|Placebo|
3233021|NCT01217723|Experimental|Thymoglobulin|Thymoglobulin will be administered on Days -2, -1 prior to the transplant and on the day of transplant.
3330783|NCT02098889|Placebo Comparator|Saline(0,9NaCl)|Placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
3233022|NCT01217723|Other|No Thymoglobulin|Patients will receive a standard preparative regimen. (i.e. one that does not normally contain Thymoglobulin.)
3233023|NCT01217736|Experimental|VTP-27999|
3330784|NCT02098902|Experimental|Smart Moms Intervention|This arm will receive the Smart Moms intervention immediately following randomization.
3330785|NCT02098902|No Intervention|Waitlist control group|This arm will receive a modified version of the Smart Moms intervention after the 6-month assessment.
3330786|NCT02098915|Experimental|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide
3330787|NCT02098915|Placebo Comparator|control arm|the control arm will receive placebo
3330788|NCT02098928|Active Comparator|Hand-acupuncture group|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
3330789|NCT02098928|Placebo Comparator|Electric-acupuncture group|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
3330790|NCT02098941||Topiramate|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs.
3330791|NCT02098941||Levetiracetam|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs.
3330792|NCT02098941||Oxcarbazepine|Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs.
3330793|NCT02098954|Experimental|experimental|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme(gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for 150mg/day, day 9-21 every cycle, after 4 cycles, erlotinib should be used daily), after 4 cycle of combined chemotherapy, patients will receive erlotinib for further treatment until progression disease.
3330794|NCT02098967|Experimental|Acute myeloid leukemia patients|
3330795|NCT02098967|Experimental|Cohort 0|
3330796|NCT02098967|Experimental|Solid tumor patients|
3233024|NCT01217736|Active Comparator|aliskiren|
3233025|NCT01217736|Placebo Comparator|placebo|
3233026|NCT01217762|Experimental|11 Gy IRay|Day 0 Lucentis followed by 11 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 2)
3233027|NCT01217762|Experimental|16 Gy IRay|Day 0 Lucentis followed by 16 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 27)
3233028|NCT01217762|Experimental|16 Gy IRay - Radiation First|16 Gy IRay and Lucentis PRN (N = 13)
3330797|NCT02098980|Active Comparator|Dietary Supplement: Vitamin D|Vitamin D supplement 4000 IU/day for 6 months
3330798|NCT02098980|Placebo Comparator|Placebo|Placebo for 6 months
3330799|NCT02099032|Experimental|3g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
3330800|NCT02099032|Experimental|5 g milk polar lipid fortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks.
3330801|NCT02099032|Placebo Comparator|Unfortified cheese product|Women will have to consume daily 100g of a cheese product instead of usual cheese products during four weeks
3330802|NCT02099045||Ultrasound examination|All patients over the age of 18 presenting in the emergency department.
3330808|NCT02099071|Experimental|Group 1|Six subjects will receive a single oral dose of ACT-389949 1 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330809|NCT02099071|Experimental|Group 2|Six subjects will receive a single oral dose of ACT-389949 5 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3233029|NCT01217762|Experimental|24 Gy IRay|Day 0 Lucentis followed by 24 Gy IRay, Lucentis at Month 1 and Lucentis PRN (N = 19)
3233030|NCT01217775|Experimental|PH80 intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
3330810|NCT02099071|Experimental|Group 3|Six subjects will receive a single oral dose of ACT-389949 20 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330811|NCT02099071|Experimental|Group 4|"Subjects will participate in two different treatment periods separated by a washout of 7-10 days between the study drug administrations.~In the first treatment period six subjects will receive a single oral dose of ACT-389949 50 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.~In the second treatment period, subjects randomized to ACT-389949 will receive a single oral dose of ACT-389949 50 mg in fed condition, 30 minutes after the start of a high fat and high calorie breakfast."
3330812|NCT02099071|Experimental|Group 5|Six subjects will receive a single oral dose of ACT-389949 100 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330813|NCT02099071|Experimental|Group 6|Six subjects will receive a single oral dose of ACT-389949 200 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330814|NCT02099071|Experimental|Group 7|Six subjects will receive a single oral dose of ACT-389949 500 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330815|NCT02099071|Experimental|Group 8|Six subjects will receive a single oral dose of ACT-389949 1000 mg and two subjects will receive a single oral dose of placebo. Treatment will be administered in the morning on an empty stomach.
3330816|NCT02099097|Active Comparator|Standard Care|"usual care, which consists of four (face-to-face or telephone) counseling sessions with a trained nurse who has expertise in helping cancer patients quit smoking. This is the same as the treatment an MSK patient who enrolls in the MSK smoking cessation program would receive.~To collect further data to improve the game intervention, the investigators will conduct semi-structured telephone interviews with patients who were randomized to the treatment arm but did not play the game during the one month intervention period. The purpose of the interviews is to elicit qualitative feedback on any barriers that may have prevented participants from playing. At the completion of the intervention period, patients will be asked if they would like to participate in a telephone interview. Telephone interviews will take about twenty minutes and will be held at a time that is convenient for the patient."
3330817|NCT02099097|Experimental|Smoking Cues Coping Skills Game (SC+SCCS/Quit IT).|Smokers randomly assigned to SC+SCCS/Quit IT will receive all the components of Standard Care. The patient will be oriented and trained face-to-face (during their hospitalization) on use of the game by study staff using an iPad. The orientation and training session will comprise: 1) Overview of the game and its objectives; 2) discussion of the rules of the game; 3) watching a 10 minute tutorial given by the game narrator (avatar); 4) answering all patient questions; and 5) evaluation of the patient's comprehension of game play via a 17 question survey. Once patients have access to QuitIT, they will also receive a set of Coping Cards
3330818|NCT02099123|Experimental|Atorvastatin|40 mg atorvastatin (2 x 20 mg atorvastatin), taken orally once daily
3330819|NCT02099123|Placebo Comparator|Placebo|Placebo (2 x 20 mg placebo) taken orally once daily
3330820|NCT02099136|Experimental|Group I (placebo)|Patients receive placebo PO BID for 14 days.
3330821|NCT02099136|Experimental|Group II (low-dose celecoxib)|Patients receive low-dose celecoxib PO BID for 14 days.
3330822|NCT02099136|Experimental|Group III (higher dose celecoxib BID)|Patients receive higher dose celecoxib PO BID for 14 days.
3330823|NCT02099136|Experimental|Group IV (higher dose celecoxib QD)|Patients receive same dose of celecoxib PO as Group III QD for 14 days.
3330824|NCT02099136|Experimental|Group V (high-dose celecoxib)|Patients receive high-dose celecoxib PO QD for 14 days.
3330825|NCT02099149||Controls|Infants born to GBS colonized mother who do not develop GBS disease
3330826|NCT02099149||Cases|Infants with culture confirmed GBS disease
3233031|NCT01217775|Placebo Comparator|Placebo intranasal spray|Start using study medication on 14th of the cycle, or the day symptoms start to bother, or if no symptoms on day 21st of the cycle but no later than day 21st of the cycle, up to 6-times per day, and continuing until day 2-3 of the menses
3233032|NCT01217788|Experimental|PH94B intranasal spray|
3233033|NCT01217788|Placebo Comparator|Placebo intranasal spray|
3330827|NCT02099175|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma:~First Cycle and every other cycle:~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Second Cycle and every other cycle:~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w~Intestinal Type Adenocarcinoma with functional p53:~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by Radiotherapy"
3330828|NCT02099188|Experimental|Multimodality treatment|"Squamocellular Carcinoma, Sinonasal Undifferentiated Carcinoma:~Docetaxel at 75 mg/m2 as IV infusion on Day 1 q3w~Cisplatin at 80 mg/m2 as IV infusion on Day 1 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 1 to Day 4 q3w~Small cell carcinoma neuroendocrine type, Pure neuroendocrine carcinoma and grade III-IV Esthesioneuroblastoma.~Cisplatin at 33 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Etoposide at 150 mg/m2/day as IV infusion from Day 1 to Day 3 q3w . Second cycle and every other cycle~Adriamycin at 20 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Ifosfamide at 3000 mg/m2/day as IV infusion from Day 1 to Day 3 q3w.~Intestinal Type Adenocarcinoma with functional p53.~Leucovorin* at 250 mg/m2/day as IV infusion from Day 1 to Day 5 q3w.~Cisplatin at 100 mg/m2 as IV infusion on Day 2 q3w~5-fluorouracil at 800 mg/m2/day as IV infusion from Day 2 to Day 5 q3w~Followed by radiotherapy"
3233034|NCT01217853||SENSIMED Triggerfish|
3330829|NCT02099201|Experimental|Group A1|Ten subjects will receive ACT-389949 40 mg and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3330830|NCT02099201|Experimental|Group A2|Ten subjects will receive ACT-389949 (Predicted to be 200 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3330831|NCT02099201|Experimental|Group A3|Ten subjects will receive ACT-389949 (Predicted to be 800 mg) and 3 subjects will receive placebo, once a day for 9 days Medication will be administered orally, in the morning, following an overnight fast.
3233035|NCT01217866||LAVH, techniques|Women aged 35-75 who underwent laparoscopic assisted vaginal hysterectomy via either suture technique vaginally or Enseal coagulation cutting device vaginally
3233036|NCT01217879||Group 1|
3233037|NCT01217905|Experimental|1|
3233038|NCT01217918|Experimental|Cohort 1|PH-797804
3233039|NCT01217918|Experimental|Cohort 2|PH-797804
3233040|NCT01217918|Experimental|Cohotr 3|PH-797804
3233041|NCT01217931|Experimental|Group 1|Pazopanib + possible Bevacizumab
3330832|NCT02099201|Experimental|Group B1|Ten subjects will receive ACT-389949 200 mg and 3 subjects will receive placebo, every 3 days for 13 days (a total of 5 doses), administered orally, in the morning, following an overnight fast.
3330833|NCT02099201|Experimental|Group B2|Ten subjects will receive ACT-389949 (provisionally 200 mg) and 3 subjects will receive placebo, every 2 days for 9 days (a total of 5 doses), administered orally, in the morning following an overnight fast. The actual dose will depend on the emerging data from Group B1.
3330834|NCT02099201|Experimental|Group C1|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
3330835|NCT02099201|Experimental|Group C2|10 subjects will receive ACT-389949 and 3 subjects on placebo. The actual dose will depend on the emerging data from the previous groups but will be within the dose range or lower than the dose range tested in Part A. The dosing schedule will be one of those already tested in Part A and/or Part B.
3330836|NCT02099214|Experimental|Patients with HFE hereditary haemochromatosis|"The patients (40) will undergo a medical examination in order to analyse their medical history, cardiovascular parameters and check inclusion and non-inclusion criterions.~Then will be performed :~An electrocardiogram~Blood tests : iron and cardiac markers (serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP), beta-hCG if needed, serum bank~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~A 3Tesla abdominal MRI~An echocardiography at rest."
3330837|NCT02099214|Experimental|Healthy volunteers|"The healthy volunteers (10 men and 10 women) will undergo :~A urinary pregnancy test (if applicable)~A 3Tesla cardiac MRI repeated twice (in order to respect the reproducibility criterion)~An echocardiography at rest."
3330838|NCT02099227||Ultrasound|those who received point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
3330839|NCT02099227||No Ultrasound|those who did not receive point-of-care ultrasound as part of their emergency department evaluation/ treatment for suspected soft tissue infections
3330840|NCT02099240|Active Comparator|Intravenous antibiotics|Intravenous antibiotics for the full duration of therapy
3330841|NCT02099240|Active Comparator|oral antibiotics|intravenous antibiotic therapy plus early switch to oral antibiotic therapy
3330842|NCT02099253|Experimental|Youth Group|People in this group, aged 18~39,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
3330843|NCT02099253|Experimental|Middle-aged Group|People in this group, aged 40~64,were accepted an initial dose of 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
3330844|NCT02099253|Experimental|Older Group|People in this group, aged 65~80,were accepted an initial dose of 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
3330845|NCT02099279||echocardiography examination|
3330846|NCT02099292|Experimental|Rituximab and DexaBEAM|Rituximab and DexaBEAM
3233042|NCT01217931|Experimental|Group 2|Pazopanib + possible Everolimus
3233043|NCT01217931|Experimental|Group 3|Everolimus + possible Bevacizumab
3330847|NCT02099305|Experimental|Intervention|Receive Adolescent Depression Awareness Program (ADAP) intervention
3330848|NCT02099305|No Intervention|Wait list control|no intervention
3330849|NCT02099331|Experimental|Melatonin|The investigators will administer melatonin at 40mg by mouth (two 20 mg tablets), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
3330850|NCT02099331|Placebo Comparator|Placebo|The investigators will administer matching Placebo by mouth (two tablets to match Melatonin), nightly prior to sleep. The administration will start 2 days prior to the scheduled surgery date and will continue until post-operative day 3.
3330851|NCT02099357|Placebo Comparator|Placebo|Daily supplementation with 3g of dextrose during eight weeks and placebo ampoules each two weeks.
3330852|NCT02099357|Experimental|Creatine|Daily supplementation with 3g of monohydrate creatine during eight weeks. Placebo ampoules each two weeks.
3330853|NCT02099357|Active Comparator|Vitamin D|Daily supplementation with 3g of dextrose during eight weeks. Vitamin D supplementation, 25000 IU each two weeks.
3330854|NCT02099383|Active Comparator|normal saline, bolus|Patients of study group will receive intravenous normal saline 20cc per kilogram of body weight, one third of which will be given as a bolus followed by delivery of the remaining two third as a constant infusion over a period of 8 hours.
3330855|NCT02099383|No Intervention|normal saline, control|Patients of control group will receive intravenous normal saline 60 cc per hour.
3330856|NCT02099396|Experimental|docetaxel+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out on the second day; q3wkb"
3233044|NCT01217931|Experimental|Group 4|Everolimus + possible Pazopanib
3330857|NCT02099396|Experimental|gemcitabine+lobaplatin|"Pretreatment: 15 mg dexamethasone is administered orally every day since one day before administration with docetaxel for continuous three days. Dexamethasone 10 mg i.v. and promethazine 25mg im are administered 30 min before administration with docetaxel to prevent anaphylactic responses.~Intravenous infusion with gemcitabine 675mg/m2 for 90 min is carried out on the first day and the eighth day of each cycle for 21 days; intravenous infusion with lobaplatin 30 mg/m2 for two hours is carried out; intravenous infusion with docetaxel 75mg/m2 for one hour is carried out on the first day; q3wkb"
3330858|NCT02099409|Experimental|Starting with FLORENCED2 followed by open loop|Start 2 Overnight periods with closed loop through FLORENCED2 Device , followed by 2 overnight periods with open loop.
3233045|NCT01217931|Experimental|Group 5|Bevacizumab + possible Pazopanib
3233046|NCT01217931|Experimental|Group 6|Bevacizumab + possible Everolimus
3233047|NCT01217970|Active Comparator|Ibudilast 20mg BID|Ibudilast 20mg oral BID 7 days
3233048|NCT01217970|Active Comparator|Ibudilast 50mg BID|Ibudilast 50mg oral BID 7 days
3233049|NCT01217970|Placebo Comparator|Placebo|Placebo oral BID 7 days (0mg ibudilast)
3330859|NCT02099409|Experimental|Start open loop followed by FLORENCED2|Start with 2 overnight periods with open loop , followed by 2 overnight with closed loop FLORENCED2
3330860|NCT02099435||Hemospray to treat lower GI bleeds|
3330861|NCT02099448||Elective Cardiac Catheterization|
3330862|NCT02099474|Experimental|Raltegravir|All women have been prescribed raltegravir before study participation.
3330863|NCT02099487|Experimental|Radiation|To evaluate safety and feasibility of hypofractionated Intensity Modulated Radiotherapy
3330864|NCT02099500|Experimental|Stem Cell Injection|Non-Randomized
3330865|NCT02099539|Experimental|ALT-803|
3330866|NCT02099552||XLHED|Those with the condition of XLHED
3330867|NCT02099565||OPTIMA study patients|The study population will consist of OPTIMA study patients who have not been lost for follow-up and have given a written informed consent.
3330868|NCT02099578|Placebo Comparator|Control Group|Freeze-dried placebo powder - two doses of 25 g/day for 8 weeks
3330869|NCT02099578|Active Comparator|25 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry and placebo powder - one dose of 25 g/day of each for 8 weeks
3330870|NCT02099578|Experimental|50 g of Freeze-dried Strawberry Powder|Freeze-dried strawberry powder - two doses of 25 g/day for 8 weeks
3330871|NCT02099604|Experimental|Vitamin D|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin
3330872|NCT02099604|No Intervention|Standard of Care|Pegylated Interferon Alpha 2b + Ribavirin
3330873|NCT02099617|Experimental|Drug Eluting Stent|Synergy II
3330874|NCT02099617|Active Comparator|Bare Metal Stent|Omega or Rebel
3330875|NCT02099656|Experimental|Lebrikizumab|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab on Days 1 and 8, and on Weeks 4 and 8.
3330876|NCT02099656|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (not specified in the protocol) and a second controller medication, will receive SC injection of lebrikizumab matching placebo on Days 1 and 8, and on Weeks 4 and 8.
3330877|NCT02099669|Experimental|Liberal transfusion strategy|"Intervention: Red Blood Cell transfusions. Transfuse pRBC at a higher threshold- maintain Hb level between 110 and 120 g/L: to achieve this, 2 units of pRBCs are transfused when Hb level is < 105 g/L and 1 unit of RBCs when Hb level is 105-110 g/L.~Transfusions administered more frequently."
3330878|NCT02099669|Active Comparator|Restrictive transfusion strategy|Intervention: Red Blood Cell transfusions. Transfuse pRBC at standard of care thresholds- maintain Hb level between 85 and 100 g/L: to achieve this, 2 units of packed red blood cells (pRBCs) will be transfused when the Hb level is < 80 g/L and 1 unit of pRBCs when Hb level is 80-85 g/L: standard administration
3330879|NCT02099695|Active Comparator|Oxybutynin Chloride|"Tablet~Dose 5,0 or 10 mg/ day"
3330880|NCT02099695|Placebo Comparator|Placebo|- Tablet
3330881|NCT02099734||A: suspicion of germ cell tumor and/or a testicular mass|patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
3330882|NCT02099734||B: family members of Group A|relatives of patients with GCTs or testicular tumors
3330883|NCT02099734||C: healthy controls unrelated to Group A or B|healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
3330884|NCT02099747|Active Comparator|hATG + CsA|Control Arm
3330885|NCT02099747|Experimental|hATG + CsA + Eltrombopag|Experimental
3330886|NCT02099760||STD testing (GC/Ct/trich)|
3330887|NCT02099773||support workers & AAC users|Support workers who use KeyWordSigning in the communication with their client who has an intellectual disability
3330888|NCT02099773||support workers & KWS users|Support workers who use aided AAC in the communication with their client who has an intellectual disability
3330889|NCT02099812||Obese|Obese individuals
3330890|NCT02099812||Non-obese|Non-obese individuals
3330891|NCT02099825|Experimental|Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
3330892|NCT02099825|Active Comparator|Non-Anxious Adult Males|One time dosage of d-cycloserine and mifepristone at Session 2 prior to public speaking exposure sessions.
3330893|NCT02099851|Experimental|Carotid body ablation|Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
3330894|NCT02099877||Nulliparous requesting epidural|"Nulliparous parturients ≥ 37 weeks gestation, with ASA I or II, with an uncomplicated course of singleton vertex pregnancy requesting epidural analgesia for pain relief will be included.~When the patient requests analgesia, cervical dilatation will be verified by the obstetric resident/attending. Then epidural analgesia will be initiated with a test dose of 3mL of 2% lidocaine and epinephrine 15 µg and a dose of fentanyl 100 µg diluted to a total volume of 10 mL with preservative- free normal saline. Before placement of the epidural, venous blood (2 mL) will be drawn into special tubes. Genotyping of OPRM1: p.118A/G will be also performed."
3330895|NCT02099890|Experimental|Anti-inflammatory Supplementation|Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
3330896|NCT02099903|No Intervention|Medical therapy for heart failure|Standard optimized medical therapy for heart failure.
3330897|NCT02099903|Experimental|Renal denervation + medical therapy.|Transcatheter Renal Denervation with irrigated radiofrequency catheter + standard medical therapy.
3330898|NCT02099916|Active Comparator|gonadotropins plus DHEA|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Prior to the stimulation will be treated with DHEA 25 mg PO tid for 12 weeks.
3330899|NCT02099916|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
3330900|NCT02099929|Experimental|Coffee with Sugar|300mL of Coffee with 30g of Sugar
3330901|NCT02099929|Experimental|Coffee without Sugar|300mL of Coffee without Sugar
3330902|NCT02099929|Experimental|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
3330903|NCT02099929|Sham Comparator|Water with Sugar|300mL of Water with 30g of Sugar
3330904|NCT02099929|Sham Comparator|Water without Sugar|300mL of Water without Sugar
3233050|NCT01217996|Other|Intervention Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (intervention).
3233051|NCT01217996|Other|Control Group|Children treated for a brain tumor (BT) or acute lymphoblastic leukemia (ALL) will complete the computerized working memory training program (control).
3233052|NCT01218074|Active Comparator|Thromboelastography alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performances.
3330905|NCT02099955|No Intervention|Screening Study|To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
3330906|NCT02099955|Experimental|Pulmonary Arm|"Vitamin D3 Supplementation and Pulmonary Function:~To determine the relationship between levels of vitamin D and overall pulmonary function, as measured by PFTs (spirometry and body plethysmography).~To determine effects of vitamin D supplementations on overall pulmonary function and selected biomarkers of inflammation (FeNO, pH, 8- isoprostane levels)."
3330907|NCT02099955|Experimental|Endocrine Arm|"Vitamin D3 Supplementation and Endocrine Function:~To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR."
3233053|NCT01218074|Experimental|Aggregometry+Tromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
3233054|NCT01218152||cancer patients|patients who are seen by oncologists and who are willing to donate an extra blood sample when blood is taken routinely
3233055|NCT01218152||NF1 patients|patients, who have neurofibromatosis type 1 and who have developped an MPNST,donating a blood sample
3233056|NCT01218165|No Intervention|Control Group|without intervention
3233057|NCT01218165|Experimental|Intervention Group|This group receives a probiotic drink daily for 6 week.
3233058|NCT01218178||Sodium bicarbonate plus NAC|Sodium bicarbonate plus NAC
3233059|NCT01218178||Saline hydration plus NAC|Saline hydration plus NAC
3233060|NCT01218191||Subarachnoid hemorrhage|Patients presenting a SAH
3233061|NCT01218217|Experimental|SQ109 75 mg|75 mg SQ109 monotherapy daily
3330908|NCT02099968|Experimental|Comprehensive Lifestyle Modification|
3330909|NCT02099968|Active Comparator|Standard Lifestyle Modification / modified DASH|
3330910|NCT02099981|Experimental|Control Group|Control subjects will receive AG.
3233062|NCT01218217|Experimental|SQ109 150 mg|150 mg SQ109 daily
3233063|NCT01218217|Experimental|SQ109 300 mg|300 mg SQ109 daily
3233064|NCT01218217|Experimental|SQ109 150 mg + RIF|150 mg SQ109 + RIF standard dose daily
3233065|NCT01218217|Experimental|SQ109 300 mg + RIF|300 mg SQ109 + RIF standard dose daily
3330911|NCT02099981|Experimental|Type 1 diabetes|Type 1 diabetic subjects will receive AG.
3330912|NCT02099994|Experimental|A - AM|Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.
3330913|NCT02099994|Experimental|B - DDDAM|pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.
3330914|NCT02099994|Experimental|C - DeDeDeAM|"Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.~Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20."
3330915|NCT02100020|Experimental|Direct Referral to Physical Activity|The REF group will be referred to a centre-based community exercise program in their respective community (either the MacWheelers or Revved Up) by a clinical neurologist where they will be prescribed exercise based on the PAGs for adults with MS, and according to their individual capabilities.
3330916|NCT02100020|No Intervention|Control|The CON group will be provided with a print copy of the PAGs and a link to an online resource for physical activity information.
3330917|NCT02100033|Experimental|acupuncture|acupuncture manipulation
3233066|NCT01218217|Active Comparator|RIF Mono|Standard dose Rifampicin monotherapy daily
3233067|NCT01218230|Active Comparator|Intravitreal Pegaptanib|
3233068|NCT01218256|Active Comparator|Hypertrophy resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
3233069|NCT01218256|Active Comparator|Endurance resistance training|Aerobic endurance training combined with hypertrophy resistance training in type 2 diabetes mellitus.
3233070|NCT01218269|Other|no arms|all patients will receive the treatment - there is only one arms
3233071|NCT01218282|Experimental|Home Exercise Training Group A1|Patients assigned to this arm maintain the prescribed walking speed during the training with a metronome
3233072|NCT01218282|Experimental|Home Exercise Training Group A2|Patients assigned to this arm cover a fixed distance in a given period of time.
3233073|NCT01218282|No Intervention|Control|
3233074|NCT01218295|Experimental|Respiratory muscle training|Patients assigned to this arm train the respiratory muscles by means of normocapnic hyperpnea.
3233075|NCT01218321||Antiepileptic treatment group|Group of patients treated by antiepileptic medications
3233076|NCT01218334||1|Cardiac Inpatient
3233077|NCT01218334||2|Cardiac Outpatient
3233078|NCT01218334||3|Cardiac Clinic Patient
3233079|NCT01218347|Experimental|Rosuvastatin|rosuvastatin treatment
3233080|NCT01218360||Participants|All participants enrolled
3233081|NCT01218373|Active Comparator|Intervention Group: HOMESWEETHOME services|Monitoring and alarm handling services. eInclusion services. Domotica services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
3233082|NCT01218373|Placebo Comparator|Control Group: No HOMESWEETHOME services|Normal care.
3233083|NCT01218386|Experimental|Study Group|"Start with estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~If day 25 is Monday: 6 days Tuesday: 10 days Wednesday: 9 days Thursday: 8 days Friday: 7 days Saturday: 6 days Sunday: 6 days of Progynova, 2x2 mg per day After this pretreatment: Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation"
3330918|NCT02100046|Experimental|ethosuximide|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
3330919|NCT02100046|Other|control group|The purpose of this study is to assess the effectiveness of ethosuximide (Zarontin®) on the pain symptoms and quality of life in patients with neuropathic traumatic pain compared to a control group.
3330920|NCT02100059|Experimental|Electrical Stimulation (TENS)|The TENS (transcutaneous electrical nerve stimulation) electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
3233084|NCT01218386|Active Comparator|Control group|Standard GnRH antagonist treatment protocol with start rFSH (Puregon®) at a dose of 150 IU From day 2 of the cycle onwards; GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation
3233085|NCT01218412|Experimental|Web-based, Mi=Based Intervention|4 session web-based, MI-based intervention.
3233086|NCT01218425|Experimental|Medication|In this study, a crossover design is applied. All participants receive all three treatments in randomized order on separate days.
3330921|NCT02100085||Observational group|Subjects in the period less than 48 weeks after the final administration of GX-188E
3330922|NCT02100111||Participants with advanced or metastatic BCC|Participants with BCC who received any treatment including surgeries, radiation, photodynamic therapy, chemotherapy, supportive/palliative care, or other therapies, will be included as a part of study.
3330923|NCT02100137||Women with endometrial hyperplasia|
3330924|NCT02100150|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3233087|NCT01218451|Experimental|Group 1|Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3233088|NCT01218451|Experimental|Group 2|Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3233089|NCT01218451|Active Comparator|Group 3|Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
3233090|NCT01218464|Experimental|Conventional plus MSC treatment|Participants will receive conventional treatment plus a dose of MSC from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
3233091|NCT01218464|Experimental|Conventional plus pacebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until 2 years study visit
3330925|NCT02100150|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and water
3330926|NCT02100163|Experimental|Virtual Reality Hypnosis|The patient receives VRH daily.
3330927|NCT02100163|Experimental|Audio Hypnosis|The patient receives Audio Hypnosis daily.
3330928|NCT02100163|Experimental|Standard Treatment|The patient receives the standard treatment. This is a control group and there are no interventions.
3330929|NCT02100176||Rotigotine and MIRT|Group 1 - 20 Patients with PD (H&Y stages 1,5-2) in therapy only with Rotigotine will undergo a Multidisciplinary intensive rehabilitation treatment (MIRT).
3330930|NCT02100176||Control group, only Rotigotine|Group 2 - 20 Patients with PD (H&Y stages 1,5-2)
3330931|NCT02100202|Placebo Comparator|Placebo|Capsules containing 250 mg of placebo, two times a day
3330932|NCT02100202|Experimental|BioTurmin|Capsules containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
3330933|NCT02100202|Experimental|BioTurmin-WD|Capsules containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
3330934|NCT02100202|Experimental|MaQxan|Capsules containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
3330935|NCT02100215|Experimental|Expert Modeling|Participants will have access to 70 minutes of expert modeling videos available over 5 weeks on an online learning management system. The investigator will be the expert model in the videos. Expert modeling videos will address content related to seven concepts: Taking report with a graphic organizer worksheet, prioritizing patient care, delegating to unlicensed assistive personnel, safety checks in patient rooms, focused physical assessments, safe medication administration, and using a standardized healthcare provider communication tool on the telephone.
3330936|NCT02100215|Active Comparator|Voice Over PowerPoint|Participants will have access to 60 minutes of voice over PowerPoint slides, available over 5 weeks on an online learning management system, specifically to match exposure and content with the expert modeling video group. The script for PowerPoint will contain content related to the aforementioned seven concepts. There will be static photos, but no expert modeling videos, on PowerPoint slides. The investigator will narrate the voice over PowerPoint.
3330937|NCT02100215|Placebo Comparator|Reading|Participants will have access to articles, policies, and procedures on an online learning management system. The estimated time required for participants to review these materials is 45 minutes
3330938|NCT02100241|Experimental|Active stretching with currents|Active stretching performed while currents are applied on hamstring muscles.
3330939|NCT02100241|Experimental|Active stretching|Active stretching are performed.
3330940|NCT02100241|No Intervention|Control group|Routine clinical practice
3330941|NCT02100254|Experimental|Arm I (personal narrative)|Participants view videos with information about CRC and screening delivered by personal narrative.
3330942|NCT02100254|Active Comparator|Arm II (fact-based message)|Participants view videos with information about CRC and screening delivered by informative fact-based message.
3330943|NCT02100267|Experimental|Asthma patients|
3330944|NCT02100267|Experimental|Healthy volunteers|
3330945|NCT02100293|Active Comparator|standard dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.6 mg/kg
3330946|NCT02100293|Active Comparator|low dose rocuronium group|pretreatment of saline 100ml and rocuronium 0.45 mg/kg
3330947|NCT02100293|Active Comparator|low dose rocuronium plus magnesium group|pretreatment of magnesium sulfate 30 mg/kg and rocuronium 0.45 mg/kg
3330948|NCT02100306|Experimental|Patients|"Patients will receive:~Auditory Feedback 100% Auditory Feedback 50% alternate"
3233092|NCT01218490|Experimental|lymphadenectomy|after surgery of the ovarian cancer, patient will have Pelvis and aortic-cava lymphadenectomy
3233093|NCT01218490|No Intervention|no lymphadectomy|after surgery, the patient will not have pelvic and aortic-cave lymphadenectomy
3330949|NCT02100332||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
3330950|NCT02100358||acute cholecystitis|acute cholecystitis
3330951|NCT02100371|Experimental|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
3330952|NCT02100384|Active Comparator|Ultrasonics|Ultrasonic instrumentation for peri-implant maintenance
3330953|NCT02100384|Active Comparator|Scalers|Titanium Scalers instrumentation for peri-implant maintenance
3233094|NCT01218503|Experimental|CHOICES - obese|behavioral weight loss treatment - overweight/obese females
3233095|NCT01218529|Experimental|Whole Brain Radiation Therapy (WBRT) + lapatinib|Whole Brain Radiation Therapy (30Gy in 10 fractions) and lapatinib 1250mg once daily for 2 weeks followed by lapatinib treatment 1500mg once daily for 4 weeks.
3233096|NCT01218555|Experimental|Lenalidomide combination with everolimus|Non-randomized study of escalating doses of daily, orally administered lenalidomide in combination with standard doses of everolimus, an orally available mammalian target of rapamycin (mTOR) inhibitor.
3330954|NCT02100397|Experimental|Dose|A dose of S.paratyphi will be given to up to 20 participants to determine the attack rate.
3330955|NCT02100423|Experimental|Treatment (curcumin, cholecalciferol)|Patients receive curcumin PO daily on days 1-28 and cholecalciferol PO daily on days 8-28 of course 1 and days 1-28 of subsequent courses. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients achieving partial response or better may receive treatment for a total of 2 years.
3330956|NCT02100436|Experimental|Cohort 3-8 years old|up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3330957|NCT02100436|Experimental|Cohort 6-35 months old|up to 100 subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart. up to 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3330958|NCT02100436|Experimental|Cohort 9-17 years old|up tp 100 subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
3330959|NCT02100449|Other|Lung ultrasound and Doppler, pneumonia|In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed in patients with high clinical suspicion of pneumonia on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
3330960|NCT02100449|Other|Lung ultrasound and Doppler, atelectasis|Patients without clinically active pulmonary disease but presenting a consolidation of suspected atelectatic nature. Fever, hypothermia, leucocytosis and leucopenia will not be present. Tracheal secretions will remain unchanged. There will be no deterioration of oxygenation. In this group, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
3330961|NCT02100462|Experimental|Chlorthalidone 12.5 mg|Chlorthalidone 12.5 mg by mouth once daily for 2 weeks
3330962|NCT02100462|Experimental|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg by mouth once daily for 2 weeks
3330963|NCT02100462|Active Comparator|Aspirin 81 mg|Aspirin 81 mg by mouth once daily for 2 weeks
3330964|NCT02100488|Active Comparator|Open-loop insulin infusion system|Standard Open-loop intensive insulin treatment with continuous insulin infusion (CSII). Commercially available insulin infusion systems will be used.
3330965|NCT02100488|Experimental|Closed-loop insulin infusion system|Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration. Automated insulin infusion based on subcutaneous continuous glucose monitoring (CGM). Commercially available insulin infusion systems and CGM devices will be used. However, insulin infusion will be driven by the by the software under investigation (CL4M Controls) based on blood glucose estimations from CGM.
3330966|NCT02100501||Atkins diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 53. enrolled patients are assigned to randomly in one of KD group or Atkins group.
3330967|NCT02100501||Ketogenic diet group|pediatric patients diagnosed with intractable epilepsy. Their ages ranged between 1 to 18 years amd indicated to dietary therapy. the targeting number of patients was 51. enrolled patients are assigned to randomly in one of KD group or Atkins group.
3330968|NCT02100527|Experimental|PF-05175157|
3330969|NCT02100527|Placebo Comparator|Placebo|
3330970|NCT02100540|Placebo Comparator|I placebo capsule|I placebo capsule
3330971|NCT02100540|Experimental|II RDC 0.3mg capsule|II RDC 0.3mg capsule
3330972|NCT02100540|Experimental|III RDC 0.6mg capsule|III RDC 0.6mg capsule
3330973|NCT02100553|Other|Non-Obese|BMI <30 kg/m^2
3330974|NCT02100553|Other|Obese|BMI >= 30 kg/m^2
3233097|NCT01218568|Experimental|Rifaximin plus lactulose|
3330975|NCT02100566|Experimental|Behavioral Counseling|Provide an advance directive document to patients along with counseling that either focuses on care giver burden or on patient autonomy.
3233098|NCT01218568|Active Comparator|lactulose|30-60ml/day
3233099|NCT01218581|Active Comparator|group A|Group A received oral letrozole (2.5 mg/day, Femara, Novartis PharmaServices, Basel, Switzerland)
3233100|NCT01218581|Active Comparator|group B|group B received goserelin subcutaneosly (3.6 mg/month, Zoladex@, Zeneka Pharma International, UK)
3330976|NCT02100566|No Intervention|Standard AD|The topic of advance directives (AD) is introduced but patient receives an AD document only upon request.
3330977|NCT02100592|Experimental|Erigo treated|Early rehabilitation treatment on Erigo Hocoma, a tilt table with integrated stepping device within 3 - 30 days from injury
3330978|NCT02100605|Active Comparator|Phytosun, decongestant, nasal spray|"Phytosun, decongestant, nasal spray~Nasal spray 20 ml contains:~22g/l hypertonic seawater Essential oils of Eucalyptus, Niaouli and Wild menthol~Instructions for use:~Shake the bottle before use~Tilt the bottle to one side; press the nozzle firmly for at least one second, repeat until obtaining the 1st spray.~Spray in each nostril with the head upright"
3330979|NCT02100605|Placebo Comparator|Isotonic saline, nasal spray|"Isotonic saline, nasal spray~20 ml nasal spray contains Isotonic water solution 0.9% sodium chloride"
3330980|NCT02100618|Experimental|HPV Group 1|Subjects who were aged 9-14 years at study entry and received two doses of the HPV-16/18 vaccine according to a 0,6-months schedule in the study HPV-048 PRI (NCT00541970).
3330981|NCT02100618|Active Comparator|HPV Group 2|Subjects who were aged 15-25 years at study entry and received three doses of the HPV 16/18 vaccine according to a 0,1,6-months schedule in the study HPV-048 PRI (NCT00541970).
3330982|NCT02100683||PDA Coil|Patients age 6 months to 21 years weighing > 5kg with an angiographically confirmed PDA with a minimum diameter of < 4 mm.
3330983|NCT02100709|No Intervention|Control Arm|This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
3330984|NCT02100709|Active Comparator|Intervention Arm|This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.
3330985|NCT02100722|Active Comparator|FFR guided PCI|Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. Only those sites with prior experience measuring FFR will be included in the FAME 3 trial. These patients in whom FFR of a particular lesion was not possible will be included in all analyses based on the intention to treat principle.
3330986|NCT02100722|Active Comparator|CABG|CABG will be performed as per clinical routine at each participating center. Both off-pump and on-pump surgery are acceptable, as long as the surgeon and the site are experienced in the particular technique. An internal mammary graft to the LAD should be attempted in all cases, if feasible. Complete arterial revascularization is strongly recommended, however, each center should use a conduit strategy with which they are most comfortable. All vessels ≥ 1,5 mm in diameter and with ≥ 50% stenosis should be bypassed, if technically feasible.
3330987|NCT02100735|Experimental|Sedation protocol|Sedation protocol is a document that will be used to guide the adjustment of sedation in the ICU.
3330988|NCT02100735|Active Comparator|Standard of care|Current practices
3233101|NCT01218607|Placebo Comparator|Placebo|
3233102|NCT01218607|Active Comparator|Active|
3330989|NCT02100761||invasive pulmonary aspergillosis|Patients with invasive pulmonary aspergillosis and will be treated with voriconazole according to their physician decision in five hospital, Jinan, China
3330990|NCT02100774||healthy male adults|no added micronutrient, tomato puree, lutein supplement, vitamin E supplement, vitamin D supplement
3233103|NCT01218620|Experimental|Regimen I (Arm I)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
3233104|NCT01218620|Experimental|Regimen I (Arm II)|"Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive low-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
3233105|NCT01218620|Experimental|Regimen II (Arm I)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral ketoconazole once daily on days 1-10 for course 2 only."
3330991|NCT02100787|Experimental|TheraTears lubricating drops|TheraTears lubricating eye drops to be used 1 drop in both eyes four times a day (QID)
3330992|NCT02100800|Experimental|COPD Group|30 patients with diagnosis of COPD
3330993|NCT02100800|Sham Comparator|Control Group|10 volunteers with extrapulmonary neoplasia
3330994|NCT02100852|Experimental|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202 is an oral daily dose with obinutuzumab at a fixed IV infusion and chlorambucil as an oral dose on specified days.
3330995|NCT02100865|Experimental|Solar powered oxygen|Solar panels used to drive an oxygen concentrator to deliver at stream of oxygen at approximately 90% FiO2 and a rate of 1-5L/min.
3330996|NCT02100865|Active Comparator|Oxygen from cylinders|Conventional oxygen delivery from compressed gas cylinders
3330997|NCT02100878||Lean adolescents|
3330998|NCT02100878||Obese adolescents|
3330999|NCT02100891|Experimental|Allogeneic HCT + Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
3331000|NCT02100917|Experimental|DMB-3111|6 mg/kg is once given in intravenous drip infusion taking 90 min
3331001|NCT02100917|Active Comparator|trastuzumab|6 mg/kg is once given in intravenous drip infusion taking 90 min
3331002|NCT02100943||OSA in Pregnancy|Pregnant women between 32 0/7 prior to 35 6/7 weeks gestation
3331003|NCT02100982|Other|Care As Usual|Before the office visit with the PCP, patient participants in the Care As Usual arm will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
3331004|NCT02100982|Experimental|Customized Care|Before the office visit with the PCP, patient participants in the intervention group will interact with the computer based components of the customized care intervention while in the waiting room. The research staff will help the participant use an iPad in the waiting room and direct them to the Discussion Prioritization tool (DPT). After participants use the DPT, the program automatically generates a customized questions prompt list (QPL) which will be printed out in the office. Study staff will hand the QPL to intervention patients to bring to their office visit with the PCP. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
3331005|NCT02100995|Experimental|STOP Intervention|The STOP treatment includes content designed to simultaneously and explicitly target both chronic pain and obesity. Treatment components are drawn from evidence-based interventions for chronic pain and obesity, separately.
3331006|NCT02100995|Active Comparator|Standard Care Weight (SCW)|The weight loss intervention includes content focused around nutrition and eating habits, stimulus control and behavioral change, and physical activity. This content has been chosen because of its demonstrated effectiveness and importance in behavioral interventions to reduce weight.
3233106|NCT01218620|Experimental|Regimen II (Arm II)|"Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and midazolam hydrochloride IV, oral omeprazole, oral tolbutamide, and oral dextromethorphan hydrobromide on days 1 and 10. After completion of course 1, patients are randomized to 1 of 2 treatment arms.~Patients receive high-dose RO4929097 once daily on days 1-3, 8-10, and 15-17 and oral rifampin once daily on days 1-10 for course 2 only."
3233107|NCT01218633|Placebo Comparator|Saline|
3233108|NCT01218633|Active Comparator|GLP-1-(9,36)-amide|
3331007|NCT02100995|Active Comparator|Standard Care Pain (SCP)|The chronic pain intervention is focused around reconceptualization of pain, decreasing catastrophizing, and increasing self-efficacy for pain. This content has been chosen because of its demonstrated effectiveness and importance in non-pharmacological interventions to improve pain management.
3331008|NCT02101047|Experimental|phenylephrine 50mcg bolus|Phenylephrine 50 mcg bolus dosing with continuous placebo infusion
3331009|NCT02101047|Experimental|Phenylephrine 100 mcg bolus|Phenylephrine 100 mcg bolus dosing wtih continuous placebo infusion.
3331010|NCT02101047|Experimental|Phenylephrine continuous infusion 100mcg/min|Continuous phenylephrine infusion of 100 mcg/min with placebo bolus dosing.
3233109|NCT01218633|Active Comparator|Exendin-9,39 @30pmol/kg/min|
3233110|NCT01218633|Active Comparator|Exendin-9,39 @300pmol/kg/min|
3331011|NCT02101073|Experimental|ALX-0061 low dose i.v.|
3331012|NCT02101073|Experimental|ALX-0061 high dose i.v.|
3331013|NCT02101073|Experimental|ALX-0061 low dose s.c.|
3331014|NCT02101073|Experimental|ALX-0061 middle dose s.c.|
3331015|NCT02101073|Experimental|ALX-0061 high dose s.c.|
3331016|NCT02101086|Experimental|Autologous Cord Blood Transfusion|Autologous cord blood transfusion 10 mL per kg for anemia
3331017|NCT02101086|Active Comparator|Allogeneic blood transfusion|Allogeneic blood transfusion 10 mL per kg for anemia
3331018|NCT02101099||Patients undergoing colonoscopy|Patients who are undergoing outpatient colonoscopy for colorectal cancer screening or for symptoms suggestive of colonic diseases.
3331019|NCT02101125|Experimental|BMS-986020 + Rosuvastatin (Treatment A, B and C)|"Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days~Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days"
3331020|NCT02101138|Experimental|Dexpramipexole|Dexpramipexole treatment
3331021|NCT02101151|Experimental|Vitamin D3 group|supplemented with 6000IU cholecalciferol/day for 3 months, followed by 3000 IU cholecalciferol/day for next 3 months
3331022|NCT02101151|Placebo Comparator|Placebo group|Placebo (starch) capsules identical to vitamin D capsules in appearance
3331023|NCT02101164|Active Comparator|Treatment Group A|1 dose of denosumab every 4 weeks for 2 doses, followed by 1 dose of pamidronate every 4 weeks for 2 doses.
3331024|NCT02101164|Active Comparator|Treatment Group B|1 dose of pamidronate every 4 weeks for 2 doses, followed by 1 dose of denosumab every 4 weeks for 2 doses.
3331025|NCT02101177||Patients under Dual therapy|- 1500 patients who started treatment between April 1st 2013 and March 31st 2014 and will be seen for their week 60 visit between July 1st 2014 and June 30th 2015 (Cohort A).
3331026|NCT02101177||Early Defaulters|- 1000 patients recruited between July 1st 2014 and estimated March 31st 2015, of which 200 are expected to be early defaulters and will be contacted by the study team (Cohort B).
3233111|NCT01218685||Health adults|
3233112|NCT01218685||Health children|
3331027|NCT02101203|Experimental|Placebo|40 subjects administered placebo
3331028|NCT02101203|Experimental|Testosterone + Buspirone|40 subjects administered 0.5 mg Testosterone + 10 mg Buspirone hydrochloride
3331029|NCT02101216|Experimental|Pharmacokinetics of low dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 50 mg (1 tablets) to 6 subjects
3331030|NCT02101216|Experimental|Pharmacokinetics medium dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 100 mg (2 tablets) to 6 subjects
3331031|NCT02101216|Experimental|Pharmacokinetics of high dose Prurisol|Pharmacokinetics of single dose of Prurisol™ 200 mg (4 tablets) to 6 subjects
3331032|NCT02101216|Experimental|Bioequivalence of Prurisol (350 mg)|Single dose of Prurisol™ 350 mg (7 x 50 mg tablets)
3331033|NCT02101216|Active Comparator|Bioequivalence of Ziagen (300 mg)|Single dose of Ziagen 300 mg (1 x 300mg tablet)
3331034|NCT02101229|No Intervention|unsual treatment|The patient will have his usual treatment in this arm
3233113|NCT01218685||Pregnants|
3233114|NCT01218685||Elderly over 65 years old|
3233115|NCT01218685||HIV patients|
3233116|NCT01218685||Kidney transplant|
3233117|NCT01218685||Oncologic patients|
3233118|NCT01218685||Rheumatologic adult patients|
3233119|NCT01218685||Rheumatologic children patients|
3233120|NCT01218737|Experimental|Association|0.3% gatifloxacin and 1.0% prednisolone acetate association in eye drops plus placebo
3233121|NCT01218737|Active Comparator|Isolated ingredients|0.3% gatifloxacin and 1.0% prednisolone acetate isolated eye drops formulations
3331035|NCT02101229|Experimental|The Diabeloop algorithm|In this arm, the insulin Asp(B28) dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
3331036|NCT02101242||Orthopedic surgery of the shoulder|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to beach chair position.
3331037|NCT02101242||Gynecological, urological or general surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation during change from supine position to Trendelenburg position.
3331038|NCT02101242||Cardiac surgery|Near-infrared spectroscopy (NIRS) can detect fluctuation of regional cerebral oxygen saturation in patients undergoing cardiac surgery with cardiopulmonary bypass (heart-lung machine).
3233122|NCT01218750|Experimental|edematous tractional epimacular membrane|Diabatic maculopathy comes to the edematous or tractional form. It is believed that epiretinal membranes are comprised from glial components. The processes of these cells may invade through the internal limiting membrane of the retina to the vitreous causing the vitreoretinal adhesion and anomalous posterior detachment of vitreous (APVD). In the macula, APVD causes vitreo-macular traction syndrome, which results in diffuse diabetic macular edema. If vitreoschisis is present, a place of dissection is crucial. If break occurs in front of the hyalocytes remaining on the retinal surface, the vitreous layer is thick and easily shrinks concentrically, which results in the formation of epimacular membrane.
3331039|NCT02101255|Experimental|Curodont Repair|Application on Day 0 and Day 360
3331040|NCT02101255|Active Comparator|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
3331041|NCT02101268|Experimental|Arm 1: Momelotinib|Participants will receive momelotinib for 24 weeks during the randomized treatment phase, after which they will be eligible to receive momelotinib in an extended treatment phase for up to an additional 204 weeks.
3331042|NCT02101268|Active Comparator|Arm 2: Best Available Therapy (BAT)|Participants in the BAT treatment arm will receive treatment at doses and schedules determined by the investigator in accordance with standard of care. Therapy may be changed at any time during the study except during the screening period. After completion of the randomized treatment phase, participants will be eligible to receive momelotinib for the duration of the study during the extended treatment phase for up to 204 weeks.
3331043|NCT02101307||RA Patients on RoActemra/Actemra treatment|
3331044|NCT02101320|No Intervention|Group 1|Patients with a resection of the lesions according to the procedure SNOLL without the use of TReCam.
3331045|NCT02101320|Experimental|Group 2|Patients with a resection of the lesions according to the procedure SNOLL with the use of TReCam.
3331046|NCT02101333|Experimental|TOCILIZUMAB MONTHLY DURING 6|intravenous injection, 8 mg/kg, monthly during 6 months
3331047|NCT02101346|Experimental|Healthy, Round 1|For feeding of 5 different fatty acid meals in order to assess the monocyte response ex vivo Mixed high fat diet Low fat diet Saturated fat diet Monounsaturated fat diet Polyunsaturated fat diet
3331048|NCT02101346|Experimental|Healthy, Round 2|"For feeding of 2 different fatty meals, in order to assess the molecular monocyte response and track the fate of fats.~Saturated fat Triolein 13C"
3331049|NCT02101372|Active Comparator|treatment as usual|
3331050|NCT02101372|Experimental|Psychoeducation Group|
3331051|NCT02101385|Experimental|Arm A (Genomically Directed Monotherapy)|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). Clinical and laboratory monitoring and dose-reductions will follow the FDA package insert guidelines.
3331052|NCT02101385|Other|Control Arm B (Observation/Standard Therapy)|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
3331053|NCT02101398|Experimental|F7A|Anodal electrode set on the left Broca's area and cathodal electrode set on its right homologue. Active stimulation.
3331054|NCT02101398|Experimental|F7C|Cathodal electrode set on the left Broca's area and anodal electrode set on its right homologue. Active stimulation.
3331055|NCT02101398|Experimental|T5A|Anodal electrode set on the left Wernicke's area and cathodal electrode set on its right homologue. Active stimulation.
3331056|NCT02101398|Experimental|T5C|Cathodal electrode set on the left Wernicke's area and anodal electrode set on its right homologue. Active stimulation.
3331057|NCT02101398|Sham Comparator|Sham|Electrodes set on the left Broca's area and its right homologue or electrodes set on the left Wernicke's area and its right homologue, but no stimulation will be delivered.
3331058|NCT02101424||Overdose|
3331059|NCT02101450|No Intervention|Intra-abdominal removal of the placenta|The uterus will be left in the abdominal cavity and the placenta will be manually removed with uterine massage as soon as possible. After removal of the placenta, the uterus will be dragged out of the abdominal cavity. The cesarean incision will be sutured with no. 1 Vicryl ®. Uterus will be replaced in the abdominal cavity. Intra-abdominal cavity will be cleaned by aspirator and mounted-gauze tampon. The weight of the placenta will be measured. The weight of the gauze tampons will be measured with gravimetric method before and after use.
3331060|NCT02101450|Experimental|Extra-abdominal removal of the placenta|"No drug or device is used. The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.~The placenta will be manually removed with uterine massage as soon as possible. The cesarean section will be completed as described in No intervention group."
3331061|NCT02101463|Other|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
3331062|NCT02101476|Active Comparator|Percocet|Oxycodone/APAP (acetaminophen)
3331063|NCT02101476|Active Comparator|Xartemis|
3331064|NCT02101489|Active Comparator|Intraop Foley catheter measurement|20 women will have intraoperative Foley catheter measurement of the urethral length
3331065|NCT02101489|No Intervention|Without intraop Foley cath measurement|20 women without intraoperative Foley catheter measurement of the urethral length
3331066|NCT02101502|Active Comparator|Institutional Capacity|Questioner for institutional employee about Institutional Capacity
3331067|NCT02101502|Active Comparator|Educational Effectiveness|Questioner for medical and assistant staffs about Educational Effectiveness
3331068|NCT02101502|Active Comparator|Health-care|Questioner for medical, assistant staffs and patients about Quality Assurance System in Health-care
3331069|NCT02101528||PD Patients|"PD patients with a diagnosis of clinically probable idiopathic PD in Hoehn-Yahr stage 2-3, with the ability to walk without any assistance, with mini-mental state examination score ≥26, without any relevant comorbidity or vestibular/visual dysfunctions limiting locomotion or balance."
3331070|NCT02101528||Controls|age and sex matched healthy volunteers
3331071|NCT02101541|Experimental|FIRM ablation|"The first part of this within-patient trial investigate the efficacy of focal impulse and rotor modulation in 20 patients with paroxysmal atrial fibrillation, evaluated by continuous pre- and post-procedural heart rhythm monitoring.~The second part consists of 20 patients with persistent or longstanding persistent atrial fibrillation following the same scheme."
3331072|NCT02101567|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3331073|NCT02101567|Active Comparator|Oxytocin and Methergine (methyl ergometrine)|The second group of patients included in the study will be given Oxytocin 5 IU ampoule by intravenous infusion and Methergine 0.2 mg IV after delivery of fetal head.
3331074|NCT02101580|Experimental|ADI-PEG 20|
3331075|NCT02101593|Experimental|ADI-PEG 20|
3331076|NCT02101606|Experimental|Tenecteplase|
3331077|NCT02101619||Moderate aortic stenosis.|
3331078|NCT02101619||Severe aortic stenosis.|
3331079|NCT02101632|Experimental|Bee Venom|Bee Venom Ointment 0,0005%
3331080|NCT02101632|Placebo Comparator|Vaseline|Vaseline ointment
3331081|NCT02101645|Experimental|LIDC treatment and bioimpedance monitoring of venous ulcers.|Lower extremity venous ulcers will be treated using periodical LIDC stimulation. Wound healing and edema reduction efforts will be monitored using bioimpedance based monitoring.
3233123|NCT01218763||ICD patients|Candidates may come from the investigator's general population, who require DR ICD or CRT-D therapy for primary or secondary ICD indication and meet all study eligibility criteria
3233124|NCT01218776||Male, Female, Kidney Disease, Elderly|Non-interventional patient registry
3331082|NCT02101658||weight data assessors|students recruited to weigh individuals in a research-based clinic
3331083|NCT02101671||trendelemburg positioning|Patients undergone laparoscopic surgery in trendelemburg position
3331084|NCT02101671||Not trendelemburg positioning|Patients undergone laparoscopic surgery not in trendelemburg position
3331085|NCT02101684|Experimental|Orteronel 300mg b.i.d.|Orteronel 300mg BID (600mg per day) will be administered to all included patients in a 28 days cycle schedule.
3331086|NCT02101697|Experimental|HIV Stigma Reduction Intervention|The HIV stigma reduction arm group will participate in a promising intervention designed to reduce HIV stigma among health professionals. The intervention builds on results of our previous research, identifying prevalence and drivers of stigma and discrimination in Indian healthcare settings among PLHIV, health care providers, and uninfected patients.The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
3331087|NCT02101697|Placebo Comparator|Time Matched Control Group|The time-matched control group will also receive three sessions; two administered by computers and one in small group format to control for attention effects. However, rather than AIDS stigma, the content will be focused on diabetes management (a disease not considered to be stigmatized).
3331088|NCT02101710|Experimental|Elantan SR 60 mg fed|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 2 and on Day 1 of treatment period 2 for Fed group 1.
3331089|NCT02101710|Experimental|Imdur SR 60 mg fed|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fed group 1 and on Day 1 of treatment period 2 for Fed group 2.
3331090|NCT02101710|Experimental|Elantan SR 60 mg fasted|Elantan SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 2 and on Day 1 of treatment period 2 for Fasted group 1.
3331091|NCT02101710|Experimental|Imdur SR 60 mg fasted|Imdur SR 60 mg is orally administered on Day 1 of treatment period 1 for Fasted group 1 and on Day 1 of treatment period 2 for Fasted group 2.
3331092|NCT02101723|Active Comparator|Micronutrient Powder (MNP) + Zn/Fe|Micronutrient Powder with 5 mg Zn and 12 mg Fe
3331093|NCT02101723|Active Comparator|MNP + Zn|Micronutrient Powder with 5 mg Zn
3331094|NCT02101723|Placebo Comparator|Control|Placebo sachets without micronutrients
3331095|NCT02101736|Experimental|Experimental Agent XL184 (Cabozantinib)|"Cohort A (≥ 16 years - closed to accrual): Starting cabozantinib of 40 mg daily by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 60 mg based on dose tolerability. Subjects who do not tolerate 40 mg will dose reduce to 20 mg. Doses will be capped at 60 mg.~Cohort B (3 - 15 years). The starting cabozantinib dose is 30 mg/m2/day by mouth per cycle. Duration of each cycle is 28 days. Subjects will dose escalate after 2 cycles to 40 mg/m2/day based on dose tolerability. Subjects who do not tolerate 30 mg/m2/day will dose reduce to 23 mg/m2/day. Doses will be capped at 60 mg/day max daily dose~Each cohort will enroll up to 24 evaluable subjects with a target minimum of 17 evaluable subjects per cohort."
3331096|NCT02101749|Active Comparator|trivalent inactivated influenza (INTANZA)|Intradermal injection
3331097|NCT02101749|Active Comparator|trivalent inactivated influenza (VAXIGRIP)|Intramuscle injection
3331098|NCT02101762||Silver Coated Catheters|Subjects that had previously received silver coated Foley catheters.
3331099|NCT02101762||ERASE CAUTI Non-Silver Coated Catheters|Subjects that received non-silver catheters from an ERASE CAUTI tray.
3331100|NCT02101801|Other|freshwater|receives vegetables from freshwater farms
3331101|NCT02101801|Active Comparator|recycled wastewater|receives vegetables from farms using recycled wastewater irrigation
3331102|NCT02101814|Other|Bariatric surgery|Roux-en-Y gastric bypass procedure is being performed by surgery in all patients in this study.
3331103|NCT02101827||Hysteroscopic surgery|Women who received hysteroscopic surgeries or examinations
3331104|NCT02101840|Active Comparator|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
3331105|NCT02101840|Active Comparator|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
3233125|NCT01218789|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
3331106|NCT02101840|Placebo Comparator|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
3331107|NCT02101853|Active Comparator|Arm A (HR and IR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT. Closed effective September 18, 2019.
3331108|NCT02101853|Experimental|Arm B (HR and IR blinatumomab)|Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT.
3233126|NCT01218815|Experimental|Culprit lesion IRA Revascularization|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
3233127|NCT01218815|Active Comparator|Complete IRA revascularization|Primary PCI of culprit lesion in IRA with DES stent
3233128|NCT01218828|Active Comparator|Standard therapy|Hydration with 0.9% saline per a standard protocol (control group)
3331109|NCT02101853|Active Comparator|Arm C (LR control)|Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, Continuation 1 over 8 weeks, Continuation 2 over 8 weeks, and then Maintenance.
3331110|NCT02101853|Experimental|Arm D (LR blinatumomab)|Patients receive Block 2 over 4 weeks, Blinatumomab Cycle 1 over 5 weeks, Continuation 1 over 8 weeks, Blinatumomab Cycle 2 over 5 weeks, Continuation 2 over 8 weeks, Blinatumomab Cycle 3 over 5 weeks, and then Maintenance.
3331111|NCT02101866|Experimental|Vapendavir 300 mg tablet|Vapendavir 300 mg tablet single dose with up to 7 day washout period followed by two vapendavir 132 mg capsules single dose
3331112|NCT02101866|Experimental|Two Vapendavir 132 mg capsules|Two Vapendavir 132 mg capsules single dose with up to 7 day washout period followed by Vapendavir 300 mg tablet single dose
3331113|NCT02101879||Breast cancer Her2 positive|Trastuzumab & Pertuzumab & Taxanes
3331114|NCT02101892|Active Comparator|Amitriptyline|Amitriptyline, 25 mg per os, daily, evening, for 8 weeks; starting dose is 12.5 mg for 2 days
3331115|NCT02101892|Placebo Comparator|placebo|sugar pills
3331116|NCT02101905|Experimental|Group A (lapatinib ditosylate, surgery)|Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3331117|NCT02101905|Active Comparator|Reference Group (surgery, lapatinib ditosylate)|Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3331118|NCT02101931|Experimental|Urine spectral analysis|The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking Amino levulinic Acid and the samples will be analyzed by photodynamic diagnostic procedure. Amino levulinic Acid gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).The above samples is taken in a four side polished quartz cuvette of 1cmx1cmx4cm and put into the table top spectral scan. This consists of a 5 mw, blue diode laser, of 405nm wavelength. The collimated laser beam falls on the urine sample and excites fluorescence and Raman signals from the porphyrin molecules which have been metabolized from the oral administration of Amino levulinic Acid.
3331119|NCT02101957|Experimental|RP103|RP103 capsule, 16 capsules per day
3331120|NCT02101957|Placebo Comparator|placebo|placebo capsule, 16 capsules per day
3331121|NCT02101970|Experimental|Weight Loss + Omega-3 FA|Participants will be instructed to follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of Omega-3 FA (fatty acids) a day beginning 2 weeks after starting their diet and exercise routine. Omega-3 FA will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.Each Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
3331122|NCT02101970|Active Comparator|Weight Loss + Placebo|Participants will be instructed to exercise and follow a diet that is reduced by 500-700 kcal/day below maintenance requirements for 24 weeks or until the individual has reached a BMI of 25kg/m2 (generally 1000-2000 calories/day). Participants will be given one capsule of placebo a day beginning 2 weeks after starting their diet and exercise routine. Placebo capsule will be increased by 1 capsule/day or every other day until participant is taking 5 capsules per day.
3233129|NCT01218828|Experimental|LVEDP-based hydration strategy|LVEDP guided hydration with 0.9% saline (treatment group)
3233130|NCT01218841|Experimental|Fish oil lipid emulsion|Parenteral lipid emulsion composed by fish oil which is rich in the omega-3 polyunsaturated fatty acids eicosapentanoic and docosahexanoic.
3233131|NCT01218841|Active Comparator|MCT/LCT lipid emulsion|Parenteral lipid emulsion containing 50% of medium-chain triglycerides and 50% of soybean oil
3331123|NCT02101996||Healthy|Not insulin resistant
3331124|NCT02101996||Insulin resistant|Insulin resistant by an insulin clamp
3331125|NCT02102009|Experimental|Vitafos|Complete enteral formula
3331126|NCT02102009|Active Comparator|Dietary Advise|Dietary advise according to the hospital routine clinical practice.
3233135|NCT01218880|Experimental|M2ES-A|
3233136|NCT01218880|Experimental|M2ES-B|
3233137|NCT01218880|Experimental|M2ES-C|
3233138|NCT01218880|Experimental|M2ES-D|
3233139|NCT01218893|Active Comparator|15-15-15|This group will receive three times 15 infected mosquito bites under chloroquine prophylaxis, as we know that this dose is protective.
3331127|NCT02102022|Experimental|ADI-PEG 20 plus modified FOLFOX6|"Dose: 36 mg/m2 given weekly~Route of Administration: Intramuscular (IM)~In combination with modified FOLFOX6, every 2 weeks, intravenous (IV) / IV bolus"
3331128|NCT02102035|Other|Dorsal digital island flap|The flap is used to cover the soft-tissue defects of the fingers.
3331129|NCT02102048|Active Comparator|Atazanavir|patients that switch cART to boosted or unboosted ATV
3331130|NCT02102048|No Intervention|other Protease Inibithors|patients that continue the previous cART without changes.
3331131|NCT02102061|Experimental|multidisciplinary intervention|
3331132|NCT02102061|No Intervention|control|
3331133|NCT02102087|Experimental|Initial Specimen Diversion Device (ISDD)|The ISDD will be used in conjunction with standard blood culture bottles.
3331134|NCT02102087|Active Comparator|Lab standard practice (LSP)|A standard blood culture kit will be used.
3331135|NCT02102113|Other|No Family History of Psychosis (FHN)|Individuals recruited with no history of psychosis in the family. They will receive the placebo, very low dose THC, and low dose THC interventions.
3331136|NCT02102113|Experimental|Family History of Psychosis (FHP)|Individuals with a family member with a confirmed diagnosis of psychosis. They will receive the placebo, very low dose THC, and low dose THC interventions.
3331137|NCT02102126|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications
3331138|NCT02102126|No Intervention|Control group|Subjects are maintained on baseline anti-hypertensive medications.
3331139|NCT02102139|Experimental|DXM + Propofol|"DXM (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During DXM loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
3331140|NCT02102139|Placebo Comparator|Saline + Propofol|"Saline (1 µg kg -1) was loaded intravenously for 10 min before anaesthesia induction.During saline loading, the depth of anaesthesia was monitored using a bispectral index (BIS) monitor. Electrocardiogram, heart rate, pulse oximetry, and non-invasive arterial blood pressure were monitored at 2-min intervals.~Anaesthesia was induced with propofol 3.5 μg mL 1 and remifentanil 5 ng mL 1 at an effect site concentration using a target-controlled infusion (TCI) device. Anaesthesia was maintained with propofol and remifentanil continuous infusions.~During surgery except the study period, propofol and remifentanil doses were adjusted to maintain BIS value of 40-60 and systolic blood pressure (SBP) within ±20% from baseline respectively."
3331141|NCT02102152|Active Comparator|TOBI / Placebo|TOBI / Placebo.
3331142|NCT02102152|Active Comparator|Placebo / TOBI|Placebo / TOBI
3331143|NCT02102165|Experimental|metastatic lesion biopsy|biopsy of metastatic lesion will be performed at program inclusion or maximum 6 months prior to inclusion. Sample of primary tumor must be available at inclusion.
3331144|NCT02102178|Experimental|Group 1 (Intensive occupational therapy)|"All patients received pharmacological treatment for pain in accordance with the World Health Organization (WHO)'s analgesic ladder and occupational therapy follow-up, with guidance regarding activities of daily living (ADLs).~They also carried out therapeutic activities such as embroidery onto gauze (tapestry), weaving a scarf on a nail frame and playing dominos."
3331145|NCT02102178|Active Comparator|Group 2 (Regular occupation therapy)|All patients received pharmacological treatment for pain in according to WHO's analgesic ladder and only guidance regarding ADLs from the occupational therapist.
3331146|NCT02102191|Active Comparator|cigarette|common cigarette sold in the stores
3233140|NCT01218893|Experimental|10-10-10|This group will receive three times 10 infected and 5 uninfected mosquito bites under chloroquine prophylaxis.
3233141|NCT01218893|Experimental|5-5-5|This group will receive three times 5 infected and 10 uninfected mosquitobites under chloroquine prophylaxis.
3331147|NCT02102191|Active Comparator|e-cigarette|e-cigarette (Ovale Elips)
3331148|NCT02102217|Experimental|Precious arm|Postoperative controls according to the PRECious protocol, which entails standardized measurement of CRP levels on postoperative day three, four and five. If CRP levels exceed 140 mg/l additional CT-scan imaging will be conducted.
3331149|NCT02102217|No Intervention|Control|Standard postoperative controls. Additional testing will only be conducted on demand.
3331150|NCT02102243|Experimental|Hyperinsulinemic euglycemic clamp|"We will perform following procedures:~DEFINITY® infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
3331151|NCT02102243|Experimental|Initial Saline Infusion|"We will perform the following procedures:~DEFINITY® infusion Human Recombinant Regular Insulin infusion Dextrose infusion Flow mediated vasodilation Endothelial cell collection Microvascular perfusion assessment using Definity Microneurography"
3233142|NCT01218893|Placebo Comparator|0-0-0|This group will receive three times 15 uninfected mosquitobites under prophylaxis.
3331152|NCT02102256|Experimental|Experimental|Device Implantation
3331153|NCT02102269|Active Comparator|actimove sling|standard orthosis: actimove sling
3331154|NCT02102269|Experimental|shoulderlift|newly developed orthosis: shoulderlift
3331155|NCT02102269|No Intervention|controle group|no orthosis
3331156|NCT02102282||Subject study|Patients with breast cancer during pregnancy
3331157|NCT02102295|Active Comparator|Experimental toothpaste|L-ascorbic acid 2-phosphate magnesium salt / fluoride
3331158|NCT02102295|Placebo Comparator|Control toothpaste|fluoride
3331159|NCT02102308|Experimental|Exercise|Multicomponent exercise
3331160|NCT02102308|Placebo Comparator|Education classes|Education classes
3331161|NCT02102321|Experimental|albendazole|albendazole 400 mg
3233143|NCT01218906||Cohort Population (Case )|Participants will be examined for febrile illness to diagnose dengue and to identify common causes of fever.
3233144|NCT01218919||Brio DBS System|Eligible subjects in this study will be screened to confirm that they meet the strict guidelines for advanced, levodopa-responsive Parkinson's disease that are not adequately controlled with medication followed by bilateral surgery to implant the Brio™ deep brain stimulation system
3233145|NCT01218932|Experimental|A|Primaquine only, followed by chloroquine/primaquine, followed by chloroquine only
3233146|NCT01218932|Active Comparator|B|Primaquine alone, followed by chloroquine, followed by chloroquine/primaquine
3331162|NCT02102321|Active Comparator|placebo|placebo
3233147|NCT01218945||Fat Removal|Patients undergoing surgical fat removal
3331163|NCT02102334||Unilateral osteoarthritis|Patients operated with a total hip replacement due to unilateral osteoarthritis of the hip. Radiographic measurements of the postoperative radiographs.
3331164|NCT02102347|Experimental|exercise group|An exercise program will be performed to increase range of motion, improve motor learning and strengthen the muscles of the lower limb. The program will include exercises 2 times a week for four weeks. The first week the exercises will be performed with 2 sets of 15 repetitions and the remaining weeks 3 sets of 15 repetitions for each exercise. To exercise will be performed with the resistance of cinnamon, It will be recommended weight by 70% of one repetition maximum painless assigned individually per patient.
3331165|NCT02102347|Experimental|phototherapy group|And, Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant.with one 905-nm diode (mean power: 1 milliwatt ; peak power: 10 megawatt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 17.5 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 15 mW; spot size: 1 cm2); frequency: 1000 Hz; 300-second irradiation time in each quadrant; total energy: 39.3 Joules per quadrant. Phototherapy will be included in the exercises group.
3331166|NCT02102347|Placebo Comparator|Phototherapy placebo|Phototherapy will be administered with a portable nine-diode cluster. The portable nine-diode cluster will be used overlapping three quadrants of the knee in random sequence: medial quadrant, lateral quadrant and posterior quadrant), with one 905-nm diode (mean power: 0 milliwatt; peak power: 0 watt; spot size: 0.44 cm2), four 875-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2) and four 670-nm diodes (mean power of each diode: 0 milliwatt; spot size: 1 cm2); frequency: 0 Hz; 300-second irradiation time in each quadrant; total energy: 0 Joules per quadrant. Phototherapy will be included in the exercises group.
3331167|NCT02102360|Experimental|Minimally invasive surgical technique (MIST)|A minimally invasive surgical technique was performed to access mandibular furcation defects in the test group, aiming to perform minimal flap reflection, minimal wound, and gentle handling of the soft and hard tissue in periodontal surgery. The use of a microsurgical approach provides magnification and optimal illumination of the surgical site improving visual acuity. Further advantages may be the reduction of flap reflection during surgery, consequently advantages in wound healing process and benefits in patient's perceptions of the procedure. A less invasive surgical procedure may lead to a less cell demand in the healing process, and a potentially reduced morbidity. The minimally invasive surgical procedures were performed using microscope.
3331168|NCT02102360|Experimental|Conventional surgical technique (CST)|A conventional surgical technique was performed to access mandibular furcation defects in the control group.
3331169|NCT02102373|Active Comparator|low-fiber diet|Patients received low-fiber diet for 24 hours before colonoscopy
3331170|NCT02102373|Active Comparator|clear liquid diet|Patients received clear liquid diet for 24 hours before colonoscopy
3331171|NCT02102386||CerOx|Patients will be monitored using the CerOx monitor. Probes will be attached bi-laterally in the OR to the forehead.
3331172|NCT02102412|Experimental|single arm|single arm patients underwent colonoscopy with aer-o-scope followed by conventional colonoscopy to assess if any mucosal damage occurred with the experimental device.
3331173|NCT02102425||Chronic kidney disease, PD|Patients with or without bandage over exit site
3331174|NCT02102438|Experimental|Trastuzumab and weekly chemotherapy|"Treatment schedule Weekly paclitaxel and Carboplatin at 80mg/m2 and Area under the curve (AUC) of 2, respectively. Weekly trastuzumab will be combined with chemotherapy (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg). Chemotherapy will be given at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
3331175|NCT02102477|Experimental|Prostatectomy/Surgery|Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy
3233148|NCT01219010|Experimental|001|Siltuximab 15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
3233149|NCT01219036|Other|Non-adherent|
3331176|NCT02102477|Active Comparator|Radiotherapy with adjuvant androgen deprivation therapy|Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy
3233150|NCT01219036|Other|Adherent|
3233151|NCT01219049|Experimental|Tyrosine 1000 mg / day|Patients receive 1000 mg tyrosine per day.
3233152|NCT01219049|Experimental|Tyrosine 2000 mg / day|Patients receive 2000 mg tyrosine per day.
3233153|NCT01219049|Placebo Comparator|Placebo|Patients receive placebo daily.
3233154|NCT01219062|Placebo Comparator|control|The patient will be performed spinal anesthesia alone, with postoperative PCA
3233155|NCT01219062|Active Comparator|Morphine|The patient will received intrathecal Morphine for 0.1 mg. in Isobaric bupivacaine in spinal anesthesia and postoperative PCA
3233156|NCT01219062|Active Comparator|bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
3233157|NCT01219088|No Intervention|Controlled group|Spinal anesthesia with 0.5% bupivacaine alone
3233158|NCT01219088|Active Comparator|Femoral nerve block|Spinal anesthesia plus femoral nerve block with 20 mL of 0.25% bupivacaine
3233159|NCT01219088|Active Comparator|Intrathecal morphine|Spinal anesthesia plus 0.1 mg of intrathecal morphine
3233160|NCT01219088|Active Comparator|Periarticular bupivacaine infiltration|Spinal anesthesia plus periarticular infiltration with 20 mL of 0.25% bupivacaine
3233161|NCT01219101|Experimental|clomiphene citrate and ethinyl estradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
3331177|NCT02102503|Experimental|MI and Medication review|The intervention starts three months post-discharge after the standard treatment at the out-patients clinic. A medication review focused on cardiovascular drugs, and a counselling session with a clinical pharmacist using Motivational Interviewing (MI)-approach, and a follow-up phone call two weeks later. For patients with negative beliefs about medicines, three additional MI-sessions in clinic or by phone are planned together with the patient. Irrespective of beliefs the intervention ends with a second medication review and counselling session, which is coordinated with the 12-months post-discharge follow-up in primary care.
3331178|NCT02102503|Active Comparator|Standard treatment|Standard treatment at the cardiology out-patient clinic. Follow-up by nurse after two weeks and by physician after two months.
3331179|NCT02102516|Experimental|SPRIX(intranasal ketorolac tromethamine)|Based on subject weight
3331180|NCT02102529||bowel endometriosis|laparoscopic colonic resection
3331181|NCT02102542||Antisialagouge|A group of patients enrolled to prove efficacy of Glyco-P for reduction of secretions.
3331182|NCT02102542||Bradycardia|A group of patients enrolled to prove efficacy of Glyco-P for modest increase of heart rate.
3331183|NCT02102542||For reversal of neuromuscular blocking agents|Group of patients enrolled to prove efficacy of Glyco-P when used in combination with neostigmine to reserve neuromuscular blocking agents.
3233162|NCT01219101|Active Comparator|clomiphene citrate and placebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
3233163|NCT01219114||1|
3233164|NCT01219127|Experimental|Derma-PACE|Pre-treatment evaluations include complete history and physical examination, chemistry and coagulation profiles, detailed past surgical and medical treatments. The local findings of the ulcer are quantitatively assessed using the S(AD) SAD classification (6) including photo-documentation for the size, shape and configuration of the ulcer
3233165|NCT01219140|Experimental|2 POMx Capsules|2 POMx Capsules daily
3233166|NCT01219140|Placebo Comparator|2 placebo Capsules|2 placebo Capsules daily
3331184|NCT02102555|Active Comparator|IV acetaminophen|Patients in the IV acetaminophen arm will receive a one gram dose of IV acetaminophen in the pre-operative area prior to their surgery.
3331185|NCT02102555|Placebo Comparator|Placebo|Patients in the placebo arm will receive normal saline in the pre-operative area.
3331186|NCT02102581||short time tourniquet|60 patients were randomly divided into 2 groups (30 cases/group): group A using the tourniquet throughout the operation, and group B using the tourniquet starting from the implantation of prosthesis to the completion of the operation(short time).
3331187|NCT02102594|Experimental|Bortezomib (Velcade)|
3331188|NCT02102607||age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
3331189|NCT02102620|Experimental|IAI triamcinolone hexacetonide|"Intra-articular injection with corticosteroid . The study group was called triamcinolone hexacetonide / lidocaine (TH / LD) and a control group, called lidocaine (LD).~Patients in TH / LD group underwent corticosteroid IAI scheme in its most symptomatic interphalangeal (IP) joint composed with triamcinolone hexacetonide(TH) (20mg/ml) and 2% lidocaine without vasoconstrictor. The IAI was realized in the 0.3 ml dose (6mg) of TH for PIP and 0.2 ml (4 mg) of HT for DIP, always associated with 0.1 mL of 2% lidocaine. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day)."
3331190|NCT02102620|Placebo Comparator|IAI lidocaine|Intra-articular injection with lidocaine. The LD group patients underwent IAI with only 2% lidocaine without vasoconstrictor in its most symptomatic IP joint. Paracetamol 750 mg / tablet were also used if required during the 12 weeks of follow-up (up to 03 tablets per day) . Both groups of patients underwent only one IAI in the most symptomatic joint and on a single occasion.
3331191|NCT02102633|Experimental|Dabigatran|Dabigatran 150 mg orally
3331192|NCT02102633|Experimental|Dabigatran + Bosutinib|Dabigatran 150 mg co-administered with Bosutinib 500 mg orally
3331193|NCT02102646|Active Comparator|Triptorelin|Triptorelin 22,5mg/24th week intramuscularly
3331194|NCT02102646|Active Comparator|orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
3331195|NCT02102659|Experimental|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium."
3233167|NCT01219153|Experimental|Extended high dose letrozole regimen /GnRH antagonist|
3233168|NCT01219153|Active Comparator|Short low dose letrozole regimen /GnRH antagonist|
3233169|NCT01219166||laparoscopic Roux-en-Y-gastric-bypass without cholecystectomy|
3233170|NCT01219166||laparoscopic Roux-en-Y-gastric baypass with cholecystectomy|
3233171|NCT01219179|Experimental|sterile water|Intervention group received sterile water if their sodium value was greater or equal to 150 mEq/liter
3233172|NCT01219192|Experimental|M2ES 15mg|
3233173|NCT01219192|Experimental|M2ES 30mg|
3233174|NCT01219192|Experimental|M2ES 45mg|
3233175|NCT01219192|Experimental|M2ES 60mg|
3233176|NCT01219205|Active Comparator|major branched retinal venous occlusion|
3233177|NCT01219205|Active Comparator|macular branched retinal venous occlusion|
3233178|NCT01219218|Experimental|A|Treatment group. Patients in this group receive actual shockwave therapy.
3233179|NCT01219231|Experimental|Exercise|
3233180|NCT01219231|Placebo Comparator|Placebo|
3331196|NCT02102659|Active Comparator|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
3331197|NCT02102672|Placebo Comparator|Sugar pill|Placebo 1 pill bid, 3 months
3331198|NCT02102672|Experimental|Trimetazidine|Trimetazidine 35 mg bid for 3 months
3331199|NCT02102685|Active Comparator|VAC Therapy|active comparator: 14 patients within the first three days the VAC therapy was placed , proceeding as follows : organize the material , bandage removal , cleaning of the wound with irrigation solution , cut the sponge and placement on the wound , use of polyvinyl alcohol and / or silver foam, insertion of the tube seal and connection to the containing recipient.
3331200|NCT02102685|Placebo Comparator|Traditional Therapy|14 patients: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
3331201|NCT02102698|Experimental|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1/D5 receptor family that is being studied as a treatment for Tourette's Syndrome
3331202|NCT02102698|Placebo Comparator|Placebo|Placebo is the inactive comparator
3331203|NCT02102711|Experimental|vitaminA drops|3000 IU/kg/die of Vitamin A oral drops, for 4 weeks.
3331204|NCT02102711|No Intervention|control|Control of matched infants not supplemented with vitamin A ( beyond standard/routine needed)
3233181|NCT01219244|Experimental|Caloric restriction|
3233182|NCT01219244|Experimental|omega-3 supplementation|
3233183|NCT01219244|Experimental|resveratrol supplementation|
3331205|NCT02102737|Experimental|6-DIG and clamp|injection of 6-DIG and hyperinsulinemic euglycemic clamp
3233184|NCT01219244|Placebo Comparator|placebo|
3233185|NCT01219244|Experimental|2nd step: intervention + physical /cognitive training|most effective dietary intervention plus physical and cognitive training
3233186|NCT01219244|Placebo Comparator|2nd step: most effective dietary intervention plus control|most effective dietary intervention plus control
3233187|NCT01219257||SpA patients|The patients may be included when their rheumatologist has decided that the patient are going to start biological medication.
3233188|NCT01219270||GFR >= 60|MDRD eGFR 60 or more
3331206|NCT02102750|Experimental|tafluprost|
3331207|NCT02102776|Active Comparator|MMC after pterygium excision|Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision. The conjunctival defect will be left bare without graft.
3331208|NCT02102776|Active Comparator|AMT after Pterygium Excision|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
3331209|NCT02102776|Active Comparator|CAG after Pterygium Excision|A conjunctival autograft will be harvested from the superior side of the operating eye's bulbar conjunctiva. Then the graft will be sutured to cover the conjunctival defect after pterygium excision. No mitomycin C will be applied.
3331210|NCT02102789|Experimental|Systemic chemotherapy|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
3331211|NCT02102789|Experimental|Systemic chemotherapy combined with HAI|"Patients will receive mFOLFOX6+HAI every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15. 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28-day cycle. FUDR will be administered through a 14-day continuous infusion with the HAI pump."
3331212|NCT02102802||Full dose MDMA|Participants will receive 125 mg MDMA possibly followed 1.5 to 2 h later by 62.5 mg MDMA
3331213|NCT02102815|Experimental|Dexamethasone|Preoperative dexamethasone 0.15mg/Kg mixed with NSS to 50 mL IV slowly push over 5 minutes
3331214|NCT02102815|Placebo Comparator|Placebo|Preoperative intravenous normal saline 50 mL slowly push over 5 minutes
3331215|NCT02102828|Placebo Comparator|Aspirin only|Patients receive aspirin therapy
3331216|NCT02102828|Experimental|extended compression|aspirin and extended compression therapy in combination
3331217|NCT02102841|Experimental|Skin biopsy|5mm skin punch biopsy on forearm
3331218|NCT02102841|Experimental|Skin suction blister|Skin suction blister induced on forearm
3331219|NCT02102841|Experimental|Mantoux, skin biopsy, suction blister|0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
3331220|NCT02102854|Active Comparator|Standard dose rATG|Standard dose rATG given as daily infusions of 1.5 mg/kg x 4-5 days
3331221|NCT02102854|Experimental|Single dose rATG|Single dose rATG give as 2 consecutive 3 mg/kg IV infusions to be completed over a 24-36 hour duration
3331222|NCT02102880|Other|Healthy Subjects|
3233189|NCT01219270||GFR <60|Under MDRD eGFR 60
3233190|NCT01219283||Control (no PGD)|Receive their planned IVF treatment without PGD. 2 morphologically best embryos are transferred.
3233191|NCT01219283||Case (PGD)|Receive PGD in addition to their planned IVF Cycle. 2 morphologically best PGD normal embryos are transferred.
3233192|NCT01219309|Active Comparator|Omega 3/6 treatment|
3233193|NCT01219309|Placebo Comparator|Placebo|
3233194|NCT01219322|Experimental|intravenous bicarbonate|Intravenous bicarbonate(05meq/cc ) 50 cc will be injected.
3233195|NCT01219322|Placebo Comparator|Intravenous injection of 50 cc normal saline|Injection of volume equivalent of normal saline to compare the establish the effect of same volume as the experimental drug
3233196|NCT01219348|Experimental|Indeolamine 2,3 deoxygenase|To inhibit immune suppression and tolerance, by blocking the IDO enzyme with vaccination against IDO.
3233197|NCT01219374||egg donors|anonymous egg donors
3233198|NCT01219400|Experimental|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
3331223|NCT02102906|Experimental|TMS treatment|Patients will receive a single session of 20 single pulses of TMS to motor cortex contralateral to affected upper limb at 120% motor threshold, with verbal encouragement throughout. Half of the patients recruited will be randomised to a 3 month delay during which they will receive treatment as normal.
3331224|NCT02102919|Experimental|Intervention group|T0 - intervention over 4 weeks with stochastic resonance whole-body vibration (SR-WBV) (start with 3 up to 6 Hz, noise 4) T1 - intervention 4 weeks (SR-WBV (start with 3 up to 6Hz, noise 4 & virtual games) - T2
3331225|NCT02102919|Sham Comparator|Sham Comparator|T0 - intervention 4 weeks (SR-WBV 1 Hz, noise 1) - T1 - intervention 4 weeks (SR-WBV 1 Hz, noise 1 & Aktiv Tramp) - T2
3331226|NCT02102945|Other|Computed tomography perfusion|Participants will undergo CT perfusion of the head after cooling following cardiac arrest.
3331227|NCT02102958|Experimental|Experimental|DSME with Nonvisual Foot Examination
3233199|NCT01219413|Experimental|aliskiren, placebo, perindopril|
3233200|NCT01219413|Experimental|perindopril, placebo, aliskiren|
3331228|NCT02102958|Active Comparator|Comparison|DSME with Usual Foot Examination Instruction
3331229|NCT02102971||Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
3331230|NCT02102984|Active Comparator|covered stents|endoscopic placement of covered biliary stents
3331231|NCT02102984|Active Comparator|uncovered biliary stents|endoscopic placement of uncovered biliary stents
3331232|NCT02103010||HNC patients|head and neck cancer patients
3331233|NCT02103023|Experimental|ID TIV + imiquimod|imiquimod ointment followed by intradermal influenza vaccine
3331234|NCT02103023|Sham Comparator|ID sham + imiquimod|imiquimod ointment followed by sham intradermal influenza vaccine
3331235|NCT02103023|Active Comparator|IM TIV + aq|aqueous cream followed by intramuscular influenza vaccine
3331236|NCT02103023|Active Comparator|ID TIV + aq|aqueous cream followed by intradermal influenza vaccine
3331237|NCT02103036|Experimental|Core Stability Exercises|"Core Stability Exercises:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Core Stability Exercises (25-30 minutes)."
3331238|NCT02103036|Experimental|Traditional Back School|"Traditional Back School:~20 sessions, distributed daily, from Monday to Friday. The first 5 sessions are common in all patients in the study, and involves the application of infrared light (IR) (10 minutes) and TENS (20 minutes) to treat acute pain. From session number 6 to session 20, the patients will receive IR + TENS 2 days a week, and the other 3 days IR+TENS+Traditional Back School (25-30 minutes)."
3331239|NCT02103049|Other|Ezetimibe, dyslipidemia, kidney transplant|
3331240|NCT02103075|Experimental|The SCA|
3331241|NCT02103075|Experimental|The age-matched control|
3233201|NCT01219426||students from the University of Nantes|To be more than 18 years old (the legal age to gamble in France)
3233202|NCT01219426||pathological gamblers seeking treatment|To be more than 18 years old (the legal age to gamble in France)and pathological gambler
3233203|NCT01219452|Experimental|umbilical cord mesenchymal stem cells|intramuscular injection of umbilical cord mesenchymal stem cell
3233204|NCT01219465|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
3331242|NCT02103075|Experimental|The young control|
3331243|NCT02103088|Experimental|Sexual and urological intervention|Standard care and the PROCAN intervention consisting of i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
3331244|NCT02103088|No Intervention|Control|Standard care consists of:systematic offer of medical treatment for erectile dysfunction, if not contra indicated. The medical treatment will consist of either daily treatment with Cialis 5 mg or phosphodiesterase type 5 inhibitor on demand before sexual activity. Alternatively use of alprostadil as either urethral pin or penile injection. Furthermore standard treatments include preoperative instruction in pelvic floor muscle training, regular outpatient visits and possible referral to rehabilitation in accordance with the rules that apply to the Danish Health legislations. In case of prolonged incontinence the patients may on request be referred to a private practicing physiotherapist.
3331245|NCT02103101|Other|Study cohort|"Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp~All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated."
3331246|NCT02103140|Experimental|Facility-Based Exercise Intervention|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
3233205|NCT01219478||control|0 metabloil risk
3233206|NCT01219478||1|1 metabloil risk
3233207|NCT01219478||2|2 metabloil risk
3233208|NCT01219478||3|3 metabloil risk
3233209|NCT01219491||Egg donor recipients|
3233210|NCT01219517|Experimental|Study Group|All patients in the study receive the same treatment. All will have 2 polar body biopsies and all embryos biopsied prior to transfer.
3233211|NCT01219530||Gestational Carriers|
3233212|NCT01219530||Intended Parents|
3233213|NCT01219543|Experimental|Part A|Daily dosing of AZD1480 to the patients with solid tumours excluding HCC
3233214|NCT01219543|Experimental|Part B|BID dosing of AZD1480 to the patients with advanced HCC (Child-Pugh A to B7)
3233215|NCT01219543|Experimental|Part C|BID dosing of AZD1480 to the patients with solid tumours excluding HCC
3233216|NCT01219543|Experimental|Expansion|BID dosing of AZD1480 to the patients with EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer and solid tumour with biopsy available.
3233217|NCT01219556||Group 1|
3233218|NCT01219569||2. Sevoflurane|Subjects will receive sevoflurane at 1.5% and 2.5% end tidal after steady state maintenance has been achieved and have pupillometry readings taken and every 10 minutes for 30 minute at each drug dose.
3331247|NCT02103140|No Intervention|Control|After baseline testing, the control group will be asked to maintain their current daily activities and exercise habits for the duration of the study (6 months). The control group will have measurements at the same time periods as the participants in the intervention arm through the completion of the study. Participants will be seen for follow-up at 3 and 6 months (study completion). The participants in the control group will receive the same incentives as those in the intervention arms (gift cards). Since the women in the control group are obese, with components of metabolic syndrome, and at relatively high risk for breast cancer, we are providing healthy lifestyle information to the group, via text messages.
3233219|NCT01219569||1.Propofol|1.Subjects will receive propofol infusion and have pupillometry readings taken in both eyes after induction, after steady state maintenance has been achieved and at 30 minutes
3233220|NCT01219582||Group 1|
3233221|NCT01219595|Active Comparator|Part 1|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
3331248|NCT02103140|Experimental|Home-Based Exercise Intervention|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
3331249|NCT02103166|Experimental|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
3331250|NCT02103166|Placebo Comparator|Physiological serum|100 ml of physiological serum (0.9% NaCl).
3331251|NCT02103179||ECC patients|Extrahepatic cholangiocarcinoma patients treated by surgical treatment
3331252|NCT02103192|Experimental|Control plus low level nutrient fortification|Control plus low level nutrient fortification
3233222|NCT01219595|Other|No treatment|20 non-UTI susceptible women will be enrolled to collect data on the types of E. coli flora present in non-UTI women.
3233223|NCT01219595|Active Comparator|Part 2A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
3233224|NCT01219595|Placebo Comparator|Part 2B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
3331253|NCT02103192|Experimental|Control plus increasing level nutrient fortification|Control plus increasing level nutrient fortification
3331254|NCT02103192|Placebo Comparator|Caffeine-free, carbonated soft drink|Caffeine-free, carbonated soft drink
3331255|NCT02103205|Active Comparator|Low iron, with lactoferrin|Low iron, with lactoferrin
3331256|NCT02103205|Active Comparator|Low iron, no lactoferrin|Low iron, no lactoferrin
3331257|NCT02103205|Placebo Comparator|Normal iron, no lactoferrin|Normal iron, no lactoferrin
3331258|NCT02103231||Full Term Birth|History of full term birth (>37 weeks gestation) including sub-group with diagnosis of hypertension
3233225|NCT01219595|Active Comparator|Part 3A|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
3233226|NCT01219595|Placebo Comparator|Part 3B|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
3233227|NCT01219608|Active Comparator|Glutamine 0.5 g/kg/day|
3233228|NCT01219608|Active Comparator|Glutamine 1 g/kg/day|
3331259|NCT02103231||Preterm Birth|History of preterm birth (<37 weeks gestation) including subgroup with diagnosis of hypertension
3331260|NCT02103244|Experimental|carboplatin|An adjusted dosing algorithm will be applied to calculate the dose of carboplatin. in 24 patients blood will be obtained in order to determine the pharmacokinetics of carboplatin after adjusted dosing
3331261|NCT02103257|Experimental|Sequential icotinib plus chemotherapy|Sequential icotinib plus chemotherapy : pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
3331262|NCT02103257|Active Comparator|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
3331263|NCT02103283|Experimental|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
3233229|NCT01219608|Placebo Comparator|Enteral Nutrition|
3233230|NCT01219621|Active Comparator|DDD Long AVD|
3233231|NCT01219621|Experimental|safeR|
3331264|NCT02103296|Active Comparator|Infant Blood|Control group. Admission labs to be drawn directly from the infant.
3331265|NCT02103296|Experimental|Cord Blood|Admission labs to be drawn from the infant's cord blood
3233232|NCT01219647|Experimental|aerobic exercise|Subjects will train on a recumbent cross trainer 20-30 minutes/session for three times/week for six months under supervision of a fitness specialist
3233233|NCT01219647|Active Comparator|stretching|Subjects will particiate in supervised stretching at same frauency, duration and intensity of aerobic exericse arm
3233234|NCT01219686|Experimental|escitalopram 20mg + pindolol 15mg|Days 1-2: escitalopram 10 mg + placebo, days 3-42: escitalopram 20mg + placebo Days 1-14: pindolol 15 mg, days 15-17: pindolol 7.5 mg
3233235|NCT01219686|Active Comparator|Escitalopram 30 mg|Days 1-2: escitalopram 10 mg+ placebo, days 3-4 escitalopram 20 mg + placebo, days 5-42: escitalopram 30mg+ placebo
3233236|NCT01219686|Active Comparator|escitalopram 20 mg|days 1-2: escitalopram 10 mg+ placebo, days 3-42: escitalopram 20 mg + placebo
3233237|NCT01219699|Experimental|BYL719|In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
3233238|NCT01219699|Experimental|BYL719 + fulvestrant|In post-menopausal patients with estrogen receptor positive locally advanced or metastatic breast cancer whose tumors have an alteration of the PIK3CA gene, and in patients whose tumors are have wild-type PIK3CA gene
3259191|NCT01468363|Active Comparator|Group 1|"Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight as needed before a dialysis session.~If OH is positive value, we will try to reach dry weight by ultrafiltration without regard to the level of blood pressure.~If OH is negative value , we will not change dry weight."
3331266|NCT02103322|Experimental|Imatinib Mesylate Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
3331267|NCT02103322|Active Comparator|Gleevec Tablets, 400 mg|Imatinib Mesylate Tablets, 400 mg. Once daily for 14 days.
3331268|NCT02103335|Experimental|Single Group Assignment|Combination Pomalidomide, low-dose Dexamethasone, and Marizomib:
3331269|NCT02103348||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3331270|NCT02103348||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to inhaled, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis (defined as at least 5 of 7 days), or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past."
3331271|NCT02103348||Healthy Controls|Those without asthma or other chronic lung disease.
3331272|NCT02103361||Stelara (ustekinumab) exposed|Stelara (ustekinumab)-exposed pregnant women
3331273|NCT02103361||Tremfya (guselkumab) exposed|Tremfya (guselkumab-exposed pregnant women
3331274|NCT02103374|Experimental|Atrovent + Bricanyl or Atrovent + Ventolin|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form Atrovent 0,5mg/1ml Bricanyl 5mg/2ml Ventolin 5mg/2,5ml
3233239|NCT01219712|Active Comparator|Preoperative Optimization|"Patients with proximal femur fracture who are > 65 yrs old and have an increased NT-proBNP would be randomized to either Standard Management or Optimized Management.~The main aim of optimization is to achieve a normal oxygen delivery to the tissues preoperatively.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal."
3233240|NCT01219712|No Intervention|Standard treatment|Patients who are randomized to this group would be managed according to existing routines within the hospital. Consequently, these patients would be transferred to the Orthopaedic ward after initial management in the Emergency Department, including fluid therapy, oxygen and pain management. Since these patients have a significantly high NT-proBNP, a Cardiologist would be consulted and a decision for optimization taken together with the attending Anaesthesiologist and Orthopaedic Surgeon prior to surgery.
3233241|NCT01219751|Experimental|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
3233242|NCT01219764|Active Comparator|Full Dose|Full dose of Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
3233243|NCT01219764|Experimental|Half dose|Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
3233244|NCT01219790|Experimental|irradiation + zometa|
3331275|NCT02103374|Placebo Comparator|Placebo|1 capsule per day lactose (in addition to the standard optimized treatment)
3331276|NCT02103387|Experimental|Cognitive Behavioral Training|Cognitive Behavioral Training 5 weekly 1.5-hour sessions of group-based cognitive behavioral training
3331277|NCT02103387|Experimental|Relaxation Training|Relaxation Training 5 weekly 1.5-hour sessions of group-based relaxation training
3331278|NCT02103387|Active Comparator|Health Education Control|Health Education Control 5 weekly 1.5 sessions of group-based health education training
3331279|NCT02103400|Experimental|Experimental group|Patients hospitalized for community-acquired pneumonia
3331280|NCT02103400|Active Comparator|Control group|Patients hospitalized for community-acquired pneumonia
3331281|NCT02103413|Experimental|EUS-BD|EUS-BD using a fully or partially covered self-expanding metallic stent will be performed by EUS guided 19 G needle puncture.
3331282|NCT02103413|Experimental|PTBD|PTBD with 8.5F catheter will be inserted under fluoroscopic and/or ultrasonography guidance by experienced interventional radiologists.
3233245|NCT01219803|Experimental|High dose GGQL Decoction|
3233246|NCT01219803|Experimental|Mild dose GGQL Decoction|
3331283|NCT02103426|Experimental|Part 1: ASP0113 CMV-seropositive healthy cohort|5 mg single dose IM injection
3331284|NCT02103426|Experimental|Part 1: ASP0113 CMV-seronegative healthy cohort|5 mg single dose IM injection
3331285|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seropositive healthy cohort|single dose IM injection
3331286|NCT02103426|Placebo Comparator|Part 1: Placebo CMV-seronegative healthy cohort|single dose IM injection
3233247|NCT01219803|Experimental|Low dose GGQL Decoction|
3331287|NCT02103426|Experimental|Part 2: ASP0113 CMV-seropositive healthy cohort|4 IM injections of ASP0113
3331288|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative healthy cohort|4 IM injections of ASP0113
3331289|NCT02103426|Experimental|Part 2: ASP0113 CMV-seronegative dialysis cohort|4 IM injections of ASP0113
3331290|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seropositive healthy cohort|4 placebo IM injections
3331291|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative healthy cohort|4 placebo IM injections
3331292|NCT02103426|Placebo Comparator|Part 2: Placebo CMV-seronegative dialysis cohort|4 placebo IM injections
3331293|NCT02103452|Experimental|ovarian endometrioma|Ovarian and endometrial samples
3331294|NCT02103452|Experimental|normal ovary|Ovarian and endometrial samples
3331295|NCT02103465|Experimental|Rotigotine|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
3331296|NCT02103465|Placebo Comparator|Placebo|80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
3331297|NCT02103491|Active Comparator|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol).
3331298|NCT02103491|Placebo Comparator|Placebo administration|In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose).
3331299|NCT02103504|Other|DePuy Attune TKA|DePuy Attune posterior stabilized fixed bearing total knee replacement
3331300|NCT02103517|Experimental|Omega-3 fatty acid capsules|Omega-3 fatty acid capsules, 4 g/day, requiring intake 2 capsules (1g each one) in the morning and two at night for 3 months.
3331301|NCT02103517|Placebo Comparator|corn oil|Corn oil in similar presentation as omega-3 fatty acid capsules, requiring intake 2 capsules in the morning and two at night for 3 months.
3331302|NCT02103530|Experimental|FLT PET/CT|Patients who had FLT PET/CT
3331303|NCT02103543|Active Comparator|Physical Therapy first|patients will undergo physical therapy 3-4 sessions followed by lumbar interlaminar epidural steroid injection
3331304|NCT02103543|Active Comparator|lumbar epidural steroid first|lumbar interlaminar epidural steroid injection followed by patients will undergo physical therapy 3-4 sessions
3331305|NCT02103556|Active Comparator|Mineral oil|4ml daily (adjusted as needed), for 4 weeks
3331306|NCT02103556|Active Comparator|Olive oil|4ml daily (adjusted as needed), for 4 weeks
3331307|NCT02103556|Active Comparator|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
3233248|NCT01219803|Placebo Comparator|Placebo|
3233249|NCT01219816|Experimental|Patients under 60 years|Hyper CVAD regimen + Epratuzumab (Cyclophosphamide Vincristine Doxorubicin Dexamethasone)
3233250|NCT01219816|Experimental|Patients older than 60 years or < =60 years|Vincristine + Aracytine + Dexamethasone
3233251|NCT01219829||Family History patients|Patients with a strong family history of pancreatic cancer or with a genetic syndrome that puts them at risk for pancreas cancer.
3331308|NCT02103569|Experimental|Arm 1: FDC of NE/EE + DCV 3DAA FDC + BMS-791325|"Cycle 1- Low dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days~Cycle 2- High dose FDC of Norethindrone and Ethinyl Estradiol tablet orally on specified days and High dose FDC of Norethindrone and Ethinyl Estradiol + FDC of Daclatasvir, Asunaprevir and BMS-791325 + BMS-791325 tablets orally on specified days"
3331309|NCT02103582|Placebo Comparator|control|Participants who are randomized to the 'control arm' will be asked to maintain their current daily activities for 12 weeks. They will also be required to visit the study site 3 times per week for 12 weeks to view videos on different wellness topics. Control participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Control participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
3331310|NCT02103582|Experimental|intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
3331311|NCT02103595|Other|Accu-Chek FlexLink Plus cross over to Accu-Chek FlexLink|
3331312|NCT02103595|Other|Accu-Chek FlexLink cross over to Accu-Chek FlexLink Plus|
3233252|NCT01219829||Recurrence patients|Patients who underwent surgery for pancreatic cancer and developed tumor recurrence after surgery
3233253|NCT01219842|Active Comparator|INVASIVE (INV) group|Modern endovascular and/or open revascularization according to the recommendations in the TASC II document.
3331313|NCT02103621|Experimental|Unifed Protocol (UP) for Discontinuation|Unified Protocol (UP) for Discontinuation is delivered in 14 weekly individual sessions of 45-60 minutes followed by 3 booster sessions scheduled at two, four and eight weeks thereafter. The UP is a cognitive behavioral treatment that focuses on increasing emotional awareness and cognitive flexibility, preventing behavioral and emotional avoidance, and situational and interoceptive emotion-focused exposure. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
3331314|NCT02103621|Active Comparator|Taper and Monitoring (TAP-M)|Taper and Monitoring (TAP-M) is delivered in biweekly individual sessions over 14 weeks, with booster sessions at two, four, and eight weeks thereafter. TAP-M consists of assessment and monitoring. Participants will also receive 7 biweekly medication management sessions over 14 weeks with a study psychiatrist to facilitate gradual taper of SRI medication.
3331315|NCT02103634||Lesion Imaging|Image patients with the standard of care of a FDG PET/CT and the experimental method of the NaF PET/MRI and compare the number of images found within and between patients to determine the most effective way of looking at breast cancers metastasized to bone
3331316|NCT02103647|Active Comparator|Immediate release capsule(lyrica capsule 150mg)|Immediate release capsule repeat treatment for 3days under fasted condition
3233254|NCT01219842|Active Comparator|NON-INVASIVE (NON) group|Patients receiving only best medical treatment (BMT).
3233255|NCT01219868|Experimental|Physician-nurse team|
3233256|NCT01219894||RUTTS Score <30%|Patients with evidence of complete healing of stent at 3 months
3233257|NCT01219894||RUTTS<30%|Group with evidence of incomplete healing of the stent
3233258|NCT01219907|Experimental|Arm I|"VACCINE THERAPY: Patients receive HER2 peptide vaccine intradermally once weekly for 3 weeks.~CHEMOTHERAPY: Patients receive cyclophosphamide IV on day -1.~IMMUNOTHERAPY: Patients receive ex vivo-expanded HER2 specific T-cell IV over 30 minutes on days 1, 10, and 20."
3233259|NCT01219920|Active Comparator|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
3233260|NCT01219920|Experimental|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
3233261|NCT01219946||1|Patients with Chronic Obstructive Pulmonary Disease
3233262|NCT01219972||Allografted patients|"All consecutive patients who underwent an allogeneic blood stem cells transplantation performed at saint Louis hospital during the study recruitment period~if alive at 100 days post-transplant~and who gave informed consent"
3233263|NCT01219998||NGAL Kinetics in neonates|to describe postoperative kinetics of urinary NGAL in neonates and to identify the threshold for accurate prediction of severe AKI requiring RRT in neonates and infants undergoing cardiac surgery with cardiopulmonary bypass
3233264|NCT01220011|Experimental|NO INTERVENTION|
3233265|NCT01220011|Active Comparator|fetoscopic laser|
3331317|NCT02103647|Experimental|sustained release tablet|sustained release tablet repeat treatment for 3days under fasted condition
3331318|NCT02103660|Active Comparator|Depo-Medroxyprogesterone Acetate|Half of women will be randomized to receive Depo-Medroxyprogesterone Acetate injections every 13 weeks
3331319|NCT02103660|Active Comparator|Progestin Implant (Jadelle)|Half of women will be randomized to receive progestin implant.
3331320|NCT02103673|Experimental|DAOIB|Drug: DAOIB 250-1500 mg/day by mouth for 6 weeks
3331321|NCT02103673|Placebo Comparator|Placebo|Placebo by mouth per day for 6 weeks
3331322|NCT02103686|Active Comparator|Immediate release capsule|Immediate release capsule treatment under fasted condition
3331323|NCT02103686|Experimental|sustained release tablet|sustained release tablet treatment under fasted condition
3331324|NCT02103686|Experimental|sustained release tablet (high fat meal)|sustained release tablet under high fat meal condition.
3233266|NCT01220037|Experimental|Young regular diet|During the time of the study this group will adhere to a standardized regular diet.
3331325|NCT02103699||Hepatitis C virus infected patients receiving simeprevir|
3331326|NCT02103712||Hypospadias|
3331327|NCT02103725|Experimental|pimecrolimus 10 mg/g cream|Active drug
3331328|NCT02103725|Placebo Comparator|Vehicle cream|Placebo drug
3331329|NCT02103738||Arm 1 (Monthly)|0.5 mg intravitreal injections of Ranibizumab monthly for the duration of the study.
3331330|NCT02103738||Arm 2 (Treat and Extend)|Three consecutive months of 0.5 mg Ranibizumab intravitreal injections (Day 1, Month 1, and Month 2). Monthly injections will continue until evidence of disease stability is observed. Specifically, monthly treatment will continue until visual acuity is deemed stable as indicated by a gain in visual acuity of ≤ 3 ETDRS letters from the prior month, no clinical evidence of lesion growth, fluid or blood, and no intraretinal or subretinal fluid on OCT. When this is achieved, the intervals between each subsequent injection will be extended by 2 weeks (intervals of 6 weeks, 8 weeks, 10 weeks, to a maximum of 12 weeks) until clinical or diagnostic evidence of disease instability is observed based on OCT findings and/or BCVA ETDRS.
3331331|NCT02103764|Experimental|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
3331332|NCT02103764|Active Comparator|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
3331333|NCT02103777|Active Comparator|High dose caffeine|High dose (loading 40 mg/kg/day equivalent to 20 mg /kg/day of caffeine base and maintenance of 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base)
3233267|NCT01220037|Experimental|Young low protein diet|During the time of the study this group will adhere to a standardized low protein diet.
3233268|NCT01220037|Experimental|Young high protein|During the time of the study this group will adhere to a standardized high protein diet.
3331334|NCT02103777|Active Comparator|Low dose caffeine|Low dose (loading 20 mg/kg/day equivalent to 10 mg /kg/day of caffeine base and maintenance of 10 mg/kg/day equivalent to 5 mg /kg/day of caffeine base) caffeine.
3331335|NCT02103790|Experimental|Home NIV installation|
3233269|NCT01220037|Experimental|Elderly|During the time of the study this group will adhere to a standardized high protein diet
3331336|NCT02103829|Active Comparator|Condition #1|Condition #1 will consist of Brief Intervention #1, a brief online suggestion that takes less than 1 minute to complete.
3331337|NCT02103829|Experimental|Condition #2|Condition #2 will consist of Brief Intervention #1 and Brief Intervention #2 that together take less than a minute to complete.
3331338|NCT02103829|Experimental|Condition #3|Condition #3 will consist of Brief Intervention #1 and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
3331339|NCT02103829|Experimental|Condition #4|Condition #4 will consist of Brief Intervention #1, Brief Intervention #2, and Brief Intervention #3, which, together, will take less than 8 minutes to complete.
3233270|NCT01220050|Experimental|Paricalcitol|
3331340|NCT02103842|Experimental|Omega-3 fatty acids|Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months
3331341|NCT02103868|No Intervention|Control|No active intervention will be given for tobacco cessation.
3331342|NCT02103868|Experimental|Medium Intervention|Tobacco Cessation Counseling : Medium intervention in the form of 3 contact sessions will be given for tobacco cessation.
3233271|NCT01220050|Active Comparator|Standard therapy|
3233272|NCT01220063|Other|Radiation + Irinotecan|"Irinotecan will be administered :~- 40 mg/m² in serum physiologique during 30 to 90 min at D1 and D8 of radiotherapy~Radiotherapy (RSHF) will be administered :~at D1, D3, D8 and D10~48 Gy, 12 Gy by fractions twice a week"
3233273|NCT01220076|Experimental|Tamoxifene|
3233274|NCT01220089|Active Comparator|Standard maintenance|During months 7 to 18, individuals in the Standard Maintenance condition will receive informational handouts by mail (or e-mail) regarding weight maintenance.
3233275|NCT01220089|Active Comparator|Intensified Maintenance|"During months 7 to 18, individuals in the Intensified Maintenance condition will continue to have monthly in-person visits with the weight loss counselor (Weight Coach)."
3233276|NCT01220115||No treatment|Patients aged 2 to less than 12
3233277|NCT01220115||No treatment patients aged 12 to less than 18|Patients aged 12 to less than 18
3331343|NCT02103868|Experimental|Low intensity intervention|Tobacco Cessation Counseling: Only a single contact session will be done for tobacco cessation.
3331344|NCT02103881|Experimental|Ketamine|Patients enrolled in this arm will be given 500 mg of intramuscular ketamine for their severe agitation they experience in the prehospital environment.
3331345|NCT02103881|Experimental|Haloperidol|Patients enrolled in this arm will be given 10 mg of intramuscular haloperidol for their severe agitation they experience in the prehospital environment.
3331346|NCT02103894|Experimental|[18F]T807 ([18F]MNI-777)|At the [18F]MNI-777 PET imaging visit, subjects will be injected with no more than 10 mCi (370 MBq) of [18F]MNI-777).
3331347|NCT02103907|No Intervention|Wait list|Wait list control group. Participants will be placed on the wait list and asked to maintain their current routine and level of activity during the 10 week period. Control group participants will receive the dynamic balance training program in a single training session after the followup (second testing session at 10 weeks).
3233278|NCT01220115||No treatment Patients greater than 18 years|patients greater than 18 years
3233279|NCT01220141||A|
3233280|NCT01220154|Experimental|Carboplatin Paclitaxel & Bevacizumab|Intraperitoneal carboplatin with weekly intravenous paclitaxel and intravenous bevacizumab
3331348|NCT02103907|Experimental|Treatment (balance training)|Targeted dynamic balance training. Dynamic balance training will consist of progressive exercise training over three phases, with exercises emphasising dynamic balance control, muscle strength and proprioception. Exercises will be performed four times per week for ten weeks. Exercises will be taught and supervised by a trained kinesiologist. Difficulty of exercises will be increased progressively over time by increasing resistance, time of timed exercises, and distance of walking exercises. Exercises will be progressed to different exercises in each new phase (total 3 phases). Participants will complete six treatment sessions at the university (during weeks 1, 2, 3, 5, 7, and 9) that will be included in the total number of sessions per week. All other sessions will be performed at home.
3331349|NCT02103946|Active Comparator|Serratus anterior muscle plane block|Serratus anterior muscle plane block with general anesthesia MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
3233281|NCT01220193||Normal cornea|
3233282|NCT01220193||Post laser refractive surgery|
3233283|NCT01220193||Cornea pathology|
3331350|NCT02103946|Active Comparator|Paravertebral block|Paravertebral block with general anesthesia. MARCAINE® 0.25%w/v solution for injection. DIPRIVAN® (propofol), 2 to 2.5 mg/kg NIMBEX® (cisatracurium besylate) Injection, 0.15-0.2 mg\Kg Fentanyl, 1-2 mic\Kg Paracetamol, 1000 mg\6 hours Fam® (Ketorolac), 30 mg
3331351|NCT02103959|Experimental|CMX-2043 2.4 mg/Kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
3331352|NCT02103959|Experimental|CMX-2043 3.6 mg/kg|Bolus injection of investigational product given prior to the cardiac catheterization and placebo given 24 hours after the first dose.
3331353|NCT02103959|Experimental|CMX-2043 2.4 mg/kg given twice|Bolus injection of investigational product given prior to the cardiac catheterization and again 24 hours after the first dose.
3331354|NCT02103959|Placebo Comparator|Placebo comparator|Placebo comparator (PBS) given prior to cardiac catheterization and again 24 hours after the first dose.
3331355|NCT02103972|Placebo Comparator|Maltodextrin|Maltodextrin
3331356|NCT02103972|Active Comparator|GM080|GM080
3331357|NCT02103985|Experimental|Treatment A|Participants will receive 100 mg JNJ-39823277 under fed (after a high fat) condition.
3331358|NCT02103985|Experimental|Treatment B|Participants will receive 100 mg JNJ-39823277 under fasted condition.
3331359|NCT02103998|Experimental|T4 + KI|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
3331360|NCT02103998|Placebo Comparator|D5W - 5% dextrose water|Receive the same volume as study drug but as D5W placebo
3331361|NCT02104011|Experimental|Patient|
3331362|NCT02104024||Kidney transplant recipients|CEUS in Kidney Transplant recipients
3331363|NCT02104024||Pancreas transplant recipients|CEUS in pancreas transplant recipients
3331364|NCT02104037|Experimental|Liraglutide treated patients|
3233284|NCT01220193||Cataract surgery|
3233285|NCT01220206|Placebo Comparator|Placebo|2 placebo capsules daily
3331365|NCT02104050|Placebo Comparator|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
3233286|NCT01220206|Experimental|one POMx capsule|One POMx capsule, one placebo capsule daily
3233287|NCT01220206|Experimental|2 POMx Capsules|2 POMx Capsules daily
3331366|NCT02104050|Experimental|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
3331367|NCT02104063||MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
3331368|NCT02104076|Experimental|Evolution® Biliary Stent-Fully Covered|
3233288|NCT01220219|Experimental|Pregabalin controlled release, 82.5 mg|
3233289|NCT01220219|Experimental|Pregabalin controlled release, 165 mg|
3233290|NCT01220219|Other|Pregabalin immediate release, 75mg|Reference Treatment
3233291|NCT01220232|Active Comparator|Abacavir/Lamivudine|
3233292|NCT01220232|Experimental|Lersivirine + Abacavir/Lamivudine|
3233293|NCT01220245|Experimental|Heparin-bonded endoluminal fempop bypass|Heparin-bonded ePTFE endoluminal femoro-popliteal bypass versus surgical femoro-popliteal bypass
3233294|NCT01220245|Active Comparator|Surgical femoro-popliteal bypass|Surgical femoro-popliteal bypass.
3233295|NCT01220258|Experimental|Azithromycin ophthalmic solution, 1%|
3233296|NCT01220271|Experimental|Phase 1: 160 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 80 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3259192|NCT01468363|No Intervention|Group 2|BCM results obtained at the beginning and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
3259193|NCT01468376|Experimental|GLU-01|
3259194|NCT01468376|Experimental|GLU-02|
3259195|NCT01468376|Experimental|GLU-03|
3233297|NCT01220271|Experimental|Phase 1: 300 mg LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: 150 mg taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3233298|NCT01220271|Experimental|Phase 2: Established dose LY2157299|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~LY2157299: Phase 1 established dose taken twice daily for 14 days on followed 14 days of pause. This on/off schedule constitutes a cycle of 28 days. Taken for a 6 cycles.~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3331369|NCT02104089||Endovascular treatment|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft
3331370|NCT02104102|Experimental|Mirror group|Composed of 30 volunteers who carry out the mirror therapy, whose name shall Mirror Group (MG).
3331371|NCT02104102|Experimental|Control Group - kinesiotherapy|Called by Control Group (CG), composed of 30 volunteers who will carry out the kinesiotherapy with the same sequence of movements for the Mirror Therapy that the MG, but without the view in the mirror, since it will be blocked.
3233299|NCT01220271|Experimental|Phase 2: no LY2157299 (control)|"During Radiation therapy:~Radiation:Approximate 1.8 - 2.0 Gy x 30 fractions. Approximate total dose = 60.0 Gy taken 5 days per week for 6 weeks.~Temozolomide: 75 mg/m2 taken daily for 6 weeks.~After Radiation Therapy:~Temozolomide: 150 mg/m2 and then 200 mg/m2 daily during the off time of LY2157299. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles."
3331372|NCT02104115|Other|Gluten free white bread|Sliced loaf of gluten free white bread
3331373|NCT02104115|Other|Normal gluten content white wheat bread|Sliced loaf of normal gluten content white wheat bread
3331374|NCT02104115|Other|High gluten content white wheat bread|Sliced loaf of high gluten content white wheat bread
3331375|NCT02104128|Experimental|Depressed patient given bupropion|All depressed patients will be given open label bupropion
3331376|NCT02104128|No Intervention|Control pts given no intervention|Control participants will be assessed at the same time points as the depressed group, but will be given no drug
3331377|NCT02104154||symptoms of liver disease|Device: Samsung LABGEO PT10 Hepatic Panel
3331378|NCT02104193|Experimental|simvastatin|they will receive simvastatin in addition to radiation therapy
3331379|NCT02104193|Active Comparator|control|they will receive radiation therapy only
3331380|NCT02104232|Experimental|THPP-I|TPs in the THPP-I group receive, in addition to enhanced usual care (EUC), between 6 to 14 sessions of THPP (simple cognitive behaviour therapy) starting from their recruitment in the second/ third trimester until up to 6 months after child birth. Sessions will be delivered by peers on an individual basis at a location of convenience to the TPs.
3331381|NCT02104232|Other|Enhanced usual care (EUC)|Enhanced usual care (EUC) will comprise communicating the results of the screening to the mother through an information sheet on self-care for mental health, communicating the results to the mother's gynaecologist, providing the gynaecologist with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
3331382|NCT02104245|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
3331383|NCT02104245|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
3331384|NCT02104258|Active Comparator|Physiotherapy ASPETAR|"The patients will follow the ASPETAR Hamstring Rehabilitation Protocol, which is a standardised physiotherapy protocol, including range of motion exercises, progressive strengthening exercises, core stability training and agility exercises [10].~The ASPETAR protocol consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
3331385|NCT02104258|Active Comparator|Physiotherapy ASPETAR+|"The patients will follow the ASPETAR+ Hamstring Rehabilitation Protocol. ASPETAR+ is similar to ASPETAR, but consists of additional lengthening exercises which will be initiated early in the rehabilitation phase.~ASPETAR+ consist of predefined rehabilitation stages including sports specific stages. Specific functional based criteria for progression will be utilized for each of the six rehabilitation stages. No pain provocation when performing the exercises will be allowed.~The rehabilitation will be initiated as soon as possible after inclusion and the patients will be supervised by experienced physiotherapists in the Rehabilitation Department at Aspetar 3 to 5 days per week."
3331386|NCT02104271|Experimental|Argon Plasma Coagulation|"Argon Plasma Coagulation (APC) treatment will be delivered using a spray-painting technique, with short applications at 40W power and argon gas flow of 1.2 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
3331387|NCT02104271|Active Comparator|Historical control|"Argon Plasma Coagulation (APC) treatment was delivered using a spray-painting technique, with short applications at 40-50W power and argon gas flow of 2.0 - 2.5 L/min. The APC equipment consists of a high frequency electrosurgical generator combined with a source of argon gas (Argon + SS601MC 4 , WEM Electronic Equipment Ltda , Ribeirão Preto , Brazil ). A flexible catheter of 2.3 mm diameter ( WEM ) Teflon coated and with a hint of heat resistant ceramic is inserted through the working channel of the colonoscope and connected to the current generator and the gas source for APC implementation."
3331388|NCT02104284|Other|Normal controls, methacholine positive|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in normal controls
3331389|NCT02104284|Other|Normal controls, mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in normal controls.
3331390|NCT02104284|Active Comparator|Asthma, Methacholine|methacholine and mannitol bronchial challenge tests: Positive methacholine challenge tests in asthmatics
3331391|NCT02104284|Active Comparator|Asthma, Mannitol|methacholine and mannitol bronchial challenge tests: Positive mannitol challenge tests in asthmatics
3331392|NCT02104297|Active Comparator|Deksmedetomidine infusion|To prevent agitation deksmedetomidine infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
3331393|NCT02104297|Experimental|Remifentanil infusion|To prevent agitation remifentanil infused during operation at the end of surgery agitation scor measured by Riker sedation agitation scale.
3331394|NCT02104297|Placebo Comparator|Saline infusion|Saline infused during operation and at the end of surgery agitation scor measured by Riker sedation agitation scale.
3331395|NCT02104310|Experimental|Fluorine-18-L-dihydroxyphenylalanine|18F-DOPA PET imaging will be used to guide radiotherapy treatment volumes and patients will be followed post-treatment to analyze response and patterns of failure
3331396|NCT02104323|Experimental|Endostatin，treatment effect evaluation|Patients receive continuous intravenous Endostatin drug pumping during the course of treatment. The drug dosage is 7.5mg/m2/d. Every course of treatment lasts three months. Patients are designed to receive total three courses of treatment if there is no disease progression. The interval between two courses is one month.
3331397|NCT02104336|Experimental|EPI-743|15 mg/kg EPI-743 to be administered three times per day for 1 year
3331398|NCT02104349|Experimental|Mindfulness meditation|Subjects who are instructed on use of the mindfulness meditation technique
3233300|NCT01220284|Experimental|Satraplatin in combo with vinorelbine|"Escalating doses of satraplatin and oral vinorelbine in subsequent cohorts of 3-6 patients according to the type and severity grade of acute toxicities observed during cycle 1.~The dose escalation process will be discontinued once the MTD is achieved."
3233301|NCT01220310|Experimental|Intervention|Online diabetes workshop observation and learning sessions
3331399|NCT02104349|No Intervention|Control|Subjects will receive standard surgery treatment without any mindfulness intervention.
3331400|NCT02104362|Other|exclusive single-fraction irradiation|
3331401|NCT02104375|Experimental|L-citrulline|L-citrulline (6 g/day for 2 weeks)
3233302|NCT01220323|Active Comparator|direct current stimulation|The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm.
3233303|NCT01220323|Sham Comparator|sham stimulation|
3331402|NCT02104375|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3331403|NCT02104388|Experimental|SJP-0035 Ophthalmic Solution|Patients randomized to the SJP-0035 Ophthalmic solution will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
3331404|NCT02104388|Placebo Comparator|Vehicle of SJP-0035 Ophthalmic Solution|Patients randomized to the placebo arm will receive 1 drop in the affected eye(s) given 4 times daily for 4 weeks.
3331405|NCT02104401|Experimental|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
3331406|NCT02104440|Experimental|Patients with cytopenia after allo-HSCT|Patients with cytopenia after allo-HSCT
3331407|NCT02104453|Experimental|E-C clamp mask holding technique|"the airway maneuver that press the mask against the patient's face (using the C of our thumb and forefinger) while pulling the jaw forward (using the E of our other fingers behind the mandible), and leaves one hand free to squeeze the bag."
3331408|NCT02104453|Experimental|two-handed ventilation with jaw thrust|the airway maneuver performed with thumbs point toward feet, palms press down and other fingers perform jaw thrust
3331409|NCT02104453|Experimental|triple airway maneuver|the airway maneuver performed with two-handed mask ventilation, jaw thrust and head-tilt chin-lift technique
3331410|NCT02104466|No Intervention|Treatment as Usual (TAU)|Participants randomized to this arm will receive usual care with no acupuncture.
3331411|NCT02104466|Experimental|TAU + 12 wks of acupuncture 1x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture once per week for a period of 12 weeks.
3233304|NCT01220336|Experimental|Health Coaching|
3233305|NCT01220349|Experimental|Echocardiographic 2D strain analysis|
3331412|NCT02104466|Experimental|TAU + 12 wks of acupuncture 2x/week|Participants randomized to this arm will receive usual care with adjunctive acupuncture twice per week for a period of 12 weeks.
3331413|NCT02104479||Immunocompromised Patients|Immunocompromised patients with suspected IPA who have Pleural effusions act as the observed study population
3331414|NCT02104479||Control Group|Patients without Immunosuppression with pleural effusions
3331415|NCT02104492|Experimental|Intervention group|a 12-week respiratory muscles training program (RMTP) with ORYGEN Dual® device and peripheric resistive muscle training program
3233306|NCT01220362|Other|Group 1|Bupivacaine 0.125%
3233307|NCT01220362|Other|Group 2|Bupivacaine 0.125%/Fentanyl 2mcg/ml
3259196|NCT01468376|Experimental|GLU-04|
3233308|NCT01220375|Experimental|1|Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell release from bone marrow and HSC movement into the peripheral circulation.
3233309|NCT01220388|Experimental|L-lysine|11 days treatment with study drug, order of periods (active treatment or placebo) being sorted out.
3233310|NCT01220388|Placebo Comparator|placebo|11 days treatment with study drug, order of periods (L-lysine or placebo) being sorted out.
3233311|NCT01220427||Clinical high-risk prostate cancer, radical prostatectomy|
3331416|NCT02104492|Active Comparator|Control Group|Peripheric resistive muscle training program and Health Education Program.
3331417|NCT02104518||G6PD testing|Blood samples will be tested for G6PD activity levels
3331418|NCT02104531||Shoulder Pain|No intervention. Subjects will have a standard static MRI taken of their shoulder, and also complete a series of shoulder motions using video fluoroscopy.
3331419|NCT02104531||Healthy Subjects|No intervention. Subjects will receive a standard shoulder MRI and perform shoulder motions while being measured with video fluoroscopy.
3331420|NCT02104570|Other|Control|In this session, participants will be evaluated before and after a muscle fatigue protocol, with no intervention.
3331421|NCT02104570|Experimental|Kinesio taping with tension|A kinesio taping technique for the deltoid muscle will be applied before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
3233312|NCT01220440|Experimental|Methylphenidate, Dexamphetamine, Placebo|The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.
3233313|NCT01220479|No Intervention|Control Healthy|
3331422|NCT02104570|Sham Comparator|Kinesio taping without tension|A kinesio taping technique will be applied on the deltoid muscle without tension (tension is considered to be the therapeutic effect) before fatigue protocol and removed after in the end of the evaluation session. Subjects will be evaluated before taping, after taping and after the fatigue protocol.
3331423|NCT02104596|Experimental|Xylitol injection|Intraarticular injection of Xylitol
3331424|NCT02104596|Placebo Comparator|Control|
3331425|NCT02104609||Normal weight women|Levonorgestrel 1.5mg by mouth once
3331426|NCT02104609||Obese women|Levonorgestrel 1.5mg by mouth once
3331427|NCT02104609||Extremely obese women|Levonorgestrel 1.5mg by mouth once
3233314|NCT01220479|No Intervention|Control Diabetic|
3233315|NCT01220479|Experimental|Exercise Diabetic|
3331428|NCT02104622|Experimental|ReWalk training|
3331429|NCT02104635|No Intervention|Control group|The control group receives standard of care from Jacaranda clinic and does not receive any additional post-partum check-in from a community health worker.
3331430|NCT02104635|Experimental|CHW-Visit|The CHW-Visit group will receive a visit at their home from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
3331431|NCT02104635|Experimental|CHW-Phone|The CHW-Visit group will receive a phone call from a community health worker (CHW) three days after delivery. The CHW will administer a checklist designed to identify maternal and newborn complications and will provide information about positive maternal health and care behaviors. The CHW will encourage women to return to the clinic at 7 days to receive a well-baby check.
3331432|NCT02104648|Placebo Comparator|Part A: Placebo|
3331433|NCT02104648|Experimental|Part A: RO4602522|
3331434|NCT02104648|Experimental|Part B: RO4602522 Multiple Doses|
3233316|NCT01220479|Experimental|Exercise Healthy|
3233317|NCT01220492|Experimental|conventional plus MSC treatment|participants will receive conventional treatment plus a dose of MSC from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
3233318|NCT01220492|Experimental|conventional plus placebo treatment|participants will receive conventional plus placebo treatment from day 0 through the week 8 study visit. Participants will then be followed until the 75 months study visit.
3233319|NCT01220518|Active Comparator|CT-P13|infliximab
3233320|NCT01220518|Active Comparator|Remicade|infliximab
3233321|NCT01220544|Experimental|HaploTransplant with NK cells|Haploidentical transplantation of mega-dose CD34+ hematopoetic stem cells with transfer of CD56+CD3-NK cells at day +2
3233322|NCT01220570|Experimental|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) + Dalotuzumab (MK-0646)
3233323|NCT01220570|Experimental|Ridaforolimus|Ridaforolimus (MK-8669)
3233324|NCT01220570|Experimental|Dalotuzumab|Dalotuzumab (MK-0646)
3233325|NCT01220583|Experimental|Arm I|Patients undergo 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) 5 days a week for 6-6.5 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiotherapy.
3233326|NCT01220583|Experimental|Arm II|Patients undergo 3D-CRT or IMRT as in arm I.
3233327|NCT01220596|Experimental|Sequential therapy|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
3233328|NCT01220596|Active Comparator|Peginterferon alfa-2a monotherapy|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
3233329|NCT01220622|Active Comparator|Nimodipine|
3331435|NCT02104648|Experimental|Part B: RO4602522 Single Dose|
3331436|NCT02104648|Experimental|Part B: moxifloxacin Single Dose|
3331437|NCT02104661|Experimental|OxCarbazepine Treatment|Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs.
3331438|NCT02104661|Placebo Comparator|OxCarbazepine Placebo|Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs
3331439|NCT02104674|Placebo Comparator|Placebo|
3331440|NCT02104674|Active Comparator|Singulair (montelukast)|
3331441|NCT02104674|Experimental|lebrikizumab|
3331442|NCT02104687|Active Comparator|Flow|The Flow therapeutic algorithm will be responsible for adjustment of intraoperative interventions - volumotherapy and administration of vasoactive drugs, with the aim to maintain the CI value >2.5 l/m/m2 (FTc - flow time <330 ms was chosen as variable defining preload; PV, peak velocity <70 ms-1 will be used as a variable defining contractility; SVR, total systemic vascular resistance between 1000-1800 cdyn.s/cm5m2 will be used as variable defining after load). After the desired values of CI have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
3331443|NCT02104687|Active Comparator|Press|The Press therapeutic algorithm will be responsible for adjustment of intraoperative interventions based upon standard pressure parameters and will include volumotherapy and administration of vasoactive drugs, with the aim to maintain the desired values of MAP of 65-105 mmHg and CVP 8-12 mmHg. After the desired values of MAP and CVP have been obtained, no further increase of therapeutic intervention (fluids, vasoactive drugs) will be performed.
3331444|NCT02104700|Active Comparator|Rilpivirine/Emtricitabine/Tenofovir|"Immediate switch: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization."
3331445|NCT02104700|Active Comparator|Nevirapine/Lamivudine/ plus other NNRTI|"Delayed switch: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks."
3331446|NCT02104713|Experimental|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The 1st group of 5 will be started on the lowest dose. If there are no adverse reactions, the 2nd group of 5 will receive a higher dose. This will be repeated for the 3rd and 4th groups with each receiving a higher dose.~Up to 2 administrations of cells per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
3331447|NCT02104726|Active Comparator|Blind Steroid Injection|Blind Steroid Injection for patients with OA deemed qualified for it clinically
3331448|NCT02104726|Active Comparator|Fluoroscopy guided steroid injection|Fluoroscopy guided Steroid Injection for patients with OA deemed qualified for it clinically. We want to see which one is better.
3331449|NCT02104778|Experimental|Dexamethasone|Dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3331450|NCT02104778|Placebo Comparator|Control|Normal saline 1 ml is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3331451|NCT02104778|Experimental|epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
3331452|NCT02104791||procalcitonin in blood|-Group 1: Healthy preterm Group: will include 50 pregnant females all at 24-34 weeks of gestational age .
3331453|NCT02104791||plasma of blood|-Group 2: Preterm premature rupture of membrane Group include 50 pregnant women
3331454|NCT02104791||procalcitonin,prematureruptureofmembrane in blood|"Complete history including (special habits like smoking and alcohol taking, menstrual history especially LMP, medical diseases, past obstetric history including duration, mode of delivery for each pregnancy, and if there were fetal or maternal complications).~Physical examination including (general condition, height, weight, vital signs).-Ultrasound to execlude multiple pregnancies, IUFD and to confirm oligohydraminos in group2.~The venous blood samples will be taken for measuring of -Procalcitonin in mothors -CRP and WBCs in mothers to detect infection -CRP in neonates of mothers of group 2.~They will be asked for their permission and consent."
3331455|NCT02104843|Experimental|Arm 1: DCV/ASV/BMS-791325 FDC + BMS-791325 + Rosuvastatin|"Treatment A: Rosuvastatin tablet orally on specified days~Treatment B: Daclatasvir, Asunaprevir and BMS-791325 Fixed dose combination (FDC) + BMS-791325 tablet orally on specified days~Treatment C: Daclatasvir, Asunaprevir and BMS-791325 FDC + BMS-791325 + Rosuvastatin tablet orally on specified days"
3331456|NCT02104856||Alair System (Bronchial Thermoplasty)|Asthma patients undergoing Bronchial Thermoplasty treatment with commercially available Alair device as per Directions For Use.
3331457|NCT02104869|Active Comparator|Recommended dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
3331458|NCT02104869|Active Comparator|Healthy adults|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 0.5 mL dose."
3233330|NCT01220622|Placebo Comparator|Placebo|
3331459|NCT02104869|Experimental|Single double dose (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: single 1.0 mL dose."
3331460|NCT02104869|Experimental|Two sequential doses (kidney transplant)|"Intervention: trivalent influenza vaccine (inactivated and fragmented).~Dosage form: each 0.5 mL dose of the vaccine contains Myxovirus influenzae strains propagated in embryonated chicken eggs, equivalent to: A/California/7/2009 (H1N1) pdm09 (15 mcg of hemagglutinin); A/Texas/50/2012 (H3N2) (15 mcg of hemagglutinin); B/Massachusetts/2/2012 (15 mcg of hemagglutinin); Thimerosal (2 mcg).~Dose: two 0.5 mL doses 21 days apart."
3233331|NCT01220635|Experimental|Skill Group Program|Positive Thoughts and Actions Program
3233332|NCT01220635|Active Comparator|Individual Support Program|Measure of Adolescent Potential for Suicide (MAPS) - modified
3233333|NCT01220648|Experimental|Nilotinib in conjunction with low dose interferon alfa|
3233334|NCT01220661|Experimental|One dose|One dose prophylactic antibiotic
3233335|NCT01220674||community dwelling older adults, normal controls|men and women 55 years of age or older who are cognitively intact.
3259197|NCT01468376|Experimental|GLU-05|
3331461|NCT02104882|Experimental|Intraoperative Radiotherapy|Following conventional frameless neuronavigation-guided microsurgical tumor resection, patients will receive IORT with 20-40 Gy (prescribed to the applicator surface). Not later than 4 weeks, radiochemotherapy (RCT) will be initiated, consisting of a total EBRT dose of 60 Gy (delivered in fractions of 2 Gy) and concomitant chemotherapy with temozolomide (50 mg/m2/d). Four weeks after RCT, cycling chemotherapy with temozolomide (150-200mg/m2/d/cycle) will be applied.
3331462|NCT02104908|Experimental|paravertebral nerve|Injection with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1)
3331463|NCT02104908|Other|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
3233336|NCT01220674||community dwelling older adults, mild cognitive impairment|men and women 55 years of age or older who have minimal cognitive decline (MMSE 20-24).
3331464|NCT02104921||Neuromuscular Disease Patients|Amyotrophic lateral sclerosis patients, myopathy patients, muscular dystrophy patients, myasthenia gravis patients, radiculopathy patients, mononeuropathy patients
3331465|NCT02104921||Healthy volunteers|
3331466|NCT02104934|No Intervention|Local Infiltration Analgesia|The Local Infiltration Analgesia group will receive local infiltration of ropivacaine 150mg, ketorolac 30mg, morphine 10mg, adrenaline 200mcg and vancomycin 500mg in a total volume of 75mls by the surgeon.
3331467|NCT02104934|Active Comparator|Adductor Canal Block|The Adductor Canal Block group of patients will receive intravenous ketorolac 30mg intra-operatively and an adductor canal block at the end of surgery. The block will be performed under real time ultrasound guidance and 30mls of 0.5% ropivacaine (150mg) is injected with a Stimuplex A100, 21G needle.
3331468|NCT02104960||PROOF|Healthy inhabitants of the city of Saint-Etienne, France, and aged 65 years at the inclusion date. (NCT00759304)
3331469|NCT02104973|Experimental|Lifestyle counseling|After obtaining the approval of schools and parents, will be established in schools, units in which individual attention is given to children, parents and teachers that request: the advice is aimed at training users on healthy diet and constant physical activity. Workshops with children, in which selected topics will be discussed based on the analysis of depth interviews with children, parents and teachers, and information on habits and resources gathered through questionnaires will be conducted. The intervention included the provision of information and feedback with the population through a website. The work will include participation in the selection of foods sold in schools.
3331470|NCT02104973|No Intervention|Control|Usual care
3331471|NCT02104986|Experimental|3 courses of Velbe-Bleomycin-Cisplatin|3 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3331472|NCT02104986|Experimental|4 courses of Velbe-Bleomycin-Cisplatin|4 VBP (Velbe-Bleomycin-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3331473|NCT02104986|Experimental|3 courses Vepeside-ifosfamide-Cisplatin|3 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3331474|NCT02104986|Experimental|4 courses Vepeside-ifosfamide-Cisplatin|4 VIP (Vepeside-ifosfamide-Cisplatin) Risk-adapted strategy - reduction of the number of chemotherapy courses
3331475|NCT02104999|Other|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
3331476|NCT02105038|Experimental|Knob|Steering in a driving simulator using a steering wheel spinner knob.
3331477|NCT02105038|Active Comparator|No Knob|Steering in a driving simulator immediately following surgical treatment of hip fractures.
3331478|NCT02105064|Active Comparator|Active rTMS|rTMS over Supplementary Motor Area, 1hz, no pauses, 20 minutes per sessions. Total: 20 sessions.
3331479|NCT02105064|Sham Comparator|Sham|Sham stimulation, 20 minutes per session, total 20 sessions
3331480|NCT02105077||Xenon|Patients undergoing surgery with xenon-based general anesthesia
3331481|NCT02105090|Placebo Comparator|Sodium chloride 0.9%|Sodium chloride 0.9% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3331482|NCT02105090|Experimental|Articaine hydrochloride 1%|Articaine hydrochloride 1% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3331483|NCT02105090|Experimental|Articaine hydrochloride 2%|Articaine hydrochloride 2% flavoured lozenge 10 ml administered orally (gargled and swallowed by patient) 3 minutes before the upper GI endoscopy
3331484|NCT02105103|Other|Accu-Chek® Insight Insulin Pump|
3331485|NCT02105129|Experimental|HMPL-523|Single/Multiple Ascending Dose. oral administration, a single dose of 5, 20, 50, 100, 200 and 300 mg (Part A) and multiple dose of HMPL-523 at dose level based on result of Part A
3331486|NCT02105129|Placebo Comparator|Placebo|Placebo: oral administration
3331487|NCT02105142|Active Comparator|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
3331488|NCT02105142|Active Comparator|ADHD Group visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
3331489|NCT02105142|Active Comparator|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Online discussion portal access granted to parent participants and will allow parents to communicate with each other in between in-person group visits
3331490|NCT02105155|Experimental|Conversion at day 7 ± 3|Conversion from Prograf to Advagraf at D7 ± 3
3331491|NCT02105155|Active Comparator|Conversion at day 90±5|Conversion from Prograf to Advagraf at 90±5
3331492|NCT02105168|Experimental|Experimental arm|Blood sample Tumorous biopsy Healthy material sample
3331493|NCT02105181|Other|Fully covered metal stent (FCMS)|There is one arm in the study : the intervention consists on placing a device which is a fully covered metal stent in the biliary tract of all patients
3331494|NCT02105194|Experimental|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
3331495|NCT02105207|Experimental|Lung Ultrasound|In Patients allocated to this arm Lung ultrasound for detection of interstitial syndrome will be performed before chest radiography.
3233337|NCT01220700|Experimental|Triclosane|triclosan coated suture material
3233338|NCT01220700|Active Comparator|Control|ordinary suture material
3331496|NCT02105207|Experimental|Chest Radiography|In Patients allocated to this arm chest radiography will be performed for the detection of indirect signs of pulmonary congestion/ADHF without ultrasound evaluation.
3331497|NCT02105220||Obese|"We will enroll patients with BMI≥40 kg/m2 to describe the impact of obesity on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
3233339|NCT01220713|Experimental|Treatment 1--1.5 atm abs|
3331498|NCT02105220||Intraabdominal Hypertension|"We will enroll patients with IAP≥12 mmHg to describe the impact of intraabdominal hypertension on chest wall compliance and respiratory mechanics.~Respiratory mechanics assessment: We will assess respiratory mechanics through different end expiratory pressure settings and recording airway and esophageal pressure tracings."
3331499|NCT02105233|Experimental|BMG|brain mimicking fluid
3331500|NCT02105259|Experimental|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for social anxiety disorder during 10 weeks and guided by a psychologist
3331501|NCT02105259|Active Comparator|Waiting list with support|Behavioral: supportive check-ups via the Internet during 10 weeks
3233340|NCT01220713|Experimental|Treatment 2--2.0 atm abs|
3233341|NCT01220713|Sham Comparator|Placebo--equivalent to breathing air|
3331502|NCT02105311|Experimental|Selective laser trabeculoplasty|Treating with the selective laser trabeculoplasty
3331503|NCT02105311|Active Comparator|Travoprost|Using eye drop: travoprost
3331504|NCT02105337||tegaderm placement|all pts will have tegaderm placed prior to goggles for VEP
3331505|NCT02105350|Experimental|MEK 162, gemcitabine, and oxaliplatin|MEK 162 (30 mg or 45 mg by mouth), twice a day, every day. Gemcitabine (1000 mg/m2 by vein), followed by oxaliplatin (85 mg/m2 by vein) every 2 weeks.
3331506|NCT02105363||Age 11-15|
3331507|NCT02105363||Age 16-20|
3331508|NCT02105363||Age 21-25|
3331509|NCT02105363||Age 26-30|
3233342|NCT01220752|Experimental|IMRT + carbon ion boost|(8 x 3 GyE) carbon ion therapy followed by 50 Gy IMRT (2 Gy/ Fx)corresponding to a total dose of approximately 74 GyE.
3233343|NCT01220765|No Intervention|Standard care|Patients randomized to the standard care group receive standard of care using pulse oximetry
3233344|NCT01220765|Experimental|Capnography|In the intervention group capnography is measured using a cannula under the nose connected to the capnograph. The capnographic device displays respiratory rate, end-tidal carbon dioxide (ETCO2) levels, and continuous waveforms.
3233345|NCT01220778|Experimental|Exercise|
3233346|NCT01220778|No Intervention|Control|
3331510|NCT02105363||Age 31-35|
3331511|NCT02105363||Age 36-40|
3331512|NCT02105363||Age 41-45|
3331513|NCT02105363||Age 46-50|
3331514|NCT02105363||Age 51-55|
3331515|NCT02105363||Age 56-60|
3331516|NCT02105363||age 61-65|
3331517|NCT02105363||Age 66-70|
3331518|NCT02105363||Age 71-75|
3331519|NCT02105363||Age 76-80|
3331520|NCT02105363||Age 81-85|
3331521|NCT02105363||Age 86-90|
3233347|NCT01220791|Active Comparator|Follicular Medrol|In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval
3233348|NCT01220791|Placebo Comparator|No medrol group|Patients will receive only Antagonist protocol for IVF as usual
3233349|NCT01220804||NPDR|Type 2 diabetic patients with nonproliferative diabetic retinopathy (NPDR)
3331522|NCT02105363||Age 91-95|
3331523|NCT02105363||Age 96-100|
3233350|NCT01220804||Control Population|Healthy volunteers
3233351|NCT01220817|Active Comparator|1 POMx capsule|1 POMx capsule daily
3233352|NCT01220817|Experimental|3 POMx capsules daily|
3233353|NCT01220830|Experimental|RFQMR on Multiple Sclerosis lesions|
3259198|NCT01468376|Experimental|GLU-06|
3331524|NCT02105363||Age 0-5|
3331525|NCT02105363||Age 6-10|
3331526|NCT02105376|Experimental|Trigeminal Nerve Stimulation (TNS)|"TNS active group~TNS will be applied by the external simulator EMS400. The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 200 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia (approximately 0.5-2mA). The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed on the forehead just above the supraorbital foramen bilaterally."
3331527|NCT02105376|Placebo Comparator|Sham|"TNS sham~The placebo intervention will consist of an initial stimulation until a mild paresthesia is achieved, and then turn off the machine after 60 seconds, after which period there is a tendency of reduction natural feeling secondary to skin sensitization paresthesia."
3331528|NCT02105389|Experimental|Individualized Yoga Intervention|Individualized Yoga Intervention sessions will be administered by a trained yoga instructor three times weekly (or up to a maximum of five times per week) for three consecutive weeks. There will be a common structure for all sessions that will include relaxation and breathing exercises as well as a series of poses focused on strengthening, flexibility, and balance. There will be low, moderate and high intensity regimens prescribed depending on the wishes and abilities of the child and parent and the judgment of the yoga instructor.
3331529|NCT02105402|Experimental|Intervention Group - PROMPT therapy|Prompts for Restructuring Oral Muscular Phonetic Targets (PROMPT)
3331530|NCT02105402|No Intervention|Waitlist or Delay Group|Participants in this group are on the waitlist for 10 weeks
3331531|NCT02105428|No Intervention|Sedentary Control|Participants will be randomized to an exercise training program or sedentary control group. The sedentary will not perform any structured physical activity or exercise. Participants will be encouraged to maintain their sedentary lifestyle and will be monitored by an accelerometer to track physical activity.
3331532|NCT02105428|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of aerobic exercise training
3331533|NCT02105441||cochlear implant|How well patients with cochlear implants understand speech in noise with implant on, compared to implant off.
3233354|NCT01220843|Placebo Comparator|Placebo|DOuble blinded, same labels than the active drug same dosage (2 tablets 3 times per day) during the meal
3331534|NCT02105493|Active Comparator|500 microgram of Nitroglycerin|500 mcg nitroglycerin was given intra-arterially through the sheath at the end of a transradial procedure
3331535|NCT02105493|Placebo Comparator|Saline 5 mL|0,9% Saline 5 mL was given intra-arterially through the sheath at the end of a transradial procedure
3331536|NCT02105506|Experimental|Tachosil patch|Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.
3233355|NCT01220843|Experimental|Sevelamer carbonate|DOuble blinded, dosage 2 tablets 3 times per day corresponding to 4.8/d to taken during meals
3233356|NCT01220882|No Intervention|Radiographic skeletal age assessment|Participant group studied will include all pediatric patients presenting to our institution with a unilateral or bilateral SCFE. Patients with metabolic and endocrine conditions will be included.
3233357|NCT01220895|Experimental|ACT (mutlimer selection) plus standard therapy|Adoptive Cellular Therapy prepared using Multimer Selection in combination with standard best available antiviral drug therapy
3233358|NCT01220895|Active Comparator|Best available antiviral drug therapy|
3233359|NCT01220908|Experimental|permanent Coil(s) implant, QOL measure|Coil implantation as treatment. Treatment is permanent implant.
3233360|NCT01220921|Experimental|Lumbar Microdiscectomy|Patients aged 18-80 with symptomatic lumbar disc herniation resulting in single nerve root compression recalcitrant to non-invasive therapies for at least 6 weeks
3233361|NCT01220921|Experimental|Single-Level Lumbar Fusion|Patients aged 18-80 with symptomatic grade I degenerative or isthmic spondylolisthesis with mechanical back pain with or without radiculopathy recalcitrant to non-invasive therapies for at least 3 months
3331537|NCT02105519|No Intervention|The group receiving no influenza vaccine|Participants in this group will not receive any influenza vaccine (negative control group).
3331538|NCT02105519|Experimental|One dose of AdimFlu-S group|Participants in this group will receive one dose of the seasonal trivalent influenza vaccine (one dose of AdimFlu-S group), formulation 2013-2014, at the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
3331539|NCT02105519|Experimental|Two dose of AdimFlu-S group|Participants in this group (Two dose of AdimFlu-S group)will receive the seasonal trivalent influenza vaccine, formulation 2013-2014, at the week 0 and 4 weeks after the initiation of the study. Each administered dose contain 15 ug virus antigen for each virus strain.
3331540|NCT02105532|Active Comparator|Restrictive Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
3233362|NCT01220934||Cohort|
3331541|NCT02105532|Active Comparator|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
3331542|NCT02105545|Experimental|Cancer Treatment Options|Blood samples and, for some patients, buccal (mouth cell) samples will be collected at diagnosis and/or relapse. Solid tumor samples will be collected in the normal course of treatment, from biopsy, blood or other specimens. For blood-based cancers such as leukemia, blood and bone marrow specimens will be collected before treatment begins, on day 29 and possibly at a later time point if relapse occurs.
3331543|NCT02105571|Experimental|Intervention|Intervention activities take place over a 6-month period for each participant, and include a weight loss competition with self-monitoring and feedback; computer-based training units on healthy weight loss, healthy eating, exercise, and sleep; and up to four motivational interviews with a health coach by cell phone.
3331544|NCT02105571|No Intervention|Control|"Continued work conditions and Usual Practices in that workplace"
3331545|NCT02105584|Experimental|LAA closure device|Implantation of LAA closure device
3331546|NCT02105597|Experimental|Mobile application|
3331547|NCT02105597|No Intervention|Standard care|
3331548|NCT02105610|Experimental|volatile anesthetics (desflurane, isoflurane, sevoflurane)|
3331549|NCT02105610|Active Comparator|total intravenous anesthesia|
3331550|NCT02105623|Active Comparator|Standard Therapy|Risk factor control Diet Exercise
3331551|NCT02105623|Experimental|Rosuvastatin therapy|Risk factor control Rosuvastatin
3331552|NCT02105649|Experimental|calf muscle strengthenig group|"experimental group~will receive the same selected physical therapy program in addition to manual and mechanical strengthening exercises and electrical stimulation program for calf muscles of both lower limbs."
3331553|NCT02105649|Other|No calf muscle strengthening group|"control group~will receive only the selected physical therapy program"
3331554|NCT02105675|Experimental|DCVAC/PCa add on to Standard of Care|Combination therapy with Dendritic Cells DCVAC/PCa and Standard of Care
3331555|NCT02105675|Active Comparator|Standard of Care|Docetaxel as an Active Comparator
3233363|NCT01220947|Experimental|Group A|Danoprevir 200 mg twice a day (BID) + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3233364|NCT01220947|Experimental|Group B|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3331556|NCT02105727|Experimental|Salt reduction|Community-based salt reduction
3233365|NCT01220947|Experimental|Group C|Danoprevir 50 mg BID + ritonavir 100 mg + Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 24 weeks
3331557|NCT02105753|Experimental|1210nm axillary laser treatments|two laser treatments right axilla and one treatment left axilla
3331558|NCT02105753|Experimental|1210nm laser treatments to the axilla|two laser treatments left axilla and one treatment right axilla
3233366|NCT01220947|Experimental|Group D|Danoprevir 100 mg BID + ritonavir 100 mg + Pegasys 180 μg sc qw + Copegus 1000 mg or 1200 mg po daily for 12 weeks or 24 weeks
3331559|NCT02105766|Experimental|male donor - female recipient|The first cohort of patients will be male donor - femalerecipients to see if this new regimen will yield higher rate of durable donor leukocyte chimerism. We will also measure anti-A, anti-B, and/or other red cell antibody titers from this initial cohort to determine the feasibility of transplanting patients with pre-existing antibodies (major ABO mismatch or other anti-donor red cell antibody)
3233367|NCT01220947|Active Comparator|Group E|Pegasys 180 microgram sc qw + Copegus 1000 mg or 1200 mg po daily for 48 weeks
3233368|NCT01220960|Experimental|Art Therapy intervention group|For participants who will be part of the art therapy intervention, the art therapy group will be a closed group for eight women with breast cancer who are in treatment and recently have had surgery. The group will meet once a week for two hours over a period of 8 weeks, and will focus on exploring the expressive capabilities of art making in a supportive group. This group will be held in the conference room at the Cedars Breast Clinic. Each week will revolve around a theme that pertains to the experience of women living with breast cancer, and will be guided by the women's needs in the group. A broad range of art materials will be made available and various art techniques explored. No art experience is necessary. The intervention group will also need to fill out simple questionnaires before the art therapy groups starts and after the group finishes
3331560|NCT02105766|Experimental|patients with preexisting antibodies|patients with preexisting antibodies (major ABO mismatch or otheranti-donor red cell antibody). The primary endpoint forthis group will be different than the first cohort. It is very likely that red cell aplasia (6 months to 2 years posttransplant) and prolonged duration of red cell transfusion are expected in this second group, thus a later time point to determine treatment success is justified.
3331561|NCT02105779|Experimental|Targeted Cognitive Training|40 hours of BFP auditory training
3331562|NCT02105779|Experimental|Social Cognitive Training|40 hours of auditory training and 10 hours social exercises
3331563|NCT02105792||Responders|Patients with Type 2 diabetes about to commence a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors or Glitazone or insulin).
3331564|NCT02105792||Progressors|Patients with Type 2 diabetes that progress to requiring insulin treatment ≤10 years from diagnosis or have no requirement for insulin treatment >10 years from diagnosis.
3331565|NCT02105805|Experimental|low energy diet|low energy diet treatment
3331566|NCT02105805|Active Comparator|Nordic recommendation|Nordic recommendation, no restrictions on energy
3331567|NCT02105818||Systemic sclerosis|Patients with diagnosed systemic sclerosis treated in the Reha Rheinfelden, Switzerland (European Centre for the Rehabilitation of Scleroderma).
3331568|NCT02105831||CEU skeletal muscle perfusion imaging|Heart failure with LVAD Contrast ultrasound skeletal muscle perfusion imaging
3331569|NCT02105844||Atrial Fibrillation|Cohort Study on patients with atrial fibrillation in Switzerland
3331570|NCT02105857|No Intervention|Standard care|Patients receiving the standard rehabilitation protocol
3331571|NCT02105857|Experimental|grade A+ knee mobilization|Patients receiving the standard rehabilitation protocol plus grade A+ knee mobilization
3331572|NCT02105870|Experimental|Intracoronary abciximab (Reopro)|Intracoronary abciximab (Reopro)
3331573|NCT02105870|Placebo Comparator|Control group|Intracoronary Reopro
3331574|NCT02105883|No Intervention|Scenario C (control)|no badge
3331575|NCT02105883|Active Comparator|Scenario B (badge)|Use of Identification badge during scenarios (roles and places)
3331576|NCT02105909|Experimental|obese subjects|DNA analysis
3331577|NCT02105909|Placebo Comparator|lean subjects|DNA analysis
3331578|NCT02105922|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3331579|NCT02105922|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3331580|NCT02105922|Active Comparator|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
3331581|NCT02105935||Normative study|male and female athletes, ages 8-14.
3331582|NCT02105935||Baseline|male and female athletes, ages 8-18.
3331583|NCT02106000||Arm 1: Non-pregnant females|Inhalation profiles will be recorded for non-pregnant females
3331584|NCT02106000||Arm 2: Pregnant females|Inhalation profiles will be recorded for the women in the 3rd stage of labour
3331585|NCT02106013||Low HDL-C|Study participants with HDL-C levels below the 10th percentile (HDL-C ≤32 mg/dL)
3331586|NCT02106013||Intermediate HDL-C|Study participants with HDL-C levels between 40th and 60th percentiles (40≤HDL-C≤67 mg/dL)
3331587|NCT02106013||High HDL-C|Study participants with HDL-C levels above the 90th percentile (HDL-C ≥78mg/dL)
3331588|NCT02106026|No Intervention|Conventional|All expectant mothers received the usual information about the advantages of maternal milk during pre-natal period. Nurses provided the information in personalized dialogue with the women during obstetric consultations.
3331589|NCT02106026|Experimental|Preventive education|It was provided by the nurses during obstetric consultation in pre-natal period and averaged 30 minutes in duration. The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures. The nurses encouraged participation and gave the education in personalized dialogue with the woman. The information was reinforced with an illustrated explanatory leaflet.
3331590|NCT02106039|Experimental|intensive monitoring|more intensive monitoring strategy of blood glucose and clinical review
3331591|NCT02106039|No Intervention|standard monitoring|glucose monitoring followed the prevailing practice at each site
3331592|NCT02106052|Active Comparator|Aerobic exercise|
3331593|NCT02106052|Other|Stretching and toning exercise|
3331594|NCT02106078|Active Comparator|Level 1|Moderated discussion board only
3331595|NCT02106078|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
3331596|NCT02106078|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools
3331597|NCT02106091|Experimental|AFM11|IV (intravenous) infusion, dose escalation
3331598|NCT02106104|Experimental|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
3331599|NCT02106104|Active Comparator|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
3331600|NCT02106117||neutropenic patients|Patients receiving treatment for hematological malignancies expected to result in prolonged neutropenia (neutrophil counts <0.5 x 10 ^9/L for more than seven days).
3331601|NCT02106130|Experimental|R - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3331602|NCT02106130|Experimental|R+M - R|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3331603|NCT02106130|Experimental|M - R+M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3331604|NCT02106130|Experimental|R+M - M|R : Rebamipide 100mg, M : Mosapride citrate 5mg, All drugs will be administered orally.
3331605|NCT02106143|Experimental|RejuvenAir™ Radial Spray Cryotherapy|Subjects will receive Rejuvenair Radial SCT prior to lobectomy.
3331606|NCT02106169|Experimental|Therapeutic education group|"At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.~The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours)."
3233369|NCT01220960|No Intervention|Control Group|The group not assigned to the intervention group will be asked to fill out questionnaires at two separate times (before and after the intervention group is run). The Control group will be offered the opportunity to join an open art therapy group upon completing the questionnaires.
3331607|NCT02106169|No Intervention|Control group|At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
3331608|NCT02106182|Experimental|Silodosin|Silodosin, 8 mg, once daily, orally administered with dinner for 12 weeks
3331609|NCT02106208|Experimental|Cheese diet|A 4-week experimental diet with all meals and foods be provided to participants, including 90g of regular cheddar cheese daily per 2500 kcal. The diet will contain 13% of saturated fat (SFA), 14% of mono-unsaturated fat (MUFA), 5% of polyunsaturated fat (PUFA) and 53% of carbohydrate (CHO).
3331610|NCT02106208|Experimental|Butter diet|A 4-week experimental diet with all meals and foods be provided to participants, the diet will contain 13% of SFA mostly from butter. The diet will contain 14% of MUFA, 5% of PUFA and 53% of CHO.
3331611|NCT02106208|Experimental|CHO diet|A 4-week experimental diet with all meals and foods will provided to participants. The diet will contain 60% of CHO, 6% of SFA, 14% of MUFA and 5% of PUFA.
3331612|NCT02106208|Experimental|MUFA diet|A 4-week experimental diet with all meals and foods be provided to participants. The diet will contain 21% of MUFA, 6% of SFA, 5% of PUFA and 53% of CHO.
3331613|NCT02106208|Experimental|PUFA diet|A 4-week experimental diet with all meals and foods will be provided to participants. The diet will contain 12% of PUFA, 14% of MUFA, 6% of SFA and 53% of CHO.
3331614|NCT02106221|Experimental|Intervention|Financial incentives will be provided based on performance in areas determined to be of high-value.
3331615|NCT02106221|Active Comparator|Control|Financial incentives are a flat rate which can be reduced if an appropriate amount of effort or improvement is not met
3331616|NCT02106234|Active Comparator|Control: NO prophylactic iv hydration|"Control group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed."
3331617|NCT02106234|No Intervention|Standard care: prophylactic iv hydration|"Standard care group:~Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will receive the standard intravenous prophylactic hydration treatment with normal saline as prescribed."
3331618|NCT02106247|Experimental|1 BI 1181181 low dose|tablet
3233370|NCT01220986||Right hepatectomy|Intervals from inflow division.
3233371|NCT01221012||men wearing Semipermeable garment|
3331619|NCT02106247|Experimental|BI 1181181 high dose|tablet
3331620|NCT02106247|Experimental|Placebo|tablet
3331621|NCT02106260|Experimental|CLS003|
3331622|NCT02106273||Bronchial blocker|Pilot study to enroll ASA class I-III patients age between 18-70 years who undergoes thoracic surgery which require one-lung ventilation.
3331623|NCT02106286|Active Comparator|Bisoprolol|Patients not betablocked at baseline receive an acute 72hr dose of beta blocker therapy before CPET
3331624|NCT02106286|No Intervention|No Bisoprolol|No beta blocker given
3331625|NCT02106299|Experimental|Regen Sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen Sling (medprin).
3331626|NCT02106299|Active Comparator|tension-free vaginal tape-obturator|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
3331627|NCT02106312|Other|Radiation|Dose reduction of preoperative radiotherapy in MLS from 50 Gy to 36 GY.
3331628|NCT02106338|Experimental|Cohort A|10 subjects (8 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo every 12 hours for 10 days
3331629|NCT02106338|Experimental|Cohort B|10 subjects (8 active, 2 placebo) receive a single oral dose of 100 or 400 mg CRS3123 or placebo every 12 hours for 10 days
3331630|NCT02106338|Experimental|Cohort C|10 subjects (8 active, 2 placebo) receive a single oral dose of 600 mg CRS3123 or placebo every 12 hours for 10 days
3233372|NCT01221012||air permeable garment type BP2|
3233373|NCT01221012||air permeable garment type BP3|
3233374|NCT01221012||air permeable garment type MO|
3233375|NCT01221012||air permeable garment type BP1|
3233376|NCT01221025|Experimental|parecoxib|Parecoxib, a water-soluble prodrug of valdecoxib, is a high-selective COX-2 inhibitor that is first available for intravenous administration.
3233377|NCT01221038||group 1|young women not using OC
3331631|NCT02106364|Experimental|LY2605541|LY2605541 administered by subcutaneous (SQ) injection once daily for 52 weeks. Initial dose is 10 units (10 U) and is titrated by investigator. Participants may continue oral antihyperglycemic medication (OAM) as prescribed by their personal physician.
3331632|NCT02106364|Active Comparator|Insulin Glargine|Insulin glargine administered by SQ injection once daily for 52 weeks. Initial dose is 10 U and is titrated by investigator. Participants may continue OAM as prescribed by their personal physician.
3233378|NCT01221038||group 2|young women using OC
3331633|NCT02106416|Experimental|PET/MRI|Patient receives PET/MRI
3331634|NCT02106429||PAD and CLI patients|Subjects undergoing non emergent lower extremity revascularization
3331635|NCT02106468|Active Comparator|prednisone 50 mg tablet|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
3331636|NCT02106468|Active Comparator|Omega-3 capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
3233379|NCT01221038||group 3|young men (database)
3233380|NCT01221051|Active Comparator|oxytocin|early cord clamping, administration of oxytocin 10 IU i.v, controlled cord traction, uterine massage after placenta expulsion
3331637|NCT02106481|Active Comparator|Femoral Nerve Catheters|Patients will receive a Single Shot Femoral Nerve Block along with a conventional continuous femoral nerve catheter
3331638|NCT02106481|Active Comparator|Single Shot Femoral Nerve Blocks|Patients will receive a Single Shot Femoral Nerve Block and a sham catheter post op.
3233381|NCT01221051|Placebo Comparator|saline solution|early cord clamping, wait for signs of placenta detachment, encourage the woman to push out placenta by her own effort, uterine massage after placenta expulsion
3233382|NCT01221064|Other|Early drainage removal|Patients randomised to early drainage removal arm will have the drain removed in postoperative day 1. Lymph will be punctured on a regular basis
3233383|NCT01221064|Other|Late drainage removal|Patients randomised to late drainage removal arm will have the drains kept until total daily drainage is 30ml and then removed
3331639|NCT02106507|Experimental|Progressive Metastatic Castration-Resistant Prostate Cancer|This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of apalutamide in combination with everolimus.
3331640|NCT02106520|Experimental|Bevacizumab 25mg|Three administrations of 25 mg of Bevacizumab spaced of 14 days
3331641|NCT02106520|Experimental|Bevacizumab 50mg|Three administrations of 50 mg of Bevacizumab spaced of 14 days
3233384|NCT01221077|Experimental|Arm A: Erlotinib plus OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
3233385|NCT01221077|Placebo Comparator|Arm B: Erlotinib plus Placebo|As of 01 March 2013, the matching placebo is no longer being administered
3331642|NCT02106520|Experimental|Bevacizumab 75mg|Three administrations of 75 mg of Bevacizumab spaced of 14 days
3331643|NCT02106520|Placebo Comparator|Placebo|Three administrations of placebo spaced of 14 days
3331644|NCT02106533|Experimental|Group 1 peak VO2 <17.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP.
3331645|NCT02106533|Experimental|Group 2 peak VO2 > 17.5 < 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
3331646|NCT02106533|Experimental|Group 3 peak VO2 > 24.5 ml/kg/min|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill . Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
3331647|NCT02106546|Experimental|Veliparib + Carboplatin + Paclitaxel|Participants received veliparib 120 mg orally twice daily (BID) on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an area under the concentration-time curve (AUC) 6 mg/mL/min and paclitaxel 200 mg/m² by intravenous (IV) infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
3331648|NCT02106546|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Participants received placebo orally BID on Days -2 to 5 (7 consecutive days) of each 21-day cycle and carboplatin at an AUC 6 mg/mL/min and paclitaxel 200 mg/m² by IV infusion on Day 1 of each 21-day cycle for up to a maximum 6 cycles of treatment, until treatment toxicity which, in the Investigator's opinion, prohibited further therapy, or until radiographic progression.
3331649|NCT02106559|Experimental|Treatment (surgery, porfimer sodium, PDT)|Patients receive porfimer sodium IV over 3-5 minutes. Beginning 24 hours later, patients undergo tumor resection and/or radical pleurectomy followed by intraoperative photodynamic therapy to the pleural space.
3331650|NCT02106572|Experimental|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900
3331651|NCT02106572|Active Comparator|Mitomycin C|intravesical instillation of Mitomycin C
3331652|NCT02106585|Experimental|Dose 1 JTT-251 or Placebo|Tablets, single dose in fed condition
3331653|NCT02106585|Experimental|Dose 2 JTT-251 or Placebo|Tablets, single dose in fed condition
3331654|NCT02106585|Experimental|Dose 3 JTT-251 or Placebo|Tablets, single dose in fed condition
3331655|NCT02106585|Experimental|Dose 4 JTT-251 or Placebo|Tablets, single dose in fed condition
3331656|NCT02106585|Experimental|Dose 5 JTT-251 or Placebo|Tablets, single dose in fed condition
3331657|NCT02106585|Experimental|Dose 6 JTT-251 or Placebo|Tablets, single dose in fed condition
3233386|NCT01221103|Experimental|DOT|Combination of dexamethasone, ofatumumab and bendamustine
3331658|NCT02106585|Experimental|Dose 7 JTT-251 or Placebo|Tablets, single dose in fed condition
3331659|NCT02106585|Experimental|Dose 8 JTT-251 or Placebo|Tablets, single dose in fed condition
3331660|NCT02106585|Experimental|Dose 9 JTT-251 or Placebo|Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition
3331661|NCT02106598|Experimental|Phase 2 - Head and Neck Cancer|Patients with early oral cavity squamous cell carcinoma, and prior to standard of care wide local resection of the primary tumor and elective neck dissection, will receive a locally-administered, peritumoral injection of fluorescent cRGDY-PEG-Cy5.5-C dots (0.25 - 1 ml) around the primary lesion while under standard-of-care anesthesia for identification of optically-avid SLNs and to assess for metastatic disease. After completion of the neck dissection, nodal specimens will be examined ex vivo for fluorescence signal. Any fluorescent and non-fluorescent nodes will be compared to determine the true positive and false positive rates for cancer detection in this pilot study. No change in standard of care surgical practice will occur.
3331662|NCT02106611||Hodgkin Lymphoma Survivor|This is a prospective cross-sectional study of 200 HL survivors whose treatment included mediastinal RT at initial diagnosis or relapse, and are at least 5 years from last HL treatment.
3331663|NCT02106624|Experimental|High Nitrogen|In this arm, daily nitrogen supply is as much as 2.5-3.0 g per kilogram (lean mass weight)
3233387|NCT01221116|No Intervention|1: Type of surgery|Two types of patients are compared (placebo vs levosimendan): CABG - coronary artery bypass grafting and AVR - aortic valve replacement (either with or without CABG - coronary artery bypass grafting)
3331664|NCT02106624|Active Comparator|conventional nitrogen|In this arm, daily nitrogen supply is 1.2-1.5g per kilogram (lean mass weight) as recommended by ESPEN guideline
3331665|NCT02106637|Active Comparator|study groups|study groups will receive Varenicline
3331666|NCT02106637|Placebo Comparator|control group|Participants allocated to the control group will receive placebo
3331667|NCT02106650|Experimental|Folotyn and Leucovorin|"Folotyn will be administered by IV push at a dose of 30 mg/m2 once weekly for 6 weeks in each cycle, followed by 1 week of rest (no treatment).~Leucovorin (25 mg tablets) will be taken orally tid for 2 days for a total of six doses (150 mg cumulative weekly dose), beginning 24 hours after each dose of Folotyn is administered.~Folic acid and Vitamin B12 is given prior to initiation of Folotyn."
3233388|NCT01221129||Dietary Restriction|
3233389|NCT01221142|Experimental|Hypothermia|Device: Cincinnati Sub-Zero Hyper-Hypothermia to core temperature of 34C for 24 hours, rewarming rate 0,5/2h until the patient reaches 36,5C
3233390|NCT01221168||Men with or without Prostate Cancer|"Men with a histological confirmed prostate cancer, and their family members in case of hereditary prostate cancer.~Men with no prostate cancer after a screening procedure for this disease, so that their biological samples can be compared to those of men with prostate cancer."
3233391|NCT01221220|Active Comparator|Behavioral Treatment|Six-month, family-based, group, behavioral weight control program
3331668|NCT02106663|Active Comparator|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs), guided by 3D electroanatomic mapping (Carto, Biosense Webster, Inc. or ESI NavX, St. Jude, Inc.) with a 3D LA geometry created either by using the roving mapping catheter or by importing a pre-recorded 3D CT image of the left atrium. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed (entrance block at a minimum).
3331669|NCT02106663|Active Comparator|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing myocardial connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter around the PV ostium or antrum, until mapping demonstrates elimination of all PV potentials (entrance block at a minimum).
3331670|NCT02106676||Pregnant women with PCOS and offspring|Exposures of interest: Polycystic ovary Syndrome (PCOS) according to Rotterdam
3331671|NCT02106676||Pregnant women without PCOS and offspring|Exposures of interest: Pregnant women without polycystic ovary Syndrome (PCOS) according to Rotterdam
3331672|NCT02106689|Experimental|Needle free system|"Intervention will consist of the gonadotropin BRAVELLE being injected using the Comfort-in™ needle free system for the duration of a standard superovulation cycle"
3233392|NCT01221220|Experimental|Behavioral Treatment plus Environmental Strategies|Six-month, family-based, group, behavioral weight control program plus home-based environmental intervention
3331673|NCT02106689|Active Comparator|Standard needle injection system|Control patients will undergo their superovulation cycle using the gold standard subcutaneous needle injection system for their gonadotropin injections
3331674|NCT02106702|Active Comparator|FAP counseling|Control arm utilizing the standard of care: access to services provided by the Forensic AIDS Project for up to 90 days after release
3233393|NCT01221246|Experimental|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
3233394|NCT01221246|Placebo Comparator|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients receive Placebo.
3233395|NCT01221259|Experimental|Drug E2212|
3233396|NCT01221259|Placebo Comparator|Placebo|
3233397|NCT01221324||Patients after open resection of colorectal cancer|
3233398|NCT01221337|Other|haemodialyzer EVODIAL-haemodialyzer VIE|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
3233399|NCT01221337|Other|haemodialyzer VIE-haemodialyzer Evodial|"Equal number of patients will start either with the haemodialyzer VIE 2,1 or EVODIAL 2,2 followed by a wash out period, before starting the other haemodialyzer."
3233400|NCT01221376|Experimental|Imatinib Mesylate|
3331675|NCT02106702|Experimental|Navigator enhanced case-management|Experimental arm: access to Navigator enhanced case-management services for one year after release
3331676|NCT02106715|Active Comparator|Training|Two exercises for training of core stability and mobility.
3331677|NCT02106715|No Intervention|Control|Control group without training
3233401|NCT01221389|Active Comparator|Colloid Control|Patients will receive 2 units of 250 ml of hydroxyethylated starch solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
3233402|NCT01221389|Active Comparator|Plasma|Patients will receive 2 units of AB+ plasma once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
3233403|NCT01221402|Experimental|Extended-release niacin|
3233404|NCT01221402|Placebo Comparator|Placebo|
3331678|NCT02106741|Experimental|Relaxation acupressure|
3331679|NCT02106741|Active Comparator|Stimulating acupressure|
3331680|NCT02106741|No Intervention|Wait-list control|
3331681|NCT02106754|Experimental|Brief Intervention|Youth may receive brief intervention from their provider based on randomization.
3331682|NCT02106754|Active Comparator|Treatment As Usual|Youth may receive treatment as usual from their provider based on randomization.
3331683|NCT02106754|Experimental|Brief Intervention with Coaching|Youth may receive brief intervention with coaching from their provider based on randomization.
3331684|NCT02106767|Active Comparator|Rosuvastatin|
3331685|NCT02106767|Experimental|Rifampin plus rosuvastatin|
3331686|NCT02106780|Experimental|1: ASP1707|
3331687|NCT02106793|Experimental|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
3331688|NCT02106793|Placebo Comparator|Placebo|Identical placebo solution
3233405|NCT01221415||Interscalene Ultrasound|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3233406|NCT01221415||Interscalene Nerve Stimulator|Subjects having orthopedic surgery requiring an interscalene peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3331689|NCT02106806|Experimental|Zinc chemotherapy|Patients in colorectal chemotherapy supplemented with zinc
3331690|NCT02106806|Placebo Comparator|Placebo chemotherapy|Patients in colorectal chemotherapy with placebo
3331691|NCT02106806|Other|Zinc Control|Healthy volunteers supplemented with zinc
3331692|NCT02106806|Other|Placebo Control|Volunteers received placebo
3331693|NCT02106819||Cerebellar Ataxia subjects|40 individuals with either hereditary or sporadic ataxia will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
3331694|NCT02106819||Healthy Control subjects|40 age matched controls will have testing of emotional communication ability and may have magnetic resonance imaging (MRI) of the brain.
3233407|NCT01221415||Popliteal Ultrasound|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3233408|NCT01221415||Popliteal Nerve Stimulator|Subjects having orthopedic surgery requiring an popliteal peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3233409|NCT01221415||Femoral Ultrasound|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the ultrasound used to locate the nerve.
3233410|NCT01221415||Femoral Nerve Stimulator|Subjects having orthopedic surgery requiring an femoral peripheral nerve block and randomized to have the nerve stimulator used to locate the nerve.
3233411|NCT01221428|Experimental|umbilical cord mesenchymal stem cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells,one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery.
3331695|NCT02106845|Experimental|P-gp probe substrate(digoxin)+regorafenib|
3331696|NCT02106845|Experimental|Group B: BCRP probe substrate (rosuvastatin) + regorafenib|
3331697|NCT02106858||Group 1|Patients treated by Physician with Stivarga under approved local prescriptions
3331698|NCT02106871|Placebo Comparator|Placebo|Placebo daily for 4 weeks
3331699|NCT02106871|Active Comparator|Sildenafil|50mg sildenafil daily for 4 weeks
3331700|NCT02106897|Experimental|Part 1, Cohort 1: BIIB059 0.05 mg/kg IV|BIIB059 0.05 mg/kg IV dose, Once on Day 1
3331701|NCT02106897|Experimental|Part 1, Cohort 2: BIIB059 0.3 mg/kg IV|BIIB059 0.3 mg/kg IV dose, Once on Day 1
3331702|NCT02106897|Experimental|Part 1, Cohort 3: BIIB059 1 mg/kg IV|BIIB059 1 mg/kg IV dose, Once on Day 1
3331703|NCT02106897|Experimental|Part 1, Cohort 4: BIIB059 3 mg/kg IV|BIIB059 3 mg/kg IV dose, Once on Day 1
3331704|NCT02106897|Experimental|Part 1, Cohort 5: BIIB059 10 mg/kg IV|BIIB059 10 mg/kg IV dose, Once on Day 1
3331705|NCT02106897|Experimental|Part 1, Cohort 6: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
3331706|NCT02106897|Experimental|Part 1, Cohort 7: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Once on Day 1
3331707|NCT02106897|Placebo Comparator|Part 1, Cohort 1-6: Placebo IV|Matching placebo IV dose, Once on Day 1
3331708|NCT02106897|Placebo Comparator|Part 1, Cohort 7: Placebo SC|Matching placebo SC dose, Once on Day 1
3331709|NCT02106897|Experimental|Part 2, Cohort 8: BIIB059 20 mg/kg IV|BIIB059 20 mg/kg IV dose, Once on Day 1
3331710|NCT02106897|Placebo Comparator|Part 2, Cohort 8: Placebo IV|Matching placebo IV dose, Once on Day 1
3331711|NCT02106897|Experimental|Part 3a, Cohort 9: BIIB059 20 mg SC|BIIB059 20 mg SC dose, Every 4 weeks for 2 doses
3331712|NCT02106897|Experimental|Part 3a, Cohort 10: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
3331713|NCT02106897|Experimental|Part 3a, Cohort 11: BIIB059 150 mg SC|BIIB059 150 mg SC dose, Every 4 weeks for 2 doses
3331714|NCT02106897|Experimental|Part 3a, Cohort 12: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
3233412|NCT01221454|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3233413|NCT01221454|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
3233414|NCT01221467|Active Comparator|Overnight closed-loop combined with real-time CGM|
3233415|NCT01221467|Active Comparator|Real-time CGM alone|
3233416|NCT01221480||Beta Blocker Use|
3233417|NCT01221480||No beta blocker use|
3233418|NCT01221493|Experimental|Cryo biospy|
3233419|NCT01221519|Experimental|1|AZD1656
3233420|NCT01221519|Experimental|2|AZD1656
3233421|NCT01221519|Experimental|3|AZD1656
3233422|NCT01221532|Experimental|SHHE Peridischarge intervention|Patients receive the Support from Hospital to Home (SHHE) Peridischarge Intervention plus usual care
3233423|NCT01221532|No Intervention|Usual Care|
3233424|NCT01221545|Experimental|A - AZD1656|AZD1656
3331715|NCT02106897|Placebo Comparator|Part 3a, Cohort 9-12: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
3331716|NCT02106897|Experimental|Part 3b, Cohort 13: BIIB059 50 mg SC|BIIB059 50 mg SC dose, Every 4 weeks for 2 doses
3331717|NCT02106897|Experimental|Part 3b, Cohort 14: BIIB059 300 mg or less SC|BIIB059 300 mg or less SC dose, Every 2 weeks for 3 doses
3331718|NCT02106897|Placebo Comparator|Part 3b, Cohort 13-14: Placebo SC|Matching placebo SC dose, Every 4 weeks for 2 doses or every 2 weeks for 3 doses
3331719|NCT02106949|Experimental|SMS|The patients of the test group receive a first SMS 48 hours after their discharge from the hospital then a total of 10 messages distributed over six months: 48 hours, S1, S2, M1, M2, M3, M4, M5, M6 and M13.
3233425|NCT01221545|Placebo Comparator|B - Placebo|Placebo
3233426|NCT01221558|Experimental|6mg lycopene|
3331720|NCT02106949|No Intervention|Without SMS|The patients of the group benefit from the usual care.
3331721|NCT02106988|Experimental|Chemotherapy + Radiation Therapy|"Radiation therapy delivered for a total dose of 50.4 to 54 Gy over 28 to 30 treatments. Within seven days of starting radiotherapy, the first cycle of chemotherapy started and repeated every 3 weeks for a total of 3 cycles.~DeVIC on day 1 of every cycle. Dexamethasone 40 mg by vein Days 1-3, Etoposide 67 mg/m2 by vein on Days 1-3, Ifosfamide 1 g/m2 by vein on Days 1-3, Mesna 0.4 g/m2 by vein on Days 1-3 with Ifosfamide, Mesna 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump, Carboplatin 200 mg/m2 by vein on Day 1. Cycles repeated every 21 days."
3331722|NCT02107001||Patients with pleuritic chest pain|Study investigators will perform lung ultrasound in each patient with pleuritic chest pain at inclusion
3331723|NCT02107027|Active Comparator|nMARQ catheter (circular catheter)|Group treated with the circular ablation catheter for atrial fibrillation ablation
3331724|NCT02107027|Active Comparator|Navistar catheter (conventional catheter)|Group treated with the conventional ablation catheter for atrial fibrillation ablation
3331725|NCT02107053|Experimental|IV iron + PJ|Each patient will serve as a self control
3233427|NCT01221558|Experimental|15mg lycopene|
3233428|NCT01221558|Placebo Comparator|placebo|
3233429|NCT01221571|Experimental|AFM13|IV (intravenous) infusion, dose escalation
3233430|NCT01221584||1|Subject 18 years of age or older on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks..
3233431|NCT01221610|Experimental|Drug Releasing Balloon|Passeo-18 Lux Drug Releasing Balloon catheter
3233432|NCT01221610|Active Comparator|Standard PT A (POBA)|Uncoated Passeo-18 PTA catheter
3233433|NCT01221636|Other|Low Metal Abatacept|Reference
3233434|NCT01221636|Experimental|High Metal Abatacept|
3233435|NCT01221688|Other|group 2|patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
3233436|NCT01221688|Experimental|group 1|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
3233437|NCT01221701|Experimental|In-Home Cognitive Behavioral Therapy|Mothers will receive 15 weekly sessions of IH-CBT plus one booster session scheduled 1 month later.
3233438|NCT01221701|No Intervention|typical home visitation|Standard of care in home visitation in which mothers can receive treatment in the community if they choose.
3233439|NCT01221714||Active/Placebo|ACTIVE VITAMIN; PLACEBO OMEGA MAX
3233440|NCT01221714||Active/Active|ACTIVE VITAMIN; ACTIVE OMEGA MAX
3233441|NCT01221714||Placebo/Active|PLACEBO VITAMIN; ACTIVE OMEGA MAX
3233442|NCT01221714||Placebo/Placebo|PLACEBO VITAMIN; PLACEBO OMEGA MAX
3233443|NCT01221740|Experimental|Milnacipran|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
3233444|NCT01221779|Placebo Comparator|sham tDCS|
3233445|NCT01221779|Experimental|anodal tDCS|
3233446|NCT01221792|Active Comparator|carvedilol|Patients randomized to carvedilol will be administered doses ranging from 6.25 to 15.625 mg/day using a flexible-dosing model. After a 1 week titration, investigators my increase daily dose by 6.25 mg/day at weeks 1 and 2 for a maximum dose of 15.625 mg/day. Weeks 3-4 will patients will remain on a stable, tolerable dose. At week 5 patients will have a 1 week taper.
3233447|NCT01221792|Placebo Comparator|Sugar Pill|Patients randomized to placebo will follow same dosing guidelines as if they were in the active comparator arm, carvedilol.
3233448|NCT01221818|Experimental|1|
3233449|NCT01221818|Experimental|2|
3233450|NCT01221818|Experimental|3|
3233451|NCT01221818|Experimental|4|
3233452|NCT01221818|Experimental|5|
3331726|NCT02107053|Experimental|No IV iron + PJ|Each patient will serve as a self control
3331727|NCT02107053|Experimental|IV iron no PJ|Each patient will serve as a self control
3331728|NCT02107066|Active Comparator|attention control|Women randomized to attention control will receive the same attention as women randomized to exercise intervention, i.e., weekly phone calls for 6 months. Each call is about 15 min. Women in the attention control will receive information on ovarian cancer health education topics.
3233453|NCT01221818|Experimental|6|
3331729|NCT02107066|Experimental|exercise|Women randomized to exercise will receive telephone-counseling weekly for 6 months to increase their exercise
3331730|NCT02107079|Active Comparator|melatonin 1 mg immediate release tablet|
3331731|NCT02107079|Active Comparator|melatonin 2,5mg immediate release capsule|
3331732|NCT02107079|Active Comparator|melatonin 0.1 mg oromucosal tablet|
3331733|NCT02107105||Observational (questionnaire)|Patients complete quality of life questionnaires over 20-30 minutes at baseline, 6 and 12 months after surgery, and 2, 3, 4, and 5 years after surgery.
3233454|NCT01221831|Experimental|estetrol dose 1 / P1|
3233455|NCT01221831|Experimental|estetrol dose 1 / P2|
3233456|NCT01221831|Active Comparator|estradiol valerate/dienogest pill|
3233457|NCT01221831|Experimental|estetrol dose 2 / P1|
3233458|NCT01221831|Experimental|estetrol dose 2 / P2|
3233459|NCT01221844|Experimental|Lactoferrin treatment in HT pregnacies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
3233460|NCT01221844|Active Comparator|Ferrous sulfate in HT pregnancies|Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.
3233461|NCT01221870|Experimental|Tesetaxel once every 3 weeks|Tesetaxel 27 mg/m2 orally once every 21 days for up to 12 months
3331734|NCT02107118|Active Comparator|ARM 1: AdMSC: adipose stem cells|AdMSC: Autologous adipose tissue-derived mesenchymal stem cell. Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured.
3331735|NCT02107118|Placebo Comparator|ARM 2 Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
3331736|NCT02107144|Experimental|trimetazidin|Patients, who are trimetazidine (TMZ) naïve, will be randomly assigned to receive trimetazidine plus previous medications (TMZ group) 48h before scheduled PCI- Paients that are TMZ naïve and randomized to TMZ group will be given oral loading of 70mg TMZ.
3331737|NCT02107144|No Intervention|Control|Patients, who are TMZ naïve, will be randomly assigned to receive just previous cardiac medication (Control group).
3331738|NCT02107170|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3331739|NCT02107170|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3331740|NCT02107183|Experimental|Nasal high-flow oxygen therapy|High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher & Paykel Healthcare) after extubation up to ICU discharge
3233462|NCT01221870|Experimental|Tesetaxel once weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks in a 28-day cycle for up to 12 months
3233463|NCT01221883|Placebo Comparator|Placebo|Placebo capsule in ER, identical follow up like those in the active arm.
3233464|NCT01221883|Experimental|Diazepam|10 mg of Diazepam mg orally at ER only (a single administration)
3331741|NCT02107183|Active Comparator|Venturi mask oxygen therapy|Oxygen delivered through standard Venturi mask after extubation up to ICU discharge
3331742|NCT02107209|Experimental|Bronchoscopic Lung volume reduction using Autologous blood.|Injection of 30 ml autologous blood plus 3ml calcium chloride plus 3 ml tranexamic acid per segment via fiber-optic bronchoscope
3331743|NCT02107209|Active Comparator|Bronchoscopic Lung volume reduction using Fibrin glue|injection of 30 ml locally prepared fibrin glue per segment via triple lumen balloon catheter passing through fiberoptic bronchoscopy
3331744|NCT02107222|No Intervention|mechanical ventilation (MV)|mechanical ventilation according to guidelines
3331745|NCT02107222|Experimental|MV + ECCO2-R(PALP-Device/MaquetCP)|MV according to the guidelines plus CO2-Removal with PALP
3233465|NCT01221896||Hyperparathyroidism|Patients with hyperparathyroidism, prior to surgery.
3233466|NCT01221909|Experimental|Tranexamic acid single dose of 500mg|
3233467|NCT01221909|Placebo Comparator|Saline|
3233468|NCT01221922|Experimental|Acne treatment|Treatment of acne scars
3233469|NCT01221935||Patients initiated on Pristiq as a first line treatment|
3233470|NCT01221935||Patients initiated on Pristiq as a 2nd-line treatment|
3233471|NCT01221935||Patients initiated on a SNRI or SSRI as a first-line treatment|
3233472|NCT01221935||Patients initiated on a SNRI or SSRI as a 2nd-line treatment|
3233473|NCT01221974|Experimental|Essure,Hydrosalpinx, Infertility|
3233474|NCT01221987||Cohort A|Females > 21 years of age, diagnosed with invasive cervical cancer
3233475|NCT01221987||Cohort B|Females > 21 years of age, diagnosed with moderate or severe cervical intraepithelial neoplasia
3233476|NCT01222000|Experimental|right controlled against moisturizing cream|
3233477|NCT01222000|Experimental|left controlled against moisturizing cream|
3233478|NCT01222013|Experimental|Imatinib Mesylate|
3233479|NCT01222026|Active Comparator|Strontium Ranelate|Receiving Strontium Ranelate + Ca/Vitamin-D
3233480|NCT01222026|Placebo Comparator|Placebo|Receiving Placebo + Ca/Vitamin D
3259199|NCT01468389|Active Comparator|Taxanes or Platinum in combination with Capecitabine|The patients will received chemotherapy combining capecitabine with platinum or taxanes until progression.
3233481|NCT01222039|Experimental|Conventional treatment plus high dose: 3x10e6 cells / Kg.|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
3233482|NCT01222039|Experimental|Conventional treatment plus low dose: 1x10e6 cells / Kg|Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin.
3233483|NCT01222052|Experimental|Arm A Taxane-containing|3 courses FEC q3weeks followed by 3 courses Docetaxel q3weeks
3233484|NCT01222052|Active Comparator|Arm B standard anthracyclin|6 courses of FEC q3weeks
3331746|NCT02107235|Experimental|Rigosertib + Cisplatin + Radiation|"Oral rigosertib will be started 7 days before initiation of concurrent treatment with cisplatin and radiation therapy and will be administered on a continuous basis for a fixed duration of 8 weeks. Three oral rigosertib escalating doses will be sequentially evaluated: 70 mg 3 times a day (TID), 140 mg TID and 280 mg TID.~Cisplatin will be administered intravenously at a dose of 40 mg/m^2 on Days 1, 8, 15, 22, 29, 36, and 43 of the 7-week concurrent treatment course.~The prescribed radiotherapy dose will be 70 Gray (Gy) in 2 Gy once-daily fraction size (total of 35 fractions) over the 7-week concurrent treatment course. The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, 5 fractions per week."
3331747|NCT02107248|Active Comparator|Sleep position: supine|Subjects will be instructed to sleep in a supine position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
3331748|NCT02107248|Experimental|Sleep position: no restrictions|Patients do not have any restrictions in sleeping position during the first eight weeks after a total hip replacement following a posterolateral surgical approach
3331749|NCT02107261|Active Comparator|Naive to botulinum toxin|Individuals with musicians dystonia who have not been treated previously with botulinum toxin.
3331750|NCT02107261|Active Comparator|Prior treatment with botulinum toxin|Individuals with musician's dystonia who have been previously treated with botulinum toxin.
3233485|NCT01222052|No Intervention|Observation|
3233486|NCT01222065||Glaucoma/Normal|Two groups will be studies: patients with glaucomatous visual field loss and age and gender matched normal patients without visual field loss
3331751|NCT02107287|Experimental|IMRT Hypofractionated|Neo-adjuvant hormone therapy for three months followed by IMRT combined with a 24-month hormonal therapy.
3331752|NCT02107326|Experimental|Webdia Software use|Use of Webdia Software during 3 months by the patient. Monthly review of blood glucose values by the medical team and automatic adjustment of insulin doses by the team.
3233487|NCT01222143|Experimental|NOVE-HiDAC and Nilotinib|All patients will be receiving nilotinib combined with mitoxantrone, etoposide and high-dose cytarabine reinduction therapy. Patients achieving complete remission will receive consolidation therapy with nilotinib combined with high-dose cytarabine and mitoxantrone.
3233488|NCT01222156|Experimental|CGCI navigation|Subjects with CGCI navigation to specific target intracardiac anatomical sites
3233489|NCT01222169|Experimental|larynx assessment under stimulation|
3233490|NCT01222169|Placebo Comparator|Larynx assessment under stimulation|
3331753|NCT02107326|No Intervention|Observation|No use of the software. No intervention.
3331754|NCT02107352||Naltrexone|50mg/day
3331755|NCT02107352||Acamprosate|1332mg/day if patient weights less than 60 kg, 1998mg/day if patient weights more than 60 kg
3331756|NCT02107352||Baclofen|30 mg/day
3331757|NCT02107352||Placebo|
3331758|NCT02107365|Experimental|Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a|Quadritherapy from Day 0 to Week 24
3331759|NCT02107378|Experimental|DCVAC/OvCa in parallel with chemo (SoC)|Combination therapy with DCVAC/OvCa and Standard of Care (SoC)
3331760|NCT02107378|Active Comparator|Standard of Care (Chemotherapy)|Standard of Care as an Active Comparator (Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy)
3331761|NCT02107391|Experimental|DCVAC/PCA added Standard Hormone Therapy|Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy
3331762|NCT02107391|Active Comparator|Standard of Care Hormone Therapy|Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate
3331763|NCT02107404|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCA Experimental therapy
3331764|NCT02107404|No Intervention|Standard Therapy|No Intervention
3331765|NCT02107417|Experimental|Experimental Group (EG) - TENS active|Experimental Group (EG) - TENS active: who will receive the application of active TENS. The participants of these group will receive TENS active within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
3331766|NCT02107417|Sham Comparator|Control Group (CG)- Placebo TENS|Control Group (CG) who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, . It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted.
3233491|NCT01222182||Eligible plan beneficiaries on atorvastatin|A group of 225 eligible patients would no longer have atorvastatin covered by their prescription plan and would need to be changed to another equivalent anti-hyperlipidemic agent.
3233492|NCT01222208|Active Comparator|Oral Nutrition|Subjects will receive an oral nutrition regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as pressurized whey protein
3331767|NCT02107430|Experimental|DCVAC/PCa arm post radiotherapy|Dendritic Cells DCVAC/PCa Experimental therapy post radiotherapy
3233493|NCT01222208|Placebo Comparator|Peripheral Parenteral Nutrition|Subjects will receive a peripheral parenteral nutrition (PPN) regimen comprised of 50% of their Resting Energy Expenditure (REE) as dextrose and 20% of their REE as amino acids.
3233494|NCT01222312|Active Comparator|Arm A cisplatin|Cisplatin 75 mg/m2, d1 Docetaxel 75 mg/m2, d1 every 3 weeks (d22) max. 6 cycles
3233495|NCT01222312|Experimental|Arm B oxaliplatin|Oxaliplatin 85 mg/m², d1 Docetaxel 50mg/m2, d1 every 2 weeks (d15) max. 8 cycles
3233496|NCT01222325|Active Comparator|swl 3000 impulses- 60 imp/min|patients in this group were submitted to extracorporeal shockwave lithotripsy (SWL) 3000 impulses at 60 impulses per minute under general anesthesia. Unique session
3233497|NCT01222325|Active Comparator|swl- 4000 impulses - 90 impulses /min|patients in this group were submitted extracorporeal shockwave lithotripsy (swl) to 4000 impulses at 90 impulses per minute under general anesthesia- unique session
3331768|NCT02107430|Active Comparator|Standard radiotherapy|Standard care
3331769|NCT02107456|Experimental|Dry Needling|The taut band of trigger point in upper trapezius muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
3331770|NCT02107469|Experimental|Ancient herbal treatment|"Phyllanthus niruri 3g fine dry powder 3 times a day with warm water before meals for 8 weeks~Sida cordifolia 7g coarse dry powder 2 times a day prepared as traditional decoction before meals for 8 weeks. Decoction: Take provided measurement cup full of water (112ml) and soak one portion (pe-packed) of the powder for 12 hours, then boil it until the upper level has been reduced to 1/4, filter, cool down to room temperature, drink"
3331771|NCT02107469|Experimental|Modern extract herbal treatment|"Phyllanthus niruri extract 2 capsules 3 times a day with warm water before meals for 8 weeks~Sida cordifolia roots extract 2 capsules 2 times a day with warm water before meals for 8 weeks"
3331772|NCT02107469|Placebo Comparator|Placebo|"Phyllanthus niruri placebo 2 capsules 3 times a day with warm water before meals for 3 weeks~Sida cordifolia placebo 2 capsules 2 times a day with warm water before meals for 3 weeks"
3331773|NCT02107495||CHF-confirmed subjects|Subjects 21 years of age or greater with clinically confirmed heart failure or have presented to the clinical site with signs, symptoms and/or risk factors suggestive of heart failure.
3331774|NCT02107495||Subjects with potentially co-morbidities|non-CHF subjects 21 years or greater, with potentially confounding comorbidities such as diabetes, renal insufficiency, hypertension and chronic obstructive pulmonary disease (COPD).
3331775|NCT02107495||Apparently healthy subjects|Apparently healthy subjects (meeting inclusion criteria) greater than 45 years of age, with no prior history of myocardial infarction (MI), acute coronary syndrome (ACS) congestive heart failure (CHF) or any other cardiac-related disease.
3331776|NCT02107521|Active Comparator|ICSI group|In this group, sperm selected for injection will be morphologically evaluated under 400x magnification
3331777|NCT02107521|Experimental|IMSI group|In this group, sperm selected for injection will be morphologically evaluated under 6600x magnification
3331778|NCT02107534|Experimental|parent training (dyslexia)|Participants take part in parent training, five two-hour sessions held biweekly.
3331779|NCT02107534|No Intervention|wait list control group|Participants of the waiting list control group had the possibility to take part in the parent training after the follow-up was completed.
3331780|NCT02107547|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
3331781|NCT02107547|Active Comparator|Labral repair|32 subjects in the study will receive labral repair as a surgical intervention
3331782|NCT02107573|Active Comparator|Rotator cuff repair without Suprascapular Nerve decompression|approximately 17 subjects in the study will receive traditional rotator cuff repair surgical intervention with no suprascapular nerve decompression surgical intervention
3331783|NCT02107573|Active Comparator|Rotator Cuff Repair with Suprascapular Nerve decompression|approximately 17 subjects in the study will undergo rotator cuff repair with arthroscopic suprascapular nerve decompression surgical intervention
3331784|NCT02107586|Active Comparator|Biceps tenodesis|32 subjects in the study will receive biceps tenodesis as a surgical intervention
3331785|NCT02107586|Active Comparator|Biceps tenotomy|32 subjects in the study will receive biceps tenotomy as a surgical intervention
3331786|NCT02107612|Experimental|Integrated system to insert two splinted (bar) miniimplants|Participants were randomly assigned to experimental group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
3331787|NCT02107612|Active Comparator|Denture|Participants were randomly assigned to comparator group following a simple randomization procedure (computer-generated list of random numbers). Allocation by telephone was carried out with an independent collaborator.
3331788|NCT02107625|Experimental|Diet A i.e. Low FODMAP diet|The patients are thoroughly informed verbally and in writing how to eat according to the low FODMAP diet. The diet imply restrictions in carbohydrate intake and the patients need to follow a list with yes/no-foods for 4 weeks.
3331789|NCT02107625|Experimental|Diet B, i.e. Traditional IBS diet|The patients are thoroughly informed verbally and in writing how to eat according to traditional IBS dietary advices. The diet imply adapting to regular dietary habit with meals 6 times a day, no to big meals, to chew food thoroughly, to peel fruits and vegetables, no carbonated beverages, no chewing gum, no soft drinks, no sugar-free candies, or cookies. Reduce spicy foods, coffee, alcohol, onion, pulses, and fatty foods. Keep strictly to the dietary advice for 4 weeks.
3331790|NCT02107638|Experimental|OMM treatment arm|Subject will receive osteopathic manipulative treatment protocol for Parkinson's disease (PARK-OMM), twice a week for 6 weeks.
3331791|NCT02107638|Active Comparator|Counseling|Subjects will receive counseling sessions weekly to match the face to face time with a physician during the OMM treatment arm. No OMM will be performed during this 6 week counseling study period.
3331792|NCT02107651||NOAC|Patients admitted for GI bleeding while in treatment with NOAC
3233498|NCT01222338|Active Comparator|Immunomodulator intervention|Two cohorts or arms of at least 60 subjects each (total 120) with pulmonary TB positive for sputum AFB smear will be randomized in a 1:1 ratio to receive once-daily, tablet of V-5 immunitor in combination with standard ATT for 2 months followed by ATT outside of trial for next 4 months or however long it needs to be.
3331793|NCT02107664||Radiation therapy for bone cancer pain|The group includes all cancer diagnoses, and different fractions of RT planned.
3331794|NCT02107690|Experimental|low temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3331795|NCT02107690|Experimental|room temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3331796|NCT02107690|Experimental|body temperature|Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures
3331797|NCT02107716|Experimental|Bicarbonate|Each participant will receive two lidocaine injections on the abdomen with different pH
3331798|NCT02107729|Experimental|Needle gauge small|injection needle 23 G
3331799|NCT02107729|Experimental|Needle gauge normal|injection needle 25 G
3331800|NCT02107729|Experimental|Needle gauge large|injection needle 27 G
3331801|NCT02107742|Experimental|Injection speed|each participant receives 3 injections with the same amount of lidocaine subcutaneously on the abdomen, given over 15, 30 and 45 seconds
3331802|NCT02107755|Experimental|Treatment (ipilimumab, stereotactic radiosurgery)|Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
3331803|NCT02107768|Experimental|Exercise recommendation|Patients randomized to the control group receive general advice for physical training and activity but no specific training or other rehabilitation efforts
3331804|NCT02107768|Experimental|Aerobic exercise|"The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added. The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20, Rate of Perceived Exertion (Borg 's RPE scale)~Two fitness goals was to be achieved during the training session:~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) .Which corresponds to 85% of maximum heart rate."
3331805|NCT02107781||Patients with open abdomen|Patients in a critical care unit with abdomen that was not closed during initial operation & will have intra-abdominal pressure monitoring using the AbViser abdominal compartment pressure measuring device.
3331806|NCT02107794|Active Comparator|Decision Aid|Observation of clinical encounter using the decision aid, via video, audio or written notes.
3331807|NCT02107794|No Intervention|Usual Care|Observations in clinical encounters, either video, audio, or observational notes.
3233499|NCT01222338|Placebo Comparator|placebo|Control Cohort 1 (60 subjects) will receive standard first-line ATT regimen: (daily Isoniazide (H) 150mg, Rifampicin (R) 300mg, Ethambutol (E) 400mg, and Pyrazinamide (Z) 400mg during first 2 months, followed by H/R three times per week for the next 4 months. Patients also will receive placebo preparation, appearing identical to V-5 immunitor, taken once daily 30 minutes prior or after meal for 2 months
3233500|NCT01222351|Experimental|BAY 94-9172|BAY 94-9172 PET/CT
3331808|NCT02107807|Experimental|Arm 1: aH5N1 adult|aH5N1 healthy and non-healthy adults
3331809|NCT02107807|Experimental|Arm 2: aH5N1 elderly|aH5N1 healthy and non-healthy elderly
3331810|NCT02107807|Active Comparator|Arm 4: aTIV elderly|aTIV healthy and non-healthy elderly
3331811|NCT02107807|Active Comparator|Arm 3: aTIV adult|aTIV healthy and non-healthy adults
3233501|NCT01222364|Active Comparator|Standard Cord Clamping|
3233502|NCT01222364|Experimental|Delayed Cord Clamping|
3233503|NCT01222377|Experimental|Arm I|Patients undergo endoscopic breast surgery.
3233504|NCT01222429|Active Comparator|diet following American Diabetes Association guidelines|Participants will follow diets based on ADA guidelines. This group will also receive weekly nutrition classes.
3233505|NCT01222429|Experimental|vegan diet|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
3331812|NCT02107820|Active Comparator|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
3331813|NCT02107820|Experimental|'Bladder Training (BT) and PTNS|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
3233506|NCT01222442|Experimental|1|400 µg AZD3199 + moxifloxacin placebo
3233507|NCT01222442|Experimental|2|1200 µg AZD3199 + moxifloxacin placebo
3233508|NCT01222442|Active Comparator|3|AZD3199 placebo + moxifloxacin 400 mg
3233509|NCT01222442|Placebo Comparator|4|AZD3199 placebo + moxifloxacin placebo
3331814|NCT02107833|Experimental|2 mg|OPRX-106 2 mg oral once daily for 5 days
3331815|NCT02107833|Experimental|8 mg|OPRX-106 8 mg oral once daily for 5 days
3233510|NCT01222455|Experimental|1|Mild hepatic impairment
3233511|NCT01222455|Experimental|2|Moderate hepatic impairment
3331816|NCT02107833|Experimental|16 mg|OPRX-106 16 mg oral once daily for 5 days
3233512|NCT01222455|Experimental|3|Severe hepatic impairment
3233513|NCT01222455|Experimental|4|Matched healthy volunteers with normal hepatic function
3233514|NCT01222468|Active Comparator|nabilone|nabilone 0.5 mg tablets dose-titrated over an 11-week period to a maximum of 3mg po daily. Subjects are allowed to drop back to the previous dose following a dose increase once if required
3233515|NCT01222468|Placebo Comparator|placebo|look-alike 0.5 mg placebo tablets titrated to a maximum daily dose of 3.0 mg daily over an 11-week phase. Subjects are allowed to drop back to the previous dose following a dose increase once during the 11-week phase if required
3233516|NCT01222481||Newly-diagnosed Head and Neck Cancer|
3233517|NCT01222546|Experimental|CH5132799|
3331817|NCT02107846|Experimental|50 Units|PRX-112 50 Units daily for 5 days
3331818|NCT02107846|Experimental|100 Units|PRX-112 100 Units daily for 5 days
3331819|NCT02107846|Experimental|200 Units|PRX-112 200 Units daily for 5 days
3331820|NCT02107846|Experimental|400 Units|PRX-112 400 Units daily for 5 days
3331821|NCT02107872|Experimental|dosing cohort 1|Patients will receive REGN1500 or placebo in dosing cohort 1
3233518|NCT01222559|Experimental|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
3233519|NCT01222559|Active Comparator|Micofracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
3233520|NCT01222611|No Intervention|Standard HAART|ART with 3 drugs including 2 NRTIs plus a ritonavir boosted PI (different to FPV) or a NNRTI
3331822|NCT02107872|Experimental|dosing cohort 2|Patients will receive REGN1500 or placebo in dosing cohort 2
3331823|NCT02107872|Experimental|dosing cohort 3|Patients will receive REGN1500 or placebo in dosing cohort 3
3331824|NCT02107872|Experimental|dosing cohort 4|Patients will receive REGN1500 or placebo in dosing cohort 4
3331825|NCT02107872|Experimental|dosing cohort 5|Patients will receive REGN1500 or placebo in dosing cohort 5
3331826|NCT02107885|Experimental|DS-1971|single ascending dose of 5mg, 10mg, 30mg, 90mg, 250mg, 500mg, 1000mg, 1500mg.
3233521|NCT01222611|Experimental|HAART inlcuding Fos APV/r|ART with 3 drugs including 2 NRTIs plus ritonavir boosted fosamprenavir
3233522|NCT01222624|Experimental|PankoMab-GEX™, 3-weekly|application, q3w
3233523|NCT01222624|Experimental|PankoMab-GEX™, 2-weekly|application q2w
3233524|NCT01222624|Experimental|PankoMab-GEX™, weekly|application q1w
3233525|NCT01222637|Experimental|CetuGEX™, weekly|application weekly
3331827|NCT02107885|Placebo Comparator|placebo|placebo matching each of the DS-1971 dosages.
3331828|NCT02107911||men who have sex with men|MSM who seek voluntary HIV counseling and testing service at the Anonymous Clinic, TRC-ARC, including those who describe risky sexual exposure to HIV within the preceding 72 hours and meet nPEP criteria.
3331829|NCT02107924||APPI of TKR-Stimulan|Surgery Stimulan beads 2.4 G Tobramycin 2.0 G Vancomycin
3331830|NCT02107924||APPI of TKR-historical|Surgery 2.4 G Tobramycin 2.0 G Vancomycin
3233526|NCT01222637|Experimental|CetuGEX™ 2-weekly|application biweekly
3331831|NCT02107937|Experimental|DCVAC/OvCa with Standard of Care|DCVAC/OvCa in parallel with chemotherapy (Standard of Care)
3331832|NCT02107937|Experimental|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa sequentially after chemotherapy
3331833|NCT02107937|Active Comparator|Standart of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
3331834|NCT02107950|Experimental|DCVAC/OvCa in parallel with chemotherapy|Combination therapy with DCVAC/OvCa and Standard of Care
3331835|NCT02107950|Active Comparator|Standard of Care|Standard of Care carboplatin and gemcitabine
3331836|NCT02107963|Experimental|Arm 1|Dose escalation of anti-GD2 CAR T cells
3233527|NCT01222650|Experimental|KSO-0400 Low Dose|
3233528|NCT01222650|Experimental|KSO-0400 High Dose|
3331837|NCT02107963|Experimental|Arm 2|Dose expansion of anti-GD2 CAR T cells
3233529|NCT01222650|Experimental|Silodosin|
3233530|NCT01222650|Placebo Comparator|Placebo|
3233531|NCT01222663|Other|Standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
3233532|NCT01222663|Experimental|Hemoperfusion|standard therapy + 2 sessions of hemoperfusion within the first 24 hours
3233533|NCT01222702|Experimental|Cadazolid 250 mg|Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3331853|NCT02108093|Experimental|RAP (retrograde autologous priming) group|In the RAP (retrograde autologous priming) group, the priming solution is partially replaced by the patient's own circulating blood, before initiation of CPB. After initiation of cardiopulmonary bypass the priming volume is approximately 900 ml.
3331854|NCT02108093|No Intervention|Control group|In the control group, the priming volume of the arterial and venous line will not be replaced by patient's own blood. The priming volume of cardiopulmonary bypass is 1300 ml in the control group.
3233534|NCT01222702|Experimental|Cadazolid 500 mg|Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3331855|NCT02108106|Experimental|AG-348|Single oral dose of AG-348
3233535|NCT01222702|Experimental|Cadazolid 1000 mg|Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
3331856|NCT02108106|Placebo Comparator|Placebo|Single oral dose of placebo
3331857|NCT02108119|Active Comparator|Probiotics|
3331858|NCT02108119|Placebo Comparator|Control placebo|
3331859|NCT02108132|Experimental|Cellular therapy|Cellular therapy : injection of mesenchymal stem cells subjected to hepatogenic induction
3331860|NCT02108145|Active Comparator|unilateral metal stent insertion|unilateral metal stent insertion was performed either left or right hepatic lobe as can be drainage more liver volume
3331861|NCT02108145|Experimental|bilateral metal stent insertion|percutaneous transhepatic biliary drainage plus bilateral metal stent.The bare stents were used for PTBS
3331862|NCT02108158|Experimental|Azzalure 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
3233536|NCT01222702|Active Comparator|Vancomycin 125 mg|Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days
3331863|NCT02108158|Active Comparator|Azzalure, 10 Speywood units/injection|Azzalure (botulinum toxin type A), powder for solution for injection, Total dose 50 s.U (5 x 10s.U)
3331864|NCT02108184|Experimental|Sequential therapy 10 days|1.(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 5 days
3331865|NCT02108184|Active Comparator|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days
3331866|NCT02108184|Active Comparator|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 10 days
3331867|NCT02108184|Active Comparator|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days
3233541|NCT01222780|Experimental|Marqibo|"Marqibo® (Vincristine sulfate liposomal) will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
3233542|NCT01222819|Experimental|IV filgrastim|as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg) in bolus IV injection, as per manufacturer's recommendations.
3233543|NCT01222819|Active Comparator|SC filgrastim|given as a single daily dose of 5 mcg/kg (rounded to 300 mcg or 480 mcg)
3233544|NCT01222845|Experimental|Pinhead oat porridge|
3233545|NCT01222845|Experimental|Rolled oat porridge|
3233546|NCT01222858|Active Comparator|Internet Education Program|Participants receive 12 weekly Internet-based weight loss lessons containing information for modification of diet and activity behaviors.
3233547|NCT01222858|Experimental|Innovative Technology Intervention|Participants receive a 12-week Internet-based eating and activity intervention including multimedia lessons and enhanced self-monitoring of weight loss behaviors with automated feedback.
3331868|NCT02108197|Experimental|CPAP Intervention|Continuous positive airway pressure (S9, ResMed)
3331869|NCT02108197|No Intervention|Wait-list|Wait list controls
3331870|NCT02108210|Experimental|Anakinra|This therapy will consist of once daily subcutaneous injections (100mg/day) during a period of 4 weeks. Patients will be monitored at week 1 and week 4 after starting medication for development of side effects. Therapy will be stopped in case of severe side effects, interfering disease or pregnancy. During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards.
3233548|NCT01222897|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3233549|NCT01222897|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
3331871|NCT02108210|Placebo Comparator|Placebo|"Patients in the placebo group will also receive once daily subcutaneous injection during a period of 4 weeks. Placebo injections will be identically in appearance compared to the Anakinra injections. Patients in the placebo group will have the same visits and monitoring for side effects as the patients randomized to the other treatment arm.~During the intervention period, use of co-medication is only allowed when used for ≤14 consecutive days, on the condition that there are no known interactions with anakinra. Oral contraceptives and/or paracetamol can be used without a limitation. During the follow-up period, there are no limitations regarding the use of medication. All co-medication will be registered precisely and reported afterwards."
3331872|NCT02108236|No Intervention|Blank control group|A control group of patients is put on a waiting list for no intervention and remaining unchanged lifestyle.
3331873|NCT02108236|Active Comparator|intervention group|An intervention group of patients is put on a waiting list for acupuncture treatment.
3331874|NCT02108249||Annex Group|Patients prospectively treated with Annex™ Adjacent Level System
3331875|NCT02108249||Retrospective Control|Patients previously treated for adjacent level disease using other systems
3331876|NCT02108301|Experimental|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
3331877|NCT02108314|No Intervention|Control Group|Participants in the control arm were blinded as to the hypothesis of the study, undergoing a series of questions in about general health behaviours before their consultation, allowing the investigators to determine eligibility for the study. The associated participant information sheets for the control arm did not specifically mention breast cancer screening, maintaining blinding throughout. There was no reminder to the physician to promote mammography to participants. The physician continued with his or her usual counseling on health screening and mammography, if any. A 3-minute health promotion video by the Singapore Heart Foundation on healthy eating habits was administered to each participant, followed by a post-consultation questionnaire. The entire process took approximately 10 minutes.
3331878|NCT02108314|Active Comparator|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
3331879|NCT02108327|Experimental|surgical blade|
3331880|NCT02108327|Active Comparator|Unipolar electrocautery|
3233550|NCT01222910|Experimental|Test|Valacyclovir hydrochloride tablets 1 gm of OHM Laboratories Inc. (a subsidiary of Ranbaxy Pharmaceuticals Inc.)
3233551|NCT01222910|Active Comparator|Reference|VALTREX® (valacyclovir HCl) caplets 1 gm of GlaxoSmithKline Research Triangle Park, NC 27709
3331881|NCT02108340|Experimental|Microwave radiometry|Patients diagnosed with acute appendicitis will undergo a measurement of the temperature of the appendix with the use of microwave radiometry in a room temperature of 20 -24 degrees celsius.
3331882|NCT02108353|Active Comparator|Melatonin 2mg|The study medication will be compared to placebo control.
3331883|NCT02108353|Placebo Comparator|Placebo|The study medication will be compared to placebo control.
3233552|NCT01222923|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
3331884|NCT02108366|Placebo Comparator|Placebo|Placebo + oseltamivir 75mg bid for 5 days
3331885|NCT02108366|Experimental|Celecoxib|Celecoxib 200mg daily + oseltamivir 75mg bid for 5 days
3331886|NCT02108379|Experimental|Rhinix Nasal Filters|All included will receive rhinix nasal filters
3331887|NCT02108405||Sepsis|Sepsis Forty eight patients developed septic complication during ICU stay (sepsis group).
3331888|NCT02108405||SIRS group|SIRS group Forty seven patients were critically ill without evidence of infectious organism (SIRS group).
3331889|NCT02108418|Experimental|TG-2349 as the original formulation|400 mg, 2 syringes
3331890|NCT02108418|Experimental|TG-2349 as a new capsule formulation|400 mg, 4 capsules
3331891|NCT02108431|Experimental|balloon catheter for transurethral bladder-drainage|intraoperatively placement of transurethral catheter after robot-assisted radical prostatectomy
3233553|NCT01222923|Experimental|1|Risperidone 1 mg ODT tablets of Ranbaxy Laboratories, Ltd
3331892|NCT02108431|Active Comparator|balloon catheter for suprapubic bladder-drainage|intraoperatively placement of suprapubic catheter after robot-assisted radical prostatectomy
3331893|NCT02108444||group with HBV reactivation|group with hepatitis B virus reactivation
3331894|NCT02108444||group without HBV reactivation|group without hepatitis B virus reactivation
3233554|NCT01222949|Experimental|Asian Healthy Volunteers|Asian males with a body weight ≤ 65 kg (12 subjects) Asian females with a body weight ≤ 65 kg (12 subjects)
3233555|NCT01222949|Experimental|Caucasian Healthy Volunteers|Caucasian males with a body weight ≤ 65 kg (12 subjects) Caucasian females with a body weight ≤ 65 kg (12 subjects) Caucasian males with a body weight > 65 kg (24 subjects)
3233556|NCT01222962|Experimental|fed treatment|18 healthy volunteers administered with a single dose of Eurartesim
3233557|NCT01222962|Experimental|Fasted Treatment|18 healthy volunteers treated with a single dose of Eurartesim
3331895|NCT02108470|No Intervention|Dental consultation without OHQoL assessment|Dentist performs consultation in the traditional method
3331896|NCT02108470|Experimental|Dental consultation using OHIP|Dental consultation using OHIP incorporating OHRQoL issues.
3331897|NCT02108483|Experimental|All participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches on Day 1.
3331898|NCT02108496|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
3331899|NCT02108496|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
3233558|NCT01222975|Experimental|1|Risperidone orally disintegrating tablets of Ranbaxy Laboratories, Ltd
3233559|NCT01222975|Active Comparator|2|Risperdal® M-Tab of Janssen Pharmaceutica Products L.P.
3233560|NCT01222988|Other|very low calorie diet program|
3233561|NCT01223014||1|Single cohort of 6 subjects
3331900|NCT02108535|Experimental|Nanocrystalline silver|Flexible polyester low-grip coated nanocrystalline silver dressing. The dressing was applied to the lesion after being soaked in sterile distilled water. About this compresses to bandage movements will have been added and comes to avoid tourniquet bandage on-site maintenance, temperature of the affected area, cushioning and absorption of wound exudate when present. Is finished with the application of crepe bandages in the form of flakes containment curative and maintenance of pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, avoiding tourniquet. The exchanges were performed every three days.
3331901|NCT02108535|Active Comparator|Silver sulfadiazine|Ranges for rayon containing cream 1% silver sulfadiazine were used. Involving this layer, bandages for dressings were added in movements back and forth to avoid the tourniquet, providing maintenance of the temperature of the affected area, cushioning and absorption of wound exudate when present. This application was completed with crepe bandages to contain the dressing and maintain pressure. This procedure aids in the bloodstream, and avoids the increased edema. The bandage is started from the periphery to the central region, scales, avoiding the tourniquet. Dressing changes were performed daily.
3331902|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose|
3331903|NCT02108548|Experimental|Part 1: ASP7657 Single Ascending Dose - Food Effect|
3331904|NCT02108548|Placebo Comparator|Part 1: Placebo|
3233562|NCT01223040|Experimental|SYSTANE® Balance Lubricant Eye Drops|SYSTANE Balance Lubricant Eye Drops dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
3233563|NCT01223053|Active Comparator|Active|Topical ketoprofen 10% Cream
3233564|NCT01223053|Placebo Comparator|Placebo Cream|Placebo Cream
3233565|NCT01223066||Women treated with Macrolane in the breasts|
3331905|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose|
3331906|NCT02108548|Experimental|Part 2: ASP7657 Multiple Ascending Dose Elderly|
3331907|NCT02108548|Placebo Comparator|Part 2: Placebo|
3331908|NCT02108548|Active Comparator|Part 2: Naproxen|
3331909|NCT02108561||Breast Cancer|Post Surgical Her2 testing
3331910|NCT02108574|Placebo Comparator|Placebo Filter|Placebo device
3331911|NCT02108574|Active Comparator|Rhinix Nasal Filter|Actual Rhinix Nasal Filter
3331912|NCT02108587|Experimental|optical coherence tomography for diagnosis|Patients undergo optical coherence tomography over 10-15 minutes.
3233566|NCT01223079|Other|r-hFSH (Gonal F)|Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
3233567|NCT01223079|Other|r-hFSH (Gonal F) and r-hLH (Luveris)|Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm. Patients will then bring 300IU/day of r-hLH until r-hCG administration.
3233568|NCT01223092||Patients undegoing infertility treatment|Male and female patients undergoing infertility treatment
3233569|NCT01223105|Experimental|Slow Freezing|oocytes will be frozen by slow freeze/ rapid thaw
3233570|NCT01223105|Experimental|Vitrification|oocytes will be frozen using rapid freezing/rapid thaw
3233571|NCT01223118|Experimental|Oocyte Vitrification|Each patient will have oocytes randomized into two groups immediately after retrieval. Half of oocytes will be vitrified, thawed and inseminated. The other half will be inseminated only. All embryos will be biopsied for PGD prior to transfer and one embryo from each group will be transferred (vitrification and control groups). Following delivery, buccal swabs will be collected on all infants.
3233572|NCT01223131|Experimental|Insulin glargine|injection once daily at bedtime
3233573|NCT01223131|Active Comparator|NPH insulin|injection once daily at bedtime or twice daily in the morning and at bedtime
3233574|NCT01223144|Experimental|Patients with essential tremor|Patients with essential tremor
3233575|NCT01223144|Active Comparator|age- and sex-matched control subjects|age- and sex-matched control subjects
3233576|NCT01223157|Experimental|Obese patients|
3233577|NCT01223157|Experimental|Normal weight subjects|
3233578|NCT01223170|Experimental|Enhanced Internet-based intervention|Behavioral: Tailored content Behavioral: Generic Internet-based information Behavioral: Discussion forum Behavioral: Behavioral monitoring
3233579|NCT01223170|Placebo Comparator|Control|Behavioral: Generic Internet-based information Behavioral: Discussion forum
3233580|NCT01223209|Experimental|LTX-315|The dose range of 0,25-2.0 mg/ML LTX-315 will be used. In combination with a fixed dose of GV-1001.
3233581|NCT01223222|Placebo Comparator|1% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3233582|NCT01223222|Active Comparator|2% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3233583|NCT01223222|Active Comparator|5% Lytixar™|6 subjects will be treated with Lytixar™ and 2 will be treated with vehicle (placebo).
3233584|NCT01223248|Experimental|stereotactic IGIMRT using a single dose of 24 Gy|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
3233585|NCT01223248|Experimental|stereotactic IGIMRT 27 Gy in 3 fractions|This is a phase III, multicenter, randomized, study comparing two dosing schedules for hypofractionated image-guided radiation therapy to bone, spine, soft tissue, and lymph nodes in patients with metastatic disease
3233586|NCT01223274|Experimental|CPAP/PEEP Intervention|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
3331913|NCT02108613|Experimental|Intervention|The intervention arm will receive sexual health counselling, exercise sessions, nutrition education, and will be assigned a peer support volunteer.
3331914|NCT02108613|No Intervention|Control|The control group will receive sexual health counseling.
3331915|NCT02108626|Active Comparator|E-Cigarette with nicotine|Electronic cigarette with cartridge fluid containing nicotine
3331916|NCT02108626|Placebo Comparator|E-Cigarette without nicotine|Electronic cigarette with cartridge fluid containing no nicotine (placebo)
3331917|NCT02108639|Experimental|DCV 3DAA FDC + BMS-791325|"Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days~Group E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
3331918|NCT02108665|Other|Radiographic hysterosalpingography|Realisation in first: radiographic hysterosalpingographyresonance then imaging hysterosalpingography
3331919|NCT02108665|Other|Magnetic resonance imaging hysterosalpingography|Realisation in first : magnetic resonance imaging hysterosalpingography then a radiographic hysterosalpingography
3331920|NCT02108678|Experimental|ACT-ME|ACT-ME is designed to reduce behavioral avoidance and to enhance acceptance-based coping. It includes: 1) Behavioral Change Training involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations; and 3) Migraine education whereby each of the educational topics listed below will be covered without detailed discussion of the topics.
3331921|NCT02108678|Experimental|Migraine Education Only|The MEO workshop will last six hours and involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine. The group leaders will present one educational topic at a time and the participants will discuss and reflect about issues and experiences related to the topic. If necessary, the group leaders will raise specific discussion questions to facilitate group dialogue and participant involvement. However, information on coping practices will be omitted.
3331922|NCT02108704|Active Comparator|Helicobacter pylori eradication therapy|Amoxycillin 1gm twice a day (BD) Clarithromycin 500mg BD Omeprazole 20mg BD
3331923|NCT02108704|Placebo Comparator|Placebo|Maltodextrin
3331924|NCT02108717|Experimental|Group I|"The raters in this group one firstly reviewed the CT scans numbered from one to 60 using LCD monitor and after mandatory rests of 20 minutes, reviewed the remaining CT examinations numbered from 61 to 120 using iPhone with TeamViewer at their first visit.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
3331925|NCT02108717|Experimental|Group II|"The raters in this group II firstly reviewed the CT scans numbered from one to 60 using iPhone with TeamViewer and 61 to 120 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the CT scans using revered devices at each session."
3331926|NCT02108730||non-focal congenital hyperinsulinism|13 children and one adult with non-focal congenital hyperinsulinism
3331927|NCT02108743|Active Comparator|Albuterol|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
3331928|NCT02108743|Placebo Comparator|Placebo|Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
3331929|NCT02108756|Experimental|L-pantoprazole sodium|
3331930|NCT02108756|Active Comparator|Panmeilu|
3331931|NCT02108769|Experimental|Yogic Breathing|"Chanting Om~Sharp deep inhalation through nostrils~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~Yogic Breathing:~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~Hold breath in this position for about 16 seconds.~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~Go to step a)."
3331932|NCT02108769|Active Comparator|Attention Control|The participants will read a text of their choice for 20 minutes.
3331933|NCT02108782|Experimental|Treatment (dovitinib lactate)|Patients receive dovitinib lactate PO on days 1-5, 8-12, 15-19, and 22-26. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3331934|NCT02108795|Experimental|remifentanil group|Remifentanil 0.05 ug/kg/min is infused to the patients.
3233587|NCT01223274|Active Comparator|Control|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
3233588|NCT01223300||Osteoporosis|
3331935|NCT02108795|Placebo Comparator|control|Normal saline 0.2 ml/kg/hour is infused to the patients
3233589|NCT01223313|Experimental|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
3331936|NCT02108808|Active Comparator|Prasugrel or Clopidogrel|Prasugrel 60mg or Clopidogrel 600mg loading dose, as clinically indicated
3331937|NCT02108808|Experimental|Ticagrelor|Ticagrelor 180mg loading dose
3233590|NCT01223326|Experimental|N-acetylcysteine|Intravenous N-acetylcysteine
3233591|NCT01223326|Placebo Comparator|Placebo|Placebo
3233592|NCT01223339|Experimental|Single Dose Japanese Cohort|This will be a single dose Cohort in which Japanese healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin or placebo through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
3331938|NCT02108834|Active Comparator|nerve block|cervical plexus block with ropivacaine
3331939|NCT02108834|Placebo Comparator|Placebo|placebo saline
3331940|NCT02108847|Experimental|Fascia Iliaca Block - Ropivacaine|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of 0.2% ropivacaine.
3331941|NCT02108847|Sham Comparator|Fascia Iliaca Block - Saline|Ultrasound guided fascia iliaca block performed preoperatively with 40 mL of Saline.
3331942|NCT02108860|Experimental|Blinded abatacept|Participants will receive blinded abatacept 125 mg administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
3331943|NCT02108860|Placebo Comparator|blinded placebo|Participants will receive blinded placebo. Placebo will be administered by subcutaneous injection once a week for at least 12 months. Subjects may be removed from treatment earlier due to a disease relapse, disease worsening, or if they have not achieved remission by treatment month 6.
3331944|NCT02108873||Retrospective Cohort|Adult patients who had scheduled an appointment for outpatient primary care. Patients were divided into two groups, including those who attended their scheduled appointment and those who missed it.
3233593|NCT01223339|Experimental|Single dose Western cohort|This will be a single dose Cohort in which Western healthy participants will receive 3 ascending single doses (1 mg, 5 mg, and 25 mg) of ertugliflozin through 3 dosing periods. A minimum wash out period of 7-days will be set between each dose administration.
3331945|NCT02108886|Experimental|Montelukast|Intervention group
3331946|NCT02108886|Placebo Comparator|Placebo|Placebo
3331947|NCT02108899|Experimental|Patients with schizophrenia|
3331948|NCT02108899|Active Comparator|Healthy subjects|
3331949|NCT02108925|Experimental|Supplementary oxygen|Study subjects receive, in randomized order, either supplementary 30% oxygen or air (21% Oxygen) from a gas tight bag
3331950|NCT02108938||Case|Subject's with Crohn's disease at least 18 years of age
3331951|NCT02108938||Control|"Findings from this study will be compared to controls. These controls will come from the well documented CNS changes which have been found in patients with IBS and chronic pancreatitis (HS-IRB# 2013-1561 and HS-IRB 2009-0171)."
3331952|NCT02108990|Experimental|Acetaminophen 1000mg|Acetaminophen 1000mg capsule orally three times a day
3331953|NCT02108990|Experimental|Acetaminophen 500mg|500mg Acetaminophen orally three times a day
3331954|NCT02109003|Experimental|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Pressure easy® device for 24h, followed by discontinuous control (every 4 hours) with a manual manometer for 24 h.
3331955|NCT02109003|Active Comparator|Manual control of Pcuff followed by continuous control.|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
3331956|NCT02109016|Experimental|Lucitanib|Lucitanib given orally once daily on a continuous schedule. Starting dose is 10 mg/day.
3331957|NCT02109055|Experimental|Pilates|Regarding upper limb exercises the limit of flexion and abduction less than 90°, with the exercises involving only the movement of flexion and extension of elbow shoulder will be respected. Along with patient data will be an exercise protocol based on the Pilates method that will be performed by a trained team of physiotherapists. Before and after the exercises the data of heart rate, blood pressure, oxygen saturation and subjective feeling of perceived exertion using the Modified Borg scale will be listed.
3331958|NCT02109055|Active Comparator|Convencional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy.
3331959|NCT02109068|Active Comparator|In-Person Counseling|Participants randomized to in-person counseling will meet via in-person or via telephone (but at least 3 of the 11 sessions must be in person) weekly for month 1, then every other week for months 2, and 3, and then monthly for months 4-6 at Yale University. The meetings will last 30 minutes. Participants will turn in their diet and exercise logs and also be weighed. A lesson will then be discussed (see above for content).
3331960|NCT02109068|Active Comparator|Telephone-based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs. Every four weeks, participants will return, via stamped, addressed envelopes, the logs to the study office.
3331961|NCT02109068|No Intervention|Usual Care|Immediately after randomization, participants in the Usual Care Group will be provided written information that emphasizes the importance of a healthy lifestyle. Usual care participants will be encouraged to follow the American Cancer Society (ACS) nutrition and physical activity guidelines. Upon completion of the study (at 6 months), usual care participants will be offered all the educational material, as well as an in-person or telephone counseling session.
3331964|NCT02109094||Pregnant|
3331965|NCT02109094||Not Pregnant|
3331966|NCT02109120||carotid endarterectomy (CEA)|CEA patients with vein blood collection
3331967|NCT02109146|Experimental|TACE|Patients after surgery receive Transcatheter Arterial Chemoembolization (TACE)
3331968|NCT02109146|Active Comparator|Control|Patients after surgery do not receive TACE
3331969|NCT02109185|Active Comparator|Mometasone Furoate Monohydrate Nasal Spray,50 μg/act.|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Mometasone Furoate Monohydrate Nasal Spray per nostril once daily for 14 days. Total Daily Dose = 4 × 50 μg = 200 μg.
3331970|NCT02109185|Active Comparator|Nasonex® Nasal Spray, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
3331971|NCT02109185|Active Comparator|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray Suspension per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
3331972|NCT02109185|Placebo Comparator|Placebo Nasal Spray, 50 μL/actuation|Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays of placebo nasal spray per nostril once daily.
3331973|NCT02109198|Experimental|Active CN-NINM PoNS|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3331974|NCT02109198|Placebo Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3331975|NCT02109211|Other|Standard care - Magill forceps|Patients will be intubated, as per standard care, with Magill forceps.
3331976|NCT02109211|Experimental|Altered Magill forceps|Patients will be intubated with modified Magill forceps.
3233594|NCT01223339|Experimental|Multiple Dose Japanese Cohort|This will be a multiple dose Cohort in which Japanese healthy participants will receive once-daily 25 mg ertugliflozin or placebo for 7 days.
3233595|NCT01223391|Experimental|Abdominal binder|Standing with abdominal compression using elastic vs. non-elastic abdominal binders.
3331977|NCT02109224|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3331978|NCT02109237|Experimental|Bronchiolitis Obliterans 2 & 3|Assessment of sleep disorders and treatment if required
3331979|NCT02109237|Active Comparator|Bronchiolitis Obliterans 0|Assessment of sleep disorders and treatment if required
3331980|NCT02109250||all Belgian patients treated with Caprelsa® (vandetanib)|It is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
3331981|NCT02109263|Experimental|saccharose|20% saccharose
3331982|NCT02109263|Placebo Comparator|breast-feeding|breast-feeding
3331983|NCT02109276|Active Comparator|Spheric Sensar(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive a Spheric Sensar(R) 3-piece IOL
3233596|NCT01223391|Placebo Comparator|No abdominal binder|Standing without abdominal compression
3233597|NCT01223430|Experimental|Si-Ni-Tang|
3233598|NCT01223430|Placebo Comparator|Placebo|
3331984|NCT02109276|Experimental|Aspheric Tecnis(R) 3-piece IOL|This group of patients with Fuchs endothelial dystrophy and cataract will undergo cataract extraction and be randomized to receive an Aspheric Tecnis(R) 3-piece IOL
3331985|NCT02109289|Experimental|Methotrexate and Etanercept|Patients already taking Methotrexate prior to the study will continue taking 15 mg weekly and start Etanercept 50 mg every week for 16 weeks
3331986|NCT02109315|Experimental|Liraglutide endovenous 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
3331987|NCT02109315|Experimental|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
3233599|NCT01223443|Experimental|PCI-stenting|Stenting the moderate SVG lesion with the paclitaxel stent
3331988|NCT02109328|Experimental|Alisertib + Paclitaxel|After the first single arm phase with Alisertib monotherapy (20 patients, primary endpoint: response-rate), 110 patients will be randomized 1:1 in the second part of the trial.
3331989|NCT02109328|Placebo Comparator|Paclitaxel + Placebo|Weekly paclitaxel + oral Placebo
3331990|NCT02109341|Experimental|Nab-FOLFIRI|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFIRI: Irinotecan, 180 mg per square meter of body surface area (m2 ) + Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2 every 2 weeks. Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm A for phase II will receive the dose of Nab-FOLFIRI as determined in the Phase I and in the same sequence."
3331991|NCT02109341|Experimental|Nab-FOLFOX|"In the phase I study, all pts enrolled in this arm will receive Nab-FOLFOX: Oxaliplatin 85 mg/m2 +Leucovorin, 400 mg/m2 and 5-Fluorouracil, 400 mg/m2 given as a bolus followed by 2400 mg/m2 given as a 46-hour continuous infusion, plus Nab-p per cohort escalation assignment starting with 90 mg/m2, every 2 weeks.~Pts continued treatment until a total of 12 administrations, disease progression or unacceptable toxicity.~Pts enrolled in arm B for phase II will receive the dose of Nab-FOLFOX as determined in the Phase I and in the same sequence"
3331992|NCT02109354|Active Comparator|HIV Regimen + Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
3331993|NCT02109354|Active Comparator|HIV Vaccine Regimen|Participants will receive a placebo for tetanus vaccine by injection (placebo tetanus toxoid vaccine), followed by 2 injection of an experimental canarypox HIV vaccine (ALVAC-HIV; months 1, 2), than 2 injection of a protein HIV vaccine boost (AIDSVAX B/E; months 4, 7), followed by a placebo for hepatitis B vaccine series (months 7.5, 8.5, 13)
3233600|NCT01223443|No Intervention|Standard medical treatment|
3233601|NCT01223482||Miscarriage with genetic testing|This is a study population of women that have had a miscarriage and had genetic testing performed. The investigators would like to know what their experiences were following their miscarriage and testing.
3233602|NCT01223482||Miscarriage without genetic testing|This cohort is considered the control group. These women have not had genetic testing done, but are asked questions regarding their miscarriage experience.
3233603|NCT01223521|Experimental|Immediate intrauterine contraception|IUD (either Cu-IUD or LNG-IUS) inserted immediately after abortion.
3233604|NCT01223521|No Intervention|Control group|Post-abortal contraception is prescribed by the hospital but on the responsibility of the patient.
3233605|NCT01223534|Active Comparator|Arm A, Standard practice, TST|Participants allocated to screening as stablished by current practice (TST)
3331994|NCT02109354|Placebo Comparator|Tetanus and HBV Vaccines|Participants will receive a tetanus vaccine injection (tetanus toxoid vaccine), followed by 2 injection of a placebo for the experimental canarypox HIV vaccine (placebo for ALVAC-HIV; months 1, 2), than 2 injection of a placebo protein HIV vaccine boost (placebo for AIDSVAX B/E; months 4, 7), followed by a hepatitis B vaccine series (months 7.5, 8.5, 13)
3331995|NCT02109380|Experimental|Bed rest|One week of bed rest.
3331996|NCT02109393|Experimental|MIRT group|"This group underwent a 4-weeks MIRT exploiting the use of a treadmill-plus (treadmill associated with visual cues and auditory feedbacks).~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
3331997|NCT02109393|Experimental|MIRT+Lokomat group|"This group underwent a 4-weeks MIRT involving the use of Lokomat® for 5 days per week in spite of treadmill-plus.~Inclusion criteria: a) diagnosis of idiopathic PSP in accordance to the NINDS-SPSP International Criteria (Litvan et al., 1996), b) age between 55 and 85 c) ability to walk unassisted for at least 6 meters, d) stable dopaminergic drugs dosage in the month preceding the admission to the study. Exclusion criteria: a) any others significant neurological or orthopedic disorders, b) osteoarthritis, osteoporosis, cutaneous lesions and/or other pressure wounds, c) body weight exceeding 135 kg (the weight limit for the use of Lokomat®), respiratory and cardiovascular diseases."
3331998|NCT02109406|Experimental|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
3331999|NCT02109406|Experimental|AZD 2115 Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
3233606|NCT01223534|Experimental|Arm B, Experimental, TST plus QFT-IT|Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.
3233607|NCT01223547|No Intervention|Control group|Participants in this arm continues their usual insulin therapy
3332000|NCT02109406|Placebo Comparator|Placebo MDI|Placebo MDI administered as two inhalations BID
3332001|NCT02109471||corneal opacities|
3332002|NCT02109510|Experimental|Nonintubated sedation anesthesia|nonintubated single port thoracoscopic bullectomy using local anesthesia under sedation Drug: Dexmedetomidine IV loading dose of 1ug/kg for 10 minutes and maintain dosage of 0.3-1 ug/kg/hr, ketamine IV 2-4 mg/kg/hr and intercostal nerve block with 2% lidocaine 2cc Device: facial O2 Mask
3332003|NCT02109510|Active Comparator|Intubated general anesthesia|intubated single port thoracoscopic bullectomy under general anesthesia Drug: propofol 2mg/kg IV , rocuronium 0.6mg/kg IV,1.2-2.4% sevoflurane, N20 50% 02 at fresh gas flow of 4L/min Device: double lumen endotracheal tube intubation
3332004|NCT02109523|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
3332005|NCT02109523|Active Comparator|Usual Care|The usual care group received routine discharge counseling performed by the cardiologists and nurses.
3332006|NCT02109536||Staff Gastroenterologists.|Staff Gastroenterologists ability to recognize loops will be assessed using an magnetic endoscopic imager.
3332007|NCT02109549||Diabetes and metformin|Patients with diabetes mellitus treated with metformin only.
3233608|NCT01223547|Active Comparator|Carb counting|Participants in this arm are taught carb counting
3233609|NCT01223547|Active Comparator|Carb counting and bolus calculator|Participants in this arm are taught carb counting and are provided with an integrated glucose meter and bolus calculator.
3233610|NCT01223586||Regression|Patients with regression of plaque volume by statin
3233611|NCT01223586||Non regression|Patients without regression of plaque volume by statin
3233612|NCT01223612|Experimental|Ranibizumab|Intravitreal injection of ranibizumab
3233613|NCT01223612|Active Comparator|Laser|Modified ETDRS laser
3233614|NCT01223625|Active Comparator|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
3233615|NCT01223625|Active Comparator|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
3233616|NCT01223638||Congenital hypothyroidism|Patient which were diagnosed with congenital hypothyroidism
3233617|NCT01223638||Controls|Patients without any endocrine or hearing problems
3233618|NCT01223651|Active Comparator|CGMS at sea level.|To assess reliability of continuous glucose monitoring system at sea level whilst subject undergo's a hyperinsulinaemic glucose clamp study.
3233619|NCT01223651|Active Comparator|CGMS reliability at simulated 8000 feet.|To assess reliability of continuous glucose monitoring system at a simulated altitude of 8,000 feet whilst the participant undergo's a hyperinsulinaemic glucose clamp study.
3233620|NCT01223664|Active Comparator|Group A(conserved therapy )|Thirty of the enrolled patients were assigned to Group A were received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3233621|NCT01223664|Experimental|Group B (BMSC Transplantion)|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine, as well as bone marrow stem cells transplantation
3233622|NCT01223677|Active Comparator|rumination focused CBT|RFCBT-group. This group training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, group discussion, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
3233623|NCT01223677|Active Comparator|rumination focused CBT (online)|The online training is based on research showing that dysfunctional forms of rumination are characterized by an abstract evaluative style of processing, whereas functional forms of of processing are more concrete and process-focused. The training uses psycho-education, functional analysis, experiential exercises and behavioral experiments to facilitate the shift from dysfunctional ruminative thinking to a more helpful concrete thinking style.
3233624|NCT01223677|No Intervention|No training control group|No training control group. Participants within this condition received no treatment, but only filled out the outcome measures at each measurement period.
3233625|NCT01223690|Placebo Comparator|Placebo|250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
3233626|NCT01223690|Active Comparator|Clarithromycin|1000 mg of clarithromycin diluted in 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
3233627|NCT01223716|Experimental|Perceptual learning|
3332008|NCT02109549||Insulin-diabetes without metformin|Patients with insulin-dependent diabetes mellitus not treated with metformin
3332009|NCT02109549||Controlgroup|The remaining patients serve as control group.
3332010|NCT02109575||Heart Transplant Recipients|Up to 10 cc of blood will be drawn from heart transplant recipients at various time points prior to and after transplant. Blood draw is the only research activity that study participants will undergo. In addition to blood draw, data will be collected from clinical records representing the participant's transplant course such as the medical record, imaging, and biopsy slides with pathology reports.
3332011|NCT02109588|No Intervention|Control|Sedentary pregnant women
3332012|NCT02109588|Experimental|Exercise group|"Supervised physical conditioning program of three 55-60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
3332013|NCT02109601|Active Comparator|Control|Control patients receive iPad tablets during their hospital stay with only LIMITED bedside training from a research assistant on how to access and effectively use their patient portal.
3332014|NCT02109601|Experimental|Intervention|Intervention patient receive iPad tablets during their hospital stay with EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
3332015|NCT02109614|Experimental|Extended release Niacin|Taking 1500-2000mg niacin daily
3233628|NCT01223716|Experimental|Video Game|
3233629|NCT01223716|Experimental|Occlusion Therapy|
3233630|NCT01223729|Experimental|Acetyl-L-Carnitine|
3233631|NCT01223729|Placebo Comparator|placebo|
3233632|NCT01223742|Experimental|ACETYL-L-CARNITINE|
3233633|NCT01223742|Placebo Comparator|placebo|
3332016|NCT02109614|Placebo Comparator|No Naicin|Placebo Comparator arm will be taking 1500mg of placebo daily
3332017|NCT02109627|Experimental|Ficlatuzumab, Cytarabine|"Ficlatuzumab 5-20 mg/kg; intravenous; Days 0, 14, 28, 42; Number of cycles: until progression or unacceptable toxicity develops.~Cytarabine 2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops."
3332018|NCT02109653|Experimental|LGX818|Adult patients, with confirmed diagnosis of BRAF V600E mutant advanced or metastatic NSCLC who have progressed on or after at least one prior systemic anticancer therapy.
3332019|NCT02109666||RA patients treated with Abatacept|RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
3332020|NCT02109679|Experimental|Treatment A|multiple doses BI 187004
3332021|NCT02109679|Experimental|Treatment B|multiple doses BI 187004 + multiple doses metformin
3332022|NCT02109679|Experimental|Treatment C|multiple doses metformin
3332023|NCT02109692|Other|cohort|blood sample : doage of miRNA
3332024|NCT02109705||Alzheimer's Disease|
3332025|NCT02109705||other Dementia|
3332026|NCT02109705||cognitive healthy|
3332027|NCT02109718|Experimental|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with Open Dressing with Petrolatum Jelly
3332028|NCT02109718|Active Comparator|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed with Silver Sulfadiazine Gauze Dressing.
3332031|NCT02109757|Experimental|Software intervention and education|This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.
3332032|NCT02109757|Active Comparator|Education only|This group will not receive software intervention prior to and after one-on-one education, only afterwards.
3332033|NCT02109770||Mother child diads or triads|Families with child affected by genetic anomaly, microdeletion, microduplication, or chromosomal anomaly
3233634|NCT01223755|Experimental|Sirolimus|
3233635|NCT01223755|Active Comparator|conventional therapy|
3233636|NCT01223768|Experimental|Acetyl-L-carnitine|
3233637|NCT01223768|Placebo Comparator|placebo|
3233638|NCT01223781|Experimental|Feedforward stimulation|Prior to any gait condition likely to invoke freez, auditory stimulation is presented
3233639|NCT01223781|Experimental|Feedback stimulation|Once a device identifies freezing, a auditory stimulation is triggered
3233640|NCT01223794||Experimental Group|Fall in higher risk
3233641|NCT01223794||Control Group|Fall in lower risk
3233642|NCT01223807|No Intervention|Control Group|The control group will receive only usual care.
3233643|NCT01223807|Experimental|Diaphragmatic breathing training|The training group will be submitted to a diaphragmatic breathing training program of 4 weeks.
3332034|NCT02109783|Active Comparator|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3233644|NCT01223820|Experimental|Capsaicin|
3233645|NCT01223833||tamoxifen|100 postmenopausal women with early breast cancer treated with tamoxifen in the adjuvant setting
3332035|NCT02109783|Active Comparator|Caffeine 2 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3332036|NCT02109783|Placebo Comparator|Caffeine 0 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
3332037|NCT02109796|Experimental|hemiplegic patient|anodal transcranial direct current stimulation
3332038|NCT02109796|Sham Comparator|patient control|Sham transcranial direct current stimulation
3332039|NCT02109822||CF patients with pulmonary exacerbations|Patients with CF who are hospitalized with a pulmonary exacerbation treated with intravenous antibiotics.
3332040|NCT02109835||Asymptomatic type 2 diabetes|Patients without previous history of coronary artery disease
3332041|NCT02109848||keratoconus|
3233646|NCT01223833||aromatase inhibitors|200 postmenopausal women with early breast cancer treated with an aromatase inhibitor in the adjuvant setting
3233647|NCT01223859|Experimental|intervention|Interstitial soft palate RF surgery
3332042|NCT02109848||post-keratoplasty|
3332043|NCT02109848||post-DSAEK|Descemet's stripping automated endothelial keratoplasty (DSAEK)
3332044|NCT02109861|Experimental|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
3332045|NCT02109861|Experimental|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
3332046|NCT02109861|Experimental|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
3332047|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 5/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3332048|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 15/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3332049|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 50/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3332050|NCT02109874|Experimental|AERAS-404 (mcg H4/nmol IC31) 150/500|"H4 antigen (supplied in 4 different concentrations): 1.0 mL containing H4 antigen at 50, 150, 500, or 1500 mcg/mL in 10 mmol/L tris and 5% glycerol~IC31 Adjuvant (supplied in 1 concentration): 0.8 mL containing IC31 adjuvant at 1250 nmol/mL, in 10 mmol/L tris and 169 mmol/L NaCl"
3332051|NCT02109874|Placebo Comparator|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|Placebo: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl. This is the identical buffer solution in which IC31 is formulated.
3233648|NCT01223872||Routine Patient Care|
3332052|NCT02109887||PCP with true CMV co-infection|
3332053|NCT02109887||PCP with innocent bystander CMV|
3332054|NCT02109887||PCP without any evidence of CMV|
3332055|NCT02109900||Serum Progesteron Levels|
3233649|NCT01223872||Previously-enrolled REACH Clinic Patients|
3332056|NCT02109913|Other|Everolimus plus exemestane|Biomarker study in patients receiving standard treatment
3332057|NCT02109926||Cases: testicular cancer patients|
3332058|NCT02109926||Group A controls|Sperm donors and husbands of women with fertility disorders All controls must have a normal spermogram
3332059|NCT02109926||Group B controls|Husbands of women with a pathological pregnancy
3332060|NCT02109965|Active Comparator|Control|Use midazolam or propofol for sedation
3332061|NCT02109965|Experimental|Dexmedetomidine|Use dexmedetomidine for sedation
3332062|NCT02109978||Responders|Patients with Type 2 diabetes that have been taking a second- or third-line glucose-lowering treatment (Sulphonylurea, DPP-4 inhibitors, GLP-1R agonists, SGLT2 inhibitors, Glitazone or insulin) for at least 4 months.
3332063|NCT02109978||Progressors|Patients with Type 2 diabetes that progressed to requiring insulin treatment ≤10 years from diagnosis or have had no requirement for insulin treatment >10 years from diagnosis.
3332064|NCT02109991|Experimental|CG-100 device|
3332065|NCT02110004|Other|Ablation procedure|Collect intra-cardiac signals
3233650|NCT01223872||New REACH Clinic Patients|
3233651|NCT01223885|Experimental|Camel's milk, Cow's milk allergy|
3233652|NCT01223898|Experimental|Nilotinib|
3233653|NCT01223911|Experimental|A|
3233654|NCT01223911|Placebo Comparator|B|
3332066|NCT02110017|Other|Patients with schizophrenia|"Twenty patients suffering from schizophrenia (DSM-IV-R), with medication and medical care. No recent relapse of the psychotic disease, nor change in medications.~No neurological comorbidity.~After anatomic scans, each subject will go through the fMRI social cognition task."
3332067|NCT02110017|Other|Healthy subjects|"Twenty healthy subjects (no mental or neurological disease)~After anatomic scans, each subject will go through the fMRI social cognition task."
3332068|NCT02110030|Experimental|Transcutaneous nerve stimulation|"The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 15 sessions at a frequency of 80 Hz and with a pulse width of 150 ns.~The group with TENS received electrical stimulation by using an approved electrotherapy device (Endomed 182, Enraf-nonius, Germany). The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2)."
3332069|NCT02110030|Active Comparator|Interferential Currents|The group with Interferential Currents (IC) received a base frequency of 4000 Hz by using the same approved electrotherapy device than the TENS group (Endomed 182, Enraf-nonius, Germany).
3233655|NCT01223924|Experimental|M2ES 7.5-90mg|M2ES dose escalating
3233656|NCT01223924|Placebo Comparator|Placebo|placebo contract
3332070|NCT02110043|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with anodal transcranial direct current stimulation (tDCS)
3332071|NCT02110043|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3332072|NCT02110056|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
3332073|NCT02110056|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3332074|NCT02110082|Experimental|Cohort 1: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
3332075|NCT02110082|Experimental|Cohort 2: Urelumab + Cetuximab|Urelumab every 3 weeks with Cetuximab weekly through Intravenous infusion
3332076|NCT02110134|Experimental|Revlite Laser System with Topical|Revlite Laser System for the Treatment of Melasma and hydroquinone skin care regimen
3332077|NCT02110134|Active Comparator|Topical|Hydroquinone skin care regimen
3332078|NCT02110186|Experimental|Discectomy and dynamic stabilization|Discectomy with posterior dynamic stabilization
3332079|NCT02110186|Active Comparator|Discectomy alone|Discectomy
3332080|NCT02110186|Active Comparator|Discectomy and fusion|Discectomy with internal fixation and fusion
3332081|NCT02110212|Active Comparator|U/S Surgery and CCC|Ultrasound (U/S) cataract surgery and continuous curvilinear capsulorhexis (CCC).
3332082|NCT02110212|Experimental|FS Laser Surgery|For femtosecond laser-assisted cataract surgery (FS Laser Surgery), subjects will receive capsulotomy, lens segmentation and, at investigator discretion, lens softening using the femtosecond laser device.
3332083|NCT02110251|Experimental|Supervised exercise therapy|Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.
3332084|NCT02110251|No Intervention|Walking advice|Standard care and a oral walking advice.
3332085|NCT02110290||Children with Physical Disabilities|This group includes children 8-18 years old participating in an adapted ski/snowboarding program with any type of physical disability, including cerebral palsy, traumatic brain injury, spinal cord injury, and amputation.
3332086|NCT02110303|Experimental|18F-F Positive - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
3332087|NCT02110303|Placebo Comparator|18F-F Positive - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
3233657|NCT01223989|Experimental|group bread|group who received an hypocaloric balanced diet including bread
3332088|NCT02110303|Experimental|18F-F Negative - Ticagrelor|Ticagrelor oral tablets, one (90mg) tablet, twice daily, 12 month duration
3332089|NCT02110303|Placebo Comparator|18F-F Negative - Placebo|Identical placebo, one tablet, twice daily, 12 month duration
3332090|NCT02110316|Other|Bioavailability|1 arm, different dosage form
3332091|NCT02110329|No Intervention|stage II-III colon cancer treated with surgery|stage II-III colon cancer treated with surgery
3332092|NCT02110342|Experimental|Treatment|
3332093|NCT02110355|Experimental|AMG 232 with Trametinib and Dabrabenib|Arm 1 of Part 1 and 2 and Part 3
3233658|NCT01223989|Active Comparator|group without bread|group who received a hypocaloric balanced diet with exclusion of bread
3233659|NCT01224028|Experimental|Tacrolimus group|
3233660|NCT01224028|Placebo Comparator|Placebo|
3332094|NCT02110355|Experimental|AMG 232 with Trametinib|Arm 2 of Part 1 and 2
3332095|NCT02110355|Active Comparator|Trametinib and Dabrafenib|Part 3
3233661|NCT01224041|Experimental|Tacrolimus group|
3233662|NCT01224054||Bypass gastric|The mixed surgery which combine the gastric reduction with some degree of disabsorption
3233663|NCT01224054||Biliopancreatic diversion|The mal-absorptive surgery which reduce the intestinal absorption of food
3332096|NCT02110368|Active Comparator|AndroGel|AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg
3233664|NCT01224054||Duodenal exclusion|This surgery provides disabsortion by duodenal derivation maintaining an intact stomach
3233665|NCT01224067|Active Comparator|Quetiapine|Quetiapine (dosage 50mg to 300mg + sertraline)Experimental
3332097|NCT02110368|Experimental|Testosterone Gel|Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.
3233666|NCT01224067|Placebo Comparator|Placebo|Participant will receive placebo for 8 weeks.
3332098|NCT02110394||bendamustine and rituximab|
3233667|NCT01224080|Experimental|Adiana Device|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
3233668|NCT01224093||First line|
3233669|NCT01224093||Relapsed/refractory|
3259200|NCT01468389|Experimental|chemotherapy followed by capecitabine alone|The patients who has received 4 cycle chemotherapy combining capecitabine with platinum or taxanes and the result was SD or CR or PR,will be given capecitabine alone until progression.
3332099|NCT02110407|Sham Comparator|training + sham stimulation|Combination of intensive training of visual-spatial abilities (LOCATO task) with sham stimulation
3332100|NCT02110407|Experimental|training + tDCS|Combination of intensive training of visual-spatial abilities (LOCATO task) with transcranial direct current stimulation (tDCS)
3332101|NCT02110420|Experimental|CC-90001 10mg (Single Dose)|
3332102|NCT02110420|Experimental|CC-90001 30mg (Single Dose)|
3332103|NCT02110420|Experimental|CC-90001 60mg (Single Dose)|
3332104|NCT02110420|Experimental|CC-90001 120mg (Single Dose)|
3332105|NCT02110420|Experimental|CC-90001 240mg (Single Dose)|
3332106|NCT02110420|Experimental|CC-90001 10mg (Multiple Doses)|
3332107|NCT02110420|Experimental|CC-90001 30mg (Multiple Doses)|
3332108|NCT02110420|Experimental|CC-90001 60mg (Multiple Doses)|
3332109|NCT02110420|Experimental|CC-90001 120mg (Multiple Doses)|
3332110|NCT02110420|Experimental|CC-90001 240mg (Multiple Doses)|
3332111|NCT02110420|Experimental|Placebo|
3233674|NCT01224119|Experimental|Amplex (synthetic bone graft)|
3332112|NCT02110420|Experimental|CC-90001 480mg (single dose)|CC-90001 480mg will be administered as a single oral dose
3332113|NCT02110420|Experimental|CC-90001 720mg (single dose)|CC-90001 720mg will be administered as a single oral dose
3332114|NCT02110420|Experimental|CC-90001 480mg (multiple doses)|CC-90001 480mg will be administered daily for 14 days
3332115|NCT02110433|Other|Placebo group|Patients will be managed per consensus guidelines Clinicians could see the patients as many times as necessary in order to optimize their therapy and could make BNP measurement (but not using Home BNP monitoring)
3332116|NCT02110433|Experimental|Cordiva System (R)|Patient will see their cardiologist every three months and benefit from telemonitoring of their weight and general well being through a specific communicant device.
3332117|NCT02110433|Active Comparator|BNP and Cordiva (R) monitoring system|In this group, patients and doctors have access to the platform detailed above (Cordiva (R) monitoring system) and had also access to BNP home monitoring (BNP heartcheck).
3332118|NCT02110446|Experimental|SS-1|SS-1 is composed of the powder of Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. Patients take 6 gram of experiment medicine three times per day.
3332119|NCT02110446|Placebo Comparator|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
3332120|NCT02110459|Experimental|Mild renal impairment|3h IV POL7080 infusion
3332121|NCT02110459|Experimental|Moderate renal impairment|3h IV POL7080 infusion
3332122|NCT02110459|Experimental|Severe renal impairment|3h IV POL7080 infusion
3332123|NCT02110459|Experimental|End stage renal disease arm 1|3h IV POL7080 infusion
3332124|NCT02110459|Experimental|End stage renal disease arm 2|3h IV POL7080 infusion
3233675|NCT01224119|Active Comparator|Autograft bone|
3233676|NCT01224132|No Intervention|Probiotics|
3332125|NCT02110459|Experimental|Normal Renal function|3h IV POL7080 infusion
3332126|NCT02110472|Other|Presbia Flexivue Microlens Corneal Inlay|Presbia Flexivue Microlens implanted in corneal pocket in nondominant eye
3332127|NCT02110511|Experimental|alpha-gal & blended lentils|3 capsules of alpha-gal taken with blended lentils
3332128|NCT02110511|Experimental|alpha-gal & whole lentils|3 calpsules of alpha-gal taken with whole lentils
3332129|NCT02110511|Experimental|alpha-gal & no lentils|3 capsules of alpha-gal taken with no lentils control
3332130|NCT02110511|Placebo Comparator|Placebo & blended lentils|3 capsules of placebo taken with blended lentils
3233677|NCT01224132|No Intervention|skim milk powder, dextrose|
3233678|NCT01224184|Active Comparator|Nutrition|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
3332131|NCT02110511|Placebo Comparator|Placebo & whole lentils|3 capsules of placebo taken with whole lentils
3332132|NCT02110511|Placebo Comparator|Placebo & no lentils|3 capsules of placebo taken with no lentils control
3332133|NCT02110524|Experimental|CVI Drug Coated Balloon|
3233679|NCT01224184|Experimental|Young Women's|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (Principal Investigator (PI): Dr. Wendee M. Wechsberg).
3332134|NCT02110537|Experimental|Active Acupuncture + flecainide|The participants in this group receive verum acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
3332135|NCT02110537|Sham Comparator|Sham acupuncture + flecainide|The participants in this group receive sham acupuncture treatment once a week for 10 weeks and flecainide 75 mg twice daily.
3332136|NCT02110550|No Intervention|IPS.emmax crown|
3332137|NCT02110550|Experimental|IPS.emmax endocrown|Patients with excessively undermined and endodontically treated molars will receive the IPS.emmax endocrown as the restoration of choice.
3332138|NCT02110563|Experimental|DCR-MYC|Patient groups (cohorts) will receive a single dose level of DCR-MYC; the dose level of DCR-MYC will be increased in subsequent cohorts
3332139|NCT02110576||Healthy Controls|Healthy controls in general good health, without chronic disease/illness, including but not limited to: cancer, diabetes mellitus, renal disease, cardiac disease, hypertension, lung disease, liver disease, complications of morbid obesity, autoimmune/inflammatory disease, or any condition of sufficient severity that it requires daily medication to manage
3332140|NCT02110589|Experimental|Patient Group 1|"Testing of Epidetect:~Adult Patients with difficult to control tonic-clonic (convulsant) epilepsy undergoing hospitalised video telemetry monitoring. Patients will be hospitalised as part of their normal investigation of the epilepsy and patients will be consented 1 week before hospitalisation. Epidetect will be used in conjunction with the normal EEG monotoring and video telemetry. The patient will be fitted with the topical sensors at the start of monotoring and then depending on the seizure activity will wear the sensors until enough data is gathered. Hospitalisation under these circumstances typically lasts no more than five days, so monitoring with the topical sensor will be no longer than this."
3332141|NCT02110589|Experimental|Patient Group 2|"Testing of Epidetect:~Paediatric patients (over 7 years) where parental consent will enable the epilepsy monitor to be used at home for 1 week and brought back in for analysis along with video evidence. This will not constitute any change in normal care or treatments, and the video evidence provided represents enhanced care through accurate seizure diary reporting. Suitable families and children will be selected and consented through scheduled clinics in paediatric neurology."
3332142|NCT02110589|Experimental|Patient group 3|"Testing of Epidetect:~Patients where the epilepsy is suspected to be psychogenic (pseudo-seizures) rather than organic epilepsy. We will test whether the epilepsy monitor will be able to differentiate between epilepsy and psychogenic seizures in the medical setting when patients are hospitlised for seizure investigation. Suitable patients will be selected and consented through scheduled clinics in paediatric neurology (under 16) and adult neurology."
3332143|NCT02110589|Experimental|Patient Group 4|"Testing of Epidetect:~Internal negative Controls. Juveniles or adults with other forms of epilepsy that do not have a hypertonic (increased muscle stiffening) phenotype e.g. absence seizures."
3332144|NCT02110589|Other|Control Group 1|"Testing of Epidetect:~Volunteers who do not have a history of seizures / epielsy, head trauma, migraine, neurological or muscular-skeletal disorders. This is to produce the baseline data for the Monitor."
3332145|NCT02110602|Experimental|Initial Diet - high in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin high amino acid diet~Visit 3 (4 days after Visit 2): Completion of high amino acid diet~Visit 4 (3 days after Visit 3): Begin low amino acid diet~Visit 5 (4 days after Visit 4): Completion of low amino acid diet, completion of study"
3332146|NCT02110602|Experimental|Initial Diet - low in amino acid levels|"Visit 1 (Day 1): Screening Visit~Visit 2 (14-21 days after Visit 1): Begin low amino acid diet~Visit 3 (4 days after Visit 2): Completion of low amino acid diet~Visit 4 (3 days after Visit 3): Begin high amino acid diet~Visit 5 (4 days after Visit 4): Completion of high amino acid diet, completion of study"
3332147|NCT02110615|Experimental|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
3332148|NCT02110628|Experimental|Roux-en-Y+Pouch Group|Abdominal approach D2 total gastrectomy with Roux-en-Y+Pouch anastomosis. Roux-en-Y+Pouch anastomosis: closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, pouch reconstruction a J pouch with a length of 15 cm was constructed by connecting the 2 Jejunal lumina, œsophago-P type jejunum Storage bag anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm.
3332149|NCT02110628|Experimental|Roux-en-Y group|Abdominal approach D2 total gastrectomy with Roux-en-Y anastomosis. Roux-en-Y anastomosis : closed the stump of duodenum, cut off the jejunum from the 20cm of Treitz ligament, œsophago-jejunal anastomosis (duct-to-duct / duct-to-duct, before the colon/after the colon), jejunum - jejunum anastomosis (duct-to-duct / duct-to-duct), the distance between anastomotic were 40cm-60cm
3332150|NCT02110641|Active Comparator|In-Person or Telephone-Based Counseling|The exact same information, content, schedule, and 30 minute sessions will be provided to telephone-based participants as offered to participants who receive in-person counseling. Participants will be taught diet, exercise and behavior change strategies via the telephone (weekly calls for month 1, every other week for months 2-3, and monthly for months 4-6). All lessons and diet and physical activity logs will be mailed to them at the beginning of the program. Participants will record their daily diet and exercise in the logs.
3332151|NCT02110641|No Intervention|Usual Care/Wait List|At 6-months the participants in the Wait List group may choose to participate in the 11 sessions either in-person or via telephone or a combination of the two modes of delivery. They will also be offered the opportunity to return to Yale at 12-months (immediately after the end of the 6-month counseling sessions) to have weight and DEXA measured.
3332152|NCT02110654|Active Comparator|mometasone furoate nasal spray|mometasone furoate nasal spray,200ug qd, 6 months
3332153|NCT02110654|Experimental|mometasone furoate nasal spray combined with montelukast|montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months
3332154|NCT02110667||Prostate cancer, post-prostatectomy|
3332155|NCT02110680|Active Comparator|TENS 1|TENS at posterior tibial nerve area
3233680|NCT01224197|Experimental|001|TMC435 100 or 200 mg capsule one single dose
3233681|NCT01224197|Experimental|002|TMC435 100 or 200 mg capsule once daily for 5 days
3233682|NCT01224223||acute asthma exaecerbtion patients|Patients experiencing acute exacerbation of their asthma
3233683|NCT01224223||chronic asthma group|Two groups are being enrolled. The first group is chronic asthma patients with FEV1 below 80% and FEV1/FVC ratio reduced by 5%
3233684|NCT01224249|Active Comparator|Fish and shellfish|
3233685|NCT01224249|No Intervention|Control|Assessment only
3233686|NCT01224262|Experimental|Fluzone + 0.45 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg)
3233687|NCT01224262|Experimental|Fluzone + 1.8 mg LIQ001|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg)
3233688|NCT01224262|Active Comparator|Fluzone|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
3332156|NCT02110680|Sham Comparator|TENS 2|TENS at shoulder area
3332157|NCT02110719|Active Comparator|Standard|"Patients will be given the following:~no preoperative medications~intraoperative medications per anesthesia~postoperatively, patients will receive ibuprofen, tylenol and narcotics as needed"
3233689|NCT01224275|Experimental|Group antenatal care|The first arm is midwife which allocated to group based antenatal care. They have education in this model of care and follow up meeting to secure the intervention
3233690|NCT01224275|No Intervention|Individual antenaal care|the second arm include midwife which allocated to traditional care as control group.
3332158|NCT02110719|Active Comparator|Multimodal|"Patients in the multimodal arm will receive the following:~preoperative celebrex and gabapentin~intraoperative IV acetaminophen, dexamethasone, zofran~postoperative scheduled IV acetaminophen, PO celebrex and gabapentin, and as needed PO narcotics~patient will be discharged on scheduled ibuprofen and acetaminophen for 3 days followed by as needed use as well as as needed narcotics"
3332159|NCT02110745|Experimental|Sevofluorane|Sevofluorane 8% in induction
3332160|NCT02110745|Experimental|Propofol|Propofol 2.5 mg/kg intravenous in induction
3332161|NCT02110771|Experimental|GAÏA - facial affect recognition targeted|"GAÏA:20hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment cognitive remediation targeted on facial affects recognition. exercises were designed by Gaudelus and Franck (2012) and tutoractiv'company. It includes photos, computer and role games exercises.Computer based exercises have 5 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcomes associated with facial affects recognition impairment."
3332162|NCT02110771|Active Comparator|RECOS - attentional process targeted|"RECOS (Cognitive REmediation for Schizophrenia): 20 hours individual cognitive remediation with therapist, 10 tasks at home, 10 week-treatment.~RECOS is a validated cognitive remediation program, developed by P. Vianin and SBT company. It includes paper and pen and computer based exercises. The original program proposes 5 modules targeting 5 cognitive functions, each patient participated in the module corresponding to his/her most altered cognitive function. In this study, all patients randomized in this arm are allocated in the attentional module.Every computer exercises have 10 difficulty levels.~2 sessions of one hour per week with therapist.~Tasks at home are given once a week and targeting functional outcome"
3332163|NCT02110784|Experimental|Eurartesim tablets|Eurartesim 320 mg piperaquine / 40 mg dihydroartemisinin film coated tablets. one or more tablets according to the body weight, once a day dor three consecutive days.
3332164|NCT02110797|Other|RETT patients|
3332165|NCT02110810|Experimental|Indomethacin|100 mg of Indomethacin suppository immediately afterwards while still under sedation
3332166|NCT02110810|Placebo Comparator|2.6-g suppository of glycerin|suppository of 2.4 g of glycerin immediately afterwards while still under sedation
3332167|NCT02110836|Active Comparator|Glucose ingestion|Glucose ingestion during exercise at a rate of 1.8 g/min.
3332168|NCT02110836|Experimental|Sucrose ingestion|Sucrose ingestion during exercise at a rate of 1.8 g/min.
3332169|NCT02110849||Prostate Cancer Patients|Prostate cancer patients who received proton radiation therapy
3332170|NCT02110862||Ulcerative colitis patients with ileal-pouch-anal anastomosis|
3332171|NCT02110875||CONTROLS|Age- and Gender-Matched Controls
3332172|NCT02110888|Experimental|SCS + PNS|Mutlticolumn SCS lead + Monocolumn SCS lead
3332173|NCT02110888|Active Comparator|SCS|Mutlticolumn SCS lead
3332174|NCT02110914|Experimental|Coaching|10 coaching sessions over a period of 6 - 9 months. The intervention is life coaching based on principles of the co-active coaching model.
3332175|NCT02110914|No Intervention|Control|Standard care
3332176|NCT02110927|Experimental|Transcutaneous microcurrent|This group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 milliampere (mA). Every 20 minutes changed from 25 hertz (Hz) to 10 Hz
3332177|NCT02110927|Placebo Comparator|Control group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
3332178|NCT02110940|Active Comparator|Conservative Physiotherapy|Subjects will be referred to the physiotherapy department to receive conventional physiotherapy treatment.
3233691|NCT01224288|Experimental|DCE-CT Scans|DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
3233692|NCT01224301|Experimental|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have access to school-based flu vaccine clinics and 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
3332179|NCT02110940|Experimental|Neurodynamic mobilization exercise|"The experimental group will be given three neurodynamic mobilization exercises which focus more on lower limbs and the major innervating cutaneous nerves - saphenous nerve, sciatica nerve and femoral nerve.~Subjects will be instructed to practice everyday, each action repeat for 10 times."
3233693|NCT01224301|Experimental|School based flu vaccine: Low intensity|Interventions: Parents in low intensity schools have access to school-based flu vaccine clinics and less than 3 communications from schools about influenza illness, influenza vaccine, and school based clinics.
3332180|NCT02110953|Experimental|Treatment (irinotecan-eluting beads)|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for a total of 2 treatments in the absence of disease progression or unacceptable toxicity. Patients with bi-lobular disease and no evidence of progression in the treated lobe may repeat treatment at the discretion of the treating physician.
3332181|NCT02110966|Experimental|Mepivacaine plus Tramadol|1.3 ml of Mepivacaine 2% epinephrine 1:100000 mixed with 0.5 ml of Tramadol (50mg/ml) will be used for the anesthetic blockade in the experimental group
3233694|NCT01224301|No Intervention|Standard of Care|Control Schools did not have any in school seasonal influenza vaccine clinics. Parents of children in control schools got no notification from the schools and sought seasonal influenza vaccines for their children as they normally would.
3233695|NCT01224314|Active Comparator|dialysis fluid potassium high|potassium concentration in the dialysis fluid 1 mmol/L higher than usual
3332182|NCT02110966|Active Comparator|Mepivacaine|The control group will receive the inferior alveolar nerve block using 1.8 ml of Mepivacaine 2% epinephrine 1: 100000.
3332183|NCT02110979|Experimental|PDA|Subjects receive an internet-based patient decision aid video. The PDA is viewed outside of the doctor's office via a personal computer in preparation for regularly scheduled face to face interaction between patients and clinicians.
3332184|NCT02110979|No Intervention|Usual care|Patients receive usual care as determined by their clinician.
3332185|NCT02110992|Experimental|Docetaxel + Stereotactic Radiation|Docetaxel 15mg/m2 IV weekly for 3 weeks. SBRT 25-40 Gy in 5 fractions given twice weekly with each treatment separated by > 48 hours.
3332186|NCT02111005||Smoking Aggressive Periodontitis group|This group comprises 20 patients who are smokers and aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
3332187|NCT02111005||Smoking Chronic Periodontitis group|This group comprises 20 patients who are smokers and aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
3332188|NCT02111005||Non-smoking Aggressive Periodontitis grp|This group comprises 20 patients who are age- and sex- matched to the 'Smoking Aggressive Periodontitis group' and are non-smokers suffering from aggressive periodontitis.
3332189|NCT02111005||Non-smoking Chronic periodontitis grp|This group comprises 20 patients who are age- and sex-matched to the 'Smoking Chronic Periodontitis group' and are non-smokers suffering from chronic periodontitis.
3332190|NCT02111018|Active Comparator|CVVH|
3332191|NCT02111018|Experimental|CytoSorb Device|
3332192|NCT02111031||Case|Patients with documented (histologically/pathologically confirmed) mBC diagnosis, at lease 65 years of age at documented mBC diagnosis, and actively treated by a physician at a participating cancer center who routinely (i.e., test at lease every quarter) use CTC testing (excluding patients who sought consults or second opinions).
3332193|NCT02111044|Active Comparator|Octreotide|Octreotide 100 mcg sc three times daily (t.i.d) for 4 weeks
3332194|NCT02111044|Experimental|ITF2984 500 mcg|ITF2984 500 mcg sc twice a day (b.i.d) for 4 weeks
3332195|NCT02111044|Experimental|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
3332196|NCT02111044|Experimental|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
3332197|NCT02111057||Perioperative RA|Patients with Rheumatoid Arthritis undergoing a primary or secondary total hip replacement, between the ages of 18 and 90.
3332198|NCT02111070|Experimental|ILYANG Inactivated split influenza vaccine|IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection
3332199|NCT02111109||Traumatic injury|
3332200|NCT02111122|Experimental|Sodium Oxybate|"Treatment (500mg Natrii oxybas/ml) will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. The dosage starts at 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
3332201|NCT02111122|Placebo Comparator|Placebo|"Treatment will be administered every day at night time for 6 weeks each orally by the patient itself. If necessary, the investigator will make sure that a relative or caregiver is able to assist in daily treatment administration. As with the active compound, placebo will be given with a starting dose of 3g per night and is adapted in steps of 1.5g during visits and telephone screenings and always noted in the medication log-book. The maximal dosage is 9g per night."
3332202|NCT02111135|Experimental|Group 1|b-OPV, m-IPV HD and m-OPV2
3332203|NCT02111135|Active Comparator|Group 2|b-OPV, t-IPV and m-OPV2
3332204|NCT02111148|Active Comparator|urea and creatinine|urea and creatinine detected in vaginal fluid wash after injecting of 5 ml saline intavaginally
3332205|NCT02111148|Active Comparator|Nitrazine|Biochemical description of Nitrazine in the vaginal wash
3332206|NCT02111148|Active Comparator|saline|5ml saline will be injected in vagina of each patient in both groups within 24 hours of membrane rupture.
3332207|NCT02111161|Active Comparator|IVIG (Privigen)|Intravenous polyspecific immunoglobulin G (Privigen). Dosage: 25 g/day (250 ml) for three consecutive days
3332208|NCT02111161|Placebo Comparator|Saline 0.9%|0.9% saline for Intravenous administration. Dosage: 250 ml for three consecutive days.
3332209|NCT02111226|Active Comparator|Passive SMS Group|Passive SMS messages focused on lifestyle adjustment
3332210|NCT02111226|Experimental|Active SMS Group|Active SMS messages based on hypertension clinical practice guidelines including rational for taking antihypertensive medication and reminders to see the health care practioner if BP is above target.
3332211|NCT02111239|No Intervention|No imaging|No preoperative imaging is performed for this group
3233696|NCT01224314|Active Comparator|dialysis fluid potassium low|potassium concentration in the dialysis fluid 1 mmol/L lower than usual
3332212|NCT02111239|Experimental|CTA|Patients randomized to this group will undergo a preoperative CTA scan.
3332213|NCT02111239|Experimental|MRA|Patients randomized to this group will undergo a preoperative MRA scan.
3332214|NCT02111265|Experimental|Propofol|Target controlled infusion propofol, the effect compartment concentration is 3-4μg/ ml for induction and maintenance of anesthesia.
3332215|NCT02111265|Experimental|Etomidate|Target controlled infusion etomidate, the effect compartment concentration is 0.5-1.0μg/ ml for induction and maintenance of anesthesia.
3332216|NCT02111278|Experimental|lumbar Manipulation|Patients randomized to this treatment group will receive lumbar manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
3332217|NCT02111278|Placebo Comparator|Sham Manipulation|Patients randomized to this treatment group will receive a sham manipulation during the first 2 physical therapy visits. Patient will receive 4 weeks of physical therapy 2 visits per week.
3332218|NCT02111291|Experimental|SANTYL®|
3332219|NCT02111291|Sham Comparator|Supportive Care|
3332220|NCT02111304|Active Comparator|Part A (Adults)|In Part A, approximately 170 adult patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 500 mg or placebo TID for up to 3 days
3233697|NCT01224327|Experimental|umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
3233698|NCT01224327|Active Comparator|Conserved therapy|Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3233699|NCT01224340|Experimental|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
3233700|NCT01224340|Experimental|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path. The player got points for collected fishes but also credits for time of flying and speed.
3233701|NCT01224340|Experimental|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
3332221|NCT02111304|Active Comparator|Part B (Pediatric)|"Following completion of Part A, the data and safety monitoring board (DSMB) will review the unblinded data to assess safety and efficacy and conduct a futility analysis prior to proceeding to Part B.~Following the DSMB recommendation of dose and dosing schedule for pediatric patients, Part B will be initiated. Approximately 156 pediatric patients with severe dehydrating diarrhea due to cholera will be enrolled and randomized 1:1 to receive iOWH032 or placebo at the recommended dose and dosing regimen."
3332222|NCT02111317|Experimental|ASP015K and verapamil|Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
3332223|NCT02111330|Experimental|Dose I - 80 mg PBF-509|one 80 mg PBF-509 capsule
3332224|NCT02111330|Placebo Comparator|Dose I - Placebo|one Placebo capsule
3332225|NCT02111330|Experimental|Dose II - 160 mg PBF-509|Two 80 mg PBF-509 capsule
3233702|NCT01224353|Placebo Comparator|Thioctacid Oral Placebo Tablet|
3233703|NCT01224353|Active Comparator|Thioctacid Oral Tablet|
3233704|NCT01224366|Experimental|Vildagliptin|
3233705|NCT01224366|Placebo Comparator|Placebo|
3233706|NCT01224379|Other|"Arm1: topping off system"|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
3332226|NCT02111330|Placebo Comparator|Dose II - Placebo|Two Placebo capsule
3332227|NCT02111330|Experimental|Dose III - 240 mg PBF-509|three 80 mg PBF-509 capsule
3332228|NCT02111330|Placebo Comparator|Dose III - Placebo|Three Placebo capsule
3332229|NCT02111343|Experimental|Computer-based auditory training (CBAT)|The CBAT programmes in the current study were specifically designed to improve speech-in-noise and dichotic listening skills of children diagnosed with CAPD. All the training programmes were designed to be installed on home-user's computer, and they were visually attractive and appealing to children. The development of the software (non commercial) for the speech-in-noise and dichotic listening training was done by two different teams in the United Kingdom and Singapore, respectively.
3332230|NCT02111343|No Intervention|Control|No intervention other than participants' regular school activities
3332231|NCT02111356|Experimental|Pinhole glasses|All subjects perform ophthalmic examinations before and after the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
3332232|NCT02111382|Experimental|CV4 (4th ventricle technique) technique|Will be conduced a real cranial osteopathic medicine technique.
3332233|NCT02111382|Sham Comparator|CV4 sham|This group will received only a sham manual therapy technique.
3332234|NCT02111382|No Intervention|Control|The participants will be in supine position for 5 minutes without any visual or verbal contact.
3332235|NCT02111408||Acute stroke|No interventions. Only tests for depression, sleepapnea and autonomic dysfunction.
3332236|NCT02111421|Experimental|parturients|Parturients after the umbilical cord was clapped in cesarean section were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
3332237|NCT02111421|Experimental|nonpregnant women|Nonpregnant women were accepted an initial dose of 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points.
3332238|NCT02111434|Experimental|testosterone|testosterone gel per day for 6 months testosterone 250 mg injection per 3-4 weeks for 6 months
3332239|NCT02111460|Experimental|Radiotherapy|Systemic Chemotherapy Combined with Loco-regional Radiotherapy
3332240|NCT02111460|Active Comparator|Chemotherapy|Chemotherapy alone without Loco-regional Radiotherapy
3332241|NCT02111473|Other|testosterone|testosterone 250 mg injection per 3-4 weeks for 6 months
3332242|NCT02111486|Experimental|breakfast #1|breakfast food containing high viscosity fibre
3332243|NCT02111486|Experimental|breakfast #2|breakfast food containing low viscosity fibre
3332244|NCT02111486|Placebo Comparator|Control|breakfast food without viscous fibre
3332245|NCT02111499|Experimental|formulation 1|topical treatment, once daily for 4 weeks
3332246|NCT02111499|Experimental|formulation 2|topical treatment, once daily for 4 weeks
3233707|NCT01224379|Other|Arm 2: monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
3233708|NCT01224392|Active Comparator|Concomitant chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
3233709|NCT01224392|Experimental|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
3233710|NCT01224405|Active Comparator|Treatment arm|ten docetaxel cycles + maintenance androgen deprivation.
3233711|NCT01224405|Experimental|suspension arm|Ten Docetaxel cycles + stop androgen deprivation therapy
3233712|NCT01224405|Experimental|intermittent arm|Intermittent Docetaxel
3233713|NCT01224405|Active Comparator|Continuous arm|Continuous Docetaxel
3233714|NCT01224418|Experimental|Tacrolimus group|
3233715|NCT01224470|Active Comparator|bupivacaine|0.5% bupivacaine 1.2 mL + normal saline 0.8 mL = total 2 mL
3332247|NCT02111499|Experimental|formulation 3|topical treatment, once daily for 4 weeks
3332248|NCT02111499|Experimental|formulation 4|topical treatment,once daily for 4 weeks
3332249|NCT02111499|Placebo Comparator|formulation 5|topical treatment, once daily for 4 weeks
3332250|NCT02111499|Active Comparator|formulation 6|topical treatment, once daily for 4 weeks
3332251|NCT02111512|Other|Egg allergic children|Children with a physician diagnosis of egg allergy will be recruited to receive the intranasal LAIV as part of a safety surveillance study
3332252|NCT02111538||Amyloidosis|Consecutive adult patients affected by systemic immunoglobulin light-chain (AL) amyloidosis
3332253|NCT02111551|Experimental|DMXB-A 75 mg|DMXB-A 75 mg dose followed by a second dose of 37.5 mg at 2 hours to maintain the blood level
3332254|NCT02111551|Experimental|DMXB-A 150 mg|DMXB-A 150 mg followed by a second dose of 75 mg at 2 hours to maintain the blood level
3332255|NCT02111551|Placebo Comparator|Sugar Pill|placebo comparator dose followed by a second placebo dose at 2 hours to maintain blind
3332256|NCT02111590||IVIG to SCIG|Patients with CIDP or MMN in maintenance therapy with IVIG every 3rd to 6th week are shifted to weekly SCIG treatment in unaltered dose.
3332257|NCT02111590||SCIG to SCIG|Patients with CIDP or MMN in maintenance therapy with SCIG (Subcuvia(R) or Hizentra(R)) are shifted to treatment with Gammanorm(R) in unaltered weekly dose.
3233716|NCT01224470|Placebo Comparator|saline|
3233717|NCT01224496|Experimental|Treatment with Chinese herbal concoction|"Patients must have a marrow study to confirm diagnosis of MDS, AA or MF. MDS is classified according to the WHO criteria and scored according to IPSS. The AA group is further classified into AA, SAA or VSAA . MF is defined by the Italian criteria and risk stratified by the Lilles Scoring system. Diagnosis of thal intermedia and major is based on previously done Hb electrophoresis and severity of disease is assessed by degree of anaemia.and frequency of blood transfusions~TCM diagnosis: Syndrome differentiation according to TCM theory will be assessed as a baseline by experienced TCM collaborators and classified into one of the few defined syndromes as follows~Yin deficiency of spleen and kidney~Yang deficiency of spleen and kidney~Deficiency of both Yin and Yang~Stagnation of dampness and poison in the blood~Excessive heat and poison"
3332258|NCT02111616|Active Comparator|Standard of Care (SCP)|Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.
3332259|NCT02111616|Experimental|Intervention Arm (SCP + PCP visit)|"Patient will attend a transition visit at the conclusion of cancer treatment. Patient will receive an individualized cancer survivorship care plan based on their cancer type and treatment.~SCP plus Coordinated PCP Visit: Care coordinators will schedule patient appointment with PCP within 4 weeks of treatment."
3332260|NCT02111629|Experimental|Fluconazole and Secnidazole|
3332261|NCT02111642|Experimental|Online risk calculator used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence used during preoperative counseling session.
3332262|NCT02111642|Placebo Comparator|Online risk calculator not used|Online risk calculator tool for the development of postoperative de novo stress urinary incontinence not used during preoperative counseling session.
3332263|NCT02111655|Other|Clasical Surveillance of AVF|"Classical evaluation of AVF includes:~Vital sings and predialysis physical examination of AVF every dialysis session.~Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session.~Weekly ktv test using biosensors or monthly if using monocompartimental Daugirdas equation.~Quarterly recirculation with urea method.~Following Spanish Nephrology VA guidelines will be consider as alarm criteria:~1.25% Increased venous pressure. 2.25% Decreased pump blood flow. 3.0,2 ktv decreased compared with previous measurement. 4.> 10% recirculation using urea method. 5.Prolonged coagulation time or cannulation difficulties in 3 consecutive dialysis sessions.~6.Pathologic physical examination with any other criteria."
3332264|NCT02111655|Experimental|Second generation surveillance of AVF|"In addition to the classical surveillance and monitoring methods, in the experimental group Doppler ultrasound and transonic dilution method will be performed on a quarterly basis.~In addition to the classical alarm criteria and derived from the results in Doppler ultrasound an transonic dilution method the following alarm criteria would also be considered in the experimental group:~25% or higher decreased in QA compared with previous measurement.~QA lower than 500 ml/min.~Stenotic area with a higher than 50% reduction of blood vessel lumen would be considered as alarm criteria only if it comes with a haemodynamic repercussion criteria defined as Peak systolic velocity (PSV) higher than 400 cm/sc, aliasing, or PSV ratio stenosis/pre-stenosis higher than 3."
3332265|NCT02111681|Experimental|Calypso-based Deep Inspiration Breath Hold (DIBH)|"This trial will investigate the feasibility of implanted anchored Beacon ® electromagnetic lung transponders (Calypso ®) to guide and monitor deep-inspiration breathhold (DIBH) treatments in patients with inoperable thoracic malignancies.~Bronchoscopic Calypso Beacon Implantation, Simulation - Free-breathing scan - 4D CT scan,- DIBH CT scan Radiation - Treatment setup, - Calypso signal recording, - RT treatment with DIBH with or without visual biofeedback Follow-up - 3 and 6 months after RT with diagnostic CT chest"
3332266|NCT02111694|Experimental|Clear versus Opaque Bottle|This is a within-subject study; all infants will be exposed to both conditions. Order of presentation will be counterbalanced across infants.
3332267|NCT02111707|Active Comparator|Rectal Indomethacin pre-ERCP|Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
3332268|NCT02111707|Active Comparator|Rectal Indomethacin post-ERCP|Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)
3332269|NCT02111720|Experimental|Maybe, Maybe Not|The intervention is an individual-level 4-session + 3 month booster series designed to assist persons with HIV in making decisions regarding the disclosure of their HIV serostatus to family members.
3332270|NCT02111720|Active Comparator|Comprehensive Risk Counseling and Services|Comprehensive Risk Counseling and Services (CRCS) will be used to provide the attention-placebo control (CDC, 2006). CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.
3332271|NCT02111733|Experimental|Hs-TnT|Hs-TNT dosage
3332272|NCT02111759|Other|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
3332273|NCT02111759|Other|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
3332274|NCT02111824|Experimental|Group 2|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
3233718|NCT01224509|Experimental|Mifepristone|
3233719|NCT01224509|Active Comparator|Non-treatment|
3233720|NCT01224522|Experimental|Visionaire|the group who will be operated by the use of Visionaire patient matched cutting blocks
3233721|NCT01224522|Active Comparator|Standard Surgical technique|The group who will be operated by means fo standard surgical technique
3233722|NCT01224535|Experimental|Maize porridge with Amaranth|Maize porridge enriched with amaranth grain flour at 70:30 maize/amaranth ratio (80g/day)
3332275|NCT02111824|Experimental|Group 3|During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
3332276|NCT02111824|No Intervention|Group 1|Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.
3332277|NCT02111837|Placebo Comparator|Standard infant formula|Standard infant formula fed ad libitum
3332278|NCT02111837|Experimental|Standard infant formula with PL1|Standard infant formula enriched with PL1 lipid fraction fed ad libitum
3332279|NCT02111837|Experimental|Standard infant formula with PL2|Standard infant formula enriched with PL2 lipid fraction fed ad libitum
3332280|NCT02111850|Experimental|1/Phase I Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
3332281|NCT02111850|Experimental|2/Phase II Experimental Therapy|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine + Anti-MAGE-A3-DP4 TCR PBL + high-dose aldeskin
3332282|NCT02111876||AHRF follow-up|
3332283|NCT02111889|Experimental|one|
3233723|NCT01224535|Active Comparator|Maize flour with multiple micronutrients|Maize porridge fortified with a multiple micronutrient powder (MixMe™)
3233724|NCT01224535|Placebo Comparator|Maize Porridge|Plain maize porridge group
3332284|NCT02111915|Other|Enhanced Usual Care (EUC)|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services
3332285|NCT02111915|Experimental|THPP-P|Trial participant s who are in the THPP group will receive, in addition to EUC, 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
3332286|NCT02111928||NovaTears®|
3332287|NCT02111941|Experimental|Treatment (vaccine therapy)|"INDUCTION PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 weeks for 5 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE PHASE: Patients receive folate receptor alpha peptide-loaded dendritic cell vaccine ID on day 1. Treatment repeats every 3 months for 7 courses in the absence of disease progression or unacceptable toxicity."
3332288|NCT02111954||F-18-FCH & Ga-68-NODAGA-MJ9|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9
3332289|NCT02111967||Diabetes mellitus type 2, Metformin|The case group consists of patients with diagnosed diabetes mellitus type 2 treated with Metformin.
3332290|NCT02111967||Diabetes mellitus type 2|The control group consists of patients with diagnosed diabetes mellitus type 2 which do not have metformin treatment
3332291|NCT02112006|Experimental|distal injection|0.5% bupivacaine injected in the forearm
3332292|NCT02112006|Active Comparator|proximal injection|20-30ml of 0.5% bupivacaine
3332293|NCT02112019|Experimental|Sialoendoscopy with saline|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and possible strictures are dilated
3332294|NCT02112019|Active Comparator|Sialoendoscopy: saline and hydrocortisone|By performing a sialoendoscopy, the ducts of the salivary glands are rinsed with saline and hydrocortisone and possible strictures are dilated
3332295|NCT02112019|No Intervention|Control: no treatment|
3332296|NCT02112032|Experimental|Dose Level 1|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 1 µg/kg every week by subcutaneous injection for up to 2 years
3233725|NCT01224548|Experimental|vegan group|participants from sites of this group will receive vegan nutritional intervention starting from Feb 2011
3233726|NCT01224548|No Intervention|control group|participants from sites of the control group will not receive the same nutritional information until June 2011
3233727|NCT01224561||Constitutional thinness|Women with a a body mass index of less than 16.5 kg/m2
3233728|NCT01224561||Healthy Volonteer|Women with a body mass index between 20 and 25 kg/m2
3233729|NCT01224587|Experimental|1|D1000078 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172),AstraZeneca,Mölndal, Sweden , under fasting condition
3233730|NCT01224587|Experimental|2|D1000082 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fasting condition
3233731|NCT01224587|Experimental|3|D1000083 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden ,under fasting condition
3233732|NCT01224587|Experimental|4|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden , under fasting condition
3233733|NCT01224587|Experimental|5|D100083 marked with approx. 5 mg Fe3O4(E172), AstraZeneca,Mölndal, Sweden, under fed condition
3233734|NCT01224587|Experimental|6|D1000085 placebo gel matrix tablet marked with approx. 5 mg Fe3O4(E172), AstraZeneca, Mölndal, Sweden , under fed condition
3233735|NCT01224600||1|patient with newly diagnosed PAD (< 1 year)
3233736|NCT01224613|Active Comparator|Intanza - self-administered|Self-administered intradermal influenza vaccine
3233737|NCT01224613|Active Comparator|Intanza - nurse-administered|Nurse-administered intradermal influenza vaccine
3233738|NCT01224652|Experimental|paclitaxel|Paclitaxel 70 mg/m2 on Days 1, 8 and 15 of a 28-day cycle
3332297|NCT02112032|Experimental|Dose Level 2|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 2 µg/kg every week by subcutaneous injection for up to 2 years
3332298|NCT02112032|Experimental|Dose Level 3|MK-3475: 2 mg/kg every 3 weeks by intravenous infusion for up to 2 years Peginterferon alfa-2b: 3 µg/kg every week by subcutaneous injection for up to 2 years
3332299|NCT02112058|Experimental|Program|A series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program. Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula. The third component was family support services.
3332300|NCT02112058|No Intervention|Control|Business as usual
3332301|NCT02112071|Experimental|Exercise|blended supervised-hombased exercise training 3-4 times/week for 12 weeks
3332302|NCT02112071|No Intervention|control|control group asked to continue usual activities
3332303|NCT02112084|No Intervention|Usual Care|Usual care participants do not receive an intervention.
3332304|NCT02112084|Experimental|Individualized DPM|Individualized DPM
3332305|NCT02112097|Experimental|For Left Upper Arm|"For Left Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3332306|NCT02112097|Experimental|For Right Upper Arm|"For Right Upper Arm Total Persistent % subdermally, For Left Upper Arm Total Persistent % subcutaneously, and For Left Upper Arm Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3332307|NCT02112097|Experimental|sPGA 50 n(%)|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, and Efficacy of Enbrel subcutaneously at Week 36 vs. Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, and Efficacy of Enbrel subdermally at Week 36. sPGA 50 n(%) clear or minimal is the % of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and % of patients with a reduction of PASI of at least 50% from baseline."
3332308|NCT02112097|Experimental|PASI 75 n(%)|"PASI 75 n(%)~Response to treatment defined as the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI, as PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, and PASI 75 n(%) subcutaneously at Week 36 vs. PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, and PASI 75 n(%) subdermally at Week 36."
3332309|NCT02112097|Experimental|Adverse Injection site reactions|Injection site reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332310|NCT02112097|Experimental|Adverse Reactions with Heart failure|Heart failure as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332311|NCT02112097|Experimental|Adverse Reactions Allergic Reactions|Allergic Reactions as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332312|NCT02112097|Experimental|Adverse Reactions Blood/low blood counts|Blood problems/low blood counts as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332313|NCT02112097|Experimental|Adverse Reactions with Nervous system|Nervous system problems, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332314|NCT02112097|Experimental|Adverse Reactions with Infections|Infections (upper respiratory infection, pyelonephritis, bronchitis, septic osteomyelitis, wound infection, pneumonia, foot abscess, leg ulcer), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332315|NCT02112097|Experimental|Adverse Reactions with Malignancies|Malignancies (lymphoma, basal & squamous skin cancer, non-cutaneous solid tumor, & Wegener's granulomatosis), as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332316|NCT02112097|Experimental|Adverse Reactions with Immunogenicity|Immunogenicity as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3233739|NCT01224652|Experimental|irinotecan|irinotecan 150 mg/m2 on Days 1 and 15 of a 28-day cycle
3233740|NCT01224665|Active Comparator|Arm I|therapeutic conventional surgery therapeutic standard lymphadenectomy
3233741|NCT01224665|Experimental|Arm II|therapeutic conventional surgery therapeutic extended lymphadenectomy
3332317|NCT02112097|Experimental|Adverse Reactions with Autoantibodies|Autoantibodies, Lupus-like syndrome, autoimmune hepatitis, as Adverse Reactions of Enbrel subcutaneously vs. Adverse Reactions of Enbrel subdermally at Week 36.
3332318|NCT02112110|Experimental|BMS-791325 (oral) and [13C]-BMS-791325 (IV)|BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days
3332319|NCT02112123|Placebo Comparator|Placebo|Matching placebo given for 5 days (qd po)
3332320|NCT02112123|Active Comparator|Icariin - 100 mg/day|Icariin given at 100 mg/day (qd po) for 5 days
3332321|NCT02112123|Active Comparator|Icariin - 200 mg/day|Icariin given at 200 mg/day (qd po) for 5 days
3332322|NCT02112123|Active Comparator|Icariin - 400 mg/day|Icariin given at 400 mg/day (qd po) for 5 days
3332323|NCT02112123|Active Comparator|Icariin - 840 mg/day|Icariin given at 840 mg/day (qd po) for 5 days
3332324|NCT02112123|Active Comparator|Icariin - 1680 mg/day|Icariin given at 1680 mg/day (qd po) for 5 days
3332325|NCT02112136|Other|GeneQuest|"No drug will be administrated in this study~Blood collection"
3233744|NCT01224717|Experimental|PTH134|
3233745|NCT01224717|Placebo Comparator|Placebo|
3233746|NCT01224717|Active Comparator|Forsteo|
3233747|NCT01224730|Experimental|Perifosine 100 mg|Perifosine 100 mg orally daily under Fed and Fasted conditions
3233748|NCT01224743|Placebo Comparator|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
3332326|NCT02112149|Experimental|LIVESTRONG Program|Participants randomized to the LIVESTRONG exercise program will attend a 12-week LIVESTRONG Program at one of the participating YMCA's in the greater Boston area or CT. We will have monthly teleconferences to discuss the study, recruitment, and the exercise program. Lastly, throughout the 12-week program, participants will record their attendance at the LIVESTRONG program as well as any exercise done outside of the program. We will provide them with a Physical Activity Log book to record their exercise.
3332327|NCT02112149|No Intervention|Wait-List Control|Baseline data will be collected from all study participants before randomization. If a participant is randomized to wait-list control, then he/she will be told that he/she will start the LIVESTRONG program after three months and after he/she returns to Yale or DFCI to complete the 3-month clinic visit.
3332328|NCT02112162|Experimental|Diagnostic (FDG PET/MRI, gene expression)|FDG PET/MRI at baseline and at 2-4 weeks before surgery (after neoadjuvant chemoradiation). Tissue samples for gene expression at baseline and during surgery
3332329|NCT02112175|Experimental|Lenalidomide|Treatment Arm A: lenalidomide 10 mg/day orally from Days 1 to 21; given in 28-day cycles for up to disease progression.
3332331|NCT02112201|Experimental|Integrated intervention for parents and adolescent girls|Twelve session parent education and support group; twelve session one-on-one adolescent skills training intervention
3233749|NCT01224743|Experimental|Blend 2|Blend 2 - combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
3233750|NCT01224743|Experimental|Blend 1|Blend 1 - combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
3332332|NCT02112201|No Intervention|Treatment as usual|Treatment as usual
3332333|NCT02112214|Active Comparator|Intervention group|10-day bismuth-based quadruple therapy for H. pylori positive subjects
3332334|NCT02112214|Placebo Comparator|Placebo group|Placebo for H. pylori positive subjects
3332335|NCT02112227|Active Comparator|Discharge planning services|Proven effective discharge-planning services will be grouped into 'patient-centered care transitions in heart failure' patients. This will be known as the PACT-HF model.
3332336|NCT02112227|No Intervention|Standard Care|Standard of care will be provided to HF patients at discharge.
3332337|NCT02112240|Experimental|Surgery with pre- and intra-op imaging|Subjects will have a preoperative flexible sigmoidoscopy where they will receive an endoscopic injection of 99mTc-sulfur colloid (up to 0.5 mCi) and 3 to 5 cc of circumferential endoscopic injections of Spot. A SPECT/CT will be performed prior to surgery to identify lymph nodes in the rectum. Subjects will proceed to their standard surgery. Intraoperative mobile gamma camera imaging of the rectum will occur before and after resection in attempt to identify sentinel lymph nodes.
3332338|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 2 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
3332339|NCT02112253|Experimental|Deep brain stimulator ventral electrode up to 3 mA|The ventral contact within the anterior globus pallidus interna near the ansa lenticularis is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
3332340|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 2 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 2 mA amplitude is reached; whichever comes first.
3332341|NCT02112253|Experimental|Deep brain stimulator dorsal electrode up to 3 mA|The dorsal contact within the superior half of the anterior globus pallidus interna is activated. Stimulator settings are 90 microseconds pulse width and stimulation frequency of 130 Hertz. Amplitude of stimulation is raised from zero until side effects occur or 3 mA amplitude is reached; whichever comes first.
3233751|NCT01224756|Experimental|Tinoridine HCl 100 mg (2 capsules) TID|
3332342|NCT02112253|Active Comparator|Deep brain stimulator empirical programming|Any of the four electrode contacts on each of the two deep brain stimulation leads can be activated in any combination with any amplitude, frequency or pulse width settings to achieve optimized clinical control of motor tics whilst minimizing side effects. Both programmer and patient may be unblinded. The assessors are blinded to stimulation settings.
3332343|NCT02112266|Other|no mail support|no mail support during follow-up
3332344|NCT02112266|Other|mail support|
3332345|NCT02112279|Experimental|Microbiota Transplant|Close relative or purchased donor microbiota transplant will be administered via colonoscopy; Donor microbiota applied via colonoscopy
3233752|NCT01224756|Placebo Comparator|Placebo TID|
3233753|NCT01224769||bendamustine +/- rituximab|
3233754|NCT01224795|Experimental|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
3233755|NCT01224795|Placebo Comparator|Placebo|Placebo Peramivir, administered intravenously.
3233756|NCT01224808|Experimental|Experimental|
3233757|NCT01224834|Placebo Comparator|1|
3233758|NCT01224834|Experimental|2|
3233759|NCT01224847|Active Comparator|Tetracaine gtt|Pre-Intravitreal injection - 1 gtt Tetracaine topically
3332346|NCT02112292|Experimental|T-C-P|Order of administrations: tetrahydrocannabinol - cannabidiol - placebo
3332347|NCT02112292|Experimental|T-P-C|Order of administrations: tetrahydrocannabinol - placebo - cannabidiol
3332348|NCT02112292|Experimental|C - T - P|Order of administrations: cannabidiol - tetrahydrocannabinol - placebo
3332349|NCT02112292|Experimental|C - P - T|Order of administrations: cannabidiol - placebo - tetrahydrocannabinol
3332350|NCT02112292|Experimental|P - T - C|Order of administrations: placebo - tetrahydrocannabinol - cannabidiol
3332351|NCT02112292|Experimental|P - C - T|Order of administrations: placebo - cannabidiol - tetrahydrocannabinol
3332352|NCT02112305|Experimental|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) on three occasional at 20 minutes interval
3332353|NCT02112305|Active Comparator|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
3332354|NCT02112331|Experimental|Raw human milk / pasteurized human milk|"Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
3332355|NCT02112331|Experimental|Pasteurized human milk / pasteurized-homogenized human milk|"Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk.~In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube :~one before the meal,~and one either 35, 60 or 90 minutes (randomized time frame) after the meal."
3332356|NCT02112344|Experimental|Total mucosal irradiation|
3332357|NCT02112357||Targeted genetic sequencing of tumour specimen|
3332358|NCT02112383|Experimental|Internet-based cognitive behavior therapy|
3332359|NCT02112383|Experimental|Cognitive behavior group therapy|
3332360|NCT02112396|Experimental|Immediate Intervention|Subjects receive 12 sessions of Community Reinforcement and Family Training (CRAFT) immediately after study inclusion
3332361|NCT02112396|Other|Waiting list group|Waiting list group members receive the Community Reinforcement and Family Training CRAFT intervention after the first follow-up (3 months post study inclusion)
3332362|NCT02112409|Experimental|cell salvage and hemodilution technique|cell salvage technique throughout scoliosis corrective surgery; Acute normovolemic hemodilution technique commenced after induction of anaesthesia and prior the starting of surgery.
3332363|NCT02112409|Active Comparator|cell salvage|cell salvage technique throughout scoliosis corrective surgery
3332364|NCT02112422|Active Comparator|Control|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
3332365|NCT02112422|Experimental|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR. The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
3332366|NCT02112435|Active Comparator|Narval ORM ® or SomnoDent ®|Mandibular advancement splint (Narval ORM ® or SomnoDent ®)
3332367|NCT02112435|Experimental|Somnyx ®|Active mandibular advancement splint (Somnyx ®)
3332368|NCT02112461|Experimental|Intervention Group|SCP-Hospice Alert
3332369|NCT02112461|No Intervention|Usual Care|Caregiver calls into monitoring system to report the patient's end of life symptoms but does not receive feedback about the symptoms and the hospice nurse does not receive the information.
3332370|NCT02112474|Experimental|Spinal Cord Stimulation Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
3332371|NCT02112474|Experimental|Spinal Cord Stimulation Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
3332372|NCT02112487|Experimental|Macitentan|10 mg once daily
3332373|NCT02112500|Experimental|Mesenchymal Stem Cell Infusion|Mesenchymal stem cells cultured and extracted from bone marrow of enrolled patients are infused.
3332374|NCT02112513||salivary estriol measurement|Serum Estriol measurement via different assays is complex, expensive, labor intensive, time consuming, and generally performed at specific reference labs. Salivary Estriol level is an ideal potential surrogate for serum Estriol. It is convenient, non-invasive, and expedient. It may not, however, be as sensitive as serum estriol concentrations at detecting the association with glucocorticoid response. This study will collect both samples to determine which one is better suited for clinical use in this condition.
3332375|NCT02112513||serum estriol measure|we will determine if changes in maternal serum estriol represent a biomarker of response to antenatal corticosteroids as evidenced by neonatal development of RDS
3332376|NCT02112513||Betamethasone pharmacokinetic|we will determine if pharmacokinetic parameters and neonatal outcomes after antenatal corticosteroid use are associated with genetic polymorphisms in drug metabolizing enzymes, transporters, and steroid pathway genes
3332377|NCT02112513||betamethasone concentration and genetics|we will determine if maternal betamethasone concentrations and genetics are associated with maternal estriol changes or RDS development
3332378|NCT02112539||ADP Blockers|platelet aggregation in response to antiplatelet drugs
3332379|NCT02112552|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.~RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23)."
3332380|NCT02112565|Experimental|Treatment (RNR inhibitor COH29)|Patients receive RNR inhibitor COH29 PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3332381|NCT02112578|Experimental|Meclizine|Meclizine 25 mg, tablets
3332382|NCT02112578|Active Comparator|Dimenhydrinate|Dimenhydrinate 50 mg, soft Capsgel
3332383|NCT02112591|Active Comparator|Transobturator suburethral tape (TOT)|transobturator approaches for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide
3332384|NCT02112591|Experimental|S-TOT|transobturator subtrigonal tape: S-TOT
3332385|NCT02112604||Ventilated patients|Patients who have been extubated within 24 hours and have been mechanically ventilated for at least 24 hours. Alice PDx, pulmonary function tests, muscle strength tests, grip strength measurements, ventilator, Sedatives and muscle relaxants given in the ICU
3332386|NCT02112617|Experimental|Proton Beam Radiation Therapy (PBRT)|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
3332387|NCT02112630|Experimental|Group 1 - Response Guided Therapy|"Treatment naive and documented relapsers : Subjects who have never been previously treated with P-IFN +/- ribavirin therapy and those who have documented relapse after P-IFN +/- ribavirin therapy.~Subjects in group 1 will receive P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir. Based on the patient's HCV-RNA levels at Treatment Week (TW) 8, TW12 and TW24 treatment with be continued for a total duration of 28 to 48 weeks.Subjects will be followed through treatment and up to 24 weeks post treatment."
3332388|NCT02112630|Experimental|Group 2 - Fixed Duration Therapy|"Partial/Null Responders /Undefined Previous Response, Compensated cirrhosis: Subjects who have compensated cirrhosis, and/or were previously treated with P-IFN +/- ribavirin without SVR (including partial responders, null responders, and those previously treated without adequate documentation of response).~Subjects in Group 2 will all be assigned to fixed duration therapy.Patients will be treated with P-IFN alfa 2a or P-IFN alfa 2b and ribavirin for a 4 week lead-in followed by the addition of boceprevir for a total of 48 weeks of therapy. Subjects will be followed through treatment and up to 24 weeks post treatment."
3332389|NCT02112643|Active Comparator|Selenium|100 micrograms of sodium selenate will be taken orally twice daily (total 200 micrograms daily) for 6 months.
3332390|NCT02112643|Placebo Comparator|Sugar pill|A placebo pill will be taken orally twice daily for 6 months.
3332391|NCT02112656|Experimental|ThermoDox 50 mg/m2|ThermoDox plus standardized RFA using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
3332392|NCT02112656|Placebo Comparator|Dummy infusion|standardized RFA alone using standardized treatment dwell time for solitary HCC lesions ≥ 3.0 cm to ≤ 7.0 cm
3233760|NCT01224847|Active Comparator|Tetraciane gtt + Lidocaine pledget|1 gtt Tetracaine pre-IVT injection + application Lidocaine pledget to injection site
3233761|NCT01224847|Active Comparator|Cocaine gtt alone|1 gtt pre-IVT injection
3233762|NCT01224860|Experimental|Telmisartan|
3233763|NCT01224860|Experimental|Losartan|
3233764|NCT01224886|Experimental|Sedentary obese|
3233765|NCT01224886|Experimental|Sedentary normal weight|
3332393|NCT02112669|Experimental|AV fistula with VasQ|Implant VasQ over AV fistula
3332394|NCT02112669|No Intervention|AV fistula|AV fistula without any adjunct device
3332395|NCT02112682|Active Comparator|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
3332396|NCT02112682|No Intervention|No completion axillary treatment|
3332397|NCT02112695|Experimental|sportswomen|3 micrograms [11C]diprenorphine
3332398|NCT02112695|Experimental|control subjects|3 micrgrams [11C]diprenorphine
3332399|NCT02112708|Experimental|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly of Rational-Emotive-Behavioral Therapy. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
3233766|NCT01224886|No Intervention|Athletes|
3332400|NCT02112708|Active Comparator|Control Group|The control group (GC) will take the usual medical care for dysthimia, according with up-dated guidelines.
3332401|NCT02112721|Experimental|Vitamin D Group|Each participant will be given an initial stat dose of 2500 μg (100,000 IU) of Ostelin (Reckitt Benckiser). Thereafter, participants will take 100 μg/day (4,000 IU, 4 tablets) Ostelin daily for a period of 16 weeks.
3332402|NCT02112721|Placebo Comparator|Placebo group|Each participant will be given an equivalent number of placebo tablets
3332403|NCT02112734|Active Comparator|vitamin D|400 IU /daily cholecalciferol/vitamin D
3332404|NCT02112734|Placebo Comparator|placebo|carrier formulation minus vitamin D
3332405|NCT02112747|No Intervention|Arm 1: website access only|There is no intervention with this arm. Completion of the website is part of enrollment.
3233767|NCT01224899|Experimental|Surgery|
3233768|NCT01224899|No Intervention|Control|
3233769|NCT01224912|Experimental|Internet Deliviered CBT for Insomnia|Cognitive behavioral self-help method for insomnia via the Internet
3332406|NCT02112747|Experimental|Arm 2: patient navigator|"The intervention consists of participants receiving the services of a patient navigator to address individual barriers to adhering to the personal prescription for colon and rectal cancer screening."
3233770|NCT01224938||Asthma patients|Asthmatics of all classes of severity will be included.
3233771|NCT01224938||Healthy control population|A healthy control population will be included to compare with the asthmatics.
3233772|NCT01224951|Active Comparator|Qvar 100|"Patients will be randomized to receive either the active arm (3/4) or a SABA as rescue medication (1/4). The patient will be asked to take Qvar 100 (2puffs) in the morning and in the evening.~Daily dose (400 microgram)."
3233773|NCT01224951|No Intervention|Control|Patients are allowed to use their SABA as rescue medication only. During the last 4 weeks, the patients will receive 400 microgram of Qvar.
3233774|NCT01224964|Active Comparator|Montelukast|
3233775|NCT01224964|Active Comparator|long-acting beta2-mimetic|
3233776|NCT01224977|Other|azithromycin|
3233777|NCT01225042|Experimental|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
3233778|NCT01225042|Placebo Comparator|placebo|Carrier material powder of identical appearance
3332407|NCT02112747|No Intervention|Arm 3: genetic counseling|There is no intervention in this arm. Patients diagnosed as positive for Lynch Syndrome use genetic counseling to discuss medical and family history and genetic risk of CRC, including genetic factors such as DNA mismatch repair genes, autosomal dominant inheritance, cancer risks associated with LS, screening recommendations, and genetic testing. There is no intervention. This is standard care.
3332408|NCT02112747|Experimental|Arm 4:Gen. counselor & patient navigator|Participants diagnosed positive for Lynch syndrome use genetic counseling as in Arm 3 and in addition receive the services of a patient navigator to address individual barriers to adhering to the CRC screening recommendations.
3332409|NCT02112760|Experimental|Patient|To evaluate the effect of specific stabilization intervention in recurrent low back pain participants
3332410|NCT02112786|Active Comparator|Intermittent then Continuous|This group will be set to intermittent stimulation first, then after the wash out period they will be switched to continuous stimulation.
3332411|NCT02112786|Active Comparator|Continuous Then Intermitent|This group will be set to continuous stimulation first, then switch to intermittent after the wash out time period.
3332412|NCT02112799|Experimental|NVR 3-778|NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
3332413|NCT02112799|Placebo Comparator|Placebo for NVR 3-778|Placebo for NVR 3-778 in varying doses of capsules by mouth for 1 day, 14 days, or 28 days
3332414|NCT02112799|Experimental|NVR 3-778 and Pegasys|NVR 3-778 and Pegasys in combination in a yet to be determined dose by mouth and subcutaneous injection for 28 days
3332415|NCT02112799|Active Comparator|Pegasys|Pegasys alone in a yet to be determined dose by subcutaneous injection for 28 days
3332416|NCT02112812|Experimental|Eradication therapy|The patients who were positive for H.pylori infection are entered into an eradication therapy protocol which includes oral esomeprazole 40mg daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
3332417|NCT02112825|Experimental|Exercise|12 weeks of blended supervised-home based exercise 3-4 times per week for 30-45 minutes
3332418|NCT02112825|No Intervention|control|Control group asked to continue usual activities
3332419|NCT02112851|Placebo Comparator|Orange flavored beverage|240ml orange beverage
3332420|NCT02112851|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
3332421|NCT02112851|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
3332422|NCT02112864|Experimental|dexamethasone 10 mg|Dexamethasone 10 mg will be given as a single-dose, pre incision, intravenously
3332423|NCT02112864|Placebo Comparator|normal saline|Patients in this group will receive 2.5 mL of normal saline intravenously, pre-incision
3332424|NCT02112890||Study Group|A random sample of subjects constituting adolescents and young adults (≥10 - ≤25 years of age) that participated in the ENSANUT 2012 in Mexico.
3332425|NCT02112903|Experimental|Encapsulated vortioxetine IR tablet, 20 mg|Single oral dose
3332426|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 5.5)|Single oral dose
3233779|NCT01225081|Experimental|ASP group|ASP1941 and pioglitazone
3233780|NCT01225081|Placebo Comparator|Placebo group|placebo and pioglitazone
3332427|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 6.0)|Single oral dose
3332428|NCT02112903|Experimental|Vortioxetine MR capsule 20 mg (pH 7.0)|Single oral dose
3332429|NCT02112916|Active Comparator|Arm A (combination chemotherapy)|Patients receive combination chemotherapy without bortezomib. See Detailed Description.
3233781|NCT01225094|Experimental|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg., and then another 2000 mg dose 6 hours after the repair. Final dose (2000 mg)is administered morning after repair.
3233782|NCT01225094|Placebo Comparator|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
3233783|NCT01225107|Placebo Comparator|Inert Placebo Capsule|
3332430|NCT02112916|Experimental|Arm B (combination chemotherapy, bortezomib)|Patients receive combination chemotherapy with bortezomib. See Detailed Description.
3332431|NCT02112929|Experimental|Inhalation of hyperpolarized xenon|One litre of hyperpolarized xenon to be inhaled during MRI scan of the lungs
3332432|NCT02112942|Experimental|Group A|Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days
3332433|NCT02112942|Experimental|Group B|HCV subjects genotype 1, IDX21459 capsules, once for 1 day
3332434|NCT02112942|Experimental|Group C|HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days
3332435|NCT02112955|Experimental|Stroke self-management program|The program is aimed at enhancing community-dwelling stroke survivors' post-stroke recovery.
3332436|NCT02112955|Active Comparator|Usual care|Usual care provided to stroke survivors discharged to their home.
3332437|NCT02112968|Experimental|Proscan|Ametropia Lasik treatment of virgin eyes.
3332438|NCT02112968|Experimental|Zyoptix|Wavefront based ametropia Lasik treatment of virgin eyes.
3332439|NCT02112968|Experimental|Supracor|Ametropia Lasik treatment of virgin eyes with presbyopia.
3332440|NCT02112981|Experimental|Sirolimus Eluting Coronary Stent|BioMime Sirolimus Eluting Stent of Meril Life Sciences
3332441|NCT02112981|Active Comparator|Everolimus-eluting Coronary stent|XIENCE family (V, Xpedition or Prime) of Everolimus-eluting stent system of Abbott Vascular Inc.
3332442|NCT02113020|Experimental|TAK-233|Oral administration
3332443|NCT02113020|Placebo Comparator|Placebo|Oral administration
3332444|NCT02113033|Experimental|Treated with Equilia system|Implantation and activation of the Vagus Nerve Stimulator, nerve electrode and cardiac lead
3332445|NCT02113046|Active Comparator|pancreatico-jejunal anastomosis|patients in which the finnish binding pancreatico-jejunal anastomosis is techically possible to perfom during distal pancreatic resektion
3332446|NCT02113046|Active Comparator|traditional anastomosis|pancreatic resections with traditional stump closure
3332447|NCT02113059||Liver resection|Patients undergoing a hemihepatectomy.
3233784|NCT01225107|Experimental|Cranberry Extract|
3332448|NCT02113072|Experimental|Probiotics & Beclomethasone|"It will be supplied in lyophilized form, in each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.~Beclomethasone HFA 50mcg spray - 100 mcg/day as initial treatment for primary and wheezing in this age group, at doses considered minimal, for 4 months."
3332449|NCT02113072|Active Comparator|Beclomethasone & Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics. It will be supplied in lyophilized form in each sachet containing 1 g of placebo, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
3332450|NCT02113085|Experimental|Self-determination enhancement|Self-determination enhancement through one-on-one coaching and mentoring workshops
3332451|NCT02113098|Experimental|Treadmill, ankle load|The experimental group will perform gait training on a treadmill with added load to the non-paretic lower limb
3332452|NCT02113098|Active Comparator|Treadmill|The control group (active comparator) will perform gait training on a treadmill
3332453|NCT02113111||Fasting|Patients being admitted to an internal integrative medicine hospital and referred to therapeutic fasting therapy
3332454|NCT02113137|Experimental|group 1: drug|Drug: group 1: drug: chlorine dioxide 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks
3332455|NCT02113137|Experimental|group 2: device:|group 2: device: small tooth brush for tongue cleaning small tooth brush for tongue cleaning
3332456|NCT02113150|Active Comparator|remifentanil|remifentanil, short acting opioid
3332457|NCT02113150|Active Comparator|ketamine|ketamine, intravenous anesthetic
3332458|NCT02113163|Active Comparator|Cohort A - Low Dose|Metformin Eicosapentaenoate 1500 mg or Metformin HCl 500 mg and Vascepa 1000 mg
3233785|NCT01225120|Experimental|Gait Training|
3233786|NCT01225133|Active Comparator|Complex Ayurvedic Treatment|In the Āyurveda arm treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
3332459|NCT02113163|Active Comparator|Cohort B - High Dose|Metformin Eicosapentaenoate 3000 mg or Metformin HCl 1000 mg and Vascepa 2000 mg
3332460|NCT02113176|Experimental|Minocycline|"200 mg IV/placebo~Followed by 100 mg IV BID x 7days~Followed by 200 mg tablet QD x 14days"
3332461|NCT02113176|Placebo Comparator|Placebo|
3332462|NCT02113202|Experimental|Tracer dose: 4.5 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 4.5 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3332463|NCT02113202|Experimental|Tracer dose: 10 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 10 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3332464|NCT02113202|Experimental|Tracer dose: 25 mg|Patients receive three days before the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform) 25 mg of the fluorescent tracer bevacizumab-IRDye800CW.
3332465|NCT02113215||Young Males|Males, age 18-35 years. 9-hour Stable isotope infusion
3332466|NCT02113215||Young Females|Females, age 18-35 years. 9-hour Stable isotope infusion
3332467|NCT02113215||Older Males|Males, age 60-75. 9-hour Stable isotope infusion
3332468|NCT02113215||Older Females|Females, age 60-75. 9-hour Stable isotope infusion
3332469|NCT02113228||Short Bowel Syndrome|Verify the total energy expenditure in patients with short bowel syndrome using the doubly labeled water method.
3332470|NCT02113228||Control Group|Verify the total energy expenditure in patients without short bowel syndrome using the doubly labeled water method.
3332471|NCT02113254|Experimental|Healthy volunteer|
3332472|NCT02113267|Experimental|Mometasone furoat|Mometasone furoate monohydrate. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
3332473|NCT02113267|Placebo Comparator|Placebo spray|Placebo. 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
3332474|NCT02113280|Active Comparator|Physiotherapy|Physiotherapy
3332475|NCT02113280|Experimental|Arthroscopy|Arthroscopy
3332476|NCT02113293|Experimental|CyclASol®|CyclASol®
3332477|NCT02113293|Placebo Comparator|Placebo|Placebo (vehicle)
3332478|NCT02113306|Experimental|t-VNS|"electrical stimulation of the concha of the ear~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
3332479|NCT02113306|Sham Comparator|sham t-VNS|"Sham stimulation of the earlobe will be conducted by positioning the electrode upside down~30sec trains of 0.25msec-duration monophasic square wave pulses at 25Hz, with a stimulation intensity not exceeding 0.5 mA"
3332480|NCT02113319|Experimental|dasatinib|
3332481|NCT02113332|Experimental|Liraglutide|Liraglutide injected once per day for 24 weeks. Dose is 1,8 mg or highest tolerable dose.
3332482|NCT02113332|Placebo Comparator|Placebo|Placebo injected once per day for 24 weeks. Dose is 1,8 or highest tolerable dose.
3332483|NCT02113345|Experimental|lifestyle counseling|Metamemory Cognitive Intervention
3332484|NCT02113358|Experimental|Normovolemic group (keeping SVV<10% in supine; <15% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 10% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
3332485|NCT02113358|Active Comparator|Restricitve group (keeping SVV < 18% in supine; <23% in prone)|"The anesthesiologist will infuse Voluven (Fresenius Kabi, Bad Homburg, Germany) 250 ml if stroke volume variation is over 18% during the surgery to keep the normovolemia.~If total Voluven use is over 1500ml and then the anesthesiologist will infuse Saline 250 ml instead.~The maintenance of basal fluid, criteria to use inotropes (If cardiac index is below 2.5 l/min/m2 ) are the same standards in the both groups."
3332486|NCT02113371|Experimental|Intervention|The intervention consists of monthly scripted, peer-led social support sessions covering health and safety topics.
3332487|NCT02113371|No Intervention|Control|Usual practices with regard to health and work conditions.
3332488|NCT02113384||Observational study|Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
3332489|NCT02113397||Continuous Therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day cycle colistimethate 75 mg inhaled two times daily. Repeat cycle.
3332490|NCT02113397||Cyclic therapy|TOBI™ Podhaler™ 112 mg inhaled by mouth twice daily for 30 days followed by a 30-day period during which no inhaled antibiotics are used. Repeat cycle.
3332491|NCT02113423|Experimental|recurrent T1-2 NPC,no treatment|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT
3332492|NCT02113488||Control: P|Patients who did attend a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3332493|NCT02113488||Case: A|Patients who did not attend (A) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3332494|NCT02113488||Control: C|Patients who cancelled (C) a scheduled appointment at the Clinical Medicine Outpatient care system at the Italian Hospital of Buenos Aires (HIBA)
3332495|NCT02113501||HGT1a|HGT1a bladder cancer patients will undergo BCG induction and maintenance followed by conventional follow-up (cystoscopy and cytology at 3months and then every 6months).
3332496|NCT02113501||HGT1b|HGT1b bladder cancer patients will undergo a 2nd TUR after BCG induction. If negative, continue with maintenance BCG followed by conventional follow-up (cystoscopy and cytology every 6months).
3332497|NCT02113514||Normal Pap smear|Women with normal pap test.
3332498|NCT02113514||Abnormal Pap smear|Women with abnormal pap test.
3332499|NCT02113527||Epigastric pain syndrome (EPS)|Patients suffering from functional dyspepsia characterized by epigastric pain syndrome according to Rome III criteria
3332500|NCT02113527||Postprandial distress syndrome (PDS)|Patients suffering from functional dyspepsia characterized by postprandial distress syndrome according to Rome III criteria
3332501|NCT02113527||Healthy subjects|Healthy subjects as control group
3332502|NCT02113540|Placebo Comparator|placebo group|taking atorvastatin like placebo 12 hours before the procedure
3233787|NCT01225133|Active Comparator|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
3233788|NCT01225185||Patients undergoing shoulder surgery|"This observational study will compare cerebral blood flow autoregulation in patients undergoing surgery in either the supine lateral position or the semi-recumbent or beach chair position. The choice of patient positioning is not randomized but based on usual surgical considerations."
3332503|NCT02113540|No Intervention|long term statin group|taking atorvastatin for a long time before entering the study (their routine treatment)
3332504|NCT02113540|Experimental|preoperation statin group|taking atorvastatin 12 hours before the procedure
3332505|NCT02113553|Experimental|Triptorelin|Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy
3332506|NCT02113566|Placebo Comparator|Placebo|2 capsules identical to comparator, 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
3332507|NCT02113566|Active Comparator|Ibuprofen|2oomg capsules (400 mg per dose), 3 times daily on Day 1 and Day 2. On Day 3 only one dose will be taken. The intervention is Acetaminophen 1000mg.
3332508|NCT02113592|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
3332509|NCT02113592|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
3332510|NCT02113605|Experimental|Cognitive behavior therapy|All included children are treated with a face-to-face exposure-based cognitive behaviour therapy for 10 weeks. There will be no comparison arm.
3332511|NCT02113618|Active Comparator|Cogmed Training|Cogmed® working memory training is a computer program that will be administered online. The program consists of 7 verbal and non-verbal working memory tasks and gives immediate performance feedback to the subject undergoing training.
3332512|NCT02113618|Placebo Comparator|Standard training|Individuals randomised to the placebo arm will receive a standard training online program from Cogmed also consisting of 90 trials to be performed 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level.
3332513|NCT02113631|Active Comparator|Telaprevir|Telapravir was administer with Peg-IFN and Ribavirin as per package insert Dose Telaprevir : PO, tablet 1125 mg BID for 12 weeks
3233789|NCT01225198|Placebo Comparator|Placebo Group|Liquid placebo with identical packaging and flavoring to the real supplement.
3332514|NCT02113631|Active Comparator|Boceprevir|Boceprevir was administer with Peg-IFN and Ribavirin as per package insert Dose Boceprevir PO capsule, 800mg TID for up to 44 weeks
3332515|NCT02113644||Overweight or obese children|Overweight or obese children according to the International Obesity Task Force (IOTF) criteria following the lifestyle intervention in the Centre for Overweight Adolescent and Children's Healthcare
3332516|NCT02113644||Lean children|Lean children according to the International Obesity Task Force (IOTF) criteria admitted at de pediatric ward for a planned surgery, for example the correction of floppy ears
3332517|NCT02113657|Experimental|Ipilimumab|Ipilimumab administered by vein at a dose of 3 mg/kg once every 3 weeks for a total of 4 doses.
3332518|NCT02113670|Experimental|SUI 1|Patients will perform urodynamic study before and after instillation of 50 ml of air
3332519|NCT02113683||MMS test|therapy monitoring of patients with colo-rectal or stomach disease or with melanoma
3332520|NCT02113696|Experimental|Placebo group|Placebo Capsules
3332521|NCT02113696|Experimental|Omega 3 intake|Omega 3 intake, morbid obesity
3332522|NCT02113709|Experimental|Visual improvement|To see how efficiently visual improvement occurs by Full-time Occlusion therapy with an eye patch in severe amblyopia.
3332523|NCT02113722|Active Comparator|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation
3332524|NCT02113722|Placebo Comparator|Standard of care|Continuing medical therapy
3332525|NCT02113735|Experimental|Group 1|H.P. Acthar® Gel , 64 U, 0.8 mL daily
3332526|NCT02113735|Placebo Comparator|Group 2|Placebo, 0.8 mL, daily
3332527|NCT02113735|Experimental|Group 3|H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily
3332528|NCT02113735|Placebo Comparator|Group 4|Placebo, 0.4 mL, 2x daily
3332529|NCT02113735|Experimental|Group 5|H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily
3332530|NCT02113735|Placebo Comparator|Group 6|Placebo, 0.2 mL, 2x daily
3233790|NCT01225198|Experimental|Vitamin/Mineral Supplement Group|Multi-vitamin/mineral supplement designed for this study for children and adults with autism spectrum disorders.
3233791|NCT01225224|Experimental|ASP015K Single Japanese Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
3332531|NCT02113748|Experimental|Downhill walking training|Exercise training including treadmill walking with a negative inclination.
3332532|NCT02113748|Active Comparator|Conventional walking training|Exercise training including treadmill walking without inclination. Possible to progress training intensity with positive inclinations.
3332533|NCT02113774|No Intervention|no therapy|
3332534|NCT02113774|Active Comparator|antimicrobial treatment according to in-vitro susceptibility|
3332535|NCT02113787|Active Comparator|Pharmacokinetic study, topamed|"For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day."
3332536|NCT02113787|Active Comparator|Pharmacokinetic study, topamax|"For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in first visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in second visit day.~For pharmacokinetics, blood samples was taken after receiving Topamed 100mg twice a day in third visit day.~For pharmacokinetics, blood samples was taken after receiving Topamax 100mg twice a day in third visit day."
3332537|NCT02113800|Experimental|Single Arm|"Patients receive Everolimus orally, 10 mg/day.~The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study."
3332538|NCT02113813|Experimental|ASP8273 Dose Escalation cohort (part 1)|oral
3332539|NCT02113813|Experimental|ASP8273 Response Expansion cohort (part 1)|oral
3332540|NCT02113813|Experimental|ASP8273 and Midazolam RP2D Expansion cohort (part 2)|oral
3332541|NCT02113813|Experimental|Food Effect Fasted cohort (part 2)|oral
3332542|NCT02113813|Experimental|Food Effect Fed cohort (part 2)|oral
3332543|NCT02113813|Experimental|Exon 20 Cohort (part 2)|oral
3332544|NCT02113826|Experimental|Pazopanib|Pazopanib 800mg po qd until disease progression
3332545|NCT02113839|Active Comparator|No frequent exacerbators|"Patients without exacerbations: 0 or 1 that did not required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
3332546|NCT02113839|Active Comparator|Frequent exacerbators|"Patients with frequent exacerbations: ≥2 or ≥1 if it required hospitalization in the previous year.~Interventions:~Spirometry~Emogas analysis~Modified Borg Dyspnea Scale~CO Exhaled breath~P01~FeNO"
3332547|NCT02113865||Grupo 0|Null or mild fibrosis
3233792|NCT01225224|Experimental|ASP015K Single Caucasian Group|Participants will be administered a single dose of ASP015K in three stages, each stage corresponding to a different dosage level.
3233793|NCT01225224|Placebo Comparator|Placebo Single Japanese Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
3233794|NCT01225224|Placebo Comparator|Placebo Single Caucasian Group|Participants will be administered a single dose of placebo in three stages, each stage corresponding to a different dosage level.
3233795|NCT01225224|Experimental|ASP015K Multiple Group|Participants will receive ASP015K in three stages, each stage corresponding to a different dosage level. ASP015K will be administered at 12-hour intervals after breakfast and dinner for seven days.
3233796|NCT01225224|Placebo Comparator|Placebo Multiple Group|Participants will receive placebo in three stages, each stage corresponding to a different dosage level. Placebo will be administered at 12-hour intervals after breakfast and dinner for seven days.
3332548|NCT02113865||Grupo 1|Cirrhosis
3332549|NCT02113865||Grupo 2|HCC diagnosis
3233797|NCT01225237|Experimental|ramosetron group|
3233798|NCT01225237|Placebo Comparator|Placebo group|
3233799|NCT01225276|Experimental|Dosage Arm 1|NewGam 10% 0.4 g/kg
3332550|NCT02113878|Experimental|BKM120|"Participants will be enrolled in cohorts of 3- 6 per dose level. Once the MTD is reached, an additional 10 patients will be treated at that dose level and an amendment will be submitted to declare the dose.~BKM120 will start 2 weeks prior to first dose of cisplatin and radiation start. During the study, BKM120 will be administered orally daily for 45 days. Starting dose 40 mg.~Cisplatin: Starting Dose 30 mg/m2, given IV, weekly on days: (1, 8, 15, 22, 29, 36 and 43).~Radiotherapy: All participants will receive daily radiotherapy with intensity-modulated radiotherapy (IMRT) for 7 weeks."
3332551|NCT02113891|Experimental|Eculizumab|Eculizumab will be given in addition to standard immunosuppression regimen (tacrolimus, mycophenalte mofeti, prednisone)
3332552|NCT02113904|Experimental|Adalimumab|
3332553|NCT02113930||Idiopathic CD4 lymphocytopenia|Constitution of a biobank of frozen cells, plasma and serum samples
3332554|NCT02113930||Genetic Study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
3332555|NCT02113969|Experimental|Vaginal Pessary|Pessary users for at least 12 months
3332556|NCT02113982|Experimental|Relapse/Refractory Acute Myeloid Leukemia|Intervention: SL-401
3332557|NCT02113982|Experimental|Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Intervention: SL-401
3332558|NCT02113995|Active Comparator|ACERTO|"Patients received 400 ml of a beverage containing water and 50 g of maltodextrin 6 hours before the operation. They received orally extra 200 ml of this beverage containing water and 25 g of maltodextrin 3 hours before the operation. Regarding the intravenous fluids, they received 1 to 1.5 liter of crystalloid fluids (ringer lactate) in the intraoperative. In the immediate postoperative they were programmed to receive 2 liters of crystalloid fluids (ringer lactate) and 1 to 2 liters in the first day of the postoperative period. The venous hydration was suspended as soon as they started to drink liquids.~Prophylaxis of nausea and vomiting with dexamethasone 8 mg at the beginning of the anesthesia and ondansetron 4-8 mg after the surgery. In the postoperative period we utilized analgesics such as dipyrone and ketorolac and, if necessary, low doses of morphine and antiemetics like ondansetron."
3233800|NCT01225276|Experimental|Dosage Arm 2|NewGam 10% 1.0 g/kg
3332559|NCT02113995|Active Comparator|Traditional care|"The analgesia in the postoperative period of the group control was performed with dipyrone, tramadol hydrochloride, and morphine. The prophylaxis of nausea and vomiting with dexamethasone 8 mg in the beginning of the anesthesia and the metoclopramide at the end of the surgery. During the anesthetic induction antibiotic prophylaxis (cefazolin 3 grams/day for 2 days) was administrated.~The control group were submitted to the protocol of traditional fasting with at least 8 hours. Patients in this group received 1 to 2 liters of crystalloid fluid (ringer lactate) in the intraoperative, and they received 3 to 4 liters of crystalloid fluids (ringer lactate, saline 0.9% and/or dextrose 5%). In the immediate postoperative, 2 to 3 liters in the first day of postoperative and, finally, 1 to 2 liters in the second day of the postoperative."
3332560|NCT02114008|Active Comparator|Abbreviated fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin).
3332561|NCT02114008|Active Comparator|Traditional fasting|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test).
3332562|NCT02114021|Experimental|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3332563|NCT02114021|Experimental|lidocaine jelly|lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3332564|NCT02114021|Placebo Comparator|distilled water|betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
3332565|NCT02114034||Non-severe asthma|"Children Controlled without treatment or with low doses of inhaled corticosteroids (<500 mg / day beclometasone equivalent) asthma~and Children with normal EFR~and Children who did not have more severe exacerbation (assessed taking oral corticosteroids) in the previous year~and Children not admitted in the previous year for asthma"
3233801|NCT01225276|Experimental|Dosage Arm 3|NewGam 10% 2.0 g/kg
3233802|NCT01225276|Placebo Comparator|Dosage Arm 4|Placebo 0.9% Saline
3332566|NCT02114034||Severe asthma|"Asthmatic child who, despite treatment with a combination of inhaled corticosteroids (at least 800 mcg / day equivalent Beclomethasone) bronchodilators and long-acting or properly taken daily leukotriene (inhaler technique and compliance verified) presents one of the 3 criteria following:~Persistence of symptoms or chronic use of bronchodilators short duration of action at least three times a week for at least 3 months~exacerbations in the previous year:~at least one care unit admission or continued resuscitation~at least two hospitalizations for acute severe asthma requiring IV therapy~at least 2 courses of oral corticosteroids for exacerbations~post BD FEV <80% or UARS post BD> 150% predicted"
3233803|NCT01225302|Experimental|Arm A|
3233804|NCT01225302|Experimental|Arm B|
3233805|NCT01225315|Experimental|Setipiprant - Dose 1|100 mg b.i.d.
3233806|NCT01225315|Experimental|Setipiprant - Dose 2|500 mg b.i.d.
3233807|NCT01225315|Experimental|Setipiprant - Dose 3|1,000 mg b.i.d
3233808|NCT01225315|Placebo Comparator|Matching Placebo|Oral placebo
3233809|NCT01225328|Experimental|Intervention|Telephone-delivered Behavioral Activation/Problem Solving (BA/PS) intervention
3233810|NCT01225341|Experimental|onabotulinumtoxinA/placebo|Patients will be injected every 3 months with onabotulinumtoxinA for a period of 12 months. At the 12 month visit, patients will receive injections of saline.
3233811|NCT01225341|Placebo Comparator|Bacteriostatic normal saline/ onabotulnimtoxinA|Patients will be injected every 3 months with saline for a period of 12 months. At the 12 month visit, patients will receive injections of onabotulnimtoxinA.
3233812|NCT01225367||pulmonary doppler|
3233813|NCT01225380|Experimental|Arm 1|GS-9190 and GS-9256 in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3233814|NCT01225380|Experimental|Arm 2|GS-9256 (active) and placebo matching GS-9190 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3233815|NCT01225380|Placebo Comparator|Arm 3|Placebo matching GS-9190 and placebo matching GS-9256 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
3233816|NCT01225393|Experimental|A|
3233817|NCT01225393|Active Comparator|B|
3233818|NCT01225393|Placebo Comparator|C|
3233819|NCT01225406||third line naive|Children on second line or other regimen who switch or start third line regimen
3233820|NCT01225406||third line experienced|children who are on third line regimen
3233821|NCT01225432|Experimental|Gait Training|
3233822|NCT01225445|Experimental|Treatment|ramipril 2.5 mg daily
3233823|NCT01225445|No Intervention|Control|
3233824|NCT01225458|Placebo Comparator|exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
3332567|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3233825|NCT01225458|Experimental|geriatric follow-up|"250 patients will be included and randomized in the geriatric follow-up arm. They will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients.~About geriatric evaluation Patients randomized in this arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
3332568|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3332569|NCT02114060|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3332570|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3332571|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3332572|NCT02114060|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3332573|NCT02114060|Placebo Comparator|Placebo|0.9% Normal Saline administered as a 0.5 mL intramuscular (IM) injection.
3332574|NCT02114073|Experimental|Cyclosporine|In the first postoperative day following a standard, fornix-based trabeculectomy, ophthalmic emulsion of Cyclosporine A, 2%, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
3332575|NCT02114073|Active Comparator|Betamethasone|In the first postoperative day following a standard, fornix-based trabeculectomy, betamethasone eye drop, every 4 hours for the first postoperative week and every 6 hours for the next 3 weeks will be prescribed for the patients.
3332576|NCT02114086||breast cancer|observation of intraoperative radiotherapy
3332577|NCT02114099|Experimental|Atorvastatin|prescribe Atorvastatin to see its effect
3332578|NCT02114112|Experimental|Group A-NCPAP Cycling group|Infants in Group A were cycled between NCPAP and nasal prongs. For the first 12 hours, infants received 10 hours of NCPAP and 2 hours of 1 litre per minute of nasal prongs (NP). For the next 12 hours, infants received 8 hours of NCPAP and 4 hours of NP. In the subsequent 24 hours, infants alternated between 6 hours of NCPAP and 6 hours of NP. In the last 24 hours of intervention they alternated between 4 hours of NCPAP and 8 hours of NP.
3332579|NCT02114112|Active Comparator|Group B-Continuous NCPAP|Infants randomized to group B received continuous NCPAP at a CPAP distending pressure of 4 cm of water for 72 hours. Both the groups after 72 hours of intervention were weaned to 1litre per minute NP. During the intervention period all infants were scored using the ACoRN respiratory score on a 12 hourly basis.
3233826|NCT01225484|Active Comparator|CFNB, periarticular infiltration|
3332580|NCT02114125|No Intervention|Usual Care Group:|Usual care consists of standard institutionalized services provided by physicians, nurses, and support staff (e.g., nurse assistants, social workers) in long-term care facilities.
3332581|NCT02114125|Experimental|High-intensity physical activity (5PA)|The intervention conducts the group-based physical activity, 5 days per- week for 8 weeks.
3332582|NCT02114125|Experimental|Low-intensity PA and CT(3PA+2CT)|The intervention conducts 3 days per-week physical activity and 2 days per-week cognitive training for 8 weeks.
3332583|NCT02114125|Experimental|High-intensity PA and CT (5PA+5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5days per- week and group-based physical activity, 5 days per- week and for 8 weeks.
3233827|NCT01225484|Active Comparator|Intraarticular catheter, periarticular infiltration|
3332584|NCT02114125|Experimental|Low-intensity cognitive training (2CT)|The intervention conducts the individual-based, multi-domains cognitive training, 2 days per- week for 8 weeks.
3332585|NCT02114125|Experimental|High-intensity cognitive training (5CT)|The intervention conducts the individual-based, multi-domains cognitive training, 5 days per- week for 8 weeks.
3332586|NCT02114138||Surgical Group|Adults undergoing major in hospital surgery; pathogenesis of perioperative acute kidney injury; urine collection
3332587|NCT02114138||Healthy Control|Healthy Adult volunteers who are willing to provide a 200 ml urine sample.
3332588|NCT02114190|Experimental|Adolescent Mindful Eating Group|Adolescents will participate in a 8 week mindful eating programs tailored for adolescents.
3332589|NCT02114190|Experimental|Parent Intergrated Group|This intervention incorporates a family systems perspective into mindful eating interventions for adolescents. This intervention will consist of 11 sessions in an 8 week period, with sessions 2,7, and 11 incorporating family sessions. The purpose of the family sessions are to increase overall family motivation for behavior change, involve family members in identifying specific targets of change and establishing agreed upon strategies.
3332590|NCT02114229|Experimental|(A) Alisertib alone|"Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).~Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated."
3332591|NCT02114229|Experimental|(B) Alisertib, chemotherapy, radiation therapy|"Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.~Interventions:~B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.~B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated."
3332592|NCT02114229|Experimental|(C) Alisertib, chemotherapy, radiation therapy|"Stratum C: Children ≥36 months old with newly diagnosed AT/RT.~Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.~Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated."
3332593|NCT02114242||Parkinson's disease patients|Patients suffering from Parkinson desease
3332594|NCT02114242||multiple system atrophy patients|"Patients suffering from probable multiple system atrophy according to clinical consensus criteria and age > 30"
3332595|NCT02114242||progressive supranuclear palsy|Patients suffering from progressive supranuclear palsy and age > 40
3332596|NCT02114255|Experimental|BCG vaccination|BCG vaccination
3332597|NCT02114255|Placebo Comparator|NaCl 0.9%|administration of NaCl 0.9%.
3332598|NCT02114281|Experimental|Care|Patient with dental care
3233828|NCT01225497|Active Comparator|Standard eccentric exercise|Participants randomised to this group shall complete 180 repetitions a day of Alfredsons heel drop protocol. This has been accepted as standard management for mid-portion Achilles pain in the first instance.
3233829|NCT01225497|Experimental|Eccentric exercise as able|Participants randomised to this group shall carry out exactly the same eccentric exercises as per Alfredsons heel drop protocol. However, these individuals will be instructed to do what they can.
3332599|NCT02114281|Active Comparator|Not care|Patient with not dental care
3332600|NCT02114294|Experimental|Isolated hip strengthening|Isolated hip strengthening (abduction, external rotation, extension)
3332601|NCT02114294|Active Comparator|Quadriceps based training|Quadriceps based training (mini-squat, straight leg raising, terminal extensions)
3332602|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
3332603|NCT02114320|Experimental|EUS-BD-1|EUS-BD-1 inserts a partially covered self-expanding metallic (hybrid) stent with a dedicated introducer for EUS-BD
3332604|NCT02114320|Experimental|EUS-BD-2|EUS-BD-2 inserts a fully covered self-expanding metallic stent
3332605|NCT02114333|Active Comparator|A - Live zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
3332606|NCT02114333|Active Comparator|B - recombinant zoster vaccine|"No previous zoster vaccine; stratified between age groups 50-59 and 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
3332607|NCT02114333|Active Comparator|C - Live zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose live vaccine, Zostavax (0.65ml, subcutaneous)~Second dose placebo, normal saline (0.65ml. subcutaneous)"
3332608|NCT02114333|Active Comparator|D - recombinant zoster vaccine|"One previous dose of zoster vaccine at least 5 years previously, age 70-85~First dose recombinant vaccine, HZ/su (0.5ml, intramuscular)~Second dose recombinant vaccine, HZ/su (0.5ml, intramuscular)"
3332609|NCT02114346|Experimental|Atorvastatin|Patients in the atorvastatin group receive 80 mg atorvastatin (2 x atorvastatin 40 mg tablets) once daily from 24 hours before to 48 hours after administration of contrast material.
3332610|NCT02114346|Placebo Comparator|Placebo|Patients in the placebo group receive 2 placebo tablets once daily from 24 hours before to 48 hours after administration of contrast material.
3332611|NCT02114359|Experimental|Platinum/fluoropyrimidine combination chemotherapy|
3332612|NCT02114359|Active Comparator|Fluoropyrimidine monochemotherapy|
3332613|NCT02114398|Experimental|usual treatment|usual treatment
3233830|NCT01225510|Experimental|Primary Cohort|
3233831|NCT01225510|Experimental|Exploratory Cohort|
3332614|NCT02114398|Experimental|usual treatment + sophrology|usual treatment + sophrology
3332615|NCT02114411||Dyspeptic patients|Patients (45 years and older, both genders) with dyspepsia referred for the GastroPanel test and gastroscopy with multiple bisopies at Homerton University Hospital (London, United Kingdom).
3332616|NCT02114424|Active Comparator|Positional vibrator belt|Positional belt to avoid supine sleep.
3332617|NCT02114424|No Intervention|No Night balance|the first 2 months without Night Balance
3332618|NCT02114437|Experimental|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
3332619|NCT02114437|Placebo Comparator|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
3332620|NCT02114463|Experimental|Local analgesic|This group uses local analgesia infusion pump of 0.2% ropivacaine 360ml through periarticular infiltration for postoperative analgesia.
3332621|NCT02114463|Active Comparator|Intravenous analgesic|This group is treated with intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg.
3332622|NCT02114476|Placebo Comparator|nonhormonal contraception|nonhormonal intrauterine device tubal sterilization
3233832|NCT01225523|Active Comparator|Preoperative chemotherapy followed by surgery|
3233833|NCT01225523|Active Comparator|Perioperative chemotherapy with surgery|
3233834|NCT01225536|Experimental|ARQ 736|
3233835|NCT01225575|Active Comparator|co.don chondrosphere®, 3-7 spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect"
3332623|NCT02114476|Experimental|progestin implant|Jadelle
3332624|NCT02114489|Experimental|Ibandronate|Unique perfusion of ibandronate 3 mg IV
3332625|NCT02114489|Placebo Comparator|Placebo|Unique perfusion of NaCl 3mg IV
3233836|NCT01225575|Active Comparator|co.don chondrosphere®,10-30spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group B is 10-30 spheroids/cm2 defect"
3332626|NCT02114502|Experimental|Carfilzomib/SAHA + Gem/Bu/Mel + Auto Stem Cell Transplant SCT|Busulfan test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5. Palifermin 60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2. SAHA 1,000 mg by mouth on Days -8 to -3. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3. Carfilzomib 27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1. SAHA 1,000 mg by mouth on Days -7 to -3. Melphalan 60 mg/m2 by vein on Days -3 and -2. Stem cell transplant on Day 0. Dexamethasone 8 mg by vein twice a day from Day -9 PM to Day -2 PM. Caphosol oral rinses 30 mL four times a day from Day -9 until discharge. Oral glutamine 15 g four times a day, swished, gargled and spit on Day -9 until discharge. Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
3332627|NCT02114528|Active Comparator|Anti-arrhythmic drug therapy|Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
3332628|NCT02114528|Active Comparator|Catheter ablation|Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.
3233837|NCT01225575|Active Comparator|co.don chondrosphere®,40-70spheroids/cm2|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group C is 40-70 Spheroids/cm2 defect"
3233838|NCT01225601||Histocytosis|Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
3332629|NCT02114567|Experimental|PSV ventilation|AECOPD Patients who were ventilated wiht PSV, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. Pressure support was set to get the tidal volume of 6ml/kg.
3332630|NCT02114567|Experimental|NAVA ventilation|AECOPD patients who were ventilated with NAVA, PEEP was titrated and set at 0, 40%, 80% and 120% PEEPi. NAVA level was set to get the tidal volume of 6ml/kg.
3332631|NCT02114580|Experimental|Aerobic exercise|
3332632|NCT02114580|Active Comparator|stretching exercise|
3233839|NCT01225614|Experimental|bipap ventilation|
3332633|NCT02114593|Experimental|Parent support program|Parent support program
3233840|NCT01225614|Active Comparator|Standard care|Standard care and ventilation if occurrence of absolute criteria of ventilation (cf infra).
3233841|NCT01225627|Experimental|Coordinated discharge|Patients will receive support by discharge coordinator for activities associated with discharge and immediate post-discharge care.
3332634|NCT02114593|No Intervention|Standard activities|Standard activities
3233842|NCT01225627|Placebo Comparator|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
3233843|NCT01225640|Experimental|PNU-100480 600 mg BID|
3233844|NCT01225640|Experimental|PNU-100480 1200 mg QD|
3332635|NCT02114619|Active Comparator|Low dose of I-131|Patients with Graves' disease who will be treated with I-131, using 100 microcurie per gram (uCi/gr) of thyroid weight
3332636|NCT02114619|Active Comparator|Intermediate dose|Patients with Graves' disease who will be treated with 150 microcurie (uCi) of I-131 per gram of thyroid weight.
3332637|NCT02114619|Active Comparator|High dose|Patients with Graves' disease who will be treated with I-131 using 200 uCi/gr of thyroid weight.
3332638|NCT02114632|Active Comparator|Polyunsaturated fatty acids|"6 capsules of food supplement Eye q per day divided in two daily doses (558 mg EPA, 174 mg DHA, 60 mg GLA per day)"
3233845|NCT01225640|Active Comparator|RHZE|conjugated tablet with 4 drug combination of RHZE, Rifafour® e275 will be used in countries where can be sourced locally
3233846|NCT01225653|Experimental|Latanoprost|Topical treatment with latanoprost
3332639|NCT02114632|Placebo Comparator|placebo|6 capsules of olive oil per day divided in two daily doses.
3332640|NCT02114645|Active Comparator|LongGnRH agonist protocol(controlgroup)|Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
3332641|NCT02114645|Experimental|Long protocol-leuprolide acetate|Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
3332642|NCT02114645|Active Comparator|GnRHantagonist protocol(control group)|GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
3332643|NCT02114645|Experimental|antagonist protocol-leuprolide acetate|GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
3332644|NCT02114658|Experimental|Arm 1|Sorafenib 400 mg bid continuous dose
3233847|NCT01225653|Placebo Comparator|Placebo|Placebo arm
3233848|NCT01225666|Experimental|Weekly low dose|MOD-4023
3332645|NCT02114671|Experimental|Faldaprevir QD high dose|capsules, oral administration with 240 ml water, fed conditions
3233849|NCT01225666|Experimental|Weekly middle dose|MOD-4023
3233850|NCT01225666|Experimental|Weekly high dose|MOD-4023
3233851|NCT01225666|Experimental|Every-other week dose|MOD-4023
3233852|NCT01225679||polysomnography|Overnight supervised polysomnography (Embla System®) was performed in a sleep laboratory, which included capnometry. Arterial blood gas analysis was performed by radial arterial puncture. Ventilatory response to progressive hypercapnia was measured using the Read breathing technique. Briefly, subjects rebreathed into an air tight 5-L bag containing a mixture of 8% carbon dioxide (CO2) and 40% oxygen (O2). The spirometer technology used to monitor ventilation was based on a bi-directional rotating vane principle (flow sensitive). A continuous record of CO2 concentration in the expired gas was obtained by a CO2 analyzer within the circuit. The ventilatory hypercapnic drive was calculated from the slope produced by changes in ventilation (L. min-1) and changes in end-tidal PCO2.
3233853|NCT01225705|Experimental|Raltegravir|45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine
3233854|NCT01225705|Active Comparator|Atazanavir/ritonavir|45 patients will receive open label atazanavir/ritonavir
3332646|NCT02114671|Experimental|Faldaprevir QD low dose|tablets/capsules, oral administration with 240 ml water, fed conditions
3332647|NCT02114671|Placebo Comparator|Placebo|capsules, oral administration with 240 ml water, fed conditions
3233855|NCT01225744|Experimental|Cetuximab plus Irinotecan, Oxaliplatin and UFT|Cetuximab plus Irinotecan, Oxaliplatin, UFToral
3233856|NCT01225757|Experimental|Echocardiography|These patients will have echocardiography guided fluid management
3233857|NCT01225757|Active Comparator|Traditional fluid management|Fluid management will be guided by monitoring of central venous pressure and urine output.
3233858|NCT01225770|Experimental|Green tea|Gargling with green tea
3233859|NCT01225770|Active Comparator|water|Gargling with water
3332648|NCT02114671|Active Comparator|Ciprofloxacin|tablets, oral administration with 240 ml water, fed conditions
3332649|NCT02114697|Active Comparator|Lifestyle modification|Lifestyle modification is tailored to each participant and includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake.
3233860|NCT01225796|Experimental|Sodium bicarbonate|This group will receive oral sodium bicarbonate 650mg three times daily for 6 months.
3233861|NCT01225796|No Intervention|Control|This group will not receive any sodium bicarbonate.
3233862|NCT01225809||AD01with or without adjuvant|Patients who have received at least one immunization of AD01 with or without adjuvant during AFF001
3233863|NCT01225874|Experimental|Stratum 3|Patients receive oral dexamethasone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; pegaspargase intramuscularly (IM) on day 4, 5, or 6; cytarabine intrathecally (IT) on day 1; and methotrexate IT on day 8 (some patients also receive methotrexate IT on days 15 and 22).
3332650|NCT02114697|Experimental|Statin therapy|Participants will receive statin medication along with instruction about regular exercise.
3332651|NCT02114710|Experimental|Hydrocortisone|little doses of hydrocortisone
3233864|NCT01225874|Experimental|Stratum 4|Patients receive oral prednisone twice daily on days 1-28; vincristine sulfate IV on days 1, 8, 15, and 22; IM SC-PEG E. coli asparaginase on days 2, 5, 8, 12, 15, and 19; daunorubicin hydrochloride IV over 15-20 minutes on days 8, 15, and 22; and methotrexate IT on days 1 and 8 (some patients also receive methotrexate IT on days 15 and 22).
3332652|NCT02114710|No Intervention|Placebo|Placebo
3332653|NCT02114723|Active Comparator|Medical Taping Concept|"3 band of a special and hypoallergenic tape, called Cure Tape ® (2 strips of 12 x 5 cm and 1 strip of 20 cm x 5 cm) are attached to the abdominal and lower back. One piece of 12 cm in length is applied right from below the navel and reached to where the pubic hair below, and another piece of 12 cm in length is applied to make a cross shape with the first piece (inside 11-12 dermatomes area). The piece of 20cm in length is placed horizontally to the lower back.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
3332654|NCT02114723|Placebo Comparator|Cross tape|Two pieces of special and squared tape of 2.5 x 2 cm called Cross Tape ® are attached to the external side of the thigh at the hip joint area (outside 11-12 dermatomes area)
3332655|NCT02114736|Experimental|Rectus femoris tenotomy|Surgical release of the proximal tendon of the rectus femoris
3233865|NCT01225913|Other|Asthma observational study arm|Asthmatics in this arm may be on varying dose of inhaled fluticasone 100-500mcg/salmeterol 50mcg bid via Advair MDI or equivalent dose via Diskus bid or Symbicort (budesonide 80-160mcg/formoterol 4.5mcg bid)or Dulera 100-200mcg mometasone/5 mcg formoterol bid, tiotropium 18mcg capsule daily. This is an observational study and additional pharmacologic intervention may include antibiotic and tapering doses of corticosteroids.
3233866|NCT01225939|Experimental|1|Single Oral dose AZD8329 tablet (fasting)
3233867|NCT01225939|Experimental|2|Single Oral dose AZD8329 solution (fasting)
3233868|NCT01225939|Experimental|3|Single Oral dose AZD8329 tablet (Fed)
3233869|NCT01225965|Experimental|EIL05, Inhalation|
3233870|NCT01225965|Placebo Comparator|Placebo, 0,9% NaCl|
3233871|NCT01225978||GeneInsight Clinic (GIC)|The Group/Cohort in this study are geneticists, physicians, and genetic counselors who are using the GeneInsight Clinic (previously known as Patient Genome Explorer) to receive and store genetic test reports and variant update information.
3233872|NCT01226030|Experimental|M2ES 7.5mg|M2ES 7.5mg
3233873|NCT01226030|Experimental|M2ES 15mg|M2ES 15mg
3233874|NCT01226030|Experimental|M2ES 30mg|M2ES 30mg
3233875|NCT01226030|Experimental|M2ES 60mg|M2ES 60mg
3233876|NCT01226056|Experimental|RAD001 in combination with sorafenib|
3233877|NCT01226069|Active Comparator|Glycerine Magnesium Sulphate paste|
3233878|NCT01226069|Active Comparator|Hirudoid cream|Topical Mucopolysaccharide polysulphate
3233879|NCT01226069|Experimental|No application|Patient will not receive any topical application to apply on the phlebitis site. The outcome assessor will monitor regularly at pre-determined schedule as patients in other active arms.
3233880|NCT01226082|Experimental|Transcranial Direct Current Stimulation|
3233881|NCT01226108|Active Comparator|antinitus patch|One patch per day, Duration: three weeks, Administration: behind the ear
3233882|NCT01226134|Experimental|1.Itopride Group|The itopride group will receive itopride 150mg per day(50mg TDS)for four weeks
3233883|NCT01226134|Placebo Comparator|2.Control placebo group|The control group will receive placebo tablets for four weeks
3332656|NCT02114736|Active Comparator|Botulinum toxin in the rectus femoris muscle|Botulinum toxin (200U Botox) injection in the rectus femoris muscle
3332657|NCT02114749|Experimental|volunteers in daily life activities|a set of wearable respiration and cardiac monitoring devices
3332658|NCT02114762|Experimental|Balloon dilation of the Eustachian tube|Insertion and inflation of balloon into Eustachian tube for up to 1 minute
3332659|NCT02114775|Active Comparator|Recombinant Growth Hormone|Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.
3332660|NCT02114775|Active Comparator|Sildenafil|Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.
3332661|NCT02114788||group 1|No intervention
3332662|NCT02114788||Group 2|Intervention with interactive website
3332663|NCT02114801|Experimental|manual brushing|manual brushing; Oral-B®, Stages 4, Rio de Janeiro, Rio de Janeiro;
3332664|NCT02114801|Experimental|electric toothbrush linked|electric toothbrush linked; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
3332665|NCT02114801|Experimental|off electric toothbrush|off electric toothbrush; Braun - Oral-B®, D2010K, Rio de Janeiro, Rio de Janeiro
3332666|NCT02114827|Experimental|Video|"Patients will view the 23-minute Guide to Stem Cell Transplantation video depicting the HSCT experience"
3332667|NCT02114827|Active Comparator|FAQ Sheet|Patients will receive HSCT FAQ sheet developed by the NCI at the NIH
3332668|NCT02114840|Experimental|Pronator quadratus preservation|Pronator quadratus preservation
3332669|NCT02114840|Active Comparator|Pronator quadratus non repair|
3332670|NCT02114840|Active Comparator|Pronator quadratus repair after disruption|
3332671|NCT02114905|Experimental|OTs Trained and Deliver CBIT|CBIT certified clinicians will train OTs in delivering CBIT to affected youth. OTs will be supervised in the practice of CBIT with youth in the New York City and Birmingham areas. Pre- and post-treatment assessment measures will be collected from 16 families (8 from each site) to evaluate intervention acceptability, feasibility, and fidelity. Patient and parent satisfaction of CBIT-OT will also be documented.
3332672|NCT02114918|Experimental|Attention Modification Program|Active computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief. AMP is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word.
3332673|NCT02114918|Placebo Comparator|Attention Control Condition|Control computer-based attention training task, which is not designed to modify biased attention patterns in anxious patients. ACC is a modified version of the dot-probe paradigm similar to the original task used by MacLeod, Mathews, and Tata. In this case, the probe randomly replaces the neutral word or the threat word.
3332674|NCT02114957|Experimental|study herb|
3332675|NCT02114970|Other|Focus Group- paper and tablet consent|Participation in a focus group of other older adults, lasting 120 minutes. Participants will answer semi-structured questions in a group format, describing their impressions of both a prototype tablet-delivered and a paper consent.
3332676|NCT02114970|Active Comparator|Randomized- paper consent|Participants will review a mock paper consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the paper informed consent form.
3332677|NCT02114970|Active Comparator|Randomized- Tablet-delivered consent|Participants will review a mock tablet-delivered consent form with a study clinician, and complete a series of questionnaires assessing their comprehension of material covered and general experience with the tablet-delivered informed consent.
3332678|NCT02114983||first episode of suspected DVT of the lower limbs|patients with first suspected episode of DVT of the lower limbs
3233884|NCT01226160|Experimental|Face-down posturing group|Postoperative face-down positioning for 10 days after surgery.
3233885|NCT01226160|Active Comparator|Non-posturing group|avoid a face-up position for 10 days after surgery
3332679|NCT02115022||Potentially resectable pancreatic cancer|Patients with a confirmed pancreatic mass (suspected neoplastic) deemed resectable or borderline resectable on multislice (at least 16 simultaneously acquired slices) pancreatic protocol computed tomography (CT), fit and willing to undergo surgery with a curative (R0) intent.
3332680|NCT02115035|Experimental|Vermurafenib|Vermurafenib dosing will be given twice daily by oral administration in cycles of 28 days
3332681|NCT02115061|Active Comparator|Cyanoacrylate|"This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.~Treatment: cyanoacrylate"
3332682|NCT02115061|Sham Comparator|Coil + cyanocrylate|"This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.~Treatment: coil + cyanoacrylate"
3332683|NCT02115074|Experimental|Fluvastatine Celebrex|dose escalation for Fluvastatine
3332684|NCT02115087|Experimental|ultrasound guided rectus sheath block|Ultrasound guided rectus sheath block
3332685|NCT02115087|Active Comparator|iv morphine|0.1 mg.kg-1 loading dose of morphine by intravenous route in intraoperative period
3332686|NCT02115100|Active Comparator|pulmonary vein+renal artery denervation|Procedure: pulmonary vein and renal artery denervation
3332687|NCT02115100|Active Comparator|Pulmonary vein isolation|Procedure: Pulmonary vein isolation
3332688|NCT02115126|Active Comparator|LMP2A-loaded conventional DC vaccine|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine
3332689|NCT02115126|Experimental|LMP2A-loaded DC vaccine + DUK-CPG-001|Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001
3332690|NCT02115152|Active Comparator|FEC|Patients will be randomized to received 4 cycles of fluorouracil, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel after surgery.
3233886|NCT01226186|Active Comparator|Nurse dispensed oral morphine solution.|
3233887|NCT01226186|Active Comparator|Self medicated oral morphine solution.|
3332691|NCT02115152|Experimental|XEC|Patients will be randomized to received 4 cycles of capecitabine, epirubicin and cyclophosphamide before surgery, and 4 cycles of docetaxel and capecitabine after surgery.
3332692|NCT02115165|Experimental|Cabazitaxel|
3332693|NCT02115178||Lithotomy or Prone position|
3233888|NCT01226212|Experimental|Synbiotic|Synbiotic (Synergy 1/B. longum)
3233889|NCT01226212|Placebo Comparator|Placebo|maltodextrose
3233890|NCT01226225|Experimental|Aerobic interval training|
3233891|NCT01226225|Active Comparator|Moderate endurance training|
3233892|NCT01226238|Experimental|Online self-help|Provision of online self-help while waiting for psychotherapy
3332694|NCT02115191|Experimental|2-octylcyanoacrylate|Application of 2-octylcyanoacrylate
3332695|NCT02115191|Active Comparator|Surgical reintervention|Surgical reintervention for urethrocutaneous fistula repair
3332696|NCT02115204|Experimental|EC-Doc|4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
3332697|NCT02115204|Active Comparator|CMF/CEF|6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks
3332698|NCT02115217|Experimental|Leukotape K, basketball training|Use of Leukotape K to ensure stability of the ankle in basketball players
3332699|NCT02115217|Placebo Comparator|Sham, basketball training|Use of sham tape
3332700|NCT02115230|Experimental|Renal denervation + medical therapy|Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
3332701|NCT02115230|No Intervention|Medical therapy|Standard optimized medical therapy for diastolic heart failure
3332702|NCT02115243|Other|Ipi/ILI|Patients will receive ipilimumab followed by ILI.
3332703|NCT02115295|Experimental|Treatment (cladribine, cytarabine, idarubicin)|"INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity."
3332704|NCT02115334|Experimental|professional-based group|professional therapists delivering the PHPA
3332705|NCT02115334|Experimental|parents-based group|parents executing the PHPA
3332706|NCT02115334|Active Comparator|control group|health education only
3332707|NCT02115360|Active Comparator|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 100 iu of calcitonin will be injected epidurally in Bupivacain-Calcitonin-fentanyl (BC) Group,
3332708|NCT02115360|Active Comparator|fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
3332709|NCT02115399||ADStaph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
3332710|NCT02115399||ADStaph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group.
3332711|NCT02115399||NAStaph-|Non-atopic healthy participants without S. aureus skin colonization. A minimum of 45 participants will be enrolled in this group
3332712|NCT02115399||NAStaph+|Non-atopic healthy participants with S. aureus skin colonization. As the NAStaph+ phenotype is expected to be rare, as many participants as possible will be enrolled in this group; however, we do not expect to enroll 45 participants in this group.
3332713|NCT02115412||medication non-adherence|
3332714|NCT02115425||Age 10-17|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
3332715|NCT02115425||Age 18-80|Age 18-80 years Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA)
3233893|NCT01226238|No Intervention|Waiting list alone|Waiting for psychotherapy alone
3233894|NCT01226251||Healthy adults|Subjects consulting a bad breath clinic at the Department of Periodontology, KULeuven
3332716|NCT02115438||Occupational Stress|
3233895|NCT01226277|Experimental|A|
3233896|NCT01226290|Experimental|VizAblate treatment|VizAblate System: subject acts as her own control
3332717|NCT02115451||Surgical treatment|Patients who undergo rehabilitation and anterior cruciate ligament reconstruction, other surgical interventions may be performed
3332718|NCT02115451||Nonsurgical treatment|Patients who undergo rehabilitation without anterior cruciate ligament reconstruction, other surgical interventions may be performed
3332719|NCT02115464|Experimental|Metformin plus Chemo-radiotherapy|Metformin orally 500 mg twice daily for the first week, 1500 mg a day in week 2 and 2000 mg a day at week 3 and then for a period of 12 months. Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
3332720|NCT02115464|Active Comparator|Chemo-radiotherapy|Concurrent cisplatin based chemotherapy with or without consolidation and radiotherapy of 60-63 Gy for 6 weeks.
3332721|NCT02115477||Group with lymphadenectomy|The group of women with high risk endometrial cancer who undergoes pelvic and/or paraaortic lymphadenectomy at primary surgery
3332722|NCT02115477||Group without lymphadenectomy|The group of women with low risk endometrial cancer who do not have lymphadenectomy at primary surgery
3332723|NCT02115490||Osteoporosis_with_Bisphosphonates|This group of patients are taking Bisphosphonates orally in their treatment
3332724|NCT02115490||Osteoporosis-without-Bisphosphonates|This group of patients has not taken Bisphosphonates in the course of treatment
3233897|NCT01226303|Experimental|standard risk|are defined as those patients with a WBC less than 10x10 9 /L at presentation
3233898|NCT01226303|Active Comparator|high risk|are defined as those patients whose highest treatment WBC is equal to or greater than 10x10 9 /L at presentation
3332725|NCT02115503||Cohort 1|Cohort 1 will consist of those having primarily Class I antibody development post-transplant
3332726|NCT02115503||Cohort 2|Cohort 2 will include those having primarily Class II antibody development post-transplant
3332727|NCT02115503||Cohort 3|Cohort 3 will consist of the remaining subjects that have a mix of Class I and II antibodies.
3332728|NCT02115516|Experimental|Stage A: Grp A1 - 3,200 PfSPZ Challenge|Group A1 (PfSPZ Challenge) (n=9) receives three injections of 3,200 PfSPZ Challenge intravenous (IV) at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3332729|NCT02115516|Experimental|Stage A: Grp A2 - 12,800 PfSPZ Challenge|Group A2 (PfSPZ Challenge) (n=9) starts when Group A1 receives the second immunization. Group A2 receives three injections of 12,800 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3332730|NCT02115516|Experimental|Stage A: Grp A3 - 51,200 PfSPZ Challenge|Group A3 (PfSPZ Challenge) (n=9) starts when Group A2 receives the second immunization. Group A3 receives three injections of 51,200 PfSPZ Challenge IV at 4-week intervals. Immunizations are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first PfSPZ Challenge injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last immunization, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A Week on 27.
3332731|NCT02115516|Placebo Comparator|Stage A: Grp A1 - 0.9% Sodium Chloride|Group A1 (placebo) (n=5) receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 19, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3332732|NCT02115516|Placebo Comparator|Stage A: Grp A2 - 0.9% Sodium Chloride|Group A2 (placebo) (n=5) starts when Group A1 receives the second immunization. Group A2 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. Early unblinding for this group may be done on Week 23, if required. All groups in Stage A are scheduled to be unblinded on Week 27.
3332733|NCT02115516|Placebo Comparator|Stage A: Grp A3 - 0.9% Sodium Chloride|Group A3 (placebo) (n=5) starts when Group A2 receives the second immunization. Group A3 receives three injections of 0.9% Sodium chloride IV at 4 week intervals. Placebo injections are given under a standard chemoprophylactic regimen with chloroquine. Two days before the first placebo injection volunteers receive one oral dose of 10 mg/kg CQ base. On Day 5 volunteers will receive 5 mg/kg CQ base. Subsequently, volunteers will receive 5 mg/kg CQ base in weekly intervals for a total of ten doses. Eight weeks after the last placebo injection, volunteers will undergo homologous CHMI with 3,200 PfSPZ Challenge IV. This group is scheduled to be unblinded with all other groups in Stage A on Week 27.
3332734|NCT02115516|Experimental|Stage B: Grp B1 - 51,200 PfSPZ Challenge|Group B1 (n=5) will receive the optimal PfSPZ Challenge immunizing dose from the dose-escalation phase (Stage A; 51,200 PfSPZ Challenge (NF54)), using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. Group B1 will receive 3 injections of 51,200 PfSPZ Challenge (NF54) on days 0, 14 and 28. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3332735|NCT02115516|Placebo Comparator|Stage B: Group B1 - 0.9% Sodium Chloride|Group B1 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28. This group will follow the the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), but for five instead of ten weeks. All volunteers in Group B1 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3332736|NCT02115516|Experimental|Stage B: Grp B2 - 51,200 PfSPZ Challenge|Group B2 (n=5) will receive 3 injections of 51,200 PfSPZ Challenge on days 0, 14 and 28, using same std chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive extended-release azithromycin (ER-AZ, 2g) on the day of 1st PfSPZ Challenge and monitored for parasitemia by quantitative real time polymerase reaction (qPCR). In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following first PfSPZ Challenge injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will continue and ER-AZ will not be administered for the 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge, 10 weeks after the last immunization.
3332737|NCT02115516|Placebo Comparator|Stage B: Group B2 - 0.9% Sodium Chloride|Group B2 (placebo) (n=2) will receive three injections of 0.9% Sodium Chloride on days 0, 14 and 28, using the same standard chemoprophylactic regimen with CQ (10 mg/kg CQ base loading dose, followed by weekly dosing with 5 mg/kg CQ base), for 5 instead of 10 wks. But Group B2 will receive ER-AZ, 2g on the day of 1st placebo injection and monitored for parasitemia by qPCR. In case that all CQ+ER-AZ treated volunteers are parasite-free until Day 11 following 1st injection, it will indicate that ER-AZ effectively killed the parasites in the liver prior to the development of parasitemia. With demonstration of the effectiveness of ER-AZ, the 2nd and 3rd immunizations will be done under ER-AZ alone, otherwise CQ prophylaxis will be continued and ER-AZ will not be administered for 2nd and 3rd injections. Group B2 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after last immunization.
3332738|NCT02115516|Experimental|Stage B: Grp B3 - 51,200 PfSPZ Challenge|Group B3 (n=9) volunteers will receive CQ and PfSPZ Challenge simultaneously every five days with one additional dose of CQ five days after the third PfSPZ Challenge injection. A 10 mg/kg CQ base loading dose is given at the time of first PfSPZ Challenge inoculation, followed by 5 mg/kg CQ base on the day of second and third inoculation and five days after the last PfSPZ Challenge inoculation. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3332739|NCT02115516|Placebo Comparator|Stage B: Group B3 - 0.9% Sodium Chloride|Group B3 (placebo) (n=2) volunteers will receive CQ and 0.9% Sodium Chloride simultaneously every five days with one additional dose of CQ five days after the third placebo injection. A 10 mg/kg CQ base loading dose is given at the time of first placebo injection, followed by 5 mg/kg CQ base on the day of second and third injections and five days after the last placebo injection. Group B3 will undergo homologous CHMI with PfSPZ Challenge 10 weeks after the last immunization.
3332740|NCT02115529|Active Comparator|Cesamet (nabilone)|0.5 mg capsule containing Cesamet (single dose) given preoperatively
3332741|NCT02115529|Placebo Comparator|Placebo|identical capsule containing placebo (single dose) given preoperatively
3332742|NCT02115555|Experimental|HIT-aided approach|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the Self Monitored Blood glucose tests.
3332743|NCT02115555|Experimental|Contracted conflict management system|Adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent.
3332744|NCT02115555|Experimental|HIT plus contracted conflict management|Adolescents and their parents randomized to this arm will be oriented on a HIT system. The system transmits self monitoring blood glucose data to a secure web portal. The subject will receive messages from the HIT system on the meter based upon the tests. In addition, adolescent-parent pairs will meet with a health educator to establish a behavioral contract that will set patient-centered self-management goals for the adolescent. This arm combines arms 1 and 2.
3332745|NCT02115568||Long-term safety follow-up|To be eligible, subjects must have actively participated in a Juventas (JVS-100) sponsored trial under IND 14203.
3332746|NCT02115594|Experimental|Fulvestrant + Entinostat|Arm A: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus entinostat (5 mg PO once weekly)
3332747|NCT02115594|Active Comparator|Fulvestrant + Placebo|Arm B: Fulvestrant (500 mg on C1D1, C1D15, C2D1, and on Day 1 of each subsequent cycle) plus placebo (5 mg PO once weekly)
3332748|NCT02115620|Experimental|Telemedicine|Patients will be followed using frequent communication of symptom status and physiologic data and remote consultations with Heart Failure specialists.
3332749|NCT02115659|Placebo Comparator|Placebo|Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
3332750|NCT02115659|Experimental|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring.
3332751|NCT02115672|Experimental|BL-8040|Patients with chronic phase CML on Imatinib therapy (400 mg/day) achieving less than an optimal response will be treated with sc injections of BL-8040, while continuing Imatinib. The first part of the study will include escalating dose groups. Up to 4 dose levels will be investigated starting at dose level 1. Patients will be accrued in a conventional 3+3 design. Applying this study design, the first cohort of 3 patients will be treated at dose level 1 (0.5 mg/kg) on Day 1, 15, 29 and 43. Patients will continue taking Imatinib 400 mg/day throughout the study. Dose escalation will continue until the maximal tolerated dose (MTD) is established and protocol specific stopping rules for toxicity are met. If no MTD is reached, dose escalation will continue up to dose level 4 (1.25 mg/kg).
3332752|NCT02115685|No Intervention|One day testing|Aim 1 will be to measure bloodflow during exercise of the legs (below the injury). This aim will examine the control of bloodflow and muscle contractions and how it changes after spinal cord injury.
3332753|NCT02115685|Experimental|Effects of long term training|Aim 3 will then look at changes in bloodflow during exercise after training. Three different eight week exercise training programs will be tested including 1) treadmill training at high intensity as defined by 70-80% of HRR or 15-17 RPE 2) treadmill training at low intensity as defined by 30-40% of HRR or <13 RPE
3332754|NCT02115698|Active Comparator|Heavy Resistance Training|Heavy Resistance Training of the lower extremities three times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3332755|NCT02115698|Experimental|Light Intensity Training|Home-based Light Intensity Training of the lower extremities three-five times weekly in combination with two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3332756|NCT02115698|Active Comparator|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
3332757|NCT02115698|Active Comparator|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
3332758|NCT02115698|Placebo Comparator|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
3332759|NCT02115711|Experimental|Community health worker|Home visits by community health worker to deliver the multi-component behavioural intervention targeted at the individual's hypertension, diabetes or smoking.
3332760|NCT02115711|No Intervention|Usual care|Patients will receive usual care in the community
3332761|NCT02115724|Experimental|Antioxidant Cocktail|Following an overnight fast, blood samples, flow-mediated dilation, and nitroglycerin mediated dilation (NMD; 0.4mg sub-lingual nitroglycerin spray) will be performed at baseline and 2 hours following either a single dose oral antioxidant cocktail (1000 mg Vitamin C, 600 IU vitamin E, 600 mg Alpha Lipoic Acid) or placebo on two days separated by at least 72 hours.
3332762|NCT02115724|Other|Biopsy|Following an overnight fast, a subcutaneous gluteal/hip fat biopsy sample will be obtained from each subject under local anesthesia, with adipose tissue (~2x1.5x1.5cm) to be harvested and placed immediately in physiological saline solution (PSS): Small arteries, 100 to 150 um in diameter, will be dissected from the fat under a dissecting microscope, transferred to an arteriographic bath chamber, and cannulated for pressurized myography.
3332763|NCT02115737|Experimental|Dialectical Behavior Therapy Skills Group|Twelve week skills based group therapy include four modules: mindfulness, emotion regulation, distress tolerance, and walking the middle path
3332764|NCT02115737|Experimental|Psychoeducation group treatment|The comparison group used in the present study is based on a publicly available treatment manual from the Services for Teens At Risk (STAR) Center at the University of Pittsburgh
3332765|NCT02115763|Experimental|Caffeine|There is only one arm, it receives both caffeine and placebo.
3332766|NCT02115776|No Intervention|Control|Receiving no prophylaxis
3332767|NCT02115776|Active Comparator|Amoxicillin|Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation
3332768|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation
3332769|NCT02115776|Active Comparator|Chlorhexidine (CHX)|Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
3332770|NCT02115776|Experimental|Amoxicillin-Potassium Clavulanate-CHX|Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation
3332771|NCT02115789||Survey Group|Adult male or female volunteers.
3332772|NCT02115802|Experimental|Activa PC+S|Specific features of LFP recorded from the deep brain nuclei will be examined for possible correlation with different natural behaviors, such as movement, walking, or speech.
3332773|NCT02115841|Experimental|E1|Experiment 1 will measure the cortical excitability change after TENS intervention.
3332774|NCT02115841|Experimental|E2|Experiment 2 will measures implicit sequential motor task performance and cortical hemodynamic response using near infrared spectroscopy (NIRS) during motor execution. Cortical excitability will also be measured contemporary
3332775|NCT02115854||bacteriologically confirmed tuberculosis|
3332776|NCT02115867|Active Comparator|Probiotic|"Probiotic arm Liquid broth~1 mL/kg every morning for 90 days"
3332777|NCT02115867|Placebo Comparator|Placebo|"Placebo arm Liquid broth~1 mL/kg each morning for 90 days"
3332778|NCT02115880|Experimental|Prevention programme|
3332779|NCT02115880|No Intervention|Control (treatment as usual)|
3332780|NCT02115893|Active Comparator|Sodium Nitrate|Dietary Supplement: Sodium nitrate 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
3332781|NCT02115893|Placebo Comparator|Sodium Cloride|Dietary Supplement: Sodium chloride 800 mg of sodium chloride added with water to get a 140 mL solution (Frisia Zout BV, Harlingen, The Netherlands)
3332782|NCT02115906||Acromegalic patients|Acromegalic patients before and after initiation of individual therapy will be investigated by 1H/31P magnetic resonance spectroscopy, thyroid sonography and oral glucose tolerance testing
3332783|NCT02115906||Healthy control subjects|Age and Body mass index matched control subjects will be investigated by 1H/31P magnetic resonance spectroscopy and oral glucose tolerance testing
3332784|NCT02115919|Experimental|Cohort A|Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
3332785|NCT02115919|Experimental|Cohort B|Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
3332786|NCT02115932|Experimental|Strength & Balance Training Intervention|Subjects in this arm will undergo once weekly home-based strength and balance training for a period of 8 weeks.
3332787|NCT02115932|No Intervention|Control|Subjects in this arm will not undertake any procedures or activities related to the study. They will continue with their prescribed medication and other medical advice from their treating physician as per usual.
3332788|NCT02115945|Experimental|epidural block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
3332789|NCT02115945|Active Comparator|femoral block|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life. The DN4 test was used to evaluate neuropathic pain.
3332790|NCT02115958|Placebo Comparator|non-cancer stem cell vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3332791|NCT02115958|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3332792|NCT02115958|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3332793|NCT02115958|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3332794|NCT02115971|Experimental|Jumping exercise|"Physical therapy with a focus on specific jumping exercise. The jumping exercise will be performed for 12 weeks (3x/week), with a break of day between workouts. The 40-minute workout is completed 2 times under supervision in the clinic's internal training group for outpatients. 1 time they train on their own at home, based on a defined training program. The training process is documented by the training protocol.~The incipient exercise intensity is taking personal performance into account. The exercise intensity is increased by a progressive scheme."
3332795|NCT02115971|Active Comparator|Strength exercise|"Physical Therapy with a focus on stability and strength exercise. Strength exercise arm has also same duration of 12 weeks with comparable intensity. The program is according to a predetermined program. The 60-minute training is completed twice under supervision in the clinic's internal training group for outpatients.There is no contact with participants of other group.~Between the two exercise sessions there is a training free day. The training process is documented by the training protocol. The incipient exercise intensity is considering personal performance. The intensity is increased after workout usual principles. The exercises are described with clear image and load parameters. The training exercises are regularly monitored."
3332796|NCT02116010|Active Comparator|E. coli, Standard of care : Silver Sulfadiazine|Burn wounds infected by E. coli treated with Standard of care : Silver Sulfadiazine
3332797|NCT02116010|Experimental|E. coli, Phages cocktail|Burn wounds infected by E. coli treated with Pherecydes Pharma Phages cocktail
3332798|NCT02116010|Active Comparator|P. aeruginosa, Standard of care : Silver Sulfadiazine|Burn wounds infected with P. aeruginosa treated with Standard of care : Silver Sulfadiazine
3332799|NCT02116010|Experimental|P. aeruginosa, Phages cocktail|Burn wounds infected by P. aeruginosa treated treated with Pherecydes Pharma Phages cocktail
3332800|NCT02116023|Experimental|Orange flavored beverage - Test1|240ml processed whole orange low dose
3332801|NCT02116023|Experimental|Orange flavored beverage - Test2|240ml processed whole orange high dose
3233903|NCT01226329|Experimental|RQP-MH|Participants in the intervention arm will receive three Patient Activation and Self-Management education sessions, plus a fourth booster session if they show difficulty mastering the content of the first three trainings.
3332802|NCT02116023|Placebo Comparator|Orange flavored beverage - Placebo|240ml orange beverage
3332803|NCT02116036|Experimental|Rivaroxaban|Rivaroxaban 20mg po daily
3332804|NCT02116049|Active Comparator|Attention Control Case Management|"Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients. This project's case management will mimic the experimental condition with a meeting schedule reflective of the experimental arm plus a booster session at 3 months."
3332805|NCT02116049|Experimental|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
3332806|NCT02116062|Other|Amniotic membrane transplantation|
3332807|NCT02116062|Other|Pterygium surgery|
3332808|NCT02116062|Other|Penetrating keratoplasty|
3233904|NCT01226329|Active Comparator|Comparison Group|"Participants in this arm will receive a pamphlet in either Spanish or English called Managing Your Mental Health Care."
3233905|NCT01226342|Experimental|TCEMS|Patients who will receive transcutaneous electrical muscle stimulation
3332809|NCT02116075|Experimental|Epidural Steroid|80mg depo-medrol 9mL 1% lidocaine
3332810|NCT02116075|Active Comparator|Epidural Prolotherapy|10ml of 5% generic dextrose
3332811|NCT02116088|Active Comparator|Receiving Teacher Coaching|Teachers who currently take part in teacher coaching
3332812|NCT02116088|No Intervention|Waiting for Teacher Coaching|Teachers who are currently waiting for taking part in teacher coaching
3332813|NCT02116101|Active Comparator|Bright Momchilovtsi yogurt|Bright Momchilovtsi yogurt Contains 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
3332814|NCT02116101|Placebo Comparator|Bright Dairy Beverage|Dairy beverage product without prebiotics
3233906|NCT01226355|Experimental|NOYA|implant NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stents Intervention: Device: stent
3233907|NCT01226355|Active Comparator|Firebird2|implant Firebird2 drug-eluting stents Intervention: Device: stent
3233908|NCT01226394|No Intervention|surveillance|
3233909|NCT01226394|Experimental|laparotomy plus HIPEC.|
3233910|NCT01226407|Experimental|Single Arm for CG200745|any progrossive solid cancer
3332815|NCT02116114|Experimental|Aquatic exercises|"3 times a week~heating~aerobic training~slowdown"
3332816|NCT02116114|No Intervention|control group|The control group participated in the study only to usual care , conventional medical treatment orientation about the disease , methods of energy conservation and evaluation.
3332817|NCT02116127|Experimental|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
3332818|NCT02116127|Sham Comparator|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
3332819|NCT02116140|Experimental|[C11]Acetate HED PET|"AMEND is a single centre substudy of the ADVENT-HF trial. This substudy is a clinical physiologic proposal designed to determine the effects of long-term (6 months) ASV on cardiac energetics and SN function in patients with chronic stable HF and sleep apnea extending our previous evaluation of short-term CPAP in patients with OSA and HF.~All subjects consenting to the ADVENT primary trial will be eligible to participate in the substudy.~Substudy consenting patients will have [11C]acetate and [11C]HED PET imaging; HR variability; plasma norepinephrine (NE) levels, urine normetanephrine levels within 2 weeks of the sleep study. Baseline measurements will be repeated after 6 months in all patients."
3233911|NCT01226446|Experimental|Addition of Vitamin D to Peg-interferon plus Ribavirin|
3332820|NCT02116166||Young|Young (20-35 years old)
3332821|NCT02116166||Old|Older (70-99 years old)
3332822|NCT02116179|Experimental|DVD Intervention|DVD Intervention presented at one 90 minute group session
3332823|NCT02116179|No Intervention|Wait list Control Group|Group will get no intervention until after 90 day follow up
3332824|NCT02116192|Active Comparator|General Healthy Diet|Control: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
3332825|NCT02116192|Experimental|Low-fructose, reduced carbohydrate diet|"Intervention: Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
3332826|NCT02116218|Experimental|acupuncture|Experimental group would receive acupuncture at specific acupoints for 15 minutes.
3332827|NCT02116218|Sham Comparator|seed|Control group would receive another intervention that we would put Vaccaria seeds near the acupoints but without acupressure for the same period.
3332828|NCT02116231|Experimental|Concurrent chemoradiotherapy|Concurrent chemoradiotherapy: IMRT was given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy.
3233912|NCT01226498|Experimental|Fresh blood auto-transfusion|
3233913|NCT01226498|Experimental|Old blood auto-transfusion|
3233914|NCT01226524|Experimental|Traditional Chinese Medicine|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulations, i.e. Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan
3332829|NCT02116231|Active Comparator|IMRT alone|IMRT is given to the patients with regimen of 66Gy-76Gy to the gross target volume of nasopharynx,66-70Gy to the gross target volume of positive nodes, 60-62Gy the high risk clinical target volume, 50-56Gy to the low risk clinical target volume.
3332830|NCT02116244|Experimental|Civamide Nasal Spray|Civamide Nasal Spray 0.01% 20ug/dose (20ul), 10ul in each nostril, twice daily for 12 weeks
3332831|NCT02116257|Experimental|Propacetamol|
3332832|NCT02116257|Placebo Comparator|PCA regimen|routine PCA drug
3332833|NCT02116270|Other|Control group|Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.
3332834|NCT02116270|Experimental|Severe renal failure|Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.
3332835|NCT02116270|Experimental|Peritoneal dialysis|Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.
3332836|NCT02116270|Experimental|Hemodialysis|Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.
3332837|NCT02116296|Other|LIfestyle counseling|
3332838|NCT02116348|Experimental|Cerebrolysin|Nerve growth factor Cerebrolysin will be given to the intervention group
3332839|NCT02116348|No Intervention|Conventional|These children will receive conventional treatment for cerebral palsy
3332840|NCT02116374||HIV-1 patients|
3332841|NCT02116387|Active Comparator|Routine Physical Therapy|"Patients randomized to this arm will follow a classic, routine, physical therapy program.~Intervention: Routine Physical Therapy"
3332842|NCT02116387|Experimental|I-Moove Physical Therapy|"Patients randomized to this arm will follow a physical therapy program using the I-Moove device.~Intervention: I-Moove Physical Therapy"
3332843|NCT02116400||Suicidal|"Patients in this group have had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
3332844|NCT02116400||Not suicidal|"Patients in this group have not had suicidal behaviour according to the C-SSRS score.~Intervention: Interview Intervention: Neuropsychological testing Intervention: Serum concentration of lithium or sodium divalproate."
3332845|NCT02116413||The study population|"The study population consists of patients admitted to intensive care, sedated and under controlled ventilatory support with septic shock criteria defined by severe sepsis associated with hypotension despite fluid resuscitation of 20-40 ml / kg and requiring vascular filling according to the following criteria:~oliguria <0.5 ml / kg / h for at least 2h skin mottling Arterial Lactate > 2 mmol / l SvcO2 <70% or SvO2 <65% Patient on noradrenaline.~Severe sepsis is defined as a systemic inflammatory response associated with a suspected or proven infection and hypotension before filling, a lactate> 4 mmol / l or organ dysfunction.~Intervention: Fluid challenge Intervention: Cardiac ultrasound"
3332846|NCT02116426||The study population|"The study population includes all adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected Acute Coronary Syndrome (ACS) without ST segment elevation.~Intervention: Blood work in the ambulance Intervention: Blood work upon arrival in the emergency room Intervention: Blood work at 3 hours post-arrival in the emergency room"
3332847|NCT02116439||Violent events|People in this group were observed to manifest violence.
3332848|NCT02116439||Victims|People in this group are the victims of the other group.
3332849|NCT02116452|No Intervention|Breast Milk|Breast FED newborns
3332850|NCT02116452|Placebo Comparator|Standard Formula|Standard Formula FED newborns
3332851|NCT02116452|Active Comparator|Supplemented Formula|GOS/PDX Formula FED newborns
3332852|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 1|single oral dose of levodopa carbidopa immediate release tablets
3233915|NCT01226537|Active Comparator|Diabetes Mellitus type 1 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3233916|NCT01226537|Placebo Comparator|Diabetes mellitus type 1 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3332853|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 1|single oral dose of levodopa carbidopa immediate release tablets
3332854|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Test 2|single oral dose of levodopa carbidopa immediate release tablets
3332855|NCT02116465|Active Comparator|Levodopa Carbidopa 100/25 tablets Ref. 2|single oral dose of levodopa carbidopa immediate release tablets
3332856|NCT02116478|Experimental|gastrocnemius recession|gastrocnemius recession
3332857|NCT02116491|No Intervention|Closed suction system|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Cloesd suction system was performed which the patient remained connected to the ventilator. The catheter was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
3332858|NCT02116491|Experimental|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
3332859|NCT02116504|Other|Global population|"All included patients :~Sampling of blood"
3332860|NCT02116517|Experimental|green tea extract first|green tea extract (EGCG) 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally cellulose 500mg tid for 6 weeks total 14 weeks
3332861|NCT02116517|Placebo Comparator|Placebo first|cellulose 500mg tid for 6 weeks, then wash-out for 2 weeks, and finally EGCG 500mg tid for 6 weeks total 14 weeks
3332862|NCT02116543|Experimental|TD-6450|TD-6450 capsules
3332863|NCT02116543|Placebo Comparator|Placebo|Placebo capsules
3332864|NCT02116556|Active Comparator|Prednisone|Prednisone PO 40mg/day for 30 days plus standard supportive care measurements
3332865|NCT02116556|Experimental|Prednisone plus Rifaximin|Prednisone PO 40mg/day for 30 days plus Rifaximin PO 1200 mg/day for 90 days plus standard supportive care measurements
3332866|NCT02116569|Experimental|Daratumumab 8 milligram per kilogram (mg/kg)|Participants will be administered intravenously with daratumumab at a dose of 8 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
3332867|NCT02116569|Experimental|Daratumumab 16 mg/kg|Participants will be administered intravenously with daratumumab at a dose of 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation.
3332868|NCT02116595|Experimental|feeding a high acid diet x 24 hrs|2 diets, one low and one high net acid loads
3332869|NCT02116595|Active Comparator|low acid diet|
3332870|NCT02116634|Experimental|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
3332871|NCT02116647|Experimental|Psychoanalytic therapy|manualized psychoanalytic psychotherapy
3332872|NCT02116647|No Intervention|Control Group|Standard care
3332873|NCT02116673|Other|Control|The control arm receives usual care discharge instructions.
3332874|NCT02116673|Experimental|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
3332875|NCT02116686||Heart failure patients with sleep apnea syndrom|For heart failure patients, a standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the America Academy of Sleep Medicine (AASM) recommendations (RemLogic® software, Broomfield, USA).
3233917|NCT01226537|Active Comparator|Diabetes type 2 taurine|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3233918|NCT01226537|Placebo Comparator|Diabetes type 2 placebo|A total of 20 patients with 10 Type I and 10 type II diabetic will be enrolled in the study.After the preliminary examinations, we will categorize 10 Type I and Type II patients into two groups randomly (each group contain 5 patients).500mg Taurine capsules will be given twice per day for 6 months.
3332876|NCT02116699|Experimental|oropharyngeal mother's milk|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
3332877|NCT02116699|Placebo Comparator|oropharyngeal sterile water|0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
3332878|NCT02116712|Experimental|Saracatinib|"Only one arm: Intervention is Saracatinib. We plan to study three escalating doses of oral saracatinib; 50, 125 and 175 mg. Saracatinib is given orally once a day.~More regarding dose escalation is included in intervention below."
3332879|NCT02116725|Experimental|Shower gel with zinc|Zinc gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3332880|NCT02116725|Placebo Comparator|Plain shower gel|Plain shower gel is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3332881|NCT02116725|Sham Comparator|Distilled water|Distilled Water is applied daily (50 µl/cm2) to wound and surrounding noninjured skin.
3332882|NCT02116738|Experimental|Flap Transposition Technique|Flap Transposition Technique
3332887|NCT02116790|Placebo Comparator|Control Group|10 participants will be given two pills: both will be placebos
3332888|NCT02116790|Active Comparator|Standard Treatment / Positive Control Group|10 participants will be given two pills: both will be Naproxen (each pill = 250mg, total dose = 500mg)
3332889|NCT02116790|Active Comparator|Experimental Group #1|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 12.5mg/50mg)
3332890|NCT02116790|Active Comparator|Experimental Group #2|10 participants will be given two pills: one will be Naproxen (250 mg) and the other will be of Sinemet (carbidopa/levodopa 25mg/100mg )
3332891|NCT02116816|Experimental|Polyphenol|Polyphenol preparations
3332892|NCT02116829|Experimental|Danish butter, dairy|
3332893|NCT02116829|Active Comparator|Olive oil, refined|
3332894|NCT02116842|Experimental|0.075% bupivacaine|Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
3332895|NCT02116842|Experimental|0.1% bupivacaine|Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
3332896|NCT02116855|Experimental|tertiary prophylaxis prophy on Hemophilia A patiets|A multi centre 2 year long term tertiary prophylaxis study designed with a three step escalating dose protocol adjusted by individual joint bleeding patterns/frequencies to study the effect and cost saving of 3 low dose /cost prophylaxis regimens in boys with severe hemophilia A and arthropathy in China. Each patient will start treatment with a low dose regimen in step I and be assessed every 3 months according to the escalating criteria.
3332897|NCT02116868|Experimental|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex. The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed. Administration of antihypertensive drugs or vasopressors is also guided.
3332898|NCT02116868|No Intervention|Standard practice (ST)|Anesthesia and analgesia is left to the discretion of the anesthesiologist in charge. The anesthesiologist is blinded to the results of pupillometry.
3332899|NCT02116881||Open colorectal surgery|Patients scheduled to undergo open colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
3332900|NCT02116881||Laparoscopic colorectal surgery|Patients scheduled to undergo laparoscopic colorectal surgery from Department of Colorectal Surgery at Cleveland Clinic
3332901|NCT02116894|Experimental|PF-03446962 plus regorafenib|
3332902|NCT02116907|Experimental|Perampanel|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
3332903|NCT02116920||VIA Positive|Those patients having acetowhite lesion over cervix on visual inspection after application of acetic acid
3332904|NCT02116933|Active Comparator|Level I|A small, level I study will compare autologous fat grafting alone to stromal vascular fraction SVF enriched autologous fat grafting int he same patient. One breast will be treated with AFG alone and act as the control, and the other breast will be treated with SVF enriched AFG adn act as the experimental side exploring the efficacy of adipose derived stem cells.
3332905|NCT02116933|Active Comparator|Level II|A larger, level II study comparing Autologous Fat Grafting to SVF enriched AFG in different patients. In this study, patients can choose to have AFG in both breasts or SVF enriched AFG in both breasts. The two patient groups will be compared. Here the group with the AFG in both breasts will be the control and the SVF enriched AFG in both breasts will be the experimental group exploring the efficacy of adipose derived stem cells.
3332906|NCT02116946|Experimental|Leukocyte-rich Platelet Rish Plasma + exercise|Leukocyte-rich PRP injection and a 12 week exercise program.
3332907|NCT02116946|Experimental|Leukocyte-poor Platelet Rich Plasma + exercise|Leukocyte-poor PRP injection and a 12 week exercise program.
3332908|NCT02116946|Placebo Comparator|Saline + exercise|Saline injection and a 12 week exercise program.
3332909|NCT02116959|Experimental|Cohort 1|"Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy.~Bilateral retinoblastoma patients will be in Cohort 1.~For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy."
3332910|NCT02116959|Experimental|Cohort 2|Patients will receive only intra-arterial (IA) therapy for more limited disease.
3332911|NCT02116985|Experimental|Dual-Loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
3332912|NCT02116985|Placebo Comparator|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
3332913|NCT02116998|Experimental|GEN-004 with Aluminum Hydroxide|
3332914|NCT02116998|Placebo Comparator|Placebo|
3233919|NCT01226550|Experimental|cytoreductive surgery and HIPEC|
3332915|NCT02117011|Other|Physical activity|An 8-week structured, moderate-intensity aerobic training exercise regimen concurrent with their radiation therapy (N=15),
3332916|NCT02117011|No Intervention|Control|Patients will continue with usual care, which includes radiation treatment.
3332917|NCT02117037|Other|study of PEC markers and chemokines/ chemokine recep|blood sample for dosage and study of PEC markers and chemokines/ chemokine receptors
3332918|NCT02117063|Experimental|Go Girls! Fitness Support Group|
3332919|NCT02117089|Experimental|Device-assisted rehabilitation|
3233920|NCT01226563|Experimental|IK-5001|IK-5001 Sodium Alginate Calcium Gluconate intracoronary injection
3332920|NCT02117102|Experimental|bladder and lumbar stimulation|Apply bladder and lumbar stimulation
3332921|NCT02117102|No Intervention|Control group|Ordinary pediatric urine collection bag
3332922|NCT02117115|Experimental|CT scan with contrast|
3332923|NCT02117128|Experimental|Tranexamic acid, IA group|Tranexamic acid 1g, intra-articular injection, post-operationally
3332924|NCT02117128|Active Comparator|Tranexamic acid, IV group|Tranexamic acid, 1g, intravenous injection, post-operationally
3332925|NCT02117128|Experimental|Tranexamic acid, IV+IA group|Tranexamic acid, 1g, intravenous injection, post-operationally; Tranexamic acid, 1g, intra-articular injection, post-operationally
3332926|NCT02117141|Experimental|HC-ER 20 mg capsule (fasted)|Single oral dose of a HC-ER 20 mg capsule (fasted)
3332927|NCT02117141|Experimental|HC-ER 20 mg capsule (fed)|Single oral dose of HC-ER 20mg capsule (fed)
3332928|NCT02117154||HbA1c, 6-day Professional CGM|6-day Continuous Glucose Monitoring System (Medtronic iPro2 Professional CGM) will be deployed on a same patient for 3 times, which is one month apart
3332929|NCT02117167|Experimental|Substudy 1: targeted agent|Arm A1/ targeted arm: targeted maintenance from a list of targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, olaparib tablet per os 300 mg bd continuous dosing savolitinib tablet per os 600 mg od continuous dosing
3233921|NCT01226563|Placebo Comparator|Saline Solution|Saline Solution intracoronary injection
3233922|NCT01226576|Experimental|Treatment|ExAblate Treatment Arm
3233923|NCT01226602|Experimental|1|Adenosinladder; Ticagrelor (180 mg), Adenosinladder ; Theophylline (5 mg/kg), Adenosinladder
3233924|NCT01226602|Placebo Comparator|2|Adenosinladder; Placebo, Adenosinladder; Theophylline (5 mg/kg), Adenosinladder
3233925|NCT01226615|Experimental|1|Chondroitin sulphate
3233926|NCT01226615|Placebo Comparator|2|Placebo
3233927|NCT01226628|Experimental|Cohort A|Phase 1: 3 patients will receive 60,000 human umbilical tissue-derived cells (hUTC)
3233928|NCT01226628|Experimental|Cohort B|Phase 1: 3 patients will receive 120,000 hUTC
3233929|NCT01226628|Experimental|Cohort C|Phase 1: 3 patients will receive 300,000 hUTC
3233930|NCT01226628|Experimental|Cohort D|Phase 1: 3 patients will receive 560,000 hUTC
3233931|NCT01226628|Experimental|Cohort E|Phase 1: 6 patients will receive 300,000 hUTC
3233932|NCT01226628|Experimental|Cohort F|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
3332930|NCT02117167|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
3332931|NCT02117167|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with durvalumab for patient without actionable genomic alterations or non eligible to Targeted substudy 1, durvalumab Intra-venous 10 mg/kg, Q2W
3332932|NCT02117167|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ standard arm pemetrexed Intra venous 500 mg/m², every 3 weeks, standard maintenance left to the investigator's choice
3332933|NCT02117180|Other|FODMAP's diet|A diet low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides And Polyols (FODMAPs)
3233933|NCT01226628|Experimental|Cohort G|Phase 1: 6 patients will receive either 60,000 or 300,000 hUTC
3233934|NCT01226628|Experimental|Phase 2a|Up to 38 patients will receive one of two optimal doses as selected from the Phase 1 portion of the study
3233935|NCT01226641|Experimental|Telemedecine|CPAP treatment with telemedicine system
3233936|NCT01226641|Active Comparator|Standard Care|Standard care, including CPAP
3233937|NCT01226654|Other|MS Patients|All subjects enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
3233938|NCT01226654|Other|Healthy Patients|Patients enrolled in this study will undergo MRI studies. A computerized neuropsychological battery of tests will be administered.
3233939|NCT01226667|Active Comparator|Flexible Dose|flexibly dosed pregabalin given BID (75-300 mg/d) increased gradually over 4 weeks then maintained at that same dosing for 4 weeks
3332934|NCT02117206|Active Comparator|L-Arginine|Femoral arterial infusion of 2 g L-Arginine for 30 min
3332935|NCT02117206|Placebo Comparator|Nacl|Femoral arterial infusion of Nacl for 30 min
3332936|NCT02117219|Experimental|MEDI4736 Evaluate MEDI4736 in MDS|Evaluate MEDI4736 monotherapy and MEDI4736 in combination with azacitidine after monotherapy progression in MDS
3332937|NCT02117219|Experimental|MEDI4736 + tremelimumab|Evaluate MEDI4736 in combination with tremelimumab
3332938|NCT02117219|Experimental|MEDI4736 + tremelimumab + azacitidine|Evaluate MEDI4736 in combination with tremelimumab and azacitidine
3332939|NCT02117232|Experimental|Visualization balloon|"Colonoscopy performed with the use of Visualization balloon"
3332940|NCT02117232|Active Comparator|Traditional CO2-insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
3332941|NCT02117258|Experimental|Z-360 60mg+Gemcitabine|Z-360 60 mg will be taken orally, twice daily (BID) after a meal.
3332942|NCT02117258|Experimental|Z-360 120mg+Gemcitabine|Z-360 120 mg will be taken orally, twice daily (BID) after a meal.
3332943|NCT02117258|Experimental|Z-360 240mg+Gemcitabine|Z-360 240 mg will be taken orally, twice daily (BID) after a meal.
3332944|NCT02117258|Placebo Comparator|Placebo+Gemcitabine|Placebo will be taken orally, twice daily (BID) after a meal.
3332945|NCT02117271|Placebo Comparator|nasal dilator strip|Breathe Right ® nasal dilator strip used during sleep
3332946|NCT02117271|Experimental|continuous positive airway pressure|nasal continuous positive airway pressure used during sleep
3332947|NCT02117284||Coronary artery disease|All patients present to participating nuclear imaging facilities for diagnosis of CAD and/or risk stratification with Rubidium PET. Subjects will be enrolled according to the clinical indications listed in the approved Ruby-Fill product monograph.
3332948|NCT02117336|Experimental|P1446A-05|
3332949|NCT02117362|Experimental|Cohort 1|1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3332950|NCT02117362|Experimental|Cohort 2|2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3332951|NCT02117362|Experimental|Cohort 3|4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3332952|NCT02117362|Experimental|Cohort 4|8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.
3332953|NCT02117375|Experimental|Patients with multiple sclerosis|80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60
3332954|NCT02117375|Experimental|Healthy volunteers|20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24
3332955|NCT02117388|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
3332956|NCT02117388|Experimental|Sleep Restriction|Sleep Restriction therapy will limit the time participants spend in bed in order to make sure they are sleepy enough to fall asleep quickly.
3332957|NCT02117388|Experimental|Combined Therapy Treatment for Insomnia|Combined Therapy involves combining Sleep Restriction and Cognitive Therapy so that the two therapies reinforce each other.
3332958|NCT02117401|Experimental|group 1|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 20 s
3332959|NCT02117401|Experimental|group 2|age: 2 to 12 months induction dosage of mivacurium chloride: 0.15 mg/kg administration: intravenous injection for 40 s
3332960|NCT02117401|Experimental|group 3|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3332961|NCT02117401|Experimental|group 4|age: 2 to 12 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3332962|NCT02117401|Experimental|group 5|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3233940|NCT01226667|Active Comparator|Fixed Dosing|75 mg BID for one week and increased to 150 mg BID for 7 weeks
3233941|NCT01226680|Experimental|Tasocitinib 0.005% QD|
3332963|NCT02117401|Experimental|group 6|age: 13 to 35 months induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3332964|NCT02117401|Experimental|group 7|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3332965|NCT02117401|Experimental|group 8|age: 13 to 35 months induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3332966|NCT02117401|Experimental|group 9|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3332967|NCT02117401|Experimental|group 10|age: 3 to 6 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3332968|NCT02117401|Experimental|group 11|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3332969|NCT02117401|Experimental|group 12|age: 3 to 6 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3332970|NCT02117401|Experimental|group 13|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 20 s
3332971|NCT02117401|Experimental|group 14|age: 7 to 14 years induction dosage of mivacurium chloride: 0.20 mg/kg administration: intravenous injection for 40 s
3332972|NCT02117401|Experimental|group 15|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 20 s
3332973|NCT02117401|Experimental|group 16|age: 7 to 14 years induction dosage of mivacurium chloride: 0.25 mg/kg administration: intravenous injection for 40 s
3332974|NCT02117453|Experimental|Group I|Rosuvastatin 20 mg/day
3332975|NCT02117453|Placebo Comparator|Group II|Placebo
3233942|NCT01226680|Experimental|Tasocitinib 0.003% QD|
3233943|NCT01226680|Placebo Comparator|Vehicle for Tasocitinib|
3332976|NCT02117466|Other|Standard dose cetuximab|Uptake of 89Zr-cetuximab: continue standard dose (500mg/m2 bsa) (standard care)
3332977|NCT02117466|Experimental|Dose escalation cetuximab|No 89Zr-cetuximab uptake: dose escalation in a 3x3 cohort design (with maximal 50% dose increase each cohort; with a maximum of 2000 mg/m2 bsa every two weeks)
3233944|NCT01226693|Experimental|Sequence 1|
3233945|NCT01226693|Experimental|Sequence 2|
3233946|NCT01226693|Experimental|Sequence 3|
3233947|NCT01226693|Experimental|Sequence 4|
3233948|NCT01226693|Experimental|Sequence 5|oral, 6mg, single dose
3233949|NCT01226693|Experimental|Sequence 6|oral, 6mg, single dose
3233950|NCT01226758|Experimental|FLU-v with adjuvant|
3233951|NCT01226758|Placebo Comparator|Placebo|Adjuvant only placebo
3332978|NCT02117492|Experimental|Vertical Cuff|Vaginal cuff closure will be done vertically.
3233952|NCT01226771|Experimental|"Group A (Loading)"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
3233953|NCT01226771|Experimental|"Group B (Priming)"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
3233954|NCT01226771|Active Comparator|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
3332979|NCT02117492|Experimental|Horizontal Cuff|Vaginal cuff closure will be done horizontally.
3332980|NCT02117505|Experimental|Group 1 (Formulation 2 Then Formulation 1)|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in first treatment period; followed by JNJ-54781532 formulation 1 as 150 mg orally (5*30 mg tablet=150 mg) in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
3233955|NCT01226784|Active Comparator|Physcial exercise|15 weeks of progressive resistance group exercise, twice/week supervised by physical therapist
3233956|NCT01226784|Active Comparator|Relaxation exercise|15 weeks of relaxation exercise, twice/week supervised by physical therapist
3332981|NCT02117505|Experimental|Group 2 (Formulation 1 Then Formulation 2)|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 mg oral tablet (5*30 mg tablet=150 mg) in first treatment period; followed by JNJ-54781532 formulation 2 as 150 mg oral tablet in second treatment period. A washout period of at least 7 days will be maintained between each treatment period.
3332982|NCT02117518||no treatment|T1D patients at ages 0-25
3332983|NCT02117557|Experimental|Single incision laparoscopic surgery|Transumbilical single incision laparoscopic surgery will be performed for patients in this group.And addition of only one trocar through the stoma for drainage tube is allowed.
3332984|NCT02117557|Active Comparator|Conventional laparoscopic surgery|Conventional laparoscopic surgery for colorectal cancer will be performed for patients in this group.
3332985|NCT02117583|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3332986|NCT02117583|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3332987|NCT02117583|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3332988|NCT02117583|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3332989|NCT02117596|Other|Sirolimus|Single arm
3332990|NCT02117609|Experimental|New DELICAL formula|New high-protein oral nutrient supplement
3332991|NCT02117609|Active Comparator|Standard DELICAL formula|Standard isoenergetic isoprotein formula
3332992|NCT02117622||Patients with diabetes mellitus requiring insulin therapy|
3332993|NCT02117635|Experimental|allogeneic human neural stem cell|"CTX DP~human neural stem cell product, single dose once only injection"
3332994|NCT02117661|Experimental|L-carnitine capsules|2000 mg daily (2x 500 mg capsules twice a day - BID) for six months
3332995|NCT02117661|Placebo Comparator|Cellulose capsules|2x capsules twice a day - BID (4 total per day) for six months
3332996|NCT02117674|Active Comparator|standard forward-viewing colonoscopy|polyp detection with standard forward-viewing colonoscopy polyp detection in the right colon with scope retroflexion
3332997|NCT02117674|Active Comparator|full-spectrum colonoscopy|polyp detection with full-spectrum colonoscopy polyp detection in the right colon with scope retroflexion
3233957|NCT01226797|Placebo Comparator|Placebo|
3233958|NCT01226797|Active Comparator|PF-04136309|
3332998|NCT02117700|Experimental|N-acetyl cysteine-1|N-acetyl cysteine 600 mg once/day + Placebo once/day for 16 weeks
3332999|NCT02117700|Experimental|N-acetyl cysteine-2|N-acetyl cysteine 600 mg twice/day for 16 weeks
3333000|NCT02117700|Placebo Comparator|Placebo|Placebo twice/day for 16 weeks
3333001|NCT02117726|Experimental|Dexmedetomidine,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Dexmedetomidine will be added at 0.2~1.4μg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of dexmedetomidine, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
3333002|NCT02117726|Active Comparator|Propofol,midazolam|Slow injection of 2mg midazolam every minute and watching patients' reaction until attaining the target level of sedation;midazolam was maintained at 0.02~0.1mg/kg/h, for 24 hours.Propofol will be added at 0.3~4mg/kg/h to maintain sedation.If target sedation level (RASS score) cannot be reached in maximum dose of propofol, continuous intravenous infusion of midazolam could be used at 0.02~0.1mg/kg/h, until the target level is reached.
3233959|NCT01226823|Placebo Comparator|Placebo|obstetrical monitoring plus placebo
3233960|NCT01226823|Experimental|Ursodeoxycholic acid|obstetrical monitoring plus active drug
3233961|NCT01226836|Experimental|Living Well with COPD for Pulmonary Rehabilitation|
3233962|NCT01226849|Experimental|Single Arm|"bortezomib, rituximab, ifosphamide, etoposide, carboplatin~Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended"
3333003|NCT02117739|Experimental|All Participants|Dapsone gel and dapsone gel vehicle applied to the skin by separate occlusive patches twice a week for 21 days followed by a 10 to 17 day rest period then another application of dapsone gel and dapsone gel vehicle by patch.
3333004|NCT02117752|Experimental|Dapsone Gel Subset 1|Dapsone gel, dapsone gel vehicle and controls applied to the skin by separate occlusive patches every 24 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
3333005|NCT02117752|Experimental|Dapsone Gel Subset 2|Dapsone gel, dapsone gel vehicle and negative control applied to the skin by separate occlusive patches every 48 to 72 hours for 21 days followed by a 10 to 17 day rest period then one application each of dapsone gel and dapsone gel vehicle by patch for 48-hours.
3333006|NCT02117765|Experimental|Treatment|"Four cohorts of 5 subjects will be recruited:~Group 1: Five subjects will be given Ustekinumab 45mg SC at 0, 4, 16, 28 and 40 weeks.~Group 2: Five subjects will be given Ustekinumab 90mg SC at 0, 4, 16, 28 and 40 weeks.~Group 3: Five subjects will be given Ustekinumab 45 mg SC at 0,4 and 16 weeks.~Group 4: Five subjects will be given Ustekinumab 90mg SC at 0, 4 and 16 weeks."
3333007|NCT02117778|Active Comparator|Interscalene|Continuous Interscalene Nerve Block
3233963|NCT01226862||Hub Hospital|Hub Hospital Cohort: Joint Commission-certified Primary Stroke Centers where patients are treated using hospital-based stroke teams and pathways; these hospital personnel also provide telemedicine consultation to satellite hospitals.
3233964|NCT01226862||Spoke Hospital|Spoke Hospital Cohort: non-stroke center certified sites, where patients are treated at an in-network telestroke community hospital using telemedicine technology with consultation provided by physicians from a hub hospital.
3233965|NCT01226862||Control Hospital|Control Hospital Cohort: non-stroke center certified sites with no telemedicine services.
3233966|NCT01226875|Active Comparator|A (Narrow focus, LP)|A (Narrow focus): stone is in lower pole of kidney and SWL using narrow focus on lithotripter
3233967|NCT01226875|Active Comparator|B (Wide focus, LP)|B: stone is in lower pole of kidney and SWL using wide focus on lithotripter
3233968|NCT01226875|Active Comparator|C (Narrow focus, no LP)|C: stone is in no-lower pole of kidney and SWL using narrow focus on lithotripter
3233969|NCT01226875|Active Comparator|D (Wide focus, no LP)|D: stone is in no-lower pole of kidney and SWL using wide focus on lithotripter
3333008|NCT02117778|Active Comparator|Supraclavicular|Continuous Supraclavicular Nerve Block
3333009|NCT02117778|Active Comparator|Suprascapular|Continuous Suprascapular Nerve Block
3333010|NCT02117804||High ESDP Score|Patients with 10 or greater score on the Early Screen for Discharge Planning at the time of admission.
3333011|NCT02117804||Low ESDP Score|Patients with 9 or lower score on the Early Screen for Discharge Planning at the time of admission.
3333012|NCT02117817|Experimental|Treatment (BKM120 in Combination with Weekly Nabpaclitaxel)|
3333013|NCT02117830|Experimental|Androxal 25 mg|
3233970|NCT01226901|Experimental|MK-4827 once daily|MK-4827
3233971|NCT01226927|Active Comparator|Continuous infusion rate|Patients received a continuous infusion of 0.2% ropivacaine at 10.1 mL/hr via their femoral nerve catheter.
3333014|NCT02117830|Experimental|Androxal 250 mg|supratherapeutic dose
3333015|NCT02117830|Placebo Comparator|Placebo|
3333016|NCT02117830|Other|Moxifloxacin 400 mg|positive control
3233972|NCT01226953|Active Comparator|Arm 1|
3233973|NCT01226953|Active Comparator|Arm 2|
3233974|NCT01226966||A|
3233975|NCT01226992|Experimental|Fecal Transplant|2 weeks of oral vancomycin pre-treatment followed by single dose fecal transplant administered by rectal enema. Fecal transplant (slurry) consists of 50 grams healthy donor stool blended in 500ml of Normal Saline.
3333017|NCT02117843|Experimental|AVI® Arsenic trioxide drug eluting stent|The Arsenic trioxide as AVI eluting drug, biodegradable polylactic acid as drug carrier.
3333018|NCT02117856|Active Comparator|1 implant|"Participants receive the following:~1 implant placed surgically in the mandibular midline; Soft reline of the existing complete lower denture; 2.25mm ball patrix placed on 1 healed implant; and Reline with 1 retentive matrix in the lower denture."
3233976|NCT01226992|Active Comparator|Oral Vancomycin Taper|2 weeks of oral vancomycin pre-treatment followed by 6-week taper of oral vancomycin
3233977|NCT01227070||Asthmatic|
3233978|NCT01227070||Healthy Control|
3233979|NCT01227083||1|Asthma control test check AQLQ(Asthma Quality of Life Questionnaire)after being cAQOL(Computerized Asthma specific quality of life)
3333019|NCT02117856|Active Comparator|2 implants|"Participants receive the following:~2 implants placed surgically in the mandibular canine sites; Soft reline of the existing complete lower denture; 2.25mm ball patrices placed on 2 healed implants; and Reline with 2 retentive matrices in the lower denture."
3333020|NCT02117869|Experimental|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin hybrid grapefruit juice plus midazolam 5mg orally on the third day.
3333021|NCT02117869|Active Comparator|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
3333022|NCT02117869|Other|water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
3333023|NCT02117882||minimally invasive approach test|minimally invasive lateral approach
3333024|NCT02117882||control lateral traditional approach|standard surgical approach
3333025|NCT02117895|Experimental|Pancreatectomy & celiac plexus resection|Left celiac plexus resection will be performed besides standard distal pancreatectomy. Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
3333026|NCT02117895|Active Comparator|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
3333027|NCT02117908|Experimental|CPAP +4 cm H2O|CPAP +4 cm H2O pressure using ResMedTM face mask
3333028|NCT02117908|Sham Comparator|ShamCPAP|shamCPAP using ResMedTM CPAP face mask modified for technical sham
3333029|NCT02117921|Experimental|MBS therapy education|
3333030|NCT02117947|Experimental|Behavioral Counseling|Behavioral counseling used evidence-based smoking cessation intervention components as well as a theoretically-framed focus on behavioral shaping to promote the adoption of smoke-free homes and cars. Sessions included two, 1-hour in-home counseling and seven, 5-15 minute telephone follow-up sessions over 16 weeks. Content included health ed around the benefits of eliminating children's exposure to secondhand smoke; skills training around adoption and maintenance of smoke-free environments; goal setting, problem solving, and positive reinforcement for progress toward goals; coping skills training for smoking urge and mood management; and home support for maternal smoking behavior change achieve through family contracts and home detailing promoting pro-smoke-free home norms.
3333031|NCT02117947|Active Comparator|Self-help control|The self-help control group received a comprehensive self-help manual that outlined all of the goals and strategies covered in counseling, however, counseling was not provided to this group.
3333032|NCT02117960|Active Comparator|CVD, Omega-3|patients with Cardiovascular disease who receive 4g/d omega-3
3333033|NCT02117960|Placebo Comparator|CVD, Placebo|patients with cardiovascular disease who receive 4 cap of placebo/day
3333034|NCT02117973|Active Comparator|Conventional Technique using Persona prosthesis|The surgeon will realize the implantation of the Persona prosthesis according to the surgical technique. Potential variables such as methodology for determining tibial rotation, measuring of bone cuts, and any intra-operative adjustments will be captured on the operative case report form.
3333035|NCT02117973|Experimental|iAssist Technique using Persona prosthesis|iAssist is an electronic displacement sensor based instrumentation system that provides intra-operative verification at each surgical step (bone cuts alignment and resection level); in order to help reduce bone cuts errors. iAssist features simple and intuitive instrumentation that is based on conventional total knee arthroplasty instrumentation. iAssist should take less than 2-3 minutes (on average) to setup
3333036|NCT02117986|Experimental|loading dose of colistin|Patients will receive a loading dose of colistin (6 million international units) followed by a maintenance dose of 3 million international units of colistin every 8 hours intravenous
3333037|NCT02117986|Active Comparator|without loading dose of colistin|Patients will receive 3 million international units of colistin every 8 hours intravenous
3333038|NCT02118025||Off-pump coronary artery bypass graft|Patients operated on with off-pump coronary artery bypass graft, beating heart surgery.
3333039|NCT02118025||Mini extracorporeal circulation bypass|Patients operated on with mini extracorporeal circulation bypass. A modified extracorporeal system.
3333040|NCT02118038||HELPMOM1|corresponds to the cohort of patients in whom psychological state will be studied in the immediate waning PPH then during a 6 months through appropriate questionnaires
3333041|NCT02118038||HELPMOM2|corresponds to the cohort of patients enrolled in group HELPMOM1 who experienced a cardiac abnormality in the initial management and will therefore be included in a cardiac monitoring
3333042|NCT02118051|Experimental|CFA , hMG,Ganirelix,choriogonadotropin alfa,progesterone.|"Corifollitropin Alfa (CFA) 150 ug from the 2nd day of the cycle for 7 days. hMG 300 IU/24h, if required from the 8th day of the Controlled Ovarian Stimulation , until the day human chorionic gonadotropin ( hCG.) Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
3333043|NCT02118051|Active Comparator|hMG ,Ganirelix,choriogonadotropin alfa,progesterone|"Human Menopausal Gonadotropin (hMG). Dose: 300 IU/24h from the 2nd day of the cycle throughout the stimulation.~Ganirelix 0.25 mg,Dose: 250μg/24h since the day observe a follicle> 14mm. Recombinant choriogonadotropin alfa,Dose: 6,500 IU, pods, when follicles> 17 mm are observed.~Micronized natural progesterone. Route of administration: vaginal. Dose: 400mg/24, from embryo transfer until the day of b-hCG."
3233980|NCT01227083||2|Asthma control test check cAQOL(Computerized Asthma specific quality of life)after being AQLQ(Asthma Quality of Life Questionnaire)
3233981|NCT01227096||Electro-acupuncture, Control|
3233982|NCT01227096||Preconditioning, No preconditioning|
3233983|NCT01227109||With infection|This group consist of cancer patients with a bacterial infection
3333044|NCT02118064|Experimental|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
3333045|NCT02118077|Experimental|G17DT|250 µg administered at Weeks 0,1,3 and 24 by intramuscular injection, followed by additional injections (boosters) of 250 µg every 6 months at investigator's discretion.
3333046|NCT02118077|Placebo Comparator|Placebo|Placebo administered at Weeks 0, 1, 3, and 24 by intramuscular injection followed by additonal injections of placebo every 6 months.
3333047|NCT02118090|Experimental|Chloroquine|Patients treat with chloroquine sulfate (NIVAQUINE) 10 mg/kg/day - 3 days
3333048|NCT02118090|Active Comparator|DHA-PP|Patient treat with DHA 40 mg and PP 320 mg, (Duo-Cotecxin®) The approximate total adult dose is 2-4 mg/kg for DHA and 20mg/kg for PP
3333049|NCT02118103|Experimental|Spinal Manipulation|bilateral lumbar spine manipulation
3333050|NCT02118103|No Intervention|No Intervention - control|no intervention
3333051|NCT02118116|No Intervention|Wait-list Control|No training, wait-listed for ASIST at a later date
3233984|NCT01227109||Without infection|This is a group of cancer patients without infection
3233985|NCT01227148|Experimental|Tightly glucose conntrol|
3233986|NCT01227148|Active Comparator|Conventional glucose control|
3233987|NCT01227161||ultrasonography children|American Society of Anesthesiologists (ASA) I-II children between the age 0-7, undergoing elective urological surgery, such as inguinal hernia repair, orchiopexy, ureteroneocystostomy
3233988|NCT01227174|Experimental|Propofol sedation|Patients will be undergo procedural sedation using propofol.
3233989|NCT01227187|Experimental|Xigris|Xigris used as anticoagulant in patients treated with hemodialysis.
3233990|NCT01227226|Active Comparator|Refresh tears|Allergan's Refresh tears artificial tear
3233991|NCT01227226|Active Comparator|Systane Ultra|Alcon's Systane Ultra artificial tear
3333052|NCT02118116|Experimental|ASIST|Applied Suicide Intervention Skills Training is a 2-day, 14 hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The course, facilitated by 2 trained facilitators, allows for a maximum enrollment of 30 participants.
3333053|NCT02118116|Experimental|ASIST uncontrolled arm|The ASIST workshop will be offered to participants who refuse to be part of the waitlist control arm. This is due to the reality in gathering data in these communities. Many times it is not possible for participants to be waitlisted, and therefore we would still want to gather data on those that refuse to participate in the RCT design and will collect uncontrolled data on these participants only.
3333054|NCT02118129|Experimental|Behavioural intervention|Behavioural intervention consisting of an educational video component and use of a handheld mobile app to track vitamin D intake.
3333055|NCT02118129|Placebo Comparator|Control group|Wait-list control group
3233992|NCT01227226|Active Comparator|Visine|Visine artificial tear
3233993|NCT01227226|Active Comparator|Blink tears|AMO's blink tears artificial tear
3333056|NCT02118142|Active Comparator|Betaine|6 gram dose of betaine delivered in encapsulated form
3333057|NCT02118142|Placebo Comparator|Dextrose|6 gram dose of dextrose delivered in encapsulated form
3333058|NCT02118155|Sham Comparator|Connective tissue graft (CTG)|The gingival recession defects were treated by connective tissue graft surgical procedure and received the sham application os low-intensity laser therapy.
3333059|NCT02118155|Experimental|Connective tissue graft plus laser (CTG+L)|The gingival recession defects were treated by connective tissue graft associated with the application of a LILT protocol
3333060|NCT02118168||No treatment|"All patients that participated to the therapeutic phase II trial of the Tat vaccine ISS T-002 and that received at least 3 immunizations and reached 48-weeks of follow-up."
3333061|NCT02118181|No Intervention|Control|
3333062|NCT02118181|Experimental|HMB|Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate
3333063|NCT02118194||Paraplegia, spinal cord injury|An exoskeleton-assisted walking system for people with paralysis from spinal cord injury at thoracic level 1 and below (paraplegia) will be used.
3333064|NCT02118207|Experimental|Control dives 1st|Subjects in this group complete the first 3 dives as control dives and the second 3 dives preceded by aerobic exercise
3333065|NCT02118207|Experimental|Predive exercise 1st|Subjects complete the first 3 dives preceded by the intervention of aerobic exercise and the second 3 with no exercise as control dives
3333066|NCT02118220|Other|Concussion Questionnaire|"The questionnaire is specifically designed to elicit occurrence and symptoms of a concussion. If the patient answers yes to question 2a, which asks At the time of the injury do you recall a blow to the head, neck, face or body that resulted in sustained symptoms of concussion (e.g., headache, dizziness, confusion, nausea, vomiting, etc.)?, the research team will administer the 22 item self-reporting symptom scale in the above mentioned SCAT3. The responses obtained from the questionnaire will be used to determine the incidence of symptomatic concussions, either known or unrecognized, in pediatric patients sustaining an orthopedic injury requiring surgical repair."
3333067|NCT02118233||Carotid Endarterectomy (CEA)|Surgical Revascularization- Carotid Endarterectomy (CEA)
3333068|NCT02118233||Carotid Angioplasty and Stenting (CAS)|Surgical Revascularization- Carotid Angioplasty and Stenting (CAS)
3233994|NCT01227239|Experimental|1|
3233995|NCT01227291|Experimental|SYL040012|SYL040012 Ophthalmic drop administration
3333069|NCT02118233||Control Group- Medical Management|Control Group- Medical Management
3333070|NCT02118246|Experimental|Dry Needling|The taut band of trigger point in vastus lateralis muscle; localized between the thumb and index finger, was needled forward and backward repeatedly until there were no more local twitch response
3333071|NCT02118246|Experimental|Kinesio Tape|Y technique with 25% tension on the tails was applied. Direction of the technique was insertion to origin of the muscle and zone of the trigger point was placed at the center of Y strip.
3233996|NCT01227304|Experimental|Test of volume responsiveness using crystalloids|
3233997|NCT01227317||Acute dyspnea in ED|Acute severe shortness of breath (SOB) in emergency Department (ED) with suspicion of acute heart failure (AHF) or Pulmonary Embolism (PE)or Community-acquired pneumonia (CAP) or acute Exacerbation of chronic obstructive pulmonary disease (AE COPD)
3233998|NCT01227330|Experimental|Medication adherence intervention|Receives 12-week behavioral feedback intervention to improve adherence to statin medication
3233999|NCT01227330|No Intervention|Control|No intervention
3234000|NCT01227330|Active Comparator|Attention-control|Receives visits on the same schedule as the intervention group, with health education that is unrelated to medications or cholesterol
3234001|NCT01227343||Female Smokers|Healthy females who smoke 10-30 cigarettes per day for the past 2 years and meet criteria for nicotine dependence.
3333072|NCT02118259|Other|The study population|"See inclusion and exclusion criteria.~Intervention: Before-after study"
3333073|NCT02118272|Other|Physica KR|
3234002|NCT01227343||Female Non-smokers|Healthy females who do not currently smoke cigarettes.
3234003|NCT01227343||Male Smokers|Healthy males who smoke 10-30 cigarettes per day for the past 2 years and who meet criteria for nicotine dependence.
3234004|NCT01227343||Male - Non-Smokers CLOSED|WE ARE NO LONGER RECRUITING MALE NON-SMOKERS
3234005|NCT01227356|Experimental|imatinb + pegIntron|
3234006|NCT01227369||Bisphosphonates|Korean postmenopausal osteoporosis patients with bisphosphonate treatment
3234007|NCT01227408|Experimental|Metronomic Chemotherapy|Doxorubicin will be administered as an intravenous bolus, careful intravenous injection. PPX will be administerd as an intravenous 10 mins. infusion. Capecitabine and methotrexate will be taken orally twice a day. Cyclophosphamide will be taken orally once a day.
3234008|NCT01227460|Experimental|Sitagliptin|
3333074|NCT02118285|Experimental|Treatment|Haploidentical donor NK cells and IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion and continues twice daily for 90 days.
3333075|NCT02118298||Multiple Sclerosis|Ages 18 - 66, 10 years or less of MS,
3333076|NCT02118298||Demographically matched controls|Ages 18 - 66, No known neurological disorder, no learning disorder, and no psychiatric disturbance that is actually interfering with life.
3333077|NCT02118311|Experimental|TREG|T regulatory cells after non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
3333078|NCT02118311|Experimental|Non-Myeloablative Only|Non-myeloablative (using fludarabine, cyclophosphamide, and total body irradiation) umbilical cord transplant.
3333079|NCT02118324|Experimental|Exercise treatment|Participants will be instructed to use the exergaming program at home for 30 mins, 3-5 times per week.
3333080|NCT02118324|No Intervention|Control group|No intervention is provided.
3333081|NCT02118350|Experimental|Mat Pilates training|Mat Pilates training performed two times at week for 16 weeks.
3333082|NCT02118350|No Intervention|Control|
3333083|NCT02118376|Experimental|exenatide|exenatide, 5ug, bid, 3months
3333084|NCT02118389|Experimental|Glucerna,Meal Replacement|Glucerna 52g instead of night meal 5weeks
3234009|NCT01227460|Placebo Comparator|Sugar Pill|
3333085|NCT02118402|Active Comparator|Fortified maize porridge (MNP)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, maltodextrin carrier (added up to 11g)
3333086|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, plus 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA, maltodextrin carrier (added up to 11g)
3333087|NCT02118402|Active Comparator|Fortified maize porridge (MNP+Fe+GOS)|The MNP contains 400 µg Vitamin A, 5 µg Vitamin D, 5 mg Tocopherol Equivalent, 0.5 mg Thiamine, 0.5 mg Riboflavin, 0.5 mg Vitamin B6 , 90 µg Folic Acid, 6 mg Niacin, 0.9 µg Vitamin B12, 30 mg Vitamin C, 0.56 mg Copper, 90 µg Iodine, 17 µg Selenium, 4.1 mg Zinc, 190 Phytase-units, 2.5 mg Fe as ferrous fumarate and 2.5 mg Fe as NaFeEDTA plus 7.5 g of galactooligosaccharides given as 10.5 g GOS-75, maltodextrin carrier (added up to 11g)
3234010|NCT01227473|Experimental|mindfulness prediabetes education group|The mindfulness-based diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with instruction in mindfulness.
3234011|NCT01227473|Active Comparator|conventional prediabetes education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
3234012|NCT01227486||Obese patients for planned surgery and endotracheal intubation|
3234013|NCT01227538||Stimulated urinary C peptide|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
3333088|NCT02118415|Experimental|Interventional|Interventional group: activated autologous NK cell treatment
3333089|NCT02118415|No Intervention|Control group|Control group: BSC
3333090|NCT02118454|Experimental|Daily IVR calls|"The Daily IVR Calls Intervention: consisting of two (2) automated voice calls (intervention messages) each day for six months, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months"
3333091|NCT02118454|Active Comparator|Weekly IVR Survey Only|The Weekly IVR Survey Only control condition: consisting of standard care, PLUS one IVR assessment call (consisting of four [4] questions) every week for 6 months.
3333092|NCT02118467|Active Comparator|Norepinephrine and epinephrine|"Patients will receive norepinephrine infusion per standard protocol. Dose range will be 0.03-0.3 mcg/kg/minute. Norepinephrine concentration will be 16 mg/250 mL. If a second vasopressor is required, epinephrine will be added. Dose range of epinephrine will be 0.03-0.3 mcg/kg/minute. Epinephrine concentration will be 16 mg/250 mL. The drugs norepinephrine and epinephrine will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both norepinephrine and epinephrine, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
3333093|NCT02118467|Active Comparator|Phenylephrine and vasopressin|"Patients will receive phenylephrine infusion per standard protocol. Dose range will be 0.3 to 3.0 mcg/kg/minute. Phenylephrine concentration will be 160 mg/250 mL. If a second vasopressor is required, vasopressin will be added. Dose range of vasopressin will be 0.1 to 0.6 milliunits/kg/minute. Vasopressin concentration will be 40 units/250 mL. The drugs phenylephrine and vasopressin will be mixed and blinded by the research pharmacy. The research pharmacist will list the dose ranges in mL/hr; this will allow the bedside nurse to program the medication per standard protocol.~If the patient's shock is not adequately treated with the highest doses of both phenylephrine and vasopressin, additional, open-label norepinephrine will be added, and titrated to achieve target blood pressure. If the patient's shock is not adequately treated with three vasopressors, additional open-label epinephrine will be added, and titrated to achieve target blood pressure."
3333094|NCT02118480|Experimental|cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
3333095|NCT02118480|Active Comparator|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood) during 3 months, 3 times per week.
3333096|NCT02118493|Experimental|Benign Biliary Stenosis, Laser|Subjects that undergo the experimental intervention, that being single use of a laser excision catheter.
3333097|NCT02118506|Active Comparator|Physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Physical practice: is the execution of the motor action."
3333098|NCT02118506|Experimental|Mental and physical practice|"Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Mental practice: is defined as motor imagery training with the aim of improving the engine performance. Is the imagination of a motor action without its physical implementation.~Physical practice: is the execution of the motor action."
3234014|NCT01227590|Experimental|Pharmacokinetics single-arm|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
3234015|NCT01227603|Experimental|Nifedipine-candesartan FDC|Each subject received single fixed dose combination of 60 mg nifedipine and 32 mg candesartan orally.
3234016|NCT01227603|Active Comparator|Nifedipine and candesartan|Each subject received one dose of nifedipine GITS 60 mg and candesartan 32 mg (2 x 16 mg tablet) as loose combination, orally.
3234017|NCT01227603|Active Comparator|Nifedipine|Each subject received one dose of nifedipine GITS 60 mg orally.
3234018|NCT01227603|Active Comparator|Candesartan|Each subject received one dose of candesartan 32 mg (2 x 16 mg tablet), orally.
3234019|NCT01227642|Experimental|pre-implant transrectal ultrasound images and planning|Transrectal ultrasound session will be performed at a separate session prior to the implant.
3333099|NCT02118519|Active Comparator|mesenchymal stem cells|Autologous Mesenchymal Stem Cells primed prior to intra articular injection into knees of patients with advanced articular cartilage injury
3333100|NCT02118519|Active Comparator|mesenchymal cells&platelet lysate|Autologous Mesenchymal Stem Cells primed prior to intra articular injection with platelet lysate into knees of patients with advanced articular cartilage injury
3333101|NCT02118532|Experimental|IN.PACT Admiral|
3333102|NCT02118545||vWF and postoperative Outcome|An independent prospective validation cohorts will be obtained from 4 different Institutions: 2 in Vienna , 1 in Salzburg and 1 in Bern
3333103|NCT02118558|Experimental|Negative Pressure Wound Therapy (NPWT)|
3333104|NCT02118558|Active Comparator|standard prophylactic therapy|
3333105|NCT02118584|Experimental|Part 1: Open-label Extension|Participants with moderate to severe UC who were enrolled in the Phase II OLE study or the Phase III studies, and who meet the eligibility criteria for enrollment will receive open-label etrolizumab in Part 1 (OLE).
3234020|NCT01227694|Experimental|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
3234021|NCT01227720|Experimental|A NSL2L|Experimental Nicotine Replacement Therapy (NRT)(L) 2 mg
3333106|NCT02118584|No Intervention|Part 2: Safety Monitoring|All participants from Part 1 (OLE), participants whose PML follow-up is not completed within the Phase II OLE study, and participants transferring from the Phase III double-blind studies after the 12-week safety follow-up will be monitored for PML (92 weeks).
3333107|NCT02118623|Active Comparator|Level 1|Moderated discussion board only
3333108|NCT02118623|Active Comparator|Level 2|Moderated discussion board plus psychoeducation
3333109|NCT02118623|Active Comparator|Level 3|Moderated discussion board plus psychoeducation plus interactive psychosocial tools.
3234022|NCT01227720|Active Comparator|B Lozenge|Marketed Nicotine Lozenge 2 mg
3234023|NCT01227720|Experimental|C NSL4M|Experimental NRT (M) 4 mg
3333110|NCT02118636||Aromatase inhibitor therapy|Subjects who are starting treatment with any of the three aromatase inhibitor (AI) medications
3234024|NCT01227720|Active Comparator|D Lozenge|Marketed Nicotine Lozenge 4 mg
3234025|NCT01227720|Experimental|E NSL4L|Experimental NRT (L) 4 mg
3234026|NCT01227720|Experimental|F NSL4H|Experimental NRT (H) 4 mg
3234027|NCT01227733||Breast Tumor|Breast Tumor Blocks
3234028|NCT01227746||Tumor biopsies|
3234029|NCT01227759|Experimental|Verum|
3234030|NCT01227759|No Intervention|Untreated|
3234031|NCT01227759|Placebo Comparator|Vehicle|
3234032|NCT01227772|Experimental|Weekly Cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at a dose of 1 mg once a week
3234033|NCT01227772|Experimental|2-weekly cohort|The gastric cancer vaccine (OTSGC-A24) will be administered at the dose of 1 mg every 2 weeks.
3234034|NCT01227772|Experimental|3-weekly cohort|The gastric cancer vaccine (OTSGC-A24)will be administered at 1 mg very 3 weeks
3234035|NCT01227798|Placebo Comparator|Placebo|100 mM sodium Chloride and 25 mM sodium phosphate at pH 7.0 +/- 0.2
3234036|NCT01227798|Active Comparator|Infergen|15mcg subcutaneous injection at fill volume of 0.5mL
3234037|NCT01227811|Active Comparator|Enablex(R) 15 mg , single dose|
3234038|NCT01227811|Experimental|Darifenacin 15 mg tablets, single dose|
3234039|NCT01227837|Sham Comparator|placebo|use of placebo in control group
3234040|NCT01227837|Experimental|omega 3|use of omega 3 2 gr/day for 6 months
3234041|NCT01227850||Parenteral nutrition patients.|
3234042|NCT01227863|Experimental|Test|Dexamethasone + neomycyn + polimixyn B
3234043|NCT01227863|Active Comparator|Comparator|Dexamethasone + neomycyn + polimixy B
3234044|NCT01227876|Experimental|Test|Ster ® (prednisolone 1% ophthalmic suspension - União Química)
3234045|NCT01227876|Active Comparator|Comparator|Pred Fort ® (prednisolone 1% ophthalmic suspension - Allergan)
3234046|NCT01227915|Experimental|Test|tobramycin 0.3% + dexamethasone 1% - União Química Lab
3234047|NCT01227915|Active Comparator|Comparator|tobramycin 0.3% + dexamethasone 1% - Alcon Lab
3333111|NCT02118649|Experimental|Game|Participants will play a video game directing their gaze to on-screen targets.
3234048|NCT01227941|Experimental|Part A: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination. Dose escalation/confirmation in participants with advanced solid tumors
3234049|NCT01227941|Experimental|Part B: MK-4827 + pegylated liposomal doxorubicin|MK-4827 and pegylated liposomal doxorubicin combination at 1 or 2 dose levels of MK-4827 to be determined from the results of Part A. Ovarian Cancer Cohort
3234050|NCT01228006|Experimental|Treatment|NatusGerin
3333112|NCT02118662|Experimental|Male Cohort|"Eight Male participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
3333113|NCT02118662|Experimental|Female Cohort|"Eight femalel participants per cohort will complete the following:~Energy Expenditure during seated in an office chair during normal rest. Energy Expenditure during seated and typing. Energy Expenditure during Treadmill walking work condition. Energy Expenditure during cycling work condition"
3333114|NCT02118675||Age 5-17 years|Participants age 5 - 17 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
3333115|NCT02118675||Age 18-80 years|Participants age 18-80 will complete the following Body Measurements Body Composition and Circumference Measurements Whole Body DXA Scan Bioelectrical Impedance Analysis (BIA) BodPod Circumferences Ultrasound
3234051|NCT01228006|Placebo Comparator|Control|Gelatin capsules identical to drug test
3234052|NCT01228032|Experimental|Intervention|
3234053|NCT01228032|No Intervention|Control|referral only
3333116|NCT02118688|Placebo Comparator|Placebo|"Drug: Placebo~Placebo suspension administered PO/NG/FT q12h to mimic risperidone~Placebo suspension administered PO/NG/FT q8h to mimic trazodone"
3333117|NCT02118688|Active Comparator|Risperidone alone|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
3333118|NCT02118688|Active Comparator|Trazodone alone|"Drug: Trazodone~Initiate trazodone dosing at 50 mg PO/NG/FT q8h~Trazodone dose can be titrated upwards every 24 hours by 25 mg per dose~Maximum trazodone daily dose 600 mg per day (200 mg every 8 hours)"
3333119|NCT02118688|Active Comparator|Risperidone and Trazodone combination|"Drug: Risperidone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)~Drug: Trazodone~Initiate risperidone at 1 mg PO/NG/FT q12h~Risperidone dose can be titrated upwards every 24 hours by increments of 0.5 mg per dose~Maximum risperidone daily dose of 6 mg per day (3 mg every 12 hours)"
3333120|NCT02118701|Experimental|SDM care planning|
3333121|NCT02118727|Active Comparator|Memantine|20mg taken by mouth every day BID for 32 weeks
3333122|NCT02118727|Placebo Comparator|Placebo|Placebo (for Memantine) taken by mouth everyday BID for 32 weeks
3333123|NCT02118753|No Intervention|ischemic preconditioning|"After baseline recordings of contractile function, the investigators will assign 2 trabeculae of each patient to either a stimulus for (1) ischemic preconditioning (IP) or (2) no IP. Subsequently, the trabeculae will be exposed to 90 min of ischemia, followed by 120 minutes of recovery. The investigators will measure the recovery of contractile function in both trabeculae.~This experiment serves as a positive control, to ensure that our model is still working properly."
3333124|NCT02118753|Experimental|eplerenone|In the next patients, a similar ischemia-reperfusion experiment will be performed, but now the 2 trabeculae will be randomized to pretreatment with eplerenone or DMSO. The percentage recovery (compared to baseline) of contractile force of the trabeculae at the end of reperfusion will serve as the primary endpoint.
3333125|NCT02118779|Experimental|Behavioural change intervention|Cognitive behavioural therapy (CBT) combined with exercise
3333126|NCT02118779|No Intervention|Standard Patient Management|Standard care like usual (i.e. annual checks with neurologist, checks with cardiologist, if needed physical therapy)
3333127|NCT02118805||Patients with ALS|No intervention is used in this study. The health of muscle is monitored over time.
3333128|NCT02118805||Patients with Myasthenia Gravis|No intervention is used in this study. The health of muscle is monitored over time.
3333129|NCT02118805||Patients with Muscle Disease|No intervention is used in this study. The health of muscle is monitored over time.
3234054|NCT01228045|Experimental|Trastuzumab in Combination with TS-ONE and cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
3234055|NCT01228058||Adult trauma patients|Patients admitted to the emergency department (ED) as the highest level of acuity following a traumatic injury at three Level 1 trauma centers in the United States (UT Houston, UC San Francisco, Oregon Health Center).
3234056|NCT01228097||Gastric Bypass|Participants who receive gastric bypass surgery.
3234057|NCT01228097||Principally Restrictive Surgery|Participants who receive gastric banding or sleeve gastrectomy surgery.
3234058|NCT01228097||Weight Stable|Participants who remain weight stable.
3234059|NCT01228110|Active Comparator|Corticosteroid group|This group was entitled to receive hydrocortisone 200 mg loading bolus followed by an intravenous infusion (300 mg in 500 ml 0.9% saline) at a rate of 12.5 mg/hour for 7 days
3234060|NCT01228110|Placebo Comparator|Placebo group|This group was meant to receive placebo (sterile normal saline in a volume equal to the study drug).
3234061|NCT01228123|Active Comparator|CVVH arm|
3234062|NCT01228123|Active Comparator|IHD arm|
3234063|NCT01228136|Active Comparator|Tranexamic acid|
3234064|NCT01228136|Placebo Comparator|Placebo|
3234065|NCT01228162|Experimental|general anaesthesia|patients receiving general anaesthesia and rocuronium bromide for muscle relaxation
3333130|NCT02118805||Patients with Stroke|No intervention is used in this study. The health of muscle is monitored over time.
3333131|NCT02118805||Patients with Parkinson's Disease|No intervention is used in this study. The health of muscle is monitored over time.
3333132|NCT02118805||Healthy Volunteers|No intervention is used in this study. The health of muscle is monitored over time.
3333133|NCT02118818||NO rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
3234066|NCT01228162|Active Comparator|spinal anaesthesia|patients receiving spinal anaesthesia without muscle relaxation
3234067|NCT01228188|Experimental|Idiopathic Full Thickness Macular Hole|Eyes which do not undergo early vitrectomy at the time of enrollment. Surgical intervention would be performed when full-thickness macular hole occurs with a minimum diameter exceeding 400 um.
3333134|NCT02118818||Rheumatic heart disease by echo|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD. We will be using next generation sequencing to identify these differences.
3333135|NCT02118844|Active Comparator|Moderate rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain moderate neuromuscular blockade (TOF-count 2-4) during gastrojejunal anastomosis
3333136|NCT02118844|Experimental|deep rocuronium neuromuscular blockade|rocuronium bolus is given if needed to maintain deep neuromuscular blockade (here defined as a Posttetanic Count 1 - 5) during gastrojejunal anastomosis
3333137|NCT02118857||Omnivore, vegetarian and vegan subjects.|These subjecs followed the diet from at least two years.
3333138|NCT02118870|Active Comparator|DAPT 360 days|Treatment 360 days DAPT
3333139|NCT02118870|Active Comparator|DAPT 90 days|Treatment 90 days DAPT
3333140|NCT02118883|Other|Essentia Water|Essentia Water, electrolyzed high-pH water
3333141|NCT02118883|Other|Bottled Water|Purified bottle water
3333142|NCT02118909|Experimental|Part 1 (Pracinostat + Itraconazole)|Single-dose pracinostat and itraconazole dosing every day for 8 days
3333143|NCT02118909|Experimental|Part 2 (Pracinostat + Ciprofloxacin)|Single dose pracinostat and ciprofloxacin 2 times a day for 7 days
3333144|NCT02118922||Healthy volunteers|Volunteers with normal corneas
3333145|NCT02118922||Patients with keratoconus|Patients diagnosed with keratoconus
3333146|NCT02118922||post-LASIK no complications|Subjects who underwent LASIK refractive surgery with no complications
3333147|NCT02118922||post-LASIK who developed ectasia|patients who underwent LASIK refractive surgery and developed ectasia as a complications
3333148|NCT02118922||Volunteers to receive PRK surgery|This group includes patients who have been diagnosed with myopia and have been scheduled to undergo PRK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen or artificial tears will be excluded.
3333149|NCT02118922||Volunteers to receive LASIK Surgery|This group includes myopic patients who are scheduled to receive LASIK surgery. Patients with high astigmatism > 2 diopter, prior ocular surgeries, and those patients taking any ocular medications except seasonal allergy medicine such as ketotifen and artificial tears will be excluded.
3333150|NCT02118922||Patients with Fuch's Endothelial Corneal Dystrophy|This group includes subjects who are diagnosed with Fuch's corneal dystrophy, at early, mild and advanced stages. The inclusion also extends to subjects with, and without keratoconus. But this exclude patients with any other corneal disorders other than keratoconus, and/or history of ophthalmological surgeries that may affect endothelium cell status, e.g. cataract surgeries.
3333151|NCT02118935|Active Comparator|Previously marketed cow's milk-based infant formula|
3333152|NCT02118935|Experimental|Marketed cow's milk-based infant formula with prebiotics|
3333153|NCT02118948|Experimental|Abuse-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on the psychological consequences of abuse, current sexual risk behavior, and the link between the two.
3333154|NCT02118948|Active Comparator|Sexual behavior-focused intervention|Participants attend 5 weekly, 2-hour intervention sessions focused on current sexual risk behavior.
3333155|NCT02118974|Experimental|Robot-assisted|Robot-assisted hysterectomy
3333156|NCT02118974|Experimental|Laparoscopic Hysterectomy|Laparoscopic Hysterectomy
3234068|NCT01228201|Experimental|Aerboic interval training|
3234069|NCT01228201|Active Comparator|Moderate continuous training|
3234070|NCT01228214|Experimental|Amiloride,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
3333157|NCT02118987|Experimental|Omalizumab|300mg of omalizumab under the skin every four weeks at three separate visits representing a treatment period of 12 weeks. During this treatment period, patients will continue receiving their regularly scheduled chemotherapy desensitizations per the prescribed treatment schedule from the patient's oncologist.
3333158|NCT02119000|Experimental|PEG electrolytes 2L/2L split dose|
3333159|NCT02119000|Active Comparator|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|
3234071|NCT01228214|Placebo Comparator|Placebo,nitrates,clopidogrel,aspirin|Comparative Efficacious Research
3234072|NCT01228227|Active Comparator|ROSUVASTATIN|
3333160|NCT02119013|Experimental|OCTEOTRIDE|Octeotride, 20 mg monthly intramuscular injection for 3 years
3333161|NCT02119013|Placebo Comparator|PLACEBO|Placebo (salin soluction), intramuscular injection monthly for 3 years
3333162|NCT02119039|Experimental|RGTA OTR 4120 (CACICOL20)|
3333163|NCT02119039|Active Comparator|Genteal HA|
3333164|NCT02119052|Experimental|OCTEOTRIDE|octeotride 20 mg, intramuscular injection monthly for 3 years
3333165|NCT02119052|Placebo Comparator|Placebo|Placebo (saline soluction), intramuscular injection monthly for 3 years
3333166|NCT02119065||Health Services Research (PET/CT scan)|Patients receive routine pre-therapy technetium Tc 99m-labeled macroaggregated albumin. Patients then undergo routine radioembolization with yttrium Y 90 resin microspheres. Within 36 hours after radioembolization, patients undergo PET/CT imaging.
3333167|NCT02119078|Active Comparator|ACE Service|Admission to the Acute Care for Elders (General Medicine Team 1) service. (See Intervention, below)
3333168|NCT02119078|No Intervention|Standard care (other General Medicine teams)|Admission to one of the 4 non-ACE general medicine teaching teams at OHSU.
3333169|NCT02119091|Experimental|Moxifloxacin|Single oral dose 400 mg
3333170|NCT02119091|Placebo Comparator|Placebo|Single oral dose
3333171|NCT02119117|Placebo Comparator|sugar pill|Group 2 will receive a placebo of CoQ10
3234073|NCT01228227|Experimental|ATORVASTATIN|
3234074|NCT01228240|Experimental|Metformin, Apo-metformin|
3234075|NCT01228253|No Intervention|1|Safe voluntary.
3234076|NCT01228253|No Intervention|2|patient with psychotrauma but without PSTD and without any psychiatric trouble at the time of inclusion
3234077|NCT01228253|No Intervention|3|patient with psychotrauma and PTSD (post-traumatic stress disorder) and in full remission at the time of inclusion
3234078|NCT01228253|No Intervention|4.3|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3234079|NCT01228253|Sham Comparator|4.2|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3333172|NCT02119117|Experimental|CoQ10|Patients will be divided into 2 groups. Group 1 will be treated with an oral supplement, 125 mg/twice daily of CoQ10 (NeoQ10, Theralogix, Rockville, Maryland, USA) for 3 months prior to IVF. This dosage will equate to a Cmax of 6.89 ug/ml (Liu and Artmann, 2009).
3333173|NCT02119130|No Intervention|TST only|Tuberculin skin test for all eligible patients, to be placed and read by clinic staff. Thereafter, for 2 years, annual TST provided for patients with TST negative/unknown history. IPT to be provided to patients with a positive TST for whom active TB has been ruled out.
3333174|NCT02119130|Experimental|QGIT|QGIT for all eligible patients, to be done at routine CD4 blood draw. Thereafter, for 2 years, annual QGIT at CD4 blood draw for patients with QGIT negative/unknown history. IPT to be provided to patients with a positive QGIT for whom active TB has been ruled out.
3333175|NCT02119143|Active Comparator|Vitamines and minerals|41 middel aged subjects receive vitamin and mineral supplementation
3333176|NCT02119143|Placebo Comparator|cellulose|41 middle aged subjects get the placebo
3333177|NCT02119169|Experimental|pigtail catheter|Pigtail catheter for pleural drainage of recurrent hepatic hydrothorax
3333178|NCT02119182||Comprehensive Assessment with MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
3333179|NCT02119182||Comprehensive Assessment without MRI|"In-Person Outcome Assessment at 2 weeks, 6 months, and 12 months.~Phone Outcome Assessment at 3 months.~Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only)."
3333180|NCT02119182||Brief Assessment|• Telephone outcome assessment at 2 weeks, 3 months, 6 months, and 12 months.
3333181|NCT02119195|No Intervention|No treatment|The composite resin restorations had marginal defects, but were clinically acceptable, did not receive treatment
3333182|NCT02119195|No Intervention|Positive control|Composite resins with alpha value in marginal adaptation criteria
3333183|NCT02119195|Experimental|Intervention|For this group, defective areas were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3M ESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure
3234080|NCT01228253|Experimental|4.1|patient with psychotrauma and with activ PTSD (post-traumatic stress disorder)at the time of inclusion
3234081|NCT01228266|Experimental|autologous mesenchymal stem cell|A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months
3333184|NCT02119208|Experimental|Lifestyle counseling|
3333185|NCT02119221|Experimental|[14C]Copanlisib|
3234082|NCT01228279|Active Comparator|DIANEAL|One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks.
3234083|NCT01228279|Active Comparator|EXTRANEAL|The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
3234084|NCT01228292|Active Comparator|Standard Anticoagulation|Hemodialysis is performed using standard anticoagulation using unfractionated heparin if no contra-indications for the use of heparin exist. If contra-indications for heparin exist a heparin coated hemofilter (Evodial) will be used. The use of unfractionated heparin or no heparin (with coated hemofilter) is a decision to be taken before every hemodialysis.
3234085|NCT01228292|Experimental|Citrasate|Hemodialysis is performed with Citrasate
3234086|NCT01228305|Experimental|Acetaminophen|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
3234087|NCT01228305|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment using a permuted-block randomization algorithm. Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
3259201|NCT01468402||Magnetic Resonanse Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroid, and their location in the myometrium was classified. Perfusion and the characterization of the T2 signal were also evaluated.
3333186|NCT02119234|Experimental|CHF5993 pMDI + Spacer|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using Aerochamber Plus Flow-vu VHC spacer
3333187|NCT02119234|Active Comparator|CHF5993 pMDI|CHF 5993 pMDI (Beclometasone/formoterol/glycopyrrolate 100/6/25 mcg per actuation) x 4 inhalations administered using standard actuator only
3234088|NCT01228331|Active Comparator|Arm I intensification (cytarabine)|"LR-S patients receive HD cytarabine IV 4 x 3 g over 12 hours daily on days 29-31 and pegaspargase IV over 2 hours on days 31, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive HD cytarabine IV 2.500 over 3 hours twice daily on days 29-31 and 106-108 and pegaspargase IV over 2 hours on days 31, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
3234089|NCT01228331|Active Comparator|Arm II intensification (clofarabine)|"LR-S patients receive clofarabine* IV 5 x 40 mg over 2 hours every day on days 29-33 and pegaspargase IV over 2 hours on days 33, 52, and 80.~LR-I and precursor B-cell ALL HR-S and HR-I patients receive clofarabine* IV over 2 hours on days 29-33 and pegaspargase IV over 2 hours on days 33, 53, 67, and 108.~Followed by standard consolidation therapy regarding to stratification containing:~methotrexate, cyclophosphamide, thioguanin, mercaptopurine, etoposide phosphate, amsacrine, cytarabine, methylprednisolone, dexamethasone, vincristine sulfate; whole-brain radiation therapy only if indicated in patients with cns involvement or T-cell ALL"
3234090|NCT01228331|Active Comparator|Arm III reinduct.(doxorubicin hydrochl.)|"LR-S patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive doxorubicin hydrochloride IV 30 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
3234091|NCT01228331|Active Comparator|Arm IV reinduct.(daunorubicin hydrochl.)|"LR-S patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1 and 8.~LR-I, HR-S and HR-I Patients receive daunorubicin hydrochloride IV 36 mg/m2 over 24 hours on days 1, 8, 22, and 29.~Followed by standard reinduction and maintenance therapy containing:~cyclophophamide, cytarabine, thioguanine, mercaptopurine, methotrexate and pegaspargase, dexamethasone, vincristine sulfate"
3333188|NCT02119234|Placebo Comparator|Placebo pMDI|Placebo pMDI x 4 inhalations
3333189|NCT02119247|Experimental|CHF6001 dry powder for inhalation via NEXThaler®|4 inhalations of CHF 6001 NEXThaler®
3333190|NCT02119247|Active Comparator|CHF 6001 DPI capsules for inhalation via Aerolizer|3 inhalations of CHF 6001 capsules via Aerolizer®
3234092|NCT01228344||Artemether-lumefantrine|
3234093|NCT01228357|Experimental|SSRI treated group|SSRI treated group is patients treated with fluoxetine, paroxetine, or sertraline
3333191|NCT02119273|Experimental|Steroid|The steroid arm will take prednisone 10mg tabs starting 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
3333192|NCT02119273|Placebo Comparator|Placebo|The placebo arm will receive placebo pills identical in appearance to prednisone 10mg pills. They will start taking them 7 days prior to surgery with a taper (4 tabs/day for 3 days, 3 tabs/day for 3 days, 2 tabs/day for 3 days, 1 tab/day for 3 days).
3333193|NCT02119338|Experimental|5-ala preoperatively|A dose of 5-ala will be taken by mouth approximately 3 hours before going to surgery.
3333194|NCT02119351|Active Comparator|ViaValve™ Safety IV Catheter|Insertion of the ViaValve™ Safety IV Catheter
3333195|NCT02119351|Active Comparator|ProtectIV® Plus Safety IV Catheter|Insertion of the ProtectIV® Plus Safety IV Catheter
3234094|NCT01228357|Active Comparator|non-SSRI treated group|non-SSRI treated group is patients treated with milnacipran, venlafaxine, nortriptyline, or mirtazapine
3333196|NCT02119364|Active Comparator|Working memory training|After baseline assessment participants will be randomized to active training or treatment as usual (waiting). The active group will start training immediately and will have 6 weeks to perform the 25 training sessions.
3333197|NCT02119364|No Intervention|Passive control group|"The control group will receive treatment as usual (special education, physiotherapy etc)."
3333198|NCT02119377||Transgender and Transsexual People|Transgender and transsexual (trans) people aged 18 years or older living in Australia were invited to complete a questionnaire assessing a range of mental and physical health domains.
3333199|NCT02119390|Other|Standard Care|Participants in the Standard Care group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care.
3234095|NCT01228370|Experimental|Silodosin|Silodosin 8mg once a day for 12 weeks
3234096|NCT01228383|Experimental|CL184+PVRV|CL184 with rabies vaccine (PVRV)
3333200|NCT02119390|Experimental|Pill Trial+|Participants in the Pill Trial+ group will complete a demographic questionnaire at the time of consent as well as other questionnaires during the course of the study. They will receive standard clinical care plus three 25-minute individualized, behavioral, staff-delivered intervention sessions at HAART initiation, and 1-, and 3-month follow-up visits. Two brief booster sessions will also be provided following sessions 1 (in clinic) and 2 (by phone).
3333201|NCT02119403|Experimental|Hand Held NitrousTM|There are no other interventions to this device
3333202|NCT02119416|Experimental|1mg/kg Caffeine|Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg
3234097|NCT01228383|Active Comparator|HRIG+PVRV|HRIG with rabies vaccine
3234098|NCT01228383|Placebo Comparator|Placebo+PVRV|Placebo with rabies vaccine (PVRV)
3234099|NCT01228383|Experimental|CL184+HDCV|CL184 with rabies vaccine (HDCV)
3234100|NCT01228383|Placebo Comparator|Placebo+HDCV|Placebo with rabies vaccine (HDCV)
3234101|NCT01228409|Other|Low dose Acitretin (17.5 mg)|
3333203|NCT02119416|Experimental|2mg/kg caffeine|Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg
3333204|NCT02119416|Experimental|Placebo|Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg
3234102|NCT01228422||1|test interferon - blausiegel
3234103|NCT01228422||2|reference interferon - Roferon A (Roche)
3234104|NCT01228448|Experimental|Participants 1-39|PET Scan done right after one radiation treatment is complete and will take 15-20 minutes. After undergoing their first PET scan, participants will have the option to undergo 1-2 additional scans throughout radiation treatment in the same manner as the first scan.
3234105|NCT01228461||AYA with Fatigue and Hodgkin Lymphoma|
3234106|NCT01228474|Experimental|SET|Single embryo transfer
3234107|NCT01228474|Active Comparator|DET|Double embryo transfer
3234108|NCT01228487||Acute knee pain|Patients with a history of knee pain < 6 months. The radiologic and arthroscopic OA stadium is less or equal II°. n=20.
3234109|NCT01228487||Chronic knee pain|Clinical manifestation of knee joint OA, radiological and arthroscopic III° or more. n=20
3234110|NCT01228487||Control group|Patients coming for post- primary repair of the cruciate ligament, having no inflammation and no sign of OA. n=10
3333205|NCT02119429|Placebo Comparator|Wheat Germ Oil|Participants will be instructed to consume 2 wheat germ oil capsules ,2g, per day for 12 weeks.
3333206|NCT02119429|Experimental|Pumpkin Seed Oil|Participants will be instructed to consume 2 pumpkin seed oil capsules ,2g, per day for 12 weeks
3333207|NCT02119481|Experimental|Mindfulness-based stress reduction|Mindfulness-based stress reduction training
3333208|NCT02119481|Active Comparator|Expressive writing condition|Expressive writing
3333209|NCT02119481|No Intervention|Waiting-list control condition|Waiting list
3333210|NCT02119507|Experimental|Curodont Repair|Single application on Day 0.
3333211|NCT02119507|Other|No treatment - control|"No treatment as control - wait and see."
3333212|NCT02119520|Active Comparator|Platelet rich fibrin + atorvastatin|In Platelet rich fibrin+ATV group PRF combined with 10 µl of 1.2% ATV was inserted into the depth of the IBD
3333213|NCT02119520|Sham Comparator|Platelet rich fibrin|In Platelet rich fibrin group PRF was inserted into the depth of the IBD.
3234111|NCT01228500|Experimental|Experimental Arm (Internal Control)|"One-half of ulcer receives negative pressure wound therapy~One-half of ulcer receives a fetal bovine collagen bioscaffold (PriMatrix, TEI Biosciences, Boston, MA) in addition to the same negative pressure wound therapy"
3234112|NCT01228513|Active Comparator|0.01% ointment|Lowest concentration
3234113|NCT01228513|Active Comparator|0.03% ointment|Middle concentration
3234114|NCT01228513|Active Comparator|0.1% ointment|Highest concentration
3333214|NCT02119520|Other|Open flap debridement|open flap debridement was followed by no grafting or regenerative intervention.
3333215|NCT02119546|Experimental|Exercise intervention|Aerobic exercise and dual-task training
3333216|NCT02119546|Active Comparator|Stretch exercise|Stretch exercise & sitting balance
3333217|NCT02119559|Other|CTC assay, Cetuximab|Detection & characterization of viable CTC in the peripheral blood.
3333218|NCT02119572|Experimental|peer support|Patients are divided into small groups and assigned with peer leaders for twelve months according to their residence. Besides the same training and follow-ups as the control arm, patients from intervention groups are suggested and encouraged to take part in the group activities with the peer leaders per month. And if possible, casual activities (such as phone call, chatting, short message; physical exercise, group member family visiting，going to supermarket together, etc.)are also recommended
3333219|NCT02119572|Active Comparator|usual education|Patients attend the usual self-management education and communicate with the professionals every two months, getting the information on diabetes diet, exercise, glucose monitor, etc. besides that the group members should attend three follow ups at baseline,6 and 12 months.
3333220|NCT02119585||Patients undergoing OLT|insertion of nasogastric tube for measurements of chest wall mechanics
3333221|NCT02119624||1|Healthy non-treatment-seeking heavy drinkers
3333222|NCT02119624||2|Healthy light drinkers
3234115|NCT01228513|Placebo Comparator|Placebo (vehicle without active)|No active ingredient
3234116|NCT01228539|Experimental|TARGET|Affect regulation psychotherapy for PTSD
3234117|NCT01228539|Active Comparator|Prolonged Exposure|Cognitive behavioral therapy for PTSD with trauma memory exposure
3234118|NCT01228552|Active Comparator|Topical, intra-oral ketoprofen gel|
3234119|NCT01228552|Placebo Comparator|Placebo gel|
3234120|NCT01228565|Placebo Comparator|Placebo|Radiotherapy+Erbitux+Placebo
3234121|NCT01228565|Experimental|OTD70DERM|Radiotherapy+Erbitux+OTD70DERM®
3234122|NCT01228578|Experimental|Multivitamins (B,C,E)|
3234123|NCT01228578|Placebo Comparator|Placebo|
3234124|NCT01228604|Experimental|Methylphenidate|
3234125|NCT01228617|Experimental|A1 Short, no buffer|Nicotine / not yet marketed
3234126|NCT01228617|Experimental|A2 Short, low buffer|Nicotine / not yet marketed
3234127|NCT01228617|Experimental|A3 Short, high buffer|Nicotine / not yet marketed
3234128|NCT01228617|Experimental|B1 Long, no buffer|Nicotine / not yet marketed
3234129|NCT01228617|Experimental|B2 Long, low buffer|Nicotine / not yet marketed
3234130|NCT01228617|Experimental|B3 Long, high buffer|Nicotine / not yet marketed
3234131|NCT01228617|Active Comparator|R = Nicotine Gum|Nicorette® Gum
3234132|NCT01228630|Experimental|Cloratadd-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to comparator drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
3234133|NCT01228630|Active Comparator|Allegra-D|Loratadine 5 mg + 120 mg of sulfate pseudoephedrina and coated tablet of placebo (identical to test drug). The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
3234134|NCT01228643|Experimental|Norzyme®|
3234135|NCT01228643|Active Comparator|Creon®|
3234136|NCT01228656|Experimental|-mometasone furoate associated with salicylic acid|
3234137|NCT01228656|Active Comparator|-mometasone furoate|
3234138|NCT01228669|Experimental|A|
3333223|NCT02119637||Study 1 TMS to S1|Cohort of healthy participants received screening, brain MRI, TMS to S1 and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
3333224|NCT02119637||Study 2 TMS targeting S2/insula|Cohort of healthy participants received screening, brain MRI before and after TMS, TMS to S2/insula and vertex, and somatosensory testing, including 2-point discrimination and gentle brushing.
3333227|NCT02119702||Infected Cohort|Perinatally HIV-infected participants at or beyond their 18th birthday at enrollment, engaged in care with ART treatment history available.
3333228|NCT02119702||Uninfected Cohort|Perinatally HIV-exposed, perinatally-uninfected participant at or beyond their 18th birthday at enrollment. Must have been previously or currently enrolled in PHACS AMP or PHACS SMARTT, and may have horizontally-acquired HIV infection.
3333229|NCT02119715|Experimental|Pegylated rhG-CSF 100μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K） 100µg/kg in cycle 2 to 4
3333230|NCT02119715|Experimental|Pegylated rhG-CSF 150μg/kg|Chemotherapy naive patients receiving chemotherapy and Pegylated rhG-CSF（HHPG-19K)150 μg/kg in cycle 2 to 4
3234139|NCT01228669|Experimental|B|
3333231|NCT02119715|Active Comparator|G-CSF 5 μg/kg/d|Chemotherapy naive patients receiving chemotherapy and rhG-CSF 5μg/kg/day in cycle 2 to 4
3333232|NCT02119728|Active Comparator|Arm I (standard of care surgery)|Patients undergo standard of care surgery on day 1.
3333233|NCT02119728|Experimental|Arm II (HPPH, photodynamic therapy)|Patients receive HPPH IV over 1 hour on day 0. Approximately 24 hours later, patients undergo photodynamic therapy on day 1.
3333234|NCT02119741||Affected Interdental Papillae Group|This is the only group in which the material will be used
3333235|NCT02119754|Experimental|Plurogel PN|Plurogel PN
3333236|NCT02119767||Natural gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have natural gradients sampled using the LBS
3333237|NCT02119767||Induced gradients|Patients requiring an elective PCI who present with either non-ST-segment elevation myocardial infarction (NSTEMI) or chronic stable angina who will have induced gradients sampled using the LBS
3333238|NCT02119780|Experimental|YVOIRE® contour|
3333239|NCT02119780|Active Comparator|Restylane SubQ™|
3333240|NCT02119793|Experimental|YVOIRE contour|
3234140|NCT01228669|Placebo Comparator|C|
3234141|NCT01228682||Patients who are treated with Samsca.|
3333241|NCT02119806|Active Comparator|Benzodiazepine group|"Premedication 0.02mg/kg-0.1mg/kg of Benzodiazepine ;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
3333242|NCT02119806|Active Comparator|Non-benzodiazepine group|"Premedication 0-50mg of propofol and/or 0-250mcg of fentanyl;~Maintenance 0.8 minimum alveolar concentration of inhaled anesthetic (MAC) and 10-30mcg/kg of fentanyl;~Postoperative 10-100mcg/kg/min of propofol"
3333243|NCT02119832|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
3333244|NCT02119845|Experimental|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
3234142|NCT01228695||steroid treatment|
3234143|NCT01228708|Active Comparator|Intervention|Patients from half the GP practices in Ringkoebing-Skjern municipality that participates in an active implementation of a guideline for COPD
3333245|NCT02119858|Experimental|Diagnostic (ICG, diffuse optical imaging, surgery)|Patients receive indocyanine green transperineally and undergo diffuse optical imaging during robot-assisted laparoscopic radical prostatectomy with bilateral lymph node dissection using the da Vinci Robotic Surgical System.
3333246|NCT02119884|Experimental|Terlipressin group|Patients receive terlipressin 2 mg IV bolus
3234144|NCT01228708|No Intervention|Control group|Patients from the half of the GP practice in Ringkoebing-Skjern that do not participate in the active implementation of a guideline for COPD. The GPs are however in postgraduate training groups with intervention groups GPs
3234145|NCT01228708|No Intervention|External control|Patients with GP practice in neighboring county Ikast-Brande where there have been no information or contact at all from the investigators
3234146|NCT01228760|Experimental|Dose level 1|
3333247|NCT02119884|Active Comparator|High Dose Octreotide group|Patients receive Octreotide 50 μg/h with an initial bolus of 100 μg
3333248|NCT02119897|Experimental|Low Level Light Therapy (LLLT)|"LLLT: The LLLT device will be positioned next to the face and neck for a total of 6 exposures: Right face, Midline face, Left face, Left neck, Midline neck, Right neck~Dose per anatomic site 50mW/cm2, 60 sec = 3.0J/cm2~Route: Extraoral~Total Treatment Time (all sites): 6 min~Schedule: Participants will be treated daily (including weekends and holidays) beginning on the first day of HCT conditioning and continuing through day +20 or hospital discharge if prior to day +20.~Evaluation: Participants will undergo formal mucositis and toxicity assessments at baseline and daily from day -1 through day +20, with a final assessment on the last day of treatment."
3333249|NCT02119910|Experimental|Technology Supported Manual|Participants in this arm will receive behavioral intervention for a period of 5 consecutive days. A total of 3, 45-minute meals will be held at regularly scheduled times (e.g., 9:00 a.m., 10:30 a.m., and 12:00 p.m.) each day for a total of 15 meals throughout treatment.
3333250|NCT02119910|No Intervention|Waitlist|Participants will serve as the control condition.
3333251|NCT02119923|Experimental|Working memory training|
3234147|NCT01228760|Experimental|Dose level 2|
3234148|NCT01228760|Experimental|Dose level 3|
3234149|NCT01228760|Experimental|Dose level 4|
3234150|NCT01228760|Experimental|Dose level 5|
3234151|NCT01228760|Experimental|Dose level 5A|
3234152|NCT01228760|Experimental|Dose level 6|
3234153|NCT01228760|Experimental|Dose level 7|
3234154|NCT01228760|Experimental|Dose level 8|
3234155|NCT01228760|Experimental|Dose level 9|
3234156|NCT01228760|Experimental|Chemotherapy-naïve subjects|
3234157|NCT01228760|Experimental|Chemotherapy exposed subjects|
3333252|NCT02119923|Placebo Comparator|Placebo training|
3333253|NCT02119949|Experimental|Working memory training|
3333254|NCT02119949|Placebo Comparator|Placebo training|
3333255|NCT02119962|Experimental|Working memory training|
3333256|NCT02119962|Placebo Comparator|Placebo training|
3333257|NCT02119975|Placebo Comparator|Placebo working memory training|
3333258|NCT02119975|Experimental|Working memory training|
3333261|NCT02120014|Experimental|Heart Failure Reduced EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
3234158|NCT01228773|Experimental|A|"Providing tailored web-based care program(Health Navigation®), which provides various information related to the CRF.~Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue etc."
3234159|NCT01228773|Other|B|Attention control arm: Providing usual care for CRF. Three months later, as attention control, they will be provided tailored web-based care program(Health Navigation®), which provides various information related to the CRF.
3234160|NCT01228786||Group A|~ 20 sporadic PHPT patients
3234161|NCT01228786||Group B|~10 normocalcemic euthyroid patients (control tissue)
3234162|NCT01228799|Active Comparator|Trabeculectomy|Trabeculectomy with Mitomycin C
3234163|NCT01228799|Active Comparator|Canaloplasty|Canaloplasty with implant of suture
3333262|NCT02120014|Experimental|Heart Failure Preserved EF|"Patient prior to clinically ordered right heart catheterization identified patients will have a blood volume measurement completed in the nuclear medicine laboratory. Patients will receive an intravenous administration of low dose iodinated I-131 labeled albumin. Blood specimens (6 cc each) will be drawn at 6 minute intervals times 6. The analysis will be completed following the testing.~Venous plethysmography will be completed on eligible patients prior to the clinically indicated right heart catheterization. Calf and forearm venous compliance will be measured.~Measurements form the right heart catheterization will be recorded for analysis."
3333263|NCT02120040|Other|Hemangioblastoma (HB) of the Central nervous system (CNS)|
3333264|NCT02120053|Experimental|Bone substitute material group|Immediate denture placement following extractions and alveolar sockets filling with bone substitute material
3333265|NCT02120053|Active Comparator|Conventional protocol|Immediate denture placement following the conventional protocol
3333266|NCT02120066|Other|Vitrectomy|
3333267|NCT02120079|Active Comparator|Lotemax|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
3333268|NCT02120079|Active Comparator|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear which is used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
3333269|NCT02120092|Active Comparator|Clopidogrel + ASA|
3333270|NCT02120092|Placebo Comparator|Clopidogrel + Placebo|
3333271|NCT02120092|Active Comparator|Ticagrelor + ASA|
3333272|NCT02120092|Placebo Comparator|Ticagrelor + Placebo|
3333273|NCT02120105||Cystinuria|
3333274|NCT02120118|Experimental|Radiation; Hyperthermia; Chemotherapy|Patients will be treated with radiotherapy with 50Gy/22fx/6 weeks, plus hyperthermia 42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will cisplatin 30mg/m2 and taxotere 20mg/m2 per week for 6 weekly cycles.
3333275|NCT02120131||test envelope|envelope flap
3333276|NCT02120131||control, trapezodal|standard incision
3333277|NCT02120144|Experimental|Intervention|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to an observation phase and an imagination phase of walking at a precise rythm for 10 minutes
3333278|NCT02120144|Active Comparator|Reading|15 young patients (<65 years old) and 15 older patients (>64 years old) are submitted to a reading phase on a computer for 10 minutes.
3333279|NCT02120170|Active Comparator|Hemoclipping during colon polypectomy for all lesion|The enrolled patients of group 1 will be performed hemoclipping for all polypectomy lesion irrespective of the presence of immediate bleeding.
3333280|NCT02120170|No Intervention|No hemoclipping if there were no bleeding during polypectomy|The patients of group 2 will be performed hemoclipping only for the immediate bleeding during colon polypectomy
3333281|NCT02120183|Experimental|Psycho-educational support group therapy|4 week psycho-educational support group focusing on topics specific to psychosocial and emotional aspects of the cancer caregiving role
3333282|NCT02120196|Experimental|rifaximin|Arm 1: 109 patients will be treated with 1200 mg of rifaximin daily for 6 months.
3333283|NCT02120196|Active Comparator|norfloxacin|Arm 2: 109 patients will be treated with 400 mg of norfloxacin daily for 6 months.
3234164|NCT01228812||RA patients|Patients with Rheumatoid Arthritis
3234165|NCT01228812||Healthy subjects|Healthy subjects matched for age and sex
3234166|NCT01228825||CABG without CPB|Patients undergoing coronary artery bypass graft (CABG) without Cardiopulmonary bypass ( CPB)
3234167|NCT01228825||CABG with CPB|Patients undergoing coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)
3234168|NCT01228838|Experimental|NGX-1998, 10% w/w capsaicin|
3333284|NCT02120222|Experimental|Treatment (selinexor)|Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
3333285|NCT02120248|No Intervention|Control|Participants receive standard WIC breastfeeding support but do not have contact with a breastfeeding peer counselor
3333286|NCT02120248|Other|Low Intensity|Participants will receive four scheduled phone calls from a peer counselor. Two prenatal calls and 2 postpartum.
3333287|NCT02120248|Active Comparator|High Intensity|Participants will receive eight scheduled phone contacts from a peer counselor. Two are prenatal and 6 are postpartum.
3333288|NCT02120274|No Intervention|Control|Pegylated Interferon-Alfa plus ribavirin for 48 weeks
3333289|NCT02120274|Experimental|Vitamins|Pegylated Interferon-Alfa plus ribavirin for 48 weeks together oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level. Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
3333290|NCT02120313|Active Comparator|inpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in a rehabilitation hospital.
3333291|NCT02120313|Experimental|outpatient rehabilitation|After discharge, patients participate in daily physical therapy for 3 weeks in an outpatient rehabilitation center.
3333292|NCT02120326|Experimental|active tDCS|
3333293|NCT02120326|Placebo Comparator|simulated tDCS|
3333294|NCT02120339|Experimental|Carvedilol|Carvedilol 0-3.125 mg daily Escalating to 6.25 twice a day
3333295|NCT02120365|Experimental|Perampanel 6mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg days prior to each test day, and then observed dosing moderate 6mg dose perampanel in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3333296|NCT02120365|Placebo Comparator|Placebo|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with placebo 7 days prior to each test day, and then observed dosing of placebo in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3234169|NCT01228838|Experimental|NGX-1998, 20% w/w capsaicin|
3333297|NCT02120365|Experimental|Perampanel 10 mg|Participants will have 3 test days each, 2 weeks apart, in a randomized order, following either pretreatment with daily perampanel 2mg 7 days prior to each test day, and then observed dosing of high dose perampanel (10mg) in the lab 1 hour before a one-time alcohol infusion . Each lab session occurs exactly a week after starting the medication for that round. The wash out period between lab test session phases will be 7-10 days. Subjects will receive 2 days of 2mg perampanel after each lab to taper down (included in the washout period). The next appointment will be brief at the start of the next phase, at which point the next week of low dose perampanel or placebo will be started. With the washout period and the 7 day taper of the next phase, the actual lab sessions will occur 14-17 days apart. All test days will involve administration of alcohol with the same 3 target doses (target BrAc=20mg%, 60mg%, and 100mg%) in a step-wise fashion.
3333298|NCT02120391|Sham Comparator|Control (Arm A)|"Patients randomized to Arm A(control group) will receive an iPhone application without any of the adherence intervention turned on. The control phone application will allow patients to record their medications and how many refills they have remaining. The application will also provide patients with links about their medication.~No adherence intervention will be done to these patients."
3333299|NCT02120391|Experimental|Cases (Arm B)|"Patients randomized to Arm B will receive an iPhone application with the adherence intervention turned on. The study coordinator will help with the installation of the iPhone application.~Participants in this group will not need to pay for the iPhone application."
3333300|NCT02120404|No Intervention|Control group (GC)|Control group: no esmolol administration
3234170|NCT01228838|Placebo Comparator|Placebo liquid|
3234171|NCT01228851|Experimental|Balance Training|Balance training using Wii Fit Balance Board
3333301|NCT02120404|Experimental|Group 10 (G10)|Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
3333302|NCT02120404|Experimental|Group 20 (G20)|Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
3333303|NCT02120430|Active Comparator|Early administration of the video|Video delivered at one month of child's life
3333304|NCT02120430|Experimental|Late administration of the video|Video delivered at seven months of child's life
3234172|NCT01228864|Experimental|Brody Belt|
3234173|NCT01228864|Active Comparator|Conventional Urinary Drainage bag|
3234174|NCT01228877|Experimental|Exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
3234175|NCT01228890|Experimental|CATCH-IT 2-R Arm|Primary care/Internet based depression prevention intervention (CATCH-IT 2-R) with a family component.
3234176|NCT01228890|Active Comparator|Attention Monitoring Psycho-education (AMPE) Arm|
3259202|NCT01468441|Experimental|GnRH agonist|Administration of GnRH agonist in alternate days, recombinant FSH and hCG microdose for ovarian stimulation.
3333305|NCT02120469|Experimental|Treatment (everolimus, eribulin mesylate)|Patients receive everolimus PO QD on days 1-21 and eribulin mesylate IV on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3333306|NCT02120482|Experimental|Combined apheresis|Patients will be treated by semiselective immunoadsorption combined with membrane filtration
3333307|NCT02120495|Experimental|intraoral condylectomy via coronoid process resction|This procedure has no facial nerve injury and skin scar,little injury to TMJ anatomy and function.
3333308|NCT02120508|Experimental|1 Hz rTMS, real|1 Hz rTMS over unaffected hemisphere for 15 minutes
3234177|NCT01228916|Experimental|Tobacco Cessation and Secondhand Smoke Reduction|Community based interventions to raise awareness regarding secondhand smoke exposure, clean indoor air laws, smokefree homes, risks of tobacco use and benefits of cessation; include talks, healthcare provider training, radio public service announcements and talk shows, tleevision interviews, cessation classes and individual sessions, health fairs, community marches for smokefree spaces, materials and resources for assisting in tobacco use cessation, estsablishing smokefree homes, adhering to smokefree laws
3234178|NCT01228916|No Intervention|Delayed Intervention Control|Assessment only during comparison period (no interventions will be provided over and above any secular trends in communities); delayed intervention will be provided at end of 1 year comparison period
3234179|NCT01228942|Other|Platinum Sensitive|Treatment with platinum-based therapy; COXEN prediction model chooses secondary agent if doublet
3234180|NCT01228942|Other|Platinum resistent|single agent based on Coxen prediction model
3333309|NCT02120508|Sham Comparator|1Hz rTMS, sham|1Hz sham rTMS, over unaffected hemisphere for 15 minutes
3333310|NCT02120521||Sepsis group|Sixty patients are critically ill with evidence of sepsis during ICU stay (sepsis group) and sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
3333311|NCT02120521||SIRS group|Sixty patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of sTREM-1 and MNDA will be monitored.
3333312|NCT02120534||Sepsis group|Forty seven patients are critically ill with evidence of sepsis during ICU stay (sepsis group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
3333313|NCT02120534||SIRS group|Forty seven patients are critically ill without evidence of infectious organism (SIRS group). At admission, Patients data include clinical status; SOFA score; central venous pressure; laboratory analysis and arterial blood gas analysis are measured. Routine cultures will be obtained. The attending physician will evaluate the patients for sepsis, severe sepsis, or septic shock as long as their stay in ICU. A serum level of CD 14 and CD88 will be monitored.
3333314|NCT02120547|Experimental|Cenicriviroc in mild liver impaired|Subjects with mild liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
3333315|NCT02120547|Experimental|Cenicriviroc in moderate liver impaired|Subjects with moderate liver impaired will receive cenicriviroc, 1 tablet once daily, for 14 days. Matching healthy subjects will receive Cenicriviroc, 1 tablet once daily, for 14 days.
3333316|NCT02120560|Active Comparator|Interrupted Anticoagulation|Patients randomized to undergo atrial fibrillation ablation with interrupted anticoagulation with apixaban (5mg twice daily; 2.5mg twice daily >80 years old, Cr > 1.5, wt < 60kg), rivaroxaban (20mg daily; 15mg daily CrCl < 50 mL/minute), dabigatran (150mg twice daily; 75mg twice daily CrCl < 30mL/minute), or warfarin (dosed case-by-case).
3333317|NCT02120560|Active Comparator|Uninterrupted anticoagulation with warfarin|Patients randomized to undergo atrial fibrillation ablation with uninterrupted anticoagulation with warfarin (dosed case-by-case).
3234181|NCT01228955||Yoga Group|Group will enter a 10 week yoga class
3234182|NCT01228981||Type-2 Diabetic Retinopathy|
3234183|NCT01228994|Active Comparator|Baclofen 30 mg/day|Baclofen medication
3234184|NCT01228994|Placebo Comparator|Placebo pill|placebo pill
3333318|NCT02120573|Active Comparator|medical students|medical students took part in workshop
3333319|NCT02120573|Active Comparator|general population|general population took part in workshop
3333320|NCT02120573|Active Comparator|nonmedical students|all students from different subjects, non medical and paramedical
3333321|NCT02120586|No Intervention|Control group|Usual care
3333322|NCT02120586|Experimental|Respiratory training group|"Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Inspiratory Muscle training (12-weeks)"
3234185|NCT01228994|Active Comparator|Baclofen 60 mg/day|Baclofen medication high dose
3234186|NCT01229007|Experimental|Biostate|
3333323|NCT02120586|Experimental|Peripheral training group|"Participants will load ≥ 50% of their maximum muscle force (Kg), after which load will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.~Intervention: Peripheral muscle training (12-weeks)"
3234187|NCT01229020||COPD patients|Patients diagnosed with COPD, by the pulmonologist at the institute,who are referred to undergo ventilation/perfusion scans.
3234188|NCT01229033|Active Comparator|Ablation|Ablation of atrial tachycardia
3234189|NCT01229033|Active Comparator|Cardioversion|Cardioversion of atrial tachycardia
3234190|NCT01229046|Active Comparator|ticarcillin-clavulanate|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
3333324|NCT02120599|Active Comparator|corn-soy-blend|This is the control group for the study, which will receive the Malawi standard of care. The treatment provided to women randomized to this arm of the study includes daily iron (60 mg) and folic acid (400 mcg) supplementation, along with 4 kg/2 weeks corn-soy blend (~357 gm/d CSB).
3333325|NCT02120599|Experimental|corn-soy-blend + multiple micronutrients|The treatment provided to women randomized to this arm of the study includes 200gm/d CSB along with a standard maternal multiple micronutrient tablet, which together provide a comparable amount of energy, protein and micronutrients to the ready-to-use supplemental food. The micronutrient supplement known as the United Nations Children's Emergency Fund (UNICEF) / World Health Organization (WHO) / United Nations University (UNU) international multiple micronutrient preparation (UNIMMAP) is widely available and has been used in many settings worldwide in pregnant women.
3333326|NCT02120599|Experimental|ready-to-use supplementary food|RUSF-P (ready-to-use supplementary food) provides 750 kcal/d, 20 g protein/d, and 200% of RDA/d for most micronutrients during pregnancy (except for vitamins A, B3, folic acid, minerals iodine, magnesium, and calcium which will remain near 100%)
3333327|NCT02120612||Historical Control Group|Historical Control Group will be assessed for knowledge prior to the implementation of the educational program.
3333328|NCT02120612||Naloxone Education Intervention Group|Group to begin receiving the Naloxone Education Intervention on the signs of opioid overdose and appropriate use of naloxone.
3333329|NCT02120638|Active Comparator|Pyrazinamide Sensitive Comparator|"Pyrazinamide containing regimen: Regimen B1 - 6ZAmkLfxClrPto\6ZlfxClrPto~Six months of chemotherapy with Pyrazinamide,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Six months of Pyrazinamide,Levofloxacin,Clarithromycin,plus Prothionamide"
3333330|NCT02120638|Experimental|Pyrazinamide Resistant Comparator|"Regimen without Pyrazinamide: Regimen B2 - 6HAmkLfxClrPto\18HlfxClrPto~Six months of chemotherapy with Isoniazid,Amikacin,Levofloxacin,Clarithromycin,plus Prothionamide,followed by~Eighteen months of Isoniazid,Levofloxacin,Clarithromycin,plus Prothionamide"
3333331|NCT02120651|Active Comparator|Fibrin monomer|40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
3234191|NCT01229059||lipid infusion in untrained humans|healthy lean humans before and after lipid infusion
3234192|NCT01229059||lipid infusion in athletes|endurance trained atheletes
3234193|NCT01229072|Experimental|1|Heparin Blausiegel
3333332|NCT02120651|Placebo Comparator|Hemostatic sponge|40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.
3333333|NCT02120677|Experimental|Itraconazole ointment|Patients with histologically proven BCC will be eligible for study enrollment. 50% itraconazole compounded in petrolatum jelly will be applied under occlusion for up to 3 to 7 days.
3333334|NCT02120690|Experimental|Trigeminal nerve stimulation - active|10-day TNS interventional protocol over an 10-day follow-up
3234194|NCT01229072|Active Comparator|2|Liquemine
3234195|NCT01229085|Experimental|Test|mometasone 0,1% + salicylic acid 5%
3234196|NCT01229098|Experimental|LEO 80185|
3234197|NCT01229137||Right Ventricular Cohort|Right Ventricle wtih SRD-1 conversion
3333335|NCT02120690|Sham Comparator|Trigeminal nerve stimulation|10-day sham interventional protocol over an 10-day follow-up
3333336|NCT02120703|Active Comparator|gabapentin|
3333337|NCT02120703|Active Comparator|Pregabalin|
3333338|NCT02120729|No Intervention|Standard of Care|Patients assigned to standard-of-care pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription and psychotropic therapy follows the institutional norm.
3333339|NCT02120729|Active Comparator|Genotype-guided Care|Patients assigned to genetically-guided pharmacotherapy, for whom CYP2D6 genotype is determined but not utilized to guide drug prescription as part of psychotropic therapy.
3333340|NCT02120742|Experimental|Social Norming|"The first group will receive SMS message reminders framed as social norming (ie Most of your peers wear helmets)."
3234198|NCT01229137||Left Ventricular Cohort|Left Ventricle with SRD-1 conversion
3234199|NCT01229137||Right Atrium Cohart|Right atrium cohort with SRD-1 conversion
3234200|NCT01229189|Experimental|Maternal and Neonatal Intervention Arm|Pregnant women will be individually randomized; a daily dose of vitamin D in 4000 IU will be given to Intervention group, started at 20-22 weeks of pregnancy till the time of delivery. The infants of this group will further stratify into two groups, one group will receive 400 IU of Vitamin D for 6 months as Intervention.
3234201|NCT01229189|Placebo Comparator|Maternal and Neonatal Control Arm|
3333341|NCT02120742|Experimental|Fear Appeal|"The second group will receive SMS message reminders framed as fear appeals (ie Not wearing your helmet increases your chance of dying in an accident)."
3333342|NCT02120742|Placebo Comparator|Control|The third group will act as the control and receive texts that relate to general road safety, but not helmet use.
3234202|NCT01229202|Active Comparator|standard of care|standard of care for trabeculectomy surgery
3234203|NCT01229202|Active Comparator|bevacizumab arm|
3234204|NCT01229215|Experimental|FCFD4514S|
3234205|NCT01229215|Sham Comparator|sham|
3234206|NCT01229241|Other|levobupivacaine|
3234207|NCT01229241|Other|ropivacaine|
3234208|NCT01229280|Experimental|Darisec(R) 7.5 mg|
3234209|NCT01229280|Active Comparator|Enablex(R) 7.5 mg|
3234210|NCT01229293|Experimental|Resurfacing Total Hip Arthroplasty|A hip replacement that leaves most of the underlying bone intact and mimics the natural biomechanical features of the hip joint. Articular surface replacement ASR, DePuy posterolateral approach used (RTHA)
3234211|NCT01229293|Active Comparator|Standard Total Hip Arthroplasty (THA)|A standard 28 mm head uncemented THA
3234212|NCT01229306|Experimental|reisolation of all PV and additional anterior line|
3234213|NCT01229306|Placebo Comparator|reisolation of all pulmonary veins|
3234214|NCT01229319|Experimental|cryo + imiquimod to Left|Cryotherapy alone to Right arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Left arm
3333343|NCT02120755|Active Comparator|AmnioClear™|AmnioClear™ Human Allograft Amniotic Membrane
3333344|NCT02120755|No Intervention|Standard of Care|Standard moist wound dressing (saline wet-to-moist or a hydrogel dressing)
3234215|NCT01229319|Experimental|Cryo + imiquimod to Right|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
3333345|NCT02120768|Experimental|Barrier resection|"Barrier resection was defined as en bloc removal of tumor with surrounding barriers. The barriers include muscular fascia, vascular adventitia, epineurium and periosteum, in some cases where there is no barrier, 3-5cm of healthy tissue is considered equivalent. Barrier resection was developed according to the above characteristics of STSs, which featured with the fact that sarcomas take the path of least resistance and initially grow within the anatomical compartment in which they arose, and the phenomenon that skip metastases are limited within the same anatomic compartment in which the primary lesion is located.Further surgery would be 1cm resection if a recurrence occurs."
3333346|NCT02120768|Active Comparator|1 cm resection|Surgical margin width is determined mainly by the distance from the tumor edge to the periphery of the specimen, different margin width of 1-5cm has been recommended for obtaining a safe margin,but the local recurrence rate remains to be 10-25%. Further surgery would be barrier resection if a recurrence occurs.
3333347|NCT02120807|Experimental|certolizumab, cisplatin and pemetrexed|Patients will receive certolizumab with 6 cycles of cisplatin & pemetrexed. Cycle of chemo will be 3 weeks. Certolizumab will be adm in the following fashion: first dose administered at the time of treatment initiation, second dose will be given after 2 weeks of treatment, third dose after four weeks of treatment, & subsequent doses given every 4 weeks thereafter. Patients will be monitored for progression of disease using RECIST 1.1 with scans to be performed every 6 weeks. Posttreatment biopsies will be performed at the time of treatment discontinuation. Two dose levels of certolizumab will be tested, 200mg & 400mg. A non-therapeutic cohort of 10 patients with adenocarcinomas who will be undergoing standard of care treatment with platinum based chemotherapy + pemetrexed +/- bevacizumab will be consented for blood draws before each cycle of treatment. This blood will be analyzed for cytokines and will serve as a reference for the experimental arm.
3333348|NCT02120820|Active Comparator|Multisensory environment|Multisensory environment (MSE): 30 minutes/session, twice a week for 10 weeks
3333349|NCT02120820|Active Comparator|Massage therapy|Massage therapy (MT): 15 minutes/session, twice a week for 10 weeks
3333350|NCT02120820|Other|Control group|Control group: usual care for 10 weeks, with attention and interactions with the caregivers only.
3333351|NCT02120820|Active Comparator|Massage in multisensory environment|Participants receive 15 minutes massage therapy in multisensory environment (MT-MSE), twice a week for 10 weeks.
3333352|NCT02120846|Experimental|Flywheel leg-press resistance exercise|Participants from the resistance exercise group will perform a 12-wk unilateral flywheel resistance training program with the paretic limb. Four sets of seven coupled concentric and eccentric actions will be completed in the leg press device using flywheel technology twice weekly. Power in each set and repetition will be measured. During all training sessions, subjects will receive visual real-time feedback of power and force produced during each concentric-eccentric action.
3333353|NCT02120846|No Intervention|Control|Daily routines
3333354|NCT02120859|Experimental|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
3333355|NCT02120859|Other|DEB angioplasty with provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
3333356|NCT02120872|Active Comparator|PRF and SMV Group|sites treated with Open Flap Debridement with Platelet Rich Fibrin along with Simvastatin
3333357|NCT02120872|Sham Comparator|PRF Group|sites treated with Open Flap Debridement with autologous Platelet Rich Fibrin
3333358|NCT02120872|Other|OFD Group|sites treated with Open Flap Debridement i.e. conventional flap surgery
3333359|NCT02120885|Experimental|Exercise group|physical activity intervention
3333360|NCT02120885|No Intervention|Control group|
3333361|NCT02120911|Experimental|Pertuzumab, trastuzumab|Pertuzumab, trastuzumab
3333362|NCT02120937|Experimental|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
3333363|NCT02120963|Experimental|intervention program|Person-centered physical therapy intervention program
3333364|NCT02120963|No Intervention|Control group|Health care as usual
3333365|NCT02120976|Experimental|Dose 1 JTT-252 or Placebo|Tablets, single dose in fasted condition
3234216|NCT01229332|Placebo Comparator|Carbidopa|
3234217|NCT01229332|Placebo Comparator|Placebo|
3234218|NCT01229345|Experimental|Breakfast & exercise|
3234219|NCT01229345|Experimental|Breakfast & no exercise|
3234220|NCT01229345|Experimental|No breakfast & exercise|
3234221|NCT01229345|No Intervention|No breakfast & no exercise|
3234222|NCT01229358|Experimental|Silver Eluting Dressing|Acticoat Absorbant™ applied as post-operative dressing
3234223|NCT01229358|Active Comparator|Standard Guaze|Standard dry gauze applied as post-operative dressing
3234224|NCT01229384|Experimental|Positive Airway Pressure Nebulization|Will administer nebulized medications using Positive Airway Pressure Nebulization
3234225|NCT01229384|Active Comparator|Standard Nebulization|Current standard of administering nebulized medications without positive airway pressure
3234226|NCT01229475|Active Comparator|Stepwise approach|Stepwise approach for repeat AF ablation
3234227|NCT01229475|Active Comparator|Linear ablation|Linear ablation for repeat procedure in patients with recurrent atrial fibrillation
3234228|NCT01229488|No Intervention|No Arms|Project was withdrawn before starting
3333366|NCT02120976|Experimental|Dose 2 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333367|NCT02120976|Experimental|Dose 3 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333368|NCT02120976|Experimental|Dose 4 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333369|NCT02120976|Experimental|Dose 5 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333370|NCT02120976|Experimental|Dose 6 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333371|NCT02120976|Experimental|Dose 7 JTT-252 or Placebo|Tablets, single dose in fasted condition
3333372|NCT02120976|Experimental|Dose 8 JTT-252|Tablets, single dose in fed condition
3333373|NCT02120976|Experimental|Dose 9 JTT-252|Tablets, single dose in fasted condition
3333374|NCT02121015|Active Comparator|Self-Directed|Access to the e-health intervention (an interactive website with didactic material and interactive tools) for participants to use at their own pace for 8 weeks (Self-Directed)
3333375|NCT02121015|Experimental|Share|Access to the same e-health intervention + an internet social networking component consisting of up to 12 other pregnant women (Share).
3333376|NCT02121028||Intracranial Atherosclerotic Disease, Stroke/TIA|Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
3333377|NCT02121080|Experimental|Cohort 1|Dosing regimen 1
3333378|NCT02121080|Experimental|Cohort 2|Dosing regimen 2
3333379|NCT02121080|Experimental|Cohort 3|Dosing regimen 3
3333380|NCT02121080|Experimental|Cohort 4|Dosing regimen 4
3333381|NCT02121080|Experimental|Cohort 5|Dosing regimen 5
3333382|NCT02121093|No Intervention|alpha band of the EEG and electromyographic activity|- 20 will be in the evaluation group (EG); then review the alpha band of EEG and EMG activity.
3333383|NCT02121093|Experimental|Vibration|"• 20 vai participar no grupo de baixa freqüência de vibração estimulação (LFVS);~20 no grupo de estimulação da vibração de média freqüência (MFVS);~20 vai participar no grupo de alta freqüência de vibração estimulação (HFVS). then review the alpha band of EEG and EMG activity."
3333384|NCT02121106|Experimental|Cognitive Remediation|Participants in this group will receive active cognitive remediation.
3333385|NCT02121106|Sham Comparator|Sham Cognitive Remediation|Participants in this group will receive a sham comparison, which is a computerized exposure to the same exercises as the active intervention, but with cognitively complex elements removed and no titration of the difficulty of tasks.
3333386|NCT02121119|Active Comparator|Lidocaine|0.5% lidocaine infusion hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
3333387|NCT02121119|Placebo Comparator|Bupivacaine|Infusion of 0.1% bupivacaine hour to 5 ml Baxter Infusor elastomeric pump 5 ml / hr.
3333388|NCT02121132||No treatment|
3333389|NCT02121145|Experimental|Vivotif + Typherix primary immunization|Vivotif + Typherix primary immunization
3333390|NCT02121145|Experimental|Vivotif booster|Volunteers previously immunized with Vivotif, now receiving a Vivotif secondary immunization
3333391|NCT02121145|Experimental|Typherix booster|Volunteers previously immunized with Typherix, now receiving a Typherix secondary immunization
3333392|NCT02121145|Experimental|Vivotif + Typherix booster|Volunteers previously immunized with Vivotif and Typherix, now receiving Vivotif and Typherix as secondary immunization
3333393|NCT02121158|Other|1|ICD implantation in addition to Optimal Medical Therapy
3333394|NCT02121158|Active Comparator|2|Optimal Medical Therapy
3234229|NCT01229514||Exposure to anesthesia|
3234230|NCT01229514||Normal controls|
3234231|NCT01229540|No Intervention|Lifestyle counseling|
3333395|NCT02121171|Experimental|Ologen Collagen Matrix Intervention|Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
3333396|NCT02121171|Active Comparator|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
3333397|NCT02121184|Active Comparator|Group A|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. Oxytocin management will continue as per the routine oxytocin protocol
3333398|NCT02121184|Experimental|Group B|Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
3333399|NCT02121223|Active Comparator|Control|Patients in control group will receive current standard therapy for STEMI: manual thrombus aspiration + Promus Element stent implantation ( with a pressure less than 12 atm), but not post-dilatation
3333400|NCT02121223|Experimental|Post-dilatation|Patients in this group will receive high pressure post-dilatation with a Quantum Maverick balloon after manual thrombus aspiration + Promus Element stent implantation
3333401|NCT02121236||Patients with benign radiolucent lesions|
3333402|NCT02121249|Experimental|Robot assisted pedicle screw fixation|posterior lumbar interbody fusion using Robot assisted pedicle screw fixation (Renaissance, Mazor Robotics Ltd, Caesare, Israel)
3333403|NCT02121249|Active Comparator|Free hand technique|using Free hand technique, posterior lumbar interbody fusion (No specific device)
3333405|NCT02121288|Experimental|Ticagrelor|oral ticagrelor 90 mg (yellow) tablet
3333406|NCT02121288|Active Comparator|Clopidogrel|oral clopidogrel 75 mg (pink) tablet
3333407|NCT02121314|Active Comparator|Fasting-Fed|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE as iv therapy; on day 2, HRZE as oral therapy in fasting condition (2 hours before meals); and on day 3 HRZE as oral therapy in fed condition (after meals).
3333408|NCT02121314|Active Comparator|Fed-Fasting|blood sampling on 3 consecutive days; by randomization, drug treatment as follows: day 1, HRZE therapy as iv therapy; day 2, HRZE as oral therapy in fed condition, and on day 3, HRZE as oral therapy in fasting condition
3333409|NCT02121327|Active Comparator|usual care|usual care group receive regular outpatient treatment
3333410|NCT02121327|Experimental|disease management|desease management program include self management education by nurse on 6months.
3234232|NCT01229553|Experimental|Decolonization group|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
3234233|NCT01229566|Active Comparator|Active Comparator|Active comparator
3333411|NCT02121340|Experimental|Behavioral Activation|CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.
3333412|NCT02121340|No Intervention|Usual Care|Usual Care
3333413|NCT02121353|Experimental|PF582|PF582 is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
3333414|NCT02121353|Active Comparator|Lucentis|Lucentis® is provided as single use vials and will be administered by intra-vitreal injection on Day 1, 28 and 56.
3333415|NCT02121366|Experimental|Insulinoma|Patients with Insulinomas will received EUS-guided ethanol ablation therapy
3333416|NCT02121379|No Intervention|control|stretching exercise
3333417|NCT02121379|Experimental|pulmonary rehablitation|warming up exercise strengthening exercise aerobic exercise cool down
3333418|NCT02121405|Experimental|Primary surgery|The patients receive primary rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with TME. To patients with pathological confirmed positive circumferential margin (CRM), postoperative concurrent radiochemotherapy is required that starts in 3 months post operation with capecitabine. Capecitabine and Oxaliplatin (CapeOx) chemotherapy starts in 4 weeks post operation to total of 6 cycles/18 weeks. To patients with pathological confirmed negative CRM, radiotherapy is omitted. The stage III patients receive 8 cycles/6 months CapeOx chemotherapy. The stage II patients with low microsatellite instability (MSI) receive 8 cycles/6 months Capecitabine chemotherapy. The stage II patients with high MSI and stage I patients do not receive adjuvant therapy.
3333419|NCT02121405|Active Comparator|Preoperative radiochemotherapy|All of the patients receive conventional concurrent radiochemotherapy with capecitabine for 5 weeks. Then all of the patients receive 2 cycles/6 weeks capecitabine chemotherapy. Patients receive rectectomy including anterior resection or abdominoperineal resection by open or laparoscopy with total mesorectal excision 8 weeks post radiotherapy. All of the patients receive 5 cycles/15 weeks capecitabine adjuvant chemotherapy.
3333420|NCT02121431|Experimental|Online-Delivered Parenting Intervention|The Online-Delivered Parenting Intervention, which is based on the Triple P--Positive Parenting Program system of interventions, is an interactive website designed to engage and activate the participant through sequenced, personalized, interactive, and video-based content. The intervention emphasizes a self-regulatory process, parent specification of goals, practical and straightforward parenting strategies, modeling, and action activation.
3333421|NCT02121431|Active Comparator|Staff-Delivered Parenting Intervention|The Staff-Delivered Parenting Intervention is based on the Triple P--Positive Parenting Program system and involves 10 face-to-face sessions with each family. This intervention is the well-established Level 4 Standard Triple P program.
3333422|NCT02121444||Cohort 1|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
3333423|NCT02121457|No Intervention|Control Group|This group did not receive any intervention.
3333424|NCT02121457|Experimental|Treatment Group|This group took one Brazil nut daily during 6 months.
3333425|NCT02121496|Experimental|Resources for Postpartum Parenting|Behavioral intervention will include techniques to help mothers get their infants to cry/fuss less and sleep more to determine if this has an effect on prevalence of postpartum depression in low SES women and if it improves the quality of mother-infant interaction and subsequent child development.
3333426|NCT02121496|No Intervention|Control Group|This group will not receive the coaching tips to help babies cry less and sleep more.
3234234|NCT01229566|Placebo Comparator|Placebo|Placebo control
3234235|NCT01229566|Experimental|AKR-963|Investigational drug
3234236|NCT01229579|Experimental|Zinc Supplement|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc
3234237|NCT01229579|Placebo Comparator|Placebo|2.5 ml supplement syrup daily without elemental zinc
3234238|NCT01229592|Experimental|Ethanol|Every three day lock using Ethanol in all the lumen of the Catheter
3234239|NCT01229592|Active Comparator|Heparine|Every three day lock using Heparine in all the lumen of the Catheter
3234240|NCT01229605|Experimental|Single Arm|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
3333427|NCT02121548|Placebo Comparator|Outreach|Gets outreach materials and info on where to get screened by CHW.
3333428|NCT02121548|Active Comparator|CHW Outreach|Comprehensive CHW outreach including home visit, detailed 1:1 education, patient navigation
3234241|NCT01229618|Experimental|1|0.14 ml/kg bw - hyperpolarized pyruvate
3234242|NCT01229618|Experimental|2|0.28 ml/kg bw - hyperpolarized pyruvate
3234243|NCT01229618|Experimental|3|0.43 ml/kg bw - hyperpolarized pyruvate
3234244|NCT01229631|Placebo Comparator|Supplementation with non-active|Subjects will be supplemented with placebo capsules (3 capsules am & 3 capsules pm)
3234245|NCT01229631|Active Comparator|Dietary supplementation with Juice plus+|Subjects will be supplemented with Juice plus+ capsules (3 capsules am & 3 capsules pm)
3234246|NCT01229644|Experimental|Cohort A|Adult newly diagnosed glioma (both low and high grade) patients, who are able to to take Crenolanib (CP-868,596) for at least 3 days prior to surgical resection.
3259203|NCT01468441|Active Comparator|GnRH antagonist|Daily administration of GnRH antagonist, recombinant FSH and hCG microdose for ovarian stimulation.
3333429|NCT02121548|Active Comparator|CHW Outreach and HPV Self-Sampling|Same as Arm 2 with a CHW outreach but also option of doing HPV home self-sampling
3333430|NCT02121561|Experimental|Self-Acceptance Group Therapy|Participants receive Self-Acceptance Group Therapy
3234247|NCT01229644|Experimental|Cohort B|Adult patients with recurrent high grade glioma, including patients treated with bevacizumab. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
3234248|NCT01229644|Experimental|Cohort C|Adult patients with biopsy proven low grade glioma who have residual measurable disease. Patients are treated with Crenolanib (CP-868,596) continuously until they fulfill one of the criteria for study discontinuation.
3333431|NCT02121574||Zero-flux and ingestible thermometer|Ingestion of a capsule thermometer pre-operatively Attachment of a zero flux temperature electrode intraoperatively Standard oesophageal thermometer
3333432|NCT02121587||Pain self-management course|This is a single group observational cohort study. Participants are adults with persistent musculoskeletal pain who choose to participate in an optional, six week pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment for individual patients.
3333433|NCT02121600|Other|Docetaxel|Patients who will be receiving Docetaxel as cancer treatment will be assigned to Arm 1. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan
3333434|NCT02121600|Other|Abiraterone|Patients who will be receiving Abiraterone as cancer treatment will be assigned to Arm 2. All patients in this cohort will have a [F-18]-FCH PET scan with full body MRI scan.
3333435|NCT02121613|Experimental|Permixon® 160 mg & Placebo|
3234249|NCT01229670|Experimental|aerobic intermittent group|aerobic intermittent group
3333436|NCT02121613|Placebo Comparator|Placebo|
3333437|NCT02121613|Other|Tamsulosine LP & Placebo|Active control arm
3333438|NCT02121626||Chemotheraphy Treatement|The study will be limited to NHS patients to reduce complications associated with the need for additional funding authorisations from private health care providers for algorithm-instigated investigations. It is not envisaged that participation in other studies running within the GI unit at The Royal Marsden Hospital will preclude entry into this study except in the event of those rare studies where the study is specifically measuring toxicity of treatment as the primary end point.
3333439|NCT02121639|Experimental|AZD5363|AZD5363
3333440|NCT02121639|Placebo Comparator|Placebo|Placebo
3333441|NCT02121652|Active Comparator|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
3234250|NCT01229670|Experimental|aerobic continuous group|aerobic continuous group
3333442|NCT02121652|Experimental|Cognitve behaviroal therapy|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
3333443|NCT02121665|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
3333444|NCT02121665|Placebo Comparator|Placebo Arm|Placebo Lozenges (4 Lozenges per day; 1 lozenge in morning,1 lozenge in the afternoon and 2 lozenges in the night). Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
3333445|NCT02121678|Experimental|Run-in - Aerobic - Resistance|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Aerobic training on ergometer bicycle~Week 12 to 24: Resistance training with dumbbells"
3333446|NCT02121678|Experimental|Run-in - Resistance - Aerobic|"Week -12 to 0: Run-in period with no training~Week 0 to 12: Resistance training with dumbbells~Week 12 to 24: Aerobic training on ergometer bicycle"
3333447|NCT02121691|Experimental|Walk by Faith|Intervention arm
3333448|NCT02121691|No Intervention|Comparison|Non-intervention arm
3333449|NCT02121704|No Intervention|Controll Group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL NOT BE USED during the investigation.
3333450|NCT02121704|Active Comparator|Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. The Magnetic Endoscope Imaging (Scope Guide) function WILL BE USED during the investigation.
3333451|NCT02121717|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 52 weeks
3333452|NCT02121717|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 52 weeks
3333453|NCT02121717|Placebo Comparator|Arm 3|Patients administrate placebo for 24 weeks.From week 25 to 52, patients are randomly switched to Arm 1 and Arm 2, and receive the treatment accordingly.
3333454|NCT02121730||Kidney Transplantation|Patients who had undergone renal transplantation for 10 years in the interregion Northwest (Normandy, Picardy and Nord-Pas de Calais).
3333455|NCT02121743|Experimental|Strattice|a strattice (10 x 10) will be used during the surgery, prior to the colostomy's conception
3333456|NCT02121743|Placebo Comparator|No strattice|the colostomy is not reinforced with a mesh
3333457|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part A)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
3333458|NCT02121782|Experimental|Quadrivalent influenza vaccine(Part B)|Day 1: GC3110A, 0.5ml, intramuscular, a single dosing
3333459|NCT02121782|Active Comparator|Trivalent influenza vaccine(Part B)|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
3333460|NCT02121821|No Intervention|Control|A control group of pregnant women receiving no intervention (i.e. no SMS reminders).
3333461|NCT02121821|Experimental|SMS reminder messages|The intervention group will be composed of pregnant women receiving SMS reminder messages via the SMS Mother Reminder system.
3333462|NCT02121873||Women with and without breast cancer|Nipple aspirator, ductal lavage microcatheter, blood draw
3333463|NCT02121886|Experimental|Parietal peritoneum|
3333464|NCT02121938||very low birth weight infants|Very low birth weight infants weighing 1500 grams at birth or less
3333465|NCT02121951|Active Comparator|Local Anesthetic infiltration and MAC|"Local Anesthetic infiltration with 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
3333466|NCT02121951|Experimental|Quadratus Lumborum block and MAC|"QL block with 0.25% levobupivacaine (Chirocaine, Abbott, Ireland) and 1% lignocaine~MAC with IV Midazolam Img\ml and Fentanyl 10 mic\ml"
3333467|NCT02121964|Other|Capsulectomy|Capsulectomy in Direct Anterior Total Hip Arthroplasty
3333468|NCT02121964|Other|Capsulotomy|Capsulotomy in Direct Anterior Total Hip Arthroplasty
3333469|NCT02121977|Active Comparator|Elevate Anterior and Apical|Prolapse repair with mesh
3333470|NCT02121977|Active Comparator|Native Tissue Repair|Prolapse repair with sutures
3333471|NCT02121990|Experimental|Cisplatin, Paclitaxel, bevacizumab & olaparib|All treatments will be given in the outpatient setting. A cycle is 21 days. The sequence of infusions on Day 1 will be IV paclitaxel (135 mg/m2), then IV bevacizumab (15 mg/kg, beginning Cycle 2). On Day 2 patients will receive IP cisplatin (75 mg/m2). Patients will be given twice-daily treatment with oral olaparib in cycles 1-6 for 7 consecutive days, starting on Day 2 (Days 2-8). IP paclitaxel (60 mg/m2) will be given on Day 8. Sequential cohorts of 3 patients will receive escalating doses of olaparib (50mg BID, 100mg BID, 200mg BID).
3333472|NCT02122003|Experimental|sorafenib|Sorafenib 400 mg bid
3333473|NCT02122016|Experimental|SmartCare|A computer driven weaning ventilator, using closed-loop ventilation, taking into account patients lung mechanics and exhaled CO2.
3333474|NCT02122016|Active Comparator|Conventional weaning protocol|A conventional weaning protocol consisting of a daily weaning screen, which is performed by physiotherapist. All patients who are mechanically ventilated for more than 24 hours are given a spontaneous breathing trial.
3333475|NCT02122029|Experimental|Bariatric Surgery|
3333476|NCT02122029|Experimental|Lifestyle counselling|
3234251|NCT01229670|No Intervention|control|home exercise group
3234252|NCT01229683||Shoulder Surgery|Patients will be given an interscalene nerve block and then strength and sensation of the hand and forearm will be tested to determine if the block is helping to anesthetize these areas.
3234253|NCT01229696|Active Comparator|At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
3234254|NCT01229696|Active Comparator|5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
3234255|NCT01229709|Experimental|Mindfulness Based Tinnitus Reduction|
3333477|NCT02122042|Experimental|HBOT|Group will be treated with HBOT for 60 treatments in 3 months.
3333478|NCT02122042|Other|Control/Crossover|Control for 3 months without treatment, and then HBOT for 60 treatments in 3 months.
3333479|NCT02122055|Experimental|Propofol/Dexmedetomidine|"Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
3333480|NCT02122055|Experimental|Midazolam/Dexmedetomidine|"Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.~After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning."
3333481|NCT02122068|Experimental|Mentalizing Imagery Therapy|Meditation and mindfulness 4 week program
3333482|NCT02122068|Active Comparator|Relaxation cd|Listening to a relaxation cd
3333483|NCT02122081|Experimental|Treatment (OSMI, allogeneic transplant)|"CONDITIONING REGIMEN: Patients undergo organ-sparing marrow irradiation BID on days -6 to -4 and receive cyclophosphamide IV over 1-2 hours every 24 hours on days -3 to -2. Patients with an unrelated donor also receive anti-thymocyte globulin every 24 hours on days -4 to -2.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 and continuing for at least 6 months and methotrexate IV on days 1, 3, 6, and 11.~TRANSPLANT: Patients undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0."
3333484|NCT02122094|Experimental|Sexual Health Promotion Intervention|The SHP Intervention consists of seven core and five optional modules covering topics related to sexual health. It is delivered in both community (outreach) settings and i clinic-based settings.
3333485|NCT02122107||breast cancer survivors who had received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3333486|NCT02122107||breast cancer survivors who had not received chemotherapy|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3333487|NCT02122107||non-cancer controls matched by age,education, and race|Participants will complete all assessments at enrollment and approximately (+/- 16 weeks) at 8, 16, and 24 month follow-ups. We will screen participants to ensure that 50% of each group will report no smoking history and 50% will report a smoking history. Blood or buccal samples will be collected by trained staff one time at baseline. Those who choose not to provide the blood samples will be asked to provide a buccal sample as an alternative to test for APOE polymorphisms. Both patients and controls alive/deceased status will be tracked.
3333488|NCT02122120||Before HEN|Patients with tube feeding with kitchen diet for at least twelve months
3333489|NCT02122133||PC 400|Patients treated with the PC 400 according to the IFU
3234256|NCT01229709|No Intervention|Tinnitus Counseling Only Control|Control group subjects will have had treatment as usual (TAU) care from the UCSF Audiology Clinic which includes Tinnitus Counseling (TC) at least three-months prior to enty into the study.
3259204|NCT01468467|Experimental|AC220|
3333490|NCT02122133||Conventional Embolic Coils|These are any approved embolic coils on the market used as part of the standard of care for treating intracranial aneurysms.
3333491|NCT02122159|Experimental|MA09-hRPE Cellular Therapy|MA09-hRPE cells for transplantation will be provided by Ocata Therapeutics as a suspension frozen to the temperature of liquid nitrogen (approximately -196 °C). They will be processed at UCLA under GMPs according to protocol. Following vitrectomy performed under general anesthesia or waking sedation at the surgeon's discretion, hRPE cells will be introduced into a subretinal bleb formed by the injection of balanced salt solution (BSS). Direct viewing will guide the implantation of thawed and washed MA09-hRPE cells, resuspended in BSS, into the created bleb over a period of one minute. To avoid cell reflux, the cannula used to introduce the cells will be held in position for an additional minute. A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
3234257|NCT01229748|Experimental|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth.(Liddle, 2002) considered in the U.S. and abroad as an empirically supported Best Practice treatment for teen substance abuse and delinquency (USDHHS 2002; Drug Strategies 2003; NIDA 1999; Rigter et al 2004).
3234258|NCT01229748|Experimental|Family Motivational Interviewing|Motivational Interviewing (MI; Miller 1983; Miller & Rollnick 1991), is a client-centered treatment designed to strengthen clients' commitment and empower them to change their substance use behavior (Miller & Rollnick 2002).
3333492|NCT02122172|Experimental|Treatment (afatinib)|Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3333493|NCT02122185|Experimental|Metformin plus chemotherapy|Patients receive metformin hydrochloride PO BID and standard chemotherapy for 6 -8 cycles. Treatment with metformin hydrochloride continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3333494|NCT02122185|Placebo Comparator|Placebo plus chemotherapy|Patients receive placebo PO BID and standard chemotherapy for 6 -8 cycles. Treatment with placebo continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
3333495|NCT02122198|Placebo Comparator|Placebo|Monthly placebo injections for 6 months under parent study (FAME) protocol (NCT01712230)
3333496|NCT02122198|Active Comparator|GnRH agonist|"Monthly injections of leuprolide acetate 3.75mg for 9 months; first 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study protocol.~Weekly application of estradiol patch 0.075mg/d months 6-9.~Daily medroxyprogesterone acetate 5mg by mouth for 12 days at week 30."
3333497|NCT02122211|Experimental|Betaine supplement|Will use powdered betaine (BetaPower, Dupont Nutrition) that is commercially available for food uses. This powder will be delivered as capsules containing 0.5 gram of powdered betaine which will be administered as eleven capsules twice per day (6 in the morning, 5 in the evening) for a daily total of 6 grams of betaine.
3333498|NCT02122224|Experimental|Group 1|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3234259|NCT01229748|Other|Standard Care|The standard care condition will represent typical services for teens with alcohol problems in the community: assessment and referral for treatment
3234260|NCT01229761|Active Comparator|infant cotrimoxazole|
3234261|NCT01229761|Placebo Comparator|infant placebo|
3234262|NCT01229761|Active Comparator|exclusive breastfeeding for 6 months|
3333499|NCT02122224|Experimental|Group 2|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3333500|NCT02122224|Experimental|Group 3|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3333501|NCT02122224|Experimental|Group 4|"Groups will rotate through each of the 3 intervention breakfasts as well as the usual breakfast supplied at the preschool for a total of 4 weeks."
3333502|NCT02122237|Experimental|Cathodal Cefaly tDCS|Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, everyday for 2 months, in 14 patients. The anode is placed over the left DLPFC.
3333503|NCT02122250|Experimental|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
3333504|NCT02122250|Active Comparator|Static web-based materials|Static version of the interactive web-based materials
3234263|NCT01229761|Active Comparator|exclusive breastfeeding for 12 months|
3234264|NCT01229774|Experimental|Etoricoxib|
3333505|NCT02122263||NAFLD after sleeve gastrectomy surgery|
3333506|NCT02122276|Experimental|SCI|SCI participated in a 4-month robot-assisted passive ankle exercise regimen.
3234265|NCT01229774|Active Comparator|Diclofenac|
3234266|NCT01229800|Active Comparator|Split dose PEG|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes.
3234267|NCT01229800|Active Comparator|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
3234268|NCT01229813|Active Comparator|bevacizumab and erlotinib (KRAS WT)|
3234269|NCT01229813|Active Comparator|bevacizumab (KRAS WT)|
3234270|NCT01229813|Active Comparator|bevacizumab (KRAS mutated)|
3234271|NCT01229813|Active Comparator|low dose capecitabine (KRAS mutated)|
3234272|NCT01229839|Experimental|infusion group|Infusion of anticancer agent followed by Embolization
3234273|NCT01229839|Experimental|lipiodol chemotherapy group|Infusion of mixture of anticancer agent and lipiodol followed by Embolization
3234274|NCT01229852|Experimental|Active DSF-rTMS|Active rTMS treatment.
3234275|NCT01229865|Experimental|VB-111|antiangiogenic and vascular disruptive agent
3234276|NCT01229878|Active Comparator|Arm 1|Hemodialysis Patients randomized to take Vitamin D supplements
3333507|NCT02122289|Experimental|Application of Smartphone|Weekly questionnaire on Smartphone
3333508|NCT02122289|Placebo Comparator|No application Smartphone|No Weekly questionnaire on Smartphone
3333509|NCT02122302|Experimental|Web-based health assessment|
3333510|NCT02122315|Experimental|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles.
3333511|NCT02122315|Active Comparator|Physical therapy|Best-evidence physical therapy intervention
3333512|NCT02122328|Active Comparator|Selective procedure|Selective laser photocoagulation of communicating vessels.
3333513|NCT02122328|Experimental|Sequential procedure|Sequential laser photocoagulation of communicating vessels
3333514|NCT02122354|Experimental|Survey + videogame|"Hide and Seek videogame"
3333515|NCT02122367|Experimental|stroke volume variation, pleth variability index|"stroke volume variation: recorded using the FloTrac/Vigileo system (Edwards Lifesciences)~pleth variability index: recorded using the Masimo Radical-7 monitor (Masimo Corporation, Irvine, CA, USA)"
3333516|NCT02122393|Active Comparator|Sertraline|
3333517|NCT02122393|Active Comparator|Cognitive Behavioural Therapy|
3333518|NCT02122393|Active Comparator|Combined Therapy|
3333519|NCT02122419||lateral|spinal anesthesia performed during lateral position
3333520|NCT02122419||sitting|spinal anesthesia performed during sitting position
3333521|NCT02122432|Experimental|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association and sends them to the dermatologist using a secured email server.~Dermatologist answer is standardized."
3333522|NCT02122432|No Intervention|Usual care|Usual care for dermatologic conditions requiring an expertise from a dermatologist involves the general practitioner 1) giving the patient a paper letter containing at least the following information: date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes) and 2) telling him to see the dermatologist of his choice (patient manages his appointments alone).
3333523|NCT02122458|Active Comparator|hearing impaired vs hearing impaired + PTSD|The investigators will have two treatment groups fitted with mild-gain open-fit hearing aids and will be monitored across 6 months.
3333524|NCT02122458|Other|delayed treatment|A third group will consist of a delayed treatment group. This group will be monitored over 12 months with hearing aids fitted at 6 months.
3333525|NCT02122458|No Intervention|Diagnostic Testing|Battery of auditory and auditory related assessment tasks.
3333526|NCT02122484|Placebo Comparator|Control group|Patients taking placebo
3333527|NCT02122484|Experimental|Colchicine|Active treatment group
3333528|NCT02122497||abdominal aortic aneurysm (AAA) endovascular|endovascular aortic repair
3333529|NCT02122497||abdominal aortic aneurysm (AAA) open|open surgical repair
3333530|NCT02122497||abdominal aortic occlusive disease (AOD)|open surgical repair
3333531|NCT02122510|Active Comparator|dexmetomedine group|dexmetomedine group will receive pre-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe labeled G 2.
3333532|NCT02122510|Active Comparator|Bupivacaine group|Bupivacaine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline in 20 ml syringe labeled G 2.
3333533|NCT02122523|Experimental|SLN identification with NIR-dye-subserosa injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
3234277|NCT01229878|Placebo Comparator|Arm 2|Hemodialysis Patients randomized to take placebo pills
3259205|NCT01468480|Experimental|Pro Root MTA- standard method|application of MTA in second group and 24 hour interval before restoration
3333534|NCT02122523|Active Comparator|SLN identification with NIR-dye-submucosal injection|Near-Infrared (NIR) dye Indocyanin Green (ICG) to identify nodes with a newly developed NIR laparoscope. The investigators compared two different injection techniques; subserosal and submucosal injection.
3333535|NCT02122536|Active Comparator|Xeomin right side; Xeomin to left side of face|Patients were randomized as to which side of the face was treated with Xeomin.
3333536|NCT02122536|Active Comparator|Botox right side; Botox to left side|Patients were randomized as to which side of the face was treated with Botox.
3333537|NCT02122575||1|Males and females between the ages of 21 and 37
3333538|NCT02122588||OVATAR study patients|Females with serous and endometrioid ovarian, peritoneal and fallopian tube cancer 18 years and older, diagnosed 3 months before enrolment into the study or later, consented to participate in this non-interventional study, who are being treated for OC, FTC (Fallopian Tube Cancer) and PC (Peritoneal Cancer) in the oncology hospitals/departments in the Russian Federation.
3333539|NCT02122601|Other|LBSA0103|single arm , LBSA0103 only
3333540|NCT02122614|Experimental|Experimental group|
3333541|NCT02122614|Active Comparator|Control group|
3333542|NCT02122627|Experimental|Vitamin D|colecalciferol 16.800 IU per week
3333543|NCT02122627|Placebo Comparator|Placebo|placebo
3333544|NCT02122653|Experimental|Older WT|Older people with weight training
3333545|NCT02122653|Experimental|Older WT and ES|Older people with weight training combined electrical stimulation.
3333546|NCT02122653|No Intervention|Young control group|Young people with control group
3333547|NCT02122666||Metabolic Syndrome|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
3333548|NCT02122666||Control|Muscle biopsy to determine sarcoplasmic reticulum composition and function, Oral Glucose tolerance test with insulin levels at time points to determine Insulin sensitivity, DEXA scan to determine lean muscle and fat mass
3333549|NCT02122679|Active Comparator|Study group|Receive tranexamic acid in operating room.
3333550|NCT02122679|Placebo Comparator|Placebo group|Receive placebo in the operating room
3333551|NCT02122692|Experimental|Lu AE58054 30 mg + itraconazole 200 mg|
3333552|NCT02122705||VPIA remifentanil|VPIA remifentanil labour analgesia
3333553|NCT02122731|Experimental|Amiloride|This is a non-randomized and non-controlled study with only one treatment arm with amiloride.
3333554|NCT02122744|Active Comparator|Super Rapid Magstim Stimulator rTMS QP|rTMS QP is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients
3333555|NCT02122744|Placebo Comparator|Placebo|rTMS QP placebo (coil perpendicular to the scalp) is delivered over the visual cortex for 30 minutes, 2 times a week for 8 weeks, in 15 patients.
3333556|NCT02122757|Placebo Comparator|Sham Anodal Cefaly tDCS|2 mA placebo anodal tDCS (the direct current is delivered just for 30 seconds) is applied over the visual cortex for 20 minutes, everyday for 2 months, in 15 patients
3333557|NCT02122757|Active Comparator|Anodal Cefaly tDCS|2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, everyday for 2 months, in 15 patients.
3333558|NCT02122809|Experimental|Chiauranib|Patients take a single dose of Chiauranib capsules for the pharmacokinetic study,then off for 5 days before the first cycle begins. In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.
3333559|NCT02122822|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
3333560|NCT02122835|Other|heart failure|aerobic exercise training
3333561|NCT02122835|Other|heart failure plus type 2 diabetes|aerobic exercise training
3333562|NCT02122848|Experimental|Bilevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
3333563|NCT02122861|Experimental|ID-LV305|Dose escalation and expansion cohort including treatment of melanoma
3333564|NCT02122874|Active Comparator|Diet|The patients follow only a 1200 Kcal diet
3333565|NCT02122874|Experimental|Diet +PENS dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
3333566|NCT02122913|Experimental|Tumor patients_Dose 1|Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
3333567|NCT02122913|Experimental|Tumor patients_Dose 2|Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
3333568|NCT02122913|Experimental|Tumor patients_Dose 3|Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
3333569|NCT02122913|Experimental|Tumor patients_Dose 4|Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
3333570|NCT02122913|Experimental|Tumor patients_Dose 5|Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
3333571|NCT02122913|Experimental|Tumor patients_Dose 6|Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
3333572|NCT02122913|Experimental|Tumor patients_Expansion|"Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part."
3333573|NCT02122926|Experimental|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
3333574|NCT02122926|No Intervention|Usual Care|Patients in the control arm of this study receive usual care.
3333575|NCT02122939|Experimental|Escitalopram|
3234278|NCT01229904|Experimental|Arm 1|patients with PTSD are randomized to either entering immediately a 6 week treatment with music therapy, or being in the delay group that enters the treatment arm after 6 weeks. This is a delayed entry RCT.
3234279|NCT01229969|Experimental|NeuroCom EquiTest® System|Measure balance assessment (test for Sensory Organization Test (SOT) and Limit of Stability (LOS).
3234280|NCT01229969|Experimental|Wii Fit|Determine if the Wii Fit is valid and feasible in detecting balance problems in older adults
3234281|NCT01229982|Experimental|L-PPDS|
3234282|NCT01229995|Active Comparator|Prefabricated Abutment|
3234283|NCT01230008||Radiotherapy in mediastinal lymphoma|Adjuvant radiotherapy or not (control group) in patients treated with R-CHOP
3234284|NCT01230008||Radiotherapy in mediastinal lymphoma|Radiotherapy will no be administered in patients treated with R-CHOP
3234285|NCT01230008||Radiotherapy in primary mediastinal lymphoma|Patients with primary mediastinal lymphoma will be treated with R-CHOP as induction therapy, if complete response is achieved, they were allocated to received or no (control group) adjuvatn radiotherapy, 3.5 G to mediastinal site.
3234286|NCT01230034|Experimental|Imidapril|10 and 20 mg/day, pill
3333576|NCT02122965|Experimental|Pharmacist-led medication review|Pharmacist-led medication review in the ED
3333577|NCT02122965|No Intervention|Usual care|Usual care includes nurse-led medication reconciliation.
3333578|NCT02122978|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3333579|NCT02122978|Experimental|MBSCT 8 week course|Mindfulness Based Self Compassion Therapy
3333580|NCT02122978|Active Comparator|Mindfulness Based Self-Compassion - Audio guided|MBSC - minimal contact
3234287|NCT01230034|Active Comparator|Ramipril|5 and 10 mg/day, pill
3234288|NCT01230047|Experimental|Psychoeducational Course|In this arm, clients receive the psychoeducational course.
3234289|NCT01230047|No Intervention|Treatment-as-usual/Waiting list|Clients assigned to this condition will receive treatment-as-usual (TAU) and be placed on a waiting list.
3333581|NCT02122991||Able-Bodied Controls|Subjects must be between the ages of 30 and 64 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
3333582|NCT02122991||Spinal Cord Injury|Subjects must be between the age of 30 and 64 years old, be English-literate and able to provide informed consent. They must be at least 1 year from the date of their spinal cord injury. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 22 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), unstable/uncontrolled seizures, neurodegenerative disease, Severe Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, any significant systemic illness or unstable medical condition (uncontrolled diabetes, hypo- or hyperthyroidism, systemic cancer), history of schizophrenia or bipolar disorder or any active psychosis, or alcohol/substance abuse or dependence (<6 months).
3333583|NCT02123004|Experimental|Ticagrelor|"Investigational product/Dosage form and strength/Manufacturer:~ticagrelor/tablet /90mg/AstraZeneca 180mg loading dose for one day ,then 90mg per day for 4 weeks"
3234290|NCT01230073|Active Comparator|ICD traditional follow-up|ICD with traditional follow-up in the outpatient clinic
3234291|NCT01230073|Active Comparator|Home-Monitoring|Home-Monitoring
3333584|NCT02123004|Active Comparator|Clopidogrel|"Investigational product/Dosage form and strength/Manufacturer:~clopidogrel/tablet /75mg/Sanofi 300mg loading dose for one day ,then 75mg per day for 4 weeks"
3333585|NCT02123030||Experimental|patients with pulmonary disease; and, patients with known or suspected lung or other cancers
3333586|NCT02123030||Control|healthy subjects (for example, family members of the patient or graduate students
3333587|NCT02123043|No Intervention|Control|The control group will not experience any wheelchair training or 'practice' with a manual wheelchair.
3333588|NCT02123043|Experimental|Motor learning-based training|The motor learning-based training, like the 'practice' condition, will consist of six visits over three weeks. Each visit will involve two 5-minute wheeling trials with 10-minutes of rest between trials. The motor learning-based training will focus on variable practice and sporadic feedback.
3333589|NCT02123043|Active Comparator|Practice wheeling|To provide a comparable amount of exposure to wheelchair propulsion, the practice group will participate in the same number of visits and wheeling time as the motor-learning based training group. This will allow us to determine whether the motor-learning based training is superior to exposure through practice. The practice group will come to the lab six times over three weeks and wheel for two 5-minute trials with a 10-minute rest break in between. Participants randomized to this group will receive no feedback.
3234292|NCT01230086|Active Comparator|ICD implantation only|ICD Implantation without testing of defibrillation threshold testing
3234293|NCT01230086|Active Comparator|Modified upper limit of vulnerability testing|"Modified testing of upper limit of vulnerability"
3234294|NCT01230086|Active Comparator|VF-Induction|traditional VF-induction with T-Wave shock
3333590|NCT02123056|Active Comparator|Metoprolol|Metoprolol 50 mg po tablets will be provided for final dosing range (25 mg po BID to 100 mg po BID) for study duration (1 year). Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
3333591|NCT02123056|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. Patients will be started at 50 mg po BID and titrated over 2 weeks to target of 100 mg po BID.
3333592|NCT02123069||Women with uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
3234295|NCT01230099|Experimental|Supportive Information Team Group|Protocolized information and support meetings led by palliative care clinicians
3333593|NCT02123069||Women without uterine fibroids|"Brachial artery catheter~Acetylcholine~Nitroprusside~Norepinephrine~Nitroprusside and phenylephrine"
3333594|NCT02123082|Other|Single-Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the single lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
3333595|NCT02123082|Experimental|Dual Lumen Ureteroscope|Subjects enrolled in this study arm will have their procedure performed using the dual lumen ureteroscopes. This scope is currently employed in clinical practice, including at UC Irvine Medical Center.
3333596|NCT02123108|Active Comparator|Basiliximab|"Basiliximab~Basiliximab Peri-transplant~• 40mg IV infusion within 4 hours of transplant x1~Basiliximab Post-transplant • 20mg IV infusion Post Operative Day #4 (POD 4) x1~Tacrolimus (with basiliximab induction)~• Post Operative Day #7 (POD 7) or subclinical acute rejection (SCr) < 1.8 mg/dl to one year: 0.03-0.1mg/kg q12h~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1: 720 mg po bid will be administered once the patient is able to tolerate PO medication.~Corticosteroids • Intraoperative: hydrocortisone 1000mg intravenous push (IVP)~Followed by:~• Standard steroid taper:"
3234296|NCT01230099|No Intervention|Usual Care Group|
3234297|NCT01230138|Experimental|FP187 - TID|FP187 250mg TID (total daily dose of 750mg)
3234298|NCT01230138|Experimental|FP187- BID|FP187 375mg BID (total daily dose of 750mg)of 750mg administered as 375mg BID
3234299|NCT01230138|Experimental|FP187-LD-BID|FP187 250mg BID (total daily dose of 500mg)
3234300|NCT01230138|Placebo Comparator|Placebo|Placebo treatment
3259206|NCT01468480|Experimental|Pro Root MTA- single visit|Intervention/Control application of MTA in third group and 15 minute interval before restoration
3333597|NCT02123108|No Intervention|Tacrolimus Group|"Tacrolimus (without basiliximab induction); standard of care group~Beginning Post Operative Day #1 to six months: 0.03-0.1 mg/kg q12h po to maintain whole blood trough concentration of 7-10 ng/mL~Six months to one year: maintain whole blood trough concentration of 5-8ng/mL~Mycophenolate/mycophenolic acid will be started Post Operatively Day 1. Immediately post transplant, while subjects have nasogastric (ng) tube; this will be delivered as CellCept (mycophenolate mofetil) oral suspension 1,000 mg BID administered via the ng tube. Enteric coated mycophenolic acid (Myfortic) - 720 mg po bid will be administered once the patient is able to tolerate PO medication.~Corticosteroids • Intraoperative: hydrocortisone IVP~Followed by:~• Standard steroid taper"
3333598|NCT02123121|Placebo Comparator|Vegetable cellulose|Participants will orally consume one capsule of vegetable cellulose following each of their main meals (i.e. breakfast, lunch, and dinner) for 90 days.
3333599|NCT02123121|Active Comparator|Resveratrol 1000 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1000 mg/day for 90 days.
3333600|NCT02123121|Active Comparator|Resveratrol 1500 mg/day|Participants will orally consume one capsule of Resveratrol following each of their main meals (i.e. breakfast, lunch, and dinner) totaling 1500 mg/day for 90 days.
3333601|NCT02123147||Sjogren's syndrome|Patients who are diagnosed with Sjogren's syndrome. Blood will be collected once every 3-6 months for up to 3 years.
3333602|NCT02123147||Healthy Control|Patients who are diagnosed with healthy control. Blood will be collected once every 6 months for up to 3 years.
3333603|NCT02123160|Experimental|Child Parent Psychotherapy (CPP)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads will be randomly assigned to either Child Parent Psychotherapy (CPP) treatment or control (usual treatment) group. CPP treatment will be conducted by a CPP study clinician over approximately six months (24 weekly sessions). CPP includes developmental guidance and fostering affect regulation , continuity in daily living, reciprocity between mother and child, and helping the mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma.
3333604|NCT02123160|Active Comparator|Usual Treatment|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred for usual treatment via referral to therapists in the community and at Columbia University Medical Center, for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Additionally, control patient dyads will be monitored through regular contact with the study research assistant. If the research assistant detects worsening of depressive symptoms or the presentation of new symptoms, a licensed study clinician will follow up to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
3333605|NCT02123173||non-intubated|VATS, non-intubated
3333606|NCT02123173||intubated|VATS, intubated
3234301|NCT01230138|Experimental|Open, flexible dosing treatment arm|Open treatment using a flexible dosing schedule for 8 weeks with maximum dose of 750mg FP187 and with a total dosing of 20 weeks. All investigations following same schedule.
3333607|NCT02123186||newborns testing for SMA|
3333608|NCT02123199||Indacaterol/QAB149|Patients treated with Indacaterol for COPD prior to enrollment in study
3333609|NCT02123212|Experimental|Mt. Sinai|Cluster randomization with EHR Alert intervention
3333610|NCT02123212|Experimental|Henry Ford Health System|Simple randomization with mailer intervention
3333611|NCT02123212|Experimental|University of Alabama, Birmingham|Crossover randomization with in-person recruitment intervention
3333612|NCT02123238|Other|Control|standard of care positioning (0 degree)
3333613|NCT02123238|Other|30 degree|30 degree bed positioning
3333614|NCT02123238|Other|60 degree|60 degree bed positioning
3333615|NCT02123264|Active Comparator|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
3333616|NCT02123264|No Intervention|No intervention|No intervention
3333617|NCT02123277|Experimental|concept proof|Balloon catheter for the Eustachian tube
3333618|NCT02123290|Experimental|Plasmodium falciparum|Patients with Plasmodium falciparum malaria
3333619|NCT02123290|Experimental|Plasmodium vivax|Patients with Plasmodium vivax malaria
3333620|NCT02123303||Veterans|
3333621|NCT02123316|Active Comparator|Pangramin Plus D. pteronyssinus|Pangramin Plus D. pteronyssinus 100% for subcutaneous injection
3333622|NCT02123316|Placebo Comparator|Placebo|Placebo for subcutaneous injection
3333623|NCT02123342|No Intervention|Exercise programme only|Participants randomized in this condition will not receive SMS reminders to execute the myPAtHS exercise programme.
3333624|NCT02123342|Experimental|SMS reminder|Participants in this study arm will receive SMS reminders to motivate them to execute the myPAtHS exercise programme.
3333625|NCT02123355|Experimental|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
3333626|NCT02123355|Sham Comparator|Normal saline|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
3333627|NCT02123368|Active Comparator|Hialuronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
3333628|NCT02123368|Active Comparator|Hyaluronic acid and MSC 10|Single intraarticular injection of Hyaluronic acid (Hyal One) 10 million Bone marrow mesenchimal stem cells
3333629|NCT02123368|Active Comparator|Hyaluronic acid AND MSC 100|Single intraarticular injection of Hyaluronic acid (Hyal One) 100 million Bone marrow mesenchimal stem cells
3333630|NCT02123381|Experimental|Arm A|All patients in the arm receive cetuximab combined with preoperative radiotherapy at first. 4-6 weeks after the rdiaotherapy，patients receive right thoracotomy with three incisions radical surgery.
3333631|NCT02123394|Placebo Comparator|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
3234302|NCT01230151|Active Comparator|Clinical|Stimulation settings predetermined clinically (Clinical)
3234303|NCT01230151|Experimental|Model|stimulation settings derived from a patient-specific computer-based model (Model)
3234304|NCT01230190|Active Comparator|Probiotic mixture|participants daily ingest a selected probiotic mixture for a period of 3 months
3234305|NCT01230190|Placebo Comparator|Placebo mixture|controls daily ingest a placebo mixture for a period of 3 months.
3234306|NCT01230203|Other|Computed tomography scan versus color duplex ultrasound|
3234307|NCT01230216|Active Comparator|intensive blood pressure control|systolic blood pressure less than 120 mmHg
3333632|NCT02123394|Experimental|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
3333633|NCT02123407|Experimental|Carbon Nanoparticles|Carbon Nanoparticles could be used in this arm.The drug is injected into the subserosa of stomach.Injections of 1.0 ml of Carbon Nanoparticles (0.2 ml in each cardinal point adjacent to the lesion) will be performed about 10 minutes before surgery.Then,gastrectomy with D2 dissection will be performed.
3333634|NCT02123407|Active Comparator|Gastrectomy with D2 dissection|Gastrectomy with D2 dissection will be performed in the control arm,no Carbon Nanoparticles or other coloring materials used
3333635|NCT02123420|Other|Implant outcome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the right molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
3333636|NCT02123420|Other|Implant outome|"This study was designed as a randomised, controlled, split-mouth trial. all enrolled patients needed single bilateral fixed implant-supported prosthesis in molar area.~A total of 18 consecutive patients were enrolled. In each eligible patient, the left molar was randomly selected to receive either Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Goteborg, Sweden) with Platform Switching (PS) or Regular Platform (RP)"
3234308|NCT01230216|Active Comparator|standard blood pressure control|systolic blood pressure less than 140 mmHg
3234309|NCT01230229|Active Comparator|Stenting|Active treatment group
3333637|NCT02123433|Experimental|13-valent vaccine|
3333638|NCT02123498|Experimental|Single Arm|
3333639|NCT02123524|Experimental|Rivaroxaban|Rivaroxaban 10mg tablet daily for 45 days
3333640|NCT02123524|Placebo Comparator|Control|Placebo tablet daily for 45 days
3333641|NCT02123537|Experimental|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System for walking daily during the 12 weeks of the study.
3333642|NCT02123563|Experimental|Ultrason Essential oils rinse|Ultrasonic debridement followed by twice daily home use of an essential-oils mouth rinse (20mL, 30 seconds for each rinse) for 3 months
3333643|NCT02123563|Placebo Comparator|Ultrason Placebo rinse|Ultrasonic debridement followed by twice daily home use of a placebo rinse (20mL, 30 seconds for each rinse) for 3 months
3333644|NCT02123589|Experimental|Deep sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3
3333645|NCT02123589|Experimental|Deep and daily interruption of sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -5 and -3.and from the second day after subject was admitted in ICU, daily interruption of sedation will be taken .
3234310|NCT01230229|Placebo Comparator|Conservative treatment|Best medical treatment
3234311|NCT01230255|Experimental|Percutaneous catheter decompression|Ultrasound guided percutaneous catheter drainage of free intra-peritoneal fluid or blood
3333646|NCT02123589|Experimental|Light sedation|Injection of 0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,then continuous intravenous infusion 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl to maintain sedation until attaining the target level of sedation,RASS score between -2 and +1.
3333647|NCT02123602|Experimental|Core stabilization|This arm will receive 3 weeks of core stabilization training followed by 3 weeks of lower extremity stretching and strengthening as appropriate to address impairments noted in the examination and to progress function.
3333648|NCT02123602|Active Comparator|Lower extremity training only|This arm with receive 6 weeks of impairment based stretching and strengthening to restore function.
3234312|NCT01230255|Active Comparator|Open abdominal decompression|Surgical treatment of elevated intra-abdominal pressure through traditional open abdominal decompression
3234313|NCT01230268|Experimental|Mulberry fruit extract|Daily 1000 mg oral Mulberry fruit extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
3234314|NCT01230281|Experimental|Black bean seed coat extract|Daily 1000 mg oral Black bean seed coat extract is given to each subject for 2 weeks from Day2 after measuring antioxidative marker without intervention on Day1.
3234315|NCT01230294||control|participants without structural heart disease
3234316|NCT01230294||CHF|patients with chronic heart failure of the left ventricle affecting the right heart
3234317|NCT01230294||PAH|patients with pulmonary arterial hypertension without left ventricular dysfunction
3234318|NCT01230320|Experimental|Simplified (S) technique|"Complete dentures fabricated according to a simplified technique, divided into the following four sessions:~Maxillary and mandibular casts will be obtained from irreversible hydrocolloid impressions made in stock trays.~Record bases will be adjusted according to vertical dimension and centric relation measurements, without facebow transfer. Casts will be mounted in a semi-adjustable articulator using standardized measures and artificial teeth will be selected.~Trial dentures will be evaluated for esthetics and maxillomandibular relationships.~Insertion of finished dentures."
3259207|NCT01468480|Experimental|MultiCal / LimeLite|application of Multical in forth group
3234319|NCT01230320|Active Comparator|Conventional (C) technique|"Complete dentures fabricated according to a conventional technique:~Initial impression and the obtainment of custom trays;~Final impression with border molding using compound;~Facebow transfer;~Determination of maxillomandibular relationship;~Try-in of anterior teeth;~Try-in of posterior teeth;~Insertion of finished dentures."
3333649|NCT02123615|Experimental|Gadolinium For abdomen|"Gadolinium For abdomen Total Persistent % subdermally, For abdomen Total Persistent % subcutaneously, and For abdomen Relative Prolongation Ability Score.~Gadolinium Magnevist® (gadopentetate dimeglumine)~1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
3333650|NCT02123615|Experimental|Gadolinium For lower back|"1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg), subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.~Gadolinium For lower back Total Persistent % subdermally, For lower back Total Persistent % subcutaneously, and For lower back Relative Prolongation Ability Score."
3333651|NCT02123615|Experimental|subjects (%) of any infections|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333652|NCT02123615|Experimental|Annual rate of any infections|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333653|NCT02123615|Experimental|subjects (%) with Antibiotic use|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333654|NCT02123615|Experimental|Annual rate with Antibiotic use|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333655|NCT02123615|Experimental|subjects (%) with Days out of work|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333656|NCT02123615|Experimental|Annual rate with Days out of work|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333657|NCT02123615|Experimental|(%) with hospitalized infections|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333658|NCT02123615|Experimental|Annual rate hospitalized infections|Annual rate hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12, Efficacy of Gammagard subcutaneously at Week 24, and Efficacy of Gammagard subcutaneously at Week 36, vs. Efficacy of Gammagard subdermally at Week 12, Efficacy of Gammagard subdermally at Week 24, and Efficacy of Gammagard subdermally at Week 36.
3333659|NCT02123615|Experimental|Adverse Injection Local Reactions|Adverse Injection Local Reactions as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333660|NCT02123615|Experimental|Adverse Reactions Headache|Headache as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333661|NCT02123615|Experimental|Adverse Reactions Fever|Fever as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3234320|NCT01230346|Experimental|Arm I|Patients receive a culturally-informed adapted motivational interviewing telephone call.
3234321|NCT01230346|Experimental|Arm II|Patients participate in a controlled condition comprising a health habits intervention group.
3234322|NCT01230346|Active Comparator|Arm III|Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
3234323|NCT01230359|Experimental|Vitamin B6 and magnesium|
3234324|NCT01230359|Placebo Comparator|Tang powder group|
3234325|NCT01230385|Experimental|Lersivirine 500 mg QD fasted (wet granulated tablet)|
3234326|NCT01230385|Experimental|Lersivirine 500 mg QD fed (wet granulated tablet)|
3234327|NCT01230385|Experimental|Lersivirine 750 mg QD fasted (wet granulated tablet)|
3234328|NCT01230385|Experimental|Lersivirine 750 mg QD fed (wet granulated tablet)|
3234329|NCT01230385|Active Comparator|Lersivirine 500 mg QD fasted (dry granulated tablet)|
3234330|NCT01230411|Placebo Comparator|placebo|IV saline administration as placebo
3234331|NCT01230411|Experimental|Ibuprofen|IV ibuprofen
3234332|NCT01230437||asthmatic patients taking montelukast|asthma with or without rhinitis
3259208|NCT01468480|Active Comparator|Dycal|application of Dycal in first group as a pulp dressing agent
3259209|NCT01468493||steroid-sensitive FSGS|
3259210|NCT01468493||steroid-dependent and resistant FSGS|
3259211|NCT01468493||Healthy volunteers|
3333662|NCT02123615|Experimental|Adverse Reactions Nausea|Nausea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333663|NCT02123615|Experimental|Adverse Reactions Vomiting|Vomiting as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333664|NCT02123615|Experimental|Adverse Reactions Fatigue|Fatigue as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333665|NCT02123615|Experimental|Adverse Reactions Diarrhea|Diarrhea as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333666|NCT02123615|Experimental|Adverse Reactions Asthma|Asthma as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333667|NCT02123615|Experimental|Adverse Reactions Oropharyngeal|Oropharyngeal as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3234333|NCT01230450|Experimental|Single-incision Mini-slings (SIMS- Ajust)|AjustTM has polypropylene fixing anchors (one is fixed and the other adjustable) which are anchored onto the obturator membrane. The pulley like system enables adjustment of the tension once the arms have been anchored. Once in place, the anchors rest at right angles to insertion which is claimed to reduce the chances of anchor dislodgment
3234334|NCT01230450|Other|standared med urethral sling (SMUS)|standard med urethral sling (SMUS)TVT-O, was done as originally described by Deleval et al.
3333668|NCT02123615|Experimental|Adverse Reactions Abdominal Pain|Abdominal Pain as Adverse Reactions of Gammagard subcutaneously at Week 12, Adverse Reactions of Gammagard subcutaneously at Week 24, and Adverse Reactions of Gammagard subcutaneously at Week 36, vs. Adverse Reactions of Gammagard subdermally at Week 12, Adverse Reactions of Gammagard subdermally at Week 24, and Adverse Reactions of Gammagard subdermally at Week 36.
3333669|NCT02123628|Active Comparator|antibiotic therapy|"patients are treated with a 6 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
3333670|NCT02123628|Active Comparator|12 week-duration of antibiotic therapy|"patients are treated with a 12 week-duration of antibiotic therapy :~Rifampin IP and PO twice daily, 10mg/kg /12H~Levofloxacin IV and PO 500-750mg once daily~Doxycycline PO 200mg once daily~Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~Fusidic acid PO 500mg twice daily~Linezolid IV and PO 600mg twice daily~Ciprofloxacin IV and PO 750to 1000mg/12h~Cefotaxime IV 100mg/kg in three IV infusions daily~Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~Cefepime IV ou intra-muscularly 2g /8-12h"
3333671|NCT02123641|Active Comparator|Heavy resistance training|Heavy resistance training of the lower and upper extremities three times weekly for 52 weeks.
3333672|NCT02123641|Experimental|Moderate intensity training|Home-based moderate intensity training of the lower and upper extremities three times weekly for 52 weeks.
3333673|NCT02123641|Experimental|Control|No training
3333674|NCT02123654|Experimental|Arm 1: DCV 3DAA + Placebo for DCV/Placebo for ASV|DCV 3DAA tablet orally twice daily for 12 weeks + Placebo for DCV tablet orally once daily and Placebo for ASV capsule orally twice daily for 24 weeks (Double blind)
3333675|NCT02123654|Active Comparator|Arm 2: DCV/ASV + Placebo for DCV 3DAA|Daclatasvir 60 mg tablet orally once daily and Asunaprevir 100 mg capsule orally twice daily for 24 weeks + Placebo for DCV 3DAA tablet orally twice daily for 12 weeks (Double blind)
3333676|NCT02123654|Experimental|DCV 3DAA|DCV 3DAA (open label) Tablet orally twice daily for 12 weeks
3333677|NCT02123667||Asthmatic patients|asthmatic patients 18 to 65
3333678|NCT02123667||Healthy volunteers|Volunteers 18 to 65
3333679|NCT02123693|Experimental|Osteopathic Manipulative Treatment|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on indirect techniques
3333680|NCT02123693|Sham Comparator|Sham therapy|5 sessions of treatment will be carried out: the first 3 weekly, and the remaining 2 after 15 days. The type of treatment will be based on specific parameters set out previously based on a predetermined protocol
3333681|NCT02123693|Other|No intervention|Patients in this group will not receive any type of intervention, both therapeutic than fictitious, and will not be evaluated by any operator
3333682|NCT02123719||Patients post liver transplantation|Patients after liver transplantation
3333683|NCT02123719||Control group|Patients with an abdominal incisional hernia without a history of immunosuppresion
3234335|NCT01230463|Active Comparator|15 mg ketorolac IV|
3234336|NCT01230463|Active Comparator|30 mg ketorolac IV|
3234337|NCT01230476|Experimental|Cetuximab and chemotherapy|2 cycles of neoadjuvant cisplatin and 5FU (3 weekly), given with weekly cetuximab, followed by 7 doses of weekly cisplatin and cetuximab concurrent with radiotherapy
3333684|NCT02123732|Experimental|DbXell|Drug: DbXell three times daily for 12 weeks and then switching to Placebo of DbXell for 12 additional months Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
3333685|NCT02123732|Placebo Comparator|Placebo|Drug: Placebo of DbXell Placebo of DbXell three times daily for 12 weeks and then switching to DbXell for 12 additional weeks Other: Lifestyle modification Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
3333686|NCT02123758|Experimental|Cohort 1|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.
3333687|NCT02123758|Experimental|Cohort 2|Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
3333688|NCT02123771||Helicobactor Pylori Infection|Comparison on the presence/absence of GGT antigen in the stool will be compared between H. pylori-positive and H. pylori-negative subjects. Rapid urease test result from the respective patients will be used as the golden standard. Should the GGT antigen in stool samples show promise in distinguishing between H. pylori-infected and uninfected individuals, sensitivity and specificity of the stool antigen test can then be established.
3333689|NCT02123784||Rotator cuff tear|Patients which demonstrate a full-thickness tear of the rotator cuff tendon and meet the inclusion criteria.
3333690|NCT02123810|Other|Control|The investigators measure quality of chest compressions before nightshift. Control group
3333691|NCT02123810|Other|OFF|The investigators measure quality of chest compressions before nightshift. After night shift group
3333692|NCT02123836|Experimental|NK cells|Peripheral blood cell will be collected by apheresis from donors. Peripheral blood mononucleated cells will be cultured with irradiated K562-mb15-41BBL cells and low dose (10 IU/mL) IL-2 for 10 days. After T-cell depletion, expanded activated NK cells will be infused. Before infusion, patients will receive immunosuppressive therapy to promote temporary engraftment of NK cells. After infusion, they will receive IL-2 to support NK cell viability and expansion in vivo. The effects of NK cell infusion will be determine by comparing MRD levels before and after treatment.
3333693|NCT02123862||Prostate Cancer|
3333694|NCT02123862||Breast Cancer|
3333695|NCT02123862||Colorectal Cancer|
3333696|NCT02123862||Solid Tumor|
3333697|NCT02123862||Benign Condition|
3333698|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
3333699|NCT02123875|Other|Physiotherapy intervention arm|Caregiver delivered, home based physiotherapy
3333700|NCT02123888|Experimental|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy.
3333701|NCT02123901|Experimental|Walking meditation & Walking|
3333702|NCT02123901|Active Comparator|Walking meditation & No exercise|
3333703|NCT02123914|Experimental|Aerobic exercise with Vit. C & Aerobic exercise|
3333704|NCT02123914|Active Comparator|exercise without vit. c supplement & no exercise|
3333705|NCT02123927|Experimental|Step 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
3333706|NCT02123927|Experimental|Step 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
3333707|NCT02123927|Experimental|Step 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
3333708|NCT02123927|Experimental|Step 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
3333709|NCT02123927|Experimental|Step 5: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
3333710|NCT02123927|Experimental|Step 6: TAK-438 80 mg|TAK-438 80 mg, tablets, orally, once on Day 1.
3333711|NCT02123927|Experimental|Step 7: TAK-438 120 mg|TAK-438 120 mg, tablets, orally, once on Day 1.
3333712|NCT02123927|Placebo Comparator|Steps 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1.
3333713|NCT02123927|Experimental|Step 8A: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3333714|NCT02123927|Experimental|Step 8 B: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 10 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
3333715|NCT02123927|Experimental|Step 9A: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3333716|NCT02123927|Experimental|Step 9B: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, under fed conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 40 mg, tablets, orally, under fasted conditions, once on Day 1, Period 2.
3333717|NCT02123927|Placebo Comparator|Steps 8 (A & B) and 9 (A & B): Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 placebo-matching tablets, orally, once on Day 1, Period 2.
3333718|NCT02123940|Experimental|nasal humidified high flow therapy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
3333719|NCT02123940|Other|standard strategy|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
3333720|NCT02123953|Experimental|TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once, daily, Days 1 to 7.
3333721|NCT02123953|Experimental|TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once, daily, Days 1 to 7.
3333722|NCT02123953|Experimental|TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once, daily, Days 1 to 7.
3333723|NCT02123953|Experimental|TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once, daily, Days 1 to 7.
3333724|NCT02123953|Experimental|TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once, daily, Days 1 to 7.
3333725|NCT02123953|Placebo Comparator|Placebo|TAK-438 placebo-matching tablets, orally, once, daily, Days 1 to 7.
3333726|NCT02123979|Placebo Comparator|placebo patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
3333727|NCT02123979|Experimental|Neupro® transdermal patch|Neupro® transdermal patch/placebo randomly allocated like a flip of a coin applied to your skin at the dose of 8 mg/day or a matching placebo patch after the oral surgery procedure is completed.
3333728|NCT02123992|Active Comparator|Elevate Apical and Posterior|The experimental arm of the study will include the implantation of the Elevate Posterior surgical mesh for the treatment of posterior vaginal prolapse
3333729|NCT02123992|Active Comparator|Native Tissue Repair|The control arm of the study will include the treatment of posterior vaginal prolapse using standard surgical sutures
3333730|NCT02124005|Experimental|Femoral block, ultrasound, bupivacaine|
3333736|NCT02124109||Control|Control group
3333737|NCT02124109||rheumatic heart disease|Patients with rheumatic heart disease
3234338|NCT01230515||Caregiver|Family members will be asked to complete a demographic survey, an assessment of the patient's current pain, and a series of questionnaires including: Caregiver Pain Medicine Questionnaire, the Stressful Caregiving Adult Reactions To Experiences of Dying Scale, and the Caregivers' Self Efficacy in Pain Management Questionnaire. Upon completion of the questionnaires, patients and caregivers will be interviewed separately.
3234339|NCT01230515||Hospice staff|Hospice staff will be asked to complete the Pain Knowledge and Attitudes survey. They will also complete the Technology Acceptance Model (TAM) questionnaire to assess the perceived utility of an opioid titration order sheet to help manage pain control. A demographic survey will also be completed.
3234340|NCT01230515||Referring physician|Referring physicians will be asked to complete the Pain Knowledge and Attitudes survey as well as the TAM questionnaire and Demographic Survey.
3234341|NCT01230515||Patient|Demographic information includes education, marital status, number in household, and employment status will be obtained from patient. Clinical data will be obtained from the patient's medical records. Information to be obtained will include information about the type of cancer, stage of disease, time since diagnosis, current treatment for cancer, type of pain, time since onset of pain, and time of first opioid prescription. The patient will also take a pain assessment survey.
3234342|NCT01230541|Placebo Comparator|Placebo|Placebo
3234343|NCT01230541|Active Comparator|Udenafil|Udenafil daily tablet
3234344|NCT01230580|Experimental|Protease Inhibitor Monotherapy|Ritonavir-boosted protease inhibitor
3234345|NCT01230580|Active Comparator|Control|Standard-of-care triple-therapy regimen
3333738|NCT02124135|Active Comparator|Clinic-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in the clinic setting.
3333739|NCT02124135|Experimental|Restaurant-based counseling|Participants in this arm will receive 1 baseline phone call with the registered dietitian to get preliminary dietary counseling tailored to their family's needs. They will then have 3 sessions in-person in a group setting with another family and the registered dietitian where a set dietary curriculum geared at promoting weight loss and/or maintenance of a healthy weight will be emphasized. All in-person visits will take place in a restaurant, while dining.
3333740|NCT02124148|Experimental|Prexasertib + Cisplatin (Part A)|"Part A: Prexasertib and cisplatin administered intravenously (IV) once every 21 days.~Part A2: Prexasertib and cisplatin administered IV every 21 days; G-CSF administered subcutaneously (SC) starting approximately 24 hours after each prexasertib dose every 21 days.~Part A3: Cisplatin administered IV on day one and prexasertib administered IV on day two once every 21 days.~Part A Expansion: Part A, A2, and/or A3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
3333741|NCT02124148|Experimental|Prexasertib + Cetuximab (Part B)|"Part B: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days.~Part B2: Cetuximab administered IV weekly and prexasertib administered IV once every 14 days; G-CSF administered SC starting approximately 24 hours after each prexasertib dose every 14 days.~Part B3: Cetuximab administered IV with prexasertib administered IV once every 14 days.~Part B Expansion: Part B, B2 and/or B3 may be expanded at the recommended dose.~Participants may remain on treatment until discontinuation criteria are met."
3333742|NCT02124148|Experimental|Prexasertib + Pemetrexed (Part C)|"Part C: Pemetrexed administered IV on day one and prexasertib administered IV on day one and two every 21 days.~Participants may remain on treatment until discontinuation criteria are met."
3234346|NCT01230606||overnight|Subjects that stay overnight at the hospital.
3234347|NCT01230606||Next Day Discharge|Subjects that are discharged on the same day of the procedure.
3234348|NCT01230619|Experimental|RV568 treatment group|
3234349|NCT01230619|Placebo Comparator|Placebo treatment group|
3234350|NCT01230632|Experimental|Dietary Supplement|3 days high fat food
3333743|NCT02124148|Experimental|Prexasertib + 5-FU (Part D)|"Part D: Leucovorin administered IV on day one, 5-FU administered IV bolus on day one and by continuous IV on days one to three (46 hours), and prexasertib administered IV on day three every 14 days.~Participants may remain on treatment until discontinuation criteria are met."
3234351|NCT01230645|Experimental|RV568 treatment group|
3234352|NCT01230645|Placebo Comparator|Placebo treatment group|
3234353|NCT01230671|Experimental|Yoga|Patients in this arm will receive yoga therapy
3333744|NCT02124148|Experimental|Prexasertib + LY3023414 (Part E)|"Part E: Prexasertib administered IV on day one and LY3023414 administered orally twice daily every 14 days.~Part E will be expanded at the recommended dose in participants with advanced or metastatic cancer, participants with PIK3CA mutations (E2 expansion), or with advanced or metastatic ER-negative, PR-negative, and HER-2 non-overexpressing breast cancer (E3 expansion).~Participants may remain on treatment until discontinuation criteria are met."
3333745|NCT02124174|Experimental|Vidaza and Valproic Acid|Vidaza and Valproic Acid
3333746|NCT02124187|Experimental|eCig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
3333747|NCT02124187|Sham Comparator|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
3333748|NCT02124187|Placebo Comparator|Nicotine free inhalator|nicotine free inhalator for 12 weeks
3333749|NCT02124200|Other|EGO/CE4, 9mg nicotine|
3333750|NCT02124213|Experimental|Cohor 1 - 30 mg|Cohort will include approximately 4 HVs/completers who will receive a single 30 mg dose of PF-06412562.
3333751|NCT02124213|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1.
3333752|NCT02124213|Experimental|Cohort 3 ( adaptive dose, optional)|Cohort 2 will include approximately 4 HVs/completers who will receive a single dose of PF-06412562. The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
3333753|NCT02124226|Experimental|Methotrexate|Starting dose of 7.5 mg/week + folic acid the day after for 3 weeks as add-on therapy to their existing medication. Study treatment dosage will be increased, the maintenance dose will be 10 mg/week + folic acid the day after for 27 weeks
3333754|NCT02124226|Placebo Comparator|Matched placebo|Placebo pills
3333755|NCT02124239|Experimental|Scalp|Treatment of scalp with 0.027% ingenol mebutate once daily for 3 days
3234354|NCT01230671|Placebo Comparator|No yoga|Patients will not have yoga in this arm
3333756|NCT02124239|Experimental|Arm|Treatment of arm with 0.06% ingenol mebutate once daily for 4 days
3333757|NCT02124239|Experimental|Face|Treatment of face with 0.027% ingenol mebutate once daily for 3 days
3333758|NCT02124252|No Intervention|Control|Women will be offered HPV testing within the health facilities in the communities randomized to this arm. Women who test HPV positive will be referred to care at the sub-district and district hospitals (current standard of care).
3333759|NCT02124252|Active Comparator|Standard Intervention|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
3333760|NCT02124252|Active Comparator|Enhanced Intervention|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
3234355|NCT01230684|Other|Endoleak imaging|In the single arm all participants are recieving both imaging techniques; CEUS and CTA
3234356|NCT01230697||Sofanenib and Hypophosphatemia|Patients with advanced renal cells carcinoma and hepatocarcinoma in treatment with Sorafenib
3234357|NCT01230723|Active Comparator|Arm 1|Everolimus-Eluting Stent
3234358|NCT01230723|Active Comparator|Arm 2|Zotarolimus-Eluting-Stent
3234359|NCT01230736|Experimental|DuoTrav|One drop in study eye(s) once daily for 8 weeks
3234360|NCT01230762|Experimental|001|dapoxetine 60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
3333761|NCT02124278|Experimental|PUL-042 Inhalation Solution|Fixed dose combination of Pam2CSK4 acetate (Pam2) and ODN M362 (ODN) administered as an inhalation solution. Single dose administration by nebulization. Starting dose will be 2.9 micrograms Pam2: 4.25 micrograms ODN. Up to 7 doubling doses may be tested.
3333762|NCT02124278|Placebo Comparator|Sterile water for injection|Sterile water for injection administered by nebulization
3234361|NCT01230775|Experimental|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
3259212|NCT01468506||Fistula patients|Consecutive patients with autogenous, brachio-cephalic, brachio-basilic or brachio-brachial arterio-venous fistula creation for hemodialysis
3259213|NCT01468519|Experimental|CSII|continuous subcutaneous insulin infusion
3333763|NCT02124291|No Intervention|No Assisted Hatching|No Assisted Hatching
3333764|NCT02124291|Active Comparator|Assisted Hatching|Mechanical Assisted Hatching - artificial rupture of the embryo external glycoprotein layer (Zona Pellucida) before embryo transfer.
3333765|NCT02124317|Experimental|nanoparticle albumin-bound paclitaxel, S-1|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycle: 6 cycles.
3333766|NCT02124330|Experimental|montmorillonite 5 g|5g Montmorillonite + 15 g protein (ratio 1:3)
3333767|NCT02124330|Experimental|Montmorillonite 3 g|3g Montmorillonite + 15 g protein (ratio 1:5)
3333768|NCT02124330|Experimental|Montmorillonite 1 g|1g Montmorillonite + 15 g protein (ratio 1:15)
3333769|NCT02124330|No Intervention|Control|A control goup will intake 15 g of protein alone
3333770|NCT02124343|Experimental|Interval Exercise|"Subjects will undertake an interval exercise session (on a harnessed treadmill) (HP Cosmos Mercury 4.0, HP Cosmos Sports and Medical Gmbh, Nussdorf-Traustein,Germany) based on the average speed calculated from the 6 minute walk test (6MWT).~Intervals are based on the work previously done by Mador et al., 2009 who used intervals of 150% (for 1 minute) followed by intervals of 75% (for 2 minutes) based on 80% average speed from the 6 minute walk test.~This study repeated these intervals 7 times with a duration of 23 minutes in total for the exercise intervention with the 75% intervals at the start and at the end of the exercise session. No warm up was undertaken for this method as it was a walking exercise test and the risk of injury was minimised with use of the harnessed treadmill."
3333771|NCT02124356||Emergency High-risk Abdominal Surgery|
3333772|NCT02124369|Other|Abraxane & gemictabine|Abraxane, IV, 125mg/m2 and gemcitabine, IV, 1000mg/m2, on days 1,8 & 15 per 28 day cycle, up to a maximum of 6 cycles.
3234362|NCT01230775|Placebo Comparator|Placebo|"Week 1:~x1 tablet/d of Placebo will be administered in week 1.~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d"
3234363|NCT01230840|Placebo Comparator|placebo|Control cookies will contain no wheat dextrin and will be taken 3 times daily for 2 weeks.
3234364|NCT01230840|Experimental|wheat dextrin|wheat dextrin (formulated according to the supporter's established method), will be baked in cookies providing three doses per day (≈5 gram of wheat dextrin in each dose)for 2 weeks.
3234365|NCT01230853|Active Comparator|Active Comparator: A|
3333773|NCT02124395||Primary Hyperoxaluria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3333774|NCT02124395||Cystinuria|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3333775|NCT02124395||Dent Disease|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3333776|NCT02124395||APRT deficiency|All rare kidney stone patients enrolled in RKSC registries that are able to communicate using the English language, are able to consent to participation in the study, have internet access with an email account and/or a valid address and are at minimum 5 years of age (for SF-10)
3333777|NCT02124408|Experimental|Intervention group|Personalized Behavioral Intervention
3333778|NCT02124408|No Intervention|Control group|
3333779|NCT02124421|Active Comparator|CRS with adjuvant IV/IP chemotherapy|Patients undergo cytoreductive surgery (CRS) alone with IV/IP combination adjuvant chemotherapy. Day 1: IV paclitaxel (135 mg/m2), day 2: IP cisplatin (75 mg/m2), and day 8: IP paclitaxel (60 mg/m2) given every 21 days for a total of 6 cycles. Standard of care treatment. Administration of quality of life questionnaires throughout study duration of follow-up
3234366|NCT01230853|Placebo Comparator|Placebo Comparator A|
3234367|NCT01230853|Active Comparator|Active Comparator: B|
3333780|NCT02124421|Experimental|CRS/HIPEC with adjuvant IV chemotherapy|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) administered using carboplatin for 90 minutes. Adjuvant systemic IV combination chemotherapy with carboplatin and paclitaxel (Carboplatin AUC 6, Paclitaxel 175mg/m2) will be given every 21 days for a total of 6 cycles. Administration of quality of life questionnaires throughout study duration of follow-up
3333781|NCT02124434||Laparoscopic Sleeve Gastrectomy|Patients undergoing Laparoscopic Sleeve Gastrectomy surgery for morbid obesity
3333782|NCT02124447|Active Comparator|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
3333783|NCT02124447|Active Comparator|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
3333784|NCT02124447|Active Comparator|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
3333785|NCT02124447|Active Comparator|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
3333786|NCT02124473|Experimental|Homeopathy|A range of homeopathic potencies were used as per the individualized requirement, decided by the treating physicians.Each dose, administered orally, (in centesimal potencies).
3333787|NCT02124473|Placebo Comparator|Placebo|Placebo, identical in appearance, consisted of 83.1% ethanol in 10 ml distilled water and was served in identical amber-coloured glass vials
3234368|NCT01230853|Placebo Comparator|Placebo Comparator B|
3234369|NCT01230866|Other|Proton Radiation Hypofractionation|5 fractions (7.6 Gy(RBE) x 5)
3234370|NCT01230866|Active Comparator|Proton Radiation Standard Fractionation|44 fractions (1.8 Gy(RBE) x 44)
3234371|NCT01230905|Other|MPI nuclear scan|Nuclear MPI for CAD for prostate cancer subjects undergoing treatment and development of normal comparison.
3234372|NCT01230918|Experimental|Diagnostic Imaging|A single dose of 800 to 1100 mBq of 99mTc-NC100692 radiopharmaceutical will be injected. Serial cardiac nuclear imaging will be done over a 3 hour period.
3234373|NCT01230944|Active Comparator|Laparoscopic Nissen|Laparoscopic Nissen fundoplication
3234374|NCT01230944|Active Comparator|Open Nissen|Open (conventional) Nissen fundoplication
3234375|NCT01230957|Experimental|Group 1|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
3234376|NCT01230957|Experimental|Group 2|Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
3234377|NCT01230957|Experimental|Group 3|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
3234378|NCT01230957|Experimental|Group 4|Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
3234379|NCT01230957|Placebo Comparator|Group 5|Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
3333788|NCT02124486|Active Comparator|Dietetic Intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers diet programme.
3333789|NCT02124486|Experimental|Bariatric surgery|Patients randomised to the bariatric surgery arm will be referred to the bariatric surgery pathway and, if judged suitable according to the bariatric surgery clinic's screening processes, undergo bariatric surgery.
3333790|NCT02124486|No Intervention|Matched obese control group|To evaluate the baseline difference in ICP between IIH patients and a matched obese control cohort we will recruit 20 obese but otherwise healthy participants who will undergo the same baseline visit as the main trial participants and then exit the study.
3333791|NCT02124486|No Intervention|MRI Test run|5 patients will undergo double baseline MR scans to validate the novel MR sequences being used in the main trial.
3333792|NCT02124499||All patients|Patients undergoing elective surgery with anesthesia
3333793|NCT02124525|Placebo Comparator|N-acetylcysteine|"Subjects receiving N-acetylcysteine (NAC): 6 pills/ day of N-acetylcysteine 500mg.~Duration: 12 weeks"
3333794|NCT02124525|Placebo Comparator|Placebo|Placebo will be taken for 12 weeks
3333795|NCT02124590|Experimental|Acute Exercise|Repeated isometric leg exercises at varying intensities and a second visit with aerobic bike exercise for 30 minutes at 50% peak VO2.
3234380|NCT01230957|Experimental|Group 6|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
3234381|NCT01230957|Experimental|Group 7|Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
3234382|NCT01230970|Experimental|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
3234383|NCT01230983|Experimental|Treatment 1: (No HD MTX / No Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, IT methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
3333796|NCT02124616||Neuromuscular diseases|Prospective cohort of children with inherited or acquired neuromuscular diseases.
3333797|NCT02124642|Active Comparator|Folic acid, 400 mcg/day|A daily 400 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 400 mcg dose approximates the current Recommended Dietary Allowance (RDA) for pregnant women of 600 mcg Dietary Folate Equivalents (400 mcg folic acid ≈ 600 mcg DFEs; conversion factor based on higher bioavailability of folic acid is: 1 mcg folic acid = 1.7 mcg DFE).
3333798|NCT02124642|Experimental|Folic acid, 800 mcg/day|A daily 800 microgram (mcg) dose of folic acid will be taken orally, along with the recommended intake for pregnancy of other vitamins, minerals and docosahexaenoic acid (DHA), beginning at enrollment until delivery. The 800 microgram dose, which is considerably higher than the current RDA, represents an amount commonly found in over-the-counter prenatal vitamin formulations.
3333799|NCT02124655|Experimental|Essential oils/0.2% chlorhexidine/Sterile water|A) 20 ml rinses for 30 seconds with essential oils/2 times daily (1/0/1). -----14 days----- B) 10 mL rinses for 30 seconds with 0.2% chlorhexidine/2 times daily (1/0/1). -----14 days----- C) 20 mL rinses for 30 seconds with sterile water (1/0/1).
3333800|NCT02124668|Experimental|Enzalutamide|Enzalutamide
3333801|NCT02124681|Placebo Comparator|Placebo|Placebo PO
3333802|NCT02124681|Experimental|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg PO QD
3333803|NCT02124694|Experimental|HTUG and IPT|This arm includes the Historical Trauma and Unresolved Grief intervention (HUTG) combined with group Interpersonal Psychotherapy (IPT).The HTUG/IPT arm is 12 two-hour sessions delivered weekly on average, except for weather delays, over 16 weeks. HTUG/IPT includes sessions on identifying relationship issues which may trigger depressive symptoms, using group support, and connecting the impact of collective tribal trauma and losses with personal lifespan and current losses. HTUG/IPT is aimed at reducing depressive symptoms related to interpersonal conflicts and grief. HTUG is a Tribal Best Practice which may serve to engage AI in IPT, an empirically supported treatment for depression.
3333804|NCT02124694|No Intervention|IPT Only|IPT is a standard empirically supported treatment. This IPT Only group is not receiving the experimental HTUG component and is being compared to the combined HTUG with IPT.
3234384|NCT01230983|Active Comparator|Treatment 2: (No HD MTX / Zinecard)|Closed 09/2000 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, dexrazoxane hydrochloride (Zinecard or DZR), IT methotrexate /cytarabine, radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), IT methotrexate/cytarabine)
3333805|NCT02124720|Experimental|Mobile application|Use of the iSTIM mobile application 2 to 4 times per week over approximately 8 to 16 weeks
3333806|NCT02124733|Active Comparator|Group 1: 30 minutes|The first 4 patients enrolled will be considered Group 1, and will receive 30 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated in terms of erythema immediately post-PDT (Day 1) and on Day 4 . If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 2
3259214|NCT01468519|Active Comparator|MDI|multiple daily insulin injections
3259215|NCT01468545||Group 1|
3259216|NCT01468545||Group 2|
3259217|NCT01468571|Experimental|Spironolactone|Drug: Spironolactone Drug: Placebo
3259218|NCT01468571|Experimental|Placebo|Drug: Placebo Drug: Spironolactone
3259219|NCT01468610|Active Comparator|Workers with MDD|
3333807|NCT02124733|Active Comparator|Group 2: 45 minutes|Patients in this group will receive 45 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema response immediately post-PDT and at Day 4. If there is no clinical reaction on Side A after 2 patients, then the dose will be advanced to the next Group. If the post-PDT reaction (erythema at Day 4) on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of the 4 patients, then the protocol will advance to Group 3.
3333808|NCT02124733|Active Comparator|Group 3: 60 minutes|Patients in this group will receive 60 min of Aminolevulinic acid based photodynamic therapy to Side A. They will be evaluated for erythema responses immediately post-PDT and at Day 4. If the post-PDT reaction on Side A equals or exceeds the reaction on Side B in the majority of the first 4 patients, then the dose will not be escalated and recruitment will continue until 15 patients have been treated (thereby completing the study). If the post-PDT reaction on Side A is less than the reaction on Side B in the majority of patients, then the protocol will terminate after 15 patients (total for all groups) have been treated.
3333809|NCT02124785|Experimental|HAV Group|Subjects who were previously vaccinated with Havrix in primary studies.
3333812|NCT02124837|No Intervention|Control group|Participants continue their normal lunch routine.
3333813|NCT02124837|Experimental|Relaxation exercise during lunch break|Participants perform relaxation exercises during each lunch break during work for a period of 2 working weeks.
3333814|NCT02124837|Experimental|Park walk during lunch break|Participants go for a walk in the closest park nearby each lunch break during work for a period of 2 working weeks.
3333815|NCT02124850|Experimental|Motolimod plus cetuximab|Cohort 1: motolimod plus cetuximab
3333816|NCT02124850|Experimental|Motolimod, cetuximab, and nivolumab|Cohort 2: motolimod, cetuximab, and nivolumab
3333817|NCT02124876||Transtibial amputees|
3333818|NCT02124902|Experimental|Washington University: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion. A total of 6 cycles will be given.
3333819|NCT02124902|Experimental|Baylor: Neoadjuvant docetaxel and carboplatin|Docetaxel will be administered intravenously at a dose of 75mg/m2 over 60 minutes on Day 1 of each 21-day cycle. Carboplatin AUC 6 will be administered intravenously over 30 minutes on Day 1 of each 21-day cycle immediately following docetaxel infusion.
3333820|NCT02124915||Transtibial amputees|
3234385|NCT01230983|Active Comparator|Treatment 3: (HD MTX / No Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, leucovorin calcium (LCV), HD methotrexate /cytarabine radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
3333821|NCT02124928||carotid artery stenosis|Patients with symptomatic or asymptomatic carotid artery stenosis indicated for carotid endarterectomy, who provide written informed consent, will be included in this study. The investigators will compare patients ultrasonographic data, serum laboratory analyses and histomorphological preferances to look for biomarkers for the plaque instability.
3333822|NCT02124941|Experimental|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans, including before and after two-weeks of placebo and NAC administration.
3333823|NCT02124941|Experimental|[18F]-FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
3333824|NCT02124941|Experimental|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
3333825|NCT02124941|Active Comparator|Medication (NAC & placebo) administration|Upon completion of baseline (abstinence) 1H-MRS scanning at 7T, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
3333826|NCT02124954|Experimental|Digoxin with/without TA-8995|Digoxin with/without TA-8995
3333827|NCT02124954|Experimental|Midazolam with/without TA-8995|Midazolam with/without TA-8995
3333828|NCT02124967|Experimental|Exercise|A one hour exercise session which includes both aerobic activity and resistance training
3333829|NCT02124980|Experimental|Recovery Line plus Treatment-as-Usual (RL+TAU)|The Recovery Line is an automated computer-based IVR system that provides CBT-based modules. The RL+TAU condition will include the customized therapeutic recommendations developed in Phase 1, and the contact reminders messages and time frame that maximized system use in Phase 2. Patients will receive an orientation, 24-hour access, encouragement to use the system from clinic staff reminder, and technical assistance line for system problems. Patients will receive 12 weeks of system access.
3333830|NCT02124980|No Intervention|Treatment-as-Usual|Treatment-as Usual involves daily methadone and associated psychosocial services. Patients are required to attend 1 group session per month and are encouraged to attend open drop-in groups available daily covering a range of topics.
3333831|NCT02124993||Sleeve gastrectomy surgery Participants|Male or female who will undergo a sleeve gastrectomy for obesity by Dr. Drake Bellanger.
3234386|NCT01230983|Active Comparator|Treatment 4: (HD MTX / Zinecard)|Closed 09/2001 Induction (Vincristine sulfate, Prednisone, doxorubicin hydrochloride, Methotrexate (MTX), mercaptopurine (6-MP), leucovorin calcium (LCV), HD methotrexate/cytarabine, dexrazoxane hydrochloride (Zinecard or DZR)), Consolidation (Vincristine sulfate), Prednisone, doxorubicin hydrochloride, mercaptopurine (6-MP), asparaginase, HD methotrexate /cytarabine, dexrazoxane hydrochloride (Zinecard or DZR), radiation therapy (XRT)). Continuation (Vincristine sulfate, Prednisone, IT methotrexate/Ara-C,mercaptopurine (6-MP), HD methotrexate/cytarabine)
3333832|NCT02125006|Experimental|Interdisciplinary program including MBSR|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
3333833|NCT02125006|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
3333834|NCT02125019||Breast cancer patients|This is a single arm study evaluating feasibility of evaluating gait and parameter changes in patients with early stage breast cancer undergoing adjuvant taxane chemotherapy.
3333835|NCT02125032|Active Comparator|Transcranial pulsed electromagnetic fields (T-PEMF)|One group receives 8 weeks of active T-PEMF treatment and another group receives 8 weeks of placebo T-PEMF. Both treatments to be performed 30 minutes once a day.
3333836|NCT02125032|Placebo Comparator|Trancranial electromagnetic pulsed fields (T-PEMF)|8 weeks of T-PEMF treatment placebo.
3333837|NCT02125045|Experimental|L-GSH|Glutathione 100 mg tablets twice a day
3333838|NCT02125045|Placebo Comparator|Placebo|Matching placebo will be administered for 4 weeks in a double blind fashion.
3333839|NCT02125058|Other|Transcutaneous sutures|Transcutaneous sutures
3333840|NCT02125058|Other|Intracutaneous sutures|Intracutaneous sutures
3333841|NCT02125071||Hepabig|Those who receiving I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation
3333842|NCT02125084|Experimental|Everolimus and Enzalutamide|"Dose Escalation Phase (18 patients): 3-6 patients will be treated at each dose level until the Maximum Tolerated Dose (MTD) is determined.~Everolimus: Orally (PO) once daily (dose to be determined;~Enzalutamide: 160mg (four 40mg capsules) PO continuous daily dosing.~Dose Expansion Phase (23 patients): Everolimus and Enzalutamide to be administered using the MTD determined in the dose escalation phase."
3333843|NCT02125097|Experimental|Intracranial Aneurysm Treatment|Barrel™ Vascular Reconstruction Device (VRD) is Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
3234387|NCT01230996|Experimental|Dose escalation study|This is a dose escalation study of IMRT for women with locally advanced cervical cancer. Three dose levels will be investigated, (although, the first dose level is considered to be the equivalent to a standard pelvic dose with parametrial boost). Before moving to the next dose level it must be confirmed by the Chief Investigator that the Maximum Administrable Dose (MAD) has not been met in the previous dose level (see section 6.3). If MAD is reached before dose level 3 the study will stop. All patients enrolled on the study will undergo the same procedures at the same time points, regardless of the dose level they are being given (see section 5).
3234388|NCT01231009|Active Comparator|Corticosteroids|Patients receive for 7 days intravenous corticosteroids, dexamethasone, and they continue receiving for 7 days corticosteroids per os
3234389|NCT01231009|Placebo Comparator|Vestibular exercises|Patients perform for 15 days certain vestibular exercises under suspicion of an expert physiotherapist
3234390|NCT01231061|Experimental|Arm A: SBRT|
3333844|NCT02125110|Experimental|study group (cohort PELAGIE)|100 children included in the cohort PELAGIE
3333845|NCT02125110|Experimental|pilot group (no cohort PELAGIE)|10 children not included in the PELAGIE cohort to optimise MRI
3333846|NCT02125123|Experimental|Nutritional Supplement and Counseling|Two servings a day; ready-to-feed nutritional supplement plus dietary counseling
3333847|NCT02125123|Active Comparator|Counseling|Dietary Counseling
3333850|NCT02125149|No Intervention|Control|Standard of care
3333851|NCT02125149|Experimental|Intervention|Exercise intervention from 12 week gestation until delivery
3333852|NCT02125162|Experimental|Treatment A|BCX4161 400 mg formulated as hard gelatin capsules given orally under fasting conditions x1
3333853|NCT02125162|Experimental|Treatment B|BCX4161 400 mg formulated as soft gelatin capsules given orally under fasting conditions x1
3333854|NCT02125162|Experimental|Treatment C|BCX4161 400 mg formulated as soft gelatin capsules given orally after a high-fat breakfast x1
3333855|NCT02125175|Experimental|Hypofractionated IMRT boost Radiotherapy|
3333856|NCT02125188|Experimental|Desmopressin|Desmopressin 3ug/kg in saline 100ml ivdrip before surgery
3333857|NCT02125188|Placebo Comparator|saline|saline 100ml ivdrip before surgery
3333858|NCT02125201|Experimental|intranasal fentanyl|Intranasal Fentanyl 1.5-2 mcg/kg
3333859|NCT02125201|Active Comparator|intravenous fentanyl|Intravenous Fentanyl 1-1.5 mcg/kg
3333860|NCT02125214|Experimental|ASA 1-2|ASA 1-2 patients 20-40 yr
3333861|NCT02125227|Experimental|Group 1 of Study A|single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755
3333862|NCT02125227|Experimental|Group 2 of Study A|single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin
3333863|NCT02125227|Experimental|Group 1 of Study B|single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast
3333864|NCT02125227|Experimental|Group 2 of Study B|single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state
3333865|NCT02125240|Experimental|Icotinib|125 mg three times daily (375 mg per day) by mouth
3333866|NCT02125240|Active Comparator|Placebo|1 tablet three times daily by mouth
3333867|NCT02125253|Experimental|Mometasone Furoate Nasal Spray, 50 mcg|Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
3333868|NCT02125253|Active Comparator|Nasonex Nasal Spray, 50 mcg|Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.
3333869|NCT02125253|Placebo Comparator|Placebo Nasal Spray|Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.
3333870|NCT02125266|Experimental|Low Dose V404 PDS|Sustained intravitreal delivery of methotrexate (0.6 mg)
3333871|NCT02125266|Experimental|High Dose V404 PDS|Sustained intravitreal delivery of methotrexate (2.3 mg)
3333872|NCT02125305|Experimental|Metformin|Metformin 750mg(D1), Metformin 500mg(D2)
3333873|NCT02125318|Experimental|Anagrelide CR (GALE-401)|
3333874|NCT02125344|Experimental|PM(Cb)|"PM(Cb):~paclitaxel 80mg/m² 18 times weekly simultaneously with NPLD (Myocet®)20mg/m² 18 times weekly simultaneously with carboplatin AUC 1.5 18 times weekly (only in patients with TNBC) Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all cycles."
3333875|NCT02125344|Active Comparator|ETC|"ETC:~epirubicin 150mg/m² every 2 weeks for 3 cycles followed by paclitaxel 225 mg/m² every 2 weeks for 3 cycles followed cyclophosphamide 2000 mg/m² every 2 weeks for 3 cycles. Patients with HER2-positive disease will receive trastuzumab 6 (8) mg/kg every 3 weeks and pertuzumab 420 (840) mg every 3 weeks simultaneously to all T and C cycles."
3333876|NCT02125357|Other|A - Abiraterone Acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care, or until PSA progression then cross-over to Arm B.
3333877|NCT02125357|Other|B - Enzalutamide|160mg PO OD as per standard of care, or until PSA progression then cross-over to Arm A.
3333878|NCT02125370||Nicotine Replacement Therapy|
3333879|NCT02125383|Experimental|Active tDCS|Receives 20 minutes of anodal tDCS three times while sleeping during the night.
3333880|NCT02125383|Sham Comparator|Sham tDCS|Receives 20 minutes of sham tDCS three times while sleeping during the night.
3333881|NCT02125396|Experimental|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
3333882|NCT02125396|Active Comparator|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
3333883|NCT02125409|Experimental|Group 1|Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.
3333884|NCT02125409|Experimental|Group 2|Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.
3333885|NCT02125422|Experimental|Cefaly tDCS|"Cathodal Cefaly tDCS is delivered over the visual cortex at 2 mA of intensity, for 20 minutes, for 5 consecutive days in 9 HV. The anode is placed over the left DLPFC.~2 mA anodal tDCS is delivered over the visual cortex, for 20 minutes, for 5 consecutive days in 9 HV"
3333886|NCT02125435|Experimental|ASP2408 dose escalation cohort|
3333887|NCT02125435|Placebo Comparator|Placebo dose escalation cohort|
3333888|NCT02125448||Resectable esophageal cancer|Neoadjuvant chemoradiotherapy. MRI and PET-CT.
3333889|NCT02125474|Experimental|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
3333890|NCT02125487|Active Comparator|Low-Fidelity Simulation|Teaching using traditional method
3333891|NCT02125487|Experimental|Hybrid Simulation|Teaching using Hybrid Simulation of breast examination
3333892|NCT02125500|Experimental|Sofosbuvir/Ledipasvir|"Non-cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 12 weeks.~Cirrhotic patients will receive SOF/LDV Fixed Dose Combination (FDC) for 24 weeks."
3333893|NCT02125513|Active Comparator|Arm A: 3 courses|Patients will receive 3 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
3333894|NCT02125513|Experimental|Arm B: 6 courses|Patients will receive 6 courses of i.v. carboplatin AUC 5 and paclitaxel 175 mg/m2 every 3 weeks, followed by cytoreductive surgery within 6 weeks from the last cycle of chemotherapy. Alternatively, the Participating Centres can use the weekly paclitaxel schedule: carboplatin AUC 6 day 1 and paclitaxel 80 mg/m2 day 1-8-15.
3333895|NCT02125526|Active Comparator|IABP group|After primary percutaneous coronary intervention, IABP will be implanted for 12-24 hours to alleviate persisting ischemia
3333896|NCT02125526|No Intervention|Control group|After primary percutaneous coronary intervention, this group undergoes standard treatment according to the guidelines
3333897|NCT02125539|Experimental|Navigating my Journey program|Client participants of counselors who were randomized to the experimental condition will receive the following intervention: The online Navigating my Journey relapse prevention program is an adjunct to outpatient treatment. We will ask client participants to complete at least 12 Navigating my Journey sessions and discuss them with their counselors.
3333898|NCT02125539|Active Comparator|Attention Control|Client participants of counselors who were randomized to the control condition will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
3333899|NCT02125552|Experimental|Ultrasound guided intravenous access|This group will have their IV placed by ultrasound guidance.
3333900|NCT02125552|Placebo Comparator|Traditional intravenous access|The patients randomized to traditional IV access will have their IVs placed by standard technique.
3333901|NCT02125565|Experimental|Local Anaesthesia|These subjects received an injection of lidocaine 1% 2ml subcutaneously prior to arterial puncture
3333902|NCT02125565|No Intervention|No Local Anaesthesia|Patients underwent arterial puncture directly with NO prior anaesthesia
3333903|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a)|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every other week for a total of 6 weeks.
3333904|NCT02125578|Experimental|BIIB017 (PEGylated Interferon Beta-1a) and Placebo|Varying doses (63 mcg up to 188 mcg) of BIIB017 will be administered SC every 4 weeks for a total of 6 weeks. To ensure blinding, each subject will receive placebo every other week.
3333905|NCT02125578|Placebo Comparator|Placebo|Placebo dose will be administered SC every other week for a total of 6 weeks.
3333906|NCT02125591|Experimental|Active PoNS CN-NINM|Active CN-NINM PoNS - Active cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3234391|NCT01231061|Experimental|Arm B: Radiosurgery|
3333907|NCT02125591|Sham Comparator|Sham PoNS CN-NINM|Sham CN-NINM PoNS - Sham cranial-nerve non-invasive neuromodulation (CN-NINM) using the Portable Neuromodulation Stimulator (PoNS) and balance/gait rehabilitation with physical therapy
3333908|NCT02125617||Castration-resistant prostate cancer, Progression after taxane|Treated with abiraterone 1000 mg/day Prednisolone 10 mg/day
3333909|NCT02125630||Systemic therapy|Standart chemotherapy
3333910|NCT02125630||Primary surgery|Standart surgery
3333911|NCT02125630||Neoadjuvant chemotherapy|Standart chemotherapy followed by surgery
3333912|NCT02125643|Active Comparator|Caffeine Pill|The caffeine will be administered.
3333913|NCT02125643|Placebo Comparator|Placebo/Flour Pill|The flour will be administered.
3333914|NCT02125656|No Intervention|Regular Sleep|A single night of regular sleep
3333915|NCT02125656|No Intervention|Sleep Deprivation|A single night of sleep deprivation
3333916|NCT02125656|Experimental|HIIT + Regular Sleep|2 weeks of HIIT and after a single night of regular sleep.
3333917|NCT02125656|Experimental|HIIT + Sleep Deprivation|2 weeks of HIIT and after a single night of sleep deprivation
3333918|NCT02125669|Active Comparator|Laser Treatment|Pulsed dye laser 595nm
3333919|NCT02125669|Sham Comparator|SHAM Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
3333920|NCT02125682|Active Comparator|low dose|patients receiving 10 mg of atorvastatin daily
3333921|NCT02125682|Active Comparator|High dose|Patients receiving 80 mg of atorvastatin daily
3333922|NCT02125695||Healthy Volunteers|Skin taping; blood sampling; optional biopsy
3333923|NCT02125695||Cutaneous lupus erythematosus|This group consists of participants affected with lupus (DLE, SCLE). Skin taping; blood sampling; optional skin biopsy (DLE participants); required skin biopsy (SCLE participants)
3333924|NCT02125695||Atopic dermatitis|Skin taping; blood sampling; optional skin biopsy
3259220|NCT01468623|Experimental|OnDose®|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
3333925|NCT02125708|Other|OvulaRing®|Twenty patients with verified PPROM between gestation week 22 and 27 should be included. After gynecological and physical examination within verification of PPROM women will be informed about the study and invited to participate in this study. Subsequently informed consent will be obtained and the OvulaRing® placed into the vaginal fornix.
3333926|NCT02125747|Other|No Respiratory Therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment.
3333927|NCT02125747|Experimental|Respiratory therapy|Patients with acute exacerbation of chronic obstructive pulmonary disease. Patients received conventional treatment and Respiratory Therapy
3333928|NCT02125760|Sham Comparator|Inspiratory Muscle Training (IMT)|Patients with subacute stroke in a neurorehabilitation setting.
3333929|NCT02125760|Experimental|High-intensity IMT|Patients with subacute stroke in a neurorehabilitation setting.
3333930|NCT02125773|Experimental|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator.
3333931|NCT02125773|No Intervention|Control|Subjects in the control arm will not be provided with the results of the risk calculators.
3333932|NCT02125786|Experimental|Stratum 1: Local Failure|"Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Treatment is surgery and a second course of focal irradiation. The total dose for the second course of irradiation will be 54Gy.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3333933|NCT02125786|Experimental|Stratum 2: Metastatic Failure|"Participants exhibit an initial pattern of failure that is metastatic (neuraxis metastatic disease without equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation. Craniospinal irradiation (36-39.6Gy) will include focal boost treatment of metastatic sites (54-59.4Gy) depending on location, extent of resection and target volume.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3333934|NCT02125786|Experimental|Stratum 3: Local and Metastatic Failure|"Participants exhibit an initial pattern of failure that is both local and metastatic (neuraxis metastatic disease with equivocal evidence of local failure). Treatment is surgery and craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3333935|NCT02125786|Experimental|Stratum 4: Local Failure|"Local Failure Participants exhibit an initial pattern of failure that is local (disease confined to primary site). Age is >36 months at time of enrollment to <21 years. Tumor shows presence of 1q gain. Treatment is optional craniospinal irradiation.~Participants may receive one or both: Photon therapy or proton therapy.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine to aid in tumor visualization."
3333936|NCT02125799|Experimental|Accelerated HF-rTMS|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
3333937|NCT02125812|Placebo Comparator|scaling and root planing|scaling and root planing
3333938|NCT02125812|Experimental|scaling and systemic moxifloxacin|scaling and root planing combined with systemic moxifloxacin
3333939|NCT02125825||Parkinson's disease on levodopa|Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms
3333940|NCT02125851|Experimental|Xanthan Gum|"A total of 12 subject will be administered sucralose slurry and the xanthan gum slurry. Six will get sucralose first (then an hour later the xanthan gum) and 6 will receive the xanthan gum first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The xanthan gum-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 1ml of xanthan gum gel, crystallized orange flavoring agent, and 1mCi of Tc99-Sulfur colloid."
3333941|NCT02125851|Experimental|Honey|"A total of 12 subject will be administered sucralose slurry and the honey slurry. Six will get sucralose first (then an hour later the honey) and 6 will receive the honey first (then an hour later the sucralose slurry).~The sucralose slurry will which will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 10 grams of sucralose and 1 millicurie (mCi) of Tc99m-Sulfur Colloid.~The honey-budesonide slurry will consist of a 1mg dose of budesonide inhalation solution (respule) mixed with 6ml of honey and 1mCi of Tc99-Sulfur Colloid."
3333942|NCT02125864|Experimental|Aflibercept|
3333943|NCT02125890|Experimental|Tranexamic Acid|We will be administering Tranexamic Acid in patients with ruptured abdominal aortic aneurysms to determine if this has an effect on primary outcome measures as significant bleeding, blood transfusion requirements.
3333944|NCT02125903|Active Comparator|Continuous Adductor Canal Block (CACB)|"Continuous Adductor Canal block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
3333945|NCT02125903|Active Comparator|Continuous Femoral Nerve Block (CFNB)|"Continuous Femoral Nerve Block performed with:~loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h~Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine"
3333946|NCT02125916|Experimental|COLD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3333947|NCT02125916|Experimental|COLD with long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3234392|NCT01231074|Experimental|Psychotropic/metformin (PIW)|"Inclusion Criteria:Psychotropic/metformin (PIW) Cohort: Children aged 10-17 years on psychotropic* medication with reported weight gain defined by 1 of the following: 1. >5% weight increase from the start of medication to 3 months on medication 2. Crossing into the 95th percentile for BMI 3. Crossing into the 85-95th percentile plus one obesity related complication~The subject will have to be on one of these medications in addition to the criteria above to be eligible for the study: haloperidol, perphenazine, clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole, thioridazine, fluphenazine, loxapine, mesoridazine, thiothixene or trifluoperazine"
3333948|NCT02125916|Experimental|ILD without long term oxygen therapy|Driving in the simulator two times, one time with and one time without oxygen therapy
3333949|NCT02125916|No Intervention|Controls|Driving in the simulator one time without oxygen therapy
3333950|NCT02125929|Experimental|robotic arm|robotic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
3333951|NCT02125929|Experimental|Laparoscopic surgery|laparoscopic surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 50
3333952|NCT02125929|Experimental|Open surgery|Open surgery for enucleation benign Pancreatic Neuroendocrine Tumors Case number = 100
3333953|NCT02125942|Experimental|meditation|Central Meditation and Imagery Therapy
3333954|NCT02125942|No Intervention|wait list|waiting list
3333955|NCT02125955|Experimental|Prebiotic fiber|The intervention group will consume an 8 gram dose of prebiotic fiber one time per day approximately 30 minutes prior to their evening meal.
3333956|NCT02125955|Placebo Comparator|Placebo|The placebo group will consume an isocaloric dose of placebo (maltodextrin; 3.3 grams) one time per day approximately 30 minutes prior to their evening meal.
3333957|NCT02125968|Active Comparator|interactive video game|"Participants in interactive video game group receive six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min interactive video game intervention, for 3 times per week for a 2-week duration.~Short- and medium-term therapeutic effects of interactive video game intervention for patients with chronic low back pain will be assessed."
3333958|NCT02125968|Sham Comparator|therapeutic exercise|"Participants received six 20-min sessions of hot pack therapy combined 20-min of diathermy therapy over the low back followed by 15-min supervised therapeutic exercise,for 3 times per week for a 2-week duration.~short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain will be evaluated."
3333959|NCT02125981|Experimental|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
3333960|NCT02125981|Placebo Comparator|Control|taking placebo drug
3333961|NCT02125994|Active Comparator|Ropivacaine 0.5%|Ultrasound guided Intercalene nerve block with ropivacaine 0.5 %
3333962|NCT02125994|Active Comparator|Ropivacaine 0.375 %|Ultrasound guided Intercalene nerve block with ropivacaine 0.375 %
3333963|NCT02126007|Experimental|Sleep and Rhythm Intervention|This arm receives a 4-week behavioral intervention aimed at improving sleep and circadian rhythms, and thereby reducing fatigue.
3333964|NCT02126007|Placebo Comparator|Dietary Modifications|This arm receives a 4-week placebo intervention focused on dietary modifications for reducing fatigue.
3333965|NCT02126020|Experimental|topical infliximab|topical infliximab 10 mg/mL QID x 3 months followed by BID x 9 months
3234393|NCT01231074|Experimental|Obese/metformin (OME)|Obese/metformin (OME) cohort: Children 10-17 years old with BMI >95th percentile and fasting insulin level>21.7U/L
3333966|NCT02126033|Experimental|celiac disease|
3333967|NCT02126046|Other|Hi-HSC-CBT|
3333968|NCT02126059|Experimental|Cognitive stimulation|One cognitive stimulation session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to cognitive stimulation.
3333969|NCT02126059|Experimental|Aroma-massage|One hand and shoulder massage session per week for a continuous 10 weeks, each session contains 30 minutes, totally 10 session massage.
3333970|NCT02126059|Experimental|reminiscence|One reminiscence session per week for a continuous 10 weeks, each session contains 50 minutes, totally 10 session topics related to reminiscence.
3333971|NCT02126059|No Intervention|Control|Control group remain regular activities
3333972|NCT02126072|Experimental|Alcohol|The study is a randomized single blinded trial in cross over design. Subjects are randomized to drink alcohol in one session and water in another session.
3333973|NCT02126072|Active Comparator|Water|Water in the same volume as the volunteer would have to drink in wine according to the protocol.
3333974|NCT02126085|Active Comparator|Intubation|Intubation and invasive mechanical ventilation + endovascular recanalisation
3333975|NCT02126085|Experimental|No Intubation|Conscious sedation and non-invasive ventilatory support + endovascular recanalisation
3333976|NCT02126098||Adults who diagosed ANCA-vasculitis|"Patients with Wegener's granulomatosis or microscopic polyangiitis were eligible to participate in the study if they had~Positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA~manifestations of severe disease,11 and a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 3 or more (scores range from 0 to 63, with higher scores indicating more active disease)"
3333977|NCT02126111|Active Comparator|DEPIGOID phleum|The active treatment arm receive active phleum pollen immunotherapy (Depigoid 100% phleum). Depigmented and polymerized allergen extract of Phleum pollen for subcutaneous injection.
3333978|NCT02126111|Placebo Comparator|DEPIGOID Placebo & DEPIGOID Phleum|"This arm receive DEPIGOID Placebo during the first year, and DEPIGOID Phleum during the second year of study.~DEPIGOID Placebo contains the same composition as in the active DEPIGOID Phleum with the only difference being the exclusion of the phleum pollen allergen extract."
3333979|NCT02126124|Active Comparator|Active dTMS Treatment|Brainsway Deep TMS Treatment
3333980|NCT02126124|Sham Comparator|Sham Treatment|Brainsway Sham Treatment
3234394|NCT01231100|Experimental|HCUE-guided care|Hand-carried ultrasound echocardiography
3333981|NCT02126137|Experimental|Ezetimibe|Ezetimibe administered by mouth 10 mg BID for 12 weeks
3333982|NCT02126150||Ethnicity|
3234395|NCT01231100|No Intervention|Standard care|
3333983|NCT02126163|Experimental|Treatment Group|The treatment group will receive three interactive Computer Tailored Intervention (CTI) sessions during the course of six months, which will include tailored feedback based on the user's responses, and two assessment only follow-up sessions at twelve and eighteen months.
3333984|NCT02126163|No Intervention|Control Group|The control group will receive four assessment only sessions during 18 months.
3333985|NCT02126189||Head and neck cancer|All patients presenting to the Head and Neck Cancer Clinic at the Princess Alexandra Hospital, Brisbane, Australia are invited to participate.
3333986|NCT02126202|No Intervention|Conservative therapy|Optimized medical therapy
3333987|NCT02126202|Experimental|Invasive therapy|Coronary angiography and revascularization if feasible
3333988|NCT02126215||Study group - MRI CO2 and O2 stress test|This is a pilot study to assess feasibility of using MRI CO2 and O2 stress testing to predict POD.
3333989|NCT02126241|Experimental|NICaS guided CRT optimization|For each subject, we will determine a set of AV and VV delays values, for which the NICaS measured CO will be maximum. In each patient, the CRT device will then be programmed according to these values.
3234396|NCT01231113|Active Comparator|artesunate-amodiaquine arm|A co-blistered pack of amodiaquine and artesunate.The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
3333990|NCT02126254|No Intervention|Control group|Control group will be treated in the cardiology and internal medicine departments according to the guidelines for the management of Heart Failure
3333991|NCT02126254|Active Comparator|Hemodynamic group|Hemodynamic group patients will be examined in the cardiology and internal medicine departments and treated according to the NICaS system in addition to current guidelines. Patients in this group will be tested within 12 hours from hospitalization and thereafter on an everyday basis until discharge
3333992|NCT02126267|Experimental|Full mouth disinfection - FMD|n = 10: Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
3333993|NCT02126267|Experimental|FMD + chlorhexidine (FMD-CX)|n = 15: Same as FMD with the inclusion of chlorhexidine in office (application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)). In addition, use was made of homemade CX 0.2% for 60 days after the scaling in a single phase.
3333994|NCT02126267|Experimental|FMD + azithromycin (FMD-AZ)|n = 15: Same as with the FMD include the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the scaling.
3234397|NCT01231113|Experimental|Dihydroartemisinin-piperaquine arm|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
3234398|NCT01231126|Placebo Comparator|spontaneous vaginal deliveries|
3234399|NCT01231126|Placebo Comparator|elective caesarians|
3234400|NCT01231126|Experimental|induced vaginal delivery by misoprostol|
3234401|NCT01231126|Experimental|caesarians section with induction attempt|
3234402|NCT01231139|Experimental|Paracetamol|Paracetamol dissolved in 0.9% Sodium Chloride
3234403|NCT01231139|Placebo Comparator|0.9% Sodium Chloride|0.9% Sodium Chloride
3234404|NCT01231165|Experimental|Amiloride,nitrates,clopidogrel,aspirin,statins|Comparative Efficacious Research
3234405|NCT01231165|Active Comparator|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
3234406|NCT01231178|Active Comparator|Alginate based beverage|
3234407|NCT01231178|Placebo Comparator|Control beverage|
3234408|NCT01231191|Active Comparator|IV Acetaminophen|Intraoperative IV acetaminophen administered
3234409|NCT01231191|Placebo Comparator|IV Placebo|Intraoperative IV normal saline administered
3234410|NCT01231204|Placebo Comparator|Placebo Infusion|Patients will be randomized to receive a continuous infusion of Normal Saline via a Paravertebral Nerve Block.
3234411|NCT01231204|Active Comparator|Ropivicaine 0.4% Infusion|Patients will be randomized to receive a continuous infusion of 0.4% Ropivicaine via a Paravertebral Nerve Block.
3234412|NCT01231217|Other|green (or white) tea|Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee
3234413|NCT01231217|Other|coffee|Patients are recommended to drink coffee but are not allowed to consume any tea
3234414|NCT01231243|Active Comparator|35% hydrogen peroxide control|The tooth bleaching will be performed using a high hydrogen peroxide concentration (35%) without light-activation with LED/light device
3234415|NCT01231243|Active Comparator|20% hydrogen peroxide|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) without light activation with a LED/laser device
3234416|NCT01231243|Experimental|35% hydrogen peroxide + light|The tooth bleaching will be performed with a high hydrogen peroxide concentration (35%) associated with LED/laser light activation
3234417|NCT01231243|Experimental|20% hydrogen peroxide + light|The tooth bleaching will be performed with a low hydrogen peroxide concentration (20%) associated with LED/laser light activation
3333995|NCT02126267|Experimental|Scaling and root planing (SRP)|(n = 13): scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
3333996|NCT02126267|Experimental|SRP + azithromycin (SRP-AZ)|n = 11: Same as scaling and root planing group (SRP) with inclusion of the use of azithromycin (500 mg) once daily for 3 consecutive days. Medication was started the same day as the end of the last scaling hemi-arch;
3333997|NCT02126267|Experimental|SRP + chlorhexidine (SRP-CX)|n = 13 : Same as group scaling and root planing (SRP) with the inclusion of home use of CX 0.2% for 60 consecutive days after the end of the first session of scaling
3333998|NCT02126280||Subclinical atherosclerosis|In vitro estimation of individual reactivity of monocytes in study participants with asymptomatic atherosclerotic plaques found in carotid arteries by ultrasound examination
3333999|NCT02126280||Healthy subjects|In vitro estimation of individual reactivity of monocytes in study participants without ultrasound signs of subclinical carotid atherosclerosis
3334000|NCT02126280||Diffuse intimal thickening|In vitro estimation of individual reactivity of monocytes in study participants with diffuse intima-media thickening of carotid arteries found at ultrasound examination
3234418|NCT01231256|Experimental|preventive health consultation|Half participants randomized to a one hour preventive health consultation with their own general practitioner and a follow up consultation 3 months later
3334001|NCT02126293|Experimental|Zinc deficient patients|If the patient is found to be zinc deficient (serum zinc < 11.5 μmol/L), the family will be contacted by the RA to commence zinc supplement: zinc citrate (Zinc Lozenges, manufactured by Douglas Laboratories Inc, London, ON, Health Canada NPN 80032476) for 3 months. As per the NPN licence the dose is 10 mg (1 lozenge) orally once a day for children age 4-8 years, and 10 mg twice a day for children age 9-18 years. This should give enough time to restore serum zinc to normal in most patients.
3334002|NCT02126293|Active Comparator|Zinc sufficient patients|Zinc sufficient patients will repeat blood and urine tests in 3 month time to compare the changes with intervention arm.
3334003|NCT02126332|Other|Conventional group|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
3334004|NCT02126332|Experimental|EA group (Epidural anesthesia )|"2 groups: a  conventional group  in which available guidelines on analgesia are applied, and an  EA  group in which patients receive thoracic EA for at least 3 days."
3334005|NCT02126345||MASTER SL|
3334006|NCT02126358|Placebo Comparator|Gemigliptin|only Gemiglitpin (Gemiglitpin/Rosuvastatin FDC:Placebo , Rosuvastatin :Placebo)
3334007|NCT02126358|Placebo Comparator|Rosuvastatin|only Rosuvastatin (Gemiglitpin/Rosuvastatin FDC:Placebo , gemigliptin :Placebo)
3334008|NCT02126358|Experimental|FDC|Gemigliptin & Rosuvastatin (Gemiglitpin only:Placebo ,Rosuvastatin only:Placebo)
3334009|NCT02126371|Other|Active|LEO32731
3234419|NCT01231256|No Intervention|Control|Controls are not offered preventive health consultations, but had questionnaires as the intervention arm
3234420|NCT01231269|Experimental|MRI|diffusion-weighted MRI
3234421|NCT01231282|Experimental|diffusion-weighted MRI|MRI
3334010|NCT02126384|Experimental|pneumovax|Single arm, open label pneumovax vaccination of healthy subjects
3334011|NCT02126397|Active Comparator|polyps resection with Laser Diode|application of the laser diode by hysteroscopy to remove the endometrial polyp
3234422|NCT01231295||Memory problems|Group with clinically validated memory problems
3234423|NCT01231295||Reference group|Group without memory problems
3334012|NCT02126397|Active Comparator|polyps resection with bipolar electrode|application of the bipolar electrode Versapoint by hysteroscopy to remove the endometrial polyp
3334013|NCT02126423||1st intravitreal injection|Conjunctival and nasopharyngeal swabs are obtained from each treatment-naive patient receiving their 1st intravitreal injection
3234424|NCT01231308|Active Comparator|Lifestyle modification|Intensive nutritional/exercise counseling for weight loss by lifestyle modification in addition to optimum medical treatment.
3234425|NCT01231308|Experimental|Roux-en-Y-Gastric Bypass|A laparoscopic gastric bypass will be performed in the treatment of type 2 diabetes in Overweight-to-Moderately Obese Patients
3234426|NCT01231347|Active Comparator|AMG 479 12 mg/kg dose + gemcitabine|Arm 2: AMG 479 12 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3234427|NCT01231347|Placebo Comparator|Placebo + gemcitabine|Arm 1: AMG 479-placebo IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3234428|NCT01231347|Active Comparator|AMG 479 20 mg/kg + gemcitabine|Arm 3: AMG 479 20 mg/kg IV days 1 and 15 plus gemcitabine 1000 mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3234429|NCT01231360|Active Comparator|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
3234430|NCT01231360|Active Comparator|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
3334014|NCT02126423||>20 intravitreal injections|Conjunctival and nasopharyngeal swabs are obtained from each patient with >20 intravitreal injection therapies.
3334015|NCT02126436|Active Comparator|Acupuncture|"Eight treatments of acupuncture will be given to participants twice weekly over four weeks. A combination of body and auricular acupuncture will be given and treatment will be pragmatic.~In addition the group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff)."
3234431|NCT01231425||With usual concomitant treatment|Two observational cohorts of patients will be evaluated: with and without concomitant analgesic/ antiinflammatory drugs. The objective is evaluate that both therapies (drugs and acupuncture) could be used as adjunctive therapy in order to maximize the analgesia that could be reached
3334016|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
3334017|NCT02126449|Experimental|Fasting mimicking diet|Short term fasting using Fasting mimicking diet around neoadjuvant chemotherapy (AC>T)
3234432|NCT01231425||Without usual concomitant treatment|This group include patients that are not been treated with analgesic drugs at the beginning of the study. As an observational and naturalistic study any indicated treatment is allowed in any time
3234433|NCT01231438|Experimental|Renvela|Treatment for 2 weeks
3234434|NCT01231438|Experimental|Etalpha|Vit D Treatment for 2 weeks
3234435|NCT01231451|Experimental|All Subjects|All Subjects will receive the same intervention
3334018|NCT02126449|No Intervention|regular diet|Standard neoadjuvant chemotherapy (AC>T)
3334019|NCT02126462|Experimental|30 µg Na-GST-1 + 30 µg Na-APR-1 (M74)|30 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 30 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
3334020|NCT02126462|Active Comparator|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
3334021|NCT02126462|Experimental|100 µg Na-GST-1 plus 100 µg Na-APR-1 (M74)|100 µg Na-GST-1/Alhydrogel plus 5 µg GLA-AF co-administered with 100 µg Na-APR-1 (M74)/Alhydrogel plus 5 µg GLA-AF
3234436|NCT01231477||Volunteers|Healthy volunteers not submitted to anesthesia nor surgery.
3234437|NCT01231477||Sevoflurane Group|This group was submitted to inhalational anesthesia with sevoflurane and otorhinolaryngological surgery.
3234438|NCT01231490|Experimental|Active|
3334022|NCT02126475||Healthy volunteers|
3334023|NCT02126475||Park patients|
3334024|NCT02126488|Experimental|treadmill perturbation|treadmill slip perturbation
3334025|NCT02126488|Placebo Comparator|treadmill placebo|treadmill training placebo
3234439|NCT01231490|Placebo Comparator|Placebo|
3234440|NCT01231529|Experimental|Part 1 Cohort 1|8 subjects with moderate hepatic impairment defined by a Child-Pugh score of 7 to 9 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
3334026|NCT02126488|Sham Comparator|observation|observation training
3334027|NCT02126501|No Intervention|Sudden wean|When ready Nasal Continuous Positive Airway Pressure (NCPAP) will be removed from the neonate
3334028|NCT02126501|Active Comparator|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
3334029|NCT02126514|Experimental|AZD3293|7 subjects will receive AZD3293
3334030|NCT02126527|Experimental|Treatment (auranofin and sirolimus)|Patients receive auranofin PO QD and sirolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3334031|NCT02126540|Experimental|Primary Cohort|Main cohort; treatment Arm with Pantheris Atherectomy System
3334032|NCT02126553|Experimental|Treatment (lenalidomide)|Patients receive lenalidomide PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3334033|NCT02126566|Experimental|Single Arm|Administration of light therapy - measurement of results before and after therapy
3334034|NCT02126579|Experimental|Arm A (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA administered in one skin location rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334035|NCT02126579|Experimental|Arm B (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334036|NCT02126579|Experimental|Arm C (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide vaccine administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after the vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334037|NCT02126579|Experimental|Arm D (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334038|NCT02126579|Experimental|Arm E (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA + PolyICLC vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334039|NCT02126579|Experimental|Arm F (Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334040|NCT02126579|Experimental|Arm G(Part 1)|"Peptide Vaccine (LPV7) + Tetanus peptide + PolyICLC + IFA vaccines administered in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Resiquimod will be applied to the vaccine site immediately after vaccine administration.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334041|NCT02126579|Experimental|Arm E2|"Peptide Vaccine (LPV7) + IFA + PolyICLC vaccines administered in one skin location. Each vaccine will be administered in the same skin site for all 6 vaccines.~Vaccines will be administered on Days 1, 8, 15, 36, 57, and 78."
3334042|NCT02126592||PCOS cohort|Women with PCOS
3334043|NCT02126592||Control cohort|Women without PCOS
3334044|NCT02126618||women with lower urinary tract symptoms|
3334045|NCT02126644|Other|Single Arm|Single arm of 10 patients - efficacy and safety assessed pre and post peel
3334046|NCT02126657|Other|Single Arm|Single arm study - pre and post peel assessment
3334047|NCT02126683|Experimental|Plaquenil first|Start Plaquenil 200mg BID orally since enrollment Duration: 6 months
3334048|NCT02126683|Experimental|Plaquenil later|Start Plaquenil 200mg BID orally since the 25th week after enrollment Duration: 6 months
3334049|NCT02126696||Patients on anti-retroviral therapy|The cohort consists of patients on first-line anti-retroviral therapy since at least 6 months, followed at one of the facilities involved in the study.
3334050|NCT02126709|Experimental|Treatment Arm|"Name: Repigel Active ingredient: Povidone iodine Dosage form: Liposomal hydrogel Administration route: Topical Strength: 3%~Application of study cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
3234441|NCT01231529|Experimental|Part 1 Cohort 2|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 1 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug.
3234442|NCT01231529|Experimental|Part 2 Cohort 3|8 subjects with mild hepatic impairment defined by a Child-Pugh score of 5 to 6 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
3234443|NCT01231529|Experimental|Part 2 Cohort 4|8 healthy subjects matched by gender, age and BMI to the subjects in Cohort 3 will receive a single oral dose of GSK1349572 50 mg in the morning followed by 72 hour serial PK sampling. There will be a screening visit within 30 days prior to the dose of study drug and a follow-up visit within 7-10 days after the study drug. This cohort will only be done if the AUC from Cohort 1 is greater than or equal to 2 times the AUC from Cohort 2.
3334051|NCT02126709|Placebo Comparator|Placebo Arm|"Name: Neutrogena hydroboost gel Active ingredient: NA Strength: NA Dosage form: Water gel Administration route: Topical~Application of placebo cream twice a day during the 8 week study period~It will be applied once in the morning and once in the night~We recommend the application to occur after the face is washed~One Finger Tip Unit is required per application to the entire face~The gel should be left on and not washed of for at least15 -30 minutes"
3334052|NCT02126722||Patients with dyspepsia on PPI|One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
3334053|NCT02126722||Patients with dyspepsia not on PPI|Fifty patients not on PPI will be enrolled among the patients with dyspepsia referred for gastroscopy at Homerton University Hospital. On the day of the endoscopic procedure the patients will bring a stool sample for the detection of faecal Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out.
3334054|NCT02126761|Active Comparator|Group 1|aTIV
3334055|NCT02126761|Experimental|Group 2|aTIV + 1X MF59
3334056|NCT02126761|Experimental|Group 3|aTIV + TIV
3334057|NCT02126761|Experimental|Group 4|aTIV + aTIV
3334058|NCT02126761|Active Comparator|Group 5|aTIV (Left deltoid) Saline (Right deltoid)
3334059|NCT02126761|Experimental|Group 6|aTIV+2X MF59 (Left deltoid) Saline (Right deltoid)
3334060|NCT02126761|Experimental|Group 7|aTIV (Left deltoid) aTIV (Right deltoid)
3334061|NCT02126774||focal epilepsy|observational study
3334062|NCT02126787|Experimental|Intensive Group Analytic Psychotherapy|Intensive Group Analytic Psychotherapy in a day clinic setting
3334063|NCT02126787|Experimental|Intensive GCBT|Intensive transdiagnostic cognitive-behavioral group therapy in a day clinic setting
3334064|NCT02126787|No Intervention|Wait-list control group|
3334065|NCT02126813|Active Comparator|500 ml.|A bladder volume of 500 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
3334066|NCT02126813|Experimental|800 ml|A bladder volume of 800 ml. or more, and incapability of voluntary micturition, is used as interventional threshold for urinary bladder catheterization.
3334067|NCT02126852|Experimental|AMG (one-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
3334068|NCT02126852|Experimental|AMG (three-dimensionally) versus EMG|Neuromuscular monitoring in patients scheduled for surgery under general anesthesia
3334069|NCT02126865|Experimental|BI 1060469 Healthy|Multiple rising dose qd for 15 days
3334070|NCT02126865|Placebo Comparator|Placebo to BI 1060469|Matching placebo as tablet for 15 days
3334071|NCT02126865|Experimental|BI 1060469 asthmatics|Multiple rising dose qd for 29 days
3334072|NCT02126865|Placebo Comparator|Placebo to BI 1060469 asthmatics|Matching placebo as tablet for 29 days
3334073|NCT02126891|Experimental|Canoeists|13 canoeists from a training center of the French canoeing team
3334074|NCT02126891|Experimental|Military|10 young recruits in military school of officers in ground forces of the French army
3334075|NCT02126904||IVR group|
3334076|NCT02126917|Experimental|HC-ER + 40% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 40% Alcohol.
3334077|NCT02126917|Experimental|HC-ER + 20% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 20% Alcohol.
3334078|NCT02126917|Experimental|HC-ER + 0% Alcohol|Open-label, single-dose, 3-period cross-over. All patients fulfilling inclusion/exclusion received HC-ER 50 mg capsule with 0% Alcohol.
3334079|NCT02126930|Active Comparator|Routine care|"The patients in this receive routine care.~Intervention: Routine care"
3334080|NCT02126930|Experimental|Pharma consult|"The patients in this arm will have a pharmaceutical consult upon hospital discharge.~Intervention: Pharma consult"
3334081|NCT02126943||Opsumit (macitentan)|10 mg tablets
3334082|NCT02126956|Experimental|ACT-128800|Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)
3234444|NCT01231542|Experimental|Arm 1|Subjects will have a screening visit within 30 days prior to the first dose of study drug, three treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects enrolled in Arm 1 will receive GSK1349572 50 mg once daily for 7 days, GSK1348572 50 mg twice daily for 7 days, and GSK1349572 50 mg twice daily in combination with rifampin 600 mg once daily for 14 days.
3234445|NCT01231542|Experimental|Arm 2|Subjects will have a screening visit within 30 days prior to the first dose of study drug, two treatment periods, and a follow-up visit 7-14 days after the last dose of study drug. Subjects in Arm 2 will receive GSK1349572 50 mg once daily for 7 days and GSK1349572 50 mg once daily in combination with rifabutin 300 mg once daily for 14 days.
3234446|NCT01231568|Experimental|Cohort 1 Treatment Sequence 1|Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3334083|NCT02126982||Clopidogrel hydrogen sulfate (CHS)|Clopidogrel hydrogen sulfate, 75 mg / day
3334084|NCT02126982||Clopidogrel Besylate (CB)|Clopidogrel Besylate , 75 mg / day
3334085|NCT02126995|Experimental|Metadoxine Immediate/Slow-release|Flexed and fixed-dose Metadoxine Immediate/Slow-release 700 mg and 1400 mg administered orally once daily
3234447|NCT01231568|Experimental|Cohort 1 Treatment Sequence 2|Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3234448|NCT01231568|Experimental|Cohort 2 Treatment Sequence 1|Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3334086|NCT02126995|Placebo Comparator|Placebo|Placebo tablet identical in appearance to study investigational product. Administered orally once daily
3334087|NCT02127008|Experimental|Resection of epidural fat|During surgical procedure, epidural fat was resected fully.
3234449|NCT01231568|Experimental|Cohort 2 Treatment Sequence 2|Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.
3234450|NCT01231594|Experimental|Cohort A|Subjects who have received </= 8 weeks of GSK2118436 monotherapy in the parent study
3234451|NCT01231594|Experimental|Cohort B|Subjects who have received >8 weeks of continuous treatment with GSK2118436 either as monotherapy or combination therapy with another approved anti-cancer agent
3334088|NCT02127008|Active Comparator|No resection of epidural fat|During surgical procedure, the epidural fat was not resected.
3334089|NCT02127021|Experimental|Norzyme® 40000 IU|Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
3334090|NCT02127021|Placebo Comparator|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal. The formulation and the form of placebo is same with the Norzyme® 40000 IU. Placebo contains microcrystalline cellulose as the main component, titanium oxide, colloidal silica, yellow iron oxide, brown iron oxide, black iron oxide, magnesium stearate, triethyl citrate, talc, and simethicone emulsion in very small amount
3234452|NCT01231594|Experimental|Cohort C|Subjects who have received >8 weeks of continuous treatment with GSK2118436 in combination with a MEK inhibitor, GSK1120212
3234453|NCT01231672||Septic shock patients|
3234454|NCT01231685|Active Comparator|ritonavir-boosted protease inhibitor|
3334091|NCT02127034|Experimental|Digoxin / digoxin + solifenacin and mirabegron|Digoxin alone then followed by digoxin with solifenacin and mirabegron
3334092|NCT02127034|Experimental|Digoxin + solifenacin and mirabegron / digoxin|Digoxin with solifenacin and mirabegron then followed by digoxin alone
3234455|NCT01231685|Experimental|Raltegravir|
3234456|NCT01231698|Experimental|esmolol|
3234457|NCT01231698|Other|control|
3234458|NCT01231711|Experimental|Vets Prevail|N=50. Participants were recent veterans (deployed after September 11, 2001) of operations in Iraq and Afghanistan who were experiencing depression/distress symptoms at the time of screening (CES-D > 8) but who were not considered to be inappropriate for a health promotion intervention (CES-D > 35 indicating severe depressed mood or exhibiting self-harm risk).
3234459|NCT01231724|Active Comparator|Allstate Nasal Spray|
3234460|NCT01231724|Placebo Comparator|Placebo Nasal Spray|
3234461|NCT01231737|Active Comparator|Prulifloxacin|
3234462|NCT01231763||Healthy volunteers|
3234463|NCT01231776|No Intervention|control group|
3234464|NCT01231776|Active Comparator|acupuncture preoperative|acupuncture before operation for one week
3234465|NCT01231776|Active Comparator|acupuncture in hospital|acupuncture all the time in hospital
3234466|NCT01231789|Sham Comparator|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min.
3234467|NCT01231789|Experimental|RIPC treatment|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
3334093|NCT02127047|Experimental|Sitagliptin|Patients receive Sitagliptin (100mg/d) without further intervention
3334094|NCT02127047|Experimental|Sitagliptin and exercise|Patients receive sitagliptin (100mg/d) and follow a physical training intervention program
3334095|NCT02127060|Experimental|Vitamin C|in postoperative time, vitamin C administered orally with other pain analgesics.
3334096|NCT02127060|Placebo Comparator|Placebo drug|in postoperative time, vitamin C do not administered.
3334097|NCT02127073|Experimental|Oxytocin|Subjects would receive 4 IU of intranasal oxytocin; one spray in each nostril, single-use.
3334098|NCT02127086|Experimental|Intervention Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm.
3334099|NCT02127086|No Intervention|Usual Care Group|The study design is a non-randomized quasi-experimental cohort design with two cohorts who will be sequentially studied. In phase 1, patients will comprise the usual care group (UCG), or control cohort, defined as receiving pain assessment and management practices that nurses are currently performing on the study units. In phase 2 the PAIN Algorithm coupled with analgesic order sets will be introduced to nurses and physicians on all participating units as the intervention. Patients enrolled in this phase will be considered the intervention group (IG), also called the experimental cohort. Nurses will be enrolled from the participating inpatient units to provide data on the clinical utility of the PAIN Algorithm
3334100|NCT02127099||Patients with OSA|Post operative patients with OSA
3334101|NCT02127099||Post-operative Patients without OSA|All post operative patients without OSA
3334102|NCT02127112|Active Comparator|Block Allograft plus Matrix Allograft|The positive control treatment will include a block allograft plus a demineralized bone matrix moldable allograft.
3234468|NCT01231802|Experimental|Arm 1: Eniluracil/5-FU/Leucovorin|Arm 1: (weekly, 28-day cycle): Approximately eighty subjects will orally self-administer eniluracil approximately 13 hr (range of 11-16 hr) before receiving 5 FU and leucovorin. The next day they will orally self-administer 5-FU and leucovorin. On the third day, they will orally self-administer leucovorin. The regimen is taken once per week for three consecutive weeks followed by one-week off-treatment.
3234469|NCT01231802|Active Comparator|Arm 2: Capecitabine|Arm 2: (bid daily, 21-day cycle): Approximately sixty subjects will self-administer oral capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
3334103|NCT02127112|Experimental|Moldable Matrix Allograft|In the test arm of the study the treatment will include a demineralized bone matrix moldable allograft.
3334104|NCT02127138|Experimental|ATP technique|This arm plan to enroll 158 subjects，Sirolimus-eluting Drug stent implantation via Active transfer of Plaque technique in the treatment of unprotected distal left main bifurcation lesions.In the ATP technique treatment of bifurcation lesions, by the balloon pre-dilation in the target side branch, the plaque will be actively transferred from side branch to main vessel. Subsequently, the plaque will be fixed by the expansive stent in main vessel. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI or stent in SB is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
3334105|NCT02127138|Active Comparator|Provisional T stenting technique|This arm plan to enroll 158 subjects.Sirolimus-eluting Drug stent implantation via Provisional T Stenting technique in the treatment of unprotected distal left main bifurcation lesions.Provisional T stenting technique is the typic step-T stenting. In brief, two wires are advanced to distal MV and SB. Pre dilation is left at operator's discretion, however, pre dilating SB is not encouraged. Kissing balloon inflation before stenting MV is left at operator's discretion. A stent with stent/artery ratio of 1.1:1 is inflated in MV. Rewire to SB is also left at operator's discretion. FKBI is recommended if there is at least one of following: residual stenosis>70%, >type B dissection and TIMI flow<3.
3334106|NCT02127151|Experimental|BMN 673|BMN 673 daily until progression, death, unacceptable toxicity, withdrawal of consent or any other criterion felt by the Investigator to preclude continuation of treatment.
3334107|NCT02127164|Experimental|"Veraflo device, Dakin's solution"|
3334108|NCT02127177|Experimental|Cpap|
3334109|NCT02127177|No Intervention|No Cpap|
3334110|NCT02127190|Placebo Comparator|CXA-10 placebo emulsion|single intravenous dose of CXA 10 placebo emulsion
3334111|NCT02127190|Experimental|CXA-10 Emulsion|single ascending intravenous doses of CXA-10 emulsion
3334112|NCT02127203||Chronic Periodontitis group (ChP)|20 patients aged > 45 years and have presence of ≥2 non-adjacent sites per quadrant that were not first molars or incisors, with probing depth (PD) ≥5 mm, which bleed on gentle probing. The demonstrated radiographic bone loss ≥30% of the root length, patient with poor oral hygiene, the amount of accumulated plaque commensurate with the amount of clinical attachment level (CAL)
3334113|NCT02127203||Resistant Control group (R)|20 age-sex matched patients who are > 45 years exhibit no signs of periodontal disease as determined by the absence of the evidence of interproximal (CAL ≤ 1mm), PD > 3 mm at any site, whole-mouth bleeding scores <10% and have no clinical signs of gingival inflammation .
3334114|NCT02127203||Aggressive Periodontitis group (AgP)|20 patients who are aged < 35 years and diagnosed with rapid attachment loss with periodontal pocket depth (PD) > 4 mm around at least three teeth other than the first molars and incisors. Rapid bone destruction (>50%bone loss at diseased sites). Weak relationship between dental plaque and the severity of gingival inflammation.
3334115|NCT02127203||Young Control group (YC)|20 age- and sex matched patients who are < 35 years and exhibit no signs of periodontal disease.
3334116|NCT02127216|No Intervention|Standard of Care Group - A|The control group
3334117|NCT02127216|Active Comparator|MOSES - Group B|Individual patients using application and pedometer without healthcare provider support
3334118|NCT02127216|Active Comparator|MOSES - Group C|Individual patients using application and pedometer with healthcare provider support
3334119|NCT02127216|Active Comparator|MOSES - Group D|Peer patient teams using application and pedometer without healthcare provider support
3234470|NCT01231815|Experimental|PET|15O-H2O PET
3234471|NCT01231815|Experimental|MRI|MRI
3234472|NCT01231828|Experimental|Carnitine|Versus placebo.
3234473|NCT01231828|Experimental|Lactulose|Versus placebo
3234474|NCT01231854|Active Comparator|Ciclosporingroup|
3234475|NCT01231854|Active Comparator|Alitretinoingroup|
3234476|NCT01231880|Experimental|Four monthly IPT|IPT give once a school term (every four months)
3234477|NCT01231880|Experimental|Monthly IPT|IPT given every month
3334120|NCT02127216|Active Comparator|MOSES - Group E|Peer patient teams using application and pedometer with healthcare provider support
3334121|NCT02127229|No Intervention|Blinded observation of ERCP|Blind observation of disposable accessories use.
3334122|NCT02127229|Experimental|Endoscopist informed of cost per procedure|Endoscopists informed following each ERCP.
3334123|NCT02127242|Experimental|air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
3334124|NCT02127242|No Intervention|hepatectomy group|Hepatic resection using an open approach is performed for all segments affected by biliary stenosis and the affected bile duct drainage area.Hepaticojejunostomy is performed in patients with common bile duct stenosis and in those considered to be at high risk for recurrence.
3334125|NCT02127255|Active Comparator|A (Acupuncturist 1)|Manual acupuncture implemented by acupuncturist 1 (clinical experience >15 years)
3234478|NCT01231880|Placebo Comparator|Placebo|No active drug in the placebo
3234479|NCT01231893|Experimental|olfactory ensheathing cell recipient|
3234480|NCT01231893|Active Comparator|control|
3334126|NCT02127255|Active Comparator|B (Acupuncturist 2)|Manual acupuncture implemented by acupuncturist 2 (clinical experience < 5 years)
3334127|NCT02127268|Active Comparator|Arm T|Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy
3334128|NCT02127268|No Intervention|Arm B|With best support according to NCCN Guideline
3334129|NCT02127294|Experimental|Transcatheter closure group|Migraine patients with patent foreman ovale (PFO)，who meet the criteria and agree to conduct closure of patent foramen ovale will be selected to this group.
3334130|NCT02127294|No Intervention|Contrast group|Migraine patients with PFO，who meet the criteria but don't agree to conduct closure of patent foramen ovale will be selected to this group.
3334131|NCT02127320|Experimental|Sequence 1|Rosuvastatin 20mg → Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg
3334132|NCT02127320|Experimental|Sequence 2|Rosuvastatin 20mg and Ezetimibe 10mg→ Rosuvastatin 20mg → Ezetimibe 10mg
3234481|NCT01231919|Experimental|Treatment (Akt inhibitor)|Patients receive oral Akt inhibitor MK2206 every other day (schedule 1) OR once weekly (schedule 2) on days 1-28. Treatment repeats every 28 days for up 12 courses (1 year) in the absence of disease progression or unacceptable toxicity.
3234485|NCT01231971||Cognitively Normal (CN)|150 newly enrolled participants with no apparent memory problems, and CN participants followed from the ADNI1 study
3234486|NCT01231971||Early Mild Cognitive Impairment (EMCI)|100 newly enrolled early amnestic MCI participants, and approximately 200 EMCI participants will be followed from the ADNI-GO study
3234487|NCT01231971||Late Mild Cognitive Impairment (LMCI)|150 newly enrolled late MCI participants, and LMCI participants followed from the ADNI1 study
3234488|NCT01231971||Alzheimer's Disease (AD)|150 newly enrolled mild AD participants
3234489|NCT01231971||Significant Memory Concern (SMC)|100 newly enrolled participants with Significant Memory Concern (SMC)
3234490|NCT01231997|Experimental|Healthy Volunteers|
3234491|NCT01231997|Experimental|Patients with mild renal impairment|
3234492|NCT01231997|Experimental|Patients with moderate renal impairment|
3234493|NCT01231997|Experimental|Patients with severe renal impairment|
3234494|NCT01232010|Experimental|Healthy Volunteers|
3234495|NCT01232010|Experimental|Patients with severe renal impairment|
3234496|NCT01232023|Experimental|100mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3234497|NCT01232023|Experimental|200mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3234498|NCT01232023|Experimental|400mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3234499|NCT01232023|Experimental|800mg|Wild type UGT1A : 3 / Variant type UGT1A : 3
3234500|NCT01232036|Active Comparator|A|Reference
3234501|NCT01232036|Experimental|B|Test
3234502|NCT01232036|Placebo Comparator|C|Placebo
3234503|NCT01232049|Experimental|A|Pitavastatin 4mg
3234504|NCT01232049|Experimental|B|Valsartan 320mg
3234505|NCT01232049|Experimental|C|Pitavastatin 4mg + Valsartan 320mg
3234506|NCT01232075|Experimental|Extended letrozole regimen|
3234507|NCT01232075|Active Comparator|Clomiphene citrate regimen|
3234508|NCT01232088||Data collection group: ICU physicians|Online survey for ICU physicians (members of the European Society of Intensive Care Medicine (ESICM)).
3234509|NCT01232101|Active Comparator|covered self expandable metallic stents|Patients with bile malignant bile duct strictures are randomized to covered or uncovered stent
3234510|NCT01232101|Active Comparator|Uncovered self expandable metallic stent|
3234511|NCT01232140|Experimental|CRP-guided antibiotic treatment|If CRP> 50 mg/l a patient receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment is withheld.
3234512|NCT01232140|Other|GOLD strategy-antibiotic treatment|According to the GOLD strategy a patient with an AECOPD should prescribed antibiotic treatment if a patient has symptoms of increased dyspnea, increased sputum production and change of sputum color. Two of these three criteria should be present, however change in sputum production is obligatory.
3234513|NCT01232153|Active Comparator|NIV preoxygenation|
3234514|NCT01232153|No Intervention|Classical preoxygenation|
3234515|NCT01232166|Experimental|Endobronchial Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
3334133|NCT02127320|Experimental|Sequence 3|Ezetimibe 10mg → Rosuvastatin 20mg and Ezetimibe 10mg → Rosuvastatin 20mg
3334134|NCT02127320|Experimental|Sequence 4|Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg → Rosuvastatin 20mg
3334135|NCT02127320|Experimental|Sequence 5|Ezetimibe 10mg → Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg
3334136|NCT02127320|Experimental|Sequence 6|Rosuvastatin 20mg → Rosuvastatin 20mg and Ezetimibe 10mg → Ezetimibe 10mg
3334137|NCT02127333||CAD patients with COPD|
3234516|NCT01232166|Active Comparator|Endobronchial Intubation, Observation|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
3334138|NCT02127333||CAD patients without COPD|
3334139|NCT02127333||healthy volunteers|
3334140|NCT02127346||Chronic Periodontitis|"Male patients~Patients are suffering from chronic periodontitis~Patients do not have any systemic diseases~Subjects should have 20 teeth at least~Age: 30 years or greater"
3334141|NCT02127346||Healthy Volunteers|"Males~Healthy with no systemic diseases or periodontitis~30 years old at least~20 teeth are present at least"
3334142|NCT02127359||Lung/Colon Adenocarcinomas|Metastatic lung and colon adenocarcinomas
3334143|NCT02127385||IUGR|
3334144|NCT02127398|Experimental|fecal microbiota transplantation|fecal microbiota transplantation
3334145|NCT02127411|Experimental|Mindfulness-based relapse prevention|Mindfulness-Based Relapse Prevention
3334146|NCT02127411|No Intervention|Waitlist|this group will stay in the waitlist until the end of follow-up assessments, when they will receive the intervention
3334147|NCT02127424|Experimental|Combination of the nurse-driven HIV targeted screening and the|Nurses will offer screening to all patients at EDs, aged 18-64 years old, identified as high-risk by a self-administered questionnaire, not know to be HIV positive, accepting to participate by providing an informed consent and not being seen at ED for post-exposure prophylaxis or unstable medical illness. The questionnaire was previously tested in one ED. In case of reactive rapid test result, blood specimen will be collected for standard enzyme-linked immunosorbent assay and Western blot confirmation. A follow-up visit with an on-site infectious disease specialist will be arranged within the following 48 hours.
3334148|NCT02127424|Active Comparator|Current practice (no intervention)|Physician-directed HIV diagnostic testing
3334149|NCT02127437|Experimental|A - treated group|
3334150|NCT02127437|Placebo Comparator|B - control group|
3334151|NCT02127450||Case: NS-CARB positive|Patient with a clinical sample positive for a NS-CARB Enterobacteriaceae
3334152|NCT02127450||Control 1: non-NS-CARB positive|Patient with clinical sample positive for a non-NS-CARB Enterobacteriaceae
3334153|NCT02127450||Control 2 : negative sample|Patient having had clinical sample(s) being stayed negative since the beginning of his admission and up to 3 days after the detection of the case
3334154|NCT02127463|Experimental|MC-1101 active|Topical Drug 1% Ophthalmic Solution Topically, two times per day; morning and bedtime
3334155|NCT02127463|Placebo Comparator|MC-1101 Vehicle Control|"Topical Drug:~Ophthalmic Solution Topically, two times per day; morning and bedtime"
3334156|NCT02127476|Experimental|KHK6640|KHK6640
3334157|NCT02127476|Placebo Comparator|Placebo|Placebo
3334158|NCT02127489|Active Comparator|Midazolam|1 mL/kg bupivacaine 0.25%.
3334159|NCT02127489|Placebo Comparator|saline|5mL rectal saline
3334160|NCT02127502||Critically ill patients sepsis suspected|
3334161|NCT02127515|Experimental|Non Invasive Prenatal Testing|Blood sample
3334162|NCT02127515|Active Comparator|Invasive Prenatal Testing|CVS or amniocentesis
3334163|NCT02127541|Experimental|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|This is a cross-over study comparing three imaging methods (68Ga-DOTA-exendin-4 PET/CT, 111In-DOTA-exendin-4 SPECT/CT, MRI) in the same patient.
3234517|NCT01232166|Active Comparator|Endobronchial intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
3334164|NCT02127554||Electric coagulation|Patients with anterior epistaxis, treated with electric coagulation
3334165|NCT02127554||Chemical coagulation|Patients with anterior epistaxis, treated with chemical coagulation
3334166|NCT02127554||Outpatient tamponade|Patients with posterior epistaxis, treated with tamponade as an outpatient
3334167|NCT02127554||Inpatient tamponade|Patients with posterior epistaxis, treated with tamponade and kept in the hospital.
3334168|NCT02127554||Surgery|Patients with posterior epistaxis, treated with surgery as inpatients
3334169|NCT02127554||Foley balloon catheter|Patients with posterior epistaxis, treated as inpatients with Foley balloon catheter
3334170|NCT02127554||Combined treatment|Patients with posterior epistaxis, treated as inpatients with a combination of methods
3334171|NCT02127580||with BAV|Patients undergoing TA-TAVI WITH predilation of the AV (Group A)
3334172|NCT02127580||without BAV|Patients undergoing TA-TAVI WITHOUT predilation of the AV
3334173|NCT02127593|Experimental|First NGM/EE (Wet Process), then NGM/EE (Dry Process)|Participants will receive 1 tablet (formulated by wet process) containing norgestimate 250 microgram (mcg) and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
3334174|NCT02127593|Experimental|First NGM/EE (Dry Process), then NGM/EE (Wet Process)|Participants will receive 1 tablet (formulated by dry process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 1, followed by 1 tablet (formulated by wet process) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, orally on Day 1 of Period 2, wherein Period 1 and Period 2 are separated by a wash out period of at least 10 days.
3334175|NCT02127606|Experimental|Vibration with tilt-table standing|Participants in this arm will undergo alternating side-to-side, whole body vibration while standing on a tilt table for multiple treatments for a total of approximately 14 minutes for 3 sessions over 3 different days
3334176|NCT02127645|Experimental|Early Rectal Cancer|patients with T1 - T2, N0, G1-2 rectal cancer
3334177|NCT02127658|Active Comparator|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
3334178|NCT02127658|Active Comparator|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
3334179|NCT02127671|Experimental|IDEAL intervention|Individual cardiovascular risk reduction counseling, coordination with primary care providers to ensure appropriate management of risk factors, and collaboration with mental health staff and social supports. All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
3234518|NCT01232166|Active Comparator|Endobronchial intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned in the right main stem bronchus under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
3234519|NCT01232166|Experimental|Endotracheal Intubation, Auscultation|In this arm, the endotracheal tube will be positioned in the trachea, 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. The study anesthesiologists will then perform bilateral auscultation of the lungs only, with the patient's thorax and head covered with blankets to blind participants to thorax movements and ETT insertion depth (Group Auscultation, n=20)
3234520|NCT01232166|Active Comparator|Endotracheal Intubation, observation|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5-3cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform observation and palpation of symmetric chest movements without auscultation of the lungs, with the patient's head covered with blankets to blind participants to ETT insertion depth (Group Observation, n=20);
3334180|NCT02127671|Other|Control|All participants will be offered group exercise classes, and programs will be provided with instruction to provide more healthy meals.
3334181|NCT02127684|Active Comparator|Standard Dosing Group|Standard Dosing Group will receive intravitreal injections of 0.3mg. ranibizumab at baseline, week 4 and 8 )sham injections at week 2 and 6). After week 8 retreatment will be given monthly if edema is greater than 290um or ETDRS visual acuity score <83
3334182|NCT02127684|Experimental|Frequent dosing group|Frequent dosing subjects will be evaluated and treated every two weeks through week 8 with intravitreal injection of 0.3mg ranibizumab. Subjects will then be evaluated monthly through week 24 and will receive treatment with ranibiumab based on residual edema and visual acuity
3334183|NCT02127697|Experimental|NVA237|Participants will receive NVA237 once daily in addition to their background therapy during the 52- week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
3334184|NCT02127697|Placebo Comparator|Placebo|Participants will receive placebo to NVA237 in addition to their background therapy during the 52-week treatment period. All participants will receive salbutamol/ albuterol as rescue medication.
3334185|NCT02127736|Experimental|Experimental group|
3334186|NCT02127736|Placebo Comparator|Control group|
3334187|NCT02127749|Experimental|Control|Subjects are not pretreated with antibiotics Subjects receive 2 ng/kg endotoxin intravenously
3334188|NCT02127749|Experimental|Antibiotics|Subjects are pretreated with broad-spectrum antibiotics: Vancomycin, Metronidazole, Ciprofloxacin Subjects receive 2 ng/kg endotoxin intravenously
3334189|NCT02127762|Experimental|Mindfulness Based Stress Reduction|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) program following medical treatment optimization. The MBSR program will be composed of eight weekly 2.5 hour sessions and one 6 hour session midway through the course.
3334190|NCT02127762|No Intervention|Wait-listed Control Group|Participants assigned to this group after medical treatment optimization will act as wait-list controls for the MBSR group. They will be enrolled in the MBSR workshop 3 months after the corresponding intervention group completes the program.
3334191|NCT02127775|Experimental|Sequence B|Day 1: Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)
3334192|NCT02127775|Experimental|Sequence A|Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)
3334193|NCT02127788||Micafungin|Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin.
3334194|NCT02127801|Experimental|Group A|Participants in group A will receive REGN1908-1909
3334195|NCT02127801|Experimental|Group B|Participants in group B will receive placebo
3334196|NCT02127814|Experimental|L. reuteri|
3334197|NCT02127814|Placebo Comparator|Identical Placebo|
3334198|NCT02127827|Experimental|investigational device off|
3334199|NCT02127840|Experimental|Synacthen|Synacthen infusion during adrenal venous sampling
3334200|NCT02127840|No Intervention|Without Synacthen|Adrenal venous sampling without Synacthen
3334201|NCT02127853|Experimental|Gabapentin|gabapentin pretreatment
3334202|NCT02127853|Placebo Comparator|Placebo|placebo drug pretreatment
3334203|NCT02127866|Experimental|CHF 5259 25 µg plus Foster 100/6 µg|
3334204|NCT02127866|Experimental|CHF 5259 50 µg plus Foster 100/6 µg|
3334205|NCT02127866|Experimental|CHF 5259 100 µg plus Foster 100/6 µg|
3334206|NCT02127866|Active Comparator|Foster 100/6 µg|
3334207|NCT02127879|Experimental|Transcranial Magnetic Stimulation|Active Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
3334208|NCT02127879|Sham Comparator|Transcranial Magnetic Stimulation with sham coil|Sham coil Treatment 10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC)
3334209|NCT02127905|Other|CD34+ selected cells|use of unrelated bone marrow or peripheral blood for hematopoietic stem cell transplantation with CD34+ selected cells
3334210|NCT02127918||ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
3334211|NCT02127944||FERTILE GROUP|WOMEN HAVE NO INFERTILITY PROBLEMS AND HAVE AT LEAST ONE CHILD
3334212|NCT02127944||UNEXPLAINED INFERTILE GROUP|WOMEN WITH INFERTILITY PROBLEMS,NO HISTORY OF PREGNANCY AND HAVE NO CHILDREN
3334213|NCT02127957|Other|Exercise|Exercise group will have 6 visit and 8 phone call. Subject will have to do prescribed exercice for 1h, 3 times a week for 12 weeks.
3234521|NCT01232166|Active Comparator|Endotracheal intubation, tube depth|In this arm, the endotracheal tube (ETT) will be positioned in the trachea, 2,5 - 4 cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then estimate ETT position by observing the ETT cm scale without lung auscultation, with the patient's thorax covered by blankets to blind participants to thorax movements (Group Tube Depth, n=20)
3234522|NCT01232166|Active Comparator|Endotracheal intubation, all three|In this arm, the endotracheal tube (ETT) will be positioned 2,5-4cm above the carina under direct visualization through a fiberoptic bronchoscope. To determine the position of the ETT the study anesthesiologists will then perform a combination of auscultation, observation and tube depth
3334214|NCT02127957|No Intervention|Control|Control group will have 4 visit and 3 phone call. They will receive standard counselling for exercise in cystic fibrosis, but no prescribed exercice will be given.
3334215|NCT02127983|Experimental|Early intervention|Early intervention arm engaging informal providers Received the intervention early in the first 12 months
3334216|NCT02127983|Active Comparator|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
3334217|NCT02127996|Placebo Comparator|Normal Saline|Infusion of Normal Saline during Percutaneous Coronary Intervention
3334218|NCT02127996|Experimental|GLP-1|Infusion of GLP-1 (7-36) amide during elective percutaneous coronary intervention
3234523|NCT01232179|Active Comparator|conventional prp|
3234524|NCT01232179|Active Comparator|targeted PRP|
3334219|NCT02128009||osteoporosis,non-osteoporosis|
3334220|NCT02128022|Experimental|GLP-1 (7-36) amide and Glibenclamide|Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
3334221|NCT02128022|Experimental|Glibenclamide alone|Glibenclamide 5 mg orally prior to PCI
3334222|NCT02128022|Active Comparator|GLP-1 (7-36) amide|GLP-1 (7-36) amide
3334223|NCT02128022|No Intervention|Saline control|0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)
3334224|NCT02128035|No Intervention|Without Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~The LEAD SHIELD will not be used in this group.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
3334225|NCT02128035|Experimental|With Lead Shield|"All routine measures to reduce radiation exposure (including lead aprons, lead collar, lead lenses, movable ceiling suspended lead shield with a long lead skirt attached to its lower margin) will be used as done routinely and will be left to the operators' discretion.~In this group, a LEAD SHIELD will be used. The Pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
3334226|NCT02128048||Heavy smokers|Assessment of body composition and muscle function
3334227|NCT02128061|Active Comparator|R-miniCHOP|"All patients will be treated with R-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² Day 1 (D1) DOXORUBICINE IV : 25 mg/m² D1 VINCRISTINE IV : 1 mg Total Dose (TD) D1 PREDNISONE PO : 40 mg/m² D1 to D5 RITUXIMAB SC* : 1400 mg TD D1~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
3334228|NCT02128061|Experimental|R2-miniCHOP|"All patients will be treated with R2-miniCHOP at a three-weeks interval for 6 cycles CYCLOPHOSPHAMIDE IV: 400 mg/m² D1 - DOXORUBICINE IV : 25 mg/m² D1 - VINCRISTINE IV : 1 mg TD D1 - PREDNISONE PO : 40 mg/m² D1 to D5 - RITUXIMAB SC* : 1400 mg TD D1 LENALIDOMIDE PO** :10 mg TD D1 to D14~*The first cycle of rituximab is delivered by IV at the dose of 375 mg/m2"
3334229|NCT02128087|No Intervention|Control group|This study arm will receive care as usual.
3334230|NCT02128087|Experimental|Two-way SMS intervention group|"Two-way messages allow the recipient of the SMS message (the patient) to respond to the messages (We hope you are feeling well today. Reply 1 if well, 2 if unwell) to request a follow-up call from the clinic."
3334231|NCT02128087|Experimental|One-way SMS intervention group|"Clients will receive a weekly one-way SMS with the message We hope you are feeling well today. There will be no prompt for response."
3334232|NCT02128100|Experimental|Folririnox with SBRT|"Folfirinox~Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours~SBRT 5 treatments of stereotactic body radiation therapy (SBRT) over the course of two weeks with a minimum of 36 hours in between each treatment."
3334233|NCT02128113|Placebo Comparator|Placebo ophthalmic solution|Placebo ophthalmic suspension, one drop, applied twice daily for a maximum of 28 days
3334234|NCT02128113|Experimental|0.5% omaveloxolone (RTA 408) opthalmic suspension|0.5% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
3334235|NCT02128113|Experimental|1% omaveloxolone (RTA 408) opthalmic suspension|1% omaveloxolone ophthalmic suspension, one drop applied twice daily for a maximum of 28 days
3334236|NCT02128126|Experimental|ISA101/ISA101b|The maximum total treatment duration for a patient is six cycles (1 cycle is 21 days) for a total of 18 weeks. On day 15 of cycles 2, 3 and 4 patients are to receive the vaccination scheme of ISA101/ISA101b. Patients will be vaccinated with a fixed dose of ISA101/ISA101b every three weeks for a total of three rounds of vaccination. Four dose levels of ISA101 have been tested. ISA101b will be tested in bridging cohorts.
3334237|NCT02128152|Experimental|Ekso Training Safety and Efficacy|
3334238|NCT02128165|Active Comparator|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
3334239|NCT02128165|Active Comparator|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere)those BMI below 45
3234525|NCT01232192|No Intervention|Antenatal model|
3234526|NCT01232192|Experimental|Antenatal Model|
3334240|NCT02128178|Active Comparator|ENOXAPARIN 2 HOURS BEFORE|Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
3234527|NCT01232218|Active Comparator|Current Standard Treatment|Current standard treatment for hemiplegic shoulder pain will be provided to this group.
3334241|NCT02128178|Active Comparator|Enoxaparin 40 mg 12 hours before|Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
3334242|NCT02128191|Active Comparator|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by 2 doses of 5 mg/kg 24 and 48 h later
3334243|NCT02128191|Placebo Comparator|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
3334244|NCT02128204|Experimental|HYADERMIS LA Facial Dermal Implant|Subjects will be randomly assigned to receive experiment treatment, lidocaine contained hyaluronate facial dermal filler, in one side of the face.
3334245|NCT02128204|Active Comparator|Hya-Dermis Facial Dermal Implant|Subjects will be randomly assigned to receive control treatment, hyaluronate facial dermal filler, in one side of the face.
3334246|NCT02128243|Experimental|Arm A: De-escalation therapy|Patients in Arm A will continue with S-1 de-escalation phase starting at week 13 until disease progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or lost to follow up whichever occurs first. In patients with drug-related severe toxicity S-1 dose will be adjusted or study treatment will be terminated.
3234528|NCT01232218|Experimental|Standard treatment + study technique|Participants will receive current standard treatment for hemiplegic shoulder pain PLUS an additional stretching/strengthening technique. Both groups will be allotted the same treatment time.
3234529|NCT01232231|Active Comparator|decolonization treatment|topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
3234530|NCT01232231|Other|education|No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
3234531|NCT01232244||Healthy young males|
3234532|NCT01232257|Experimental|Healthy volunteers|
3234533|NCT01232257|Experimental|CKD patients|Patients with CKD stage 3-4 (GFR 15-60 ml/min)
3334247|NCT02128243|Experimental|Arm B: Chemotherapy by Investigator's choice|Patients in Arm B will continue to receive the same polychemotherapy as during induction therapy until tumor progression, toxicities requiring discontinuation, withdrawal of consent, pregnancy, death or loss to follow up whichever occurs first.
3334248|NCT02128256|Experimental|Cerament G injection|Cerament G is injected to fill a bone defect after debridement of the infected bone.
3334249|NCT02128282|Experimental|Escalation CX-4945 plus Cis/Gem|"CX-4945 capsules at the combination MTD on Days 0, 1 and 2, and Days 7, 8 and 9.~PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle."
3334250|NCT02128282|Active Comparator|Cisplatin plus Gemcitabine|Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
3234534|NCT01232257|Experimental|Hemodialysis patients|
3334251|NCT02128282|Experimental|10-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 10-day continuous dosing (Day 0 through Day 9). PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
3334252|NCT02128282|Experimental|21-day CX-4945 plus Cis/Gem|CX-4945 capsules at 1000mg/BID, 21-day continuous dosing PLUS Cisplatin 25 mg/m.sq. by IV infusion on Days 1 and 8. PLUS Gemcitabine 1,000 mg/m.sq. by IV infusion on Days 1 and 8. On a 21-day cycle.
3334253|NCT02128295|Experimental|Primiparous mothers|Mother who are primiparous
3334254|NCT02128295|Experimental|Multiparous mothers|Mothers who are multiparous
3334255|NCT02128308|Experimental|Levofloxacin and Streptomycin added|Levofloxacin and Streptomycin added : Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Levofloxacin 750mg (500mg x 1.5 tab) qd, Streptomycin 1g IM qd
3334256|NCT02128308|Experimental|Moxifloxacin and Kanamycin added|Cycloserine(CS) 250mg bid, P-aminosalicylic acid(PAS) 2 pack bid, Prothionamide(PTH) 250mg (125mg x 2 tab) bid, Pyrazinamide(PZA) 1500mg (500mg x 3 tab) qd, Moxifloxacin 400mg (400mg x 1 tab) qd, Kanamycin 1g IM qd
3334257|NCT02128321|Experimental|Isavuconazole + Repaglinide + Caffeine|Isavuconazole three times a day on Days 5 and 6 and once a day on Days 7 through 17, repaglinide on Days 1 and Day 14, caffeine on Days 3 and 16
3334258|NCT02128334||Patients with advanced prostate carcinoma|
3334259|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and healthcare workers to communicate through a secure, password protected online portal with data transfer capabilities. Effectiveness of the portal in improving several health outcomes from baseline-12 months will be assessed in this study.
3334260|NCT02128360|Active Comparator|Minimal stimulation protocol|Low dose Letrozole 2.5 mg over 5 days, starting from cycle day 2, overlapping with low dose gonadotropins, starting from day 3 of the Letrozole at 150 units per day. GnRH antagonist to avoid premature LH surge will be introduced when one or more of the growing follicles reached approximately 14 mm in size
3334261|NCT02128360|Active Comparator|High dose protocol|High dose of gonadotropins (≥300 IU/day) starting from cycle day 3. GnRH antagonist will be introduced to avoid premature LH surge when one or more of the growing follicles will reach approximately 14 mm in size
3334262|NCT02128373|Active Comparator|Arm I (usual care)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers are not present. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer
3234535|NCT01232257|Experimental|Peritoneal dialysis patients|
3234536|NCT01232270|Active Comparator|fentanyl|
3234537|NCT01232270|Placebo Comparator|saline|
3334263|NCT02128373|Experimental|Arm II (usual care with CLOSER intervention)|Participants receive usual care (care from physician, physician nurse, and social worker) for 5 weeks. During the week 5 office visit, distance caregivers will use a computer-assisted intervention to be present electronically with video and audio feed to provide psychosocial support. In the pre-physician interview patients will verbally complete the FACT, POMS-B, Tension-Anxiety subscale, Distress Thermometer. Distance caregivers will verbally complete the POMS-B, Tension-Anxiety subscale, and Distress Thermometer. Up to 96 hours after the week 5 visit, patients and caregivers will be interviewed about their experience during the intervention
3334264|NCT02128386||Renal sympathetic denervation|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus renal sympathetic denervation
3334265|NCT02128386||Intensified antihypertensive treatment|Olmesartan 40 mg once daily + Amlodipine 5 or 10 mg once daily + Hydrochlorothiazide 25 mg one daily plus second-line antihypertensive agents (e.g. mineralocorticoid receptor antagonists or alpha-1-blockers)
3334266|NCT02128399||patients before and after intervetion|
3334267|NCT02128412|Active Comparator|Stent oversize group|"Oversized stent deployed at low pressure:~A stent premounted on a balloon with a nominal diameter halfway between the lumen diameter and the true vessel diameter (approximated by external elastic lamina) as assessed by IVUS. This will be based on the smallest of the vessel reference diameters proximal and distal to the lesion. In addition the vessel diameter must be greater than this diameter throughout the length of the lesion. This stent will be implanted at an inflation pressure of 10 atmospheres or less for at least 15 seconds and a second IVUS will be performed to assess the end point."
3334268|NCT02128412|Active Comparator|High pressure group|"Stent deployed at high pressure:~A stent premounted on a balloon with a nominal diameter approximately equal to the vessel segment lumen reference diameter as previously assessed by IVUS will be used. This stent will be implanted at an inflation pressure of 14 atmospheres or more for at least 15 seconds and a second IVUS will be performed to assess the end point"
3334269|NCT02128425|Experimental|FOLFOXIRI|FOLFOXIRI
3334270|NCT02128425|Active Comparator|FOLFOX|FOLFOX
3334271|NCT02128451|Active Comparator|Meperdine group|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
3334272|NCT02128451|Active Comparator|Fentanyl group|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
3334273|NCT02128464|Active Comparator|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
3334274|NCT02128464|Active Comparator|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
3334275|NCT02128503|Other|HBV DNA level monitoring|Group with HBV DNV level being monitored regularly
3334276|NCT02128516|Active Comparator|whey protein|whey protein
3334277|NCT02128516|Placebo Comparator|placebo|placebo
3334278|NCT02128516|Experimental|pea protein|pea protein
3334279|NCT02128529||Chronic obstructive pulmonary disease|Patients with chronic obstructive pulmonary disease will undergo a single visit with the collection of data from his/her records.
3334280|NCT02128555|Active Comparator|Arthrodesis|Ankle arthrodesis (fusion)
3334281|NCT02128555|Experimental|Total Ankle Replacement|Total Ankle Replacement
3334282|NCT02128568|Active Comparator|Waitlist + YRI only|Participants will complete the assessment and collection of biomarkers and be placed on a waitlist. Once the trial of the first arm has been concluded, participants complete another round of assessments and are offered the YRI sessions. The epigenetic biomarkers collected will be compared with the experimental arm.
3334283|NCT02128568|Experimental|YRI only|Immediately following assessment and collection of biomarkers, participants will be offered the YRI sessions.
3334284|NCT02128581|Placebo Comparator|Saline|a saline infusion will be started and maintained till the end of the study at 1300 (300 minutes).
3334285|NCT02128581|Active Comparator|Exendin-9,39 @ 300|Exendin-9,39 @ 300pmol/kg/min
3334286|NCT02128581|Active Comparator|Exendin-9,39 @ 750|Exendin-9,39 @ 750pmol/kg/min
3234538|NCT01232309|Active Comparator|High Dose Chitin-Glucan|Daily oral dose of 4.5 g of chitin-glucan
3234539|NCT01232309|Active Comparator|Low Dose Chitin-Glucan|Daily oral dose of 1.5 g chitin-glucan
3334287|NCT02128594|Experimental|Standard of Care|Standard of care
3334288|NCT02128607|Active Comparator|Real SNAG|A real sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
3334289|NCT02128607|Placebo Comparator|Sham SNAG|A sham (placebo) sustained natural apophyseal glide (SNAG / Mulligan technique) applied on the lumbar spine from a sitting position, and in a trunk flexion direction with the use of the belt.
3334290|NCT02128620|No Intervention|Control Group|Users randomized to the www.sjekkdeg.no A version, consisting en the educative web app, not including the Game-Based Appointment System
3334291|NCT02128620|Experimental|Intervention Group|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
3334292|NCT02128633|Placebo Comparator|placebo|"Individuals that were randomized for treatment  A  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  A  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Placebo gel)."
3234540|NCT01232309|Experimental|Low Dose Chitin-Glucan + Olive Extract|Daily oral dose of 1.5 g chitin-glucan + 135 mg olive extract
3234541|NCT01232309|Placebo Comparator|Placebo|Placebo (Rice Flour)
3234542|NCT01232322||Pulmicort Respules|Those with an exposure
3234543|NCT01232348||Symbicort|Those with an exposure
3334293|NCT02128633|Experimental|Experimental gel|"Individuals that were randomized for treatment  B  - The product was delivered in a transparent plastic syringe with 10 mls identified by the letter  B . The syringes were given to individuals in an opaque plastic envelope sealed and with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (5% sodium fluoride, potassium oxalate 5%, strontium chloride 10% ) ."
3334294|NCT02128633|Active Comparator|Positive control|"Individuals that were randomized for treatment  C  . The product tested were always delivered in a transparent plastic syringe with 10 mls marking identified by the letters  C  . The syringes were given to individuals in an opaque plastic envelope sealed and delivered along with a reminder of the correct way to use the products. Guidance for the use of substances was to make application with a new toothbrush, 1 time a day (at night, before bed, after brushing the teeth) with the product received, for 1 minute and the amount of 0.25 g (0.5 ml) of the product as the demarcation the syringe. It was recommended that after using the products, they were expelled without rinsing the oral cavity with water (Fluoride neutral NaF gel 2 %)."
3334295|NCT02128646|Experimental|Treatment Group 1|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 1 will have an open surgery for abdominal hernia repair.
3334296|NCT02128646|Experimental|Treatment Group 2|Treatment Group patients will receive an opioid-sparing, multimodal, postsurgical pain regimen consisting of intraoperative local wound infiltration with 266 mg EXPAREL followed by, when not contraindicated, administration of a 30 mg dose of IV ketorolac at the end of surgery. Patients scheduled in Treatment Group 2 will have a laparoscopic abdominal hernia repair.
3334297|NCT02128646|Active Comparator|Control Group 1|Patients scheduled in Control Group 1 will have an open surgery for abdominal hernia repair. The Control Group patients will receive traditional treatment.
3334298|NCT02128646|Active Comparator|Control Group 2|Patients scheduled in Control Group 2 will have laparoscopic abdominal hernia repair. The Control Group patients will receive traditional treatment.
3234544|NCT01232361||Methylphenidate|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
3334299|NCT02128659|Experimental|SHE Project|Receives SHE Project Intervention during Week 1 of enrollment
3334300|NCT02128659|Active Comparator|Wait-List Control|Receive SHE Project intervention during Week 2 of Enrollment
3334301|NCT02128672|Active Comparator|Conventional SCS lead|Conventional Thoracic-lumbar SCS lead placement
3234545|NCT01232361||Amphetamine / dextroamphetamine|"Subjects will be stratified by medication, HIV status and HIV antiretroviral therapy as follows:~Stratum A - 15 HIV uninfected subjects; Stratum B - 15 HIV-1 infected subjects who are taking concomitant (prescribed) efavirenz; Stratum C - 15 HIV-1 infected subjects who are taking a (prescribed) protease inhibitor (PI)* with concomitant ritonavir (at boosting doses) or lopinavir/ritonavir.~*PI may be any of the following: atazanavir, darunavir, fosamprenavir, indinavir, saquinavir or tipranavir"
3234546|NCT01232374|Experimental|Nimotuzumab plus chemo-irradiation|Nimotuzumab，chemotherapy(cisplatin )，radiotherapy
3234547|NCT01232374|Placebo Comparator|Placebo plus chemo-irradiation|Placebo，chemotherapy(cisplatin)，radiotherapy
3234548|NCT01232387||Fetomaternal hemorrhage - Mothers|Mothers in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
3234549|NCT01232387||Fetomaternal hemorrhage - Babies|Babies in Mother-baby pairs in which the testing for fetomaternal hemorrhage on the mother's blood demonstrates the presence of fetal cells.
3234550|NCT01232400|Experimental|esmolol|Esmolol will be used preferentially to control hypertension.
3334302|NCT02128672|Experimental|SCS Experimental Lead Placement|Experimental SCS lead placement in a novel position
3334303|NCT02128685|Active Comparator|Dydrogesterone|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
3234551|NCT01232400|No Intervention|Standard care|Standard care for SAH includes other hypertensives such as nicardipine.
3234552|NCT01232413|Placebo Comparator|Treatment A|Placebo
3234553|NCT01232413|Experimental|Treatment B|ASP1941 low dose
3234554|NCT01232413|Experimental|Treatment C|ASP1941 high dose
3234555|NCT01232413|Active Comparator|Treatment D|Moxifloxacin
3234556|NCT01232426|Experimental|Operative|operative treatment of a Mallet fracture with a biodegradable Meniscus Arrow®
3234557|NCT01232426|Active Comparator|Conservative|Conservative treatment of a Mallet fracture with a Mallet splint
3234558|NCT01232439|Experimental|opioid receptor kappa antagonist|
3234559|NCT01232478|Experimental|Comprehensive Adherence Program (CAP)|The comprehensive adherence program emphasizes the patient's active, collaborative role in identifying adherence barriers and solving them to improve adherence to prescribed treatment regimens. Problem-solving sessions will be used to address barriers to adherence that are identified by the adolescent. The intervention also includes provision of a written, Prescribed Treatment Plan, assessment and remediation of gaps in Knowledge of Disease Management, and evaluation and re-instruction/re-training of skills needed to perform daily treatments.
3234560|NCT01232478|Experimental|Standard Care (SC)|Standard care (SC) for adolescents and young adults seen in outpatient CF clinics in Year 1 of the Study. CAP intervention during Year 2 of the Study.
3334304|NCT02128685|Placebo Comparator|Placebo pill|Patients allocated to the dydrogesterone group will receive oral dydrogesterone 40mg stat, followed by 10mg orally three times a day, and placebo will be used in the control group accordingly. Patients will be followed up with weekly pelvic ultrasound till 12 completed weeks of gestation or 1 week after the bleeding stopped, whichever is longer.
3334305|NCT02128698|Experimental|Protein and computer-assisted exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
3334306|NCT02128698|Placebo Comparator|Placebo and computer-assisted exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using Nintendo Wii Balance Board and Wii Fit Plus Software during 6 months after bariatric surgery.
3234561|NCT01232530||Safety Active Surveillance Group|For the active surveillance, all age groups, including children less than 5 years of age, will be identified from the census database and encouraged to attend the health facility whenever sick. Those with a diagnosis of malaria and treated with an antimalarial drug will be actively monitored for AEs.
3334307|NCT02128698|Active Comparator|Protein and usual exercise|Patient group which takes daily protein supplements and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
3334308|NCT02128698|Active Comparator|Placebo and usual exercise|Patient group which takes daily control product and is advised to do exercise 4 times per week by using written exercise instructions during 6 months after bariatric surgery.
3334309|NCT02128737|No Intervention|Control|10 hours time-in-bed all nights of study
3234562|NCT01232530||Safety Passive Surveillance Group|For the people under passive surveillance, sick subjects attending the health facilities, diagnosed with malaria and treated with an antimalarial drug will be identified from the census database. The treatment administered will be recorded in a drug exposure log book and the patients will be encouraged to report passively any AE/ADR.
3234563|NCT01232530||Early Pregnancy Exposure to ACTs Group|All the pregnant women identified during the repeat surveys will be included in a pregnancy cohort. At the time the pregnant woman is identified, her possible exposure to ACTs will be extracted from the drug exposure log book or elicited by history. Births identified through the repeat surveys or any other outcome of pregnancy will be retrospectively matched with antimalarial treatment exposure, particularly during the first trimester of the pregnancy.
3334310|NCT02128737|Experimental|1 Recovery Night|2 baseline nights, five nights sleep restriction, 1 recovery night, five nights sleep restriction, 4 recovery nights
3334311|NCT02128737|Experimental|3 Recovery Nights|2 baseline nights, five nights sleep restriction, 3 recovery nights, five nights sleep restriction, 2 recovery nights
3334312|NCT02128737|Experimental|5 Recovery Nights|2 baseline nights, five nights sleep restriction, 5 recovery nights, five nights sleep restriction, 1 recovery nights
3334313|NCT02128750|Experimental|revascularization group|Subjects in this arms have an contrast echographie with sonovue(r) then a revascularization and finnaly an other contrast echographie with sonovue.
3334314|NCT02128776|Active Comparator|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
3234564|NCT01232530||ACT Effectiveness Monitoring Group|"Besides monitoring AEs and ADRs, data on the effectiveness of ACTs when used in real life conditions and on a large scale will be collected in the active surveillance area. For patients with a microscopically confirmed diagnosis of malaria, clinical symptoms and a blood sample for thick and thin blood smears, will be collected before antimalarial treatment, at day 28 after treatment and at any unscheduled visit. Treatment administration will not be supervised."
3234565|NCT01232543|Experimental|Product 0405|Topical Active Investigational Product 0405
3334315|NCT02128776|Active Comparator|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
3334316|NCT02128789|No Intervention|Control Condition|Subjects receive usual care and support. No study intervention provided
3234566|NCT01232595|Experimental|LFF571 (POC)|
3334317|NCT02128789|Experimental|Elder Tree Condition|Elder Tree website. Subjects receive usual care, support and access to the study intervention website.
3334318|NCT02128802|Experimental|Surgical Gastric Bypass|Patients will undergo surgical gastric bypass according to standard institutional protocols
3334319|NCT02128802|Experimental|Medical Weight Loss Management|Patients will receive best practices medical management for weight loss under current institutional protocols
3334320|NCT02128815|Experimental|Coaching|diabetes health coaching + usual diabetes self-management education
3334321|NCT02128815|No Intervention|Usual Care|Usual care or self-management education
3334322|NCT02128841|Experimental|All patients|CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.
3334323|NCT02128854|Experimental|Tablets Intervention|Individuals randomized to this arm will receive: 1) peripheral devices for monitoring blood glucose, blood pressure, and weight; 2) 8 weekly tablet-delivered education and skills training sessions; 3) two booster sessions delivered via tablet-based videoconferencing at 3 and 6 months.
3334324|NCT02128854|No Intervention|Usual Care|Apart from study visits, individuals randomized to the Usual Care group will receive usual care for diabetes management as provided by their primary care physician. The provider will be responsible for determining changes in the treatment regimen and determining the timing of follow-up visits for diabetes care. Between scheduled office encounters, contact will be initiated by the individual.
3234567|NCT01232595|Active Comparator|Vancomycin (POC)|
3234568|NCT01232595|Experimental|LFF571 Dose level 1 (cohort 2)|
3234569|NCT01232595|Experimental|LFF571 Dose level 2 (cohort 2)|
3234570|NCT01232595|Experimental|LFF571 Dose level 3 (cohort 2)|
3234571|NCT01232595|Experimental|LFF571 Dose level 4 (cohort 2)|
3234572|NCT01232608|Experimental|Exercise|12 months of exercise training
3234573|NCT01232608|No Intervention|Control|Normal follow-up by primary physician
3234574|NCT01232621|Experimental|Physician introduction|Physicians will introduce Research Coordinators (RCs) by name to SDMs and acknowledge patient eligibility to participate in a study using a standardized script.
3234575|NCT01232621|Active Comparator|Non-physician introduction (usual approach)|RCs will either introduce themselves or be introduced by a non-physician member of the health care team.
3334325|NCT02128880|Experimental|CARRII|CARRII: This is a highly interactive Internet intervention consisting of 6 Cores of Intervention material, including Core 1, Overview, Core 2: Your Risk for AEP, Core 3: Drinking, Core 4: Contraception, Core 5: Thoughts and Decisions, and Core 6: Commit to It.
3334326|NCT02128880|Active Comparator|Patient Education|CARRII Education: This is a static website containing educational information on the following topics: What is Alcohol Exposed Pregnancy (AEP)?, Fetal Alcohol Spectrum Disorders, Impact of AEP, Prevalence of AEP, Causes and Prevention of AEP, Treatment for AEP, and Links to related information.
3334327|NCT02128893|Experimental|Isavuconazole alone|Isavuconazole three times a day on Days 1 and 2 and once a day on Days 3, 4, and 5
3234576|NCT01232634||All Subjects|
3234577|NCT01232647|Active Comparator|Vitamin k1|1.0 mg of vitamin K1 (phylloquinone) and placebo MK4 will be given to one of the treatment arm for 18 months
3234578|NCT01232647|Placebo Comparator|placebo vitamin K1 and MK4|placebo pill of both vitamin K1 and MK4 given for 18 months to the control arm
3234579|NCT01232647|Active Comparator|Menatetrenone MK4|45 mg MK4 given daily and placebo vitamin K1 will be given to one of treatment arm for 18 months
3334328|NCT02128893|Experimental|Isavuconazole and Esomeprazole|Esomeprazole daily for 10 days starting on Day 1 and isavuconazole three times a day on Days 6 and 7 and once a day on Days 8, 9, and 10
3334329|NCT02128906|Active Comparator|Cisplatin-IMRT|Cisplatin 40 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
3234580|NCT01232660|Active Comparator|Delayed|Delayed addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
3334330|NCT02128906|Active Comparator|Docetaxel-Cetuximab-IMRT|Docetaxel 15 mg/m2 weekly x 7; Cetuximab 400 mg/m2 load, one week prior to IMRT; Cetuximab 250 mg/m2 weekly x 7; IMRT: once daily, M-F, 7 weeks (70 Gy)
3334331|NCT02128945|Experimental|FLUDATEP|[18F] - Fludarabine PET/CT
3334334|NCT02128971|Active Comparator|Ferrochel® 90 mg|Ferrochel® capsule 90 mg OD for 30 days
3334335|NCT02128971|Active Comparator|Sumalate® 90 mg|Sumalate® capsule 90 mg OD for 30 days
3334336|NCT02128971|Active Comparator|Ferrous Fumarate 90 mg|Ferrous Fumarate capsule 90 mg OD for 30 days
3334337|NCT02128971|Active Comparator|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg OD for 30 days
3334338|NCT02128971|Active Comparator|Ferric glycinate 90 mg|Ferric glycinate capsule 90 mg OD for 30 days
3334339|NCT02128971|Active Comparator|Placebo|Placebo capsule OD for 30 days
3334340|NCT02128984|Experimental|Vitafos Junior|Symbiotic Formula with DHA and antioxidants
3334341|NCT02128984|Active Comparator|Standard Formula|Standard isocaloric and isonitrogenous formula.
3334342|NCT02129010||Subarachnoid hemorrhage with and without Terson syndrome|Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome
3334343|NCT02129023|Experimental|exergame|Participants were asked to use exergame (Xbox 360) half hour for three times per week in the 12-week study period.
3334344|NCT02129023|No Intervention|control|Participants were not asked to use exergames.
3334345|NCT02129049|Experimental|Supportive care (Enhancing Connections Telephone Program)|See Detailed Description.
3334346|NCT02129088|Experimental|Cohort 1|Participants will receive esketamine 14 milligram (mg) as intranasal spray into each nostril on Day 1.
3234581|NCT01232660|Experimental|Immediate|Immediate addition of hydroxychloroquine in patients with discordant CD4+ cell responses to suppressive HAART
3234582|NCT01232673|Experimental|BMAC treatment active group|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC. This ammount is applied by one ml per injection into the critical limb ischemia along the calf vessels.
3234583|NCT01232673|No Intervention|Control Study Group|Standard treatment group of patients with CLI after surgical or interventional revascularisation will serve as control.
3234584|NCT01232686|No Intervention|Control area|In the control areas we will monitor the prevalence and treatment of communicable diseases without giving the participants online access to disease surveillance information
3234585|NCT01232686|Experimental|Intervention area|In these areas we will give study participants online access to epidemiological data for communicable diseases
3234586|NCT01232699|Active Comparator|Internet Obesity Treatment|Participants will attend weekly class sessions on line and track food and exercise in an on-line journal.
3234587|NCT01232699|Experimental|Internet Obesity Treatment with MI|Participants will attend weekly classes on line, record food and exercise in an on-line journal, and will have no more than 6 individual motivational interviewing sessions.
3234588|NCT01232699|Experimental|Contingent MI|Intervention is the same as for the MI arm, however participants will only receive MI if meeting certain treatment participation conditions.
3234589|NCT01232712|Experimental|ImMucin|Treatment with ImMucin and rhGMCSF (recombinant human granulocyte-monocyte colony stimulating factor)
3334347|NCT02129088|Experimental|Cohort 2|All participants will receive esketamine 14 mg as intranasal spray into each nostril on Day 1 of Period 1 as Treatment A and esketamine 14 mg as intranasal spray followed by intranasal administration of placebo solution after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Period 2 as Treatment B in a fixed sequence.
3334348|NCT02129101|Experimental|Treatment (azacitidine, sonidegib, decitabine)|"Patients receive azacitidine SC or IV on days 1-7, sonidegib PO QD on days 1-28 or 1-7* or decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: Sonidegib PO QD is given on days 1-7 if in combination with azacitidine or on days 1-28 is given if in combination with decitabine."
3334349|NCT02129114|Experimental|ReDura Onlay|The Dural Repair Patch manufactured by Guangzhou Medprin Regenerative Medical Technologies Co., Ltd.
3334350|NCT02129114|Active Comparator|DuraGen|Dural Graft Matrix manufactured by Integra LifeSciences (U.S.) Corporation.
3334351|NCT02129127|Experimental|Drug Coated Chocolate|Paclitaxel Coated Chocolate Balloon Angioplasty
3334352|NCT02129140||Hernia graft/mesh|Hernia repair patients implanted with biologic hernia graft during surgery
3334353|NCT02129153|Experimental|LIFT (Parent information)|"LIFT (Parent information): during their child's 7th and 8th grade years research staff will 1. communicate with parents about their child's academic and behavioral performance in school, roughly twice-monthly 2. invite parents to participate in a 2-hour parent support session to help teach parents to communicate better with their child and support better academic and behavioral performance in school~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
3334354|NCT02129153|No Intervention|Usual care group|"Usual care control group/No Intervention consists of neither communication of academic information to parents nor invitation to parent support sessions.~students take a baseline survey then 3 surveys (one/year)~parents take a baseline survey then 2 surveys (one/year)"
3334355|NCT02129166|Placebo Comparator|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
3334356|NCT02129166|Active Comparator|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
3334357|NCT02129179|Experimental|GLP-1|
3334358|NCT02129218|Experimental|Cohort 1: Low glycemic load with standard diet|Patients follow a low glycemic load diet with a standard dietary intervention for 12 weeks.
3334359|NCT02129218|Experimental|Cohort 2: Low glycemic load with intensified diet|Patients follow a low glycemic load diet with intensified dietary intervention for 12 weeks.
3334360|NCT02129218|Active Comparator|Cohort 3: Medium glycemic load with standard diet|Patients follow a medium glycemic load diet with standard dietary intervention for 12 weeks.
3334361|NCT02129218|Active Comparator|Cohort 4: Medium glycemic load with intensified diet|Patients follow a medium glycemic load diet with intensified dietary intervention for 12 weeks.
3334362|NCT02129231|Placebo Comparator|placebo|calcined magnesia 100 mg tablets once a day for 16 weeks
3334363|NCT02129231|Active Comparator|ezetimibe/simvastatin|ezetimibe/simvastatin 10/20 mg tablets once a day for 16 weeks
3334364|NCT02129231|Active Comparator|rosuvastatin|rosuvastatin 20 mg tablets once a day for 16 weeks
3334365|NCT02129257|Experimental|FOLFIRI-AFLIBERCEPT|Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen. Treatment will be repeated every 2 weeks. FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours. FOLFIRI administration will immediately follow the aflibercept one. In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
3334366|NCT02129270|Active Comparator|Lidocaine HCl 2%|Lidocaine HCl 2% (200mg/10ml) 10 ml.
3334367|NCT02129270|Experimental|Lidocaine HCl 1%|Lidocaine HCl 1% (100mg/10ml) 15-20 ml.
3334368|NCT02129283|Experimental|Simulation training|End-of-life simulation training of critical care physicians and nurses using standardized patients to improve communication and interpersonal skills.
3234590|NCT01232725|Experimental|Donor Human Milk|VLBW infants randomized to be fed donor human milk, fortified as appropriate, for all feedings for which maternal milk is not available, including infants who receive no maternal milk
3234591|NCT01232725|Experimental|Preterm Formula|VLBW infants randomized to receive preterm infant formula for any feedings for which maternal milk is unavailable, including infants receiving no maternal milk
3334369|NCT02129283|No Intervention|Control|No simulation training
3334370|NCT02129296|Active Comparator|hemiosphere® BALLOON|Balloon filled with air according to the manufacturing company orders 600 or 720 ml air
3334371|NCT02129296|Active Comparator|Fluid filled balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
3334372|NCT02129309|Experimental|Systemic Apelin infusion|"Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers~Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures"
3334373|NCT02129309|Experimental|Apelin infusion - forearm|"Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.~Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures."
3334374|NCT02129322|Active Comparator|Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : Sorafenib maintenance
3334375|NCT02129322|Experimental|S-1 and Sorafenib|Leading 4 cycles: S-1 + Oxaliplatin Q3W + Sorafenib daily Sequential : 4 cycles of S-1 + Sorafenib maintenance
3334376|NCT02129335||stress|patient with glioblastoma diagnosis and partners
3334377|NCT02129361|Experimental|Adapted Screening and Brief Intervention|Adapted Screening and Brief Intervention: Participants will be screened for substance use, receive education regarding the effects of substance misuse, participate in a motivation interview, and participate in a booster session one month later
3334378|NCT02129361|Active Comparator|Screening & Education Attention Control|Screening & Education Attention Control: Participants will be screened for substance use, receive education regarding the effects of substance misuse, and participate in a booster session one month later
3334379|NCT02129374|Experimental|Direct repair of pars defect|The pars defect was repaired with 4.5mm cortical screw.
3334380|NCT02129374|No Intervention|Conservative treatment|The pars defect of spondylolysis was not repaired with cortical screw.
3334381|NCT02129400|Experimental|10min Xenon 15%, FiO2 75%|10 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3334382|NCT02129400|Experimental|10min Xenon 30%, FiO2 60%|10 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3334383|NCT02129400|Experimental|30min Xenon 15%, FiO2 75%|30 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3334384|NCT02129400|Experimental|30min Xenon 30%, FiO2 60%|30 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3334385|NCT02129400|Experimental|45min Xenon 15%, FiO2 75%|45 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3334386|NCT02129400|Experimental|45min Xenon 30%, FiO2 60%|45 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3334387|NCT02129400|Experimental|90min Xenon 15%, FiO2 75%|90 minutes of 15 % xenon-inhalation (with 75 % FiO2)
3334388|NCT02129400|Experimental|90min Xenon 30%, FiO2 60%|90 minutes of 30 % xenon-inhalation (with 60 % FiO2)
3334389|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 75%|10 minutes of air medicinalis (with 75 % FiO2)
3334390|NCT02129400|Placebo Comparator|10min air medicinalis, FiO2 60%|10 minutes of air medicinalis inhalation (with 60 % FiO2)
3334391|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 75%|30 minutes of air medicinalis inhalation (with 75 % FiO2)
3334392|NCT02129400|Placebo Comparator|30min air medicinalis, FiO2 60%|30 minutes of air medicinalis inhalation (with 60 % FiO2)
3334393|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 75%|45 minutes of air medicinalis inhalation (with 75 % FiO2)
3334394|NCT02129400|Placebo Comparator|45min air medicinalis, FiO2 60%|45 minutes of air medicinalis inhalation (with 60 % FiO2)
3234592|NCT01232764|Experimental|Multi-disciplinary wound care team|Stepped wedge study design i.e. start date of exposure is randomized.
3234593|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.75mg/0.03cc|1/3 of study participants will be randomized to this treatment in one eye (study eye) and the other eye will receive laser (fellow eye)
3334395|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 75%|90 minutes of air medicinalis inhalation (with 75 % FiO2)
3334396|NCT02129400|Placebo Comparator|90min air medicinalis, FiO2 60%|90 minutes of air medicinalis inhalation (with 60 % FiO2)
3334397|NCT02129413|Experimental|Delta system treatment|
3334398|NCT02129439|Experimental|SB012|"SB012 will be available in this clinical trial in a concentration of 7.5 mg/ml hgd40 in 30ml PBS. The maximum daily dose will not exceed 225mg.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 12 of the 18 subjects will receive verum SB012 (in a 2:1 randomization SB012:Placebo)"
3334399|NCT02129439|Placebo Comparator|Placebo|"Placebo will be administered with an identical volume of 30ml PBS.~The study will be continued until 18 subjects have completed the four-week treatment phase according to te protocol. 6 of the 18 subjects will receive placebo (in a 2:1 randomization SB012:Placebo)"
3334400|NCT02129452||CDR (Clinical dementia rating) 0|10 participants complaining subjective memory problem and acquiring CDR 0
3334401|NCT02129452||CDR 0.5|10 participants complaining subjective memory problem and acquiring CDR 0.5
3334402|NCT02129452||CDR 1|10 participants with mild cognitive impairment and acquiring CDR 1
3334403|NCT02129452||CDR 2|10 participants with moderate to severe cognitive impairment and acquiring CDR 2
3234594|NCT01232777|Active Comparator|Bevacizumab (Avastin) 0.625mg/0.025cc|1/3 of patients will be randomized to this treatment in 1 eye (study eye) and the other eye will receive laser (fellow eye).
3234595|NCT01232777|Active Comparator|Laser ablation|1/3 of study participants will be randomized to this treatment in both eyes (study eye and fellow eye)
3234596|NCT01232803|Active Comparator|2% N-9 gel|Rectal application of 2% N-9 gel
3234597|NCT01232803|Placebo Comparator|HEC placebo gel|Rectal application of HEC placebo gel
3234598|NCT01232803|No Intervention|no-treatment arm|no intervention
3334404|NCT02129491||Pediatric Stroke and Hemiplegia|Any infant or child with acute stroke or hemiplegia
3334405|NCT02129504|Experimental|coronal advanced technique|root coverage with the porcine collagen matrix using the coronal advanced technique (standard technique)
3334406|NCT02129504|Experimental|extended flap technique|root coverage with the porcine collagen matrix using the extended flap technique (new surgical technique)
3334407|NCT02129517|Experimental|Arm I (IMPACT Intervention)|Oncology nurses watch tailored, web-based informational video clips addressing knowledge, attitudes, subjective norms, and perceived behavioral control (barriers of discussing clinical trials with patients). They also watch role-play video clips to help improve perceived behavioral control and address attitudinal barriers.
3334408|NCT02129517|Active Comparator|Arm II (online educational materials)|Oncology nurses view online clinical trials educational materials developed based upon NCI clinical trials educational materials for health care providers. The educational materials contain text and tables as presented on the NCI Website.
3334409|NCT02129530|Experimental|Community Social Mobilization Program|A manualized intervention developed with Sonke Gender Justice Network using a workshop intervention manual and a community mobilization toolkit will be used.
3334410|NCT02129530|No Intervention|Control Arm|The Control Arm does not receive the Community Mobilization Intervention
3234599|NCT01232803|Experimental|Tenofovir 1% gel|rectal application of Tenofovir 1% gel
3234600|NCT01232816||Delayed graft function|These are patients in whom dialysis is required following transplantation.
3234601|NCT01232816||Immediate function|These are patients in whom no dialysis is required and creatinine declines by >20% in the first 24 hours following transplantation.
3234602|NCT01232881||Tumor and Serum Collection|"Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.~Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib."
3234603|NCT01232907|Experimental|L-Carnitine|This study has a single subject design. Each subject acts as its own control. All subjects will go through intervention phase (treatment with L-Carnitine).
3234604|NCT01232933|Experimental|VPS System|Use of navigational VPS system to place catheter
3234605|NCT01232959|Experimental|Transvaginal Surgery|Gallbladder will be removed through the vagina
3234606|NCT01232972|Experimental|oocyte freezing|includes any women who elects to preserve her fertility by vitrifying her unfertilized eggs.
3234607|NCT01232985|Experimental|RD047-26|Study Device
3234608|NCT01232998||Patient Satisfaction with nursing care|
3234609|NCT01232998||satisfaction of waiting time for first time visit|
3234610|NCT01232998||patient satisfaction|
3234611|NCT01233024|Placebo Comparator|Low fiber control|no treatment dinner bar, no treatment breakfast bar
3234612|NCT01233024|Experimental|Promitor soluble corn fiber|12g in dinner bar, 11g in breakfast bar
3234613|NCT01233024|Experimental|FiberSym resistant starch|12g in dinner bar, 11g breakfast bar
3334415|NCT02129569|Experimental|Arm I (psychoeducational and behavioral interventions)|Participants meet with a nurse in-person for approximately 30 minutes to receive information about strategies for cognitive self-management of distress and an individualized walking prescription to gradually increase their walking to 30 minutes per day, 5 times per week. Participants wear a pedometer for at least 3 consecutive days during weeks 1, 6, and 12. Participants are also contacted by the nurse via telephone at 1 and 3 weeks for supplemental counseling support.
3334416|NCT02129569|Active Comparator|Arm II (control)|Participants meet with a nurse in-person for approximately 20 minutes to receive NCI educational booklets and a link to the ACS website. Participants are also contacted by the nurse via telephone at 1 and 3 weeks but the calls are primarily social in nature and do not include counseling support.
3334417|NCT02129582|Experimental|Treatment (TMI, fludarabine, busulfan, allogeneic HPCT)|"CONDITIONING: Patients undergo TMI BID on days -10 to -7. Patients also receive fludarabine phosphate IV over 1 hour on days -6 to -2 and busulfan IV or PO on days -5 and -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic progenitor cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive anti-thymocyte globulin IV on days -3 and -2, tacrolimus IV or PO beginning on day -1 for at least 6 months with taper beginning at 4 months, and methotrexate IV on days 1, 3, 6, and 11."
3334418|NCT02129595|Active Comparator|resveratrol|resveratrol will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
3334419|NCT02129595|Placebo Comparator|placebo|A placebo will be given for 30 or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
3334420|NCT02129634|Active Comparator|CB-PTA arm|After successful crossing of the trial lesion, a conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
3234614|NCT01233024|Experimental|Orafti P95 fructooligosaccharide|12g in dinner bar, 11g in breakfast bar
3234615|NCT01233024|Experimental|Orafti HPX inulin|12g in dinner bar, 11g in breakfast bar
3334421|NCT02129634|Experimental|DEB-PTA arm|After successful crossing of the trial lesion, angioplasty with a conventional angioplasty balloon is performed before DEB-PTA. This is because the paclitaxel coating may be scrapped off the balloon if the DEB is used to cross the trial lesion. A conventional angioplasty balloon with a diameter matching the trial vessel is advanced over the guidewire and is inflated at the trial lesion site, according to the normal practice of the operator. A DEB with a diameter matching the trial vessel and lesion length is then advanced over the 0.018 inch guidewire and inflated at the trial lesion site for 60 seconds. If the lesion length is longer than the length of the balloon, a second inflation with another DEB will be required. The maximal total lesion length of the treated lesions will not exceed 20cm. Comparisons of pre- and post-angioplasty percentage stenosis will be made in the same angiographic projection(s).
3334422|NCT02129673|Experimental|VS101 Insert Dose A|VS101 Insert Dose A placed under the conjunctiva
3334423|NCT02129673|Experimental|VS101 Insert Dose B|VS101 Insert Dose B placed under the conjunctiva
3334424|NCT02129673|Experimental|VS101 Insert Dose C|VS101 Insert Dose C placed under the conjunctiva
3334425|NCT02129673|Active Comparator|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
3334426|NCT02129686|Experimental|Immediate Acupuncture Group|"Immediate acupuncture arm will receive acupuncture 3 times per week during week 1 and week 2, then 2 times per week from week 2 to week 8 for a total of 18 sessions. The crossover will take place after 8th week.~The immediate acupuncture arm will enter a follow-up phase without acupuncture for 8 weeks from week 9 to week 16, while the standard usual care will be provided."
3234616|NCT01233063|Experimental|Alive2|Lifestyle Intervention delivered via email and web
3234617|NCT01233063|Experimental|Alive2 plus automated phone/print|All of Arm 1 components, plus biweekly tailored automated phone coaching plus monthly tailored automated print materials.
3234618|NCT01233063|Placebo Comparator|Control|Monthly emailed newsletter on other aspects of wellness, excluding diet and physical activity
3334427|NCT02129686|Active Comparator|Delayed Acupuncture Group|The patients on the usual care/delayed acupuncture arm will continue their standard usual care with their physicians and care team. The crossover will take place after 8th week. After crossover, the patients initially on the usual care/delayed acupuncture arm will receive the identical acupuncture protocol but a less frequent schedule from week 9 to week 16: 2 times per week at week 9, then 1 time per week from week 10 to week 16 for a total of 9 sessions
3334428|NCT02129699|Other|None, standard chemotherapy only|"4 - 6 cycles of standard chemotherapy + best supportive care including any bone protective agent except denosumab.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
3234619|NCT01233089|Experimental|CARE|Investigational single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
3234620|NCT01233089|Active Comparator|AIR OPTIX AQUA|Commercially available single-vision contact lenses worn bilaterally on a daily wear basis and replaced monthly
3334429|NCT02129699|Experimental|Standard chemotherapy + Denosumab|"4 - 6 cycles of standard chemotherapy + denosumab 120 mg, administered subcutaneously every 3-4 weeks until unacceptable toxicity, patient refusal, or patient's death. Denosumab should be administered on day 1 of each cycle, before or after the administration of chemotherapy. After stop of first-line chemotherapy, denosumab must be continued life-long, regardless of tumour progression and concomitantly with subsequent lines of systemic treatment, as long as tolerable for the patient.~Standard chemotherapy consis of a combination of platinum-based doublet agents plus gemcitabine or pemetrexed."
3334430|NCT02129712|Placebo Comparator|Non-adaptive cognitive training|Non-adaptive cognitive training
3334431|NCT02129712|Experimental|Adaptive cognitive triaining|Adaptive cognitive training
3234621|NCT01233089|Active Comparator|AIR OPTIX AQUA MULTIFOCAL|Commercially available multifocal contact lenses worn bilaterally on a daily wear basis and replaced monthly
3334432|NCT02129738|Experimental|LoFric|LoFric catheters
3334433|NCT02129751|Experimental|bupropion hydrobromide|study drug
3334434|NCT02129751|Placebo Comparator|placebo|placebo
3334435|NCT02129764|Experimental|Prednisone|Prednisone will be given 30mg/day for 2 weeks and then tapered off.
3334436|NCT02129764|Active Comparator|Allopurinol|Allopurinol will be given 100 mg/day initially, and then titrated to 200 mg/day.
3334437|NCT02129790|Experimental|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A will include psychoeducation and coping strategies.
3334438|NCT02129816|Active Comparator|Bryophyllum|50% in 350mg Lactose, 2-2-2
3334439|NCT02129816|Placebo Comparator|Placebo|Lactose 350mg, 2-2-2
3234622|NCT01233102|Active Comparator|Conserved Therapy|Conserved Therapy
3234623|NCT01233102|Experimental|Interventional Therapy|"Patients with liver cirrhosis will be randomly divided into three groups.~1. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group.2. Umbilical cord MSCs will be infused to patients intravenously for another group. The control group will receive conserved therapy. The efficacy of different interventional therapies will be compared."
3334440|NCT02129816|Experimental|Solifenacin|10mg in 350mg Lactose, 2-2-2
3334441|NCT02129829||Observational Group|Patients whose viral load, ALT value and fibrosis status does not meet EASL criteria for treatment and are observed 6 monthly
3334442|NCT02129829||Treatment Group (Tenofovir disoproxil)|Patients who meet EASL treatment criteria who receive Tenofovir disoproxil
3334443|NCT02129842||Atrial Fibrillation|
3334444|NCT02129868|Experimental|Closed-loop on day 1 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 1 after CGM sensor insertion.
3234624|NCT01233115||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with combined photodynamic therapy and intravitreal bevacizumab injections
3334445|NCT02129868|Active Comparator|Closed-loop on day 3 of CGM sensor life|Glucose level is controlled by the automated closed-loop glucose control system on day 3 or 4 after CGM sensor insertion.
3334446|NCT02129881|Experimental|Autologous regulatory T Cell Product|"Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed below:~Prednisolone Day 0: 500 mg IV (250mg pre-op, 250mg intra-op) Day 1: 125 mg IV Day 2 to 14: 20.0 mg/day oral Week 3 to 4: 15.0 mg/day oral Week 5 to 8: 10.0 mg/day oral Week 9 to 12: 5.0 mg/day oral Week 13 to 14: 2.5 mg/day oral Week 15 to End: Cessation Mycophenolate Mofetil (MMF) Day -7 to -2: 500 mg/day oral Day -1 to 14: 2000 mg/day oral Week 3 to 36: 1000 mg/day oral Week 37 to 40: 750 mg/day oral Week 41 to 44: 500 mg/day oral Week 45 to 48: 250 mg/day oral Week 49 to End: Cessation Tacrolimus Day -4 to 14: 3-12 ng/ml oral Week 3 to 12: 3-10 ng/ml oral Week 13 to 36: 3-8 ng/ml oral Week 37 to End: 3-6 ng/ml oral"
3334447|NCT02129894|Active Comparator|abdominal binder|Post cesarean section patients will get a abdominal binder placed
3334448|NCT02129894|No Intervention|No Abdominal Binder|Post cesarean section patients will not have abdominal binder
3234625|NCT01233128||polypoidal choroidal vasculopathy|patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months
3234626|NCT01233141||one group only|all participants
3234627|NCT01233154|Experimental|L. paracasei|L. paracasei
3234628|NCT01233154|Experimental|L. acidophilus + B. lactis|L. acidophilus + B. lactis
3234629|NCT01233167|Experimental|clopidogrel|
3234630|NCT01233167|Placebo Comparator|placebo|
3334449|NCT02129920||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation and treated with rivaroxaban
3334450|NCT02129933|Experimental|Tracer bevacizumab-IRDye800CW|"Two days prior to the fluorescence endoscopy procedure (with the near infrared fluorescence endoscopy platform), all patients will receive the fluorescent tracer bevacizumab-IRDye800CW intravenously.~*amendement June 2015: topical administration of bevacizumab-800CW"
3334451|NCT02129946|Active Comparator|Resistant Starch Bagels|Bagels made from high-resistant starch flour (provides 24g resistant starch per day)
3334452|NCT02129946|Placebo Comparator|Control Bagels|Bagels made from wheat flour
3334453|NCT02129959||laparoscopy|laparoscopic cholecystectomy, laparoscopic gastrectomy, laparoscopic colectomy, laparoscopic appendectomy, laparoscopic assisted vaginal hysterectomy, robot-assisted laparoscopic radical prostatectomy
3334454|NCT02129972|Experimental|video capsule endoscopy|
3334455|NCT02129985|Experimental|Exenatide|patients were all received a short-term intensive insulin therapy,then randomised to Exenatide group(10 ug two times a day for three months)
3334456|NCT02129985|Active Comparator|Metformin|patients were all received a short-term intensive insulin therapy,then randomised to metformin group(850mg two times a day for three months)
3334457|NCT02129998||Standard IVF/ICSI treatment|
3334458|NCT02130011|No Intervention|without feeding/fluid instructicon|Ten patients treated with preoperative chemoradiotherapy without feeding/fluid instructions
3334459|NCT02130011|Experimental|with feeding/fluid instructions|Ten patients treated with preoperative chemoradiotherapy with feeding/fluid instructions
3334460|NCT02130037|Active Comparator|psychotherapy only|
3334461|NCT02130037|Experimental|application|
3334462|NCT02130050||OSA Patient|•male patients aged 30 to 65 yr who are newly diagnosed as severe OSA (AHI >=30/hr)
3234631|NCT01233167|Experimental|steply discontinued clopidogrel|
3234632|NCT01233180|Active Comparator|Gua Sha|Single Gua Sha treatment of the neck and shoulder region.
3234633|NCT01233180|Active Comparator|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region.
3234634|NCT01233193|Experimental|Intervention|The intervention group receive an pharmacist intervention (health education, Home Blood Pressure Monitoring and Referral to physician as needed) This group will be followed for 6 months
3234635|NCT01233193|No Intervention|Control|The control group receive usual care in the community pharmacy
3234636|NCT01233206|Experimental|Experimental group|Patients receiving metformin pretreatment and co-administration
3234637|NCT01233206|Placebo Comparator|Control group|Placebo
3234638|NCT01233219||Group A|Homozygous patients for the more frequent allele of the polymorphism A118G of OPRM1 gene
3334463|NCT02130050||Control subjects:|•male control subjects are recruited from Heath Check-up Center. Subjects who are matched with OSA patients at age (+/-2 yrs), body height (+/-3cm) and body weight (<100 kg: +/-3kg, >100 kg: +/-4kg) are screened. Only subjects who are not sleepy (ESS<10) and have no OSA (AHI<5/hr PSG)
3334464|NCT02130076||Stop|Patients with stable RA stopping TNF inhibition
3234639|NCT01233219||Group B|Both homozygous and heterozygous patients for the less frequent allele of the polymorphism A118G of OPRM1 gene
3234640|NCT01233245||Group 1|
3334465|NCT02130076||Continue|Patients with stable RA continuing TNFi therapy
3334466|NCT02130089|Other|All patients|Intensive tailored education
3234641|NCT01233271|Experimental|1|Space TGC system with incorporated eMPC advised insulin titration to establish glycaemic control
3234642|NCT01233297|Active Comparator|Antibiotics|Azithromycin (10 mg/kg once a day for 3 days)
3234643|NCT01233297|Placebo Comparator|Placebo|Placebo mixture (once a day for 3 days)
3334467|NCT02130102||Users of ModuLAAr|A group of volunteers (aged 60+), living in assisted living homes, will be provided with module based technical solutions to improve their independency and quality of life.
3334468|NCT02130128|Experimental|Navigation and tissue sampling|Guided bronchoscopic navigation and lung tissue sampling using the LungPoint ATV System
3234644|NCT01233323||All study patients (single arm study)|All eligible patients will be included in the only study arm and will undergo study testing.
3234645|NCT01233349|Experimental|Litramine|
3334469|NCT02130141|Experimental|Dark chocolate, dietary counselling|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
3334470|NCT02130141|Active Comparator|Dietary counselling|Usual snacks are limited.
3334471|NCT02130154||Young males|Healthy, Lean, Caucasian, Young males
3334472|NCT02130154||Old males|Healthy, Lean, Caucasian, Older males
3334473|NCT02130167|Experimental|0.01% Atropine|
3334474|NCT02130167|Active Comparator|0.05% Atropine|
3234646|NCT01233349|Placebo Comparator|Placebo|
3234647|NCT01233362|Active Comparator|Arm 1: Adults; 14 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3234648|NCT01233362|Active Comparator|Arm 2: Adults; 28 days interval|89 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3234649|NCT01233362|Active Comparator|Arm 3: children; 14 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3234650|NCT01233362|Active Comparator|Arm 4: children; 28 days interval|89 children (1-17 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3234651|NCT01233362|Active Comparator|Arm 5: Adults; 14 days Interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 14 days inter-dose interval
3234652|NCT01233362|Active Comparator|Arm 6: Adults; 28 days interval|15 Adults (=> 18 years aged) receiving study agents (Vaccine/Placebo) at 28 days inter-dose interval
3234653|NCT01233375|Experimental|CO-1.01|
3234654|NCT01233388||Text message surveillance|enroll for text message surveillance
3234655|NCT01233401||Mothers|
3234656|NCT01233401||Other Infant Caregivers|Includes fathers, grandparents, and other adults who are infant caregivers
3234657|NCT01233414|Experimental|Parent Training|
3234658|NCT01233414|Active Comparator|Psychoeducation|
3234659|NCT01233440|Experimental|Cohort 1|25 IU/kg dose
3234660|NCT01233440|Experimental|Cohort 2|50 IU/kg dose
3234661|NCT01233440|Experimental|Cohort 3|75 IU/kg dose
3234662|NCT01233453|Active Comparator|the everolimus eluting ® stent|the everolimus eluting XIENCE-V®, XIENCE-Prime® or PROMUS® stent
3234663|NCT01233453|Active Comparator|Biolimus A9 stent|the Biolimus A9 eluting NOBORI® stent
3234664|NCT01233505|Experimental|Treatment (veliparib, capecitabine, oxaliplatin)|Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3234665|NCT01233531|Other|A--Monthly cash transfers|Monthly cash transfer payments
3234666|NCT01233531|Other|B--No cash transfers|No cash transfers.
3234667|NCT01233544|Experimental|Stereotactic body radiation therapy|Colorectal liver metastases treated by SBRT
3334475|NCT02130180||ED T1DM and hyperglycemia without criteria for DKA|
3334476|NCT02130180||Well controlled T1DM|
3334477|NCT02130180||ED DKA|
3334478|NCT02130206|Active Comparator|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
3334479|NCT02130206|Placebo Comparator|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
3334480|NCT02130206|Active Comparator|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
3334481|NCT02130206|Placebo Comparator|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
3334482|NCT02130219|Experimental|Chronic daily headache group|"Patients with chronic daily headache with suspicion of intracranial hypertension selected. Selection based on clinical symptoms (headache description, leading symptoms)and para-clinical pathological findings (optical nerve papilla edema). Not enough evidence to diagnose any other headache type. Simultaneous CSF pressure measurements and non-invasive ICP measurement will be performed.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT."
3334483|NCT02130219|Experimental|Multiple sclerosis group|"Multiple sclerosis (MS) group patients selected based on clinical symptoms and brain MRI changes typical for the disease. Diagnosis based on McDonalds criteria. CSF test for oligoclonal bands required as supporting diagnostic criteria. Patients selected with disease relapse symptoms. Simultaneous noninvasive ICP and CSF pressure measured.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
3334484|NCT02130219|Experimental|Stroke group|"Patients selected for this group have stroke/intracranial hemorrhage that might be complicated with intracranial hypertension. Stroke/intracranial hemorrhage diagnosed based on clinical findings and changes on brain CT/MRI. Patients with stroke less than 33% of middle cerebral artery territory included. Patients with intracranial hemorrhage 20-40 ml volume included. Patients unable to cooperate or sign informed consent excluded.~Bilateral non-invasive ICP measurements performed. Results compared with brain MRI/CT lesion volume, mid-line shift.~Interventions: non-invasive intracranial pressure measurement; brain MRI/CT"
3334485|NCT02130219|Experimental|Normal pressure hydrocephalus group|"Patients meeting normal pressure hydrocephalus diagnosis criteria selected to compare invasive CSF pressure versus non-invasive ICP.~Interventions: non-invasive intracranial pressure measurement; lumbar puncture and cerebrospinal fluid pressure measurement; brain MRI/CT"
3334486|NCT02130232|Experimental|Lifestyle Intervention|The goal of the intervention is to help women achieve the lower bound of the GWG range recommended by the Institutes of Medicine (IOM) for a given prepregnancy BMI category (i.e., 11 lbs for obese women and 15 lbs for overweight women). The pregnancy lifestyle intervention will be delivered by trained study dieticians via individual counseling sessions: 2 in-person and 11 telephone sessions delivered on a weekly basis, followed by telephone sessions delivered every other week through the end of pregnancy.
3334487|NCT02130232|Active Comparator|Usual Care|Usual Medical Care
3334488|NCT02130245|Active Comparator|Early cholecystectomy|Laparoscopic cholecystectomy well be done after the immediate admission
3334489|NCT02130245|Active Comparator|Delayed cholecystectomy|Laparoscopic cholecystectomy after a period of conservative treatment
3334490|NCT02130271||Healthy|"Healthy subjects with no pain.~Radioactive dye~PET/MRI~Blood draw"
3234668|NCT01233544|Active Comparator|Radiofrequency ablation|Colorectal liver metastases treated by RFA
3334491|NCT02130271||Sciatica|"Subjects with sciatica and scheduled for an epidural steroid injection (ESI).~Radioactive dye~PET/MRI~Blood draw"
3334492|NCT02130310|Experimental|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 3 treatments, or until ulcer closure, whichever occurs first.
3334493|NCT02130310|Placebo Comparator|Placebo injection|The placebo will be administered by injecting normal saline at each centimeter of the ulcer bed.
3234669|NCT01233557||Bone Metastases|
3234670|NCT01233570|Experimental|Topical tacrolimus|Once daily topical application
3234671|NCT01233583||Betamethasone/Calcipotriol (Dovobet)|patients in whom decision to treat with Dovobet by their dermatologist
3234672|NCT01233583||Acitretin (neotigason)|patients in whom decision to treat with neotigason by their dermatologist
3234673|NCT01233583||narrow-band UVB|patients in whom decision to treat with narrow band UVB by their dermatologist
3234674|NCT01233583||Anti TNF-alpha|patients in whom decision to treat with anti TNF-alpha(adalimumab-etanercept-infliximab) by their dermatologist
3334494|NCT02130323|Active Comparator|Loop Electrosurgical Excision Procedure|Excision of the cervical transformation zone by way of the loop electrosurgical excision procedure (LEEP) or cold knife conization (CKC).
3334495|NCT02130323|Experimental|Imiquimod|Imiquimod 12.5mg intravaginally once weekly for 16 weeks
3334496|NCT02130336|Experimental|Aerobic interval training|"Frequency: Exercise 3 times a week. Twice under supervision and home exercise once a week.~Duration: Totally 40 minutes in one session. Intensity: 10-minute warm-up and 5-minute cool-down at 40% maximal heart rate (HRmax), participants and exercise 4-minute high-intensity training at 85-90% HRmax and 4 times separated by 3-minute active recovery at 70% HRmax.~Type: Using treadmill while under supervision."
3334497|NCT02130336|Experimental|Continuous moderate-intensity exercise|"Frequency: 5 times a week. Twice under supervision and home exercise 3 times a week.~Duration: Totally 45 minutes per session. Intensity: 10-minute warm-up at 40% maximal heart rate (HRmax), 30-minute moderate intensity exercise at 50-70% HRmax and 5-minute cool-down at 40% HRmax Type: Using treadmill under supervision."
3234675|NCT01233596|Active Comparator|Monocanalicular intubation|Monocanalicular intubations (MCI; n=35 eyes) through the inferior canaliculus intubations performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
3334498|NCT02130336|No Intervention|Control group|Subjects in control group will receive general exercise knowledge and counseling.
3334499|NCT02130349||Crohns Disease|IBD patients diagnosed with Crohn's disease
3234676|NCT01233596|Active Comparator|Bicanalicular intubation|Bicanalicular intubation (BCI; n=35 eyes) performed under general anaeshesia in children between 10 and 36 months of age suffering from congenital nasolacrimal duct obstruction (CNLDO).
3234677|NCT01233622|Experimental|Vildagliptin (metformin + glimepiride)|
3234678|NCT01233622|Placebo Comparator|Placebo (metformin + glimepiride)|
3234679|NCT01233635|Experimental|A Group 1 no drug|Patients who have not taken ACE/ARB, randomized to no drug.
3234680|NCT01233635|Experimental|A Group 2|Patients who have not taken ACE/ARB, randomized to take cozaar.
3234681|NCT01233635|Experimental|B|Patients currently taking ACE/ARB will have their prescription changed to cozaar.
3234682|NCT01233648|Active Comparator|AF|
3234683|NCT01233648|Active Comparator|SR|
3234684|NCT01233661|Experimental|short AVD pacing|short AVD pacing
3234685|NCT01233661|No Intervention|prior (stable) programming|prior (stable) programming
3234686|NCT01233674||patients referred for standard of care MRI|
3234687|NCT01233700|Experimental|Motivational Interviewing|Subjects will receive two, individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on assisting subjects to delineate their reasons for or against proceeding with living organ donation and assisting subjects to resolve any lingering concerns about their decisions regarding donation.
3334500|NCT02130349||Ulcerative colitis|IBD patients diagnosed with ulcerative colitis
3334501|NCT02130349||IBD-Undefined|IBD patients with undefined IBD
3334502|NCT02130362||Immunosuppressant Therapy|Pediatric patients who are being prescribed and treated with immunosuppressant therapy
3334503|NCT02130362||Adalimumab (Humira) Treatment|Pediatric patients who are prescribed and treated with adalimumab
3334504|NCT02130375|Experimental|stress urinary incontinence|Women with stress urinary incontinence
3334505|NCT02130388|Other|Renal Insufficiency|Based on creatinine clearance
3334506|NCT02130388|Other|Renal Sufficiency|Based on creatinine clearance
3334507|NCT02130401|Experimental|TNM (thermoneuromodulation device)|A standardized active thermal neuromodulation waveform will be used for all patients. The device is non-invasive and does not use electrical stimulation.
3334508|NCT02130414|Active Comparator|Sandimmun® IV|Sandimmun® IV 2mg/kg as a 24 hour infusion (2mg/kg/day)
3334509|NCT02130414|Experimental|CyCol® capsules|CyCol®: 75 mg OD & BID for 7 days
3334510|NCT02130414|Experimental|CyCol® capsules 37.5 mg|CyCol®: 37.5 mg OD or BID for 7 days
3334511|NCT02130414|Experimental|CyCol® capsules, 150 mg|CyCol®: 150 mg OD or BID for 7 days
3334512|NCT02130440|Active Comparator|Resveratrol nasal spray|2 sprays per nostril 3 times a day for a period of two months
3334513|NCT02130440|Placebo Comparator|Placebo|2 sprays per nostril 3 times a day for a period of two months
3334514|NCT02130453|Experimental|ReSTE Cardiac Imaging|Echocardiography strain measurement performed taking about 10 minutes. After resting strain measurement done, first set of nuclear images performed. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving the Regadenoson, measurements repeated. These measurements will take about 2 minutes to complete.
3334515|NCT02130453|Other|SPECT Cardiac Imaging|After resting strain measurement done, first set of nuclear images taken. Once these images are completed, participant given Regadenoson 0.4 mg by vein over about 10 seconds. Within 2 to 4 minutes of receiving Regadenoson, measurements repeated. These measurements take about 2 minutes to complete. At about 30 minutes after Regadenoson given, participant will have final images for the nuclear portion of the testing.
3334516|NCT02130466|Experimental|Pembro+D+T (Parts 1, 2 & 3)|Participants receive pembrolizumab intravenously (IV) on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose (twice per day, or BID) starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, once daily (QD) starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3334517|NCT02130466|Placebo Comparator|Placebo+D+T (Part 3)|Participants receive placebo IV on Days 1 and 22 of each 6-week cycle; dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through study treatment discontinuation; and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3334518|NCT02130466|Experimental|Pembro+T (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and trametinib tablets, 2 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3334519|NCT02130466|Experimental|Pembro+D (Parts 1 & 2)|Participants receive pembrolizumab IV on Days 1 and 22 of each 6-week cycle and dabrafenib capsules, 150 mg/day total, orally, in a divided dose BID starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3334520|NCT02130466|Experimental|Pembro+T Concurrent Dosing (Parts 4 & 5)|Participants receive trametinib tablets, 1.5 mg monotherapy, orally, QD for 4 weeks. Starting with Week 5, participants receive pembrolizumab IV on Day 1 of each 3-week cycle and a concurrent dosing schedule for trametinib tablets, 1.5 mg, orally, QD starting on Day 1, through completion of 2 years of treatment or through study treatment discontinuation.
3334521|NCT02130466|Experimental|Pembro+T Intermittent Dosing (Parts 4 & 5)|Participants receive trametinib 1.5 mg monotherapy, orally QD for 2 weeks. Starting with Week 3, participants receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle and an intermittent dose schedule for trametinib tablets, 1.5 mg, orally, QD with 1 week OFF trametinib and 2 weeks ON trametinib through completion of 2 years of treatment or through study treatment discontinuation.
3334522|NCT02130479|Experimental|Contingency Management-Family Engagement|The Contingency Management-Family Engagement or CM-FAM model integrates behavioral (e.g., drug testing linked with consequences) and cognitive behavioral (e.g., functional analyses of drug use, self-management and drug refusal skills training) strategies based on the Community Reinforcement Approach with effective family engagement strategies used in Multisystemic Therapy.
3334523|NCT02130479|Active Comparator|Treatment as Usual|Standard community-based substance abuse treatment services.
3334524|NCT02130492|Experimental|FDG arm|Patients will receive increasing doses of FDG.
3334525|NCT02130505|Active Comparator|T2DM|Patients with type 2 diabetes mellitus, defined as having met the diagnostic criteria as outlined by the World Health Organization
3234688|NCT01233700|Active Comparator|Enhanced Standard Care|Subjects will receive two individual telephone sessions with an interventionist, each lasting approximately 30-45 minutes. The sessions will focus on providing educational information to subjects regarding healthy lifestyle issues (healthy eating, diet, exercise, quitting smoking).
3234689|NCT01233700|No Intervention|Standard Care|Subjects will receive the standard care and education provided by the Living Donor Program at their medical center.
3234690|NCT01233713|Active Comparator|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering ileostomy, followed by a stoma reversal operation.
3234691|NCT01233713|Active Comparator|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
3234692|NCT01233739|Placebo Comparator|Placebo|
3234693|NCT01233739|Experimental|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
3234694|NCT01233752||Group A|Homozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the more frequent allele of the polymorphism A118G of OPRM1 gene
3234695|NCT01233752||Group B|Both homozygous and heterozygous patients,using PCA administration with morphine chlorhydrate for postoperative analgesia, for the less frequent allele of the polymorphism A118G of OPRM1 gene
3234696|NCT01233765||Control volunteers with periodontal health|Control volunteers with periodontal health
3334526|NCT02130505|Active Comparator|FCH|Patients with familial combined hyperlipidemia, defined as familial hyperlipidemia with a dominant inheritance pattern, elevated plasma apolipoprotein (apo) B concentrations (>1.2 g/L) and elevated triglyceride (TG) levels (>1.7 mmol/L) at the time of diagnosis
3334527|NCT02130505|Active Comparator|FH|Patients with familial hyperlipidemia, defined as having met the diagnostic criteria as outlined by the world Health Organization
3334528|NCT02130505|Active Comparator|Healthy controls|Healthy controls
3334529|NCT02130518|Experimental|Auriclosene (AIS)|Auriclosene Irrigation Solution, 0.2%, 8 treatments over 4 weeks
3334530|NCT02130518|Placebo Comparator|Auriclosene Vehicle Solution|Auriclosene Vehicle Solution, 8 treatments over 4 weeks
3334531|NCT02130531|Experimental|Cohort 1|"Two dose periods in any sequence (subjects will be assigned to 1 of 2 possible sequences):~Emixustat HCl Tablet Strength B (mid dose); 1 tablet once daily & 1 placebo tablet once daily for 7 days~Emixustat HCl Tablet Strength A (low dose); 1 tablet twice daily for 7 days"
3334532|NCT02130531|Experimental|Cohort 2|"Three dose periods in any sequence (subjects will be assigned to 1 of 6 possible sequences):~Emixustat HCl Tablet Strength A (low dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength B (mid dose); 1 tablet daily for 7 days~Emixustat HCl Tablet Strength C (high dose); 1 tablet daily for 7 days"
3334533|NCT02130596|Experimental|Acceptance-Based Behavioral Intervention|
3334534|NCT02130596|Active Comparator|Nutritional Counselling|
3334535|NCT02130609|Experimental|Skintel|
3334536|NCT02130648||Prenatal diagnosis|Prenatal diagnosis witch A sampling of blood de 14 ml
3334537|NCT02130661|Experimental|Part A|Subjects will receive 250 mg of rilapladib once daily (QD) for 14 days (Days 1-14)
3334538|NCT02130661|Experimental|Part B|Subjects will receive 25 mg of rilapladib QD for 1 day (Day 1), 200 mg of itraconazole twice daily (BID) for 1 day (Day 8) and QD for 2 days (Days 9-10). Subjects will receive 25 mg of rilapladib + 200 mg of itraconazole for 1 day (Day 11) and 200 mg of itraconazole QD for 6 days (Day 12-17)
3334539|NCT02130674|Experimental|Dipeptiven|0.75 g/ kg/ d Dipeptiven ( L- alanine- L- glutamine; 82 mg/ ml L- alanine, 134.6 mg/ ml L- glutamine; Fresenius Kabi, Switzerland) continuous intravenous infusion
3334540|NCT02130700|Experimental|Chemotherapy-Naive Patients|VT-464: given orally twice daily in 28-day cycles
3334541|NCT02130700|Experimental|Previous Chemotherapy Patients|VT-464: given orally twice daily in 28-day cycles
3334542|NCT02130700|Experimental|AR Positive 1 - 9% TNBC|VT-464: given orally once daily in 28-day cycles
3334543|NCT02130700|Experimental|Male ER Positive|VT-464: given orally once daily in 28-day cycles
3334544|NCT02130700|Experimental|AR Positive >10% TNBC|VT-464: given orally once daily in 28-day cycles
3334545|NCT02130713|Active Comparator|Group A, antibiotics|Prulifloxacin 600 mg
3334546|NCT02130713|Active Comparator|Group B, antibiotics plus nutraceuticals|Prulifoxacin plus Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg
3334547|NCT02130726|Experimental|Minimally-invasive Gastrectomy|Patients allocated to the 'Minimally-invasive Gastrectomy' group will undergo minimally-invasive/laparoscopic total gastrectomy. If, during surgery, laparoscopic resection does not seem feasible, the procedure may be converted to an open one.
3334548|NCT02130726|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive total resection of the stomach via laparotomy. This group is considered the control group
3234697|NCT01233765||Patient volunteers with chronic periodontitis|Patient volunteers with chronic periodontitis
3234698|NCT01233778|Experimental|Canola Oil|
3234699|NCT01233778|Experimental|High Oleic Acid Canola + DHA|
3234700|NCT01233778|Experimental|High Oleic Canola Oil|
3334549|NCT02130739||thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
3334550|NCT02130752|Experimental|Ultrasonic scalpel surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
3334551|NCT02130752|Experimental|Monopolar electrocautery surgery group|During the procedures of the abdominal approach D2 distal gastrectomy, use monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes; some great vessels can ligation by nylon, silk line or Hemolock.
3334552|NCT02130778|Active Comparator|Saline infusion|infusion of saline
3334553|NCT02130778|Active Comparator|Saline infusion with GLP1|infusion of saline with GLP1
3234701|NCT01233778|Experimental|Flax & Safflower Oil (60:40)|
3234702|NCT01233778|Experimental|Safflower & Corn Oil (75:25)|
3234703|NCT01233791|Experimental|Vaginal Diazepam Suppository|Patients in this arm will be asked to use one vaginal suppository every night for 28 days
3234704|NCT01233791|Placebo Comparator|Vaginal Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
3234705|NCT01233804|No Intervention|Opting in|Currently, pregnant women have to sign a consent stating that they want the influenza vaccine (at the clinics where the study is being conducted). Therefore, this group is the same as usual care. However, women will then be asked if they would like to take part in parts 2 and 3 of the study.
3234706|NCT01233804|Experimental|Opting Out|Women will sign a consent form only if they do not want to receive the flu vaccine.
3234707|NCT01233830|Experimental|1|
3234708|NCT01233830|Placebo Comparator|2|
3234709|NCT01233843|Other|Drug and radiation|Radiotherapy : 70 grays , fractionization : 2Gy/day, 5 days / week, for 7 weeks . Concurrent administration of Carboplatin: 70 mg/m2/day (day 1 until day 4)and 5FU 600 mg/m2/day (day 1 until day 4). Weeks 1; 4; 7.
3334554|NCT02130791|Experimental|PSD then TSD|baseline sleep, five nights sleep restriction, four nights recovery sleep, one night total sleep deprivation, one night recovery sleep
3334555|NCT02130791|Experimental|TSD then PSD|baseline sleep, one night total sleep deprivation, four nights recovery sleep, five nights sleep restriction, one night recovery sleep
3334556|NCT02130804|Experimental|Salsalate|Salsalate (4 g/day)
3334557|NCT02130804|Placebo Comparator|Placebo|Placebo (4 g/day)
3334558|NCT02130817|Experimental|Belatacept|"Belatacept (nujolix):~Tacrolimus withdrawal~Standard of care(SOC) treatment:~Plasmapheresis/Intravenous Immunoglobulin G (IVIG) therapy~Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg starting in the operating room.~Maintenance immunosuppression:~Myfortic: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.~Steroids: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30."
3334559|NCT02130830|Experimental|Topical anesthesia|Application of topical 2,5% lidocaine + 2,5% prilocaine gel to the anal canal before the procedure
3334560|NCT02130830|Placebo Comparator|Placebo|Application of placebo gel into the anal canal before the procedure
3334561|NCT02130843||MALE PATIENTS BEFORE UDS|MALE PATIENTS BEFORE UDS WITH DIFFICULT CATHETERIZATION
3334562|NCT02130856|Experimental|Neonatal Kit|The neonatal kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Lady Health Workers will be equipped with a hand held electric scale to identify low birth weight newborns.
3334563|NCT02130856|No Intervention|Control (Standard care)|"In the control arm, Lady Health Workers will visit the home according to the regular schedule (same as in the intervention clusters) and will deliver the standard post-natal care consisting of:~be present at delivery (though not conduct the delivery) and thorough examination of newborn and mother post delivery~check mother for vaginal bleeding and abnormal blood pressure and make referral to nearest health facility as appropriate~refer any newborn with congenital anomaly or evidence of asphyxia~if unable to attend delivery for any reason, visit within first 24 hours post delivery~assess newborn in first month of life during visits and provide basic treatment for acute respiratory infections, pneumonia, and diarrhea in the home~encourage breastfeeding"
3334564|NCT02130869|Experimental|Group A: Neuroblastoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group A participants receive busulfan, melphalan, CD133+ selected autologous stem cell infusion, hu14.18K322A, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3334565|NCT02130869|Experimental|Group B: Lymphoma|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group B participants receive bendamustine, etoposide (or etoposide phosphate), cytarabine, melphalan, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3234710|NCT01233843|Experimental|drug and radiation|"Induction chemotherapy by Docetaxel 100mg/m2, day 1; cisplatin 100mg/m2, day 1; 5-Fluorouracil 1000mg/m2 (from day 1 to day 5), for a total of three cycles .Those cycles are administrated at day 1; day 22, day43.~This induction chemotherapy is followed ( for responders or stable disease patients)by radiotherapy (70 grays for 7 weeks) and concurrent Erbitux( weekly administration)."
3234711|NCT01233882|Experimental|Healthy Volunteers|
3234712|NCT01233882|Experimental|Mild Renal Impairment|
3234713|NCT01233882|Experimental|Moderate Renal Impairment|
3234714|NCT01233882|Experimental|Severe Renal Impairment|
3334566|NCT02130869|Experimental|Group C: High-Risk Tumors|"All participants first receive standard of care high-dose chemotherapy specific to their tumor type. Group C participants receive melphalan, etoposide (or etoposide phosphate), carboplatin, CD133+ selected autologous stem cell infusion, IL-2, haploidentical natural killer cell infusion, G-CSF, and GM-CSF.~Cells for infusion are prepared using the CliniMACS System."
3334567|NCT02130882|Active Comparator|Drug|Benralizumab (30mg) will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
3334568|NCT02130882|Placebo Comparator|Placebo|Placebo will be administered sc every 4 weeks for 3 doses (at weeks 0, 4 and 8). Eosinophil counts will be blinded during this time and background HES therapy will not be tapered.
3334569|NCT02130895|Experimental|Intervention|STOPP Criteria Decision Support Content Intervention arm will receive CDS suggestions based on the STOPP criteria.
3334570|NCT02130895|No Intervention|Control|Control arm will provide care as usual during the intervention period.
3334571|NCT02130908|Experimental|Lean fish|
3334572|NCT02130908|Experimental|Fatty fish|
3334573|NCT02130908|Experimental|Lean meat|
3234715|NCT01233895|Experimental|AVE1642/ AVE1642 with Velcade|
3234716|NCT01233908||PTSD|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and developed an associated posttraumatic stress disorder
3234717|NCT01233908||PTSD - negative|Patients which underwent surgical repair for primary rhegmatogenous retinal detachment and did not develope an associated posttraumatic stress disorder
3234718|NCT01233934|Active Comparator|Dexchlorpheniramine 1% Cream|
3234719|NCT01233934|Experimental|Dexchlorpheniramine 1% Gel|
3234720|NCT01233947|Experimental|AFP464|74 mg/m2 AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycle.
3234721|NCT01233947|Experimental|AFP464 + Faslodex|AFP464 administered as a 3 hour IV infusion on Days 1 and 8 of a 21-day cycles and Faslodex administered per package label.
3234723|NCT01233973|No Intervention|control subjects|verbal narrative of advance care planning
3234724|NCT01233973|Experimental|intervention group|video decision aid viewed by subjects
3234725|NCT01233986||Case group - Large artery atherosclerosis|
3234726|NCT01233986||Control group-Small vessel occlusion|
3234727|NCT01234012|Experimental|Treatment: IMF-001|100 or 200 mcg will be administered to patients subcutaneously every 2 weeks for 6 injections.
3234728|NCT01234025|Experimental|Part 1 Cohort 1|
3234729|NCT01234025|Experimental|Part 1 Cohort 2|
3234730|NCT01234025|Experimental|Part 2 Arm A|
3234731|NCT01234025|Experimental|Part 2 Arm B|
3334574|NCT02130921|No Intervention|Control|Community Health Workers (CHWs) in the control group will be invited to one group lecture didactically reviewing medical ethics, and the attending CHWs will be requested to pay a home visit to participating IDUs and FMs after the lecture.
3334575|NCT02130921|Experimental|Intervention|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
3334576|NCT02130934||childhood cancer survivors|Cardiac 3D MRI
3334577|NCT02130947|Experimental|Exercise Intervention Arm|The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours.
3334578|NCT02130947|No Intervention|Non-Exercise Control Arm|Participants in the Non-Exercise Control Arm will not exercise for 12 weeks.
3334579|NCT02130973|Active Comparator|Standard Clinical Practice Regimen|Standard Clinical Practice (Daily) Regimen: 18 months of daily subcutaneous Forteo followed by denosumab therapy for 18 months (18 months of Forteo then 3 injections of Prolia at 18, 24 and 30 months).
3334580|NCT02130973|Experimental|Experimental (cyclic) regimen|Experimental (Cyclic) Regimen: three separate 6-month cycles of daily subcutaneous Forteo, each followed by one subcutaneous injection of Prolia (Forteo from 0 to 6 months, and then from 12 to 18 months and then from 24 to 30 months, for a total dose of 18 months; 3 injections of Prolia at 6, 18 and 30 months).
3334581|NCT02131012|Experimental|Celecoxib|1-4 mg intravitreal injection ofCelecoxib
3334582|NCT02131038||Ectoin group|Ectoin Allergy Nasal Spray
3334583|NCT02131038||Cromolyn group|Cromolyn sodium
3234732|NCT01234038|Experimental|Part 1 Cohort 1|
3234733|NCT01234038|Experimental|Part 1 Cohort 2|
3234734|NCT01234038|Experimental|Part 2 Arm A|
3234735|NCT01234038|Experimental|Part 2 Arm B|
3234736|NCT01234051|Experimental|Docetaxel, oxaliplatin, palliative chemotherapy|
3234737|NCT01234064|Active Comparator|Graduated Compression Stockings|
3234738|NCT01234064|Other|No Graduated Compression Stockings|
3334584|NCT02131051||Azelastine group|Azelastine nasal spray Azelastine eye drops
3334585|NCT02131051||Ectoin group|Ectoin Allergy Nasal Spray Ectoin Allergy Eye Drops
3334586|NCT02131077|Experimental|treatment|ALLO-ASC-TI injection
3334587|NCT02131077|Placebo Comparator|Placebo|Saline injection
3334588|NCT02131090|Experimental|Tegaderm TM|Participants in this arm of the study will receive the Tegaderm dressing to secure the epidural catheter
3334589|NCT02131090|Experimental|Lock-it Plus|Participants in this arm of the study will receive the Lock-it Plus dressing to secure the epidural catheter
3334590|NCT02131090|Experimental|Epifix|Participants in this arm of the study will receive the Epifix dressing to secure the epidural catheter
3334591|NCT02131103|Active Comparator|Early ( < 24hr)|Early percutaneous coronary intervention means performed coronary intervention between 3-24 hours after successful fibrinolytic therapy.
3334592|NCT02131103|Active Comparator|Delay ( > 24 hours)|Delay percutaneous coronary intervention means received coronary intervention >24 hours to 2 weeks after successfully fibrinolytic therapy.
3334593|NCT02131103|Active Comparator|Early|"We randomized the patients into two groups early (≤ 24 hours) and delay group (> 24 hours) All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
3334594|NCT02131116|Experimental|IMT|Integrated Metacognitive Therapy
3334595|NCT02131116|No Intervention|TAU|No intervention group/Treatment as Usual
3334596|NCT02131142|Experimental|BioFreedom|
3334597|NCT02131181||Delirium|Patients with delirium and patients without delirium
3334598|NCT02131194|Experimental|Lenstatin|Lenstatin (2) capsules orally per day for (6) months
3334599|NCT02131194|Placebo Comparator|Sugar Pill|Placebo manufactured to mimic Lenstatin (2) capsules orally per day for (6) months
3334600|NCT02131207||Diagnostic (MRI and biopsy)|Participants undergo pelvic magnetic resonance imaging (MRI). Within 1-2 weeks, patients undergo scheduled prostate biopsy.
3334601|NCT02131220|Experimental|Prourokinase|Intracoronary bolus infusion of 20mg prourokinase using selective catheter
3234739|NCT01234077|No Intervention|ECG recording|In-laboratory vs. in-home recordings
3234740|NCT01234090||Persons with Aphasia|
3234741|NCT01234116|Active Comparator|Kaletra|Arm 1: Kaletra two tabs twice a day + Truvada one pill once a day.
3234742|NCT01234116|Active Comparator|Raltegravir|Arm 2: Raltegravir 400 mg, one pill twice a day + Truvada one pill once a day.
3234743|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by zoledronic acid or not.
3234744|NCT01234129||zoledronic acid or not zoledronic acid|patients with multiple myeloma will be treated with cytoreductive therapy following by stem cell transplant and did not received zoledronic acid
3234745|NCT01234129||zoledronic acid|Patients with multiple treated with cytoreductive therapy following by stem cell transplant will be planned to received zoledronic acid
3334602|NCT02131220|Active Comparator|Tirofiban|Intracoronary tirofiban bolus infusion using selective catheter (10ug/kg)
3334603|NCT02131220|Placebo Comparator|Normal saline|Intracoronary saline bolus infusion using selective catheter (20ml)
3334604|NCT02131246|Experimental|Faster-acting insulin aspart|Each subject will be allocated to two treatments (in random sequence).
3334605|NCT02131246|Active Comparator|NovoRapid®|Each subject will be allocated to two treatments (in random sequence).
3334606|NCT02131285|Experimental|Sensory training|Experimental group received balance rehabilitation aimed at improving motor strategies and sensory strategies. Subjects in this group were treated to improve recovery of sensory impairment and were given exercises in the impaired sensory conditions, inhibiting the reliable sensory systems and forcing the Central Nervous System to use the impaired ones.
3334607|NCT02131285|No Intervention|No sensory strategy|Control group received usual care rehabilitation which did not include training of sensory strategies.
3334608|NCT02131298|Other|Fixed sequence|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B (palbociclib with itraconazole)
3334609|NCT02131337|Other|Contact force lesions|
3334610|NCT02131350|Experimental|Ranibizumab with Photocoagulation|
3334611|NCT02131363|Experimental|Ingrowing Toenail Treatment Kit|"Ingrowing Toenail Treatment Kit consists of 3 components:~Toe nail clip: one clip to be applied each week, for 6 weeks.~Aerosol spray: to be applied up to 5 times a day, no more than one spray per hour.~Nail adhesive: used to attach the clip to the nail."
3334612|NCT02131376|Active Comparator|Cortical renorrhaphy|Cortical renorrhaphy is performed after partial nephrectomy using a running barbed suture on MH (36mm) needle. Polymer locking clips are used to maintain tension. A base layer running stitch is performed prior to the cortical renorrhaphy.
3334613|NCT02131376|Experimental|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
3234746|NCT01234142|Experimental|Cohort 1|
3234747|NCT01234142|Experimental|Cohort 2|
3334614|NCT02131389|Other|Iconacy Hip System|Iconacy hip system prosthesis components
3334615|NCT02131441|Other|laparoscopic hepatectomy|laparoscopic hepatectomy
3234748|NCT01234142|Experimental|Cohort 3|
3234749|NCT01234142|Experimental|Cohort 4|
3334616|NCT02131441|Other|open liver resection|open liver resection
3334617|NCT02131454|Experimental|Education and Inhalation technique training|Training in technique of drug inhalation in asthma and COPD patients and education about the role of inhalation therapy in the course of the disease.
3234750|NCT01234155|No Intervention|Control|
3334618|NCT02131454|No Intervention|Education|Basic education about asthma and COPD.
3334619|NCT02131467|Experimental|Perampanel|Perampanel 2 mg tablets will be initiated once daily at bedtime. The dose will be titrated over 6 weeks starting at 2 mg OD at baseline visit for 1 week, followed by 2mg increases every 1 week to a maximum of 12 mg/day. If side effects occur then patients will be decreased to previous dose level. If unable to tolerate increases, patients will enter the maintenance phase at previously tolerated dose, for minimum 4 weeks. Patients reaching 12 mg (maximal dose) will be maintained at that dose for 4 weeks. Taper will be over 2 weeks 1 tablet every 2 days from a maximum of 6 tablets per day to stop.
3334620|NCT02131480|Experimental|Soft tissue|
3234751|NCT01234155|Experimental|Exercise - Continuous Walking|
3334621|NCT02131480|Experimental|Uterus|
3334622|NCT02131493|Active Comparator|Gemcitabine|Gemcitabine：1000mg/m2，iv 30min，d1, d8,d15 q4w, 6 cycles
3334623|NCT02131493|Experimental|S-1+ Gemcitabine|S-1：40~60mg bid，d1~14; (S-1 dosage：BSA <1.25m2，40mg bid，1.25m2≤BSA≤1.5m2，50mg bid，BSA>1.5m2， 60mg bid) Gemcitabine：1000mg/m2，iv 30min，d1, d8 q3w, 8 cycles
3334624|NCT02131506|Experimental|Lapatinib, Caelyx|"Lapatinib is given at escalating doses orally and continuously on days 1-21.~Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1."
3234752|NCT01234155|Experimental|Exercise - Interval Walking|
3234753|NCT01234181|Experimental|BMSCs transplantation|
3234754|NCT01234181|Sham Comparator|No BMSCs transplantation|
3234755|NCT01234194|Active Comparator|Group 1|
3234756|NCT01234194|Active Comparator|Group 2|
3234757|NCT01234220||Adrenal Venous Sampling (AVS)|Patients with Primary Aldosteronism (PA) undergoing AVS to discriminate PA forms with unilateral from bilateral excess aldosterone production.
3234758|NCT01234233|No Intervention|Group 1|Control group - no intervention: no preoperative warming
3234759|NCT01234233|Active Comparator|Group 2 - 10 min prewarming|10 min prewarming preoperatively
3234760|NCT01234233|Active Comparator|Group 3 - 20 min prewarming|20 min prewarming preoperatively
3234761|NCT01234233|Active Comparator|Group 4 - 30 min prewarming|30 min prewarming preoperatively
3234762|NCT01234246||Patients with colorectal cancer|Patients with colorectal cancer are included
3234763|NCT01234246||Partners|Partners of patients with colorectal cancer are included
3234764|NCT01234259|Experimental|Study group|Device: Venus Freeze (MP)2 V2 system
3234765|NCT01234259|Sham Comparator|control group:|Sham comparator
3234766|NCT01234272|Experimental|ITM-IVPCA|ITM-IVPCA:intrathecal morphine and IV-fentanyl patient controlled analgesia
3234767|NCT01234272|Active Comparator|PCEA|PCEA:epidural PCA(patient controlled analgesia)
3234768|NCT01234285|Experimental|intravenous heparin aPTT 40-50 seconds|Patients 11-15: IV heparin, target aPTT range 40-50 seconds
3234769|NCT01234285|Experimental|intravenous heparin|Patients 26-40: IV heparin, target range aPTT 50-60 seconds
3234770|NCT01234285|Experimental|Intravenous heparin|Patients 41-55 IV heparin, target aPTT range 60-70 seconds
3234771|NCT01234285|Active Comparator|sq heparin three times a day|Patients 1-10 will receive subcutaneous heparin three times a day
3234772|NCT01234298|Experimental|SPD489 Low-Dose|
3234773|NCT01234298|Experimental|SPD489 High-Dose|
3234774|NCT01234298|Placebo Comparator|Placebo|
3234775|NCT01234311|Placebo Comparator|placebo|Matching placebo
3234776|NCT01234311|Experimental|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
3234777|NCT01234324|Experimental|Arm 1: ECX + Panitumumab|
3234778|NCT01234324|Active Comparator|Arm 2: EXC alone|
3234779|NCT01234363|Experimental|Magnetic Resonance Elastography, Supersonic Shear Imaging|Magnetic Resonance Elastography and Supersonic Shear Imaging
3234780|NCT01234376||Control patients|
3234781|NCT01234376||Patients with eosinophilic esophagitis|
3234782|NCT01234389|Other|H. pylori positive patients|
3234783|NCT01234389|Other|H. pylori negative patients|
3334625|NCT02131519||internal jugular vein catheter|pediatric patients required internal jugular vein catheter
3334626|NCT02131545|Experimental|Quetiapine|Quetiapine 25 mg
3234784|NCT01234415|Experimental|Patient|
3334627|NCT02131558|Experimental|ICG Dye|Patients received injections of Indocyanine green (ICG) for sentinel lymph node (SLN) visualization using near-infrared (NIR) imaging.
3334628|NCT02131571||HIV patients older than 50 years|HIV infected patients older than 50 years in current follow up
3334629|NCT02131584|Experimental|Supportive care (ruxolitinib phosphate)|Patients receive ruxolitinib phosphate PO BID (approximately 12 hours apart) for up to 2 years in the absence of disease progression or unacceptable toxicity.
3334630|NCT02131597|Experimental|Treatment (guadecitabine)|Patients receive guadecitabine SC on days 1-5. Treatment repeats every 4-8 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 3 courses are taken off therapy after 6 courses. Patients may continue to receive treatment after 24 courses if the investigator determines it is in the patient's best interest.
3334631|NCT02131610||Obstructive slep apnea patients|Patients with OSA
3334632|NCT02131610||Control group|Subjects without OSA
3334633|NCT02131623||Validation Group|Subjects with ALGS or PFIC and/or their caregivers
3334634|NCT02131649|Experimental|18F-FCH PET/MRI Scan|Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging. Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences. Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
3334635|NCT02131675||Boost shake|children that have had type 1 diabetes for more than 1 year
3334636|NCT02131688|Experimental|Mitoxantrone Hydrochloride Liposome|
3334637|NCT02131701|Active Comparator|Training group|The training group received individualized information about moderate training and was also offered training in group twice a week during 12 months. The training included both endurance training (nordic walking, water gymnastics) and training in gym.
3334638|NCT02131701|Active Comparator|Prescription of exercise|Individualized sessions for exercise prescription aiming at moderate exercise of 30 minutes at least 5 days a week
3334639|NCT02131714|Active Comparator|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
3334640|NCT02131714|Placebo Comparator|lifestyle counseling|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character.
3334641|NCT02131727|Experimental|Hand Hygiene Improvement Intervention|Hand Hygiene Improvement Intervention: Participants receive a 4 minute training video about actions to take to reduce risk of respiratory and GI infections that includes hand hygiene practices, along with educational posters and hand hygiene supplies.
3334642|NCT02131727|Placebo Comparator|Ask Me 3|Participants in the control group received a 4 minute training video about the Ask Me 3 program for clearer communication with health care providers, a brochure, and a key chain containing principles for clear communication with health care providers.
3234785|NCT01234428|Other|surgery|
3234786|NCT01234441|Sham Comparator|Control|This group of patients will receive a non-nutritive beverage, and no exercise.
3234787|NCT01234441|Active Comparator|Protein|This group of patients will ingest 30 grams of a liquid whey protein supplement during the first hour of their dialysis session
3234788|NCT01234441|Active Comparator|Protein + Exercise|This group will ingest 30 grams of a liquid whey protein supplement as well as exercise for 30-45 minutes during their dialysis treatment
3234789|NCT01234454|Experimental|Risperidone Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
3234790|NCT01234454|Experimental|Olanzapine Treatment Group|A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
3234791|NCT01234454|No Intervention|Thiothixene|Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
3234792|NCT01234493|Active Comparator|fixation|Syndesmosis fixation with one 3.5mm fully threaded screw
3234793|NCT01234493|Active Comparator|no fixation|No syndesmosis fixation
3234794|NCT01234506|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 0.8g/day of BeneFlax containing 300 mg SDG. 1000 IU vitamin D as standard of care.
3234795|NCT01234506|Placebo Comparator|Placebo|An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
3234796|NCT01234519|Experimental|Phase 1 - Cohort 1|"Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).~Patients will be enrolled in cohorts of 3 at a specified AEZS-108 dose beginning with 160mg/m^2. Enrollment will be suspended until all members of a cohort have been observed for dose limiting toxicities (DLT) for a period of 3 weeks (1 cycle of AEZS-108) from initial treatment with AEZS-108. Dose escalation will proceed within each cohort according to a specific scheme where DLT is defined."
3334643|NCT02131740|Experimental|Eye rubbing intervention|eye rubbing performed for 1 minute in horizontal direction, clockwise rest for 5 seconds eye rubbing for a further 1 minute
3334644|NCT02131740|Active Comparator|No eye rubbing|no eye rubbing - comparator
3334645|NCT02131753|Other|Cladribine s.c. injection, HCL treatment|Cladribine 0.14 mg/kg body weight for 5 consecutive days (d 1 - 5) as subcutaneous bolus injection for patients with hairy cell leukemia needing treatment
3334646|NCT02131779|Experimental|Co-Educational Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part health series with men and women dyads. Technical assistance and support will be given as needed to community health advisors. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
3334647|NCT02131779|Active Comparator|Men's Workshops|Community health advisors will be trained using traditional/classroom methods and provided with technical assistance/support as needed to deliver 4 part educational sessions to men only groups to relay information about making an informed decision about prostate cancer screening. Workshop sessions will include didactic lecture, group discussions, video and group exercises.
3234797|NCT01234519|Experimental|Phase 1 - Cohort 2|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3234798|NCT01234519|Experimental|Phase 1 - Cohort 3|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3234799|NCT01234519|Experimental|Phase 1 - Cohort 4|Determination of maximum tolerated dose (MTD) and recommended parenteral administration dosing for AEZS-108 in 4 sequential cohorts of patients (3-6 patients/cohort).
3234800|NCT01234519|Experimental|Phase 2|AEZS-108 at MTD to determine efficacy in up to 40 patients.
3234801|NCT01234532|Experimental|entinostat & anastrozole neoadjuvant|"Neoadjuvant entinostat daily on days 1, 8, 15, 22, and 29 + anastrozole daily on days 4-29 followed by surgery ie either lumpectomy or mastectomy.~Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
3334648|NCT02131792|Experimental|Lateral Rectus Muscle Slanted Recession|Slanted recession of the lateral rectus muscle for the intermittent exotropia with convergence weakness
3334649|NCT02131805|Experimental|Electronic Skin Surface Brachytherapy|The patient will undergo quality of life assessment and skin imaging (ultrasonography and reflectance confocal microscopy). Brachytherapy will be performed over six outpatient visits over 2-3 weeks, on non-consecutive days. Patients will then be followed for 5 years. Reflectance confocal microscopy is optional for the participating sites.
3334650|NCT02131818|Experimental|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
3334651|NCT02131818|Placebo Comparator|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
3334652|NCT02131831||cirrhosis|
3334653|NCT02131844|Experimental|Facilitated early mobilization|Early mobilization facilitated by a dedicated health professional
3334654|NCT02131844|Active Comparator|Usual care|Instructions about early mobilization covered in a preoperative education session
3334655|NCT02131857|Experimental|Staff|active interventional program based on Mindfulness training
3334656|NCT02131857|Experimental|Parents|active interventional program based on Mindfulness training
3334657|NCT02131857|Experimental|Patients with CF|active interventional program based on Mindfulness training
3334658|NCT02131870|Active Comparator|L plantarum DSM 9843|
3334659|NCT02131870|Placebo Comparator|Placebo|
3334660|NCT02131883|Experimental|Group-Cognitive Behavioral Therapy|Group-Cognitive Behavioral Therapy for 7 patients and 2 therapists, 3 hours sessions a week in 12 weeks and a 3 hours booster session 12 weeks after
3334661|NCT02131883|Other|Wait-List with treatment as usual|Wait-List with treatment as usual waiting in 9 months for the intervention with group-CBT
3334662|NCT02131896|Experimental|Mediterranean Diet|Mediterranean Diet
3334663|NCT02131896|Active Comparator|Regular nutritional instructions|Regular nutritional instructions
3334664|NCT02131909|Experimental|mirror therapy|5 sessions mirror therapy 15 minutes per week for 5 weeks
3334665|NCT02131909|Placebo Comparator|bimanual rehabilitation exercises|5 sessions control therapy 15 minutes per week for 5 weeks
3234802|NCT01234545||A|
3234803|NCT01234558|Placebo Comparator|Normal Saline|IV placebo
3334666|NCT02131922|Placebo Comparator|Hygenization Treatment|Basic oral hygiene instructions Supragingival plaque removal
3334667|NCT02131922|Experimental|Intensive Treatment|One-Stage Full-Mouth Disinfection. Scaling and root planing, four quadrants in one session. Extraction of radix relicta. Subgingival chlorhexidine (PerioKIN) (0.2%) in all pockets. Oral hygiene instructions.
3334668|NCT02131935||ISR Group|Patients Group Experienced In-Stent Restenosis (ISR)
3334669|NCT02131935||Non-ISR|Patients Group Without in-stent restenosis (ISR)
3234804|NCT01234558|Experimental|GLYX-13, 1 mg/kg|
3234805|NCT01234558|Experimental|GLYX-13, 5 mg/kg|
3234806|NCT01234558|Experimental|GLYX-13, 10 mg/kg|
3234807|NCT01234584|Experimental|Group A|23 implants using SPK Abutments
3234808|NCT01234584|Active Comparator|Group B|implants using CPK Abutments
3334670|NCT02131948|Experimental|Intranasal insulin|40 IU of intranasal insulin
3334671|NCT02131948|Placebo Comparator|Intranasal placebo|Placebo comparator to intranasal insulin
3334672|NCT02131961|Experimental|Study arm|Collagenase ointment topical application, once daily for 14 days, modified Contact Cast System, applied at days 0,3, and 7.
3334673|NCT02131987||Dislocation|Patients operated with hip hemiarthroplasty for a femoral neck fracture with a postoperative dislocation of the prosthesis
3334674|NCT02131987||Non-dislocated|Patents without dislocation of a hemiarthroplasty for a femoral neck fracture
3334675|NCT02132000|Active Comparator|tamoxifen|tamoxifen,20mg/day
3334676|NCT02132000|Experimental|toremifene|toremifene,60mg/day
3334677|NCT02132013|Experimental|Intervention SUBLIME|Intervention group
3334678|NCT02132013|No Intervention|Control|Regular care
3234809|NCT01234597|Active Comparator|Arm A: Without Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the treating physician"
3234810|NCT01234597|Experimental|Arm B: Continous Glucose Monitoring (CGM) sensor|"Run-in phase: insulin glargine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer .~Treatment phase: the patients are connected to a CGM sensor. Insulin glulisine is administered at initial dosage according to FBG measurements performed by the patient by using a glucometer. Then, adjustment of the dosage is performed by the national coordinator based on the data collected in the past previous days of CGM sensor monitoring."
3234811|NCT01234610|Experimental|Exercise|Exercise
3334679|NCT02132026|Active Comparator|Alendronic Acid|50 patients will receive once weekly Alendronic Acid tablets (70mg).
3334680|NCT02132026|Placebo Comparator|Alendronic Acid placebo|25 patients will receive alendronic acid placebo tablets.
3334681|NCT02132026|Active Comparator|Denosumab|50 patients will receive 6 monthly denosumab injections
3334682|NCT02132026|Placebo Comparator|Denosumab Placebo|25 patients will receive a 6 monthly placebo injection.
3334683|NCT02132039|Active Comparator|12-step sitting Tai Chi Chuan|The intervention is a simplified Tai Chi Chuan exercise, which consists of 12 steps, including weight shifting in different sitting positions, trunk and upper limb movements, and alternate thigh lift in a smooth and coordinated manner.
3234812|NCT01234610|No Intervention|Control|No exercise
3234813|NCT01234623||UCB eyedrops, single arm|One-centre pilot study, open, non randomized.
3234814|NCT01234636|Active Comparator|cis9,trans 11 CLA oil|50 volunteers on cross over design , receiving 4g/day of cis9,trans11 CLA
3234815|NCT01234636|Placebo Comparator|Placebo oil|50 volunteers cross over design, placebo oil 4g/day
3334684|NCT02132039|Placebo Comparator|Control|We provide participants in the control group with a level of social contact equivalent to the intervention group, which comprises structured conversations on topic other than physical activity.
3334685|NCT02132065|No Intervention|Standard pain keller|
3334686|NCT02132065|Experimental|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
3334687|NCT02132078||Lung transplant recipients with uncomplicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
3334688|NCT02132078||Lung transplant recipients with complicated diverticulitis|Retrospective data analysis of treatment, outcome and recurrency-rate
3334689|NCT02132091|Experimental|Intermittent Fasting|Intermittent Fasting
3334690|NCT02132091|Experimental|Intermittent Fasting + Antioxidants|Intermittent Fasting; 400 IU Vitamin E; 1000 mg Vitamin C
3334691|NCT02132104|Experimental|amnion graft in severe IUA|patients, who are with severe IUA, treated by uterine application of amnion membrane + Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
3334692|NCT02132104|Sham Comparator|non-amnion graft in severe IUA|patients, who are with severe IUA, treated by Foley balloon+ hormones (Femoston) following hysteroscopic adhesiolysis.
3334693|NCT02132143|Experimental|Progression-free survival&Concurrent chemoradiotherapy|"The first day of radiotherapy given pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, two cycles of chemotherapy given during radiotherapy; then continue to give two cycles of consolidation chemotherapy, 21 days as a cycle.~Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W."
3234816|NCT01234662|Active Comparator|Group 1|Spinal anesthesia + intrathecal opioid bolus (SPA)
3334694|NCT02132143|Active Comparator|Progression-free survival&sequential chemoradiotherapy|Patients received adjuvant chemotherapy for four cycles,pemetrexed(Powder for Injection) 500mg/m2 + cisplatin(Powder for Injection) 75mg/m2, 21 days as a cycle.Then accept the Intensity-modulated radiation therapy(IMRT),5000cGy～6000cGy/5～6W.
3334695|NCT02132182||Patients newly diagnosed with osteosarcoma|Blood draw
3234817|NCT01234662|Active Comparator|Group 2|CSE + epidural opioid bolus (CSE)
3234818|NCT01234662|Experimental|Group 3|CSE + continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs (CSEPCEA)
3234819|NCT01234688|Experimental|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
3334696|NCT02132208||Trauma|Severe trauma patients admitted in the resuscitation room of our emergency department.
3334697|NCT02132221|Experimental|Cognitive Behavioral Therapy (CBT)|cognitive therapy (10 weekly sessions)
3334698|NCT02132221|No Intervention|no CBT- wait list|no cognitive therapy
3334699|NCT02132234|Experimental|Biological treatment|"Patients with high disease activity receiving biological treatment according to rheumatologic indication:~etanercept 50 mg s.c. every week~adalimumab 40 mg s.c. every 2 weeks~certolizumab 400 mg s.c. every 2 weeks for 4 weeks, then 200mg every 2 weeks~infliximab 3 or 5 mg/kg i.v. 2 and 6 weeks from the first admission, then every 8 weeks"
3334700|NCT02132234|Placebo Comparator|control group|Patients with high disease activity receiving other than biological treatment and receiving placebo.
3334701|NCT02132260|Experimental|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.)
3334702|NCT02132260|Active Comparator|Naftin® Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2%
3334703|NCT02132260|Placebo Comparator|Placebo Topical Cream|Placebo Topical Cream
3334704|NCT02132273|Experimental|Educational Story|Participants receiving this intervention will have access to the educational story as they prepare for the overnight sleep study.
3334705|NCT02132273|No Intervention|Typical Preparation|Participants will receive traditional materials, directions, what to bring list, only. They will not recieve access to educational story
3334706|NCT02132286|Experimental|Quetiapine -XR (extended release)|Quetiapine-XR (extended release) 150-300mg- treatment in MDD patients with S/Lg alleles in MDD
3334707|NCT02132286|Active Comparator|Citalopram|Citalopram 10-20 mgm/day treatment for 8 weeks in MDD with S/Lg alleles
3334708|NCT02132299|Experimental|Group 1|Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10^4, 1.35x10^5, and 2.7x10^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.
3334709|NCT02132299|Experimental|Group 2(A)|Group 2: Two sub groups: 2A and 2B. Grp 2A (n=20) receives 5 vaccinations IV of 1.35x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 2 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3334710|NCT02132299|Placebo Comparator|Group 2(B)|Group 2: Two sub groups: 2A and 2B. Grp 2B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 2 starts 1 wk after Grp 1 has completed 2nd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 2 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 2. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 2 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3234820|NCT01234688|No Intervention|Control|Patients allocated to the control group remained in regular dialysis treatment during the same timeframe.
3234821|NCT01234701||Primary liver tumors, non-cirrhotic|This single Cohort/Group will include all consecutive patients that received pre-operative Magnetic Resonance Imaging (MRI) and underwent resection for primary liver tumors.
3234822|NCT01234727||Diabetes|Patients with Type 1 or Type 2 diabetes requiring insulin.
3234823|NCT01234740|Experimental|Arm I|Patients undergo intracerebral microdialysis during debulking craniotomy or stereotactic biopsy. Beginning 24 hours later, patients receive oral bafetinib twice daily for 1 day. Beginning at least 2 weeks after surgery, patients continue to receive oral bafetinib twice daily in the absence of disease progression or unacceptable toxicity.
3234824|NCT01234753|No Intervention|Usulal care|Usual care by a visit to physician at the hospital out-patient clinic
3234825|NCT01234779|Experimental|A|
3234826|NCT01234779|Experimental|B|
3234827|NCT01234779|Active Comparator|C|
3234828|NCT01234779|Placebo Comparator|D|
3234829|NCT01234792|Experimental|NIC-6|6 mg Experimental nicotine gum
3234830|NCT01234792|Active Comparator|NIC-4|4 mg Nicotine Gum
3234831|NCT01234792|Active Comparator|NIC-2|2 mg Nicotine Gum
3234832|NCT01234805|Experimental|Supportive care (yoga therapy)|Patients participate in yoga classes comprising postures, deep relaxation, breathing practices, and meditation twice weekly for 75 minutes during weeks 1-6. Patients then practice yoga at home twice weekly for 45 minutes during weeks 7-12.
3234833|NCT01234818|Experimental|LNG-IUS, endometrial hyperplasia|
3234834|NCT01234844|Other|care of guinea pigs|"Each patient serves as own control receiving pet therapy and usual occupational therapy on alternate days."
3234835|NCT01234857|Experimental|Part A: ridaforolimus + dalotuzumab|Approximately 15 patients will be enrolled to the ridaforolimus-dalotuzumab combination treatment arm. Subsequent Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to exemestane single-therapy treatment.
3234836|NCT01234857|Active Comparator|Part A: exemestane|Exemestane 25 mg daily; single-agent therapy.
3234837|NCT01234857|Experimental|Part B: ridaforolimus + dalotuzumab|Patients are randomly assigned in a 1:1 ratio to treatment with the ridaforolimus (20 mg daily five days a week)/dalotuzumab (intravenous infusion 10 mg/kg once weekly) combination therapy or cross-over to one of two single-therapy treatments (ridaforolimus alone or dalotuzumab alone). With the implementation of Amendment 3, this study arm will not be opened.
3234838|NCT01234857|Experimental|Part B: ridaforolimus|Ridaforolimus; 40 mg daily five days a week, single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
3234839|NCT01234857|Experimental|Part B: dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg weekly; single-agent therapy. With the implementation of Amendment 3, this study arm will not be opened.
3234840|NCT01234896|Experimental|Nicotine Gum 6|6 mg Nicotine medicated gum
3234841|NCT01234896|Active Comparator|Nicotine Gum 4|4 mg Nicotine Gum
3234842|NCT01234896|Active Comparator|Nicotine Gum 2|2 mg Nicotine Gum
3234843|NCT01234896|Active Comparator|Nicotine Lozenge|4 mg Nicotine Lozenge
3234844|NCT01234909||Atopic dermatitis|Pediatric patients ages 1-18 years old with atopic dermatitis
3234845|NCT01234935|Experimental|Arm I|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3234846|NCT01234935|Experimental|Arm II|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15 and oral dasatinib once daily on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity. NOTE: *Courses with dasatinib repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.
3234847|NCT01234948||Chronic periodontitis patients|Chronic periodontitis patients had at least one site per quadrant with clinical probing depth (CPD) > 5mm and radiographic evidence of bone loss
3234848|NCT01234948||Generalised chronic gingivitis patients|Generalised chronic gingivitis patients presented with bleeding on probing (BOP) at > 30% of sites, CPDs < 4mm and no evidence of bone loss
3334711|NCT02132299|Experimental|Group 3(A)|Group 3: Two sub groups: 3A and 3B. Grp 3A (n=20) receives 5 vaccinations IV of 2.7x10^5 PfSPZ Vaccine; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last immunization, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). 24 weeks after the last immunization, volunteers from Grp 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3334712|NCT02132299|Placebo Comparator|Group 3(B)|Group 3: Two sub groups: 3A and 3B. Grp 3B (n=4) receives 5 placebo injections of normal saline (NS) by IV administration; 4 doses at 4 wk intervals; 5th dose at 8 wks after 4th dose. Grp 3 starts 1 wk after Grp 1 has completed 3rd dose; and received clearance from Safety Monitoring Committee (SMC). Grp 3 starts with 4 volunteers (3 safety + 1 placebo control to maintain blinding) receiving their first doses (at each dosing time point) before the remaining 20 volunteers in Grp 3. The remaining 20 volunteers start inoculations 48 hrs after first 4 safety volunteers at each dosing time point. Three weeks after last placebo injection, Grp 3 will undergo the first CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54).
3334713|NCT02132299|Experimental|Group 4|The fourth group will include 6 volunteers who will be unblinded and will receive 5 vaccinations of 2.7 x 10^5 PfSPZ Vaccine by IV administration. Four vaccinations at 4 weeks intervals of 2.7x10^5 PfSPZ will be given and the fifth dose will be administered 8 weeks after the 4th. Volunteers from Group 4 will start their vaccinations 48 hours after the four safety volunteers from Group 3 have received their first dose, at each dosing time point. This group will participate in only one CHMI assessment at 24 weeks to assess duration of protection at 24 weeks.
3334714|NCT02132299|Placebo Comparator|Group 5|The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
3334715|NCT02132325|Experimental|Dignity Therapy|
3334716|NCT02132338|Experimental|The Education Health Program|Intervention forth knowledge and attitudes necessary for self-care
3334717|NCT02132351||Hepatologists|Doctors working as hepatologists
3334718|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
3334719|NCT02132364|No Intervention|typical follow-up|no intervention
3234849|NCT01234948||Periodontally healthy subjects|Healthy subjects had < 10% sites with BOP and no sites with CPD > 3mm
3334720|NCT02132390|Experimental|Arm I|Patients who didn't have CIA receive oral toremifene daily. Treatment continues for 5 years in the absence of disease progression or unacceptable toxicity
3334721|NCT02132390|Experimental|Arm II|Patients who had CIA receive toremifene as in arm I
3334722|NCT02132390|Experimental|Arm III|Patients without CIA receive oral toremifene and goserelin for ovarian function suppression
3334723|NCT02132390|Experimental|Arm IV|Patients with CIA receive oral toremifene and goserelin for ovarian function suppression.
3234850|NCT01234961|Experimental|Redesigning Daily Occupations|The ReDO intervention focuses on how people compose their everyday lives. Supporting people in how to change and modify their patterns of daily occupations is a new intervention method for people with stress-related disorders, but it has been shown to be effective in improving quality of life and self-rated health in other target groups. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and improved work capacity. The program is group based and comprises 16 weeks, with sessions 2 x 2 hours per week, followed by 3-4 booster sessions.
3234851|NCT01234961|Active Comparator|Care as usual|Standard rehabilitation provided by the Social Insurance Office, such as stress management, physical therapy, mindfulness training.
3234852|NCT01234974|Experimental|Pasireotide|Pasireotide 60 mg day 1 every 28 days
3234853|NCT01234987||Breast cancer|
3234854|NCT01234987||Colon cancer|
3234855|NCT01234987||Lung Cancer|
3234856|NCT01235000||2010-11 influenza vaccine recipients|Participants of an earlier clinical trial (TITRE II) to evaluate prime-boost response across B lineages in 2009-10
3234857|NCT01235013|Experimental|Maraviroc|
3234858|NCT01235013|No Intervention|Control|Patients continue with their usual treatment
3234859|NCT01235026|Experimental|Synbiotic|"Dietary Supplement: Synbiotic: combination of the prebiotic Oligofructose with the probiotic Bifidobacterium animalis subsp. lactis Bb12"
3234860|NCT01235026|Placebo Comparator|Placebo|Dietary supplement: placebo: maltodextrin
3234861|NCT01235039|Experimental|Formulation A|VIAject®25 for subcutaneous application
3234862|NCT01235039|Experimental|Formulation B|VIAject®7 for subcutaneous application
3234863|NCT01235039|Experimental|Formulation C|Insulin Lispro for subcutaneous application
3234864|NCT01235052|Experimental|TEP with 18F-FMISO|TEP with 18F-FMISO
3234865|NCT01235065|Active Comparator|direct laryngoscope|emergency intubation with direct laryngoscopy technique
3234866|NCT01235065|Active Comparator|video laryngoscope|emergency intubation with video laryngoscopy technique
3234867|NCT01235078||Intraosseous vascular access|subjects with urgent vascular access needs in whom intraosseous vascular access has been attempted and/or established.
3234868|NCT01235091|Other|Standard|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
3234869|NCT01235091|Experimental|SI/WWE|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam
3234870|NCT01235091|Experimental|SI/WWE/PD|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing along with Well-Woman Exam and Peer-delivered Enhanced Intervention
3234871|NCT01235104||Total nephrectomy|
3334724|NCT02132403|Experimental|IMPRIME PGG, BTH1704, & Gemcitabine|Imprime PGG with BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day cycle with Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day cycle.
3334725|NCT02132416|Active Comparator|Surgical management|Operative fixation of unstable thoracic cage injuries and chest wall deformity. Thoracic Epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
3334726|NCT02132416|Active Comparator|Conservative management|Conservative management of unstable thoracic cage injuries and chest wall deformity. Thoracic epidural anaesthesia will be offered. Paracetamol, Opioids and NSAID will be used as pain medication.
3334727|NCT02132429|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 daily for 14 days.
3334728|NCT02132429|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo daily for 14 days.
3334729|NCT02132442|Experimental|Vitamin D supplementation|Ergocalciferol 50,000 IU per week for 6 weeks, then bi-weekly for 6 mo
3234872|NCT01235130|Active Comparator|OMEGA-3|Long-Chain N-3 polyunsaturated fatty acids (OMEGA-3)
3234873|NCT01235130|Placebo Comparator|Placebo|Placebo soybean oil
3234874|NCT01235143|Experimental|desflurane anesthesia|maintenance anesthesia with desflurane
3234875|NCT01235143|Active Comparator|sevoflurane|maintenance anesthesia with sevoflurane
3234876|NCT01235169|Experimental|Proximal Femoral Nail Antirotation|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation
3234877|NCT01235182||acute dyspnea, field, diagnostic|All patients with shortness of breath as the primary complaint (defined as eitherthe sudden onset of dyspnea without history of chronic dyspnea or an increase in the severity of chronic dyspnea and were age >18 years.
3234878|NCT01235208|Experimental|Eurodiet treatment|
3234879|NCT01235221|Experimental|BIIB041 (Fampridine-SR)|Participants take 10 mg sustained-release tablets of fampridine twice daily for up to 27 months or until the product is commercially available.
3234880|NCT01235247|Experimental|reminders, no reminder|
3234881|NCT01235260||001|Becaplermin users A cohort of becaplermin users (ie patients with diabetes treated with becaplermin)
3234882|NCT01235260||002|Becaplermin nonusers A cohort of becaplermin nonusers (ie patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
3234883|NCT01235273|Experimental|GH replacement therapy|
3234884|NCT01235273|Placebo Comparator|Placebo|
3334730|NCT02132442|Placebo Comparator|Placebo|Placebo capsules, on capsule per week for 6 weeks, then bi-weekly for 6 mo.
3334731|NCT02132455|Experimental|3 minutes in the right side colon|Colonoscopy, at least 3 minutes in the right side colon from the total withdrawal time
3334732|NCT02132455|Experimental|4 minutes in the right side colon|Colonoscopy, at least 4 minutes in the right side colon from the total withdrawal time
3334733|NCT02132455|No Intervention|6 minutes whole withdrawal time|Colonoscopy, at least 6 minutes whole withdrawal time regardless of time spent in any segment
3334734|NCT02132455|Experimental|8 minutes whole withdrawal time|Colonoscopy, at least 8 minutes whole withdrawal time regardless of time spent in any segment
3334735|NCT02132481|Experimental|EMA Only|See intervention
3334736|NCT02132481|Experimental|EMI Only|See intervention
3334737|NCT02132481|Experimental|EMA+EMI|See intervention
3334738|NCT02132481|Active Comparator|Neither - RSAU|See intervention
3334739|NCT02132494|Experimental|Physical activity|60 minutes of daily physical activity during one school year
3334740|NCT02132494|No Intervention|Control|
3334741|NCT02132546|Experimental|Chlorhexidine 0,2%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX.
3334742|NCT02132546|Experimental|Chlorhexidine 0,2% with ADS|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.2% CHX with ADS.
3334743|NCT02132546|Experimental|Chlorhexidine 0,12%|After surgery, the patient was given instruction following the post-operative protocol. Oral hygiene with toothbrush and dental floss was suspended only in the area that underwent periodontal surgery and the patient was given an anonymous bottle of mouthwash. According to random assignment (random generator, www.random.org), the bottle contained 0.12% CHX.
3334744|NCT02132559||DHEA administration,no treatment|The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
3234885|NCT01235286|Experimental|remote ischemic preconditioning|
3234886|NCT01235299||Healthy subjects|
3234887|NCT01235299||Subjects suffering from Diabetes mellitus|
3234888|NCT01235299||Subjects suffering from peripheral arterial occlusive disease|
3234889|NCT01235312||Healthy subjects|
3234890|NCT01235312||Patients suffering from Diabetes mellitus|
3234891|NCT01235312||Patients suffering from peripheral arterial occlusive disease|
3234892|NCT01235325|Placebo Comparator|Placebo oil capsule|Banner Pharmacaps Europe
3234893|NCT01235325|Experimental|phylloquinone (1000 mcg)|Banner Pharmacaps Europe
3234894|NCT01235364|Experimental|Digital|The patient was randomized to digital insertion of the Foley catheter
3234895|NCT01235364|Experimental|Speculum|
3234896|NCT01235390|Experimental|5 g of walnuts|
3234897|NCT01235390|Experimental|40 g of walnuts|
3234898|NCT01235416|Active Comparator|AMG 706 50mg|50 mg, once daily. (Cohort 1)
3234899|NCT01235416|Active Comparator|AMG 706 75mg|75 mg, twice daily. (Cohort 2)
3234900|NCT01235416|Active Comparator|AMG 706 125mg|125 mg, once daily. (Cohort 3)
3334745|NCT02132585||Sjogren|Sjogren Patients evaluated with Speckle tracking echocardiography
3334746|NCT02132585||Control|Controls Speckle tracking echocardiography
3334747|NCT02132624|Experimental|CAR T cells|Autologous 3rd generation CD19-targeting CAR T cells
3234901|NCT01235429|Experimental|Educational|Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
3334748|NCT02132663|Experimental|Infant formula containing an alternate source of DHA|
3234902|NCT01235429|Active Comparator|Delayed education|The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
3234903|NCT01235455||Group 1|
3234904|NCT01235468|Experimental|CB expnasion|ex-vivo expansion of cord blood for transplantation
3234905|NCT01235481|Experimental|Exercise DVD|Exercise DVD to be used by participants 30-60 minutes, once daily to facilitate maintenance exercise training
3234906|NCT01235481|Other|Usual Care|Participants advised to perform maintenance exercise training 30-60 minutes, once daily without benefit of exercise DVD
3234908|NCT01235520|Experimental|1|
3334749|NCT02132663|Active Comparator|Marketed routine infant formula|
3334750|NCT02132689|Active Comparator|Actilyse|Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin).
3334751|NCT02132689|Active Comparator|UHF/LMWH|Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin).
3334752|NCT02132702|Experimental|Ekso treatment|
3234909|NCT01235520|Experimental|2|
3234910|NCT01235520|Placebo Comparator|3|
3234911|NCT01235533|Experimental|N-3 fatty acids|Participants in this arm were received three capsules of n-3 fatty acids. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g。
3334753|NCT02132715|Active Comparator|Resistance exercise|Traditional isotonic lower-extremity resistance training
3334754|NCT02132715|Experimental|KAATSU exercise|Lower-extremity exercise with blood flow mildly restricted
3334755|NCT02132728|No Intervention|Control group|In the group with 11 volunteers, the control group did no change in normal food intake.
3334756|NCT02132728|Experimental|Flaxseed group|In this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
3334757|NCT02132728|Experimental|Rice and low carb group|In this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
3234912|NCT01235533|Placebo Comparator|Placebo|Participants in this arm were received three identical capsules per day. All capsules included olive oil.
3234913|NCT01235559|Placebo Comparator|Placebo|
3234914|NCT01235559|Experimental|bitopertin [RO4917838] 1|
3234915|NCT01235559|Experimental|bitopertin [RO4917838] 2|
3234916|NCT01235572|Experimental|Health services research (early discharge, outpatient care)|Patients are discharged within 72 hours after completion of chemotherapy and undergo standard outpatient care by a RN, PA, or resident/fellow at a local facility or the study center approximately 3 times per week, as clinically indicated for up to 45 days.
3234917|NCT01235585|Experimental|Bitopertin oral dose level 1|
3234918|NCT01235585|Experimental|Bitopertin oral dose level 2|
3234919|NCT01235585|Placebo Comparator|Placebo|
3234920|NCT01235624|Other|patient|Patient suffering of adRP that accept to participate at this study have a blood prelevement for genetic analysis (intervention)
3234921|NCT01235637|Active Comparator|Alfentanil|
3234922|NCT01235637|Sham Comparator|Sufentanil|
3234923|NCT01235650||Spinal fusion|Patients who underwent complex surgical procedures (spinal fusions) which necessitated arterial line placement and intermittent arterial blood gas analysis
3234924|NCT01235663|Experimental|advisory support|advisory support for six months to prolong the breast-feeding period
3234925|NCT01235676|Experimental|Diet|Calorie restriction to reduce weight gain
3234926|NCT01235676|Experimental|Exercise|Exercise to reduce weight gain
3234927|NCT01235754|Placebo Comparator|placebo gel|placebo transdermal gel
3234928|NCT01235754|Experimental|testosterone gel|transdermal testosterone gel
3234929|NCT01235767|Experimental|ASF supplement pre-pregnancy to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
3234930|NCT01235767|Experimental|ASF Supplement mid-gestation to term|Supplement of animal-source foods rich in iron, zinc, vitamin A, and vitamin B12
3234931|NCT01235767|No Intervention|Routine prenatal care|Nutrition education and iron-folate supplements during pregnancy
3234932|NCT01235806|Other|MRI|MRI of the scaphoid bone fracture suspicion
3234933|NCT01235819|Active Comparator|Insulin alone|Type 1 DM only on Insulin
3334758|NCT02132728|Experimental|Flaxssed and low carb group|In this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
3334759|NCT02132741||Treated hypertension|Patients on treatment for hypertension
3334760|NCT02132741||CKD-ESRD|Pre- & post haemodialysis
3334761|NCT02132741||Healthy individuals|Healthy volunteers
3334762|NCT02132741||CKD|Pre-dialysis CKD & those with a functional renal transplant
3334763|NCT02132741||Hypertension|Untreated
3334764|NCT02132793|Active Comparator|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
3334765|NCT02132793|Experimental|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
3334766|NCT02132806|Experimental|OFD with piezosurgery|Open flap debridement with Piezosurgery
3334767|NCT02132806|Experimental|OFD with piezosurgery+biomaterial|Open flap debridement with Piezosurgery with biomaterial mp3
3334768|NCT02132806|Experimental|OFD with piezosurgery+mp3+bracket|Open flap debridement with Piezosurgery with biomaterial mp3 + bracket
3334769|NCT02132819|Placebo Comparator|Feeding During Transfusion|The feeding process will be continued during the transfusion
3334770|NCT02132819|Active Comparator|witholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
3334771|NCT02132845|Active Comparator|Arm A (standard of care therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Patients receive standard of care therapy based on the discretion of the treating physician.
3334772|NCT02132845|Experimental|Arm B (target-directed therapy)|Patients undergo collection of tissue and blood samples for analysis via next generation sequencing. Based on the results of the next generation sequencing, patients receive target-directed therapy.
3334773|NCT02132858||Ancillary-Correlative (genetic mutation analysis)|Patients undergo collection of blood and tissue samples for analysis via sequencing.
3334774|NCT02132871||1|
3334775|NCT02132897|Other|TR (Test - Reference)|Sequence : Auration CR 400 Single Dose/Tegretol CR 400 Single Dose
3334776|NCT02132897|Other|RT (Reference - Test)|Sequence: Tegretol CR 400 Single Dose/Auration CR 400 Single Dose
3334777|NCT02132923||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
3334778|NCT02132962|Active Comparator|Healthy controls|Amino acid infusion
3334779|NCT02132962|Active Comparator|Cirrhosis|Amino acid infusion
3334780|NCT02132975|Experimental|With motorised probe handler|The surgeon use the motorised probe handler to do the biopsy
3334781|NCT02132975|Experimental|Without motorised probe handler|The surgeon do the biopsy as he usually do.
3334782|NCT02132988|Experimental|OPT-822/OPT-821|
3334783|NCT02133014|Experimental|surgical operation therapy|Using the method of laparoscopic-assisted percutaneous catheter drainage of SAP.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline.
3334784|NCT02133014|No Intervention|conventional therapy|using the method of conventional conservative therapy without surgical management.
3334785|NCT02133027|Experimental|Rouviere's Sulcus|Rouviere's sulcus is a 2 to 5 cm sulcus running to the right of the liver hilum anterior to the caudate process and usually containing the right portal triad or its branches.Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
3334786|NCT02133027|Other|traditional anatomy method|Ratcheted grasper is inserted through the lateral 5-mm port to retract the gallbladder fundus in cephalad fashion. An atraumatic grasper is inserted through the middle 5-mm port to retract the gallbladder infundibulum laterally, exposing the anteromedial aspect of the triangle of Calot.
3334787|NCT02133040||T3 > 4 nmol/l|Acute hyperthyroidism with a T3 > 4 nmol/l
3334788|NCT02133053||Ectoin Group|Ectoin Allergy Nasal Spray (Medical Device, drug-like)
3334789|NCT02133053||Beclomethasone Group|Beclomethasone nasal spray
3334790|NCT02133079|Experimental|gp96 group|autologous gp96 vaccination + basal treatment
3334791|NCT02133092||Patients with respiratory syncytial virus (RSV) infection|The RSV infection is laboratory confirmed
3234934|NCT01235819|Active Comparator|Insulin and Exenatide|Newly detected Type 1 DM on Insulin and exenatide
3234935|NCT01235819|Active Comparator|Insulin and Sitagliptin|Newly detected Type 1 DM using Insulin and Sitagliptin
3234936|NCT01235832|Active Comparator|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
3234937|NCT01235832|Active Comparator|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
3334792|NCT02133105|Active Comparator|Levosimendan|Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
3334793|NCT02133105|Active Comparator|Dobutamine|Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
3334794|NCT02133118||Patients on metformin mono-therapy who receive add-on|
3234938|NCT01235832|Experimental|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
3234939|NCT01235845|Experimental|DC-DCIK|
3234940|NCT01235858|Other|Gown group|Anesthesiologists wearing sterile gown for epidural insertion
3234941|NCT01235858|Other|No Gown group|Anesthesiologists not wearing gown for epidural insertion
3234942|NCT01235871|Experimental|SB1578|
3234943|NCT01235871|Placebo Comparator|Placebo|
3234944|NCT01235884|Active Comparator|Lactobacillus reuteri|Dietary Supplement
3234945|NCT01235884|Placebo Comparator|Placebo|Dietary Supplement
3234946|NCT01235936|Experimental|AKB-6548|
3334795|NCT02133144|Experimental|High fat diet|Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
3334796|NCT02133144|Experimental|High carbohydrate diet|Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
3334797|NCT02133157|Experimental|Sulfatinib capsule|cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.
3334798|NCT02133170|Active Comparator|Psychopharmacological + MBCT|psychopharmacological treatment plus Mindfulness Based Cognitive Therapy (MBCT)
3334799|NCT02133170|Active Comparator|psychopharmacological + psychoeducation|psychopharmacological treatment plus structured group psychoeducation;
3334800|NCT02133170|Other|Psychopharmacological treatment.|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
3234947|NCT01235962|Experimental|pazopanib|Pazopanib oral agent, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
3234948|NCT01235962|Placebo Comparator|placebo|placebo matching pazopanib 200 mg tablets, administered at 600 mg daily initial dose for 8-12 weeks. Dose can be escalated to 800 mg daily based on safety evaluation. Complete treatment is 12 months. Dose can be reduced, interrupted or discontinued due to adverse events or intolerance.
3234949|NCT01235988||Eltrombopag & standard of care|
3334801|NCT02133183|Experimental|Arm I (sapanisertib before and after surgery)|Patients receive sapanisertib PO according to the results from Part I. Patients also undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3334802|NCT02133183|Experimental|Arm II (sapanisertib after surgery)|Patients undergo surgery on day 0. Within 45 days after surgery, patients receive sapanisertib PO according to the results from Part I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3334803|NCT02133196|Experimental|1/High-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus high-dose Aldesleukin
3334804|NCT02133196|Experimental|2/Low-Dose Aldesleukin|Non-myeloablative lymphodepleting preparative regimen of cyclophosphamide and fludarabine plus young TIL plus low-dose Aldesleukin
3334805|NCT02133209|Active Comparator|Stress Management for Headaches|This intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills for managing migraine headaches.
3234950|NCT01235988||Standard of care|
3234951|NCT01236014||Eltrombopag & standard of care|
3234952|NCT01236014||Romiplostim & standard of care|
3234953|NCT01236014||Standard of care|
3334806|NCT02133209|Active Comparator|Mindfulness Based Stress Reduction|Intervention involves a standardized mindfulness-based stress reduction (MBSR) group intervention following the guidelines originally conceived and developed by the Center for Mindfulness in Medicine, Health Care and Society at the University of Massachusetts. The intervention also included an extended period of training in addition to the usual 8 weeks.
3334807|NCT02133222|Experimental|Metastatic (stage IV) melanoma|
3334808|NCT02133248||kidney recipient waitlist|Subjects on waitlist for Kidney transplant who are sensitized
3334809|NCT02133248||chronic antibody mediated rejection|Kidney transplant recipient who are diagnosed with chronic antibody mediated rejection
3334810|NCT02133248||control|Normal subjects-no kidney transplant or chronic rejection
3334811|NCT02133274|No Intervention|Standard oncologic care|Standard oncologic care
3334812|NCT02133274|Experimental|Early Palliative Care|A first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
3334813|NCT02133274|Experimental|Psychosocial plus early Palliative Care|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy plus early palliative care. Regarding the early Palliative Care, a first medical consult at the Palliative Care Service will be scheduled after 2 to 3 weeks from the study inclusion and every 3 to 4 weeks thereafter.
3334814|NCT02133287|Experimental|AVI® Arsenic trioxide drug eluting stent|Study group: Arsenic trioxide drug eluting stent delivery system (AVI®)
3334815|NCT02133287|Active Comparator|Firebird2® sirolimus eluting stent system|Control group: sirolimus eluting cobalt-chromium alloy stent system(Firebird 2®)
3334816|NCT02133300|Experimental|electrical stimulation|Compex 3 professional NMES for 60' per day
3334817|NCT02133300|No Intervention|control|
3334818|NCT02133313||Peritoneal Dialysis Patients|Patients on Peritoneal Dialysis
3334819|NCT02133326|Experimental|Caldolor|800 mg of Caldolor® will be infused at the rate of 5-7 minutes as per the manufacturer's guidelines or
3334820|NCT02133326|Experimental|Ofirmev|1000 mg of Ofirmev® will be infused at the rate of 15 minutes as per the manufacturer's guidelines.
3334821|NCT02133339|Experimental|TRN-157|
3334822|NCT02133339|Placebo Comparator|Placebo|
3334823|NCT02133365|Active Comparator|Mindfulness and Interoceptive Exposure|Atrial fibrillation patients will receive 4-5 manualized, individualized sessions of Mindfulness and Interoceptive Exposure.
3334824|NCT02133365|No Intervention|Medical care as usual|Atrial fibrillation patients will receive medical and cardiac care as usual.
3334825|NCT02133378|Experimental|Hemopatch|Use of Hemopatch on bleeding spot
3334826|NCT02133378|Sham Comparator|Control|Traditional techniques hemostasis (dry or wet gauze compression or similar)
3334827|NCT02133391|Active Comparator|Practice-based reminder/recall or Usual care arm|"Practices participating in state immunization registry invited to reminder/recall (R/R) webinar trainings and provided educational materials to encourage immunization within their practices (child and adolescent trials only)~Patients not randomized to the collaborative centralized R/R arm will receive usual care from their provider, which does not include R/R (adult trials only)"
3334828|NCT02133391|Experimental|Collaborative centralized R/R|Collaborative centralized reminder/recall (R/R) effort will be conducted by state immunization registry in collaboration with accountable care organizations and practices
3334829|NCT02133404|Experimental|ASP7991 group|receiving ASP7991 and Cinacalcet-placebo
3334830|NCT02133404|Active Comparator|Cinacalcet group|receiving Cinacalcet and ASP7991-placebo
3234954|NCT01236027||HIV-negative women|HIV-negative women who agree to have specimens collected for validation of laboratory procedures
3234955|NCT01236040|Experimental|Group A|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
3334831|NCT02133417||Women|Women with mammographically-detected breast lesions
3334832|NCT02133430|Experimental|Bispectral index (BIS) group|Bispectral index as measured by a BIS Processor is used to guide doses of anesthetic for maintaining the BIS values of 40-60
3334833|NCT02133430|No Intervention|Control group|Clinical signs is used to guide doses of anestheitics.
3334834|NCT02133443|Active Comparator|Pressure Support Ventilation|Device: PSV - pressure support ventilation
3334835|NCT02133443|Active Comparator|Neurally Adjusted Ventilatory Assist|Device: Partial ventilator support with partial ventilation mode (NAVA)
3334836|NCT02133456||SIBP's vaccine|SIBP's vaccine group is the population injected with this vaccine.
3334837|NCT02133469|Experimental|PCV7 (Vaccine)|Randomized group of 1634 subjects to be administered a single dose of PCV7 (Hib vaccine offered at end of study).
3334838|NCT02133469|Active Comparator|Hib vaccine|Randomized group of 1634 subjects to be administered a single dose of Hib Vaccine(PCV7 vaccine offered at end of study).
3334839|NCT02133482|Experimental|BI 639667|single rising doses given as oral solution
3334840|NCT02133482|Placebo Comparator|Placebo|placebo solution
3334841|NCT02133495|Experimental|open label|Non Cadaveric human BellaDerm Acellular dermal tissue
3334842|NCT02133521|Placebo Comparator|Placebo|Placebo 3 x 1 tablet, given everyday for 28 days of study period
3334843|NCT02133521|Experimental|DLBS1033|DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
3334844|NCT02133560|Other|Medication Administration + Education|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip during months 1-3 and completing the medication administration log during months 1-6. During months 1-6 subjects will meet with study staff and receive educational materials on a monthly basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
3334845|NCT02133573|Experimental|Progesterone|Vaginal gel, 90mg twice a day (BID)
3334846|NCT02133573|Placebo Comparator|Vaginal Lubricant|Vaginal twice a day (BID)
3234956|NCT01236040|Experimental|Group B|Subjects will receive 2 doses of a formulation of GSK2592984A vaccine at a 21-day interval.
3234957|NCT01236040|Placebo Comparator|Group C|Subjects will receive 2 doses of a placebo at a 21-day interval.
3234958|NCT01236040|Experimental|Group D|Subjects will receive 2 doses of a formulation of GSK2590066A vaccine at a 21-day interval.
3234959|NCT01236040|Experimental|Group E|Subjects will receive 2 doses of a formulation of GSK2340274A vaccine at a 21-day interval.
3334847|NCT02133586|Placebo Comparator|Clean Air - O3|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3334848|NCT02133586|Experimental|NO2-O3|"Day #1: Two-hour exposure to 500ppb nitrogen dioxide with intermittent exercise.~Day #2: Two-hour exposure to 300ppb ozone (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3334849|NCT02133586|Placebo Comparator|Clean Air - NO2|"Day #1: Two-hour exposure to clean, filtered air with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3334850|NCT02133586|Experimental|O3 - NO2|"Day #1: Two-hour exposure to 300ppb ozone with intermittent exercise. Day #2: Two-hour exposure to 500ppb nitrogen dioxide (beginning approximately 22 hours after completion of the Day #1 exposure) with intermittent exercise.~Day #3: Follow-up (no exposure)"
3334851|NCT02133599|Other|Iohexol|All patients will receive two Iohexol clearance tests, 5 mL each time before cycle 1 and 4 of HDMTX
3234960|NCT01236040|Experimental|Group F|Subjects will receive 2 doses of a formulation of GSK2340273A vaccine at a 21-day interval.
3334852|NCT02133612|Experimental|single arm paclitaxel and cisplatin|
3334853|NCT02133625|Experimental|Pioglitazone and Carboplatin|"MTD Determination~Pioglitazone: 45 mg Once Daily by mouth,Cycle 1Days 1-28; Subsequent cycles: Days 1-21~Carboplatin:6 AUC IV 60 minute infusion (or per institutional policy) Cycle 1: Day 8; Subsequent cycles: Day 1"
3234961|NCT01236066||Study Group|Australian children aged < 5 years who have been vaccinated with RotaTeq or Rotarix from 2007 to 2009 as well as all children aged < 5 years hospitalised for all-cause gastroenteritis, rotavirus gastroenteritis or bronchiolitis.
3334854|NCT02133625|Experimental|MTD Expansion Carboplatin and Pioglitazone|"MTD Expansion:~Carboplatin alone on cycle 1, day 1.~Pioglitazone Over days 15-21 of the cycle pioglitazone will be administered alone.~On cycle 2, day 1, both carboplatin and pioglitazone will be administered. Cycle 2 and onward are 21-day cycles, with pioglitazone administered once daily and carboplatin administered once every 3 weeks"
3334855|NCT02133638|Active Comparator|Sevoflurane|Sevoflurane Based Volatile Induction and Maintenance of Anaesthesia
3334856|NCT02133638|Active Comparator|Propofol|Propofol Based Total Intravenous Anesthesia
3334857|NCT02133677|Experimental|temozolomide+WBRT|temozolomide: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks WBRT:30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week)
3334858|NCT02133690|Experimental|Vaccine Arm|3 doses, 4 weeks apart, of Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
3334859|NCT02133690|Placebo Comparator|Placebo group|3 doses, 4 weeks apart, of Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
3334860|NCT02133703|Experimental|Mutation Carrier: Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool.
3334861|NCT02133703|Experimental|Mutation Carrier: Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support intervention without a preference clarification tool.
3334862|NCT02133703|Active Comparator|Mutation Carrier: Enhanced Print DA|BRCA1/2 carriers randomized to this arm will be sent a print-based decision aid with a print preference clarification tool.
3334863|NCT02133703|Active Comparator|Mutation Carrier: Print DA|BRCA1/2 carriers randomized to this arm will receive a print decision aid without a preference clarification tool.
3234962|NCT01236079|Experimental|Assisted Referral & IVR|
3234963|NCT01236079|No Intervention|Usual Care|
3234964|NCT01236131||Endometrial biospy samples|The Endometrial Biopsy samples will be provided by women enrolled in the University of Pittsburgh IRB PRO10010112 and PRO10010159
3334864|NCT02133703|Experimental|Inconclusive Results: DA|Participants who receive inconclusive results who are randomized to this arm will have access to an Internet decision tool designed to facilitate management decision making
3334865|NCT02133703|No Intervention|Inconclusive Results: Usual care|Participants who receive inconclusive/uninformative results who are randomized to this arm will receive usual care but no additional decision support intervention
3334866|NCT02133716|Experimental|expressed breast milk|"A single dose of expressed breast milk was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
3234965|NCT01236144|Experimental|AC220 Intervention|
3234966|NCT01236144|Experimental|Plerixafor Intervention|
3234967|NCT01236144|Experimental|Ganetespib|
3334867|NCT02133716|Active Comparator|sucrose 24% oral|"A single dose of sucrose was administered through a sterile syringe in the mouth 2 minutes before venopuncture to neonates, accompanied at all times provided the technique allows it to non-nutritive sucking and containment.~The doses administered: 0.1ml in infants less than 27 weeks , 0.25 ml for infants 27-31 weeks , 0.5 ml for infants 32-37 weeks."
3334868|NCT02133729|Experimental|Gestational diabete|
3334869|NCT02133755|Other|Bromocriptine mesylate (Cycloset)|Cycloset 1.6 to 3.2 mg daily for 3 months
3334870|NCT02133794|Experimental|Tomosynthesis|
3334871|NCT02133807|Experimental|Specific Lp(a) apheresis & Atorvastatin|"Specific Lp(a) apheresis was performed with Lp(a) Lipopak immunosorbent columns (POCARD Ltd., Moscow, Russia) with sheep polyclonal monospecific antibodies against human Lp(a)/apo(a) weekly during 18 months. On the background - standard medical therapy in accordance with the recommendations for secondary prevention of CHD."
3334872|NCT02133807|No Intervention|Atorvastatin|Standard medical therapy in accordance with the recommendations for secondary prevention of CHD
3334873|NCT02133820|Active Comparator|12 hourly capsule fasted|4 mg 12 hourly capsule - strong pain killer fasted
3334874|NCT02133820|Active Comparator|12 hourly capsule fed|4 mg 12 hourly capsule - strong pain killer fed
3334875|NCT02133820|Experimental|12 hourly capsule with antagonist fasted|4 mg 12 hourly capsule strong painkiller with antagonist fasted
3234968|NCT01236157||Chest Pain|All patients that call to the SAMU-ACS because of chest pain are included
3234969|NCT01236209|Active Comparator|web page|"Control group:~Information web page with some mindfulness exercises"
3334876|NCT02133820|Experimental|12 hourly capsule with antagonist fed|4 mg 12 hourly capsule strong painkiller with antagonist fed
3334877|NCT02133833|Experimental|Quantum Spectrum Radiation Emitter|five pieces of Quantum Spectrum Radiation Emitter will be placed on the affected shoulder daily for three weeks.
3334878|NCT02133846|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3334879|NCT02133846|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions).
3334880|NCT02133846|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3334881|NCT02133846|Placebo Comparator|Placebo|0.9% sodium chloride as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3334882|NCT02133859||Chronic Heart Failure patients using ASV|Patients with chronic heart failure who are using or willing to use adaptive servo ventilation (ASV) therapy will be enrolled. Respiratory data will be collected from this group every 3 months over a 12 month period
3334883|NCT02133885|Active Comparator|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
3334884|NCT02133885|Placebo Comparator|Placebo Group|These subjects will start with placebo (this will look like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive a minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
3334885|NCT02133898|Other|L-methyfolate|Single-arm open label administration of L-methylfolate 15mg once daily for 90 days
3234970|NCT01236209|Experimental|Webpage and situational feedback|"Intervention group:~have access to the same web-page with information about coping with pain and relaxation and are completing 3 diaries and receiving personalized feedback for 4 weeks at home through a smartphone."
3234971|NCT01236222|No Intervention|Control group|
3234972|NCT01236222|Experimental|Cycling to school|
3234973|NCT01236235||ARV-naïve HIV patients initiated on ATV/RTV-based therapy|"Anti-retroviral (ARV)-naïve HIV patients initiated on ATV/RTV-based therapy between 2008-2010~One cohort being observed for 3 different countries"
3234974|NCT01236248|Experimental|Prevention Program|Girls and their mothers who are assigned to participate in a tobacco, alcohol, and other drug use prevention program aimed at young girls.
3234975|NCT01236248|No Intervention|No Prevention Program|Girls and their mothers who are assigned to participate in questionnaires only.
3234976|NCT01236261||Fungemia|Patients with a fungal isolate from a blood culture
3234977|NCT01236274||Antipsychotic agents AND MI|In the self-controlled case series study, patients who experienced a myocardial infarction and received an antipsychotic agent during up to standard (UTS) follow-up in the GPRD will be included and will act as their own control.
3234978|NCT01236274||Myocardial Infarction|In the case-control study, all cases with a first recorded occurrence of MI during up to standard (UTS) follow-up in the GPRD will be identified
3234979|NCT01236274||No Myocardial Infarction|In the case-control study, a control group with subjects who never experienced a myocardial infarction will be matched to cases (5:1) by age, gender, General Practitioner and registration in the GPRD on the date of MI of the case
3234980|NCT01236313||TEE report|Cardiac surgery patients requiring TEE
3234981|NCT01236404|Experimental|PB1023 Injection|Subcutaneous injection PB1023
3234982|NCT01236404|Placebo Comparator|Placebo (0.9% Sodium Chloride Injection)|Subcutaneous Injection Placebo
3234983|NCT01236417|Experimental|Exercise|Subjects will be participating in a home-based flexibility and exercise program
3334886|NCT02133911|No Intervention|Controls|
3334887|NCT02133911|Experimental|Ranolazine|Initial dose is 375 mg bid. After 2 - 4 weeks the dose is increased to 500 mg bid and after another 2-4 weeks to 750 mg bid. In case of side effects the dose of the drug is to be decreased to the highest dose that the patient is still able to tolerate.
3334888|NCT02133924|Experimental|Natalizumab with steroids|"For subjects whose GVHD assay is Ann Arbor score 3, the study treatment will consist of two drugs, prednisone (or methylprednisolone) and natalizumab.~Protocol treatment must start within 3 days of the subject's diagnosis of acute GVHD."
3334889|NCT02133937|Experimental|High Concentration Liquid Formulation (HCLF)|
3334890|NCT02133937|Active Comparator|Lyophilized formulation|
3334891|NCT02133950|Experimental|freeze all embryos following PGD|no fresh embryo transfer; elective cryopreservation of all embryos after PGD
3334892|NCT02133950|Active Comparator|elective fresh embryo transfer|
3334893|NCT02133963||women with no history of depression|Non-Probability Sample of women with no history of depression
3334894|NCT02133963||women with a past depression history|Non-Probability Sample of women with a past history of depression
3334895|NCT02133976|Active Comparator|cognitive therapy|Cognitive therapy will be delivered to decrease pain interference
3334896|NCT02133976|Active Comparator|mindfulness training|Mindfulness training will be delivered to decrease pain interference
3234984|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 10mg|Ezetimibe 10mg tablet and Atorvastatin 10mg tablet coadministered
3234985|NCT01236430|Experimental|10mg Ezetimibe/10mg Atorvastatin|10mg Ezetimibe/10mg atorvastatin combination tablet
3334897|NCT02133976|Active Comparator|behavior therapy|Behavior therapy will be delivered to decrease pain interference
3334898|NCT02133976|Active Comparator|treatment as usual|Subjects will engage in their usual care for low back pain.
3334899|NCT02133989|Experimental|Ticlopidine+Ginko biloba|Switch to ticlopidine + ginko biloba
3334900|NCT02133989|Active Comparator|Clopidogrel|Keep clopidogrel
3334901|NCT02134002|Experimental|Disulfiram|disulfiram 250 mg/day
3334902|NCT02134002|Placebo Comparator|Placebo|Placebo
3334903|NCT02134041||traumatic brain injury|mild traumatic brain injury
3234986|NCT01236430|Active Comparator|Ezetimibe 10mg and Atorvastatin 80mg|Ezetimibe 10mg tablet and Atorvastatin 80mg tablet coadministered
3234987|NCT01236430|Experimental|10mg Ezetimibe/80mg Atorvastatin|Ezetimibe/atorvastatin 10mg/80mg combination tablet
3334904|NCT02134041||without TBI|without TBI
3334905|NCT02134054||Biologic|Patients on treatment with biologics (infliximab or adalimumab)
3334906|NCT02134067|Experimental|TAS-119|"TAS-119 tablets, oral, dose-escalating, 28-day cycle.~Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms."
3334907|NCT02134080|Active Comparator|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
3234988|NCT01236443|Experimental|HPPH|3 mg/m2
3234989|NCT01236469||Retrospective Patients|Pediatric (21 years of age or younger) patients who received a CryoValve SG Aortic Valve distributed during the 2000 to 2003 period as an aortic valve replacement.
3234990|NCT01236482|Active Comparator|Oxytocin|
3234991|NCT01236482|Experimental|Oxytocin - ergometrine|
3334908|NCT02134080|Placebo Comparator|Placebo|Placebo (sugar pill) will be administered orally at 4mg daily for four weeks.
3334909|NCT02134093|Placebo Comparator|Normal saline|Continuous pump infusion of normal saline with identical volume, compared with the low dose and high dose group,until the end of surgery
3334910|NCT02134093|Experimental|High dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 1μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.4μg/kg/h until the end of surgery
3334911|NCT02134093|Experimental|Low dose group, dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg for 15 minutes before anesthesia induction ,then continuous pump infusion dexmedetomidine at 0.2μg/kg/h until the end of surgery
3334912|NCT02134106|Active Comparator|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000 Units (U)/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 million units (MU) 8 hourly for 5 days will be prescribed.
3334913|NCT02134106|Experimental|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
3234992|NCT01236495|Experimental|spinal morphine 0.2 mg|spinal morphine 0.2 mg
3234993|NCT01236495|Active Comparator|spinal morphine 0.3 mg|spinal morphine 0.3 mg
3234994|NCT01236508|Experimental|Nuclear imaging|PET/CT imaging with F-18 fluorodeoxyglucose
3234995|NCT01236599|No Intervention|traditional care|Preterm Infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off and wrapped up in a sterile preheated field
3334914|NCT02134132|Active Comparator|platelet rich plasma|The patients with diabetic foot ulcer who receive PG treatment.
3334915|NCT02134132|Placebo Comparator|Placebo|The patients with diabetic foot ulcer who receive placebo.
3334916|NCT02134145||Self Selected Investors|A self selected crowdfunding backers from teh Scanadu Scout Crowdfunding campaign.
3334917|NCT02134158|Experimental|sham and then anodal|visit 2 sham stimulation (120 seconds) and visit 3 anodal stimulation (30 minutes)
3334918|NCT02134158|Experimental|anodal and then sham|visit 2 anodal stimulation (30 minutes) and visit 3 sham stimulation (120 seconds)
3334919|NCT02134171|Experimental|Biological investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
3334920|NCT02134197|Experimental|Lupartumab Amadotin (BAY1129980)|Dose escalation with consecutive expansion at MTD (maximum tolerated dose) with BAY1129980.
3234996|NCT01236599|Experimental|Polyethylene bag with previous drying|infants were placed under the radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel), dried off, and wrapped up in a polyethylene bag, leaving their faces discovered as well as the access at umbilical catheters or veined access.
3234997|NCT01236599|Experimental|Polyethylene bag without previous drying|Preterm infants were placed under a radiant warmer (BLOSSON, Series 900, it Marks Fisher and Paykel) and without previous body drying (only the head was dried), were wrapped up with the polyethylene bag, leaving their faces discovered as well as the access to umbilical catheters or veined access
3234998|NCT01236612|Experimental|Immunization + bloodstage challenge|
3234999|NCT01236612|Active Comparator|Immunization + mosquito challenge|
3235000|NCT01236612|Placebo Comparator|Control - Bloodstage challenge|
3235001|NCT01236612|Placebo Comparator|Control - Mosquito challenge|
3235002|NCT01236625||No adhesiolysis|All patient undergoing elective laparotomy or laparoscopy with no need for adhesiolysis during the procedure.
3235003|NCT01236625||Adhesiolysis|All patient undergoing elective laparotomy or laparoscopy requiring adhesiolysis during the procedure.
3235004|NCT01236638|Experimental|Momelotinib|
3235005|NCT01236651|Experimental|meperidine and duration of 1st stage of labor|meperidine 100mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
3235006|NCT01236651|Experimental|drotaverine and duration of 1st stage of labor|drotaverine 40mg i.v in 1st stage of labor and calculate the duration of the 1st stage of labor
3235007|NCT01236664|Experimental|Memory Training|
3334921|NCT02134223|Experimental|dialectical behavior therapy|Primary intervention group: receiving one year of dialectical behavior therapy
3334922|NCT02134223|Placebo Comparator|treatment as usual|Comparison group: receiving one year of treatment as usual
3334923|NCT02134223|No Intervention|Receiving no treatment at all|Healthy control group
3334924|NCT02134249|Active Comparator|Group A (Diosmin group)|In group A, (Diosmin group), 2 tab / 8 hs Diosmin ( 500mg) will be given from at day of HCG injection and for 14 days.
3334925|NCT02134249|Active Comparator|Group B(Cabergoline group)|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be given at day of HCG injection and for 8 days .
3334926|NCT02134262|Experimental|Dose Level -1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3334927|NCT02134262|Experimental|Dose Level 1|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3334928|NCT02134262|Experimental|Dose Level 2|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3334929|NCT02134262|Experimental|Dose Level 3|Cyclophosphamide or Bendamustine as Pre-treatment, and in combination with CD19-CAR-T. In case when sufficient cell number of CD19-CAR-T has been manufactured, the physician judges whether the 2nd infusion of CD19-CAR-T should be performed based on the condition of the subject.
3334930|NCT02134275|Experimental|Whole body vibration training|Whole body vibration training (timed stand on vibration platform) 3 20-minute sessions per week for 6 months
3334931|NCT02134275|Placebo Comparator|Control group|No significant changes to diet, exercise and lifestyle.
3334932|NCT02134288|Active Comparator|Belatacept|Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
3334933|NCT02134288|Active Comparator|Everolimus|Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.
3334934|NCT02134301|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3334935|NCT02134327|Experimental|Premedication with Midazolam|
3334936|NCT02134340|Experimental|[I-124]-CPD-1028 PET/CT|"Administration of [I-124]-CPD-1028 Injection followed by a maximum of 3 PET/CT imaging sessions.~A pre-targeting dose of CPD-1061 may be given prior to injection of [I-124]-CPD-1028."
3334937|NCT02134366|Experimental|Clobazam|Subjects who are assigned the clobazam treatment group will receive a 10mg loading dose followed by a maintenance dose of 5-25 mg bid starting 12 hrs after the loading dose. If subjects are found to have failed to respond to treatment with clobazam, the physician investigator has the ability to either start another AED or increase the dose of clobazam depending on the clinical situation. Subjects still being treated with clobazam at discharge will be given a 30 day supply of clobazam.
3334938|NCT02134366|Active Comparator|Clonazepam|Subjects who are assigned to the clonazepam treatment group will receive a dose of 1-2mg clonazepam dose tid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
3235008|NCT01236664|Active Comparator|Control workshop|
3235009|NCT01236677||Community acquired pneumonia,age≥14 ys|Patients with community acquired pneumonia,age≥14 ys and less than one week after the onset of symptoms, without pregnancy,breast-feeding,HIV infection,recent 90-day hospitalized history and in nursing homes or rehabilitation hospitals
3235010|NCT01236703||ICU patients|ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
3235011|NCT01236716|Experimental|Albumin paclitaxel plus carboplatin|Treatment of Albumin paclitaxel plus carboplatin
3235012|NCT01236716|Active Comparator|Gemcitabine plus carboplatin|Treatment of Gemcitabine plus carboplatin
3334939|NCT02134366|Active Comparator|Lorazepam|Subjects who are assigned to the lorazepam treatment group will receive a 1-2mg dose of lorazepam qid. Following the initial treatment if a physician investigator determines that the subject's treatment has failed, the investigator has the option of treating the subject with clobazam at which point the individuals would be treated in the same method as those originally assigned to the clobazam treatment group.
3334940|NCT02134379||Heart Failure|Subjects have implanted Medtronic device and a primary diagnosis of left ventricular systolic dysfunction
3334941|NCT02134392|Experimental|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
3334942|NCT02134405|Experimental|Rebamipide and Esomeprazole|Rebamipide tablets 100mg tid for 8 weeks Esomeprazole tablets 20mg od for 8 weeks
3334943|NCT02134405|Active Comparator|Rebamipide and placebo|Placebo drug with Rebamipide 100mg tid
3334944|NCT02134418|Experimental|Irony CBT training|CBT of irony comprehension
3334945|NCT02134418|No Intervention|No Intervention|No Intervention
3334946|NCT02134431||HIV positive|HIV-positive subjects ages 10-14 years old and 18-21 years old taking tenofovir in their antiretroviral regimen.HIV positive subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. HIV-1 levels and tenofovir levels in tissue will be measured.
3235013|NCT01236729||Knee replacement recipients|Patients (aged 75 years or over) with late-stage arthritis who have undergone or are undergoing primary knee replacement
3235014|NCT01236781|Experimental|Group A: Screening|Group A comprises 500 asymptomatic women with no history of breast cancer who are scheduled for routine screening of the breasts with FFDM.
3334947|NCT02134431||HIV negative|HIV-negative subjects ages 10-14 years old and 18-21 years old. HIV negative subjects will undergo lower endoscopy (specifically either flexible sigmoidoscopy or colonoscopy) with biopsies to obtain colorectal tissue samples. These tissue samples will be pretreated with tenofovir and challenged with laboratory HIV-1.
3334948|NCT02134444|Experimental|Experimental Group|Experimental group will receive the assigned intervention which is a game-based rehabilitation program delivered at home.
3334949|NCT02134444|Active Comparator|Control group|Control group will receive a vestibular rehabilitation program which will include the Herdman gaze stabilization exercises and balance training program.
3334950|NCT02134457|Experimental|Ranibizumab 0.12 mg|"20 µl of the 6 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 regular re-injections can be applied."
3235015|NCT01236781|Experimental|Group B: Diagnostic Enriched Population|Approximately 50 asymptomatic women with no history of breast cancer who have been informed of positive (abnormal) findings from a recent (within 30 days) FFDM screening will be recruited to Group B prior to their diagnostic imaging (e.g., diagnostic FFDM and/or ultrasound and/or other).
3235016|NCT01236794|Experimental|Lifestyle and Exercise Intervention|
3235017|NCT01236807|Active Comparator|MR Inform|Management guided by the result of the MR perfusion scan. Possible intervention: coronary artery revascularization.
3235018|NCT01236807|Active Comparator|FFR Inform|Management guided by the result of FFR measurement. Possible intervention: coronary artery revascularization.
3334951|NCT02134457|Experimental|Ranibizumab 0.20 mg|"20 µl of the 10 mg/ml ranibizumab concentration will be applied intravitreally. After an initial response the same dose as in the first injection can be re-applied after at least four weeks post injection.~A maximum number of 3 re-injections can be applied."
3235019|NCT01236820||Normal|Healthy population
3235020|NCT01236820||CKD Patients|Chronic Kidney Disease, in Stage III-V
3334952|NCT02134470|Experimental|Testosterone|Chemical testing of saliva is an objective method to quantify steroid hormones. Recent studies indicate that salivary testosterone is significantly higher than in other body fluids. Therefore, saliva may serve as pre-screening parameter to select suspicious cases for further target evaluation. The aim of the present project is to detect administered testosterone in saliva and compare these levels to those in blood and urine. Therefore, each participant represents its own control.
3334953|NCT02134483|Experimental|Parathyroid allo-transplantation|patients who have permanent hypoparatyroidism
3334954|NCT02134496|No Intervention|no assessment of motorfunction in PACU|no assessment of motorfunction after spinal anesthesia in PACU
3334955|NCT02134496|Active Comparator|motorfunction assessment in PACU|Assesment of motorfunction after spinal anesthesia
3334956|NCT02134509|Experimental|Experimental App|This is a 3-week smartphone-based training program that trains behavioral strategies for smoking cessation by helping smokers self-monitor their smoking habits, recognize when and how often they smoke, identify triggers for smoking, and learn methods to become more mindful of triggers, to quit smoking with a target quit date of 3 weeks.
3334957|NCT02134509|Active Comparator|Active comparator app|This is a 3-week smartphone application for smoking cessation in which smokers self-monitor their smoking habits, mood, and experience, to quit smoking with a target quit date of 3 weeks.
3334958|NCT02134535||laboratory specimens|cervical biopsies vaginal biopsies blood
3235021|NCT01236820||HD patients|End-stage renal disease patients undergoing hemodialysis
3334959|NCT02134561|Other|All subjects|psychological interview, MRI, neurological tests, cognitive tests
3235022|NCT01236833|No Intervention|Fasting|
3235023|NCT01236833|Active Comparator|Lactated Ringer's Solution|
3235024|NCT01236846|Placebo Comparator|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml) for 12 weeks
3334961|NCT02134600|Experimental|Omega-3 enriched fruit juice|Single arm study: Omega-3 enriched fruit juice in increasing dosage
3235025|NCT01236846|Experimental|VDR Genotype (aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
3235026|NCT01236846|Experimental|VDR Genotype (AA)|Daily intake of yogurt drink fortified (500 ml) with 1000 IU vitamin D for 12 weeks
3235027|NCT01236846|Experimental|VDR genotype (Aa)|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
3235028|NCT01236859|Placebo Comparator|placebo|The patients in the placebo group received equal numbers of identical looking placebo 2 h before operation
3235029|NCT01236859|Active Comparator|gabapentin|Patients in the gabapentin group received two capsules of gabapentin 300 mg (Neurontin®, Pfizer) at 2 h before operation.
3235030|NCT01236872|Experimental|Beetroot juice|250ml beetroot juice ingestion
3235031|NCT01236872|Placebo Comparator|Water|250ml low-nitrate water placebo
3235032|NCT01236885|Experimental|Supportive care (Glucommander)|Patients receive blood glucose management with IV insulin using Glucommander.
3334962|NCT02134613|Experimental|anti-TNF-alpha scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
3334963|NCT02134626|Experimental|Simvastatin|Arm 1: Simvastatin 40mg / pill, one pill once a day for three months
3334964|NCT02134626|Placebo Comparator|Placebo pill|Arm 2: Placebo one pill once a day for three months
3334965|NCT02134639||Patient who is suspected of endocrine tumors|According to symptomatology, biology or imaging or pathological context
3334966|NCT02134652||Suspected Dengue|Children with an acute febrile illness, and two of the following: headache, retro-orbital pain, myalgias, arthralgia, rash, hemorrhagic manifestations, or plasma leakage (i.e. shortness of breath, abdominal distention/pain) will all receive a diagnostic bedside ultrasound.
3334967|NCT02134665||severe acute pancreatitis|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as severe acute pancreatitis.
3334968|NCT02134665||Pneumonia|patients who received vancomycin therapy and whose serum vancomycin level was monitored, and who also had diagnosed as pneumonia.
3334969|NCT02134678|Experimental|self-system therapy|self-system therapy for depression
3334970|NCT02134678|Active Comparator|cognitive therapy|cognitive therapy for depression
3334971|NCT02134691|Experimental|Prolonged Exposure|Behavioral: Prolonged Exposure (PE) PE is a 16 week, 90 minute culturally informed treatment program.
3334972|NCT02134691|Active Comparator|Applied Relaxation|Behavioral: Applied Relaxation (AR) AR is a 16 week, 90 minute treatment program.
3334973|NCT02134704|Experimental|Scoliosis Group|
3334974|NCT02134704|Experimental|Healthy Volunteers Group|
3334975|NCT02134717|Experimental|sarcoidosis stage II|All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.
3334976|NCT02134730|No Intervention|Wait list|Schools in waitlist condition will be offered the intervention after the 12-months follow up. Waitlist means that the schools work as usual with issues of mental health.
3334977|NCT02134730|Experimental|FRIENDS for life|The intervention is delivered for 10 consecutive weeks, 60 minutes per session.
3334978|NCT02134743|Experimental|Experimental Group|At this group the patients will receive dental implants which have a modified SLA surface. These surface have wettability, which could improve and accelerate the osseointegration.Intervention: implant placement.
3334979|NCT02134743|Active Comparator|Control Group|The patient of this group will receive implant with conventional surface, SLA (Sandblasted and Acid-Etched Surface).Intervention: implant placement.
3334980|NCT02134769|No Intervention|Control|No use of Bionecteur; handling according to institutional guideline
3334981|NCT02134769|Active Comparator|Bionecteur|Use of Bionecteur; handling according to institutional guideline
3334982|NCT02134782|Experimental|Individualized Yoga Intervention Group|Yoga will be administered individually by a trained yoga instructor, and offered daily for 21 days (5 days per week or 15 days in total). There will be a common structure for all sessions that will include relaxation and breathing exercises. Additional poses focused on strength, flexibility, and balance will be incorporated at low, moderate or high intensity levels based upon the wishes and abilities of the child and parent and the judgment of the yoga instructor. The target intensity will be documented and may change with each yoga session. Each yoga session will vary in duration between 15 and 45 minutes. Modifications will be made to accommodate devices such as central venous lines, particularly if accessed. For children who are in isolation, the research team will follow hospital policies and procedures.
3334983|NCT02134782|Active Comparator|iPad Activity Control Group|For those randomized to the control group, visits by the same yoga instructors will occur at the same schedule as the yoga intervention. Contact will be offered daily (5 days per week) for 21 days. The yoga instructor will offer games, music, movies or books on a study-supplied iPad. The instructor will offer to interact with the child (for example, read to, or play games with the child) for a maximum of 45 minutes (the maximum length of yoga sessions). This approach will allow us to control for contact frequency and the individual providing contact, and consequently, to better measure the independent effect of yoga. These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities.
3334984|NCT02134795|Experimental|TNM (trade name), a form of brainstem stimulation|ThermoNeuroModulation (TNM) device with a standardized active neuromodulation waveform will be used for all patients. The device will be used twice for ~19 minutes each time. There will be a gap of roughly 1 hour between the two device applications.
3334985|NCT02134808|Active Comparator|Creatine|Subjects randomized to this study arm will receive 10 grams of creatine daily for 8 weeks.
3235033|NCT01236898|Experimental|NPC-09|Period 1: NPC-09 800mg single oral dosing NPC-09 800mg three times oral dosing a day Period 2: NPC-09 800mg three times oral dosing a day for 5 consecutive days
3235034|NCT01236911||Calcium after moderate-severe TBI|Patients with moderate -severe TBI with less as 24 hrs , admitted in emergency. We will measure seric calcium to compare the differences between both groups
3334986|NCT02134808|Placebo Comparator|Placebo|Subjects randomized to this study arm will receive 10 grams of placebo daily for 8 weeks.
3334987|NCT02134821||Low pain sensitivity group|total Pain Sensitivity Questionnaire score <6.5
3334988|NCT02134821||High pain sensitivity group|total pain sensitivity questionnaire score ≥ 6.5
3235035|NCT01236924|Experimental|Lifestyle counseling|
3235036|NCT01236937|Active Comparator|Bellows-based breath hold biopsy|CT guided biopsy is preformed with the use a bellows-based breath
3235037|NCT01236937|No Intervention|No Bellows-based breath hold.|CT guided biopsy is preformed without the use a bellows-based breath
3334989|NCT02134834|Experimental|Ascending single dose of OP0595|
3334990|NCT02134834|Placebo Comparator|Normal Saline|
3334991|NCT02134847|Experimental|Intervention cohort|This cohort will work on the SCS intervention schedule
3334992|NCT02134847|No Intervention|Control cohort|This group will work on a traditional schedule
3334993|NCT02134860|Active Comparator|Isocaloric diet|3 daily meals
3334994|NCT02134860|Active Comparator|Alternate daily fasting|One meal (25% of caloric need) every second day and four meals (175% of caloric need) every second day
3235038|NCT01236950|Experimental|Delmopinol mouthrinse|Subjects use the delmopinol mouthrinse
3235039|NCT01236950|No Intervention|Control|Subjects with no use of mouthrinse
3334995|NCT02134873|Active Comparator|0.1ml 24% sucrose concurrent opioids|0.1ml 24% sucrose concurrent opioids
3334996|NCT02134873|Active Comparator|0.5ml 24% sucrose concurrent opioids|0.5ml 24% sucrose concurrent opioids
3334997|NCT02134873|Active Comparator|1.0ml 24% sucrose concurrent opioids|1.0ml 24% sucrose concurrent opioids
3334998|NCT02134873|Active Comparator|0.1ml 24% sucrose no opioids|0.1ml 24% sucrose no opioids
3334999|NCT02134873|Active Comparator|0.5ml 24% sucrose no opioids|0.5ml 24% sucrose no opioids
3335000|NCT02134873|Active Comparator|1.0ml 24% sucrose no opioids|1.0ml 24% sucrose no opioids
3335001|NCT02134886|Experimental|Treatment (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3335002|NCT02134899|Experimental|Everolimus|everolimus based immunosuppression
3335003|NCT02134899|Active Comparator|Calcineurin|Calcineurin inhibitors maintenance
3335004|NCT02134938|Experimental|Konjac Glucomannan|650g KJM-G
3335005|NCT02134938|Experimental|Half Control/Half Konjac Glucomannan|325g KJM-G
3335006|NCT02134938|No Intervention|Control|0g KJM-G
3235040|NCT01236950|Experimental|Essential oils mouthrinse|Subjects using the essential oils mouthrinse
3335007|NCT02134964|Experimental|OLT1177 Capsules|"A total of 5 patients in each cohort will receive OLT1177 Capsules:~Cohort 1 will receive a single 100 mg dose of OLT1177~Cohort 2 will receive a single 300 mg dose of OLT1177~Cohort 3 will receive two 1000 mg doses of OLT1177 (seven days apart)~Cohort 4 will receive 100 mg doses of OLT1177 QD for 8 days~Cohort 5 will receive 300 mg doses of OLT1177 QD for 8 days~Cohort 6 will receive 1000 mg doses of OLT1177 QD for 8 days"
3335008|NCT02134964|Placebo Comparator|Placebo Capsules|"A total of 1 patient in each cohort will receive Placebo Capsules:~Cohort 1 will receive a single placebo capsule~Cohort 2 will receive three placebo capsules~Cohort 3 will receive ten placebo capsules (seven days apart)~Cohort 4 will receive a single placebo capsule QD for 8 days~Cohort 5 will receive three placebo capsules QD for 8 days~Cohort 6 will receive ten placebo capsules QD for 8 days"
3335009|NCT02134990|Experimental|Oshadi D and Oshadi R with Docetaxel|Oshadi D and Oshadi R anti cancer agents with Docetaxol chemotherapy
3335010|NCT02135003|Experimental|Buddy arm, Standard of care arm|"Standard of care: Patients enrolled for pre-ART care received general health education, clinical monitoring, CD4 testing and other clinically indicated investigations, treatment of opportunistic infections, and cotrimoxazole prophylaxis.~Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. buddies attended at least two HIV health education. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments"
3335011|NCT02135029|Experimental|Bococizumab (PF-04950615;RN316)|Bococizumab (PF-04950615;RN316)
3335012|NCT02135029|Active Comparator|Atorvastatin|
3335013|NCT02135029|Placebo Comparator|Placebo|
3335014|NCT02135042|Active Comparator|Arm I (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen comprising cisplatin IV over 60-120 minutes and fluorouracil IV over 96 hours continuously beginning at least 4 weeks after completion of IMRT. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3335015|NCT02135042|Experimental|Arm II (chemoradiation, gemcitabine hydrochloride, paclitaxel)|Patients receive GT regimen comprising paclitaxel IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 at least 4 weeks after completion of IMRT. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3335016|NCT02135042|Active Comparator|Arm III (chemoradiation, cisplatin, fluorouracil)|Patients receive PF regimen as in Arm I of Phase II.
3335017|NCT02135042|Experimental|Arm IV (chemoradiation, observation)|Patients undergo clinical observation.
3335018|NCT02135055|Experimental|Normal immune function|The value of monocyte human leukocyte antigen-DR (mHLA-DR) is equal to or more than 15000 monoclonal antibody.
3335019|NCT02135055|Experimental|Moderate immunosuppression|The value of mHLA-DR is equal to or more than 10000 and less than 15000 monoclonal antibody.
3335020|NCT02135055|Experimental|Sever immunosuppression|The value of mHLA-DR is equal to or more than 5000 and less than 10000 monoclonal antibody.
3235041|NCT01236963|Experimental|Essential oils mouthrinse|Subjects use the essential oils mouthrinse
3335021|NCT02135055|Experimental|Immune paralysis|The value of mHLA-DR is less than 5000 monoclonal antibody.
3235042|NCT01236963|Active Comparator|Dental floss|Subjects use dental floss
3235043|NCT01236976|Experimental|Intervention Group|Participants in Group A will receive a triad of interventions comprising body weight supported treadmill training (BWSTT) using the Therastride Treadmill System, functional electrical stimulation (FES)-assisted cycling, and trunk and upper and lower limb exercise. These interventions will be provided at the spinal unit.
3335022|NCT02135068|Experimental|CL and exercise with proactive snacking|Subject will consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
3335023|NCT02135068|Active Comparator|CL and exercise without proactive snacking|Subject will not consume oral glucose prior to starting exercise regimen while on the Medtronic MiniMed Closed Loop (CL) System
3335024|NCT02135081||Single Ventricle|"Subjects will be single ventricle patients who will be prospectively recruited when they are at the first stage of Fontan reconstruction; they will be followed throughout all 3 stages with cerebral blood flow measurements and brain MRIs.~Additional single ventricle patients who will not participate in the study for all 3 stages but who may participate for one of two. For example, patients who completed their Stage I and hemi Fontan/bidirectional Glenn operations before this study began will be recruited before Fontan stage completion. Also, patients whose Stage I and hemi Fontan/bidirectional Glenn surgeries will be completed during the study, but who will not complete all 3 surgical stages before this project ends. Cerebral blood flow measurements and brain MRIs will be completed after each surgical stage which occurs during study participation."
3335025|NCT02135081||Normal Control Group|Children likely to have a normal brain MRI will be asked to participate. After the brain MRI is obtained as part of routine clinical care, and a normal brain scan is confirmed, measurement of cerebral blood flow using velocity mapping in the jugular veins and the aorta will be performed. This will add approximately 10 minutes to the scan but no extra sedation medications will be administered to obtain this data.
3335026|NCT02135120|Active Comparator|Morphine group|Patients will receive a combined spinal epidural anesthesia technique with intrathecal morphine
3335027|NCT02135120|Active Comparator|Morphine-femoral group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block
3335028|NCT02135120|Active Comparator|Morphine-femoral-sciatic group|Patients will receive a combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block
3335029|NCT02135133|Experimental|Idelalisib & Ofatumumab|Idelalisib will be given orally continuously at 150 mg BID. On day 57, ofatumumab will begin with the 300 mg dose, given after idelalisib is taken. Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8). The overall induction treatment period will then be 8 months, comprised of two months of single agent idelalisib followed by 6 months of ofatumumab with idelalisib. After the completion of the induction treatment, idelalisib will continue indefinitely in arbitrarily defined 28 day cycles in all participants who have not had excessive toxicity and do not have progressive disease.
3335030|NCT02135159|Experimental|TDM1 concommitant with RT|T-DM1 (First injection day 1) followed by brain sequential RT (start day D3), second injection T-DM1 day 22.
3335031|NCT02135159|Experimental|TDM1 during and after RT|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 15), second injection T-DM1 day 36.
3335032|NCT02135159|Experimental|RT before TDM1|Brain sequential RT (start day 1) followed by T-DM1 (First injection day 22), second injection T-DM1 day 43.
3335033|NCT02135159|Experimental|TDM1 before RT|T-DM1 (First injection day 1) followed by brain sequential and concomitant RT (start day D18), second injection T-DM1 day 22.
3335034|NCT02135172|Experimental|Sitting|During the sitting treatment condition, walking and standing will be restricted. Participants will be in a designated room with access to a computer, books/magazines throughout the day. Participants will have a cannula fitted and the first of the half-hourly blood samples will be taken (time point: -1hr). Participants will then be asked to sit quietly for 60 minutes to achieve a steady state. Following this, participants will have another blood sample taken and then be provided with a standardised mixed meal breakfast (09:00am) (time point: 0h). Blood sampling will continue at 30 minutes intervals for 3 hours following breakfast. A second, lunch meal (12:00pm), will be then be consumed over 15 minutes. Blood sampling will then continue at 30 minute intervals for 3 hours following lunch.
3335035|NCT02135172|Experimental|Standing|This is the same as the sitting condition, but participants will be asked to break their sitting time by standing close to their chair for 5 minutes, after 15 and 45 minutes of each hour following breakfast. The standing protocol will be repeated after lunch. Individuals will be asked to stand in the same position with no further instructions provided. In total, individuals will accumulate 12 bouts (60 minutes) of standing throughout the test period.
3335036|NCT02135172|Experimental|Walking|This is identical to the standing condition, but the breaks in sitting time will be punctuated with 5 minute bouts of light-intensity treadmill walking (equivalent to around 4.0km•h-1) rather than standing. In total, individuals will accumulate 12 bouts (60 minutes) of light-intensity activity throughout the test period. The light-intensity walking activity undertaken here replicates the low-grade ambulatory activity associated with everyday life.
3335037|NCT02135185|Experimental|Rehabilitation effort|custom work endurance combining dietary management adapted to the nutritional status and an APA. Included patients benefit from support for 19 weeks from the start of treatment
3335038|NCT02135185|Active Comparator|Control|Control with dietary management adapted to the nutritional status
3335039|NCT02135198|Experimental|2 mg AZD7325|2 mg AZD7325 in orange capsule, Size 0, single oral dose
3335040|NCT02135198|Experimental|10 mg AZD7325|10 mg AZD7325 in orange capsule, Size 0, singe oral dose
3259221|NCT01468623|Active Comparator|Body Surface Area (BSA)|Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.
3259222|NCT01468636|Active Comparator|Oral Zinc|
3335041|NCT02135198|Placebo Comparator|Placebo|10 mg Microcrystalline cellulose in orange capsule, Size 0, single oral dose
3335042|NCT02135211|Experimental|Lifestyle counseling|This is a single arm, quasi-experimental, pre- and post- test study design to test the feasibility and acceptability of a multiple risk factor, lifestyle intervention in patients receiving surgical treatment for lung cancer or those suspected of having lung cancer.
3335043|NCT02135224|Active Comparator|Fentanyl|20 microgram per hour
3335044|NCT02135224|Placebo Comparator|Normal saline|0.4 ml per hour
3335045|NCT02135237|Active Comparator|Control Group|Standard Care
3335046|NCT02135237|Experimental|Experimental Group|Standard Care plus Prize Contingency Management for Alcohol Abstinence
3335047|NCT02135250|Experimental|placebo|the placebo is not drug
3335048|NCT02135250|Experimental|Xinkeshu tablet|4 Xinkeshu tablets are given three times per day
3335049|NCT02135263|Experimental|Methylphenidate|
3335050|NCT02135263|Experimental|Enalapril|
3335053|NCT02135289||IMID patients|Patients with IMID
3335054|NCT02135289||Control - subjects without IBD|Patients without IBD
3259223|NCT01468636|Placebo Comparator|Placebo|
3335057|NCT02135315|Experimental|intensive controle group|the end point in this group was to maintain the systolic blood pressure (SBP) between 110 and 120 mmHg using continuous Isosorbide Dinitrate (RISORDON) perfusion associated, if needed, with Labetalol (TRANDATE) continuous perfusion.
3335058|NCT02135315|Active Comparator|standard control group|the end point in these group was to maintain the systolic blood pressure between 120 and 140 mmHg using a continuous perfusion of Isosorbide Dinitrate (RISORDON) or other drugs depending on the physician choice.
3335059|NCT02135328|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing type 2 diabetes through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
3335060|NCT02135328|Active Comparator|Audio brochure|Participants received an audio version of a standard brochure about type 2 diabetes prevention and management.
3335061|NCT02135341|Experimental|Group A: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
3335062|NCT02135341|Experimental|Group B: Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
3335063|NCT02135354|Experimental|Azithromycin|"N = 250~From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
3335064|NCT02135354|Placebo Comparator|Placebo|"N = 250~From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
3335065|NCT02135367|Experimental|PRP|This group of patients will be treated by three weekly Platelet rich Plasma intra-articular injections in the knee.
3335066|NCT02135367|Active Comparator|HA|"This group of patients will be treated by three weekly hyaluronic acid (HA) intra-articular injections in the knee.~The HA used is Hyalubrix 30 mg/2ml (Fidia Farmaceutici Spa, Padova, Italy)"
3335067|NCT02135380|Other|Autologous Stromal Vascular Fraction|Single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
3335068|NCT02135380|Other|Autologous Adipose Derived MSCs|3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
3335069|NCT02135380|Active Comparator|Control|"corticosteroids i.e. Prednisolone ≤10mg/day or ≤20 mg every alternate day~Immunosuppressants like Cyclophosphamide or Azathioprine at a dose of 2mg/kg/day not exceeding 150 mg/day~Antioxidants like N-acetylcysteine (NAC) at a dose upto 1800 mg/day.~Pirfenidone at dose upto 1200 to 1800 mg/day"
3235044|NCT01236976|Other|Control Group|Participants in Group B will receive an upper body strength and fitness program. This program may be provided at the spinal unit, or an appropriately equipped gymnasium as approved by the SCIPA Full-On Project Committee. It will be based on the Burn Rubber Burn (BRB) exercise program already established in Sydney. BRB is a circuit-based exercise program incorporating resistance and cardiovascular training. For this protocol, the circuit will comprise several stations using different pieces of equipment.
3235045|NCT01236989|Experimental|Anatomical resection|
3235046|NCT01236989|Active Comparator|Non-anatomical resection|
3335070|NCT02135393|Experimental|13C5-folic acid or 13C5-6S-5-FormylTHF|Physiological 500 nmol (220 µg folic acid equivalent) dose of dietary supplement 13C5-folic acid or 13C5-6S-5-FormylTHF given to subjects with in situ transjugular intrahepatic portosystemic stent at the time of routine venography patency check followed by regular portal venous sampling for 85 minutes at pre determined intervals and then physiological 500 nmol dose of 13C-6S-5-FormylTHF or 13C5-folic acid respectively at the next annual routine venography patency check followed by portal venous sampling for 85 minutes
3335071|NCT02135406|Experimental|Multiple Myeloma Patients|Adult subjects (18 years or older) with multiple myeloma and with poor prognosis by virtue of having relapsed/progressive disease within one year of first autologous stem cell transplantation.
3335072|NCT02135419|Experimental|Arm I (treatment)|Patients are directed to receive either topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under anesthesia if the clinician believes none of the other treatment approaches will be effective. The number and timing of such treatments will be at the discretion of the investigator. Patients with persistent HSIL should continue a protocol-approved treatment or a new protocol treatment should be considered. All participants will have samples collected for laboratory biomarker analysis.
3335073|NCT02135419|Active Comparator|Arm II (active monitoring)|Patients undergo active monitoring with examinations for clinical observation every 6 months. Every 12 months, patients undergo biopsies of visible lesions. Patients have cytology sampling performed at every visit. All participants will have samples collected for laboratory biomarker analysis.
3235047|NCT01237002||Group 1|117 patients with cumulative clamping time between 60 and 120 minutes
3235048|NCT01237002||Group 2|72 patients with cumulative clamping time longer than 120 minutes
3235049|NCT01237028|Experimental|oral calcitriol|Calcio®
3235050|NCT01237028|No Intervention|placebo|
3335074|NCT02135458|Experimental|Telemonitoring|Home-based patient management using AUTONOM@DOM telemonitoring system to record and transmit heart rate, blood pressure and weight; along side conventional care (patient therapeutic education or personalised care program)
3335075|NCT02135458|Active Comparator|Conventional care|Conventional care including patient therapeutic education or personalised care program
3259224|NCT01468649|Experimental|Breast Cancer SLN Mapping|Fifty participants consented who will be undergoing standard of care for breast cancer SLN mapping with Tc-99m will be enrolled in this study.
3335076|NCT02135471|Experimental|acellular dermal matrix graft|
3335077|NCT02135471|Experimental|enamel matrix derivative|
3335078|NCT02135484|Experimental|Alpharadin|Participants treated with standard dosing of Alpharadin 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
3335079|NCT02135510|Active Comparator|metoclopramide|
3335080|NCT02135510|Active Comparator|dexamethason|
3335081|NCT02135510|Active Comparator|palonosetron|
3335082|NCT02135523|Experimental|single arm: involved-field radiation therapy group|
3335083|NCT02135536|Experimental|NGM282 Dose 1|NGM282 Dose 1
3235051|NCT01237067|Experimental|Group 1|Dose esc: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis
3235052|NCT01237067|Experimental|Group 2A|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
3259225|NCT01468662||STEMI|
3335084|NCT02135536|Experimental|NGM282 Dose 2|NGM282 Dose 2
3335085|NCT02135536|Experimental|NGM282 Dose 3|NGM282 Dose 3
3335086|NCT02135549|Experimental|SugarDown 4 grams|SugarDown 4 gram dose in tablet form, before meals, daily for one week
3335087|NCT02135549|Experimental|SugarDown 8 grams|SugarDown 8 gram dose in tablet form, before meals, daily for one week
3335088|NCT02135549|Placebo Comparator|Placebo|Placebo dose in tablet form, before meals, daily for one week
3335089|NCT02135562|Experimental|Supportive Care (PSMF)|Participants will take part in a Protein-Sparing Modified Fast (PSMF) Intervention for weight loss. Participants will undergo a dietary intervention high in protein for 6 weeks or until they have loss 15% of their body weight. This intervention will be followed by weight maintenance in which participants reintroduce non-starchy vegetables to their diet. At this time participants will also receive informational material and dietary education which teaches participants how to read nutrition labels and calculate carbohydrate loads in foods. Participants are given the Obesity and Weight-Loss Quality of Life Questionnaire to survey the impact of the intervention
3335090|NCT02135575|Experimental|Premenopausal women|The Premenopausal women are randomized to exercise by spinning (cycle)
3335091|NCT02135575|Experimental|Postmenopausal women|The Postmenopausal women are randomized to exercise by spinning (cycle)
3335092|NCT02135588|Experimental|Active Treatment|Intra-pleural deoxyribonuclease 5mg and intra-pleural Alteplase 10mg, every 12 hours over 72 hours (total of 6 treatments)
3335093|NCT02135601|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3335094|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3335095|NCT02135627|Experimental|Control group|Current standard endoscopic therapy such as epinephrine injection, sclerotherapy, mechanical (endoclip). contact electrocautery/thermal, and non-contact electrocalcautery (APC) ± radiation therapy, angioembolization, and/or surgery.
3335096|NCT02135627|Active Comparator|TC-325|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.
3335097|NCT02135640|Experimental|denosumab 60 mg|solution
3335098|NCT02135640|Experimental|denosumab 120 mg|solution
3335099|NCT02135640|Placebo Comparator|placebo|solution
3335100|NCT02135666|Experimental|2-dose Primed Group|Adolescent subjects in this group received 2 doses of Twinrix Adult (720/20) (licensed as Ambirix in the EU) according to a 0, 6 months schedule in the primary study HAB-084 (208127/084).
3335101|NCT02135666|Experimental|3-dose Primed Group|Adolescent subjects in this group received 3 doses of Twinrix Junior (360/10) according to a 0, 1, 6 months schedule in the primary study HAB-084 (208127/084).
3335102|NCT02135679||Cohort 1|Patients with early stage NSCLC undergoing stereotactic radiotherapy
3335103|NCT02135679||Cohort 2|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy
3335104|NCT02135679||Cohort 3|Patients with stage I-III NSCLC undergoing standard, fractionated radiotherapy alone
3335105|NCT02135679||Cohort 4|Patients with locally advanced NSCLC undergoing standard chemoradiotherapy with the novel signal transduction inhibitor, nelfianvir.
3335106|NCT02135679||Cohort 5|Patients with resectable stage IIIa NSCLC undergoing pre-operative chemoradiotherapy
3335107|NCT02135679||Cohort 6|(Patients with suspected (no tissue diagnosis) early stage NSCLC undergoing stereotactic radiotherapy)
3335108|NCT02135705||Lomitapide|Lomitapide as prescribed by Physician.
3335109|NCT02135718||Group 1|Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the MDI inhaler twice daily for 5 to 9 days during the second period.
3335110|NCT02135718||Group 2|Subjects will use the MDI inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.
3335111|NCT02135731|No Intervention|Paper|Usual care -medication review on paper
3335112|NCT02135731|Experimental|Computer|Medication review software with pictures
3335113|NCT02135744|No Intervention|Control|Group of patients undergo standard care as determined by the primary inpatient team
3335114|NCT02135744|Experimental|Bundle|Group of patients that receive the screening and educational tool
3335115|NCT02135770|Experimental|Unfractionated Heparin|Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion
3335116|NCT02135770|Placebo Comparator|Placebo|Normal saline packed in same form with trial drugs.
3335117|NCT02135783|Experimental|Decompressive Craniectomy|Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
3335118|NCT02135783|Active Comparator|non-Decompressive Craniectomy|non-Decompressive Craniectomy afte Hematoma Removal in Patients with Intracerebral Hemorrhage
3335119|NCT02135796||Sepsis/Septic Shock|Individuals who are admitted to the Intensive Care Unit (ICU) with an infection called Sepsis or Septic Shock. This group will receive transthoracic echocardiography as part of the study.
3335120|NCT02135809|Experimental|FCSEMS|Patients will receive the WallFlex Pancreatic Stent.
3235053|NCT01237067|Experimental|Group 2B|Randomized: A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
3335121|NCT02135822|Experimental|nanoparticle albumin-bound paclitaxel, gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 and 8, in combination with gemcitabine which is given at 1000 mg/m2, on day 1 and 8, each 21-day cycle. Number of cycle: 6 cycles.
3335122|NCT02135835|Experimental|Shenfu Zhusheye|80 ml Shenfu Zhusheye + 70 ml 5% glucose injection, ivdrip, once a day for 7 days.
3335123|NCT02135835|Placebo Comparator|5% glucose injection|150 ml 5% glucose injection, ivdrip, once a day for 7 days.
3335124|NCT02135874|Experimental|Treatment (combination chemotherapy)|See Detailed Description.
3335125|NCT02135887||MB-6+FOLFOX chemotherapy|MB-6, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
3335126|NCT02135887||Placebo+FOLFOX chemotherapy|Placebo, 6 capsules tid be taken with meals plus FOLFOX chemotherapy, will be given for 18 weeks
3335127|NCT02135913|Experimental|Viatamin D|All children enrolled into the study will be prescribed standard of care vitamin D.
3335128|NCT02135926|Active Comparator|Best medical care|Best clinical care in dedicated stroke unit
3335129|NCT02135926|Active Comparator|Thrombectomy|All subjects randomly assigned to the thrombectomy arm, except those with rapidly improving neurologic symptoms or no angiographic evidence of occlusion, will be treated with the endorsed study devices (stent retriever).
3335130|NCT02135939|Active Comparator|American Heart Association diet|Participants randomized into this arm will follow an American Heart Association diet plan for 8 weeks.
3335131|NCT02135939|Experimental|Whole-food plant-based vegan diet|Participants randomized into this arm will be asked to follow a whole-food plant-based vegan diet plan for 8 weeks.
3335132|NCT02135952|Active Comparator|SRP+MTZ+AMX|Scaling and root planing (SRP) + metronidazole (MTZ; 400 mg thrice a day [TID] for 14 days) + amoxicillin (AMX; 500 mg TID for 14 days)
3335133|NCT02135952|Placebo Comparator|SRP+placebo|Scaling and root planing + placebo
3335134|NCT02135965|Experimental|Albuterol 2mg|2 mg of Albuterol is in a pill form or placebo
3335135|NCT02135965|Experimental|Albuterol 4mg|4mg of Albuterol or placebo is given in pill form
3335136|NCT02135965|Experimental|Caffeine 100mg|100mg of Caffeine or placebo is given in a pill form.
3335137|NCT02135965|Experimental|Caffeine 200mg|200mg of Caffeine or placebo is given in a pill form
3335138|NCT02135965|Experimental|Albuterol 2mg & Caffeine 100mg|100mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
3335139|NCT02135965|Experimental|Albuterol 2mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 2mg or placebo is given in a pill form.
3335140|NCT02135965|Experimental|Albuterol 4mg and Caffeine 100mg|100mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
3335141|NCT02135965|Experimental|Albuterol 4mg and Caffeine 200mg|200mg of Caffeine in combination with Albuterol 4mg or placebo is given in a pill form.
3335142|NCT02135978|Experimental|One-to-one training group for shoulder home exercise program|Patients will attend two sessions of one-to-one training with a physical therapist to learn the shoulder home exercise program. The sessions are 4 weeks apart. They will also review a handout on techniques to protect their shoulder during wheelchair propulsion and transfers.
3335143|NCT02135978|Active Comparator|Enhanced training group for shoulder home exercise program|Patients will attend four classes held each week for 4 consecutive weeks. The classes are led by a physical therapist and a peer mentor (with a spinal cord injury). Two to four research patients are in each class. Classes begin with an interactive education presentation on techniques and recommendations to protect the shoulder during transfers, wheelchair propulsion, raises and activities of daily living. This is followed by performance of the home exercise program. Patients will be called every 3 to 6 months by a peer mentor to receive encouragement, praise, and/or problem solve barriers to exercise.
3335144|NCT02135978|No Intervention|Historical control group|Historical control group has received no intervention. Eligibility criteria, outcome measures and study duration for historical control group is matched for the experimental group and active comparator.
3335145|NCT02135991|Experimental|Project CHOICE + Getting To Outcomes|Boys and Girls Club sites will receive a) training and materials for Project CHOICE and b) training, ongoing technical assistance for two years, and materials for Getting To Outcomes
3335146|NCT02135991|Active Comparator|Project CHOICE only|Boys and Girls Club sites will receive a) training and materials for Project CHOICE
3335147|NCT02136017||Changchun biologial's vaccine|Changchun Biological's vaccine group is the population injected with this vaccine.
3335148|NCT02136030|Experimental|Lipo-AB|
3335149|NCT02136030|Active Comparator|Amphotericin B|
3335150|NCT02136043|Experimental|Group 1|Insertion of catheter into nasal cavity carried out by patient. Fixation of catheter during treatment with patient´s hand.
3335151|NCT02136043|Experimental|Group 2|Insertion of catheter into nasal cavity carried out by health professional. Fixation of catheter during treatment with helmet.
3335152|NCT02136056|Experimental|Self-management program (SMP)|Participants in the experimental group receive six weekly group-sessions of self-management and patient education; specifically targeting self-management of the return to work process and disease symptoms.
3335153|NCT02136056|No Intervention|Treatment as usual|Participants in the control-group receive standard rehabilitation care and follow-up in the job-center.
3335154|NCT02136082|Experimental|Asha Support + Training|Asha Support + Training: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
3335155|NCT02136082|Experimental|Asha Support + Food|Asha Support + Food 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; and c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
3335156|NCT02136082|Experimental|Asha Support + Training + Food|Asha Support + Training + Food: 1) Group discussions delivered over a six month period that cover four main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; and d) Healthy Eating for Self and Family; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen; 4) Food supplementation of high protein food such as urad dal or tur dal.
3335157|NCT02136082|Active Comparator|Asha Support Only|Asha Support Only 1) Group discussions delivered over a six month period that cover three main categories a) Staying Healthy; b) Caregiving; c) Staying Upbeat; 2) Referral for Life Skills Classes to teach women about selling fruit and vegetables and dried fish, sewing and embroidery and computer skills; 3) Asha Support. Women are visited by an Asha to discuss the group sessions, any difficulties the women may be experiencing with staying on ART, and ways to help women stay on the regimen.
3335158|NCT02136095|Experimental|IFC-group|The investigators included patients undergoing laparoscopic cholecystectomy by a single surgeon between September and December 2013 at a single centre university department with unrestricted referral of patients. The included patients represented all patients undergoing laparoscopic cholecystectomy by one surgeon during the study period. All patients underwent intra-operative fluorescent cholangiography (IFC) with concomitant angiography, according to a standardized protocol, during their laparoscopic cholecystectomy.
3335159|NCT02136108|Experimental|OPENtext|OPENtext will target cognitive, affective, and behavioral strategies through a single, brief in-person assessment, followed by 12 weeks of theoretically-informed text messages, a core set of information organized in a 'frequently asked questions' structure, interactive peer support, static resources on key patient-identified topics, and a library of peer stories accessible throughout the study period.
3335160|NCT02136108|Active Comparator|OPENnav|Peer Navigation is currently offered to some individuals in this Medicaid population but not all. Peer navigators interact with patients by phone/text and at home visits. Efforts focus on drivers of a patient's ED use, and may include providing or identifying patient support, improving health literacy, assisting with transportation vouchers, health education, family support, accessing housing services, and orienting to other community support services.
3335161|NCT02136121|Experimental|da Vinci Sp Surgical System|da Vinci Sp Surgical System - Robotic - assisted single-port surgery
3335162|NCT02136147||Children with ADHD medication|Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
3335163|NCT02136147||Lisdexamphetamine medication|Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3335164|NCT02136147||Atomoxetine medication|Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3335165|NCT02136147||Methylphenidate medication|Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
3335166|NCT02136147||Guanfacine medication|Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
3335167|NCT02136173|Experimental|sequential balloons|effect of weight loss by applying sequential balloons
3235062|NCT01237106|Experimental|In Vitro Maturation (IVM)|
3235063|NCT01237119|Experimental|Liraglutide|A once-daily glucagon-like peptide 1 (GLP-1) analogue. Currently has regulation approval for use in type 2 diabetics (ref: guidelines)
3235064|NCT01237119|Placebo Comparator|Placebo|Liraglutide-Placebo manufactured by Novo Nordisk.
3335168|NCT02136186|No Intervention|Standard of care|patients will receive standard of care discharge instructions
3335169|NCT02136186|Active Comparator|Philips Telehealth|patients will be discharged with a telemonitoring device for 30 days
3335170|NCT02136199|Other|Active Implementation of Share EBM Toolkit|Investigators led implementation of tailored activities and tactics (Shared EBM Toolkit) designed to promote the use of the decision aids in clinical encounters (i.e. journal clubs, value map streaming).
3335171|NCT02136199|Other|Passive Implementation of Share EBM Toolkit|Locally supported dissemination of Shared EBM Toolkit designed to promote the use of the decision aids in clinical encounters.
3235065|NCT01237145||non-EAA, pigeon|subject with BAL because of diseases not suspected to be EAA
3235066|NCT01237145||EAA, pigeon|Bird fanciers with a typical clinical presentation suspected for pigeon induced EAA
3235067|NCT01237158||healthy controls|
3235068|NCT01237158||bipolar disorder type I|
3235069|NCT01237171||Sub-lobar resection with Cesium-131|All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
3335172|NCT02136212|Experimental|Approach-positive AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure designed to increase automatic approach responses for positive social cues.
3335173|NCT02136212|Placebo Comparator|Control AAT|Participants will receive 4 sessions over 2 weeks of a computerized AAT procedure in which there is no contingency between arm movement and positive social cues.
3335174|NCT02136225|Experimental|Counseling|Intervention: Means restriction counseling. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun in the home where youth are present.
3335175|NCT02136225|Experimental|Counseling and locking devices|Intervention: Means restriction counseling and locking devices. Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present. Parents will also receive locking devices to store their guns securely.
3335176|NCT02136225|No Intervention|Control group|Youth in the control group will receive usual care.
3335177|NCT02136251||shoulder replacement|Subjects who had shoulder replacement surgery at The University of Nebraska and The Nebraska Medical Center at least 5 or more years ago and autologous bone graft around the anchor-peg glenoid prosthesis was used.
3335178|NCT02136264|Active Comparator|PCFA interventional dietary counselling|personalized categorical food avoidance dietary counselling
3335179|NCT02136264|Sham Comparator|conventional DASH diet counselling|"DASH = conventional dietary approach to stop hypertension"
3335180|NCT02136277||Colorectal patients|Subjects undergoing colorectal surgery
3335181|NCT02136290|Other|Usual Care|Weight loss counseling
3335182|NCT02136290|Experimental|Prepackaged meal|Prepackaged meals
3335183|NCT02136303|Placebo Comparator|S1-Placebo|placebo capsule with all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
3335184|NCT02136303|Experimental|S1-1L|capsule containing 1 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3335185|NCT02136303|Experimental|S1-2L|capsule containing 2 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3335186|NCT02136303|Experimental|S1-5L|capsule containing 5 mg lutein out of kale, intervention for 4 weeks, S1: Dosage-dependency
3335187|NCT02136303|Experimental|S2-Kale_extract|
3235070|NCT01237184||biocortical fixation|Bi-cortically fixed implants intentionally engaging sinus floor beyond up to 1-2mm without graft but using stopper drill and self-threading concept
3235071|NCT01237184||unicortical fixation|Short implants placed in proximity of the sinus without sinus floor involvement
3235072|NCT01237184||indirect sinus lift|implants engaging both crest and sinus floor but with green stick fracture
3335188|NCT02136303|Experimental|S2-Kale_purée|
3335189|NCT02136303|Placebo Comparator|S3-Placebo|
3335190|NCT02136303|Experimental|S3-AMD-Patients|
3335191|NCT02136303|Experimental|S3-non-AMD|
3335192|NCT02136303|Placebo Comparator|S1-Placebo-Tagetes|capsule containing all ingredients, but without active compound, intervention for 4 weeks, S1: Dosage-dependency
3335193|NCT02136303|Experimental|S1-1L-Tagetes|capsule containing 1 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3335194|NCT02136303|Experimental|S1-2L-Tagetes|capsule containing 2 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3335195|NCT02136303|Experimental|S1-5L-Tagetes|capsule containing 5 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3335196|NCT02136303|Experimental|S1-10L-Tagetes|capsule containing 10 mg lutein out of tagetes, intervention for 4 weeks, S1: Dosage-dependency
3335197|NCT02136316|Experimental|ASP7962 low dose|
3335198|NCT02136316|Experimental|ASP7962 medium dose|
3335199|NCT02136316|Experimental|ASP7962 high dose|
3335200|NCT02136316|Placebo Comparator|Placebo|
3335201|NCT02136329|Experimental|Sildenafil|All subjects in groups 1-6 will receive SIldenafil but in escalating doses.
3335202|NCT02136342|Experimental|chlorogenic acid|
3335203|NCT02136355|Experimental|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
3335204|NCT02136368|Experimental|Multi-Modal, Mind Motor Exercise (M4)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of mind-motor exercise.
3335205|NCT02136368|Active Comparator|Multi-Modal Exercise (M2)|Attend 60 minute exercise class three times per week for 24 weeks. Exercise class includes 45 minutes of multi-modal exercise and 15 minutes of balance and range of motion exercises.
3335206|NCT02136381|Experimental|LEAP intervention|A newly developed internet-based lifestyle programme (Living, Eating, Activity and Planning through retirement (LEAP)) will promote three key health and social behaviours; healthy eating following a Mediterranean diet, increasing physical activity and improve social connectedness.
3335207|NCT02136381|Other|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~This website contains general information on improving life style and health."
3235073|NCT01237236|Experimental|LEE011|
3335208|NCT02136394||Severe/moderate acid reflux|
3235074|NCT01237249|Active Comparator|MPV followed by Revlimid/Low Dose Dexamethasone (Rd)|Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
3335209|NCT02136394||Mild/absent acid reflux|
3335210|NCT02136407||Blood donors|N=540
3335211|NCT02136407||Thrombocyte donors|N=75
3335212|NCT02136433|Experimental|Tablet - self exercise|"Existing tablet Apps that encourage finger movement in a fun manner while playing a game will be used. The apps will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training using a tablet."
3335213|NCT02136433|Active Comparator|GRASP self exercise|"GRASP (Graded Repetitive Arm Supplementary Program)(Harris et al., 2009)is an arm and hand exercise program developed for individuals with stroke with upper extremity impairments GRASP provides a method for patients to undertake a self-directed arm and hand exercise program.~The exercises will be taught to the participants and then they will be requested to exercise alone (or with family) everyday for one hour in addition to their regular rehabilitation sessions (Occupational, Physical Therapy, speech).~The intervention will include 15-20 sessions of 60 minutes of self-training"
3335214|NCT02136446|Experimental|EchoGlo™ Peripheral Nerve Block Catheter|Echogenic nerve block catheter (test)
3335215|NCT02136446|Active Comparator|Pajunk® EpiLong Catheter|Non-echogenic nerve block catheter (control)
3335216|NCT02136459|Experimental|Small tube size|Size 6.5 ETT for female, size 7.0 ETT for male
3335217|NCT02136459|Active Comparator|Large tube size|Normal tube size, size 7.5 for female, size 8 for male
3335218|NCT02136472||Subfertile women|"Women who visit the fertility clinic of the Maastricht University Medical Centre who start with a basic fertility work-up. Women diagnosed with an unexplained subfertility or with (signs of) a decreased ovarian reserve are asked for further participation in the study of the cardiovascular profile.~As a control group parous women with an uncomplicated pregnancy more than 6 months ago will be asked for participation."
3335219|NCT02136485|Experimental|MBSR|8 weekly sessions each lasting 2.5 hours
3335220|NCT02136485|Other|Control|Control arm - waiting list control, once the intervention group has completed MBSR the control group will be invited to participate in MBSR
3335221|NCT02136524|Experimental|Capsule formulation|
3335222|NCT02136524|Experimental|Tablet formulation|
3335223|NCT02136537|Active Comparator|Best medical therapy|Claudicants treated according to local protocol - no added treatment
3335224|NCT02136537|Experimental|Best medical therapy plus NMES|In addition to best medical therapy, subjects will receive bilateral neuromuscular stimulation of their legs, 4 hours per day.
3235075|NCT01237249|Experimental|Alternating MPV with Revlimid/Low Dose Dexamethasone|Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)
3335225|NCT02136550|Experimental|Smoking cessation|36 smokers will participate in the study and will be evaluated at baseline, 6 months e 12 months of the smoking cessation program. If they quit the program, they will be asked to continue the study.
3335226|NCT02136563||Darbepoetin alfa|
3335227|NCT02136589|Experimental|Dicrofenac|
3335228|NCT02136615||overweight and obese male volunteers|BMI between 23-40 kg/m2
3335229|NCT02136628|Experimental|RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
3335230|NCT02136628|No Intervention|Control|Conventional midline mass closure technique. Upon completion of the surgical procedure was the closure of abdominal wall which will be made with the number 0 monofilament PDS, starting with knot at one end of the wound, continuous with continuous súrgete, moving each point to a centimeter away from the other. Each point will be a distance of one centimeter from the edge of the fascia. At the opposite end of the wound the same procedure was initiated and found the two suture lines at the midpoint of the wound will proceed to tying the two sutures with 4 square knots.
3335231|NCT02136641|Active Comparator|Midazolam|1. Sedation with Midazolam 0.03 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3335232|NCT02136641|Experimental|Midazolam+Fentanyl Combination|2. Sedation with Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3335233|NCT02136641|Experimental|Midazolam+Ketamine Combination|3. Sedation with Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, Intravenous, administered as a single dose. Was given to those patients randomly assigned to this group, who were scheduled for procedures previously defined in the inclusion criteria.
3335234|NCT02136654|Experimental|Culturally tailored diabetes program|"Culturally tailored diabetes program~culturally tailored diabetes education~lifestyle counselling~medication adherence counseling~peer supporter~communication training~family member involvement"
3335235|NCT02136654|No Intervention|Usual Care|Usual Care includes continuing to visit primary care physician for ongoing diabetes management Printed diabetes education materials.
3335236|NCT02136667||Exposed|Women with a history of preeclampsia 10 years ago
3335237|NCT02136667||Unexposed|Women with a history of uncomplicated pregnancy 10 years ago
3335238|NCT02136693|Placebo Comparator|Placebo|3.5 g /day of inert compound for 180 days after STARR
3335239|NCT02136693|Experimental|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
3335240|NCT02136706|No Intervention|10/30 min rest/stress|Rest and stress T99m-MPI obtained 10 minutes and 30 minutes after tracer injection. After the myocardial perfusion imaging the investigators will have 10 minute waiting period to take images and then wait the 30 minutes, standard of care to take the images.
3335241|NCT02136719|Active Comparator|Group A|bimanual uterine compression immediately after delivery of placenta for 5 minutes in 260 women
3335242|NCT02136719|No Intervention|Group B|no intervention (260 women).
3235076|NCT01237262|Active Comparator|TNF alfa inhibitors|Male and female adult patients with a diagnosis of moderate to severe psoriasis (when PASI score is > 10 and BSA is > 10%). The overall study enrolment plan is 20 patients. Patients will be screened before the beginning of clinical trial by blood sample in order to exclude major contraindications to use of anti TNF α drugs.
3235077|NCT01237275|Experimental|SSRI treated group|SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline
3235078|NCT01237288|Experimental|Z-521|
3335243|NCT02136732|Experimental|Active self-management intervention|Participants will receive home visits and phone calls from a registered nurse and social worker. The registered nurse and social worker will provide participants one on one coaching, education, support and referrals to community resources to help them manage their chronic conditions.
3235079|NCT01237314||Glargine Group|After baseline titration of metformin, this group will take glargine along with metformin.
3235080|NCT01237314||Exenatide Group|After baseline titration of metformin, this group will take exenatide along with metformin.
3335244|NCT02136732|Active Comparator|Attention control phone calls|Participants will receive an initial visit and then a phone call every other month from a social services aide who can provide information about community resources that might be helpful.
3335245|NCT02136745|Experimental|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
3235081|NCT01237314||Glargine and Exenatide Group|After baseline titration of metformin, this group will take glargine and exenatide along with metformin.
3235082|NCT01237366|Experimental|Reslient Affective Processing Therapy (RAPT)|
3235083|NCT01237366|No Intervention|Attention-Control|Participants will complete 7 sessions where they will be asked to write about neutral topics and complete psychological measures for the purposes of matching for attention and reimbursement.
3235084|NCT01237379||Health Controls|
3335246|NCT02136758|Experimental|Lifestyle modification|The intervention group participated in individualized therapeutic lifestyle plans to reduce cardiovascular risk. Participants were introduced to factors contributing to cardiovascular disease and met individually with a registered dietitian, exercise physiologist, stress management instructor, and psychologist to learn effective strategies for integrating healthy changes into their current lifestyle.
3335247|NCT02136758|No Intervention|Usual care controls|Control group received standard care from their primary physicians, but did not participate in any component of the lifestyle program or receive any information, advice, or counseling regarding healthy lifestyle behaviors.
3335248|NCT02136771|Active Comparator|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3; producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
3235085|NCT01237379||Bipolar Patients with High-Risk of Mania|
3235086|NCT01237379||Bipolar Patients with Ultra-High Risk|
3335249|NCT02136771|Placebo Comparator|Placebo|Oily drops as placebo
3335250|NCT02136784|Experimental|morphine sulfate|30mg, single dose,
3335251|NCT02136784|Experimental|hydrocodone|10mg single dose
3335252|NCT02136784|Experimental|hydromorphone HCI|4mg single dose
3335253|NCT02136784|Experimental|oxycodone|10 mg single dose
3335254|NCT02136784|Experimental|buprenorphine|4 mg single dose
3335255|NCT02136784|Placebo Comparator|oral tablet placebo|single dose
3335256|NCT02136784|Placebo Comparator|sublingual tablet placebo|single dose
3335257|NCT02136797|Experimental|CMVpp65-CTL T-cells|The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 10^6 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
3335258|NCT02136823|Placebo Comparator|sugar pill|sugar pill, oral administration, placebo capsule
3335259|NCT02136823|Experimental|riluzole|50mg tablet, single oral dose, one day (single dose)
3335260|NCT02136823|Experimental|isradipine|5mg capsule, single oral dose, one day (single dose)
3335261|NCT02136823|Experimental|memantine|5mg tablet, single oral dose, one day (single oral dose)
3335262|NCT02136823|Experimental|therapeutic stretching|Manual therapeutic stretching of tested muscle by licensed clinician
3335263|NCT02136836||gastric adenocarcinoma|
3335264|NCT02136875|Experimental|Double dose of Advair for AECOPD|Double dose of Salmeterol + Fluticasone Propionate (Advair) Self-administered prescription Self-management education on the use of a self-administered prescription
3335265|NCT02136888|Experimental|Group A|"Ponesimod will be administered orally, once daily for 22 days starting on Day 2, and will comprise the following multiple-dose up-titration: 3 days of 10 mg (Days 2 to 4), 3 days of 20 mg (Days 5 to 7), 5 days of 40 mg (Days 8 to 12), 3 days of 60 mg (Days 13 to 15), 3 days of 80 mg (Days 16 to 18), and 5 days of 100 mg (19 to 23).~Placebo matched for ponesimod will be given on Day -1. Placebo tablets matched for moxifloxacin will be administered on Days 1 and 24."
3335266|NCT02136888|Experimental|Group B|Placebo matched for ponesimod will be administered orally, once daily on Day -1 and on Day 2 through Day 23. In half of Group B subjects, 400 mg moxifloxacin will be administered orally on Day 1 and a matching placebo tablet on Day 24. In the other half of Group B subjects, a matching placebo tablet will be administered on Day 1 and 400 mg moxifloxacin on Day 24.
3335267|NCT02136901|Experimental|Investigational arm|The patients randomized to the Investigational Group will receive the NUsurface® Meniscus Implant.
3335268|NCT02136901|Active Comparator|Control Arm|The patients randomized to the Control Group of the study will receive Non-Surgical Care (the current standard of care for this patient population).
3335269|NCT02136927|Experimental|SPARC1210|Intravenous administration of SPARC1210
3335270|NCT02136927|Active Comparator|Reference1210|Intravenous administration of Reference1210
3335271|NCT02136940|Experimental|AMA0076 0.1%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3335272|NCT02136940|Experimental|AMA0076 0.25%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3335273|NCT02136940|Experimental|AMA0076 0.50%|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3335274|NCT02136940|Placebo Comparator|Placebo|Eligible subjects who meet the inclusion/exclusion criteria will be randomized to active or placebo (vehicle) in a 1:1:1:1 allocation ratio.
3335275|NCT02136953|Experimental|Exercise|12-weeks of structured, individual aerobic exercise, 3 times a week, increasing from 15-30 minutes to 30-40 minutes per session.
3235087|NCT01237379||First Manic Episode Bipolar Youth|
3335276|NCT02136953|Active Comparator|Cognitive Behavioural Therapy (CBT)|12-weeks of manual-based group CBT, 2 hours per week, 8 participants per group.
3335277|NCT02136953|Experimental|Exercise and CBT|Combined 12-week Exercise program and CBT.
3335278|NCT02136953|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
3335279|NCT02136966|Experimental|Programme|"Distribution of Micronutrients powders (MNP)~Intensive counseling on Infant and Young Child Nutrition~Cooking demonstrations"
3335280|NCT02136966|No Intervention|Controle|"Usual Infant growth monitoring and promotion activities~No distribution of micronutrients powders~No Intensive counseling~No cooking demonstrations"
3335281|NCT02136979|Active Comparator|Propofol group|patients with propofol-based anesthesia
3335282|NCT02136979|Active Comparator|Sevoflurane group|patients with sevoflurane-based anesthesia
3335283|NCT02136992|Placebo Comparator|Placebo (without active ingredient)|placebo will be taken two tablets 3 times a day during the whole study process.
3335284|NCT02136992|Experimental|Pirfenidone（200mg）|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
3335285|NCT02137005||Cerebral Palsy|Patients with cerebral palsy who were seen at the Center for Gait and Movement Analysis (CGMA) at Children's Hospital Colorado as children.
3335286|NCT02137018|Active Comparator|laparotomy with PPL mesh implantation|control group: laparotomy with PPL mesh implantation (traditional method)
3335287|NCT02137018|Experimental|laparotomy with PPL fixation by BP|laparotomic surgery with PPL mesh fixation by BP (new fixing method)
3335288|NCT02137018|Active Comparator|laparoscopy with PPL mesh implantation|control group: laparoscopy with PPL mesh implantation (traditional method)
3335289|NCT02137018|Experimental|laparoscopy with PPL fixation by BP|laparoscopic surgery with PPL mesh fixation by BP (new fixing method)
3335290|NCT02137031|Experimental|Mini Link REAL-Time Transmitter|
3335291|NCT02137044|Experimental|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
3335292|NCT02137044|No Intervention|Usual Care|Subjects assigned to usual care were informed by the CCM of their depressive and pain symptoms and that they should consult with their MS or primary care provider about possible care for these conditions. Study personnel did not make any further attempts to influence usual care participants' depression or pain management unless a psychiatric emergency arose (e.g., suicidal ideation was detected at baseline or any of the outcome assessments).
3335293|NCT02137057||control ( patients without diabetes)|patients without diabetes
3335294|NCT02137057||DM ( patients with diabetes)|patients with diabetes
3335295|NCT02137070||Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss at local surgical centers or UFHEALTH & Shands Hospital.
3235088|NCT01237392|Active Comparator|Contact Ultrasonic Debridement Device|
3235089|NCT01237392|Active Comparator|Standard Sharp Debridement|
3235090|NCT01237405||Knee Osteoarthritis|"Unilateral or bilateral knee osteoarthritis on radiograph associated with knee pain on most days of any one-month in the last year in at least one knee.~Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi)."
3235091|NCT01237418||Myocardial Infarction|Any patient over 18 years admitted for myocardial infarction (MI) of less than 48 hours, characterized by the typical rise and fall of troponin or CPKMb
3235092|NCT01237431|Experimental|liver transplanted patients|Target group to confirm the hypothesis. Transplantation has to be between 6 an 24 Month before participation.
3235093|NCT01237431|Active Comparator|kidney transplanted patients|Control group, age, gender and medication matched. Transplantation has to be between 6 an 24 Month before participation.
3235094|NCT01237444|Experimental|lopinavir/ritonavir plus lamivudine|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
3235095|NCT01237444|Active Comparator|lopinavir/ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype"
3235096|NCT01237457|Experimental|Treatment|
3235097|NCT01237470|Experimental|Desarda group|Patients with primary inguinal hernia operated using the Desarda technique
3235098|NCT01237470|Experimental|Lichtenstein group|Patients with primary inguinal hernia operated using the Lichtenstein technique.
3235099|NCT01237483|Other|Erbitux Radiotherapy|Radiotherapy during 5 weeks and concurrent Erbitux once a week.
3235100|NCT01237496|Experimental|1|
3235101|NCT01237509||group1|Patients with T1D
3235102|NCT01237522|Active Comparator|Homozygote for the A270S wildetype|
3235103|NCT01237522|Active Comparator|Homo- or heterozygote for A270S minor alleles|
3235104|NCT01237535|Experimental|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel)Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.
3335296|NCT02137070||Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
3335297|NCT02137083|Experimental|Docetaxel Plus Fulvestrant|"Docetaxel:75mg/m2 D2 every 21 days~Fulvestrant:500mg D1, D15, D29, D57, every 28 days later"
3335298|NCT02137083|Active Comparator|Docetaxel|Docetaxel:75mg/m2 D2 every 21 days
3335299|NCT02137109||natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab per the local label specifications.
3335300|NCT02137122|Experimental|Cognitive Training|Participants will undergo 60 hours of cognitive training. Cognitive training will involve computerized games that stress elements of cognition. The training control will be the same tasks set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
3335301|NCT02137122|Placebo Comparator|Training Control|Participants will undergo 60 hours of training control. Training control will involve the same computerized games as in the cognitive training condition but are set at an easy difficulty setting. The group will undergo either transcranial direct current stimulation or sham stimulation.
3335302|NCT02137135|Experimental|follicular phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
3335303|NCT02137135|Active Comparator|luteal phase|Visual anlogue score vas used to evaluate pain. The anxiety/depression scale (HAD) was used to assess anxiety and depression. The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
3335304|NCT02137161|Active Comparator|Dexamethasone+Tobramycin eye drop|An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
3335305|NCT02137161|Experimental|Bromfenac|Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
3335306|NCT02137174|Active Comparator|Home and school visits|
3335307|NCT02137174|No Intervention|Control|
3335308|NCT02137187|Experimental|Drug therapy|Control Arm: optimized drug therapy (plus implantable defibrillator (ICD) according to guidelines)
3335309|NCT02137187|Active Comparator|Device: AV junction ablation & CRT|AV junction ablation + CRT (CRT-P or CRT-D according to guidelines) + optimized drug therapy
3335310|NCT02137200|Active Comparator|Delayed pushing|
3335311|NCT02137200|Experimental|Immediate pushing|
3335312|NCT02137213|Experimental|Arm A: Naloxone then placebo|Subjects assigned to Arm A will receive methadone with naloxone for one week and then methadone with placebo for one week
3335313|NCT02137213|Experimental|Arm B: Placebo then naloxone|Subjects assigned to Arm B will receive methadone with placebo for one week and then methadone with naloxone for one week
3335314|NCT02137239|Experimental|Belatacept + Everolimus|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; belatacept (infusion) regimen of 10 mg/kg i.v. on Day 1, Weeks 1, 2, 4, 8 and 12 post transplant and then a maintenance dose of 5 mg/kg every 4 weeks after 12 weeks post transplant; everolimus (tablet) daily dosing at 3.0 mg/day, 2 divided doses, starting on Day 3 dosing adjusted based on blood sample tests; methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
3335315|NCT02137239|Experimental|Tacrolimus + Mycophenolate mofetil|Thymoglobulin (i.v. infusion) induction, daily (or less frequently, as tolerated) not to exceed 10 days, to reach a total cumulative dose between 3.0 and 5.5 mg/kg; tacrolimus (tablet) daily dosing beginning at 0.1 mg/kg/day, then adjusted based on blood sample tests; MMF (tablet) daily dosing between 0.5 to 2.0 g/day divided in 2 doses (up to 3 g/day if African Americans/Blacks); methylprednisolone (infusion) prior to each Thymoglobulin infusion and prednisone (tablet), once methylprednisolone is no longer needed. (Corticosteroids to be discontinued by Day 7 or as soon thereafter as thymoglobulin infusions are completed)
3335316|NCT02137265|Active Comparator|Clomiphene citrate|Clomiphene citrate 50 mg daily during 4-6 months
3335317|NCT02137265|Placebo Comparator|Placebo|Placebo (1 pill daily) during 4-6 months
3335318|NCT02137278|Active Comparator|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment
3335319|NCT02137278|Experimental|Vasoactive drug therapy|Continue current vasoactive therapy
3335320|NCT02137291||Left-sided double-lumen tube|Lung isolation with a left-sided double-lumen tube (BronchoCath, Mallinckrodt Medical, Cornamaddy, Athlone, Westmeath, Ireland)
3335321|NCT02137291||Modified right-sided double-lumen tube|Right-sided double-lumen tube modified in accordance with Bussières et al. in Can J Anesth 2007
3335322|NCT02137304|Experimental|neuromuscular patients|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)
3335323|NCT02137317|Experimental|LAPPE/DP|In the LAPPE experiment the farmer will work as usual (mixing/loading/application/cleaning). wearing the LAPPE solution and carrying a new hand pressured backpack sprayer with a standardized nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the DP solution.
3335324|NCT02137317|Active Comparator|DP/LAPPE|In the DP experiment the farmer will work as usual (mixing/loading/application/cleaning) wearing the DP solution and carrying his usual backpack sprayer with his usual nozzle. Conditions such as dosage, work practices and weather conditions will remain uncontrolled but be observed. After one week this process will be repeated wearing the LAPPE solution.
3335325|NCT02137330|Experimental|Obalon Arm|Children swalowed up to 3 intragastric balloons
3335326|NCT02137330|No Intervention|Dietary and lifestyle changes Arm|
3235105|NCT01237535|Experimental|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].
3235106|NCT01237535|No Intervention|No luteal support|
3335327|NCT02137343|Experimental|Rilotumumab|Rilotumumab plus Cisplatin and Capecitabine (CX).
3335328|NCT02137343|Placebo Comparator|Placebo|Rilotumumab-placebo plus Cisplatin and Capecitabine (CX).
3335329|NCT02137356|Experimental|treatment arm|standard dose pelvic radiation therapy, standard dose capecitabine, dose-escalated selinexor treatment
3335330|NCT02137395|Experimental|Dexamethasone|Patients are received dexamethasone via intravenous (iv) route of 0.5 mg.kg-1 (maximum dose of 8 mg) in group D at the induction of anesthesia.
3335331|NCT02137395|Placebo Comparator|Placebo|An equal volume of saline iv in group S at the induction of anesthesia.
3335332|NCT02137408|Active Comparator|200 mg docosahexaenoic acid|Participants will be randomized to 200 mg of docosahexaenoic acid (DHA) administered PO daily (1-200mg capsule of DHA). This is a standard dose used in prenatal vitamins. Participants will be supplemented by mouth daily between 18-20 weeks gestation through 6 weeks post-partum.
3335333|NCT02137408|Active Comparator|1000 mg docosahexaenoic acid|Participants will be randomized to 1000 mg of docosahexaenoic acid (DHA) administered PO daily (5- 200mg capsules of DHA). Participants will be supplemented daily PO between 18-20 weeks gestation through 6 weeks post-partum.
3335334|NCT02137421|Experimental|CAD, Metabolic syndrome .|"Arm1:coronary artery disease with metabolic syndrome . Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
3335335|NCT02137421|Experimental|Healthy subjects .|"Arm2:healthy subjects Intervention:Resveratrol (3, 4´, 5 trihydroxystilbene), 50 micromolar,12hour treatment .~Each experiment repeats three times ."
3335336|NCT02137434|Placebo Comparator|Low calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 40 mg of calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3335337|NCT02137434|Experimental|High dietary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of skimmed milk containing 540 mg of dietary calcium, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3335338|NCT02137434|Experimental|High supplementary calcium fatty meal|Fatty meal consisting of biscuit, butter and drink made of albumin and sugar containing 540 mg of supplementary calcium from calcium carbonate, 600 kcal, with approximately 10% of energy from protein, 53% from fat, and 37% from carbohydrates.
3335339|NCT02137460||Young normal controls|"age : 20 ~ 55~without dementia, MCI, or other major neurological/psychiatric illness"
3335340|NCT02137460||Elderly normal controls|"age : 55 ~ 90~without dementia, MCI, or other major neurological/psychiatric illness"
3335341|NCT02137460||MCI (Mild cognitive impairment)|"age : 55 ~ 90~without major neurological/psychiatric illness~concern regarding a change in cognition, lower performance in episodic memory domains that is greater than would be expected for the subject's age and educational background and preservation of independence in functional abilities"
3335342|NCT02137460||AD (Alzheimer's diseases)|"age: 55 ~ 90~National Institute of Aging and the Alzheimer's Association (NIA-AA) Probable AD dementia"
3335343|NCT02137525|Active Comparator|Morphine 6 mg|Placebo Sublingual Spray (PSS) + Intravenous Morphine (IVM 6 mg), every 30 minutes for two hours as needed (or until rescue), maximum exposure morphine 30 mg
3335344|NCT02137525|Experimental|Fentanyl 100 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 100 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 500 µg
3235107|NCT01237548||All participants|Normal People who have smoked Water-pipe, at least once before.
3235108|NCT01237561|Experimental|spirometry, patient activation tool|"Receive Portable Spirometer~Spirometry training of staff~Provide clinician with web-based COPD interactive guideline tool~Provide clinician with patient activation tool~Train clinicians (tools, integration into workflow)~Academic Detailing"
3235109|NCT01237561|No Intervention|Usual Care|Spirometer and spirometry training of staff
3235110|NCT01237574||Patients|Patients with chronic alcoholic and/or metabolic liver disease
3335345|NCT02137525|Experimental|Fentanyl 200 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 200 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 1000 µg
3335346|NCT02137525|Experimental|Fentanyl 400 µg|Intravenous Placebo (IVP) + Fentanyl Sublingual Spray (FSS 400 µg), every 30 minutes for two hours as needed (or until rescue), maximum exposure fentanyl 2000 µg
3235111|NCT01237600|Experimental|Cultivated limbal transplantation|
3335347|NCT02137551|Experimental|ABM Intervention in FQHC|Pharmacy technicians within El Rio will implement the ABM
3335348|NCT02137551|Experimental|ABM Intervention in a Supermarket Pharmacy|Pharmacists within Fry's will implement the ABM
3335349|NCT02137551|No Intervention|Usual care|Patients will refill prescriptions at their usual pharmacy in the customary way.
3335350|NCT02137564|Experimental|Treatment (gamma secretase inhibitor PF-03084014)|Patients receive gamma secretase inhibitor PF-03084014 PO BID on days 1-21. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with PR, CR, or SD at the end of 4 courses may receive an additional 4 courses of gamma secretase inhibitor PF-03084014 in the absence of disease progression or unacceptable toxicity.
3235112|NCT01237639|Experimental|Restrictive Red blood cell Transfusion|Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L
3235113|NCT01237639|Active Comparator|Liberal Red blood Cell Transfusion|Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L
3235114|NCT01237652||ISH and normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
3235115|NCT01237652||ISH, Normotensive|This is a prospective cohort study to compare the incidence of perioperative myocardial ischemia between ISH and normotensive patients admitted for elective non-cardiac surgery. To reduce the number of confounding factors for perioperative myocardial ischemia, RCRI Class I or II patients will be recruited.
3335351|NCT02137577|Experimental|DEB catheter|use DEB catheter(trade name: Lotus/Tulip) to treat the stenosis or occlusion in below popliteal artery of experimental arm
3235116|NCT01237665|Experimental|IXO regimen|single-group
3235117|NCT01237691|Experimental|HOPE supervision|Parolee supervised under California's new HOPE parole model.
3235118|NCT01237691|Active Comparator|Parole-as-usual|Parolees supervised under California parole-as-usual.
3335352|NCT02137577|Active Comparator|common PTA balloon catheter|use common PTA balloon catheter(trade name:Amphirion Deep) to treat stenosis or occlusion in below popliteal artery of control group
3335353|NCT02137590|Experimental|Spanish Black Radish|Spanish Black Radish product
3335354|NCT02137616|Active Comparator|risperidone|low dosage of antipsychotic drug
3335355|NCT02137616|Active Comparator|olanzapine|low doseage of antipsychotic
3335356|NCT02137616|Active Comparator|quetiapine|low doseage of antipsychotic
3335357|NCT02137616|Active Comparator|aripiprazole|low doseage of antipsychotic
3335358|NCT02137629||Korean patients|All Korean patients intended to be treated with Vidaza® according to the approved package insert
3335359|NCT02137642|Active Comparator|RM-131|
3235119|NCT01237704|Active Comparator|Traditional rehabilitation (TR)|
3235120|NCT01237704|Active Comparator|Transcutaneous electrical stimulation (ES)|
3235121|NCT01237717||normotensive subjects|subjects without hypertension, and without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,
3235122|NCT01237717||Hypertensive subjects|"subjects with hypertension,~currently not treated at least within 6 months~without diabetes, ischemic heart disease, major arrhythmia, heart failure, secondary hypertension, high grade renal disease,"
3235123|NCT01237730|Active Comparator|Cefuroxime group|Use the cefuroxime as prophylactic antiobiotics, according to the clinical guideline.
3335360|NCT02137642|Placebo Comparator|Placebo|
3335361|NCT02137668|Experimental|Oral Vancomycin|Every participant with PSC or BA will received the same Arm of Oral Vancomycin
3335362|NCT02137681|Experimental|2 cycles|2 cycles RTX
3335363|NCT02137681|Active Comparator|standard 4 cycles|standard 4 cycles RTX
3335364|NCT02137694|Other|PapU-APV|No drug and no placebo will be used in this study. For the study participants, only their medical history data and vaginal auto-takings ( APV) and urinary will be collected.
3335365|NCT02137707||Gilenya treatment|Gilenya oral form once a day
3335366|NCT02137720|Experimental|Telephonic Diabetes Self-Management Support|This group receives all the Educational Print Materials received by the comparison condition plus telephone calls from a health educator to provide tailored diabetes self-management training and support. Participants with significant emotional distress at baseline also receive additional calls focused on distress management.
3335367|NCT02137720|Active Comparator|Educational Print Materials|Participants randomized to this arm will receive print materials on diabetes, glycemic control, self-management, and distress/depression.
3335368|NCT02137733|Active Comparator|Bisoprolol group|Daily oral administration of bisoprolol 0.625 mg tablet once a day should be given (Step 1). If tolerability is confirmed by an investigator, the dose should be increased to 1.25 mg (bisoprolol 0.625 mg, 2 tablets; or bisoprolol 2.5 mg, half tablet; once daily) (Step 2). In the same manner, the doses should be increased to 2.5 mg (bisoprolol 2.5 mg, 1 tablet; or bisoprolol 5 mg, half tablet; once daily, Step 3), to 3.75 mg (bisoprolol 2.5 mg, 1.5 tablets once daily, Step 4), and to 5 mg (bisoprolol 2.5 mg, 2 tablets; or bisoprolol 5 mg, 1 tablet; once daily, Step 5).
3335369|NCT02137733|Active Comparator|Carvedilol group|Daily oral administration of carvedilol 1.25 mg, 1 tablet twice a day (after breakfast and supper) should be given (Step 1). If tolerability is confirmed by an investigator after administering 2.5 mg/day of carvedilol, the dose should be increased to 5 mg (carvedilol 2.5 mg, 1 tablet twice daily) (Step 2). In the same manner, the dose should be increased to 10 mg (carvedilol 2.5 mg, 2 tablets twice daily, Step 3), to 15 mg (carvedilol 2.5 mg, 3 tablets twice daily, Step 4), and to 20 mg (carvedilol 10 mg, 1 tablet twice daily, Step 5).
3335370|NCT02137746|Experimental|DCVAC/PCa Arm|Dendritic Cells DCVAC/PCa Experimental therapy
3335371|NCT02137759|Active Comparator|Std RT/TMZ (Cohort 1)|"Standard radiation therapy~Standard temozolomide"
3235124|NCT01237730|Experimental|Tailored antibiotics group|Tailored antibiotic is selected according to the patient's oropharyngeal microorganisms.
3235125|NCT01237756|Experimental|pediatric|
3335372|NCT02137759|Experimental|Std RT/TMZ + belinostat (Cohorts 2a, 2b)|"Standard radiation therapy~Standard temozolomide~Belinostat"
3335373|NCT02137798|Experimental|CARTOUNIVU|Radiofrequency catheter ablation of atrial fibrillation will be performed using fluoroscopy image integrated 3-dimentional electroanatomical mapping system
3335374|NCT02137798|Active Comparator|CARTO3|Radiofrequency catheter ablation of atrial fibrillation will be performed using 3-dimentional electroanatomical mapping system without fluoroscopy image integration technique
3335375|NCT02137811||Patients that received MICK assay|Patients with pathological diagnoses of cancer or leukemia who have had a MiCK assay (CorrectChemo) test performed
3335376|NCT02137824|Experimental|sinus floor elevation|
3335377|NCT02137863|Placebo Comparator|Control|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.~1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
3335378|NCT02137863|Active Comparator|Dexmedetomidine|"Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.~During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.~Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.~1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
3235126|NCT01237769|Active Comparator|Vitamin D|All patients will be instructed to exercise and lose weight according to the NCEP-ATP III diet. The participants will be randomized in an open manner into one of the following 2 treatment groups: a) cholecalciferol (VitD3) (2200 IU/day) plus lifestyle measures or b) only lifestyle measures. Recruitment will be completed within one year. The reassessment of the patients will be done 3 months after starting of treatment.
3235127|NCT01237769|Active Comparator|Lifestyle measures|
3235128|NCT01237782|Experimental|Propolis solution|A proprietary denture cleanser with propolis as the active agent.
3235129|NCT01237782|Placebo Comparator|Saline solultion|Physiologic saline solution.
3335379|NCT02137889|Experimental|Arm 1- relapsed/refractory CLL patients|Patients with relapsed/refractory CLL with two or three prior treatment regimens
3335380|NCT02137889|Experimental|Arm 2 - rituximab or ofatumumab refractory CLL patients|Patients with relapsed/refractory CLL with four or more prior treatment regimens
3335381|NCT02137902|Experimental|Tobacco/Physical Activity Intervention|Includes a psychosocial component that utilizes a counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for tobacco and physical activity, adherence with nicotine replacement therapy, and self-monitoring with a pedometer-based walking program. The intervention will provide 12 weeks of nicotine replacement therapy for participants.
3335382|NCT02137902|Experimental|Diet plus BP/CHOL Intervention|Consists of a psychosocial component that includes counselor-facing computer-assisted intervention with tailored counseling feedback focused on increasing intrinsic motivation, goal setting for managing hypertension and hypercholesterolemia, and adherence with antihypertensives and statins with supportive dietary changes. The intervention provides a cookbook of heart healthy regional recipes and medication bag for storing medications.
3335383|NCT02137928|Experimental|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months)
3335384|NCT02137928|Active Comparator|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months
3335385|NCT02137941|Active Comparator|techniques to optimize potential (TOP)|
3335386|NCT02137941|Active Comparator|heart coherence (HC)|
3335387|NCT02137941|Placebo Comparator|controls|
3335388|NCT02137954|Active Comparator|lidocaine|Lidocaine. Initial dose IV will be 5 mg/kg per day during the first 24 hours the 8 mg/kg per day
3335389|NCT02137954|Placebo Comparator|placebo|
3335390|NCT02137967|Experimental|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medication
3335391|NCT02137967|Active Comparator|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament
3235130|NCT01237795|Experimental|0.01% fluorosurfactant|An experimental formula for denture hygiene containing 0.01% fluorosurfactant.
3235131|NCT01237795|Experimental|1.0% chloramine T|An experimental formula for denture hygiene containing 1.0% chloramine T.
3335392|NCT02137993|Experimental|A-prexa|A-prexa 5, 10mg
3335393|NCT02137993|Active Comparator|Zyprexa|Zyprexa 5, 10mg
3335394|NCT02138019|Experimental|Fibrin glue|In ophthalmic field, the use of organic glues has provided good results for the repair of leaking blebs and perforated corneal ulcers, conjunctival closure in strabismus surgery, surgery for retinal detachment, cataract surgery, trabeculectomy, and mucous membrane grafting to repair lesions of the conjunctival fornix. In this study, the investigators try to evaluate the effect of Fibrin Glue assisted external eye surgery.
3335395|NCT02138032|Experimental|Gains Framed Message|gains framed visual fridge magnet and information sheet about smoking cessation (benefits of quitting smoking)
3335396|NCT02138032|Experimental|Loss Framed Message|loss framed visual fridge magnet and information sheet about smoking cessation (losses of continued smoking)
3335397|NCT02138045|Placebo Comparator|Placebo treatment|"Placebo solution will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
3335398|NCT02138045|Active Comparator|Liraglutide treatment|"Liraglutide will be slowly titrated to maximum tolerable dose in order to minimize potential side-effects, hence treatment will follow:~First and second week: 0.6 mg/day; Third and fourth week: 1.2 mg/day and Fifth and to sixth week: 1.8 mg/day."
3335399|NCT02138058|Placebo Comparator|Placebo|a 12 week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention
3335400|NCT02138058|Experimental|topiramate|a 12 week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention
3335401|NCT02138071||Individual|Treatment in the 'Individual group therapy' will include physiotherapy protocols usually used by physiotherapist working at Maccabi Healthcare Services (Exercises, Modalities, Maual therapy and Back Care education)
3335402|NCT02138071||group|Participants in group therapy will receive 6-8 group treatments (6-12 pateints per group) which will also include exercises and back-care education. No intervention will be done by the investigator.Therapists will use protocols commonly used in Maccabi Healthcate Services.
3235132|NCT01237795|Experimental|0.2% chloramine T|An experimental formula for denture hygiene containing 0.2% chloramine T.
3335403|NCT02138084|Experimental|Cohort 1: BMS-663068 + Rifabutin|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen B: BMS-663068 tablet with Rifabutin capsule by mouth as specified"
3335404|NCT02138084|Experimental|Cohort 2: BMS-663068 + Rifabutin + Ritonavir|"Regimen A: BMS-663068 tablet by mouth as specified~Regimen C: BMS-663068 tablet, Rifabutin capsule and Ritonavir (RTV) capsule by mouth as specified"
3335405|NCT02138123|Experimental|IOL-shell technique|In this group, before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
3235133|NCT01237795|Active Comparator|Proprietary dentifrice.|A proprietary denture-specific dentifrice.
3335406|NCT02138123|Active Comparator|Conventional procedure|In this group, a Sensar IOL (AMO Laboratories) was implanted in the capsular bag with the injector system after the lens material was completely removed. The nuclear fragmentation was performed using the Phaco-chop technique, which was then followed by ultrasound emulsification of the nuclear fragments piece by piece. Due to lack of cortical shell within the capsular bag, special care was taken to carry out the emulsification of the last nuclear fragment at a relatively more anterior anatomical position between the iris plan and the anterior chamber.
3335407|NCT02138149||spinal cord injury|individuals with neurogenic lower urinary tract dysfunction
3335408|NCT02138149||control group|individuals with physiologic bladder function
3335409|NCT02138162|Experimental|1:Single dose of enzalutamide in hepatically impaired subjects|Single dose of enzalutamide
3235134|NCT01237808|Active Comparator|Standard arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) without ATRA
3235135|NCT01237808|Experimental|Investigational arm|6 cycles of chemotherapy (low-dose cytarabine and etoposide) with ATRA (All-trans-Retinoic acid)
3335410|NCT02138162|Experimental|2:Single dose of enzalutamide in healthy subjects|Single dose of enzalutamide
3335411|NCT02138175||Patients at risk for bleeding|Patients at risk for bleeding
3335412|NCT02138188||T1D patients on CSII|Patients affected by Type 1 Diabetes on insulin pump therapy
3335413|NCT02138201||control|individuals with normal bladder function
3335414|NCT02138201||neurogenic bladder|individuals suffering from neurogenic lower urinary tract dysfunction
3335419|NCT02138292|Experimental|Trametinib (2mg)/Digoxin (0.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8-week cycle, duration of treatment can last from 8 to 104 weeks."
3335420|NCT02138305|Other|Patients referred for CABG|"Patients who after undergoing standard of care diagnostic coronary angiography will be referred for CABG~ComboMap XT Guidewire~'SPY' NIRF During CABG"
3335421|NCT02138318|Other|chromoendoscopy|
3335422|NCT02138318|Other|High definition (HD) endoscopy|
3335423|NCT02138331|Experimental|Exosomes|The exosomes have exosome-associated proteins such as the tetraspanin proteins, CD9 and CD81, Alix, Tsg101, and RNA that consists primarily of short RNAs of less than 300 nm. Some of these RNAs are microRNAs that are predominantly pre-microRNAs..Additionally, CB-SC displayed very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.
3335424|NCT02138344||SCI subjects|Chronic and traumatic SCI subjects
3335425|NCT02138344||Healthy control subjects|
3335426|NCT02138344||Subjects with peripheral nerve diseases|
3235136|NCT01237834||Heavy smokers, 15 or more cigarettes/day|Nicotine dependent.
3235137|NCT01237834||Light smokers (chippers)|Less than 2 cigarettes/day, at least 2 days/week. Non nicotine-dependent.
3235138|NCT01237834||Non smokers|
3335427|NCT02138357|Placebo Comparator|Placebo Patch|"The Placebo is in the form of a patch. We will be using placebo patches labeled 5mcg/hour, 10mcg/hour, and 20mcg/hour that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
3335428|NCT02138357|Experimental|buprenorphine transdermal delivery system (BTDS)|"buprenorphine transdermal delivery system (BTDS), brand name Butrans. Butrans is in the form of a patch. We will be using 5mcg/hour, 10mcg/hour, and 20mcg/hour patches that will be changed every 7 days.~Each subject will participate in this arm of the study for four weeks."
3335429|NCT02138370||stage II and III colorectal cancer|
3335430|NCT02138383|Experimental|Dose Escalation and Dose Expansion|"Dose Escalation: To find the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.~Dose Expansion: To find the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel."
3335431|NCT02138396|Experimental|FSS first, then FCI|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single dose of fentanyl sublingual spray (FSS) at the first visit. After a washout period of at least seven days, they receive a single intramuscular fentanyl citrate injection (FCI) at the second treatment visit.
3335432|NCT02138396|Experimental|FCI first, then FSS|At each of two treatment visits participants fast for 10 hours before dosing, and receive naltrexone before and after dosing. Participants in this group receive a single intramuscular fentanyl citrate injection (FCI) at the first visit. After a washout period of at least seven days, they receive a single dose of fentanyl sublingual spray (FSS) at the second treatment visit.
3335433|NCT02138409|Experimental|ON FSS 100 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 100 µg
3335434|NCT02138409|Experimental|ON FSS 200 µg|Participants classified as opioid-naïve (ON), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, and further randomized to a dose of 200 µg
3235139|NCT01237847|Other|Wait List|
3235140|NCT01237847|Experimental|2 phone sessions|
3335435|NCT02138409|Experimental|OE FSS 400 µg|Participants classified as opioid-experienced (OE), randomized to receive one dose of fentanyl sublingual spray (FSS) 10 minutes before treatment procedure, at a dose of 400 µg
3335436|NCT02138409|Placebo Comparator|ON PSS|Participants classified as opioid-naïve (ON) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
3335437|NCT02138409|Placebo Comparator|OE PSS|Participants classified as opioid-experienced (OE) and randomized to receive one dose of matching placebo sublingual spray (PSS) 10 minutes before treatment procedure
3335438|NCT02138422|Placebo Comparator|Placebo|Placebo administered intravenously every 2 weeks
3335439|NCT02138422|Active Comparator|Xilonix|Xilonix administered intravenously every 2 weeks
3335440|NCT02138435||VSD-patients|Patients who had VSD closure between 1990 and 1995. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
3335441|NCT02138435||Control|A group of healthy control subjects. They will be tested by a MRI exercise test and a gas-exchange exercise test measuring cardiac output.
3235141|NCT01237847|Experimental|4 phone sessions|
3235142|NCT01237873|Experimental|Ali/Amlo|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
3235143|NCT01237925|Experimental|Dexchlorpheniramine 1% gel|
3235144|NCT01237925|Active Comparator|Dexchlorpheniramine 1% cream|
3235145|NCT01237938|Experimental|Low Glycemic Diet|
3235146|NCT01237964|Experimental|Xiaflex ( Collagenase use)|all 10 patients will be selected from out burn's clinic pool and will be injected using collagenase
3235147|NCT01237977|Experimental|Botulinum toxin type A(Meditoxin®)|
3235148|NCT01237977|Active Comparator|Botulinum toxin type A(Botox®)|
3235149|NCT01238003||Hospitalized patients|
3235150|NCT01238016|Other|device|Device implant and EEG recording
3335442|NCT02138448|Experimental|Intervention practices|Intervention practices will implement an interactive preventive health record in addition to their standard personal health record functionality.
3335443|NCT02138448|No Intervention|Control practices|Control practices will continue to field their existing personal health record
3335444|NCT02138474|Experimental|Lacticum acidum homaccord|Lacticum acidum homaccord 30 mL bottle of medicated sucrose pillules take 5 pillules of the medication in the morning and in the evening for 4 weeks
3235151|NCT01238029|Experimental|Capecitabine, Lapatinib, Vinorelbine|
3235152|NCT01238042|Experimental|Light Dose Escalation|Light Dose escalated from 150 joules/cm to 200 joules/cm
3235153|NCT01238055|Experimental|Docetaxel + Sunitinib|Docetaxel and Sunitinib
3335445|NCT02138474|Placebo Comparator|Placebo|Unmedicated sucrose pillules, take 5 pillules twice daily for 4 weeks
3335446|NCT02138487|Active Comparator|Restricted postoperative activity|"Women in the restricted postoperative activity group must abstain from exercise and heavy lifting for 3 months postoperatively"
3335447|NCT02138487|Experimental|Liberal postoperative activity|"Women in the liberal postoperative activity group will be allowed to resume their normal activities without restriction."
3335448|NCT02138500|Experimental|Cohort 1: PF-06372865 10 mg|
3335449|NCT02138500|Experimental|Cohort 2: PF-06372865 TBD dose|
3335450|NCT02138500|Experimental|Cohort 3: PF-06372865 TBD dose|
3335451|NCT02138513|Experimental|Online MBCT|
3335452|NCT02138513|Experimental|group MBCT|
3335453|NCT02138513|No Intervention|Treatment as usual|3 months waiting list, subsequent assignment to group or online MBCT
3335454|NCT02138526|Active Comparator|fasted|Intake of pazopanib in agreement with drug label - fasted state
3335455|NCT02138526|Experimental|Continental breakfast|Intake of a reduced equivalent pazopanib dose with a continental breakfast
3335456|NCT02138539|Active Comparator|4% Hydroquinone|4% hydroquinone applied to one side of the face.
3335457|NCT02138539|Experimental|Herbal depigmenting agent|Herbal depigmenting agent applied on the other side of the face.
3335458|NCT02138552|Active Comparator|OCT 0.1% vs. Placebo|0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3335459|NCT02138552|Active Comparator|OCT 0.15% vs. Placebo|0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3335460|NCT02138552|Active Comparator|OCT 2.0% vs. Placebo|0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)
3335461|NCT02138565|Experimental|Bariatric surgery|
3335462|NCT02138591|Experimental|Vitamin D3|"Vitamin D3 (cholecalciferol) 50,000 IU by mouth daily for each of the five days prior to surgery.~Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2"
3335463|NCT02138591|Placebo Comparator|Placebo pill|Placebo pill by mouth daily for each of the five days prior to surgery. Blood draw pre-operatively Blood draw post-operative Day 1 Blood draw post-operative Day 2
3235154|NCT01238055|Active Comparator|Docetaxel|Docetaxel only
3235155|NCT01238068|Active Comparator|Gamma nail, fracture stabilization, better walking|
3235156|NCT01238094|Experimental|FOLFIRI or XELIRI/simvastatin|FOLFIRI or XELIRI/simvastatin
3335464|NCT02138617|Experimental|*1/*1 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 310 mg/m2,(IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3335465|NCT02138617|Experimental|*1/*28 Genotype|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 260 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3335466|NCT02138617|Experimental|*28/*28|FOLFIRI (5-fluorouracil (5-FU), leucovorin, irinotecan) Irinotecan dose 180 mg/m2, FOLFIRI (IV, Day 1, 15); Bevacizumab (IV, Day 1, 15), repeat treatment cycle every 28 days.
3335467|NCT02138630|Placebo Comparator|Placebo|
3335468|NCT02138630|Experimental|Capsaicin|"Single Capsule, Capsimax 100 mg, ingested 60 min prior to exercise"
3335469|NCT02138643|Active Comparator|Endoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
3335470|NCT02138643|Sham Comparator|Laparoscopic surgery|Patients with symptomatic achalasia confirmed by clinical and laboratory tests, which meet the criteria for inclusion and exclusion. These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
3235157|NCT01238107|Experimental|High dose|
3235158|NCT01238107|Experimental|Low dose|
3235159|NCT01238107|Placebo Comparator|Placebo|
3235160|NCT01238133|Experimental|Treatment (RO4929097, paclitaxel, carboplatin, surgery)|Patients receive gamma-secretase inhibitor RO4929097 PO QD on days 1-3, 8-10, and 15-17, paclitaxel IV over 60 minutes on days 1, 8, and 15 (day -1 of course one), and carboplatin IV over 60 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after completion of neoadjuvant therapy, patients undergo definitive breast surgery.
3335471|NCT02138656|Active Comparator|Best standard care only - not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice.~Parents aware that infant is not receiving chiropractic treatment"
3335472|NCT02138656|Sham Comparator|Best Standard Care and Sham - Blind|Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus sham chiropractic treatment. Parents unaware of whether infant is receiving real treatment or sham.
3335473|NCT02138656|Experimental|BSC & Chiropractic - Not blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents aware that infant is receiving chiropractic treatment."
3335474|NCT02138656|Experimental|BSC & Chiropractic - Blind|"Best Standard Care (as defined by Map of Medicine care pathway) - counseling and advice plus real chiropractic treatment.~Parents not aware that infant is receiving chiropractic treatment."
3335475|NCT02138669|Other|Intacs Device|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
3335476|NCT02138682||l-123 Ioflupane|Study group includes those clinically diagnosed with Parkinson disease who are aged 75 and older who have agreed to donate brain tissue at time of death and are able to participate in the imaging scan process.
3335477|NCT02138695||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
3235161|NCT01238146|Experimental|Arm I|Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.
3235162|NCT01238146|Experimental|Arm II|Patients receive rituximab and bendamustine hydrochloride as in arm I.
3235163|NCT01238159|Experimental|CCRT+MIDLE|Patients who are planned to be treated with CCRT plus MIDLE chemotherapy. CCRT means concurrent chemoradiation, and MIDLE represent systemic chemotherapy.
3235164|NCT01238224|Placebo Comparator|Placebo|A single dose of placebo is administered 30 min before a mixed meal.
3335478|NCT02138708|Experimental|Shunt closed|patients with heart disease and shunt who, following hemodynamic exploration, will be selected for closure of their shunt
3335479|NCT02138721|No Intervention|No local treatment|Routine care in metastatic prostate cancer.
3335480|NCT02138721|Experimental|Local treatment|Radical Prostatectomy (RP) + routine care in metastatic prostate cancer.
3335481|NCT02138734|Experimental|N-803+BCG|(Phase Ib and IIb) for BCG-naive patients
3335482|NCT02138734|Active Comparator|BCG alone|(Phase IIb) for BCG-naive patients
3335483|NCT02138760|No Intervention|MRI guided cognitive fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional cognitive (freehand) biopsies of MRI suspicious targets
3235165|NCT01238224|Active Comparator|Tadalafil|A single dose of tadalafil 20 mg is administered 30 min before a mixed meal.
3235166|NCT01238237|Experimental|Cetuximab|
3335484|NCT02138760|Experimental|UroNav fusion biopsy|Men in this arm will undergo MRI followed by systematic biopsy and then additional UroNav fusion biopsy of MRI suspicious targets
3335485|NCT02138773|Experimental|Fed, formulation-A|drug administered at 0.5h after the start of a standard breakfast
3335486|NCT02138773|Experimental|Fed, formulation-B|drug administered at 0.5h after the start of a standard breakfast
3335487|NCT02138773|Experimental|Fasted, formulation-A|drug administered under fasted condition (fasting for at least 10 hours)
3335488|NCT02138773|Experimental|Fasted, formulation-B|drug administered under fasted condition (fasting for at least 10 hours)
3335489|NCT02138799|Experimental|1: single dose of enzalutamide|
3335490|NCT02138799|Experimental|2: multiple doses of rifampin and single dose of enzalutamide|
3335491|NCT02138812|Experimental|BAY1161909 + Paclitaxel|Participants received oral doses of BAY1161909 starting from 0.75 mg twice daily, from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in combination with weekly intravenous paclitaxel on D1, D8, and D15 of the 28-day cycles. For single-dose Pharmacokinetic (PK) cohort: in Cycle 1, participants received a single oral dose of 6 mg BAY1161909 on C1D1 with no BAY1161909 dosing for the remainder of Cycle 1.
3335492|NCT02138851|Experimental|Ficus Carica|Ficus Carica 300g/day
3335493|NCT02138851|Placebo Comparator|Placebo|Placebo 300g/day
3335494|NCT02138864|Experimental|18F-FP-(+)-DTBZ only|PET tracer: 18F-FP-(+)-DTBZ
3335495|NCT02138877|Active Comparator|After coming stent|Dismembered pyeloplasty with insertion of an after coming stent
3335496|NCT02138877|Active Comparator|Stentless|Stentless dismembered pyeloplasty
3335497|NCT02138903||ZEEP and tubing-spontaneous ventilation|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
3235167|NCT01238250||Copy Number Variants|Individuals with documented pathogenic or likely pathogenic copy number variants related to autism and other neurodevelopmental disorders.
3235168|NCT01238250||Gene Variants|Individuals with documented pathogenic or likely pathogenic variants in a gene related to autism and other neurodevelopmental disorders.
3235169|NCT01238289|Placebo Comparator|Control group|This arm continues with standard care at community clinic
3235170|NCT01238289|Experimental|Peer Education|This group receives 8 weeks of peer led self management education classes and subsequent monthly support groups for a total of 10 months
3235171|NCT01238302|Placebo Comparator|Conventional group|
3235172|NCT01238302|Experimental|PRP group|
3235173|NCT01238315|Other|HuCNS-SC|
3235174|NCT01238328|Experimental|Transplantation|
3335498|NCT02138903||trans-thoracic echocardiography|Prospective clinical study in ICU with ventilated patients eligible to weaning trials of mechanical ventilation (ZEEP and tubing-spontaneous ventilation) comparing hemodynamic and cardiac effects evaluated by trans-thoracic echocardiography.
3335499|NCT02138929|Experimental|Everolimus + LDE 225|"Dose Escalation: Everolimus at a dose of 10 mg by mouth daily with dose escalation of LDE 225 from 200 mg - 800mg by mouth daily. Study cycle is 28 days.~Dose Expansion: Everolimus at a dose of 10 mg by mouth daily. LDE 225 at MTD from Dose Escalation. Study cycle is 28 days."
3335500|NCT02138942|Experimental|The study population|"See inclusion/exclusion criteria.~Intervention: LIR"
3335501|NCT02138955|Experimental|Liposomeal curcumin ascending dose phase 1b|
3335502|NCT02138968|Experimental|Multidimensional intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
3335503|NCT02138968|No Intervention|Usual care|Usual care
3335504|NCT02138981|Active Comparator|Immediate Resection|patients received immediate surgical hepatic resection
3335505|NCT02138981|Experimental|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
3335506|NCT02138994|Active Comparator|Triple Antibiotic Ointment Neosporin|Daily direct application to the wound, covered with conventional dressing. Dressing should be changed daily or as directed by the health care provider.
3335507|NCT02138994|Experimental|Next Science Wound Gel|Daily direct application to the wound, covered with a conventional non-alginate dressing. Dressing should be changed daily or as directed by the health care provider.
3335508|NCT02139020||No treatment|"Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples:~Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al [11]~Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. [10]~Group 3 = patients treated with a molecular targeted agent as a part of a clinical study"
3335509|NCT02139033|Experimental|Arm 1|Retain 1-2 drops, bilaterally, BID
3335510|NCT02139059|Active Comparator|initial urinary drainage|initial urinary drainage to stabilize renal functions before ureteroscopy
3335511|NCT02139059|Active Comparator|direct ureteroscopy|direct ureteroscopy without initial urinary drainage
3335512|NCT02139072||CoaguChek XS|INR measured by CoaguChek XS in patients with APL at visit 1 and visit 2, in addition to routine measure by standard lab draw
3235175|NCT01238354|Active Comparator|Without friend|Being in the weight loss programme without friend or family member
3235176|NCT01238354|Experimental|With friend|Having the friend or family member stay together with the patient for 2-3 days for every 3 week stay at the clinic in the weight loss programme
3235177|NCT01238367|Experimental|recombinant factor VIII (N8)|
3335513|NCT02139072||Standard Lab Draw|INR measured by standard lab draw at visit 1 and visit 2 for non-APL patients, in addition to routine measurement by CoaguChek XS
3335514|NCT02139085|Active Comparator|GSV Electrocoagulation|GSV Electrocoagulation Source: Electrosurgical Generator(FX-Valley Lab; USA) Energy: 60 Watts x 10 seconds
3335515|NCT02139085|Active Comparator|GSV Radiofrequency|GSV Radiofrequency Source: Closure FAST(Covidien, USA) Energy: 60 Joules / cm
3335516|NCT02139098|Experimental|Amitriptyline flexible dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
3235178|NCT01238380||Diabetes diagnosed under 30 years|Patients currently under 50 years of age diagnosed with diabetes under 30 years.
3335517|NCT02139098|Experimental|Zolpidem flexible dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
3335518|NCT02139098|Active Comparator|Amitriptyline fixed dosing|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
3335519|NCT02139098|Active Comparator|Zolpidem fixed dosing|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
3335520|NCT02139098|Active Comparator|Amitriptyline continuous dosing|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
3335521|NCT02139111|Placebo Comparator|Placebo|Placebo Arm
3335522|NCT02139111|Active Comparator|PRC-063 25 mg and Placebo|PRC-063 25 mg and placebo capsule by mouth once daily
3335523|NCT02139111|Active Comparator|PRC-063 45 mg and Placebo|PRC-063 45 mg and placebo capsule by mouth once daily
3335524|NCT02139111|Active Comparator|PRC-063 70 mg and Placebo|PRC-063 70 mg and placebo capsule by mouth once daily
3335525|NCT02139111|Active Comparator|PRC-063 85 mg and Placebo|PRC-063 85 mg and placebo capsule by mouth once daily
3335526|NCT02139150|Experimental|Serial FLT PET Imaging|"Patients will receive a target injection of up to 10 mCi of FLT. Optionally, dynamic PET imaging over a chosen index lesion (based on size and/or high FDG-avidity on preceding CT and/or FDG PET/CT scans done for clinical purpose such as staging), may be performed. Otherwise, static PET images are obtained at approximately 60 min (+15 min) post FLT injection. In general this body scan will cover at least the region from skull base to the upper thigh for extracranial malignancies; depending on the specific location, extremities maybe also be scanned (e.g., extremity sarcoma), or the scan may be restricted to the brain (e.g. glioma)."
3335527|NCT02139163||patients with pneumonia|
3335528|NCT02139189|Experimental|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
3335529|NCT02139202|Other|Full Program|"The intervention will (1) use the GlowCaps, a remote monitoring and reminder pill bottle; (2) be assigned an engagement advisor from the study team; (3) be asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence for the first three months; and (5) will determine their preferences for Way to Health platform communication methods during the study.~The group receiving the program intervention will also have their claims data analyzed for the 1 months post-enrollment."
3335530|NCT02139241|Experimental|Ramosetron|Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia
3335531|NCT02139241|Placebo Comparator|Control|Intravenous administration of 2ml normal saline before the induction of general anesthesia
3235179|NCT01238393|Experimental|Ranibizumab|('intravitreal ranibizumab' )
3235180|NCT01238406|Experimental|MD-logic Artificial Pancreas (MDLAP) system|Use of the closed loop MD-logic Artificial Pancreas(MDLAP)System
3235181|NCT01238406|Active Comparator|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
3235182|NCT01238419|Experimental|Physiotulle|
3235183|NCT01238419|Placebo Comparator|Urgotul|
3235184|NCT01238432||Inpatient population|Children with asthma who are admitted to the hospital with an exacerbation.
3235185|NCT01238432||Outpatient population|Children with asthma who have not been admitted to the hospital with an exacerbation.
3235186|NCT01238432||Healthy controls|Children without asthma or any other chronic condition.
3335532|NCT02139254||Low risk|Pregnant women with a low risk for metabolic diseases
3335533|NCT02139254||High risk|Pregnant women with a high risk for metabolic diseases
3335534|NCT02139267|Experimental|1mg of GX-188E per dose|1mg of GX-188E per dose will be administered on 1mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12 week.
3335535|NCT02139267|Experimental|4mg of GX-188E per dose|4mg of GX-188E per dose will be administered on 4mg group participants through intramuscular route using EP device. The injection points are at 0 week, 4 week and 12week.
3335536|NCT02139293|Experimental|auricular vagus nerve stimulation|"Study participants (healthy) are treated with auricular vagus nerve stimulation using five needle electrodes connected to an electrical stimulation device (PrimeStim). After acclimatization the stimulation is turned on for 20 minutes followed by 20 minutes of paused stimulation, 20 minutes of stimulation, and 10 minutes paused stimulation. This intervention is repeated on four consecutive days, whereas at each intervention only one of the four stimulation points (and one fixed reference point) is stimulated. Needle electrodes are applied at each study visit.~Stimulation points in the auricle are stimulated in random order. One stimulation pattern is tested. Stimulation amplitudes are adjusted with respect to a distinct but comfortable sensation at the auricle.~During the described protocol various biosignals are continuously recorded, including ECG, respiration, blood perfusion, oxygen saturation, transcutaneous oxygen tension, blood pressure and skin temperature."
3335537|NCT02139319|Experimental|Botulinum toxin|Single intra-articular injection
3335538|NCT02139319|Placebo Comparator|Placebo|Single intra-articular injection
3335539|NCT02139332|Active Comparator|Resource & Referral group|Individuals randomized to the control group will receive a resource & Referral service immediately after their baseline research visit.
3335540|NCT02139332|Experimental|PFR Group|Individuals randomized to the Immediate group will receive the intervention program immediately after completing the baseline assessment.
3335541|NCT02139345|Experimental|TC-A PS|Subject will be implanted with the TC-A PS Total Knee Replacement System
3335542|NCT02139345|Active Comparator|TC-PLUS Solution PS|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System.
3335543|NCT02139371|Experimental|64Cu-DOTA-AE105 PET|One injection of 64-Cu-DOTA-AE105 (app. 200 Mbq IV) followed by 3 PET scans 1,3 and 24 hours post injection
3335544|NCT02139397|Experimental|DFMO and Bortezomib|Subjects will take DFMO by mouth 2 times a day for each day of a 21 day cycle and Bortezomib will be given by IV push on days 1, 4, and 8 of each 21 day cycle.
3335545|NCT02139410||IGF-1 1st and 2nd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
3335546|NCT02139410||IGF-1 3rd and 4rd quartile|Reduction of IGF-1 serum value in a cohort of patients with cognitive impairment
3335547|NCT02139423|Experimental|All newborns who fail universal newborn|CMV PCR
3335548|NCT02139436|Experimental|FES-row-training|Subjects will perform 6 months of FES-row-training.
3235187|NCT01238458|Experimental|[18F]AV-45 PET amyloid binding imaging|
3235188|NCT01238484|Active Comparator|Control|Patients in the control group will be treated with the current standard of care including shoe modification and home stretching exercises.
3235189|NCT01238484|Experimental|Experimental|Patients assigned to the experimental group will receive the current standard of care as well as the Ankle Dorsiflexion Dynasplint.
3335549|NCT02139436|Other|Wait-list time control|Subjects will wait for 6 months before performing 6 months of FES-row-training.
3335550|NCT02139436|Active Comparator|Arms-only-row-training|Subjects will perform 6 months of arms-only row training followed by 6 months of FES-row-training
3335551|NCT02139449||ICD/CRT registry|ICD / CRTregistry in Severance or Ewha Womans University Medical Center
3335552|NCT02139462|Experimental|Standard training|Therapists will receive standard training in FBT.
3335553|NCT02139462|Experimental|Novel training|Therapists will receive a novel, more efficient training in FBT
3335554|NCT02139475||Colonoscopy|patients undergoing colonoscopy after colorectal cancer surgery
3335555|NCT02139488||neoadjuvant or definitive chemoradiation|Esophageal cancer patients planned for neoadjuvant or definitive chemoradiation.
3235190|NCT01238497||Registry 1 - SOURCE XT|Registry 1: All patients implanted with a SAPIEN XT valve, via Transfemoral access using NovaFlex (for 23mm and 26mm valve), or via Transapical access using Ascendra2 (23mm, 26mm and 29mm valve)
3235191|NCT01238497||Registry 2 - Ascendra+|Registry 2: All patients implanted with a SAPIEN XT Valve, via Transapical or Transaortic access using Ascendra+ delivery system (23mm, 26mm and 29mm valve)
3335556|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 14 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 14 consecutive days
3335557|NCT02139501|Experimental|rhTPO, 300Units/kg ,one times every other day for 7 times|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,one times every other day for 7 times.
3335558|NCT02139501|Experimental|rhTPO, 300Units/kg ,daily for 7 consecutive days|10 enrolled patients randomly receive rhTPO at a dose of 300Units/kg ,daily for 7consecutive days.
3335559|NCT02139514|Active Comparator|Virtual Reality Social Cognition Training|Virtual Reality Social Cognition Training
3335560|NCT02139514|No Intervention|Control|Participants in the Control condition will be offered treatment following the Control condition.
3335561|NCT02139553|Experimental|Rhythmic rehabilitation|Patients undergo a first evaluation, and a second evaluation one month later to determine their natural evolution. The following month, patients get 12 sessions of rhythmic therapy. A third evaluation is organized straight after this month and a fourth evaluation, 3 months after to assess the after-effects of the therapy.
3335562|NCT02139566|Experimental|Hi-tech video consent|This group will be shown a professionally animated video that presents the major components of the informed consent document. Intervention is Video Consent (high-tech) PDF informed consent document.
3335563|NCT02139566|Experimental|Low-tech video consent|"Participants in this arm will be provided with informed consent information through viewing a talking head video produced by a non-professional presenter, with widely available and inexpensive video equipment. Intervention is video consent (low-tech), PDF informed consent document."
3235192|NCT01238497||Registry 3 - NovaFlex+ 29 mm|Registry 3: All patients implanted with a SAPIEN XT valve, 29mm only, via Transfemoral access using NovaFlex+
3235193|NCT01238510|Active Comparator|Provisional fKBT|Stent technique that final kissing balloon technique(fKBT) is performed if side branch flow was aggravated to TIMI0-2 after stent deployment
3235194|NCT01238510|Active Comparator|Routine fKBT|Stent technique that fKBT was mandatory irrespective of side branch flow after stenting.
3235195|NCT01238523|Experimental|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
3335564|NCT02139566|Experimental|FAQ consent|"Participants in this arm will be provided with informed consent content through an interactive frequently asked questions format, in which the participant will click on a question and be shown text that provides an answer to that question. Major informed consent topics will have one or more question and answer pairs. Intervention is FAQ format consent, PDF informed consent document"
3335565|NCT02139566|Active Comparator|Standard consent process|Participants in this arm will be provided with informed consent content by being shown a standard informed consent document in a scrolling window within the browser window, PDF informed consent document
3335566|NCT02139579|Experimental|Avastin|bevacizumab 7.5mg/kg+paclitaxel 200mg/m2＋carboplatin area under curve(AUC)=6, every 3 weeks，maximum 4 cycles
3335567|NCT02139605|Active Comparator|D2 Lymphadenectomy|Intervention D3 Lymphadenectomy
3335568|NCT02139605|Experimental|D3 Lymphadenectomy|Comparator D2 Lymphadenectomy
3335569|NCT02139618|Experimental|Methyl Aminolevulinate (MAL)|1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
3335570|NCT02139618|Placebo Comparator|Placebo|1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 4 weeks apart)
3335571|NCT02139631|Experimental|Healthy volunteers|The volunteers initially underwent a clinical examination, spirometry and echocardiography to prove the health state. Then, different levels of positive end expiratory pressure (PEEP) is applied by the noninvasive ventilation in all individuals and the hemodynamic repercussions are evaluated by the doppler echocardiography
3335572|NCT02139657|Experimental|RIG-C|Single 20 IU/kg dose of RIG-C by intramuscular injection
3335573|NCT02139670||pregnant womens|
3335574|NCT02139683|Experimental|HIFU treatment|HIFU treatment in patient diagnosed with fibroadenoma
3335575|NCT02139696||MS patients initiating fingolimod|Patients will be imaged using PET and MRI at baseline, and twice during treatment.
3335576|NCT02139709|Experimental|Ganglioside|1.0 gram ZETA dairy lipid powder (Fonterra NZ)
3335577|NCT02139709|Placebo Comparator|Placebo|1.0 gram milk fat fraction void of ganglioside
3335578|NCT02139722|No Intervention|Provider Panel Notification (PPN) Alone|The comparison procedures consist of a panel notification given to providers and an audio-visual presentation on diet and exercise given to patients.
3335579|NCT02139722|Experimental|Video Doctor, PA + PPN|Video Doctor (VD) and Provider Alert (PA) intervention combined with Provider Panel Notification (PPN)
3335580|NCT02139735|Experimental|Ultrasound|3 MHz (Mega Hertz) ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ (Temporomandibular joint) and masseter muscles bilaterally
3335581|NCT02139735|Experimental|Ultrasound associated with stretchting|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
3335582|NCT02139735|Experimental|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
3335583|NCT02139748|Active Comparator|Dental Implant & ADM|Dental implant placement plus simultaneous grafting use one layer of ADM.
3335584|NCT02139748|Experimental|Dental Implant & ADM & bone xenograft|Dental implant placement plus simultaneous grafting use one layer of ADM with bovine xenograft.
3335585|NCT02139761|Active Comparator|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
3335586|NCT02139761|Placebo Comparator|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
3335587|NCT02139774||Active Survelliance|Men age 65 and older who are undergoing active surveillance as primary treatment for their prostate cancer.
3335588|NCT02139774||Radiation|Men age 65 and older who are undergoing radiation only as primary treatment for their prostate cancer.
3335589|NCT02139774||Endocrine Therapy|Men age 65 and older who are undergoing endocrine therapy as primary treatment for their prostate cancer.
3335590|NCT02139774||Surgery|Men age 65 and older who are undergoing surgery as primary treatment for their prostate cancer.
3335591|NCT02139787|Experimental|Radio Story|Participants listen to a radio story about a family's' success with preventing or managing hypertension or obesity through diet and physical activity; the focus was for the entire family to implement healthful lifestyle behaviors so the children can learn as well.
3335592|NCT02139787|Active Comparator|Control -listened to a brochure|Participants received an audio version of a standard brochure about hypertension or obesity prevention.
3335593|NCT02139813|Experimental|Laparoscopic Omega Loop Bypass|Laparoscopic Mini-gastric bypass
3335594|NCT02139813|Active Comparator|Laparoscopic Roux-en-Y Gastric ByPass|Procedure of reference in bariatric surgery
3335595|NCT02139839|Placebo Comparator|Gelatin pill first|
3335596|NCT02139839|Experimental|Lactobacillus capsules first|
3335597|NCT02139852|Experimental|capsaicin|Capsaicin
3335598|NCT02139852|Placebo Comparator|Placebo|
3335599|NCT02139865|Experimental|30%|Training at 30% 1RM
3335600|NCT02139865|Experimental|80%|Training at 80% 1RM
3335601|NCT02139891|Experimental|"MultiPoint Pacing On"|Patients will be randomized to the MPP-ON Arm vs MPP-OFF in in crossover fashion with 3 months in each period.
3335602|NCT02139891|Active Comparator|"MultiPoint Pacing Off"|Patients will be randomized to the MPP-OFF arm vs MPP-ON in crossover fashion with 3 months in each period.
3335603|NCT02139904|Placebo Comparator|Active Symptom Control|Active symptom control includes palliative care and standard care methods used to manage symptoms
3335604|NCT02139904|Active Comparator|Vinorelbine|Active symptom control (ASC) as per local practice plus vinorelbine administered at a dose of 60mg/m2 orally on day 1, day 8 and day 15 on a 3- weekly cycle, incrementing to 80mg/m2 weekly on a 3-weekly cycle in the absence of any significant toxicity for subsequent cycles. Patients will continue chemotherapy until evidence of radiological progression (or unacceptable toxicity or patient withdrawal).
3335605|NCT02139917|Experimental|Transitional Palliative Care|"Transitional palliative care include:-~telephone follow up for early identification of signs and symptoms~home visit for spiritual support"
3335606|NCT02139917|No Intervention|Customary care|"Customary care receive care :-~hospital based medical follow up~general nursing assessment and advice"
3235196|NCT01238523|Experimental|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
3235197|NCT01238562|Experimental|YPEG-Filgrastim, 10mcg/kg|
3335607|NCT02139930|Active Comparator|Normal Nicotine Control Group|These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.
3335608|NCT02139930|Experimental|Immediate Nicotine Reduction Group|This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.
3335609|NCT02139930|Experimental|Gradual Nicotine Reduction Group|This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.
3335610|NCT02139956||stress urinary incontinence|group 1 women with stress urinary incontinence by ultrasonography
3235198|NCT01238562|Experimental|YPEG-Filgrastim, 20mcg/kg|
3235199|NCT01238562|Experimental|YPEG-Filgrastim, 30mcg/kg|
3235200|NCT01238562|Experimental|YPEG-Filgrastim, 45mcg/kg|
3335611|NCT02139956||continent group|group 2 women without stress urinary incontinence by ultrasonography
3335612|NCT02139995|Experimental|Transfusion trigger based on WCTS-CP|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCTS-CP
3335613|NCT02139995|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience
3335614|NCT02140008|Experimental|I-gel group|
3335615|NCT02140008|Active Comparator|Air-Q group|
3335616|NCT02140021|Experimental|Screening (biospecimen collection)|Patients undergo collection of anal, cervical, vaginal, and oral samples during their scheduled pelvic exam.
3335617|NCT02140034|Experimental|Study Arm: Extensive Peritoneal Lavage|The peritoneal cavity of subject will be washed with 10 liters of warmed normal saline (1 liter per cycle for 10 cycles) . The abdomen will be closed as per standard
3335618|NCT02140034|No Intervention|Control Arm: Standard Treatment|The peritoneal cavity of subjects will be washed with 2 liters or less of warmed normal saline. The abdomen will be closed as per standard.
3335619|NCT02140047|Experimental|MT-2301-Low|
3335620|NCT02140047|Experimental|MT-2301-High|
3335621|NCT02140047|Active Comparator|ActHib|
3335622|NCT02140073|Experimental|omeprazole+domperidone SR|patients with GERD receive omeprazole 20mg + domperidone SR 30mg , 2 capsules in the morning
3335623|NCT02140073|Active Comparator|omeprazole|omeprazole 40mg in the morning
3335624|NCT02140086|Experimental|Buteyko based Remedial Breathing Therapy|Buteyko based Remedial Breathing Therapy
3335625|NCT02140086|No Intervention|Waiting List|Training in the course of the study
3235201|NCT01238562|Experimental|YPEG-Filgrastim, 60mcg/kg|
3335626|NCT02140099|Experimental|Healthy Relationships Education/Skills|The experimental intervention is the group-based, 15-session Healthy Relationships Plus Program (HRPP). In this study, the HRPP will be offered in a condensed 8-day format (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the program for 2 hours, and on day 8, participants will attend the program for 1 hour. The program will be facilitated by high school teachers. Eight HRPP groups will run concurrently during the study period.
3335627|NCT02140099|Other|Classroom Activities|The control condition is a group-based, 15-session program focusing on typical Classroom Activities. The primary activity is to create a school welcome packet for incoming Grade 9 students, with other activities including reading and physical exercise. The control condition will be offered on 8 consecutive weekdays (July 8-11 and 14-17, 2014). On days 1 to 7, participants will attend the control program for 2 hours, and on day 8, participants will attend the control program for 1 hour. The control group will be facilitated by bachelor's level research assistants and pre-service teachers. Eight control groups will run concurrently during the study period.
3335628|NCT02140112|Active Comparator|Trichuris suis ova|TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks
3335629|NCT02140112|Placebo Comparator|Placebo|Placebo 8 doses every 2 weeks
3335630|NCT02140125|Experimental|ASP2408 low dose group|
3335631|NCT02140125|Experimental|ASP2408 middle dose group|
3335632|NCT02140125|Experimental|ASP2408 high dose group|
3335633|NCT02140125|Placebo Comparator|Placebo group|
3335634|NCT02140138|Experimental|Arm A (i.d. vaccinations with needle free injection device)|"Duration: Patients in Arm A will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
3335635|NCT02140138|Experimental|Arm B (i.d. vaccination by conventional injection)|"Duration: Patients in Arm B will receive a total of 4 vaccinations with CV9104 in weeks 1, 2, 3 and 5. These patients will undergo radical prostatectomy at least 1 week but not later than 2 weeks after the 4th vaccination (week 6 or 7). After surgery high risk or very high risk patients will be offered to receive 2 additional vaccinations with CV9104 at week 8 and 10 post surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the medial part of the upper arms and thigh~Dose: 2 x 160 μg mRNA per injection (2 x 200 μL), equals 320 μg mRNA per RNActive® drug product component"
3335636|NCT02140138|Other|Arm C (i.d. vaccination with needle free injection device)|"Duration: Patients in Arm C will receive no vaccination before radical prostatectomy. After surgery high risk or very high risk patients will be offered to receive 6 vaccinations with CV9104 at week 8, 9, 10, 12, 14 and 16 after surgery.~Administration: At each vaccination visit each of the 6 components of CV9104 vaccine will be injected individually, divided in two separate intradermal injections. These 12 Injections will be distributed over the 4 limbs (3 injections in each upper arm and thigh).~Administration site: Skin of the lateral parts of the upper arms (over the deltoid regions) and the lateral part of the thighs.~Dose: 2 x 80 μg mRNA per injection (2 x 100 μL), equals 160 μg mRNA per RNActive® drug product component"
3235202|NCT01238614|Experimental|PSF-JIT|Mothers in this arm receive prescreening questions and clinicians receive just-in-time handouts to aid in diagnosis.
3335637|NCT02140151|No Intervention|Sham|Sham Injection
3335638|NCT02140151|Active Comparator|Quarterly Ranibizumab 0.5mg|Quarterly intravitreal injection of 0.5mg ranibizumab
3335639|NCT02140177||Adult Medical Inpatients|Adult medical inpatients; We will enroll adult patients, ages 18 years and older, admitted to identified inpatient medical units during designated data collections days.
3335640|NCT02140203|Active Comparator|Young Yoga Group|People who are younger than 60 year-old They have received Yoga training in one-year experimental period
3335641|NCT02140203|No Intervention|Young Control Group|People who are younger than 60 year-old No Yoga training through out the one-year experimental period
3335642|NCT02140203|No Intervention|Aged Control Group|People who are equal or older than 60 year-old They have not received any yoga training during the one-year experimental period
3335643|NCT02140203|Active Comparator|Aged Yoga Group|People who are equal or older than 60 year-old They have received any yoga training during the one-year experimental period
3335644|NCT02140216||Day 0 blood transfusion|Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.
3335645|NCT02140216||Day 1 or 2 blood transfusion|Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.
3335646|NCT02140216||No blood transfusion|Patients undergoing elective spine surgery receiving no blood transfusion.
3335647|NCT02140229|Active Comparator|Usual care|Usual care and follow-up every 3 months
3335648|NCT02140229|Experimental|US-driven therapy|Clinical evaluation according to DAS28 + US every 3 months
3335649|NCT02140229|Active Comparator|ACR/EULAR remission criteria-driven therapy|Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months
3335650|NCT02140242|Active Comparator|daunorubicin 60 mg/m2|study part 1 - dose daunorubicin standard dose daunorubicin in induction 1 (60 mg/m2) on days 3-5
3235203|NCT01238614|Experimental|PSF|Mothers in this arm receive screening questions on the prescreener form
3235204|NCT01238614|Placebo Comparator|Control|Mothers in this arm receive no maternal depression CHICA additional care
3335651|NCT02140242|Active Comparator|Double induction|study part 2: induction cycles double induction (only patients with good response)
3335652|NCT02140242|Experimental|Single induction|study part 2: induction cycles single induction (only patients with good response)
3335653|NCT02140255|Experimental|Cohort 1, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
3335654|NCT02140255|Experimental|Cohort 2, Regimen 1L: 2 NRTIs + NVP + LPV/r|Participants will receive 2 NRTIs + NVP + LPV/r.
3335655|NCT02140255|Experimental|Cohort 1, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
3235205|NCT01238627|Experimental|Nicotine Sublingual Tablet Mint (NSTM)-2|Experimental 2 mg NSTM
3235206|NCT01238627|Active Comparator|Microtab-2|2 mg Nicotine tablet
3335656|NCT02140255|Experimental|Cohort 2, Regimen 2R: 2 NRTIs + NVP + RAL|Participants will receive 2 NRTIs + NVP + RAL.
3235207|NCT01238627|Experimental|NSTM-4|Experimental 4 mg Nicotine Sublingual Tablet Mint
3235208|NCT01238627|Active Comparator|Microtab-4|2 x 2 mg Nicotine tablet
3235209|NCT01238679|Experimental|Cohort 1|Participants received an oral solution of 0.03 milligrams (mg) of PF-04958242, every 12 hours for 14 days.
3235210|NCT01238679|Experimental|Cohort 2|Participants received an oral solution of 0.05 mg of PF-04958242, every 24 hours for 14 days.
3335657|NCT02140255|Experimental|Cohort 1, Regimen 2RV: 2 NRTIs + NVP + RAL + VRC01|Participants will receive 2 NRTIs + NVP + RAL + VRC01.
3335658|NCT02140268|Active Comparator|Midazolam 7.5 mg|Volunteers will receive Midazolam 7.5 mg administered by mouth as a syrup
3335659|NCT02140268|Experimental|AZD1722 15 mg|Volunteers will received AZD1722 15 mg administered by mouth, as a tablet
3335660|NCT02140268|Experimental|AZD1722 15 mg and Midazolam 7.5 mg|Volunteers will receive AZD1722 15 mg tablet and Midazolam 7.5 mg syrup, by mouth
3335661|NCT02140281|Experimental|Sequence 1 (Treatment A/B)|Subjects will be randomised to receive Treatment A in Period 1 followed by Treatment B in period 2
3335662|NCT02140281|Experimental|Sequence 2 (Treatment B/A)|Subjects will be randomised to receive Treatment B in Period 1 followed by Treatment A in period 2
3335663|NCT02140294|Experimental|Polymeric nutritional supplement|
3335664|NCT02140294|Active Comparator|Standard Nutritional Treatment|
3335665|NCT02140307|Experimental|Meditation training, group format|"The course Relaxation Response-based Mental Health Promotion (publicly referred to as Open and Calm) is given in group format.~The intervention entails 9 courses (1 per week of 2.5 hrs), a course book (120 pages), audio support (6 guided meditative practices), access to a webpage with additional information, and the possibility of two personal sessions with the intervention instructor (a certified psychologist)."
3335666|NCT02140307|Active Comparator|Meditation training, individual format|"The course Relaxation Response-based Mental Health Promotion (Open and Calm) is given by the same instructor as for group formats using precisely the same material and methods, but in about 6-9 (as to each persons' individual needs and preferences) face-to-face meetings."
3335667|NCT02140307|No Intervention|Wait-list control|This arm is an inactive wait-list control.
3335668|NCT02140320|Experimental|Single dose (healthy volunteers)|
3335669|NCT02140320|Experimental|14 day repeat dose (healthy volunteers)|
3335670|NCT02140320|Experimental|14 day repeat dose (asthma patients)|
3335671|NCT02140320|Experimental|28 day repeat dose (healthy volunteers)|
3335672|NCT02140333|Experimental|Erlotinib 100mg|Erlotinib 100mg
3335673|NCT02140333|Active Comparator|Erlotinib 150mg|Erlotinib 150mg
3335674|NCT02140346|Experimental|28 day repeat dose (low dose)|
3335675|NCT02140346|Experimental|28 day repeat dose (high dose)|
3335676|NCT02140359|No Intervention|Control Group: Usual Care|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet with case managers according to the usual procedures for new residents and will be given a standard case manager interaction.
3335677|NCT02140359|Experimental|Motivational Network Interview Recipients|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
3335678|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia preservation|Scarpa's fascia preservation Lymphoscintigraphy 3D imaging Abdominal ultrasound
3335679|NCT02140385|Active Comparator|Abdominoplasty-Scarpa's fascia ablation|Scarpa's fascia ablation Lymphoscintigraphy 3D imaging Abdominal ultrasound
3335680|NCT02140398|Experimental|Currettage|Endometrial Currettage (endometrial scrapping) will be performed at the time of laparoscopic ovarian drilling
3335681|NCT02140398|No Intervention|Nothing|No endometrial curettage at time of Laparoscopic ovarian drilling
3335682|NCT02140424||youth with type 1 diabetes|
3335683|NCT02140424||healthy controls|
3335684|NCT02140437|Experimental|Fulvestrant and anastrozole|Anastrozole 1 mg PO QD Fulvestrant 500mg IM d1,15, 29 and 4 weeks after
3335685|NCT02140437|Active Comparator|Anastrozole|Anastrozole 1 mg PO QD
3335686|NCT02140450|Active Comparator|Timolol|Timolol eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
3335687|NCT02140450|Active Comparator|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
3335688|NCT02140450|Active Comparator|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
3335689|NCT02140450|Active Comparator|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
3335690|NCT02140450|Sham Comparator|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
3335691|NCT02140463||metastatic cancer|metastatic gastrointestinal cancer metastatic genitourinary cancer other rare cancer lung cancer
3335692|NCT02140476|Experimental|Thyroid Goiter|Benign thyroid disease with a nodule equal or lesser than 4 cm in diameter of any gender or ethnical origin. Half of these patients will undergo either bipolar or conventional thyroidectomy.
3335693|NCT02140476|Active Comparator|Papillary Thyroid Cancer|Patients of any gender or ethnical origin with papillary thyroid cancer no greater than 4 cm in diameter. Half of these patients will undergo either bipolar or conventional thyroidectomy.
3335694|NCT02140489|Experimental|Sequence 1|amosartan → rosuvastatin → amosartan and rosuvastatin
3335695|NCT02140489|Experimental|Sequence 2|rosuvastatin → amosartan and rosuvastatin → amosartan
3335696|NCT02140489|Experimental|Sequence 3|amosartan and rosuvastatin → amosartan → rosuvastatin
3335697|NCT02140502||Men undergoing prostate biopsy|
3335698|NCT02140515|Active Comparator|Luveris|Evaluation the effect of Luveris protocol on Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
3335699|NCT02140515|Active Comparator|Gonal-F& Luveris|Evaluation the effect of Gonal-F& Luveris protocols of Induction of ovulation in Patients with Hypogonadotropic Hypogonadism
3335700|NCT02140528|Experimental|Mesenchymal stem cell receipients|Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.
3335701|NCT02140528|Placebo Comparator|Placebo|Placebo injection in the site of fracture in patients with tibia fracture.
3335702|NCT02140541||Blood eosinophil count ≤ 400/µl|
3335703|NCT02140541||Blood eosinophil count > 400/µl|
3235211|NCT01238679|Experimental|Cohort 3|Participants received an oral solution of 0.10 mg of PF-04958242, every 24 hours for 14 days.
3235212|NCT01238679|Experimental|Cohort 4|Participants received an oral solution of 0.15 mg of PF-04958242, every 24 hours for 14 days.
3235213|NCT01238679|Experimental|Cohort 5|Participants received an oral solution of 0.20 mg of PF-04958242, every 24 hours for 14 days.
3335707|NCT02140580|Active Comparator|Minimally invasive surfactant therapy|Minimally invasive surfactant therapy - delivery of exogenous surfactant to the lung via brief catheterisation of the trachea with an instillation catheter in a preterm infant who is being supported with continuous positive airway pressure (CPAP) via nasal prongs or mask. Poractant alfa (Curosurf) at a dosage of 200 mg/kg will be administered over 15 - 30 seconds. Total duration of the procedure will be less than 5 minutes, followed by reinstitution of CPAP.
3335708|NCT02140580|Sham Comparator|Continuation on CPAP|Standard control treatment. After randomisation, infants will receive a sham treatment from a treatment team not engaged in clinical care. This will not involve removal of prongs or discontinuation of CPAP but will require setting up intubation equipment, screening the baby, testing suction unit, repositioning of the baby and changing the baby's monitoring. CPAP will thereafter continue.
3335709|NCT02140606|Experimental|Cafusertib Hydrochloride + Cytarabine|Cafusertib (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c. Patient to receive escalating dose of cafusertib hydrochloride.
3335710|NCT02140619|Active Comparator|multiple health education interventions|The group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular text message during 1 year after discharge.
3335711|NCT02140619|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, text message and Digital Video Disc (DVD)
3335712|NCT02140632|Experimental|Local steroid injection|"The local injection of steroid is performed by the same investigator after the randomization. Using a sterile technique, 20mg methylprednisolone acetate premixed with lidnocaine is injected using a 25-gauge x 5/8 needle. The needle is inserted medially to the palmaris longus tendon at the distal palmar crease in the wrist at an angle of 45-degree to the forearm. The steroid is injected at approximately 1cm below the skin. The needle will be repositioned if there is any resistance to injection, or any pain or paraesthesia in the median nerve territory."
3335713|NCT02140632|Active Comparator|Wrist splinting|After randomization, the hands of the patients in the splinting group are splinted in neutral position with standard cotton-polyester splint. Patients are encouraged to use the splints during nighttime whenever possible for one month.
3335714|NCT02140658|Active Comparator|multiple health education interventions|The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
3335715|NCT02140658|Placebo Comparator|conventional health education|The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
3335716|NCT02140671||Patients with an asthma diagnosis|
3335717|NCT02140671||Patients where there is diagnostic doubt|
3335718|NCT02140684||eNO monitoring|Patients undergoing eNO monitoring at the index prescription date
3335719|NCT02140684||No eNO monitoring|
3335720|NCT02140697|Experimental|Hippophae rhamnoides L. Leaf Extract|Hippophae rhamnoides L. Leaf Extract 3g/day
3235214|NCT01238679|Experimental|Cohort 6|Participants received an oral solution of 0.25 mg of PF-04958242, every 24 hours for 14 days.
3335721|NCT02140697|Placebo Comparator|Placebo|Placebo 3g/day
3335722|NCT02140710|Active Comparator|Osteopathic treatment group|visceral osteopathic treatment algorithm
3235215|NCT01238679|Placebo Comparator|Matching Placebo|Participants received an oral solution of matching placebo, every 12 or 24 hours for 14 days.
3335723|NCT02140710|No Intervention|Control group|no intervention
3335724|NCT02140723||preoperative short course radiation|preoperative short course radiation with 8 weeks delay of surgery
3335725|NCT02140736||Patients with chemo-induced symptomatic anemia|
3335726|NCT02140749|Experimental|sc-FOS 2g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 2 g/day (4 weeks)
3335727|NCT02140749|Experimental|sc-FOS 4g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 4 g/day (4 weeks)
3335728|NCT02140749|Experimental|sc-FOS 8g/day|Placebo (4 weeks) Short-chain fructooligosaccharide 8 g/day (4 weeks)
3335729|NCT02140801|Experimental|Ticagrelor|Ticagrelor 90mg tablet, twice daily
3335730|NCT02140801|Experimental|Clopidogrel|Clopidogrel 75mg tablet, daily
3335731|NCT02140814|Experimental|Niacinamide|All subjects in this study will take niacinamide at a dose of 30 mg per kilogram of body weight by mouth daily, in two divided daily doses, for 12 months.
3335732|NCT02140827|Experimental|IMP education|patients in this group are educated about bowel preparation by instant messaging program and meanwhile a booklet was also sent to them.
3335733|NCT02140827|No Intervention|normal education|patients in this group are educated about bowel preparation on the day of reservation by nurse for about 15 minutes and meanwhile a booklet was also sent to them.
3335734|NCT02140853||MDR group|patients of MDR pathogen infection
3335735|NCT02140853||non-MDR group|patients of non-MDR pathogen infection
3235216|NCT01238692|Experimental|LBH589|
3235217|NCT01238692|Experimental|LBH589 plus Rituximab|
3235218|NCT01238705|Active Comparator|Felodipine,Irbesartan,Sexual Dysfunction|
3235219|NCT01238705|Active Comparator|Felodipine,Metoprolol,Sexual Dysfunction|
3335736|NCT02140866|Experimental|Hand Exercise|The intervention group will receive an exercise program for the hand/arm in combination with a compensatory intervention program (CIP).
3335737|NCT02140866|Active Comparator|Compensatory Intervention Program (CIP)|The control group will receive the Compensatory Intervention Program (CIP) only.
3235220|NCT01238718|Active Comparator|lidocaine|
3235221|NCT01238718|Placebo Comparator|normal saline|
3235222|NCT01238731||Valve replacement|Patients undergoing valve replacement for severe valve disease will be screened for study entry
3235223|NCT01238744|Placebo Comparator|Study I: control drink|
3235224|NCT01238744|Experimental|Study I: flaxseed drink|
3335738|NCT02140879|Placebo Comparator|Capsule 1|Placebo is a mixture of corn and soy oils.
3335739|NCT02140879|Active Comparator|Capsule 2|Active supplement group, will take capsules containing oil '2' which is an algal oil.
3335740|NCT02140892|Experimental|respiratory physical therapy manual technique|respiratory physical therapy manual technique- Autogenic Drainage
3335741|NCT02140892|Experimental|respiratory physical therapy technique- IPV|respiratory physical therapy technique- Intrapulmonary Percussive Ventilation
3335742|NCT02140892|No Intervention|standart medical care|standard medical care
3235225|NCT01238744|Active Comparator|Study II: flaxseed drink|
3335743|NCT02140905||Patients undergoing hemodialysis.|Subjects participating in the study
3335744|NCT02140918|Experimental|Fludrocortisone 100 μg|"100 μg/day (25 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3335745|NCT02140918|Experimental|Fludrocortisone 200 μg|"200 μg/day (50 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3335746|NCT02140918|Experimental|Fludrocortisone 400 μg|"400 μg/day (100 µg four times daily) of fludrocortisone during 5 days~Investigations the sixth day"
3335747|NCT02140918|Placebo Comparator|Placebo|"Placebo (four times daily) during 5 days~Investigations the sixth day"
3335748|NCT02140931|Active Comparator|Angiogenic Cell Precursors|Intra-muscular injections of Angiogenic Cell Precursors (ACPs) in the ischemic leg
3335749|NCT02140931|Placebo Comparator|Cell culture medium|Intra-muscular injections of cell culture medium in the ischemic leg
3335750|NCT02140983|Active Comparator|Liraglutide|90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
3335751|NCT02140983|Placebo Comparator|Placebo|90 days of placebo pen, up to 1.8mg/day.
3335752|NCT02140996|Experimental|Ad-sig-hMUC-1/ecdCD40L vector vaccine|Experimental: Ad-sig-hMUC-1/ecdCD40L vector vaccine This trial has six cohorts with 3 subjects planned for each cohort. Subjects in the 1st cohort will receive 1 dose of vaccine injection at the lowest planned dose of the vector, 1 x 10^9 VP. If none of the patients in the 1st cohort experience Dose limiting toxicity (DLT), a 2nd cohort will receive 1 dose of 1x10^10 VP. If none of the patients in the 2nd cohort experience DLT, the dose escalation will continue with the 3rd cohort receiving 1 doses of 5 x 10^10 VP per injection. The patients in the 4th cohort will receive 1 injection of 1x10^11 if no DLT occurs in the preceding cohort. Additional patients will be added to cohort 5 or 6 if DLTs are encountered in the first 3 patients tested in each of these cohorts.
3335753|NCT02141009|Other|Prevnar 13|Prevnar 13, 1 administration of 1 single dose (0.5mL)
3235226|NCT01238744|Experimental|Study II: flaxseed tablets|
3235227|NCT01238757|Active Comparator|Non-Invasive Pressure support|"in this arm, non-invasive pressure support will be recorded under 3 conditions:~with the initial Expiratory Trigger Setting (ETS) with ETS +15% with ETS -15%"
3235228|NCT01238757|Active Comparator|NAVA|"Neurally Adjusted ventilatory Assist is a ventilation mode where the ventilator is piloted by the electrical activity of the diaphragm. Ventilation is triggered and cycled off by the electrical activity of the diaphragm, the pressure delivered being proportional to this activity.~The proportion named gain is chosen to obtain under NAVA the same peak pressure than during Presure Support"
3235229|NCT01238770|Experimental|Cyclophosphamid + Pazopanib|Cyclophosphamid + Pazopanib
3335754|NCT02141022|Experimental|PACR Program: Plasticity based, Adaptive Cognitve Remediation|PACR Program Use: To use PACR, the participant navigates to the PACR study web site. The participant then logs into the PACR (using a study provided screen name and study identification number). A game-like experience begins, where the participant is presented with games in a set order. Each game consists of targeted exercises that contain the core science stimuli and tasks. The scheduling mechanism ensures that a participant progresses through the exercises in a defined order, generally moving from more simple (early sensory processing) exercises to more complex (multimodal, cognitive control) exercises over the course of the three-month experience.
3335755|NCT02141022|Active Comparator|Ordinary Computer Games|Active Control Program Use (Ordinary Computer Games): The active control program is composed of 13 ordinary computer games matched to the PACR condition overall. This condition is designed to be a face-valid approach to cognitive remediation. The control condition is also designed to account for nonspecific treatment effects, including placebo response, interactions with research personnel, and experience with computers and computer-related activities, and any halo or expectation effect on study assessments.
3335756|NCT02141035|Experimental|Acetyl-l-carnitine|Acetyl-l-carnitine will be administered for 2 months duration at a dosage of 3000 mg/d starting at the time of decompression surgery.
3335757|NCT02141035|Placebo Comparator|Placebo|Placebo will be given for 2 months starting at the time of decompression surgery
3335758|NCT02141048|Experimental|Positive Parenting Skills Training|Participants assigned to the intervention group will receive the Positive Parenting Skills Training.
3335759|NCT02141048|No Intervention|Wait-list control|Participants assigned to the wait-list control group will receive no intervention for the duration of this trial. Only after the one-year follow-up assessment has been completed will they receive the Positive Parenting Skills Training.
3335760|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation A (Treatment A)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
3335761|NCT02141061|Experimental|Telapristone Acetate, Proellex Formulation B (Treatment B)|Subjects who meet the eligibility criteria will be randomized to receive either 12 mg Treatment A or 12 mg Treatment B as their first assigned treatment. After a 7-day washout period subjects will receive the alternative treatment.
3235230|NCT01238783|Experimental|AL-15469A 0.5% and AL-65150.3% Ophthalmic Suspension|
3235231|NCT01238783|Experimental|AL-15469A 0.5%|
3235232|NCT01238783|Experimental|AL-6515 0.3%|
3235233|NCT01238783|Placebo Comparator|Vehicle|
3335762|NCT02141100|Experimental|6-thioguanine, 6-mercaptopurine and methotrexate|"This is the only treatment arm; all eligible patients will receive standard methotrexate/6-mercaptopurine (6MP/MTX) maintenance therapy supplemented with 6-thioguanine (6TG).~Patients are enrolled when they have 12 to 3.5 months remaining of their maintenance therapy. After dose reduction in 6MP to 2/3 of the current dose 6TG therapy is initiated with a starting dose of 2.5 mg/m2/day. The 6TG dose will hereafter be increased at 2.5 mg/m2/day every 14 days until a max. of 12.5 mg/m2/day is reached or until the thiopurine metabolite profile (Ery-TGN/Ery-MeMP) has been increased by at least a factor 5."
3335763|NCT02141113|Active Comparator|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
3335764|NCT02141113|Placebo Comparator|Sugar Pill Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)~mg Guanfacine Hydrochloride (orally, QD)"
3335765|NCT02141126|Experimental|Resistance training|Usual care and resistance exercises.
3335766|NCT02141126|Other|Usual care|Usual inpatient physiotherapy
3335767|NCT02141139|No Intervention|Control arm|no medication or acetaminophen
3335768|NCT02141139|Experimental|NSAIDS (ketorolac intravenous, ibuprofen)|ketorolac IV (just before surgery) and ibuprofen for 1 weeks
3335769|NCT02141152||gastric cancer|This study will recruit a total of 130 gastric cancer patients. It is expected to recruit about 250 gastric cancer patients per year. Since the incidence of each mutation is low, the different types of mutations are assumed to be mutually exclusive. So, about 30% of these patients are expected to have a mutation with a target drug. Overall response (OR) is the primary endpoint of this study. OR rate (ORR) will be compared between the group (called targeted group) of patients who have a mutation with a target drug and that (called untargeted group) of patients who have no mutation. The ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 gastric cancer patients, about 39 patients will belong to the targeted group and about 91 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 89% of power. The study on gastric cancer will take 7 months for patient accrual.
3335770|NCT02141152||colorectal cancer|This study will recruit a total of 130 colorectal cancer patients. It is expected to recruit about 300 colorectal cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The median ORR is expected to be about 25% for the targeted group and about 5% for the untargeted group. With N=130 colorectal cancer patients, about 33 patients will belong to the targeted group and about 97 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on colorectal cancer will take about 6 months for accrual.
3335771|NCT02141152||biliary tract cancer/pancreatic cancer|This study will recruit a total of 78 biliary tract cancer/pancreatic cancer patients. It is expected to recruit about 100 biliary tract cancer/pancreatic cancer patients per year. About 20% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 35% for the targeted group and about 5% for the untargeted group. With N=78 biliary tract cancer/pancreatic cancer patients, about 16 patients will belong to the targeted group and about 62 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 87% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
3335772|NCT02141152||Rare cancer|Rare cancer is hepatocellular carcinoma, melanoma and neuroendocrine tumor. This study will recruit a total of 87 hepatocellular carcinoma/rare cancer patients. It is expected to recruit about 150 biliary tract cancer/pancreatic cancer patients per year. About 25% of these patients are expected to have a mutation with a target drug. ORR will be compared between the targeted group and the untargeted group. The ORR is expected to be about 30% for the targeted group and about 5% for the untargeted group. With N=87 biliary tract cancer/pancreatic cancer patients, about 22 patients will belong to the targeted group and about 65 will belong to the untargeted group. The chi-square test with a 2-sided alpha=5% has 86% of power. The study on biliary tract cancer/pancreatic cancer will take about 7 months for accrual.
3335773|NCT02141152||genitourinary cancer|
3335774|NCT02141165|Experimental|Primary.|Diagnosis, autoCPAP, follow up.
3335775|NCT02141165|Active Comparator|Hospital|Diagnosis, autoCPAP, follow up
3235234|NCT01238796|Experimental|Normal renal function|Subjects with normal renal function
3235235|NCT01238796|Experimental|Severe renal impairment|Subjects with severe renal impairment
3235236|NCT01238796|Experimental|End stage renal disease|Subjects with end stage renal disease
3235237|NCT01238809||1|
3235238|NCT01238874|No Intervention|No intervention|Mostly observational study with 1 patient global assessment.
3235239|NCT01238887|Placebo Comparator|microcrystalline cellulose|
3235240|NCT01238887|Active Comparator|Hydroxycitric acid|2800 mg divided in three doses per day
3235241|NCT01238887|Active Comparator|Hydroxycitric Acid|5400 mg divided into three doses per day
3235242|NCT01238913||benign esophageal lesions|All patients who have a benign esophageal lesion where it is medically indicated that they receive a stent.
3235243|NCT01238926|Experimental|PD vitamin supplementation|
3235244|NCT01238926|Experimental|PD exercise intervention|
3235245|NCT01238926|Experimental|PD vitamin + exercise|
3235246|NCT01238926|No Intervention|PD control|
3235247|NCT01238939|Experimental|Treatment|
3235248|NCT01238965|Experimental|Arm I|Patients receive oral panobinostat 3 times a week. Patients also receive leucovorin calcium IV over 2 hours on days 1 and 15 followed by fluorouracil IV continuously over 46 hours on days 1-2 and 15-16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3235249|NCT01238978|Experimental|Vildagliptin|
3235250|NCT01238978|Active Comparator|other Oral Antidiabetic Drug in a different therapeutic class|
3235251|NCT01239004|Placebo Comparator|Placebo|
3235252|NCT01239004|Experimental|Colesevelam|
3235253|NCT01239017|Experimental|Dose 1|SC REGN475 Dose 1 and IV Placebo
3235254|NCT01239017|Experimental|Dose 2|SC REGN475 Dose 2 and IV Placebo
3235255|NCT01239017|Experimental|Dose 3|SC REGN475 Dose 3 and IV Placebo
3235256|NCT01239017|Experimental|Dose 4|SC Placebo and IV REGN475 Dose 4
3235257|NCT01239017|Placebo Comparator|Dose 5|SC Placebo and IV Placebo
3235258|NCT01239030|Active Comparator|10 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
3335776|NCT02141178|Active Comparator|Bupivacaine|Patients will received 0.5% Bupivacaine subcutaneously for local anesthesia during surgery
3335777|NCT02141178|Experimental|Exparel|Patients will received Exparel subcutaneously for local anesthesia during surgery
3335778|NCT02141191|Experimental|HS/sham|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
3335779|NCT02141191|Experimental|sham/HS|Subjects will utilize inhaled hypertonic saline (7%) delivered using the tPAD device during one session and perform a sham treatment with the tPAD during the other. The order will be randomized.
3335780|NCT02141230|Experimental|Alli® 60 mg|Participants purchasing Alli®
3335781|NCT02141243|Experimental|Group A|"All participants will receive both the lingual frenotomy and sham procedure. Group A infants will receive lingual frenotomy for intervention #1 and a sham procedure for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and a laser, (iLaseTM 940 ± 15 nm) or scissors, will be used to release its attachment to the level of the periosteum."
3335782|NCT02141243|Experimental|Group B|"All participating infants will receive both the lingual frenotomy and sham procedure. Group B infants will receive the sham procedure for intervention #1 and a lingual frenotomy for intervention #2. Newborns that continue to have difficulty with breastfeeding after both interventions will undergo intervention #3, a labial frenotomy.~Sham/placebo procedure: infant brought into a procedure room and kept there for as long as the average experimental procedure would take (~5 minutes).~Lingual frenotomy: tongue will be elevated, expose frenulum with a grooved director or 2 cotton tipped applicators, and then incise frenulum tissue with a straight scissor.~Maxillary labial frenotomy: 0.1 ml of 1% lidocaine will be injected into the area, upper lip lifted, frenum stretched, and an iLaseTM 940 ± 15 nm laser used to release its attachment to the level of the periosteum."
3335783|NCT02141256|Experimental|Protein enriched products|Protein enriched products will be given to elderly residents of a care home for 10 days. Does this lead to an increased protein intake or do elderly compensate for the extra amount of protein?
3335784|NCT02141282|Experimental|ABT-199 after ibrutinib therapy|Single daily doses increasing weekly as tolerated
3335785|NCT02141282|Experimental|ABT-199 after ibrutinib or idelalisib therapy|Single daily doses increasing weekly as tolerated
3335786|NCT02141282|Experimental|ABT-199 after idelalisib therapy|Single daily doses increasing weekly as tolerated
3335787|NCT02141308||Rare Chorioretinal Disease|Up to 150 patients diagnosed with a rare retinal or choroidal disease will be considered and evaluated for enrollment in this study.
3335788|NCT02141321|Experimental|Misoprostol|Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
3335789|NCT02141321|Placebo Comparator|Placebo|Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets. Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
3335790|NCT02141347|Other|Part A|Dose escalation of tremelimumab mono therapy for advanced solid malignancies
3335791|NCT02141347|Other|Part B|Combination therapy of tremelimumab and MEDI4736 for advanced solid malignancies
3335792|NCT02141347|Other|Part C|Fixed dose of tremelimumab for malignant mesothelioma
3335793|NCT02141373|Experimental|Glubran 2|Glubran 2 will be used at end of surgery
3335794|NCT02141373|No Intervention|Standard Surgery|
3335795|NCT02141386|Experimental|Treatment A|plasticity-based, adaptive, computerized cognitive remediation (PACR)
3335796|NCT02141386|Active Comparator|Treatment B|"Ordinary Computer Games (an active control condition)"
3335797|NCT02141412|Active Comparator|Group I|Patients in Group I will receive dexmedetomidine 0.25 µg/kg IV (over 10 min) at closure of sevoflurane
3335798|NCT02141412|Active Comparator|Group II|Patients in Group II will receive dexmedetomidine 0.5 µg/kg IV (over 10 min) at closure of sevoflurane
3335799|NCT02141412|Active Comparator|Group III|Patients in Group III will receive dexmedetomidine 1 µg/kg IV (over 10 min) at closure of sevoflurane
3335800|NCT02141412|Placebo Comparator|Group IV|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
3335801|NCT02141425|Experimental|ASP015K low dose|
3335802|NCT02141425|Experimental|ASP015K medium dose|
3335803|NCT02141425|Experimental|ASP015K high dose|Optional, depending on safety review and regulatory authority input
3335804|NCT02141425|Placebo Comparator|Placebo|
3235259|NCT01239030|Active Comparator|15 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
3235260|NCT01239030|Active Comparator|20 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
3235261|NCT01239030|Active Comparator|40 mg|Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
3235262|NCT01239030|Placebo Comparator|Placebo|Placebo Capsules
3335805|NCT02141477|Experimental|Omacetaxine + Decitabine|"Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.~Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
3335806|NCT02141529|Active Comparator|Unipolar PRF|Unipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
3335807|NCT02141529|Experimental|Bipolar PRF|Bipolar pulsed radiofrequency thermocoagulation, intraarticularly in knee joint, 42oC of temperature during ten minutes
3235263|NCT01239069|Experimental|DE-110 ophthalmic suspension high dose|
3235264|NCT01239069|Experimental|DE-110 ophthalmic suspension low dose|
3335808|NCT02141542|Experimental|Tremelimumab and MEDI3617|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Tremelimumab-Fixed doses of Tremelimumab are given once per cycle~MEDI3617-MEDI3617 is administered twice per cycle"
3335809|NCT02141568|Experimental|Intervention Group for Prospective Study|"Intervention: Medical and psychological treatment at the Soroka UMC functional neurology outpatient clinic. Treatment will be conducted by a multidisciplinary staff. Patients will undergo an initial meeting with a neurologist and afterwards will be directed to other members of the team (psychologist, physical therapist) on a case by case basis."
3335810|NCT02141568|No Intervention|No Intervention|Patient records will be analyzed via Clalit Health Service electronic records. No additional intervention will occur
3335811|NCT02141594||Early glaucoma|The study group consisted of consecutive unilateral glaucoma patients, categorized as early stage by Hodapp-Anderson-Parrish classification.
3335812|NCT02141594||Normal subjects|Normal control subjects had a normal ocular examination, Intraocular pressure (IOP) <22 mmHg, no past history of high IOP, no family history of glaucoma, normal optic disc morphology and visual field in both eyes. One eye of control subject was randomly selected.
3335813|NCT02141607||Hemorrhagic Shock|"Hypovolemic shock characterized by:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Rapid loss of significant amount of blood~Lactate levels ≥ 2 mmol/L"
3335814|NCT02141607||Cardiogenic shock|"State of inadequate circulation of blood because of ventricular failure due to acute cardiac conditions, concomitant presence of:~Hypotension: systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Need for a continuous infusion of inotropic drugs~Cardiac Index <2.2 L/min/m2 or use of inotropic drugs (dobutamine/isoprenaline/phosphodiesterase inhibitors or levosimendan)~Signs of reduced heart function~Cardiac overload or altered left/right ventricular function"
3335815|NCT02141607||Septic shock|"Septic shock is defined as sepsis-induced hypotension, defined as systolic blood pressure < 90 mm Hg or a drop of > 40 mm Hg from baseline or mean arterial pressure < 70 mm Hg persisting despite adequate fluid resuscitation.~Only community medical acquired sepsis with a sepsis onset within 48 hours from hospital admission (i.e. different from nosocomial infection).~Lactate levels ≥ 2mmol/L."
3335816|NCT02141607||control group|"The control group will consist on:~5 healthy blood donors: serving only for the purposes of obtaining reference values for proteomics analysis~a cohort of 20 patients hospitalized for sepsis OR cardiac syndromes not developing shock: will be recruited from patients admitted to the hospital during the study period. The clinical status of the patients will be assessed during hospitalization to ascertain shock and AHF development. Shock development will be an exclusion criteria."
3235265|NCT01239069|Placebo Comparator|Placebo|
3335817|NCT02141646|Experimental|Motivational interviewing|
3335818|NCT02141646|Experimental|Behavioral skills training|
3335819|NCT02141685||IVF patients undergoing aCGH Testing|Women undergoing fresh IVF treatment and array-comparative genomic hybridization testing (aCGH), as recommended based on medical need by the clinical site reproductive endocrinologist.
3335820|NCT02141698|Experimental|Cohort 1: TAK-438 1 mg|TAK-438 1 mg, tablets, orally, once on Day 1.
3335821|NCT02141698|Experimental|Cohort 2: TAK-438 5 mg|TAK-438 5 mg, tablets, orally, once on Day 1.
3335822|NCT02141698|Experimental|Cohort 3: TAK-438 10 mg|TAK-438 10 mg, tablets, orally, once on Day 1.
3335823|NCT02141698|Experimental|Cohort 4: TAK-438 20 mg|TAK-438 20 mg, tablets, orally, once on Day 1.
3335824|NCT02141698|Experimental|Cohort 5: TAK-438 15 mg|TAK-438 15 mg, tablets, orally, once on Day 1.
3335825|NCT02141698|Experimental|Cohort 6: TAK-438 40 mg|TAK-438 40 mg, tablets, orally, once on Day 1.
3335826|NCT02141698|Experimental|Cohort 7: TAK-438 30 mg|TAK-438 30 mg, tablets, orally, once on Day 1.
3335827|NCT02141698|Experimental|Cohort 8A: Food-effect|TAK-438 20 mg, tablets, orally, under fasted conditions, once on Day 1, Period 1, followed by a 13 day washout period, followed by TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 2.
3335828|NCT02141698|Experimental|Cohort 8B: Food-effect|TAK-438 20 mg, tablets, orally, under fed conditions, once on Day 1, Period 1.
3335829|NCT02141698|Experimental|Cohort 9: TAK-438 Multiple Dose 1|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3235266|NCT01239082|Other|Arm 1|Colonoscopy (one time screening)
3235267|NCT01239082|Other|Arm 2|FIT (annually)
3235268|NCT01239095|Experimental|Green Tea and Milk Thistle Supplements|Patients will receive green tea extract and milk thistle extract supplements for one week prior to surgery and for 30 days after surgery.
3235269|NCT01239134|Experimental|TRX518|
3235270|NCT01239147|Other|Whole grain diet|
3235271|NCT01239147|Other|Refined grain diet|
3235272|NCT01239173|Active Comparator|1|Post-traumatic stress disorder patient receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3235273|NCT01239173|Placebo Comparator|2|Post-traumatic stress disorder receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3235274|NCT01239173|Active Comparator|3|Controls receiving propanolol 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3235275|NCT01239173|Placebo Comparator|4|Controls receiving placebo 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
3235276|NCT01239186||Oligozoospermia|infertile patients presenting a reduced sperm count (less than 20 Millions of spermatozoa/ml)
3235277|NCT01239199|Experimental|Exhaled NO|
3235278|NCT01239225|Experimental|Abdominal ultrasound|Abdominal ultrasound
3235279|NCT01239238||Care as usual|Therapy is guided based on symptoms and lung function. Assessments: home monitoring, symptoms, lung function, FeNO, asthma control, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
3235280|NCT01239251||breast cancer patients taking endocrine therapy|Breast cancer patients, currently taking adjuvant endocrine therapy will be equipped with a GlowCap device for a period of 30 days. The GlowCap will become part of their medication taking routine.
3235281|NCT01239277|Experimental|protein (elderly)|
3235282|NCT01239277|Experimental|protein and carbohydrate (elderly)|
3235283|NCT01239277|Experimental|protein and carbohydrate (young)|
3235284|NCT01239277|Experimental|protein and leucine (elderly)|
3235285|NCT01239303|Active Comparator|citrulline|
3235286|NCT01239303|Placebo Comparator|alanine|
3235287|NCT01239329||Complex multiple disabilities|People with complex multiple disabilities, living in a care institution participating in the Governor Kremers Centre (GKC.)
3235288|NCT01239368|Experimental|Cohort B - Relapsed Multiple Myeloma|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) .Rapamycin (Rapa) for Relapsed Multiple Myeloma
3235289|NCT01239368|Experimental|Cohort A - Prevention of Relapse|Th1/Tc1.Rapa Prevention of Relapse
3235290|NCT01239407|No Intervention|Treatment as usual|"The treatment as usual arm consists of two phone or in-person interviews:~Patients are asked questions about their mental health, their views of mental health, and how they cope with their mental health (including any treatment they might be receiving).~Patients are asked the same questions 6 months after the initial interview."
3235291|NCT01239407|Experimental|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
3235292|NCT01239433||mechanically ventilated patients|ICU patients on mechanical ventilation. Daily endotracheal suctioning performed to reduce secretions. Data recorded during these therapeutic interventions.
3335830|NCT02141698|Experimental|Cohort 10: TAK-438 Multiple Dose 2|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3335831|NCT02141698|Experimental|Cohort 11: TAK-438 Multiple Dose 3|TAK-438 tablet, orally, fixed dose, on Day 1 and Days 8-14. Dose to be determined from data collected in Cohorts 1-7.
3335832|NCT02141698|Experimental|Cohort 12: Ethnic Bridging|TAK-438 tablets, dose 1, orally, on Days 1-7 of Period 1, followed by a 4-week washout period followed by TAK-438 tablets, dose 2, orally, Days 1-7 of Period 2, followed by a 4-week washout period, followed by esomeprazole tablets, 40 mg, orally, on Days 1-7 of Period 3. TAK-438 doses to be determined from data collected in Cohorts 9-11.
3335833|NCT02141698|Placebo Comparator|Cohorts 1-7: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1
3335834|NCT02141698|Placebo Comparator|Cohorts 9-11: Placebo|TAK-438 placebo-matching tablets, orally, once on Day 1, where available, if required.
3335835|NCT02141711|Experimental|Cohort 1: TAK-438 10 mg|TAK-438 10 mg tablets, orally, once, daily, for 7 days.
3335836|NCT02141711|Experimental|Cohort 2: TAK-438 20 mg|TAK-438 20 mg tablets, orally, once, daily, for 7 days.
3335837|NCT02141711|Experimental|Cohort 3: TAK-438 40 mg|TAK-438 40 mg tablets, orally, once, daily, for 7 days.
3235293|NCT01239459|Experimental|Severe impaired renal function|Subjects with severe renal impairment as defined by Cockroft-Gault formula
3235294|NCT01239459|Experimental|Normal renal function|Subjects with normal renal function as defined by Cockroft-Gault formula
3235295|NCT01239485|Experimental|Irinotecan|
3235296|NCT01239498|Experimental|Saline + Lidocaine/Adrenaline|
3335838|NCT02141711|Experimental|Cohort 4: TAK-438 30 mg|TAK-438 30 mg tablets, orally, once, daily, for 7 days.
3335839|NCT02141711|Placebo Comparator|Cohorts 1-4: Placebo|TAK-438 placebo-matching tablets, orally, once, daily, for 7 days.
3335840|NCT02141724||neuromuscular patients|neuromuscular patients using wheelchair
3335841|NCT02141737|Placebo Comparator|Group C|Induction protocol: patients will be given 2 ml normal saline solution, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3335842|NCT02141737|Experimental|Group L1|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 20 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3335843|NCT02141737|Experimental|Group L2|Induction protocol: patients will be given 2 ml diluted lidocaine injection in which 30 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3235297|NCT01239498|Placebo Comparator|Lidocaine/Adrenaline only|
3235298|NCT01239524|Other|DE-group|surgical denervation by excising 1 cm of proximal thoracodorsal nerve
3235299|NCT01239524|Other|IN group|thoracodorsal nerve is saved intact
3235300|NCT01239537||Baxter H1N1 vaccine|Previously received 2 dose schedule of Baxter H1N1 vaccine
3235301|NCT01239537||GSK H1N1 vaccine|Previously received 2 dose schedule of GSK H1N1 vaccine
3259226|NCT01468688|Experimental|STI571 (imatinib mesylate) and BKM120|The study will comprise of 2 parts. A dose escalation and a dose expansion part. Patients will receive increasing doses of BKM120 (40, 60, 80, 100 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. 35 patients will enter the expansion phase with 18 patients having a pharmacokinetic (PK) run-in period of 8 days receiving imatinib monotherapy or BKM120 monotherapy.
3259227|NCT01468688|Experimental|STI571+BKM120|BKM120 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
3335844|NCT02141737|Experimental|group L3|Induction protocol: patients will be given 2 ml lidocaine injection in which 40 mg lidocaine is contained, 1 minutes later, 0.3 mg/kg etomidate is injected within 30 to 60 s, and 90 s after the injection of etomidate, 0.2 mg/kg midazolam, 3 μg/kg fentanyl, 0.6 mg/kg rocuronium are given sequently.
3335845|NCT02141763|Experimental|240/160/160 mg of UCB4940|240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3235302|NCT01239550|Experimental|Insulin Detemir Treatment|"Insulin detemir treatment: Insulin detemir will be administered subcutaneously, once daily. Dose ranges from approximately 0.1 U/kg up to 0.6 u/kg or higher. The dosing regimen will employ a strategy similar to the 303algorithm, where, with close interaction with study personnel (rather than self-titration), bedtime insulin dosing will be titrated up by 3 units until AM fasting sugars within the prescribed protocol range are achieved (90-110 mg/dl). Subjects will have contact with study personnel on weekly basis for glycemia monitoring and adjustments. Similarly, documented hypoglycemia (blood sugars less than 70) will trigger a dose reduction, and it is expected that with weight loss, tolerable insulin dosages will drift downward. The treatment period is 24 weeks."
3259228|NCT01468688|Experimental|STI571 monotherapy run-in|STI571 Monotherapy 8 day run-in followed by STI571 and BKM120 combination therapy
3259229|NCT01468727|Experimental|xylitol wipe|
3335846|NCT02141763|Experimental|160/80/80 mg of UCB4940|160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3335847|NCT02141763|Experimental|80/40/40 mg of UCB4940|80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3335848|NCT02141763|Experimental|560/320/320 mg of UCB4940|560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)
3335849|NCT02141763|Placebo Comparator|Placebo|0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial
3335850|NCT02141776|Sham Comparator|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
3335851|NCT02141776|Active Comparator|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
3335852|NCT02141789|Experimental|Outpatient Cognitive Behavioral Psychotherapy|Outpatient Cognitive Behavioral Therapy is a well-known and frequently applied psychotherapy approach that does not need further description.
3335853|NCT02141802|Active Comparator|Control|Normal standing time
3335854|NCT02141802|Experimental|Doubling standing time|Doubled standing time calculated by doubling baseline standing time
3259230|NCT01468727|Placebo Comparator|placebo wipe|
3335855|NCT02141815|Experimental|Arabinoxylan-oligosaccharides|Arabinoxylan-oligosaccharides 10g BID
3335856|NCT02141815|Placebo Comparator|Maltodextrine|Maltodextrine BID
3335857|NCT02141828|Experimental|EPZ-5676|EPZ-5676 Dose escalation and expansion cohorts
3335858|NCT02141880||Treatment|All subjects will be under the same protocol which is eating and drinking on one afternoon.
3335859|NCT02141893|Active Comparator|CALMA|Participants only received a family education intervention (previously tested) known as CALMA
3335860|NCT02141893|Experimental|Calma plus|Participants in Arm 2 received the CALMA family education intervention and physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs.
3335861|NCT02141906|Experimental|Oncozene-DEB-TACE|"Screening Visit (procedures should be done within 28 days of treatment day):~Study visit assessments will be performed prior to Oncozene-DEB-TACE delivery (except pharmacokinetic blood draw).~Labs may be done within 3 days of the procedure. All visits can be completed +/- 10 days of planned visit day~Follow up after completion of treatment every 4-6 weeks:"
3335862|NCT02141919|Experimental|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Radiation Therapy (SABR)
3335863|NCT02141958|Experimental|Fenretinide|Fenretinide will be administrated orally once per day for 21 consecutive days, in up to three treatment cycles of ascending doses, with a minimum of 7-day drug-free period between cycles. Twelve (12) patients will be on Fenretinide.
3335864|NCT02141958|Placebo Comparator|Placebo|Four (4) patients will be on Placebo.
3335865|NCT02141971||Non-demented; Ages 30-40|Four non-demented Down syndrome patients between the ages of 30-40 years old
3335866|NCT02141971||Non-demented; Ages 40-50|Four non-demented Down syndrome patients between the ages of 40-50 years old
3335867|NCT02141971||Demented; Ages 50-60|Four demented Down syndrome patients between the ages of 50-60 years old
3335868|NCT02142010|Other|paclitaxel liposome injection plus cisplatin|
3335869|NCT02142036|Experimental|ATI based targeted therapy.|EMA-approved ATI based targeted therapy. Patients will receive therapy based on molecular aberrations identified in the metastatic lesion.
3335870|NCT02142062||Venography and IVUS imaging guiding treatment|
3335871|NCT02142075|Experimental|Daptomycin, IV|"Patients with creatinine clearance ≥30 ml/min will receive 10 mg/kg of daptomycin (Cubicin®) once daily,~Patients with creatinine clearance <30 ml/min will receive the same daptomycin dose (10 mg/kg) but less frequently, every 48h instead of every day"
3335872|NCT02142088|Other|Glucose Monitoring|Each patient will undergo simultaneous Glucose monitoring with 2 devices. One is GlySure's intervascular continuous measurement sensor (test device) introduced through a CVC, and the other measures glucose intermittently from repeated venous blood samples drawn through an indwelling ventflon style catheter
3335873|NCT02142101||GFR >60|5 patients with polycystic kidney disease with eGFR > 60 ml/min.
3335874|NCT02142101||GFR 15-60|5 patients with polycystic kidney disease with eGFR between 15-60 ml/min.
3335875|NCT02142101||GFR <15|5 patients with polycystic kidney disease with eGFR <15 ml/min.
3335876|NCT02142114|Active Comparator|Eye injection by 30 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size (may be that day or within 1 week of the 1st injection). When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
3335877|NCT02142114|Active Comparator|Eye injection by 32 gauge needle|
3335878|NCT02142127|Experimental|14C-labelled GFT505 120 mg|
3335879|NCT02142140|Experimental|Medication Monitoring & Case Management|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Participants randomized to this group will meet with the study clinicians 4 times a year for medication monitoring and adjustment. This group will also receive a monthly call from a case manager who will explore the child's academic, social and emotional functioning. Depending on the needs of the child and family, the case manager may offer 1 to 5 intervention sessions with the child (e.g. social skills, anger management), the family (e.g. family counselling), and the school (e.g. consultation with the teacher).
3335880|NCT02142140|Active Comparator|Community Follow-up Group|All children entered into this study will be prescribed medication for their ADHD symptoms (usually a long-acting stimulant). Based on the individual needs of the child and family, they could receive the following interventions - Academic and organization skills, social skills training and parent training. Families randomized to this group will be referred to their pediatricians or family physicians for medication follow-up and their local Community Health Clinic (CLSC) for other psychosocial interventions that may be required and available.
3335881|NCT02142166|Experimental|SAB analysis|"Patients with acute aneurysmal SAH, confirmed by CT or MRI, or lumbar puncture~Daily (21 days) analysis of Biomarker in serum, in liquor and in micro-dialysate"
3335882|NCT02142166|Experimental|Control|"Patients who undergo a lumbar puncture for myelography as part of the investigation of a cervical or lumbar foraminal stenosis without cranial or myeläre pathology -or- Patients who receive perioperative prophylactic lumbar drainage without cranial or myeläre pathology~Single analysis of Biomarker in serum and liquor"
3335883|NCT02142179|Experimental|KARE Intervention|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
3335884|NCT02142179|No Intervention|A traditional curriculum education.|The control group will receive a traditional curriculum education.
3335885|NCT02142192|Experimental|natalizumab|natalizumab 300mg SC every 4 weeks for up to 12 treatment administrations (i.e. Day 1 through Week 44)
3335886|NCT02142205|Experimental|BG00002 (natalizumab)|300 mg IV infusion every 4 weeks
3335887|NCT02142231|Placebo Comparator|Laser Acupuncture|Subjects and Therapists are blinded. Instead of a real Laser Acupuncture device (able to elicit physiologic responses) them is given a sham-laser device only radiating non-energetic red LED-light. Without palpation, therapists treat the acupoint Heart 7, on both wrists, each for 1 minute, with additional 18 minutes of resting time after.
3235303|NCT01239550|No Intervention|Comparator: No insulin|"The main hypothesis is that diabetes can be changed  with early and careful insulinization capturing effects on brain function ultimately leading to weight loss. . Seek to determine in a quantitative manner whether insulin detemir restores brain dopamine neurotransmission, a control group not treated with insulin is required. The strength of this study is our ability to test the specific molecular (D2R, DAT, functional MRI responses) and integrated output (functional brain responses, mood, cognitive function, reward responses etc.) of CNS dopaminergic pathways in order to shed unprecedented light upon mechanisms of detemir action in obesity and diabetes."
3235304|NCT01239563|Experimental|Thymoglobulin|Thymoglobulin induction group
3235305|NCT01239563|Active Comparator|Basiliximab|Basiliximab induction - 20 mg, day 0 and day 4
3235306|NCT01239589||1|patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
3235307|NCT01239589||2|patients admitted as for an acute bipolar manic episode and treated with quetiapine XR
3335888|NCT02142231|Active Comparator|Acupuncture|Acupuncture at the acupoint Heart 7, on both wrists, each for 1 minute, eliciting a deqi-response, additional stimulation and total needle-in time of 20 minutes (2 minutes treatment and 18 minutes of resting time)
3335889|NCT02142244|Experimental|Near infra red sentinel node biopsy|Sentinel node biopsy adding indocyanine green injection at the tumor/biopsy site during the surgical procedure to the standard technique (blue die and lymph scintigraphy) and near infra red light for fluorescence. The indocyanine green saline solution - 5mg diluted in 10ml. will be injected in 4 points around the biopsy site - 4ml each - total 0.8mg - single procedure.Near infra red lens and camera will be used to detect the fluorescence and localize the sentinel node for biopsy.
3335890|NCT02142257||Gastric Bypass|Morbidly obese individuals who meet the criteria for and have chosen to undergo Gastric Bypass surgery.
3335891|NCT02142257||AspireAssist Aspiration Therapy|Morbidly obese individuals who meet the criteria for and have chosen to participate in Aspiration Therapy using the AspireAssist.
3335892|NCT02142270||Victims of cardiac arrest, either SCD or aborted SCA|
3335893|NCT02142270||Premature death|"All residents of districts of interest will be surveyed during 3 years. premature deaths occurring in residents of districts of interest will be checked for past medical history, circumstances of death, and autopsy report (if possible). Investigators will also analyze the employment of resuscitation attempts during the timeframe of sudden cardiac arrest (SCA) in various patient populations throughout African countries.~The arm group of the study is every resident of the district of interest"
3335894|NCT02142296|Other|Eylea|The intravitreal dose of Eylea will be 2mg (50ul) per injection. The medication will be supplied in single use vials. Given monthly for 3 months and then every 8 weeks until week 52. This is an open-label study.
3335895|NCT02142309|Experimental|Glimepiride|up to 4 mg/day
3335896|NCT02142309|Experimental|Vildagliptin|50 mg bid
3335897|NCT02142309|Experimental|Pioglitazone|up to 30 mg/day
3235308|NCT01239602||Normal control|
3235309|NCT01239602||with Stem cell therapy plus G-CSF|
3235310|NCT01239602||G-CSF along|
3235311|NCT01239615||healthy volunteers|
3235312|NCT01239654|Active Comparator|everolimus|everolimus-eluting stent
3335898|NCT02142309|Experimental|Canagliflozin|300 mg/day
3335899|NCT02142335|Experimental|Rituxan/Abraxane|This is a single arm study. All patients recieve treatment.
3335900|NCT02142348||osteoprosis research|
3335901|NCT02142400|Experimental|DS-1093|Group 1 will receive 10mg, group 2 will receive 25mg of DS-1093
3335902|NCT02142400|Placebo Comparator|placebo|placebo to match DS-1093 dosage
3335903|NCT02142413||Acute Ischemic Stroke|Patients older than 18 years with an acute ischemic stroke (according to WHO criteria), stroke onset within 2 days, language: German, MRI compatibility, admission to the stroke unit at the Charité, Campus Benjamin Franklin.
3335904|NCT02142439|Experimental|Intervention group 1|Exercise counseling 1 time/week, Strength training 3 times/week, dose: 5 RM x 3 sets.
3335905|NCT02142439|Experimental|Intervention group 2|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 10 RM x 3 sets.
3335906|NCT02142439|Experimental|Intervention group 3|Exercise counseling 1 time/week. Strength training 3 times/week, dose: 30 RM x 3 sets
3335907|NCT02142439|No Intervention|Control group|Exercise counseling 1 time/week
3335908|NCT02142452|Experimental|mobile health intervention|Behavioral intervention. Women with excessive weight gain in pregnancy will be recruited in their 3rd trimester. They will begin with a 5 week group session on weight management. After they deliver the baby, they will begin receiving text messages supporting behavior change they learned in their 3rd trimester. They will follow up at 6 weeks postpartum and 4 months postpartum.
3335909|NCT02142452|Placebo Comparator|Control Group|Women will receive usual prenatal care from their OB. Postpartum, they will receive a monthly newsletter relevant to the new mother on her nutrition and physical activity. They will be followed at 6 weeks postpartum and 4 months postpartum.
3335910|NCT02142478||Adapted scheme|Participants referred by their GP practices to Centre A will take part in the Adapted Exercise for Health (EFH) scheme.
3235313|NCT01239654|Active Comparator|zotarolimus|zotarolimus-eluting stent
3235314|NCT01239667|Experimental|Life style counseling|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
3335911|NCT02142478||Standard scheme|Participants referred by their GP practices to Centre B will take part in the Standard Exercise for Health (EFH) scheme.
3335912|NCT02142517|Active Comparator|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
3335913|NCT02142517|Active Comparator|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
3335914|NCT02142530|Experimental|Carfilzomib/ Belinostat|"Carfilzomib and Belinostat will be administered on a 28-day schedule.~Carfilzomib will be given on days 1-2, 8-9, and 15-16 of each cycle, beginning at a dose of 20 mg/m2 (dose level 0).~Belinostat will be given on days 1-5 beginning at a dose of 600 mg/m2.~Belinostat dosing will precede carfilzomib dosing on days when both drugs are administered. In dose level 1 and beyond, carfilzomib will be given at a dose of 20mg/m2 with cycle 1, and then escalated with cycle 2~A maximum of four dose levels are planned with carfilzomib escalated no higher than 20/36 mg/m2 and belinostat escalated no higher than 900 mg/m2."
3335915|NCT02142543|Placebo Comparator|placebo|placebo powder containing zinc oxide, karaya gum, and yellow dye, which was added to imitate the color of the original powder, applied twice a day until the ulcer had resolved, an expected average of 3-5 days
3335916|NCT02142543|Experimental|2-DeNT powder|2-DeNT powder containing dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum, applied twice a day until the ulcer had resolved, applied twice a day until the ulcer had resolved, in an expected average of 3 to 5 days
3335917|NCT02142556|Experimental|Quetiapine XR|Patients had schizophrenia and fulfilled the criteria including having a score of 4 (moderate) or greater on any of the 7 items of the Positive and Negative Syndrome Scale (PANSS) Positive Symptom Subscale and needed to switch from previous antipsychotics due to insufficient efficacy or insufficient tolerability (N=61). They will receive the intervention of administration of quetiapine XR.
3335918|NCT02142569|Active Comparator|Chinese Red Yeast Rice (CRYR)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 Sugar Pill/Placebo capsules for 12 weeks.
3235315|NCT01239693|Active Comparator|IFA group|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
3235316|NCT01239693|Active Comparator|MMN group|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients' Children from 6 to 18 months of age: None
3235317|NCT01239693|Experimental|LNS group|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
3235318|NCT01239706|Experimental|NTx 265|
3235319|NCT01239719|Experimental|Dexamethasone + Clemastine|Dexamethasone + clemastine fumarate cream
3235320|NCT01239719|Active Comparator|Dexamethasone|Dexamethasone 0.5 mg
3335919|NCT02142569|Active Comparator|Tocotrienol-enriched Fraction of Palm Oil (TRF)|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 TRF and 2 Sugar Pill/Placebo capsules for 12 weeks.
3335920|NCT02142569|Active Comparator|CRYR + TRF|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the TRF + CRYR arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 2 CRYR and 2 TRF capsules for 12 weeks.
3335921|NCT02142569|Placebo Comparator|Sugar Pill|20 subjects with cholesterol level (200 to 240 mg/dl), ages 35-70 years of age who meet all the eligibility criteria in the screening phase of the study will be assigned to the placebo (sugar pill) arm of the study to evaluate the cholesterol-suppressive actions of CRYR and Tocotrienol-enriched Fraction of Palm Oil (TRF). Subjects will be asked to take 4 placebo tablets for 12 weeks. Additionally during a two-week run-in period, subjects will be asked to follow the American Heart Association Step 1 dietary regimen and to take a placebo capsule daily to determine their ability to comply with the diet and a pill regimen.
3335922|NCT02142582|Active Comparator|WHO ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
3335923|NCT02142582|Active Comparator|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
3335924|NCT02142595|Experimental|dexmeditomidine group D|The sedative solution was prepared as a 10µg /ml dexmedetomidine in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3335925|NCT02142595|Experimental|Midazolam group M|The sedative solution was prepared as a 0.375mg/ml midazolam or normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3335926|NCT02142595|No Intervention|group control|normal saline in an unlabeled 20ml syringe. The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
3335927|NCT02142621|Active Comparator|transpyloric tube feeds|Continuous transpyloric tube feeds administered through an oral/nasal feeding tube.
3335928|NCT02142621|Active Comparator|gastric tube feeds|Continuous gastric tube feeds administered through an oral/nasal feeding tube.
3335929|NCT02142634|Experimental|A|Budesonide granules 9 mg
3335930|NCT02142634|Placebo Comparator|B|Placebo granules
3335931|NCT02142647|Active Comparator|meat group|Infants in this group will receive complementary foods with high protein content mainly from meat
3335932|NCT02142647|Active Comparator|dairy group|infants in this group will receive complementary foods mainly from dairy
3335933|NCT02142660||Sprayshield|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie
3335934|NCT02142673|Active Comparator|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
3335935|NCT02142673|Active Comparator|Filling pressure 60|The hysteroscope filling pressure will be to 50mm Hg
3335936|NCT02142673|Active Comparator|Filling pressure 40|The hysteroscope filling pressure will be to 40mm Hg
3335937|NCT02142686|Active Comparator|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm.
3335938|NCT02142686|Active Comparator|Filling pressure 50.|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg in this group
3235321|NCT01239758|Experimental|ACE-031 (Extension of cohort 1 from core study, A031-03)|
3235322|NCT01239758|Experimental|ACE-031 (Extension of cohort 2 from core study, A031-03)|
3235323|NCT01239758|Experimental|ACE-031 (Extension of cohort 3 from core study, A031-03)|
3335939|NCT02142686|Active Comparator|illing pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm Hg.
3335940|NCT02142699|Active Comparator|Heme arginate 1mg/kg|"This is the lower of the 2 doses of Heme arginate (HA). This will be given as a single dose of 1mg/kg on the first study visit.~This is given over 1 hour intravenously."
3335941|NCT02142699|Active Comparator|Heme arginate 3mg/kg|"This is the larger dose, Heme arginate 3mg/kg (up to a maximum dose of 250mg)~This will be given intravenously, as a single dose on the first study visit, over one hour."
3335942|NCT02142725|Experimental|LT-02|LT-02 0.8g four times daily
3335943|NCT02142725|Experimental|B: LT-02|LT-02 1.6g twice daily
3335944|NCT02142725|Placebo Comparator|Placebo|LT-02 Placebo
3335945|NCT02142751|Experimental|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
3335946|NCT02142751|Active Comparator|Meropenem intravenous|1g every 8 hours (15-30 min infusion)
3335947|NCT02142751|Other|Ceftriaxone intravenous|1g every 24h (2-4 min)
3335948|NCT02142764|Experimental|Multiple Sclerosis|Human Leukocyte Antigen (HLA)-A2 patients whose Multiple Sclerosis has just been diagnosed
3335949|NCT02142764|Other|Control|HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
3335950|NCT02142764|Experimental|Multiple Sclerosis patients treated|HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
3335951|NCT02142777|Experimental|Investigational|All study subjects will take a 10mg pill by mouth twice daily over a 6 week period. Subjects will receive either placebo or S -Equol. They will not know which they are receiving.
3335952|NCT02142790|Experimental|paclitaxel liposome injection weekly|paclitaxel liposome injection 100mg/m2 administered by intravenous on day1 and day8 of a 21-day cycle for at least 4cycles or till progression or intolerable
3235324|NCT01239771|Experimental|1|TC-5214
3235325|NCT01239771|Placebo Comparator|2|Placebo matched to TC-5214
3335953|NCT02142790|Experimental|paclitaxel liposome injection every 3 weeks|paclitaxel liposome injection 175mg/m2 administered by intravenous on day1 of a 21-day cycle for at least 4cycles or till progression or intolerable
3335954|NCT02142816|Active Comparator|Doppler|Fluid directed by oesophageal doppler
3335955|NCT02142816|Active Comparator|PVI|Fluid therapy directed by Pleth Variability Index
3335956|NCT02142829|Active Comparator|EXPAREL|EXPAREL (bupivacaine liposome injectable suspension)
3335957|NCT02142829|Active Comparator|On-Q Pain Ball|Device for delivering bupivacaine.
3335958|NCT02142842|Experimental|Treatment|Autologous stromal vascular fraction (SVF) and platelet rich plasma (PRP) will be injected into joints of 16 patients with grade 2, 3 radiographic OA severity with 16 patients as control.
3335959|NCT02142855|No Intervention|Old Control|Older individuals (65-75 y) with no exercise intervention
3335960|NCT02142855|Experimental|Old Concentric|Older individuals (65-75 y) studied before and after 8 weeks concentric exercise training
3335961|NCT02142855|Experimental|Old Eccentric|Older individuals (65-75 y) studied before and after 8 weeks eccentric exercise training
3335962|NCT02142855|No Intervention|Young Control|Young individuals (18-30 y) with no exercise intervention
3235326|NCT01239784|Experimental|All Subjects|A total of 20 children and their parents will be recruited for this study. Ten children will have had the Glenn procedure and 10 infants will have had the arterial switch operation.
3235327|NCT01239810||Control group|Receiving no treatment
3335963|NCT02142855|Experimental|Young Concentric|Young individuals (18-30 y) studied before and after 8 weeks concentric exercise training
3335964|NCT02142855|Experimental|Young Eccentric|Young individuals (18-30 y) studied before and after 8 weeks eccentric exercise training
3335965|NCT02142881|Experimental|Antihypertensive medication intensification|
3335966|NCT02142881|Other|Usual care|
3335967|NCT02142920|Experimental|[14C] PF 05212384|Receive PF-05212384 89 mg Dose
3235328|NCT01239810||hyaluronic acid|treatment group receiving intraarticular hyaluronic acid
3235329|NCT01239823|Experimental|Whole Body Vibration Training|The subjects will participate in a 12-week whole body vibration exercise program with 2 sessions (1/2 hour) per week.
3335968|NCT02142933|Other|rectal swab and vagino-perineal swab|single-arm
3335969|NCT02142946||RIS MS patients|Radiologically Isolated Syndrome (RIS) MS patients
3235330|NCT01239823|Experimental|Exercise without vibration|The subjects will participate in a 12-week exercise program with 2 sessions (1/2 hour) per week.
3235331|NCT01239836|Experimental|Self-management|
3335970|NCT02142946||CIS MS patients|Clinically Isolated Syndrome (CIS) patients during a stable phase
3335971|NCT02142946||RRMS patients|Relapsing-remitting (RR) MS patients during a stable phase
3235332|NCT01239836|Sham Comparator|General Health Lecture|
3335972|NCT02142946||SPMS Patients|Secondary progressive MS patients (SPMS)
3335973|NCT02142946||PPMS Patients|Primary progressive MS patients (PPMS)
3235333|NCT01239836|Experimental|Combined workshop and self-management|
3235334|NCT01239836|Experimental|Workshop|
3235335|NCT01239862|Experimental|Autologous cell transplantation|We conducted a prospective, non-randomized, single-center longitudinal study in five patients. Inclusion criteria were age 18-50 years, chronic and accelerated silicosis, forced expiratory volume in 1s <60% and >40%, forced vital capacity ≥60% and arterial oxygen saturation >90%. BMDMCs were administered through bronchoscopy (2×107 cells) into both lungs. Physical examination, laboratory evaluations, quality of life questionnaires, thoracic computed tomography scans, lung function tests, and perfusion scintigraphy were performed before the beginning of treatment and up to 360 days after BMDMC (Bone Marrow Derived Mononuclear Cells) therapy. Additionally, whole-body and planar scans were evaluated 2 and 24 h after instillation.
3335974|NCT02142946||Controls|Age and gender matched controls
3335975|NCT02142946||CI Patients|Cochlear Implant patients pre- and post-operatively
3335976|NCT02142946||UVL Patients|Unilateral vestibular loss patients in acute and compensated state
3335977|NCT02142946||Chronic UVL|Chronic unilateral vestibular loss patients
3335978|NCT02142946||Phobic|Phobic vertigo patients
3335979|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3335980|NCT02142959|Experimental|omaveloxolone (RTA 408) Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3335981|NCT02142959|Placebo Comparator|Lotion vehicle/Placebo|Lotion vehicle/placebo will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3235336|NCT01239875|Experimental|Arm A|Patients receive pneumococcal polyvalent vaccine intramuscularly in weeks -4, 2, and 10. Patients undergo cryoablation followed by dendritic cell vaccine (CA-DC) intratumorally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
3235337|NCT01239875|Experimental|Arm B|Patients receive pneumococcal polyvalent vaccine as in arm A. Patients also receive autologous dendritic cell-tumor fusion vaccine (TL-DC) intradermally in weeks 0, 2, 4, 6, 10, 14, 18, and 22.
3335982|NCT02142985|Experimental|crystalloid solution|vascular filling with 500 ml of crystalloid solution within 10 minutes
3335983|NCT02142998|Active Comparator|GERD Symptoms|
3335984|NCT02142998|Active Comparator|No GERD Symptoms|
3335985|NCT02143011|Other|orange juice|no sugar
3335986|NCT02143011|Other|sugar beverage|no sugar
3335987|NCT02143037|Active Comparator|Control Group|usual care
3335988|NCT02143037|Experimental|Experimental Group|usual care plus prize contingency management for attending treatment
3335989|NCT02143050|Experimental|Dabrafenib, Trametinib and Metformin|Dabrafenib 150 mg PO BID until progression or unacceptable toxicity. Trametinib 2 mg PO QD until progression or unacceptable toxicity. Metformin 500 mg PO BID x 2 weeks, then 850 mg PO BID until progression or unacceptable toxicity.
3335990|NCT02143076||Sickle Cell Disease|Participants will complete three questionnaires during the course of the study: Demographic Questionnaire, Medical Adherence Measure Questionnaire, and Acceptability Questionnaire. All questionnaires will be completed in a private clinic room.
3335991|NCT02143089|Active Comparator|Group 1|Use of urinary catheterization in Cesarean section
3235338|NCT01239888|Active Comparator|Oxytocin|
3335992|NCT02143089|No Intervention|Group 2|NO urinary catheterization during Cesarean section
3335993|NCT02143128||ESScore reliability|Same patients evaluated by two or more health professionals
3335994|NCT02143128||ESScore|Tool used for evaluation of patients after surgery
3335995|NCT02143128||ESScore without evaluation|Scored by tool, but not evaluated by it
3335996|NCT02143128||No ESScore|Regular ward routines
3335997|NCT02143154||GBS positive women|Women wih GBS positive bacteruria with plan for treatment with vancomycin in labor, or women with positive GBS screening cultures with a plan to receive vancomycin in labor
3335998|NCT02143167|Experimental|SR-fampridine/placebo|24 weeks of SR-fampridine followed by four weeks of inactive placebo.
3335999|NCT02143167|Experimental|Placebo/SR-fampridine|24 weeks of inactive placebo followed by four weeks of SR-fampridine
3336000|NCT02143193|Experimental|Skin to Skin Contact|implement mother-baby Skin-to-Skin contact immediately after vaginal birth
3336001|NCT02143193|No Intervention|Standard of Care|standard care for newborn and mother immediately after vaginal birth
3336002|NCT02143206||Exercise Method|Patients attend exercise 80 minute exercise sessions of which 30 minutes includes aerobic exercise on a NuStep and Biodex elliptical machine. Patients pain levels are scored when using the NuStep then when using the Biodex and these scores are compared to determine which machine give the best outcome for pain management
3336003|NCT02143219|Other|FOLFIRINOX|FOLFIRINOX (D1-D15, for maximum 12 cycles) = Oxaliplatine + Folinic acid + Irinotecan + 5-FU
3336004|NCT02143232|Experimental|Remote patient monitoring (Telus RPM)|The remote monitoring device (Telus RPM) is used by every patient in the study post operatively at home.
3336005|NCT02143245|Other|Revision Population|"The study population is both men and women who have had previous shoulder surgery with symptoms suggestive of deep infection. These include the presence of pain, stiffness, and radiologic signs of infection including implant lucencies or migration.~Patients in this population will undergo a synovial biopsy, in addition to undergoing an open tissue biopsy at the time of their procedure. Diagnostic accuracy will be compared, and all participants will be tracked over time."
3336006|NCT02143258|Experimental|Neurointerventional|Stenting of the venous sinus is the neuro-interventional treatment that is being offered to patients with idiopathic intracranial hypertension that are refractory to medical management.
3336007|NCT02143271|Experimental|KHK7580|
3336008|NCT02143284|Experimental|Endoscopy exploratory single arm|Exploratory single arm, the system will be used in otherwise standard procedures, and will be reviewed in terms of performance, usability, ease of use and safety.
3336009|NCT02143297||SAHS negative|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally do not have the disease according to standard PSG
3336010|NCT02143297||SAHS positive|Subjects derived to the sleep unit due to suspicion of suffering from sleep apnea which finally have the disease according to standard PSG
3336011|NCT02143323|Active Comparator|Glutathione S-Transferase Theta1(GSTT1)/Mu1(GSTM1) wild/wild|Augmentin tablet
3336012|NCT02143323|Active Comparator|GSTT1/GSTM1 wild/null type|Augmentin tablet
3336013|NCT02143323|Active Comparator|GSTT1/GSTM1 null/wild type|Augmentin tablet
3336014|NCT02143323|Active Comparator|GSTT1/GSTM1 null/null type|Augmentin tablet
3336015|NCT02143336|Experimental|Subcuticular suture|Subcuticular suture (absorbable) for skin closure
3336016|NCT02143336|Active Comparator|Skin staples|Standard skin staples for wound closure
3235339|NCT01239888|Active Comparator|Oxytocin and Tibolone|
3235340|NCT01239888|Placebo Comparator|Placebo|
3235341|NCT01239940|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
3336017|NCT02143349|Experimental|Coleus forskohlii extract|Ingestion of 250 mg capsle (Coleus forskohlii extract) twice a day for 12 weeks
3336018|NCT02143349|Placebo Comparator|Placebo|Ingestion of 250 mg capsule (placebo) twice a day for 12 weeks
3336019|NCT02143362|Experimental|Dexmedetomidine group|"Infusion of dexmedetomidine(0.8μg/kg) at10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4 μg•kg-1•h-1during anesthesia maintenance.~The infusion rate of dexmedetomidine was reduced to 0.1 μg•kg-1•h-1 for awaken test."
3336020|NCT02143362|Placebo Comparator|Control group|"Infusion normal saline(0.8μg/kg) at 10 minutes before anesthesia induction.~Infusion normal saline at 0.4 μg•kg-1•h-1 during anesthesia maintenance.~The infusion rate of normal saline was reduced to 0.1 μg•kg-1•h-1 for awaken test."
3336021|NCT02143375|Experimental|810 Diode Laser|810 nm Diode Laser, contact, continuous wave,320micron,
3235342|NCT01239940|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
3235343|NCT01239953|Active Comparator|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon (SeQuent Please, B. Braun)
3235344|NCT01239953|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent (Xience Prime, Abbott Vascular)
3235345|NCT01239979||Stable, Unstable , control|
3235346|NCT01240005|Experimental|DCIK|
3235347|NCT01240018|Placebo Comparator|Placebo|
3235348|NCT01240018|Active Comparator|High dose Lb. casei|
3235349|NCT01240044|No Intervention|Control Group|In this group the newborns remained at rest 20 minutes and receive no intervention of respiratory therapy.
3235350|NCT01240044|Experimental|Physical Therapy|In this group the newborns are submitted to the mechanical vibrator.
3336024|NCT02143414|Experimental|Cohort I (blinatumomab, POMP)|"INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients not achieving CR or CRi after Induction, receive blinatumomab IV continuously over 24 hours on days 1-28 in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive prednisone PO on days 1-5, vincristine sulfate IV on day 1, mercaptopurine PO on days 1-28, and methotrexate PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for 18 cycles in the absence of disease progression or unacceptable toxicity. (Closed to accrual 06/29/17)"
3336025|NCT02143414|Experimental|Cohort II (dasatinib, prednisone, blinatumomab)|"INDUCTION: Patients receive dasatinib PO BID on days 1-84 and prednisone PO on days 1-24 with tapering on days 25-32 in the absence of disease progression or unacceptable toxicity.~RE-INDUCTION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28. Treatment repeats every 42 days for 2 cycles in the absence of disease progression or unacceptable toxicity.~POST-REMISSION: Patients receive blinatumomab IV continuously over 24 hours on days 1-28 and dasatinib PO QD on days 1-42. Treatment repeats every 42 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive dasatinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive prednisone PO on days 1-5. Treatment repeats every 28 days for 18 cycles in the absence of disease progression or unacceptable toxicity."
3336026|NCT02143427|Experimental|Social Skills Training|Social Skills Training child-focused and subsequent social competence training which combines patient- and parent-/teacher and peer-focused interventions
3336027|NCT02143427|Active Comparator|Treatment Program with techniques to activate resources|Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training child-focused
3336028|NCT02143440|Other|Newly diagnosed type 2 patients|The initial assessment of daily insulin dose.
3235351|NCT01240044|Experimental|Thoracoabdominal rebalancing|In this group the newborns receive the thoracoabdominal rebalancing.
3235352|NCT01240057|Placebo Comparator|expectant management during pregnancy|watchful waiting during pregnancy
3235353|NCT01240057|Experimental|fetal endoluminal tracheal occlusion|fetoscopic balloon occlusion at 27 to 29+6 weeks of gestation
3235354|NCT01240070|Active Comparator|Usual Care|Clinical practice in type 2 diabetes treatment
3235355|NCT01240070|Active Comparator|Intensive Care|Intensive multi-factorial treat-to-target intervention, according to international guidelines, that includes both lifestyle intervention and a step-wise strategy for pharmacological treatment with a treat-to-target approach.
3235356|NCT01240083|Experimental|Thetaburst Stimulation|1: Thetaburst stimulation: right DLPFC continuous TBS followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 stimuli, 80% motorthreshold
3235357|NCT01240083|Experimental|High frequency rTMS|2: Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC, 110% motor threshold, followed by 1000 stimuli of 10 Hz over the left DLPFC , 110% motorthreshold
3336029|NCT02143453|Experimental|High intensity interval training|
3336030|NCT02143453|Experimental|Endurance training|
3336031|NCT02143466|Experimental|AZD6094|AZD9291 in combination with AZD6094
3336032|NCT02143466|Experimental|Selumetinib|AZD9291 in combination with selumetinib
3336033|NCT02143466|Experimental|MEDI4736|AZD9291 in combination with MEDI4736. Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study.
3336034|NCT02143466|Experimental|AZD6094 (monotherapy)|AZD6094 in monotherapy (for Japan only)
3336035|NCT02143479||1:early conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® in the first 3 months after transplantation
3336036|NCT02143479||2:late conversion from Prograf® to Advagraf®|patients converted from Prograf® to Advagraf® between 3 months and one year after transplantation
3336037|NCT02143505|Experimental|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements for 3 years
3336038|NCT02143505|Placebo Comparator|placebo|identical-appearing placebo supplements for 3 years
3235358|NCT01240083|Experimental|Placebo Stimulation|3: Sham Stimulation (Sham coil): right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
3235359|NCT01240096|Active Comparator|Mirtazapine|mirtazapine 15 mg daily
3336039|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel|High Dose Na-GST-1/Alhydrogel® Only
3235360|NCT01240096|Placebo Comparator|Placebo|Placebo once daily
3336040|NCT02143518|Experimental|30 µg Na-GST-1/Alhydrogel + CpG 10104|Low Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
3336041|NCT02143518|Experimental|100 µg Na-GST-1/Alhydrogel + CpG 10104|High Dose Na-GST-1/Alhydrogel® Plus 500 µg CpG 10104
3235361|NCT01240109|Active Comparator|propofol|
3235362|NCT01240109|Active Comparator|sevoflurane|
3336042|NCT02143531|Active Comparator|Group I|Patients will receive 4 mg of Ondansetron IV upon occurrence of nausea or vomiting
3336043|NCT02143531|Active Comparator|Group II|Patients will receive 1mg of Haloperidol IV upon occurrence of nausea or vomiting
3235363|NCT01240148|Experimental|1|150 μL intradermal injection of 1 μmol/L AZD3161
3235364|NCT01240148|Experimental|2|150 μL intradermal injection of 6 μmol/L AZD3161
3235365|NCT01240148|Experimental|3|150 μL intradermal injection of 30 μmol/L AZD3161
3235366|NCT01240148|Active Comparator|4|150 μL intradermal injection of 10 mg/mL Lidocaine
3235367|NCT01240148|Placebo Comparator|5|150 μL intradermal injection of AZD3161 placebo
3235368|NCT01240161||Patients with high grade gliomas|All subjects will have radiographically suspected or surgically proven de novo high grade gliomas. There are no control patients.
3235369|NCT01240174|Other|Intervention Arm|Single arm in the study of doctors receiving feedback about their antibiotic prescribing rate for acute bronchitis.
3235370|NCT01240187|Experimental|Experimental 1|
3235371|NCT01240187|Experimental|Experimental 2|
3336044|NCT02143544|Active Comparator|Preoperative intra-aortic balloon pump.|Intervention: Preoperative placement of the intra-aortic balloon pump.
3336045|NCT02143544|No Intervention|Control|No preoperative placement of the intra-aortic balloon pump.
3336046|NCT02143557|Experimental|Fat-Modified Breast Milk|Infants in this arm of the study were fed their own mother's breast milk where the fat layer was removed by centrifugation. Prior to feeding, extra energy and nutrients were added to the defatted breast milk.
3336047|NCT02143557|Active Comparator|MCT-formula group|Infants in this arm of the study were fed a MCT-containing medical food which is the current standard of care.
3235372|NCT01240213|Active Comparator|Vitamin D|2000 IU per day of Vitamin D
3235373|NCT01240213|Placebo Comparator|Placebo|
3235374|NCT01240226|Experimental|A|
3235375|NCT01240226|Experimental|B|
3235376|NCT01240239||telephone group|The telephone group must be healthy adults scheduled for an ENT surgery.
3336048|NCT02143570|Experimental|Darifenacin + Physiotherapy|Patients allocated to this group will receive Darifenacin 7.5mg daily in addition to physiotherapy for 12 weeks. This dose may be increased up to 7.5mg twice daily in follow-up visits in cases of refractory symptoms.
3336049|NCT02143570|Active Comparator|Physiotherapy|Patients allocated to this arm will receive a tailored pelvic floor exercise programme in addition to a matching placebo pill.
3336050|NCT02143596|Active Comparator|Bun/Cr based hydration|receive intravenous normal saline infusion and adjust infusion rate by Bun/Cr followed in the first 72 hours
3336051|NCT02143596|No Intervention|control|receive intravenous normal saline infusion as clinician's adjustment
3235377|NCT01240239||telemedicine group|This group if qualified will randomly be chosen to be in the telemedicine group.
3336052|NCT02143609|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336053|NCT02143609|Placebo Comparator|Sham oxygen|sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336054|NCT02143622|Experimental|LJM716+cetuximab|
3336055|NCT02143635|Experimental|Arm A|
3235378|NCT01240239||pre-anesthesia consultation|This will be the group that will be randomized to the pre-anesthesia clinic.
3235379|NCT01240252|Experimental|Type 2 Diabetes Mellitus Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3336056|NCT02143635|Experimental|Arm B|
3336057|NCT02143635|Experimental|Arm C|
3336058|NCT02143635|Experimental|Arm D|
3235380|NCT01240252|Experimental|Overweight or Obese Subjects with Normal Glucose Tolerance|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3235381|NCT01240252|Placebo Comparator|Non-Obese Control Subjects|Two hours after the start of deuterated glucose, subjects will receive human insulin (U100 Humulin) at a rate of 80 mU/m^2 surface area per minute one time over 4 hours.
3336059|NCT02143661||Critically ill patients in the newly designed ICU rooms|Critically ill patients treated in one of the newly designed ICU rooms.
3336060|NCT02143661||Critically ill patients in the conventional ICU rooms|Critically ill patients treated in one of the conventional rooms on the same ICU.
3235382|NCT01240265|Experimental|Vitamin D 150,000 units once|Single dose of vitamin D3 150,000 IU given orally once
3235383|NCT01240265|Experimental|Vitamin D 5000 units daily|Vitamin D3 5000 IU daily given orally for 28 days
3235384|NCT01240291|Experimental|alanyl-glutamine|Intravenous alanyl-glutamine (0.5 g/kg body weight/day)
3336061|NCT02143674|Experimental|INTERVENTION|Muscle stretching and Strength Training
3336062|NCT02143674|Experimental|Educated about physical exercises|
3336063|NCT02143687|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
3235385|NCT01240291|Placebo Comparator|normal saline|Intravenous placebo (normal saline; 0.9 %)
3235386|NCT01240369||VEGF-C low|
3235387|NCT01240369||VEGF-C high|
3235388|NCT01240369||miR-326 low|
3235389|NCT01240369||miR-326 high|
3235390|NCT01240395|Experimental|MBCT intervention|
3235391|NCT01240395|No Intervention|Control group|
3235392|NCT01240408|Experimental|Treatment group 1|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
3235393|NCT01240408|Experimental|Treatment group 2|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
3336064|NCT02143687|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
3336065|NCT02143687|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336066|NCT02143687|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
3336067|NCT02143700||Stable and exacerbated patients|Patients diagnosed of chronic obstructive pulmonary disease in a stable or exacerbated situation. Cognitive assessment of these patients will be performed.
3336068|NCT02143726|Active Comparator|sorafenib|Patients receive sorafenib 400 mg PO twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may cross over and receive everolimus 10 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3336069|NCT02143726|Experimental|sorafenib and everolimus|Patients receive sorafenib 400 mg PO twice daily and everolimus 5 mg PO once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3336070|NCT02143739||Newly diagnosed asthma patients|The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.
3336071|NCT02143752||Mindfulness|Smokers enter a Mindfulness Training for Smokers course
3336072|NCT02143752||Quit Line|Smokers attempt smoking cessation with the help of the Wisconsin Tobacco Quit Line
3336073|NCT02143765|Experimental|Mitiglinide|Mitiglinide 10 mg three times a day, orally, for 12 weeks
3336074|NCT02143765|Active Comparator|Acarbose|Acarbose 50 mg three times a day, orally, for 12 weeks
3336075|NCT02143791||Burst stimulation|At permanent implant with the Prodigy system, patients will be programmed with Burst stimulation
3336076|NCT02143804|Experimental|CG0070|oncolytic virus genetically modified to express GM-CSF
3336077|NCT02143817|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
3336078|NCT02143817|Experimental|Whole body vibration training plus L-citrulline|Lower-body exercise training on a vibration platform combined with L-citrulline supplemetation (6 grams/day)
3336079|NCT02143817|Experimental|Whole body vibration training & placebo|Lower-body exercise training on a vibration platform combined with placebo supplementation (6 grams/day)
3336080|NCT02143817|Experimental|L-citrulline supplementation|(6g per day)containing L-citrulline
3336081|NCT02143830|Experimental|Arm A: Good Risk Patients|Patients 18 years old or younger with marrow aplasia or single lineage cytopenias will be receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days), as used in our most current study that led to > 90% survival rates . Busulfan pharmacokinetics will not be used. All patients will receive rabbit ATG (4 doses x 4 days) prior to and granulocyte-colony stimulating factor (G-CSF) after transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells for all patients will be peripheral blood stem cells mobilized by treatment of the donor with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). Enrollment on this arm will include up to 50 patients.
3336082|NCT02143830|Experimental|Arm B: Intermediate Risk Patients|"Patients 18 years old or younger with MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). Busulfan pharmacokinetics will be used in this arm, as the dose of busulfan is higher. All patients will receive rabbit ATG (thymoglobulin) (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for prophylaxis against GVHD. The source of the stem cells for all patients will be peripheral blood stem cells induced and mobilized by treatment of the donor. T-cell will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).~The maximum number of patients enrolled in this arm will be 10."
3336083|NCT02143830|Experimental|Arm C: High Risk Patients|Patients 19 years old or older with marrow aplasia or MDS or AML will receive intravenous busulfan (4 doses x 2 days), cyclophosphamide (4 doses x 4 days) and fludarabine (4 doses x 4 days). In this study, we will test whether outcomes can be improved, yet engraftment maintained, with a slightly reduced dose of busulfan. Patients will receive rabbit ATG (4 doses x 4 days) prior to and G-CSF post transplant to promote engraftment. Cyclosporine will not be used for GVHD prophylaxis. The source of the stem cells will be peripheral blood stem cells collected from donors treated with G-CSF. T-cell depletion will be performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device). The maximum number of patients enrolled will be 10.
3336084|NCT02143856|Experimental|100 mg GLPG1205 fasted|Single dose of 100 mg GLPG1205 as two capsules of 50 mg after an overnight fast
3336085|NCT02143856|Experimental|100 mg GLPG1205 fed|Single dose of 100 mg GLPG1205 as two capsules of 50 mg exactly 30 minutes after the start of a high-fat, high-calorie breakfast
3336086|NCT02143882|Experimental|LAIV|All children will receive LAIV, currently available as the marketed product Fluenz
3336087|NCT02143908|Placebo Comparator|placebo supplementation|2000 mg placebo tablets/day
3336088|NCT02143908|Active Comparator|Supplementation|lysine 2000 mg tablets/day supplementation
3336089|NCT02143921|Experimental|Training Intervention|One service provider group received training
3336090|NCT02143921|No Intervention|Control|Control group service providers did not received intervention training
3336091|NCT02143934|Active Comparator|Primaquine|Primaquine, 0.5mg/kg/day, 20 days directly observed treatment Chloroquine, 25mg/kg total dose, divided over 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
3336092|NCT02143934|Placebo Comparator|Placebo|Placebo, 20 days directly observed treatment Chloroquine, mg/kg, 3 days directly observed treatment Artemether-Lumefantrine, 3 days BD
3235394|NCT01240434|Active Comparator|Fascia closure of the surgical trocars|Arm in which all the surgical trocar orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone)
3336093|NCT02143960|Active Comparator|Velashape III device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation
3336094|NCT02143960|Active Comparator|Noninvasive Cryolipolysis Device|A noninvasive device that reduces fat by freezing fat cells
3336095|NCT02143986||Macrophagic activation syndrome|
3336096|NCT02143986||Still's disease|
3336097|NCT02143986||Hyperferritinemia|
3336098|NCT02143986||Sepsis|
3336099|NCT02143999||Cohort|
3336100|NCT02144025|Experimental|Topical cyclosporine|This is a single arm study of patients who have received allogeneic bone marrow transplants performed with a reduced intensity conditioning regimen. In this arm, patients who are candidates to this trial, will receive topical cyclosporine twice a day for 12 months to prevent ocular graft versus host disease.
3336101|NCT02144038|Experimental|Phase Ib: LGH447 + BYL719|Dose-escalation, LGH447 in combinatinon with BYL719
3235395|NCT01240434|No Intervention|Trocar site without closure|All the orifices of the trocar site are left open, closing only the skin.
3235396|NCT01240447|Other|Best support treatment|
3235397|NCT01240447|Experimental|Racotumomab vaccine|
3235398|NCT01240460|Experimental|1|Twice-daily dosing (every 12 hours) XL765
3235399|NCT01240460|Experimental|2|Once-daily dosing XL147
3235400|NCT01240460|Experimental|3|Once-daily dosing XL765
3235401|NCT01240499|Experimental|Health-At-Every-Size (HAES)|
3336102|NCT02144038|Experimental|Phase II: LGH447 + BYL719|LGH447 + BYL719 (dosing according to MTD/RP2D from Phase Ib portion of the study)
3336103|NCT02144038|Experimental|Phase II: LGH447 alone|LGH447 alone (dosing according to single-agent RDE)
3336104|NCT02144051|Experimental|AZD5312|"AZD5312 will be given intravenously (IV) as an infusion, over one hour. For the purpose of planning, each 4 week period (28 days) will be called a Cycle. AZD5312 will initially be administered 4 times within the first 11 days, (on Days [1, 4, 8 and 11]± 2), with no dosing on sequential days. Patients will receive weekly treatments on Days 15 and 22 to complete Cycle~1. During the subsequent cycles, patients will receive weekly treatment on Days 1, 8, 15 and 22 (±2)."
3235402|NCT01240499|Active Comparator|Social Support (SS)|
3235403|NCT01240499|No Intervention|Control|
3336105|NCT02144064|Active Comparator|Group A(heparin group)|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
3336106|NCT02144064|No Intervention|Group B|group B (n = 100) receive no thing
3336107|NCT02144090|Experimental|Fractional flow reserve|Fractional flow reserve measurement
3336108|NCT02144103|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
3336109|NCT02144116|Experimental|Experimental group|Patients with fibromyalgia included in a dance-movement therapy programme
3336110|NCT02144116|Active Comparator|Control group|Patients with fibromyalgia who receive a standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
3336111|NCT02144129|Experimental|active WB-EMS|2 sessions/week with 20 min of active WB-EMS application
3235404|NCT01240512|Active Comparator|High Dose Arm|4000 IU/day Vitamin D3 (cholecalciferol) supplementation
3336112|NCT02144129|Experimental|Passive WB-EMS|2 sessions/week with 20 min of passive WB-EMS application in a resting supine position
3336113|NCT02144129|No Intervention|Inactive Control Group|sedentary non-training control group
3336114|NCT02144142|Experimental|Moisturizer with each subject's own antimicrobial bacteria|Each subject will have a moisturizer containing their own antimicrobial bacteria species spread over their arms in the clinic
3336115|NCT02144168|Active Comparator|prebiotics-free enteral formula|Patients in this arm will be receiving standard, prebiotics-free enteral formula : Osmolite 1 cal
3336116|NCT02144168|Experimental|prebiotics containing enteral formula|Patients in this arm will be receiving prebiotics containing enteral formula:Ensure Fos for 14 days
3336117|NCT02144181|Active Comparator|Group A|Subjects will receive two low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one low-density Ulthera System Treatment.
3336118|NCT02144181|Active Comparator|Group B|Subjects will receive three low-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two low-density Ulthera System Treatments.
3336119|NCT02144181|Active Comparator|Group C|Subjects will receive two high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive one high-density Ulthera System Treatment.
3336120|NCT02144181|Active Comparator|Group D|Subjects will receive three high-density Ulthera System Treatments. Protocol amended Sept 2014: Subjects will receive two high-density Ulthera System Treatments.
3336121|NCT02144194|Experimental|Maintenance treatment|"Initial treatment Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Followed by:~Oral Vinorelbine 60mg/m2 D1, D8 or 80mg/m2 D1, D8 (dose schedule at investigator's discretion) Every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue"
3336122|NCT02144194|Experimental|Observation arm|"Initial treatment: Vinorelbine-Docetaxel Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks for 6 cycles~Patients in the observation arm will not be administered any treatment after Vinorelbine-Docetaxel"
3336123|NCT02144207|Active Comparator|Glidescope: Unrestricted View|Unrestricted view of the larynx.
3336124|NCT02144207|Active Comparator|Glidescope: Restricted View|Restricted view of the larynx.
3336125|NCT02144246|Other|Pre-intervention|Patients will act as their own controls. Will have no hormones for 3 months
3336126|NCT02144246|Experimental|Post-intervention|Ortho-cyclen (or a generic equivalent) which is Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg
3336127|NCT02144272|Experimental|LY3114062 (SC)|LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.
3336128|NCT02144272|Experimental|LY3114062 (IV)|LY3114062 given once intravenous (IV).
3336129|NCT02144272|Placebo Comparator|Placebo|Placebo (sodium chloride injection) given as a single SC dose.
3336130|NCT02144298||cold blood cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cold blood cardioplegia.
3336131|NCT02144298||cristalloid cardioplegia|observe the perioperative course of sublingual microcirculatory alterations in patients undergoing coronary artery bypass grafting (CABG) using cristalloid cardioplegia.
3235405|NCT01240512|Active Comparator|Low Dose Arm|400 IU/day Vitamin D3 (cholecalciferol) supplementation
3336132|NCT02144311|Experimental|MRI with DW-MRI & DCE-MRI & FDG PET/CT|Study participants will have 1 scan within the 7 days immediately preceding surgery (PET/CT as standard of care and MRI as a research exam). MRI and PET/CT scanning procedures will be identical to those used in routine clinical examinations of the abdomen and pelvis.
3336133|NCT02144324|Experimental|Tandem Appliance|This group of patients will receive the new appliance which is called the Tandem Appliance
3336134|NCT02144324|No Intervention|Traditional Treatment|Patients in this group will be treated by the traditional Face Mask appliance.
3235406|NCT01240525|Other|CD4 DLI|Patients will receive trial product manipulated CD4 DLI post transplant as trial treatment.
3235407|NCT01240525|Other|No DLI|Patients will receive no DLI post transplant as trial treatment.
3235408|NCT01240538|Experimental|Treatment (virus and chemotherapy)|Patients receive wild-type reovirus IV over 60 minutes QD on days 1-5. Some patients also receive cyclophosphamide PO on days 1-21. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3336135|NCT02144350|Experimental|Intervention|patients will undergo daily hyperbaric oxygen sessions in addition to IV steroids for 10 days.
3235409|NCT01240629|Experimental|Arm I|Patients receive doxorubicin-GnRH agonist conjugate AEZS-108 intravenously (IV) over 2 hours once every 21 days (21 days = 1 cycle). Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3336136|NCT02144350|Sham Comparator|Sham|Patients will undergo sham hyperbaric air sessions in addition to IV steroids for 10 days
3336137|NCT02144376|Placebo Comparator|Maltodextrin|7 days without use of laxatives other than standardised rescue therapy 7 grams maltodextrin taken 3 times daily, at least 4 hours apart, for up to 7 days
3336138|NCT02144376|Active Comparator|Ispaghula|7 days without use of laxatives other than standardised rescue therapy 7 grams ispaghula/ psyllium taken 3 times daily, at least 4 hours apart, for up to 7 days
3336139|NCT02144389|Active Comparator|Praziquantel (PZQ)|A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school.
3336140|NCT02144389|Experimental|Arachidonic acid (ARA)|A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school.
3336141|NCT02144389|Experimental|PZQ + ARA|A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school.
3336142|NCT02144402|Active Comparator|infant formula with DHASCO|standard infant formula with docosahexaenoic acid (DHA)
3336143|NCT02144402|Experimental|infant formula with DHASCO-B|standard infant formula with DHA-B
3336144|NCT02144415|Experimental|EB-1020 400 mg|EB-1020 400 mg, administered as four 100-mg IR capsules and 4 matching placebo capsules
3235410|NCT01240642|Experimental|ASA404|
3235411|NCT01240655|Experimental|LCL161 + Paclitaxel|
3235412|NCT01240668||Hyponatremia Patients|Euvolemic or hypervolemic hyponatremia with serum sodium ≤130 mmol/L
3336145|NCT02144415|Experimental|EB-1020 800 mg|EB-1020 800 mg, administered as eight 100-mg IR capsules
3336146|NCT02144415|Active Comparator|lisdexamfetamine 150 mg|lisdexamfetamine 150 mg, administered as 3 capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 matching placebo capsules
3336147|NCT02144415|Active Comparator|d-amphetamine 40 mg|d-amphetamine 40 mg, administered as 4 capsules, each containing two 5-mg d-amphetamine tablets and 4 matching placebo capsules
3336148|NCT02144415|Placebo Comparator|Placebo|Placebo, administered as 8 matching placebo capsules
3336149|NCT02144428||Cow's milk allergy|Subjcets with a sure diagnosis of cow'a milk allergy on exclusion diet
3336150|NCT02144441|Experimental|Patient self-administered insulin|The study's only arm
3336151|NCT02144454|Active Comparator|Meal rich in saturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in saturated fats
3336152|NCT02144454|Experimental|Meal rich in monounsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in monounsaturated fats
3336153|NCT02144454|Experimental|Meal rich in n-6 polyunsaturated fats|Subjects are asked to consume a breakfast (0 min) and lunch (330 min) rich in n-6 polyunsaturated fats
3336154|NCT02144467||Large-sample healthy participants|MRI scanning.
3336155|NCT02144480|Experimental|Intensive training|intensive aerobic training in moderate intensity day5 postoperatively. 30 minutes per sessions, 2 sessions per day, 10 sessions per week. There will be 20 sessions in total.
3336156|NCT02144480|Sham Comparator|traditional training|traditional rehabilitation
3336157|NCT02144493||Patients with recurrent CBD stone|
3336158|NCT02144493||Patients without recurrent CBD stone|
3336159|NCT02144506|Experimental|T&E|"Home-based exercises program T&E.This exercise program proposes 50 exercises with a booklet, cards and an electronic tablet. The participants choose their exercises on the basis of a rating scale of perception of exercise difficulty."
3336160|NCT02144506|Active Comparator|OTAGO|"Programm OTAGO is a home-based exercises program."
3336161|NCT02144532|Experimental|Patients with EDS hypermobility type|Patients with EDS hypermobility type wearing compression garment then compression garment removal
3336162|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 33Fr bougie size and 2 cm distance from the pylorus.
3336163|NCT02144545|Experimental|Bougie Size 33Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 33Fr bougie size and 5 cm distance from the pylorus
3336164|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 2 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
3336165|NCT02144545|Experimental|Bougie Size 42Fr Distance pylorus 5 cm|Sleeve gastrectomy with a 42Fr bougie size and 2 cm distance from the pylorus
3336166|NCT02144558|Experimental|Spinal cord injured (SCI) men, para or tetraplegic|SCI men will have 4 medical visits associated to sperm retrieval (penile vibratory stimulation (PVS) or masturbation)
3336167|NCT02144571|Experimental|Lifestyle|Diet and physical activity intervention group. Measurements taken at baseline, 12 weeks and 1 year.
3336168|NCT02144571|No Intervention|Wait-list control|No-treatment control group. Measurements taken at baseline, 12 weeks and 1 year. People in the control condition can elect to take the intervention after 1 year.
3336169|NCT02144584|Placebo Comparator|Placebo plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will titrate up on the dose of placebo until taking twice daily. Participants will continue for 90 days with placebo. Continue with standard of care for other treatment of stroke.
3336170|NCT02144584|Active Comparator|Memantine plus standard of care|Participants will start taking either memantine or placebo within 24 hours after baseline testing and randomization is completed, but no later than day 8 post-symptom onset. Participants will use a titration schedule starting at 7mg daily for 1 week, increasing by 7mg (1 capsule) per week until at a goal dose of 28mg daily (goal dose) as recommend by the manufacturer. Participants will continue memantine for 90 days. Continue with standard care for stroke.
3336171|NCT02144623|Experimental|Valproate|
3336172|NCT02144636|Experimental|treament|herbalife protein shake along with exercise
3336173|NCT02144636|No Intervention|control|diet and exercise only
3336174|NCT02144649|No Intervention|Group I (control, no juice)|Patients consume no tomato juice.
3336175|NCT02144649|Experimental|Group II (tangerine tomato juice)|Patients will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks)
3336176|NCT02144649|Experimental|Group III (red tomato juice)|Patients consume two cans of red tomato juice daily until their scheduled surgery (approximately 4 weeks).
3336177|NCT02144662|Experimental|Ranibizumab|Ranibizumab
3336178|NCT02144688|Experimental|Change in ARVs to improve cognition|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
3336179|NCT02144727|Active Comparator|D2 distal subtotal gastrectomy|D2 distal subtotal gastrectomy D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
3336180|NCT02144727|Experimental|D1+ distal subtotal gastrectomy|D1+ distal subtotal gastrectomy D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
3336181|NCT02144740|Other|NWT-03, then placebo|4 weeks 2g NWT-03 followed by placebo , separated by a 4wk wash-out period
3336182|NCT02144740|Other|Placebo, then NWT-03|4 weeks placebo followed by 2g NWT-03, separated by a 4wk wash-out period
3336183|NCT02144753|Experimental|NTX-1|NTX-1 (18 g)
3235413|NCT01240681|Other|FLT PET and BOLD MRI scan|All subjects will have the study intervention of FLT PET and BOLD MRI at baseline and after the first cycle of chemotherapy
3235414|NCT01240694|Experimental|CEP-33457|200 mcg of CEP-33457
3336184|NCT02144753|Active Comparator|Psyllium|psyllium (15 g)
3336185|NCT02144766|Experimental|Ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
3336186|NCT02144766|Placebo Comparator|saline|caudal block with 1 ml/kg of saline
3336187|NCT02144779|Active Comparator|Usual care|No treatment for this group
3336188|NCT02144779|Experimental|Assigned to palliative care team|The intervention group will be assigned to a palliative care team member that will facilitate communication and meetings between families and the medical team
3336189|NCT02144792|Active Comparator|Control group (healthy persons)|Normal controls take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3336190|NCT02144792|Active Comparator|Patients with drug-resistant epilesy|Patients with drug-resistant epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3336191|NCT02144792|Active Comparator|Patients with drug-sensitive epilepsy|Patients with drug-sensitive epilepsy take a [11C] -verapamil PET scan. While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
3336192|NCT02144805|Active Comparator|Suturing in a single layer|The technique used for single layer to close the uterine incision following cesarean sectio
3336193|NCT02144805|Active Comparator|Suturing in two layer|The technique used for two layer technie to close the uterine incision following cesarean sectio
3336194|NCT02144818|Active Comparator|GnRH agonist|
3336195|NCT02144818|Active Comparator|hCG|
3336196|NCT02144818|Active Comparator|dual triggering: GnRH agonist and hCG|
3235415|NCT01240707|Other|LF tests, Fiberoptic bronchoscopy|Spirometry, Peak Expiratory Flow (PEF). Bronchoscopic assessment of soot in central airways.
3235416|NCT01240720|Experimental|I131-F16SIP|"Phase I: Multicentre, open-label, two-step singlearm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-F16SIP, given at the RD of 55.5 mCi/m2, as determined in phase I."
3336197|NCT02144831|Active Comparator|anti-thrombotic treatment|10 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
3336198|NCT02144831|Active Comparator|anti-thrombotic|30 days of ASA (75-325 mg) + Clopidogrel (75mg) anti-thrombotic treatment
3336199|NCT02144844|Experimental|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
3336200|NCT02144844|No Intervention|Treatment as Usual (TAU)|Treatment as Usual (TAU) Control
3336201|NCT02144870|Active Comparator|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
3336202|NCT02144870|Active Comparator|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
3336203|NCT02144883|Active Comparator|Materials|Self-help materials mailed to subjects home.
3235417|NCT01240759|Experimental|S-707106 Dose A|One S-707106 A tablet + 3 Placebo A tablets
3235418|NCT01240759|Experimental|S-707106 Dose B|One S-707106 B tablet + 3 Placebo A tablets
3235419|NCT01240759|Experimental|S-707106 Dose C|S-707106 Dose C = Four S-707106 B tablets
3235420|NCT01240759|Active Comparator|Metformin|The standard of care dose of metformin for the individual patient + 3 Placebo A tablets
3235421|NCT01240772|Experimental|DGALM|doppler-guided arterial ligation with mucopexy
3235422|NCT01240772|Active Comparator|SH|stapled haemorrhoidopexy according to Longo
3235423|NCT01240798||Depression, anxiety|
3235424|NCT01240824|Experimental|BCG + aminophylline|Bacillus Calmette-Guerin (BCG) plus one of three escalating doses of aminophylline administered intravesically.
3235425|NCT01240837|Active Comparator|glucose|
3336204|NCT02144883|Experimental|Telephone Counseling and Materials|Subjects received up to 9 telephone counseling calls plus self-help quit kit and 5 additional mailings
3336205|NCT02144896|Experimental|Ankle splinting|Older adults will have one leg randomly assigned to ankle splinting for 4 weeks. The non-splinted leg will serve as the control.
3336206|NCT02144896|No Intervention|No Ankle Splinting|The non splinted leg will serve as the control
3336207|NCT02144909|Experimental|Partners in Care with Semi-Structured Support Group|Partners in Care with Semi-Structured Support Group: participants will receive the Partners in Care intervention followed by 6 semi-structured support groups, conducted every other week for 3 months. Half of the support groups will be conducted by professionals with diabetes specific knowledge, e.g., pharmacists, physicians, nutritionists. While the other half will be conducted by the trained diabetes self-management facilitator.
3336208|NCT02144909|No Intervention|Partners in Care Standard Follow-up|Participants will receive the Partners in Care intervention followed by monthly healthy lifestyle tips related to diabetes self-management
3336209|NCT02144922|Placebo Comparator|Control|Patients continue taking their antihypertensive medication alone.
3336210|NCT02144922|Active Comparator|Pitavastatin|Pitavastatin 4 mg is given to study patients after a baseline assessment and continued for 1 year without further dose titration. Patients continue taking their antihypertensive medication during the entire follow-up period.
3336211|NCT02144935||myelitis, transverse or acute flaccid myelitis|Observational study with online survey participation highlighting outcomes recovery. The surveys can be completed by the child and parent, or if too young to participate, parent only. The survey asks how the child is doing after hospitalization within 6 months of diagnosis, and every 4 months until study end in 2024.
3235426|NCT01240837|Active Comparator|sucrose|
3336212|NCT02144948|Experimental|E.-coli-Nissle|10 patients will be enrolled Intervention: E.-coli-Nissle (Mutaflor), oral suspension Dose: 1 ml / day frequency: qd
3336213|NCT02144961||Ultrasound|Breast ultrasound in female patients who are post-mastectomy pursuing autologous tissue breast reconstruction surgery.
3336214|NCT02144974||Patients undergoing total pelvic exenteration|Patients undergoing total pelvic exenteration for gynecological malignancies and reconstruction of the pelvic floor with a TMG flap.
3235427|NCT01240837|Experimental|palm sugar|
3235428|NCT01240850|Active Comparator|Prednisone|
3235429|NCT01240850|Experimental|Methotrexate+Prednisone|
3235430|NCT01240876|Experimental|CEP-37247|
3235431|NCT01240876|Placebo Comparator|Matching placebo|
3235432|NCT01240889|Active Comparator|montelukast|luekotriene inhibitor
3336215|NCT02145000|Experimental|Rotavirus vaccine (BRV-PV)|Live attenuated bovine-human [UK] reassortant rotavirus vaccine manufactured by the Serum Institute of India, Limited (SIIL). The pentavalent vaccine (BRV-PV) contains rotavirus serotypes G1, G2, G3, G4, and G9 (≥5.6 log10 FFU/serotype/dose). The vaccine is in lyophilized form and supplied with 2.5 ml of citrate bicarbonate buffer that is added for reconstitution just before oral administration.
3336216|NCT02145000|Placebo Comparator|Placebo|Same constituents as the active vaccine but without the viral antigens; manufactured by SIIL.
3235433|NCT01240889|Active Comparator|Fluticasone|Nasal steroid
3235434|NCT01240928|Experimental|MK-2206 + exemestane +/- goserelin|Oral MK-2206 and oral exemestane and subcutaneous goserelin (for pre-menopausal participants only)
3336217|NCT02145013||Portal hypertension|Hepatectomy
3336218|NCT02145013||No portal hypertension|Hepatectomy
3336219|NCT02145052|Active Comparator|Continuous suture|0 non-looped PDS using a tapered needle starting at the superior and the inferior portions of the wound. Fascia is then approximated with at least 1cm distance from the edge of the fascia and 1cm advancement. The two sutures are then knotted in the center with 8 square knots.
3336220|NCT02145052|Active Comparator|Interrupted Suture|Using a tapered needle, 0 non-looped PDS interrupted figure of eight suture 1cm from the edge and advancing 1cm between each suture.
3336221|NCT02145065|Active Comparator|Plain Balloon Angioplasty|Plain Balloon Angioplasty
3336222|NCT02145065|Experimental|microcrystalline Paclitaxel Coated Balloon (PAK)|plain balloon angioplasty followed by mcPCB dilation
3336223|NCT02145091|Experimental|One all-day session|"Participants will complete on all-day study session with a moderately-high dose of psilocybin.~Preparation will include two days of screening, and an additional 8 hours of session preparation over at least 2 days. Follow-up will consist of an interview and MRI scan one day after the all-day session, a questionnaire follow-up 2 months after the all-day session, and a final follow-up 12-18 months after the all-day session."
3336224|NCT02145091|Experimental|Two all-day sessions|"Participants will complete two all-day study sessions, the first with placebo and the second with a moderately-high dose of psilocybin.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the second all-day session."
3235435|NCT01240941|Experimental|MK-2206|MK-2206 maximum tolerated dose found from Phase Ib trial (under a separate NCT number) taken orally on a weekly basis
3235436|NCT01240954|Active Comparator|OSIRIS|
3235437|NCT01240954|Experimental|OSIRIS other concentration 1|
3235438|NCT01240954|Experimental|OSIRIS other concentration 2|
3235439|NCT01240980|Experimental|BMS-903452 (0.1 mg) or Placebo - A1|(Healthy Subjects)
3235440|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - A2|(Healthy Subjects)
3235441|NCT01240980|Experimental|BMS-903452 (3.0 mg) or Placebo - A3|(Healthy Subjects)
3235442|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A4|(Healthy Subjects)
3235443|NCT01240980|Experimental|BMS-903452 (30 mg) or Placebo - A5|(Healthy Subjects)
3235444|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A6|(Healthy Subjects)
3235445|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - A7|(Healthy Subjects)
3235446|NCT01240980|Experimental|BMS-903452 (0.6 mg) or Placebo - B1|(Subjects with type 2 Diabetes Mellitus)
3235447|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - B2|(Subjects with type 2 Diabetes Mellitus)
3235448|NCT01240980|Experimental|BMS-903452 (120 mg) or Placebo - B3|(Subjects with type 2 Diabetes Mellitus)
3235449|NCT01240980|Experimental|BMS-903452 (10 mg) or Placebo - A11|(Healthy Subjects)
3235450|NCT01240980|Experimental|BMS-903452 (60 mg) or Placebo - A12|(Healthy Subjects)
3336225|NCT02145091|Experimental|Three all-day sessions|"Participants will complete three all-day study sessions, the first two with placebo and the third with a moderately-high dose of psilocybin. The majority of participants (over 90%) will be assigned to either one or two all-day sessions. A small minority of participants (less than 10%) will be assigned to three all-day sessions.~Preparation will include two days of screening and 8 hours of session preparation over at least 2 days, before the first all-day session. Follow-up will consist of an interview and MRI scan one day after each all-day session, a questionnaire follow-up 2 months after each all-day session, and a final follow-up 12-18 months after the third all-day session."
3336226|NCT02145091|Experimental|MRI of the acute effects of psilocybin|This is an optional arm consisting of two sessions where either placebo, a very-low dose of psilocybin, or a moderately-low dose of psilocybin will be administered. During each session, participants will undergo MRI scanning shortly after the administration of each dose. Study sessions may occur over one or two days. Participants who have previously completed an all-day session with psilocybin in this study will be eligible to volunteer for this arm.
3336227|NCT02145104|Experimental|Arm A|cilinidpine 10mg + valsartan 160mg
3336228|NCT02145104|Experimental|Arm B|cilnidipine 5mg + valsartan 160mg
3336229|NCT02145104|Active Comparator|Arm C|valsartan 160mg
3235451|NCT01240993|Active Comparator|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs (e.g., health care, child care, housing and education). The PE counselor will also provide a choice of pamphlets on age-related parenting topics each week from a series of pamphlets designed specifically for this study.
3336230|NCT02145117|Other|MBSR Training|Mindfulness Based Stress Reduction (MBSR) Training
3336231|NCT02145130|Experimental|denovoDerm|Autologous tissue-engineered dermal substitute
3336232|NCT02145130|Experimental|denovoSkin|Autologous tissue-engineered dermo-epidermal skin substitute
3336233|NCT02145143|Experimental|thyroid cancer patients|Patients will have lesional dosimetry with 124I PET/CT performed to quantify the baseline iodine avidity of index metastatic lesion(s). Patients will then receive vemurafenib (960 mg orally BID) for about 4 weeks, after which a second 124I PET/CT will be performed. For patients in whom the second 124I PET/CT demonstrates that > or = 2000 cGy can be achieved in at least one tumor with < 300 mCi of 131I, Thyrogen-stimulated standard dosimetry & therapeutic 131I will be performed/administered concurrently with vemurafenib. The drug will then be discontinued & tumor assessments will be conducted with serial radiologic scan(s) & thyroglobulins (scans will be performed at baseline, before 131I, 3-4 months following 131I, & 6 months after 131I). Patients whose tumors fail to demonstrate adequate iodine incorporation following vemurafenib to warrant 131I therapy, the study drug will be discontinued, a final tumor assessment will be performed, & the patient will be taken off the study.
3336234|NCT02145195|Experimental|Vitamin D (10 microgram/day)|Tablets with 10 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
3336235|NCT02145195|Experimental|Vitamin D (20 microgram/day)|Tablets with 20 microgram vitamin D3 (cholecalciferol) daily for 20 weeks.
3336236|NCT02145195|Placebo Comparator|Placebo control|Tablets with 0 microgram vitamin D daily for 20 weeks.
3336237|NCT02145208|Experimental|Medi-Tate iTind|TIND System
3336238|NCT02145221|Experimental|Music therapy|Music therapy post surgery
3336239|NCT02145221|No Intervention|No intervention|
3336240|NCT02145234|Experimental|SAD Panel 1:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3336241|NCT02145234|Experimental|SAD Panel 2:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3336242|NCT02145234|Experimental|SAD Panel 3:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3336243|NCT02145234|Experimental|SAD Panel 4:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3336244|NCT02145234|Experimental|SAD Panel 5:BMS-986089/Placebo|"BMS-986089 in a single subcutaneous administration~OR~Placebo matching with BMS-986089 in a single subcutaneous administration"
3336245|NCT02145234|Experimental|MAD Panel 1:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 multiple subcutaneous administrations weekly"
3336246|NCT02145234|Experimental|MAD Panel 2:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3336247|NCT02145234|Experimental|MAD Panel 3:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3336248|NCT02145234|Experimental|MAD Panel 4:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3336249|NCT02145234|Experimental|MAD Panel 5:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administration every 2 weeks~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3336250|NCT02145234|Experimental|MAD Panel 6:BMS-986089/Placebo|"BMS-986089 in multiple subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 in multiple subcutaneous administrations weekly"
3336251|NCT02145234|Experimental|MAD Panel 7:BMS-986089/Placebo|"BMS-986089 a single subcutaneous administrations weekly~OR~Placebo matching with BMS-986089 a single subcutaneous administration every 2 weeks"
3336252|NCT02145260|Active Comparator|Lower dialysate sodium|Dialysate sodium concentration of 138 mmol/L
3336253|NCT02145260|Experimental|Higher dialysate sodium|Dialysate sodium concentration of 142 mmol/L
3336254|NCT02145273|Experimental|Intervention|Subjects screen positive for depression and are offered a group Therapy intervention for depression: Interpersonal Psychotherapy for Depression Group.
3336255|NCT02145273|No Intervention|Control|Subjects screen positive for depression and are offered Treatment as usual: External referral.
3336256|NCT02145273|No Intervention|comparison|Subjects screen negative for depression: no referral or intervention.
3336257|NCT02145286|Experimental|Radiation Therapy|Stereotactic Body Radiation Therapy
3235452|NCT01240993|Experimental|Mothers and Toddlers Program|This intervention is an introductory, short-term, supportive, psychodynamic therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing. Mothers meet with an individual, MBT-trained psychodynamically-oriented therapist for 12 sessions. The intervention is conducted a clinic where mothers are enrolled in treatment for their substance abuse.
3235453|NCT01241006|Active Comparator|Dexamethasone|Single dose of Dexamethasone 12 mg PO and 4 days of placebo capsules
3235454|NCT01241006|Active Comparator|Prednisone|Prednisone 60mg PO capsules for 5 days
3336258|NCT02145312|Experimental|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
3336259|NCT02145325|Experimental|Expanded Tregs|Immune cells in the blood will be removed by leukopheresis procedure and stored for later manufacture of subject's Expanded Tregs cellular product. Two months following subject's kidney transplantation, subject will be given an Expanded Tregs infusion intravenously in the Northwestern Clinical Research Unit.
3336260|NCT02145338|Experimental|Antibiotic prophylaxis|Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
3336261|NCT02145338|Other|No prophylaxis|The control arm will be a strategy of no prophylaxis. Participants will self-monitor their symptoms as usual and report to their General Practitioner if they develop symptoms and signs suggestive of UTI requiring treatment.
3336262|NCT02145351|Active Comparator|Pacing off|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
3336263|NCT02145351|Experimental|Pacing on|In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.
3336264|NCT02145364|Experimental|Ultherapy® treatment of acne scars|Subjects receiving dual depth treatment of acne scars using the 7MHz,3.0mm and 10MHz,1.5mm transducers.
3336265|NCT02145377|Experimental|PXVX0200 10E8 then placebo|PXVX0200 10E8 on day 0; Placebo on day 14
3336266|NCT02145377|Experimental|Placebo, then PXVX0200 10E8|Placebo on day 0; PXVX0200 10E8 on day 14
3336267|NCT02145377|Experimental|PXVX0200 10E9 then Placebo|PXVX0200 10E9 on day 0; Placebo on day 14
3336268|NCT02145377|Experimental|Placebo then PXVX0200 10E9|Placebo on day 0; PXVX0200 10E9 on day 14
3336269|NCT02145377|Active Comparator|Shanchol|Two doses of Shanchol, on day 0 and day 14
3336270|NCT02145442|Experimental|Obex|Obex®, two oral sachets daily during three months.
3336271|NCT02145455|Active Comparator|Mechanical alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes mechanical alignment via measured resection to establish knee alignment.
3336272|NCT02145455|Active Comparator|Anatomic alignment|Patients in this arm will have the Unity Total Knee Replacement System implanted using a surgical technique that utilizes anatomic alignment via ligament balancing with the tibial cut perpendicular to the tibial anatomic axis.
3235455|NCT01241019|Experimental|Topiramate|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia and topiramate
3336273|NCT02145481|No Intervention|Survey development|Patients with coronary artery disease will be given a survey to complete assessing their knowledge, communication with physicians, involvement, and treatment preferences after completing the treatment decision-making process.
3336274|NCT02145481|Experimental|Decision Aid|Patients with stable coronary artery disease will be given a decision aid to review prior to making a treatment decision.
3336275|NCT02145481|Active Comparator|CAD Education|Patient with coronary artery disease will be given a general educational handout on coronary artery disease.
3336276|NCT02145494|Experimental|Treatment|Radiotherapy
3235456|NCT01241019|No Intervention|Control|Newborns with hypoxic ischemic encephalopathy treated with mild hypothermia
3336277|NCT02145507|Other|Arm 1: Room Temperature Storage/Filtration|In vitro whole blood storage, leukoreduction and processing of donated whole blood.
3336278|NCT02145507|Other|Arm 2 : Cold storage|In vitro analysis of whole blood following refrigerated storage for > 66 hours prior to leukoreduction and subsequent processing of packed red blood cells.
3336279|NCT02145520|Experimental|Magnesium sulfate|Magnesium sulfate. Single dose intravenous over one hour.
3336280|NCT02145520|Placebo Comparator|placebo|"Treatment will be delivered to enrolled patients as currently practice in PEC (Epinephrine nebulization +5%hypertonic saline with/without dexamethasone).~•All patients will be randomized to receive either Magnesium sulfate over 1 hour or placebo.•Bronchiolitis severity score (BSS) will be recorded at 0, 4, 8, 12, 16,20,24,36,48,60,72 hours, and on discharge."
3235457|NCT01241032|Experimental|Udenafil|Udenafil 200mg
3235458|NCT01241032|Active Comparator|Udenafil + Alcohol|Udenafil 200mg + Alcohol
3336281|NCT02145533||Group I|patient with ruptured aneurysms
3336282|NCT02145533||Group II|patients with non-ruptured aneurysms
3336283|NCT02145533||Group III|Healthy volunteers
3336284|NCT02145546|Experimental|Amiodarone|Patient will take Amiodarone orally
3336285|NCT02145546|Experimental|Sotalol|Patients will take sotalol orally
3336286|NCT02145546|Experimental|Propafenone|Patients will take propafenone orally
3336287|NCT02145546|No Intervention|Control|Patients will take no antiarrhythmic drugs except β-blocker
3336288|NCT02145559|Experimental|Metformin XR|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will recieve metformin XR (500 mg daily with the evening meal)(through day 21). On day 15, patients randomized to metformin XR will have their dose increased to 1000 mg daily if there is no grade ≥ 2 toxicity due to metformin XR. Patients who develop grade 2 toxicity due to metformin will be maintained on metformin XR 500 mg daily for the rest of the study, while patients who develop > grade 2 toxicity will be taken off study. From day 22 onwards, all patients will be on combination of sirolimus and metformin.
3336289|NCT02145559|Active Comparator|Delayed Metformin|All eligible patients with histologically-confirmed advanced solid tumors will be started on sirolimus (3 mg daily) alone for the first 7 days. On day 8, patients will be randomized to receive no metformin for two weeks (through day 21). From day 22 onwards, all patients will be on combination of sirolimus and metformin. Patients who were initially not randomized to metformin XR will begin taking it at 500 mg daily with an evening meal and titrated up to 1000 mg daily after one week, as above. Each cycle will be 4 weeks.
3336290|NCT02145572||Obese adolescents with type 2 diabetes|No intervention
3336291|NCT02145572||Obese adolescents without diabetes|No intervention
3336292|NCT02145572||Healthy non-obese adolescents|No intervention
3336293|NCT02145585||Robotic pharmacological system|Robotic pharmacological system/Automated anesthesia delivery system
3336294|NCT02145598|Experimental|Lenalidomide|Lenalidomide 10mg/day
3336295|NCT02145598|Placebo Comparator|Placebo|Placebo
3336296|NCT02145611|Active Comparator|vildagliptin|Vildagliptin: Dosage: 100 mg/day; Duration: 12 weeks
3336297|NCT02145611|Active Comparator|glibenclamide|Glibenclamide: Dosage: 5 mg to 20 mg; Duration: 12 weeks
3336298|NCT02145624|Active Comparator|Repevax|Repevax in pregnancy
3336299|NCT02145624|Active Comparator|Boostrix-IPV|Boostrix-IPV in pregnancy
3336300|NCT02145624|No Intervention|unvaccinated|unvaccinated mothers
3336301|NCT02145637|Experimental|Afatinib plus Ruxolitinib combination (single arm)|
3336302|NCT02145650||All Participants|Patients with a diagnosis of CP, MS, Stroke, SCI, or TBI will be evaluated for spasticity by their healthcare provider. Patients diagnosed with spasticity requiring treatment will be enrolled in the study. There is no intervention administered in this study.
3336303|NCT02145689|Experimental|onabotulinumtoxinA Dose 1|Up to 4 treatments of onabotulinumtoxinA Dose 1 injected into muscles of the study limb on fulfillment of the retreatment criteria.
3336304|NCT02145689|Experimental|onabotulinumtoxinA Dose 2|Up to 4 treatments of onabotulinumtoxinA Dose 2 injected into muscles of the study limb on fulfillment of the retreatment criteria.
3336305|NCT02145702|Experimental|Exercise Group|Subjects randomized to this group will start 12 weeks of supervised aerobic exercise after baseline testing.
3336306|NCT02145702|Experimental|Control Group|Subjects randomized to this group will continue with 12 weeks of Standard Care. After 12 weeks, the subjects will cross over to the exercise arm and undergo baseline testing again and then start 12 weeks of exercise intervention.
3336307|NCT02145715|Experimental|Velcade, Thalidomide, Dexamethasone (VTD) + Panobinostat|"Up to 16 cycles of VTD+Panobinostat followed by panobinostat maintenance for 1 year or until disease progression.~Induction - Cycles 1-16 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1 and 8~Thalidomide: 100mg (PO)on days 1 -21~Dexamethasone: 20 mg (PO) on days 1, 2, 8 and 9~Panobinostat: 10mg, 15mg or 20mg days 1, 3, 5, 8, 10 and 12 Dose depends on cohort entry at registration during the dose escalation phase. The recommended dose will be used during the expansion phase.~Panobinostat monotherapy maintenance for 1 year. Panobinostat will be given at the same dose as the recommended dose during expansion phase"
3336308|NCT02145728|Experimental|Individual Cognitive Functional Therapy|The intervention being tested has four main components: (1) a cognitive component, for each patient, their vicious cycle of pain will outlined in a diagram based on their findings from the examination and the Orebro Musculoskeletal Pain Screening Questionnaire; (2) specific movement exercises designed to normalize maladaptive movement behaviours; (3) targeted functional integration of activities in their daily life previously, reported to be avoided or provocative by the patient; and (4) a physical activity and lifestyle programme.
3336309|NCT02145728|Active Comparator|Group Exercise Classes|6 classes will take place in total. The class has 3 components each week. First, a 30 minute talk and discussion on chronic pain, and some tips for participants. Second, a 40 minute exercise circuit, involving aerobic exercise, and gentle stretching and strengthening exercises. Finally, a 5 minute relaxation/mindfulness session will take place at the end. The total time involved is approximately 1 hour and 15 minutes.
3235459|NCT01241045||misoprostol|"2 groups:-~Group 1:-those with Ph<5. (n=50).~Group 2:-those with Ph > or=5. (n=50). -Each group is subdivided into another two groups:-~Group 1A (n=25). - Group 1B (n=25).~Group 2A (n=25). - Group 2B (n=25).~All the women in group 1A and group 2A will receive intravaginal misoprostol tablets moistened with 3 ml of 5% acetic acid, and all the women in group 1B and group 2B will receive intravaginal misoprostol tablets moistened with water, 400 micrograms every 4 hours for a maximum of 5 doses within 24 hours. If the patient will not have adequate uterine contractions, the same regimen will be repeated over the following 24 hours"
3235460|NCT01241071|Experimental|Myofascial treatment|Myofascial release techniques of different muscles implicated in low back pain
3235461|NCT01241071|Placebo Comparator|Placebo|
3235462|NCT01241084|Placebo Comparator|Placebo|Antileukotrienes+Placebo
3235463|NCT01241084|Active Comparator|Lactobacillus reuteri|Antileukotrienes+Lactobacillus reuteri
3336311|NCT02145767|Experimental|Progesterone|Progesterone 200mg suppository administered vaginally at bedtime until 34 completed weeks of pregnancy.
3336312|NCT02145767|Placebo Comparator|Placebo|Similar appearing suppository containing vehicle alone administered vaginally at bedtime until 34 completed weeks of pregnancy.
3336313|NCT02145780|Experimental|2g of grape polyphenol extract supplement|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
3336314|NCT02145780|Placebo Comparator|2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
3336315|NCT02145793|Active Comparator|ADHD Group Curriculum|Participants assigned to the group visit intervention agree to participate in 5 group visits every 3 months rather than individual ADHD follow-up visits to the clinic. Parents and children participate in separate but simultaneously run groups. Group portion is 60 minutes and then parent-child dyads complete individual visits for medication titration and physical exam.
3336316|NCT02145793|No Intervention|Control|Participants continue to go to the clinic for 5 routine ADHD follow-up visits to the clinic every 3 months as usual clinical protocol.
3336317|NCT02145819|Placebo Comparator|A: spontaneous LH peak|In group A, embryos are thawed 4 days after LH surge, with a re-evaluation and transfer 5 days after LH surge.
3336318|NCT02145819|Active Comparator|B: hCG|In group B, embryos are thawed 5 days after hCG administration, with a re-evaluation and transfer 6 days after hCG.
3336319|NCT02145832|Experimental|Fluconazole|"Fluconazole Kabi, Fresenius 2mg/ml~Fluconazole will be administered at a loading dose of 25 mg/kg on the first day and followed by a maintenance dose of 12 mg/kg or 20 mg/kg once daily, depending of corrected gestational age (GA) at the beginning of treatment:~12 mg/kg/day for neonates corrected GA (GA + postnatal age) < 30 weeks~20 mg/kg/day for neonates corrected GA (GA + postnatal age) ≥ 30 weeks~The infusion will last two hours."
3336320|NCT02145832|Experimental|Micafungin|"Mycamine 50mg - 10 mg/mL of micafungin~Micafungin will be administered as a loading dose of 15 mg/kg on the first day of treatment and followed by a maintenance dose of 10 mg/kg once daily.~The infusion will last two hours."
3336321|NCT02145845|Experimental|Treatment|Injectable SIS
3336322|NCT02145871|Active Comparator|Standard fluid management|The non-intervention group will receive maintenance crystalloid fluid at 10cc/kg/h. Blood loss will be replaced 1:1 with albumin. Transfusion will follow transfusion criteria. Fluid management will not be dependent on the EV1000
3336323|NCT02145871|Experimental|Goal directed fluid therapy (GDT)|In the GDT arm, patient's SV will be optimized before induction with crystalloid boluses prior to induction of general anesthesia. The GDT arm will have fluid therapy guided by the Edwards EV1000-clinical platform and maintenance crystalloid fluid will be 3cc/kg/h. During the surgical procedure when SVV rises above 12 an albumin bolus will be administered at 250 ml increments until the SVV falls below 8. Transfusion will follow transfusion criteria.
3235464|NCT01241097|Experimental|high-dose simvastatin, combined, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
3336324|NCT02145884|Experimental|timolol maleate 0.5% gel|timolol gel 1 to 2 drops twice a day to lesions for 4 months
3336325|NCT02145897|Experimental|Autologous Stromal Vascular Fraction|single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
3336326|NCT02145897|Experimental|Autologous Adipose Derived MSCs|One dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
3336327|NCT02145897|Active Comparator|Control|
3235465|NCT01241110|Active Comparator|azitromicin,PID treatment,ofluxacin|
3235466|NCT01241123|Placebo Comparator|Traditional Ambulation regimen|All patients will receive pedometers to record the total amount of ambulation. These patients will ambulate without limitations or goals. Most surgeons request that post-operative patients ambulate at least 2 to 3 times a day.
3336328|NCT02145910|Experimental|WBRT + Vemurafenib|Patients undergo WBRT once daily (QD) for 10 doses
3336329|NCT02145910|Experimental|SRS + Vemurafenib|Patients undergo SRS (gamma knife, tomotherapy, cyberknife, or megavoltage LINAC radiation therapy) on day 1
3336330|NCT02145923|Other|allogeneic MMSCs infusion|Subjects will undergo peripheral blood stem cell mobilisation and collection with subsequent high-dose chemotherapy. After finalization of high-dose chemotherapy subjects will receive bone marrow derived allogeneic multipotent mesenchymal stromal cells intravenous infusion two hours prior to autologous peripheral blood cells infusion.
3235467|NCT01241123|Active Comparator|Walkers|All patients will receive pedometers to record the total amount of ambulation. Patients in the experimental group will have assigned nursing staff assisting in ambulation in these patients at least three times a day.
3235468|NCT01241136|Placebo Comparator|Open traditional pilonidal cystectomy|traditional complete wide-excision pilonidal cystectomy
3336331|NCT02145936|Experimental|oleic acid diet|Participants are provided with meals enriched in oleic acid (18:1)
3336332|NCT02145936|Experimental|palmitic acid diet|Participants are provided with meals enriched in palmitic acid (18:0)
3336333|NCT02145936|Experimental|stearic acid diet|Participants are provided with meals enriched in stearic acid (18:0)
3336334|NCT02145949|Experimental|Essential Amino Acids (EAA)|"Aim 1: Twice-daily ingestion of 20 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 2.2 g (11% of total); isoleucine, 2.0 g (10%); leucine, 3.6 g (18%); lysine, 3.2 g (16%); methionine, 0.6 g (3%); phenylalanine, 3.2 g (16%); threonine, 2.8 g (14%); and valine, 2.4 g (12%).~Aim 2: Twice-daily ingestion of 23 g of EAA for 1 wk before through 6 wk after TKA.~Supplement composition for the EAAs: histidine, 1.28 g (5% of total); isoleucine, 1.8 g (8%); leucine, 7.4 g (32%); lysine, 3.6 g (15%); methionine, 1.76 g (8%); phenylalanine, 3.1 g (13%); threonine, 1.9 g (8%); valine, 2.08 g (9%); and tryptophan, 0.5 g (2%)."
3336335|NCT02145949|Placebo Comparator|Placebo (Alanine)|"Aim 1: Twice-daily ingestion of 20 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 20 g (100%) alanine.~Aim 2: Twice-daily ingestion of 23 g of Alanine (Non-essential amino acid) for 1 wk before through 6 wk after TKA.~The placebo supplement consists of 23 g (100%) alanine."
3336336|NCT02145962|Active Comparator|Forearm tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the medical services site of the Autonomous University of Nuevo Leon, Monterrey, Mexico. These study patients should receive treatment in the forearm region.
3336337|NCT02145962|Active Comparator|Thorax tissue exposure with ELF-MF|This study arm should include subjects with diabetic foot ulcers recruited at the IMSS Regional General Hospital N. 1 and Servicios de Salud de Morelos, Cuernavaca, Mexico. These study patients received treatment in the thorax region.
3336338|NCT02145975|Experimental|Fentanyl|"Procedure: Fentanyl for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
3336339|NCT02145975|Active Comparator|Morphine|"Procedure: Morphine for rescue of acute postoperative pain in the postanesthesia care unit~Intervention:~The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized."
3336340|NCT02145988|Experimental|DLBS1033|DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
3336341|NCT02145988|Placebo Comparator|Placebo|Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period
3336342|NCT02146014|Experimental|Transcranial Direct Current Stimulation|These subjects will receive real transcranial direct current stimulation.
3235469|NCT01241136|Experimental|Minimal invasive pilonidal cystotomy|Using only Keyes Trephines to unroof and curette the pilonidal cyst cavity
3336343|NCT02146014|Placebo Comparator|Sham tDCS|These subjects will receive sham transcranial direct current stimulation (placebo)
3336344|NCT02146027|Experimental|Fermented Milk Drink Yakult 40|"Lactobacillus casei Shirota, contained in the Fermented Milk Drink Yakult 40~Once daily Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks."
3336345|NCT02146027|Placebo Comparator|Placebo|"The placebo would be an analogous product without Live Lactic Bacteria (Lactobacillus casei Shirota) presented in the same bottle and similar flavor.~Both, Yakult 40 and placebo should be stored refrigerated between 1° and 10°C and"
3336346|NCT02146053|Active Comparator|Ferrous sulfate|ferrous sulfate taken at mealtimes twice daily during 1 week of the treatment period.
3336347|NCT02146053|Placebo Comparator|Placebo|placebo taken at mealtimes twice daily during 1 week of the treatment period.
3336348|NCT02146079|Experimental|Semaglutide 0.5 mg|Dose-escalation trial
3336349|NCT02146079|Placebo Comparator|Semaglutide placebo 0.5 mg|
3336350|NCT02146079|Experimental|Semaglutide 1.0 mg|Dose-escalation trial
3336351|NCT02146079|Placebo Comparator|Semaglutide placebo 1.0 mg|
3336352|NCT02146092|Active Comparator|Standard physiotherapy|Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
3336353|NCT02146092|Experimental|Incentive Spirometry|"Patients in the Incentive Spirometry arm will receive standard physiotherapy care in addition to training and use of an incentive spirometer. The physiotherapy care includes routine care as per current institutional standards.~They will also receive an incentive spirometer on the first postoperative day and will be taught how to use it with an accompanying instructional sheet for later reference. Teaching will emphasize slow deep breathing, sustained vacuum pressure, and gradual increase in difficulty. Patients will be instructed to use the spirometer 10 times every hour until 30 days after surgery."
3336354|NCT02146118|Experimental|Erlotinib and Silibin|
3336355|NCT02146144|No Intervention|no peeling|where the ILM peeling will not be made
3336356|NCT02146144|Active Comparator|active peeling|where the ILM peeling will be made
3336357|NCT02146157|Active Comparator|herb and mineral combination product|Subjects will consume 3 herb and mineral combination product softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period.
3336358|NCT02146157|Placebo Comparator|placebo|Subjects will consume 3 softgels daily, 1 softgel immediately before each of the 3 largest meals, throughout the 12-week supplementation period
3336360|NCT02146183|Placebo Comparator|placebo / Corn starch|Carbohydrate-containing composition that comprises 2 g carbohydrate per kg of body weight. This composition will be 500 mg placebo starch corn.
3336361|NCT02146183|Active Comparator|Carbohydrate steviol glycosides|500 mg steviol glycosides.
3336362|NCT02146196|Experimental|Heart failure, robotic assisted training|4 weeks robotic assisted training with the Lokomat®
3336363|NCT02146196|Experimental|Post cardiac surgery|One week robotic assisted gait training with the Lokomat®
3336364|NCT02146209|Experimental|Test Product Formula A|Metronidazole benzoate
3336365|NCT02146209|Active Comparator|Reference Product Formula B|Flagyl 125 mg/5 ml oral suspension
3336366|NCT02146209|Active Comparator|Reference Product Formula C|Flagyl 400 mg Tablets
3336367|NCT02146222|Experimental|Arm I (high dose X-82, docetaxel)|Patients receive high dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15. Beginning course 2, patients also receive docetaxel IV over 60 minutes on day 1.
3336368|NCT02146222|Experimental|Arm II (low dose X-82, docetaxel)|Patients receive low dose VEGFR/PDGFR dual kinase inhibitor X-82 PO QD on days 2-15 and docetaxel IV as in Arm I.
3336369|NCT02146235|Experimental|Treatment Group - Music Therapy|The experimental group participates in once weekly group music therapy session for 6 weeks using playing of simple wind instruments, singing, and music visualization. The Music therapy session lasts 45 min. and encourages patients to use breathing techniques to achieve a relaxation response. Extructured techniques involving singing, music improvisation supports breath pattens and provides supporting coping styles. The use of wind instruments involves a focus of breathing efficiently and elongating the exhalation to prolong musical tones and transferring breath control. Music Visualization involving deep breathing techniques provides optimal mind-body connection, influences breathing rhythms through more indirect means while reducing stress, accessing altered states and encourages healing imagery.
3336370|NCT02146235|No Intervention|Standard Pulmonary Rehabilitation|"Pulmonary rehabilitation is a program to people with chronic lung diseases like COPD, emphysema, and chronic bronchitis lead full, satisfying lives and restore them to their highest functional capacity. Pulmonary rehab is aimed to improve quality of life by:~Decreasing respiratory symptoms and complications Encouraging self-management and control over daily functioning Improving physical conditioning and exercise performance Improving emotional well-being Reducing hospitalizations~Pulmonary rehab programs include:~Medical management Exercise Breathing retraining Education Emotional support Nutrition counseling"
3336371|NCT02146261|Experimental|1|Subcutaneous administration of E6011 50 mg
3336372|NCT02146261|Experimental|2|Subcutaneous administration of E6011 100 mg
3336373|NCT02146261|Experimental|3|Subcutaneous administration of E6011 200 mg
3336374|NCT02146261|Experimental|4|Subcutaneous administration of E6011 400 mg
3336375|NCT02146261|Placebo Comparator|5|Subcutaneous administration of placebo
3235470|NCT01241149|Active Comparator|Normal pH, abnormal Impedance|After 24hr pH-metry and impedance, those patients with normal pH (i.e. DeMeester score <14.7) but with abnormal impedance scores will be offered anti-reflux surgery
3336376|NCT02146287|Active Comparator|Early Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 28 weeks PMA
3336377|NCT02146287|Active Comparator|Late Cycled Light|Infants received day night cycling of light on a 12-hour on and 12-hour off basis beginning at 36 weeks PMA
3336378|NCT02146300|Experimental|Allergen and xylometatsolin|Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
3235471|NCT01241149|Placebo Comparator|Abnormal pH|After 24hr pH-metry and impedance, those with abnormal pH scores (i.e. DeMeester score >14.7)will be offered anti-reflux surgery
3336379|NCT02146313|Experimental|Dose-escalation Cohort|DMUC4064A will be administered to participants at a starting dose of 1.0 milligram per kilogram (mg/kg) by IV infusion q3w and would be monitored for DLTs for 21 days after first infusion of Cycle 1 (cycle length=21 days).
3336380|NCT02146313|Experimental|Platinum-resistant Ovarian Cancer Dose-expansion Cohort|Platinum-resistant Ovarian Cancer participants will be administered with the identified RP2D during the Dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
3336381|NCT02146313|Experimental|Unresectable Pancreatic Cancer Dose-expansion Cohort|Unresectable pancreatic cancer participants will be administered with the identified RP2D during the dose-escalation of DMUC4064A q3w IV for up to until disease progression or death, whichever occurs first.
3235472|NCT01241162|Experimental|Single arm study|Biological/Vaccine: Autologous dendritic cell vaccine with adjuvant
3235473|NCT01241175|Experimental|magnesium sulfate|
3336382|NCT02146339|Experimental|Unfortified-3g-5g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3235474|NCT01241175|Placebo Comparator|normal saline|
3235475|NCT01241188|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3336383|NCT02146339|Experimental|Unfortified-5g-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3336384|NCT02146339|Experimental|3g-5g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3336385|NCT02146339|Other|3g-Unfortified-5g milk polar lipid fortified cheese product|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
3336386|NCT02146339|Experimental|5g-unfortified-3g milk polar lipid fortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3336387|NCT02146339|Other|5g-3g milk polar lipid fortified-unfortified cheese product|Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of [1,1,1]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3336388|NCT02146378||Vyndaqel|
3336389|NCT02146391|Experimental|Androxal 25 mg|
3336390|NCT02146404|Active Comparator|Euglycemia|Plasma glucose levels will be clamped at a constant value of ~5.0 mmol/l
3336391|NCT02146404|Experimental|Hypoglycemia|Plasma glucose levels will be clamped at a stable value of ~3.0 mmol/l
3336392|NCT02146417|Active Comparator|Normal pressure pneumoperitoneum & deep neuromuscular block|Normal pressure pneumoperitoneum
3235476|NCT01241188|Active Comparator|2 TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3235477|NCT01241201|Placebo Comparator|Placebo|placebo for probiotic treatment
3336393|NCT02146417|Experimental|Low pressure pneumoperitoneum & deep neuromuscular block|Low pressure pneumoperitoneum
3336394|NCT02146443|Active Comparator|Baseline|Completion of the star shaped manual dexterity test, five rounds clockwise and five rounds counter clockwise without any intervention. Time and number of errors are recorded. Measurement of static arm strength with the stretched arm test. test subject is asked to hold a 2.5 kg weight in stretched arm for as long as possible. Maximum endurance time is recorded.
3235478|NCT01241214|Experimental|Investigational drug - Dose 1|
3235479|NCT01241214|Experimental|Investigational drug - Dose 2|
3336395|NCT02146443|Active Comparator|Fatigue|Prior to completion of the star shaped manual dexterity test, the test subject is asked to stand up still and hold a 2.5-kg weight with the dominant arm fully extended as long as possible without moving. Maximum endurance time is recorded. After this, the test subject completes the the star shaped manual dexterity test and time and number of errors are recorded.
3336396|NCT02146443|Active Comparator|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test. Completion time and number of errors are recorded.
3336397|NCT02146443|Active Comparator|Fatigue and Stress|The test subject will be fatigued prior to the test (as detailed in the fatigue arm), and asked to identify cards during completion of the star shaped manual dexterity test (as detailed in the stress arm). Completion time and number of errors are recorded.
3336398|NCT02146456|No Intervention|Colloid|During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.
3336399|NCT02146456|Experimental|Tranexamic acid|"During the operation, Lactate Ringer's solution is used as the maintenance fluid, and colloid is infused for the compensation of the intraoperative blood loss.~In addition, 1 g of tranexamic acid in 100 ml normal saline is administered intravenously over 30 min after finishing the procedure of hip implant insertion."
3336400|NCT02146469|Experimental|None varicella vaccine history|2 doses with an 3 months interval
3336401|NCT02146469|Experimental|1 year after first dose|A second dose with an 1 year interval
3336402|NCT02146469|Experimental|3 years after first dose|A second dose with an 3 year interval
3336403|NCT02146469|Experimental|5 years after first dose|A second dose with an 5 year interval
3336404|NCT02146469|Experimental|Testing group for conbined immunization|1 dose Varicella vaccine and 1 dose MMR given at the same time
3336405|NCT02146469|Placebo Comparator|Control group for conbined immunization|1 dose MMR
3336406|NCT02146495|Active Comparator|Amygdala EEG-NF|Amygdala activity based EEG-NF
3336407|NCT02146495|Placebo Comparator|Sham EEG-NF|Sham EEG-NF
3336408|NCT02146495|No Intervention|Change in drug therapy|Pain and sleep quality measured after a change in drug therapy performed by the treating physician irrespective of the study - an observational arm
3336409|NCT02146495|Active Comparator|A/T EEG-NF|EEG-NF based on alpha/Theta ratio
3336410|NCT02146508|Experimental|Endoscopic treatment|Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
3336411|NCT02146521||patients undergoing CT|Emergency department's patients undergoing CT scanning for evaluation of acute abdominal pain and tenderness
3336412|NCT02146534|Experimental|fampridine|extended release fampridine 10mg BID PO for 14 weeks
3336413|NCT02146534|Placebo Comparator|placebo|placebo pill BID PO for 14 weeks
3336414|NCT02146547|Active Comparator|aripiprazole oral|the recommended starting dose for aripiprazole is 10 or 15 mg/day with a maintenance dose of 15 mg/day administered on a once-a-day schedule without regard to meals.Aripiprazole is effective in a dose range of 10 to 30 mg/day.
3336415|NCT02146547|Active Comparator|Aripiprazole depot|"The recommended starting and maintenance dose of aripiprazole depot is 400 mg. Titration of the dose of this medicinal product is not required. It should be administered once monthly as a single injection (no sooner than 26 days after the previous injection).~After the first injection, treatment with 10 mg to 20 mg oral aripiprazole should be continued for 14 consecutive days to maintain therapeutic aripiprazole concentrations during initiation of therapy.~If there are adverse reactions with the 400 mg dosage, reduction of the dose to 300 mg once monthly should be considered."
3336416|NCT02146547|Active Comparator|Paliperidone|The recommended dose of paliperidone for the treatment of schizophrenia is 6 mg once daily, administered in the morning. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended range of 3 mg to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. When dose increases are indicated, increments of 3 mg/day are recommended and generally should occur at intervals of more than 5 days.
3336417|NCT02146547|Active Comparator|Paliperidone palmitate|The first two administrations of paliperidone palmitate (150 mg at visit 3 and 100 mg one week later) need to be administered deep into the deltoid muscle in order to attain therapeutic concentrations rapidly. No oral supplementation with paliperidone is needed. Following the second dose, monthly maintenance doses can be administered in either the deltoid or gluteal muscle. The recommended monthly maintenance dose is 75 mg, although some patients may benefit from lower doses within the recommended range of 25 to 150 mg based on individual patient tolerability and/or efficacy.
3336418|NCT02146573|Experimental|CCI Provider for Parent-patient dyad|Parents and patients are randomly assigned to a Continuity Care Intensivist (CCI) Provider who has received specialized communication training. The parent-patient dyad will receive standardized care from the CCI throughout their time in the PICU in addition to being assigned a rotating physician of record.
3336419|NCT02146573|No Intervention|Usual Care for Parent-patient dyad|Patients and parents randomly assigned to usual care in the PICU which includes the rotation of the physician of record approximately every 7 days. There is no standardized process by which patients may be assigned a primary attending who would follow them throughout their stay. In the usual care arm it may never happen that they are assigned a primary intensivist, regardless of the length of their hospitalization.
3336420|NCT02146586||Dystrophinopathies|
3336421|NCT02146586||Gold Standard Clinical Evaluators (GS-CEs)|
3336422|NCT02146586||Sites Clinical Evaluators (CEs)|
3336423|NCT02146612||Group Receiving Supplement|Amino acid supplement group
3336424|NCT02146625|Experimental|Dose level 1 of CJ-40002|"Single dose~8 volunteers will be administered dose level 1 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3336425|NCT02146625|Experimental|Dose level 2 of CJ-40002|"Single dose~8 volunteers will be administered dose level 2 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3336426|NCT02146625|Experimental|Dose level 3 of CJ-40002|"Single dose~8 volunteers will be administered dose level 3 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3336427|NCT02146625|Experimental|Dose level 4 of CJ-40002|"Single dose~8 volunteers will be administered dose level 4 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3336428|NCT02146625|Experimental|Dose level 5 of CJ-40002|"Single dose~8 volunteers will be administered dose level 5 of CJ-40002 or placebo comparators.(CJ-40002:placebo=6:2)"
3336429|NCT02146638|Active Comparator|Morphine|Patients received morphine 0.02 mg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
3336430|NCT02146638|Experimental|Fentanyl|Patients received Fentanyl 0.3 mcg/Kg/h infused at 2 ml/h for 24 hours. The infusion contained morphine and saline.
3336431|NCT02146651|Experimental|BioChaperone insulin lispro 0.2U/Kg|BioChaperone insulin lispro 0.2U/Kg
3336432|NCT02146651|Experimental|BioChaperone insulin lispro 0.1U/Kg|BioChaperone insulin lispro 0.1U/Kg
3336433|NCT02146651|Experimental|BioChaperone insulin lispro 0.4U/Kg|BioChaperone insulin lispro 0.4U/Kg
3336434|NCT02146651|Active Comparator|Humalog® 0.2U/Kg|Humalog® 0.2U/Kg
3336435|NCT02146664|Experimental|DLBS1033|DLBS1033 enteric-coated tablet is administered at the dose of 490 mg, one tablet three times daily, everyday for eight weeks of study period
3336436|NCT02146664|Placebo Comparator|Placebo|Placebo is administered one tablet three times daily, everyday for eight weeks of study period
3336437|NCT02146677|Other|Sham|newborns will be osteopathically evaluated and softly touched
3336438|NCT02146677|Other|Usual care|newborns will be undergone usual routine neonatology care
3336439|NCT02146677|Other|OMT|newborns will receive osteopathic evaluation and treatment according to international guidelines. Osteopathic treatment use will be indirect techniques.
3336440|NCT02146690|Other|osteopathic manipulative treatment|newborns will receive osteopathic manipulative evaluation and treatment during the entire period of hospitalization plus usual care
3336441|NCT02146690|Other|sham|newborns will receive sham treatment for the entire period of hospitalization plus usual care
3336442|NCT02146690|Other|usual care|newborns allocated in the usual care arm will receive standard care only
3336443|NCT02146703|Experimental|gemcitabine and S-1|
3235480|NCT01241214|Experimental|Investigational drug - Dose 3|
3235481|NCT01241214|Experimental|Investigational Drug - Dose 4|
3235482|NCT01241214|Other|Active Matching Reference|
3235483|NCT01241214|Placebo Comparator|Matching Placebo|
3235484|NCT01241227||Chronic liver disease|All patients with chronic liver disease followed using FibroScan and non-invasive markers
3235485|NCT01241253|No Intervention|Cross-over study|beans and rice in a 50 gram carbohydrate dose
3336444|NCT02146716|No Intervention|Control|
3336445|NCT02146716|Experimental|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation session in addition to standard treatment for patients with withdrawal alcohol symptoms.
3336446|NCT02146729|Experimental|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
3235486|NCT01241266||1|Target subject population are the consecutive patients hospitalized due to peptic ulcer bleeding. Subjects should be: ≥18 years; admitted to the hospital with an overt upper GI bleed (hematemesis/coffee ground vomiting, melena, hematochezia and other clin
3336447|NCT02146729|Active Comparator|Open Treatment|Midline posterior incision with instrumentation.
3336448|NCT02146742|Experimental|1. ASP1707 lowest dose|
3336449|NCT02146742|Experimental|2 ASP1707 higher dose|
3336450|NCT02146742|Experimental|3. ASP1707 Highest dose|
3235487|NCT01241331|Experimental|BLI1100|BLI1100 topical cream
3336451|NCT02146781|Placebo Comparator|0.80 mL Saline Placebo Cohort 1|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan and are skin test positive or negative at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens.~Cohort # 1: Subjects will receive four 0.200 mL volume intradermal injections of saline control as a placebo control using the Biojector device.~Intervention: Saline Control via Intradermal route."
3336452|NCT02146781|Experimental|2.16 mg of CryJ2-DNA-LAMP plasmid vaccine Cohort 2|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 2: Subjects receive four (4) injections of 0.200 mL volumes (2.7 mg/mL) for a single dose of 2.16 mg of CryJ2-DNA-LAMP plasmid vaccine; intradermally (ID) administered using the Biojector device (each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
3336453|NCT02146781|Experimental|1.08 mg CryJ2-DNA-LAMP plasmid vaccine Cohort 3|"Healthy male and female subjects 18 to 63 years of age who have lived in Japan and are skin test positive at Screening to Japanese Red Cedar, Mountain Cedar and/or CryJ2 allergens and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain cedar pollen seasons.~Cohort # 3: Subjects will receive two (2) injections of 0.200 mL (2.7 mg/mL) for a single dose intradermally (ID) for a single dose of 1.08 mg CryJ2-DNA-LAMP plasmid vaccine administered using the Biojector device, each dose administered by separate Biojector device injections at different skin sites. These subjects will receive the same batch vaccine used in Phase 1A and 1B~Intervention: Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intradermal injection"
3336454|NCT02146794|Experimental|Renal denervation|renal denervation
3336455|NCT02146807|Experimental|Picosecond Laser System|
3235488|NCT01241331|Placebo Comparator|Vehicle cream|Vehicle topical cream
3235489|NCT01241357||Observation only|This study has a single arm and no intervention.
3235490|NCT01241370||Lean healthy subjects|Homeostasis Model Assessment score (HOMAs) ≤ 2, Body Mass Index (BMI) ≤ 28 kg/m2
3235491|NCT01241370||Insulin-resistnat subjects|HOMAs > 2, BMI > 28 kg/m2
3235492|NCT01241370||Type 2 diabetic patients|
3336456|NCT02146820|Experimental|Picosecond Laser System|
3336457|NCT02146846||Imatinib, CML|Patients with chronic myeloid leukemia who receive Imatinib as treatment in Iran entered in this study
3336458|NCT02146859||general anesthesia|Patient having general anesthesia
3336459|NCT02146872||Very Premature CAD|Patients who have received a coronary intervention procedure on the basis of atherosclerosis before the age of 40
3336460|NCT02146872||Healthy middle-aged 1st degree relatives|Healthy 1st degree relatives aged 30-65 years of patients with very premature CAD.
3336461|NCT02146872||PCAD families|Families severely affected by premature CAD
3336462|NCT02146885||Weight Control|Weight Control
3336463|NCT02146898|Active Comparator|Lateral|patient placed in the lateral postion for spinal anesthesia
3235493|NCT01241383|Experimental|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
3235494|NCT01241396||001|Any MMY treatment Any line of treatment for MMY
3235495|NCT01241409|Experimental|Treatment sequence ABC|
3235496|NCT01241409|Experimental|Treatment sequence ACB|
3235497|NCT01241409|Experimental|Treatment sequence BAC|
3336464|NCT02146898|Active Comparator|Sitting|patient placed in the sitting position for spinal anestheisa, then supine
3235498|NCT01241409|Experimental|Treatment sequence BCA|
3235499|NCT01241409|Experimental|Treatment sequence CAB|
3235500|NCT01241409|Experimental|Treatment sequence CBA|
3235501|NCT01241422|Experimental|Treatment A: JNJ 40929837|
3235502|NCT01241422|Placebo Comparator|Treatment B: Placebo|
3235503|NCT01241422|Other|Treatment C: Montelukast|
3235504|NCT01241474|Experimental|Fish oil|
3336465|NCT02146898|Active Comparator|Recline|patient placed in the sitting position for spinal anesthesia administration. After spinal placed, the patient turned to a 30-degree upperbody tilt, followed by a slow recline to supine over 5 minutes
3336466|NCT02146911|Experimental|Bupropion|Bupropion hydrochloride SR, Sandoz Canada, Boucherville, Quebec. Dispense for 12 weeks. One tablet (150mg) once daily for first three days, then twice daily for the remainder of 12 weeks.
3336467|NCT02146911|Experimental|Varenicline|Varenicline tartrate (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet or two 0.5mg tablets) twice daily for the remainder of 12 weeks.
3235505|NCT01241474|Placebo Comparator|Maize (corn) oil|
3235506|NCT01241487|Experimental|1|valsartan/amlodipine
3235507|NCT01241500|Experimental|ON 01910.Na + best supportive care (BSC)|Patients will receive ON 01910.Na 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards and best supportive care (BSC).
3235508|NCT01241500|No Intervention|Best supportive care (BSC)|Patients will receive best supportive care (BSC).
3235509|NCT01241526|Experimental|Disease management program|
3235510|NCT01241526|Active Comparator|Usual site management|
3336468|NCT02146924|Experimental|Arm I (cellular immunotherapy closed to accrual January 2019)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells after 28 days.
3235511|NCT01241578|Experimental|Mobile Phone Intervention|Participants receive a behavioral intervention via mobile phone and brief in-person counseling sessions.
3235512|NCT01241617|Active Comparator|Duet TRS|Endo GIA with integrated Duet TRS
3235513|NCT01241617|Active Comparator|Endo GIA|Endo GIA stapler with Single Use Loading units
3235514|NCT01241643|Experimental|CYT107|repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
3235515|NCT01241643|No Intervention|Control|Control arm with possible CYT107 injection after 12 months of study participation
3235516|NCT01241656|Experimental|Mail DVD|
3235517|NCT01241656|Experimental|Invite to SMA to view and discuss DESI|
3235518|NCT01241656|Experimental|SMA and DVD|
3235519|NCT01241656|No Intervention|Encouraged to talk to physician|
3235520|NCT01241669|Experimental|Arm 1|
3235521|NCT01241669|Experimental|Arm 2|
3235522|NCT01241682|Experimental|DC immunotherapy + CTX|Patients with mesothelioma who are fit enough to be treated with chemotherapy and enough tumor material was available are asked for participation in this study. After 4 cycles of Alimta chemotherapy, a leukapheresis is performed of which the monocytes are used for differentiation to DCs using different cytokines. The procedure to grow DCs in vitro and pulse them with tumor lysate is performed according to our earlier performed phase I study that was approved by our local ethics committee. Three doses of properly pulsed autologous DCs (MesoCancerVac) are then re-injected every two weeks. Patients will be treated with a low dose of CTX for seven day in a row the week before the 1st vaccination, the weeks in between the 2nd, and for one week after the 3rd vaccination.
3235523|NCT01241695|Experimental|Test|Diben DRINK (200 ml) / a diabetes-specific oral nutritional supplement
3235524|NCT01241695|Placebo Comparator|Control|Fresubin(R) energy fibre DRINK / an isoenergetic standard oral nutritional supplement
3235525|NCT01241708|Experimental|Tandem Transplantation with Melphalan and Bortezomib|Tandem autologous hematopoietic stem cell transplantation with melphalan followed by melphalan and bortezomib in patients with multiple myeloma
3235526|NCT01241721|Experimental|Positron Emission Mammography (PEM)|Positron Emission Mammography (PEM)
3235527|NCT01241734|Experimental|Revlimid (Lenalidomide) in Combination|Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation
3235528|NCT01241747|Experimental|Supervised Exercise|Supervised program consisting of graded treadmill walking, with progressive increments in exercise duration from 15 to 40 minutes at an exercise intensity of 40% of exercise capacity.
3235529|NCT01241747|Active Comparator|Control|Light resistance training without any walking
3235530|NCT01241773|Experimental|001|TMC435 Two 75 mg capsules once daily for 14 days
3235531|NCT01241773|Experimental|002|efavirenz One 600 mg tablet once daily for 14 days
3235532|NCT01241773|Experimental|003|TMC435 + efavirenz Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet once daily for 14 days
3235533|NCT01241773|Experimental|004|TMC435 Two 75 mg capsules once daily for 7 days
3235534|NCT01241773|Experimental|005|raltegravir One 400 mg tablet twice daily for 7 days
3235535|NCT01241773|Experimental|006|TMC435 + raltegravir Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
3235536|NCT01241799|Experimental|1|Pancreatic biopsy with stylet in then stylet out
3235537|NCT01241799|Experimental|2|Pancreatic biopsy with stylet out then stylet in
3235538|NCT01241812|Experimental|A.|10 weeks of partially supervised lower limb muscle strengthening targeting the following muscles groups: quadriceps, hamstrings, hip abductors.
3235539|NCT01241812|No Intervention|B|
3235540|NCT01241825|Active Comparator|1.|The subject group will chew sugarless chewing gum for a specific amount of time while undergoing capsule endoscopy.
3336469|NCT02146924|Active Comparator|Arm II (cellular immunotherapy)|Patients receive lymphodepleting regimen per treating physician's discretion 3-14 days before the T-cell infusion. Patients receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells IV over 15 minutes on day 0. Patients who have evidence of disease, whose tumor(s) continue to express the appropriate antigen target may receive an optional second infusion of CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/nem-enriched T cells after 28 days.
3336470|NCT02146937|Experimental|Combination therapy- bicalutamide and finasteride|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
3336476|NCT02146963||alcohol withdrawal|
3336477|NCT02146976|Experimental|Propofol|introvenious infusion of propofol
3336478|NCT02146976|Experimental|Inhaled anaesthetic (Sevoflurane)|sevoflurane (1.0-1.3% Minimum Alveolar Concentration)
3336479|NCT02146989||Cerebral Palsy|Children and adolescents with spastic unilateral Cerebral Palsy (with perinatal acquired hypoxic ischemic incidents), aged 7 to 18 years, MACS levels I-III.
3336480|NCT02146989||Healthy controls|Children and adolescents without Cerebral Palsy
3336481|NCT02147002|Active Comparator|omega 3 acids 1|Patients with CKD stage I (GFR 90 and more ml/min/1,73 m2)
3336482|NCT02147002|Active Comparator|omega 3 acids 2|Patients with CKD stage II (GFR 80-89 ml/min/1,73 m2)
3336483|NCT02147002|Active Comparator|omega 3 acids 3|Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2)
3336484|NCT02147002|Active Comparator|omega 3 acids 4|Patients without diabetes mellitus, hypertensions,CKD with normal level of creatinine in serum
3336485|NCT02147015|Experimental|Personalized variable dose of glucocorticoids arm|Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
3336486|NCT02147015|Other|Fixed dose of glucocorticoids arm|Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.
3336487|NCT02147028|Experimental|Hippocampal sparing whole brain RT|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
3336488|NCT02147028|Active Comparator|Control: Conventional whole brain RT|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
3336489|NCT02147041|Experimental|EGCG(Epigallocatechin Gallate)|EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
3235541|NCT01241825|Placebo Comparator|2.|The control group will not chew chewing gum while undergoing capsule endoscopy.
3235542|NCT01241838|Placebo Comparator|Normal left ventricular size|Postoperative patient with normal left ventricular size
3235543|NCT01241838|Active Comparator|Left ventricular hypertrophy|Postoperative patient with left ventricular hypertrophy
3235544|NCT01241851|Active Comparator|Aerobic exercise|
3235545|NCT01241851|Active Comparator|Resistance exercise|
3235546|NCT01241851|No Intervention|Control|
3235547|NCT01241864|Experimental|Allogenic islet cells (human, U. Chicago)|
3235548|NCT01241877|Experimental|astaxanthin|
3235549|NCT01241877|Placebo Comparator|placebo|
3235550|NCT01241890||Children with Cystic Fibrosis, care as usual|Treatment according to the Dutch Central Guidance Committee (CBO) guidelines for CF. Assessments: home monitoring, symptoms, lung function, quality of life and diagnostic assessments of non-invasive inflammatory markers in exhaled air and exhaled breath condensate.
3235551|NCT01241929|Experimental|video decision aid|Video decision aid arm
3235552|NCT01241929|No Intervention|Usual Care -- Verbal Description Arm|Verbal description of CPR (i.e., without the video).
3235553|NCT01241942|Experimental|EVLP with STEEN Solution™|The perfusion of the lungs will be performed using STEEN Solution™ and then physiologically assessed. Lungs deemed suitable will be transplanted after Ex-vivo Perfusion w/ STEEN Solution™.
3235554|NCT01241942|Active Comparator|Conventional Lung transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
3235555|NCT01241955|No Intervention|verbal description of CPR|verbal description of CPR
3235556|NCT01241955|Experimental|Video decision aid|Video decision aid of CPR
3336490|NCT02147041|Placebo Comparator|placebo|cellulose (500mg, three times a day, 12 weeks)
3336491|NCT02147054|Active Comparator|Rocuronium with >95% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve >95% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
3336492|NCT02147054|Active Comparator|Rocuronium with 50% inhibition|"IV Rocuronium to be given:~Bolus dose of Rocuronium 0.3 mg/kg to achieve 50% inhibition as indicated by Train of Four monitoring~Continuous infusion of 1.5 mg/kg/hr to maintain level of inhibition~To continue until two rises in butyrylcholinesterase seen or for a maximum of 5 days"
3336493|NCT02147054|No Intervention|No Rocuronium|No Rocuronium will be given
3336494|NCT02147080|Experimental|Tailored Intervention|Subject has access to the tailored web intervention
3336495|NCT02147080|Active Comparator|Skin Cancer Foundation Website|Subject has access to the pre-existing Skin Cancer Foundation website
3336496|NCT02147080|No Intervention|Assessment Only Condition|Subjects will only complete assessments
3336497|NCT02147106||Videoconsultation|Performing two videoconsulations with the treating medical oncologist
3336498|NCT02147119||Patients post- cardiac catheterisation|
3336499|NCT02147145||Observation Cohort|
3336500|NCT02147171|Active Comparator|Active lutein group|44 participants taking VisionAce daily for a period of 1 year
3336501|NCT02147171|Placebo Comparator|Placebo group|44 participants taking placebo daily for a period of 1 year
3336502|NCT02147210||1-Case|patients who developed CTG secondary to antibody-mediated kidney rejection (AMR), diagnosed by microscopic analysis.
3336503|NCT02147210||2-Control|patients with antibody-mediated kidney rejection (AMR) but without CTG
3336504|NCT02147223|Active Comparator|Flavanol rich product A|250 mg flavanols
3336505|NCT02147223|Active Comparator|Flavanol rich product B|500 mg flavanols
3336506|NCT02147223|Active Comparator|Flavanol rich product C|750 mg flavanols
3336507|NCT02147223|Placebo Comparator|Flavanol free product|flavanol free
3336508|NCT02147249|Experimental|erythema migrans patients treated with antibiotics|adult patients with erythema migrans will be treated with oral antibiotics
3336509|NCT02147262|Active Comparator|ACA-doxy 14 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 14 days
3235557|NCT01241968|Active Comparator|A|A - Treatment group. Patients in this group receive actual shockwave therapy.
3235558|NCT01241968|Placebo Comparator|B|Placebo group. This group of patients undergo the same procedure as the treatment group, however shockwaves are not delivered to the heart.
3336510|NCT02147262|Active Comparator|ACA-doxy 28 days|patients with chronic atrophic acrodermatitis treated with doxycycline for 28 days
3336511|NCT02147275||hypertension disease|patients have hypertension disease, whether well-controlled or uncontrolled, more than 3 year
3336512|NCT02147340||Heart failure patients with ICD|Heart failure patients with ICD and RPM system equipped with sensors for the measurement of weight and pressure
3336513|NCT02147366|Experimental|Behavioral (Lifestyle)|Only standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
3336514|NCT02147366|Experimental|Behavioral (Music & lifestyle changes)|Experimental: Music along with standard lifestyle modifications The prehypertensives and stage I hypertensives will be randomized to receive each of the two three experimental conditions: music along with standard lifestyle modifications or only standard lifestyle modifications in random order over the course of three months.
3336515|NCT02147379|Experimental|Lurasidone|Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.
3336516|NCT02147379|No Intervention|Treatment as usual|Patients randomized to this arm will continue their usual treatment.
3336517|NCT02147418||Group 1: HPV-positive Cancer|Oropharyngeal cancer patients testing positive for human papillomavirus (HPV)
3336518|NCT02147418||Group 2: HPV-positive Cancer|Oropharyngeal cancer patients who test positive for human papillomavirus (HPV)
3235559|NCT01241981||Digital Breast Tomosynthesis|Digital Breast Tomosynthesis
3235560|NCT01241994|No Intervention|basal hemodialysis|
3336519|NCT02147418||Group 3: Healthy Controls|Patients with benign conditions
3336520|NCT02147431|Experimental|Semaglutide|
3336521|NCT02147431|Placebo Comparator|Placebo|
3235561|NCT01241994|Active Comparator|AASD|
3235562|NCT01242033|Experimental|one cup red raspberries|treatment meal consists of one cup red raspberries
3336522|NCT02147444||Non-valvular atrial fibrillation|"Patients diagnosed with non-valvular atrial fibrillation~Patients who are treated or will be treated with rivaroxaban"
3235563|NCT01242033|Experimental|two cups red raspberries|treatment meal consists of two cups red raspberries
3336523|NCT02147457||ELBW (CASES)|Extremely low birth weights, born in 2000-2005, birth weight below 1000 grams, who were initially admitted (2000-2005) at the Neonatal Intensive Care Unit, UZ Leuven Belgium and have been well characterized and documented in the postnatal period.
3336524|NCT02147457||CONTROLS|Survivors (CASES) (n = 140) will be matched with two healthy controls. One control will be matched to sex, birth year and residential area and will be suggested by the index patient (e.g. school friend, neighbor), the second control will be age and sex matched from the area of the field.
3336525|NCT02147470|Other|prerenal AKi, acute tubular necrosis and hepatorenal syndrome|All subjects will undergo CEUS with the use of Definity to measure renal blood flow. At the same time clinical tools (urine output, response to volume expansion, urine sodium, urine output, fractional excretion of sodium and urea and urine microscopy) will be used to differentiate between prerenal AKI, ATN and HRS. the quantity and patterns of RBF measured by CEUS will be compared between these three groups.
3336526|NCT02147483|Active Comparator|Treatment as usual|Treatment as usual as prescribed by clinician.
3336527|NCT02147483|Experimental|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention will be provided in eight in person sessions to prevent alcohol use.
3336528|NCT02147496|Experimental|2% M.F. Milk|Dietary treatment: 2% m.f. milk
3336529|NCT02147496|Experimental|1% M.F. Chocolate Milk|Dietary treatment: 1% m.f. chocolate milk
3336530|NCT02147496|Experimental|1.5% M.F. Drinkable Yogurt|Dietary treatment: 1.5% m.f. drinkable yogurt
3336531|NCT02147496|Experimental|Tropical Punch|Dietary treatment: fruit-flavoured beverage
3336532|NCT02147496|Experimental|Water|Dietary treatment: calorie-free control
3336533|NCT02147509|Experimental|Severe dry eye|"0.02% Fm, SH~0.02% Fm, SH, AS~0.02% Fm, SH, 0.05% CsA~0.02% Fm, SH, tBCL (0.05% CsA: 0.05% cyclosporin A; tBCL: therapeutic bandage contact lenses; 0.02% Fm: 0.02% Fluorometholone; AS: Autologous Serum; SH: Sodium Hyaluronate)"
3336534|NCT02147535|Experimental|Methylphenidate|
3336535|NCT02147548|Experimental|etifoxine (Anxiolytic)|etifoxine, 100 mg, a single oral intake
3336536|NCT02147548|Active Comparator|lorazepam|lorazepam, 2 mg, a single oral intake
3336537|NCT02147548|Placebo Comparator|Placebo|2 capsules of Placebo, a single oral intake
3336538|NCT02147574|Experimental|antiperistaltic ileosigmoid anastomosis|To assess the operative results after laparoscope subtotal colectomy with antiperistaltic ileosigmoid anastomosis for the slow-transit constipation.
3235564|NCT01242033|Experimental|four cups red raspberries|treatment meal consists of four cups red raspberries
3235565|NCT01242033|Placebo Comparator|bread|treatment meal consists of two slices white bread
3336539|NCT02147600||Chronic plaque psoriasis|Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
3336540|NCT02147639|Experimental|Sodium Nitrate|Patients will ingest a single oral dose of sodium nitrate (~8.4 mmol)
3336541|NCT02147639|No Intervention|Baseline|This is a baseline study visit, which will serve to assess inclusion and exclusion criteria, as well as provide untreated measurments of skeletal muscle blood flow and perfusion.
3336542|NCT02147639|Experimental|Dose-escalation trial|This is an optional study visit, where subjects will ingest twice the dose of sodium nitrate (~16.8 mmol).
3336543|NCT02147639|Placebo Comparator|Placebo-control trial|This is an optional study visit, where patients will ingest a placebo.
3336544|NCT02147639|Experimental|Increased exercise intensity|This is an optional study visit, where patients will be asked to repeat all of the blood flow assessments, but the exercise intensity will be increased.
3235566|NCT01242033|Active Comparator|vitamin C|treatment meal consists of two slices white bread and 200 mg vitamin C in the form of supplemental ascorbic acid
3235567|NCT01242046|Experimental|Caffeine|Participants will ingest a tablet with 400 mg caffeine
3235568|NCT01242046|Placebo Comparator|Placebo|Participants will ingest an inert placebo tablet
3235569|NCT01242059|Experimental|Control Tomato Soup|
3235570|NCT01242059|Experimental|10 g of yellow pea fiber|
3235571|NCT01242059|Experimental|20 g of yellow pea fiber|
3235572|NCT01242059|Experimental|10 g of yellow pea protein|
3235573|NCT01242059|Experimental|20 g of yellow pea protein|
3336545|NCT02147652|Experimental|Personalized music|
3336546|NCT02147665|Experimental|Hookah smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after Hookah smoking.
3235574|NCT01242072|Experimental|PaCE|Palifosfamide, Carboplatin and Etoposide
3235575|NCT01242098||Fostair switch cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and switch to Fostair
3235576|NCT01242098||Seretide continuation cohort|Seretide patients who, at an index date, had a step down in therapy (reduction in ICS dose of ≥50%) and continue on Seretide
3235577|NCT01242124|Experimental|side-to-side stapled esophagogastric anastomosis arm|
3235578|NCT01242124|Active Comparator|circular-stapled esophagogastric anastomosis arm|
3235579|NCT01242137||Extensive metabolizers|
3235580|NCT01242137||Intermediate mtabolizers|
3336547|NCT02147678|Experimental|Group E|Etomidate/remifentanil group. Patients in group E will be given etomidate and remifentanil during the operation, the speeds are 10~15 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
3336548|NCT02147678|Experimental|Group P|Propofol/remifentanil group. Patients in group P will be given propofol and remifentanil during the operation, the speeds are 50~75 μg/kg/min and 0.2~0.4 μg/kg/min, respectively.
3336549|NCT02147704|Other|Goup I|Group I: Fimasartan 60 mg in a low-sodium intake period --> Fimasartan 60 mg in a high-sodium intake period
3336550|NCT02147704|Other|Group II|Group II: Fimasartan 60 mg in a high-sodium intake period --> Fimasartan 60 mg in a low-sodium intake period
3336551|NCT02147717|Experimental|Laser stimulation|"Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
3336552|NCT02147717|Placebo Comparator|fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
3336553|NCT02147730||surgical patients|all surgical patients undergoing gastrectomy, knee-hip-shoulder arthroplasty, hallux valgus surgery, hernia repair, saphenectomy, cesarean section,colectomy, hysterectomy, nephrectomy mastectomy during study period
3336554|NCT02147743|Experimental|CCP+MDFT|Multidimensional Family Therapy (MDFT) is a multisystemic, flexible intervention system (Liddle, 2002). It is a strengths-based approach promoting protective factors and reducing risk factors for delinquency, substance use, and school problems. MDFT organizes interventions in key areas of the teen's life: self of the adolescent (includes HIV-STD risk behaviors), parenting, family environment, and school/vocational functioning.
3235581|NCT01242137||Poor metabolizers|
3235582|NCT01242150|Experimental|NCPAP Helmet|Infants with mild Acute Respiratory Failure who need NCPAP
3235583|NCT01242150|Active Comparator|NCPAP facial mask|Infants with mild Acute Respiratory failure who need NCPAP
3235584|NCT01242202|Experimental|ASP group|Concomitant administration of ASP1941 and α- glucosidase inhibitor
3336555|NCT02147743|Other|CCP+SAU|Services as Usual (SAU) are determined on a case-by-case basis by the CCP Case Manager. SAU includes a variety of services offered by a number of community partners.
3235585|NCT01242215|Experimental|ASP group|ASP1941 and sulfonylurea
3235586|NCT01242215|Placebo Comparator|Placebo group|placebo and sulfonylurea
3235587|NCT01242228|Experimental|ASP group|Concomitant administration of ASP1941 and DPP-4 inhibitor
3235588|NCT01242254|Experimental|Group A|Patients will receive an intravitreal injection of KH902 0.5mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
3235589|NCT01242254|Experimental|Group B|Patients will receive an intravitreal injection of KH902 2.0mg/eye/time monthly, after 3-time treatment patients will go on an as needed (PRN) dosing phase till week 52
3235590|NCT01242267|Other|Thalidomide with melphalan|Safety/Efficacy -
3235591|NCT01242280|Active Comparator|Self-expandable esophageal stent|"The patient will receive a self-expandable esophageal stent (SX-Ella-Danis) without endoscopical guidance but under slight sedation. An immediate X-ray will be done to assess the correct placement of the stent.~After a maximum of 7 days, the stent will be removed by using the specifically designed devices."
3336556|NCT02147756|Active Comparator|CO2RE|Fractional CO2 laser system that utilizes a sealed off, all metal carbon dioxide gas tube that is Radio Frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The system has a programmable 2 axis scanning laser beam device that allows the physician to select the skin area coverage from a selection of predetermined patterns in different sizes based on the skin area to be treated. The versatility of the fractional CO2RE system enables precise, effective and simultaneous treatment of the skin's surface in the middle, and deep dermal levels.
3336557|NCT02147756|Active Comparator|RePair|Fractional CO2 system that comprises an infrared laser controlled by an embedded processor and a handpiece that directs the laser treatment. The device laser has a wavelength of 10.6μm and its tissue chromophore is water. It delivers multiple low energy pulses in microscopic spots as the handpiece glides over the skin surface. The selected energy determines the depth and width for each microscopic treatment zone (MTZs).
3336558|NCT02147782||control|Healthy people from physical examination centers are recruited as controls.
3336559|NCT02147782||CKD1|"with clinical one or more symptoms and signs of kidney injury listed as below：~Urinary albumin ( urinary albumin excretion rate≥30 mg/24 h.albumin-creatinine ratio≥3mg/mmol)~urinary sediments abnormality~renal tubular lesions~renal histological abnormalities~abnormal structure showed by imaging~history of renal transplantation~GFR≥90（ml/min/1.73m²)"
3336560|NCT02147782||CKD2|with clinical symptoms and signs of kidney injury, and 60<=GFR<=89（ml/min/1.73m²)
3336561|NCT02147782||CKD3|with clinical symptoms and signs of kidney injury, and 30<=GFR<=59（ml/min/1.73m²)
3336562|NCT02147782||CKD4|with clinical symptoms and signs of kidney injury, and 15<=GFR<=29（ml/min/1.73m²)
3336563|NCT02147782||CKD5|with clinical symptoms and signs of kidney injury, and GFR<15（ml/min/1.73m²)
3336564|NCT02147795||Control cohort|Standard care before implementation (pre-implementation)
3336565|NCT02147795||PBM cohort|After implementation of PBM program (post-implementation)
3336566|NCT02147808|Experimental|All subjects|All subjects will receive a single oral midazolam dose on Day 1 while fasting. Days 2 to 4 will be Washout days. On Day 5, subjects will begin a 5-day regimen of telotristat etiprate. On Day 9, subjects will receive a morning dose of telotristat etiprate with a single dose of midazolam while fasting.
3336567|NCT02147821|No Intervention|Standard|Standard treatment will be defined as current practice whereby two mediastinal chest tubes are used for drainage, as well as an additional pleural tube if the pleura is opened during surgery. As part of current standard practice, the pleural and mediastinal spaces will be suctioned during the achievement of hemostasis prior to the insertion of chest tubes.
3336568|NCT02147821|Experimental|Intervention|The treatment arm of the study will involve standard placement of the mediastinal tubes with the exclusion of the pleural tube.
3336569|NCT02147847|Experimental|Video game based training 1|Video Game play with training strategy 1
3235592|NCT01242280|Active Comparator|Sengstaken-Blakemore tube|The esophageal tamponade will be done as described elsewhere. The gastric content will be checked hourly and the correct placement of the tube will be checked by an immediate X-ray. The esophageal balloon will be inflated a maximum of 24 hours.
3235593|NCT01242293|Active Comparator|0.9% Saline with glucose 5%|rate of infusion is 125cc/h
3235594|NCT01242293|Active Comparator|Ringer lactate|rate of infusion is 250cc/h
3336570|NCT02147847|Experimental|Video game based training 2|Video Game play with training strategy 2
3336571|NCT02147860|Placebo Comparator|Sensor Augmented Pump Therapy|Each camp participant will be randomized to full day and night CLC or sensor augmented pump therapy for up to 7 days/6 nights. The subject will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
3336572|NCT02147860|Experimental|Diabetes Assistant (DiAs) with USS Virginia|"With the use of the UVA Artificial Pancreas (DiAs), the study will assess safety and feasibility and are not powered for statistical significance. These studies are intended to train staff on system function and obtain data regarding safe and feasible system use.~Camp participants will be randomized to either closed-loop control using the DiAs or sensor-augmented pump therapy only. These studies would generate up to 120 days of closed-loop data and 120 comparable days of open-loop data."
3336573|NCT02147873|Active Comparator|azacitidine with birinapant|Azacitidine 75 mg/m2 IV on days 1-5, 8 & 9 OR days 1-7 and birinapant 13 mg/m2 IV twice a week (days 1 & 4) for 3 out of 4 weeks
3336574|NCT02147873|Placebo Comparator|Azacitidine and placebo|Azacitidine 75mg/m2 IV days 1-5, 8 & 9 OR days 1-7 and placebo IV twice a week (days 1 & 4) for 3 out of 4 weeks
3336575|NCT02147886|Experimental|Cabaletta 15gr|Cabaletta 15gr
3336576|NCT02147886|Experimental|Cabaletta 30gr|Cabaletta 30gr
3336577|NCT02147912|Active Comparator|Aerobic exercise|A six week aerobic exercise intervention in COPD depressed population.
3235595|NCT01242293|Active Comparator|Ringer lactate - Controls|rate of infusion is 125cc/h
3336578|NCT02147912|No Intervention|Control sample|"Only participants randomized in the arm named Aerobic exercise will receive a six weeks aerobic exercise intervention."
3336579|NCT02147925|Active Comparator|Liraglutide|Liraglutide combined with metformin
3336580|NCT02147925|Active Comparator|Insulin glargine|Insulin glargine combined with metformin
3336581|NCT02147925|Active Comparator|Sitagliptin|Sitagliptin combined with metformin
3235596|NCT01242306|Placebo Comparator|BMS arm|bare metal stent arm
3235597|NCT01242306|Active Comparator|SES arm|sirolimus eluting stent arm
3336582|NCT02147938||1: early conversion from Prograf® to Advagraf®|patients converted during the first 6 months post-transplantation
3336583|NCT02147938||2: late conversion from Prograf® to Advagraf®|patients converted between 6 and 12 months post-transplantation
3336584|NCT02147964|Experimental|Acyline; T Gel; placebo dutasteride, placebo ketoconazole|"All men will receive Acyline 300 ug/kg subcutaneous (SQ) injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 1: placebo oral ketoconazole + placebo oral dutasteride for 4 months"
3336585|NCT02147964|Experimental|Acyline; T gel; Ketoconazole; placebo|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 2: oral ketoconazole 400 mg + placebo oral dutasteride for 4 months"
3336586|NCT02147964|Experimental|Acyline; Tgel; Ketoconazole; Dutasteride|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 3: Ketoconazole 400mg orally daily + Dutasteride 2.5 mg orally on day 1, followed by 0.5mg daily for 4 months"
3336587|NCT02147964|Experimental|Acyline; Tgel; HCG|"All men will receive Acyline 300 ug/kg SQ injections every 2-weeks + Testosterone 1% Gel 5g daily and then randomly assigned.~Group 4: Human Chorionic gonadotropin (HCG) 60 IU injection every other day for 4 months."
3235598|NCT01242319||Multi-modal practice intervention|15 intervention practices receive academic detailing, patient activation computer kiosk, decision supported PDA, and coronary risk factor management toolbox
3235599|NCT01242319||Usual care|15 practices receive academic detailing reviewing the ATP III cholesterol management guidelines
3235600|NCT01242332|No Intervention|placebo|po 2 hrs before surgery
3336588|NCT02147977|Active Comparator|dietary supplement: n-3 PUFA|"n-3 polyunsaturated fatty acids from fish oil~capsules of 500 mg. 2 g a day."
3336589|NCT02147977|Placebo Comparator|olive oil|Capsules of 500 mg. 2 g a day.
3336590|NCT02148003|Active Comparator|RFA at 90 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 90 degrees Celsius
3235601|NCT01242332|Experimental|Pregabalin|75 mg po 2 hrs before surgery
3336591|NCT02148003|Active Comparator|RFA at 80 degrees Celsius|Radiofrequency ablation (RFA) of the lumbar facets nerve supply will be performed at 80 degrees Celsius
3336592|NCT02148016|Experimental|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
3336593|NCT02148016|Active Comparator|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
3336594|NCT02148016|Experimental|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
3336595|NCT02148016|Active Comparator|PRK only (Traditional Technique)|PRK alone will be performed.
3336596|NCT02148029|Active Comparator|Control|Standard care: anticoagulation, compression & ad-lib ambulation
3336597|NCT02148029|Experimental|Exercise|Standard care + Interventional Exercise therapy
3336598|NCT02148042||Anorexics|
3336599|NCT02148042||Controls|
3336600|NCT02148055|Other|A group of 20 pregnant patients.|20 patients referred for intrauterine spontaneous fetal death explored by MRI and autopsy.
3235602|NCT01242345|No Intervention|No Intervention|Standard monitoring.
3235603|NCT01242345|Experimental|Capnography|Arm with capnographic monitoring
3336601|NCT02148068||Bariatric Surgery - Gastric Bypass|This population will undergo a laparoscopic roux-en-y gastric bypass
3336602|NCT02148068||Bariatric Surgery - Sleeve Gastrectomy|This group will undergo a laparoscopic sleeve gastrectomy
3336603|NCT02148081||Critically ill children|
3336604|NCT02148094|Experimental|Truvada|Participants will be initiated on PrEP and asked to select one of two PrEP delivery options. Participants will return to the study site every three months for an additional follow-up visit. At follow-up visits, participants will receive HIV testing and counselling, pregnancy testing, syndromic screening for STIs, and clinical diagnosis of adverse events. Those who test HIV-positive will be discontinued on PrEP, exited from the study and referred for HIV care and treatment. Those who have an adverse event will be clinically evaluated to determine whether they should suspend PrEP use and will be provided with the appropriate management for the adverse event. Participants who test HIV-negative will receive patient-centred counselling around PrEP.
3336605|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6, 1 puff|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg
3336606|NCT02148120|Active Comparator|CHF1535 NEXThaler 100/6 µg, 4 puffs|Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg
3336607|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 1 puff|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
3336608|NCT02148120|Experimental|CHF1535 NEXThaler 200/6 µg, 4 puffs|Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg
3336609|NCT02148120|Placebo Comparator|Placebo NEXThaler|Placebo
3336610|NCT02148133|Experimental|Eltrombopag|Subjects were assigned the investigational product (eltrombopag 25 mg/day) orally once a day under fasting condition. The dose adjustment was done every 2 weeks according to the platelet count (increased by eltrombopag 25 mg/day every 2 weeks according to the platelet count up to 100 mg/day).
3336611|NCT02148159|Experimental|Cachexia Acupuncture-A|"Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points that are selected based on the potential mechanisms of cachexia. Intervention will be done by a licensed acupuncturist who has over 5 years of experience as an independent clinician and has experience particularly in the management of cancer related symptoms. Acupuncture treatment will consist of 8 sessions over 8 week period.~Acupuncture needles: Single-use, sterile stainless steel and disposable [acupuncture needles-Peace Classic Needles®, Acu-Market] Other name: Mechanism based acupuncture"
3235604|NCT01242358|Experimental|Capnography|Arm with capnographic monitoring
3235605|NCT01242358|Placebo Comparator|Standard monitoring|Standard monitoring
3235606|NCT01242384|No Intervention|Expectant Management|
3235607|NCT01242384|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
3235608|NCT01242397|Other|CRT ON|After implant, patients will be randomized to CRT pacing ON vs OFF in crossover fashion with 3 months in each period
3235609|NCT01242397|Other|CRT- OFF|After implant, patients will be randomized to CRT pacing OFF vs ON in crossover fashion with 3 months in each period
3336612|NCT02148159|Sham Comparator|General Acupuncture-B|"General Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points. These points are the real acupuncture points; however, these points are not specific to cachexia management. Participants will receive the acupuncture treatment over 8 weeks (total of 8 sessions) in the same manner as the experimental group; the only difference will be the place(type) and number of points targeted.~Acupuncture needles: single-use, sterile stainless steel and disposable needles [Peace Classic Needles®, Acu-Market] Other name: General acupuncture"
3336613|NCT02148172|Active Comparator|Standard Plyometric Training|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice delivered at a standard dosage of sets and repetitions.
3336614|NCT02148172|Experimental|Plyometric Training with BWS|Participants will undergo treatment 2 times a week for 8 weeks with plyometric exercises deemed to be consistent with best practice with a treatment volume of sets and repetitions that exceeds standard practice. Higher number of practice trials will be completed with body weight support (BWS) to reduce load. Participants will start at 30 percent of body weight and will be slowly weaned away over time.
3235610|NCT01242410|No Intervention|Expectant Management|
3336615|NCT02148185|Experimental|MT-1303|
3336616|NCT02148198|Active Comparator|1g NWT-03, then placebo|7 days 1g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3336617|NCT02148198|Placebo Comparator|placebo, then 1g NWT-03|7 days placebo, followed by 7days 1g NWT-03, separated by a 5-day wash-out period
3336618|NCT02148198|Active Comparator|2g NWT-03, then placebo|7 days 2g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3235611|NCT01242410|Experimental|Placement of cervical pessary since 23 weeks until 37 weeks|
3235612|NCT01242423|Experimental|superficial 2nd degree burn|Group A (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a superficial 2nd degree burn on ≥1% and ≤30% of the surface of the body.
3235613|NCT01242423|Experimental|deep 2nd degree burn|Group B (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who have sustained a deep 2nd degree burn on ≥1% and ≤30% of the surface of the body.
3336619|NCT02148198|Placebo Comparator|placebo, then 2g NWT-03|7 days placebo, followed by 7days 2g NWT-03, separated by a 5-day wash-out period
3336620|NCT02148198|Active Comparator|5g NWT-03, then placebo|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3235614|NCT01242423|Experimental|skin excision for the purpose of a skin graft|Group C (n=50): Consent-capable male and female patients between ≥18 and ≤80 years of age who require a skin excision for the purpose of a skin graft. The minimal size of the skin-graft donor site must not be less than 1% of BBS.
3235615|NCT01242462|Active Comparator|AB|2 hours of treatment with conventional ventilation strategy, then crossover to 2 hours of treatment with mid-frequency ventilation strategy
3336621|NCT02148198|Placebo Comparator|placebo, then 5g NWT-03|7 days 5g NWT-03, followed by 7 days placebo, separated by a 5-day wash-out period
3336622|NCT02148224||healthy without diabetes|
3235616|NCT01242462|Active Comparator|BA|2 hours of treatment with mid-frequency ventilation strategy, then crossover to 2 hours of treatment with conventional ventilation strategy
3235617|NCT01242475|Experimental|0.1µg/0.1 mL C-Tb|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3336623|NCT02148237|No Intervention|Treatment as Usual|Participants in Treatment as Usual (TAU) will receive standard breastfeeding (BF) services from the WIC program and participate in research assessments. Standard services include an on-site and home-visiting lactation consultant, occasional one-on-one peer counseling, and an enhanced food package for BF women.
3235618|NCT01242475|Active Comparator|2TU Tuberculin PPD RT 23 SSI|The C-Tb and 2 TU Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT AND LEFT forearms according to a double blind randomisation scheme
3235619|NCT01242488|Experimental|CDP6038 60 mg sc every 2 weeks plus methotrexate|
3235620|NCT01242488|Experimental|CDP6038 60 mg sc every 4 weeks plus methotrexate|
3235621|NCT01242488|Experimental|CDP6038 120 mg sc every 2 weeks plus methotrexate|
3336624|NCT02148237|Experimental|Contingency Management|These participants will receive usual WIC care. The frequency, duration, content, and size of the meetings and participation requirements will be the same as for the TAU group, except that this group will also receive contingency management (CM). Members will demonstrate breastfeeding and receive cash incentives weekly if they breastfeed.
3336625|NCT02148263|Experimental|Full-Time Senofilcon A Contact Lens Wear|This group will start wearing contact lenses 8 or more hours per day on the first day of wear
3336626|NCT02148263|Experimental|Graduated Senofilcon A Contact Lens Wear|This group will start wearing contact lenses on a graduated schedule (day 1 = 2 hours, day 2 = 4 hours, day 3 = 6 hours, day 4 = 8 hours, day 5 = 8 or more hours).
3336627|NCT02148276||Research Participants|All participants will complete two measures of social harm at monthly research appointments for a three month period. The social harms assessments will be (1) the ACASI-SHQ that was developed in Phase 1 and (2) the HIV Vaccine Trials Network (HVTN) Social Impact Assessment.
3235622|NCT01242488|Experimental|CDP6038 120 mg sc every 4 weeks plus methotrexate|
3235623|NCT01242488|Experimental|CDP6038 240 mg sc every 2 weeks plus methotrexate|
3235624|NCT01242488|Experimental|CDP6038 240 mg sc every 4 weeks plus methotrexate|
3235625|NCT01242488|Active Comparator|Tocilizumab 8 mg/kg iv every 4 weeks plus methotrexate|
3235626|NCT01242488|Placebo Comparator|Placebo sc every 2 weeks plus methotrexate|
3235627|NCT01242488|Placebo Comparator|Placebo sc every 4 weeks plus methotrexate|
3235628|NCT01242501|Experimental|60 Min. Risk Reduction Counseling|Single 60 min Social Cognitive Theory-based counseling session delivered in STI clinic setting in Cape Town South Africa. Includes educational, motivational, and sexual risk reduction skills components delivered in a single face-to-face counseling session.
3235629|NCT01242501|Active Comparator|20-min single session education|Single brief HIV/STI education only session for men and women receiving sexually transmitted infection clinic services in South Africa. Includes only brief educational information on sexual risks for HIV infection in a single face-to-face counseling session.
3235630|NCT01242553||Normal|Normal results from clinical exam and free of ocular pathology.
3235631|NCT01242553||Retina|Clinical exam results consistent with retina pathology
3235632|NCT01242553||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
3235633|NCT01242553||Cornea|Clinical exam results consistent with cornea pathology.
3235634|NCT01242566|Experimental|temozolomide|Administration of temozolomide 150-200 mg/m2/day for 5 consecutive days every 4 weeks for a maximum of 12 cycles or until disease progression or prohibited toxicity
3336628|NCT02148289|Active Comparator|Nitrate rich beverage|Nitrate rich beverage will contain 140ml nitrate rich beetroot juice + 200ml blackcurrant juice containing 12.7mmol nitrate
3235635|NCT01242579|Active Comparator|Maraviroc Vaginal Gel|Drug: Maraviroc dosage form: vaginal gel dosage: 2.5g frequency: once daily duration: 11 days
3235636|NCT01242579|Active Comparator|Dapivirine Vaginal Gel|Drug: Dapivirine dosage form: vaginal gel dosage: 2.5g dapivirine frequency: once daily duration: 11 days
3336629|NCT02148289|Placebo Comparator|Nitrate free beverage|Nitrate free beverage will 140ml water + 200ml blackcurrant juice containing <0.5mmol nitrate
3336630|NCT02148315|Experimental|garden intervention|garden kit and access to garden-based lessons
3336631|NCT02148315|No Intervention|no garden|control - receives garden and lessons at end of study
3336632|NCT02148328|Experimental|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants.
3336633|NCT02148328|Active Comparator|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3336634|NCT02148328|Experimental|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3336635|NCT02148328|Active Comparator|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
3336636|NCT02148341|Experimental|Community of Practice Facilitation|Medical Centers assigned to this arm will recieive the communtiy of practice facilitation. In this process we will contact existing members of the community of practice (called the Heart Failure Network) at the facility as well as attempt to identify new providers and other staff at the facility with an interest in improving heart failure care. The facilitation includes: describing the national H2H program, providing talking points and strategies for local providers to obtain support from their local facility to initiate local projects related to H2H, providing a forum for successful sites to describe how they initiated projects to sites yet to initiate projects.
3336637|NCT02148341|Experimental|Usual Care|Medical centers in this arm will hear of H2H through usual routs (calls with facilty Directors and Chiefs of staff).
3336638|NCT02148354|Experimental|Group with support by the therapist.|Intervention group that do the Smiling is Fun program and receives support by the therapist (a brief weekly two-minute call without clinical content).
3336639|NCT02148354|Experimental|Group without support by the therapist|Intervention group that do the Smiling is Fun program and does not receive support by the therapist.
3235637|NCT01242579|Placebo Comparator|Matching Placebo Gel|Drug: placebo dosage form: vaginal gel dosage: 2.5g placebo frequency: once daily duration: 11 days
3235638|NCT01242579|Experimental|Maraviroc/Dapivirine Gel|Drug: Maraviroc/Dapivirine dosage form: combination vaginal gel dosage: 2.5g - Maraviroc 0.1%, Dapivirine 0.05% frequency: once daily duration: 11 days
3235639|NCT01242592|Experimental|Homeopathy|
3235640|NCT01242592|Placebo Comparator|Placebo|
3336640|NCT02148354|Other|Waiting list control group|"Control group that could access the Smiling is Fun program after waiting for 12 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
3336641|NCT02148367|Active Comparator|Erythropoietin (EPO)|Participants (n=20) will receive EPO with a dose of 40,000 IU EPO subcutaneously (s.c.) once weekly for 4 weeks.
3336642|NCT02148367|Placebo Comparator|placebo|Participants (n=10) will receive placebo s.c. once weekly for 4 weeks
3336643|NCT02148380|Experimental|chemotherapy group(B)|pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
3336644|NCT02148380|Experimental|combination therapy group(A)|pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
3336645|NCT02148380|Experimental|gefitinib group (group C)|received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death
3235641|NCT01242605|Experimental|single armed|This is not a randomised trial, there is only one study group. All patients will receive cisplatin/gemcitabine chemotherapy in addition to oral daily dosing of selumetinib
3235642|NCT01242618|Experimental|engineered nasal cartilage graft|Biological intervention: autologous nasal chondrocytes expanded in vitro and cultured in a collagen Type I/III scaffold
3235643|NCT01242631|Experimental|Everolimus 10 mg daily|
3235644|NCT01242657|No Intervention|Brief Advice|Standard of care arm with no intervention; includes standard communication regarding youth tobacco cessation such as a brief discussion and printed materials
3235645|NCT01242657|Active Comparator|Not On Tobacco (N-O-T) Program|Teens randomized to this arm participated in the N-O-T program, a proven teen cessation program.
3235646|NCT01242657|Experimental|Quit & Fit|Teens randomized to this arm participated in the Not On Tobacco (N-O-T) program with an added physical activity module.
3235647|NCT01242670|Experimental|Ross River Virus Vaccine|Subjects will be randomized in equal numbers (1:1:1) to receive one of three different lots of the vaccine on Day 1, Day 22 and Day 181. (The study is blinded with regard to which vaccine lot is administered to a subject but all subjects will receive 3 injections with a 2.5 µg aluminum hydroxide adjuvanted dose of RRV vaccine.)
3235648|NCT01242683|Experimental|Case-Management for Behavior Change|Individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
3235649|NCT01242683|Experimental|Case-Management plus Home Visits|Community health worker lifestyle support for weight loss strategies conducted in participants' homes and neighborhood. Also, receive individual and group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator. 12 month of intensive intervention followed by 12 months of maintenance intervention.
3235650|NCT01242683|Placebo Comparator|Usual Primary Care|Continuation of usual primary care managed by the participants' usual physician or nurse practitioner source of care.
3336646|NCT02148393|Active Comparator|Control|In the control group, following oocyte retrieval, intensified luteal phase support for fresh embryo transfer (with Pregnyl®, Utrogestan® and Progynova®) will be performed. Fresh ET in the uterine cavity will be performed on the 5th day of embryo development at blastocyst stage under ultrasound guidance whenever possible.
3336647|NCT02148393|Experimental|Intervention|"Elective vitrification with subsequent-cycle embryo thawing/transfer (CryoBioSystem®) will be performed. Hence, no luteal phase support will be provided immediately after oocyte retrieval. Instead, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation.~On the day of embryo transfer, blastocyst(s) will be warmed one by one until one or two blastocysts are suitable for transfer. ET to the uterine cavity will be performed under ultrasound guidance whenever possible."
3336648|NCT02148406|Experimental|Arm I (YST intervention)|Patients undergo YST intervention comprising four individualized, 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation during outpatient chemotherapy sessions in weeks 2, 4, 6, and 8. Patients practice awareness - noticing the current state and establishing relaxed breathing for 5 minutes; movement - 7 minutes of gentle movements coordinated with the breath (such as raising and lowering the arms); breathing practice - 3 minutes of inhaling cool air as if through a straw; and meditation - 5 minutes of focus on letting go of physical and mental tension. Patients review a handout describing the YST and to encourage patients to practice daily with strategies to increase adherence to home practice. Patients also receive an audio recording of the YST and devices to play the recording and are asked to keep a home practice log.
3336649|NCT02148406|Active Comparator|Arm II (attention control)|Patients attend four 30-minute sessions with an interventionist in weeks 2, 4, 6, and 8. During these sessions, patients are encouraged to discuss their experiences while receiving chemotherapy and do not receive instruction of movement, meditation or breathing practices. Patients will also be asked to write brief diary entries daily at home.
3336650|NCT02148432|Experimental|dexmedetomidine 0.5 mcg/kg/hr|
3336651|NCT02148432|Active Comparator|dexmedetomidine 1.0 mcg/kg/hr|
3336652|NCT02148458|Other|Control group|Western diet for 8 weeks, followed by 8 weeks of Western diet with intermittent fasting.
3336653|NCT02148458|Experimental|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting.
3336654|NCT02148471||Healthy controls|Healthy living liver donors with healthy liver on imaging and/or liver histology
3336655|NCT02148471||Simple steatosis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
3336656|NCT02148471||Nonalcoholic steatohepatitis|Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
3336657|NCT02148471||Minimal findings|Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology. This group was initially used as a control group. Later in the study, this group was replaced by healthy donors as true healthy controls.
3336658|NCT02148484|Experimental|1|Prolonged exposure for adolescents
3336659|NCT02148484|Active Comparator|2|Client centered therapy
3336660|NCT02148497|Other|Dry Eye Disease or Sjogren's Disease|Capturing images of the tear surface using the multi-colored Placido disk
3235651|NCT01242696||Coronary artery stenting|All subjects who are candidates for coronary artery stenting, signed the Informed Consent Form and are eligible to receive a TAXUS Element stent will be evaluated for enrollment in this study.
3235652|NCT01242722||1|Two experimental and/or intervention groups under 1 arm.
3336661|NCT02148497|Other|Control|Capturing images of the tear surface using the multi-colored Placido disk
3336662|NCT02148510|Experimental|Monobloc|Treatment with an appliance that holds the lower jaw in a fixed protruded position
3336663|NCT02148510|Active Comparator|Bibloc|Bibloc device where a maxillary splint is connected to a mandibular splint by a connector allowing a slight opening of the jaw without compromizing the protrusion (Narval)
3336664|NCT02148536||HPS-TIPS group|
3336665|NCT02148549|Experimental|Optimal chemotherapy courses|Neoadjuvant chemotherapy 4 courses of FIRINOX early 5 patients, and 8 courses of FIRINOX subsequent 5 patients
3336666|NCT02148562||Chronic Hepatitis B|Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
3336667|NCT02148562||End stage liver disease|Diagnosis of advanced liver disease related to Hepatitis B
3336668|NCT02148575|Experimental|Self-Management Group|"Managing Cancer Care: A Personal Guide (MCC) is a set of magazine-format, printed modules that includes information about key self-management topics, worksheets, conversation starters, and targeted links to local and internet resources, among other features."
3336669|NCT02148575|Active Comparator|Symptom Management Group|Participants in the Symptom Management Group will be given a symptom management toolkit that provides information on the most commonly experienced symptoms and side effects of cancer treatment, including fatigue, nausea, and sleep problems, among others. Each chapter includes information on when and why the symptom may occur, how the symptom can be managed, and when to call a provider.
3336670|NCT02148601|Experimental|Fecal Microbiota Transplantation|Fecal microbiota transplantation from healthy donors will be infused by colonoscopy
3336671|NCT02148601|Active Comparator|Standard Antibiotic Therapy|Standard antibiotic therapy according to European Guidelines (vancomycin and metronidazole) will be administered to the patients
3336672|NCT02148614|Placebo Comparator|Placebo|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
3336673|NCT02148614|Active Comparator|Libramed|Subjects will be randomly assigned to treatment with placebo or LibramedR with a double blind clinical trial.
3235653|NCT01242735|Experimental|Exercise|12-week moderate-intensity behavioral exercise intervention (AE)
3235654|NCT01242735|Active Comparator|Health and Wellness|12-week health and wellness education control (HEC)
3336674|NCT02148627|Experimental|LY3041658 (IV)|Single dose of LY3041658, administered as a slow intravenous (IV) infusion in escalating dose cohorts.
3336675|NCT02148627|Experimental|LY3041658 (SC)|Single dose of LY3041658 administered subcutaneously (SC).
3336676|NCT02148627|Placebo Comparator|Placebo|Single dose of placebo (0.9% sodium chloride injection) administered as a slow IV infusion.
3336677|NCT02148640|Experimental|CT-P13|Infusions of biosimilar infliximab (Remsima) with same dose and frequency as pre-inclusion treatment with innovator infliximab (Remicade)
3235655|NCT01242761||Symptomatic rotator cuff tear|Patients with symptomatic rotator cuff tears presenting to hospital clinic after having ultrasound exam in community with indications for surgery
3235656|NCT01242774|Experimental|Panobinostat|
3336678|NCT02148640|Active Comparator|INX|Continued infusions of innovator infliximab (Remicade) with same dose and frequency as prior to inclusion
3336679|NCT02148653|Experimental|Multifunctional diet (MFD)|Subjects eat a diet designed according to the Nordic Nutrition Recommendations with the addition of important amounts of various functional food concepts: Low GI and GI-modulating food items; Natural antioxidant-rich items, Long chain omega-3 fatty acid-rich fish; Betaglucan-rich barley and oat food/drinks; Cholesterol-modulating foods.
3235657|NCT01242787|Active Comparator|Entecavir 0.5 mg|Entecavir 0.5 mg
3235658|NCT01242787|Experimental|LB80380|Optimal dose of LB80380 (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
3336680|NCT02148653|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Nutrition Recommendations but lacking the functional items included in the MFD.
3336681|NCT02148666||experimental : intracoronary stem cells|intracoronary stem cells will be injected in infarct related artery.
3336682|NCT02148679|Experimental|DASH/SRD|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions~Intervention: pre-prepared, home delivered DASH/SRD-compliant meals for 4 weeks after hospital discharge"
3336683|NCT02148679|Placebo Comparator|Attention Control|"Patients receive Heart Failure Society of America pamphlet, How to eat a low sodium diet at hospital discharge~Study staff will phone patients at weeks 2 and 3 to confirm patients' understanding of dietary instructions"
3336684|NCT02148692|Experimental|Higher PEEP|PEEP of 12 cmH2O or higher and lung recruitment maneuvers
3336685|NCT02148692|Active Comparator|Lower PEEP|PEEP of 4 cmH2O without lung recruitment maneuvers
3336686|NCT02148705|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2 g NexoBrid sterile powder mixed with 20g sterile Gel Vehicle per 1% of TBSA (~ surface of an adult palm) for four hours.
3336687|NCT02148705|Placebo Comparator|Gel Vehicle|Gel Vehicle is applied to the burn wound at a dose of 20 g sterile Gel per 1% of TBSA (~ surface of an adult palm) for four hours.
3235661|NCT01242826|Experimental|A|
3336688|NCT02148705|Active Comparator|Standard of Care (SOC)|Subjects in the SOC group may be treated with a combination of surgical and non-surgical eschar removal procedures, according to the investigator's judgment.
3336689|NCT02148731||Comprehensive Geriatric Assessment (CGA)|Functional status, Comorbidities, Objective physical performance, Nutrition, Cognition, Depression, Social support
3336690|NCT02148744|Experimental|XmAb7195 or Placebo|
3336691|NCT02148757|Other|DVT|Doppler Ultrasound
3336692|NCT02148770|Experimental|Neurofeedback|Neurofeedback training: Up-regulation of DLPFC.
3336693|NCT02148770|Sham Comparator|Neurofeedback SHAM|Neurofeedback training: Sham-regulation of DLPFC.
3336694|NCT02148783|Experimental|methylphenidate administration|All participants will receive oral methylphenidate 60 mg before the second TMS study. The participants will receive oral methylphenidate 60 mg before the second PET scan. Subjects will then be treated with oral methylphenidate, using a forced titration. Dose titration will be incremental within 6 days (dose-escalation phase) , starting at 5 mg orally twice daily for 3 days, and 10 mg twice daily for the next 3 days. Then the dose will be increased to 30 mg twice daily starting from day 7 given twice daily for additional 3 weeks.
3336695|NCT02148796|Active Comparator|Broncho-Vaxom (BV)|One capsule of Broncho-Vaxom for children contains: 3.5 mg of lyophilized bacterial lysates of Haemophilus influenzae, Streptococcus (pneumonia, pyogenes and sanguinis (viridans)), Klebsiella (pneumoniae and ozaenae), Staphylococcus aureus and Moraxella catarrhalis. The content of the capsule will be mixed with a palatable liquid such as fruit juice.
3336696|NCT02148796|Placebo Comparator|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
3336697|NCT02148822||Malnourished|Children with either height for age z score or body mass index for age z score below 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
3336698|NCT02148822||Not malnourished|Children with either height for age z score or body mass index for age z score equal or higher than 2 standard deviations according to the World Health Organization Growth Standards for children younger than 5 years and the 2007 WHO Growth Reference for children of 5 years or older.
3336699|NCT02148848|Active Comparator|Early bisphosphonate use|"Give risedronate (actonel) at 2 weeks after hemiarthroplasty for an osteoporotic femoral neck fracture. In addition, calcium and vitamin D supplementation will be given to all patients.~Risedronate (35 mg) 1 tablet orally once a week"
3235662|NCT01242839|Experimental|CACICOL20|Arm that receives CACICOL20 treatment each 2 days for 3 months/until closure of the ulcer
3235663|NCT01242839|Placebo Comparator|Placebo|The placebo is applicated each 2 days on patient cornea for 3 months/ until ulcer closure.
3235664|NCT01242839|Experimental|CACICOL20 and Placebo|Patient applies the treatment each 2 days for 3 months or until closure of the ulcer. This treatment is alternatively CACICOL20 or Placebo : so the patient receives CACICOL20 each 4 days. CACICOL20 and placebo strips are strictly similar and cannot be identified.
3235665|NCT01242852|Experimental|Additional diagnostic tests|Participants in the experimental arm will undergo standard hysteroscopy with treatment-on-the spot of predefined intrauterine abnormalities. In two of the participating clinics, also a 'Saline Infusion Sonography' (SIS) will be performed, 1 week before the hysteroscopy. After the additional diagnostic test(s), standard IVF/ICSI treatment will be initiated.
3336700|NCT02148848|No Intervention|Late bisphosphonate use|"Give only calcium and vitamin D supplementation during the first 3 months after the surgery.~Bisphosphonate, risedronate (Actonel), will be given at 3 months after surgery for an osteoporotic femoral neck fracture."
3336701|NCT02148861|Experimental|Insulin 287 + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
3235666|NCT01242852|No Intervention|Routine fertility workup|Patients allocated to the conventional strategy will be scheduled for IVF and undergo standard treatment, without SIS or hysteroscopy.
3235667|NCT01242865|Other|Attention and Interpretation Therapy|
3336702|NCT02148861|Active Comparator|Insulin degludec + placebo|Subjects will receive one of two treatment combinations: either insulin 287 + placebo or insulin degludec + placebo. Dose escalation design (4 dose levels).
3336703|NCT02148887||SCI patients with upper limb impairment - Upper limb training|
3336704|NCT02148887||SCI patients with lower limb impairment - Lower limb training|
3336705|NCT02148887||Healthy controls - Upper limb training|
3235668|NCT01242878||healthy volunteers|ethnically matched people who do not have sickle cell disease
3235669|NCT01242878||patients|sickle cell disease patients
3336706|NCT02148887||Healthy controls - Lower limb training|
3336707|NCT02148887||Healthy controls - No intervention|
3336708|NCT02148900||Marfan|Diagnosis of Marfan syndrome, according to Ghent criteria.
3336709|NCT02148900||Marfan Related Disorders|Diagnosis of Loeys-Dietz syndrome, vascular Ehlers-Danlos syndrome, or Familial Thoracic Aortic Aneurysm and Dissection.
3336710|NCT02148900||Control Subjects|Unaffected by Marfan or Marfan related disorders.
3336711|NCT02148913|Active Comparator|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 15 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
3336712|NCT02148913|Active Comparator|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1, +5, and +6 IV over 10 minutes.
3336713|NCT02148913|Active Comparator|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
3336714|NCT02148913|Active Comparator|Cohort 3: Carfilzomib 27mgm2|Carfilzomib 27 mg/m2 on days -2, -1 and +5 IV over 10 minutes.
3336715|NCT02148965|Experimental|Lifestyle intervention|Physical Exercise / Physical Activity. Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
3336716|NCT02148965|No Intervention|Control Group|A group of eligible women, twice as large as the intervention group, will not receive the exercise intervention but will be followed-up equally to compare outcomes in the future.
3336717|NCT02148978|Experimental|Saxagliptin administration|Saxagliptin Administration- The participants in this study will undergo an OGTT (Oral Glucose Tolerance Test) at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin. After 6 weeks of treatment the participants will return to perform a second OGTT.
3336718|NCT02148991||Irbesartan|Patients on irbesartan treatment
3336719|NCT02149004||Site Bonn|
3336720|NCT02149004||Site Heidelberg|
3336721|NCT02149004||Site Munich|
3336722|NCT02149004||Site Hamburg|
3336723|NCT02149004||Site Hannover|
3235670|NCT01242904|Experimental|bimodal solution|200 mls of 30% glucose in sterile water is added by the patient to the usual icodextrin day dwell, to create the bimodal solution intraperitoneally
3235671|NCT01242904|Active Comparator|icodextrin|200 mls of icodextrin is added by the patient to the usual icodextrin day dwell
3235672|NCT01242917|Placebo Comparator|Placebo|
3235673|NCT01242917|Experimental|CCX354-C 100mg twice daily|
3235674|NCT01242917|Experimental|CCX354-C 200mg once daily|
3235675|NCT01242930|Experimental|Imetelstat (7.5 mg/kg)|Imetelstat (7.5 mg/kg) with or without lenalidomide standard of care
3235676|NCT01242930|Experimental|Imetelstat (9.4 mg/kg)|Imetelstat (9.4 mg/kg) with or without lenalidomide standard of care
3235677|NCT01242943|Experimental|L19SIP I131|"Phase I: Multicentre, open-label, two-step single-arm dose escalation study in sequential cohorts of patients with cancer.~Phase II: Prospective, open-label, single-arm, multicentre study of 131I-L19SIP, given at the RD as determined in phase I."
3336724|NCT02149004||Site Cologne|
3336725|NCT02149004||Site Freiburg|
3336726|NCT02149004||Site Frankfurt|
3336727|NCT02149004||Site Essen|
3336728|NCT02149017|Experimental|SNUBH-NM-333(18F), Safety, Efficacy|10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients
3336729|NCT02149030|Active Comparator|A1|A1) Cytological screening in A1 and A3. Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
3235678|NCT01242956|Experimental|Verum group|video-based training after stroke
3336730|NCT02149030|No Intervention|A2|A2) infrequent information of screening results, only at the age 30 years.
3336731|NCT02149030|Other|A3|A3) Cytological screening in A1 and A3. With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
3336732|NCT02149043||Ulcerative Colitis patients|30 patients with active ulcerative colitis will be put throe thermography and colonoscopy. Their stool will be tested for fecal calprotectin and their blood for CRP and other laboratory measures.
3336733|NCT02149043||Healthy volunteers|30 healthy individuals matching sex and BMI to those of ulcerative colitis patients will be put throe thermography and have their stool tested for fecal calprotectin and their blood for CRP.
3235679|NCT01242956|Placebo Comparator|Placebo group|non-video group
3235680|NCT01242982|Experimental|Operation|Closed reduction and operated for fixation with 2 antegrade intramedullary Kirschner wires.
3235681|NCT01242982|Active Comparator|Conservative treatment|Treated conservatively with reduction and then Plaster of Paris.
3235682|NCT01242995||pancreatobiliary disorders/thin scope|All patients will be evaluated with cholangioscopy and/or pancreatoscopy using the thin scope.
3235683|NCT01243047|Active Comparator|Arm A|Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily
3235684|NCT01243047|Active Comparator|Arm B|Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.
3235685|NCT01243060|Experimental|Almorexant 100mg|Subjects will receive a one-time dose of Almorexant 100mg.
3336734|NCT02149056||Impaired Glucose Tolerance|
3336735|NCT02149082||Infrascanner exam|Infrascanner Model 2000 exams may be conducted either before or after an associated head CT for pediatric patients presenting to the emergency department (ED) or pediatric intensive care unit (PICU) with a known or suspected traumatic head injury undergoing a head CT scan to evaluate for the presence or absence of an intracranial hematoma. The time between the head CT scan and the Infrascanner exam will be within 6 hours. The exam involves placing a sensor on the designated areas of the head with the most common locations for traumatic hematoma. Readings from the monitor evaluating each region will be evaluated and recorded. The 8-point exam can be accomplished within 5 minutes or less.
3336736|NCT02149095|Experimental|TransCon PEG treprostinil|Dosing will begin at 0.116 mg/kg TransCon PEG treprostinil subcutaneous injection and the dose escalated in subsequent cohorts to MTD.
3235686|NCT01243060|Experimental|Almorexant 200mg|Subjects will receive a one-time dose of Almorexant 200mg.
3336740|NCT02149134|Experimental|New extensively hydrolyzed casein formula|Subjects with cow's milk allergy treated with a new formula
3336741|NCT02149147||Physical Activity Variety|participants will complete the Self-Efficacy questionnaire, the Physical Activity Enjoyment Scale, the Behavioral Regulation in Exercise-2 questionnaire, and an Outcome Expectations questionnaire. Participants will be instructed to wear the SenseWear® armband which will measure physical activity-related energy expenditure for the course of the study. The armband will be worn every day for at least 10 hours per day. In addition, participants will be asked to complete a physical activity diary to record their physical activity as well as additional information about the environment in which the physical activity was conducted. Participants will be instructed to engage in their normal physical activity regimen, wear the armband, and complete the physical activity diary for 3 weeks.
3235687|NCT01243060|Active Comparator|Zolpidem|Subjects will receive a one-time dose of Zolpidem 10mg.
3235688|NCT01243060|Placebo Comparator|Placebo|Subjects will receive a one-time dose of Placebo.
3235689|NCT01243073|Experimental|imetelstat|Induction dosing of 9.4 mg/kg weekly, followed by intermittent maintenance dosing.
3336742|NCT02149160|Experimental|FRM-0334; Arm 1|low dose, Capsule, Once Daily, Day 1 through Day 28
3336743|NCT02149160|Experimental|FRM-0334; Arm 2|high dose, Capsule, Once Daily, Day 1 through Day 28
3336744|NCT02149160|Placebo Comparator|Placebo Comparator; Arm 3|Placebo, Capsule, Once Daily, Day 1 through Day 28
3336745|NCT02149186|Experimental|Rehabilitation|
3336746|NCT02149212|Active Comparator|Clinical Treatment|Phlebotonics: Aminaftone 75 mg BID Limb elastic compression support (Elastic stockings: Venosan / Elastic Bandages: Atamed) Unna boot dressing
3336747|NCT02149212|Active Comparator|Iliac vein stenting|Wallstent
3235690|NCT01243086|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3336748|NCT02149225|Experimental|APVAC1 and 2 vaccine plus polyICLC and GMCSF concurrent to TMZ|
3336749|NCT02149238|Active Comparator|flavanol rich drink intervention|flavanol rich drink
3336750|NCT02149238|Active Comparator|methylxanthine rich drink intervention|methylxanthine rich drink
3336751|NCT02149238|Active Comparator|flavanol + methylxanthine rich drink intervention|flavanol + methylxanthine rich drink
3336752|NCT02149251||Pre-genetic diagnosis|Women in this group had ICSI and PGD to exclude genetically affected children or for sex selection
3336753|NCT02149251||Control group|This group will include women who had IVF without PGD
3235691|NCT01243086|Active Comparator|Ranibizumab and OZURDEX|Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections. Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and OZURDEX will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration.
3235692|NCT01243099||In-stent (BMS) restenosis|
3235693|NCT01243099||De-novo coronary lesion|
3235694|NCT01243125|Experimental|NVC-422|
3235695|NCT01243125|Placebo Comparator|Saline|
3235696|NCT01243164|Experimental|Wheelchair Skills Training Program|A standardized wheelchair skills training program to teach 32 specific wheelchair skills.
3336754|NCT02149277|Active Comparator|Filgrastim|Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
3336755|NCT02149277|Placebo Comparator|Sodium Chloride|Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
3336756|NCT02149316|Experimental|RIPC+RIPostC|
3336757|NCT02149316|Sham Comparator|control|
3336758|NCT02149329|Experimental|Short treatment|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
3336759|NCT02149329|No Intervention|Extended treatment|Extended treatment with imipenem-cilastatin or meropenem for at least 6 more days. The treatment with a carbapenem will be continued until patients have been treated for at least 9x24 hours and have been afebrile (tympanic membrane temperature <38.0°C) for at least five consecutive days or until resolution of neutropenia (ANC > 0,5 x10^9/L), whichever comes first.
3336760|NCT02149355||controls|teeth molding in subjects without congenital fourth nerve palsy
3336761|NCT02149355||congenital fourth nerve palsy|teeth molding in patients suffering from congenital fourth nerve palsy
3336762|NCT02149381|Experimental|CBASP|Cognitive Behavioral System of Psychotherapy is a manual-based group intervention for chr depression (20 weeks).
3336763|NCT02149381|Active Comparator|Befriending|Befriending is a social support intervention
3336764|NCT02149381|Active Comparator|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
3336765|NCT02149394|Experimental|Ice|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale.The experimental group received an ice popsicle made of 10 mL mineral water.The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice was supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort.
3235697|NCT01243190|Experimental|Ofatumumab|Loading dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
3336766|NCT02149394|Active Comparator|Water|The concealment of allocation was performed through the use of individual opaque envelopes numbered externally in sequence, containing information of the group randomly defined. This step was carried out by a researcher who did not take part in data collection.Thirst intensity was measured within the range from 1 to 10 according to the numeric visual analogue scale. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
3336767|NCT02149407|Active Comparator|Glycerin group (GG)|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
3336768|NCT02149407|Active Comparator|Rectal stimulation group (SG)|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
3336769|NCT02149407|Sham Comparator|Control group (CG)|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
3235698|NCT01243203|Placebo Comparator|Placebo|patient will receive placebo pills
3235699|NCT01243216|Experimental|Ultrasound Group|Patients in the Ultrasound Group will have a pre-procedure ultrasound of the spine prior to needle placement
3336770|NCT02149433|Experimental|Prednisone versus placebo|Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days
3336771|NCT02149446|Experimental|Surgisis reinforcement of staple line|The stapler used to divide the pancreas is reinforced with Surgisis (COOK Medical).
3336772|NCT02149446|No Intervention|No reinforcement of staple line|The stapler used to divide the pancreas is not reinforced with any material
3336773|NCT02149459|Experimental|treatment arm|Partial brain re-irradiation combined with metabolic intervention (low carbohydrate diet and/or metformin treatment)
3336774|NCT02149472||Pregnant women with PPH|All pregnant women in participating hospitals are asked for their informed consent (n = 9.500). All women will complete a bleeding score generating questionnaire during their pregnancy. Only from women developing postpartum haemorrhage > 1000 cc blood samples will be drawn (n = 600).
3336775|NCT02149498||Parkinson Disease (PD)|Idiopathic PD patients (according to the UK PD Society brain bank clinical diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no atypical features or secondary cause)
3336776|NCT02149498||Healthy Controls|Healthy individuals
3336777|NCT02149511||SCI subjects|
3336778|NCT02149511||healthy control subjects|
3336779|NCT02149550|Active Comparator|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
3336780|NCT02149550|Experimental|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
3336781|NCT02149550|Experimental|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
3235700|NCT01243216|No Intervention|No Ultrasound Group|Patients in the No Ultrasound Group will not have a pre-procedure ultrasound of the spine performed prior to needle placement.
3235701|NCT01243255||1|Patients with hypercholesterolemia on lipid lowering pharmacological treatment
3235702|NCT01243281|Active Comparator|drug combination|
3235703|NCT01243307|Experimental|CT327 treatment period 1|Subjects in Group 1 will receive CT327 during treatment/testing period 1 and placebo during treatment/testing period 2
3235704|NCT01243307|Experimental|CT327 treatment period 2|Subjects in Group 2 will receive placebo during treatment/testing period 1 and CT327 during treatment/testing period 2
3235705|NCT01243346|Experimental|Crenolanib (CP-868,596)|
3235706|NCT01243359|Experimental|Treatment (sunitinib malate, bevacizumab)|Patients receive sunitinib malate PO on days 1-28 and bevacizumab IV over 30-90 minutes on day 29. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3235707|NCT01243372||Correlative (BRAF V600E mutation analysis)|Previously collected formalin-fixed and paraffin-embedded baseline tumor samples are analyzed for BRAF V600E mutation. Mutation status is correlated with clinical response and outcome data from patients enrolled on CALGB-C80405.
3336782|NCT02149550|Active Comparator|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes
3336783|NCT02149550|Experimental|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes
3336784|NCT02149550|Experimental|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito
3336785|NCT02149563|Active Comparator|Treatment|One hundred participants will receive home treatment with oxygen-enriched air (40% O2) through a nasal tube during the night (7 hours) for one month.
3336786|NCT02149563|Placebo Comparator|Placebo|100 participants will receive regular air treatment (21% O2) through a nasal tube (identical to the procedure providing 40% O2) for one month
3336787|NCT02149576|Active Comparator|LDCT Surveillance Program Group|This cohort will follow a strict schedule of Low Dose Computed Tomography Imaging scans and clinical visits 3, 6, and 12 months after surgery. At each encounter, a history, physical examination, and review of the LDCT results will be performed. Patients with normal clinical and imaging findings will proceed to the next scheduled clinical encounter. Patients with abnormal findings will be managed according to predetermined algorithms.
3336788|NCT02149576|Other|Historical Control Group|The control group will be a retrospective cohort taken from 1-year before the implementation of the LDCT surveillance program. The post-operative follow-up of these participants was not standardized, but rather left up to the discretion of the individual surgeons, and involved chest radiograph imaging as opposed to Low Dose Computed Tomography.
3336789|NCT02149589|Experimental|Focal ARDS|In Focal ARDS prone position will be promote early, with low PEEP and moderate Vt.
3336790|NCT02149589|Other|non focal ARDS|In non-Focal ARDS, Recruitment maneuvers, high PEEP and low V twill be used
3336791|NCT02149602||oropharyngeal and hypopharyngeal HNSCC|Intensity Modulated Radiotherapy HPV positive and HPV negative
3235708|NCT01243385|Other|Metformin|Metformin at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
3336792|NCT02149615|Experimental|isotretinoin|Retinal nerve fibre layer measurement in patients under isotretinoin treatment
3336793|NCT02149615|Active Comparator|lymecycline|Retinal nerve fibre layer measurement in patients under lymecycline treatment
3336794|NCT02149615|Active Comparator|minocycline|Retinal nerve fibre layer measurement in patients under minocycline treatment
3336795|NCT02149615|Active Comparator|doxycycline|Retinal nerve fibre layer measurement in patients under doxycycline treatment
3336796|NCT02149628|Active Comparator|desflurane|use desflurane as a primary anesthetics during anesthesia guided by bispectral index (BIS)
3235709|NCT01243398|Experimental|Gefitinib 500mg once daily|Gefitinib 500mg once daily
3235710|NCT01243398|Placebo Comparator|Placebo|Gefitinib 500mg once daily
3336797|NCT02149628|Experimental|propofol|propofol infusion with target-controlled infusion(TCI) device guided by BIS
3336798|NCT02149641||Nasopharyngeal cancers|Intensitiy modulated radiotherapy with chemotherapy
3235711|NCT01243437|Experimental|ciprofloxacin|
3235712|NCT01243437|Active Comparator|doxycycline|
3336799|NCT02149667||Total Hip Arthroplasty|Single study group previously implanted with the following combination of components: MicroPort Orthopedics Femoral Stems, DYNASTY® BioFoam® Acetabular Components, DYNASTY® A-Class® Cross Linked Polyethylene Liners, and MicroPort Orthopedics Metal or Ceramic Femoral Heads
3336800|NCT02149680||Experimental group|Patient who has had an epidural blood patch following accidental dura puncture during pregnancy
3336801|NCT02149680||Control Group|Women in the same group, equal numbers of those with or without epidurals, without accidental dural puncture, similar parity would constitute the control group. They would be chose at random, 10 times the number in the experimental group (n = 600).
3336802|NCT02149693|Experimental|high-fidelity simulation and teamwork training|high-fidelity simulation and teamwork training
3336803|NCT02149693|Active Comparator|traditional resuscitation training|traditional resuscitation training
3336804|NCT02149706|Experimental|NeuroVax|NeuroVax
3235713|NCT01243476|Experimental|lenalidomide|Experimental treatment branch with Lenalidomide 5 mg/day (oral use)
3235714|NCT01243476|Placebo Comparator|placebo|Placebo branch (oral use)
3235715|NCT01243489|Other|patient diary|compliance supporting measure: patients uses patient diary from month 6 to 12
3336805|NCT02149706|Placebo Comparator|IFA Incomplete Freund's Adjuvant|Incomplete Freund's Adjuvant IFA
3336806|NCT02149719|Experimental|Desensitisation to peanut|Desensitisation using boiled peanut
3235716|NCT01243489|Other|"Information service Leben mit CML"|"compliance supporting measure: patient uses the Information service Leben mit CML"
3235717|NCT01243502|Experimental|0.01% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.01% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
3235718|NCT01243502|Experimental|0.001% CT327 (or placebo)|Six (of eight) subjects received a single topical dose of 0.001% CT327 followed by a 7 day wash-out period. The subjects then received a single topical dose of CT327 on five consecutive days. Two subjects received placebo.
3235719|NCT01243515||Chronic Kidney Disease|minimum 7 subjects (male and female)
3235720|NCT01243515||Healthy subjects|minimum 3 subjects (male and female)
3235721|NCT01243528||Patients in neurological rehabilitation|Patients suffering from a neurological disease
3235722|NCT01243541|Experimental|Arm I|Patients wear an Elasto-Gel cold glove and sock on their dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel.The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
3336807|NCT02149719|Experimental|Control|Subjects allocated to the control group will undergo routine care for 12 months, following which they will be offered the active treatment with boiled peanut (as a one-way cross-over intervention).
3336808|NCT02149745|Experimental|Calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by calling the patient's name
3336809|NCT02149745|Experimental|Not calling the patient's name|The anesthesiologist tries to recover the patient's consciousness by giving verbal stimulus other than the patient's name
3336810|NCT02149758|Experimental|Etoricoxib|Etoricoxib 60 mg once daily
3336811|NCT02149758|Placebo Comparator|matching placebo|matching placebo once daily
3235723|NCT01243541|Experimental|Arm II|Patients wear an Elasto-Gel cold glove and sock on their non-dominant hand and foot every two weeks on days the patient is scheduled for paclitaxel. The glove and sock is worn for 15 minutes prior to paclitaxel infusion, 3 hours during treatment, and for 15 minutes after completion of chemotherapy for a total of 210 minutes.
3235724|NCT01243554|Experimental|Exercise training|Supervised exercise training at the hospital during pregnancy: the women will attend at least 2 weekly sessions consisting of aerobic exercise (walking on treadmills), strength training (for upper body, back, abdomen and legs) as well as pelvic floor muscle exercises. Each session is 60 minutes and lead by a physiotherapist or experienced exercise physiologist. The women will also go through motivational interviewing sessions throughout the intervention period and are encouraged to do home exercise training in addition to the exercise at the hospital
3235725|NCT01243554|No Intervention|Control|Usual care as provided by the health services in Norway. The investigators will not advice the women to be inactive
3235726|NCT01243606|Experimental|Single Diagnosis Treatment Protocols|Four disorder-specific cognitive-behavioral treatments will be conducted in accordance with treatment manuals of demonstrated efficacy. SDPs will be matched to the principal anxiety disorder diagnosis.
3336812|NCT02149771|Experimental|TACE&Stents|chemoembolization combined with endovascular stents and iodine-125 seed strand implantation
3336813|NCT02149771|Active Comparator|TACE|Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
3336814|NCT02149784|Experimental|Surgical treatment group|Unresectable mCRC patients who respond to chemotherapy will receive surgical resection of primary tumor.
3336815|NCT02149784|No Intervention|Chemotherapy group|Unresectable mCRC patients who were respond to chemotherapy will continue with chemotherapy.
3336816|NCT02149797|Active Comparator|Four port laparoscopic cholecystectomy|This group of patients undergone classical four port laparoscopic cholecystectomy
3336817|NCT02149797|Active Comparator|SILC-Pick'n roll-Beginning (group I)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's beginning arm."
3336818|NCT02149797|Active Comparator|SILC-Pick'n roll-Experienced (group II)|"This group of patients undergone single-incision laparoscopic cholecystectomy using our new technique called Pick'n roll, this group was designed new intervention's experienced arm."
3235727|NCT01243606|Experimental|Unified Protocol|The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders will be individually administered in accordance with a treatment protocol.
3235728|NCT01243606|No Intervention|Waitlist Control|Waitlist participants will not receive treatment during a 16-week waitlist period, but will receive the treatment of their choice immediately following the 16 week waiting period.
3336819|NCT02149823|Active Comparator|Intranasal Oxytocin Group 1|Placebo on visit 1, oxytocin 24IU on visit 2, then 40 IU on visit 3
3336820|NCT02149823|Active Comparator|Intranasal Oxytocin Group 2|oxytocin 24IU on visit 1, placebo on visit 2, then oxytocin 40IU on visit 3
3235729|NCT01243658|Experimental|Oxytocin|Oxytocin
3336821|NCT02149823|Active Comparator|Intranasal Oxytocin Group 3|oxytocin 40IU on visit 1, oxytocin 24IU on visit 2, then placebo on visit 3.
3336822|NCT02149823|Active Comparator|Intranasal Oxytocin Group 4|after visit 4, placebo on subsequent visit , then oxytocin 40IU at following visit
3336823|NCT02149823|Active Comparator|Intranasal Oxytocin Group 5|after visit 4, oxytocin 40IU on subsequent visit, then placebo at following visit
3336824|NCT02149849|No Intervention|Standard lateral positioning|
3336825|NCT02149849|Experimental|Modified lateral positioning|Modified lateral positioning. This will ensure less pressure and stretch on shoulder than standard lateral positioning.
3336826|NCT02149862|Experimental|cancer|patients with an indication of partial or total bladder resection will have urine infrared analysis
3336827|NCT02149862|Placebo Comparator|control group|"Lithiasic patients should be operated a urinary calculation, without catheter double J, will have urine infrared analysis"
3336828|NCT02149888|Experimental|Tenofovir/emtricitabine|MSM receiving once daily TDF/FTC-based (Truvada®) pre-exposure prophylaxis
3235730|NCT01243658|Placebo Comparator|Placebo|Placebo
3235731|NCT01243684|Active Comparator|Healty volunteers|
3235732|NCT01243684|Experimental|Patients|
3235733|NCT01243697|Experimental|desogestrel|Tablets of 75 µg, once daily during 112 days
3336829|NCT02149901|Experimental|Pseudoephedrine + 480 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 480 ml
3336830|NCT02149901|Placebo Comparator|Pseudoephedrine + 50 ml water|Pseudoephedrine 30 mg PO 45 minutes before water 50 ml
3336831|NCT02149901|Experimental|Placebo + 480 ml water (optional)|Placebo PO 45 minutes before water 480 ml
3336832|NCT02149901|Placebo Comparator|Placebo + 50 ml water (optional)|Placebo PO 45 minutes before water 50 ml
3336833|NCT02149914|Experimental|PPI treatment|Patients with GERD would be assessed by ANSWatch. Ryodoraku, UGI endoscopy, and GerdQ before taking PPIs and after taking PPI 20mg tablet by mouth everyday for 4 weeks.
3336834|NCT02149927|Experimental|Sevoflurane|Single arm: dose escalation of study medication
3235734|NCT01243710|Experimental|Taurolidine with heparin|
3235735|NCT01243710|Active Comparator|Heparin|
3235736|NCT01243723|Experimental|Eductyl suppository|
3235737|NCT01243723|Placebo Comparator|Placebo suppository|
3235738|NCT01243736|No Intervention|Standard prep|One group will receive the standard bowel preparation, which consists of eating no solid foods after 7 p.m. the evening prior to the capsule endoscopy test and being able to consume clear liquids up to 4 hours prior to the capsule endoscopy test
3336835|NCT02149940|Experimental|clinical pharmacy intervention|
3336836|NCT02149953|Experimental|Glycine intake|Dietary supplement: Glycine intake
3336837|NCT02149966|Experimental|AG-348|Multiple oral doses of AG-348
3336838|NCT02149966|Placebo Comparator|Placebo|Multiple oral doses of placebo.
3336839|NCT02149979|Experimental|Temperature Controlled Laser Soldering|Efficacy and safety of Temperature Controlled Laser Soldered wound incisions closure
3336840|NCT02149992|Experimental|Myo-inositol, folic acid|"myo-inositol, oral, 2g, two times per day for 5 total days~folic acid, oral 200 micrograms, two times per day for 7 days~Continuous Glucose Monitoring Surveillance device for 7 days during study period~Capillary glucose monitoring 4 times per day"
3235739|NCT01243736|Active Comparator|Combination Prep|"The other group will receive the combination bowel preparation, which consists of taking the standard bowel preparation plus:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
3235740|NCT01243788|Active Comparator|Ipratropium/Albuterol|Ipratropium/Albuterol 36/206ug QID
3336841|NCT02150005|Experimental|Periodontal treatment|The test group received oral hygiene instructions, supragingival and subgingival scaling and root planning using curettes and an ultrasonic appliance.
3235741|NCT01243801|Active Comparator|Epidural ketamine|"Bolus of epidural ketamine during the induction of anesthesia~Epidural infusion of ketamine during the first 48 h after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
3235742|NCT01243801|Active Comparator|Intravenous ketamine|"Bolus of intravenous ketamine administered during the induction of anesthesia~Intravenous infusion during the first 48 hours after surgery~Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine plus fentanyl"
3235743|NCT01243801|Placebo Comparator|Placebo|"Postoperative analgesia: Epidural Patient Controlled Analgesia with ropivacaine and fentanyl"
3235744|NCT01243814|Active Comparator|supartz|active intervention arm
3235745|NCT01243814|Placebo Comparator|saline injection|placebo intervention arm
3336842|NCT02150005|No Intervention|Control|
3336843|NCT02150018||non invasive ventilation (NIV)|
3336844|NCT02150031|Other|Control|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~No prophylactic Chlorhexidine regimen.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3336845|NCT02150031|Active Comparator|CHX-Mouthwash|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®, Johnson and Johnson, Barcelona, Spain).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3336846|NCT02150031|Active Comparator|CHX-MW/SUB_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA) (at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and subgingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done with the Heraeus Citojet Intraligamental Syringe (Kulzer Heraeus S.A., Madrid, Spain) at six points on each tooth (3 points on the vestibular surface and 3 on the palatine surface).~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3336847|NCT02150031|Active Comparator|CHX-MW/SUPRA_IR|"Blood extraction using the intravenous access 18-22 gauge angiocath catheter (Becton Dickinson, Sparks, MD, USA)(at baseline, 30 seconds and 15 minutes after tooth extraction).~Mouthwash with 0.2% Chlorhexidine (10 ml for 1 minute) (Oraldine Perio®) and then supragingival irrigation with 1% Chlorhexidine on the tooth to be extracted; the irrigation will be done continuously around the tooth to be extracted by a conventional syringe.~Local anesthesia with lidocaine plus adrenaline (1:100,000).~Tooth extraction."
3336848|NCT02150070|Experimental|Intravenous ASP2408|
3336849|NCT02150070|Experimental|Subcutaneous ASP2408 low dose|
3336850|NCT02150070|Experimental|Subcutaneous ASP2408 middle dose|
3336851|NCT02150070|Experimental|Subcutaneous ASP2408 high dose|
3336852|NCT02150070|Placebo Comparator|Intravenous Placebo|
3336853|NCT02150070|Placebo Comparator|Subcutaneous Placebo|
3336854|NCT02150083|Experimental|OR retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is NOT replaced for the duration of the surgery. The surgery is completed and the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will be instructed to void. The voided volume and residual volume will be recorded.
3336855|NCT02150083|No Intervention|PACU retrograde fill|At completion of sling placement in the operating room, the bladder will be filled retrograde via a cystoscope with 300 mL sterile saline or water to inspect for bladder perforation. The cystoscope is removed and the foley catheter is replaced for the duration of the surgery and when complete the patient is transferred to the post-anesthesia care unit. Once she is able to ambulate, she will undergo a retrograde bladder fill with 300 mL of normal saline. The foley catheter will be removed and she will be instructed to void. The voided volume and residual volume will be recorded.
3336856|NCT02150096|Active Comparator|Continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3336857|NCT02150096|Active Comparator|Pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3336858|NCT02150096|Active Comparator|low level laser therapy group|the group will be treated with 3J during 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
3336859|NCT02150096|No Intervention|control group|group of women no treated, only evaluated in two moments and this group will be compared with orthers: laser, pulsed ultrasound and continuous ultrasound.
3336860|NCT02150122|Experimental|10 micrograms (400 IU) vitamin D3|Participants will be given a daily supplement containing 10 micrograms (400 IU) vitamin D3 to take for 5 months.
3336861|NCT02150122|Experimental|20 micrograms (800 IU) vitamin D3|Participants will be given a daily supplement containing 20 micrograms (800 IU) vitamin D3 to take for 5 months.
3336862|NCT02150122|No Intervention|Placebo|Participants will be given a placebo, similar in appearance to the vitamin D3 tablets, to take for 5 months.
3336863|NCT02150135|Experimental|Oncothermia group|Patients were treated with oncothermia 2 or 3 times a week. Treatment was performed for about 1 hours per each visits.
3336864|NCT02150148|Experimental|Mentored Gardening Intervention|Participants in this arm will be provided with either a raised bed garden or 4 earthboxes, gardening supplies, and plants and seeds. A master gardener from the Cooperative Extension will mentor them over the course of a year to plant three gardens (spring, summer and fall).
3336865|NCT02150148|Other|Wait-List|Participants in this arm will be provided with the same gardening supplies as the other group, but will receive them one year after enrollment in the study. They also will receive instruction from a master gardener from the Cooperative Extension at this time as well.
3336866|NCT02150161|Experimental|lidocaine/ ketamine infusion|lidocaine 1mg/Kg bolus, followed by continuous infusion 1 mg/kg/h AND ketamine 1mg/Kg bolus followed by continuous infusion 1 mg/kg/h
3336867|NCT02150161|Active Comparator|fentanyl|iv fentanyl, 3ug/kg bolus
3235746|NCT01243827|Experimental|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
3336868|NCT02150174|Experimental|Patients with schizophrenia|
3336869|NCT02150174|Active Comparator|Healthy subjects|
3336870|NCT02150187|Experimental|HCap Formula|Pill of HCap Formula every other day for 6 month during the treatment phase; Follow up phase: nothing.
3336871|NCT02150187|Placebo Comparator|Placebo|Same as treatment with placebo pills
3235747|NCT01243827|Experimental|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
3235748|NCT01243853|Active Comparator|Alpha-galactosidase|
3235749|NCT01243853|Placebo Comparator|Placebo|
3235750|NCT01243866|Experimental|Early treatment|comprehensive dental treatment
3336872|NCT02150200|Other|A group : Conventional hospitalization|Patients discharged after 3 days hospital stay after laparoscopic hysterectomy
3336873|NCT02150200|Experimental|B group : shorter stay|Patients going home within 24 hours discharged the first day after laparoscopic hysterectomy.
3336874|NCT02150226|Experimental|Experimental: Zirconia monolithic crowns and bridges|Evaluation of Lava Plus zirconia dental crowns and bridges
3336875|NCT02150239||postoperative pain|
3336876|NCT02150252|Experimental|BY HWT，placebo-BY HWT ， Gait parameter|
3336877|NCT02150265|No Intervention|Waiting list control group|6 week waiting list
3336878|NCT02150265|Experimental|Individual cognitive behavioral therapy with SMART|SMART manual cognitive behavioral therapy individual weekly sessions for 6 weeks
3336879|NCT02150278|Experimental|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
3336880|NCT02150291|Active Comparator|Group A|one capsule of 5 mg of Folic acid twice daily and a tablet of Neurobion three times per day during hepatitis C treatment
3336881|NCT02150291|Active Comparator|Group B|Patients will receive one capsule of 5 mg of Folic acid twice daily during hepatitis C treatment
3336882|NCT02150291|Active Comparator|Group C|Patients will receive a tablet of Neurobion three times per day during hepatitis C treatment
3336883|NCT02150291|Placebo Comparator|Group D|Patients will receive matching placebo capsule to take during hepatitis C treatment
3336884|NCT02150304||intravenous aminophylline|intravenous aminophylline use during spinal anesthesia
3336885|NCT02150304||no intravenous aminophylline|no use of intravenous aminophylline during spinal anesthesia
3336886|NCT02150317|Active Comparator|TACE+Sorafenib|TACE followed by Sorafenib
3336887|NCT02150317|Experimental|TACE|TACE alone
3336888|NCT02150330|Active Comparator|DHEAS in DOR Group|Additional usage of DHEAS supplement in patients with DOR under ovarian hyper-stimulation protocol.
3336889|NCT02150330|Active Comparator|Normal Control|Patients under ovarian hyper-stimulation protocol. No DHEAS supplement.
3336890|NCT02150330|Active Comparator|Shame DOR Group|Patients with DOR under ovarian hyper-stimulation protocol. No DHEAS supplement.
3336891|NCT02150356|Experimental|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
3336892|NCT02150356|Placebo Comparator|Control|Diet based on refined cereal products for a period of 8 weeks.
3336893|NCT02150369||Patient, care partner, primary nurse case|In Phase I of this pilot, a case is comprised of the metastatic RCC patient receiving IL-2, their care partner, and their primary nurse. In Phase II, the IL-2 patient can either have MM or metastatic RCC. The care partner for this study will be the family member or friend staying with the IL-2 patient throughout treatment.
3336894|NCT02150395|Experimental|music therapy|pt received a protocolized music therapy intervention that included altered state induction, music driven guided visualiztion, and psychoeducation on relaxation techniques to be used during simulation for radiation therapy. Prescribed pre-recorded music program provided to be used during simulation.
3336895|NCT02150395|No Intervention|control|no intervention
3336896|NCT02150408|Experimental|assesment by 68Ga-DOTATATE PET-CT|
3336897|NCT02150421||e-book|study the course materials by using e-book
3336898|NCT02150434|Sham Comparator|Compressed Air|compressed air delivered at a fixed flow of 2 L/min
3336899|NCT02150434|Active Comparator|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
3336900|NCT02150434|Experimental|Automated oxygen titration|oxygen at a variable flows delivered by the FreeO2
3235751|NCT01243866|No Intervention|Regualr treatment|Regular treatment consisted of children who would be on a waiting list for regular dental treatment at KFAFH for at least 8 months
3235752|NCT01243879|Active Comparator|Fasting with stimuli|Fasting in the presence of food-related stimuli
3235753|NCT01243879|Sham Comparator|Fasting without stimuli|Fasting in the absence of food-related stimuli
3235754|NCT01243905|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the child (TAU)
3336901|NCT02150447|Active Comparator|Intervention group|Proton pump inhibitor (lansoprazole) therapy for the prevention of gastric cancer bleeding
3235755|NCT01243905|Placebo Comparator|Treatment as usual|Treatment as usual for the child (TAU)
3235756|NCT01243918|Experimental|VNI/Optiflow, Immunodeficient patients|VNI = non invasive ventilation
3235757|NCT01243918|Experimental|Optiflow/VNI, Immunodeficient patients|VNI = non invasive ventilation
3235758|NCT01243918|Experimental|Ospal/Optiflow, Immunocompetent patients|
3336902|NCT02150447|Placebo Comparator|Placebo group|Placebo for the prevention of gastric cancer bleeding
3336903|NCT02150473|Experimental|Adalimumab|receive adalimumab 40 mg eow injections in combination with MTX for 24 weeks
3336904|NCT02150473|Placebo Comparator|Placebo|receive placebo injections in combination with MTX for 24 weeks
3336905|NCT02150512|Experimental|Transpulmonary thermodilution (TPTD)|The intervention group (TPTD guided therapy) follows a fluid resuscitation protocol based on stroke volume variation (SVV) and extravascular lung water (EVLW). Initial trigger for fluid loading when circulatory insufficiency is present will be SVV.
3235759|NCT01243918|Experimental|Optiflow/Ospal, Immunocompetent patients|
3336906|NCT02150512|Active Comparator|Surviving Sepsis Guidelines (SSG)|The standard group (SSG guided therapy) follows a fluid resuscitation protocol based on the Surviving Sepsis Campaign recommendations. Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg).
3336907|NCT02150525|Experimental|Arm I (oral omega-3 fatty acid)|Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
3336908|NCT02150525|Placebo Comparator|Arm II (placebo)|Patients received equivalent, matched oral placebo (seven capsules) daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
3336909|NCT02150538|Active Comparator|Right ventricular stimulation|patients with conventional Right Ventricular Stimulation (only RV) with optimized algorithms for minimization of pacing
3336910|NCT02150538|Experimental|Biventricular Stimulation|Patients with biventricular stimulation (Right Ventricle and Left Ventricle)
3336911|NCT02150551|Experimental|Mesenchymal Stromal Cells (MSCs)|A fixed dose of Mesenchymal Stromal Cells (MSCs) will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
3336912|NCT02150564|Other|Navigation only group|Sonowand system will be used for navigation control arm as well as sononavigation experimental arm.Navigation will be used to plan the craniotomy and throughout the procedure as desired by the operating surgeon. At no point of time however will the Ultrasound be used.
3336913|NCT02150564|Experimental|SonoRCT Test group|Surgery to resect the tumor with the aid of sononavigation. In addition to the navigation function, the Ultrasound will be available at all times. This study will help in assessing the usefulness sononavigation in improving radicality of resection in malignant gliomas and also to access the accuracy of SonoWand in predicting residue.
3336914|NCT02150577|Experimental|Implementation|Evidence Based Quality Improvement
3336915|NCT02150577|No Intervention|Control|Usual Quality Improvement
3336916|NCT02150590|Active Comparator|Oxygen|oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336917|NCT02150590|Placebo Comparator|Sham oxygen|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336918|NCT02150603||Adults with congenital heart disease|
3336919|NCT02150616|Experimental|Moderate altitude sojourn|Sojourn at moderate altitude (2048 m)
3336920|NCT02150616|Experimental|Low altitude sojourn|Sojourn at low altitude (490 m, baseline)
3336921|NCT02150616|Active Comparator|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
3336922|NCT02150616|Placebo Comparator|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights
3336923|NCT02150629||SCI patients|
3235760|NCT01243931|Experimental|Surgery|OCT is assisting in surgery guidance.
3235761|NCT01243970|Active Comparator|phenylephrine infusion|
3235762|NCT01243970|Active Comparator|Ephedrine infusion|
3235763|NCT01243983|Experimental|LX211|
3235764|NCT01243983|Placebo Comparator|Placebo|
3235765|NCT01243996|Experimental|Infant treated with high dose ibuprofen|
3336924|NCT02150629||Healthy subjects|
3336925|NCT02150642||Neurological Injury|
3336926|NCT02150642||No Neurological Injury|
3235766|NCT01244009|Experimental|MK-4827|All Participants
3235767|NCT01244022||Colorectal cancer patients|Patients with pathohistologically verified colorectal cancer or adenoma with epithelial dysplasia
3235768|NCT01244074|Experimental|biofeedback|
3235769|NCT01244100|Experimental|PL2200|
3336927|NCT02150655|Experimental|Probiotic|Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 oral capsules
3336928|NCT02150655|Placebo Comparator|Placebo|Sugar pill
3336929|NCT02150668|Experimental|HOPS Intervention|School counselors deliver HOPS intervention to students during the school day. This includes 16, 20-minute sessions with the student and two joint family meetings.
3235770|NCT01244139|Experimental|Active study drug|Treatment
3235771|NCT01244139|Experimental|Comparator|Dummy drug
3235772|NCT01244152|Experimental|Intervention|
3235773|NCT01244152|Active Comparator|Control Group|
3235774|NCT01244165|Other|Cytrix|Observational Study
3235775|NCT01244165|Other|Control Group|Patients with similar indications who were treated at the same centers using other products
3235776|NCT01244178|Experimental|Tight Glucose Control Hyperinsulinemic Group|
3235777|NCT01244178|Experimental|Non-Tight Glucose Control Hyperinsulinemic Group|
3235778|NCT01244178|Active Comparator|Standard Insulin Protocol Group|
3235779|NCT01244204|Experimental|Vitamin D|
3235780|NCT01244204|Placebo Comparator|Placebo|
3235781|NCT01244217|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old
3235782|NCT01244217|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
3336930|NCT02150668|Active Comparator|HSI Intervention|School counselors deliver the HSI intervention which focuses on improving focus and efficiency of work completion. This consists of 16, 20-minute sessions, with the student and two joint family meetings.
3336931|NCT02150681|Experimental|Mindfulness-based cognitive therapy|8 class sessions of mindfulness therapy given in a group setting, with one 2-hr session per week for 8 weeks.
3336932|NCT02150694|Experimental|Apelin agonist infusion|Studies to measure change in blood flow in response to apelin agonists (1/10/100nmol) using forearm venous occlusion plethysmography and Aellig hand vein technique.
3336933|NCT02150694|Experimental|Apelin receptor antagonist infusion|Aellig hand vein technique will be used to investigate the change in vein diameter in response to an apelin blocking agent
3336934|NCT02150694|Experimental|Apelin agonist/antagonist co-infusion|Forearm blood flow study to measure blood flow by forearm venous occlusion plethysmography following intraarterial infusion of apelin receptor agonists and antagonist.
3336935|NCT02150707||Dipeptidyl-Peptidase IV Inhibitors|Newly started on DPP4 inhibitor for hyperglycaemia
3235783|NCT01244217|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
3235784|NCT01244230|Experimental|Age 6 months - 2 years|Patients between 6 months and 2 years old - Type: Experimental
3235785|NCT01244230|Experimental|Age 2 - 11 years|Patients between 2 and 11 years (and under 10.5 kg)
3235786|NCT01244230|Experimental|Age 2 - 11 years (and over 10.5 kg)|Patients between 2 and 11 years (and over 10.5 kg)
3336936|NCT02150707||Glucagon-Like Peptide 1|Newly started on GLP-1 for hyperglycaemia or obesity
3336937|NCT02150720|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
3336938|NCT02150720|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery,
3336939|NCT02150720|Active Comparator|Usual hemostasia|Electrocauterization
3336940|NCT02150733|Experimental|Group 1 - Normal hepatic function|Subjects with normal hepatic function
3336941|NCT02150733|Experimental|Group 2 - Mild hepatic impairment|Subjects with mild hepatic impairment by Child-Pugh classification scores
3336942|NCT02150733|Experimental|Group 3 - Moderate hepatic impairment|Subjects with moderate hepatic impairment by Child-Pugh classification scores
3336943|NCT02150733|Experimental|Group 4 - Severe hepatic impairment|Subjects with severe hepatic impairment by Child-Pugh classification scores
3336944|NCT02150746||Pancreatic Cancer CTC|Peripheral/Central Venous Blood Draw Peritoneal Wash
3336945|NCT02150772|Other|Shear Wave Elastography|All included patients have SWE performed
3336946|NCT02150785|Experimental|Adminstering Streptokinase|treatment with 15,000 units/Kg of streptokinase in ischemic stroke patients with symptoms onset for less than 3 hours
3336947|NCT02150798|Experimental|High fat and low carbohydrate diet|High fat low carbohydrate diet composition was 40 % of carbohydrates, 40 % of lipids (12 % saturated, 18 % monounsaturated and 10% polyunsaturated, ) and 20 % of protein for two months
3336948|NCT02150798|Active Comparator|Control diet|the standard diet composition was 50 % of carbohydrates, 30 % of lipids (10 % saturated, 10 % polyunsaturated, and 10 % monounsaturated) and 20 % of protein for two months
3336949|NCT02150811||Hunner's ulcer|
3336950|NCT02150824|Experimental|BI 187004 low dose mono QD|patient to receive one tablet containing low dose of BI 187004 or matching placebo
3235787|NCT01244256|Experimental|Treatment with Clotrimazole + Gentamicin + Beclomethasone|
3235788|NCT01244256|Active Comparator|Treatment with Clotrimazole + Gentamicin|
3336951|NCT02150824|Experimental|BI 187004 medium dose mono QD|patient to receive one tablet containing medium dose mg of BI 187004 or matching placebo
3336952|NCT02150824|Experimental|BI 187004 high dose mono QD|patient to receive one tablet containing high dose of BI 187004 or matching placebo
3336953|NCT02150824|Experimental|BI 187004 high dose QD add on|patient to receive one tablet containing high dose of BI 187004 or matching placebo add on to metformin background dose
3336954|NCT02150850||Registry|Patients who have who have sustained an AFF that consent to participating in the registry only.
3336955|NCT02150850||Cases|Patients who have sustained an AFF that consent to participating in the registry and undergoing EOS® imaging.
3336956|NCT02150850||Controls|For each case we will identify one age- (± 5 years), sex-, height- (± 6 cm) and cumulative bisphosphonate or denosumab exposure ( ±2 years) matched control who has not sustained an AFF to undergo EOS® imaging.
3235789|NCT01244269|Experimental|Methylphenidate 10|Methylphenidate 10mg three times daily for a total of 7 doses.
3235790|NCT01244269|Placebo Comparator|Placebo 10|Placebo capsule three times daily for a total of 7 doses.
3235791|NCT01244269|Experimental|Methylpheindate 20|Methylphenidate 20mg three times daily for a total of 7 doses.
3235792|NCT01244269|Placebo Comparator|Placebo 20|Placebo capsule three times daily for a total of 7 doses.
3235793|NCT01244282|Experimental|All Participants|fMRI studies with sensory stimulation in the presence of 0 mg, 250 mg, 350 mg, and 510 mg cumulative doses of ferumoxytol
3235794|NCT01244295|Experimental|Complicated Grief Treatment|Targeted psychotherapy for complicated grief
3235795|NCT01244295|Active Comparator|Interpersonal Therapy|Standard IPT is a comparator treatment
3235796|NCT01244321||CoSeal Group|Subjects with indication for LVAD implantation, meeting the requirements for LVAD implantation. Patients for whom LVAD removal is anticipated not earlier than 6 weeks after LVAD implantation.
3235797|NCT01244321||CoSeal Control Group|Subjects who had a LVAD for more than 6 weeks.
3235798|NCT01244334|Active Comparator|Difluprednate Ophthalmic Emulsion 0.05%|
3235799|NCT01244334|Active Comparator|Prednisolone acetate suspension 0.1%|
3336957|NCT02150902|Experimental|Augmented- WACA|Augmented- wide area circumferential catheter ablation for atrial fibrillation
3336958|NCT02150902|Active Comparator|WACA|Wide area circumferential catheter ablation procedure for atrial fibrillation
3336959|NCT02150915|Experimental|new acupoint|Subjets in this arm receive acupuncture therapy in a new acupoint (leopard spot needling technique)
3336960|NCT02150915|Active Comparator|classical acupoint|Subjects in this arm receive acupuncture therapy in a classical acupoint in the pericardial conduit (leopard spot needling technique)
3336961|NCT02150928|Experimental|Erwinaze / Erwinase|
3336962|NCT02150941|Experimental|BioVac Direct Suction Device|Experimental arm
3336963|NCT02150941|Active Comparator|Standard Endoscopy Suction|Control arm
3336964|NCT02150993|Experimental|Arm A : TDF + FTC (or 3TC) + ZDV|Tenofovir + Emtricitabine or Lamivudine + Zidovudine
3336965|NCT02150993|Experimental|TDF+FTC (or 3TC) +LPV/r|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir
3235800|NCT01244347|Experimental|folic acid 4 mg|
3235801|NCT01244347|Active Comparator|folic acid 0.4 mg|
3235802|NCT01244360|Placebo Comparator|Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
3235803|NCT01244360|Active Comparator|Dietary Supplement: resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
3235804|NCT01244373||Patients with senile cataract|Patients with senile cataract
3235805|NCT01244386||Inflammatory bowel disease|Patients with inflammatory bowel disease requiring CT for clinical purposes will be studied.
3235807|NCT01244464|Experimental|Study Group|
3235808|NCT01244542|Experimental|Patients with schizophrenia|
3235809|NCT01244542|Active Comparator|Healthy controls|controls matched with patients on age, sex and education level
3336966|NCT02150993|Experimental|Arm C : TDF +FTC (or 3TC) + RAL|Tenofovir + Emtricitabine or Lamivudine + Raltegravir
3336967|NCT02151006|Active Comparator|DHEA|women will receive DHEA 6 weeks before starting IVF/ICSI
3336968|NCT02151006|No Intervention|Control|
3336969|NCT02151019|Experimental|Experimental Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using IMRT
3336970|NCT02151019|No Intervention|Control Arm|50.4 Gy / 28# external beam pelvic radiotherapy delivered using a 3-Dimensional (3-D) planned technique
3235810|NCT01244555|Experimental|Massage treatment|
3235811|NCT01244555|Experimental|Ultrasound|
3336971|NCT02151032||Colorectal Cancer Screening Booklet + Audio CD|Participants read the booklet about colorectal cancer screening tests, and listen to an audio CD that will narrate the booklet. Questionnaire completion before and after viewing the program.
3336972|NCT02151032||Video with Non-Moving Images on iPad|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
3336973|NCT02151032||Video with Animated Images on iPad|Participants watch a video with animated images about colorectal cancer screening tests on an iPad. Questionnaire completion before and after viewing the program.
3336974|NCT02151045|Active Comparator|Non target epidural infiltration at L3-L4 stage|"In this control arm, there are patients with a non target posterior epidural space infiltration of corticoids done at L3-L4 stage on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
3336975|NCT02151045|Experimental|Epidural infiltration on contact of disco radicular conflict|"In this experimental arm, there are patients with an epidural infiltration of corticoids done in lateral on contact of disco radicular conflict on scan control.~These patients must have a discal hernia confirmed by scanner or RMI"
3336976|NCT02151071|Other|Breast conserving surgery|Females ≥ 30 years of age with a diagnosis of invasive breast cancer or ductal carcinoma in situ (DCIS), scheduled for BCS +/- SLNB or ALND
3336977|NCT02151084|Experimental|Arm A (Continuous Dosing)|"Run-In: Selumetinib, orally, BID for 7 days (Day -7 to Day -1)~On treatment: Selumetinib, orally, BID from Day 1-21 of every 28 day cycle. Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
3336978|NCT02151084|Experimental|Arm B (Sequential Dosing)|"Run-In: Selumetinib, orally, BID for 5 days (Day -7 to Day -3) with 2 days washout~On treatment: Selumetinib, orally, BID from Day 1-5 and 8-19 of every 28 day cycle.~Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle."
3336979|NCT02151084|Experimental|Arm C (Standard Care)|Cisplatin/gemcitabine, intravenously, on Days 1 and 8 of every 28 day cycle.
3336980|NCT02151097||High risk prostate cancer|Men ≥18 years of age diagnosed with high risk prostate cancer, defined as clinical stage ≥T2c, or Prostate Specific Antigen (PSA)>20 ng/ml, or Gleason Score 8-10, scheduled to have radical prostatectomy.
3336981|NCT02151123||Diagnosed colon cancer patients|Patients undergoing colectomy for colonic adenocarcinoma.
3336982|NCT02151136|Experimental|24% sucrose + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml 24% sucrose will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
3235812|NCT01244555|No Intervention|Wait-list|
3235813|NCT01244568|No Intervention|Usual care|
3235814|NCT01244568|Experimental|Prostate cancer treatment DESI|
3235815|NCT01244581|Experimental|Amoxicillin-clavulanate|Oral amoxicillin-clavulanate 40 mg/kg/day divided in two daily doses for 7 days
3235816|NCT01244581|Placebo Comparator|Placebo|
3235817|NCT01244594|Experimental|High cadence, low resistance|Subjects in this arm will cycle with functional electrical stimulation at a higher cadence (speed) and a lower resistance.
3235818|NCT01244594|Experimental|Low cadence, high resistance|Subjects in this arm will cycle with functional electrical stimulation at a lower cadence (speed) and a higher resistance.
3235819|NCT01244607|Placebo Comparator|Placebo|
3235820|NCT01244607|Experimental|NI-0801|
3235821|NCT01244646||1|Patients with Diabetes Mellitus Type 2
3235822|NCT01244659|Experimental|Tacrolimus from EMS|Group 1: Tacrolimus from EMS + Myfortic® + Steroids
3235823|NCT01244659|Active Comparator|Prograf|Group 2: Prograf® + Myfortic® + Steroids
3235824|NCT01244672|Active Comparator|Trans-anal dearterialization|24 patients were assigned to the Transanal hemorrhoidal dearterialization with mucopexy arm, which is a Doppler guided procedure for suture ligation of hemorrhidal arteries rather than excisional
3235825|NCT01244672|Active Comparator|Ferguson|17 patients were randomized to Ferguson method, which is the operative gold standard for hemorrhoids. This is an excisional surgery.
3259231|NCT01468753|Experimental|Vaginal Insemination|Women will perform vaginal insemination during the fertile period of the menstrual cycle with the collected semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
3336983|NCT02151136|Placebo Comparator|Sterile water + standard care|In addition to standard care (topical anesthetic (Ametop or EMLA) + upright holding + distraction + pacifier, if used), a maximum of 2 ml sterile water will be administered orally in 0.25 ml aliquots 2 minutes prior to the needle insertion, at the time of needle insertion, and repeated at 2 minute intervals until the completion of the procedure
3336984|NCT02151162|Experimental|Stress management plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3336985|NCT02151162|Active Comparator|Stress management plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3336986|NCT02151162|Active Comparator|Psychoeducation leaflet plus omega-3|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3336987|NCT02151162|Active Comparator|Psychoeducation leaflet plus placebo|Thirty participants will be allocated to the arm. These interventions will terminate until 3 months from registration for each participant.
3336988|NCT02151175|Experimental|LIFUP|
3336989|NCT02151188|Other|Bread and water|co-ingestion control session
3336990|NCT02151188|Experimental|bread with cow milk co-ingestion|co-ingestion bread with cow milk
3336991|NCT02151188|Experimental|bread with soy milk co-ingestion|co-ingestion bread with soy milk
3336992|NCT02151188|Experimental|preload cow milk|preload cow milk 30 min, then bread
3336993|NCT02151188|Experimental|preload soy milk|preload soy milk 30 min, then bread
3336994|NCT02151201|Experimental|Influenza vaccination video education|Influenza vaccination video education
3336995|NCT02151201|Placebo Comparator|Hand Washing video education|Hand Washing vaccination video education
3336996|NCT02151214|Experimental|Parenteral nutrition|Parenteral nutrition will be administered to the patients
3336997|NCT02151214|No Intervention|Normal per os nutrition|The patients will eat orally
3336998|NCT02151227||magnesium intake categories|comparators: categories of magnesium intake except lowest category of magnesium intake , controls: lowest category of magnesium intake
3336999|NCT02151240|Experimental|Arm I|Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV; Second administration: Foscarnet Sodium and Sodium Chloride Injection 3g: 250ml, IV
3337000|NCT02151240|Active Comparator|Arm II|First administration: Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Acyclovir for Injection 0.25g + 0.9% Sodium Chloride Injection 250ml, IV; Second administration: Acyclovir for Injection 0.25g+ 0.9% Sodium Chloride Injection 250ml, IV
3337001|NCT02151279|Placebo Comparator|control group|Chitosan as wine fining agent
3337002|NCT02151279|Active Comparator|Shrimp allergic patients|Chitosan as wine fining agent
3337003|NCT02151305|Experimental|Total intravenous anesthesia group|This group received propofol and remifentanil for the maintenance of general anesthesia.
3337004|NCT02151305|Experimental|Inhalation anesthesia group|This group received sevoflurane for the maintenance of general anesthesia.
3337005|NCT02151344|Experimental|Cohort 1|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
3337006|NCT02151344|Experimental|Cohort 2|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0 and one dose at Day 28. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
3337007|NCT02151344|Experimental|Cohort 3|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 2 months later.
3337008|NCT02151344|Experimental|Cohort 4|Participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine at Day 0. They will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month later.
3337009|NCT02151344|Experimental|Cohort 5|Participants will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28.
3337010|NCT02151357|Experimental|DCBCI0901|DCBCI0901 7.5mg/m2, iv infusion for day 1-day 5 and day 15-day 20
3337011|NCT02151370||Cohort|
3337012|NCT02151383|Experimental|Serelaxin|Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.
3337013|NCT02151396|Experimental|Cogmed Working Memory Training|Cogmed (TM) working memory training following standard, recommended administration procedures
3337014|NCT02151409|Experimental|NNC 0151-0000-0000 i.v.|Dose escalation trial
3337015|NCT02151409|Experimental|NNC 0151-0000-0000 s.c.|Dose escalation trial
3337016|NCT02151409|Placebo Comparator|Placebo|
3337017|NCT02151422|Experimental|Breathing exercises|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
3337018|NCT02151435||Patients with IPF|Observation of longitudinal biomarkers in IPF patients
3337019|NCT02151474|Experimental|INCB047986 4 mg QD|INCB047986 4 mg will be orally self-administered once daily (QD) for 28 days.
3337020|NCT02151474|Experimental|INCB047986 8 mg QD|INCB047986 8 mg will be orally self-administered once daily (QD) for 28 days.
3337021|NCT02151474|Experimental|INCB047986 12 mg QD|INCB047986 12 mg will be orally self-administered once daily (QD) for 28 days.
3337022|NCT02151474|Experimental|INCB047986 placebo QD|INCB047986 placebo will be orally self-administered once daily (QD) for 28 days.
3337023|NCT02151500|Experimental|Stress and Health Interview|Stress and Health Interview is an experiential assessment technique
3337024|NCT02151500|No Intervention|Wait-list Control|Standard medical care until the 6-week follow-up is completed
3337025|NCT02151513||Cancer Pain|Placement of an intrathecal pump
3337026|NCT02151539||Observational (medical chart review)|Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.
3337027|NCT02151552|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer [18F](+/-)NOS.
3337028|NCT02151565|Experimental|HTEMS|High-tone external muscle stimulation 5 times within 10 days
3259232|NCT01468766|Active Comparator|Resistance training|
3337029|NCT02151565|Active Comparator|TENS|Transcutaneous electrical nerve stimulation 5 times within 10 days
3337030|NCT02151578|No Intervention|nothing at home level|No intervention at community level. The study drugs (arthemeter/Lumefantrine and Cotrimoxazole) available at the health facility drug stores level and prescribed exclusively to sick children attending to the health facility for care seeking. No Community Heath Worker /Key Opinion leader (CHWs/KOLs) selected in those clusters
3337031|NCT02151578|Experimental|Home management of malaria|"At the community level, the Community health workers/ keay opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc"
3259233|NCT01468766|Active Comparator|Relaxation training|
3259234|NCT01468779|Placebo Comparator|Sugar pill|The patients submitted to periampullary cancer surgery will receive sugar pills in the preoperative and postoperative period.
3259235|NCT01468779|Active Comparator|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
3337032|NCT02151578|Experimental|Home management of malaria and pneumonia|"At the community level, the Community health workers/ key opinion leader (HWs/KOLs) trained and equipped to provide the antimalarial drug (arthemeter/Lumefantrine ) or antibiotic (Cotrimoxazole) to any child with fever (hot body) without any other signs of complications like impaired consciousness, convulsions, etc. The treatment decision making for the CHWs/KOLs based on the algorithm"
3337033|NCT02151604|Experimental|129 Xenon MR Imaging|Xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
3337034|NCT02151617|Experimental|Cohort 1-PF-06743649 or placebo|Subjects will be randomized to receive PF-06743649 or placebo as 2 single doses in periods 1 and 2 either in the fed or fasted state followed by once daily dosing for 14 days in period 3
3337035|NCT02151617|Experimental|Cohort 2-PF-06743649 or placebo|
3337036|NCT02151617|Experimental|Cohort 3-PF-06743649 or placebo|
3337037|NCT02151617|Experimental|Cohort 4-PF-06743649 or placebo|
3337038|NCT02151617|Experimental|Cohort 5-PF-06743649 or placebo|
3337039|NCT02151630|Active Comparator|Pyruvic acid|Patients will receive pyruvic acid solution 70% prepared by solving of pyruvic acid in water/ethanol solution. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
3337040|NCT02151630|Active Comparator|Salicylic acid|Patients will receive a combination of salicylic acid 16.7%, lactic acid 16.7%, and collodion 100%. Patients will be advised to apply the solution twice daily for a period of four weeks. Application of petrolatum to the surrounding normal skin protects against the corrosive effect of the concentrated acid.
3337041|NCT02151656|Experimental|F17464|Oral administration - During 6 weeks - 4 capsules daily
3337042|NCT02151656|Placebo Comparator|Placebo|Oral administration - During 6 weeks - 4 capsules daily
3337043|NCT02151669|Experimental|Mediterranean Diet Group|Nutritional intervention to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
3337044|NCT02151669|No Intervention|Control group|Participants of control group will be referred to your doctor or nurse with reference to a report on specific according to your personal situation dietary recommendations.
3337045|NCT02151695|Active Comparator|Panretinal photocoagulation|
3337046|NCT02151695|Experimental|Aflibercept intravitreal injections|
3337047|NCT02151708|Active Comparator|motilitone 90mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3337048|NCT02151708|Active Comparator|motilitone 180mg|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3337049|NCT02151708|Placebo Comparator|placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
3337050|NCT02151721|Experimental|vorinostat, gefitinib, combination|single arm vorinostat plus gefitinib
3337051|NCT02151734|Experimental|KALOMIN™ Tab.|KALOMIN™ Tab./Placebo to Umckamin syrup
3337052|NCT02151734|Active Comparator|Umckamin syrup|Umckamin syrup/Placebo to KALOMIN™ Tab.
3337053|NCT02151747||Sanger|BRCA 1/2 test results by Sanger sequencing
3337054|NCT02151747||NGS|BRCA 1/2 test results by NGS
3337055|NCT02151760|Experimental|18F-DCFPyL|
3337056|NCT02151799|Experimental|Body contouring surgery|
3337057|NCT02151812|Experimental|Agent Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single Agent(TM) balloon that completely covers the restenotic lesion
3337058|NCT02151812|Active Comparator|SeQuent Please Paclitaxel-coated balloon|drug-coated balloon dilatation of the index lesion using a single SeQuent(R) Please balloon that completely covers the restenotic lesion
3337059|NCT02151825|Experimental|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
3337060|NCT02151825|Placebo Comparator|Placebo|3 capsules of Maltodextrin per day
3337061|NCT02151864|Experimental|LDE225|LDE225 200mg-800mg oral daily
3235826|NCT01244685|Active Comparator|probe|Patients in the 'goal-directed fluid' Lactated Ringers solution according to ideal body weight for the first 24 hours. The fluids will be changed after the first 24 hours and continued until the patient is tolerating a regular diet. The Deltex CardioQ esophageal probe will be evaluated every 15 minutes in the Post Anesthesia Care Unit (PACU) by the Anesthesia service. Stroke Volume (SV), Flow Time Corrected (FTc), and Peak Velocity (PV) will be measured. A short FTc (<330 ms) indicative of hypovolemia will receive a 3cc/kg fluid challenge with Lactated Ringers crystalloid solution over 5 minutes. A SV increase of >10% will receive a further 3cc/kg fluid challenge. A SV increase of <10% will not receive further fluid challenge.
3337062|NCT02151890|Experimental|Laparoscopic Stem Cell Transplantation.|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by IH staining by stem cell marker OCT4. Immunohistochemical expression of stem cell marker OCT4 was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS)Laparoscopic injected of stem cell Sample in the ovaries.. Participants were followed up monthly for a period of six months by hormonal (FSH, LH and E2), clinical (resuming menstruation), US (folliculometry), histopathological (HP), and IH expression of stem cell marker OCT4 of the endometrial biopsy (stem cell positivity according to ESS) outcome.
3337063|NCT02151916|Experimental|Dental care, AG, MI & fluoride varnish|The intervention comprises four components; provision of dental care to the mother during pregnancy (2nd trimester), preventive treatment with fluoride varnish to the teeth of children, and two behavioral interventions, namely oral health anticipatory guidance and motivational interviewing with the caregiver/mother.
3337064|NCT02151916|Other|Delayed intervention|Three fluoride varnish applications to the teeth of children and oral health anticipatory guidance and motivational interviewing for the caregiver when the child is aged 24, 30 and 36 months. Dental care also will be offered to the mothers/caregivers in the delayed intervention group when their children are aged 2 to 3 years old. Before the children are aged 2 years, standard dental care will be the comparator, which usually involves provision of dental care only if the participant is in pain.
3337065|NCT02151929|Experimental|Bioresorbable Vascular Scaffold|Implantation of of an everolimus eluting bioresorbable scaffold in patients with STEMI treated with primary PCI
3337066|NCT02151929|Active Comparator|Everolimus Eluting stent|Implantation of of an everolimus eluting stent in patients with STEMI treated with primary PCI
3337067|NCT02151942||Control group|Procedure/Surgery : Endovascular Aneurysm Repair with no prior procedure rehearsal
3337068|NCT02151942||Rehearsal group|Procedure/Surgery : Endovascular Aneurysm Repair with prior procedure rehearsal
3337069|NCT02151955|Experimental|Individual parent infant intervention|Children and parents will be offered an assessment and then a tailored individual 10 to 15 week based attachment and parent intervention to promote parent child relationship.
3337070|NCT02151968|Active Comparator|Traditional blind peribulbar block|
3337071|NCT02151968|Experimental|Ultrasound-guided peribulbar block|
3337072|NCT02152020||Cancer survivors|
3337073|NCT02152033|Experimental|Home-based Continuing Care|The components of Home-based Continuing Care (HCC) include brief parent training, brief Young Adult (YA) orientation and recovery planning, telephone-based continuing care (TCC) and home-based contingency management. Both parent and YA participants will attend sessions with a family specialist.
3337074|NCT02152033|Other|Services as Usual|YAs completing residential care usually are referred to continuing outpatient services and/or self-help groups.
3337075|NCT02152046||Spring loaded retractor|The Alfonso Eyelid Speculum, newborn size
3337076|NCT02152046||Screw retractor|Cook Eyelid Speculum, infant size
3259236|NCT01468831|Placebo Comparator|Participants Group 1|Participants that will receive three months of bevizcumab injections followed by placebo twice daily for 24 months
3259237|NCT01468831|Experimental|Participants Group 2|Participants that will receive three months of bevacizumab injections followed by 100mg of minocycline twice daily for 24 months
3337077|NCT02152059|Experimental|BIBF1120|BIBF1120 200 mg twice daily continuously
3337078|NCT02152072||medical students|
3337079|NCT02152098|Experimental|Chronic Exercise|Chronic Exercise
3337080|NCT02152098|Experimental|Acute Early onset of rehabilitation|Acute Early onset of rehabilitation
3337081|NCT02152098|Experimental|Chronic control|Chronic control
3337082|NCT02152098|Experimental|Acute Delayed onset of rehabilitation|Acute Delayed onset of rehabilitation
3337083|NCT02152111|Experimental|Dietary Supplement: Coconut flour|Diet hipoernergetic plus 26g/day coconut flour during three months (12weeks).
3337084|NCT02152111|Active Comparator|Nutritional Treatment|All patients received an individualized diet plan and balanced. The diet was calculated to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of total energy value
3337085|NCT02152124||Controlled on LA-SMSA|Patients with controlled acromegaly on long-acting somatostatin analogs
3337086|NCT02152124||Controlled on LA-SMSA and pegvisomant|Patients with controlled acromegaly on long-acting somatostatin analogs and pegvisomant
3337087|NCT02152124||Controlled after surgery|Controlled acromegaly patients without need for medical therapy after surgery
3337088|NCT02152124||Healhy controls|Healthy volunteers
3337089|NCT02152124||Uncontrolled on LA-SMSA|Patients with uncontrolled acromegaly (i.e. with serum IGF-1 levels above age-specific thresholds and/or symptoms due to active acromegaly (e.g. excessive sweating, arthralgia)) on LA-SMSA monotherapy in maximal dosage
3337090|NCT02152150|Experimental|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content)
3337091|NCT02152150|Active Comparator|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content)
3337092|NCT02152176|Experimental|Patient Controlled Analgesy group|Titration of morphine by Patient Controlled Analgesy. The opioid titration will be performed by the patient using PCA (Vygon Freedom 5) according to the principle of self with a refractory period of 5 minutes.
3337093|NCT02152176|No Intervention|Control group|titration will be perform in the usual manner in accordance with the recommendations : a nurse will assess pain using a visual analog scale in the control group to assess the need for a new bolus of morphine
3337094|NCT02152189||Screening population|
3235827|NCT01244685|No Intervention|Standard Fluid|Patients in the 'standard fluid' group will receive Lactated Ringers solution for 24 hours post-operatively at 1 times maintenance rate according to ideal body weight. Then the fluids will be changed to physiologic maintenance with D5½NS at the same rate. Fluids will be decreased by ½ once the patient is tolerating a clear liquid diet, and then discontinued once the patient is tolerating a regular diet.
3235828|NCT01244698|Other|Antibiotics until Drain Removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
3337095|NCT02152202|Experimental|Semi-upright position|Semi-upright position defined as 45 degrees incline from horizontal of the patients bed during nocturnal sleep, for two postoperative nights. Daytime naps will be excluded. A regular pillow may be used by the patients based upon the level of comfort and also to support the head in a neutral position.
3337096|NCT02152202|Other|Control group (Supine position)|In this group patients' bed will be set into Supine/0 degree angle during sleep in the night time. Patient will be managed according to routine care
3337097|NCT02152215|Active Comparator|Acellular dermal matrix membrane|An acellular dermal matrix membrane will be used as a barrier between the osseous graft and the soft tissue flap.
3337098|NCT02152215|Experimental|Polylactic acid membrane|A polylactic acid membrane will be used as a barrier between the osseous graft and the soft tissue flap.
3337099|NCT02152228|Experimental|Oral Parathyroid Hormone (1-34)|Oral administration of EnteraBio's Oral Parathyroid Hormone (1-34)
3337100|NCT02152241||Patients with IBD|Adult patients with IBD diagnosed during childhood
3337101|NCT02152267|Experimental|tDCS 1mA|the parameters used in the TDCS will be 1mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3337102|NCT02152267|Experimental|tDCS 2mA|the parameters used in the TDCS will be 2mA, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3235829|NCT01244698|Experimental|Early discontinuation of antibiotics|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
3337103|NCT02152267|Sham Comparator|tDCS Sham|the parameters used in the TDCS will be sham, cathodal over right DLPFC and anodal over supraorbital contralateral area.
3337104|NCT02152280|Experimental|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
3337105|NCT02152280|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
3337106|NCT02152306|Experimental|Fimasartan and Amlodipine|Combination of Fimasartan and Amlodipine
3337107|NCT02152306|Active Comparator|Fimasartan|Fimasartan Monotherapy
3337108|NCT02152319|Experimental|KHV reporting|Clinicians will view the motor symptom severity reports and videoconference to titrate medications.
3337109|NCT02152319|Active Comparator|Standard care|Subjects in this group will still use KHV at home to minimize any placebo effects that could be attributed to using the system; however, clinicians will view the motor symptom severity reports and videoconference to titrate medications solely for the experimental subjects.
3337110|NCT02152332|Experimental|Treatment Sequence Group ADBC|Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
3337111|NCT02152332|Experimental|Treatment Sequence Group BACD|Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen).
3337112|NCT02152332|Experimental|Treatment Sequence Group CBDA|Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen).
3337113|NCT02152332|Experimental|Treatment Sequence Group DCAB|Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen).
3337114|NCT02152358|Active Comparator|Ganciclovir|Patients with a positive CMV PCR
3337115|NCT02152358|Placebo Comparator|Ganciclovir placebo|Patients with a positive CMV PCR
3337116|NCT02152358|Active Comparator|Aciclovir|Patients with a PCR positive for HSV
3337117|NCT02152358|Placebo Comparator|Aciclovir placebo|Patients with a positive PCR for HSV
3337118|NCT02152397|Active Comparator|Therapist-led brief intervention (TBI)|"Participants will receive therapist-led, computer-assisted intervention sessions with a therapist. The interventions are designed to address extramedical prescription opioid use and overdose risk behaviors. This includes a review of the participants' strengths, values, and goals; feedback regarding their opioid use and overdose risk behaviors; developing a discrepancy between their opioid and other drug use and ability to meet goals and values; and the formulation of a change plan for each participant."
3337119|NCT02152397|No Intervention|Enhanced usual care|Participants will receive therapist-led, computer-assisted control sessions with a therapist.
3337120|NCT02152410|Experimental|acupuncture group|The patient receives acupuncture session lasts between 20 to 30 minutes. Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA).
3235830|NCT01244737|Experimental|New diagnosis of brain tumor|In children with a new diagnosis of central nervous system tumor, a PET scan will be performed using [18F] FLT.
3337121|NCT02152410|Active Comparator|Morphine group|Each patient must receive a bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement (VAS> 30).
3337122|NCT02152423|Other|LOVENOX|patients are given a curative dose of Enoxaparin (LOVENOX)
3337123|NCT02152423|Active Comparator|ENOXAMED|patients are given a curative dose of Enoxaparin (ENOXAMED)
3337124|NCT02152436||Before simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured before simulation-based curriculum
3337125|NCT02152436||After simulation-based curriculum|125 surgical interventions will be observed and outcomes will be measured after simulation-based curriculum
3337126|NCT02152449|No Intervention|Control group|"Control group: systematic advice on swallowing, plus:~If no weight loss compared to usual weight: no intervention~if weight loss <5%: advice on a fat- and protein-enriched diet~if weight loss ≥5%: advice on a fat- and protein-enriched diet + 1 unit of ONS/day per os"
3337127|NCT02152449|Experimental|oral nutritional supplementation|"Experimental ONS Group: systematic advice on swallowing + systematic advice on a fat- and protein-enriched diet, plus:~if no weight loss compared to usual weight: 1 ONS/day per os~if weight loss <5% compared to usual weight: 2 ONS/day per os~if weight loss ≥5% compared to usual weight: 3 ONS/day per os"
3337128|NCT02152462|Other|Exergaming|Exercise Intervention: Participants in the Wii Fit exergaming group will have a goal of 150 min/wk of moderate intensity exercise for the last 5 mo of the 6 mo intervention. Heart rate (HR) monitors will quantify exercise intensity. Participants will exercise at a HR equal to 45-65% of their VO2max. Participants will be instructed by the exercise physiologist on how to achieve the required HR. The training will consist of 3 days/wk of supervised Wii Fit physical activity. Exercise duration will increase gradually from 75 to 150 min/wk by wk 477. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. Participants will complete daily exercise diaries recording the type and duration of physical activity, and HR.
3337129|NCT02152462|No Intervention|Control|Control Group: After baseline testing the control group will be asked to maintain their current daily activities for the duration of the study. The control group will have the option to exercise at the Wii Fit stations following their completion of the study. They will receive the same measures as the exercise group.
3337130|NCT02152475|Experimental|PDT with blue light and curcumin|PDT treatment was performed with light and curcumin.The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence. The curcumin concentration of 30 mg/L was used.
3337131|NCT02152475|Active Comparator|Curcumin|The curcumin concentration of 30 mg/L was used.
3235831|NCT01244737|Experimental|Possible recurrent brain tumor|In children in whom there is concern for recurrent central nervous system tumor, a PET scan will be performed using [18F] PET.
3235832|NCT01244737|Experimental|Brain tumor response to chemotherapy|"In children with a newly diagnosed central nervous system tumor who will be treated with post-operative chemotherapy, a PET scan will be performed using [18F] FLT before the start and after two cycles of chemotherapy.~Despite much effort and working with referring physicians at multiple hospitals, enrollment in this arm remained low, and it seemed unlikely that meaningful enrollment would be accomplished. A revised study plan was submitted to the granting agency and FDA, and this arm was closed to further enrollment."
3337132|NCT02152475|Active Comparator|Blue light|The irradiation parameters were: blue-light emitting diode (LED) illumination (455±30 nm), 400 mW of average optical power, 5 min of application, illumination area of 0.666 cm2, 600 mW/cm2 of intensity and 120 J/cm2 of fluence.
3337133|NCT02152501|Experimental|Exercise Energy Expenditure 300 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 300 kcal/day.
3337134|NCT02152501|Experimental|Exercise Energy Expenditure 600 kcal/day|Subjects will be randomly assigned to this group and will exercise energy expenditure of 600 kcal/day.
3337135|NCT02152514|Active Comparator|Intrathecal Morphine/Sufentanil and PCA|Patients will receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will have a PCA for analgesia rescue in the post-operative period.
3337136|NCT02152514|Placebo Comparator|PCA alone|Patients will NOT receive an intrathecal injection of Morphine 250 mcg and Sufentanil 10 mcg before the induction of anesthesia. They will only have a PCA for analgesia in the post-operative period.
3337137|NCT02152527||Trimetazidine|Patients for coronary artery bypass grafting surgery who had preoperative trimetazidine usage in standard ischemic coronary disease therapy.
3337138|NCT02152527||Control|Patients for coronary artery bypass grafting surgery who had standard therapy for ischemic coronary disease without trimetazidine.
3337139|NCT02152553|Active Comparator|Hydrocortisone|Near-physiologic doses of Hydrocortisone are being given to subjects. The first day between 09.00 and 12.00 0,024 mg Hydrocortisone/kg per hour. The first day between 12.00 and 20.00 0,012 mg Hydrocortisone/kg per hour. The first day between 20.00 and 24.00 0,008 mg Hydrocortisone/kg per hour. The second day between 00.00 and 11.00 0,030 mg Hydrocortisone/kg per hour. Hydrocortisone infusion: 0,4 ml Solu Cortef 100 mg (50 mg/ml) added in 999,6 ml sodium chloride 0,9% solution (1 mg Solu Cortef/ 50 ml total solution volume).
3235833|NCT01244750||First line TKI treatment: Imatinib|Diagnosed CML patients who receive first line TKI treatment: Imatinib
3235834|NCT01244750||First line TKI treatment: Nilotinib|Diagnosed CML patients who receive first line TKI treatment: Nilotinib
3235835|NCT01244750||First line TKI treatment: Dasatinib|Diagnosed CML patients who receive first line TKI treatment: Dasatinib
3235836|NCT01244750||Imatinib treated patients|Imatinib treated patients if their study index date is between January 2, 2008 and September 30, 2010
3235837|NCT01244763|Experimental|Experimental Drug|
3235838|NCT01244776|Experimental|Acellular corneal matrix|
3235839|NCT01244789|Active Comparator|Observation|postoperative observation only
3337140|NCT02152553|Placebo Comparator|Placebo|The same volume of sodium chloride 0,9% as in the other arm where Hydrocortisone is given in saline 0,9% solution. The given volume of sodium chloride will variate chronically as in Hydrocortisone arm.
3337141|NCT02152579|Experimental|Isosorbide-5-mononitrate, tablet|Single treatment arm.
3337142|NCT02152592|No Intervention|PCM/NAPR group|paracetamol 1000 mg orally four times a day for 48 hours postoperatively and naproxen 500 mg orally twice a day for 48 hours postoperatively (standard hospital pain protocol for treatment of acute postoperative pain at home after painful day-case surgery)
3235840|NCT01244789|Experimental|Combination chemotherapy|postoperative 6 courses of 3 weekly iv carboplatin-paclitaxel combination chemotherapy
3235841|NCT01244802||Group 1: 18 to 45 years of age|Between the ages of 18 and 45 at the time of yellow fever vaccination
3337143|NCT02152592|Active Comparator|PCM/Oxy1 group|Controlled Release oxycodone 10 mg orally twice a day for 24 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
3337144|NCT02152592|Active Comparator|PCM/Oxy2 group|CR oxycodone 10 mg orally twice a day for 48 hours and paracetamol 1000 mg orally four times a day for 48 hours postoperatively
3337145|NCT02152618|Experimental|Treatment|
3337146|NCT02152618|No Intervention|Comparison|
3337147|NCT02152644||amyloid|unique cohort of Adult patients older than 21 years with carpal tunnel syndrome with surgical indication (moderate to severe symptoms that do not respond to conservative treatment physiotherapy, splinting, activity modification) for more than 6 months.
3337148|NCT02152657|Experimental|Mesenchymal stem cell transplantation|
3337149|NCT02152683|Experimental|long protocol|Renova
3337150|NCT02152683|Experimental|short protocol|Renova
3337151|NCT02152709|Experimental|10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number: YHB2008063S1.
3337152|NCT02152709|Active Comparator|5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside.Produced by Beijing Tiantan Biological Products Co., Ltd. Lot number:20080603.
3235842|NCT01244802||Group 2: 55 years of age and above|Aged 55 or greater at the time of yellow fever vaccination
3235843|NCT01244841|No Intervention|Standard care|Randomised to standard post MI care and length of hospital stay decided by treating physician.
3235844|NCT01244841|Active Comparator|Early discharge|Randomised patient where all post MI investigations, treatment, follow-up plans and information will be performed within 3 days, and the patients are thereafter discharged.
3337153|NCT02152722||Total Body Irradiation Subjects|Subjects undergoing total body irradiation prior to chemotherapy. It is expected that all of these subjects will be receiving ablative radiation prior to bone marrow transplant. Breath will be collected before and after the first radiation exposure on each day of total body irradiation.
3337154|NCT02152735|Active Comparator|Cleaning the uterine cavity|Cleaning the uterine cavity: participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus.
3337155|NCT02152735|No Intervention|Not cleaning the uterine cavity|These participants will have their uterine cavities left alone after complete delivery of the placenta. The placenta will be inspected after delivery to make sure it is complete, including the membranes.
3337156|NCT02152748||Glioblastoma|The aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples.
3337157|NCT02152774|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
3235845|NCT01244854|Other|Arm 1|Enhanced Usual Care; patients receive care as usual, with additional mailings on wellness newsletter topics
3235846|NCT01244867|Experimental|20 microgram H5 VLP vaccine + Alhydrogel|
3235847|NCT01244867|Experimental|30 micrograms H5 VLP vaccine + Alhydrogel|
3235848|NCT01244867|Experimental|45 micrograms H5 VLP vaccine + Alhydrogel|
3235849|NCT01244867|Experimental|45 micrograms H5 VLP vaccine|
3235850|NCT01244867|Placebo Comparator|Placebo|
3235851|NCT01244880|Experimental|Saline/PF-02545920|Treatments are co-administered
3235852|NCT01244880|Experimental|Ketamine/PF-02545920|Treatments are co-administered
3235853|NCT01244880|Placebo Comparator|Saline/Placebo|Treatments are co-administered
3235854|NCT01244880|Experimental|Ketamine/Placebo|Treatments are co-administered
3235855|NCT01244945|Experimental|L. reuteri DSM 17938|
3235856|NCT01244945|Placebo Comparator|Placebo|
3235857|NCT01244958|Active Comparator|Rituximab 1000 mg|Administration of 1000 mg Rituximab in Part I, followed by either re-treatment with 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
3235858|NCT01244958|Placebo Comparator|Placebo|Administration of Placebo in Part I followed by re-treatment with either 1000 mg Rituximab or with 500 mg Rituximab in Part II of the study
3235859|NCT01244971|Active Comparator|Acarbose|
3235860|NCT01244971|Active Comparator|Exercise|
3337158|NCT02152774|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.
3337159|NCT02152787|Experimental|1) propofol 1.0mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3337160|NCT02152787|Experimental|2) propofol 0.5mg/kg group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3337161|NCT02152787|Placebo Comparator|3) normal saline group|According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery
3337162|NCT02152800|Experimental|Vacyless® 1000 mg|one Vacyless® 1000 mg tablets, 3 times daily for 7days
3337163|NCT02152800|Experimental|Vacyless® 500mg|Two Vacyless® 500mg tablets, 3 times daily for 7 days
3337164|NCT02152800|Active Comparator|Valtrex® 500 mg|Two Valtrex® 500 mg tablets, 3 times daily for 7days
3337165|NCT02152813|Active Comparator|1. Bilateral TENS (Bi-TENS) group|Subjects having bilateral electrical stimulation and task-orientated exercises
3337166|NCT02152813|Placebo Comparator|Unilateral TENS (Uni-TENS) group|Subjects having unilateral TENS over their affected lower limb only, and task-oriented exercises
3337167|NCT02152839|Experimental|Old Unilateral Exercise|Old individuals (65-75y) studied before and after 6 weeks of unilateral resistance exercise training
3337168|NCT02152839|Experimental|Young Unilateral Exercise|Young Individuals (18-30y) studied before and after 6 weeks unilateral resistance exercise training
3235861|NCT01244971|Experimental|Exercise + Acarbose|
3235862|NCT01244997|Experimental|Immediate implant placement|This arm is an immediate placement of a dental implant following tooth extraction.
3235863|NCT01244997|Active Comparator|Delayed Implant|This is the traditional method for implants. This arm will be done following a healing of the area.
3235864|NCT01245010|Experimental|Water|Water and education provision
3235865|NCT01245010|Active Comparator|Control|Education only
3337169|NCT02152852|Experimental|Community Health Worker Intervention|Community Health Worker Intervention-home visits from community health workers providing education and support for self-management of type 2 diabetes, resources for diabetes control, and assistance in effective communication with medical providers
3337170|NCT02152852|No Intervention|Usual Care Control Group|Usual Care Control Group- Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support diabetes self-management (such as classes and support groups) and educational pamphlets.
3337171|NCT02152865|Active Comparator|Lupeol|Patients are supposed to apply lupeol on one side of face two times per day for 8 weeks
3337172|NCT02152865|Placebo Comparator|Control vehicle|Patients are supposed to apply vehicle control to another side of face two times per day for 8 weeks
3337173|NCT02152878|Active Comparator|Active stimulation|Active stimulation (tDCS) will be used in the dose of 2mA /30 min per day, for 10 days and two extra sessions every other week (total of 12 sessions).
3235866|NCT01245023|Active Comparator|laparoscopy|laparoscopic adhesiolysis and application of Sprayshield spray to prevent further adhesions
3337174|NCT02152878|Placebo Comparator|Sham stimulation|For Sham Transcranial Direct Current Stimulation, the device is automatically turned off after 30 seconds of stimulation and remains turned off.
3235867|NCT01245023|Placebo Comparator|placebo-control|anaethesia and skin incisions without laparoscopy or related procedures
3235868|NCT01245036|Active Comparator|Glucocorticoid arm|Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 6 weeks (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 6 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
3235869|NCT01245075|Active Comparator|Deep Brain Stimulation|Stimulator setting is ON
3337175|NCT02152891|Experimental|CHAP-EMS/CP@clinic Program Intervention|12 month implementation of the intervention
3337176|NCT02152891|No Intervention|Control|Will complete a survey at baseline and at 1 year, no program or intervention provided
3337177|NCT02152904||Peptic ulcer bleeding patients|Endoscopy
3337178|NCT02152917|Active Comparator|Tranexamic acid|A dose of tranexamic acid (10mg/Kg) will be administered 20 minutes before inflating the pneumatic tourniquet and another dose 15 minutes after the tourniquet release.
3235870|NCT01245075|Sham Comparator|Placebo|Stimulator setting is OFF
3235871|NCT01245088|Experimental|chondroitin sulfate|400 mg (one table) TID
3235872|NCT01245127|Experimental|Canakinumab|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
3235873|NCT01245153|Experimental|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught Foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water. Subjects will contract pelvic floor muscle in standing position by contracting the pelvic floor muscle, hold and count 1 to 5, then relax and count 1 to 5. Subjects are instructed to do the exercise 15 times/set, 3 sets/day, every day for 6 weeks.
3337179|NCT02152917|Active Comparator|Floseal®|Floseal® will be applied in regions of potential bleeding before the release of the pneumatic tourniquet.
3337180|NCT02152917|No Intervention|Control group|
3337181|NCT02152930|Active Comparator|Supervised Exercise Therapy|Standard treatment: Supervised Exercise Therapy during 12 weeks
3337182|NCT02152930|No Intervention|Controlled group|
3337183|NCT02152943|Experimental|Treatment (everolimus, letrozole, trastuzumab)|Patients receive everolimus PO QD and letrozole PO QD. Patients also receive trastuzumab IV over 30-90 minutes once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3337184|NCT02152956|Experimental|Flotetuzumab|CD123 x CD3 bispecific DART® antibody
3337185|NCT02152969|Other|Part B|Arm to evaluate influence of Chlorthalidone on pharmacokinetics of amlodipine and telmisartan.
3337186|NCT02152969|Other|Part A|Arm to evaluate influence of amlodipine and telmisartan on pharmacokinetics of Chlorthalidone.
3337189|NCT02152995|Experimental|Treatment (iodine I-124 PET/CT, trametinib, iodine I-131)|Patients undergo iodine I-124 PET/CT on day 5 of week 1. Beginning day 6, patients receive trametinib PO daily for 4 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo second iodine I-124 PET/CT on week 5. If I-124 PET/CT shows enough iodine absorption, patients may receive iodine I-131 PO and continue receiving trametinib for another 2 days. If I-124 shows that the thyroid is not absorbing iodine, patients may continue trametinib at the doctor's discretion and do not receive iodine I-131.
3337190|NCT02153008||Symptomatic population for GAS|This study is a diagnostic study to aid in the detection of Strep throat. No intervention or medication is a part of this study.
3337191|NCT02153021|Placebo Comparator|Lifestyle counseling|alimentation information: a nutritionist provides nutritional orientation; exercise training: 3 days by week the patients will have specific sessions of resistance training (30 minutes) and aerobic training (30 minutes); phototherapy: all patients will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral. In Sham group,the equipment will be off.
3235874|NCT01245153|Active Comparator|Control group|Patients receive Pelvic floor muscle training without inserting any kinds of equipment.
3337192|NCT02153021|Active Comparator|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
3337193|NCT02153034||Buruli ulcer patients, no intervention|Buruli ulcer patients administered standard standard care by the attending physician
3337194|NCT02153034||Healthy contacts, no intervention|Healthy volunteers who will be contacts of patients recruited or non-endemic controls. No intervention will be administered
3337195|NCT02153047|Experimental|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
3337196|NCT02153047|No Intervention|Brief smoking cessation advice|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
3337197|NCT02153060|Experimental|20mg dexamethasone group|Dexamethasone 20 mg per day, 4 consecutive days
3337198|NCT02153060|Experimental|40mg dexamethasone group|Dexamethasone 40 mg per day, 4 consecutive days
3235875|NCT01245166|Active Comparator|Acarbose|
3235876|NCT01245166|Experimental|Metformin/Acarbose|
3337199|NCT02153125|Experimental|Eplerenone|25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment
3337200|NCT02153125|Placebo Comparator|Placebo|
3337201|NCT02153151||In vitro effect of AMP-514|Patients undergo blood sample collection at baseline, during the second week of RT, at the end of RT, and at 1 month after the end of RT
3337202|NCT02153177|Active Comparator|NSAID and pain medication arm|After a rotator cuff repair procedure subjects in the NSAID and pain medication arm will receive both Ibuprofen and Hydrocodone/Acetaminophen, and also Omeprazole.
3337203|NCT02153177|Active Comparator|pain medication arm|Patients in the pain medication arm will receive Hydrocodone/Acetaminophen after the rotator cuff repair procedure.
3337204|NCT02153190|Experimental|HYBRID-OPEN|"Patients are randomized on the schedule; hybrid period and after open period. During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.~During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
3235877|NCT01245179|Experimental|Panobinostat|All patients will receive Panobinostat at specified dose levels and dosing schedules.
3259240|NCT01468922|Experimental|A|Combination pazopanib plus ARQ197 at doses established during escalation phase
3337205|NCT02153190|Experimental|OPEN-HYBRID|"Patients are randomized on the schedule: open period and after hybrid period. During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.~During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day. Overall, an increase of time spent in range when using artificial pancreas in the hybrid period should be observed with a reduction of both hypo and hyperglycemia episodes."
3337206|NCT02153203|Experimental|Behavioral approach|The Prevent-Teach-Reinforce Model will be implemented with families in their home settings.
3235878|NCT01245205|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive Akt inhibitor MK2206 PO QOD for 28 days (35 days for course 1) and lapatinib ditosylate PO QD or BID on days 1-28 (days 9-35 for course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3337207|NCT02153203|Active Comparator|Educational approach|Each child's parent will participate in one 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior in children with autism spectrum disorders.
3337208|NCT02153229|Experimental|patients who undergo RP plus photofrin-based PDT|
3235879|NCT01245244|Experimental|Morphine|
3235880|NCT01245244|Placebo Comparator|Placebo|
3235881|NCT01245257||Alcoholic Hepatitis|Patients with alcoholic hepatitis
3337209|NCT02153229|Experimental|patients who undergo RP alone|
3337210|NCT02153242||Supra Ventricular Tachycardia (SVT)|Patients undergoing SVT studies
3337211|NCT02153255||Children With Mucopolysaccharidosis Type IVa|
3235882|NCT01245296|Other|Early cord clamping (ECC)|Early cord clamping consisted of early (< 10 s) clamping of the umbilical cord and obtaining blood gas samples after clamping.
3235883|NCT01245296|Other|Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (> 180 s) clamping of the umbilical cord and obtaining blood gas samples before clamping (within 30 seconds).
3235884|NCT01245309|Experimental|scratching|endometrial scratching prior ivf cycle
3235885|NCT01245309|Placebo Comparator|PLACEBO|PLACEBO PROCEDURE
3337212|NCT02153268|Experimental|single arm, Liposuction, BonoFill Transplantation|"Liposuction - will be performed on Visit 2 for all eligible subjects~BonoFill Transplantation - will be performed on Visit 6 for all eligible subjects"
3337213|NCT02153281|Experimental|Phenelzine treatment|Subjects will undergo a PET and MRI scan before and after the treatment.
3337214|NCT02153294|Experimental|Ventilation with lower tidal volumes|Use of low tidal volume (4 to 6 ml/kg PBW) after intubation and during all mechanical ventilation
3337215|NCT02153294|Other|Ventilation with higher tidal volumes|Use of high tidal volume (8 to 10 ml/kg PBW) after intubation and during all mechanical ventilation
3235886|NCT01245322|Active Comparator|Lactobacilli|different lactobacilli.
3235887|NCT01245335|Active Comparator|BMAC Treatment|Intervention- Injection of 40 ml of autologous bone marrow concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
3235888|NCT01245335|Placebo Comparator|Placebo Injection|Injection of placebo (diluted peripheral blood) into ischemic tissue of the lower extremity
3235889|NCT01245348||Schizophrenia|Patient with schizophrenia
3235890|NCT01245348||Bipolar|Patient with bipolar disorder
3235891|NCT01245361|Experimental|Infliximab|Group I: Infliximab 3 mg/kg wk 0,2,6
3235892|NCT01245361|Placebo Comparator|sodium chloride|RA 1 solution for infusion, intravenous use Sterile normal saline 0.9% sodium chloride
3337216|NCT02153307|Experimental|Implantable loop recorders Reveal ICM LINQ®,|
3337217|NCT02153320|Experimental|HBsAg + adjuvant 1 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 1 in study 287615 (NCT00508833).
3337218|NCT02153320|Experimental|HBsAg + adjuvant 2 Group|Single blood sample taken from subjects who had received GSK candidate vaccine containing HBsAg together with an adjuvant 2 in study 287615 (NCT00508833).
3337219|NCT02153320|Experimental|HBsAg + adjuvant 3 Group|Single blood sample taken from subjects who had received GSK candidate vaccines containing HBsAg together with an adjuvant 3 in study 287615 (NCT00508833).
3337220|NCT02153333||HRV Group|Subjects who had received 2 doses of HRV vaccine in previous studies.
3337221|NCT02153333||Placebo Group|Subjects who had received 2 doses of placebo in previous studies.
3337222|NCT02153372|Experimental|BMC2012|The large bone defect was then be bridged as per clinical standard, filled with a clinically established scaffold (ß-TCP), and 1.3 x106/ml BMC were loaded per 1 ml ß-TCP in situ.
3337223|NCT02153385|Experimental|Yoga group|Two yoga sessions per week for 8 weeks
3337224|NCT02153385|No Intervention|Control group|Usual level of physical activity; no involvement in any yoga practice during the course of the study
3337225|NCT02153411||8645 asthmatic patients|Men and women, 18 years of age and older. Asthmatic since at least one year before inclusion. Patient's informed consent obtained.
3337226|NCT02153424||NVAF patients in Mexico treated with Apixaban|All patients with NVAF at the sentinel site for the CNFV in Mexico who received at least 1 dose of Apixaban to reduce the risk of stroke or systemic embolism during the specified 24-month study period
3337227|NCT02153437|Experimental|Arm A: BMS-919373|BMS-919373 oral Solution/tablet single dose for one day
3337228|NCT02153437|Active Comparator|Arm B: Sotalol|Sotalol oral Tablet single dose for one day
3337229|NCT02153437|Placebo Comparator|Arm C: Placebo for BMS-919373|Oral solution/tablet one single dose for one day
3337230|NCT02153450|Experimental|Treatment (stereotactic radiosurgery, metformin hydrochloride)|"Patients receive metformin hydrochloride PO daily or BID on days -11 to -1. Patients then undergo stereotactic radiosurgery 5 days a week for 5 weeks and receive concurrent metformin hydrochloride* PO BID for 5 weeks. Patients undergo laparotomy on week 6 (or weeks 5-7). Systemic therapy continues as soon as it is considered feasible by the treating physicians.~*NOTE: Metformin hydrochloride should be stopped 2 days before laparotomy."
3337231|NCT02153463|Experimental|Activity Counselling|Physical Activity Counselling weekly for 8 weeks
3337232|NCT02153463|No Intervention|Standard Care|Standard care with no change in medications for 8 weeks
3337233|NCT02153502|Experimental|AVP-786|
3337234|NCT02153502|Placebo Comparator|Placebo|
3337235|NCT02153515|Experimental|Fingerprick of autologous blood (FAB)|Fingerprick of autologous blood (FAB) four times a day for 2 months
3337236|NCT02153541|Placebo Comparator|Mineral oil|For those participants who receive mineral oil placebo, we do not anticipate any change in the usage of rescue inhalers, spirometer scores, asthma diaries, and expired fractionated nitrous oxide levels.
3337237|NCT02153541|Active Comparator|Antipyrine-benzocaine otic solution|Will be used on 50% of participants.
3337238|NCT02153554|Experimental|Trained|Training civil servants in Medellin (Colombia) on attention to violence against women.
3337239|NCT02153554|No Intervention|Non trained|
3337240|NCT02153567|Placebo Comparator|Control (Placebo) group|"Identical looking placebo (once daily)~Double blinding of study medication is achieved by repacking Escitalopram 5mg and 10mg as blue and green capsules respectively.. Identical appearing placebos packed in blue and green capsules will be used for the control group."
3337241|NCT02153567|Experimental|Escitalopram|Escitalopram 5mg & 10mg daily
3337242|NCT02153580|Experimental|Group I (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Non-Hodgkin lymphoma (NHL)."
3337243|NCT02153580|Experimental|Group II (lymphodepletion, cellular immunotherapy)|"LYMPHODEPLETING REGIMEN: Patients receive a chemotherapy regimen based on disease type and extent of disease comprising of cyclophosphamide, bendamustine hydrochloride, fludarabine phosphate, etoposide.~CELLULAR IMMUNOTHERAPY: Beginning 3-10 days later after lymphodepletion, patients receive autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes IV over 10-15 minutes on day 0. Patients with relapsed, residual or progressive disease may receive an optional second infusion of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes >= 28 days post T cell infusion.~Disease status: Patients with Chronic lymphocytic leukemia (CLL) and/or Prolymphocytic Leukemia (PLL)."
3337244|NCT02153593|Experimental|Tranexamic acid|Tranexamic acid, 1g intra-articular before closing the surgery wound
3235893|NCT01245400|Experimental|Z-Lig|Z-Lig Anterior Cruciate Ligament Reconstruction (ACLR) graft implantation performed under anesthesia during an arthroscopic procedure.
3337245|NCT02153593|Experimental|Fibrin glue|One intra-articular dose of fibrin glue (Evicel 5mL) before closing the wound surgery
3337246|NCT02153593|Active Comparator|Usual hemostasia|Electrocauterization
3337247|NCT02153606|Active Comparator|Glycerin Suppository|
3337248|NCT02153606|Sham Comparator|Sham Suppository|
3337249|NCT02153619|Experimental|Meaning-Centered Grief Therapy (MCGT)|Part 1: Open Trials. Participants (n = 5 for Step 1 & n = 5 for Step 2) will receive 16 1-hour (approx) weekly sessions MCGT, & all therapy sessions will be audio recorded. Will make every effort to complete 16 sessions in 16 weeks, due to normal life activities, this is considered an approximation (i.e. there may be weeks where sessions don't take place &/or weeks where more than 1 session takes place in a week). If participant provides us with permission, we will also video record the sessions. Assessments will be administered at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). They will provide their feedback about MCGT & the measures. PI will review the open trial sessions to help refine the MCGT manual & treatment integrity forms. Sessions for Step 1 participants in Part 1 will be held at the MSK Counseling Center. Sessions for Step 2 participants in Part 1 will be conducted via videoconferencing.
3337250|NCT02153619|Experimental|MCGT or Supportive Psychotherapy|Part 2: Pilot RCT. Will randomize 66 parents to 16 weekly 60-90 minute (approx) sessions of MCGT or SP delivered via videoconferencing. Again, sessions will be audio recorded. If the participant provides us with permission, we also audio/video record the sessions. We will examine aspects of study implementation & therapy process, including a) recruitment progress, b) implementation of the intervention, c) administration of the assessments, & d) retention. We will also examine acceptability, defined as measures of satisfaction at T3. Psychosocial outcomes will be assessed with self-report measures at 4 time points: pre-intervention (T1), mid-intervention (T2), post-intervention (T3), & at 3-months post-intervention (T4). Post-intervention qualitative exit interviews will assess acceptability of the intervention. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention .
3337251|NCT02153658|No Intervention|Arm 1|Subjects followed the current hygiene instructions, standard washing in a shower with soap.
3337252|NCT02153658|Active Comparator|Arm 2|Subjects cleaned the foreskin with soapy water using a syringe once a day.
3337253|NCT02153658|Active Comparator|Arm 3|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.
3337254|NCT02153684||Mild COPD, symptomatic|Smokers fitting GOLD 1B criteria for COPD
3337255|NCT02153684||Mild COPD, asymptomatic|Smokers fitting GOLD 1A criteria for COPD
3337256|NCT02153684||Symptomatic smokers, at risk for COPD|Smokers who do not meet spirometric criteria for COPD
3337257|NCT02153684||Healthy, non-smoking controls|Non-smokers, matched to smoking groups for age (>40 yrs of age) and gender
3337258|NCT02153697|Experimental|Pigmanorm Cream, Q-switched Ruby laser,solar lentigines|Solar lentigines on the left back of the hand side are treated with Pigmanorm Cream once a day for 7 weeks. Solar lentigines on the right back of the hand side are treated with a Q-switched Ruby laser at Baseline and if required at day 28.
3337259|NCT02153749|Experimental|Cognitive Regulation of Craving|Training in craving regulation component of Cognitive Behavioral Therapy(CBT) for addictions.
3235894|NCT01245400|Active Comparator|Allograft|Allograft bone/tendon graft implantation performed under anesthesia during an arthroscopic procedure.
3235895|NCT01245426|Experimental|GW870086 2mg|GW870086 2mg once daily in the morning for 27 ± 2 days
3235896|NCT01245426|Experimental|GW870086 4mg|GW870086 4mg once daily in the morning for 27 ± 2 days
3235897|NCT01245426|Placebo Comparator|Placebo|Placebo once daily in the morning for 27 ± 2 days
3337260|NCT02153749|Experimental|Mindfulness-Based Regulation of Craving|Training in craving regulation component of Mindfulness Based Therapy(MBT) for addiction.
3337261|NCT02153749|No Intervention|No training control|No training sessions will be provided in this arm.
3337262|NCT02153762|Experimental|Right side|Patients were randomized to apply Locoid Lipocream on the right side of the target lesion followed by Hylatopic Plus lotion on the left side of the target lesion with the reverse order on the other side.
3337263|NCT02153762|Active Comparator|Left first|Patients were randomized to apply Locoid Lipocream on the left side of the target lesion followed by Hylatopic Plus lotion on the right side of the target lesion with the reverse order on the other side.
3337264|NCT02153775|Experimental|Progressive muscle relaxation|Progressive muscle relaxation: single 20-minutes session
3337265|NCT02153775|No Intervention|Reading newspaper of the day|Reading newspaper of the day : single 20-minutes session
3337266|NCT02153801|Active Comparator|Low Inferior Mesenterci Artery Ligation|The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
3337267|NCT02153801|Other|High Inferior Mesenterci Artery Ligation|"For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
3337268|NCT02153814|Sham Comparator|Control|Will undergo sham procedure twice
3235898|NCT01245426|Experimental|GW870086 1mg|GW870086 1mg once daily in the morning for 27 ± 2 days
3337269|NCT02153814|Experimental|One Endometrial Scratch Procedure|Will undergo one sham procedure and one endometrial scratch procedure
3337270|NCT02153814|Experimental|Two Endometrial Scratch Procedures|Will undergo endometrial scratch procedure twice
3337271|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule|PSORI-CM01（YXBCM01）granule 1.1g os once a day for 12weeks.
3337272|NCT02153840|Experimental|PSORI-CM01（YXBCM01）granule low dose group|PSORI-CM01（YXBCM01） granule 5.5g os once a day for 12weeks.
3337273|NCT02153840|Placebo Comparator|placebo|Placebo granule 1.1g os once a day for 12weeks.
3337274|NCT02153853||Rectal cancer|Patients undergoing laparoscopic surgery for rectal cancer at the Department of Gastrointestinal Surgery, Hvidovre Hospital, Copenhagen, Denmark.
3337275|NCT02153866|Placebo Comparator|rotavirus|vaccinate one dose rotavirus vaccine for each of 700 participants aged 8~9months
3337276|NCT02153866|Placebo Comparator|measles-rubella|vaccinate one dose measles-rubella vaccine for each of 350 participants aged 8~9 months.
3337277|NCT02153866|Placebo Comparator|measles-mumps-rubella|vaccinate one dose measles-mumps-rubella vaccine for each of 350 participants aged 8~9 months.
3337278|NCT02153866|Experimental|rotavirus, measles-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-rubella vaccine for each of 700 participants aged 8~9 months.
3235899|NCT01245426|Experimental|GW870086 3mg|GW870086 3mg once daily in the morning for 27 ± 2 days
3337279|NCT02153866|Experimental|rotavirus, measles-mumps-rubella|simultaneously vaccinate one dose rotavirus vaccine and one dose measles-mumps-rubella vaccine for each of 700 participants aged 8~9 months.
3337280|NCT02153879|Experimental|Fenofibrate|Fenofibrate 145 mg/day for 12 weeks
3337281|NCT02153879|Experimental|Niacin plus Laropiprant|Niacin 2g/day plus Laropiprant for 12 weeks
3337282|NCT02153892|Other|Multi-center, prospective, single-arm study|To assess the safety and performance of the GDS Accucinch System when used percutaneously to reduce functional mitral regurgitation.
3337283|NCT02153931||Volunteers|Parents of children with NF1
3337284|NCT02153944|Experimental|1|Methylphenidate
3337285|NCT02153944|Placebo Comparator|2|Placebo
3337286|NCT02154009||Healthy Volunteers|Volunteers will be studied for Fellows to practice and gain normative values for pupillometric function.
3337287|NCT02154009||Patients|Referred patients with known or suspected abnormalities of one or more components of the autonomic nervous system
3337288|NCT02154074|Active Comparator|N1 group: Isoflurane & saline|for normal patients: inhale Isoflurane + the same volume of saline during operation
3337289|NCT02154074|Experimental|N2 group: Isoflurane & Dexmedetomidine|for normal patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
3337290|NCT02154074|Active Comparator|D1 group: Isoflurane & saline|for diabetes patients: inhale Isoflurane + the same volume of saline during operation
3337291|NCT02154074|Experimental|D2 group: Isoflurane & Dexmedetomidi|for diabetes patients: inhale Isoflurane + intravenous pumping Dexmedetomidine during operation
3337292|NCT02154100|Experimental|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
3337293|NCT02154100|Placebo Comparator|Placebo|12 weeks tart cherry juice taken in two doses of 240 ml per day.
3337294|NCT02154113|Active Comparator|Velashape II device|Controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with mechanical manipulation.
3235900|NCT01245452|Experimental|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
3235901|NCT01245452|Active Comparator|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
3337295|NCT02154113|Active Comparator|Ultrashape|The UltraShape Contour I V3 uses focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption.
3337296|NCT02154126|Other|Accuracy assessment|
3337297|NCT02154152|Experimental|Homoeopathic Medicine Causticum|The drug namely Causticum 200C potency shall be administered as 4 globules, prescribed once a week for 3 months with placebo to follow for the remaining period.
3337298|NCT02154165|Active Comparator|Blue light wavelenght 460 nm|
3337299|NCT02154165|Active Comparator|Turquoise light wavelength 499 nm|
3337300|NCT02154178|Experimental|Biomarker group|"Intervention group, in which the duration of empirical antifungal therapy will be based on the results of biomarkers.~Biomarker group"
3337301|NCT02154178|No Intervention|Control group|Control group, in which the duration of empirical antifungal therapy will be based on international recommendations (14 days).
3337302|NCT02154191|Experimental|Surgical Intervention Group|The Surgical Intervention Group will undergo the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
3337303|NCT02154191|No Intervention|Non-Intervention Group (Control)|No Intervention.This group will consist of patients wait listed for surgery but further back in the queue.
3337304|NCT02154217|Experimental|Bimatoprost|once daily
3337305|NCT02154217|Experimental|Latanoprost/Timolol|once daily
3337306|NCT02154230|Experimental|sulphate-bicarbonate-calcium water and low-calorie diet (SW-D)|"Experimental arm: Those patients assigned to this interventional arm of the study will be asked to follow a low-calorie diet. For the first 12 weeks, the diet will cover only basal metabolism expenditure ± 10%. At the end of this 12 weeks, for the following 12 weeks, patients will follow a maintenance diet which will cover both basal metabolism and physical activity expenditure. Patients will be invited to maintain the same level of physical activity preceding enrollment throughout the entire study period. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
3337307|NCT02154230|Active Comparator|tap water and low-calorie diet (TW-D)|Active comparator: Those patients assigned to this interventional arm of the study will be asked to follow the same low-calorie diet of the experimental arm. During the first 4 weeks these patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Rome tap water at room temperature.
3337308|NCT02154256|Experimental|Increasing incentives|The investigators will offer incentives to users that begin low, and get higher over time.
3337309|NCT02154256|Experimental|Decreasing incentives|The investigators will offer incentives to users that start high, and decrease over time.
3337310|NCT02154256|Experimental|Stable incentives|The investigators will offer incentives that stay stable over time.
3337311|NCT02154256|No Intervention|Usual care control|The investigators will offer incentives that are identical to the incentives normally offered by the investigators' partner company.
3337312|NCT02154269|Experimental|G-CSF|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
3337313|NCT02154269|Placebo Comparator|Saline|Subjects will be randomly assigned to receive saline for five days, during 4 cicles.
3337314|NCT02154282|Experimental|ipod games|Administered ipod games with cognitive testing before and after
3337315|NCT02154295|Active Comparator|Eagle Eye Platinum|Eagle Eye Platinum Catheter as the comparator.
3337316|NCT02154295|Active Comparator|Revolution|Revolution Catheter as the comparator
3337317|NCT02154295|Active Comparator|TVC Insight 40MHz|TVC Insight as comparative catheter.
3337318|NCT02154295|Active Comparator|Atlantis Pro|Atlantis Pro catheter as comparator
3337319|NCT02154308|Experimental|IL-YANG influenza vaccine|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
3337320|NCT02154321||Attention Deficit Hyperactivity Disorder|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
3337321|NCT02154321||Healthy Control|This study aims to recruit 100 adult participants: 50 of which are adults diagnosed with Attention Deficit Hyperactivity Disorder and 50 healthy controls. All participants will perform a total of two tasks while connected to electroencephalogram (EEG) sensors; the first task is a resting state task and after that a cognitive challenge task (attention control). Study activity is performed in a single visit which lasts two hours. Participants will also be asked to complete some behavioral questionnaires.
3235902|NCT01245465|Experimental|Profermin|Daily oral intake of a food for special medical purposes (Profermin)
3235903|NCT01245504||Lower-limb amputee|Subjects with at least one lower limb amputated at teh trans-tibial level
3235904|NCT01245517|Experimental|Dietary Phosphorus Education Program|
3235905|NCT01245530|Active Comparator|Aricept|Intervention: Drug: Aricept
3235906|NCT01245530|Experimental|INM-176|Intervention: Drug: INM-176
3235907|NCT01245543|Experimental|AC480IV|Dose range finding study
3235908|NCT01245543|Experimental|Docetaxel|Dose range finding study in subjects with solid tumors
3337322|NCT02154334|Experimental|Cohort 1|One Intranasal spray of 14 milligram (mg) esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A). Two intranasal sprays of 50 microgram (mcg) mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg at time -1 hour prior to 1 intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg on Day 16 in Period 2 (Treatment B).
3235909|NCT01245556|Experimental|BMS-908662 or Ipilimumab (A)|
3235910|NCT01245556|Experimental|BMS-908662 or Ipilimumab (B)|
3235911|NCT01245569|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
3337323|NCT02154334|Experimental|Cohort 2: Sequence 1|One Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 (Treatment A) and pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 2 (Treatment C).
3337324|NCT02154334|Experimental|Cohort 2: Sequence 2|Pretreatment with 2 sprays of oxymetazoline 0.05 percent (%) weight by volume (w/v) solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1 (Treatment C) and 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 2 (Treatment A).
3337325|NCT02154360|Experimental|Aprepitant|"Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days.~6 participants will be receiving an antiretroviral regimen containing atazanavir/ritonavir (300/100 mg) daily plus two other antiretrovirals.~6 participants will be receiving an antiretroviral regimen containing darunavir/ritonavir (800/100 mg) daily plus two other antiretrovirals."
3337326|NCT02154399|Experimental|Treatment (EF5)|Patients receive EF5 IV over 1-2.5 hours. Beginning 24-55 hours later, patients undergo tumor hypoxia measurement using a polarographic needle electrode and intraoperative tumor measurement before undergoing surgical biopsy or resection.
3337327|NCT02154412|Experimental|Respiratory training|Subjects will be seated in own wheelchair with head-up tilt. Assembled together, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. Subjects will perform maximal inspiratory and expiratory efforts against a pressure load. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
3337328|NCT02154412|No Intervention|No respiratory training|Participants will not participate in the respiratory muscle training.
3337329|NCT02154438|Experimental|ketamine|ketamine 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
3337330|NCT02154438|Placebo Comparator|Placebo|normal saline 0.5mg/kg loading dose and followed by 0.5mg/kg/h during operation
3337331|NCT02154464|Active Comparator|Paracetamol|
3337332|NCT02154464|Placebo Comparator|Placebo|
3337333|NCT02154503|Experimental|Microneedling|"By randomization, the side for treatment will be determined. Topical anaesthetic will be then placed onto the treatment area under occlusion for thirty minutes to one hour. This will then be removed with 70% alcohol. The area will be rolled with microneedles in two planes: coronally and sagitally. In each plane, five passes will be made. Patients will restart application of Minoxidil the following day to both sides of the lesion.~The same half of the scalp will be treated for the rest of the sessions, with topical anaesthetic applied by patient 30 minutes to an hour prior to start of treatment session. Patients will undergo microneedling on alternate weeks for a total of six treatments in 12 weeks. If there is >30% growth seen after six weeks, then the entire area will be treated."
3337334|NCT02154516|Active Comparator|Control Total Hip Replacement Device|"Total Hip replacement surgery using control device consisting of a hard-on-soft bearing or a ceramic-on-ceramic bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~OXINIUM heads on polyethylene liners or~Ceramic heads on ceramic liners (all uncemented components)"
3337335|NCT02154516|Experimental|Investigational Hard-on-Hard Total Hip Replacement Device|"Total Hip replacement surgery using an experimental device consisting of a hard-on-hard bearing which includes:~R3 acetabular cup, and an uncemented SYNERGY or ANTHOLOGY femoral stem~R3 ODH acetabular cup liners (sizes 38/50, 40/52, 42/54 and 44/56 mm)~R3 ODH femoral heads (sizes 38, 40, 42 and 44 mm)~Taper sleeves Ti -6AL-4V (sizes -4, +0, +4, and +8)"
3235912|NCT01245569|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
3235913|NCT01245582|Experimental|SECOX regimen|Oxaliplatin (Eloxatin) 85mg/m2 , 2 hour infusion, day 1 Capecitabine (Xeloda) 850 mg/m2 BID orally daily, from day 1 to 7 Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
3337336|NCT02154529|Experimental|Phase 1b, Arm 1|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 150mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3337337|NCT02154529|Experimental|Phase 1b, Arm 2|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 250mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3337338|NCT02154529|Experimental|Phase 1b, Arm 3|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 300mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3337339|NCT02154529|Experimental|Phase 1b, Arm 4|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 350mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3337340|NCT02154529|Experimental|Phase 1b, Arm 5|Tesevatinib in combination with Trastuzumab. Tesevatinib will be orally administered to subjects at 400mg once daily in combination with Trastuzumab 8mg/kg every 3 weeks.
3337341|NCT02154529|Experimental|Phase 2a, Group 1|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive breast cancer and brain metastases that have progressed after radiation therapy.
3337342|NCT02154529|Experimental|Phase 2a, Group 2|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will include those with HER2-positive metastatic breast cancer who do not have brain metastases, or who have asymptomatic brain metastases, or who have minimally symptomatic brain metastases that do not require immediate radiation therapy or neurosurgery.
3337343|NCT02154529|Experimental|Phase 2a, Group 3|Tesevatinib in combination with Trastuzumab. In the Phase 2a expansion group, tesevatinib will be orally administered to all subjects once daily at the MTD dose determined in Phase 1b in combination with Trastuzumab 8mg/kg every 3 weeks. Subjects will be limited to those with HER2-positive metastatic breast cancer with pathologically confirmed leptomeningeal metastases with or without brain metastases. Brain metastases do not have to have progressed after radiation therapy in this group.
3337344|NCT02154542|Active Comparator|Experimental A|NAVA then standard mode
3337345|NCT02154542|Active Comparator|Experimental B|Standard mode then NAVA
3337346|NCT02154555|No Intervention|no debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During all three postoperative visits, no debridement will be performed.
3337347|NCT02154555|Experimental|debridement|The postoperative clinical visits will occur at one week, one month, and three months following surgery. During the one week postoperative visit, the randomized unilateral debridement will be performed. Debridement includes removing any crust or mucous in the nose. During the one month and three month visit, the PI will only examine the nose.
3337348|NCT02154568|Experimental|Hyperpolarized helium MRI of the chest|
3337349|NCT02154594|Experimental|Acacia|Rinse with 20 ml of Acacia catechu mouthwash twice daily for 15 days
3337350|NCT02154594|Active Comparator|Chlorhexidine gluconate|Rinse with 10 ml of chlorhexidine mouthwash twice daily for 15 days
3337351|NCT02154594|Placebo Comparator|Distilled water|Rinse with 10 ml distilled water twice daily for 15 days.
3337352|NCT02154607|No Intervention|Symptomatic treatment|Symptomatic analgetic Treatment only was performed without any Manipulation of OLP lesions.
3337353|NCT02154607|Active Comparator|CO2-Laser Treatment|CO2-Laser Vaporisation was performed of OLP lesions under local anaesthesia.
3235914|NCT01245582|Active Comparator|Sorafenib alone|Sorafenib (Nexavar) 400 mg BID orally daily, from day 1 to 14 (continuously)
3235915|NCT01245608|Experimental|Polypill|Single daily dose of PolyPill and 6-monthly visits
3235916|NCT01245608|No Intervention|Control|Only 6-monthly visits
3235917|NCT01245621|Active Comparator|Early entry group|Early entry group will begin the intervention at time of diagnosis of advanced cancer
3235918|NCT01245621|Active Comparator|Later entry group|Later entry group will begin the intervention 12 weeks after enrollment in the study.
3235919|NCT01245634|Experimental|A|
3235920|NCT01245634|Placebo Comparator|B|
3235921|NCT01245660|Experimental|Patient|
3235922|NCT01245686|Active Comparator|One-on-one counseling|Participants in this arm will receive 4 intensive one-on-one counseling sessions (either in person or on the phone) and 3 brief maintenance sessions.
3235923|NCT01245686|Active Comparator|Web counseling|Participants in this arm will receive 4 intensive counseling sessions over the web. They will also receive 3 maintenance sessions over the web.
3235925|NCT01245725|Experimental|Tirofiban (Aggrastat)|
3235926|NCT01245725|Placebo Comparator|Placebo|
3337354|NCT02154620|No Intervention|Plaster cast|The patient will be treated in a dorsal plaster cast for 4 weeks following the injury to the wrist
3337355|NCT02154620|Experimental|Volar plate|The patient will undergo surgery to the injured wrist with a Synthes Two-column plate (TCP) with a volar approach. Cast will be worn 2 weeks after surgery.
3235927|NCT01245777|Experimental|ferric carboxymaltose|Hb> 11 g/dl and Ferritin < 35 (controlled by CRP): 500mg to correct iron deficiency Hb ≥ 10 and < 11g/dl; Ferritin < 35 (controlled by CRP): 700 mg Hb ≥9 and < 10 g/dl; Ferritin < 35 (controlled by CRP): 800 mg Hb < 9g/dl; Ferritin < 35 (controlled by CRP): 900 mg
3337356|NCT02154633|Experimental|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
3337357|NCT02154633|Active Comparator|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes
3337358|NCT02154646|Experimental|LY2157299 + Gemcitabine|150 mg LY2157299 is administered orally twice daily for 14 days followed by 14 days without study drug (28 day cycle.) Gemcitabine 1000 milligram per square meter will be administered intravenously (IV) on Days 8, 15, and 22 in each cycle (28 day cycle). Participants may continue to receive treatment until discontinuation criteria are met.
3337359|NCT02154659|Other|postprandial reflux group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
3337360|NCT02154659|Other|normal group|Esophageal pH monitoring is the current gold standard for diagnosis of gastroesophageal reflux disease. It provides direct physiologic measurement of acid in the esophagus and is the most objective method to document reflux disease, assess the severity of the disease and monitor the reflux acidity.
3337361|NCT02154685|Other|Retrieval-Extinction: Smoking Cues|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
3235928|NCT01245790|Experimental|1|Healthy subjects (Stage 1)
3235929|NCT01245790|Experimental|2|Mild renal impairment (Stage 2)
3337362|NCT02154685|Other|Non-Retrieval Extinction: Neutral Cues|This is the group that will not receive retrieval-extinction training and will be exposed to neutral cues.
3337363|NCT02154698|Active Comparator|22-gauge Standard Needle|Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)
3337364|NCT02154698|Active Comparator|22-gauge ProCore Needle|Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)
3235930|NCT01245790|Experimental|3|Moderate renal impairment (Stage 2)
3235931|NCT01245790|Experimental|4|Severe renal impairment (Stage 2)
3235932|NCT01245790|Experimental|5|End stage renal disease (Stage 1)
3235933|NCT01245803|Experimental|rosuvastatin,one month,lipid lowering|additional rosuvastatin(10mg) is given at 18hr and 4-6hr before PCI
3235934|NCT01245803|Placebo Comparator|sugar pill, one month|sugar pill is given 18-24hr and 4-6hr before PCI as control
3235935|NCT01245816|Experimental|Eflornithine plus Sulindac|Eflornithine 500 mg and Sulindac 150 mg
3235936|NCT01245816|Active Comparator|Elfornithine plus Placebo|Eflornithine 500 mg and Placebo
3235937|NCT01245816|Active Comparator|Sulindac plus Placebo|Sulindac 150 mg and Placebo
3235938|NCT01245829|Placebo Comparator|Matt|A standard non antimicrobial laminated chart which will form the control group (group 1).
3259241|NCT01468961|Experimental|Internet-based CBT|
3337365|NCT02154711||Mitochondrial Disease|Individuals with genetic diagnoses (nuclear or mitochondrial) of mitochondrial disease
3337366|NCT02154711||Unaffected|Healthy individuals, without mitochondrial disease
3337367|NCT02154724|Other|aDBS|The aDBS (adaptive Deep Brain Stimulation) device is applied both in aDBS and in DBS modality, for two hours in random order for two days. The aDBS can be programmed to deliver aDBS controlled by local fields potential or conventional DBS.
3337368|NCT02154737|Experimental|erlotinib and gemcitabine|"Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg~Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle."
3337369|NCT02154750|Active Comparator|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
3337370|NCT02154750|Experimental|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled
3337371|NCT02154776|Experimental|LEE011 + buparlisib + letrozole|open label, dose escalation evaluating max tolerated dose of the triple combination
3337372|NCT02154789|Experimental|polidocanol|
3337373|NCT02154789|Active Comparator|cryotherapy|
3337374|NCT02154789|Active Comparator|infra-red coagulation|
3235939|NCT01245829|Experimental|Cellomed|Observation charts coated in a laminate with antimicrobial properties (Cellomed) will form group 2.
3235940|NCT01245842|No Intervention|Usual care|
3337375|NCT02154802|Experimental|video: community member|Participant watches video of a community member
3337376|NCT02154802|Experimental|video: physician|Participant watches video of a physician
3337377|NCT02154802|Experimental|video: choice of video|Participant can choose to watch video of either the community member of the physician
3337378|NCT02154802|No Intervention|no video|
3337379|NCT02154815||PPT|Patients with a pre-emptive kidney transplantation from deceased or living donors
3235941|NCT01245842|Experimental|Exercise group|
3235942|NCT01245855|No Intervention|PGE1 group and control group|the control group: received only the conventional medications, the PGE1 group: received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
3235943|NCT01245868|Experimental|Bupivacaine|Bupivacaine as used routinely
3235944|NCT01245868|Placebo Comparator|Lidocaine added to bupivacaine|lidocaine is added to bupivacaine
3337380|NCT02154815||PDT|Patients who have experienced a pre-transplant dialysis period of less than 36 months
3337381|NCT02154828||Integrative practices|"Children included in this project are children 3 to 6 years with diagnosis F84.0 F84.1 according to CIM-10.~these children must be supported in care units that meet the criteria defined integrative practices."
3337382|NCT02154841|Experimental|Questionnaire, taste test, visual food test|The participants will complete a questionnaire that asks them about their taste preferences. They will also will be shown photos of various food stuffs and asked to choose their preferred meal. They will also be asked to put five sponge sticks (a single use item commonly used for mouth care) dipped in one of a five different liquids into their mouths and give their comments what each taste was and on how much they enjoyed it. These five liquids represent the four well-described tastes (sweet, sour, salty, bitter) and a more recently proposed taste, savoury. The intention of this part of the trial is to assess the patient's ability to detect alteration in pure taste and to identify if any of these tastes are preferred.
3337383|NCT02154854|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
3337384|NCT02154854|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
3337385|NCT02154867|Experimental|Fecal transplantation|Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
3337386|NCT02154867|Placebo Comparator|Placebo fecal transplantation|Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.
3337387|NCT02154880||HIV positive under 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3337388|NCT02154880||HIV negative under 50 yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3337389|NCT02154880||HIV positive over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3337390|NCT02154880||HIV negative over 50yo|PFT's, lab work, 6MWT, questionnaires, at baseline 18months and 36 months.
3235945|NCT01245881|Experimental|Treatment group|Broad-spectrum UV block plus non-ablative 1,550-nm fractional treatment
3235946|NCT01245881|Active Comparator|Control group|
3337391|NCT02154893|Experimental|Device and exercise|Device with ultrasound and laser associated with therapeutic exercise
3235947|NCT01245894|Active Comparator|Low-dose Rosuvastatin|5mg Rosuvastatin/day
3235948|NCT01245894|Active Comparator|High-dose Rosuvastatin|Rosuvastatin 40mg/day
3235949|NCT01245907|Experimental|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
3235950|NCT01245907|No Intervention|Waiting-list/control|No intervention for 10 weeks but the same registrations and diaries and forms as the interventional group
3235951|NCT01245920|Experimental|FDBA + Membrane Group|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
3235952|NCT01245920|Active Comparator|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
3235953|NCT01245946|Experimental|Photodynamic therapy|
3337392|NCT02154893|Experimental|Device|Device with ultrasound and laser
3337393|NCT02154893|Placebo Comparator|Placebo|Without any treatment
3337394|NCT02154919||complete revascularization group|this group underwent second PCI procedure on the non-culprit vessels and reveived 100-120 IU/kg unfractionated heparin during PPCI, followed by 3 days administration of low molecular weight heparin or Fondaparinux sodium after procedure. Patients in the CP group and CR group after second PCI procedure were given conservative medicine such as Statins which were not contraindicated to the patients.
3337395|NCT02154919||conservative pharmacotherapy group|patients in conservative group undergoing pharmacotherapy after PPCI. The drugs were the same between two groups.
3235954|NCT01245946|Experimental|Conventional therapy|
3235955|NCT01245959|Experimental|Induction chemotherapy and concurrent chemoradiotherapy|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
3337396|NCT02154932|Active Comparator|double dose misoprostol|2 doses, 3 and 1 hours, prior surgery (group B, 35 cases).
3337397|NCT02154932|Active Comparator|single dose Misoprostol|intra-vaginal single dose of 400 microgram Misoprostol 1 hour pre-operatively (group A, 34 cases)
3337398|NCT02154958||Unexplained infertility|
3337399|NCT02154971||Patients|HIV infected for more than 10 years, aged over 40, treated with antiretroviral therapy
3337400|NCT02154971||Control|non-HIV (matched for age and gender)
3337401|NCT02154984|Experimental|Behavioral (time restricted diet)|Participants follow a time restricted diet, which restricts daily eating to an 8 hour time window between 12:00-8:00 pm. Participants are allowed to consume non-caloric beverages (water, black tea, black coffee, diet soda, etc.) during the fasting hours and required to record daily food consumption in the smartphone app for 6 months. Participants are also coached by telephone over approximately 10-15 minutes weekly for 1 month and then biweekly for 5 months.
3337402|NCT02154997||Type 1 and Type 2 Diabetes|pregnant women which have a known condition of type 1 or type 2 diabetes
3337403|NCT02154997||Gestational diabetes|pregnant women which have developed Gestational diabetes
3337404|NCT02154997||Control group|Pregnant women whom do not suffer from any altered glucose metabolism
3337405|NCT02155023|Experimental|Insulin dosing and glucose sensors|To test the glucose sensors different levels of glycemia are needed. To provoke different glycemic levels the following intervention will be performed: Lunch (with fast glucose absorption characteristics) will be served. Up to 30 minutes after the usual insulin dosing time, the subjects will take his/her lunch dose of insulin adjusted to the chosen lunch plus additional approximately 25% (in the range of 0-50% according to the discretion of the Investigator) of insulin - in order to provoke moderate postprandial hypoglycaemia with glucose values < 70 mg/dl.
3337406|NCT02155036|No Intervention|Usual care|Usual care
3337407|NCT02155036|Active Comparator|Exercise|exercise intervention
3337408|NCT02155049|Experimental|Prostaglandin Analogues|The patients will receive a single daily drop of bimatoprost for six months.
3235956|NCT01245959|Active Comparator|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
3235957|NCT01245985|Experimental|treatment arm|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
3235958|NCT01245998|Active Comparator|dalteparin 5000 I.U./24 h s.c.|
3337409|NCT02155062|Experimental|Whole grain rye|3-4 portions per day of WG rye containing foods (approximately 20 WG per portion)
3337410|NCT02155062|Experimental|Whole grain wheat|3-4 portions per day of WG wheat containing foods (approximately 20 WG per portion)
3337411|NCT02155062|Placebo Comparator|Refined cereal|No intake of WG wheat or WG rye cereals, only refined cereals or non-AR containing WG cereals (e.g. WG rice or oats)
3337412|NCT02155075|Experimental|Arm 1|"Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant.~All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI."
3337413|NCT02155075|Experimental|Arm 2|Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
3337414|NCT02155088|Experimental|Combination Therapy: BYL719, Gemcitabine, (Nab)-Paciltaxel|Dose escalation, followed by expansion, of BYL719 in combination with Gemcitabine and (Nab)-Paclitaxel. BYL719: once daily. Gemcitabine: Days 1,8, 15 of 28-day cycle. (Nab)-Paclitaxel: Days 1,8, 15 of 28-day cycle.
3235959|NCT01245998|Active Comparator|dalteparin 15000 I.U./24 h s.c.|
3235960|NCT01246024|Experimental|Hypoxia|
3235961|NCT01246037|Experimental|First placebo|First half year placebo, second half year bisoprolol
3235962|NCT01246037|Experimental|First Bisoprolol|First half year bisoprolol, second half year placebo
3235963|NCT01246089|Experimental|Ranabizumab|Myopic eyes with retinal neovascularization
3235964|NCT01246102|Experimental|1|starting at 20 mg/m2
3235965|NCT01246141||Repair group|patients in repair group underwent tricuspid repair for functional tricuspid regurgitation.
3235966|NCT01246141||replacement group|In this group, patients underwent tricuspid valve replacement for functional tricuspid regurgitation.
3235967|NCT01246154||EXERCISE TOLERANCE|
3235968|NCT01246167|Active Comparator|Conservative|Active physiotherapy and self-training
3235969|NCT01246167|Active Comparator|Philos locking plate|After operative treatment active physiotherapy and self-training
3235970|NCT01246167|Active Comparator|Epoca prosthesis|After operative treatment active physiotherapy and self-training
3235971|NCT01246193|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
3235972|NCT01246193|Active Comparator|Combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
3337415|NCT02155127|Experimental|walking intervention|Subjects are randomized to walking/functional strength program with weekly coaching or usual care. The program is for 12 weeks. The intervention includes 3 lower extremity strengthening exercises, and progressive walking.
3337416|NCT02155127|No Intervention|usual care|these subjects receive information on walking program, however do not receive any coaching over 12 weeks
3337417|NCT02155140|Active Comparator|Jejunal feeding|Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
3337418|NCT02155140|No Intervention|No jejunal feeding|No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks
3337419|NCT02155153|Experimental|Sugar Free Chewing Gum|All patients receiving sugar free gum
3337420|NCT02155153|No Intervention|Control|Patients receiving no intervention
3337421|NCT02155166|Active Comparator|intracervical anesthesia|Intracervical anesthesia with lidocaine 2%
3235973|NCT01246219|Experimental|GH treatment|4 years of GH treatment
3235974|NCT01246219|Placebo Comparator|Placebo|1 year treatment with placebo followed by optional 3 years of GH treatment
3337422|NCT02155166|Active Comparator|ibuprofen|ibuprofen 400 mg
3337423|NCT02155179||Good prognosis|Sperm samples >15mill/ml >30% progresive sperms
3337424|NCT02155179||bad prognosis|Sperm samples <5mill/ml <5% progresive sperms
3337425|NCT02155192||Cohort 1|Participants who participated in NCT01483599 (X-PLORE) study.
3337426|NCT02155192||Cohort 2|Participants who participated in NCT00267969 (PHOENIX 1) study.
3337427|NCT02155192||Cohort 3|Participants who participated in NCT00307437 (PHOENIX-2) study.
3337428|NCT02155192||Cohort 4|Participants who participated in NCT00454584 (ACCEPT) study.
3337429|NCT02155205|Experimental|Telotristat etiprate|Single dose of telotristat etiprate followed by a 7-day washout.
3337430|NCT02155205|Active Comparator|Moxifloxacin|Single dose of moxifloxacin followed by a 7-day washout.
3337431|NCT02155205|Placebo Comparator|Placebo|Single dose of placebo with a 7-day washout to follow.
3337432|NCT02155218|Active Comparator|Standard Injection Rate|Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size, given at an injection rate of 2 - 2.5 cc/second.
3337433|NCT02155218|Experimental|Patient Tailored Injection Rate|"Subjects will be given a small amount of contrast (approximately 1 cc test bolus) followed by administration of the remainder of the volume of contrast they are getting for their clinical study. This will be approximately 30-40 cc, depending on patient size. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the contrast - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves. The injection rate will vary from 1 to 3 cc/second."
3337434|NCT02155231||previous enrolled|
3337435|NCT02155231||New Enrolled|
3337436|NCT02155244||Common bile duct stones|Common bile duct stones traeted with ERCP
3337437|NCT02155244||CBDS|treated with ERCP combined with surgery
3235975|NCT01246219|No Intervention|Non treatment group|
3259242|NCT01469026|Active Comparator|Early PET/CT|
3337438|NCT02155270|Active Comparator|Precut|A corneal precut of 600µm will be performed.
3337439|NCT02155270|Active Comparator|Stab incision|A stab incision without corneal precut will be performed.
3337440|NCT02155296|Experimental|Schools receiving RPI|"This arm contains schools receiving RPI. RPI offers a continuum of practices that range from informal (e.g., using affective statements that communicate feelings) to formal (e.g., hosting a restorative circle where participants are encouraged to express emotions and form emotional bonds). The circles or group meetings that are designed to take place between school staff and students, are the crux of RPI. School staff are encouraged to use the restorative practices to build relationships and resolve staff issues (restorative staff community), as well as when interacting with parents (restorative approach with families). All restorative practices encourage acting with youth and setting high expectations. When a school becomes proficient in all 11 essential practices it is officially recognized as a Restorative Practices School."
3337441|NCT02155296|Experimental|Schools not receiving RPI|This arm is the control arm and consists of schools that are not receiving RPI.
3337442|NCT02155348|Active Comparator|Multifocal group|Bilateral cataract surgery with implantation of multifocal IOLs
3337443|NCT02155348|Active Comparator|Monovision|Bilateral cataract surgery with monovision
3337444|NCT02155361|Active Comparator|Topical Citrullus colocynthis fruit oil|Topical Citrullus colocynthis fruit oil (1%) 1 cc twice daily
3337445|NCT02155361|Placebo Comparator|Placebo (Vehicle)|Topical vehicle oil 1 cc twice daily
3337446|NCT02155374|Active Comparator|Sliding scale insulin|Sliding scale insulin Glucose 7.8-12 mmol/l --> 2 IU insulin, glucose 12.1-17 mmol/l --> 4 IU insulin, glucose ≥17.1 mmol/l --> 6 IU insulin. In case of insufficient control, insulin doses will be increased
3337447|NCT02155374|Experimental|Intermediate acting insulin|Intermediate acting insulin, 0.01 IU / mg prednison / kg body weight with a maximum of 0.5 unit insulin per kg body weight. In case of age > 70 years or diminished renal function (GFR <30ml/min)
3337448|NCT02155387||Coronary artery bypass graft surgery|with cardiopulmonary bypass
3337449|NCT02155387||Pulmonary metastasectomy by thoracotomy|with one lung ventilation
3337450|NCT02155387||Minimal invasive mitral valve surgery|with cardiopulmonary bypass and one lung ventilation
3259243|NCT01469026|Active Comparator|Conventional diagnostics including CT|
3337451|NCT02155400|Experimental|Prototype development|10 patients (this phase will be terminated once prototype is confirmed ready) Intervention: prototype device
3337452|NCT02155400|Active Comparator|Treatment arm - Prototype|- 18 patients Intervention: Prototype device (heating both sole of foot and popliteal fossa with compression)
3337453|NCT02155400|Active Comparator|Control arm - Forced Air Warming Blanket|18 patients Intervention: Forced air warming blanket (Bair hugger)
3337454|NCT02155400|Active Comparator|Comparison - Sole of foot only|9 patients heating sole of foot only Intervention: prototype device
3337455|NCT02155400|Active Comparator|Comparison - Popliteal fossa only|9 patients heating popliteal fossa only Intervention: prototype device
3337456|NCT02155426||Treatment|Treatment: Chemotherapy or targeted therapy
3337457|NCT02155439|Active Comparator|Triamcinolone|kortikosteroid
3337458|NCT02155439|Active Comparator|5-fluorouracil|antimitotic drug
3337459|NCT02155452||With ALA|Patients with malignant glioma. 25 patients will be provided the ALA for inducing fluorescence
3337460|NCT02155452||Without ALA|5 tumor tissue samples from ACTREC tumor tissue repository will be obtained. These would be malignant gliomas or other brain tumor samples where ALA is usually not administered and will be used as controls and for calibration purposes
3337461|NCT02155478|Other|AMO ZCB00|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL
3337462|NCT02155478|Active Comparator|ISERT 250|ISERT 250 (HOYA, Japan): a standard IOL
3337463|NCT02155491||Prospective cohort 1|In order to observe temporal trends in management of VTE a first cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
3337464|NCT02155491||Prospective cohort 2|In order to observe temporal trends in management of VTE a second cohort of 5000 consecutive unselected patients treated for acute VTE will be recruited. Recruitment into the second cohort will commence when recruitment is completed in the first cohort. This cohort will take approximately 9 months to recruit. Potential patients must be assessed for eligibility within 30 days of their acute VTE diagnosis. They will be followed prospectively for 36 months.
3337465|NCT02155504|Experimental|ASP3700 single ascending dose cohort|Part 1
3337466|NCT02155504|Placebo Comparator|Placebo single ascending dose cohort|Part 1
3337467|NCT02155504|Experimental|ASP3700 alone|Part 2
3337468|NCT02155504|Active Comparator|ASP3700 and itraconazole|Part 2
3337469|NCT02155517|Experimental|Propofol Infusion|"Propofol will be administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider and Cortinez (arcomed ag, Medical System, Switzerland )..~The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.~STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
3337470|NCT02155530|Experimental|High efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
3337471|NCT02155530|Active Comparator|Low efficacy statin group (homogeneous)|homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
3337472|NCT02155556||Healthy volunteers|
3337473|NCT02155569|Active Comparator|Transperitoneal Cesarean|
3337474|NCT02155569|Active Comparator|Extraperitoneal Cesarean|
3337475|NCT02155582|Experimental|Arm 1|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients
3337476|NCT02155582|Experimental|Arm 2|45 mg and 60 mg for the diabetic patients
3337477|NCT02155595||500 with BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
3235976|NCT01246232|Experimental|Amisulpride|400mg, 2 x 200mg amisulpride capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules for the remaining 8 weeks.
3235977|NCT01246232|Placebo Comparator|Placebo|400mg, 2 x 200mg amisulpride capsules, or 2 matching placebo capsules for the first 4 weeks, then the option of titrating up to 800mg, 4 x 200mg amisulpride capsules, or 4 matching placebo capsules for the remaining 8 weeks.
3337478|NCT02155595||500 without BP treatment|patients will undergo lab tests, X-ray, bone scan or MRI, as needed
3337479|NCT02155621|Experimental|Genome Sequencing|There is only one arm to this study.
3337480|NCT02155634|Experimental|Lenalidomide|Lenalidomide maintenance given until disease progression. Long term follow-up 5 years post last patient randomized.
3337481|NCT02155634|No Intervention|Observation|Observation until disease progression. Long term follow-up 5 years post last patient randomized.
3337482|NCT02155673|Experimental|Low Dose GCS-100|Low dose of GCS-100
3337483|NCT02155673|Experimental|High Dose GCS-100|GCS-100 High dose
3337484|NCT02155686|Experimental|Biosensors|Participants in this arm are equipped both with home telecare/automation and with biometric sensors
3337485|NCT02155686|Active Comparator|Automation|Participants in this arm are equiepd with home automation only
3337486|NCT02155699|Experimental|Exercise 1|65% of V02 Max, 3x per week, 3 months
3337487|NCT02155699|Experimental|Exercise 2|85% of VO2 Max, 2x per week, 3 months
3337488|NCT02155699|No Intervention|Waitlist|Waitlist (three months)
3337489|NCT02155751|Experimental|Full NELIP group|"These women (n=10) will receive the full NELIP intervention and will be introduced to both the dietary program and the exercise program as described above under detailed description."
3337490|NCT02155751|Experimental|Exercise program only/ELIP|These women (n=10) will only be given the exercise component (ELIP) of NELIP, as outlined below in interventions. Once dietary intake has been assessed, this group will not be given any dietary intervention but will be encouraged to eat a healthy, balanced diet. Access to the nutritionist in the clinic is available and encouraged.
3337491|NCT02155751|Experimental|Nutrition program only/NLIP|These women (n=10) will only be given the nutrition program (NLIP) of NELIP as outlined below in intervention. They will be encouraged to be more active but will not be given an exercise intervention.
3337492|NCT02155751|No Intervention|Control|A control group (n=30) of obese pregnant women will also be recruited and will be matched by pre-pregnancy BMI, maternal age and parity, with no intervention, but will attend the clinic for standard obstetric care and follow-up.
3337493|NCT02155764|Experimental|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
3337494|NCT02155764|Active Comparator|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
3337495|NCT02155764|Active Comparator|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
3337496|NCT02155777|No Intervention|No intervention|No intervention.
3235978|NCT01246271||Sub urethral sling|
3235979|NCT01246271||sus with anterior vainal wall repair|
3337497|NCT02155777|Active Comparator|OrthoNovum 1/35|OrthoNovum 1/35
3337498|NCT02155790|Experimental|Renal Denervation by Neurolysis|Infusion of 0.3 ml of dehydrated alcohol (96%-98%) into the peri-adventitial space of the renal artery, to achieve renal denervation by Neurolysis, via three simultaneous deployed needles, situated at the distal end of the Peregrine System Infusion Catheter.
3337499|NCT02155803|Experimental|Sarcoidosis related Calcium Dysregulation|Subjects with Sarcoidosis associated calcium dysregulation will be administered 80 units of Acthar Gel (adrenocorticotropic hormone) twice a week for 12 weeks. Clinical visits will be scheduled for -30 days, day of 1st dose and 4,8,12 and 16 week after 1st dose to monitor the health of subjects.
3337500|NCT02155816|Placebo Comparator|Placebo|MCT (medium chain triglyceride)
3337501|NCT02155816|Experimental|Omega 3|Omega-3 fatty acid ethyl esters, 2 soft gels of total 1000mg (660mg EPA +340mg DHA)/day.
3337502|NCT02155816|Experimental|Omega 7 + 3|210mg of Omega-7 fatty acid and 1000mg (660mg EPA +340mg DHA) of Omega-3
3337503|NCT02155842|Experimental|High intensity endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume high intensity endurance exercise, followed by 6 months non-supervised endurance exercise
3337504|NCT02155842|Active Comparator|Moderate continuous endurance exercise|Four weeks comprehensive cardiac rehabilitation with moderate volume moderate intensity endurance exercise, followed by 6 months non-supervised endurance exercise
3337505|NCT02155855|Experimental|Telemedicine|"Telemedicine group will test blood glucose at least 4 times a day Each time the meter time-stamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit."
3337506|NCT02155855|Active Comparator|Control|Control Subjects will continue routine care which requires blood glucose testing at least 4 times a day. Parents will use customary ways to communicate (pager, email, fax or phone) with the Diabetes team, if they are concerned about glycemic control..
3337507|NCT02155868|Experimental|Intervention|"Cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C.~Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it."
3337508|NCT02155868|Placebo Comparator|Control|Only cerebral NIRS monitoring by means of FORE-SIGHT Universal Cerebral Oximeter MC-2030C during cardiac surgery and the first six hours after it.
3337509|NCT02155894|Experimental|Disease control, Telemedicine, doctor|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a doctor at week 13, 26, 39.
3235980|NCT01246284|Active Comparator|A|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3235981|NCT01246284|Active Comparator|B|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3337510|NCT02155894|Experimental|Disease control, Telemedicine, nurse|Using an online platform for self assessment and with the Flare instrument as decision support, the patients are contacted over the telephone by a nurse at week 13, 26, 39.
3337511|NCT02155894|No Intervention|Usual care|Usual care: control of disease activity with consultations in the outpatient clinic.
3337512|NCT02155907||Rtest, Atrial fibrillation|Patients with ischemic stroke or TIA within the last week. Sinus rhythm on the surface ECG. Age ≥ 60 years. Given written informed consent
3337513|NCT02155920|Experimental|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
3337514|NCT02155933||Hyperandrogenemia|Peripubertal girls with hyperandrogenemia
3337515|NCT02155933||Controls|Peripubertal girls without hyperandrogenemia
3337516|NCT02155946|Experimental|Arm 1|Group receives active brain stimulation plus memory rehabilitation
3337517|NCT02155946|Sham Comparator|Arm 2|Group receives sham brain stimulation plus memory rehabilitation
3337518|NCT02155946|Active Comparator|Arm 3|Group receives active brain stimulation plus reminiscence training
3337519|NCT02155946|Active Comparator|Arm 4|Group receives sham brain stimulation plus reminiscence training
3337520|NCT02155959||one group|one group receiving a toric intraocular lens during cataract surgery.
3235982|NCT01246284|Active Comparator|C|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment
3235983|NCT01246284|Placebo Comparator|D|Please note that the letter are assigned to different areas of injections within the same patient. All patients will be receiving the same treatment.
3235984|NCT01246297|Other|Control|Usual Care
3235985|NCT01246297|Active Comparator|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of twice weekly exercise classes with an educational component.
3235986|NCT01246310|Experimental|Inositol|
3235987|NCT01246310|Placebo Comparator|Placebo|
3235988|NCT01246323|Active Comparator|combined anesthesia|Patients will receive spinal and general anesthesia for benign laparoscopy gynecological surgery
3235989|NCT01246323|No Intervention|Control|
3235990|NCT01246336||Patients with parkinsonism|Patients suffering from Parkinson's disease or parkinsonism
3235991|NCT01246336||Healthy controls|Patients not suffering from Parkinson's disease or any other neurological disorder
3235992|NCT01246362|Placebo Comparator|Control|Given placebo tablets preoperatively
3337521|NCT02155972|Active Comparator|Bifidobacterium infantis|Bifidobacterium infantis (Align) 10.00 million cfu capsule once daily
3337522|NCT02155972|Placebo Comparator|Placebo|Placebo capsule once daily
3337523|NCT02155998||PREVENT study patients|Patients with locally advanced prostate cancer with high and very high risk of recurrence, who underwent surgery or radiotherapy within 3 months prior to enrolment, 18 years and older, consented to participate in this non-interventional study, being treated for prostate cancer in the oncology institutions / departments in the Russian Federation.
3337524|NCT02156011||Instrumented knee implant|"4-6 subjects with an instrumented TKA, that has been implanted within the study Kniemessprothese: Belastungsmessung bei Patienten mittels einer instrumentierten Knie-Endoprothese (EA4/069/06) approved and conducted at the Charité- Universitätsmedizin in Berlin, Germany, will be involved in this project."
3337525|NCT02156024|Placebo Comparator|placebo|placebo drink, 1 dose at a time, twice a day, duration: 4 weeks
3337526|NCT02156024|Active Comparator|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
3337527|NCT02156037|Experimental|dashboard team care intervention|Dashboard team
3337528|NCT02156037|Active Comparator|usual diabetes team control|usual clinical diabetes team with no access to the diabetes dashboard
3337529|NCT02156050|Active Comparator|OBLOO device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
3337530|NCT02156050|Experimental|BBLOO Device (MEDIPREMA)|two sessions of 4 hours Phototherapy treatment
3337531|NCT02156063|Experimental|NT100|NT100 Dose 1
3337532|NCT02156063|Placebo Comparator|Placebo|Placebo
3337536|NCT02156128|Experimental|Cogmed|Participants in a 3,5 week vocational rehabilitation program (containing cognitive therapy and physical exercise) are instructed to use a computer-based working memory training program (named CogMed) each weekday (5 days a week) for 5 weeks. Each training session consists of 8 different tasks and lasts 40-50 minutes.
3337537|NCT02156128|Active Comparator|Control group|These subjects will participate in the vocational rehabilitation program for 3,5 weeks. The program includes cognitive therapy (ACT) and physical activity, but no working memory training.
3337538|NCT02156141|Experimental|Supervised high intensity training|"8 weeks of supervised high intensity training, 10 minutes, 3 times a week (once a week supervised) on a cycle ergometer followed by 8 weeks of unsupervised optional training.~Participants: Patients with Kennedy's disease or healthy control subjects (individually matched with patients).~Participants: Patients with Kennedys disease and healthy control subjects."
3337539|NCT02156141|Experimental|Unsupervised High intensity training|"8 week control period with no training followed by 8 weeks of unsupervised high intensity training on a cycle ergometer.~Participants: Patients with Kennedy's disease."
3337540|NCT02156180||Early stage oral cavity / oropharyngeal cancer|Exhaled breath
3337541|NCT02156193|Experimental|Prophylactic clip|Before conventional snare polypectomy, hemoclips will be applied on the base of stalk.
3337542|NCT02156193|Active Comparator|No prophylactic management|Conventional snare polypectomy will be performed without any preventive management.
3337543|NCT02156206||123 women line|Women who call the 123 emergency line and have also immediate services from the 123 women emergency line
3337544|NCT02156206||No treatment|Women who call the 123 emergency line and do not have immediate services from the 123 women emergency line
3337545|NCT02156219||Under separation|Exposure to the separation of women and men in the metro of Mexico City.
3337546|NCT02156219||No treatment|Non exposure to the separation of women and men in the metro of Mexico City.
3337549|NCT02156245|Experimental|"Conventional group"|
3337550|NCT02156245|Experimental|"Combined group"|
3337551|NCT02156284|Experimental|Empathic behaviour by nurses|Patients who received empathic behaviour was performed by a trained nurse.
3337552|NCT02156297||Induction Group|
3337553|NCT02156297||Consolidation Group|
3337554|NCT02156297||Salvage Group|
3337555|NCT02156297||Maintenance Group|
3337556|NCT02156297||Alleviatitive Group|
3337557|NCT02156323|Experimental|Treatment Sequence 1|Participants will be randomized to one of two treatment sequences. Sequence 1 is: Period 1, RO7033877; Period 2, CMS; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
3337558|NCT02156323|Experimental|Treatment Sequence 2|Participants will be randomized to one of two treatment sequences. Sequence 2 is: Period 1, CMS; Period 2, RO7033877; Period 3, RO7033877 + CMS. Each period is separated by a wash-out period of at least 6 days between last dose and start of next treatment.
3235993|NCT01246362|Active Comparator|Etoricoxib|Given etoricoxib preoperatively
3337559|NCT02156336|Placebo Comparator|PLACEBO|"500 mg PLACEBO PO 2 times a day for 1 week (Week 1)~1000 mg PLACEBO PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
3337560|NCT02156336|Active Comparator|RANOLAZINE|"500 mg RANOLAZINE PO 2 times a day for 1 week (Week 1)~1000 mg RANOLAZINE PO 2 times a day for 5 weeks (Weeks 2,3,4,5,6)"
3235994|NCT01246388||Chronic Liver Disease|
3235995|NCT01246414||Allergic asthma|Patients with allergic asthma
3235996|NCT01246414||Non-allergic asthma|Patients with non-allergic asthma
3235997|NCT01246414||Non-asthmatic controls|Non-asthmatic controls
3337561|NCT02156349|Other|Control Group|Patients treated by usual customary medical practice (Usual Care) in the out-patient facility i.e. Diabetes specialized medical practice, Medical Care Center or hospital outpatient clinic.
3337562|NCT02156349|Other|Intervention group|"Patients are treated according to the concept Integrated personalized diabetes management."
3337563|NCT02156362|Other|follow up|
3337564|NCT02156375|Experimental|Ustekinumab 90 mg/mL|
3337565|NCT02156375|Experimental|Ustekinumab 5 mg/mL|
3337566|NCT02156388|Experimental|Ia-GW003 50μg/kg|2-3 subjects
3337567|NCT02156388|Experimental|Ia-GW003 150μg/kg|2-3 subjects
3337568|NCT02156388|Experimental|Ia-GW003 300μg/kg|3-6 subjects
3337569|NCT02156388|Experimental|Ia-GW003 400μg/kg|3-6 subjects
3337570|NCT02156388|Experimental|Ia-GW003 500μg/kg|3-6 subjects
3337571|NCT02156388|Experimental|Ia-GW003 600μg/kg|3-6 subjects
3337572|NCT02156388|Experimental|Ib-GW003 150μg/kg|6-8 subjects
3337573|NCT02156388|Experimental|Ib-GW003 300μg/kg|6-8 subjects
3337574|NCT02156401||Cohort 1: Suspect of Pulmonary Embolism (PE)|
3337575|NCT02156401||Cohort 2: Suspect of Deep Vein Thrombosis (DVT)|
3337576|NCT02156401||Cohort 3: Incidental Venous Thromboembolism (VTE)|
3337577|NCT02156414||Clinically Localized Prostatic Neoplasm|Radical Prostatectomy Extended Lymphadenectomy
3337578|NCT02156427|Experimental|VITICELL|In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
3235998|NCT01246427|Experimental|BRN01|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
3235999|NCT01246427|Placebo Comparator|Placebo|"A 2 to 4 weeks run-in period is planned, during which all patients receive single blinded hot flash evaluation treatment which is actually a placebo (2 tablets every morning and every evening during 2 to 4 weeks). At the end of this period, the hot flash score is calculated. If the score is ≥10, the patient can be randomized to one of the 2 arms:~Experimental: BRN01~Placebo Comparator: Placebo"
3236000|NCT01246440|Experimental|Catumaxomab|
3337579|NCT02156427|Placebo Comparator|PLACEBO|In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
3236001|NCT01246453|Active Comparator|urokinase|
3337580|NCT02156440|Placebo Comparator|Placebo|Placebo capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
3337581|NCT02156440|Experimental|SierraSil Joint Formula 14|SierraSil Joint Formula 14 capsules: one capsule taken 3 times per day with water. Subjects are to drink 6 to 8 glasses of water daily.
3337582|NCT02156453||Total knee arthroplasty|Patients undergoing uncomplicated total knee replacement
3236002|NCT01246453|Active Comparator|Alteplase|
3236003|NCT01246492|Placebo Comparator|45g glucose|glucose water
3337583|NCT02156479||Allo-HSCT recipients|Patients receiving an allogeneic hematopoietic stem cell transplantation for the first time, being either CMV seropositive or receiving a graft from a CMV seropositive donor or both, donor and recipient are CMV seropositive
3337584|NCT02156505|Experimental|DoubleBare stent|Placement of double bare stent
3236004|NCT01246492|Active Comparator|45g glucose + 150mg aspartame|glucose water aspartame
3236005|NCT01246492|Active Comparator|45g glucose + 20 mg saccharin|glucose water saccharin
3236006|NCT01246492|Active Comparator|45g glucose + 85mg asculfame - K|glucose water aseulfame- k
3337585|NCT02156518|Experimental|Vocal Function Exercises|Vocal Function Exercises
3337586|NCT02156518|Active Comparator|Vocal hygiene|Vocal hygiene
3337587|NCT02156531|Placebo Comparator|Attention Control Condition|3.c.14.5. Arm 1: Attention Control Condition. The minimally effective attention-control group procedure is identical to the active CBM procedure except that during the presentation of the trials where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. Thus, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active versions of CBM in Arms 2 and 3.
3337588|NCT02156531|Experimental|Arm 2: Self-administered CBM only|3.c.14.6. Arm 2: Self-Administered CBM Only. Youth assigned to this arm will receive the self-administered active CBM intervention. As described above in detail, in the 80% of CBM trials where a neutral and disgust face are both presented, the probe always replaces the neutral face. Thus, participants are trained to disengage their attention from threat. These youth do not receive Adherence Promotion telephone calls.
3236007|NCT01246518|Active Comparator|MOB015 for 3 months|
3236008|NCT01246518|Active Comparator|MOB015 for 9 months|
3236009|NCT01246531||Urolithiasis|Case arm: men above fifty years-old with urolithiasis
3236010|NCT01246531||Control|Control arm: men above fifty years-old without urolithiasis
3236011|NCT01246544||Data collection group: physicians|Online survey for physicians/members of the innovation alliance Berlin-Brandenburg (INABBRA)
3236012|NCT01246570|Experimental|Maintenance program|"Patients will attend a motivational exercise session once monthly. They will also be tested (exercise test with measurement of peak oxygen uptake) every third months."
3236013|NCT01246570|Active Comparator|Control|Usual care. The patients will receive the usual care provided by the hospital and community health services
3236014|NCT01246596|Active Comparator|chronic periodontitis|
3236015|NCT01246596|Active Comparator|aggressive periodontitis|
3236016|NCT01246596|Active Comparator|healthy patient (orthodontics extraction)|
3236017|NCT01246622|Experimental|Treatment (biological therapy)|Patients receive lenalidomide PO on days 6-26 and cytarabine IV over 3 hours on days 1-5. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
3236018|NCT01246635|Experimental|TRUFIT CB with accelerated rehab.|
3236019|NCT01246635|Experimental|TRUFIT CB with standard rehab.|
3236020|NCT01246635|Active Comparator|• Microfracture with rehabilitation|
3236021|NCT01246648|Active Comparator|chronic periodontitis|
3236022|NCT01246648|Active Comparator|agressive periodontitis|
3236023|NCT01246648|Active Comparator|healthy patients|
3337589|NCT02156531|Experimental|Arm 3: Self-administered CBM + Adherence Promotion|3.c.14.7. Arm 3: Self-Administered CBM + Adherence Promotion. Youth assigned to this arm will receive both the self-administered active CBM intervention and the telephone coach calls to deliver the Adherence Promotion (AP) procedures. AP procedures are intended to compensate for the important nonspecific 'scaffolding' provided by research staff when CBM has been traditionally delivered in laboratories. This includes technical assistance with use of the program, support/encouragement, motivational enhancement, and brainstorming solutions to barriers to regular sessions. The addition of AP to the 3rd arm of this trial attempts to recreate much of this nonspecific, yet likely important, support of in-person interventions, which we hypothesize will lead to greater participant adherence to the program and therefore better clinical outcomes.
3337590|NCT02156544|Experimental|CKD-519 25mg|CKD-519 25mg or placebo
3337591|NCT02156544|Experimental|CKD-519 50mg|CKD-519 50mg or placebo
3337592|NCT02156544|Experimental|CKD-519 100mg|CKD-519 100mg or placebo
3337593|NCT02156544|Experimental|CKD-519 200mg|CKD-519 200mg or placebo
3337594|NCT02156544|Experimental|CKD-519 400mg|CKD-519 400mg or placebo
3337595|NCT02156557|Experimental|peptide application|"Investigational Agent Administration~KCCFPAQ-GGGSK-(5-FITC)-NH2~1.2 mg lyophilized powder per single-use amber vial~Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~Final concentration of 76.4 μM for single, one-time topical application~The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)"
3337596|NCT02156570|Experimental|Sofosbuvir and ribavirin|"Sofosbuvir tablet 400 mg daily Ribavirin tablet weight based dosing (1000mg <75 kg, 1200mg >/= 75kg) daily~Treatment will be for 6 weeks in all participants."
3236024|NCT01246674||Hypothesis generating study|Consecutive total hip arthroplasty patients
3236025|NCT01246687|Experimental|e-Intervention group|Receive stage-specific dietary intervention via the website & standard care at the outpatient clinic.
3337597|NCT02156583||Older, left ventricular assist device|Older heart failure patients undergoing left ventricular assist device implantation
3236026|NCT01246687|No Intervention|Control group|Continue with the standard diabetes care at the outpatient clinic without getting access to the web-based intervention.
3236027|NCT01246700|Experimental|Group A|Participants received 12 weeks of Sensory Attention Focused Exercise, then received 12 weeks of no exercise.
3236028|NCT01246700|Experimental|Group B|Participants received no treatment for 12 weeks, then received Sensory Attention Focused Exercise for 12 weeks.
3236029|NCT01246739|No Intervention|Follow-up|Patients who are diagnosed with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), who are followed only.
3337598|NCT02156596|Active Comparator|Intravenous NSAI|patients received 100 mg of ketoprofen (NSAID) by IV root and in parallel 3 nebulisation of serum saline (SS) over 30 minutes.
3337599|NCT02156596|Experimental|Nebulised Morphine|patients received 3 nebulisation of morphine (5 mg each) and in parallel 50 ml of SS by IV root over 30 minutes.
3337600|NCT02156609|Experimental|Percutaneous coronary intervention|Percutaneous ventricular support with the HeartMate PHP during high risk percutaneous coronary intervention
3337601|NCT02156622||Depression Care Manager|All enrolled in AIM 3 received decision support from Depression Care Manager
3337602|NCT02156635|Experimental|Active tdcs / CIMT|Participants in the acute post-stroke stage will receive active tDCS associate to rehabilitation (CIMT)
3337603|NCT02156635|Sham Comparator|Sham stimulation / CIMT|Participants in the acute post-stroke stage will receive sham stimulation associate to rehabilitation (CIMT)
3337604|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
3337605|NCT02156661|Active Comparator|Oxytocin|"Oxytocin: Syntocinon-Spray, Novartis~intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT"
3337606|NCT02156661|Placebo Comparator|Placebo|Placebo nasal spray
3337607|NCT02156700||Liver tumors|Measurement of tumor stiffness by Shear wave elastography - SWE™
3337608|NCT02156713|Experimental|CIMT Camp|Members of this study will participate in the group CIMT camp.
3337609|NCT02156726||Low dose FCR in Elderly/Comorbid CLL|low dose FCR
3337610|NCT02156739|Experimental|Diagnostic (contrast-enhanced MRI)|Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.
3337611|NCT02156752|Experimental|ACT|Behavioral weight loss plus techniques from Acceptance and Commitment Therapy
3236030|NCT01246739|Experimental|Surgery|Patients diagnosed with adrenal tumour and with biochemically mild hypercortisolism (so-called subclinical Cushing´s syndrome), operated with adrenalectomy
3236031|NCT01246752|Experimental|Human Stem Cell Transplantation|Patients receive an allogenic stem cell transplantation from an HLA-matched unrelated or related donor
3236032|NCT01246752|Active Comparator|Consolidating Chemotherapy|Patients receive a standard chemotherapy as consolidation therapy
3236033|NCT01246765||Pregnant women using atypical antipsychotic(s)|Pregnant women who have taken at least one type of atypical antipsychotic at some point during this pregnancy.
3236034|NCT01246765||Pregnant women not using atypical antipsychotics|Pregnant women who have not taken an atypical antipsychotic during pregnancy.
3236035|NCT01246778||With/without sunitinib|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
3236036|NCT01246778||With/without sunitinib IP|Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion
3236037|NCT01246804|Experimental|ginkgo biloba + raltegravir|15 days ginkgo biloba 120mg BID + raltegravir 400mg SD
3236038|NCT01246804|Active Comparator|raltegravir|single dose raltegravir 400mg
3236039|NCT01246830||3D cephalometric analysis|
3337612|NCT02156752|Active Comparator|SR|Behavioral weight loss plus self-regulation techniques
3337613|NCT02156752|Active Comparator|WLO|Behavioral weight loss plus cooking tips and demonstrations
3337614|NCT02156778|Active Comparator|Extended Standard Care (Stroke Card)|
3337615|NCT02156778|Active Comparator|Standard Care|
3337616|NCT02156791|Experimental|gpASIT+TM|
3236040|NCT01246830||2D cephalometric analysis|
3337617|NCT02156817||Late Preterm Infants (LPT)|34 weeks and 0-6 days gestational age
3337618|NCT02156817||Moderate preterm infants (MPT)|32 weeks and 0-6 days gestational age
3337619|NCT02156843|Experimental|Pyridorin|Pyridorin (pyridoxamine dihydrochloride) 300 mg oral BID (twice daily, every 12 hours) Capsule
3337620|NCT02156843|Placebo Comparator|Placebo|Placebo Oral Capsule taken BID (twice daily, every 12 hours)
3337621|NCT02156856||Hemodynamic optimisation|
3337622|NCT02156856||No hemodynamic optimisation|
3337623|NCT02156869|Experimental|Intervention arm|The intervention was the use of a decision aid.
3236041|NCT01246843||metastatic Renal Cell Carcinoma without treatment|patients with metastasized RCC who did not receive treatment
3236042|NCT01246843||mRCC with treatment|"patients with metastastic renal cell cancer or GIST who are on treatment with Sunitinib or Sorafenib for~≥ 8 weeks"
3337624|NCT02156869|No Intervention|Control arm|Usual care
3337625|NCT02156882||TB patients and Tb suspects|Patients with confirmed tuberculosis who are treated by the National TB Programme
3337626|NCT02156921|No Intervention|Control group|Self-guided training without app-based training (written hand-outs)
3337627|NCT02156921|Active Comparator|Intervention group|Self-guided training with app-based training
3337628|NCT02156934|Experimental|Muscle derived stem cell|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
3337629|NCT02156947||Chronic cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
3337630|NCT02156947||Acute cholecystitis|Laparoscopic cholecystectomy was performed. Gallbladder adhesion score and intraoperative findings of patients were assessed. Adhesion score, gallbladder perforation during the dissection, convertion to open cholecystectomy, operation time, drain usage and intraoperative complications were recorded.
3337631|NCT02156960|Experimental|Denosumab and/or teriparatide treatment|Denosumab and/or teriparatide treatment in osteoporotic patients
3236043|NCT01246882|Experimental|Augmented activity feedback|Feedback three times per week about 10-m walking speed, plus amount and types of physical activity measured using wireless bilateral ankle sensors that detect bouts of walking and cycling speed, duration, and distance.
3236044|NCT01246882|Active Comparator|speed-only feedback|Feedback three times per week about overground walking speed over 10 meters.
3337632|NCT02156973|No Intervention|Group One Usual care|Patients attending for CT coronary angiography all receive an information leaflet with their appointment letter, and a brief verbal description of the scan by the radiographer immediately before it is undertaken, as standard care. All patients attending will be offered the opportunity to complete a short questionnaire (until all patients are recruited - anticipated to be 4 weeks). The Speilberger State-Trait Anxiety Index has been abbreviated and validated for use in outpatient settings to gauge levels of pre-procedural anxiety. This will be undertaken on arrival and repeated immediately before the scan, to see if patients feel better prepared after the standard interaction with staff.
3236045|NCT01246908|Experimental|CX157 (TriRima)|CX157 (TriRima) in a reversible monoamine oxidase inhibitor (MAOI)
3236046|NCT01246908|Placebo Comparator|Placebo|
3337633|NCT02156973|Experimental|Group Two Video information|The patient video will be introduced to Group Two once Group One has been completed. In addition to the information sheet these patients (again, for four weeks or until recruitment is complete) will be sent an internet hyperlink to its presence on YouTube (video-sharing website) and the Hospital website with their appointment letter. Patients who do not have internet access will be offered the opportunity to see the video in the preparation room while waiting for their scan. Questionnaires will be administered as before, again done twice to examine any late impact of the information on patient anxiety, and the patient will undergo their test.
3337634|NCT02156986||9 month old infant|
3337635|NCT02156986||12 month old infant|
3337636|NCT02156986||18 month old toddler|
3337637|NCT02156986||24 month old toddler|
3337638|NCT02156986||36 month old toddler|
3337639|NCT02156999|Experimental|Osteoporosis|
3337640|NCT02157012|Experimental|The condition of rheumatoid arthritis|
3337641|NCT02157025|Experimental|Cartoon Intervention|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry
3337642|NCT02157025|Active Comparator|Usual Care|Usual care procedures for Humphrey perimetry in young children
3236047|NCT01246921|Active Comparator|fluticasone proprionate 0.05 %|Group reveiving 12 months NB-UVB phototherapy twice a week in combination with fluticasone proprionate 0.05 % cream in an intermittent scheme
3337643|NCT02157038|Experimental|Procedures|RNA/DNA blood sample will be collected. Participant will complete questionnaires, MRI and strength and reflex testing.
3337644|NCT02157077|Experimental|Aflibercept|Patients will receive 2 mg of aflibercept by intravitreal injection every 4 weeks until week 8, followed by every 6 weeks to week 26
3337645|NCT02157090|Active Comparator|Herpes Patch SOS (Hansaplast®)|
3337646|NCT02157090|Active Comparator|Herpes vesicle patch of Compeed®|
3337647|NCT02157129|Experimental|LipoAerosol©|LipoAerosol© inhalation, 5x/d for 30min
3337648|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
3259244|NCT01469078|Active Comparator|100 mg Monofer®|
3337649|NCT02157142|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
3337650|NCT02157155|Experimental|Intervention|Insulin reduction and mimic infection with LPS
3337651|NCT02157155|No Intervention|Control|Normal insulin and no LPS
3337652|NCT02157181|Experimental|HCL, 2CdA +/- Rituximab|"Risk stratification~HCL variant will be treated with cladribine plus rituximab, independent of previous therapy~Relapses of HCL will be treated with cladribine plus rituximab, duration of remission of the previous therapy is < 3 years.~All repeated relapses (> 1st relapse) after previous therapies with purine analogues and/or interferon will be treated with cladribine plus rituximab.~Cladribine (LITAK®) 0.14 mg/kg daily Days 8-12 subcutaneous bolus injection Rituximab (Mabthera®) 375 mg/m2 daily Days 1, 8, 15, 22 infusion~Relapses of HCL will be treated with cladribine monotherapy, if the duration of remission of the previous therapy is > 3 years.~Cladribine (LITAK®) 0.14 mg/kg daily Days 1-5 subcutaneous bolus injection"
3337653|NCT02157207|Placebo Comparator|Placebo|Placebo will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. Placebo microcrystalline cellulose capsules will be of similar taste, color and appearance.
3337654|NCT02157207|Experimental|Antioxidant|"Supplementation will be ingested in front of laboratory personnel in two doses, separated by 30 minutes to increase absorption, consumed 90 and 60 minutes before the testing protocol. The first dose will consist of 300 mg of α-lipoic acid, 500 mg of vitamin C, and 200 IU of vitamin E, and the second dose will be 300 mg of α-lipoic acid, 500 mg of vitamin C, and 400 IU.~of vitamin E."
3337655|NCT02157220|Experimental|Randomised group 1|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
3337656|NCT02157220|Experimental|Randomised group 2|This study is looking at a group of patients with knee osteoarthritis or other pathology requiring total knee arthroplasty. This group of patients were randomised to receive either a mobile bearing prosthesis or a fixed bearing prosthesis.
3337657|NCT02157233|Experimental|Hot environment|Subjects will perform the intervention in a hot environment (33°C)
3337658|NCT02157233|Sham Comparator|Neutral environment|Subjects will perform the intervention in a neutral environment (22°C)
3337659|NCT02157246|Other|Group A, pimonidazole, no CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI, Pimonidazole
3337660|NCT02157246|Other|Group B, CRT|Biopsy, Blood sample, F-MISO PET, pCT, functional MRI
3337661|NCT02157272|Experimental|Rivaroxaban|Rivaroxaban 20mg qd, Rivaroxaban 15mg qd if creatinine clearance between 30-49 ml/min (calculated by Cockroft-Gault equation)
3337662|NCT02157272|Active Comparator|Warfarin|To Keep an INR between 2.0 and 3.0
3337663|NCT02157285|No Intervention|Routine Counseling|Subjects randomized to receive routine counseling before selecting a method of contraception
3337664|NCT02157285|Experimental|Peer Mentor counseling|Subjects randomized to receive peer counseling before selecting a method of contraception
3337665|NCT02157311|Experimental|Four consecutive days on treatment and 3 days off|All patients will take a combination of three HIV treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
3337666|NCT02157324|Experimental|acalabrutinib|Starts with acalabrutinib for 7 days, then combined with ACP-319 afterwards.
3337667|NCT02157324|Experimental|ACP-319|Starts with ACP-319 for 7 days, then combined with acalabrutinib afterwards.
3337668|NCT02157337|Experimental|atrovastatin|
3337669|NCT02157337|Placebo Comparator|placebo|
3337670|NCT02157350|Experimental|Panretinal Laser Photocoagulation|See interventional description.
3337671|NCT02157363|Active Comparator|Repositioning Group|The patient is placed on a vacuum mattress in supine position for the abdominal part using a midline laparotomy. After completion of the abdominal part, the abdomen is closed and dressed in standard fashion and the patient is repositioned under full anesthesia is a left-lateral decubitus (LLD) position. After the thorax is sterile prepped and draped, a right dorso-lateral thoracotomy in the 4th to 6th intercostal space under preservation of body of the serratus muscle is performed.
3337672|NCT02157363|Experimental|Single positioning|The patient is placed on a vacuum mattress and in a left-screwed supine position for the entire operative procedure. The pelvis and the lower extremities are placed at 0° rotation, whereas the torso is rotated leftwards to an angle of 45° (Fig. 1). The patient is prepped and draped from the shoulders to the inguinal region. A midline laparotomy is done for the abdominal part and the abdomen closed afterwards. For the thoracic part, the operating table is tilted about 30° to the left, and a right anterolateral thoracotomy is performed in the 4th to 6th intercostal space.
3337673|NCT02157389|Experimental|placebo|Administration of a pharmacological placebo (sodium chloride) via transdermal application to investigate the influence on pain perception in chronic back pain patients and to investigate the influence of attitude and experience with medication on the placebo effect
3337674|NCT02157402|Experimental|Intervention Group|The intervention group will received activities and social events designed according 8 social marketing Benchmark criteria to promote healthy lifestyles.
3337675|NCT02157402|No Intervention|Control Group|The control group will not received any intervention activities and social events to promote healthy lifestyles.
3337676|NCT02157415|Experimental|Long-term catherized patients|Uro-Tainer Polihexanide 0.02% 100ml rinsing solution
3337677|NCT02157428|Placebo Comparator|saline|patients received 20 ml of saline during 1 minute, after end of surgery.
3337678|NCT02157428|Active Comparator|flumazenil|patients received 1 mg of flumazenil, after end of surgery
3236048|NCT01246921|No Intervention|no intervention|Group receiving 12 months NB-UVB phototherapy twice weekly, without any topical treatment
3236049|NCT01246934|No Intervention|COMPLICATION|
3236050|NCT01246947|Active Comparator|Mitral surgery alone|Mitral valve surgery randomization for no repair of the moderate tricuspid regurgitation
3236051|NCT01246947|Active Comparator|Mitral surgery w/Tricuspid valve repair|Mitral valve surgery with randomization to repair the moderate tricuspid regurgitation
3236052|NCT01247012|Active Comparator|Lipid minimization|
3236053|NCT01247012|Experimental|Omegaven|
3236054|NCT01247025||Veterans|Veterans receiving mental health services at the Eastern Colorado Healthcare System (ECHCS)/Denver Veterans Affairs Medical Center (VAMC)
3236055|NCT01247038|Experimental|Metal on ceramic articulation|The arm consists of patients with Ceramic femoral heads articulating with metal acetabular cups
3337679|NCT02157441|Experimental|all patients|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
3337680|NCT02157454|Experimental|Website access|Two-week access to the colorectal cancer module of the website www.krankheitserfahrungen.de
3236056|NCT01247038|Active Comparator|Metal-on-metal|The arm consists of patients with Metal femoral heads articulating with metal acetabular cups
3337681|NCT02157454|No Intervention|Control|Participants who are randomized to the control group don't have access to the website until they have finished the last questionnaire at 6 weeks follow up.
3337682|NCT02157467|Experimental|Arm 1: NGMN/EE + BMS-955176|"Cycle 1- Active Ortho Cyclen QD on Days 1 to 21. Inert Ortho Cyclen tablets on Days 22 to 28~Cycle 2- Active Ortho Cyclen QD alone on Days 29 to 39 (11 days), followed by concomitant administration of active Ortho Cyclen QD + BMS-955176 80 mg QD on Days 40 to 49 (10 days)"
3337683|NCT02157480|No Intervention|control|usual follow-up for 6 weeks
3236057|NCT01247051|Experimental|Precoating|
3337684|NCT02157480|Experimental|electrostimulation 3 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions three times per week for 6 weeks
3337685|NCT02157480|Experimental|electrostimulation 5 days per week|20 minutes ambulatory bi-quadricipital electrostimulation sessions five times per week for 6 weeks
3337686|NCT02157493|Experimental|Arrowhead Business Group Curriculum|The Arrowhead Business Group (ABG) Curriculum is a 22-session youth entrepreneurship/life-skills intervention delivered by trained American Indian paraprofessionals from the community to mixed-gender groups of approximately 25 youth. The intervention is delivered over a 3 night/4 day camp along with weekend workshops once a month for 6 months during the academic year. Depending on the time of enrollment, subjects will receive follow-up assessments at 6-month intervals for up to 36-months post-intervention. (Subjects in this cohort will also receive the activities associated with the control condition.)
3337687|NCT02157493|Active Comparator|Recreational League Control Condition|The Recreational League Control Condition will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Sports and recreational activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
3337688|NCT02157532|Active Comparator|Best standard treatment|intravenous r-tPA or any other medical management
3337689|NCT02157532|Active Comparator|Mechanical thrombectomy|Endovascular mechanical thrombectomy with stent-retrievers
3337690|NCT02157545||pyridostigmine|administration of rocuronium to determine its potency.
3337691|NCT02157545||control arm (no pyridostigmine)|determination of potency of rocuronium in patients not taking pyridostigmine
3337692|NCT02157558|Experimental|All subjects|All subjects will receive a single oral dose of fexofenadine on Day 1 while fasting. Days 2 to 5 will be Washout days. On Day 6, subjects will begin a 5 day telotristat etiprate regimen. On Day 10 subjects will be given the morning telotristat etiprate dose concomitantly with a single dose of fexofenadine while fasting.
3236058|NCT01247051|Active Comparator|Standard priming|
3236059|NCT01247077|Active Comparator|placebo|Placebo and thyroxin + methimazole
3236060|NCT01247077|Placebo Comparator|selenium|selenium + methimazole + thyroxin
3236061|NCT01247103|Placebo Comparator|Part A: single ascending dose|AZD4316: single oral dose, with 1 group with/without food
3236062|NCT01247103|Placebo Comparator|Part B: multiple ascending dose|AZD4316: multiple oral doses
3337693|NCT02157571|Experimental|Prulifloxacin|"Prulifloxacin film-coated tablet : 600 mg/tablet, oral administration of a single tablet.~Placebo of levofloxacin hydrochloride tablet, without active components."
3337694|NCT02157571|Active Comparator|Levofloxacin|"Levofloxacin hydrochloride tablet 500 mg/tablet, oral administration of a tablet daily.~Placebo of prulifloxacin film-coated tablet without active components."
3337695|NCT02157584|Experimental|Treatment A|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fed condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fasted condition.
3236063|NCT01247129|Experimental|SIEA,delay procedure,widening of diameter|
3236064|NCT01247142||Invasive pulmonary aspergillosis (IPA)|Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria) or putative IPA (Blot et al. Am J Respir Crit Care Med 2012)
3236065|NCT01247142||Controls|Patients without signs of infection.
3236066|NCT01247155||first day review|
3236067|NCT01247155||non-first day review|
3236068|NCT01247168|Experimental|1|
3236069|NCT01247181|Experimental|Mobile phone text message|
3236070|NCT01247181|Active Comparator|No Mobile phone text message|Usual care provided at clinic
3236071|NCT01247194|Active Comparator|Cohort A|"PPI-461 50 mg~or placebo"
3236072|NCT01247194|Active Comparator|Cohort B|"PPI-461 100 mg~or placebo"
3236073|NCT01247194|Active Comparator|Cohort C|"PPI-461 200 mg~or placebo"
3236074|NCT01247233|Active Comparator|Standard or Hypofractionated radiotherapy|"Whole breast RT, 50 Gy + boost 16 Gy. Whole breast hypofractionated RT without boost, either 40 Gy or 42.5 Gy"
3236075|NCT01247233|Experimental|Accelerated Partial Breast Irradiation (APBI)|APBI using 3D CRT technique, in 5 days, 38.5 Gy to the tumor bed
3236076|NCT01247246|Placebo Comparator|Placebo|
3236077|NCT01247246|Active Comparator|SCV-07 0.1mg/kg|
3236078|NCT01247246|Active Comparator|SCV-07 0.3mg/kg|
3236079|NCT01247246|Active Comparator|SCV-07 1.0mg/kg|
3236080|NCT01247259|Active Comparator|SLIT-mono|
3236081|NCT01247259|Active Comparator|SLIT-poly|
3236082|NCT01247311|Active Comparator|1.|"1,25 Vitamin D (0.50ug *3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
3259245|NCT01469078|Active Comparator|200 mg Monofer®|
3259246|NCT01469078|Active Comparator|500 mg Monofer®|
3337696|NCT02157584|Experimental|Treatment B|Subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) on Day 1 in a fasted condition. Days 2 to 5 will be Washout Days. On Day 6, subjects will receive a single 500 mg (as free base) dose of telotristat etiprate (as 2 × 250 mg tablets) 1 in a fed condition.
3236083|NCT01247311|Active Comparator|2.|"25 Vitamin D (5000IU * 3 per week)~This is a prospective randomized double blind placebo controlled study of 125 stable CKD subjects examining the impact of vitamin D supplementation (1,25 vitamin D or 25 vitamin D formulations) compared to placebo on arterial stiffness and other parameters of vascular health"
3236084|NCT01247311|Placebo Comparator|3.|Placebo given orally 3xweek for six months
3236085|NCT01247337|Experimental|Single arm chemotherapy treatment|
3236086|NCT01247376|No Intervention|No Cooling and compression|
3337697|NCT02157597|Active Comparator|Control Arm|"The control patients will have open display of the NIRS monitor in the OR, but recording without display in the CICU, along with a request to the surgical and intensive teams to react to the data in their usual way. The disparity between the OR and CICU reflect the current opinions of the clinicians in these different environments regarding the necessity of NIRS monitoring within their sphere of practice.~In this way, continuous recording of cerebral and somatic oximetry will be made in all patients. However for control patients the monitor display will be switched off in the CICU using a pre-programmed research mode, which permits both ongoing recording and also the display of technical error messages (such as inadvertent disconnections or probe displacement)."
3337698|NCT02157597|Experimental|NIRS based management|The trial interventions of NIRS based management consists of provision to the cardiac surgical and intensive care teams of a protocol to guide their interpretation of cerebral and somatic NIRS monitoring and interventions to try in the event of monitored desaturation during the pre- and post-bypass periods (when the circulation is perfused by the beating of the native heart). The investigators believe that there is insufficient data to inform an evidence-based protocol for the bypass phase of surgery, particularly regarding the interpretation of NIRS data under conditions of hypothermia.
3337699|NCT02157610|Experimental|Standard Treatment (ST)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline. Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months.
3236087|NCT01247376|Experimental|Intervention with cooling and compression|
3236088|NCT01247389|Active Comparator|midline incision|
3236089|NCT01247389|Active Comparator|transverse incision|
3236090|NCT01247402|Active Comparator|Paclitaxel eluting balloon|Freeway 0.035 Paclitaxel eluting balloon (3 microgram Paclitaxel/mm2)
3236091|NCT01247402|Active Comparator|Standard balloon angioplasty|standard balloon angioplasty
3236092|NCT01247415||Anaphylaxis|Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis
3337700|NCT02157610|Experimental|Motivation + Problem Solving (MAPS)|Participants receive free self-help materials mailed at baseline, 6, and 12 months. Participants receive a referral to the Oklahoma Quitline.Participants receive a 12-week supply of the nicotine patch and lozenge. Nicotine patch regime based on participant's self-reported smoking rate. REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months. Saliva test performed at 3, 6, 12, and 18 months. 6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
3337701|NCT02157636|Experimental|CPI-0610|
3337702|NCT02157649|Experimental|ER Tablet under Fasted Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, to subjects under fasted conditions.
3337703|NCT02157649|Active Comparator|IR Tablet under Fasted conditions|IR Tablet combination tablet of Codeine/Guaifenesin 20mg/400mg administered under fasted conditions as a single tablet every 4 hours during a 12 hour study [three doses]
3337704|NCT02157649|Experimental|ER Tablet under Fed Conditions|Administration of a single dose of two ER Tablets, combination of Codeine/Guaifenesin 30gm/600mg, following a standard high-fat breakfast.
3337705|NCT02157662||No coronary disease and risk factors >=3|
3337706|NCT02157662||Coronary disease and risk factors 0-1|Diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 0-1 risk factor (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor.
3337707|NCT02157662||No coronary disease and risk factors 0-1|
3337708|NCT02157662||Coronary disease and risk factors >=3|Subjects with diffuse coronary atherosclerosis extended to more than 5 of the 16 segments according to the American Heart Association classification38 and 3 or more risk factors (reported by the subject or documented at the MDCT) with the exclusion of patients with type 1 or type 2 diabetes mellitus as single risk factor
3337709|NCT02157675|Experimental|Polyherbal capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
3236093|NCT01247415||Allergic-like reactions|Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group
3236094|NCT01247415||ORS cases|ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus ≥1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration) (ref: Public Health Agency of Canada: User Guide: Report of Adverse Events Following Immunization (AEFI) Appendix III National Case Definitions of AEFIs of Special Interest: oculo-respiratory Syndrome. http://www.phac-pc.gc.ca/im/aefi_guide/ann3-eng.php
3236095|NCT01247415||Controls|Controls will be individuals who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine.
3236096|NCT01247454|Other|academic detailing|All arms will receive this intervention
3337710|NCT02157675|Placebo Comparator|Placebo capsule|Subjects take 1 capsule with breakfast and 1 capsule with lunch. Subjects should take capsules immediately prior to meals and not with carbonated beverages.
3337711|NCT02157688||case|Patient with a folliculitis Decalvans
3337712|NCT02157688||control|Control without folliculitis decalvans
3337713|NCT02157701|Experimental|Polyherbal capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
3337714|NCT02157701|Placebo Comparator|Placebo capsule|1 capsule taken with breakfast and 1 capsule with lunch. Capsules should be taken immediately prior to meals and not with carbonated beverages.
3236097|NCT01247454|Experimental|Electronic Health Record (EHR) prompt|One intervention arm will receive the EHR prompt along with the academic detailing
3236098|NCT01247454|Experimental|EHR prompt and patient prompt|The final arm will receive this combined intervention plus the academic detailing
3337715|NCT02157714|Experimental|PRX002|PRX002
3337716|NCT02157714|Placebo Comparator|Placebo|Placebo
3337717|NCT02157727||Exposed group, during Tele-expertise|Infants hospitalized in health facilities performing tele-expertise
3337718|NCT02157727||Exposed group, Prior Tele-expertise|Infants hospitalized in health facilities performing Tele-expertise prior implementation of Tele-expertise
3337719|NCT02157727||Control group, Prior Tele-expertise|
3337720|NCT02157727||Control group, during Tele-expertise|Infants hospitalized in health facilities not performing Tele-expertise while the exposed group use Tele-expertise
3236099|NCT01247467||Breast Tumor|Breast Tumor Blocks
3337721|NCT02157740||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
3337722|NCT02157740||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
3337723|NCT02157740||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
3337724|NCT02157740||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
3337725|NCT02157766|Active Comparator|MNP with Asthma: Mindfulness Based Stress Reduction|
3337726|NCT02157766|No Intervention|MNP w/ Asthma: Wait List Control|
3337727|NCT02157766|Active Comparator|MNP, no asthma - Mindfulness Based Stress Reduction|
3236100|NCT01247480||Breast cancer patients|
3337728|NCT02157766|Active Comparator|MNP, no asthma: Health Enhancement Program|
3337729|NCT02157766|No Intervention|MNP, no asthma - Wait List Control|
3337730|NCT02157766|Active Comparator|Long Term Meditator|
3337731|NCT02157792|Experimental|Part A|This part will be 3 + 3 dose escalation study of M6620 in combination with gemcitabine as well as gemcitabine and cisplatin in participants with advanced solid tumors.
3337732|NCT02157792|Experimental|Part B|This part will be 3 + 3 dose escalation study of M6620 in combination with cisplatin or cisplatin and etoposide in participants with advanced solid tumors.
3337733|NCT02157792|Experimental|Part B2|This part will be 3 + 3 dose escalation study of M6620 in combination with irinotecan in participants with advanced solid tumors.
3337734|NCT02157792|Experimental|Part C1|This will be the expansion part of the study in which participants with advanced non-small cell lung cancer (NSCLC) will be administered M6620 in combination with gemcitabine.
3337735|NCT02157792|Experimental|Part C2|This will be the expansion part of the study in which participants with advanced triple negative breast cancer (TNBC) will be administered M6620 in combination with cisplatin.
3337736|NCT02157792|Experimental|Part C3|This will be the expansion part of the study in which participants with platinum-resistant advanced small cell lung cancer (SCLC) will be administered M6620 in combination with cisplatin or carboplatin.
3337737|NCT02157805|Active Comparator|rare beef meat|beef meat cooked during 5 minutes at 55°C
3337738|NCT02157805|Active Comparator|well cook beef meat|beef meat cooked during 30 minutes à 90°C
3337739|NCT02157818|Active Comparator|midazolam|midazolam IV bolus 0.05ml/kg bolus in 1minute. rescue drug(Midazolam) 1 mg, IV boluses for double blinding setting, we use saline, 0.4 mcg/kg IV bolus in 10 minutes and 0.5 mcg/kg/h, as placebo.
3337740|NCT02157818|Experimental|Dexmedetomidine|"Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.25-0.75 mcg/kg/h for RSS 3-5. Midazolam 1mg bolus IV pro re nata (PRN).~for double blinding setting, IV bolus 0.05ml/kg bolus in 1minute."
3337741|NCT02157831|Experimental|Subjects from UPCC 10903|
3236101|NCT01247506||1|tumor tissues of HCC patients
3236102|NCT01247506||2|paired nontumor tissues of HCC patients
3236103|NCT01247519|No Intervention|observation|
3236104|NCT01247519|Experimental|Intervention|
3236105|NCT01247532|Experimental|Waitlist|
3337742|NCT02157844||COPD and OSA|Subjects with diagnosis of COPD and OSA
3337743|NCT02157844||COPD|Subjects with diagnosis of COPD
3337744|NCT02157844||OSA|Subjects with diagnosis of OSA
3337745|NCT02157844||controls|Gender, age, BMI matched controls
3337746|NCT02157896||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study, and had a score between 6 and 25 on the National Institutes of Health Stroke Scale (NIHSS).
3337747|NCT02157922|Active Comparator|Alginate oligosaccharide|Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period
3337748|NCT02157922|Placebo Comparator|Placebo|Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period
3337749|NCT02157961||General Practitioner / Family Physician in German Primary care|
3337750|NCT02157961||Medical Specialists|Working in the ambulatory setting
3337751|NCT02157974|Experimental|PCOS, medication naive + Byetta|PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.
3337752|NCT02157974|No Intervention|Control|Up to 25 girls without PCOS
3337753|NCT02157974|No Intervention|PCOS medication naive|Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.
3337754|NCT02157974|No Intervention|PCOS on COCPs|Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.
3337755|NCT02157974|No Intervention|PCOS on metformin|Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures
3337756|NCT02157987|Experimental|bevacizumab|bevacizumab spray
3337757|NCT02158000|Active Comparator|Group A|In group A , 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles are allocated to receive one tab / 8 hs of Diosmin ( 500mg) beginning from the day of ovum retrieval and for 3 days (till the day of embro trasfer) in addition to aspiration of the fluid by an IUI catheter.
3337758|NCT02158000|No Intervention|Group B|In group B (control group) 100 women with excessive endometrial fluid by transvaginal ultrasound during ICSI cycles, no thing will be done
3337759|NCT02158013|Active Comparator|Diltiazem, calcium channel blocker|Diltiazem gel 2% applied twice daily for 8 weeks
3337760|NCT02158013|Experimental|Levorag, Hibiscus plant extract|Levorag Emulgel applied twice daily for 8 weeks
3337761|NCT02158026||infertility without polycystic ovarian syndrome|1000 women with infertility without polycystic ovarian syndrome who are already decided to be treated with ICSI will be recruited
3337762|NCT02158052|Experimental|Transplantation|Single arm combined bone marrow and kidney transplantation
3337763|NCT02158065|No Intervention|Usual care|Patients will receive information (leaflet) and guidance on the benefits associated with increased physical activity in COPD patients and their health status
3337764|NCT02158065|Experimental|Coaching program|In addition to usual care, patients will receive the coaching program
3337765|NCT02158104||Latent trigger point in the upper trapezius muscle|
3337766|NCT02158117|Experimental|nasal naloxone|8 and 16 mg/ml, comparator 1 mg/ml. Three daily occasions with at least 3 days washout between treatment (min 8 days).
3236106|NCT01247545|Placebo Comparator|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
3236107|NCT01247545|Active Comparator|Remote ischaemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
3337767|NCT02158130||Healthy Living|non exercise healthy living control group
3337768|NCT02158130||General Health|Exercise Group (8 KKW) One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. We will recruit 1 year post study intervention.
3337769|NCT02158130||Weight Loss|Exercise Group (20 KKW) Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session. We will recruit 1 year post study intervention.
3337770|NCT02158143|Experimental|vitamin D3|
3337771|NCT02158156|Experimental|Excercise|10 weeks of home training on a cycle-ergometer. Exercise 30 minutes every other day or at least three times a week.
3337772|NCT02158182|Experimental|lactulose|
3337773|NCT02158182|Experimental|L-ornithine L-aspartate|
3337774|NCT02158182|Experimental|Rifaximin|
3337775|NCT02158182|Placebo Comparator|Placebo|
3337776|NCT02158195||Patients|
3337777|NCT02158195||controls|
3337778|NCT02158208||Patients with HD|
3337779|NCT02158208||Controls|
3337780|NCT02158221|Active Comparator|Migraine patients with high genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
3337781|NCT02158221|Active Comparator|Migraine patients with low genetic load|PACAP intravenous infusion 1.5 microgram/min for 20 min
3337782|NCT02158234|Experimental|Dose Escalation: SBRT and Cisplatin|Stereotactic Body Radiation Therapy (SBRT) and Cisplatin. Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy/ Cisplatin 15 mg/m^2
3337783|NCT02158260|Experimental|position changing|During the examination, subjects changed position in the following sequence: left lateral head-down position, supine position, prone head-down position, right lateral head-down position, supine position, left lateral position, prone position, prone hip-high position, right lateral position and sitting position.
3337784|NCT02158260|No Intervention|free position|
3337785|NCT02158286||Esophagectomy, Emptying from gastric tube|Validate paracetamol clearance technique to scintigraphy for measuring emptying rate from the gastric tube.
3337786|NCT02158299|Experimental|Avitene,Drainaging,reexamine|
3337787|NCT02158299|Experimental|Sapylin,Drainaging,reexamine|
3337788|NCT02158299|Active Comparator|Drainaging,reexamine|
3337789|NCT02158312|Experimental|transcranial direct current stimulation|bihemispheric transcranial direct current stimulation, anodal at ipsilesional M1 while cathodal at contralesional M1, for 20 minutes
3337790|NCT02158312|Placebo Comparator|sham stimulation|same as the experimental stimulation condition but only for 2 minutes
3337791|NCT02158325|Active Comparator|3.0-3.9 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0-3.9 mm in diameter)
3337792|NCT02158325|Experimental|4.0-5.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (4.0-5.0 mm in diameter)
3337793|NCT02158325|Active Comparator|5.1-6.0 mm|pediatric cataract surgery performed with different anterior capsulorhexis sizes (5.1-6.0 mm in diameter)
3337794|NCT02158338||Asthma|Mothers of children thought to have asthma
3337795|NCT02158338||Non-asthma|Mothers of children without diagnosed respiratory problems
3337796|NCT02158351||Simple steatosis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
3337797|NCT02158351||Non-alcoholic steato-hepatitis|We will run a cross-sectional observational study including two groups of human subjects: patients with simple steatosis (SS) or non-alcoholic steatohepatitis (NASH). Grouping in patients SS or NASH will be performed based on the histological diagnosis of the type of NAFLD obtained at operation (sleeve gastrectomy or cholecystectomy). BMI will be considered as a confounding variable to be statistically analyzed. Main hypothesis: GM can lead to liver inflammation in patients with liver fat accumulation.
3337798|NCT02158377|Active Comparator|Tapered Screw-vent implants (TSV)|TSV implants to replace missing tooth/teeth
3337799|NCT02158377|Experimental|Trabecular Metal dental implants (TM)|TM dental implants to replace missing tooth/teeth
3337800|NCT02158390|Experimental|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
3337801|NCT02158390|No Intervention|Community treatment as usual|Children access educational and speech-language interventions available to them through schools and community resources.
3337802|NCT02158403|Other|Clinical Management Recommendations|Clinical management recommendations for reducing pump thrombosis
3337803|NCT02158416||Hematology-oncology|hematology-oncology outpatients requiring platelet transfusion
3337804|NCT02158429|Active Comparator|3 Dimensional ultrasound|an additional 5-10 minutes of ultrasound using three dimensional technique
3337805|NCT02158429|Active Comparator|2 dimensional|an additional 5-10 minutes of ultrasound using standard two-dimensional technique
3337806|NCT02158455|Experimental|NT SVG grafts|NT SVG randomized for revascularization of left or right coronary territory
3337807|NCT02158455|Active Comparator|RA grafts|RA grafts randomized for revascularization of left or right coronary territory
3337808|NCT02158468|Active Comparator|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
3337809|NCT02158468|Active Comparator|Postconditioning|4 cycles of postconditioning (30s ischemia, 30s reperfusion) after primary PCI/stenting
3337810|NCT02158468|No Intervention|Control group|Standard infarction treatment without conditioning intervention
3337811|NCT02158481|Active Comparator|Dietary ingredients: polyphenols and carotenoids|Dietary ingredients: polyphenols and carotenoids
3337812|NCT02158481|Placebo Comparator|Placebo product|Placebo product
3337813|NCT02158559|Experimental|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
3337814|NCT02158559|Placebo Comparator|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
3337815|NCT02158585|Placebo Comparator|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
3337816|NCT02158585|Active Comparator|Lamotrigine|Lamotrigine will be taken orally for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day, or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Patients who withdraw at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
3337817|NCT02158598|No Intervention|wash-out|2 months
3337818|NCT02158598|Experimental|Vitamin D chewable tablet supplementation|A chewable vitamin D tablet containing 1000 IU to be taken once a day for 2 months.
3337819|NCT02158598|Experimental|Vitamin D pill supplementation|A vitamin D pill containing 1000 IU to be taken once a day for 2 months.
3337820|NCT02158611|Other|Lifestyle counseling|
3337821|NCT02158624|Experimental|Ranibizumab|
3337822|NCT02158637||Cancer patients receiving treatment|Patients receiving active treatment for cancer or initiating treatment for cancer in the next 7 days
3337823|NCT02158650|Experimental|Video Group|Patients randomized to Group II will be emailed the educational video, pre- and post- knowledge assessments, and patient satisfaction survey with instructions on what order to fill them out. Group II patients will report to the treatment visit and undergo discussion of options and treatment as per standard of care. An additional knowledge assessment survey will be administered to Group II patients after discussion with treating physician.
3337824|NCT02158650|No Intervention|Control Group|Patients randomized to Group I will be come to the clinic for the treatment visit and discuss options and treatment as per standard of care. Pre- and post- discussion knowledge assessments and satisfaction surveys will be administered at the time of the treatment visit.
3337825|NCT02158676|Experimental|Prebiotic|6 g/day of prebiotic (fructooligosaccharides) for 15 days.
3337826|NCT02158676|Experimental|Synbiotic|6 g/day of synbiotic (fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019) for 15 days.
3337827|NCT02158676|Placebo Comparator|Placebo|6 g/day of placebo (maltodextrin) for 15 days.
3337828|NCT02158689|Active Comparator|human menopausal gonadotropin (hMG)|hMG at a dose of 300 IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3337829|NCT02158689|Active Comparator|Letrozole|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day will be initiated on the second or third day of spontaneous menstruation and continued for 5 days. Again on the second or third day of spontaneous menstruation, 150 IU of hMG will be started until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of hCG as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3337830|NCT02158702|Experimental|Pomalidomide and Dexamethasone|"PO pomalidomide 4mg from D1-21 and PO dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~PO or IV cyclophosphamide 300mg/m2 on D1, 8 and 15 can be added at the discretion of the treating physician to induce added response under the following circumstances: 1) If there is less than a MR after 3 cycles in the absence of disease progression, or 2) If there is disease progression within the first 3 cycles of Pomalidomide and Dexamethasone treatment.~Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
3337831|NCT02158715||Smartphone positioning during Chest compression|
3337832|NCT02158741|No Intervention|Usual Primary Care|Usual Primary Care will be received by half the participants during the course of the Study
3337833|NCT02158741|Active Comparator|Home Visits and educational support|Intervention comprised of Home Visits and group educational sessions. Home Visits and will be conducted by Diabetes Education staff in lieu of usual care conducted at the Diabetes clinic. Lifestyle support and educational will be offered in the form of monthly Diabetes Wellness Days offered in the community where nutrition, exercise and support will be given to help improve self-management of diabetes.
3337834|NCT02158754||Corus CAD (ASGES)|Subjects receiving CorusCAD (ASGES) gene expression test as part of their diagnostic workup for typical and/or atypical symptoms of obstructive coronary artery disease.
3337835|NCT02158754||Control|Matched subjects in the same practice that did NOT receive Corus CAD (ASGES) as part of their diagnostic workup.
3337836|NCT02158780|Experimental|Scrotal Orchidopexy|Single incision
3337837|NCT02158780|Other|Inguinal Orchidopexy|Double Incision (Standard)
3337838|NCT02158793|Experimental|Face Transplant recipient|Single Arm study, all participants will receive Craniomaxillofacial allotransplantation
3337839|NCT02158819|No Intervention|TKA with standard instrumentation|This arm consists of the Genesis II Total knee implant system or the Legion Primary total knee system with standard instrumentation
3337840|NCT02158819|Active Comparator|Total knee arthroplasty with Visionaire|This arm will consist of the Genesis II Total Knee Implant System or Legion Primary Total Knee System with the Visionaire patient-matched instrumentation
3337841|NCT02158832|Experimental|Acupuncture + Electrical Stimulation|Acupuncture needles are inserted beneath the skin and electrical stimulation applied for 20 minutes.
3337842|NCT02158832|No Intervention|Control|Participants who are randomized to receive no intervention will still receive physical assessment.
3337843|NCT02158845|Active Comparator|LNG-IUS|LNG-IUS: levonorgestrel intrauterine system
3236108|NCT01247558||Test Cohort|100 randomized subjects administered Metanx®
3236109|NCT01247558||Control Cohort|400 subjects with diabetes mellitus meeting the same inclusion and exclusion criteria as the test cohort who have not been treated with Metanx®.
3337844|NCT02158845|Active Comparator|GnRHa|GnRHa: leuprolide
3337845|NCT02158858|Experimental|Arm 1: Prior JAKi (JAK inhibitor) Monotherapy Arm|"Cohort 1A: Open to patients with MF who are Transfusion Dependent (TD) and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi.(CPI-0610 alone)~Cohort 1B: Open to patients with MF who are not TD and who have previously been treated with a JAKi and are intolerant, resistant, refractory or lost response to the JAKi, or are ineligible to be treated with a JAKi. (CPI-0610 alone)"
3236110|NCT01247610||ADHD group|
3236111|NCT01247610||Control group|
3337846|NCT02158858|Experimental|Arm 2: Prior JAKi Combination Arm|"Cohort 2A: Open to patients with MF who are Transfusion Dependent (TD) and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)~Cohort 2B: Open to patients with MF who are not TD and are currently taking ruxolitinib but have disease that is not being adequately controlled by ruxolitinib. (CPI-0610 + Ruxolitinib)"
3337847|NCT02158858|Experimental|Arm 3: JAKi Naïve Combination Arm|Open to patients with MF who have not previously received a JAKi. (CPI-0610 + Ruxolitinib) and have DIPSS risk category Intermediate-2 or higher
3337848|NCT02158858|Experimental|Arm 4: Essential Thrombocytopenia (ET) Monotherapy Arm|Open to high-risk patients with ET who are resistant or intolerant to hydroxyurea (HU)
3337849|NCT02158871|Experimental|Contact-based mental health education|"The Beyond Silence' program is 12 hours in length: six 1.5-2 hour in-person group sessions every other week, plus five online sessions between each of the in-person sessions."
3337850|NCT02158871|Active Comparator|Mental health literacy training|"Mental Health First Aid training consists of twelve hours of standardized, module-based mental health literacy training offered in a group format. It will be offered as 2 full-day training sessions (or four half-day sessions)."
3236112|NCT01247636|Experimental|Home-exercise|
3236113|NCT01247649|Experimental|Study group|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
3236114|NCT01247662||ASD group|
3236115|NCT01247662||ADHD group|
3236116|NCT01247662||Normally developing control group|
3236117|NCT01247688|Experimental|Umbilical Cord Blood Transplant Treatment Plan|Cytoxan, Fludarabine, Total Body Irradiation (TBI), Cord Blood Stem Cell Infusion
3236118|NCT01247701|Experimental|Umbilical Cord Blood Transplant|Busulfan,Cyclophosphamide, Fludarabine, Cord Blood Stem Cell Infusion
3337851|NCT02158897|No Intervention|Control|Participants will consume their normal diet. Body weight and physiological change at two time points (approximately 2-3 months apart) will be examined. The participants will be crossed over to the diet group.
3337852|NCT02158897|Experimental|Prolon Diet|Participants will be provided with a 5-day supply of fasting-mimicking diet, including energy bars, soups, drink packets and dietary supplements. Participants will diet for 3 cycles. Each one-month cycle consists of 5 days of dieting with a calorie intake estimated at 600-1200 calories per day. The rest of the month participants will eat normally. After 3 cycles, participants will be examined again after consuming their normal diet after 2-3 months.
3337853|NCT02158910||Aricept Group 1|Subjects starting at 5 mg Aricept and increasing their dose to 10 mg Aricept
3337854|NCT02158910||Aricept Group 2|Subject starting at 10 mg Aricept and increasing their dose to 23 mg Aricept
3337855|NCT02158923|Experimental|Individualized ventilation|Intraoperatively ventilated patients with a tidal volume (VT) of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed.
3337856|NCT02158923|Experimental|Individualized vent. + postop. CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, and a FiO2 of 0.8. After intubation, all patients were conduct an alveolar recruitment maneuver (MRA) and PEEP level individualized spanned (see Calculation of optimal PEEP). Every 40 minutes will be assessed the need to adjust the level of PEEP by evaluating the dynamic compliance of the respiratory system (Crs). Faced with a decline in Crs> 10% a new MRA and optimal PEEP setting will be assessed. Postoperatively a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
3337857|NCT02158923|No Intervention|Standard ventilation|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed.
3337858|NCT02158923|Active Comparator|Standard vent. + postoperative CPAP|Intraoperatively ventilated patients with a tidal volume of 8 ml / kg of ideal body weight, PEEP 6 cmH2O and FiO2 0.8. In these groups no recruitment maneuvers or optimal PEEP setting will be performed. Postoperatively, a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
3337859|NCT02158962|Experimental|Behavioral - Education|"3 Educational Sessions~Session 1 - Reducing Risk for Intimate Partner Violence (IPV); Session 2 - Reducing risk for Sexually Transmitted Infections including HIV (STI/HIV) Session 3 - A group session which reinforces skills for reducing IPV and STI/ HIV risk reduction."
3236119|NCT01247714|Active Comparator|Group 1|The group 1 will receive the experimental product T-Diet plus Diabet NP for the first month followed by a reference diet corresponding to a current marketed product (Glucerna SR, Abbott) for the second month, then the patients will receive a control product non specific for diabetic patients (T-Diet plus Standard)for the third month, and finally a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the fourth month.
3236120|NCT01247714|Active Comparator|Group 2|The group 2 will receive a reference diet corresponding to a current marketed product (Glucerna SR, Abbott)for the first month, followed by the experimental product T-Diet plus Diabet NP for the second month, then the patients will receive a specific diet for diabetic patients (Novasource, Nestlé Healthcare Nutrition)for the third month, and finally a control product non specific for diabetic patients (T-Diet plus Standard)for the fourth month
3236121|NCT01247740|Experimental|1|three chamber bag for parenteral nutrition containing lipids, glucose, amino acids and electrolytes
3337860|NCT02158962|Active Comparator|Behavioral - Education|"3 Educational Sessions~Session 1 - Breast Health Education and Developing A Breast Cancer Risk Reduction Plan Session 2 - Reducing risk for overweight and obesity and Developing a Healthy Eating and Activity Plan Session 3 - A group session which integrates and reinforces skills from Sessions 1 and 2."
3337861|NCT02158988|No Intervention|without HIPEC|"Preoperative chemotherapy 3 cycles, each cycle 21 days. Patients with negative or unknown HER-2 status receive Epirubicin 50 mg/m² infusion (maximum 100mg/d). Oxaliplatin 130 mg/m² infusion (maximum 260 mg/d) and capecitabine oral 625 mg/m² two times a day (maximum 2500 mg/d).~Patients with positive HER-2 status receive:~Cisplatin : 80 mg/m² infusion (maximum of 160 mg/d). Capecitabine: oral 1000 mg/m2 (two times a day maximum of 4000 mg/d), on day 1-14.~Trastuzumab: 8 mg/kg infusion (on cycle 1 and 6 mg/kg on cycle 2 and 3). CRS is performed and 4-12 weeks after CRS 3 cycles of postoperative chemotherapy have to be applied. In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
3236122|NCT01247740|Active Comparator|2|compounded monobag including lipids, glucose, amino acids and electrolytes
3236123|NCT01247753|Experimental|Intervention|
3236124|NCT01247753|No Intervention|Control|
3236125|NCT01247766||Patients with rheumatoid arthritis (RA) who receive abatacept|
3236126|NCT01247766||Patients with RA who receive BDM drugs|biologic disease-modifying (BDM)
3236127|NCT01247766||Patients with RA who receive non-biologic DMARDs|disease-modifying anti-rheumatic drugs (DMARDs)
3337862|NCT02158988|Experimental|With HIPEC|"Patients will be treated with a preoperative chemotherapy as described for the control group. EOX or CCT depending on the HER-2 status.~CRS will be performed 2 to 3 weeks after end of last chemotherapy cycle. HIPEC with mitomycin C and cisplatin either at the time of CRS or a delayed HIPEC within 5-7 days.~HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied.~Patients may get a HIPEC intervention without surgical cytoreduction if contraindication to the drugs can be excluded.~In case of therapy failure patients will be continued to be treated by the responsible investigator according to his medical status."
3337863|NCT02159001|Active Comparator|ECT treatment right after recruitment|This group receives electroconvulsive therapy treatment right after they are recruited.
3337864|NCT02159001|Placebo Comparator|ECT after 4 weeks period.|This group receives electroconvulsive therapy treatment after 4 weeks waiting period.
3236128|NCT01247779|Active Comparator|Standard Coelioscopy|gynecologic surgery - standard coelioscopy
3236129|NCT01247779|Experimental|Robot-assisted coelioscopy|gynecologic surgery - robot assisted coelioscopy
3236130|NCT01247792|No Intervention|"Before"|No Intervention Observation of current practice
3236131|NCT01247792|Other|"After"|SOPs for decision-making and communication Assessment of practice after implementation of SOPs
3236132|NCT01247805|Experimental|Treatment A|Revatio: 1 x 20 mg IR oral tablet.
3236133|NCT01247805|Experimental|Treatment B|2 x 10 mg sildenafil citrate IR oral tablet.
3236134|NCT01247805|Experimental|Treatment C|2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
3236135|NCT01247818|Experimental|PH-10 Treatment (High Dose Cohort)|
3236136|NCT01247818|Experimental|PH-10 Treatment (Mid Dose Cohort)|
3236137|NCT01247818|Experimental|PH-10 Treatment (Low Dose Cohort)|
3236138|NCT01247818|Placebo Comparator|Vehicle Control|
3236139|NCT01247831|Other|glaucoma patients|All of the patients treated with SLT need further IOP reduction for control of their glaucoma.
3236140|NCT01247844|Other|Day 7|removal of Shang Ring at 7 days
3236141|NCT01247844|Other|Day 14|removal of Shang Ring at 14 days
3236142|NCT01247844|Other|Day 21|removal of Shang Ring at 21 days
3337865|NCT02159014|Experimental|Phase 1|Facilitated group-based physical activity (aerobic dance), online physical activity (video based aerobic dance) and nutritional intervention (nutritional education, cooking skill training, access and use of NHS Change4Life Eat Well web resource).
3337866|NCT02159014|Active Comparator|Phase 2|Self-paced online physical activity (video based aerobic dance) intervention and use of NHS Change4Life Eat Well web resource.
3337867|NCT02159027|Placebo Comparator|placebo|placebo identical in appearance to maraviroc 150 and 300 mg tablets will be added to each subjects antiretroviral regimen at doses as recommended by the package insert
3337868|NCT02159027|Experimental|maraviroc|Maraviroc Tablets are available as 150 mg and 300 mg tablets. Each subject will add maraviroc to their current antiretroviral regimen with dosage based on recommendations as per maraviroc package insert
3337869|NCT02159066|Experimental|LGX818 + MEK162|
3337870|NCT02159066|Experimental|LGX818 + MEK162 + LEE011|
3337871|NCT02159066|Experimental|LGX818 + MEK162 + BGJ398|
3337872|NCT02159066|Experimental|LGX818 + MEK162 + BKM120|
3337873|NCT02159066|Experimental|LGX818 + MEK162 + INC280|
3337874|NCT02159092|Experimental|Contingency Management|Monetary incentives are given for submitting negative saliva cotinine tests.
3236143|NCT01247857|Active Comparator|Preoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity before surgery
3337875|NCT02159092|No Intervention|Fixed Rate Control|Fixed amounts of payments are provided for submitting saliva samples
3236144|NCT01247857|Active Comparator|Postoperative Nebulization|Nebulization of 30 mg of Ropivacaine in the peritoneal cavity after surgery
3236145|NCT01247857|Placebo Comparator|Control|Nebulization of normal saline 3 ml before and after surgery
3337876|NCT02159105||Women undergoing cesarean delivery|"FAST scan and non-invasive hemoglobin measurement~Women undergoing cesarean delivery will undergo a non-invasive hemoglobin measurement both before and after surgery. An abdominal ultrasound will be performed to establish normal levels of intra-abdominal fluid after cesarean delivery."
3337877|NCT02159131|Experimental|OC containing levonorgestrel and ethinyl estradiol + GSK126574|Eligible subjects will enter a run-in-period of 21 days (may extend to 49 days) to stabilize on OC containing levonorgestrel and ethinyl estradiol in order to synchronize the menstrual cycles of multiple subjects. Subjects completing run-in-period will enter Treatment period 1 and will be dosed OC once daily on Days 1 to 10. At day 11 subjects will enter Treatment period 2 and will be dosed with OC containing levonorgestrel and ethinyl estradiol + 744 once daily on Day 12 to 19. Subjects completing Treatment period 2 will have 7 OC free days (Day 22 to 28) during which withdrawal menses should occur. Subjects will then be followed up for 7 to 14 days (Day 28 to 35/49).
3337878|NCT02159144|Experimental|healthy adults|
3337879|NCT02159157|No Intervention|Arm A|"Physical Therapy consult for post op care and general physical activity recommendation 1-4 weeks prior to starting chemotherapy.~Phone calls designed to support the patient to maintain current activity level."
3337880|NCT02159157|Placebo Comparator|Arm B|"Physical Therapy consult for post-op care 1-4 weeks prior to starting chemotherapy.~Exercise prescription aimed at increasing physical activity by a minimum of 10 MET hours/week.~Motivational phone calls aimed at encouraging the patient to adhere to their exercise prescription."
3337881|NCT02159170|Experimental|NGF|injection of 50 µl NGF, once into the left volar forearm and injection of 50 µl NaCl (sodium chloride) once into the right volar forearm
3337882|NCT02159196|Active Comparator|acetylcysteine and salbutamol|Nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator), administered every 6 hours (i.e., 4 times per day) within 24 hours after initiation of ventilation until tracheal extubation.
3337883|NCT02159196|Experimental|acetylcysteine or salbutamol|"Nebulisation on strict clinical indications; nebulisation of 3 mL-solution of acetylcysteine (fluimucil 100mg/ml, a mucolytic) in case of occurrence of persistent thick and tenacious sputum and only after active humidification is set.~Nebulisation of 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml, a bronchodilator) in case of occurrence of bronchospasm."
3337884|NCT02159209||Drug Induced Renal Injury (DIRI)|This is a prospective observational cohort study of patients who have developed acute kidney injury Stage 2 or a glomerular disorder following exposure to specific drugs that have been associated with DIRI.
3337885|NCT02159222|Experimental|Additional physical therapy|
3337886|NCT02159235||AIHD-patients (ICD-10 I21)|Patients suffering from acute ischemic heart disease according to ICD-10 I21
3337887|NCT02159235||CIHD-patients (ICD-10 I25)|patients suffering from chronic ischemic heart disease according to ICD-10 I25
3337888|NCT02159248|Experimental|Tolfenamic acid + gemcitabine + radiation|
3337889|NCT02159261||Cohort 1|Female patients ≥ 18 years old requiring contraception.
3337890|NCT02159274||BCS without oncoplastic techniques|BCS without oncoplastic techniques
3236146|NCT01247870|Experimental|Metformin|Metformin 1 g twice daily for 28-35 days
3236147|NCT01247870|Placebo Comparator|Placebo|Matched placebo capsules
3236148|NCT01247883|Active Comparator|single dose PF-04634817 tablet|subjects receive a single dose of PF-04634817 as a tablet
3236149|NCT01247883|Active Comparator|single dose PF-04634817 solution|subjects receive a single dose of PF-04634817 as a solution
3236150|NCT01247896|Experimental|Active|
3236151|NCT01247896|Placebo Comparator|Placebo|
3337891|NCT02159274||BCS with oncoplastic techniques|BCS with oncoplastic techniques.
3337892|NCT02159287|Experimental|Low molecular-weight heparin|these patients will receive 1 mg of enoxaparin (clexane) per kilogram of body weight subcutaneous every 12 hour with warfarin 5mg QD and both drugs will be continued until the target INR level (2.5) is reached then clexane will be discontinued.
3337893|NCT02159287|Active Comparator|unfractionated heparin|This group will receive continuous intravenous unfractionated heparin sodium infusion 1000 unit per hour initially and then the dose will be adjusted to maintain a therapeutic aPTT level (two times to baseline) then warfarin will be started (5 mg QD).
3337894|NCT02159300||Patients|Patients with fibromyalgia pain Intervention: experience brain activity recording
3337895|NCT02159300||Healthy Controls|Healthy controls without chronic pain of any type.
3337896|NCT02159313|Experimental|BAY63-2521 with Non sparkling water|Single dose of a whole 2.5 mg riociguat tablet (fasted) with 240 mL of non-sparkling water at room temperature
3236152|NCT01247909|Experimental|Ceftriaxone|Ceftriaxone in infants with sepsis and bacterial meningitis
3236153|NCT01247909|Active Comparator|Penicillin and gentamicin|Penicillin and Gentamicin in infants with sepsis and bacterial meningitis
3337897|NCT02159313|Experimental|BAY63-2521 with applesauce|Single dose of a crushed 2.5 mg riociguat tablet suspended in 50 mL applesauce, to be eaten with a spoon (fasted)
3337898|NCT02159313|Experimental|BAY63-2521 with water|Single dose of a crushed 2.5 mg riociguat tablet suspended in a glass with 25 mL water, to be drunk and flushed twice with 25 mL water in the same glass (fasted)
3236154|NCT01247935|Experimental|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
3337899|NCT02159313|Experimental|BAY63-2521 after breakfast|Single dose of a whole 2.5 mg riociguat tablet taken within 5 minutes after the last bite of a continental breakfast (fed) with 240 mL of non-sparkling water at room temperature
3337900|NCT02159326|Experimental|Arm1|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
3337901|NCT02159326|Experimental|Arm2|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment, a single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
3337902|NCT02159339||gene-methylation|"gene-low-level of methylation: patients with early stage gastric carcinoma containing low-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-middle-level of methylation: patients with early stage gastric carcinoma containing middle-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-high-level of methylation: patients with early stage gastric carcinoma containing high-level of methylation change of E-cadherin,GFRA1,p16,SRF and ZNF382 CpG island.~gene-without of methylation: patients with early stage gastric carcinoma NOT containing methylated E-cadherin,GFRA1,p16,SRF or ZNF382 CpG island."
3337903|NCT02159378|Other|GD with Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
3337904|NCT02159378|Other|GD without Insulin treatment|"At the end of the study patients will be divided into two groups: GD with Insulin treatment versus GD without Insulin treatment In each group, the serum fructosamines rate will be estimated with a confidence interval of 95% and compared from a Student test."
3337905|NCT02159391|No Intervention|Usual Intervention|A standard intervention will be performed by nursing staff during hospital admission. Written information about the consequences of driving under the influence of alcohol and/or drugs will be provided. No psychological intervention.
3236155|NCT01247935|Experimental|transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
3236156|NCT01247935|No Intervention|Control|patient are monitored for pain and discomfort
3337906|NCT02159391|Experimental|Brief Motivational Interview|A Brief Motivational Interviewing will be performed during hospital admission by a psychologist experienced with this intervention.
3337907|NCT02159404||Allergic Rhinoconjunctivitis|Patients with diagnosed Allergic Rhinoconjunctivitis
3337908|NCT02159404||Healthy controls|
3337909|NCT02159417|Experimental|Therapeutic Education|Intensive training individual or collective teaching
3337910|NCT02159430||HereditaryAngioEdema|Patients from the Eastern Sicily HAE register
3337911|NCT02159443||Study Participants|Those who meet eligibility criteria and consent to participate in the study.
3337912|NCT02159456|Experimental|Continuous enteral feeding|Continuous enteral feeding via infusion pump is applied for at least 7 days after the start of enteral feeding
3337913|NCT02159456|Active Comparator|Intermittent enteral feeding|Intermittent enteral feeding via gravity-based infusion is applied for at least 7 days after the start of enteral feeding.
3337914|NCT02159495|Experimental|Treatment (lymphodepletion, T-cell immunotherapy)|Patients undergo a lymphodepleting regimen 3-10 days prior to CD123+ CAR T cell infusion as determined by the principal investigator and the protocol team. Patients receive either cyclophosphamide IV on days -4 and/or -3; fludarabine phosphate and cyclophosphamide IV on days -5 to -3; fludarabine phosphate IV on days -5 to -3 and cyclophosphamide IV on days -4 and/or -3. Patients receive autologous or allogeneic CD123+ CAR Tcells IV over 15 minutes on day 0. Patients with evidence of disease at > 28 days, continuing expression of the CD123 antigen, and not having experienced a DLT may receive a second infusion of CD123+ CAR T cells after 28 days.
3337915|NCT02159508|No Intervention|Individualised on-demand counselling|Individualized on-demand counselling group was assigned to receive baseline nutritional counselling, that consisted of one dietetic consultation before (chemo)radiotherapy. During (chemo)radiotherapy on-demand counselling group patients received further counselling only on demand.
3337916|NCT02159508|Experimental|Intensive nutritional counselling|Intensive nutritional counselling consisted of protocolled counselling given by a dietitian once at baseline and on the 2nd and 4th week of treatment and at the end of chemoradiotherapy.
3337917|NCT02159534|Experimental|Primebrain|"' Stimulation ' Infants group will receive Primebrain stimulation whose items were selected according to a Delphi process and discussed at the European Academy of Childhood Disability (2013).~This sensorimotor stimulation programme is administered at home by parents (trained and monitored by a physical therapist), once a day between term-age and 6 months of corrected age.~In addition, these infants undergo systematic monitoring for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
3236157|NCT01247948|Experimental|navigation assisted spine surgery|
3236158|NCT01247961|Experimental|10 mg intravenous dexamethasone|Subjects randomized to intervention arm will receive single dose of 10 mg intravenous dexamethasone.
3236159|NCT01247961|Placebo Comparator|Placebo|Equal volume of normal saline administered as a single intravenous dose at enrollment.
3236160|NCT01247987|Active Comparator|Blastocyst cryopreservation|Subjects randomly assigned to this arm of the study will have all of their embryos cryopreserved at the blastocyst stage, followed by thaw and transfer in a subsequent menstrual cycle.
3259247|NCT01469091|Active Comparator|Smoking intervention, Nicotine replacement therapy.|
3337918|NCT02159534|Other|usual care|"Infants in the comparison group receive usual care for preterm and infants born with low birth weight as organized in Belgium ( INAMI convention )."
3337919|NCT02159560|Active Comparator|End holed catheter|Single holed, end holed epidural catheter
3337920|NCT02159560|Active Comparator|Three holed catheter|closed ended, three side holed epidural catheter
3337921|NCT02159599|Active Comparator|Darunavir/Ritonavir + 2 nucleos(t)idos|Darunavir/Ritonavir ( (800mg/100mg) + Tenofovir/emtricitabine (300mg/200mg) or Abacavir/lamivudine (600 mg/300mg)
3337922|NCT02159599|Experimental|Darunavir/ritonavir + Lamivudine|Darunavir/Ritonavir (800mg7100mg) + lamivudine (300mg)
3337923|NCT02159612||FSHD|A cohort of adult danish patients with facioscapulohumeral muscular dystrophy is invited to perform a MRI scan.
3337924|NCT02159625|Experimental|Abdominal Compression Elastic Support|To compress the abdomen at 15 mmHg for 3 hours during the course of hemodialysis treatment.
3337925|NCT02159638|Other|comparisson CGM accuracy|Each patient will have both subcutaneous tissue CGM sensors (Guardian Enlite sensor and Dexcom G4 Platinum sensor) inserted at the same time. The HemoCue Analyser- venous blood and finger-stick blood in cuvette, will be used to measure the concentration of glucose
3337926|NCT02159651||1: Dermatomyositis group|patients with interstitial pneumonia associated with dermatomyositis
3337927|NCT02159651||2: Polymyositis group|patients with interstitial pneumonia associated with polymyositis
3337928|NCT02159664|Experimental|didgeridoo practice|
3236161|NCT01247987|Experimental|Bipronuclear oocyte cryopreservation|Subjects randomly assigned to this arm of the study will have all of their bipronuclear oocytes cryopreserved, followed by thaw, extended culture, and transfer in a subsequent menstrual cycle.
3236162|NCT01248000||classical Hodgkin lymphoma|All cases of classical Hodgkin lymphoma diagnosed between 2006 and 2008 in the province of Modena, Reggio Emilia, Parma and Ferrara will be considered eligible for this study.
3236163|NCT01248026|Experimental|Buttermilk|
3236164|NCT01248026|Placebo Comparator|Placebo|
3337929|NCT02159677||Healthy Subjects|Healthy subjects aged 21-80 years with no history of present or past disabling back or neck pain, sciatica, cervical radiculopathy, or any generalized neuromuscular condition except for mild polyneuropathy or common mononeuropathies (e.g. carpal tunnel syndrome, ulnar neuropathy at the elbow.) Additionally, subjects cannot have any history of any moderate-to-severe ongoing medical condition producing generalized disability, such as advanced cardiac or renal disease, or metal spine implants of any type.
3337930|NCT02159677||Radiculopathy Subjects|Subjects aged 21-80 years with a history consistent with radiculopathy based on clinical, radiologic, and standard electrophysiological criteria, as determined by spine expert.
3337931|NCT02159677||Musculoskeletal Back Pain Subjects|Subjects aged 21-80 years with low back or neck pain without evidence to suggest neuropathic component; i.e. without radiation of pain, sensory loss or weakness.
3337932|NCT02159677||Undiagnosed Lower Back or Neck Pain Subjects|Subjects aged 21-80 years with a major complaint of lower back or neck pain.
3337933|NCT02159716|Experimental|Metastatic Pancreatic (ductal) adenocarcinoma (PDA)|
3236165|NCT01248039||Total arthroplasty|Patients with osteoarthrosis going for hip or knee arthroplasty
3236166|NCT01248052|Experimental|LY2979165 (Part A)|single oral doses at dose levels ranging from 20 to 1000 mg
3337934|NCT02159716|Experimental|Serious Epithelial Ovarian Cancer|
3337935|NCT02159716|Experimental|Malignant Epithelial Pleaural Mesothelioma|
3337937|NCT02159755|Experimental|Treatment (ibrutinib, palbociclib)|Patients receive ibrutinib PO QD on days 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3337938|NCT02159781|Experimental|periodontal treatmnent|
3337939|NCT02159794|Experimental|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
3337940|NCT02159820|Active Comparator|DTC Arm|Patients are randomly assigned to receive lower-dose decitabine treatment followed by TC regimen (ie, DTC arm).
3337941|NCT02159820|Active Comparator|TC regimen|Patients were randomly assigned to receive carboplatin plus paclitaxel (ie, TC arm).
3337942|NCT02159833|Experimental|Intervention|Intranasal challenge with food protein or vehicle control
3337943|NCT02159846||Test Group and Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
3337944|NCT02159846||Test Group & Control Group|20 patients with established T2DM were recruited from the M-OPD, HTAA, Kuantan; and equally divided into the Test and the Control groups (10 patients in each group).These patients were either fed with 4 g daily mixed herbs (on wet weight basis) or placebo (maize starch).
3337945|NCT02159885|Experimental|Telemonitoring|In this arm, subjects will receive usual care at the sleep clinic as well as telemonitoring of their use of their automatically adjusting continuous positive airway pressure pressure (APAP) machine. They will receiving phone calls for poor adherence and/or poor efficacy of treatment.
3337946|NCT02159885|No Intervention|Usual Care|"Subjects in this arm will receive usual care for management of obstructive sleep apnea and use of automatically titrating continuous positive airway pressure."
3337947|NCT02159911||200 mcg misoprostol|Misoprostol administered orally one hour before surgery
3337948|NCT02159911||400 mcg misoprostol|Misoprostol administered orally one hour before surgery
3337949|NCT02159924||Asymptomatic|
3337950|NCT02159937||Patients with metastatic cancer|Blood sampling by vena punction.
3337951|NCT02159963|Experimental|Supervised training|8 weeks of high intensity training three times a week, once supervised. Followed by 8 weeks home based, unsupervised optional training.
3337952|NCT02159963|Experimental|Unsupervised training|"Participants have 8 weeks of non-intervention Control period, followed by 8 weeks of home based, unsupervised high intensity interval training."
3236167|NCT01248052|Placebo Comparator|Placebo (Part A)|single oral dose
3236168|NCT01248052|Experimental|LY2979165 - low dose (Part B)|single oral low dose of LY297165 (dose to be determined by Part A)
3259248|NCT01469091|No Intervention|Controlgroup|
3337953|NCT02159989|Experimental|Treatment (sapanisertib, ziv-aflibercept)|Patients receive sapanisertib PO QD on days 2-4, 9-11, 16-18, and 23-25 and ziv-aflibercept IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3337954|NCT02160015|Experimental|Treatment (lenalidomide, ibrutinib, rituximab)|Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3337955|NCT02160028|Active Comparator|Standard information|This group is given anesthetics and standard information before dental treatment about the anesthetics.
3337956|NCT02160028|Experimental|Extended information|This group is given anesthetics and extended information before dental treatment about the anesthetics.
3337957|NCT02160054||Group 1|patients with kidney transplantation who converted the immunosuppressant from cyclosporine to Graceptor ®
3337958|NCT02160067|Experimental|Treatment A|Second generation patch BTDS 12.6mg
3337959|NCT02160067|Experimental|Treatment B|Second generation patch BTDS 3.15mg
3337960|NCT02160067|Active Comparator|Treatment C|First generation patch BuTrans 20mg
3337961|NCT02160067|Active Comparator|Treatment D|First generation patch BuTrans 5mg
3337962|NCT02160080|Experimental|Boc+Peg-int alfa+Rbv|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
3337963|NCT02160106|Experimental|TEW-7197|Dose Escalation of TEW-7197: TEW 7191 tablets will be given once daily (QD) or twice daily (BID) for 5 days followed by 2 days without treatment in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
3236169|NCT01248052|Experimental|LY2979165 - high dose (Part B)|single oral high dose of LY2979165 (dose determined from Part A)
3236170|NCT01248052|Placebo Comparator|Placebo - Part B|single oral dose
3236171|NCT01248078|Active Comparator|Cefazolin A|administered before skin incision
3337964|NCT02160119||Healthy Controls|
3337965|NCT02160119||Autism Spectrum Disorders|
3337966|NCT02160132|Experimental|A 1-2-3Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
3337967|NCT02160132|Active Comparator|B 1-3-5Group|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
3337968|NCT02160158|Experimental|Cohort 1|
3337969|NCT02160158|Experimental|Cohort 2|
3337970|NCT02160171||Term neonates|Term neonates who are undergoing continuous video amplified Electroencephalogram (aEEG)/Electroencephalogram (EEG) monitoring for clinical purposes (e.g. because seizures were suspected, or the neonate is being treated with therapeutic hypothermia). EEGs will be analysed off line by 'Algorithm for Neonatal Seizure Recognition'
3337971|NCT02160197|No Intervention|No Immobilisation|No immobilisation post op, allowing patients to weight bear as tolerated.
3337972|NCT02160197|Active Comparator|Functional Bracing|Immobilise patients in Functional brace, allowing patients to weight bear as tolerated.
3337973|NCT02160197|Active Comparator|Plaster Immobilisation|Immobilise patients in plaster, allowing patients to weight bear as tolerated.
3337974|NCT02160210|Experimental|Ultrafine Endoscope|The ultrafine endoscope for colonoscopy with water method is performed in screening the colorectal diseases.
3337975|NCT02160223|Experimental|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at the end of surgery
3337976|NCT02160223|Active Comparator|Neostigmine|Group N patients will receive 50 µg kg-1 neostigmine and 05 mg atropin at the end of surgery
3337977|NCT02160236|Active Comparator|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
3337978|NCT02160236|Active Comparator|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
3337979|NCT02160236|Placebo Comparator|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
3337980|NCT02160249|Experimental|Community-based rehabilitation and facility based care|"Community-based rehabilitation is delivered to participants and their caregivers at their home by a specialist CBR worker. It comprises psychoeducation, adherence support, rehabilitation (including self-care and social skills), family support groups and accessing existing community organisations. It also involves community awareness raising and education and mobilisation of community leaders.~Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education."
3337981|NCT02160249|Active Comparator|Facility-based care|Facility based care (usual care) consists of anti-psychotic medication prescribed by a nurse or clinical officer in a health centre and basic psycho-education.
3337982|NCT02160262|Experimental|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed
3236172|NCT01248078|Active Comparator|Cefazolin B|after umbilical cord clamping
3236173|NCT01248078|Placebo Comparator|saline solution|administered before skin incision
3236174|NCT01248091|Placebo Comparator|Placebo gel|
3236175|NCT01248091|Experimental|Nitroprusside Gel|
3337983|NCT02160275|Active Comparator|Open Loop|4 days patient-managed insulin pump therapy with blinded continuous glucose monitoring
3337984|NCT02160275|Experimental|Closed Loop|4 days of automated blood glucose control with the Artificial Pancreas (Inreda Diabetic BV)
3337985|NCT02160301|Experimental|Multimodal pain control|Oxycodone 5-15mg PO q4hrs prn pre- and post-op, Acetaminophen 1000mg IV once pre-op, Acetaminophen 1000mg PO q8hrs pre-op and x2 weeks post op, prn thereafter, Gabapentin 100mg/200mg PO a8hrs pre-op and x2 weeks post op, Dexamethasone 8mg IV once intra-op, Celecoxib 400mg PO once pre-op.
3337986|NCT02160301|Active Comparator|Standard pain control|Oxycodone 5-15mg PO q4hrs prn, Acetaminophen 1000mg PO q8hrs prn.
3337987|NCT02160340||Vitreomacular adhesion|Male or female subjects aged over 40 years with vitreomacular adhesion
3337988|NCT02160353|Experimental|Combined hormonal therapy|Abiraterone acetate: 1000mg/day (four 250g tablets, orally once a day) for 126 days Prednisolone; 5mg/day (1 tablet orally once a day, concomitant to abiraterone acetate) for 126 days GnRh agonist for 4 injections (at 28 day intervals)
3337989|NCT02160366||Biomarker/Molecular Data Collection and Analyzation|Advanced cancer participants
3236176|NCT01248117|Experimental|Previously Treated|With prior anti-vegf therapy, only, no sooner than 30 days prior to enrollment into trial
3337990|NCT02160379||post Roux-en-Y-gastric bypass|Formerly obese females 1-5 years after gastric bypass
3337991|NCT02160379||matched controls|non-operated females age-and weight-matched to post Roux-en-Y-gastric bypass subjects
3337992|NCT02160379||healthy young controls|non overweight (BMI between 19 and 25 kg/m2) healthy females
3337993|NCT02160392||Endometrial biopsy|HIV + and HIV negative women underwent lower and upper genital tract sampling.
3337994|NCT02160405|Experimental|Normal diet|
3337995|NCT02160418|No Intervention|Control|36 Participants will be sent a new toothbrush and will be asked to use it in place of their current brush. They also receive twice daily reminders via sms to brush their teeth.
3337996|NCT02160418|Experimental|Financial Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. They will also be offered financial incentives twice a day to brush their teeth.
3337997|NCT02160418|Experimental|Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
3337998|NCT02160418|Experimental|Financial and Cognitive Incentives|36 Participants will receive a toothbrush and twice daily reminders to brush their teeth. Twice daily they receive financial incentives to brush their teeth. Twice a week, they will receive text messages (SMS) with a short quiz question related to oral hygiene behavior and oral health. Participants will receive a reward if they answer correctly via text message.
3337999|NCT02160431|Experimental|CBT for pediatric OCD|Participants complete standard CBT for OCD
3338000|NCT02160444|Experimental|CBT plus Parent as CBT Coach Training|CBT plus Parent as CBT Coach Training
3338001|NCT02160457|Experimental|Intervention with IGA|Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis (IGA)
3338002|NCT02160457|No Intervention|Intervention without IGA|'Care as usual' - Individually tailored interdisciplinary interventions based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations BUT NOT (IGA).
3338003|NCT02160470|Experimental|Exposure with Retrieval|Exposure Therapy with Retrieval
3338004|NCT02160470|Experimental|Exposure with Compounding|Exposure Therapy with Compound Extinction
3338005|NCT02160470|Experimental|Exposure with Retrieval and Compounding|Exposure Therapy with Retrieval and Compound Extinction
3338006|NCT02160470|Active Comparator|Therapist-Guided Exposure Therapy|Therapist-guided Exposure Therapy
3338007|NCT02160483|Experimental|Magnetic resonance imaging|Functional magnetic resonance imaging using arterial spin labelling, functional connectivity, diffusion tensor imaging, magnetic resonance spectroscopy to evaluate women with chronic pelvic pain and/ or endometriosis
3338008|NCT02160496|Active Comparator|20% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 20% protein, 30% fat and 50% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3338009|NCT02160496|Active Comparator|27% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 27% protein, 30% fat and 43% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3338010|NCT02160496|Active Comparator|35% protein hypocaloric diet|Participants were advised with a hypocaloric diet with the following composition: 35% protein, 30% fat and 35% carbohydrates. A wide variety of healthy foods typically coming from a mediterranean diet and specific exercise recommendations are provided to the subjects.
3338011|NCT02160509||- The patients who undergo ultrasonography in the ED|
3338012|NCT02160522||Cuffed ETT|Patients that are intubated with a cuffed endotracheal tube.
3338013|NCT02160548|Placebo Comparator|'Standard care'|Standard care= Intravenous fluids, Oxygen by face mask, Intubation if necessary, Mechanical ventilation (Engstrom Pro by GE) if necessary, Cardiac monitor (Infunix IP4050), Atropine (anti-muscarinic drug; G-Atropine) by intravenous route, Pralidoxime (acetylcholinesterase reactivating oxime drug; PAM-A) by intravenous route.
3338014|NCT02160548|Experimental|'Standard care+ 2.5 mg Salbutamol'|Standard care+ 2.5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 2.5 mg stat and once only with standard care
3236177|NCT01248117|Experimental|Treatment-Naive|Treatment-Naive: no previous treatment for PCV
3236178|NCT01248143|Experimental|Green tea|
3338015|NCT02160548|Experimental|'Standard care+ 5 mg Salbutamol'|Standard care+ 5 mg Salbutamol= Nebulized salbutamol (Ventolin respiratory solution) 5 mg stat and once only with standard care
3338016|NCT02160561|Experimental|Intervention Arm|Experimental - Intervention Arm patients who are in critical illness with acute respiratory failure and are mechanically ventilated will be placed in an upright reverse trendelenburg position
3236179|NCT01248143|Experimental|FPP|
3236180|NCT01248156||Intervention|Patients with persistent, long standing persistent and paroxysmal AF, who will receive ablation at sites that potentially maintain human AF.
3236181|NCT01248156||Control|Patients with persistent, long standing persistent and paroxysmal AF, who receive conventional ablation as determined by the operator at each site, and based upon Heart Rhythm Society guidelines.
3236182|NCT01248169||Hydralazine|This group will receive administration of the antihypertensive Hydralazine for the attempted control of their blood pressure and stabilization of their hemodynamic state.
3236183|NCT01248169||Labetalol|This group will receive administration of the antihypertensive Labetalol for the attempted control of their blood pressure and stabilization of their hemodynamic state.
3236184|NCT01248195|Other|Phase I: 1 arm 'amisulpride open label'|For 4 weeks, all patients will be treated with amisulpride open label.
3259249|NCT01469104|Placebo Comparator|3 day fast|After receiving a standard diet on day 1, subject will fast on days 2, 3, and 4. Water and calorie-fee beverages will be allowed during this 72 hour period.
3338017|NCT02160574|Active Comparator|ZuraPrep|ZuraPrep will be compared statistically to ZuraPrep without IPA and both to the Positive Control (0.1% Sodium Lauryl Sulfate). The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.
3338018|NCT02160587|Active Comparator|ZuraPrep|Irritation scores of the following applied to test sites will be compared: ZuraPrep, ZuraPrep without IPA, ChloraPrep, and 0.9% Physiological Saline.
3338019|NCT02160600|Experimental|split bolus|Patients will undergo diagnostic Split bolus DECT scan
3338020|NCT02160600|Experimental|Standard|Patients will undergo routine multiphase diagnostic CT
3338021|NCT02160613|Other|Open flap for periodontitis patients|Open flap debridement
3338022|NCT02160639|No Intervention|usual care|usual care includes diabetes self management education
3338023|NCT02160639|Active Comparator|diabetes self management support|diabetes self management support in addition to usual care, which includes diabetes self management education
3338024|NCT02160652||Patients|Patients with malignant ureteral obstruction, treated with laparoscopic ureteral re-implantation, who have a life expectancy of over 6 months and are willing and able to participate in the study.
3338025|NCT02160665|Placebo Comparator|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
3338026|NCT02160665|Other|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
3236185|NCT01248195|Active Comparator|Phase II: 'amisulpride double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'amisulpride double blind'
3338027|NCT02160665|Active Comparator|Test:Tazarotene Cream, 0.05%|Test: Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
3338028|NCT02160678|Active Comparator|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
3338029|NCT02160678|Other|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
3338030|NCT02160678|Placebo Comparator|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
3338031|NCT02160691|Experimental|Anxiety Meter|The Anxiety Meter (experimental) group will receive a real-time display of physiological arousal on the Anxiety Meter during the intervention period in visit #4.
3338032|NCT02160691|No Intervention|No Anxiety Meter|The control group will have the Anxiety Meter during the intervention period, but the marker will not move.
3338033|NCT02160704|Experimental|Arm 1(IP)|Enclomiphene citrate capsules 25 mg 1x daily for 16 weeks
3338034|NCT02160704|Placebo Comparator|Arm 2 (Placebo)|Placebo capsule 1x daily for 16 weeks
3338035|NCT02160717||Turner Syndrome|Female with Turner Syndrome
3338036|NCT02160717||Healthy Controls|Healthy Female
3338037|NCT02160743|Experimental|CJ-30056 20mg/500mg|fasting, fed
3338038|NCT02160743|Experimental|group 2|fed, fasting
3338039|NCT02160756|Active Comparator|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) softgel capsule on Day 1.
3338040|NCT02160756|Experimental|Treatment B|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
3338041|NCT02160756|Experimental|Treatment C|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
3338042|NCT02160756|Experimental|Treatment D|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
3338043|NCT02160821|Experimental|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block TAPB Ultrasound guided TAPB
3338044|NCT02160821|Experimental|Caudal Epidural Block|Caudal Epidural Block Caudal Block Neuraxial Block Ultrasound Guided Caudal Block
3338045|NCT02160834|Experimental|B-MOBILE smartphone-based intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
3338046|NCT02160834|Experimental|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
3338047|NCT02160834|No Intervention|Control|
3338048|NCT02160860||Children|Children
3338049|NCT02160886|Experimental|Child-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the children themselves, using the Swedish version of the Perceived Efficacy and Goal Setting System (PEGS).~A PEGS interview will be performed with the children. The children identifies tasks they find difficult to perform and prioritize three tasks, they want to perform better, as goals for intervention."
3338050|NCT02160886|Experimental|Parent-goal|"The children will receive goal- directed task oriented interventions based on goals identified by the parents using the Canadian Occupational Performance Measure (COPM).~Using the COPM interview technique, the parents are encouraged to talk about an ordinary day to identify occupational performance issues their child is not able to perform. Identified performance issues are rated for importance and the parents selects the three most important issues as goals for intervention."
3338051|NCT02160912||Ectoin Mund- & Rachenspray|treatment with Ectoin Mund- & Rachenspray 1%
3338052|NCT02160912||Emser Pastillen|treatment with Emser Pastillen
3338053|NCT02160925|Experimental|Preoperative 99mTc-Sestamibi SPECT/CT|
3338054|NCT02160938||3 year follow-up cohort|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At as close to the age of 3 as possible, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
3338055|NCT02160938||Limited follow-up cohort|Women with children who will not reach the age of 2 years 6 months by the end of our study but have a prenatally diagnosed CNV will be recruited into the limited follow-up study. Each center will describe the study to eligible women and will verbally obtain their permission to be contacted by the Study Follow-up Specialist. The Study Follow-Up Specialist will contact the patient, explain the study, and obtain full written informed consent.
3338056|NCT02160951|Experimental|LGH447|LGH447, QD
3338057|NCT02161003|Experimental|Stem Cells Isolation|"Stem cell isolation technique and Stem Cells Injection Technique The method of isolation of MSC from bone marrow will be carried out using the Ficoll-Paque technique for the isolation of mononucleated cells followed by the separation of MSC by adherence to plastic. Finally, the cells will be resuspended and counted using a hemocytometer.~Mononucleated cells will be cultured and incubated at 37°C in an atmosphere of 95% relative humidity and 5% CO2."
3236186|NCT01248195|Active Comparator|Phase II 'olanzapine double blind'|Patients who do not meet remission criteria during phase I (4 weeks open label amisulpride), flow to phase II where they are randomised to 1 of 2 6-week double blind treatment arms, one of which is 'olanzapine double blind'
3236187|NCT01248195|Other|Phase III: 1 arm 'clozapine open label'|Patients who do not meet remission criteria during phase II (6-week double blind amisulpride vs olanzapine), flow to phase III, where only 1 arm is available: 'clozapine open label'
3338058|NCT02161029|Active Comparator|New drill biopsy instrument|To take biopsies from gastric submucosal tumors with a new drill biopsy instrument used with flexible endoscopes.
3338059|NCT02161029|Active Comparator|Conventional biopsy instrument|To take biopsies from gastric submucosal tumors with conventional biopsy forceps used with flexible endoscopes
3236188|NCT01248195|Experimental|Psychosocial intervention|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Psychosocial Intervention' arm.
3236189|NCT01248195|No Intervention|Psychosocial Intervention phase: 'TAU'|Patients who meet remission criteria during any of the phases of the medication component, patients who drop out of the medication component and patients who did not meet remission criteria at the end of the medication component, will flow to the psychosocial intervention component, where they are randomised to 1 of 2 arms, one of which is the 'Treatment as usual' arm.
3236190|NCT01248208|Experimental|FluMist (LAIV) group|FluMist influenza vaccine 0.2 mL intranasal vaccine once
3338060|NCT02161042||fresh blood Transfusion|
3338061|NCT02161042||Old blood transfusion|
3338062|NCT02161055|Experimental|Strict control group|"Intensive insulin therapy: Keep Target blood glucose levels between 4.4-7.0 mmol/L;~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
3338063|NCT02161055|Experimental|Moderate control group|"Intensive insulin therapy: Keep target blood glucose levels between 7.1 and 10.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours"
3236191|NCT01248208|Active Comparator|Flu shot (TIV) group|"Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months will receive intramuscular influenza vaccination. History/Treatment of asthma in the past 12 months is defined as follows:~wheezing in the past 12 months~use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months~emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months."
3236192|NCT01248234|Active Comparator|Propofol|Propofol alone will be used to put an elderly hypertensive patient to sleep for surgery.
3236193|NCT01248234|Active Comparator|Etomidate|Etomidate alone will be used to put an elderly hypertensive patient to sleep.
3236194|NCT01248234|Active Comparator|Propofol and Etomidate|A combination of Etomidate and Propofol will be used to put an elderly hypertensive patient to sleep for surgery.
3338064|NCT02161055|Experimental|Slight control group|"Intensive insulin therapy: Keep target blood glucose levels between 10.1 and 13.0 mmol/L.~Blood glucose levels were monitored and controlled using the Yale Insulin Infusion Protocol. Rapid blood glucose levels were monitored once every 2 hours."
3338065|NCT02161055|Active Comparator|Non-intensive insulin therapy|Rapid blood glucose levels were measured once every 2 hours. When blood glucose levels were ≤ 13.0 mmol/L, no intervention was performed; When blood glucose levels were > 13.0 mmol/L, regular insulin was subcutaneously injected separately. During fasting, insulin was injected once every 8 hours. During venous or enteral nutrition infusion, insulin was infused at 30 minutes before nutrition infusion. When blood glucose levels were ≤ 13.0 mmol/L, insulin infusion was terminated.
3338066|NCT02161081|Experimental|Myocardial CT perfusion (21-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 21-second scan duration.
3338067|NCT02161081|Active Comparator|Myocardial CT perfusion (30-second)|A total of 60 symptomatic patients will be randomized to dynamic CT perfusion protocol with 30-second scan duration.
3338068|NCT02161094|Experimental|Group 1: Physicians|Give incentives to physicians based on their patient's HbA1c improvement
3338069|NCT02161094|Experimental|Group 2: Diabetic patients|Give incentives to patients based on their own HbA1c improvement
3338070|NCT02161094|Experimental|Group 3: Both Physicians and Patients|Give incentives to both based on the HbA1c improvements from the physicians' patients
3338071|NCT02161094|No Intervention|Group 4: Control group|Receive no incentive but will be provided diabetes education booklet and group education courses for DM control as usual
3338072|NCT02161107|Experimental|Grass-SPIRE 1|Grass-SPIRE regimen 1 given 2 weeks apart
3338073|NCT02161107|Experimental|Grass-SPIRE 2|Grass-SPIRE regimen 2 given 2 weeks apart
3338074|NCT02161107|Placebo Comparator|Placebo|Placebo given 2 weeks apart
3338075|NCT02161120|Active Comparator|Traditional rye bread|As part of habitual diet participants are expected to consume 100-200 grams of traditional Finnish rye bread daily
3236195|NCT01248247|Experimental|Group 1 - Erlotinib|Erlotinib 150 mg by mouth each day of a 28 day cycle.
3236196|NCT01248247|Experimental|Group 2 - Erlotinib + MK-2206|"Erlotinib 150 mg by mouth each day of a 28 day cycle.~MK-2206 135 mg by mouth every week of a 28 day cycle."
3338076|NCT02161120|Experimental|Low-FODMAP rye bread|As part of habitual diet participants are expected to consume 100-200 grams of low-FODMAP rye bread daily
3338077|NCT02161159||Patients With Urinary Incontinence Due to iOAB|Patients with urinary incontinence due to iOAB treated with BOTOX® in accordance with physician standard practice.
3338078|NCT02161172||Mild traumatic brain injury|Traumatic brain injury patients with Glasgow coma score (GCS) of 13-15.
3236197|NCT01248247|Experimental|Group 3 - AZD6244 + MK-2206|AZD6244 100 mg by mouth daily of a 28 day cycle. MK-2206 100 mg by mouth every week of a 28 day cycle.
3236198|NCT01248247|Experimental|Group 4 - Sorafenib|Sorafenib 400 mg by mouth twice a day for a 28 day cycle.
3236199|NCT01248260|Experimental|Higher-strength folic acid|Higher-strength folic acid (4mg).
3338079|NCT02161198|Experimental|Y-75|volunteers receive 3 packages twice a day up to 14 weeks
3236200|NCT01248260|No Intervention|Low-strength folic acid|Low-strength (0.8mg) folic acid (standard of care)
3236201|NCT01248273|Experimental|immunization|This trial will investigate the safety and immune responses following immunization with the unimolecular pentavalent Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21. This is a phase I study to assess toxicity and immunogenicity.
3236202|NCT01248286|Experimental|Whole grain rice|
3338080|NCT02161198|Placebo Comparator|Placebo|volunteers receive 3 packages twice a day up to 14 weeks
3338081|NCT02161211|Experimental|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
3338082|NCT02161211|Experimental|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
3338083|NCT02161211|Experimental|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
3338084|NCT02161224|Experimental|1: FG-4592 in subjects with moderate hepatic impairment|
3338085|NCT02161224|Experimental|2: FG-4592 in healthy subjects|
3338086|NCT02161237|Experimental|standard dose group|Oral
3338087|NCT02161237|Experimental|optimized dose group|Oral
3338088|NCT02161250|Experimental|Resistant starch|The test beverage consumed has the resistant starch.
3338089|NCT02161250|Experimental|Control|The control beverage uses maltodextrin rather than the resistant starch.
3338090|NCT02161276|Experimental|TNTL capsule and Placebo|3-4 capsules 3 times a day Used before meals
3338091|NCT02161302|Experimental|Active tDCS|tDCS will be applied in the head of the patients in 20 minute sessions, daily from Monday to Friday for 2 weeks (10 sessions total). The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area, and it will use a 2 mA current.
3338092|NCT02161302|Sham Comparator|tDCS Sham|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
3338093|NCT02161315||Observation group|Steroid Aromatase Inhibitors
3338094|NCT02161315||Control group|Non-Steroid Aromatase Inhibitor
3338095|NCT02161328||ICU patients undergoing a dilatative tracheotomy.|
3338096|NCT02161354|Experimental|2mg dose of NTC-510 or placebo|Subjects will be dosed with 2 mg of NTC-510 or placebo.
3338097|NCT02161354|Experimental|4 mg dose of NTC-510 or placebo|Subjects will be dosed as a split dose of 2 mg followed by 2 mg an hour later of NTC-510 or placebo.
3338098|NCT02161354|Experimental|6 mg dose of NTC-510 or placebo|Subjects will be dosed with 6 mg of NTC-510 or placebo.
3338099|NCT02161354|Experimental|2 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 2mg of NTC-510A or placebo
3338100|NCT02161354|Experimental|4 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 4 mg of NTC-510A or placebo
3236203|NCT01248286|Active Comparator|Refined grain rice|
3236204|NCT01248299|Experimental|Chemotherapy plus best supportive care|Chemotherapy plus best supportive care with follow up at each cycle of the treatment with FU-CDDP; LV5FU2-CDDP; FOLFOX; TPF
3338101|NCT02161354|Experimental|6 mg dose of NTC-510, NTC-510A or placebo|Subjects will be dosed with 6 mg of NTC-510A or placebo
3236205|NCT01248299|Active Comparator|Best supportive care|Best supportive care with follow up every 6 weeks
3236206|NCT01248312||morbidly obese|BMI >45
3236207|NCT01248312||thin patients|BMI <45
3236208|NCT01248325|Experimental|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
3338102|NCT02161367|Experimental|Simethicone, OVOL|Patients in the intervention arm will receive, in a blinded fashion, 160mg of simethicone orally four times a day for the first five postoperative days. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
3338103|NCT02161367|Placebo Comparator|Oral Suspending Vehicle, Ora-Plus|Patients in the control arm will receive, in a blinded fashion, 160mg of the placebo orally four times a day for the first five postoperative days. The placebo will be prepared by pharmacy to be identical to the test drug formulation except for being pharmacologically inert. Patients will be evaluated by a trained research assistant on a daily basis while in hospital. Passage of flatus, bowel movements, and postoperative pain will be evaluated at those visits. A two-week, and 30-day phone call to patients discharged from hospital will be done to assess for outcomes after discharge. Follow-up will end after the 30th postoperative day.
3236209|NCT01248325|Active Comparator|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
3236210|NCT01248338|Active Comparator|metoprolol, tablets|metoprolol succinate 50-100 mg orally daily for one year
3236211|NCT01248338|Experimental|nebivolol|nebivolol 5 mg capsule once daily for one year
3236212|NCT01248351|Experimental|autologous stored platelets|
3236213|NCT01248377||Cephalosporins allergic patients|
3236214|NCT01248390|Experimental|Interactive Metronome therapy|Fifteen one-hour training sessions using Interactive Metronome system, in addition to treatment as usual.
3236215|NCT01248390|No Intervention|Treatment as Usual|Standard of care symptom management.
3236216|NCT01248403|Active Comparator|paclitaxel + placebo|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ Placebo (2 tablets / day) d1-d28"
3236217|NCT01248403|Experimental|paclitaxel + RAD001|"Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.~+ RAD001 10mg (2 x5 mg tablets / day) d1-d28"
3338104|NCT02161380|Experimental|1 Chronic Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
3338105|NCT02161380|Experimental|2 Acute Bilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
3338106|NCT02161380|Experimental|3 Acute Unilateral Severe Vision Loss|injection of scAAV2-P1ND4v2
3338107|NCT02161393|Experimental|Physical Activity Intervention|12 week home-based walking programme consisting of weekly physical activity consultations and a pedometer-driven walking programme
3338108|NCT02161393|Active Comparator|Pulmonary Rehabilitation Programme|6-week supervised outpatient programme consisting of twice-weekly exercise sessions and once-weekly education sessions.
3338109|NCT02161419|Active Comparator|BAY1000394|Roniciclib 5 mg bid 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
3338110|NCT02161419|Placebo Comparator|Placebo|Matching placebo 3 days on / 4 days off in combination with chemotherapy (carboplatin/etoposide or cisplatin/etoposide) during 6 cycles (21 days each) followed by monotherapy
3338111|NCT02161432|Experimental|Treatment A|single dose of BI 187004 in fasted state
3236218|NCT01248429||Patient treated by TKI|Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week
3236219|NCT01248442|Experimental|Cholecalciferol|
3338112|NCT02161432|Experimental|Treatment B|single dose of BI 187004
3338113|NCT02161432|Experimental|Treatment C|single dose of BI 187004 in fed state
3236220|NCT01248442|Placebo Comparator|Placebo|
3236221|NCT01248481||Group 1|
3236222|NCT01248494|Experimental|BEZ235 + Letrozole|
3338114|NCT02161445||AHF group|patients with AHF diagnosed based on clinical, biological and echocardiographic findings. Two sub-groups of patients were identified within HF group: Patients with reduced (<45%) LVEF (HFrEF) and those with preserved (≥45%) LVEF (HFpEF).
3338115|NCT02161445||non AHF group|we included patients with acute dyspnea and for whom acute heart failure was excluded
3338116|NCT02161471||Aortic coarctation|Patients after repair of coarctation of the aorta
3338117|NCT02161471||Tetralogy of Fallot|Patients after repair of tetralogy of Fallot
3338118|NCT02161471||TGA atrial switch|Patients with transposition of the great arteries after atrial switch (Senning procedure)
3338119|NCT02161471||TGA arterial switch|Patients with transposition of the great arteries after arterial switch operation
3338120|NCT02161471||Normal|Normal controls
3338121|NCT02161510|Experimental|Part I: MK-2248 200 mg (Panel A)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
3338122|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel B)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338123|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel C)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth for 7 days.
3236223|NCT01248494|Experimental|BKM120 + Letrozole|
3236224|NCT01248494|Experimental|Intermittent BKM120 + Letrozole|
3236225|NCT01248520|Placebo Comparator|General health information|Pregnant women receiving text messages containing general health messages without including information regarding the importance of the influenza vaccination
3236226|NCT01248520|Active Comparator|Influenza and general health information|Pregnant women receiving text messages with influenza facts and the importance of the influenza vaccination, as well as general health messages Intervention: Text messages with influenza facts
3338124|NCT02161510|Experimental|Part I: MK-2248 ≤800 mg (Panel D)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338125|NCT02161510|Experimental|Part II: MK-2248 200 mg (Panel E)|HCV participants will take MK-2248 200 mg by mouth once daily for 7 days.
3236227|NCT01248546||Digital mammography|
3236228|NCT01248572|Experimental|Softec HD IOL|
3236229|NCT01248611|Experimental|fentanyl|cancer patients with pain
3236230|NCT01248624|Active Comparator|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
3236231|NCT01248624|Placebo Comparator|Conventional Cancer Care|This control arm receives standard cancer care.
3236232|NCT01248637||Pimonidazole hydrochloride|Oral pimonidazole is administered at a dose of 0.5gm/m2 once approximately 24 hrs prior to surgery
3236233|NCT01248650|Active Comparator|TRK-820 5 μg|Taking TRK-820 5μg(two 2.5μg soft capsules) once on the first day of hospitalization by oral route
3236234|NCT01248650|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg soft capsule) once on the first day of hospitalization by oral route
3338126|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel F)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338127|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel G)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338128|NCT02161510|Experimental|Part II: MK-2248 ≤800 mg (Panel H)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338129|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel I)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338130|NCT02161510|Experimental|Part III: MK-2248 ≤800 mg (Panel J)|Based on safety, PK, and PD data from the preceding panel, HCV participants will take MK-2248 at approximately ≤800 mg by mouth once daily for 7 days.
3338131|NCT02161588|Experimental|Semaglutide|
3338132|NCT02161588|Placebo Comparator|Placebo|
3338133|NCT02161601|Experimental|Correctly and incorrectly applied cricoid pressure|
3338134|NCT02161614|Placebo Comparator|Placebo|Patients will use placebo for 30 days
3338135|NCT02161614|Experimental|Estradiol Valerate|patients will use estradiol valerate 1mg/day during 30 days
3338136|NCT02161627|Experimental|Automatic Control|Automatic Control using Saluda Medical External Trial System
3338137|NCT02161627|Active Comparator|Manual Control|Manual Control using Saluda Medical External Trial System
3338138|NCT02161640||Control|Age/sex matched control participants, not suffering from inflammatory bowel disease or any other chronic inflammatory disease
3338139|NCT02161640||Inflammatory Bowel Disease|Patients with active or remissive inflammatory bowel disease
3338140|NCT02161653|No Intervention|Prednisone|Prednisone 40 mg daily by mouth during 30 days.
3338141|NCT02161653|No Intervention|Pentoxifylline|Pentoxifylline 400 mg thrice in day by mouth during 30 days
3338142|NCT02161653|Experimental|Prednisone plus metadoxine|Prednisone 40 mg daily by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
3338143|NCT02161653|Experimental|Pentoxifylline plus metadoxine|Pentoxifylline 400 mg thrice in day by mouth plus Metadoxine 500 mg thrice in day by mouth during 30 days.
3338144|NCT02161666||Patients|Morbidly obese patients with normal glucose tolerance undergoing gastric bypass surgery
3338145|NCT02161666||Controls|Age, sex and BMI-matched healthy controls
3338146|NCT02161679|Experimental|IMMU-132|IMMU-132 infusion is administered
3338147|NCT02161679|Active Comparator|IMMU-132 plus Carboplatin|IMMU-132 infusion and Carboplatin infusion are administered to the participants in this arm of study.
3338148|NCT02161692|Experimental|High dose chemotherapy|"Characterized by the following sequence:~High dose cyclophosphamide (7 grams/squared meter) x 1 cycle 2 cycles of high-dose etoposide and cisplatin~1 cycle of high dose carboplatin (Area Under the Curve 27) with stem cell rescue"
3338149|NCT02161692|Active Comparator|Conventional dose chemotherapy|Cisplatin, Etoposide, and Bleomycin (PEB) x 4 cycles
3338150|NCT02161744|Experimental|ADSCs administration|Patients with Chronic Obstructive Pulmonary Disease will be treated with a single dose of autologous adipose derived stem cells. Stem cells will be isolated using standard Lipoaspiration procedure under sterile conditions.
3338151|NCT02161770|Other|Normal hepatic function|Patients without a history or presence of hepatic disease
3236235|NCT01248663|Active Comparator|antecolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing an antecolic duodeno-jejunostomy
3236236|NCT01248663|Experimental|retrocolic reconstruction|After completion of pancreaticoduodenectomy and reconstruction of the pancreaticojejunostomy and hepaticojejunostomy, the reconstruction of the intestinal passage will be conducted by performing a retrocolic duodeno-jejunostomy
3338152|NCT02161770|Other|Mild hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh A
3338153|NCT02161770|Other|Moderate hepatic impairment|Patients defined by the Child-Pugh classification system to be Child-Pugh B
3338154|NCT02161783||Treatment|This regimen consists of cyclophosphamide and fludarabine with low dose total body irradiation (TBI), followed by hematopoietic stem cell infusion.
3338155|NCT02161796|Experimental|1: young male subjects|3x single dose of FG-4592 and a placebo
3338156|NCT02161796|Experimental|2: young female subjects|3x single dose of FG-4592 and a placebo
3338157|NCT02161796|Experimental|3: elderly male subjects|3x single dose of FG-4592 and a placebo
3338158|NCT02161796|Experimental|4: elderly female subjects|3x single dose of FG-4592 and a placebo
3338159|NCT02161809|Experimental|Physical Activity Intervention|This arm (10 summer day camps) will receive the Physical Activity intervention the first year and both healthy eating and physical activity the second and thrid years.
3338160|NCT02161809|Other|Healthy EAting Intervention|This arm (10 summer day camps) will receive the Healthy Eating intervention the first year and both healthy eating and physical activity the second and thrid years.
3338161|NCT02161822|Experimental|Simvastatin|single arm : Simvastatin
3236237|NCT01248689|Active Comparator|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
3236238|NCT01248689|Active Comparator|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
3236239|NCT01248689|Active Comparator|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
3338162|NCT02161835|Experimental|Training|Participants exercise 3 times a week, 30 minute, on an ergometer bike.
3338163|NCT02161835|No Intervention|Control|Participants is tested with the 4 objective myotonia test and measurements of self-assessed myotonia by the Myotonia Behavior Scale is collected.
3338164|NCT02161848||Patients|Patients with verified singe large-scale mtDNA deletions and chronic progressive external ophthalmoplegia.
3338165|NCT02161848||Controls|Healthy controls matched for age and gender.
3338166|NCT02161848||Patient group as Controls|Patients with mitochondrial DNA 3243A>G mutations
3338167|NCT02161861|Experimental|group cFEE|"The group cFEE will be similarly inseminated with 100000/ml motile spermatozoa and will be supplemented with cFEE 100µM during 18 hours.~The cFEE will increase the fusiogenic capacities of a gamete,"
3338168|NCT02161861|No Intervention|untreated group|control group
3338169|NCT02161874|Experimental|T3 with DCD tapered implant|T3 with DCD tapered prevail implant
3338170|NCT02161874|Active Comparator|Nanotite certain tapered implant|Nanotite Certain tapered implant
3338171|NCT02161887||Complementary Medicine Group|Patients receiving chiropractic care, acupuncture, or meditation for chronic pain
3338172|NCT02161887||Conventional Medicine Group|Patients receiving conventional medicine care (physical therapy, medication management) for chronic pain.
3338173|NCT02161900|Active Comparator|Routine exercise|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
3338174|NCT02161900|Experimental|Yogic and Routine exrcises (exercise I)|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
3236240|NCT01248702|Experimental|Critical Pathway|
3236241|NCT01248702|No Intervention|Standard Practice|
3338175|NCT02161913|Active Comparator|SCI Education Control Group|The SCIEC condition is a 16-session, highly structured educational intervention that provides information on how SCI affects the body; methods for maximizing function, coping, and living with SCI; and staying healthy with SCI. It also includes general guidelines for improving health behavior. Each SCIEC session follows the same structure, beginning with a presentation of the objectives for the current session and a brief review of material from the previous session before introducing the session's topic and presenting information on one or two key problem areas. SCIEC utilizes a traditional didactic model with information delivered by an expert SCI educator in a classroom or lecture setting.
3338176|NCT02161913|Experimental|Multi-family Group Treatment|The MFG Program uses a structured problem-solving and skills training program to provide participants with SCI and their caregivers with tools and information to improve coping and help family members to connect through positive behavioral exchanges. MFG educators are health professionals with experience in management of SCI, such as physical therapists, recreational therapists, occupational therapists, and psychologists. MFG will last for 16 sessions across 9 months.
3338177|NCT02161926|Experimental|obese men from 60 to 70 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
3338178|NCT02161926|Active Comparator|obese men from 30 to 40 years old|Dietary restrictions in obese men (30<Body Mass Index<40 kg/m2)
3338179|NCT02161952|Experimental|Pirfenidone|Pirfenidone 400 mg capsules, orally administered thrice daily to yield a daily dose of 1200 mg during two years.
3338180|NCT02161952|Placebo Comparator|Matched equivalent placebo|Matched equivalent placebo
3338181|NCT02161965|Experimental|Rivaroxaban|"Rivaroxaban (oral tablet) for patients with atrial fibrillation:~20 mg once daily for patients with GFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with GFR of 15 to 49 ml.~Rivaroxaban (oral tablet) for patients with pulmonary embolism: 2 x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
3338182|NCT02161965|Active Comparator|vitamin K antagonists|Adjusted dose of warfarin or fluindione (oral tablet) titrated according to target international normalized ratio with a target range 2.0 to 3.0.
3338183|NCT02161991|Experimental|aprepitant group|Patients assigned to aprepitant group should receive aprepitant for the control of CINV, aprepitant 125 mg for day1, 80mg for day2 and day3.
3338184|NCT02161991|Placebo Comparator|placebo|Patients assigned to placebo group should receive placebo for the control of CINV compared with aprepitant group.
3338185|NCT02162004|Experimental|Continuous correction|The insulin pump is set to automatically deliver the patient's usual insulin basal rate. The insulin pump bolus calculator is run every 10 minutes by the attending physician. Bolus calculations are based on glucose sensor values.
3338186|NCT02162004|No Intervention|Control|Regular sensor-augmented pump therapy.
3338187|NCT02162017|Experimental|The lying flat intervention|Patients in lying flat intervention to be nursed lying flat (0°) immediately after diagnosis of acute stroke is made and to remain in this position for 24 hours
3338188|NCT02162017|Active Comparator|The sitting-up intervention|Patients in the sitting up intervention to be nursed with their head elevated (≥30°) by raising the head of the bed (or with extra pillows or wedge) immediately after the diagnosis of acute stroke is made, and to remain in this position for the next 24 hours
3338189|NCT02162030|Other|Full ACT|Acceptance and Commitment Therapy
3338190|NCT02162030|Other|Modified ACT|Acceptance and Commitment Therapy
3338191|NCT02162043||Usability assessment|Patients without any experience with visual field testing will be recruited and tested with different versions of the developed self-test. This will help identify usability features that will make the test user-friendly.
3338192|NCT02162043||Hospital-based clinical trial|The new test will be evaluated on patients attending Manchester Royal Eye Hospital to provide an estimate of its diagnostic performance.
3338193|NCT02162043||Community-based trial|Patients attending Manchester Royal Eye Hospital's outpatient clinics will be recruited to trial the new test on their friends and family in order to evaluate the uptake and performance of the new test in a home environment without any researchers/clinicians presence.
3338194|NCT02162056|Experimental|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffold for coronary artery disease.
3338195|NCT02162069|Experimental|transcatheter aortic valve replacement|Patients receive transcatheter aortic valve replacement.
3338196|NCT02162082|Experimental|stent or scaffold|implantation of stents or scaffolds after recanalization of coronary chronic total occlusions
3338197|NCT02162095||Chronic obstructive pulmonary disease|Approximately 100 participants with documented chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) < 0.7).
3338198|NCT02162095||Control|Approximately 100 participants with exclusion of chronic obstructive pulmonary disease (post-bronchodilator Forced expiratory volume in 1 second (FEV1)/Forced vital capacity (FVC) > 0.7).
3338199|NCT02162121|Experimental|Stimulating catheter|"After Spinal Anesthesia (Levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15 ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
3236242|NCT01248754|Experimental|18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
3236243|NCT01248806||Smokers or former smokers, Aged ≥ 50|Men and women current daily smokers or former smokers, Aged ≥ 50
3236244|NCT01248819|Active Comparator|Instillation|Instillation of Ropivacaine 100 mg in the abdominal cavity
3236245|NCT01248819|Experimental|Nebulization|Nebulization of Ropivacaine 60 mg in the abdominal cavity
3236246|NCT01248832|Experimental|Telephone Counseling|Telephone Counseling
3236247|NCT01248832|Active Comparator|Self-help Materials|Self-help Materials
3259250|NCT01469104|Active Comparator|CHO-free diet|After receiving a standard diet on day 1, a carbohydrate-free diet will be provided on days 2, 3, and 4.
3338200|NCT02162121|Active Comparator|Non-stimulating catheter|"After Spinal Anesthesia (levobupivacaine 0,5% 15mg) all patients in the arm will receive continuous lumbar plexus block with non-stimulating catheter (Stimolong, Pajunk, Germany). Mepivacaine 1% 15ml will be administrated. As post-operative analgesia Ropivacaine 0,2% will be continuous administrated."
3338201|NCT02162134|Other|no chewing gum.|the no chewing gum group was control and receive no chewing gum postoperatively. While they received all other medications like anesthesia, antibiotics etc
3338202|NCT02162134|Experimental|sugar free chewing gum|sugar free chewing was given to patients 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started.
3338203|NCT02162134|Experimental|sugared chewing gum|sugared chewing gum will be given 4 hours after surgery then continue it 8 hourly (20 to 25 minutes each time) until oral feeding is started
3338204|NCT02162160|Experimental|Probiotic creme|Women receing probiotic creme
3338205|NCT02162160|Placebo Comparator|placebo|Women receiving a moisturizer
3338206|NCT02162173|Experimental|Endoscopy|All patients underwent the same endoscopy.
3338207|NCT02162199|Experimental|Debio 1450|Debio 1450 40 mg, capsules, orally, once in the morning under fasted conditions
3338208|NCT02162199|Placebo Comparator|Placebo|Placebo 0 mg, matching capsules, orally, once in the morning under fasted conditions
3338209|NCT02162212|Active Comparator|ADA guideline Instructed|The control intervention will be instruction in basic wellness activities according to the American Diabetes Association guidelines
3236248|NCT01248858|Experimental|GSK2126458 and GSK1120212|The first combination schedule that will be tested involves giving both GSK2126458 and GSK1120212 continuously once a day in the morning until the subjects withdraw from the study. Other dosing schedules with both drugs will also be tested and these schedules are described below GSK2126458 will be dosed twice per day (morning and evening) continuously and GSK1120212 will be dosed once a day in the morning on a continuous schedule. Subjects will be treated with both drugs and remain in the study as long as they are benefiting from therapy. Another schedule that will be tested involves giving GSK2126458 twice each day (morning and evening) on an intermittent schedule (4 days of treatment, 10 days rest, then 4 days treatment, 10 days rest). GSK1120212 will be dosed once each day in the morning on a continuous schedule. Subjects will be treated with both drugs as long as they are benefiting from therapy.
3236249|NCT01248871|Active Comparator|SEVO|sevoflurane-remifentanil/sufentanil combination
3338210|NCT02162212|Experimental|Optimized Shoulder Movement Program|"The experimental intervention is the Optimized Shoulder Movement Program. Participants will be trained in a progressive home exercise program that includes passive stretching of end range shoulder flexion and external rotation, and active shoulder motion based on the participant's baseline activity count ."
3338211|NCT02162225|Experimental|Beet Juice|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
3338212|NCT02162238|Placebo Comparator|purified water|Filtered water Pump water purified by the LSF-filtering device Intervention: Device: LSF-filtering device
3236250|NCT01248871|Active Comparator|SERE|volatile agent only during reperfusion
3236251|NCT01248871|Active Comparator|propofol|propofol-remifentanil/sufentanil
3338213|NCT02162238|Experimental|zinc enriched purified water|Zinc water water purified and zinc-enriched by the LSF-filtering device Intervention: Device: LSF-filtering device
3338214|NCT02162251||E2020|
3236252|NCT01248897||erbB2+/Her2 Breast Cancer Patients|erbB2+/Her2 Breast Cancer Patients Treated with Lapatinib and Other Anti-erbB2/Her2 Therapy
3236253|NCT01248910|Experimental|Alpine Skiing|
3236254|NCT01248910|No Intervention|Control group|
3338215|NCT02162264||E2020|
3338216|NCT02162277||Osteoporosis diagnostic kit|
3236255|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + G-CSF|
3236256|NCT01248923|Experimental|ARRY-520 (Schedule 1) + bortezomib + dexamethasone + G-CSF|
3236257|NCT01248923|Experimental|ARRY-520 (Schedule 2) + bortezomib + dexamethasone + G-CSF|
3236258|NCT01248975|Experimental|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)|FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
3338217|NCT02162290|Experimental|Interval exercise|Exercise bouts in low and high intensities
3338218|NCT02162290|Experimental|Continuous exercise|Exercise continuously with moderate intensity
3338219|NCT02162303|Experimental|Colchicine|Colchicine 0.6 mg tablets,once daily, for 6 months
3338220|NCT02162303|Placebo Comparator|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment.
3338221|NCT02162316|Active Comparator|H.Pylori eradication therapy|A-cillin®, Pantoline® and Clari® is administered with a tablet of placebo (Motilitone®)
3338222|NCT02162316|Experimental|Motilitone®|30 mg is administered with 3 tablets of placebo (Patoline®, Clari® and A-cilin)
3338223|NCT02162329|Other|Healthy Control Group|Healthy participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete. Electroencephalography (EEG) and magnetic resonance imaging (fMRI) scan performed. These should take a total of about 90 minutes to complete.
3236259|NCT01248975|Active Comparator|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)|FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
3236260|NCT01248975|Placebo Comparator|FP/SAL 250/50mcg BID plus placebo BID|P/SAL 250/50mcg BID plus placebo BID
3236261|NCT01248988||Synflorix Group|Infants and children who received at least one dose of Synflorix™ as a part of routine practice at a private clinic or hospital
3236262|NCT01249001|Experimental|Group 1|This group will receive oral aprepitant on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the capsule on the first day of the second study cycle of chemotherapy.
3338224|NCT02162329|Experimental|Tibetan Meditation Group|Participants fill out several questionnaires at baseline, at completion of meditation classes, and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Electroencephalography (EEG) performed at baseline, at completion of classes, and at follow up visit. Participants have magnetic resonance imaging (fMRI) scan of brain at baseline, at completion of meditation classes, and at follow up visit. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
3338225|NCT02162329|Other|Wait-List Group|"Participants fill out several questionnaires at baseline and at follow up visit. The forms should take about 30 minutes to complete. Participants complete computer tests to check memory and concentration taking about 20 minutes to complete. Tests, EEG, and fMRI should take a total of about 90 minutes to complete. Participants receive the standard of care for cancer patients.~After 8 week follow up visit, Wait-List Group offered meditation program."
3338226|NCT02162342||Rehabilitative intervention|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
3236263|NCT01249001|Experimental|Group 2|This group will receive an aprepitant capsule on the first day of the first study cycle of chemotherapy. They will then cross-over to receive the oral aprepitant on the first day of the second study cycle of chemotherapy.
3236264|NCT01249014|No Intervention|Control|No peri-operative warming.
3338227|NCT02162355|Experimental|GLPG0634 in Japanese subjects|Per panel, 6 Japanese healthy subjects will receive one of the three doses (50 mg, 100 mg or 200 mg) of GLPG0634 as tablets once daily for 10 days
3338228|NCT02162355|Placebo Comparator|Placebo in Japanese healthy subjects|Per panel, 2 or 4 (last panel only) Japanese healthy subjects will receive placebo as tablets once daily for 10 days
3338229|NCT02162355|Experimental|GLPG0634 in Caucasian subjects|In the last panel, 6 Caucasian healthy subjects will receive one dose of GLPG0634 (200 mg) as tablets once daily for 10 days
3338230|NCT02162355|Placebo Comparator|Placebo in Caucasian healthy subjects|In the last panel, 4 Caucasian healthy subjects will receive receive placebo as tablets once daily for 10 days
3338231|NCT02162381|Experimental|methylphenidate provided|the study group will be given a single pill containing methylphenidate 10mg to be taken 2 hours before their visual field test
3338232|NCT02162381|Active Comparator|control|control group will not be given any placebo and will perform a repeat visual field testing without any prior preparation
3338233|NCT02162394||Referred for Holter monitoring|
3338234|NCT02162407|Experimental|Insulin detemir 60 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3338235|NCT02162407|Experimental|Insulin detemir 120 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3338236|NCT02162407|Active Comparator|Human insulin 6 pmol/kg/min|Subjects will be randomised to one of six treatment sequences (the 3 test drugs given at 3 different trial days 7-28 days apart in randomised order)
3338237|NCT02162420|Experimental|Treatment Plan for Dyskeratosis Congenita|Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, and total body irradiation, followed by stem cell transplant for the treatment of dyskeratosis congenita.
3338238|NCT02162420|Experimental|Treatment for Severe Aplastic Anemia|Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.
3338239|NCT02162459||whey beverage|consumption of 52 grams of whey protein supplement following resistance exercise
3236265|NCT01249014|Experimental|Warmed fluids|Patients will receive warmed i.v. fluids administered pre- and intra-operatively.
3236266|NCT01249014|Experimental|Warmed fluids and warm air|Patients will receive warmed i.v. fluids administered pre- and intra-operatively, and warmed air blown into a blanket covering the body intra-operatively.
3236267|NCT01249079||Schizophrenia Family|
3236268|NCT01249105|Experimental|Part 1|Patients with recurrent glioblastoma multiforme (GBM) who require reoperation.
3236269|NCT01249105|Experimental|Part 2|Participants with GBM and with anaplastic glioma
3236270|NCT01249144|Active Comparator|Tecnis Z9002 Intraocular Lens (IOL)|
3236271|NCT01249144|Active Comparator|Softec HD Intraocular Lens (IOL)|
3236272|NCT01249170|Other|First year fellow|
3236273|NCT01249170|Other|Second Year Fellow|
3236274|NCT01249183|Experimental|1- VAXIGRIP and REPEVAX concomitantly|
3236275|NCT01249183|Active Comparator|2-REPEVAX 28 days after VAXIGRIP|
3236276|NCT01249196|Placebo Comparator|Placebo|
3236277|NCT01249196|Experimental|SK-PC-B70M 200mg bid|
3236278|NCT01249196|Experimental|SK-PC-B70M 300mg bid|
3236279|NCT01249196|Other|Donepezil|
3236280|NCT01249209|Other|lifestyle advice|
3236281|NCT01249222|No Intervention|conventional treatment|
3236282|NCT01249222|Experimental|Plasmapheresis|
3236283|NCT01249235|Active Comparator|Patch|The operative eye will be patched.
3236284|NCT01249235|Experimental|Bandage Contact Lens|The operative eye will have a bandage contact lens
3236285|NCT01249248||Male basketball players|
3236286|NCT01249248||Female basketball players|
3236287|NCT01249248||Baseball players|
3236288|NCT01249248||Softball players|
3236289|NCT01249248||Football players|
3236290|NCT01249248||Female vollyball players|
3236291|NCT01249248||Male soccer players|
3236292|NCT01249248||Female soccer players|
3236293|NCT01249300||Dysphagia|Patients with CVA which causes dysphagia
3236294|NCT01249339|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes.
3236295|NCT01249339|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
3236296|NCT01249339|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes.
3236297|NCT01249339|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
3338240|NCT02162459||chocolate milk beverage|consumption of chocolate flavored milk following resistance exercise
3338243|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler|Single dose of Salmeterol/fluticasone Easyhaler
3338244|NCT02162485|Experimental|Salmeterol/fluticasone Easyhaler with charcoal|Single dose of Salmeterol/fluticasone Easyhaler with concomitant charcoal administration (Carbomix granules)
3338245|NCT02162485|Active Comparator|Seretide Diskus|Single dose of Seretide Diskus
3338246|NCT02162485|Active Comparator|Seretide Diskus with charcoal|Single dose of Seretide Diskus with concomitant charcoal administration (Carbomix granules)
3338247|NCT02162498|Experimental|Feeding buddies intervention|Sites receiving a comprehensive feeding buddy program implemented by the Window of Opportunity program.
3338248|NCT02162498|No Intervention|Standard of care|Sites from Window of Opportunity program who are not yet receiving the comprehensive feeding buddies program and are only receiving standard of care PMTCT support.
3338249|NCT02162511|Experimental|ARM A Malignant TBI|Malignant diseases Conditioning including total body irradiation and chemotherapy
3338250|NCT02162511|Experimental|ARM B Malignant Non-TBI|Malignant diseases chemotherapy based conditioning
3338251|NCT02162511|Experimental|ARM C Non-malignant|Non-malignant diseases Chemotherapy based conditioning
3338252|NCT02162524|No Intervention|No Exercise Control|Healthy Living Group
3338253|NCT02162524|Active Comparator|Aerobic Exercise Group|Persons are aerobically exercising.
3236298|NCT01249352|Active Comparator|STANDARD CHEMORADIATION|"Cisplatin 75 mg/m2, IV IV doses on D1 of each chemotherapy cycle, for 4 cycles Fluorouracil 1000 mg/m2, IV IV doses in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
3236299|NCT01249352|Experimental|CHEMORADIATION + NIMOTUZUMAB|"Nimotuzumab 200 mg, IV weekly IV doses for up to 26 weeks. Cisplatin 75 mg/m2, IV IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.~Fluorouracil 1000 mg/m2, IV IV dose in a 24-hour continuous infusion, from D1 to D4 of each chemotherapy cycle, for 4 cycles.~Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day Equivalent to 28 fractions for 5 and a half weeks."
3236300|NCT01249378|Active Comparator|10 g non emulsified of milk fat|They are compared using the repeated measurements taken within subjects
3338254|NCT02162537|Other|Arm A (standard arm)|Arm A: Initial Cerebral Radiotherapy and Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab)
3338255|NCT02162537|Other|Arm B (experimental arm)|Arm B: Chemotherapy (Cisplatin and pemetrexed with or without Bevacizumab) and Cerebral Radiotherapy if clinical or radiological progression brain
3338256|NCT02162550|Experimental|Bydureon|injectable medication Bydureon
3338257|NCT02162550|Placebo Comparator|Placebo|a similar looking injectable
3338258|NCT02162563|Experimental|Arm B: FOLFOXIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive 5FU, irinotecan, oxaliplatin (FOLFOXIRI) and bevacizumab.~Intervention: FOLFOXIRI with bevacizumab"
3236301|NCT01249378|Active Comparator|40 g non emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
3236302|NCT01249378|Active Comparator|40 g finely emulsified of milk fat|The subjects receive three sequences of different breakfasts. They are compared using the repeated measurements taken within subjects.
3236303|NCT01249391|Active Comparator|Intervention (splinting)|Splinting of nominated joint in this group
3236304|NCT01249391|No Intervention|Control|Observation and usual treatment only.
3236305|NCT01249430|Experimental|Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)|Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8. Treatment continues for 1 course in the absence of disease progression or unacceptable toxicity.
3236306|NCT01249443|Experimental|Treatment (carboplatin, paclitaxel)|"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.~Before February 1, 2013, patients also received vorinostat PO once daily on days 1-5 with paclitaxel and carboplatin."
3236307|NCT01249456||Femara(Letrozole)|
3236308|NCT01249469|Placebo Comparator|Vehicle|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
3236309|NCT01249469|Experimental|Skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand.
3338259|NCT02162563|Active Comparator|Arm A: FOLFOX/FOLFIRI & bevacizumab (inclusion completed)|"Patients with RAS or BRAF mutated and/or right-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
3338260|NCT02162563|Experimental|Arm D: FOLFOX/FOLFIRI & panitumumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus panitumumab.~Intervention: FOLFOX/FOLFIRI with panitumumab"
3236310|NCT01249482||Late eradication|Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
3338261|NCT02162563|Active Comparator|Arm C: FOLFOX/ FOLFIRI & bevacizumab|"Patients with RAS and BRAF wildtype and left-sided tumors will receive doublet fluoropyrimidine-containing chemotherapy (FOLFOX or FOLFIRI), plus bevacizumab.~Intervention: FOLFOX/FOLFIRI with bevacizumab"
3338262|NCT02162589||POEM for Achalasia|Any patient who has undergone clinically indicated and/or standard of care POEM for the treatment of Achalasia.
3338263|NCT02162615||Restorelle Direct Fix A|Anterior/Apical prolapse repair with Restorelle Direct Fix A
3338264|NCT02162615||Native Tissue Repair Anterior|Anterior/Apical prolapse repair with native tissue only
3236311|NCT01249482||Negative HP|For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
3236312|NCT01249482||Early eradication|Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
3236313|NCT01249508|Experimental|implemented nutrition label|A one-group pre-/post-design is used for the evaluation of the university canteen-based nutrition labeling program. This means that all participants of the program are exposed to the nutrition label implemented in the university canteen. The subject essentially serves as its own control based on pre-test behaviour. The nutrition label implemented is a star rating label calculated and assigned to each meal offered at the university canteens and based on the content of energy, saturated fat, sodium and fibre (expressed as vegetable portion).
3338265|NCT02162615||Restorelle Direct Fix P|Posterior/Apical prolapse repair with Restorelle Direct Fix P
3338266|NCT02162615||Native Tissue Repair Posterior|Posterior/Apical prolapse repair with native tissue only
3338267|NCT02162628||Exair for Total Repair|Total repair with Exair Prolapse Repair System alone or in combination with native tissue repair
3338268|NCT02162628||Total Native Tissue Repair|Total repair with native tissue only
3338269|NCT02162641||SCC of the anus|
3338270|NCT02162654|Active Comparator|Remote ischemic preconditioning|Inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
3338271|NCT02162654|Sham Comparator|Sham preconditioning|Sham inflation of a blood pressure cuff around an arm with the patient under general anesthesia prior to start aneurysm treatment
3236314|NCT01249534||Patients after gastroesophageal cancer surgery|
3236315|NCT01249547|Experimental|axitinib arm|
3236316|NCT01249560||raltegravir|"To illustrate the cause and effect relationship between the abnormalities of the distribution(casting) of the molecules of co-activation and the rate of apoptose, we compare also 2 groups: a first group of patients with a rate of apoptose normal ( n=10 ), and another group of patients having a rate of apoptose aggravated ( n=10 ).~20 eligible patients will receive their treatment to J1 and will be estimated for the residual concentration of the raltegravir ®, the antiretroviral activity, the tolerance and the observance at the treatments of the study in the visits of evaluation of M1, M2, M3, M6, M12, and / or in case of premature stop(ruling) of the try(essay). Every visit will give rise to a clinical evaluation of the patient. The arisen of unwanted events"
3236317|NCT01249573|Experimental|fascia therapy|arm where fascia therapy is used as a treatment for an acute ankle distortion
3338272|NCT02162693|Experimental|Mesenchymal progenitor cells|Administrated for intra-articular use of Mesenchymal progenitor cells
3338273|NCT02162693|Active Comparator|Sodium Hyaluronate|Administrated for intra-articular use of Sodium Hyaluronate.
3338274|NCT02162732|Experimental|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3338275|NCT02162745|Experimental|Isotonic solution (NaCl 0.9%)|Single nasal irrigation with 1 ml of isotonic solution (NaCl 0.9%) per each nostril
3338276|NCT02162745|Experimental|Hypertonic solution (NaCl 3%)|Single nasal irrigation with 1 ml of hypertonic solution (NaCl 3%) per each nostril
3338277|NCT02162745|No Intervention|Supportive care|Wiping the nose, positioning the child, changing a wet diaper, feeding.
3338278|NCT02162784|Experimental|Budesonide/procaterol 180/10mcg X1|HFA MDI, oral inhalation, 180/10mcg, one puff
3338279|NCT02162784|Experimental|Budesonide/Procaterol, 180/10mcg X2|HFA MDI, oral inhalation, two puffs
3338280|NCT02162784|Active Comparator|Albuterol HFA MDI 100 mcg X2|HFA MDI, oral inhalation, 100mcg, two puffs
3338281|NCT02162797|Experimental|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
3338282|NCT02162797|Experimental|zinc supplementation|Intervention group A. Patients who will orally receive zinc for 3 months.
3338283|NCT02162810|Active Comparator|oral steroids|Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
3338284|NCT02162810|Placebo Comparator|placebo-controlled|Simple Syrup will be used as the placebo
3338285|NCT02162823||Pancreatic cancer|Patients with pancreatic cancer and age&sex-matched controls without any cancer from a distinct population area (district of Stockholm). Patients with pancreatic cancer will be subjected to pancreatic surgery
3338286|NCT02162836|Experimental|Cohort 1|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
3338287|NCT02162849|Experimental|Varenicline + Placebo Patch|"Varenicline dosing follows the recommended 12 week course: 0.5 milligram mg/day by mouth for Days 1-3, 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter. Participant takes Varenicline 1-10 days after Visit 1.~Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo. Some of the counseling sessions may be recorded by video and/or audio tape.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
3338288|NCT02162849|Experimental|Nicotine Patch + Placebo Tablet|"Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.~Starting on Day 8, and then every day after that, participant applies 1 nicotine patch.~Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone.~Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. During counseling on Day 8, participant sets a quit date for stopping smoking for about 1 week after participant starts taking the study drug/placebo.~Study staff calls participant 1 day before quit date and 3 days after quit date to check on progress in quitting smoking."
3236318|NCT01249573|Experimental|transcutaneous fibrolysis|arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion
3236319|NCT01249573|Placebo Comparator|placebo|arm where placebo therapy is used as a treatment for an acute ankle distortion
3236320|NCT01249586|Placebo Comparator|Traditional teaching|A traditional class of blindness prevention.
3236321|NCT01249612|Placebo Comparator|Control treatment|Elbow joint icing using two plastic bags with crushed ice
3236322|NCT01249612|Active Comparator|Active treatment|Knee joint icing using two plastic bags with crushed ice
3236323|NCT01249638|Experimental|Cap+Bev until PD followed by CAPIRI +Bev|"Capecitabine + Bevacizumab~In case of Progression Escalation to:~Capecitabine + Irinotecan + Bevacizumab"
3338289|NCT02162875|Experimental|MDA once a year|Community wide treatment (CWT) once a year for four years with single dose praziquantel 40mg/kg
3338290|NCT02162875|Experimental|MDA 2nd year CWT follwed by 2 years SBT|Treatment with praziquantel as arm 1 given by two years of community wide treatment (CWT) followed by two years of school-based treatment (SBT)
3338291|NCT02162875|Experimental|Praziquantel every second year CWT|Treatment with praziquantel given every second year as CWT
3338292|NCT02162875|Experimental|MDA once a year SBT|Treatment with praziquantel as above given as 4 years of SBT
3338293|NCT02162875|Experimental|MDA given for 2 years as SBT|Treatment with praziquantel as above given for 2 years as SBT followed by 2 years without MDA
3338294|NCT02162875|Experimental|MDA as SBT 1year and 1 year without MDA|Treatment with praziquantel given as one years of SBT alternating with one year without treatment
3338295|NCT02162888|Other|Eagle-BDM; Teva-BDM; Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
3338296|NCT02162888|Other|Teva-BDM; Eagle-BDM;Teva-BDM|Eagle-BDM: IV Teva-BDM: IV
3338297|NCT02162888|Other|Teva-BDM, Teva-BDM, Eagle-BDM|Eagle-BDM: IV Teva-BDM: IV
3236324|NCT01249638|Active Comparator|Capiri + Bev|Capecitabine + Irinotecan + Bevacizumab
3236325|NCT01249677|Experimental|insulin glargine|patients with type 2 diabetes on previous therapy with metformin were examined before and after eight weeks of treatment with insulin glargin, aimed to normalize fasting plasma glycaemia
3236326|NCT01249690|Experimental|PAD|
3338298|NCT02162901|Experimental|Choice-Class with IVR Calls|Participants enrolled in this arm of the study will have chosen to attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months.
3236327|NCT01249690|Experimental|TAD|
3236328|NCT01249755||delirious patients|The cohort is divided in delirious and non-delirious patients
3236329|NCT01249768||Cohort|The cohort will consist of 150 patients with a hypokinetic rigid syndrome and a disease duration of maximum 36 months
3236330|NCT01249781||resilience in caregivers whose child with ALL|
3236331|NCT01249794|No Intervention|Best available treatment|
3236332|NCT01249794|Experimental|non invasive ventilation|
3338299|NCT02162901|Experimental|Choice-DVD with IVR calls|Participants enrolled in this arm of the study will have chosen to watch a DVD at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3338300|NCT02162901|Experimental|Random-Class with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3338301|NCT02162901|Experimental|Random-DVD with IVR calls|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will be given a DVD to watch at home to be introduced to the educational intervention, and will then receive follow-up/support IVR calls for a period of 12 months
3338302|NCT02162901|Active Comparator|Random-Class only|Participants randomized to this arm of the study will be randomized a second time into one of three groups. Participants in this group will attend one 2-hour class to be introduced to the intervention and will receive a workbook to use at home.
3338303|NCT02162914|Active Comparator|Regorafenib/active|Subjects randomized to be treated with Regorafenib (active product) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
3338304|NCT02162914|Placebo Comparator|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib (placebo) will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off). Duration of one cycle is 28 days.
3338305|NCT02162927|Experimental|Potassium Nitrate (N)|This involves 1 serving (2 pills) of potassium nitrate KNO3- (N) (8 mmols NO3-). The supplementation period is six days. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
3338306|NCT02162927|Placebo Comparator|Potassium Chloride|This involves 1 serving (2 pills) of the nitrate-free placebo (PL) potassium chloride (8 mmol KCl) for a six-day supplementation period. This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
3236333|NCT01249807||1|Patients, Family, Community member
3338307|NCT02162940||patients taking statins|Visual anlogue score vas used to evaluate pain. The SF 36 test was used to evaluate quality of life.
3338308|NCT02162940||patients not taking statins|Visual anlogue score vas used to evaluate pain.The SF 36 test was used to evaluate quality of life.
3338309|NCT02162966|Experimental|High Dose Colistin|High dose colistin protocol
3338310|NCT02162966|Active Comparator|Standard Dose Colistin|Standard dose of colistin
3338311|NCT02163005|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
3338312|NCT02163018|Experimental|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1.
3338313|NCT02163018|Placebo Comparator|Placebo|Subcutaneous administration of placebo
3338314|NCT02163031|Active Comparator|right radial approach|devices used in the coronary angiography by right radial approach
3236334|NCT01249820|Experimental|group A|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
3236335|NCT01249820|Experimental|group B|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
3236336|NCT01249846|Experimental|Arm 1|Each one of the two selected periodontal pockets (target pockets) will be randomized to the Frequent PerioChip® treatment or to the Routine PerioChip®.
3236337|NCT01249846|Placebo Comparator|Arm 2|Each one of the two selected target pockets will be randomized to the Frequent PerioChip® treatment or to the Frequent Placebo Chip treatment.
3236338|NCT01249859||Signet ring cell carcinoma|
3338315|NCT02163031|Active Comparator|left radial approach|devices used in the coronary angiography by left radial approach
3338316|NCT02163044||Statin|Patients on statin treatment
3338317|NCT02163070|Experimental|whey drink|consumption of 220 milliliters of whey drink three times a week,
3338318|NCT02163070|Experimental|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
3338319|NCT02163070|Experimental|vitaminE|consumption of 400 milligrams of vitamin E three times a week,
3338320|NCT02163070|No Intervention|D- control|control group: no intervention,
3338321|NCT02163083|No Intervention|Lymphadenectomy using standard Methods|Lymphadenectomy will be performed as a standard procedure
3338322|NCT02163083|Experimental|Lymphadenectomy using ICG|A fluorescent dye (indocyanine green) will be ultrasound-controlled preoperatively injected in the prostate. During robot-assisted radical intervention by DaVinci ® robot the lymphadenectomy is performed using the fluorescence lymphography.
3338323|NCT02163096||History of Wheezing, Benign Joint Hypermobility Syndrome|
3338324|NCT02163096||Asthma, Benign Joint Hypermobility Syndrome|
3338325|NCT02163109||Critically-ill patients|Adult patients requiring intubation and mechanical ventilation on an intensive care unit, predicted to require a further 48 hours of artificial ventilation
3338326|NCT02163122|Experimental|NAC Followed by EEC|This arm will undergo allergy assessment first by NAC. After a rest and washout period, the same individuals will undergo assessment in an EEC.
3338327|NCT02163122|Experimental|EEC Followed by NAC|This arm will undergo allergy assessment first in an EEC. After a rest and washout period, the same individuals will undergo assessment by NAC.
3338328|NCT02163122|Experimental|Dose-finding Phase|An initial group of 6 to 12 participants with cat allergy as defined by the eligibility criteria will undergo a single-visit, stepwise dose-escalating nasal allergen challenge only, with the aim of estimating the most appropriate single dose of allergen to use in the randomized phase. Eligible participants who participate in the dose-finding phase may proceed to the randomized phase of the trial after a minimum 28-day washout period.
3338329|NCT02163148||Public Speaking Anxiety|Intervention to be administered: One speech exposure session.
3236339|NCT01249859||non signet ring cell adenocarcinoma|
3338330|NCT02163161|Experimental|Treatment A|
3338331|NCT02163161|Experimental|Treatment B|
3338332|NCT02163161|Experimental|Treatment C|
3338333|NCT02163174|Active Comparator|Pentoxyfilline arm|Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
3338334|NCT02163174|Placebo Comparator|Placebo arm|Intravenous saline as a Placebo 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics.
3338335|NCT02163200||pressure of total hip replacement|Patients 60 y.o. or more both sex with a history of hip arthropathy without previous bedsores or CVA
3338336|NCT02163213|Other|Serum Bovine Immunoglobulin|"Serum-Derived Bovine Immunoglobulin (SBI) 5.0 g by mouth twice daily;~Effects of SBI will be compared with observations and measurements performed at baseline PRIOR to starting the SBI treatment"
3338337|NCT02163239||10mm Cannula|Subjects that are scheduled for a robot-assisted laparoscopic single-incision surgery for cholecystectomy, benign hysterectomy or salpingo-oophorectomy under the care of the study investigator
3338338|NCT02163252|Active Comparator|Standard|A 12-week internet-based weight loss program that involves weekly video lessons, a self-monitoring platform where participants submit their weight, calorie, and activity information, and weekly automated feedback.
3338339|NCT02163252|Experimental|Early intervention|Participants randomized to Early Intervention will receive the same internet-based weight loss program compared to the Standard group. In addition, Early Intervention participants achieving less than optimal weight loss following several weeks of treatment will be given the opportunity to come to the Weight Control and Diabetes Research Center for an individual visit. At this visit, an interventionist will discuss with the participant any barriers that he or she may be experiencing and recommend alternate strategies to assist in their weight loss. One such strategy would be to recommend the use of meal replacement products or portion controlled meals. In addition to this one-time visit, the interventionist will follow up with the participant via phone weekly, for 2 weeks following this in-person visit.
3338340|NCT02163265|Experimental|Surgery|Patients suffering from Pectus excavatum and Pectus carinatum will be surgically treated
3338341|NCT02163278|Experimental|DBPR108|
3338342|NCT02163278|Placebo Comparator|matching placebo|
3338343|NCT02163291|Experimental|paclitaxel liposome|S-1 plus paclitaxel liposome
3338344|NCT02163304|Active Comparator|Artificial Sweetner|Artificial Sweetener
3338345|NCT02163304|Placebo Comparator|Tasteless Solution|12 oz tasteless solution
3338346|NCT02163304|Active Comparator|Sucrose|12 oz 75 g sucrose beverage
3338347|NCT02163317|Experimental|Treatment (MRI-guided focal SRS)|Patients undergo 3 fractions of MRI-guided focal SRS every other day for 1 week. Patients undergo additional MRI scans between the 2nd and 3rd fractionated treatments, at 6 months following the end of radiation therapy, and at 12 and 24 months.
3236340|NCT01249911|Experimental|Lreuteri|Group of 130 infants allocated to receive L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
3236341|NCT01249911|Placebo Comparator|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
3236342|NCT01249924|Other|CPAP Group|CPAP Treatment
3338348|NCT02163330|Active Comparator|Acetazolamide|active comparator group will receives 500 mg azetazolamide daily
3338349|NCT02163330|Placebo Comparator|sugar pill|placebo comparator group will receives placebo daily.
3338350|NCT02163343||No treatment|
3338351|NCT02163356|Experimental|Primary therapy|Fenretinide/LXS oral powder 1500 mg/m2/day for 7 days plus ketoconazole 6 mg/kg/day for 7 days plus single dose vincristine (dose escalating) given on day 3. Starting dose of vincristine is 0.75 mg/m2/dose. Followed by 14 days of rest.
3338352|NCT02163369|Experimental|Peppermint and Lavender Essential Oils|
3338353|NCT02163382|Experimental|Neurovent Monitor XIII|1 hour Ventilation with NAVA
3338354|NCT02163408||Healthy Volunteers|100 healthy volunteers will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality and image contrast will be compared between the two protocols.
3338355|NCT02163408||Patients with Carotid Artery Disease|40 patients will take MRI with/without contrast using both conventional protocol and our developed protocol. Image quality, image contrast, and composition analysis will be compared between the protocols.
3338356|NCT02163460|Experimental|Drain|In group 1(Drain), a 4.8 mm diameter continuous closed-suction tubular drain : was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
3338357|NCT02163460|Experimental|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
3338358|NCT02163473||Septic patients|Blood Draw Biological samples: The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
3338359|NCT02163473||Healthy Control|The investigators will collect blood and compare the expression of HIF complex in 3 distinct ways: between patients and controls, within the same patient in a time-dependent fashion, and between different patients.
3338360|NCT02163512||Non-refractory ascites|
3338361|NCT02163512||Refractory ascites|
3338364|NCT02163551||Spinal Cord Injury|Participants with spinal cord injury (n = 20) will be age 30-60 years with motor complete spinal cord injuries, otherwise known as American Spinal Injury Association (ASIA) classification A or B, between the levels of C3 and T12. Patients will have to be able to breathe independently without the use of a ventilator. Subjects will be divided equally into four different injury level categories. The four categories are high tetraplegia (C3 - C5), low tetraplegia (C6-C8), high paraplegia (T1-T6), and low paraplegia (T7-T12).
3338365|NCT02163551||Controls|Twenty healthy age-matched adults will also participate.
3338366|NCT02163564|No Intervention|Focus groups|The first part of the study is to conduct focus groups of adolescents with insomnia and depression. The treatment arm is informed by responses provided by teens in the focus group portion.
3338367|NCT02163564|Active Comparator|Treatment|A modified cognitive behavioral therapy for insomnia is the treatment intervention in this treatment arm.
3338368|NCT02163590|Experimental|2Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 2Hz frequency.
3338369|NCT02163590|Experimental|0,5Hz mobilisation|A bilateral postero-anterior mobilisation applied to the fourth thoracic vertebra, at a 0,5Hz frequency.
3338370|NCT02163590|Placebo Comparator|Placebo|A simulation technique, that mimic the other groups, in this case only manual contact will be applied, without any oscillation.
3338371|NCT02163603||Pelvic osteotomy|
3338372|NCT02163616|Experimental|PPH Treatment|800mcg sublingual misoprostol
3338373|NCT02163629|Experimental|psychotherapeutic intervention|"The psychotherapeutic intervention stress management is based on therapeutic, behavioral and cognitive strategies. They are active and put the patient actor of his adaptation of the heart transplantation entire process. The approached components are emotional, cognitive and behavioral (techniques of communication and problem solving)."
3236343|NCT01249924|Other|Control Group|Routine care
3259251|NCT01469117||Pediatric developmental disabilities|Children aged 1-13 years old with development disabilities, requiring enteral tube feeding for at least 14 days
3338374|NCT02163629|No Intervention|Usual medical care|
3338375|NCT02163642||Non-CF Bronchiectasis|Cyranose® 320
3338376|NCT02163655|Placebo Comparator|PLACEBO|PLACEBO: placebo, oral, every 24 hours for maximum 5 days
3338377|NCT02163655|Experimental|FUROSEMIDE|FUROSEMIDE: 20mg furosemide, oral, every 24 hours for maximum 5 days
3338378|NCT02163668|Experimental|Yoga group|8 months of progressive Yoga training
3338379|NCT02163668|No Intervention|Control group|No training, just pre and post testing
3338380|NCT02163681|Experimental|Hyperpolarized Helium 3 MRI of the chest|Using hyperpolarized helium-3 as an inhaled contrast agent for MRI, we will assess the lung ventilation.
3338381|NCT02163694|Active Comparator|Veliparib Placebo with Carboplatin and Paclitaxel|Veliparib Placebo on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
3338382|NCT02163694|Experimental|Veliparib with Carboplatin and Paclitaxel|Veliparib on Day -2 through 5 of a 21-day cycle. Carboplatin on Day 1 of a 21-day cycle and paclitaxel on Day 1, 8, and 15 of a 21-day cycle.
3338383|NCT02163707|Other|Psilocybin Dose 1|0.3 mg/kg (approximately 20mg/70kg)
3338384|NCT02163707|Other|Psilocybin Dose 2|0.45 mg/kg (approximately 30 mg/70 kg)
3338385|NCT02163707|Other|Psilocybin Dose 3|0.6 mg/kg (approximately 40 mg/70 kg)
3338386|NCT02163720||Yondelis®-Caelyx®-relapse ovarian cancer|Yondelis®-Caelyx®-relapse ovarian cancer
3338387|NCT02163746|Active Comparator|CO2 (carbon dioxide) laser|Patients randomized to this group will undergo CO2 laser excision of the sinus tracts in affected axilla
3338388|NCT02163746|Active Comparator|Surgical Deroofing|Patients randomized to this group will undergo surgical deroofing of the sinus tracts in affected axilla
3338389|NCT02163772|Experimental|Intracordal hyaluronate injection (HI)|The intervention of Intracordal hyaluronate (Restylane) injection is given in this group No other therapies are given
3236344|NCT01249937|Placebo Comparator|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3236345|NCT01249937|Active Comparator|Ranibizumab and Triamcinolone acetonide|"Recent research has discovered that persons with wet or dry ARMD show an immune response, as if the body is fighting off an infection. The body creates a complex immune response to the growth of blood vessels into the eye tissue, which triggers side effects. It is believed that preventing this inflammation can lead to greater visual gains and a need for fewer treatment injections.~Animal studies have shown that Triamcinolone Acetonide, a corticosteroid (class of drugs that reduce inflammation) can prevent damage to vision from this inflammation. The hypothesis is that treatment with both Ranibizumab and Triamcinolone Acetonide will allow even greater vision improvements than Ranibizumab treatment alone for wet age-related macular degeneration."
3236346|NCT01249950||adolescents|adolescents with morbid obesity
3236347|NCT01249963|Experimental|Experimental Group|Patients of this group will receive 400 ml per day of T-Diet plus Atémpero product during 28 days.
3338390|NCT02163772|No Intervention|Conservative management (CM)|In this arm, only observation is arranged. No therapy is given.
3338391|NCT02163785|Active Comparator|Supine position|Abdominoperineal resection - perineal time- in supine position
3236348|NCT01249963|Active Comparator|Control Diet|Patients of this group will receive 2 packets (76 g) per day of AlitraQ (Abbott) product during 28 days.
3236349|NCT01249976|Experimental|catheter-spearing diagnostic methods|experimental
3338392|NCT02163785|Experimental|Prone position|Abdominoperineal resection - perineal time- in prone position
3338393|NCT02163798|Experimental|Tai Chi Group|Participants in this group received a 12-week instructor-led Tai Chi training program.
3338394|NCT02163798|Experimental|Walking Group|Participants in this group received a 12-week instructor-led brisk walking training program.
3338395|NCT02163798|No Intervention|Control Group|Participants in the control group did not receive intervention during the 12 weeks, and were told that they would be provided two sessions of free health and fitness evaluation with an interval of three months (12 weeks).
3338396|NCT02163850|Experimental|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
3338397|NCT02163850|Active Comparator|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
3338398|NCT02163863|Experimental|BioMimics 3D|The BioMimics 3D Stent System, delivering a self-expanding Nitinol stent with 3D helical centerline geometry.
3338399|NCT02163863|Active Comparator|Control|CR Bard LifeStent System, delivering a self-expanding Nitinol stent
3338400|NCT02163876|Experimental|HuCNS-SC cells|Intramedullary transplantation of HuCNS-SC cells in the cervical spine
3338401|NCT02163876|No Intervention|non-surgery arm|non-surgery arm
3338402|NCT02163889||Candida Positive Patients|Symptomatic adult patients, confirmed via blood culture with species identification to be positive for Candida
3338403|NCT02163941|Experimental|Compassion Training|8 weeks of training in Cognitively-Based Compassion Training (CBCT). Classes will meet once per week for 2 hours and participants will be asked to meditate at home for 20 minute each day.
3338404|NCT02163954|Active Comparator|Clopidogrel|Patients treated with clopidogrel for 14 days
3338405|NCT02163954|Experimental|Ticagrelor|Patients treated with ticagrelor for 14 days
3338406|NCT02163980|Placebo Comparator|Caudal ropivacaine + normal saline|1.5ml kg-1 ropivacaine 0.15% with normal saline (Control group, n=40).
3338407|NCT02163980|Experimental|Caudal ropivacaine + dexmedetomidine|1.5ml kg-1 ropivacaine 0.15% with dexmedetomidine 1 μg kg-1 (DEX group, n=40)
3338408|NCT02164006|Experimental|TGR-1202 + brentuximab vedotin|TGR-1202 oral daily dose in combination with a fixed IV infusion of brentuximab vedotin
3236350|NCT01249989|Experimental|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
3338409|NCT02164019|Active Comparator|long-stem cemented hemiarthroplasty (LSCH)|"(LSCH), Hip, Ball, Rod and Cement Replace the ball of the hip joint with a metal ball and a rod that is placed inside the thigh bone with cement to keep the implant in place. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
3338410|NCT02164019|Active Comparator|intramedullary nailing (IMN)|"Intramedullary nailing (IMN), Rod and Screws A metal rod is placed inside your thigh bone and secured in place by metal screws just below the hip and above the knee. The study participation period for each patient is 360 days from the date of surgery and includes 5 defined timepoints that include the suture removal visit at 3 weeks and follow-up clinical visits for radiographs and rehabilitation progress checks at 6 weeks, 12 weeks, 6 months, and 12 months after surgery. At each follow-up visit, a combination of questionnaires and physical tests will be administered to assess physical function, general health status, disability level, and pain control. Some patients may be in a rehabilitation center or on hospice care and will miss their follow-up appointments. To collect data for the primary endpoint, the 6 week and/or 12 week TESS can be done over phone if necessary."
3338411|NCT02164032|Placebo Comparator|Insulin dilution buffer|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
3338412|NCT02164032|Active Comparator|Intranasal Insulin administration|"During a subsequent 4-week treatment phase subjects will be randomly assigned to receive intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia.~Ectopic lipid content and heart function will be assessed weekly by non-invasive 1H magnetic resonance spectroscopy."
3338413|NCT02164045|Experimental|BMS-663068- Fasted|BMS-663068 tablet twice a day by mouth on specified days
3338414|NCT02164045|Experimental|BMS-663068- Fed|BMS-663068 tablet twice a day by mouth on specified days
3338415|NCT02164058|Experimental|TandemHeart System + PCI|TandemHeart System prior to percutaneous coronary intervention
3338416|NCT02164058|Active Comparator|PCI|Percutaneous coronary intervention
3338417|NCT02164071||Multiple Myeloma (MM)|Patients with Myltiple Myeloma, symptomatic or asymptomatic
3338418|NCT02164071||Myelodysplastic Syndromes or Acute Myeloid Leukemia|Patients with Myelodysplastic Syndromes (MDS), any International Prognostic Scoring System (IPSS) risk, or Acute Myeloid Leukemia (AML)
3338419|NCT02164071||Chronic Lymphocytic Leukemia (CLL)|Patients with Chronic Lymphocytic Leukemia
3338420|NCT02164084|Experimental|SB204|SB204 8% topically twice daily for 4 days and once on Day 5
3338421|NCT02164084|Placebo Comparator|Vehicle Gel|Vehicle Gel topically twice daily for 4 days and once on Day 5
3338422|NCT02164097|Experimental|ODSH and ICE Chemotherapy|"Patients will receive standard doses of ICE Chemotherapy:~Ifosfamide 1800 mg/m2 mixed with Mesna 360 mg/m2 IV over 2 hours on days 1, 2, 3, 4, and 5~Carboplatin 400 mg/m2 IV over 1 hour on days 1 and 2~Etoposide 100 mg/m2 IV over 1 hour on days 1, 2, 3, 4, and 5~ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first ifosfamide dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for five consecutive days, on days 1-5, for a total of 120 hours of continuous ODSH infusion."
3338423|NCT02164110|Experimental|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
3338424|NCT02164110|Active Comparator|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
3338425|NCT02164123|Experimental|Spinal mobilization|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute. The subject will be comfortable prone lying.
3236351|NCT01249989|Experimental|Simultaneous MBC Condition|Participants in the simultaneous condition will target FV+, Sed- and PA+ simultaneously. Participants will wear accelerometers and enter diet and sedentary activity 5 days/week on their Smartphone. All 3 goal thermometers will be activated from the outset of prescription (FV, Sed, PA). In week 1-2, participants will close 1/3 of the gap between their baseline FV, Sed, and PA behavior and their goals. In week 3-4 participants will close 2/3 of the gap, and 100% of their goals in weeks 5-6. Participants will maintain their target behaviors for FV, Sed and PA through week 12.
3338426|NCT02164123|Active Comparator|Spinal Mobilization II|20 subjects will be randomized to this arm. A postero-anterior (PA) mobilization, to the fourth thoracic vertebra will be applied, for 3 sets of one minute, but in this case, the subject will be seated, in a position that influence the sympathetic trunk, at the thorax.
3338427|NCT02164123|Placebo Comparator|Placebo|20 subjects will be randomized to this arm. Only manual contact will be applied, without any oscillation. The subject will be comfortable prone lying. The intervention time is the same of the other arms.
3236352|NCT01249989|Active Comparator|Stress Management Control|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
3236353|NCT01250015||control|given standard nhs advice leaflet
3338428|NCT02164136|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3338429|NCT02164136|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3338430|NCT02164149||Quality of colon cancer surgery|Patients with primary colon cancer
3338431|NCT02164162|Experimental|Experimental group|"Participants received 12 sessions of robotic assisted body weight-supported treadmill training on the Lokomat. Training occurred approximately 3 days/ week for 4 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support.~Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session."
3338432|NCT02164162|Active Comparator|Control group|Participants received 20 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 4 weeks, and each training session lasted 1 hour .Patients allocated to the Control Group performed a general exercise program and a conventional gait training with a 5-minute rest between them. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long.
3338433|NCT02164175||HeRO Graft|End stage renal disease patients who receive HeRO Graft implant for dialysis access
3338434|NCT02164188|No Intervention|control|Initially this control group will not receive an intervention (wait list). After 8 weeks this goup will receive the Flourishing protocol (cross over).
3338435|NCT02164188|Experimental|Flourishing protocol|This group will receive the intervention Flourishing protocol and after that it will not receive any other intervention (cross over).
3338436|NCT02164214|Experimental|patients PSORIATIC ARTHRITIS|etanercept Treatment
3338437|NCT02164214|Active Comparator|patients RHEUMATOID ARTHRITIS|etanercept Treatment
3236354|NCT01250015||interventional|given standard nhs advice leaflet with numerical information and pictograms
3236355|NCT01250041|Active Comparator|femoral block|
3338438|NCT02164227|Experimental|respiratory pattern|Deep and slow inspiration is used in the initial and active stages, at which time the contractions vary from uncomfortable to strong, lumbosacral pain and cervical dilation may occur between 3 and 8 cm in this case the mother is driven to inspire slowly and the level of inspiratory reserve volume followed by slow exhalation to functional residual capacity; Sigh with post-expiratory pause that corresponds to a small spontaneous exhalation to relax occurs in tidal volume; Expiratory delay that corresponds to a prolonged propelled with the lips during the lull and expiration in the expiration time that corresponds to a slow inspiration followed by two or three puffs with the short lips will be used propelled.
3338439|NCT02164227|No Intervention|Control|Follows the service routine
3338440|NCT02164253|Experimental|Deferiprone|Deferiprone, 25 to 30 mg/kg per day, oral use
3338441|NCT02164266|Experimental|Part 1: Healthy Volunteers|
3338442|NCT02164266|Experimental|Part 2: Patients with T2D, Group A|Low dose daily oral administration of RO6799477
3338443|NCT02164266|Experimental|Part 2: Patients with T2D, Group B|High dose daily oral administration of RO6799477
3338444|NCT02164279||Progressor (ND)|Group of patients with an albuminuria > 100mg/L, by Urinary sample collection
3236356|NCT01250041|Experimental|saphenous block|
3338445|NCT02164279||Non-Progressor (non-ND)|Group of patients without an albuminuria > 100mg/L, by Urinary sample collection
3338446|NCT02164292||ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
3338447|NCT02164305|Experimental|Strengthening group|4-week exercise training, 3 times a week, 30 minutes per visit.
3338448|NCT02164305|Experimental|Neuromuscular group|4-week exercise training, 3 times a week, 30 minutes per visit
3338449|NCT02164305|Sham Comparator|Control|Only have 2 assessments.
3236357|NCT01250080|Experimental|Glutamine|
3236358|NCT01250080|Sham Comparator|Control|
3236359|NCT01250106|Experimental|Probiotic capsule|
3236360|NCT01250106|Placebo Comparator|placebo capsule|
3236361|NCT01250132|Other|Moderate to severe Traumatic Brain Injury|"Assessment of hypopituitarism. Blood tests at different moments:~day 0~when leaving intensive care unit~month 3~month 12"
3236362|NCT01250158|Experimental|Liver-PILP kit|Liver-PILP kit
3338450|NCT02164331|Experimental|JNC guideline training|Providers will receive current JNC guideline training for treating patients with uncontrolled hypertension.
3338451|NCT02164331|No Intervention|Control|Provider patient panels will be assessed for number of uncontrolled hypertensives before receiving the JNC guidelines training. These baseline characteristics will serve as their control conditions.
3338452|NCT02164344|Experimental|Probiotics|HIV-1 infected patients take daily dietary supplement with probiotics for at least 3 months
3338453|NCT02164357||EVT|Patients receiving endovascular treatment (EVT) within 4.5 hours after onset because intravenous thrombolytic therapy (IVT) is contraindicated
3338454|NCT02164357||IVT + EVT|Patients receiving intravenous thrombolytic therapy (IVT) followed by endovascular treatment (EVT) within 4.5 hours after onset
3338455|NCT02164357||IVT (intravenous thrombolytic therapy)|Patients that will received IVT only within 4.5 hours after onset
3338456|NCT02164370||non-pregnant controls|Acid-base in healthy non-pregnant women in childbearing age
3338457|NCT02164370||healthy pregnant control group|healthy pregnant volunteers matched in gestational age to cases
3338458|NCT02164370||severe pre-eclampsia|Acid-base in severe pre-eclampsia
3236363|NCT01250197|Experimental|Formulation A|AR-12286 Ophthalmic Solution Formulation A
3236364|NCT01250197|Experimental|Formulation B|AR-12286 Ophthalmic Solution Formulation B
3236365|NCT01250236||verum|brimonidine 0.1% eye drops twice daily
3338459|NCT02164409||Patient|Subjects for this study will be either H. pylori positive with an active infection, cleared of an H. pylori infection or be both H. pylori antibody positive and have a malignancy of the gastrointestinal tract, specifically gastric adenocarcinoma.
3338460|NCT02164409||Control|A small subset of patients without H. pylori infection will be enrolled as well (n=30) to serve as a control group.
3338461|NCT02164435|Other|Renal Denervation|
3338462|NCT02164448|Experimental|dexmedetomidine group|
3338463|NCT02164448|Placebo Comparator|control group|
3236366|NCT01250236||placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
3236367|NCT01250249|Active Comparator|BCG Vaccine - Intradermal injection|"Subjects must be in the age group of 0 - 14 years of age.~2. Subject's parent should be able to understand and have to sign the informed consent form after being explained by the investigator. They must be aware of the experimental nature of the therapy, its potential benefits, side effects and risks.~3. Ability to comply with the schedule of treatment and follow-up.~4. Absence of BCG scar~5. Tuberculin negative~6. No evidence of any other infection~7. No evidence of skin disease~Skin testing with tuberculin is not generally carried out before giving BCG but when performed, those who are found to be positive reactors need not to be immunized"
3338464|NCT02164461|Experimental|ADXS11-001|
3236368|NCT01250262|Active Comparator|Standard care|Subjects will receive normal medical care and follow up during the four month study period if assigned to this group.
3236369|NCT01250262|Active Comparator|Isolated Lumbar Resistance Exercise Program|Lumbar extension exercise protocol to increase strength and reduce pain.
3236370|NCT01250262|Active Comparator|Total Body Resistance Exercise Program|Training protocol for 1 set for each exercise: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl
3236371|NCT01250275|Experimental|Acute Phase: traditional canola oil|Participants will receive banana bread containing traditional canola oil once weekly during the 5-week schedule
3236372|NCT01250275|Active Comparator|Acute Phase: high oleic canola oil|Participants will receive banana bread containing high oleic canola oil once weekly during the 5-week schedule
3236373|NCT01250275|Active Comparator|Acute Phase: soybean oil|Participants will receive banana bread containing soybean oil once weekly during the 5-week schedule
3236374|NCT01250275|Active Comparator|Acute Phase: high linoleic safflower oil|Participants will receive banana bread containing high linoleic safflower oil once weekly during the 5-week schedule
3236375|NCT01250275|Active Comparator|Acute Phase: coconut oil|Participants will receive banana bread containing coconut oil once weekly during the 5-week schedule
3338465|NCT02164474|Experimental|High-Intensity Interval Training (HIIT)|Participants will perform a series of high-intensity intervals with an interval length of 60-seconds at 90% of peak aerobic capacity workload, and a rest length of 60-seconds.
3338466|NCT02164474|Active Comparator|Moderate-Intensity Continuous Exercise|Participants will engage in exercise at 45% of peak aerobic capacity workload.
3338467|NCT02164487||B1 blood levels|
3338468|NCT02164500|Experimental|Ruxolitinib|
3338469|NCT02164526||No treatment|
3338470|NCT02164552||Vitamin D3 pills|Vitamin D3 (cholecalciferol) supplementation (50,000 IU/week for 8 weeks) followed by 1000 IU/day for 16 weeks
3338471|NCT02164552||Placebo pill|Placebo pills will be given 1 per week for 8 weeks followed by 1 per day for 16 weeks
3338472|NCT02164565|Experimental|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
3338473|NCT02164565|Experimental|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
3338474|NCT02164578|Experimental|Rivaroxaban|"Patients receive IMP in 5mg b.i.d. for 20 weeks~+ addidional 32 weeks (extension study for 80 patients)"
3338475|NCT02164578|Active Comparator|Aspirin|Patients receive IMP in a dosage of 100mg once daily for 20 weeks. Thereof 80 patients receive treatment for addidional 32 weeks (extension study)
3338476|NCT02164604|Experimental|Ranibizumab|All eyes receive one intravitreal injection with 0.03ml ranibizumab
3338477|NCT02164617|Experimental|Wheelchair-bound Senior Elastic Band|Wheelchair-bound Senior Elastic Band (WSEB) exercise program has three phases: 1) warm-up: 6 movements to loosen up the body and elevate the energy for a safe transition to the next phase, 2) aerobic motions: 6 low-to-medium speed exercises to enhance the cardiovascular-respiratory workout, and 3) static stretching: 6 low-speed, gentle stretching exercises to build up muscle power/endurance and increase range of motion and flexibility. It is conducted three times per week, 40 minutes per practice.
3338478|NCT02164617|No Intervention|control|routine care
3338479|NCT02164630|Experimental|Hope Therapy|Patients assigned to this arm will receive Hope Therapy in three individual intervention sessions. Intervention will be administered by an experienced therapist.Training focuses on effective goal setting and augmenting hopeful thinking.
3338480|NCT02164630|Other|Pain Education|Patients assigned to this arm will receive Pain Education in three individual intervention sessions. Intervention will be administered by an experienced therapist. Training will focus on understanding TMD-related pain and learning pain management techniques.
3338481|NCT02164643|Experimental|Florbetapir (18F)|
3338482|NCT02164643|Experimental|Flutemetamol (18F)|
3338483|NCT02164656|Experimental|mindfulness training|8 week course in mindfulness for smokers
3338484|NCT02164682||IV PCA group|
3338485|NCT02164682||IV PCA+ caudal block group|
3338486|NCT02164708|Experimental|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
3338487|NCT02164734|Active Comparator|Endotracheal intubation|Endotracheal intubation for surfactant administration, following remifentanil and atropine pre-medication
3338488|NCT02164734|Experimental|Laryngeal mask airway|Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
3236376|NCT01250275|Experimental|Chronic Phase: traditional canola oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing traditional canola oil for a total of 8 weeks
3236377|NCT01250275|Active Comparator|Chronic Phase: safflower oil|A total of 25 participants with peripheral arterial disease will be assigned foods containing an oil mixture representing the typical western diet for a total of 8 weeks
3338489|NCT02164747||Control group before telemedicine|Residents of nursing homes without telemedicine before implementation of telemedicine in nursing homes with telemedicine
3338490|NCT02164747||Control group after telemedicine|Residents of nursing homes without telemedicine after implementation of telemedicine in nursing homes with telemedicine
3338491|NCT02164747||Exposed group, before telemedicine|Residents of nursing homes with telemedicine prior implementation of telemedicine
3338492|NCT02164747||Exposed group, after telemedicine|Residents of nursing homes with telemedicine after implementation of telemedicine
3338493|NCT02164760|Experimental|Dermal substitute with STSG|Novomaix dermal substitute in combination with STSG
3338494|NCT02164760|No Intervention|STSG alone|STSG alone
3236378|NCT01250288||Consumers|Consumers (patients or their designated proxies) who have registered to use the personal health management technology platform offered by the Brooklyn Health Information Xchange (BHIX) or Long Island Patient Information Xchange (LIPIX).
3338495|NCT02164773|Active Comparator|magnesium sulfate|magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.
3338496|NCT02164773|Placebo Comparator|o.9%normal saline|0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.
3338497|NCT02164786||Acute severe disease|
3338498|NCT02164799||Shock|Patients found to have persistent hypotension after resuscitation or vasopressor requirement
3338499|NCT02164799||Pre-shock|Patients with markedly abnormal vital signs (Heart Rate (HR)>130, Respiratory Rate (RR)>24, Shock Index >1, Lactate > 4.0mmol/L, or Systolic Blood Pressure (SBP) <90mm/hg) without shock, as defined previously.
3338500|NCT02164812|Experimental|Moxifloxacin, Placebo, Efavirenz|Moxifloxacin, Placebo, Efavirenz single dose as specified
3338501|NCT02164825|Experimental|Single-shot nerve block|Efficacy compared to epidural
3338502|NCT02164825|Active Comparator|Continuous epidural|Continuous epidural perfusion
3338503|NCT02164838|Experimental|Axitinib|
3338504|NCT02164877|Experimental|pectin|Patients allocated to experiment group will receive standard enteral nutrition formula(Fresubin) supplemented with 15g pectin each day for 4 weeks.
3338505|NCT02164877|Placebo Comparator|control|Patients allocated to control group will receive standard enteral nutrition formula(Fresubin) for 4 weeks
3338506|NCT02164890|Other|Pharmacokinetics of micafungin|
3338507|NCT02164903||Imatinib|Patients in first line treatment with imatinib for no more than 3 years.
3338508|NCT02164903||Dasatinib|Patients in first line treatment with dasatinib for no more than 3 years.
3338509|NCT02164942||Single Arm|Specimen Collection
3338510|NCT02164955||Relapsed and Refractory Multiple Myeloma Patients|Single Cohort of Relapsed and Refractory Multiple Myeloma Patients treated with IMNOVID (pomalidomide)
3338511|NCT02164968||Obstructive bronchitis|1-5 year old patients who have visited the TAYS emergency room due to obstructive bronchitis and have been instructed to begin a three-month period of inhaled corticosteroid (ICS) treatment as per national guidelines.
3338512|NCT02165007|Experimental|peripheral blood stem cell graft that are CD34+ selected|peripheral blood stem cell graft that are CD34+ selected. All patients will undergo reduced intensity conditioning regimen which followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device and Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year (see intervention).
3338513|NCT02165020|Experimental|Rectal toxicities after prostate hypofractionated radiotherapy|Rectal toxicities after prostate hypofractionated radiotherapy with hyaluronic acid
3338514|NCT02165033|Experimental|Budesonide/Procaterol 180/10 X 4 puffs|Multiple dose of SYN006 HFA MDI (Budesonide 180ug + Procaterol 10ug/puff), 4 puffs each day for consecutive 7 days
3338515|NCT02165046|Experimental|SYN006 HFA MDI, 180/10 mcg/dose|SYN006 HFA MDI(Budesonide/Procaterol Hydrochloride, 180/10mcg), Single dose, 4 puffs
3338516|NCT02165046|Active Comparator|Pulmicort pMDI|Budesonide 200mcg, single dose, 4 puffs
3338517|NCT02165046|Active Comparator|Meptin Air 10mcg|Procaterol hydrochloride 10mcg, single dose, 4 puffs
3338518|NCT02165059||Study Group|Patients undergoing surgical full thickness biopsy of the stomach and/or proximal jejunum for the clinical evaluation of GI neuromuscular disorder.
3338519|NCT02165059||Control Group|"Patient undergoing esophagectomy, sleeve gastrectomy for obesity, Roux-en-Y gastric bypass, Whipple surgery, transplant surgery.~Patients who are organ donors and undergoing surgery are also part of the control group."
3338520|NCT02165085||Vascular-Ehlers Danlos syndrome|N=50 patients with vascular Ehlers-Danlos syndrome
3236379|NCT01250288||Providers|Providers who are authorized to view the data entered by consumers in either (1) BHIX's personal health management system, along with BHIX health information exchange data; OR LIPIX's secure messaging system (SMS), along with LIPIX health information exchange data.
3236380|NCT01250301|Experimental|De-nicotinised cigarettes + standard treatment|
3338521|NCT02165085||Spontaneous arterial dissection(s)|N=50 patients
3338522|NCT02165085||Healthy volunteers|n=100 Healthy volunteers
3338523|NCT02165098|Experimental|Cariprazine PR tablet B|Cariprazine prolonged release tablet B - fed
3338524|NCT02165098|Experimental|Cariprazine PR tablet A|Cariprazine prolonged release tablet A - fed
3338525|NCT02165098|Experimental|Cariprazine capsule|Cariprazine capsule - fasted
3338526|NCT02165098|Experimental|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
3338527|NCT02165098|Experimental|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
3338528|NCT02165137||trauma patients|type and severity of patients, circumstances and trauma pre- and post-injury / -quality initiative
3338529|NCT02165150|Experimental|Wheelchair-bound Senior Elastic Band|WSEB interventions three times per week, 40 minutes per practice
3338530|NCT02165150|No Intervention|Control|routine care
3338531|NCT02165163|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3338532|NCT02165163|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3236381|NCT01250301|Active Comparator|Standard treatment|
3236382|NCT01250314|Other|With fracture|Patients with fracture
3236383|NCT01250314|Other|Without fracture|Patients without fracture
3338533|NCT02165176|Experimental|10mg acute oral cannabis|10mg acute oral cannabis
3236384|NCT01250327|Experimental|Melody|insertion of a pulmonic valved stent
3236385|NCT01250327|Active Comparator|Bare stent|insertion of a bare metal stent
3338534|NCT02165176|Experimental|25mg acute oral cannabis|25mg acute oral cannabis
3338535|NCT02165176|Experimental|50mg acute oral cannabis|50mg acute oral cannabis
3236386|NCT01250327|Active Comparator|Surgery|conventional surgery methode.
3338536|NCT02165189|Experimental|Simeprevir plus Sofosbuvir plus Ribavirin (Arm 1)|Participants will be administered simeprevir capsule 150 milligram (mg), sofosbuvir 400 mg tablet, and ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram [kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg weight), orally once daily up to 12 weeks.
3338537|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 2)|Participants will be administered simeprevir capsule 150 mg and sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
3338538|NCT02165189|Experimental|Simeprevir plus Sofosbuvir (Arm 3)|Participants will be administered simeprevir 150 mg capsule and sofosbuvir 400 mg tablet orally once daily 24 weeks.
3338539|NCT02165215|Experimental|Open-Label Induction Phase: Etrolizumab|All participants will receive treatment with open-label etrolizumab 105 milligrams (mg) subcutaneous (SC) injection once every 4 weeks (Q4W) up to Week 10.
3338540|NCT02165215|Experimental|Double-Blind Maintenance Phase: Etrolizumab|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive etrolizumab 105 mg SC injection Q4W from Week 12 up to Week 62.
3338541|NCT02165215|Placebo Comparator|Double-Blind Maintenance Phase: Placebo|Participants who achieved a clinical response at Week 10 during the induction phase and randomized to this arm for the double-blind maintenance phase will receive placebo (matched to etrolizumab) SC injection Q4W from Week 12 up to Week 62.
3338542|NCT02165228|Experimental|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
3338543|NCT02165228|Active Comparator|Nutrition Enhancement|Nutrition education class and behavioral intervention
3338544|NCT02165228|No Intervention|Control|No class or behavioral intervention
3338545|NCT02165254|Other|high dose tai chi intervention|
3338546|NCT02165254|Other|standard dose tai chi intervention|
3338547|NCT02165267|Experimental|Arm 1: VRC01 (6 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0, followed by IV infusions of 20 mg/kg of VRC01 administered in 100 mL of normal saline over at least 30 minutes to 1 hour at Days 28, 56, 84, 112, and 140.
3236387|NCT01250340|Experimental|Aspirin|100 mg/day for 30 days
3236388|NCT01250340|Placebo Comparator|Placebo|1 cp /day for 30 days
3236389|NCT01250353|Experimental|conjunctival autograft|The conjunctival autograft was performed after the pterygium surgery like usual technique.
3338548|NCT02165267|Experimental|Arm 2: VRC01 (3 IV infusions)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Day 0 and over at least 30 minutes to 1 hour at Days 56 and 112.
3338549|NCT02165267|Experimental|Arm 3a: VRC01 (1 IV infusion plus multiple SC injections)|Participants will receive an IV infusion of 40 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of 5 mg/kg of VRC01 administered every 2 weeks for 20 weeks.
3338550|NCT02165267|Placebo Comparator|Arm 3b: Placebo for VRC01 (infusion plus injections)|Participants will receive an IV infusion of sodium chloride placebo administered in 100 mL of normal saline over 1 hour at Week 0, followed by SC injection of placebo for VRC01 administered every 2 weeks for 20 weeks.
3338551|NCT02165267|Experimental|Arm 4: 10 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 10 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
3338552|NCT02165267|Experimental|Arm 5: 30 mg/kg of VRC01 (3 IV infusions)|Participants will receive an IV infusion of 30 mg/kg of VRC01 administered in 100 mL of normal saline over 1 hour at Month 0 and over at least 30 minutes to 1 hour at Months 2 and 4.
3338553|NCT02165280|Active Comparator|Guided IMagery (GIM)|If randomized to GIM, they will then be given an audio Compact Disc. Patients will be instructed to listen to the recording least once per day in a calm location during the week leading up to surgery. They will then be seen prior to surgery in the surgical waiting area where they will evaluated for anxiety, preparedness and study compliance.
3338554|NCT02165280|No Intervention|Standard of Care (SOC)|"Each participant will complete a baseline set of questionnaires. The Pelvic Floor Distress Inventory (PFDI) is a 20 question self-administered questionnaire on the presence and both of pelvic floor symptoms .~The Pelvic Organ Prolapse Quantification System (POPQ) measures the topography of the vagina and is considered to be gold standard for quantifying prolapse .~The State-Trait Anxiety Inventory (STAI) has been used extensively in research and clinical practice since its introduction in 1966 and is the most widely cited measure of anxiety.~New measurements at the 6-week follow-up appointment will include the Patient Global Impression of Improvement (PGII), and a postoperative questionnaire eliciting overall satisfaction and development of new pelvic symptoms."
3338555|NCT02165293|Experimental|RO7033877|
3338556|NCT02165306|Experimental|Intervention|Patients enrolled in the intervention arm will receive two educational sessions on the importance of medication and barriers to adherence
3338557|NCT02165306|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the neurologist/neurosurgeon and nurses.
3338558|NCT02165319|Active Comparator|Barrel|Endotracheal tube with barrel-shaped cuff will be used during general anesthesia.
3338559|NCT02165319|Active Comparator|Tapered|Endotracheal tube with tapered-shaped cuff will be used during general anesthesia.
3338560|NCT02165332|Placebo Comparator|Part 1: Placebo|Saline solution, given as a minimum of a 2 hour infusion
3338561|NCT02165332|Experimental|Part 1: RO7033877|Single ascending dose
3338562|NCT02165332|Experimental|Part 2: RO7033877|Single-dose 4-way crossover
3236390|NCT01250353|Experimental|latex biomembrane application|The latex biomembrane was applied after pterygium surgery to recover the bare sclera area. This device was closed to conjunctiva with running suture anchored at some places to episclera. The sutures was removed at fourteenth day after surgery.
3236391|NCT01250366|Experimental|Arm 1: INX-08189 (9 mg) or Placebo|
3338563|NCT02165358||Patients|Patients verified with either becker muscular dystrophy or limb-girdle muscular dystrophy type 2I
3338564|NCT02165358||Controls|Healthy controls matched for age and gender.
3338565|NCT02165371|Experimental|Sinovuyo Caring Families Programme|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly 3 hour sessions. Program is manualized.
3338566|NCT02165371|No Intervention|No intervention|Control group receives not intervention
3338567|NCT02165410|Experimental|Eye tracking and RMI|
3338568|NCT02165423|Experimental|Control|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
3338569|NCT02165423|Experimental|Intervention|Ten parents will be randomized to the control group defined as 'usual care' and ten to the intervention group, stratified by type of transplant.
3338570|NCT02165436|Placebo Comparator|Control|No gum
3338571|NCT02165436|Active Comparator|Chewing Gum|Bubble gum-flavored sugar-free gum - chew for 15-30 minutes 5 times/day
3338572|NCT02165449|Experimental|Ketamine|
3338573|NCT02165475|Experimental|Biofeedback|
3338574|NCT02165475|Experimental|medical treatment|
3338575|NCT02165475|Experimental|combination of the two treatments|
3338576|NCT02165514|Experimental|Lunar iDXA (DEXA) scan|Spinal scans taken by DEXA scanner
3338577|NCT02165527|Experimental|x-ray with iXDA scan|Tota body scan taken by the Lunar iXDA. During the scan, subject will be asked to lay on their back. Following the Lunar iDXA scan, the computer of the Luna iXDA will calculate bone length. The calculation of bone length will be compared to a calculation from the subject's conventional x-ray to determine accuracy.
3338578|NCT02165540|Experimental|Doula|Patients will have a doula support person during their procedure.
3338579|NCT02165540|No Intervention|Routine care/No Doula|Patients will have routine care with clinical staff only.
3338580|NCT02165553|Experimental|Hibiscus sabdariffa calyces extract as a cold drink|Subjects are asked to consume 250 ml of Hibiscus calyces drink after a high fat breakfast
3338581|NCT02165553|Placebo Comparator|Water|Subjects are asked to consume 250 ml of water after a high fat breakfast
3338582|NCT02165566|Experimental|Regular-insulin,|regular-insulin or lispro-insulin at 0.04 units/kg/hour continuous infusion crossover and random assignement
3338583|NCT02165566|Experimental|Lispro insulin|patients randomly assigned in a crossover way to one of the 2 treatments
3338584|NCT02165579||Age > 21, diabetes, osteomyelitis|1 Cohort, standard care, observational patients are: Diagnosis of diabetes mellitus Age ≥ 21 years Infectious Disease Society of America stage 3 infection
3338585|NCT02165592||Patients with hemophilia|Patients with hemophilia who meet the inclusion criteria
3338586|NCT02165618|No Intervention|GCT|In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.
3338587|NCT02165618|Active Comparator|GCT-RASP|Medication review, based on but not limited to the RASP list
3338588|NCT02165631||Group A-Simbinza|Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
3338589|NCT02165631||Group B-Timolol|Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
3338590|NCT02165644|Experimental|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with current standard of care which is Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
3338591|NCT02165644|Active Comparator|Standard of care|Subjects will receive only standard of care for subarachnoid hemorrhage which will include Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
3338592|NCT02165657|Experimental|Excimer laser|Excimer laser treatment
3338593|NCT02165670||Ischemic heart disease|Patients undergoing percutaneous coronary intervention (PCI)
3338594|NCT02165696|Experimental|Manual lymphatic drainage and compression bandaging|Experimental group: 30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
3338595|NCT02165696|Active Comparator|Manual lymphatic drainage|Control group: 30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
3236392|NCT01250366|Experimental|Arm 2: INX-08189 (25 mg) or Placebo|
3236393|NCT01250366|Experimental|Arm 3: INX-08189 (50 mg + 9 mg) or Placebo|
3338596|NCT02165709|Experimental|Salpingectomy|Participants will be offered a risk-reducing salpingectomy, and if they choose this options the surgeon will proceed with a salpingectomy.
3338597|NCT02165709|Active Comparator|Traditional sterilization|Participants will be offered a risk-reducing salpingectomy, and those that choose a traditional sterilization will be in this treatment arm.
3338598|NCT02165774|Active Comparator|sacral neuromodulation ON|active sacral neuromodulation (neuromodulator ON)
3338599|NCT02165774|Placebo Comparator|sacral neuromodulation OFF|placebo sacral neuromodulation (neuromodulator OFF)
3338600|NCT02165787||patients|
3338601|NCT02165787||healthy control subjects|
3338602|NCT02165800|Active Comparator|O-PANP-TME|Open pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3338603|NCT02165800|Experimental|L-PANP-TME|Laparoscopy-assisted pelvic autonomic nerve preservation total mesorectum excision for male mid-low rectal cancer patients
3338604|NCT02165813|Active Comparator|Nitazoxanide|oral nitazoxanide suspension twice daily for 3 days
3236394|NCT01250366|Experimental|Arm 4: INX-08189 (50 mg) or Placebo|
3236395|NCT01250366|Experimental|Arm 5: INX-08189 (9 mg) or Placebo + Ribavirin|
3236396|NCT01250366|Experimental|Arm 6: INX-08189 (25 mg) or Placebo + Ribavirin|
3338605|NCT02165813|Placebo Comparator|Placebo|oral placebo suspension twice daily for 3 days
3338606|NCT02165852|Experimental|Papillectomy without injection|Conventional snaring mucoal resection without submucosal injection
3236397|NCT01250366|Experimental|Arm 7: INX-08189 (100 mg) or Placebo|
3236398|NCT01250392|Other|Control Arm|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment.
3338607|NCT02165852|Active Comparator|Papillectomy with injection|Conventional mucosal resction method following injeciton of diluted epinephrine mixture.
3236399|NCT01250392|Experimental|Active Choice Only Arm|The active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
3236400|NCT01250405|Active Comparator|Cinacalcet|
3236401|NCT01250405|Placebo Comparator|Placebo|
3236402|NCT01250431|Experimental|EFT (Emotional Freedom Techniques)|10 sessions of EFT.
3236403|NCT01250431|No Intervention|Wait List|10 week wait period.
3236404|NCT01250444|Experimental|Inspiratory Muscle Training|It will me performed a loaded training of ventilatory muscles in patients with Hypertension. Its is done with the practice of breathing exercises associated to an training device, specific for this kind of intervention.
3236405|NCT01250457|Experimental|Topical timolol|topical Timolol 0.5% solution applied twice daily
3338608|NCT02165865|Experimental|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
3338609|NCT02165878||Children and adolescent|children and adolescent CKD patients of any etiology
3338610|NCT02165891|Other|Urokinase|insertion of a chest drain with urokinase instillation
3338611|NCT02165891|Other|VATS|primary video-assisted thorascopic surgery Other interventions except drainage procedure are the same in both arms
3338612|NCT02165917|Placebo Comparator|Excision only|Laparoscopic excision of endometriotic lesions followed by 3 month of GnRH-Analogue administration
3338613|NCT02165917|Active Comparator|Excision plus hyaluronic acid gel|Standard Laparoscopic excision of endometriotic lesions plus application of 10 cc of a hyaluronic acid gel (Hyalobarrier® ), followed by 3 month of GnRH-analogue administration
3338614|NCT02165930|Experimental|Treatment A|
3338615|NCT02165930|Experimental|Treatment B|
3338616|NCT02165943||Vitoss Bone Graft with BMA|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage age was recommended and who received Vitoss bone graft with BMA to fill the cavity.
3338617|NCT02165943||Vitoss bone graft|Patients with a benign bone lesion of the extremity or pelvis for which surgical curettage was recommended and who received Vitoss bone graft to fill the cavity.
3338618|NCT02165956|Experimental|New Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
3338619|NCT02165956|Active Comparator|Standard Infant Cereal|The amount of cereal administered will be free and from 6 to 12 months of age.
3236406|NCT01250470|Experimental|Treatment (vaccine therapy)|"Patients receive Montanide ISA-51/survivin peptide vaccine SC followed by sargramostim SC on day 0. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~TREATMENT EXTENSION: After completion of study treatment, select patients may receive additional doses of Montanide ISA-51/survivin peptide vaccine SC and sargramostim SC. Treatment repeats every 3 months in the absence of disease progression or unacceptable toxicity."
3236407|NCT01250483||BPH|men aged more than 40 years who presented with BPH/LUTS and showed negative results of transrectal prostate biopsy before the period of AB medication
3338620|NCT02165969|Experimental|endoscopic endonasal surgery with UPSIT|endoscopic endonasal surgery with UPSIT prior to surgery and at months 1, 3, 6, and 12 after surgery.
3236408|NCT01250483||prostate cancer|men aged more than 40 years who presented with BPH/LUTS and showed positive results of transrectal prostate biopsy before the period of AB medication
3338621|NCT02165982||Patients controles|Inpatients suffering from anorexia nervosa at Institut Mutualiste Montsouris
3338622|NCT02165982||Individus sains témoins|Healthy controls selected from the general population
3338623|NCT02165995|Experimental|Navigated Transcranial Magnetic Stimulation (nTMS)|Participant assessed by nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Motor mapping and speech mapping performed at these visits. This should take about 1½-2 hours to complete.
3338624|NCT02166008|Active Comparator|Repamipide|Rebamipide (100) 1 tab oral tid for 1 year or peptic ulcer occurred
3338625|NCT02166008|Placebo Comparator|placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient. It will be prescribed as the same regimen of Rabamipide.
3338626|NCT02166021|Experimental|IT- Treated|Injection to IT (Group 1). After 6 months, 8 patients (group 1A) will be treated with MSC once again in IT, and 8 additional patients (group 1B) will receive a placebo.
3338627|NCT02166021|Experimental|IV - Treated|Injection to IV (Group 2). After 6 months, 8 patients (group 2A) will be treated with MSC once again in IV, and 8 additional patients (group 2B) will receive a placebo.
3338628|NCT02166021|Placebo Comparator|Placebo|Placebo at the first injection (group 3). After 6 months, 8 patients (group 3A) will be treated with MSC in IT, and 8 additional patients (group 3B) will be treated with MSC in IV.
3338629|NCT02166034|Experimental|garden intervention|Schools assigned to the garden intervention receive raised bed garden kits and access to a toolkit of garden-based curriculum
3338630|NCT02166034|No Intervention|Control|Wait-list control (no garden intervention + lessons) until end of the study.
3338631|NCT02166060|Experimental|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
3338632|NCT02166086||Endoscopic imaging|Any patient who has undergone advanced imaging procedures for diagnosis and/or treatment of a pancreatico-biliary disorder.
3338633|NCT02166099||SpyGlass Choledochoscopy procedure|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of a pancreatico-biliary disorder
3338634|NCT02166112||Permacol mesh placement|No intervention performed
3338635|NCT02166125||Endoscopic suturing|Any patient who has undergone clinically indicated and/or standard of care endoscopic suturing within the Gastrointestinal tract.
3338636|NCT02166138|Experimental|Laser treated Group|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits. Thus, patients in this group will be getting the Non-Abilative laser treatment.
3338637|NCT02166138|Placebo Comparator|Not Laser treated Group|Patients in this group will be given the laser treatment with the 1540 non-abilative laser device, but the device will not be set to provide treatment. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
3338638|NCT02166151|Experimental|Omalizumab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
3338639|NCT02166164|Experimental|Experiemental pain models|all study participants will be tested with the same experimental pain models: Brief thermal sensitization, Long thermal stimulation, and Heat-pain-detection threshold.
3236409|NCT01250496|Experimental|Aminophylline|75 mg of intravenous aminophylline.
3236410|NCT01250496|Placebo Comparator|Placebo|Matching normal saline placebo (sterile salt water).
3338640|NCT02166177|Experimental|Autologous Regulatory T cell therapy|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose)
3338641|NCT02166190|Experimental|Radiofrequency Ablation (EndoHbp probe)|Radiofrequency Ablation using EndoHPB Probe
3338642|NCT02166190|Active Comparator|Stenting only|Stenting only
3338643|NCT02166216||Healty subjects|Healthy subjects that participate in a high intensity, endurance bicycle race.
3338644|NCT02166229|Experimental|Divalproex sodium|Divalproex sodium will be initiated at 125 mg twice daily and increased monthly to a maximum dose of 500 mg twice daily.
3236411|NCT01250535|Experimental|Warfarin plus lovastatin|Warfarin plus lovastatin
3236412|NCT01250535|Placebo Comparator|Warfarin plus placebo|Warfarin plus placebo
3236413|NCT01250548|Active Comparator|2|
3236414|NCT01250548|Placebo Comparator|Apremilast|Placebo Compared to apremilast arm
3236415|NCT01250574||Postoperative infections|
3236416|NCT01250574||Bacterial infections in the GI tract|
3236417|NCT01250587|Experimental|PDC31|
3236418|NCT01250600|Experimental|Remote-care|Home exercise monitored by the remote care system
3236419|NCT01250600|Active Comparator|Control|Home exercise under expert's instruction
3236420|NCT01106794||Patient samples|Fresh-frozen and fixed tumor samples, correspondent normal brain tissue samples, cerebrospinal fluid, urine, and serum samples from patients affected with diffuse intrinsic pontine glioma or brainstem glioma
3236421|NCT01250626||a single-group study|Pediatric OPD, age < 18 y/o.
3236422|NCT01250652|Active Comparator|Levocetirizine|24 patients will received 20 mg Levocetirizine daily
3236423|NCT01250652|Experimental|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
3338645|NCT02166242|Experimental|experimental|patients pathologic diagnosis advanced non-small cell lung cancer who had received more than two lines standard treatment, according to NCCN Non-small cell lung cancer guideline, there were no standard treatment scheme for these patients. Approximately 40 patients will be included in the study, patients will received oral ethaselen dispersible tablet, 600 mg bid dose, patients may quit the study whenever they would like or investigator evaluate that progression disease has developed, or any grade of SAE developed during the study.
3236424|NCT01250665||clinically isolated syndrome|In this study the term clinically isolated syndrome (CIS) is defined according to the Task Force on Differential Diagnosis in MS, as a monophasic presentation of neurological symptoms with suspected underlying inflammatory demyelinating disease (Miller 2008).
3236425|NCT01250665||remitting, relapsing MS|remitting relapsing MS according to the criteria by Poser (Poser 1983) or McDonald (McDonald 2001)
3338646|NCT02166255|Experimental|Treatment (APN401)|Patients receive autologous siRNA-transfected peripheral blood mononuclear cells APN401 IV over 30 minutes.
3338647|NCT02166268|Active Comparator|Avanz Phleum pratense|Avanz Phleum pratense 15,000 SQ+ (standardised quality), suspension for subcutaneous injection.
3338648|NCT02166268|Placebo Comparator|Placebo|Placebo, suspension for subcutaneous injection.
3338649|NCT02166294|Experimental|NEOX® CORD 1K|Cryopreserved, umbilical cord allograft (NEOX® CORD 1K) with off-loading instructions.
3338650|NCT02166294|Active Comparator|Pressure bandage|Standard of Care Pressure bandage with off-loading instructions
3236426|NCT01250678||neurocognitive impaired|MS patients treated with natalizumab who at the beginning of the study suffer from cognitive impairment
3236427|NCT01250678||neurocognitive non-impaired|MS patients treated with natalizumab who at the beginning of the study do not suffer from cognitive impairment
3338651|NCT02166294|Experimental|Standard of Care Cross over to NEOX|Subjects in the Standard of Care (pressure bandage) group that have not healed greater than 50% at the Week 12 visit, or have a wound that is worsening, will be offered participation in the cross-over arm of the trial. The cross-over arm of the study will be treated with NEOX CORD 1K and followed for 12 weeks.
3236428|NCT01250691||hospital acquired pneumonia|
3236429|NCT01250691||isolated rooms|
3236430|NCT01250691||ward-type ICU|
3236431|NCT01250743|Experimental|Ascorbic Acid (Vitamin C)|
3236432|NCT01250782|Placebo Comparator|Physiological Serum|
3236433|NCT01250782|Active Comparator|Glutamine|
3236434|NCT01250795|Experimental|15 ug HAI-05 plus Alhydrogel|vaccine
3338652|NCT02166320|Active Comparator|Partially covered SEMS|Boston Scientific Ultraflex SEMS
3338653|NCT02166320|Experimental|Fully covered SEMS|Boston Scientific Wallflex Esophageal SEMS.
3338654|NCT02166359|Active Comparator|Glucose group|Glucose use of 2.5% or 4.25% dextrose solution at least 4 hours
3236435|NCT01250795|Experimental|45 ug HAI-05 plus Alhydrogel|vaccine
3236436|NCT01250795|Experimental|90 ug HAI-05 plus Alhydrogel|vaccine
3236437|NCT01250795|Experimental|90 ug HAI-05 in saline|vaccine
3236438|NCT01250795|Placebo Comparator|Saline|placebo
3338655|NCT02166359|Experimental|Extraneal (Icodextrin) group|Extraneal (Icodextrin) use at least 8 hours
3338656|NCT02166372||Obese diabetic patients|Diabetic patients with BMI over 25 Age 20 to 67 Diabetes medically controlled at our center for at least six months
3338657|NCT02166398|Active Comparator|Amosartan 5/50 tab|Amosartan 5/50 tab given by oral administration
3338658|NCT02166398|Experimental|UI15AML055MT tab|UI15AML055MT tab given by oral administration
3338659|NCT02166411|Experimental|myomectomy using barbed sutures|.Myoma bed is sutured with barbed sutures
3338660|NCT02166411|Active Comparator|myomectomy using conventional sutures|Myoma bed is sutured with conventional sutures
3338661|NCT02166424|Active Comparator|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
3338662|NCT02166424|Placebo Comparator|olive oil|2880mg olive oil daily
3236439|NCT01250821|Experimental|Ovulation induction|
3236440|NCT01250847|Experimental|Seroquel-XR|The subjects At-Risk Mental States will be treated with Quetiapine(Seroquel-XR) from baseline to end of trial.
3236441|NCT01250847|Experimental|Schizophrenia Comparator|The subject with schizophrenia will be treated with standard treatment
3236442|NCT01250847|No Intervention|Healthy Control Comparator|The subjects will not be required to treat
3236443|NCT01250860|Sham Comparator|Control Group|Control DoboMed group - only specific active exercises: symmetrical positions for exercising; asymmetrical active movements; thoracic spine kyphotization; transverse plane derotation; apical area involvement; concave ribs mobilization; exteroceptive facilitation; respiration-directed movements of the thorax and spine; three-dimensional displacement of vertebra; active autocorrection.
3236444|NCT01250860|Experimental|Experimental group|"Experimental DoboMed and Kaltenborn manual therapy. Suitable techniques were chosen according to manual examination: cervical spine; thoracic spine; lumbar spine; costovertebral articles; pelvis position. During the 15 sessions in group DK we used:derotational manual terapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method; the manual techniques used in continuation study were different from techniques in pilot study."
3236445|NCT01250886|Placebo Comparator|Normal saline solution|Blood sample is obtained from patient in either forearm immediately before a Normal saline solution administered on the same site. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3236446|NCT01250886|Active Comparator|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3236447|NCT01250886|Active Comparator|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
3338663|NCT02166437||Alendronate|Patients treated with alendronate
3338664|NCT02166437||Minodronate|Patients treated with minodronate
3338665|NCT02166437||Denosmab|Patients treated with denosmab
3338666|NCT02166450||Control group|Denture wearers without clinical signs of denture-related stomatitis confirmed with negative Candida swabs.
3236448|NCT01250938|Experimental|ESI - Community Outreach|All families receive the same Early Social Intervention - Community Outreach (ESI-CO) treatment for 3 months in addition to 6 months of community resource support.
3236449|NCT01250951|Experimental|Deferasirox|
3236450|NCT01250964|Active Comparator|Wound-assisted lens injection|Wound-assisted lens injection is considered neither superior or inferior to wound-directed lens injection.
3338667|NCT02166450||Denture-related stomatitis group|"Denture wearers with clinical signs of denture-related stomatitis, confirmed with positive Candida swabs.~Treated for fungal infection, with nystatin [100 000 IU every 6 h for 3 weeks, applied on the infected area of the mucous membrane of the palate and cheeks]."
3338670|NCT02166489|Experimental|mesenchymal stem cell transplantation|Intravenous injection of mesenchymal stem cell in patients with PKD
3338671|NCT02166502||Nevirapine|The patients in this study are newborn infants clinically prescribed combination antiretroviral treatment with nevirapine for prevention of mother-to-child HIV transmission.
3338672|NCT02166515||experiment group|patients with cervical cancer, endometrial cancers or ovary cancer
3338673|NCT02166515||control group|postmenopausal women with benign tumor
3338674|NCT02166528||experiment group|patients with FPFD
3338675|NCT02166528||control group|patients without FPFD
3338676|NCT02166541|Experimental|INRS with BCSK|"Intensive Neurophysiological Rehabilitation System (INRS) including the Biomechanical correction of the spine according to Kozyavkin (BCSK).~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
3338677|NCT02166541|Sham Comparator|INRS, traditional spinal manipulation|"Intensive Neurophysiological Rehabilitation System (INRS) including spinal manipulation by the traditional technique.~The daily treatment for about 2 hours are in general equal for all children except for the type of spinal manipulation. Duration of all treatment will be noted in a Treatment Diary."
3338678|NCT02166554|Placebo Comparator|Control Arm|Standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with saline placebo following surgery
3338679|NCT02166554|Experimental|Cross-linked Hyaluronan Hydrogel Arm|HyaRegen
3236451|NCT01250964|Active Comparator|Wound-directed lens injection|Wound-directed lens injection is neither considered superior nor inferior to wound-assisted lens injection.
3338680|NCT02166567|Experimental|YoPro and FACS|Spermatozoa to be used for ICSI will be stained with the YoPro Dye and then be sorted with FACS to select non-YoPro stained spermatozoa, known to have significantly less fragmented DNA.
3236452|NCT01251029|Experimental|sugar pil and saline|
3236453|NCT01251055|Placebo Comparator|Placebo|
3338681|NCT02166567|Active Comparator|Swim-up|Spermatozoa will be processed using the conventional swim-up me
3338682|NCT02166593|Experimental|Pravastatin 40mg/Fenofibrate160mg|Pravastatin (40mg/day) Fenofibrate (160mg/day)
3338683|NCT02166593|Active Comparator|Atorvastatin Sodium|Atorvastatin Sodium (10mg/day)
3338684|NCT02166619|Experimental|tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric tDCS will be applied with duration of 20 minutes, intensity of 2 mA where anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. After tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
3236454|NCT01251055|Experimental|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1 4000 mg/day
3236455|NCT01251068|Experimental|gest age, cerebral ,somatic oxygenation measurement|
3236456|NCT01251081|Experimental|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
3236457|NCT01251081|Sham Comparator|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
3236458|NCT01251107|Experimental|Arm B|BEACOPP (Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for 4 escalated cycles followed by 4 standard cycles
3236459|NCT01251107|Active Comparator|Arm A|ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for 6 to 8 cycles
3236460|NCT01251133|Experimental|LBVH0101|
3236461|NCT01251133|Active Comparator|Hiberix|
3236462|NCT01251172|Experimental|Treatment (RO4929097 after autologous stem cell transplant)|"STEM CELL TRANSPLANTATION AND CHEMOTHERAPY: Patients undergo standard mobilization and collection of autologous peripheral stem cells (>= 4.0 x 10^6 CD34+ cells/kg). Patients then receive high-dose melphalan IV on days -3 and -2 and undergo autologous stem cell transfusion on day 0. Patients with progressive disease, stable disease, partial response, stringent complete response, or complete response are taken off study; patients with residual/persistent disease (VGPR) continue to therapeutic treatment.~THERAPEUTIC TREATMENT: Beginning 100-110 days after transplantation, patients receive oral gamma-secretase inhibitor RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3236463|NCT01251185|Experimental|CHF|Single-arm, open label, subjects with Congestive Heart Failure, with ischemic etiology.
3236464|NCT01251198||Acute coronary Syndrome|Patients affected are patients with acute coronary syndrome with ST segment elevation ST (myocardial infarction) in 48 hospitalized in one of the centers (emergency, ambulance, intensive care unit, cardiac catheterization lab).
3338685|NCT02166619|Sham Comparator|Sham tDCS + physical therapy|Firstly, patients will undergo electrophysiological evaluation: motor evoked potential, motor threshold and silent period in both hemispheres. After those procedures, bihemispheric sham tDCS will be applied. Anodal electrode will be on the affected hemisphere and the cathodal electrode, on the non-affected hemisphere. Sham tDCS will be performed by ramping current flow for the first 10 seconds of stimulation, but switching the stimulator off after 30 seconds. After bihemispheric sham tDCS, patients will be submitted to 40 minutes of physical therapy protocol. Experimental sessions will be repeated five times per week to complete 10 sessions.
3338686|NCT02166632|Experimental|Intracapsular Injection|Patients in the experimental group will undergo direct injection of ExparelTM into the knee joint; once the total knee replacement (arthroplasty) has been completed, patients will receive a given amount of ExparelTM administered during surgery into the joint where the knee replacement (arthroplasty) (TKA) was performed.
3338687|NCT02166632|Active Comparator|Periarticular Injection|Patients in this group will undergo local injection of ExparelTM to help to reduce post-surgery pain. Once the total knee replacement (arthroplasty) has been completed, patients in this group will receive a given amount of ExparelTM administered during surgery into the soft tissues around the bone where the knee replacement (arthroplasty) (TKA) was performed.
3338688|NCT02166645|Experimental|Prone position|Prone position per 48 hours after extubation
3338689|NCT02166645|Active Comparator|Supine position|Supine position per 48 hours after extubation
3338690|NCT02166658|Experimental|Single Arm|Patients receive Cabazitaxel 25 mg/m2 i.v. infusion. This trial is a single arm trial.
3338691|NCT02166671|Experimental|HBV booster vaccination|
3338692|NCT02166684|Experimental|Do-it-yourself devices|All subjects will use do-it-yourself devices for self-monitoring health parameters
3338693|NCT02166710|Experimental|Adductor canal femoral nerve blockade|Patients will receive continuous adductor canal femoral nerve blockade for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
3338694|NCT02166710|Placebo Comparator|Simulated nerve blockade|Patients will receive a simulated continuous femoral nerve block at the level of the adductor canal for 48 hours with a catheter connected to a pump infusing bupivacaine 0.125% and multi-modal analgesia for pain management following total knee arthroplasty. Knee extensor muscle strength will be measured at different time-points prior and after surgery.
3338695|NCT02166723||CRYOABLATION|Cryoballoon ablation will be applied to all patients with persistent atrial fibrillation. It consists on applying the Arctic Front Cryoballoon to the pulmonary veins and freezing the antrum. In addition debulking of the atrial roof will be performed by a single application of the cryoballoon to the left and right roof, the septal wall and the lateral ridge wall.
3236465|NCT01251211|Active Comparator|botulinum toxin type A|botulinum toxin type A will be injected subcutaneously in the painful area (maximum 300 units)
3236466|NCT01251211|Placebo Comparator|sodium chloride 9 %|sodium chloride 9 % will be used as a neutral placebo
3236467|NCT01251224|Active Comparator|Education Group|This group will receive IPM education at baseline, and then the full IPM intervention after completing the study.
3236468|NCT01251224|Experimental|IPM Group|This group will receive the full IPM intervention at baseline.
3338696|NCT02166736|Experimental|Instantaneous wave-free ratio (iFR)|
3338697|NCT02166736|Active Comparator|Fractional Flow Reserve (FFR)|
3236469|NCT01251237|Experimental|Moviprep Orange|All patients receive 2 litres of NRL0706 solution.
3236470|NCT01251250|Experimental|Arm I|Patients receive oral Azadirachta indica once daily on days 1-28. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3236471|NCT01251263|Other|Group 1|Cyclic OC users prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
3236472|NCT01251263|Other|Group 2|Spontaneous ovulation group prior to initiating study OC. Estradiol or placebo given in a certain sequence depending on the randomization.
3236473|NCT01251302||Prospective Cohort|Patient presenting with chest pain or anginal equivalent and receiving a resulted age, sex and gene expression score (ASGES) to assist in diagnosis.
3338698|NCT02166749||Subtotal abdominal hysterectomy|107 women
3338699|NCT02166749||Total abdominal hysterectomy|105 women
3236474|NCT01251302||Retrospective Cohort|Patients presenting with chest pain or anginal equivalent who did not receive an age, sex and gene expression score (ASGES) to assist in diagnosis. Note: this cohort was historical.
3236475|NCT01251328|Active Comparator|General anaesthesia|General anaesthesia is performed under standardized conditions
3236476|NCT01251328|Active Comparator|Sedation|Sedation is performed under standardized conditions
3338700|NCT02166762|Experimental|QLV interval measurement|QLV measurements collected during implantation of CRT-D device
3338701|NCT02166788|Other|Arm 1: Inguinal Lymphadenectomy|Inguinal Lymphadenectomy (IL) is removal of the easily accessible superficial groin lymph nodes (LNs) and has a median LN retrieval of 11 lymph nodes
3338702|NCT02166788|Other|Arm 2: Ilio-inguinal Lymphadenectomy|Ilio-inguinal Lymphadenectomy (I-IL) is the removal of the same superficial groin lymp nodes (LN) removed during an IL but also combined with the more surgically complex removal of the ipsilateral pelvic LN. About twice as many LN are removed with I-IL compared to IL.
3338703|NCT02166801|Active Comparator|Early intervention for infants|A 30w intensive intervention according to the small step program, with daily practice sections conducted by parents at home, with weekly support by therapists.
3236477|NCT01251341|Experimental|Compassion Meditation Group|
3236478|NCT01251341|Active Comparator|Health Education and Wellness Group|
3236479|NCT01251341|Experimental|Mindful Attention Training|
3236480|NCT01251406|Placebo Comparator|Placebo|Subcutaneous administration for daily for 8 hours a day for 10 days
3338704|NCT02166801|Active Comparator|Usual care|Usual care means that the Children in this arm of the study participate in the established follow up program that is established at the Astrid Lindgrens Children's Hospital and offered to all Children that displays a delayed early gross and fine motor development.
3338705|NCT02166814|Experimental|Fimasartan and Rosuvastatin|Combination of Fimasartan and Rosuvastatin
3338706|NCT02166814|Active Comparator|Fimasartan|Fimasartan monotherapy
3338707|NCT02166814|Active Comparator|Rosuvastatin|Rosuvastatin monotherapy
3338708|NCT02166827|Active Comparator|NeuroAD|NeuroAd Treatment, synchronized TMS and cognitive training stimulation
3338709|NCT02166827|Sham Comparator|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
3338710|NCT02166840|Experimental|Self expanding metal stent|Patients with self expanding metal stent inserted into bile duct.
3338711|NCT02166840|Active Comparator|Plastic stent|Patients with obstructive jaundice who got a plastic stent inserted into bile duct.
3338712|NCT02166853|Experimental|conventional group|"a conventional group, in which intravenous sedation with midazolam will be administered"
3338713|NCT02166853|Experimental|sevoflurane group|"a sevoflurane group, in which patients will inhale sevoflurane during a 48 hour-period, through dedicated devices"
3338714|NCT02166866||Experimental arm|
3338715|NCT02166879||Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS)|Chart review from patients undergoing elective surgery.
3338716|NCT02166892|Active Comparator|Normal weight|Normal weight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
3338717|NCT02166892|Active Comparator|Overweight children|Overweight children will be served food in two different occasions using two sets of plates (same size). One set will be plane and the second is a specially designed plate that demonstrate the recommended food consumption and portion.
3338718|NCT02166905|Experimental|Arm I (CDX-1401, poly ICLC)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 and poly ICLC as in Phase I.
3338719|NCT02166905|Experimental|Arm II (CDX-1401, poly ICLC, IDO1 inhibitor INCB024360)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, and IDO1 inhibitor INCB024360 as in Phase I.
3338720|NCT02166918||patients with schizophrenia|320 patients with a diagnosis of schizophrenia according to Diagnostic and Statistical Manual IV edition (DSM-IV) criteria, confirmed by the Structured Clinical Interview for DSM-IV - Patient Version (SCID -IP), will be included in the study.
3338721|NCT02166918||unaffected first-degree relatives|240 unaffected first-degree relatives of the recruited patients (120 unaffected parents and 120 unaffected siblings)
3236481|NCT01251406|Experimental|rhNRG-1 Dose 1|Subcutaneous administration for daily for 8 hours a day for 10 days
3338722|NCT02166918||healthy control|320 healthy control subjects.
3338723|NCT02166931|Placebo Comparator|placebo|placebo with the same color, order, taste as BRAND'S® Essence of Chicken , 70cc daily for 2weeks
3338724|NCT02166931|Experimental|Chicken Essence|BRAND'S® Chicken Essence 70cc, daily for 2 weeks
3338725|NCT02166944|Experimental|tamoxifen|tamoxifen 40 mg daily for one year
3338726|NCT02166944|Placebo Comparator|placebo|placebo drugs
3338727|NCT02166957||Long disruption > 5cm +/- loss of SES|
3338728|NCT02166957||Short disruption < 5cm|
3338729|NCT02166970|Experimental|Single stent deployment|Metallic stent deployment in hilar obstruction. Insertion of metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
3236482|NCT01251406|Experimental|rhNRG-1 Dose 2|Subcutaneous administration for 8 hours a day for 10 days
3236483|NCT01251419|Experimental|Testimonial and Union Arm|The testimonial and union arm will receive the same letter as the testimonial treatment arm but with the addition of the union affiliation of the employee giving the testimonial.
3338730|NCT02166970|Active Comparator|Multiple stent deployment|Metallic stent deployment in hilar obstruction. Insertion of multiple metallic stent to the dominant targeted duct such as right anterior (segments V and VIII), right posterior (segments VI and VII) or left (segments II-IV).
3338731|NCT02166983|Experimental|Arm IA (Lumosity, relaxation, compensatory strategies)|Participants complete Lumosity cognitive exercises. Lumosity cognitive exercises are online video game-based activities that are designed to practice various cognitive skills including processing speed, attention, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises (guided imagery, progressive muscle relaxation, and/or autogenics) at least 10 minutes a day for 6 weeks and compensatory strategies (the use of external devices such as a notebook, day planner, or smartphone for cuing, reminding, and organizing; the use of memory strategies such as repetition, paraphrasing, and active listening; and the use of executive strategies such as self-talk for planning and attention orientation) as much as possible.
3338732|NCT02166983|Experimental|Arm IB (Active Journaling, relaxation, compensatory strategy)|Participants complete Active Journal cognitive exercises. Active Journaling requires participants to keep a written diary or journal where she discusses what her thoughts and feelings about various events with a focus on describing the meaning of the activities and experiences, particularly new things that were learned. Active Journaling is a method of practicing various cognitive skills including communication, organization, memory and executive function. Participants complete cognitive exercises at least 20 minutes a day, 5 days a week for 6 weeks. Participants also complete relaxation exercises and compensatory strategies as in Arm IA.
3338733|NCT02166983|Experimental|Arm II (Lumosity only)|Participants complete Lumosity exercises as in Arm IA.
3236484|NCT01251419|Experimental|Control|The control arm will receive a letter signed by our partner company's Chief Medical Officer, explaining the health and monetary benefits of switching from brand name prescription medication to generic prescription medication.
3338734|NCT02166996|Active Comparator|A|Suture removal time 7 days.
3338735|NCT02166996|Experimental|B|Suture removal time 14 days.
3338736|NCT02167009|Experimental|Prostate Artery Embolization|Embospheres microspheres
3338739|NCT02167048|Experimental|Normal-dose Psychostimulant, Low-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
3338740|NCT02167048|Active Comparator|Low-dose Psychostimulants, Normal-dose|Normal-dose: Dose participants are currently taking as part of their prescription (on more than or equals to 20 mg/day of Psychostimulants) Low-dose: Half the normal dose
3338741|NCT02167048|No Intervention|No intervention, No intervention|This arm is completely no intervention, and is ONLY for healthy volunteers. We are testing healthy volunteers of the same age to give us an estimate of order effects to help us correct for better performance in the 2nd session due simply to taking the same tests twice (note: the tests are Version A and B).
3338742|NCT02167061|Experimental|(Part 1) DA-1229_01 → E+M|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
3338743|NCT02167061|Experimental|(Part 1) E+M → DA-1229_01|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg E : Evogliptin 5 mg M : Metformin XR 1000 mg
3338744|NCT02167061|Experimental|(Part 2) DA-1229_01 fast → fed|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
3338745|NCT02167061|Experimental|DA-1229_01 fed → fast|DA-1229_01 : Evogliptin/Metformin XR 5/1000mg Fast : administration on an empty stomach Fed: administration after high-fat diet
3338746|NCT02167087|Experimental|Sentinel node mapping|Sentinel node mapping with indocyanine green injected orally and anally to the tumor.
3236485|NCT01251419|Experimental|Testimonial Treatment Arm|The testimonial treatment arm will receive the exact same letter as the control arm, but the letter will feature an employee's testimonial along with the first name, last initial, city and state of the employee giving the testimonial.
3338747|NCT02167100||Retained in Care|Each patient who had at least 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring until 31st of March 2014.
3338748|NCT02167100||Lost to follow-up (LTFU)|Each patient who had at 2 practice visits separated by ≥90 days in a year involving HIV laboratory monitoring but did not maintain regular attendance at HHMP until 31st March, 2014.
3338749|NCT02167113||study population|
3338750|NCT02167126|Experimental|Kinesio Taping|Kinesio Taping was applied as experimental group.
3338751|NCT02167126|Placebo Comparator|Micropore|Micropore Tape was used as placebo tape
3338752|NCT02167152|Experimental|Ischemic Preconditioning Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a pressure calculated based on the person's blood pressure.
3338753|NCT02167152|Active Comparator|Control Group|Participants randomized to this group will have a blood pressure cuff placed on each arm, and these cuffs will be inflated one at a time to a set pressure (30mmHg, or millimeters of mercury on a blood pressure measuring machine).
3338754|NCT02167165||Digoxin and AF|Patients consulting the emergency deprtment (ED) for AF and receiving Digoxin treatment
3338755|NCT02167178||Volunteers receiving 0.9% NaCl|Volunteers receiving 0.9% NaCl to optimise stroke volume
3338756|NCT02167178||Volunteers receiving gelofusine|Volunteers receiving gelofusine to optimise stroke volume
3338757|NCT02167191|Experimental|HIT|High intensity interval training sessions on an cycle ergometer
3338758|NCT02167230|Experimental|Jailed-balloon technique|Apply jailed-balloon technique to protect the side branch during coronary bifurcation PCI
3338759|NCT02167230|Active Comparator|Jailed-wire technique|Apply jailed-wire technique to protect the side branch during coronary bifurcation PCI
3338760|NCT02167243|Experimental|Reinforcement for performing BG testing|Subjects will receive reinforcement for BG testing. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
3338761|NCT02167243|Active Comparator|No reinforcement for BG testing|Subjects will receive standard of care without reinforcement for Self Monitoring Blood Glucose
3338762|NCT02167269|Active Comparator|Baby EAR-JR|The subjects receive Baby EAR circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Jackson-Rees (JR) circuit and the procedure will be repeated.
3338763|NCT02167269|Active Comparator|JR-Baby EAR|The subjects receive Jackson-Rees (JR) circuit from the start until primary and secondary outcomes are achieved. Then the fresh gas flow will be increased to 500 ml/kg/min for 10 minutes before switching to Baby EAR circuit and the procedure will be repeated.
3338764|NCT02167295||Focus group|The focus groups will consist of 6 to 8 persons each (N = 32). The focus group discussions will last for about 60 to 90 minutes. The discussion topics will be based on previous literature and experience and will include reasons for betel quid chewing or for quitting, pros and cons of betel quid chewing, barriers to and facilitators of abstinence, health beliefs and experiences about betel quid chewing and other issues.
3236486|NCT01251432||chronic otitis media|adults who have had tympanostomy tube(s) inserted for chronic otitis media
3338765|NCT02167295||In-depth interviews.|We will conduct 15 one-to-one interviews, each lasts for about 45 to 60 minutes. Participants will be interviewed by a trained interviewer using a structured interview. The interview will be designed to collect information on socio-demographic background, current and/or former betel quid use, other substance use (smoking and/or alcohol consumption), as well as other variables including usage parameters, psychosocial and environmental influences on betel quid chewing, barriers to and interest in quitting, and knowledge of adverse effects on health.
3338766|NCT02167295||Self-report questionnaire|This study is expected to enroll 30 participants who have smoking and betel nut chewing behaviors.Participants will complete 4 separate visits to CMUH, during which they will complete the same self-report questionnaire designed to measure withdrawal symptoms relating to betel quid chewing. To better measure betel quid withdrawal symptoms and to distinguish the 6 symptoms from those of smoking withdrawal, Participants will be required to attend one visit regular cigarette smoking and betel nut chewing behavior without restriction (as control), one visit after 12 hours of overnight betel quid deprivation (no cigarette deprivation), one visit after 12 hours of overnight cigarette deprivation (no betel quid deprivation), and one visit after 12 hours of both overnight betel quid and cigarette deprivation.
3338767|NCT02167308|Active Comparator|Laser acupuncture group|Subjects will receive 24 activated laser acupuncture treatments. The laser will be applied for 10 seconds to each of the selected acupuncture points.
3338768|NCT02167308|Sham Comparator|Control group|Subjects in the control group will undergo sham laser acupuncture treatment with no laser power output. Acupuncture points, application duration, and total number of treatments will be identical to the Laser acupuncture group.
3338769|NCT02167321|Active Comparator|Arm A|"Arm A; standard neoadjuvant chemoradiotherapy group~fluoropyrimidine based concurrent chemoradiotherapy-> TME -> adjuvant chemotherapy (Low risk: fluoropyrimidine-based chemotherapy, High risk: FOLFOX)"
3236487|NCT01251432||Eustachian tube dysfunction|adults who have had tympanostomy tube(s) inserted for the clinical diagnosis of Eustachian tube dysfunction
3236488|NCT01251458|Experimental|Torisel|
3236489|NCT01251471|Experimental|Escitalopram|Escitalopram, p.o., 10 mg/d; optional 20 mg/d after 2 weeks for 8 weeks
3338770|NCT02167321|Experimental|Arm B|"Arm B : adjuvant FOLFOX group~Total mesorectal excision (TME) --> 12 cycles of FOLFOX every 2 weeks (or Total mesorectal excision (TME) --> Concurrent chemoradiotherapy + 12 cycles of FOLFOX every 2 weeks)"
3338771|NCT02167334|Experimental|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
3338772|NCT02167334|Active Comparator|Oxygenation with simple breathing mask|spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
3338773|NCT02167347|Experimental|Family Intervention|Culturally Adapted Family intervention for Psychosis Sessions will be offered weekly basis
3338774|NCT02167347|No Intervention|Control|"Caregiver ' s Patients who will be randomized to the treatment as usual arm will receive routine care"
3338775|NCT02167360|Experimental|Single Arm|
3236490|NCT01251510||Healthy adults|
3236491|NCT01251510||Type 2 diabetes|
3338776|NCT02167373|No Intervention|Control|
3338777|NCT02167373|Experimental|Intervention|Cogito Companion Intervention. Participants will be provided with a mobile phone application that provides feedback on their mental health. The participants' clinicians will be provided with a desktop application to review their patients' results.
3338778|NCT02167386|Experimental|Enhanced PrEP Adherence|Enhanced PrEP Adherence: peer navigators, PrEP support group, on-line support group, text message reminders
3338779|NCT02167386|Active Comparator|Standard PrEP Adherence|Standard PrEP Adherence: support groups, case management
3338780|NCT02167399||smart phone inclinometer|For the smart phone analysis we will be using the tilt meter application which is a digital inclinometer application available on the I phone. The phone will be placed in the vertical position utilizing the bubble level feature of the application. The application will be set to display measurements to the closest tenth of the degree, set to log measurements every 0.2 seconds. The subject will stand with knee extended to 0 degrees and quadriceps muscle activated and upper extremity support on opposite side of stance limb. The phone will be placed in the vertical position on the anterior portion of the middle third of the subject's thigh attached using double sided adhesive tape. Being placed as close as possible to level when attached to the anterior thigh with subject in single limb stance with a reading of less than 1 deg as minimum for correct set-up prior to testing. Immediately prior to testing recording will be initiated logging measurements for later assessment.
3338781|NCT02167399||2-D video analysis|two dimensional video analysis by first placing markers on the subject at the midpoint of the femoral condyles, midpoint of the ankle malleoli, and the proximal thigh along a line from the anterior superior iliac spine (ASIS) to the knee marker. Testing will take place in front of a digital video camera with tape on the floor to give a reference point for the subject being tested. Participants will be tested twice on day 1 and then again 5-9 days later. Subjects will be allowed 2-3 practice trials prior to each test in order to allow the subject to feel comfortable with each test. Following the practice trials the subject will perform 3 trials of each test on bilateral lower extremities. This set up was consistent with the set up by Munro et al.
3236492|NCT01251523|Active Comparator|PACE Plus|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3236493|NCT01251523|Active Comparator|PACE|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3236494|NCT01251523|No Intervention|Control|Physicians enrolled in the study will be randomized to one of three arms: Control, PACE intervention or PACE Plus intervention. Their pediatric asthma patients enrolled in the study will follow them into their randomization assignment.
3236495|NCT01251549|Experimental|Experimental: A|A group of paraplegics.
3236496|NCT01251562|Experimental|Cohort 1|"5.62 mg/kg~Sterile Compound C31510 for Injection"
3236497|NCT01251562|Experimental|Cohort 2|"11.25 mg/kg~Sterile Compound C31510 for Injection"
3236498|NCT01251562|Experimental|Cohort 3|"22.5 mg/kg~Sterile Compound C31510 for Injection"
3236499|NCT01251562|Experimental|Cohort 4|33.0 mg/kg
3236500|NCT01251562|Experimental|Cohort 5|"44.0 mg/kg~Sterile Compound C31510 for Injection"
3236501|NCT01251562|Experimental|Cohort 6|"58.7 mg/kg~Sterile Compound C31510 for Injection"
3236502|NCT01251562|Experimental|Cohort 7|"78.2 mg/kg~Sterile Compound C31510 for Injection"
3236503|NCT01251562|Experimental|Cohort 8|"104.3 mg/kg~Sterile Compound C31510 for Injection"
3338782|NCT02167412||Syncope without POTS|Patients meeting syncope criteria without POTS. There will be no intervention for this study arm.
3338783|NCT02167425||Late Post-IMAT Cohort|Enrollment into the Late Post-IMAT Cohort will occur over a 9-month period in beginning in the second year of the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
3338784|NCT02167425||Early Post-IMAT Cohort|Enrollment into the Early Post-IMAT Cohort will occur over a 9-month period immediately following the intervention and will be followed by a 3-month period of follow-up after the close of enrollment.
3338785|NCT02167425||Late Pre-IMAT Cohort|Enrollment into the Late Pre-IMAT Cohort will begin one year prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
3338786|NCT02167425||Early Pre-IMAT Cohort|Enrollment into the Early Pre-IMAT Cohort will begin two years prior to implementation of the intervention. Enrollment will occur over a 9-month period and will be followed by a 3-month period of follow-up after the close of enrollment.
3338787|NCT02167438|Experimental|Investigational|Application of the Hem-Avert device.
3338788|NCT02167438|No Intervention|Control|No Application of the Hem-Avert device.
3338789|NCT02167464|Active Comparator|Aldosterone Antagonist|Prescribe an aldosterone antagonist such as Spironolactone 12.5-25 mg daily as a starting dose with a maximum recommended dose of 50 mg daily.
3338790|NCT02167464|Active Comparator|Referral Hypertension specialist|Referral to a hypertension specialist
3338791|NCT02167464|Active Comparator|Renin treatment-guided therapeutics|Renin treatment-guided therapeutics. A treatment algorithm is provided to guide treatment based upon renin levels.
3338792|NCT02167464|Active Comparator|Renin-guided therapeutics and referral|Renin treatment-guided therapeutics and referral to hypertension specialist. Treatment based upon algorithm for treatment related to renin level in addition to referral to a hypertension specialist.
3338793|NCT02167477|Active Comparator|Laryngoscopy sequence 1|Macintosh laryngoscopy Storz C-MAC, standard blade Storz C-MAC, D-BLADE
3338794|NCT02167477|Active Comparator|Laryngoscopy sequence 2|Macintosh Storz C-MAC, D-BLADE Storz C-MAC, standard blade
3236504|NCT01251562|Experimental|Cohort 9|"139.0 mg/kg~Sterile Compound C31510 for Injection"
3236505|NCT01251601||Raltegravir in Pregnancy|HIV positive pregnant women currently on raltegravir as part of combination antiretroviral therapy
3236506|NCT01251627|Experimental|Decitabine|Eligible patients will recieve Dacogen 20mg/m2 in 1 hour iv infusion for 5 days every 28 days (1 cycle)plus Best Supportive Care.A total of 6 courses is planned.
3338795|NCT02167490|Active Comparator|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
3338796|NCT02167490|No Intervention|Arm 2: observation|No axillary staging
3338797|NCT02167516|Experimental|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
3236507|NCT01251640|Experimental|Arm 1|
3236508|NCT01251666|Other|Magstream + Oc Sensor + Hemoccult II|"Each patient will perform all three tests:~Magstream: 2 samples (each on a different stool)~OC Sensor: 2 samples (each on a different stool)~Hemoccult II: 6 samples (2 samples per stool, on 3 different stools)~Each test will be considered as positive if at least one sample is positive (cutoff for Magstream 55 ng/ml and for OC Sensor 150 ng/ml).~Screening will be considered as positive if at least one of the three tests is positive, leading to a colonoscopy"
3338798|NCT02167516|Active Comparator|glucosamine sulfate capsule|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
3338799|NCT02167542|Experimental|NPPV group|Patients assigned to noninvasive positive pressure ventilation (NPPV) are connected to the ventilator through a face mask (VBM Endoscopy Mask) that is secured to the patient's face by the investigator.
3338800|NCT02167542|Active Comparator|CPAP valve group|Patients assigned to CPAP valve (Boussignac valve, Vygon, Inc) are connected to this device through a standard face mask that is secured to the patient's face with elastic straps.
3338801|NCT02167555|Active Comparator|Wild Bluberries|Active Comparator
3338802|NCT02167555|Placebo Comparator|Placebo|Placebo Comparator
3338803|NCT02167568||Corpus callosum agenesis/dysgenesis|patients with Corpus callosum agenesis/dysgenesis
3338804|NCT02167568||parents|parents of patients with corpus callosum agenesis/dysgenesis
3338805|NCT02167581||epithelial odontogenic tumours|
3338806|NCT02167607|Active Comparator|Purple Potato|Active Comparator
3338807|NCT02167607|Placebo Comparator|White Potato|Placebo Comparator
3338808|NCT02167620|Placebo Comparator|Metformin|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
3338809|NCT02167620|Placebo Comparator|Placebo|Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
3338810|NCT02167633|Active Comparator|Decompression surgery plus fractionated radiotherapy|
3236509|NCT01251679|No Intervention|Control|Control: nutrition, physical activity and smoking cessation education
3236510|NCT01251679|Experimental|Hand washing|Intervention 1: hand washing education and material
3236511|NCT01251679|Experimental|Hand washing and surgical mask|Intervention 2: hand washing education and material AND paper surgical face masks
3338811|NCT02167633|Experimental|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in one fraction to cover as large a fraction as possible the defined target volume
3338812|NCT02167646|Other|Bilaterally innervated flap|Two nerve branches attached with the flap for sensory reconstruction.
3338813|NCT02167659|Experimental|BIS Assessment|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include L-Dex, skin assessment and self-report forms. Patients with < 6.5 L-Dex units change will continue follow-up for 36 months. Patients with an L-Dex value change ≥ 6.5 will undergo circumference measurement and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
3338814|NCT02167659|Active Comparator|Tape Measure|"Patients will undergo measurements by trained staff. Measurements will be performed pre-op and at 3, 6, 12, 15*, 18, 21*, 24, and 36 months post-op. Measures include arm volume (tape measure), skin assessment and self-report forms. Patients with no volume increase will continue follow-up for 36 months. Patients with a volume change of between ≥ 5% and < 10% in the at-risk limb will undergo L-Dex testing and begin treatment for 4 weeks with a 23-32 mmHg compression sleeve with gauntlet. At the end of 4 weeks patients will have their arms measured. Those demonstrating improvement will continue with follow up. Those not demonstrating improvement will be removed from the study and their medical oncologist or surgeon will be notified.~*At discretion of the site PI or attending physicians."
3338815|NCT02167672||Consumers|Women who have had a Hysterectomy in the previous 2 years
3236512|NCT01251692|Experimental|1|A retrospective chart review of 26 eyes of 23 patients with recurrent corneal erosions treated by PTK from 1996 to 2000 was performed. All eyes had failed to respond to conventional therapy. Data regarding the preoperative and postoperative best-corrected visual acuity (BCVA), spherical equivalent (SE), symptomatic relief, incidence of recurrence, and complications arising from the laser treatment were analyzed. The mean duration of symptoms prior to PTK was 18 months (range, 8 to 36 months). The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser. Mean postoperative follow-up was 12 years (range, 10 to 14 years).
3236513|NCT01251718||Donepezil Hydrochloride|
3338816|NCT02167672||Doctors|Obstetricians and Gynaecologists
3338817|NCT02167685||CMX001|Subjects who have previously participated in CMX001-301 or other CMX001 study.
3236514|NCT01251731|Experimental|Treatment Group 1|
3236515|NCT01251731|Experimental|Treatment Group 2|
3338818|NCT02167698|Experimental|Airway pressure release ventilation arm|"This group of children would be ventilated using the Airway pressure release ventilation (APRV) mode.~Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups."
3338819|NCT02167698|Active Comparator|Low-tidal volume ventilation arm|Low-tidal volume ventilation using pressure-regulated volume control mode with target tidal volume of 6 ml/kg or less and other lung-protective strategies. Restrictive fluid therapy, protocolized sedo-analgesia titration, steroid therapy, protocolized supportive care, protocolized early enteral nutrition would be provided to both the groups. Biomarkers would be measured in both groups
3236516|NCT01251731|Experimental|Treatment Group 3|
3338820|NCT02167711|Experimental|SIRT|
3338821|NCT02167724|Experimental|Patients with schizophrenia|
3338822|NCT02167737|Experimental|Bedside Decision Aid Group|This arm will include study participants who are randomized to the group utilizing the bedside decision aid, which has hospital staff arrange fall-risk reduction interventions (e.g., home safety checks, exercise programs, vision checks, etc.).
3338823|NCT02167737|Active Comparator|Control Arm|"Participants in the control/comparator arm will experience the same study procedures with the exception of not using the Bedside Decision Aid and instead being given the Centers for Disease Control (CDC) brochure, What You Can Do to Prevent Falls, and arranging for their own fall prevention strategies."
3338824|NCT02167750|Placebo Comparator|Cherry flavored beverage - Mix 1|Mix 1 flavored still beverage
3338825|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 2|Mix 2 flavored still beverage with phytochmicals and caffeine
3338826|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 3|Mix 3 flavored still beverage with phytochemicals and caffeine
3338827|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 4|Mix 4 flavored still beverage with phytochemicals and caffeine
3338828|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 5|Mix 5 flavored still beverage with phytochemicals and caffeine
3338829|NCT02167750|Experimental|Cherry Flavored Beverage - Mix 6|Mix 6 flavored still beverage with caffeine
3338830|NCT02167763|Experimental|VeraCept Intrauterine Contraceptive|The VeraCept low-dose Intrauterine Copper Contraceptive
3338831|NCT02167763|Active Comparator|TCu380|A commercial standard T-shaped copper IUD (TCu380)
3338832|NCT02167776|Experimental|Church-based teaching|Teaching about male circumcision provided to church leaders in addition to standard teaching available from Ministry of Health.
3338833|NCT02167776|No Intervention|No church-based teaching|Standard of care. Teaching about male circumcision provided by Ministry of Health.
3338834|NCT02167789|No Intervention|PhD|
3236517|NCT01251731|Experimental|Treatment Group 4|
3236518|NCT01251783|Active Comparator|Infant Formula|Infant Formula without lactobaillus or Metlin or Metlos
3236519|NCT01251783|Active Comparator|Fully breast milk|Group non randomized with fully breast milk
3236520|NCT01251783|Experimental|Metlin+Metlos+Lactobacillus GG|Infant Formula added with Metlin+Metlos (6g/L) and Lactobacillus GG 0.3x107UFC
3236521|NCT01251783|Active Comparator|Metlin+Lactobacillus GG|Infant Formula added with Metlin (6g/L) + Lactobacillus GG 0.3x107 UFC
3236522|NCT01251783|Active Comparator|Metlos+Lactobacillus GG|Infant Formula added with Metlos (6g/L)+Lactobacillus GG 0.3x107UFC
3236523|NCT01251783|Active Comparator|Lactobacillus GG|Infant Formula added with Lactobacillus GG 0.3x107UFC without Metlin or Metlos
3236524|NCT01251796|Experimental|ARQ 197 and Erlotinib|ARQ 197 and erlotinib hydrochloride
3236525|NCT01251809|Experimental|PEG-rASNase 500|500 U/m2 BSA at day 0
3236526|NCT01251809|Experimental|PEG-rASNase 1000|1000 U/m2 BSA at day 0
3236527|NCT01251809|Experimental|PEG-rASNase 1500|1500 U/m2 at day 0
3236528|NCT01251809|Active Comparator|Oncaspar|2000 U/m2 at day 0
3236529|NCT01251822|Experimental|PEG 3350|PEG 3350 plus electrolytes in solution plus placebo tablets
3236530|NCT01251822|Active Comparator|Prucalopride|Prucalopride tablets plus placebo solution
3236531|NCT01251835|Active Comparator|Sitaxsentan|
3236532|NCT01251835|Experimental|Sitaxsentan plus Rifampin|
3338835|NCT02167828|Experimental|Social Support|Participants will be trained to give one another ongoing, theory-based but personally-tailored advice, recommendations, and support to encourage entry to HIV medical care, remaining in care, and adhering to medication regimens when they are prescribed. The intervention's intent is to increase mutual support, positive attitudes, intentions, plans, and collective self-efficacy for care engagement.
3338836|NCT02167828|No Intervention|No Intervention|Participants in this arm will not receive an intervention.
3338837|NCT02167841|Experimental|Knee-Chest position|In this arm, the women will perform daily the Knee-Chest position between weeks 32-37. In week 37 the investigators will check via ultra sound if there was a successful version (if not, the woman would go to External Cephalic Version)
3338838|NCT02167841|No Intervention|External Cephalic Version|In this group the women will perform External Cephalic Version without doing maternal Knee-Chest position before.
3236533|NCT01251848|Active Comparator|Treatment A|
3236534|NCT01251848|Active Comparator|Treatment B|
3338839|NCT02167854|Experimental|LJM716, BYL719 AND TRASTUZUMAB|A treatment cycle will consist of 28 days. Treatment doses for trastuzumab and LJM716 will be fixed at trastuzumab 2mg/kg weekly, and LJM716 20mg/kg weekly. The exception to this is if dose de-escalation results in treatment of patients at dose level 1, where LJM will be dosed at 10mg/kg weekly. On Arm A, BYL719 was administered orally once daily continuously at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. On Arm B, BYL719 will be administered orally once daily during 4 of 7 days in a week, at one of 5 dosing levels, beginning with dose level 3, 250mg orally daily. This means BYL719 will be given to patients on Arm B during days 1-4, 8-11, 15-18, and 22-25 of each cycle. The dose-finding phase will follow a Continuous Reassessment Methods (CRM) phase I biostatistical design.
3338840|NCT02167906|Experimental|hand oa patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
3338841|NCT02167906|Active Comparator|without Hand OA patients|assess the carotid-femoral arterial stiffness determined by measuring the PWV
3338842|NCT02167919|Experimental|Prostatic artery embolization|Microspheres measuring 100-300 microns will be injected under fluoroscopic guidance into the left and right prostatic arteries for embolization.
3338843|NCT02167932||Breast Cancer Patients|Breast Cancer patients undergoing chemotherapy will participate in the Walk with Ease program during their treatment.
3338844|NCT02167945|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
3338845|NCT02167958|Experimental|Treatment|"Day -6, -5 Fludarabine 30 mg/M2 IV over 30-60 minutes Cyclophosphamide 14.5 mg/kg IV over 1-2 hours*, Mesna 14.5 mg/kg IV in 4 divided doses~Day -4 through -2 Fludarabine 30 mg/M2 IV over 30-60 minutes~Day -1 Total Body Irradiation 200 cGy, donor apheresis~Day 0 T cell replete PBSC~Days 3, 4 Cyclophosphamide 50 mg/kg IV Mesna 50 mg/kg IV in 4 divided doses~Day 5 Begin tacrolimus ,mycophenolate, and G-CSF"
3338846|NCT02167971|Experimental|Active Coil|The patients assigned to this group will undergo repetitive Transcranial Magnetic Stimulation over 10 sessions (each one with 2,000 pulses) on left dorsolateral prefrontal cortex.
3338847|NCT02167971|Sham Comparator|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
3338848|NCT02167984||at term newborns|Infant with GE >=37w
3338849|NCT02167984||preterm newborns|Infant with GE <37w
3338850|NCT02168010|Experimental|Experiment|Test Drug Group: 2 times a day; 4 tablets per time (2 tablets of Analgecine and 2 tab. of placebo)
3338851|NCT02168010|Active Comparator|PosCtrl|PosCtrl: Positive Control Group. 2 times a day; 4 tablets / time (2 tab. of Neurotropin and 2 placebo tablets).
3338852|NCT02168010|Placebo Comparator|Placebo|Placebo Group: 2 times a day; 4 tablets / time (4 placebo tablets).
3338853|NCT02168023|Experimental|DACC impregnated dressing|Patients undergoing elective or emergency caesarean section with DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
3338854|NCT02168023|Active Comparator|Standard surgical dressing|Patients undergoing elective or emergency caesarean section with standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
3338855|NCT02168036||Patients with lung disease|General admission criteria for this project will require at least one of the following: (1) symptoms consistent with pulmonary disease with mediastinal lymph node involvement ; (2) chest X-ray and chest CT scan consistent with lung disease and mediastinal lymph node involvement; (3) Individuals with a lung biopsy consistent with lung disease and presenting with enlarged mediastinal lymph nodes; and (4) patients with diseases of organs with known association with lung disease and mediastinal lymph node involvement.
3338856|NCT02168049|Experimental|Heart and Lung Function Monitioring|
3236535|NCT01251848|Experimental|Treatment C|
3236536|NCT01017055||Voice and Swallowing Evaluations|
3236537|NCT01251874|Experimental|Treatment (veliparib, F 18 fluorothymidine, carboplatin)|Patients receive carboplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-7 or 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may undergo fluorothymidine PET scan and peripheral blood cell and tumor tissue collection periodically for correlative studies.
3338857|NCT02168075|Experimental|Group 1|0.25g/kgof 20% mannitol administered at drilling of skull.
3338858|NCT02168075|Experimental|Group 2|0.5g/kg of 20% mannitol administered at drilling of skull.
3338859|NCT02168075|Experimental|Group 3|1.0 g/kg of 20% mannitol administered at drilling of skull.
3338860|NCT02168075|Experimental|Group 4|1.5g/kg of 20% mannitol administered at drilling of skull.
3338861|NCT02168088||Index case|Subjects who have died of sudden unexplained death
3236539|NCT01251939||Treatment with ibuprofen|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and echocardiographic evidence of hemodynamically significant PDA
3236540|NCT01251939||Controls|Gestational age <32 weeks and <1500 g, postnatal age older than 48 hours and without significant PDA
3236541|NCT01251991|Experimental|Combinatorial treatment|
3338862|NCT02168088||Biologically related family member|Biologically related family member of the deceased individual
3338863|NCT02168114|Experimental|Duchenne Muscular Dystrophy|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
3338864|NCT02168114|Experimental|Non-affected Subjects|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
3338865|NCT02168127|Experimental|Active drug group|PRC-063 - Active methylphenidate hydrochloride extended-release capsules drug group
3338866|NCT02168140|Experimental|Treatment (CPI-613 and bendamustine hydrochloride)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 of week 1 and on days 1 and 4 of weeks 2 and 3. Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3338867|NCT02168166|Active Comparator|Executive Function Training|"Two weeks of training of cognitive domain of executive functioning~Using online program (Scientific Brain Training Pro)~Four exercises"
3338868|NCT02168166|Placebo Comparator|Placebo Training|"Two weeks of training with exercises not affecting working memory, information processing speed, or cognitive load~Exercises maintain other traditional progressive aspects to preserve appearance of dynamic titration of difficulty levels~Using online program (Scientific Brain Training Pro)~Four exercises"
3338869|NCT02168179|Experimental|Supportive Care (KeraStat Skin Therapy)|Patients apply KeraStat Skin Therapy topically BID during radiation therapy.
3338870|NCT02168192|Placebo Comparator|Traditional Lecture|These subjects received a 10 minute power point lecture on BBN skills.
3338871|NCT02168192|Experimental|Simulation-Debrief|These subjects received a formal debrief process, reviewing their prior baseline simulation.
3338872|NCT02168205|Experimental|4 mg Pomalidomide - Fed|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fed conditions.
3236542|NCT01251991|Active Comparator|Single treatment: Psyllium husks|
3236543|NCT01251991|Active Comparator|Single treatment: Isolated soy protein|
3236544|NCT01251991|Placebo Comparator|Control|
3236545|NCT01252004||TT Syndrome|Will be included over a period of one year, prospectively, all patients newly diagnosed
3338873|NCT02168205|Experimental|4 mg Pomalidomide - Fasted|On Day 1, participants will receive a single oral dose of 4 mg pomalidomide under fasted conditions
3338874|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Non-smoking|Participants will remain in the clinical site for a total of 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
3338875|NCT02168205|Experimental|4 mg Pomalidomide + caffeine - Smoking|Participants will be required to smoke approximately 20 cigarettes a day for 10 days. They will receive orally a 200-mg caffeine capsule on Day 6, and on Day 8, participants will receive a single oral dose of 4 mg pomalidomide.
3338876|NCT02168218|Experimental|high protein|20% protein diet
3338877|NCT02168218|Active Comparator|low protein|7.5% protein diet
3338878|NCT02168231||Complex abdominal wall repair Strattice|Complex abdominal wall repair Strattice
3338879|NCT02168244|Active Comparator|Ice pack|Pre-treatment with ice - Ice applied to the skin 2-3 minutes before injecting biologic drug injection
3338880|NCT02168244|Active Comparator|Heating Pack|Pre-treatment with heat - Heat applied to the skin 2-3 minutes before injecting biologic drug injection
3236546|NCT01252017|Experimental|Nilotinib|Single arm, open label study
3338881|NCT02168244|No Intervention|No treatment before injection|No treatment applied to the skin 2-3 minutes before injecting biologic drug injection
3338882|NCT02168257|Experimental|RAM Cannula CPAP|CPAP provided by RAM Cannula
3338883|NCT02168257|Active Comparator|Binasal Prong CPAP|CPAP provided by binasal prong
3338884|NCT02168283|Experimental|treatment arm|active fluid management includes 3 components: dietary counseling, diuretics, and intensive dialysis regimen
3338885|NCT02168283|Active Comparator|control arm|dietary counseling alone
3338886|NCT02168296|Placebo Comparator|No added Plant-based ingredient|No Plant-based ingredient added to starchy meal
3236547|NCT01252030|Experimental|intervention|stimulation of physical activity by messages sent through e mail or SMS; in combination with monitoring of physical activity with physical activity monitors
3236548|NCT01252030|Placebo Comparator|control|no stimulation of physical activity
3236549|NCT01252043||cohort|cholestatic children without esophageal variceal bleeding
3338887|NCT02168296|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
3338888|NCT02168296|Active Comparator|High dose added to starchy meal|Plant-based ingredient in high dose added to starchy meal
3338889|NCT02168296|Active Comparator|Low dose added to liquid|Plant-based ingredient in low dose added to liquid
3338890|NCT02168296|Active Comparator|High dose added to liquid|Plant-based ingredient in high dose added to liquid
3338891|NCT02168322|Experimental|collagen membranes|collagen barrier that help in isolating unwanted tissues in periodontal regneration
3338892|NCT02168335|Experimental|Treatment group|"OrasaltsTM~1 level scoop of OrasaltsTM will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
3338893|NCT02168335|Placebo Comparator|Control group|"Sea salt~1 level scoop of sea salt will be dissolved in warm water. Participants will rinse and gargle the mouth for 30 seconds, then expel and not swallow the mixture, twice daily"
3236550|NCT01252043||study|cholestatic children with esophageal variceal bleeding
3236551|NCT01252043||cholestatic children without EV|cholestatic children without esophageal variceal bleeding
3236552|NCT01252056|No Intervention|Control|
3236553|NCT01252056|Active Comparator|Probucol|Probucol treatment
3236554|NCT01252056|Active Comparator|Combination|Probucol and Cilostazol
3236555|NCT01252069|Experimental|A|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ended by a drug free period until return of menses.
3338894|NCT02168348||Diabetic patients with a lesion on the foot|
3236556|NCT01252069|Experimental|B|PGL4001 10mg (oral tablets) for 3 months followed by a period of 10 days of progestin (oral tablets) during 3 periods each ended by a drug free period until return of menses.
3338895|NCT02168374|Experimental|Chlorhexidine - CHX|Deciduous teeth were filled with GIC containing 1.25% chlorhexidine.
3338896|NCT02168374|Experimental|Doxycycline - DOX|Deciduous teeth were filled with GIC containing 4.5% doxycycline.
3338897|NCT02168374|Placebo Comparator|Glass ionomer cement - GIC|Deciduous teeth were filled with GIC without chlorhexidine or doxycycline.
3338898|NCT02168400|Experimental|active tDCS|Subjects that are randomly assigned to this arm will receive 10 active transcranial direct current stimulation (tDCS) sessions
3338899|NCT02168400|Sham Comparator|sham tDCS|Subjects randomly assigned to sham-tDCS (transcranial direct current stimulation) will receive very low current stimulation at beginning and end of session, mimicking the feeling of current stimulation in the scalp, but not reaching levels that will stimulate brain function.
3338900|NCT02168426|Active Comparator|Guardix|6g per body
3236557|NCT01252082|Active Comparator|Scalig and Rootplaning|patients will receive scaling and root planing therapy
3236558|NCT01252082|No Intervention|control|patients in control group will not receive periodontal treatment in the time period of the study
3338901|NCT02168426|Active Comparator|Seprafilm|1 sheet per body
3338902|NCT02168465|Other|teaching self-management of intermittent catheter|Single group pre-post test of feasibility, teaching self-management
3338903|NCT02168504||Healthy controls|Healthy male and female subjects older than 18 years of age without the symptoms of Parkinson's disease. The ages of subjects in this group will be matching to the ages of subjects in Parkinson's disease group
3338904|NCT02168504||Parkinson's disease patients|male and female subjects older than 18 years of age at the early stage the disease
3338905|NCT02168517||Group I|Overweight osteoarthritis patients
3338906|NCT02168517||Group II|Normal weight osteoarthritis patients.
3338907|NCT02168517||Group III|Overweight healthy men.
3236559|NCT01252108|Experimental|Treatment|All subjects receive SQ109
3236560|NCT01252121|Other|Systane, Hialid, Unisol|1 drop Systane in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
3236561|NCT01252121|Other|Systane, Unisol, Hialid|1 drop Systane in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
3236562|NCT01252121|Other|Hialid, Systane, Unisol|1 drop Hialid in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Unisol in study eye at Visit 4, with a minimum of 24 hours between each visit.
3236563|NCT01252121|Other|Hialid, Unisol, Systane|1 drop Hialid in study eye at Visit 2, 1 drop Unisol in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
3236564|NCT01252121|Other|Unisol, Systane, Hialid|1 drop Unisol in study eye at Visit 2, 1 drop Systane in study eye at Visit 3, 1 drop Hialid in study eye at Visit 4, with a minimum of 24 hours between each visit.
3236565|NCT01252121|Other|Unisol, Hialid, Systane|1 drop Unisol in study eye at Visit 2, 1 drop Hialid in study eye at Visit 3, 1 drop Systane in study eye at Visit 4, with a minimum of 24 hours between each visit.
3338908|NCT02168517||Group IV|Normal weight healthy men.
3338909|NCT02168530|Placebo Comparator|Placebo|
3338910|NCT02168530|Experimental|Vismodegib|
3338911|NCT02168543|Experimental|Alendronate|1% Alendronate gel once in periodontal pocket (Gums)
3338912|NCT02168543|Placebo Comparator|Placebo|Placebo gel once in periodontal pocket (Gums)
3338913|NCT02168556|Placebo Comparator|Standard of Care|Patient underwent urodynamic testing by receiving only standard of care with mailed information and during test teaching.
3338914|NCT02168556|Active Comparator|Music|Patient underwent urodynamic testing while listening to music that was 60 beats per minute and received standard of care information and teaching.
3338915|NCT02168556|Active Comparator|Video|Patient watched an informational video prior to urodynamic testing.
3338916|NCT02168569|Active Comparator|Cohort 1|5 sites, namely Manhiça, Dondo, Montepuez, Tete and Chokwe
3338917|NCT02168569|Active Comparator|Cohort 2|3 sites, namely Montepuez, Dondo and Chokwe
3338918|NCT02168582||low back pain|
3338919|NCT02168595|Experimental|Cohort 1|2 mg/kg GMI-1271 or matching placebo
3338920|NCT02168595|Experimental|Cohort 2|5 mg/kg GMI-1271 or matching placebo
3338921|NCT02168595|Experimental|Cohort 3|10 mg/kg GMI-1271 or matching placebo
3338922|NCT02168608|Experimental|Remote ischemia precondition|patients in this arm accepted RIPC procedure after induction of anesthesia
3338923|NCT02168608|Experimental|None remote ischemia precondition|patients in this arm didn't accept RIPC procedure after induction of anesthesia
3338924|NCT02168621|Active Comparator|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument. A follow-up visit after 2-4 weeks is scheduled for oral hygiene control and re-motivation/re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining probing pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
3338925|NCT02168621|Active Comparator|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval. Follow-up 2-4 weeks after the last session of SRP for oral hygiene control and re-instruction if indicated. At 3 and 6 months re-evaluation is performed and re-instrumentation of all sites showing a remaining pocket depth of ≥5 mm carried out. Final evaluation at 18 months.
3338926|NCT02168634|Experimental|Botulinum toxin|5U Botulinum toxin in 1cc normal saline, administered in one of the two itchy points
3338927|NCT02168634|Placebo Comparator|Normal Saline|1cc normal saline, administered in the other itchy point
3338928|NCT02168647|Experimental|Behavioral Lifestyle counseling|Intervention group participants will take part in behavioral lifestyle counseling provided by a Registered Dietitian Nutritionist from week 14 of gestation through childbirth.
3236566|NCT01004952||screening questionnaire|This study will involve two phases. Guided by EDTM, we will first build models of decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing)using in-home ethnographic interviews with 25 melanoma FDRs (Phase I). In Phase II, we will test the validity of each composite model. This will be completed using EMA data collection with 60 different melanoma FDRs from Phase I who will report on their sunscreen use, shade-seeking, use of hat, and use of UVR protective clothing and decision-making regarding these outcomes via interactive voice response (IVR) system and audio narrative diaries (using a digital voice recorder). We will examine the validity of each model and examine the influence of theory-driven affective and cognitive predictors of UVR protection maintenance across time.
3236567|NCT01252160|Experimental|QUTENZA|Cutaneous patch
3236568|NCT01252199|Experimental|cαStx1/cαStx2|
3236569|NCT01252199|Placebo Comparator|Control|
3236570|NCT01252212|Experimental|Receiving SMS alerts|The patients randomized to this arm will have a SMS message sent to them regarding medication adherence for antiretroviral medications, anti-hypertensive medications, anti-depressants, hyperglycemic controlling medications and hypercholesterolemia controlling medications as well as life style supportive suggestions.
3236571|NCT01252212|Active Comparator|No SMS messages|The patients randomized to this arm will have a SMS message sent to them regarding healthy life style supportive suggestions.
3236572|NCT01252225|Active Comparator|Nebulised Lidocaine followed by Placebo throat spray|
3236573|NCT01252225|Active Comparator|Nebulised Placebo followoed by Lidocaine Throat Spray|
3236574|NCT01252225|Placebo Comparator|Nebulised placebo followed by placebo throat spray|
3236575|NCT01252264||Individuals with craniofacial anomalies|Individuals who have a craniofacial anomaly (head, face, or eye disorder)
3236576|NCT01252264||Control Subjects|Family members of individuals with a craniofacial anomaly
3236577|NCT01252303|Experimental|Nutrisystem|Group will receive Nutrisystem meals in addition to the behavioral weight loss program.
3236578|NCT01252303|Active Comparator|Control|Group will receive a behavioral weight loss program only.
3236579|NCT01252316|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
3236580|NCT01252316|Active Comparator|Recruitment with Volunteers|UPHS volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3236581|NCT01252316|Active Comparator|Recruitment with Nurses|UPHS Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3338929|NCT02168647|Active Comparator|Control|Participants in the control arm will receive no form of lifestyle intervention.
3338930|NCT02168673||Group 1|Healthy non-smokers
3236582|NCT01252316|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect 3) CPR Skills"
3338931|NCT02168673||Group 2|Healthy non-smokers
3338932|NCT02168686|Experimental|Part A: Dose 1|ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV
3236583|NCT01252329|Active Comparator|Elective lymph node treatment arm|Patients entering this arm will undergo selective nodal dissection of the draining lymph nodes with subsequent radiation and/or chemotherapy if indicated.
3236584|NCT01252329|No Intervention|Clinical observation arm|Patients who enter into this arm will undergo regular, periodic clinical nodal observation with subsequent evaluation and treatment if indicated upon discovery of a palpable lymph node.
3338933|NCT02168686|Experimental|Part A: Dose 2|ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV
3338934|NCT02168686|Experimental|Part A: Dose 3|ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV
3338935|NCT02168686|Experimental|Part A: Dose 4|ADVM-043 administered at a dose that will be determined
3236585|NCT01252342|Experimental|Intramyometrial oxytocin|
3338936|NCT02168686|Experimental|Part B (optional): Intrapleural administration|ADVM-043 administered intrapleurally at a dose that will be determined
3338937|NCT02168699|Other|Ultrasound examination|Ultrasound examination of the axillary region in children
3338938|NCT02168712|Active Comparator|Moderate continuous exercise training|Moderate intensity continuous exercise training
3338939|NCT02168712|Experimental|Interval exercise training|High intensity interval exercise training
3338940|NCT02168725|Experimental|briciclib|The starting dose of briciclib in the Escalation Stage will be 17 mg/week, with subsequent dose escalation levels of 35 mg, 70 mg, 140 mg, 280 mg, 560 mg, and 1120 mg. The dose of briciclib in the RPTD Confirmation Stage will be the dose as determined during the escalation stage. At each dose level, briciclib will be administered as a 2-hour intravenous infusion, once-a-week per 3-week cycles.
3338941|NCT02168738|Active Comparator|13-C labeled PC-DHA|
3338942|NCT02168738|Active Comparator|13-C labeled TG-DHA|
3338943|NCT02168738|Experimental|13-C labeled AceDoPC-DHA|
3338944|NCT02168751|Active Comparator|propofol|propofol doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
3338945|NCT02168751|Experimental|sevoflurane|Sevoflurane doses to maintain hypnoses between 40-60 bis(Bispectral Index Scale)during the lung resection surgery
3236586|NCT01252342|Placebo Comparator|Intramyometrial Saline|
3236587|NCT01252368||RAS active drugs|ACE inhibitors and sartanes
3236588|NCT01252368||healthy participants|
3236589|NCT01252381|Active Comparator|Vitamin D|
3236590|NCT01252381|Placebo Comparator|Calcium tablet|
3236591|NCT01252394||Hemodialysis patients|
3236592|NCT01252407|Experimental|tens|
3236593|NCT01252433|Experimental|Entree energy density 100%|100% energy density
3236594|NCT01252433|Experimental|Entree energy density 85%|85% energy density
3338946|NCT02168764|Experimental|Treatment|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
3338947|NCT02168764|Active Comparator|Control|Both arms of the study receive the ATI Neurostimulation System. Subjects are implanted with the ATI Neurostimulator and instructed to use the ATI Remote Controller to treat cluster attacks of at least moderate intensity by stimulating for 15 minutes before using any acute medications.
3236595|NCT01252433|Experimental|Entree energy density 75%|75% energy density
3338948|NCT02168790|Experimental|Amniotic membrane ring|Application of amniotic membrane device for 6-7 days.
3338949|NCT02168829|Active Comparator|Rivaroxaban|Rivaroxaban 15 mg daily
3338950|NCT02168829|Active Comparator|Acetylsalicylic acid (ASA)|ASA 75-160 mg daily (if intolerant to ASA, no antiplatelet therapy will be prescribed)
3236596|NCT01252446||ADHD|The sample of 187 children and adolescent in the age of 6 to 17 years referred to the Child and Adolescent Clinic, Haugesund, Norway during the period of one year and diagnosed in ICD 10 system as ADHD.
3338951|NCT02168868||Control Group of Children|2-12 years old age & sex-matched controls (age-matched within ±12 months) - typically developing (TD) children and their mothers.
3236597|NCT01252459|Experimental|Arm A: AA-PET based target volume delineation|Experimental intervention (Arm A): High-precision re-irradiation. Target volume delineation based on AA-PET.
3338952|NCT02168868||Children-Autism Spectrum Disorder|2-12 years old children diagnosed with ASD according to DSM-IV (299.00) or DSM-V (299.00), and their mothers. 4:1 case:control ratio.
3338953|NCT02168881|Active Comparator|misoprostol|oral misoprostol in solution 25 microgram every 2 hours
3236598|NCT01252459|Active Comparator|Arm B: T1Gd-MRI based target volume delineation|Control intervention (Arm B): High-precision re-irradiation. Target volume delineation based on T1Gd-MRI.
3236599|NCT01252472||Flomax|Male patients scheduled for cataract surgery with current or past use of Flomax
3338954|NCT02168881|Active Comparator|dinoprostone|3 mgs dinoprostone vaginally every six hours
3338955|NCT02168894|Experimental|Group 1 - Acupuncture With Electrical Stimulation|Participants in Group 1 have acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3338956|NCT02168894|Experimental|Group 2 - Acupuncture Sessions Without Electrical Stimulation|Participants in Group 2 have acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3236600|NCT01252472||Control|Male adult patients scheduled for cataract surgery with no history of Flomax use
3236601|NCT01252498||Radiotherapy|Patients receiving radiotherapy or chemoradiotherapy for head and neck cancer
3236602|NCT01252511|Active Comparator|long biliopancreatic limb, 75 cm|
3236603|NCT01252511|Active Comparator|long Roux limb, 150 cm|
3236604|NCT01252524|Placebo Comparator|Placebo|A placebo tablet PO TID before each meal with 8 oz of water for 6 months.
3236605|NCT01252524|Experimental|Calcium polycarbophil|Calcium polycarbophil 625 mg PO TID before each meal with 8 oz of water for 6 months
3236606|NCT01252537||Initiation of antituberculosis therapy|Patients initiating treatment for tuberculosis with and without HIV co-infection in primary health care centres in Ethiopia
3236607|NCT01252550|Active Comparator|Activia®|Activia® (125g/pot)
3236608|NCT01252550|Placebo Comparator|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
3236609|NCT01252576||women with and without sexual dysfunction|women with and without female sexual dysfunction
3236610|NCT01252589||Adults with CML|Adult patients (18 years of age or older) with confirmed diagnosis of CML
3236611|NCT01252602||Prenatally depressed|Women who tested positive for prenatal depression with a score of > 12 on the Edinburgh Postnatal Depression Scale
3236612|NCT01252602||Not Prenatally Depressed|Women who tested not depressed on the prenatal depression scale with a score < 13
3236613|NCT01252615|Experimental|patient only|Patient with the ICD is involved in the intervention
3236614|NCT01252615|Experimental|patient and partner|patient with the ICD and intimate partner are involved in the intervention
3236615|NCT01252628|Experimental|PX-866 (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
3236616|NCT01252628|Active Comparator|Cetuximab (SCCHN)|Phase 2 (Squamous Cell Carcinoma of the Head and Neck)
3236617|NCT01252628|Experimental|PX-866 (CRC)|Phase 2 (Colorectal Carcinoma)
3236618|NCT01252628|Active Comparator|Cetuximab (CRC)|Phase 2 (Colorectal Carcinoma)
3236619|NCT01252641|Experimental|SB-728-T|Subjects will receive one intravenous infusion of SB-728-T
3236620|NCT01252654||1 IntraLase flaps|Patients who have undergone flap creation with IntraLase laser
3236621|NCT01252654||2 Visumax flaps|Patients who have undergone flaps created with Visumax laser
3236622|NCT01252680|Experimental|Group 1: Healive+Healive|75 subjects to receive two doses of Healive 6 months apart
3236623|NCT01252680|Experimental|Group 2: Healive+Havrix|75 subjects to receive one dose of Healive and another dose of Havrix 6 months apart
3236624|NCT01252680|Experimental|Group 3: Havrix+Havrix|75 subjects to receive two doses of Havrix 6 months apart
3338957|NCT02168894|Active Comparator|Group 3 - Waitlist Group|Participants in Group 3 have acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment. Nerve function tests performed at visit before acupuncture and at end of study visit. These tests consist of hand tasks and balance tests. Questionnaires completed at baseline, visit before acupuncture, after 6 and 12 acupuncture visits, and at end of study visit.
3338958|NCT02168907|Experimental|Treatment (CPI-613, bendamustine hydrochloride, rituximab)|Patients receive 6,8-bis(benzylthio)octanoic acid intravenously IV over 2 hours on days 1-4 (week 1) and days 1 and 4 (weeks 2 and 3). Patients also receive bendamustine hydrochloride IV over 30 minutes on days 4 and 5 and rituximab on day 5 of week 1. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3338959|NCT02168920|Experimental|Aripiprazole, 2 mg/day|
3338960|NCT02168920|Experimental|Aripiprazole, 3 mg/day|
3338961|NCT02168920|Experimental|Aripiprazole, 6 mg/day|
3338962|NCT02168920|Placebo Comparator|Placebo|
3338963|NCT02168959|Active Comparator|Femoral nerve block|bupivacaine
3338964|NCT02168959|No Intervention|No femoral nerve block|No block
3338965|NCT02168972|Experimental|Global mapping and ablation device|
3338966|NCT02168985|Experimental|Attend TFH Program|Couples attend the three-day Faithful House Training program immediately
3236625|NCT01252680|Experimental|Group 4: Havrix+Healive|75 subjects to receive one dose of Havrix and another dose of Healive 6 months apart
3338967|NCT02168985|No Intervention|Wait-listed for TFH Program|Couples attend The Faithful House program three-months after the initial group
3338968|NCT02168998|No Intervention|No clown|Routine venipuncture without distraction
3338969|NCT02168998|Active Comparator|Clown|A medical clown is present in the procedure room during venipuncture
3338970|NCT02169011|Active Comparator|Latissimus Dorsi Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the Latissimus Dorsi flap and if needed an implant.
3338971|NCT02169011|Active Comparator|TAP Flap Reconstruction|Patients are allocated to delayed breast reconstruction with the TAP-flap and if needed an implant in combination with an acellular dermal matrix.
3338972|NCT02169024|Experimental|Expect With Me group prenatal care|receiving prenatal care through an Expect With Me group
3338973|NCT02169024|Active Comparator|Individual Care Only|Standard of Care- individual prenatal care
3236626|NCT01252693|Experimental|Ozarelix|
3236627|NCT01252693|Active Comparator|Goserelin|
3236628|NCT01252719|Experimental|Single-Dose IV Oritavancin Diphosphate|
3338974|NCT02169037|Experimental|FIRM ablation|These patients will be treated by ablation of patient-specific rotors and focal sources (FIRM) alone.
3338975|NCT02169037|Active Comparator|Conventional AF ablation with PVI|These patients will treated by conventional AF ablation by pulmonary vein isolation (PVI) alone.
3338976|NCT02169050||No intervention|There is no intervention to subjects in this study. All subjects are morbidly women seeking bariatric surgeries.
3338977|NCT02169063|Experimental|Diagnostic (11C-acetate, 18F-fluoride, PET)|Patients receive carbon-11 acetate IV and fluorine F 18 sodium fluoride IV over 1 minute and undergo PET at baseline and at 6-12 weeks after systemic therapy starts.
3338978|NCT02169076|Active Comparator|CRT-On|Cardiac Resynchronization Therapy enabled on ICD/Pacemaker device
3338979|NCT02169076|Sham Comparator|CRT-Off|Cardiac Resynchronization Therapy disabled on ICD/Pacemaker device
3338980|NCT02169089|Experimental|Spironolactone|Spironolactone
3236629|NCT01252719|Active Comparator|IV Vancomycin|
3236630|NCT00927719||ACAM2000® vaccinia vaccine Cohort|Participants had received ACAM2000®, vaccinia virus Smallpox vaccine.
3236631|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 1|
3236632|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 2|
3236633|NCT01252758|Experimental|albuterol sufate DPI (TBS-7) dose 3|
3236634|NCT01252758|Placebo Comparator|placebo|
3236635|NCT01252758|Active Comparator|Ventolin HFA dose 1|
3236636|NCT01252758|Active Comparator|Ventolin HFA dose 2|
3236637|NCT01252771|Experimental|PKM report and algorithm|Phosphate kinetic modeling was performed and displayed in graphical form laboratory results and an estimated phophorus protein ratio
3236638|NCT01252797|Active Comparator|Stereotactic Radiosurgery (15 Gy)|Group A: If the tumor which will be surgically removed is at least 2 cm and up to 4 cm in maximum diameter, then this group will receive Dose Level II (15 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
3338981|NCT02169089|Placebo Comparator|Placebo|Placebo
3338982|NCT02169102|Other|Control|
3338983|NCT02169102|Sham Comparator|Sham Laser|
3338984|NCT02169102|Experimental|Laser 1|Low Power Laser applied at 0.16 Joules/point. 2 points of laser irradiation
3338985|NCT02169102|Experimental|Laser 2|Low Power Laser applied at 16 Joules/point. 2 points of laser irradiation
3338986|NCT02169128||Patients and their significant others|Patients affected by necrotizing fasciitis and their significant others
3338987|NCT02169141||PK of Levofloxacin-Capreomycin|Pharmacokinetics (PK) in M/XDR-TB patients receiving at least Levofloxacin and Capreomycin as part of their WHO treatment for M/XDR-TB
3338988|NCT02169154|Experimental|Diclofenac Sodium/Menthol Gel|1% diclofenac sodium + 3% menthol
3338989|NCT02169154|Active Comparator|Diclofenac Gel|1% diclofenac sodium + 0.09% menthol
3338990|NCT02169154|Active Comparator|Menthol Gel|3% menthol
3338991|NCT02169154|Placebo Comparator|Placebo Gel|0.09% menthol
3338992|NCT02169154|Active Comparator|Voltaren Gel|1% diclofenac sodium
3338993|NCT02169154|Placebo Comparator|Sodium lauryl sulfate|0.2% Sodium lauryl sulfate
3338994|NCT02169154|Placebo Comparator|Saline|0.9% saline
3236639|NCT01252797|Experimental|Stereotactic Radiosurgery (12Gy)|Group B: If the tumor which will be surgically removed is larger than 4 cm and up to 6 cm in diameter, then this group will receive Dose Level I (12 Gy) of radiation: stereotactic radiosurgery (SRS) followed by surgery to remove the tumor.
3236640|NCT01252823|Experimental|Implantable loop recorder (ILR) in hemodialysis patients|implantation of loop recorder in hemodialysis patients
3338995|NCT02169167|Experimental|Resin salve treatment|The resin salve may be spread directly onto the diabetic ulcer, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the ulcer area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of ulcer secretion.
3338996|NCT02169167|Active Comparator|Octenidine treatment|Octenidine treatment is implemented with the similar manner as resin salve treatment by using sterile gauze that is impregnated with the octenidine dihydrochloride.
3338997|NCT02169180|Experimental|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
3338998|NCT02169193|Experimental|99mTc-Rhenium Sulfide Nanocolloid|99mTc-Rhenium Sulfide Nanocolloid
3338999|NCT02169206|Other|shoulder radiography|Bilateral shoulder AP standard plain x-ray in 0 and 90 degrees of arm abduction. Non-affected shoulder is used to be compared with the affected shoulder.
3236641|NCT01252836|Placebo Comparator|Control|Treatment with Tegaderm
3236642|NCT01252836|Experimental|AWBAT-D|Application of AWBAT-D on donor site.
3339000|NCT02169232|Active Comparator|Videolaryngoscope|Intubation by videolaryngoscope
3339001|NCT02169232|Active Comparator|Fiberoptic|Intubation by fibroscope
3339002|NCT02169245|Experimental|Average Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and fiber for this age group for 2 weeks.
3339003|NCT02169245|Experimental|Average Protein and High Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of protein and higher than average amount of fiber for this age group for 2 weeks.
3339004|NCT02169245|Experimental|High Protein and Average Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with an average amount of fiber and higher than average amount of protein for this age group for 2 weeks.
3339005|NCT02169245|Experimental|Higher Protein and Fiber at Breakfast|Dietary control of protein and fiber intake at breakfast. Participants will eat a 400 kcal breakfast with a higher than average amount of protein and fiber for this age group for 2 weeks.
3339006|NCT02169258|Placebo Comparator|Selective Strategy|non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia
3339007|NCT02169258|No Intervention|Registry|Clinical decisions are reached by consensus of operators, patients and family as usual care
3339008|NCT02169258|Active Comparator|Systemic Strategy|Routine coronary angiography before PTA without a previous non-invasive stress test
3339009|NCT02169297|Experimental|Ultrasound-Guided Sub-Paraspinal Block|Patients allocated to the treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location and an intravenous PCA post-operatively
3339010|NCT02169297|Placebo Comparator|PCA only|Patients allocated to the control group had two sham multi-perforated soaker catheters taped to their back and received intravenous PCA post-operatively
3236643|NCT01252849|Experimental|First Arm: One iStent, medication|Device: One iStent, medication
3236644|NCT01252849|Experimental|Second Arm: Two iStents, medication|Device: Two iStent devices, medication
3339013|NCT02169323|Experimental|Step-down|Step-down of the inhaled corticosteroid (ICS) dose
3339014|NCT02169362|Experimental|Platelet Rich Plasma - Bio-Bandage™|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
3339015|NCT02169362|Sham Comparator|Saline Spray, Standard of Care|
3236645|NCT01252849|Experimental|Third Arm: Three iStents, medication|Device: Three iStent devices, medication
3236646|NCT01252862|Experimental|Two iStents devices|Two iStents devices will be implanted
3236647|NCT01252875|Other|LDL-C to100 mg/dL (+/-10 mg/dL)|"Target : 100 mg/dL (+/-10 mg/dL):~Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of 100 mg/dL(+/-10 mg/dL)."
3236648|NCT01252875|Other|LDL-C < 70 mg/dL|70 mg/dL: Patients recruited in this arm will receive statin +/-other lipid lowering therapy in order to reach a LDL-C concentration of less than 70 mg/dL.
3236649|NCT01252888|Experimental|Two iStent devices and medication|Implantation of two iStents through small temporal clear corneal incision
3236650|NCT01252914|Experimental|One iStent Supra Stent and medication|The study assesses the efficacy and safety of one iStent Supra stent in the reduction of intraocular pressure associated with primary open-angle glaucoma
3259252|NCT01469130|Experimental|MEK162|"MEK162 will be administered orally once on Day 1 of Cycle 1 and continuously on a BID schedule, starting on Day 2 of Cycle 1 and on Day 1 of subsequent cycles. Each cycle will be 28 days in duration. Dose will be escalated and starting dose is 30 mg. Any doses that are missed should be skipped and should not be replaced or made up during the evening dosing or on a subsequent day, whichever applies.~The prescribed BID doses should be taken 12 ± 2 hrs apart."
3339016|NCT02169375|Experimental|Mu Rhythm with adaptation|
3339017|NCT02169375|Experimental|Mu Rhythm without adaptation|
3339018|NCT02169388|Experimental|Probiotic|Microbial composition using Probiotic，3 capsules / times, 2 times / day for 4 weeks
3339019|NCT02169388|Placebo Comparator|placebo|Microbiota modulation using placebo，3 capsules / times, 2 times / day for 4 weeks
3339020|NCT02169401||Treated subjects|All subjects recruited and treated with the Axium Neurostimulator
3339021|NCT02169518||Diabetes Arm|Patients with Type 1 and Type 2 diabetes
3339022|NCT02169518||Bariatric Arm|Obese patients scheduled for bariatric surgery
3339023|NCT02169531|Experimental|ex vivo activated immune cells|Up to 20 patients diagnosed with type 2 diabetes mellitus and hyperglycemia will be enrolled and assigned to a single treatment group. Patients will give a small amount of peripheral blood and the blood will be processed and cultured in our laboratory. The ex vivo activated autologous blood cells will be infused intravenously back to patients. The treatment will be done twice a week for consecutive 4 weeks. The metabolic parameters of patients before and after the therapy will be compared to determine if the therapy is safe and effective.
3339024|NCT02169544||RA patients who are prescribed Abatacept|Abatacept
3339025|NCT02169544||Patients who are prescribed other RA treatments|
3339026|NCT02169557|Experimental|Fexinidazole|
3339027|NCT02169570|Active Comparator|Vitamin D|Vitamin D supplementation Anti Tuberculosis Treatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks and color and taste matched placebo for calcium for 3 months
3339028|NCT02169570|Placebo Comparator|Placebo|Anti Tuberculosis Treatment with placebo color matched for vitamin D and color and taste matched placebo for calcium
3236651|NCT01252927|Experimental|ASIST intervention|The gatekeeper training intervention group received the Applied Suicide Intervention Skills Training (ASIST) 10.0 in addition to TAU. ASIST is a two-day (fourteen hour), intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The intervention was offered to students on a weekend and was conducted by three senior ASIST trainers and one junior trainer, with two trainers assigned to each training group.
3236652|NCT01252927|No Intervention|Control group: training as usual|Training as usual consisted of didactic teaching and a tutorial with case-based examples around suicide risk factors in their first year of medical school. Third- and fourth-year students may also have the opportunity to practice their skills with real patients during their clerkship rotations or in the emergency department.
3339029|NCT02169570|Experimental|Vitamin D and Calcium|Vitamin D and Calcium supplementation Anti TuberculosisTreatment with 600,000 IU of (I/M) vitamin D3 for 3 doses at 0, 4 and 12 weeks with daily 1000 mg calcium carbonate for 3 months
3339030|NCT02169583|Experimental|Part A (Cohort 1)|Approximately 8 subjects (6 Active, 2 Placebo) will be randomized to receive single escalating IV doses i.e.10 milligrams (mg), 25 mg and 100 mg, plus one oral 100 mg dose (on the last occasion) of GSK1325756 or matching placebo, with a 7-days washout between doses. Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 100 mg. Additional subjects/Cohorts may be enrolled.
3339031|NCT02169583|Experimental|Part B (Cohorts 2 and 3)|Approximately 8 subjects (6 Active, 2 Placebo) per cohort will be randomized to receive escalating repeated IV doses of GSK1325756 or matching placebo (Cohort 2: 25 mg, Cohort 3: 50 mg) for 5 days. Repeated (BID) doses of GSK1325756 will begin the morning of Day 1 and continue through the morning of Day 5 (9 total doses). Dose escalations will be based on review of PK and safety data from preceding dose level. The projected doses for each group are subject to modification based upon PK and safety data from preceding cohorts. Pharmacokinetic parameters will be reviewed from at least 4 active subjects from preceding dose before dose escalating to the next dose level. The maximum dose administered will be 50 mg BID. Additional subjects/Cohorts may be enrolled.
3339032|NCT02169596|Other|Coronary Artery Disease|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
3236653|NCT01252979|Experimental|Medium Chain Triglyceride|
3236654|NCT01252992||1:paradoxical reaction negative (RP-)|control group with tuberculosis but without paradoxical reaction
3339033|NCT02169596|Other|Healthy Normals|Blood tests to assess platelet function and EndoPAT assessment for endothelial function testing before and after ticagrelor administration (90mg BD)
3236655|NCT01252992||1:paradoxical reaction negative (RP+)|group with tuberculosis and paradoxical reaction
3339034|NCT02169609|Experimental|Dinutuximab. Immunotherapy|"Dinutuximab will be administered at 17.5 mg/m2/day for 4 days up to 5 courses. Each dose should be infused IV over approximately 10 hours.~Immunotherapy (sargramostim + isotretinoin + interleukin2) Sargramostim will be administered at 250 micrograms/m2/d by subcutaneous (SC) injection daily from Day 0 through 13 (daily with the infusion of Dinutuximab and for 3 days before and 7 days afterward).~Isotretinoin (13-cis-retinoic acid, or RA) (160mg/m2/day or 5.33mg/kg/day if < 12kg) PO divided into 2 doses daily x 14 days.~Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion for 4 days during the first week of each course 2 and 4 given on Days 0 - 3"
3339035|NCT02169635|Experimental|Macula buckle|Macular buckle: perform episcleral macular buckle surgery using a three-armed silicone capsule to support the posterior staphyloma in high myopia.
3339036|NCT02169648|Experimental|ranibizumab|Experimental: Intravitreal injection of Ranibizumab
3339037|NCT02169661|Experimental|Burger and Beetroot Study|
3339038|NCT02169687|Experimental|Hifu|
3339039|NCT02169700|Experimental|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling.
3339040|NCT02169700|Sham Comparator|Sham Ischemic compression. Dry Needling|Sham Ischemic compression was carried out after dry needling.
3236656|NCT01253031||Group 1|young normal hearing
3236657|NCT01253031||Group 2|older normal hearing
3236658|NCT01253031||Group 3|older hearing impaired
3236659|NCT01253057||Experimental Group|
3236660|NCT01253057||Control Group|
3236661|NCT01253096|Experimental|L19IL2|
3236662|NCT01253109||SENSIMED Triggerfish|
3236663|NCT01253122|Experimental|TRx0037|
3236664|NCT01253122|Active Comparator|TRx0014|
3236665|NCT01253161|Experimental|Pasireotide LAR Treatment|The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.
3236666|NCT01253213|Experimental|BR55|
3236667|NCT01253239||TECNIS/ReZoom|Patients who received a TECNIS multifocal IOL in one eye and a ReZoom multifocal IOL in the opposite eye.
3236668|NCT01253239||TECNIS/TECNIS|Patients who received TECNIS multifocal IOLs in both eyes
3259253|NCT01469143|Experimental|NN1218|
3259254|NCT01469143|Active Comparator|insulin aspart|
3259255|NCT01469156|Experimental|Ranibizumab 2.0 mg|Intraocular injection of 2.0 mg/0.05 cc ranibizumab.
3339041|NCT02169700|No Intervention|Control group|No intervention. Control group
3339042|NCT02169713|Experimental|Treatment Sequence 1|Tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron) then followed by tamsulosin HCl with solifenacin and mirabegron
3339043|NCT02169713|Experimental|Treatment Sequence 2|Tamsulosin HCl with solifenacin and mirabegron then followed by tamsulosin HCl alone (with matching placebo for solifenacin and mirabegron)
3339044|NCT02169726||Musculoskeletal injuries|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
3236669|NCT01253252|Experimental|Specific procedure|"A [18F] Fluorodeoxyglucose PET Scan Imaging will be added to their conventional follow up (CT scan, usual blood sampling, ECG…) i.e. within one month before endovascular surgery (inclusion visit), at one month and 6 month of follow-up.~Furthermore, blood sampling for biological investigations (biological markers of the inflammation, proteolysis and coagulation potentially related to morphology and evolution of AAA) will be done."
3236670|NCT01253278|Experimental|20 mg LY2393910|
3339045|NCT02169752|Active Comparator|Ambrisentan|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
3339046|NCT02169752|Placebo Comparator|Placebo|Subjects will be randomly assigned in a 1:1 ration according to the computer generated random numbers to receive either placebo (sugar pill) or ambrisentan.
3339047|NCT02169765|Active Comparator|Hepatic resection|Indications for HR were the presence of appropriate residual liver volume determined by volumetric computed tomography and lack of hepatic encephalopathy.
3339048|NCT02169765|Experimental|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
3339049|NCT02169778|Experimental|Intermittent energy restricted diet|The intermittent energy restricted group will undergo 3 nonconsecutive days of partial fasting per week. During the 3 days of partial fasting, participants will be asked to consume a very-low calorie diet (VLCD) providing 550kcal/day for women and 650kcal/day for men. The VLCD products provide 110kcal/pack and include a variety of shakes, smoothies and soups. For the feeding days a diet matching energy needs will be prescribed, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
3339050|NCT02169778|Experimental|Continuous energy restricted diet|The continuous energy restricted group will be prescribed a low calorie diet (LCD) with 33% energy restriction, using meal replacements (such as smoothies, soups and cereal bars) and conventional food. The diets' macronutrient composition of the two groups will be matched (50% carbohydrates, 20% protein and 30% fat).
3339051|NCT02169804|Experimental|70 years or older|Non-smoking healthy adult males >or equal to 70 years of age.
3339052|NCT02169804|Experimental|Under 60 years of age|Non-smoking healthy adult males<60 years of age.
3339053|NCT02169817|Experimental|Enterogermina + Enterolyte|2 vials of Enterogermina per day for 5 days and Enterolyte according to investigator´s recommendation
3339054|NCT02169843|Experimental|Sevoflurane & Dexmedetomidine|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Dexmedetomidine 0.2µg/kg/h.
3339055|NCT02169843|Active Comparator|Sevoflurane & Placebo|inhale Sevoflurane + intravenous pumping Remifentanil 0.1µg/kg/min + intravenous inject cisatracurium besilate 0.08mg/kg in fixed time interval + finally add sufentanil 0.15µg/kg,and intravenous pumping Placebo(for Dexmedetomidine )0.05ml/kg/h.
3236671|NCT01253278|Experimental|60 mg LY2393910|
3236672|NCT01253278|Experimental|150 mg LY2393910|
3236673|NCT01253278|Experimental|450 mg LY2393910|
3236674|NCT01253278|Placebo Comparator|Placebo|
3236675|NCT01253330|No Intervention|Comparison 1st|Not enrolled in the CMSText website text messaging system during last 3 months of study participation.
3339056|NCT02169856|Other|control group|"control group was not given any EFTs (emotional freedom techniques) therapy for postoperative nausea and vomiting.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
3339057|NCT02169856|Experimental|EFTs study group|"EFTs (emotional freedom techniques) was applied to the patietns. one session of 5 to 10 min at 6 hours postoperatively.~Following medications were given to both groups. details are in respective interventions.~Tab. Midazolam 7.5 mg Inj. Midazolam IV 0.7 mg/kg inj. propofol (2.5 mg/kg) inj. atracuium (0.5 mg/kg). sevoflurane (2.5 vol %) oxygen in air mixture (0.50 ratio) Inj. Cefuroxime 1.5 gm. IV Inj. Ketorolac 30mg IV Inj. Zantac 50 mg IV inj. Metoclopramide 10mg IV"
3339058|NCT02169882|Active Comparator|Rifampicin 450 mg (standard dose)|"Twenty patients will receive 1 tablet of 450 mg Rifampicin and 2 tablets of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT).~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3236676|NCT01253330|Experimental|Participant 1st|Enrollment in the CMSText website text messaging system during first 3 months of study participation.
3236677|NCT01253356|No Intervention|No IABP|Standard of care and no IABP
3236678|NCT01253356|Active Comparator|Intra-Aortic Balloon Pump (IABP)|Standard of care, IABP inserted < or = 3 hours before noncardiac surgery, maintained for > or = 12-24 hours after surgery
3236679|NCT01253382|Active Comparator|ecallantide|
3236680|NCT01253382|Placebo Comparator|placebo|phosphate buffered saline
3236681|NCT01253395|Experimental|Strength training|Supervised strength training.
3236682|NCT01253395|Active Comparator|Aerobic exercise|Supervised aerobic exercise.
3259256|NCT01469156|Active Comparator|Ranibizumab 0.5 mg|Intraocular injection of 0.5 mg/0.05 cc ranibizumab.
3259257|NCT01469169|Experimental|Arm 1|
3339059|NCT02169882|Experimental|Rifampicin 900 mg per oral|"Twenty patients will receive 2 tablets of 450 mg Rifampicin and 1 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3236683|NCT00839137||no exercise program group|group will continue with current level of activity and will be asked not to start an exercise program. They will be seen in the clinic three times a week for 12 weeks. These visits will be very brief; blood pressure, heart rate, oxygen level and peak flow will be measured at each visit
3236684|NCT00839137||exercise group|will meet three times a week for 12 weeks, following specific exercise program
3236685|NCT01253434|Experimental|1|
3339060|NCT02169882|Experimental|Rifampicin 1350 mg per oral|"Twenty patients will receive 3 tablets of 450 mg Rifampicin and 0 tablet of placebo once daily for 30 days.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)~After completion of one-month treatment, patients will receive 1 tablet of 450 mg Rifampicin.~Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Patients will also receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)"
3339061|NCT02169908|Other|Occurrence of painful neuropathy|Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.
3339062|NCT02169921|Experimental|TurboHawk|This study is designed as a single arm study. For angioplasty, the Atherectomy Catheter, TurboHawk is used in this arm. Spider FX, the Distal Embolus Protection Device, can concomitantly be used with TurboHawk
3339063|NCT02169934|Experimental|Radiolabeled TRV130|
3339064|NCT02169947|Active Comparator|Weight loss core|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program.
3339065|NCT02169947|Experimental|Weight loss core plus maintenance|Participants will receive a culturally adapted version of the Diabetes Prevention Program core (16 session) program PLUS 12 maintenance sessions.
3339066|NCT02169960|Active Comparator|Middle School, General|OVK Resiliency Training Program - Cognitive Behavioral Therapy designed to modify negative thoughts and feelings. This program also includes a social problem-solving component.
3339067|NCT02169960|No Intervention|High School, General|No intervention - no Resiliency training, no online intervention for high school students who do not score at risk for development of mental health issues
3236686|NCT01253434|Experimental|2|
3236687|NCT01253434|Experimental|3|
3236688|NCT01253434|Experimental|4|
3236689|NCT01253434|Experimental|5|
3236690|NCT01253473|Active Comparator|ipratropium/albuterol|1 puff 4 times daily
3236691|NCT01253473|Experimental|Budesonide|budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
3236692|NCT01253473|Experimental|budesonide/formoterol|budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily
3236693|NCT01253486|Experimental|Disease-related expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period
3236694|NCT01253486|Active Comparator|Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
3236695|NCT01253486|Sham Comparator|Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
3236696|NCT01253486|No Intervention|Control condition|Participants in the control condition do not receive any intervention and complete only the assessments
3236697|NCT01253499|Experimental|TRx0037|Double blind placebo controlled study of TRx0037 in healthy elderly volunteers to assess safety, tolerability, bioavailability and pharmacokinetics
3236698|NCT01253512|Experimental|THR-18 0.25mg/kg|Treatment with combination with Tissue Plasminogen Activator (tPA) treatment
3236699|NCT01253512|Placebo Comparator|Placebo treatment|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
3236700|NCT01253512|Experimental|THR-18 0.5mg/kg|Treatment in combination with Tissue Plasminogen Activator (tPA) treatment
3236701|NCT01253551|Experimental|001|Treatment sequence AB Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
3236702|NCT01253551|Experimental|002|Treatment sequence BA Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6 with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10 with a morning dose of raltegravir and a morning and afternoon dose of telaprevir on Day 11.
3236703|NCT01253590||post op cancer patients experiencing atrial fibrillation|This small study aims to assess the feasibility and acceptance of remote cardiac monitoring of postoperative cancer patients experiencing atrial fibrillation and will collect continuous data on heart beat over a period of 4-6 weeks upon discharge.
3236704|NCT01253603|Experimental|1|QAW039 capsules once daily for 28 days
3236705|NCT01253603|Experimental|2|Placebo to QAW039 capsules once daily for 28 days
3236706|NCT01253603|Experimental|3|Fluticasone propionate inhaler twice daily for 28 days
3236707|NCT01253616|Experimental|VNS plus tones|
3236708|NCT01253629|Experimental|25 mg bid AFQ056|1 capsule of 25 mg and 1 capsule of placebo per intake
3236709|NCT01253629|Experimental|50 mg bid AFQ056|2 capsules of 25 mg per intake
3236710|NCT01253629|Experimental|100 mg bid AFQ056|1 capsule of 100 mg and 1 capsule of placebo per intake
3339068|NCT02169960|Active Comparator|Middle School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues. OVK Resiliency Training is also provided.
3339069|NCT02169960|Active Comparator|High School, Top 10%|Smart, Positive, Active, Realistic X-factor thoughts (SPARX), Breaking Free, This Way Up online interventions offered to middle school students who score in the Top 10% of their grade for development of mental health issues.
3339070|NCT02169973|Experimental|Part A|3 to 5 participants will undergo Positron Emission Tomography (PET)/computed tomography scan after administration of 11C-MK-3168 on Day 1.
3339071|NCT02169973|Experimental|Part B|3 to 12 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive 2 single doses of JNJ-42165279: 100 mg on Days 1 and up to 250 mg on Day 8. Participants will undergo PET scans after 1 hour of each administration of JNJ-42165279 on Days 1 and 8, with 11C-MK-3168 administration.
3339072|NCT02169973|Experimental|Part C|4 to 8 participants will undergo PET scan after administration of 11C-MK-3168 on Day 1. Participants will receive once daily dose of JNJ-42165279 (up to 100 mg) from Day 1 to Day 7. Participants will undergo PET scans after 24 hour of administration of JNJ-42165279 on Days 1 and 7, with 11C-MK-3168 administration.
3339073|NCT02169986|No Intervention|control group|Parents/caregivers will receive the standard of care.
3339074|NCT02169986|Experimental|electronic reminders|In this group, the parents/caregivers will receive two daily electronic reminders in addition to the standard of care.
3339075|NCT02169999|Experimental|Personalized Diabetes Care Website|Subjects are exposed to Personalized Diabetes Care website.
3339076|NCT02169999|No Intervention|No Exposure To Website|Subjects are not exposed to Personalized Diabetes Care website
3339077|NCT02170012|Experimental|Cohort 1-PF-06743649 or placebo|
3339078|NCT02170012|Experimental|Cohort 2-PF-06743649 or placebo|
3339079|NCT02170012|Experimental|Cohort 3-PF-06743649 or placebo|
3339080|NCT02170012|Experimental|Cohort 4-PF-06743649 or placebo|
3339081|NCT02170012|Experimental|Cohort 5-PF-06743649 or placebo|
3339082|NCT02170038|Experimental|Arm 1|Healthy premenopausal subjects will receive multiple oral doses of Microgynon for 21days
3236711|NCT01253629|Placebo Comparator|Placebo|2 capsules of placebo per intake
3236712|NCT01253655|Experimental|PF-05212365|
3236713|NCT01253681|Experimental|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
3236714|NCT01253694|Experimental|Patients with 3-5 consecutive Avastin injections|These patients will receive 0.5 mg of intravitreal Ranibizumab monthly for 6 months.
3236715|NCT01253694|Experimental|Patients with 6 or more consecutive injections of Bevacizumab|Patients will receive 0.5 mg of intravitreal Ranibizumab during the first 6 months.
3339083|NCT02170038|Experimental|Arm 2|Healthy premenopausal subjects will receive a single intramuscular dose of Noristerat
3339084|NCT02170090|Experimental|Gemcitabine plus Cisplatin|"Chemotherapy will be administered on days 1 and 8 every 3 weeks, Cisplatin (25 mg per square meter of body-surface area) and Gemcitabine (1000 mg per square meter) for 24 weeks (8 cycles)~and Observation~Second randomisation for R1 resected patients: 8 cycles Cisplatin and Gemcitabin or 6 cycles Cisplatin and Gemcitabin followed by IMRT with capecitabine"
3339085|NCT02170090|Active Comparator|Capecitabine|"Capecitabine will be administered from day 1 to 14 every 3 weeks (1250 mg per square meter of body-surface area, twice daily) for 24 weeks (8 cycles)~and Observation~Second randomisation for R1 resected patients: 8 cycles capecitabine or 6 cycles capecitabine followed by IMRT with capecitabine"
3339086|NCT02170103|Experimental|Ultrasound and microbubbles|Patients who provide emergent consent will be randomized to either conventional therapy for a heart attack, or conventional therapy and ultrasound with microbubbles. The ultrasound will be applied both before and after emergent heart catheterization, in order to break up the blood clots that are not only in the artery supplying the heart muscle, but also in the small branches (capillaries) that are fed by this artery.
3339087|NCT02170103|Other|Standard of care|Emergent PCI/antithrombotic/antiplatelet therapy with Echocardiogram to assess LVEF (Left Ventricular Ejection Fraction) and Aspirin, Plavix, or Direct Thrombin Inhibitor.
3339088|NCT02170116|Experimental|BIBR 1048 MS dose 1|
3339089|NCT02170116|Experimental|BIBR 1048 MS dose 2|
3339090|NCT02170116|Experimental|BIBR 1048 MS dose 3|
3339091|NCT02170116|Experimental|BIBR 1048 MS dose 4|
3339092|NCT02170116|Experimental|BIBR 1048 MS dose 5|
3339093|NCT02170116|Placebo Comparator|Placebo|
3339094|NCT02170129|Active Comparator|100% AAB|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 100% AAB (Bio-Oss) followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
3375836|NCT03722017|Experimental|Intervention--deprescribing protocol|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
3236716|NCT01253707|Experimental|Dose Escalation|
3339095|NCT02170129|Active Comparator|50% AAB plus 50% autologous bone|Surgical procedures were performed according to a lateral approach technique at the edentulous region distal to the position of the first premolar. A mucoperiosteal buccal flap was elevated, exposing the lateral bony wall of the sinus antrum. A round diamond bur, 2 mm in diameter, was used to outline the demarcation of the lateral window, which was removed, thus completely exposing the underlying Schneiderian membrane. The membrane was separated from the housing bone, and a tension-free reflection exposing the sinus walls was achieved by gently pushing it away using a large flat curette (Kramer-Nevins, Hu-Friedy, Chicago, IL). The established voids were then filled with 50% AAB (Bio-Oss) plus 50% autologous bone harvested locally with a bone scraper followed by sealing the open lateral window by the placement of a collagen membrane (Bio Gide) and primary soft tissue closure using Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, Sint-Stevens-Woluwe, Belgium).
3339096|NCT02170142||No treatment|All subjects studied are normal healthy neonates without a condition. MRI will be used to assess normal brain development.
3339097|NCT02170155||Patients with CSM|
3339098|NCT02170155||Patients with spinal injury (SCI)|
3339099|NCT02170155||Healthy controls|
3339100|NCT02170181||OLIGOMETASTATIC ARM|SBRT to Oligometastases
3339101|NCT02170181||CONSOLIDATION ARM|SBRT as Consolidation to Residual Disease
3339102|NCT02170181||NORTON-SIMON ARM|SBRT to Debulk Gross Disease
3339103|NCT02170181||RE-IRRADIATION ARM|
3236717|NCT01253720|Experimental|PACE CALL/Fit4Life|"Fit4Life intervention activities:~Website: Provides weekly nutrition, physical activity, and weight loss information.~Counseling Calls: Participants and their parents will get phone calls from their Health Coach to assess progress & problems.~Health Coach Question & Answer: Participants will be assigned a Health Coach that they can contact at any time to ask questions or express any concerns.~Text & Picture Messages: Participants will receive daily text messages to help remind them of being healthy. Messages will relate to the weekly topics and general checking in questions.~Parent Materials: Parents will receive a packet of printed materials that relate to parenting skills regarding being a healthy role model for their child and healthy eating and exercise tips."
3236718|NCT01253720|No Intervention|Control|The Control group will receive monthly mailings on basic nutrition and physical activity information.
3339104|NCT02170194|Experimental|Resilience Enhancement Group|The resilience enhancement group will begin with a 90-minute session with the study psychologist, which will include a brief introduction to cognitive behavioral therapy (CBT), but focus primarily on psychoeducational, relaxation techniques and planning positive activities. The majority of the time will be focused on reviewing techniques that promote stress management. Emphasis will be placed on relaxation approaches such as controlled breathing, meditation and yoga. Focus will also be aimed at reviewing how engagement in positive activities may help prevent avoidance, promote social support and wellness. Over the subsequent 6 weeks, daily text messages to all participants will accentuate the positive, including providing recommendations on beneficial activities to engage in, encouraging such activities including in vivo exposure, and fostering behavioral changes.
3339105|NCT02170194|Placebo Comparator|Control Group|"The control group will be provided with an initial informational session providing them with details of where they can get help if they have worsened symptoms over time. In addition, the psychologist will briefly review the apps, but not provide the same pscyhoeducational detail given to the resilience enhancement group. They will receive daily texts with inspirational aphorisms (e.g., Early to bed and early to rise makes a man healthy, wealthy, and wise.) for 6 weeks."
3339106|NCT02170233||Sepsis|This group will contain patients meeting criteria for sepsis for enrollment in the study (target population).
3339107|NCT02170233||Normals|This group will be healthy patients who will have data points recorded for controls for the study to assess the reliability of these measures on healthy patients.
3339108|NCT02170246|No Intervention|Antiretroviral Therapy (ART) only|Acute HIV-infected subjects (n=7) will be randomly assigned to a group that will receive antiretroviral therapy (the current standard of care for HIV patients) for 72 weeks.
3339109|NCT02170246|Experimental|ART + Telmisartan|Acute HIV-infected subjects (n=14) will be randomly assigned to a group that will receive treatment with telmisartan in addition to ART. Subjects will receive 40mg telmisartan daily for 4 weeks, followed by 80mg telmisartan daily for 44 weeks, to be taken in conjunction with ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily. After telmisartan is stopped, subjects will continue to take ART for an additional 24 weeks (total 72 weeks).
3339110|NCT02170259|Experimental|suboccipital technique|The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region.
3339111|NCT02170259|Experimental|The articulatory technique|- The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases.
3339112|NCT02170259|Experimental|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT.
3339113|NCT02170259|No Intervention|Control group|Control group. The control group was not applied a treatment technique
3339114|NCT02170272|Experimental|Home-based Lymphedema Care Program|Home-based Lymphedema Care Program (HBLCP): Participants will undergo one training session with a lymphedema therapist, and then receive a self-care video and educational manual to review at home. After completion of training session, follow-up measures occur at 1, 2, and 3 months.
3339115|NCT02170285|Experimental|Interventional tDCS|The primary intervention will be cathodal (inhibitory) tDCS (see below).
3339116|NCT02170285|Sham Comparator|Sham tDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
3339117|NCT02170311|Experimental|Z-213 100mg|Group/Cohort Label: 100 mg iron Z-213 will be administered by intravenous infusion.
3339118|NCT02170311|Experimental|Z-213 500mg|Group/Cohort Label: 500 mg iron Z-213 will be administered by intravenous infusion.
3236719|NCT01253733|Experimental|SMS and Internet|The SMS and Internet group will receive information, tips, strategies, and questions related to the self management of chronic disease (cystic fibrosis, inflammatory bowel disease, or type 1 diabetes) on a web-based program and via SMS messages.
3236720|NCT01253733|No Intervention|Control|The Control group will receive monthly tip sheets on various health topics for adolescents and young adults.
3339119|NCT02170311|Experimental|Z-213 800mg|Group/Cohort Label: 800 mg iron Z-213 will be administered by intravenous infusion.
3339120|NCT02170311|Experimental|Z-213 1000mg|Group/Cohort Label: 1000 mg iron Z-213 will be administered by intravenous infusion.
3236721|NCT01253759||1|Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)
3236722|NCT01253798|Active Comparator|Group training on land|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip.
3236723|NCT01253798|Active Comparator|Group training in water|Group training in water and on land are carried out by the same principles, which is to improve general function, and to improve function and strength around the operated hip
3339121|NCT02170324|Experimental|GLP-1 agonism group|Exenatide injection 10 ug twice daily for 10 days subcutaneously.
3339122|NCT02170324|Placebo Comparator|Placebo group|0.9 % sodium choride 0.1 ml twice daily for 10 days subcutaneously.
3339123|NCT02170337|Experimental|AMG 282|AMG 282 administered as subcutaneous and intravenous doses.
3339124|NCT02170337|Placebo Comparator|Placebo|No active drug
3339125|NCT02170350|Experimental|Brief mindful meditation practice|Patients use brief mindful meditation practice (sitting meditation in which the mind is guided to focus in the present, thinking of your existence, and allowing sensations to arise with an openness and curiosity) over 12 minutes daily for 14 days during radiation therapy.
3339126|NCT02170402|Experimental|Previously Treated Patients (PTPs)|"PTPs will participate sequentially with:~Part 1: Pharmacokinetic parameters of ADVATE measured in subset of 24 participants, consisting of:~12 adults (>12 years of age)~12 children (≤12 years of age)~Part 2: On-demand treatment with ADVATE for 6 months~Part 3: Prophylaxis regimen with ADVATE for 6 months"
3339127|NCT02170415|Active Comparator|Intervention limb|"Medical review and analgesic optimisation.~Pain education (in the form of leaflet and website recommendations)~Psychological input for patients with evidence of psychological morbidity.~Protective analgesia - one pre-procedure dose of 150mg oral pregabalin.~Five days post-procedure oral pregablin twice daily at a dose of 75mg twice a day.~Patients offered a paravertebral block, local anaesthetic infiltrated around the wound by the surgeon.~Daily, focused visits from the hospital pain team.~Any patient displaying concerning pain symptoms, behaviour or who underwent prolonged (>3 hours surgery) may be booked for early 'preemptive' review in pain clinic."
3339128|NCT02170415|No Intervention|Usual care|These partcipants will receive usual care before, during and after their breast surgery
3339129|NCT02170428||growth and development|Growth and development of a random sample of healthy Danish infants
3339130|NCT02170441||Patients at risk for drug-resistant TB|No intervention
3339131|NCT02170454|Active Comparator|rTMS|rTMS on pharyngeal cortical area in healthy subjects
3339132|NCT02170454|Placebo Comparator|Placebo|Sham rTMS on pharyngeal cortical area in healthy subjects
3339133|NCT02170467|Experimental|Control|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in controls and camparison with pateints with anorexia nervosa.
3339134|NCT02170467|Experimental|patients with anorexia nervosa|Assessment of intestinal permeability in small intestine (Lactulose/ Mannitol ratio) in patients with anorexia nervosa before and after re-feeding.
3339135|NCT02170506|Experimental|submental sensitive transcutaneous electrical stimulation.|Each Healthy subjects will be his own witness. Urostim 2 stimulation Arm
3339136|NCT02170545||Multi-Part Proximal Humerus Fracture|All participants that meet the entry criteria will be included in the study cohort.
3236724|NCT01253837|Experimental|L19TNFa|"Phase I: Prospective, open-label, dose escalation study.~Phase II: Prospective, single-arm, open-label study, equivalent to the stage 1 of the Simon two-stage phase II design."
3236725|NCT01253863|Other|determining damaged tissue|
3339137|NCT02170558||Patients implanted w/TM-Ardis|Patients who are receiving a TM-Ardis implant for degenerative disc disease will have a CT scan immediate post op (2 weeks) and again at 6 months to determine if fusion can be assessed with the study metal reduction software. Will utilize TM- Ardis implant and Metal Reduction CT software
3339138|NCT02170571|Experimental|Dabigatran etexilate|
3339139|NCT02170584|Experimental|BIBR 953 ZW IV|
3339140|NCT02170584|Active Comparator|BIBR 1048 MS oral solution|
3339141|NCT02170584|Experimental|BIBR 1048 MS tablet|
3339142|NCT02170584|Placebo Comparator|BIBR 953 ZW IV Placebo|
3236726|NCT01253876|Experimental|Soy milk|
3236727|NCT01253876|Experimental|Caw's milk|
3236728|NCT01253889|Active Comparator|Oral Glucose with soother|Oral Glucose 25% first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
3339143|NCT02170597|Experimental|BIBR 1018 MS HPMC capsule fasted|
3339144|NCT02170597|Experimental|BIBR 1048 MS HPMC capsule after high fat meal|
3339145|NCT02170597|Active Comparator|BIBR 1048 MS gelatine capsule fasted|
3339146|NCT02170610|Experimental|BIBR 1048 MS capsule|
3339147|NCT02170610|Experimental|BIBR 1048 capsule with pantoprazole|
3339148|NCT02170610|Experimental|BIBR 1048 capsule with food|
3339149|NCT02170623|Experimental|Period 1: BIBR 1048 MS with Pantoprazole|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) with 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule I with pantoprazole (bid for 3 days);~BIBR 1048 MS Capsule K with pantoprazole (bid for 3 days);~BIBR 1048 MS Drinking solution with Pantoprazole (bid for 3 days)"
3375837|NCT03718260|Experimental|Cohort 1|Men who are node positive or who have persistently detectable PSA after initial radical prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3339150|NCT02170623|Experimental|Period 2: BIBR 1048 MS|"Three treatments of different formulations of 50 mg BIBR 1048 MS (bid for 3 days) without Pantoprazole. Fixed sequence.~BIBR 1048 MS Capsule K (bid for 3 days);~BIBR 1048 MS Drinking solution (bid for 3 days)"
3339151|NCT02170636|Experimental|Period 1: BIBR 1048 MS + Pantoprazole|"Five treatments with oral administration of 50 mg BIBR 1048 MS (bid for 3 days) and 40 mg Pantoprazole (bid). Randomised sequence.~BIBR 1048 MS Capsule E with pantoprazole; BIBR 1048 MS Capsule F with pantoprazole; BIBR 1048 MS Capsule G with pantoprazole; BIBR 1048 MS Tablet H with pantoprazole; BIBR 1048 MS Drinking solution with pantoprazole"
3339152|NCT02170636|Experimental|Period 2: BIBR 1048 MS|"Three treatments (fixed sequence) with oral administration of 50 mg BIBR 1048 MS (bid for 3 days).~BIBR 1048 MS Capsule E without pantoprazole;~BIBR 1048 MS Tablet H without pantoprazole;~BIBR 1048 MS Drinking solution without pantoprazole"
3339153|NCT02170675|Experimental|Dabigatran etexilate + Ketoconazole|"Period 1 - Dabigatran etexilate~Period 2 - Dabigatran etexilate and single dose of 400 mg Ketoconazole on Day 8 and 9~Period 3 - Dabigatran etexilate and multiple doses of 400 mg Ketoconazole on Day 10 to 16"
3339154|NCT02170701|Experimental|BIBR 1048|Ascending doses (in mg) given twice daily
3339155|NCT02170714||ASC|Consecutive children hospitalized for an episode of acute ASC, defined as a PUCAI > 65. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms. A follow-up of 2 years for the colectomy risk was evaluated for all patients.
3339156|NCT02170740|Experimental|BIBR 1048 MS|
3339157|NCT02170740|Experimental|BIBR 1048 MS + Pantoprazole|
3339158|NCT02170753|Experimental|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy
3339159|NCT02170753|Active Comparator|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
3339160|NCT02170766|Experimental|BIBR 1048 low1|"Two treatments of one single dose of BIBR 1048 12.5 mg without or with Pantoprazole~BIBR 1048 12.5 mg without Pantoprazole~BIBR 1048 12.5 mg with 40 mg Pantoprazole (bid)"
3339161|NCT02170766|Experimental|BIBR 1048 low2|"Two treatments of one single dose of BIBR 1048 25 mg without or with Pantoprazole~BIBR 1048 25 mg without Pantoprazole~BIBR 1048 25 mg with 40 mg Pantoprazole (bid)"
3339162|NCT02170766|Experimental|BIBR 1048 medium|"Two treatments of one single dose of BIBR 1048 50 mg without or with Pantoprazole~BIBR 1048 50 mg without Pantoprazole~BIBR 1048 50 mg with 40 mg Pantoprazole (bid)"
3339163|NCT02170766|Experimental|BIBR 1048 high|"Two treatments of one single dose of BIBR 1048 100 mg without or with Pantoprazole~BIBR 1048 100 mg without Pantoprazole~BIBR 1048 100 mg with 40 mg Pantoprazole (bid)"
3339164|NCT02170792|Experimental|BIBR 1048 MS with ranitidine|Low, medium or high dose in combination with ranitidine
3339165|NCT02170792|Experimental|BIBR 1048 MS without ranitidine|Low, medium or high dose
3339166|NCT02170805|Experimental|Substudy 1|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation A without pantoprazole;~BIBR 1048 MS capsule formulation A with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
3339167|NCT02170805|Experimental|Substudy 2|"Three treatments of single administrations of BIBR 1048 MS 50 mg with or without pantoprazole; randomised sequence~BIBR 1048 MS capsule formulation B without pantoprazole;~BIBR 1048 MS capsule formulation B with coadministration of 40 mg pantoprazole (bid);~BIBR 1048 MS powder plus solution without pantoprazole"
3339168|NCT02170818|Experimental|Educational Workshop on Speaking-Up|Educational Workshop on Speaking-Up Before Simulated Case
3339169|NCT02170818|Sham Comparator|Unrelated Education|Unrelated Education (CPR) before simulated case (Educational Workshop on Speaking-up after case and debriefing)
3339170|NCT02170831|Experimental|BIBR 1048 MS low dose|
3339171|NCT02170831|Experimental|BIBR 1048 MS medium dose 1|
3339172|NCT02170831|Experimental|BIBR 1048 MS medium dose 2|
3339173|NCT02170831|Experimental|BIBR 1048 MS high dose|
3236729|NCT01253889|Placebo Comparator|Oral water with soother|Oral water first given two minutes before the first contact by the physician performing the np-ECHO. A soother will be held in the infant's mouth to ensure that continuous contact is maintained throughout the testing period. Repeat application of solution as per study protocol. No other non-pharmaceutical interventions for stress reduction will be applied. During each np-ECHO, infants have additional handling only if it is required to maintain physiological stability.
3236730|NCT01253889|Active Comparator|Oral glucose with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
3339174|NCT02170831|Placebo Comparator|BIBR 1048 Placebo|
3339175|NCT02170844|Experimental|BIBR 1048 MS (Japanese)|Japanese subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
3339176|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Japanese)|Japanese subjects will receive placebo of BIBR 1048 MS
3339177|NCT02170844|Experimental|BIBR 1048 MS (Caucasian)|Caucasian subjects received an increasing dose (50 mg to 150 mg) of BIBR 1048 MS
3339178|NCT02170844|Placebo Comparator|BIBR 1048 MS Placebo (Caucasian)|Japanese subjects will receive placebo of BIBR 1048 MS
3339179|NCT02170857|No Intervention|Open Curettage Only|patients will be treated by the conventional surgical method, i.e. open curettage without injecting any material.
3236731|NCT01253889|Placebo Comparator|Oral water with soother and tucking|For the infants randomized to receive facilitated tucking throughout the procedure, the bedside nurse will provide gentle, firm containment of the extremities. The facilitated tucking will commence immediately after the baseline BIIP score is taken, but before the glucose/water is administered.
3236732|NCT01253915|Experimental|Carbon Dioxide|
3236733|NCT01253915|Placebo Comparator|Placebo|
3339180|NCT02170857|Experimental|Open Curettage with Hyaluronic Acid|Hyaluronic Acid injection will be employed in conjunction with the ordinary surgical procedure.
3236734|NCT00773773|Experimental|Patients undergoing prostatic biopsy|This study will enroll two groups of 250 patients who are to undergo prostatic biopsy as part of their routine medical care because of suspicion of prostate cancer (elevated PSA between 2 and 10 ng/ml, abnormal rectal examination, or both). The first group will contain 250 patients of African-American descent and the second will contain 250 Caucasian men.
3236735|NCT01253928|Active Comparator|Pioglitazone 45mg per day|Pioglitazone 45mg qd will be added to the current treatment
3236736|NCT01253928|Placebo Comparator|placebo|placebo qd will be added to current treatment
3236737|NCT01253941|Experimental|Mud Bath therapy|
3339181|NCT02170883|Experimental|Interactive SMS|"Intervention with interactive SMS (text messaging) by which patients are asked to disclose their level of agreement with the following statement I follow my asthma medication plan and pharmacist follow-up"
3339182|NCT02170883|Active Comparator|Usual care|Pharmacist conducted patient education, counseling and action-plan
3339183|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule A+Pantoprazole|
3339184|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule B+Pantoprazole|
3236738|NCT01253941|No Intervention|no Mud Bath Therapy|
3236739|NCT01253954||ICU patients with IFI|1
3236740|NCT01253967||Group A|Subjects who are hospitalised for acute gastroenteritis
3339185|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule C+Pantoprazole|
3339186|NCT02170896|Experimental|Period 1: BIBR1048 MS Capsule D+Pantoprazole|
3236741|NCT01253967||Group B|Subjects who visit an emergency room for acute gastroenteritis
3236742|NCT01253967||Group C|Subjects who have rotavirus positive laboratory results and developed acute gastroenteritis at least 48 hours after hospitalisation.
3339187|NCT02170896|Active Comparator|Period 1: BIBR1048 MS solution+Pantoprazole|
3339188|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule C|
3339189|NCT02170896|Experimental|Period 2: BIBR1048 MS Capsule D|
3339190|NCT02170896|Active Comparator|Period 2: BIBR1048 MS solution|
3236743|NCT01254058||Glaucoma Group|
3236744|NCT01254058||Age-Matched Controls|
3339191|NCT02170909|Experimental|BIBR 1048 MS low dose|
3339192|NCT02170909|Experimental|BIBR 1048 MS medium dose|
3339193|NCT02170909|Experimental|BIBR 1048 MS high dose|
3339194|NCT02170922|Experimental|Sequence 1|BIBR 1048 MS tablet (fasted) - BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet after high fat meal
3339195|NCT02170922|Experimental|Sequence 2|BIBR 1048 MS solution (fasted) - BIBR 1048 MS tablet (fasted) - BIBR 1048 MS tablet after high fat meal
3339196|NCT02170935|Experimental|BIBR 1048 capsule|
3339197|NCT02170948|Experimental|Dex 0.5|Ropivacaine and Lidocaine plus Dexmedetomidine (0.5mg/kg) plus Normal Saline
3236745|NCT01254071|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
3339198|NCT02170948|Experimental|Dex 1.0|Ropivacaine and Lidocaine plus Dexmedetomidine (1.0mg/kg) plus Normal Saline
3339199|NCT02170961||acute heart failure (AHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
3236746|NCT01254084|Placebo Comparator|Placebo tea|Dietary Supplement: Placebo tea 3 gram twice daily, orally
3236747|NCT01254084|Active Comparator|Gynostemma pentaphyllum Tea|Gynostemma Pentaphyllum tea 3 grams twice daily, orally
3236748|NCT01254097|Placebo Comparator|Probiotic|Participants are provided in double blinded fashion, probiotic given to take with antibiotics prescribed by their provider.
3236749|NCT01254097|Placebo Comparator|Placebo|Participants are provided in double blinded fashion, Look alike placebo given to take with antibiotics prescribed by their provider.
3236750|NCT01254110||1|Enterally fed with leucine
3236751|NCT01254110||2|Enterally fed with glutamine
3236752|NCT01254110||3|Enterally fed with protein powder
3236753|NCT01254123|Active Comparator|Exenatide|
3236754|NCT01254123|Placebo Comparator|Placebo|
3339200|NCT02170961||Non acute heart failure (NAHF)|patients consulting the emergency department for dyspnea. the diagnosis of AHF was based on clinical, biological (BNP) and echocardiographic data.
3339201|NCT02170974|Experimental|BIBR 1048 MS polymorph II|
3339202|NCT02170974|Active Comparator|BIBR 1048 MS polymorph I|
3339203|NCT02170987|Experimental|Dabigatran etexilate low|
3339204|NCT02170987|Experimental|Dabigatran etexilate high|
3339205|NCT02170987|Placebo Comparator|Placebo to dabigatran etexilate|
3339206|NCT02170987|Active Comparator|Moxifloxacin|
3339207|NCT02171000|Experimental|BIBR 1048|BIBR 1048 MS
3339208|NCT02171013|Experimental|Dabigatran etexilate batch A|
3339209|NCT02171013|Experimental|Dabigatran etexilate batch B|
3339210|NCT02171026|Experimental|Dabigatran etexilate + Amiodarone|
3339211|NCT02171026|Active Comparator|Amiodarone|
3339212|NCT02171039|Experimental|dabigatran plus atorvastatin|
3339213|NCT02171039|Active Comparator|dabigatran|
3339214|NCT02171039|Active Comparator|atorvastatin|
3339215|NCT02171052|Experimental|Dabigatran etexilate plus digoxin|
3339216|NCT02171052|Active Comparator|Dabigatran etexilate|
3339217|NCT02171052|Active Comparator|Digoxin|
3339218|NCT02171078||Alliance for Clinical Trials Database|Use existing data from clinical trials sponsored by one of the leading cancer cooperative groups to evaluate how risk of recurrence and side effects of treatment vary based on patient and cancer characteristics.
3339219|NCT02171078||National Cancer Database|Use existing data to evaluate the effectiveness of the latest imaging technology for detecting recurrence and improving survival in patients previously treated for breast cancer.
3339220|NCT02171078||Stakeholder Engagement|Engage cancer survivors, providers, and health outcomes researchers in the development of an improved patient-centered approach to guide post-treatment care, as well as identification of the highest priority strategies for prospective randomized trials.
3339221|NCT02171091||study arm|One tracheal sample will be obtained using sterile (5 ml) sterile saline solution using irrigation and wall suction from each patient every day for 72 hours, total sampling time is approximately 10 seconds per specimen. Lung samples or fiberoptic obtained samples will be collected at same time intervals as the tracheal samples when possible and if they are done as standard of care. Samples will not be collected for research only and the time for this procedure will not be extended to collect extra tissue. A blood sample (10ml) will be collected simultaneously with the airway samples and also will be used for baseline control measurements.
3236756|NCT01254136|Experimental|Treatment A - INCB007839 300mg BID|This is a single arm, open label study in which all patients will receive a single dose of the investigational product INCB007839 in combination with a standard regimen of trastuzumab and vinorelbine.
3236757|NCT01254162|Experimental|Placebo Gel|
3339222|NCT02171104|Experimental|IMD - Except Haplo-identical|"Inherited Metabolic Disease (IMD) - Except Haplo-Identical~See intervention descriptions."
3339223|NCT02171104|Experimental|OP - Except Haplo-Identical|"Severe Osteoperosis (OP) - Except Haplo-Identical~See intervention descriptions."
3339224|NCT02171104|Experimental|OP and IMD -Haplo-Identical Only|"Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)~-Haplo-Identical Only~See intervention descriptions."
3339225|NCT02171104|Experimental|cALD SR-A (Standard-Risk, Regimen A)|See intervention descriptions.
3339226|NCT02171104|Experimental|cALD SR-B (Standard-Risk, Regimen B)|See intervention descriptions.
3339227|NCT02171104|Experimental|cALD HR-C (High-Risk, Regimen C)|See intervention descriptions.
3339228|NCT02171104|Experimental|cALD HR-D (High-Risk, Regimen D)|See intervention descriptions.
3339229|NCT02171117|No Intervention|CT-group|standard induction and consolidation chemotherapy only, without microtransplantation
3339230|NCT02171117|Experimental|MST-group|standard induction and consolidation chemotherapy with microtransplantation
3339231|NCT02171143|Experimental|ASP2409 Dose Escalation|
3339232|NCT02171143|Placebo Comparator|Placebo Dose Escalation|
3236758|NCT01254175|Experimental|rHPIV3cp45 Vaccine|Participants will receive one dose of the rHPIV3cp45 vaccine at baseline and a second dose at Month 6.
3236759|NCT01254175|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of the placebo vaccine at baseline and a second dose at Month 6.
3339233|NCT02171169||Transsacral lumbar interbody fusion|
3339234|NCT02171169||Transforaminal lumbar interbody fusion|
3339235|NCT02171182||Qutenza patients w/ post-operative peripheral neuropathic pain|
3339236|NCT02171208|Active Comparator|Reference, Test, Reference (RTR)|Doses will be separated by a washout period
3339237|NCT02171208|Active Comparator|Test, Reference, Reference (TRR)|Doses will be separated by a washout period
3339238|NCT02171221|Experimental|Oral DFP-11207|DFP-11207: daily oral dosing, 28 day treatment cycle
3339239|NCT02171273|Experimental|Chronic circadian disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
3339240|NCT02171273|Experimental|Chronic sleep restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
3339241|NCT02171273|Active Comparator|Control (sleep extension)|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
3339242|NCT02171286||No Treatment|
3339243|NCT02171299|Experimental|intervetional group (local anaesthetic)|intraoperative wound infiltration with ropivacaine 10%.
3339244|NCT02171299|No Intervention|control (no local anesthetic)|no infiltration of the wound with local anaesthetic
3339245|NCT02171312||Concussion Cohort|Participants with possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
3236760|NCT01254201||Dry Eye|Female patients over the age of 18 years with ocular complaints of dryness, grittiness, irritation, or related symptoms, without any identifiable cause.
3236761|NCT01254201||Fibromyalgia|Female patients over the age of 18 years diagnosed with Fibromyalgia.
3236762|NCT01254201||Healthy Control|Female patients over the age of 18 years with no symptoms of dry eyes and with no known diagnosis of Fibromyalgia.
3339246|NCT02171312||Healthy Controls|Participants without possible concussion related dizziness will complete iDETECT battery testing and routine balance and vestibular testing.
3339247|NCT02171325|Experimental|irinotecan|irinotecan； 60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
3339248|NCT02171338|Other|Antibiotic treatment based on PCT-level|"Information regarding the PCT-levels in the intervention group is available to the treating doctor and the test subjects are randomized for treatment based on the level of PCT (PCT algorithm).~With a PCT ≥0.25 µg/l and ≥0.10 µg/l for pneumonia and AECOPD respectively antibiotic treatment is advised to be started."
3339249|NCT02171338|No Intervention|Control|"Test subjects randomized for standard treatment (control group) are treated in accordance with the existing treatment guidelines of Holbaek Hospital.~PCT-level will be measured but the treating doctor has no access to the result."
3236763|NCT01254240|Experimental|UVA/B phototherapy treatment|UVA/B phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
3236764|NCT01254240|Active Comparator|UVB phototherapy treatment|UVB phototherapy units, stand alone cabins, patients undress, step in the cabin and receive treatment in a duration of seconds to minutes. The noticable difference between the UVA/B and UVB treatment is only in the settings of the cabin.
3236765|NCT01254253|Experimental|Group a|no severe cardiac perfusion defects
3236766|NCT01254253|Experimental|Gooup b|reversible cardiac perfusion defects
3236767|NCT01254253|Experimental|Group c|irreversible cardiac perfusion defects
3236768|NCT01254266|Experimental|conservative treatment|conservative weight reduction treatment in an inpatient unit.
3236769|NCT01254266|Experimental|bariatric surgery|inpatient program as a pre- and post- operational 'envelope' for bariatric surgeries.
3339250|NCT02171351|Experimental|effect of neuromuscular electrostimulation (NMES)|
3236770|NCT01254279|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m² intravenously every 3 weeks, in combination with oral prednisone or prednisolone 10 mg daily
3339251|NCT02171351|Experimental|effect of neuro electrostimulation (NES)|
3339252|NCT02171351|Experimental|effect of voluntary contractions (VC)|
3339253|NCT02171364|Experimental|virtual simulation|This intervention group is to choose the best effective method operation to patients by simulating 3D atrial computer model which consider patient's heart size and shape.
3339254|NCT02171364|Active Comparator|conventional ablation|The other intervention group is to operate the atrial fibrillation by physician's personal experience, not by virtual simulation.
3339255|NCT02171377|Experimental|Group 2 : quadricipital electrical stimulation|stimulation in addition to rehabilitation (30 min bilateral quadricipital electrical stimulation pd, 5 days per week, 8 weeks)
3339256|NCT02171377|Active Comparator|Group 1 : Pulmonary rehabilitation|Pulmonary rehabilitation 3 to 5 times per week, 8 weeks
3339257|NCT02171390|Active Comparator|Daily testosterone transdermal gel|
3339258|NCT02171390|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
3339259|NCT02171403||Lactose intolerance|Patients with a positive lactose-breath test and complaints during the test
3236771|NCT01254357||YA Burned Subjects|Any person between the years of 19-30 years old treated for a burn injury, having incurred within past 12 months.
3236772|NCT01254370|Experimental|Catioprost|
3236773|NCT01254370|Active Comparator|Travatan Z|
3236774|NCT01254383|Active Comparator|Treatment A|Viagra 50 mg tablet, administered with approximately 240 mL water under fasted conditions
3236775|NCT01254383|Experimental|Treatment B|Sildenafil ODT tablet 50 mg, administered without water under fasted conditions
3236776|NCT01254383|Experimental|Treatment C|Sildenafil ODT tablet 50 mg, administered with water under fasted conditions.
3339260|NCT02171403||Lactose malabsorption|Patients with a positive lactose-breath test and no complaints during the test
3339261|NCT02171403||Healthy controls|Subjects with a negative lactose-breath test
3236777|NCT01254435|Active Comparator|'Free' positioning withdrawal|Withdrawal of the colonoscope with the patient positioned at the discretion of the endoscopist
3339262|NCT02171416|Placebo Comparator|Placebo|Placebo s.c every 7 days
3339263|NCT02171416|Experimental|Rilonacept 160mg|Rilonacept s.c every 7 days
3236778|NCT01254435|Experimental|'Fixed' position withdrawal|Patient positioned in the left lateral position to visualise the caecum, ascending colon and hepatic flexure; supine to visualise the transverse colon; and in the right lateral position to visualise the splenic flexure, descending colon and the sigmoid colon
3236779|NCT01254448|Placebo Comparator|Placebo|Subjects will receive a placebo capsule orally once a day for 28 days (Group 1) or 10 days (Group 2).
3236780|NCT01254448|Experimental|TC-5619|Subjects will receive a TC-5619 orally once a day for 28 days (Group 1) or 10 days (Group 2).
3236781|NCT01254461|Experimental|A|
3236782|NCT01254461|Experimental|B|
3236783|NCT00701207|No Intervention|2.|control group-no intervention
3339264|NCT02171442|Experimental|BIBR 953 ZW Intravenously|
3339265|NCT02171442|Active Comparator|BIBR 1048 Oral Solution|
3236784|NCT00701207|No Intervention|3|Healthy control group-blood and sputum samples
3339266|NCT02171455|Experimental|Dabigatran etexilate low dose|
3339267|NCT02171455|Experimental|Dabigatran etexilate medium dose|
3339268|NCT02171455|Experimental|Dabigatran etexilate high dose|
3339269|NCT02171468|Experimental|Dabigatran high dose|
3339270|NCT02171468|Experimental|Dabigatran low dose|
3339271|NCT02171481|Experimental|Dabigatran etexilate polymorph II|
3339272|NCT02171481|Active Comparator|Dabigatran etexilate polymorph I|
3339273|NCT02171494|Experimental|IVAX warfarin|Treatment A: IVAX warfarin
3339274|NCT02171494|Active Comparator|BMS coumadin|Treatment B: BMS coumadin tablets
3236785|NCT00701207|Experimental|1.|nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months
3236786|NCT01254474|Experimental|MAP 4 procedure|Assess MAP 4 mapping capabilities in cardiac chambers in patients suffering from regular or fibrillating tachycardia's
3236787|NCT01254500||patients with brain lesions|
3236788|NCT01254500||young normal controls|
3236789|NCT01254500||old normal controls|
3236790|NCT01254513|Experimental|Arm A - Docetaxel every 3 weeks + Prednisone|"Docetaxel: 60 mg/m²/day at C1 then 70 mg/m²/day for subsequent cycles every 3 weeks~Prednisone 10 mg/day continuously"
3236791|NCT01254513|Experimental|Arm B - Docetaxel weekly + Prednisone|"Docetaxel weekly 35 mg/m²/day on day 1 and day 8 of each cycle (J1 = J21)~Prednisone 10 mg/day continuously"
3236792|NCT01254526|Experimental|A|
3236793|NCT01254526|Experimental|B|
3236794|NCT01254539|Experimental|Autologous bone marrow stem cells intraspinal transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
3339275|NCT02171507|Active Comparator|Dabigatran etexilate|
3339276|NCT02171507|Active Comparator|Diclofenac|
3339277|NCT02171507|Experimental|Dabigatran etexilate + diclofenac|
3339278|NCT02171520|Experimental|Dabigatran etexilate generation I|
3339279|NCT02171520|Active Comparator|Dabigatran etexilate generation II|
3339280|NCT02171533|Experimental|Fixed sequence|Treatments will be given in a fixed sequence
3339281|NCT02171533|Experimental|Crossover|Treatments will be given in randomized sequences
3339282|NCT02171546|Active Comparator|Dabigatran etexilate capsules|
3339283|NCT02171546|Experimental|Dabigatran etexilate capsules and quinidine sulfate tablets|
3339284|NCT02171546|Active Comparator|Fexofenadine tablets|
3339285|NCT02171546|Experimental|Fexofenadine and quinidine sulfate tablets|
3339286|NCT02171559|Experimental|Dabigatran etexilate capsules after enoxaparin ampoules|
3339287|NCT02171559|Active Comparator|Dabigatran etexilate capsules without enoxaparin|
3339288|NCT02171572|Experimental|Dabigatran etexilate low|
3339289|NCT02171572|Experimental|Dabigatran etexilate high|
3339290|NCT02171585|Experimental|Dabigatran without Clarithromycin|
3339291|NCT02171585|Experimental|Dabigatran with Clarithromycin|
3236795|NCT01254539|Experimental|Intrathecal infusion of autologous bone marrow stem cells|Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells.
3339292|NCT02171598|Experimental|Fixed sequence 1|multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.
3339293|NCT02171598|Experimental|Crossover|clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order
3236796|NCT01254539|Placebo Comparator|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
3236797|NCT01254578|Experimental|Treatment (lenalidomide)|"Patients receive oral lenalidomide once daily on days 1-28. Courses repeat every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.~Patients undergo blood and bone marrow biopsies and aspirate collection at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies. Buccal swab samples are also collected at baseline and analyzed for genetic polymorphisms."
3236798|NCT01254617|Experimental|Treatment (lenalidomide and cetuximab)|Patients receive lenalidomide PO QD on days 1-21 and cetuximab IV over 1-2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3236799|NCT00660673|Experimental|1|Levodopa-carbidopa intestinal gel
3236800|NCT01254682|Active Comparator|Hyaluronic acid sodium salt (1%, 20mg/2ml)|
3236801|NCT01254682|Other|Standard arthroscopic procedure|
3236802|NCT01254695|Active Comparator|Standard settings|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 210 μsec
3236803|NCT01254695|Experimental|Experimental Setting 1|Amplitude: Sensory threshold Frequency:6.9 Hz Pulse width 210 μsec
3236804|NCT01254695|Experimental|Experimental setting 2|Amplitude: Sensory threshold Frequency:31 Hz Pulse width 210 μsec
3236805|NCT01254695|Experimental|Experimental setting 3|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 330 μsec
3236806|NCT01254695|Experimental|Experimental setting 4|Amplitude: Sensory threshold Frequency:14 Hz Pulse width 90 μsec
3236807|NCT01254708|Active Comparator|Control|Standard of care group. Medication as prescribed by the primary physician would be used by this group. Such medications might include azoles as voriconazole
3236808|NCT01254708|Experimental|liposomal amphotericin B (AmBisome ®)|Inhaled Liposomal preparation of Amphotericin B.
3339294|NCT02171598|Experimental|Fixed sequence 2|intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel
3339295|NCT02171624|Experimental|dabigatran etexilate|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
3339296|NCT02171624|Experimental|quinidine|quinidine run-in, followed by dabigatran+quinine and dabigatran alone in randomized order
3339297|NCT02171637|Experimental|BIBW 2992|
3339298|NCT02171650|Experimental|BIBW 2992|
3339299|NCT02171663|Experimental|BIBW 2992|
3339300|NCT02171676|Experimental|Docetaxel + BIBW 2992|Dose escalation
3236809|NCT01254734|Experimental|Arm I|Patients undergo transoral robotic microsurgery.
3236810|NCT01254773|Experimental|Bapineuzumab SC Dose 1; 2 mg|
3236811|NCT01254773|Experimental|Bapineuzumab SC Dose 2; 7 mg|
3339301|NCT02171689|Experimental|BIBW 2992 MA2|
3339302|NCT02171702|Experimental|BIBW 2992|dose escalation
3339303|NCT02171702|Experimental|BIBW 2992, fasted|food effect part: maximum tolerated dose of BIBW 2992
3339304|NCT02171702|Experimental|BIBW 2992, fed|food effect part: maximum tolerated dose of BIBW 2992
3339305|NCT02171715|Experimental|BIBW 2992 MA2, final formulation|
3339306|NCT02171715|Experimental|BIBW 2992 MA2, trial formulation II|
3236812|NCT01254773|Experimental|Bapineuzumab SC Dose 3; 20 mg|
3236813|NCT01254773|Placebo Comparator|Placebo|
3236814|NCT01254786|Active Comparator|CPAP2 - HFPPV group|the non-dependent lung will be ventilated with CPAP of 2 cm H2O for 30 min followed with HFPPV for min.
3236815|NCT01254786|Active Comparator|HFPPV-CPAP2 group|the non-dependent lung will be ventilated with HFPPV for 30 min followed with CPAP of 2 cm H2O for 30 min.
3236816|NCT01254799|Placebo Comparator|Placebo|Women in this arm will receive identical Placebo capsules twice daily for 5 days
3236817|NCT01254799|Active Comparator|Doxycycline|Women in this arm will receive 100 mg doxycycline capsules twice daily for 5 days
3236818|NCT01254812||Bilateral dual TAP-block|
3236819|NCT01254812||Placebo Bilateral dual TAP-block|
3236820|NCT01254825|Experimental|Adductor-Canal-Block, Ropivacain|Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
3236821|NCT01254825|Placebo Comparator|Adductor-Canal-Block (ACB) - Saline|Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.
3339307|NCT02171715|Active Comparator|BIBW 2992 MA 2 drinking solution|
3339308|NCT02171728|Experimental|BIBW 2992|dose escalation
3339309|NCT02171741|Experimental|Docetaxel + BIBW 2992|
3339310|NCT02171754|Experimental|BIBW 2992 + Ritonavir|
3339311|NCT02171754|Active Comparator|BIBW 2992|
3339312|NCT02171767|Experimental|BIBW 2992 MA2 - single rising dose|
3339313|NCT02171780|Experimental|BI 1744 CL single rising doses|
3339314|NCT02171780|Placebo Comparator|Placebo|
3339315|NCT02171793|Experimental|BI 1744 CL|
3339316|NCT02171793|Placebo Comparator|Placebo|
3339317|NCT02171806|Experimental|BI 1744 CL multiple rising doses|
3339318|NCT02171806|Placebo Comparator|Placebo|
3339319|NCT02171806|Experimental|BI 1744 CL medium dose, females|
3339320|NCT02171832|Experimental|Mildly liver impaired patients|
3339321|NCT02171832|Experimental|Moderately liver impaired patients|
3339322|NCT02171832|Experimental|Healthy volunteers|
3339323|NCT02171845||Foetus|
3339324|NCT02171858||stroke|Patients admitted to hospital who are diagnosed with stroke will be treated as usually a our center by observation, venous or arterial thrombolysis depending on extension, condition, thrombolysis feasibility.
3375838|NCT03718260|Experimental|Cohort 2|Men with biochemical failure after initial prostatectomy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3236822|NCT01254864|Experimental|Abiraterone Acetate + Prednisone (AP)|Abiraterone Acetate at 1000 mg orally each day, given in combination with 5 mg of Prednisone orally twice daily.
3236823|NCT01254864|Experimental|Group 1: AP + Sunitinib|AP (Abiraterone Acetate + Prednisone) Plus Sunitinib; Randomized from AP group to receive Sunitinib if disease worsens. Assignment to crossover group AP + Dasatinib with further disease progression.
3236824|NCT01254864|Experimental|Group 2: AP + Dasatinib|AP (Abiraterone Acetate + Prednisone) Plus Dasatinib; Randomized from AP group to receive Dasatinib if disease worsens. Assignment to crossover group AP + Sunitinib with further disease progression.
3236825|NCT00660218|Experimental|Radiation therapy, cetuximab, paclitaxel poliglumex|Radiation therapy to 69.96 Gy, 2.12 Gy per day for 33 treatments, starting week 2. Cetuximab loading dose of 400 mg/m² week 1, 250 mg/m² weekly for 7 weeks. Paclitaxel poliglumex starting week 2 40 mg/m².
3236826|NCT01254903|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
3339325|NCT02171871|Experimental|CONTROL GROUP|"Healthy non-smoking volunteers (18-40 years old) will be subject, after giving their brief medical history, to IOS and to the nitrogen washout test. The IOS will be conducted in four positions (standing, sitting, right and left lateral decubitus), whereas the nitrogen washout test in two (sitting and decubitus).~Then the subjects will be exposed to a smoking environment for 20 minutes."
3339326|NCT02171884||Group E1|Singletons born following ART via IVF/ICSI (short culture)
3339327|NCT02171884||Group EC1|Singletons born following ART via IVF/ICSI and freezing-thawing of the embryo
3339328|NCT02171884||Group T1|Singletons conceived naturally
3339329|NCT02171884||Group E2|Singletons born following ART with IVF/ICSI (prolonged culture)
3339330|NCT02171897|Experimental|Patients treated with osteosynthesis|
3339331|NCT02171897|Experimental|Patients treated with total hip replacement|
3339332|NCT02171910|Active Comparator|Doxapram|Propofol sedation with a doxapram 1mg/kg i.v. bolus at induction and an i.v. infusion 1mg/kg/h) during the procedure
3236827|NCT01254916||Patients with chronic rhinosinusitis|
3236828|NCT01254929||F-18 PET bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo an F-18 PET bone scan for diagnostic imaging.
3339333|NCT02171910|Placebo Comparator|Placebo|Propofol sedation with a placebo i.v. bolus at induction and a placebo i.v. infusion during the procedure
3339334|NCT02171923||Remitted depressed patients|Formerly depressed patients in remission for 6 months or more
3339335|NCT02171923||healthy controls|healthy subjects with no history of mental disorders
3339336|NCT02171936||chronic pain|
3339337|NCT02171949|No Intervention|Control group|
3339338|NCT02171949|Active Comparator|Bone marrow mononuclear cell therapy|
3236829|NCT01254929||Tc-99m MDP bone scan group|Patients with a diagnosis of cancer and clinical concern for bone metastases. They will undergo a Tc-99m MDP bone scan for diagnostic imaging.
3236830|NCT01254942|Active Comparator|Usual Care|Usual care following hip fracture
3236831|NCT01254942|Experimental|Intervention|Follow-up Fracture Clinic
3339339|NCT02171962|Experimental|Zilver® PTX® VI|
3339340|NCT02171975|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthetic.
3236832|NCT01254955||organ transplant patients|
3236833|NCT01254955||healthy controls|
3339341|NCT02171975|Experimental|Group P|This group had their spinal anaesthetic done based on pre-procedure ultrasound guided paramedian spinal
3339342|NCT02171988|Active Comparator|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
3339343|NCT02171988|Active Comparator|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
3339344|NCT02171988|Active Comparator|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
3339345|NCT02171988|Active Comparator|Bisoprolol+pyridostgmine|start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
3339346|NCT02172001|Experimental|Iron isomaltoside 1000|Iron isomaltoside 1000. Dose: 1000 mg, 1500 mg or 2000 mg
3339347|NCT02172001|Placebo Comparator|Placebo (NaCl 0,9%)|Sodium Chloride. Dose: 100 ml or 5 ml
3339348|NCT02172014|Experimental|Fentanyl|midazolam and fentanyl citrate infusion
3339349|NCT02172014|Placebo Comparator|Control|midazolam and normal saline infusion
3339350|NCT02172027||Lung Cancer, Pleural effusion|
3339351|NCT02172053|Active Comparator|Compensatory Workplace Exercise (CWE)|Comparative Group will receive a light training protocol including warming up, stretching and resisted exercise using elastic bands.
3339352|NCT02172053|Experimental|Individual Resistance Exercise (IRE)|Intervention group will receive training protocol including warming up, stretching a specific resistance training with increase progressive load.
3339353|NCT02172066|Experimental|Narrative Exposure Therapy (NET)|During NET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for emotions, cognitions, sensory information, and physiological reactions to link the traumatic events to an autobiographical context, namely time and place. In total the Individuals receive 6 sessions of NET, every session lasting between 1,5 and 2 hr depending on the needs of the participant.
3236834|NCT01254968||examining group|20 healthy subjects (11 men, 9 women, average age 23.94)
3339354|NCT02172066|No Intervention|No treatment control|
3339355|NCT02172079|Experimental|Real mobilization-with-movement (MWM)|For the MWM group, an accessory posterior-lateral gliding movement in the humeral head combined with a movement of active shoulder flexion will be applied. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior aspect of the head of the humerus
3339356|NCT02172079|Sham Comparator|Sham mobilization-with-movement (MWM)|The sham condition will replicate the treatment condition except for the hand positioning. The therapist locates one hand over the belly of the pectoralis major muscle and the other over scapula without applying any pressure. The patient will be asked to move the arm in a similar manner as in the MWM group
3339357|NCT02172092|Experimental|Ketoacidosis|Patients treated for diabetic ketoacidosis at the Intensive care unit, Vrinnevi Hospital, Norrköping.
3339358|NCT02172105|Experimental|BI 1744 CL|
3339359|NCT02172105|Placebo Comparator|Placebo|
3339360|NCT02172118|Experimental|severely renally impaired patients|
3339361|NCT02172118|Experimental|healthy volunteers|
3236835|NCT01254968||control group|6 healthy subjects (3 men, 3 women, average age 23.6)
3236836|NCT01254981|Experimental|Nobori|Percutaneous coronary intervention with implantation of coronary stent (Nobori)
3236837|NCT01254981|Experimental|Cypher|Percutaneous coronary intervention with implantation of coronary stent (Cypher)
3339362|NCT02172131|Experimental|BI 1744 CL|Single rising dose of BI 1744 CL as intravenous (i.v.) infusion
3339363|NCT02172131|Placebo Comparator|Placebo|
3339364|NCT02172144|Experimental|BI 1744 CL|
3339365|NCT02172144|Placebo Comparator|Placebo|
3339366|NCT02172144|Active Comparator|Moxifloxacin (Avalox®)|
3339367|NCT02172157|Experimental|BI 1744 CL i.v. (intravenous) infusion|
3236838|NCT01254994|Active Comparator|Control group|The patients were prescribed the tradition comprehensive medical treatment without entecavir.
3339368|NCT02172157|Active Comparator|BI 1744 CL Oral solution|
3339369|NCT02172170|Experimental|BI 10773 single rising dose|
3339370|NCT02172170|Placebo Comparator|Placebo|
3339371|NCT02172183|Experimental|CBT group|This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
3339372|NCT02172183|Active Comparator|Psychopharmacological treatment|Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.
3339373|NCT02172196|Experimental|Treatment sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5~Treatment C: Sitagliptin once daily from day 1 to 5"
3339374|NCT02172196|Experimental|Treatment sequence CAB|"Treatment C: Sitagliptin once daily from day 1 to 5~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and sitagliptin once daily from day 1 to 5"
3339375|NCT02172209|Experimental|BI 10773 tablet administered with food|50 mg BI 10773 after a standardised high fat breakfast
3339376|NCT02172209|Active Comparator|BI 10773 tablet administered to fasted subjects|50 mg BI 10773 p.o. after an overnight fast of at least 10 hours
3339377|NCT02172222|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7~Treatment C: Linagliptin once daily from day 1 to 7"
3236839|NCT01254994|Experimental|ETV group|All the patients were prescribed the tradition comprehensive medical treatment with entecavir. Entecavir was supplied by the Sino-US Shanghai Squibb Pharmaceutical Co., Ltd. Patients took 0.5 mg entecavir following oral fasting one time per day.
3236840|NCT01255007|Experimental|Post chemotherapy group|The first group consists of patients with colorectal liver metastases who have had treatment with chemotherapy and are now awaiting surgery. This group would have had Multidetector Liver CT (MDCT) imaging prior to the chemotherapy, and will now undergo post chemotherapy MDCT as part of standard clinical care in addition to Gd-EOB-DTPA enhanced liver MRI and Diffusion Weighted MRI (DW-MRI). The MRI will be performed as an additional imaging investigation after obtaining informed consent.
3339378|NCT02172222|Experimental|Sequence CAB|"Treatment C: Linagliptin once daily from day 1 to 7~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI10773 and linagliptin once daily from day 1 to 7"
3339379|NCT02172235|Active Comparator|Pioglitazone|
3339380|NCT02172235|Experimental|Pioglitazone + BI 10773 low|
3339381|NCT02172235|Experimental|Pioglitazone + BI 10773 medium|
3339382|NCT02172235|Experimental|Pioglitazone + BI 10773 high|
3339383|NCT02172235|Experimental|Pioglitazone low + BI 10773 medium|
3339384|NCT02172235|Experimental|Pioglitazone + BI 10773 1 hour after Pioglitazone|
3339385|NCT02172248|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4"
3339386|NCT02172248|Experimental|Sequence CAB|"Treatment C: metformin twice daily from day 1 to 3 and once in the morning on day 4~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 once daily from day 1 to 4 and metformin twice daily from day 1 to 3 and once in the morning on day 4"
3339387|NCT02172261|Experimental|Sequence ABC|"Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1~Treatment C: Glimepiride once on day 1"
3236841|NCT01255007|Experimental|Pre and Post Chemotherapy Group|The second group consists of patients with colorectal liver metastases who are due to receive neoadjuvant chemotherapy. This group will be imaged prior to receiving and after receiving chemotherapy. This will all be done prior to surgical resection of their colorectal liver metastases.
3236842|NCT01255020|Active Comparator|α-Keto Acid plus restricted protein diet|Participants randomized to this group will receive 12 months treatment of α-Keto Acid. The dose of α-Keto Acid is 100mg/kg per day and will divided into three times per day, and the α-Keto Acid will be asked to be taken during the meal. In addition, the participants will be asked to restrict the protein intake. The protein intake is restricted as 1g/kg/d.
3236843|NCT01255020|Placebo Comparator|Placebo plus restricted protein diet|All participants will receive 12 months treatment of placebo, at the same time they will be asked to restrict the protein intake.The dose of placebo is 100mg/kg per day, and the protein intake is restricted as 1g/kg/d.
3339388|NCT02172261|Experimental|Sequence CAB|"Treatment C: Glimepiride once on day 1~Treatment A: BI 10773 once daily from day 1 to 5~Treatment B: BI 10773 and glimepiride once on day 1"
3339389|NCT02172274|Experimental|[14C]-BI 10773 - oral solution|
3339390|NCT02172287|Experimental|Tiotropium (Ba679 BR)|Tiotropium capsule once daily by oral inhalation
3339391|NCT02172287|Active Comparator|Salmeterol|Salmeterol inhalation aerosol twice daily
3339392|NCT02172287|Placebo Comparator|Placebo|"Tiotropium (Ba679 BR)- placebo one capsule once daily by inhalation~Salmeterol- placebo, inhalation aerosol twice daily"
3236844|NCT01255033||Pulmonary surgical patients|Patients submitted for scheduled lung surgery requiring one-lung ventilation
3339393|NCT02172300|Experimental|Tiotropium|Tiotropium inhalation capsules via HandiHaler
3339394|NCT02172300|Placebo Comparator|Placebo|Placebo inhalation capsules via HandiHaler
3339395|NCT02172313|Experimental|Fed conditions|Fasting for 10 hours overnight followed by a high-fat, high-calorie meal, after the meal dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
3339396|NCT02172313|Experimental|Fasting conditions|Fasting for 10 hours overnight followed by dosing of the tablet with 240 mL of water and a post-dose fasting period of 4 hours
3339397|NCT02172313|Experimental|Reference dosing condition|Fasting for 6 hours overnight followed by dosing of the tablet with 120 mL of water and a post-dose fasting period of 30 min
3339398|NCT02172326|Experimental|Tiotropium inhalation capsules|
3339399|NCT02172339|Experimental|Tiotropium|group comparison (healthy, renal impairment)
3339400|NCT02172352|Experimental|Ba 679 BR low dose|
3339401|NCT02172352|Placebo Comparator|Placebo inhalation powder|
3339402|NCT02172352|Experimental|Ba 679 BR middle dose|
3339403|NCT02172352|Experimental|Ba 679 BR high dose|
3339404|NCT02172378|Experimental|Tiotropium inhalation capsules|
3339405|NCT02172378|Placebo Comparator|Placebo inhalation capsules|
3339406|NCT02172391|Experimental|Tiotropium|Tiotropium inhalation powder capsules 18 mcg, one capsule once daily for 28 days
3339407|NCT02172391|Placebo Comparator|Placebo|Placebo inhalation powder capsules, one capsule once daily for 28 days
3339408|NCT02172404|Experimental|HandiHaler® vs. MDI|sequence during treatment phase: first Placebo capsule administered via HandiHaler then Ipratropium metered dose inhaler
3339409|NCT02172404|Experimental|MDI vs. HandiHaler®|sequence during treatment phase: first Ipratropium metered dose inhaler then Placebo capsule administered via HandiHaler Ipratropium metered dose inhaler
3339410|NCT02172417|Experimental|Cimetidine + Tiotropium followed by Tiotropium|
3236845|NCT01255046|Active Comparator|Donepezil plus STA-1|
3236846|NCT01255046|Placebo Comparator|Donepezil plus placebo|
3236847|NCT01255059||Female lung cancer group|Female, non-smoker, non-small cell lung cancer
3236848|NCT01255059||Health control|Female, non-smokers, no lung cancer or other types of cancers' healthy population
3236849|NCT01255072|Active Comparator|Active rTMS + placebo|Patients, free from medication for at least one week (washout of 3 weeks for fluoxetine users) will receive 20 sessions of active rTMS delivered to the left Dorsolateral PreFrontal Cortex. Each patient will take placebo pills for 60 day,starting parallel on the first rTMS day.
3339411|NCT02172417|Experimental|Ranitidine + Tiotropium followed by Tiotropium|
3339412|NCT02172430|Experimental|Tiotropium|
3339413|NCT02172430|Active Comparator|Oxitropium bromide|
3339414|NCT02172443|Experimental|tiotropium inhalation capsules|
3339415|NCT02172443|Active Comparator|Atrovent MDI|
3339416|NCT02172456|Experimental|Tiotropium|
3339417|NCT02172469|Experimental|Tiotropium & Placebo|
3339418|NCT02172469|Active Comparator|Atrovent & Placebo|
3339419|NCT02172482||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
3339420|NCT02172495||Symptoms of COPD|Patients with symptoms of COPD receiving Tiotropium bromide 18 micrograms
3236850|NCT01255072|Sham Comparator|SHAM|Patients, free from medication at least for one week (washout of 3 weeks for fluoxetine users)receiving 20 sessions of Sham TMS delivered to the left dordolateral prefrontal cortex, at the same time this washed out of antidepressives patients start taking Citalopram 20mg/day, for 60 days.
3339421|NCT02172508|Experimental|Tiotropium|
3236851|NCT01255085|Experimental|10 g of yellow pea fiber|
3236852|NCT01255085|Experimental|20 g of yellow pea fiber|
3236853|NCT01255085|Experimental|10 g of yellow pea protein|
3236854|NCT01255085|Experimental|20 g of yellow pea protein|
3236855|NCT01255085|Experimental|Control Tomato Soup|
3236856|NCT01255098||Experimental Group|
3236857|NCT01255098||Control Group|
3339422|NCT02172508|Placebo Comparator|Placebo|
3339423|NCT02172521||COPD and proven hyperinflation|Patients with COPD and proven hyperinflation receiving tiotropium bromide 18 microgram
3339424|NCT02172534|Experimental|Tiotropium bromide low|Single dose: 2.5 µg Tiotropium
3339425|NCT02172534|Experimental|Tiotropium bromide medium|Single dose: 5 µg Tiotropium
3339426|NCT02172534|Experimental|Tiotropium bromide high|Single dose: 10 µg Tiotropium
3339427|NCT02172534|Experimental|Tiotropium bromide low (28 days)|multiple dose: 2.5 µg Tiotropium
3339428|NCT02172534|Experimental|Tiotropium bromide medium (28 days)|Multiple dose: 5 µg Tiotropium
3339429|NCT02172534|Placebo Comparator|Placebo|single or multiple dose of Placebo
3339430|NCT02172547||COPD patients who stopped smoking during treatment|
3339431|NCT02172560||Premature withdrawal from tiotropium|
3339432|NCT02172573|Experimental|Pramipexole|
3339433|NCT02172573|Experimental|Bromocriptine|
3339434|NCT02172573|Placebo Comparator|Placebo|
3339435|NCT02172586|Experimental|Telmisartan|
3339436|NCT02172586|Experimental|Telmisartan + Hydrochlorothiazide|
3339437|NCT02172586|Active Comparator|Losartan|
3339438|NCT02172586|Active Comparator|Losartan + Hydrochlorothiazide|
3339439|NCT02172599|Experimental|multi-component intervention|"Sit-stand workstation provision~The multi-component intervention will align with the World Health Authority's promotion of a healthy workplace model, which emphasises that best-practice workplace health interventions should involve an integrated approach involving organisation and individual level approaches to behaviour change (WHO, 2010). Thus, participants will receive a sit-stand workstation with additional support to use the sit-stand workstation."
3339440|NCT02172599|Experimental|Sit-stand workstation only|"Sit-stand workstation provision~Participants in this arm will receive a sit-stand workstation. They will not receive any support to use the sit-stand workstation, except some health and safety advice upon installation."
3236858|NCT01255124||Health infants (ClinicalTrials.gov ID: NCT01183611)|The subjects participated in the clinical trial 'The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates' in 2007 (ClinicalTrials.gov ID: NCT01183611).
3339441|NCT02172599|No Intervention|Usual practice (seated workstation)|This arm is the control group. They will continue to use their usual seated workstation for the duration of the study.
3339442|NCT02172612|Experimental|Arm 1 - Intervention|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
3236859|NCT01255176|No Intervention|placebo group|not receive physical therapy intervention, there will only support the achievement of a handbook on the abdomen of the baby.
3339443|NCT02172612|No Intervention|Arm 2 - Control|Those included in the control group will receive a generic brochure about medication safety and inappropriate medication use in the elderly.
3339444|NCT02172638|Experimental|FAST-TRACK Group|Patients in this group will be managed according to an specifically designed FAST-TRACK protocol which will include: Preoperatory nutritional management and coaching by surgeon, anesthetist, nutritionist and specifically trained nurse personnel, reduced preoperatory fasting, avoiding use of intraabdominal drainages, specific anesthetic management to reduce intraoperative stress, avoiding use of Nasogastric tube, avoiding the need for major opioid in postoperatory analgesia and use of an standardized postoperatory management protocol directed to obtain an early oral intake and mobilization with a the goal of normal diet and deambulation in the 3rd day after surgery.
3339445|NCT02172638|Active Comparator|Classical management group|Patients assigned to this group will receive the standard management preformed in our center until now. This management includes a preoperatory control exclusively by the surgeon and anesthetist, minimum of 8h fasting previous to surgery, loose use of intraabdominal drainage , systematic use of nasogastric tube whenever rectum resection or omentectomy is performed, Postoperative analgesia following standing Vall d'Hebron protocols for Moderate-severe postoperative pain, which include use of combined analgesia with non opioids drugs and major Opioids, and usual flexible, non standardized postoperatory management with mobilization and oral intake progression depending on perceived evolution by attending surgeon.
3236860|NCT01255176|No Intervention|control group|not receive any type of intervention, and infants remain at rest
3236861|NCT01255176|Experimental|Thoracoabdominal rebalancing|infants who receive physical therapy through the application of the handlings of the RTA.
3236862|NCT01255189|Experimental|Device: near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements
3236863|NCT01255202||twin preganacies|
3339446|NCT02172651|Experimental|Vitamin D3 - Blinded Registration|One capsule of vitamin D3 10,000 IU orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative vitamin D3 for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
3339447|NCT02172651|Placebo Comparator|Placebo - Blinded Registration|One placebo capsule orally once daily for 14 days until the date of surgery. To allow for some flexibility in the scheduling of surgery, patients can be treated with preoperative placebo for up to 28 days. On the morning of surgery, prior to operating, a second blood sample will be collected for follow-up 25(OH)D, calcium, and albumin determination. Colon and liver resection will occur per institutional standards of care, and malignant and adjacent benign tissue will be collected for the laboratory endpoints described in this protocol.
3339448|NCT02172677|Experimental|Healthy participants|Structural and functional MRI and memory assessment
3339449|NCT02172690|Experimental|Laparoscopic Staging|For Patients diagnosed as Locally Advanced Gastric Cancer(cT2+NanyM0)by CT and EUS, undergo laparoscopic staging.
3339450|NCT02172703|Other|Non-invasive ICP measurement|non-invasive ICP measurement with NON-INVASIVE ICP ABSOLUTE VALUE METER (carried out simultainusly with standard invasive ICP measurement catheter and probes)
3339451|NCT02172716|Experimental|Nonsurgical periodontal treatment|Nonsurgical periodontal treatment will be conducted following a full-mouth approach; no antibiotics or chemical plaque control will be provided.
3339452|NCT02172729|Experimental|ACB with lidocaine 5 mg/ml|Adductor canal block (ACB) with 20 ml lidocaine 5 mg/ml, single bolus
3339453|NCT02172729|Experimental|ACB with lidocaine 15 mg/ml|Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
3236864|NCT00605982|Experimental|1|Women with core biopsy proven DCIS with or without microinvasion seen for surgical consultation at Memorial Sloan-Kettering Cancer Center and for whom operative intervention is planned.
3339454|NCT02172768|Experimental|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
3339455|NCT02172768|Active Comparator|daily dosing|micafungin daily for 8 days
3339456|NCT02172781|Experimental|Ipratropium - unit dose vial|
3339457|NCT02172781|Experimental|Tiotropium - inhalation capsule - low dose|
3339458|NCT02172781|Placebo Comparator|Placebo matching tiotropium - inhalation capsule|
3339459|NCT02172781|Placebo Comparator|Placebo matching to ipratropium - unit dose vial|
3339460|NCT02172781|Experimental|Tiotropium - inhalation capsule - high dose|
3339461|NCT02172794|Experimental|tiotropium|
3339462|NCT02172794|Active Comparator|salmeterol|
3339463|NCT02172807|Experimental|Tiotropium low & Placebo|Tiotropium 18 µg inhalation capsule and Placebo MDI
3339464|NCT02172807|Experimental|Tiotropium high & Placebo|Tiotropium 36 µg inhalation capsule and Placebo MDI
3339465|NCT02172807|Active Comparator|Oxitropium & Placebo|Oxitropium MDI (100 µg/puff) and Placebo inhalation capsules
3236865|NCT01255215|Experimental|Inhaled Nitric Oxide|iNO, a gaseous molecule, will be administered by inhalational route over a maximum period of 72 hours.
3236866|NCT01255215|Placebo Comparator|Room air|Room air will be delivered by air compressor through an indistinguishable mask system.
3339466|NCT02172846|Experimental|Treatment (PBT, paclitaxel, and carboplatin)|"CHEMORADIATION THERAPY:~PBT daily 5 days a week over 3 weeks for a total of 15 fractions~Paclitaxel intravenously (IV) over 1 hour weekly for 3 weeks~Carboplatin intravenously (IV) over 30 minutes weekly for 3 weeks.~CONSOLIDATION CHEMOTHERAPY (B=beginning 4-6 weeks after completion of radiation therapy, patients may receive):~Paclitaxel IV over 1 hour on day 1~Carboplatin IV over 30 minutes on day 1~At the discretion of the treating physician~Treatment repeats every 3 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
3339467|NCT02172859|Active Comparator|lumiVida™|lumiVida™ (2 x 0.5 g sachets to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days.
3339468|NCT02172859|Placebo Comparator|Placebo|Placebo (2 x 0.5 g sachets of casein hydrolysate to be dissolved in 150ml water/ day): First dose 2h after breakfast and second dose 60-90min before bed-time for 19 days
3339469|NCT02172872|Active Comparator|standard combination chemotherapy|
3339470|NCT02172872|Experimental|decitabine|
3236867|NCT01255228|Experimental|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
3236868|NCT01255228|Experimental|diet intervention|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
3339471|NCT02172885|Experimental|Mesenchymal stem cells|Five Mesenchymal Stem Cell infusions
3339472|NCT02172898||Heavily Drinking Controls|Heavy alcohol drinking will be defined as > 40 grams per day on average in women and > 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment. Heavy drinkers, who have just become abstinent within prior 2 weeks, including those we convince to seek treatment as part of the recruiting process, are eligible for enrollment. Control subjects must meet the following criteria: (1) AST, ALT, and total bilirubin levels must be within normal range; (2) no prior history of known alcoholic liver disease; and (3) absence of hepatosplenomegaly (from physical examination or radiographic imaging) or stigmata of liver disease.
3339473|NCT02172898||Subjects with AH|Diagnosis of AH will be established on published criteria based on history of heavy alcohol consumption (defined as > 40 grams per day on average in women and > 60 grams per day on average for men for a minimum of 6 months and within the 6 weeks prior to study enrollment), clinical evaluation and appropriate laboratory testing (as defined as total bilirubin > 2 mg/dL and AST > 50 U/L). When diagnosis of AH remains in question, a liver biopsy (if clinically feasible and subject has no contraindications) will be required. We plan to enroll patients with AH in special population infected with hepatitis B (HBV), hepatitis C (HCV), or HIV.
3339474|NCT02172924|Active Comparator|Early Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids since no more than 7 days will be given Decidual Stromal Cell therapy.
3236869|NCT01255241||othopaedic surgical intervention|children with lower limbs deformities
3236870|NCT01255254|Experimental|A: Scaling group|The experimental group will receive oral hygiene instruction (OHI) and full-mouth scaling using standard rigid Gracey curettes (Hu-Friedy® Manufacturing Inc., Chicago, IL, USA) and ultrasonic instrumentation (EMS piezoelectric system, Electro Medical Systems, Nyon, Switzerland) at week 1-2 and at a second reinforcement visit at 6-8 weeks. Subjects will also be instructed to rinse with 10ml of Chlorhexidine 0.2% mouthrinse twice daily for 30 seconds for the duration of the study.
3375839|NCT03718260|Experimental|Cohort 3|Men with biochemical failure after initial radical prostatectomy and salvage radiotherapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3236871|NCT01255254|No Intervention|B: Control group|The control group will receive no periodontal treatment during the study. After completion of the study, these patients will be given oral hygiene instruction and a full mouth scaling.
3236872|NCT01255267||Acute coronary syndrome patients|
3236873|NCT01255267||Chronic coronary artery disease patients|
3236874|NCT01255267||Healthy control|
3236875|NCT01255280|Active Comparator|Information, Motivation, Behavioral skills|The comparison condition will only receive the two IMB risk reduction sessions. The intervention will begin with modules that focus directly with sexual risk reduction practices. It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits. This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information). The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
3236876|NCT01255280|Experimental|Behavioral Activation Therapy and Risk Reduction Counseling|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention. Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
3236877|NCT01255293|Active Comparator|1000 centistoke silicone oil|
3236878|NCT01255293|Active Comparator|5000 centistoke silicone oil|
3236879|NCT01255332||C13-urea breath test: positive|lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days
3236880|NCT01255345||Adult females with CPP living in Denmark|
3236881|NCT01255358|Experimental|Ery-Dex|Patients treated with monthly treatment of Ery-Dex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes)
3236882|NCT01255371|Active Comparator|Arm A : Lopinavir|"Emtricitabine/tenofovir :~TDF300mg.FTC200mg (Fixed Dose Combination)~1 tablet per day~Lopinavir/ritonavir :~LPV200mg/RTV50mg~2 tablets twice a day"
3236883|NCT01255371|Experimental|Arm B : Atazanavir|"Lamivudine/tenofovir :~3TC300mg/TDF300mg (Fixed Dose Combination)~1 tablet per day~Atazanavir/ritonavir :~ATV300mg/RTV100mg~2 tablets once a day"
3236884|NCT01255384||Non Diabetic-Controls|Pregnant women with uncomplicated pregnancy will be followed, their offsprings will be evaluated and followed for 5 years
3339475|NCT02172924|Active Comparator|Late Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids for longer than 7 days will be given Decidual Stromal Cell therapy.
3339476|NCT02172937|Experimental|Decidual Stromal Cells as last line treatment|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids without any signs of improvement will be given DSCs to evaluate a possible effect. DSCs will be thawed from the freezer in plasma.
3339477|NCT02172937|Active Comparator|Decidual Stromal Cells|Patients with therapy-refractory GVHD and on calcineurin inhibitor and high dose corticosteroids will be given DSCs as early as possible at one or more occasions at weekly intervals dependent on clinical response. DSCs will be thawed from the freezer in plasma.
3339478|NCT02172963|Experimental|Decidual Stromal Cell therapy for Hemorrhagic Cystitis|
3339479|NCT02172976|Experimental|FOLFIRINOX|Oxaliplatin 85mg/m², Irinotecan 180mg/m², 5-FU 400mg/m² Bolus i.v., 5-FU continuous Infusion 2400 mg/m² Natriumfolinate 400mg/m² 46h d1; qd15 6 cycles pre- and 6 cycles post- surgery
3339480|NCT02172976|Active Comparator|Gemcitabine|Gemcitabine 1000 mg/m² d1, d8, d15; qd 29; 6 cycles after surgery
3339481|NCT02173002|Active Comparator|Standard care|Standard care
3339482|NCT02173002|Experimental|myIBDcoach|myIBDcoach
3236885|NCT01255384||Diabetic Pregnancy|Pregnant women followed in the high risk clinic because of diabetes will be followed and their offspring's will be evaluated and followed for 5 years
3236886|NCT01255397|Experimental|Male Infertility Protocol|
3339483|NCT02173015|No Intervention|Low Fall Risk|"Individuals who have a functional reach greater than 8 and a unipedal stance time greater than 5 s."
3339484|NCT02173015|No Intervention|High Fall Risk, No Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, but do not qualify for compensatory step training due to health concerns."
3339485|NCT02173015|Experimental|High Fall Risk, Training|"Individuals who have a functional reach of 8 or less OR a unipedal stance time of 5 s or less, and qualify for compensatory step training."
3236887|NCT01255410|Experimental|Healthy Adults (Group 1)|Healthy adults will receive a single dose of 10^6 plaque forming unit (PFU) rHMPV-Pa vaccine intranasally.
3236888|NCT01255410|Experimental|Seropositive Children-Vaccine (Group 2)|Seropositive children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
3236889|NCT01255410|Placebo Comparator|Seropositive Children-Placebo (Group 2)|Seropositive children will receive a single dose of placebo vaccine intranasally.
3236890|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^5) (Group 3)|Seronegative infants and children will receive a single dose of 10^5 PFU rHMPV-Pa vaccine intranasally.
3236891|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 3)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
3339486|NCT02173028||Optimal beta blocker titration|We will compare the efficacy of two management strategies for beta-blocker up-titration: Standard in-office visits vs. Remote follow-up.
3339487|NCT02173028||Without optimal titration of beta blocker|This analysis will be conducted within the Cardiac Resynchronization Therapy observational study Modular Registry (CRT MORE - ClinicalTrials.gov Identifier: NCT01573091).
3339488|NCT02173041|Other|Standard Usual Care|Community program which follows with referral services
3339489|NCT02173041|Experimental|Prevention Awareness Groups (PAG)|Prevention Awareness Groups (PAG) is a community based integrated substance abuse prevention program targeting vulnerable populations. It comprises of community programs, physician led counseling followed by treatment follow up in community based clinic.
3339490|NCT02173067||2% lidocaine|35 patients received 5.4 mL of 2% lidocaine.
3339491|NCT02173067||2% lidocaine with epinephrine|35 patients recieved 5.4 mL of 2% lidocaine with 1:100,000 epinephrine.
3339492|NCT02173080||Polycystic liver disease patients|will receive PLD-Q, EORTC QLQ-30 symptoms subscale, EQ5D-VAS score and SF36
3339493|NCT02173080||ADPKD group without PLD|will receive PLD-Q
3339494|NCT02173080||Healthy controls|receive PLD-Q
3339495|NCT02173080||PLD patient focus group|to discuss and improve PLD-Q
3339496|NCT02173080||PLD clinical expert focus group|to discuss and improve PLD-Q
3339497|NCT02173093|Experimental|Treatment (IL-2, GM-CSF, GD2Bi-aATC)|Patients receive IL-2 SC daily on days -2 to 35, GM-CSF SC twice weekly x 5 weeks, and GD2Bi-aATC IV over 30 minutes twice weekly x 4 weeks for a total of 8 infusions. Laboratory evaluations of immune responses are obtained prior and after immunotherapy.
3339498|NCT02173106|Experimental|Group A: steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and 3.5~5mg/kg/d cyclosporin for 6 months.
3339499|NCT02173106|No Intervention|Group B: no steroid & Cyclosporin|no steroid and cyclosporin and waiting for spontaneous remission for 6 months
3339500|NCT02173119||HCC patients having MRI post-TACE|HCC patients who have undergone conventional lipiodol based chemoembolization.
3339501|NCT02173132|Active Comparator|acetyl-L-carnitine|2 g acetyl-L carnitine twice a day for 90 days
3339502|NCT02173132|Placebo Comparator|sugar pill|Placebo twice a day for 90 days
3339503|NCT02173145|Active Comparator|Azithromycin first, Placebo second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo.
3339504|NCT02173145|Active Comparator|Placebo first, Azithromycin second|Medication with Azithromycin 500mg/d 3x/week p.o. o.d. for 12 weeks or placebo. Placebo will be capsulated similar to verum and given 3 times a week.
3339505|NCT02173171||Previously treated with T-VEC|Received at least 1 dose of talimogene laherparepvec on Amgen or BioVEX-sponsored clinical trial
3339506|NCT02173184|Placebo Comparator|Placebo|Placebo vehicle (0.9% NaCl solution)
3339507|NCT02173184|Experimental|Gynevac|Gynevac suspension for injection, a vaccine containing Lactobacillus strains 15, 34, 79, 84, 127 inactivated by formaldehyde in 0.9% NaCl solution
3339508|NCT02173197||OT arm|"Through the initial evaluation of the complex patients' needs, the OT will propose a targeted intervention to the needs emerged and decide which approach will use to achieve the goal (i.e. compensatory or restorative).~We will describe the characteristics of the population included and identify common needs and problems of the complex patients through the COPM.~The needs and problems identified will be grouped into macro-areas, and the OT will propose the appropriate treatment on the basis of the area identified, the patient's needs and the available resources regardless of the origin of the disease."
3236892|NCT01255410|Experimental|Seronegative Infants and Children-Vaccine (10^6) (Group 4)|Seronegative infants and children will receive a single dose of 10^6 PFU rHMPV-Pa vaccine intranasally.
3339509|NCT02173210||Prior preterm birth|Pregnant women with a prior preterm birth, eligible to receive 17 hydroxyprogesterone caproate (17OHPC)
3339510|NCT02173223|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3339511|NCT02173223|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3339512|NCT02173236|Experimental|platform-switched implants|platform-switched implants vs. platform-matched implants
3339513|NCT02173236|Active Comparator|platform-matched implants|platform-switched implants vs. platform-matched implants
3339514|NCT02173249|Experimental|AC 170 0.24%|
3339515|NCT02173262|Other|G-CSF|Participants will receive a daily injection of G-CSF while on chemotherapy for prevention of febrile neutropenia.
3339516|NCT02173262|Other|Ciprofloxacin|Participants will receive Ciprofloxacin 500 mg twice a day by mouth for 10 days of each cycle during chemotherapy for prevention of febrile neutropenia.
3236893|NCT01255410|Placebo Comparator|Seronegative Infants and Children-Placebo (Group 4)|Seronegative infants and children will receive a single dose of placebo vaccine intranasally.
3339517|NCT02173275||derivation cohort|n = 309
3339518|NCT02173275||validation cohort|n = 309
3339519|NCT02173288|Active Comparator|Standard medical therapy|Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
3236894|NCT01255462|Experimental|LFG316 0.15mg|
3236895|NCT01255462|Experimental|LFG316 0.5mg|
3236896|NCT01255462|Experimental|LFG316 1.5mg|
3339520|NCT02173288|Active Comparator|Midodrine group|Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
3339521|NCT02173288|Active Comparator|Tolvaptan group|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
3339522|NCT02173288|Experimental|Tolvaptan plus midodrine arm|Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day
3236897|NCT01255462|Experimental|LFG316 5mg|
3236898|NCT01255475|Experimental|Intervention|
3339523|NCT02173301|Experimental|XP23829 400 mg QD (once daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg QD for 12 weeks including titration period
3236899|NCT01255475|Placebo Comparator|Control|
3339524|NCT02173301|Experimental|XP23829 800 mg QD|After 4-week screening period, eligible subjects will be randomized to XP23829 800 mg QD for 12 weeks including titration period
3339525|NCT02173301|Experimental|XP23829 400 mg BID (twice daily)|After 4-week screening period, eligible subjects will be randomized to XP23829 400 mg BID for 12 weeks including titration period
3339526|NCT02173301|Placebo Comparator|Placebo|After 4-week screening period, eligible subjects will be randomized to Placebo for 12 weeks
3339527|NCT02173314|Experimental|Treatment|
3236900|NCT01255488|Experimental|EBN-Search (without full-text manuscripts)|In the intervention arm research subjects will be provided access to EBN-Search (a fictitious search engine) with nine abstracts relating to the clinical case but no full-text manuscripts.
3236901|NCT01255488|Active Comparator|EBN-Search (with full text manuscripts)|Research subjects will be exposed to 9 abstracts and corresponding full-text manuscripts related to the simulated clinical encounter.
3236902|NCT01255501|Experimental|NI-0701|
3339528|NCT02173314|No Intervention|Comparison|
3339529|NCT02173327|Other|Continuously Helm CPAP|Continuously helm CPAP for 6 hours
3339530|NCT02173327|Other|Intermittent Mask CPAP|Intermittent Mask CPAP for 10minuttes every 2 hours in a 18 hours period postoperative.
3339532|NCT02173366|Experimental|Change Club Intervention|
3339533|NCT02173405|Active Comparator|Treatment Group|20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.
3236903|NCT01255501|Placebo Comparator|Placebo|
3339534|NCT02173405|Placebo Comparator|Placebo group|20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles.
3339535|NCT02173418|Experimental|Ropivacaine|Phrenic nerve block with Ropivacaine
3339536|NCT02173418|Placebo Comparator|Placebo|Phrenic nerve block with Sodium chloride
3236904|NCT01255514|Experimental|VAD|VAD : high dose dexamethasone -> response(CR, PR)-> VAD chemotherapy(vincristine + doxorubicin + dexamethasone)-> PBSC -> aSCT
3236905|NCT01255514|Experimental|PAD|PAD : high dose dexamethasone -> response(MR,NC,PD)-> PAD chemotherapy(bortezomib + doxorubicin + dexamethasone)-> PBSC -> aSCT
3236906|NCT01255527|Active Comparator|Busulfan|
3236907|NCT01255527|Active Comparator|Melphalan|
3339537|NCT02173431||BMI 20 to 24.99|30 patients
3339538|NCT02173431||BMI 25 to 29.99|30 patients
3236908|NCT01255566||Medical therapy cohort|For patients electing continued medical therapy, medication was prescribed based on the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
3236909|NCT01255566||Surgical cohort|For patients electing ESS, surgery was performed by the enrolling rhinologist. In addition, medical management was administered in the perioperative and postoperative periods as dictated by the disease process and the judgment of the treating rhinologist. Treatment was not specifically dictated or prescribed by the study protocol.
3236910|NCT01255579|Active Comparator|SF|Extrafine Fluticasone/Salmeterol
3339539|NCT02173431||BMI 30 to 34.99|30 patients
3339540|NCT02173431||BMI 35 to 39.99|30 patients
3339541|NCT02173431||BMI 40 to 44.99|30 patients
3339542|NCT02173431||BMI 45 to 49.99|30 patients
3339543|NCT02173431||BMI more than 50|30 patients
3339544|NCT02173457|Experimental|Arm 1|Patients administrate Chiglitazar 32mg once daily for 24 weeks
3339545|NCT02173457|Experimental|Arm 2|Patients administrate Chiglitazar 48mg once daily for 24 weeks
3339546|NCT02173457|Active Comparator|Arm 3|Patients administrate Sitagliptin 100mg once daily for 24 weeks
3339547|NCT02173470|No Intervention|Control|Routine clinical care (which includes a conventional chest X-ray).
3339548|NCT02173470|Experimental|CT scan|Routine clinical care, which includes a chest x-ray, with an additional ultra low-dose non contrast enhanced chest CT with IR (performed preoperatively).
3339549|NCT02173483|Other|Quadriceps graft|Proximally from patella the Quadriceps graft is harvested and used as a knew anterior cruciate ligament after rupture.
3339550|NCT02173483|Other|Hamstrings Graft|The Hamstrings graft is harvested and used as a knew anterior cruciate ligament after rupture.
3339551|NCT02173496||Colour contrast sensitivity|Colour contrast sensitivity
3339552|NCT02173509|Experimental|Educational multifaceted intervention|Multidisciplinary and multifaceted educational intervention about antibiotic prescription and dispense, in physicians and pharmacists.
3339553|NCT02173561|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
3339554|NCT02173561|Experimental|Individual Cognitive Processing Therapy-Cognitive Only|
3339555|NCT02173574|Experimental|Open-Label Single Arm Cohort|
3339556|NCT02173587|Experimental|Mussel oil capsules|Four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) per day for first two months and two mussel oil capsules (containing 400mg mussel oil and 400mg corn oil) per day thereafter for four months.
3236911|NCT01255579|Active Comparator|FB|Extrafine Formoterol and beclometasone HFA
3236912|NCT01255618||study group, control group|
3339557|NCT02173587|Placebo Comparator|Corn oil capsuels|Four corn oil capsules (containing 1600mg corn oil) for first two months and two mussel oil capsules (containing 800mg corn oil) per day thereafter for four months.
3339558|NCT02173600|Experimental|Group-level Intensive Dietary Counselling|Active learning through 4-6 60-minute sessions workshop, enrolling 8-12 people each time.
3339559|NCT02173600|Active Comparator|Individual-level Intensive Dietary Counselling|Individualised dietary counselling delivered at the health-care point
3339560|NCT02173613|Experimental|Procalcitonine|every 2 days, they will receive the dose of PCT and decide to stop antibiotic treatment according to the algorithm 2. They will notify the results of clinical evaluations in the electronics and all adverse event report forms.
3339561|NCT02173613|No Intervention|contrôle|Only clinical reassessments will be conducted and documented. Data on antibiotic will be listed and all adverse events. Data on the PCT from D2 to D4, D6, D8 and D15 output or will not be available to the prescriber.
3339562|NCT02173626|Other|GSH Medical Staff|Volunteers from the Good Samaritan Hospital medical staff were included on a first come first serve basis
3236913|NCT01255644|Experimental|Antiviral drug|
3339563|NCT02173639|Experimental|BI 1356/metformin|
3339564|NCT02173639|Experimental|BI 1356 + Metformin|
3339565|NCT02173652|Experimental|BI 1356, high dose|Treatment A: 7 days of BI 1356 treatment given once daily
3339566|NCT02173652|Active Comparator|BI 1356, low dose|Treatment B: 7 days of BI 1356 treatment given twice daily
3236914|NCT01255657|Experimental|ABT-806 Arm|
3236915|NCT01255683||Chronic rhinosinusitis|
3339567|NCT02173665|Experimental|BI 1356 BS - Powder in bottle (PIB)|
3339568|NCT02173665|Experimental|BI 1356 BS - Tablet|
3339569|NCT02173665|Active Comparator|Placebo|
3339570|NCT02173678|Experimental|COMBIVENT® HFA|
3339571|NCT02173678|Active Comparator|COMBIVENT® CFC|
3339572|NCT02173678|Placebo Comparator|Placebo HFA-MDI (metered dose inhaler)|
3339573|NCT02173691|Experimental|Tiotropium|
3339574|NCT02173691|Active Comparator|Salmeterol|
3339575|NCT02173691|Placebo Comparator|Placebo|
3339576|NCT02173717|Experimental|Dabigatran etexilate|"Four treatments of 150 mg Dabigatran etexilate (single oral administration) in a fixed sequence.~Single oral administration of dabigatran etexilate on Day 1;~Oral administration of 600 mg rifampicin q.d. in the evening for 7 days (Days 2 to 8) followed by an oral morning dose of dabigatran etexilate on Day 9;~Single oral administration of dabigatran etexilate on Day 16, after 7 days of rifampicin washout;~Single oral administration of dabigatran etexilate on Day 23, after 14 days of rifampicin washout"
3339577|NCT02173730|Experimental|BIBR 1048 MS without Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day
3339578|NCT02173730|Experimental|BIBR 1048 MS with Pantoprazole|150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.
3339579|NCT02173743|Experimental|PRP group|PRP during barbotage
3339580|NCT02173743|Other|Control group|Regular barbotage
3339581|NCT02173756|Experimental|oral morphine gel|1 mg / ml of Morphine hydrochloride, presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
3236916|NCT01255696|Experimental|ALV003|ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
3236917|NCT01255696|Placebo Comparator|Placebo|Excipients for ALV003 absent the experimental compounds
3236918|NCT01255709|Experimental|Arm T1 Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
3339582|NCT02173756|Placebo Comparator|placebo gel|1 mg / ml of Placebo gel that is presented in a 5 mL sterile syringe (single dose). Gel will be applied 8 times per day and for the duration of the mucositis (between 8 to 21 days).
3339583|NCT02173782|Experimental|Berodual® Respimat ® high dose|
3339584|NCT02173782|Active Comparator|Berodual® MDI|
3339585|NCT02173782|Experimental|Berodual® Respimat® low dose|
3339586|NCT02173782|Placebo Comparator|Placebo|
3339587|NCT02173795|Experimental|Berodual® Respimat® - Berodual® MA HFA|"randomized sequence~Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)~Berodual® MA HFA (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per puff for 49 days)"
3339588|NCT02173808|Experimental|Contraceptive|
3339589|NCT02173834|Other|Lean subjects|Lean, young, healthy, Caucasian, male subjects
3339590|NCT02173834|Other|Obese subjects|Obese, Young, Healthy, Caucasian, male subjects
3339591|NCT02173847|Experimental|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Diode laser welding of the flap in its final position. 12 months follow up study
3339592|NCT02173860|Active Comparator|FFR-guided revascularization|Patients with valvular heart disease scheduled for elective cardiac surgery and concomitant significant coronary artery disease will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions in vessels pre-specified as suitable for surgical revascularization. If the FFR is ≤0.80, then CABG will be performed. If the FFR is >0.80 then no graft will be placed in that particular vessel. Patients in whom FFR of a particular lesion is not possible can be included if at least one additional lesion is suitable for FFR measurement and grafting.
3339593|NCT02173860|Active Comparator|Angio-guided revascularization|Concomitant CABG will be performed as per clinical routine in all vessels with at least one stenosis > 50%. The vessel should be pre-specified as suitable for surgical revascularization before randomization. An internal mammary graft to the LAD should be attempted in all cases, if possible. Further revascularization strategy is left to the discretion of each center.
3339594|NCT02173873|Experimental|one injection of ziv aflibercept intravitreal route|Intervention: Inject 0.05 ml of zaltrap into the vitreous of blind eyes with various diseases (AMD, CRVO) and monitor vision and OCT 1 day and 1 week after injection
3339595|NCT02173886|Experimental|Bupropion|Bupropion SR and XL, single dosages of each separated by a wash-out period
3339596|NCT02173899|Experimental|varicella-1|The second varicella vaccine and 1 year of the interval time between 2 doses
3339597|NCT02173899|Experimental|varicella-3|The second varicella vaccine and 3 years of the interval time between 2 doses
3236919|NCT01255709|Active Comparator|Arm C Primatene Mist|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
3236920|NCT01255709|Experimental|Arm T2 Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
3236921|NCT01255735||Vocal nodules|Two groups of children who are hoarse and have vocal nodules will be examined to see whether voice therapy is effective as a treatment strategy
3339598|NCT02173899|Experimental|varicella-5|The second varicella vaccine and 5 years of the interval time between 2 doses
3339599|NCT02173912|Experimental|Sequence 1|"Single-dose crossover~Test: CJ-30059~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Once daily Oral administration with at least 14 days of washout period"
3339600|NCT02173912|Experimental|Sequence 2|"Single-dose crossover~Reference: Candesartan cilexetil 16 mg and Amlodipine besylate 10mg~Test: CJ-30059~Once daily Oral administration with at least 14 days of washout period"
3339601|NCT02173925||Functional dyspepsia group|Patients who had epigastric pain or discomfort with normal upper endoscopy and no organic evidence for explaining these symptoms
3339602|NCT02173925||Control group|Subjects with normal endoscopic finding who do not have any gastrointestinal symptoms
3339603|NCT02173938||Treatment seekers|
3236922|NCT01255748||Treatment with Radiation Therapy|Includes 16 different arms to capture patient data by disease site
3236923|NCT01255774|Experimental|Ranibizumab|Open Label use of Ranibizumab for wet age related macular degeneration
3236924|NCT01255800|Experimental|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take the study drug by mouth every day."
3236925|NCT01255813|Placebo Comparator|Placebo|
3236926|NCT01255813|Experimental|Sub-perception|
3236927|NCT01255813|Experimental|Full Stimulation|
3236928|NCT01255826|Active Comparator|Sustained lung inflation followed by CPAP|"Sustained pressure-controlled inflation using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel, Auckland, New Zealand).~This will be followed by early CPAP."
3236929|NCT01255826|Active Comparator|Conventional self inflating bag and mask ventilation|Intermittent bag and mask ventilation using a self-inflating bag with an oxygen reservoir.
3236930|NCT01255839|Active Comparator|Double-balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
3236931|NCT01255839|Active Comparator|Prostglandin E2|The prostaglandin 2 minprostin (3mg) was applied vaginally
3339604|NCT02173951|Active Comparator|arm 1 iron chelation|Active Comparator arm : iron chelation Included 32 thalassemia major patients with low serum ferritin (≥500) . They will receive low dose Deferiprone( DFP )on 50 mg/kg/d.
3339605|NCT02173951|Placebo Comparator|arm 2 blood transfusion|Placebo Comparator arm: blood transfusion only Included 32 thalassemia patients with low serum ferritin (≥500). They receive blood transfusion with no chelation. Patients will start deferiprone 75 mg/kg/d when reaching Primary end point which is elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6
3339606|NCT02173964|Experimental|pinaverium bromide|pinaverium bromide 50 mg tablet per oral administration one time
3339607|NCT02173964|Placebo Comparator|water|water ~100mL
3236932|NCT01255852|Experimental|Atorvastatin group|Patients in atorvastatin group will received 40 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
3236933|NCT01255852|No Intervention|Control group|Patients in control group will receive 20mg atorvastatin daily treatment.
3339608|NCT02173977|Active Comparator|ARM A- Agonist/Antagonist protocol|The Ultrashort GnRH Agonist/antagonist method entails pre-treatment with oral contraceptive pills before the combination of GnRH ultrashort agonist and antagonist protocol
3339609|NCT02173977|Active Comparator|ARM B- Antagonist protocol|The standard IVF method entails Flexible Multidose GnRH Antagonist protocol during COH
3339610|NCT02173990|Experimental|Aflibercept-FOLFIRI|On day 1 of each cycle patients will receive aflibercept followed by irinotecan, 5-FU and leucovorin (FOLFIRI regimen). This treatment will be repeated every 2 weeks until RECIST progression or intolerance.
3339611|NCT02174003||Open Treatment Group|The Open Treatment Group (all participants in this study) will receive the active / WBH treatment in an open fashion.
3339612|NCT02174016|Experimental|Ketogenic diet|All subjects will be started on ketogenic diet formula feeding after enrollment for 2 weeks.
3339613|NCT02174029||Ventilation- mandatory mode only|those patient ventilator days during which they had only received a mandatory mode of ventilation
3339614|NCT02174029||Ventilation- voluntary mode only|Those patient days on a mechanical ventilator who have not received prior mandatory ventilation during this episode of mechanical ventilation.
3236934|NCT01255878|Experimental|stabilization splint|
3236935|NCT01255878|Experimental|Gabapentine|
3236936|NCT01255891|Other|Adjuvant|Adjuvant suppression plus radiation therapy
3236937|NCT01255917||Chronic pancreatitis|
3339615|NCT02174029||voluntary with preceding mandatory|Those patient ventilator days where the patient had at least one prior day of mandatory mechanical ventilation during this episode of respiratory support.
3339616|NCT02174042|Experimental|Tangning Tongluo Capsule|Type 2 diabetes
3339617|NCT02174055||Cancer Patients|This protocol aims to design, develop and pilot test a psychometric assessment for depression in older cancer patients. The study is divided in three phases. In Phase 1, approximately 15 depressed patients (as determined clinically) and approximately 15 non-depressed patients will undergo individual interviews. In Phase 2, the team will use the themes and subthemes obtained in Phase 1 to write a set of indicators into questionnaire form. In Phase 3, the newly developed questionnaire will be given to a sample of approximately 150 cancer patients who meet the eligibility criteria. Survey results obtained from this sample of 150 patients will be used to assess internal consistency, conduct item analysis, and determine the unique content of the proposed instrument.
3339618|NCT02174068|Experimental|paracetamol|drug interaction between paracetamol and nefopam in healthy volunteers.
3236938|NCT01255956|Experimental|Rapamycin eluting stent|Patients treated with rapamycin eluting stent (n=100)
3339619|NCT02174094|Experimental|Clobazam|Clobazam - 1.0, 1.5 or 2.0 mg/kg/day (maximum 60 or 80 mg/day) twice daily (BID); Clobazam oral suspension 2.5 mg/mL, clobazam scored tablets 10 mg, orally
3339620|NCT02174094|Placebo Comparator|Placebo|Placebo to clobazam oral suspension 2.5 mg/mL and placebo to clobazam scored tablets 10 mg, orally
3236939|NCT01255956|Experimental|Paclitaxel eluting balloon catheter|Patients treated with paclitaxel eluting balloon catheter (n=100)
3236940|NCT01255969|No Intervention|Control|
3339621|NCT02174107|Experimental|Arm A|Percutaneous vertebroplasty
3339622|NCT02174107|Experimental|Arm B|External radiotherapy
3339623|NCT02174120|Experimental|Group A|During maintenance of anesthesia, etomidate was give by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml to keep bispectral index between 40 to 60.
3339624|NCT02174120|Experimental|Group B|During maintenance of anesthesia, Propofol was give by target controlled infusion, the effect-site concentration is 2 to 4 micrograms/ml to keep bispectral index between 40 to 60.
3339625|NCT02174120|Experimental|Group C|During maintenance of anesthesia, etomidate will be given by target controlled infusion for 2 h first, and then propofol will be given by target controlled infusion, the effect-site concentration is 0.3 to 0.6 micrograms/ml and 2 to 4 micrograms/ml, respectively. Bispectral index should be kept between 40 to 60.
3236941|NCT01255969|Experimental|Exercise|Patients in this arm will undergo to personalized exercise program.
3236942|NCT01255982||1|Diagnosed with bipolar I or II disorder, and with an acute episode of bipolar depression at inclusion
3236943|NCT01255995||Control Patients|Controls without PXF who require cataract surgery
3236944|NCT01255995||Pseudo Exfoliation patients|PXF subjects with or without glaucoma who require cataract surgery
3236945|NCT01256021|Experimental|Treatment Group 1|Meditoxin
3236946|NCT01256047|Active Comparator|group A|preoperative immunonutrition
3236947|NCT01256047|No Intervention|group B|ordinary diet
3236948|NCT01256073|Experimental|IPH2101|
3236949|NCT01256099|Experimental|Guided Internet-CBT for insomnia|
3236950|NCT01256099|Placebo Comparator|Control treatment|
3236951|NCT01256099|Experimental|Guided Internet-CBT for insomnia (9)|(9 weeks instead of 8)
3236952|NCT01256099|Active Comparator|Guided Internet-CBT for depression|
3236953|NCT01256112|Experimental|NAE + Behavioral Intervention|Parents of participants receive training in behavioral support at home, in addition to a standard nutrition and physical activity education (NAE) program.
3236954|NCT01256112|Active Comparator|Nutrition/Activity Education|Parents and participants receive a standard nutrition and physical activity education (NAE) program.
3236955|NCT01256125||Allogene MSCs transplantation|Allogene MSCs transplantation were performed in patients with chronic liver diseases through peripheral vein plus the same medical treatments.
3236956|NCT01256125||control|only medical treatments were performed in patients with chronic liver diseases.
3236957|NCT01256138||transplantation|
3236958|NCT01256138||control|
3236959|NCT01256151|Active Comparator|Alprazolam conventional tablet|Alprazolam conventional tablet
3236960|NCT01256151|Experimental|Alprazolam sublingual tablet|Alprazolam sublingual tablet
3236961|NCT01256203|Experimental|Sunscreen|Solar Protection Formula SPF® 60 will be applied on the skin of each subject. Applications will be followed by photobiological testings to assess skin protection.
3339626|NCT02174133||patients after HTX|
3236962|NCT01256216|Other|Signature Custom Cutting Guides|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Signature Cutting Guides Surgical Technique.
3236963|NCT01256216|Other|CAS (Computer Assisted Surgery)|Patients receiving a Vanguard Total Knee implanted utilizing non implantable Computer Assisted Surgery Technique.
3339627|NCT02174133||patients after LVAD implantation|
3339628|NCT02174133||patients with coronary heart disease|
3236964|NCT01256229|Experimental|Developmentally delayed - Hearing aids|This arm contains deaf children that have developmental delays and are randomized to be treated with the conventional therapy, hearing aids.
3236965|NCT01256229|Experimental|Developmentally Delayed - Cochlear implant|This arm contains deaf children that have developmental delays and are randomized to be treated with cochlear implantation.
3236966|NCT01256229|Active Comparator|Not developmentally delayed|This control arm contains deaf children that do not have developmental delays and will be treated with cochlear implantation.
3236967|NCT01256242|Experimental|Group 1|Standard Suture Repair + Augment Rotator Cuff
3236968|NCT01256242|Active Comparator|Group 2|Standard Suture Repair
3236969|NCT01256255||influenza infection|Patients with the diagnosis of influenza infection by standard laboratory technique
3236970|NCT01256268|Experimental|Endometrial Cancer|Phase 1A + Cohort 1B - Recurrent or Metastatic Endometrial Cancer. Patients with recurrent or metastatic endometrial cancer with up to 1 prior chemotherapy. Ridaforolimus at the Phase 1A MTD and schedule will be administered with paclitaxel at the Phase 1A MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
3236971|NCT01256268|Experimental|Ovarian Cancer|Phase 1 A + Cohort 1B - Recurrent or Metastatic Ovarian Cancer. Patients with platinum-sensitive, recurrent ovarian cancer with up to 2 prior chemotherapy regimens. Ridaforolimus at the phase 1A MTD and schedule will be administered with paclitaxel at the phase 1 MTD (175 mg/m2) IV and carboplatin at the phase 1 MTD (AUC 5 to 6) in mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Treatment will continue until disease progression or adverse events prohibit further therapy.
3339629|NCT02174133||healthy volunteers|
3339630|NCT02174146|Other|non-surgical therapy|non-surgical periodontal therapy with ultrasonic scalers and periodontal curettes
3339631|NCT02174159|Experimental|Panel A: MK-8507 600 mg|Single oral dose of MK-8507 600 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
3339632|NCT02174159|Experimental|Panel B: MK-8507 150 mg|Single oral dose of MK-8507 150 mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast
3339633|NCT02174159|Experimental|Panel C: MK-8507 <=600 mg|Single oral dose of MK-8507 <=600 mg mg (supplied as 10 mg and 100 mg tablets) administered after an overnight fast. Inclusion of Panel C in the study, and the dose selected, will be decided pending evaluation of results for Panels A and B.
3339634|NCT02174172|Experimental|Arm A: Atezolizumab with Ipilimumab|Participants will receive atezolizumab along with ipilimumab.
3339635|NCT02174172|Experimental|Arm B: Atezolizumab with Interferon alfa-2b|Participants will receive atezolizumab along with Interferon alfa-2b.
3339636|NCT02174172|Experimental|Arm C: Atezolizumab with PEG- interferon alfa-2a|Participants will receive atezolizumab along with PEG- interferon alfa-2a.
3339637|NCT02174172|Experimental|Arm D:Atezolizumab with PEG-interferon alfa-2a and Bevacizumab|Participants will receive atezolizumab along with PEG- interferon alfa-2a and bevacizumab.
3339638|NCT02174172|Experimental|Arm E: Atezolizumab with Obinutuzumab|Participants will receive atezolizumab along with obinutuzumab or atezolizumab alone.
3339639|NCT02174185||bladder cancer, conduit diversion|new patients with bladder cancer scheduled for radical cystectomy and subsequent conduit diversion
3339640|NCT02174185||bladder cancer, orthotopic neobladder|new patients with bladder cancer scheduled for radical cystectomy and subsequent orthotopic neobladder
3236972|NCT01256307|Experimental|training group|training and educational program
3339641|NCT02174211|Active Comparator|Arm A: Ranibizumab (Lucentis)|Previous Vitrectomy
3339642|NCT02174211|Active Comparator|Arm B: Ranibizumab (Lucentis)|Non-vitrectomised, PVD / no PVD
3339643|NCT02174211|Active Comparator|Arm C: Aflibercept (Eylea)|Non-vitrectomised, PVD / no PVD
3236973|NCT01256307|Other|control group|
3236974|NCT01256320|No Intervention|Control Group|no shell egg consumption and usual dietary practices
3236975|NCT01256320|Active Comparator|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
3339644|NCT02174224|Experimental|SMC + BI + Case Management|This arm will include all interventions in Standard Medical Care + Brief Intervention Arm. Case management will also be given to this arm. General needs based assessments will be conducted by the outreach worker. These assessments will be done at the hospital or at the youth's home, whichever they prefer. This assessment tool addresses education, vocational training, employment, housing, medical insurance, follow-up care and pro-social activities. Although each youth in this arm will receive the same needs-based assessment, individual youth will have variable needs, which will guide each unique and individualized case management plan.
3339645|NCT02174237|Experimental|LNP1892|Dosage Form: Tablet Two Parts. Part A: Single Ascending Dose (SAD) starting with 25 mg (Maximum 5 cohorts). Part B: Multiple Ascending Dose (MAD), 10 days dosing, Maximum 3 cohorts. Six subjects in each cohort will receive LNP1892
3339646|NCT02174237|Placebo Comparator|Placebo|Two subjects in each cohort will receive matching placebo.
3339647|NCT02174250|Experimental|Istradefylline 40mg|Period 1: Day 1, istradefylline 40mg then crossover to Period 2
3339648|NCT02174250|Experimental|Rifampin 300mg BID + istradefylline 40mg|Period 2: Days 1-20 rifampin 300mg BID + istradefylline 40mg Day 8 only
3339649|NCT02174263|Experimental|Supportive care (tocilizumab)|Patients receive tocilizumab IV over 1 hour every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11) and then every 4 weeks for 12 weeks (weeks 13, 17, and 21).
3339650|NCT02174289|Active Comparator|Active Bi-ventricular Pacing|
3339651|NCT02174289|Placebo Comparator|No Biventricular pacing|
3339652|NCT02174315|Experimental|Contingency Management|
3339653|NCT02174315|No Intervention|Non-Contingent Control Group|
3236976|NCT01256320|Active Comparator|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
3236977|NCT01256346||Babies|Preterm newborn infants thought to be 24-32 weeks gestational age.
3339654|NCT02174328|Experimental|acetylsalicylic acid|This group will receive 1 tablet of acetylsalicylic acid (100 mg) orally daily from 5-10 weeks gestation until the end of gestation, about week 36
3339655|NCT02174328|Placebo Comparator|Placebo|This group will receive 1 tablet of placebo orally each day from 5-10 weeks gestation until the end of gestation, about week 36
3339656|NCT02174354||Psoriasis|Patients with psoriasis taking methotrexate
3339657|NCT02174367||Psoriasis|Patients with moderate to sever psoriasis attending a tertiary referral center. patients will be evaluated with a questionnaire, measurement of height,weight, waist circumference, fasting bloods, abdominal ultrasound and transient elastography.
3339658|NCT02174380|No Intervention|Passive Household Contact Evaluation|Passive case finding refers to the current National TB program of voluntary self-reporting of symptomatic patients to the health system for diagnosis of TB and initiation of effective chemotherapy
3339659|NCT02174380|Experimental|Active Household Contact Evaluation|The intervention program includes households visits of all newly diagnosed TB cases enrolled in TB treatment within a DISA NTP clinic in SJL district. During the home visit health staff will evaluate all household contacts for symptoms of active TB. Any person reporting cough for >14 days will be asked to provide a spot sputum for microscopy and referred to the clinic for chest x-ray and clinical evaluation. All household contacts ≤19 years will be referred to the clinic for chest x-ray, pediatric clinical evaluation and initiation of treatment for active or latent TB as required. Counseling including TB infection control practices and importance of diagnosis and treatment completion for TB cases will be provided to household members.
3339660|NCT02174393|Experimental|Microneedling Plus Universal Peel|"(1) Microneedling treatment by the MicroPen with a Post-Microneedling Skin Care Regimen and the (2) Universal Peel by Topix with a Post-Universal Peel Skin Care Regimen will both be performed on a monthly basis for a total of three treatment sessions each.~Microneedling will be done on Study Weeks 1, 5, and 9. Universal Peel will be done on Study Weeks 3, 7, and 11."
3339661|NCT02174406||women scheduled for breast screening|"Each patient will have the following:~Screening whole breast ultrasound~DBT (Full field digital mammography + tomosynthesis views in the CC and MLO projections). The only change in patient management will be the addition of digital breast tomosynthesis views in patients scheduled for FFDM alone. DBT is currently clinically approved and being offered on a voluntary basis to patients scheduled for FFDM."
3236978|NCT01256359|Experimental|Docetaxel and AZD6244|Docetaxel with AZD6244
3236979|NCT01256359|Experimental|Docetaxel and Placebo|Docetaxel without AZD6244
3339662|NCT02174445|Experimental|Imatinib|Imatinib 400-800mg, daily, maximum 6 years
3339663|NCT02174445|Active Comparator|Nilotinib|Nilotinib, 300mg, twice daily, maximum 6 years
3339664|NCT02174458||Bariatric Surgery only|Patients after Bariatric Surgery but no secondary reconstructive procedures
3236980|NCT01256372|Experimental|AP214; dose-level 1|AP214; dose-level 1
3236981|NCT01256372|Experimental|AP214; dose-level 2|AP214; dose-level 2
3236982|NCT01256372|Placebo Comparator|Placebo to AP214|Placebo
3339665|NCT02174458||Body Contouring surgery|Post-bariatric patients and patients with no history of bariatric surgery but after natural weight loss
3339666|NCT02174484||Pacemaker recipients|Patients implanted with a single or dual pacemaker and with Home-Monitoring system activated and periodic IEGM activated
3236983|NCT01256437|Experimental|ointment Threolone|Treatment with topical application of combined anti inflammatory and anti bacterial agent.
3236984|NCT01256437|Active Comparator|ointment Synthomycine|ointment once daily for 1 month
3236985|NCT01256437|Placebo Comparator|Aqua cream|
3339667|NCT02174497||Control|Three day Bowel Preparation
3339668|NCT02174497||Study Arm|One day Bowel Preparation
3339669|NCT02174536|Active Comparator|Decidual Stromal cell therapy|Decidual stromal cell therapy (approximately 1x10^6 cells/kg) for hemorrhagic cystitis in addition to Misoprostol therapy (0,2mg, 3 times/day) on two occasions at weekly intervals.
3339670|NCT02174536|Placebo Comparator|Placebo|Receives placebo (masked i.v. infusion, same amount as an infusion of decidual stromal cells) in addition to Misoprostol therapy (0,2mg, 3 times/day).
3339671|NCT02174549|Experimental|Tirapazamine|Administration with dose escalated tirapazamine before embolization until maximally tolerated dose achieved.
3339672|NCT02174575|Active Comparator|Sevoflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
3339673|NCT02174575|Active Comparator|Desflurane|Patients are randomized into 2 groups (Desflurane group and Sevoflurane group) depending on the anesthetic agents administered during anesthesia.
3339674|NCT02174588|Experimental|balanced propofol group|
3339675|NCT02174588|Active Comparator|propofol alone group|
3236986|NCT01256463|No Intervention|Comparison|
3236987|NCT01256463|Experimental|HIV prevention intervention|The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
3339676|NCT02174601||colonoscopy group|
3339677|NCT02174614|Active Comparator|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
3236988|NCT01256489|Other|Infliximab|Every patient enrolled in the study will receive monthly infusions of Infliximab throughout the term of the study. Infliximab will be administered intravenously.
3236989|NCT01256515|Experimental|Health Education Training Group 1|One form of health education training
3236990|NCT01256515|Active Comparator|Health Education Training Group 2|Another form of health education training
3339678|NCT02174614|Experimental|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment
3339679|NCT02174614|Experimental|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized games 3 times per week for the first 4 weeks.
3339680|NCT02174640|Active Comparator|Coffee|Coffee Beverage
3339681|NCT02174640|Placebo Comparator|Water|Water
3339682|NCT02174653|Active Comparator|EPs® 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (1 x 20 mg and 1x placebo) three times a day (in the morning, midday and evening; total daily dose 60 mg) over the individual treatment duration of 14 consecutive days."
3339683|NCT02174653|Active Comparator|EPs(R) 7630|"Active Comparator 20 mg EPs® 7630 film-coated tablet~During the common cold free period: One film-coated tablet (20 mg) three times a day~During a common cold episode: Two film-coated tablets (2 x 20 mg = 40 mg) three times a day (in the morning, midday and evening; total daily dose 120 mg) over the individual treatment duration of 14 consecutive days."
3339684|NCT02174653|Placebo Comparator|Placebo|"During the common cold free period: One film-coated tablet (placebo) three times a day~During a common cold episode: Two film-coated tablet (placebo) three times a day (in the morning, midday and evening) over the individual treatment duration of 14 consecutive days."
3339685|NCT02174666|Active Comparator|Red clover extract|Group recieving daily red clover extract containing isoflavones (80 mg/d), along with calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
3339686|NCT02174666|Placebo Comparator|Placebo group|Group recieving daily placebo extract (with no isoflavone content), calcium (1040 mg/d), vitamin D (25µg/d) and magnesium (487mg/d).
3339687|NCT02174692|Experimental|Elderly|"Exercise One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
3339688|NCT02174692|Experimental|Young|"Exercise~One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 minutes rest between sets"
3339689|NCT02174705|Experimental|Sucrose|Sucrose prior to vaccine injections
3339690|NCT02174705|Active Comparator|Rotavirus|Rotavirus prior to vaccine injections
3339691|NCT02174718|Experimental|Daily 4000IU transdermal D patch|Only in the stage 2, Efficacy Study
3339692|NCT02174718|Active Comparator|Daily placebo patch plus oral placebo|Only in the stage 3, non-inferiority Study
3339693|NCT02174718|Active Comparator|Daily placebo patch plus oral vitamin D|Only in the stage 3 Non-inferiority Study
3339694|NCT02174718|Active Comparator|Daily 4000IU topical patch plus oral placebo|Only for the 3rd Stage of the study, Non-inferiority Study
3339695|NCT02174718|Placebo Comparator|Daily transdermal placebo patch|Only in the stage 2, Efficacy Study
3339696|NCT02174744||numerical scale|
3339697|NCT02174757|Experimental|Inersan|Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2.
3339698|NCT02174757|Experimental|Inersan and Doxycycline together|"Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.~Inersan - 2 Lozenges daily (one lozenge in morning and one lozenge in night) for 2 weeks. Each lozenge contains at least 1 billion CFU of Lactobacillus brevis CD2."
3339699|NCT02174757|Active Comparator|Doxycycline|Doxycycline: 1 Tablet once daily (in afternoon) for 2 weeks. Each tablet contains 100 mg Doxycycline.
3339700|NCT02174770|Experimental|ACL BFR group|This group is patients with post-op from ACL reconstruction who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
3339701|NCT02174770|Active Comparator|ACL Standard Therapy|This group is patients with post-op from ACL reconstruction who are randomized into the standard therapy arm. They will receive ACSM guided-strength training as part of their post-operative physical therapy program.
3339702|NCT02174770|Other|Chronic Muscle Weakness|This is a crossover group where all subjects will be randomized to begin with either standard or blood flow restriction therapy for 4 weeks. After completion of the initial training, each subject will be switched to the opposite in an AB/BA crossover design.
3339703|NCT02174770|Experimental|Knee Arthroscopy BFR|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the blood flow restriction arm. They will receive BFR strength training as part of their post-operative physical therapy program for two months during normal post-op rehab.
3339704|NCT02174770|Active Comparator|Knee Arthroscopy Standard|This group is patients with post-op from soft-tissue only knee arthroscopy who are randomized into the standard physical therapy arm. They will receive ACSM-guided strength training as part of their post-operative physical therapy program during normal post-op rehab.
3339705|NCT02174783|Active Comparator|Control group|Standard of care group
3339706|NCT02174783|Experimental|Mediterranean diet|Mediterranean diet for 6 months
3339707|NCT02174783|Experimental|Protein-Sparing Modified Fast (PSMF)|PSMF for 6 months
3339708|NCT02174796|Experimental|Surgical treatment group|"patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).~intervention: surgical correction (Ravitch or Nuss type intervention)."
3339709|NCT02174796|Experimental|Orthopedic treatment group|patients who chose an orthopedic treatment by vacuum bell. intervention : orthopedic treatment by vacuum bell.
3339710|NCT02174809|Experimental|5As|Physicians' use of the 5As tool to discuss gestational weight gain with their pregnant patients
3339711|NCT02174809|Active Comparator|Usual care|Usual care by physicians in addressing gestational weight gain with their pregnant patients
3339712|NCT02174822|Experimental|Paroxetine + AVP-786|Paroxetine once daily orally Days 1-20. AVP-786 twice daily orally for Days 13 - 20.
3236991|NCT01256528|Experimental|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
3236992|NCT01256541|Experimental|Kristalose|Kristalose as Bowel Evacuant
3236993|NCT01256554|Experimental|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation. Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
3236994|NCT01256580|Active Comparator|Monotherapy|Bevacizumab (Avastin; Genentech, Inc.)1.25 mg by intravitreal injection on day 0 and then prn (as-needed) based on ophthalmic examination and OCT findings
3236995|NCT01256580|Active Comparator|Combination therapy|Intravitreal injection of bevacizumab 1.25 mg (Avastin; Genentech, Inc.) combined with reduced fluence PDT(Visudyne®; Novartis,) and 200 ug of intravitreal dexamethasone(4mg/ml, American regent, Inc) on Day 0 and then monthly retreatment with bevacizumab as-needed and triple therapy every 3 months as-needed.
3236996|NCT01256606||Positive for fetal aneuploidy|
3339713|NCT02174822|Experimental|AVP-786 + paroxetine|AVP-786 twice daily orally Days 1-20. Paroxetine once daily orally for Days 9 - 20
3339714|NCT02174822|Experimental|Duloxetine + AVP-786|Duloxetine twice daily orally Days 1 - 13. AVP-786 twice daily orally Days 6 - 13.
3339715|NCT02174822|Experimental|AVP-786 + duloxetine|AVP-786 twice daily orally Days 1 - 13. Duloxetine twice daily Days 9 - 13.
3339716|NCT02174835|Experimental|Cohort A - Period 1|Twice daily dosing orally for 7 days
3339717|NCT02174835|Active Comparator|Cohort A - Period 2|Twice daily dosing orally for 7 days
3236997|NCT01256606||Negative for fetal aneuploidy|
3339718|NCT02174835|Experimental|Cohort A - Period 3|Twice daily dosing orally for 7 days
3339719|NCT02174835|Experimental|Cohort B - Period 1|Twice daily dosing orally for 7 days
3339720|NCT02174835|Active Comparator|Cohort B - Period 2|Twice daily dosing orally for 7 days
3339721|NCT02174835|Experimental|Cohort B - Period 3|Twice daily dosing orally for 7 days
3236998|NCT01256619|Active Comparator|marvelon|
3236999|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD with PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, with Posterior Vitreous Detachment (PVD Positive). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
3339722|NCT02174874||Oral Ondansetron|Arm that receive oral solution .8 mgms per ml ondansetron - Apotex Brand DIN 02291967
3339723|NCT02174874||Oral disintegrating tablets|Arm that receives the disintegrating tablets either 4mg or 8 mgs Glaxo Brand 4 mg DIN 02239372, 8 mg DIN 02239373
3339724|NCT02174887|Experimental|Nab-paclitaxel + Gemcitabine|Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days The patients will receive 2 cycles of treatment every 28 days
3339725|NCT02174900|Experimental|G6PD deficient 0.25 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
3237000|NCT01256632|Active Comparator|Subfoveal CNV, secondary to AMD w/o PVD|20 eyes with Subfoveal Choroidal Neovascularization, secondary to Age Related Macular Degeneration, without Posterior Vitreous Detachment (PVD Negative). All study eyes will receive 0.5mg, of intravitreous monthly injections of Ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after the first 4 injections, will be on an as needed basis, based on predefined criteria.
3237001|NCT01256645|No Intervention|restrictive transfusion|No transfusion given to correct anemia unless vital indication is given
3237002|NCT01256645|Experimental|liberal transfusion|transfusions are given in single units until Hb is > 12 mg/dl
3237003|NCT01256697|Experimental|Alga Dunaliella Bardawil|
3237004|NCT01256697|Placebo Comparator|Sugar pill|
3237005|NCT01256710||Trifecta Valve Group|
3237006|NCT01256723||J-LESSON Central committee|
3339726|NCT02174900|Active Comparator|G6PD deficient receiving AL only|G6PD deficient males receiving Artemether-Lumefantrine (AL) combination
3339727|NCT02174900|Active Comparator|G6PD normal 0.25 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine
3237007|NCT01256736|Experimental|Tocilizumab 8mg/kg + DMARDs|
3237008|NCT01256762|Experimental|Imetelstat + Paclitaxel (with or without bevacizumab)|
3237009|NCT01256762|Experimental|Paclitaxel (with or without bevacizumab) alone|
3237010|NCT01256775|Placebo Comparator|NCX4016 placebo|NCX4016 placebo b.i.d for 6 months
3237011|NCT01256775|Active Comparator|NCX4016|ncx4016,800 mg b.i.d., on top of aspirin 100 mg o.d.
3339728|NCT02174900|Active Comparator|G6PD normal 0.4 mg/kg PQ + AL|G6PD normal males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
3339729|NCT02174900|Experimental|G6PD-deficient 0.4 mg/kg PQ + AL|G6PD deficient males receiving Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine
3339730|NCT02174926|Active Comparator|Conservative treatment|Written lifestyle guidance and fiber supplements
3237012|NCT01256801||cytokine|The patients are randomized to receive the cytokine infusion in the pleural cavity
3237013|NCT01256814|Experimental|Behaviorial Intervention|SystemCHANGE-HIV is a 10-week, small-group intervention that will promote behavior changes to improve the following: physical activity, sleep behaviors and mental wellness. S
3237014|NCT01256814|Active Comparator|Control|"The control group will receive the manual Symptom Management Manual: Strategies for People Living with HIV/AIDS."
3237015|NCT01256827||ranibizumab in MARINA/ANCHOR|Exudative AMD patients previously enrolled in the ranibizumab treatment arms of the MARINA or ANCHOR studies with subsequent enrollment into the HORIZON extension study.
3237016|NCT01256853|Experimental|MVA Vaccine|
3237017|NCT01256866|Active Comparator|DEXMEDETOMIDINE, SEDATION|
3339731|NCT02174926|Experimental|Elective laparoscopic sigmoid resection|
3339732|NCT02174939|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3339733|NCT02174939|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3339734|NCT02174952|Experimental|TAU+SH|Families allocated to receive their usual treatment + self-help (TAU+SH) will receive 12 weeks of a self-help version of the New Forest Parenting Programme in addition to the usual treatment they are receiving from their clinician. They will also receive an introductory DVD aimed at highlighting key components of the intervention.
3339735|NCT02174952|No Intervention|TAU|Families in the Treatment as Usual (TAU) condition will receive nothing additional to the treatment offered by their paediatrician or Child & Adolescent Mental Health Services (CAMHS) during the trial phase. Families in the TAU condition will be offered the self-help manual at the end of the trial.
3339736|NCT02174965|Experimental|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
3237018|NCT01256866|Active Comparator|Midazolam, sedation,|
3237019|NCT01256905|Experimental|Armodafinil|
3339737|NCT02174965|Active Comparator|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
3339738|NCT02174978|Experimental|Group 1: 10 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 10 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume. Doses administered intramuscular at week 0, 4, 8, and 24. On week week 27, there is a P falciparum Controlled Human Malaria Infection (CHMI) challenge.
3339739|NCT02174978|Experimental|Group 2: 30 µg FMP012 adjuvanted AS01B|FMP012 with AS01B adjuvant system: 30 µg FMP012 antigen reconstituted with 500 µL AS01B adjuvant to equal 0.5 mL final volume administered intramuscular at week 2, 6, 10, and 24. On week week 27, there is a challenge with P falciparum Controlled Human Malaria Infection (CHMI).
3339740|NCT02174978|Other|Infectivity control|Non-immunized infectivity control challenged with P falciparum Controlled Human Malaria Infection (CHMI)
3339741|NCT02174991|Experimental|0.5% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3339742|NCT02174991|Experimental|0.7% Rho-Kinase Inhibitor|AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It is a potent Rho-kinase inhibitor with single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays (deLong MA, et al. IOVS 2009; 50: ARVO E-abstract 4058). Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork (Wang RF, et al. IOVS 2009; 50:ARVO E-abstract 1465). Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most of patients and the only side effect was ocular hyperemia in a minority of subjects (Williams, Novack, Van Haarlem, & Kopczynski, 2011). It is currently in phase II testing.
3339743|NCT02175004|Experimental|IONIS-TTR Rx|
3339744|NCT02175017|Experimental|ONO-4538|ONO-4538 water-soluble injection, 100 mg/vial, 3 times once every 2 weeks in each 6-week cycle
3339745|NCT02175030|Active Comparator|Copper T380 IUD|Randomized to copper T380 IUD for EC (emergency contraception)
3339746|NCT02175030|Active Comparator|LNG20 IUD|Randomized to LNG20 IUD for EC (emergency contraception)
3339747|NCT02175043|Experimental|the operation to add in CFAE to conventional liner ablation|The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
3237020|NCT01256931||organ transplant patients|
3237021|NCT01256931||healthy controls|
3339748|NCT02175043|Active Comparator|only doing conventional liner ablation|The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation
3339749|NCT02175056|Experimental|HL2351|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
3237022|NCT01256957|Active Comparator|Indoor air HEPA filtration|HEPA filters operating in the participant's bedroom and living room.
3237023|NCT01256957|No Intervention|Control|Control
3237024|NCT01256970||Polycystic Ovary Syndrome.|Polycystic ovary syndrome was diagnosed according to the 2003 Rotterdam criteria, which require a minimum of two of the following three criteria: PCOM, chronic anovulation and hyperandrogenism.
3237025|NCT01256970||Normal Control|Normal control women were women who did not present with any of three PCOS criteria.
3237026|NCT01256996|Experimental|Low-abrasive powder|
3237027|NCT01257009|Other|1|Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
3237028|NCT01257009|Other|2|Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
3237029|NCT01257022|Experimental|Family Function Intervention|Familias Unidas Intervention Program
3237030|NCT01257022|No Intervention|Treatment as Usual|Control
3237031|NCT01257035||18F-FAZA-PET/CT|
3237032|NCT01257048|Placebo Comparator|1|Single Dose evaluation placebo (V5)
3237033|NCT01257048|Active Comparator|2|Single Dose evaluation formoterol (V5)
3237034|NCT01257061|Experimental|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g
3237035|NCT01257061|Active Comparator|Group 2|Dexchlorpheniramine maleate 10 mg/g
3237036|NCT01257074|Experimental|Drug 1|Penciclovir 10mg/g
3237037|NCT01257074|Active Comparator|Drug 2|Acyclovir 50mg/g
3237038|NCT01257100||Cases with NPC|Cases with NPC
3237039|NCT01257100||Hospital based controls|Hospital based controls
3237040|NCT01257113|Experimental|supervised exercise|The group gets 10 supervised exerciseclasses at the physiotherapy clinic in addition to homebased exercises
3237041|NCT01257113|Experimental|homebased exercises|The group gets 1 supervised exerciseclass before they do all their exercises at home
3339750|NCT02175056|Placebo Comparator|Placebo|1, 2, 4, 8, 12 mg/kg (SC) / Single-Dose
3339751|NCT02175056|Active Comparator|Kineret(Anakinra)|100 mg (SC) / Single-Dose
3339752|NCT02175069|Experimental|Interscalene Nerve Block - 5ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 20ml Gadopentetate-Dimeglumine 0.05 mmol Shoulder Surgery"
3339753|NCT02175069|Active Comparator|Interscalene Nerve Block - 20ml|"ultrasound guided interscalene plexus block (UISB)~Ropivacaine 0.75%, 5ml Gadopentetate-Dimeglumine 0.0125 mmol Shoulder Surgery"
3339754|NCT02175082|Active Comparator|Forced exercise cycling|Cycling exercise at approximately 90 rpm
3339755|NCT02175082|Active Comparator|Self-selected pace cycling|Cycling at self selected rate, with same aerobic level as forced cycling group
3339756|NCT02175095|Experimental|Regorafenib and FLT-PET|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy). Additional [18F]FDG-PET will be performed before treatment and at 8 weeks (just once at the point of first response evaluation).
3339757|NCT02175134|No Intervention|conventional diagnostic flow arm|Perform the laparoscopic biopsy as a discretion of attending physician's decision
3339758|NCT02175134|Experimental|two-step algorithm-based approach|"Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.~Blood ELISPOT >= 6 spots or ascites adenosine deaminase > 20 IU/L, and~Ascites ELISPOT/Blood ELISPOT rato > 3"
3339759|NCT02175160|Experimental|Braking and functionality with right knee osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right knee osteoarthritis
3339760|NCT02175160|Experimental|Braking and functionality with right knee arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with right total knee arthroplasty
3339761|NCT02175186|Experimental|ALBIS|Albis Tab 2 tab twice a day 12weeks
3339762|NCT02175186|Placebo Comparator|Placebo|placebo Tab 2 tab twice a day 12weeks
3339763|NCT02175238|Experimental|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
3339764|NCT02175238|Active Comparator|BI 691751 fasted|single dose BI 691751 in fasted state
3339765|NCT02175251|Active Comparator|low frequency (1Hz)|low frequency
3339766|NCT02175251|Sham Comparator|Sham Comparator|Sham Comparator
3237042|NCT01257126|Experimental|diclofenac potassium|
3237043|NCT01257126|Active Comparator|nimesulide|
3339767|NCT02175251|Experimental|high frequency (20Hz)|high frequency
3339768|NCT02175264||Patients and Families with isolated non syndromic CDH cases|
3237044|NCT01257139|No Intervention|dual-agent therapy or docetaxel alone|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, according to PS or age
3237045|NCT01257139|Experimental|dual-agent therapy or docetaxel or best supportive care|dual-agent therapy based on Carboplatin (Carboplatin-Pemetrexed for non epidermoid forms, Carboplatin-Gemcitabin for epidermoid forms) or Docetaxel alone, or best supportive care, allocated on the basis of a simplified geriatric scale, plus a more thorough geriatric evaluation if necessary
3339769|NCT02175290||Spinocerebellar Ataxia 3 Yemenite Jews patients|
3339770|NCT02175303|Experimental|Decidual stromal cell therapy for toxicity and inflammation|Patients with toxicity, inflammation or hemorrhages will receive decidual stromal cells at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals dependent on clinical response.
3339771|NCT02175316|Experimental|Experimental: EECP for DOMS|All enrolled subjects will receive EECP treatment Delayed Onset Muscle Soreness.
3339772|NCT02175329|Experimental|CAD/CAM veneering|CAD/CAM manufactured e.max CAD veneers on zirconia framework
3339773|NCT02175329|Active Comparator|manually layered|Manually layered veneering on CAD/CAM fabricated zirconia bridge framework
3339774|NCT02175342|Experimental|Tiotropium-1.25 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 0.625 mcg/puff
3339775|NCT02175342|Experimental|Tiotropium-2.5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 1.25 mcg/puff
3339776|NCT02175342|Experimental|Tiotropium-5 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 2.5 mcg/puff
3339777|NCT02175342|Experimental|Tiotropium-10 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 5 mcg/puff
3237046|NCT01257165|Experimental|Zopiclone 5 mg|Zopiclone 5 mg pill + placebo pill + placebo drink
3237047|NCT01257165|Experimental|Zopiclone 10 mg|2 x zopiclone 5 mg pills + placebo drink
3237048|NCT01257165|Active Comparator|Ethanol 0.8 g/L|2 x placebo pills + ethanol 50 g/70 kg
3237049|NCT01257165|Placebo Comparator|Placebo|2 x placebo pills + placebo drink
3237050|NCT01257178|Experimental|Normal hepatic function|6mg, oral, once on day 1
3339778|NCT02175342|Experimental|Tiotropium-20 Respimat|Two puffs of tiotropium inhalation solution from a Respimat device, 10 mcg/puff
3339779|NCT02175342|Placebo Comparator|Placebo Respimat|
3339780|NCT02175342|Active Comparator|Tiotropium-18 lactose powder Handihaler|
3339781|NCT02175342|Placebo Comparator|Placebo lactose powder Handihaler|
3339782|NCT02175355|Experimental|Low dose of Micardis®|
3339783|NCT02175355|Experimental|Medium dose of Micardis®|
3339784|NCT02175355|Experimental|High dose of Micardis®|
3339785|NCT02175355|Active Comparator|Hydrochlorothiazide|
3339786|NCT02175355|Placebo Comparator|Placebo|
3339787|NCT02175381|Experimental|Carbo/GEM|
3339788|NCT02175394|Active Comparator|Microgynon®|Microgynon® once daily during period 1 (day 1 to day 14)
3339789|NCT02175394|Experimental|Microgynon® and BI 1356|Microgynon® combined with BI 1356, once daily during period 2 (day 15 to day 21)
3339790|NCT02175407|Experimental|ASP1707 alone|
3339791|NCT02175407|Experimental|ASP1707 + itraconazole|
3339792|NCT02175420|Active Comparator|TFV alone|Typhim Vi
3339793|NCT02175420|Experimental|BCG+TFV|BCG (SSI, Denmark) followed after 14 days by Typhim Vi
3339794|NCT02175433|Experimental|Dose Escalation of AGS67E 0.05 mg/kg Without GF|Participants will receive 0.05 milligram per kilogram (mg/kg) AGS67E without growth factor (GF) by intravenous infusion once every three weeks.
3339795|NCT02175433|Experimental|Dose Escalation of AGS67E 0.1 mg/kg Without GF|Participants will receive 0.1 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3237051|NCT01257178|Experimental|Mild hepatic impairment|6 mg, oral, once on day 1
3237052|NCT01257178|Experimental|Moderate hepatic impairment|6 mg, oral, once on day 1
3339796|NCT02175433|Experimental|Dose Escalation of AGS67E 0.3 mg/kg Without GF|Participants will receive 0.3 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3339797|NCT02175433|Experimental|Dose Escalation of AGS67E 0.6 mg/kg Without GF|Participants will receive 0.6 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3339798|NCT02175433|Experimental|Dose Escalation of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3339799|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg Without GF|Participants will receive 1.2 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3339800|NCT02175433|Experimental|Dose Expansion of AGS67E 0.9 mg/kg Without GF|Participants will receive 0.9 mg/kg AGS67E without GF by intravenous infusion once every three weeks.
3339801|NCT02175433|Experimental|Dose Escalation of AGS67E 1.2 mg/kg With GF|Participants will receive 1.2 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
3339802|NCT02175433|Experimental|Dose Escalation of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
3339803|NCT02175433|Experimental|Dose Escalation of AGS67E 1.8 mg/kg With GF|Participants will receive 1.8 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
3339804|NCT02175433|Experimental|Dose Expansion of AGS67E 1.5 mg/kg With GF|Participants will receive 1.5 mg/kg AGS67E with GF by intravenous infusion once every three weeks.
3339805|NCT02175446|Experimental|Experimental1|"Bevacizumab and eribulin~In this study all patients will receive:~Eribulin 1.23 mg/m2 on days 1, 8 every 3 weeks intravenously~Bevacizumab 15 mg/kg every 3 weeks intravenously or Bevacizumab 10 mg/kg every 2 weeks intravenously"
3339806|NCT02175485|Experimental|Fexofenadine HCl|2 tablets of Dellegra Combination Tablets (Fexofenadine Hydrochloride 30 mg+Pseudoephedrine Hydrochloride 60 mg/tablet), oral, administrated 2 hours after start of exposure with 8,000 grains/cubic meter of Japanese cedar pollen
3339807|NCT02175498|Experimental|Homoeopathic medicines|4 pills once a week of the indicated similium for a period of one year
3339808|NCT02175511|Experimental|Cloud-based home BP monitoring|170 were assigned to the experimental group
3339809|NCT02175511|No Intervention|Traditional Care|212 patients were assigned to the traditional care group (paper-based data)
3339810|NCT02175524||Case|Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing.
3339811|NCT02175524||Control|Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing.
3339812|NCT02175537|Experimental|Microclinic social induction training|BMI of 30 and over; or BMI of 25 and over and self-reported pre-diabetes or type II diabetes will receive the Microclinic Social Induction Diabetes and Obesity Program. The intervention is a training on diabetes self-management, disease monitoring, diabetes prevention, prevention of complications, health behavior change, and social network supports in order to improve chronic disease risk factors.
3339813|NCT02175537|No Intervention|Controls|Receiving no intervention but parallel primary and secondary outcome measures as intervention study arm
3339814|NCT02175550|Experimental|NR CC|
3237053|NCT01257178|Experimental|Severe hepatic impairment|6 mg, oral, once on day 1
3339815|NCT02175563|No Intervention|Without feedback|Participants compress the chest of the manikin without smartphone based feedback app.
3339816|NCT02175563|Experimental|With feedback|Participants compress the chest of the manikin with a smartphone based feedback app.
3339817|NCT02175576|Experimental|Vanguard XP Bicruciate Knee System|153 patients receive Vanguard XP Bicruciate Knee System
3339818|NCT02175576|Active Comparator|Vanguard CR Knee System|153 patients receive Vanguard CR Knee System
3339819|NCT02175589|Other|Study group|Colchicine Cessation in FMF patients with one MEFV mutation
3237054|NCT01257191|Experimental|Carbon Black|
3339820|NCT02175589|No Intervention|Control group|The control group includes FMF patients that will be kept on a daily colchicine treatment
3339821|NCT02175602|Experimental|Cohort 2|Sertraline (50 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Sertraline (50 milligrams each morning) days 23-29
3339822|NCT02175602|Experimental|Cohort 1|Escitalopram (10 milligrams each morning) day 1-7, DCV 3DAA FDC + 75 mg BMS-791325 twice daily days 13 to 22, DCV 3DAA FDC + 75 mg BMS-791325 twice daily + Escitalopram (10 milligrams each morning) days 23-29
3339823|NCT02175654|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks, followed by one week of rest, according to the 3/1 regimen
3339824|NCT02175667|Experimental|Global Postural Reeducation|Participants receiving GPR treatment during 45 minutes to stretch muscular chains
3339825|NCT02175667|No Intervention|Control|Participants not receiving GPR treatment
3339826|NCT02175680|Experimental|PRO 140|PRO 140 350mg weekly SQ injection.
3339827|NCT02175693||E2014|
3339828|NCT02175706|Active Comparator|Resolute Integrity®|The coating of Resolute Integrity consists of zotarolimus as antiproliferative agent and the BioLinx® polymer system. This polymer system consists of a blend of three different polymers: (1) the hydrophobic C10 polymer, which aids in the control of drug release; (2) the hydrophilic C19 polymer, which supports biocompatibility; and (3) polyvinyl pyrro-lidinone, which increases the initial drug burst and enhances the elution rate.
3237055|NCT01257191|Experimental|Diesel Exhaust Particles|
3237056|NCT01257191|Experimental|Fine Concentrated Ambient Particles|
3339829|NCT02175706|Active Comparator|Promus Element®|"Promus Element utilizes everolimus, which has been shown to reduce tissue proliferation in the coronary vessels following stent implantation.~Promus Element is composed of the Element platform, a thin fluoropolymer coating, and Everolimus."
3339830|NCT02175719||E2014|
3339831|NCT02175732|Experimental|KnowIt|Please see the 'KnowIt' intervention description below. Diabetes education, behavioral management
3339832|NCT02175732|Experimental|OnTrack|Please see the 'OnTrack' intervention description below. Diabetes Distress Reduction, Problem Solving Therapy
3339833|NCT02175784|Experimental|ipragliflozin group|oral
3339834|NCT02175784|Experimental|placebo group|oral
3237057|NCT01257191|Experimental|Ultrafine Concentrated Ambient Particles|
3237058|NCT01257191|Placebo Comparator|Placebo|
3339835|NCT02175797|Other|Pacemaker + leads|all patients must have a MRI exam after pacemaker implantation
3339836|NCT02175836||SCD possitive versus SCD negative group|The total Heart Failure patients subgroup experiencing Sudden Cardiac Death surrogate end-points during follow up versus the patients subgroup that is free from Sudden Cardiac Death surrogate end-points.
3237059|NCT01257243|Experimental|DRUG 1|Syrup of oxomemazine, guaifenesin and potassium iodate
3237060|NCT01257243|Active Comparator|DRUG 2|Syrup of guaifenesin
3339837|NCT02175849||Drug resistant TB patients|Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
3339838|NCT02175849||Contacts|Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
3339839|NCT02175862||Trauma patients before PS-HEMS|"The before period was between december 1 2009 to april 30 2010 (five months)."
3237061|NCT01257256||infertile patients|male infertile patients(ICD-9:606),female infertile patients(ICD-9:628)
3237062|NCT01257269||1|Patients with confirmed hereditary TTP due to congenital ADAMTS13 deficiency
3237063|NCT01257269||2|Family members of patients with confirmed hereditary TTP
3339840|NCT02175862||Traume patients after PS-HEMS|"The after period was between may 1 2010 to april 30 2011 (12 months)."
3339841|NCT02175875||comatose patients|180 mg ticagrelor followed by 90 mg BID for comatose patients after cardiac arrest
3237064|NCT01257295|Placebo Comparator|control|No additions of fiber to a breakfast meal
3237065|NCT01257295|Active Comparator|low viscous, low gelling|low viscous, low gelling fibre added to breakfast meal
3339842|NCT02175888|Experimental|Oral iron supplement every day for 14 days|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days
3339843|NCT02175888|Active Comparator|Oral iron supplement every second day for 28 days|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days
3339844|NCT02175901|Experimental|Amoxicillin/metronidazole|Amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, Metronidazole 400mg qid
3339845|NCT02175901|Active Comparator|Amoxicillin/clarithromycin|Amoxicillin/clarithromycin-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
3339846|NCT02175914|Experimental|Erythromycin|Oral treatment with Erythromycin 500mg twice daily.
3237066|NCT01257295|Active Comparator|high viscous, low gelling|high viscous, low gelling fibre added to breakfast meal
3237067|NCT01257295|Active Comparator|low viscous, high gelling|low viscous, high gelling fibre added to breakfast meal
3339847|NCT02175927|Experimental|High Dose Amoxicillin|High dose amoxicillin/metronidazole-based quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg tid, Metronidazole 400mg qid
3339848|NCT02175927|Active Comparator|Tetracycline|Classical quadruple therapy for 14 days: Lansoprazole 30mg bid, Bismuth Potassium Citrate 220mg bid, Tetracycline 500mg qid, Metronidazole 400mg qid
3339849|NCT02175940||Myopic Choroidal Neovascularization patients|
3339850|NCT02175940||Control patients undergoing cataract surgery|
3339851|NCT02175953|Experimental|Interventiongroup|Psychotherapy
3339852|NCT02175953|No Intervention|Waitling list group|waiting list
3339853|NCT02176044|Placebo Comparator|Glucose infusion|Placebo infusion of sterile 5% glucose - 500ml infused over 4 hours.
3339854|NCT02176044|Active Comparator|Sodium Nitroprusside infusion|Sodium nitroprusside dissolved in 5% glucose solution. Infused at 0.5mcg/kg/min for 4 hours.
3339855|NCT02176057|Experimental|Antibiotic|Azithromycin, suspension (liquid), 1 gram, one-time dose
3339856|NCT02176057|No Intervention|Observation|
3237068|NCT01257295|Active Comparator|high viscous, high gelling|high viscous, high gelling fibre added to breakfast meal
3237069|NCT01257295|Active Comparator|fibre supplement|high viscous, high gelling fibre is added, not to the breakfast meal, but as supplement
3237070|NCT01257321||post tonsillectomy|children
3339857|NCT02176096|Experimental|Glycosade|
3237071|NCT01257334|Experimental|Treatment Group|BI 10773 10 mg, 25 mg administered once daily
3237072|NCT01257334|Placebo Comparator|Control Group|Placebo administered once daily
3339858|NCT02176122|Active Comparator|Meropenem|Meropenem 1g adm every 8 hours IV up to study day 4.
3339859|NCT02176122|Experimental|Piperacillin-tazobactam combination product|Piperacillin/tazobactam 4.5g adm every 6 hours IV up to study day 4.
3339860|NCT02176135|Experimental|Dose escalation|Auranofin 3 to 6 mg/day oral administration for 12 weeks
3339861|NCT02176161|Experimental|Surgical Prostate Cancer Patients|"Radical Prostatectomy patients with:~High risk surgical pathology (Gleason 8 or higher, positive surgical margins, evidence of extra capsular extension or seminal vesicle invasion)~Prior Radiation Therapy OR~Prior Radiation Therapy with rising PSA.~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
3339862|NCT02176161|Experimental|Radiation Patients|"Radiation Patients with Biochemical Recurrence (rising PSA).~Metformin Hydrochloride Extended Release 750mg twice per day for 9 months."
3339863|NCT02176174||White|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
3339864|NCT02176174||Black|Self-reported ethnic group of Black, using the United Kingdom Census categories, as recorded in electronic health records.
3237073|NCT01257373||patiens with Firebird 2 stent|The group of 1300 patients, in which only Fireibrd2 stent is implanted, will be collected. All inclusive patients should be definitely diagnosed type 2 diabetic mellitus （DM）, either before or during the present hospitalization and with complex coronary lesion.
3339865|NCT02176174||South Asian|Self-reported ethnic group of South Asian, using the United Kingdom Census categories, as recorded in electronic health records.
3339866|NCT02176174||Mixed/Other|Self-reported ethnic group of Mixed or other, using the United Kingdom Census categories, as recorded in electronic health records.
3237074|NCT01257386|Experimental|Asacol®|Import Mesalazine
3237075|NCT01257386|Active Comparator|Mesalazine|Marketed Mesalazine
3237076|NCT01257399|Experimental|Asacol®|Import Mesalazine
3339867|NCT02176187|Experimental|natural technique, without instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
3339868|NCT02176187|Experimental|optimal technique, with instructions|randomised sequence of Berodual® Respimat® and Berodual® MDI
3339869|NCT02176200|Experimental|Berodual® Respimat®|
3339870|NCT02176200|Active Comparator|Berodual® HFA-MDI|
3339871|NCT02176213|Experimental|Pomalidomide, Cyclophosphamide, Dexamethasone|Three oral drugs will be given in 28-day cycles: Pomalidomide 4 mg daily x 21 days; cyclophosphamide 50 mg BID x 21 days; and dexamethasone 40 mg weekly x 3 (20 mg weekly if the patient aged ≥ 75 years old)
3339872|NCT02176239||Gammaplex® IVIg|
3339873|NCT02176252|Experimental|AZD1722|Dose escalation from 5 mg to 90 mg BID
3339874|NCT02176265|Experimental|Qvanteq bioactive coronary stent system|Open-label, single arm, non-randomized study
3339875|NCT02176278|No Intervention|Usual Care Group|"Usual care (UC) group:~After undergoing a comprehensive assessment, all patients will receive UC in accordance to the practice of the health institution and return at 12 months for a repeat comprehensive assessment."
3339876|NCT02176278|Experimental|Empowered Care Group|"Empowered care (EC) group:~After undergoing a comprehensive assessment, all patients will be given a JADE comprehensive assessment report which is a personalize risk report with treatment targets and decision support with explanation from the doctor and nurse. In addition to receiving UC in accordance to the practice of the health institution, the nurse will provide telephone reminder to patient 3-monthly to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns. All patients will return at 12 month for a repeat comprehensive assessment."
3339877|NCT02176278|Experimental|Team-based, Empowered Care Group|"Team-based, empowered care (TEC) group:~After undergoing a comprehensive assessment, patients randomized to the TEC group will be given a JADE comprehensive assessment report which is a personalized risk report for patient empowerment. They will receive telephone reminders and doctor-nurse follow up at least 3 monthly to achieve multiple targets recommended. The patients will also be given JADE reports 3-monthly and return at 12 month for a repeat comprehensive assessment."
3339878|NCT02176304|Active Comparator|Suprapatellar Knee Injection Site|Patients will be injected specified dose of lidocaine and depomedrol through suprapatellar-lateral knee entry site.
3339879|NCT02176304|Active Comparator|Anterolateral knee injection|Patients will be injected specified dose of lidocaine and depomedrol through anterolateral knee entry site.
3339880|NCT02176317|Experimental|Autologous Umbilical Cord Blood (UCB)|All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
3339881|NCT02176330|Active Comparator|Usual care|ePAQ-PF followed by a face to face consultation.
3339882|NCT02176330|Experimental|Virtual Clinic|ePAQ-PF followed by a telephone consultation.
3339883|NCT02176369|Experimental|vinorelbine|50 mg three times a week for a three weeks cycle
3237077|NCT01257399|Active Comparator|Mesalazine|Marketed Mesalazine
3237078|NCT01257412|Experimental|1|
3339884|NCT02176369|No Intervention|Close observation/Best Supportive Care|Close observation/Best Supportive Care (BSC)
3339885|NCT02176395|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3339886|NCT02176395|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3339887|NCT02176395|No Intervention|healthy volunteer|
3339888|NCT02176460|Experimental|colchicine|0.5mg twice daily for 16 weeks
3339889|NCT02176460|Placebo Comparator|placebo tablet|1 tablet twice daily for 16 weeks
3339890|NCT02176473|Experimental|Computerized Cognitive Behavioral Therapy|A computerized version of CBT has been developed in an effort to more widely disseminate the powerful effects of this psychotherapy modality, with studies showing efficacy comparable to that of traditional CBT.8 The present study aims to further investigate the feasibility of combining ECT and computerized CBT (c-CBT).
3237079|NCT01257412|Experimental|2|
3237080|NCT01257412|Placebo Comparator|3|
3237081|NCT01257451|Experimental|Vildagliptin|
3237082|NCT01257451|Placebo Comparator|Placebo|
3237083|NCT01257464|Active Comparator|Sitagliptin|
3237084|NCT01257464|Placebo Comparator|Placebo|
3237085|NCT01257490|Experimental|Intensive counseling|4 sessions of intensive counseling plus bupropion
3237086|NCT01257490|Active Comparator|Brief Counseling|Brief physician advice to quit plus bupropion
3237087|NCT01257516|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3339891|NCT02176499|Experimental|Telmisartan, low dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
3339892|NCT02176499|Experimental|Telmisartan, high dose|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
3339893|NCT02176499|Placebo Comparator|Placebo|3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
3339894|NCT02176512|Experimental|Sequence 1|"four treatment periods:~Treatment A~Treatment B~Treatment B~Treatment A"
3339895|NCT02176512|Active Comparator|Sequence 2|"four treatment periods:~Treatment B~Treatment A~Treatment A~Treatment B"
3339896|NCT02176538|Experimental|Product 0405|Topical active investigational Product 0405
3339897|NCT02176538|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
3339898|NCT02176551|Experimental|Product 0405|Topical active investigational Product 0405
3339899|NCT02176551|Placebo Comparator|Placebo for Product 0405|Topical Placebo for Product 0405
3339900|NCT02176564||Chronic obstructive pulmonary disease|Patients with COPD treated with inhaled bronchodilators
3237088|NCT01257516|Experimental|Pregabalin controlled release, 330 mg|
3237089|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, low-fat|
3237090|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, medium-fat|
3237091|NCT01257529|Experimental|Pregabalin controlled release, 330 mg, high-fat|
3339901|NCT02176577|Experimental|Product 0405|Topically Active Investigational Product 0405
3339902|NCT02176590|Experimental|Power PATH|Classroom PATHS Social Emotional Learning Curriculum (for preschool classrooms) plus Coping Power parent intervention (teaches parents what children are learning in the classroom PATHS program and also provides parents with mental health intervention and parenting topics to promote family well-being)
3339903|NCT02176590|Active Comparator|Head Start as usual|Head Start as usual (will measure the effects of Head Start programming as usual on the primary outcomes)
3339904|NCT02176603||Patients with Phenylketonuria|Patients with Phenylketonuria due to phenylalanine hydroxylase deficiency
3339905|NCT02176603||Control group|Control group of healthy volunteers
3339906|NCT02176616|Active Comparator|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
3237092|NCT01257529|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3237093|NCT01257555||Treatment Group|
3237094|NCT01257594|Experimental|No cytoreductive surgery planned|Patients who are not candidates for surgery as part of their routine care will enroll into the medical arm of the trial. They will initiate pulsatile erlotinib dosing and continue therapy until either disease progression or intolerable toxicity.
3339907|NCT02176616|Experimental|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
3339908|NCT02176629|Experimental|Condition virtual reality (VR)|The subject is placed in front of a Barcotm screen capable of displaying high quality images.
3339909|NCT02176629|Active Comparator|Condition classic cognitive stimulation (CSC)|It is proposed about using the test dam Zazzo suitable for elderly. This classic test measures sustained attention.
3339910|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg after meal
3339911|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg after meal,
3339912|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg after meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg after meal
3339913|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg after meal
3339914|NCT02176668|Experimental|YH4808 NF 100|7 days repeat administration of YH4808 New Formulation 100mg before meal
3339915|NCT02176668|Experimental|YH4808 OF 200|(Partial cross over design) 7 days repeat administration of YH4808 Old Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 New Formulation 200mg before meal
3339916|NCT02176668|Experimental|YH4808 NF 200|(Partial cross over design) 7 days repeat administration of YH4808 New Formulation 200mg before meal, 4 Weeks of wash out period, 7 days repeat administration of YH4808 Old Formulation 200mg before meal
3339917|NCT02176668|Experimental|YH4808 NF 400|7 days repeat administration of YH4808 New Formulation 400mg before meal
3339918|NCT02176681|Active Comparator|Insulin alone|Use the usual frequency and dose
3339919|NCT02176681|Experimental|Insulin and Vildagliptin|vildagliptin 50 mg/day during 3 months
3237095|NCT01257594|Experimental|Cytoreductive surgery planned|"Patients scheduled for salvage resection as part of their routine care will be considered for this cohort. They will receive 1 pre-operative dose of 2000 mg erlotinib. Resection will occur ≤ 3 hours after the pre-operative dose. After recovery from surgery, patients will resume pulsatile erlotinib dosing."
3237096|NCT01257607|Experimental|1% MIM-D3 Ophthalmic Solution|
3237097|NCT01257607|Experimental|5% MIM-D3 Ophthalmic Solution|
3237098|NCT01257607|Placebo Comparator|Placebo Ophthalmic Solution|
3237099|NCT01257620|Placebo Comparator|Placebo|Placebo
3237100|NCT01257620|Experimental|Probiotic|Life Start Two
3237101|NCT01257633||The study population|Laryngeal cancer patients requiring surgical tumor resection.
3237102|NCT01257646||Recent stroke group|These patients have hemiplegia following a stroke within the last 6 months
3237103|NCT01257646||Old stroke group|The patients have hemiplegia following a stroke that took place at least a year ago
3237104|NCT01257659|Experimental|STARR arm|In this group of patients, the STARR transanal stapling system is used to treat the rectocele.
3237105|NCT01257659|Active Comparator|Elevate arm|In this group of patients, a posterior Elevate mesh is placed transvaginally to treat the rectocele.
3237106|NCT01257672|Experimental|ondansetron|ondansetron, syrup, 0,15 mg/Kg of body weight, 1 dose
3237107|NCT01257672|Active Comparator|domperidon|domperidone, syrup, 0,5 mg/Kg of body weight, one dose
3237108|NCT01257672|Placebo Comparator|placebo|placebo, syrup, one dose
3237109|NCT01257685||Control Group|Normal group
3237110|NCT01257685||NAFLD Group|NAFLD in the present study was defined a value of LAI <5 HU using an unenhaned CT.
3237111|NCT01257711|Other|Billroth II reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Billroth II reconstruction.
3339920|NCT02176694|No Intervention|Standard Care|Aside from the asthma education provided at enrollment and placement of the SmartInhaler (i.e.,electronic monitoring device), adolescents will continue to receive usual care through their primary care providers.
3339921|NCT02176694|Experimental|Text Messaging|A technology based system which allows adolescents to compose, schedule and send one-time or recurring text messages to their own cell phones.
3339922|NCT02176707||Idiopathic pulmonary fibrosis sufferers|
3339923|NCT02176720|No Intervention|Standard diagnostics without PET|Standard of care brain imaging modalities, predominantly MRI
3339924|NCT02176720|Experimental|FDOPA PET-CT|PET-CT with administration of FDOPA as an experimental radiopharmaceutical. This arm includes standard of care imaging plus FDOPA PET-CT
3339925|NCT02176733|Experimental|cyclosporine|
3339926|NCT02176746|Placebo Comparator|non-cancer stem cell vaccine|This is no cancer stem cells vaccine in this group
3339927|NCT02176746|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3339928|NCT02176746|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3237112|NCT01257711|Other|Roux-en-Y reconstruction|Following Radical Distal Subtotal Gastrectomy, patient will be randomised to restore the continuity of the intestine with the stomach using Roux-en-Y reconstruction.
3237113|NCT01257724|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
3237114|NCT01257724|Active Comparator|Self-serve evidence service|Organizations allocated to the control group will only be provided website access to a listing of systematic reviews that are organized by year of publication with links to the record on PubMed (or another publicly available source when not available on PubMed) and access to worksheets that help community-based organizations find and use research evidence.
3237115|NCT00077285|Experimental|pts with intermediate- and high-risk rhabdomyosarcoma|
3237116|NCT01257776|Active Comparator|Mesenchymal stem cells 0,5 million * weight (kg)|Group of low dose of Mesenchymal stem cells.
3339929|NCT02176746|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3339930|NCT02176759|Experimental|Regular FePP|Rice (50g dry weight) fortified with 4mg regular FePP
3339931|NCT02176759|Experimental|Regular FePP with citrate added during extrusion|Rice (50g dry weight) fortified with 4mg regular FePP and citrate added during the extrusion process
3339932|NCT02176759|Experimental|Regular FePP with citrated added at consumption|Rice (50g dry weight) fortified with 4mg regular FePP and citrate shortly added before consumption
3339933|NCT02176759|Active Comparator|Ferrous sulphate|Rice (50g dry weight) fortified with 4mg ferrous sulphate
3339934|NCT02176772||Tuberculosis, no HIV and severe anemia|
3339935|NCT02176785|Sham Comparator|Sham tDCS|tDCS will be applied, but then turned off after 30 seconds.
3339936|NCT02176785|Experimental|Anodal tDCS 2mA 10 Minutes|Anodal tDCS will be applied bi-frontally for 10 minutes at 2mA
3339937|NCT02176785|Experimental|Cathodal tDCS 2mA 10 Minutes|Cathodal tDCS will be applied Bi-Frontally for 10 minutes at 2mA
3339938|NCT02176811||Non-alcoholic Fatty Liver Disese|no treatment
3339939|NCT02176811||healthy controls|no treatment
3339940|NCT02176824|Experimental|Triple Chronotherapy|Total Sleep Deprivation, Sleep phase advance, and Bright Light Therapy. Carex Health Brands Day-Light Classic 10,000 Lux
3339941|NCT02176824|Sham Comparator|Sham Triple Chronotherapy|Total sleep deprivation, Three day fixed wake schedule, and sham light therapy.
3339942|NCT02176824|Active Comparator|Treatment As Usual|Normal inpatient care including pharmacotherapy, psychotherapy, milieu therapy, and social work interventions.
3339943|NCT02176850||Micardis®|
3339944|NCT02176876|Experimental|GS-5745|Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.
3339945|NCT02176876|Placebo Comparator|Placebo to match GS-5745|Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.
3339946|NCT02176889|Experimental|Lactospore|One tablet once daily, 30 minutes before a meal, preferably in the morning for 30 days
3339947|NCT02176889|Placebo Comparator|Placebo|One tablet once daily, 30 minutes before a meal, preferably in the morning, for 30 days.
3339948|NCT02176902|No Intervention|Arm I (control)|Patients receive no intervention.
3339949|NCT02176902|Experimental|Arm II (fish oil)|Patients receive dietary counseling with research dietitian weekly for 1 month and then monthly for 11 months. Patients are given guidelines with recommended meals to follow a low-fat diet comprising 20% Kcal from fat, 15% Kcal from protein, and 65% Kcal from carbohydrates for 1 year. Patients also receive 4 fish oil capsules per day PO for 1 year.
3339950|NCT02176915|Experimental|Group program|8-session group weight loss program and 4 follow-up phone counseling sessions
3339951|NCT02176915|Active Comparator|Print Materials|8 weekly mailings of print materials covering weight loss topics through US mail.
3339952|NCT02176941||ATHEROMA group|"ATHEROMA group will include patients undergoing cardiovascular surgery or have pacemaker/defibrillator implantation and have a clinically significant atherosclerotic disease"
3339953|NCT02176941||Control Surgery group|"Control Surgery group will include patients undergoing other surgery or pacemaker/defibrillator implantation without evidence of clinical CV disease or history of previous CV disease."
3339954|NCT02176954|Experimental|Test A, Test B, Comparator|The subjects first test Coloplast Test A followed by Coloplast Test B and finally Comparator.
3339955|NCT02176954|Experimental|Test A, Comparator, Test B|The subjects first test Coloplast Test A followed by Comparator and finally Coloplast Test B.
3339956|NCT02176954|Experimental|Test B, Test A, Comparator|The subjects first test Coloplast Test B followed by Coloplast Test A and finally Comparator.
3339957|NCT02176954|Experimental|Test B, Comparator, Test A|The subjects first test Coloplast Test B followed by Comparator and finally Coloplast Test B.
3339958|NCT02176954|Experimental|Comparator, Test A, Test B|The subjects first test Comparator followed by Coloplast Test A and then Coloplast Test B
3339959|NCT02176954|Experimental|Comparator, Test B, Test A|The subjects first test Comparator followed by Coloplast Test B and then Coloplast Test A.
3339960|NCT02176967|Experimental|Group A (clinical observation)|Patients undergo clinical observation for 96 weeks in the absence of disease progression.
3339961|NCT02176967|Experimental|Group B (clinical observation, first-line chemotherapy)|Patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients undergo surgery or receive first-line chemotherapy comprising carboplatin IV over 1 hour on day 1 (courses 1, 2, 4, 6, and 7), etoposide IV over 1 hour on days 1-3 (courses 1, 3, 4, 5, and 7), cyclophosphamide IV over 1 hour on day 1 (courses 2, 3, 5, 6, and 8), and doxorubicin hydrochloride IV over 15 minutes on day 1 (courses 2, 4, 6 and 8). Treatment with chemotherapy repeats every 21 days for 2-8 courses in the absence of disease progression or unacceptable toxicity. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
3339962|NCT02176967|Experimental|Group C (clinical observation, first-line chemotherapy)|Patients at high risk for deterioration and a poor outcome immediately receive first-line chemotherapy as in Group B. All other patients undergo clinical observation for 3 years in the absence of disease progression. Upon disease progression, patients receive first-line chemotherapy as in Group B. Once a PR or better is achieved, patients undergo clinical observation for 3 years.
3339963|NCT02176980|Active Comparator|Medical provider (MP) brief alcohol counseling & referral|"Screening of HCV-infected patients for alcohol use using the 10-item Alcohol Use Disorders Identification Test (AUDIT).~Patients self-administer the AUDIT.~HCV providers review the AUDIT with the patient.~If the patient is using any alcohol, the HCV provider conducts brief alcohol counseling using the FRAMES model, based on the evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) method.~Medical provider will explain the importance of alcohol abstinence in the presence of HCV infection.~Patient is referred to an alcohol treatment programs outside the liver clinic. Typical counseling will take the form of individual and group therapy."
3339964|NCT02176980|Experimental|Brief alcohol counseling & 6 months of HCV-alcohol treatment|"Steps 1 through 5 as described in comparator arm above.~6 months of group therapy, offered weekly.~6 months of individual therapy, in person or by phone, offered every two weeks.~Therapy content emphasizes interplay between alcohol use and liver health/HCV.~Informal collaboration between HCV providers and addictions therapists.~Shared EMR charting.~Referral to study-provided psychiatry as needed."
3339965|NCT02176993||Application of surface cooling|Surface cooling during 60 minutes.
3339966|NCT02177006||Caregivers|Caregivers of children 2-6 years of age
3339967|NCT02177006||Pediatric clinicians|Pediatricians and nurse practitioners at Lake Forest Pediatric Associates
3339968|NCT02177019|Experimental|Development of personal health plan|Personal Health Plan
3339969|NCT02177045|Experimental|Microbubbles contrast media for US|Sonovue, Bracco, microbubbles contrast media
3339970|NCT02177058|Experimental|Immediate INTERACT implementation|INTERACT Quality improvement program training and implementation between APR 2013 and MAR 2014
3339971|NCT02177058|Active Comparator|Delayed intervention with reporting|Quarterly surveys/data reporting between APR 2013 and MAR 2014. They receive INTERACT training starting on MAR 2014.
3339972|NCT02177058|No Intervention|Delayed intervention not reporting|No data collected from these nursing homes for one year since baseline. They receive INTERACT training starting on MAR 2014.
3339973|NCT02177071|No Intervention|INFLIXIMAB AND ANTI METABOLITE|continuing scheduled infliximab treatment and anti-metabolite
3339974|NCT02177071|Other|STOP INFLIXIMAB CONTINUING ANTI METABOLITE|discontinuing infliximab and continuing the anti-metabolite
3339975|NCT02177071|Other|CONTINUING INFLIXIMAB AND discontinuing anti-metabolites|CONTINUING INFLIXIMAB AND DISCONTINUING ANTI METABOLITE
3339976|NCT02177084|Experimental|PTNS + conservative treatment|"PTNS consists in the insertion of a small electrode above the medial malleolus adjacent to the posterior tibial nerve. An adhesive surface electrode is placed under th arch of the foot. Both electrodes are connected to the neurostimulator that generates electricity. A neuromodulation session lasts 30 minutes.~The treatment plan includes 12 weekly sessions, followed by two sessions at 2-week intervals and the last one after one month. Two additional sessions of reinforcement (top-up) are provided at intervals of 6 months or earlier in case of worsening of symptoms"
3339977|NCT02177084|No Intervention|conservative treatment|
3339978|NCT02177097||40 patients (uTHA)|Patients undergoing primary uncemented total hip arthroplasty surgery.
3339979|NCT02177097||40 patients (hTHA)|40 patients undergoing primary hybrid total hip replacement surgery.
3339980|NCT02177097||40 patients (TKA)|40 patients undergoing total knee replacement surgery.
3339981|NCT02177110||Study|Patients who have fresh frozen and FFPE tissue taken prior to treatment
3237117|NCT01257776|Active Comparator|Mesenchymal stem cells 1 million * weight (kg)|Group of mid dose of mesenchymal stem cells
3237118|NCT01257776|No Intervention|Controlled group|Controlled group with no intervention
3339982|NCT02177110||Control|Fresh frozen tissue and FFPE tissue is available
3339983|NCT02177149|Active Comparator|Standard of Care|DBS using standard of care.
3339984|NCT02177149|Experimental|DBS Clinical Support System|DBS using Clinical Support System.
3339985|NCT02177175|Experimental|Carvedilol|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
3339986|NCT02177175|Placebo Comparator|placebo|Treatment in both carvedilol and placebo groups will be systematically up-titrated at weeks 3, 6, and 9 (+/- 1 week) after randomization to a goal dose of 25mg twice daily.
3237119|NCT01257789||gastric bypass patients|Consecutive series of 300 patients undergoing laparoscopic gastric bypass
3237120|NCT01257815|Experimental|Ranibizumab 0.5mg|
3237121|NCT01257828|Placebo Comparator|Placebo|Placebo medication and decompressive cervical spine surgery
3237122|NCT01257828|Experimental|Riluzole|Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery
3237123|NCT01257841|Placebo Comparator|Fasting alone|
3237124|NCT01257841|Active Comparator|Fasting plus leptin|
3339987|NCT02177188|Experimental|Haemorrhage simulation|
3339988|NCT02177214||ventral hernia|Adult patients scheduled for elective laparoscopic repair of ventral hernia, with inclusion of primary and incisional hernias. Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
3339989|NCT02177227|Experimental|Total Knee Arthroplasty with PSI|Total Knee Replacement with the use of the Attune TruMatch (TM) Patient-Specific Instrumentation
3339990|NCT02177227|No Intervention|Total Knee Replacement|Total Knee Replacement, as per Standard of Care
3339991|NCT02177240|Active Comparator|GRS (GlideRite®)|GlideScope® intubation with GRS® stylet of a simulated difficult airway
3339992|NCT02177240|Active Comparator|FIS (Flex-it® )|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
3339993|NCT02177253|Experimental|Ipratropium bromide / Salbutamol Inhalation solution|
3339994|NCT02177253|Placebo Comparator|Placebo Inhalation solution|
3339995|NCT02177253|Experimental|Ipratropium bromide Inhalation solution|
3339996|NCT02177253|Active Comparator|COMBIVENT Inhalation Aerosol (ipratropium bromide/salbutamol)|
3339997|NCT02177253|Placebo Comparator|Placebo Inhalation Aerosol|
3339998|NCT02177279|Other|Visit A- 120g wheat bran cereals|A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
3339999|NCT02177279|Other|Visit B-40g wheat bran cereals|A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
3340000|NCT02177279|Other|Follow up-40g (8days), 120g (1day) wheat bran cereals|Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
3340001|NCT02177292|Experimental|IMRT & IGRT Radiation Therapy|In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
3340002|NCT02177305|Experimental|Tiotropium dose group 1|0.02 mcg tiotropium solution
3237125|NCT01257854||Busulfan, pharmacogenetic, pharmacokinetic, children|Children who receive Busulfan IV and have a pharmacokinetic of Busulfan
3237126|NCT01257867|Experimental|Lithia spring water|Lithia water (active) for 4 weeks then placebo water for 4 weeks
3237127|NCT01257867|Placebo Comparator|Natural spring water|Placebo water for 4 weeks then lithia water (active) for 4 weeks
3340003|NCT02177305|Experimental|Tiotropium dose group 2|0.04 mcg tiotropium solution
3340004|NCT02177305|Experimental|Tiotropium dose group 3|0.08 mcg tiotropium solution
3340005|NCT02177305|Experimental|Tiotropium dose group 4|0.16 mcg tiotropium solution
3340006|NCT02177305|Experimental|Tiotropium dose group 5|0.28 mcg tiotropium solution
3340007|NCT02177305|Experimental|Tiotropium dose group 6|0.40 mcg tiotropium solution
3340008|NCT02177318||Patients with COPD|
3237128|NCT01257893|Experimental|Aspirin 81 mg|Subjects will take 81 mg aspirin per day for 10-14 consecutive days
3340009|NCT02177331|Experimental|Lacidipine|
3340010|NCT02177344|Experimental|Low dose of ipratropium bromide|
3340011|NCT02177344|Experimental|High dose of Ipratopium bromide|
3340012|NCT02177344|Active Comparator|Atrovent|
3340013|NCT02177344|Placebo Comparator|Placebo|
3340014|NCT02177357|Experimental|Pramipexole - escalation dose|
3237129|NCT01257893|Placebo Comparator|Placebo|Subjects will take matching placebo capsule (excipient: methylcellulose) for 10-14 consecutive days.
3237130|NCT01257906|Experimental|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel Test Product
3340015|NCT02177357|Placebo Comparator|Placebo|
3340016|NCT02177370|Experimental|Fenoterol metered dose inhaler (MDI)|
3237131|NCT01257906|Active Comparator|ZIANA®|Topical Gel Reference Product
3340017|NCT02177370|Active Comparator|DSCG MDI|
3340018|NCT02177383|Experimental|Docosahexaenoic acid|1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek) provides 1.14 g DHA/daily
3340019|NCT02177383|Placebo Comparator|Olive oil|1 liter/day of placebo beverage (containing 0.8% olive oil)
3237132|NCT01257906|Placebo Comparator|Vehicle Control|Topical Gel Placebo
3237133|NCT01257919|Experimental|Azelaic Acid Foam 15%|Dermal application of Azelaic Acid Foam 15%
3237134|NCT01257919|Active Comparator|Azelaic Acid Gel 15%|Dermal application of Azelaic Acid Gel 15%
3237135|NCT00074425|Experimental|1|BufferGel
3340020|NCT02177396|Experimental|Telmisartan|
3340021|NCT02177396|Active Comparator|Valsartan|
3340022|NCT02177409|Experimental|Telmisartan|4-week placebo run-in, 8-week fixed dose period
3340023|NCT02177409|Active Comparator|Amlodipine|4-week placebo run-in, 8-week fixed dose period
3340024|NCT02177422|Experimental|Telmisartan|
3340025|NCT02177435|Experimental|Telmisartan plus Hydrochlorothiazide|
3340026|NCT02177435|Experimental|Telmisartan|
3340027|NCT02177448|Experimental|BIBR277 and placebo matching enalapril|
3340028|NCT02177448|Active Comparator|Enalapril and placebo matching BIBR277|
3340029|NCT02177461|Experimental|Telmisartan|
3340030|NCT02177461|Active Comparator|Enalapril|
3340031|NCT02177461|Experimental|Telmisartan + clonidine TTS1|
3340032|NCT02177461|Active Comparator|Enalapril + clonidine TTS1|
3340033|NCT02177474|Experimental|Telephone based peer support|The telephone based peer support was delivered by 11 women with chd aged 54 to 73 years, living all over Germany. Participants could call according to their needs during scheduled times on workdays.
3340034|NCT02177474|Other|Waitlist Group|Waitlist condition with delayed telephone based peer support starting at 5 months
3340035|NCT02177487|Experimental|Telmisartan + Hydrochlorothiazide|
3340036|NCT02177500|Experimental|Telmisartan + hydrochlorothiazide and matching placebo|
3340037|NCT02177500|Experimental|Telmisartan and matching placebo|
3340038|NCT02177513|Active Comparator|1|
3340039|NCT02177513|Active Comparator|2|
3340040|NCT02177513|Active Comparator|3|
3340041|NCT02177513|Placebo Comparator|4|
3237136|NCT00074425|Experimental|2|Pro 2000/5 Gel (P)
3237137|NCT00074425|Placebo Comparator|3|Placeo Gel
3237138|NCT00074425|No Intervention|4|
3237139|NCT01257932||Diagnostic Tool|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
3237140|NCT01257945|Experimental|Flexibility & Function|Subjects take part in an exercise program based on flexibility and function.
3237141|NCT01257945|Experimental|Aerobic Exercise|Subjects will take part in an aerobic exercise program
3237142|NCT01257945|Other|Home exercise|Standard of care home exercise program
3340042|NCT02177513|Active Comparator|5|
3340043|NCT02177526|Other|Imaging - CT and MRI examinations|Abdominal and pelvic CT and pelvic MRI imaging will be performed in 30 patients.
3340044|NCT02177539|Active Comparator|Cyclopentolate|
3340045|NCT02177539|Experimental|Cyclopentolate+tropicamide+phenylephrine|
3340046|NCT02177552|Experimental|Experimental chemotherapy|Intravenous carboplatin (C) AUC5 day 1 plus intravenous docetaxel (T) 60 mg/m2 day 1 plus oral capecitabine (X) 1000 mg/m2 twice daily from day 1-14, every 4 weeks.
3340047|NCT02177552|Other|Standard chemotherapy|Intravenous epirubicin (E) 50 mg/m2 day 1 plus intravenous oxaliplatin (O) 130 mg/m2 day 1 plus oral capecitabine (X) 625 mg/m2 twice daily continuously, every 3 weeks
3340048|NCT02177565|Experimental|carrier plus BMSCs|carrier plus in vitro expanded autologous BMSCs
3340049|NCT02177565|Placebo Comparator|carrier alone (control).|Carrier alone
3340050|NCT02177578|Experimental|Temozolomide plus radiation therapy to the tumor and SVZ|"Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy of radiation therapy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series and FLAIR series, plus the bilateral subventricular zone Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed, areas of contrast enhancement on T1 post gadolinium series MRI plus the ipsilateral subventricular zone Will be prescribed to 14 Gy in 2 Gy fractions"
3340051|NCT02177578|Active Comparator|Temozolomide and neural progenitor cell sparing radiation|"Patients will receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).~Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan will include the tumor bed and MRI abnormalities based on T1 post gadolinium series and FLAIR series.~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan will include the tumor bed and MRI changes based on T1 post gadolinium series.~Will be prescribed to 14 Gy in 2 Gy fractions"
3340052|NCT02177591||CAD and MI|Patients with a history of coronary artery disease who have had a myocardial infarction in the past.
3340053|NCT02177591||CAD, no MI|Patients who have a history of coronary artery disease and have not had a myocardial infarction in the past.
3237143|NCT01257958|Experimental|19 nor vitamin d|
3237144|NCT01257971||1|Patients with hypercholesterolaemia
3237145|NCT01257984|Experimental|Arm 1|
3340054|NCT02177591||no CAD|Patients with no documented history of coronary artery disease.
3340055|NCT02177604|Experimental|Wingate HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction 3 supervised sessions of Wingate High-intensity Interval Training.
3237146|NCT01257984|Experimental|Arm 2|
3237147|NCT01257997||Healthy subjects|18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body mass index from 20 to 27.
3340056|NCT02177604|Experimental|Modified HIT|7 days of high-fat overfeeding (50% excess calories) in conjunction with 3 supervised sessions of Modified High-Intensity Interval Training
3340057|NCT02177604|Active Comparator|No Exercise Control|7 days of high-fat overfeeding (50% excess calories) with no supervised exercise
3340058|NCT02177617|Active Comparator|Botox only|Participants randomized to receive Botox injections alone.
3340059|NCT02177617|Active Comparator|Botox plus Physical Therapy|Participants randomized to receive Botox injection combined with Physical Therapy
3340060|NCT02177630||Magnetic resonance imaging and endomyocardial biopsy|Magnetic resonance imaging and endomyocardial biopsy
3237148|NCT01258010|Experimental|Tranexamic acid|Study subjects will be randomized to receive a bolus dose of 30 mg/kg of tranexamic acid administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of tranexamic acid of 16 mg/kg/h administered up to 6 hours after surgery.
3237149|NCT01258010|Placebo Comparator|Normal saline (NaCl 0.9%)|Study subjects will be randomized to receive a bolus dose of normal saline (NaCl 0.9%) of equivalent volume administered over 30 minutes starting after the induction of anesthesia followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
3237150|NCT01258023|Experimental|transplant recipients|Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation
3237151|NCT01258036||Fractured Mothers|Fractured Mothers and their daughters
3237152|NCT01258036||Non fractured mothers|Mothers non fractured and their daughters
3237153|NCT01258062|Experimental|of GelVac™ nasal powder H5N1 influenza vaccine.|
3237154|NCT01258062|Placebo Comparator|Placebo|
3237155|NCT01258088|Active Comparator|Cohort 1: AN2728 Ointment|
3237156|NCT01258088|Placebo Comparator|Cohort 1: AN2728 Vehicle|
3237157|NCT01258088|Active Comparator|Cohort 3: AN2728 Ointment|
3237158|NCT01258088|Placebo Comparator|Cohort 3: AN2728 Vehicle|
3237159|NCT01258114|Active Comparator|SPA treatment (ST)|"Drug : spa treatment during 18 days soon after randomization the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises) ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
3340061|NCT02177643|Active Comparator|Diacerein|Diacerein 50 mg immediate release capsule, once daily for the starting 28 days and Diacerein 50 mg immediate release capsule twice a day for the remains of the study.
3340062|NCT02177643|Placebo Comparator|Placebo|Placebo capsules once a day for the starting 28 days and two times daily for the remainder of the study.
3340063|NCT02177656|No Intervention|Usual care|Patients in the usual care group received six patient educational materials in the hospital, a baseline and follow-up phone call by blinded research assistants.
3340064|NCT02177656|Experimental|MI tailored intervention|The MI intervention was provided by a heart failure specialist nurse. The nurse conducted a home-based motivational interviewing intervention followed up by three phone calls over the course of 90 days. The intervention began with a conversation about the participant's self-identified goals. In the home intervention, the nurse focused on self-care areas that the participant identified as high priority. During the home-based intervention, the participant also set specific goals, which the nurse followed up with and reinforced over the follow-up phone calls.
3237160|NCT01258114|Sham Comparator|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
3237161|NCT01258127||Pemetrexed and Carboplatin|For patients in arm pemetrexed/carboplatin, folic acid (350-1000 μg) must be given daily beginning approximately 5-7 days prior to first dose of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 μg) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy. Dexamethasone (4 mg of oral or equivalent) given twice daily should be taken on the day before, the day of, and the day after each dose of pemetrexed, for rash prophylaxis unless medically contraindicated. Patients must receive pemetrexed at day 1 at the dose of 500 mg/m2 as an IV infusion over approximately 10 minutes, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
3340065|NCT02177669||Normals without ocular disease|
3340066|NCT02177682|Experimental|Afuresertib|"Three subjects will be enrolled and given afuresertib 125 mg orally and monitored for toxicity. After completion of PK sampling in 3 days (Cycle 0), daily repeated dose of 125 mg will be given for 21 days (Cycle 1). If no DLT event is found after 21 days of repeated dosing, up to 6 subjects will be enrolled and given afuresertib 150 mg. If afuresertib 150 mg is assessed to be tolerable, up to 6 subjects can be enrolled and given afuresertib 200 mg. If afuresertib 200 mg is assessed to be intolerable, up to 6 subjects will be enrolled and given afuresertib 150mg or 175 mg. In any Dose levels, if DLT occurs in more than 2 subjects, that Dose level will be considered as intolerable."
3340069|NCT02177721|Experimental|Raxibacumab arm|"This is an open-label, single arm study. The study will be implemented for subjects who receive FDA-approved raxibacumab as part of medical treatment of anthrax or for post-exposure prophylaxis.~Intervention: Sampling of subjects or use of subjects salvaged standard of care samples may be considered for the following assessments (if available/applicable): pregnancy test, pharmacokinetics (PK) sampling, protective antigen, toxin neutralizing antibody (TNA), anti-raxibacumab antibodies."
3340070|NCT02177734|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 1 at a 21 day interval
3340071|NCT02177734|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 2 at a 21 day interval
3340072|NCT02177734|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 3 at a 21 day interval
3340073|NCT02177734|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3277510A H7N9 vaccine formulation 4 at a 21 day interval
3340074|NCT02177734|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3277509A H7N9 vaccine formulation 5 at a 21 day interval
3237162|NCT01258127||Vinorelbine and Carboplatin|Patients in arm vinorelbine and carboplatin follow the regimen: The scheduled infusion time is 6-10 minutes for IV vinorelbine at the dose of 25 mg/m2 d1,8, then carboplatin target area under the concentration curve (AUC) 6 (i.v. infusion over 30 minutes) on day 1 of a 21-day cycle. A total of four cycles is intended.
3237163|NCT01258140|Active Comparator|1|Patients examined with normal-dose Computed tomography pulmonary angiography
3340075|NCT02177734|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3340076|NCT02177747|Experimental|Diabet patients|Smartphone ophthalmoscopy followed by traditional slit-lamp dilated ophthalmoscopy
3340077|NCT02177760|Experimental|Sirolimus|Sirolimus (0.05 mg/kg/day) day -5 for aGVHD prophylaxis through day +100 or until T-regulatory cells >9% of CD4 effector cells; whichever comes first.
3340078|NCT02177799||gastroenteritis|
3340079|NCT02177825|Experimental|Imatinib Mesylate|Imatinib Mesylate at 110 mg/m2 up to 440mg/m2 PO per day for twelve months taken in one morning dose (if dose is less than 200 mg/day) or two doses (morning and evening)
3340080|NCT02177851|Experimental|Single oral iron supplement per day (120 mg)|Single oral iron dose of 120 mg per day for 3 consecutive days
3340081|NCT02177851|Active Comparator|B.i.d. oral iron supplement (2x 60 mg)|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days
3340082|NCT02177864|Experimental|Fiber|
3340083|NCT02177864|Placebo Comparator|Placebo|
3237164|NCT01258140|Active Comparator|2|Patients examined with low-dose Computed tomography pulmonary angiography
3237165|NCT01258166||Tramuatic ulnar translocation|Patients who suffered a traumatic ulnar translocation following injury.
3237166|NCT01258179||Sepsis Group|Patients suffering from sepsis in the postoperative course after major abdominal surgery
3237167|NCT01258179||Control Group|Patients without suffering sepsis during postoperative follow up after major abdominal surgery
3340084|NCT02177890|Experimental|Transcutaneous vagal nerve stimulation|Active vagal nerve stimulation to the left auricular branch of the vagus nerve
3340085|NCT02177890|Placebo Comparator|Sham vagal nerve stimulation|Placebo vagal nerve stimulation - stimulator attached to the ear but rotated 180 degrees so that it is not stimulating the vagus nerve.
3340086|NCT02177903|Other|Bair PawsPatient Adjustable Warming System|Bair PawsPatient Adjustable Warming System for active pre-warming
3340087|NCT02177903|Other|Passive pre-warming|Passive pre-warming
3340088|NCT02177916|Experimental|Traditional teaching|
3340089|NCT02177916|Experimental|DVD|
3340090|NCT02177929|Experimental|adapted canoeing, handbike, conventional physiotherapy|Individuals are divided into three groups: one group adapted canoeing, one group of handbike and one grup of conventional physiotherapy.
3340091|NCT02177955|Placebo Comparator|midazolan|7.5 mg midazolan 45 minutes before the surgery
3340092|NCT02177955|Placebo Comparator|diazepam|10 mg diazepam 45 minutes before the surgery
3237168|NCT01258192|Experimental|nab-paclitaxel plus cisplatin|
3237169|NCT01258205|Experimental|Part B|One dose level of AMG 139 administered as a multiple doses IV in subjects with mild-severe Crohn's disease.
3340093|NCT02177968||Elderly fallers or non-fallers|characteristics of these groups
3340094|NCT02177981|Active Comparator|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
3340095|NCT02177981|Sham Comparator|Control|The cuff will be placed around the arm but not inflated.
3237170|NCT01258205|Experimental|Part A|Three dose levels of AMG 139 administered as a multiple doses IV or SC in healthy subjects.
3340096|NCT02177994|Experimental|Group A ceftriaxone after cord clamping|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone via l intravenous infusion single dose after cord clamping."
3340097|NCT02177994|Active Comparator|Group B ceftriaxone before skin incision|"165 patients pregnant at 37weeks or more undergoing elective cesarean section randomly distributed to receive~1 gm. ceftriaxone vial intravenous infusion single dose 30-60 minutes before skin incision."
3340098|NCT02178020||knee arthroplasty, standard polyethylene|total knee arthroplasty with Standard Compression Molded tibial Polyethylene Liner
3340099|NCT02178020||knee arthroplasty, Highly Cross-Linked (XLP) polyethylene|knee arthroplasty with Highly Cross-Linked tibial Polyethylene Liner
3340100|NCT02178033|Other|low-volume (2L) PEG|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, both doses are taken the day before colonoscopy, starting on the evening at about 18:00. Solution intake should be completed before 22.00 h.
3340101|NCT02178033|Active Comparator|Split dose low-volume PEG solution|All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®*, Norgine, Harefield, United Kingdom); Bowel cleansing preparation is divided into two equal doses (each MOVIPREP® sachet dissolved in one liter of water, according to manufacturer's instruction). Each dose must be followed by at least 0.5 L of clear fluid at each administration, and should be taken in a maximum time of 2 hours. In this arm, the first dose is taken on the evening before colonoscopy (at about 20:00 h), the second one is taken early in the morning on the day of the procedure, starting about 4 h before the scheduled procedure time.
3340102|NCT02178046||Gingivitis|optical measurements
3340103|NCT02178072|Other|HPV positive|HPV positive patients
3340104|NCT02178072|Other|HPV negative|HPV negative patients
3340105|NCT02178085|Experimental|Flow imaging|Glaucoma patients and healthy subjects who will undergo ocular flow imaging
3340106|NCT02178098|Experimental|ETC-1002|ETC-1002 180 mg/day
3340107|NCT02178098|Placebo Comparator|Placebo|Placebo control
3340108|NCT02178111|Experimental|Never perform episiotomy|In this group the birth attendant will sought to avoid the use of episiotomy, and try not to carry out the procedure unless considered absolutely needed
3340109|NCT02178111|Active Comparator|Selective episiotomy|Patients will be subjected to the usual routine (selective episiotomy, ie, in the presence of indications described in the literature, according to the discretion of the physician or nurse assisting the birth)
3340110|NCT02178124|Experimental|dosage 1|drug : 9 people(87.5mg/25cm2) placebo : 3 people(0mg/25cm2)
3237171|NCT01258218||Accent MRI Group|
3237172|NCT01258231||Cardiac surgery|Adult patients undergoing cardiac surgery
3237173|NCT01258244||Audiovisual feedback on CPR|EMS technicians will receive audiovisual feedback from the ZOLL device on depth, frequency, and interruptions to cardiac compressions
3237174|NCT01258257|Active Comparator|Lumbar drain (LD) / Tuohy drain|Intervention: Insertion of a lumbar drain All patients in the LD group receives a lumbar drain during anesthesia required for aneurysm treatment. Drainage of CSF is started after the post-procedural CT scan on day one after aneurysm securement.
3237175|NCT01258257|No Intervention|No Lumbar drain (NoLD)|Patients randomized to the control group should not receive a lumbar drain before the planned control angiography to be performed on day 7 to 10 after SAH. If the patient develops hydrocephalus, and no EVD was placed initially for CSF drainage, a lumbar drain may be installed at the discretion of the local investigator. These patients are analyzed in the intention-to-treat analysis, but are not suitable for per-protocol analysis.
3237176|NCT01258270|Active Comparator|(AQUACEL® Ag Surgical Dressing|
3237177|NCT01258270|Active Comparator|Standard island gauze and tape dressing|A standard island dressing consists of adhesive tape and gauze.
3237178|NCT01258283||The study population|See inclusion and exclusion criteria.
3237179|NCT01258296|Active Comparator|Active fentanyl patch|25 mcg/hr fentanyl patch
3237180|NCT01258296|Placebo Comparator|Placebo patch|Inactive patch that resembles treatment patch but contains no drug
3237181|NCT01258309|Experimental|1|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
3237182|NCT01258309|Active Comparator|2|olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution
3237183|NCT01258322|Experimental|pioglitazone|
3340111|NCT02178124|Experimental|dosage 2|"dosage2 period 1 : oral administration drug : 12 people(10mg)~dosage 2 period 2: transdermal administration drug : 9 people(175mg/50cm2) placebo : 3 people(0mg/50cm2)"
3340112|NCT02178137|Active Comparator|Glucosamine/Chondroitin|"Glucosamine/Chondroitin twice a day for a daily total dose of 1500 mg of Glucosamine and 1200 mg of Chondroitin.~Tablets will have 750 mg Glucosamine Sulphate and 600 mg of Chondroitin Sulphate. These will be taken twice a day after breakfast and dinner."
3340113|NCT02178137|Active Comparator|Diacerien|Diacerien 50 mg twice a day in capsule form. To be taken twice a day after breakfast and dinner
3340114|NCT02178137|Placebo Comparator|Placebo pill|Placebo tablets with Zinc sulfate twice a day. These will contain pharamacologically non active ingredients (Usually expedients).
3237184|NCT01258335|Active Comparator|Omega 3 Fatty acids|"II. Study arms:~a. Participants in the dry AMD study group will be randomized into two arms with a 4:1 ratio: i. Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)"
3237185|NCT01258335|Placebo Comparator|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
3340115|NCT02178150|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 8 weeks, every day 1 tablet
3340116|NCT02178150|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 8 weeks, one tablet every day
3340117|NCT02178163|Experimental|Ancillary-Correlative (comprehensive genomic analysis)|Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray. Based on the results of the genomic analysis, patients may begin therapy.
3340118|NCT02178176|Experimental|Education, encouragement, card sort|
3340119|NCT02178176|Active Comparator|Education, encouragement|
3340120|NCT02178189|Active Comparator|Standard-calorie infant formula|Infants assigned to this arm were fed standard-calorie infant formula (20 kcal/oz) from 72 hours of life until 21 days of age.
3237186|NCT01258361||The study population|Patients will be recruited during anesthesia consultations carried out before programmed pelvic or visceral surgeries.
3237187|NCT01258413|Experimental|Laparoscopic Radical Hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
3237188|NCT01258413|Active Comparator|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament are removed + pelvic lymphadenectomy
3340121|NCT02178189|Experimental|High-calorie infant formula|Infants assigned to this arm were fed high-calorie infant formula (24 kcal/oz) from 72 hours of life until 21 days of age.
3340122|NCT02178215|Placebo Comparator|Placebo shower gel|•Wash forearm by prepared placebo shower gel twice a day
3340123|NCT02178215|Active Comparator|Holly Mangrove Shower Gel|•Wash forearm by Holly Mangrove Showver gel twice a day
3340124|NCT02178228||Subjects over age 18|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are over the age of 18
3340125|NCT02178228||Subjects age 15-17|Subjects undergoing non-emergent small bowel or large bowel surgery and reconnection of bowel that are age 15-17 with one permission of one parent.
3340126|NCT02178254|Experimental|Sequence 3|N=10 subjects receive 3grams oral sachet of Monurol in Period 1; 1.0gram of Intravenous (IV) ZTI-01 for Period 2 (1-hour infusion); and 8.0 grams IV ZTI-01 for Period 3.
3340127|NCT02178254|Experimental|Sequence 1|N=10 subjects receive 1.0gram of Intravenous (IV) ZTI-01 for Period 1 (1-hour infusion); 8.0 grams IV ZTI-01 for Period 2 (1-hour infusion); and 3grams oral sachet of Monurol in Period 3.
3340128|NCT02178254|Experimental|Sequence 2|N=10 subjects receive 8.0 grams IV ZTI-01 for Period 1(1-hour infusion); 3grams oral sachet of Monurol in Period 2 and 1.0gram of IV ZTI-01 for Period 3 (1-hour infusion)
3340129|NCT02178267|Experimental|Lactobacillus reuteri|The study was performed by two groups. And these groups were constituted from the newborn preterm infants who are received probiotics (Lactobacillus reuteri) and no probiotics.
3237189|NCT01258426||Normal, IGT, T2DM|
3237190|NCT01258439|Active Comparator|1.Raltegravir plus truvada|Raltegravir 400mg twice daily plus truvada 300mg/200mg once daily for 24 weeks
3340130|NCT02178280|No Intervention|unresectable hilar cholangiocarcinoma|control group
3340131|NCT02178280|Experimental|liver transplantation|liver transplantation combined with neoadjuvant radiochemotherapy
3340132|NCT02178293|Active Comparator|Benzidamine hydrochloride|
3340133|NCT02178293|Experimental|Ketoprofen lysine salt|
3340134|NCT02178306|Experimental|Telmisartan|
3340135|NCT02178319|Active Comparator|open group|the patients under go the open esophagogastric devascularization and splenectomy
3340136|NCT02178319|Experimental|laparoscopic group|the patients under go the laparoscopic esophagogastric devascularization and splenectomy
3340141|NCT02178371|Experimental|UTWC (control group)|the control group performs the same tasks than the experimental group, but without healthy hand constraint/containment.
3375840|NCT03718260|Experimental|Cohort 4|Men with biochemical failure after initial radical prostatectomy with or without adjuvant/ salvage radiotherapy who are currently on salvage hormone therapy will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3375841|NCT03718260|Experimental|Cohort 5|Men who have prior PSMA directed treatment for oligometastatic disease, such as lesion directed therapy (e.g. stereotactic radiosurgery) or systemic therapy (e.g. hormone therapy or chemotherapy) with subsequent biochemical failure will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3375842|NCT03718260|Experimental|Cohort 6|Men with biochemical failure after primary radiation therapy (external beam, brachytherapy or combinations together with or without hormone therapy) will be restaged with [18F]-DCFPyL PET/ CT scan (PSMA PET)
3340142|NCT02178371|Experimental|mCIMT|"The study is conducted over a period of 5 weeks of treatment, using a movement restriction time healthy upper extremity of 2 hours daily.~The restriction applied in the study is performed with the closed hand position and thumb inside the fist through a transparent film that reaches the wrist joint.~In periods mCIMT, monitored the activities designed to enhance their functionality, based on motivation, avoiding frustrations are made."
3340143|NCT02178384|Experimental|Altered-cast technique|Removable partial dentures will be made using altered-cast technique for free saddles.
3237191|NCT01258439|Active Comparator|2. ritonavir boosted darunavir plus truvada|Darunavir 800mg with ritonavir 100mg plus truvada 300mg/200mg once daily for 24 weeks
3237192|NCT01258452|Experimental|CHF 5074 (fed group)|oral tablet, single dose
3340144|NCT02178384|Active Comparator|Precision attachments|Removable partial dentures will be made using precision attachments which will be located on the distal abutment teeth.
3340145|NCT02178384|Active Comparator|Resilient layer|Removable partial dentures will be made using a resilient-layer on the distal extension of each appliance.
3340146|NCT02178397|Experimental|EXPERIMENTAL ARM B|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin in combination with erlotinib~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed in combination with erlotinib"
3340147|NCT02178397|Active Comparator|STANDARD ARM A|"INDUCTION chemotherapy: 4 cycles of~pemetrexed with cisplatin or carboplatin~or gemcitabine with cisplatin or carboplatin~THEN, for responders and for patients with stable disease :MAINTENANCE chemotherapy by Pemetrexed"
3237193|NCT01258452|Experimental|CHF 5074 (fasting group)|oral tablet, single dose
3237194|NCT01258465|Active Comparator|Pivotal Response Training|A naturalistic behavioral intervention designed to facilitate verbal communication.
3340148|NCT02178410|Active Comparator|Vitamin D + fish oil|
3340149|NCT02178410|Active Comparator|Vitamin D + fish oil placebo|
3340150|NCT02178410|Active Comparator|Vitamin D placebo + fish oil|
3340151|NCT02178410|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3340152|NCT02178423|Experimental|Ultrasound|Ultrasound for diagnosis of CVC position in children
3340153|NCT02178436|Experimental|Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)|Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3340154|NCT02178436|Experimental|Group II: Phase II Group I (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
3340155|NCT02178436|Experimental|GroupIII: Phase II Group II (gemcitabine, selinexor)|Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3340156|NCT02178449|Experimental|Verum|Dexamethasone and Ropivacaine
3340157|NCT02178449|Active Comparator|Placebo|Ropivacaine and Saline
3340158|NCT02178462||Primary ovarian cancer patients|Intervention will not be administered.
3340159|NCT02178462||Primary endometrial cancer patients|Intervention will not be administered.
3340160|NCT02178462||Benign gynecological disease patients|Intervention will not be administered.
3340161|NCT02178462||Healthy controls|Intervention will not be administered.
3340162|NCT02178488|Active Comparator|Cholecalciferol|150 patients with MRSA resistent Cholecalciferol 4000 international units (IU)/day for 12 month
3340163|NCT02178488|Placebo Comparator|Sugarpill|150 patients with MRSA resistent Placebo daily 12 month
3340164|NCT02178501|Experimental|Omega-3 PUFA|OMEGA-3 PUFA 2000 mg once daily (1000 mg EPA and 1000 mg DHA)
3340165|NCT02178501|Placebo Comparator|Placebo|Placebo once daily
3340166|NCT02178514|Experimental|Formula Feeding group by BabyNes Nutrition System|In this arm, all infants will be fed with BabyNes Nutrition System since enrollment until 12 month of age
3340167|NCT02178514|No Intervention|Breastfeeding group|used as reference to compare with formula feeding group
3340168|NCT02178527|Experimental|Mulitfaceted podiatry Intervention|Foot and ankle exercises, foot orthoses, footwear provision
3340169|NCT02178527|Placebo Comparator|Usual podiatry care|Continued provision of usual NHS (National Health Service) podiatry care
3340170|NCT02178566|Placebo Comparator|Inhaled Treprostinil Placebo|A dose of placebo resembling inhaled treprostinil will be administered to all study participants in the placebo comparator arm prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled trepostinil dose will be administered each time to all patients .
3340171|NCT02178566|Active Comparator|Inhaled Treprostinil|A dose of inhaled treprostinil will be administered to all study participants prior to each of their Pulmonary Rehab sessions. A dose of inhaled albuterol will be administered prior to each inhaled agent. Vitals signs will be taken prior to administering the dose and no medication will be given if the systolic blood pressure in < 85 mm Hg. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
3340172|NCT02178579||Multiple Myeloma (MM) treatment with bortezomib|No intervention planned.
3340173|NCT02178579||Multiple Myeloma (MM) treatment with carfilzomib|No intervention planned.
3340174|NCT02178605||Cervical arthrodesis candidates|Patients scheduled to undergo cervical arthrodesis to treat their spinal pathology will undergo cervical arthrodesis with rhBMP-2
3340175|NCT02178618|Active Comparator|Partially covered biliary self expandable metal stent|
3340176|NCT02178618|Active Comparator|Uncovered biliary self expandable metal stent|
3340177|NCT02178631|Experimental|Deprexis|Online self-help
3340178|NCT02178631|Active Comparator|CAU|Care as usual
3340179|NCT02178644|Experimental|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
3340180|NCT02178657|Experimental|Bone marrow transplantation low dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)
3340181|NCT02178657|Experimental|Bone marrow transplantation high dose|Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)
3237195|NCT01258465|Active Comparator|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to facilitate communication via picture icons.
3237196|NCT01258478|Experimental|rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
3237197|NCT01258478|Sham Comparator|usual care|Usual care before surgery is provided
3237198|NCT01258517||group 1, group 2, group 3, group 4|administration of beractant with single lumen ET tube administration of poractant with single lumen ET tube administration of beractant with double lumen ET tube administration of poractant with double lumen ET tube
3237199|NCT01258530|Experimental|Treatment A|Over-encapsulated oseltamivir 75 mg (1 capsule)
3340182|NCT02178657|No Intervention|Control|
3340183|NCT02178670|Placebo Comparator|non-cancer stem cell vaccine|There is no cancer stem cell vaccine in this group
3340184|NCT02178670|Experimental|giving low dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3340185|NCT02178670|Experimental|giving middle dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3340186|NCT02178670|Experimental|giving high dose vaccine|The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.
3340187|NCT02178683|No Intervention|Tacrolimus and Mycophenolate Mofetil|Non-myeloablative allogeneic SCT from an HLA-Identical or non-identical family onor or unrelated donors, with fludarabine and low-dose TBI, with immunosuppression utilizing tacrolimus and MMF.
3340188|NCT02178735|Experimental|Anterior compartment prolapse|Woman with cystocele who underwent anterior vaginal tailored mesh surgery
3340189|NCT02178735|Experimental|Posterior compartment prolapse|Woman with rectocele, enterocele, uterine prolapse, vaginal stump prolpase who underwent posterior vaginal tailored mesh surgery
3237200|NCT01258530|Experimental|Treatment B|oseltamivir 75 mg (1 capsule)
3237201|NCT01258543||Non-specific back pain|
3340190|NCT02178735|Experimental|anterior and posterior prolapse|Woman with cystocele and rectocele/uterine prolapse/vaginal vault prolapse/enterocele who underwent anterior and posterior vaginal tailored mesh surgery
3340191|NCT02178748|Experimental|Group 1|Group 1 (Schistosoma mansoni uninfected): 12-24 BCG-vaccinated volunteers with no helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
3340192|NCT02178748|Experimental|Group 2|Group 2 (Schistosoma mansoni infected): 12-24 BCG-vaccinated volunteers with helminth infection. Single dose of 1x10^8pfu MVA85A intramuscular vaccination at D0.
3340193|NCT02178761|Active Comparator|Angioplasty alone|plain old balloon angioplasty alone
3340194|NCT02178761|Active Comparator|Stenting|Balloon angioplasty plus stenting
3340195|NCT02178761|Active Comparator|drug-eluting balloon|Balloon angioplasty with drug-eluting balloon
3340196|NCT02178761|Active Comparator|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stent
3340197|NCT02178774||parturients|tissue oxymetry
3340198|NCT02178813|Experimental|Administration of minocycline|"All patients in the study will receive minocycline periprocedurally with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
3340199|NCT02178826|Experimental|Rapid Maxillary Expansion|A Rapid Maxillary Expander will be fitted and the palate will be expanded approximately 5mm.
3340200|NCT02178826|Placebo Comparator|Placebo group|A Sham appliance is fitted and activated for 10-14 days. The patients in this group will after it has been revealed they were randomized into the placebo group have a true Rapid Maxillary Expander fitted and the palate will be expanded approximately 5 mm.
3340201|NCT02178839|Experimental|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
3237202|NCT01258556|Experimental|Probiotic yogurt|
3237203|NCT01258556|Placebo Comparator|Placebo yogurt.|
3237204|NCT01258569|Active Comparator|Entereg|
3340202|NCT02178839|Placebo Comparator|Maltodextrin|8.5 g/d Maltodextrin
3340203|NCT02178852|Experimental|TNS-active|TRIGEMINAL NERVE STIMULATION (TNS)
3237205|NCT01258569|Placebo Comparator|Placebo|
3340204|NCT02178852|Placebo Comparator|TNS-sham|TRIGEMINAL NERVE STIMULATION (TNS) - sham
3340205|NCT02178865||translocation carrier|balanced translocation carriers who have undergone IVF
3340206|NCT02178878||Progress, Pain|Progress, Pain
3340207|NCT02178891|Other|short implants|
3340208|NCT02178904||Suspected Coronary Artery Disease|Subjects with symptoms suspicious of obstructive CAD who are referred for non-emergent clinically-indicated invasive coronary angiography or stress-rest MPI. Intervention: Procedure/Surgery: CT and stress test
3340209|NCT02178917|Experimental|patients with central neuropathic pain|Randomised to 20 neurofeedback therapy sessions
3340210|NCT02178917|Other|Control: patients with central neuropathic pain|Randomised to no neurofeedback treatment
3237206|NCT01258621|Experimental|Laparoscopic Distal Pancreatectomy|
3237207|NCT01258634|Other|Pre-op treatment|
3237208|NCT01258647|Experimental|Feeding group|The feeding group will include 20 mother/infant dyads. The infants will be between 8 and 10 months of age.
3237209|NCT01258673|Experimental|Fimasartan/HCTZ combination group|
3237210|NCT01258673|Active Comparator|Fimasartan group|
3237211|NCT01258686|Experimental|silymarin, treatment|
3237212|NCT01258686|Placebo Comparator|placebo|
3237213|NCT01258699|Experimental|3|BK-C-0701 480mg
3237214|NCT01258699|Experimental|2|BK-C-0701 320mg
3237215|NCT01258699|Active Comparator|1|Thioctacid HR tab 600mg
3237216|NCT01258712|Experimental|1|
3237217|NCT01258712|Placebo Comparator|2|
3340211|NCT02178917|No Intervention|patients with no central neuropathic pain|Observed for development of central neuropathic pain
3340212|NCT02178930|Other|Integrated self management support|The intervention involves the introduction of an interactive chronic disease support platform into doctor-patient consultations, in addition to a self-management support program. Specifically, the intervention comprises the following interlinked components: within consultation engagement; at home exploration; phone and web-based health coaching.
3340213|NCT02178930|No Intervention|Usual care|The control group will receive usual care from study sites until all study participants have completed 12 months of follow up from their Baseline Visits. At this point access to the study intervention will be expanded to include control sites.
3237218|NCT01258725|Experimental|amnioinfusion|The investigators propose an open trial comparing baseline Doppler waveforms in the uteroplacental and fetal pulmonary circulation in patients presenting with severe, idiopathic olighydramnios (AFI<5, no apparent ethiopathology), managed either with single or with serial amnioinfusions. The patients will be followed up weekly in the fetomaternal unit, Dept. of ObGyn for measuring AFI repeatedly to assess the need for further infusions. These will be carried out when the AFI falls below 5cm again
3237219|NCT01258751|Experimental|PF-05212377|
3340214|NCT02178943||Heart Transplant Recipients|Heart allograft recipients undergoing scheduled surveillance visits that are part of a long-term management plan.
3340215|NCT02178982||standard treatments of ARDS|
3237220|NCT01258764|Active Comparator|Lisinopril|
3237221|NCT01258764|Active Comparator|Hydrochlorothiazide|
3237222|NCT01258777|Experimental|001|200 mg golimumab or placebo Single dose of 200 mg subcutaneously
3237223|NCT01258777|Experimental|002|400 mg golimumab or placebo Single dose of 400 mg subcutaneously
3340216|NCT02178982||protocol treatment of ARDS|
3340217|NCT02179008|Experimental|DE-117 Low Dose ophthalmic solution|One drop Low Dose DE-117 in each eye QD for 90 days
3340218|NCT02179008|Experimental|DE-117 Low/Middle Dose ophthalmic solution|One drop DE-117 Low/Middle Dose ophthalmic solution in each eye QD for 90 days
3340219|NCT02179008|Experimental|DE-117 Middle Dose ophthalmic solution|One drop Middle Dose DE-117 in each eye QD for 90 days
3340220|NCT02179008|Experimental|DE-117 Middle/High Dose ophthalmic solution|One drop Middle/High Dose DE-117 in each eye QD for 90 days
3340221|NCT02179008|Experimental|DE-117 High Dose ophthalmic solution|One drop High Dose DE-117 in each eye QD for 90 days
3340222|NCT02179008|Active Comparator|latanoprost ophthalmic solution 0.005%|One drop latanaprost in each eye QD for 90 days
3340223|NCT02179034|Placebo Comparator|Tobacco Flavor|In this arm, subjects will receive tobacco flavor- without nicotine (placebo). Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3340224|NCT02179034|Active Comparator|Low Dose Nicotine|In this arm, subjects will receive a low dose of nicotine (6 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3340225|NCT02179034|Active Comparator|High Dose Nicotine|In this arm, subjects will receive a high dose of nicotine (12 mg/ml) added to the tobacco flavor. Participants will then be exposed to 3 levels of a menthol additive in random order: no dose, low dose and high dose.
3237224|NCT01258829|Experimental|Non-invasive haemodynamic optimisation|Optimization of pressure production by the heart, as measured by systolic blood pressure in the systemic circulation
3340226|NCT02179060||Cooling group|The RhinoChill® cooling is started as soon as possible to the patients with Cardiac arrest, and before the return of spontaneous circulation
3237225|NCT01258829|Active Comparator|ECHO optimisation|Optimization of AV/VV delay using the guideline recommendations
3237226|NCT01258842|Experimental|B. lactis HN019|
3237227|NCT01258842|Placebo Comparator|Placebo|
3237228|NCT01258868|Experimental|1|Celebrex+ tumor cell vaccine
3340227|NCT02179060||Control group|Standard care, no cooling during pre-hospital care
3340228|NCT02179073||neurogenic bladder dysfunction|
3340229|NCT02179086|Active Comparator|Arm A1 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3340230|NCT02179086|Experimental|Arm B (photon IMRT)|"Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3237229|NCT01258907|Experimental|A|
3237230|NCT01258907|Experimental|B|
3237231|NCT01258907|Placebo Comparator|C|
3237232|NCT01258920|Experimental|Paliperidone palmitate|Paliperidone palmitate Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
3237233|NCT01258933|Experimental|Ofatumumab|Ofatumumab 300 mg dose 1, then 1,000 mg weekly * 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.
3237234|NCT01258959||Ophthalmic surgery patients|Patients (men and women) of at least 18 years of age undergoing an ophthalmic procedure on the posterior section of the eye under local anaesthesia, i.e. with a peribulbar block. Inclusion and exclusion criteria for the study are the same as for the peribulbar anaesthesia.
3237235|NCT01258972|Active Comparator|Angioplasty POBA|Side Branch balloon angioplasty with main branch DES
3237236|NCT01258972|Experimental|Tryton Side Branch Stent|Side Branch treated with Tryton Side Branch Stent with main branch DES
3237237|NCT01259050|Experimental|Zinc and Copper|
3237238|NCT01259076||Group 1|Participants who are eligible for and have opted to undergo gastric bypass surgery
3340231|NCT02179086|Active Comparator|Arm A2 (control)|"Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3340232|NCT02179086|Experimental|Arm C (proton beam radiation therapy)|"Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.~In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity."
3340233|NCT02179099|Experimental|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
3340234|NCT02179125|Experimental|Bronchoscopic LVR-coil treatment|Bronchoscopic lung volume reduction with coil treatment
3340235|NCT02179138|Other|TFV 1% Gel|TFV 1% gel with the user-filled paper applicator
3340236|NCT02179151|Placebo Comparator|Placebo|Intervention: ZGN-440 Placebo for Injectable Suspension
3237239|NCT01259076||Group 2|Participants who are eligible for but decided not to undergo gastric bypass surgery.
3237240|NCT01259141|Experimental|Moxifloxacin|
3340237|NCT02179151|Experimental|ZGN-440 Injectable Suspension (1.8 mg)|Intervention: ZGN-440 for Injectable Suspension
3340238|NCT02179151|Experimental|ZGN-440 Injectable Suspension (2.4 mg)|Intervention: ZGN-440 for Injectable Suspension
3340239|NCT02179216|Active Comparator|Hydration|•Group 1: First day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl). Second day, Orthostatic Hypotension test with venous contention in the morning.
3340240|NCT02179216|Active Comparator|Venous contention|•Group 2: First day, Orthostatic Hypotension test after implementation of venous contention in the morning. Second day, Orthostatic Hypotension test after hydration by three large glasses of clear liquid (33cl).
3340241|NCT02179229|Placebo Comparator|CONTROL|Patient in the CONTROL arm will receive a powder containing only tapioca-resistant starch comparable in colour, texture and taste to the synbiotic.
3340242|NCT02179229|Experimental|SYNBIOTIC|Patients in this group will receive Probinul neutro® a synbiotic preparation containing (perpacket): lyophilised bacteria (5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subsp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarius and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus thermophilus), prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
3237241|NCT01259141|Experimental|Cephalosporins and azithromycin|
3237242|NCT01259154||RFITT+UPPP|
3340243|NCT02179242|No Intervention|Control arm|This arm will receive routine care following their heart failure which includes no cardiac rehab intervention.
3340244|NCT02179242|Experimental|Cardiac rehab|This arm will receive cardiac rehab intervention 3 times per week for 4 weeks following discharge.
3237243|NCT01259154||UPPP|
3237244|NCT01259167||BACK group|training with a traditional protocol of Therapeutic Physical Exercise
3237245|NCT01259167||"Group C."|Control group with sedentary people undergoing usual care.
3340245|NCT02179255|Experimental|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) plus FSH 450 to 600 units per day administered subcutaneous (SQ) daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
3340246|NCT02179255|Active Comparator|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
3340247|NCT02179268|Active Comparator|sertraline & control|sertraline 50-150mg tables for 1 year,Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3340248|NCT02179268|Active Comparator|citalopram & Control|citalopram 20-40mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3340249|NCT02179268|Active Comparator|venlafaxine & control|venlafaxine 75-100mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3340250|NCT02179268|Active Comparator|reboxetine & control|reboxetine 4-8mg tables by mouth every day for 1 year, Control (cognitive behavioral therapy by psychiatrists, 50min, every week for three months, every month, for nine months).
3237246|NCT01259167||JOBA group|training with JOBA® Core Trainer
3237247|NCT01259180|Experimental|Acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
3237248|NCT01259180|Sham Comparator|Sham acupuncture group|twice a week, 6 weeks real acupuncture treatment, 12 sessions
3237249|NCT01259180|No Intervention|Control group|observation.
3237250|NCT01259193|Experimental|Sorafenib and Zoledronic Acid|
3237251|NCT01259206||diabetic patients|
3237252|NCT01259206||diabetic patients and healty controls|there are two groups in this study. One group is obese type 2 diabetic patiens and other group is healty controls.
3237253|NCT01259219|Experimental|Rifabutin (Mycobutin)|Rifabutin is a red-violet powder souble in chloroform and methanol, sparingly souluble in ethanol, and very slightly soluble in water. Mycobutin capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. Mycobutin capsules for oral administered contain 150mg of rifabutin, USP, per capsule, along with the inactive ingredients microcrystalline cellulose magenesium stearate, red iron oxide3, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink.
3237254|NCT01259232||schizophrenia patients,untreated|
3237255|NCT01259232||schizophrenia relatives|
3237256|NCT01259232||controls|
3340251|NCT02179281|Experimental|Suspend Before Low feature turned ON|"MiniMed™ 640G system with the Suspend Before Low feature turned ON; continuously set on at 3,6 mmol/L (65 mg/dL). Suspend On Low Alert and Resume Basal Alert for the SmartGuard group should be set OFF.~Administered intervention: Medtronic MiniMed™ 640G system"
3340252|NCT02179281|Active Comparator|Suspend Before Low feature turned OFF|"MiniMed™ 640G system with the Suspend Before Low and Suspend On Low features are both turned OFF; Alert On Low is set at 65 mg/dL (3,6 mmol/L). Resume Basal Alert should be set OFF as well.~Administered intervention: Medtronic MiniMed™ 640G system"
3340253|NCT02179294|Active Comparator|Pethidine|Pethidine is pain relief in labour
3340254|NCT02179294|Active Comparator|Remifentanil|Remifentanil intravenous patient controlled analgesia
3340255|NCT02179307|Experimental|Arm label 1-Set, 3-Set|12-week progressive strength training protocol of different volumes
3340256|NCT02179320|Active Comparator|Dry needling|Dry needling for myofascial pain syndrome, in the trapezius muscle.
3340257|NCT02179320|Sham Comparator|Sham needling|Superficial dry needling in the trapezius muscle
3340258|NCT02179346||Cartilage defects in the hip joint|NOVOCART® Inject Autologous Chondrocyte Implantation
3340259|NCT02179359|Experimental|Reduced Toxicity Ablative Regimen|For use in patients with a matched sibling donor or unrelated UCB donor and DBA patients who are <12 years and/or have mild/moderate iron exposure.
3340260|NCT02179359|Experimental|Reduced Intensity Preparative Regimen|For use in patients with unrelated donor bone marrow and for DBA patients who are >12 years and/or have significant iron exposure.
3340261|NCT02179359|Experimental|Myeloablative Preparative Regimen|For use in patients with a matched sibling donor, unrelated umbilical cord blood and in those with severe thalassemia.
3340262|NCT02179372|Experimental|Eicosapentaenoic acid|Subject with Cronn's Disease and/or Ulcerative colitis in clinical remission will receive 2 g/day of eicosapentaenoic acid for 6 months
3340263|NCT02179372|Placebo Comparator|Medium chain fatty acid (placebo)|Subjects with Crohn's Disease and/or Ulcerative colitis will be receive 2 g/day of medium chain fatty acid for 6 months
3340264|NCT02179385|Experimental|Health coaching|Patients receive health coaching via the phone, face to face or group support, according to patients' choice
3340265|NCT02179385|Placebo Comparator|Standard of Care|
3340266|NCT02179411|Active Comparator|healthy volunteers|healthy volunteers
3340267|NCT02179411|Active Comparator|renal transplant recipients|renal transplant recipients
3237258|NCT01259258|Active Comparator|varicocelectomy with dye|subinguinal varicocelectomy for 40 patients who received 2 ml intratunical space injection of methylene blue before spermatic vein ligation
3340268|NCT02179411|Active Comparator|renal transplant recipients grave|renal transplant recipients grave
3340269|NCT02179450||Blepharospasm|Patients suffering from Blepharospasm
3340270|NCT02179450||Cervical Dystonia|Patients suffering from cervical dystonia
3340271|NCT02179450||Bilateral facial palsy|Patients suffering from bilateral facial palsy of inflammatory origin
3340272|NCT02179450||Healthy Control|Control subjects
3237259|NCT01259258|Active Comparator|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
3237260|NCT01259271|Experimental|Supra-threshold|Supra-threshold is defined as the nerve stimulation amplitude at which a subject can tolerate sensory responses (like tingling, tapping in the thumb, index or middle fingers) but will not cause pain or duress to the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers and they feel the paresthesia or tingling sensation.
3340273|NCT02179463||Neoadjuvant Chemotherapy|undergo neoadjuvant chemotherapy before surgery
3340274|NCT02179476|Experimental|Glyder|Glyder Facet Restoration Device
3340275|NCT02179489|No Intervention|Control|surgery alone
3340276|NCT02179489|Experimental|Hipec|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC
3340277|NCT02179502|Experimental|GLPG1690 single dose|Single oral dose of GLPG1690 suspension or solid formulation - ascending doses
3340278|NCT02179502|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension or solid formulation
3340279|NCT02179502|Experimental|GLPG1690 multiple doses|Multiple oral doses of GLPG1690 suspension - ascending doses
3340280|NCT02179502|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3340281|NCT02179528|Active Comparator|etoposide,maintenance therapy|etoposide,25mg qd d1-20，repeat every 28 days
3340282|NCT02179528|No Intervention|blank control|blank control
3340283|NCT02179541||Group 1|All Group 1 patients were diagnosed with OME, diagnoses made by endoscopic-otoscopic examination findings and type-B tympanograms. They were all scheduled for ventilation tube insertion. Diagnosis of OME was confirmed during this surgery. All patients were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements. Viscosity was measured by the Brookfield DV-II+ProCP Viscometer.
3340284|NCT02179541||Group 2|Children in Group 2 had totally normal tympanic membranes and type A tympanograms. They had no hearing loss, Eustachian tube dysfunction, or any other ear-related problem, and were included in the study as healthy controls. Excluded from the study were patients presenting with acute otitis media, tympanosclerotic plaques, mental retardation, and children who were difficult to cooperate with. All subjects were examined by 4 mm 0-degree Storz endoscope and light source. The Adobe Photoshop Elements 7.0 program was used for RGB measurements.
3340285|NCT02179541||Group 1a|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion below the mean viscosity value of 450 cP (centipoise) were assigned to Group 1a.
3340286|NCT02179541||Group 1b|To determine whether higher or lower viscosity of an effusion impacted RGB values, the patient group was subdivided into two subgroups according to viscosity level. Patients with an effusion above the mean viscosity value of 450 cP (centipoise) were assigned to Group 1b.
3340287|NCT02179554||cardiopulmonary bypass|Patients undergoing elective surgery requiring cardiopulmonary bypass
3340288|NCT02179567|Experimental|Doc/Bev|Docetaxel/Bevacizumab
3340289|NCT02179580|Experimental|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days
3340290|NCT02179580|Placebo Comparator|Placebo|Placebo at a rate of 3.0 g three times per day for 28 days
3340291|NCT02179593|Other|2-Segment SARPE|Maxilla expansion using one sagittal section of the maxilla.
3340292|NCT02179593|Other|3-Segment SARPE|Maxilla Expansion using two parasagittal section of the maxilla.
3237261|NCT01259271|Experimental|Sub-threshold|Sub-threshold is defined as the nerve stimulation amplitude just below the sensory perception of the subject. The intervention (TAMS device), is stimulating through tyco extended wear electrodes that are placed directly on top of non dominant hand healthy median nerve fibers. Subjects do not feel the paresthesia or tingling sensation despite there being a signal transmitted..
3237262|NCT01259271|Sham Comparator|Sham Control|All subjects in the sham arm will go through the same process / experimental setup as in each of the active stimulation arms; however there will be no stimulation signal during the sham stimulation (output set and SNS box locked at 0 V). As this is the Sham control, there is no intervention but rather the intevention (TAMS device) setup (Tyco electrodes, wires and stimulator) are sent with the subject as if it were on (and just like Subthreshold arm the subjects cannot feel the stimulation). Audible alerts (to signify that the box is unplugged) will be disabled throughout the duration of the study. This sham arm will be used to assess the placebo effect caused by the stimulation and hence isolate the true effect of stimulation.
3237263|NCT01259310||Women with epilepsy|Women with epilepsy, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
3340293|NCT02179606|Experimental|Dermalax Implant Plus|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
3340294|NCT02179606|Active Comparator|Restylane Sub-Q|Subject injected in the nasolabial folds of one side of the face in the initial treatment period.
3340295|NCT02179619|Experimental|Dermalax(Deep)|subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
3340296|NCT02179619|Active Comparator|Restylane|Subject injected in one nasolabial fold (NLF) of one side of their face (blinded, split-face study design) in the Initial Treatment period
3340297|NCT02179632|Experimental|Disclosure intervention zero|Treatment Group 1: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. A. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. A, according to manufacturer, in 2012. Dr. A will be a physician the researchers have chosen who does not appear on the website and therefore did not receive any payments in 2012. Participants should report $0/not listed as the response. Following this stage, participants will be told that Dr. A does not appear on the website and therefore did not receive any payments.
3340298|NCT02179632|Experimental|Disclosure intervention low|"Treatment Group 2: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. B. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. B, according to manufacturer, in 2012. Dr. B will be a physician the researchers have chosen who received an aggregate amount that is a low payment (below $100) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. B in 2012."
3340299|NCT02179632|Experimental|Disclosure intervention high|"Treatment Group 3: This group will be directed to ProPublica's Dollars For Docs physician payment disclosure registry for State of Massachusetts, and be asked to search for Dr. C. Participants will be asked to complete a worksheet reporting the total dollar amount listed for Dr. C, according to manufacturer, in 2012. Dr. C will be a physician the researchers have chosen who received an aggregate amount that is a high payment (above $250) in 2012. Participants should report the dollar amount listed as the response. Following this stage, participants will be told the exact dollar amount for payments received by Dr. C in 2012."
3340300|NCT02179632|No Intervention|Control group|Control Group: The control group will not be exposed to the disclosure website, but will participate in another online information-seeking task. These participants will visit the Farmer's Almanac website and be asked to search for temperature reports.
3340301|NCT02179645|Experimental|GRC 27864|Test Treatment GRC 27864
3340302|NCT02179645|Active Comparator|Celecoxib|Active Comparator Treatment
3340303|NCT02179645|Placebo Comparator|Placebo|Placebo Treatment
3340304|NCT02179658|Experimental|OPT-80 group|Oral
3340305|NCT02179658|Active Comparator|Vancomycin group|Oral
3340306|NCT02179684|Experimental|Early surgery|Patienst with Bell´s Palsy with an early surgical intervention (< 3month), according to 'baby-sitter' method
3340307|NCT02179684|Active Comparator|Conventional treatment and follow-up|Patienst with Bell´s Palsy treated with conventional treatment and standardized physiotherapy according to Jaqueline Diels model.
3340308|NCT02179697|Active Comparator|Surgery + Bracing vs. Bracing Alone|"Randomize between 2 treatments:~Treatment 1: Surgery + Bracing Treatment 2: Bracing alone"
3340309|NCT02179697|Other|Patient's choice|Patient will decide which group is best for him/her. The patient will be followed at the same points as Group 1.
3340310|NCT02179710||Motivational Interviewing|Review of adherence dashboard by the investigator with the patient to facilitate and engage intrinsic motivation within the client in order to change behavior.
3340311|NCT02179723|Experimental|Leukosan Adhesive|Leukosan Adhesive applied to one wound (left or right)
3237264|NCT01259310||Women without epilepsy|Healthy women, age 18-40 years, who express a desire to conceive and have stopped or plan to stop taking birth control.
3237265|NCT01259323|Experimental|Cohort 1|
3237266|NCT01259323|Experimental|Cohort 2|
3237267|NCT01259323|Experimental|Cohort 3|
3340312|NCT02179723|Active Comparator|Transcutaneous suture|Transcutaneous suture applied to second wound (left or right)
3340313|NCT02179736|Experimental|Active treatment|
3237268|NCT01259336|Active Comparator|Itraconazole|Role of itraconazole in CCPA
3237269|NCT01259336|Experimental|treatment in cavitary pulmonary aspergillosis|Patients in this arm are given conservative management with antitussives, brochial artery embolisation.
3340314|NCT02179749|Active Comparator|Experimental: mifepristone 1200 mg daily|1200 mg mifepristone daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
3340315|NCT02179749|Placebo Comparator|Placebo daily, 1-week|Placebo pills daily for 1-week given in conjunction with 8 weeks of standardized behavioral therapy
3340316|NCT02179762|Experimental|Arm I (moderate intensity exercise)|Patients perform moderate intensity exercise on a stationary bike for 20-50 minutes, three days a week for 16 weeks.
3340317|NCT02179762|Experimental|Arm II (HIIT exercise on a standard stationary bike)|Patients perform HIIT exercise on a standard stationary bike, three days a week for 16 weeks.
3340318|NCT02179762|Experimental|Arm III (HIIT exercise on a cybercycle)|Patients perform HIIT exercise on a cybercycle using racing or other games, three days a week for 16 weeks.
3340319|NCT02179775|Active Comparator|propranolol|
3340320|NCT02179775|Active Comparator|Quince's oxymel|
3340321|NCT02179775|Placebo Comparator|placebo|
3340322|NCT02179814|Experimental|AMPT|"Experimental:~alpha-methyl-paratyrosine (AMPT, trade name: Demser), body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 time points over 24 hours"
3340323|NCT02179814|Sham Comparator|Diphenhydramine & placebo|Diphenhydramine (25mg, trade name in Switzerland: Benocten) at the first medication intake time point, placebo at the second to fourth intake time point (medication intake over 24 hours)
3340324|NCT02179840|Active Comparator|Intravenous|Anesthesia is maintained via intravenous agents. Mechanical ventilation adjustment will be performed.
3340325|NCT02179840|Active Comparator|Inhalational|Anesthesia is maintained via inhalational agents. Mechanical ventilation adjustment will be performed.
3340326|NCT02179853|Experimental|Anakinra|This is a dose escalation study (4 mg/kg, 6 mg/kg and 8 mg/kg).
3340327|NCT02179866|Experimental|[14C]-labeled RO5285119|Single oral dose - drinking solution
3340328|NCT02179879||Video validation group|This will include video taping of experts (defined as one who has performed more than 500 labor epidurals in preceding 5 year period) and novices (defined as one who has done less than 50 epidurals in preceeding 2 years) perfoming labor epidural
3340329|NCT02179905||Irritable bowel syndrome, Control|
3237270|NCT01259349|Experimental|one percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
3340330|NCT02179931|Experimental|Flupentixol/melitracen film-coated tablet|test treatment - 0.5 mg/10 mg; oral as a single dose
3340331|NCT02179931|Other|Flupentixol/melitracen coated tablet (Deanxit®)|reference treatment - 0.5 mg/10 mg, oral as a single dose
3340332|NCT02179944||Participants|
3340333|NCT02179957||CT and FFR|Coronary stenoses which have been analysed with both CT and FFR
3340334|NCT02179970|Other|Plerixafor (Mozobil)|Plerixafor (Mozobil), continuous 7 day IV infusion. Starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
3340335|NCT02179983|No Intervention|Standard care|Standard care for exacerbation and follow-up without rehabilitation
3340336|NCT02179983|Experimental|Pulmonary rehabilitation|6 weeks of exercise and patient education after exacerbation (pulmonary rehabilitation)
3340337|NCT02179996|Active Comparator|Three vaccine injections|Infants in this study arm will receive three vaccine injections at two, three and four months after birth (vaccine: DTP-pertussis-Hib).
3340338|NCT02179996|Experimental|Two vaccine injections|Infants in this study arm will receive two vaccine injections at two and four months after birth (vaccine: DTP-pertussis-Hib).
3340339|NCT02180009||normal control|healthy people
3340340|NCT02180009||sepsis|mild response to infection
3340341|NCT02180009||severe sepsis|infection with at least one organ dysfunction
3340342|NCT02180009||septic shock|patients with septic shock
3340343|NCT02180022|Placebo Comparator|Placebo|Patients treated with placebo for 12 weeks
3340344|NCT02180022|Experimental|Onion peel extract|Patients treated with onion peel extract for 14 days
3237271|NCT01259349|Active Comparator|40 percent ultrasound|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
3340345|NCT02180035|Experimental|Symbiotic & Nutritional intervention|Symbiotic (dietary fibers + probiotic bacteria) 6g sachet twice daily for 6 months, dietary prescription and nutritional counseling
3340346|NCT02180035|Placebo Comparator|Maltodextrin & Nutritional intervention|Maltodextrin (placebo for symbiotic) 6g sachet twice daily for 6 months, dietary intervention and nutritional counseling.
3340347|NCT02180048|Active Comparator|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
3340348|NCT02180048|Active Comparator|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
3340349|NCT02180048|Placebo Comparator|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
3340350|NCT02180074||I|Women without PAD (ABI >1.0 and <1.4) or CAD, and < 2 risk factors for cardiovascular disease (to serve as healthy controls)
3340351|NCT02180074||II|Women without PAD (ABI>1.0 and <1.4) or CAD and > 2 risk factors for cardiovascular disease
3237272|NCT01259362|Active Comparator|Transcranial Magnetic Stimulation|Cocaine addicted will receive a 20 day TMSr to right dorsolateral prefrontal cortex.
3340352|NCT02180074||III|Women with PAD as defined by ABI <0.9 and a coronary angiogram without any significant coronary artery disease.
3340353|NCT02180074||IV|Women with CAD without PAD, as defined by >50% stenosis by coronary angiography and ABI >1.0 and <1.4.
3340354|NCT02180074||V|Women with both CAD and PAD.
3340355|NCT02180087|Placebo Comparator|placebo group|Group 1 : Placebo group (P). 0 mg/kg ketoprofen IV every 6 hours for 48 hours (or 0 mg/kg every 24 hours) for 48 hours
3340356|NCT02180087|Other|ketopofen quarter dose|"Group 2 : Ketoprofen quarter dose (K ¼). 0,125 mg/kg ketoprofen IV every 6 hours (0,5 mg/kg every 24 hours) for 48 hours."
3340357|NCT02180087|Other|ketoprofen half-dose|"Group 3 : Ketoprofen half-dose (K ½). 0,25 mg/kg ketoprofen IV every 6 hours (1 mg/kg every 24 hours) for 48 hours."
3340358|NCT02180087|Other|Ketoprofen full dose|"Group 4 : Ketoprofen full dose (KPD). 0,5 mg/kg ketoprofen IV every 6 hours (or 2 mg/kg every 24 hours) for 48 hours"
3340359|NCT02180113|Other|Fibroscan®|Fibroscan® is an active non implantable medical device using ultrasound. It has been designed to measure liver stiffness in a painless, rapid and non invasive manner. It is a diagnostic aid tool. In this study, Spleen Stiffness Measurement will be assessed using a dedicated FibroScan® device which has been developed specifically to assess spleen stiffness.
3340360|NCT02180126||Positive ANCA|Patients with borderline positive ANCA results.
3340361|NCT02180139|Experimental|Primary motor cortex (M1) stimulation|Treatment by transcranial direct current stimulation will be targeted to the motor cortex for all treatment sessions with Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral M1, 15 minutes (Goal: decrease contralateral M1 excitability)
3340362|NCT02180139|Experimental|Cerebellum stimulation|Treatment with transcranial direct current stimulation will be targeted to the cerebellum at every session with anode to ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits)
3340363|NCT02180139|Experimental|Combined M1 and Cerebellum stimulation|Treatment with transcranial direct current stimulation will be placed with M1 anode contralateral + cerebellum anode. M1 will first be 'primed' with anode on contralateral M1, cathode on face, for 10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the contralateral M1 with increased excitability to engage a potentially larger effect from the following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect on the motor circuits including M1)
3237273|NCT01259362|Sham Comparator|Transcranial Magnetic Stimlation|cocaine addicted will receive a 20 day sham TMSr to right dorsolateral prefrontal cortex
3237274|NCT01259414|Experimental|group1|Chemoembolization with solvent with specific gravity less than lipiodol
3340364|NCT02180139|Placebo Comparator|Sham stimulation|transcranial direct current stimulation will be given in placebo form. Sham stimulation: electrode placement will be same as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds following standard practice for sham tDCS.
3340365|NCT02180152|Experimental|Postprandial walk|
3340366|NCT02180152|No Intervention|sedentary pregnant women|
3340367|NCT02180178||Consecutive patients undergoing coronary angiography|Consecutive patients undergoing coronary angiography at the University Medical Center Mainz - no inclusion criteria specified. The absorb substudy will include consecutive patients who received an Absorb scaffold based on clinical indication.
3340368|NCT02180191||Obesity|27 obese individuals (20 men and 7 women with mean BMI: 39.98±5.56 kg/m2)
3340369|NCT02180191||Diabetes|26 patients with newly diagnosed type 2 diabetes (18 men and 8 women with mean BMI: 28.63±5.08 kg/m2)
3340370|NCT02180191||Control|Healthy control subjects (22 men and 6 women with mean BMI: 23.02±1.70 kg/m2)
3340371|NCT02180204|Experimental|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum dose: 25 mg
3340372|NCT02180204|Active Comparator|Alteplase|Alteplase 0.9 mg/kg IV - Maximum dose: 90 mg
3340373|NCT02180217|Experimental|osilodrostat (LCI699)|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then osilodrostat during a double-blind, placebo controlled RW Period.
3340374|NCT02180217|Placebo Comparator|LCI699 Placebo|Consisted of a single-arm, open-label, osilodrostat dose-titration in individual patients and then placebo during a double-blind, placebo controlled RW Period.
3237275|NCT01259414|Experimental|group2|Chemoembolization with Solvent with specific gravity equivalent to lipiodol
3237276|NCT01259453|Active Comparator|Standard vaccination schedule|Standard dosing at 0, 1, and 6 months
3237277|NCT01259453|Active Comparator|Accelerated Schedule|Accelerated dosing at 0, 1, and 2 months
3237278|NCT01259479|Experimental|1|Dose escalation, continuous treatment without DLTs
3340377|NCT02180256|Experimental|Endoscratching, non-RIF|Endometrial scratching. Women with no more than 1 previous unsuccessful embryo transfer. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
3340378|NCT02180256|No Intervention|Control, non-RIF|No intervention. Women with no more than 1 previous unsuccessful embryo transfer.
3340379|NCT02180256|Experimental|Endoscratching, RIF|Endometrial scratching. Women with 2 or more previous unsuccessful embryo transfers. Pipelle in the first seven days of the menstrual cycle, just before starting controlled ovarian stimulation.
3340380|NCT02180256|No Intervention|Control, RIF|No intervention. Women with 2 or more previous unsuccessful embryo transfers.
3340381|NCT02180269|Experimental|Cohort A|Single oral dose of either JNJ-54861911, 25 milligram (mg) tablet or matched placebo tablet on Day 1.
3340382|NCT02180269|Experimental|Cohort B|Single oral dose of either JNJ-54861911, 50 mg (2*25 mg tablets) or matched placebo tablets on Day 1.
3340383|NCT02180269|Experimental|Cohort C|Single oral dose of either JNJ-54861911, 100 mg (4*25 mg tablets) or matched placebo tablets on Day 1.
3340384|NCT02180282|Experimental|Acne Treatment|Acne treatment using the M22-IPL acne filter
3340385|NCT02180295|Experimental|V212 Lot 1|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3340386|NCT02180295|Experimental|V212 Lot 2|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3340387|NCT02180295|Experimental|V212 Lot 3|Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart
3340388|NCT02180308||PET/MRI|Patient receives PET/MRI
3340389|NCT02180321|Active Comparator|Control|
3340390|NCT02180321|Experimental|Tranexamic acid|
3340391|NCT02180334|Experimental|Mosapride|"Mosapride citrate 5 mg (Gasmotin®): 1 tablet (5 mg) will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
3237279|NCT01259505|Experimental|Safety|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
3340392|NCT02180334|Placebo Comparator|Control|"Placebo drug: 1 tablet will be administered 1 hour before MMTT.~Linagliptin 5 mg (Trajenta®): 1 tablet (5 mg) per day should be taken for 7 days during run-in period. 1 tablet (5 mg) will be administered 1 hour before MMTT.~Acetaminophen 500 mg (Tylenol®): 3 tablets (1500 mg) will be administered at once with the mixed meal for calculating gastric emptying time."
3340393|NCT02180347||Multifocal contact lenses|Coopervision Proclear Multifocal
3237280|NCT01259518|Experimental|Once monthly administration of TRIN2755|
3237281|NCT01259518|Experimental|Once weekly administration of TRIN2755|
3340394|NCT02180347||Single vision contact lenses|Coopervision Proclear Sphere
3340395|NCT02180360|Experimental|Capoeira training group|"The Capoeira training was performed during eight weeks, twice a week with duration of 60min each session, divided in 1) initial part: 10min warm-up with activities of low intensity or the ginga used in Capoeira; 2) main part: from the Basic Programmed Lesson (40min) and ; 3) final part: Capoeira presentation of 10min. In this last moment, the participants remained in a circle and, in pairs, executed the movements practiced earlier in the sessions. In order to perform the Basic Programmed Lesson, the activities were divided in four stages, composed by ginga and other movements: dodging, unbalancing, traumatizing and acrobatic. The volunteers would perform the initial part of the basic lesson (ex. 1st stage) and afterwards, when performing the subsequent part (ex. 2nd stage), would first repeat the 1st basic lesson, with the purpose of continuing the learning process and improving the previous lesson."
3340396|NCT02180360|No Intervention|Control group|The Control group did not perform any physical exercise during the intervention period (eight weeks).
3340397|NCT02180373||vein graft bypass|patients who have had peripheral bypass
3340398|NCT02180373||SFA stent|Patients who have had SFA stenting
3340399|NCT02180386|Experimental|Experimental group|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
3340400|NCT02180412|Experimental|Panhematin|Panhematin plus glucose
3340401|NCT02180412|Placebo Comparator|Placebo|Placebo (saline) plus glucose
3340402|NCT02180425||Healthy Group|The subjects in this group do not have a history of acne.
3340403|NCT02180425||Acne Group, Topical Retinoid|These subjects have been prescribed a topical retinoid for their acne. They will participate in the study for a period of 1 month.
3340404|NCT02180425||Acne Group, Isotretinoin|These subjects have been prescribed isotretinoin for their acne. They will participate in the study for a period of 5-6 months.
3340405|NCT02180464|Experimental|LAS41004|Topical application of approximately 2 - 6 mg/cm2 to an area of 20 - 300 cm2, each once daily
3340406|NCT02180464|Active Comparator|control|Topical application of approximately 2 - 6 mg/cm2 of IMPs 1 and 2 to an area of 20 - 300 cm2, each once daily
3237282|NCT01259531|Experimental|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
3237283|NCT01259544|Active Comparator|Di -petide breath tests and ePFT secretin induced|Di peptide breath tests will be performed on subjects with known chronic pancreatitis
3237284|NCT01259544|Active Comparator|c13 di peptide breath tests|Healthy volunteers to compare breath tests results to subjects with chronic pancreatitis
3237285|NCT01259557|Experimental|Botulinum toxin type A(Meditoxin®)|
3340407|NCT02180477|Experimental|UHAC 62 XX TF1 tablet|
3237286|NCT01259570|Active Comparator|Skimmilk enriched with VD encapsulated in CM|
3237287|NCT01259570|Active Comparator|VD will be dissolved in milkfat and homogenized into skimmilk|VD will be dissolved in milkfat and homogenized into skimmilk
3237288|NCT01259570|Active Comparator|3% fat milk wherein the VD will be in CM|3% fat milk wherein the VD will be in CM
3237289|NCT01259570|Active Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
3237290|NCT01259583|Experimental|CO2|CO2 insufflation instead air insufflation in unsedated colonoscopy
3237291|NCT01259583|Experimental|Warm Water irrigation|warm water irrigation during the insertion phase of colonoscopy
3237292|NCT01259609|Experimental|Diabetic Macular Edema Group|
3237293|NCT01259609|Active Comparator|Epiretinal Membrane Group|
3340408|NCT02180477|Experimental|UHAC 62 XX TF2 tablet|
3340409|NCT02180477|Active Comparator|UHAC 62 XX capsule|
3237294|NCT01259609|No Intervention|Healthy Control|
3237295|NCT01259622|Placebo Comparator|placebo|
3237296|NCT01259622|Experimental|K201|intravenous K201
3237297|NCT01259635|Experimental|Bio feedback for freezing|When ever freezing occures, a metronom sound will be heard
3237298|NCT01259648|Experimental|0.5 µg / kg remifentanil|Induction anesthesia includes 0.5 µg/kg remifentanil in addition to classic induction anesthesia protocol.
3237299|NCT01259648|Experimental|1.0 µg/kg remifentanil|Induction anesthesia includes 1.0 µg/kg remifentanil in addition to the classic induction protocol.
3237300|NCT01259648|Placebo Comparator|NaCl|An equivalent volume (1 ml for 10 kg of weight) of isotonic 0.9% NaCl is injected in addition to the classic anesthesia induction protocol
3237301|NCT01259661|Experimental|Experimental Group|
3237302|NCT01259661|Active Comparator|Control Group|
3237303|NCT01259674|Experimental|AboMeg-B-09 syrup|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
3237304|NCT01259674|Placebo Comparator|Placebo|Placebo syrup
3237305|NCT01259687||Study group|
3237306|NCT01259700|Experimental|High risk management|
3237307|NCT01259700|Experimental|Salt reduction|
3237308|NCT01259700|Experimental|high risk management and salt reduction|
3340410|NCT02180490|Experimental|UHAC 62 XX tablet|
3340411|NCT02180490|Active Comparator|UHAC 62 XX capsule|
3340412|NCT02180503|Experimental|BI 1356 BS - low dose|
3340413|NCT02180503|Experimental|BI 1356 BS - high dose|
3340414|NCT02180516||Meloxicam|
3340415|NCT02180516||Other NSAIDs|
3237309|NCT01259700|No Intervention|Usual care|
3237310|NCT01259739|Experimental|Flavanol rich cocoa|(596 mg), dissolved in water, twice daily intervention
3237311|NCT01259739|Experimental|flavanol poor cocoa drink|( 13mg) dissolved in water, twice daily intervention
3237312|NCT01259752|Experimental|compression stockings|
3237313|NCT01259752|Placebo Comparator|standard non compressive stockings|
3340416|NCT02180529|Experimental|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention. Two hours after taking the drug participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
3340417|NCT02180529|Placebo Comparator|Placebo|Participants in the control group will receive placebo. On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of Placebo every day of intervention. Two hours after taking the placebo participants will be assessed cognitively by means of Mindstreams and MoCA (Montreal Cognitive Assessment).
3340418|NCT02180542||Ischemic stroke patients|Patients admitted with ischemic stroke from march 2012 to april 2014
3237314|NCT01259765|Active Comparator|VHH|"The active substance is VHH batch 203027."
3237315|NCT01259765|Placebo Comparator|Placebo|Placebo product
3340419|NCT02180555||ICU patients|
3340420|NCT02180568|Experimental|Lipiodol|Lipiodol-guided lung localization technique
3340421|NCT02180568|Active Comparator|Hookwire|Hookwire-guided lung localization technique
3340422|NCT02180581|Experimental|Probiotic (2 * 10^9 cfu/d)|Daily intake of bifidobacterium animalis ssp. Lactis (BB12) and Lactobacillus Rhamnosus GG (LGG) in a dosage of 10^9 cfu/day of each strain. The probiotics are provided as powder in a sachet, and can be added to food or drink
3340423|NCT02180581|Placebo Comparator|Placebo|provided as powder in a sachet, and can be added to food or drink
3340424|NCT02180607||Healthy Controls|Response to social feedback, monetary incentive delay, and go/no-go tasks
3237316|NCT01259791|Experimental|Statin|Individual-specific statin causing myopathy - i.e., Patients will receive the specific statin previously associated with myopathic symptoms in them (can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously).
3237317|NCT01259791|Placebo Comparator|Placebo|Identical placebo to patient-specific statin
3340425|NCT02180607||MDD patients|Response to social feedback, monetary incentive delay, and go/no-go tasks
3340426|NCT02180620|Experimental|No exercise|participants will remain sedentary during testing
3340427|NCT02180620|Experimental|Meal then exercise|45 min of resistance training will be performed after a standard meal
3340428|NCT02180620|Experimental|exercise then meal|45 min of resistance training will be performed prior to a standard meal
3340429|NCT02180633||Fellow Eyes|Patients that suffer from unilateral idiopathic macular hole, and whose fellow eyes don't show any sign of retinal pathology.
3340430|NCT02180633||Controls|Healthy subjects age-matched to the other group, with no visible retinal pathologies.
3237318|NCT01259804|Experimental|Peanut immunotherapy|Peanut flour
3237319|NCT01259817|Experimental|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
3340431|NCT02180685|Other|Anchor fixation|Medial fixation of the reconstruction at the medial femural condyle with suture anchors.
3237320|NCT01259817|Active Comparator|Aspirin|81 or 100 mg daily.
3237321|NCT01259830|Experimental|Arcoxia® 120 mg|
3237322|NCT01259830|Placebo Comparator|Sugar pill|
3237323|NCT01259843||Acute Aortic Syndrome|Patients admitted to cardiology, radiology or surgery for a clinical picture suggestive of acute aortic syndrome whose diagnosis was subsequently confirmed in due course of hospitalization by further investigations.
3237324|NCT01259882|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Cohort 1
3237325|NCT01259882|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Cohort 2
3237326|NCT01259882|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Cohort 3
3237327|NCT01259882|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Cohort 4
3237328|NCT01259882|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Cohort 5
3237329|NCT01259882|Experimental|Cohort 6: Experimental intervention: PF-05089771 or placebo|Cohort 6
3237330|NCT01259895||Obesity|BMI > 30kg/m2
3237331|NCT01259895||Normal weight|BMI between 19 and 24,9kg/m2
3237332|NCT01259908||Laparoscopic vs open Ygraft|Patients with advanced atherosclerosis in aorto iliac segment operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared on the basis of the operative procedure for the primary endpoint, composite endpoint (all-cause mortality, systemic morbidity and graft thrombosis).
3237333|NCT01259921|Experimental|Neurofeedback T4-P4|40 sessions of SMR neurofeedback training using T4-P4 placement administered twice weekly
3237334|NCT01259921|Active Comparator|Neurofeedback T3-T4|40 sessions of SMR neurofeedback using T3-T4 placement training administered twice weekly
3237335|NCT01259934|No Intervention|Arm A|Observation only - no therapy
3340432|NCT02180685|Other|Screw fixation|Medial fixation of the reconstruction at the medial femural condyle with a screw.
3340433|NCT02180698|Experimental|Treatment (TLR4 agonist GLA-SE, radiation therapy)|Patients receive TLR4 agonist GLA-SE intratumorally once weekly for 8 weeks. Within 2 weeks of starting treatment, patients also undergo radiation therapy over 2 weeks for a total of 5-6 fractions.
3340434|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 1|acalabrutinib Regimen 1
3340435|NCT02180711|Experimental|Part 1: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory, or treatment naive subjects
3340436|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 1|acalabrutinib Regimen 1 for relapsed, refractory Marginal Zone Lymphoma subjects
3340437|NCT02180711|Experimental|Part 2: acalabrutinib Regimen 2|acalabrutinib Regimen 2 + rituximab for relapsed, refractory Marginal Zone Lymphoma subjects
3340438|NCT02180711|Experimental|Part 3: acalabrutinib Regimen 1|acalabrutinib Regimen + lenalidomide + rituximab for relapsed, refractory Follicular Lymphoma subjects
3340439|NCT02180737|Experimental|Dexmeditomedine|Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.
3340440|NCT02180750|Experimental|Intervention: Memory Work Therapy|Residential week intervention consisting of memory box, memory book, tree of life, Active Citizen book, all activities facilitated.
3340441|NCT02180750|Active Comparator|Control: standard care|Usual care services.
3340442|NCT02180763|Experimental|Gammanorm® 165 mg/mL|
3340443|NCT02180776|Active Comparator|Group A|Patients assigned to group A wore the Summit 456 TLSO (intervention) for four weeks in phase 1 of the study, followed by four weeks of observation (control) in phase 2.
3340444|NCT02180776|Placebo Comparator|Group B|Patients assigned to group B started four weeks of observation (control) in phase 1, followed by four weeks of summit 456 TLSO (intervention) in phase 2 of the study.
3340445|NCT02180789|Experimental|Harnalidge® OCAS®|
3340446|NCT02180802|Experimental|motivational intervieing group|The behavioral intervention targets were improved eating and physical activity behavior in order to reduce obesity levels. Each adolescent was encouraged to eat a variety of foods from each of the four major food groups and low-fat alternatives . Moreover, each adolescent was encouraged to achieve at least 60 minutes of moderate-to-vigorous intensity physical activity daily as recommended by the World Health Organization
3340447|NCT02180802|Experimental|motivational interviewi group with parental involvement|an additional single session with parents or guardians over 60 minutes in the clinic
3340448|NCT02180802|Active Comparator|Control|The patients received routine care
3340449|NCT02180815||ReVENT implanted group|
3340450|NCT02180841|Experimental|Soy 25g|Soy protein powder (25g/day)
3340451|NCT02180841|Experimental|Soy 50g|Soy protein powder 50 g/day
3340452|NCT02180841|Placebo Comparator|Control|Control powder
3340453|NCT02180854|Experimental|Intervention (8 hours)|EWS every 8 hours
3340454|NCT02180854|Active Comparator|Control (12 hours)|EWS every 12 hours
3237336|NCT01259934|Experimental|Arm B Interferon 1 year|Interferon Therapy: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 12 months
3237337|NCT01259934|Experimental|Arm C Interferon 2 years|"Two year arm Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months"
3340455|NCT02180880|Experimental|Pregabalin and Oxcarbazpepine|Pregabalin and Oxcarbazepine
3340456|NCT02180906||Patients with NSTI|Definition: An infection that requires acute hospitalization with intensive care treatment and/or surgery as a consequence of severe soft tissue infection in subcutis, muscle and/or fascia and are spreading along tissue structures.
3340457|NCT02180919|No Intervention|Control period|All patients with receive standard optimal medical care according to ESC Heart Failure guidelines, NICE COPD guidelines or other best practice care pathways as relevant to their condition.
3340458|NCT02180919|Experimental|Telemonitoring|telemonitoring will be carried out in the patient's home using the conformity European (CE) marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a television (TV) channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
3340459|NCT02180932|Experimental|periodontal disease|Saliva samples
3340460|NCT02180945||Intracranial Dural Arteriovenous Fistula|Adult patients requiring endovascular treatment of Intracranial Dural Arteriovenous Fistulae.
3340461|NCT02180971|Experimental|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
3340462|NCT02180971|Experimental|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
3340463|NCT02180984|Active Comparator|BED randomized to rTMS|"30 obese individuals currently diagnosed with BED and meeting criteria for the study will be randomized to active rTMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. For the real treatment condition, stimulation will target the left DLPFC at 110% of the resting motor threshold. Each session of 10 Hz stimulation will apply 1000 pulses to the left hemisphere, with a duty cycle of 5s on and 55s off, for a total stimulation time of 20 min."
3340464|NCT02180984|Sham Comparator|Sham BED TMS|"30 obese individuals currently diagnosed with BED will be randomized to receive sham TMS treatment. Blinded to participants and study staff, except to the doctor applying the TMS treatment.~Intervention: Neurosoft device targeting the left DLPFC (neuro-navigational method).~Proposed schedule of treatment:~20 sessions of neuronavigated rTMS, one session per day, 3 days/week over approximately 7 weeks. Focal rTMS will be performed using a Neurosoft device and a 'figure of eight' coil. Brainscience Neuronavigation will be used to guide the placement of the coil to the target PFC region using a template MRI for all participants. The coil will be placed at a 45° angle to the mid-sagittal line to induce a posterior to anterior current in the underlying neural tissue. Sham treatment condition, will follow the same protocol however no real TMS will be delivered."
3340465|NCT02180984|No Intervention|Control (obese non BED)|15 controls, obese but without a current or past diagnosis of BED will complete the baseline measurements only.
3340466|NCT02180984|No Intervention|Controls (normal weight)|15 controls, normal weight and without a current or past diagnosis of BED will complete baseline measures only.
3340467|NCT02180997|Experimental|Tamsulosin 1|Volunteers will be taken Tamsulosin and solifenacin
3237338|NCT01259947|Experimental|Lippia alba|
3340468|NCT02180997|Experimental|Solifenacin 1|Volunteers will be taken Tamsulosin and solifenacin
3340469|NCT02180997|Experimental|Co-administration 1|Volunteers will be taken Tamsulosin and solifenacin
3340470|NCT02180997|Experimental|Tamsulosin 2|Volunteers will be taken Tamsulosin and solifenacin
3340471|NCT02180997|Experimental|Solifenacin 2|Volunteers will be taken Tamsulosin and solifenacin
3340472|NCT02180997|Experimental|Co-administration 2|Volunteers will be taken Tamsulosin and solifenacin
3340473|NCT02181010|Experimental|Intervention|The intervention is a multi-level, multi-component intervention designed to increase access to and consumption of healthier foods in low-income, urban, minority neighborhoods. Intervention components will occur at the policy level; food wholesaler level; small food retail outlet level; neighborhood level; household level.
3340474|NCT02181010|No Intervention|Control|Similar to many community- based public health research programs, the control arm will not receive any intervention components during the initial intervention period. However, after all assessments are completed they will receive a 'delayed intervention' protocol, where the community receives the intervention elements as described in the intervention arm after assessment measures have been completed.
3340475|NCT02181023|Experimental|Aclidinium - Glycopyrronium|Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
3340476|NCT02181023|Experimental|Glycopyrronium - Aclidinium|Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).
3340477|NCT02181036|Experimental|family work shop|2 to 3 hours per session, one session per week, for a total of 6 weeks of family work shop
3340478|NCT02181062|Experimental|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
3237339|NCT01259960||BMI < 25|Body Mass Index (BMI) according to WHO definition. BMI < 25 is defined as 'normal weight'.
3237340|NCT01259960||25 <= BMI < 30|Body Mass Index (BMI) according to WHO definition. BMI >= 25 and < 30 is defined as 'overweight'.
3237341|NCT01259960||BMI >= 30|Body Mass Index (BMI) according to WHO definition. BMI >= 30 is defined as 'obese'.
3340479|NCT02181062|No Intervention|Wait-list control|After 3 months, participants will be invited to participate in the intervention. No additional measures or outcomes will be recorded.
3237342|NCT01259973|Experimental|Risperidone|
3237343|NCT01259973|Placebo Comparator|Placebo|
3237344|NCT01259973|Experimental|Haloperidol|
3237345|NCT01259986|Experimental|Laser treatment|
3340480|NCT02181088|Experimental|Group 1 (ChAd63 RH5 low dose)|1 dose of ChAd63 RH5 5 x 10^9 vp intramuscularly
3340481|NCT02181088|Experimental|Group 2A (ChAd63 RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly
3340482|NCT02181088|Experimental|Group 2B (ChAd63 RH5 full dose and MVA RH5 low dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 1 x 10^8 pfu 8 weeks later intramuscularly
3340483|NCT02181088|Experimental|Group 2C (ChAd63 RH5 full dose and MVA RH5 full dose)|1 dose of ChAd63 RH5 at 5 x 10^10 vp intramuscularly and 1 dose MVA RH5 at 2 x 10^8 pfu 8 weeks later intramuscularly
3237346|NCT01259999|Experimental|Energy dense formula|
3237347|NCT01260012|Experimental|praziquantel+antioxidant|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In additions, antioxidant suppliment will be given daily for a period of one year
3340484|NCT02181101|Experimental|AA-BA|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years
3340485|NCT02181101|Experimental|AB-BA|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years
3237348|NCT01260012|Active Comparator|Praziquantel +placebo 2mths then antioxidant for 10 months|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
3237349|NCT01260012|No Intervention|Praziquantel therapy with placebo supplement|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonstrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for a period of one year.
3340486|NCT02181101|Experimental|AA-BB|FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years
3237350|NCT01260025|Experimental|PEDylated Recombinant Human Endostatin|PEDylated Recombinant Human Endostatin
3237351|NCT01260051||Epidural Recipients|
3237352|NCT01260051||Non-Epidural Recipients|
3237353|NCT01260064|Active Comparator|Open appendectomy|The subjects will have open appendectomy procedure.
3237354|NCT01260064|Active Comparator|Metal endoclip|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
3237355|NCT01260064|Active Comparator|Intracorporeal suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
3340487|NCT02181101|Active Comparator|AB-BB|FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years
3340488|NCT02181114|Experimental|Expert System Coaching|Patients in the intervention group will receive coaching based off the answers provided in the computer-based Expert System that is designed to track their readiness level to pursue a living donor kidney transplant.
3340489|NCT02181114|No Intervention|Control|Patients in the control group will only receive the standard of care education that is offered at the UCLA Kidney and Pancreas Transplant Center which consists of a powerpoint presentation on their Evaluation Day appointment.
3340490|NCT02181153|Other|siblings of patients with IBD|Blood and fecal samples from 100 siblings of children affected with IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form.
3340491|NCT02181153|Other|patients without family history of IBD|Blood and fecal samples of 100 healthy children without a family history of IBD will be collected at the day of enrolment. Clinical risk factors for IBD will be also recorded in a case report form
3237356|NCT01260077||Experimental group|The sample was composed of 78 individuals (156 ears), 40 females (80 ears) and 38 males (76 ears).
3237357|NCT01260090|Experimental|Vagus Nerve Stimulation|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
3237358|NCT01260090|Sham Comparator|No Stimulation|
3237359|NCT01260103|Active Comparator|Temozolomide (TMZ)|Study subjects receive TMZ for 13 cycles
3237360|NCT01260103|Experimental|ANP Therapy|Escalating doses of ANP therapy are given daily for 52 weeks.
3237361|NCT01260116||1|Ziprasidone,Zeldox capsule
3237362|NCT01260129|Experimental|Silodosin 8 mg|
3340492|NCT02181166|Experimental|kinesiotherapy + High voltage electrical stimulation|Same protocol group kinesiotherapy + high voltage electrial stimulation with two rectangular electrodes (3x5 cm) active silicon-carbon and an electrode rectangular dispersive (10x18cm) aluminum wrapped with a damp felt in water. The active electrodes are positioned in central myofascial trigger point of the upper trapezius muscle after application of water soluble gel. The dispersive electrode was placed in the lumbar region. The following parameters will be use: frequency of 10 Hz, twin pulses of 20μs to 100ms between pulses and the maximum voltage tolerated by voluntary until the motor threshold (visible muscle contraction) to increase every five minutes, totaling 30 minutes of stimulation. The negative polarity will be use.
3340493|NCT02181166|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: These exercises involve stretching of the cervical, anterior and posterior chain of the upper trunk and active mobilization of the cervical, shoulder movements of flexion, extension, abduction and adduction of the shoulder and upper limb. The exercises lasted 50 minutes, with 10 minutes of walking, and stretching was performed with two repetitions of 20 seconds, and active mobilization exercises of three sets of eight repetitions and final relaxation of 10 minutes were performed.
3340494|NCT02181166|Experimental|kineshioterapy + isquemic compression|The same protocol group kinesiotherapy + ischemic compression in central myofascial trigger point of the upper trapezius muscle. This procedure was performed for 90 seconds.
3340495|NCT02181179|Active Comparator|Yoga|This will involve participating in at least two 60-minute Vinyasa yoga sessions each week for eight weeks (weeks 1-8). This will begin the week following a baseline laboratory appointment. These sessions will be conducted at a local Austin studio that has numerous locations in the area.
3340496|NCT02181179|No Intervention|Waitlist|If randomized to this group, participants will complete weekly assessments only and not yoga during their time in the study. Following full completion of the study (i.e., after week 10), participants will be compensated with a voucher for 2 free months of yoga.
3340497|NCT02181192|Experimental|delayed radiotherapy|PET/CT and Radiotherapy after achievement of PSA marginal value Additive imaging
3340498|NCT02181192|Active Comparator|instant radiotherapy|Instant Radiotherapy according to guidelines
3340499|NCT02181205|Experimental|placebo|sphenopalatine ganglion block performed with normal saline as the placebo
3340500|NCT02181205|Active Comparator|bupivacaine|sphenopalatine ganglion block performed with bupivacaine
3340501|NCT02181218|Experimental|Dose Level 0 (starting dose) (8 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3340502|NCT02181218|Experimental|Dose Level 1 (10 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3340503|NCT02181218|Experimental|Dose Level 2 (12 mg/m2 romidepsin)|"Romidepsin will be administered intravenously (IV) over 2 hours on Days 2 and 8;~Gemcitabine IV over 30 minutes on Day 1~Oxaliplatin IV over 2 hours on Day 1~Dexamethasone orally on Days 1-4~Pegfilgrastim subcutaneously on Day 3~Drugs may be administered in any order on Day 1.~Each cycle is 21 days.~May continue on therapy for up to 8 cycles total if achieving adequate disease control (CR, PR, or stable disease) and without significant toxicity"
3375843|NCT03718260|Experimental|Cohort 7|[18F]-DCFPyL as a problem-solving tool in patients with prostate cancer when confirmation of the site of disease and/or disease extent may impact clinical management. Patients in this cohort require approval from an independent adjudication by Cancer Care Ontario.
3237363|NCT01260129|Experimental|Silodosin 4 mg|
3237364|NCT01260155|Experimental|Treatment A Fasted|
3237365|NCT01260155|Experimental|Treatment B Fasted|
3237366|NCT01260155|Experimental|Treatment C Food Effect|
3237367|NCT01260168||Colorectal cancer patients|Subjects will be men and women, 40-90 years of age, inclusive, each with a colonoscopic biopsy-based diagnosis of colorectal cancer (CRC) and/or an intact pre-malignant colorectal lesion large enough to require surgical excision or complex colonoscopic polypectomy.
3237368|NCT01260207|Experimental|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
3340504|NCT02181244|Experimental|Egg, one a day, for breakfast|The intervention consists in feeding the subjects egg, one a day for breakfast during 5 weeks. At the end of the intervention, blood will be obtained to measure plasma lipids, glucose, insulin and inflammatory markers. All measurements will be finished 24 weeks after the intervention is finished. All data will be reported 1 year after completion of the study.
3340505|NCT02181244|Experimental|Oatmeal, one cup a day|In this arm, subjects will consume oatmeal for a period of 5 weeks. Blood samples will be taken and different parameters will be measured including plasma lipids, glucose, insulin and inflammatory markers. All these measurements will be finished 24 weeks after completion of the study. All data will be reported 1 year after completion of the study.
3237369|NCT01260207|No Intervention|Usual care|Patients in this arm will not receive IVR follow-up. One year after discharge, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
3340506|NCT02181257|Other|Newly Diagnosed Bronchiolitis Obliterans (NEW BOS)|"Participants with NEW BOS will be randomized to Early Photopheresis Intervention (EPI) or Control (Standard of Care). EPI patients will receive 24 treatments in a 6-month period and may continue maintenance treatments.~The Control group will receive local Standard of Care for the management of BOS. Therapy will involve changes in immunosuppressive agents."
3340507|NCT02181257|Other|Refractory Bronchiolitis Obliterans Syndrome (REFRACTORY BOS)|Participants with REFRACTORY BOS will be electronically assigned to either ECP treatment or Observation based on the participant's pre-enrollment Forced Expiratory Volume in 1 second (FEV1). Values from pulmonary function tests from the preceding 12 months will be entered into a web-based treatment allocation which will perform an automated calculation. Patients who have a statistically significant rate of decline within the preceding 6 months, and a derived protocol defined slope, will be assigned to the ECP Treatment arm. If a patient does not meet these criteria, the participant will be assigned to the Observation arm.
3340508|NCT02181270|Experimental|high intensity exercise|High-intensity interval exercise (HIIE): Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
3237370|NCT01260220|Active Comparator|Circumferential|Completing a complete circle of RF lesions around the left and right pulmonary veins
3237371|NCT01260220|Experimental|Segmental|Isolating the left and right pulmonary veins through RF lesions with a segmental antral approach.
3340509|NCT02181270|Experimental|Continuous moderate exercise group|Continuous moderate exercise group (CME): Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
3340510|NCT02181283|Active Comparator|W+W|Web-delivered alcohol/prescribed drug misuse brief intervention with Web booster sessions (W+W).
3340511|NCT02181283|Active Comparator|W+P|Web-delivered brief intervention with Peer-delivered booster sessions (W+P).
3340512|NCT02181283|No Intervention|Enhanced Usual Care|Enhanced usual care.
3340513|NCT02181309|Experimental|Meloxicam low dose, fasted|
3340514|NCT02181309|Experimental|Meloxicam medium dose, fasted|
3340515|NCT02181309|Experimental|Meloxicam high dose, fed|
3237372|NCT01260233|No Intervention|Control|No intervention. Patients will receive standard of care.
3237373|NCT01260233|Experimental|Smoking cessation program|Receives smoking cessation program
3340516|NCT02181309|Active Comparator|Meloxicam high dose, fasted|
3340517|NCT02181322|Experimental|Meloxicam - low dose, fasted|
3340518|NCT02181322|Experimental|Meloxicam - medium dose, fasted|
3340519|NCT02181322|Experimental|Meloxicam - high dose, fasted|
3340520|NCT02181322|Experimental|Meloxicam - high dose, fed|
3237374|NCT01260246|Experimental|sitagliptin|sitagliptin 100mg/daily for 6 months
3237375|NCT01260246|Placebo Comparator|placebo|placebo match for 6 months
3340521|NCT02181335|Experimental|Respimat ® Budesonide low dose + Turbohaler® Placebo|
3340522|NCT02181335|Experimental|Respimat ® Budesonide high dose + Turbohaler® Placebo|
3340523|NCT02181335|Active Comparator|Turbohaler® Budesonide + Respimat Placebo®|
3340524|NCT02181348|Active Comparator|Intervention (Vitamin E supplementation)|Vitamin E 400 mg once daily for 3 months
3340525|NCT02181348|Placebo Comparator|placebo (edible oil)|
3340526|NCT02181361||hirudin plus aspirin|14 days after stroke onset, patients in the hirudin plus aspirin group received natural hirudin 0.75g, three times a day and aspirin 100mg, once daily.
3340527|NCT02181361||Warfarin|14 days after stroke onset, patients in warfarin group were given an initial dose of 1.25mg of warfarin,once daily. 3 days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.
3375844|NCT03712371|Experimental|Chitosan dose escalation|
3375845|NCT03706911|Experimental|VM-1500A-LAI 150mg|VM-1500A-LAI 150mg IM single dose
3375846|NCT03706911|Experimental|VM-1500A-LAI 300mg|VM-1500A-LAI 300mg IM single dose
3237376|NCT01260259|Experimental|Remote Ischemic Preconditioning (RIPC)|
3237377|NCT01260259|Sham Comparator|Control|
3237378|NCT01260285|Experimental|Vardenafil|
3237379|NCT01260298||MC1 Ultrasonic Device|
3237380|NCT01260337|Active Comparator|Diabetes Support and Education (DSE)|
3237381|NCT01260337|Experimental|Portion controlled diet (PCD)|behavior modification
3237382|NCT01260363|Active Comparator|Naropin, Adrenalin, applicationsite|
3237383|NCT01260363|Active Comparator|Femoral nerve block|
3237384|NCT01260376|Experimental|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
3340528|NCT02181439|Other|Right irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the right maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the left non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
3340529|NCT02181439|Other|Left irradiated sector|"The low-energy laser (LLLT Low Level Laser Therapy) SIROLaser Advance: laser diode (970nm) is applied twice at day 0 and at M1. For each patient, randomized in this arm, only the left maxillary canine is actually irradiated. Irradiation is performed by scanning an area from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction and the cement enamel junction (CEJ) to the bottom of the vestibule in the vertical direction as well in buccally as in Palatine.~The same procedure will be applied to the right non-irradiated area, the only difference being that the laser will not be activated (placebo, laser inactive). Indeed, only the beam director will be lit and a beep start and end will be heard by the patient. In addition, the practitioner evaluating obtention or not of the class I will not know either which area has been irradiated or not."
3340530|NCT02181465|Experimental|Group 1|One injection of G17DT followed by up to three booster injections depending on antibody response over 16 week period
3340531|NCT02181465|Experimental|Group 2|Three injections of G17DT with option of one booster after 16 weeks
3340532|NCT02181478|Experimental|Treatment (intra-osseous UCB with hMSC co-transplant)|"REDUCED INTENSITY CONDITIONING (RIC):~Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1.~Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2.~GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100.~TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0."
3340533|NCT02181491|Experimental|P943 PET Scan|
3340534|NCT02181543|Experimental|Clonidine|Clonidine 1μg/Kg, IV, single dose, anesthesia intraoperative.
3340535|NCT02181543|No Intervention|No Clonidine|Usual care of Instituto de Medicina Integral Prof. Fernando Figueira.
3340537|NCT02181582|Experimental|Emapunil Administration|Single Arm Study
3340538|NCT02181621|Placebo Comparator|Solosite gel|Hydrogel with preservatives, used to create a moist wound environment.
3340539|NCT02181621|Active Comparator|Iodosorb|Cadexomer iodine gel
3340540|NCT02181647|Experimental|Intervention|Safe Touches Personal Safety Training for Children
3340541|NCT02181647|Other|Comparison|Received Safe Touches after week-1 assessment completed (delayed intervention).
3340542|NCT02181660|Experimental|Dose Escalation Cohort|ASP2215
3340543|NCT02181686||Sentus QP group|Patients with standard indication for CRT-D therapy who will be implanted with Sentus QP LV lead and the BIOTRONIK HF-T QP device.
3237385|NCT01260376|No Intervention|Placebo|Placebo tablets will be administered 4 times previous to and during the investigation day
3237386|NCT01260389|No Intervention|control group|Usual pharmacist care in patients with Chronic Obstructive Pulmonary Disease (COPD).
3340544|NCT02181686||VR-T/DR-T group|Patients with standard indication for ICD therapy who will be implanted with either single chamber ICD or dual chamber ICD of the Iperia ICD family
3237387|NCT01260389|Experimental|pharmaceutical care intervention|A pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
3237388|NCT01260402|Active Comparator|Epicardial|
3237389|NCT01260402|Experimental|Endocardial|
3237390|NCT01260415|Experimental|Folfox/Folfiri, Panitumumab|Eligible patients will recieved chemotherapy/panitumumab for 2 months (4 cycles) pre-operatively and 4 months post-operatively, plus a further 6 months of pantimumab post-chemotherapy
3340545|NCT02181699|Experimental|KHK2823|single agent KHK2823 administered at selected dose levels
3340546|NCT02181712|Experimental|Mesenchymal Stem cells|Subjects who have never received Mesenchymal Stem Cells
3340547|NCT02181712|Experimental|Booster Mesenchymal Stem Cells|Subjects who have previously received Mesenchymal Stem Cells
3237391|NCT01260428||healthy active subjects|with and without high altitude intolerance
3237392|NCT01260441|Active Comparator|Standard CPR|"Individuals will learn the Standard form of CPR (30:2, compressions:breathes) Main data points being collected over various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
3340548|NCT02181725|Experimental|Multimodal Rehabilitation Program|Multimodal Rehabilitation Program, consisting of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM)
3340549|NCT02181725|Active Comparator|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
3340550|NCT02181751|Experimental|Treatment Group|Children in the Treatment Group will receive treatment between 0 and 4 months from the study start date. The intervention will be a Trauma Focused Cognitive Behavioural Therapy Group.
3340551|NCT02181751|Other|Waitlist Group|Children in the wait-list group will receive treatment from 5-8 months of the studies start date. The intervention once this group receives treatment will be a Trauma Focused Cognitive Behavioural Therapy Group
3340552|NCT02181764|Experimental|KRN23|Single SC administration on day 1
3340553|NCT02181777|Experimental|GRASP|GRoup trAining for Social skills in Psychosis
3340554|NCT02181777|Active Comparator|Standard care|Treatment as usual as provided by care team
3340555|NCT02181855|Other|Atypical GERD syptoms treated with GERD-X|Patients treated by means of full-thickness gastroplication
3340556|NCT02181881|Active Comparator|DuoPACT|A 6-session HIV medication adherence support program for couples.
3237393|NCT01260441|Active Comparator|Chest Compressions Only CPR|"Individuals will learn the chest compression only form of CPR (no rescue breathes) Main data points being collected at various increments are: 1) Comfort Level with using CPR 2) Secondary Training multiplier effect and 3) CPR Skills"
3340557|NCT02181881|Active Comparator|Life Steps|A 3-session HIV medication adherence support program for individuals.
3340558|NCT02181881|No Intervention|Treatment as usual (TAU)|HIV positive individuals will continue to follow their current HIV treatment plan.
3340559|NCT02181894||Orally intubated infants|Subjects will be <72 hours of age and orally intubated. Following consent, four measures will be reported (i.e. body weight, nasal to tragus length, suprasternal notch to xyphoid process and shoulder to elbow length). Measures will be compared against a chest x-ray and placement of ETT at the subjects lip to identify the most accurate method to place endotracheal tubes in the newborn.
3340560|NCT02181907|Experimental|UH-AC 62 XX tablet|
3340561|NCT02181907|Active Comparator|UH-AC 62 XX capsule|
3237394|NCT01260480|Experimental|[18F]-ML-10|
3237395|NCT01260506|Experimental|VB-111|Antiangiogenic and vascular disruptive agent
3237396|NCT01260519|Experimental|active arm: heparin|
3237397|NCT01260532||Graves' disease|no intervention
3237398|NCT01260532||Hashimoto's thyroiditis|no intervention
3340562|NCT02181920|Experimental|Metamizole - Diclofenac|metamizole followed by diclofenac
3340563|NCT02181920|Experimental|Diclofenac - Metamizole|diclofenac followed by metamizole
3340564|NCT02181920|Experimental|Metamizole - Placebo|metamizole followed by placebo
3340565|NCT02181920|Experimental|Placebo - Metamizole|placebo followed by metamizole
3340566|NCT02181933|Experimental|Nevirapine|Mother: two doses, Infant: one dose
3340567|NCT02181933|Active Comparator|Zidovudine (ZDV) + Lamivudine (3TC)|
3340568|NCT02181946|Experimental|Fluconazole with and without Nevirapine|
3340569|NCT02181959|Experimental|Pharmaton® with DMAE|
3340570|NCT02181959|Active Comparator|Pharmaton® without DMAE|
3340571|NCT02181959|Placebo Comparator|Placebo|
3340572|NCT02181972|Experimental|Gingko biloba|
3340573|NCT02181972|Placebo Comparator|Placebo|
3340574|NCT02181985|Active Comparator|TNK-tPA + heparin|
3237399|NCT01260532||Healthy subjects|no intervention
3237400|NCT01260545|Experimental|Infusion|A standard 3+3 design will be employed to determine maximum tolerated dose
3340575|NCT02181985|Experimental|TNK-tPA + enoxaparin|
3340576|NCT02181985|Experimental|TNK-tPA + abciximab + heparin|
3340577|NCT02181998|Active Comparator|tenecteplase + unfractioned heparin|
3340578|NCT02181998|Experimental|tenecteplase + enoxaparin|
3340579|NCT02182011|Experimental|Tenecteplase|Single i.v. bolus followed by infusion, weight adjusted
3340580|NCT02182011|Active Comparator|Alteplase|Single i.v. bolus followed by infusion
3340581|NCT02182011|Active Comparator|Streptokinase|I.V. infusion
3340582|NCT02182024|Experimental|Dabigatran high dose in healthy subjects|healthy subjects with a creatinine clearance of >80 mL/m
3340583|NCT02182024|Experimental|Dabigatran high dose in mild renal impairment|patients with a creatinine clearance of >50 up to 80 mL/min
3340584|NCT02182024|Experimental|Dabigatran high dose in moderate renal impairment|patients with a creatinine clearance of >30 up to 50 mL/min
3237401|NCT01260558|Active Comparator|Arm 1|Sirolimus-Permanent-Polymer Eluting Stent
3237402|NCT01260558|Active Comparator|Arm 2|Sirolimus-Polymer-free Eluting Stent
3237403|NCT01260571|Experimental|Benzoyl Peroxide and Sulfur|Topical Medications containing benzoyl peroxide and sulfur
3237404|NCT01260597|Experimental|Life Style Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report not being quit and are randomized to the intervention condition, tailored messages are delivered via the IVR system. The automated calls would include an assessment of the individual's interest in another quit attempt and deliver brief, tailored messages to perceived barriers for re-engaging into treatment. The system is programmed to transfer the caller to a live quit line counselor if the individual is willing to re-engage in cessation treatment.
3340585|NCT02182024|Experimental|Dabigatran high dose in severe renal impairment|patients with a creatinine clearance of up to 30 mL/min
3340586|NCT02182024|Experimental|Dabigatran low dose in haemodialysis patients|patients requiring haemodialysis
3340587|NCT02182037|Experimental|BIBT 1011 BS|
3340588|NCT02182037|Placebo Comparator|BIBT 1011 BS placebo|
3340589|NCT02182050|Experimental|BIBF 1120 ES low dose|
3340590|NCT02182050|Experimental|BIBF 1120 ES high dose|
3340591|NCT02182050|Placebo Comparator|Placebo|
3340592|NCT02182063|Experimental|BIBF 1120 low dose|
3340593|NCT02182063|Experimental|BIBF 1120 high dose|
3340594|NCT02182076|Active Comparator|fasted administration of BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules in fasting state
3340595|NCT02182076|Experimental|fed administration of BIBF 1120|three 50 mg BIBF 1120 soft gelatine capsule immediately after a high fat, high caloric meal
3340596|NCT02182089||Dialysis patients with greater than 20% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
3340597|NCT02182089||Patients with less than 10% IDH|"Study Population:~The sample will be enriched for subjects prone to IDH, defined as patients who experience IDH for greater than 20% of HD treatments in the past 2 months. The study population will consist of 48 patients total, 75% of patients (n=36) prone to IDH and 25% of patients with less than 10% of IDH during the last two months (n=12)."
3340598|NCT02182102|Experimental|BIBF 1120 + Pemetrexed|
3340599|NCT02182128|Experimental|BIBF 1120|
3340600|NCT02182141|Experimental|BIBF 1120|
3340601|NCT02182154|Experimental|BIBF 1120 ES|
3340602|NCT02182167|Experimental|IV NAC|"Participants will receive IV N-acetylcysteine or placebo. The dosing regimen is based on the regimens used in paracetamol poisoning .~Initial dose: 150 mg/kg body mass of N-acetylcysteine/WFI infused in 200 mL of 5% dextrose intravenously over 60 minutes, followed by continuous infusion: 50 mg/kg body mass in 500 mL of 5% dextrose over next 4 hours, followed by 100 mg/kg body mass in 1 litre of 5% dextrose over 16 hours."
3340603|NCT02182167|Placebo Comparator|Placebo|Water
3237405|NCT01260597|Active Comparator|Life Counseling|For individuals who report being quit, a brief congratulatory message will be delivered, independent of each arm of the study they were randomized to. For individuals who report still smoking the IVR will thank them for their time and the call will end.
3237406|NCT01260610|Active Comparator|Tenofovir|
3237407|NCT01260610|Active Comparator|Telbivudine|
3237408|NCT01260610|Experimental|Tenofovir plus Telbivudine|
3237409|NCT01260636|Experimental|MultiHance contrast agent|MultiHance administered at a dose of 0.1 mmol/kg (0.2 mL/kg)
3237410|NCT01260636|Active Comparator|Magnevist|Magnevist administered at a dose of 0.2 mmol/kg
3237411|NCT01260675||NanoBUP Capsules|Investigational Formulation of Buprenorphine HCl/Naloxone HCl 8 mg/2 mg oral capsules
3340604|NCT02182180||Protocol participants|All participants enrolled on the protocol
3340605|NCT02182193|Experimental|BIBF 1120 capsules charge 1|
3340606|NCT02182193|Experimental|BIBF 1120 capsules charge 2|
3340607|NCT02182193|Active Comparator|BIBF 1120 drinking solution|
3340608|NCT02182206|Experimental|BIBF 1120|
3237412|NCT01260675||Suboxone Sublingual Tablets|Buprenorphine HCl/Naloxone HCl 8 mg/2 mg sublingual tablets
3340609|NCT02182219|Experimental|BIBF 1120|
3340610|NCT02182232|Experimental|BIBF 1120 with paclitaxel and carboplatin|
3340611|NCT02182232|Experimental|BIBF 1120 monotherapy|
3340612|NCT02182245|Experimental|Combination Therapy|
3340613|NCT02182245|Experimental|Monotherapy|
3237413|NCT01260714|Experimental|Treatment (azacitidine, mitoxantrone hydrochloride, etoposide)|Patients receive induction therapy comprising azacitidine SC QD on days 1-7, mitoxantrone hydrochloride IV over 30 minutes, and etoposide IV over 1 hour on days 4-8. Patients may receive up to 2 additional courses of the same treatment as re-induction or consolidation therapy beginning 35-60 days from the start of the previous course.
3340614|NCT02182258|Placebo Comparator|Placebo|
3340615|NCT02182258|Active Comparator|BIBF 1120 intravenous|
3340616|NCT02182258|Experimental|BIBF 1120 capsule|
3340617|NCT02182271|Experimental|BI 201335 ZW - single rising dose|
3340618|NCT02182271|Placebo Comparator|Placebo|
3237414|NCT01260727|Experimental|Group 1|Participants will receive PENNVAX-G vaccine administered by intramuscular injection (IM) via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3237415|NCT01260727|Experimental|Group 2|Participants will receive PENNVAX-G vaccine administered via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3237416|NCT01260727|Experimental|Group 3: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via Biojector 2000 needleless device in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3237417|NCT01260727|Placebo Comparator|Group 3: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via Biojector 2000 needless device in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3237418|NCT01260727|Experimental|Group 4: Subgroup 1|Participants will receive PENNVAX-G vaccine administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3340619|NCT02182284|Experimental|BI 201335 NA - low dose|
3340620|NCT02182284|Experimental|BI 201335 NA - high dose|
3340621|NCT02182297|Experimental|BI 201335 NA in single rising doses|
3340622|NCT02182297|Placebo Comparator|Placebo|
3340623|NCT02182310|Placebo Comparator|BI 201335 placebo|crossover part
3340624|NCT02182310|Experimental|BI 201335 low dose|crossover part
3340625|NCT02182310|Experimental|BI 201335 high dose|crossover part
3340626|NCT02182310|Active Comparator|Moxifloxacin|crossover part
3340627|NCT02182310|Experimental|BI 201335 or Placebo|tolerability part in female subjects
3340628|NCT02182323|Experimental|BI 201335 in single rising doses|
3340629|NCT02182323|Placebo Comparator|Placebo|
3340630|NCT02182323|Experimental|BI 201335 NA fasted or fed|"two randomized sequences:~BI 201335 NA or placebo fasted~BI 201335 NA or placebo after high-fat breakfast"
3340631|NCT02182336|Experimental|BI 201335 NA|
3340632|NCT02182349|Experimental|BI 201335 NA|multiple doses of BI 201335 NA soft gelatin capsule on days 1-8 and 11-15 and one single dose of [14C]-BI 201335 NA radiolabelled drug on day 9
3340633|NCT02182362|Experimental|BI 201335 NA in rising doses|single dose of BI 201335 NA on day 1, multiple dosing days 4-24
3340634|NCT02182362|Placebo Comparator|Placebo|
3340635|NCT02182362|Experimental|BI 201335 NA|highest tolerated dose of BI 201335 on day 1-28 in patients with Gilbert's syndrome
3340636|NCT02182375|Experimental|BI 201335 NA|"400 mg raltegravir (bid) from day 1-14 and once on day 15;~240 mg BI 201335 NA (bid) from day 7-14 with a loading dose of 480 mg in the morning of day 6 and once on day 15"
3340637|NCT02182388|Experimental|BI 207127 NA|single rising dose part
3340638|NCT02182388|Placebo Comparator|Placebo|
3340639|NCT02182388|Experimental|BI 207127 NA, fasted or fed|
3340640|NCT02182401|Experimental|BI 207127 NA|fixed sequence
3340641|NCT02182414|Active Comparator|BI 207127 NA (TF-I)|trial part 1: 800 mg BI 207127 NA Trial formulation I (TF-I)
3340642|NCT02182414|Experimental|BI 207127 NA (TF-II)|trial part 1: 800 mg BI 207127 NA Trial formulation II (TF-II)
3340643|NCT02182414|Experimental|BI 207127 NA delayed release|trial part 1: 800 mg BI 207127 NA TF-II, delayed release
3340644|NCT02182414|Experimental|BI 207127 NA extended release (10% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (10% Hydroxypropyl methyl cellulose (HPMC))
3340645|NCT02182414|Experimental|BI 207127 NA extended release (15% PEO)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (15% Polyethylene oxide (PEO))
3340646|NCT02182414|Experimental|BI 207127 NA extended release (20% HPMC)|trial part 1: 800 mg BI 207127 NA TF-II, extended release (20% HPMC)
3340647|NCT02182414|Experimental|BI 207127 (TF-II), fed|trial part 2
3340648|NCT02182414|Experimental|BI 207127 (TF-II), fasted|trial part 2
3237419|NCT01260727|Placebo Comparator|Group 4: Subgroup 2|Participants will receive placebo vaccine for PENNVAX-G administered IM via CELLECTRA EP in either deltoid on Days 0 and 28. They will then receive placebo vaccine for MVA-CMDR administered IM by needle and syringe in either deltoid on Days 84 and 168.
3340649|NCT02182453|Experimental|BI 10773 - single rising dose|
3340650|NCT02182453|Placebo Comparator|Placebo|
3340651|NCT02182466||Colonic endoscopy indicated|
3340652|NCT02182479|Experimental|Berodual® via Respimat®, high dose|
3237420|NCT01260753|Experimental|UR-63325|
3237421|NCT01260753|Active Comparator|Fluticasone propionate nasal spray|
3237422|NCT01260753|Placebo Comparator|Placebo|
3237423|NCT01260766|Active Comparator|Active Comparator: Oplon Active Patch|
3237424|NCT01260766|Placebo Comparator|Placebo Comparator: Placebo patch|
3237425|NCT01260792||Children|Children between 5 and 18 years old.
3237426|NCT01260792||Adults|Parents of children between 5 and 18 years old
3237427|NCT01260805|Active Comparator|Reference Drug|
3237428|NCT01260805|Active Comparator|Test Drug|
3237429|NCT01260818|Experimental|Tranexamic Acid|
3237430|NCT01260818|Placebo Comparator|control group|
3237431|NCT01260831|Experimental|Intervention Hospitals|hospitals randomized to implement bedsidePEWS documentation system (vital sign assessment record)
3340653|NCT02182479|Experimental|Berodual® via Respimat®, low dose|
3340654|NCT02182479|Active Comparator|Berodual® via MDI, high dose|
3340655|NCT02182479|Placebo Comparator|Placebo via Respimat®|
3340656|NCT02182479|Placebo Comparator|Placebo via MDI|
3340657|NCT02182505|Experimental|Berodual® Respimat®, low dose|
3340658|NCT02182505|Experimental|Berodual® Respimat®, high dose|
3340659|NCT02182505|Active Comparator|Berodual® MDI Aerochamber®|
3340660|NCT02182518|Experimental|Epinastine + Pseudoephedrine|
3340661|NCT02182518|Experimental|Epinastine|
3340662|NCT02182531|Experimental|Epinastine and Pseudoephedrine combination|
3340663|NCT02182531|Active Comparator|Epinastine|
3340664|NCT02182531|Active Comparator|Pseudoephedrine|
3340665|NCT02182544|Experimental|WAL801CL dry syrup + Placebo|
3340666|NCT02182544|Active Comparator|Ketotifen fumarate dry syrup + Placebo|
3237432|NCT01260831|Active Comparator|Control Hospitals|hospitals randomized to continue with their pre existing documentation system (vital sign assessment record)
3237433|NCT01260844|Experimental|single dose of briakinumab|single dose briakinumab cocktail of CYP substrates
3340667|NCT02182557|Experimental|WAL 801 CL Dry Syrup + Placebo|
3340668|NCT02182557|Active Comparator|Ketotifen Fumarate Dry Syrup + Placebo|
3340669|NCT02182570|Experimental|WAL 801 CL|
3340670|NCT02182583|Experimental|Ba253BINEB|
3340671|NCT02182583|Active Comparator|Ba253MDI|
3340672|NCT02182596|Experimental|DAUNORUBICINE - ARACYTINE - MYLOTARG -|"Adaptive Bayesian method for dose-finding in phase I/II clinical trials based on treatment efficacy and toxicity (Thall, Russel, 1998), with successive patients cohorts and three combined dose levels:~DNR 45 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 100 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~DNR 60 mg/m2 IV days 1 to 3 + AraC 200 mg/m2 CI days 1 to 7 + Mylotarg 3mg/m2 IV days 1, 4, 7.~Two consolidation courses for CR patients:~Amsacrine: 90 mg/m2 IV Day 1 Cytarabine: 1g/m2 twice a day IV Days 1 to 4 Mylotarg: 3 mg/m2 IV Day 1."
3340673|NCT02182609|Experimental|99mTc-rhAnnexin V-128|
3340674|NCT02182622|Experimental|Dose Level -1|Docetaxel 60mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 200mg oral daily
3340675|NCT02182622|Experimental|Dose Level 1|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice a day LDE225 200mg oral daily
3340676|NCT02182622|Experimental|Dose Level 2|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 400mg oral daily
3340677|NCT02182622|Experimental|Dose Level 3|Docetaxel 75mg/m2 IV every 21 days Prednisone 5mg oral twice daily LDE225 800mg oral daily
3237434|NCT01260870|Experimental|Cotavance|
3237435|NCT01260870|Active Comparator|Standard balloon angioplasty|POBA
3237436|NCT01260909||Real-time kV/MV Prostate Imaging|
3237437|NCT01260935|Active Comparator|Arm A|Laparoscopic Hill
3237438|NCT01260935|Active Comparator|Arm B|Laparoscopic Nissen
3237441|NCT01260974|Experimental|Caspofungin|Study group
3340678|NCT02182635|Experimental|Ba253BINEB|
3340679|NCT02182648|Experimental|etomidate group|infusion of etomidate at 2 minutes before anesthesia induction
3340680|NCT02182648|Active Comparator|propofol group|infusion of propofol at 2 minutes before anesthesia induction
3340681|NCT02182648|Active Comparator|sevoflurane group|inhale sevoflurane for anesthesia induction and maintenance
3340682|NCT02182661|Experimental|Ba253BINEB|
3340683|NCT02182674|Experimental|Combivent HFA|
3340684|NCT02182674|Active Comparator|Combivent (CFC)|
3340687|NCT02182700|Experimental|Combivent® aerosol|
3340688|NCT02182713|Experimental|Arm 1 - CombiventTM followed by Salbutamol|
3340689|NCT02182713|Active Comparator|Arm 2 - Salbutamol followed by CombiventTM|
3340690|NCT02182726||MOBEC|
3340691|NCT02182739||Meloxicam|
3340692|NCT02182752|Active Comparator|Ropivacaine - Tramadol|
3340693|NCT02182752|Active Comparator|Ropivacaine|
3340694|NCT02182765|Experimental|Nevirapine|"Part I: Study days 15-43~Part II: Study day 44 to end of trial"
3340695|NCT02182765|Active Comparator|Amprenavir|"Part I: Study days 0 to 43~Part II: Study day 44 to end of trial"
3340696|NCT02182765|Active Comparator|Abacavir|"Part I: Study days 0 to 43~Part II Study day 44 to end of trial"
3340697|NCT02182778|Experimental|Gemcitabine/Cisplatin group|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
3340698|NCT02182778|Experimental|Gemcitabine/Cisplatin /S-1 group|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
3340699|NCT02182791|Experimental|Nevirapine tablets|"once a day (q.d.) Day 2-15,~twice a day (b.i.d.) Study day 16-30"
3340700|NCT02182791|Active Comparator|EE/NET tablets|Single dose on Study Day 0 and 30
3340701|NCT02182817||GA-Exposed Group|Exposure to general anaesthesia below 15 months of age
3340702|NCT02182817||Unexposed Group|Children not exposed to general anaesthesia or surgery from GUSTO cohort. (GUSTO: Growing Up Towards Healthy Outcomes in Singapore: a prospective longitudinal study providing normative data from the local population)
3237442|NCT01260987|Active Comparator|AK split-face treatment|Split-face treatment of two symmetrical areas with moderate to severe actinic keratoses. One area is treated with conventional PDT the other with fractional laser assisted PDT.
3237443|NCT01260987|Active Comparator|Fractional laser assisted PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is pretreated with fractional CO2 laser followed by methyl-aminolevulinate PDT.
3340703|NCT02182856|Experimental|Ipratropium bromide/salbutamol sulphate|"Randomised sequence of four different treatments~Ipratropium bromide 500 µg/salbutamol sulphate 3 mg~Ipratropium 500 µg~Salbutamol sulphate 3 mg~Salbutamol sulphate 6 mg"
3340704|NCT02182869|Experimental|Combivent® HFA|
3237444|NCT01260987|Active Comparator|Konventional PDT for BCC|Difficult to treat nodular basal cell carcinomas in the face is treated with methyl-aminolevulinate PDT.
3237445|NCT01261013||keratoconus stage I in whom KeraRing ICRS were implanted|
3340705|NCT02182869|Active Comparator|Combivent® CFC|
3340706|NCT02182882|Experimental|GINSANA|
3237446|NCT01261013||keratoconus stage II in whom KeraRing ICRS were implanted|
3237447|NCT01261013||keratoconus stage III in whom KeraRing ICRS were implanted|
3237448|NCT01261026||Ectopic pregnancy, extra-uterine pregnancy|Ectopic pregnancy, control
3237449|NCT01261026||Abnormal intrauterine pregnancy|
3340707|NCT02182882|Placebo Comparator|Placebo|
3340708|NCT02182908|Other|Non surgical aneurysm of abdominal aorta|PET-Scan
3237450|NCT01261039|Active Comparator|Solar bed UV-radiation|Solar bed UV-radiation
3237451|NCT01261039|Sham Comparator|Solar bed with UV filter|Solar bed with UV filter
3237452|NCT01261078|Placebo Comparator|Placebo|8 mg bupivacaine only
3237453|NCT01261078|Active Comparator|Epi 25|8 mg of bupivacaine mixed with 25 mcg of epinephrine
3237454|NCT01261078|Active Comparator|Epi 50|8 mg of bupivacaine mixed with 50 mcg of epinephrine
3340709|NCT02182934|Experimental|Ginsana|
3340710|NCT02182934|Placebo Comparator|Placebo|
3340711|NCT02182960|Experimental|Ibuprofen|
3340712|NCT02182960|Active Comparator|Brufen|
3340713|NCT02182986||Subjects Enrolled Pre-Transplant|"Subjects (N=approximately 357) Enrolled Pre-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
3340714|NCT02182986||Subjects Enrolled Post-Transplant|"Subjects (N=approximately 588) Enrolled 3 Yrs Post-Transplant~Subjects with evidence of EBV infection prior to transplant~Subjects without evidence of EBV infection prior to transplant, who are at risk of developing EBV infection after transplant"
3340715|NCT02183012|Experimental|A: Ibuprofen extrudate, fed state|
3340716|NCT02183012|Experimental|B: Ibuprofen extrudate, fasted state|
3340717|NCT02183012|Active Comparator|C: Ibuprofen lysinate tablet, fed state|
3340718|NCT02183012|Active Comparator|D: Ibuprofen lysinate tablet, fasted state|
3340719|NCT02183012|Active Comparator|E: Ibuprofen tablet, fed state|
3340720|NCT02183012|Active Comparator|F: Ibuprofen tablet, fasted state|
3340721|NCT02183025|Experimental|Meloxicam 7.5 mg|
3340722|NCT02183025|Experimental|Meloxicam 15 mg|
3340723|NCT02183025|Active Comparator|Mefenamic acid 1500 mg|500 mg three times daily
3340724|NCT02183038|Experimental|Meloxicam low & Placebo|
3340725|NCT02183038|Experimental|Meloxicam high & Placebo|
3340726|NCT02183038|Active Comparator|Naproxen sodium & Placebo|
3340727|NCT02183051|Experimental|Meloxicam 15 mg|
3340728|NCT02183051|Experimental|Meloxicam 7.5 mg|
3340729|NCT02183051|Experimental|Meloxicam 3.75 mg|
3340730|NCT02183051|Experimental|Meloxicam 1.875 mg|
3340731|NCT02183051|Active Comparator|Ibuprofen 400 mg|
3340732|NCT02183051|Active Comparator|Ibuprofen 200 mg|
3340733|NCT02183051|Placebo Comparator|Placebo|
3340734|NCT02183064|Experimental|Meloxicam|
3340735|NCT02183064|Active Comparator|Usual care prescription NSAID|
3340736|NCT02183077|Experimental|Meloxicam gel|
3340737|NCT02183077|Active Comparator|Meloxicam tablet|
3340738|NCT02183090|Experimental|Meloxicam ampoule|
3340739|NCT02183090|Active Comparator|Meloxicam tablet|
3340740|NCT02183103|Active Comparator|meloxicam rapid release tablet after an overnight fast|
3340741|NCT02183103|Experimental|meloxicam rapid release tablet after high fat breakfast|
3340742|NCT02183116|Experimental|Meloxicam|
3340743|NCT02183129|Experimental|Meloxicam|
3340744|NCT02183129|Active Comparator|Diclofenac|
3340745|NCT02183142|Active Comparator|Mobic Germany|
3340746|NCT02183142|Experimental|Mobic China|
3340747|NCT02183155|Experimental|Meloxicam - low|
3340748|NCT02183155|Experimental|Meloxicam - medium|
3340749|NCT02183155|Experimental|Meloxicam - high|
3340750|NCT02183155|Placebo Comparator|Placebo|
3237455|NCT01261078|Active Comparator|Epi 100|8 mg of bupivacaine mixed with 0.1 mg of epinephrine
3237456|NCT01261078|Active Comparator|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
3237457|NCT01261091|Experimental|Early Tracheostomy|Patients randomized to early tracheostomy receive (preferably dilatative) tracheostomy within 3 days from intubation.
3237458|NCT01261091|Active Comparator|Prolonged Intubation|Patients randomized to this arm will be tried to wean off the ventilator and get (an) extubation trial(s) if regarded feasible. In case of failure or non-feasibility, they receive tracheostomy between days 7 to 14 from intubation.
3237459|NCT01261104||Hearing impaired elderly|
3340751|NCT02183155|Active Comparator|Extended-release indomethacin|
3340752|NCT02183168|Experimental|Meloxicam suppository|
3237460|NCT01261104||Hearing impaired adults|
3340753|NCT02183168|Experimental|Meloxicam tablet|
3340754|NCT02183168|Active Comparator|Indomethacin suppository|
3340755|NCT02183181|Experimental|Meloxicam capsule|Capsules 15 mg
3340756|NCT02183181|Active Comparator|Meloxicam tablet|Tablets 15 mg
3340757|NCT02183194|Experimental|Lutonix Paclitaxel Drug Coated Balloon|
3237461|NCT01261117|Active Comparator|intravenous ibuprofen|Extremely low birth weight patients receiving iv ibuprofen
3237462|NCT01261117|Active Comparator|Oral ibuprofen|Extremely low birth weight patients receiving oral ibuprofen
3237463|NCT01261130|Experimental|Part I-A: 10μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation A
3340758|NCT02183207|Experimental|PEG insertion arm via EG Scan|Percutaneous endoscopic insertion of gastrostomy via visualization through E.G. ScanTM
3340759|NCT02183220|Experimental|Metamizol high & Placebo|
3237464|NCT01261130|Experimental|Part I-B: 30μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation B
3237465|NCT01261130|Experimental|Part I-C: 100μgNaGST1/Alhydrogel|Part I (non-endemic area), Formulation C
3340760|NCT02183220|Experimental|Metamizol low & Placebo|
3340761|NCT02183220|Active Comparator|Acetylsalicylic acid & Placebo|
3237466|NCT01261130|Experimental|Part I-D: 10μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation D
3340762|NCT02183220|Placebo Comparator|Placebo|
3237467|NCT01261130|Experimental|Part I-E: 30μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation E
3340763|NCT02183233|Experimental|Eschscholtzia Californica|
3340764|NCT02183233|Placebo Comparator|Eschscholtzia Californica Placebo|
3340765|NCT02183246|Experimental|Porfiromycin + Radiotherapy|
3340766|NCT02183246|Placebo Comparator|Placebo + Radiotherapy|
3237468|NCT01261130|Experimental|Part I-F: 100μgNaGST1/Alhydrogel/GLA|Part I (non-endemic area), Formulation F
3237469|NCT01261130|Experimental|Part II-A: 10μgNaGST1/Alhydrogel|Part II (endemic area), Formulation A
3237470|NCT01261130|Experimental|Part II-B: 30μgNaGST1/Alhydrogel|Part II (endemic area), Formulation B
3237471|NCT01261130|Experimental|Part II-C: 100μgNaGST1/Alhydrogel|Part II (endemic), Formulation C
3237472|NCT01261130|Experimental|Part II-D: 10μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation D
3237473|NCT01261130|Experimental|Part II-E: 30μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation E
3237474|NCT01261130|Experimental|Part II-F: 100μgNaGST1/Alhydrogel/GLA|Part II (endemic area), Formulation F
3237475|NCT01261130|Active Comparator|Part II-G: Butang® hepatitis B vaccine|Part II (endemic), HepB comparator
3237476|NCT01261143|Experimental|BK-C-0701, diabetic neuropathy|
3237477|NCT01261143|Active Comparator|alpha lipoic acid, diabetic neuropathy, capsule|
3237478|NCT01261156|Experimental|Study Arm 1|
3237479|NCT01261156|Experimental|Study Arm 2|
3237480|NCT01261169||Myfortic|
3237481|NCT01261182|Experimental|In School Feeding|
3237482|NCT01261182|Experimental|Take Home Rations|
3237483|NCT01261182|No Intervention|Control|
3237484|NCT01261234|Experimental|Cilostazol group|Continuous administration of cilostazol (unrestricted use of other antiplatelet agents and concomitant drugs)
3237485|NCT01261234|Active Comparator|Non-Cilostazol group|Antiplatelet agent other than cilostazol (unrestricted use of concomitant drugs)
3340767|NCT02183259|Experimental|ESR 1150 CL capsule|
3340768|NCT02183259|Experimental|ESR 1150 CL ampoule|
3340769|NCT02183272|Active Comparator|Intranasal Ketamine|0.2 mg / kg dose of intranasal ketamine for treatment of suicidality will be given in two separate doses on the day of admission to the hospital.
3340770|NCT02183272|Placebo Comparator|Intranasal Saline Placebo|0.2 mg / kg dose saline intranasal will be given in two separate doses on the day of hospital admission.
3340771|NCT02183285|Experimental|PHL 00747 capsules|
3340772|NCT02183285|Experimental|PHL 00747 tablets|
3340773|NCT02183285|Placebo Comparator|Placebo|
3340774|NCT02183298|Experimental|BI 1356 BS - single rising dose|
3340775|NCT02183298|Placebo Comparator|Placebo|
3340776|NCT02183311|Experimental|BI 1356 BS - single rising dose|
3340777|NCT02183311|Experimental|BI 1356 BS - multiple rising dose|
3340778|NCT02183311|Active Comparator|Placebo|
3340779|NCT02183324|Experimental|Low dose of BI 1356 BS|
3340780|NCT02183324|Experimental|Medium dose of BI 1356 BS|
3340781|NCT02183324|Experimental|High dose of BI 1356 BS|
3340782|NCT02183324|Placebo Comparator|Placebo|
3340783|NCT02183337|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
3340784|NCT02183337|Active Comparator|Pioglitazone|"Treatment sequence AB_C or C_AB~Treatment A: 5 days BI 1356 until steady state followed by~Treatment B: combined treatment of BI 1356 with pioglitazone for 7 days~Treatment C: 7 days of treatment with Pioglitazone alone"
3340785|NCT02183350|Experimental|BI 1356 BS - single rising dose|
3340786|NCT02183350|Placebo Comparator|Placebo|
3340787|NCT02183363|Experimental|BI 1356 - Tablet TFII|
3340788|NCT02183363|Experimental|BI 1356 - Tablet iFF|
3340789|NCT02183363|Active Comparator|BI 1356 - Tablet TFIIb|
3237486|NCT01261260|Placebo Comparator|Uridine|1g BID
3237487|NCT01261273||Stable angina|Patient admitted with stable angina
3340790|NCT02183376|Experimental|BI 1356 - healthy subjects|
3340791|NCT02183376|Experimental|BI 1356 - mild liver impairment|
3340792|NCT02183376|Experimental|BI 1356 - moderate liver impairment|
3237488|NCT01261273||Acute Coronary Syndrome|Patients admitted with Acute Coronary Syndrome
3237489|NCT01261273||Female|Participant female patients
3237490|NCT01261273||Bifurcation|One or more lesions treated during the baseline in bifurcation
3237491|NCT01261273||Insulin Dependent Diabetes Mellitus|Patients that were insulin-dependent diabetes mellitus at admission
3237492|NCT01261273||Non-Insulin Dependent Diabetes Mellitus|Patients that were non-insulin-dependent diabetes mellitus at admission
3237493|NCT01261273||Small Vessels|vessels smaller or equal to 2.75mm
3340793|NCT02183376|Experimental|BI 1356 - severe liver impairment|
3340794|NCT02183389|Experimental|Treatment B: BI 1356 and Warfarin|BI 1356 for 12 days combined with a single dose of warfarin on day 6
3340795|NCT02183389|Active Comparator|Treatment A: Warfarin|Warfarin as single dose
3340796|NCT02183402|Experimental|Digoxin with BI 1356|
3340797|NCT02183402|Active Comparator|Digoxin|
3340798|NCT02183415|Experimental|BI 1356 BS, low dose|
3340799|NCT02183415|Experimental|BI 1356 BS, medium dose|
3340800|NCT02183415|Experimental|BI 1356 BS, high dose|
3340801|NCT02183415|Placebo Comparator|Placebo|
3237494|NCT01261273||NOBORI Long Lesions|Lesions longer or equal to 20mm
3340802|NCT02183428|Experimental|BI 1356|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
3340803|NCT02183428|Active Comparator|Glyburide|"Treatment sequence AB_C or C_AB~Treatment A: 5 days of treatment with BI 1356 once per day until steady state followed by~Treatment B: 1 day of combined treatment of BI1356 and glyburide~Treatment C: 1 day of treatment with glyburide alone"
3340804|NCT02183441|Experimental|BI 1356 plus ritonavir|Treatment A: 3 days of ritonavir, 1 day BI 1356
3340805|NCT02183441|Active Comparator|BI 1356|Treatment B: BI 1356 alone
3340806|NCT02183467|Experimental|BI 1356, low dose|
3340807|NCT02183467|Experimental|BI 1356, high dose|
3237495|NCT01261273||Renal Insufficiency|Patients that at admission had renal insufficiency (> 2.0 mg/dL - 176 µmol/mL) at admission
3340808|NCT02183467|Placebo Comparator|Placebo|
3340809|NCT02183467|Active Comparator|Moxifloxacin|
3340810|NCT02183480|Experimental|Linagliptin, low dose|
3340811|NCT02183480|Experimental|Linagliptin, medium dose|
3340812|NCT02183480|Active Comparator|Linagliptin, high dose|
3340813|NCT02183493|Experimental|Fed administration of BI 1356|
3237496|NCT01261273||Elderly|Patients more or equal 80 years old
3237497|NCT01261273||Restenosis|One or more lesions treated during the baseline in were restenotic lesions
3340814|NCT02183493|Active Comparator|Fasted administration of BI 1356|
3340815|NCT02183506|Active Comparator|Metformin|
3340816|NCT02183506|Experimental|BI 1356 BS and metformin|Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
3237498|NCT01261273||Multivessel Treatment|Patients who underwent the treatment of more than 1 vessel during the index procedure
3237499|NCT01261273||Complex Lesions|Patients who underwent a PCI on the Left Main Trunk, on a Chronic Total Occluded lesion or located on a Saphenous Vein Graft
3237500|NCT01261273||Overall|Total Population
3237501|NCT01261299|Experimental|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
3237502|NCT01261312|Experimental|Daily Regimen|"SGI-110 daily x5 dosing on a 28-day course~SGI-110 daily x10 dosing on a 28-day course"
3237503|NCT01261312|Experimental|Weekly Regimen|"SGI-110 weekly dosing for three weeks on a 28-day course~SGI-110 twice weekly dosing for three weeks on a 28-day course"
3237504|NCT01261364|Active Comparator|Treatment as Usual|
3237505|NCT01261364|Experimental|Pharmacogenetic guided treatment|
3340817|NCT02183532|Experimental|BI 1356 BS|
3340818|NCT02183545|Experimental|BI 1060469|single rising doses given as tablet
3340819|NCT02183545|Placebo Comparator|Placebo|given as tablet (matching placebo of BI 1060469)
3340820|NCT02183558|Experimental|OGTT by randomization|Women without risk factors for GDM are offered OGTT in gestational week 28
3340821|NCT02183558|Experimental|OGTT by indication|Women with risk factors for OGTT are offered diagnostic 2 hour OGTT in pregnancy week 28
3340822|NCT02183571|Experimental|Glucophage® high dose|Part I: Treatment A + B
3340823|NCT02183571|Experimental|Glucophage® low dose|Part II: Treatment C+ D
3340824|NCT02183584|Experimental|Rifampicin and Linagliptin|
3340825|NCT02183597||Advanced breast cancer|Women with advanced breast cancer
3340826|NCT02183610|Experimental|[14C] BI 1356 as oral (p.o.) solution|
3340827|NCT02183610|Experimental|[14C] BI 1356 solution for i.v. infusion|
3340828|NCT02183623|Experimental|BI 1356 BS and Simvastatin|
3340829|NCT02183636|Experimental|Treatment 1 (T1)|Linagliptin/pioglitazone, FDC formulation C5
3340830|NCT02183636|Experimental|Treatment 2 (T2)|Linagliptin/pioglitazone, FDC formulation C8
3340831|NCT02183636|Active Comparator|Reference (R)|Linagliptin tablet and pioglitazone tablet (Actos®)
3340832|NCT02183649|Experimental|pentoxyverine citrate vs. placebo|All subjects were allocated to receive both verum and placebo in randomised order
3340833|NCT02183662|Experimental|BI 224436|
3340834|NCT02183662|Placebo Comparator|Placebo|
3340835|NCT02183688|Experimental|ASA + paracetamol + caffeine|
3340836|NCT02183688|Active Comparator|ASA + paracetamol|
3340837|NCT02183688|Active Comparator|ASA|
3340838|NCT02183688|Active Comparator|Paracetamol|
3340839|NCT02183688|Active Comparator|Caffeine|
3340840|NCT02183688|Placebo Comparator|Placebo|
3340841|NCT02183701|Experimental|Telmisartan|4 weeks placebo run-in, 6-weeks fixed dose period
3340842|NCT02183701|Active Comparator|Losartan + Hydrochlorothiazide|4 weeks placebo run-in, 6-weeks fixed dose period (Losartan 50 mg / HCTZ 12.5 mg)
3340843|NCT02183714|Experimental|Songha Night ®|
3340844|NCT02183714|Placebo Comparator|Placebo|
3237506|NCT01261377|Active Comparator|Bi-level positive airway pressure (BPAP)|bi-level will be titrated to optimize oxygenation and ventilation.
3237507|NCT01261377|Active Comparator|Nocturnal oxygen|oxygen will be provided as per standard of care.
3340845|NCT02183740|Experimental|Multifaceted educational program|"A multifaceted educational program for nursing home staff consisting of:~One seven hours educational meeting (interactive workshop) conducted in the nursing home. Theoretical input and case-base discussions considering guidelines for nurse led assessment og interventions of patients fecal incontinence.The content will be made available as educational material.~Recruitment of one local opinion leader per nursing home unit.~Seven educational outreach meetings (1 hour 30 minutes per meeting) during the three months intervention period."
3340846|NCT02183740|No Intervention|Control|The control arm will not receive any educational program and will continue with usual care. Data with information about ordinary care will be gathered as part of the data collection procedure in the study.
3340847|NCT02183753|Active Comparator|Wood smoke|The dose of WSP to be used (500 µg/m3 for 2 hours) is based on prior studies which indicate the exposure is well tolerated, and is similar to that found in some indoor exposures in homes heated by wood burning (24-26). The route of administration (breathing air containing WSP at rest, nasally) is intended to mimic natural exposures.
3340848|NCT02183753|Placebo Comparator|clean air|Chapel Hill air which has been filtered to remove ambient air pollutants.
3340849|NCT02183766|Placebo Comparator|Maltodextrin|6 mL once a day diluted in juice during 30 days.
3340850|NCT02183766|Active Comparator|Galactooligosaccharide prebiotic|6 mL once a day diluted in juice during 30 days.
3340851|NCT02183779|Experimental|Reynaud|patients with reynaud phenomena
3237508|NCT01261377|Active Comparator|Continuous positive airway pressure|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
3340852|NCT02183779|Experimental|Healthy|Healthy volunteers
3340853|NCT02183805|Experimental|Metastatic triple negative breast cancer|Abraxane,Cyclophosphamide,Carboplatin
3340854|NCT02183818||Healthy nonsmokers|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
3340855|NCT02183818||Smokers with COPD|Physical assessment, EKG, blood and urine draw, chest x-ray, pulmonary function test (PFT), and bronchoscopy
3340856|NCT02183831||Capsular tension ring non insertion group|The patients who had same cataract surgery procedure without CTR insertion
3340857|NCT02183831||Capsular tension ring insertion group|The patients who underwent capsular tension ring insertion just before IOL implantation during cataract surgery
3340858|NCT02183844|Experimental|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
3340859|NCT02183857|Other|Ultrasound|Patients in group Ultrasound will have their femoral arterial lines inserted under the guidance of US. The Ultrasound equipment used is a SonoSite 180 PLUS with an L25/10- to 5-MHz linear array transducer (SonoSite, Inc., Bothell, WA)
3340860|NCT02183857|Other|Landmark|No Device is used. Patients in group Landmark will have their femoral line inserted using the blinded, external landmark-guided technique. After localization of the femoral artery by identifying the pulse in the femoral triangle immediately distal to the inguinal ligament.
3340861|NCT02183870|Experimental|Crizotinib|Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
3340862|NCT02183883|Experimental|Afatinib|Afatinib, tablet, 40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision
3340863|NCT02183896|Experimental|Platelet-rich plasma (PRP)|Intra-articular injections in the hip of autologous platelet-rich plasma (PRP) at week 1 and 2 post-operatively. Dose 5 mL. PRP is derived from the patient's own blood.
3340864|NCT02183896|Placebo Comparator|Saline|Intra-articular injections in the hip of saline, solution week 1 and 2 post-operatively. Dose: 5 mL at each injection.
3340865|NCT02183909|Experimental|Study intervention|
3340866|NCT02183922|Placebo Comparator|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
3340867|NCT02183922|Experimental|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
3340868|NCT02183922|Experimental|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid group received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
3340869|NCT02183935|No Intervention|Lifestyle counseling, metformin|Age, gender and BMI matched controls will be managed by lifestyle counseling and metformin if indicated.
3237509|NCT01261403|Experimental|Group 1|1 Unit of PDA001 or 4 units Vehicle Control intravenous on Day 0 and Day 7
3237510|NCT01261403|Experimental|Group 2|4 Units PDA001 or 4 units Vehicle Control intravenous (Placebo) on Day 0 and Day 7
3237511|NCT01261403|Placebo Comparator|Vehicle control|Placebo - Vehicle Control Arm
3237512|NCT01261416||Infants with seizures|
3237513|NCT01261429|Experimental|Nilotinib|
3237514|NCT01261442||Diabetic patients with DSPN|
3237515|NCT01261442||Diabetic patients without DSPN|
3237516|NCT01261455|Active Comparator|Superior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from superior conjunctival tissue.
3375847|NCT03706911|Experimental|VM-1500A-LAI 600mg|VM-1500A-LAI 600mg IM single dose
3375848|NCT03706911|Experimental|VM-1500A-LAI 1200mg|VM-1500A-LAI 1200mg IM single dose
3237517|NCT01261455|Experimental|Inferior Conjunctival Autograft|Conjunctival autograft following pterygium excision is taken from inferior conjunctival tissue.
3340870|NCT02183935|Active Comparator|Duodeno - jejunal liner|Duodeno-jejunal liner (Endobarrier) will be implanted for the duration of 12 months. During this time subjects will be regularly monitored for investigated parameters. In addition, subjects will be carefully monitored upon device removal for additional 12 months.
3340871|NCT02183948|Experimental|oxytocin|nasal spray
3340872|NCT02183948|Placebo Comparator|Placebo|nasal spray
3340873|NCT02183961|Experimental|Laryngopharyngeal reflux|EER was detected using three methods: oropharyngeal pH was monitored for 24 hours using the Restech system; detection of pepsin in middle ear fluid obtained during myringotomy was done using Peptest, and detection of pepsin in adenoid specimen was done immunohistochemically using antibody P3635Rb-h.
3340874|NCT02183974|Experimental|Peptest|44 children at the age between 1 to 7 years diagnosed with bilateral or unilateral OME who underwent adenoidectomy and myringotomy with insertion of ventilation tube. Effusion was collected and analysed using Peptest, which contains monoclonal antibodies targeted against pepsin. Result of the Peptest was stated as positive (2 lines), negative (1 line) and invalid (no line).
3340875|NCT02183987|Experimental|Active Knowledge Translation Group|CKD clinics receiving the active knowledge translation intervention.
3340876|NCT02183987|No Intervention|Passive Knowledge Translation Group|Clinics will have access to the Canadian Society of Nephrology (CSN) guidelines on the optimal timing of dialysis initiation (current practice). These guidelines have been published in the Canadian Medical Association Journal (CMAJ) and have been recently presented at the annual meeting of the Canadian Society of Nephrology.
3340877|NCT02184000||1. the control group healthy adult volunteers|
3237518|NCT01261468|Active Comparator|Active SCS|
3237519|NCT01261468|Sham Comparator|Inactive SCS|
3237520|NCT01261481|Experimental|Tolvaptan Intact Tablet Orally|
3237521|NCT01261481|Experimental|Tolvaptan via Nasogastric Tube|
3340878|NCT02184000||2. patients with chronic hepatitis B or C|
3340879|NCT02184000||3. pacients with liver cirrhosis type B or C|
3340880|NCT02184026|Experimental|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
3340881|NCT02184052||Meloxicam|
3340882|NCT02184065||Meloxicam|
3340883|NCT02184078|Experimental|single group|"Nevirapine:~Study days 15-28 dose given once a day (q.d.) Study days 29-42 dose given twice a day (b.i.d.)~Rifabutin:~Study Days 0 to 42"
3340884|NCT02184091|Experimental|Nevirapine|Single dose administration
3340885|NCT02184104|Active Comparator|Aeroshot|A single 100 mg caffeine dose administered using the Aeroshot device.
3340886|NCT02184104|Active Comparator|Energy Drink|A single 100 mg caffeine dose administered as an oral solution.
3340887|NCT02184117||All patients|Entire cohort undergoes paired testing
3340888|NCT02184130|Experimental|TMS|
3340889|NCT02184156|Experimental|Ampion < 5 kDa ultrafiltrate of 5% HSA|4 mL intra-articular injection of Ampion
3340890|NCT02184156|Placebo Comparator|Placebo solution|4 mL placebo intra-articular injection
3340891|NCT02184182|Experimental|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
3340892|NCT02184221|Experimental|High frequency stimulation|alpha burst, 8~12Hz, run 2 seconds, rest 8 seconds, lasts 20 minutes each time
3340893|NCT02184221|Active Comparator|Low frequency stimulation|0.5Hz, run 0.5 seconds, rest 1.5 seconds, lasts 20 minutes each time
3340894|NCT02184234|Experimental|Antistax film coated tablets|
3340895|NCT02184247|Experimental|anhydrous theophylline, 350 mg|
3340896|NCT02184247|Active Comparator|anhydrous theophylline, 300 mg|
3340897|NCT02184260|Experimental|Metamizole|
3340898|NCT02184260|Placebo Comparator|Placebo|
3340899|NCT02184273|Experimental|Magnesium metamizol|
3340900|NCT02184273|Placebo Comparator|Placebo|
3340901|NCT02184286|Experimental|Nevirapine + Saquinavir-sgc|
3340902|NCT02184299|Experimental|Nevirapine + Prednisone|"week 1-2: Nevirapine + Prednisone~week 3-24: Nevirapine alone"
3340903|NCT02184299|Active Comparator|Nevirapine|week 1-24: Nevirapine
3340904|NCT02184312|Experimental|Nevirapine XR low dose|
3237522|NCT01261494|Experimental|GFT505 80mg|
3237523|NCT01261494|Placebo Comparator|Matching placebo|
3340905|NCT02184312|Experimental|Nevirapine XR medium dose|
3340906|NCT02184312|Active Comparator|Nevirapine XR high dose|
3237524|NCT01261520|Other|Culturally-tailored video|The culturally-tailored video was designed to focus on Chinese women's cultural health beliefs and align with Chinese customs, norms, and values, which includes two segments: 1) a soap-opera and 2) recommendation from a Chinese female physician.
3237525|NCT01261533|Experimental|FCVB team|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)
3237526|NCT01261546|Experimental|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
3340907|NCT02184312|Active Comparator|Nevirapine (VIRAMUNE®)|commercial product
3340908|NCT02184325|Experimental|Kiddi® Pharmaton Fizz, effervescent tablets|with reduced amount of minerals
3340909|NCT02184325|Active Comparator|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
3340910|NCT02184325|Active Comparator|Comparator product|in the form of a product that is a market leader
3340911|NCT02184338|Experimental|BIRB 1017 BS in single rising doses|
3340912|NCT02184338|Placebo Comparator|Placebo|
3340913|NCT02184351|Experimental|Roxanes's clotrimazole troches|
3340914|NCT02184351|Active Comparator|Mycelex® troches|
3237527|NCT01261546|Placebo Comparator|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
3340915|NCT02184364|Experimental|Low dose of Klimadynon®|
3340916|NCT02184364|Experimental|Medium dose of Klimadynon®|
3340917|NCT02184364|Experimental|High dose of Klimadynon®|
3340918|NCT02184364|Active Comparator|Oestrofeminal®|
3340919|NCT02184364|Placebo Comparator|Placebo|
3340920|NCT02184377||RLN+SLN paralysis|unilateral recurrent laryngeal and superior laryngeal nerve paralysis
3340921|NCT02184377||RLN paralysis|unilateral recurrent laryngeal nerve paralysis
3340922|NCT02184390|Experimental|tutorial|Parents who receive access to the tutorial immediately
3237528|NCT01261572|Experimental|High dose group|ASP3350 high dose
3237529|NCT01261572|Experimental|Low dose group|ASP3350 low dose
3237530|NCT01261598|Other|1|Patients treated with curative and exclusive radiotherapy (60 Gy minimum), with possibly prior chemotherapy
3340923|NCT02184390|No Intervention|wait list control|Parents who are assessed at the same time points as the intervention arm, but do no receive access to the tutorial
3340924|NCT02184429|Experimental|Single Ascending Dose-1|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
3340925|NCT02184429|Experimental|Single Ascending Dose-2|Single ascending doses of PF-06669571 administered to healthy volunteers in a cross over study design
3340926|NCT02184429|Experimental|Multiple Ascending Dose-1|Daily dose of PF-06669571 in healthy volunteers
3340927|NCT02184429|Experimental|Multiple Ascending Dose-2|Daily dose of PF-06669571 in healthy volunteers
3340928|NCT02184429|Experimental|Multiple Ascending Dose-3|Daily dose of PF-06669571 in healthy volunteers
3340929|NCT02184429|Experimental|Multiple Ascending Dose-4|Daily dose of PF-06669571 in healthy volunteers
3340930|NCT02184429|Experimental|Multiple Ascending Dose-5|Daily dose of PF-06669571 in healthy volunteers
3237531|NCT01261598|Other|2|Patient treated with concomitant chemotherapy and radiotherapy (60 Gy minimum), with possibly prior chemotherapy chemotherapy Treatment
3237532|NCT01261637|Experimental|0.25% Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
3340931|NCT02184468|Other|Dual dispatch|Simultaneously dispatching of EMS, firefighters and/or police in OHCA
3340932|NCT02184481|Experimental|Working memory training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level adapted to the working memory capacity of the participant.
3340933|NCT02184481|Placebo Comparator|Placebo training|Participants executed the training for three weeks, three times a week, half an hour per session. The training was a game in which the participant was a person who had to become strong to fight with a fantasy figure. The person could become stronger when giving the right answers in eight different working memory tasks. The level in the placebo condition was easy and did not adapt to the working memory capacity of the participant.
3340934|NCT02184507|Experimental|Supplement pre CABG|Consumption of the supplement 7 days before surgery and placebo 30 days post surgery
3340935|NCT02184507|Experimental|Supplement post CABG|Consumption of placebo 7 days before surgery and supplement 30 days post surgery
3340936|NCT02184507|Experimental|Supplement pre and post CABG|Consumption of the supplement 7 days before and 30 days post surgery
3340937|NCT02184507|Placebo Comparator|Placebo|Consumption of placebo 7 days before and 30 days post surgery
3340938|NCT02184533|Experimental|Treatment (sodium selenite and radiation therapy)|Patients receive sodium selenite PO 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.
3340939|NCT02184559|Experimental|TAP block|
3237533|NCT01261637|Placebo Comparator|Placebo|20ml saline
3237534|NCT01261650|Active Comparator|transcranial direct current stimulation|transcranial direct current stimulation of the primary motor cortex
3340940|NCT02184559|Active Comparator|infiltration continues|
3340941|NCT02184585|Experimental|Cohort 1: Fasted state|Treatment will be administered orally to 42 subjects in the fasted state. Subjects will be required to fast overnight (minimum 10 hours) and for a minimum of 4 hours after each dose. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
3340942|NCT02184585|Experimental|Cohort 2 : Fed state|Treatment will be administered orally to 42 subjects in the fed state (high fat breakfast). Dosing will take place within 30 minutes of the start of the meal. Subjects will participate in 3 treatment periods and assigned to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA) in accordance with the randomization schedule generated by Clinical Statistics. The three treatment periods will be separated by a minimum washout period of 28 days
3237535|NCT01261650|Sham Comparator|sham treatment|
3237536|NCT01261663||NOS intake either at end of meals or as snackings.|
3237537|NCT01261676||Caesarean section|
3237538|NCT01261676||Vaginal birth (control)|
3237539|NCT01261689|Active Comparator|Epidural analgesia|Women will be allocated to the EA group. In the EA group, women are given an EA as soon as they are in labour.
3237540|NCT01261689|Other|Care as-usual pain treatment|Women will be allocated to the care-as-usual group. In this care-as-usual(restrictive) group, women receive pain relief only on their explicit request. If necessary epidural analgesia.
3237541|NCT01261702|Placebo Comparator|Placebo|Normal saline IV
3340943|NCT02184598|Placebo Comparator|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
3340944|NCT02184598|Experimental|Cognitive training|Cognitive training with 6 different games each of which gets progressively more difficult as children obtain proficiency.
3340945|NCT02184637|Experimental|Cohort 1- TQ w/DHA+PQP|Tafenoquine (TQ) will be co-administered with Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) on Day 1. DHA+PQP alone will be administered at 24 hours (h) (Day 2) and 48 h (Day 3) post first dose administration.
3340946|NCT02184637|Experimental|Cohort 2 - TQ w/AL|Tafenoquine co-administered with Artemether + Lumefantrine (AL) on Day 1. AL alone will be administered at 8h (Day 1), 24h and 36h (Day 2), 48h and 60 h (Day 3) post first dose administration.
3340947|NCT02184637|Experimental|Cohort 3 - DHA+PQP alone|Dihydroartemisinin + Piperaquine tetraphosphate (DHA+PQP) will be administered on Day 1 and at 24 hours (Day 2) and 48 hours (Day 3) post first dose administration
3340948|NCT02184637|Experimental|Cohort 4 - AL alone|Artemether + Lumefantrine will be administered on Day 1 and 8h, 24 and 36h (Day 2), 48h and 60 h(Day 3) post first dose administration
3340949|NCT02184637|Experimental|Cohort 5 - TQ alone|A single dose of Tafenoquine will be administered on Day 1
3340950|NCT02184650||Premature infants|Premature infants with a GA < 32 weeks
3340951|NCT02184663|Active Comparator|Standard care without APA program|
3340952|NCT02184663|Experimental|standard care with APA program|
3340953|NCT02184676|Other|Children born to mother/father with type 1 diabetes|
3340954|NCT02184689|Experimental|Fexinidazole|
3340955|NCT02184702||shoulder arthroscopy|
3340956|NCT02184715|Active Comparator|Virtual reality video game|Participants received rehabilitation treatment and additional virtual reality system (30 minutes of interactive virtual reality system play, two times per week, in eight sessions over a 4-week span) for 1 month, followed by rehabilitation treatment for 1 month
3340957|NCT02184715|Placebo Comparator|Virtual reality system|received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system (30 minutes of interactive video game play, two times per week, in eight sessions over a 4-week span) during the one month of intervention period.
3340958|NCT02184728|No Intervention|EMMA(TM)|"A small capnograph for measuring ET-CO2 - the EMMA capnometer~1"
3237542|NCT01261702|Experimental|Magnesium sulphate|Magnesium sulphate 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
3340959|NCT02184754||MEI|
3340960|NCT02184780||GUSTO Neurocognitive Cohort|This study involves retrospective analysis of data from an existing cohort of 600 infants who were enrolled in the neurocognitve arm of the GUSTO study (Growing up in Singapore Towards Healthy Outcomes). GUSTO is a prospective observational cohort study done in Singapore, where subjects were followed up from in-utero up to 36 months of age and beyond. The infants have already undergone a rigorous battery of neurocognitive tests at 6, 18, 24 and 36 months of age and their detailed demographic and medical information are available.
3340961|NCT02184793|Other|EMD (Inclinomax) then usual care|"EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h.~Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h."
3340962|NCT02184793|Other|usual care then EMD (Inclinomax)|"Usual care : recording the head of bed inclination degree with masked digital display and alarm off for 24h.~EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on for 24h."
3340963|NCT02184806|Experimental|1- orthotopic graft|
3340964|NCT02184806|Experimental|2- heterotopic graft|
3340965|NCT02184819|Active Comparator|levosimendan|study drug
3340966|NCT02184819|Placebo Comparator|placebo|placebo group
3340967|NCT02184832|Experimental|Low tryptophan diet|2 days of a low tryptophan diet
3340968|NCT02184832|Experimental|High tryptophan diet|2 days of a high tryptophan diet
3340969|NCT02184845|Experimental|NobelActive 3.0|
3340970|NCT02184858|Experimental|lisinopril|dose titration of investigational product (lisinopril) dependant on blood pressure, levels of renin and aldosterone and on adverse events.
3340971|NCT02184871||intrahepatic cholangiocarcinoma|Patients committed to surgery and stratified according to exposure to different risk factors for ICC, basing on modified ReNaM questionnaire.
3237543|NCT01261715|Active Comparator|Woman with previous ceasarean section - staples|
3237545|NCT01261741|Experimental|Memantine|
3340972|NCT02184884||MACE group|the patients with MACE after OPCAB
3340973|NCT02184884||no MACE group|the patients without MACE after OPCAB
3340974|NCT02184897|Active Comparator|AM group|Lenograstim is administered at 8 am and apheresis is started at 10 am on D4.
3340975|NCT02184897|Experimental|PM group|Lenograstim is administered at 6 pm and apheresis is started at 8 am on D5
3340976|NCT02184910||gastritis and pepsinogen|
3340977|NCT02184923|Experimental|verticality measurements|
3340978|NCT02184936||acute ischemic stroke|
3340979|NCT02184949||Primary Sample|All percutaneous coronary intervention patients who meet the primary eligibility criteria for this study.
3340980|NCT02184949||Subsample|Patients drawn from the main sample who specifically underwent a primary percutaneous coronary intervention procedure.
3340981|NCT02184975|Experimental|Stitches|Cold Knife Conization with stitches
3340982|NCT02184975|Active Comparator|No stitches|Cold Knife Conization without stitches
3340983|NCT02185001|Active Comparator|Surgical Treatment Group|Direct Medial Patellofemoral Ligament (MPFL) Repair
3340984|NCT02185001|Active Comparator|Conservative Treatment Group|Immobilization, stabilization bracing, and physical therapy
3340985|NCT02185027||complications and compliance with GIHP recommendations|Description at 1 month post-intervention of an potential event
3340986|NCT02185066|Experimental|Group 1|"Single-dose crossover~Reference: Atorvastatin 20mg and Metformin XR 500mg~Test: CJ-30056 20/500mg~Once daily Oral administration with 7days of washout period"
3340987|NCT02185066|Experimental|Group 2|"Single-dose crossover~Test: CJ-30056 20/500mg~Reference: Atorvastatin 20mg and Metformin XR 500mg~Once daily Oral administration with 7days of washout period"
3375849|NCT03706911|Experimental|VM-1500A-LAI 600 mg Multiple|VM-1500A-LAI Multiple dose (2 injections every 4 weeks)
3340988|NCT02185079|Active Comparator|Group C|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
3340989|NCT02185079|Experimental|Group M|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be subjected to training to proficiency based on the metrics developed for labor epidural catheter placement in a epidural simulator.
3340990|NCT02185092|Placebo Comparator|Sugar Pill|1 pill orally daily
3340991|NCT02185092|Active Comparator|Lactobacillus GG|1 pill (2 x 10x 9 CFU) daily orally
3237546|NCT01261741|Placebo Comparator|Placebo|
3340992|NCT02185118|Experimental|oxygen plus isoflurane/sevoflurane|"All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection.~The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients."
3340993|NCT02185144|Experimental|PATH for Triples (PFT)|The Nurse Health Navigator (NHN) meets at least weekly with the experimental participants to implement the adherence component of PFT using approaches tailored to the communication and comprehension of the person that includes memory aids, education regarding side effects and other treatment aspects, engagement with participants' social networks and treatment providers, and active community outreach. PFT will be implemented for 6 months and participants will be followed for an additional 3 months to allow examination of potential decay of the intervention after it is withdrawn.
3340994|NCT02185144|Placebo Comparator|Treatment as Usual (TAU)|Participants in the the Treatment as Usual (TAU) group receive usual treatment after inpatient care.
3340995|NCT02185157|Experimental|Experimental: Dual Task exercises|Dual-task training, includes 18 sessions model of cognitive and 12 motor dual-task exercises model, were administered in groups of four participants in a comfortable environment, without distraction effects. The 50-minute sessions included 30 minutes of motor dual-task exercises, and then, the participants were divided into pairs. The first pair performed free walks during 10 minutes at their maximal speeds, while the other received individual cognitive dual-task training for the same time, and these activities will be exchanged, so that all pairs could walk and receive cognitive training.
3340996|NCT02185157|Other|Control intervention: Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
3340997|NCT02185170|Experimental|Fluorescence assesment|"All patients undergo a transurethral resection.~There are four different steps in the study:~the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner."
3340998|NCT02185196|Active Comparator|Vitamin D3|Vitamin D3, Doses form: 20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
3340999|NCT02185196|Placebo Comparator|Miglyol-oil|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days.
3341000|NCT02185209|Experimental|Placebo|Patients with periimplantitis undergoing surgical treatment with will receive placebo three times daily (TID)
3341001|NCT02185209|Active Comparator|amoxicillin + metronidazole|Patients with periimplantitis undergoing surgical treatment with amoxicillin (500 mg TID) + metronidazole (400 mg TID) for 7 days
3341002|NCT02185209|Active Comparator|phenoxymetylpencillin + metronidazol|Patients with periimplantitis undergoing surgical treatment with phenoxymetylpencillin, (800mg×2 TID) + metronidazol (400 mg TID) for 7 days
3341003|NCT02185222|Experimental|Cholecalciferol 100 000 UI (Unité Internationale)|Oral solution in single-dose : 100 000 UI per month
3341004|NCT02185222|Placebo Comparator|Placebo|Oral solution in single-dose per month
3341005|NCT02185235|Experimental|Biofeedback & Electrical Stimulation|Twice a week, 20 minutes for each time. One course includes 18 times treatment.
3341006|NCT02185235|Active Comparator|Biofeedback & Pelvic Floor Training|Pelvic floor training every 20 minutes for each time, twice a week. and total for 18 times.
3341007|NCT02185248|No Intervention|Control Group|General clinical counseling in regards to child's BMI category and necessary changes to diet and activity regimen.
3341008|NCT02185248|Experimental|Wellness Plan|Received a wellness action plan. The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
3341009|NCT02185261|Experimental|interferon Alfa-2b group|Acute leukemia patients who are minimal residual disease positive after hematopoietic stem cell transplantation receive interferon Alfa-2b
3341010|NCT02185287||Lower urinary tract dysfunction, female, age: 18-40 years|
3237547|NCT01261754|Active Comparator|Metastatic prostate adenocarcinoma|
3237548|NCT01261754|Active Comparator|Healthy Volunteers|
3341011|NCT02185287||Healthy female subjects, age: 18-40 years|
3375850|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive|Chronic Lymphocytic Leukemia Patients That Are Treatment Naive will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
3237549|NCT01261754|Active Comparator|Newly Diagnosed, High-Risk Prosate Cancer Patients|
3237550|NCT01261767|Experimental|Anti-IL-20|
3237551|NCT01261767|Placebo Comparator|Placebo|
3237552|NCT01261806|Experimental|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up: 10 session intervention in foster families' homes designed to enhance parental nurturance, synchrony, and provide skills such that parents can help children calm down when overwhelmed.
3341012|NCT02185300|Experimental|Sequence ABCDE|Subject will be administered treatments in the sequence ABCDE where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 minutes(mins), re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 minutes, re-dispersed, and then taken by subject
3341013|NCT02185300|Experimental|Sequence BCDEA|Subject will be administered treatments in the sequence BCDEA where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3237553|NCT01261806|Active Comparator|Developmental Education for Families|10 session intervention in foster families' homes that targets cognitive and motor skills of children
3341014|NCT02185300|Experimental|Sequence CDEAB|Subject will be administered treatments in the sequence CDEAB where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3341015|NCT02185300|Experimental|Sequence DEABC|Subject will be administered treatments in the sequence DEABC where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3341016|NCT02185300|Experimental|Sequence EABCD|Subject will be administered treatments in the sequence EABCD where, A = Single dose of DTG 20 mg of the pediatric granule formulation reconstituted with purified water; B = Single dose of DTG 20 mg DT dispersed in LMC water; C = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water; D= Single dose of DTG 20 mg DT dispersed in LMC water, held for 30 mins, re-dispersed, and then taken by subject; E = Single dose of DTG 20 mg DT dispersed in CONTREX mineral water, held for 30 mins, re-dispersed, and then taken by subject
3341017|NCT02185313|Experimental|gaze holding|
3341018|NCT02185326|Experimental|Microflare and growth hormone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3341019|NCT02185326|No Intervention|Microflare protocol alone|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later
3341020|NCT02185352|Experimental|Inductional BEEP regimen|"Induction BEEP regimen:~Every 3 weeks a cycle for a total of 3 cycles (around 2 months)~Bevacizumab 15mg/kg IVF on D1~Etoposide 70 mg/m2 IVF QD, D2-4~Cisplatin 70 mg/m2 IVF on D2~WBRT:~3000cGy in 10 fractions"
3341021|NCT02185352|No Intervention|WBRT alone|"standard WBRT:~3000cGy in 10 fractions"
3341022|NCT02185365||Developmental dysplasia of the hip (DDH)|Patients will complete 2 magnetic resonance imaging (MRI): T1-rho and dGEMRIC. The T1-rho MRI does not require the injection of a contrast agent, while the dGEMRIC MRI requires a gadolinium injection to visualize cartilage in the hip.
3341023|NCT02185378|Active Comparator|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
3237554|NCT01261832|Experimental|Dual antiplatelet therapy for 1 year|Dual antiplatelet therapy for 1 year : dual antiplatelet combination therapy with aspirin and clopidogrel for 1 year
3341024|NCT02185378|Active Comparator|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
3341025|NCT02185391|Experimental|fact-finding group|Intervention: Audience Response System and motivational telephone interview
3341026|NCT02185391|No Intervention|control group|
3341027|NCT02185417|Active Comparator|Hydrochlorothiazide|Hydrochlorothiazide daily dose of 50 mg or 25 mg for duration of study
3341028|NCT02185417|Active Comparator|Chlorthalidone|Chlorthalidone daily dose of 25 mg or 12.5 mg for duration of study
3341029|NCT02185430|Placebo Comparator|Control group|saline solution
3341030|NCT02185430|Active Comparator|dexmedetomidine group|dexmedetomidine
3341032|NCT02185456|No Intervention|Healthy|Patients with no history of bacterial vaginosis. These women will be monitored monthly and with daily self swabs.
3341033|NCT02185456|Active Comparator|G1 BV in clinical & molecular remission|Patients will receive standard of care intervention, oral metronidazole 500 mg twice a day for 7 days. They will then be monitored to confirm that initial BV treatment was effective by Nugent and Amsel, and by the qPCR test (LbRC). These will be monitored with monthly visits and daily self swabs. Those who recur with symptomatic BV may enroll in the B2 arm for more aggressive treatment.
3341034|NCT02185456|Experimental|G2. Molecular conversion subarm|Half of G1 patients who convert to poor qPCR test results while remaining asymptomatic will be randomized into this G2 arm and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days, with continued monthly visits and daily swabs.
3375851|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
3237555|NCT01261832|Experimental|Triple antiplatelet therapy for 1 month|Triple antiplatelet therapy for 1 month : triple antiplatelet therapy including cilostazol for 1 month and after then, dual antiplatelet therapy for 11 months
3237556|NCT01261832|Experimental|Triple antiplatelet therapy for 6 months|Triple antiplatelet therapy for 6 months : triple antiplatelet combination therapy including cilostazol for 6 months and after then, dual antiplatelet therapy for 6 months and cilostazol
3237557|NCT01261858|Experimental|Stainless steel and Kryptonite|Sternal closure with stainless steel and kryptonite
3341035|NCT02185456|Active Comparator|B1 Initially poor qPCR responders|The B1 arm are patients who enter remission after standard of care treatment, oral metronidazole 500 mg twice a day for 7 days, but who have poor initial qPCR scores. Half of such patients will be randomized into B1, half into B2. B1 patients will be monitored with monthly visits and via daily swabs, but will receive no further treatment while BV negative. Patients who recur with BV may enroll as B2 patients for more aggressive treatment.
3341036|NCT02185456|Experimental|B2 BV Remission to conversion|A subgroup of B1 patients who convert to consistently poor qPCR scores during the study (conversion) will be randomized into Arm B2 and receive intervention: 750 mg metronidazole/ 200 mg miconazole vaginal suppository daily for 7 days. These patients will continue monthly visits and daily self swabs. B2 patients who recur with symptomatic BV will be dropped from the study and given other options for therapy.
3341037|NCT02185469|Active Comparator|pneumatic retinopexy group|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
3237558|NCT01261858|Active Comparator|Stainless steel|Sternal closure with only stainless steel
3341038|NCT02185469|Active Comparator|vitrectomy group|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
3341039|NCT02185482|Experimental|Physician Supported Care|The intervention is an individualized, stepped-care depression treatment program provided by a depression clinical specialist primary care physician.
3341040|NCT02185482|Other|Usual care|Usual care patients will be advised to consult with their primary care physician regarding depression. Primary care physicians prescribe antidepressant medication and can refer patients to the Mental Health Services.
3341041|NCT02185495|Experimental|High-risk individuals|"The elder and heavy smokers, which are high-risk individuals for early lung cancer. These subjects will be examined using Observer nodule detection and  Computer-aided nodule detection."
3341042|NCT02185508||Lumbar spine surgery with IONM|Patients diagnosed with 1 or 2 level lumbar disk disease and radicular symptoms who underwent decompressive surgery, and for whom IONM records exist.
3341043|NCT02185547|Experimental|ICBT in combination with sertraline treatment|Internet cognitive behavioral therapy in combination with sertraline treatment
3341044|NCT02185547|Active Comparator|ICBT|Only Internet cognitive behavioral treatment, no additional depression treatment
3341045|NCT02185573|No Intervention|Conventional Technique|Multi-layer filling technique
3341046|NCT02185573|Active Comparator|Bulk fill technique|Bulk fill technique
3341047|NCT02185573|Experimental|SonicFill technique|SonicFill technique
3341048|NCT02185586|Experimental|LALC|lower abdominal laparoscopic cholecystectomy
3341049|NCT02185586|Experimental|SLC|single laparoscopic cholecystectomy
3341050|NCT02185586|Placebo Comparator|UALC|upper abdominal laparoscopic cholecystectomy
3341051|NCT02185599||Colposcopy with DySIS|The prospective arm will recruit patients referred for colposcopy and will be examined using DySIS.
3341052|NCT02185599||Standard colposcopy|The retrospective arm will collect historical data from colposcopy examinations performed using a standard colposcope.
3341053|NCT02185612|No Intervention|Control|Participants will be randomized to a 1 year wait list. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
3341054|NCT02185612|Experimental|Savings program|Participants will be randomized to the EARN.org online savings program for 6 months. Participants take 0 month, 6 month, and 12 month surveys on depression, anxiety, alcohol and tobacco use, locus of control, and overall self-rated health.
3341055|NCT02185625|Experimental|Safe Delivery smartphone application|
3341056|NCT02185625|No Intervention|Control|
3341057|NCT02185638|Experimental|A20-50|"A20-50 (2 capsules). Each capsule contains:~Yerba Mate (Ilex paraguariensis), Guarana seed (Paullinia cupana), Magnesium Oxide , Caffeine , Damiana (Turnera microphylla), Green tea (Camellia sinensis), Ginger (Zingiber Officinale), Kola nut (Cola acuminate or nitida), Pyridoxine Hydrochloride, Tibetan Ginseng root (Rhodiola crenulata), Schisandra (Schisandra Chinensis), Jujube (Ziziphus Jujuba) , Cocoa nut (Theobroma cacao), Chinese Skullcap (Scutellaria Baicalensis), Black tea leaf (Thea sinensis), Rice flour (to fill)~Dose = 2 capsules have a total of 200 mg of caffeine"
3341058|NCT02185638|Active Comparator|YGD|"YGD blend (2 capsules). Each capsule contains:~Yerba Maté (leaf) , Guarana (seed) , Damiana (leaf) , Rice flour: to fill ,~The 2 capsules of the YGD blend contain about 40 mg xanthines (caffeine and caffeine-like stimulants)."
3341059|NCT02185638|Placebo Comparator|Placebo|"Placebo (2 capsules). Each capsule contains:~Rice Flour"
3237559|NCT01261871||Robotic laparoscopic prostatectomy|Patients who are undergoing primary surgical treatment for a diagnosis of prostate operatively will be enrolled. IOP will be measured throughout the case to assess for change. The various techniques employed for a radical prostatectomy will be compared. Patients undergoing RRP (open surgery) will act as controls. Those undergoing LRP (minimally invasive surgery) will be compared with the control group to assess for differences in IOP that may result from the different approaches. three arms will be used for the comparison: open, laparoscopic intraperitoneal approach), and laparoscopic (extraperitoneal approach).
3237560|NCT01261884|No Intervention|Routine prenatal care|
3341060|NCT02185651|Active Comparator|Zavesca® 100 mg|"3 study participants are given Zavesca® prescription 100 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
3341061|NCT02185651|Active Comparator|Zavesca® 300 mg|"3 study participants are given Zavesca® prescription 300 mg for administration before ERT infusion. Week 0 infusion is completed at study site, with blood collection for anti-GAA antibody level before, during and after the ERT infusion. A punch muscle biopsy is completed the day after ERT infusion with pre-medication Zavesca®. Health Survey is completed.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
3341062|NCT02185664|Active Comparator|Landmark technique|The landmark technique is the standard technique used for internal jugular vein cannulation.
3237561|NCT01261884|Experimental|Exercise support|
3341063|NCT02185664|Experimental|Static Ultrasound technique|Static ultrasound technique was used to assist internal jugular vein cannulation.
3341064|NCT02185677||MSA-P|
3341065|NCT02185677||MSA-C|
3341066|NCT02185690|Other|Binimetinib efficacy/safety|"This is a Phase I/Ib, open-label, dose-escalation, multi-center, non-randomized study designed to evaluate the safety and tolerability of oral Binimetinib in combination with carboplatin and pemetrexed.~Phase I part A standard 3+3 dose-escalation will be used to determine the maximum administered dose (MAD) and the RP2D for the combination in subjects with advanced non-squamous lung carcinoma.~Phase Ib part Once RP2D has been identified, an expansion cohort will be accrued; these patients will be stratified by KRAS genotype.~The RP2D will be expanded by enrolling additional patients, stratified by KRAS genotype, to a total of 30 patients eligible for the safety set (including those treated at the same dose combination in the dose-escalation phase of the study who are eligible for the safety set) to be evaluated for safety, tolerability, pharmacokinetics and biologic activity of MEK162."
3237562|NCT01261884|Experimental|Exercise intervention|
3237563|NCT01261897|Active Comparator|Adductor-Canal-Blockade with Ropivacaine|
3237564|NCT01261897|Placebo Comparator|Adductor-Canal-blockade with saline|
3237565|NCT01261910|No Intervention|Usual education (standard care)|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant.
3237566|NCT01261910|Experimental|Intensive initial education|On the day of the transplant evaluation at the transplant center, participants receive usual transplant education regarding living donor kidney transplant. In addition, participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
3237567|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency|metabolism of 30 mg alitretinoin single dose in 8 patients with Hepatic Insufficiency
3237568|NCT01261923|Experimental|Alitretinoin - Hepatic Insufficiency Controls|metabolism of 30 mg alitretinoin single dose in 8 healthy controls.
3237569|NCT01261936||women with a diagnosis of CBD|women in the fertile age, with an ascertained diagnosis of CBD, followed up for heavy periods and needing a specific treatment.
3237570|NCT01261949|Experimental|Combined frontal and temporal rTMS|Combined low frequency frontal and temporal transcranial magnetic stimulation of auditory cortex and right DLPFC
3237571|NCT01261949|Experimental|Temporal low frequency rTMS|temporal low frequency rTMS of auditory cortex
3341067|NCT02185703|Experimental|Chordate System S020 in treatment mode|
3341068|NCT02185703|Sham Comparator|Chordate System S020 in placebo mode|
3237572|NCT01261962|Experimental|Chemotherapy and zinc|Patients in adjuvant chemotherapy supplemented with zinc
3237573|NCT01261962|Placebo Comparator|Chemotherapy placebo|Patients in adjuvant chemotherapy with placebo
3237574|NCT01261962|Other|Control and zinc|Healthy patients supplemented with zinc
3237575|NCT01261962|Other|Control Placebo|Healthy volunteers received placebo
3237576|NCT01262001|Experimental|Cohort 1/1-EX|Subjects with moderate to severe idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
3237577|NCT01262001|Experimental|Cohort 2/2-EX|Subjects with mild to moderate idiopathic pulmonary fibrosis (IPF) who have evidence of disease progression
3237578|NCT01262014|Experimental|Experimental single arm|Single arm of pazopanib 800 mg (2x400mg) given as a single agent.
3237579|NCT01262040|Experimental|pts having a thorascopic, laparoscopic or robotic procedure|The procedure will begin with washings (peritoneal) and two assessments of the extent of peritoneal disease. First, a four quadrant inspection of the peritoneal cavity under white light, this is the standard of care assessment. Then, a repeat four quadrant inspection of the peritoneal cavity under NBI will be done, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI. For those patients scheduled for thorascopic procedures: The procedure will begin with sampling of pleural effusions when clinically indicated. Then there will be two assessments of the pleural surfaces. First, an inspection of the pleural cavity under white light, this is the standard of care assessment. Then, a repeat inspection under NBI, this is the only experimental component of the design. White light imaging will always be done first, followed by NBI.
3237580|NCT01262053|Experimental|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated.
3237581|NCT01262053|Experimental|Active Intervention|The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders.
3237582|NCT01262053|Active Comparator|Control|Parallel control with no intervention
3237583|NCT01262066|Experimental|LifeSkills workshop intervention|Participants attended 10 1-hr weekly sessions. The content of the groups followed the LifeSkills Workshop manual and Video(Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
3341069|NCT02185716|Active Comparator|local infiltration|Group L (n=25) will be given total 30 ml 0.25 % levobupivacaine infiltration around trocar-site with injector in sterilized conditions without administering TAP block at the end of the operation
3341070|NCT02185716|No Intervention|Control|Only routine general anesthesia will be applied
3341071|NCT02185716|Experimental|TAP|Group T (n=25) will be given bilateral total 30 ml 0.25 % levobupivacaine administering TAP block under the guidance of ultrasound at the preoperative period.
3341072|NCT02185742|Experimental|Strength Based Case Management|Strength Based Case Management
3341073|NCT02185742|No Intervention|Contemporary, HIV+ Jail Detainees|No intervention
3341074|NCT02185755|Active Comparator|Internet-Based Glucose Monitoring System|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and provide feedback limited to non-medicine related comments and suggestions.
3341075|NCT02185755|Other|Normal Medication Positive Control|The subjects will be prescribed a new medication as appropriate for normal therapy. This group will receive no biweekly feedback nor require to report online, but will see the endocrinologist every 3 months up to 6 months.
3341076|NCT02185768|Experimental|DC-BEADS + Idarubicin|Chemoembolization with DC BEAD loaded with idarubicin
3341077|NCT02185781|Experimental|Autologous NK Cells infusions|
3237584|NCT01262066|No Intervention|Enhanced usual care|The Usual Care group received a self-help brochure on BP control developed by the National Heart, Lung, and Blood Institute (NHLBI). In addition, with the participants' permission, their BP readings were sent to their listed physicians, along with the 1-page JNC-7 express summary for the management of high BP.
3237585|NCT01262079||Group 1: 6-15 years old|
3237586|NCT01262079||Group 2: 16-25 years old|
3237587|NCT01262079||Group 3: 26-35 years old|
3237588|NCT01262079||Group 4: 36-45 years old|
3237589|NCT01262079||Group 5: 46-55 years old|
3237590|NCT01262079||Group 6: 56-65 years old|
3237591|NCT01262079||Group 7: 66-75 years old|
3341078|NCT02185807|Active Comparator|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians, and receive face- to face discussion with their physicians as well.
3341079|NCT02185807|Placebo Comparator|control group|The control patients receive verbal information and discussion from their physicians.
3341080|NCT02185820|Experimental|1|"Treatment schedule for 8 cycles of induction:~Carfilzomib = 20 mg/m2 IV once daily on days 1 of cycle 1 only followed by 27/36/45/56 mg/m2 days 8, 15 in cycle 1, then for all subsequent doses 27/36/45/56 mg/m2 IV once daily on days 1, 8, 15 followed by 13-day rest period (day 16 through 28).~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22 every 28 days.~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib = at the MTD achieved in the phase I of the study on days 1, 8, 15 in 28-days cycles.~Pomalidomide = 4 mg daily on days 1 - 21 every 28 days. Dexamethasone = 20 mg on days 1, 8, 15, 22."
3341081|NCT02185833|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3341082|NCT02185833|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3237592|NCT01262079||Group 8: 76-85 years old|
3237593|NCT01262079||Group 9: > 85 years old|
3237594|NCT01262144||Case group|
3237595|NCT01262157|Sham Comparator|placebo|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
3237596|NCT01262157|Active Comparator|Shock wave therapy|12 treatment sessions twice a week during 9 weeks with an interim of 3 weeks no treatment
3237597|NCT01262170|Experimental|CigRx Lozenge|CigRx Lozenge
3237598|NCT01262170|Active Comparator|Tobacco Lozenge|Tobacco Lozenge
3237599|NCT01262183|Experimental|Concurrent chemoradiation therapy with panitumumab|
3237600|NCT01262183|Active Comparator|Concurrent chemoradiation therapy without panitumumab|
3237601|NCT01262196|Experimental|MP4OX|250-mL dose
3237602|NCT01262196|Placebo Comparator|Control|250-mL of normal saline solution
3237603|NCT01262209|Experimental|Low Vision Aids|"All patients will receive:~A low vision examination:~Low vision refraction~Distance best corrected visual acuity~Near best corrected visual acuity~Contrast Sensitivity~Quality of life questionnaire~Low vision therapy: to teach strategies for more effective use of remaining vision and use of low-vision devices~Prescribed low vision devices including binocular telescope (2.1x or 3.5x), monocular telescope, 6x telemicroscopes, microscopes, magnifiers, portable CCTV and absorptive filters."
3237604|NCT01262222||pts undergoing major surg procedure referred to cardiology|Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
3237605|NCT01262235|Experimental|TKM-080301|
3237606|NCT01262248||patients with colorectal polyps|
3237607|NCT01262261|Experimental|Probuphine|patients are first inducted on sublingual buprenorphine then switched to 4 Probuphine Implants
3237608|NCT01262274|Active Comparator|ANA|
3237609|NCT01262274|Experimental|ANA+UFT|
3237610|NCT01262300|Experimental|VZV vaccine|"Varicella Zoster Virus vaccine (Zostavax), single dose X 1 injection~All subjects in this trial will receive the VZV vaccine. The Investigators will primarily compare immune responses in those that are receiving high dose vs. standard dose vitamin D supplementation and those that have high and low 25-hydroxyvitamin D levels."
3237611|NCT01262313|Sham Comparator|Control Group|"The Control group will have an hour-long meeting of instruction by a registered dietitian on using the provided A Healthier You: Everyday Healthy Eating and Physical Activity for Life book, based on the Dietary Guidelines for Americans 2005."
3341083|NCT02185846|Active Comparator|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3341084|NCT02185846|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San.Ve Tic. A. Ş., Turkey, one tablet, once
3341085|NCT02185859|Experimental|Perioperative lidocaine infusion|
3341086|NCT02185859|Experimental|Perioperative magnesium infusion|
3341087|NCT02185859|Active Comparator|Noraml saline infusion|
3341088|NCT02185872|Active Comparator|Aerobic and Resistance Training|Participants completed 24 exercise sessions based on current guidelines. Aerobic exercise (50 min) was performed on machines every session and resistance training (20 min) was performed on machines two sessions per week. Aerobic intensity was prescribed at 40-50% of heart rate reserve (HRR) Weeks 1-4 and 50-60% HRR Weeks 5-8. Resistance training was supervised by an ACE certified personal trainer. One-repetition maximums (1-RM) were assessed Week 1 (i.e., seated bicep curl, military press, seated lat pulldown, seated leg extension, triceps pulldown, bench press, reverse leg curl, seated leg press). For Weeks 2-3 participants completed, 3 sets of 15 reps at 50% 1-RM; Weeks 4-5, 3 sets of 12 reps at 60% 1-RM; Weeks 6-7, 3 sets of 10 reps at 70% 1-RM; Week 8, 3 sets of 8 reps at 75% 1-RM. Three sets of 15 unweighted crunches were completed each day. One minute of rest was taken between each set and each exercise.
3341089|NCT02185872|Experimental|High-intensity functional training|Participants completed a total of 24 sessions that were pre-programmed and led by a certified instructor (CrossFit Level 2), which lasted up to 60 minutes in duration. The first two class periods were structured as an introduction to common movements used in high-intensity functional training (HIFT; e.g., squats, deadlift, press, jerks, barbell, dumbbell, and medicine ball cleans, pullups, kettlebell swings, among others). No scheduled workouts were given on days 1 and 2. Beginning on day 3 each HIFT class consisted of 10-15 minutes of stretching and warmup, 10-20 minutes of instruction and practicing techniques and movements, and 5-30 minutes for the workout of the day, performed at vigorous intensity, relative to each person's ability and fitness level. All weights and movements were individually prescribed and recorded for each participant.
3341090|NCT02185885|Experimental|Increased bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted according to department guidelines with the modification that MAP is kept between 70 and 80 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
3237612|NCT01262313|Experimental|lifestyle counseling intervention|"This group will participate in the weekly Healthy Creations classes for 8 weeks presented by a Registered Dietitian and a certified fitness trainer. This is a community based lifestyle intervention program."
3237613|NCT01262326|Experimental|Low Carbohydrate Diet|Subjects are placed on a low carbohydrate diet where only 5% of energy intake is derived from dietary carbohydrate.
3341091|NCT02185885|No Intervention|Regular bloodpressure during CPB|The cardiopulmonary bypass (CPB) procedure is conducted in accordance with departmental guidelines, where MAP is sought to be ≥ 45 mm Hg. This is achieved by refract intravenous doses of phenylephrine to a total maximum of 2.0 mg, and after that continuous intravenous infusion of norepinephrine up to 0.4 μg/kg/min if necessary.
3341092|NCT02185898|Active Comparator|Leading U.S. tobacco-burning non-menthol cigarette|Leading U.S. non-menthol cigarette
3341093|NCT02185898|Active Comparator|Leading U.S. tobacco-burning menthol cigarette|Leading U.S. menthol cigarette
3341094|NCT02185898|Experimental|Electronic cigarette #1|VUSE® (menthol flavor, 29 mg nicotine)
3341095|NCT02185898|Experimental|Electronic cigarette #2|VUSE® (original flavor, 29 mg nicotine)
3341096|NCT02185898|Experimental|Electronic cigarette #3|VUSE® (original flavor, 14 mg nicotine)
3341097|NCT02185898|Experimental|U.S. Market-sample electronic cigarettes (two brands)|blu™ (any variety) and NJOY® (any variety)
3341098|NCT02185911||Cohort 1|Patients with CKD
3341099|NCT02185924|Experimental|CONTINUOUS FEMORAL BLOCK AND PARECOXIB|Continuous infusion of0,2% of ropivacaine at 10 ml/h and 2 mls (40 mg) of iv parecoxib
3341100|NCT02185924|Placebo Comparator|CONTINUOUS FEMORAL BLOCK AND PLACEBO|Continuous infusion of 0.2% ropivacaine at 10 ml/h and 2 mls of iv N/S0.9%
3341101|NCT02185937|No Intervention|water|imatinib intake with water
3341102|NCT02185937|Active Comparator|cola|imatinib intake with cola
3341103|NCT02185950|Experimental|Ultrasound group|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm, and the application parameters with a matched control side of the patient, in a region with contralateral uninjured skin.
3341104|NCT02185950|Experimental|Group paraffin|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.
3341105|NCT02185950|Experimental|Ultrasound group + endermotherapy|Therapeutic ultrasound, 3 MHz, continuous with intensity 1W/cm2 will be applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) with exposure time of 2 minutes for each effective radiation area head (ERA), a total of 4 minutes of application in an area of 9X5 cm. The application of endermotherapy will be held shortly after the therapeutic ultrasound in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
3237614|NCT01262326|Active Comparator|Low Calorie Diet|Subjects have there caloric intake reduced to 1200 or 1500 kcal/day (women and men respectively).
3237615|NCT01262378|Other|Harmonic knife|surgery using the Harmonic knife
3237616|NCT01262378|Active Comparator|HF knife|
3237617|NCT01262391|Experimental|AD-PED 2.5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 2.5 mg of solifenacin succinate.
3237618|NCT01262391|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 5 mg of solifenacin succinate.
3341106|NCT02185950|Experimental|Group paraffin + endermotherapy|Paraffin therapy is heated with thermostat own equipment, being applied to the selected region (burn scar deep 2nd degree or 3rd degree, grafted) and control (uninjured), with a length of 9X5 cm, at a temperature of 38 ° C with appropriate brush in layers (4 layers), remaining for 20 minutes. After the period of application of paraffin will be removed and discarded, with no reuse.The application of endermotherapy will be held shortly after the paraffin therapy in a timely manner across the surface of the scar, for about 2 seconds per head area with a negative pressure between 100-200 mmHg, a total of 4 minutes application in an area of 9 x 5 cm. The same application parameters will be performed with one hand matched control patient, in a region with contralateral uninjured skin.
3341107|NCT02185963|Experimental|Rosuvastatin|Rosuvastatin will be started in type 2 DM and having 1 or more cardiovascular risk factors
3341108|NCT02185976|Active Comparator|cartoon|paediatric patients undergoing general anesthesia. This group will choose a cartoon movie to watch throughout the preparation until the induction of anesthesia
3341109|NCT02185976|No Intervention|routine|paediatric patients undergoing general anesthesia
3341110|NCT02185989|Active Comparator|Electrical muscle stimulation and bicycling|Patients will undergo early electrical stimulation of the quadriceps and early leg bicycling in addition to routine care (which comprises early standard mobilization)
3237619|NCT01262391|Experimental|AD-PED 10 mg|Male and female adolescents aged 12 to less than 18 years old who receive PED of 10 mg of solifenacin succinate.
3237620|NCT01262391|Experimental|CH-PED 2.5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 2.5 mg of solifenacin succinate.
3341111|NCT02185989|No Intervention|Standard early passive/active rehabilitation|In this control group, patients will undergo routine care that comprises standard early passive/active rehabilitation delivered by physiotherapist with the assistance of ICU nurses
3341112|NCT02186002|Experimental|Group 1|A single oral dose of 10 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo.
3341113|NCT02186002|Experimental|Group 2|A single oral dose of 50 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 50 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3341114|NCT02186002|Experimental|Group 3|A single oral dose of 200 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 200 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3237621|NCT01262391|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
3341115|NCT02186002|Experimental|Group 4|A single dose of 500 mg ACT-451840 or placebo to be administered to subjects in the fasted state, followed by an observation period of 4 days. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 500 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3341116|NCT02186002|Experimental|Group 5|A single oral dose of 1000 mg ACT-451840 or placebo to be administered to subjects in the fasted state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. If indicated by the pharmacokinetic data obtained in the preceding groups and if not previously performed, a food effect investigation will be conducted after a washout period of at least 7 days. A dose of 1000 mg ACT-451840 or placebo is to be administered to subjects in the fed state, followed by the second observation period of 4 days. Six subjects who received ACT-451810 in the fasted state are to receive ACT-451840 in the fed state and 2 subjects who received placebo in the fasted state to receive matching placebo in the fed state.
3341117|NCT02186002|Experimental|Group 6|A single oral dose of ACT-451840 or placebo to be administered to subjects in the fed state. Six subjects are to receive ACT-451840 and 2 subjects to receive matching placebo. The dose of ACT-451840 to be determined on the basis of the pharmacokinetic results for the previous groups
3237622|NCT01262391|Experimental|CH-PED 10 mg|Male and female children aged 5 to less than 12 years old who receive PED of 10 mg of solifenacin succinate.
3237623|NCT01262404||HealthEd,Minfdulness,Compassion|HealthEd receives training health education. Mindfulness receives training in mindfulness meditation. Compassion receives training in compassion meditation.
3237624|NCT01262417|Experimental|- Seprafilm group|patients receiving resorbable barrier membrane during the first surgery
3237625|NCT01262417|Other|- No-treatment control group|patients without seprafilm barrier during the first surgery
3237626|NCT01262430|Active Comparator|OtisMed|
3237627|NCT01262430|Active Comparator|Computer Assisted Surgery (CAS)|
3237628|NCT01262443|Experimental|Therapy Cool Flex catheter group|Therapy Cool Flex Catheter . No more available data
3237629|NCT01262469|Experimental|Lapatinib + Capecitabine|lapatinib 1250 mg/day (once daily) Capecitabine 2x850 mg/m2/day, days 1-14 during the first cycle and 2x1000 mg/m2/day, days 1-14, every 21 days for following cycles ( if no unacceptable toxicity is observed).
3237630|NCT01262482|Experimental|Oxaliplatin + Sorafenib|
3237631|NCT01262495|Other|orchidectomy|as specified in the summary
3341118|NCT02186028|Experimental|Vitamin D 400 IU|"Vitamin D-400IU/ml- 1ml daily~Neonates will be administered Vitamin D 400 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
3341119|NCT02186028|Active Comparator|Vitamin D 200IU|"Vitamin D 400IU/ml : 0.5ml daily~Neonates will be administered Vitamin D 200 IU orally daily by the mother or other caregiver for a period of six months. The neonates will be followed up for compliance at 2 weeks, 6, 10 and 14 weeks and thereafter at 6 months of age."
3341120|NCT02186041||De-Novo patients|Patients tested and de novo implanted with Interstim®. These patients will be followed-up for 5 years after the implant visit.
3341121|NCT02186041||Device replacement|Patients implanted with Interstim® for a device replacement. These patients will be followed-up for 5 years after the implant visit.
3341122|NCT02186041||Not-implanted patients|Patients who are tested and are not implanted with the Interstim® system. The data of the follow up of the test will be captured up to one year after the end-test visit
3341123|NCT02186054|Other|Imaging- MRI examinations|Liver MRI imaging will be performed on 50 patients.
3341124|NCT02186067|Experimental|Referral System|"Referral System:~Primary Level Secondary Level Tertiary Level"
3341125|NCT02186067|No Intervention|Control|Usual/routine care will be provided to the patients
3341126|NCT02186080|Experimental|Gemigliptin|Gemigliptin 50mg qd added to subjects current diabetes treatment
3341127|NCT02186080|Placebo Comparator|Placebo|Placebo (identical in appearance to gemigliptin)
3341128|NCT02186093||Korea|patients in South of Korea
3237632|NCT01262508||Risk Population|Patients being suspected to be at risk of hemodynamic instability due to medical history
3237633|NCT01262521|Experimental|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
3237634|NCT01262521|Placebo Comparator|Water|150 ml Chapelle mineral water
3237635|NCT01262534||1|Clinical profile of patients Comorbidities and associated type of treatments will be collected.
3237636|NCT01262534||2|Quality of Life The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire to analyze the overall quality of life of patients and Dermatology Life Quality Index (DLQI) to analyze the quality of life of patients in dermatological terms).
3237637|NCT01262534||3|Patient Preferences about treatment Patient Benefit Index (PBI) for treatment to record patient preferences regarding psoriasis treatment.
3237638|NCT01262586|Experimental|Vildagliptin|
3341129|NCT02186093||United Kingdom|patients in England
3341130|NCT02186093||Spain|patients in Spain
3341131|NCT02186093||United State of America|patients in USA
3341132|NCT02186106|Experimental|Loading dose substitution|Substituted with a highdose of cholecalciferol at study start
3341133|NCT02186106|No Intervention|Historic controls|Control subjects from journal archive
3237639|NCT01262586|Active Comparator|Glimepiride|
3237640|NCT01262612|Active Comparator|immediate treatment with cediranib|8 patients with ascites and 8 patients with pleural effusion will start immediate treatment with cediranib
3237641|NCT01262612|Active Comparator|start cediranib after 28 days BSC|patients in group B will start with cediranib after one month best supportive care.
3237642|NCT01262625|Experimental|Group A: CCTA Diagnostic|Participants randomized to diagnostic evaluation using CCTA to determine therapeutic course of action.
3237643|NCT01262625|Active Comparator|Group B: SPECT MPI/ICA Diagnostic|Standard-of-care diagnostic assessment using SPECT MPI, possibly followed by diagnostic ICA dependent on SPECT MPI results.
3237644|NCT01262664|Experimental|Prohibitin-TP01|Prohibitin-TP01 starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
3237645|NCT01262690|Experimental|Dose|6 treated, 3 placebos
3237646|NCT01262703|Experimental|REVA Medical ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
3237647|NCT01262729|Experimental|Xenon-Arm|Patients in Xenon-Arm will be inhalated with xenon within 2 hours additionally to therapeutical hypothermia after successful cardiopulmonary resuscitation.
3237648|NCT01262729|Active Comparator|MTH|Patients after successful cardiopulmonary resuscitation will be treated only with therapeutical hypothermia
3237649|NCT01262742|Active Comparator|Carbetocin 80mcg|
3237650|NCT01262742|Active Comparator|Carbetocin 90mcg|
3237651|NCT01262742|Active Comparator|Carbetocin 100mcg|
3237652|NCT01262742|Active Comparator|Carbetocin 110mcg|
3237653|NCT01262742|Active Comparator|Carbetocin 120mcg|
3237654|NCT01262768|Experimental|2D Portion Size Measurment Aids (PSMAs)|The 2D PSMAs are life-size photographs of the 3D PSMAs.
3237655|NCT01262768|Experimental|3D Portion Size Measurement Aids (PSMAs)|The 3D PSMAs include foam rubber replicas of a golf ball, a hockey puck, a tennis ball and a baseball.
3237656|NCT01262794|Experimental|CDP6038 0.3 mg/kg|
3237657|NCT01262794|Experimental|CDP6038 1 mg/kg|
3237658|NCT01262794|Experimental|CDP6038 3 mg/kg|
3237659|NCT01262794|Experimental|CDP6038 6 mg/kg|
3237660|NCT01262794|Placebo Comparator|Placebo|
3237661|NCT01262807|Experimental|Exercise|This group will receive instructions on specific exercises to perform after randomization.
3237662|NCT01262807|No Intervention|Standard Care|This group will receive standard care
3237663|NCT01262833||Cases|Patients with erectile dysfunction by ILEF questionnaire
3237664|NCT01262833||Controls|Patients without erectile dysfunction by ILEF questionnaire
3237665|NCT01262859|Experimental|Study Intervention|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
3237666|NCT01262885|Experimental|Part A Cohort 1|GSK2251052 500 mg (6 subjects), Placebo (1 subject)
3237667|NCT01262885|Experimental|Part A Cohort 2|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
3237668|NCT01262885|Experimental|Part A Cohort 3|GSK2251052 2000 mg (6 subjects), Placebo (1 subject)
3341134|NCT02186119|Experimental|abicipar pegol 2 mg (group A)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, and 20, followed by a sham procedure at weeks 12, 16, and 24.
3341135|NCT02186119|Experimental|abicipar pegol 2 mg (group B)|Abicipar pegol 2 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
3341136|NCT02186119|Experimental|abicipar pegol 1 mg|Abicipar pegol 1 mg administered to the study eye by intravitreal injection at day 1, weeks 4, 8, 16, and 24, followed by a sham procedure at weeks 12 and 20.
3341137|NCT02186119|Active Comparator|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
3341138|NCT02186132|Experimental|Atropine 0.6 mg|Atropine 0.6 mg intravenous
3237669|NCT01262885|Experimental|Part A Cohort 2 - fed|GSK2251052 1000 mg (6 subjects), Placebo (1 subject)
3237670|NCT01262885|Experimental|Part B Cohort 1|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3341139|NCT02186132|Active Comparator|Atropine 1.2 mg intravenous|Atropine 1.2 mg intravenous
3341140|NCT02186145|Experimental|Association of metronidazole; nystatin and dexamethasone|Intravaginal cream containing metronidazole (500 mg), nystatin ( 100.000 UI) and dexamethasone (0,32 mg) once a day. Period: 10 days.
3237671|NCT01262885|Experimental|Part B Cohort 2|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3237672|NCT01262885|Experimental|Part B Cohort 3|Placebo (3 subjects), GSK2251052 (9 subjects) dose to be determined
3341141|NCT02186145|Active Comparator|Flagyl|Vaginal cream of metronidazole 500 mg, nystatin 100.000 UI - once a day. Period: 10 days
3341142|NCT02186158|Experimental|Vitamin C|Each patient of this group will be received a direct intravenous injection of 2,5 ml ascorbic acid twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, ascorbic acid's capsules produced by the University Hospital Bordeaux's central pharmacy to keep the double blind way of this study will be given at patient at the morning and at the lunchtime.
3341143|NCT02186158|Placebo Comparator|Placebo|Each patient of this group will be received a direct intravenous injection of 2,5 ml NaCl 9% twice a day (at the morning and the lunchtime) from d1 to d2 included. From d3 to d7 included, mannitol's capsules produced by the University Hospital Bordeaux's central pharmacy will be given at patient at the morning and at the lunchtime.
3341144|NCT02186184|Experimental|Orthokeratology in the first year|The participants would wear orthokeratology in the first year and then switch to spectacle in the second year
3341145|NCT02186184|Active Comparator|Spectacle in the first year|The participants would wear spectacle in the first year and then changed to orthokeratology in the second year
3341146|NCT02186197||Shock and/or Respiratory Failure|
3341147|NCT02186236||Lung and Colorectal cancer patients|Eligible people who consent to participation will provide urine (both in lung cancer and colorectal cancer) and blood (in lung cancer only) samples at pre-specified times.
3341148|NCT02186262||Primary gliomas, Recurrent gliomas|
3341149|NCT02186275|Experimental|Vitamin D3 3000 or 4000 UI/day then 2,000 UI/day|"3000 UI or 4,000 UI/day as induction therapy (according to weight) for 4 weeks then 2,000 UIday as maintenance therapy for 48 weeks.~The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA))."
3341150|NCT02186275|Active Comparator|Vitamin D3 800 UI/day then 800 UI/day|800 UI/day as induction therapy for 4 weeks, then 800 UI/day as maintenance therapy for 48 weeks. The administration of vitamin D will be considered as an adjunct to conventional therapy (corticosteroids, exclusive enteral nutrition or immunosuppressive agents (ISA)).
3341151|NCT02186288||Adult ICU patients|
3341152|NCT02186314|Active Comparator|Apical stimulation|Pacemaker Biotronik: apical stimulation
3341153|NCT02186314|Active Comparator|Bifocal stimulation|Pacemaker Biotronik: bifocal stimulation
3237673|NCT01262885|Experimental|Part A Cohort 4|Placebo (1 subject), GSK2251052 (6 subjects) dose to be determined
3237674|NCT01262911|Active Comparator|1.0 g SRT2379|Single dose of 1.0g of SRT2379
3341154|NCT02186327|No Intervention|Standard care|The control arm will continue to receive standard care as they did prior to enrollment.
3341155|NCT02186327|Experimental|Integrative health coaching|Subjects in this arm will receive 6 sessions of integrative health coaching over a 3 month period, in addition to standard care.
3341156|NCT02186340|Experimental|Inspiratory muscle training|
3237675|NCT01262911|Placebo Comparator|1.0 g Placebo|Single dose of 1.0g of placebo
3237676|NCT01262924|Experimental|Group A|dTPa vaccine
3237677|NCT01262924|Experimental|Group B|Pa vaccine
3237678|NCT01262924|Active Comparator|Group C|Tedivax-Adult™/ Td-Rix™
3237679|NCT01262937||Biliary Confocal Imaging|
3237680|NCT01262937||Esophageal Confocal Imaging|
3237681|NCT01262963|Experimental|Study Medication|GSK2118436 suspension
3237682|NCT01263041|Experimental|glutamine, PT, sepsis|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
3237683|NCT01263041|No Intervention|Control|after been allocated, will receive nothing and observed for the same outcomes
3341157|NCT02186353|Experimental|Intact/minimally processed whole grains|Partial feeding study
3341158|NCT02186353|Experimental|Highly processed whole grains|Partial feeding study
3341159|NCT02186353|Active Comparator|Refined grains|Partial feeding study
3341160|NCT02186366|Experimental|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
3341161|NCT02186366|Active Comparator|Buspirone|Buspirone by mouth 5mg three times per day for 6week
3341162|NCT02186379|Experimental|RePace Intervention Group|"Re-Pace intervention-five weekly intervention sessions lasting about 1 hour each.~Lab Test Meal-2 test meals 6-8 weeks apart."
3341163|NCT02186379|Active Comparator|Usual Care Control Group|One 25 minute education session (week 6) 2 lab test meals 6-8 weeks apart (baseline and week 6)
3341164|NCT02186392|No Intervention|Control department|The control department where the conventional light is installed.
3341165|NCT02186392|Experimental|Circadian Light luminaries|The department where the special circadian light is installed. The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
3341166|NCT02186405|Experimental|LEVOTHYROXINE|administration of levothyroxine
3341167|NCT02186418|Experimental|ARU-1801|Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.
3341168|NCT02186431|Experimental|history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers with a history of corneal infiltrative events
3237684|NCT01263041|Experimental|L-arginine,NEC, PT|enteral or via NG tube dose of 260 mg/kg/day divided every 12 hours from starting feeding up to 30 says post natal age + usual care and medications
3341169|NCT02186431|Active Comparator|without a history of corneal infiltrative events|To quantify and compare baseline tear proteins and ocular response in contact lens wearers without a history of corneal infiltrative events.
3341170|NCT02186444||PHI Navigator|Personalized Health Information Navigator (PHIN).
3341171|NCT02186444||NCI Information Booklets (IB)|National Cancer Institute (NCI) Information Booklets (IB).
3341172|NCT02186457|Experimental|Polymyxin B in Normal Saline|Polymyxin B (500,000 U) in 1 liter of 0.9% Normal Saline
3341173|NCT02186457|Placebo Comparator|Placebo: Normal Saline|0.9 % Normal Saline
3341174|NCT02186470|Experimental|Treatment (image-guided intensity-modulated APBI)|Patients undergo image-guided intensity-modulated APBI twice daily (BID) in the prone position over a period of 5-10 days for a total of 10 treatment. Within 4-6 weeks post-APBI, patients undergo lumpectomy.
3341175|NCT02186483|Experimental|Metformin|Metformin and Rosuvastatin: Volunteers will be taken Metformin-Rosuvastatin-Co-administration
3341176|NCT02186483|Experimental|Rosuvastatin|Metformin and Rosuvastatin: Volunteers will be taken Rosuvastatin-Co-administration-Metformin
3341177|NCT02186483|Experimental|Co-administration|Metformin and Rosuvastatin: Volunteers will be taken Co-administration-Metformin-Rosuvastatin
3341178|NCT02186496|Experimental|Candesartan and Amlodipine|Candesartan 8mg and Amlodipine 5mg, PO, 1days or 22days
3341179|NCT02186496|Experimental|CKD-330|CKD-330 8/5mg, PO, 1days or 22days
3341180|NCT02186522||Critical Care Patients|Patients staying in the ICU for at least 48 hours, requiring external support of one or more organs (invasive ventilation, inotropes/vasopressors or renal replacement therapy) and who are not expected to die within 48 hours of study entry.
3341181|NCT02186535|Other|Daily dosing|Daily oral capsule of Vitamin D in 4000 IU/day with daily oral capsules of 1000mg of calcium
3341182|NCT02186535|Other|weekly dosing|Oral capsule Vitamin D 50,000 IU/week with a oral capsule of 1000mg of calcium, daily
3341183|NCT02186548|Active Comparator|Closed surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo closed surgical exposure, which is an intervention to correct the position of PDC:s.
3341184|NCT02186548|Active Comparator|Open surgical technique|After randomization, the PDC:s randomized to this arm, are to undergo open surgical exposure, which is an intervention to correct the position of PDC:s.
3341185|NCT02186574|Active Comparator|Pre-emptive tenofovir|Tenofovir disoproxil
3341186|NCT02186574|Placebo Comparator|Placebo|Placebo
3341187|NCT02186600|Active Comparator|Control|Women randomized to the control group will receive calcium and vitamin D intake for 12 months. Calcium intake will be determined by analyzing 3 day dietary intake of calcium at baseline and then prescribing calcium carbonate supplements to ensure women have ~1200 mg of calcium daily. Vitamin D intake will be determined using baseline measures of Serum 25 (OH) D. Subjects who have serum D levels of 30 ng/ml or greater will be prescribed 1,000 IU vitamin D3 daily; subjects with levels of 20-29 ng/ml will be prescribed 2,000 IU Vitamin D3; and subjects with levels of 10-19 ng/ml will be prescribed 3,000 IU Vitamin D3.
3341188|NCT02186600|Experimental|Risedronate|"Subjects in the risedronate group will take 35 mg of the bisphosphonate risedronate weekly for 12 months plus CaD. They will be asked to follow the protocol for administration of risedronate including taking the medication upon arising in the morning with an 8 ounce glass of water, remaining upright for at least 30 minutes, and having no oral intake except water for at least 30 minutes."
3341189|NCT02186600|Experimental|Exercise|Subjects in the exercise group will participate in bone-loading exercises three times weekly in addition to taking CaD for 12 months. Women will exercise at community Young Men's Christian Association's fitness centers (YMCA) and exercises will be monitored by on-site Exercise Trainers. Exercises will consist of high-impact weight-bearing exercises (jogging with weighted vests) and resistance exercises for upper and lower extremities. Progressive increases in weight loads will be prescribed to provide maximal strength gains.
3341190|NCT02186613|Experimental|Experimental|These mothers and their babies will receive Primary Care standard care (office visits at 1, 2, 4 and 6 months) plus the telephone support
3341191|NCT02186613|No Intervention|No intervention|Standard care (office visits at 1, 2, 4 and 6 months)
3341192|NCT02186626|Experimental|WN/DEN4Δ30 Vaccine|Participants will receive one dose of the WN/DEN4Δ30 vaccine at study entry and one dose at Day 180.
3341193|NCT02186626|Placebo Comparator|Placebo|Participants will receive one dose of the placebo at study entry and one dose at Day 180.
3341194|NCT02186639||COPD|40 COPD patients (20 non-frequent and 20 frequent-exacerbators). No intervention.
3341195|NCT02186639||Controls|"Subjects with no apparent lung disease and normal lung function testing. Matched for age, gender and smoking history (pack years).~No intervention."
3341196|NCT02186678|Experimental|assesment by 68Ga-DOTATATE PET-CT|
3237685|NCT01263067|Experimental|Lifespan Integration Therapy (LI)|
3237686|NCT01263067|Active Comparator|Waitlist Control- Lifespan Integration|
3237687|NCT01263080|Active Comparator|mirtazapine+folic acid|mirtazapine 30mg QD, folic acid 0.4mg QD
3341197|NCT02186691|Experimental|RV and LV ejection fraction assesment|assesment RV and LV ejection fraction after PVR measured by MRI
3341198|NCT02186704||ICD with DX system|Implantable cardioverter-defibrillator recipients with DX system
3341199|NCT02186704||Dual chamber ICD|Dual chamber implantable-cardioverter-defibrillator recipients (retrospective cohort from IMPACT study)
3341200|NCT02186704||Single chamber ICD|Single chamber implantable cardioverter-defibrillator recipients (retrospective cohort from Cornell registry)
3341201|NCT02186717|Experimental|Chewing gum|Chewing gum
3341202|NCT02186717|No Intervention|No Chewing Gum|No Chewing Gum
3341203|NCT02186730|Experimental|Stressbsuters|"Computerised Cognitive Behaviour package consisting of eight 30-45 minute sessions of CBT designed for 12-18 year olds. Each Stressbusters session is an interactive presentation featuring narration synchronised with videos, animations, graphics and printouts.~The programme has a narrator guiding individuals through each of the eight sessions in a linear progression. Each session builds on the knowledge gained in previous sessions and on tasks carried out at home. Sessions contain flexible add-ons such as written fact sheets (for example about bullying, sleep problems) which can be printed out and taken away together with home practice related handouts from the programme (for example mood diary sheets). Session topics include getting activated, relapse prevention, challenging negative thoughts and problem solving"
3341204|NCT02186730|Active Comparator|Websites|Any individuals randomised to arm 2 of the trial will spend the equivalent time accessing currently available self help websites that provide information about low mood/depression. These four websites will be the same as those used in our initial feasibility study of which, based on our preliminary data, there is evidence for their usefulness.
3341205|NCT02186743|Experimental|Intervention Diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
3341206|NCT02186743|Active Comparator|Active control diet|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
3341207|NCT02186756|Experimental|EMG-Biofeedback and Usual Care|"Patients in the intervention group started EMG-biofeedback training within three days after inclusion. In total 14 sessions of EMG-biofeedback training were applied. They started with three sessions of therapy in week 1-3 and had one session per week in week 4-8.~Patients were encouraged to do a home exercise program, in which they consciously relaxed the muscle analogously to the biofeedback session for about 15 minutes per day. Additionally, they should try to apply the techniques in stressful situations, for example appointments at the dentist's."
3237688|NCT01263080|Active Comparator|mirtazapine+folic acid placebo|mirtazapine 30mg QD, folic acid placebo 1 tablet QD
3237689|NCT01263080|Active Comparator|mirtazapine placebo+folic acid|mirtazapine placebo 1 tablet QD, folic acid 0.4mg QD
3341208|NCT02186756|No Intervention|Usual care|The patients in the control group had only two encounters with the therapist in the eight week interval. At these encounters pain was assessed by a visual analogue scale and their trapezius muscle activity was measured during 5 minutes analogously to the intervention group. However, afterwards they did not continue with muscle straining and relaxation.
3341209|NCT02186769|Active Comparator|Risperdal® Consta®|25 Mg or 50 mg
3341210|NCT02186769|Experimental|L03004|25 mg or 50 mg
3341211|NCT02186782|Active Comparator|Clomiphene citrate-Estradiol group|Women will receive clomiphene citrate and estradiol
3341212|NCT02186782|Active Comparator|Clomiphene citrate group|Women will receive clomiphene citrate and placebo
3237690|NCT01263080|Placebo Comparator|mirtazapine placebo+folic acid placebo|mirtazapine placebo 1 tablet QD, folic acid placebo 1 tablet QD
3237691|NCT01263145|Experimental|Treatment (Akt inhibitor MK2206 and paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and Akt inhibitor MK2206 PO QD on days 2, 9, and 16. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3237692|NCT01263158|Experimental|Expectant group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Expectancy of standard oxytocin treatment for 3 hours.
3237693|NCT01263158|No Intervention|Early oxytocin group|Arrest in labour progress for 2-3 hours and no progress after amniotomy. Oxytocin treatment started within 20 minutes.
3237694|NCT01263171|Other|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy prior to short course pre-operative radiotherapy followed by adjuvant chemotherapy.
3341213|NCT02186860|Experimental|CAR-T cells|Targeting CD19
3341214|NCT02186886|Other|Golimumab|Golimumab: Patients with body weight less than 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 50 mg every 4 weeks, thereafter // Patients with body weight greater than or equal to 80 kg initial dose of 200 mg, followed by 100 mg at week 2, then 100 mg every 4 weeks, thereafter
3341215|NCT02186899|Active Comparator|General Anesthesia Femoral continuous|General anesthesia plus continuous femoral nerve block
3237695|NCT01263184||sportive wheelchair users|
3237696|NCT01263184||sportive non disabled|
3341216|NCT02186899|Active Comparator|General anesthesia Femoral bolus|General anesthesia plus single shot femoral nerve block
3341217|NCT02186899|Active Comparator|Femoral Sciatic Obturator Nerve block|Ultrasound guided femoral plus sciatic plus obturator nerve block
3341218|NCT02186912|Experimental|mandible|Nobel Active Nobel Procera IBO
3341219|NCT02186912|Experimental|maxilla|Nobel Active Nobel Procera IBO
3341220|NCT02186925||Bladder, Kidney and Prostate Cancer Patients|
3237697|NCT01263184||non sportive wheelchair users|
3237698|NCT01263210|Active Comparator|Pneumococcal vaccine|Half of the children were randomized to receive heptavalent pneumococcal conjugate vaccine (before this vaccine was included in the national immunization programme).
3237699|NCT01263210|No Intervention|Control|Half of the children were randomized to no vaccination and functioned as controls.
3237700|NCT01263236|Experimental|LY2940094 - single dose|Single oral dose of 2-800 milligram (mg) LY2940094
3237701|NCT01263236|Experimental|LY2940094 - multiple dose|Daily oral dose of 2-200 mg LY2940094 for 14 days
3237702|NCT01263236|Experimental|Placebo|Single oral dose or daily oral dose for 14 days
3237703|NCT01263249|Active Comparator|Catheter Anterior to Femoral Nerve|Each subject will have one lower extremity (Right or Left) randomized to receive a perinural catheter, placed anterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
3237704|NCT01263249|Active Comparator|Catheter Posterior to Femoral Nerve|Each subject will have the opposite lower extremity (Right or Left) randomized to receive a perinural catheter, placed posterior to the femoral nerve, with a continuous infusion of local anesthetic and then the outcomes will be measured.
3341221|NCT02186951|Experimental|Amoxicillin clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
3341222|NCT02186951|Placebo Comparator|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
3341223|NCT02186964|Experimental|tension free primary closure|patients treated by tension free primary closure
3341224|NCT02186964|Experimental|karydakis|patients treated by Karydakis method
3237705|NCT01263275|Experimental|Active tDCS|
3237706|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 400 IU|
3237707|NCT01263288|Active Comparator|Vitamin D3 (cholecalciferol) 1000 IU|
3237708|NCT01263288|Placebo Comparator|Placebo|
3341225|NCT02186964|Experimental|Limberg flap|patients treated by Limberg flap procedure
3341226|NCT02186977|Active Comparator|Intramuscular group|These subjects will receive one intramuscular injection of 1.0cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur-MSD) with syringe and needle in the deltoid region.
3341227|NCT02186977|Experimental|Intradermal group (Mantoux)|These subjects will receive one intradermal injection with mantoux technique in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur-MSD) will be injected.
3341228|NCT02186977|Experimental|Intradermal group (VAX-ID) A|These subjects will receive one intradermal injection with the newly developed intradermal injection device VAX-ID in the forearm. 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
3341229|NCT02186977|Experimental|Intradermal group (VAX-ID) B|These subjects will receive two intradermal injections with two newly developed intradermal injection devices VAX-ID in both forearms each 0.1cc of HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) will be injected.
3237709|NCT01263327|Experimental|HPV 16/18|Participants in this arm would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
3341230|NCT02186990|Active Comparator|propofol|
3341231|NCT02186990|Active Comparator|etomidate|
3237710|NCT01263340||People with COPD|
3237711|NCT01263353|Experimental|Functional tumors, pre-treated|
3237712|NCT01263353|Experimental|Functional tumors, treatment naïve|
3237713|NCT01263353|Experimental|Nonfunctional tumors, pretreated 1|
3341232|NCT02186990|Active Comparator|propofol-etomidate|
3341233|NCT02187003|Experimental|Rivipansel Treatment Arm|
3237714|NCT01263353|Experimental|Nonfunctional tumors, pretreated 2|
3237715|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 1|
3237716|NCT01263353|Experimental|Nonfunctional tumors, treatment-naïve 2|
3237717|NCT01263366|Experimental|Norepinephrine|
3341234|NCT02187003|Placebo Comparator|Placebo Treatment Arm|
3341235|NCT02187068|Experimental|Dexmedetomidine obese 1|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3341236|NCT02187068|Experimental|Dexmedetomidine obese 2|10 obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3341237|NCT02187068|Experimental|Dexmedetomidine non-obese 1|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.25 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3341238|NCT02187068|Experimental|Dexmedetomidine non obese 2|10 non-obese patients scheduled for elective laparoscopic surgery were given dexmedetomidine dexmedetomidine 0.5 μg.kg-1 iv over 10 minutes and then dexmedetomidine 0.5 mcg.kg-1.h-1 for approximate 2 h (range 58-320 min). Blood samples were taken at 2, 5, 10, 15, 20, 30, 45, 60, 90, 120 min after beginning dexmedetomidine administration, and at 0, 2, 5, 10, 20, 30, 60, 90, 120, 240 and 360 min after stopping infusion.
3341239|NCT02187081|Experimental|Sorafenib+RFA|We give radiofrequency ablation plus Sorafenib for the treatment of HCC
3341240|NCT02187081|Active Comparator|RFA alone|We give Radiofrequency ablation alone for the treatment of HCC
3341241|NCT02187094|Placebo Comparator|Placebo|One capsule of placebo administered as a single dose.
3341242|NCT02187094|Experimental|2 mg TC-6499|One capsule of 2 mg TC-6499 administered as a single dose.
3341243|NCT02187094|Experimental|5 mg TC-6499|One capsule of 5 mg TC-6499 administered as a single dose.
3341244|NCT02187094|Experimental|10 mg TC-6499|One capsule of 10 mg TC-6499 administered as a single dose.
3341245|NCT02187107|Experimental|TMC114 + rtv|Every participant recieves 2 tablets of TMC114, 300 mg, combined with one tablet of rtv (ritonavir), 100mg, orally twice daily, every 12 hours
3237718|NCT01263379|Experimental|LEAES treatment|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)
3237719|NCT01263392|Active Comparator|Polyvinyl Chloride Catheter|Re-use clean polyvinyl chloride catheters for intermittent catheterization of children with spina bifida.
3237720|NCT01263392|Active Comparator|Hydrophilic catheter|Use hydrophilic catheters (Speedicath) for intermittent catheterization of children with spina bifida.
3237721|NCT01263405||Normal|normal volunteers without sarcoma
3237722|NCT01263405||Sarcoma|Sarcoma
3237723|NCT01263418|Experimental|Ofatumumab|
3237724|NCT01263431|Active Comparator|Hemorrhoidectomy|Excision of hemorrhoid cushions
3237725|NCT01263431|Experimental|Hemorrhoidal dearterialization|Ligation of therminbal branches oh hemorrhoid arteries
3237726|NCT01263522|Experimental|Endurance training|
3237727|NCT01263522|Experimental|interval training|
3341246|NCT02187120|Experimental|Tranexamic Acid|"As soon as possible after injury, emergency medical services clinicians will administer 1g Tranexamic Acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) delivered intravenously using a slow push of the syringe.~As soon as possible after the patient arrives at hospital, clinicians will administer 1g Tranexamic acid (10ml ampoule containing 100mg/ml Tranexamic Acid in water for injection) added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
3341247|NCT02187120|Placebo Comparator|Placebo|"As soon as possible after injury, emergency medical services clinicians will administer a 10ml ampoule containing 0.9%w/v Sodium Chloride via intravenous injection using a slow push of the syringe (ampoules containing Sodium Chloride appear identical to the ampoules containing Tranexamic Acid).~As soon as possible after the patient arrives at hospital, clinicians will administer a second 10 ml ampoule containing 0.9%w/v Sodium Chloride added to up to one litre 0.9%w/v Sodium Chloride and the entire volume infused intravenously over 8 hours."
3341248|NCT02187133|Experimental|Treatment|Patients receive carfilzomib IV over 30 minutes twice weekly on days 1, 2, 8, 9, 15, and 16 or weekly on days 2, 9, and 16; bendamustine hydrochloride IV over 60 minutes on days 1 and 2; and rituximab IV over 30-90 minutes on day 9 (course 1 only) and day 1 (subsequent courses). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3341249|NCT02187146||ART population|Patients undergoing IVF/ICSI/FET treatment at the Birmingham Womens Fertility Centre 2013-2014
3341250|NCT02187185|Active Comparator|Sonicare Elite-Flexcare|Arm 1 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the Sonicare/Elite/Flexcare toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
3341251|NCT02187185|Active Comparator|Manual Toothbrush|Arm 2 participants will abstain from brushing and flossing teeth in selected sites which will typically be one maxillary and mandibular posterior sextant during a three week, no-hygiene phase via placement of acrylic stents. After the stent-induced biofilm overgrowth (SIBO) induction, the resolution phase of the study will involve a randomization that places half of the subjects on the manual toothbrush. Thus, the resolution phase is a RCT designed to treat SIBO in subjects with varying levels of disease. Participants will reinstate normal full mouth oral hygiene and daily plaque control, exclusive of flossing, with dispensed dentifrice and toothbrush. Participants will be followed for four weeks during SIBO resolution.
3341252|NCT02187198|Experimental|Buprenorphine low dose|Participants in this arm will receive a low dose (less than or equal to 8/2mg) of buprenorphine for 12 weeks.
3341253|NCT02187198|Experimental|Buprenorphine high dose|Participants in this arm will receive a high dose (16-24mg) of buprenorphine for 12 weeks.
3341254|NCT02187211|Experimental|Minocycline Low Dose|Participants in this arm will receive a low dose (200mg/day) of Minocycline for 10 days
3341255|NCT02187211|Experimental|Minocycline High Dose|Participants in this arm will receive a high dose (400mg/day) of Minocycline for 10 days
3341256|NCT02187211|Placebo Comparator|Placebo|Participants in this arm will receive the Placebo for 10 days
3341257|NCT02187224|Experimental|Progesterone|For the three days prior to each test day every participant in this arm will receive progesterone.
3341258|NCT02187224|Placebo Comparator|Placebo|For the three days prior to each test day every participant in this arm will receive placebo.
3341259|NCT02187237|Experimental|Laser therapy|
3341260|NCT02187250|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
3341261|NCT02187250|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
3341262|NCT02187250|Active Comparator|roflumilast|In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.
3341263|NCT02187263||hereditary DCM|
3341264|NCT02187263||inflammatory DCM|
3341265|NCT02187263||LVNC|
3341266|NCT02187263||HCM|
3341267|NCT02187263||ARVC|
3341268|NCT02187263||acute myocarditis|
3341269|NCT02187276||Alzheimer disease or mixed dementia|Patients were evaluated four times. In the first consultation, without taking cholinesterase inhibitors (ChEI), after three, six and 12 months taking ChEI.
3341270|NCT02187289|Active Comparator|Standard care|Weeks 1-12, Standard Care only (Compression Sleeve, daytime wear)
3341271|NCT02187289|Experimental|Standard Care plus Night-time Compression Bandages|Weeks 1 - 12, Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered Compression Bandages.
3341272|NCT02187289|Experimental|Standard Care Plus Night-time Compression System Garment|Weeks 1 - 12, Standard care (day-time sleeve) plus night-time use of a custom-made Night-time Compression System Garment
3341273|NCT02187302|Experimental|CRLX101 + bevacizumab|"CRLX101 in combination with bevacizumab:~CRLX101 15 mg/m^2 IV on days 1 and 15 of a 28-day cycle;~bevacizumab 10 mg/kg IV on days 1 and 15 of a 28-day cycle."
3341274|NCT02187302|Active Comparator|Standard of Care|Standard of care treatment include one of the following agents to which the patient can have no prior exposure: sorafenib; everolimus; pazopanib; axitinib; bevacizumab; sunitinib, or other approved drug considered by the Medical Monitor to represent an acceptable standard of care therapy
3341275|NCT02187315|Experimental|Melodie group|Induction chemotherapy followed by cisplatin chrono-chemotherapy concurrent combined with intensity-modulated radiation therapy
3341276|NCT02187315|Other|Routine-chemotherapy group|Induction chemotherapy followed by cisplatin routine-chemotherapy concurrent combined with intensity-modulated radiation therapy
3341277|NCT02187328|Experimental|Grapefruit juice|12.5 OZ Grapefruit juice: Subject will ingest grapefruit juice 12.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon prior to their evening visit
3341278|NCT02187328|Placebo Comparator|Apple juice|10.5 OZ Apple juice: Subject will ingest apple juice 10.5 OZ twice on the day of their scheduled laboratory visit. Once in the morning and once in the afternoon 3 hours prior to their evening visit.
3341279|NCT02187341|Experimental|5-HTP|200 mg 5-HTP capsule will be ingested 2h prior to reporting to the laboratory.
3341280|NCT02187341|Placebo Comparator|Placebo|For these visit subjects will ingest placebo (Sugar pill) capsule 2 hours before reporting to the laboratory.
3341281|NCT02187367|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
3341282|NCT02187367|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
3237728|NCT01263522|Experimental|strength endurance training|
3237729|NCT01263522|Placebo Comparator|control|
3341283|NCT02187380||Control group|Pharmacists received no depression training, delivered usual care to patients starting a new treatment with depression.
3341284|NCT02187380||Intervention group|Pharmacists received a depression training day and provided structured medication counselling to patients starting a new treatment with antidepressants
3341285|NCT02187406|No Intervention|Control|
3341286|NCT02187406|Experimental|Traditional ankle athletic taping|Described by Purcell and Schuckman (2009)
3341287|NCT02187406|Experimental|modified ankle athletic taping|Described by Montag and Asmussen (1992)
3341288|NCT02187419|Active Comparator|5 Therapist-Delivered Hypnosis Session|Participants will complete five therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3341289|NCT02187419|Active Comparator|3 Therapist-Delivered Hypnosis Session|Participants will complete three therapist-delivered hypnosis relaxation sessions with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3341290|NCT02187419|Active Comparator|5 Phone Calls; Hypnosis Recordings Only|Participants will complete five phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3237730|NCT01263535|Experimental|SENSIMED Triggerfish|
3237731|NCT01263548||Vyvanse|This is an open-label study which means that all study participants will be taking active study medication, Vyvanse.
3341291|NCT02187419|Active Comparator|3 Phone Calls; Hypnosis Recordings Only|Participants will complete three phone calls with a hypnosis research therapist, and receive five audio (CD or MP3) recordings of hypnotic inductions and instructed in daily home practice.
3341292|NCT02187432||ADPKD|EuroCYST is and observational trail aiming to investigate disease progression across the different stages of disease and stage specific morbidity and mortality factors in a longitudinal observational multi center study and to evaluate the levels of and associations between the impacts of patients reported disease outcome (quality of life (QoL), pain, self-estimated health status, health burden).
3341293|NCT02187445|Experimental|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
3341294|NCT02187484|Experimental|Single rising doses of BIBR 277|
3341295|NCT02187497|Experimental|Low dose of BIBR 277|
3341296|NCT02187497|Experimental|Medium dose of BIBR 277|
3341297|NCT02187497|Experimental|High dose of BIBR 277|
3341298|NCT02187510|Experimental|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
3341299|NCT02187510|Active Comparator|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
3341300|NCT02187523|Experimental|Telmisartan/HCTZ FDC|
3341301|NCT02187523|Active Comparator|Telmisartan and HCTZ individual tablets|
3341302|NCT02187536|Experimental|Telmisartan combined with Simvastatin|Telmisartan once daily (day 1 to day 6) and Simvastatin given once (day 6)
3341303|NCT02187536|Active Comparator|Simvastatin and telmisartan placebo|Telmisartan placebo once daily (day 1 to day 6) and Simvastatin given once (day 6)
3341304|NCT02187549|Experimental|HYMOVIS|HYADD(TM) 4 Hydrogel Intra-Articular Injection
3341305|NCT02187549|Placebo Comparator|Placebo|Saline Intra-Articular Injection
3341306|NCT02187562|Experimental|Meloxicam/Aspirin|Meloxicam days 1-10 / Aspirin days 5-10
3237732|NCT01263574|Placebo Comparator|Heparinized Saline|This group will maintain their central lines patent with heparinized saline.
3237733|NCT01263574|Experimental|Ethanol lock solution group|Administration of the 70% ethanol lock solution will occur between cycles of parenteral nutrition. Randomized lock solutions will be administered three days per week. When patients have completed their parenteral nutrition, their central venous catheters will be flushed with 5mL saline, per current standards
3341307|NCT02187562|Active Comparator|Aspirin|Aspirin 2 days
3341308|NCT02187575|Experimental|UHAC 62 XX tablet|
3341309|NCT02187575|Active Comparator|UHAC 62 XX capsule|
3341310|NCT02187588|Experimental|Eschscholtzia Californica - low dose|
3341311|NCT02187588|Experimental|Eschscholtzia Californica - high dose|
3237734|NCT01263613|Other|Biopsy|biopsy
3237735|NCT01263626||Cough as Primary Complaint|"Male and female volunteers 18 years of age and older~Cough as chief complaint~Referred to the GI clinic to evaluate if reflux is the cause of their chief complaint~pH testing for standard of care purposes"
3341312|NCT02187588|Active Comparator|Ibuprofen|
3237736|NCT01263626||Healthy Volunteers|"Male and female volunteers 18 years of age and older~No history of chronic or acute cough and throat clearing~Ability to read a 5th grade script written in English for approximately 20 minutes"
3237737|NCT01263652|Active Comparator|IMmed|Patients receiving intra-muscular medication and oral placebo
3237738|NCT01263652|Active Comparator|POmed|Patients receiving intra-muscular placebo and oral medication
3237739|NCT01263678|Other|Non-Coaching|Usual care for patients with a diagnosis of spinal stenosis after viewing a DA and completing a survey.
3341313|NCT02187588|Placebo Comparator|Placebo|
3341314|NCT02187601|Experimental|CLD with MPBA and BID|Chronic Liver Disease (CLD) patients of all degrees will be offered to be tested on the MPBA (multi purpose breath analyzer) and BID (BreathID) on a walk- in basis with , proving they meet inclusion/exclusion criteria.
3341315|NCT02187601|Experimental|HV with MPBA and BID|Healthy volunteers (HV) with no known liver disease will undergo the breath test with the MPBA and the BID before and after substrate ingestion.
3341316|NCT02187614|Experimental|Diclofenac and Placebos|Participants in this group will receive a Diclofenac 75 mg intramuscular injection, and two placebo saline solutions intravenously.
3341317|NCT02187614|Active Comparator|Morphine and Placebos|Participants in this group will receive Morphine 0.1 mg/kg intravenously, along with an additional intravenous placebo and an intramuscular placebo injection.
3341318|NCT02187614|Active Comparator|Paracetamol and Placebos|participants in this group will receive intravenous Paracetamol 1 gm solution, along with an additional intravenous placebo and an intramuscular placebo injection.
3341319|NCT02187627|Experimental|Part 1: Tracer Selection|Participants will receive a single dose of one tracer on one occasion and a single dose of a different tracer after 7 to 14 days and will be followed for 7 to 14 days for safety. At the end of Part 1, one tracer with the best performance will be selected for further study in Part 2.
3237740|NCT01263678|Other|Coaching|Patients randomized to coaching group will receive one week post viewing of Decisional Aid.
3341320|NCT02187627|Experimental|Part 2A: Test-Retest|Participants will receive a single dose of selected tracer from Part 1 on one occasion and then same tracer will be administered after 6 weeks. Participants will be followed for 7 to 14 days after last PET tracer administration for safety.
3341321|NCT02187627|Experimental|Part 2B: Dosimetry|Participants will receive a single dose of selected tracer from Part 1 and will be followed for 7 to 14 days for evaluation of radiation dosimetry.
3341322|NCT02187640|Experimental|Self-administered acupressure|A 10-day self-administered acupressure program was implemented by the participants who were adult psychiatric in-patients and randomly assigned into this treatment group. The patients would receive a 3-session training of this therapy conducted by a qualified acupressure therapist and each session lasted about an hour. They would be assessed by the trainer to ensure that they are able to identify the five acupoints and applied a constant and an appropriate pressure on each acupoint before actual implementation.
3341323|NCT02187640|Sham Comparator|Sham control group|Sham control group: Patients would receive 3-session training and be assessed by the trainer. However, they would be trained to locate five non-acupoints adjacent to the actual acupoints and with minimal pressure applied.
3341324|NCT02187653||Lumbar|Patients undergoing lumbar surgery
3237741|NCT01263730|Active Comparator|Tai Chi Training|The active group will be given 12 weeks of tai chi training
3341325|NCT02187653||Cervical|Patients undergoing cervical surgery
3341326|NCT02187666||Lumbar|Patients undergoing lumbar spinal surgery
3341327|NCT02187666||Cervical|Patients undergoing cervical spine surgery
3341328|NCT02187679|Experimental|Abobotulinum toxin A|Abobotulinum toxin A Injection
3341329|NCT02187692|No Intervention|TAU|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
3341330|NCT02187692|Experimental|MCT|Treatment as Usual (TAU) vs meta-cogntive training (MCT) condition will be contrasted. In the TAU patients attend regular day programm that includes psychoeducation, social training, vocational rehabilitation, psychotherapy. The MCT condition is an active condition that includes structuralized therapy modules twice a week for four weeks (eight modules in total). There will be no additional differences in the interventions between two groups. Participants will be randomized from patients from the same population into two conditions.
3341331|NCT02187705||Patients with normotension at baseline|
3237742|NCT01263730|No Intervention|Waitlist control group|There is a waitlist control group that will receive the training following a 12 week no treatment period of time
3341332|NCT02187705||Patients with essential hypertension at baseline|
3237743|NCT01263743|Experimental|This is a single arm study|Relaxation Response training will be given to all participants
3237744|NCT01263756||ASD group|Adolescents and adults with Autism Spectrum Disorders (ASDs).
3341333|NCT02187705||Patients with isolated hypertension at baseline|
3237745|NCT01263769|Experimental|Axitinib|Axitinib Starting dose: 5 mg by mouth twice each day for 12 weeks.
3341334|NCT02187718|Other|SNPGA|Sentinel Node Procedure under General Anaesthesia
3341335|NCT02187718|Other|SNPLA|Sentinel Node Procedure under Local Anaesthesia
3341336|NCT02187757|Experimental|PreLipid|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90days along with lifestyle modification.
3237746|NCT01263808|Experimental|Indacaterol 150 µg|Indacaterol 150 µg
3237747|NCT01263808|Experimental|Indacaterol 300 µg|Indacaterol 300 µg
3237748|NCT01263808|Experimental|Indacaterol 600 µg|Indacaterol 600 µg
3237749|NCT01263808|Placebo Comparator|Placebo|Placebo
3237750|NCT01263808|Active Comparator|Placebo/moxifloxacin|Placebo/moxifloxacin
3341337|NCT02187757|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
3341338|NCT02187796||Normal Cognition|HIV+ individuals with no detectable neurocognitive impairment
3341339|NCT02187796||ANI (asymptomatic neurocognitive impairment)|"HIV+ individuals where impairment involves at least two cognitive domains, and results in neuropsychological testing performance at least 1 Standard Deviation (SD) below the appropriate mean age/education norm for:~Information processing speed~Sensory/motor skills~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities"
3341340|NCT02187796||MCD (Mild Cognitive Disorder)|HIV+ individuals with cognitive impairment same as ANI but patient or caregivers report that cognitive deficit interferes with mental acuity, work efficiency, home making or social activity
3341341|NCT02187796||HAD (HIV-associated dementia)|"HIV+ individuals where impairment involves at least two cognitive domains and results in neuropsychological testing at least 2 SD below the appropriate mean age/education norm for:~Information processing speed~Short-term and long-term memory~Ability to learn new skills and solve problems~Attention, concentration, and distractibility~Logical and abstract reasoning functions~Ability to understand and express language~Visual-spatial organization Visual-motor coordination~Planning, synthesizing and organizing abilities Cognitive impairment significantly interferes with work, home life, social activities or ADL's."
3341342|NCT02187796||Healthy Controls (HIV-)|Our P300 COGNISION apparatus has been used only in subjects over the age of 60, whereas our participants in the HAND study will all be younger than 60. So, we cannot use COGNISION normative data base for comparison. We will add 10 HIV- healthy controls to our planned 40 HIV+ subjects. These HIV- participants will be age- and gender-matched to the HIV- Asymptomatic Neurocognitive Impairment (ANI) patients, and will undergo all the same assessments
3341343|NCT02187822|Experimental|Dose Escalation + Dose Expansion|"Dose Escalation followed by Dose Expansion.~Dose Escalation Phase: The maximum tolerated dose (MTD) for TPI 287 given concurrently with Fractionated Stereotactic Radiotherapy (FSRT) will be determined using the standard 3+3 study design.~Dose Expansion Phase: Participants will be treated with TPI 287 at MTD given concurrently with FSRT to further assess toxicity and tumor response."
3341344|NCT02187835||schizophrenia|patients with a diagnosis of schizohrenia
3341345|NCT02187835||control|healthy control group
3341346|NCT02187848|Experimental|SAR408701 Main Dose Escalation Cohort|Dose escalation administered intravenously, once every two weeks
3341347|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC)|Administered intravenously at the maximum tolerated dose (MTD), once every 2 weeks, to patients with colorectal cancer
3341348|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC|Administered intravenously at the MTD, once every 2 weeks, to patients with carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) expressing non-squamous non-small cell lung cancer (NSCLC) of at least 50% of tumor cells at or above 2+ intensity
3341349|NCT02187848|Experimental|SAR408701 Expansion Cohort gastric adenocarcinoma|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing gastric adenocarcinoma
3341350|NCT02187848|Experimental|SAR408701 Loading Dose Escalation cohorts (Escalation bis)|Loading dose escalation administered intravenously at first cycle, followed by MTD, once every 2 weeks
3341351|NCT02187848|Experimental|SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing non-squamous NSCLC of at least 1% but below 50% of tumor cells at or above 2+ intensity
3341352|NCT02187848|Experimental|SAR408701 Expansion Cohort colorectal cancer (CRC-L)|Loading dose of determined MTD-L administered intravenously at first cycle, followed by MTD, once every 2 weeks
3341353|NCT02187848|Experimental|SAR408701 Expansion Cohort small cell lung cancer (SCLC)|Administered intravenously at the MTD, once every 2 weeks, to patients with CEACAM5 expressing SCLC
3341354|NCT02187848|Experimental|SAR408701 Dose Escalation every 3 weeks cohort|Dose escalation administered intravenously, once every three weeks
3341355|NCT02187874|Active Comparator|early umbilical cord occlusion|Cord clamping will be performed before 30 seconds after delivery, annoting the exact time of clampage and initiating reanimation and postnatal care procedures as usual. 60 second after delivery of the new born, 10 IU of Oxytocin will be administered intramuscularly.
3341356|NCT02187874|Experimental|delayed umbilical cord occlusion|"One of the paediatricians will hold the newborn ( in vaginal deliveries between 20-30 cm under the mother, in C-sections between the legs of the mother) until clamping of the umbilical cord is indicated by a second paediatrician who will be controlling the time and overall state of the baby. The baby will be wrapped during this time in a thermal blanket in a flexed lateral decubitus position to minimise stress and heat loss. Time of clamping: after 30 to 60 seconds( preferably 60). If loss of the baby's wellbeing is suspected, the paediatrician will assess the newborn's heart rate , stopping the procedureif this falls under 100ppm, initiating at that moment the necessary reanimation procedures.~60 second after the delivery of the new born 10 IU of oxytocin will be administered intramuscularly."
3341357|NCT02187900|Experimental|TWH for the treatment of IgAN|Interventions :The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
3341358|NCT02187900|Active Comparator|MMF for IgAN|MMF for the treatment of IgAN for 6 months
3341359|NCT02187913|Experimental|Resistant starch|The test snack bar consumed has the resistant starch
3341360|NCT02187913|Experimental|Control|The control bar uses maltodextrin rather than the resistant starch.
3341361|NCT02187926||Roflumilast|Roflumilast will be administered according to the prescribing information of the approved label in Greece.
3341362|NCT02187939|Active Comparator|Summer wellness program - nutrition & physical activity|The GROOVE condition uses conventional means to address health-related activities and content within the context of a science museum summer enrichment program. The emphasis is on nutrition, physical activity, and healthy lifestyle.
3341363|NCT02187939|Experimental|Summer program plus virtual world technology|The GROOVE+ condition enhances the conventional approach to address health-related activities and content within the context of a science museum summer enrichment program by employing technology and a 3-D virtual world as a key educational strategy. The emphasis is on nutrition, physical activity, and healthy lifestyle.
3341364|NCT02187952|Experimental|Behavioral feeding intervention|Behavioral feeding intervention will be conducted as usual. The intervention will not be altered for purposes of the study.
3341365|NCT02187952|No Intervention|Waitlist control|
3341366|NCT02187978|Experimental|Early total enteral feeding (ETEF)|"Feeding will be initiated on D1 with 80ml/kg/day of expressed breast milk or LBW formula milk.~No intravenous fluid will be provided. Feeds will be advanced till 150ml/kg/day is attained."
3341367|NCT02187978|Active Comparator|Conventional enteral feeding (CEF)|"Feeding will be initiated on D1of life with 20ml/kg of expressed breast milk or LBW formula milk.~Remaining requirement as intravenous fluids. Feeds advanced by 20ml/kg/day for next 2 days and then 30ml/kg/day for the next three days until 150ml/kg/day is reached."
3341372|NCT02188017|Active Comparator|80 units|80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading
3341373|NCT02188017|Active Comparator|40 units|40 units of ACTHAR gel will be given twice a week for 22 weeks after loading
3341374|NCT02188030|Active Comparator|Group Exercise Training (GET).|Group Exercise Program. The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum 12. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
3341375|NCT02188030|Active Comparator|Individual Exercise Training|Individual Exercise Program. The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al. and Sundstrup et al . During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session.
3341376|NCT02188043|Other|Relay Model|"AUDIT score 8+: Brief Motivational Intervention with alcohol therapist. AUDITscore16+:Brief Motivational Intervention and appointment at Alcohol Treatment Clinic~-"
3341377|NCT02188043|No Intervention|Usual Referral Procedure|Hospital staff refer patient to Alcohol Treatment Clinic according to usual procedure
3341378|NCT02188082|Experimental|IvabRadine hemisulfate Sustained-release Tablets|5-15mg qd
3341379|NCT02188082|Placebo Comparator|placebo|5-15mg qd
3341380|NCT02188095||Excia T®|
3341381|NCT02188121|Experimental|Statin and/or Angiotensin Receptor Blocker|Simvastatin 20mg PO daily and/or Losartan 25mg PO daily
3341382|NCT02188121|No Intervention|Usual treatment|"We will compare the initial treatment intervention with usual treatment (control arm), with both arms superimposed on a system of regular monitoring base. The investigators will make no effort to alter or influence treatment or use of that treatment for subjects in the control arm. Note that our goal in the Control arm is to characterize usual treatment. We will not intervene in this care except in emergencies. Some patients who need care for metabolic syndrome may not be receiving it - just as they would if not in our trial."
3341383|NCT02188134||65 and older|No intervention will be administered
3341384|NCT02188147|Experimental|SWD 1000|Short Term Wearable Defibrillator
3341385|NCT02188173||dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
3237751|NCT01263821|Experimental|Arm I|Patients undergo magnetic resonance spectroscopic imaging, functional magnetic resonance imaging (MRI), diffusion-weighted MRI, and perfusion-weighted MRI. Patients then undergo maximum surgical resection followed by intensity-modulated radiation therapy (IMRT) 5 days a week for 6 weeks.
3237752|NCT01263834|Active Comparator|Mitomycin c|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
3237753|NCT01263834|Experimental|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
3237754|NCT01263847|Placebo Comparator|No Galactooligosaccharide|0 g galactooligosaccharide added to calcium-containing yogurt beverage
3237755|NCT01263847|Active Comparator|5 g Galactooligosaccharide|5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
3341386|NCT02188186|Active Comparator|Conventional treatment|"Initial dual combination therapy with sulfonylurea and metfomin. Dose of sulfonylurea (glimepride 2-8 mg) and metfomin (500-2550 mg) can be ecalated at investigator's discreition at every visit.~Insulin therpy can be added as a rescue therapy at investigator's discreition."
3341387|NCT02188186|Experimental|Initial triple combination treatment|"Initial dual combination therapy with metformin, sitagliptin (Januvia 100 mg), and lobeglitazone (Duvie 0.5 mg).~Insulin therpy can be added as a rescue therapy at investigator's discreition."
3341388|NCT02188199||Knee Replacement|Patients undergoing knee replacement surgery
3341389|NCT02188199||Hip Replacement|Patients undergoing hip replacement
3341390|NCT02188212|Other|NobelProcera Crown Shaded Zirconia|NobelProcera Crown Shaded Zirconia molar
3341391|NCT02188225|Experimental|Acupuncture|12 sessions of acupuncture / 3 sessions weekly/ 20 minutes each session
3341392|NCT02188225|Active Comparator|fluoxetine|10 mg daily
3341393|NCT02188238||Saliva Sample Collection|Collection of stimulated whole mouth saliva . Whole mouth saliva is collected through stimulation by inert gum, and collecting saliva in a sterile tube.
3341394|NCT02188251|Experimental|Activamp|Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks
3237756|NCT01263847|Active Comparator|10 g Galactooligosaccharide|10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
3237757|NCT01263860|Experimental|24-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
3237758|NCT01263860|Active Comparator|48-Week treatment group|Genotype 6 chronic hepatitis C patients with rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
3341395|NCT02188251|Placebo Comparator|Placebo|1 capsule taken twice daily for 12 weeks
3341396|NCT02188264|Experimental|Treatment (selumetinib and cyclosporine)|Patients receive selumetinib PO BID on day -7 of course 1 and then on days 1-28 (one dose on day 1 only). Patients also receive cyclosporine PO BID on day -3 of course 1 and then on days 1-28 (one dose on day 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3341397|NCT02188277|Experimental|Xeomin®|4-8 Units per kg body weight. Single injection cycle.
3237759|NCT01263886|Experimental|AVE8062 and combination|"Day 1: AVE8062~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
3237760|NCT01263886|Placebo Comparator|Placebo|"Day 1: placebo~Day 2: docetaxel followed by cisplatin or paclitaxel followed by carboplatin"
3237761|NCT01263899|Experimental|SB1518|
3237762|NCT01263912|Active Comparator|LCPUFA Supplement|DHA/ARA supplement providing 200 mg/day docosahexaenoic acid (DHA) from DHASCO®-S oil and 200 mg/day arachidonic acid (ARA) from ARASCO® oil (DSM Nutritional Products).
3341398|NCT02188277|Active Comparator|Botox®|4-6(8) Units per kg body weight. Single injection cycle.
3341399|NCT02188290||HAPLO group|Control group of all eligible patients who received an HSCT from a haploidentical donor without ATIR administration between 1 January 2006 and 30 June 2013
3341400|NCT02188290||MUD group|Control group of eligible patients who received an HSCT from a fully matched unrelated donor between 1 January 2010 and 31 December 2012
3341401|NCT02188290||MMUD group|Control group of eligible patients who received an HSCT from a 1-locus mismatched unrelated donor between 1 January 2010 and 31 December 2012
3341402|NCT02188290||UCB group|Control group of eligible patients who received a double umbilical cord blood transplantation between 1 January 2010 and 31 December 2012
3341403|NCT02188316|Active Comparator|Jumbo forceps polypectomy|89 patients were randomized to jumbo forceps arm and 120 diminutive colorectal polyps were removed by jumbo forceps polypectomy.
3341404|NCT02188316|Active Comparator|Hot biopsy electrocauterization|90 patients were randomized to hot biopsy forceps arm and 117 diminutive colorectal polyps were removed by hot biopsy electrocauterization.
3341405|NCT02188329||Households with children under 13|Interviews were conducted with the parent or guardian of a child or children under age 13.
3341406|NCT02188329||Home-based providers|Individuals who provide care in a home-based setting to children under age 13 who are not their own.
3341407|NCT02188329||Center-based providers|Directors of early care and education programs that provide care to children not yet in kindergarten.
3341408|NCT02188329||Center-based workforce|Classroom-assigned instructional staff sampled from each center-based provider who completed an interview.
3341409|NCT02188342|Experimental|HIT exercise training|
3341410|NCT02188368|Experimental|A: POM 4mg+Steroids+(CFZ, BTZ, CY or CLA)|"POM 4 mg PO days 1-21 Steroids at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~BTZ (bortezomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CFZ (carfilzomib) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CLA (clarithromycin) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~CY (cyclophosphamide) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
3341411|NCT02188368|Experimental|B: POM 3mg+PLD with or without steroids|"POM 3 mg PO days 1-21 Steroids (if the patient had received them) at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject).~PLD at the same dose and on the same days as the patient's lenalidomide-containing treatment (it varies for each subject)."
3341412|NCT02188368|Experimental|C: POM MTD + other drugs|"Phase 1:~POM at escalating doses of 2 mg (Cycle 1), 3 mg (Cycle 2) or 4 mg (Cycle 3+) All other agents at the same dose and on the same days as the patients were receiving them in the lenalidomide-containing regimen they had failed~Phase 2:~POM at the MTD All other agents, at the same dose and on the same days as phase 1"
3341413|NCT02188381||Normal controls without hypertension|Control subjects will have a systolic BP <140mmHg with no cardiovascular disease. These subjects will provide a one time stool sample and a blood sample.
3341414|NCT02188381||Controlled hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
3341415|NCT02188381||Resistant hypertension|Resistant hypertension subjects will have systolic blood pressure (BP) ≥140 mmHg despite ≥3 anti-hypertensive medications of different classes. These subjects will provide a one time stool sample and a blood sample.
3341416|NCT02188381||Prior enrolled in NCT 02133872|These subject will be asked to provide two stool samples and two blood samples. One at baseline and one after 3 months of therapy.
3341417|NCT02188381||Remodeled Resistent Hypertension|Subjects with controlled hypertension will provide a one time stool sample and a blood sample.
3341418|NCT02188394|Experimental|Anesthetic blockades with bupivacaine|Patients will receive a bilateral greater occipital nerve blockade with bupivacaine 0,5%
3237763|NCT01263912|Placebo Comparator|A Placebo|400 mg/day corn oil
3341419|NCT02188394|Placebo Comparator|Isotonic saline injection|Patients will receive a bilateral occipital injection with isotonic saline
3237764|NCT01263951|Experimental|Everolimus and sorafenib|All patients will receive everolimus and sorafenib daily.
3237765|NCT01263964||stroke, troponin elevation|Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
3237766|NCT01263964||non-stemi (controll group)|Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
3237767|NCT01263977|Experimental|Thermodilution controlled volume management|Volume management based on parameters: GEDI, ELWI, CI
3237768|NCT01263977|Active Comparator|Volume management based on surviving sepsis campaign|volume management based on surviving sepsis campaign guidelines: CVP, Urin output, MAP, ScvO2
3237769|NCT01263990|No Intervention|Nexfin|Nexfin is used in all patients
3237770|NCT01264003|Active Comparator|1|Antibiotic prohylaxis / Lichtenstein repair
3237771|NCT01264029|Experimental|Group A|Movement meditation for 2 hours
3237772|NCT01264029|Active Comparator|Group B|Non-moving sitting meditation for 2 hours
3237773|NCT01264029|Active Comparator|Group C|Mall Walking for 2 hours
3341420|NCT02188407|Experimental|Sevoflurane|Sevoflurane group (S group)- The group anaesthesied with sevoflurane
3341421|NCT02188407|Active Comparator|Propofol|Propofol 4-6 mg/kg/h iv
3341422|NCT02188420|Experimental|Latency minus 3ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 3ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3341423|NCT02188420|Experimental|Latency minus 5ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 5ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3341424|NCT02188420|Experimental|Latency minus 7ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency - 7ms) where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3341425|NCT02188420|Active Comparator|Latency plus 100ms|"Transcranial Magnetic Stimulation will be applied to the primary motor cortex at the interstimulus interval of (Latency + 100ms), known to have no effect, where latency refers to the amount of time for the arrival of a sensory evoked potential as determined by EEG."
3341426|NCT02188433|Experimental|Cut down to quit (CDTQ)|"For those subjects who claim that they cannot quit smoking ≤7 days, they will receive a leaflet (i.e. include a roadmap of smoking reduction strategy) plus a brief intervention using the AWARD model: (a) Ask about smoking history, (b) Warn about the high risk, (c) Advise to quit as quitting can greatly reduce risks, and participants will be advised to cut down cigarette consumption at their own pace, but the process should not exceed 3 months. (d) Refer smokers to a smoking cessation clinic, and (e) Do it again: repeat the intervention and encourage smokers who fail to quit or relapse to reduce again during each telephone follow-up.~For the subjects have intention to quit smoking ≤7 days, the investigator will follow-up them after a week. For those who report quitted, they will be followed up as other participants. However, if they report failed to quit, they will receive the same interventions and will be followed-up as other participants in the experimental group."
3341427|NCT02188433|Active Comparator|Quit Immediately (QI)|QI group subjects will receive a smoking cessation booklet (provided by COSH) plus brief intervention using AWARD model similar to CDTQ group. For the subsequent telephone follow-up repeat the health warning that 'one in two smokers will be killed by smoking' and encourage smokers who fail to quit or relapse to try again.
3341428|NCT02188446|Experimental|Smoking and alcohol cessation education|
3341429|NCT02188446|No Intervention|Standard treatment|Standard treatment is information about benefits of stopping drinking and smoking before surgery and if wanted, advice about who to contact to get support.
3341430|NCT02188472|Active Comparator|Penicillin V|Penicillin V 2 tablets of 330 mg twice dayly for 7 days
3237774|NCT01264029|Active Comparator|Group D|Weekly Discussion
3237775|NCT01264042|Experimental|FeSo4|
3237777|NCT01264068|No Intervention|Insomnia control|
3237778|NCT01264068|Experimental|Suan Tsao Jen Tang|
3341431|NCT02188472|Active Comparator|Trimethoprim|2 Tablet Trimethoprim of 100 mg twice daily for 7 days
3341432|NCT02188472|Placebo Comparator|Placebo|2 Placebo Tablets twice daily for 7 days
3341433|NCT02188498||Polysomnography with Holter monitoring|Patients will undergo resting electrocardiogram (ECG) test at the beginning of the night and be monitored by a Holter device for the duration of the sleep study.
3237779|NCT01264068|Experimental|Jia-Wey Shiau-Yau San|
3237780|NCT01264120|Experimental|Health Psychology Intervention|A 50 minute health psychology behavioural intervention with sessions pre-surgery, post-surgery and at 3 month follow up.
3341434|NCT02188511|Experimental|Group A|Electronic cigarette (nicotine/placebo) - Day 8 Intervention: Electronic cigarette exposure will be limited to one day.
3341435|NCT02188511|Experimental|Group B|Electronic cigarette (nicotine/placebo) - Days 7 through 8 Electronic cigarette exposure will be limited to two days
3341436|NCT02188511|Experimental|Group C|Electronic cigarette (nicotine/placebo) - Days 6 through 8 Electronic cigarette exposure will be limited to 3 days
3341437|NCT02188511|Experimental|Group D|Electronic cigarette (nicotine/placebo) - Days 5 through 8 Electronic cigarette exposure will be limited to 4 days
3341438|NCT02188511|Experimental|Group E|Electronic cigarette (nicotine/placebo) - Days 4 through 8 Electronic cigarette exposure will be limited to 5 days.
3341439|NCT02188524|No Intervention|Control Group|No exercise program
3341440|NCT02188524|Experimental|Exercise Group|exercise program
3341441|NCT02188537|Experimental|Nelfinavir, Bortezomib, Dexamethasone|"The trial is designed as an add-on therapy, where nelfinavir is added to the approved bortezomib-containing therapy. Bortezomib and dexamethasone background treatment will be given in the Swissmedic-approved dose and schedule and according to international therapeutic standard."
3237781|NCT01264120|No Intervention|Control Group|The control group receive usual care through the bariatric surgery process.
3341442|NCT02188550|Experimental|Single|This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
3237782|NCT01264146|Active Comparator|calcaneal plating HBOT|Open reduction and internal fixation of calcaneal fracture + HBOT
3237783|NCT01264146|Placebo Comparator|calcaneal plating|Open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
3237784|NCT01264159|Placebo Comparator|Control|
3341443|NCT02188563|Experimental|Comprehensive intervention|New evidence-based comprehensive smoking cessation intervention including several elements that have proven successful in non-cancer patients but not used for cancer patients before.
3341444|NCT02188563|Active Comparator|Enhanced usual care|Intervention consistent with the U.S. Department of Health and Human Services guidelines for tobacco treatment.
3341445|NCT02188602||High Chloride Dose|Patients receiving high dosing of chloride
3341446|NCT02188602||Low Chloride Dose|Patients receiving low dosing of chloride
3341447|NCT02188615|Experimental|experimental group|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
3341448|NCT02188615|Active Comparator|Radical Chemoradiotherapy|only Radical Chemoradiotherapy
3341449|NCT02188615|Active Comparator|Mckeown MIE|only Mckeown MIE
3341450|NCT02188628|Experimental|H-Man|H-Man is a novel, portable, inexpensive end-effector upper limb robot.
3237785|NCT01264159|Active Comparator|Lung impedence-guided treatment|
3237786|NCT01264172|Active Comparator|PCCP, Proximal femur fracture|Patients, who received a minimal-invasive surgical treatment with the PCCP-plate
3237787|NCT01264172|Active Comparator|Osteosythesis with nails, prox. femur frac.|Patients, who received a minimal-invasive surgical treatment including a osteosynthesis with nails
3237788|NCT01264172|Active Comparator|DHS, proximal femur fracture|Patients, who received a conventional surgical treatment with the dynamic hip screw (DHS)
3341451|NCT02188628|Active Comparator|Additional Conventional Therapy|Repetitive goals based arm therapy
3237789|NCT01264185||Asia--Thailand; S. America--Brazil|
3237790|NCT01264185||Africa--Zambia|
3237791|NCT01264198|Sham Comparator|Stretching Exercises|The patients will perform twice weekly home based static stretching workout.
3237792|NCT01264198|Experimental|Resistance Training|The patients will perform twice weekly supervised RT for 3 months
3341452|NCT02188641|Other|Diet|Low-fat diet
3341453|NCT02188641|Other|Exercise|3-day/week exercise programme
3341454|NCT02188641|Other|Diet and exercise|healthy low fat diet and 3day/week exercise programme
3341455|NCT02188641|Other|Healthy lifestyle (Control) group|Control group was provided with health education using videotaped presentation
3341456|NCT02188654|Experimental|Metformin|500 mg metformin
3341457|NCT02188654|Placebo Comparator|Placebo|500 mg of placebo tablets
3341458|NCT02188667|Active Comparator|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
3237793|NCT01264211|Experimental|Diacerein|
3341459|NCT02188667|Sham Comparator|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
3237794|NCT01264211|Placebo Comparator|Placebo|
3237795|NCT01264224|Experimental|PAC-14028|
3237796|NCT01264237|Experimental|Etoricoxib|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib. Patients who experience at least a 30% reduction in pain intensity will be randomized to either continued treatment with etoricoxib 90 mg qd or matching placebo (at a 1:1 ratio) for 4 weeks.
3341460|NCT02188680|Active Comparator|Low FODMAPS diet and positive breath testing for fructose|Patients with breath testing positive have a low FODMAPS diet. The test will be considered as positive if we observe an increase of more than 20 ppm of H2 and/or CH4 on a sample with regard to the basal concentration
3341461|NCT02188680|Sham Comparator|negative breath testing for fructose|patients with negative breath test have a low FODMAPS diet
3341462|NCT02188693||Gemcitabine, Experimental|Gemcitabine 1250 mg/m2, IV on day 1 of 21 day cycle,with a follow up for every 12 weeks until disease progression or the date of first documented death from any cause
3341463|NCT02188693||Observational|Observation for every 12 weeks until disease progression or the date of first documented death from any cause
3341464|NCT02188732|Experimental|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
3341465|NCT02188732|Active Comparator|CBHH+SMT|"CBHH+SMT Community-Based Health Home (CBHH) PLUS Self-Management Training (SMT) of I-IMR~I-IMR integrates psychiatric illness self-management with strategies for medical illness self-management . The psychiatric component includes psychoeducation about illness and treatment, cognitive behavioral approaches to increase medication adherence, training and relapse prevention, teaching coping skills to manage persistent symptoms, and social skills training. The medical illness component consists of an individually tailored curriculum focused on managing physical illnesses using parallel skills and strategies taught for psychiatric illness self-management, as well as a nurse health care manager to facilitate coordination of necessary preventive and ongoing health care. The I-IMR curriculum consists of 10 modules delivered by an I-IMR specialist through eight months of weekly sessions customized to the specific needs and disorders of each client."
3341466|NCT02188732|Active Comparator|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
3237797|NCT01264237|Placebo Comparator|Placebo|The study will use an Enriched Enrollment Randomized Withdrawal (EERW) design consisting of a 2-week open-label enrichment phase, during which subjects will receive etoricoxib, followed by a 4-week randomized, double-blind, placebo-controlled treatment phase, during which subjects will receive either etoricoxib or placebo.
3237798|NCT01264250|Experimental|1|
3237799|NCT01264250|Placebo Comparator|2|
3237800|NCT01264263||1|
3237801|NCT01264289|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
3237802|NCT01264289|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
3237803|NCT01264302|Experimental|Finasteride tablets 5 mg|Finasteride tablets 5 mg of Dr.Reddy's Laboratories Limited
3237804|NCT01264302|Active Comparator|Proscar 5 mg Tablets|Proscar 5 mg Tablets of Merck & Co. Inc
3341467|NCT02188745|Experimental|Alternating Therapy|"Study will use an 8-week/16-week alternating regimen of 17B-estradiol/AI (aromatase inhibitor) therapy. Use of only one Aromatase inhibitor throughout the study is preferred.~17B-estradiol: One tablet containing 2 mg 17B-estradiol will be taken orally three times daily, for a total dose of 6 mg/day.~Letrozole: One tablet containing 2.5 mg letrozole will be taken orally once per day.~Anastrozole: One tablet containing 1 mg anastrozole will be taken orally once per day.~Exemestane: One tablet containing 25 mg exemestane will be taken orally once per day."
3341468|NCT02188758||Adults - CFPE Treatment|Other: CF Pulmonary Exacerbation (CFPE) Treatment
3341469|NCT02188771|Experimental|RegenoGel SP 2ml|"RegenoGel-SP is a new viscosupplement intended for the intra-articular treatment of OA.~Following signing the Informed Consent form (Visit 1), subjects who conform to the inclusion criteria will be evaluated for vital signs, blood hematology, chemistry, INR, aPTT and ECG, and will be subjected to a 30-40ml blood withdrawal that will be used for the production of autologous RegenoGel-SP. Subjects randomized to receive RegenoGel-SP will receive a single, intra-articular injection (Visit 2)."
3341470|NCT02188797|Experimental|Group MI risk reduction program|Participants receive four 1-hour group motivational interviewing sessions focused on reducing substance use and sexual risk behavior. They also receive an HIV information brochure and Community Resource Guide.
3341471|NCT02188797|No Intervention|Usual care control|Participant receive HIV information brochure and Community Resource Guide.
3341472|NCT02188810|Active Comparator|Group 1|Single dose of control vaccine (a single dose of 0.5 mL TIV).
3341473|NCT02188810|Experimental|Group 2|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 0.5x PAL, i.e. 30 μg).
3341474|NCT02188810|Experimental|Group 3|Single dose of the test article (0.25 mL TIV, which is 7.5 μg of each influenza strain with 1x PAL, i.e. 60 μg).
3341475|NCT02188810|Experimental|Group 4|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 2x PAL (i.e., 120 μg).
3341476|NCT02188810|Experimental|Group 5|Single dose of the test article (0.25 mL of TIV which is 7.5 μg of each influenza strain with 4x PAL (i.e., 240 μg).
3341477|NCT02188810|Experimental|Group 6|Single dose of the test article (0.125 mL of TIV with 4x PAL i.e., 240 μg).
3341478|NCT02188823|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about exercise, sleep, mindfulness, and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3341479|NCT02188836|Experimental|Electromagnetic device|The electromagnetic stimulation was performed by using a device capable of generating an electromagnetic field around the fracture site. This was applied once a day, one hour for 8 weeks.
3237805|NCT01264315|Other|Lenalidomide in maintenance|
3237806|NCT01264328|Experimental|Panitumumab + Paclitaxel|Treatment consisted of intravenous panitumumab 6 mg/kg q2w, administered in one hour the first day and in 30 minutes thereafter (if no infusional reaction was observed) plus intravenous paclitaxel 80 mg/m2 weekly administered one hour after panitumumab in one hour infusion, until progression or unacceptable toxicity. Panitumumab does not require prophylactic premedication from the first infusion. Paclitaxel was administered with: dexamethasone 10 mg, diphenhydramine 30 mg and antiH2 (cimetidine 300 mg or ranitidine 50 mg). Dose modifications of paclitaxel included 4.8 mg/kg (80% of the initial dose) and 3.6 mg/kg (60%) when recovered from a grade 3-4 skin toxicity to grade ≤2. Continuing paclitaxel on the day of the planned infusion required no grade ≥2 mucositis and hematologic recovery with an absolute neutrophil count ≥1,500/ml and a platelet count ≥75,000.
3341480|NCT02188836|Placebo Comparator|Placebo device|A device with the same characteristics to the real device, except for the generation of the electromagnetic stimulation. It generates sham stimulation.
3341481|NCT02188862||Rheumatic heart disease cases|Patients with rheumatic heart disease as defined in the case criteria
3341482|NCT02188862||Population controls|Individuals from the general population divided into new controls (recruited specifically for this study) and existing controls (recruited to previous population genetics studies in the region)
3341483|NCT02188875|Experimental|SMS Text Messages & Fitbit One|All study participants were provided a Fitbit One to facilitate self-monitoring of PA. Those who were randomly assigned to the intervention group were asked to indicate 3 preferred times of the day to receive text message prompts to do PA throughout the 6-week study period.
3341484|NCT02188875|Active Comparator|Fitbit One Only|An active control group was also provided the Fitbit One to facilitate self-monitoring of PA throughout the 6-week study period.
3237807|NCT01264341|Experimental|Bevacizumab combined with temsirolimus|Bevacizumab 10mg/kg intravenous every 2 weeks Temsirolimus 25mg intravenous once weekly
3237808|NCT01264354|Experimental|1|Clevudine 30mg
3237809|NCT01264354|Experimental|2|Clevudine 20mg+Adefovir dipivoxil 10mg
3237810|NCT01264354|Experimental|3|Clevudine 20mg
3237811|NCT01264367|Experimental|1|Clevudine 30mg
3237812|NCT01264367|Active Comparator|2|Clevudine 30mg + peg-interferon 180mcg
3237813|NCT01264393|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an internet-based weight loss program, and the option of attending face-to-face group sessions
3237814|NCT01264393|Active Comparator|Shape Up Rhode Island + Online Weight Loss Program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention in addition to an internet-based weight loss program
3237815|NCT01264393|Active Comparator|Shape Up Rhode Island + Internet Resources|Participants in this arm will receive the Standard Shape Up Rhode Island statewide intervention plus access to internet resources
3237816|NCT01264406||Exercise Group (20 KKW)|Exercise group will obtain 20 KKW, perform in 4-5 sessions per week for approximately 50-70 minutes per session.
3341485|NCT02188888||Tachycardic patients|Patients will receive a continuous esmolol infusion to maintain heart rate between 94 and 80 bpm. Norepinephrine will be titrated to achieve a MAP between 65 and 75 mmHg.
3341486|NCT02188901|Other|single arm|
3341487|NCT02188914||Inhalant use disorder group|Subjects must have a diagnosis of inhalant use disorder, according to the DSM-5, who are under a treatment program for addictive disorders.
3341488|NCT02188914||Normal control group|Normal control without a history of drug abuse or dependency.
3341489|NCT02188927|Experimental|Implementation of ANL|"Intervention: Procedure : Implementation of routine Advanced Notification Letter included in Standard Invitation procedure~Advanced Notification Letter will be implemented in invitation procedure and send two weeks before Standard Invitation (Standard Invitation will be send six weeks before planned screening colonoscopy)"
3341490|NCT02188927|Active Comparator|No included ANL|Intervention: Behavioral : No included Advanced Notification Letter Sending Standard Invitation six weeks before planned screening colonoscopy
3341491|NCT02188940|Active Comparator|Exercise, dietary and behavioral therapy|The interventions of active comparator will be education program, dietary and behavioral therapy and exercise training.
3341492|NCT02188940|Sham Comparator|Dietary and behavioral therapy|The intervention in sham comparator will be education program, dietary and behavioral therapy and stretching and breathing exercise.
3341493|NCT02188953|Experimental|ACCS100|Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
3341494|NCT02188953|Placebo Comparator|Calcium carbonate|Participants will consume 1 gram of calcium carbonate at each meal (up to three times per day) for seven days. The calcium carbonate will be administered by mixing a powder sachet into water.
3341495|NCT02188966|Experimental|Geographical Information System|Availability of Geographical Information System data from ambulances destined for the Emergency Department of Regional Hospital Horsens.
3341496|NCT02188992||Cohort 1|Patients with sepsis syndrome, without criteria for severe sepsis/septic shock. These patients are recruited from the emergency department.
3341497|NCT02188992||Cohort 2|Patients with community acquired sepsis syndrome REQUIRING critical care admission due to severity of sepsis. These patients are recruited from the critical care areas (ICU/HDU).
3341498|NCT02188992||Cohort 3|Patients without sepsis syndrome. Age and gender matched to cohort 1, and recruited from Emergency Department.
3341499|NCT02189005|Experimental|PreCrea|Study dietary supplement (Precrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification program.
3341500|NCT02189005|Placebo Comparator|Placebo 600 mg capsules|Placebo was given to patients twice daily 30 mins before food for 90 days along with lifestyle modification program.
3237817|NCT01264406||Exercise Group (8 KKW)|One exercise group will obtain 8KKW (kcal/kg/week) over 3-4 sessions per wee, which will result in each session lasting approximately 30 minutes
3341501|NCT02189018|Active Comparator|Control|Ad lib activity at home
3341502|NCT02189018|Experimental|Active Exercise|Active exercise on treadmill
3341503|NCT02189018|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
3341504|NCT02189018|Experimental|Weight loss and active exercise|Weight loss plus active exercise on treadmill
3237818|NCT01264406||Control group|This group will be instructed to maintain their baseline level of exercise.
3341505|NCT02189031||Upper Extremity Amputee|Robust custom tactor to facilitate embodiment and proprioception
3341506|NCT02189031||Able Bodied|Bypass tactor
3237819|NCT01264432|Experimental|Treatment (veliparib, LDRWAR)|Patients receive veliparib PO BID on days 1-21 (days 5-21 of course 1). Patients undergo LDFWAR in BID on days 1 and 5 of weeks 1-3. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3237820|NCT01264445|Experimental|Group A|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
3341507|NCT02189044|Other|exercises; muscle strength|Evaluate the effects of Pilates exercises on respiratory muscle strength in elderly women before and after eleven weeks of training
3341508|NCT02189057|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on AssureRx GeneSight genotyping results.
3341509|NCT02189057|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
3341510|NCT02189070||Responders|Responding participants
3341511|NCT02189070||Non-responders|Non-responding participants
3341512|NCT02189083|Experimental|High dose TSD|Subjects in this arm receive high dose (217 g/day) TSD for 16 weeks.
3341513|NCT02189083|Active Comparator|Low dose TSD|Subjects in this arm receive low dose (69 g/day) TSD for 16 weeks.
3341514|NCT02189096||No change from current practice|"Phase 1 (4 months)~No change from current practice. Each Paramedic crew routinely documents patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be electronically captured. The data will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria [signs of systemic inflammation] and suspicion of infection) by the study investigators. An estimate will be made of the time of completion of the ePRF in relation to patient transport."
3341515|NCT02189096||NEWS and Sepsis Screening|"Phase 2 (4 months)~The ten crews will undertake implementation of NEWS and Sepsis Screening. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, the patients transfer will be as per normal protocol but receiving ED staff will receive the information about NEWS score and Sepsis screening as part of a structured handover."
3237821|NCT01264445|Experimental|Group B|Adjuvanted GSK investigational HIV vaccine at Months 0 and 1 followed by Ad35-GRIN investigational HIV vaccine at Month 4.
3237822|NCT01264445|Experimental|Group C|Ad35-GRIN investigational HIV vaccine at Month 0 followed by Adjuvanted GSK investigational HIV vaccine at Months 3 and 4.
3237823|NCT01264445|Experimental|Group D|Adjuvanted GSK investigational HIV vaccine and Ad35-GRIN investigational HIV vaccine co-administered (simultaneous administration with separate injections)at Months 0, 1, and 4.
3237824|NCT01264458||Traumatic Injury|Trauma patients arriving at Saint Mary's Emergency Department
3341516|NCT02189096||Point of care lactate measurement|"Phase 3 ( 4 months)~The ten crews will undertake Point of Care Lactate measurement when NEWS ≥ 4 or when the patient screens positive for Sepsis. Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection).~If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge. The lactate level, along with the NEWS score and sepsis screening, will be given to the receiving ED staff as part of a structured handover."
3341517|NCT02189109|Experimental|Dose Escalation|NVX-108 (DDFP liquid emulsion) i.v. in conjunction with Radiation Treatment and Temozolimide. 0.05-0.35cc/kg.
3237825|NCT01264458||Control group|
3237826|NCT01264471||Gulf War Syndrome patients|Gulf War veterans who have been diagnosed with Gulf War Syndrome.
3341518|NCT02189135|No Intervention|Usual care|Usual care from physician/ doctor
3341519|NCT02189135|Experimental|Telemedicine|Mobile wireless glucometer with feedback from physicians
3341520|NCT02189148||Cohort|"Each participant will :~give consent~provide a blood sample (10 ml)~be measured (weight and height for BMI calculation)~undergo a blood pressure measurement~have an ultrasound exam (uterine arteries Doppler, placental volume, thickness of the placenta)~answer to a short questionnaire (5 pages)"
3341521|NCT02189174|Experimental|CLR457|
3341522|NCT02189187|Experimental|Mindfulness Based Stress Reduction (MBSR) program|Mindfulness Based Stress Reduction (MBSR) is an 8-week program that consists of training in mindfulness practices, the application of mindfulness to daily life, and information about healthy living and the role played by thoughts and emotions in health.
3341523|NCT02189187|Active Comparator|Healthy Living Course (HLC)|Healthy Living Course (HLC) an 8-week psycho-educational program that consists of lectures and discussion on healthy living, stress management, time management, and unhealthy behaviors (e.g. smoking, drinking).
3341524|NCT02189200|Active Comparator|Oat bran group|oat bran (40g per day)
3341525|NCT02189200|Placebo Comparator|Placebo group|refined rice flour (40g per day)
3341526|NCT02189226|Experimental|probe-based confocal laser endomicroscopy (pCLE) group|
3341527|NCT02189226|Active Comparator|chromoendoscopy (CE) group|
3237827|NCT01264484||Advantage prosthetic heart valve|All patients who were enrolled and implanted with an Advantage valve in the Herzzentrum Nordrhein-Westfalen (Bad Oeynhausen, Germany) and Deutsches Herzzentrum München (Munich, Germany) during the previous Advantage clinical study study and who agree to participate in this long-term follow-up study by informed consent.
3237828|NCT01264510|Other|patients implanted with a Bone-anchored hearing aid(Baha)|
3237829|NCT01264536|Experimental|Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
3237830|NCT01264536|Placebo Comparator|maltodextrin|Maltodextrin is an inert sugar.
3341528|NCT02189239|Active Comparator|Zeller Entspannung film coated tablets|Relaxing film coated tablets, 570 mg (Zeller Entspannung Filmtabletten), 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) preferably during meals with a glass of water.
3341529|NCT02189239|Placebo Comparator|Placebo tablets|Placebo medication is identical in presentation, color and shape, 3x1 tablet per day for the first three days (morning, midday, evening), at day four 2x1 tablet (morning, midday) during meals with a glass of water.
3341530|NCT02189239|Sham Comparator|No Treatment|No medication intake.
3341531|NCT02189265||Full cohort|All singleton births in the Netherlands. Stillbirths are excluded from the denominator for all outcomes other than perinatal mortality, stillbirth and congenital anomalies.
3341532|NCT02189278|Experimental|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
3341533|NCT02189278|No Intervention|Treatment as usual|Treatment as usual control.
3341534|NCT02189291|Experimental|Immediate catheter removal|The indwelling Foley catheter will be removed prior to exiting the operating room.
3237833|NCT01264562||Chemotherapy group|Breast cancer patients treated with chemotherapy
3237834|NCT01264562||Non-chemotherapy group|Breast cancer patients not treated with chemotherapy
3237835|NCT01264562||Healthy controls|Women without a cancer diagnosis, matched for age and education
3237836|NCT01264575|Experimental|BPV6E1|
3237837|NCT01264575|Experimental|BPV7E1|
3237838|NCT01264575|Experimental|BPV8E1|
3237839|NCT01264575|Experimental|BPV9E1|
3237840|NCT01264575|Experimental|BPV10E1|
3237841|NCT01264575|Experimental|BPV11E1|
3237842|NCT01264575|Experimental|BPV6E2|
3237843|NCT01264575|Experimental|BPV7E2|
3237844|NCT01264575|Experimental|BPV8E2|
3237845|NCT01264575|Experimental|BPV9E2|
3237846|NCT01264575|Experimental|BPV10E2|
3237847|NCT01264575|Experimental|BPV11E2|
3237848|NCT01264588|Active Comparator|topical calcium glycerophosphate lotion|
3237849|NCT01264588|No Intervention|standard-of-care|
3237850|NCT01264627|Experimental|Mindful Breathing (MB)|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. No other intervention is included. No FDA drug or device is involved."
3341535|NCT02189291|Active Comparator|Post op day 1 catheter removal|Patients assigned to this group will follow the standard of care at present, with removal of indwelling catheter on the morning of postoperative day 1.
3341536|NCT02189304|Experimental|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
3237851|NCT01264627|Other|Usual Care (UC)|Usual Care consists of the standard care made available to participants through their primary physician. No intervention is included. No FDA drug or device is involved.
3341537|NCT02189304|Experimental|PT009|PT009; Budesonide and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
3341538|NCT02189304|Active Comparator|Symbicort Turbohaler|Symbicort Turbohaler; Budesonide and Formoterol Fumarate Inhalation Powder taken as 2 inhalations
3341539|NCT02189330|Experimental|Tafamidis|
3237852|NCT01264640|Experimental|A|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
3237853|NCT01264653|Experimental|experimental group,control group|Intraocular adrenalin,topical mydriatics, experimental group: Intervention: Procedure:refractive cataract surgery with Intraocular adrenalin, control group:refractive cataract surgery with topical mydriatics
3237854|NCT01264666|Experimental|Chinese tea flavor liquor|
3237855|NCT01264666|Placebo Comparator|Water|Water combined with meal as control.
3237856|NCT01264666|Placebo Comparator|Chinese Meijiao Liquor|
3237857|NCT01264692|Experimental|Treatment A|ACT-280778
3237858|NCT01264692|Placebo Comparator|Treatment B|Placebo
3341540|NCT02189330|Experimental|Tafamudus Free Acid|
3341541|NCT02189330|Experimental|20 mg new soft gelatin capsule|
3341542|NCT02189330|Experimental|4 capsules of 20 mg tafamidis of commercial formulation|
3341543|NCT02189330|Experimental|4 capsules of 12.2 mg tafamidis of free acid tablet|
3341544|NCT02189343|Experimental|Dose Escalation Cohort|Dose Escalating Cohorts of ACY-1215 in combination with pomalidomide and dexamethasone.
3341545|NCT02189356|Experimental|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
3341546|NCT02189356|Other|contol group|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group.
3341547|NCT02189369|Experimental|Day 3 embryo-Own-above cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
3237859|NCT01264692|Other|Treatment C|Amlodipine
3237860|NCT01264731|Active Comparator|peptide vaccine plus imiquimod|Peptide Vaccine: Days 1, 8, 15, 36, 57, 78 Imiquimod: Applied daily on days 1-85.
3341548|NCT02189369|Experimental|Day 5 embryo-Own-above cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with higher receptivty rates
3341549|NCT02189369|Experimental|Day 3 embryo-Donor-above cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
3341550|NCT02189369|Experimental|Day 5 embryo-Donor- above cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with higher receptivty rates
3341551|NCT02189369|Experimental|Day 3 embryo-Donor-lower cutoff|Day 3 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
3341552|NCT02189369|Experimental|Day 5 embryo-Donor-lower cutoff|Day 5 embryo transfer for IVF with donor oocytes, and prostaglandine levels with lower receptivty rates
3341553|NCT02189369|Experimental|Day 3 embryo-own-lower cutoff|Day 3 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
3237861|NCT01264731|Active Comparator|Imiquimod|Imiquimod: Applied daily on days 1-85.
3237862|NCT01264757|Active Comparator|Education|Educational brochure about physical activity provided.
3341554|NCT02189369|Experimental|Day 5 embryo-own-lower cutoff|Day 5 embryo transfer for IVF with own oocytes, and prostaglandine levels with lower receptivty rates
3341555|NCT02189395|Experimental|NPH and regular insuline group|For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
3341556|NCT02189395|Active Comparator|glargine and humalog group|Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.
3341557|NCT02189408|Experimental|PRP|one intraoperative application of PRP in the interventional group
3341558|NCT02189408|No Intervention|Control|No application of any substance during knee arthroscopy
3341559|NCT02189421|Other|Direct peroral cholangioscopy|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
3237863|NCT01264757|Experimental|Pedometer|A pedometer was provided in addition to educational materials.
3237864|NCT01264783|Experimental|RNS60|RNS60
3237865|NCT01264783|Placebo Comparator|Placebo|Placebo
3237866|NCT01264796|Experimental|behavioral intervention, counseling|2hr group education for 6 weeks
3237867|NCT01264796|No Intervention|delyed intervention|control group
3237868|NCT01264809|Experimental|A : immediate physical activity counseling|Participants randomized in the experimental group (group A) will receive physical activity counseling during a one-to-one consultation at both baseline and 3 months.
3341560|NCT02189434||Cytoreductive surgery|Patients having undergone cytoreductive surgery with or without HIPEC will have serum procalcitonin lab draws
3341561|NCT02189447|Experimental|Refractive surgery|Patients with keratoconus treated with simultaneous photorefractive keratectomy and Corneal collagen cross-linking.
3341562|NCT02189460||Healthy adults|20 young adults aged between 30 and 50 years old. 20 middle aged adults aged between 50 and 70 years old. 20 older adults of 70 years old and more.
3237869|NCT01264809|Active Comparator|B : later physical activity counseling|Exercise consultation will be realised only at 3 months in the control group(group B). Furthermore, patients of group B will not received any physical activity counseling at baseline.
3341563|NCT02189486||Prostate Cancer Cohort|Men with prostate cancer who have elected radical prostatectomy for their treatment of their prostate cancer within two years after prostate biopsy.
3341564|NCT02189499|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
3341565|NCT02189512|Other|brain death organ donors|cases - blood sampling
3341566|NCT02189512|Other|abdominal aortic aneurysm repair|controls - blood sampling
3341567|NCT02189525||Sports induced concussion|Exposure to sports induced concussion
3341568|NCT02189525||Routine Athletic Exertion|Exposure to routine athletic exertion without sports-induced concussion (non-concussion control)
3341569|NCT02189538|Experimental|ω-3 PUFA|Modular low fat diet (18%) including 9% as ω-3 PUFA
3341570|NCT02189538|Active Comparator|Low fat enteral diet|Modular low fat (18%)
3341571|NCT02189551|Active Comparator|Lokomat Pro|gait robot established on the market
3341572|NCT02189551|Experimental|Lokomat Pro FreeD|gait robot based on the Lokomat Pro with changes in guidance of the hip, approved for the Swiss market
3237870|NCT01264822||Treatment Arm 1 Rabeprazole Sodium|
3237871|NCT01264848|Experimental|Balloon angioplasty and/or stenting|Balloon angioplasty and/or stenting of stenosed internal jugular vein and/or azygous vein and/or brachiocephalic vein
3341573|NCT02189564|Active Comparator|Intrinsic reward|Feedback about good performance
3341574|NCT02189564|Experimental|Intrinsic and extrinsic reward|Feedback about good performance + money
3341575|NCT02189564|Experimental|Intrinsic reward (average performance)|Feedback about random selection of trials
3341576|NCT02189577|Experimental|CHF 5259|CHF 5259
3237872|NCT01264861|Experimental|Arm 1:|Arm 1: Eligible subjects will receive escalating doses of safinamide for the 6-week duration of treatment. Each dose level will be last 10-14 days. Doses 200mg and 300mg will have a 3 day intermediate step up dose, 150mg and 250mg dose.
3237873|NCT01264874|Experimental|Vitamin D3|Vitamin D3 administration
3341577|NCT02189577|Placebo Comparator|Placebo|Placebo
3341578|NCT02189590|Experimental|air-Q|Patients will receive the air-Q with size based on manufacturer recommendations of body weight
3341579|NCT02189590|Experimental|i-gel|Patients will receive the i-gel with size based on manufacturer recommendations of body weight
3341580|NCT02189603|Experimental|Senior group(over 65 years old)-HE|Anti-HEV IgG seronegative participants over 65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3237874|NCT01264874|Placebo Comparator|placebo|matched placebo
3237875|NCT01264900|Experimental|Cognitive Behavioral Therapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment
3341581|NCT02189603|Active Comparator|Younger groups(16-65 years old)|Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
3341582|NCT02189603|No Intervention|Senior group(over 65 years old)-Cont|Anti-HEV IgG seropositive participants over 65 years old were enrolled. This is the safety control group, without any intervention.
3341583|NCT02189616|Other|regular care group|receive regular care which contains filling a paper asthma diary daily.
3341584|NCT02189616|Experimental|SMS reminder group|receive weekly mobile phone short message reminders for 3 months
3237876|NCT01264900|Active Comparator|Supportive Psychotherapy|Twelve weekly 50-minute sessions of individual supportive (client-centered) psychotherapy
3341585|NCT02189616|Experimental|SMS reminder and SMS consultation group|receive weekly mobile phone short message reminders and can consult asthma nurse by mobile phone short message when needed for 3 months
3341586|NCT02189642||Genito-Urinary/Urology Surgical Procedure Types|Pediatric patients undergoing circumcision, orchidopexy, hypospadias repair, hernia repair, cystoscopy, pyeloplasty, and ureteral reimplants or ureteral stents.
3341587|NCT02189642||Otolaryngology Surgical Procedure Types|Pediatric patients undergoing tonsil and/or adenoid removal, tympanostomy, tympanoplasty, and mastoidectomy.
3341588|NCT02189642||Orthopaedics Surgical Procedure Types|Patients undergoing hip and knee arthroscopies, hardware removal, and tendon lengthening.
3341589|NCT02189642||Plastic Surgery Surgical Procedure Type|Pediatric patients undergoing alveolar cleft repair.
3341590|NCT02189655|No Intervention|Group Control|Hyperbaric bupivacaine 0.5% 2.5 mL was administered intrathecally in 30 seconds.
3341591|NCT02189655|Experimental|Group Diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
3341592|NCT02189681|Active Comparator|Group C|Patients in this group underwent Conventional landmark guided midline spinal anaesthesia.
3341593|NCT02189681|Experimental|Group P|This group had pre-procedure ultrasound guided L5S1 paramedian spinal anaesthesia performed
3237877|NCT01264913||Shift Workers|
3237878|NCT01264913||Day Workers|
3237879|NCT01264926||rotator cuff tear, pain|
3237880|NCT01264978|Experimental|repetitive neuromuscular stimulation|repetitive neuromuscular stimulation of the quadriceps arm are patients actively stimulated at increasing intensity to afford maximal contraction during training sessions
3237881|NCT01264991|Experimental|APM group|
3237882|NCT01264991|Placebo Comparator|Sham group|
3237883|NCT01265004||Stitches, rupture of achilles tendon|Patients, in who the achilles tendon rupture was treated with tendon surgery including a special way of stitching to preserve the sliding ability of the tendon.
3341594|NCT02189694|Active Comparator|Insulin pump therapy|Glucose levels will be controlled for 3 consecutive nights using insulin pump therapy. Subjects will carry on with their normal conventional insulin pump therapy and will be allowed to freely implement therapeutic adjustments..
3341595|NCT02189694|Active Comparator|Single-hormone closed-loop strategy|Glucose levels will be controlled by single-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by single-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pump's parameters will then be changed manually to implement the computer generated recommendations.
3341596|NCT02189694|Active Comparator|Dual-hormone closed-loop strategy|Glucose levels will be controlled by dual-hormone closed-loop strategy for 3 consecutive nights. A member of the research team will be present at the diabetic camp to ensure protocol implementation and patient's safety. Glucose levels will be controlled by dual-hormone closed-loop strategy between 22:00 until 7:00 next morning. Glucose sensor readings will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses. Pumps' parameters will then be changed manually to implement the computer generated recommendations.
3341597|NCT02189707|Experimental|Probiotic Bifidobacterium 1x1010 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3341598|NCT02189707|Experimental|Probiotic Bifidobacterium 1x109 cfu|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3341599|NCT02189707|Placebo Comparator|Placebo powder in capsules|One capsule of study product, mixed with provided yogurt, will be consumed once a day.
3237884|NCT01265004||Fibrin-glue, rupture of achilles tendon|Patients, who received a surgical treatment including a fixing of the tendon with fibrin-glue.
3237885|NCT01265004||Stiches and Fibrin-glue|Patients, in who the achilles rupture was treated with stitches and fibrin-glue.
3237886|NCT01265017|Experimental|Active Treatment|"interventions include Estradiol, medroxyprogesterone, hydrocortisone, GH as follows~Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection"
3237887|NCT01265017|Placebo Comparator|Placebo|Matching placebo
3237888|NCT01265030|Experimental|Sirolimus|"Preoperative sirolimus:~loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligram)~starting 24 hours after the initial loading dose, subjects will receive a dose of 4 milligram/meters2 daily; Per Os (PO), by mouth days 2 through 28"
3237889|NCT01265043|Experimental|OHI|Patients provided with oral hygiene instruction and electric toothbrush
3237890|NCT01265043|Experimental|OHI + CHX mouthrinse|Patients provided with oral hygiene instruction and Corsodyl mouthrinse
3237891|NCT01265043|Experimental|OHI + CHX mouthrinse + assisted brushing|Oral hygiene instruction, Corsodyl mouthrinse, and assisted brushing
3341600|NCT02189733|Experimental|Caplacizumab - Treatment A|Single s.c. dose of reconstituted lyophilized solution of caplacizumab followed by single s.c. dose of liquid formulation of caplacizumab
3341601|NCT02189733|Experimental|Caplacizumab - Treatment B|Single s.c. dose of liquid formulation of caplacizumab followed by single s.c. dose of reconstituted lyophilized solution of caplacizumab
3341602|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to 1 hour after birth|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from birth to one hour after birth.
3237892|NCT01265069|Active Comparator|high dose dual therapy|Group A - high dose dual therapy (rabeprazole 20 mg qid, amoxicillin 750 mg qid for 14 days)
3341603|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from birth to 1 hour after birth.
3341604|NCT02189746|Active Comparator|Continuous Kangaroo Mother Care to discharge|In addition to standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia, the infants will receive continuous KMC most of the time possible from one hour after birth to discharge.
3237893|NCT01265069|Experimental|concomitant therapy|Group B - concomitant therapy (rabeprazole 20 mg, amoxicillin 1000 mg, metronidazole 500 mg, clarithromycin 500 mg, bid for 10 days).
3237894|NCT01265082||Patients in remission with pruritus|
3237895|NCT01265082||Patients in remission without pruritus|
3341605|NCT02189746|Sham Comparator|Standard Kangaroo Mother Care to discharge|Infants will receive standard WHO thermoregulation care which includes warm delivery rooms, immediate drying, Kangaroo Mother Care (KMC) whenever possible, early and exclusive breastfeeding, postponed bathing and weighing if needed, appropriate bundling and placing the infant in air incubator, radiant heater, or heat mattress if the infant develops hypothermia from 1 hour after birth to discharge.
3341606|NCT02189772|Experimental|MDX (metadoxine extended release)|"Route of administration: oral~The dose of MDX (approximately 14-22 mg/kg) will be determined by the subject's weight at the baseline visit as follows:~40-49 kg 700 mg consisting of a 700 mg tablet~50-64 kg 1050 mg consisting of a 700 mg tablet, a 350 mg tablet~65-100 kg 1400 mg consisting of two 700 mg tablets"
3237896|NCT01265095||VRE bacteremia|VRE bacteremia patients
3237897|NCT01265108|Experimental|Intravenous iron sucrose|Infusion of 200 mg iron sucrose (Venofer) in 100 ml normal (0.9%) saline.
3237898|NCT01265108|Placebo Comparator|Intravenous normal saline|Infusion of 100 ml normal (0.9%) saline.
3341607|NCT02189772|Placebo Comparator|placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
3341608|NCT02189785||Healthy Controls|Healthy men and women ages 18-25 years
3341612|NCT02189811|Experimental|IPV|IPV at birth, 6 weeks, 10 weeks, 14 weeks, followed by tOPV at 18 and 22 weeks
3341613|NCT02189811|Experimental|bOPV|bOPV at birth, 6, 10, and 14 weeks. followed by tOPV at 18 and 22 weeks of age
3341614|NCT02189811|Experimental|bOPV and IPV|bOPV at birth, 6, 10 weeks, and IPV+bOPV at 14 weeks, and tOPV at 18 and 22 weeks of age
3341615|NCT02189811|Experimental|bOPV and IPV and IPV2|bOPV at birth, 6, 10 weeks and bOPV+IPV at 14 weeks and tOPV+IPV2 at 18 weeks and tOPV alone at 22 weeks of age
3341616|NCT02189811|Active Comparator|tOPV|tOPV at birth, 6, 10, 14, 18 and 22 weeks of age
3341617|NCT02189824|Experimental|Infusion of partially matched unrelated donor cells|
3341618|NCT02189876|Experimental|FemAALES|Females of African American Legacy Empowering Self Intervention. A nine session, theoretically grounded small group intervention.
3341619|NCT02189876|Active Comparator|Standard of Care|A one-time STD/family planning testing and counseling session provided to all study participants.
3341620|NCT02189902|Active Comparator|4000 IU/d of D3 by mouth for 12 weeks|4000 IU/d of D3 by mouth for 12 weeks
3341621|NCT02189902|Experimental|7000IU/d of D3 by mouth for 12 weeks|7000IU/d of D3 by mouth for 12 weeks
3341622|NCT02189928|Experimental|With per-CID protocol|Usual care patients (thrombolysis or not ) with remote ischemic per-conditioning using an electronic tourniquet .
3341623|NCT02189928|Other|Without per-CID protocol|Usual care patients (thrombolysis or not).
3341624|NCT02189967|Active Comparator|conventional fractionation|radiotherapy with conventional fractionation (5 x 2Gy per week)
3341625|NCT02189967|Active Comparator|accelerated fraction|radiotherapy with accelerated fraction (7 x 2 Gy per week)
3341626|NCT02189980|Placebo Comparator|Saline & nasal clip|Saline and nasal clip inhaled post-operatively
3341627|NCT02189980|Experimental|Aromatherapy blend & nasal clip|Aromatherapy blend and nasal clip inhaled post-operatively
3341628|NCT02189993||Total Parenteral Nutrition Use|The cohort investigated consisted of patients with intestinal failure requiring total parenteral nutrition use.
3237899|NCT01265121|Experimental|CPAP treatment|This acromegalic patients is going to have sleep apnea treated for 3 months with a with a continuous positive air pressure device (CPAP)
3237900|NCT01265121|Placebo Comparator|Nasal adhesive|This acromegalic patients will be treated will an external nasal dilator adhesive intended to serve as a placebo treatment
3341629|NCT02190006||Polycystic ovarian syndrome|Women with polycystic ovarian syndrome undergoing ICSI
3341630|NCT02190019|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
3341631|NCT02190019|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 10 treatments identical in duration will be administered over a two week period.
3341632|NCT02190032|Active Comparator|Control group|"Intubating a manufacturer-provided-angled double-lumen tube (=Conventional-angled group,MallinckrodtTM endotracheal tube, Covidien)"
3341633|NCT02190032|Experimental|Tube angle modification|The angle of the double lumen tube(MallinckrodeTM endotracheal tube) is modified individually.At sniffing position, the distal tip of the tube is placed at the patient's cricoid cartilage level and the tube is bent at the intersection point of the two airway axes (oropharyngeal axis and tracheal axis) with an angle between the two axes.
3237901|NCT01265134||Experimental Group|the healthy elders
3237902|NCT01265134||Control Group|the elders who have fallen once
3341634|NCT02190058|Experimental|DS-1971a|DS-1971a suspension, up to 4650mg/day
3341635|NCT02190058|Placebo Comparator|placebo|matching DS-1971a suspension
3237903|NCT01265147|Active Comparator|Cisplatin|cisplatin combine with IMRT
3237904|NCT01265147|Experimental|Nedaplatin|Nedaplatin combine with IMRT
3237905|NCT01265160||the group of Jiangzhuo prescription|
3237906|NCT01265160||the group of fenofibrate|
3237907|NCT01265160||the group of placebo|
3341636|NCT02190084|Active Comparator|transcranial magnetic stimulator|Neurostar repetitive transcranial magnetic stimulator. The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
3341637|NCT02190084|Sham Comparator|Sham coil treatment|Neurostar repetitive transcranial magnetic stimulator. 20 treatments identical in duration will be administered over a four week period.
3341638|NCT02190097|Experimental|paleolithic diet|subjects in this arm are given detailed instructions and coaching in following a paleolithic type diet for 4 months, with the option to continue for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
3341639|NCT02190097|Active Comparator|American Diabetes Association diet|subjects in this arm are given detailed instructions and coaching in following an ADA type diet for 4 months, with the option to switch over to the paleolithic diet arm for another 4 months. studies of ovarian and metabolic parameters will be done at baseline, 2 and 4 months
3341640|NCT02190110||Suspected pulmonary embolism patients|Adult patients (more than 18 years old) suspected of PE will be recruited at the time of the medical evaluation and before a final diagnosis is established
3341641|NCT02190123||ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets
3341642|NCT02190136|Active Comparator|Protein whole foods|Ingestion of 20-25 grams per serving consumed 4-6 times per day; 1 within an hour of waking in the morning and the other 2.5-3 hours apart during the day.
3341643|NCT02190136|Experimental|Protein Resistance Exercise Training|Ingestion of 4-6 protein-rich meals per day and 3 times per week of resistance functional training.
3341644|NCT02190136|Experimental|Protein Stretching/Yoga Training|Ingestion of Protein-rich diet 4-6 meals/day and stretching/yoga training 3 times per week
3237908|NCT01265173|Active Comparator|Cefotaxime|iv 2G q 8hrs for general, dose titration if needed (eg.CKD)
3237909|NCT01265173|Experimental|Ceftriaxone|iv 2G q 24hrs
3237910|NCT01265173|Experimental|Ciprofloxacine|iv 400mg q 12hrs for general, dose titration if needed (eg.CKD)
3237911|NCT01265186||Ventilated term newborns|Ventilated newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
3237912|NCT01265186||Control group: healthy term newborns|Control group: healthy newborns with a corrected gestational age ≧ 37 weeks of gestation until the 28th day of life respectively ≦ 44 weeks of gestation
3341645|NCT02190149||ADVATE (Factor VIII)|Participants will remain on their current (pre-study) treatment regimen of ADVATE throughout the study period
3341646|NCT02190149||RIXUBIS (Factor IX)|Participants will remain on their current (pre-study) treatment regimen of RIXUBIS throughout the study period
3237913|NCT01265251||Test-retest|Forty-four healthy elderly 60-82 years old
3237914|NCT01265251||Validity|Twenty six patients with various diseases and various ages
3341647|NCT02190162|Active Comparator|Tantum Verde® mouthwash|solution of Tantum Verde
3341648|NCT02190162|Placebo Comparator|placebo mouthwash|saline with mint flavor
3341649|NCT02190188|No Intervention|No specific treatment|No specific treatment after partial meniscectomy
3341650|NCT02190188|Other|Wedge Insole with 5mm wedge angel|Participants wear a wedge insole after partial meniscectomy
3341651|NCT02190188|Other|Knee Brace|Participants wear a knee brace after partial meniscectomy
3341652|NCT02190201|Experimental|videolaryngoscope|DLT intubation with McGrath videolaryngoscope
3237915|NCT01265251||Feasibility|Twenty seven patients under the preoperative investigation for INPH
3341653|NCT02190201|Active Comparator|Direct laryngoscope|DLT intubation with Macintosh laryngoscope
3341654|NCT02190227|Other|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
3341655|NCT02190292||PANS group|All current Swedish cases investigated with the Cunningham panel (approximately 150 individuals) will be invited to participate in the study. 50 of these will be re-assessed with the Cunningham panel.
3341656|NCT02190292||Psychiatric controls|60 individuals with psychiatric disorder (eg. ADHD, autism spectrum disorder, psychosis, major depression, obsessive-compulsive disorder) will be recruited.
3341657|NCT02190292||Healthy controls|25 age and sex matched children to the PANS group will be recruited.
3341658|NCT02190305|Experimental|Diagnostic: Multiplo HBc/HIV/HCV + Reveal HBsAg|Subjects tested with investigational devices and approved comparator assay algorithms for HIV and hepatitis B and C.
3341659|NCT02190318|Experimental|Losartan|Losartan is taken orally 100mg/d
3341660|NCT02190318|Experimental|spirolactone|spirolactone is taken orally 20mg/d
3341661|NCT02190318|Experimental|losartan in combination with spirolactone|Losartan is taken orally 100mg/d and spirolactone is taken orally 20mg/d
3341662|NCT02190318|Sham Comparator|blank control|patients with antihypertensives besides ACEI/ARBs and spirolactone.
3341663|NCT02190331|Experimental|Interventional program|The training protocol is constituted by 4 strengthening exercises (Side Lying External Rotation, Prone Horizontal Abduction with External Rotation, Y to I exercise and Chin Tuck) and 3 stretching exercises(one- Sided Unilateral Self Stretch Exercise, one-sided Unilateral Self Stretch Exercise, Static Sternocleidomastoid Stretch and Static Levator Scapulae Stretch
3237916|NCT01265264|Experimental|ulodesine Placebo + Allopurinol 300mg|Oral dose administered daily for 84 days.
3237917|NCT01265264|Experimental|ulodesine 5mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3237918|NCT01265264|Experimental|ulodesine 10mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3237919|NCT01265264|Experimental|ulodesine 20mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3237920|NCT01265264|Experimental|ulodesine 40mg + Allopurinol 300mg|Oral dose administered daily for 84 days.
3237921|NCT01265277||at home|Infants 0-3 months who will stay at home with a parent
3237922|NCT01265277||child care|Infant 0-3 months who will attend a licensed child care center
3341664|NCT02190331|Active Comparator|Control group|The control group will only participate in the Physical Education classes
3341665|NCT02190344|Experimental|Functionality of 8-channel paddle coil system|
3341666|NCT02190357|Experimental|rifaximin|400 mg bid,orally
3341667|NCT02190357|No Intervention|controlled group|no intervention
3341668|NCT02190370|Experimental|Resources activation|At first patients get informed about Tics in general. Through different exercises existing resources and skills are activated and strengthened. Feeling of self-esteem and self-respect are strengthened. Also the emotional awareness is strengthened. Relaxation methods are also introduced.
3341669|NCT02190383|Experimental|Habit Reversal Training|At first patients get informed about Tics in general. Then the individual Tics are specified and the tic-reaction is looked at further. The Tic-Symptoms are observed and the premonitory urge is specified. For all individual tics a specific reversal movement is developed. Relaxation methods are introduced.
3341670|NCT02190396||Group 1|Placental calcification of Grade 3
3341671|NCT02190396||Group 2|No placental calcification noted, the control group.
3341672|NCT02190409|Experimental|Test, Control|Test: Minimum two tapered implants (Ankylosis, Dentsply Friadent) were placed to each patient. After surgical preparation of implant sockets, PRF that was prepared preoperatively was placed randomly to one of the sockets (PRF+). Acellular plasma portion of PRF was used to wet the implant placed into the PRF-coated socket Control: Other socket was selected as a control group (No Platelet Rich Fibrin used): In the control group no extra intervention used and the conventional procedure was done. Thus the readings of the experimental arm compared with this control.
3341673|NCT02190448|Experimental|study herbal tea|Supplementation of 3-5, 8 oz cups of study tea daily for 4 weeks.
3341674|NCT02190448|Placebo Comparator|herbal placebo tea|Supplementation of 3-5, 8oz cups of tea daily for 4 weeks.
3341675|NCT02190461|Experimental|Early Respiratory Rehabilitation|Starting the Early Respiratory Rehabilitation programme during the admission and continues it at home immediately after discharge for a period of 3 months.
3341676|NCT02190461|Active Comparator|Conventional Respiratory Rehabilitation|Started a conventional Respiratory Rehabilitation programme at home one month after discharge from hospital and continues for 3 months.
3341677|NCT02190474|Experimental|Mindfulness Group|These adolescents will be invited to participate in a group mindfulness meditation program based on a protocol refined by the investigative team. The weekly group meetings will be taught by an MBSR teacher at the Yale School of Medicine, with experience teaching mindfulness interventions to adults, children, and adolescents.
3341678|NCT02190487||TAS group|patients who had thoracic aortic surgery due to dissection
3341679|NCT02190500|Active Comparator|Mobile Stroke Unit Management|Acute ischemic stroke patients treated in the Mobile Stroke Unit
3341680|NCT02190500|No Intervention|Standard Management|Acute ischemic stroke patients receiving standard management
3341681|NCT02190526|Experimental|Mesalazine(asacol 800 mg)|patients receive asacol (800 mg/TDS) and a placebo agent similar to amitriptyline (10 mg/HS) for 8 weeks
3341682|NCT02190526|Experimental|Amitriptyline|patients receive amitriptyline (10 mg/HS) and a placebo like asacol (800 mg/ TDS) for 8 weeks
3341683|NCT02190526|Placebo Comparator|placebo group|patients receive placebo like asacol (800 mg/TDS) and placebo similar to amitriptyline (10 mg/HS) for 8 weeks
3237923|NCT01265290|Experimental|Telemetric ECG monitoring|Telemetric Full Disclosure ECG monitoring
3341684|NCT02190539|Experimental|Homeopathic treatment|A feasibility study examining whether patients with advanced breast cancer would follow a homeopathic protocol for three to six months.
3341685|NCT02190565|Placebo Comparator|Placebo|Placebo consisting of two sham multivitamin and mineral tablets and two capsules of oil
3341686|NCT02190565|Active Comparator|Food supplement|Food supplement consisting of fish oil (omega 3 fatty acids DHA and EPA) and multivitamin and mineral tablets with extra iron and folic acid
3341687|NCT02190578|Experimental|Diagnostic: Reveal G4|Subjects tested with investigational devices and approved comparator assay algorithms for HIV
3341688|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Management Plan|"Patients in study arm will receive:~Enhanced Clinic Intervention~Enhanced Health Plan~Unified Management Plan"
3341689|NCT02190617|Active Comparator|CHW Home Visit Only|"Patients in study arm will receive:~CHW Home Visit~Usual clinic care with enhanced health plan"
3341690|NCT02190617|Active Comparator|Enhanced Clinic+ Unified Plan+ CHW|"Patients in study arm will receive:~CHW Home Visit~Enhanced Clinic intervention~Enhanced health plan~Unified asthma management plan"
3341691|NCT02190617|No Intervention|Usual Care|-Usual clinic care with enhanced healthplan
3341692|NCT02190630|Active Comparator|Part time (12hour) wear|the' Modified Clark Twin Block' will be worn part time
3341693|NCT02190630|Active Comparator|Full time (24hour) wear|the ' Modified Clark Twin Block' will be worn full time
3341694|NCT02190643|Experimental|Adherence condition|Brief smoking cessation counseling session (based on 5 A's approach) that includes a module focused on improving adherence to using the nicotine patch, plus 8-week supply of nicotine patches.
3341695|NCT02190643|Active Comparator|Standard condition|Brief smoking cessation counseling session (based on 5 A's approach) that does not include a module focused on improving nicotine patch adherence, plus 8-week supply of nicotine patches.
3341696|NCT02190656||Anterior resection|Patients having had an anterior resection for rectal cancer who are more than 12 months post surgery
3341697|NCT02190669||exercise in individuals without diabetes|exercise in individuals without diabetes
3341698|NCT02190669||exercise in type 1 diabetes|exercise in type 1 diabetes
3341699|NCT02190669||exercise in type 2 diabetes|exercise in type 2 diabetes
3341700|NCT02190695|Active Comparator|Decitabine|Decitabine 20mg/m2 IV over 1hour daily times 5 days every 28 days
3341701|NCT02190695|Experimental|Decitabine and Carboplatin|Decitabine 20mg/m2 IV over 1hour daily times 5 days, plus Carboplatin AUC 5 IV over 1hour on day 8. repeat every 28 days.
3341702|NCT02190695|Experimental|Decitabine and Arsenic|Decitabine 20mg/m2 IV over 1 hour daily for 5 days plus Arsenic Trioxide 0.15mg/kg IV daily for 5 days. repeat every 28 days
3341703|NCT02190708|Experimental|PQ912 & Midazolam & Omeprazole|day2 - day6 800mg PQ912 twice per day po day1 / day6 2.5 mg Midazolam once per day day1 / day6 20 mg Omeprazole once per day
3341704|NCT02190734|Other|wheelchair, walking on treadmill, walking overground|Sitting in wheel chair Gait training on treadmill Gait training overground
3237924|NCT01265290|Experimental|24 hours standard Holter monitoring|
3237925|NCT01265303|Other|Catheter ablation|
3341705|NCT02190760|Active Comparator|Group I (ISB-P)|Interscalene block with perineural injection of dexamethasone 0.1 mg/kg
3341706|NCT02190760|Active Comparator|Group II (ISB-S)|Interscalene block with systemically injection of dexamethasone 0.1 mg/kg.
3341707|NCT02190760|Active Comparator|Group III - ISB-C|Interscalene block without adjuvant.
3341708|NCT02190773||Chronic periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment
3341709|NCT02190773||Agressive periodontitis|Surgical periodontal treatment and GCF collection 3 months after treatment.
3237926|NCT01265303|Other|Pacemaker implantation|
3237927|NCT01265303|Other|Pharmacotherapy|
3237928|NCT01265329|No Intervention|Control|No sperm selection
3237929|NCT01265329|Experimental|Annexine V negative|Sperm selection with Annexine V protein
3237930|NCT01265342|Placebo Comparator|Placebo|
3341710|NCT02190773||Control group|Periodontally healthy individuals
3237931|NCT01265342|Experimental|Beclomethasone|Beclometasone suspension 400 mcg will be administered through a nebuliser twice a day, in the morning and in the evening, for 10 days
3237932|NCT01265355|Experimental|Anti-rotavirus protein|
3341711|NCT02190786|Experimental|KUX-1151, Low dose|
3341712|NCT02190786|Experimental|KUX-1151, Middle dose|
3341713|NCT02190786|Experimental|KUX-1151, High dose|
3341714|NCT02190799|Experimental|Convalescent plasma|Enrolled patients will receive 2 units of the convalescent plasma after meeting the eligibility criteria
3341715|NCT02190812|Experimental|Forearm supporter|This study measured the effect of proper forearm supporter to alleviate pain and improve the wrist and grip strength in the subjects with tennis elbow.
3341716|NCT02190812|Experimental|Grip ball|In this study a portable grip ball training system is developed. This study use the grip ball to train the wrist muscle. It's expected to reduce the risk of injury of the elderly in their daily lives.
3341717|NCT02190838|Experimental|Dacarbazine with Metformin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Metformin 850 mg BID.
3341718|NCT02190838|Experimental|Dacarbazine and Melatonin|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days with Melatonin 3 mg before sleep daily.
3237933|NCT01265355|Placebo Comparator|Maltodextrin|
3237934|NCT01265368|Experimental|Study medication|
3237935|NCT01265381||Cohort of Chernobyl Cleanup Workers in Ukraine|Thyroid cancer cases and matched controls in the cohort
3341719|NCT02190838|Active Comparator|Dacarbazine|32 patients will receive Dacarbazine 1000 mg/m^2 once every 28 days
3341720|NCT02190851|Experimental|electrical nerve stimulation (TENS)|"Two electrodes are attached around the internal malleolus and connected to the TENS unit, by UROSTIM 2.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
3237936|NCT01265433|Experimental|WT-1-vaccine Montanide + GM-CSF|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3237937|NCT01265433|Active Comparator|Montanide adjuvant + GM-CSF (This arm is closed)|The study will be a randomized phase II trial to determine the 1-year progression free survival after treatment with WT-1 analog peptide vaccine in patients with MPM after completion of combined modality therapy.
3341721|NCT02190851|Placebo Comparator|Control group|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
3237938|NCT01265485|Experimental|treatment|
3237939|NCT01265576|Placebo Comparator|Sorafenib with placebo|Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
3341722|NCT02190877||Cohort 1: Subjects taking diuretic medication|All subjects will be in the same group, Cohort 1
3341723|NCT02190890|Experimental|Dry needling: 4 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 4 local twitch responses were elicited.
3341724|NCT02190890|Experimental|Dry needling: 6 local twitch responses|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until 6 local twitch responses were elicited.
3237940|NCT01265576|Experimental|Sorafenib plus VT-122|
3237941|NCT01265589|Placebo Comparator|I=surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
3237942|NCT01265589|Experimental|II=surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
3237943|NCT01265602|Experimental|LAS41007|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3237944|NCT01265602|Active Comparator|LASW1510|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3237945|NCT01265602|Placebo Comparator|vehicle|All patients will be instructed to apply the IMP twice daily, once in the morning and once in the evening. Per application, not more than 1.5 g of the IMP should be applied, which is sufficient to cover a total area of 75 cm2 (corresponding to 3 single TAs, each with a size of 25 cm²) in maximum. The IMPs will be applied for 90 days in maximum.
3237946|NCT01265628||Glaucoma|
3237947|NCT01265628||Retinitis pigmentosa (RP)|
3237948|NCT01265628||Anterior Ischemic Optic Neuropathy (AION)|
3237949|NCT01265641|Experimental|1|
3237950|NCT01265641|Experimental|2|
3237951|NCT01265641|Experimental|3|
3237952|NCT01265641|Placebo Comparator|4|
3237953|NCT01265654||All patients|Patients with ABC and two lines of hormonal treatment
3237954|NCT01265680|Experimental|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital
3237955|NCT01265680|No Intervention|Control|No added administration other than our standard of care.
3237956|NCT01265732|Active Comparator|oral single dose dispersion 100mg|Subjects receive a single dose of PF-04191834 as a dispersion
3237957|NCT01265732|Active Comparator|oral wet milled suspension 100mg|Subjects receive a single dose of PF-04191834 as a suspension
3341725|NCT02190890|Experimental|Dry needling: Until no more local twitch responses elicited|Deep dry needling in the active myofascial trigger point in the upper trapezius muscle. The muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the MTrP until no more local twitch responses were elicited.
3341726|NCT02190890|Active Comparator|Control|The needle was inserted 1.5 cm away from the trigger point in the trapezius muscle and withdrawn without any consecutive insertion.
3341727|NCT02190929||Vasculitis Contact Registry Patients|Patients will be recruited from within the Vasculitis Clinical Research Consortium (VCRC) Patient Contact Registry to participate in an online questionnaire. More than 3000 patients, representing all the different types of idiopathic vasculitis, are currently enrolled into the on-line registry. The different types of vasculitis available for study include: Behçets disease, Churg-Strauss Syndrome, CNS Vasculitis, Giant Cell Arteritis, granulomatosis with polyangiitis (Wegener's granulomatosis), Henoch-Schöenlein Purpura, Microscopic Polyangiitis, Polyarteritis Nodosa, or Takayasu's Arteritis.
3341728|NCT02190942||Vasculitis Contact Registry Patients|Consent will be obtained from at least 20 randomly selected patients with each of the following self-identified diagnoses in the VCRC Patient Contact Registry: Behçet's disease, EGPA, GCA, GPA, MPA, PAN and TAK that have already completed the VCRC Diagnostic Questionnaires. Permission will be obtained to contact subjects' primary vasculitis care providers to request that the providers complete an online version of this questionnaire (or print copy, if they prefer), and request specific chart items from their office to further verify the data.
3341729|NCT02190955||NEPTUNE contact registry patients|Patients and caregivers will be recruited from the Nephrotic Syndrome Study Network (NEPTUNE) Patient Contact Registry. Over 1000 patients and caregivers are members of the registry and have already provided permission to be contacted for future research studies. Analysis of the one-time online questionnaire will be done in collaboration with investigators from the NEPTUNE Consortium.
3341730|NCT02190968|Experimental|Mindful Mood Balance|An 8 session internet intervention targeting residual depressive symptoms.
3341731|NCT02190968|Active Comparator|Usual Depression Care|Usual Depression Care through Kaiser Permanente Colorado
3341732|NCT02190981||Ultrasound for Small Bowel Obstruction|Emergency department patients undergoing point-of-care ultrasound to evaluate for suspected small bowel obstruction
3341733|NCT02190994|No Intervention|A. Normal function, non-GC replacement|No glucocorticoid replacement will be given perioperatively.
3341734|NCT02190994|Active Comparator|B. Normal function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
3341735|NCT02190994|Active Comparator|C. Impaired function, low-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1. 80mg hydrocortisone at day 2; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet at day 4 and day 5; 2.5mg at day 6;
3341736|NCT02190994|Active Comparator|D. Impaired function, high-dose GC|Hydrocortisone 100mg i.v. before anesthesia induction, and postoperative day 1 and day 2. 60mg hydrocortisone at day 3; 60mg at day 3; 20mg at day 4; 5mg oral prednisone acetate tablet per day, since postoperative day 3.
3341737|NCT02191007|Experimental|Calcipotriol/Betamethasone and Calcipotriol|Calcipotriol/Betamethasone ointment 1/d for 4 weeks; Calcipotriol ointment bid for 6 weeks on-demand treatment period;
3341738|NCT02191007|Sham Comparator|Calcipotriol/Betamethasone and urea cream|alcipotriol/Betamethasone ointment 1/d for 4 weeks , urea cream 1/d for 6 weeks on-demand treatment period
3237958|NCT01265732|Active Comparator|oral wet milled suspension 300mg|Subjects receive a single dose of PF-04191834 as a suspension
3237959|NCT01265745|Active Comparator|Valortim|Valortim 1mg,5mg,10mg
3237960|NCT01265745|Placebo Comparator|Placebo|Saline solution will be used as the placebo
3237961|NCT01265758|Experimental|Telemetric ECG monitoring|Telemetric 14-days Full Disclosure ECG recording.
3237962|NCT01265758|Active Comparator|Standard 24-hours Holter ECG recording|Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.
3341739|NCT02191007|Active Comparator|Calcipotriol/Betamethasone|Calcipotriol/Betamethasone ointment 1/d for 4 weeks, Calcipotriol/Betamethasone ointment 1/d for 6 weeks on-demand treatment period
3237963|NCT01265771|Experimental|Telemetry ordered by a Cardiologist|
3237964|NCT01265771|Experimental|24 hours standard Holter monitoring|
3237965|NCT01265771|Experimental|Telemetry ordered by a Pediatrician|
3237966|NCT01265810|Other|sodium chloride -> supersaturated calcium-phosphate|Patients in this arm start first with sodium chloride 0.9% mouth rinses and go crossover to supersaturated calcium-phosphate mouth rinses.
3237967|NCT01265810|Other|supersaturated calcium-phosphate -> sodium chloride|Patients in this arm start first with supersaturated calcium-phosphate mouth rinses and go crossover to sodium chloride 0.9% mouth rinses.
3237968|NCT01265836||1|
3237969|NCT01265849|Experimental|LI + CIZ + SOC|LI plus CIZ (cyclophosphamide, indomethacin and zinc) is given as adjuvant therapy prior to standard of care (SOC).
3341740|NCT02191020|Experimental|Total glucosides of paeony & Acitretin Capsules|During the first week，0.6g，oral，b.i.d.During the other weeks，0.6g，oral，t.i.d
3341741|NCT02191020|Active Comparator|Acitretin Capsules|20mg/day oral,when subject's weight less than 70kg;otherwise,30mg/day oral.
3341742|NCT02191059|Experimental|Intermittent High Dose of Icotinib|"Intermittent High Dose of Icotinib in Combination With Docetaxel:~Icotinib 625mg tablet b ymouth three times per day for day1-2, Docetaxel 75mg/m2 injection intravenous drip for day 3, 3 weeks as 1 cycle"
3341743|NCT02191072|Experimental|omalizumab|omalizumab 300mg subcutaneously once
3341744|NCT02191085|No Intervention|Standard Management|"Patients in the Standard Management arm will be assessed without any interventions.Patients will be assessed by a sleep respirologist and follow a management plan that is determined by the sleep physician and patient. This plan may involve polysomnography or the initiation of PAP therapy. If further testing is ordered, follow-up may occur with the physician or with an ACP, at the physician's discretion. For patients initiating PAP therapy, the decision to delegate follow-up to an ACP will be left up to the physician, as the intent of this study is to observe real-world practice and not to change the management of individual patients."
3341745|NCT02191085|Active Comparator|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient."
3341746|NCT02191098|Experimental|ALT-803|ALT-803
3341747|NCT02191111|Experimental|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
3341748|NCT02191111|No Intervention|Control|These sites will continue practice as usual, with no contact from study staff.
3341749|NCT02191124|Experimental|measurement-based care|MBC allows psychiatrists to individualize treatment decisions for each patient based on the change of psychopathology and tolerance toward antidepressants. Treatment decisions were made by treating psychiatrists according to ratings of self-report scales obtained at each treatment visit. Paroxetine was started at 20mg/day and then raised to 30mg/day by week 4, 40mg/day by week 6, 50mg/day by week 8 and 60mg/day by week 10. Mirtazapine was started at 15mg/day and raised to 30mg/day by week 1 and 45mg/day by week 4. Dose adjustments were dependent on how long a patient had received a particular dose, symptom changes and side effects.
3237970|NCT01265849|Active Comparator|Standard of Care (SOC)|SOC for previously untreated SCCHN patients is currently surgery followed by either radiotherapy or combined radiochemotherapy depending the patient's risk status for relapse determined at surgery.
3341750|NCT02191124|Active Comparator|Standard treatment|Patients in the ST group are treated by their psychiatrists according to their clinical needs as judged at each outpatient visit, receiving either open-label paroxetine (20-60mg/day) or mirtazapine (15-45mg/day) within the therapeutic dose range.
3237971|NCT01265849|Experimental|LI + SOC|LI is administered without CIZ to determine the contribution of CIZ to the effects of LI.
3237972|NCT01265862|Active Comparator|LMA-Fastrach® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of LMA-Fastrach®, establishment of ventilation~Evaluation of glottic view through LMA-Fastrach® using fibrescope~Tracheal intubation with the GlideRite® tube through the LMA-Fastrach®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3341751|NCT02191150||Cohort 1|Patients with CKD
3341752|NCT02191163|Experimental|Antistax®|1 x 360 mg for 42 days
3341753|NCT02191163|Placebo Comparator|Placebo|
3341754|NCT02191176|Experimental|Dextromethorphan syrup - low dose|
3341755|NCT02191176|Experimental|Dextromethorphan syrup - high dose|
3237973|NCT01265862|Experimental|I-gel® and GlideRite® tube|"Induction of general anesthesia with 1,5-2,5 mg/kg propofol and 1-3 mcg/kg fentanyl and neuromuscular relaxation with 0,6 mg/kg of rocuronium.~Direct laryngoscopy, evaluation of laryngeal view grade according to Cormack-Lehane classification~Insertion of I-gel®, establishment of ventilation~Evaluation of glottic view through I-gel® using fibrescope~Tracheal intubation with the GlideRite® endotracheal tube through the I-gel®~With the endotracheal tube in place, the anaesthesiologist will proceed to the removal of supraglottic device"
3237974|NCT01265888|Experimental|Dosing Group 1|1 Liter per Minute (LPM)of inhaled nitric oxide via nasal cannula: approximately 5 parts per million (ppm)
3341756|NCT02191176|Placebo Comparator|Placebo|
3341757|NCT02191189|Active Comparator|Treatment A, p.o.|50 mg Nevirapine administered orally in 100 mL water
3341758|NCT02191189|Experimental|Treatment B, ascending colon|50 mg Nevirapine administered to the ascending colon via Enterion™ capsule
3341759|NCT02191189|Experimental|Treatment C, jejunum|50 mg Nevirapine administered to the jejunum via Enterion™ capsule
3341760|NCT02191189|Experimental|Treatment D, ileum|50 mg Nevirapine administered to the ileum via Enterion™ capsule
3341761|NCT02191189|Experimental|Treatment E, descending colon|50 mg Nevirapine administered to the descending colon via Enterion™ capsule
3341762|NCT02191202||Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
3341763|NCT02191215||Nevirapine (Viramune®)|
3237975|NCT01265888|Experimental|Dosing Group 2|2 LPM of inhaled nitric oxide via nasal cannula: approximately 15 ppm
3341764|NCT02191228|Experimental|Group 1|Linagliptin in subjects with normal renal function
3341765|NCT02191228|Experimental|Group 2|Linagliptin in patients with mild renal insufficiency (RI)
3341766|NCT02191228|Experimental|Group 3|Linagliptin in patients with moderate RI
3237976|NCT01265888|Experimental|Dosing Group 3|4 LPM of inhaled nitric oxide via nasal cannula: approximately 20 ppm
3237977|NCT01265901|Active Comparator|Sunitinib|Sunitib as Standard therapy per Label.
3237978|NCT01265901|Experimental|IMA901 plus GM-CSF added to sunitinib after single dose of cy|After 1 cycle of sunitinib, intradermal vaccinations with IMA901 plus GM-CSF as adjuvant after a single dose of cyclophosphamide will be applied for a period of 4 months while continuing treatment with sunitinib
3237979|NCT01265914|Placebo Comparator|placebo|
3341767|NCT02191228|Experimental|Group 4|Linagliptin in patients with severe RI
3341768|NCT02191228|Experimental|Group 5|Linagliptin in patients with end-stage renal disease (ESRD)
3341769|NCT02191228|Experimental|Group 6|Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
3341770|NCT02191228|Experimental|Group 7|Linagliptin in patients with normal renal function and T2DM
3341771|NCT02191241|Experimental|Red Vine Leaf Extract|
3341772|NCT02191254|Experimental|Antistax®|1 tablet per day for 12 weeks
3341773|NCT02191254|Placebo Comparator|Placebo|
3341774|NCT02191280|Experimental|Antistax®, low dose|
3341775|NCT02191280|Experimental|Antistax®, high dose|
3341776|NCT02191280|Placebo Comparator|Placebo|
3341777|NCT02191293||Viramune®|
3341778|NCT02191306||HIV Positive Patients (Study Group)|
3341779|NCT02191306||Non HIV Positive Patients (Control)|
3341780|NCT02191319||Viramune®|Patients switching from protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) containing antiretroviral regimen to Viramune®
3341781|NCT02191332||Viramune|
3341782|NCT02191345|No Intervention|10 minute break|Participants asked to take a 10 minute break as usual 3 times per week for 4 weeks
3341783|NCT02191345|Experimental|Guided Imagery|Participants listen to one of 6 pre-recorded guided imagery tracks 3 times per week for 4 weeks
3341784|NCT02191358||"Tested patients (prospective)"|Patients whose providers decide to have them undergo testing via the YouScript Personalized Prescribing System will be recruited for the study. Data will be gathered at baseline and 120 days later. The decision to utilize YouScript and all treatment decisions will be made at the discretion of the provider in accordance with their usual care practice, and will be made prior to the decision to participate in the study.
3341785|NCT02191358||"Untested patients (retrospective)"|Patients for comparison to the prospectively followed patients will be derived from Inovalon's MORE2 healthcare database. Patients meeting the same enrollment criteria (excluding the YouScript testing) will be matched on key characteristics to the tested patients. Outcomes will be compared between the prospectively enrolled patients undergoing pharmacogenetic testing with the YouScript Personalized Prescribing System at the discretion of their treating physician.
3341786|NCT02191371|Experimental|propofol|Propofol is used as a maintenance anesthetic to patients in the propofol group. Intervention: propofol infusion by target-controlled infusion for maintaining anesthesia propofol (Fresofol MCT 2%) target effect site concentration: 4~5 mcg/ml, during general anesthesia
3341787|NCT02191371|Experimental|desflurane|"Desflurane is used as a maintenance anesthetic to patients in the desflurane group.~Intervention: Desflurane administration for maintaining anesthesia desflurane (Suprane) inhalation as 6~8 vol% during general anesthesia"
3341788|NCT02191384|Experimental|Orcinoside 25mg per day|
3237980|NCT01265914|Experimental|FP-01.1|
3341789|NCT02191384|Experimental|Orcinoside 50mg per day|
3341790|NCT02191384|Experimental|Orcinoside 100mg per day|
3341791|NCT02191384|Experimental|Orcinoside 200mg per day|
3341792|NCT02191384|Experimental|Orcinoside 400mg per day|
3341793|NCT02191384|Experimental|Orcinoside 600mg per day|
3341794|NCT02191384|Placebo Comparator|placebo|
3341795|NCT02191410|Active Comparator|High Frequency Positive Pressure Ventilation|
3341796|NCT02191410|Placebo Comparator|Continuous Positive Airway Pressure|
3341797|NCT02191423|Experimental|postpartum depression|"Women suffering from postpartum depression, assessed by fMRI and then treated by dyadic psychotherapy~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~All women in this group participate in 8-weeks of dyadic psychotherapy (DP) at the outpatient Psychiatric Department, Tel-Aviv Medical Center.~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
3341798|NCT02191423|Other|normal controls|"Normal control women not suffering from postpartum depression assessed by fMRI~All participants will undergo two functional brain scans at the Tel Aviv Medical Center. The two scans will take place one week apart, one scan will include administration of oxytocin (24IU) and the other will include the use of placebo (the order in which the two different treatments is applied will be random).~A final end-of-study clinical evaluation, will be conducted at the end of 8 weeks. The evaluation will include a psychiatric evaluation, the MADRS, and a physical examination, the mother-infant interaction will be videotaped, and the YIPTA, BDI, EPDS & STAI will be administered. Salivary OXT samples will be collected from the mother and from the infant and infants will undergo a developmental assessment."
3341799|NCT02191436||Patients with haemophilia|Hemophilia patients (children, youth and adults) and parents of children with hemophilia under 18
3341800|NCT02191462|Experimental|Niagen 100mg|1 Niagen capsule (1 x 100 mg capsule) and 9 Placebo capsules
3341801|NCT02191462|Experimental|Niagen 300mg|3 Niagen capsules (3 x 100mg capsule) and 7 Placebo capsules
3341802|NCT02191462|Experimental|1000mg Niagen|10 Niagen capsules (10 x 100mg capsule)
3341803|NCT02191475|Active Comparator|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy, dose of imipenem/cilastatin 500mg, IVdrip, 3~4 times/d, or meropenem 1g, IVdrip, 3 times/d; vancomycin for 15mg/kg,2 times/d, or linezolid 300mg, IVdrip, 2 times/d; these drugs are required to state organ function in patients with drug doses adjustment, treatment for 3-5 days.
3341804|NCT02191475|Experimental|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin / tazobactam (tazocin ®), with or without antifungal therapy, dose of tigecycline first dose 100 mg, 50 mg, every 12 hours, piperacillin / tazobactam 4.5g, ivdrip, 3-4 times a day, each time the infusion of 3 hours, treatment for 3-5 days.
3341805|NCT02191488|Experimental|Experimental: 5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
3341806|NCT02191501|Experimental|Pyloric restriction|Endoscopic method of pyloric restriction in order to decrease gastric emptying. The hypothesis is that this will cause and early and prolonged satiety which will inturn lead to decreased food consumption and lead to weight loss.
3341807|NCT02191527|Experimental|Point of Care Testing|The point-of-care devices will be located in the MCH services, where a trained lay counselor will do the tests.
3237981|NCT01265927|Experimental|GRN163L + Trastuzumab|
3237982|NCT01265940|Experimental|Pazopanib + Vinflunine|
3341808|NCT02191527|No Intervention|Laboratory Testing - Standard of care|Samples sent to the laboratory for analysis, (standard of care)
3341809|NCT02191540|Experimental|Abnoba Viscum F 20mg|
3341810|NCT02191553|Active Comparator|Control Group: Relaxation Techniques|Relaxation techniques which do not involve either formal or informal mindfulness training. Subjects in this group practice Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
3237983|NCT01265979||GIST treated with regorafenib/placebo|patients with advanced, metastatic gastro-intestinal stromal tumors treated with regorafenib or placebo
3237984|NCT01266005|Experimental|1|Clevudine 30mg
3237985|NCT01266005|Active Comparator|2|Entecavir 0.5mg
3237986|NCT01266031|Experimental|Bevacizumab|10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle.
3237987|NCT01266031|Experimental|Vorinostat and Bevacizumab|"Vorinostat: 400 mg/day by mouth on days 1 to 7 and days 15 to 21 of a 28 day cycle.~Bevacizumab: 10 mg/kg/dose by vein on days 1 and 15 of a 28 day cycle."
3341811|NCT02191553|Experimental|Loving Kindness Meditation (Metta)|Loving-kindness meditation following Kristin Neff protocol
3341812|NCT02191553|Experimental|Body Scan|Body scan as described in standard MBSR protocol
3341813|NCT02191553|Experimental|Sitting Practice|Sitting practice as mindfulness meditation described in standard MBSR protocols.
3341814|NCT02191566|Experimental|S-1/Oxaliplatin|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months; Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
3341815|NCT02191631|Experimental|Internet-delivered CBT|Participants will receive 12 weeks of internet-delivered cognitive behavior therapy with psychologist support.
3341816|NCT02191631|No Intervention|Wait list|Participants will receive no treatment for 12 weeks. After that period participants will receive Internet-delivered Cognitive Behavior Therapy.
3341817|NCT02191644|Placebo Comparator|Refined rice|
3237988|NCT01266044|Experimental|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3237989|NCT01266044|Active Comparator|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3237990|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations. Questionnaires - Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
3237991|NCT01266057|Experimental|Hydroxychloroquine + Sirolimus|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Sirolimus starting dose of 2 mg by mouth every day for a 21 day cycle.
3237992|NCT01266057|Experimental|Hydroxychloroquine + Vorinostat|Hydroxychloroquine starting dose of 200 mg by mouth every day for a 21 day cycle. Vorinostat starting dose of 200 mg by mouth per day for a 21 day cycle.
3341818|NCT02191644|Experimental|Whole grains and legumes|
3341819|NCT02191657|Experimental|Cohort 1|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 33 mg/kg deferiprone three times a day for a total daily dosage of 99 mg/kg
3341820|NCT02191657|Experimental|Cohort 2|Subjects in this arm were healthy volunteers who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg
3341821|NCT02191657|Experimental|Cohort 3|Subjects in this arm were asymptomatic HIV-infected individuals who received a dose of 50 mg/kg deferiprone three times a day for a total daily dosage of 150 mg/kg.
3341822|NCT02191670||METALYSE®|
3237993|NCT01266083|Experimental|WT1 peptide vaccine|This is a Phase II study evaluating the safety and efficacy of the WT1 peptide vaccine in patients who are in CR from Acute Myeloid Leukemia (AML).
3341823|NCT02191683||Health of women before conception|Tanzanian women aged 18-40 years focusing on prevalence of anaemia, infections, nutritional status, and NCDs.
3341824|NCT02191683||480 women during pregnancy|"Describe how 1st and 2nd trimester anaemia compared to 3rd trimester anaemia alters foetal growth and newborns' body composition.~Evaluate anaemia's effect on villous branching in placenta, and uterine and umbilical artery blood flow.~Evaluate effect on vascular endothelial growth factor A/placental growth factor balance and insulin-like growth factor axis.~Determine which markers for foetal programming such as methylation of regulatory genes related to metabolism and haematopoiesis may be discovered early after exposure to anaemia."
3341825|NCT02191709|Experimental|Dextromethorphan syrup|Bisoltussin® Syrup
3341826|NCT02191709|Active Comparator|Dextromethorphan soft pastilles|Silomat® DMP soft pastilles
3341827|NCT02191722|Experimental|JIA patients|All participants will be evaluated before and after reading the comics booklet
3341828|NCT02191735||Troponin I|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3341829|NCT02191735||Myoglobin|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP Myoglobin test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3341830|NCT02191735||CK-MB|Subjects who have undergone a routine test order of Troponin for suspected Acute Coronary Syndrome / Myocardial Infarction (ACS/MI) and who have a RAMP CK-MB test result that is within the test reportable range. Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3341831|NCT02191735||NT-proBNP|Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
3341832|NCT02191748|Active Comparator|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site.
3375852|NCT03702231|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose.
3237994|NCT01266096|Experimental|newly diagnosed or recurrent head/neck melanoma|This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.
3237995|NCT01266109|Experimental|CM-FAM|
3237996|NCT01266109|Active Comparator|US|
3237997|NCT01266135|Experimental|Arm 1: QAX576 10 mg/kg|
3237998|NCT01266135|Placebo Comparator|Arm 2: Placebo|
3237999|NCT01266174|Experimental|Eltoprazine|eltoprazine pill 2.5mg bid, eltoprazine pill 5mg bid, eltoprazine 7.5mg bid
3341833|NCT02191748|Experimental|Needling and Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site.
3341834|NCT02191748|No Intervention|No treatment|No treatment will be done to these vitiligo patches as a control.
3238000|NCT01266174|Placebo Comparator|Placebo|placebo pill 2.5mg bid, placebo pill 5mg bid, placebo 7.5mg bid
3238001|NCT01266187|Experimental|Arm B|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
3238002|NCT01266187|Active Comparator|Arm A|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
3238003|NCT01266200|Active Comparator|Minimal-invasive treatment (Mantis)|Patients, who received a minimal-invasive surgery and the fracture was fixed by a system called Mantis
3238004|NCT01266200|Active Comparator|Conventional technique (XIA)|Patients who received a surgical treatment including one long cut (conventional operation technique) and the fracture was fixed by a conventional system called XIA
3238005|NCT01266213|Experimental|Fulvestrant plus Goserelin|
3341835|NCT02191761|Experimental|SM04755|
3341836|NCT02191774||Gestational length up to 63 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
3341837|NCT02191774||Gestational length 64-70 days|Medical abortion at home using 200 mg of Mifepristone orally at the clinic followed by 0.8 mg Cytotec vaginally at home 48 hours later
3341838|NCT02191787|Experimental|Seresis® + Placebo|"2 capsules Seresis® o.d. for 5 days~2 capsules Placebo o.d. the day before treatment with Seresis®"
3341839|NCT02191813|Experimental|Seresis®|
3238006|NCT01266213|Experimental|Anastrozole plus Goserelin|
3341840|NCT02191813|Placebo Comparator|Placebo|
3341841|NCT02191826|Experimental|SOM0226 single dose|
3238007|NCT01266213|Active Comparator|Goserelin alone|
3238008|NCT01266226|Experimental|ACP treated|The patients are going to get an injection of 4mL autologous conditioned plasma under the footprint following an arthroscopic repair of the rotator cuff.
3238009|NCT01266226|Placebo Comparator|Control group|The patients are going to get an injection of 4mL saline solution under the footprint following an arthroscopic repair of the rotator cuff.
3341842|NCT02191826|Experimental|SOM0226 multiple doses|
3341843|NCT02191839|Active Comparator|alpha 1 antitrypsin|patients receive 4 grams of IV alpha 1 antitrypsin preoperatively
3341844|NCT02191839|Placebo Comparator|placebo|10 patients will randomely receive placebo
3341845|NCT02191852|Experimental|Seresis®|2 capsules per day for a period of 16 consecutive weeks
3341846|NCT02191878|Experimental|Phase 1 Escalation / Phase 2 Expansion|"Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD.~Phase 2 - dose expansion at the MTD."
3341847|NCT02191891|Experimental|BI 836845 + afatinib|BI 836845 low or high dose (weekly IV infusion), afatinib 30mg or 40mg (once daily oral dosing)
3341848|NCT02191904|Active Comparator|Truview EVO2®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively.
3341849|NCT02191904|Active Comparator|Airtraq®|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
3341850|NCT02191904|Active Comparator|Direct laryngoscopy|Patients were randomly assigned into three groups with the sealed envelope method according to the laryngoscope type, which we had and we were used to; Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes were used in direct laryngoscopy Group DL (n=50), Truview EVO2® Group TV (n=50) and Airtraq® Group ATQ (n=50), respectively
3341851|NCT02191917|Experimental|Measurement of Respiratory Muscle Strength|
3341852|NCT02191930|Experimental|B-CAP|Patients with ECOG of 2 or less (3 or less if caused by HL) and CIRS-G score of 6 or less (overall) and 3 or less per organ system receive 6 cycles of B-CAP (Brentuximab vedotin, cyclophosphamide, doxorubicine, predniso(lo)ne). Cycle length is 21 days
3341853|NCT02191930|Experimental|Brentoximab Vedotin only|Patients with CIRS-G score of 7 ore more receive Brentuximab Vedotin as single agent therapy for up to 16 cycles. Cycle length is 21 days
3341854|NCT02191943|Active Comparator|Control (fluoride varnish)|
3341855|NCT02191943|Experimental|resin infiltration (Icon)|
3341856|NCT02191956|Active Comparator|Behavioral Parent Training|Standard of care intervention
3341857|NCT02191956|Experimental|Behavioral Parent Training - Enhanced|Standard of Care Behavioral Parent Training plus new delivery methods
3341858|NCT02191969|No Intervention|Control|This group will be receiving adjuvant chemotherapy for colorectal cancer. They will not participate in the Walk With Ease program. They will be followed up using standard of care.
3238010|NCT01266239|Active Comparator|SES-KB|Sirolimus-eluting stent (SES) is deployed in the main vessel (MV)and subsequent kissing balloon inflation is performed in the bifurcation.
3238011|NCT01266239|Active Comparator|SES-NK|SES is deployed in the MV without kissing balloon inflation.
3238012|NCT01266239|Active Comparator|EES-KB|Everolimus-eluting stent (EES) is deployed in the MV and subsequent kissing balloon inflation is performed in the bifurcation.
3238013|NCT01266239|Active Comparator|EES-NK|EES is deployed in the MV without kissing balloon inflation.
3238014|NCT01266252|Experimental|Dexmedetomidine|
3238015|NCT01266278|Experimental|Kinesiotape|Kinesiotape will be applied to the correct shoulder position of the participants.
3238016|NCT01266304||community members|Pittsburgh area community members, including people who attend an integrative medicine clinic and people who attend a conventional medicine clinic.
3341859|NCT02191969|Experimental|Intervention|"This group will be receiving adjuvant chemotherapy for colorectal cancer. They will participate in the Walk With Ease (WWE) program during the course of their chemotherapy treatment. They will be requested to initiate the WWE starting on Day 1 of adjuvant chemotherapy. Participants are asked to walk at a safe and comfortable pace, increasing their minutes per day at a rate they can sustain, with the ultimate goal of 30 minutes/day for at least 5 days/week. They are asked to maintain a daily walking log that is provided to them, entering total minutes per day.~Participants will be asked to do the walking program independently (self-directed, not in a formal group with an instructor) throughout chemotherapy."
3341860|NCT02191982|Experimental|Intervention|This arm will begin the Walk With Ease program after the completion of chemotherapy.
3341861|NCT02191982|Active Comparator|Wait List Control|The arm will begin the Walk With Ease program three months after completion of chemotherapy.
3238017|NCT01266330|Active Comparator|Low Dairy|<0.5 standard dairy servings/day
3341862|NCT02191995|Experimental|body awareness yoga|body awareness yoga session prior to breakfast meal
3341863|NCT02191995|No Intervention|Control Arm|No intervention
3341864|NCT02192008|Active Comparator|Part A|Cohort naive to typhoidal Salmonella challenged with either S. Typhi or S. Paratyphi
3341865|NCT02192008|Active Comparator|Part B|Cohort previously challenged with S. Typhi or Paratyphi re-challenged with either S. Typhi or S. Paratyphi.
3341866|NCT02192034|Experimental|Navigation Group|This group will receive standard clinic instructions for the colonoscopy and two additional phone calls from the patient navigator to discuss the purpose, preparation, and additional information regarding the colonoscopy procedure.
3341867|NCT02192034|Placebo Comparator|Control|This group will receive only clinic instructions without intervention from the patient navigator.
3341868|NCT02192047|Experimental|palm olein margarine|8 weeks
3341869|NCT02192047|Experimental|IE palm olein margarine|8 weeks
3341870|NCT02192047|Experimental|IE soybean oil-based margarine|8 weeks
3341871|NCT02192060|Experimental|Test|Using of a suspension containing Triclosan
3341872|NCT02192060|Placebo Comparator|Control|Using of a suspension without Triclosan or other active ingredient
3341873|NCT02192073|Active Comparator|Suprapectoral Biceps Tenodesis|Suprapectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the superior border of the pectoralis major insertion
3341874|NCT02192073|Active Comparator|Subpectoral Biceps Tenodesis|Subpectoral Biceps Tenodesis involves detaching the long head of biceps from it's origin and reattaching it to humerus in the inferior border of the pectoralis major insertion
3341875|NCT02192086|Experimental|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
3238018|NCT01266330|Experimental|Adequate dairy|3.5 standard dairy servings per day
3238019|NCT01266343||Experimental Group|
3238020|NCT01266343||Control Group|
3341876|NCT02192086|Active Comparator|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
3341877|NCT02192125|Experimental|REWIRE-System|The training system consists of a so-called Tymoplate® (Tyromotion, Austria), a medical device class 1 with CE certification and approval by the FDA for use in neurorehabilitation after stroke. The Tymoplate® is connected to a computer and allows by means of a base plate with integrated pressure sensors and custom-developed training software different postural biofeedback exercise.
3341878|NCT02192138|Experimental|Therapeutic thoracentesis|Patients with pleural effusion who require therapeutic thoracentesis will be enrolled into the study
3341879|NCT02192177||Group 1|Pregnant subjects diagnosed with obstetric cholestasis who didn't have any foreknown systemic disease.
3341880|NCT02192177||Group 2|entirely healthy pregnant subjects, the control group.
3238021|NCT01266356||Experimental Group|
3238022|NCT01266356||Control Group|
3238023|NCT01266369|Experimental|masitinib 3 mg/kg/day|masitinib 3 mg/kg/day
3238024|NCT01266369|Experimental|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
3238025|NCT01266408||DRSP/EE/metafolin|Women using oral contraceptives containing drospirenone, ethinylestradiol and metafolin
3238026|NCT01266408||Other OC users|Women using oral contraceptives containing other estrogen/progestogen combinations
3238027|NCT01266421||Dienogest (DNG)|Women using DNG) for the treatment of endometriosis
3238028|NCT01266421||Other approved endometriosis drugs (OAED)|Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.
3341881|NCT02192203|Experimental|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
3341882|NCT02192203|Active Comparator|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
3341883|NCT02192203|Active Comparator|Menthol Only Gel|3% menthol
3341884|NCT02192203|Placebo Comparator|Placebo Only Gel|0.09% menthol
3341885|NCT02192216|Experimental|Exercise & Chemotherapy|Following a control period during active chemotherapy the patients undergo ten weeks of supervised exercise comprised of resistance and aerobic training in combination with protein supplementation during ongoing chemotherapy.
3341886|NCT02192229|Active Comparator|intervention group|The intervention group will be supplemented with 50.000 IU vitamin D3 every week for 12 consecutive weeks
3341887|NCT02192229|Placebo Comparator|Placebo group|The placebo group will receive placebo Tablet which will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
3341888|NCT02192242|Experimental|Acute ischemic pain|acute ischemic pain was induced by treadmill testing in all patients investigated
3341889|NCT02192255|Experimental|Intervention phone call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
3341890|NCT02192255|No Intervention|Control arm - usual care|Those in the control arm received usual care.
3341891|NCT02192268|Active Comparator|HFOO|Children of the HFOO group will be subjected to two daily sessions of this resource which should be the same throughout her hospitalization with Shaker equipment.
3341892|NCT02192268|Active Comparator|Assisted Coughing|The children in the control group will be subjected to two daily sessions of assisted coughing.
3341893|NCT02192268|Active Comparator|PEP|The children will be subjected to PEP group two daily sessions of this resource which should be the same throughout her hospitalization with facial mask and valve Spring load with expiratory pressure of 10cmH2O.
3341894|NCT02192281|Experimental|Playworks|Playworks was implemented during the entire school year, and outcome measures were collected in spring of the school year.
3341895|NCT02192281|No Intervention|Control|Playworks was not implemented at these schools.
3341896|NCT02192294|Experimental|Bosutinib|
3341897|NCT02192320|Experimental|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone: 0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
3238029|NCT01266421||Non-approved endometriosis drugs (NAED)|Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.
3238030|NCT01266434|Experimental|simvastatin|
3341898|NCT02192320|Active Comparator|Atorvastatin|Atorvastatin: 20 mg (every evening orally) for 5 weeks
3341899|NCT02192333|No Intervention|Arm I (usual care)|Participants receive usual care. After 12 months, participants may receive a survivorship clinic visit and boosters as in Arm II.
3341900|NCT02192333|Experimental|Arm II (survivorship care)|Participants attend a survivorship clinic visit that includes care plans, screening recommendations, physician coordination, health promotion education, symptom management and palliative care, late effects education, psychosocial and medical assessments, and referrals for services and care as appropriate. Participants also receive phone-based survivorship boosters over approximately 15-30 minutes at 4-8 weeks and 12-16 weeks after the initial clinic visit.
3341901|NCT02192346|Experimental|2.4 mg/kg α-TEA|Patients will receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
3341902|NCT02192346|Experimental|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
3341903|NCT02192346|Experimental|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
3341904|NCT02192346|Experimental|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
3341905|NCT02192346|Experimental|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
3341906|NCT02192346|Experimental|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
3341907|NCT02192346|Experimental|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
3341908|NCT02192346|Experimental|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
3341909|NCT02192346|Experimental|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
3341911|NCT02192372||metabolic syndrome|Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women).
3341912|NCT02192372||control|Age and sex adjusted control subjects
3341913|NCT02192398|Active Comparator|Guanfacine (2mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3341914|NCT02192398|Active Comparator|Guanfacine (1mg)|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3341915|NCT02192398|Placebo Comparator|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~Subjects will be instructed to take one capsule in the evening for 4 weeks."
3341916|NCT02192411|Active Comparator|Standard Lidocaine|50mL 1% lidocaine in 450mL normal saline
3341917|NCT02192411|Experimental|1/4 dose lidocaine|12.5mL 1% lidocaine in 487.5mL normal saline
3341918|NCT02192424|Active Comparator|Metformin alone|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
3341919|NCT02192424|Experimental|Metformin + Intermittent Insulin Therapy|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy, initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months). Participants will stop their metformin for 2 weeks every 3 months, during which time they will receive intermittent intensive insulin therapy for 2 weeks. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months.
3341920|NCT02192437|Experimental|Methionine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine). Control diet for 4 weeks followed by a washout for 3-4 weeks, then a methionine restricted diet (70%) for 4 weeks, followed by 3-4 weeks washout period and then a methionine restricted diet (90%) for 4 weeks.
3341921|NCT02192437|Experimental|Methionine and cysteine restricted diet|Intervention will be a Sulfur amino acid restricted diet (methionine and cysteine). Control diet for 4 weeks followed by a washout for 3-4 weeks then a methionine and cysteine restricted diet (50%) followed by 3-4 weeks washout period and then a methionine and cysteine restricted diet (65%) for 4 weeks.
3341922|NCT02192450|Active Comparator|Insulin glargine|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
3341923|NCT02192450|Experimental|Insulin degludec|"Each treatment arm last for 12 months - 3 months of run-in/cross-over and 9 months of maintenance.~Patients will be randomised (1:1) to treatment with basal-bolus therapy with insulin aspart/degludec or insulin aspart/glargine in random order.~After 12 months of treatment patients will cross-over to the other basal-bolus therapy.~Insulin degludec and insulin glargine is administered once daily at the evening meal and insulin aspart is administered three times daily before the main meals."
3341924|NCT02192463|Experimental|Nevirapine (NVP) ER 300 mg (KCR 20%) Medium Release|
3341925|NCT02192463|Experimental|NVP ER 300 mg (KCR 25%) Medium Release|
3341926|NCT02192463|Experimental|NVP ER 300 mg (KCR 30%) Slow Release|
3341927|NCT02192463|Experimental|NVP ER 400 mg (KCR 25%) Medium Release|
3341928|NCT02192463|Experimental|NVP ER 300 mg (KCR 40%) Slow Release|
3341929|NCT02192463|Experimental|NVP ER 300 mg (ECR 20%) Fast Release|
3341930|NCT02192463|Experimental|NVP ER 400 mg (KCR 20%) Medium Release|
3341931|NCT02192463|Experimental|NVP ER 400 mg (KCR 30%) Slow Release|
3341932|NCT02192463|Experimental|NVP ER 400 mg (KCR 40%) Slow Release|
3341933|NCT02192463|Experimental|NVP ER 400 mg (ECR 20%) Fast Release|
3238031|NCT01266434|Placebo Comparator|B1-6-12|
3238032|NCT01266473|Experimental|Physiotherapy techniques|Cough Technique vs Forced Expiration Technique
3341934|NCT02192463|Active Comparator|Nevirapine IR 1 tablet|
3341935|NCT02192463|Active Comparator|Nevirapine IR 2 tablets|
3341936|NCT02192476|Active Comparator|conventional|15 participants are allotted in this arm and each participants received conventional neuro rehabilitation programme 5 days a week for 6 weeks.
3341937|NCT02192476|Experimental|intervention|15 participants allotted in this arm and each participants received California tri-pull taping method along with conventional neuro rehabilitation was given 5 days a week for 6 weeks
3341938|NCT02192489|Experimental|CC-220 0.3mg|CC-220 0.3 mg capsules by mouth (PO) daily for 12 weeks
3341939|NCT02192489|Experimental|CC-220 0.6mg|CC-220 0.6mg capsules by PO daily for 12 weeks
3341940|NCT02192489|Placebo Comparator|Placebo|Identically matching placebo PO daily for 12 weeks
3341941|NCT02192515|Experimental|APD356 10 mg|Subjects will be randomized to APD356 10 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
3238033|NCT01266486|Experimental|Metformin|
3238034|NCT01266499|Active Comparator|Group 1: will receive PO Garamycin 80mg x 4/d|will receive PO Garamycin 80mg x 4/d
3341942|NCT02192515|Experimental|APD356 20 mg|Subjects will be randomized to APD356 20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug.
3341943|NCT02192515|Experimental|APD356 XR-20 mg|Subjects will be randomized to APD356 XR-20 mg group (6 subjects) or placebo group (2 subjects) to receive single dose of study drug on Day 1 and multiple doses of study drug on Day 8-14 once daily before breakfast.
3341944|NCT02192515|Experimental|APD356 10 mg and APD356 XR-20mg (orange tablet)|"Subjects will be randomized to Sequence A (8 subjects) or Sequence B (8 subjects) to receive study drug in the sequence shown below.~Sequence A: 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, single dose => XR-20 mg orange tablet, q. d., multiple doses (fasted) => XR-20 mg orange tablet, q. d., multiple dose (fed)~Sequence B: XR-20 mg orange tablet, single dose => 10 mg tablet, 2 doses (12 hours apart) => XR-20 mg orange tablet, q. d., multiple dose (fed) => XR-20 mg orange tablet, q. d., multiple doses (fasted)"
3341945|NCT02192528||cardiac surgical patients|patients undergoing a cardiac surgical procedure
3238035|NCT01266499|Active Comparator|Group 2 : will receive PO Colistin (Polymyxin E) 100mg x 4/d|
3238036|NCT01266499|Active Comparator|Group 3: will receive both medications|
3238037|NCT01266499|Placebo Comparator|Group 4: will not receive PO treatment|
3341946|NCT02192567|Experimental|DS-5573a does escalation (step 1) and expansion (step 2)|"Step 1 of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg.~Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg Step 2: 30 subjects will be enrolled and treated at the dose determined in Step 1."
3341947|NCT02192580|Active Comparator|Omega-3|omega-3 (DHA+EPA) in divided 3 times/day in addition to standard regimens: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
3341948|NCT02192580|No Intervention|Control|control group received just standard regimens without omega-3
3341949|NCT02192593|Experimental|Computer CBT|A 10-session computerized cognitive-behavioral therapy intervention
3341950|NCT02192593|No Intervention|Usual Care|
3238038|NCT01266512|Experimental|IMRT & docetaxel-cisplatin|"Concurrent chemo-RT:~Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -~Resting period: 2 weeks -~Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -~Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration"
3238039|NCT01266525|Experimental|SAR110894 - 0.5 mg|SAR110894, 0.5 mg once daily along with Donepezil.
3238040|NCT01266525|Experimental|SAR110894 - 2 mg|SAR110894, 2 mg once daily along with Donepezil.
3341951|NCT02192619||observational|
3341952|NCT02192632|Experimental|Epiduo- dermatologist's detailed instruction|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into detailed instruction for application of epiduo from dermatologist
3341953|NCT02192632|Experimental|Epiduo- drug insert only gruop|After randomly assigned to side of epiduo application, half of total patients were also re-assigned into drug insert only group
3341954|NCT02192632|Placebo Comparator|BPO group|After randomly assigned to side of BPO application, patients apply BPO during 12 week
3341955|NCT02192645|Experimental|Sanfujiu|"Formula for Sanfujiu: Huangjiezi; Xixin; Yanhusuo; and so on Acupoint for Sanfujiu: Different ten acupoints determined according to Chinese medicine theory for each time.~Timepoint: Five times of 3 years at Sanfu Point application: The patients will be treated with herbal cake-separated moxibustion on acupoints and lasted 60 minutes each time."
3341956|NCT02192645|Placebo Comparator|placebo|"Formula for placebo: Fuxiaomai; and so on. the appearance is similar as drugs of Sanfujiu Acupoint for placebo: Ten acupoints determined according to Chinese medicine theory are the same as Sanfujiu group of each timepoint .~Timepoint: Five times per year for 3 years. Point application: The patients will be treated with placebo on acupoints and lasted 60 minutes each time."
3341957|NCT02192645|No Intervention|waiting list|No intervention in the first year. Accept Sanfujiu in the second and the third years.
3341958|NCT02192658||People with Disability (PWD) (N= 850)|"PWD will be identified thanks to the disability screening tool developped by the Washington Group (WG). This tool is based on the WHO International Classification of Functionning (ICF).~A stratified cluster sampling in 2 steps will be used in both, Yaounde and Ouagadougou. Each city will be divided in enumeration areas (EAs). First step : EAs will be drawn randomly with probability proportional to their size in number of households. Second step: in each EA, 30 households will be randomly drawn and each person living in these households will be screened for disability with the WG tool, according to the inclusion and exclusion criteria."
3341959|NCT02192658||Non-Disabled People (control group) (N= 850)|For each PWD, 1 non-disabled control person will be randomly chosen from the census list of the same enumeration area. Control will also be matched on age and sex.
3341960|NCT02192671|Experimental|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
3341961|NCT02192671|Active Comparator|Radiofrequency ablation|RFA is performed in less than one week after clinical diagnosis.
3341962|NCT02192697|Experimental|Phase I dose-escalation group|Oral administration
3341963|NCT02192697|Experimental|Phase I EGFR-T790M mutation group|Oral administration
3341964|NCT02192697|Experimental|Phase II group|Oral administration
3341965|NCT02192710|Active Comparator|Hypnovel® (midazolam)|Midazolam oral intake before anesthesia
3341966|NCT02192710|Experimental|Electronic tab|
3341967|NCT02192723|Experimental|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.
3341968|NCT02192723|Active Comparator|Risperidone|Risperidone, 2~6mg/day, twice day, 8 weeks
3341969|NCT02192723|Active Comparator|Olanzapine|5~20mg/day
3238041|NCT01266525|Experimental|SAR110894 - 5 mg|SAR110894, 5 mg once daily along with Donepezil.
3341970|NCT02192723|Active Comparator|Quetiapine|400~750mg/day
3341971|NCT02192723|Active Comparator|Aripiprazole|Aripiprazole, 10~30mg/day, twice per day, 8 weeks
3341972|NCT02192723|Active Comparator|Ziprasidone|Ziprasidone, 80~160mg/day, twice per day, 8 weeks
3341973|NCT02192736|Other|Intra-nasal infusion of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-nasally
3341974|NCT02192749|Experimental|Umbilical cord mesenchymal stem cells|
3341975|NCT02192762|Experimental|Withdrawal regulation training|Withdrawal coping skills
3341976|NCT02192762|Active Comparator|Relaxation training|Relaxation skills instruction
3341977|NCT02192827|Experimental|Single Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once
3341978|NCT02192827|Experimental|Two Dose Dexamethasone|0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once in the Emergency Department (ED), followed by another dose of dexamethasone at home, which will be prescribed from the ED. The second dose will be the same dosage, but will be prescribed and may be pill or liquid form.
3341979|NCT02192840|Active Comparator|rDES Group|"Regular drug-eluting stent implantation, one of the following:~Device: LucChopin (Balton, Poland) Device: Prolim (Balton, Poland) Device: Xience Pro (Abott Vascular) Device: Biomatrix (Biosensors) Device: Promus (Boston Scientific) Device: Cypher (Cordis) Device: Taxus (Boston Scientific) Device: Coroflex Please (BBraun) Device: Resolute Integrity (Medtronic)"
3341980|NCT02192840|Experimental|BiOSS Group|New dedicated bifurcation stent BiOSS Expert (Balton, Warsaw, Poland) implantation
3341981|NCT02192853|Experimental|Sitagliptin|Patients with Type 2 Diabetes Mellitus and healthy control subjects are given tablets of sitagliptin in either a dosage of 25, 100 or 200 mg tablet in 3 different days.
3341982|NCT02192853|Placebo Comparator|placebo|
3341983|NCT02192866||Peanut allergic|No intervention(s) to be administered.
3341984|NCT02192866||Other food allergic|No intervention(s) to be administered.
3341985|NCT02192866||Controls|No intervention(s) to be administered.
3341986|NCT02192892|Experimental|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from Corn Soy Blend drum dried with α-amylase
3341987|NCT02192892|Placebo Comparator|CSB drum dried - α-amylase|CSB drum dried - α-amylase: Porridge from Corn Soy Blend drum dried without α-amylase
3341988|NCT02192892|Experimental|CSB + α-amylase|CSB + α-amylase: Porridge from Corn Soy Blend with α-amylase
3341989|NCT02192892|Placebo Comparator|CSB - α-amylase|CSB - α-amylase: Porridge from Corn Soy Blend without α-amylase
3341990|NCT02192892|Experimental|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
3341991|NCT02192892|Placebo Comparator|RSB - α-amylase|RSB - α-amylase: Porridge from Rice Soy Blend without α-amylase
3341992|NCT02192892|Active Comparator|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
3341993|NCT02192892|Active Comparator|Commercial porridge flour|Porridge from commercial porridge flour
3341994|NCT02192892|Active Comparator|Commercial porridge bar|Porridge from commercial porridge bar
3341995|NCT02192892|Experimental|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from Corn Soy Blend PLUS drum dried with α-amylase
3341996|NCT02192892|Placebo Comparator|CSB PLUS drum dried - α-amylase|CSB PLUS drum dried - α-amylase: Porridge from Corn Soy Blend PLUS drum dried without α-amylase
3341997|NCT02192892|Experimental|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
3341998|NCT02192892|Placebo Comparator|CSB PLUS - α-amylase|CSB PLUS - α-amylase: Porridge from Corn Soy Blend PLUS without α-amylase
3341999|NCT02192892|Experimental|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
3342000|NCT02192892|Placebo Comparator|RSB PLUS - α-amylase|RSB PLUS - α-amylase: Porridge from Rice Soy Blend PLUS without α-amylase
3342001|NCT02192892|Experimental|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
3342002|NCT02192892|Placebo Comparator|WSB PLUS - α-amylase|WSB PLUS - α-amylase: Porridge from Wheat Soy Blend PLUS without α-amylase
3342003|NCT02192892|Active Comparator|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
3342004|NCT02192918|Experimental|Airbrush|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Participants will receive access to one of each of the following after the 6-month assessment at no cost: massage, pedicure, yoga class, and dance class. Participants will schedule these activities on their own and the study staff will arrange for payment for the appointment.
3342005|NCT02192918|Experimental|Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class. These activities are being given as healthy alternatives to the relaxation sensation of indoor tanning.
3342006|NCT02192918|Active Comparator|Delayed Airbrush Plus|Participants will receive the American Academy of Dermatology Sun Smart pamphlet at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will also receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class.
3238042|NCT01266525|Placebo Comparator|Placebo|Placebo (for SAR110894) once daily along with Donepezil.
3238043|NCT01266538||IBD patients|Patients diagnosed with Inflammatory Bowel Disease (IBD)
3238044|NCT01266538||patients after a Large Bowel Resection|Patients after a Large Bowel Resection, with or without a pouch.
3342007|NCT02192931|Active Comparator|Creatine monohydrate|5 grams of daily creatine monohydrate for 8 weeks
3342008|NCT02192931|Placebo Comparator|Placebo|5 g of placebo for 8 weeks
3342009|NCT02192931|No Intervention|Healthy Control|
3342010|NCT02192944|Active Comparator|Chloroquine|Chloroquine base 600 mg single dose
3342011|NCT02192944|Active Comparator|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose
3342012|NCT02192957|Other|Ottawa AF Cardioversion|elective electrical cardioversion for atrial fibrillation (AF) using the Ottawa AF protocol
3342013|NCT02192983||chemotherapy regimen|those with XELOX regimen and those with EOX regimen
3342014|NCT02192996|Other|Probiotics supplementation|"Five very low birth weight (VLBW) infants enrolled within 2 days of birth, with a weight < 1300 g and gestational age < 29 weeks and without any malformation or metabolic disease at birth were supplemented with two daily doses of a mixture of Bifidobacterium breve and Lactobacillus salivarius , probiotic strains isolated from human milk during their first weeks of life. The lyophilized powder has contained at least 1x10^9 colony forming units (CFU) per doses of each one of the probiotic bacteria."
3342015|NCT02193009|Experimental|SIPsmartER, behavioral intervention|Aimed at decreasing sugar-sweetened beverage consumption
3342016|NCT02193009|Active Comparator|Move More, behavioral intervention|Aimed at physical activity promotion
3342017|NCT02193022|Experimental|Miltefosine|
3342018|NCT02193035|Experimental|Single group|Patients with severe aortic stenosis treated with transcatheter aortic valve replacement (TAVR). Microparticle levels will be measured before and after TAVR.
3342019|NCT02193048||Patients newly diagnosed with Crohn's disease|This study will evaluate a new clinical scoring system in patients receiving routine treatment
3342020|NCT02193061|Active Comparator|ROTA 1|two doses of monovalent vaccine Rotarix followed by one dose of sterile water
3342021|NCT02193061|Active Comparator|ROTA 2|three doses of pentavalent vaccine RotaTeq
3342022|NCT02193061|Active Comparator|ROTA 3|one dose of monovalent Rotarix vaccine followed by two doses of pentavalent vaccine Rotateq
3342023|NCT02193061|Active Comparator|ROTA 4|one dose of pentavalent RotaTeq vaccine followed by two doses of monovalent vaccine Rotarix
3342024|NCT02193061|Active Comparator|ROTA 5|two doses of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix
3238045|NCT01266538||Control group|Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
3342025|NCT02193061|Active Comparator|ROTA 6|one dose of pentavalent vaccine RotaTeq followed by a dose of monovalent vaccine Rotarix and a dose of pentavalent vaccine RotaTeq
3342026|NCT02193061|Active Comparator|ROTA 7|a dose of monovalent vaccine Rotarix followed by a dose of pentavalent vaccine and a dose of monovalent vaccine Rotarix
3342027|NCT02193100||13C-glucose|experimental (13C-glucose)
3342028|NCT02193100||No glucose|control (no glucose)
3238046|NCT01266551|No Intervention|lifestyle counseling|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring. In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
3238047|NCT01266564||Cohort|
3342029|NCT02193113|Experimental|KVD001 Injection Dose 1|Single 100 microliters (uL) intravitreal injection of KVD001 Injection Dose 1
3342030|NCT02193113|Experimental|KVD001 Injection Dose 2|Single 100uL intravitreal injection KVD001 injection Dose 2
3342031|NCT02193113|Experimental|KVD001 Injection Dose 3|Single 100uL intravitreal injection of KVD001 injection Dose 3
3342032|NCT02193126|Experimental|Treatment|
3342033|NCT02193126|No Intervention|Comparison|
3342034|NCT02193139|Experimental|WL8713, 6 mg|6 mg WL8713 administered daily
3238048|NCT01266577|Other|One Arm|Subjects receive the same scan
3238049|NCT01266616|Experimental|Cohort 1: Vaccine alone IM/EP|HIV MAG pDNA alone IM/EP
3342035|NCT02193139|Experimental|WL8713, 12 mg|12 mg WL8713 administered daily
3342036|NCT02193139|Experimental|WL8713, 18 mg|18 mg WL8713 administered daily
3342037|NCT02193139|Experimental|WL8713, 24 mg|24 mg WL8713 administered daily
3342038|NCT02193139|Placebo Comparator|Placebo|placebo administered daily
3342039|NCT02193191|Experimental|Plerixafor|Patients will receive a single dose of subcutaneous plerixafor with peripheral blood studies at approximately 0-2 hours before, approximately 6-12 hours after, and approximately 20-48 hours after plerixafor administration, with leukapheresis in the last 3 patients on the protocol. Collected HPCs will be transferred to the MSKCC CTCEF to determine if the HPCs are amenable to transduction with a lentiviral vector encoding the normal ß- globin gene.
3342040|NCT02193204|Experimental|Social Drinkers Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers with depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3342041|NCT02193204|Experimental|Social Drinkers No Depressive Symptoms|30 non-dependent light socially drinking (SD) smokers without depressive symptoms will be recruited to participate in two laboratory sessions (Stress and Neutral / Relaxing). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3342042|NCT02193204|Experimental|Alcohol Dependent, Non-Depressive|30 treatment-engaged 28-day abstinent, alcohol dependent (AD) smokers, without Depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3342043|NCT02193204|Experimental|Alchohol Dependent Depressive Symptoms|30 treatment-engaged 28-day abstinent, alcohol dependent smokers with depressive symptoms. All AD subjects will either be admitted to the Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center for five weeks of inpatient stay and study participation (inpatient), or they will be scheduled for a two night stay on the CNRU following 3 weeks of abstinence (outpatient). This arm will be exposed to both the personal stress imagery and neutral imagery interventions.
3238050|NCT01266616|Placebo Comparator|Cohort 1: Placebo|Placebo given as an injection in each upper arm
3238051|NCT01266616|Experimental|Cohort 2: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 50 mcg of IL-12 pDNA IM/EP
3238052|NCT01266616|Placebo Comparator|Cohort 2: Placebo|Placebo given as an injection in each upper arm
3238053|NCT01266616|Experimental|Cohort 3: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 250 mcg of IL-12 pDNA IM/EP
3238054|NCT01266616|Placebo Comparator|Cohort 3: Placebo|Placebo given as an injection in each upper arm
3238055|NCT01266616|Experimental|Cohort 4: Vaccine plus IL-12 IM/EP|HIV MAG pDNA plus 1,000 mcg of IL-12 pDNA IM/EP
3238056|NCT01266616|Placebo Comparator|Cohort 4: Placebo|Placebo given as an injection in each upper arm
3238057|NCT01266616|Experimental|Cohort 5: Vaccine plus IL-12 IM|HIV MAG pDNA plus 1,000 mcg (or highest dose reached) IL-12 pDNA IM
3238058|NCT01266616|Placebo Comparator|Cohort 5: Placebo|Placebo given as an injection in each upper arm
3238059|NCT01266629||capsule patients|All patients that will undergo endoscopic capsule
3238060|NCT01266655|Experimental|Baclofen|
3342044|NCT02193217|Experimental|MT-1303-Low|MT-1303-Low dose
3342045|NCT02193217|Experimental|MT-1303-High|MT-1303-High dose
3342046|NCT02193217|Active Comparator|Fingolimod|Fingolimod
3342047|NCT02193217|Placebo Comparator|Placebo|Placebo
3342048|NCT02193256|Active Comparator|Varenicline plus Prazosin|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Prazosin: 1mg for 3 days, then 3mg for 4 days (Week 1), (2) 6mg for 3 days, then 8mg for 4 days (Week 2), and (3) 8mg (Week 3).
3342049|NCT02193256|Placebo Comparator|Varenicline plus Placebo|Varenicline: .5mg for 3 days then 1mg daily for 4 days (Week 1) then 2mg daily thereafter (Weeks 2-3). Placebo: placebo will be given instead of prazosin (Weeks 1-3)
3342050|NCT02193269|Placebo Comparator|sugar pill|0.0mg
3342051|NCT02193269|Active Comparator|Minocycline|200mg
3238061|NCT01266655|Placebo Comparator|Placebo|
3342052|NCT02193295|Experimental|Lifestyle Intervention|Caloric Restriction.
3342053|NCT02193295|Experimental|NAFLD|Placebo or ACC inhibitor treatment for 12 weeks.
3342054|NCT02193295|Experimental|NAFLD Extension|A 48-week open-label extension arm with following either completion of either both arms or one arm of the 12-week double-blind crossover study.
3342055|NCT02193308|Experimental|Telmisartan/Amlodipine FDC|
3342056|NCT02193308|Active Comparator|Telmisartan + Amlodipine mono|
3238062|NCT01266668||Primary breast DLBCL|Primary breast DLBCL was defined as that involving single extranodal organ (i.e. breast) regardless of the status of nodal disease.
3238063|NCT01266668||Nodal DLBCL|The disease was only limited to the lymph nodes or lymphoid organs without extranodal organ involvements.
3238064|NCT01266681|Active Comparator|Amiodarone|this group will be given Amiodarone to maintain sinus rhythm powst cardioversion.
3238065|NCT01266681|Active Comparator|Dronedarone|this group will be given dronedarone to maintain sinus rhythm post DC cardioversion
3238066|NCT01266694|Experimental|Cochicine|Colchicine arm: patient receiving 1 mg per day for 14 days
3238067|NCT01266694|Placebo Comparator|Placebo|patients placebo controlled
3238068|NCT01266707|Experimental|Vaccine|VEGRF1, VEGFR2
3238069|NCT01266720|Experimental|Phase 1 study|"Interventions:~Biological: VEGFR1, VEGFR2 Drug: Gemcitabine"
3342057|NCT02193321|Experimental|Amniotic membrane patch placement|One amniotic membrane patch will be placed on the epicardial surface of the heart immediately following a CABG procedure prior to wound closure.
3342058|NCT02193321|No Intervention|Control|Amniotic membrane patch will not be placed after CABG procedure prior to wound closure.
3238070|NCT01266733|Experimental|Interdisciplinary treatment|
3342059|NCT02193334|Active Comparator|KP-100IT|Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
3342060|NCT02193334|Placebo Comparator|Placebo|Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times
3342061|NCT02193360|Experimental|Single arm Dose Escalation|
3342062|NCT02193373|Active Comparator|Sub-Occipital Release|Osteopathic Manual Medicine
3238071|NCT01266733|No Intervention|Usual treatment|
3342063|NCT02193373|Active Comparator|Rib-Raising|Osteopathic Manual Medicine
3342064|NCT02193373|Active Comparator|Stellate Ganglion Release|Osteopathic Manual Medicine
3342065|NCT02193373|Active Comparator|All techniques|Osteopathic Manual Medicine
3342066|NCT02193373|Sham Comparator|All Techniques-S|Sham Osteopathic Manual Medicine
3342067|NCT02193373|Sham Comparator|Sub-Occipital Release-S|Sham Osteopathic Manual Medicine
3238072|NCT01266746||Macular hole|The patients of idiopathic macular hole enrolled in the study
3238073|NCT01266746||Macular hole retinal detachment|The patients of macular hole retinal detachment enrolled in the study
3238074|NCT01266746||Myopic traction maculopathy|The patients of macular hole with myopic traction maculopathy enrolled in the study
3238075|NCT01266759|Experimental|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
3238076|NCT01266759|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
3238077|NCT01266772|Active Comparator|montelukast group|Children with asthma treated with montelukast and budesonide.
3238078|NCT01266772|Placebo Comparator|Placebo group|Children with asthma treated with placebo tablet and budesonide.
3238079|NCT01266798|Experimental|Portal arm|
3342068|NCT02193373|Sham Comparator|Rib-Raising-S|Sham Osteopathic Manual Medicine
3342069|NCT02193373|Sham Comparator|Stellate Ganglion Release -S|Sham Osteopathic Manual Medicine
3342070|NCT02193386|Active Comparator|Usual Care|No intervention, no follow-up, only registration of usual therapy
3342071|NCT02193386|Experimental|Intervention period|Predefined, evidence-based program and support
3342072|NCT02193399|Experimental|Physiotherapy exercises|Strength exercises for the muscles proximal upper limbs and lower limbs and proprioception exercises
3342073|NCT02193399|No Intervention|Control group|Patients undergoing allogeneic transplantation without treatment of physiotherapy
3342074|NCT02193412|Experimental|patients|"noxious stimulus~change in operating table slope: head-down tilt position~change in operating table slope: head-up tilt position"
3342075|NCT02193438|Active Comparator|Spice 1|Red chili pepper extract
3342076|NCT02193438|Active Comparator|Spice 2|Cinnamon extract
3238080|NCT01266798|No Intervention|Treatment as usal|
3342077|NCT02193438|Active Comparator|Spice 3|Refreshing agent
3342078|NCT02193438|Placebo Comparator|Placebo|Tomato juice
3342079|NCT02193451|Experimental|Urodynamics|Invasive urodynamic cystometry including pressure flow studies, along with usual diagnostics in male LUTS
3342080|NCT02193451|Active Comparator|Usual care|Usual diagnostics in male LUTS; flow rate test, symptom score and bladder diary
3342081|NCT02193464||inflammatory bowel disease|
3342082|NCT02193477|No Intervention|Control|Patients were given no TEAS.
3342083|NCT02193477|Experimental|TEAS Treatment|Patients were given 30min of TEAS before general anesthesia induction, 1th day and 2nd day after surgery.
3342084|NCT02193477|Sham Comparator|Sham TEAS|Patients were given 30min of sham TEAS before general anesthesia induction,1th day and 2nd day after surgery.
3342085|NCT02193503|Experimental|treatment|MVX-1-loaded capsules and injection of irradiated autologous tumor cells
3342086|NCT02193542||Pregnant patient|Pregnant woman presenting for vaginal or cesarean delivery
3342087|NCT02193555|Other|Non-presbyopic group|"Non-presbyopic group: age ranging from 7 to 39 years~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue 1- Day Moist, etafilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
3238081|NCT01266811|Experimental|001|Siltuximab Velcade and dexamethasone Given in 21-day treatment cycles Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
3238082|NCT01266811|Other|002|Placebo Velcade and dexamethasone Given in 21-day treatment cycles Placebo as 1-hour IV infusion on Day 1 of every cycle Velcade 1.3 mg/m2 IV push on Days 1 4 8 and 11 for Cycles 1-8 and on Days 1 and 8 for Cycles 9 and higher Dexamethasone 20 mg orally on the day of and the day after each Velcade dose
3342088|NCT02193555|Other|Presbyopic group|"Presbyopic group: age 40 and above~At each scheduled lens fitting visit, subjects will be allocated one pair of CLs to correct their refractive error. One pair of control (Acuvue Oasys for Presbyopia, senofilcon A) or prototype (Iteration X, etafilcon A) CLs will be allocated for each lens fitting/assessment visit. Lenses will be worn for approximately 1 hour per visit.~For each fitting visit, lenses will be fitted bilaterally."
3342089|NCT02193568|Experimental|Arm I (light sedation)|Patients receive light sedation (awake) and undergo craniotomy.
3342090|NCT02193568|Active Comparator|Arm II (intubated general anesthesia)|Patients receive intubated general anesthesia and undergo craniotomy.
3342091|NCT02193581||Suspicious skin lesions.|Patients with a suspicious skin lesion referred for a biopsy are tested using MDS
3342092|NCT02193594|Experimental|CCRT group|The patient in CCRT group will receive the preoperative concurrent chemoradiotherapy for 5 weeks and sequential radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 6 cycles.
3342093|NCT02193594|Active Comparator|CT group|The patient in CT group will receive radical D2 total gastrectomy and postoperative adjuvant chemotherapy of 8 cycles.
3342094|NCT02193607|Active Comparator|No TVT-O|Improved reconstruction pelvic surgery
3342095|NCT02193607|Experimental|Combined surgery group|Improved reconstruction pelvic surgery TVT-O procedure
3342096|NCT02193620|Placebo Comparator|Placebo group|Placebo soft capsules
3238083|NCT01266837|Other|single arm|Treatment with Everolimus
3238084|NCT01266863|Experimental|E test method|
3342097|NCT02193620|Experimental|Study group|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
3342098|NCT02193633|Experimental|AZD2014 3 on/4 off & weekly paclitaxel|3 days on, 4 days off AZD2014 BD administered orally Days 1-3 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
3342099|NCT02193633|Experimental|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 BD administered orally Days 1-2 each week in combination with paclitaxel administered via IV infusion on Day 1 each week, in 7-week cycles (6 weeks treatment followed by 1 week rest).
3342100|NCT02193659|Experimental|Cereals|For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet. The energy intake of the designed diet was similar into the three groups (ranging 1900-2000 Kcal per day).
3238085|NCT01266889||study group, control group|
3238086|NCT01266915||Control group|Normal disease free (non lupus) subjects
3238087|NCT01266915||Diseased Control|
3238088|NCT01266915||Diseased group 1|Those subjects with systemic lupus erythematosus.
3238089|NCT01266915||Diseased group 2|Subjects diagnosed with cutaneous lupus.
3238090|NCT01266928|Active Comparator|vitaminCE|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
3238091|NCT01266928|No Intervention|no drug|no drug
3238092|NCT01266941|Experimental|Mild Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
3238093|NCT01266941|Experimental|Moderate Hepatic Impairment|Mild and moderate hepatic patients will be recruited first, approximately 9 subjects should complete each of these treatment arms.
3342101|NCT02193672|Experimental|PET/CT + [18F]Fluciclatide|"At baseline: Participants have PET/CT imaging within 7 days prior to initiation of chemotherapy treatment. Participants monitored at 24 hours post scan via telephone.~On treatment: Participants have PET/CT imaging at end of the first cycle and prior to the initiation of the second cycle of chemotherapy. Participants assessed at 24 hours post scan via telephone call.~Baseline and on treatment PET/CT imaging performed with agent [18F] Fluciclatide."
3342102|NCT02193685||Subjects with HAEC|There is no intervention involvement. The clinical data and biologic specimens collected during the study will serve as an invaluable resource for a wide spectrum of clinical and translational ancillary studies directly related to the aims and goals of the study.
3342103|NCT02193685||Subjects without HAEC|A subgroup of children who have Hirschsprung Disease may or may not develop enterocolitis; therefore we will be identifying the bio-markers in children with or without associated enterocolitis.
3342104|NCT02193698|Experimental|Lenalidomide+Dexamethasone|Cycle1 : Lenalidomide 15mg/day (day 1-21) Cycle2-6 : Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
3342105|NCT02193711|Experimental|Topical Arthritis Cream|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
3342106|NCT02193711|Placebo Comparator|Placebo|1-1.5 ml applied to the skin over the knee in the morning and at bedtime over the entire study period, for a total of 2-3 ml/day.
3342107|NCT02193724||Retinoblastoma|Participants identified with heritable retinoblastoma will undergo a skin biopsy or blood draw to collect cells for processing and analysis.
3238094|NCT01266941|Experimental|Matched healthy volunteers|Once a moderate subject has been recruited, a healthy control subject should be recruited (matched to the moderate subject on gender, ethnicity, body mass index +/-15%, age +/-5 years). In total there will be 9 matched healthy volunteers 1 for each subject with moderate hepatic impairment.
3238095|NCT01266941|Experimental|Severe Hepatic Impairment|Severe subjects will not be enrolled into the study until 9 moderate subjects and their matched control subjects have completed the study and the safety and PK data have been reviewed.
3238096|NCT01266954|Experimental|Stage 1|Three to six patients on a medium dose of GSK2141795 for four weeks
3342108|NCT02193737|Experimental|Early oral fluid recovery.|
3342109|NCT02193737|Active Comparator|Delayed oral fluid recovery.|
3238097|NCT01266954|Experimental|Stage 2|Nine to eighteen subjects on a low, medium or high dose of GSK2141795 for four weeks
3238098|NCT01266980|Experimental|Severe Renal Imparement|Nine subjects with severe renal impairment (as defined by a Clcr<30mL/min) will be recruited for this study. they will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
3238099|NCT01266980|Experimental|Matched healthy volunteers|For each of the 9 renally impaired subjects a healthy control subject (as defined by a Clcr>80mL/min matched to the severe subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years)) will be recuited. They will receive FF/ GW642444M (200/25mcg) once daily for 7 days.
3238100|NCT01267006|Placebo Comparator|Placebo|Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3238101|NCT01267006|Experimental|GSK1325756 200 mg|Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3238102|NCT01267006|Experimental|GSK1325756 50 mg|Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule.
3238103|NCT01267006|Experimental|GSK1325756 100 mg|Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule.
3238104|NCT01267032|Experimental|Arm 1|Integrated Care + Cognitive-Behavioral Treatment for Insomnia
3238105|NCT01267032|Sham Comparator|Arm 2|Integrated Care + Desensitization Treatment for Insomnia
3238106|NCT01267058|Experimental|Group A|Subjects will receive the combined diphtheria, tetanus, acellular pertussis vaccine
3342110|NCT02193750|Placebo Comparator|Placebo|1 placebo muesli bars and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
3342111|NCT02193750|Experimental|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
3342112|NCT02193750|Experimental|High Oligosaccharide Group|1 intervention muesli bar and 1 serving intervention muesli per day (5.43 total fructans/GOS)
3342113|NCT02193763|Experimental|90 days and under--Interventional|Neonates aged 90 days and under randomized to ultrasound assisted lumbar puncture
3238107|NCT01267058|Active Comparator|Group B|Subjects will receive the acellular pertussis vaccine and one month later the combined diphtheria and tetanus vaccine
3238108|NCT01267058|Active Comparator|Group C|Subjects will receive the combined diphtheria and tetanus vaccine and one month later the acellular pertussis vaccine
3238109|NCT01267071|Experimental|A|GSK962040 (50 mg, SD, oral)
3238110|NCT01267071|Experimental|B|14C GSK962040 (100 μg, SD, iv)
3342114|NCT02193763|No Intervention|90 days and under--control|Neonates aged 90 days and under randomized to lumbar puncture using the anatomical landmark approach
3342115|NCT02193763|Experimental|Over 90 days--Interventional|Neonates aged over 90 days randomized to ultrasound assisted lumbar puncture
3238111|NCT01267084|Experimental|Part 1|Patients will receive trabectedin+ketoconazole followed by trabectedin alone. Each cycle will be will be separated by 21 days. Patients will receive 6 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
3238112|NCT01267084|Experimental|Part 2|Patients will receive 1 of 2 treatment sequences; Sequence 1: trabectedin+ketoconazole followed by trabectedin alone or Sequence 2: trabectedin alone followed by trabectedin+ketoconazole. Each cycle will be separated by 21 days. Patients will receive 15 total consecutive doses of ketoconazole. Dexamethasone or equivalent steroid will be administered before trabectedin in each cycle.
3238113|NCT01267097|Experimental|Cognitive Behavioural Therapy (CBT)|Group-based lifestyle counseling for parents
3342116|NCT02193763|No Intervention|Over 90 days--Control|Neonates aged over 90 days randomized to lumbar puncture using the anatomical landmark approach
3342117|NCT02193789|Experimental|Anastomosis site stricture|anastomosis site stricture after subtotal gastrectomy with Billroth-I anastomosis
3342118|NCT02193802|Other|Endoscopy|"CHANCE is a single arm study: all patients will undergo one capsule endoscopy ( PillCam® COLON 2 capsule and PillCam Crohn's) of the whole intestine AND one ileocolonoscopy.~The patients will be then treated according to the preference of their physician and a second capsule endoscopy AND an ileoconoscopy will be performed 6 at 12 months later.~Both exams will be evaluated locally by two independent investigators and all the recorded films will be evaluated and compared by four central readers."
3342119|NCT02193841|Active Comparator|C & P|Curettage with puncture (C & P) will be performed alone
3342120|NCT02193841|Active Comparator|C & P with Vitoss|A predetermined amount of Vitoss morsels will be injected following the curettage and puncture (C & P)
3342121|NCT02193854|Experimental|Mobile phone|"General practitioners (GPs) received TD consultation through Sana system.~Mobile phones with Sana system installed were provided to 10 rural GPs from three different districts of Mongolia."
3238114|NCT01267097|Experimental|Psycho-Education Program (PEP)|Group-based lifestyle counseling for parents
3238115|NCT01267110|Experimental|Intervention|
3238116|NCT01267110|Active Comparator|Control|
3238117|NCT01267123|Experimental|Trendelenburg position|The endoscopist places the patient in 15° Trendelenberg position immediately prior to the initiation of the colonoscopy.
3238118|NCT01267123|Other|Standard care|The patient will have colonoscopy in the standard horizontal position
3238119|NCT01267162||TDF Treatment|
3238120|NCT01267188|Experimental|NBI-98854|Open-label, dose titration of active drug
3238121|NCT01267214|Experimental|Osteotomy plus Hyalgan|Osteotomy at Week 0 Hyalgan injection at Week 2, 3, 4, 5, 6, 24, 25, 26, 27, 28
3238122|NCT01267214|Other|Osteotomy alone|
3238123|NCT01267305|Active Comparator|lung lmwh1|use LMWH once daily after lung resection
3238124|NCT01267305|Experimental|lung lmwh2|use LMWH twice daily after lung resection
3238125|NCT01267305|Experimental|lung Fondaparinux|use Fondaparinux once daily after lung resection
3238126|NCT01267305|Active Comparator|eso lmwh1|use LMWH once daily after esophagectomy
3238127|NCT01267305|Experimental|eso lmwh2|use LMWH twice daily after esophagectomy
3342122|NCT02193867|Experimental|Open-Label Sebelipase Alfa|All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.
3238128|NCT01267305|Experimental|eso Fondaparinux|use Fondaparinux once daily after esophagectomy
3342123|NCT02193893|Active Comparator|Stem/progenitor cells transplantation.|Intervention: Biological: Cell-based therapeutics Autologous bone marrow-derived stem/progenitor cells will be transplanted intrathecally (via a standard lumbar puncture) into early vs. progressive ALS subjects.
3342124|NCT02193893|Sham Comparator|Standard treatment of ALS|Symptomatic treatment of ALS without biologic cell-based treatment
3342125|NCT02193906|Experimental|Intervention group|Cognitive training.
3342126|NCT02193906|Placebo Comparator|Placebo group|Placebo task.
3342127|NCT02193919||cohort 1 placebo + UVB|cohort 1 placebo + UVB
3342128|NCT02193919||South Beach Diet + UVB|South Beach DIet + UVB
3342129|NCT02193919||Ornish Diet + UVB|Ornish Diet + UVB
3342130|NCT02193932|Experimental|EEG Triggered fMRI using Micro Maglink|EEG Triggered fMRI to be performed using the Micro Maglink
3342131|NCT02193958|Experimental|Phase 1: Lowest dose of FF-10501-01|FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342132|NCT02193958|Experimental|Phase 1: 2x lowest dose of FF-10501-01|2x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342133|NCT02193958|Experimental|Phase 1: 4x lowest dose of FF-10501-01|4x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342134|NCT02193958|Experimental|Phase 1: 6x lowest dose of FF-10501-01|6x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342135|NCT02193958|Experimental|Phase 1: 8x lowest dose of FF-10101-01|8x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342136|NCT02193958|Experimental|Ph 2a: FF-10501-01 at 8x in MDS/CMML|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
3238129|NCT01267331|Experimental|stem cells injection|Direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG
3238130|NCT01267331|Placebo Comparator|palcebo intramyocardial injection|Direct intramyocardial injection of placebo containing saline and 5% human serum albumin during CABG.
3342137|NCT02193958|Experimental|Ph1:8x lowest dose FF10101-01 for 21 day|FF-10501-01 tablets BID every 21 days of a 28 day cycle.
3238131|NCT01267344|Active Comparator|GEMOX|Intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks.
3238132|NCT01267344|Experimental|E-GEMOX|Arm A will receive E-GEMOX with additional intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above.
3342138|NCT02193958|Experimental|Ph1: 8x lowest dose FF-10101-01 28 day|FF-10501-01 tablets BID every 28 days of a 28 day cycle.
3342139|NCT02193958|Experimental|Ph1: 10X lowest dose FF-10501-01 14 day|10x lowest dose of FF-10501-01 tablets BID every 14 days of a 28 day cycle.
3342140|NCT02193971|Active Comparator|BS-DES with prasugrel 10mg daily|BS-DES with prasugrel 10mg daily
3342141|NCT02193971|Active Comparator|BS-DES with prasugrel 5mg daily|BS-DES with prasugrel 5mg daily
3342142|NCT02193971|Experimental|BD-DES with prasugrel 10mg daily|BD-DES with prasugrel 10mg daily
3342143|NCT02193971|Experimental|BD-DES with prasugrel 5mg daily|BD-DES with prasugrel 5mg daily
3342144|NCT02193984|Experimental|Peer support|Study participants are assigned a volunteer peer supporter who has been trained to offer support on diabetes management.
3342145|NCT02193984|No Intervention|Control|No intervention
3342146|NCT02193997|Experimental|Fiber 1|Fiber bar containing inulin as fiber soucre taken once daily for 4 weeks
3238133|NCT01267357||Serous papillary endometrial ca patients|30 patients diagnosed with SP endometrial ca
3342147|NCT02193997|Experimental|Fiber 2|Fiber bar containing soluble corn as fiber soucre taken once daily for 4 weeks
3342148|NCT02193997|Placebo Comparator|Placebo|Bar with low fiber content (placebo) once daily for 4 weeks
3342149|NCT02194010||Participants evaluated at INC sites|Participants being evaluated at the INC sites will participate in both the DSI and HMSN-R-ODS by completing these PROs during their visit.
3342150|NCT02194010||INC Contact Registry|INC Contact Registry completes the HMSN-R-ODS on web http://rarediseasesnetwork.epi.usf.edu/INC/
3342151|NCT02194023|Placebo Comparator|Placebo (PCB)|Placebo mouthrinse: physiological saline solution (0.9% w/w solution of NaCl in deionized water)
3342152|NCT02194023|Experimental|0.12%NF|0.12% Chlorhexidine digluconate new formulation
3342153|NCT02194023|Experimental|0.03%NF|0.03% Chlorhexidine digluconate new formulation
3342154|NCT02194023|Active Comparator|PAT (Perio-Aid Treatment)|Commercialized 0.12% Clorhexidine digluconate (Perio-Aid Treatment, Dentaid, Spain)
3238134|NCT01267357||Endometrioid endometrial ca|32 patients diagnosed with Endometrioid endometrial ca
3238135|NCT01267370|Active Comparator|Soy polysaccharide fiber|Dietary fiber for treatment of chronic constipation in children
3238136|NCT01267370|Placebo Comparator|purified soy extract, with no fiber)|blinded control group
3342155|NCT02194036|Experimental|Learning oriented physiotherapy|Learning oriented physiotherapy is a treatment approach based on knowledge from neuroscience and particularly aimed to curb physical symptoms and ailments, but also to regain a sense of better physical balance and mental control. Therapy sessions are normally given every 2 weeks with individual homework lessons between. The therapy will last between 6 to 12 months depending on learning process and individual needs.
3342156|NCT02194036|Active Comparator|Widely Recognized Psychiatric Treatment|Standard Outpatient Treatment within the Psychiatric clinic
3238137|NCT01267383|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
3238138|NCT01267383|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
3238139|NCT01267396|Experimental|Sertraline Hydrochloride tablets 100 mg|Sertraline Hydrochloride tablets 100 mg of Dr.Reddy's Laboratories Limited
3238140|NCT01267396|Active Comparator|Zoloft 100 mg Tablets|Zoloft 100 mg Tablets of Pfizer
3238141|NCT01267435|Other|determining correct tunnel positions|
3238142|NCT01267448|Active Comparator|Saxagliptin + Metformin XR|Saxagliptin 5 mg + Metformin XR 1000 mg will be automatically titrated weekly in 2 weeks to Saxagliptin 5 mg + Metformin XR 2000 daily for a total duration of 12 weeks.
3342157|NCT02194049|Experimental|BKM 120, cisplatin, etoposide|Patients receive PI3K Inhibitor BKM120 PO QD on days 1-21, cisplatin IV over 2 hours on day 1 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3342158|NCT02194075|Active Comparator|Fluvoxamine+Methylphenidate Hydrochloride|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~Methylphenidate Hydrochloride: tablet, 18mg-36mg/d, were treated with a course of 8 weeks."
3342159|NCT02194075|Placebo Comparator|Fluvoxamine+sugar pill|"Fluvoxamine: tablet, 100mg-300mg/d, were treated with a course of 8 weeks.~sugar pill: tablet, 1-2 tablets/d, were treated with a course of 8 weeks."
3342160|NCT02194101||Supernormal oxygen delivery goal therapy|Patients will be aged over 70 yr and weight over 35 kg, and undergoing proximal femur fracture (PFF) surgery under peripheral nerve block and laryngeal mask airway anesthesia.
3342161|NCT02194114|Experimental|Dietary Protein Intake|One treatment Arm; Protein Diet: All patients will be fed the following five diets, in random order, each for 17-19 days: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
3342162|NCT02194127|Experimental|Anthocyan capsules|capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)
3342163|NCT02194127|Placebo Comparator|Placebo|
3342164|NCT02194140|Other|oral contrast|oral iodinated contrast material
3342165|NCT02194153||Metalyse|Metalyse weight-adjusted
3342166|NCT02194166|Experimental|Pre-Randomization (Trastuzumab IV)|Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.
3342167|NCT02194166|Experimental|Group A: Trastuzumab SC (First Vial Formulation, then SID)|Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.
3342168|NCT02194166|Experimental|Group B: Trastuzumab SC (First SID, then Vial Formulation)|Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).
3342169|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fasted|
3342170|NCT02194179|Experimental|NVP XR 400 mg (KCR 25%) fed|
3342171|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fasted|
3342172|NCT02194179|Experimental|NVP XR 400 mg (KCR 20%) fed|
3342173|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fasted|
3342174|NCT02194179|Experimental|NVP XR 300 mg (KCR 25%) fed|
3342175|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fasted|
3342176|NCT02194179|Experimental|NVP XR 300 mg (KCR 20%) fed|
3342177|NCT02194179|Active Comparator|NVP IR 200 mg (Viramune®)|
3342178|NCT02194192|Experimental|Group E|Ephedrine 10 mg in Normal Saline 10 ml
3342179|NCT02194192|Active Comparator|Group O|Ondansetron 8 mg in Normal saline 10 ml
3342180|NCT02194192|Placebo Comparator|Group P|Normal saline 10 ml
3342181|NCT02194205|Experimental|COMBIVENT HFA|
3238143|NCT01267448|Active Comparator|the Control goup Glipizide XL|The control group will receive Sulphonylurea (Glipizide XL 10mg orally) for a total duration of 12 weeks.
3238144|NCT01267474|Experimental|Nutritional education|
3238145|NCT01267474|No Intervention|Control|
3238146|NCT01267487|Active Comparator|Fixed doses plus PO protamine|"Intraoperative fixed dose schemes (as in fixed doses plus placebo group) plus continuous infusion of 25mg/hour of protamine during first 6 PO hours"
3238147|NCT01267487|Active Comparator|Titrated doses plus PO protamine|"Same as titrated doses arm, plus continuous infusion of 25mg/ hour of protamine during first 6 PO hours"
3238148|NCT01267487|No Intervention|Fixed doses plus placebo|"Before CPB, fixed heparin dose of 400 Units per kg of body weight to achieve an Activated Coagulation Time (ACT) > 480 seconds.~Reversal of heparin after CPB using 1 : 1 ratio (1 mg of protamine for each 100 units (1mg) of heparin), plus 0.8 mg/kg of protamine at the end of the surgery.~Continuous infusion of placebo (saline 0.9%) during the first 6 PO hours."
3238149|NCT01267487|Active Comparator|Titrated doses plus placebo|"Titrated doses of heparin before and during CPB and reversal with protamine after CPB calculated by the construction of individualized Bull's dose-response curve.~Continuous infusion of placebo (saline 0.9%) during first 6 PO hours."
3238150|NCT01267500|Experimental|Non-surgical therapy|patching or fusion exercises
3238151|NCT01267513||normal volunteers|Normal individuals, aged 18 -75
3238152|NCT01267513||Hospitalized patients|Pulmonary and cardiac ICU, Trauma
3342182|NCT02194205|Placebo Comparator|Placebo HFA|
3342183|NCT02194205|Active Comparator|COMBIVENT (CFC)|
3342184|NCT02194205|Placebo Comparator|Placebo CFC|
3342185|NCT02194218|Experimental|Nevirapine XR 4 doses|
3342186|NCT02194218|Active Comparator|Nevirapine XR 2 doses|
3342187|NCT02194231|Experimental|Trabectedin|Patients will receive trabectedin treatment
3342188|NCT02194244|Experimental|Granules Fasted|
3342189|NCT02194244|Experimental|Granules Fed|
3342190|NCT02194244|Active Comparator|Tablet Fasted|
3342191|NCT02194244|Active Comparator|Tablet Fed|
3342192|NCT02194257|Experimental|[14C]-cyclohexane ambroxol oral solution + ambroxol lozenge|
3342193|NCT02194257|Experimental|[14C]-benzyl ambroxol oral solution + ambroxol lozenge|
3342194|NCT02194270|Experimental|Ambroxol hydrochloride - soft pastille|
3342195|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - low dose|
3342196|NCT02194270|Active Comparator|Ambroxol hydrochloride - syrup - high dose|
3342197|NCT02194283|Experimental|Ambroxol - in single rising doses|
3238153|NCT01267552|Experimental|Non drainage arm|No drains will be placed during operation
3238154|NCT01267552|Active Comparator|Drainage arm|Closed suction drains will be placed during operation
3238155|NCT01267565|Other|intubated and ventilated patients|patients undergoing mechanical ventilation for an anticipated length of more than 48h
3238156|NCT01267565|Other|non intubated patients|non intubated patients with an independant indication of bronchoscopy including an endotracheal aspiration during the procedure
3238157|NCT01267578|Experimental|peptide vaccination|
3342198|NCT02194283|Placebo Comparator|Placebo|
3342199|NCT02194296|Experimental|Ambroxol hydrochloride - lozenge|
3342200|NCT02194296|Active Comparator|Ambroxol hydrochloride - syrup|Mucosolvan®
3238158|NCT01267591||control|
3238159|NCT01267591||type 1 diabetes|
3238160|NCT01267591||obesity|
3238161|NCT01267604|Active Comparator|Recombinant FSH|225IU rFSH
3342201|NCT02194309|Experimental|Telmisartan low + amlodipine|
3342202|NCT02194309|Experimental|Telmisartan high + amlodipine|
3238162|NCT01267604|Experimental|Recombinant FSH Inositol Melatonin|225IU rFSH, 4g Inositol and 3mg Melatonin
3238163|NCT01267617||chronic hemodialysis outpatients|
3342203|NCT02194322|Experimental|BIBN 4096 BS - in single rising doses|
3342204|NCT02194322|Placebo Comparator|Placebo|
3342205|NCT02194335|Experimental|BIBN 4096 BS - in single rising doses|
3342206|NCT02194335|Placebo Comparator|Placebo|
3342207|NCT02194348|Experimental|BIBN 4096 BS - in single rising doses|
3342208|NCT02194348|Placebo Comparator|Placebo|
3342209|NCT02194361|Experimental|Anthocyan capsules|
3342210|NCT02194361|Placebo Comparator|Placebo|
3342211|NCT02194374|Experimental|ROR1R-CAR-T Cells|"Peripheral blood mononuclear cells (PBMC) collected via venipuncture and/or steady state leukapheresis at discretion of PI. Participants receive a cycle of lympho-depleting chemotherapy as chosen by treating physician 4 to 5 days before ROR1R-CAR-T cell infusion : Fludarabine, Cyclophosphamide, and Rituximab (FCR), Bendamustine and Rituximab (BR), or Fludarabine, Bendamustine, and Rituximab (FBR).~Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
3342212|NCT02194400|Placebo Comparator|Placebo|Saline infusion
3342213|NCT02194400|Experimental|RSLV-132|0.3 - 10 mg/kg experimental drug
3342214|NCT02194413|Experimental|Arm 1 (healing touch)|"Patients receive daily HT sessions comprising pain drain, chakra connection, magnetic clearing, and mind clearing over 30 minutes from day 1 until 2 days before discharge from the hospital (therapeutic touch).~Interventions: therapeutic touch, quality-of-life assessment, and questionnaire administration"
3342215|NCT02194413|Active Comparator|Arm II (usual care)|"Patients receive routine nursing care from doctors and nurses from day 1 until 2 days before discharge from the hospital.~Interventions: quality-of-life assessment, and questionnaire administration"
3342216|NCT02194426|Experimental|MP0250|"see section intervention description below"
3342217|NCT02194452|Experimental|Diagnostic (gallium Ga 68-edotreotide PET/CT)|"Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.~Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis"
3342218|NCT02194478|Other|8 Week Meditation|Allina Health employees undergoing 8 week meditation intervention
3342219|NCT02194491|Experimental|[11C]AS2471907 administration (Part 1)|Up to 4 single dose IV administrations (≤ 10 mL infused over approximately 1 minute) are planned, totaling less than 100 μg.
3238164|NCT01267630||Surgical ICU|Patients are admitted to the surgical ICU of Chiang Mai University Hospital within 48 hours .
3238165|NCT01267643|Experimental|Alefacept|
3238166|NCT01267669|Experimental|EVL plus Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
3238167|NCT01267669|Placebo Comparator|EVL plus Placebo|Emergency EVL plus placebo infusion for 5 days
3238168|NCT01267682|No Intervention|Usual care|Participants receive standard clinical care
3238169|NCT01267682|Experimental|Treatment|Behavioral: cognitive stimulation
3238170|NCT01267708||Study Group|All those tested
3238171|NCT01267721||Study Group|A single group of 100 consecutive patients will undergo additional blood sampling at different time points
3238172|NCT01267734|Experimental|EECSS + DDAT|Promus Element stent + double-dose clopidogrel anti-platelet therapy
3238173|NCT01267734|Active Comparator|ZECSS + DDAT|Endeavor Resolute stent + double-dose clopidogrel anti-platelet therapy
3238174|NCT01267734|Experimental|EECSS + TAT|Promus Element stent + triple anti-platelet therapy
3342220|NCT02194491|Experimental|ASP3662 administration (Part 2)|The dose levels used in part 2 will depend on the ongoing analysis of EO (enzyme occupancy) from previously dosed subjects.
3342221|NCT02194504|No Intervention|No dietary advice|No dietary intervention
3342222|NCT02194504|Experimental|Dietary advice, Targeted|12-wk dietary advice
3342223|NCT02194504|Experimental|Dietary advice, Western|12-wk dietary advice
3342224|NCT02194517|No Intervention|control (B)|Patients performing CHO and FP exchanges calculation with standard method.
3342225|NCT02194517|Experimental|ELKa (A)|Patients counting CHO and FP exchanges with ELKa toolset.
3342226|NCT02194530||Peanut allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3342227|NCT02194530||Allergic/atopic individuals (not peanut)|Subjects should not be allergic to peanut. 20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3238175|NCT01267734|Active Comparator|ZECSS + TAT|Endeavor Resolute stent + triple anti-platele therapy
3238176|NCT01267747||Atrial fibrillation or flutter patients|Patients with 'lone' paroxysmal, persistent, or permanent atrial fibrillation
3238177|NCT01267760|Active Comparator|conventional HD|conventional 4-hour HD
3238178|NCT01267773|Active Comparator|Sequential Treatment|
3342228|NCT02194530||Non-allergic individuals|20 individuals will be recruited for this group. Each blood draw will require 105 ml of whole blood to be collected in ten heparinized 10 mL tubes and one EDTA tube.
3342229|NCT02194543||HD 3D|The patients received surgeries with HD 3D on their left eyes.
3342230|NCT02194543||Conventional|The patients received surgeries with conventional method on the other eye.
3342231|NCT02194556|Experimental|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
3342232|NCT02194556|Active Comparator|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive icotinib (125 mg three times per day) as maintenance treatment until disease progression or intolerable toxicity.
3342233|NCT02194569|Experimental|High citrate group|Blood flow according to weight.Target citrate concentration is 4,5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 0.8-1.1 mg/dL.
3238179|NCT01267773|Experimental|Integrated Treatment|
3238180|NCT01267786|Active Comparator|Sevoflurane|1MAC intraoperatively
3342234|NCT02194569|Experimental|Low citrate group|Blood flow according to weight. Target citrate concentration is 2.5 mmol/L blood flow delivered as prismocitrate 18/0 pre-filter. After correction for filtration fraction, the required further amount of substitution fluid is given post filter to achieve a hemofiltration rate of 30 ml/kg/hr. Blood citrate concentrations are tailored to achieve an iCa of 1.3-1.6 mg/dL.
3342235|NCT02194595|Experimental|Basal insulin and exenatide|Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
3342236|NCT02194595|Active Comparator|Basal insulin only|Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
3342237|NCT02194595|Active Comparator|Basal Insulin and bolus insulin|Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
3342238|NCT02194608|Experimental|Telemedicine system|Participants will self-test blood glucose level, weight, and blood pressure and results will be uploaded and transmitted directly via a hometelehealth system to a central location (HUB). Blood draws will be administered at baseline and follow-up visits.
3342239|NCT02194608|No Intervention|Usual care|Participants will self-record their blood glucose levels, blood pressure and weight in a diary. Blood draws will be administered at baseline and follow-up visits.
3342240|NCT02194634|Experimental|Conbercept treatment group|Conbercept injection and sham laser treatment at day 0 for 1st time, the investigators will decide whether the subjects need to get repeated treatment according to monthly assessment.
3342241|NCT02194634|Active Comparator|Laser treatment group|Laser treatment and sham injection at day 0 for 1st time, the investigators will decide whether the repeated laser treatment is needed according to monthly results during the visit after 3 months.
3342242|NCT02194660||M- main hospital|Patient enrolled in the main hospital
3342243|NCT02194660||B- Beihu branch|Patients enrolled in the Beihu branch
3342244|NCT02194673|Experimental|Trans free palm margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3238181|NCT01267786|Active Comparator|desflurane|1 MAC intraoperatively
3238182|NCT01267799||photocopier exposure|
3238183|NCT01267799||control|
3342245|NCT02194673|Experimental|Interesterified palm based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3342246|NCT02194673|Experimental|IE soybean oil-based margarine|One high fat muffin will be serves together with a glass of low fat milk shake.
3342247|NCT02194686|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3238184|NCT01267812|Experimental|Treatment (bortezomib and rituximab)|Patients receive bortezomib SC or IV over 3-5 seconds and rituximab IV on days 1, 8, 15, and 22. Treatment with bortezomib repeats every 3 months for up to 8 courses and treatment with rituximab repeats every 6 months for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3238185|NCT01267838|Active Comparator|T Stenting group|PCI of bifurcation lesion with modified T Stenting.
3238186|NCT01267838|Active Comparator|Culotte stenting group|PCI of bifurcation lesion with Culotte stenting
3238187|NCT01267877|Active Comparator|Guideline unfavorable article|
3238188|NCT01267877|Active Comparator|Guideline favorable article|
3238189|NCT01267903|Experimental|320U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 young adults aged 16-22 years old on day0,28
3238190|NCT01267903|Experimental|640U /0.5ml in young adults|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 young adults aged 16-22 years old on day0,28
3238191|NCT01267903|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 20 children aged 5-15 years old on day0,28
3238192|NCT01267903|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 20 children aged 6-15 years old on day0,28
3238193|NCT01267903|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 20 children aged 6-15 years old on day0,28
3238194|NCT01267916|Experimental|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
3238195|NCT01267916|Experimental|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
3238196|NCT01267916|Experimental|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
3238197|NCT01267916|Experimental|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
3342248|NCT02194686|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3342249|NCT02194712||travellers|travellers with recent (<12 weeks) high risk water contact are included in the study and asked to provide samples for CAA testing
3342250|NCT02194751|Experimental|Oncoquest-L vaccine|Patients will receive a total of 5 single injections of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration.
3342251|NCT02194764|Experimental|Expirimental Formulation|Participants will be administered a single encapsulated dose of the test formulation (Model Naltrexone 50mg containing 2-butanol). Breath samples will be taken over 90 minutes (-5, 0, 5, 10, 20, 40, 60, 90). Subjects will then be randomly crossed over to the four interventions (Formulation 1, Formulation 2, Formulation 3, Formulation-free positive control) three formulations from the first part of the study and a control administration (a capsule-in-capsule design).
3238198|NCT01267916|Experimental|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
3238199|NCT01267916|Experimental|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
3238200|NCT01267942|Experimental|Intravenous intraoperative Enhancin|Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.
3238201|NCT01267942|Active Comparator|Postoperative oral Enhancin.|Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.
3238202|NCT01267968|Experimental|Cohort 1|GSK2251052 1500 mg Single dose (i.v., 60 min)
3238203|NCT01267968|Experimental|Cohort 2|GSK2251052 1500 mg IV q12h x 5 doses infused over 60 minutes
3238204|NCT01267981|Placebo Comparator|Preparation 1|Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.
3238205|NCT01267981|Active Comparator|Preparation 2|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy."
3342252|NCT02194777|Experimental|BIBN 4096 BS - in single rising doses|
3342253|NCT02194777|Placebo Comparator|Placebo|
3342254|NCT02194790|Experimental|community-based Integrated CKD care|Standard CKD care + multidisciplinary team and home visit by community care team
3342255|NCT02194790|No Intervention|Conventional CKD care|standard CKD care
3342256|NCT02194803||Cohort with routine OCT monitoring|
3238206|NCT01267981|Active Comparator|Preparation 3|"Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.~2 liters of polyethylene glycol between 7 pm and 9 pm.~500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy."
3238207|NCT01268007||Normal ECG measurements|Observational, un-blinded, non-interventional study designed to collect ECG data on at least one (1) male patient in an outpatient setting.
3342257|NCT02194803||Cohort without routine OCT monitoring|
3342258|NCT02194816||Parkinson's Disease Patients|Any individuals who has a diagnosis of Parkinson's disease (PD), parkinsonism, or a parkinson's plus syndrome will be allowed to participate.
3342259|NCT02194829|Experimental|Arm A (phase I, dose level 1)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Patients also receive WEE1 inhibitor MK-1775 PO daily on days 1, 2, 8, 9, 15, and 16.
3238208|NCT01268020|Experimental|[18F]-FMH3-01 PET Imaging|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
3238209|NCT01268033|Experimental|Rituximab|two infusions of Rituximab - at the dose of 375 mg/m²
3238210|NCT01268033|Placebo Comparator|placebo|two infusions of placebo
3238211|NCT01268072||Cohort 2|Subjects who are recruited on admission to hospital for AECOPD.
3238212|NCT01268072||Cohort 1|Subjects with COPD who are stable, but at risk of presenting with an AECOPD.
3238213|NCT01268085|Experimental|Radiation Safety Alert|A provider placing an electronic order for a CAT scan will receive a radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part.
3238214|NCT01268085|Active Comparator|Control|Parallel control with no intervention
3238215|NCT01268124|Experimental|Treatment|
3238216|NCT01268137|Active Comparator|stimulation on|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
3238217|NCT01268137|Placebo Comparator|Stimulation off|At first stage, electrodes will be implanted in all patients, who will be continuously stimulated for several months. After this stage, the random-crossed part of the study will start, and patients who responded to DBS will be randomly distributed in two groups: on stimulation or off stimulation group, for the next three months. Subsequently, patients will be allocated in the other group (on or off, crossed part) for three months
3238218|NCT01268163|Active Comparator|1|European Taxotere® (Taxotere EU) 60-100 mg/m^2
3238219|NCT01268163|Experimental|3|Hospira Docetaxel Injection 60-100 mg/m^2
3238220|NCT01268163|Active Comparator|2|American Taxotere® (Taxotere US) 60-100 mg/m^2
3238221|NCT01268176|Active Comparator|Low fat meal|Those subjects who receive a low fat meal prior to vitamin D3 administration
3342260|NCT02194829|Experimental|Arm B (phase I, dose level 2)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 as in Arm A.
3342261|NCT02194829|Active Comparator|Arm C (phase II, placebo)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine hydrochloride as in Arm A. Patients also receive placebo PO daily on days 1, 2, 8, 9, 15, and 16.
3342262|NCT02194829|Experimental|Arm D (phase II, WEE1 inhibitor MK-1775)|Patients receive paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and WEE1 inhibitor MK-1775 (recommended phase II dose) as in Arm A.
3342263|NCT02194842|Active Comparator|Enzalutamide|Enzalutamide will be given at a dose of 160 mg daily
3342264|NCT02194842|Experimental|Enzalutamide and Ra223|Ra223 will be administered 50kBq/kg standard dose monthly for 6 months and given in combination with enzalutamide at a dose of 160 mg daily.
3342265|NCT02194855|Experimental|laparoscopic operation on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3238222|NCT01268176|Active Comparator|High fat meal|Those subjects who receive a high fat meal prior to vitamin D3 administration
3238223|NCT01268176|Active Comparator|No meal|Those subjects who do not receive a meal and continue to fast. They only receive the vitamin D3 dose.
3342266|NCT02194855|Experimental|laparoscopic operation on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3342267|NCT02194855|Experimental|conventional open surgery on rocuronium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3342268|NCT02194855|Experimental|conventional open surgery on cisatracurium|according different surgical type, all patients were divided into 2 groups: the laparoscopic surgery group and open surgery group.Each group were randomly assigned to the rocuronium group and cisatracurium group.
3342269|NCT02194881||Ivacaftor 1|patients with CF who are homozygous or heterozygous for the G551D mutation and treated with Ivacaftor
3342270|NCT02194894|Active Comparator|NAFLD patients|Twenty patients with NAFLD will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
3342271|NCT02194894|Active Comparator|Healthy controls|Twenty healthy controls will take 3g of APAP daily for 14 days. Serum liver chemistries and trough acetaminophen (APAP) concentrations will be measured on treatment days 0, 2, 4, 7, 9, 11, 14 and on follow up day 17
3342272|NCT02194907|Active Comparator|Anterior insula cortex activation|Participants will receive training sessions using a special feedback technique to learn to actively increase blood flow in the front of the brain, while thinking of and viewing emotional faces, scenes, and text.
3342273|NCT02194907|Active Comparator|Primary auditory cortex activation|Participants will have training sessions using a special feedback technique to learn to actively increase blood flow in the back of the brain while thinking of and viewing emotional faces, scenes, and text.
3342274|NCT02194920||Parathyroid reimplantation|
3342275|NCT02194946|Active Comparator|CKD-related management group|"Patients in basic care group are provided with basic western medicine treatment according to Kidney Disease: Improving Global Outcomes(KDIGO) and The National Kidney Foundation Kidney Disease Outcomes Quality Initiative(KDOQI) guidelines but not prescribed any Chinese herbal medicine.~The basic western medicine treatment mainly includes dietary protein restriction(0.6g/kg·d, for Chinese), Blood pressure control, treating anemia with erythropoietin,treatment of abnormal calcium-phosphate metabolism, and treatment of fluid, electrolyte and acid-base disorders."
3238224|NCT01268202|Experimental|Pravastatin|Pravastatin : 40mg/day during 12 months
3238225|NCT01268215|Experimental|A (two study drugs group)|The standard management + two study drugs (endotracheal instillation of a mixture containing budesonide and Infasurf)
3238226|NCT01268215|Active Comparator|B (one study drug group)|The standard management + one study drug (endotracheal instillation of Infasurf only).
3238227|NCT01268215|Sham Comparator|C (no study drug group)|The standard management only.
3342276|NCT02194946|Experimental|CM therapies group|Participants will receive CM therapies and CKD-related management concurrently. One or several the following CM patterns will be allowed: a. Chinese herbal formula via oral administration; b. Chinese patent medicine via oral administration; c. Chinese herbal formula via colonic administration; d. Chinese patent medicine via colonic administration.
3238228|NCT01268228||Residual ic ECG ST elevation in SB|
3238229|NCT01268228||Residual ic ECG ST elevation in MB|
3238230|NCT01268241||Observation|Hemizygous male or heterozygous female patients of any age with genetically confirmed diagnosis of Anderson-Fabry disease.
3238231|NCT01268254||red wine|red wine usual consumer versus abstemious
3238232|NCT01268280|Experimental|Treatment Sequence 1|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 CK-2017357 500 mg
3238233|NCT01268280|Experimental|Treatment Sequence 2|Dosing Period 1 Placebo; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 CK-2017357 250 mg
3238234|NCT01268280|Experimental|Treatment Sequence 3|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 500 mg
3238235|NCT01268280|Experimental|Treatment Sequence 4|Dosing Period 1 CK-2017357 250 mg; Dosing Period 2 CK-2017357 500 mg; Dosing Period 3 Placebo
3238236|NCT01268280|Experimental|Treatment Sequence 5|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 Placebo; Dosing Period 3 CK-2017357 250 mg
3238237|NCT01268280|Experimental|Treatment Sequence 6|Dosing Period 1 CK-2017357 500 mg; Dosing Period 2 CK-2017357 250 mg; Dosing Period 3 Placebo
3238238|NCT01268319|Experimental|(+)HR-LCP and EPD|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation with an embolic protection device (EPD)in place prior to any angioplasty.
3342277|NCT02194959|Experimental|Peer PN|A scheduling phone call will be made to all patients within 14 days of their initial referral to the study. Following the scheduling of their appointment, each patient will be mailed an informational pamphlet with written instructions for the colonoscopy once they have scheduled the procedure. The first reminder PPN phone call will be made two weeks before a patient's scheduled colonoscopy. The second reminder PPN call will be made three days before the scheduled colonoscopy. For all calls, at least three attempts (at different times of the day and different days of the week) will be made to reach patients. All telephone calls will be audio-recorded to facilitate fidelity monitoring. All colonoscopy appointments will be made within the Division of Gastroenterology at each of the hospital sites. The Project Coordinator will be responsible for confirming completion (and no-shows) for all colonoscopy appointments.
3342278|NCT02194959|Active Comparator|Pro PN|Participants randomized to standard patient navigation received care that they would normally receive if they were not participating in the study with navigation from the GI staff, and three phone calls that involved scheduling and reminding the participant about their colonoscopy appointment.
3342279|NCT02194972|Experimental|soluble dietary fiber|pectin, a kind of soluble dietary fiber
3238239|NCT01268319|Placebo Comparator|(+)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 27 Subjects who meet this criteria will be randomized to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
3238240|NCT01268319|Placebo Comparator|(-)HR-LCP and No EPD (standard of care)|These subjects will meet all angiographic criteria.The target plaque will NOT contain a LipiScan IVUS signal that meets the Higher Risk Lipid Core Plaque (HR-LCP) definition contained in the protocol. 54 Subjects who meet this criteria will be assigned (not randomized) to standard pre-dilation and stent implantation without an embolic protection device (EPD)in place prior to any angioplasty.
3238241|NCT01268332|Experimental|Intravaginal Ring|Insertion of intravaginal ring at enrollment. The intravaginal ring should stay in place for 12 consecutive weeks and will be removed by a physician at the Week 12 study visit.
3238242|NCT01268332|No Intervention|No Intravaginal Ring|Intravaginal ring will not be inserted into participants.
3238243|NCT01268345|Experimental|Andon|Andon blood glucose test strips with test meter
3238244|NCT01268345|Active Comparator|Lifescan|
3342280|NCT02194972|No Intervention|Placebo|Placebo
3342281|NCT02195024|Active Comparator|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
3342282|NCT02195024|No Intervention|No MRI group|Patients that refuse to undergo cMRI for any reason but accept to attend the trial can be further observed according to the protocol
3342283|NCT02195050||Therapeutic target arm|Statin treated patients with and without raised triglycerides who do not have diabetes or dysglycemia. Statin treated patients with type 2 diabetes.Statin treated patients with CKD stages 4 and 5 (eGFR ≤30mL/min).
3342284|NCT02195050||Nerve function arm|Patients with severe hypertriglyceridaemia (fasting TG > 5.5mmol/l.) are recruited for nerve function assessment and corneal confocal microscopy.
3342285|NCT02195050||Genetic screening arm|For LAL deficiency screening, patients will be recruited over a 5 year period with a documented triglyceride level of more than 10 mmol/l at any time, low HDLC, raised ALT, combined hyperlipidaemia, or non-alcoholic fatty liver disease. Patients recruited from Manchester will be offered additional genetic testing for familial hypercholesterolaemia.
3238245|NCT01268358|Experimental|Lamazym 6.25|
3238246|NCT01268358|Experimental|Lamazym 12.5|
3238247|NCT01268358|Experimental|Lamazym 25|
3238248|NCT01268358|Experimental|Lamazym 50|
3238249|NCT01268358|Experimental|Lamazym 100|
3342286|NCT02195063||Pain management|patients undergoing transdermal treatment for pain
3342287|NCT02195063||Scar care|patients undergoing transdermal treatment for scars
3342288|NCT02195063||Wound care|patients undergoing transdermal treatment for wounds
3342289|NCT02195063||UDT|patients receiving urinary drug tests
3342290|NCT02195076||Breast Cancer patients|
3342291|NCT02195076||Lung cancer patients|
3342292|NCT02195076||Healthy controls|
3342293|NCT02195089|Experimental|BLS_ILB_E710c 500mg|"Drug: BLS_ILB_E710c 500mg~Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 & 8)"
3342294|NCT02195089|Experimental|BLS_ILS_E710c 1000mg|"Drug: BLS_ILS_E710c 1000mg~Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 & 8)"
3342295|NCT02195089|Experimental|BLS_ILS_E710c 1500mg|"Drug: BLS_ILS_E710c 1500mg~Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 & 8)"
3238250|NCT01268371|Active Comparator|Promus Element|Everolimus-eluting stent
3238251|NCT01268371|Active Comparator|Nobori|Biolimus-eluting stent with biodegradable polymer
3238252|NCT01268384|Experimental|FDR_GX|Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles
3238253|NCT01268397|Active Comparator|ORIF|Open reduction and internal fixation with a volar plate
3238254|NCT01268397|Active Comparator|plaster treatment|Closed reduction and plaster treatment
3238255|NCT01268410||acute respiratory failure|
3238256|NCT01268423|Experimental|Early percutaneous tracheostomy|
3238257|NCT01268423|Active Comparator|Prolonged translaryngeal intubation|
3238258|NCT01268436||Injectable pain medication|Patients who receive an injectable form of pain medication.
3238259|NCT01268436||Oral pain medication|Patients who receive oral pain medication only
3238260|NCT01268449|Active Comparator|Laser group|
3238261|NCT01268449|Placebo Comparator|Placebo group|Randomly,half of the patients receive placebo.
3238262|NCT01268462|Experimental|Heliox + PEP (Group 1)|
3238263|NCT01268462|Experimental|Oxygen+PEP(Group 2)|
3238264|NCT01268462|Experimental|Heliox ( Group 3)|
3238265|NCT01268462|Active Comparator|Oxygen (Group 4)|
3238266|NCT01268540|Experimental|NHT15|Aspheric Toric Intraocular Lens Models NHT15
3238267|NCT01268540|Active Comparator|FY-60AD|Aspheric Non-toric Intraocular Lens: Model FY-60AD
3342296|NCT02195102||transcatheter aortic valve Replacement|Patients with symptomatic severe aortic stenosis who are not candidates for surgical aortic valve replacement because of coexisting illnesses.
3342297|NCT02195115|Active Comparator|Laparoscopic cholecystectomy|surgical removal of gallbladder
3342298|NCT02195115|Active Comparator|Non-operative treatment|Administration of amitriptyline 25mg daily, Low Fat-Low Cholesterol Diet
3342299|NCT02195141|Active Comparator|conventional fraction|Radiotherapy (25x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily
3342300|NCT02195141|Experimental|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
3342301|NCT02195154|Experimental|18F-DTBZ for Vascular Parkinsonism|This neuroimaging study includes the 18F-FP-(+)-DTBZ PET, MRI structure images, diffusion tensor imaging, susceptibility weighted imaging, resting state and gait-related imagery task functional MRI. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject group, each subject will have 3 visits in this study. Safety measurement for 18F-FP-(+)-DTBZ will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
3342302|NCT02195167|Experimental|Dasotraline|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
3342303|NCT02195180|Experimental|standard of care combined with ERY001|standard of care = Gemcitabine or folfox
3342304|NCT02195180|Sham Comparator|standard of care alone|standard of care = Gemcitabine or folfox
3342305|NCT02195193|No Intervention|Usual Care (UC)|"The standard interventions from Clinical Pathway for Acute Coronary Syndromes in China-Phase 3 (CPACS-3) study that are limited to in-patient ACS care (refer to Usual Care [UC]), will be implemented in the participating hospitals, and hence will be received by all patients in both intervention (IC) and control (UC) groups; standardized cardiovascular disease education also will be provided to all participants.CPACS-3 registration number is NCT01398228"
3342306|NCT02195193|Experimental|Intervention Care (IC)|Besides of the UC, an nurse-coordinated integrated care model for Acute Coronary Syndromes(ACS) and depression will be delivered to intervention group, including ACS secondary prevention therapies at and after discharge, screening and treatment of depression during hospitalization and after discharge.
3342307|NCT02195206||Healthy|Adult
3342308|NCT02195219|Experimental|open reduction internal fixation|open reduction internal fixation
3342309|NCT02195219|Active Comparator|non operative treatment|'sling rest and early functional recovery
3342310|NCT02195245|No Intervention|Control|Control - Observational (non interventional) data is collected from current state of the art absorber devices.
3342311|NCT02195245|Experimental|memsorb|New CO2 filter - data is collected using the new CO2 absorber.
3342312|NCT02195258||salbutamol|
3342313|NCT02195271|Active Comparator|Melatonin|0,25mg/Kg sl before tDCS
3238268|NCT01268540|Experimental|NHT30|Aspheric Toric Intraocular Lens Model NHT30
3238269|NCT01268540|Experimental|NHT53|Aspheric Toric Intraocular Lens Models NHT53
3238270|NCT01268579|Experimental|ribavirin|This will be a single institution non-randomized study for patients with tonsil and/or base of tongue squamous cell cancer. This is a pilot study to obtain pharmacodynamic data regarding the effects of ribavirin on tonsil squamous cell cancer.
3238271|NCT01268592|Experimental|positive cancer diagnosis|female patients diagnosed with cancer who wish to preserve their fertility by vitrifying their oocytes
3342314|NCT02195271|Experimental|tDCS|Transcranial direct current stimulation once time. Dose 2 mA, 20 seconds.
3342315|NCT02195284|Experimental|Sub-study 1|Subjects will be randomized to either use ELLIPTA inhaler first and then DISKUS/ACCUHALER inhaler or use DISKUS/ACCUHALER inhaler first and then ELLIPTA inhaler
3342316|NCT02195284|Experimental|Sub-study 2|Subjects will be randomized to either use ELLIPTA inhaler first and then MDI (metered-dose inhaler) or use MDI first and then ELLIPTA inahler
3342317|NCT02195284|Experimental|Sub-study 3|Subjects will be randomized to either use ELLIPTA inhaler first and then TURBUHALER inhaler or use TURBUHALER inhaler first and then ELLIPTA inhaler
3342318|NCT02195297|Active Comparator|ANTICELLULITE GMG GIULIANI|Each included subject applied ANTICELLULITE GMG GIULIANI mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
3342319|NCT02195297|Active Comparator|SOMATOLINE|Each included subject applied SOMATOLINE CREAM mono-laterally (on the left or on right side according to a previously defined randomization list) once a day, at evening, for an uninterrupted period of 4 weeks.
3342320|NCT02195323|Experimental|MSC recipient|The patients with CKD who underwent intravenous injection of MSC.
3342321|NCT02195336|Experimental|dMRT, Bevacizumab, Chemotherapy|"dMRT: Magnetic Resonance Tomograph, Baseline, day 8, day 28, day 92, progression/relapse.~Bevacizumab: 7.5mg/kg every 3 weeks for 3 cycles. Standard of care NSCLC first-line chemotherapy, doublets containing paclitaxel and carboplatin are preferred, every 3 weeks for 3 cycles.~Thereafter Bevacizumab 7.5mg/kg every 3 weeks until progression/relapse or unacceptable toxicity."
3342322|NCT02195375|Experimental|Flutiform 500/20 µg BID|Flutiform 250/10 (2 puffs BID)
3342323|NCT02195375|Experimental|Flutiform 250/10 µg BID|Flutiform 125/5 (2 puffs BID)
3342324|NCT02195375|Active Comparator|Seretide Accuhaler 50/500 µg BID|Seretide Accuhaler 50/500 (BID)
3238272|NCT01268605|Active Comparator|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
3238273|NCT01268605|Active Comparator|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
3238274|NCT01268618|Experimental|Probiotic|
3238275|NCT01268618|Placebo Comparator|Placebo|
3342325|NCT02195388||CR with AH|Patients after ACS with arterial hypertension treat with comprehensive cardiac rehabilitation
3342326|NCT02195388||N-CR with AH|Patients after ACS with arterial hypertension don't treat with comprehensive cardiac rehabilitation.
3342327|NCT02195388||CR without AH|Patients after ACS without arterial hypertension treat with comprehensive cardiac rehabilitation
3238276|NCT01268631|Active Comparator|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
3342328|NCT02195401||Sleeping in a cleanroom|Each child and his or her parent slept in a cleanroom for two weeks. Within 24 hours pre and post this two week experience blood and hair samples were taken from the children and the parents filled out rating scales.
3342330|NCT02195453|Experimental|Yangzhengxiaoji Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Yangzhengxiaoji Capsule four granules t.i.d po"
3342331|NCT02195453|Placebo Comparator|Placebo Capsule|"Gemcitabine or Pemetrexed~Cisplatin~Placebo Capsule four granules t.i.d po"
3342332|NCT02195466|Experimental|TPV + RTV + FCZ|
3342333|NCT02195492||Synvisc®|
3342334|NCT02195505||Synvisc®|
3342335|NCT02195505||Usual treatment of knee|nonsteroidal antiinflammatory drugs, antalgics
3342336|NCT02195544||Synvisc®|
3342337|NCT02195557||Synvisc®|
3342338|NCT02195570|Experimental|QSN with CM (QSN-CM).|Women will receive standard of care Quit Smoking Now tobacco education and support plus prize-based contingency management. Their smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Women will earn chances to win prizes each time they test negative for smoking according to biochemical measures.
3342339|NCT02195570|Active Comparator|QSN Only|Women receive the standard of care Quit Smoking Now tobacco education and support only. Smoking status will be monitored from quit date through 3 months postpartum via carbon monoxide and salivary cotinine levels. Incentives are given for providing breath and salivary samples but are not contingent on smoking status.
3342340|NCT02195596|Experimental|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center. A fitness expert nurse is responsible for monitoring the performance and adapt to the physical condition of the patient.Each exercise session consists of warming up time period, period of work and back to calm. Exercise intensity during the work period increases progressively as the program progresses. Aerobic exercise is performed on a cycle ergometer or treadmill.Muscle strength exercises and joint mobility are performed with dumbbells and ankle weights adapted to each patient."
3342341|NCT02195596|Active Comparator|Low intensity aerobic exercise+strength|The control group performed an exercise program similar to intervention but at low intensity that is below 35 or 40% of heart rate reserve (HRR).
3342342|NCT02195609|Other|Omega-3|600 mg (EPA, DHA and Omega-3) twice a day
3342343|NCT02195609|Other|Soy Isoflavones|54.4mg oral twice a day
3342344|NCT02195635|Experimental|Period 1|Single oral dose of 500 mg telotristat etiprate on Day 1
3342345|NCT02195635|Other|Period 2|Subcutaneous injections of 200 µg octreotide acetate three times daily with a single oral dose of 500 mg telotristat etiprate on Day 6
3342346|NCT02195648|Experimental|Suboccipital inhibition|The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles.
3342347|NCT02195648|No Intervention|Control|No intervention will be done to the participants during the study. After study completion, the participants will be offered to receive the therapy.
3342348|NCT02195661|Active Comparator|Melatonin sleep EEG induced group|"All children who were referred to the neurophysiology department who were either unable to keep still for their EEG, or required a sleep EEG as part of their epilepsy work-up and whose caregivers agreed to the administering of sedation with melatonin. Melatonin by mouth (3mg for children < 15kg, 6mg for those > 15kg) 1 hour before the scheduled EEG by the unit nurse. Children who can swallow the capsules directly, those who cannot are given the contents of the powder in the capsule mixed in a few millilitres of water. If the child fails to fall asleep within one hour of administration of the melatonin then a second dose 3mg is given) ."
3342349|NCT02195661|Other|Comparison group for children sedated using previous practice|Since the choral hydrate had been withdrawn a direct comparison group was not possible. However a study performed the previous year in the department measured a several parallel useful outcomes. This study had addressed the usefulness of electroencephalograms in a South African population. A proportion of this group screened in 2012 in our unit underwent sleep studies, sedated with chloral (n=22). These patients were drawn from the same regional pool, with the same disease demographics, and the same sleep deprivation and procedural techniques to the current group. This group was screened for several common denominators to the current study themes, and comparison will be made between these, namely the proportion of patients with successful attainment of sleep studies, the proportion of studies with excessive artifact (precluding interpretation) and the usefulness of the data attained detailing whether the studies were able to assist or alter patient management.
3342350|NCT02195726|Sham Comparator|Sham remote ischemic preconditioning'|In the control group Sham remote ischemic preconditioning will be performed with inflation of 10 mmHg more than baseline
3342351|NCT02195726|Experimental|Remote ischemic preconditioning|"In the experimental group, patients will receive for four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg upper than baseline), followed by 5-minute intervals of reperfusion.~In subjects presenting with BMI > 30 a dedicated blood pressure cuff for obese patients will be used. Coronary angiography will be performed in 45 minutes from last inflation"
3342352|NCT02195739||Nicotine replacement therapy cohort|Cohort defined as patients in whom nicotine replacement therapy (in any preparation) was initiated at the index smoking cessation attempt as the first recorded smoking cessation intervention.
3342353|NCT02195739||Other smoking cessation therapy|Cohort defined as patients in whom other (non-nicotine replacement therapy) smoking cessation pharmacotherapy's were initiated at the index smoking cessation attempt (e.g. bupropion, varenicline) as the first recorded smoking cessation intervention
3342354|NCT02195739||Smoking cessation advice cohort|Cohort (control patients) defined as patients whose first recorded smoking cessation intervention involved smoking cessation advice leading to a quit attempt unassisted by pharmacological smoking cessation aids, at the index smoking cessation attempt.
3238277|NCT01268631|Active Comparator|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
3238278|NCT01268657|Experimental|Cognitive Behavioral Exposure Therapy|
3238279|NCT01268670|Active Comparator|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
3238280|NCT01268670|Active Comparator|Oxycodone|Subjects will receive topical LET and oral oxycodone.
3238281|NCT01268670|Placebo Comparator|Placebo|Subjects will receive topical LET and oral placebo.
3238282|NCT01268696||control group|healthy volunteers
3342355|NCT02195752||Prescribed Compounded Pain Cream|The study is limited to patients who have been prescribed treatment with a topical compounded pain cream as a component of their ordinary care by a qualified physician.
3342356|NCT02195765|Experimental|enamel matrix derivative|Open flap debridement associated with Enamel matrix derivative gel (Emdogain, Straumann)
3342357|NCT02195765|Active Comparator|Open flap debridment|Open flap debridement
3342358|NCT02195778||Young, 18 to 30|
3342359|NCT02195778||Middle, 31 to 50|
3342360|NCT02195778||Older, 51 to 70|
3342361|NCT02195791|Active Comparator|Pioglitazone|
3238283|NCT01268696||Metabolic group|Patients with metabolic syndrome
3238284|NCT01268709|Active Comparator|doxepin|
3238285|NCT01268709|Active Comparator|nortriptyline|
3238286|NCT01268709|Placebo Comparator|placebo|
3342362|NCT02195791|Placebo Comparator|Placebo|
3342363|NCT02195804|Experimental|Ranitidine HCL ODT Vanilla-Mint|
3342364|NCT02195804|Experimental|Ranitidine HCL ODT RM Vanilla-Mint|
3342365|NCT02195804|Active Comparator|Ranitidine HCL|Maximum Strength ZANTAC 150®
3342366|NCT02195817|Other|Selincro® 18 mg with continuous psychosocial support: Cohort A|Selincro® as-needed; tablets, orally, 12-week Treatment Period in conjunction with continuous psychosocial support
3342367|NCT02195817|Other|Initial psychosocial support: Cohort B|Initial psychosocial support followed by usual care practice, 12-week Observational Period
3342368|NCT02195830|Other|Single arm - Ultrasound|All participants will have an Ultrasound measurement of their inferior vena cava at enrolment as described in the intervention
3342369|NCT02195843|Active Comparator|Emperical|Anatomical optimization of device and leads
3342370|NCT02195843|Active Comparator|Electrical|Electrical optimization by RVLV Conduction Time with VectSelect
3342371|NCT02195856|Active Comparator|Diseased condition|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
3342372|NCT02195856|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
3238287|NCT01268722|Active Comparator|Balloon|
3238288|NCT01268722|Experimental|Stent|
3238289|NCT01268735|Experimental|Lubricating eyedrops containing HP-guar|
3238290|NCT01268748|Other|4 ports laparoscopic cholecystectomy|
3238291|NCT01268748|Other|One port transumb. laparoscopic surgery|
3238292|NCT01268761|Experimental|GnRH antagonist|• GnRH antagonist (Cetrorelix 0.25)
3238293|NCT01268761|Placebo Comparator|Placebo (saline solution)|• Placebo (saline solution)
3238294|NCT01268787|Active Comparator|EV 71 vaccine 5ug|EV71 Vaccine 5ug
3238295|NCT01268787|Experimental|EV 71 vaccine 10ug|EV71 vaccine 10ug
3238296|NCT01268800||AML induction|Adults AML patients who were referred for intensive induction therapy
3238297|NCT01268813|Experimental|Exhaled breath uptake blood test|Diabetic patients receiving oral hypoglycemic drug will be tested for biomarkers in their breath and blood samples
3238298|NCT01268813|No Intervention|Exhaled breath and blood test|Breath and blood samples will be collected from healthy volunteers and analyzed using Gas Chromatography-Mass Spectroscopy. The results will be compared to the experimental arm.
3238299|NCT01268826||dosage of the urinary osmolality|dosage of the urinary osmolality
3342373|NCT02195882|Experimental|Exercise program|
3342374|NCT02195908|Experimental|Single point PC6|"choose single point: Neiguan(PC6).Neiguan(PC6): On the anterior aspect of the forearm,between the tendons of the palmaris longus and the flexor carpi radialis, 2 B-cun proximal to the palmar wrist crease.Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3342375|NCT02195908|Experimental|Single point CV12|"choose another single point Zhongwan（CV12）. Zhongwan(CV12): On the upper abdomen, 4 B-cun superior to the centre of the umbilicus, on the anterior median line. Manipulating until achieving a de Qi sensation, then the needle is connected through a electro-acupuncture apparatus,the positive pole is linked to the needle, and the reference pole is located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA.The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3342376|NCT02195908|Experimental|Matching points PC6+CV12|"Choose both Neiguan point(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days."
3342377|NCT02195908|Active Comparator|only antiemetic|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.
3342378|NCT02195934|Other|Standard orange juice (OJ) followed by blood OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
3342379|NCT02195934|Other|Blood orange juice followed by standard OJ|This randomized 2-way cross over study will compare the effect of blood orange juice with that of a standard (blonde) orange juice consumed daily for 28 days, on markers of cardiovascular disease, with a 3 week washout period in between.
3342380|NCT02195960|Placebo Comparator|placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
3342381|NCT02195960|Active Comparator|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
3342382|NCT02195973|Experimental|Paclitaxel + LDE225|Patients will receive intravenous paclitaxel on days 1, 8, and 15 every 28 days (3 weeks on followed by one week off). This constitutes one cycle. in addition to the paclitaxel oral LDE225 will be taken daily. Dosages of each drug will vary according to the study cohort and phase. The study consists of six cycles of treatment followed by clinic visits every 2-3 months for up to two years.
3342383|NCT02195999||Individuals with DMD|"Magnetic Resonance Imaging is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.~Pulmonary Function testing (PFT) are a series of non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.~Metabolic exercise testing using stationary bicycle (exercise capacity and MVO2) evaluates global cardiopulmonary functional status.~Echocardiogram with multiple-echo Dixon method helps to assess cross-sectional and longitudinal variations in myocardial structure."
3342384|NCT02196012|Experimental|Lifestyle counseling|The intervention condition will contain multiple components: nutrition education, physical activity, social support, social media (Pinterest and Facebook), and smartphone applications for self-monitoring. Students in this condition will have access to the private study website, which will be the central platform for delivery of the program materials and social support. The website, developed using Wordpress.com, will include nutrition materials, exercise videos, a forum, and links to the study's Facebook and Pinterest pages
3342385|NCT02196012|Active Comparator|attention control condition|Students randomized to the attention control condition will receive educational emails three times per week. Nutrition materials will be sent once a week, and links to the YouTube exercise videos will be sent twice a week. At the start of the program, students will be emailed a link to the Pandora workout station. The materials sent to the control group will be the same materials posted on the website for the intervention group. Participants will access the emailed lessons and videos each week at their own convenience. Individuals in the attention control condition will not have access to the study website or social media pages.
3342386|NCT02196025|Experimental|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
3238300|NCT01268839|Experimental|001|Efavirenz 600mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 14 days,TMC278 25mg tablet once daily for 28 days
3342387|NCT02196051|Experimental|Exercise Training|Participants will engage in a single bout of elliptical exercise for 45 minutes (3X15 spaced by 5 minutes rest) at baseline. Subjects will be studied before and after this one bout to measure hepatic de novo lipogenesis. Participants will then take part in six weeks of exercise training on an elliptical trainer 3 times per week each time for 45 minutes. Hepatic de novo lipogenesis will be compared pre and post to examine wether improving muscle glucose uptake will decrease hepatic de novo lipogenesis as the glucose is taken up by muscle and not directed to the liver.
3342388|NCT02196064||Safety of the three-drug combination TDF/FTC/RPV|A total of 176 patients will be included in this study, as well as 352 patients naive for RPV who initiated any ART that does not include RPV, who will serve as control group.
3342389|NCT02196090|Experimental|Single arm|Study uses the single case series design with only one arm. All participants in the one arm will have procedures with treatment as usual (Exposure and Response Prevention) alternating with procedures including the vagal maneuver (Cold Face Gel Mask).
3342390|NCT02196103|Experimental|Expectant management|
3342391|NCT02196116|Active Comparator|Group 1|Controls
3342392|NCT02196116|Experimental|Group 2|Cognitively-impaired subjects without dementia and without memory
3342393|NCT02196116|Experimental|Group 3|Cognitively-impaired subjects without dementia and with memory
3238301|NCT01268852|Active Comparator|Damon|Standard self ligating orthodontic Damon brackets
3238302|NCT01268852|Experimental|Insignia|Innovative self ligating orthodontic bracket
3238303|NCT01268865||HBV-infected|
3238304|NCT01268865||HCV-infected|
3238305|NCT01268904||Pediatric status epilepticus|
3238306|NCT01268917|Experimental|preoperative aspirin use|
3238307|NCT01268917|No Intervention|preoperative aspirin nonuse|
3238308|NCT01268930|Active Comparator|Bipolar coagulation|In this arm, after the complete excision of ovarian endometrioma, ovarian hemostasis is provided by bipolar electrocoagulation.
3238309|NCT01268930|Active Comparator|Hemostatic matrix|In this arm, after complete excision of ovarian endometrioma, ovarian hemostasis is provided by hemostatic matrix.
3342394|NCT02196129|Experimental|Sinbaro-3|1cc Harpagophytum Procumbens(freeze drying) pharmacoacupuncture adminstered to 6 acupoints at the site of pain Administered once and once only before any interventions
3342395|NCT02196129|Placebo Comparator|Hwangryun(distillation)|1cc Hwangryun(distillation) pharmaco-acupuncture administered to 6 acupoints at the site of pain Administered once and once only before any other intervention
3342396|NCT02196142|Active Comparator|Cortisol first, Placebo second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
3342397|NCT02196142|Active Comparator|Placebo first, Cortisol second|Drug: Cortisol 20mg, Drug: Mannitol (used as placebo)
3342398|NCT02196155|Active Comparator|BTX-A|Botulinum A toxin is injected each 100 U in both gastrocnemius muscle-bellies and 50 U in the soleus muscle, i.e. a total of 250 U.
3238310|NCT01268956||Lymphatic progenitor cell|Circulating lymphatic progenitor cell
3238311|NCT01268956||Control|healthy people
3342399|NCT02196155|Active Comparator|Cortisone|Depot Medrol is injected at the plantar fascia insertion site at the calcaneus
3342400|NCT02196155|Placebo Comparator|Saline|Placebo saline is injected in both gastrocnemius muscle-bellies and in the soleus muscle
3342401|NCT02196181|Experimental|Arm I (continuous dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3342402|NCT02196181|Experimental|Arm II (intermittent dosing)|Patients receive dabrafenib PO BID and trametinib PO QD on days 1-7 and 29-56. Cycles repeat every 56 days in the absence of disease progression or unacceptable toxicity.
3342403|NCT02196194||tiotropium|
3342404|NCT02196207|Experimental|Eloctate Prophylaxis|Prevention Trial, Arm A: rFVIIIFc (Eloctate) 65 IU/kg weekly will be administered by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
3238312|NCT01268969|Active Comparator|excision and krydakis reconstruction|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
3238313|NCT01268969|Active Comparator|surgical excision and limberg closure|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia . The fasciocutaneous flap was transposed medially so that the defect would be covered without any tension.
3238314|NCT01268982|Experimental|preserved socket|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket.
3238315|NCT01268995|Experimental|Cyclosporine A|Patients in this arm will be switched from immunosuppressive therapy with Tacrolimus to Cyclosporine A. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
3342405|NCT02196207|Experimental|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab 1.5 mg/kg weekly (following 4-wk induction at 3 mg/kg weekly) will be administered by subcutaneous injection in previously untreated children with severe hemophilia A beginning before the first bleed and continued for up to 48 weeks.
3342406|NCT02196207|Experimental|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance plus Emicizumab 1.5 mg/kg weekly by subcutaneous injection in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
3342407|NCT02196207|Active Comparator|Eloctate ITI Alone|Eradication Trial, Arm B: Eloctate 100 IU/kg every other day will be administered by intravenous infusion as immune tolerance alone in previously treated children and adults with severe hemophilia A and high-titer inhibitors and continued for up to 48 weeks.
3342408|NCT02196272|Experimental|Nurse-led email program through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse care manager (NCM).
3238316|NCT01268995|Active Comparator|Tacrolimus|Patients in this arm will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, patients in this arm will commence insulin treatment with NPH-insulin to reach normoglycemia. After the achievement of normoglycemia the insulin treatment will be continued for three more weeks and than terminated.
3342409|NCT02196272|No Intervention|Management of diabetic patients|Usual care, educational program and usual management of Diabetic patients
3342410|NCT02196285|Experimental|Double viral vaccine (MR)|Measles and rubella vaccine
3342411|NCT02196298|Experimental|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
3342412|NCT02196298|Active Comparator|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
3238317|NCT01269021|Experimental|mycophenolate mofetil|
3238318|NCT01269021|Active Comparator|Prednisone|
3238319|NCT01269060|Experimental|Single incision sigmoidectomy|Single incision laparoscopic sigmoidectomy for sigmoid colon cancer
3342413|NCT02196311||Supracondylar humerus fractures|We are looking to compare open reduction internal fixation versus circular external fixation for supracondylar humerus fractures.
3342414|NCT02196337||Women of reproductive age|Age: 18-44 years
3342415|NCT02196337||Pregnant women|Age: 18-44 years
3342416|NCT02196337||Lactating women|Age: 18-44 years
3342417|NCT02196337||Young infants|Age: younger than 6 months
3342418|NCT02196337||Toddlers|Age: between 6 and 24 months
3342419|NCT02196337||School-aged children|Age: 6-12 years
3342420|NCT02196350|Experimental|Intervention A: Diet|Intervention A: One week of very low calorie diet, 12 weeks of low calorie diet; exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen).
3238320|NCT01269086|No Intervention|Usual Care|Traditional care with no systematic assessment of family member´s health problems or risk factors.
3238321|NCT01269086|Experimental|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
3342421|NCT02196350|Experimental|Intervention B: Exercise|"Intervention B: Combination of strength and endurance training, 3 x per week 60 minutes according to the Exercise Program Diabetes (Beweegprogramma Diabetes).~Healthy isocaloric diet."
3238322|NCT01269099|Active Comparator|Control|Control-group
3238323|NCT01269099|Experimental|IV-PCA|IV-PCA group
3342422|NCT02196350|Experimental|Intervention C: Diet and Exercise|"Intervention C: one week very low calorie diet, followed by 12 weeks healthy isocaloric diet.~One week exercise according to the Dutch Norm for Healthy Behaviour (Nederlandse Norm Gezond Bewegen) followed by 12 weeks strength and endurance training (3 x per week 60 minutes) according to the Exercise Program Diabetes (Beweegprogramma Diabetes)"
3238324|NCT01269112|Placebo Comparator|heparin|CVVHDF performed using unfractionated heparin as anticoagulant and Prismasol as reinjection and dialysate fluids
3238325|NCT01269112|Active Comparator|citrate regional anticoagulation|CVVHDF performed using Prismocitrate 18/0 solution (Trisodium citrate 18 mmol/L
3238326|NCT01269138||Factor VII Deficient Patients|Patients affected by Inherited Factor VII deficiency undergoing treatment for bleeding episodes, surgery , prophylaxis.Any patient with levels of FVII less than 50% of normal or a mutation known to be associated to a FVII deficiency. Any patient with a FVII deficiency for whom treatment of bleeding episodes, prevention related to surgery and primary/secondary prophylaxis is considered necessary by his/her treating physician can be enrolled.
3238327|NCT01269151|Experimental|Lucentis (Ranibizumab)|
3238328|NCT01269164|Experimental|Face Transplantation|Surgical Procedure Composite Facial Transplant
3342423|NCT02196350|No Intervention|Control - Historical data|Historical data from the GPs Information System from 60 newly diagnosed type 2 diabetes patients in the last five years will be used as control.
3342424|NCT02196363||Pregnant mothers|No intervention
3342425|NCT02196376||orthostatic tachycardia syndrome|participants with postural orthostatic tachycardia syndrome
3342426|NCT02196376||control subjects|participants not diagnosed with postural orthostatic tachycardia syndrome
3342427|NCT02196389|Active Comparator|Nozovent|Nasal Dilator
3342428|NCT02196389|Active Comparator|Nasanita|Nasal Dilator
3342429|NCT02196389|Active Comparator|Breath Right|Nasal Dilator
3342430|NCT02196389|Active Comparator|Airmax|Nasal Dilator
3342431|NCT02196402||study population|"Consecutive adult (18-80 yrs) outpatients undergoing colonoscopy for routine indications (screening, symptoms, surveillance).~Exclusion criteria:~patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer~patients with inadequate bowel preparation~patients in which cecal intubation was not achieved or scheduled for partial examinations~polyps could not be resected due to ongoing anticoagulation or could not be retrieved for pathologic assessment"
3342432|NCT02196428|Other|Telemonitoring and Teleconsultation|
3342433|NCT02196441|Experimental|Group 2|0.5% bupivacaine Deep topical fornix nerve block anaesthesia (DTFNB)
3342434|NCT02196441|Experimental|Group 1|2% tetracaine local anaesthetic drops
3342435|NCT02196454|No Intervention|Vaccine Information Statement|Study participants will receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
3342436|NCT02196454|Experimental|Video & Vaccine Information Statement|Participants will view an educational video about the HPV vaccine with a male or female narrator. Participants will also receive the HPV Vaccine Information Statement (VIS) which is part of routine care.
3342437|NCT02196467|Experimental|Myoblast transplantation & strength|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearms, resuspended in saline. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
3342438|NCT02196467|Sham Comparator|Saline injection & strength|The same saline solution used in the previous arm, but without cells, will be injected similarly per centimeter cube in the Extensor carpi radialis of the contralateral patient's forearm. The strength will be evaluated after 3 and 6 months and the presence of dystrophin after 3 or 6 months.
3342439|NCT02196480|No Intervention|Methotrexate|JIA patients on stable dose of methotrexate vaccinated with PPV23
3238329|NCT01269177||Patients with acute cardiogenic pulmonary edema|
3238330|NCT01269190|Experimental|Diagnostic (widefield multispectral imaging and HRME)|Patients undergo evaluation of oral cavity using a widefield multispectral imaging device and a high-resolution optical system (HRME) at baseline, after induction of general anesthesia, and prior to surgery.
3238331|NCT01269203|Active Comparator|Curcumin|1000 mg/day Curcumin + 5 -15 mg/day Lenalidomide
3238332|NCT01269203|Placebo Comparator|Placebo|Placebo daily + 5 -15 mg/day Lenalidomide
3238333|NCT01269216|Active Comparator|5-FU with leucovorin|
3238334|NCT01269216|Active Comparator|TS-1 with Irinotecan|
3238335|NCT01269242|Experimental|bindarit 600 mg|
3238336|NCT01269242|Experimental|bindarit 1200 mg|
3238337|NCT01269242|Placebo Comparator|placebo|
3238338|NCT01269255|Experimental|Combination group|
3238339|NCT01269268||active tuberculosis|active TB patients : diagnosed with TB through microbiologic examination
3238340|NCT01269268||healthy control|healthy control : no evidence of respiratory disease, no respiratory symptoms, and no history of close contact of active pulmonary TB patients
3238341|NCT01269281|Experimental|Sumatriptan Succinate tablets 100 mg|Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited
3238342|NCT01269281|Active Comparator|Imitrex 100 mg Tablets|Imitrex 100 mg Tablets of Glaxosmithkline
3238343|NCT01269294|Experimental|001|TMC435 2 capsules of 75 mg once daily for 7 days in Treatment A
3238344|NCT01269294|Other|002|Placebo for TMC435 2 placebo capsules once daily for 7 days in Treatment A
3238345|NCT01269294|Other|003|Placebo for moxifloxacin 1 placebo tablet on Day 7 of Treatments A B and D
3238346|NCT01269294|Experimental|004|TMC435 2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
3238347|NCT01269294|Other|005|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment C
3342440|NCT02196480|Experimental|anti-TNF|JIA patients refractory to methotrexate immediately before the association of anti-TNF vaccinated with PPV23
3342441|NCT02196493|Experimental|Azithromycin|250mg azithromycin three times weekly for 12 weeks
3342442|NCT02196519|Experimental|Test|All test arm subjects received Sylys Surgical sealant around anastomotic junction after closure.
3342443|NCT02196532||migraine group|Patients with migraine
3342444|NCT02196532||healthy control|Sex- and agematched healthy subjects
3342445|NCT02196545|Experimental|Exercise|Exercise, patients train on a specifically programmed movement trainer three times a week for 30 minutes (total duration 12 weeks)
3342446|NCT02196545|No Intervention|Treatment as usual|Treatment according to guidelines of German Society for Psychiatry, Psychotherapy and Nervous Diseases (DGPPN) and German Society of Neurology (DGN) without movement trainer exercise
3342447|NCT02196571|Experimental|Exercise and lifestyle change|Women in the experimental group will be included in structured exercise programme two times per week with duration of 50 minutes.Participants will start with training sessions right after they are diagnosed with GDM and they will exercise until the end of the pregnancy or occurence of contraindications. Programme will consist of aerobic exercises (20 minutes), resistance exercises (20 minutes), plevic floor, stretching and relaxation exercises (10 minutes). Women in control group will receive standard antenatal care.
3342448|NCT02196571|No Intervention|Control|Standard antenatal care
3342449|NCT02196597||resection with RCT|rectal resection in the case of rectal carcinoma with preoperative radiochemotherapy
3342450|NCT02196597||resection without RCT|patients with rectal resection without preoperative radiochemotherapy
3342451|NCT02196610||HEALTHY SUBJECTS group|A group of 20 healthy staff volunteers identified from the Division of Nephrology, Dept. of Medicine and the Kidney Research Centre at the Ottawa Hospital Research Institute will be invited to participate. Measurements of arterial stiffness will be performed by Applanation tonometry. Healthy status will be defined by a self-reporting questionnaire obtained over the phone prior to enrolment and 2 subsequent non-invasive measurements of arterial blood pressure (BP) prior to testing. Subjects will be included if diastolic BP is ≤ 90 mm Hg and systolic BP ≤ 140 mm Hg on 2 consecutive measurements.
3342452|NCT02196610||END-STAGE RENAL DISEASE (ESRD) group|A group of 20 patients with stage 5 Chronic Kidney Disease (estimated glomerular filtration rate <15 ml/min/m2), who attend chronic hemodialysis treatments at The Ottawa Hospital (TOH) will be invited to participate. Measurements of arterial stiffness will be performed in this group by Applanation tonometry.
3342453|NCT02196623|Experimental|Hypoxic Exercise|Supervised, progressive aerobic exercise for 8 weeks under hypoxic conditions
3342454|NCT02196623|Sham Comparator|Normoxic exercise|Supervised, progressive aerobic exercise for 8 weeks under normoxic conditions
3342455|NCT02196636|Experimental|Part 1: Single Ascending Dose (SAD)|Adaptive model per protocol
3342456|NCT02196636|Experimental|Part 2: Food Effect (FE)|Fasted versus Fed
3342457|NCT02196649|Experimental|Endoscopic Clipping|Participants randomised to the arm will receive endoscopic clips to their defect following EMR.
3342458|NCT02196649|No Intervention|No Endoscopic Clipping|These participants will receive standard of care practice only.
3342459|NCT02196662|Experimental|Treatment A|IBD98-M: mesalamine-sodium hyaluronate 200mg-28.75mg X2
3342460|NCT02196662|Experimental|Treatment B|IBD98-M without HA: Mesalamine 200mg X2
3342461|NCT02196662|Experimental|Treatment C|Delzicol 200 mg X2
3342462|NCT02196727||Patients undergoing Bascom operation|
3342463|NCT02196740|Active Comparator|creosote|Creosote ，once，three weeks Triple Antibiotic Paste ，none
3342464|NCT02196740|Experimental|Triple Antibiotic Paste|Triple Antibiotic Paste,once,three weeks creosote,none
3342465|NCT02196753||CIED related infection|"All patients will undergo standard diagnostic process that will consist of: medical interview, physical examination, laboratory tests, blood cultures (3 sets, 1 hour apart, repeated after 24 hours and -if applicable - with fever peak above 38°C); imaging studies (echocardiography: transthoracic, and if there are no contraindications transesophageal, in case of negative or equivocal result repeated after 7-10 days, or in series if necessary, computed tomography scan for pulmonary embolism if indicated); if there are abnormalities in other systems, decisions concerning further diagnostics will be made by the physician in charge.~Apart from standard diagnostic procedures patients will undergo whole body PET CT scan to localize infection or inflammation.~Then the investigators team will make a decision concerning further treatment (antibiotics and complete device removal vs conservative treatment)."
3238348|NCT01269294|Other|006|Moxifloxacin 1 tablet of 400 mg on Day 7 of Treatment C
3238349|NCT01269294|Placebo Comparator|007|Placebo for TMC435 4 placebo capsules once daily for 7 days in Treatment D
3238350|NCT01269307|Active Comparator|1:1 ketamine - propofol mixture|
3238351|NCT01269307|Active Comparator|propofol|propofol
3238352|NCT01269333|Active Comparator|fluvoxamine|
3238353|NCT01269333|Experimental|omeprazole|
3238354|NCT01269333|Placebo Comparator|placebo|
3238355|NCT01269359||radiation|
3238356|NCT01269398|No Intervention|GO-LIF procedure, posetrior facets fusion|
3238357|NCT01269398|Other|solid fusion, GO-LIF procedure|ability to achieve solid fusion, comibing the GO-LIF procedure for spinal fixation and stabilization with percutaneous posetrior facets fusion
3238358|NCT01269411|Experimental|Treatment (RO4929097 and surgery)|"PART A: Patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive oral RO4929097 once daily on days 1-7 and undergo surgery on day 8. Beginning 28 days later, patients receive oral RO4929097 once daily on days 1-3, 8-10, and 15-17. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3238362|NCT01269437|Experimental|Budesonide, Novolizer|Budesonide Dry Powder Inhaler
3238363|NCT01269437|Active Comparator|BudesonideTurbuhaler|Budesonide Dry Powder Inhaler
3238364|NCT01269450|Active Comparator|Utrogestan|
3342466|NCT02196753||Non-infective|Control group consisting of 20 pts with implanted CIEDs who underwent PET CT due to non infectious indications and have no data for infectious process in follow-up
3238365|NCT01269450|Placebo Comparator|placebo|
3238366|NCT01269463|Active Comparator|Methylphenidate HCl ER Capsules|Methylphenidate hydrochloride extended release capsules
3342467|NCT02196779||Patients undergoing abdominoplasty|Skin circulation to abdominal flap is evaluated during surgery using laser fluorescent imaging.
3342468|NCT02196792|Active Comparator|E-Poly/32 mm|E-Poly polyethylene liner in a titanium cup with a stem with 32 mm cobalt-chromium (CoCr) femoral head.
3342469|NCT02196792|Active Comparator|E-Poly/36 mm|E-Poly polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
3342470|NCT02196792|Active Comparator|ArComXL/32 mm|ArComXL polyethylene liner in a titanium cup with a stem with 32 mm CoCr femoral head.
3342471|NCT02196792|Active Comparator|ArComXL/36 mm|ArComXL polyethylene liner in a titanium cup with a stem with 36 mm CoCr femoral head.
3342472|NCT02196805|Experimental|1|
3342473|NCT02196805|Experimental|2|
3342474|NCT02196818||Mpact Acetabular Shell|Monitor the performance of the Mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.
3342475|NCT02196844|Experimental|Yoga Group|Couple-Based Hatha Yoga Program: 5-6 weeks of a yoga program, three sessions per week (up to 15 sessions) during radiation treatment. At fifth session, CD given for practicing yoga at home. 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
3238367|NCT01269463|Placebo Comparator|Capsule without active drug|Double blind crossover assignment of the placebo comparator.
3238368|NCT01269476|Experimental|SNX-001|
3342476|NCT02196844|Experimental|Wait-List Control Group|"10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule, at radiation treatment completion, and again 3 months later. Saliva samples to measure the level of cortisol collected at baseline visit, at end of treatment, and 3 months after radiation therapy. 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.~Participants given the option to take part in the couple-based Hatha Yoga program (off study) after they finish their last questionnaire packet."
3342477|NCT02196844|Experimental|Caregivers|"Yoga Group - Caregivers: 5-6 weeks of yoga during patient's radiation treatment. At fifth session, caregiver given CD for practicing yoga at home. During each week of patient's radiation, caregiver completes questionnaire about their feelings about yoga sessions. 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation, at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after patient's radiation therapy.~Waitlist-Control Group - Caregivers: 10 questionnaires completed before patient's first radiation treatment, each week during radiation, 5 halfway through radiation. at radiation completion, and again 3 months later. Saliva samples collected at baseline visit, at end of treatment, and 3 months after radiation therapy.~Caregivers given option to take part in yoga program after they finish their last questionnaire packet."
3342478|NCT02196883|Active Comparator|MRI Pathology|
3342479|NCT02196883|Active Comparator|Physical Exam Pathology|
3238369|NCT01269476|Placebo Comparator|Placebo|
3238370|NCT01269489||general population|a representative sample from general Slovenian population
3238371|NCT01269502|Experimental|Skin temperature measurement|Regular measurement of skin temperature on feet for one year
3342480|NCT02196896|Experimental|deprexis®|Patients in this arm use deprexis® as an additional treatment during their inpatient stay and as an aftercare intervention.
3238372|NCT01269502|Active Comparator|Active control|Daily inspection of feet for one year
3238373|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART-|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
3238374|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART-|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3238375|NCT01269515|No Intervention|Control ART-|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3238376|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 25 weeks ART+|Etoricoxib for 25 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 5 weeks.
3238377|NCT01269515|Active Comparator|Etoricoxib 90 mg qd for 2 weeks ART+|Etoricoxib for 2 weeks. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3238378|NCT01269515|No Intervention|Control ART+|No Etoricoxib. Vaccination (Tetanus Toxoid, conjugated pneumococcal, seasonal influenza) after 1 week.
3238379|NCT01269528||Born in 2007-2008|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
3238380|NCT01269528||Born in 2009-2010|Methacholine Challenge Test (MCT). Monthly telephone contact. Visits to the study site. Fractional exhaled nitric oxide. Blood test.
3238381|NCT01269541|Active Comparator|Mupirocin|Topical treatment
3238382|NCT01269541|Active Comparator|Rifampicin+Clindamycine or Trimethoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3xVII Trimethoprimsulfa 400mg/80mg 2x2
3238383|NCT01269554||Children with diarrhea in Bissau|
3238384|NCT01269554||Children without diarrhea in Bissau|
3238385|NCT01269554||Children without diarrhea in Finland|
3238386|NCT01269554||Children with diarrhea in Finland|
3238387|NCT01269554||Adults without diarrhea in Finland|
3238388|NCT01269554||Adults with diarrhea in Finland|
3238389|NCT01269554||Adults without diarrhea in Bissau|
3238390|NCT01269554||Adults with diarrhea in Bissau|
3342481|NCT02196896|Placebo Comparator|Information|Patients in this arm receive online information about depression as a placebo comparator in addition to their treatment during their inpatient stay and as an aftercare intervention.
3342482|NCT02196909|Active Comparator|HIBM patient|motor function, muscle strength, NMR, 24h urine and serum collections at baseline, then annually
3342483|NCT02196909|Active Comparator|Controls|motor function, muscle strength, 24h urine and serum collections at baseline only
3342484|NCT02196935||ERCP/EUS|All patients who undergo ERCP and EUS for clinical indications will undergo a detailed prospective assessment of clinical course.
3342485|NCT02196948|Experimental|Electrolysis Percutaneous Therapeutic (EPTE)|Electrolysis Percutaneous Therapeutic (EPTE) consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon, to initiate a local inflammatory process allowing phagocytosis and repair of the affected tissue. The technique is pain-free since the electrical intensity is adapted to each patient. In addition, patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
3342486|NCT02196948|Experimental|Eccentric exercise|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 4 weeks.
3342487|NCT02196961|No Intervention|Observation|After complete resection of Merkel cell carcinoma, patients randomized to the observational arm will be observed only
3342488|NCT02196961|Experimental|Nivolumab|After complete resection of Merkel cell carcinoma, patients randomized to the treatment arm will receive nivolumab at a fixed dose of 480 mg by IV infusion every 4 weeks for up to one year (i.e.13 doses).
3342489|NCT02196974|Experimental|cryobiopsy|
3342490|NCT02196987||Urination, urethral catheterisation|Act of urination during urethral catheterisation in males
3342491|NCT02196987||Lie, catheterisation, urethra|Urethral catheterisation without medical professional guidance
3342492|NCT02197000|Experimental|DIM-Avail 100mg|women will receive DIM 100mg*1/d, a nutritional supplement for 24 months.
3342493|NCT02197013||Introcan Safety 3|Closed IV Catheter
3342494|NCT02197013||Introcan Safety|IV catheter
3342495|NCT02197026|Experimental|Synvisc group|injection of Synvisc® at day 1, day 8 and day 15; in the mean time it will be recommended to decrease or stop all other OA treatments
3342496|NCT02197026|Active Comparator|Osteoarthritis standard treatment group|Treatment will be left to the discretion of the investigator who could prescribe any therapies, except viscosupplementation product
3342497|NCT02197039||The High risk group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the high risk group if they still have major stigmata of recent hemorrhage at the second-look endoscopy or have early recurrent bleeding before the schedule time for follow-up.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
3342498|NCT02197039||The control group|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole or pantoprazole immediately after successful endoscopic hemostasis. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole or pantoprazole infusion.~Patients are defined in the control group if they does not have recurrent bleeding before the schedule time for follow-up, and have only minor stigmata of hemorrhage or clean ulcer base at the second-look endoscopy.~Recurrent bleeding is defined as: 1) continuous melena, hematochezia, or the presence of recurrent bloody aspirates through a nasogastric tube and 2) relapse of hemodynamic instability, including systolic blood pressure <90 mmHg, heart rate >120 beats per minute, or a drop in hemoglobin concentration by more than 2 g/dL."
3342499|NCT02197052||Computer Based Survey Arm|Participants randomized to the computer based self-completed survey arm were issued a tablet computer to answer survey questions. All participants were encouraged to ask for technical assistance if needed at any point, and like in the face-to-face interviews, electronic survey could be re-initiated at the point of discontinuation after any interruption. Those in the tablet survey arm also could complete the survey in their preferred language and all were additionally given headsets so they could use audio assist with identical, pre-recorded questions in the selected language.
3342500|NCT02197052||Face-to-face interview arm|Participants randomized to this condition were interviewed in-person by a fully bilingual (English-Spanish), bi-cultural research assistant trained in cultural humility, standard research protocols and interviewing practices. Interviews were conducted in clinical rooms in respondent's preferred language, were easily interrupted for medical care, and the survey could be re-initiated at the point of discontinuation after any interruption. Participant responses during face-to-face interviews were recorded by the research assistant on paper and later recorded electronically.
3342501|NCT02197091||Observational (communication in oncology treatment)|Patients complete questionnaires, including the FACIT-TS-G, the FACIT-Sp12, the MOS-SSS, and the DT. Doctors also complete a questionnaire. Patients' medical records may be reviewed, if necessary.
3342502|NCT02197104|Experimental|Citocoline|
3342503|NCT02197117|Active Comparator|Remote ischemic conditioning|Standard blood pressure cuff placed on upper arm and inflated to 200 mmHg. The cuff is left inflated at this level for 5 minutes and then rapidly deflated to 0 mmHg left deflated for 5 minutes0 this cycle is repeated 4 times in total.
3342504|NCT02197117|Sham Comparator|Control|Standard blood pressure cuff placed on upper arm and left un-inflated for 40 minutes, and then cuff is removed.
3238391|NCT01269567|Active Comparator|Drainage|Rectal excision with aspiration pelvic drainage
3238392|NCT01269567|Experimental|No drainage|Rectal excision without aspiration pelvic drainage
3238393|NCT01269580||Diabetic|Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria
3238394|NCT01269580||Not diabetic|Adult not diabetic with chronic critical ischemia
3238395|NCT01269606|Experimental|Treatment sequence 1 - IM treatment group|
3238396|NCT01269606|Experimental|Treatment sequence 2 - IM treatment group|
3342505|NCT02197143|Experimental|Esomeprazole|40 mg Esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3342506|NCT02197143|Experimental|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3342507|NCT02197143|Experimental|placebo|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
3342508|NCT02197156|Experimental|10 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 10 mg
3342509|NCT02197156|Experimental|20 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 20 mg
3342510|NCT02197156|Experimental|30 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 30 mg
3342511|NCT02197156|Experimental|40 mg HC-ER|Hydrocodone bitartrate extended release (HC-ER) 40 mg
3342512|NCT02197156|Active Comparator|10 mg HC / 325 mg APAP|10 mg Hydrocodone (HC) / 325 mg acetaminophen (APAP)
3342513|NCT02197156|Placebo Comparator|Placebo|Matching placebo
3342514|NCT02197169|Experimental|DNX-2401 alone|Single intratumoral injection of DNX-2401
3342515|NCT02197169|Experimental|DNX-2401 + Interferon gamma (IFN-γ)|Interferon gamma (IFN-γ) beginning at Day 14
3342516|NCT02197182|Experimental|LUXSOL Cream|LUXSOL Cream is a copper containing cream to be administered intravaginally before bedtime for 10 consecutive nights.
3238397|NCT01269606|Experimental|Treatment sequence 1 - IV treatment group|
3238398|NCT01269606|Experimental|Treatment sequence 2 - IV treatment group|
3238399|NCT01269619|Experimental|Dynamic|Use of Dynamic back support
3238400|NCT01269619|Active Comparator|Static|Use of static back support
3238401|NCT01269632|Other|HIV infected|young adult infected by HIV
3238402|NCT01269632|Other|HIV uninfected|a control group of HIV uninfected young adult will be included for comparison in physiopathological module (metabolic, cardiovascular, and immunological)
3238403|NCT01269645|Active Comparator|Usual care|"Usual care and provision of National Cancer Institute brochure Taking Part in Cancer Treatment Research Studies. Participants will be asked to read this brochure after completion of the baseline surveys and will be given a copy to take home with them."
3238404|NCT01269645|Experimental|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
3238405|NCT01269658|Experimental|Azithromycin ophthalmic solution, 1%|
3238406|NCT01269658|Placebo Comparator|Vehicle|
3238407|NCT01269671|Experimental|Melatonin, Peppermint Oil, Simethicone|
3342517|NCT02197182|Active Comparator|Metronidazole cream|Metronidazole cream is the active comparator drug to be self-administered intravaginally each night before bedtime for 10 consecutive nights. Dosage is per package insert.
3342518|NCT02197195|Experimental|Chocolate Milk Beverage|Chocolate milk beverage and sitting quietly
3342519|NCT02197195|Experimental|Chocolate Milk Beverage and Exercise|Chocolate milk beverage and exercising
3342520|NCT02197195|Experimental|Fruit Drink Beverage|Fruit drink beverage and sitting quietly
3238408|NCT01269671|Placebo Comparator|Sugar pill|
3342521|NCT02197195|Experimental|Fruit Drink Beverage and Exercise|Fruit drink beverage and exercising
3238409|NCT01269684|Experimental|1|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
3238410|NCT01269697|Active Comparator|Nutrof|patient receive the treatment of Nutrof Total
3238411|NCT01269697|Placebo Comparator|Placebo of Nutrof|Patient receive the treatment of the placebo of Nutrof Total
3238412|NCT01269723|Active Comparator|Broccoli sprout homogenate|"The broccoli sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
3238413|NCT01269723|Placebo Comparator|alfalfa sprout homogenate|"Alfalfa sprouts and water are chopped in a blender until a uniform mix is obtained. Salt or sugar may be added to the shake."
3238414|NCT01269762|Experimental|LipoCol Forte|Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.
3238415|NCT01269775|Experimental|Face to face lecture|The lecturer allocated 1.5 hours for delivering the lecture by using provided slides about the topic and 0.5 hours for question and answer.
3238416|NCT01269775|Experimental|Internet based teaching|For providing materials for interactive internet-based group the professor's lecture was converted to an interactive electronic content. This content started with a case introduction followed with asking questions and then based on each student's answer a learning pathway would be assigned to his/her.
3342522|NCT02197208|Active Comparator|Spontaneous NC|Timing by the onset of LH surge as shown daily blood monitoring of serum estradiol and LH levels
3342523|NCT02197208|Experimental|hCG induced NC|Timing by giving hCG when the dominant follicle reaches >=17mm in diameter on ultrasound monitoring
3342524|NCT02197221|Experimental|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3 +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
3342525|NCT02197221|Active Comparator|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
3342526|NCT02197260|Experimental|Protocol A|Antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the first, non-surgical phase of periodontal therapy (T1), and placebo during the second, surgical phase (T2)
3342527|NCT02197260|Active Comparator|Protocol B|Placebo during the first, non-surgical phase of periodontal therapy (T1), and antibiotics (3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days) during the second, surgical phase (T2)
3342528|NCT02197286|Experimental|Vitamin D (cholecalciferol)|Intervention: Capsules containing the active ingredient, cholecalciferol @ 4,000 international units (IU). One capsule daily, oral administration for 10 weeks.
3342529|NCT02197286|Placebo Comparator|Placebo|"Daily matching placebo gelatin capsule (also contains microcrystalline cellulose).~Capsules are identical in size, color and taste to experimental drug."
3342530|NCT02197299|Experimental|Carnitine|Oral administration of 4.5 g L-carnitine L-tartrate (containing 3 g L-carnitine; Carnipure, Lonza Ltd., Switzerland) once daily for 24 weeks
3238417|NCT01269775|Experimental|Computer based teaching|For providing material for computer-based group the lecture of the same professor was recorded in studio environment and was synchronized with the slides that were similar to those for lecture-based group. Then the lecture and the slides were converted to a CD as a multimedia CD.
3238418|NCT01269788|Active Comparator|pH positive-omeprazole|
3342531|NCT02197299|Placebo Comparator|Sugar pill|Oral administration of placebo sugar pill
3342532|NCT02197312|Other|NobelProcera Bridge Shaded Zirconia|posterior region
3342533|NCT02197325|Active Comparator|PICSO|Participants enrolled in the PICSO treatment Group will be treated with PICSO concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction
3342534|NCT02197325|No Intervention|Parallel control|Participants enrolled in will receive treatment based on the standard guidelines for treatment of a myocardial infarction.
3342535|NCT02197338|Experimental|Short Wire, Small Tome|Short wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3342536|NCT02197338|Active Comparator|Short Wire, Standard Tome|Short wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3342537|NCT02197338|Active Comparator|Long Wire, Small Tome|Long wire system, small sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3342538|NCT02197338|Active Comparator|Long Wire, Standard Tome|Long wire system, standard sized sphincterotome will be used to perform the Intervention of Bile Duct Cannulation.
3342539|NCT02197351|Experimental|Gastric Symptoms|Patients with gastric symptoms including dyspepsia undergoing upper endoscopy will undergo white light biopsy narrow band imaging guided biopsy protocolled biopsy
3342540|NCT02197364||ILD, Other respiratory diseases, Healthy control group|"ILD: those with interstitial lung disease.~Other respiratory diseases: those with other respiratory disease including pulmonary tuberculosis, pneumonia, bronchiectasis, chronic obstructive pulmonary disease.~Healthy control group: those who is healthy."
3342541|NCT02197390|Experimental|Health Care plus Public Health|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs). The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
3238419|NCT01269788|Placebo Comparator|pH positive-placebo|
3238420|NCT01269788|Active Comparator|pH positive-fluoxetine|
3342542|NCT02197390|Experimental|Health Care|The Health Care intervention involves the implementation of an obesity care model within a Federally Qualified Health Center (FQHC) and includes a Family Wellness Program delivered by Community Health Workers (CHWs).
3342543|NCT02197390|Experimental|Public Health|The Public Health intervention involves working with early care and education centers, schools, community recreation organizations, and restaurants to promote four health behaviors: fruit and vegetable consumption, physical activity, water consumption, and quality sleep.
3342544|NCT02197390|Experimental|Control|No intervention.
3238421|NCT01269788|Active Comparator|pH negative-omeprazole|
3342545|NCT02197403|Experimental|alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
3342546|NCT02197403|Active Comparator|alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
3342547|NCT02197403|Active Comparator|Non-alcohol drinker & dexmedetomidine|dexmedetomidine, 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion during surgery
3342548|NCT02197403|Active Comparator|Non-alcohol drinker & propofol|Propofol (2% fresofol) 25~75mcg/kg/min continuous infusion
3342549|NCT02197429|Experimental|Acupuncture|Acupuncture
3238422|NCT01269788|Active Comparator|pH negative-fluoxetine|
3238423|NCT01269788|Placebo Comparator|pH negative-placebo|
3238424|NCT01269814||Go-home group|The patients with a Rockall score of 0 or 1 will be prescribed medical therapy, and will be scheduled for elective gastroscopy.
3342550|NCT02197429|No Intervention|Wait-list Control|Wait-list Control
3342551|NCT02197442|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
3238425|NCT01269827|Experimental|pentoxifylline|
3238426|NCT01269827|Placebo Comparator|placebo|
3238427|NCT01269853|Experimental|Arm 2|
3342552|NCT02197442|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
3342553|NCT02197468||Probiotics|"Preterm infants given probiotics: GA 24-27 weeks/Birth weight < 1000 g~Preterm infants not given probiotics: GA 28-31 weeks/Birth weight 1000-1500 g~Full-term infants not given probiotics (control)"
3342554|NCT02197494|Experimental|Test|Valsartan Tablets USP 320 mg DIVIS
3342555|NCT02197494|Active Comparator|Reference|Diovan® (Valsartan) 320 Tablets
3342556|NCT02197507|Experimental|RA patients|
3342557|NCT02197533|Experimental|Written list|Patients in the intervention group will receive both verbal information and a written supplement (Appendix 1), produced during the discussion by CM or a fellow (not the individual who obtained consent), on treatment recommendations for OAB. They will leave clinic with this written list of recommendations and will be able to take it home with them.
3238428|NCT01269853|Experimental|Arm 1|
3238429|NCT01269866|Other|Cymbalta|Cymbalta 60 to 120 mg
3238430|NCT01269879|Active Comparator|Active control (Flexi-Bar only)|Flexi-Bar vibration training only over 12 weeks with three distinct exercises and 10min training twice daily
3238431|NCT01269879|Experimental|Intervention Flexi-Bar + XCO-Trainer|Combination intervention using vibration device Flexi-Bar and XCO-Trainer (oscillating mass witin a tube moved during running 40-60min/week suggested)
3238432|NCT01269892|Other|lactose-free milk|it is kind of nutritional regime
3238433|NCT01269892|Other|conventional milk|it is kind of nutritional regime
3342558|NCT02197533|No Intervention|Control|Patients in the control group will receive the same verbal information on the treatment recommendations for OAB, however, these patients will not receive the written list of management strategies for their condition.
3342559|NCT02197546|Other|acupuncture plus local anesthesia|Bilateral acupuncture with 1.5 mm long indwelling fixed needles
3342560|NCT02197546|No Intervention|Local anesthesia alone|Standard therapy - local anesthesia alone without acupuncture
3342561|NCT02197559||BMS group, DES group|All the participants in this group will be performed with bare-metal stents or drug -eluting stents
3342562|NCT02197585|Experimental|Glue|Mesh fixation with glue
3342563|NCT02197585|Active Comparator|Suture|Mesh fixation with suture
3342564|NCT02197598|Experimental|Selincro® (nalmefene) 18 mg, tablets|One tablet orally for 12 weeks on days when the patient perceives a risk of drinking alcohol, preferably 1-2 hours prior to the anticipated risk of drinking.
3238434|NCT01269905||Group A|Group A patients received mechanical heart valve replacement MHVR (and were educated in INR self-management using the Coagu-Check monitor.
3238435|NCT01269905||Group B|Group B patients received MHVR and their anticoagulation was managed by their general practitioners.
3238436|NCT01269905||Group C|Group C patients received stentless bioprosthesis, with initial 6 weeks on oral anticoagulation managed by their general practitioners.
3342565|NCT02197611||Validation group|Group of patients who we will consult the characteristics of the scale designed and will be made the statistical calculations of validity, reliability and reproducibility
3342566|NCT02197637|Experimental|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle
3342567|NCT02197663|Experimental|Acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
3342568|NCT02197663|Sham Comparator|sham acupuncture|The total course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen.
3342569|NCT02197676|Experimental|SGI-110|
3342570|NCT02197689|Experimental|SMS Medication Reminder|763 patients were assigned to experimental group
3342571|NCT02197689|No Intervention|No SMS Reminder|435 patients were assigned to control group as no SMS reminder
3342572|NCT02197702|Placebo Comparator|Placebo|2 ml identical placebo taken by mouth at baseline and 3.5 months.
3342573|NCT02197702|Active Comparator|Vitamin D|Vitamin D (100,000IU) given in a 2 ml oral dose at baseline and 3.5months.
3342574|NCT02197715|Experimental|computer-adaptive SAFE|Computer-adaptive SAFE will consist of 4 60-minute sessions. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method. Session 4 will focus on effective strategies to communicate with a sexual partner. Computer-adaptive SAFE will use an audio computer-assisted self-interviewing (ACASI) format.
3342575|NCT02197715|Experimental|Face-to-face SAFE|Face-to-face SAFE will consist of 4 60-minute sessions using motivational interviewing techniques. Each session will be led by an experienced counselor. Sessions 1 and 2 will explore participants' reasons to become and rewards for becoming pregnant/having children or avoiding it, introduce reproductive biology in the context of different contraceptive methods and explore the participant's ambivalence toward using different contraceptive methods. Session 3 will provide in-depth coverage of contraceptive methods and the need for use of a barrier method, and relevant skills regarding how to use and negotiate use of contraceptive methods. Session 4 will focus on effective strategies to communicate with a sexual partner.
3342576|NCT02197715|Active Comparator|Usual Care|Usual care comprises four 60-minute provider-led individual care sessions about HIV, STIs, and their risks, as well as prevention methods. Contraceptive methods are discussed within this context. There will be no demand on participants to attend these sessions. Participants will receive written take-home materials to review on their own and/or with their sex partners.
3342577|NCT02197728|Active Comparator|Hohl uterine manipulator ®|Total laparoscopic hysterectomy is performed using the Hohl uterine manipulator ®
3342578|NCT02197728|Active Comparator|Colpo-Probe™ Vaginal Fornix Delineator|Total laparoscopic hysterectomy is performed using the Colpo-Probe™ Vaginal Fornix Delineator
3342579|NCT02197741||opiate without bolus|continuous opiate administration without bolus application
3342580|NCT02197741||opiate with bolus|continuous opiate administration with additional bolus application
3342581|NCT02197754|Experimental|Polyphenol Diet|After 2 weeks of adaptation to a controlled diet, polyphenol-rich fruits (berries and apple) and beverages (tea) will be fed (8 wks) as part of a controlled diet (10 wks total).
3342582|NCT02197793|Experimental|Community Mobilization Program|Intervention activities will map onto six mobilization domains identified as key components for communities to mobilize for change around testing, linkage and retention in care (Treatment as Prevention (TasP)).
3342583|NCT02197793|No Intervention|Control Arm|The control arm does not receive the Community Mobilization Intervention.
3342584|NCT02197819|Experimental|External Rotation Brace|Shoulder placed in an external rotation brace for 4 weeks
3238437|NCT01269931||Group 1 (EBUS-TBNA simulator training)|Group 1 (EBUS-TBNA simulator training): pulmonary medicine trainees with >30 bronchoscopy procedures experience, >nine months of pulmonary fellowship training and no clinical EBUS-TBNA experience (n=4).
3342585|NCT02197819|Active Comparator|Traditional Sling|Patient placed in traditional sling
3342586|NCT02197832|Experimental|EA|in the cycle immediately preceding the scheduled FET treatment, an endometrial biopsy would be arranged on day 21-23 of the menstrual cycles and they will be instructed to use non-hormonal means of contraception during that cycle.
3342587|NCT02197832|Placebo Comparator|Control|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix but not into the uterine cavity, only entering the endocervical canal as control.
3342588|NCT02197845|Experimental|Phase I: Recruitment into Specialty Care|Participants in the Phase I Experimental Arm are enrolled into SCD specialty care. PN's will contact patient up to 3 times to assure patients have had an initial visit by 3 months time.
3342589|NCT02197845|Experimental|Phase II: Patient Navigator Arm|Participants in the Phase II Experimental Arm follow routine clinical care and are assigned a Patient Navigator. A specially trained (SCD specefic)PN will work with participants for one year. Participants will be contacted by their Navigator weekly for the first 6 months, then biweekly for the second 6 months.
3238438|NCT01269931||Group 2 (Clinical EBUS-TBNA training)|Group 2 (Clinical EBUS-TBNA training): pulmonary medicine trainees in the 2nd half of their final year of pulmonary training or recent graduates (within one year), with >50 bronchoscopy procedures experience who completed a one-month elective with the Interventional Pulmonary Medicine (IPM) service with ≥15 and ≤25 EBUS-TBNA procedures experience (n=4).
3238439|NCT01269944||Medial compartment knee osteoarthritis|Patients with medial compartment osteoarthritis of the knee, as proven by x-rays and clinical examination
3238440|NCT01269957||Mouth breathing|
3238441|NCT01269957||Nasal breathing|
3238442|NCT01269970||locally advanced esophageal carcinoma (cT2-3N0/+)|
3342590|NCT02197845|No Intervention|Phase II: Passenger Arm|No Intervention. Participants in the Phase II Passenger Arm follow routine clinical care.
3342591|NCT02197871|No Intervention|blank control|usual diet
3342592|NCT02197871|Experimental|nutrition supplementation|In addition to usual diet,the patients will be given enteral nutrition emulsion, which is a oral nutrition liquid composed of proteins,omega-3 fatty acids,carbohydrate,vitamins.Every package contains 200ml and provides 260 kcal energy.
3342593|NCT02197884|Experimental|Itraconazole + JNJ-54861911 (Part 1)|Single dose of JNJ-54861911, 25 milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
3342594|NCT02197884|Experimental|Clarithromycin + JNJ-54861911 (Part 2)|Single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
3238443|NCT01269983|Experimental|fascial manipolation|8 treatment sessions: 4 of fascial manipulation treatment, and 4 of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
3238444|NCT01269983|Active Comparator|physiotherapy|8 treatment sessions of standard physiotherapy (rexing exercise, stretching, abdominal and paravertebral isometric muscular recruiting)
3238445|NCT01269996|Active Comparator|Metformin followed by gliclazide and protaphane|
3238446|NCT01269996|Active Comparator|Janumet followed by Lantus insulin injection|
3342595|NCT02197910|Active Comparator|High content of wheat bioactive peptides|100 gr pasta/day, containing around 15 mg bioactive peptides (High content of wheat bioactive peptides)
3342596|NCT02197910|Placebo Comparator|Low dose of wheat bioactive peptides|100 gr pasta/day, containing around 3 mg bioactive peptides
3342597|NCT02197923||Biopsy: adenomyosis|Myometrial biopsy Pipelle
3342598|NCT02197923||Biopsy: Healthy|Myometrial Biopsy Pipelle
3342599|NCT02197936||Peristalsis adenomyosis|with adenomyosis
3342600|NCT02197936||Peristalsis control|No adenomyosis
3342601|NCT02197949||Breast cancer patients with infiltrated axillary l|
3342602|NCT02197962|Experimental|Extracorporeal radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwave per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
3342603|NCT02197962|Placebo Comparator|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo radial shockwave per week, without any energy flow intensity. Frequency of 8Hz will appear in the screen. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
3342604|NCT02197975|Experimental|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
3238447|NCT01270022|Experimental|Implementation|
3238448|NCT01270022|Active Comparator|dissemination|
3238449|NCT01270035|Experimental|ADA 80 mg eow + MTX|
3238450|NCT01270048|Experimental|Bunsimgieum extract|"name of product: 'mild-x-gwarip'~standard code for item: 200005689~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
3342605|NCT02197975|Experimental|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
3342606|NCT02197975|Placebo Comparator|Placebo MDI|Placebo MDI. Administered as 2 inhalations
3238451|NCT01270048|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
3238452|NCT01270061|Active Comparator|HIV testing|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
3238453|NCT01270061|Experimental|General Health Screening|In Group 2 (Intervention), a theory-based video is used to obtain informed consent for a free general health screening that includes a blood pressure check, blood glucose measurement, and an HIV test.
3342607|NCT02197988|Active Comparator|Transversus Abdominis Plane Block|Transversus Abdominis Plane Block Exparel 1.33% (20ml Volume)
3342608|NCT02197988|Active Comparator|Thoracic Epidural Anesthesia|Thoracic Epidural Anesthesia 0.125% bupivicaine with 2 mcg/ml Fentanyl
3342609|NCT02198001|Active Comparator|tooth extraction and insertion of PRF|Experimental: Atraumatic tooth extraction with antibiotics( amoxicillin clavulanate combination) .Insertion of PRF membrane in tooth-extraction site.
3342610|NCT02198001|Placebo Comparator|No PRF|Atraumatic extraction with antibiotic without PRF insertion
3342611|NCT02198014|Experimental|Manual Therapy group|We employed joint traction, passive muscle stretching and isometric exercises, active resisted and proprioception exercises. The treatment in this group consisted of two sessions per week for one hour each.
3342612|NCT02198014|Experimental|Educational gruop|"This group received educational sessions and home exercises. The exercises are aimed at improving quadriceps strength, flexibility, range of motion and knee proprioception.~Each educational session of 90 minute every two weeks, with exercises daily home"
3342613|NCT02198014|No Intervention|Control group|The control group (group C) did not receive any treatment. The patients of this group were assessed by the same reviewers and under the same conditions as the subjects of the two intervention groups.
3342614|NCT02198027|Experimental|Bupivacaine infiltration|10 ml of 0.25 % Bupivacaine
3238454|NCT01270074|Experimental|azithromycin liquid preparation|azithromycin will be given at a dose of 10mg/kg given three times per week from three months of age to three years of age
3342615|NCT02198027|Placebo Comparator|Normal saline infiltration|10 ml of normal saline
3342616|NCT02198053||Ticagrelor2|Ticagrelor with a loading dose of 180mg followed by 90 mg twice per day
3238455|NCT01270074|Active Comparator|inert liquid preparation|inert liquid preparation will be given three times per week from three months of age to three years of age
3342617|NCT02198053||Ticagrelor1|Ticagrelor with a dose of 90mg followed by 90 mg twice per day .
3342618|NCT02198066|Other|Dry Sterile Dressing|Subjects in this study arm received a dry sterile dressing (Primapore®, Smith & Nephew), a one-piece, peel-and-stick, non-transparent dressing. This dressing is the standard of care at the study facility for this population and was left in place for either 24 to 48 hours.
3342619|NCT02198066|Active Comparator|Metallic Silver Dressing|Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith & Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
3238456|NCT01270087|Other|Adalimumab|
3342620|NCT02198066|Active Comparator|Ionic Silver Dressing|Subjects in this arm received an ionic silver dressing (Dermanet Ag®, DeRoyal), a semi-transparent dressing that includes silver, alginate, and maltodextrin. The dressing was cut to fit the incision and then covered with a transparent dressing (Transseal®, DeRoyal). This dressing should not be used on patients with known sensitivity to alginates (a seaweed based component).
3342621|NCT02198079||Cystic Fibrosis|Children with Cystic Fibrosis
3238457|NCT01270100|Experimental|Recovery management intervention|
3238458|NCT01270152|Experimental|group 50 mg ascorbic acid|this arm received a dose of 50 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3238459|NCT01270152|Experimental|group 100mg ascorbic acid|this arm received a dose of 100 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3342622|NCT02198092||Patient Group FAP|"Clinical diagnosis of familial adenomatous polyposis (FAP).~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3342623|NCT02198092||Patient Group Lynch Syndrome|"Clinical diagnosis of Lynch Syndrome, also known as HNPCC.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3375853|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients That Are Treatment Naïve|Treatment naïve Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL) patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
3238460|NCT01270152|Experimental|group 200mg ascorbic acid|this arm received a dose of 200 mg of ascorbic acid administered inside the catheter and maintained for up to 60 minutes
3238461|NCT01270178||Entecavir|
3238462|NCT01270191|Experimental|Exenatide|In the exenatide therapy group, subjects will be instructed in the techniques for injection and be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months. If FPG still greater than 200 mg/dL after 4 weeks of exenatide treatment, they will use insulin for rescue therapy and will be withdrawn from this study.
3238463|NCT01270191|Active Comparator|Humulin-N|In the insulin therapy group (Humulin-N), subjects will be instructed in the techniques for insulin injection and home capillary glucose monitoring. The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
3238464|NCT01270204||Normal Volunteers|Patients older than 55 years of age with no history of voice, swallowing, reflux, or progressive neurologic disease affecting the swallowing mechanism.
3238465|NCT01270204||Patients with Dysphagia|Patients older than 55 years of age with the following condition: Dysphagia (the sensation of swallowing difficulty), globus, gastroesophageal reflux, or any other condition requiring referral for a dynamic swallowing study.
3238466|NCT01270217|Experimental|Brief motivational interview|
3238467|NCT01270217|No Intervention|No discussion|
3238468|NCT01270230|Experimental|Comparison Group, Standard HIV-CT|The comparison group will receive standardized HIV counseling and testing (HIV-CT), with referrals to case management.
3238469|NCT01270230|Experimental|Intervention Group, Bruthas Counseling|Participants assigned to this arm receive four individual HIV prevention counseling sessions.
3238470|NCT01270243||Control|No tonsilar or adenoid problems
3342624|NCT02198092||Patient Group MAP / MYH|"Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.~The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.~If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery."
3342625|NCT02198092||Control Group (FAP Genetically-Related)|"Genetically related family member of enrolled FAP patient.~Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.~The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.~If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.~Blood draws in FAP patients should always be accompanied by blood draws in their family member controls."
3238471|NCT01270243||Adenotonsillectomy (recurrent)|Recurrent adenotonsillitis
3238472|NCT01270243||Adenotonsillectomy (obstruction)|Upper airway obstruction
3342626|NCT02198105||Femoropopliteal stenosis|"Consecutive patients with symptomatic peripheral artery disease due to femoro-popliteal stenosis/occlusion.~Intervention with Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon-PTA."
3342627|NCT02198118|No Intervention|Control Group|Control group (CG) subjected only to evaluations and to no exercises.
3342628|NCT02198118|Experimental|Study Group|Study group (SG) instructed to perform domiciliary exercises for the upper limbs
3342629|NCT02198131|Experimental|Supportive Care (pulsed dye laser)|Patients undergo pulsed dye laser monthly for three months.
3342630|NCT02198144|Other|barbershop-based BP measurement|BP monitoring by barbershop based Barbers and BP lowering medication(s)
3342631|NCT02198157|Active Comparator|intermittent urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will receive intermittent catheterization
3342632|NCT02198157|Active Comparator|continuous urinary catheter|nullipara women with epidural anaesthesia who pose urination difficulty will receive continuous catheterization
3342633|NCT02198170|Experimental|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period
3342634|NCT02198170|Experimental|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
3342635|NCT02198183||Near-infrared spectroscopy|Casmed Fore-Sight Elite and Non-invasive Cardiac Output Monitor (NICOM)
3342636|NCT02198196|Experimental|Weight Talk-Mindfulness|WT-M retain the evidence-based elements of WT-S (control condition), including the DASH diet, physical activity components, and an emphasis on self-monitoring. However, each call in WT-M will include an emphasis on mindfulness and stress management that will not be included in the control condition.
3342637|NCT02198196|No Intervention|Weight Talk-Standard|Weight Talk-Standard is a phone and web-based weight loss intervention offered by employers as a benefit to their employees. Weight Talk is based on the NIH Clinical Guidelines on Identification, Evaluation and Treatment of Overweight and Obesity in Adults and utilizes the curriculum developed for the Diabetes Prevention Program. Weight Talk-S contains no additional stress management techniques.
3342638|NCT02198209|Other|single arm|"Liraglutide (Victoza)~acute study: one injection of 0.6 mg s.c. before IVGTT~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
3238473|NCT01270269|No Intervention|Patients (Controls)|Patients (Controls) will not receive formal (study-related) rehabilitation interventions and will only receive usual care.
3238474|NCT01270269|Experimental|Behavioral: Phys & Func Rehab|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
3238475|NCT01270269|Experimental|Behavioral: Cog/Phys/Func Rehab|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
3238476|NCT01270282|Experimental|AM-101 0.81 mg/mL|Gel for injection; single or triple injection
3238477|NCT01270282|Placebo Comparator|Placebo|Gel for injection; single or triple injection
3238478|NCT01270308|Experimental|Lansoprazole DR Capsules 30 mg|Lansoprazole DR Capsules 30 mg of Dr.Reddy's Laboratories Limited
3238479|NCT01270308|Active Comparator|Prevacid 30 mg Capsules|Prevacid 30 mg Capsules of TAP Pharmaceuticals Inc. USA
3238480|NCT01270334||ph above cutoff|
3238481|NCT01270334||PH under cutoff|
3238482|NCT01270347|Experimental|Aeroquin|Aeroquin, Inhaled Levofloxacin (MP-376)
3238483|NCT01270347|Active Comparator|TIS|Tobramycin Inhalation solution (TIS) [TOBI® Novartis Pharmaceuticals]
3238484|NCT01270360||asymptomatic subjects with positive FOBT|individuals having undergone a positive faecal occult blood test (FOBT) and a reference colonoscopy
3238485|NCT01270373|Active Comparator|FAC x 3 followed by Docetaxel x 3|
3238486|NCT01270373|Experimental|Docetaxel x 3 followed by FAC x 3|
3238487|NCT01270386|Experimental|Apatinib|Apatinib 750 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3238488|NCT01270386|Placebo Comparator|Placebo|Placebo qd p.o., and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3238489|NCT01270399||malignant neoplasm's cells|
3238490|NCT01270399||natural cells|
3342639|NCT02198248|Experimental|Low-dose glucocorticoid|"Prednisolone will be commenced with dose of 0.5mg/kg/day and will be tapered and off within 6 months. If a patient fails to achieve BVAS=0, an investigator can postpone the procedure of stopping prednisolone (prednisolone 5mg/day x 2 weeks, 4mg/day x 2 weeks, 3mg/day x 4 weeks, 2mg/day x 4 weeks, 1mg/day x 4 weeks, then off prednisolone). Once starting the procedure, prednisolone must be off after 16 weeks. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy."
3342640|NCT02198248|Active Comparator|High-dose glucocorticoid|"Prednisolone will be commenced with dose of 1.0mg/kg/day and will be tapered to 10mg/day within 6 months. Patients will also receive rituximab (375mg/m2/w x4).~After achieving remission, patients will be receive rituximab (1g/body or 0.5g/bodyx2) every 6 months as remission maintenance therapy. There's no limitation by the protocol regarding further prednisolone tapering."
3342641|NCT02198261||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
3342642|NCT02198261||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
3342643|NCT02198274|Experimental|BIBH 1|
3342644|NCT02198287|Experimental|BIIX 1 XX, rising doses|
3342645|NCT02198287|Placebo Comparator|Placebo|
3342646|NCT02198300|Active Comparator|rDES Group|regular drug-eluting stent implantation in coronary lesion within bifurcation LucChopin Xience Promus Resolute Integrity Biomatrix Prolim
3342647|NCT02198300|Experimental|BiOSS LIM Group|BiOSS LIM® stent implantation into coronary lesion within bifurcation.
3342648|NCT02198313|Experimental|BIIX 1 XX - D1|
3342649|NCT02198313|Experimental|BIIX 1 XX - D2|
3342650|NCT02198313|Experimental|BIIX 1 XX - D3|
3342651|NCT02198313|Placebo Comparator|Placebo|
3342652|NCT02198326|Experimental|BIBN 4096 BS - in single rising doses|
3342653|NCT02198326|Placebo Comparator|Placebo|
3342654|NCT02198339|Experimental|BIBN 4096 BS - ranging dose|"sequential adaptive design, allocation of verum treated patients to dose groups not fixed in advance~IV infusion over 10 minutes"
3342655|NCT02198339|Placebo Comparator|Placebo|IV infusion over 10 minutes
3342656|NCT02198352|Experimental|BIBN 4096 BS - in single rising doses|
3342657|NCT02198352|Placebo Comparator|Placebo|
3342658|NCT02198365||Group 2|Group 1: normal pap smear Group 2: cervical neoplasia
3342659|NCT02198378|Active Comparator|Morphine|Morphine group: administration of morphine will start with a 0.05 mg/kg bolus followed by reinjection of 2 mg every 5 minutes until effective analgesia is obtained, defined as NRS ≤ 3.
3342660|NCT02198378|Experimental|MEOPA and paracetamol|"The patient will be equipped with a facemask delivering MEOPA.The gas flow received by the patient is adapted to his/her ventilation.~During the same time, an intravenous injection of 1 g paracetamol will be administered."
3342661|NCT02198391||3 x 1 tablet per day|Echinaforce Junior tablets (low dose)
3342662|NCT02198391||5 x 1 tablet per day|Echinaforce Junior tablets (high dose)
3342663|NCT02198404|Experimental|sedation with propofol|propofol injection: induction with propofol at 20 mg/kg/h. When patient is sleeping, the dosage is deceased to 6 mg/kg/h
3238491|NCT01270412|Experimental|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml of platelet-derived preparation rich in growth factors
3238492|NCT01270412|Active Comparator|Hyaluronic acid|Drug: hyaluronic acid 20 mg / 2 ml Other Name: Arthrease
3238493|NCT01270438|Experimental|Arm I (RO4929097, combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen comprising oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, fluorouracil IV continuously over 46 hours, and bevacizumab IV over 30-90 minutes on days 1-2. Patients also receive oral gamma-secretase inhibitor RO4929097 on days 1-3 and 8-10. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3238494|NCT01270438|Experimental|Arm II (combination chemotherapy, bevacizumab)|Patients receive FOLFOX6 regimen and bevacizumab as in arm I. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3238495|NCT01270451|Other|Lifestyle group counseling|Included patients will be randomised into two groups: to the intervention group or to the control group.
3238496|NCT01270477|Experimental|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.
3342664|NCT02198417|Experimental|Metformin|Metformin ER 1500 mg per day treatment for 12 weeks
3342665|NCT02198443|Active Comparator|Tenofovir+emtricitabine|
3342666|NCT02198443|Experimental|Elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|
3238497|NCT01270490|Experimental|Interferon-gamma|
3342667|NCT02198456||3D echocardiography|
3342668|NCT02198469|Experimental|Er:YAG AFL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
3342669|NCT02198469|Active Comparator|MAL-PDT|Eligible patients were successively randomised to receive treatment with a single session of Er:YAG AFL MAL-PDT or 2 sessions of MAL-PDT with a 1-week interval between sessions
3342670|NCT02198482|Active Comparator|Daunorubicin, Cytarabine (DA)|"DA~Induction I:~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-7~Induction II:~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT due to comorbidities, high HCT-CI or patient wish will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine (MiDAC).~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. infusion on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC may be given prior to alloHSCT."
3342671|NCT02198482|Experimental|Volasertib, Daunorubicin, Cytarabine|"VDA~Induction I~Volasertib i.v., d1~Daunorubicin 60 mg/m² i.v., d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-8 Induction II~Volasertib i.v., d1~Daunorubicin 50 mg/m² i.v. d 2-4~Cytarabine 100 mg/m² cont. i.v., d 2-6~Consolidation therapy:~Patients with genetic favourable risk and those patients not eligible for allogeneic HSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (V-MiDAC).~Volasertib i.v., d1~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 2. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 2.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 2-4 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 2-4 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with V-MiDAC may be given prior to alloHSCT."
3342672|NCT02198482|Experimental|Daunorubicin, Cytarabine, Volasertib|"DAV~Induction I~Volasertib i.v., d7~Daunorubicin 60 mg/m² i.v., d 1-3~Cytarabine 100 mg/m² i.v., d 1-7 Induction II~Volasertib i.v., d5~Daunorubicin 50 mg/m² i.v. d 1-3~Cytarabine 100 mg/m² cont. i.v., d 1-5~Consolidation therapy:~Patients with genetic fav. risk and those patients not eligible for alloHSCT will proceed to 3 cycles of age-adapted consolidation therapy with mitoxantrone and intermediate-dose cytarabine in combination with Volasertib (MiDAC-V).~Volasertib i.v., d4~Mitoxantrone Younger adults (18 to 60 yrs): 10 mg/m2 by i.v. on day 1. Elderly patients (>60 yrs): 8 mg/m2 by i.v. on day 1.~Intermediate-dose cytarabine:~Younger adults (18 to 60 yrs): 1500 mg/m2 q12h on days 1-3 Elderly patients (>60 yrs): 1000 mg/m2 q12h on days 1-3 An allogeneic HSCT is intended for patients with intermediate I/II and adverse-risk genetics. Optionally, one cycle of consolidation with MiDAC-V may be given prior to alloHSCT."
3342673|NCT02198495|Active Comparator|Ferric carboxymaltose|Supplementation of ferric carboxymaltose 500 mg at week 0, 10, 20, 30
3342674|NCT02198495|Active Comparator|Iron sucrose|Supplementation of iron sucrose 100 mg at week 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38
3342675|NCT02198508|Active Comparator|DFX single treatment|a single oral dose of DFX 30 mg/kg once daily, (Exjade®, Novartis Pharmaceuticals Corporation, USA )
3342676|NCT02198508|Active Comparator|DFP single treatment|single oral dose of DFP 40 mg/kg/day twice a day, (Kelfer®, Cipla Ltd., India)
3342677|NCT02198508|Experimental|combination treatment|sequential oral doses of DFX 30 mg/kg/d, DFP 40 mg/kg/d and DFP 40 mg/kg/d (dosing interval: seven hours).
3342678|NCT02198521||Bilateral Carpal Tunnel Syndrome (CTS)|
3342679|NCT02198534||ophthalomogically normal subjects|
3342680|NCT02198547|Experimental|Ropivacaine Magnesium sulfate|"Locoregional anesthesia for valgus allux correction with ropivacaine 7,5 mg/ml and Mg 4 mg/Kg.~Sciatic block at popliteal level."
3342681|NCT02198547|Active Comparator|Ropivacaine|Patients undergoing allux valgus correction with locoregional anesthesia with ropivacaine 7,5 mg/ml, without MG
3342682|NCT02198560||Normal (Eyes without pathology)|
3342683|NCT02198586||No treatment|The population of this study is 45 to 75 years old at the time of inclusion in the parent study (ClinicalTrials.gov ID: NCT01835717).
3342684|NCT02198599|Experimental|Mobility-enhancing-nursing intervention|A 30 day mobility enhancing-nursing intervention for patients with Multiple Scerosis and stroke to expand kinaesthetic competence in order to increase compensation of limitations, improve functionality, and quality of life
3342685|NCT02198599|No Intervention|Standard usual rehabilitation care|Participants in the control group will receive usual care, which is based on the principles of rehabilitation nursing. Based on patients functional ability (EBI data) the nursing process is used to determine objectives and interventions. The main focus is on providing a therapeutic environment and supporting and advancing abilities to perform the Activities of Daily Living, support mobility and kinesthetic perception.
3342686|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
3342687|NCT02198625|No Intervention|FiO2 80%,Nonprotective Lung Ventilation|
3342688|NCT02198625|Experimental|FiO2 30%,Nonprotective Lung Ventilation|FiO2 30%,Nonprotective Lung Ventilation
3342689|NCT02198625|Experimental|FiO2 80%,protective Lung Ventilation|FiO2 80% and protective Lung Ventilation
3238498|NCT01270490|No Intervention|No intervention|No adjunctive treatment
3238499|NCT01270568|Experimental|Positive Psychology|8 weekly positive psychology exercises
3238500|NCT01270568|Active Comparator|Relaxation Response|Meditation-based treatment
3238501|NCT01270568|Sham Comparator|Recollection|Recollection of daily events, recorded weekly
3238502|NCT01270594|Experimental|COPD Counseling Intervention|Pharmacist counseling intervention delivered via telephone.
3238503|NCT01270594|Other|Usual Care|
3342690|NCT02198625|Experimental|FiO2 30%,protective Lung Ventilation|FiO2 30% and protective Lung Ventilation
3342691|NCT02198638|Other|Patients or healthcare workers|
3342692|NCT02198677|Experimental|AP|Anterior to posterior pressures 5x10 seconds per set with 10 seconds rest between each set
3238504|NCT01270607|Experimental|Acupuncture|
3342693|NCT02198677|Experimental|Lateral glides|Lateral glides 5x10 seconds per set with 10 seconds rest between each set
3375854|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Ibrutinib|Ibrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
3238505|NCT01270633|Other|Treatment|PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
3238506|NCT01270633|Active Comparator|Standard of Care|Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
3238507|NCT01270646|Experimental|Intraventricular Electrical Activation|
3238508|NCT01270672|Experimental|carvedilol, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3238509|NCT01270685||1|Veterans with spinal cord injuries and disorders
3342694|NCT02198690|Experimental|Mammography Decision Aid|Development and pilot testing of the decision aid (DA) has been described previously. In brief, the DA is written at a 6th grade reading level and includes information on 1) breast cancer risk factors for women >75 years; 2) health/life expectancy; 3) likely outcomes if screened and not screened with mammography; 4) competing mortality risks; 5) breast cancer treatments; and 6) a values clarification exercise. The last page asks users their intentions of being screened on a 15-point validated scale and invites users to share this information with their clinician. PCPs whose patients are randomized to receive the DA will be sent a copy of the DA via email and a link to an optional training on using the DA (5 informational slides and a 3-minute video).
3342695|NCT02198690|Placebo Comparator|Home safety pamphlet|To reduce response bias and to compensate for the time and attention required by the intervention group to read the DA, patients in the control arm will be provided a two page pamphlet on home safety for older adults developed by the American Geriatrics Society (AGS) Foundation for Health in Aging. PCPs whose patients are randomized to the receive the home safety pamphlet, will be sent an email informing them that their patient will be coming in early to read health educational materials for older adults as part of a study. We otherwise do not plan any intervention for control group PCPs because we do not want to change their usual behavior. However, if PCPs in the control arm request a copy of the educational materials then we will email them a copy of the home safety pamphlet.
3238510|NCT01270685||2|Comparison group: general Veteran population (without spinal cord injuries or disorders)
3342696|NCT02198703|Experimental|AB-Life|1 capsule of AB-Life daily during 12 weeks consumed immediately before, after or during the breakfast. The daily dose corresponds to the intake of 1.8E+10 CFU. According to the product's stability and the duration of the experiment, all participants receive at least 1.2E+09 CFU/capsule/day by the end of the study.
3342697|NCT02198703|Placebo Comparator|Placebo|1 capsule of placebo daily during 12 weeks consumed immediately before, after or during the breakfast.
3342698|NCT02198716|Other|Drug eluting stent|Percutaneous coronary intervention
3342699|NCT02198716|Other|Bare Metal Stent|Percutaneous Coronary Intervention
3342700|NCT02198729|Active Comparator|Endoscopic Mucosal Resection|Participants randomised to this arm will receive standard of care Endoscopic Mucosal Resection for removal of their lesions.
3342701|NCT02198729|Experimental|Endoscopic Submucosal Dissection|Participants randomised to this arm will receive Endoscopic Mucosal Dissection to remove their lesion.
3342702|NCT02198742|Active Comparator|Miller blade|Subjects must have >500 intubations in order to participate in this study. There is no placebo group, and each subject wil be his or her own control.
3342703|NCT02198742|Active Comparator|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable. There is no placebo group, and each subject wil be his or her own control.
3342704|NCT02198742|Active Comparator|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacterer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
3342705|NCT02198755|Active Comparator|High Resolution Ultrasound|High Resolution Ultrasonography (HRUS) with a Hitachi-Aloka Noblus Scanner
3342706|NCT02198755|Active Comparator|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI)
3342707|NCT02198768||Ankle Fracture|Patients with isolated ankle fractures.
3342708|NCT02198768||Ankle Fracture-Dislocation|Patients with ankle fracture-dislocations.
3342709|NCT02198781||Cohort|Basic science study
3342710|NCT02198807|Experimental|Fosmidomycin-Piperaquine|Fosmidomycin sodium capsules 450 mg, dosage: 30mg/kg twice daily for 3 days Piperaquine phosphate tablets 320 mg, dosage: 16 mg/kg once a day for 3 days
3342711|NCT02198820||General|All patients included who underwent surgery with general anesthesia
3342712|NCT02198820||Loco Regional|All patients included who underwent surgery with loco regional anesthesia
3342713|NCT02198846|Experimental|Insulin pump|insulin pump
3342714|NCT02198846|Active Comparator|conventional treatment|intensification of conventional treatment
3342715|NCT02198859|Experimental|Lithium|Oral lithium carbonate dose escalation: Level 1 of 600 mg/day, then escalating to Level 2 of 900 mg/day, then the final Level 3 of 1200 mg/day.
3342716|NCT02198872|Experimental|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
3342717|NCT02198872|Active Comparator|Land Group|Patients of this group perform physical training on bicycle.
3342718|NCT02198885||Control|This group receives the standard prehospital care en route to hospital, and they do not receive the FAST ultrasound en route.
3342719|NCT02198885||FAST|This group receives the FAST ultrasound en route to hospital.
3342720|NCT02198898|No Intervention|GUARDIX|no guadix
3342721|NCT02198898|Experimental|guadix|guadix treatment
3342722|NCT02198911|Active Comparator|Order 1|Gum chewing order for sessions, 1-3 respectively: NO GUM, MCC, C
3342723|NCT02198911|Active Comparator|Order 2|Gum chewing order for ice-cream sessions, 1-3 respectively: MCC, C, NO GUM
3342724|NCT02198911|Active Comparator|Order 3|Gum chewing order for ice-cream sessions, 1-3 respectively: C, NO GUM, MCC
3342725|NCT02198924|Experimental|Parecoxib and Celecoxib|"Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3."
3238511|NCT01270685||3|Health care providers with face-to-face contact with Veterans with SCI/D
3342726|NCT02198924|Placebo Comparator|placebo|"Patients in the control group are supplied with the corresponding placebo with the same instructions.~Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3."
3342727|NCT02198937||Smokers|Healthy smokers
3238512|NCT01270685||4|Infection control Chiefs/Officers
3238513|NCT01270698|Experimental|IMMU-130|
3238514|NCT01270724|Experimental|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)|Two to four cycles of induction therapy with open label GemPOx followed by consolidation and autologous stem cell transplant (ASCT).
3238515|NCT01270737|Active Comparator|Whole soy|
3238516|NCT01270737|Active Comparator|daidzein|
3238517|NCT01270737|Placebo Comparator|milk powder|
3238518|NCT01270763||The Look AHEAD Study|The Look AHEAD Study includes intensive lifestyle intervention treatment, focusing on caloric intake and physical activity, and a treatment arm focused on diabetes support and education.
3238519|NCT01270776|Experimental|Aqueous Chlorhexidine|The group received skin antisepsis using 2% aqueous chlorhexidine solution.
3238520|NCT01270776|Active Comparator|2% Chlorhexidine 70% isopropyl alcohol|The group will receive skin antisepsis with 2% chlorhexidine solution in alcohol.
3238521|NCT01270789|Experimental|Liraglutide|
3238522|NCT01270789|Placebo Comparator|Placebo|
3238523|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 400 to 500 calories|
3238524|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 600 to 750 calories|
3238525|NCT01270815|Experimental|Pregabalin controlled release, 330 mg, 800 to 1000 calories|
3238526|NCT01270815|Other|Pregabalin immediate release, 300 mg|Reference
3238527|NCT01270854|Experimental|Plasmalyte|Administration of Plasmalyte A as the standard intravenous fluid during the first 24 hours after arrival to the hospital
3238528|NCT01270854|Active Comparator|Normal Saline|Administration of Normal Saline as the standard intravenous fluid during the first 24 hours after arrival to the hospital
3238529|NCT01270893|Experimental|Nilotinib and Surgical Resection|
3238530|NCT01270893|Experimental|Nilotinib and Potential Resection|
3342728|NCT02198937||Non-Smokers|Healthy non-smokers
3342729|NCT02198950||ICU patients|all patients admitted into the ICU
3342730|NCT02198976||Barrett's Oesophagus|Patients with Barrett's Oesophagus with either high grade dysplasia (HGD) or intramucosal cancer (IMC)
3342731|NCT02198989|Experimental|peer support and yoga music therapy|"Patients in the group will receive peer support and yoga music therapy before bed.~Patients in the group will received the group education courses and clinical medical therapy."
3238531|NCT01270906|Experimental|CHIR-258 (TKI258)|
3238532|NCT01270932|Experimental|Lenalidomide and Dexamethasone|"Lenalidomide:Daily for 21 days of a 28 day cycle~Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4."
3342732|NCT02198989|No Intervention|Control group|Patients in the group will received the group education courses and clinical medical therapy.
3342733|NCT02199002|Other|healthy volunteers|healthy volunteers (no gastric complains)
3342734|NCT02199002|Other|PPI responders|proven reflux, good symptom relief upon PPI therapy
3238533|NCT01270945|Experimental|CV-18C3 and standard of care|CV-18C3 and standard of care
3238534|NCT01270945|Active Comparator|standard of care|Percutaneous revascularization
3238535|NCT01270984|Experimental|Luckyvec 400mg film coated tablet|400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
3238536|NCT01270984|Active Comparator|Glivec 100mg film coated tablet|100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
3238537|NCT01270997|Experimental|HD203|Subcutaneous injection (SC) HD203 25mg twice a week for 48 weeks
3238538|NCT01270997|Active Comparator|Enbrel|Subcutaneous injection (SC) Enbrel® 25mg twice a week for 48 weeks.
3238539|NCT01271023|Experimental|Closed-Loop Control|The Control to Range algorithm will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
3238540|NCT01271049|Placebo Comparator|Control Food Product|Consumption of placebo food product
3238541|NCT01271049|Experimental|Novel Food Product|Consumption of novel food product
3238542|NCT01271062|Active Comparator|T2DM patients before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
3238543|NCT01271062|Active Comparator|Non-diabetic patient before gastric bypass surgery|oral glucose tolerance test , botnia clamp, preoperative as well as 10 days postoperative and 1 year postoperative, gastric bypass surgery.
3238544|NCT01271062|Active Comparator|non diabetic patients, non-bariatric abdominal surgery|oral glucose tolerance test , botnia clamp, elective laparoscopic abdominal surgery.
3238545|NCT01271062|Active Comparator|severely obese T2DM patients following a very low caloric diet|oral glucose tolerance test , botnia clamp, before as well after following a very low caloric diet. Very low caloric diet.
3238546|NCT01271075|Active Comparator|Bilastine A|A: Crossover Bilastine 20 mg, Bilastine 40 mg, Placebo, Bilastine 80 mg
3238547|NCT01271075|Active Comparator|Bilastine B|B: Crossover Bilastine 80 mg, Placebo, Bilastine 40 mg, Bilastine 20 mg
3238548|NCT01271088|Experimental|N-acetylcysteine|N-acetylcysteine: Experimental N-acetylcysteine 600 mg twice daily + vancomycine and/or amikacin
3238549|NCT01271088|No Intervention|Control|Vancomycine and/or amikacin alone
3342735|NCT02199002|Other|PPI non-responders|proven reflux disease, poor symptom control (less then 50% symptom reduction) upon PPI therapy (2x40mg omeprazole)
3342736|NCT02199002|Other|Barrett - no dysplasia|proven barrett with no dysplasia on biopsies
3342737|NCT02199002|Other|barrett - high grade dysplasia|proven barrett with high grade dysplasia on biopsies
3342738|NCT02199015|Experimental|Spasticity, Cerebral Palsy|To perform a Lateral spinal cord surgical implant of electrodes for electrical neuromodulation of a cohort of selectyed patients with refractory Spastic Cerebral Palsy To compare spasticity and speech trouble´s evolution on a cohort of treated patients, by evaluating their pre and post operative status into one year follow up.
3342739|NCT02199054|Placebo Comparator|Run-in Intervention|Control wheat pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of control wheat pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3342740|NCT02199054|Active Comparator|Wheat-Safflower Oil Arm|Wheat-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of wheat-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3342741|NCT02199054|Active Comparator|Soy-Safflower Oil Arm|Soy-safflower oil pretzel bites (12 pieces total) will be consumed with a flavored oil dip containing a standardized quantity of triglycerides (50 g long chain fatty acids) at the start of a 7 hour clinic visit as well as 6 pieces of soy-safflower oil pretzels will be eaten twice a day (total of 12 pieces/day) for 28 days. During these 28 days, participants will monitor their oil consumption and maintain a legume-free diet.
3238550|NCT01271101||anticoagulant|
3238551|NCT01271114|Experimental|Hypertonic Saline and Terlipressin|
3238552|NCT01271114|Active Comparator|Normal Saline and norepinephrine|
3342742|NCT02199093|Experimental|Functional Rehabilitation of apraxia|The participants will be randomly assigned to an experimental group, to receive intervention in upper limb apraxia at home since two approaches, a rehabilitative and another compensatory (providing adaptive strategies at home). The treatment will be performed three times a week, 30 minutes a day, during a 4-week period.
3342743|NCT02199093|Active Comparator|Traditional health educative protocol|Control group will receive treatment with a traditional health educative protocol to improve his functionality in activities of daily living. The treatment will be performed twice in two month.
3342744|NCT02199106|Experimental|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Intervention: Left temporal verum cTBS"
3342745|NCT02199106|Experimental|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Intervention: Left temporal placebo cTBS"
3342746|NCT02199119|Experimental|Control|Sitting quietly for 30 min No TV No exercise
3342747|NCT02199119|Experimental|TV viewing only|watching TV for 30 min
3342748|NCT02199119|Experimental|Exercise only|exercising for 30 min
3342749|NCT02199119|Experimental|TV viewing and Exercise|30 min of moderate exercise on a treadmill while watching TV
3342750|NCT02199132||Nasopharyngeal Carcinoma|
3342751|NCT02199145|Other|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria /creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
3342752|NCT02199158|Experimental|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
3342753|NCT02199171|Experimental|HIPEC carboplatin|"Patients receive hyperthermic carboplatin intraperitoneally over 60 minutes during the planned surgical cytoreductive procedure.~Doses as appropriate for assigned dose level in 500 cubic centimeters (cc)"
3342754|NCT02199184|Experimental|Treatment (DA-EPOCH and ofatumumab or rituximab)|Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
3375855|NCT03685708|Experimental|Chronic Lymphocytic Leukemia Patients Receiving Treatment With Acalabrutinib|Acalabrutinib monotherapy for at least 6 months prior to administration of the first vaccine dose in patients with Chronic Lymphocytic Leukemia (CLL) or small lymphocytic lymphoma (SLL). Patients will receive HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
3238553|NCT01271140|Experimental|Insulin/dextrose clamp|
3238554|NCT01271153|Active Comparator|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours
3238555|NCT01271153|Placebo Comparator|Placebo|An equivalent infusion of placebo will be infused for 2.5 h
3238556|NCT01271166|Experimental|Glivec®, modified FOLFOX, Avastin®|
3238557|NCT01271179|Active Comparator|sequential perfusion|sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
3238558|NCT01271179|Placebo Comparator|sole perfusion|sole perfusion of liver grafts with high-viscosity UW solution only
3238559|NCT01271192|Active Comparator|Surgical resection and adjuvant therapy|Patients receive surgical resection and undergo FOLFIRI for 12 cycles, from 2-4 weeks after operation. Patients undergo radiotherapy once daily 5 days a week for 5-6 weeks, from 8-12 weeks after operation
3238560|NCT01271192|Experimental|Neoadjuvant followed by operation|Patients receive neoadjuvant chemoradiotherapy (mFOLFIRI for 5 cycles and undergo radiotherapy as in arm I from the second cycle of FOLFIRI), surgery and FOLFORI for 7 cycles from 2-4 weeks after operation.
3342755|NCT02199210|Experimental|Prompting forethought|"A demographic questionnaire will be filled out by each participant. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants forethought will be prompted and each participant will be asked to report his/her forethought,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
3342756|NCT02199210|No Intervention|No prompting|"A demographic questionnaire will be filled out by each participants. After randomization, participants will be presented with the background information of the simulated scenario.Subsequently:~participants will sit and wait for a predetermined time before entering into the simulator,~participants then will be asked to manage a simulated massive transfusion scenario,~at completion of the scenario, each participant will be interviewed about their thought process before entering to the simulation room,~each participant will undergo individualized debriefing and a syllabus on massive transfusion will be briefly discussed with them and also provided as a reading material for learning."
3238561|NCT01271218|Placebo Comparator|Placebo|Participants ingested 2,200 mg/day of a placebo or active dietary supplement. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks. The supplements were prepared in caplet form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
3238562|NCT01271218|Active Comparator|Active Supplement|Participants were randomly assigned to ingest in a double-blind manner caplets containing a commercially available glucosamine/chondroitin (GC) dietary supplement (Curves Joint and Connective Support™, Curves International, Waco, TX) or a suitable placebo (P). The GC supplement provided a total of 1,500 mg/d of glucosamine, 1,200 mg/d of chondroitin sulfate, 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d MSM, 300 mg/d of boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. Participants ingested three caplets in the morning and the remaining three caplets in the evening 30-minutes before a meal for 14-weeks.
3238563|NCT01271231|Placebo Comparator|Group IP1|
3238564|NCT01271231|Experimental|Group IP2|
3342757|NCT02199223|Experimental|panitumumab + regorafenib|
3342758|NCT02199236|Experimental|endorectal brachytherapy, concurrent chemo and questionnaires|This is a phase I, dose-escalation study to evaluate the safety of endorectal brachytherapy with concurrent capecitabine or 5-fluoruracil (5-FU) in the management of locally recurrent/residual rectal or anal cancer in patients who have received pelvic external beam radiation therapy (EBRT) +/- chemotherapy. We will use magnetic resonance imaging (MRI) with dynamic contrast enhancement (DCE) and diffusion weighted imaging (DWI) series to contribute to the assessment of tumor response.
3342759|NCT02199249|Active Comparator|Open Reduction Tightrope fixation (OT)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
3342760|NCT02199249|Active Comparator|Open Reduction screw fixation (OS)|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
3238565|NCT01271231|Active Comparator|Group IP3|
3238566|NCT01271257|Experimental|hourly misoprostol|20 microgram misoprostol intake per hour
3238567|NCT01271257|Active Comparator|traditional misoprostol|80 microgram misoprostol intake per 4 hours
3342761|NCT02199262|Experimental|control groupe|agitation diagnosis and management according to implemented guidelines= reminder implementation
3342762|NCT02199262|Experimental|music intervention + reminder|agitation diagnosis and management according to implemented guidelines+ music intervention
3342763|NCT02199262|Experimental|reflexology + reminder|agitation diagnosis and management according to implemented guidelines + reflexology
3342764|NCT02199288||Cohort|
3342765|NCT02199301|Experimental|BMTKT|Transplantation Conditioning for bone marrow transplantation (BMT) Kidney transplantation and BMT (BMTKT)
3342766|NCT02199327|Active Comparator|Mitomycin C|Mitomycin C 0.04% 4 times daily for 7 days and 7 days off until resolution of neoplasia (3-6 cycles).
3342767|NCT02199327|Active Comparator|Interferon alfa 2b|Interferon alfa-2b 1 million IU/ml 4 times daily until complete resolution of the tumor
3342768|NCT02199340|Experimental|Cystic fibrosis|"iStep exercise test~CPET exercise test"
3342769|NCT02199340|Active Comparator|Healthy control|- iStep exercise test
3342770|NCT02199353|Experimental|Stimulation of Activities Daily Living|"The experimental group received the Stimulation of Activities of Daily Living (SADL) programme which is a new treatment approach created by the authors of this study for the training of activities of daily living (ADL) through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The sequence of the sessions was always the same, varying the activities, subject, cognitive functions and BADL to work on. Each session started with an activity of temporal and space orientation, continued with the performance of the specific activity of the session and finished with a reminiscence activity.~The treatment was applied twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
3238568|NCT01271283|Experimental|Arm I|Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies.
3238569|NCT01271296|Active Comparator|Liquorice|Liquorice eq to 150 mg glycyrrhizinic acid. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
3238570|NCT01271296|Active Comparator|Grapefruit juice|200 ml pink grapefruit juice three times a day. Results are compared to a baseline assessment without liquorice/grapefruit juice ingestion.
3238571|NCT01271296|No Intervention|Baseline|Baseline assessment without intake of liquorice or grapefruit juice
3238572|NCT01271309||Acute Myocardial Infarction patients|Patients with thoracic pain lasting at least 20 min and ST changes or left B block, not present in previous ECG.
3342771|NCT02199353|Active Comparator|Conventional ADLoccupational therapy|"The control group treatment was based on a conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
3342772|NCT02199366||Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
3342773|NCT02199379|Experimental|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
3342774|NCT02199392|Experimental|Lenvatinib 24 mg|The Pretreatment Phase will have two periods: Screening and Baseline 1. The Treatment Phase will have three periods: Treatment Period 1, Treatment Period 2, and Treatment Period 3 with a Baseline 2 assessment prior to Treatment Period 2 and a Baseline 3 assessment prior to Treatment Period 3. In the Treatment Phase, subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
3342775|NCT02199405|Experimental|massage and Sishi Daoyin|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
3342776|NCT02199405|Active Comparator|conventional massage and cervical traction|Conventional massage , 15 minutes, three times one week for 4 weeks Cervical traction , 15 minutes, three times one week for 4 weeks
3342777|NCT02199418|Experimental|Paclitaxel and Cisplatin|"Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 16 weeks. Cisplatin: 25 mg/m² weekly on day 1 ,8,and 15 q day 28 for 4 cycles.~Trastuzumab (only for human epidermal growth factor receptor-2(HER2)-positive patients): Loading dose: 4 mg/kg, Maintenance dose: 2 mg/kg, day 1 q day 8 for 16 weeks. Post-surgery: up to a total duration of 1 year"
3342778|NCT02199431|Experimental|Lu AF1167 capsule 0.5 mg|Single oral dose (day 1)
3342779|NCT02199431|Experimental|Lu AF11167 0.5 mg capsule + itraconazole 200 mg capsule|Itraconazole administered once daily for 7 days (day 3-9); Lu AF11167 administered as a single dose on day 8
3342780|NCT02199444|Experimental|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
3342781|NCT02199444|Placebo Comparator|Placebo|The patients received placebo three times a day
3342782|NCT02199457|Other|SVSS and reference devices|Vital signs will be measured on the same subject with the reference devices and with the SVSS. The subject will have blood pressure, pulse, blood oxygen, body temperature and respiration rate measured using standard equipment. The same subject will then use the investigational device which measures all vital signs at the same time, by placing the index finger on a sensor.
3342783|NCT02199470||C-peptide minimal detectable|C-peptide level between 0,01-0,08 ng/mL
3342784|NCT02199470||C-peptide sustained|C-peptide level between higher or equal to 0,08 ng/mL
3342785|NCT02199470||C-peptide not detectable|C- peptide level equal to or lower than 0,01 ng/mL
3238573|NCT01271335|Experimental|Collagenase (MZ-004)|Local intra-coronary administration of MZ-004 at or into the CTO
3238574|NCT01271348|Active Comparator|Etoricoxib|
3342786|NCT02199522|Experimental|titration induction of propofol|titration induction of propofol by Fresenius pump at the speed of 1 mg•kg-1•min-1
3342787|NCT02199522|No Intervention|convention induction of propofol|propofol 2mg•kg-1 intravenously by Fresenius pump at the speed of 250mg•min-1
3342788|NCT02199548||Study Participants|All enrolled participants will take part in a face-to-face interview.
3342789|NCT02199561|Experimental|Fecal Microbiota Transplant|Open label single arm delivering fecal transplant to each participant
3342790|NCT02199587|Active Comparator|Endocrine test with medical clown|children who are referred to endocrine test will have the procedure with a medical clown, or without. The pain and anxiety perception of the child and caregivers will be compare between the two scenarios
3342791|NCT02199587|No Intervention|Endocrine test without medical clown|
3342792|NCT02199600|Other|GMK Sphere Knee Replacement|Patients who comply with the protocol and received GMK Sphere component.
3342793|NCT02199613|Experimental|Treatment simplification|Open-label darunavir 800mg in conjunction with the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet, both taken together once daily with food
3342794|NCT02199626|Experimental|CCE-2|Second generation of Colon capsule endoscopy in pediatric Crohn's disease
3342795|NCT02199639||Spain|Group of patients with hemophilia recruited in the Region of Murcia (Spain) and evaluated in the Universidad Católica San Antonio between June and July 2014.
3342796|NCT02199639||El Salvador|"Group of patients with hemophilia recruited in the city of San Salvador (El Salvador) and evaluated in the Hospital Nacional Rosales and the Hospital Nacional de niños Benjamín Bloom from San Salvador in April 2014."
3342797|NCT02199639||Bolivia|Group of patients with hemophilia recruited in the city of Santa Cruz (Bolivia) and evaluated at the Hospital Nacional de niños in Santa Cruz August 2014.
3342798|NCT02199665|Experimental|Selinexor, carfilzomib, dexamethasone|Patients receive selinexor PO, carfilzomib IV, and dexamethasone PO QD or IV. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3342799|NCT02199678|Placebo Comparator|Placebo|Placebo
3342800|NCT02199678|Active Comparator|ketamine 25 mg|ketamine
3342801|NCT02199678|Active Comparator|ketamine 35 mg|ketamine
3342802|NCT02199678|Active Comparator|ketamine 50 mg|ketamine
3342803|NCT02199704|Other|No control or comparison arm.|This case series study has no control or comparison arm. There is only one arm being evaluated (the self directed parenting intervention).
3342804|NCT02199756||Cesarean section|Women with cesarean section
3238575|NCT01271348|Placebo Comparator|Placebo tablet|
3342805|NCT02199769|Experimental|Clinical Decision Support|Visit-based, EMR-enabled case identification and real-time decision support to identify patients without diabetes who have a RBG>= 125mg/dL and no resulted diabetes screening.
3342806|NCT02199769|No Intervention|Usual care|Diabetes screening/testing and diagnosis per usual care at the discretion of the treating physician.
3342807|NCT02199782|Active Comparator|Welsh|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
3342808|NCT02199782|Active Comparator|English|Participants will complete the cognitive assessment in Welsh and in English these will be compared to assess whether first language Welsh speakers perform better in Welsh.
3342809|NCT02199808||7-9 year olds|These are children who are between 7 and 9 years old when they are tested.
3342810|NCT02199808||10-12 year olds|These are children who are between 10 and 12 years old when they are tested.
3342811|NCT02199821|Active Comparator|Soybean oil formula commonly used in the hospita|
3342812|NCT02199821|Experimental|Formula with soybean oil, medium-chain triglyce|
3342813|NCT02199834|Experimental|Peer group|24 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support to this group under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
3342814|NCT02199834|Other|Refused peer group|Patients who fit the criteria of peers but refuse to be contacted by peer supporters will be signed as refused group. Half of the patients in this group will be randomized to receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
3342815|NCT02199834|Experimental|Report group|Patients in this group will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values twice a year through mails.
3342816|NCT02199834|No Intervention|Usual care|Patients will receive standard usual care with clinicians' follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
3342817|NCT02199847|Experimental|Pharmaton® Caplets|
3342818|NCT02199847|Placebo Comparator|Placebo|
3342819|NCT02199860|Experimental|SD I - single rising doses|
3342820|NCT02199860|Experimental|SD II - single rising doses|
3342821|NCT02199860|Experimental|SD II - single rising doses + Placebo|
3342822|NCT02199860|Placebo Comparator|Placebo|
3342823|NCT02199873|Experimental|BIIX 1 XX - single rising dose|
3342824|NCT02199873|Placebo Comparator|Placebo|
3342825|NCT02199886|Experimental|BIBH 1|dose escalation: 0.5, 2, 10 or 20mg/m**2, 7 days prior to surgery
3342826|NCT02199899|Experimental|BIIF 1149 BS - single rising doses|BIIF 1149 BS oral drinking solution and a BIIF 1149 BS tablet
3342827|NCT02199899|Placebo Comparator|Placebo|
3342828|NCT02199912|Experimental|Patients with colorectal surgery|
3342829|NCT02199925|Experimental|Gammaplex 5% IGIV|Gammaplex 5% IGIV administered intravenously
3238576|NCT01271361|Experimental|primary PCI with thrombectomy|thrombectomy before implantation of drug eluting stent
3238577|NCT01271361|Active Comparator|primary PCI without thrombectomy|implantation of a drug eluting stent without thrombectomy
3342830|NCT02199938||musculoskeletal tumors|Patients with suspected or confirmed bone or soft tissue tumors undergoing biopsy or surgery
3342831|NCT02199951||Dihydroartemisinin and piperaquine|The patients will take Eurartesim® (DHA/PQP) with a dose regimen of one administration every 24 hours over a period of three days, i.e. at Day 1, then after 24 hours (Day 2) and after 48 hours (Day 3) from the first administration. The dose will be based on body weight. Two strengths of Eurartesim® will be provided for dosing in children and adults: 20/160mg and 40/320mg of DHA and PQP respectively. Body weight (kg) Daily dose (mg) Number of tablets per dose 20/160mg DHA/PQ 40/320mg DHA/PQ 5 to <7 10 mg DHA and 80 mg PQP ½ tablet 7 to <13 20 mg DHA and 160 mg PQP 1 tablet 13 to < 24 40 mg DHA and 320 mg PQP 1 tablet 24 to < 36 80 mg DHA and 640 mg PQP 2 tablets 36 to < 75 120 mg DHA and 960 mg PQP 3 tablets 75 to < 100 160 mg DHA and 1280 mg PQP 4 tablets > 100.
3342832|NCT02199977|Other|test only (free)|The participant is entitled to a free malaria rapid diagnostic test, but no ACT voucher.
3342833|NCT02199977|Other|test (free) & conditional ACT voucher|The participant is entitled to a free malaria rapid diagnostic test, and an ACT voucher conditional on a positive test result.
3342834|NCT02199977|Other|test only (not free)|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), but no ACT voucher.
3342835|NCT02199977|Other|test (not free) & conditional ACT voucher|The participant is entitled to a malaria rapid diagnostic test for a charge (i.e., not for free), and an ACT voucher conditional on a positive test result.
3342836|NCT02200003|Experimental|Attention Bias Modification|640 Trials (20 minutes) four times over four weeks
3238578|NCT01271374|Active Comparator|Hyzaar-Treatment Arm B|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
3238579|NCT01271374|Active Comparator|Azor-Treatment A|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
3342837|NCT02200003|Sham Comparator|Sham Attention bias modification|640 Trials (20 minutes) four times over four weeks
3342838|NCT02200016|Experimental|SAX|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters
3342839|NCT02200016|Active Comparator|LAX|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters
3342840|NCT02200029|Experimental|Ademetionine IV|
3342841|NCT02200029|Experimental|Ademetionine oral|
3342842|NCT02200068|Active Comparator|PHR Group|This group will have access to a personal health record website SANOIA in addition to all resources they use or find online
3342843|NCT02200068|No Intervention|Non-PHR Group|This group will not be informed of the Personal Health Record Website and will use Internet as they usually do.
3342844|NCT02200081|Experimental|MGN1703|MGN1703, solution in Dulbecco's Phosphate-Buffered Saline (DPBS), 2 mL of 60 mg/4 mL (15 mg/mL), administered SC at 2 application sites twice weekly
3342845|NCT02200081|Other|Standard of care|Continous first line therapy
3238580|NCT01271387|Experimental|Moderate Hepatic Impairment|
3342846|NCT02200094||Outpatients with essential hypertension|
3342847|NCT02200107|Experimental|self management education|self management education program delivered by family doctor in primary care clinics and during and physical therapy design
3342848|NCT02200107|No Intervention|control|Routine follow up according to standard practice
3342849|NCT02200133|Experimental|Individualized Survivorship Care Plan (SCP)|"Participant information sheet and instructions on how to use the SCP~Patient version of individualized SCP that includes but is not limited to: (1) a treatment summary that consists of disease characteristics and treatment details (including HCT), and (2) recommendations for preventive care and screening for late complications based on patient treatment exposures (age, type of transplant, use of TBI, corticosteroid exposure as part of HCT, and history of GVHD)~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants may receive other materials their transplant center routinely provides to patients for follow-up care (e.g., discharge summary or clinic note)"
3342850|NCT02200133|No Intervention|Usual care (no SCP)|"Materials that their transplant center routinely provides to patients for follow-up care~Newest Vital Sign nutrition label to measure health literacy and its instructions~Participants randomized to the usual care arm who complete the 6 month study assessments will receive their individualized SCP upon completion of the patient's participation. Participants who withdraw from the study or who do not complete the 6 month assessment will not receive the individualized SCP."
3342851|NCT02200146|Active Comparator|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
3342852|NCT02200146|Experimental|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
3342853|NCT02200159||dexmedetomidine|
3342854|NCT02200172|Active Comparator|Melatonin|A single daily sublingually administered tablet of 3mg non-animal synthetic source melatonin (immediate-release) at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
3342855|NCT02200172|Placebo Comparator|Placebo|A single daily sublingually administered tablet of placebo at 21.00 hours (±1 hour), starting on Study Day 1 and stopping on Study Day 28 of admission or earlier in the event of death or discharge.
3238581|NCT01271387|Experimental|Mild Hepatic Impairment|
3238582|NCT01271387|Experimental|Healthy Volunteers|
3238583|NCT01271439|Experimental|cetuximab|
3342856|NCT02200185|Placebo Comparator|IV titrated morphine|"patient will receive 2 mg morphine each 5 min, associated to continuous nebulisation of saline serum (placebo).~Morphine administration is stopped when VAS becomes under 50% and treatment failure is defined as VAS > 50%, 30 minutes after the beginning of the protocol."
3342857|NCT02200185|Experimental|Low dose nebulised morphine|"patient will receive 10 mg of morphine prepared with 4 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo"
3342858|NCT02200185|Experimental|High dose nebulised morphine|"patient will receive 20 mg of morphine prepared with 3 ml saline serum (SS) and nebulised with 6 l/min flow during 10 minutes.~Nebulisation will be repeated 3 times, in addition, patients receive 2 ml IV SS every 5 minutes as placebo."
3342859|NCT02200198|Active Comparator|Inspiratory group|Inspiratory muscle training
3342860|NCT02200198|Sham Comparator|Sham group|Sham training
3342861|NCT02200198|Experimental|Expiratory group|Expiratory muscle training
3342862|NCT02200224|Experimental|Rapid Testing/Treatment Group|All subjects enrolled in the rapid testing group will receive rapid CT/NG and TV testing in addition to the CT/NG Nucleic Acid Amplification Test (NAAT) and wet mount testing that is currently used in the ED.
3342863|NCT02200224|No Intervention|Control|All subjects enrolled in the control group will receive CT/NG and TV testing according to the current standard of care for Johns Hopkins ED.
3342864|NCT02200237|Placebo Comparator|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
3342865|NCT02200237|Experimental|EV71 with adjuvant aluminium phosphate|Inactive whole monovalent EV71 virion vaccine formulated with phosphate-buffered saline based adjuvanted aluminium phosphate 150 μg/0.5ml
3342866|NCT02200250||Post Barretts Excision|Patients who have undergone an EMR for Barretts Oesophagus
3342867|NCT02200263|Experimental|Lutein plus Zeaxanthin|Participants randomized to this arm will receive 20 mg of Lutein (L) plus 20 mg of Zeaxanthin (Z) per day: Two pills (10 mg L+ 10 mg Z per pill) for the duration of one year.
3342868|NCT02200263|Placebo Comparator|Placebo softgels|Participants randomized to this arm will receive two pills per day of placebo-gels corresponding to the active compound in look and feel for the duration of one year
3342869|NCT02200276|Other|Influenza Immunization|Influenza immunization in adults over age 75
3342870|NCT02200289||Mother-infant pairs|Mother-infant pairs from the GRAPHS birth cohort study
3342871|NCT02200315|Experimental|No Antimicrobial prophylaxis|No use of antimicrobial prophylaxis during surgery
3342872|NCT02200341|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|Mindfulness-Based Cognitive Therapy (MBCT) 8-week intervention
3238584|NCT01271478|Experimental|Telmisartan plus Captopril|captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day)
3238585|NCT01271478|Experimental|Telmisartan plus Placebo|telmisartan 80 mg/day (1 tablet of 40 mg orally twice a day) plus 1 tablet of placebo orally twice a day
3238586|NCT01271478|Experimental|Captopril plus Placebo|patients received captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
3238587|NCT01271478|Placebo Comparator|Placebo|2 tablets of placebo orally twice a day
3238588|NCT01271491||Cases|Children hospitalized in the ICU with bronchiolitis
3238589|NCT01271491||Controls|Children hospitalized in the general ward with bronchiolitis
3342873|NCT02200341|Active Comparator|Progressive Relaxation Training - Psychoeducation|Progressive Relaxation Training and Psychoeducation (PRT-PsyEd) 8-week intervention
3342874|NCT02200354|Experimental|pemetrexed with bevacizumab|pemetrexed rechallenge with bevacizumab pemetrexed (500mg/m2 day1) bevacizumab (15mg/kg day1)
3342875|NCT02200367|Experimental|e-mental health collaborative programme|It is a complex intervention to support primary care providers of rural primary care service to manage depressed patients. Primary care providers at the intervention sites were supported by psychiatrist using an electronic platform.Patients were monitored through a call center.
3342876|NCT02200367|Other|Usual Care|Patients in this arm received all the interventions that are guaranteed for the persons with depression in Chile: treatment in the primary clinics with the primary care team and referral to the regional specialized psychiatric service
3342877|NCT02200380|Experimental|CDX-301|
3342878|NCT02200380|Experimental|CDX-301 and plerixafor|
3342879|NCT02200393|Experimental|Abdominal FES|Participants in the Abdominal Functional Electrical Stimulation (AFES) group will receive AFES 5 times per week (20 to 40 mins per day), on four alternate weeks.
3238590|NCT01271517|Active Comparator|Insulatard|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugars
3238591|NCT01271517|Active Comparator|Lantus|Treatment once daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
3238592|NCT01271517|Active Comparator|Levemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
3238593|NCT01271530|Experimental|Exercise|
3342880|NCT02200406|Other|Desvenlafaxine|"Open-label pilot study~Desvenlafaxine will be administered during 56 consecutive days~Desvenlafaxine will be administered in the morning at a 50 mg dose during weeks 1 and 2, and at 50-100 mg doses (based on the study psychiatrist's judgment) during the 6 following weeks."
3342881|NCT02200419|Other|Transfusion Algorithm|Hospitals will be randomized to the intervention arm of the study in a stratified manner.
3238594|NCT01271530|No Intervention|Control|
3238595|NCT01271556|Experimental|1, salmeterol, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to each test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (salmeterol 50 mcg MDI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3238596|NCT01271556|Placebo Comparator|2, placebo, saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. Patients and healthy subjects underwent a rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment (placeboI), and mixed venous blood was withdrawn for measurements of hematocrit (Htc), Hb, and albumin concentration 10 minutes before and 10 minutes after the infusion. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3238597|NCT01271556|Active Comparator|3, salmeterol, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Salmeterol 50 mcg on days A was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment, pulmonary function tests were performed.
3342882|NCT02200432|No Intervention|Control|The study's current rule-based CTHC system is embedded within the Decide2Quit.org web service. Control smokers will receive the current Decide2Quit.org system, including informational web pages, an interactive quit plan, plus pushed email messages. The messages will be selected using the current rule-based CTHC system. The CTHC selects messages based on decision rules (e.g: readiness to quit, gender) using information from a smoker's baseline profile. Participants will receive one message per day for 30 days
3342883|NCT02200432|Experimental|Intervention|The PERSPeCT intervention smokers will receive all components of the Decide2Quit.org web service, but persuasive email messages will be selected by the PERSPeCT recommender system developed in Aim 2. PERSPeCT will use data (see Figure 1) to predict messages that would be most influential to the participant. Intervention smokers will receive one PERSPeCT-generated message per day for 30 days. With each message rating, the PERSPeCT system will further adapt to patient preferences.
3238598|NCT01271556|Placebo Comparator|4, placebo, no saline infusion|In 10 COPD patients and 10 healthy subjects, tiotropium and long-acting and short-acting beta-2 agonists were withdrawn at least 72 hours if assumed, 24 hours, and 12 hours, respectively, prior to test day. Placebo was administered between 8 AM and 10 AM. 240 and 290 minutes after inhalatory treatment (placebo), pulmonary function tests were performed.
3238599|NCT01271569|Other|In the treatment arm|
3342884|NCT02200471|Experimental|VeinViewer|VeinViewer will be used in conjunction with routine cosmetic dermatology procedures. Patients and physicians will complete questionnaires.
3238600|NCT01271582|Experimental|FOLFIRI|Patients with colorectal cancer or gastric cancer will be treated with FOLFIRI(Irinotecan, 5FU, leucovorin) regimen upto 12 cycles. (Single arm study)
3238601|NCT01271595|Active Comparator|acupuncture|12 sessions of acupuncture according to TCM
3342885|NCT02200484|Experimental|Parent Training/Obesity Prevention|Mother-child dyads randomized to the active intervention in the pilot study will be administered 8 weeks of a combined parenting training and obesity prevention program that was adapted through analysis of formative research interviews with adolescent mothers with feedback from an expert panel of multidisciplinary research team members and community members.
3342886|NCT02200484|Active Comparator|8-week Wellness Program (Control)|Participants randomized to control condition during intervention piloting will receive print-based health and wellness materials once weekly for 8-weeks + 2 follow up telephone calls at the beginning and conclusion of the 8-week program.
3342887|NCT02200549|Experimental|Control group|Neither cycle training nor inspiratory muscle training.
3342888|NCT02200549|Experimental|Cycle training group|A 30-minute cycling training session is performed 3 days a week using calibrated cycle ergometer.
3342889|NCT02200549|Experimental|Combined group|A 30-minute Combined training session is performed 3 days a week using calibrated cycle ergometer and threshold loading device.
3342890|NCT02200562|Experimental|Ipilimumab and Dabrafenib|
3342891|NCT02200575||Patients with non-secondary, essential hypertension|
3342892|NCT02200588||Patients|Patients followed in the First Episode Psychosis Clinical Program (PAFIP) with psychotic disorder
3342893|NCT02200588||Controls|Healthy subjects without psychotic disorder
3342894|NCT02200601|Experimental|Seipher Wellness|
3342895|NCT02200640|Experimental|Low dose of Micardis®|
3342896|NCT02200640|Experimental|High dose of Micardis®|
3342897|NCT02200640|Active Comparator|Low dose of COZAAR®|
3342898|NCT02200640|Active Comparator|High dose of COZAAR®|
3342899|NCT02200653|Experimental|Low dose of MICARDIS®|
3238602|NCT01271595|Sham Comparator|sham acupuncture|superficial acupuncture at non acupuncture sites
3342900|NCT02200653|Experimental|High dose of MICARDIS®|
3342901|NCT02200653|Active Comparator|Low dose of COZAAR® / LORZAAR®|
3342902|NCT02200653|Active Comparator|High dose of COZAAR® / LORZAAR®|
3342903|NCT02200679||Autism Spectrum Disorders|Cases were children living in target communities who are identified as positive based on questionnaire screen and the following diagnosis with DSM-Ⅳ, ADOS and ADI-R
3342904|NCT02200692||plasma transfusion|Patients receiving plasma transfusion.
3342905|NCT02200705|Other|single arm, open label|Early stage Breast cancers up to 1.5cm
3342906|NCT02200718|Experimental|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA V Beta Peptides BV5S2, BV6S5 and BV13S1 emulsified in incomplete Freund's adjuvant
3342907|NCT02200718|Placebo Comparator|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil a surfactant system designed to make a water-in-oil emulsion
3342908|NCT02200731|Experimental|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience.
3342909|NCT02200731|No Intervention|Control|In Denmark, standard care after treatment does not include systematic psychosocial support. Families are able to seek support on their own or contact a support group offered by the Danish Cancer Society. However support specializing the families with childhood cancer survivors and their siblings after ending medial treatment is limited.
3342910|NCT02200744||Dislocation reduction using propofol|
3342911|NCT02200757|Experimental|Aldoxorubicin|
3342912|NCT02200757|Active Comparator|Topotecan|
3342913|NCT02200783|Active Comparator|Radial|Cardiac catheterization and coronary angioplasty performed via standard radial artery technique.
3342914|NCT02200783|Active Comparator|Femoral|Cardiac catheterization and coronary angioplasty performed via standard femoral artery technique.
3342915|NCT02200783|Experimental|TripTable|Cardiac catheterization and coronary angioplasty performed with standard transradial technique plus using the TRIPTable device.
3342916|NCT02200796|Experimental|Low Protein Meal|Low Protein Test Meal (15 g)
3342917|NCT02200796|Experimental|Moderate Protein Meal|Moderate Protein Meal (30 g)
3342918|NCT02200796|Experimental|High Protein Meal|High Protein Meal (45g)
3342919|NCT02200796|Experimental|Control Meal|High Carbohydrate Control Meal (7 g of protein)
3342920|NCT02200809|Experimental|MR-guided focal laser ablation|
3342921|NCT02200822|No Intervention|non-intervention arm|continuation of neurohumoral blocker therapy based on maximum tolerated guideline recommended dose (this group is the control arm for as well withdrawal of beta blocker therapy as withdrawal of RAAS blocker therapy)
3238603|NCT01271621|Active Comparator|Macintoch group|Intubation with Macintoch Laryngoscope
3238604|NCT01271621|Experimental|Glidescope|Inubation by Glidescope
3342922|NCT02200822|Active Comparator|withdrawal of beta blockers|"Intervention arm with systematic withdrawal of beta blocker therapy at a reverse sequence of guideline recommended uptitration.~(this group is the experimental arm for beta blocker withdrawal. This group receives no intervention with regards to the withdrawal of RAAS blockade). Per 2 weeks:~bisoprolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~metoprolol: 200 mg/d → 100 mg/d → 50 mg/d → 25 mg/d → stop~nebivolol: 10mg/d → 5 mg/d → 2,5 mg/d → 1,25 mg/d stop~carvedilol: 50 mg bid → 25 mg bid → 12,5 mg bid → 6,25 mg bid → stop"
3342923|NCT02200822|Active Comparator|withdrawal of RAAS blockers|"intervention arm with systematic withdrawal of spironolactone followed by withdrawal of ACE-I/ARB at a reverse sequence of guideline recommended uptitration (this group receives no intervention regarding the withdrawal of beta blockers. This group is the experimental arm for withdrawal of RAAS blockers)~first spironolactone/eplerenone: per two weeks: 25 mg/d→12,5 mg/d → stop~after 2 weeks stop spironolactone/eplerenone start withdrawal of ACE-I/ARB per two weeks:~captopril: 50 mg tid→25 mg tid→12,5 mg tid→6,25 mg tid→stop~enalapril: 10 mg bid→5 mg bid→2,5 mg bid→1,25 mg bid→stop~lisinopril: 20 mg/d→10 mg/d→5 mg/d→2,5 mg/d→stop~ramipril: 10 mg/d→5 mg/d→2,5 mg/d→1,25 mg/d→stop~candesartan: 32 mg/d→16 mg/d→8 mg/d→4 m/d→stop~valsartan: 160 mg bid→80 mg bid→40 mg bid→20 mg bid→stop"
3238605|NCT01271647|Experimental|chinese herb|
3342924|NCT02200822|Active Comparator|withdrawal of RAAS - and beta blockers|"intervention arm with systematic withdrawal of spironolactone, secondly ACE-I/ARB and finally beta blockers. (this group is the experimental group for both study interventions (withdrawal of beta blockers and RAAS blockers)~First: spironolactone/eplerenone cfr reduction schedule supra~After 2 weeks of stop spironolactone withdrawal of ACE-I or ARB cfr reduction schedule supra~After 2 weeks of stop ACE-I/ARB withdrawal of beta blocker cfr reduction schedule supra"
3375856|NCT03685175|Experimental|Formal Study|Hyperpolarized 13C-pyruvate, is injected into patients before receiving cardiotoxic therapy and immediately after, for a cardiac MRI scan
3238606|NCT01271647|Experimental|placebo|
3238607|NCT01271660|Active Comparator|Pregabalin|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
3342925|NCT02200848|Experimental|Lenalidomide, Ibrutinib, Rituximab|Rituximab on day 1, lenalidomide days 1-21 and ibrutinib continuously for 6 cycles or until disease progression or intolerance to the combination. Single agent ibrutinib will then be continued until disease progression or intolerance.
3342926|NCT02200874||before NST-implementation (group A)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: Before implementation of Nutrition Support Team (NST).
3342927|NCT02200874||After NST-implementation (group B)|Patients with a NRS of 3 or more than 3 or NUTRIC score of 4 or more than 4 within the first three days after admittance to hospital. Time point: After implementation of Nutrition Support Team (NST).
3342928|NCT02200887||Advanced Parkinsons Disease|Polysomnogram
3342929|NCT02200887||Parkinsons Disease with Dyskinesia|Polysomnogram
3238608|NCT01271660|Placebo Comparator|Placebo|"30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period."
3238609|NCT01271673||Women undertaking Breast Self Examination|Women attending Preventive Oncology Clinic during the month of November- December 2010,and undertaking BSE training whose Residential address mentioned as Mumbai and whose Contact number is available.
3342930|NCT02200887||De novo Parkinsons Disease|Polysomnogram
3342931|NCT02200887||Healthy Volunteers|Polysomnogram
3342932|NCT02200900|Active Comparator|Group 1 ( CPAP followed by HFNC)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.
3342933|NCT02200900|Active Comparator|Group 2 (HFNC followed by CPAP)|In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.
3342934|NCT02200913|Experimental|core stabilization exercise|core stabilization exercise 2 times/week 10 weeks
3342935|NCT02200913|Experimental|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
3238610|NCT01271699||Observation|Patients at age 18-50 with a confirmed or probably diagnosis of Multiple Sclerosis according to the McDonald diagnostic criteria for MS
3238611|NCT01271738|Active Comparator|Breast Conserving Surgery (BCS)|
3238612|NCT01271738|Active Comparator|Breast Conserving Surgery with Additional 5 Margins (BCS + M)|
3342936|NCT02200926|Experimental|Placebo|The breathing was performed normally in this groups.
3342937|NCT02200926|Experimental|Loaded breathing training|subjects will trained to inspire deeply against the resistance setting by using BreathMAX® at the loaded of 18 cmH2O with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
3238613|NCT01271751|Experimental|GFT505 80mg|
3238614|NCT01271751|Placebo Comparator|Matching placebo|
3238615|NCT01271764|No Intervention|endometrial cancer|
3238616|NCT01271777|Experimental|GFT505 80mg|
3342938|NCT02200926|Experimental|Unloaded breathing training|subjects will trained to inspire deeply (no resistance) with breathing frequency control at 6 breaths/minute. Breathing pattern will be controlled at duty cycle of 0.4 (inspiratory time = 4 sec and total respiratory time = 10 sec). The training program will be performed at home for 30 minutes/day, 7 days/week for 8 weeks.
3342939|NCT02200939|Experimental|Partial-thickness tear|Medium or large partial-thickness tear or very small full-thickness tear of the supraspinatus tendon surgically treated by implantation of the bioinductive implant.
3342940|NCT02200939|Experimental|Full-thickness tear|Medium or large full-thickness tear of the supraspinatus tendon surgically treated with the bioinductive implant adjunctive to surgical repair.
3342941|NCT02200952||Patients at risk of OHSS|Patients at risk of OHSS on the oocytes triggering day with an oestradiol > 4000pg/ml or a number of follicles greater than 24 of a diameter greater than 12 mm
3342942|NCT02200965|Active Comparator|Received a letter on 3 occasions|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
3342943|NCT02200965|Active Comparator|Received letter on 1 occasion|"My Diabetes, My Information, My Plan Document:~To deliver a structured, understandable, well designed, user friendly, user developed and approved document / letter to all people with diabetes that contains all information about their key care processes in diabetes to promote self-awareness, patient activation and process completion of their own diabetes outcomes.~This communication (3 mailings per patient (at 0 and 3 and 6 months) will be distributed to the 50% of the whole epidemiological base of people with diabetes (n=>16,000) with the non-interventional group (that will receive the same document once at 3 months) acting as control."
3375857|NCT03685175|Experimental|Feasibility Study|Hyperpolarized 13C-pyruvate injection, is given to patients after completing cardiotoxic therapy, and again at 1 to 6 six months after the first cardiac MRI scan
3238617|NCT01271777|Placebo Comparator|Matching placebo|
3238618|NCT01271790|Active Comparator|Arm 1|GS-9451 and Tegobuvir (GS-9190) in combination with Pegasys® and Copegus® for 16 or 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3238619|NCT01271790|Active Comparator|Arm 2|GS-9451 (active) and Tegobuvir (GS-9190) placebo in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® may be continued for up to 48 weeks total duration depending on individual response to therapy
3238620|NCT01271790|Placebo Comparator|Arm 3|Placebo matching Tegobuvir (GS-9190) and GS-9451 in combination with Pegasys® and Copegus® for 24 weeks; Pegasys® and Copegus® will be continued for up to 48 weeks total duration
3238621|NCT01271816||Presymptomatic ARVC gene carriers|ARVC gene positive patients without manifest ARVC after standard screening clinical testing.
3238622|NCT01271829|No Intervention|Control|While on the control arm subjects will be given a meal with no avocado.
3238623|NCT01271829|Active Comparator|Avocado supplement|While on the avocado supplement arm subjects will be given a meal in which a given amount of calories will be replaced by calories contributed by avocados.
3342944|NCT02200978|Active Comparator|ATO and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; ATO 0.16mg/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20 mg (1-3 years), or 30 mg ( > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; ATO 0.16mg/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① ATO 0.16mg/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance."
3342945|NCT02200978|Experimental|RIF and chemotherapy|"Induction:~ATRA 25mg/m2 d1-CR ≯42 days; RIF 0.135/kg d5-CR ≯42 days; mitoxantrone (MA) 10mg/m2 d3, or 7mg/m2 d2-4 (high risk).~Consolidation 1:~ATRA 25mg/m2 d1-15; MA 10mg/m2 d1-2; Intrathecal injection (IT)：Ara-C 15mg (age < 1 year), or 20mg (age 1-3 years), or 30mg (age > 3 years), dexamethasone 2mg.~Consolidation 2:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Consolidation 3:~ATRA 25mg/m2 d1-15; RIF 0.135/kg d1-15; MA 10mg/m2 d1; Ara-C 1g/m2 q12h d1-2 (high risk); IT.~Maintenance:~① RIF 0.135/kg.d w1-2; ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. ② ATRA 25mg/m2.d w1-2; MTX 20mg/m2 qw w3-12; 6MP 50mg/m2 qn w3-12. Rotation between ① and ② until the end of maintenance treatment."
3342946|NCT02200991|Experimental|Lixisenatide|"Lyxumia solostar: Initially started with 10 μg once-daily and increased up to 20 μg once daily (dose increased by 5 μg every week), subcutaneous injection in the abdomen, administered 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
3342947|NCT02200991|Active Comparator|Sitagliptin - Januvia|"50 mg tablet, administered orally once-daily, 30 minutes before breakfast. The period of administration is 4 weeks.~Lantus solostar as base treatment: Subcutaneous injection in the abdomen."
3342948|NCT02201004|Experimental|tofogliflozin|Tofogliflozin administered once daily for 52 weeks. Insulin administered as base treatment.
3342949|NCT02201004|Placebo Comparator|placebo|Placebo administered once daily for 16 weeks. After 16-weeks, Tofogliflozin administered once daily for 36 weeks. Insulin administered as base treatment.
3342950|NCT02201030|Experimental|NBP606|13-valent pneumococcal conjugate vaccine
3342951|NCT02201030|Active Comparator|Prevnar13|13-valent pneumococcal conjugate vaccine
3342952|NCT02201043|Active Comparator|Thalidomide 150mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks;100mg/qd.po.2weeks; 150mg/qd.po.to the end
3342953|NCT02201043|Active Comparator|Thalidomide 100mg|Thalidomide 25mg/qd.po.2weeks; 50mg/qd.po.2weeks; 100mg/qd.po.to the end
3342954|NCT02201043|Placebo Comparator|Placebo|Placebo po.
3342955|NCT02201069|Experimental|health coaching|12 weeks of health coaching using weekly contact in the first month and biweekly contacts in months 2-3.
3342956|NCT02201082|Experimental|Nebulization and airway clearance technique|nebulization combined to airway clearance
3342957|NCT02201082|Active Comparator|Nebulization|nebulization
3342958|NCT02201095|No Intervention|Normal care|Normal care - no active warming
3342959|NCT02201095|Active Comparator|Forced air warming|Underbody forced air warming blanket
3342960|NCT02201095|Active Comparator|Conduction warming mattress|Underbody conduction warming mattress
3342961|NCT02201121|Experimental|phenylephrine group, dopamine group, ephedrine group|"phenylephrine group: use the phenylephrine to increase the SAP from low to high level.~dopamine group: use the dopamine to increase the SAP from low to high level. ephedrine group:use the ephedrine to increase the SAP from low to high level."
3342962|NCT02201134|Other|sevoflurane|
3342963|NCT02201147|Experimental|cold biopsy polypectomy|
3342964|NCT02201147|Experimental|Cold snare polypectomy|
3342965|NCT02201160|Active Comparator|omega 3|The subjects will take 4 capsules/day during 6 months. Each capsule of the active n-3 PUFA supplement contained 500 mg of fish oil (each capsule provides 300 mg of n-3 PUFA (EPA+DHA) with 3.75 U vitamin E to prevent peroxidation).
3342966|NCT02201160|Placebo Comparator|Sun Flower|The subjects will take 4 capsules/day during 6 months. The placebo capsule contained 500 mg of sunflower oil with 3.75 U vitamin E.
3342967|NCT02201173|Experimental|Locomotor Training|
3342968|NCT02201186|Experimental|manuka honey enema treatment|Study patients diagnosed with acute pouchitis after bowel surgery for ulcerative colitis will perform manuka honey enemas twice a day for 30 days.
3342969|NCT02201199|Active Comparator|insulin glargine U100|1 single dose
3342970|NCT02201199|Experimental|insulin glargine U200|1 single dose
3342971|NCT02201199|Experimental|insulin glargine U500|1 single dose
3238624|NCT01271829|Active Comparator|Avocado included|While on the avocado included arm subjects will be given a meal in which the calories of avocado will be added to the calories of the control meal.
3342972|NCT02201225|Active Comparator|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
3342973|NCT02201225|Sham Comparator|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve twice daily
3342974|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in tube)|1% diclofenac sodium plus 3% menthol gel (in 30g aluminium tube). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3342975|NCT02201238|Experimental|Diclofenac sodium/menthol gel (in roll-on device)|1% diclofenac sodium plus 3% menthol gel (in roll-on applicator device supplied in 30g plastic bottles). Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3342976|NCT02201238|Active Comparator|Diclofenac sodium tablets|50mg diclofenac sodium tablets administered orally, three times daily for three consecutive days with 6h between adjacent doses on the same day
3342977|NCT02201238|Active Comparator|Voltaren gel|Voltaren gel supplied in 100g aluminium tube. Dose given- 4g applied topically to a 400cm2 (20cm x 20cm) area of the skin, four times daily for three consecutive days with 5h between adjacent doses on the same day
3342978|NCT02201264||Primary PCI for STEMI patients|Primary PCI for patients presenting with ST elevation MIs
3342979|NCT02201303|Experimental|Part 1|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of CXCL1 will be added to whole blood in vitro and CD11b up regulation on peripheral blood neutrophils will be analyzed
3342980|NCT02201303|Experimental|Part 2|Blood sample will be collected from the RSV-infected children <2 years and healthy adults participants. Escalating concentrations of danirixin will be added to whole blood in vitro with a fixed concentration of CXCL1 to determine inhibition of CD11b expression on peripheral blood neutrophils
3342981|NCT02201316|Experimental|Sequence 1 (ABC)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342982|NCT02201316|Experimental|Sequence 2 (ACB)|Subjects will receive treatments in the sequence ACB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342983|NCT02201316|Experimental|Sequence 3 (BAC)|Subjects will receive treatments in the sequence BAC where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342984|NCT02201316|Experimental|Sequence 4 (BCA)|Subjects will receive treatments in the sequence BCA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342985|NCT02201316|Experimental|Sequence 5 (CAB)|Subjects will receive treatments in the sequence CAB where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342986|NCT02201316|Experimental|Sequence 6 (CBA)|Subjects will receive treatments in the sequence CBA where, A=Single dose of reference mosapride citrate 5mg (GASMOTIN); B= Single dose of formulation 1 GR107719B 5mg (mosapride citrate); C= Single dose of formulation 2 GR107719B 5mg (mosapride citrate). All treatments will be administered orally in fasted state. Each treatment will be separated by a washout period of at least 7 days and no more than 14 days.
3342987|NCT02201342|Experimental|Udenafil Dose Level 1 qd|Udenafil tablet dose Level 1 daily for 5 days
3342988|NCT02201342|Experimental|Udenafil Dose Level 1 bid|Udenafil Dose Level 1 twice daily for 5 days.
3342989|NCT02201342|Experimental|Udenafil Dose Level 2 qd|Udenafil tablet dose level 2 once daily for 5 days.
3342990|NCT02201342|Experimental|Udenafil Dose Level 2 bid|Udenafil tablet dose level 2 twice daily for 5 days
3342991|NCT02201342|Experimental|Udenafil Dose Level 3 qd|Udenafil tablet dose level 3 daily for 5 days
3342992|NCT02201342|No Intervention|No Drug|No drug
3342993|NCT02201355|Experimental|chemoradiation|Hypofractionated, PET-directed, Intensity Modulated Radiotherapy Concurrent with Weekly Cisplatin Chemotherapy
3342994|NCT02201368|Experimental|Triheptanoin|
3342995|NCT02201368|Active Comparator|MCT (Medium-Chain Triglycerides)|
3342996|NCT02201381|Experimental|Metabolic Treatment|"Subjects will take the following treatments and have their data collected from their medical records every 3 months.~Oral atorvastatin up to 80mg uid, for study duration.~Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration.~Oral doxycycline 100mg uid, for study duration.~Oral Mebendazole 100mg uid, for study duration."
3342997|NCT02201407||CHB Participants Treated With Peginterferon alfa-2a|As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with local labeling and not directed by the protocol. Participants with CHB who are receiving peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics, and in line with the local labeling will be followed for the duration of treatment with peginterferon alfa-2a (48 weeks) and up to 24 weeks after peginterferon alfa-2a treatment (72 weeks in total).
3342998|NCT02201433||medical staff and member of an association|"members of medical staff and member of an association of parents of premature infants.~This cohort is necessary to build protocol interview for part 2 of the study"
3342999|NCT02201433||fathers|fathers of preterm newborns
3343000|NCT02201433||fathers or médical staff|This cohort is build for data validation. We will include fathers who have experienced this situation. Caregivers of NICU who are not participating in the first part
3343001|NCT02201459|Active Comparator|Nilotinib|Control arm, this compound been licensed in this indication.
3343002|NCT02201459|Experimental|Peg-IFN alfa 2a (Pegasys®) and Nilotinib|Arm testing the efficacy of a combination of nilotinib and Peg-IFN alfa 2a as frontline therapy for first line chronic phase CML patients.
3238625|NCT01271842||Extra corporeal oxygenation|Survivors of ARDS due to influenza A (H1N1)2009 infection who needed an extracorporeal oxygenation at the time of infection
3238626|NCT01271842||No extracorporeal oxygenation|Survivors of ARDS due to influenza A (H1N1) 2009 infection who did not need an extracorporeal oxygenation at the time of infection
3238627|NCT01271881|Active Comparator|Percutaneous Transluminal Angioplasty (PTA) alone|Intervention: Procedure: PTA alone without use of the GORE VIABAHN
3238628|NCT01271881|Experimental|PTA with covered stent|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
3343003|NCT02201485|Active Comparator|PTA in combination with stent-placement|In this group, the patients will undergo percutaneous balloon angioplasty with or without stent-placement angioplasty in combination with stent-placement.
3343004|NCT02201485|Active Comparator|PTA alone|In this group, the patients will undergo percutaneous balloon angioplasty alone. The patients will transfer to the stent placement in the following cases: 1) reocclusion with thrombosis; and 2) at least 2 reocclusion events.
3343005|NCT02201498|Active Comparator|Formocresol/OZE|Conventional pulpotomy technique, with formocresol and zinc oxide eugenol
3343006|NCT02201498|Active Comparator|Biodentine|New technique, with biodentine
3343007|NCT02201511|Experimental|Arm 1|
3343008|NCT02201511|Experimental|2|
3343009|NCT02201511|Experimental|3|
3343010|NCT02201511|Experimental|4|
3343011|NCT02201537|Other|Imag-NCT|"The ultrasound functional imaging will be performed at J15 (before the patient is discharged from service Transplantation) and at 3 and 12 months after the transplant.~The functional imaging examinations will be held as follows:~1st stage - the conventional Doppler ultrasound:~2nd stage - the elastography:.~Step 3 - CEUS: It is performed on an ultrasound machine with a specific module with the same probes as conventional ultrasound. It requires the injection of 1.5 ml of SonoVue ®, a contrast ultrasound.~Renal biopsy will be performed after the functional ultrasound at 3 and 12 months."
3343012|NCT02201550||Liraglutide|Patients with type 2 diabetes undertaking treatment with liraglutide
3343013|NCT02201563|Experimental|Minocycline|oral Minocycline 100 mg twice a day for 3 months.
3343014|NCT02201576|Experimental|Bortezomib|Five plasma exchanges, two cycles of bortezomib + dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
3343015|NCT02201576|Active Comparator|Control|Five plasma exchanges, dexamethasone, 4 courses of polyclonal intravenous immunoglobulins
3343016|NCT02201589|Experimental|Endovascular repair of ascending aorta|Endovascular repair with Valiant PS-IDE Stent Graft
3343017|NCT02201602|Experimental|Gliclazide|Gliclazide, 80 mg tablet, half to maximal dose, 3 weeks
3343018|NCT02201602|Active Comparator|Glibenclamide|Glibenclamide, 5 mg tablet, half to maximal dose, 3 weeks
3343019|NCT02201615|Experimental|Perineal Massage & Control|"Perineal Massage every 30 min, a 10 min 4 times in the first stage of labour, 1 times in the second stage of labour.~Control routine care procedure at the clinic."
3343020|NCT02201628|Experimental|Nasopharyngeal and oesophageal temperatures|An oesophageal and nasopharyngeal temperature probe will be placed and temperature will be measured at these site
3343021|NCT02201641|Experimental|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
3343022|NCT02201641|Experimental|Cone Beam computed tomography (CBCT)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
3343023|NCT02201641|Active Comparator|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
3343024|NCT02201641|Active Comparator|Glass ionomer cement ( Fuji IX™)|Glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
3238629|NCT01271894|Experimental|Reduced dose Efavirenz arm|Participants randomized in main study to receive EFV (400 mg once daily; 2 x 200 mg + 1 x placebo once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
3343025|NCT02201654|Other|EBUS patients|All patients in our study are in the same arm, as each patient serves as their own internal control. More specifically, each enrolled patient will receive both traditional EBUS (with the usage of stylet) and experimental EBUS (EBUS without a stylet) at each lymph node that is included in the experimental analysis.
3343026|NCT02201667|Experimental|Ticagrelor group|Patients wil be given 180 mg loading dose of ticagrelor and 300mg loading dose of aspirin followed by PCI, then will receive 90 mg ticagrelor twice daily with aspirin maintenance dose to 30 days after randomization.
3343027|NCT02201667|Active Comparator|Clopidogrel group|Patients will be given clopidogrel 300mg loading dose and 300mg loading dose of aspirin followed by PCI, then will receive 75mg clopidogrel once with aspirin maintenance dose to 30 days after randomization.
3343028|NCT02201680||parents and children|Anxiety tests
3343029|NCT02201693|Experimental|Cyclic exclusive MODULEN IBD|Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
3343030|NCT02201693|Experimental|MODULEN IBD supplementation (25% of caloric requirements)|MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
3343031|NCT02201706|Experimental|Multi-electrocoagulation retinectomy|Retinal re-detachment in eyes with silicone oil filled,a modified surgery named Multi-electrocoagulation retinectomy will be used to re-attach the retina.
3343032|NCT02201719||Hysterectomy Adenomyosis|Adenomyosis present
3343033|NCT02201719||Hysterectomy no adenomyosis|Adenomyosis not present
3343034|NCT02201732|Experimental|Arm A : Operative hysteroscopy|operative hysteroscopy with direct visualization
3343035|NCT02201732|Active Comparator|Arm B : Aspirative curettage|curettage is the standard surgical treatment in most centers
3343036|NCT02201758|Placebo Comparator|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
3343037|NCT02201758|Experimental|flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
3343038|NCT02201797|Experimental|DCE and DWI MRI|MRI SCAN 1 and MRI SCAN 2 must be completed no less than 2 calendar days (to ensure 24 hours for clearance of gadolinium) and no greater than 14 days apart, and both must be completed prior to new treatment initiation. The same MRI unit and configuration must be used for MRI SCAN 1 and MRI SCAN 2.
3343039|NCT02201810|Experimental|2nd level intervention: Rate Reduction|Rate reduction intervention
3343040|NCT02201810|Experimental|2nd level intervention: Recycling|Recycling Group
3343041|NCT02201810|Experimental|2nd level intervention: Choice|Choice Group
3343042|NCT02201823|Experimental|ABTL0812|ABTL0812 oral
3343043|NCT02201836|Active Comparator|One time music therapy session|One time music therapy session which consists of music meditation, including as assessment/evaluation of confined body breathing function as expressed through drawing and coloring post music imagery session. This is followed by an entrainment wind playing/breath expansion music therapy intervention. At the end of the session, the subjects are given a donated wind instrument for play at home.
3343044|NCT02201836|Active Comparator|Weekly group music therapy intervention|The weekly group music therapy intervention consists of children and teens using guided visualization and expressing their fears and or fantasies related to breathing with one another. This is followed by creative music improvisations with part-playing on flutes, slide whistles, recorders and melodicas.
3343045|NCT02201836|No Intervention|Control|
3238630|NCT01271894|Active Comparator|Normal Efavirenz dose arm|Patients randomized in the main study to receive EFV (600 mg once daily; 3 x 200 mg once daily) plus tenofovir/emtricitabine (300/200 mg) fixed-dose combination once daily
3238631|NCT01271920|Experimental|AUY922 + Trastuzumab|
3238632|NCT01271972|Experimental|Cohort 1|Dose 1
3343046|NCT02201849|Experimental|Study Drug|Oral capsules
3343047|NCT02201849|Active Comparator|Active Control|Oral capsules
3343048|NCT02201849|Placebo Comparator|Placebo|Oral capsules
3343049|NCT02201862||Euploid Subjects|Subject's with fetal euploidy confirmed by chromosome analysis
3238633|NCT01271972|Experimental|Cohort 2|Dose 2
3238634|NCT01271972|Experimental|Cohort 3|Dose 3
3238635|NCT01271972|Experimental|Cohort 4|Dose 4
3343050|NCT02201862||Aneuploid Subjects|Subject's with fetal aneuploidy confirmed by chromosome analysis
3343051|NCT02201875||Healthy subjects|male, aged 18-65 moderately trained healthy, no treatment
3343052|NCT02201875||obstructive sleep apneas|patients with apnea/hypopnea index > 15 BMI < 30 Age < 50 yrs
3343053|NCT02201875||cardiac failure|NYHA class I to III ejection fraction < 40% age < 65 yrs BMI < 30
3343054|NCT02201888|Experimental|Computer-assisted cognitive training|Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention (4 minutes), attention/perception (5 minutes), working memory (8 minutes), auditory and visual memory (8 minutes), executive function (10 minutes), language (6 minutes), and games (4 minutes).
3343055|NCT02201888|Active Comparator|Computerized active condition|Patients allocated to this condition completed the same number of sessions as the cognitive training group but followed a computerized typing program (www.rapidtyping.com). This had similar design characteristics to the CRT condition, in that it was hierarchically organized with exercise level of difficulty being adjusted to the individual's level of performance and feedback being given at the end of each exercise. Additionally, patients in this condition played computerized games requiring typing (crosswords, word puzzles, etc) and were taught basic internet navigation by a supervisor. Exposure to the computer was of equivalent duration to the CRT condition.
3343056|NCT02201888|Placebo Comparator|Treatment as usual|Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities
3343057|NCT02201914|Experimental|Clomiphene citrate|
3343058|NCT02201914|Experimental|Daily FSH and LH plus Cetrorelix|
3238636|NCT01271972|Experimental|Cohort 5|Dose 5
3238637|NCT01271972|Experimental|Expansion Cohort 1|Dose 4
3238638|NCT01271972|Experimental|Expansion Cohort 2|Dose 5
3238639|NCT01271985|Active Comparator|PolyPill|PolyPill once daily and Minimal Care
3238640|NCT01271985|Active Comparator|Minimal care|Minimal care.
3343059|NCT02201914|Experimental|Triptorelin plus daily FSH and LH|
3343060|NCT02201927|Experimental|patient with right parietal lobe lesion|Patient with right parietal lobe lesion
3343061|NCT02201927|Experimental|patient stroke|patient with cerebral vascular accident
3343062|NCT02201927|Experimental|healthy volunteers|healthy volunteers
3343063|NCT02201966||Female gymnasts with low back pain|Subset of competitive female gymnasts who report significant low back pain that affects their ability to perform gymnastics.
3343064|NCT02201966||Female gymnasts without low back pain|Subset of competitive female gymnasts who deny significant low back pain that affects their ability to perform gymnastics.
3238641|NCT01271985|No Intervention|Usual care|Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.
3238642|NCT01271998|Experimental|healthy volunteer|healthy volunteers
3238643|NCT01272024|Active Comparator|Information/Education Group|Assistance in using Symptom Management Toolkit
3238644|NCT01272024|Experimental|Nurse Intervention|Participants are given intensive nurse contacts to reduce uncertainty and maximize problem solving, and later, to transition to the treatment phase of their cancer.
3238647|NCT01272050|Active Comparator|Arm A: 64 Gy - Radiation Therapy|Arm A: 64 Gy (32 x 2 Gy) without hormonal treatment
3238648|NCT01272050|Active Comparator|Arm B: 70 Gy - Radiation Therapy|Arm B: 70 Gy (35 x 2 Gy) without hormonal treatment
3238649|NCT01272063||Dry AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
3238650|NCT01272089|Experimental|Pataday|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once daily for one week
3238651|NCT01272102||Glaucoma|subjects with glaucoma
3238652|NCT01272154|Experimental|Primary cervical dystonia Patients|
3238653|NCT01272154|Experimental|Primary upperlimb Dystonia Patients|
3238654|NCT01272154|Experimental|Secondary Cervical or Upperlimb Dystonia due to cerebral palsy|
3343065|NCT02201979||Breast lift in combination with implants.|Patients undergoing breast lifts in combination with implants are studied using laser fluorescent imaging to evaluate blood supply.
3343066|NCT02201992|Experimental|Arm A (crizotinib)|Patients receive crizotinib PO BID on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3343067|NCT02201992|Active Comparator|Arm B (observation)|Patients undergo observation.
3343068|NCT02202005|Experimental|Nevirapine|
3343069|NCT02202005|Active Comparator|Viramune®|
3343070|NCT02202018|Experimental|Active KT Intervention|CKD clinics receiving the active knowledge translation intervention.
3343071|NCT02202018|No Intervention|Usual standard of care|Clinics will continue their standard of care education and approach to use of home dialysis.
3343072|NCT02202057||Parkinson's disease|Men and women with Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation and Fluoroscopic swallowing evaluation.
3343073|NCT02202057||Healthy adults|Men and women without Parkinson's disease, between 45 and 85 years of age. The following will be done: Respiratory resistive load on inhalation.
3343074|NCT02202070|Experimental|Botox injection first, followed by placebo|50 units Botox injection in masseter and temporalis muscles in the first 3 months, then second injection of normal saline at placebo in second 3 months
3343075|NCT02202070|Experimental|Placebo injection first, followed Botox|Injection of normal saline at placebo in first 3 months, then 50 units Botox injection in masseter and temporalis muscles in the second 3 months.
3343076|NCT02202083|Experimental|oxytocin|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
3343077|NCT02202096|Experimental|Intervention (plus usual care)|Patient education: One-on-one visit Discharge planning: Assessment of barriers to discharge Medication reconciliation: Patient medication review Appointment before discharge: Additional measure to ensure awareness of next clinic visit Transition coach Patient-centered discharge instructions: Enhanced Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology Timely follow-up: Barriers to clinic follow-up visits will be discussed Timely PCP communication Follow-up telephone call Patient hotline: 24 hour follow-up following call to Ask My Nurse number
3343078|NCT02202096|No Intervention|Usual Care|Usual care-Standard of care that all colorectal cancer patients normally receive
3238655|NCT01272154|Other|Healthy volunteers|
3238656|NCT01272206|Experimental|A|
3238657|NCT01272206|Experimental|B|
3238658|NCT01272258|Experimental|Arm 1|PRO 140
3238659|NCT01272258|Placebo Comparator|Arm 2|Placebo
3238660|NCT01272271||Children|
3238661|NCT01272271||Adults|
3238662|NCT01272297|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
3238663|NCT01272310|Experimental|Combination therapy|
3238664|NCT01272323||Placebo|Subjects previously randomised to receive placebo in study CP005
3343079|NCT02202122||Study Group|OSA Scoring
3343080|NCT02202148||alcohol withdrawal|
3343081|NCT02202174||Supraglottic Airway Device|Patients will receive a supraglottic airway device as a primary means of ventilation. The following devices may be used: LMA Unique, LMA ProSeal, LMA Supreme, LMA Flexible, Ambu Aura-I, Ambu Aura Once, Air-Q, I-Gel, or other supraglottic airway device. Choice of the device will be clinician dependent and based on the patients body weight per manufacturer guidelines
3343082|NCT02202187|Experimental|GSK2140944|Dose range 100mg to 3000mg single dose
3343083|NCT02202187|Placebo Comparator|Matching Placebo|Placebo
3343084|NCT02202200|Experimental|PD-0332991|
3343085|NCT02202213|Experimental|Lu AF11167 hard capsules; 0.25, 0.5 and 1 mg|"Part A: Lu AF11167 monotherapy Part B: Lu AF11167 adjunctive therapy to risperidone~Three times daily oral dosing for 14 days."
3343086|NCT02202213|Placebo Comparator|Matching placebo|Daily oral dosing matching the experimental arm.
3343087|NCT02202226|Experimental|Lu AF35700 oral solution (1 mg/mL)|Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
3343088|NCT02202226|Placebo Comparator|Matching placebo|Oral solution
3238665|NCT01272323||Cat-PAD Group 1|Subjects previously randomised to receive Cat-PAD dose 1 in study CP005
3238666|NCT01272323||Cat-PAD Group 2|Subjects previously randomised to receive Cat-PAD dose 2 in study CP005
3343089|NCT02202239|Experimental|Group E|Etomidate was used in both induction and maintenance of anesthesia.
3343090|NCT02202239|Active Comparator|Group P|Propofol was used in both induction and maintenance of anesthesia.
3343091|NCT02202265|Active Comparator|Control diet (standard dietary)|Patients will receive a control diet based on standard dietary guidelines
3238667|NCT01272336|Active Comparator|AIH/Sham|Subjects with chronic, motor-incomplete SCI receive AIH and then SHAM
3238668|NCT01272336|Active Comparator|Sham/AIH|Subjects with chronic, motor-incomplete SCI receive SHAM and then AIH
3238669|NCT01272349|Experimental|Low oxygen|
3238670|NCT01272349|Sham Comparator|Room Air|
3238671|NCT01272362|Experimental|Indacaterol|
3238672|NCT01272375|Experimental|Treatment A PF-04764793|PF-04764793 using inhaler A
3238673|NCT01272375|Experimental|Treatment B PF-04764793|PF-04764793 using inhaler A
3238674|NCT01272375|Experimental|Treatment C PF-04764793|PF-04764793 using inhaler A
3238675|NCT01272375|Experimental|Treatment D PF-04764793|PF-04764793 using inhaler A
3238676|NCT01272375|Experimental|Treatment E PF-04764793|PF-04764793 using inhaler B
3238677|NCT01272375|Experimental|Treatment F PF-04764793|PF-04764793 using inhaler B
3238678|NCT01272375|Experimental|Treatment G PF-04764793|PF-04764793 using inhaler B
3238679|NCT01272401||Breast cancer patients and survivors|
3343092|NCT02202265|Experimental|Olive oil (30ml a day)|Patients will receive a control diet based on standard dietary guidelines + 30ml of olive oil a day
3343093|NCT02202265|Experimental|Nuts (30g a day)|Patients will receive a control diet based on standard dietary guidelines plus 30g of nuts a day
3343094|NCT02202278||ovarian hyperstimulation patients|Moderate OHSS is defined as abdominal distension and discomfort, nausea with or without vomiting, ovarian enlargement (ovarian size of 8-12 cm) and ascites that revealed by ultrasonografic examination. Severe OHSS criteria is defined as ovarian enlargement, ascites with or without hydrothorax, haematocrit >45%, weight gain >2 kg, white blood cell count >15.000, oliguria, creatinine of 1.0-1.5, creatinine clearance of >50 ml/min, liver dysfunction.
3343095|NCT02202278||without ovarian hiperstimulation|Control group is composed of patients who underwent long luteal protocol but do not demonstrate symptoms of OHSS
3343096|NCT02202291|Experimental|Patient with Raynaud's phenomenon|
3343097|NCT02202304|Experimental|Chlorhexidine/Thymol varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush by painting it over the surfaces of these teeth."
3343098|NCT02202304|Placebo Comparator|Placebo varnish|"Participants to the study will receive an application of either the placebo or the product being studied every 3 months. This will be applied on all abutment teeth using a microbrush and painting it on all the surfaces of these teeth.."
3343099|NCT02202330|Placebo Comparator|Standard Care, Organized Discharge|Stroke patients are given instructions before discharge regarding diet, need for rehabilitation, possible complications, medication use and information booklets are also handed out. This information is imparted by a multidisciplinary team consisting of a neuro physician, a stroke nurse, a dietitian and a physiotherapist. These are verbal instructions and handouts are written in English. On the day of discharge, or 24 hours prior to discharge, a discharge coordinator details the skills learnt . A detailed written discharge summary is given out detailing all aspects of care, follow-up, medications and test results.
3343100|NCT02202330|Experimental|Video Arm, Standard Discharge|"Intervention is as follows:~5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
3343101|NCT02202343|Experimental|School-based health and nutrition education|
3343102|NCT02202356|Experimental|ALS-008176 Single Dose|Single dose of ALS-008176 administered orally as a suspension
3238680|NCT01272414|Experimental|BoTox Treatment|Subjects receive BoTox injection to levator complex
3238681|NCT01272414|Placebo Comparator|Saline injection|Saline injection to levator complex
3343103|NCT02202356|Placebo Comparator|Placebo Single Dose|Single dose of placebo administered orally as a suspension
3238682|NCT01272427|Experimental|noncaloric beverage|noncaloric sweetened beverage administered 30 min prior to mealtime
3238683|NCT01272427|Experimental|noncaloric beverage (60 min)|noncaloric sweetened beverage administered 60 min prior to mealtime
3343104|NCT02202356|Experimental|ALS-008176 Multiple Doses|Multiple doses of ALS-008176 administered orally as a suspension
3343105|NCT02202356|Placebo Comparator|Placebo Multiple Doses|Multiple doses of placebo administered orally as a suspension
3343106|NCT02202369|Experimental|Multimodal Analgesia (MMA) Treatment|
3343107|NCT02202369|Active Comparator|Standard of Care Pain Managment Protocol|
3343108|NCT02202382|Placebo Comparator|non-V + P group|no surgery and placebo (12 weeks)
3238684|NCT01272427|Experimental|glucose beverage|glucose beverage administered 30 min prior to mealtime
3343109|NCT02202382|Active Comparator|V + P group|Surgery with placebo (12 weeks)
3343110|NCT02202382|Active Comparator|non-V + KRG group|no surgery with KRG (korean red ginseng, 1.5 gm daily 12weeks)
3343111|NCT02202382|Experimental|V + KRG group|Surgery with KRG (1.5 gm daily 12weeks)
3238685|NCT01272427|Experimental|glucose beverage (60 min)|glucose beverage administered 60 min prior to mealtime
3238686|NCT01272427|Experimental|whey protein beverage|whey protein beverage administered 30 min prior to mealtime
3343112|NCT02202395|Active Comparator|0.25mg|LTS 0.25mg,qd MTX qw
3343113|NCT02202395|Active Comparator|0.5mg|LTS 0.5mg, qd MTX qw
3343114|NCT02202395|Active Comparator|1.0mg|LTS 1.0mg,qd MTX qw
3343115|NCT02202395|Placebo Comparator|Placebo|Placebo qd MTX qw
3343116|NCT02202408|Experimental|SKI2670|"Single-dose escalation/ Subjects received an oral single dose of SKI2670 capsule by dosing group~-Dosing Group 1, Dosing Group 2, Dosing Group 3, Dosing Group 4"
3343117|NCT02202408|Placebo Comparator|Placebo|Subjects received an oral single dose of placebo capsule matched to the SKI2670 dose (Placebo for SKI2670)
3343118|NCT02202421|Active Comparator|T-ABA Parent Training Only|Participants in the T-ABA Parent Training Only group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
3238687|NCT01272427|Experimental|whey protein beverage (60 min)|whey protein beverage administered 60 min prior to mealtime
3343119|NCT02202421|Experimental|T-ABA Parent Group + Individual Therapy|Participants in the T-ABA Parent Group plus Individual Therapy group will be given Targeted Applied Behavior Analysis (T-ABA) Intervention with five weeks of parent group training and five weeks of parent-therapists one-on-one sessions. They will also be offered eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions.
3238688|NCT01272453||Control Group|Data from patients in the control group will be obtained retrospectively from patient medical records and stored image data
3238689|NCT01272453||Prospective Patient Group|Data from patients in the Flash group will be obtained prospectively from scanner consoles and medical records.
3238690|NCT01272466|Experimental|peptides from antiapoptotic proteins|
3238691|NCT01272479||HCV (+)|Hemodialysis patients with chronic hepatitis C
3238692|NCT01272479||HCV (-)|Hemodialysis patients without chronic hepatitis C
3238693|NCT01272479||Control|Healthy volunteers
3238694|NCT01272492|Experimental|Computer Use|Participants use the computer with the infant/toddler nutrition/feeding education modules
3238695|NCT01272492|No Intervention|Control|Only answers survey questions.
3238696|NCT01272505|Placebo Comparator|conventional SILC|Conventional method of single incision laparoscopic cholecystectomy
3238697|NCT01272505|Active Comparator|HS-SILC|
3238698|NCT01272531||lithium|All study subjects will be started on lithium and taken off other medications, such as antidepressants, antipsychotic or other mood stabilizers used to control their mood. They will be stabilized over a 3 month time period, observed for one month, the followed every 2 months for 2 years.
3238699|NCT01272531||valproate|Subjects that do not achieve stabilization or relapse while on lithium monotherapy will be started on valproate (VPA), in an identically designed prospective trial of VPA.
3238700|NCT01272544||participation in a dental health program|Group 1 - children who participated to a dental health program Group 2 - children who did not participate to dental health program
3343120|NCT02202447|Experimental|EC1169|"PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.~PART A: EC1169 given as IV bolus QW on Weeks 1 and 2 of a 3 week cycle. Dose based on dose escalation plan starting with 0.2 mg/m2~PART B: EC1169 cohort 1 - taxane naive mCRPC patients that have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide but must not have previously received taxane-based systemic chemotherapy for mCRPC (previous treatment with six cycles of docetaxel for metastatic castration-sensitive prostate cancer (mCSPC) is permissible).~PART B: EC1169 cohort 2 - taxane exposed mCRPC patients who have progressed while receiving (or subsequent to receiving) abiraterone and/or enzalutamide and who have progressed subsequent to receiving > 2 cycles of a taxane-based regimen for mCRPC."
3343121|NCT02202473|Active Comparator|Lamivudine|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd
3343122|NCT02202473|Experimental|Lamivudine+Oxymatrine Capsules|Lamivudine (Manufacturer: GlaxoSmithKline) 100mg po, qd; oxymatrine Capsules (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) 200 mg, po, tid.
3343123|NCT02202486||Migraine with aura|Brain MRI
3343124|NCT02202486||Migraine without aura|Brain MRI
3238701|NCT01272544||participation in a preventive program|Group 1 - children who participated to the preventive program Group 2 - children who did not participate
3238702|NCT01272557|Active Comparator|Sorafenib 400 mg bid (oral) continuously|Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).
3238703|NCT01272557|Experimental|q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19|During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period
3238704|NCT01272570||Aromatase Inhibitor|"Diagnosis of BCa- Histologic confirmed diagnosis of BCa: Stage 0, I, II, or III with no evidence of metastatic disease.~Treatment- AI as clinically indicated (AI may be anastrozole, exemestane or letrozole). Subjects may have had prior tamoxifen or raloxifene. Subjects may have had chemotherapy and/or radiation therapy. Must be within the first year of consecutive AI therapy. If a subject started AI, discontinued, then restarted, they will be accepted into the study as long as the past therapy did not exceed 12 months and the current therapy has not exceeded 12 months."
3238705|NCT01272570||Control|• No Diagnosis of cancer.- Patients must not have a diagnosis of any cancer (Not including a history of thyroid or skin cancer).
3238706|NCT01272596||Multiple Sclerosis Patients|Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
3238707|NCT01272609|Experimental|LCP + Timolol|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5 ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
3238708|NCT01272609|Active Comparator|LCP|Three sessions of LCP in 595 nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure © spaced out of 1 month.
3343125|NCT02202486||Chronic migraine|Brain MRI
3343126|NCT02202512|Experimental|BI 1060469 low dose|Low-Dose,Tablet,oral administration with 240 ml water,over 10 days
3343127|NCT02202512|Experimental|BI 1060469 high dose|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
3343128|NCT02202512|Active Comparator|Cimetidine|
3343129|NCT02202512|Active Comparator|Naproxen|
3343130|NCT02202512|Experimental|BI 1021958|High-Dose,Tablets,oral administration with 240 ml water, over 10 days
3343131|NCT02202525||Essential arterial hypertension|Patients with essential arterial hypertension needing a new antihypertensive therapy
3343132|NCT02202564|Experimental|LT+ADV-TK|Liver transplantation and double-dose ADV-TK/ganciclovir administration The first ADV-TK dose was administered before closing the peritoneal layer; the second ADV-TK dose was administered 2 months after LT; ganciclovir was slowly administered 36 hours after LT and twice daily for 14 days.
3343133|NCT02202564|Active Comparator|LT|Orthotopic liver transplantation
3343134|NCT02202577|Experimental|Chlorhexidine - Isopropyl alcohol|Pre-operative skin preparation with Chlorhexidine Gluconate- Isopropyl alcohol
3343135|NCT02202577|Experimental|Povidone-Iodine Scrub and Paint|Pre-operative skin preparation with Povidone-Iodine Scrub and Paint
3343136|NCT02202590|Experimental|Imaging|Subject will swallow the SECM capsule and Imaging will be performed using the SECM Imaging system.
3343137|NCT02202603|Active Comparator|Teriparatide group 1|Subcutaneous injection of Teriparatide
3343138|NCT02202603|Placebo Comparator|excipients|Oral pill without API
3343139|NCT02202603|Experimental|API|Oral administration of pill with API
3343140|NCT02202603|Experimental|API optimization 1|Oral administration of pill with API, for PK optimization #1
3343141|NCT02202603|Experimental|API optimization 2|Oral administration of pill with API, for PK optimization #2
3343142|NCT02202603|Experimental|API optimization 3|Oral administration of pill with API, for PK optimization #3
3343143|NCT02202603|Experimental|API optimization 4|Oral administration of pill with API, for PK optimization #4
3343144|NCT02202603|Experimental|API optimization 5|Oral administration of pill with API, for PK optimization #5
3238709|NCT01272622|Other|Arm I|"Children and adolescents >= 18 years of age new diagnosed with craniopharyngioma~>= 5 years of age and with incomplete resected tumor => randomized in two arms: immediate irradiation after surgery"
3238710|NCT01272622|Other|Arm II|incomplete resection, wait and watch, MRI-controls every 3 months, and irradiation at the time of progression of residual tumor
3238711|NCT01272648|Active Comparator|Rehabilitation|note intervention
3238712|NCT01272648|Placebo Comparator|Control|same radiotherapy but no rehabilitation
3343145|NCT02202603|Experimental|API optimization 6|Oral administration of pill with API, for PK optimization #6
3343146|NCT02202603|Experimental|API optimization 7|Oral administration of pill with API, for PK optimization #7
3343147|NCT02202603|Active Comparator|Teriparatide group 2|Subcutaneous injection of Teriparatide
3343148|NCT02202603|Experimental|Excipients|Oral pill without API
3343149|NCT02202603|Experimental|API Optimized|expanded group size with API in optimized dosage and administration form.
3343150|NCT02202629|Placebo Comparator|Cherry flavoured beverage 1|10floz cherry flavoured test article
3343151|NCT02202629|Experimental|Cherry flavoured beverage 2|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3238713|NCT01272674|Active Comparator|exercise training|4 weeks of supervised physical exercise training
3343152|NCT02202629|Experimental|Cherry flavoured beverage 3|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3343153|NCT02202629|Experimental|Cherry flavoured beverage 4|10floz of cherry flavoured test article with fruit, vegetable and herbal extracts
3343154|NCT02202642|Experimental|limbal stem cells|"Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of limbal stem cells need special cell-cell contact and cell-extracellular matrix interaction to support their survival"
3343155|NCT02202668|Experimental|TRS|
3343156|NCT02202681|Experimental|OFDI Capsule Imaging|Subject will swallow the OFDI Capsule and imaging will be performed using the OFDI system.
3238714|NCT01272674|No Intervention|control|sedentary lifestyle
3238715|NCT01272674|No Intervention|healthy control|
3343157|NCT02202694|Experimental|Intervention|Culturally Adapted Cognitive Behavior Therapy
3343158|NCT02202694|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3343159|NCT02202707|Other|Gabapentin|Open label single arm study. All participants will receive Gabapentin.
3238716|NCT01272687||Observation|Adults (>18 years) with a confirmed diagnosis of Parkinson's disease
3238717|NCT01272700|Experimental|PCV|Peak airway pressure were set to deliver a tidal volume of 10 ml/kg of ideal body weight
3343160|NCT02202720|Experimental|sevoflurane|
3343161|NCT02202733|Other|Cooking|A skill-based cooking intervention for caretakers of an overweight/obese child aged 3-10 years.
3343162|NCT02202772|Experimental|Gem and Low Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 2.5mg/100ml; 1 time a week for 6 weeks; 2 hours
3238718|NCT01272700|Active Comparator|VCV|After anesthetic induction, anesthesia maching were set to deliver a tidal volume of 10 ml/kg of ideal body weight
3238719|NCT01272713|Other|Oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
3238720|NCT01272713|Other|No oxygen therapy|"Standard acute coronary syndrome treatment as per hospital protocol~No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%."
3238721|NCT01272726||ADHD|Women with symptoms of ADHD. Women who either think they may have ADHD or have been previously diagnosed with ADHD but have not been treated for it.
3238722|NCT01272739|Experimental|Study Group|Subjects will take 500 mg of the investigational product 15 minutes prior to the 3 main meals of the day.
3343163|NCT02202772|Experimental|Gem and High Cab|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours
3343164|NCT02202772|Experimental|Gem, High Cab, and Low Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 66mg/100ml; 1 time a week for 6 weeks; 2 hours
3343165|NCT02202772|Experimental|Gem, High Cab, Mod Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 80mg/100ml; 1 time a week for 6 weeks; 2 hours
3343166|NCT02202772|Experimental|Gem, High Cab, High Cis|Gemcitabine: Intravesical; 2000mg/100ml; 1 time a week for 6 weeks; 2 hours Cabazitaxel: Intravesical; 5mg/100ml; 1 time a week for 6 weeks; 2 hours Cisplatin: Intravesical; 100mg/100ml; 1 time a week for 6 weeks; 2 hours
3343167|NCT02202798||Syringe device|Endotracheal tube cuff pressure measured by 2 new syringe devices.
3343168|NCT02202811|Experimental|Obstructive Sleep Apnea|Forced Desynchrony, OSA
3343169|NCT02202811|Placebo Comparator|Control|Forced Desynchrony, Control
3343170|NCT02202824|Experimental|Survey questionnaire version 1|Study participants will receive version 1 of the survey questionnaire
3238723|NCT01272739|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
3238724|NCT01272752|Experimental|Study Group|Subjects will take 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
3238725|NCT01272752|Placebo Comparator|Control Group|Subjects will take a placebo 15 minutes prior to the three main meals of the day.
3238726|NCT01272765|Placebo Comparator|Control Group|
3238727|NCT01272765|Experimental|Risperdal Group|Subjects who are on a stable dose of Ripserdal and taking 500 mg IHBG-10 15 minutes prior to the three main meals of the day.
3238728|NCT01272765|Experimental|Seroquel Group|Subjects who are on a stable dose of Seroquel and taking 500 mg of IHBG-10 15 minutes before the three main meals of the day.
3343171|NCT02202824|Experimental|Survey questionnaire version 2|Study participants will receive version 2 of the survey questionnaire
3343172|NCT02202824|Experimental|Survey questionnaire version 3|Study participants will receive version 3 of the survey questionnaire
3343173|NCT02202863|Experimental|Red Wine Grape Pomace Flour (WGPF)|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks, except for the daily intake of 20 g of WGPF. WGPF was consumed in bread, biscuits or as flour mixed with water during lunch. Bread and biscuits with 20% WGPF were prepared especially in a bakery. WGPF intake was supervised every day at lunch. Participants were asked to consume the flour supplement with their regular meals on weekends.
3343174|NCT02202863|No Intervention|Control|Subjects were asked to maintain their regular eating habits and lifestyles for 16 weeks.
3343175|NCT02202876|Active Comparator|Aim 1: Children with Cystic Fibrosis|Cystic Fibrosis children aged 1 to 9 years with normal glucose tolerance receiving Oral Glucose Tolerance Test
3343176|NCT02202876|Active Comparator|Aim 1: Control Children|Children with out Cystic Fibrosis aged 1 to 9 years controls with normal glucose tolerance receiving Oral Glucose Tolerance Test
3343177|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - High Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating High Glycemic Index Meal
3343178|NCT02202876|Active Comparator|Aim 2a: Teens with Cystic Fibrosis - Low Glycemic Meal|Cystic Fibrosis subjects 12 years of age or older with normal glucose tolerance eating Low Glycemic Index Meal
3343179|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Test Soda|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of a test soda. A week later these participants will have an Oral Glucose Tolerance Test.
3343180|NCT02202876|Active Comparator|Aim 2b: Cystic Fibrosis Consuming Fruit Juice|Participants with Cystic Fibrosis 12 years of age or older with normal glucose tolerance or impaired glucose tolerance consuming a test beverage of fruit juice. A week later these participants will have an Oral Glucose Tolerance Test.
3238729|NCT01272765|Experimental|Zyprexa Group|Subjects who are on a stable dose of Zyprexa and taking 500 mg of IHBG-10 15 minutes prior to the three main meals of the day.
3238730|NCT01272778|Experimental|Lorazepam 0.2 mg|All subjects receive lorazepam 0.2 mg in this crossover design.
3238731|NCT01272778|Experimental|Lorazepam, 0.5 mg|All subjects receive lorazepam 0.5 mg in this crossover design.
3343181|NCT02202902|Experimental|Group 1 : 1H magnetic resonance spectroscopy and CMRI|Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance
3343182|NCT02202902|Experimental|Group 2 : 1H magnetic resonance spectroscopy and CMRI|Group 2: Cushing's syndrome patients with normal glucose intolerance
3343183|NCT02202902|Experimental|Group 3 : 1H magnetic resonance spectroscopy and CMRI|age-, sex- and BMI-matched healthy volunteers
3238732|NCT01272778|Experimental|Lorazepam, 1.0 mg|All subjects receive lorazepam 1.0 mg in this crossover design.
3343184|NCT02202915|Experimental|Fidelity Checklist Arm|Therapists are receiving training using the fidelity Checklist
3343185|NCT02202928|Sham Comparator|Chemo-radiotherapy|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will just regularly follow up.
3343186|NCT02202928|Experimental|DC-CIK|After accepting concurrent radiotherapy and chemotherapy according to NCCN guidelines, patients will receive 3 cycles of autologous tumor lysate pulsed DC-CIK treatment.
3343187|NCT02202941|Experimental|Procalcitonin guided treatment|Patients who will be randomized to this arm will receive antibiotics therapy based on procalcitonin-guided algorithm.
3343188|NCT02202941|Active Comparator|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
3343189|NCT02202954|Active Comparator|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
3343190|NCT02202954|No Intervention|Conventional rehabilitation|conventional therapy in the community
3343191|NCT02202967|Active Comparator|Misoprostol|Misoprostol
3343192|NCT02202967|Placebo Comparator|Placebo|Placebo
3238733|NCT01272778|Experimental|Lorazepam, 2.0 mg|All subjects receive lorazepam 2.0 mg in this crossover design
3238734|NCT01272778|Placebo Comparator|Sugar pill|All subjects receive a sugar pill in this crossover design.
3343193|NCT02202993|Experimental|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
3238735|NCT01272791|Experimental|Gemcitabine, bavituximab|Gemcitabine will be administered on Days 1, 8, 15 of each 28-day (4 weeks) cycle until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will receive 3 mg/kg weekly (in addition to gemcitabine) until disease progression or unacceptable toxicities
3238736|NCT01272791|Active Comparator|Gemcitabine|Patients randomized to Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities.
3343194|NCT02203006|Other|OVIHD|Cohort and a blood sample collection will be done with data and blood of HIV infected patients
3343195|NCT02203045|Active Comparator|Tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
3343196|NCT02203045|Experimental|Non- tourniquet|All lower extremities will be exsanguinated by elevation for 2 minutes. For lower extremities in the tourniquet group (TQT), a pneumatic tourniquet will be inflated according to standard practice (>200 mmHg). For the NOTQT group, the tourniquet will only be inflated during component cementation. In both groups, tourniquet will be deflated after bone cement has set. In both groups, electrocautery will be used as needed throughout the procedure.
3343197|NCT02203058|Experimental|Pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) with pursed-lips breathing.
3343198|NCT02203058|Placebo Comparator|No pursed-lips breathing|All patients performed both tests (six-minute walk test and Glittre ADL test) without pursed-lips breathing.
3343199|NCT02203084||Children with Chronic Medical Conditions|The Social Determinants Questionnaire will be administered to the three groups of children with chronic diseases (cystic fibrosis, diabetes mellitus type I, or chronic renal insufficiency). The questionnaire questions will be asked by a research assistant. Each participant will have the same general and background information questions then will have questions specific to their chronic medical condition.
3343200|NCT02203097|Experimental|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
3343201|NCT02203123|Other|Ultrasound, inferior vena cava, aorta, normal saline|
3238737|NCT01272817|Other|Cladribine + melphalan|Cladribine + melphalan conditioning
3238738|NCT01272817|Other|TLI|Total lymphoid irradiation conditioning
3343202|NCT02203136||Muscle Invasive Bladder Cancer (MIBC)|During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
3343203|NCT02203175|Placebo Comparator|Group C (plasebo): no pretreatment|saline injection
3343204|NCT02203175|Active Comparator|propofol and fentanyl|propofol 50 mg with fentanyl 50 mcgr iv during anesthesia induction ones time
3343205|NCT02203188|Experimental|Lid debridgement scaling|Perform lid debridgement scaling
3343206|NCT02203188|No Intervention|Control|No Treatment
3343207|NCT02203201||Study group|NCWS patients who had showed a negative celiac disease serology and a Marsh 0-1 duodenal histology, but who had displayed a positive EmA assay in the culture medium of the duodenal biopsies (EmA-biopsy).
3343208|NCT02203201||Control group|NCWS patients with negative EmA-biopsy.
3343209|NCT02203214||Ligamys|All patients treated with Ligamys can be included in the study. Patients must meet all of the inclusion criteria and none of the exclusion criteria to be enrolled.
3343210|NCT02203227|Placebo Comparator|Placebo|Capsule containing 250 mg of placebo, two times a day
3343211|NCT02203227|Experimental|BioTurmin|Capsule containing 250 mg of BioTurmin (Curcuma longa rhizomes extract), two times a day
3343212|NCT02203227|Experimental|BioTurmin-WD|Capsule containing 250 mg of BioTurmin-WD (water dispersible curcuminoids), two times a day
3343213|NCT02203227|Experimental|MaQxan|Capsule containing 10 mg of MaQxan (Tagetes erecta flower extract), two times a day
3343214|NCT02203240|Experimental|Cocoa|3 servings of polyphenol-rich cocoa beverage consumed per day.
3343215|NCT02203240|Placebo Comparator|Placebo|3 servings of non-cocoa beverage consumed per day.
3343216|NCT02203253|Active Comparator|Thalidomide Group|Thalidomide 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
3343217|NCT02203253|Placebo Comparator|Placebo Group|Placebo (for Thalidomide) tablet 100 mg by mouth twice a day on days 1-5; Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
3238739|NCT01272843||Carotid endarterectomy patients|
3238740|NCT01272843||Lumbar stenosis laminectomy patients|
3238741|NCT01272856|Experimental|Open Label Abatacept|
3238742|NCT01272895|Experimental|GENOUS stent|
3238743|NCT01272973|Experimental|Oral 1|
3238744|NCT01272973|Experimental|Oral 2|
3238745|NCT01272973|Experimental|Oral 3|
3238746|NCT01272973|Active Comparator|S.c.|
3343218|NCT02203266|Experimental|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
3343219|NCT02203266|Active Comparator|Demonstration|Current best practice - inhaler technique education
3343220|NCT02203266|No Intervention|Control|Usual care in the community pharmacy setting
3238747|NCT01272986|Placebo Comparator|Healthy patients|
3238748|NCT01272986|Active Comparator|Asymptomatic myocardial Ischemic patients|
3238749|NCT01272986|Active Comparator|Acute Coronary Syndrome Patients|
3238750|NCT01273012|Placebo Comparator|Placebo|The group of patients treated with placebo.
3238751|NCT01273012|Experimental|Infloran|The group of patients treated with Infloran.
3238752|NCT01273077||Evaluation of Rotarix Program|All infants in Nova Scotia DHA 9 and PEI born after October1, 2010 until September 31, 2012 will be eligible for Rotarix immunization as part of the publicly funded immunization program. New Brunswick will serve as the non-intervention control location.
3343221|NCT02203279|Experimental|Rebase II Fast|The direct chair-side relining materiel 'Rebase II Fast' will be used.
3343222|NCT02203279|Experimental|Flexacryl|The direct chair-side relining material Flexacryl will be used
3343223|NCT02203279|Experimental|Vertex|Vertex is a heat-cured resin material which is going to be used for indirect relining
3343224|NCT02203292|Active Comparator|Liberal|Liberal transfusion strategy. Patients will have red blood cells transfused only if Hb < 9.0 g/dL
3343225|NCT02203292|Experimental|Restrictive|Restrictive transfusion strategy. Patients will have red blood cells transfused only if Hb < 7.0 g/dL
3343229|NCT02203318||control|healthy children with normal bilateral testis
3343230|NCT02203318||undescended palpable testis|patient whose affected testis is not descended to the normal position but palpable and exist intact in the upper area
3343231|NCT02203318||non-paplpable testis|patient whose affected testis is not palpable during the physical examination
3238753|NCT01273077||Retrospective Surveillance|All laboratory- confirmed cases of rotavirus gastroenteritis and all cause diarrhea admitted to the trial hospitals from 2008-2010 will be entered in the database.
3343232|NCT02203344||Light sedation|Light sedation is defined as RASS of +1 to -2.
3343233|NCT02203344||Deep sedation|Deep sedation is defined as RASS of -3 to -5
3343234|NCT02203370||all patients|All patients will be measured throughout the procedure with both devices. There no further separation into groups as both sensors can be placed on the same patient.
3343235|NCT02203383||Pts with CSA for CRT implantation|Patients with heart failure (EF<40%) and moderate to severe CSA (>15 events per hour, >50% Central)
3343236|NCT02203383||No Sleep Apnoea for CRT implantation|Heart failure (EF < 40%) but no significant sleep apnoea (<5 events per hour).
3343237|NCT02203396|Experimental|Severe Aplastic Anemia|Drug: rabbit ATG, Cyclosporine, Levamisole
3343238|NCT02203409||Laparoscopic ALPPS group|"Patients with small future liver remnant who are operated with the Associating Liver Partition and Portal vein ligation for Staged hepatectomy approach"
3343239|NCT02203422|Experimental|combination treatment group|60 enrolled patients are randomly picked up to take cyclosporin A in combination with rhTPO at the indicated dose.
3238754|NCT01273077||Prospective Surveillance|Will begin on December 1, 2010. Data will be collected to identify hospitalizations for all cause diarrhea and rotavirus gastroenteritis at all 3 sites through the first two consecutive rotavirus seasons following vaccination.
3238755|NCT01273077||Safety Intussusception|Each trial hospital will identify cases of severe diarrhea and intussusception in Rotarix vaccine recipients through the first two consecutive rotavirus seasons following vaccination.
3343240|NCT02203422|Active Comparator|single treatment group|60 enrolled patients are randomly picked up to take cyclosporin A at the indicated dose.
3343241|NCT02203448||FACET WEDGE spinal system|The FACET WEDGE spinal system provides additional stability to a spinal segment to enhance fusion conditions.
3343242|NCT02203461|Experimental|Group I|STRIBILD® Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat
3343243|NCT02203461|Active Comparator|Group II|Truvada®/Kaletra® Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir
3343244|NCT02203461|Experimental|Group III|Truvada®/Prezista®/Norvir® Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir
3343245|NCT02203487|Experimental|BIIF 1149 BS - single rising dose|
3343246|NCT02203487|Placebo Comparator|Placebo|
3343247|NCT02203500|Experimental|Lacidipine|
3343248|NCT02203500|Experimental|Telmisartan|
3238756|NCT01273077||ED Rotavirus Snap Shot Study|During rotavirus peak season, a prospective study of a sample of children under the age of 2 years presenting with diarrhea with or without vomiting to the ER of participating trial centers will be conducted.
3343249|NCT02203500|Experimental|Lacidipine + Telmisartan|
3343250|NCT02203513|Experimental|1-prexasertib|Prexasertib monotherapy treatment
3343251|NCT02203539|Experimental|bright light|Intervention: exposure to bright light
3343252|NCT02203539|Experimental|blue-enriched light|Intervention: exposure to blue-enriched light
3343253|NCT02203539|Experimental|normal light|Intervention: exposure to normal light
3343254|NCT02203552|Experimental|Arm I (minocycline hydrochloride)|Beginning 1 week prior to chemotherapy, patients receive minocycline hydrochloride orally PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
3343255|NCT02203552|Placebo Comparator|Arm II (placebo)|Beginning 1 week prior to chemotherapy, patients receive placebo PO BID for 9 weeks. Laboratory biomarker analysis will also be obtained weekly on protocol. Questionnaire administration weekly.
3343256|NCT02203604|Experimental|Treatment (aldesleukin, ipilimumab)|"INDUCTION: Patients receive ipilimumab IV over 90 minutes on days 1, 22, 43, and 64 and high-dose aldesleukin IV on days 22-26 and 43-47.~MAINTENANCE: Beginning on weeks 24, patients without disease progression or unacceptable toxicity receive ipilimumab IV over 90 minutes once every 12 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity."
3343257|NCT02203617|Experimental|educational baby books|books embedded with educational information (pediatric anticipatory guidance)
3343258|NCT02203617|Active Comparator|non-educational baby books|baby books given with same illustrations but no educational information
3343259|NCT02203617|No Intervention|no books|not given any baby books
3343260|NCT02203643|Experimental|CCyd|"Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3343261|NCT02203643|Experimental|CRd|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. This treatment will be followed by autologous stem cell transplantation (ASCT). Carfilzomib Cyclophosphamide and Dexamethasone administered for 4 28-day cycles, as consolidation treatment.~After the end of consolidation all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3238757|NCT01273077||KAB Questionnaire for HCP and Parents|Data will be collected by a validated survey given to Parents, Healthcare providers and Program organizers throughout the 2 year program.
3238758|NCT01273090|Experimental|Treatment|
3238759|NCT01273103|Experimental|Treatment|[14C]- GSK2248761 200 mg
3238760|NCT01273116|Experimental|CWS in Hospital|CWS in Hospital in addition to usual care
3238763|NCT01273233|Experimental|Group 1: 200U EV71 vaccine|12 adults received 3 doses of 200U EV71 vaccine 14 days apart
3238764|NCT01273233|Experimental|Group 2: 400U EV71 vaccine|12 adults received 3 doses of 400U EV71 vaccine 14 days apart
3238765|NCT01273233|Placebo Comparator|Group 1: Placebo|6 adults received 3 doses of placebo 14 days apart
3238766|NCT01273233|Placebo Comparator|Group 2: Placebo|6 adults received 3 doses of placebo 14 days apart
3238767|NCT01273246|Experimental|Children Group 1: 200U EV71 vaccine|12 children received 3 doses of 200U EV71 vaccine 28 days apart
3343262|NCT02203643|Experimental|CRd long treatment|"Carfilzomib Lenalidomide and Dexamethasone administered for 4 28-day cycles. Stem cells collection will be performed. Carfilzomib Lenalidomide and Dexamethasone administered for 8 28-day cycles.~After that all patients will be randomized to receive:~Lenalidomide or Lenalidomide and Carfilzomib until any sign of progression or intolerance."
3343263|NCT02203656|Placebo Comparator|Placebo Supplement|Daily placebo supplement for 30 days after discharge.
3343264|NCT02203656|Experimental|Nutritional Supplement|Daily nutritional supplement for 30 days after discharge.
3343265|NCT02203656|Experimental|In-home exercise + placebo|in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
3343266|NCT02203656|Experimental|In-home exercise + nutrition|in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
3343267|NCT02203656|Experimental|Testosterone|Single testosterone injection within 24 hours of hospital discharge.
3343268|NCT02203669|Active Comparator|Structured In-Office Therapy|Structured In-Office Therapy: Study subjects will receive structured, therapist-supervised occupational/physical therapy twice per week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Patients in this arm will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These patients will also receive exercise and stretching handouts to use at home between therapy visits. Will complete the DASH at week 1 and week 4.
3343269|NCT02203669|No Intervention|No therapy|Study subjects in this arm will not receive post-operative occupational /physical therapy. Will complete the DASH at week 1 and week 4.
3343270|NCT02203669|Active Comparator|Home Therapy|Home Therapy: Study subjects will receive a handout of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist to complete independently at home for four (4) weeks. Will complete the DASH at week 1 and week 4.
3343271|NCT02203695|Experimental|SRT plus Enzalutamide|Arm 2 (experimental): (SRT) Salvage radiation therapy (Three dimensional conformal radiation therapy (3D-CRT)/IMRT [Intensity-modulated radiation therapy]) 66.6-70.2 Gy as 1.8 Gy M-F for 37-39 fx PLUS Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
3343272|NCT02203695|Placebo Comparator|SRT plus placebo|Arm 1 (control): Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT (Intensity-modulated radiation therapy)) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx PLUS Placebo PO daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
3343273|NCT02203708|Active Comparator|BPD prevention|Supportive Program for Mother with BPD (SuPMother-B) : BPD mothers participate to prevention program in groups or/and house calls.
3343274|NCT02203708|No Intervention|Usual care of BPD mothers|BPD mothers don't participate to Supportive Program (SuPMother-B).
3343275|NCT02203734|Experimental|Moderate Pressure Massage|Moderate Pressure Massage Therapy
3343276|NCT02203734|Sham Comparator|Light Pressure Massage|Light Pressure Massage Therapy
3343277|NCT02203760|Experimental|Pazopanib plus Gemcitabine|Arm A: Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
3238768|NCT01273246|Placebo Comparator|Children Group 1: Placebo|6 children received 3 doses of placebo 28 days apart
3238769|NCT01273246|Experimental|Children Group 2: 400U EV71 vaccine|12 children received 3 doses of 400U EV71 vaccine 28 days apart
3343278|NCT02203760|Active Comparator|Pazopanib|Pazopanib 800 mg orally once daily
3343279|NCT02203773|Experimental|ABT-199 + Azacitidine|Treatment Naive Acute Myelogenous Leukemia
3343280|NCT02203773|Experimental|ABT-199 + Decitabine|Treatment Naive Acute Myelogenous Leukemia
3343281|NCT02203773|Experimental|ABT-199+Decitabine+Posaconazole|Treatment Naive Acute Myelogenous Leukemia
3343282|NCT02203799|Experimental|Peanut Oral Immunotherapy (POIT)|The peanut OIT is taken in the form of peanut flour. It will be given in small cups containing the amount of flour that needs to be eaten for one dose. One dose should be taken per day.
3343283|NCT02203812|Experimental|Probiotic Arm|L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.
3343284|NCT02203812|Placebo Comparator|Placebo Arm|Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).
3343285|NCT02203825|Experimental|CM-CS1 T-cell infusion|"The treatment will consist of a single infusion of CM-CS1 cells.~The following dose levels will be evaluated:~Cohort 1: 1x 10^6 CM-CS1 T-cells Cohort 2: 3x 10^6 CM-CS1 T-cells Cohort 3: 1x 10^7 CM-CS1 T-cells Cohort 4: 3x 10^7 CM-CS1 T-cells"
3343286|NCT02203864|Experimental|BIBW2 with IL-2 secreting cell line|
3343287|NCT02203864|Experimental|BIBW2 without IL-2 secreting cell line|
3343288|NCT02203877|Placebo Comparator|Maltodextrin|1 capsule/day for 16 weeks
3238770|NCT01273246|Placebo Comparator|Children Group 2: Placebo|6 children received 3 doses of placebo 28 days apart
3238771|NCT01273246|Experimental|Infants Group 1: 100U EV71 vaccine|24 infants received 3 doses of 100U EV71 vaccine 28 days apart
3343289|NCT02203877|Experimental|Lactobacillus fermentum CECT5716|L.fermentum 3,00E+09cfu/day. 1 capsule/day for 16 weeks
3343290|NCT02203890||Apparently Healthy|Apparently healthy preschool children who attend 3 daycare centers of the Secretariat of Beneficials Works of the First Lady in Guatemalan Western Highlands
3375858|NCT03683251|Experimental|PDS Implant Cohort 1 (US only)|"Participants with PDS implant from Study GX28228 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
3238772|NCT01273246|Placebo Comparator|Infants Group 1: Placebo|8 infants received 3 doses of placebo 28 days apart
3238773|NCT01273246|Experimental|Infants Group 2: 200U EV71 vaccine|24 infants received 3 doses of 200U EV71 vaccine 28 days apart
3343291|NCT02203903|Experimental|Tumor associated antigen lymphocytes (TAA-T)|"For Arm A Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first.~For Arm B Patients (pre-HSCT): TAA-T will be infused any time > 7 days after previous therapy for relapsed disease.~For Arm C Patients (post-HSCT): TAA-T will be infused any time after neutrophil engraftment post-HSCT or day 30, whichever comes first. All infusions will be within 5 months post-HSCT.~Five different dosing levels will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.~Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2 Dose Level Five: 1 x 108 cells/m2 (ONLY applicable to Arm A patients)~Arm C patients will ONLY be enrolled at: Dose Level Four (4 x 107 cells/m2)"
3343292|NCT02203929||Phakic eyes|Phakic eyes will be monitored with 4 preoperative optical coherence tomography scans as these patients will undergo phacoemulsification and intraocular lens implantation prior to their macular hole surgery
3343293|NCT02203929||Pseudophakic eyes|Phakic eyes will be monitored with 2 preoperative optical coherence tomography scans as there is no surgical intervention prior to the macular hole treatment.
3343294|NCT02203942||Vaginal Infections (BV, VVC, trich)|NAAT testing Amsel criteria Nugent score yeast culture TV culture
3343295|NCT02203955|Active Comparator|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally per day for 12 months
3343296|NCT02203955|Placebo Comparator|Maltodextrin|4 chews (maltodextrin) daily for 12 months
3343297|NCT02203968|Placebo Comparator|Normal saline|Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
3343298|NCT02203968|Active Comparator|Fibrinogen concentrate|Fibrinogen concentrate (RiaSTAP™) is a freeze-dried lyophilised plasma product presented in powdered form. The powder is reconstituted with water for intravenous injection at a concentration of 20 mg fibrinogen per ml. The concentrate is formulated with human albumin, L-arginine, sodium citrate and sodium chloride. RiaSTAP™ is supplied as a purified lyophilisate in a 1g dosage form and is reconstituted in 50 ml of sterile water. The final volume of RiaSTAP™ to be infused in this study will therefore be 300 ml.
3343299|NCT02203994|Experimental|extracorporeal shock wave therapy (ESWT)|"one-time treatment of the spastic muscle/ spastic muscles (adductor muscles and/ or M. triceps surae) with extracorporeal shock wave therapy (device: Duolith® SD 1 T-Top (Storz Medical AG, Tägerwilen, Switzerland))"
3343300|NCT02204020|Experimental|5-azacytidine|5-aza SC or IV 32mg/m2 - 75mg/m2 (based on dose escalation)
3238774|NCT01273246|Placebo Comparator|Infants Group 2: Placebo|8 infants received 3 doses of placebo 28 days apart
3238775|NCT01273246|Experimental|Infants Group 3: 400U EV71 vaccine|24 infants received 3 doses of 400U EV71 vaccine 28 days apart
3238776|NCT01273246|Placebo Comparator|Infants Group 3: Placebo|8 infants received 3 doses of placebo 28 days apart
3343301|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - low dose|
3343302|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - medium dose|
3238777|NCT01273259|Experimental|200 mg /day arm|
3238778|NCT01273259|Experimental|25 mg/day arm|
3238779|NCT01273272|Experimental|Cognitive Behavioral Therapy (CBT)|Comprehensive, CBT-based, multi-component treatment. Comprehensive CBT intervention in addition to standard treatment
3238780|NCT01273272|Active Comparator|Treatment as usual (TAU)|Standard Treatment (medical and psychosocial)
3343303|NCT02204033|Experimental|99mTc - labelled hMAb BIWA 4 - high dose|
3343304|NCT02204033|Experimental|186 Re - labelled hMAb BIWA 4 - escalating dose|
3238781|NCT01273298|Experimental|Bisoprolol|
3238782|NCT01273298|Placebo Comparator|Sugar pill|
3343305|NCT02204046|Experimental|BIWA 4|"Generic Name: Bivatuzumab~186Re-labelled humanised monoclonal antibody BIWA 4"
3343306|NCT02204059|Experimental|hMAb BIWA 4|Bivatuzumab: 186 Re-labelled humanised monoclonal antibody BIWA 4
3238783|NCT01273324||ADM|ADM Cup
3238784|NCT01273337|Experimental|ALD-401|ALD-401 is derived from Autologous Bone Marrow of the Stroke Subject
3343307|NCT02204085|Experimental|GO-203-2c|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle"
3238785|NCT01273337|Sham Comparator|Sham Comparitor|Sham Bone Marrow harvest and sham dosing procedure.
3238786|NCT01273350|Other|Single arm|"Single arm observational study looking at a low risk cohort of individuals with carotid stenosis"
3238787|NCT01273363||1|Male and female over 18. Patients with asthma diagnosed in accordance with the Global Initiative for Asthma within 6 months before inclusion into the study and without changes in treatment for 2 months before inclusion
3238788|NCT01273376|Experimental|RX-10100 high dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
3238789|NCT01273376|Experimental|RX-10100 low dose|"RX-10100~Study drug is to be given orally, in tablet form, twice daily, for 8 weeks"
3238790|NCT01273376|Placebo Comparator|Placebo|Matching placebo is to be given orally, in tablet form, twice daily, for 8 weeks
3238791|NCT01273389|Experimental|CNTO 136|CNTO 136 is used in the form of final vialed product, as a single-use, sterile solution in a 2 ml glass vial. Each 1 mL of the solution contains sirukumab 100mg active drug substance, sorbitol, acetate buffer, and polysorbate 20, at a pH of 5.0, without any preservatives.
3238792|NCT01273389|Placebo Comparator|Placebo|
3238793|NCT01273402|Experimental|TF2 and IMP288|TF2 will be administered at least 4 days before the radiolabeled IMP-288.
3238794|NCT01273415||hormone receptor-positive breast cancer|postoperative hormone receptor-positive breast cancer
3238795|NCT01273428|Active Comparator|HP011-101|
3238796|NCT01273428|Active Comparator|HP828-101|
3238797|NCT01273428|Other|Standard Care|
3238798|NCT01273441|Active Comparator|Sequential treatment:|
3343308|NCT02204085|Experimental|GO-203-2c + Decitabine|"Dose escalation will occur for GO-203-2c using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~GO-203-2c given daily on predetermined schedule of a 28-day treatment cycle. Decitabine will be administered at a dose of 20mg/m2 on days 8-12 of a 28-day treatment cycle."
3343309|NCT02204098|Active Comparator|Cohort 1:Neoadjuvant endocrine therapy alone|"Will be treated with standard of care adjuvant endocrine therapy as determined by their treating physician~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy"
3343310|NCT02204098|Experimental|Cohort 2:Neoadjuvant endocrine + mammaglobin-A DNA vaccine|"Will be treated with standard of care adjuvant endocrine therapy~Optional biopsy approximately 14 days following initiation of neoadjuvant therapy~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device"
3343311|NCT02204098|Active Comparator|Cohort 3: Neoadjuvant chemotherapy alone|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in cohort 3"
3343312|NCT02204098|Experimental|Cohort 4: Neoadjuvant chemotherapy + mammoglobin-A DNA vaccine|"Will be treated with standard of care neoadjuvant chemotherapy as determined by their treating physician~If archival tissue not sufficient, a research biopsy to obtain primary tissue must be done prior to day 28~Treated with 4 mg of mammaglobin-A DNA vaccine at 3 time points (Days 28, 56, and 84)~All study injections will be administered using a TriGrid electroporation device~Subjects who begin neoadjuvant endocrine therapy but are determined to not be responding at the Day 14 biopsy may begin chemotherapy treatment, at the discretion of the treating physician. These subjects may be enrolled in either cohort 4"
3343313|NCT02204111||Control Cluster|Care as usual
3343314|NCT02204111||Treatment Cluster|Care as usual and patient directed, multidimensional treatment proposals
3343315|NCT02204137||Completion of Questionnaires|"Participants will complete an assessment consisting of the Falls Risk Questionnaire, a primarily self-administered geriatric assessment (GA) developed by the Cancer and Aging Research Group, a quality of life scale (FACT GOG/NTX) and the Falls Efficacy Scale-International.~Each questionnaire contains approximately 150 questions and will take between 30 minutes and one hour to complete."
3343316|NCT02204163|Experimental|Eutropin|Eutropin 0.24mg/kg/week
3238799|NCT01273441|Experimental|Concomitant treatment|
3238800|NCT01273454||001|OROS Hydromorphone 8 16 32 mg once a day for 4 weeks
3238801|NCT01273467|Experimental|001|CNTO 0007 or placebo (Stage A) a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
3238802|NCT01273467|Experimental|002|CNTO 0007 or placebo (Stage B) a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
3238803|NCT01273480|Experimental|002|Sequence 2 Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
3238804|NCT01273480|Experimental|001|Sequence 1 Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
3238805|NCT01273493|Experimental|Trabectedin 1.3 mg/m^2 plus Dexamethasone|Control group Trabectedin 1.3 mg/m^2 i.v.will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
3343317|NCT02204163|Active Comparator|Genotropin|Genotropin 0.24mg/kg/week
3343318|NCT02204189|Experimental|TongFuSan|TongFuSan 1g per time, change every day, the duration is seven days
3238806|NCT01273493|Experimental|Trabectedin 0.58 mg/m^2 plus Dexamethasone|Hepatic dysfunction group Trabectedin 0.58 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1. Dexamethasone will be administered 30 minutes prior to trabectedin.
3238807|NCT01273506|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 50 mg TRF single oral dose
3343319|NCT02204202||Grade A0|Double-lung transplant recipients with no evidence of rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
3343320|NCT02204202||Grades A2-3|Double-lung transplant recipients with mild to moderate rejection who undergo both [18F]FDG and [18F]ISO-1 PET imaging scans
3343321|NCT02204215|Experimental|electric acupuncture & conservative|Electric acupuncture therapy on four limbs 30 min each time, twice per day; or conservative treatment without electric acupuncture.
3343322|NCT02204228||TITAN™ Reverse Shoulder System (TRS)|TITAN™ Reverse Shoulder System (TRS) is a semi-constrained total shoulder construct.
3343323|NCT02204241|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1-2 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8-9, 15-16 of Cycle 1, then for all subsequent doses 36/45/56/70 mg/m2 IV once daily on days 1-2, 8-9, 15-16, followed by 12-day rest period (day 17 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1-2, 15-16."
3238808|NCT01273506|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50 mg TRF single oral dose
3238809|NCT01273532|Experimental|001|tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose
3238810|NCT01273532|Experimental|002|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
3238811|NCT01273545||001|PRILIGY (dapoxetine hydrochloride) The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists and in Italy by urologists
3343324|NCT02204254|Experimental|Radiofrequence|3 sessions of radiofrequency at 3 weeks intervals V1, V2 (W3 or W4) and V3 (between W6 and W8), with clinical examination, evaluation of tolerance, adverse events report, photos, surface biopsy (SSSB), and confocal microscopy (V1 and V3). Follow up visit V4 (M6) with clinical evaluation, photos, SSSB, confocal microscopy, adverse events report and treatment satisfaction.
3343325|NCT02204254|Placebo Comparator|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
3343326|NCT02204267|Experimental|prolonged ECG monitoring|Regular stroke unit treatment and diagnostic procedures according to guidelines and additional prolonged ECG monitoring
3343327|NCT02204267|No Intervention|no additional ECG recording|Regular stroke unit treatment and diagnostic procedures according to guidelines
3343328|NCT02204280||Type 2 Diabetic|Patiens with type 2 diabetic which conform to the WHO in 1999 diabetes diagnostic criteria.
3343329|NCT02204280||Diabetic With macro-or Microalbuminuria|Patients with diabetic with macro-or microalbuminuria.
3343330|NCT02204280||proteinuria,nondiabetic renal disease|Patients with proteinuria due to nondiabetic renal disease,such as IgA nephropathy,FSGS,Hypertensive renal damage and MN.
3343331|NCT02204280||healthy controls|Healthy person.
3343332|NCT02204306|Other|TSER *2/*2 *2/*3|Patients with TSER *2/*2 *2/*3 genotypes will be assigned to this group and receive standard chemotherapy contains fluorouracil. (FOLFOX 6/XELOX/SOX)
3343333|NCT02204306|Other|TSER*3/*3 (fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
3343334|NCT02204306|Other|TSER*3/*3 (non-fluorouracil)|Patients with TSER*3/*3 genotype will be randomly assigned to fluorouracil group (FOLFOX 6/XELOX/SOX) or non-fluorouracil group (DC or DO).
3343335|NCT02204332|Experimental|Cabazitaxel|"Cabazitaxel at a dose of 25 mg / m² in a 5% dextrose or 0.9% NaCl intravenously over 1 hour, every 3 weeks (1 cycle).~Besides, patient will be treated with BSC."
3343336|NCT02204332|Other|Best Supportive Care|Best Supportive Care (BSC), with evaluations every 3 weeks (1 cycle).
3343337|NCT02204345|Experimental|RO5479599 + Carboplatin + Paclitaxel|RO5479599 800 milligrams (mg) will be administered in the Safety Run-In Phase by intravenous infusion q3w on Day 1 of 3-weekly cycles (each cycle of 21 days) in combination with carboplatin (to produce an area under the curve [AUC] of 6 mg/milliliter [mL]*minute) and paclitaxel 200 mg per square meter (mg/m^2) by intravenous infusion q3w for 4 to 6 cycles. Thereafter, RO5479599 will be continued as a monotherapy (carboplatin and paclitaxel may be continued at the investigator's discretion) until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
3343338|NCT02204358|Experimental|autologous bone marrow stem cells|Using collagen scaffold loaded with autologous bone marrow stem cells to treat severe intrauterine adhesions or endometrial dysplasia.
3343339|NCT02204384|Experimental|HFD Meal: high fiber from food|HFD Meal: high amount of fiber from diet food sources (total fiber 9.7g; soluble fiber 5.4g)
3343340|NCT02204384|Experimental|HFS Meal: High fiber from supplement|HFS Meal: high amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - Fiber Mais, Nestlé
3343341|NCT02204384|Experimental|UF Meal: usual amount of fiber|UF Meal: usual amount of fiber (total fiber 2.4g; soluble fiber 0.8g)
3343342|NCT02204397|Experimental|INGAP Peptide, Ustekinumab|INGAP Peptide, Ustekinumab subcutaneous
3343343|NCT02204423|Experimental|Trans-Radial PCI|
3343344|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
3343346|NCT02204475|Active Comparator|BOC/PR|All participants begin treatment with a 4-week lead-in of PR followed by 24 weeks of BOC/PR. At Treatment Week (TW) 28 TN participants who have undetectable HCV RNA at TW 8 will complete BOC/PR therapy. At TW 28 TN participants who have detectable HCV RNA at TW 8, as well as prior relapsers and prior partial responders, will continue on BOC/PR for an additional 8 weeks and then continue on PR for an additional 12 weeks. At TW 28 all cirrhotics and previous null responders will continue on BOC/PR for an additional 20 weeks.
3343347|NCT02204475|Experimental|Grazoprevir/Elbasvir|Participants will undergo treatment with grazoprevir 100 mg + elbasvir 50 mg for 12 weeks.
3343348|NCT02204488|Active Comparator|Total Joint Arthroplasty|Total Joint Arthroplasty
3343349|NCT02204488|Active Comparator|Trapeziectomy|Trapeziectomy
3343350|NCT02204501|Experimental|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
3343351|NCT02204501|Experimental|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
3343352|NCT02204514||Surgery for external snapping hip|
3343353|NCT02204527|Experimental|vitamin D3|supplementation of 100.000 IU of vitamin D3
3343354|NCT02204527|Placebo Comparator|Placebo pill|Placebo
3343355|NCT02204540|Experimental|Monitoring by webcam|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming food) while being recorded and monitored by webcam.
3343356|NCT02204540|Active Comparator|In-person monitoring|Participants will perform a task for a mock clinical study (e.g., swallowing a pill, consuming good) while being monitored in-person.
3343357|NCT02204605|No Intervention|Control|Visits are not videotaped
3343358|NCT02204605|Experimental|Videoed Patients|Patients will have their visit videotaped.
3375859|NCT03683251|Experimental|PDS Implant Cohort 2 (US only)|"Participants with PDS implant from Study GR40548 treated with refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
3343359|NCT02204618|Experimental|cochlear implantation|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
3343360|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
3343361|NCT02204631|Experimental|Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~After enrollment and baseline data collection, the participant will be given the handbook. The clinician giving out the handbook will give an overview of the handbook and flip through the important sections. The clinician will encourage the participant to bring it back and forth.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception)."
3343362|NCT02204631|No Intervention|Non Head and Neck Educational Handbook|"Prior to starting treatment, patients will be approached for trial participation and baseline questionnaires (demographics, psychological distress, symptom burden, and illness perception).~The first group of participants will not receive the handbook but will receive the current standard care in the head and neck disease center.~Participants will complete questionnaires at 3 weeks into treatment and 2 weeks after treatment has ended (information satisfaction, psychological distress, symptom burden, and illness perception).~At completion of Phase I, all 30 participants will also be given a copy of the handbook and an accompanying questionnaire."
3343363|NCT02204644|Experimental|Flumatinib mesylate tablets|Flumatinib mesylate tablets 600mg qd for 12 months
3343364|NCT02204644|Active Comparator|Imatinib mesylate tablets|Imatinib mesylate tablets 400mg qd for 12months
3343365|NCT02204670||Overweight Adolescents Performing Resistance Training|Overweight adolescents that meet pre-specified enrollment criteria will all undergo supervised resistance exercise for a 6-week period. Prior to training, all participants will undergo a single bout of resistance training to determine the acute release of Irisin with resistance training. This will be the primary exposure variable. After the acute session, all participants will perform resistance training three times per week for a period of 4 weeks. During each session participants will perform 3 sets of 8-12 repetitions (60-85% of 1RM) for major muscle groups (quadriceps, shoulders, and pectoral).
3343366|NCT02204683|Other|Aflibercept|Subjects who have had a vitrectomy previously
3343367|NCT02204683|Other|Aflibercept in Non-Vitrectomized eyes|Patients who have not had vitrectomy.
3343368|NCT02204696||Tonsillectomy|All participants will undergo baseline sleep study, a second preoperative sleep study after a period of watchful waiting, and a postoperative sleep study.
3343369|NCT02204709|Experimental|Diploid Trout entrees|Subjects will consume a 200 gram portion of 2N trout (diploid; two sets of chromosomes) twice weekly in a prepared meal.
3343370|NCT02204709|Experimental|Triploid Trout entrees|Subjects will consume a 200 gram portion of 3N trout (triploid; three sets of chromosomes) twice weekly in a prepared meal.
3238812|NCT01273558|No Intervention|Part 1: no Intervention|In Part 1 of the study, patients will not receive any study drug.
3238813|NCT01273558|Experimental|Part 2: canagliflozin|In Part 2 of the study, patients will receive canagliflozin once daily on Days 1 through 8.
3343371|NCT02204709|Experimental|Tilapia entrees|Subjects will consume a 200 gram portion of tilapia twice weekly in a prepared meal.
3343372|NCT02204722|Experimental|Group B|the group who has more than 10% of the BCR-ABL(IS) level for three months will receive 600mg/day of Imatinib after three months.
3343373|NCT02204722|Experimental|Group A|the group who has more than 10% of the BCR-ABL(IS) level for three months will maintain the dose, 400mg/day of Imatinib, after three months.
3343374|NCT02204735|Experimental|MORNING|Participants will be instructed to consume 50% of their energy intake in their first eating bout, 30% in their second eating bout, and 20% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 600 kcal in their first eating bout, 360 kcal in their second bout, and 240 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
3238814|NCT01273571|Experimental|001|Canagliflozin/Metformin Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8 followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
3343375|NCT02204735|Experimental|EVENING|Participants will be instructed to consume 20% of their energy intake in their first eating bout, 30% in their second eating bout, and 50% in their third eating bout. For example, a participant prescribed a 1200 kcal/d diet needs to consume 240 kcal in their first eating bout, 360 kcal in their second bout, and 600 kcal in their third bout. Participants will be provided with sample meal plans meeting this prescription.
3343376|NCT02204774||Dilatated or aneurysmatic Aorta|Complete cohort, which will be followed over 3 years
3343377|NCT02204787|Experimental|active tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a 2 mA intensity during 20 minutes.
3343378|NCT02204787|Sham Comparator|Sham tDCS|Transcranial Direct Current Stimulation : 10 sessions twice a day during 5 days, with a sham stimulation during 20 minutes. Initial stimulation followed by turning off the device as to ensure blinding.
3343379|NCT02204800||Small clear cell renal tumors (Wild Type)|No specific chromatin remodeling gene (CRG) alteration
3343380|NCT02204800||Small clear cell renal tumors (Mutant)|Specific chromatin remodeling gene (CRG) alteration
3238815|NCT01273584|Active Comparator|Metformin|"Tablet Metformin 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
3343381|NCT02204813|Experimental|Post RYGB Surgery|Healthy, weight stable individuals, with previous Roux-en-Y gastric bypass surgery. No clinical evidence of type 2 diabetes before and after surgery. Each participant will receive placebo or the indicated doses of xenin-25.
3238816|NCT01273584|Placebo Comparator|Placebo|"Tablet Placebo 500 mg, starting dose of 1 tablet twice a day with meals, gradually titrated upwards by 1 tablet every week to a maximum dose of 2 tablets three times a day.~Tablets started at recruitment and continued till the delivery of the baby"
3238817|NCT01273610|Experimental|Lapatinib and trastuzumab|Patients receive lapatinib ditosylate PO QD and trastuzumab IV once weekly OR once every 3 weeks. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3238818|NCT01273649|Experimental|ice, rate of force development|to monitor the long term effect of cryotherapy in rate of force development.
3343382|NCT02204826|Experimental|V + KRG group (n = 20)|three capsules of KRG (500 mg/dose) daily and varicocelectomy.
3343383|NCT02204826|Active Comparator|non-V + KRG group|three capsules of KRG (500 mg/dose) daily
3343384|NCT02204826|Active Comparator|V + P group (n = 20)|placebo capsules and varicocelectomy
3343385|NCT02204826|Placebo Comparator|non-V + P group|non-V + P group (n = 20) placebo capsules
3343386|NCT02204839|Experimental|Basal dose reduction|Total daily basal (Glargine, Lantus, Sanofi-Aventis, or Detemir, Levemir, Novo Nordisk) reduction of 20% versus normal basal dose.
3343387|NCT02204852|Experimental|Iloprost+eptifibatide|Co-administration of 1 ng/kg/min Ilomedin® and 0.5 µg/kg/min Integrilin® as 48h continuous i.v infusions
3343388|NCT02204852|Placebo Comparator|Saline|Double dummy 0.9% saline as 48h continuous i.v infusion
3343389|NCT02204865||Pacemaker/ICD with ApneaScan|Patients with HFREF due to receive a pacemaker or ICD with ApneaScan function
3343390|NCT02204878|Placebo Comparator|A|1ml of saline was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. 1ml saline Q12h will be given within 72 hours after surgery
3343391|NCT02204878|Experimental|AT|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
3343392|NCT02204891|Experimental|Probiotics in SIBO|Administration of probiotics in patients with IBS and SIBO
3343393|NCT02204891|Active Comparator|Probiotics|Administration of probiotics in patients with IBS without SIBO
3343394|NCT02204904||Allo-HSCT prospective|Subjects who will be consented before they received an allo-HSC infusion. They will be consented and enrolled on the study during the Screening Period.
3343395|NCT02204904||Allo-HSCT partial prospective/retrospective|Subjects who will be consented after they received an allo-HSC infusion but before they reach 24 months post-infusion on study. Subjects in this cohort will participate prospectively in at least the Month 24 Visit in order to obtain prospective on-study data for this and all visits after Month 24
3343396|NCT02204904||Allo-HSCT retrospective|Subjects who received an allo-HSC infusion on or after January 1, 2013 and died before study data collection.
3343397|NCT02204930|Experimental|Haemostat|PeproStat
3343398|NCT02204943|Experimental|Bone Biopsy and Circulating Tumor Cell Samples|
3238819|NCT01273662|Experimental|Axitinib|
3238820|NCT01273688|Active Comparator|Eccentric training only|Eccentric training only active control group (Flex-Bar)
3238821|NCT01273688|Experimental|Eccentric training and elbow brace|Combined eccentric training (Flex-Bar) and elbow brace (Epi-Hit)
3238822|NCT01273701|Experimental|TSTSU-N|TSTSU-N stands for Treatment for Schedule Two Substance Use, No Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-N will not receive telephone reminding before each visit.
3343399|NCT02204956|Experimental|Sustained Care|A 40-minute, in-hospital motivational counseling session about smoking cessation, 8 Interactive Voice Response (IVR) phone calls and/or texts over 90 days, including the possibility of a warm transfer to a telephone tobacco quit line and up to 8-weeks of free transdermal nicotine patches.
3238823|NCT01273701|Experimental|TSTSU-T|TSTSU-T stands for Treatment for Schedule Two Substance Use, Telephone Reminding. Subjects will be referred by the Yunlin District Prosecutors Office for one-year psychosocial interventions to get slow prosecutions. After the referral, they will be randomized in a 1:1 ratio to either TSTSU-N group or TSTSU-T group. During the intervention, subjects of TSTSU-T will receive telephone reminding before each visit.
3343400|NCT02204956|Active Comparator|Usual Care|A brief 5-10 minute tobacco education session that all hospitalized smokers will receive, delivered by a hospital nurse. During this session, they will be provided with written handouts describing the stages of readiness for change in quitting, self-monitoring of smoking, self-management of smoking situations, relapse prevention, managing stress, other quitting tips and use of nicotine replacement therapy.
3343401|NCT02204969|Sham Comparator|Transcranial magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
3343402|NCT02204969|Placebo Comparator|lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
3343403|NCT02204995|Active Comparator|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
3343404|NCT02204995|Active Comparator|Trapeziectomy|Trapeziectomy
3343405|NCT02205008|Active Comparator|Arm A|curative resection of the stomach with D2 plus intraperitoneal chemotherapy plus adjuvant systemic chemotherapy with S-1
3343406|NCT02205008|Placebo Comparator|Arm B|curative resection of the stomach with D2 plus adjuvant systemic chemotherapy with S-1
3343407|NCT02205021||All subjects|
3343408|NCT02205034|Active Comparator|first arm|4IU of oxytocin every other day
3343409|NCT02205034|Active Comparator|second arm|4 IU of oxytocin daily
3343410|NCT02205034|Active Comparator|third arm|4 IU of oxytocin twice daily
3343411|NCT02205047|Active Comparator|Standard chemotherapy|Cisplatin/capecitabine or cisplatin/5-fluorouracil
3343412|NCT02205047|Experimental|Experimental arm 1|Cisplatin/capecitabine plus trastuzumab or cisplatin/5-fluorouracil plus trastuzumab
3343413|NCT02205047|Experimental|Experimental arm 2|cisplatin/capecitabine plus trastuzumab and pertuzumab or cisplatin/5-fluorouracil plus trastuzumab and pertuzumab
3343414|NCT02205060|Experimental|virtual reality exposure therapy (VRET)|
3343415|NCT02205060|Experimental|cognitive and behavioral approaches therapy without VRET|
3238824|NCT01273701|Active Comparator|OPD|OPD stands for Outpatient Department. Subjects in this arm will be methamphetamine users who voluntarily visit psychiatric clinics for treatment of mental disorders in National Taiwan University Hospital, Yunlin Branch. They will be referred to this study by their treating psychiatrists.
3238825|NCT01273714|Active Comparator|BST|bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each)
3238826|NCT01273714|Experimental|TT|extracapsular total thyroidectomy
3343416|NCT02205073|Placebo Comparator|Dosing Period 1|
3343417|NCT02205073|Active Comparator|Dosing Period 2|
3238827|NCT01273727|No Intervention|No Ozurdex|Arm 1(control) - Patients who have had epi-retinal membrane peeling and have macular edema at least 3 months (90 days) after surgery. These patients will followed without Ozurdex. The patients will be treated with current standard of care, including topical and intravitreal or subtenon's medication.
3238828|NCT01273727|Experimental|Ozurdex 3 months after surgery|Patients who have had epi-retinal membrane peeling and have residual macular edema 3 months after surgery. These patients will receive an Ozurdex implant
3343418|NCT02205073|Experimental|Dosing Period 3|
3343419|NCT02205086|Other|Diagnosis|Test diagnostic decision support software
3343420|NCT02205099|Experimental|SKL15508 High Dose|SKL15508 High Dose
3343421|NCT02205099|Experimental|SKL15508 Medium Dose|SKL15508 Medium Dose
3343422|NCT02205099|Experimental|SKL15508 Low Dose|SKL15508 Low Dose
3343423|NCT02205099|Placebo Comparator|Placebo|Placebo
3343424|NCT02205112|Experimental|Nemonoxacin 500 mg|Nemonoxacin 500mg/250mL, intravenous administration, once daily for 7~14 days
3343425|NCT02205112|Active Comparator|Levofloxacin 500mg|Levofloxacin: 500mg/100mL, intravenous administration, once daily for 7~14 days
3343426|NCT02205138|Experimental|ALLOB® cells with ceramic scaffold|ALLOB® cells with ceramic scaffold Implantation
3343427|NCT02205151|Other|Treatment AB|"Treatment A (1 day) → wash-out(14days) → Treatment B (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
3343428|NCT02205151|Other|Treatment BA|"Treatment B (1 day) → wash-out(14days) → Treatment A (1 day)~Treatment A : Fimasartanm and Amlodipine~Treatment B : Fimasartan/Amlodipine combination"
3343429|NCT02205164|Experimental|Palonosetron + Aprepitant|Oral aprepitant will be given on days 1-3 (day 1, 125 mg 1 h before chemohterapy; days 2-3, 80 mg) multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
3238829|NCT01273727|Experimental|Ozurdex 6 months or longer after surgery|Patients who have had epiretinal membrane peeling and have residual macular edema at least 6 months after surgery
3238830|NCT01273740|Experimental|External support|Bypass graft with external support
3238831|NCT01273740|Experimental|No external support|Bypass with graft without external support
3343430|NCT02205164|Active Comparator|Palonosetron|multiple intravenous bolus of palonosetron 0.25 mg, 30 minutes before chemotherapy, every other single days, for a minimum of 2 administration (day 1, 3), in case of a 3 days chemotherapy regimen, and a maximum of 5 doses (day 1,3,5,7, 9) in case of a 10 days chemotherapy.
3343431|NCT02205190|Other|Treatment AB|"Treatment A (1 day) → wash-out(7days) → Treatment B (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
3343432|NCT02205190|Other|Treatment BA|"Treatment B (1 day) → wash-out(7days) → Treatment A (1 day)~Treatment A : Fimasartan and Rosuvastatin~Treatment B : Fimasartan/Rosuvastatin combination"
3343433|NCT02205203|Active Comparator|Face-to-Face w/ Anxiety Coach (FTF-AC)|In this condition therapists will provide 6 to 12 50-minute, face-to-face therapy sessions using Mayo Clinic Anxiety Coach. The sessions are expected to initially occur weekly and be within the office although the therapist can leave the office to conduct exposure. The therapist is expected to utilize Anxiety Coach within the session, encourage the patient to use the application to complete homework, and review progress in-session via the web-based portal.
3343434|NCT02205203|Experimental|Treatment as Usual (TAU)|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure). Therapists can communicate with patients between sessions (e.g., phone calls), as long as this medium is not the primary mode of treatment.
3343435|NCT02205216|Active Comparator|Active tDCS|Active tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
3343436|NCT02205216|Sham Comparator|Sham tDCS|Sham tDCS combined with a rehabilitative intervention consisting of cognitive training and sensory cueing.
3343437|NCT02205229||Patients receiving a topical compounded medication|
3343438|NCT02205242|Experimental|Azithromycin|"N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
3343439|NCT02205242|Placebo Comparator|Placebo|"N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days~N= 30 During 7 days post discharge from hospital (0 months), 3 months and 9 months, the patient will wear the Dynaport® which will register the patient's physical activity"
3343440|NCT02205255|Experimental|Azithromycin|N = 250 From day 1 up to and including day 3: 500 mg azithromycin PO once a day From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days
3343441|NCT02205255|Placebo Comparator|Placebo|N = 250 From day 1 up to and including day 3: 500 mg placebo PO once a day From day 4 up to and including day 90: 250 mg placebo PO once every 2 days
3343442|NCT02205268|Experimental|Neurofeedback training|20 sessions of near infrared spectroscopy neurofeedback training to increase activation to bilateral prefrontal cortex. Two sessions per week.
3343443|NCT02205281|No Intervention|Standard Care|
3343444|NCT02205281|Experimental|Lifestyle Intervention|
3343445|NCT02205294|No Intervention|Assessment Only|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
3343446|NCT02205294|Active Comparator|Assessment and Treatment|Subjects will have an osteopathic assessment to determine areas of tension in specific areas of the body. These areas of tension will receive osteopathic treatment, using myofascial release techniques. These areas include: the thoracic diaphragm, the heart and pericardium, the iliac fascia, the femoral sheath, the sartorius muscle, the pelvic diaphragm and the interosseous membrane (IM) of the lower extremity
3343447|NCT02205320|Experimental|Treatment Sequence I (DRL, A, B)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form A, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
3343448|NCT02205320|Experimental|Treatment Sequence II (DRL, B, A)|Patients will receive study drugs in the following cross-over sequence: DRL_PG, Pegfilgrastim Form B, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
3343449|NCT02205320|Experimental|Treatment Sequence III (A, DRL, B)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, DRL_PG, Pegfilgrastim Form B. Each drug is administered as a single, 6 mg, subcutaneous injection.
3343450|NCT02205320|Experimental|Treatment Sequence IV (A, B, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form A, Pegfilgrastim Form B, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
3238832|NCT01273753|Active Comparator|Exercise|After baseline measurements, all subjects will undergo a phase involving intradialytic exercise. Subjects will serve as their own controls.
3238833|NCT01273779|Placebo Comparator|Placebo|
3343451|NCT02205320|Experimental|Treatment Sequence V (B, A, DRL)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, Pegfilgrastim Form A, DRL_PG. Each drug is administered as a single, 6 mg, subcutaneous injection.
3343452|NCT02205320|Experimental|Treatment Sequence VI (B, DRL, A)|Patients will receive study drugs in the following cross-over sequence: Pegfilgrastim Form B, DRL_PG, Pegfilgrastim Form A. Each drug is administered as a single, 6 mg, subcutaneous injection.
3343453|NCT02205346||no treatment|no treatment
3343454|NCT02205359|Experimental|aCRT ON|The aCRT algorithm has been developed to provide RV-synchronized LV pacing when intrinsic AV conduction is normal or BiV pacing otherwise
3343455|NCT02205359|Active Comparator|aCRT OFF|Standard CRT
3343456|NCT02205372|Experimental|MT-3995|
3343457|NCT02205372|Placebo Comparator|Placebo|
3343458|NCT02205385|Active Comparator|Traditional Traction Neurectomy|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the current standard of care surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). In the active comparator arm, gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally. It may be buried in healthy muscle to further pad the nerve ending. The intention is to place the inevitable recurrent end-neuroma away from superficial locations in which it is likely to become mechanically irritated."
3343459|NCT02205385|Experimental|Targeted Muscle Reinnervation|"Patients will be randomized to either the current standard of care surgical treatment for neuromas (traction neurectomy) or the experimental intervention (targeted reinnervation). This arm involves the use of the experimental surgical treatment.~Patients will undergo the same pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle."
3343460|NCT02205398|Experimental|c-MET positive mCRC and HNSCC|c-MET positive and K/NRAS WT mCRC and c-MET positive HNSCC patients
3238834|NCT01273779|Experimental|Talactoferrin alfa|
3238835|NCT01273792||Patients with Susac syndrome|
3238836|NCT01273792||Matched healthy controls|
3343461|NCT02205411|Experimental|HeartAssist 5® VAD System|Implant of the HeartAssist 5® VAD System
3343462|NCT02205411|Active Comparator|Control VAD|
3238837|NCT01273831|Other|atracurium|Patients who underwent general anesthesia received atracurium
3238838|NCT01273831|Other|cisatracurium|Patients who underwent general anesthesia received cisatracurium
3238839|NCT01273844|Experimental|Bortezomib|Patients will receive two 21-day cycles of induction therapy with vel / dex regimen. Bortezomib 1.3mg/m2 on days 1, 4, 8 and 11 will be given by intravenous bolus injection while Dexamethasone 40 mg/d will be taken orally on days 1-4.
3238840|NCT01273909||Perforator Flap Breast Reconstruction|Patients who undergo perforator flap breast reconstruction with or without concomitant vascularized lymph node transfer
3238841|NCT01273909||Vascularized Lymph Node Transfer|Patients who undergo perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
3343463|NCT02205424||Ischaemic stroke patients|Patients who have suffered an ischaemic stroke, as determined clinically and verified with imaging (CT brain; MRI).
3343464|NCT02205424||Healthy control participants|People who have never suffered a stroke, and are matched to the ischaemic stroke patient group according to age, education, and vascular risk factors.
3343465|NCT02205437||Controls|Healthy subjects without psychotic disorder.
3343466|NCT02205437||Drug-naive patients|Drug-naive (never medicated) schizophrenia patients.
3343467|NCT02205437||Patients responder to treatment|Patients with a good clinical response to treatment (define by a marked improvement of positive symptoms) at 3 months and at 1 year.
3343468|NCT02205437||Patients non-responder to treatment|Patients with a poor clinical response to treatment at 3 months and at 1 year.
3343469|NCT02205437||Patients with metabolic side effects|Patients with metabolic side effects associated to treatment.
3343470|NCT02205437||Patients with non-metabolic side effects|Patients with no metabolic side effects associated to treatment.
3343471|NCT02205450||Children under 2 years with Prader-Willi Syndrome|
3343472|NCT02205463|Experimental|KD019|Patients with HER2+ metastatic or unresectable adenocarcinoma of the esophagus, gastroesophageal junction or stomach will receive trastuzumab and mFOLFOX-6 in combination with KD019 to evaluate the safety, toxicity and MTD of this regimen. There will be four dose cohorts for KD019. KD019 will be administered orally continuously daily on a 28 day cycle. Trastuzumab and mFOLFOX-6 will be administered as infusions every 2 weeks at standard doses without escalation. The sequence on the days when all agents are administered will be KD019 followed by trastuzumab and mFOLFOX-6.
3238842|NCT01273922|Placebo Comparator|Low Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo.
3238843|NCT01273922|Placebo Comparator|High Dose NDV-3 investigational vaccine|15 subjects will receive vaccine and 5 subjects will receive placebo
3238844|NCT01273935||Responder|Responder versus Non-Responder as a result of platelet function test
3238845|NCT01273935||Non-Responder|According to the result of platelet function test
3343473|NCT02205489|Experimental|GZ402673 LEMTRADA|First course: Intravenous infusion for 5 consecutive days. Second course (will occur 12 months after the first course of treatment): Intravenous infusion for 3 consecutive days.
3343474|NCT02205502|Experimental|Lidocaine|"Proper amount of lidocaine will be injected lacerated wound.~dosage form: fluid~dosage: not exceeding 1mg/kg~frequency: once~duration: n/a"
3343475|NCT02205502|Placebo Comparator|Normal saline|Normal saline will be used as a placebo for lidocaine
3343476|NCT02205515|Other|Radiotherapy|SBRT or EBRT
3343477|NCT02205528|Placebo Comparator|Treatment Period: Placebo QD|Participants will receive daily SC placebo injections during the 12-week, double-blind treatment period.
3343478|NCT02205528|Experimental|Treatment Period: NNC0090-2746 QD|Participants will receive daily 1.8-mg SC injections of NNC0090-2746 during the 12-week, double-blind treatment period.
3343479|NCT02205528|Active Comparator|Treatment Period: Liraglutide QD|Participants will receive open-label liraglutide via SC injection during the 12-week treatment period. The dose scheme will be as follows: 0.6 milligrams (mg) each day during Week 1, followed by 1.2 mg each day during Week 2, and 1.8 mg each day from Weeks 3 to 12.
3343480|NCT02205541|Experimental|Eculizumab|"300mg concentrate for solution for infusion. According to the patient body weight, there will be 3 to 5 injections administered in IV infusion at D0, D7, D14, D21 and D28.~Eculizumab (ECZ) will be administrated intravenously as a 30-minute injection."
3343481|NCT02205541|Placebo Comparator|Placebo|"Infusion of a solution with 5% glucose. The administration scheme will be the same as the Eculizumab arm : there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~Placebo will be administrated intravenously as a 30-minute injection."
3343482|NCT02205554|Active Comparator|Omnitram-Tramadol-Placebo|Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses.
3343483|NCT02205554|Active Comparator|Tramadol-Placebo-Omnitram|Tramadol 20 mg every 6 hours for 9 doses, followed by Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses.
3343484|NCT02205554|Active Comparator|Placebo-Omnitram-Tramadol|Placebo every 6 hours for 9 doses, followed by Omnitram 20 mg every 6 hours for 9 doses, followed by Tramadol 50 mg every 6 hours for 9 doses.
3343485|NCT02205567||Group 2|1000 mg/day of Bergamot-derived product
3343486|NCT02205567||Group 1|500 mg/day of Bergamot-derived product
3238846|NCT01273948|Experimental|Bavituximab 3 mg/kg|Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3238847|NCT01273948|Experimental|Bavituximab 0.3 mg/kg|Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3343487|NCT02205580|Experimental|Sufentanil infusion rate 0.02μg•kg-1•h-1|Sufentanil infusion rate 0.02μg•kg-1•h-1 lasted for 48 hours
3343488|NCT02205580|Experimental|Sufentanil infusion rate 0.03μg•kg-1•h-1|Sufentanil infusion rate 0.03μg•kg-1•h-1 lasted for 48 hours
3343489|NCT02205580|Experimental|Sufentanil infusion rate 0.04μg•kg-1•h-1|Sufentanil infusion rate 0.04μg•kg-1•h-1 lasted for 48 hours
3343490|NCT02205593|Placebo Comparator|Control|patient group receiving regular follow-up visits (baseline, 3 months, 6 months, 9 months)
3343491|NCT02205593|Active Comparator|Haut Tief patient education|patient group receives the educational program with regular follow-up visits (baseline, 3 months, 6 months, 9 months).
3343492|NCT02205606|Active Comparator|HGP0816 5mg|
3343493|NCT02205606|Active Comparator|HGP0816 10mg|
3238848|NCT01273948|Active Comparator|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks
3238849|NCT01273974|Experimental|intradermal influenza vaccine|
3238850|NCT01273974|Active Comparator|intramuscular influenza vaccine|
3238851|NCT01273987|Experimental|neobladder with round lig|ileal neobladder suspened with round ligament
3238852|NCT01273987|No Intervention|standard neobladder|conventional standard neobladder
3238853|NCT01274000|Placebo Comparator|placebo group|
3343494|NCT02205606|Active Comparator|HGP0816 20mg|
3343495|NCT02205606|Experimental|HCP1306 5/10mg|
3343496|NCT02205606|Experimental|HCP1306 10/10mg|
3343497|NCT02205606|Experimental|HCP1306 20/10mg|
3343498|NCT02205619|Experimental|Ultrasonic instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic instrumentation (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) treatment group
3343499|NCT02205619|Experimental|Hand instrumentation|Prior to extraction, the teeth (N = 12) were randomly included into hand curette (Gracey curettes, American Eagle, Missoula, MT, USA) treatment group hand instrumentation (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA)
3343500|NCT02205619|Experimental|subgingival airpolishing with glycine|"Prior to extraction, the teeth (N = 12) were randomly included into air-polishing (Air Flow Master Piezon®, EMS SA, Nyon - Swiss) with the glycine powder (Air-flow® Powder Perio, EMS) treatment group.~subgingival airpolishing with glycine(Air-flow® Powder Perio, EMS SA, Nyon, Swiss)"
3238854|NCT01274000|Experimental|YM060 low-dose group|
3238855|NCT01274000|Experimental|YM060 middle-dose group|
3343501|NCT02205619|Experimental|ultrasonic following airpolishing|Prior to extraction, the teeth (N = 12) were randomly included into ultrasonic following airpolishing ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) with the glycine powder treatment group
3343502|NCT02205632|Other|High myopic patients with lacker craks|
3343503|NCT02205632|Other|High myopic patients without lacker cracks|
3343504|NCT02205645|Experimental|FibroFix™ Meniscus scaffold|The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
3343505|NCT02205658||Autism|Individuals, aged 18-95 years, with a pre-existing diagnosis of Autism Spectrum Disorder with or without a co-morbid diagnosis of Sensory Processing Disorder.
3238856|NCT01274000|Experimental|YM060 high-dose group|
3238857|NCT01274013||Study Group|Individuals with chronic Hepatitis C
3343506|NCT02205658||Sensory Processing|Individuals, aged 18-95 years, with a pre-existing diagnosis of Sensory Processing Disorder with no co-morbid diagnosis of Autism Spectrum Disorder
3343507|NCT02205658||Typical|Typically functioning individuals aged 13-95 years
3343508|NCT02205671|Experimental|Intervention|Building Better Caregivers Small-group Workshop
3238858|NCT01274013||Control Group|Healthy individuals
3343509|NCT02205684|Experimental|Physical activity|Aerobic High Intensity Training (HIT)
3343510|NCT02205684|Active Comparator|Computer game skills training|Playing Nintendo Wii Sports
3343511|NCT02205697|Experimental|Implementation intention|The entire cohort will be asked to create an implementation intention to increase their intake of fruit and vegetables over the study period.
3343512|NCT02205710|Experimental|Computerized cognitive training|Series of gamified tasks.
3343513|NCT02205710|Placebo Comparator|Computerized game training|Series of gamified tasks.
3343514|NCT02205723|Experimental|Smartphone Asthma Control|Smartphone Asthma Control
3343515|NCT02205723|Active Comparator|Control|Control group
3343516|NCT02205736|Other|Living Room Visit participants|Latino women who received breast health education while attending a Living Room Visit.
3238859|NCT01274026||evaluation of benefit of sapropterin|Intervention 'sapropterin dihydrochloride': 20 individuals, either known to be non-responsive, or naive to sapropterin, are given a 4 week administration of sapropterin. Pre-, and Post- evaluation of behavior, executive function, neurotransmitter function, and genomic expression are assessed and evaluated for change.
3238860|NCT01274039||Patient with a trabeculectomy planed|
3238861|NCT01274052||Gestational Diabetes Mellitus|Women with Gestational Diabetes Mellitus
3238862|NCT01274052||Normal Glucose Tolerance|Women with Normal Glucose Tolerance
3343517|NCT02205749|Other|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
3343518|NCT02205749|Other|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
3343519|NCT02205749|Other|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
3343520|NCT02205762|Experimental|Stratum I|"Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV).~Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences."
3343521|NCT02205762|Experimental|Stratum II|"A uniform intensive 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms INDOMETHACIN and 6-MP/MTX (mercaptopurine and Methotrexate)."
3343522|NCT02205762|Experimental|Stratum III|"Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy.~The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum."
3343523|NCT02205762|Experimental|Stratum IV|To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
3343524|NCT02205762|Experimental|Stratum V|"Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH~- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice."
3343525|NCT02205762|Experimental|Stratum VI|"Natural history and management of other SS-LCH not eligible for stratum I group 2.~Treatment Options- Management (mostly wait & see and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator.~Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy.~Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V."
3343526|NCT02205775|Placebo Comparator|twice placebo before PCI|
3343527|NCT02205775|Experimental|atorvastatin 80 + 40 mg pre PCI|
3343528|NCT02205775|Experimental|rosuvastatin 40 + 40 mg before PCI|
3343529|NCT02205775|Experimental|rosuvastatin 5 + ezetimibe 10 mg twice before PCI|
3343530|NCT02205827|No Intervention|Single-arm|healthy volunteers
3343531|NCT02205840|Experimental|SI-614|
3343532|NCT02205840|Placebo Comparator|Placebo Vehicle|
3343533|NCT02205853|Other|The patient-directed (PD) strategy|A single-faceted patient-directed (PD) strategy that will embed the change at patient level.
3238863|NCT01274065||Psychiatric illnesses|Participants will reside at the South Dakota Developmental Center (SDDC), which serves a unique population of people with developmental disabilities and co-occuring psychiatric disorders.
3343534|NCT02205853|Other|The multi-faceted (MF) strategy|A multi-faceted (MF) strategy that will embed the change at the patient, professional and organizational levels.
3343535|NCT02205866|Active Comparator|Group A|Non Obese patients
3343536|NCT02205866|Experimental|Group B|Obese patients
3343537|NCT02205879|Experimental|pregabalin|
3343538|NCT02205879|Placebo Comparator|Placebo|
3343539|NCT02205892|Active Comparator|Lupeol|
3343540|NCT02205892|Placebo Comparator|Vehicle|
3343541|NCT02205905|Experimental|14C PER977|Open-label, single-dose, non-randomized study of 14C PER977 in six healthy male subjects
3343542|NCT02205918||Sham TMS|"Participants in this group will receive one, 30 minute session of inactive (sham) TMS."
3343543|NCT02205918||Active TMS|Participants in this group will receive one, 30 minute session of 1hz TMS.
3343544|NCT02205931|Experimental|Ketogenic diet|8 week trial of the ketogenic diet (KD) therapy. Children allocated to KD therapy will have their diets individually calculated by a paediatric dietitian with consideration of daily calorie requirements, adequate protein intake for growth and vitamin and mineral supplementation. All diets will be implemented according to a classical KD protocol, i.e. based on a ratio of fat to carbohydrate and protein that will usually be between 2:1 and 4:1.
3343545|NCT02205931|Active Comparator|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug (AED) for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy according to a standardised manual (consensus document) written following the initial workshop of the paediatric neurologists from all the trial centres.
3343546|NCT02205944|No Intervention|Control Group|The control group will receive routine vascular access pre-op teaching and care.
3343547|NCT02205944|Experimental|Normal Exercise Group|"Group 1 (Normal Exercise Group): progressive handgrip exercise~Group 2 (Restricted Blood Flow Exercise Group): progressive handgrip exercise with controlled tourniquet"
3343548|NCT02205957||Training quality|Tunisian residents in anesthesiology and intensive care
3238864|NCT01274078|No Intervention|conventional food|Regular eating habits during exercise period
3238865|NCT01274078|Active Comparator|Blueberries|Intervention: Addition of blueberries (150g/day) to regular food during the exercise period on days with exercise
3343549|NCT02205970|Active Comparator|TENS active|TENS (interactive): frequency (90 and 150 pps) and pulse duration (300 and 400μs)
3343550|NCT02205970|Sham Comparator|TENS sham|Placebo lasting 35 minutes.
3343551|NCT02205996|Active Comparator|Controls|Weight-matched healthy controls. Euglycaemic Hypoglycaemic insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
3238866|NCT01274091|Experimental|P/S-ratio 1.0|"Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:~polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0."
3238867|NCT01274091|Experimental|P/S-ration 0.3|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
3343552|NCT02205996|Active Comparator|Type 2 diabetes|People with a known diagnosis of type 2 diabetes. Euglycaemic Hypoglycaemic Insulin clamp. Using hyperinsulinaemic clamps, blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
3343553|NCT02206009|Experimental|Collagen membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
3343554|NCT02206022|Experimental|Remifentanil|Patients who undergone a Central Venous Catheter (CVC) insertion under remifentanil infusion
3343555|NCT02206022|Placebo Comparator|Placebo|Patients who undergone a Central Venous Catheter (CVC) insertion under placebo infusion
3238868|NCT01274104|Active Comparator|Vitamin D|Subjects will take 5,000 IU-capsules of vitamin D3 three times a day (for a total of 15,000 IU) for 14 days
3238869|NCT01274104|Placebo Comparator|Control|Subjects will take 3 capsules of placebo every day for 14 days
3238870|NCT01274117|Placebo Comparator|One-stage transposition of the basilic vein|One-stage transposition of the basilic vein
3238871|NCT01274117|Experimental|Two-stage transposition of the basilic vein|Two-stage transposition of the basilic vein
3343556|NCT02206035|Experimental|Tacrolimus, Methotrexate and Tocilizumab (Tac/MTX/Toc)|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant. Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11. Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
3343557|NCT02206048|Experimental|High-Resolution Microendoscopy (HRME)|Before participant's cold knife cone biopsy (CKC), topical application of 0.01% proflavine solution applied to cervix. HRME probe applied to cervix and high-resolution images obtained. Participant undergoes cervical biopsies of any abnormal areas noted with colposcopy and/or HRME. Immediately following the CKC, the removed surgical specimen evaluated. Proflavine reapplied to surgical specimen and repeat evaluation with HRME performed and high-resolution images obtained.
3238872|NCT01274130|Experimental|Ranitidine|
3238873|NCT01274130|Experimental|Verapamil|
3343558|NCT02206074|Active Comparator|T2DM|Crossover design where participants will start in the Beetroot juice condition, and after a washout period, move into the other condition.
3343559|NCT02206074|Placebo Comparator|Placebo|Crossover design where participants will start in the placebo condition, and after a washout period, move into the other condition.
3343560|NCT02206087|Experimental|Cohort 1|100 mg PER977 or placebo administered following heparin sodium
3238874|NCT01274143|Active Comparator|Telephone-delivered risk intervention|Participants in this arm receive a personalized telephone-risk assessment intervention provided by a trained cancer risk counselor.
3343561|NCT02206087|Experimental|Cohort 2|200 mg PER977 or placebo administered following heparin sodium
3343562|NCT02206087|Experimental|Cohort 3|300 mg PER977 or placebo administered following heparin sodium
3343563|NCT02206087|Experimental|Cohort 4|400 mg PER977 or placebo administered as a single agent followed by 3-day wash-out. A second dose of 400 mg PER977 or placebo will be administered following heparin sodium injection
3343564|NCT02206087|Experimental|Cohort 5|500 mg PER977 or placebo will be administered following heparin sodium injection
3238875|NCT01274143|Active Comparator|Mailed pamphlet intervention group|Participants in this group receive a mailed pamphlet containing information about familial colorectal cancer risk and screening.
3343565|NCT02206087|Experimental|Cohort 6|600 mg PER977 or placebo will be administered following heparin sodium injection
3343566|NCT02206100|Experimental|Cohort 1|100 mg PER977 (10 subjects); the dose may be repeated two (2) times after an approximate one (1) hour interval for a maximum total of three (3) doses
3343567|NCT02206100|Experimental|Cohort 2|200 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour for a maximum total of two (2) doses
3343568|NCT02206100|Experimental|Cohort 3|300 mg PER977 (10 subjects); the dose may be repeated once at approximately one hour after the initial dose for a maximum of total of two (2) doses
3343569|NCT02206100|Experimental|Cohort 4|4 x 25 mg PER977 (10 subjects); study drug will be administered every 30 minutes for a total of 4 doses (cumulative dose of 100 mg PER977)
3343570|NCT02206113|Experimental|Standing workstation - 16 weeks|This arm, Standing workstation - 16 weeks, received the intervention of a standing workstation for 16 weeks. For the first 8 weeks, the participants were instructed how long to stand per hour for an 8 hour shift. The second 8 weeks their use was monitored for sustainability.
3343571|NCT02206113|Active Comparator|Standing workstation - second 8 weeks|This arm, Standing workstation - second 8 weeks, received the intervention of a standing workstation for 8 weeks of the study. For the first 8 weeks, the worked at their normal desks without an intervention. The second 8 weeks they received a standing workstation and their use was monitored.
3343572|NCT02206126|Experimental|Energy restriction group|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
3343573|NCT02206126|No Intervention|Control group|The control group was advised not to change their food intake.
3343574|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 5mg|Candesartan 8mg + Amlodipine 5mg, po, q.d.
3343575|NCT02206165|Experimental|Candesartan 8mg + Amlodipine 10mg|Candesartan 8mg + Amlodipine 10mg, po, q.d.
3343576|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 5mg|Candesartan 16mg + Amlodipine 5mg, po, q.d.
3238876|NCT01274156|Active Comparator|shock wave treatment|
3238877|NCT01274156|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
3238878|NCT01274195|Experimental|Busulfan|
3238879|NCT01274208||Gaucher Disease with Hepatitis C|
3343577|NCT02206165|Experimental|Candesartan 16mg + Amlodipine 10mg|Candesartan 16mg + Amlodipine 10mg, po, q.d.
3343578|NCT02206165|Active Comparator|Candesartan 8mg|Candesartan 8mg, po, q.d.
3238880|NCT01274221|Placebo Comparator|Placebo|
3238881|NCT01274221|Active Comparator|SPD489|
3238882|NCT01274234|Experimental|COMBO Stent|COMBO Stent
3238883|NCT01274247|Active Comparator|Topical Benzocaine|For infants treated with topical benzocaine prior to the procedure
3238884|NCT01274247|No Intervention|no benzocaine|No benzocaine applied
3238885|NCT01274260|Active Comparator|Experimental Group|Intervention: Subjects in this study group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
3238886|NCT01274260|Placebo Comparator|Placebo Group|Intervention: The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline. The placebo group with receive the masked study drug in infusion rates that mimic the infusions received by the experimental group.
3238887|NCT01274273|Experimental|Interleukin-2, interferon, bevacizumab|
3238888|NCT01274273|Active Comparator|Interleukin-2 and interferon-alfa|
3238889|NCT01274299||Infants|Healthy 0-4 years of age both boys and girls
3343579|NCT02206165|Active Comparator|Candesartan 16mg|Candesartan 16mg, po, q.d.
3343580|NCT02206165|Active Comparator|Amlodipine 5mg|Amlodipine 5mg, po, q.d.
3343581|NCT02206165|Active Comparator|Amlodipine 10mg|Amlodipine 10mg, po, q.d.
3343582|NCT02206178|Experimental|acetaminophen|"The purpose of this study is to assess the effectiveness of acetaminophen in association with N-acetylcysteine.~The objective of this study is to evaluate if the association in healthy volunteers of acetaminophen and N-acétylcystéine~- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
3343583|NCT02206178|Placebo Comparator|placebo|"- decrease the antinociceptive effect of acetaminophen in comparison to a group control~- and if this antinociceptive effect may depend of the genetic polymorphism of GSH enzyme"
3343584|NCT02206191||Mothers of 6-11 year olds|
3343585|NCT02206204|Experimental|Group A|Subjects in Group A receive selexipag on Days 3 to 23 and moxifloxacin-matching placebo on Days 2 and 24. Selexipag administered orally, twice a day, for 21 days according to the following multiple dose up-titration regimen: 400 μg on Days 3-5, 600 μg on Days 6-8, 800 μg on Days 9-11, 1000 μg on Days 12-14, 1200 μg on Days 15-17, 1400 μg on Days 18-20, and 1600 μg on Days 21-23 (only morning dose on Day 23).
3343586|NCT02206204|Experimental|Group B1|Subjects in Group B1 receive 400 mg moxifloxacin, orally on Day 2 and moxifloxacin-matching placebo, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
3343587|NCT02206204|Experimental|Group B2|Subjects in Group B2 receive moxifloxacin-matching placebo, orally on Day 2 and 400 mg moxifloxacin, orally on Day 24. Subjects receive placebo for selexipag, orally on Days 3 to 23.
3238890|NCT01274325|Experimental|Sereflo|Sereflo (25/125)
3238891|NCT01274325|Active Comparator|Seretide|Seretide (25/125)
3238892|NCT01274364|Experimental|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
3238893|NCT01274364|Active Comparator|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
3343588|NCT02206230|Experimental|Hypofractionated radiation therapy|Hypofractionated radiation therapy of 60 Gy in 20 fractions (3 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
3343589|NCT02206230|Active Comparator|Standard radiation therapy|Standard radiation therapy of 60 Gy in 30 fractions (2 Gy per fraction) with concurrent temozolomide 75 mg/m2 given 7 days/week. After a 4-week break, temozolomide days 1-5 every 28 days for 6 cycles.
3343590|NCT02206243||Embozene|Patients receiving Embozene microspheres
3238894|NCT01274377|Experimental|Recipients Using 3-5/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 Human Leukocyte Antigen (HLA) Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
3238895|NCT01274377|Experimental|Recipients Using 6/6 Matched Donors|There will be an equal number of subjects (10) receiving transplants from 3-5/6 HLA Matched Donors as those receiving transplants from 6/6 HLA Matched Donors for a total of 20 subjects on study.
3238896|NCT01274390||Shorter-storage red blood cell units|Red blood cell units stored <= 10 days
3238897|NCT01274390||Longer-storage red blood cell units|Red blood cell units stored >= 21 days
3343591|NCT02206256|Active Comparator|Low calorie diet|Low calorie diet 2 weeks pre-operatively
3343592|NCT02206256|Active Comparator|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
3343593|NCT02206269||Alair System|This is a single arm study with Alair system used.
3343594|NCT02206295|Experimental|Treatment Sequence AB|"Subjects will receive Treatment A in Period 1 followed by Treatment B in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
3375860|NCT03683251|Experimental|PDS Implant Cohort 3 (US only)|"Participants in the intravitreal ranibizumab arm of Study GX28228 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 168 to Week 240.~Eligible participants from Study GX28228 will be enrolled upon completion of their final visit."
3238898|NCT01274403|Experimental|Melphalan, prednisone plus Thalidomide|
3238899|NCT01274403|Active Comparator|Melphalan and Prednisone|
3238900|NCT01274442|Active Comparator|CONTROL: no dental implants lost|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, who did not lose their implants.
3238901|NCT01274442|Experimental|CASE: patients lost one or more implants|Group of patients who received an implant during a dental implant surgery in the University Hospital in Ghent in 2004-2007, but who lost one or more implants.
3238902|NCT01274455|Experimental|Therapy|
3238903|NCT01274481|Experimental|Iloprost|All patients will have their response to Iloprost compared to baseline pre-treatment.
3238904|NCT01274507|Other|All participants|
3238905|NCT01274546||"In Office"|These subjects will come into the office to perform the consenting process, and complete all evaluations required at the only visit in the study.
3238906|NCT01274546||"Telephone Arm"|These subjects will be consented over the phone and give a verbal consent to participate. They will complete all aspects of the study over the phone except for the knee society score evaluation and the x-ray.
3238907|NCT01274598|Experimental|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|Lactobacillus rhamnosus GG ATCC 53103 1 x 10^10 twice a day for 28 days
3238908|NCT01274650|Other|Decubitis Ulcer|Patients admitted to the hospital with decubitus ulcers in the ischial, sacral, or coccyx area.
3238909|NCT01274663|Experimental|10 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3343595|NCT02206295|Experimental|Treatment Sequence BA|"Subjects will receive Treatment B in Period 1 followed by Treatment A in Period 2. There will be a washout period lasting at least 6 days between treatments.~Treatment A: up-titration from Day 1-18 will performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with 8 film-coated tablets, 200 μg each, b.i.d. from Day 19 to the morning dose of Day 23.~Treatment B: up-titration from Day 1-18 will be performed in 200 μg steps every fourth day with multiples of 200 μg film-coated tablets starting with 400 μg selexipag b.i.d. The up-titration will be followed by treatment with one single film-coated tablet, 1600 μg, b.i.d. from Day 19 to the morning dose of Day 23."
3343596|NCT02206308|Experimental|single arm|Three escalating single-dose groups of chimeric anti-CD20 monoclonal antibody(SCT400) : 250 mg/m2 , 375 mg/m2，500 mg/m2, once a week for 4 doses;
3343597|NCT02206321||Navigation total knee arthroplasty|Navigation total knee arthroplasty
3343598|NCT02206321||Conventional total knee arthroplasty|Conventional total knee arthroplasty
3343599|NCT02206334|Experimental|Stereotactic Body Radiation Therapy (SBRT)|Patients undergo 3-5 fractions of image-guided stereotactic body radiation therapy to all existing metastases over 1-3 weeks with at least 40 hours between treatments for an individual metastasis.
3343600|NCT02206347|Other|attention focus|
3343601|NCT02206360||Individuals at elevated risk for pancreatic cancer|Individuals with an elevated risk of developing pancreatic cancer as either equal to or greater than five times the general population risk, or five times the average risk (1.5%) of developing pancreatic cancer by age 70; that is a 7.5% lifetime risk.
3343602|NCT02206386|Experimental|MentalHealthTraining-Net|MHTraining-Net is an implementation strategy that uses a web-based platform with several long distance tools (e.g. e-learning modules, consultation, telephone calls, toolkits, and discussion boards) to deliver four types of implementation activities: infrastructure development, training and education, quality improvement, and social networking.
3343603|NCT02206386|Active Comparator|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded trainings in the use of the protocol and depression screening posted by Brightree.
3343604|NCT02206412||HMGB1 group|
3343605|NCT02206425|Experimental|bortezomib + melphalan + prednisone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343606|NCT02206425|Experimental|bortezomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343607|NCT02206425|Experimental|carfilzomib + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343608|NCT02206425|Experimental|bortezomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343609|NCT02206425|Experimental|carfilzomib + lenalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3238910|NCT01274663|Experimental|30 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3375861|NCT03683251|Experimental|PDS Implant Cohort 4 (US only)|"Participants in the intravitreal ranibizumab arm of Study GR40548 who will receive the PDS implant upon study entry and refill-exchanges of 100 mg/mL ranibizumab Q24W. Participants will switch to an every 12 weeks (Q12W) visit schedule from Week 144 to Week 240.~Eligible participants from Study GR40548 will be enrolled upon completion of their final visit."
3238911|NCT01274663|Experimental|100 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3238912|NCT01274663|Experimental|300 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3238913|NCT01274663|Experimental|600 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3238914|NCT01274663|Experimental|800 mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3238915|NCT01274663|Experimental|xxx mg PF-05175157 or Placebo|Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
3238916|NCT01274676|Active Comparator|carotid stenting with MOMA|
3238917|NCT01274676|Active Comparator|Carotid stenting with filter wire EZ|
3343610|NCT02206425|Experimental|bortezomib + cyclophosphamide + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343611|NCT02206425|Experimental|bortezomib + cyclophosphamide + ascorbic acid|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib. Due to a potential drug-drug interaction between ixazomib and ascorbic acid, patients will receive ixazomib in the clinic in the morning and will be instructed to take ascorbic acid in the evening, followed by cyclophosphamide.
3343612|NCT02206425|Experimental|bortezomib + PLD + dexamethasone|MTD determination. Ixazomib will be administered on Days 1, 8 and 15 of a 28-day cycle at a starting dose of 3 mg in Cycle 1, and then intra-patient dose-escalation will proceed to 4 mg in Cycle 2. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3238918|NCT01274689||cohort|cohort of consecutively enrolled patients with lagophthalmos
3238919|NCT01274702|Experimental|Visual Reconstitution Therapy|
3343613|NCT02206425|Experimental|bortezomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343614|NCT02206425|Experimental|carfilzomib + pomalidomide + dexamethasone|Ixazomib will be administered PO at 4 mg on Days 1, 8 and 15 of a 28-day cycle. All other agents will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed. Patients that were on a 21-day cycle schedule will follow a 28-day cycle schedule and receive ixazomib on days 1, 8 and 15. Other drugs will be administered on the same days as they were given on their prior 21-day cycle schedule, except that, in the new 28-day schedule, day 1 of other drugs will be the same as day 1 of ixazomib.
3343615|NCT02206438|Experimental|1)C-LMA group|
3343616|NCT02206438|Active Comparator|2)Air-Q group|
3343617|NCT02206464|Experimental|Group 1|H7 DNA vaccine on Day 0 and H7N9 MIV at StudyWeek 16
3343618|NCT02206464|Experimental|Group 2|H7 DNA and H7N9 MIV administered on Day 0 and H7N9 MIV boost at Study Week 16
3343619|NCT02206464|Experimental|Group 3|H7N9 MIV on Day 0 and H7N9 MIV at Study Week 16
3343620|NCT02206477|Experimental|DMSO treatment group|The treatment group will be exposed to DMSO according to our built protocol. On the seventh post-operative day, the patient will be guided to set 10 cc of DMSO soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
3343621|NCT02206477|Placebo Comparator|the control group|The control group will be treated with the same post-operative protocol, but with 0.9% saline instead of DMSO. On the seventh post-operative day, the patient will be guided to set 10 cc 0.9% saline soaked gauze compresses on the breast, twice a day for 20 minutes, for the term of 6 weeks. This treatment will be holed for 24 hours on tissue expander inflation dates. A repeated course of compresses will be taken after adjuvant radiotherapy, starting 24 hours after the last therapy.
3343622|NCT02206490|Active Comparator|Naltrexone Study Drug|Subjects will take naltrexone 4.5 mg daily for three months.
3343623|NCT02206490|Placebo Comparator|Naltrexone placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the naltrexone study drug.
3238920|NCT01274702|Active Comparator|Saccadic Eye Movement Training|
3238921|NCT01274728||ST-elevated myocardial infarction|Those with a condition of chestpain (or equal complains) and ECG changes confirming STEMI.
3238922|NCT01274741|Active Comparator|Seeking Safety (SS)|17 sessions of present-focused therapy Seeking Safety
3238923|NCT01274741|Experimental|Creating Change (CC)|17 sessions of past-focused Creating Change
3238924|NCT01274754||erythromycin group|Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.
3238925|NCT01274754||control group|no administration of erythromycin
3238926|NCT01274767||High risk cohort|Patients having history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have a negative test for H. pylori based on histology
3238927|NCT01274767||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
3238928|NCT01274780|Experimental|Darunavir / Ritonavir|
3238929|NCT01274780|Experimental|Atazanavir / Ritonavir|
3238930|NCT01274793|Active Comparator|Mosapride|In the control group were orally administered 5 mg mosapride citrate tablet s three times a day for 4 continu ous weeks if no severe adverse effects were found.
3238931|NCT01274793|Experimental|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
3343624|NCT02206490|Active Comparator|dextromethrophan study drug|subjects will take a sustained release dextromethorphan pill twice a day.
3343625|NCT02206490|Placebo Comparator|dextromethoprhan placebo|Subjects will take a 3 month course of a placebo pill identical in appearance to the dextromethorphan study drug.
3343626|NCT02206503|Experimental|Cyclophosphamide; Lenalidomide; Dexamethasone|"MM Patients who experienced biochemical progression during Rd treatment without CRAB (signs of organ damage, multiple myeloma-related, as renal impairment and/or anemia and/or new bone lesions and/or hypercalcemia), will continue:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days.~Dexamethasone orally at the dose of 40 mg once a week.~Adding:~· Cyclophosphamide orally at the dose of 50 mg/day on days 1-21 every 28 days. CRd combination will be continued for 9-4week cycles. Patients will not receive any maintenance therapy."
3343627|NCT02206516|Experimental|patients|Stimulation using tDCS will be administered daily, 5 days a week for 4 weeks. each session will last 22 minutes during which the anode electrode will be positioned over the right Inferior Frontal Gyrus (IFG) and the Katode electrode over the right Orbito Frontal Gyrus (OFG).
3343628|NCT02206529|Active Comparator|Social Network Engagement+Std Treatment|"Social Network Engagement = content and activities to help the parent engage his/her social network in supporting healthy lifestyle behaviors.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
3343629|NCT02206529|Other|Standard Treatment|"This comparator arm consists of historical controls, participants in the FOCUS trial who received standard treatment.~Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)"
3343630|NCT02206542|Experimental|Robot-assisted group|Electroacupuncture, physical therapy and upper limb rehabilitation robot
3343631|NCT02206542|Active Comparator|Control group|Electroacupuncture and physical therapy
3343632|NCT02206555|Experimental|Treatment group (TRUVADA)|Homosexual men and heterosexual men and women at high risk of HIV infection
3343633|NCT02206568|Experimental|URAL vs. Insulin lispro|Each subject will randomly be allocated to a treatment sequence consisting of 2 dosing visits during which the subject in a euglycaemic clamp setting will receive either a single dose of insulin lispro or URAL at predefined fixed dose levels in a randomized order.
3343634|NCT02206581||young healthy adult athletes|Hydration Monitor measurement of the ultrasound velocity and measures of hydration status including urine specific gravity, plasma and urine osmolality in male and female young adults after undergoing 3% acute dehydration and a 2-hr rehydration period
3343635|NCT02206594|Experimental|Descemetorhexis|
3343636|NCT02206633||Elderly, assisted living residents|Hydration Monitor ultrasound measurements
3343637|NCT02206646||Metalyse|weight-adjusted dose
3343638|NCT02206659|Experimental|Telmisartan|2-week placebo run-in period followed by 6 weeks of treatment with telmisartan
3343639|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
3343640|NCT02206711|Experimental|Single oral dose of [14C] BMS 955176|A single 180 mg oral dose of [14C] BMS-955176 containing approximately 80 microcurie of total radioactivity.
3238932|NCT01274793|Experimental|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
3238933|NCT01274806|No Intervention|Usual care|
3343641|NCT02206711|Experimental|Nasoduodenal (ND) Tube Cohort|A single dose of [14C] BMS 955176 on Day 1 with ND placement 1 hour post dose to facilitate continuous bile collection though 8 hours post dose.
3343642|NCT02206724|Experimental|STEREOTACTIC BODY RADIOTHERAPY|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland
3238934|NCT01274806|Experimental|Physical therapy|
3238935|NCT01274819|Experimental|Dynamic light|ICU patients exposed to dynamic light during ICU stay
3238936|NCT01274819|No Intervention|Normal Light|control group is exposed to normal light during ICU stay
3238937|NCT01274832||Late-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease > 10 years
3238938|NCT01274832||Early-treated PD patients|Patients affected by Parkinson Disease, implanted with STN DBS and with an history of disease <7 years
3343643|NCT02206737|Experimental|E-Cigarette|3 doses of e-cigarette to be given No nicotine Low dose nicotine High dose nicotine
3343644|NCT02206750|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3343645|NCT02206750|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3343646|NCT02206763|Experimental|Momelotinib (MMB)+erlotinib|Participants will receive momelotinib (MMB) plus erlotinib.
3343647|NCT02206789|Active Comparator|penetrating keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators.~3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
3238939|NCT01274845|Other|Heliox|
3238940|NCT01274858||lung cancer surgery|
3238941|NCT01274871||lung cancer surgery|
3238942|NCT01274884|Active Comparator|Acromioclavicular joint dislocation|Surgery: Arthroscopic repair using the Tightrope fixation device
3238943|NCT01274910|Active Comparator|Fish oil group|Treatment Group.
3238944|NCT01274910|Placebo Comparator|Control group|Placebo group
3238945|NCT01274923|Sham Comparator|shock wave treatment|
3238946|NCT01274923|Sham Comparator|"MEDISPEC Sham"|"MEDISPEC Probe does not deliver energy but creates same noise and sensation of active probe"
3238947|NCT01274936|Experimental|Qishe|
3238948|NCT01274936|Placebo Comparator|Control|Qishe Placebo
3238949|NCT01274949|Experimental|LI-ESWT|Low intensity shock wave treatment- 12 sessions
3238950|NCT01274962|Experimental|A - neoadjuvant chemotherapy|Patients in arm A will receive 6 cycles of FOLFOX chemotherapy prior to radiotherapy and surgery as well as 6 cycles of chemotherapy in adjuvant
3238951|NCT01274962|Experimental|Arm B - adjuvant chemotherapy|Patients in arm B will receive 12 cycles of FOLFOX after radiotherapy and surgery
3238952|NCT01274988|Experimental|Deep Brain Stimulation|Continuous deep brain stimulation of bilateral nucleus accumbens
3343648|NCT02206789|Active Comparator|therapeutic keratoplasty|"each arm will have two groups A and B.. Only on topical steroids(prednisolone acetate1%) group A On topical steroids + 2% cyclosporine Group B . Methodology of drug administration In both agroups 1. Schedule of topical steroid administration : 6 times for 2 weeks; 5 times for 2 weeks; 4 times for a month; 3 times for a month, and, subsequently twice-a-day until 1 year is completed . Topical steroids will be withdrawn at the end of ine year.Systemic steroids may be administered in the initial 2 weeks at the discretion of the investigators. (For all patients with fungal keratitis topical steroids will be administered only after 2 weeks post keratoplasty.) Until then diclofenac sodium0.1% may be used 3. Patients randomized to receive 2% cyclosporine will receive the same 3 times a day for 2years~."
3343649|NCT02206802||Predicted as non-responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as non-responders. 5% minoxidil topical foam will be administered to subjects in this group.
3343650|NCT02206802||Predicted as responders|Patients that the minoxidil response in-vitro diagnostic kit predicted as responders. 5% minoxidil topical foam will be administered to subjects in this group.
3343651|NCT02206815|Active Comparator|Ticagrelor+Warfarin|Ticagrelor:Plain, round, yellow, film-coated tablet, 90mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
3343652|NCT02206815|Active Comparator|Clopidogrel+Aspirin+Warfarin|Clopidogrel:Light red bisulfate tablets, containing one 75mg; Aspirin:Plain, round, white, film-coated tablet, 100mg; Warfarin:Plain, round, white, film-coated tablet, 2.5mg
3343653|NCT02206841||NAFLD|Patients with suspected nonalcoholic fatty liver disease will be screened. Of all patients fulfilling inclusion criteria, baseline characteristics will be obtained. In addition, laboratory, radiologic evaluations such as ARFI, SWE, and transient elastography will be performed. A diagnostic liver biopsy will be performed for analysis of steatosis and fibrosis. Parts of the remaining liver tissue will be stored by frozen tissue and paraffin block for future study. Several serum and plasma samples are collected of patients and stored for future analysis such as targeted SNP arrays, super-enhancer RNA (eRNA) expression, whole exome sequencing, RNA chip sequencing, RNA microarray, genomic DNA, metabolomics, fecal microbiome, metabolite, metagenome/metatranscriptome analyses.
3343654|NCT02206854|Experimental|R-flurbiprofen|200 mg R-flurbiprofen in gelatine capsules once
3343655|NCT02206867|Experimental|LBAL|Developed by LG Life Sciences
3343656|NCT02206867|Active Comparator|Humira®|Abbvie
3343657|NCT02206893|Experimental|Mobile: Professional and peer support|A mobile app that provides both professional support and peer support
3343658|NCT02206893|Experimental|Mobile: Peer support|A mobile app that provides peer support, but not professional support
3343659|NCT02206893|Experimental|Mobile: Professional Support|A mobile app that provides professional support, but no peer support
3343660|NCT02206893|Active Comparator|Mobile: No Support|A mobile app that provides neither peer support nor professional support
3343661|NCT02206893|Active Comparator|Web: No Support|A web app that provides neither peer support, nor professional support
3343662|NCT02206906||Study Participants|All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
3238953|NCT01274988|Active Comparator|Standard Control|methadone maintenance treatment
3343663|NCT02206932|Other|Sofosbuvir + Simeprevir|Subjects will be enrolled and treated with simeprevir 150 mg and sofosbuvir 400 mg once daily for 12 weeks
3343664|NCT02206945|Experimental|neurofeedback|Two imaging sessions of neurofeedback.
3343665|NCT02206945|Placebo Comparator|control feedback|Two imaging sessions of feedback
3343666|NCT02206958|Other|No treatment control group|No treatment control group
3343667|NCT02206958|Experimental|Behavioral Urinary Incontinence Treatment|12 week program combining behavioral treatments for urinary incontinence and physical activity
3343668|NCT02206971|Active Comparator|Feedback Group|receive a Smoking Cessation Manual, the opportunity for smoking cessation counseling on the phone, and urine analyses feedback via the mail plus a phone call to discuss the information
3343669|NCT02206971|No Intervention|Standard Care|receive a Smoking Cessation Manual and the opportunity for smoking cessation counseling on the phone
3343670|NCT02206984|Active Comparator|tamoxifen|Tamoxifen is administered orally, at a dose of 20 mg,daily, for 21 days
3343671|NCT02206984|Active Comparator|Anastrozole|1mg given orally daily for 21 days
3343672|NCT02206984|Active Comparator|fulvestrant|500 mg, administered as two 250 mg IM injections, given on days 1 and 14
3238954|NCT01275001||Intervention children|Children who are receiving a Suzuki-like violin instruction through their participation in an Early Childhood/Headstart preschool program
3238955|NCT01275001||Control Group|Preschool-age children who are not receiving Suzuki-like violin instruction
3238956|NCT01275014|Placebo Comparator|Placebo|
3343673|NCT02206997||Passive Insulation standard treatment|no active warming before start of anesthesia and no active warming at PACU
3343674|NCT02206997||Active prewarming treatment|active warming before start of anesthesia and active warming at PACU following recommendations of S3-guideline
3238957|NCT01275014|Experimental|Dexamethasone|
3238958|NCT01275027|Experimental|Nutralin|Individuals with Type 2 Diabetes
3238959|NCT01275027|Placebo Comparator|Placebo|Individuals with Type 2 Diabetes
3343675|NCT02207010|Experimental|AZD1775|Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
3343676|NCT02207023|No Intervention|Memory Training Program|Participants will participate in 7 memory training coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
3238960|NCT01275040|Experimental|Mobile screening team|The Primary Health Care clinics where the mobile screening team will visit and active screening for DM complications will take place.
3238961|NCT01275040|Active Comparator|No mobile screening team|No mobile team will visit clinics and active screening for DM complications will not be done. Patients and Health Workers will receive Education, same as intervention arm but no enhanced care.
3238962|NCT01275105|Other|Vehicle|
3238963|NCT01275105|Active Comparator|Brimonidine Tartrate 0.01%|
3343677|NCT02207023|Experimental|Healthy Lifestyle Training Program|Participants will participate in 7 lifestyle coaching sessions (two in the first month) over a 6 month period. The coaching sessions will be administered by phone.
3343678|NCT02207036|Experimental|Facebook intervention|Assignment to private group on Facebook with 3 months of content delivered to the group.
3343679|NCT02207036|Active Comparator|Referral|Referral to smokefree.gov website
3343680|NCT02207049|Active Comparator|Three Meals (TM)|Preschoolers will be provided their caloric needs within three meals.
3343681|NCT02207049|Active Comparator|Meal plus Snack (M+S)|Preschoolers will be provided three meals and two snacks, with total amount of food provided in the day the same as the Three Meal (TM) arm.
3343682|NCT02207049|Active Comparator|Three Meal plus Snack (TM+S)|Preschoolers will be provided three meals and two snacks with total amount provided in the meals equal to the Three Meal (TM) arm and total amount provided in the snacks equal to Meal plus Snacks (M+S) arm.
3343683|NCT02207062|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD in the absence of disease progression or unacceptable toxicity.
3343684|NCT02207075||Subjects with SPMS|"Secondary progressive MS Subjects either untreated or on consistent treatment for six months prior to enrollment.~SPMS subjects will have two baseline [11C]PK-11195 PET scans (separated by 24 to 72 hours, test-retest) and subsequent scans at 6, 12 and 24 months. SPMS Subjects will have brain MRI's at baseline, 6, 12 and 24 months."
3343685|NCT02207075||Normal Control Subjects|Healthy Controls will have 2 baseline [C11]PK-1195 PET scans and 1 MRI.
3343686|NCT02207101|Active Comparator|E-OJ-01 (OXYJUN)|E-OJ-01 (OXYJUN). Dose: 01 capsule to be taken orally daily after lunch.
3343687|NCT02207101|Placebo Comparator|Placebo|Matching placebo capsules [for E-OJ-01 (OXYJUN)] composed of microcrystalline cellulose. Dose: 01 capsule to be taken orally daily after lunch.
3343688|NCT02207114|No Intervention|Observational|9 blood biomarkers (including C reactive protein and Procalcitonin) will be assessed across 3 days. Results will not be shared with the subject's medical team. At 3 days, the definitive diagnosis of infection will be determined using Center for Disease Control (CDC) criteria; this will serve as the gold standard for determining biomarker test characteristics. Additional data to collect: demographics, comorbidities, medication use (like antibiotics), lab cultures, x-rays, sepsis resolution, length of hospital stay, and ultimate outcome (i.e., discharge, death). Phase I will identify the biomarker(s) providing the greatest negative predictive value in identifying patients at very low likelihood bacterial infection.
3343689|NCT02207114|Experimental|Biomarker Algorithm Intervention|"The Algorithm arm is equivalent to the intervention. Biomarker algorithm along with the patient's biomarker assay results will be given to clinical team to assist in deciding to continue antibiotics.~The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs."
3343690|NCT02207127||MRI, DISE, and Surgery|All participants will undergo MRI and DISE prior to undergoing surgical treatment of obstructive sleep apnea.
3343691|NCT02207140|Experimental|probiotic|HOWARU Restore
3343692|NCT02207140|Placebo Comparator|placebo|microcrystalline cellulose
3343693|NCT02207153||Chronic Hemodialysis|Initiation of chronic hemodialysis or currently undergoing chronic hemodialysis at one of the study centres
3238964|NCT01275105|Active Comparator|Oxymetazoline HCl 0.025%|
3343694|NCT02207153||Peritoneal Dialysis|Initiation of chronic peritoneal dialysis or currently undergoing chronic peritoneal dialysis at one of the study centres
3343695|NCT02207166||user group|volunteers who are willing to receive 40 minutes video monitoring and questionnaires while operation a electronic blood pressure measuring machines.
3343696|NCT02207179|No Intervention|Single Arm|LumaScan Image Guided Surgery
3343697|NCT02207192||Morbidly obese|Consecutive morbidly obese adults (BMI over or equal to 40 kg/m2) scheduled for bariatric surgery were prospectively recruited.Subjects with respiratory and cardiac history (asthma, Chronic obstructive pulmonary disease, heart failure) were excluded.
3343698|NCT02207205|Other|Catheter vs venipuncture blood samples|Evaluation of whether there is any difference in results of whole blood clotting time in blood samples drawn from an indwelling catheter versus direct venipuncture
3238965|NCT01275105|Active Comparator|Brimonidine Tartrate 0.025%|
3238966|NCT01275157|Experimental|LY2452473|15 mg, containing 100 micro curies of 14C labeled LY2452473 taken once only
3238967|NCT01275183|Experimental|Raltegravir and cisplatin|
3238968|NCT01275209|Experimental|HCD122|
3238969|NCT01275235||Exposure to Type II Diabetes for two siblings|Two sibling pairs with the same parents, between the ages of 20 to 34 in the Baton Rouge Area, having mother with diabetes while pregnant with one.
3238970|NCT01275248|Experimental|Ondansetron 0.5 mg|Ondansetron oral tablet 0.5 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3343699|NCT02207257|Experimental|Cohort 1|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 25 mg PER977 or placebo (n=10).
3343700|NCT02207257|Experimental|Cohort 2|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 50 mg PER977 or placebo (n=10).
3343701|NCT02207257|Experimental|Cohort 3|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 100 mg PER977 or placebo (n=10).
3343702|NCT02207257|Experimental|Cohort 4|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 300 mg PER977 or placebo (n=10). Study amendments expanded the cohort to include an additional 7 subjects (randomized 1:6 PER977:placebo) and up to an additional 4 placebo and 8 active subjects (ongoing).
3375862|NCT03683251|Experimental|PDS Implant Cohort 5 (ex-US only)|Participants from Study WR42221 who completed Week 24 but were not eligible to be randomized within WR42221 and who will be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
3343703|NCT02207257|Experimental|Cohort 5|Subjects will receive 60 mg edoxaban in the morning on Days 1-2. On Day 3 and 4, they will receive a single dose of 60 mg edoxaban, followed 3 hours later by a single dose of 600 mg PER977 or placebo (n=10). A protocol amendment expanded the cohort to include an additional 2 placebo and up to an additional 4 active subject.
3343704|NCT02207270|Experimental|Same day discharge|Patients who experienced uncomplicated PCI as well as an uncomplicated 6-hour observation period, will be randomly assigned to same day discharge.
3343705|NCT02207270|Other|Overnight stay standard care|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard care.
3343706|NCT02207296|Other|PVI group|Fluid optimisation using PVI
3238971|NCT01275248|Experimental|Ondansetron 0.75 mg|Ondansetron oral tablet 0.75 mg taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3238972|NCT01275248|Placebo Comparator|Placebo|Placebo oral tablet taken twice a day in addition to a serotonin reuptake inhibitor (SRI) for 12 weeks in the core period and for up to 30 months in the extension period.
3238973|NCT01275261|No Intervention|Foley catheter|Usual care - patients will have a Foley catheter placed on admission.
3238974|NCT01275261|Experimental|Nursing protocol to avoid Foley Catheter|No catheter will be placed on admission, and a nursing order protocol will be followed to avoid catheterization and avoid complications.
3343707|NCT02207296|No Intervention|Control group|Standard care using a hemodynamic protocol during general anesthesia
3343708|NCT02207309|Active Comparator|Pazopanib|800mg, oral, 24 months
3238975|NCT01275274|Active Comparator|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone.
3238976|NCT01275274|Experimental|Retinoic acid|Tretinoin in addition to standard of care
3343709|NCT02207309|Placebo Comparator|Placebo|800mg, oral, 24 months
3343710|NCT02207335|Experimental|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
3343711|NCT02207335|Active Comparator|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
3343712|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with FlexPen®|
3343713|NCT02207348|Experimental|Liraglutide 0.6 mg s.c. with the PDS290 pen-injector|
3343714|NCT02207361|Experimental|Paclitaxel, Carboplatin，injection|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
3343715|NCT02207361|Active Comparator|Paclitaxel, Epirubicin，injection|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
3343716|NCT02207387|Experimental|MCW|Music Contingent Walking (MCW) group: study-specific musical device that measures gait and plays music in a portable manner as the participant is walking is set at a threshold individually calculated per participant, and the music will stop playing when walking strides fall below this threshold.
3343717|NCT02207387|Experimental|NCMW|Non-contingent Music Walking (NCMW) group: music on all the time regardless of the stride size.
3343718|NCT02207387|Experimental|NMW|Non-music walking (NMW/silent) group: no music on at all regardless of step size.
3343719|NCT02207387|Experimental|MCW+rasagiline|"Music contingent walking with rasagiline group: same paradigm as the previous MCW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
3343720|NCT02207387|Experimental|MMW+rasagiline|"Non-music (silent) walking with rasagiline group: same paradigm as the previous NMW, but with rasagiline prescribed as adjunct therapy.~Dosage: 0.5 mg/day for the first 2 weeks to be subsequently increased to 1 mg/day"
3343721|NCT02207426|Experimental|TobrAir® 6.0|Tobramycin 75mg inhalation solution
3238977|NCT01275287|Active Comparator|Standard of care|Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here.
3238978|NCT01275287|Experimental|Eculizumab arm|"Standard of care for ANCA vasculitis + eculizumab treatment~Standard of care for ANCA vasculitis treatment- depends on severity of disease and individual characteristics and medical history of each patient so this won't be described here."
3343722|NCT02207426|Experimental|TOBI® / PARI LC® PLUS Nebulizer|Tobramycin 300mg nebulizer solution
3343723|NCT02207426|Experimental|TOBI® Podhaler™|Tobramycin 112mg (4x28mg) inhalation powder
3238979|NCT01275352|Active Comparator|Arm 1|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
3238980|NCT01275352|Active Comparator|Arm 2|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
3238981|NCT01275352|Placebo Comparator|Arm 3|Caucasian hypertensive patients who are homozygous for ClC-Ka Arg/Arg 83 allele
3238982|NCT01275352|Placebo Comparator|Arm 4|Caucasian hypertensive patients who are homozygous for the ClC-Ka Gly/Gly83 allele
3343724|NCT02207439|Experimental|Single Arm Phase 2|
3343725|NCT02207452|Other|Salbutamol + Ipratropium|Treatment period 1: Salbutamol 5mg nebulised, single Dose. Treatment period 2: Ipratropium 500mcg nebulised, single dose.
3343726|NCT02207452|Other|Ipratropium + Salbutamol|Treatment period 1: Ipratropium 500mcg nebulised, single dose. Treatment period 2: Salbutamol 5mg nebulised, single Dose.
3343727|NCT02207504|Experimental|crizotinib and enzalutamide|"A traditional 3+3 dose escalation scheme will be used to identify the recommended phase 2 dose (RP2D) of crizotinib when used in combination with standard fixed dose enzalutamide.~Crizotinib- given orally daily-28 day cycle~Enzalutamide- given orally daily-28 day cycle"
3343728|NCT02207517|Experimental|Office-based verg/accomm therapy (OBVAT)|OBVAT requires a participant to undergo a specific vision therapy regimen with 16 weekly, 60-minute in-office treatment sessions. Vision Therapists (O.D., M.D., Orthoptists, or specially-trained technicians) administer the therapy in the office. OBVAT procedures are then supplemented with various home therapy procedures
3375863|NCT03683251|Experimental|PDS Implant Cohort 6 (ex-US only)|Participants from Study WR42221 randomized to the Q24W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q24W
3375864|NCT03683251|Experimental|PDS Implant Cohort 7 (ex-US only)|Participants from Study WR42221 randomized to the Q36W arm, who will continue to be treated with refill-exchanges of ranibizumab 100 mg/mL Q36W
3343729|NCT02207517|Placebo Comparator|Office-based placebo therapy (OBPT)|"Office-based Placebo Therapy (OBPT) requires a participant to undergo a specific therapy regimen of 16 weekly, 60 minute, in-office treatment sessions. Vision therapists (optometrists, ophthalmologists, orthoptists, or specially-trained technicians) administer the therapy in the office. OBPT procedures are then supplemented with placebo home therapy procedures.~The procedures for OBPT are designed with the intent of not providing a beneficial training effect on vergence, accommodation, saccadic accuracy, or visual attention beyond normal activities. However, the procedures are designed to simulate real vision therapy in such a way that it will be difficult for participants and parents to know that they have been assigned to the control group and thus are not receiving bonafide OBVAT"
3343730|NCT02207543|Experimental|Medical telephonecontact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
3343731|NCT02207582|Experimental|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
3343732|NCT02207582|Placebo Comparator|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
3343733|NCT02207595|Experimental|UCB5857 Cohort 1|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3343734|NCT02207595|Experimental|UCB5857 Cohort 2|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3343735|NCT02207595|Experimental|UCB5857 Cohort 3|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3343736|NCT02207595|Experimental|UCB5857 Cohort 4|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3343737|NCT02207595|Experimental|UCB5857 Cohort 5|UCB5857 and Placebo: Single dose followed by multiple doses over 14 days
3343738|NCT02207647||Patients with syndromes requiring lumbar puncture|
3343739|NCT02207660||Cisplatin,P-HDFL|The general principles for patients schedule for P-HDFL regimen treatment were as followings: patients must have had white cell count > 3000/mm3, platelet count > 100000/mm3, a normal serum creatinine (≦1.5 mg/dL) or a measured creatinine clearance ([urine creatinine level (mg/dL) X 24-hr urine amount (mL)]/[serum creatinine level (mg/dL) X 1,440 min]) of ≧ 40 mL/min [12,15], total bilirubin ≦ 2 mg/dL, and transaminase (≦3X the upper normal limits). Also, patients needed to have measurable disease by radiographic studies (plain X-ray, CT or MRI scans), no serious active underlying medical issues, and Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
3343740|NCT02207673|Active Comparator|Spikes as biomarker|"In arm  spikes the resection of epileptogenic tissue is guided by epileptiform spikes in the aECoG (current standard). (Independent of the randomisation ictiform spike patterns will always be resected.)"
3343741|NCT02207673|Experimental|HFOs as biomarker|"In arm HFOs resection of epileptogenic tissue is guided by HFOs in the aECoG (new). (Independent of the randomisation ictiform spike patterns will always be resected.)"
3343742|NCT02207686||von Hippel-Lindau disease|Patients with von Hippel-Lindau disease who have had at least one vHL-related tumor removed
3343743|NCT02207699|Experimental|Benzonatate 200 mg|
3343744|NCT02207699|Experimental|Benzonatate 800 mg|
3343745|NCT02207699|Active Comparator|Moxifloxacin 400 mg|
3343746|NCT02207699|Placebo Comparator|Placebo|
3343747|NCT02207712|Active Comparator|Standard Arm|Those receiving only their prescribed ranibizumab treatment only
3238983|NCT01275378|Active Comparator|Collaborative Care Plus|Collaborative care model with specific theory-based elements to address common reasons for ADHD treatment failure
3238984|NCT01275378|Active Comparator|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
3343748|NCT02207712|Experimental|Intervention Arm|Noctura 400 Eye Mask in conjunction with their prescribed ranibizumab treatment.
3343749|NCT02207738|Experimental|microneedling radiofrequency device|microneedling radiofrequency
3343750|NCT02207738|Active Comparator|bipolar radiofrequency device|bipolar radiofrequency treatment
3343751|NCT02207764|Experimental|Reiki Intervention|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
3238985|NCT01275391|No Intervention|Treatment as Usual Group 1|Participants will receive treatment as usual and will complete a baseline and 1-month post-visit assessment
3238986|NCT01275391|No Intervention|Treatment as Usual Group 2|Participants will receive treatment as usual and complete only the 1-month post-visit assessment
3238987|NCT01275391|Experimental|Intervention Group 1|Computer Screening, Brief Intervention, Referral toTreatment. Participants will receive the intervention and complete a baseline and 1-month post-visit assessment
3238988|NCT01275391|Experimental|Intervention Group 2|Computer Screening, Brief Intervention, Referral toTreatment Participants will receive the intervention and complete only the 1-month post-visit assessment
3238989|NCT01275404|Experimental|(SMRP) + nurse practitioner information phone calls|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
3238990|NCT01275404|Experimental|SMRP+ACT-ED|Part A will use focus groups to gain feedback and refine the intervention. Part B will consist of a randomized pilot study where 70 men will be randomly assigned to one of two conditions: Sexual Medicine Rehabilitation (SMRP) plus nurse practitioner information phone calls and monitoring (SMRP+I), or SMRP plus the novel psychological intervention of Acceptance and Commitment Therapy for ED (SMRP+ACT-ED).
3238991|NCT01275417||adult|100 volunteers age ranged 18-80 years old
3238992|NCT01275417||children|60 children under 10 years old.
3238993|NCT01275443|Experimental|300mg TMC278LA|Single gluteal intramuscular injection (300mg) at day 1
3238994|NCT01275443|Experimental|1200mg TMC278LA|Single gluteal intramuscular injection (1200mg) at day 1
3238995|NCT01275443|Experimental|600mg TMC278LA|Single gluteal intramuscular injection (600mg) at day 1
3238996|NCT01275443|Experimental|150mg TMC278LA|This arm was included in the adaptive design of the study, but was not recommended for use based on the review of results from 300mg and 600mg arms by the protocol steering committee
3343752|NCT02207764|No Intervention|nursing presence control|Each patient in the control group will receive usual care including the study nurse presence for the 15-minute period.
3343753|NCT02207777|Experimental|Roux-en-Y gastric bypass (RYGB)|Subjects in this group are scheduled to undergo roux-en-Y gastric bypass surgery to obtain approximately 16-18% (with a range of 16-25%) weight loss.
3343754|NCT02207777|Active Comparator|Low-calorie diet|Subjects in this group will participate in a low-calorie diet intervention to obtain approximately 16-18% (with a range of 16-25%) weight loss.
3343755|NCT02207790|Experimental|E2609 low-dose and placebo in healthy Japanese subjects|Cohort 1 will consist of Japanese subjects randomized to a low-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3343756|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy Japanese subjects|Cohort 2 will consist of Japanese subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3343757|NCT02207790|Experimental|E2609 high-dose and placebo in healthy Japanese subjects|Cohort 3 will consist of Japanese subjects randomized to a high-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3343758|NCT02207790|Experimental|E2609 mid-dose and placebo in healthy White subjects|Cohort 4 will consist of White subjects randomized to a mid-dose of E2609 as an orally administered tablet along with subjects receiving matching placebo tablets (matched in number and appearance).
3343759|NCT02207842||Volatile anesthesia exposure|
3343760|NCT02207842||No volatile anesthesia exposure|
3343761|NCT02207855||Chloroprocaine|Neonates and infants who have received chloroprocaine for epidural anesthesia.
3343762|NCT02207868||no treatment|
3343763|NCT02207881|Placebo Comparator|placebo|placebo gel, 25mg, 3 times up to 10 days
3343764|NCT02207881|Experimental|VDO gel|VDO gel 25mg, 3 times a day up to 10 days
3343765|NCT02207920|Experimental|Group 1|"At study entry and Month 1, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid."
3343766|NCT02207920|Experimental|Group 2|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive placebo for DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
3238997|NCT01275469|Experimental|GFT505 80mg|
3238998|NCT01275469|Placebo Comparator|Matching placebo|
3343767|NCT02207920|Experimental|Group 3|"At study entry and Month 1, participants will receive DNA-HIV-PT123 in their left deltoid and placebo for AIDSVAX B/E in their right deltoid.~At Months 3 and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid."
3238999|NCT01275482|Experimental|isolated contractions caused|The investigators do TFM causing isolated contractions in de muscle fibers containing de latent trigger point.
3239000|NCT01275482|Active Comparator|No isolated contraction caused|The investigators don´t cause contraction during the TFM
3239001|NCT01275495|Experimental|Telephone Assessment and Skill-Building Kit (TASK II)|The TASK II group will fill out a checklist about their needs and concerns, and will receive written tip sheets by mail that address the needs and concerns that they feel are most important. A nurse will call by telephone (lasting about 30 minutes or less) once a week for a total of 8 weeks, with another call at 12 weeks, to provide more information, answer questions, and to discuss more written tip sheets based on the caregiver's needs and concerns.
3343768|NCT02207920|Experimental|Group 4|At study entry and Months 1, 3, and 6, participants will receive DNA-HIV-PT123 in their left deltoid and AIDSVAX B/E in their right deltoid.
3343769|NCT02207933|Experimental|AP shifting group|
3343770|NCT02207933|Active Comparator|gait training group|
3343771|NCT02207959|Experimental|Surveillance Endoscopy|White light examination, vital-dye enhanced fluorescence examination (VFI), High Resolution Microendoscope (HRME)
3343772|NCT02207985|Experimental|Hematopoetic stem cell transplantation|Patients with pancreatic adenocarcinoma that have undergone Whipple surgery and show no sign of disease recurrence can be treated with hematopoietic stem cell transplantation to achieve an immunological anti-tumor effect.
3343773|NCT02207998|Experimental|Homeopathic complex and physiotherapy|"Homeopathic complex and physiotherapy: (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of 168 tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist."
3343774|NCT02207998|Placebo Comparator|Placebo and physiotherapy|"Placebo and Physiotherapy: Placebo will comprise of 168 unmedicated lactose tablets; 56 tablets will be issued forth nightly to assess participant's compliance in taking their medicine. Participants will be given instruction to take two tablets, dissolved under the tongue 20 minutes away from meals, twice daily, starting from day one.~Physiotherapy treatment will consist of lower back classic massage, lumber joint manipulation and the application of a hot pack. Treatment sessions will last for 30 minutes, once every two weeks at the same physiotherapy practice from the same specific and identified physiotherapist ."
3343776|NCT02208115|Experimental|Meal composition - High GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
3343777|NCT02208115|Experimental|Meal composition - Low GI|Changing the glycaemic index of the meal consumed after exercise (High GI versus Low GI).
3343778|NCT02208128|No Intervention|Receptor-Tyrosinkinase-Inhibitor|Guidelines-oriented therapy with approved systemic medications for renal cell carcinoma individually for each patient (Receptor-Tyrosinkinase-Inhibitor) (e.g.Sunitinib, Pazopanib, Bevacizumab, Everolimus, Axitinib, Temsirolimus). With 1.progression turning to second line treatment with one of the upper mentioned medications. Third line therapy due to the individual molecular modifications for each patient.
3343779|NCT02208141||lean and obese children and adolescents|study cohort may be stratified for lean (definded as BMI <1.28 SDS) and overweight/obese (definded as BMI>= 1.28 SDS) children for posthoc analyses no intervention
3343780|NCT02208154|Active Comparator|Standard care|"Standard infection prevention measurements will be implemented before the baseline period and carried out throughout the entire trial. They consist of:~Chlorhexidine 2% body washings (CHX-BW) for all ICU patients. The face and neck of the patient will not be cleansed with Chlorhexidine to prevent irritation of the eyes and face.~A hand hygiene improvement program (HHIP) based on the program designed by the World Health organisation (WHO).~Standard oropharyngeal care consists of oral washing with sterile water (3-4 times daily) and tooth brush twice daily."
3343781|NCT02208154|Experimental|Chlorhexidine oral care (CHX-Oro)|Chlorhexidine digluconate oromucosal gel 1%, 2cm, to be administered 4 times daily, during invasive mechanical ventilation.
3343782|NCT02208154|Experimental|Selective oropharyngeal decontamination|Selective oropharyngeal decontamination (SOD) mouth paste containing colistin and tobramycin in a 2% concentration and nystatin 1 x 10^5 units, dosage 0.5g , to be administered 4 times daily during the entire period of invasive mechanical ventilation.
3343783|NCT02208154|Experimental|Selective digestive decontamination|Selective digestive decontamination (SDD), suspension via the nasogastric tube containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u., dosage 10ml, to be administered together with SOD (see above) 4 times daily during entire period of mechanical ventilation.
3343784|NCT02208167|Other|Chronic HIV infection|HXTC infusion
3343785|NCT02208167|Other|Acute HIV infection|HXTC infusion
3343786|NCT02208180|Experimental|Return of genomic results on cardiovascular disease risk|Participants will receive genomic cardiovascular disease risk information.
3343787|NCT02208180|Active Comparator|Return of lifestyle results on cardiovascular disease risk|Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study.
3239002|NCT01275495|Active Comparator|Information, Support, and Referral (ISR)|The ISR group will receive existing educational materials about stroke and caregiving developed by the American Stroke Association and weekly telephone calls by a nurse (lasting about 30 minutes or less) for a total of 8 weeks, with another call at 12 weeks.
3239003|NCT01275508|Experimental|FITC-Adalimumab|
3343788|NCT02208193|Experimental|healthy controls group|Healthy volunteers
3343789|NCT02208193|Experimental|Alzheimer subjects group|"Group A Alzheimer group: patients with mild to severe stages of Alzheimer's disease: subgroup A1 Alzheimer group hospitalized at the Paul Spillmann Centre (Centre Paul Spillmann, CPS) (CHU de Nancy, France); subgroup A2 Alzheimer group monitored at the Resource and Research Memory Centre (Centre Mémoire de Ressources et de Recherche, CMRR) (CHU de Nancy, France)"
3343790|NCT02208219|Experimental|Music-supported Therapy (n=40)|Participants in this group will receive a Music-supported Therapy training at the Hospital during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
3343791|NCT02208219|Experimental|home-based Music-supported Therapy(n=40)|Participants in this group will receive a Music-supported Therapy training at home during 1 month in addition to the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy).
3343792|NCT02208219|Active Comparator|Conventional treatment (n=40)|Participants in this group will receive the standard rehabilitation program offered by the Public Health System in the Hospital, which comprises 2 hours of treatment per day (1 session of 1 hour of Occupational Therapy and 1 session of 1 hour of Physiotherapy). In order to balance the number of treatment hours between arms, this group will receive extra time of Conventional Treatment during 1 month.
3343793|NCT02208232||MC 6125 AS IOL|cataract surgery with implantation of intraocular lens MC 6125 AS in one eye
3343794|NCT02208245|Active Comparator|Ultrasound: Axillary block|For the axillary group, the ultrasound probe will be placed upright in the armpit to obtain a cross section of this region. After visualization of the nerves form the brachial plexus by ultrasound, 5 mL of ropivacaine 0.5% will be injected around each nerve to be blocked (median, ulnar, radial and musculocutaneous). If resistance to the injection of the solution is present or the patient complains of severe pain, the needle will be immediately repositioned.
3375865|NCT03681184|Placebo Comparator|Placebo|Lumasiran-matching placebo (normal saline [0.9% NaCl]) was administered subcutaneously (SC) at Day 1 and Months 1, 2 and 3 during the 6-Month Double-blind (DB) Period, followed by lumasiran SC, 3.0 mg/kg, at Months 6, 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month Open-label Extension (OLE) period.
3239004|NCT01275521|Experimental|BONT-A intra-prostatic injection|
3239005|NCT01275521|Active Comparator|optimized medical BPH treatment|
3239006|NCT01275547|Experimental|S-ketamine & midazolam spray|all 20 minutes as a patient controlled analgesia alternating s-ketamine / midazolam
3239007|NCT01275547|Active Comparator|morphine, patient controlled analgesia|morphine as an active comparator as a patient controlled analgesia system
3239008|NCT01275560|Experimental|Metronidazole|3 intakes per day during 10 days
3239009|NCT01275560|Active Comparator|Carbosylane|3 intakes per daysduring 10 days
3239010|NCT01275573|Other|healthy volunteers|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3239011|NCT01275573|Other|painful Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3239012|NCT01275573|Other|painless Parkinson's disease patients|All the patients and healthy volunteers will receive high frequency Repetitive Transcranial Magnetic Stimulation and placebo stimulation
3239013|NCT01275599|Experimental|Open-Label Arm|"The treatment period will include 3 phases:~14 day run-in period~7 day co-administration period~31 day follow-up period"
3239014|NCT01275612|Experimental|Cell therapy|
3343795|NCT02208245|Active Comparator|Ultrasound: Infraclavicular block|For the infraclavicular group, the ultrasound probe will be placed in the infraclavicular region (the junction between the clavicle and the coracoid process) to obtain a cross-sectional imaging of the axillary artery. After visualization of the axillary artery by ultrasound, the block will be performed using the technique in plan for visualization of the needle. The needle is placed in position 6-8 hours of the artery, and 20 mL of ropivacaine 0.5% will be injected, observing a dispersal of local anesthetic around the artery.
3239015|NCT01275638|Placebo Comparator|Prednisolone (20 mg/day) for 10 days.|
3343796|NCT02208271||Control|pre-operative total hip patients with no existing total hip implant
3239016|NCT01275651||Ancillary-Correlative (AR activity in CRPC)|Previously collected bone marrow tissue and blood samples are analyzed for AR activity, AR splice variations, expression of androgen transport/synthesis/metabolism genes, AKR1C3 protein levels, and testosterone and dihydrotestosterone levels via RT-PCR, SNP microarrays, IHC, gene expression analysis, and mass spectrometry methods.
3239017|NCT01275690||subjects with PH undergoing right heart catheterization|
3239018|NCT01275703||patients with PH undergoing exercise testing|
3343797|NCT02208271||Metal on polyethylene|patients who have a failed metal on polyethylene total hip implant and are presenting for revision surgery
3343798|NCT02208271||Metal on Metal|patients who have a failed metal on metal total hip implant and are presenting for revision surgery
3343799|NCT02208284|Experimental|Cohort 1-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3343800|NCT02208284|Experimental|Cohort 2-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3343801|NCT02208284|Experimental|Cohort 3-PF-06427878 or placebo|Single ascending doses of PF-06427878 or placebo to investigate the safety, tolerability, and PK.
3343802|NCT02208323|Experimental|Bubble CPAP|Bubble CPAP for 28 days
3343803|NCT02208336||Observational (electronic medical record review)|Patients' electronic medical records are reviewed for adherence, severe myelosuppression, and patient morbidity retrospectively and prospectively.
3343804|NCT02208362|Experimental|Stratum I (T lymphocytes intratumoral)|"CLOSED TO ACCRUAL 03/02/2018.~Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions."
3343805|NCT02208362|Experimental|Stratum II (T lymphocytes intracavitary)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intracavitary catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Patients who progress on intracavitary or intratumoral administration may move to intraventricular catheter for the optional infusions
3239019|NCT01275716|Experimental|Patients who are shown the images|
3343806|NCT02208362|Experimental|Stratum III (T lymphocytes intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intraventricular catheter over 5-10 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available.
3343807|NCT02208362|Experimental|Stratum IV (T lymphocytes intratumoral and intraventricular)|Patients receive IL13R alpha 2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
3239020|NCT01275716|No Intervention|Patients who are not shown the images|
3343808|NCT02208362|Experimental|Stratum V (T lymphocytes intratumoral and intraventricular)|Patients receive IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral catheter and intraventricular catheter over 5 minutes weekly for 3 weeks. Beginning as early as 1 week later, patients may receive additional T cell infusions as long as patients continue to remain eligible and there is product available. Based on clinical response after the first 3 infusions, the study principal investigator may decide to continue with the optional infusions at either one or both sites (instead of requiring injections at both sites).
3239021|NCT01275729|Experimental|Lasix|Pt to get dose of furosemide after meeting entry criteria - dose dependent on previous exposure to diuretics
3239022|NCT01275742|No Intervention|Usual Care|
3239023|NCT01275768|Experimental|Experimental arm|Insertion and activation of the endo-biliary RF catheter at the site of the stricture before insertion of a Self-expandable Metal Stent (SEMS)
3239024|NCT01275768|Placebo Comparator|Control arm|Insertion and sham activation of the endo-biliary RF catheter at the site of the stricture before insertion of a SEMS
3239025|NCT01275781|Experimental|A|[14C]-AZD9742 1000 mg intravenous over 2 hours
3239026|NCT01275794||1|Patients have an established diagnosis of T2D, Age 35 years and more, Experience of therapy with one OAD during the from 6 months to 5 years before the registration in the Program
3239027|NCT01275807|Experimental|acupuncture|10 acupuncture sessions
3239028|NCT01275807|Active Comparator|self care|psychological support, phisical exercice, diet, self care groups
3239029|NCT01275820||Nutralin|All 10 subjects in the study will consume the investigational food product.
3343809|NCT02208375|Experimental|Arm I (olaparib, vistusertib)|CONTINUOUS AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 5-28 of course 1 and alone on days -3 to -1 of week -1) and vistusertib PO BID on days 1-28 (alone on days 1-4 of week 1).
3343810|NCT02208375|Experimental|Arm II (olaparib, vistusertib)|INTERMITTENT AZD2014 DOSING: Patients receive olaparib PO BID on days 1-28 (days 3-28 on course 1 and alone on days -5 to -3 of week -1) and vistusertib 4 PO BID for 2 days on and 5 days off (alone on days 1-2 of week 1).
3343811|NCT02208375|Experimental|Arm III (olaparib, capivasertib)|INTERMITTENT AZD5363 DOSING: Patients receive olaparib PO BID on days 1-28 (on days 5-28 of course 1 and alone on days -3 to -1 of week -1) and capivasertib PO BID for 4 days on and 3 days off (alone on days 1-4 of week 1).
3343812|NCT02208388|Experimental|Computed tomography perfusion|Patients with Computed tomography perfusion
3343813|NCT02208388|Active Comparator|Fractional flow reserve|Patients with Fractional flow reserve
3343814|NCT02208401|Active Comparator|conventional cold snare polypectomy|conventional cold snare polypectomy
3343815|NCT02208401|Experimental|Cold snare polypectomy with suction|Cold snare polypectomy with suction
3343816|NCT02208414|Experimental|Crab or shrimp|Intervention: treated with crab and shrimp energy signature vial using NAET
3239030|NCT01275846|Experimental|Health Guide using AHA protocols|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
3343817|NCT02208414|Placebo Comparator|Placebo|Treated with water vial
3343818|NCT02208427|Experimental|3M_RH|Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
3343819|NCT02208427|Active Comparator|9M_INH|Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
3343820|NCT02208440|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3343821|NCT02208440|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3343822|NCT02208453|Experimental|InSpace implantation|InSpace device implantation
3343823|NCT02208479||cardiac surgery|
3343824|NCT02208492|Experimental|Levetiracetam|
3343825|NCT02208492|Active Comparator|Carabamazepine|
3239031|NCT01275859|Experimental|Letrozole, Lapatinib|Letrozole 2.5mg po qd + Lapatinib 1500mg po qd for 18-21 wks
3343826|NCT02208505|Experimental|Dexmedetomidine|we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).
3343827|NCT02208505|Active Comparator|Remifentanil|we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.
3343828|NCT02208518||Elastography analysis|Consecutive patients undergoing for upper endoscopy ultrasound
3343829|NCT02208531|No Intervention|Control|
3343830|NCT02208531|Experimental|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
3343831|NCT02208544|Experimental|FDG-PET/CT-driven|"Following treatment based on FDG-PET/CT:~negative: watchful waiting including confirmatory ultrasound~positive: diagnostic thyroid surgery as planned"
3343832|NCT02208544|Other|Current Practice|diagnostic thyroid surgery despite results of FDG-PET/CT
3343833|NCT02208557|Active Comparator|Control|Laparotomy closure will be done by continuous PDS suture following a SL:WL ratio of 4:1 only is used for midline laparotomy closure.
3343834|NCT02208557|Experimental|Reinforcement with Absorbable Mesh|"Closure of the midline laparotomy incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore & Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a sandwich method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1."
3343835|NCT02208570|Experimental|P(+)V(+)|PPV>14% before anesthesia induction, HES 6ml/kg infused
3343836|NCT02208570|Experimental|P(+)V(-)|PPV>14% before anesthesia induction, no additional volume infused
3343837|NCT02208570|Experimental|P(-)V(+)|PPV<14% before anesthesia induction, HES 6ml/kg infused
3343838|NCT02208570|Experimental|P(-)V(-)|PPV<14% before anesthesia induction, no additional volume infused
3343839|NCT02208583|Active Comparator|AR dependent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: Docetaxel & Prednisone; CRPC patients with druggable gene mutations: DP & Targeted drugs"
3343840|NCT02208583|Active Comparator|AR independent CRPC|"Assignment to Treatment Group based on druggable gene mutations analysis:~CRPC patients without druggable gene mutations: cisplatin & Etoposide; CRPC patients with druggable gene mutations: EP & Targeted drugs"
3343841|NCT02208596|Experimental|Group A|In group A, propofol (1%) was mixed with etomidate in the ration of 1:1 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3343842|NCT02208596|Experimental|Group B|In group B, propofol (1%) was mixed with etomidate in the ration of 7:5 (volume). The mixture will be injected continuously until the eyelash reflex disappears. During the operation, supplementary mixture will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3343843|NCT02208596|Experimental|Group C|In group C, propofol (1%) will be injected continuously until the eyelash reflex disappears. During the operation, supplementary propofol will be administered if the patient has spontaneous movement that hampered the conduct of the procedure.
3239032|NCT01275872|Experimental|Guided Imagery and Progressive Muscle Relaxation|
3343844|NCT02208609|Experimental|Maize Tortillas with 20% Amaranth|Children in this arm were fed maize tortillas fortified with 20% amaranth
3343845|NCT02208609|Experimental|Maize Tortillas without 20% Amaranth|Children in this arm were fed maize tortillas without amaranth
3343846|NCT02208622|Experimental|Study 1: Whey Supplement Day 1|Children in this arm received the whey supplement as part if their diet on day 1.
3343847|NCT02208622|Experimental|Study 1: Whey Supplement Day 2|Children in this arm received whey supplement as part of their diet on day 2.
3343848|NCT02208622|Experimental|Study 2: Whey Supplement|Children in this arm received a whey supplement as part of their diet.
3343849|NCT02208622|No Intervention|Study 2: Control|Children in this arm did not receive a whey supplement as part of their diet.
3343850|NCT02208635|Experimental|Biofortified Maize|Participants in this arm were fed zinc biofortified maize (~30 µg Zn/g).
3343851|NCT02208635|Experimental|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
3343852|NCT02208635|Active Comparator|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
3239033|NCT01275885|Active Comparator|Vitamin D3 10µg|
3239034|NCT01275885|Active Comparator|Vitamin D3 30µg|
3343853|NCT02208648||Deceased|"Peri-operative mortality (within 90 days). Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
3343854|NCT02208648||Matched control|"Patients who survived beyond 90 days peri-operatively. Pairs of CT scans (deceased plus matched control) will be anonymised and stored on a secure server. Abbreviated Calcium scores will be generated for all patients in the trial by a trained radiologist using a calcium scoring method. The radiologist will be blinded to the group that the patient belongs to, to minimise bias. Scans (deceased patients and matched controls) will be analysed in batches of 30 pairs. Radiologist (s) will be blinded to group allocation. Scans will not be paired at the time of reading."
3343855|NCT02208674|No Intervention|Usual Care|Primary care provider-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per usual care.
3343856|NCT02208674|Experimental|Protocolized, pharmacist-delivered CKD Action Plan|Protocolized, pharmacist-delivered screening and treatment for risk factors (hypertension, albuminuria, dyslipidemia) per KDIGO and JNC-8 recommendations.
3343857|NCT02208687|Experimental|Energetic|Self management group program aimed at reconditioning and social participation
3343858|NCT02208687|Other|Control group|Usual care
3343859|NCT02208700|Experimental|Oxepa|Other: Therapeutic nutrition with EPA, GLA and antioxidants.
3343860|NCT02208700|Active Comparator|Jevity 1.5|Other: Jevity 1.5 Complete Balanced Nutrition with Fiber .
3343861|NCT02208713|Experimental|Stem cell recipient|The patients with FSHD who underwent muscle derived stem cell and Adipose derived mesenchymal stem cell with intramuscular injection.
3343862|NCT02208726|Placebo Comparator|Sucrose pillules|Unmedicated sucrose pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
3343863|NCT02208726|Experimental|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH. Pillules will be taken once daily, in the morning, 30 minutes after breakfast, for 14 days, up to 7 days before the first academic examination.
3343864|NCT02208739|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy was given to all patients at baseline
3343865|NCT02208739|Active Comparator|Oral hygiene instructions|Oral hygiene instructions were given to all patients at baseline
3343866|NCT02208752|Active Comparator|Exercises|exericises on motor control and strengthening exercises on the Rotator Cuff
3343867|NCT02208752|Placebo Comparator|Control group- No exercises|No exercises
3343868|NCT02208765|Other|Study cohort|Any patient referred to the Nuclear Cardiology Laboratory of the University Hospital of Grenoble for myocardial perfusion imaging for diagnosis or prognosis evaluation of suspected or know coronary artery disease
3343869|NCT02208778|Experimental|Duloxetine|Duloxetine 30 mg a day (2 weeks), then 60 mg a day (4weeks), taken by mouth
3343870|NCT02208778|Placebo Comparator|Placebo (for Duloxetine)|Sugar pill: 1 capsule a day (2 weeks), then 2 capsules a day (4 weeks) taken by mouth
3239035|NCT01275885|Active Comparator|Vitamin D3 40µg|
3239036|NCT01275898||Beach chair|Patients scheduled for surgical procedure in beach chair position (Shoulder surgery)
3239037|NCT01275898||Sitting position|Patients scheduled for surgical procedure in sitting position (Neurosurgery)
3239038|NCT01275898||Head down position|Patients scheduled for surgical procedure in head down position (daVinci robotic surgery)
3239039|NCT01275898||Prone position|Patients scheduled for surgical procedure in prone position
3343871|NCT02208778|Experimental|Remifentanil|Intravenous infusion with maximum estimated plasma target of 1.0 ng/ml, during less than 20 minutes
3343872|NCT02208778|Placebo Comparator|Placebo (for Remifentanil)|Intravenous infusion of normal saline, during less than 20 min
3343873|NCT02208791|Active Comparator|Tacrolimus/MPS/Prednisone|This arm will be maintained with current conventional triple immunosuppression. Sirolimus will not be added to this arm
3343874|NCT02208791|Experimental|Sirolimus/Low Tacrolimus/MPS/Prednisone|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid..
3343875|NCT02208804|Experimental|Surefire Infusion System|Hepatic arterial administrations using the Surefire Infusion System
3343876|NCT02208804|Active Comparator|Standard End-hole Microcatheter|Hepatic arterial administrations using the standard end-hole microcatheter
3343877|NCT02208817||Ill patients|Ill patients who require Paediatric Intensive Care or Paediatric High Dependency Care
3343878|NCT02208817||Well Controls|Matched controls who are well (PEWS<3)
3343879|NCT02208817||Parent feedback|Feedback from parents/carers of children recruited into the PRefill study
3239040|NCT01275911|Experimental|Esmolol|
3239041|NCT01275911|Active Comparator|Remifentanil|
3239042|NCT01275924|Active Comparator|Tightrope|Treatment with Tightrope Syndesmosis Repair Kit
3343880|NCT02208817||Healthcare professionals feedback|Feedback from healthcare professionals who have cared for a child with the device on
3343881|NCT02208830|Experimental|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
3343882|NCT02208830|Experimental|pulmonary rehabilitation|Duration of 8 week, twice weekly exercise program with: lower limb strength training and aerobic training per 30 minutes.
3343883|NCT02208856|Placebo Comparator|Placebo|
3343884|NCT02208856|Experimental|BIBR 796 BS food effect|
3343885|NCT02208856|Experimental|BIBR 796 BS|
3343886|NCT02208869||Patients diagnosed with FH|"Subjects of both sexes above the age of 18 with TC ≥7.5 mmol/L or LDL-C ≥4.9 mmol/L will be included in the Program. Clinical diagnosis of FH will be established using both the Dutch and the British criteria.~Those with secondary causes of hypercholesterolemia, such as untreated diabetes mellitus (HbA1c >8%) or hypothyroidism (thyroid-stimulating hormone >1.5 upper normal limit), renal failure (creatinine clearance <30 ml/min), holestatic liver diseases, including biliary cirrhosis, tumors with an active process in the last 5 years will be excluded from the study."
3343887|NCT02208882|Experimental|Panel 1: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3343888|NCT02208882|Experimental|Panel 2: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3343889|NCT02208882|Experimental|Panel 3: BMS-986120 or Placebo + Midazolam|BMS-986120 or Placebo (multiple dose) + Midazolam (single dose) by mouth as specified
3239043|NCT01275924|Active Comparator|Syndesmotic screw|Treatment with a quadricortical syndesmotic screw
3239044|NCT01275937|Other|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days followed by40mg once daily orally for two months.
3239045|NCT01275937|Active Comparator|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days followed by 40mg once daily orally for two months.
3343890|NCT02208882|Experimental|Panel 4: BMS-986120 or Placebo|BMS-986120 or Placebo multiple dose by mouth as specified
3343891|NCT02208895||iSTAT Study Group|Measure glucose of pleural fluid via glucometer, in the laboratory, and using the iSTAT device to see if the three methods give a similar reading or not.
3343892|NCT02208908||Patient with cancer hospitalize inpalliative situation|"An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.~An assessment of the traceability of clinical assessment and appropriate treatment prescribed or will be conducted on day 3 and repeated the day of the release of hospitalization (or day 15) from information recorded in the patient record"
3239046|NCT01275963||Control|Healthy individuals without structural heart disease
3239047|NCT01275963||CAD|Patients with coronary artery disease
3239048|NCT01275963||DCM|Participants with dilated cardiomyopathy
3239049|NCT01275963||HNCM|Patients with hypertrophic non-obstructive cardiomyopathy
3343893|NCT02208921||T2DM patients with Chronic Kidney Disease|T2DM patients with Chronic Kidney Disease
3343894|NCT02208934|Experimental|PBF-999 (5 mg)|5 mg of PBF-999
3343895|NCT02208934|Experimental|PBF-999 (10 mg)|10 mg of PBF-999
3343896|NCT02208934|Experimental|PBF-999 (20 mg)|20 mg of PBF-999
3239050|NCT01275963||HOCM|Patients with hypertrophic obstructive cardiomyopathy
3239051|NCT01275963||RCM|Patients with restrictive cardiomyopathy
3239052|NCT01275963||Amyloidosis|Patients with cardiac manifestation of amyloidosis
3239053|NCT01275963||HFPEF|Patients with heart failure with preserved ejection fraction (diastolic heart failure)
3239054|NCT01275976|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor, 100 U/kg bodyweight
3239055|NCT01275976|Placebo Comparator|Saline 0.9%|Saline 0.9%
3239056|NCT01275989|Sham Comparator|21|sham acupuncture
3239057|NCT01275989|No Intervention|15|Control
3239058|NCT01275989|Active Comparator|20|intervention
3239059|NCT01276002|No Intervention|No stenting|Control group, no stenting of the pancreatic duct in case of a disrupted duct
3239060|NCT01276002|Active Comparator|Pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting in this arm
3239061|NCT01276015|Experimental|botulinum toxin A|botulinum toxin A diffusion in cerebral palsy
3239062|NCT01276028|Experimental|Acupuncture|This group will start acupuncture treatments within 3 weeks of consent and continue to receive up to 20 treatments over a six month period. The number of treatments will be jointly determined by the participant and the acupuncturist.
3239063|NCT01276028|Other|Waitlist|This group of participants will be asked to wait 6 months and will then be allowed to receive acupuncture.
3239064|NCT01276067|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
3239065|NCT01276067|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
3343897|NCT02208934|Experimental|PBF-999 (40 mg)|40 mg of PBF-999
3343898|NCT02208934|Placebo Comparator|Placebo|Placebo for the 5, 10, 20 and 40 mg dose
3343899|NCT02208947|Active Comparator|PREPARE|"Partnership HealthPlan of California (PHC) pays primary care physicians (PCPs) to discuss and document ACP with Medi-Cal beneficiaries aged 65 and older and those younger than 65 with a life-limiting illness (usual care). The control condition, or enhanced usual care, adds a packet of educational information about ACP and access to the PREPARE website and verbal encouragement by their PCP delivered during a routine clinic visit to usual care."
3375866|NCT03681184|Experimental|Lumasiran|Lumasiran was administered SC, 3.0 mg/kg, at Day 1 and Months 1, 2 and 3 during the 6-Month DB Period, followed by lumasiran SC, 3.0 mg/kg at Month 6, and lumasiran-matching placebo SC at Months 7 and 8 during the 3-Month Blinded Treatment Extension Period, followed by lumasiran SC, 3.0 mg/kg, at Month 9 and then every three months during the 51-Month OLE period.
3375867|NCT03678389|Experimental|1|ENDOSPHENOIDAL COIL
3343900|NCT02208947|Experimental|PREPARE + consumer financial incentive|The experimental condition adds a consumer-directed financial incentive to enhanced usual care (provider-directed financial incentive and educational packet with information about the PREPARE website). Specifically, subjects will receive an immediate financial reward upon completing self-directed ACP (e.g., PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
3343901|NCT02208960|Experimental|Neonatal Kit|Mothers in the neonatal kit clusters will receive a neonatal kit and training on how to use the kit components during their third trimester of pregnancy. The kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, 4% chlorhexidine (CHX) lotion, sunflower oil emollient, ThermoSpot, a Mylar infant sleeve, and a reusable, non-electric, heating device. Community Health Workers will be equipped with a hand-held battery operated scale to identify low birth weight newborns.
3343902|NCT02208960|Experimental|Neonatal Stimulation|During home visits in the 3rd trimester, mothers in the neonatal stimulation clusters will be taught 3 core messages pertaining to neonatal stimulation. First, mothers will be taught how to make eye contact and talk to their child. This type of interaction encourages social inclusion, attachment, and development of social-communication skills. Second, mothers will be taught techniques to foster responsive feeding and caregiving. Finally, mothers will be encouraged to sing songs and nursery rhymes, including those with gentle touch in order to support the development of communication skills, and introduce a tactile component to caregiving. These messages will be reiterated at subsequent home visits by the CHW after the baby is born.
3343903|NCT02208960|Experimental|Neonatal Kit and Neonatal Stimulation|Participants in this arm of the study will receive both a neonatal kit (described in Arm 1) and neonatal stimulation (described in Arm 2).
3343904|NCT02208960|No Intervention|Control (Standard Care)|"In control clusters, CHWs will visit the home according to the regular schedule (same as in the intervention clusters) and deliver the standard CHW post-natal care that consists of talking to mothers about:~Exclusive breastfeeding and proper nutrition for both the mother and the baby.~Ensuring warmth to the baby.~Full immunization and growth monitoring of newborn.~Hygiene and sanitation practices.~Family Planning and promote the proper use of Insecticides Treated Nets.~Identifying any danger sign/complication for both mothers and new-borns and refer for prompt treatment (within 24 hours) for management and treatment.~Promoting the use of services such as birth registration.~Giving advice on proper care of the umbilical cord."
3239066|NCT01276080|Experimental|1|Donepezil Hydrochloride 10 mg Tabletof OHM Laboratories, Inc.
3239067|NCT01276080|Active Comparator|2|ARICEPT® (donepezil hydrochloride) 10 mg Tablet of Eisai, Inc.
3239068|NCT01276093|Experimental|PVI ablation|Pulmonary Vein Ablation
3343905|NCT02208973|Experimental|PBF-680 (5 mg)|5 mg of PBF-680
3343906|NCT02208973|Experimental|PBF-680 (10 mg)|10 mg of PBF-680
3343907|NCT02208973|Experimental|PBF-680 (20 mg)|20 mg of PBF-680
3343908|NCT02208973|Experimental|PBF-680 (40 mg)|40 mg of PBF-680
3343909|NCT02208973|Experimental|PBF-680 (60 mg)|60 mg of PBF-680
3343910|NCT02208973|Placebo Comparator|Placebo|Comparator to the doses of 5, 10, 20, 40 and 60 mg. ( subjects for each dose level 6 are located to active treatment and two to placebo
3343911|NCT02208986|Active Comparator|0.2mg Triptorelin|Ovulation trigger with 0.2mg Triptorelin in one subcutaneous injection.
3343912|NCT02208986|Active Comparator|0.3mg Triptorelin|Ovulation trigger with 0.3mg Triptorelin in one subcutaneous injection.
3343913|NCT02208986|Active Comparator|Active Comparator: 0.4mg Triptorelin|Ovulation trigger with 0.4mg Triptorelin in one subcutaneous injection.
3343914|NCT02209012||ALA|Subjects who received ALA in CP0108
3343915|NCT02209012||Vehicle|Subjects who received Vehicle in CP0108
3239069|NCT01276093|Active Comparator|Amiodarone medical treatment|Amiodarone medical treatment
3343916|NCT02209025|Placebo Comparator|Placebo drink|A drink with the same components as the theobromine drink except for the theobromine
3343917|NCT02209025|Experimental|Theobromine|500mg theobromine in a drink
3343918|NCT02209038|Experimental|Expanded AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~4 answer choices:~Yes, I would like to complete a comprehensive version of an advance directive.~Yes, I would like to complete an expanded version of an advance directive.~Yes, I would like to complete a brief version of an advance directive.~No, I do not wish to complete an advance directive."
3343919|NCT02209038|No Intervention|Standard AD Choice|"Would you like to complete an advance directive with the assistance of any person(s) you choose?~2 answer choices:~Yes, I would like to complete an AD.~No, I do not wish to complete an advance directive."
3343920|NCT02209038|Experimental|Expanded Life-sustaining therapy Choice|"For each hypothetical illness state described in the living will:~4 answer choices:~No, I would not want life support.~Yes, I would want life support.~I would want life support if my doctor believes it could help, but I want to stop receiving life support if at any time my doctor believes it is only delaying the moment of my death.~I do not wish to specify a preference at this time."
3343921|NCT02209038|No Intervention|Standard Life-sustaining Therapy Choice|"For each hypothetical illness state described in the living will:~3 answer choices:~No, I would not want life support.~Yes, I would want life support.~I do not wish to specify a preference at this time."
3343922|NCT02209051|Active Comparator|AMNIOEXCEL|Human Amniotic Membrane Allograft
3343923|NCT02209051|Active Comparator|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading of wound.
3343924|NCT02209077|Experimental|Healthy Volunteers|OCT performed to collect data from the back of the eye
3343925|NCT02209077|Experimental|Glaucoma group|OCT performed to collect data from the back of the eye
3239070|NCT01276119|Experimental|Cohort A, CDP6038 0.001 mg/kg, iv|
3239071|NCT01276119|Experimental|Cohort B, CDP6038 0.01 mg/kg, iv|
3239072|NCT01276119|Experimental|Cohort C, CDP6038 0.03 mg/kg, iv|
3239073|NCT01276119|Experimental|Cohort D, CDP6038 0.1 mg/kg, iv|
3239074|NCT01276119|Experimental|Cohort E, CDP6038 0.3 mg/kg, iv|
3239075|NCT01276119|Experimental|Cohort G, CDP6038 1.0 mg/kg, iv|
3239076|NCT01276119|Experimental|Cohort I, CDP6038 3.0 mg/kg, iv|
3239077|NCT01276119|Experimental|Cohort K, CDP6038 10.0 mg/kg, iv|
3239078|NCT01276119|Placebo Comparator|Cohort A, Placebo, iv|
3343926|NCT02209090|Experimental|maternal modified sims position|"Women in this group will adopt the modified Sims position, lying on the side of the foetal back.~This position is maintained for the greater part of labour, at least 40 minutes, every hour. The mother can use other positions during resting time of no more than 20 minutes each hour, but never use a lateral position against the side of the foetal back."
3343927|NCT02209090|Sham Comparator|maternal free positions|Women can adopt the position they wish and which is most comfortable, except for lateral positions which can only be used for a maximum of 20 minutes each hour to avoid confounding factors.
3343928|NCT02209103|Experimental|Citrus flavonoid|Citrus flavonoid
3343929|NCT02209103|Experimental|Citrus flavonoid formulation|Citrus flavonoid formulation
3343930|NCT02209103|Placebo Comparator|Placebo|Placebo
3343931|NCT02209116|Active Comparator|QB Open|Participants and their clinician will receive results of the Qb Test
3239079|NCT01276119|Placebo Comparator|Cohort B, C, D, E, G, I, K, Placebo, iv|
3343932|NCT02209116|Other|Qb Blind|Participants and their clinician will be blind to the results of the Qb test
3343933|NCT02209129||women at high risk for breast cancer|
3239080|NCT01276119|Experimental|Cohort F, CDP6038 0.3 mg/kg, sc|
3239081|NCT01276119|Experimental|Cohort H, CDP6038 1.0 mg/kg, sc|
3343934|NCT02209142|Experimental|pan-genomic screen|A pan-genomic screen by blood prelevement and psychometric data collection will be set-up on a subset of MDE and control samples to identify mRNA candidates for a transcriptional signature of MDE,
3239082|NCT01276119|Experimental|Cohort J, CDP6038 3.0 mg/kg, sc|
3239083|NCT01276119|Placebo Comparator|Cohort F, H, J, Placebo, sc|
3239084|NCT01276132||Subjects who are designated to receive same-day PCI|
3343935|NCT02209142|Sham Comparator|control|a pan genomic screening by blood prelevement and psychometric data collection wil be performed on healthy subject
3343936|NCT02209155|Active Comparator|R-verapamil 75 mg tablet|375 mg/day; one in the morning, two in the afternoon and two at bedtime daily
3239085|NCT01276132||Subjects who had been admitted to the hospital after their PCI|
3239086|NCT01276158|Active Comparator|Ultrasound|Arterial line placed with Ultrasound guidance.
3239087|NCT01276158|Active Comparator|Doppler|Arterial line placed with doppler guidance
3239088|NCT01276210|Experimental|Treatment|See Detailed Description
3239089|NCT01276249||Fortevo Endograft|All subjects diagnosed with a qualifying AAA suitable for elective endovascular repair, who meet the inclusion/exclusion criteria for the registry, are eligible for enrollment if treated with the Fortevo Endograft.
3239090|NCT01276262|Placebo Comparator|Treatment A|Monophasic oral contraceptive (Microgynon® 30) with placebo tablets
3343937|NCT02209155|Placebo Comparator|Placebo|one in the morning, two in the afternoon and two at bedtime daily
3239091|NCT01276262|Experimental|Treatment B|Monophasic oral contraceptive (Microgynon® 30) and fostamatinib
3343938|NCT02209168||Infertile Indian Population|200 Infertile Indian population
3343939|NCT02209168||Infertile arabian population|200 Infertile Arabian population
3343940|NCT02209168||Infertile caucasian population|200 Infertile Caucasian population
3343941|NCT02209194||Aortoiliac Aneurysms Iliac Aneurysms|Endovascular repair of aortoiliac or iliac aneurysms
3343942|NCT02209207|Active Comparator|Continuous walking training|n=10 patients with COPD Walking intensity 60 percent of 6-minute walking test speed
3343943|NCT02209207|Active Comparator|Interval walking training|n=10 patients with COPD Walking intensity 120 percent of 6-minute walking test speed for 1 minute alternating with 1 minute of rest
3343944|NCT02209220|Active Comparator|Automatic positive airway pressure|Automatic positive airway pressure treatment of obstructive sleep apnea
3343945|NCT02209220|Active Comparator|Continuous positive airway pressure|Continuous positive airway pressure for the treatment of obstructive sleep apnea
3239092|NCT01276275||Exposure Group 1|First time users of ticagrelor
3239093|NCT01276275||Exposure Group 2|First time users of clopidogrel
3343946|NCT02209233|No Intervention|Control|If randomized to the control group, patients will not be receiving massage therapy.
3343947|NCT02209233|Experimental|Massage Therapy|If randomized to the intervention group, patients will receive massage therapy of the hand, arm, shoulder, and neck by the licensed massage therapist on duty. The massage will be given in a manner that is congruent with standard of care practices by the Heart and Surgical Hospital and the licensed massage therapist.
3343948|NCT02209246|Experimental|Intervention|The intervention group will be comprised of patients who will complete the PROMIS- CAT for pain interference, pain behavior and physical function prior to the encounter with the physician and then will complete the MISS-21 after the encounter.
3239094|NCT01276275||Exposure Group 3|First time users of prasugrel
3239095|NCT01276340||1|women with urinary incontinence
3239096|NCT01276366|Active Comparator|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
3239097|NCT01276366|Active Comparator|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
3239098|NCT01276366|Active Comparator|Breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
3239099|NCT01276392||Heparin|10 Patients undergoing continuous renal replacement therapy using heparin for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
3239100|NCT01276392||CiCa|10 Patients undergoing continuous renal replacement therapy using citrate for providing anticoagulation. Blood samples taken at 8 predefined timepoints.
3239101|NCT01276405||Cohort|
3239102|NCT01276418|Experimental|Treatment|
3239103|NCT01276431|Other|Buprenorphine transdermal patch|For two age groups: 50-60 years and >= 75 years of age
3239104|NCT01276444|Active Comparator|Pulmonary artery catheter (PAC)|PAC was used to guide hemodynamic therapy after combined valve repair
3239105|NCT01276444|Active Comparator|COMPLEX|An combination of transpulmonary thermodilution and continuous monitoring of central venous saturation was used to guide hemodynamic therapy after combined valve repair surgery.
3343949|NCT02209246|Experimental|Control|The control group will complete the PROMIS- CAT for pain interference, pain behavior and physical function after the encounter and after completing a satisfaction questionnaire (MISS-21).
3343950|NCT02209285|No Intervention|Control group|The control group will receive usual care, which is provided by the community care access centre (CCAC). Usual care may include in-home visits by regulated health care providers, personal support workers, and care coordination through the community care access centre. Case conferences may occur on an as-needed basis.
3239109|NCT01276496|Experimental|Treatment (cilengitide, paclitaxel)|"Patients receive cilengitide IV over 1 hour on days* 1, 8, and 15 and paclitaxel IV over 1 hour on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Some patients receive cilengitide IV over 1 hour on days 1, 2, 8, 9, 15, and 16."
3239110|NCT01276522|Experimental|Canakinumab|A 6-month open-label, single treatment arm study of canakinumab 150 or 300 mg (in case of insufficient response to 150 mg) subcutaneous injection once per month.
3239111|NCT01276548|Experimental|Genexol®-PM plus Carboplatin|
3239112|NCT01276548|Active Comparator|Genexol® plus Carboplatin|
3239113|NCT01276561|Active Comparator|Single Incision Splenectomy|Patients will undergo splenectomy through a single incision in the umbilicus regardless of the technique or equipment used
3239114|NCT01276561|Active Comparator|Laparoscopic Splenectomy|Patient will undergo standard laparoscopic splenectomy, port placement is surgeon dependent
3239115|NCT01276587|Experimental|Single arm|
3239116|NCT01276600|Experimental|Arm 1|1 tablet orally weekly
3239117|NCT01276600|Experimental|Arm 2|One tablet orally twice weekly
3239118|NCT01276600|Experimental|Arm 3|Two tablets orally twice weekly
3239119|NCT01276600|Experimental|Arm 4|One tablet orally daily
3239120|NCT01276613|Experimental|Intraoperative Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal.
3239121|NCT01276613|Experimental|Intraoperative Gemcitabine + Losartan|"Losartan 50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.~Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min. Drug infusion started 100 minutes prior to complete gross tumor removal in order to have drug administration complete at tumor removal."
3239122|NCT01276626|Experimental|Bifidobacterium longum|
3239123|NCT01276626|Placebo Comparator|Maltodextrin|
3239124|NCT01276665|Experimental|Restrictive regimen group|treated with a restrictive fluid regimen of 2ml/kg/h of crystalloids in combination with sympathicomimetics.
3239125|NCT01276665|Active Comparator|Control group|treated according to an internationally accepted standard fluid regimen (6 ml/kg/h of crystalloids and correction of the hypotony with fluid boluses)
3239126|NCT01276678||Control|300 healthy controls free from any pharmacologic therapy
3239127|NCT01276678||Suspected CAD - Cardiac Cathetrization|subject's ≥18 years undergoing coronary angiography (inpatient cohort)or who have undergone coronary angiography within 5 years
3239128|NCT01276691|Active Comparator|Acute, Aspirin|81 mg asprin provided 30 minutes prior to firefighting- Acute single dosage
3239129|NCT01276691|Placebo Comparator|Acute, Placebo|Acute single dosage of placebo provided 30 minutes prior to firefighting
3239130|NCT01276691|Active Comparator|Chronic, Aspirin|81 mg asprin provided prior to firefighting- 14 day dosage
3239131|NCT01276691|Placebo Comparator|Chronic, Placebo|14 day dosage of placebo provided prior to firefighting
3239132|NCT01276704|Experimental|flaxseed lignan, SDG|Secoisolariciresinol diglycoside
3239133|NCT01276704|Placebo Comparator|Placebo|Matched Placebo
3239134|NCT01276717|Experimental|Vorinostat + Carfilzomib|
3239135|NCT01276730|Experimental|Group A|Treatment consists of Interferon, given as a sub-cutaneous injection, 3 times per week for 4 weeks, 20 mg Retinoic Acid tablets, 2 times a day for 30 days. starting from the first day of radiation.
3239136|NCT01276730|Active Comparator|Group B|"Treatment consists of radiation and chemotherapy using Cisplatin. Cisplatin, given intravenously, will be administered on the first day of each week, mixed with saline solution, before and after the Cisplatin infusion.~Radiation will be given for a few minutes daily, five days a week, for approximately 5 weeks.~Two weeks after completion of external radiotherapy, subject will receive internal radiation (brachytherapy) once a week for two weeks. For this internal radiation a specially designed instrument will be inserted into the vagina that will be connected to a machine for a few minutes."
3239137|NCT01276743||T1DM|Children and adolescents with T1DM
3239138|NCT01276743||Unaffected Population|Population not known to be affected by T1DM
3239139|NCT01276769|Active Comparator|ET|The control arm receive the paclitaxel plus epirubicin
3239140|NCT01276769|Experimental|PC|the experimental arm which receive the paclitaxel combined with carboplatin
3239141|NCT01276782|Placebo Comparator|Pregnant SLE|Pregnant SLE patients with autoimmune thyroid antibodies will be randomized to levothyroxine or Placebo
3239142|NCT01276795|Experimental|Glucose and whey protein|Patients who are randomly allocated to this group will receive a drink made of anhydrous beet dextrose and pressurized whey protein in water (200 g/L + 100g/L). Patients will sip the drink for 4 hours of the 6 hour study.
3239143|NCT01276795|Active Comparator|Glucose only|The patients who are randomly allocated to this arm will receive a drink composed of anhydrous beet dextrose in water (200g/L). They will sip the drink for 4 hours of the 6 hour study.
3239144|NCT01276808|Experimental|Magnetic navigation PCI|These patients will be treated with magnetically navigated percutaneous coronary intervention
3239145|NCT01276808|Active Comparator|Conventional PCI|These patients will be treated with normal standard percutaneous coronary intervention
3239146|NCT01276834|Experimental|everolimus-based immunosuppression|immunosuppression with everolimus, prednisone and mycophenolate
3239147|NCT01276834|Active Comparator|standard immunosuppression|immunosuppression with tacrolimus, prednisone and mycophenolate
3343951|NCT02209285|Active Comparator|Self-Management Program for Older Adults with Multimorbidity|Individuals in the intervention group will receive a six-month self-management intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
3343952|NCT02209298||CoreValve Transcatheter Valve|Medtronic CoreValve SystemTM is designed to replace the native or surgical bioprosthetic aortic heart valve without open heart surgery and without concomitant surgical removal of the failing valve. The support frame is manufactured by Nitinol, which has multi-level, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from a single layer of porcine pericardium into a tri-leaflet configuration. The bioprosthesis is processed with alpha-amino oleic acid (AOA™), which is a compound derived from oleic acid, a naturally occurring long-chain fatty acid. AOA™ is an antimineralization treatment shown to reduce both early and late valvular calcification.
3343953|NCT02209311|Experimental|Tissue engineered construction implantation|
3343954|NCT02209324|Experimental|ASP2151|
3343955|NCT02209337|Experimental|SRS-I|Implantation of SRS-I
3343956|NCT02209350|Active Comparator|Group 1|Operations technique on the abdominal aorta. Aorta-femoral bypass. Medication: after surgery all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
3343957|NCT02209350|Active Comparator|Group 2|Standard endovascular treatment (stenting) in patients with the iliac segment occlusive disease. Medication: after stenting all patients are prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
3343958|NCT02209363|Experimental|Positive airway pressure (PAP)|Auto-adjusting positive airway pressure
3343959|NCT02209363|Sham Comparator|nasal dilator strips|Sham treatment
3343960|NCT02209376|Experimental|Arm 1|
3343961|NCT02209389||Positive OctavaPink|Following a positive OctavaPink result, an MRI is performed and any additional testing (required by the MRI).
3239148|NCT01276873|Experimental|Closed System|Application of Tracheal aspiration closed system, controlled by the use of Open system to tracheal aspiraiton.
3239149|NCT01276886||Acute Diverticulitis|
3343962|NCT02209389||Negative OctavaPink - control|"For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and recalled for an MRI and any additional testing (required by the MRI).~MRI won't be performed to all negative OctavaPink results. Only one negative control will be assigned to each OctavaPink positive result."
3343963|NCT02209402|No Intervention|Usual Care|
3343964|NCT02209402|Experimental|Exercise Training|
3343965|NCT02209415|Active Comparator|Standard outpatient follow-up|Outpatient clinic visits 3,6,9,12,18 and 24 mths after surgery
3343966|NCT02209415|Experimental|Intervention PET/CT and EUS|PET/CT and EUS at 3,6,9,12,18 and 24 months after surgery
3343967|NCT02209428|Active Comparator|IDH wild type|Patients with IDH wild type, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
3343968|NCT02209428|Experimental|IDH mutation|Patients with IDH mutations, according to the result of genetic sequencing of their surgical resected specimens. Intervention: oral temozolomide, 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
3343969|NCT02209467|No Intervention|Group balance training late start|Participants randomized to late start act as No intervention group during the study period.
3343970|NCT02209467|Experimental|Group balance training early start|Group balance training focusing on core stability exercises 2 times per week for 7 weeks and 2 home training sessions per weeks.
3343971|NCT02209480|Experimental|Alexander Technique|5 lessons of AT, each lasting up to 45 minutes, weekly intervals The lessons aimed at sensory awareness of everyday movements and movement sequences, such as sitting, walking, lying, or lifting in order to replace habitual patterns using conscious control; and different techniques were applied, such as demonstration, verbal instructions, hands on techniques and others
3343972|NCT02209480|Active Comparator|Heat pad application|5 treatments by means of a heat pad, 15-0 minutes, sitting or lying position, quiet room Heat pad: Zapp-Sack® contained certain grains and a ginger extract, and could be heated up in the microwave.
3343973|NCT02209480|Active Comparator|guided imagery|guided imagery relaxation technique , 45 minutes, 5 sessions in weekly rhythm including body scan, breathing relaxation, visualization
3343974|NCT02209493|Experimental|Food supplementation: nopales|Consumption of 2 cups/day of cooked nopales (prickly pear cactus leaves) with each of two main meals for 2 weeks
3343975|NCT02209493|Sham Comparator|Food supplementation: cucumber|Consumption of 2 cups/day peeled and chopped cucumber with each of two main meals for 2 weeks
3343978|NCT02209558|No Intervention|Standard Written Sternal Precautions|"Patients will receive education that is the standard of care at North Shore Long Island Jewish Health Systems in their post-operative sternal precautions."
3343979|NCT02209558|Experimental|Visual Sternal Precautions|"Patients will receive both standard of care written sternal precautions, as well as visual sternal precautions."
3343980|NCT02209571|Experimental|Cystic Fibrosis|Breath test and venous blood markers in cystic fibrosis patients
3343981|NCT02209571|Active Comparator|Control|Breath test and venous blood markers in healthy subjects
3343982|NCT02209623||Pregnant Women receiving TDAP|
3343983|NCT02209636|Experimental|Lanthanum carbonate|Eligible subjects who are randomly assigned to the experimental arm will receive lanthanum carbonate (1500-4500 mg/day in divided doses) titrated to serum phosphorus levels.
3375868|NCT03665636|Experimental|Triheptanoin|Open Label Study
3375869|NCT03645863|Experimental|Cohort 1|Subject will receive MT-6548 on Day 1, 4, and 7. Subject will receive Iron supplement A on Day 1, 4, or 7. Subject will receive Iron supplement B on Day 1, 4, or 7.
3375870|NCT03645863|Experimental|Cohort 2|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement C on Day 1 or 4.
3375871|NCT03645863|Experimental|Cohort 3|Subject will receive MT-6548 on Day 1 and 4. Subject will receive Iron supplement D on Day 1 or 4.
3343984|NCT02209636|Placebo Comparator|placebo|Eligible subjects who are randomly assigned to the placebo arm will receive placebo tablets (identical to the active lanthanum carbonate tablets) to be taken 3 times daily and titrated to serum phosphorus levels.
3343985|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation A|
3343986|NCT02209649|Experimental|Telmisartan and Lacidipine FDC, formulation B|
3343987|NCT02209649|Active Comparator|Lacidipine and Telmisartan, mono|
3343988|NCT02209662|Experimental|APIC-PRP and Standard of Care|APIC-PRP
3343989|NCT02209662|Placebo Comparator|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
3343990|NCT02209675|Other|patients with elevated liver enzymes|Patients with elevated liver enzymes and/or hyperbilirubinemia post transplantation for hepatitis C virus related disease will have liver biopsy
3343991|NCT02209688|Experimental|ESR 1150 CL dose escalation fasted|
3343992|NCT02209688|Experimental|ESR 1150 CL fed|
3343993|NCT02209688|Placebo Comparator|Placebo|
3343994|NCT02209701|Experimental|Porfiromycin|
3343995|NCT02209714|Experimental|BIIF 1149 BS|
3343996|NCT02209714|Placebo Comparator|Placebo|
3239150|NCT01276899||Neoadjuvant setting|
3239151|NCT01276899||Metastatic setting|
3343997|NCT02209727|Experimental|131I-Sibrotuzumab|single therapy dose administered over 60 minutes at week 4
3343998|NCT02209740||Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
3343999|NCT02209753|Experimental|BIRB 796 BS, low dose|
3344000|NCT02209753|Experimental|BIRB 796 BS, medium dose 1|
3344001|NCT02209753|Experimental|BIRB 796 BS, medium dose 2|
3344002|NCT02209753|Experimental|BIRB 796 BS, high dose|
3344003|NCT02209753|Placebo Comparator|Placebo|
3344004|NCT02209779|Experimental|BIBR 796 BS, low dose|twice daily doses of 5 mg for 4 weeks
3239152|NCT01276925|Active Comparator|B3: Blockade of three nerves|Peripheral nerve blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with ropivacaine.
3239153|NCT01276925|Active Comparator|B2: Blockade of 2 nerves|"Peripheral nerve blockade of the anterior division of the obturator nerve and the lateral femoral cutaneous nerve with ropivacaine.~Sham blockade of the femoral nerve with saline."
3344005|NCT02209779|Experimental|BIBR 796 BS, medium dose 1|twice daily doses of 10 mg for 4 weeks
3344006|NCT02209779|Experimental|BIBR 796 BS, medium dose 2|twice daily doses of 20 mg for 4 weeks
3344007|NCT02209779|Experimental|BIBR 796 BS, high dose|twice daily doses of 30 mg for 4 weeks
3239154|NCT01276925|Sham Comparator|K: Control group|Sham blockade of the femoral nerve, the anterior division of the obturator nerve, and the lateral femoral cutaneous nerve with saline.
3344008|NCT02209779|Active Comparator|Placebo|
3344009|NCT02209792|Placebo Comparator|Placebo|
3344010|NCT02209792|Experimental|BIRB 796 BS, low dose|2 x 5 mg b.i.d.
3344011|NCT02209792|Experimental|BIRB 796 BS, medium dose 1|20 mg b.i.d.
3344012|NCT02209792|Experimental|BIRB 796 BS, medium dose 2|2 x 5 mg + 20 mg b.i.d.
3344013|NCT02209792|Experimental|BIRB 796 BS, high dose|3 x 20 mg b.i.d.
3344014|NCT02209805|Experimental|BIRB 796 BS, low dose|
3344015|NCT02209805|Experimental|BIRB 796 BS, high dose|
3344016|NCT02209805|Placebo Comparator|Placebo|
3344017|NCT02209805|Experimental|BIRB 796 BS, medium dose|
3344018|NCT02209818|Experimental|Laser Irradiation One Dose|Laser irradiation will be applied in one dose for patients in this group, but only on one side of the jaw. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
3344019|NCT02209818|Experimental|Laser Irradiation Two doses|Laser irradiation will be applied in two doses for patients in this group, but only on one side of the jaw. The second dose will be given after 24 hour of the first one. The other side of the jaw will receive a placebo procedure (i.e. a red light beam will be emitted on the gingival tissues as if they are irradiated by a laser beam).
3344020|NCT02209831|Experimental|BIBR 796 BS + pantoprazole|
3344021|NCT02209831|Active Comparator|BIBR 796 BS without pantoprazole|
3344022|NCT02209844|Experimental|BI 44847 powder|single rising dose reconstituted with natrosol solution
3344023|NCT02209844|Placebo Comparator|Placebo|reconstituted with natrosol solution
3344024|NCT02209870||E-checklist group|The patients after CPR team using E-checklist system
3344025|NCT02209883||Group normal|The patients which have not clinical diagnosis of chronic obstructive lung disease.
3344026|NCT02209883||Group COPD|The patients which have chronic obstructive lung disease in clinical evaluation
3344027|NCT02209896|Experimental|BlueWind Reprieve System|The Reprieve implant will be implanted for eligible patients. Implant parameters settings will be set according to patient's sensations.
3344028|NCT02209909|Experimental|aspirin continuation|Intervention : Low-dose aspirin (< 100mg/day) is used before OPCAB surgery in the aspirin continuation group.
3344029|NCT02209909|Experimental|aspirin discontinuation|Intervention: Low-dose aspirin is stopped more than 4 days before OPCAB surgery in the aspirin discontinuation group.
3344030|NCT02209922|Active Comparator|Transcranial direct current stimulation|"ARM1: Transcranial direct current stimulation (tDCS) intervention and simultaneous balance training.~Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week."
3344031|NCT02209922|Sham Comparator|ARM 2|ARM2: Sham tDCS and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
3344032|NCT02209935|Active Comparator|Usual Care|Typically, usual care is when therapies are not initiated until the treating team places an order for each element of care (physical, occupational, speech, and emotional therapy consultation).
3344033|NCT02209935|Experimental|Early Rehabilitation Protocol|Physical, occupational, speech, and emotional evaluation and support personalized to the subject's severity of illness and developmental status.
3344034|NCT02209961||glaucoma and ocular hypertension|glaucoma and ocular hypertension
3344035|NCT02209974|Placebo Comparator|Inhaled Placebo|Inhaled placebo administered to healthy (n=7) and to a half (n=8) of COPD patients
3344036|NCT02209974|Experimental|Inhaled corticosteroids (Fluticasone, 0.5 mg)|Inhaled corticosteroids administered to the other half (n=8) of COPD patients
3344037|NCT02209987|Experimental|GS-5745 SC|Participants will receive a single dose of GS-5745 by SC injection.
3344038|NCT02209987|Experimental|GS-5745 IV|Participants will receive a single dose of GS-5745 by IV infusion.
3344039|NCT02210013||Caucasian women|200 Caucasian infertile women undergoing their first or second IVF cycle
3239155|NCT01276938|Active Comparator|IORT 21 Gy|Single fraction 21 Gy Intraoperative Radiation Therapy for breast tumors with diameter between 10 and 25 mm
3239156|NCT01276938|Experimental|IORT 18 Gy|Single fraction 18 Gy Intra Operative Radiation Therapy in breast tumors smaller than 10 mm.
3344040|NCT02210013||Indian women|200 Indian women undergoing their first or second IVF cycle.
3344041|NCT02210026|Experimental|Experimental|Infants will be assessed on standard bubble nasal CPAP, then on Seattle-PAP bubble nasal CPAP, then again on standard bubble nasal CPAP.
3344042|NCT02210078|Experimental|Treatment (allogeneic CMV-specific cytotoxic T-lymphocytes)|Patients receive allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes IV. Patients with partial response, stable disease, or progressive disease may receive an additional dose of allogeneic cytomegalovirus-specific cytotoxic T-lymphocytes at a minimum of 2 weeks from the first infusion.
3344043|NCT02210104|Experimental|Ipilimumab + Cyclophosphamide + CD4+T Cells|Starting Dose of Ipilimumab 1.0 mg /kg by vein on Days 1, 22, 43, and 64. Cyclophosphamide 300 mg/m2 administered intravenously 2 days prior to T cell infusion as an outpatient procedure. Antigen-specific CD4+ T cells administered at a dose 10^10 cells/m^2.
3239157|NCT01276951|Placebo Comparator|Placebo|
3239158|NCT01276951|Active Comparator|6,5g Dose Group|
3239159|NCT01276951|Active Comparator|12g Dose Group|
3344044|NCT02210117|Experimental|Arm A (nivolumab, surgery)|"Patients receive nivolumab IV over 60 minutes on day 1 every 2 weeks for 6 weeks. Approximately 4 weeks later, patients undergo nephrectomy, metastasectomy or biopsy.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
3344045|NCT02210117|Experimental|Arm B (nivolumab, bevacizumab, surgery)|"Patients receive nivolumab IV over 60 minutes and bevacizumab IV over 90 minutes on day 1 every 2 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
3344046|NCT02210117|Experimental|Arm C (nivolumab, ipilimumab, surgery)|"Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes on day 1 every 3 weeks for 6 weeks. Patients also undergo nephrectomy, metastasectomy or biopsy as in Arm A.~Beginning 4-6 weeks after surgery, patients in all arms who have clinical response, stable disease, or even slight progression of disease to therapy preoperatively, receive maintenance nivolumab IV over 60 minutes on day 1. Cycles repeat every 4 weeks for 2 years in the absence of disease progression or unacceptable toxicity."
3344047|NCT02210130||patients HIV+ CSVD+|patients with HIV and cerebral small vessel disease
3239160|NCT01276951|Active Comparator|25g Dose Group|
3239161|NCT01276951|Active Comparator|50g Dose Group|
3344048|NCT02210130||control HIV+ CSVD-|patients with HIV and without cerebral small vessel disease
3344049|NCT02210143||AERSA-I gingival recession|The AERSA classification was developed based on 15 mm2 which is the lowest cut-off point and the group of AERSA ≤ 15 mm2 named as AERSA-I (low risk group)
3344050|NCT02210143||AERSA-II gingival recession|AERSA > 15 mm2 named as AERSA-II (high risk group).
3344051|NCT02210143||Miller gingival recession|Gingival recessions classified according to Miller
3344052|NCT02210156|Placebo Comparator|Placebo|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
3344053|NCT02210156|Experimental|Omniplus Supreme|Two envelopes of the product in 240 ml of water in a disposable cup, 90 days of actual consumption.
3239162|NCT01276964||1. Women in the fertile age|Healthy women in the fertile age (between 20-45 years) with apparently normal periods
3239163|NCT01276977|Experimental|Zolmitriptan 5 mg nasal spray|
3239164|NCT01276977|Active Comparator|Eletriptan 40 mg Tablet|
3239165|NCT01276990|Placebo Comparator|Placebo|Matching placebo in dosing regimen 1-8
3239166|NCT01276990|Experimental|BI 224436 dosing regimen 1|Dosing regimen 1
3239167|NCT01276990|Experimental|BI 224436 dosing regimen 2|Dosing regimen 2
3239168|NCT01276990|Experimental|BI 224436 dosing regimen 3|Dosing regimen 3
3239169|NCT01276990|Experimental|BI 224436 dosing regimen 4|Dosing regimen 4
3239170|NCT01276990|Experimental|BI 224436 dosing regimen 5|Dosing regimen 5
3239171|NCT01276990|Experimental|BI 224436 dosing regimen 6|Dosing regimen 6
3239172|NCT01276990|Experimental|BI 224436 dosing regimen 7|Dosing regimen 7
3239173|NCT01276990|Experimental|BI 224436 dosing regimen 8|Dosing regimen 8
3239174|NCT01277003|Experimental|Aculife Magnetic Wave Therapist|patients with carpal tunnel syndrome treated with Aculife
3239175|NCT01277003|Active Comparator|TENS|patients with carpal tunnel syndrome treated by TENS
3239176|NCT01277016|No Intervention|MDex:|"MDex:~Administration of oral melphalan (M) at 0.22 mg/kg and dexamethasone (Dex) at 40 mg daily for 4 consecutive days every 28 days (MDex) until end of therapy"
3239177|NCT01277016|Experimental|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
3239178|NCT01277029||lower urinary tract symptoms|
3239179|NCT01277068|Active Comparator|the adjustable gastric banding|
3239180|NCT01277068|Active Comparator|the sleeve gastrectomy|
3239181|NCT01277068|Active Comparator|the gastric bypass|
3239182|NCT01277094|Experimental|1|
3239183|NCT01277094|Placebo Comparator|2|
3344054|NCT02210169|No Intervention|Intermittent infusion of vancomycin|Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age.
3344055|NCT02210169|Active Comparator|Continuous infusion of vancomycin|A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period.
3344056|NCT02210182|Experimental|Oral pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
3344057|NCT02210182|Placebo Comparator|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
3344058|NCT02210234|Active Comparator|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat brand cereal during the day for 3 weeks.
3344059|NCT02210234|Active Comparator|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat brand cereal the day for 3 weeks.
3344060|NCT02210260|Active Comparator|Continuous infusion of local anaesthetic|Continuous infusion of local anaesthetic into the surgical wound
3344061|NCT02210260|Experimental|Spinal and infusion of local anaesthetic|A one off spinal anaesthetic plus a continuous infusion of local anaesthetic into the surgical wound
3344062|NCT02210273|Experimental|Treatment|Subjects undergoing treatment with the Solace Bladder Control (Vesair) Balloon on day 0
3344063|NCT02210273|Sham Comparator|Solace Sham Treatment|Subjects undergoing sham treatment on day 0, and treatment with the Solace Bladder Control (Vesair) Balloon at 3 months
3239184|NCT01277107|Experimental|Zaleplon AP formulation|Gastric Retentive Dual Release Zaleplon (Zaleplon AP)
3239185|NCT01277107|Placebo Comparator|Placebo|Identical placebo capsule
3344064|NCT02210299|Other|Exposure study|2-6 months-old children and 12-18 months-old children
3344065|NCT02210312||elective non-cardiac surgery and non-neurosurgical procedures|300 Patients aged 60 years and older undergoing elective non-cardiac surgery and non-neurosurgical procedures in general anaesthesia or combined general/regional anaesthesia with a duration of operation of 120 minutes or longer. 80 age-, gender- and education-matched healthy controls.
3344066|NCT02210325|Active Comparator|Ceftriaxone plus Azithromycin|A single intramuscular dose of 500 mg ceftriaxone plus a single oral dose of 1000 mg azithromycin
3344067|NCT02210325|Experimental|Solithromycin|A single oral dose of 1000 mg solithromycin
3344068|NCT02210338|Experimental|Karl Storz C-MAC|Intubation of patient using the Karl Storz C-MAC video laryngoscope
3239186|NCT01277120||Cohort|
3239187|NCT01277133||Cohort|
3344069|NCT02210338|Experimental|Bonfils Intubation Fibrescope|Intubation of patient using Bonfils Intubation Fibrescope
3344070|NCT02210351|Experimental|MRI test|
3344071|NCT02210364|Experimental|lurbinectedin (PM01183) and capecitabine|
3344072|NCT02210377|Experimental|Tianjiu (auto-moxibustion)|The participants in the Tianjiu group will be treated with Chinese herbal patches at acupoints on the abdomen and plantar, three times per week, for 4 hours each time during HD.
3344073|NCT02210377|Placebo Comparator|Non-Tianjiu (Non auto-MO)|The participants in the control group will be given placebo patches (brown clay patches) on the same sites.
3344074|NCT02210390|Experimental|Intervention|Psycho-education Sessions will be offered weekly basis
3344075|NCT02210390|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3239188|NCT01277146|Experimental|OMP-59R5|
3239189|NCT01277172|Experimental|Group 1 / PBO-326|This group will be treated three cycles with PBO-326, after the third cycle the patients will receive Mabthera for another three cycles.
3239190|NCT01277172|Active Comparator|Group 2 / Mabthera|This group will be treated three cycles with Mabthera, after the third cycle the patients will receive PBO-326 for another three cycles.
3239191|NCT01277172|Experimental|Group 3 / PBO-326|This group will be treated six cycles with PBO-326
3344076|NCT02210403|Active Comparator|Upper limb motor function training + tDCS|Bi-hemispheric tDCS with motor function training
3344077|NCT02210403|Sham Comparator|upper limb motor function training + sham tDCS|sham tDCS with motor function training
3344078|NCT02210416||LAP repair|patients receiving laparoscopic inguinal hernia repair
3239192|NCT01277172|Active Comparator|Group 4 / Mabthera|This group will be treated six cycles with Mabthera
3239193|NCT01277185|Active Comparator|Low Calcium Diet (600-1200 mg/d)|
3239194|NCT01277185|Active Comparator|High Calcium Diet (1100-2300mg/d)|
3239195|NCT01277198||surgery without using a flexible cystoscopy|surgery without using a flexible cystoscopy: patients who did not undergo a flexible cystoscopy during laparoscopic stone surgery
3239196|NCT01277198||surgery with using a flexible cystoscopy|surgery with using a flexible cystoscopy: patients who underwent a flexible cystoscopy during laparoscopic stone surgery
3239197|NCT01277224|Experimental|Movi2 Program|
3239198|NCT01277224|No Intervention|Control|
3239199|NCT01277237|Active Comparator|Omacor|
3239200|NCT01277237|Placebo Comparator|Lactose tablet|
3344079|NCT02210416||open repair|patients receiving open flat mesh repair of inguinal hernia
3344080|NCT02210429|Active Comparator|IV Opioids|
3344081|NCT02210429|Active Comparator|Supraclavicular Single-Shot Block|
3344082|NCT02210429|Active Comparator|Supraclavicular Catheter|
3344083|NCT02210429|Active Comparator|Supraclavicular Angiocath|
3344084|NCT02210442|Experimental|Educaguia intervention|Implementation of practice clinical guidelines with educational games
3344085|NCT02210442|Active Comparator|Control group|Implementation of clinical practice guidelines with standard practice care
3344086|NCT02210455|Experimental|The Strongest Families FASD intervention|It is a web-based parent training program with a coach. The program is comprised of 11 sessions, each focusing on a different parenting strategy, delivered using easy to read text, instructional videos and audio clips. One Booster Session is conducted 1 month after completion of Session 11.
3344087|NCT02210455|Active Comparator|Psychoeducation|It is a static webpage on IRIS providing FASD information and resources, including recommended book titles, websites and organizations that may be helpful.
3344088|NCT02210468|Experimental|APIC-CF 4cc,|APIC-CF 4cc, once at first day
3344089|NCT02210468|Experimental|APIC-CF, 2cc|APIC-CF, 2cc, one at first day
3344090|NCT02210468|Placebo Comparator|Saline|
3344091|NCT02210481||GLUC-MAC-COHORT|post vitrectomy for retinal detachment or epimacular membrane patients
3344092|NCT02210494|Experimental|Secretrol|
3344093|NCT02210507|Experimental|White cassava gari|A single meal containing 400 gm of garified non-biofortified (white) cassava with retinyl palmitate reference dose.
3344094|NCT02210507|Experimental|White cassava gari + red palm oil|A single meal containing 400 gm of garified non-biofortified (white) cassava with red palm oil.
3344095|NCT02210507|Experimental|Biofortified cassava gari|A single meal containing 400 gm of garified biofortified cassava.
3344096|NCT02210520|Experimental|laser|3 J/cm², 2 minutes in 6 points around the back spine
3239201|NCT01277250|Other|Usual Care|Standard smoking cessation information provided to all hospitalized patients as part of discharge packet.
3344097|NCT02210520|Experimental|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine
3344098|NCT02210520|Experimental|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
3344099|NCT02210520|No Intervention|control|no treatment.
3344100|NCT02210546|Experimental|Magnetic Resonance Imaging (MRI)|Patients will undergo MRI yearly
3344101|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|Patients will undergo yearly two-view (Mx) and breast US
3344102|NCT02210559|Experimental|Arm A|FG-3019 + Gemcitabine + Nab-paclitaxel
3344103|NCT02210559|Other|Arm B|Gemcitabine + Nab-paclitaxel
3344104|NCT02210572|Experimental|Bimuno Galacto-oligosaccharide|Dietary intervention
3344105|NCT02210572|Placebo Comparator|Low- FODMAPs diet|Dietary intervention
3344106|NCT02210585|Active Comparator|Kneehab|5 sessions per week
3344107|NCT02210585|Placebo Comparator|Placebo|5 sessions per week
3344108|NCT02210598|Active Comparator|inpatient Foley balloon induction|"Inpatient Foley induction participants will be placed in the dorsal lithotomy position, a Foley catheter will be placed transcervically and its balloon filled with 60mL of sterile saline. One of two methods will be used to place the transcervical foley based on provider preference and determination of which method will offer the greatest chance for successful placement. Method A is placement of the foley blindly by palpation of the cervix. Method B utilizes direct visualization with sterile speculum placement. Method will be documented in the data collection forms. The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded."
3344109|NCT02210598|Experimental|outpatient Foley balloon induction|Patients randomized to the experimental group will undergo outpatient Foley induction of labor. Either of the above two described methods will be used to place an 18 French Foley catheter transcervically and its balloon filled with 60mL of sterile saline. The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours. When the patient returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
3344110|NCT02210611|Active Comparator|36 hours|Intrauterine insemination 36 hours after ovulation induction
3344111|NCT02210611|Active Comparator|42 hours|Intrauterine insemination 42 hours after ovulation induction
3344112|NCT02210624|Experimental|Single arm|"Experimental: HYNR-CS inj.~Treatment group with HYNR-CS inj."
3344113|NCT02210637||Retrospective Cohort|Retrospective Cohort of scheduled outpatient appointment
3344114|NCT02210650|Other|Ureteral stone removal|Group 1 will receive the standard treatment of having only the ureteral stone removed
3344115|NCT02210650|Other|Asymptomatic kidney stones and ureteral stone removed|Group 2 will include the step of having the asymptomatic kidney stones removed in addition to the ureteral stone
3239202|NCT01277250|Experimental|Smoking Cessation Program|"Web-based program tailored to patients who smoke and are hospitalized. Program is tailored to participant's specific hospital experience and other characteristics. E-messages, social support and a transition coach are provided to each participant in this condition."
3344116|NCT02210663|Experimental|veliparib (ABT-888)|
3344117|NCT02210676|Experimental|Patients with Mallet Finger|All enrolled patients
3344118|NCT02210702|Experimental|Ethinyl Estradiol 35mcg/Noethindrone 1mg|21 day supply of Ethinyl Estradiol 35mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
3344119|NCT02210702|Experimental|Ethinyl Estradiol 20mcg/Norethindrone 1mg|21 day supply of Ethinyl Estradiol 20mcg/Norethindrone 1mg will be taken beginning at Week 3 postpartum
3344120|NCT02210702|No Intervention|No hormonal contraception|Women choosing copper IUD, spermicides, barrier methods, or sterilization (tubal ligation or partner vasectomy).
3344121|NCT02210715|Experimental|switch to Isentress|28 subjects will be prescribed Raltegravir at the standard dose of 400 mg p.o. b.i.d. for 24 months.
3344122|NCT02210715|Active Comparator|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
3344123|NCT02210728|Active Comparator|Medication only|Stimulant medication (methylphenidate or amphetamine product approved for clinical use in Canada), with dose optimized for each patient based on report of efficacy and side effects.
3344124|NCT02210728|Active Comparator|Cognitive behavioral therapy + medication|Patients are first titrated to an optimal dose of stimulant medication. They then undergo the 12 weeks of group cognitive behavioral therapy.
3344125|NCT02210728|Experimental|Cognitive behavioral therapy alone|12 weeks of structured group cognitive behavioral therapy, focusing on acquisition of skills in organization, time management, goal attainment, cognitive restructuring, stress management, anger management, impulse control, self-esteem, and relationship management.
3344126|NCT02210754|Experimental|E-cigarette 1|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)
3344127|NCT02210754|Experimental|E-cigarette 2|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/propylene glycol (PG) vehicle)
3344128|NCT02210754|Experimental|E-cigarette 3|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)
3344129|NCT02210754|Experimental|E-cigarette 4|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)
3344130|NCT02210754|Experimental|E-cigarette 5|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)
3344131|NCT02210754|Active Comparator|Combustible Cigarette|Marlboro Cigarette
3344132|NCT02210767|Experimental|Walnut Diet|Provides ~2 oz. walnuts/day (2-3% of total calories from alpha-linolenic acid [ALA])
3344133|NCT02210767|Active Comparator|Walnut Control Diet|Provides same fatty acid profile (<7% SFA, 9% MUFA, 14-15% PUFA, 2-3% ALA) as Walnut Diet, but is devoid of walnuts and their bioactives
3239203|NCT01277276||Diagnostic tool|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
3239204|NCT01277289|Experimental|Ery-dex|Ery-dex (dexamethasone sodium phosphate)is administered as intra-erythrocyte drug at monthly interval
3344134|NCT02210767|Placebo Comparator|Low ALA Diet|Provides similar macronutrient and linoleic acid profile but replaces ALA with oleic acid (<7% SFA, 12% MUFA, 12% PUFA, 0.5% ALA)
3344135|NCT02210793|Active Comparator|Transepithelial PRK|20 eyes to undergo a no touch , all-laser advanced surface ablation technique termed transepithelial PRK using the Amaris laser platform (Schwind eye-tech solutions Gmbh, Germany)
3344136|NCT02210793|Active Comparator|Conventional LASIK|20 eyes to undergo LASIK using a mechanical microkeratome (M2, Moria Surgical, Antony, France) and the Mel 80 excimer laser system(Carl Zeiss Meditec)
3344137|NCT02210806|Active Comparator|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg.
3344138|NCT02210806|Active Comparator|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
3344139|NCT02210806|Placebo Comparator|Placebo|One inhalation of placebo DPI . Total 0 mcg
3344140|NCT02210806|Active Comparator|Treatment R1|One inhalation of Proventil® MDI Total 90 mcg
3344141|NCT02210806|Active Comparator|Treatment R2|Two inhalations of Proventil® MDI, 180 mcg total
3344142|NCT02210819||Rivaroxaban|Patients who will be treated for an acute venous thromboembolism (VTE) with rivaroxaban.
3344143|NCT02210819||Standard of care|Patients who will be treated for an acute venous thromboembolism (VTE) with current standard of care.
3344144|NCT02210832|Experimental|Best practices for pregnant smokers|Five As plus referral to pregnancy-specific tobacco quit line
3344145|NCT02210832|Experimental|Best practices plus financial incentives|Best practices plus providing financial incentives contingent on biochemically verified abstinence. Incentives are in the form of vouchers exchangeable for retail items and available through 12-weeks postpartum.
3344146|NCT02210832|No Intervention|Never-smoker comparison condition|We will follow a group of never-smoker pregnant women matched to smokers on key sociodemographic and obstetrical characteristics for purposes of comparisons in birth/health outcomes at delivery and through 1 year postpartum
3239205|NCT01277289|Placebo Comparator|Placebo|placebo comparator (sodium chloride instead of dexamethasone sodium phosphate) is administered in infusion at monthly interval.
3344147|NCT02210845|Active Comparator|Financially incentivized weight loss|Participants can be assigned to the financially incentivized weight loss group in which they can receive 50 dollars at the end of the month if they achieve their monthly weight loss goal.
3344148|NCT02210845|Placebo Comparator|Standard of Care|Participants can be assigned to standard of care where they receive no intervention.
3344149|NCT02210845|Active Comparator|Supervised Exercise|Participants can be assigned to the supervised exercise arm which they will receive supervised professional training once a week.
3344150|NCT02210858|Experimental|Treatment (tipifarnib)|Patients receive tipifarnib PO BID on days 1-21. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3344151|NCT02210871|Experimental|Normal hepatic function|
3344152|NCT02210871|Experimental|Mild hepatic impairment|
3344153|NCT02210871|Experimental|Moderate hepatic impairment|
3344154|NCT02210871|Experimental|Severe hepatic impairment|
3344155|NCT02210884|Experimental|Vitamin D|Weekly oral dose of 15,000 IU of Vitamin D3
3344156|NCT02210884|Placebo Comparator|Placebo|Placebo capsule containing no vitamin D
3344157|NCT02210910|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3344158|NCT02210910|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair, and placement of the InSpace™ system.
3239206|NCT01277328||Cohort|Cohort
3239207|NCT01277367|Active Comparator|A|These members will be offered no additional incentives
3239208|NCT01277367|Experimental|B|These members will receive regular communications by Discovery Vitality.
3344159|NCT02210923||Resistant hypertensive patients with Rheos system|"We will program 6 electrical device activation setting twice in a random order to see what happens with the aforementioned respiratory and cardiovascular variables. The following electrical settings will be programmed for 4 minutes each setting:~20 Hz, 3 Volts, 480 microseconds~20 Hz, 6 Volts, 480 microseconds~50 Hz, 3 Volts, 480 microseconds~50 Hz, 6 Volts, 480 microseconds~90 Hz, 3 Volts, 480 microseconds~90 Hz, 6 Volts, 480 microseconds"
3344160|NCT02210936|Other|PDMP Data|
3344161|NCT02210949|Other|Erythropoietin Iron|"Erythropoietin and iron:~Administration of Erythropoietin (600 IU/kg (14.4 g/L)) twice weekly for three weeks .~Administration of Iron (Ferinject (iron(III)carboxymaltose)) intravenously 1000 mg once."
3344162|NCT02210962|Experimental|essential fatty acids|The experimental treatment is a food supplement containing fish oil. The daily dose of 4 capsules provides 1320 mg of eicosapentaenoic acid and 880 mg of docosahexaenoic acid, 26 weeks intervention
3344163|NCT02210962|Placebo Comparator|olive oil|Placebo capsules contain olive oil and trace amount of fish oil to assure comparable taste, 26 weeks intervention
3344164|NCT02210975|Experimental|Electrical Stimulation Therapy|
3344165|NCT02210988|Experimental|acupuncture|The acupuncture treatment for the intervention group was provided once daily for 2 weeks.
3344166|NCT02211001|Experimental|Pilates Group|The individuals were treated with Mat Pilates Method.
3344167|NCT02211001|Experimental|Segmented Dynamic Exercises Group|The individual were treated with ball exercises.
3344168|NCT02211001|Experimental|Global Postural Reeducation Group|The individuals were treated with postures of Souchard Method.
3344169|NCT02211027|Experimental|Vaccine|The vaccine is composed of lethally irradiated semi-allogenic human fibroblasts (MRC-5) transfected with genomic tumor DNA from the patients own tumor.
3239209|NCT01277367|Experimental|C|These members will nominate a charity which will benefit financially based on participants' level of physical activity.
3239210|NCT01277367|Experimental|D|These members are entered into a prize draw for a monthly cash prize if they achieve physical activity targets.
3344170|NCT02211040|Experimental|No general practitioner involvement|The selection and motivation of adults will be conducted by a researcher in the waiting room. There is no extra motivation of the general practitioner.
3344171|NCT02211040|Experimental|General practitioner involvement|An intervention group in which general practitioners select and motivate adults to be more physical active and eat more fruit and vegetables.
3344172|NCT02211053|Active Comparator|Levothyroxine|Levothyroxine infusion 20 mg IV bolus then 10 mg/h infusion
3344173|NCT02211053|Placebo Comparator|Placebo|Infusion matched to intervention arm
3344174|NCT02211066|Active Comparator|Clopidogrel|Clopidogrel 75 mg will be administered daily for 1 year
3239211|NCT01277367|Experimental|E|These members will receive a direct payment.
3239212|NCT01277367|Experimental|F|These members will be offered the opportunity to choose one of three incentive options at the time of enrollment in the study.
3239213|NCT01277380||Experimental Group|
3344175|NCT02211066|Experimental|Ticagrelor|Ticagrelor 90 mg will be administered daily for 1 year
3344176|NCT02211079|Experimental|JNJ-54861911 + Caffeine + Midazolam +Tolbutamide|JNJ-54861911, 50 milligram (mg) (2*25 mg tablets) orally once daily from Day 2 to Day 9 along with caffeine 100 mg (2*50 mg tablets), midazolam 2 mg (1 milliliter [mL], 2 mg/mL solution), and tolbutamide 500 mg tablet, orally on Day 1, 2, and 9.
3239214|NCT01277380||Control Group|
3344177|NCT02211092|Experimental|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
3344178|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
3239215|NCT01277380||Negative control group|
3239216|NCT01277393||Experimental Group|
3239217|NCT01277393||Control Group|
3344179|NCT02211105||Laparoscopic Nissen Fundoplication|Patients whose GERD is being treated surgically through Laparoscopic Nissen Fundoplication.
3344180|NCT02211105||Transoral Incisionless Fundoplication|Patients whose GERD is being treated surgically through Transoral Incisionless Fundoplication.
3344181|NCT02211118|Experimental|IN-DEX|Subjects will be administered 1 mcg/kg or 1.5 mcg/kg intranasal dexemdetomidine (IN-DEX) and monitored for up to 5 hours.
3344182|NCT02211144|Experimental|BIRB 796 BS|in escalating doses
3239218|NCT01277406|Experimental|4SC-201+FOLFIRI|
3239219|NCT01277406|Active Comparator|FOLFIRI|
3239220|NCT01277419||Ankylosing spondylitis|Ankylosing spondylitis according to the modified New York criteria or with the clinical diagnosis of AS/r-axSpA fulfilling the ASAS Classification Criteria AND the mNY criteria plus having the indiaction for starting a bDMARD therapy according to the treating rheumatologist
3239221|NCT01277419||Non-radiographic axial spondyloarthritis|Patients with clinical characteristics of axial SpA but not fulfilling the modified New York criteria for which radiographic sacroiliitis is essential or with the clinical diagnosis of nr-axSpA fulfilling the ASAS Classification Criteria not fulfilling the mNY criteria and the indiaction for starting a bDMARD therapy according to the treating rheumatologist
3239222|NCT01277419||Juvenile spondyloarthritis|Patients with juvenile spondyloarthritis (juvenile ankylosing spondylitis, juvenile non-AS-spondyloarthritis).
3239223|NCT01277419||Crohn's disease|Patients with Crohn's disease
3239224|NCT01277419||Acute anterior uveitis|Patients with acute anterior uveitis
3239225|NCT01277419||Axial psoriatic arthritis|Patients with the clinical diagnosis of psoriatic arthritis with axial involvement (sacroiliac joints and/or spine) (axPsA)
3239226|NCT01277432||Psychiatrist interview|"All patients will receive the same assessments as the 'active comparator' arm, but in addition those patients found to have positive symptoms for mild to severe depression by PHQ9 or CESD (PHQ>10 and/or CES>16) and a random sample of subjects with no or mild symptoms will also undergo a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
3344183|NCT02211144|Placebo Comparator|Placebo|
3344184|NCT02211157|Experimental|BIBR 796 BS, fasted|dose escalation
3344185|NCT02211157|Experimental|BIBR 796 BS, fed|50 mg BIRB 796 BS (food effect)
3344186|NCT02211157|Placebo Comparator|Placebo|
3344187|NCT02211170|Experimental|BIBR 796 BS, low dose|
3344188|NCT02211170|Experimental|BIBR 796 BS, high dose|
3344189|NCT02211170|Placebo Comparator|Placebo|
3344190|NCT02211183|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridement, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3344191|NCT02211183|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridement, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3344192|NCT02211196|Experimental|Health Services Research (smoking cessation intervention)|Participants complete a survey over approximately 10-15 minutes related to their provider's cessation advice and assistance with quitting.
3344193|NCT02211209|Placebo Comparator|Placebo|Volanesorsen-matching placebo administered subcutaneously once-weekly for 52 weeks.
3344194|NCT02211209|Experimental|Volanesorsen|Volanesorsen 300 mg administered subcutaneously once-weekly for 52 weeks.
3344195|NCT02211248|Active Comparator|Conventional Group|Conventional treatment and follow up
3344196|NCT02211248|Experimental|Multidisciplinary Group|Multidisciplinary assistance
3375872|NCT03631225||Guided-Care Arm|Physicians will use the reported Vectra score to guide treatment decisions
3375873|NCT03631225||Usual Care Arm|Physicians will treat patient per standard of care without the use of the Vectra score
3344197|NCT02211274|Experimental|Study Group|Individuals who want to leave the CLC will be allowed to participate in the study, there will be no assignment to groups. Individuals who want to leave the CLC will undergo transition care planning using the investigators' standardized toolkit. The investigators will compare outcomes to administrative data from other similar VA nursing homes.
3344198|NCT02211287|Experimental|Intervention|The intervention will include five key elements: a Project Nurse - ACP facilitator; family education on comfort care at the end of life for individuals with dementia using the 'Comfort Care at the end of life for persons with dementia' booklet; a family meeting with follow-up telephone call; documentation of ACP decisions, and orientation and education directed towards General Practitioners (GPs) and nursing home staff about the intervention.
3344199|NCT02211287|No Intervention|Usual care|Care will continue as usual for the nursing home residents
3344200|NCT02211300|Experimental|Optiscanner values vs YSI|Matched samples up to 12 times per 24 hour period
3344201|NCT02211326|Experimental|genotype-guided group|Interventions：on day1~day3, patients received dose according to IWPC formula (PGx-1) included clinical variables and genotype data for VKORC1, CYP2C9*1, CYP2C9*2, and CYP2C9*3; on day4~day7, patients received dose according to Lenzini formula consisted of clinical variables, VKORC1, CYP2C9*2, CYP2C9*3 and previous INR and dosing information (PGx-2); and on day8, the clinicians adjusted the dose according to observed INR.The overall follow-up period is 12 weeks.
3344202|NCT02211326|Active Comparator|control group|Interventions：on day1~day3, patients were given initial dose (2.25mg); and starting from day4, the clinicians began to adjust the dose for patients according to observed INR.The overall follow-up period is 12 weeks.
3344203|NCT02211339|Experimental|Peer-led intervention group|Individuals met twice a week for 8 weeks and participated in a peer-mediated social communication skills group.
3344204|NCT02211339|Active Comparator|Staff-led social activity group|Individuals met twice a week for 8 weeks and participated in staff-led social activities.
3344205|NCT02211352|Active Comparator|Active(Korean Red Ginseng) first group:|Korean Red Ginseng Capsules 2g,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
3239227|NCT01277432||Depression screening|"All study participants will undergo a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal.~All patients will also undergo detailed psychological and behavioral assessments using validated questionnaires.~Several specialist questionnaires will also be conducted with all patients, including those on depression, self care and quality of life;~Patient Health Questionnaire (PHQ-9)~Depression Anxiety and Stress Scale (DASS-21)~Diabetes Distress Scale (DDS-17)~Life events questions (Inter-Heart Study)~Diabetes Empowerment Scale (C-DES 20)~Summary of Diabetes Self Care Activities (SDSCA-15)~Euroqol-5D (EQ-5D)"
3239228|NCT01277445|Placebo Comparator|Placebo|15g/day maltodextrin for 28 days
3239229|NCT01277445|Active Comparator|Prebiotic|Consumption of 15g/day of inulin-fructan for 28 days
3344206|NCT02211352|Placebo Comparator|Placebo capsules|placebo Capsules(2g),daily, 8 week and than crossover to Korean Red Ginseng capsules(2g), daily 8week
3344207|NCT02211378|Experimental|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
3344208|NCT02211378|Active Comparator|Hotseat|Trainees are in the 'hotseat' actively participating during all 3 simulation sessions
3344209|NCT02211391|Experimental|Casein Protein|Casein protein (30g) will be consumed as the last food/caloric beverage and within 30 minute of sleep
3344210|NCT02211391|Placebo Comparator|Non-caloric Placebo|The non-caloric placebo beverage will will be consumed as the last food/caloric beverage and within 30 minute of sleep
3344211|NCT02211417|Experimental|DS107G|DS107G 2g capsules taken by mouth daily for 56 days.
3344212|NCT02211417|Placebo Comparator|Placebo|Placebo capsules 2g taken by mouth daily for 56 days.
3344213|NCT02211430|Experimental|Cognitive-Behavioral Counseling (CBC)|Cognitive-Behavioral Counseling (CBC) consists of two 45-minute on-site intervention sessions (session 1 and 3), one 15 minute on-site session (session 2), and one 15-minutes phone session (booster session).
3344214|NCT02211430|Active Comparator|Best Practice (BP) Control|Best Practice (BP) Control Condition consists of two 10-15 min, on-site intervention sessions (session 1 and 3), one brochure pick-up (session 2), and receipt of a newsletter by mail (booster session).
3239230|NCT01277458||Non white HIV positive men who have sex with men|
3239231|NCT01277471|Experimental|Arm A: 6 and 2 meals/day|6 meals/day for the first 12 weeks followed by 2 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
3239232|NCT01277471|Active Comparator|Arm B: 2 and 6 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
3239233|NCT01277484|Experimental|Decitabine, MDS treatment, IV injection|For the patients who achieve remission after allogeneic BMT and meet the enrollment criteria, decitabine will be given at a dose of 5mg/kg/day ~ 15mg/kg/day iv over 1 hour for 5 consecutive days starting 42-90 days after transplantation. The drug will be repeated every 4 weeks for up to 12 cycles.
3344215|NCT02211443|Experimental|Single arm|"Two phase study of Recombinant full human Anti-epidermal growth factor receptor(EGFR) Monoclonal Antibody:~First phase: seven escalating single-dose groups : 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 mg/kg~Second phase: multiple-dose groups 0.5, 1.0, 2.0, 3.0 mg/kg: weekly once for 4 doses; 5.0, 6.0 mg/kg: every two weeks for 2 doses; 4.0 mg/kg: weekly or every two weeks depends on the results of previous dose groups."
3344216|NCT02211469|Experimental|Panel 1: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3344217|NCT02211469|Experimental|Panel 2: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3344218|NCT02211469|Experimental|Panel 3: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3344219|NCT02211469|Experimental|Panel 4: BMS-986104 or Placebo|BMS-986104 or Placebo single dose by mouth as specified
3344220|NCT02211482|Other|Dolutegravir , lamivudine|Dolutegravir 50 mg QD plus lamivudine 300 mg QD
3344221|NCT02211508|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
3344222|NCT02211508|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
3344223|NCT02211521|Experimental|PRP group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of autologous Platelet-Rich Plasma (3ml).
3344224|NCT02211521|Active Comparator|Hyaloronan group|Patients randomized to this group of treatment will receive 1 blinded knee intra-articular injections of hyaluronic acid (3ml)
3344225|NCT02211547|No Intervention|Control|No treatment to be rendered following separator placement.
3344226|NCT02211547|Placebo Comparator|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
3239234|NCT01277497|Experimental|Sevelamer carbonate|1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
3239235|NCT01277497|Active Comparator|Calcium acetate|1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks
3239236|NCT01277536||hospitalization >24 hours|
3239237|NCT01277562||Breast Cancer|Non-metastatic breast cancer with recent diagnosis of osteopenia or osteoporosis
3239238|NCT01277562||Prostate Cancer|Non-metastatic prostate cancer with recent diagnosis of osteopenia or osteoporosis
3239239|NCT01277575|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
3239240|NCT01277575|Sham Comparator|Placebo stimulation|Sham stimulation (placebo condition) no intervention
3239241|NCT01277588||Patient|
3239242|NCT01277588||Physcician|
3239243|NCT01277614|Experimental|Lifestyle counseling|This is a 6-month intervention in which participants with 2 or more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
3344227|NCT02211547|Experimental|Treatment|Single blind laser treatment (the laser will be positioned and operated, and energy transfer will take place).
3344228|NCT02211560|Placebo Comparator|Placebo|Identical looking cellulose capsules
3344229|NCT02211560|Experimental|Phosphatidylserine|Phosphatidylserine-omega-3, DHA enriched
3344230|NCT02211573|No Intervention|Control group|Patients of this group don't performed physical training
3344231|NCT02211573|Experimental|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
3344232|NCT02211599|Experimental|15% protein meal and sweetened beverage|Breakfast and lunch will each contain 15% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
3344233|NCT02211599|Experimental|30% protein meal and sweetened beverage|Breakfast and lunch will each contain 30% protein. A sweetened flavored beverage will be served with each meal; one drink will be sweetened with sugar and the other with sucralose (a non-nutritive sweetener). Order will be randomized.
3344234|NCT02211612|Experimental|Saturated fatty acids (SFA)-group|Weight gain created by addition of muffins baked on saturated fat
3239244|NCT01277614|Placebo Comparator|Health Literature|
3239245|NCT01277627|Active Comparator|Nevirapine|
3239246|NCT01277627|Active Comparator|Non-nevirapine|
3239247|NCT01277640|Placebo Comparator|matched placebo|
3239248|NCT01277640|Placebo Comparator|universal placebo|
3239249|NCT01277640|Active Comparator|dapivirine|
3239250|NCT01277653||PIVKA-II and AFP 6 months|PIVKA-II and AFP measurement every 6 months
3239251|NCT01277653||tumor maker interval every 6 month|tumor maker interval every 6 month
3344235|NCT02211612|Experimental|Polyunsaturated fatty acids (PUFA)-group|Weight gain created by addition of muffins baked on polyunsaturated fat
3239252|NCT01277679|Other|Healthy Volunteer|Healthy Volunteer cohort
3239253|NCT01277679|Other|Heart Failure|Heart Failure cohort
3344236|NCT02211625|Experimental|TRV734 125 mg|Part A, open-label will evaluate the the safety, PK and PD profile of a 125mg dose of TRV734 in which subjects are fasted, fed a standard meal, or fed a high-fat meal. Part A will also inform the dosing paradigm for Part B.
3344237|NCT02211625|Active Comparator|Multiple ascending dose study, active and placebo comparators|Part B will assess the safety, tolerability, PD and PK of TRV734. Subjects will be randomized in a ratio of 3:1:1 to receive either multiple doses of TRV734, oxycodone IR 10mg or placebo.
3239254|NCT01277692|Experimental|Part 1: Single Dose Escalation in Healthy Subjects|The doses currently planned are 10, 30mg, 100mg, 200mg
3239255|NCT01277692|Experimental|Part 2: Repeat Dose Escalation in Healthy Subjects|The first planned dose is currently 10mg QD and the planned maximum dose is 100mg QD
3344238|NCT02211651||ObeseDYS|Obese subjects with dysfunctional vascularization and inflammation of placenta.
3344239|NCT02211651||ObeseNL|Obese subjects with normal vascularization and inflammation of placenta
3239256|NCT01277692|Experimental|Part 3: Single Dose Escalation in HCV Infected Subjects|The planned doses for Part 3 are 5mg, 30mg, and 100 mg.
3239257|NCT01277705|Experimental|Group A|
3239258|NCT01277705|Experimental|Group B|
3239259|NCT01277705|Active Comparator|Group C|
3239260|NCT01277731|Experimental|Methylprednisolone replacement|"This study will enroll the patients who were previously experienced dexamethasone-induced hiccup. Patients who experienced dexamethasone-induced hiccup during chemotherapy will enroll to study arm.~Run-in period * Dexamethasone 10mg-20mg q day iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Treatment period * Methylprednisolone 60mg-125mg iv during chemotherapy~▶ measure hiccup and nausea/vomiting severity~Response will be evaluated by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE) and NRS to hiccup at 24hrs after start methylprednisolone.~Nausea and vomiting will be assessed as CTCAE 4.0"
3239261|NCT01277770||Kidney Transplant Recipients|Kidney Transplant Recipients at the University of Minnesota since 1984. The study looks at a 10 year followup of steroid-free maintenance immunosuppression, post-transplant infections and evaluation of the DGF nomogram in Thymoglobulin on patients at the University of Minnesota.
3239262|NCT01277809|No Intervention|Usual Care|Participants will receive care as usual (Usual Care Group; UCG) that is provided by their long-term care unit.
3344240|NCT02211651||LeanNL|Lean subjects with normal vascularization and inflammation of placenta.
3375874|NCT03619655|Experimental|"Cohort A - SPECT CT and NaF PET"|Intervention 1: SPECT CT Intervention 2: NaF PET
3344241|NCT02211664|Experimental|Passeo-18-Lux & Pulsar-18|"The interventional procedure sequence consists of the following steps:~pre-dilation of the lesion with a Passeo-18 balloon (mandatory)~dilation of the lesion with a Passeo-18 Lux drug releasing balloon (mandatory); a maximum of 2 Passeo-18 Lux balloons can be used per lesion (drug load cannot exceed 12µg)~stenting of the lesion with a Pulsar-18 stent (mandatory)~post-dilation of the lesion with a Passeo-18 balloon (not mandatory)"
3344242|NCT02211677||Low Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hb, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 1-4 called the low risk group.
3344243|NCT02211677||Intermediate Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 5-11 called the intermediate risk group.
3344244|NCT02211677||High Risk Group|Each of the eight independent prognostic factors (age, sex, T and N stages, hemoglobin during radiotherapy, variation tendency of Hemoglobin, neutrophil-lymphocyte ratio before radiotherapy and platelet during radiotherapy) was assigned a number of points proportional to its regression coefficient to calculate prognostic index (PI), which ranged from 1 to 17. Patients with PI equal to 12-17 called the high risk group.
3344245|NCT02211690|Experimental|dolutegravir 50mg with co-formulated emtricitabine-tenofovir|One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days
3344246|NCT02211703||Observation|This is an epidemiology study in which all the data from the subjects enrolled will be collected and analysis to investigate the current patient warming condition and actual perioperative hyperthermia rate in the elective operation with general anesthesia. During the whole procedure none intervention is administered.
3344247|NCT02211716|Experimental|BeGraft|Patient's treated with the BeGraft PMCF Stent Graft System from Bentley Innomed for the treatment of iliac lesions.
3344248|NCT02211729|Active Comparator|Seasonal malaria chemoprevention|Sulphadoxine-Pyrimethamine Amodiaquine Placebo Azithromycin
3344249|NCT02211729|Experimental|seasonal malaria chemoprevention plus AZ|Sulphadoxine-Pyrimethamine+ Amodiaquine + Azithromycin 4 rounds during malaria transmission season
3344250|NCT02211742|Active Comparator|dapagliflozin|10mg dapagliflozin per 24h for 3 days per cross-over phase (equals 2 x 30mg)
3344251|NCT02211742|Placebo Comparator|placebo sugar pills|placebo tablet, 1 per 24h for 3 days in total per cross-over phase (equals 2 x 3 tablets)
3344253|NCT02211807||Patients initiating an Efavirenz|Patients initiating an Efavirenz-containing antiretroviral regimen
3344254|NCT02211807||Patients initiating an Efavirenz-free regimen|
3344255|NCT02211833|Experimental|BI 2536 with pemetrexed|combination therapy phase may be followed by BI 2536 monotherapy for eligible patients
3344256|NCT02211846|Experimental|Mirabegron|Administered under fed and fasted conditions
3344257|NCT02211859|Experimental|BI 2536|single escalating dose, followed by repeated administration in patients with clinical benefit
3344258|NCT02211872|Experimental|Treatment A|BI 2536 BS single rising dose
3344259|NCT02211872|Experimental|Treatment B|BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
3344260|NCT02211898|Experimental|BNS003|
3344261|NCT02211911|Experimental|Bisacodyl|
3344262|NCT02211911|Experimental|Sodium picosulfate|
3344263|NCT02211924|Experimental|BI 44847|single rising dose
3344264|NCT02211924|Placebo Comparator|Placebo|
3344265|NCT02211937|Active Comparator|Treatment A|BI 44847 suspension high dose, fasted
3344266|NCT02211937|Experimental|Treatment B|BI 44847 tablet high dose, fasted
3344267|NCT02211937|Experimental|Treatment C|BI 44847 tablet high dose, fed
3344268|NCT02211937|Active Comparator|Treatment D|BI 44847 solution low dose, fasted
3344269|NCT02211937|Experimental|Treatment E|BI 44847 tablet low dose, fasted
3344270|NCT02211950|Experimental|Treatment A|single dose BI 44847 administered to white subjects
3344271|NCT02211950|Experimental|Treatment B|100 mg acarbose for 2 days, on the second day a single dose BI 44847 administered to white subjects
3344272|NCT02211950|Experimental|Treatment C|single dose BI 44847 after a Japanese diet of 6 days administered to white subjects
3344273|NCT02211950|Experimental|Treatment D|single dose BI 44847 administered to asian subjects
3344274|NCT02211950|Experimental|Treatment E|single dose BI 44847 administered to african subjects
3344275|NCT02211963|Experimental|BI 44847|
3344276|NCT02211963|Placebo Comparator|Placebo|
3344277|NCT02211976|Experimental|Bisacodyl|
3344278|NCT02211976|Experimental|Simeticone|
3344279|NCT02211976|Experimental|Bisacodyl and simeticone|
3344280|NCT02211989|Experimental|BI 14332 CL|single rising dose
3344281|NCT02211989|Placebo Comparator|Placebo|
3344282|NCT02212002||Control|Control group: infants born to GBS-negative mothers, who thus did not receive any antibiotic treatment before/at delivery.
3344283|NCT02212002||IAP|IAP group: infants born to GBS-positive mothers who have received adequate intrapartum antibiotic prophylaxis (IAP). According to the Institutional treatment protocol for GBS prophylaxis (derived from CDC guidelines), intravenous ampicillin is given every 4 hours until delivery (first dose 2 g, following doses 1 g each). IAP is considered adequate when the mother received at least two doses of ampicillin before delivery.
3344284|NCT02212015|Experimental|Pazopanib + Paclitaxel|
3344285|NCT02212041|Experimental|Electronic cigarettes|Free disposable electronic cigarettes will be provided during 6 weeks to smokers with serious mental illness.
3344286|NCT02212054|Experimental|conservative & operative treatment|anal dilation; colon lavage; probiotics
3344287|NCT02212054|Active Comparator|operative treatment|one stage pull- through radical colectomy
3344288|NCT02212067|Experimental|Semaglutide|Total of 12 visits
3344289|NCT02212067|Placebo Comparator|Placebo|Total of 12 visits
3344290|NCT02212067|No Intervention|Healthy subjects|Total of 2 visits
3239263|NCT01277809|Active Comparator|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program. This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the walking group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
3239264|NCT01277809|Experimental|Walking Program|Participants will walk five times per week under the supervision of a licensed physiotherapist.
3239265|NCT01277835|Experimental|Lidocaine Infusion|
3239266|NCT01277835|Placebo Comparator|Placebo|Saline Infusion
3239267|NCT01277874|Active Comparator|Nasal CPAP|Standard Nasal CPAP
3344291|NCT02212080|Experimental|BAY1214784|Dose 1 to 7 of BAY1214784
3344292|NCT02212080|Placebo Comparator|Placebo|Placebo Dose 1 to 7 of BAY1214784
3239268|NCT01277874|Active Comparator|Oscillatory NCPAP|NCPAP will be given to infant via prongs in the infant's nose. A Bird Industries pneumatic oscillating diaphragm to drive a Bird Industries phasatron which is attached by T-connector to the NCPAP patient circuit.
3239269|NCT01277900||Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
3344293|NCT02212093||pneumonia and mechanical ventilation|The data are collected retrospectively from this one group.
3344294|NCT02212119|Placebo Comparator|Saline|Saline injection up to 5 cc in arm with paratonia (one time injection)
3344295|NCT02212119|Active Comparator|Botulinum Toxin|Up to 300 U (5 cc) of Botulinum toxin diluted 2:1 (2 cc per 100 U of Botulinum toxin) (one time injection)
3344296|NCT02212132||Patient|Neuropsychological evaluation, psychopathological assessment and fatigue
3239270|NCT01277913|Experimental|Vitamin D 1000 IU|vitamin D will be given 1000 IU for 12 months
3344297|NCT02212132||Control group|Neuropsychological evaluation, psychopathological assessment and fatigue
3344298|NCT02212145||Screened group|Screened group is defined as those individuals who were willing to participate in the cardiovascular prevention program and all the individuals who lived in Sollentuna during the intervention.
3344299|NCT02212145||Relatives to the screened group|Relatives to individuals included in the screened group, who lived in Stockholm County at least during one year at the time of the intervention.
3344300|NCT02212145||Control group|"Matched controls is going to be selected randomly from the population of Stockholm County minus Sollentuna Municipality with relevant background factors. The whole population will be used as a comparison group when evaluating the result from all the municipality of Sollentuna during 1988-1993."
3239271|NCT01277913|Active Comparator|Vitamin D 500IU|vitamin D 500 IU will be given for 12 months once daily
3344301|NCT02212158|Experimental|motivational interviewing group|"Motivational Group Intervention:~Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies."
3344302|NCT02212171|Experimental|TRIAP intervention|
3344303|NCT02212171|No Intervention|Usual care|Usual care: Patients in the control group will be treated according to Osakidetza recommendations.
3239272|NCT01277939|Experimental|Therapeutic Education System (TES)|Experimental (E) condition, the Therapeutic Education System (TES) delivered via effective informational technologies and multimedia learning tools.
3239273|NCT01277939|Active Comparator|Standard Care|The Control (C) condition, Standard Care, consisting of psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
3239274|NCT01277952|Experimental|DBS Surgery|Deep brain stimulation (DBS) will be the treatment option in this study along with behavioral interventions for participants with severe disability due to Traumatic Brain Injury (TBI) 24 months post their injury, the participants will have severe disabilities in behavioral and emotional self-regulation, cognitive impairments and somatic symptoms.
3239275|NCT01277965|Other|50% VO2 max, BFR reduced by 50%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
3239276|NCT01277965|Other|50% VO2 max,BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
3239277|NCT01277965|Other|75% VO2 max, BFR reduced by 80%|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%.
3239278|NCT01277965|Other|75% VO2 max, pump switched off|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed.
3239279|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change.
3239280|NCT01277978||Carbetocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 100 ug Carbetocin (the clinical standard dose) following delivery of the baby.
3239281|NCT01277978||Oxytocin|Women undergoing elective caesarean sectio in regional anesthesia randomised to receive 5 IU oxytocin (the clinical standard dose) following delivery of the baby.
3239282|NCT01277991|Experimental|Sequence 1|
3239283|NCT01277991|Experimental|Sequence 2|
3239284|NCT01278004|Placebo Comparator|Placebo|Placebo capsule
3239285|NCT01278004|Experimental|Drug|
3239286|NCT01278017|Experimental|ceftriaxone|
3239287|NCT01278056|Experimental|Exjade|
3239288|NCT01278082|Experimental|A|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
3344304|NCT02212184|Sham Comparator|Control Group|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
3344305|NCT02212184|Experimental|Intevention Group|"All patients will receive the Manual Diaphragm Release Technique, during 6 days of treatment. They will undertake four evaluations throughout treatment: before and immediately after the Day 1 (Baseline 1 and Post 1) and before and after Day 6 (Baseline 6 and Post 6).~In the other Days (2nd to 5th) patients will only receive the intervention and won't be evaluated."
3344306|NCT02212210|Active Comparator|Methylprednisolone|1cc of 80mg methylprednisolone to be diluted with 1cc preservative free normal saline
3344307|NCT02212210|Placebo Comparator|Normal saline|2cc preservative free normal saline
3344308|NCT02212223|Experimental|Group 1: Somali immigrant group, 10 µg (400 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months
3344309|NCT02212223|Experimental|Group 2: Somali immigrant group, 20 µg (800 IU) vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months
3344310|NCT02212223|Placebo Comparator|Group 3: Somali immigrant group, 0 µg vitamin D3|Subjects belonging to Somali immigrant population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months
3344311|NCT02212223|Experimental|Group 4: Original Finnish group, 10 µg (400 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 10 µg (400 IU) vitamin D3 to take for 6 months.
3344312|NCT02212223|Experimental|Group 5: Original Finnish group, 20 µg (800 IU) vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 20 µg (800 IU) vitamin D3 to take for 6 months.
3344313|NCT02212223|Placebo Comparator|Group 6: Original Finnish group, 0 µg vitamin D3|Subjects belonging to original Finnish population are given a daily supplement containing 0 µg (0 IU) vitamin D3 to take for 6 months.
3344314|NCT02212236|Experimental|Psychological preparation + TAU|TAU=treatment as usual
3344315|NCT02212236|No Intervention|Treatment as usual|Usual care including medication, nursing, and psychologist support.
3344316|NCT02212249|Active Comparator|Systemic sclerosis|patients with systemic sclerosis
3239289|NCT01278082|Placebo Comparator|B|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
3239290|NCT01278095|Experimental|GLPG0555 solid dispersion, fasting|50 mg as solid dispersion capsule, in fasting condition
3239291|NCT01278095|Experimental|GLPG0555 solid dispersion, fed|50 mg as solid dispersion capsule, after breakfast
3239292|NCT01278095|Experimental|GLPG0555 nanosuspension, fed|50 mg as nanosuspension, given after breakfast
3344317|NCT02212249|Sham Comparator|primary raynaud disease|patients with primary raynaud disease
3344318|NCT02212262||Multiple Myeloma Patients|Patients with multiple myeloma will undergo a blood draw and a bone marrow aspirate. Extra bone marrow will be taken for study purposes only.
3344319|NCT02212262||Healthy subjects|Healthy subjects and multiple myeloma patients will undergo a blood draw
3344320|NCT02212275|Experimental|Dextromethorphan in ASD|8-12 years old: > 30 boys will be recruited who have a known or suspected diagnosis of ASD confirmed by DSM-5 checklist and the ADOS-2 at screening. They will have the cortical metric measured 20 min prior to receiving DXM and 2 hours after receiving a single age and weight appropriate dose of DXM. The outcome reported is the difference in the cortical metric after the DXM dose and before the DXM dose.
3239293|NCT01278108|Experimental|1|single ascending doses
3239294|NCT01278108|Placebo Comparator|2|single dose placebo
3344321|NCT02212275|Active Comparator|Dextromethorphan in controls|30 typically developing boys 8-12 years old who have the cortical metric measured 20 min before receiving a single age and weight appropriate dose of DXM and 2 hours after the single dose of DXM. The reported value will be the difference between the cortical metric 2hrs after the single dose of DXM and the cortical metric 20 minutes prior to the single dose of DXM.
3344322|NCT02212288||PKU patients|Adult PKU patients;Blood samples;Urine sample only at inclusion
3344323|NCT02212288||Healthy controls|Adult Healthy controls;Blood samples;Urine samples only at inclusion
3344324|NCT02212314|Experimental|Response Inhibition Training|Treatment group will receive immediate treatment after pre-test.
3344325|NCT02212314|No Intervention|Waitlist Crossover|Waitlist group will not receive intervention while treatment group is active, but waitlist group will be offered treatment after post-test is completed.
3344326|NCT02212327||PD subjects|
3344327|NCT02212327||Controls|
3344328|NCT02212340|Experimental|TIVA group|Anesthesia is maintained with fresofol and remifentanil
3344329|NCT02212340|Active Comparator|Des group|Anesthesia is maintained with desflurane and remifentanil
3344330|NCT02212353||Site 1 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 1 in delivering to care to neck of femur patients.
3344331|NCT02212353||Site 2 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 2 in delivering to care to neck of femur patients.
3344332|NCT02212353||Site 3 Health Care Professionals|Observational research. This is a cohort of health care professionals working in site 3 in delivering to care to neck of femur patients.
3344333|NCT02212366|Experimental|Active TDCS|2-week course of daily (5 days/week) active bilateral anodal TDCS, duration 30 minute each session. Current 2 mA.
3344334|NCT02212366|Sham Comparator|Sham TDCS|2-week course of daily (5 days/week) Sham bilateral tDCS. Duration 30 minute each session.
3344335|NCT02212392|No Intervention|control|This arm was not given any prophylactic antibiotics. Patients were managed in the surgical ward by post graduate residents under the supervision of consultants
3344336|NCT02212392|Experimental|Antibiotics|this arm was given IV antibiotics, prophylactically, right from the day of admission. They were given intravenous broad spectrum (MEROPENEM) twice daily at 12 hours interval for 7-10 days
3375875|NCT03619655|Experimental|"Cohort B - SPECT CT and 18F-DCFPyL PET/CT"|Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT
3239295|NCT01278108|Experimental|3|multiple dose, 7 days, capsules (dosing depends on outcome of single-dose part; can be once or twice daily).
3344337|NCT02212405|Sham Comparator|rTMS Sham + PET|An advanced sham coil will be used that mimicks the sound and sensation of real repetitive Transcranial Magnetic Stimulation. The repetitive Transcranial Magnetic Stimulation sham intervention is followed by radiotracer and PET.
3344338|NCT02212405|Experimental|rTMS 1Hz + PET|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 20 trains each comprising of 50 pulses at 1Hz. The inter-train interval is 15 seconds. The intervention is followed by radiotracer and PET.
3344339|NCT02212405|Experimental|rTMS 10Hz + PET.|Deep repetitive Transcranial Magnetic Stimulation will be applied to the insula for 30 minutes. This will consist of 34 trains each comprising of 30 pulses at 10Hz. The inter-train interval is 3 seconds. The intervention is followed by radiotracer and PET.
3344340|NCT02212418|Experimental|Abdominal hypopressive technique|
3344341|NCT02212431|Experimental|Cysteamine|"Dosing will be in accordance with licensed use of cysteamine for cystinosis, i.e. 450mg qds.~Dose will be escalated:~450mg od for one week 450mg bd for one week 450mg tds for one week 450mg qds for two weeks"
3344342|NCT02212444|Experimental|Dynamic elastomeric fabric orthoses (DEFO)|The DEFO will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
3344343|NCT02212444|Active Comparator|Off-the-self orthotics|Off-the-shelf-Orthotics: Patients in the usual care group will be referred for off -the-shelf triplanar orthoses as indicated by a biomechanical assessment of foot posture while standing / walking on visit 1. The off the shelf orthotic will be provided after taking the baseline measures and orthoses measurements at the baseline session ~ 3 weeks later. The orthoses will be supplied via post and used for a period of 12 weeks.
3344344|NCT02212470|Active Comparator|Drug Eluting Balloon|Admiral In.Pact Drug Eluting Balloon
3239296|NCT01278108|Placebo Comparator|4|multiple dose, capsules, 7 days; scheme to match that of Study Arm 3.
3239297|NCT01278121|Other|Diet A: High-fat diet|"Diet given for 3 days to reset all of the participants"
3239298|NCT01278121|Active Comparator|Diet B: A carbohydrate-restricted diet|The diet will be given for 10 days, 6 meals a day
3344345|NCT02212470|Active Comparator|Nitinol Stent|Complete SE Self-expandible Nitinol stent
3344346|NCT02212483|Experimental|Intervention group|"After randomisation and agreement of the patient and the family, the  intervention group  will benefit from a first home intervention of a MIEC during the 4 weeks following inclusion, then a final visit at the end of the study after 12 months."
3344347|NCT02212483|Active Comparator|Control group|"The  control group  is one of the two comparative groups who will benefit from a first home intervention of a MIEC but without advices (only audit + sampling), then a final and a complete visit at the end of the study.~This group has been suppressed with the last amendment. But data of the subjects included in this group will be analyzed."
3344348|NCT02212483|Other|Non intervention group|"The  non intervention  group is the second comparative group with no initial visit, but will benefit from a complete home intervention of a MIEC at the end of the study."
3344349|NCT02212496||Cancer-associated stroke|Cryptogenic embolic stroke with active cancer
3344350|NCT02212496||Cryptogenic embolic stroke|Cryptogenic embolic stroke without active cancer
3344351|NCT02212522||Isis-Diab patients|French T1D patients with genetic data (GWAS), and environmental data (questionnaire and environmental databases), clinical data
3344352|NCT02212522||Isis-Diab controls|French control population with genetic data (GWAS) and environmental data (questionnaire and environmental databases
3344353|NCT02212535|Experimental|Plerixafor|Adult patients affected by major sickle cell syndrome (SS or Sβ thalassemia)
3239299|NCT01278134|Experimental|Arm B Extension|All patients in treatment arm B were offered to receive Pegasys/Cogepus therapy for an additional 24 weeks.
3344354|NCT02212548|Experimental|Hydrogel|The patient will be in the dorsal lithotomy position and prepared and draped. A transrectal ultrasound (TRUS) will be used for alignment of the needle and to ensure safe delivery. The hydrogel precursor and accelerator solutions will be mixed and connected to the Y connector that has been flushed with saline and to a syringe holder that ensures both syringe barrels are injected at the same time. After aspirating to ensure the tip of the needle is not intravascular, the perirectal space will be adequately dissected from the apex to midgland by injecting saline into the space between denonvilliers fascia and the anterior rectal space under TRUS guidance. Maintaining the needle position and angulation, the saline syringe is disconnected and the hydrogel system connected. After aspirating to ensure the needle tip is not in a blood vessel and under TRUS guidance, the 'PEG Hydrogel (SpaceOAR) is injected in a smooth, continuous technique.
3344355|NCT02212561|Experimental|Treatment Arm|Interventions: Selinexor, Fludarabine, and Cytarabine. Methotrexate/hydrocortisone/cytarabine (intrathecal triples) will be given prior to cycle 1.
3344356|NCT02212600||Population|We will include male and female patients who are over 50 years of age and who have an acute, displaced or undisplaced proximal humerus fracture caused by low energy trauma
3344357|NCT02212613|Experimental|Brexpiprazole|Brexpiprazole - Up to 2 mg/day, once daily dose, tablets, orally
3344358|NCT02212626|Experimental|Rotarex|After assessment of the lesion by angiography the occlusion is intraluminally crossed with the wire according to physician's discretion. The device is introduced and the catheter is activated while its tip is still proximal to the occlusion to allow lubrication of the spiral inside the catheter with the aspirated blood. The catheter is advanced into the occlusion with occasional retraction into the already recanalized lumen. Care must be taken to achieve sufficient cooling of the catheter tip and evacuation of the debris to get an appropriate blood flow along the catheter. In order to minimize peripheral embolization of clot the distal end of the occlusion should not be passed too fast before all loose material has been sucked back into the catheter. Several passages of the occlusion may be needed to clean out all wall-adherent thrombotic material. If residual underlying stenosis of >30% persist further endovascular treatment can be performed according to the physician's discretion.
3239300|NCT01278134|Experimental|RO5024048 & ritonavir-boosted danoprevir without Ribavirin (B)|
3239301|NCT01278134|Experimental|RO5024048 and ritonavir-boosted danoprevir with Ribavirin (A)|
3239302|NCT01278147|No Intervention|controle|patient without fatigue education program
3239303|NCT01278147|Experimental|Education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
3239304|NCT01278186|Experimental|Paclitaxel-eluting balloon|Paclitaxel-eluting balloon catheter (SeQuent Please, B. Braun)
3239305|NCT01278186|Experimental|Paclitaxel-eluting stent|Paclitaxel-eluting stent
3239306|NCT01278199|Other|2|Medicals measures in the treatment of non-severe acute hemoptysis
3344359|NCT02212639|Experimental|Digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
3344360|NCT02212652|Active Comparator|Standard of Care plus Vitamin D|If randomized to this arm, each participant will receive a 30 day supply of 10,000 IU of VitD3 for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
3344361|NCT02212652|Placebo Comparator|Standard of Care plus Placebo|If randomized to this arm, each participant will receive a 30 day supply of placebo supplements for research purposes in addition to receiving standard of care. We will ask that they take one of these supplements daily with their largest meal of the day until their surgery.
3239307|NCT01278199|Experimental|1|bronchial artery embolization (BAE)
3344362|NCT02212665|Experimental|High intense interval training (HIIT)|3 x 20 sec, 3 x week
3344363|NCT02212665|Experimental|Increased daily activity detected by the pedometer|10.000 steps a day
3344364|NCT02212665|Experimental|Increased daily activity detected by te pedometer+HIIT|10.000 steps + 3 x 20 sec, 3 x week
3344365|NCT02212665|Experimental|Increased daily activity (pedometer)+group intervention|10.000 steps + group intervention
3344366|NCT02212665|No Intervention|Control group|
3344367|NCT02212691||Sickle cell disease|Patients diagnosed with sickle cell disease
3344368|NCT02212691||Healthy control|Healthy individuals recruited through fliers and have no history of cognitive disorders
3344369|NCT02212704|Experimental|Vestibular stimulation|This is the experimental paradigm applied in all participants
3344370|NCT02212717|Active Comparator|EUS-guided gallbladder drainage|
3344371|NCT02212717|Active Comparator|Percutaneous cholecystomy|
3344372|NCT02212756|Experimental|B Group|1st oral administration of Metformin 1000mg and 2nd oral administration of Metformin 1000mg and DW1029M 1200mg
3344373|NCT02212756|Experimental|A Group|1st oral administration of DW1029M 1200mg and Metformin 1000mg and 2nd oral administration of Metformin 1000mg
3344374|NCT02212769|Experimental|A Group|1st oral administration of Losartan 50mg and 2nd oral administration of Losartan 50mg and DW1029M 1200mg
3239308|NCT01278212|Experimental|AHF-RT|"accelerated hypofractionated radiotherapy (AHF-RT)~30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy"
3344375|NCT02212769|Experimental|B Group|1st oral administration of DW1029M 1200mg and Losartan 50mg and 2nd oral administration of Losartan 50mg
3344376|NCT02212782|Experimental|A Group|1st oral administration of Linagliptin 5mg and 2nd oral administration of DW1029M 1200mg and Linagliptin 5mg
3344377|NCT02212782|Experimental|B Group|1st oral administration of DW1029M 1200mg and Linagliptin 5mg and 2nd oral administration of Linagliptin 5mg
3344378|NCT02212795|Experimental|A Group|1st oral administration of Zabofloxacin 183mg, 2nd oral administration of Zabofloxacin 367mg and 3rd oral administration of Levofloxacin 250mg
3344379|NCT02212795|Experimental|B Group|1st oral administration of Zabofloxacin 367mg, 2nd oral administration of Levofloxacin 250mg and 3rd oral administration of Zabofloxacin 367mg
3344380|NCT02212795|Experimental|C Group|1st oral administration of Levofloxacin 250mg, 2nd oral administration of Zabofloxacin 183mg and 3rd oral administration of Zabofloxacin 367mg
3344381|NCT02212808|Experimental|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario.
3344382|NCT02212808|Experimental|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacists will review a list of patients receiving the targeted antibiotics on a daily basis to identify patients who have received one or more targeted antibiotics for 72 hours (± 24 hours). The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations.
3344383|NCT02212821|Placebo Comparator|Placebo|intravenous infusion
3344384|NCT02212821|Experimental|Erythromycin|intravenous infusion
3344385|NCT02212847|Experimental|vestibular stimulation|
3344386|NCT02212860|Experimental|Single Fraction|Stereotactic neoadjuvant ablative radiation give in one single dose of 21 Gy. Lumpectomy to follow within 14-20 from radiation treatment date.
3344387|NCT02212860|Experimental|Three Fractions|Stereotactic neoadjuvant ablative radiation give in three doses of 10 Gy (30 Gy given in 3 fractions, one treatment every second business day). Lumpectomy to follow within 14-20 days from last radiation treatment.
3344388|NCT02212873|No Intervention|Control|Equal number of age-matched overweight and obese students will be selected from a control school. There will be no intervention, and students will participate in their usual health and physical education classes plus any other curriculum activities provided by the school.
3375876|NCT03619655|Experimental|"Cohort C - SPECT CT and WB-MRI"|Intervention 1: SPECT CT Intervention 2: WB-MRI
3344389|NCT02212873|Experimental|MyBFF@school program|Students will participate in all 3 components of MyFF@school for a total of 32 weeks; 1-hour of SSG thrice weekly plus 30 to 45 minutes of either nutrition or psychology classes once a week. All students including those in the control arm will be assessed at baseline, week-16 and at end of the study. They will undergo anthropometric measurements, body fat assessment, clinical examination and fitness test by modified Harvard step-test.
3239309|NCT01278225||EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
3344390|NCT02212886|Experimental|GA Depot 80mg|Monthly IM injection
3344391|NCT02212886|Experimental|GA Depot 40mg|Monthly IM injection
3344392|NCT02212912|Other|Improvement intervention|Improvement intervention is a multifaceted quality improvement method including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators, a quality coordinator, and monitoring and feedback system of performance measures.
3344393|NCT02212912|Other|no intervention|The control group indicated that the physicians will not be provided with the information of multifacet improvement tools including evidence-based clinical pathway, standard operating procedures (SOP) of performance indicators a quality coordinator, and monitoring and feedback system of performance measures. They just provide patients with routine care
3344394|NCT02212925|Experimental|BI 14332 CL|
3344395|NCT02212925|Placebo Comparator|Placebo|
3344396|NCT02212938|Experimental|BI 14332 CL fasted|
3344397|NCT02212938|Experimental|BI 14332 CL fed|
3344398|NCT02212951|Experimental|BIOD-531 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
3344399|NCT02212951|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injection of 0.6 U/kg immediately before the start of the standardized breakfast
3344400|NCT02212951|Active Comparator|Humulin R U-500|Subcutaneous injection of 0.6 U/kg immediately before the start of a standardized breakfast
3344401|NCT02212951|Experimental|BIOD-531 post-meal|Subcutaneous injection of 0.6 U/kg 20 minutes after the start of the standardized breakfast
3344402|NCT02212990|Active Comparator|Acetaminophen Arm|Acetaminophen Suspension 160mg / 5mL Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
3344403|NCT02212990|Placebo Comparator|Placebo Arm|Placebo Suspension Oral dose immediately following IIV and every 4 to 6 hours up to 24 hours (Maximum 5 oral doses)
3344404|NCT02212990|Active Comparator|Ibuprofen Arm|Ibuprofen Suspension 100mg / 5mL Oral dose immediately following IIV and every 6 to 8 hours up to 24 hours (Maximum 4 oral doses)
3344405|NCT02213003|Experimental|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the omentum.
3344406|NCT02213016|Sham Comparator|Transcranial magnetic stimulation|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
3344407|NCT02213016|Active Comparator|Transcraneal magnetic stimulation|Active repetitive Transcranial magnetic stimulation, 5 Hz, 5 sessions per week for three weeks: Total of 15 sessions.
3344408|NCT02213016|Sham Comparator|Sham Comparator|Sham repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
3239310|NCT01278225||Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits. After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
3239311|NCT01278238|Active Comparator|Phenylephrine|
3344409|NCT02213016|Active Comparator|Active Comparator|Active repetitive Transcranial magnetic stimulation, 5 Hz, 2 sessions per week for 7 1/2 weeks: Total of 15 sessions.
3344410|NCT02213029|Experimental|Oxytocin or Placebo challenge (Cohort 1)|Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered.
3344411|NCT02213029|Experimental|Epelsiban or Placebo (Cohort 2)|Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges.
3344412|NCT02213029|Experimental|Biopsy cohort (Cohort 3)|Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies.
3344413|NCT02213081|Experimental|Ulipristal|25 patients with chronic, endometriosis-related pelvic pain refractory to medical and/or surgical therapies will receive 15mg ulipristal every other day (three times a week- Monday, Thursday, Saturday) for three months.
3344414|NCT02213107|Experimental|Enzalutamide and dutasteride|Two oral drugs.
3344415|NCT02213120||Dizziness|Patients with Dizziness
3344416|NCT02213146|Experimental|BioChaperone human insulin|BioChaperone Human Insulin
3344417|NCT02213146|Active Comparator|Human insulin|Huminsulin® Normal
3344418|NCT02213146|Active Comparator|Insulin lispro|Humalog®
3344419|NCT02213159|Active Comparator|Dexmedetomidine|prior to anticipated end of surgery bolus of 1 microgram/kg Dexmedetomidine intravenously over 10 minutes followed by 0.5 micrograms/kilogram/hour intravenous infusion until removal of laparoscopes
3239312|NCT01278238|Active Comparator|Lower limb compression|
3239313|NCT01278238|Placebo Comparator|Placebo|
3344420|NCT02213159|Active Comparator|Morphine|prior to anticipated completion of surgery morphine 0.08 mg/kilogram intravenous bolus over 10 minutes followed by a saline infusion until removal of the laparoscopes
3344421|NCT02213172|Experimental|Bifidobacterium longum R0175|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
3344422|NCT02213172|Experimental|Lactobacillus paracasei HA-196|10 x 10^9 CFU per capsule, 1 capsule daily for 8 weeks
3344423|NCT02213172|Placebo Comparator|Placebo|1 capsule daily for 8 weeks
3344424|NCT02213185|Experimental|EMLA patches and SWI|EMLA patches 1.5 hrs before sterile water injections
3239314|NCT01278251||Endobutton|
3239315|NCT01278264|Active Comparator|iTAP-group|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
3239316|NCT01278264|Active Comparator|aTAP-group|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
3239317|NCT01278277|Placebo Comparator|placebo supplementation|patients will be assigned, in a cross-over design, to placebo or supplement administration
3239318|NCT01278277|Active Comparator|Saffron|Saffron Supplementation 20 mg/die
3239319|NCT01278290|Active Comparator|Triptorelin test AND LHRH test|Patients undergo two tests with a test interval of at least 15 days
3239320|NCT01278290|Active Comparator|LHRH test AND Triptorelin test|Patients undergo two test with a test interval of al least 15 days.
3239321|NCT01278316|Experimental|Cognitive training|Cognitive Intervention Tasks Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
3239322|NCT01278316|Active Comparator|Control|The control group will perform computerized tasks that utilize cognitive performance, but were not systematically developed to improve cognitive performance.
3239323|NCT01278329|Experimental|Music|"Mothers in the music group were provided a pre-recorded Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India) with a running duration of approximately 50 minutes and a cassette player with headphones. They were asked to listen to the recorded music daily in the evening just before going to the bed with a minimum of ambient noise."
3344425|NCT02213185|Active Comparator|EMLA patches and isotonic saline|EMLA patches 1.5 hrs before isotonic saline
3344426|NCT02213185|Placebo Comparator|Placebo patches and SWI|PLACEBO patches 1.5 hrs before sterile water injections
3344427|NCT02213185|Placebo Comparator|Placebo patches and isotonic saline|PLACEBO patches 1.5 hrs before isotonic saline
3344428|NCT02213211|Experimental|Diagnosis and treatment of malaria|"School-based diagnosis and treatment of uncomplicated malaria using malaria RDTs and Artemether lumefantrine as part of Learner Treatment Kits (LTK) used by teachers.~Drug: Artemether lumefantrine (artemisinin-based combination therapy [ACT], Coartem). Three-day doses of 20mg/120mg, 40mg/240mg, 60mg/360mg and 80mg/480mg Coartem are provided, according to weight, upon a positive rapid diagnostic test (RDT) result."
3344429|NCT02213211|No Intervention|No intervention|No intervention provided
3344430|NCT02213224|Experimental|Perindopril|Perindopril 4mg qd taken in the morning;
3239324|NCT01278329|No Intervention|Control|Standard routine ante-natal care.
3239325|NCT01278355||Pain Patients|
3239326|NCT01278368|Active Comparator|Preoperative chemotherapy (PCHT)|Patients who underwent pancreatic resection after PCHT.
3239327|NCT01278368|Active Comparator|Control|Patient who underwent pancreatic resection without preoperative therapy
3344431|NCT02213224|Experimental|Telmisartan|Telmisartan 80mg qd taken in the morning;
3344432|NCT02213224|Placebo Comparator|Amlodipine|Amlodipine；5mg qd taken in the morning.
3239328|NCT01278381||Pancreaticoduodenectomy (PD)|Patients undergoing PD from 2002 to 2010
3239329|NCT01278420|Other|Tecnis MF|
3239330|NCT01278420|Other|ReSTOR|
3239331|NCT01278433|Experimental|Study Group|Participants receiving their first dose of polio vaccine
3239332|NCT01278446|Experimental|Test Formula|New hydrolyzed whey formula
3239333|NCT01278446|Active Comparator|Control Formula|Commercially available hydrolyzed infant formula
3239334|NCT01278459|Experimental|Atorvastatin first|Participants receive 4 week treatment with atorvastatin 20mg/day, followed by 4 week washout, followed by 4 week treatment with placebo.
3239335|NCT01278459|Experimental|Placebo first|Participants receive 4 week treatment with placebo, followed by 4 weeks washout, followed by 4 weeks treatment with atorvastatin 20mg/day.
3239336|NCT01278472|Experimental|Single Port Cholecystectomy|Laparoscopic Cholecystectomy with single port transumbilical access
3344433|NCT02213276|Experimental|Healthy males|Oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT).
3344434|NCT02213302|Placebo Comparator|Isotonic serum|placebo administration
3344435|NCT02213302|Active Comparator|Midazolam|midazolam intravenous administration 0.02mg/kg
3344436|NCT02213315|Experimental|100mg arm|100mg dose
3344437|NCT02213315|Experimental|150mg arm|150mg dose
3344438|NCT02213315|Placebo Comparator|Placebo|Placebo
3344439|NCT02213328|Experimental|Truvada|All participants will take Truvada, once daily by mouth for the first 12 weeks of the study. After Week 12 of the study, only participants who indicate a willingness to use Truvada PrEP and who do not have any medical reasons not to do so will continue to receive the Truvada tablets through Week 52.
3344440|NCT02213341||Positive blood test to milk, egg, and/or peanut|Family history to atopy
3344441|NCT02213341||Negative blood test to allergy|A negative skin prick test to egg, milk, and peanut and a negative Immunoglobulin E (IgE) to egg, milk, and peanut.
3344442|NCT02213354|Experimental|Group 2|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3344443|NCT02213354|Experimental|Group 6|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3344444|NCT02213354|Experimental|Group 5|60 subjects receive Sanofi A/H7N9 antigen 15 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
3344445|NCT02213354|Experimental|Group 4|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 57, and Day 169
3344446|NCT02213354|Experimental|Group I|60 subjects receive Sanofi A/H7N9 antigen 3.75 mcg plus Novartis MF59 adjuvant intramuscularly (IM) on Day 1, Day 29 and Day 169
3344447|NCT02213354|Experimental|Group 3|60 subjects receive Sanofi A/H7N9 antigen 7.5 mcg plus Novartis MF59 adjuvant IM on Day 1, Day 29 and Day 169
3344448|NCT02213367|Active Comparator|20 mg Bilastin|20mg Bilastine once daily
3344449|NCT02213367|Active Comparator|Bilastin 40mg|40 mg Bilastine once daily, intake of two tablets 20mg Bilastine
3344450|NCT02213367|Active Comparator|Bilastin 80mg|80 mg Bilastine once daily, intake of four tablets 20mg Bilastine
3344451|NCT02213393|Experimental|Protein enriched products|The intervention group receives protein enriched products (CwC products) in the hospital and receives these also after discharge during 12 weeks.
3344452|NCT02213393|Active Comparator|Usual menu|The control group receives the usual protein and energy rich menu in the hospital and receives regular products, no protein enrichment, after discharge during 12 weeks.
3344453|NCT02213406|Experimental|intervention group|Fat detection threshold test, intake of high and low fat yogurt, fMRI-measurements
3344454|NCT02213419|Experimental|ethanol double lavage|Endoscopic ultrasonography-guided double ethanol lavage
3344455|NCT02213432|Experimental|Day 1 vaccination|"Different timing of influenza vaccination: Day 1~Day 1 vaccination group: patients will be vaccinated against influenza at the day (Day 1) when chemotherapy starts."
3344456|NCT02213432|Active Comparator|Day 11 vaccination|"Different timing of influenza vaccination: Day 11~Day 11 vaccination group: patients will be vaccinated against influenza at the 11th days after chemotherapy starts"
3344457|NCT02213471||Elevated risk for melanoma|Individuals at increased risk for melanoma due to past history of melanoma, family history of melanoma, the presence of many moles, the presence of a genetic mutation known to increase the risk of melanoma.
3344458|NCT02213484||Marfan syndrome|Individuals with a clinical diagnosis of Marfan syndrome
3344459|NCT02213484||Aortopathy syndrome|Individuals with one of the following clinical diagnoses: Loeys-Dietz syndrome, Turner syndrome, Ehlers-Danlos type IV syndrome, Thoracic Aortic Aneurysm and Dissection syndromes.
3344460|NCT02213523|Experimental|Plant concentrate A|Plant concentrate A containing Rosemary:Quercetin:Turmeric 5:3:1 Low dose (300 mg) to high dose (600 mg)
3239337|NCT01278472|Active Comparator|4 Port Cholecystectomy|Laparoscopic Cholecystectomy using 4 separate conventional trocars
3239338|NCT01278498|Experimental|escitalopram|prevention of poststroke depression in patients with acute stroke.
3344461|NCT02213523|Experimental|Plant concentrate B|Plant concentrate B containing Holy Basil: Wasabi: Broccoli 5:5:1 Low dose (300 mg) to high dose (600 mg)
3239339|NCT01278498|Placebo Comparator|placebo|prevention of poststroke depression in patients with acute stroke.
3239340|NCT01278511|Experimental|Canadian C-Spine Rule|
3239341|NCT01278524||Critically ill patients|Patients staying in the ICU on the 25th of January
3239342|NCT01278537|Experimental|Empowerment, shared-decision making,|Patients receive a booklet with informations. Assessment of health-related risk factors. Assessment of psychological and physical social support Delirium protection. Early mobilization.
3239343|NCT01278537|No Intervention|control group|
3344462|NCT02213523|Experimental|Plant concentrate C|Plant concentrate C containing Holy Basil:Rosemary:Broccoli seed:Turmeric 2:2:1:1 Low dose (300 mg) to High dose (600 mg)
3344463|NCT02213523|Experimental|Plant concentrate D|Plant concentrate D containing Rosemary:Licorice:Turmeric 1:1:1 Low dose (300 mg) to High dose (600 mg)
3344464|NCT02213536||VMAT WBRT|Patients requiring whole brain radiotherapy as part of their cancer managment.
3344465|NCT02213549|Placebo Comparator|Placebo|3 placebo capsules/day for 12 weeks
3344466|NCT02213549|Experimental|Ume paste and ginger powder|3 experimental capsules/day for 12 weeks.
3344467|NCT02213562|Experimental|200 mg CFO|200 mg of chrysanthemum flower oil
3344468|NCT02213562|Experimental|300 mg CFO|300 mg of chrysanthemum flower oil
3239344|NCT01278550||Average risk cohort|Patients having no history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have H. pylori positive OR negative
3344469|NCT02213562|Experimental|400 mg CFO|400 mg of chrysanthemum flower oil
3344470|NCT02213588|Active Comparator|AOX blend|Rosemary:Quercetin:Turmeric (300 mg total)
3344471|NCT02213588|Placebo Comparator|Placebo|Maltodextrin
3344472|NCT02213601|Experimental|Yoga|8-week Gentle Vinyasa Flow yoga intervention
3344473|NCT02213601|No Intervention|Wait-list Control Group|
3344474|NCT02213614|Experimental|Spring Lithium Water|"The Long term goal of this research project is the implementation of an effective, inexpensive therapy in communities with high risk of violence. Therapy will be based on a daily dietary supplement LIWA at appropriate doses.~The short-term objective is to prove that Lithium water (LIWA) as a daily supplement is an intervention that prevents gun violence from occurring, and is a factor that decrease the violence for gun in our communities Gun violence poses a serious threat to America's children and youth. Existing data clearly point to the need for improved strategies for keeping guns out of the hands of children and youth and those who would harm them."
3239345|NCT01278550||High risk cohort|Patients have history of endoscopically confirmed ulcer bleeding, need long-term aspirin for cardiovascular or cerebrovascular prophylaxis and have successful eradication of H. pylori based on histology
3344475|NCT02213614|Experimental|Placebo: Natural Spring water|This group will be drink natural spring water for 4 months in tres cicles
3344476|NCT02213627|Experimental|Corifollitropin alfa|From day 2-3 of mense, a single 100 microgram dose of corifollitropin alfa is administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3344477|NCT02213627|Experimental|Recombinant FSH|From day 2-3 of mense, daily injections of 150 IU of recombinant FSH will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3344478|NCT02213627|Experimental|HP-hMG|From day 2-3 of mense, daily doses of 225 IU of HP-hMG will be administered. Daily doses of 0.25 mg GnRH antagonist will start on day 6 of stimulation and a single dose of 0.2 mg of GnRH agonist will be administered for triggering final oocyte maturation.
3344479|NCT02213640|Experimental|Arm A Anodal tDCS and prismatic adaptation|anodal tDCS over the primary motor cortex : stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
3344480|NCT02213640|Placebo Comparator|Arm B: control|Prismatic adaptation with placebo stimulation
3344481|NCT02213653|Experimental|Concomitant iron and I.V. epoietin zeta|
3344482|NCT02213653|Experimental|Iron and I.V. epoietin zeta sequential|
3344483|NCT02213653|Active Comparator|Epoietin zeta|
3344484|NCT02213679|Experimental|Guanidinoacetic acid|Supplementation with dietary guanidinoacetic acid
3239346|NCT01278576|Experimental|Intramuscular ending Targeting|Botox 200 units placed at the upper 2/10-3/10 length of the GCM
3239347|NCT01278576|Active Comparator|Midbelly Targeting|A total of 200 units will be placed at the four quadrants of the midbelly portion of the GCM.
3239348|NCT01278589|Experimental|• Plantago asiatica L. extract 5g|
3239349|NCT01278589|Experimental|Plantago asiatica L. extract 10g|
3239350|NCT01278589|Experimental|Plantago asiatica L. extract 20g|
3344485|NCT02213679|Placebo Comparator|Placebo|Supplementation with cellulose
3344486|NCT02213692||Crush-clamping Method (group A)|Liver parenchymal is crushed by surgeon's fingers or basic surgical clamps to isolate small vessels and biliary radicals, and then divided by suture ligation, electrocautery, or vascular clips.
3344487|NCT02213692||Harmonic Scalpel Method (group B)|Liver parenchymal transection is transected by harmonic scalpel, and small vessels and biliary radicals (<3mm) is also divided by harmonic scalpel. Vessels and biliary radicals (≥ 3mm) were divided by suture ligation, electrocautery, or vascular clips.
3344488|NCT02213705|Experimental|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|Administration of allogeneic MSCs in the treatment of severe diffuse SSc or rapidly progressive and refractory to conventional treatments by prior cyclophosphamide
3344489|NCT02213718|Experimental|Desflurane|desflurane (7%-8% end-tidal concentration), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h)
3344490|NCT02213718|Active Comparator|propofol|intravenous administration of sufentanil (1μg/kg), etomidate(0.3mg/kg) and vecuronium (0.08mg/kg). The anesthesia is maintained with propofol (TCI:3.5-4.0μg/min), sufentanil (TCI: 2-3 ng/ml) and vecuronium (0.04mg/kg/h).
3344491|NCT02213731|Other|Cryoballoon ablation|Subjects will wear holter monitors at baseline, 6 months and 12 months
3344492|NCT02213744|Experimental|MM-302 + trastuzumab|MM-302 + trastuzumab
3344493|NCT02213744|Active Comparator|Chemotherapy of Physician's Choice plus trastuzumab|Chemotherapy limited to one of the following: Gemcitabine, Capecitabine or Vinorelbine
3239351|NCT01278589|Placebo Comparator|Placebo|
3239352|NCT01278602|Experimental|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
3239353|NCT01278628|Experimental|Lifestyle modification|
3344494|NCT02213757|Experimental|Premarin vaginal cream|Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
3344495|NCT02213757|Placebo Comparator|Placebo vaginal cream|Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
3344496|NCT02213770||Intervention group|Group that followed high- intensity interval training program in TEX study.
3239354|NCT01278641|Experimental|1|Intervention i arm 1 comprises graded strength resistance training, 75 minutes twice a week for 12 weeks.
3239355|NCT01278641|Experimental|2|Intervention in arm 2 comprises low intensive temperate pool exercise 50 minutes, twice a week for 12 weeks.
3239356|NCT01278641|No Intervention|3|Reference group, continues with normal activities during the study period of 12 weeks.
3344497|NCT02213770||Control group|Followed up on a regular basis for HTx recipients in Norway.
3344498|NCT02213783|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 2-5 days
3344499|NCT02213783|Experimental|Extended infusion arm|Infusion of 0.5 g of imipenem for 4 hr every 6 hr for 2-5 days
3344500|NCT02213796|Other|1h infusion of 1 g meropenem|
3344501|NCT02213809|Experimental|Case method education in COPD|Two hours of case method education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers. The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
3344502|NCT02213809|Active Comparator|Traditional education in COPD|Two hours of traditional education in COPD are given two times within 3 months to the general practitioners at nine primary health care centers.The education covers examination, including interpretation av spirometry, and treatment of patients with COPD. The learning outcomes are predefined and are the same in both arms. The same person will teach at both times of education.
3375877|NCT03604445|Experimental|BI 905677|Schedule A: 3 week cycle (treatment every 3 weeks). Schedule B: 4 week cycle (treatment every 2 weeks). Recruitment into Schedule B will start after the MTD of Schedule A is reached.
3239357|NCT01278654|Active Comparator|Personal incentive|If participants attain their walkstation usage goal, they are entered into bi-weekly lotteries to win money.
3239358|NCT01278654|Active Comparator|Token incentive|Participants who attain their walkstation usage goal will be entered into a bi-weekly prize to win a token reward.
3239359|NCT01278680|No Intervention|Hold-out control|Hold-out control: participants will be asked to refrain from using the walkstations for the duration of the study (90 days).
3239360|NCT01278680|Active Comparator|Personal incentive|Personal incentive: Participants will receive $3 for each time they use the walkstation.
3239361|NCT01278680|Experimental|Charitable incentive|Charitable incentive: $3 will be donated to charity every time the participant uses the walkstation.
3239362|NCT01278693|Other|placebo|it is as like as L-carnitine in shape
3239363|NCT01278693|Other|L-carnitine|it is kind of supplement
3239364|NCT01278706|No Intervention|no treatment|
3239365|NCT01278706|Experimental|one biopsy, proliferative phase|
3239366|NCT01278706|Experimental|one biopsy, secretory phase|
3344503|NCT02213822||Pts with Solid Tumors/ Hematological Cancer|Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.
3344504|NCT02213835|Experimental|Specific Carbohydrate diet (SCD)|"The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include Breaking the Vicious Cycle by Elaine Gottschall and Recipes for the Specific Carbohydrate Diet by Raman Prasad."
3344505|NCT02213848|Experimental|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
3344506|NCT02213848|Placebo Comparator|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
3344507|NCT02213861|Experimental|1.0% SHAPE Gelled Solution once daily|
3344508|NCT02213861|Experimental|0.5% SHAPE Gelled Solution twice daily|
3344509|NCT02213861|Experimental|1.0% SHAPE Gelled Solution twice daily|
3344510|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
3344511|NCT02213887|Experimental|Start Pantoprazole|"Participants have been diagnosed with gastroesophageal reflux disease but have not started pharmacological treatment.~Intervention: Days 2-8"
3239367|NCT01278706|Experimental|two biopsies|
3239368|NCT01278719||Antrochaonal polyp; non recurrent type|
3239369|NCT01278719||Antrochoanal polyp; recurrent type|
3344512|NCT02213887|Experimental|Stop Pantoprazole|"Participants have been taking pantoprazole for more than 8 weeks and are asymptomatic for gastroesophageal reflux disease.~Intervention: Days 2-8"
3344513|NCT02213913|Experimental|Treatment (lenalidomide, DA-EPOCH-R)|"INDUCTION PHASE: Patients receive lenalidomide PO daily on days 1-14. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~DA-EPOCH-R: Patients receive etoposide IV continuously on days 1-4, prednisone PO BID on days 1-5, vincristine sulfate IV continuously on days 1-4, doxorubicin hydrochloride IV continuously on days 1-4, cyclophosphamide IV over 15 minutes on day 5, and rituximab IV over 4 hours on day 1 (per institutional guidelines). Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION PHASE: Patients who are transplantation (HSCT)-eligible receive BEAM-conditioning regimen followed by autologous (auto)-HSCT or HSCT at the discretion of the treating physician. Patients who do not undergo HSCT in first remission receive lenalidomide maintenance for 12 months."
3344514|NCT02213939||CPB + Cytosorb|On pump myocardial revascularization with the use of the cytokine adsorbing circuit (Cytosorb)
3344515|NCT02213939||CPB / Control|Controll group; on pump myocardial revascularization
3344516|NCT02213939||OPCAB / Control|Controll Group; off-pump myocardial revascularization
3344517|NCT02213952|Experimental|Platelet-Rich Plasma|Our goal is to evaluate the efficacy of the autologous Platelet-Rich Plasma (PRP) in the treatment of vascular ulcers, comparing to the conventional treatment (cure with humid environment), in primary care patients with chronic venous ulcer.
3344518|NCT02213952|Active Comparator|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
3344519|NCT02213965||Vasofix® Safety|Peripheral IV catheter Vasofix® Safety
3344520|NCT02213965||Introcan Safety®|Peripheral IV catheter Introcan Safety® IV catheter
3344521|NCT02213991|Experimental|Intraoperative Radiotherapy|"Intervention:~Intraoperative Radiotherapy~* Operation day~Breast conservative surgery + Intraoperative radiotherapy 20 Gy~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity. Purse string suture pulles up tissues and wraps up the applicator. IORT with 20Gy is followed. After IORT, applicator was out of the operative field, and usual wound closure will be done.~* Postoperative period~± Chemotherapy~WBRT (46 Gy) for 4~5 weeks~± Endocrine therapy or target therapy"
3344522|NCT02214004|Experimental|Trastuzumab and Letrozole|- Concurrently initiate two drugs on Day 1 of Cycle 1
3239370|NCT01278719||Ethmoidal polyp - non recurrent type|
3239371|NCT01278719||Ethmoidal polyp - recurrent type|
3239372|NCT01278732||untreated persons with suspected hypertension|
3239373|NCT01278758|Experimental|ASA404 + standard therpy|
3239374|NCT01278784|Experimental|Healthy volunteer|
3239375|NCT01278810|Experimental|Icaritin|
3239376|NCT01278823|Experimental|surgery|Surgery: laparoscopic roux en y gastric bypass operation
3239377|NCT01278823|Active Comparator|Medical treatment|Medical Treatment: Comprehensive medical management of diabetes including medications, diet intervention, lifestyle modification, exercise regimen
3239378|NCT01278836|Other|fascio-cutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
3239379|NCT01278849|Experimental|ASA404 + standard therpy|
3344523|NCT02214030|Active Comparator|Assiut Femoral Compression Device|the sheaths were removed 2 hours after PCI instead of conventional 6hours. To standardize compression times, AFCD were applied to patient and complete femoral artery compression were applied for 5 minutes, followed by a gradual release of pressure over the ensuing 8 minutes. Therefore each patient received a minimum of 13 minutes of compression, with further compression applied only if full hemostasis had not been achieved at that point with maximum of 30 minutes.
3344524|NCT02214030|Placebo Comparator|Manual compression|The intra-arterial sheaths were removed 6 hours after PCI in the MC group according to the standard local protocols.
3344525|NCT02214043||Group 2|
3344526|NCT02214043||group 1|
3344527|NCT02214056||The study population|"There is only one group in this study. Please see the inclusion/exclusion criteria.~Intervention: Patient recruitment Intervention: Mobile team exam"
3344528|NCT02214069||Patients with Atrial Fibrillation|Patients with Atrial Fibrillation admitted to the hospital for drug loading with Dofetilide or Sotalol willing to record and transmit heart rhythm using AliveCor.
3239380|NCT01278875||Acute Coronary Syndrome|Subjects with ACS within 72 hours of clinical presentation
3239381|NCT01278875||Stable CAD subjects|Patients with stable, chronic CAD
3344529|NCT02214082|No Intervention|Next day discharge|this group will be discharged as is the standard practice at our facility; i.e. the day after the PCI procedure
3344530|NCT02214082|Experimental|Same Day Discharge|Patients in this arm will be discharged on the same day as their angioplasty.
3344531|NCT02214095|Active Comparator|glucosamine sulphate capsules|500 mg Glucosamine Compound, three times daily for 3 months following initial cause related therapy.
3344532|NCT02214095|Placebo Comparator|lactose capsules|lactose capsules three times daily for 3 months
3344533|NCT02214108|Experimental|Phisical activity with Nintendo Wii|3 hours of weekly of physical activity, divided in 1 hour interday with Nintendo WII. games applied: Wii Boxing, Wii Tennis; Wii Bowling
3344534|NCT02214108|No Intervention|phisical activity with phisiotherapist|3 hours of weekly physical activity, divided in 1 hour interday. applying cardiovascular and muscular endurance static exercises.
3344535|NCT02214134||Lung cancer|Patients with diagnosis of lung cancer at any stage
3344536|NCT02214134||Malignant pleural mesothelioma|Patients with diagnosis of malignant pleural mesothelioma at any stage
3344537|NCT02214134||Thymic malignancy|Patients with diagnosis of thymic malignancy at any stage
3344539|NCT02214173|Experimental|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
3344540|NCT02214173|Placebo Comparator|placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
3344541|NCT02214199|Active Comparator|Exercise Therapy|Home exercises for 30 minutes (2/weeks) with muscle stretching and strengthening the shoulder girdle.
3344542|NCT02214199|Experimental|Manipulative Therapy Techniques|Lift Technique for mid-thoracic spine. Mobilization by low cervical spine on the upper lateral thoracic translation. Technical Dog flexion for high thoracic spine (T1-T4). Technical Dog flexion for mid-thoracic spine (T5-T8). Technical Dog flexed to low thoracic spine (T9-T12). Direct drive technology prone to mid-thoracic spine.
3239382|NCT01278875||Control subjects|Healthy individuals
3239383|NCT01278888|Active Comparator|PLEACE 1|Anterolateral vs. posterolateral thoracotomy
3344543|NCT02214251|Experimental|PK-16CH EXG system|PK-16CH EXG is a wireless physiological signal acquisition system for monitoring the bio-signals, such as EEG, ECG, and EMG. The system can concomitant EEG and EMG recording during ambulation.
3344544|NCT02214264|Experimental|Loving-Kindness training|Participants receive Loving-Kindness meditation training for approximately 12 minutes.
3344545|NCT02214264|Experimental|Breath Awareness training|Participants receive Breath Awareness meditation training for approximately 12 minutes.
3344546|NCT02214264|Experimental|Gratitude training|Participants will receive Gratitude training for approximately 12 minutes.
3239384|NCT01278888|Active Comparator|PLEACE 2|Video assisted thoracic surgery (VATS) vs. anterolateral thoracotomy
3344547|NCT02214264|Other|Control|Participants write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
3344548|NCT02214303||Allergic asthma|Allergic asthma (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
3344549|NCT02214303||Allergic rhinitis|allergic rhinitis patients (sensibilisation to D. pteronyssinus, 5 grass mixture allergens or birch pollen allergens)
3344550|NCT02214303||Control group|Healthy subjects
3344551|NCT02214316|Experimental|Interventional 1|Interventional experimental arm with hypertonic saline
3344552|NCT02214329|Experimental|Sensor-based exercise training|The intervention group receives sensor-based balance training with real-time joint feedback through an interactive interface on LC monitor screen.
3344553|NCT02214329|Active Comparator|In-home balance training|The control group performs similar exercise as intervention group at home without use of sensor or any joint feedback from sensor data.
3344554|NCT02214342|Experimental|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
3344555|NCT02214342|No Intervention|Control|The control group will keep their normal activity without receiving any intervention.
3344556|NCT02214368|Experimental|NIV bundle group|early use of NIV, and combination fiberoptic bronchoscopy and sedation
3344557|NCT02214368|Other|Conventional treatment group|standard supplemental oxygen, and conventional application of noninvasive ventilation.
3344558|NCT02214381|Active Comparator|Mycet/Cyclophosphamid|4 x Myocet 60 mg/m² q3w in combination with 4 x cyclophosphamide 600 mg/m² q3w depending on early response assessment by ultrasound or on toxicity profile.
3344559|NCT02214381|Active Comparator|Myocet/Cyclophosphamide/Paclitaxel|2 x Myocet 60 mg/m² q3w in combination with 2 x cyclophosphamide 600 mg/m² q3w followed by 6 x paclitaxel 80 mg/m² q1w depending on early response assessment by ultrasound or on toxicity profile.
3344560|NCT02214394|Experimental|Propofol|Subjects will be given Propofol during routine surgery and then using the SMART Device the breath will be captured and compared to blood plasma using High-performance liquid chromatography Analysis.
3344561|NCT02214433|Experimental|Part A Period 1 Debio 1450 IV Solution|Part A Debio 1450 IV solution infused over two hours on Day 1 after fasting
3344562|NCT02214433|Experimental|Part A Period 2 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 5, after fasting
3344563|NCT02214433|Experimental|Part A Period 3 Debio 1450 Tablet|Debio 1450 Tablet oral dosing once on Day 9, 30 minutes after a high calorie, high fat breakfast, after fasting
3344564|NCT02214433|Experimental|Part A Period 4 Debio 1450 Tablet|After preparation with Pantoprazole, Pantoprazole taken with Debio 1450 Tablet oral dosing once on Day 14, after fasting
3344565|NCT02214433|Placebo Comparator|Part B Placebo All Cohorts|Placebo IV solution on days 1-5 and then Placebo Tablet or Capsule on Days 6-10, according to the cohort dosing schedule
3344566|NCT02214433|Experimental|Part B Debio 1450 Cohort 1|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Tablet, once daily on days 6-10
3344567|NCT02214433|Experimental|Part B Debio 1450 Cohort 2a|Debio 1450 IV solution, once daily on day 1
3344568|NCT02214433|Experimental|Part B Debio 1450 Cohort 3|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
3344569|NCT02214433|Experimental|Part B Debio 1450 Cohort 4|Debio 1450 IV solution, twice daily on days 1-5, then Debio 1450 Capsule, twice daily on days 6-10
3344570|NCT02214433|Experimental|Part B Debio 1450 Cohort 2b|Debio 1450 IV solution, once daily on days 1-5, then Debio 1450 Capsule, once daily on days 6-10
3344571|NCT02214433|Experimental|Part C Debio 1450|Debio 1450 (IV formulation in Period 1, capsule formulation in Periods 2, 4 and 5 (with Pantoprazole), and Debio 1450 oral solution in Period 3).
3344572|NCT02214446||primary caregivers of children newly diagnosed with cancer|Explore Factors related to Truth Telling in Primary Caregivers of Children Newly Diagnosed with Cancer
3344573|NCT02214459|Experimental|mhealth counseling|DASH Mobile mhealth enhanced coaching
3344574|NCT02214472|Experimental|Biofeedback|Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
3239385|NCT01278901||Cohort of consecutive patients undergoing EGD treated with PPI|Patients positive for helicobacter pylori undergoing EGD, started on PPI therapy for a month, repeated diagnostic tests for Helicobacter pylori after a month of therapy (urease test, histology and breath test)
3239386|NCT01278940|Experimental|Dendritic Cells (DC) malignant melanoma|22 patients were included in this arm.
3239387|NCT01278940|Experimental|DC vaccine plus IL-2|To improve the efficacy of the DC vaccine, IL-2 was administrated at the vaccination site through direct lymph node injection. 9 patients were included in this arm.
3239388|NCT01278966|Experimental|The Modified Atkins Diet|Treatment with the Modified Atkins Diet for 6 months
3344575|NCT02214472|Placebo Comparator|Placebo medication|Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.
3344576|NCT02214485|Experimental|integrated care (IC)|Subjects will receive such care twice weekly for 12 weeks.
3344577|NCT02214485|Experimental|lower extremity strength training (LEST)|Subjects will receive training twice weekly for 12 weeks
3344578|NCT02214498|Active Comparator|Enalapril/hydrochlorothiazide|This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
3344579|NCT02214498|Placebo Comparator|Placebo|This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
3344580|NCT02214511||MDD patients|emotional facial stimuli cyberball game
3344581|NCT02214511||healthy subjects|emotional facial stimuli cyberball game
3239389|NCT01278979|Active Comparator|Assessment of perineal tears|Consenting women sustaining perineal tear after child birth
3239390|NCT01278979|Other|Visual and digital assessment|Consenting women that sustained perineal tear after child birth.
3344582|NCT02214524|Experimental|Bair hugger forced air warming therapy|Use of Bair Hugger forced-air warming system perioperatively to keep patient normothermia
3344583|NCT02214524|No Intervention|conventional warming care|conventional warming care
3344584|NCT02214537|Experimental|MACS|Patients with MACS Selection
3239391|NCT01279005||20-50 YEARS OLD MSM|
3239392|NCT01279018||Patients treated with docetaxel|Patients treated according to the DBCG 07 protocol, that have received docetaxel as part of the adjuvant treatment.
3239393|NCT01279031|Experimental|Abbott WHITESTAR Signature System|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound
3239394|NCT01279031|Experimental|Alcon Infiniti|Alcon Infiniti with the OZIL Torsional Handpiece
3239395|NCT01279083|Experimental|Concentration 1|
3239396|NCT01279083|Experimental|Concentration 2|
3344590|NCT02214563|Active Comparator|Thrice-weekly cholecalciferol|Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
3344591|NCT02214563|Active Comparator|Monthly cholecalciferol|Capsules containing a dose equivalent to 9,000 IU/week will be given at the end of the first hemodialysis session in the 3rd week of each month. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.
3344592|NCT02214563|Placebo Comparator|Thrice-weekly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
3344593|NCT02214563|Placebo Comparator|Monthly placebo|Olive oil coated by soft capsule made of gelatin and glycerin.
3344594|NCT02214589|Active Comparator|Oral glucose and NNS|Oral glucose and NNS
3344595|NCT02214589|Active Comparator|Oral glucose and facilitated tucking and NNS|Oral glucose, facilitated tucking and NNS
3344596|NCT02214589|Active Comparator|Facilitated Tucking and NNS|Facilitated tucking and NNS
3344597|NCT02214602|Experimental|Study group(Epirubicin)|in this arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor
3239397|NCT01279083|Experimental|Concentration 3|
3239398|NCT01279083|Experimental|Concentration 4|
3239399|NCT01279083|Placebo Comparator|Vehicle Solution|
3344598|NCT02214602|No Intervention|Control group|in this arm -control group- : patients will not receive immediate intravesical instillation of of epirubicin after compete transurethral resection of bladder tumor.
3344599|NCT02214641|Experimental|Lifestyle intervention|Resilient, Empowered, Active Living (REAL) Diabetes
3239400|NCT01279083|Active Comparator|Timolol Maleate Ophthalmic Solution|
3344600|NCT02214641|Active Comparator|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose.
3344601|NCT02214654||ticagrelor，clopidogrel，antiplatelet drugs|
3344602|NCT02214667|Experimental|DDMI-IGT|Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
3239401|NCT01279122|No Intervention|Nanoflex IOL|
3239402|NCT01279135|Active Comparator|Conventional RT|Patients in this arm will receive conventional radiation with or without chemotherapy
3239403|NCT01279135|Experimental|Tomotherapy based IGRT|Patients in this arm will receive Tomotherapy based IGRT with or without chemotherapy
3239404|NCT01279148||Biopsy/Ablation - CONTROL GROUP|The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded by pushing the start button again.
3344603|NCT02214667|Active Comparator|Usual care|Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
3344604|NCT02214680|Experimental|Combination of Brimonidine and Timolol|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
3344605|NCT02214693|Experimental|Group 1(Severe decrease in GFR)|Severe decrease in GFR
3344606|NCT02214693|Experimental|Group 2(Moderate decrease in GFR)|Moderate decrease in GFR
3344607|NCT02214693|Experimental|Group 3(Mild decrease in GFR)|Mild decrease in GFR
3344608|NCT02214693|Experimental|Group 4(Normal GFR)|Normal GFR
3344609|NCT02214706|Experimental|sirolimus topical 40microgram/cm2|sirolimus topical 40microgram/cm2
3344610|NCT02214706|Experimental|Pulsed Dye Laser + Erbium yag + sirolimus|Pulsed Dye Laser + Erbium yag laser + topical sirolimus
3344611|NCT02214706|Experimental|Pulsed Dye Laser + topical sirolimus|Pulsed Dye Laser + topical sirolimus
3344612|NCT02214706|Experimental|Pulsed Dye Laser|Pulsed Dye Laser
3344613|NCT02214719|Experimental|Baseline observation for EASI-IDM use|Baseline observation period to gather information on current practice about diabetes care
3344614|NCT02214732|Experimental|MBCT + Treatment as Usual (TAU)|"Behavioural: Mindfulness Based Cognitive Therapy~Participants in the MBCT group attend an 8 week course of a modified MBCT program for pregnant women, delivered by a licensed clinical psychologist."
3344615|NCT02214732|No Intervention|Treatment as Usual (TAU)|Participants in the TAU group access community resources for pregnant women experiencing psychological distress.
3344616|NCT02214745||Mentally retarded Israeli Arab children|
3344617|NCT02214745||Israeli Arab children with cerebral palsy|
3344618|NCT02214745||Israeli Jewish children with cerebral palsy|
3344619|NCT02214745||Mentally retarded Israeli Jewish children|
3344620|NCT02214758|Other|Dietary counseling|
3344621|NCT02214758|Other|Oral health counseling|
3344622|NCT02214758|No Intervention|nutrition no counseling|
3344623|NCT02214758|No Intervention|oral health no counseling|
3344624|NCT02214771||1: CDI in patients treated with fidaxomicin|Diagnosed with a CDI and treated with fidaxomicin
3344625|NCT02214771||2: CDI in patients receiving treatment other than fidaxomicin|Diagnosed with a CDI, regardless of the prescribed treatment (not fidaxomicin)
3239405|NCT01279148||Biopsy/Ablation - STUDY GROUP:|"The tracking device will be placed on the patient's skin at the desired point of entry. Without displaying the PercuNav screen to the physician, a screen capture will be taken to record the approach path. The physician will then be un-blinded and shown the PercuNav screen and will correct the desired approach path and another screen capture will be taken. At the point of insertion, the time stamp will be recorded and the start button will be pressed. Once the physician states they are at the defined target a screen capture will be taken on the PercuNav and the distance to target and time stamp will be recorded. At the end of the procedure, and if clinically indicated, a verification CT computed tomography scan will be taken with the needle in place and, sent to the PercuNav. Radiation dosage, due to CT imaging, will also be recorded."
3344626|NCT02214784|Active Comparator|Active Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30minutes over 12 weeks.
3344627|NCT02214784|Placebo Comparator|Modified Neurotech Vital Device|50% of 140 patients on a 12 week treatment programme with the device used 5 days out of 7 for 30 minutes over 12 weeks.
3344628|NCT02214797|Other|Presbyopic group - Low Add|"40 years and over Add of less than +1.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion. Each lenses will be worn for a week with a minimum 2 day washout period between the lens types. Each lens will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3344629|NCT02214797|Other|Presbyopic group - Med Add|"40 years and over Add of +1.50D to +1.75D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3344630|NCT02214797|Other|Presbyopic group - High Add|"40 years and over Add of +2.00D to +2.50D~Control lens : Lotrafilcon B and Senofilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3344631|NCT02214797|Other|Non-presbyopic group|"18 to 39 years old No Add~Control lens : Lotrafilcon B and Etafilcon A~Test lens: Etafilcon A~Up to 4 test lens designs will be assessed against commercial control/s in each parallel arm in a randomised cross over fashion, with a minimum 2 day washout period between the lens types. Each lens assessment will require 2 scheduled clinic attendances - a fitting visit and an evaluation visit."
3344632|NCT02214810|Active Comparator|Control- Marcain|Group 1 will receive non-liposomal bupivacaine introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
3344633|NCT02214810|Experimental|Experimental- Exparel|Group 2 will receive a mixture of non-liposomal bupivacaine and Exparel introduced into the soft tissue surrounding the fracture at the conclusion of the surgery.
3239406|NCT01279161||diabetes|The study will include 1500 children with type 1 diabetes, aged 6-18 years. These will be patients from Diabetes Outpatient Clinics and patients hospitalized in Departments of Paediatrics, Endocrinology and Diabetology in University and Municipal Hospitals from Poland (Białystok, Warszawa, Łódź, Gdańsk, Wrocław, Katowice).
3239407|NCT01279161||control|Reference group will be made of 1500 children from the above mentioned Clinics and Departments in whom type 1 diabetes was excluded. In these children diagnostics procedures will be conducted for reasons other than body weigh related diseases (excluding simple obesity). The children will not receive any treatment that might influence their body weight.
3344634|NCT02214823|Experimental|FES-Cycling|"Timeframe: Within 72 hours of ICU admission. Program: Standard care physiotherapy AND up to one hour of supine cycling daily using a cycle ergometer (RT300 supine model Restorative Therapies, Ltd or Letto 300.) attached to a six channel stimulator (SAGE) and 2 additional RT50 wireless stimulator channels.~One leg will undergo cycling alone without the electrodes turned on (sham) and the other leg will undergo cycling and muscle stimulation. Electrodes will be placed on all major lower limb muscles. Intervention will be provided individually and supervised by a physiotherapist in ICU only. Duration /Intensity: Up to 1 hour at least 5 times a week for 28 days or ICU discharge, if 20 sessions have not occurred at this time, intervention will continue until this is achieved. Intensity of muscle stimulation will be delivered at a level able to cause visible muscle contractions, confirmed by palpation.~A subgroup of 10 individuals will be involved in biomarker analyses."
3344635|NCT02214823|Active Comparator|Standard Care|"Both groups will receive usual medical and nursing care in the ICU and ward. Both groups (control and intervention) will receive standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.~A subgroup of 10 individuals will be involved in biomarker analyses. This will involve collection of muscle biopsy, blood and urine analyses at baseline and ICU discharge."
3239408|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
3344636|NCT02214836|Experimental|Kidney stones|"Device: Verasonics Data Acquisition System (VDAS)~Other Names:~Verasonics Data Acquisition System (VDAS) Verasonics Ultrasound Engine Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified.~Subjects in this arm will be imaged by ultrasound by the VDAS. Stone location and size will be determined and compared to clinical determination of stone location and size."
3375878|NCT03602833|Experimental|Compound 451238|To assess the safety and tolerability of combining radiotherapy with compound 451238, treating advanced STS.
3375879|NCT03594123|Experimental|Brexpiprazole Arm 1|Oral tablet; taken once daily. Total daily dose of 2 mg/day
3344637|NCT02214849|Experimental|LATCH Intervention|Women enrolled in the WIC program and receiving breastfeeding peer counseling services will receive text messages to support them with their breastfeeding intentions. They will start receiving automated text messages starting in pregnancy and continuing throughout the first 6 months after giving birth. Messaging during pregnancy will emphasize what to expect in the hospital, the onset of lactation, skin-to-skin contact with baby, early and often breastfeeding in post-partum period, milk transfer (suck & swallow), positioning (with links), common breastfeeding problems and how to seek help. Throughout the study, participants will be able to respond to automated text messages with specific questions that will be received and answered by their WIC program peer counselors. Texting will also have prompts to respond occasionally (at minimum once every two weeks) to ensure that phone is still in service and that the participant in the intervention arm are receiving intervention.
3344638|NCT02214862|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)amino]-2-naphthyl} ethylidene) malononitrile Radiopharmaceutical tracer, intravenous, single dose of 360+/-20 megabecquerel
3344639|NCT02214875|Experimental|CQI/BTS|"Experimental: CQI/BTS~CQI/BTS interventions will be applied through rapid structured cycles of data collection, testing of solutions and review of changes will be done. At each site, Quality Improvement Teams (QIT) will be established among facility staff. Local Government/State QI teams will provide oversight function of facility based QI initiatives. Break Through Collaborative Series (BTS) will hold quarterly in each study state at a central location with participants from intervention sites. Sessions will provide opportunity for teams to learn from each other; adapt and implement changes using the Plan-Do-Study-Act (PDSA) model. Process indicators will be used to measure quality improvement from the intervention sites and collaboratives."
3344640|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
3344641|NCT02214888|Experimental|BIRB 796 BS, low dose|
3344642|NCT02214888|Experimental|BIRB 796 BS, high dose|
3344643|NCT02214888|Placebo Comparator|Placebo|
3344644|NCT02214901|Experimental|BIBW 2948 BS in single rising doses|
3344645|NCT02214901|Placebo Comparator|Placebo|
3344646|NCT02214914|Experimental|BI 11634 drinking solution|single rising dose
3344647|NCT02214914|Placebo Comparator|Placebo|
3344648|NCT02214914|Experimental|BI 11634 tablet|
3344649|NCT02214927|Experimental|BI 11634 single rising dose|tablet
3344650|NCT02214927|Experimental|BI 11634 cross-over|sequence: 1. tablet 2. drinking solution
3344651|NCT02214940|Experimental|BI 11634|multiple rising dose
3239409|NCT01279174|Experimental|Whole-body-vibration exercises|Patients in this study group will attend whole body vibration exercise sessions of one hour three times a week for six weeks, using the Galileo® Fitness device. Initial training sessions will focus on patient acclimatization, and afterwards improved on muscular capacity and body coordination. During exercise sessions, patients will do 6 training cycles of 3 minutes each. The goals of this treatment are improved proprioception of the ankle and knee joints, as well as optimization of neuronal reactivation of the muscles and thereby improved joint stability. This should also increase endogenous analgesia
3239410|NCT01279213|Active Comparator|paliperidone clozapine BPRS|patients assigned to clozapine plus paliperidone controls at 6 and 12 weeks
3239411|NCT01279213|Placebo Comparator|clozapine plus placebo BPRS|patients assigned to placebo plus clozapine should show less improvement
3239412|NCT01279239||Poly trauma|20 Patients suffering from poly trauma who meet inclusion criteria would be recruited
3239413|NCT01279239||Healthy control|20 healthy volunteers would be recruited to obtain basal metabonomics fingerprinting
3239414|NCT01279252|Experimental|Antibiotic regimen|
3344652|NCT02214940|Placebo Comparator|Placebo|
3344653|NCT02214953|Experimental|BI 11634 ER formulation A|
3344654|NCT02214953|Experimental|BI 11634 ER formulation B|
3344655|NCT02214953|Experimental|BI 11634 ER formulation M|
3344656|NCT02214953|Experimental|BI 11634 ER formulation C|
3239415|NCT01279278|No Intervention|Control|
3239416|NCT01279278|Experimental|Co-signed Letter|
3239417|NCT01279291|Experimental|KHK2866 as monotherapy|Groups of subjects will receive a weekly infusions of KHK2866 as treatment for advanced cancer. If there no severe side effects, the dose will be increased for future subjects. A total of four groups are anticipated. Once an acceptable dose is determined an additional seven subjects will be treated at that dose.
3239418|NCT01279291|Experimental|KHK2866, gemcitabine+carboplatin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with gemcitabine and carboplatin. The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3239419|NCT01279291|Experimental|KHK2866, weekly paclitaxel|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with weekly paclitaxel (80 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3344657|NCT02214953|Active Comparator|BI 11634 IR tablet|
3344658|NCT02214966|Experimental|Telmisartan/Ramipril, fed|
3344659|NCT02214966|Active Comparator|Telmisartan/Ramipril, fasted|
3344660|NCT02214979|Experimental|Telmisartan/Ramipril|
3344661|NCT02214979|Active Comparator|Telmisartan + Ramipril capsule|
3344662|NCT02214979|Active Comparator|Telmisartam + Ramipril tablet|
3344663|NCT02214992|Experimental|Telmisartan/Ramipril|Fixed dose combination tablet
3344664|NCT02214992|Active Comparator|Telmisartan + Ramipril capsule|
3344665|NCT02214992|Active Comparator|Telmisartan + Ramipril tablet|
3344666|NCT02215005|Experimental|Telmisartan + Ramipril|5 days qd
3344667|NCT02215005|Active Comparator|Telmisartan|5 days qd
3344668|NCT02215005|Active Comparator|Ramipril|5 days qd
3344669|NCT02215018|Experimental|BI 44370 TA solution|
3344670|NCT02215018|Experimental|BI 44370 TA tablet|
3344671|NCT02215018|Placebo Comparator|Placebo solution|
3344672|NCT02215018|Placebo Comparator|Placebo tablet|
3344673|NCT02215031|Experimental|BI 44370|
3344674|NCT02215031|Placebo Comparator|Placebo|
3344675|NCT02215044|Experimental|BI 2536 in combination with gemcitabine|
3344676|NCT02215057|Experimental|Group 2|topical anesthetic drops patients were prepared for bilateral ICL/TICL procedure on the same day.Group I (1 eye) received topical anesthetic drops
3239420|NCT01279291|Experimental|KHK2866, pegylated liposomal doxorubicin|"Open to subjects with ovarian, fallopian tube, or primary peritoneal cancer only.~One group of subjects will receive one dose below the maximum tolerated dose of KHK2866 identified in Phase 1a along with monthly PLD (40 mg/m2). The dose of KHK2866 will be increased to the MTD for the next group if no severe side effects are noted. Once an acceptable dose is determined an additional seven subjects will be treated at that dose."
3344677|NCT02215057|Experimental|Group 1|received topical anesthesia plus intracameral lidocaine 1% topical anesthesia plus intracameral lidocaine 1%'
3344678|NCT02215083|Experimental|L-Glutamine|All patients will receive 20-30 grams of l-glutamine daily for 9 weeks (+/- 1 week)
3344679|NCT02215096|Experimental|Phase 1-Dose Escalation|Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination. If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated. If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated. Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK. Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).
3344680|NCT02215096|Experimental|Phase 2- Dose Expansion|Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate
3344681|NCT02215109||BRVO, Retinal vessel diameter|The retinal vessel diameter was measured Branch Retinal Vein Occlusion patients after intravitreal bevacizumab injection.
3239421|NCT01279304||Group 1. Low risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. all nodes negative: ycN0~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~a. only micrometastases in the SN, and no risk factors (grade 3, LVI, tumour size > 3 cm)~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~no metastases in the post chemo SN"
3239422|NCT01279304||Group 2: Intermediate risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 1-3 nodes positive: ypN1~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~micrometastases in the SN and at least 1 risk factor; or~≤ 2 macrometastases and no risk factor~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~micrometastases in the post chemo SN and no risk factors (grade 3, LVI, tumour size > 3 cm)"
3239423|NCT01279304||Group 3. High risk|"Surgical strategy is full axillary lymph node dissection after primary systemic treatment and in case of:~a. 4 or more nodes positive: ypN2~or~Surgical strategy is sentinel node procedure only performed prior to primary systemic treatment and in case of:~≤ 2 macrometastases in the sentinel node prior to primary systemic treatment in the presence of risk factors like Grade 3, lymphangioinvasion, tumour size > 3 cm; or~3 macrometastases, 2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases.~or~Surgical strategy is sentinel node procedure only performed after primary systemic treatment and in case of:~Micrometastases in the post chemo SN, and at least one risk factor~≤ 3 macrometastases in the post chemo SN; or~2 macrometastases and 1 micrometastase, 1 macrometastase and 2 micrometastases"
3344682|NCT02215122|Experimental|MGR001|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via CRC749 inhaler.
3344683|NCT02215122|Experimental|Advair® Diskus®|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Diskus® inhaler.
3344684|NCT02215122|Experimental|Seretide™ Accuhaler™|FP/SAL 250/50 µg 3 x inhalations (total dose 750/150 µg) administered via Accuhaler™ inhaler.
3344685|NCT02215135|Experimental|Corifollitropin in PCOS|In GnRH antagonist protocol, a single dose corifollitropin alfa was administered for ovarian stimulation following rFSH daily injection to stimulate follicle development. GnRH agonist was given to trigger final oocyte maturation when three follicles reached 17 mm in size. The IVF or ICSI was planned then all embryos were elective cryopreserved.
3344686|NCT02215148||Brain injured patients with hyponatremia|Patients with acute brain injury who develop hyponatremia and are administered tolvaptan via the nasogastric tube, deemed necessary by the primary medical team.
3344687|NCT02215174|Experimental|Asians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
3344688|NCT02215174|Experimental|Caucasians|Drug: Rosuvastatin Rosuvastatin 20mg po x1 Other Name: Crestor
3344689|NCT02215187|Experimental|Problem-Solving Training|PST is a cognitive-behavioral intervention. Delivery of the PST + usual care condition will be administered to caregivers over the course of 6 one-hour per week, telephone calls/sessions that will entail education related to problem-solving skills/problem-solving model and application to caregiving and managing caregiver related problems.
3344690|NCT02215187|Sham Comparator|Attention Control|Attention/social contact control. Health education (non-skill focused).
3344691|NCT02215213|Active Comparator|Intervention Group|Arm 1 is receiving vitamin D supplementation in 2000 IU/day ,
3344692|NCT02215213|Active Comparator|Arm 2 intervention group|Arm 2 is receiving vitamin D supplementation in 4000/IU per day
3344693|NCT02215213|Active Comparator|Arm 3 control group|Arm 3 is receiving vitamin D supplementation in 400 IU/day
3344694|NCT02215239|Experimental|Working type A & Workplace intervention|Participants: Workers tend to be seated during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
3344695|NCT02215239|No Intervention|Working type A & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
3239424|NCT01279330|No Intervention|Control|Patients receive by mail the materials needed for stool samples.
3239425|NCT01279330|Experimental|Co-signed Letter|
3239426|NCT01279356||Patients with liver diseases of various etiologies|"viral hepatitis~cholestatic liver diseases~auto-immune hepatitis~NAFLD~ALD~sarcoidosis of the liver"
3239427|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control treatment in IBS treatment
3239428|NCT01279382|Other|Hypnotherapy (HYP)|HYP was given to a subgroup of patients as intervention in IBS treatment
3344696|NCT02215239|Experimental|Working type B & Workplace intervention|Participants: Workers tend to be standing during work hours. Intervention: WHO Healthy Workplace Framework and Model. Duration: 16 weeks.
3344697|NCT02215239|No Intervention|Working type B & Usual care|Participants: Workers tend to be standing during work hours. Intervention: Usual care. Duration: 16 weeks.
3344698|NCT02215265|No Intervention|A: No adjuvant treatment|Group A Patients with tumours which exhibit no adverse histological features. Patients in this group will not receive any adjuvant treatment as per standard of care.
3344699|NCT02215265|Active Comparator|B1: Postoperative radiotherapy 60 Gray|"Arm B1: postoperative radiotherapy (PORT) at a dose of 60 Gray (Gy) in 30 fractions over 6 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
3344700|NCT02215265|Experimental|B2: Postoperative radiotherapy 50 Gray|"Arm B2: Postoperative radiotherapy (PORT) at a dose 50 Gray in 25 fractions over 5 weeks.~Group B: Patients with: T3 tumours (or T1-T2 tumours with additional risk factors), TNM 7th edition pN2a (metastasis in single ipsilateral node 31-60 mm diameter) or pN2b (metastasis in multiple ipsilateral nodes <61 mm diameter) disease, tumours with evidence of perineural and/or vascular invasion, and/or a histologically normal tissue margin around the primary tumour of 1-5mm and, in the case of TLM, marginal biopsies free of tumour."
3344701|NCT02215265|Active Comparator|C1: Postoperative radiotherapy 60 Gray with Cisplatin|"Arm C1: postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks with concurrent Cisplatin chemotherapy (POCRT). Cisplatin may be given 3 weekly (100mg/m2 week 1 and week 4 of radiotherapy) or weekly (40mg/m2 weekly during radiotherapy), according to local practice.~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
3344702|NCT02215265|Experimental|C2: Postoperative radiotherapy 60 Gray without chemotherapy|"Arm C2: Postoperative radiotherapy at a dose of 60 Gray in 30 fractions over 6 weeks without chemotherapy (Test Arm C2).~Group C: Patients with tumours of any T or any N stage, which exhibit the following high risk pathological features will be included: A histologically normal tissue margin around the primary tumour of <1mm and, in the case of TLM, marginal biopsies free of tumour and /or extracapsular spread (ECS) of nodal disease"
3344703|NCT02215278|Experimental|low phytic acid bean (lpa variety)|
3344704|NCT02215278|Experimental|high iron biofortified bean variety|
3344705|NCT02215278|Experimental|normal iron, normal phytic acid bean|
3344706|NCT02215291||Patients undergoing EGD or esophagoscopy|The cohort includes patients undergoing EGD or esophagoscopy for initial diagnosis or initial staging and mapping, surveillance of non-treated disease, and treatment (initial or ongoing) or post-treatment surveillance
3344707|NCT02215304|Active Comparator|Bifidobacterium longum R0033|Bifidobacterium longum ssp infantis R0033, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3239429|NCT01279382|Other|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
3239430|NCT01279395||naproxen|Patients age 40-70 who fulfill the American College of Rheumatology (ACR) criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed naproxen (1000 mg/day) for a minimum of two weeks.
3344708|NCT02215304|Active Comparator|Lactobacillus helveticus R0052|Lactobacillus helveticus R0052, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3344709|NCT02215304|Active Comparator|Bifidobacterium bifidum R0071|Bifidobacterium bifidum R0071, 3*10E9 colony forming units (CFU) in 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3344710|NCT02215304|Placebo Comparator|Placebo|potato starch 1 sachet per day to be diluted in 10 mL water by mouth for eight weeks
3344711|NCT02215317||OSA group|Patients found to have OSA based on an overnight sleep study
3344712|NCT02215317||Non-OSA group|Patients found not to have OSA based on an overnight sleep study
3344713|NCT02215330|Placebo Comparator|Sugar pill|"Maltodextrin filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
3375880|NCT03594123|Experimental|Brexpiprazole Arm 2|Oral tablet; taken once daily. Total daily dose of 3 mg/day
3239431|NCT01279395||diclofenac|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis. The group consists of patients who have been prescribed diclofenac (150 mg/day)for a minimum of two weeks.
3239432|NCT01279395||celecoxib|Patients age 40-70 who fulfill the ACR criteria for a diagnosis of primary osteoarthritis are considered eligible. This group has been prescribed celecoxib (200 mg/day) for a minimum of two weeks.
3239433|NCT01279421|Experimental|Social Network HIV Testing|Participants in this arm will be recruited through social networks and will receive an HIV test.
3344714|NCT02215330|Experimental|Eplerenone|"Eplerenone 25mg pills triturated and filled into capsules.~1 Pill starting dosage~Follow-up visits (every two weeks, beginning at week 4):~If subretinal fluid is present and the patient takes two pills a day dosage stays the same.~If no subretinal fluid is present, the patient will continue the present dosage for another 2 weeks and will then stop the medication.~If no subretinal fluid is present and the patient takes no medication everything stays the same.~If subretinal fluid is present again (recurrence) and the patient takes no medication, the medication will be re-started again, the patient has to take one tablet beginning at the following day"
3344715|NCT02215343|Experimental|High fibre diet (wheat bran extract)|
3344716|NCT02215343|Experimental|High PUFA diet (fish oil supplement)|
3344717|NCT02215356|Active Comparator|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5, cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles, while chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times). Progressive patients will be administered oral icotinib 125 mg three times daily.
3239434|NCT01279421|Experimental|Peer Network Intervention|Eight (8) current or former crack users will be recruited to facilitate small networks of crack users in a three-day intervention. They will also facilitate monthly meetings open to all community members regarding HIV prevention and interpersonal violence.
3239435|NCT01279434|Experimental|Vitamin E plus Pentoxiphyllin|
3239436|NCT01279434|Active Comparator|Vitamin E|
3344718|NCT02215356|Experimental|Icotinib with concurrent radiotherapy|Chest radiotherapy (total dose 60-66Gy, 2Gy per time, once a day, five times a week, a total of 30-33 times), while icotinib 125mg three times daily (375 mg per day) by mouth. Maintenance icotinib will be administered after radiotherapy. Progressive patients will receive chemotherapy, using the platinum-based two-drug chemotherapy regimen.
3344719|NCT02215382|Active Comparator|sugammadex|
3344720|NCT02215382|Active Comparator|neostigmine + atropine|
3344721|NCT02215395|Experimental|CVR treatment cycle|Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
3344722|NCT02215408|No Intervention|Control|Patient received usual care from the provider in the local clinic.
3344723|NCT02215408|Experimental|CVRS Intervention|CVRS pharmacist followed the patient for 12 months in order to decrease the patient's risk of developing cardiovascular disease.
3344724|NCT02215421|Experimental|Play Mommio for 2 months|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
3344725|NCT02215421|No Intervention|No game play|No intervention control.
3344726|NCT02215434|Placebo Comparator|Biolipid B2 (blanked/placebo)|"The study is a single-center, single-blind, placebo-controlled, parallel group trial.~It consists of a 4-week screening period plus a 12-week treatment phase. At the screening visit, all participants underwent a physical examination including vital signs and breast and pelvic examination.~They were randomly assigned in a 1:1 ratio to receive a transdermal vehicle biolipid B2 (identical placebo) provided by Evidence Pharmaceuticals Inc, SP,BRAZIL.~The testosterone and placebo emulsion were alcohol-free matrixes that were applied topically to the forearm daily for the period of 12 weeks."
3344727|NCT02215434|Active Comparator|Testosterone, Transdermal, Behavior|Testosterone 0.5%, daily, 3 months
3344728|NCT02215447|Experimental|NAB-Paclitaxel with carboplatin|NAB paclitaxel (100 mg/m2 IVI) every week (d1,8,15) in three weekly cycle. Carboplatin (AUC=5 IVI) (d1) in three weekly cycle. Study treatment will continue until progressive disease, unacceptable toxicity, or ceased by patient or clinician preference.
3344729|NCT02215460|Experimental|Full-mouth scaling (FMS)|
3344730|NCT02215460|Experimental|FMS chlorhexidine rinse|
3344731|NCT02215460|Experimental|FMS azithromycin tablets|
3344732|NCT02215460|Placebo Comparator|FMS placebo rinse|
3344733|NCT02215460|Experimental|Quadrant scaling (QS)|
3344734|NCT02215460|Experimental|QS chlorhexidine rinse|
3344735|NCT02215460|Experimental|QS azithromycin tablets|
3344736|NCT02215460|Placebo Comparator|QS placebo tablets|
3344737|NCT02215460|Placebo Comparator|FMS placebo tablets|
3344738|NCT02215460|Placebo Comparator|QS placebo rinse|
3344739|NCT02215473|Experimental|gingivitis mouth rinse|
3344740|NCT02215473|Experimental|periodontitis mouth rinse|
3239437|NCT01279460||CKD Cohort of patients with renal insufficiency|patients with renal insufficiency grade II-IV
3344741|NCT02215473|Active Comparator|gingivitis no mouth rinse|
3344742|NCT02215473|Active Comparator|periodontitis no mouth rinse|
3344743|NCT02215499|Active Comparator|Xyrem®|Oral suspension
3344744|NCT02215499|Experimental|JZP-386|Oral suspension
3344745|NCT02215499|Placebo Comparator|Placebo|Oral suspension
3344746|NCT02215512|Experimental|RRx-001 + WBRT|RRx-001 administered intravenously twice a week (10, 17, 33, 55 mg) in subjects with brain metastases receiving whole brain radiation therapy (WBRT).
3344747|NCT02215525|Experimental|UVA and Herbal|Twenty four daily one hour sessions using Extra-corporeal electro-magnetic irradiation device combined with Herbal Food Supplement Selenium containing tables as an Anti Oxidant (Tablet A) starting 10 days before the radiation sessions and to continue for 24 weeks
3344748|NCT02215525|Experimental|Herbal|Chronic HCV patients, non complicated will be treated by Herbal tablets only . 500 mg twice tablets every 6 hours daily for 6 months.
3344749|NCT02215538|Experimental|OROS methylphenidate|This was a 4-week double-blind arm. Medication was initiated at 18 mg/day and increased every 2 or 3 days by 9 mg based on treatment response and side effects. Maximum dose - 90 mg/day. Patients were seen weekly. Generally a stable dose was seen in 2 weeks and maintained the last 2 weeks of the arm. Side effects were assessed at each visit.
3344750|NCT02215538|Placebo Comparator|placebo|This arm was identical to the active medication arm except that placebo replaced the active medication.
3344751|NCT02215551||Study Group|"Younger than 90 years old. no communication barriers (e.g., English speaking, household telephone) Affirmative response to each of the three following questions: a) Do patients have pain, weakness, numbness, or tingling in their legs when walking standing? b) Does this pain, weakness, numbness or tingling in their legs interfere with their daily activities? c) Have patients tried at least one non-surgical treatment for their leg symptoms (e.g., physical therapy, pain medications, spinal injection)? Have been scheduled for surgery on lower back for a condition called lumbar spinal stenosis.~Whom have non degenerative causes of LSS such as tumor, infection, trauma, hemorrhage, or epidural lipomatosis, Prior lumbar spinal surgery, spondylolisthesis with spinal instability, significant cognitive impairment."
3344752|NCT02215564||No treatment|Young adults tested by PCR for B. pertussis carriage
3239438|NCT01279473|Experimental|Nilotinib|
3239439|NCT01279499|Active Comparator|SEVO group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes.If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
3344753|NCT02215577|Experimental|In-situ split with portal vein ligature|In-situ liver split at time when portal vein ligature is performed
3344754|NCT02215577|Active Comparator|Portal embolization or ligation|Intervention: Preoperative portal embolization (+/-ablation) followed by liver resection, or local resections and/or ablations followed by lobectomy, two-stage hepatectomy
3259258|NCT01469195||Group A - No lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group A - no lead protection will be used.
3344755|NCT02215590|Experimental|Re-Step|"The system consists of a pair of special shoes which sole height and angles change in a specific given order, thereby facilitating motor learning and problem solving in real time.~This unpredictable change will introduce a situation of necessary adaptation to keep balance."
3344756|NCT02215603|No Intervention|Prolonged sitting|9 h of prolonged sitting
3344757|NCT02215603|Experimental|Prolonged sitting + interval standing bouts|Stand bout for 15-min every 30 minutes during the 9 hours of sitting
3344758|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting|30-min moderate-intensity exercise bout followed by 8 h of sitting
3344759|NCT02215603|Experimental|Moderate exercise bout + Prolonged sitting +Standing bouts|30-min moderate-intensity exercise bout and stand bout for 15-min every 30 minutes during the remaining 8 hours of sitting
3344760|NCT02215629|Experimental|Experimental VS4718|Oral VS-4718 administered BID during a 28 day cycle.
3344761|NCT02215655|Active Comparator|Motivational interviewing|Motivational interviewing counselling will be administered to the subjects
3344762|NCT02215655|No Intervention|No intervention: control group|No motivational interviewing counselling will be administered to the subjects
3344763|NCT02215668|No Intervention|No physical exercise|Women are never subjected to any exercise prior to mammography.
3344764|NCT02215668|Experimental|Physical exercise (Upper limb)|Women will be subjected to physical exercise on upper limb prior to mammography.
3344765|NCT02215668|Active Comparator|Group 2|Women are subjected to physical exercise in the lower limbs prior to mammography
3344766|NCT02215681|Experimental|acupuncture|acupuncture treatment
3344767|NCT02215681|No Intervention|standard treament|watchful waiting
3344768|NCT02215694|Experimental|probiotic group|consumed 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
3344769|NCT02215694|Placebo Comparator|placebo group|consumed 2g of powder daily without probiotics
3344770|NCT02215707|Experimental|Group 1|"Group 1: 5 doses of 2.7x10^5 PfSPZ Vaccine; homologous 3D7 CHMI~Grp 1 (n=15) gets 5 doses of 270,000 PfSPZ per dose (4 doses at 4 wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 and 2 start immunizations together.~1 subj in each of Grps 1 and 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/Grp 2 pilot subjects: 1st subject will be immunized, observed on site for minimum 1 hr; the 2nd subject may be immunized, will also be observed for minimum 1 hr. If no safety concerns are identified after 24 hrs that trigger the stopping rules, then rest of subjects in Grps 1 and 2 will be immunized.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (Pf3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
3375881|NCT03591510|Experimental|Chemotherapy followed by Midostaurin|"In Part 1, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing fludarabine, cytarabine, daunorubicin/idarubicin) and consolidation (Block 3: cytarabine + mitoxantrone, Block 4: cytarabine + etoposide, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy.~In Part 2, midostaurin with standard induction (Block 1 induction according to local practice, Block 2 induction containing cytarabine + mitoxantrone) and consolidation (Block 3: cytarabine + etoposide, Block 4: cytarabine + mitoxantrone, Block 5: cytarabine) followed by single agent midostaurin post-consolidation therapy."
3344771|NCT02215707|Experimental|Group 2|"Grp 2: 5 doses of 2.7x10^5 PfSPZ Vaccine; heterologous 7G8 CHMI~Grp 2 (n=15) gets 5 doses of 270,000 PfSPZ/dose (4 doses at 4wk intervals, 2 month delay before 5th dose) by DVI. Grps 1 / 2 start immunizations together.~1 subj in each of Grps 1 / 2 will be immunized approx 24 hrs before rest of grp (pilot subjects). For Grp1/ 2 pilot subj: 1st subj will be immunized, observed on site for min 1 hr; 2nd subj may be immunized, will also be observed for min 1 hr. If no safety concerns after 24 hrs that trigger stopping rules, then rest of Grps 1 / 2 will be immunized.~Approx 3 wks after final dose, Grps 1/3 have homologous CHMI; 2-3 days later, Grp 2 will undergo heterologous CHMI (Pf7G8) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1/3 have 2nd homologous CHMI; 2-3 days later, Grp 2 will undergo 2nd heterologous CHMI (7G8 strain) with 6 Infectivity Controls. Subj will be followed for 8 wks after last CHMI for safety purposes."
3344772|NCT02215707|Experimental|Group 3|"Grp 3 (n=15) will receive 3 doses by DVI of 450,000 PfSPZ/dose (of PfSPZ Vaccine) at 8 wk intervals (starting approx. 4 wks after Grps 1 and 2 get 1st immunization).~3 subjects in Grp 3 will be immunized approx 24 hrs prior to rest of grp (pilot subjects). The 3 subjects will be immunized sequentially with min 2 hr observation period between subjects (and a 2 hr observation of 3rd subject as well). If no safety concerns identified in pilot subjects after 24 hours that trigger the stopping rules, the rest of subjects in Grp 3 will be immunized as scheduled.~Approx 3 wks after final dose, Grps 1 and 3 will undergo homologous CHMI (3D7 strain) with 6 Infectivity Controls. Approx 24 wks after last dose, Grps 1 and 3 will undergo 2nd homologous CHMI (3D7) with 6 Infectivity Controls. Subjects will be followed for 8 wks after last CHMI for safety purposes."
3344773|NCT02215707|No Intervention|CHMI Controls.1|n = 6, infectivity controls for 1st homologous CHMI (3D7) occurring approximately 3 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
3344774|NCT02215707|No Intervention|CHMI Controls.2|n = 6, infectivity controls for 1st heterologous CHMI (7G8) occurring approximately 3 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
3344775|NCT02215707|No Intervention|CHMI Controls.3|n = 6, infectivity controls for 2nd homologous CHMI (3D7) occurring approximately 24 weeks after final immunization of Groups 1 and 3. This group does not receive the PfSPZ Vaccine.
3344776|NCT02215707|No Intervention|CHMI Controls.4|n = 6, infectivity controls for 2nd heterologous CHMI (7G8) occurring approximately 24 weeks after final immunization of Group 2. This group does not receive the PfSPZ Vaccine.
3239440|NCT01279499|Active Comparator|SEVO-BIS group|Anaesthesia will be induced with IV Propofol (2 mg/kg TW [TW = ideal body weight, IBW + 0.4 * difference to the excess weight]), Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).Intraoperatively Sevoflurane will be guided by a target BIS of 40 - 50 .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes. If the positive sympathetic response persists, then Nifedipine 10 mg will be administered sublingual, if HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of positive sympathetic stress responses that required pharmacologic intervention will be recorded.
3239441|NCT01279499|Active Comparator|Propo- Remi group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a R bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of R to 1.0 μg/kg/min . If HR < 70/ minute, and Diltiazem 10-20 mg IV will be administered if HR > 70/ minute, followed by esmolol administration if response to diltiazem is unsatisfactory. The duration and frequency of stress responses that required intervention is recorded."
3344777|NCT02215720|Experimental|Cetuximab + Temsirolimus|Cetuximab: 400mg/m² IV for 120 minutes Temsirolimus: 15mg IV for 60 minutes
3344778|NCT02215733||Patients prescribed antihypertensives|
3344779|NCT02215746|Experimental|Treatment A|BI 44370 TA drinking solution 100 mg fasted
3344780|NCT02215746|Experimental|Treatment B|BI 44370 TA drinking solution 100 mg fed
3259259|NCT01469195||Group B plus lead protection|Patients who are admitted for an elective percutaneous coronary intervention procedure ( or stable acute coronary syndrome patients) will be ask to participate in the study and sign an informed consent (see inclusions and exclusions).The Investigators will approach patients in whom a long procedure time and higher radiation exposure are anticipated (like patients with chronic total occlusion, heavily calcified or tortuous coronary arteries). In those, the fluoroscopy time on average, is longer than usual. In group B - lead protection will be used from the umbilicus and down.
3344781|NCT02215746|Experimental|Treatment C|BI 44370 TA drinking solution 200 mg fasted
3344782|NCT02215746|Experimental|Treatment D|BI 44370 TA drinking solution 200 mg fed
3344783|NCT02215746|Experimental|Treatment E|100 mg BI 44370 BS as two tablets 50 mg fasted
3344784|NCT02215746|Experimental|Treatment F|100 mg BI 44370 BS as two tablets 50 mg fed
3344785|NCT02215759|Experimental|BI 44370 TA|
3344786|NCT02215759|Placebo Comparator|Placebo|
3344787|NCT02215772|Experimental|BI 44370 BS|200 mg containing 2.43 megabecquerel (MBq) 14C-radioactivity
3344788|NCT02215785|Experimental|kiwifruit cohort|Patients that presented at Primary Care Centres with registered -Roma III criteria based- constipation and who accepted to participate in the study were followed-up for two weeks before intervention and three weeks under 3-daily kiwifruit intake.
3344789|NCT02215798||Cymbalta|
3344790|NCT02215811|Experimental|Mesenchymal stromal cells|
3344791|NCT02215824|Experimental|BIWH 3|in escalating doses
3344792|NCT02215824|Placebo Comparator|Placebo|
3344793|NCT02215837|Sham Comparator|Chemotherapy|After accepting chemotherapy according to NCCN guidelines, patients will just regularly follow up.
3344794|NCT02215837|Experimental|Ag-D-CIK|After accepting chemotherapy according to NCCN guidelines,patients will receive 3 cycles of autologous tumor lysate pulsed D-CIK treatment.
3344795|NCT02215850|Experimental|SLC-0111|
3344796|NCT02215863|Active Comparator|PCV13 and Fluad|437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
3344797|NCT02215863|Active Comparator|Fluad alone|437 Fluad recipients: one vaccine injection administered on Day 0
3239442|NCT01279499|Active Comparator|Propo-Remi-BIS group|"General Anaesthesia (GA) will be induced with a continuous IV Propofol (P) infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (R, 1 μg/kg IBW) and succinylcholine (1mg/kg IBW). GA will be maintained with continuous intravenous administration of P at 150-300mcg/kg/min (IBW).~The depth of anesthesia will be adjusted to accomplish a BIS score 40 -50. If BP or HR is > 15% of baseline will a bolus of R IV (1 μg/kg IBW) will be given and an the infusion rate of R will be increased to 1.0 μg/kg/min . If this response persists and HR < 70/ min, Nifedipine 10 mg will be given s.l. and if HR > 70/ min Diltiazem 10-20 mg IV will be given, followed by esmolol infusion if no response is observed."
3239443|NCT01279512|Experimental|Metformin reciepiants|Infertile overweight women with PCO who received Metformin
3239444|NCT01279512|Experimental|Acarbose reciepiants|Infertile overweight women with PCO who received Acarbose
3344798|NCT02215863|Active Comparator|PCV13 alone|437 PCV13 recipients: one vaccine injection administered on Day 0
3344799|NCT02215876|Experimental|Single Arm|Doxorubucin and Cyclophosphamide q2 or q3 weekly x 4 cycles plus Eribulin on days 1 and 8 of a 21 day cycle x 4 cycles
3344800|NCT02215889|Experimental|Surgery|
3344801|NCT02215902|Experimental|Hemopurifier|Affinity plasmapheresis
3344802|NCT02215915|Experimental|IVUS guided DES implantation|Stent size and length were selected by online IVUS measurements, and adjunct high-pressure dilation was performed according to the discretion of operators based on the IVUS criteria for stent optimization.
3344803|NCT02215915|Active Comparator|Angiography guided DES implantation|Stent size and length were chosen by visual estimation, and adjunct high-pressure dilation was performed if an optimal result was not achieved, which was defined as angiographic residual diameter stenosis 20% and absence of angiographically detected dissection.
3344804|NCT02215928||Ancillary-correlative (tumor genomic profiling)|Tissue samples are collected at baseline and blood for liquid biopsy is collected at baseline and every 6-8 weeks during active treatment. Tissue samples are analyzed via sequencing for tumor genomic profiling.
3344805|NCT02215980|Experimental|A|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21.~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days until progression or intolerance."
3344806|NCT02215980|Experimental|B|"Lenalidomide: at the dose of 25 mg/daily as oral administration (PO) on days 1-21~Dexamethasone: at the dose of 20 mg as oral administration (PO) once weekly. Each cycle will be repeated every 28 days, for a total of 9 cycles.~Maintenance until progression or intolerance:~- Lenalidomide: 10 mg/daily on days 1-21 of each 28-day cycle"
3344807|NCT02215993|Active Comparator|Prasugrel|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 60 mg prasugrel followed by 10mg per day for 30 days.
3344808|NCT02215993|Active Comparator|Ticagrelor|After 300mg or 600mg loading dose of clopidogrel, this medication will be replaced by 180 mg ticagrelor followed by 90mg twice a day for 30 days.
3344809|NCT02216006|Active Comparator|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner."
3344810|NCT02216006|Active Comparator|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation the effect of preoxygenation is eliminated with an anti-preoxygenation maneuver."
3344811|NCT02216019||study cohort|Patient undergoing planned heart surgery with cardiopulmonary bypass
3344812|NCT02216032|Experimental|Treatment Group|We will deliver the TMW Curriculum to 106 Treatment families. The TMW Curriculum is comprised of 1) 12 educational modules, 2) animations and videos of real parent-child interactions to teach parents about the science behind child brain development, and model strategies for improving parents' child-directed speech, 3) video modeling and collaborative goal setting, and 4) quantitative linguistic feedback from Language ENvironment Analysis (LENA) recordings.
3344813|NCT02216032|Other|Control Group|We will deliver a Nutrition Curriculum to 100 Control families. The Nutrition Curriculum provides information about the importance of healthy nutrition for child development, strategies for healthy eating, and meal preparation.
3344814|NCT02216045|Active Comparator|Peginterferon ,Ribavirin|drug :Peginterferon, Ribavirin,
3344815|NCT02216045|Experimental|Peginterferon, Ribavirin, camel milk|drug :Peginterferon, Ribavirin, camel milk
3344816|NCT02216058|Experimental|NOYA|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
3344817|NCT02216084|Experimental|Recombinant ADAMTS13|The study is comprised of 3 dose cohorts and two dose escalation steps [Cohort 1: 3 subjects; Cohort 2: 3 subjects; Cohort 3: 8 subjects]. Subjects will be enrolled and dosed sequentially. Subjects will be recruited to the next dose level only after short-term safety has been demonstrated and reviewed by an independent Data Monitoring Committee (DMC) at the preceding dose level. The first 2 subjects in any cohort will be ≥ 18 years of age. The effects of the investigational product on vital signs, hematology, and clinical chemistry parameters (up to 96 ± 2 hrs blood sampling timepoint) will determine short-term safety. The DMC will recommend whether to proceed with the study or in case of a safety concern recommend remedial actions and/or to discontinue the study. Subject participation will continue until 28 ± 3 days after infusion of the investigational product. Subject participation in one Dose Cohort (1-3) is expected to be approximately 6-8 weeks.
3344818|NCT02216110||Surgery group|Patients who underwent surgery as treatment of early gastric cancer
3344819|NCT02216110||ESD group|Patients who underwent endoscopic submucosal dissection (ESD) as treatment of early gastric cancer, instead of surgery
3344820|NCT02216149|Experimental|S-1 plus oxaliplatin (SOX)|Oxaliplatin 130 mg/m2 d. 1 followed by oral S-1 25 mg/m2/day BID d1-14.
3239445|NCT01279525|Experimental|Multifactorial intervention|Multifactorial intervention to prevent falls
3239446|NCT01279538|Experimental|ASKP1240 lowest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
3239447|NCT01279538|Experimental|ASKP1240 low dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
3239448|NCT01279538|Experimental|ASKP1240 high dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
3239449|NCT01279538|Experimental|ASKP1240 highest dose|Participants received a single 30-minute study drug infusion on Study Day 1, followed by a 90-day follow-up period.
3239450|NCT01279538|Placebo Comparator|Placebo|Participants received a single 30-minute matching placebo infusion on Study Day 1, followed by a 90-day follow-up period.
3239451|NCT01279551|Experimental|GTN|In this arm the investigators administer local application of 0.4% nitroglycerin ointment and ketorolac tromethamine 10 mg
3239452|NCT01279551|Active Comparator|Control|In this arm the investigators administer local application of lidocaine cloridrato 2.5% and ketorolac tromethamine 10 mg.
3239453|NCT01279577|Experimental|Low dose TSO|Low dose suspension of TSO
3344821|NCT02216149|Active Comparator|Oxaliplatin plus capecitabine (XELOX)|Intravenous oxaliplatin 130 mg/m2 d.1 followed by oral capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14.
3344822|NCT02216162|Experimental|A: Interventional adapted physical activity + enhanced geriatr|Geriatric (functionality, gait, nutrition) follow-up, biological tests, anti-aromatase agents blood dosing, clinical assessment. Weekly Taï-Chi exercises.
3239454|NCT01279577|Experimental|Medium dose TSO|Medium dose suspension of TSO
3344823|NCT02216162|Other|Arm B: control|Clinical follow-up according to the Guidelines, annual geriatric and nutritional assessment
3344824|NCT02216175|Experimental|SLIT followed by Conventional OIT|Participants will receive up to 7 months of SLIT followed by 6 months conventional OIT to cow's milk
3344825|NCT02216175|Active Comparator|Conventional OIT|Participants will receive up to 7 months of low dose OIT, followed by 6 months conventional OIT to cow's milk
3344826|NCT02216175|Placebo Comparator|Delayed start OIT|Participants will receive up to 7 months placebo, followed by 6 months conventional OIT to cow's milk
3344827|NCT02216188|Experimental|A: AFFITOPE® PD01A + Adjuvant|one injection of 15µg AFFITOPE® PD01A/ adjuvanted
3344828|NCT02216188|Experimental|B: AFFITOPE® PD01A + Adjuvant|one injection of 75µg AFFITOPE® PD01A/ adjuvanted
3344829|NCT02216188|Other|Control|Untreated control group
3344830|NCT02216227|Experimental|Surgical Site Infection Checklist|"Patient has a known positive Staph aureus pre-op screening result (MRSA or MSSA):~ecolonize with intranasal Mupirocin ointment BID x 5 days~hlorhexidine gluconate (CHG) bathing (daily x 5 days, using wipes or liquid)~efazolin plus Vancomycin (no Vanco for MSSA positive)~Patient has a known negative Staph aureus pre-op screening result:~HG bathing (night before & morning of surgery using wipes or liquid)~efazolin~Patient was not screened or results are unknown at time of surgery:~ecolonize with intranasal Mupirocin ointment (start BID x 5 days; discontinue if negative screen)~HG bathing (start daily bath 5 days before operation if possible; at a minimum bathe the night before & morning of surgery using wipes or liquid)~efazolin plus Vancomycin"
3344831|NCT02216240|Active Comparator|Accident and emergency|Patients randomised to A&E were treated as per standard care and given no information other than that pertaining to the study.
3344832|NCT02216240|Experimental|Paramedic|Treatment at the scene by a paramedic. Valsalva manoeuvre with subsequent administration of 6mg and 12mg of adenosine unless the supraventricular tachycardia terminated. Patients were taken to accident and emergency if the tachycardia did not terminate, restarted, or the patient had continuing symptoms, a persistently abnormal ECG (other than T wave inversion) or was heamodynamically unstable. Prior to discharge from the ambulance patients received an information pack and a referral letter for their GP to refer them to an arrhythmia clinic.
3344833|NCT02216253|Active Comparator|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|The combination of L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract will be administered in tablet twice a day 7 days before and after surgery
3344834|NCT02216253|Placebo Comparator|Placebo|Placebo tablet twice a day 7 days before and after surgery
3344835|NCT02216266|Active Comparator|Physostigmine|Physostigmine administered intravenously at a dose of 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
3344836|NCT02216266|Placebo Comparator|Sodium Chloride solution|solution administered intravenously 24 mg + 25 min a 0,04 mg/kg milligram(s)/kilogram
3344837|NCT02216279|Experimental|Pulmonary Hypertension Patients|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
3239455|NCT01279577|Experimental|High dose TSO|High dose suspension of TSO
3239456|NCT01279577|Placebo Comparator|Placebo|Placebo solution
3344838|NCT02216279|Active Comparator|Control Non-Smoking Participants|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
3239457|NCT01279590|Experimental|PPD10558|Dosing will be forced-titrated as follows: 40 mg orally twice daily for 4 weeks and 80 mg orally twice daily for 8 weeks
3239458|NCT01279590|Active Comparator|Atorvastatin|Dosing will be forced titrated as 40 mg orally once daily for 4 weeks, and 80 mg orally once daily for 8 weeks
3239459|NCT01279590|Placebo Comparator|Placebo|Dosing will be 2 placebo capsules twice daily for 12 weeks
3239460|NCT01279603|Experimental|GO-203-2c|
3239461|NCT01279629||Tazarotene 0.1%|
3239462|NCT01279629||Calcipotriol 0.005%|
3239463|NCT01279642|Experimental|ultrasound|Use of ultrasound to PICC placement
3239464|NCT01279642|Active Comparator|Control group|PICC placement by inspection and visualization of site
3239465|NCT01279655|Experimental|tDCS and training|Transcranial Direct current stimulation (tDCS) is applied together with a bimanual learning task. tDCS is delivered through two gel-sponge electrodes (eldith DC Stimulator, neuroConn GmbH, Ilmenau, Germany) embedded in a saline-soaked solution. tDCS will be applied for 20 min, with a current intensity of 1mA.
3239466|NCT01279655|No Intervention|Control|No intervention is applied
3239467|NCT01279655|Placebo Comparator|Sham tDCS + Training|The training consists of a bimanual training task. tDCS is only applied for a few seconds and will than be ramped-down.
3239468|NCT01279668|Experimental|Montelukast|
3239469|NCT01279668|Placebo Comparator|Placebo|
3239470|NCT01279707|Experimental|A: Veltuzumab and chemotherapy|Veltuzumab and modified UKALL XII chemotherapy
3239471|NCT01279707|Experimental|B: epratuzumab and chemotherapy|epratuzumab and modified UKALL XII chemotherapy
3239472|NCT01279707|Experimental|C: veltuzumab and epratuzumab and chemotherapy|Veltuzumab and Epratuzumab and modified UKALL XII chemotherapy
3344839|NCT02216292||Preterm Single Donor Milk Group|The prospective study group = preterm single donor milk group (PSDM-Group) from June 2012 - April 2013
3239473|NCT01279720|Experimental|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
3239474|NCT01279733||Microarray Analysis|
3239475|NCT01279746||ultrasond compression of deep veins|
3239476|NCT01279785||Prostate Cancer Patients|Male participants who are scheduled to undergo standard of care prostatectomy for presumed localized prostate cancer at the NIH Clinical Center and have evidence of a recent (within 12 months of study entry) trans-rectal biopsy documenting adenocarcinoma of the prostate.
3239477|NCT01279811|Other|Single Arm|Vasopressor Crossover - Dopamine & NORepinephrine
3239478|NCT01279824|Active Comparator|Usual Care|Patients will receive behavioral swallowing therapy comprising combination's of treatment strategies / exercises chosen from an approved hierarchy. This formulation of treatment will be designed and applied by the treating clinician.The treatment will be provided daily for a one-hour over a consecutive 3-week period.
3239479|NCT01279824|Placebo Comparator|sham NMES|Patients will receive behavioral swallowing therapy comprising combinations of treatment strategies / exercises chosen from an approved hierarchy with the addition of non stimulating electrodes. A faux NMES device will be utilized with an active current display and non stimulating electrodes. The treatment will be provided daily for a one-hour over a consecutive 3-week period.
3344840|NCT02216292||Control Group|Retrospective control group receiving no donor milk = control group from March 2011 - May 2012
3344841|NCT02216305|Active Comparator|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
3344842|NCT02216305|Active Comparator|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
3344843|NCT02216318|Placebo Comparator|red light|red light during the whole day
3344844|NCT02216318|Active Comparator|Blue light|Blue light during early day
3344845|NCT02216331|Experimental|Group 1 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
3344846|NCT02216331|Experimental|Group 1 TMC207 and rifapentine|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifapentine administered as 4 tablets of 150 mg per tablet on each of Study Days 20-41.
3344847|NCT02216331|Experimental|Group 2 TMC207 alone|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 1.
3344848|NCT02216331|Experimental|Group 2 TMC207 and rifampicin|A single 400 mg dose of TMC207 will be administered as 4 tablets of 100 mg per tablet on Study Day 29 and 600 mg of rifampicin administered as 4 capsules of 150 mg per capsule on each of Study Days 20-41.
3344849|NCT02216344||Pulse Oximeter (the device)|The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
3344850|NCT02216370||Cryptogenic Stroke or TIA|
3239480|NCT01279824|Experimental|NMES therapy|Patients will receive a protocol of standardized behavioral swallowing intervention combined with NMES. This formulation of treatment will be prescribed from a standard protocol and will be applied daily for one-hour over a consecutive 3-week period.
3239481|NCT01279837|No Intervention|Usual care|Control (Usual care) group in which patients will receive swallowing and prescribed dietary intervention during the radiotherapy period prescribed by the attending physician.
3344851|NCT02216370||Healthy Volunteers|Healthy Volunteers as comparative group adjusted to investigated group by age and gender
3344852|NCT02216383|Experimental|Carbetocin|One dose of 100 micrograms intramuscular Carbetocin given for active management of the third stage of labour, immediately after the birth of the baby
3344853|NCT02216383|Active Comparator|Syntocinon|One dose of 10 International Units intramuscular Syntocinon given for active management of the third stage of labour, immediately after the birth of the baby
3344854|NCT02216383|Active Comparator|Syntometrine|One dose of 500micrograms/5 International Units intramuscular Syntometrine given for active management of the third stage of labour, immediately after the birth of the baby
3344855|NCT02216409|Experimental|Treatment (Hu5F9-G4)|Hu5F9-G4 monotherapy
3344856|NCT02216448|Other|simulator training|Training knee simulator in Lab
3344857|NCT02216448|Other|OR training|Training in the OR - 2 knee arthroscopies.
3344858|NCT02216461|Experimental|Low dose of BIBW 2948 BS|
3344859|NCT02216461|Experimental|Medium dose of BIBW 2948 BS|
3239482|NCT01279837|Experimental|High Intensity Pharyngocise|Patients receive twice daily swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises.
3239483|NCT01279837|Active Comparator|Low Intensity Pharyngocise|Patients will receive a one time only swallowing intervention session by a speech language pathologist, instructing them in the battery of isometric / isotonic exercises plus a home practice instruction digital video tape to support self directed practice of this program at home.
3239484|NCT01279876|Active Comparator|Melatonin|
3344860|NCT02216461|Experimental|High dose of BIBW 2948 BS|
3344861|NCT02216461|Placebo Comparator|Placebo|
3344862|NCT02216474|Sham Comparator|Sham transcranial direct current stimulation (frontal cortex)|Transcranial direct current stimulation will be ramped up over 60 seconds and then ramped down gradually to encourage blinding to condition.
3344863|NCT02216474|Experimental|Anodal transcranial DC stimulation (frontal cortex)|Anodal transcranial direct current stimulation to prefrontal cortex for approximately 15 minutes plus ramp up and down time
3344864|NCT02216487|Experimental|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan.
3344865|NCT02216500|Experimental|Ketogenic Therapy|Ketogenic Therapy will be administered.
3344866|NCT02216513|Active Comparator|Desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days
3344867|NCT02216513|Placebo Comparator|placebo|normal saline IV for 4 hours for 5 consecutive days
3344868|NCT02216539|Experimental|Self-hypnosis|Patients trained to self-hypnosis before surgery
3344869|NCT02216539|Active Comparator|Usual pain management|Patients receiving the usual post-operative pain management protocols
3239485|NCT01279876|Placebo Comparator|Placebo|
3344870|NCT02216552|Experimental|Resveratrol|Intervention: Resveratrol Oral supplementation of resveratrol (ResVida) 75 mg twice daily (with breakfast and dinner) for a total daily dose of 150 mg for the duration of 30 days.
3344871|NCT02216552|Placebo Comparator|Placebo|Intervention: Placebo Control Oral supplementation of placebo twice daily (with breakfast and dinner) for a total duration of 30 days.
3239486|NCT01279889||Cesarean Delivery|Healthy pregnant women having an elective cesarean delivery
3239487|NCT01279902|Experimental|Rituximab plus CHOP Immunochemotherapy|"Interventions: conventional R-CHOP every 3 weeks for 3 cycles~Rituximab 375 mg/M2 IV day 1~Cyclophosphamide 750 mg/M2 IV day1~Vincristine 1.5 mg/M2 (max. 2 mg) IV day1~Prednisolone 50 mg bid day 1-5, every 3 weeks"
3239488|NCT01279915|Experimental|ASP group|ASP0456 receiving group
3344872|NCT02216565|Other|Medical treatment|Conventional medical non-interventional treatment
3344873|NCT02216565|Other|Endovascular treatment|Conventional medical treatment plus endovascular treatment
3344874|NCT02216578|Experimental|cabozantinib|cabozantinib 60 mg oral daily
3344875|NCT02216604|Experimental|Intervention group|Multimodal Exercise intervention (console-based training, age-specific resistance training and body awareness)
3344876|NCT02216604|No Intervention|Control|age, disease and gender matched
3239489|NCT01279915|Placebo Comparator|Placebo group|Placebo treatment
3344877|NCT02216617|Experimental|Induction chemotherapy TPA|"3 Cycles of induction chemotherapy TPA : (Taxotere, Cisplatin, Afatinib)~1 cycle = 3 weeks, three cycles of treatment in total (or 9 weeks)~Docetaxel 75 mg / m2 at D1 Cisplatin 75 mg / m 2 at D1 Afatinib: x mg / day D2 to D21 by level: (Level 1: 20 mg / day; Level 2: 30 mg / day; Level 3: 40 mg / day)"
3344878|NCT02216630|Experimental|Adipose-Derived Stem Cell (ADSC) Therapy|This arm, as the sole arm, will consist of the ADSC treatment procedure. Intervention will consist of Adipose Derived Stem Cell (ADSC) Therapy
3344879|NCT02216643|Experimental|thrombectomy|mechanical thrombectomy with stentriever Solitaire FR® and/or thromboaspiration with Penumbra System® in patients with large vessel occlusion in cerebral anterior circulation vessels
3344880|NCT02216643|No Intervention|best medical treatment|best medical treatment in patients with acute ischemic stroke with anterior circulation large vessel occlusion
3344881|NCT02216656|Placebo Comparator|Plascebo|
3344882|NCT02216656|Experimental|KHK7580 low dose|
3344883|NCT02216656|Experimental|KHK7580 middle dose|
3344884|NCT02216656|Experimental|KHK7580 high dose|
3344885|NCT02216656|Active Comparator|KRN1493|
3344886|NCT02216669|Experimental|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
3344887|NCT02216708|Experimental|intravenous fluid for rehydration rapidly over 6 hours|intravenous fluid for rehydration rapidly over 6 hours
3344888|NCT02216708|Experimental|receive slow rehydration recommended by WHO (12 hours)|receive intravenous fluid followed by ORS (slow rehydration recommended by WHO) over 12 hours
3344889|NCT02216721||Non primary aldosteronism|Non primary aldosteronism patients undergoing usual anti hypertensive treatment
3344890|NCT02216721||Primary Aldosteronism|Patients with confirmed primary aldosteronism undergoing treatment
3344891|NCT02216734|Experimental|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
3239490|NCT01279928||Type 1 Diabetes Paediatric|Paediatric patients aged 8-18 with diagnosed Diabetes Mellitis Type 1 attending paediatric clinic at John Hunter Hospital.
3239491|NCT01279941|No Intervention|Testing Only|
3239492|NCT01279941|Experimental|Testing & Intervention|
3344892|NCT02216734|No Intervention|Standard of Care Arm|Standard of Care: Nurses may identify HIV+ mothers lost to follow-up (LTFU); village health workers (VHWs) may conduct home visits to reduce LTFU of HIV+ mothers. LTFU activities are not standardised throughout all Ministry of Health and Child Care facilities.
3344893|NCT02216747|Active Comparator|prednisone 60 mg/meter square Body Surface Aera|A - 60 mg Prednisone/meter square Boby Surface Area( 30 twice)/day until there are 3 days of undetected protein in urine and tapering down to 40 mg ,30 mg, 20 mg ,10 mg and 5 mg and end.
3344894|NCT02216747|Active Comparator|prednisone 45 mg/meter square BSA|B- 45 mg prednisone / day until there are 3 days of undetected protein in urine and then 30 mg / day for two weeks and to 30,20,10,5 mg until treatment is ended.
3344895|NCT02216747|Active Comparator|prednisone 30 mg/meter squer BSA|C- treatment of twice daily prednisone 30 mg per day until there are 3 days of undetectible protein in urine and then tapering down to 20 ,10 ,5 until treatment is ended.
3344896|NCT02216760|Active Comparator|Ripple Mapping guided VT ablation|Ripple Mapping (Imperial College) software (Biosense Webster) will be used to identify conduction channels within the ventricular scar substrate to guide ablation lesions in patients with monomorphic VT.
3344897|NCT02216760|Active Comparator|Conventional VT Ablation|Standard substrate ablation as per local operator preference will be used to guide ablation in the ventricular scar in patients with monomorphic VT.
3344898|NCT02216786|Experimental|Fulvestrant and AZD2014 (continuous)|Experimental arm
3344899|NCT02216786|Active Comparator|Everolimus and Fulvestrant|Comparator arm
3344900|NCT02216786|Active Comparator|Fulvestrant|Control 1
3344901|NCT02216786|Experimental|Fulvestrant +AZD2014 (intermittent)|Experimental arm
3375882|NCT03590405|Experimental|uterus transplantation|uterus transplantation from living donor with the donor being close relative
3375883|NCT03585478|Active Comparator|Latiglutenase|IMGX003
3239493|NCT01279967|No Intervention|A|Arm A is control arm with best supportive care.
3239494|NCT01279967|Experimental|B|Arm B is the treatment arm with best supportive care plus ADI-PEG20.
3344902|NCT02216799|Active Comparator|Regular Insulin incorporated in parenteral nutrition|Regular insulin ( Actrapid, 100 unit/mL0 Solution for injection, Insulin Human (rDNA), Novo Nordisk, will be added to parenteral nutrition to run over 24 hours as 80% of the total insulin requirement of the preceding day administered via subcutaneous sliding scale
3344903|NCT02216799|Active Comparator|Insulin glargine|Insulin glargine adminstred at daily night, calculated as 80% of the total insulin requirement of the preceding day from the insulin administered via subcutaneous sliding scale
3344904|NCT02216825|Experimental|Delayed release capsule, L. reuteri NCIMB 30242|
3344905|NCT02216825|Experimental|Standard vegetarian capsule, L. reuteri NCIMB 30242|
3344910|NCT02216877|Placebo Comparator|Placebo|Oral placebo twice daily for 8 weeks. 12 subjects.
3344911|NCT02216877|Experimental|Mablet 360 mg once daily|Oral Mablet 360 mg once daily and oral placebo once daily for 8 weeks. 12 subjects.
3344912|NCT02216877|Experimental|Mablet 360 mg twice daily|Oral Mablet 360 mg twice daily for 8 weeks. 12 subjects.
3344913|NCT02216890|Experimental|SGN-CD70A|
3344914|NCT02216903||Yonsei AF Cohort|Patients with atrial fibrillation who undergoing catheter ablation of atrial fibrillation
3344915|NCT02216916|Experimental|HM781-36B|
3344916|NCT02216942|Active Comparator|Vitapex|Endodontic treatment using Vitapex
3344917|NCT02216942|Experimental|Guedes Pinto Paste|Endodontic treatment using Guedes Pinto
3239495|NCT01279980|Active Comparator|Epidural|Subjects will have an epidural catheter placed to provide postoperative pain relief. This is standard care for those undergoing an enhanced recovery program.
3239496|NCT01279980|Active Comparator|Painbuster|Subjects will have a local anaesthetic wound catheter inserted into the wound at time of surgery rather than an epidural for the provision of postoperative pain relief.
3344918|NCT02216968|Experimental|AA - Increase vegetable intake|"60 African-American (AA) preschool children will participate in the Intervention Group. 60 AA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
3344919|NCT02216968|Experimental|HA - Increase vegetable intake|"60 Hispanic-American (HA) preschool children will participate in the Intervention Group. 60 HA children will belong to the Control Group.~6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
3344920|NCT02216981|Experimental|Intensive Cognitive Behavioural Therapy|Intensive CBT (an average of 12-18 hours of CBT offered in an intensive format, delivered on 2-3 days per week over a period of 3 weeks)
3344921|NCT02216981|Active Comparator|Weekly Cognitive Behavioural Therapy|Weekly CBT (an average of 12-18 hours of CBT delivered in 60-90 minute sessions on a weekly basis)
3344922|NCT02216981|No Intervention|Wait list|Wait list (3 months). Participants randomized to wait list will commence treatment after 3 months, in the treatment condition to which they are re-randomized (either Intensive or Weekly CBT).
3344923|NCT02216994|Other|surgery treatment|The patients with a predicting score of more than 5 are diagnosed with HD, and are performed surgery to remove the aganglionic bowel. The patients with a score less than 5 are mostly indicative of HAD, and receive conservative treatments that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments. one stage pull through procedure to remove the dysganglionic bowel segments.
3239497|NCT01279993|Experimental|Kerato refractive Surgery|
3239498|NCT01280019|Experimental|FRC guided|Patients receive an alveolar recruitment manoeuvre if FRC falls below 94% of baseline FRC
3239499|NCT01280019|Active Comparator|Saturation guided|Patients receive an alveolar recruitment manoeuvre if peripheral oxygen saturation falls below 90%
3239500|NCT01280032|Experimental|Kypho-IORT|
3239501|NCT01280045|Experimental|AROMATASE INHIBITOR|this would be compared before and after VAGINAL HYSTERECTOMY
3239502|NCT01280045|Active Comparator|GNRH ANALOG|this would be compared before and after VAGINAL HYSTERECTOMY
3239503|NCT01280071|Experimental|dipyridamole, aminophylline|
3239504|NCT01280084||No labour analgesia/nitrous oxide|Women who use no analgesia during labour or who only used nitrous oxide.
3239505|NCT01280084||Systemic opioids|Women who receive only systemic opioids for analgesia during, either intravenously or intramuscularly
3239506|NCT01280084||Intermediate dose epidural fentanyl|Women who receive a total epidural fentanyl dose less than 150 micrograms
3239507|NCT01280084||High dose epidural fentanyl|Women who receive a total epidural fentanyl dose more than 150 micrograms
3239508|NCT01280097||Prospective cohort study|Observational only
3259260|NCT01469247|Experimental|Radiation Therapy|Starting dose of 24 Gray (Gy) in 2 Gy fractions.
3239509|NCT01280136|Experimental|It's Your Game Tech|An interactive web-based HIV, sexually transmitted infection (STI), and pregnancy prevention program for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
3344924|NCT02217007|Experimental|SNC-102 sustained release tablet|SNC-102 oral tablet 4 weeks at 800mg BID plus 4 weeks at 1600mg in the morning and 800mg in the evening
3344925|NCT02217020|Experimental|FOLFOXIRI|patients received FOLFOXIRI alone for 4 cycles before surgery.
3344926|NCT02217033|Placebo Comparator|Purified Water|"In this arm, eligible subjects will begin to consume purified water (placebo) just prior to the 1st cycle of chemotherapy. Subjects will continue to consume the placebo through their chemotherapy and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume placebo for a minimum of 168 days."
3344927|NCT02217033|Experimental|'R' (Electro-kinetically altered beverage)|"Patients randomized to this arm will begin to consume R (Electro-kinetically altered beverage) just prior to the 1st cycle of chemotherapy and continue it through their chemotherapy cycles and then for an additional 12 weeks after completing chemotherapy.~Subjects will consume a specific volume based on the following weight categories: <150 lb = 2 bottles/day; ≥150 lb and <225 lb = 3 bottles/day; ≥225 lb = 4 bottles/day. Subjects will consume R for a minimum of 168 days."
3344928|NCT02217046|Experimental|device replacement|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
3344929|NCT02217046|No Intervention|control group|remove previously inserted cardiac device and the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
3344930|NCT02217059||Prehypertension|Using the JNC7 definition
3344931|NCT02217059||Stage I Hypertension|Using the JNC7 definition
3344932|NCT02217059||Stage II Hypertension|Using the JNC7 definition
3344933|NCT02217072|No Intervention|Control|Control
3344934|NCT02217072|Experimental|Parents as Tutors|Educational support intervention
3344935|NCT02217072|Experimental|school intervention|Educational support intervention
3344936|NCT02217098|Active Comparator|GIC Restorations|Restorations using Glass Ionomer Cement
3344937|NCT02217098|Experimental|Compomer Restorations|Restorations using Compomer
3344938|NCT02217098|Experimental|Carbomer Restorations|Restorations using Glass Carbomer
3344939|NCT02217111|Experimental|voice therapy|
3344940|NCT02217124|Experimental|Apple group|twenty four participants will be randomly selected for the apple group, in which they will receive 37.5 grams equal to 120kcal of dried apples twice a day for eight weeks. This snack of apples will be eaten once between breakfast and lunch and once between lunch and dinner and both will be consumed with an eight ounce bottle of water.
3344941|NCT02217124|Placebo Comparator|Muffin control|twenty four participants will be randomly selected to make up the muffin control group, in which one 120kcal muffin control snack will be consumed twice each day for eight weeks. The muffin control will be consumed one between breakfast and lunch and one between lunch and dinner, each snack will be consumed with an eight ounce bottled water.
3344942|NCT02217150||Metastatic Lesions to the spine|Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
3239510|NCT01280149|Experimental|substance P-low dose allergen|Substance P injections with 8 sequential, increasing doses of allergen
3239511|NCT01280149|Experimental|substance P-moderate dose allergen|Substance P with sequential, increasing doses of allergen
3344943|NCT02217163|Experimental|Single Arm|The combination therapy of Carfilzomib, cyclophosphamide and dexamethasone (KCyd) will be used to treat eligible patients for up to 6 cycles.This will be followed by an autologous bone marrow transplantation and 2 further consolidation cycles of KCyd. Depending on their disease response, patients will be managed expectantly or be started on maintenance.
3344944|NCT02217176||endotracheal intubation|
3344945|NCT02217176||laryngeal mask airway|
3344946|NCT02217189|Experimental|Zinc sulfate|60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
3344947|NCT02217189|No Intervention|Healthy control|60 fertile (age 31.6±3.3 year) men, no treatment.
3344948|NCT02217202|Experimental|ConvaTec Ag|Use of ConvaTec Ag sugical cover dressing post-operatively until wound has healed.
3344949|NCT02217215||Negative and Referral Cytology Results|CNDS Advanced Cervical Scan Colposcopy
3344950|NCT02217228|Experimental|Sebacia microparticles and laser|Gold microparticle suspension + laser treatment x 3 over the course of two weeks
3344951|NCT02217228|Experimental|Vehicle suspension and laser|Vehicle suspension + laser treatment x 3 over the course of two weeks
3344952|NCT02217228|Experimental|Sebacia microparticles without laser|Gold microparticle suspension treatment x 3 over the course of two weeks
3344953|NCT02217241|Experimental|Intervention|Students in the intervention group participated in a one-hour interactive, small-group handoff workshop facilitated by a study investigator. The workshop focused on the importance of specific handoff skills to patient safety.
3344954|NCT02217241|No Intervention|Control|
3344955|NCT02217254|Active Comparator|two 3-minute cryoablations|two 3-minute cryoablations per pulmonary vein during an atrial fibrillation ablation procedure
3344956|NCT02217254|Active Comparator|One 3-minute cryoablation|One 3-minute cryoablation per pulmonary vein during an atrial fibrillation ablation procedure
3344957|NCT02217267|Placebo Comparator|Placebo group|Normal Saline 50 ml intravenous infusion in 1 hour once a week 4 times
3344958|NCT02217267|Active Comparator|Lidocaine group|Lidocaine 3mg/kg in Normal Saline to 50 ml intravenous infusion in 1 hour once a week 4 times
3375884|NCT03585478|Placebo Comparator|Placebo|Placebo
3344959|NCT02217293|Active Comparator|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury
3344960|NCT02217293|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
3344961|NCT02217306||Contrast Sensitivity|Determine changes in contrast sensitivity frequences and visual function (visual acuity) after one month of treatment photocoagulation in macular edema
3344962|NCT02217319|Active Comparator|Sevoflurane|Patients receive Sevoflurane 1 MAC (minimal alveolar concentration) after induction of anesthesia with propofol, remifentanil and atracurium for 30 minutes as preconditioning.
3344963|NCT02217319|Placebo Comparator|TIVA|Patients received the standard total intravenous anesthesia (TIVA) with propofol, remifentanil and atracurium.
3344964|NCT02217358|Experimental|NBI endoscopy|150 patients with suspected lesion in larynx and hypopharynx on standard ENT white light endoscopy examination will undergo NBI endoscopy in order to compare the outcomes of these two examination methods
3344965|NCT02217371|Experimental|ADHD patient|
3344966|NCT02217371|Active Comparator|Healthy volunteers|
3344967|NCT02217397|Experimental|OA, CPAPm, combination therapy|
3344968|NCT02217423|Experimental|Obstructive increased AC|"Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
3344969|NCT02217423|Experimental|Obstructive disfunction with normal AC|"Patients with obstructive respiratory disease with normal abdominal circumference.~Patient with obstructive respiratory disease with increased abdominal circumference.~chest physiotherapy. Chest physiotherapy airway clearance modality. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest wall (compression, vibration) and cough."
3344970|NCT02217423|Experimental|Restrictive increased AC|"Patients with restrictive respiratory disease with increased abdominal circumference. chest physiotherapy chest wall expansion.~The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
3344971|NCT02217423|Experimental|Restrictive disfunction with normal AC|"Patients with restrictive respiratory disease with normal abdominal circumference.~Chest physiotherapy chest wall expansion. The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression) and incentive spirometry."
3344972|NCT02217449||HD|Prediction of histology
3344973|NCT02217449||Virtual Chromoendoscopy|Prediction of histology
3344974|NCT02217462||Pregnant women|
3344975|NCT02217488|Experimental|DG3173|
3344976|NCT02217488|Placebo Comparator|Vehicle|
3344977|NCT02217514|Experimental|Treatment sequence 1 in male subjects|Midazolam alone and 1 h after low dose BI44370BS in male subjects
3344978|NCT02217514|Experimental|Treatment sequence 1 in female subjects|Midazolam alone and 1 h after low dose BI44370BS followed by medium dose BI 44370 in an additional visit in female subjects
3344979|NCT02217514|Experimental|Treatment sequence 2|Midazolam before and 48 h after high dose BI44370BS
3344980|NCT02217514|Experimental|Treatment sequence 3|Midazolam before and 24 h after high dose BI44370BS
3344981|NCT02217514|Experimental|Treatment sequence 4|Midazolam before and 1 h after high dose BI44370BS
3344982|NCT02217540|Experimental|Experimental Group|Experimental Group consist of the physiotherapy standard protocol and active movement plus accessory mobilizations of the humeral head using Mulligan Concept Mobilisation with Movement.
3344983|NCT02217540|Active Comparator|Control Group|Standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
3344984|NCT02217553|Experimental|vitamin D (cholecalciferol)|All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
3344985|NCT02217579|Placebo Comparator|Control|Isocaloric food without the test protein and prebiotic fiber.
3344986|NCT02217579|Experimental|Protein|Dietary protein consumed as two daily servings of 5 grams protein/serving.
3344987|NCT02217579|Experimental|Fiber|Prebiotic fiber consumed as two daily servings of 8 grams protein/serving.
3344988|NCT02217579|Experimental|Protein plus prebiotic fiber|Protein and prebiotic fiber consumed as two daily servings of 5 grams protein/serving plus 8 grams fiber/serving.
3344989|NCT02217605|Experimental|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) followed by 75 minutes 31P MRS
3344990|NCT02217631|Experimental|BI 653048 BS H3PO4|dose escalation
3344991|NCT02217631|Active Comparator|Prednisolone low dose|
3344992|NCT02217631|Active Comparator|Prednisolone high dose|
3344993|NCT02217631|Placebo Comparator|Placebo|
3344994|NCT02217644|Experimental|BI 653048 H3PO4 solution|single rising doses
3344995|NCT02217644|Experimental|BI 653048 H3PO4 low dose capsule|
3344996|NCT02217644|Experimental|BI 653048 H3PO4 high dose capsule|
3344997|NCT02217644|Placebo Comparator|Placebo|
3344998|NCT02217657|Active Comparator|operator informed to contact force|Thermocool Smart Touch Catheter, operator informed to contact force (Biosense Webster)
3344999|NCT02217657|Experimental|operator blinded to contact force|Thermocool Smart Touch catheter, operator blinded to contact force information (Biosense Webster)
3345000|NCT02217670|Experimental|Metformin (test)|single oral dose of Metformin 1000 mg granules
3345001|NCT02217670|Active Comparator|Metformin (reference)|Single dose of Glucophage 1000 mg film-coated tablet
3345002|NCT02217683|No Intervention|Young blood transfusion|The first group of patients (n=30) will be randomized to receive leukoreduced blood transfusion stored for less than 10 days
3345003|NCT02217683|No Intervention|Old blood transfusion|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days
3345004|NCT02217683|Active Comparator|Old blood transfusion and Nitric Oxide|This randomized group of patients (n=30) will receive leukoreduced blood transfusion stored for more than 30 days while breathing nitric oxide (80 part per million) and oxygen
3345005|NCT02217696|Experimental|Computerized reading training first|Cross-over design: group first receives the intervention
3345006|NCT02217696|Experimental|Waiting Control First|Cross-over design: group first serves as waiting control
3345007|NCT02217709|Experimental|Treatment (phenelzine sulfate)|Patients receive phenelzine sulfate 30 mg by mouth (PO) twice daily (BID) (starting dose of 15 mg daily escalated to 30 mg BID over 16 plus or minus 5 days). Patients who have been treated at 30 mg BID for over 3 cycles with resolution of any and all toxicities to grade < or = 1 may increase the dose to a maximum of 45 mg BID at the discretion of the treating investigator. Treatment may continue in the absence of disease progression or unacceptable toxicity.
3345008|NCT02217722|Experimental|Ulcerative Colitis Diet counseling|Patients will receive a structured novel diet termed the UCD for 6 weeks. . patients that completed induction phase with remission(PUCAI<10) will be asked if they are willing to adhere to the UCD for an additional 20 weeks.
3345009|NCT02217722|Experimental|Antibiotic Treatment|Patients failing to enter or maintain remission by 6 weeks, or with worsening disease at any time after week 2 will be considered failures on an intention to treat basis. Eligible patients at this time at aged 10 or above may receive a 14 day antibiotic course with Doxycycline, amoxicillin and metronidazole.In addition to the description above children who refused to UCD or with low adherence to UCD may be enrolled directly to this arm.
3345010|NCT02217735|Experimental|Writing Intervention - Expressive Arm|Participants are asked to write about the most traumatic or stressful experience of their entire lives in three, 20 minute writing sessions.
3345011|NCT02217735|Active Comparator|Writing Intervention - Neutral Arm|Participants are asked to write about what they did the day before, refraining from including emotional details.
3345012|NCT02217748|Experimental|Survey questionnaire version 1|Name generator order: leisure, money, support
3345013|NCT02217748|Experimental|Survey questionnaire version 2|Name generator order: leisure, support, money
3345014|NCT02217748|Experimental|Survey questionnaire version 3|Name generator order: money, leisure, support
3345015|NCT02217748|Experimental|Survey questionnaire version 4|Name generator order: money, support, leisure
3345016|NCT02217748|Experimental|Survey questionnaire version 5|Name generator order: support, leisure, money
3345017|NCT02217748|Experimental|Survey questionnaire version 6|Name generator order: support, money, leisure
3345018|NCT02217774|Experimental|MGUIDE assisted implant placement|Implant placement, using MGUIDE MORE system for implant planning and placement
3345019|NCT02217787|Other|fasted condition|
3345020|NCT02217787|Other|fed condition|
3239512|NCT01280149|Experimental|substance P-low/moderate dose allergen|substance P with 16 sequential increasing doses of allergen
3239513|NCT01280149|Active Comparator|substance P-placebo|Placebo injections of substance P and placebo
3239514|NCT01280149|Experimental|placebo-low dose allergen|Placebo injections with 8 sequential increasing low dose allergen injections
3345021|NCT02217813|Experimental|1. Tafamidis|
3345022|NCT02217813|Experimental|2. Tafamidis|
3345023|NCT02217826|Experimental|DG3173|
3345024|NCT02217826|Placebo Comparator|Saline|
3239515|NCT01280149|Placebo Comparator|placebo-placebo|substance P placebo and allergen placebo (weekly)
3345025|NCT02217826|Active Comparator|Octreotide|
3345026|NCT02217839|Experimental|DG3173|
3345027|NCT02217839|Experimental|DG3173+Octreotide|
3345028|NCT02217852|Experimental|A1 nitrendipine|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and nitrendipine will be added (dose range 10mg-20mg bid).
3345029|NCT02217852|Experimental|A2 hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 140/90mmHg but lower than 160/100mmHg and hydrochlorothiazide will be added (dose range 12.5mg-25mg)
3345030|NCT02217852|Experimental|B1 captopril plus Hydrochlorothiazide|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and captopril plus Hydrochlorothiazide will be added (dose range：captopril 25mg-50mg tid, Hydrochlorothiazide 12.5mg-25mg qd).
3239516|NCT01280162|Experimental|3 day therapy|Total dose split over 3 days (3 tablets per day)
3239517|NCT01280162|Experimental|2 day therapy|Total dose split over 2 days (4.5 tablets per day)
3239518|NCT01280175|Experimental|pMDI + charcoal block|BDP/formoterol 100/6 µg pMDI with charcoal ingestion
3239519|NCT01280175|Experimental|pMDI + Aerochamber Plus|BDP/formoterol 100/6 µg with Aerochamber Plus
3239520|NCT01280175|Active Comparator|pMDI|BDP/formoterol 100/g µg pMDI
3345031|NCT02217852|Experimental|B2 Beijing hypotensive No.0|this arm will include Tibetan patients with hypertension whose BP is higher than 160/100mmHg and Beijing hypotensive will be added (dose range：Beijing hypotensive No.0 one pile qd or less ).
3345032|NCT02217865||Colorectal Cancer Participants|Colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
3345033|NCT02217865||Caregivers of Colorectal Cancer Participants|Caregivers of colorectal cancer participants undergoing follow-up after curative resection of colorectal cancer.
3345034|NCT02217891||participants from existing MSK protocol 12-245|"Participants' responses regarding the benefits and harms of incidental findings arising from tumor genomic profiling will be used to generate novel questionnaire items to assess the construct of perceived personal and clinical utility, which will be tested, along with items designed to assess knowledge about tumor genomic profiling and incidental findings.~Part 2, the investigators will conduct 30-minute cognitive interviews to assess participants' understanding and opinions about the novel items designed to assess perceived personal and clinical utility of incidental findings and knowledge about incidental findings arising from tumor genomic profiling."
3345035|NCT02217917|Experimental|Cohort 1|Single ascending dose in 3 period cross-over design (with optional 4th period)
3345036|NCT02217917|Experimental|Cohort 2|Multiple ascending dose
3345037|NCT02217917|Experimental|Cohort 3|Multiple ascending dose
3345038|NCT02217930|Placebo Comparator|Placebo|"Placebo matched to WCK 2349, oral tablet(s)~Placebo matched to moxifloxacin overencapsulated tablet"
3345039|NCT02217930|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg positive control (overencapsulated tablet)
3345040|NCT02217930|Experimental|WCK 2349|WCK 2349 supratherapeutic dose determined in Part 1, oral tablet(s)
3345041|NCT02217943|Active Comparator|Roux-en-Y gastric bypass|Subjects who receive a Roux-en-Y gastric bypass
3345042|NCT02217943|Active Comparator|Sleeve Gastrectomy|Subjects who receive a sleeve gastrectomy
3345043|NCT02217956|Experimental|HCIP + bevacizumab|"4 dose level of cisplatin are planned: Level 1 : 50 mg/m2 (start level) Level 2 : 60 mg/m2 Level 3 : 70 mg/m2 Level 4 : 80 mg/m2 Level -1: 40 mg/m2 (in case of DLT at level 1)~bevacizumab: Treatment starts between week 10 and 14 after HCIP. Dosage: 15 mg/kg for a total of 22 injections every 3 weeks for 15 months"
3345044|NCT02217969|Experimental|Electronic alert to SLUScore increase|Patients whose anesthesia care team members are receiving alerts to increments in their SLUScore (progressive hypotensive exposures) are anticipated to be given interventions aimed at minimizing further hypotensive exposures. The decision of whether or not to intervene as well as the type(s) of interventions will be at the sole discretion of the patient's anesthesia care team
3345045|NCT02217969|No Intervention|Control (no alert)|Routine anesthesia care at the discretion of the anesthesia care team
3345046|NCT02217995|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|MBCT will be delivered in ten 2.5 hour group sessions with 15 participants per group.
3345047|NCT02217995|No Intervention|Waitlist|Wait list as per usual.
3345048|NCT02218021|Experimental|Samidorphan Dose 1|
3345049|NCT02218021|Experimental|Samidorphan Dose 2|
3345050|NCT02218021|Experimental|Samidorphan Dose 3|
3345051|NCT02218021|Placebo Comparator|Placebo|
3345052|NCT02218021|Active Comparator|Oxycodone Dose 1|
3345053|NCT02218021|Active Comparator|Oxycodone Dose 2|
3345054|NCT02218034|Experimental|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3345055|NCT02218034|Experimental|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3345056|NCT02218034|Active Comparator|TAZORAC® Gel 0.1%|TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3345057|NCT02218034|Active Comparator|TAZORAC® Cream 0.1%|TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
3345058|NCT02218047|Active Comparator|Best available therapy (BAT)|Best available therapy, as chosen by the investigator for patients who had been on HU in the 1 Year PROUD-PV study
3239521|NCT01280188|Experimental|Desmopressin|Day 1 - participants continue desmopressin intranasal. Day 2 up to Day 4 - Desmopressin oral melt to optimum dose. Continue optimum dose for the four week treatment and one year follow-up periods.
3239522|NCT01280214|Experimental|Triamcinolone|
3239523|NCT01280227|Experimental|1|Patients uses the symptom assessment tool SiSom. A summary of their reported symptoms are printed out and given to the pediatrician and nurse before the consultation. The consultation is videotaped.
3345059|NCT02218047|Experimental|Pegylated-Proline-interferon alpha-2b|AOP2014 for those patients who had been on AOP2014 in the PROUD-PV study
3345060|NCT02218060|Experimental|Force|Patients receiving coronary CT angiography on the SOMATOM Force before clinically indicated cardiac catheterization or after clinically indicated nuclear stress test
3345061|NCT02218060|Other|Control|Patients who have already received comparable CT examinations on current routine 2nd generation dual-source CT systems
3345062|NCT02218073|Experimental|Treatment Sequence AB|Participants will receive 10 milligram (mg) JNJ-42756493 tablet orally on Day 1 of Period 1 and 100 microgram (mcg) of JNJ-61818549 as intravenous injection 2 hours after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 2.
3239524|NCT01280227|No Intervention|2|"The control group do not use the symptom assessment tool SiSom before the consultation. The control group receives usual care and the consultation is videoptaped."
3345063|NCT02218073|Experimental|Treatment Sequence BA|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection after the intake of 10 mg JNJ-42756493 oral solution on Day 1 of Period 1 and JNJ-42756493 10 mg tablet orally on Day 1 of Period 2.
3345064|NCT02218086|Experimental|professionals|balancing on the slackline / wobbling board 3 times by 30 seconds balancing on the slackline with a fix visual anchor / moving visual anchor 3 times by 30 seconds
3345065|NCT02218086|Experimental|beginners|balancing on the slackline / wobbling board 3 times by 30 seconds pre-training compared to post-training
3345066|NCT02218099|Experimental|1: Single dose of ASP8232|Subjects receive a single oral dose of ASP8232
3239525|NCT01280240|Active Comparator|Monofer 500 mg|
3239526|NCT01280240|Active Comparator|Monofer 250 mg|
3259261|NCT01469260|No Intervention|Routine care|ACOG Exercise in Pregnancy pamphlet
3345067|NCT02218099|Experimental|2: Multiple doses of ASP8232 or placebo|Subjects receive multiple oral doses of ASP8232 or placebo
3345068|NCT02218112||OB - Bariatric surgery (gastric bypass)|Obese patients who will undergo a bariatric surgery (gastric bypass)
3345069|NCT02218112||OB- Control group|Obese patients who will not undergo surgery - Control group
3345070|NCT02218125|Experimental|Group 1- MVA Mosaic|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
3345071|NCT02218125|Placebo Comparator|Group 2 - Placebo|Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
3345072|NCT02218125|Experimental|Group 3 - MVA Mosaic|Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
3345073|NCT02218125|Placebo Comparator|Group 4- Placebo|Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
3345074|NCT02218138|Experimental|Learning 2 BREATHE|Learning 2 BREATHE, Mindfulness-based group program
3345075|NCT02218138|Experimental|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
3345076|NCT02218151|Experimental|Patient-Centered Medical Home (PCMH)|"Day-to-Day Care:~Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
3345077|NCT02218151|Active Comparator|Standard Care|"These subjects will begin as inpatients or outpatients, where advanced practice providers (APPs) (nurse practitioners and physician assistants) will perform histories and physical exams. Nurses will collect labs and providers will enter orders in our electronic health record (EHR). All steps will be repeated daily until discharge to home. Suitability for discharge is determined by standard clinical criteria including stable blood counts, freedom from active or severe complications (e.g. active infection, severe GVHD), and ability to care for self.~Caregivers: identified by the subject as the person taking primary care of them will answer surveys and also collect stool samples to analyze in conjunction with those from subjects."
3345078|NCT02218177||Non-responders receiving aflibercept therapy|Non-responders to ranibizumab who are now receiving aflibercept therapy
3345079|NCT02218177||Non-responders receiving PDT combo therapy|patients who are non-responders to ranibizumab who have been switched to combination photodynamic therapy (PDT)
3345080|NCT02218177||Responders to ranibizumab|Patients who are responders to ranibizumab and are continuing monthly injections.
3345081|NCT02218229|Experimental|Shock waves|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
3345082|NCT02218229|No Intervention|Night splint|The wrist night splint was firmly fixed in a neutral position to immobilize the affected wrist. Patients were ordered to wear the splint while resting at night and at least 8 hours per day during the period of study
3345083|NCT02218255|Active Comparator|Day 3 eSET combined with Eeva|Traditional Morphology + Eeva™ results
3345084|NCT02218255|Active Comparator|Day 5 eSET combined with Eeva|Traditional Morphology + Eeva™ results
3345085|NCT02218255|No Intervention|Day 5 eSET with Traditonal Morphology|
3239527|NCT01280279||group with nocturnal polyuria and nocturia|Patients were enrolled when they had the urine volume at nighttime more than one third of total daily urine volume (NPU) and voided more than two times at nighttime (nocturia)
3345086|NCT02218281|Experimental|C2Q-Teen app|Smoking cessation treatment delivered through a smartphone app via mindfulness training.
3345087|NCT02218281|Active Comparator|NCI's QuitSTART app|Smoking cessation treatment delivered through a smartphone app by NCI, without mindfulness training.
3239528|NCT01280305|Experimental|raloxifene|
3239529|NCT01280305|Placebo Comparator|Placebo|
3345088|NCT02218281|Active Comparator|Written smoking cessation materials only|Receipt of written smoking cessation materials.
3345089|NCT02218294|Experimental|[14C] BCX4161|Includes a radiolabelled dose of [14C] BCX4161 and unlabelled BCX4161
3345090|NCT02218333|Placebo Comparator|Control drink|An isocaloric drink to milk
3239530|NCT01280318|Other|1|patients with operable head and neck squamous cell carcinoma
3345091|NCT02218333|Experimental|Milk|Protein enriched milk (Styrk)
3345092|NCT02218346|Active Comparator|Treatment A (unfed)|Treatment A: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, following a 10-hour overnight fast.
3345093|NCT02218346|Active Comparator|Treatment B (fed)|Treatment B: Single oral dose of AG-221 mesylate at Hour 0 on Day 1, 30 minutes after the start of a high-fat breakfast.
3345094|NCT02218359|Experimental|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin to be administered by aerosol via the AFIS Inline System.
3345095|NCT02218359|Placebo Comparator|Aerosolized Placebo|Aerosolized placebo to be administered by aerosol using the AFIS Inline System.
3239531|NCT01280318|Other|2|patients treated by neck ansd head surgery for a non-oncological disease
3239532|NCT01280318|Experimental|3|patients treated before surgery with 3 doses of neoadjuvant cetuximab
3239533|NCT01280331|Experimental|Q8003 12 mg/8 mg|Combination
3239534|NCT01280331|Active Comparator|Morphine sulfate 24 mg|Single component
3239535|NCT01280331|Active Comparator|Oxycodone HCl 16 mg|Single component
3239536|NCT01280344|Experimental|0.03 mg/kg BID|Ipamorelin 0.03 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
3239537|NCT01280344|Experimental|0.06 mg/kg BID|Ipamorelin 0.06 mg/kg, BID (2 investigational drug infusions and 1 placebo infusion)
3239538|NCT01280344|Experimental|0.06 mg/kg TID|Ipamorelin 0.06 mg/kg, TID (3 investigational drug infusions)
3239539|NCT01280344|Placebo Comparator|Placebo|Matching placebo, TID (3 placebo infusions)
3239540|NCT01280370||1|1.patients treated in a laparoscopic manner
3239541|NCT01280370||2.|2. patients treated in open operative manner
3239542|NCT01280383|Experimental|non-invasive NAVA|application of non-invasive NAVA in critically ill patients
3239543|NCT01280396||SGAs|patients receiving SGAs
3239544|NCT01280448||Case Group|
3239545|NCT01280448||Control Group|
3239546|NCT01280461||Experimental Group|
3239547|NCT01280461||Control Group|
3239548|NCT01280487|Experimental|Oral ZSTK474|Daily oral dosing for 21 days per cycle
3239549|NCT01280500|Placebo Comparator|Group A - Usual Care Controls|Group A will consist of 20 primary care clinics who are part of the Carolinas Healthcare System network but have not yet adopted the Electronic Medical Record System. These practices do use the same billing databases as the remaining clinics, allowing easy identification of asthma patients and their health services utilization patterns. Data from the billing systems will be used to retrospectively populate a database for these clinics from January 2009 forward.
3345096|NCT02218385||ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
3239550|NCT01280500|Active Comparator|Group B - EMR Control Practices|There are currently 65 primary care practices within the Carolinas Healthcare System network that have electronic medical record with decision support (EAP)access at baseline. These practices will serve as a second level of control for comparison with the intervention groups. Each of these practices is currently using Cerner PowerChart and at the start of the study and will have access to the asthma decision support tools; an electronically generated Asthma Action Plan (AAP); and a built-in system of population management reports which will be pushed to the practices on an on-going basis to help in patient recall and management. The EAP approach to care has been developed with input from clinicians, hospital administrators, hospital information services personnel, and Cerner consultants.
3239551|NCT01280500|Active Comparator|C Integrated Approach to Care|There are 10 practices within the Carolinas Healthcare System (CHS) network that have already received additional training for improving outcomes for patients with chronic diseases termed the Integrated Approach to Care (IAC). This IAC approach developed by CHS is based on the Chronic Care Model (CCM). The IAC approach includes a heavy emphasis on the use of health information technology that practices receive during the initial EAP rollout.
3239552|NCT01280500|Active Comparator|Group D - Shared Decision Making (SDM)|This approach has great potential for improved patient outcomes and provides an additional step in the successful implementation of patient self-management. The research team will develop the SDM intervention during the first 6 months of the study. In particular, the Shared decision making (SDM) intervention will be designed to be deployed within the 4 large clinics that care for the majority of the community's underserved and disadvantaged patients. The SDM intervention development will be overseen by the study advisory board and actively recruit providers from within the clinics for feedback about the intervention.
3239553|NCT01280500|Active Comparator|School Based Care (SBC)|Activities included: spending individual time with students to assess, treat, and monitor and to educate students in proper asthma management; facilitate access to health care and medicine; and communicate with parents.
3239554|NCT01280513|Experimental|High Protein intake|
3239555|NCT01280513|Experimental|Low Protein intake|
3239556|NCT01280526|Experimental|Romidepsin dose 10mg/m²|Romidepsin dose 10mg/m²
3239557|NCT01280526|Experimental|Romidepsin dose 12mg/m²|Romidepsin dose 12mg/m²
3239558|NCT01280526|Experimental|Romidepsin dose 14mg/m²|Romidepsin dose 14mg/m²
3345097|NCT02218398|Experimental|Bronchodilator|Albuterol 3-4 times per day, steroids when necessary.
3345098|NCT02218398|No Intervention|No drug|No drug
3345099|NCT02218411|Experimental|Exercise|Exercises routine based on the Otago exercise programme
3345100|NCT02218437|Experimental|MSC+ATG|The first agent MSC injection, began two weeks after ATG application; Each patient was injected three times, one time per week; Study on single dose tolerance and efficacy index; Each subjects received three dose groups of treatment.
3345101|NCT02218476|Other|APS Patient|
3239559|NCT01280526|Experimental|Romidepsin dose 8mg/m²|Romidepsin dose 8mg/m²
3239560|NCT01280539|Experimental|TENS|Transcutaneous electrical nerve stimulation will be applied on the impaired hand
3239561|NCT01280539|Sham Comparator|Sham TENS|Sham TENS will be applied to the impaired hand
3239562|NCT01280565|Experimental|Masitinib|Participants receive masitinib (7.5 mg/kg/day), given orally twice daily.
3239563|NCT01280565|Active Comparator|Dacarbazine|Participants receive dacarbazine, given via IV bolus at 1,000 mg/m2 once every 3 weeks. Following a protocol amendment, the dacarbarzine treatment group has been closed
3239564|NCT01280669|Experimental|Group 1|Intravitreal injections of 440mcg sirolimus (low-dose monthly group)
3239565|NCT01280669|Experimental|Group 2|Intravitreal injections of 880mcg sirolimus (high-dose every other month group)
3239566|NCT01280682|Experimental|rituximab|
3345102|NCT02218502|Other|If simple rules are conclusive|All patients included will undergo an ultrasound scan in which both the RMI and simple ultrasound-based rules are applied. This scan will take place in the hospital of inclusion. For 80% of all patients, this will be the only intervention.
3239567|NCT01280708||Capture data|
3239568|NCT01280734|Active Comparator|Melatonin|Circadin(R) 2 mg tablet 2 hours at 23:00
3239569|NCT01280734|Active Comparator|Zolpidem|Stilnox (R) 10 mg tablet at 23:00
3239570|NCT01280734|Placebo Comparator|Placebo|
3239571|NCT01280747||1|Eligible fibromyalgia patients receive usual care with pregabalin prior authorization requirements in place
3239572|NCT01280747||2|Eligible fibromyalgia patients receive usual care without pregabalin prior authorization requirements in place
3239573|NCT01280747||3|Eligible painful diabetic peripheral neuropathy patients receive usual care with pregabalin prior authorization requirements in place
3239574|NCT01280747||4|Eligible painful diabetic peripheral neuropathy patients receive usual care without pregabalin prior authorization requirements in place
3239575|NCT01280760||Non invasive ventilation|Non-invasive ventilation after invasive mechanical ventilation weaning
3239576|NCT01280773|No Intervention|PSV weaning|Patinens in the PSV group will be weaned using PSV mode.
3239577|NCT01280773|Experimental|NAVA weaning|Patients in NAVA group will eb weaned using NAVA mode.
3239578|NCT01280786|Experimental|Elesclomol Sodium|
3239579|NCT01280799|Experimental|Active Treatment|
3239580|NCT01280825||Adult Patients|Adults receiving health care at the University of Chicago Medical Center.
3259262|NCT01469260|Experimental|Pedometer|ACOG Exercise in Pregnancy pamphlet, pedometer use, ultimate goal of 10,000 steps per day
3259263|NCT01469273|No Intervention|Control group|Only observation; observation period: 1 year.
3345103|NCT02218502|Other|If simple rules are inconclusive|If the simple ultrasound-based rules, used in the first ultrasound scan, yield an inconclusive result (approx. 20% of all patients), patients are refered to the center hospital to undergo a second ultrasound (by an expert) and a DW-MRI scan. Furthermore, these group of patients will be asked to give an extra blood sample in order to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
3345104|NCT02218515|Other|Open Flap Debridement|Open Flap Debridement (Control Group)
3345105|NCT02218515|Experimental|Enamel Matrix Derivative|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)
3345106|NCT02218515|Experimental|Enamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
3345107|NCT02218528|Placebo Comparator|Starchy meal|No Plant-based ingredient added to a starchy meal
3345108|NCT02218528|Active Comparator|Low dose added to starchy meal|Plant-based ingredient in low dose added to starchy meal
3345109|NCT02218528|Placebo Comparator|Starchy meal and side dish|No Plant-based ingredient added to starchy meal and side dish
3345110|NCT02218528|Active Comparator|Low dose added to starchy meal and side dish|Plant-based ingredient in low dose added to starchy meal and side dish
3345111|NCT02218528|Active Comparator|Medium dose added to starchy meal and side dish|Plant-based ingredient in medium dose added to starchy meal and side dish
3239581|NCT01280838|Experimental|Theory-based behavioral intervention|Participants in this arm will receive a single-session, theory-based intervention (Hombre Seguro) at baseline that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and Motivational Interviewing (MI) to increase clients' use of condoms with FSWs. The intervention lasts approximately 45 minutes.
3239582|NCT01280838|Active Comparator|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
3239583|NCT01280864||Interstitial Cystitis Alone|
3239584|NCT01280864||Irritable Bowel Syndrome Alone|
3345112|NCT02218528|Active Comparator|High dose added to starchy meal and side dish|Plant-based ingredient in high dose added to starchy meal and side dish
3345113|NCT02218554|Experimental|Study Group|Subject has been diagnosed with BRONJ
3345114|NCT02218554|No Intervention|Control Group|Subject has not developed any signs or symptoms of BRONJ
3345115|NCT02218567|Other|Patients|
3345116|NCT02218567|Other|Caregivers|
3345117|NCT02218580|Experimental|Massage therapy & standard care|"Massage therapy will be provided by caregiver for 15 minutes at bedtime at home, every night, for a 2-week period.~Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen."
3345118|NCT02218580|Active Comparator|Standard care|Standard care will include medications routinely prescribed in the treatment of JIA, physiotherapy and occupational therapy exercises, splints, warmth application and acetaminophen.
3345119|NCT02218593|Experimental|WREX orthosis|WREX Orthosis
3345120|NCT02218606|Experimental|Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID|Arm 1: Abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
3345121|NCT02218606|Experimental|Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily|Arm 2: Cabazitaxel 25 mg/m2 IV + abiraterone acetate 1000 mg po daily + prednisone 5 mg po BID
3345122|NCT02218619|Experimental|Taurourodeoxycholic Acid (TUDCA)|TUDCA 1750 mg/day x 12 months
3345123|NCT02218619|Placebo Comparator|Sugar pill (placebo)|Placebo at same dose, frequency, and duration as experimental treatment
3345124|NCT02218632|Active Comparator|lactose-free diet|lactose-free diet (standard therapy) vs. lactose-free diet plus temporary oral galactose supplements
3345125|NCT02218632|Active Comparator|lactose free diet|lactose-free diet (standard therapy)
3345126|NCT02218645|Experimental|WE 941 OD|
3345127|NCT02218645|Active Comparator|Brotizolam|
3239585|NCT01280864||Healthy Controls|
3239586|NCT01280877|Experimental|Verum stimulation|Complete treatment with transorbital alternating current stimulation (tACS)
3345128|NCT02218658|Experimental|WE 941 OD|
3345129|NCT02218658|Active Comparator|Brotizolam|
3345130|NCT02218671|Experimental|WE 941 OD under deglutition|
3345131|NCT02218671|Experimental|WE 941 OD under non-deglutition|
3345132|NCT02218684|Experimental|Telmisartan + Lacidipine - low dose|
3345133|NCT02218684|Experimental|Telmisartan + Lacidipine - medium dose|
3345134|NCT02218684|Experimental|Telmisartan + Lacidipine - high dose|
3345135|NCT02218684|Placebo Comparator|Placebo|
3345136|NCT02218697|Experimental|Co-Ad Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of Pneumovax™ 23 vaccine at Day 0 and 1 dose of placebo at Day 28.
3345137|NCT02218697|Experimental|Control Group|Subjects received 1 dose of Influsplit™ Tetra vaccine and 1 dose of placebo at Day 0 and 1 dose of Pneumovax™ 23 vaccine at Day 28.
3345138|NCT02218710||Growth hormone deficiency|
3345139|NCT02218710||healthy controls|
3345140|NCT02218723|Active Comparator|Sequence ABECD|Subject will be administered treatment in sequence ABECD. Where, A: a single dose of FF [100 microgram (mcg) per blister from 0.6% blend] delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345141|NCT02218723|Active Comparator|Sequence BCADE|Subject will be administered treatment in sequence BCADE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3375885|NCT03581383|No Intervention|Current Care Model (Control)|The Current Care Model will not have any intervention beyond the standard of care for Hepatitis C provided by an interdisciplinary team at the University of Kentucky.
3239587|NCT01280877|Sham Comparator|Sham stimulation|Same electrode montage set-up is used during tACS- and placebo-stimulation. Sham stimulation condition consists of minimal treatment with low intensity/few impulses tACS.
3239588|NCT01280890|Experimental|Staff training using VIPS framework|The staff will be trained to give person-centred care using the VIPS framework
3345142|NCT02218723|Active Comparator|Sequence CDBEA|Subject will be administered treatment in sequence CDBEA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345143|NCT02218723|Active Comparator|Sequence DECAB|Subject will be administered treatment in sequence DECAB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345144|NCT02218723|Active Comparator|Sequence EADBC|Subject will be administered treatment in sequence EADBC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345145|NCT02218723|Active Comparator|Sequence DCEBA|Subject will be administered treatment in sequence DCEBA. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3239589|NCT01280890|Experimental|Staff training using DCM|Staff will be supervised in how to give person-centred care using Dementia Care Mapping
3239590|NCT01280890|Placebo Comparator|Control group|Traditional lectures using films will be given to care staff
3239591|NCT01280916|Experimental|Mind-body intervention|Mindful Awareness in Body-oriented Therapy
3239592|NCT01280916|No Intervention|Treatment as Usual|
3239593|NCT01280929|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
3239594|NCT01280929|Experimental|Ranibizumab|Group 2: Intravitreous injections of ranibizumab every 4 weeks at month-0, month-1 and month-2 that can be repeated after month-3.
3239595|NCT01280929|Experimental|Ranibizumab + Panretinal Photocoagulation (PRP)|Group 3: Combination treatment of ranibizumab intravitreous injections plus PRP (2 weeks +/- 1 week after injection), at month-0, month-1 and month-2 that can be repeated after month-3.
3239596|NCT01281020||Treatment with fixed combination|Patients who receive treatment with latanoprost/timolol fixed combination
3239597|NCT01281020||Treatment with unfixed therapy|Patients who receive latanoprost and timolol therapy
3239598|NCT01281033|Active Comparator|thrombus-aspiration group|In patients in the thrombus-aspiration group, the thrombus-aspiration is manually performed.
3239599|NCT01281033|Experimental|AngioJet Rheolytic Thrombectomy|AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter.
3239600|NCT01281085||No treatment|Shoulder conditions including rotator cuff condition treated conservatively, shoulder instability treated conservatively, diaphyseal humerus fracture or subcapital humerus fracture treated surgically and frozen shoulder
3239601|NCT01281098|Active Comparator|Panretinal Photocoagulation (PRP)|Group 1: Panretinal photocoagulation treatment (PRP) at week-0 that can be repeated every 6 weeks.
3239602|NCT01281098|Experimental|Pegaptanib + Panretinal Photocoagulation (PRP)|Group 2: Combination treatment of pegaptanib intravitreous injections at weeks 0, 6 and 12 that can be repeated every 6 weeks. Plus PRP after first injection (2 weeks +/- 1 week)and that can be repeated every 12 weeks.
3239603|NCT01281111|Experimental|BG00012 plus ASA|
3239604|NCT01281111|Experimental|BG00012 plus ASA matching placebo|
3239605|NCT01281111|Placebo Comparator|BG00012 Placebo plus ASA|
3239606|NCT01281111|Experimental|BG00012 Placebo plus ASA matching placebo|
3239607|NCT01281111|Experimental|BG00012|modified dose regimen
3259264|NCT01469273|Experimental|Early Treatment group (E)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning before feeding/nursing, first application 48h after birth, latest. Observation period: 1 year.
3259265|NCT01469273|Experimental|Late Treatment Group (L)|1 x 1 ml of EcN suspension/day on 10 consecutive days, application in the morning after feeding/nursing, starting on the first day of the 7th month of life. Observation period: 1 year.
3259266|NCT01469286|Active Comparator|TEA|Needleless electroacupuncture at ST36 and PC6
3345146|NCT02218723|Active Comparator|Sequence EDACB|Subject will be administered treatment in sequence EDACB. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345147|NCT02218723|Active Comparator|Sequence AEBDC|Subject will be administered treatment in sequence AEBDC. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345148|NCT02218723|Active Comparator|Sequence BACED|Subject will be administered treatment in sequence BACED. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345149|NCT02218723|Active Comparator|Sequence CBDAE|Subject will be administered treatment in sequence CBDAE. Where, A: a single dose of FF (100mcg per blister from 0.6% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; B: a single dose of FF (80mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 320mcg; C: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 400mcg; D: a single dose of FF (140mcg per Blister from a 0.8% blend) delivered via the UD-DPI by inhalation of 4 Blisters giving a total dose of 560mcg; E: a single dose of FF (100mcg per Blister from a 0.8% blend) delivered via the ELLIPTA DPI by inhalation of 4 Blisters giving a total dose of 400mcg
3345150|NCT02218749|Experimental|Initially triaged to physiotherapist|Initially triaged to physiotherapist
3345151|NCT02218749|Active Comparator|Initially triaged to physician|Initially triaged to physician
3345152|NCT02218762|Experimental|Sequence 1|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of A-B-B-A in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
3345153|NCT02218762|Experimental|Sequence 2|Subjects will receive FSC 100/50 mcg delivered via the Ddpi (Treatment A) and FSC 100/50 mcg delivered via the Rdpi (Treatment B) in the sequence of B-A-A-B in four treatment periods of 10 days each. Subjects will receive both active treatment and matching placebo at the same time from two separate devices twice daily. There will be no wash-out between treatment periods
3345154|NCT02218775|Experimental|LY2456302|LY2456302 dosed orally at 10 mg daily for 2 weeks in healthy volunteers
3239608|NCT01281150|Experimental|Treatment (veliparib, paclitaxel, carboplatin)|"DOSE-ESCALATION: Patients receive veliparib PO twice daily BID on days 1-5, 8-12, and 15-19 and paclitaxel IV over 1 hour and carboplatin IV over 30 minutes in course 1 and 3 hours in subsequent courses on days 3, 10, and 17. After 4 courses, patients receive paclitaxel and carboplatin on days 3 and 10 only. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. (Completed as of 12/2012)~EXPANSION COHORT: Patients receive veliparib PO BID on days 1-21 and paclitaxel IV over 1 hour and carboplatin IV over 3 hours on days 3 and 10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3239609|NCT01281163|Experimental|Treatment (Akt inhibitor MK2206 and lapatinib ditosylate)|Patients receive lapatinib ditosylate PO QD on days 1 and 15-28 of course 1 and on days 1-28 of subsequent courses. Patients also receive AKT inhibitor MK2206 PO QD on days 8, 15, and 22 of course 1 and on days 1, 8, 15, and 22 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3345155|NCT02218801||Colorectal adenocarcinoma liver metastasis|Unresectable, borderline or initially unresectable liver metastasis from a colorectal cancer
3345156|NCT02218814|Experimental|Adductor Canal Block:|Adductor Canal Nerve Block: The patient is placed in a supine position with the extremity to be blocked slightly externally rotated. On the medial thigh, at the midpoint between the inguinal crease and the medial condyle, 13-6-MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) is placed in a transverse orientation to visualize the femoral artery in short axis deep to the sartorius muscle. Sterile field and patient sedation achieved. A 21-gauge,100 mm, short-bevel needle (Stimuplex; B Braun) is inserted under ultrasound guidance in in-plane technique to position the needle tip anterolateral to the artery and just deep to the posterior fascia of the sartorius muscle. Once in position, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
3259267|NCT01469286|Placebo Comparator|Sham-TEA|Needleless acupuncture at sham-points
3345157|NCT02218814|Active Comparator|Femoral Nerve Block|Femoral Nerve Block. The procedure is conducted with the patient in a supine position with a 13-6 MHz linear ultrasound transducer (SonoSite HFL38x; Washington, US) applied to the skin at the level of the inguinal crease. The femoral artery, fascia iliac, and femoral nerve are visualized. Sterile field and patient sedation achieved. A 22-gauge, 50-mm, short-bevel stimulating needle (Stimuplex; B Braun, Bethlehem, Pennsylvania) connected to twitch monitor B/Braun Stimuplex DIG RC is inserted under ultrasound guidance using an in-plane technique from lateral to medial until a quadriceps motor response is elicited at a current between 0.5 and 0.2 mA with a pulse width of 0.1millisecond from a twitch monitor . After negative aspiration, 30 mL of Bupivacaine (100 mg) is deposited adjacent to the femoral nerve and deep to the fascia iliac, with intermittent aspiration. After completion of the procedure, a sterile dressing is placed over the needle insertion site.
3345158|NCT02218827|Experimental|dry eye patients|Loteprednol Etabonate (FML) topical treatment 1 drop 4 times daily for 1 month then Loteprednol Etabonate (FML) 1 drop 2 times daily for 1 month
3345159|NCT02218840||Behavioral|Evaluation of cigar smoking topography
3345160|NCT02218853||Bipolar I disorder, with psychosis|Individuals diagnosed with Bipolar I disorder, with psychotic features
3345161|NCT02218853||Bipolar I disorder, without psychosis|Individuals diagnosed with Bipolar I disorder, without psychotic features
3345162|NCT02218853||Healthy Controls|Must have no personal history of any psychotic or mood disorder, or a family history of psychotic or recurrent mood disorder among their first-degree relatives
3345163|NCT02218866||Group 1|All participants will be examined by a neurologist to test sensation, reflexes, and strength and complete a few questionnaires. Tests will be performed to measure nerve function and small punch skin biopsies will be taken to assess nerve fiber density. Blood and urine tests will measure various markers of interest. Participants will be seen before and after their bariatric surgery.
3345164|NCT02218866||Group 2|"In addition to the procedures described for Group 1, participants in Group 2 will have the following procedures:~During bariatric surgery, a small biopsy from the liver and abdominal fat will be taken to examine how fat is processed within the body.~At the first visit, after a skin biopsy is taken, a small capsaicin patch will be placed on the lower thigh. The patch will remain in place for 48 hours and will cause the nerves in the immediate area to pull back from the skin. A biopsy will be taken from the patch area 48 hours, 1 month, and 3 months after the initial biopsy. This procedure will be repeated after surgery.~MRIs may be performed before and after bariatic surgery.~Participants may be asked to complete additional tests to evaluate nerve function"
3345165|NCT02218866||Group 3|Group 3 will comprise of individuals who are not overweight. Participants in this group will undergo a similar evaluation to Group 2.
3345166|NCT02218879||Patients with relapsing MS|
3345167|NCT02218892||Juvenil Idiopathic Arthritis|The group consists of children age 7-14 with an diagnosis of active Juvenile Idiopathic Arthritis.
3345168|NCT02218905|Experimental|Sit to stand test|One minute sit to stand in 40 inches armless chair. Fatigue, breathlessness and failure to maintain tempo will lead to decease the test
3345169|NCT02218918|Active Comparator|Supervised Treadmill Walk Training|Based on 6 minute walk distance, treadmill speed initiated and progression on basis new 6 minute walk distance every 2 weeks
3345170|NCT02218918|Experimental|Supervised Ground walk training|Ground walk training progressed on the basis of 6 minute walk distance (70 - 90%), Weekly 3 days and for 6 weeks
3345171|NCT02218931|Experimental|Targeted ESTEEM diet|"The ESTEEM dietary pattern is similar to that in a Mediterranean diet associated with reduced risk of pre-eclampsia.~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
3345172|NCT02218931|No Intervention|Current clinical practice|The control group will be provided the usual antenatal dietary advice. This includes advice on healthy and physical activity in women with normal weight and obesity and overweight. Folic acid and vit D supplementation are provided as per national recommendations. Participants will provide outcome data at point of delivery and food frequency questionnaire at baseline and 36 weeks or delivery depending on which is sooner.
3345173|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
3345174|NCT02218944|Experimental|Response Inhibition Training: A|In the experimental condition, 20% of responses are no-go, with the majority of no-go responses paired with smoking images.
3345175|NCT02218944|Active Comparator|Response Inhibition Training: B|In the active comparator condition, 20% of responses are no-go trials, with no-go responses spread evenly across the various images.
3345176|NCT02218944|Placebo Comparator|Benign|A benign condition has also been added to control for the possibility that response inhibition training, regardless of target, increases behavioral control and hence decreases relapse likelihood. The benign condition has 50% no-go trials, with no-go responses spread evenly across images.
3345177|NCT02218957|Active Comparator|Standard RYGB|Standard RYGB
3345178|NCT02218957|Experimental|Extended Pouch RYGB|Restrictive/extended pouch RYGB
3345179|NCT02218970|Experimental|strength training|Strength training for leg muscles during10 weeks, 3 times a week: hack squat and plantar flexion, standing upright in a hack squat machine and lying down in a calf rise machine. Exercises will be carried out at 85% of 1-RM intensity under supervision at the institution where participants are having their SUD treatment.
3345180|NCT02218970|Other|control|patients treated for substance-related disorder but not participating in strength training intervention (no training control group)
3345181|NCT02218983|Experimental|Limited transthoracic echocardiogram (LTTE)|LTTE (SonoSite Ultrasound), which will be performed every 10 - 30 minutes, after each fluid challenge or transfusion, until two consecutive equivalent measurements are reached without fluid challenge or transfusion
3345182|NCT02218983|Active Comparator|Usual care|measurements on :blood pressure, heart rate, urine output, lactate, lactate clearance (after 6 hrs), base deficit, creatinine
3345183|NCT02218996||Psychosocial treatment|Children and adolescents with anxiety disorders
3345184|NCT02219022|Active Comparator|Control group|Patient remain with their usual clinical treatment.
3345185|NCT02219022|Experimental|Experimental group|"Patients in experimental group participated in a 12-week progressive resistance training using a maximum repetition exercise in which patients performed 1 Maximum Repetition with the maximum bearable weight. Once the 1 Maximum Repetitionwas determined, training was divided into the following regimen: 2 series of 8 repetitions, the first with 50% and the second with 70% of 1 Maximum Repetition.~The exercises were knee extension and flexion and hip abduction and adduction, elbow extension and flexion, wrist extension and flexion and shoulder abduction and adduction and spine extension and flexion all performed in machines. The 1 Maximum Repetition load was reevaluated every 6 weeks.~Patient remain with their usual clinical treatment."
3345186|NCT02219035||stroke-ischaemic|no interventions
3345187|NCT02219035||stroke -haemorrhagic|no intervention
3345188|NCT02219035||stroke: not confirmed|no intervention
3345189|NCT02219061||GMT|
3345190|NCT02219074|Experimental|Sebacia microparticle and laser treatment|
3345191|NCT02219074|Sham Comparator|Vehicle and laser treatment|
3345192|NCT02219100|Experimental|Home administration of mifepristone|This arm consisted of women who chose home administration of 200 mg mifepristone.
3345193|NCT02219100|No Intervention|Clinic administration of mifepristone|This arm consisted of women who underwent clinic administration of 200 mg mifepristone.
3345194|NCT02219113|Experimental|ADRC injection|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After ADRC isolation autologous cells suspension will be injected intraarticularly into knee joint.
3345195|NCT02219126|Experimental|Homogenized and pasteurized milk|Milk that has undergone homogenization ans pasteurization treatment
3345196|NCT02219126|Experimental|Nonhomogenized and nonpasteurized milk|Unhomogenized and unpasteurized milk (raw milk)
3345197|NCT02219139|Other|ESTA abutment Roxolid|"One study abutment per patient will be placed. After healing for 6 to 7 weeks, patients will be asked to stop oral hygiene at the study site for 2 weeks.~Sulcus fluid and plaque samples will be taken at the abutment site at several visits before and during abdication of oral hygiene.~The study finishes with biopsy visit. Afterwards a regular abutment will be placed and the patients will be treated according to the standard protocol of the clinic to obtain their final restoration."
3239616|NCT01281215|Experimental|Pharmaceutical Education|The patients will receive pharmaceutical education.
3345198|NCT02219152|Experimental|tranexamic acid|tranexamic acid will be administrated using the bronchoscope
3345199|NCT02219152|Placebo Comparator|saline|the saline will be administrated using an infusion during the biopsy.
3345200|NCT02219165|Experimental|IVIG 2 g/kg|Intravenous human immunoglobulin Day 1: As soon as there is suspicion of TSS, randomisation will be performed in order for the study treatment to be administered within the 12h following PICU admission (or following the manifestation of the first signs of shock). Concurrently, the TSS antibiotherapy following Surviving Sepsis Campaign recommendations is given
3239617|NCT01281215|No Intervention|Control|
3239618|NCT01281228|Experimental|exenatide|Infusion of exenatide; loading dose 50 ng/min during 30 min, followed by a maintenance dose 20ng/min for the rest of the tests.
3239619|NCT01281228|Experimental|exenatide + exendin (9-39)|exenatide infusion: loading dose 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the test. And infusion of exendin(9-39) 600pM/kg/min.
3239620|NCT01281228|Placebo Comparator|saline|saline infusion, with the same infusion speed
3345201|NCT02219165|Placebo Comparator|Albumin 4%|Same study scheduling as the first arm. Only the study treatment given is different (albumin instead of IGIV)
3345202|NCT02219178|Experimental|RsqVD|Oral lenalidomide 25mg days 1 - 14 of 21 day schedule Subcutaneous bortezomib 1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule Oral dexamethasone 20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
3345203|NCT02219191|Experimental|puerarin tablet 50 mg|Patients were orally administrated with 50 mg puerarin tablet three times a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3345204|NCT02219191|Active Comparator|Atorvastatin tablet 20 mg|Patients were orally administrated with 20 mg Atorvastatin tablet once a day for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3345205|NCT02219204|Active Comparator|Acupuncture treatment|"This will be performed twice weekly for 30 days. There will be 8 sessions of acupuncture treatments in total.~The needles to be use around the eyes will have the dimensions of 0.25 (diameter) x 13mm (length), while 0.25 x 25mm needles will be used behind the ear (feng chi) and 0.30 X 25mm needles on the upper and lower limbs. These needles will remain in the points for 20 minutes. The depth of penetration will be about 1-2 mm."
3345206|NCT02219204|Active Comparator|Herbal treatment|"This formulation is called qi ju gan lu yin or Lycium berry, a chrysanthemum beverage. This is a modified version of qi ju di huang wan published previously. The senior TCM collaborator, Prof Wei QP has made this modification in order to treat the dry eye patients with lung-kidney yin deficiency."
3345207|NCT02219204|No Intervention|Eye drops|
3345208|NCT02219217|Experimental|No arms|All participants will be administered Tivicay® (dolutegravir 50 mg once daily) for 10 days, then will undergo a nine-day wash out period and then take Stribild® (245 mg of tenofovir disoproxil, 200 mg of emtricitabine, 150 mg of elvitegravir and 150 mg of cobicistat) for 10 days.
3345209|NCT02219230|Experimental|Prosthetic knee|Subjects crossed over between interventions (three different prosthetic knees). Knee conditions include 1) Active knee (Ossur Power Knee II); 2) Adaptive knee (Ossur Rheo); and 3) Passive knee (Various manufacturers)
3345210|NCT02219243|No Intervention|Waitlist Control|This is a 1-month waitlist control to be compared with the active online interpretation training interventions. This is a no intervention control group
3345211|NCT02219243|Experimental|Active Interpretation Training|Online Interpretation Training Condition 2 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
3239621|NCT01281254|Placebo Comparator|Placebo plus PLD|Arm B: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)
3239622|NCT01281254|Experimental|AMG386 plus PLD|Arm A: PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
3239623|NCT01281267|Experimental|Face transplantation|
3239624|NCT01281280||VNS Therapy|
3345212|NCT02219243|Experimental|Placebo Interpretation Training|Online Interpretation Training Condition 1 provides three sessions of a computerized training. Each session will last approximately 20-30 minutes, and participants will undergo 1 session each week.
3345213|NCT02219269||Medically complex contraception users|Cohort includes women of reproductive age with diverse medical conditions (listed in inclusion criteria) who are referred to Family Planning felowship-trained physicians, seeking contraception counseling and administration.
3239625|NCT01281280||Best Medical Practice|
3345214|NCT02219295|Experimental|sweet -block|application of different sugars, artificial sweeteners and sweet-taste antagonists in a single dose in 300 ml tap water every week up to 7 times and collection of blood samples over 3 hours
3345215|NCT02219295|Experimental|bitter block|application of purified bitter tasting ingredients of vegetables and hop in 300 ml tap water , collection of blood samples for 3h (-15,0,15,30,60,120,180 min)
3345216|NCT02219295|Experimental|umami-block|"application of glutamate and glutamate +IMP~same procedure as above"
3239626|NCT01281319||Asymptomatic normal pregnant women|
3239627|NCT01281319||Women with high risk pregnancy|Women at risk for preterm birth or recurrent abortions that are being followed at the high risk pregnancy unit (outpatients clinic, high risk day care center)
3239628|NCT01281319||Women admitted with preterm labor|Women that are admitted to the gynecology department due to pregnancy complications: preterm labor with intact membranes (PTL) or with preterm PROM.
3345217|NCT02219295|Other|gastroscopy|gastroscopy with and without oral intervention with artificial sweetener saccharin to take tissue samples from the upper bowel for the investigation of taste receptor cells in the upper bowel in human beings
3345218|NCT02219347|Other|DMARD cessation|All patients recruited to the study who have a Disease Activity in 28 Joints C-Reactive Protein (DAS28-CRP) score of < 2.4 and who do not have power Doppler synovitis on a 7-joint musculoskeletal ultrasound scan will stop their DMARD therapy. These patients will then be followed-up for a period of 6 months or until flare of their arthritis activity, whichever is sooner.
3345219|NCT02219373|Experimental|Gabapentin|
3345220|NCT02219373|Experimental|Oxcarbazepine|
3345221|NCT02219373|Placebo Comparator|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
3345222|NCT02219386|Active Comparator|Deep dry needling|The group of DDN receive this treatment and stretch
3345223|NCT02219386|Other|muscle stretch|The stretch applied was as described by Simons et al. (Simons et al., 1999). During the stretch the physiotherapist took up the slack, avoiding pain elicitation, maintaining the tension for four seconds and releasing the tension for eight seconds; this cycle was repeated three times
3345224|NCT02219399|Experimental|300 mg DHA|300 mg DHA
3345225|NCT02219399|Placebo Comparator|Placebo|olive oil or high oleic acid sunflower oil placebo
3345226|NCT02219399|Experimental|600 mg DHA|600 mg DHA
3345227|NCT02219412|Experimental|ticagrelor mono-therapy|Take ticagrelor 90 mg Bid for 2 weeks.
3345228|NCT02219412|Active Comparator|aspirin/ticagrelor dual-therapy|Take ticagrelor 90mg Bid plus Aspirin 100mg Qd and treated for 2 weeks.
3345229|NCT02219425|Other|endometrial biopsy|
3345230|NCT02219451|Experimental|exercise training|We studied twenty-six chronic heart failure outpatients and they were assigned to 2 groups: Untrained (n=13) and trained (n=13).
3345231|NCT02219490|Experimental|ABT-450/r/ABT-267 plus ABT-333 with or without ribavirin (RBV)|ABT-450/r/ABT-267 and ABT-333 coadministered with or without ribavirin (RBV) for 12 or 24 weeks
3239629|NCT01281332|Active Comparator|Menopod device|Menopod®
3239630|NCT01281332|Sham Comparator|Sham device|Inactive device.
3345232|NCT02219529|Experimental|MCE|patients were assigned to swallow MCE first, followed by the gastroscopy
3345233|NCT02219529|Active Comparator|Standard gastroscopy|patients were assigned to swallow MCE first, followed by the gastroscopy
3239631|NCT01281358|Experimental|HOP-ON intervention|Participants will receive a CD-ROM (or DVD and booklet if no access to computer) highlighting motor skills which could be encouraged with premature infants
3239632|NCT01281358|Active Comparator|SMILES|Participants will received a CD-ROM (or DVD and booklet if no access to a computer) which contains information on interacting with their premature infant
3239633|NCT01281384|Active Comparator|Standard imaging (echocardiography)|Subjects will undergo their clinically indicated echocardiogram as ordered by their attending physician.
3239634|NCT01281384|Active Comparator|Advanced Imaging (Cardiac MRI)|Subjects will undergo their clinically indicated echo as ordered by their attending physician, plus a cardiac MRI, which will be scheduled within 14 days of the echo.
3345234|NCT02219542|Placebo Comparator|a standard general anesthesia|a standard general anesthesia and with transversus abdominis plane block 20 ml 0.9% sodium chloride
3345235|NCT02219542|Experimental|transversus abdominis plane block|a standard general anesthesia with transversus abdominis plane block 20 mL 0.25% ropivacaine
3239635|NCT01281397||Patients undergoing elective cardiac surgery|Patients undergoing elective cardiac surgery will be enrolled in study. Data about antiplatelet therapy ingestion prior to surgery will be included.
3239636|NCT01281410|No Intervention|Standard physiotherapy|Standard Physiotherapy without Inspiratory Muscle Training
3239637|NCT01281410|Experimental|Inspiratory muscle training|Inspiratory muscle training with a device named Respifit in addition to the usual physiotherapy program
3239638|NCT01281436|Other|Web-based Provider training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
3239639|NCT01281436|Active Comparator|HeartSmartKids with web-based training|The providers assigned to Group 2 will receive the web-based training described in the other arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
3239640|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q8h)|
3345236|NCT02219555||Non-surgical treatment|When clinically indicated, subjects will receive a standard of care carpal tunnel injection whose volume and specific steroid drug will be based on the recommendation of the treating clinician
3345237|NCT02219555||Surgical treatment|When clinically indicated, subjects will receive standard of care carpel tunnel release surgery as recommended by treating clinician
3239641|NCT01281462|Experimental|Ceftaroline fosamil and NXL104 (q12h)|
3345238|NCT02219568|Experimental|obscure gastrointestinal bleeding|Those patients who developed obscure gastrointestinal bleeding either overt or occult bleeding who will then undergo video capsule endoscopy and CT enterography.
3345239|NCT02219581|Placebo Comparator|Placebo|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of placebo intravenously in addition to a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty. The first dose of placebo will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
3239642|NCT01281462|Active Comparator|Doripenem|
3239643|NCT01281488|Experimental|Treatment 1 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.018 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3239644|NCT01281488|Experimental|Treatment 2 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.036 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3239645|NCT01281488|Experimental|Treatment 3 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.07 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3239646|NCT01281488|Experimental|Treatment 4 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.14 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3239647|NCT01281488|Experimental|Treatment 5 (fluorescence imaging and surgery)|Patients undergo NIR fluorescence imaging with ICG and an additional 0.21 mg/kg/dose on the da Vinci Surgical System followed by standard approach robot-assisted laparoscopic partial nephrectomy.
3239648|NCT01281514|Experimental|Treatment|See Detailed Description
3345240|NCT02219581|Experimental|Dexamethasone 10 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 10 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
3239649|NCT01281527|Experimental|Paliperidone Palmitate|Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)
3239650|NCT01281540|Experimental|001|Cisapride one 10 mg tablet 4 times a day for 8 weeks
3345241|NCT02219581|Experimental|Dexamethasone 20 mg|Subjects undergoing primary total joint arthroplasty of the knee will receive two doses of 20 mg dexamethasone. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting. Additionally, subjects will also receive a standard multimodal postoperative pain management regimen typically used for total knee arthroplasty.
3345242|NCT02219594|Experimental|Gemstone CT|Gemstone CT ：Discovery CT750 HD（high definition） ，GE（General Electric Co.） Healthcare, Milwaukee； CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient
3345243|NCT02219594|Active Comparator|320-detector row spiral CT|320-detector row spiral CT：Aquilion One, Toshiba, Nasu, Japan. CT image for patient with suspected in-stent restenosis which Gemstone CT or 320-detector row spiral CT was assigned randomly to patient .
3345244|NCT02219607||epidural|
3239651|NCT01281540|Placebo Comparator|002|Placebo one placebo tablet 4 times a day for 8 weeks
3239652|NCT01281553|Experimental|001|Cisapride 0.2 mg/kg suspension q.i.d.for 8 weeks.
3345245|NCT02219607||general anesthesia|
3345246|NCT02219620|Experimental|Music, Imagery, Movement intervention|Music, Imagery, Movement intervention: psychosocial intervention incorporating Music, Imagery and Movement
3239653|NCT01281553|Placebo Comparator|002|Placebo Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
3239654|NCT01281566|Experimental|001|Cisapride 0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
3239655|NCT01281566|Placebo Comparator|002|Placebo liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
3239656|NCT01281579|Experimental|001|Canagliflozin 50 mg Tablets oral 50-mg once daily on Day 1 and on Days 4 through 9.
3239657|NCT01281579|Experimental|002|Canagliflozin 100 mg Tablets oral 100-mg once daily on Day 1 and on Days 4 through 9.
3239658|NCT01281579|Experimental|003|Canagliflozin 300 mg Tablets oral 300-mg once daily on Day 1 and on Days 4 through 9.
3239659|NCT01281592|Experimental|LOR-253 HCl|LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
3239660|NCT01281605|Active Comparator|Active titration algorithm|titrate insulin dose by contacting with investigator by telephone weekly.
3239661|NCT01281605|Experimental|Usual titration algorithm|contact with investigator only at routine study visit.
3345247|NCT02219620|Active Comparator|Social Control|social control/interaction group
3345248|NCT02219633|Experimental|LEO 39652 cream|Topical application
3345249|NCT02219633|Placebo Comparator|LEO 39652 cream vehicle|Topical application
3345250|NCT02219646|Experimental|Vardenafil|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Study Group were treated with vardenafil 10 mg twice/daily.
3345251|NCT02219646|Placebo Comparator|Control|The study protocol consists of a Screening/Enrolment Phase lasting up to 4 weeks, a Treatment Phase of 24 weeks, and Follow-up/Observation Treatment-free Phase of 24 weeks after the Treatment Phase. During treatment phase, patients enrolled in the Control Group were treated with tablets twice/daily identical to the Study Group, but containing placebo.
3345252|NCT02219659|Active Comparator|Sedation protocol with interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Every morning both drugs are stopped (Daily Interruption) and patient's wakefulness is assessed per protocol. If patient's pain and RASS score stays within the target, both drugs are kept off. If patient shows any signs and symptoms of pain or agitation (described in the study protocol), both drugs are restarted at a half dose of the previous dose and titrated to target pain and RASS score. Every morning both drugs are stopped and when patient is awake and met the SBT safety screen, 120-min continuous positive airway pressure (CPAP) trial is performed.
3345253|NCT02219659|Active Comparator|Sedation protocol without Interruption|Continuous infusion of fentanyl and midazolam is started per protocol. Both drugs are titrated to target pain score (0 to 3) using Critical Care Pain Observation Tool (CPOT) and target sedation score (0 to -3) using Richmond Agitation Sedation Scale (RASS). Daily interruption of fentanyl and midazolam is not performed. Every morning 120-min CPAP trial is performed as long as the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen.
3345254|NCT02219659|Active Comparator|Fentanyl push first|This arm attempts to manage patient's pain and agitation with analgesia first. Fentanyl intravenous (IV) pushes are administered every 5 minutes as needed to target pain and sedation score, up to 4 doses per hour. Every morning 120-min CPAP trial is performed as long as patient's RASS score is 0 to -2 and patient passes the SBT safety screen. If fentanyl IV push doses alone cannot manage patient's pain and agitation (could not reach the target score), notify the study team. Fentanyl infusion is started and titrated to target pain and sedation score up to 6 hours. If fentanyl infusion is titrated up twice consecutively and target pain and sedation score are not met, notify the study team. Propofol infusion is started and titrated to target RASS score up to 6 hours.
3345255|NCT02219672|Experimental|Triptolide group|cART for 6 months, and the experimental group will take Triplitode 2 tabs tid po for another 12 months
3345256|NCT02219672|Active Comparator|Comparator group|combined antiretroviral therapy (cART): TDF+3TC+LPV/r+RAL for 18 months
3345257|NCT02219698|Experimental|Symptomatic treatment|
3345258|NCT02219711|Experimental|MGCD516|MGCD516 oral capsule, administered in escalating doses in Phase 1, beginning with daily dosing and exploring other regimens as necessary, in 21 or 28 days cycles
3345259|NCT02219724|Experimental|MOXR0916: Dose Escalation Stage|Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days.
3239662|NCT01281618||Those with barrett's esophagus|Those with barrett's esophagus: no dysplasia or low grade dysplasia
3239663|NCT01281631|Experimental|Low dose NP001|Low drug dose
3239664|NCT01281631|Experimental|High dose NP001|High drug dose
3239665|NCT01281631|Placebo Comparator|Placebo|normal saline
3239666|NCT01281657||Prescribed fingolimod 0.5 mg/day|
3239667|NCT01281670|No Intervention|No vibration|
3239668|NCT01281670|Active Comparator|vibration|
3239669|NCT01281683||TACE|
3239670|NCT01281683||RFA|
3239671|NCT01281696|Experimental|Bevacizumab, etoposide, cisplatin (BEEP)|
3239672|NCT01281722||healthy adults|healthy adults with the age among 20 to 95 years old
3239673|NCT01281722||melanoma cases|the people who are diagnosed melanoma in NTU hospital
3239674|NCT01281748|Experimental|methylprednisolone|
3239675|NCT01281748|Placebo Comparator|normal saline solution|
3239676|NCT01281761|Experimental|cetuximab/irinotecan/simvastatin|"D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily)~every 2weeks"
3239677|NCT01281774|Experimental|CSL112|Multiple ascending intravenous doses of CSL112
3239678|NCT01281774|Placebo Comparator|Placebo|Multiple intravenous infusions of placebo
3239679|NCT01281787|Active Comparator|Losartan|angiotensin II-receptor blocker
3239680|NCT01281787|No Intervention|no treatment|no preventive treatment
3239681|NCT01281787|Active Comparator|Metoprolol|beta-adrenergic antagonist
3239682|NCT01281800|Active Comparator|Cisplatin with pemetrexed|
3239683|NCT01281800|Experimental|Cisplatin with gemcitabine in long infusion|
3345260|NCT02219724|Experimental|MOXR0916: Expansion Stage|Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years).
3345261|NCT02219737|Experimental|Treatment (ibrutinib, R-ICE)|Patients receive ibrutinib PO QD on days 1-21, rituximab IV on day 1, ifosfamide IV on day 3, carboplatin IVPB on day 3, and etoposide IVPB on days 2-4. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3345262|NCT02219750|Active Comparator|Preprandial premix therapy|switch twice-daily insulin Preprandial premix therapy mean that transition of advance insulin based on the basal insulin daily total dose at study entry divided into two equal dose of preprandial NovoMix 30. Patient discontinued all pre-study oral antidiabetic drug(OAD), including sulfonylureas, glinides, Thiazolidinedione(TZD) and Dipeptidyl peptidase-4(DPP-4) inhibitor but left metformin alone
3345263|NCT02219750|Active Comparator|Basal-plus insulin|switch twice-daily insulin Basal-plus insulin consisted of continued previous basal insulin and add-on once-daily insulin aspart(NovoRapid) before breakfast. The starting dose of insulin aspart was 4 unit(U) before breakfast and continued under previous basal insulin dose.
3345264|NCT02219776|Active Comparator|Chlorhexidine Standard of Care Arm|Use of Chlorhexidine to cleanse pre-operative surgery site
3345265|NCT02219776|Experimental|Benzoyl Peroxide Experimental Arm|Use of Chlorhexidine scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient
3345266|NCT02219789|Experimental|Treatment (alisertib, fulvestrant)|Patients receive fulvestrant IM on day 1 (days 1 and 15 of course 1 only) and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3345267|NCT02219802|Active Comparator|Drug-eluting stent|Treatment of infarct related laesion with a drug-eluting stent
3345268|NCT02219802|Experimental|Drug-coated balloon|After treatment of the infarct related artery with a drug-coated ballon, an additional BMS is advised to be used in case of residual stenosis > 50% or coronary artery dissection type > B.
3345269|NCT02219828|Placebo Comparator|Placebo|placebo sc
3239684|NCT01281813|Experimental|001|Darunavir (DRV) 400 milligram (mg) tablet intake of 2 tablets once daily in combination with Ritonavir (rtv)
3239685|NCT01281813|Experimental|002|Darunavir 600 mg tablet intake of 1 tablet twice a day in combination with Ritonavir
3345270|NCT02219828|Active Comparator|Anakinra|Anakinra 2mg/Kg up to 100mg (maximum dose)
3345271|NCT02219841||No intervention group|Receive general life-style advice and information on heart healthy diet Undergo catheter ablation for AFib
3345272|NCT02219841||Life-style intervention|patients will receive personilized low-calorie diet menu and undergo supervised exercise in the cardiac rehabilitation facility for 3 months before ablation with an aim of loosing >10% of body weight. They will continue diet and exercise for 1 year following ablation procedure Will receive catheter ablation for AFib
3345273|NCT02219854|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3345274|NCT02219854|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3345275|NCT02219867|Experimental|Ketamine|Active Comparator
3345276|NCT02219880|Placebo Comparator|Placebo|Inert tablets matched for colour, size and consistency to active arm treatment. Both treatment arm tablets will match in appearance, and neither participants nor the trial clinicians will know what they are taking.
3345277|NCT02219880|Experimental|Kava - standardised 240mg kavalactones|Standardised 240mg kavalactones per day - fixed dose regime of two tablets of kava twice per day
3345278|NCT02219893|Experimental|MOC31PE Immunotoxin|Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.
3345279|NCT02219906|Placebo Comparator|Placebo|Placebo capsule given three times daily X 3 weeks
3345280|NCT02219906|Experimental|Resveratrol|Resveratrol 1 gram three times daily X 3 weeks
3345281|NCT02219919|Experimental|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
3345282|NCT02219919|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3345283|NCT02219945|Experimental|Group 1 - 20 PTB patients aged >18yrs|Group 1 - 20 TB patients aged > 18 yrs 5 min exhaled breath sampling with nose clamp
3345284|NCT02219945|Experimental|Group 2 - 20 TB suspects > 18 yrs|Group 2 - 20 non-TB patients > 18 yrs (screened for TB - but appear to test negative for TB, and diagnosed with other conditions including bronchiectasis, etc) 5 min exhaled breath sampling with nose clamp
3345285|NCT02219945|Experimental|group 3 - 20 lung patients, non-TB|Group 3 - 20 patients with a lung disease - no TB suspects (recruited from Lung Clinics in Yogyakarta; lung cancer, COPD, etc) 5 min exhaled breath sampling with nose clamp
3345286|NCT02219945|Experimental|Group 4 - 20 healthy controls|Group 4 - 20 apparently healthy matched controls 5 min exhaled breath sampling with nose clamp
3345287|NCT02219945|Experimental|Group 5 - 7 newly diagnosedMDR PTB pts|Group 5 - 7 newly diagnosed MDRTB patients enrolled before start of treatment, to be followed 8 months, until after end of treatment 5 min exhaled breath sampling with nose clamp
3345288|NCT02219945|Experimental|group 6 - cohort of TB suspects|300 more individuals, suspected to have TB - final diagnosis by standard procedures plus sputum culture plus follow-up for >2 years 5 min exhaled breath sampling with nose clamp
3239686|NCT01281813|Experimental|003|Ritonavir 100 mg capsule to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3239687|NCT01281813|Experimental|004|Ritonavir 100 mg tablet to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
3239688|NCT01281813|Experimental|005|Darunavir 375 mg composed via various tablets (2x150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir (1x 100mg rtv tablet) twice daily
3259268|NCT01469312|Placebo Comparator|Control|The control arm consists of the traditional pasta.
3345289|NCT02219958||RAMP-HT and Non-RAMP-HT|
3345290|NCT02219971|Experimental|Kukoamine B Mesilate 0.005mg/kg|Pre-test,open study: Kukoamine B Mesilate 0.005mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
3345291|NCT02219971|Experimental|Kukoamine B Mesilate 0.02mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.02mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3239689|NCT01281813|Experimental|006|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir oral solution 80 milligram per milliLitre (mg/mL) (dose dependent on weight) twice daily
3239690|NCT01281813|Experimental|007|Darunavir 375 mg composed via various tablets (2x 150mg DRV tablets + 1x 75mg DRV tablet) in combination with Ritonavir powder for oral suspension prepared as 100mg/10mL (dose dependent on weight) twice daily
3345292|NCT02219971|Experimental|Kukoamine B Mesilate 0.04mg/kg +Placebo|"Dose Escalation: Kukoamine B Mesilate 0.04mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3345293|NCT02219971|Experimental|Kukoamine B Mesilate 0.08mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.08mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3345294|NCT02219971|Experimental|Kukoamine B Mesilate 0.12mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.12mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3345295|NCT02219971|Experimental|Kukoamine B Mesilate 0.24mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.24mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3345296|NCT02219971|Experimental|Kukoamine B Mesilate 0.48mg/kg + Placebo|"Dose Escalation: Kukoamine B Mesilate 0.48mg/kg single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.~Placebo: single and intravenous(IV) drip for 1 hour in healthy volunteers."
3345297|NCT02219984||patients anticoagulated|
3345298|NCT02220010|Experimental|Pancreatic stent|If POPF grade B or C is detected on post operative day 3 or more, a pancreatic stent is endoscopically positioned in the pancreatic duct.
3345299|NCT02220010|No Intervention|Drain only|If POPF grade B or C is detected on post operative day 3 or more, only the per-operatively placed drain is used as treatment
3345300|NCT02220023|Experimental|Nitric Oxide|40 ppm, one time administration, inhaled.
3345301|NCT02220036|Active Comparator|Magnesium Oxide|magnesium tablets, 250 milligram magnesium, 12 weeks, every day 1 tablet
3345302|NCT02220036|Placebo Comparator|Placebo|Placebo tablets, the same in color, odor and appearance with magnesium tablets, 12 weeks, one tablet every day
3345303|NCT02220049|Experimental|Velcade|Dose level Dose(mg/m²) d1-5, d8-12, d15-19 Cohort -2 Velcade 0.3 mg/m² Cohort -1 Velcade 0.4 mg/m² Cohort 1 Velcade 0.5 mg/m² Cohort 2 Velcade 0.6 mg/m² Cohort 3 Velcade 0.7 mg/m² Cohort 4 Velcade 0.8 mg/m² Cohort 5 Velcade 0.9 mg/m² Cohort 6 Velcade 1.0 mg/m² Cohort 7 Velcade 1.1 mg/m²
3345304|NCT02220062|Active Comparator|EUS-CPN group|Group that be performed by Endoscopic ultrasound guided bilateral celiac plexus neurolysis
3345305|NCT02220062|Experimental|EUS-CGN group|Group that be performed by Endoscopic ultrasound guided celiac ganglia neurolysis
3345306|NCT02220075||spontaneous group|maintain spontaneous breathing during the operation, and recording tidal volume, ET CO2, respiratory rate, peak airway pressure, SpO2
3345307|NCT02220075||controlled group|controlled ventilation(tidal volume 8ml/kg, ET CO2 35~40mmHg) during the operation, recording peak airway pressure, SpO2
3345308|NCT02220088|Experimental|TAI of FOLFOX|Retreatment With Transcatheter arterial infusion of oxaliplatin , fluorouracil, and leucovorin
3345309|NCT02220088|Active Comparator|Sorafenib|treatment with sorafenib
3345310|NCT02220114|Other|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"Sabril®: sachet for oral solution 500 mg, 50 to 100mg/Kg/day, twice a day, 14 days.~Vigabatrin new ST formulation: Soluble tablets 100 or 500 mg, 50 to 100mg/Kg/day, twice a day, 12 weeks."
3345311|NCT02220127|Experimental|8 mm collimator|GKR with a single shot of the 8 mm collimator
3345312|NCT02220127|Experimental|4 mm collimator|GKR with a single shot of the 4 mm collimator
3345313|NCT02220140|No Intervention|Control|Service as usual
3345314|NCT02220140|Experimental|Intervention group|Participants are offered access to the web based resilience program and are invited to join a short introduction course.
3345315|NCT02220153|Experimental|UCB7665 Intravenous 1|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3239691|NCT01281813|Experimental|008|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir 100mg tablet twice daily
3239692|NCT01281813|Experimental|009|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir oral solution as 80 mg/mL (dose dependent on weight) twice daily
3345316|NCT02220153|Experimental|UCB7665 Intravenous 2|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3345317|NCT02220153|Experimental|UCB7665 Intravenous 3|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3345318|NCT02220153|Experimental|UCB7665 Intravenous 4|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3345319|NCT02220153|Experimental|UCB7665 Intravenous 5|Single dose calculated based on body weight for 60 minutes intravenous infusion.
3345320|NCT02220153|Experimental|UCB7665 Subcutaneous 1|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
3345321|NCT02220153|Experimental|UCB7665 Subcutaneous 2|Single dose calculated based on body weight for 60 minutes subcutaneous infusion.
3345322|NCT02220153|Placebo Comparator|Intravenous Placebo|Single dose placebo comparator for each active arm of intravenous infusion.
3345323|NCT02220153|Placebo Comparator|Subcutaneous Placebo|Single dose placebo comparator for each active arm of subcutaneous infusion.
3345324|NCT02220166|Experimental|Triticum monococcum|60 days of daily administration of 100 grams of water biscuits of Triticum monococcum
3345325|NCT02220179|No Intervention|control|service as usual
3259269|NCT01469312|Active Comparator|Modified pasta|Dreamfields, Miracle Noodles
3239693|NCT01281813|Experimental|010|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependent on weight) twice daily
3239694|NCT01281852|Experimental|Treatment (paclitaxel, cisplatin, veliparib)|Patients receive paclitaxel IV over 3 hours on day 1, cisplatin IV over 1 hour on day 2, and veliparib PO on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3239695|NCT01281878|Experimental|Pyridoxal-phosphate|Treatment with pyridoxal-phosphate in increasing dosages every six weeks starting with 5mg/kg body weight up to 20 mg/kg body weight. treatment duration 24 weeks
3239696|NCT01281891|Experimental|Local Infiltration Analgesia|Combination of ropivacaine, ketorolac and adrenaline
3239697|NCT01281891|Active Comparator|Intrathecal morphine|Morphine special (preservative-free) injected intrathecally
3239698|NCT01281904|No Intervention|Standard of Care|Participants randomized into the standard of care group will be asked to continue following the instructions of the healthcare provider throughout the 10 week study period. They will not be asked to perform any study intervention.
3239699|NCT01281904|Active Comparator|Relaxation Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their relaxing effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
3345326|NCT02220179|Experimental|Intervention group 1|Participants are offered access to the web based resilience program
3345327|NCT02220179|Experimental|Intervention group 2|Participants are offered access to the web based resilience program and are also invited to join a short introduction course about the program
3345328|NCT02220192|Experimental|Focal LEEP|All patients will undergo focal treatment of high-grade cervical intraepithelial neoplasia using LEEP. A two-week follow-up assessment will evaluate the side effects of the treatment and any unusual symptoms. This will be done through a phone survey. At six months a clinic visit is required to assess whether there are any precancerous cells of the patient's cervix.
3345329|NCT02220218|Experimental|Treatment Sequence ABDC|Treatment A (canagliflozin and metformin immediate release [IR] fixed dose combination [FDC] tablet 50 milligram [mg]/500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345330|NCT02220218|Experimental|Treatment Sequence BCAD|Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345331|NCT02220218|Experimental|Treatment Sequence CDBA|Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345332|NCT02220218|Experimental|Treatment Sequence DACB|Treatment D (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (canagliflozin tablet 50 mg along with metformin IR tablet 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345333|NCT02220231|Experimental|capnothorax group|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
3345334|NCT02220244|Experimental|MD1003|MD1003 100mg capsule, 1 capsule TID for 12 months
3345335|NCT02220244|Placebo Comparator|Placebo|Placebo capsule, 1 capsule TID for 6 months, then switch to MD1003 100mg capsule, 1 capsule TID for 6 months
3345336|NCT02220257||Newly diagnosed type 1 diabetes|
3345337|NCT02220270||patient with PDA or ASD|
3345338|NCT02220296|Experimental|Part 1 insulin 338|
3345339|NCT02220296|Placebo Comparator|Part 1 placebo|
3345340|NCT02220296|Experimental|Part 2 insulin 338|
3345341|NCT02220296|Active Comparator|Part 2 insulin glargine|
3345342|NCT02220309||Anxiety and mood disorders|
3345343|NCT02220335|Experimental|Pulmonary Arterial Denervation (PADN)|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes were tightly in contact with the endovascular surface. About four to eight ablations at 10 W for 60 seconds each were performed in ostium of the left PA, ostium of the right PA , and the distal bifurcation area of the main PA.
3239700|NCT01281904|Active Comparator|Stimulating Acupressure|In addition to their standard of care, participants will be asked to apply pressure on each of 9 acupressure points (bilaterally where indicated) that have been carefully selected for their excitatory effect. (There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily over a period of 6 weeks followed by 4 weeks of intervention wash-out where the participant will be asked to perform no acupressure at all.
3239701|NCT01281930|Experimental|Wick placement into abscess cavity|
3345344|NCT02220335|Active Comparator|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.
3345345|NCT02220348|Experimental|linaclotide|Linaclotide 72μg, 145 μg, or 290 μg capsules, once daily for 3 days, oral administration
3345346|NCT02220361|Placebo Comparator|placebo group|received 20 ml intravenous physiological saline
3239702|NCT01281930|Active Comparator|Full packing of abscess cavity|
3239703|NCT01281943|Experimental|Temsirolimus and Pegylated Liposomal Doxorubicin|Temsirolimus 25mg andPegylated liposomal doxorubicin 25mg/m2
3239704|NCT01282008||Focus Groups|Focus Groups about smoking messages
3345347|NCT02220361|Experimental|low dose dexmedetomidine group|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
3345348|NCT02220361|Experimental|hemabate+high dose dexmedetomidine group|received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline
3345349|NCT02220374|Experimental|Supportive Finger Tape|Participants will be randomised to either placebo or supportive taping
3345350|NCT02220387||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to polycyclic aromatic hydrocarbons exhaust"
3345351|NCT02220387||smokers with COPD and healthy control|"Consists of 2 subgroups~patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
3345352|NCT02220400|Experimental|Ketamine|Ketamine infusion group
3345353|NCT02220400|Placebo Comparator|Placebo|Normal saline infusion
3345354|NCT02220426|Other|Xenon inhalation|Inhalation of 5 doses of 750ml of hyperpolarized 129Xe gas
3345355|NCT02220439||Case: non-rotavirus seroconverters|Infants not demonstrating seroconversion to rotavirus vaccination, as measured anti-RV Immunoglobulin A < 20 U/ml
3239708|NCT01282034|Active Comparator|Marrow stimulation|
3345356|NCT02220439||Control: rotavirus seroconverters|Infants demonstrating seroconversion to rotavirus vaccination, as measured by anti-rotavirus Immunoglobulin A > 20 U/ml
3345357|NCT02220452|Experimental|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
3345358|NCT02220452|Active Comparator|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
3345359|NCT02220465|Experimental|PA+ Smoking Cessation (LMPA)|This intervention integrates low-to-moderate physical activity (PA) with evidence based smoking cessation programming. Over the 4-week treatment period, the intervention (1 in-person and 3 phone counseling sessions) focuses on (a) gradually increasing routine PA during the pre-quit period and maintaining PA post quit day (b) increasing daily PA (steps/day) using a weekly tailored algorithm with the goal of achieving 10,000 steps by Week 4 (quit day) and (c) training participants to use PA as a primary urge management strategy, thereby embedding PA within evidence-based smoking cessation counseling. Other components include additional smoking urge management skills, increasing motivation to quit, overcoming barriers and maintaining PA for quitting and staying smoke-free .
3345360|NCT02220465|Active Comparator|Standard Care Smoking Counseling (SCC)|The control intervention parallels the format of the LMPA intervention with focus only on behavioral and cognitive urge management strategies (avoiding/escaping high-risk situations, stimulus control) and minimizing the probability that participants in the control group would increase increase/use PA during the intervention period. Participants are provided a pedometer without any instructions or encouragement around increasing walking/steps during the 8-week intervention period.
3239709|NCT01282034|Experimental|Medical device: MaioRegen|
3239710|NCT01282047|Experimental|Lenalidomide|
3345361|NCT02220478|Active Comparator|Signature Cutting Guides|Patients indicated for a Posterior Lateral THA utilizing non implantable Signature Cutting Guides during surgery.
3345362|NCT02220478|Active Comparator|Conventional Instrumentation|Patients indicated for a Posterior Lateral THA utilizing non implantable Conventional Instrumentation during surgery.
3239711|NCT01282073|Experimental|Mycophenolate mofetil, low dose steroid|
3239712|NCT01282073|Active Comparator|Cyclosporin, low dose steroid|
3239713|NCT01282099||Cardiac patients|Postoperative congenital heart disease patients requiring stay in the PICU
3239714|NCT01282099||non-cardiac patients|non-cardiac patients requiring stay in the PICU
3239715|NCT01282125||sleep apnea|100 patients suffering from obstructive sleep apnea syndrome
3239716|NCT01282125||controls|100 subjects matching cases to age, sex, and body weight
3239717|NCT01282151|Experimental|Taxotere|Docetaxel plus Cisplatin
3239718|NCT01282151|Active Comparator|Pemetrexed|Pemetrexed plus Cisplatin
3239719|NCT01282190|Experimental|Motivational interview|
3239720|NCT01282255|Experimental|A|
3239721|NCT01282255|Placebo Comparator|B|
3239722|NCT01282268|Active Comparator|Arbaclofen|
3345363|NCT02220491|Active Comparator|Whole-brain radiotherapy|"All subjects will have a non-contrast CT scan using a slice thickness of 2.5mm or less.~The Brain contour will be generated using the segmentation wizard and edits as required.~PTV_Brain is an expansion of the Brain by 5mm. 99% of PTV_Brain is to be covered by 95% of 20 Gy in 5 fractions using 6-10 MV photons in a parallel-opposed pair lateral beam arrangement."
3345364|NCT02220491|Experimental|Single-fraction radiotherapy|Immobilized in the mask, the subject will be imaged for radiotherapy planning with a CT slice thickness of 1.25 mm or less and an axial resolution of < 0.7 mm (CT field of view < 35 cm). Subjects that require contrast with GFR 45-59 will have pre-hydration, contrast dose modification and/or Mucomyst administration to preserve renal function, according to standard practice for radiological imaging at the institution.
3345365|NCT02220504|Experimental|Intervention group|Antipsychotic treatment discontinuation (DT)
3345366|NCT02220504|Active Comparator|Control group|Maintenance antipsychotic treatment (MT)
3345367|NCT02220517|Experimental|A: MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
3345368|NCT02220517|Experimental|B: MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
3345369|NCT02220530||Sedation group|Colonoscopies performed with conscious sedation with iv midazolam and fentanyl
3345370|NCT02220530||Control group|Colonoscopies performed without sedation.
3345371|NCT02220543|Experimental|Back on Track intervention|Back on Track intervention is a biopsychosocial primary care intervention
3345372|NCT02220543|Active Comparator|Primary care as usual|Primary care as usual comprises maximally 12 individual regular physical therapy sessions for a maximum of 8 weeks.
3345373|NCT02220595|Experimental|Carotid stenting|Carotid artery stenting for treatment of carotid artery stenosis
3345374|NCT02220595|Active Comparator|Carotid endarterectomy|Carotid artery endarterectomy for treatment of carotid artery stenosis
3345375|NCT02220608|Experimental|Arm 1: Dose Level 1 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
3345376|NCT02220608|Experimental|Arm 2: Dose Level 2 (Bortezomib & G-CSF)|G-CSF will be administered daily for 5 days (Days 1-5). On Day 4 at approximately 1800 hours, bortezomib will be administered. Apheresis will begin on Day 5 either 15 or 18 hours following Day 4 bortezomib dose; 20L of peripheral blood will be processed with a cumulative target collection goal of > 6.0x106 CD34+cells/kg. If the target collection goal is not met after one apheresis procedures, up to three additional days of G-CSF and apheresis may be repeated.
3345377|NCT02220621|Experimental|Treatment|After the hysteroscopic adhesiolysis, crosslinked hyaluronic acid gel is applied into the uterine cavity, then a Foleys balloon catheter is inserted into the uterine cavity.
3345378|NCT02220621|Active Comparator|Control|After hysteroscopic adhesiolysis, a Foleys balloon catheter is inserted into the unterine cavity.
3345379|NCT02220634|Experimental|Regadenoson|Intravenous infusion of the A2A agonist regadenoson has a preferential vasodilator effect on pulmonary vasculature that is comparable to iNO, the current gold standard for pulmonary vasoreactivity studies.
3345380|NCT02220647|Experimental|Treatment A (FDC)|
3345381|NCT02220647|Active Comparator|Treatment B (single agents)|
3345382|NCT02220660|Active Comparator|Free dose combination|
3345383|NCT02220660|Experimental|Fixed dose combination|
3239723|NCT01282268|Placebo Comparator|Placebo|
3345384|NCT02220673|Experimental|BHT 0.1%|
3345385|NCT02220673|Experimental|BHT 0.5%|
3239724|NCT01282281||Individuals aged 14-18 and 19-65 with a diagnosis of BD|
3239725|NCT01282307|Experimental|Method Guided Self-Determination|The Method Guided Self-Determination consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
3239726|NCT01282307|No Intervention|Treatment as usual|
3239727|NCT01282320|Experimental|Increased Physical Activity|Individually tailored training one hour, 2-3 sessions per week.
3239728|NCT01282320|No Intervention|"Activity as usual (Buisness as usual)"|
3239729|NCT01282333|Experimental|Treatment (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib orally every 12 hours on days 1-12, gemcitabine hydrochloride IV over 30 minutes on days 3 and 10, and cisplatin IV over 60-120 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with suspected or known germline BRCA mutations may continue to receive single-agent veliparib continuously in the absence of disease progression or unacceptable toxicity. Patients may undergo blood, tumor tissue, and hair follicle sample collection periodically for pharmacokinetic and correlative studies.
3239730|NCT01282346|Experimental|SOLX Gold Shunt|
3239731|NCT01282359|Other|Clinical Practice Group|Patients collected in centres randomized as usual clinical practice, who will not receive the limited educational asthma program.
3345386|NCT02220673|Placebo Comparator|Placebo for RMT-B|
3345387|NCT02220673|Placebo Comparator|Placebo for HFA-MDI|
3345388|NCT02220686|Experimental|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
3345389|NCT02220686|No Intervention|Usual Care|Physician will follow their institution's standard of care for smoking cessation.
3345390|NCT02220738|Experimental|ABT-957|ABT-957 administered twice-daily for 7 days
3345391|NCT02220738|Placebo Comparator|Placebo|Placebo administered twice-daily for 7 days
3345392|NCT02220751|Placebo Comparator|chronic periodontitis|Non-surgical periodontal therapy.
3345393|NCT02220751|Active Comparator|Chronic periodontitis + type 2 diabetes|Non-surgical periodontal therapy + systemic doxycycline non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before first scaling and root planning session.
3345394|NCT02220751|No Intervention|Control|Periodontal- and systemically healthy patients were included as control group.
3345395|NCT02220777|Experimental|1. ASP8477 and placebo|Part 1: SAD in postmenopausal females and Part 2: SAD in vasectomized male
3239732|NCT01282359|Other|"Gold Standard educational group"|Patients will receive a formal program of structured and individualized education, enrolled in centres recognized by using high standard procedures in asthma education.
3345396|NCT02220777|Experimental|2. ASP8477 alone|Part 3, fasted or fed
3345397|NCT02220777|Experimental|3. omeprazole alone|Part 4, Drug-Drug Interaction
3345398|NCT02220777|Experimental|4. ASP8477 + omeprazole|Part 4: Drug-Drug Interaction
3345399|NCT02220803|Active Comparator|Acetazolamide and CPAP|"Acetazolamide: Diamox®. Hard white capsule, 250 mg. The total treatment is 4 weeks (2+2 weeks). Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg) dosages.Evening medication should be taken 2 hours before bedtime.~CPAP: Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines. The standard setting is a pressure delivery in the pressure range 5-15 mbar. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Total duration of CPAP treatment is 4(2+2) weeks."
3345400|NCT02220803|Active Comparator|CPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed at the end of each treatment regimen. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 4(2+2) weeks.
3239733|NCT01282359|Other|Intervention group|This group will receive a limited educational asthma program (minimal educational intervention)
3239734|NCT01282385|Experimental|simvasatin|"a) patients responding to treatment with beta-blockers, in which she was treated with nadolol Subsequently randomized into two treatment arms, double-blind:~a.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~a.2: placebo capsules with external characteristics similar to simvastatin.~b) non-responders to treatment with beta blockers, receive treatment with carvedilol.Subsequently randomized into two treatment arms, double-blind~b.1: simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance.~b.2: placebo capsules with external characteristics similar to simvastatin."
3239735|NCT01282385|Placebo Comparator|placebo|
3239736|NCT01282398|Experimental|simvastatin|The experimental group will take simvastatin 40mg for at least two years.
3239737|NCT01282398|Placebo Comparator|placebo|the control group wiil take placebo pills for at least two years.
3239738|NCT01282437|Experimental|Prophylactic Cranial Irradiation|
3345401|NCT02220803|Experimental|Acetazolamide|Acetazolamide (Diamox®) 250 mg. Hard white capsule. The total length of acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum dosage (750mg) following titration will be administered as morning (250 mg) and evening(500mg)dosages.Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 300 ml of water (room temperature) in an upright body position and preferably in connection to a meal.
3345402|NCT02220816|Experimental|Competitive Training|The patients will receive only competitive activities designed to restore attention abilities. These include pencil-and-paper tasks completed under competitive circumstances and competitive virtual games specifically designed to treat different aspects of attention (divided, selective, sustained, etc).
3345403|NCT02220816|Active Comparator|Non-Competitive Training|The patients will receive conventional attentional training. Pencil and paper tasks focused on different aspects of attention (divided, selective, sustained, etc.) will be completed by all participant under individual or group-therapy sessions. No competitive training will be allowed.
3239739|NCT01282437|No Intervention|Observation|Patients will not receive PCI, but will be observed and the same items will be measured as in the PCI-arm.
3239740|NCT01282450|Experimental|Single arm|Eligible patients
3239741|NCT01282502|Experimental|Midostaurin with chemoradiation|
3239742|NCT01282515|Experimental|ELP active|one PDT treatment with 2 ml hexaminolevulinate 6 mg/ml gel
3239743|NCT01282515|Active Comparator|topical steroids|treatment with clobetasol propionate 0.05% ointment used daily for 6 weeks
3239744|NCT01282541|Active Comparator|Transconjunctival|
3239745|NCT01282541|Active Comparator|Transcutaneous|
3239746|NCT01282554|Experimental|stimulated group|stimulated group
3239747|NCT01282554|No Intervention|control group|Control group : non stimulated group.
3239748|NCT01282567|Other|diabetic patients|
3239749|NCT01282580|Experimental|Dietary fish (canned salmon, albacore)|Fish products: Canned albacore and salmon will be provided at no cost to the patient. Supplies of tuna and salmon will be provided in quantities sufficient for one month of daily intake by the subject. If desired, a subject can request a sufficient amount to allow for preparation of a meal for the family or household at no more than two times per week. Labels or portions of labels from the cans will be collected at the monthly study visits, and canned supplies will be replenished monthly or at more frequent intervals if needed. Subjects will be allowed to keep unused cans.
3345404|NCT02220829|Active Comparator|Preventive administration of Rapaflo|Rapaflo treatment will start on day one of radiation therapy (early administration- before symptoms onset) and continue for a total duration of 6 months: 8 mg daily during 4 months and 8 mg every other day for 2 months.
3345405|NCT02220829|Other|Standard care|Administration of alpha-blocker Rapaflo at the onset of symptomatic urinary problems caused by radiation therapy. 8 mg of Rapaflo is administered daily until disappearance of symptoms.
3345406|NCT02220842|Experimental|Arm 1 Cohort A (Safety Evaluation):Atezolizumab + Obinutuzumab|Relapsed/refractory FL and DLBCL participants will receive obinutuzumab alone on Days 1, 8, and 15 of Cycle 1 (Cycle length = 21 days), followed by atezolizumab and obinutuzumab on Day 1 of Cycles 2-8, and then atezolizumab alone on Day 1 of Cycle 9 and every cycle thereafter until unacceptable toxicities or disease progression.
3345407|NCT02220842|Experimental|Arm 1 Cohort B (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory FL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3345408|NCT02220842|Experimental|Arm 1 Cohort C (Expansion): Atezolizumab + Obinutuzumab|Relapsed/refractory DLBCL participants will receive atezolizumab and obinutuzumab as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3345409|NCT02220842|Experimental|Arm 2 Cohort D (Safety Evaluation):Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab (on Day 1) and tazemetostat (on Days 1-21) of each 21-day cycle until unacceptable toxicities or disease progression.
3345410|NCT02220842|Experimental|Arm 2 Cohort E (Expansion): Atezolizumab + Tazemetostat|Relapsed/refractory DLBCL participants will receive atezolizumab and tazemetostat as per schedule and dose decided from the safety evaluation stage, until unacceptable toxicities or disease progression.
3345411|NCT02220868|Other|Sofossbuvir, Riabvirin, Stribild|Open-Label SIngle Arm of Sofosbuvir, Ribavirin and Stribild
3345412|NCT02220881|Experimental|Mold making silicone toe separator|The subject in experimental group will use mold making silicone toe separator everyday
3345413|NCT02220881|Other|Observation|This group will follow the physician instruction of care for the hallux valgus
3239750|NCT01282580|Experimental|Lovaza-Omega 3 fatty acid capsules|Lovaza capsules will be provided at no cost to the patient. Pill bottles will be provided to the patient, with the start date and number of pills recorded. The supplement will be provided in sufficient supply for one month at a time. Pill bottles will be collected at monthly follow-up visits, and any unused capsules will be documented and discarded as biohazardous waste.
3239751|NCT01282593|Other|CD9 expression level|Impact of CD9 expression level on motility assays
3239752|NCT01282606|Experimental|Drug I: SI-6603 (Low)|
3345414|NCT02220933|Experimental|MD1003|MD1003 100mg capsules, 1 capsule tid for 24 months
3345415|NCT02220933|Placebo Comparator|Placebo|Placebo capsule, 1 capsule tid for 12 months, then switch to MD1003 100mg capsule, 1 capsule tid for 12 months
3345416|NCT02220946|Active Comparator|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. Each patient received a 20 minute session once a week for total 8 sessions
3345417|NCT02220946|Placebo Comparator|plasebo|sham electrical stimulation
3345418|NCT02220959|Experimental|walk test|morbid obese patients (BMI>40) undergoing laparoscopic sleeve gastrectomy walking 60 meters under 1 minute before and after the measurement of Forced vital capacity (FVC)
3345419|NCT02220972|Experimental|Arm A: First on Perampanel with a crossover to Placebo|Treatment Arm A will initially receive perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD with a crossover to placebo.
3345420|NCT02220972|Experimental|Arm B: First on Placebo with a crossover to Perampanel|Treatment Arm B will initially receive placebo with a crossover to perampanel 2 mg QD titrated up to 4 mg QD and finally to 6 mg QD.
3375886|NCT03581383|Experimental|PREP-C Model|The PREP-C care model will provide Hepatitis C care with the standard interdisciplinary team expanded by a social worker and a patient navigator team. The social worker/ patient navigator team will use the standardized Psychosocial Readiness Evaluation and Preparation for hepatitis C treatment (PREP-C) tool and will guide PREP-C related interventions to overcome barriers to HCV treatment uptake and completion.
3239753|NCT01282606|Experimental|Drug II: SI-6603 (Middle)|
3239754|NCT01282606|Experimental|Drug III: SI-6603 (High)|
3239755|NCT01282619|Experimental|Huperzine A Sustained-Release Tablet|
3239756|NCT01282619|Active Comparator|Huperzine A Tablet|
3239757|NCT01282619|Placebo Comparator|Placebo|
3239758|NCT01282632|Experimental|Risperidone|Commence at 0.5 mg once daily Increase, blindly, to 1 mg and then by 1 mg at discretion of clinicians through weeks 1-4 to a maximum of 3 mg.
3239759|NCT01282632|Experimental|Olanzapine|Commence at 2.5 mg once daily Increase to 5.0 mg, blindly, and then by 5 mg at the discretion of the clinician through weeks 1 - 4 to a maximum of 15 mg
3345425|NCT02221011|Experimental|shock wave (three times)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Once a week for 3 weeks
3345426|NCT02221011|Sham Comparator|Sham shock wave|E-SWT, Elettronica Pagani, Italy Sham without energy, 1500 beats in FCU, FCR and 4000 beats diffuse in intrinsic muscle
3345427|NCT02221011|Experimental|Shock wave (one time)|E-SWT, Elettronica Pagani, Italy 3.5 bars 1500 beats in FCU, FCR 3 bars 4000 beats diffuse in intrinsic muscle Only one dose
3345428|NCT02221024|Experimental|Flushing every 24 hours|Flushing with positive pressure with normal saline every 24 hours
3345429|NCT02221024|Active Comparator|Flushing every 12 hours|Flushing with positive pressure with normal saline every 12 hours
3345430|NCT02221037|Experimental|GSK2862277|GSK2862277 will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will undergo either ventilated or collapsed lung BAL procedure. Regular assessments will be conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
3345431|NCT02221037|Placebo Comparator|Placebo|Placebo will be administered as single orally inhaled aerosol over approximately 3 to 5 minutes; approximately 1-3 hours prior to the subjects scheduled surgery, before the initiation of pre-operative procedures. After surgery subject will be undergo either ventilated or collapsed lung BAL procedure. Regular assessments will conducted until the time of patient discharge. Subjects will be followed up as outpatients at Day 28
3239760|NCT01282645||PSI in PEEK|All study subjects have received a Patient Specific Implant (PSI) made of PEEK to repair a cranial defect
3345432|NCT02221063|Active Comparator|low [thiamin] fortified fish sauce|Fish sauce will contain 2 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
3345433|NCT02221063|Active Comparator|higher [thiamin] fortified fish sauce|Fish sauce will contain 8 mg thiamin hydrochloride / mL fish sauce + iron (as NaFeEDTA)
3345434|NCT02221063|Placebo Comparator|Placebo fish sauce|Fish sauce will contain only iron (as NaFeEDTA), no thiamin
3345435|NCT02221076|Experimental|Confocal Laser Endomicroscopy (CLE)|The patient will undergo a 10 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs.
3345436|NCT02221089|Experimental|Retaron|
3345437|NCT02221089|Placebo Comparator|Placebo|
3345438|NCT02221102|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo edoxaban from day 1 to day 30
3345439|NCT02221102|Experimental|edoxaban 30mg|Receiving a 30-mg dose of edoxaban and placebo aspirin from day 1 to day 30
3345440|NCT02221102|Experimental|edoxaban 60mg|Receiving a 60-mg dose of edoxaban and placebo aspirin from day 1 to day 30
3345441|NCT02221115|Other|Google Glass|Investigators using Google Glass during clinic visit
3345442|NCT02221115|No Intervention|No Google Glass|Investigator will not be using Google Glass during clinic visit
3239761|NCT01282658||Colorectal cancer|
3239762|NCT01282671|Experimental|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months.
3239763|NCT01282671|No Intervention|Control group|No breathing exercises.
3239764|NCT01282684|Active Comparator|single oral dose of 200 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3345443|NCT02221154|Experimental|Inofolic®|standard ovarian stimulation and Inofolic®
3239765|NCT01282684|Active Comparator|single oral dose of 400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3239766|NCT01282684|Active Comparator|single oral dose of 800 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3239767|NCT01282684|Active Comparator|single oral dose of 1600 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3239768|NCT01282684|Active Comparator|single oral dose of 1000 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3239769|NCT01282684|Active Comparator|single oral dose of 1400 mg PLX5622|6 subjects will be randomized to take a single oral dose of PLX5622 and 2 subjects will be randomized to take placebo.
3239770|NCT01282684|Placebo Comparator|Placebo|2 patients per cohort will be randomly assigned to take placebo. 12 patients total will be randomized to take placebo in this study.
3239771|NCT01282697|Experimental|rapamycin+irinotecan at a given dose|
3239772|NCT01282736|Experimental|Integrative Response Therapy|IRT is based on affect regulation theories of binge eating and adds emphasis on cognitive restructuring techniques. IRT is a 10 session, group-based, guided-self-help treatment that works to decrease binge eating by primarily enhancing emotion coping skills, in addition to transforming faulty interpretations and reducing vulnerabilities (e.g., interpersonal events) that risk overwhelming emotion and problematic cognitions.
3345444|NCT02221154|Active Comparator|Gonadotropins;Folic Acid|standard ovarian stimulation without Inofolic®
3345445|NCT02221167|No Intervention|Exclusive breastfeeding|Infants in the exclusive breastfeeding group will continue to breastfeed.
3239773|NCT01282736|Active Comparator|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy guided self-help (CBT-GSH), based on the restraint model of binge eating, has been adapted from individual format to a 10 session, group-based therapy for the purpose of this study. The book 'Overcoming Binge Eating' is employed in the present study and consists of Part 1, an educational background on BED, and Part 2, a 6 step treatment program to overcome binge eating.
3239774|NCT01282749|Experimental|SisterTalk Hartford First|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
3239775|NCT01282749|Other|SisterTalk Hartford Second|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
3345446|NCT02221167|Active Comparator|Donor Milk|"Infants in this arm will continue to breastfeed and will be given 10 ml of donor breast milk by syringe after each breastfeeding until their mother's milk comes in. (until the onset of lactogenesis II)"
3345447|NCT02221180|Experimental|Treatment Sequence ABDC|Treatment A (1 immediate release (IR) fixed dose combination [FDC] tablet containing canagliflozin 150 milligram [mg] and metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345448|NCT02221180|Experimental|Treatment Sequence BCAD|Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 1, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345449|NCT02221180|Experimental|Treatment Sequence CDBA|Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 2, followed by Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 3, then Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345450|NCT02221180|Experimental|Treatment Sequence DACB|Treatment D (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fasted condition) on Day 1 of treatment period 1, followed by Treatment A (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed condition) on Day 1 of treatment period 2, followed by Treatment C (1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fasted condition) on Day 1 of treatment period 3, then Treatment B (1 canagliflozin tablet 50 mg and 1 canagliflozin tablet 100 mg along with 1 IR tablet of metformin 500 mg orally under fed condition) on Day 1 of treatment period 4. A washout period of 7 days will be maintained between each treatment period.
3345451|NCT02221193|Experimental|site specific vs panoral disinfection|
3345452|NCT02221206|Active Comparator|Treatment|mini-screw implant anchorage-assisted retraction of maxillary incisors
3345453|NCT02221206|No Intervention|Control|regular maximum anchorage
3345454|NCT02221232|Experimental|ZuraPrep Config 1|Isopropyl alcohol (IPA) 70% Standard scrub time.
3345455|NCT02221232|Experimental|ZuraPrep Config 2|Isopropyl alcohol (IPA) 70% Half scrub time.
3345456|NCT02221232|Placebo Comparator|ZuraPrep Vehicle|ZuraPrep without IPA
3345457|NCT02221232|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3345458|NCT02221245||Patients with Esophageal Cancer|Tumor Biopsy via Ultrasound Endoscopy
3345459|NCT02221258|Experimental|FURESTEM-RA Inj.+DMARDs|FURESTEM-RA Inj. 1. 2.5x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 2. 5.0x10^7 stem cells+DMARDs after registration FURESTEM-RA Inj. 3. 1.0x10^8 stem cells+DMARDs after registration
3345460|NCT02221271|Experimental|NPB-01|
3239776|NCT01282775|No Intervention|Environment / Usual Care|
3345461|NCT02221297|Experimental|Supplement product with plant stanol ester|
3345462|NCT02221297|Placebo Comparator|Placebo supplement product|
3345463|NCT02221323|Experimental|Insulin lispro|
3345464|NCT02221336|Placebo Comparator|Non-MONARCA II system|Use of smartphone for normal communicative purposes only. No self-monitoring and no feedback loop.
3345465|NCT02221336|Experimental|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
3345466|NCT02221362||Observational|No interventions
3345467|NCT02221375|Experimental|BHT low|
3345468|NCT02221375|Experimental|BHT medium|
3345469|NCT02221375|Experimental|BHT high|
3345470|NCT02221375|Experimental|BI 54903 XX low|
3345471|NCT02221375|Experimental|BI 54903 XX medium 1|
3345472|NCT02221375|Experimental|BI 54903 XX medium 2|
3345473|NCT02221375|Experimental|BI 54903 XX high|
3345474|NCT02221375|Experimental|BI 54903 XX medium single dose|
3345475|NCT02221375|Active Comparator|Ciclesonide|
3345476|NCT02221388|Active Comparator|BI 671800 ED capsules|
3345477|NCT02221388|Experimental|BI 671800 HEA tablet in fasted state|
3345478|NCT02221388|Experimental|BI 671800 HEA EC tablet in fasted state|
3345479|NCT02221388|Experimental|BI 671800 HEA tablet in fed state|
3239777|NCT01282775|Other|WEB+ Environment|Web-based weight loss program (WEB) + Environment - Participants have access to a proven Web-based weight loss program with weekly lessons focused on lifestyle behavior changes
3239778|NCT01282775|Other|WEB + Cash Incentive for Weight Loss|Web-based Weight Loss Program + Cash Incentive for Weight Loss - participants have access to a proven web-based weight loss program plus they are paid cash based on the percent weight lost at 12 months compared to baseline.
3345480|NCT02221388|Experimental|BI 671800 HEA EC tablet in fed state|
3345481|NCT02221388|Experimental|BI 671800 HEA, 50 mg tablet in fasted state|
3345482|NCT02221401|Experimental|Treatment A (FDC)|
3239779|NCT01282788|No Intervention|Traditional Diet|Infants in communities randomized to the traditional diet arm will not receive food supplements.
3239780|NCT01282788|Experimental|Cereal|All infants in communities randomized to the Cereal Arm will receive caterpillar cereal from 6-18 months of age.
3345483|NCT02221401|Active Comparator|Treatment B (single agents)|
3345484|NCT02221414|Experimental|Treatment A (FDC)|
3345485|NCT02221414|Active Comparator|Treatment B (single agents)|
3239781|NCT01282827|Experimental|rtACS (Verum condition)|Repetitive transorbital alternating current stimulation (rtACS)
3239782|NCT01282827|Placebo Comparator|Placebo stimulation|no intervention (Sham stimulation)
3345486|NCT02221427|Active Comparator|Static labour progression curve (F)|Guideline with the following expected labour progression: if the cervix dilates at least 1 centimetre per hour assessed after 4 hours. Labour dystocia is diagnosed if progression proceeds slower than this definition throughout the active phase of the first stage of labour. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours, three hours for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
3345487|NCT02221427|Experimental|Dynamic progression curve (Z)|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes.
3345488|NCT02221440|Placebo Comparator|air, second stage of labor|"Patients randomized to the group will receive sham administered by nasal catheter.~The therapy will continue until after delivery"
3345489|NCT02221440|Experimental|oxygen, second stage of labor|"Patients randomized to the group will receive oxygen administered by low flow nasal oxygen at a flow rate of 2 L/min.~The therapy will continue until after delivery"
3345490|NCT02221453|Other|Triamcinolone Acetonide Treatment|Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection
3345491|NCT02221466||diabetic patients|Diabetic patients given HBOT
3345492|NCT02221466||None diabetic patients|None diabetic patients given HBOT
3345493|NCT02221479|Active Comparator|Granulocyte colony-stimulating factor (G-CSF) alone|G-CSF administered up to 8 days
3345494|NCT02221479|Experimental|G-CSF plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
3345495|NCT02221492|Active Comparator|granulocyte colony-stimulating factor alone|G-CSF administered up to 8 days
3345496|NCT02221492|Experimental|granulocyte colony-stimulating factor plus plerixafor|G-CSF administered up to 8 days (Day 1 to Day 8) and plerixafor administered for 4 days (Day 4 to Day 7)
3345497|NCT02221505|Experimental|LOP628 - Solid Tumor|with LOP628
3345498|NCT02221505|Experimental|LOP628 - AML|With LOP628
3345499|NCT02221505|Experimental|LOP628 - Solid Tumor Expansion|With LOP628
3345500|NCT02221518|Experimental|Patients with OCD|Behavioral: Exposure & Response Prevention (EX/RP)
3345501|NCT02221531|Experimental|Short infusion|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
3345502|NCT02221531|Other|Bolus application|Carbetocin 100 microgram will be applied intravenously by bolus application over about 15 seconds
3345503|NCT02221544|Experimental|rTMS treatment followed by Sham|A course of low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) followed by rTMS maintenance period (1 month) and followed by sham treatment in order to show the efficacy of treatment
3345504|NCT02221544|Experimental|Sham treatment followed by rTMS|A course of sham followed by followed by sham maintenance period (1 month) and than followed by low-frequency repetitive transcranial magnetic stimulation (rTMS) delivered over the supplementary motor area (SMA) in order to show the effectiveness of rTMS
3345505|NCT02221570|Active Comparator|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
3345506|NCT02221570|Placebo Comparator|Placebo|placebo of baclofen
3345507|NCT02221583|Experimental|Group 1|Astagraf XL + Mycophenolate mofetil then cross over to Prograf + Mycophenolate
3345508|NCT02221583|Experimental|Group 2|Prograf + Mycophenolate mofetil then cross over to Astagraf XL + Mycophenolate
3239783|NCT01282840|Other|Bladder wall blood perfusion pattern|
3239784|NCT01282853|Active Comparator|A1|one biopsy specimen taken from gastric antrum was put into RUT kit
3239785|NCT01282853|Experimental|A4|4 biopsy specimens taken from gastric antrum were put into RUT kit
3239786|NCT01282853|Experimental|B1|one biopsy specimen taken from gastric body was put into RUT kit
3239787|NCT01282879|Experimental|itraconazole, prophylaxis, Oral solution|For GVHD patients who are required systemic glucocorticoids therapy, itraconazole oral solution will be administered at a dose of 200mg every 12 hours.
3239788|NCT01282892||patients with NAFLD|
3239789|NCT01282892||excess of visceral fat|
3239790|NCT01282905||Healthy controls|
3239791|NCT01282905||Ulcerative colitis|
3239792|NCT01282918|Other|Study group|Patients without DF (Defibrillation) testing during ICD implantation
3239793|NCT01282918|Other|Control group|Patients with DF testing during ICD implantation (according to standardized procedure)
3345509|NCT02221596|Experimental|vitamin D + aerobic training|vitamin D capsules every weekday (10,000IU/day) and exercise
3345510|NCT02221596|Active Comparator|vitamin D + no aerobic training|vitamin D capsules every weekday (10,000IU/day) and no exercise
3345511|NCT02221596|Active Comparator|placebo + aerobic training|placebo capsule every weekday and exercise
3345512|NCT02221596|No Intervention|placebo + no aerobic training|placebo capsule every weekday and no exercise
3345513|NCT02221609|Experimental|Treatment based on Movement System Impairment based model|Treatment based on Movement System Impairment based classification model is composed by patient education, analysis and modification of daily living activities and prescription of specific exercises
3345514|NCT02221609|Active Comparator|General exercise|The general exercise program consists of stretching exercises of the trunk and lower limbs muscles and strengthening exercises of the trunk muscles (Hayden et al., 2005; Rainville et al., 2004).
3239794|NCT01282944|Experimental|Combined Financial Incentive & Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Subjects connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. Participants also receive weekly feedback regarding which participants in the peer group achieved their walking goals during the previous week.~Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200.~Financial incentive and peer network terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
3345515|NCT02221622|Experimental|Allopregnanolone 2 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3239795|NCT01282944|No Intervention|Active Control|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or peer networks in this group."
3259270|NCT01469325|Active Comparator|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil.
3345516|NCT02221622|Experimental|Allopregnanolone 4 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3345517|NCT02221622|Experimental|Allopregnanolone 6-18 mg|Drug: Allopregnanolone injection (intravenous solution) once per week for 12 weeks
3345518|NCT02221622|Placebo Comparator|Placebo|Drug: Placebo injection (intravenous solution) once per week for 12 weeks
3345519|NCT02221635||rTMS+Risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.At the same time,risperidone (2-4mg) was took orally.
3345520|NCT02221635||Risperidone|Risperidone (2-4mg) was took orally.
3345521|NCT02221687|Experimental|Synbiotic formula|"Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)"
3345522|NCT02221687|Placebo Comparator|Control formula|"Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~Control FoF : 6 months of consumption (from 6 to 12 months of age)"
3345523|NCT02221687|No Intervention|Breast-fed group|"- Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~Breast milk : at least 4 month (from birth until at least 4 months of age)"
3345524|NCT02221700|Experimental|Group I (leg massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, thrice weekly for 4 weeks.
3345525|NCT02221700|Experimental|Group II (leg massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the affected legs at the foot and toes, ending at the knee, twice weekly for 6 weeks.
3345526|NCT02221700|Experimental|Group III (head/neck/shoulder massage 3 x weekly for 4 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder thrice weekly for 4 weeks.
3345527|NCT02221700|Experimental|Group IV (head/neck/shoulder massage 2 x weekly for 6 weeks)|Patients undergo massage therapy over 30 minutes to the head, neck, and shoulder twice weekly for 6 weeks.
3345528|NCT02221713||Group A: perforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with perforated diverticulitis (i.e., Hinchey III or IV).
3345529|NCT02221713||Group B: unperforated diverticulitis|Patients with acute diverticulitis will be recruited from the A&E department at King's, prior to commencement of antibiotics. Rectal swabs will be obtained from patients with a chief complaint of acute abdominal pain upon initial assessment, prior to initial antibiotics. All specimens will be initially frozen, but only patients specimens with an admitting diagnosis of acute diverticulitis and colonic imaging (CT imaging or visualization at surgery) will be analysed. This group will include patients with unperforated diverticulitis (Hinchey I or II).
3345530|NCT02221713||Group C: asymptomatic diverticulosis|Patients with asymptomatic diverticulosis will be recruited from the 2-week wait (2ww) colorectal cancer pathway. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
3345531|NCT02221713||Group D: normal controls|Patients with or without haemorrhoids, and no other colonic pathology will be recruited from the 2ww colorectal cancer pathway. These will be the normal controls. Patients presenting with a chief complaint of fresh PR bleeding, with no other complaints, will be recruited prior to diagnostic imaging, either by CT, CT colonography, or endoscopy. They will provide a stool sample or rectal swab prior to bowel cleansing, if required for their evaluation, as that may alter the microbiome. Those patient samples with diverticulosis (and or haemorrhoids, as the other most common cause of fresh PR bleeding) will be analysed.
3345532|NCT02221726|Experimental|JNJ-35684-AAA-023: 5.5 cm^2 Patch|
3345533|NCT02221726|Experimental|JNJ-35684-AAA-023: 44 cm^2 Patch|
3345534|NCT02221752|Experimental|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
3345535|NCT02221752|Experimental|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
3345536|NCT02221765|Experimental|Arm 1|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit 3 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg."
3345537|NCT02221765|Experimental|Arm 2|"Visit 1 - sham visit: placebo 0.9% (w/v) saline single-dose, administered subcutaneously.~Visit: 2 - single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.~Visit 3 - placebo 0.9% (w/v) saline single-dose, administered subcutaneously."
3345539|NCT02221791|Active Comparator|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
3345540|NCT02221791|Active Comparator|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
3345541|NCT02221791|Placebo Comparator|Placebo|Participants will consume 70g white chocolate + placebo capsules
3345542|NCT02221804|Experimental|COPD - reduced activity levels|COPD patients who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
3345543|NCT02221804|Experimental|Healthy - reduced activity levels|Healthy age-matched controls who have voluntarily decreased their daily physical activity levels to no more than 1500 steps/day for 14 days.
3345544|NCT02221804|No Intervention|COPD - unchanged activity levels|
3345545|NCT02221830|Placebo Comparator|Placebo|Normal Saline (standard of care)
3345546|NCT02221830|Experimental|Treatment|normal saline + oxytocin
3345547|NCT02221856|Experimental|Motion View|
3345548|NCT02221856|Active Comparator|Conventional Orthodontic Treatment|
3239796|NCT01282944|Experimental|Financial Incentive Arm|Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will be entered in lottery with an approximate 3 in 10 chance of winning $50 and an approximate 3 in 100 chance of winning $200. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 2 months.
3345549|NCT02221895|Experimental|Early Follow-up|Postpartum follow up appointment 2-3 weeks after delivery
3345550|NCT02221895|Active Comparator|Traditional Follow-up|Postpartum follow up 6-8wk after delivery (current clinical standard)
3345551|NCT02221908||Patients brought to Hahnemann Hospital ED|
3345552|NCT02221921|Experimental|MicroPort's Transcatheter Aortic Valve and Delivery System|single arm with intervention that percutaneous implantation of the MicroPort's Transcatheter Aortic Valve and Delivery System
3345553|NCT02221934|Experimental|Signal more likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
3345554|NCT02221934|Active Comparator|Signal less likely to block nerve|Electrical signal delivered to nerve by Altius, a device designed for high-frequency nerve block
3345555|NCT02221960|Experimental|Monotherapy Arm|MEDI6383
3345556|NCT02221960|Experimental|Combination Arm|MEDI6383 and MEDI4736
3345557|NCT02221973|Experimental|milk with 1.2g/d sterols and 8g/d hawthorn powder|
3259271|NCT01469325|Sham Comparator|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
3345558|NCT02221973|Experimental|milk with 1.8g/d sterols and 8g/d hawthorn powder|
3345559|NCT02221973|Active Comparator|milk without sterols and hawthorn powder|
3345560|NCT02221986|Experimental|Interdisciplinary rehabilitation|"The intervention consists of 6 weeks intensive outpatient physiotherapy in conjunction with 0-6 weeks of occupational therapy if need is indicated. The physical intervention contains supervised group exercise of 90 minutes three times a week in groups up to four patients included continuously.~The occupational therapy intervention consists of individual training 60 minutes twice a week for patients having deficits in activity or participation levels measured by the Assessment of Motor and Process Skills (AMPS)."
3345561|NCT02221986|No Intervention|Care as usual|The control group receives usual standard of care (e.g. no training, individual training or group training in the municipality). The amount of training in this group is based on a questionnaire at the follow-up trials.
3345562|NCT02221999|Active Comparator|Chemotherapy only|Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles
3345563|NCT02221999|Experimental|GnRHa|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously
3345564|NCT02221999|Experimental|letrozole|Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day
3345565|NCT02222012|Active Comparator|single channel|
3345566|NCT02222012|Experimental|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|
3345567|NCT02222025|Experimental|Injury Prevention Programme|see intervention prescription
3345568|NCT02222025|No Intervention|Control|The coaches of the control group will receive the instruction to regularly perform a common warm-up consisting of running and ball-based exercises (sham treatment, no neuromuscular and stability exercises).
3345569|NCT02222038|Other|skin biopsy|4mm punch biopsy
3259272|NCT01469338|Experimental|Supportive care (management of therapy complications)|Patients receive cabazitaxel IV over 1 hour on day 1, prednisone PO QD, and octreotide pamoate IM on day 1. Patients also receive octreotide acetate SC TID on days 1-14 of course 1 only. Treatment with cabazitaxel repeats every 21 days and treatment with prednisone and octreotide pamoate repeats every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3259273|NCT01469351|Active Comparator|Drug|the GLP-1 receptor analog liraglutide is the active drug. The dose is 1.8mg daily
3345570|NCT02222051|Experimental|Tai Chi|Simplified 24 Yang Style 12 weeks, 1x/week, 60-90 minutes
3345571|NCT02222051|Active Comparator|Neck exercise|conventional neck exercises 12 weeks, 1x/week, 60 min stretching and strengthening, neck education
3345572|NCT02222051|No Intervention|Usual care|Usual care, no specific study intervention this group is offered Tai Chi or neck exercises at the end of the study
3345573|NCT02222064|Experimental|Mindfulness|8 week self-managed mindfulness based intervention
3345574|NCT02222090||patients who have been prescribed warfarin|
3345575|NCT02222090||patients who have been prescribed apixaba|
3345576|NCT02222103||Suspected obstructive sleep apnea in adults|Already scheduled in-lab sleep study
3345577|NCT02222116|Experimental|MGuard Prime|MGuard Prime
3345578|NCT02222116|Active Comparator|Control|BMS or DES
3345579|NCT02222142||Isoflurane group|Isoflurane inhalational anesthesia during OPCAB
3345580|NCT02222142||Propofol group|Total intravenous anesthesia with propofol during OPCAB
3345581|NCT02222155|Active Comparator|CCX168 low dose plus standard of care|Capsule, 10mg, twice daily, 12 weeks
3345582|NCT02222155|Active Comparator|CCX168 high dose plus standard of care|Capsule, 30 mg, twice daily, 12 weeks
3345583|NCT02222155|Placebo Comparator|Placebo BID plus standard of care|Capsule, placebo, twice daily, 12 weeks
3345584|NCT02222168|Experimental|1 BI 409306|tablet, fasted, oral administration with 240 ml water
3345585|NCT02222168|Experimental|2 BI 409306|tablet, fed, oral administration with 240 ml water
3345586|NCT02222168|Experimental|3 BI 409306|tablet, oral administration with 240 ml water at bed time
3345587|NCT02222194||VAM|"Patients with operable and resectable cT1-2-selected T3 cN1cM0 NSCLC undergo VAM for mediastinal lymph node staging. After VAM, patients without tissue proof of N2/3 disease at surgical staging undergo a VATS or thoracotomy with systematic lymph node dissection during the same anaesthesia or at a later stage.~Sensitivity, NPV and accuracy of staging with VAM will be calculated. Provided N2 lymph node metastases are proven by VAM the patient goes off study protocol and can further be assessed/treated according to local clinical practice."
3345588|NCT02222220|Placebo Comparator|metoclopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
3345589|NCT02222220|Experimental|metocliopramide|61 participating subjects were randomized into 2 groups: 30 received metoclopramide up to 30 mg/day and 31 received placebo, each for 4 weeks in a double-blind mode
3345590|NCT02222233|Experimental|BI 671800 HEA delayed release (enteric coated) tablet|
3345591|NCT02222233|Experimental|BI 671800 HEA solution released in jejunum|BI 671800 HEA solution in the Enterion® capsule released in the jejunum
3345592|NCT02222233|Experimental|BI 671800 HEA solution released in ascending colon|BI 671800 HEA solution in the Enterion® capsule released in the ascending colon
3345593|NCT02222233|Experimental|BI 671800 HEA solution released in descending colon|BI 671800 HEA solution in the Enterion® capsule released in the descending colon
3345594|NCT02222233|Experimental|BI 671800 HEA particulate released in ascending colon|BI 671800 HEA as particulate in the Enterion® capsule released in the ascending colon
3345595|NCT02222259|Experimental|GA and Integrated Care Plan|Participants allocated to the intervention group will be seen in the geriatric oncology clinic where they will be assessed using a geriatric assessment. Based on the issues identified in the geriatric assessment, a care plan will be developed with the participant to address the issues.
3345596|NCT02222259|No Intervention|Standard oncology care|Participants randomized to standard oncology care will receive usual care from their oncology team.
3345597|NCT02222285|Placebo Comparator|Sequence 3: placebo/placebo|Placebo/placebo consists of placebo for 7 weeks followed by 7 weeks of placebo treatment
3345598|NCT02222285|Active Comparator|Sequence 2: placebo/ Treatment|Sequence 2: placebo/ Treatment , consists of placebo for 7 weeks followed by 7 weeks of treatment with Vayarin_005
3345599|NCT02222285|Active Comparator|Sequence one: Treatment/Treatment|Treatment/Treatment- consists of PS_005 for 7 weeks followed by 7 weeks of additional treatment with Vayarin_005
3345600|NCT02222298|Experimental|VAAPS group|patients undergoing video assisted ablation of pilonidal sinus
3345601|NCT02222298|Active Comparator|conventional treatment group|patients undergoing conventional off-midline Bascom cleft lift procedure
3345602|NCT02222311||Autistic Children|Children diagnosed with autism spectrum disorder according to the criteria of the Diagnostic Statistical Manual-V will have blood samples taken for laboratory analysis.
3345603|NCT02222311||Healthy Children|Children with no developmental or physical diseases will have blood samples taken for laboratory analysis.
3345604|NCT02222311||Children with Attention Deficit Disorder|Blood samples from children with Attention Deficit Disorder will be measured for Vitamin D and oxidative stress markers.
3345605|NCT02222324|Placebo Comparator|Treatment A|Placebo
3345606|NCT02222324|Experimental|Treatment B|E2609 Low dose
3345607|NCT02222324|Experimental|Treatment C|E2609 High dose
3345608|NCT02222324|Active Comparator|Treatment D|Moxifloxacin
3345609|NCT02222350|Experimental|DS-8500a 10mg once daily|10mg DS-8500a tablet given orally once daily
3345610|NCT02222350|Experimental|DS8500a 75 mg once daily|75mg DS-8500a tablet given orally once daily
3345611|NCT02222350|Placebo Comparator|placebo to match DS-8500a tablet|placebo matching DS-8500a tablet
3345612|NCT02222363|Experimental|VLX600|Dose of VLX600 in patients with refractory advanced solid tumors
3259274|NCT01469351|Placebo Comparator|placebo|non active intervention
3345613|NCT02222376|Active Comparator|Conventional treatment|Weekly ulcer debridement and daily cleansing
3345614|NCT02222376|Experimental|Pirfenidone|Weekly ulcer debridement, daily cleansing, plus twice a day topical pirfenidone application
3345615|NCT02222389|Experimental|CM for alcohol|CM for alcohol
3345616|NCT02222389|Experimental|CM for drugs|CM for drugs
3345617|NCT02222389|Experimental|CM for both substances|CM for both substances
3345618|NCT02222389|Other|Non-Contingent group|No CM for either substance, the Non-Contingent (NC) group
3345619|NCT02222402|Experimental|INTRA-DIALYTIC EXERCISE TRAINING|"Using a modified cycle ergometer, aerobic exercise will be performed in a semi-recumbent position, 3 times per week during the first two hours of haemodialysis. The initial prescription will be set in the moderate intensity range of 40-60% of peak aerobic capacity, progressing to 75% level by the end of the intervention.~Twice per week patients will also complete lower extremity muscular conditioning exercise, using ankle weights, after the aerobic cycling exercise."
3345620|NCT02222402|No Intervention|HAEMODIALYSIS RENAL REPLACEMENT THERAPY|"Haemodialysis is the most common dialysis (renal replacement) treatment for kidney failure.~They may also receive dietary advice, counselling, input from social workers, and other forms of educational support."
3259275|NCT01469403|No Intervention|control group|Standard procedure for knee arthroplasty
3259276|NCT01469403|Active Comparator|Weight loss program|The intervention program consists of 8 weeks of low-diet, using formula foods, and dietary counseling before surgery. When using formula foods the patients can achieve a quicker weight reduction and a greater reduction in fat mass than using conventional dietetic hypo caloric diet.
3345621|NCT02222415|Placebo Comparator|Training + placebo drink|Exercise + non-caloric placebo drink
3345622|NCT02222415|Experimental|Exercise + Protein drink|exercise + Drink containing Protein, Carbohydrates and Fat
3345623|NCT02222428|Experimental|BI 1744 CL/BI 54903 XX FDC|
3345624|NCT02222428|Active Comparator|BI 54903 XX|
3345625|NCT02222428|Active Comparator|BI 1744 CL|
3345626|NCT02222441|Experimental|Fixed sequence modafinil DDI arm (Cohort 1)|Fixed sequence study with treatment A of palbociclib alone, followed by treatment B of palbociclib with modafinil in Cohort 1.
3345627|NCT02222441|Experimental|Fixed sequence pioglitazone DDI arm (Cohort 2)|For Cohort 2, fixed sequence study with treatment A of palbociclib alone, followed by treatment C of palbociclib with pioglitazone.
3345628|NCT02222454|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for pressure ulcers.
3345629|NCT02222467|Experimental|Klox BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for venous leg ulcers.
3345630|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 60/12.5mg
3345631|NCT02222480|Experimental|Fimasartan 60 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 60/25mg
3345632|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 12.5 mg|Combination of Fimasartan/Hydrochlorothiazide 120/12.5mg
3345633|NCT02222480|Experimental|Fimasartan 120 mg, Hydrochlorothiazide 25 mg|Combination of Fimasartan/Hydrochlorothiazide 120/25mg
3345634|NCT02222480|Placebo Comparator|Placebo|placebo
3345635|NCT02222506|Experimental|KLOX BioPhotonic System|Treatment with KLOX BioPhotonic System in adjunction to Standard Of Care for diabetic foot ulcers.
3345636|NCT02222519||Statin use group|patients taking statins for at least 3 months
3345637|NCT02222519||non statin use|no history of taking statin
3345638|NCT02222532|Experimental|Tetronine|Oral T3 (Tetronine) is given 1 mcg/kg every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
3345639|NCT02222532|Placebo Comparator|Placebo|Placebo (saccharin lactic) is given every 6 hourly through naso-gastric tube since induction of anesthesia for 60 hours
3345640|NCT02222545|Experimental|OMS721 low dose|Administration of OMS721 at a low dose
3345641|NCT02222545|Experimental|OMS721 medium dose|Administration of OMS721 at a medium dose
3345642|NCT02222545|Experimental|OMS721 high dose|Administration of OMS721 at a high dose
3345643|NCT02222571|Active Comparator|Control|9-week parenting group focused on safety
3345644|NCT02222571|Experimental|Parents and Tots Together Program|Parents and Tots Together Program is a 9-week, group-based parenting intervention
3345645|NCT02222584||IBD group|patients with with inflammatory bowel disease who are visiting the out-patient clinic of severance hospital from July 2014 to February 2015
3345646|NCT02222597||positive infrascanner finding|
3345647|NCT02222623|Active Comparator|glargine insulin|Basal glargine given once daily in the morning before breakfast plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
3345648|NCT02222623|Active Comparator|NPH insulin|Basal NPH given twice daily before breakfast and at bedtime plus standard hospital corrective doses of insulin aspart before meals and at bedtime.
3345649|NCT02222636|Placebo Comparator|Group 1,Normal saline,1 milliliter|Patients will be assigned to receive intranasal normal saline 1 milliliter
3345650|NCT02222636|Experimental|Group 2,dexmedetomidine 1μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 1μg.kg-1) 1 milliliter
3345651|NCT02222636|Experimental|Group 3,dexmedetomidine 2μg.kg-1,1 milliliter|Patients will be assigned to receive intranasal dexmedetomidine( 2μg.kg-1 )1 milliliter
3345652|NCT02222649|Experimental|Vitamin D3|Group supplemented with high single dose of 200,000 IU of vitamin D3 (cholecalciferol)
3345653|NCT02222649|Placebo Comparator|placebo group|Placebo capsules with starch
3345654|NCT02222662|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
3345655|NCT02222662|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
3345656|NCT02222675|Experimental|Sonographically assisted breast surgery|Sonographically assisted breast surgery
3345657|NCT02222675|Active Comparator|Conventional breast surgery|Conventional breast surgery
3345658|NCT02222701||Replacement|Composite resins with Alpha values for the marginal adaptation criteria were used as the positive control and were made with resin composite (Filtek Supreme, 3M ESPE), eith rubber dam isolation and the adhesive system L-Pop Prompt (3M-ESPE)
3345659|NCT02222701||No treatment|Composite resin restorations (Z100, 3M ESPE) in general clinically acceptable, did not receive treatment.
3345660|NCT02222701||Refurbishing|For this group, The dentists finished the occlusal, lingual or facial surfaces of defective RBC restorations with the medium series of aluminum oxide disks (Sof-Lex,3M ESPE) or carbide burs (12 and 30 blades,Brasseler USA, Dental Instrumentation,Savannah, Ga.) and then polished them with afine series of aluminum oxide disks (Sof-Lex, 3M ESPE) and diamond-impregnated composite polisher (ComposiPro Diacomp, Brasseler). For restorations in which proximal surface areas were affected, the clinicians smoothed them with interproximal aluminum oxide finishing strips (Sof-Lex Finishing Strips, 3M ESPE).
3345661|NCT02222727|Active Comparator|Donepezil|Participants in the donepezil arm will receive the drug for 21 days as specified in the protocol in addition to current best medical treatment for aSAH patients.
3345662|NCT02222727|No Intervention|Control|Control group participants will not receive a placebo drug but will undergo cerebral blood flow imaging in the same manner as the donepezil patients. All other aspects of treatment will be identical to that of aSAH patients not involved in the study.
3239797|NCT01282944|Experimental|Peer Network Arm|"Daily use of pedometer for 6 months. Walking goal set based on level of walking during 2 week run-in period.~Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals. Each peer network participant will be given access to a secure online message board that will allow the 5 participants in each peer network to communicate online. All participants in a peer network will receive a list of ways in which his or her new network could support each individual's walking goals. Participants will also receive weekly feedback regarding which participants in the peer group were successful in achieving their walking goals during the previous week.~Peer network is terminated after 4 months. Daily use of pedometer continues for an additional 2 months."
3345663|NCT02222740|Experimental|Group 1|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice per day (BID) for 7 days, followed by 20 mg BID for 7 days, followed by 30 mg BID for 7 days
3345664|NCT02222740|Experimental|Group 2|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER) Twice Per Day (BID) for 7 days, followed by 30 mg BID for 7 days, followed by 40 mg BID for 7 days
3345665|NCT02222766|Experimental|Parents and Tots Together Program|9-week group-based parenting program
3345666|NCT02222766|Active Comparator|Control|Minimal attention control- weekly mailed information on general child development for 9 weeks
3345667|NCT02222779||Patients with Parkinson´s Disease|
3345668|NCT02222779||Patient´s with Alzheimer´s Disease|
3345669|NCT02222779||Patients with Multiple Sclerosis|
3345670|NCT02222779||Patients with any other neurodegenerative diseases|
3345671|NCT02222792||Septic patient group|The septic patient group will be comprised of patients presenting with bone and joint prosthetic device infection confirmed by intraoperative microbiological culture (at least 2 deep positive samples for the same bacterial strain).
3345672|NCT02222792||Non-septic patient group|The non-septic patient group will be comprised of prosthetic patients presenting with symptoms of mechanical loosening, and whose deep intraoperative samples have all proved negative
3345673|NCT02222792||Intermediate group|An intermediate group will be comprised of patients with only one deep positive sample.
3345674|NCT02222805|Other|Early cord clamping (ECC)|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
3345675|NCT02222805|Other|Delayed cord clamping (DCC)|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
3345676|NCT02222831|Experimental|Day 0 - Study arm|"Day 0 denudation and time lapse culture on IVF-oocytes.:~After insemination the oocytes will subsequently be denuded and cultured in the EmbryoScope (day 0).~The embryo culture media will be collected at day 2-5."
3345677|NCT02222831|No Intervention|Day 1 - control arm|"After insemination oocytes in the control group will be incubated in a standard incubator overnight. On day 1 the oocytes in the will be denuded and further cultured in the EmbryoScope.~The embryo culture media will be collected at day 2-5."
3259277|NCT01469416|Active Comparator|Rosuvastatin|
3345678|NCT02222844|No Intervention|Preoperative CT scan|CT-imaging of chest and abdomen / pelvis before surgery (standard treatment)
3345679|NCT02222844|Experimental|Preoperative MRI scan|Standard treatment plus an additional MRI scan before surgery
3345680|NCT02222844|No Intervention|Observational|Observational only
3345681|NCT02222883||patients with primary diagnosis|patients with primary diagnosis of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
3345682|NCT02222883||patients with platinum-sensitive recurrence|patients with platinum-sensitive recurrence of ovarian cancer for testing of BRCA status regarding germline and somatic mutation
3345683|NCT02222909|Experimental|Intervention CBOs|"Will receive co-developed IT intervention developed together with intervention group community based members. Set of primarily web based tools to improve connection with clients, Johns Hopkins Medicine and one another, referrals, and volunteer services."
3345684|NCT02222909|No Intervention|Control CBOs|Community Based Organizations that are being followed for data collection only for the period of one year
3345685|NCT02222935|Experimental|Balance exercise training|Balance exercise training - thrice week, 2 weeks, 10 repetition Maximum/ set, 2 sets
3345686|NCT02222935|Active Comparator|Routine Back exercise Program|Routine Back exercise Program - 10 Repetition Maximum / set, 2 sets, three times weekly, 2 weeks
3345687|NCT02222948|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 at Weeks 0, 2, 4 and 8
3345688|NCT02222948|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 at Weeks 0, 2, 4 and 8
3345689|NCT02222948|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 at Weeks 0, 2, 4 and 8
3239798|NCT01282957|No Intervention|Active Control|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 6 months
3239799|NCT01282957|Experimental|Financial Incentive Group I|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $100 and 2 in 10 odds of winning $10. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
3239800|NCT01282957|Experimental|Financial Incentives Group II|Daily use of three home-monitoring devices: glucometer, blood pressure cuff and scale for 3 months. If all three devices used daily, participant entered in lottery with 1 in 100 odds of winning $50 and 2 in 10 odds of winning $5. Financial incentive terminated after 3 months. Daily use of devices continues for additional 3 months. (Intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.)
3239801|NCT01282970|Experimental|BI 135585|once daily doses as oral solution or tablet formulation over 14 days
3345690|NCT02222948|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 at Weeks 0, 2, 4 and 8
3345691|NCT02222948|Placebo Comparator|Placebo|Placebo (for Vatelizumab) at Weeks 0, 2, 4 and 8
3345692|NCT02222961|Experimental|BIIR 561 CL|
3345693|NCT02222961|Placebo Comparator|Placebo|
3345694|NCT02222974|Experimental|BIIR 561 CL|
3345695|NCT02222974|Placebo Comparator|Placebo|
3345696|NCT02222987|Active Comparator|Terbogrel|
3345697|NCT02222987|Experimental|Terbogrel with Clopidogrel|
3345698|NCT02222987|Active Comparator|Clopidogrel|
3345699|NCT02223000|Active Comparator|BIBV 308 SE solution|
3345700|NCT02223000|Experimental|BIBV 308 SE capsule 1|
3345701|NCT02223000|Experimental|BIBV 308 SE capsule 2|
3345702|NCT02223013|Active Comparator|BIBV 308 SE solution|
3239802|NCT01282970|Placebo Comparator|Placebo to BI 135585|once daily doses as oral solution or tablet formulation over 14 days
3239803|NCT01282983|Active Comparator|fiber|
3239804|NCT01282983|Placebo Comparator|Placebo|
3345703|NCT02223013|Experimental|BIBV 308 SE capsule L|
3345704|NCT02223013|Experimental|BIBV 308 SE capsule S|
3345705|NCT02223026|Experimental|Linagliptin/metformin fed|
3239805|NCT01283048|Experimental|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
3239806|NCT01283061|Experimental|zafirlukast|Zafirlukast Tablets 20 mg of Dr. Reddys Laboratories Limited
3239807|NCT01283061|Active Comparator|Accolate|ACCOLATE tablets manufactured by IPR pharmaceuticals and manufactured for Astrazeneca Pharmaceuticals
3345706|NCT02223026|Active Comparator|Linagliptin/metformin fasted|
3345707|NCT02223039|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
3345708|NCT02223039|Experimental|AbGn-168H High Dose|Subject to receive high dose of AbGn-168H intravenously
3345709|NCT02223039|Placebo Comparator|Placebo|Subject to receive placebo intravenously
3345710|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1|Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3345711|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1|One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3345712|NCT02223052|Experimental|CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3345713|NCT02223052|Experimental|CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2|One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered.
3345714|NCT02223078|Experimental|G17DT|Three 250 µg injections over a six week period (weeks 0,2 and 6)
3239808|NCT01283074||Cohort|
3239809|NCT01283100|Experimental|Treatment A|GSK1349572 50mg q24h x 7 days
3239810|NCT01283100|Experimental|Treatment B|GSK2248761 200mg q24h x 7 days
3239811|NCT01283100|Experimental|Treatment C|GSK1349572 50mg q24h x 7 days + GSK2248761 200mg q24h x 7 days
3239812|NCT01283126|Experimental|Euglycemic and hypoglycemic clamp|Subjects will complete clamp study visit.
3239813|NCT01283165||health education|This was an intervention follow up Knowledge Attitude and Practice study that investigated the distribution of polyparasitism with schistosomiasis, STHs and P. falciparum among primary schoolchildren.
3239814|NCT01283178|Experimental|Arm I|Patients undergo intensity-modulated image-guided adaptive radiotherapy once daily 5 days a week for 6 weeks. Patients also receive cisplatin IV on days 1 and 22. Treatment continues in the absence of disease progression or unacceptable toxicity.
3239815|NCT01283191|Experimental|Behavioral Incentives|Vouchers for complying with target behavior
3239816|NCT01283191|Placebo Comparator|Education Control|Education class
3239817|NCT01283204|Active Comparator|SP(S-1 with cisplatin)|"SP <Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO)~Day 1 : CDDP 60mg/m2/day IVF 2hours~Day 15~21 : Rest"
3345715|NCT02223078|Placebo Comparator|Placebo|Three 250 µg injections of a placebo over a six week period (weeks 0,2 and 6)
3345716|NCT02223091|Experimental|Consultation by a trained physician|The physicians of this group receive a free consultation training program on skills regarding consultations on complementary medicine for breast-cancer patients. The training was developed by a multi-professional team and is comprised of three parts: (1) online-training, (2) on-site-training, and (3) consultation manual. Each of the physicians will counsel 10 patients. The patients in this group therefore receive a consultation by a trained physician.
3345717|NCT02223091|Active Comparator|Consultation by an untrained physician|The physicians of the control arm receive no training. Each will counsel 10 patients. The patients in this group therefore receive a consultation by an untrained physician.
3239818|NCT01283204|Active Comparator|FL/Tax(Paclitaxel with Leucovorin with 5-FU)|"FL/Tax <Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
3239819|NCT01283204|Active Comparator|FL/Doc(Decetaxel with Leucovorin with 5-FU)|"FL/Doc <Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
3239820|NCT01283204|Active Comparator|FOLFOX(Oxaliplatin with Leucovorin with 5-FU)|FOLFOX <Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
3345718|NCT02223104|Active Comparator|Sensura|Ostomy pouch
3345719|NCT02223104|Experimental|Flexima Active|Ostomy pouch
3345720|NCT02223117|Experimental|Intervention|Thrombosomes
3345721|NCT02223117|Placebo Comparator|Placebo|Buffer/placebo Control
3345722|NCT02223130|Experimental|Intervention Group|Participants will attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys. After their baseline interview and before their first follow-up interview, participants attend the Intervention Group, which consist of 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who uses Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions, and behaviors in response to stressful/discrimination experiences.
3345723|NCT02223130|No Intervention|Waitlist Control|"Participants are not given the Intervention Group while they are enrolled in the study. Instead, they only attend the baseline, first follow-up, and final follow-up study visits, at which they take computer surveys.~After they have completed the study, participants from the first two cohorts are offered the option of attending an intervention group that is identical in content to the intervention group being studied.The third cohort is offered the intervention group after they have completed the first follow-up but before they complete the final follow-up due to timing and budgetary restraints. No data is collected and no incentives are given during these intervention groups."
3239821|NCT01283217|Experimental|DS(Docetaxel with S-1)|Docetaxel with S-1
3345724|NCT02223156||MediYoga|
3345725|NCT02223156||Music relaxation|
3345726|NCT02223156||No treatment|
3345727|NCT02223169|Experimental|Egg albumin-derived peptide|Each participant will consume 1 sachet of Egg albumin-derived peptide (3 g) each day mixed with a fruit juice drink for 42 days.
3345728|NCT02223169|Placebo Comparator|Placebo|Participants will consume one sachet of the placebo mixed with a fruit juice drink that will appear and taste similar to the albumin derived peptide sachet.
3239822|NCT01283217|Active Comparator|SP(S-1 with cisplatin)|S-1 with cisplatin
3239823|NCT01283230||chronic liver disease|Any cause of liver disease that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis such as hepatitis B, hepatitis C, alcoholic liver disease.
3239824|NCT01283230||Healthy liver and kidney donor|Healthy liver and kidney donor who have normal liver condition
3239825|NCT01283243||HIV patients with normal liver status|HIV patients without abnormal liver function and chronic liver disease
3345729|NCT02223182|Experimental|Viaskin Milk 150 mcg|
3345730|NCT02223182|Experimental|Viaskin Milk 300 mcg|
3345731|NCT02223182|Experimental|Viaskin Milk 500 mcg|
3239826|NCT01283256||Experimental|
3345732|NCT02223182|Placebo Comparator|Viaskin Placebo|
3345734|NCT02223221|Experimental|With PGS|"IVF/ICSI cycles with PGS. Select embryos by SNP-array based PGS for the number of all chromosomes on day 5, only euploid embryos will be transferred.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
3345735|NCT02223221|Active Comparator|Without PGS|"IVF/ICSI cycles without PGS. Selection of embryos are based on blastocyst morphology criteria on day 5.~A maximum of 2 embryos will be transferred for each treatment cycle. Up to 3 treatment cycles will be offered."
3345736|NCT02223234|Active Comparator|Control|Control- monthly mailed information on children's health
3345737|NCT02223234|Experimental|Email and 4 Home Visits|Weekly emails and 4 home visits with a health educator
3345738|NCT02223234|Experimental|Email and 2 Home Visits|Weekly emails and 2 home visits
3239827|NCT01283269|Experimental|Memory Support System or Computer|
3239828|NCT01283295||Immune complications|Transplant recipients who develop a clinically recognized complication with potential immune etiology or ramifications. Examples include opportunistic infection, rejection, malignancy, alloantibody formation or immunosuppressive drug toxicity.
3239829|NCT01283295||Stable Transplant Recipient|Patients who demonstrate immune stability characterized by stable graft function without evident complication. These patients serve as comparators for Group 1
3239830|NCT01283295||Pre-Transplant Longitudinal|Patients who are candidates for kidney, pancreas, liver or lung transplant will be enrolled and followed longitudinally.
3239831|NCT01283295||Organ Donors|Donors for individuals meeting the criteria for Cohorts 1-3
3239832|NCT01283295||Disease state|Individuals with liver, renal or pulmonary diseases that may lead to the development or organ failure.
3239833|NCT01283295||Normal Volunteers|
3259278|NCT01469416|Experimental|Rosuvastatin + clopidogrel|
3259279|NCT01469429|Placebo Comparator|Arm I (Lozenge placebo)|Patients receive lozenge placebo PO QID.
3239834|NCT01283308|Active Comparator|Standard of Care|Participants randomized to the standard of care group will receive standard lifestyle advice for diabetes prevention consistent with expert recommendations for a healthy lifestyle, including losing 5-10% of their excess body weight, following standard dietary recommendations to reduce calorie and fat intake, and exercising at least 150 minutes per week.
3239835|NCT01283308|Experimental|Lifestyle Intervention|Intervention arm participants will participate in a step-wise model of diabetes prevention with the goal of reducing diabetes risk, primarily through (1) a weight loss of at least 7% and (2) 150 minutes or more per week of moderate level physical activity.
3239836|NCT01283347|Experimental|18F-DTBZ for Parkinson's Disease|"25 age-matched healthy volunteers will be enrolled. For assessing the correlation between the 18F-DTBZ binding and the severity of disease, the patients with PD will be divided into three groups according to their motor scores: mild, moderate, and advanced. We will enroll 25 patients in each group. Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study, as one screening visit, one imaging visit, and one safety evaluation visit.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
3239837|NCT01283360|Placebo Comparator|HEC Placebo Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
3239838|NCT01283360|Active Comparator|Tenofovir 1% Gel|In Stage 2, participants will be randomized to receive either tenofovir 1% gel or HEC placebo gel. Following a baseline visit, participants will return to the clinic, where a single dose of the study gel will be administered. Within approximately 30 minutes, rectal swab, stool, and rectal biopsy specimens will be obtained via anoscopy. After a one-week recovery period participants will return to the clinic for assessment. If no significant adverse events (AEs) are reported they will begin to self-administer once-daily outpatient doses of the study gel for 7 days, after which they will return to the clinic for evaluation and specimen collection.
3239839|NCT01283373|Experimental|A|Dose escalation cohorts
3239840|NCT01283373|Experimental|B|Dose expansion cohorts
3239841|NCT01283399||Rituximab + Methotrexate|All participants with active refractory RA who were eligible to receive treatment with methotrexate and rituximab in the Investigators' opinion as per the routine clinical practice following inadequate response to a single cycle of anti-TNF therapy.
3345739|NCT02223247|Experimental|TVB-2640|Oral TVB-2640 capsules or tablets of various dose strengths administered QD for 21 - 28 day dosing cycles, alone or in combination with certain standard chemotherapy agents
3345740|NCT02223273|Experimental|Multifaceted Strategy|"Multifaceted Intervention~Simulation Based Team Training~Case Manager~Check lists~Reminders~Educational Materials"
3239842|NCT01283412|Active Comparator|Arm P|Placebo infusion
3239843|NCT01283412|Experimental|Arm D|Dexmedetomidine infusion
3239844|NCT01283425|Experimental|Test|InsuPatch use for 3 months.
3345741|NCT02223273|No Intervention|Usual Care|Hospital Standard Treatment
3345742|NCT02223286||ASGES (Treatment Group)|Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
3345743|NCT02223286||Non-ASGES (Control Group)|Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
3345744|NCT02223299|Experimental|Deplin w Supplements|deplin 15mg plus L-Tyrosine 6g/d and L-Tryptophan 2g/d for 30 days
3345745|NCT02223299|Placebo Comparator|Deplin w placebo|deplin 15mg daily plus Placebo A and Placebo B for 30 days
3345746|NCT02223312|Experimental|TAPA-pulsed DC vaccine|The subject will take low-dose cyclophosphamide by mouth for 5 days starting 7 days prior to the vaccine cycle. The vaccine contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered SQ with low-dose GM-CSF following the low-dose cyclophosphamide cycle. A total of six (6) cycles of cyclophosphamide and six (6) DC vaccines cycles will be administered alternating every 14 days.
3345747|NCT02223325||Elderly, acute pancreatitis|No intervention
3345748|NCT02223325||Adults <65 y, acute pancreatitis|No intervention
3345749|NCT02223377|Active Comparator|Morphine|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
3345750|NCT02223377|Active Comparator|Hydromorphone|"Analgesia with equipotent doses of Morphine and Hydromorphone will be administered in titrated doses. Doses are 1ml=1mg of morphine or 0.2 mg of hydromorphone. Potency ratio of 1:5 (M: HM).~0.05mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml)"
3239845|NCT01283425|No Intervention|Control|
3239846|NCT01283438|Experimental|Barricaid Device|Intervention: Barricaid Device
3345751|NCT02223403|Experimental|submaximal steady state exercise|90 minutes after respective beetroot juice ingestion, subjects walked on treadmill at a pre-determined steady state workload for a total of 15 minutes with oxygen consumption recorded for the last 10 minutes
3345752|NCT02223403|Experimental|six minute walk test|subjects performed six-minute walk at self-determined pace 30 minutes after treadmill exercise was performed
3239847|NCT01283438|Active Comparator|Standard of Care|Standard (Limited) Discectomy Only
3239848|NCT01283451||Exercise|NIRS values of all participants will be measured at baseline and following each 30-60 second exercise.
3239849|NCT01283477|Experimental|ACUPUNCTURE|
3239850|NCT01283477|Sham Comparator|SHAM ACUPUNCTURE|
3345753|NCT02223416|Experimental|RGB-10|
3345754|NCT02223416|Active Comparator|Forsteo|
3345755|NCT02223468||CASE-CONTROL|CASE: Liver transplant recipients (n=20) CONTROL: A healthy person with a similar age (±10 years) to the control selected from the same family setting (n=20)
3345756|NCT02223481|Experimental|Terbogrel low dose|
3345757|NCT02223481|Experimental|Terbogrel high dose|
3345758|NCT02223481|Placebo Comparator|Placebo|
3345759|NCT02223494|Experimental|Terbogrel|
3345760|NCT02223507|Experimental|BIIR 561 CL|
3345761|NCT02223507|Placebo Comparator|Placebo|
3239851|NCT01283490|Active Comparator|DASD Group|Benzocaine 20% will be placed using the DASD for one minute. Immediately after DASD application a needle puncture with a 27 gauge needle to the depth of 3 millimeters will be performed.
3239852|NCT01283490|Sham Comparator|Sonic Vibration (SV)|A modified tooth brush which only allows sonic vibration (SV), that has the appearance and sound of the DASD will be used to apply the benzocaine 20% for one minute. Following application with the SV a needle puncture with a 27 gauge needle to the depth of 3millimeters.
3239853|NCT01283503|Experimental|BKM120|
3239854|NCT01283529||Children 0 - 15 years|Children undergoing neurosurgery in general anesthesia
3345762|NCT02223533|Experimental|Wound catheter|analgesia with wound catheter after colon surgery
3345763|NCT02223533|Active Comparator|morphine|analgesia with morphine after colon surgery
3239855|NCT01283568||1 - Gamaline+Hipericin - fertile women|
3239856|NCT01283568||2- Gamaline+Hipericin - climateric women|
3239857|NCT01283568||3- Gamaline- control - fertile women|
3345764|NCT02223559||right heart catheterization patients|
3345765|NCT02223572|Experimental|osteoporotic hip fracture|
3345766|NCT02223585|Experimental|Cross-over single arm|
3345767|NCT02223598|Experimental|Dose Escalation - CB-5083|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies
3345768|NCT02223598|Experimental|Dose Expansion - CB-5083, Dexamethasone|CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with relapsed and refractory multiple myeloma; in addition, subjects who develop progressive disease at the end of Cycle 1, or beyond, may receive their current dose of CB-5083 in combination with oral or IV low dose Dexamethasone (40 mg)
3345769|NCT02223598|Experimental|Dose Expansion - CB-5083|CB-5083 will be administered orally, daily, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with diffuse large B-cell lymphoma (DLBCL) or Waldenstrom Macroglobulinemia, if such arm is opened, per Sponsor
3345770|NCT02223611|Experimental|S1 capsule plus Cisplatin|"S1: 40mg, bid, when body surface area (BSA)<1.25 m2, 50mg; bid when 1.25 m2≤BSA<1.5 m2; 60mg, bid when 1.5 m2≤BSA 60mg from day 1 to 14. Cisplatin: 75 mg/m2 on day 1.~3 weeks/4cycles"
3345771|NCT02223611|Active Comparator|Vinorelbine plus Cisplatin|"Vinorelbine: 25 mg/m2 intravenously on day 1, and day 8. Cisplatin: 75 mg/m2 intravenously on day 1.~3 weeks/4cycles"
3345772|NCT02223624|Experimental|eccentric aerobic exercise group|Eccentric aerobic exercise group: Participants in this group will participate in an eccentric aerobic exercise rehabilitation program for a total of eight weeks, two sessions per week. Outcome measurements will be taken post exercise program and also after a 3 month follow-up period. Each session will be approximately 60 minutes in duration and include approximately 10 minutes of warm up (stretches), eccentric stepper aiming for 20 minutes, walking and light weights, followed by a five minute cool-down period.
3345773|NCT02223624|Active Comparator|Concentric aerobic exercise group|"Concentric aerobic exercise group (usual care): The length of the concentric aerobic exercise based rehabilitation program will be the same as the study group- twice weekly exercise sessions for 8 weeks. Outcome measurements will also be taken after a 3-month follow-up period.~Participants in the concentric aerobic exercise group will participate in the same warm-up and cool down period as the eccentric group. They will also complete walking and light weights. To replace the 20 minutes of eccentric exercise, concentric participants will complete approximately 20 minutes of exercise bike, stair climbing and rowing as able with required rests."
3345774|NCT02223624|No Intervention|Waiting list control|Waiting list (no exercise): Participants assigned to this group will not receive any intervention during the study period. They will be assessed like other participants at baseline and after eight weeks, but not at three-month follow-up due to ethical concerns around withholding care known to be effective. Given that there is a waiting list for the current exercise program of 4-12 weeks, it is felt that delaying care for a set period of eight weeks is not of ethical concern. Following the completion of assessments, waiting list participants will be able to complete the traditional exercise program as usual but not as participants of the study's experimental groups.
3345775|NCT02223676|Experimental|Intervention|Clinical pharmacists conduct medication history
3345776|NCT02223676|No Intervention|Control|standard procedures for admission is followed
3345777|NCT02223728|Experimental|Treatment Condition|Telehealth Lifestyle Program
3345778|NCT02223728|Sham Comparator|Attention Control Condition|Health Education Program
3345779|NCT02223741||Korean medicine conjugate rehabilitation|those with more than 30 days of herbal drugs or more than 12 times of acupuncture (Korean medical treatment) within six months in addition to conventional rehabilitation
3345780|NCT02223741||Conventional rehabilitation|those with one of the treatments; physical, occupational, speech-language or cognitive-behavioral therapies
3345781|NCT02223767|Experimental|Verum TMS|10 Hz TMS over medial prefrontal cortex
3345782|NCT02223767|Experimental|Sham TMS|10 Hz sham TMS over medial prefrontal cortex
3345783|NCT02223780|Placebo Comparator|control|standard management
3345784|NCT02223780|Active Comparator|early palliative care|early palliative care
3345785|NCT02223806|Active Comparator|Self-assessment of uterine tonus|Uterine tonus assessment every 15 minutes for 2 hours by educated patient, which is standard-of-care.
3239858|NCT01283568||4 - Gamaline control - climateric women|
3239859|NCT01283594|Experimental|Tozadenant (SYN115) 60 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3345786|NCT02223806|Experimental|Midwife uterine tonus assessment|Uterine tonus assessment every 15 minutes for 2 hours by midwive.
3239860|NCT01283594|Experimental|Tozadenant (SYN115) 120 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3239861|NCT01283594|Experimental|Tozadenant (SYN115) 180 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3239862|NCT01283594|Experimental|Tozadenant (SYN115) 240 mg BID|Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
3345787|NCT02223819|Experimental|Crizotinib|Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
3345788|NCT02223832|Experimental|ACT-128800|"A single oral dose of 40 mg ACT-128800 will be administered as~1 capsule given in the fasted state in the morning"
3345789|NCT02223845|Experimental|Music|Played music during embryo transfer
3345790|NCT02223845|No Intervention|Control|No music played during embryo transfer
3345791|NCT02223884|Experimental|weekly docetaxel and carboplatin|
3345792|NCT02223897|Experimental|Conventional treatment, huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
3345793|NCT02223897|Placebo Comparator|Conventional plus placebo|Received conventional treatment and 50 ml saline once per week for the first month and once per month for 6 months(9 times in total).
3345794|NCT02223910|Active Comparator|Motor Cortex|Feedback training of functional connectivity between motor cortex and the rest of the brain
3345795|NCT02223910|Placebo Comparator|Control region|Feedback training of functional connectivity between medial prefrontal cortex of healthy hemisphere and the rest of the brain
3345796|NCT02223923|Experimental|Dose Escalation|AZD6738 PO 20 to 380mg BD increasing
3345797|NCT02223923|Experimental|AZD6738 - Expansion Phase|AZD6738 starting dose and regimen to be determined in dose escalation phase
3345798|NCT02223923|Experimental|AZD6738 + Radiotherapy (Head and Neck)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
3345799|NCT02223923|Experimental|AZD6738 + Radiotherapy (Abdomen / Pelvis)|AZD6738 starting dose to be determined in dose escalation phase + increasing doses of radiotherapy (20 or 30Gy)
3345800|NCT02223936|Other|children with Prenatal enlarged nuchal transluce|
3239863|NCT01283594|Placebo Comparator|Sugar Pill|White-coated, modified-oval placebo tablets.
3239864|NCT01283607|Active Comparator|Digicoach|Women randomized in the Digicoach group will be treated by the Digicoach therapy. Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for in vitro fertilization (IVF) women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
3345801|NCT02223936|Other|Control|
3345802|NCT02223949|Experimental|Cook double balloon catheter|Insertion of the Cook double balloon catheter to the cervix until both balloons are properly located in the cervical canal. After properly located it is inflated with 20 ml of saline. Then both balloons are additionally inflated to a total of 80 ml each balloon. Twelve hours later the balloons are deflated and the device is removed.
3345803|NCT02223949|Active Comparator|PGE1 tablet insertion|Insertion of 25 mg PGE1 (Prostaglandin E1) tablet is inserted in the posterior fornix. The patient woll the be instructed to stay in bed for the next 60 minutes. After six hours a repeated dose will be administered. Total of 4 PGE1 doses within 24 hours.
3345804|NCT02223962|Experimental|Physical activity|The fitbit Ultra was used to provide real-time feedback on physical activity. An experienced physiotherapist contacted the subjects 3 times a week to receive information about the amount of steps from the previous days. In agreement with the patient, a new goal for the coming weeks was set and patients were motivated to achieve their individual goal.
3345805|NCT02223962|Placebo Comparator|Usual Care|During the hospital stay, the patients in the control group will be informed about the beneficial effects of being physically inactive.They will not receive feedback about their activities performed and will not be stimulated to become more active.
3345806|NCT02223975||Vulval Disease|Patients who have undergone vulval skin biopsy or surgery for a vulval condition within Gloucestershire Hospitals NHS Foundation Trust.
3239865|NCT01283607|No Intervention|Control|Women in the control group will get the usual treatment, there will be no additional intervention.
3239866|NCT01283620|Other|Usual Care|
3345807|NCT02223988|Experimental|subglottic secretion drainage|
3345808|NCT02224001|Experimental|Asian rhinoplasty, septal cartilage|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
3345809|NCT02224014||Lendormin D tablets|
3345810|NCT02224027|Active Comparator|i-gel|Each novice performs i-gel insertion in difficult laryngoscopy scenario.
3345811|NCT02224027|Active Comparator|proceal laryngeal mask airway|Each novice performs proceal laryngeal mask airway insertion in difficult laryngoscopy scenario.
3345812|NCT02224027|Active Comparator|tracheal tube|Each novice performs tracheal intubation in difficult laryngoscopy scenario.
3345813|NCT02224040|Experimental|Ceftriaxone I.V|The participants in this arm will receive the following drug and dosage: adult: Ceftriaxone intravenous 2 gr once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day (maximum dose 2.5 g/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
3345814|NCT02224040|Experimental|Ceftriaxone I.V+Azithromycin P.O|The participants in this arm will receive the following drugs and dosages: adult: 2 g intravenous ceftriaxone and 500 mg oral azithromycin once a day. Pediatric: intravenous 75 mg/kg ceftriaxone once a day and oral 20 mg/kg azithromycin suspension once a day. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards. Patients will be hospitalized during the entire treatment course (including the afebrile period).
3345815|NCT02224040|Experimental|Azithromycin P.O|The participants in this arm will receive the following drug and dosage: adult: azithromycin oral 500 mg once a day. Pediatric: oral 20 mg/kg azithromycin suspension once a day (maximum dose 1000 mg/day). Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
3345816|NCT02224040|Experimental|Azithromycin P.O+Cefixime P.O|The participants in this arm will receive the following drugs and dosages: adult: 500 mg azithromycin and 400 mg cefixime. Pediatric: oral 20 mg/kg azithromycin suspension once a day and oral 10 mg/kg cefixime. Patients will receive antibiotic treatment until defervescence and for 3 days afterwards.
3345817|NCT02224066|Experimental|Ticagrelor|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
3345818|NCT02224066|Active Comparator|Aspirin/Clopidogrel|Patients with high-on-treatment platelet reactivity (PRU ≥ 208)
3345819|NCT02224066|No Intervention|Registry arm|Patients with normal-on-treatment platelet reactivity (PRU < 208) will continue with Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI.
3345820|NCT02224079|Experimental|BIIB 722 CL|
3239867|NCT01283620|Experimental|modified CIMT (mCIMT)|
3239868|NCT01283633|Experimental|programming with non-experienced nurse|Programming done by an experienced neuromodulation clinician will be compared to the patient satisfaction of a programming session with an inexperienced nurse via remote presence robotics, which will be directed by the experienced clinician
3239869|NCT01283646|Experimental|Apevitin BC|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
3239870|NCT01283646|Active Comparator|Vitamin B Complex + Vitamin C|Children (5 to 6 years): 3.5 ml 3 times a daily Children (7 to 15 years): 5 ml 3 times a daily
3345821|NCT02224079|Placebo Comparator|Placebo|
3345822|NCT02224092|Active Comparator|Active|Active is a multivitamin multimineral with phytonutrient product.
3345823|NCT02224092|Placebo Comparator|Placebo|Placebo is a sugar pill.
3345824|NCT02224105|Experimental|BI 653048 BS|escalating doses
3345825|NCT02224105|Active Comparator|Prednisolone low|
3345826|NCT02224105|Active Comparator|Prednisolone high|
3345827|NCT02224105|Placebo Comparator|Placebo|
3345828|NCT02224118|Experimental|CNTO 3649 10 mcg/kg (single dose)|A single dose of 10 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3345829|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (single dose)|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3345830|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (single dose)|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3345831|NCT02224118|Experimental|CNTO 3649 300 mcg/kg (single dose)|A single dose of 300 microgram per kilogram (mcg/kg) of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
3345832|NCT02224118|Experimental|CNT0 3649 30 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 30 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
3345833|NCT02224118|Experimental|CNTO 3649 100 mcg/kg (multiple dose)|Participants with type 2 diabetes mellitus will be administered 100 mcg/kg CNTO 3649 as subcutaneous injection once a week for 4 weeks.
3345834|NCT02224118|Placebo Comparator|Placebo|Matching placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
3345835|NCT02224131|Experimental|Monitoring Arm|dose adjustment of both aspirin and clopidogrel in suboptimal responders identified based on a point of care assay(TEG)
3345836|NCT02224131|Active Comparator|Conventional Arm|fixed dose regiment of both aspirin and clopidogrel in all patients following stent deployment according to international guidelines
3345837|NCT02224144|Experimental|Vitamin D3 plus Calcitriol|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU daily for 12 months~1 pill of Rocaltrol (calcitriol) 0.5 mcg daily for 12 months"
3345838|NCT02224144|Placebo Comparator|Vitamin D3 plus Placebo|"1 pill of Vitamin D3 (cholecalciferol) 1000 IU per day for 12 months~1 pill of placebo (sugar pill) per day for 12 months"
3345839|NCT02224170|Experimental|Lidocaine group|
3345840|NCT02224170|Active Comparator|Dexamethasone group|
3345841|NCT02224183|Active Comparator|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
3345842|NCT02224183|Active Comparator|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
3345843|NCT02224196|Experimental|manual ventilation|
3345844|NCT02224196|Active Comparator|pressure-controlled ventilation|
3345845|NCT02224209|Experimental|Staged angioplasty|"Using Abbott EPD systems (Accunet/Emboshield), a balloon, stent~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device; Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
3259280|NCT01469429|Experimental|Arm II (LBR lozenge)|Patients receive lyophilized black raspberries lozenge PO (8gms/day)
3345846|NCT02224209|Active Comparator|Routine single-stage CAS|"Using a balloon, stent~Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield); Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation; After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
3345847|NCT02224222||Patients undergoing vascular procedures|Including all non-interventional surgical procedures, excluding varix surgery
3345848|NCT02224222||Patients undergoing cardiac procedures|Including all non-interventional surgical procedures, excluding HTX
3345849|NCT02224235|Experimental|Group 1- COBRA 1 week DAPT|COBRA PzF coronary stent followed by dual anti-platelet therapy (DAPT) for one week
3345850|NCT02224235|Active Comparator|Group 2 - DES 6 month DAPT|Resolute Integrity DES followed by dual anti-platelet therapy (DAPT) for at least 6 months
3345851|NCT02224235|Experimental|Group 3 - COBRA Aspirin|COBRA PzF coronary stent followed by aspirin alone
3345852|NCT02224248|Experimental|Health checks with fitness testing|
3345853|NCT02224248|Active Comparator|Health checks without fitness testing|
3345854|NCT02224261|Experimental|Physical Therapy|"Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises stretching cords and patient education."
3345855|NCT02224261|Active Comparator|Control|Control protocol includes standard progressive active and action-assisted arm exercises & patient education.
3239871|NCT01283659|Active Comparator|Standard imaging (coronary angiography)|Subjects will undergo a coronary angiogram as planned by their attending doctor
3259281|NCT01469429|Placebo Comparator|Arm III (Saliva Substitute placebo)|Patients receive Saliva Substitute placebo PO QID.
3345856|NCT02224287|Other|Fluoroscopy|Technologist control of fluoroscopy Surgeon control of fluoroscopy
3345857|NCT02224300|Experimental|Education|"Intervention group will receive the ELC for six weeks (15.9. - 26.10.2014) and comparison group will not receive it.~Members of the intervention group in will work in teams of 10 nurses with weekly questions (released in Mondays) based on patient-description existing in Moodle. One member of the team will send the solutions to questions once a week (in Thursdays) Moodle. Researcher will download the model-answer to Moodle once a week (in Fridays) and nurses will compare their answer to model answer (self-evaluation)."
3345858|NCT02224339||plaque neovascular and stress echo|After the SE and CEUS examination, patients will be grouped per the result of SE and CEUS as follows: group I: plaque neovascularization and normal wall motion; group II: plaque neovascularization and abnormal wall motion; group III: no plaque neovascularization and abnormal wall motion; group IV: no plaque neovascularization and normal wall motion.
3345859|NCT02224352|Experimental|Single-Arm Study|Functional neuromuscular electrical stimulation of abdominal-wall muscles triggered by an airway pressure signal
3345860|NCT02224365|Experimental|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
3345861|NCT02224365|Placebo Comparator|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
3345862|NCT02224378|Experimental|peep induced CVP|
3345863|NCT02224378|Active Comparator|passive leg raising(PLR)|
3345864|NCT02224391|Experimental|Arm I (ABM training)|Patients receive ABM training over 30 minutes through a smartphone on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
3345865|NCT02224391|Sham Comparator|Arm II (sham training)|Patients undergo sham training on days 1-14. Patients then receive nicotine patches for up to 8 weeks.
3345866|NCT02224417|Other|Diabetes Educational Program (DEP) only|Participants will receive the Diabetes Educational Program, as required, which is part of usual care at the Polyclinic. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one).
3345867|NCT02224417|Other|DEP + Process Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified process goals.
3345868|NCT02224417|Other|DEP + Outcome Incentive Arm|Participants will receive the Diabetes Educational Program, as required. They will receive the Fitbit ™, the eCAP, and a glucometer (if they do not already have one). They will also have the opportunity to earn financial incentives for meeting specified outcome goals.
3345869|NCT02224430||schizophrenia/schizoaffective disorder|Participants with schizophrenia/schizoaffective disorder.
3345870|NCT02224443|Experimental|Group A, dexmedetomidine , 0.3µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed Continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
3345871|NCT02224443|Experimental|Group B,dexmedetomidine , 0.5µg.kg-1.h-1|Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
3345872|NCT02224443|Placebo Comparator|Group C ,normal saline|Normal saline infusion will be given with the same infusion volume as group A and B
3345873|NCT02224456|Experimental|Tenofovir|Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.
3345874|NCT02224469|Experimental|ECoG (electrocorticography) sensing|Use ECoG-based Brain Computer interface to control assistive technology
3345875|NCT02224495|Placebo Comparator|Control|Standard of care
3345876|NCT02224495|Experimental|Structured exercise training|8-week outpatient exercise-training program, encompassing 3 sessions per week, including endurance and resistance training
3345877|NCT02224521|Experimental|Cohort 1|Subjects will be assigned to any of the 4 dosage regimen (A, B, C, D) in four periods. A= GSK2190915 Solution, 50mg single dose, fasted; B = GSK2190915 Capsule Formulation A, 50mg single dose (1 x 50mg capsule), fasted; C= GSK2190915 Capsule Formulation B, 50mg single dose (1 x 50mg capsule), fasted; D= GSK2190915 Capsule Formulation C, 50mg single dose (1 x 50mg capsule), fasted.
3345878|NCT02224521|Experimental|Cohort 2|The selected formulation will be dosed with GSK2190915 capsule formulation at 20mg (fasted), 100mg (fasted), 100mg (fed) and 200mg (fasted).
3345879|NCT02224521|Experimental|Cohort 3|Cohort 3 will be a 4-way complete crossover study with single doses of 20mg and 200mg of up to two capsule formulations taken forward from cohort 2 in 10 healthy adult subjects in the fasted state.
3345880|NCT02224521|Experimental|Cohort 4|The regimen for Cohort 4 will be either the highest dose (200mg) of the capsule formulation (A, B or C) taken forward from the previous cohorts or the solution formulation (200mg).
3345881|NCT02224521|Experimental|Cohort 5|Subjects will take milled and micronised tablet formulations of GSK2190915 in the fasted state in periods 1 and 2, and will take milled and micronised tablet formulations of GS2190915 in the fed state in periods 3 and 4.
3345882|NCT02224521|Experimental|Cohort 6|Tablet formulations (milled and micronised, different to the Cohort 5 formulations) of GSK2190915 will be dosed in the fasted and fed (after a light breakfast) states.
3345883|NCT02224534|Experimental|Ticagrelor and Clopidogrel.|The patients assigned to the TICA group have loading dose of ticagrelor 180 mg just after the randomization, and then ticagrelor 90 mg twice daily during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
3239872|NCT01283659|Active Comparator|Advanced imaging (CTA)|Subjects will undergo a CTA scan first. Based on the CTA results, subjects may or may not proceed to coronary angiography. CTA results will be reviewed by the attending physician.
3239873|NCT01283698|Experimental|LAS 41004 dosage 1|dosage 1, once daily
3345884|NCT02224534|Active Comparator|Clopidogrel|The patients assigned to the CLPD group have loading dose of clopidogrel 600 mg just after the randomization, and then clopidogrel 75 mg daily should be maintained during the study period. All patients also have aspirin 300 mg as a loading dose and 100 mg once daily as a maintenance dose.
3345885|NCT02224547|Experimental|Radiotherapy|For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
3345886|NCT02224573|Experimental|GWP42003-P|
3345887|NCT02224586||light treatment|clinical routine treatment according to the doctor's advice
3345888|NCT02224651|Experimental|(1-1000mg) Immediate Release formulation|
3345889|NCT02224651|Placebo Comparator|Immediate Release Placebo arm|
3345890|NCT02224651|Experimental|(10-500) mg Modified Release formulation|
3345891|NCT02224651|Placebo Comparator|Modified Release Placebo arm|
3345892|NCT02224677||Children with Craniofacial Microsomia|125 children with craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for children at the first visit include: assessment of development, video, photographs, and a hearing evaluation. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, saliva sample, hearing evaluation, speech assessment.
3345893|NCT02224677||Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 children without craniofacial microsomia will be asked to come in for two study visits - when they are about 12 months old and again when they are about 36 months old. Procedures for the first visit include: assessment of development, video, and photographs. Procedures for the final study visit include: assessment of development, photographs (2D & 3D), video, and speech assessment.
3345894|NCT02224677||Parents of Children with Craniofacial Microsomia|125-250 parents of children with craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete more questionnaires, have their picture taken, and donate saliva.
3345895|NCT02224677||Parents of Children without Craniofacial Microsomia|Please note: we are not recruiting this group through ClinicalTrials.gov 100 parents of children without craniofacial microsomia will be asked to complete three visits - when their child is about 12 months old, 24 months old, and 36 months old. Parents will be asked to complete an interview at the first visit. The second visit consists of a telephone interview where parents will be asked about their child's hearing and health history. At the final study visit, parents will be asked to complete questionnaires and an interview.
3345896|NCT02224677||Teacher/Day Care Provider|When the children participants are around 36 months old, we will ask parents for permission to contact their child's teacher/day care provider. We would like the teacher/day care provider to fill out a questionnaire.
3345897|NCT02224716||Pre-intervention All patients admitted with a diagnosis of CAP|
3345898|NCT02224716||Post intervention All patient admitted with a diagnosis of CAP|
3345899|NCT02224742|Experimental|LeucoPatch|Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
3345900|NCT02224742|Active Comparator|Usual care|Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
3345901|NCT02224768||HCP and Patient inclusion|"HCP inclusion - HCP Experience with treatment of patients with study compound who have been exposed to risk minimization tools~Patient inclusion - Patients treated with study compound as per label who have been exposed to the risk minimization materials"
3345902|NCT02224781|Experimental|Arm A (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm C."
3345903|NCT02224781|Experimental|Arm B (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients re-register and cross over to Arm D.
3239874|NCT01283698|Experimental|LAS 41004 dosage 2|dosage 2, once daily
3239875|NCT01283698|Experimental|LAS 41004 dosage 3|dosage 3, once daily
3239876|NCT01283698|Placebo Comparator|placebo|once daily
3239877|NCT01283698|Active Comparator|Reference|once daily
3239878|NCT01283711|Experimental|apollo|
3239879|NCT01283724|Experimental|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
3239880|NCT01283737|Experimental|DBX|DBX Putty in glass syringe
3239881|NCT01283737|Active Comparator|Mosaicplasty|
3239882|NCT01283750|No Intervention|Augmented Usual Care|
3239883|NCT01283763|Experimental|Topical Imiquimod|16 weeks topical Imiquimod
3239884|NCT01283763|Active Comparator|Conization|Large loop excision of the transformation zone
3239885|NCT01283776|Experimental|treatment arm|Cyclophosphamide
3345904|NCT02224781|Experimental|Arm C (BRAF inhibitor therapy)|Patients receive dabrafenib mesylate PO BID and trametinib dimethyl sulfoxide PO daily on days 1-42. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
3345905|NCT02224781|Experimental|Arm D (immunotherapy)|"IMMUNOTHERAPY INDUCTION (CYCLES 1-2): Patients receive nivolumab IV over 30-60 minutes and ipilimumab IV over 30-90 minutes on days 1 and 22. Treatment repeats every 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity.~IMMUNOTHERAPY MAINTENANCE (CYCLES 3-14): Patients receive nivolumab IV over 30-60 minutes on days 1, 15, and 29. Treatment repeats every 6 weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity."
3259282|NCT01469429|Experimental|Arm IV (LBR Saliva Substitute)|Patients receive lyophilized black raspberries Saliva Substitute PO (8gms/day).
3345906|NCT02224794||Fast-Track Group|includes subjects who complete the Fast-Track EVAR protocol
3345907|NCT02224794||Standard P-EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are completed with bilateral percutaneous access
3345908|NCT02224794||Standard EVAR Group|includes subjects who do not complete the Fast-Track EVAR protocol, and their procedures are not completed with bilateral percutaneous access (i.e. converted to femoral cutdown or open surgical repair)
3345909|NCT02224807|Active Comparator|Progressive Resistance Training (PRT) and a healthy diet|PRT will be done with resistance bands; participants will receive instruction on three resistance band exercises (triceps, biceps, and shoulder overhead) from an American College of Sports Medicine (ACSM) certified exercise specialist. Participants also will receive dietary counseling from a registered dietitian on correcting nutrient deficiencies that are detected during analysis of their 2-day dietary recalls.
3345910|NCT02224807|Experimental|PRT and a healthy diet, plus weight loss|This arm will receive all components of the active comparator arm, plus counseling to achieve a weight loss of 1.5-2 pounds/week. Participants will be trained on how to achieve this caloric deficit through both dietary restriction and increased physical activity. Weight loss will be promoted via a healthy, nutritionally adequate diet consistent with American Cancer Society guidelines. Protein levels will be based on 0.8 g/kg body weight. The distribution of food groups will be customized for preferences. An exercise program will be tailored taking into account kcal expenditure for various activities at a specific body weight; expenditures of 200-400 kcal/day will serve as a goal. Aerobic training of large muscles (legs) will be emphasized to achieve a greater kcal deficit; ramping of intensity and volume over time will be pursued as per the ACSM guidelines. Participants will train once weekly while supervised by an exercise physiologist and daily at home.
3345911|NCT02224833|Experimental|Intervention|
3345912|NCT02224833|No Intervention|Control|
3345913|NCT02224859|Other|Safety|"Following an initial examination of the scalp and head for baseline evidence of skin integrity (intact, without breaks, lacerations, etc.) and appearance (healthy/normal, no erythema/irritation, etc.) the HCP will place the CSD on the patient and secure the attached Velcro strap to hold the device in place~At specific time points (approximately 15 minutes, 1 hour, 3 hours and 6 hours) the HCP (through human intervention)will remove the CSD for examination and completion of the Skin Assessment Scale based on the appearance of the patient's scalp and adjacent areas of the head. Additionally, the patient's head will be observed for excessive scalp sweating/moisture accumulation."
3345914|NCT02224872|Experimental|Bone marrow transplant|Thymoglobulin on days -9 to -7 Fludarabine on days -6 to -2 Cyclophosphamide on days -6, -5, 3, 4 TBI on day -1 BMT on day 0 Mesna on days 3, 4 Tacrolimus on days 5-365 Mycophenolic acid mofetil on days 5-35
3345915|NCT02224885|Other|addition of nCLE to help target biopsy|The patient, scheduled for a liver or lung CT-guided percutaneous biopsy or ablation will undergo a probe-based confocal laser endomicroscopy procedure after the imaging procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
3345916|NCT02224898||Definite/Suspected Chronic Pancreatitis|Patients with diagnosis of chronic pancreatitis with at least two of the following features: clinical course consistent with chronic pancreatitis, calcification in the pancreas on US/CT/EUS, ERCP showing ductal abnormalities (Cambridge Classification), exocrine insufficiency, histology showing irregular fibrosis, acinar cell loss, islet cell loss, and inflammatory cell infiltrates, or other features suggestive of chronic pancreatitis (such as pancreatic pseudocyst). The study group will also include patients with suspected chronic pancreatitis based on history of documented pancreatitis with lingering symptoms or signs of early chronic pancreatitis on imaging. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
3345917|NCT02224898||Healthy Control Group|Patients with no history of chronic gastrointestinal symptoms lasting greater than 8 weeks, no gastrointestinal disease or condition diagnosis, and are not currently experiencing gastrointestinal symptoms. Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
3345918|NCT02224911||Laser Interstitial Thermal Therapy|This is a minimally invasive procedure for focal treatment of prostate cancer.
3345919|NCT02224924|Active Comparator|autologous blood patch injection (ABPI)|
3345920|NCT02224924|Experimental|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|
3345921|NCT02224937|Experimental|Melatonin:Melatonincreme 12,5%|Application of melatonincream 12,5% on 80% of the body-surface at start of investigation.
3345922|NCT02224937|Placebo Comparator|Placebo|Application of placebo cream on 80% of the body-surface at start of investigation.
3345923|NCT02224950|Placebo Comparator|Control|"Non-medicated Emollient with no Clothing Covering Upper Limb - Baseline/Control Cells"
3345924|NCT02224950|Active Comparator|Sleeve 2|Non-medicated Emollient plus Lyocell/Chitosan Sleeve
3345925|NCT02224950|Placebo Comparator|Placebo Sleeve|Non-medicated Emollient plus Cotton Sleeve
3345926|NCT02224963|Experimental|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
3375887|NCT03581383|Experimental|Modified ECHO Model|The modified Extension for Community Healthcare Outcomes (ECHO) Model will provide patient care through collaboration of the expanded interdisciplinary team (including social worker patient navigator team) with community providers.
3345927|NCT02224963|Active Comparator|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
3345928|NCT02224976|Experimental|Intensified training|Volunteers will increase exercise training by 30% from baseline
3239886|NCT01283789|Experimental|Lapatinib and RAD-001|"RAD-001 will be administered orally as a once-daily dose of 5 mg (one 5 mg tablet) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD-001 in the morning, at the same time each day.~Lapatinib will be administered orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take lapatinib at bedtime, at the same time each day. Lapatinib should be taken by the patient in a fasting state."
3239887|NCT01283802||IOCUS|
3345929|NCT02224989|Experimental|Mind-Body Bridging|An awareness training program using mindfulness-based techniques.
3345930|NCT02225015|Active Comparator|FTGC at 1 month|Individuals randomized to the intervention group will receive a tailored cancer risk assessment via a follow-up telephone genetic counselling (FTGC) session within one month of study enrollment.
3345931|NCT02225015|No Intervention|Standard Care + FTGC in 12 months|Individuals randomized to the intervention group will receive a tailored cancer risk assessment at 12 months following study enrollment
3345932|NCT02225028|Active Comparator|Physical Activity Counseling|Participants who are randomized to the physical activity counseling intervention group will work with a physical activity coach over the course of 6 months to come up with a physical activity program that works for each individual. Participants will have 16 phone calls and discuss goals and values, track physical activity, troubleshoot barriers, and work on keeping exercise interesting and motivating. Participants will also learn strategies for managing stress and battling unhelpful thoughts that may get in the way of activity. By the end of the intervention, the goal is to be regularly doing 150 minutes of physical activity each week. The physical activity coach will work with participants to ensure that they are increasing activity safely in order to prevent injuries.
3345933|NCT02225028|No Intervention|Usual Care|Participants randomized to the usual care control group will receive a packet of exercise related-information at the end of the baseline assessment as well as a letter from study staff informing them of their randomization status and their test results. The letter will provide information on biological markers that are in the at-risk range, advice to seek medical advice regarding lifestyle changes such as diet and exercise and information on how to contact study staff regarding test results. We will offer to forward test results to their health care provider provided they furnish written release of information We will emphasize our interest in providing them with a follow-up assessment in 6 months.
3345934|NCT02225054|Placebo Comparator|Ropivacaine,Normal Saline,Saline Bolus|Ropivacaine 15 mL 0.5% Normal Saline mL 0.9% Saline Bolus
3345935|NCT02225054|Experimental|Ropivacaine,Dexmedetomidine,Saline Bolus|Ropivacaine15 mL 0.5% Dexmedetomidine0.5 u/kg Saline Bolus
3239888|NCT01283815|Active Comparator|Conservative management|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
3239889|NCT01283815|Experimental|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group
3239890|NCT01283841|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
3239891|NCT01283841|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
3239892|NCT01283854|Experimental|Exercise group|Each participant randomised to the exercise group will receive routine, regular antenatal care. In addition, these women will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist.
3259283|NCT01469442|Experimental|external biliary duct stent|'External Biliary duct stent in the bile duct by cystic way'
3259284|NCT01469442|No Intervention|without external biliary duct stent|
3345936|NCT02225054|Active Comparator|Ropivacaine,Saline,Dexmedetomidine|Ropivacaine 15 mL 0.5% Normal Saline 1 mL 0.9% Dexmedetomidine single IV bolus 0.5 u/kg over 30 minutes
3345937|NCT02225067|Experimental|C13-CAC|
3345938|NCT02225093|Experimental|1:Caffeine, Dextromethorphan and Enzalutamide|1-sequence crossover here
3345942|NCT02225197|Experimental|CyberKnife Radiosurgery|
3345943|NCT02225210|Experimental|Group dexmedetomidine ,dexmedetomidine|Continuous pump infusion dexmedetomidine with loading dose of 0.4μg.kg-1 for 10 minutes ,then followed by maintenance dose of 0.2~0.7µg.kg-1 to maintain Sedation-Agitation Scale between 3 and 4.
3345944|NCT02225210|Active Comparator|Group midazolam,midazolam,fentanyl|Quickly inject midazolam and fentanyl with loading dose of 0.1mg.kg-1 and 1 μg.kg-1 separately until attaining Sedation-Agitation Scale between 3 and 4,then followed by maintenance dose of 0.05~0.1mg.kg-1.h-1 and fentanyl 0.5~1μg.kg-1.h-1 separately.
3345945|NCT02225236|Experimental|Classroom Intervention|The intervention focuses on training executive functioning (e.g., working memory and inhibition) and metacognition (i.e., the ability to predict, check, monitor, coordinate and control cognitive operations) using play activities and structured language and reinforcement.
3345946|NCT02225236|No Intervention|No treatment control|No intervention
3345947|NCT02225262|Experimental|CyberKnife Radiosurgery|
3375888|NCT03581383|Experimental|Telemedicine Arm|The telemedicine Model will track outcomes and record patient experiences with HCV management and treatment with telemedicine.
3375889|NCT03581019|Experimental|Uterus transplantation|Uterus transplantation
3375890|NCT03578367|Experimental|Asciminib 60mg QD + Imatinib 400mg QD|Asciminib 60 mg taken once daily in combination with Imatinib 400 mg taken once daily
3239893|NCT01283854|No Intervention|Control group|Women allocated to the control group will not participate in the home-based exercise program, and will continue their normal physical activity throughout pregnancy. This group will receive routine, regular antenatal care, together with the additional outcome assessments at baseline (14 weeks gestation) and cessation of the study (28 weeks gestation).
3239894|NCT01283867|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets of Dr. Reddy's Laboratories Limited
3239895|NCT01283867|Active Comparator|Cellcept|Cellcept 500 mg tablets of Roche Laboratories Inc.
3345948|NCT02225275|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive obinutuzumab IV over 3-4 hours on days 1, 2, 8, and 15 of course 1 and day 1 of courses 2-6 and lenalidomide PO QD on days 9-28 of course 1 and days 1-28 of all subsequent courses. Treatment with obinutuzumab repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue to receive lenalidomide PO QD in the absence of disease progression or unacceptable toxicity.
3345949|NCT02225288|Experimental|Group A|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group A: 48 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3345950|NCT02225288|Experimental|Group B|Period 1: Apply one E2022 tape to the designated site (back or upper arm) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or upper arm, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group B: 72 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3345951|NCT02225288|Experimental|Group C|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group C: 96 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3345952|NCT02225288|Experimental|Group D|Period 1: Apply one E2022 tape to the designated site (back or chest) for 24 hours (applying in the morning and removing next morning) Period 2: Apply one E2022 tape to the designated site (back or chest, but different from Period 1) for 24 hours (applying in the morning and removing next morning) Period 3: Apply one E2022 tape to back (contralateral to Period 1 and 2). After the specified intervals (Group D: 120 hours), apply a new E2022 tape to the same site (for 24 hours after the first and second applications [applying in the morning and removing next morning])
3345953|NCT02225301|Experimental|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention.
3345954|NCT02225314|Experimental|Brain Fitness|Brain Fitness is a computer-based cognitive training programs designed to augment auditory processing speed and accuracy over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
3239896|NCT01283893||Laparoscopy group|Laparoscopy group: patients who underwent laparoscopic distal gastrectomy with D2 lymphadenectomy
3239897|NCT01283893||Open group|Open group: patients who underwent open distal gastrectomy with D2 lymphadenectomy
3345955|NCT02225314|Experimental|InSight|InSight is a computer-based cognitive training programs designed to augment visual processing and working memory over an 8-week period to individuals with PD and MCI at a community Parkinson's and Movement Disorders specialty clinic.
3345956|NCT02225314|Active Comparator|Active Control|An active control arm is necessary to model practice effects in an untreated group. Participants in this group will view and complete quizzes on a computerized learning program designed to improve knowledge about literature, art, and history.
3345957|NCT02225327|Active Comparator|Fluad alone|56 Fluad recipients: one vaccine injection administered on Day 0
3345958|NCT02225327|Active Comparator|Fluad and PPV23 on the different arms|56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
3345959|NCT02225327|Active Comparator|Fluad and PPV23 on the same arm|56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
3345960|NCT02225327|Active Comparator|PPV23 alone|56 PPV23 recipients: one vaccine injection administered on Day 0
3345961|NCT02225340||Controls|
3239898|NCT01283906|Experimental|MuGard|Mucoadhesive Oral Wound Rinse
3239899|NCT01283906|Sham Comparator|Control Rinse|Aqueous Control Rinse.
3239900|NCT01283919|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
3345962|NCT02225340||Familial hypercholesterolemia|
3345964|NCT02225379|Experimental|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference method and data generated by the non- invasive study device (Hypo Sense) during approximately 4 hours, in which a hypoglycemic event will be induced.
3375891|NCT03578367|Experimental|Asciminib 40mg QD + Imatinib 400mg QD|Asciminib 40 mg taken once daily in combination with Imatinib 400 mg taken once daily
3375892|NCT03578367|Active Comparator|Imatinib 400mg QD|Imatinib 400 mg taken once daily
3375893|NCT03578367|Active Comparator|Nilotinib 300mg BID|Nilotinib 300 mg taken twice daily
3375894|NCT03565991|Experimental|Combination of avelumab and talazoparib|Single arm open label
3239901|NCT01283919|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
3239902|NCT01283932|Experimental|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg of Dr. Reddys Laboratories Limited
3259285|NCT01469455|Experimental|DT01|
3375895|NCT03564145|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 40 weeks.
3375896|NCT03564119|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
3345965|NCT02225392|Active Comparator|Delayed bronchial thermoplasty|"After randomisation they will wait for 25 weeks (control group) and then start with bronchial thermoplasty.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
3345966|NCT02225392|Experimental|Immediate bronchial thermoplasty|"After randomisation they start immediate with bronchial thermoplasty treatment.~Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated."
3345967|NCT02225405|Experimental|Treatment (cisplatin, docetaxel, nintedanib)|"RUN-IN PHASE: Patients receive induction therapy comprising cisplatin IV over 2 hours on day 1, docetaxel IV over 1 hour on day 1, and nintedanib PO BID from day 2 of course 1 to day 7 of course 3. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery.~EXPANSION PHASE: Patients receive single-agent nintedanib PO BID on days 1-28. Patients then receive 3 courses of induction chemotherapy and undergo surgery as above. Treatment continues even if patients experience disease progression, unless treatment is judged to be not in the best interest of the patient by the treating physician."
3345968|NCT02225418|Sham Comparator|Placebo TQL block|30 ml single shot TQL block with saline 0,9%
3239903|NCT01283932|Active Comparator|Protonix|Protonix 40 mg DR Tablets of Wyeth Laboratories
3345969|NCT02225418|Active Comparator|Active TQL block|30 ml single shot TQL block with ropivacaine 0,75%
3345970|NCT02225431|Active Comparator|Standard saline infusion|All patients received standard intravenous saline hydration (0.9% sodium chloride, 1 ml/kg/h for 12 hours before and after procedure)
3345971|NCT02225431|Experimental|Double saline infusion|All patients received double dose of intravenous saline hydration (0.9% sodium chloride, 2 ml/kg/h for 12 hours before and after procedure)
3345972|NCT02225444||OsteoAMP treatment group|The OsteoAMP treatment group contains patients randomized to receive their own bone (retrieved from the surgical site) augmented with the OsteoAMP growth factor to assist with posterolateral arthrodesis at 1 or 2 adjacent levels between L1-S1.
3239904|NCT01283945|Experimental|Lucitanib|
3345973|NCT02225457|Experimental|Hypercaloric diet and polyphenols|"polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.~Hypercaloric diet will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
3345974|NCT02225457|Active Comparator|Hypercaloric diet and placebo|"Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.~Overfeeding will consist in a hypercaloric diet providing an excess of 50% KCal over daily requirements, and will last 30 days."
3345975|NCT02225470|Experimental|Arm A, E7389 (Eribulin Mesylate)|The eribulin mesylate dose will be 1.4 mg/m2 administered as an intravenous bolus over 2 to 5 minutes on Days 1 and 8 of each 21-day cycle.
3345976|NCT02225470|Active Comparator|Arm B, Vinorelbine injection|The vinorelbine dose will be 25 mg/m2 administered as an intravenous bolus on Days 1, 8, and 15 of each 21-day treatment cycle.
3345977|NCT02225483||Hemophilia A|Boys with Factor VIII coagulant activity less than or equal to 1%.
3345978|NCT02225496|Experimental|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm. Functional assessment performed at pre-treatment, within 1-4 weeks post-op from TORS (before adjuvant therapy), and after completion of treatment at the following time points: 6 months (±2 months), 12 months (±2 months), and 24 months (±6 months). Functional measures include video-fluoroscopic examination of swallowing (modified barium swallow [MBS] study) with administration of the Performance Status Scale-Head and Neck (PSS-HN) and MD Anderson Dysphagia Inventory (MDADI) questionnaire.
3345979|NCT02225509|Other|Patients with thyroid nodules|Patients with thyroid nodules with an indication for FNA biopsy to detect thyroid cancer. These patients will undergo FNA at the time of first visit and also when considered necessary by the clinician during the course of the study.
3345980|NCT02225522|No Intervention|Standard Care|Patients in this arm receive standard genetic evaluation without the addition of next generation sequencing for the diagnosis of their presumed genetic condition
3345981|NCT02225522|Experimental|Rapid whole genome sequencing (StatSeq)|Patients in this arm will receive standard of care genetic evaluation and next generation sequencing of their genome to achieve rapid diagnosis of genetic conditions.
3239905|NCT01283984|Experimental|1|AZD2115
3345982|NCT02225535|Placebo Comparator|Usual Care (NP)|Rural NP with client in-person, usual care
3345983|NCT02225535|Active Comparator|PT in-person|Urban PT travels to rural area to manage patient's back pain in-person.
3345984|NCT02225535|Active Comparator|PT/NP Telehealth|Intervention: Rural NP is joined by PT via Telehealth for interprofessional videoconference with patient
3345985|NCT02225548|Experimental|Selegiline and Tadalafil|Tadalafil 2.5mg for 4 weeks then oral selegiline 5mg daily for 2 weeks then increased to 5mg twice daily for 2 more weeks
3345986|NCT02225561|Experimental|Intervention arm|Pharmaco- mechanical optimization
3345987|NCT02225561|Active Comparator|Mechanical optimization only|Mechanical optimization only
3375897|NCT03564119|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
3239906|NCT01283984|Placebo Comparator|2|Placebo to AZD2115
3239907|NCT01283997|Placebo Comparator|Placebo Group|1 dose on first day of induction therapy, then every 12 hours for 10 weeks.
3239908|NCT01283997|Experimental|Minocycline Group|200 mg orally for 1 dose, then 100 mg orally every 12 hours for 10 weeks.
3345988|NCT02225574|Experimental|Advanced CML + Philadelphia positive Acute Leukemia-Group 1|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle."
3345989|NCT02225574|Experimental|Chronic Phase CML - Group 2|"Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.~Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.~Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
3345990|NCT02225600|Other|patients with BPD|cross-over administration of 40 IU oxytocin, 24 IU oxytocin and placebo
3345991|NCT02225600|Active Comparator|healthy patients|Cross-over of 40 IU oxytocin, 24 IU oxytocin and placebo
3345992|NCT02225613|Active Comparator|Usual protocol|2 weeks conventional rehabilitation 3 weeks conventional rehabilitation
3345993|NCT02225613|Active Comparator|Spa protocol|2 weeks conventional rehabilitation 3 weeks aquatic rehabilitation
3345994|NCT02225626|Experimental|BI 1060469 fed|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administr
3345995|NCT02225626|Experimental|BI 1060469 fasted|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
3345996|NCT02225639|Active Comparator|PRC-063|
3345997|NCT02225639|Placebo Comparator|Placebo|
3345998|NCT02225652|Experimental|FEC + filgrastim x 3 cycles q 14-21 days and Weekly Paclitaxel|"FEC (FLUOROURACIL 500 mg/m2 IV infusion of 30 minutes + EPIRUBICIN 60 mg/m2 IV infusion of 1 hour + CYCLOPHOSPHAMIDE 500 mg/m2 IV infusion of 30 minutes).~From day 7 until hematological recovery = Filgrastim 300 microg s.c. After 21 days from the last FEC cycle = Paclitaxel 100 mg/m2 IV infusion of 1hour (weekly for 8 cycles, at day 1)."
3239909|NCT01284010||Group 1|Diagnostic, complete remission, and germ-line specimens are analyzed for DNA profiling and gene resequencing by the Affymetrix SNP6.0 microarray platform, PCR, and fluorescence in situ hybridization (FISH). Frequency of genetic alterations are performed by the Agilent 2100 Bioanalyzer. Results are then compared with the data already generated from pediatric patients.
3239910|NCT01284023||Controls|Uninjured volunteers
3239911|NCT01284036|Other|PF-05230905|9 subjects will participate in each dose cohort. 6 subjects will receive investigational product (PF-05230905) and 3 subjects will receive placebo
3239912|NCT01284049|Active Comparator|Intralipid 20%®|reference treatment by standard lipid emulsion not enriched in n-3 EFA (Intralipid 20%®)+ vitamin E.
3239913|NCT01284049|Experimental|OMEGAVEN 10%®|Interventional treatment by a lipid emulsion enriched in n-3 EFA (OMEGAVEN 10%®).
3239914|NCT01284075|Experimental|Guided Imagery and Music therapy group (GIMT)|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
3345999|NCT02225691|Experimental|paired testing of blood glucose|Patient will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Paired testing arm will undergo paired testing of blood glucose.
3346000|NCT02225691|No Intervention|control arm|Non-insulin patients will be randomly assigned to one of 2 arms, namely (i) paired testing (PT) arm; and (ii) control (CL) arm. Patients in the control arms will not undergo paired testing and will be managed as before.
3346001|NCT02225704|Experimental|Radium-223 and enzalutamide|Radium-223 50kBq/kg by intravenous injection on day 1 of every 4 week cycle for maximum of 6 cycles Enzalutamide 160mg orally daily
3346002|NCT02225717|Experimental|Non pregnant women|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
3346003|NCT02225717|Experimental|Preterm Labor|Pregnant women admitted for preterm labor
3346004|NCT02225717|Experimental|Healthy pregnancy|Healthy pregnancy : women 15-16 weeks of gestation, at 35-36 weeks of gestation, and >37 weeks of gestation and planed cesarean prior labor
3346005|NCT02225756|Experimental|Cyclosporine A dose 1|
3346006|NCT02225756|Experimental|Cyclosporine A dose 2|
3346007|NCT02225756|Placebo Comparator|Placebo|
3346008|NCT02225769|Experimental|e-POCT|Febrile children managed using the e-POCT tool. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
3346009|NCT02225769|Active Comparator|ALMANACH|Febrile children managed using the ALMANACH algorithm. ALMANACH is an improved Integrated Management of childhood Illness (IMCI) algorithm based on mobile phones and tablets that has already been assessed for safety and efficacy.
3239915|NCT01284075|Active Comparator|White Noise Group (WN)|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
3239916|NCT01284075|Active Comparator|No Interventions Group (CP)|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
3239917|NCT01284088|Experimental|PrePex™|Adult male circumcision by the PrePex™ Device
3239918|NCT01284088|Active Comparator|Surgical|Adult male surgical circumcision
3239919|NCT01284101|Active Comparator|Forceps delivery of donor graft|Using the forceps to insert the donor graft.
3239920|NCT01284101|Experimental|Tan Endoglide for insertion of the donor graft|Use of the Tan Endoglide for insertion of the donor graft.
3239921|NCT01284166|Experimental|Triple Combination Therapy|Triple Combination Therapy with dorzolamide hydrochloride/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
3259286|NCT01469468|Experimental|Single arm, fixed sequence dosing|
3259287|NCT01469481|Experimental|1|
3346010|NCT02225769|No Intervention|Routine practice|Febrile children managed according to routine care such as provided by routine health facility health workers.
3346011|NCT02225782|Active Comparator|1.0 mg alteplase (tPA)|1.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
3346012|NCT02225782|Experimental|2.0 mg alteplase (tPA)|2.0 mg tPA to be injected at the catheter site for a maximum of 3 repeats if the catheter site occlusion is not resolved with 30 minute wait between each repeat
3346013|NCT02225795|Experimental|Single Arm: All subjects|Hematopoietic stem cell transplantation
3346014|NCT02225808|Experimental|CBT for anxiety in autism|Cognitive-behavioral therapy (CBT) teaches skills for coping with anxiety and consist of 12 weekly sessions. CBT is conducted with child and parent.
3346015|NCT02225821|Active Comparator|antibiotic prophylaxis|a single gift of 1000 mg cefazolin in 10 cc of NaCl 0.9% (intervention group)
3346016|NCT02225821|Placebo Comparator|No antibiotic prophylaxis|a single gift of 10 cc NaCl 0.9%, given in the same manner (control group).
3346017|NCT02225834|Experimental|early Atorvastatin treatment|Ischemic stroke patients treated with with atorvastatin 80 mg at admission until discharge
3346018|NCT02225834|No Intervention|no early treatment with atorvastatin|Ischemic stroke patients not treated with with atorvastatin 80 mg until discharge
3346019|NCT02225847|Active Comparator|Control|Members of this group will continue with their daily life activities and will not receive gardening intervention. The control group will be given a set of psychometric assessments for health and quality of life evaluations and undergo a Functional Magnetic Resonance Imaging (fMRI) brain scan, followed by a second round of psychometric assessments and a fMRI brain scan administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
3346020|NCT02225847|Experimental|Gardening|Members of this group will be given a set of psychometric assessments for health and quality of life evaluations and a Functional Magnetic Resonance Imaging (fMRI) brain scan prior to receiving the gardening activities intervention. The gardening intervention will consist of twice weekly group sessions lasting 60 minutes in duration that will take place in a greenhouse. The duration of the experimental intervention will be six weeks for a total of 12 individual gardening activity sessions. Following the completion of the gardening intervention, a second round of psychometric assessments and a fMRI brain scan will be administered seven to eight weeks after the initial baseline psychometric assessments and fMRI brain scan.
3346021|NCT02225873|Experimental|strength-endurance exercises|Group 1 (experimental) will carry out motor control exercises through cranio-cervical flexion training and strength-endurance exercises.
3346022|NCT02225873|Placebo Comparator|strength-endurance and proprioception|Group 2 (control) will carry out exercises to improve muscle strength-endurance and proprioception.
3346023|NCT02225886|Experimental|Ascorbic acid|Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.
3346024|NCT02225886|Placebo Comparator|Control group|Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.
3346025|NCT02225899||Subjects with Cystic Fibrosis|Cross-sectional, observational study
3346026|NCT02225899||healthy volunteers|Cross-sectional, observational study
3346027|NCT02225899||Subjects with CF in a vitamin D study|This is a longitudinal observational study in subjects enrolled in a high-dose vitamin D study. The investigator (Jessica Alvarez) does not assign the intervention to the subjects of the study.
3346028|NCT02225912|Experimental|PrevinC|PrevinC contains isopropyl alcohol, sesame oil, aloe vera oil extract, and lemon oil.
3239922|NCT01284179|Experimental|Hypnotherapy|Participants will be randomized to either the home hypnotherapy or educational group. The HHT protocol will consist of sequences of two different types of sessions, longer biweekly sessions (LS), each approximately 30-40 minutes in length, and shorter daily sessions (SS), approximately 12 minutes in length. On the first day of each sequence, the patient will listen to the appropriate LS. The patients will listen to the SS on a daily basis in between each LS. Every 2 weeks a new sequence will begin, for a total of 12 weeks of treatment.
3346029|NCT02225912|Placebo Comparator|Control solution|The control solution (distilled water and lemon oil) was similar in color, oily consistency and odor to that of PrevinC.
3346030|NCT02225938||Intensive care survivors|Patients surviving an admission to an intensive care unit
3346031|NCT02225951|Active Comparator|Test group|Nutritional product as breakfast.
3346032|NCT02225951|Other|Control Group|Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.
3346033|NCT02225964||aMCIp,aMCIs|progressive aMCI,stable aMCI
3346034|NCT02225977||Gilenya treated - 1 month|Patient's taking continuous oral Gilenya at prescribed dose for 1 month.
3346035|NCT02225977||Gilenya treated - 3 months|Patient's taking continuous oral Gilenya at prescribed dose for 3 months.
3346036|NCT02225977||Gilenya treated - 6 months|Patient's taking continuous oral Gilenya at prescribed dose for 6 months.
3346037|NCT02225977||Gilenya treated - 12 months|Patient's taking continuous oral Gilenya at prescribed dose for 12 months.
3346038|NCT02225977||Gilenya qualified - untreated|Patient's qualifying to start treatment with oral Gilenya at prescribed dose but still as yet untreated.
3346039|NCT02225990|Active Comparator|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
3346040|NCT02225990|Active Comparator|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
3346041|NCT02225990|Experimental|Experimental Group, Sub-Acute|This group consists of sub-acute stroke patients who are between three weeks and six months post-stroke and will receive the QualPro protocol. If the participant is an inpatient at Shands Rehabilitation Hospital at the beginning of the study, his/her first three weeks of research therapy sessions will take place at the Shands Rehabilitation Hospital. After being discharged, the remainder of the study sessions will take place at either UF Health Rehab Center- Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
3346042|NCT02225990|Experimental|Experimental Group, Chronic|This group consists of chronic stroke patients who are greater than six months post-stroke and will receive the QualPro protocol. The study sessions will take place at either UF Health Rehab Center-Magnolia Parke or in the North Tower (6th floor) physical therapy department of Shands Hospital.
3239923|NCT01284179|Other|Educational|Participants will be randomized to receive either home hypnotherapy or an educational program. The control group will receive an educational digital audio program on MP3 players. These digital audio files will contain general information about FCP and FGIDs. These audio files will be similar to the intervention audio files in length. Patients will be instructed to begin listening on the day of randomization. Patients will be instructed to continue their other medical treatment for chest pain during the study. The control group will be assessed at the same times as the HHT group.
3239924|NCT01284192|Experimental|ASP3026|Subjects will receive escalated doses of ASP3026 to determine the maximum tolerated dose (MTD)
3346043|NCT02226016|Experimental|Ptosis|Device (measurement of levator strength in patients with upper lid ptosis)
3346044|NCT02226029|Experimental|Lipid emulsion 1|Rapeseed oil 20%, sucrose FAE P-1670 0.7%, water 79.3%
3346045|NCT02226029|Experimental|Lipid emulsion 2|Rapeseed oil 20%, sodium stearoyl lactylate P45 veg 1.5%, water 78.5%
3346046|NCT02226042|Experimental|Mindfulness-based Cognitive Therapy|Individuals currently in remission from depression will choose to enter the Mindfulness-based Cognitive Therapy (MBCT) arm and undergo the 8 week MBCT group programme
3346047|NCT02226042|No Intervention|Non-MBCT arm|Individuals currently in remission from depression will choose not to undergo the 8 week MBCT group programme
3239925|NCT01284205|Experimental|MCC|Intravesical Administration of Mycobacterial Cell-Wall DNA Complex
3239926|NCT01284205|Active Comparator|BCG|Intravesical Administration of Bacillus Calmette-Guerin
3239927|NCT01284218||Aripiprazole cohort|
3239928|NCT01284218||Other atypical cohort|
3346048|NCT02226042|No Intervention|Healthy volunteers|Individuals who have never experienced major depression
3346049|NCT02226055||Arterial stiffness: CKDu patients|Cohort of 50 patients with CKD of unknown aetiology Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3346050|NCT02226055||Arterial stiffness: CKD known cause|Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3346051|NCT02226055||Arterial Stiffness: Healthy Sri Lankan volunteers|Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
3346052|NCT02226055||2nd aim: 250 CKDu patients for investigation of aetiology|"To recruit a cohort of up to 250 CKDu patients from specific CKDu clinics in Anuradhapura and Padavi-Sri Pura for detailed history, basic anthropometric tests, and further analysis of serum, and urine. Analysis for biomarkers of kidney damage, proteomics, exosomes, and DNA adducts will be used to seek information that may complement already collected data and help refine aetiological hypotheses.~Inclusion and Exclusion criteria as per CKDu cases in cohort 1"
3346053|NCT02226068|Other|CsA-ECP|Sequence of therapy: First ciclosporin was given and after relapse extra corporal photopheresis was given
3346054|NCT02226068|Other|ECP-CsA|Sequence of therapy: First extra corporal photopheresis was given and after relapse ciclosporin was given
3346055|NCT02226094|Experimental|DWT device dose A|Deep Wave Trabeculoplasty (DWT) dose A (10 second spot treatments).
3346056|NCT02226094|Active Comparator|Ellex Tango SLT machine|Selective Laser Trabeculoplasty (SLT)
3346057|NCT02226094|Sham Comparator|DWT Sham|Deep Wave Trabeculoplasty (DWT) but device not applied to ocular surface.
3346058|NCT02226094|Experimental|DWT device dose B|Deep Wave Trabeculoplasty (DWT) dose B (20 second spot treatments).
3346059|NCT02226107|Experimental|Peer-PN|Peer Patient Navigation
3239929|NCT01284218||Other antidepressant cohort|
3239930|NCT01284218||Mood stabilizer cohort|
3346060|NCT02226107|Active Comparator|Pro-PN|Professional Patient Navigation
3346061|NCT02226133|Experimental|Exclusion of Left Atrial Appendage|Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,
3346062|NCT02226146|Experimental|Bertilimumab|Intravenous injection over 30 minutes of 10 mg/kg of Bertilimumab in physiological solution (PBS)
3346063|NCT02226185|Experimental|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
3346064|NCT02226185|Placebo Comparator|placebo|identical-appearing placebo supplements for 2-3 years
3346065|NCT02226211|Experimental|air-Q group|
3346066|NCT02226211|Experimental|aura-i group|
3346067|NCT02226224||early gastric cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3346068|NCT02226224||Locally Advanced Gastric Cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3346069|NCT02226224||early esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3346070|NCT02226224||locally advanced esophagus cancer|EUS examination on the specimen right after surgery mark the deepest invasive site on the specimen
3346071|NCT02226237|No Intervention|Control Group|in which patients received no specific treatment, only the usual general guidelines
3346072|NCT02226237|Experimental|group of pelvic floor exercises|in which patients were instructed to perform home exercises daily
3346073|NCT02226237|Experimental|anal electrostimulation group|in which patients, and are instructed to perform the exercises mentioned in the group of pelvic floor exercises, also underwent anal electrostimulation
3346074|NCT02226250|Experimental|3 Placebo Beverages|Sugar beverage 2 hr before meal and with meal and 2 hr after meal
3375898|NCT03555149|Active Comparator|Regorafenib (Control)|Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
3346075|NCT02226263|Experimental|probiotics Lactobacillus acidophilus boucardii strain.|Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks .The probiotic presentation used was powder in an envelope with 160mg (Carnot ® Laboratories), scientific products, Mexico, (Registration Number 274M91SSA). This was stored in a dry place at room temperature, avoiding sunlight.
3346076|NCT02226276|Experimental|Diagnostic (copper Cu 64-DOTA-trastuzumab PET)|Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.
3346077|NCT02226289|Experimental|bevacizumab-containing|bevacizumab with the latest received cytotoxic regimen
3346078|NCT02226302||Female Group 2|Females with BMI >30 kg/m2 who are having a hysterectomy for benign conditions
3346079|NCT02226302||Females Group 1|Females with BMI <30 kg/m2 who are having a hysterectomy for benign conditions
3346080|NCT02226302||Males|2 males with BMI <30 kg/m2 and 2 males with BMI >30 kg/m2
3346081|NCT02226315||Multiple gestations|Women with a multiple gestation who were evaluated with the MaterniT21 PLUS LDT and have passed their Estimated Date of Delivery (EDD).
3346082|NCT02226328|Experimental|Propofol sedation|"Refract bolus propofol sedation as monotherapy administered by a sedation-trained nurse endoscopist.~Induction with 10-60 mg bolus, repeated every 45-60 sec. until moderate sedation.~Maintenance with 10-20 mg of propofol in case of discomfort."
3346083|NCT02226328|Active Comparator|Midazolam and Fentanyl sedation|"1-2 mg of Midazolam with 0.025-0.05 mg of fentanyl for induction 10 prior to procedure initiation.~Maintenance with 1 mg Midazolam in case of discomfort."
3346084|NCT02226341|Active Comparator|CellCept daily & ACTHar gel biw|Patients will be treated with CellCept 3 grams daily and ACTHar gel 80 U biw for 3 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
3346085|NCT02226341|Active Comparator|CellCept daily & ACTHar gel qod|Patients will be treated with CellCept 3 grams daily for 3 months, and ACTHar gel 80 U qod for the first month and ACTHar gel 80 U biw for the following 2 months. After 3 months, patients with complete response will stop ACTHar gel but continue CellCept 3 grams daily for another 3 months whereas patients with partial response will continue CellCept 3 grams daily and be offered the option to continue ACTHar 80 U biw for another 3 months. After 6 months, all patients will continue CellCept at a dose of 2 grams daily for another 18 months.
3346086|NCT02226354|Active Comparator|Flaxseed oil|9.73ml Flaxseed oil once daily, for 28 days
3346087|NCT02226354|Experimental|Ahiflower oil|9.73ml Ahiflower oil once daily, for 28 days
3346088|NCT02226367|Active Comparator|prazosin hydrochloride|Prazosin hydrochloride taken orally. Titrated to a maximum dose 4 mg in the morning, 6 mg in the afternoon, and 10 mg at bedtime. (20 mg total daily at maximum dose) Dose increase will occur if the participant does not have unacceptable side effects.
3346089|NCT02226367|Placebo Comparator|placebo|Placebo. Oral capsule with comparable appearance to active treatment. Titrated in same manner as active treatment.
3346090|NCT02226380|Experimental|mFOLFOX6,chemotherapy regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
3346091|NCT02226393|Experimental|Prolonged exposure|See intervention description
3346092|NCT02226393|Active Comparator|Child-parent Play Therapy|see intervention description
3346093|NCT02226406|Experimental|Legs Cycloergometer Group (A)|Patients randomized in this group will do 10 minutes of legs cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
3239931|NCT01284218||Stimulant cohort|
3239932|NCT01284231|Experimental|MEDI-565 - Dose Escalation|Up to 15 dose-escalation cohorts will be enrolled
3239933|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 1|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
3239934|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 2|20 subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biologic dose
3239935|NCT01284231|Experimental|MEDI-565 Dose Expansion Arm 3|Subjects with selected gastrointestinal tumor type will receive MEDI-565 at the maximum tolerated dose or optimum biological dose
3239936|NCT01284257||Enteric coated mycophenolate sodium (EC-MPS) arm|Patients to whom EC-MPS is prescribed by their practitioner.
3239937|NCT01284257||MMF arm|Patients to whom MMF is prescribed by their practitioner.
3239938|NCT01284270|Other|All Patients|All patients undergo the same study procedures
3239939|NCT01284283|Other|Single|Device: Scandinavian Total Ankle Replacement System (STAR Ankle)
3239940|NCT01284309|Experimental|Mirabegron|
3239941|NCT01284309|Placebo Comparator|Placebo|
3239942|NCT01284322|Experimental|Fresolimumab|
3239943|NCT01284348|Experimental|Sotatercept - 15 mg|Sotatercept 15 mg Subcutaneous (SC) Day 1 every 42 days
3346094|NCT02226406|Experimental|Hands Cycloergometer Group (B)|Patients randomized in this group will do 10 minutes of hand cycloergometer active exercise. Continuously evaluated with electric impedance tomography.
3346095|NCT02226406|Experimental|Walk in place (C)|Patients randomized in this group will do 10 minutes of active walk in place. Continuously evaluated with electric impedance tomography.
3346096|NCT02226419|Experimental|Break in L-carnitine treatment|Patients do not take their L-carnitine (Levocarnitine) treatment for 2-4 days until plasma carnitine and acylcarnitine have fallen. While patients abstain from taking the treatment, they are admitted for cardiac telemetry monitoring.
3346097|NCT02226432|Sham Comparator|Kinesics|- Classic Rehabilitation and Kinesic Therapy
3346098|NCT02226432|Sham Comparator|surgery|"- Surgery:~Selective Peripheral Neurotomy is surgical a method of section on suplying peripheral nerves of motor fascicles to relieve harmful spasticity. An intraoperative stimulation of motor fascicles is done, and those which abnormal spreading on far placed myotomes are more evident are chosen to be sectioned."
3346099|NCT02226432|Active Comparator|Magnetic Stimulation|- Postoperative Antagonistic Peripheral Magnetic Stimulation with 1.5 tesla intensity, infrathreshold 80 per cent of minimal intensity able to produce always muscle contraccion. Trials repeated twice a week in sessions of 30 minutes during 6 months
3346100|NCT02226445||ADHD medication and psychosocial counseling|
3346101|NCT02226458|Experimental|EPI-743|15 mg/kg oral solution three times per day, maximum of 200 mg per dose
3239944|NCT01284348|Experimental|Sotatercept 30 mg|Sotatercept 30 mg SC Day 1 every 42 days
3239945|NCT01284374||Male Adolescents|Male adolescents, 13-17 years old, who are seen at community adolescent health clinics and are offered HPV vaccine
3346102|NCT02226471||NW-NBP group|normal weight and blood pressure subjects
3346103|NCT02226471||NW-HTN group|Normal weight with hypertension subjects
3346104|NCT02226471||OB-NBP group|obese-normal blood pressure subjects
3346105|NCT02226471||OB-HTN group|Obese-hypertension subjects
3239946|NCT01284374||Parents of Male Adolescents|Parents of Male Adolescents, whose adolescents are being seen at community adolescent health clinics and are offered HPV vaccine
3346106|NCT02226484|Experimental|Quercetin|Two 250 mg capsules of oral quercetin (Q) twice-a-day (BID) one hour before meals with a glass of water for 6 weeks.
3239947|NCT01284374||Health Care Providers for Males 13-17 yo|Health care providers who provide medical care to male adolescents in pediatric and adolescent clinics
3239948|NCT01284387|Experimental|3 μg ACC-001 / QS-21 50 μg IM dose 1|3 μg ACC-001 / QS-21 50 μg IM
3346107|NCT02226497|Active Comparator|Arm I (standard outpatient supportive care)|Patients receive standard outpatient supportive care after completion of chemotherapy.
3346108|NCT02226497|Experimental|Arm II (home telemonitoring device)|Patients receive standard outpatient supportive care as in Arm I and use the home telemonitoring device for the duration of chemotherapy-induced cytopenia (up to 3-4 weeks).
3346109|NCT02226510|Placebo Comparator|Placebo|Placebo capsules (with an identical appearance to the active drug) and containing only microcrystalline cellulose PhEur
3239949|NCT01284387|Experimental|10 μg ACC-001 / QS-21 50 μg IM dose 2|10 μg ACC-001 / QS-21 50 μg IM
3239950|NCT01284387|No Intervention|Placebo - Phosphate buffered saline (PBS) IM dose|Placebo - Phosphate buffered saline (PBS) IM
3239951|NCT01284400|Experimental|Disease management|
3239952|NCT01284400|No Intervention|Usual treatment and care|
3346110|NCT02226510|Active Comparator|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day (metformin XL 500mg x2/day). They will continue on Metformin XL 500mg x2/day for two weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day (and stopped if this cannot be tolerated).
3346111|NCT02226523||ACS|subjects with final diagnosis of ACS, or non-ACS
3346112|NCT02226536|Placebo Comparator|control|Diet group Control group
3346113|NCT02226536|Active Comparator|fractioned diet without glucose|Fractioned diet without glucose
3346114|NCT02226575|Experimental|Distress management|The distress management program (cognitive behavioral therapy) alongside standard care
3346115|NCT02226575|No Intervention|Control|Controls only dilivery standard care
3239953|NCT01284413|Experimental|S-1, Gemcitabine, Cisplatin|
3239954|NCT01284439|Experimental|TearA|
3346116|NCT02226588|Experimental|Secondary prevention|Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
3346117|NCT02226588|Active Comparator|Universal prophylaxis|Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby
3346118|NCT02226601|Active Comparator|Aprepitant|"Aprepitant~40 mg IV pre-operatively~40 mg PO post-op day #1~40 mg PO post-op day #2"
3346119|NCT02226601|Placebo Comparator|Placebo|"electrolyte (0.9% NaCl) infusion) pre-operatively~capsule without medication on post-op day #1~capsule without medication on post-op day #2"
3346120|NCT02226614|Experimental|head cooling|head cooling
3346121|NCT02226640||Non-Diabetic Lean Athletes|Athletes with a Body Mass Index (BMI) less than or equal to 25 kg/m2.
3239955|NCT01284439|Experimental|TearB|
3239956|NCT01284452|Placebo Comparator|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
3239957|NCT01284452|Active Comparator|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
3239958|NCT01284465|Experimental|Intervention group|Education and patient liaison combination
3239959|NCT01284465|Experimental|Control group|Education only
3239960|NCT01284478|Other|Dexamethasone Implant|Patients will be treated with the Ozurdex (Dexamethasone Implant)
3239961|NCT01284530|Experimental|Conversion-25|25 mg
3239962|NCT01284530|Experimental|Conversion-50|50 mg
3239963|NCT01284530|Experimental|Conversion-100|100 mg
3239964|NCT01284530|Experimental|Conversion-200|200 mg
3239965|NCT01284543|Active Comparator|Busin glide delivery of donor graft|Use of the Busin glide to insert the donor graft
3239966|NCT01284543|Experimental|Tan EndoGlide for insertion of the donor graft|Use of the Tan EndoGlide for insertion of the donor graft
3346122|NCT02226640||Non-Diabetic Lean No Diabetes History|Adults with a BMI < 25 kg/m2 and no family history of diabetes
3346123|NCT02226640||Non-Diabetic Lean Yes Diabetes History|Adults with a BMI < 25 kg/m2 and family history of diabetes
3346124|NCT02226640||Non-Diabetic Obese|Adults with BMI greater than or equal to 30 kg/m2.
3346125|NCT02226640||Non-Diabetic Obese Female PCOS|Female adults with BMI > 30 kg/m2 and Polycystic Ovarian Syndrome (PCOS).
3346126|NCT02226640||Diabetic No Medication|Have diabetes and currently receiving no medication or early treatment with one medication. Some participants receiving insulin may also be included in this study
3346127|NCT02226640||Diabetic GAD Ab+|Have diabetes with Latent Autoimmune Diabetes in Adults (LADA).
3346128|NCT02226640||Diabetic With NASH|Have diabetes with Nonalcoholic Steatohepatitis (NASH), which is chronic liver disease with fat in the liver, inflammation, and damage not associated with drinking alcohol.
3346129|NCT02226666||Patients having MRI with Eovist|Subjects having a clinically ordered MRI with Eovist. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the can. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
3346130|NCT02226666||Patients having MRI with Multihance|Subjects having a clinically ordered MRI with Multihance. Patients consenting for the study will be monitored before and after getting MRI contrast. For the study oxygen saturation (amount of oxygen level in the blood) and breathing will be monitored during the scan. Breathing will be measured with a non-invasive respiratory monitoring device attached to the MR scanner. Each patient will answer survey questions after the scan about their experiences concerning MRI contrast.
3346131|NCT02226679|Experimental|Algisyl-LVR device implantation|Algisyl-LVR™ employed as a method of left ventricular augmentation and restoration in patients with dilated cardiomyopathy. Algisyl-LVR™ will be injected into the myocardium under direct visualization during the surgical procedure.
3346132|NCT02226692||nonspecific chronic low back pain|Physical examination and follow-up assessment by questionnaires at 2, 4, 6, and 12 months
3346133|NCT02226705|Experimental|Multiple Surgeries|Patients undergoing transnasal endoscopic surgery
3239967|NCT01284556|Placebo Comparator|Placebo|placebo tablets
3239968|NCT01284556|Experimental|60 mg group|Patients titrated to 60mg phenobarbital for maintenance period, then titrated down.
3239969|NCT01284556|Experimental|100 mg group|Patients titrated to 100mg phenobarbital maintenance period, then titrated down
3239970|NCT01284569|Experimental|ALX-0061|
3346134|NCT02226718||questionnaire|
3346135|NCT02226731|Experimental|Early Belfort-Dildy balloon device|
3346136|NCT02226731|Other|Late Belfort-Dildy balloon device|
3346137|NCT02226744|Active Comparator|Focused breathing|Focused deep breathing techniques used to produce specific physiological and psychological states
3346138|NCT02226744|Active Comparator|Focused breathing 2|Focused deep breathing techniques used to produce specific physiological and psychological states
3346139|NCT02226757|Experimental|Paclitaxel-trastuzumab|Paclitaxel-trastuzumab weekly
3346140|NCT02226770|Other|ICD|Implantation of an Implantable Cardioverter Defibrillator (ICD) in patients with heart failure
3346141|NCT02226783|Experimental|Treatment A AZD1722 salt tablet (fasted)|Part A-Treatment A: morning dose of AZD1722 salt tablet 5 to 10 minutes before start of intake of breakfast; evening dose 5 to 10 minutes before start of intake of dinner
3239971|NCT01284569|Placebo Comparator|Placebo|
3239972|NCT01284582|Experimental|ATH03 Group A|ATH03, 10 µg, 0.2% Alum
3346142|NCT02226783|Experimental|Treatment B AZD1722 salt tablet (fed)|Part A Treatment B: morning dose of AZD1722 salt tablet 30 minutes after start of intake of breakfast; evening dose 30 minutes after start of intake of dinner
3239973|NCT01284582|Experimental|ATH03 Group B|ATH03, 30 µg, 0.2% Alum
3239974|NCT01284582|Experimental|ATH03 Group C|ATH03, 100 µg, 0.2% Alum
3346143|NCT02226783|Experimental|Treatment C AZD1722 salt tablet (fasted)|Part A Treatment C: morning dose AZD1722 HCl tablet then breakfast served 1 hour after dosing; evening dose 3 hours after start of intake of dinner and 1 hour before the next meal consumption
3239975|NCT01284595|Experimental|AZD8931|[14C] AZD8931
3239976|NCT01284647|Experimental|Teprenone capsule|
3346144|NCT02226783|Experimental|Treat D AZD1722 free-base tablet (fast)|Part B Treatment D: morning dose of AZD1722 free-base tablet administered 5 to 10 minutes before the start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner
3346145|NCT02226783|Experimental|Treat E AZD1722 free-base+Omeprazole|Part B Treatment E: morning dose of AZD1722 free base tablet administered 5 to 10 minutes before start of intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
3346146|NCT02226809||General anesthesia|Evaluation of RNMB. Application of accelerometry to patients after general anesthesia receiving at least one intermediate action nondepolarizing neuromuscular blocking agent dose
3239977|NCT01284647|Active Comparator|sucralfate|
3239978|NCT01284660|Active Comparator|I. DHA|Oral ingestion 5 tablets DHA + EPA (daily ingestion DHA 2040 mg and EPA 2710 mg)- (Omega 3 - 950,the Solgar Pharmaceutical Co., Israel).
3346147|NCT02226822||Adult patients with documented T2DM|Adult patients with documented history of type 2 diabetes mellitus who are initiating their second line oral or parenteral anti-diabetics medication after first line oral diabetic therapy
3346148|NCT02226861|Experimental|1|Subjects will receive CD34-selected stem cells followed by fixed dose ULG IL-2 (100,000 IU/m2) given subcutaneously for 12 weeks+Sirolimus until Day +60
3346149|NCT02226887|Experimental|MESH|
3346150|NCT02226887|Active Comparator|NO MESH|
3346151|NCT02226900|Experimental|Hybrid Revascularization|The hybrid myocardial revascularization group will be accomplished by a two-step scheme, comprised by off-pump LIMA-to-left anterior descending grafting, followed by percutaneous coronary interventions with Promus Element (everolimus second generation drug eluting stent) for the remaining coronary lesions.
3346152|NCT02226900|Other|Conventional Surgical Coronary Bypass Grafting|Conventional Coronary Artery Bypass Grafts with in pump technique.
3346153|NCT02226913|Experimental|lidocaine & sodium bicarbonate|2% lidocaine with 1: 80,000 epinephrine buffered with 0.18 mL of 8.4% sodium bicarbonate
3346154|NCT02226913|Active Comparator|lidocaine & placebo|2% lidocaine with 1:80,000 epinephrine with 0.18 mL of sterile distilled water
3346155|NCT02226926|Experimental|Aggrenox|Dipyridamole extended release / Acetylsalicylic acid
3346156|NCT02226926|Active Comparator|Persantin Retard|Dipyridamole extended release
3346157|NCT02226926|Active Comparator|Acetylsalicylic acid|
3346158|NCT02226939|Experimental|BILN 2061 ZW|
3346159|NCT02226939|Placebo Comparator|Placebo|
3239979|NCT01284660|Placebo Comparator|II. Placebo|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
3239980|NCT01284686|Active Comparator|dopamine|ON DOPA:The patient will take his usual treatment with dopamine
3346160|NCT02226952|Experimental|Group 1|BILN 2061 W, medium dose, in patients with genotype 1, minimal fibrosis
3346161|NCT02226952|Experimental|Group 2|BILN 2061 W, high dose, in patients with genotype 1, minimal fibrosis
3346162|NCT02226952|Experimental|Group 3|BILN 2061 W, high dose, in non-genotype 1 patients, minimal fibrosis
3346163|NCT02226952|Experimental|Group 4|BILN 2061 W, low dose, in patients with genotype 1, minimal fibrosis
3346164|NCT02226952|Experimental|Group 5|BILN 2061 W, medium dose, in patients with genotype 1, advanced fibrosis
3346165|NCT02226952|Placebo Comparator|Placebo|
3239981|NCT01284686|Experimental|without dopa|OFF Dopa: The patient will be deprived of his treatment usual dopaminergique for at least 12 hours
3239982|NCT01284725|Experimental|immunosuppressive treatment discontinuation,|
3346166|NCT02226978|Experimental|TPV/r with valaciclovir|VAL 2 days (on days 1 and 13), TPV/r 12 days (on days 2 to 13)
3346167|NCT02226991|Experimental|TPV/RTV/EFV|tipranavir (TPV) + ritonavir (RTV) from day 1 to day 24 efavirenz (EFV) from day 10 to day 23
3346168|NCT02227004||MRI in patients with Pacemaker or ICD|Perform MRI in patients with pacemaker or ICD and evaluate patient and device safety
3346169|NCT02227017|Experimental|TPV/RTV capsules fed|
3346170|NCT02227017|Experimental|TPV/RTV capsules fasted|
3346171|NCT02227017|Active Comparator|TPV/RTV solutions fed|
3346172|NCT02227017|Active Comparator|TPV/RTV solutions fasted|
3346173|NCT02227030|Experimental|BIIB 722 CL single rising dose|
3346174|NCT02227030|Experimental|BIIB 722 CL cross over|
3239983|NCT01284725|Active Comparator|Continuation of immunosuppressive therapy|with MMF or AZA, with a background therapy with hydroxychloroquine, and possibly low-dose corticosteroids
3346175|NCT02227030|Placebo Comparator|Placebo solution|
3346176|NCT02227030|Placebo Comparator|Placebo tablet|
3346177|NCT02227056|Experimental|Methylphenidate treatment|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
3346178|NCT02227056|No Intervention|Control|On three different days each participant will be re-evaluated without recieveing Methylphenidate.
3346179|NCT02227069|Experimental|M518101|M518101 is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
3346180|NCT02227069|Placebo Comparator|M518101 Vehicle|M518101 vehicle is applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
3346181|NCT02227069|Active Comparator|sodium lauryl sulfate|A solution of 0.2% sodium lauryl sulfate is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
3346182|NCT02227069|Sham Comparator|Saline|A solution of 0.9% saline is applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
3346183|NCT02227082|Experimental|radiotherapy and olaparib|radiotherapy: 61.18 Gy olaparib: dose escalating
3346184|NCT02227095|Experimental|After-school exercise program|40 min/day vigorous aerobic games after school
3346185|NCT02227095|Active Comparator|Sedentary after-school program|Attention-control condition similar to experimental condition with the exception of exercise
3346186|NCT02227134|Other|Difficult Airway|Children with a history of difficult airway intubation.
3346187|NCT02227134|Other|Obstructive Sleep Apnea|Children with a history of obstructive sleep apnea.
3346188|NCT02227160|Experimental|Psychosocial group intervention|Subjects will seek outpatient counseling, support groups, in addition to 10 weekly group meetings
3346189|NCT02227160|Active Comparator|Control|Subjects will seek outpatient counseling and support groups only
3346190|NCT02227173|Experimental|Single-Sequence, A B C|"Treatment A:~Single oral dose of montelukast, flurbiprofen, and digoxin on Day 1~Treatment B:~BMS-986020 orally twice daily (BID) on Day 8 through Day 10~Treatment C:~BMS-986020 orally BID, single oral dose of montelukast, flurbiprofen, and digoxin on Day 11; BMS-986020 BID on Day 12 through Day 17"
3346191|NCT02227186|No Intervention|Control arm|No school-located influenza vaccination clinic
3346192|NCT02227186|Experimental|School-located influenza vaccination clinics|School-located influenza vaccination clinics
3346193|NCT02227212|Experimental|Insulin glargine U300|Once daily subcutaneous injection for 4 weeks
3346194|NCT02227225||Postoperative Delirium|
3346195|NCT02227264|Experimental|Cinacalcet|"Cinacalcet, Mimpara®: 30 mgx1 for four weeks. In case of persistent hypercalcemia after two weeks of treatment with Mimpara® 30 mgx1, the dosage of Mimpara® will be increased to 60 mg daily.~Second intervention: Parathyroid adenomectomy."
3346196|NCT02227277|Experimental|Conditional 12-week ART interruption|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
3346197|NCT02227277|Experimental|Continuous ART|18 participants will receive peg-IFN-α2b (1 μg/kg/week) for 20 weeks.
3346198|NCT02227277|No Intervention|Control with continuous ART|18 participants will continue their current ART regimens and be observed for 20 weeks.
3346199|NCT02227290|Experimental|Naftin Cream, 2%|Once Daily
3346200|NCT02227290|Placebo Comparator|Placebo Cream|Once Daily
3346201|NCT02227303|Other|Lifestyle counseling|
3346202|NCT02227342|Experimental|Fecal Microbiota Transplantation|serial Fecal Microbiota Transplantation
3346203|NCT02227355||PD Patients < 70 years of age|Patients with Parkinson's Disease (PD) <70 years of age.
3346204|NCT02227355||PD Patients ≥ 70 years of age|Patients with Parkinson's Disease (PD) ≥ 70 years of age.
3346205|NCT02227381||Microarray / NGS test|
3375899|NCT03555149|Experimental|Atezolizumab + Imprime PGG + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
3346206|NCT02227394|Experimental|Z7200|"Z7200 is contained in single dose capsules (HPMC) and it is administered through a single dose dry powder inhaler (DPI), that is structurally correspondent to Aerolizer/Cyclohaler device.~Strength: Each delivered dose contains budesonide 80 mcg/inhalation and formoterol fumarate dihydrate 2.25 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01) provided."
3346207|NCT02227394|Active Comparator|Symbicort® Turbohaler|Symbicort® Turbohaler® inhalation powder; AstraZeneca UK Limited. Budesonide and formoterol fumarate dihydrate concentration Strength: Each delivered dose contains budesonide 160 mcg/inhalation and formoterol fumarate dihydrate 4.5 mcg/inhalation; two inhalations (i.e. total dose budesonide/formoterol is 320 mcg/9 mcg).
3346208|NCT02227407|Experimental|Energy expenditure, gait pattern, RGOs|using motion capture system and forceplates to monitor gait pattern while wearing reciprocating gait orthoses to calculate the mechanical energy cost
3346209|NCT02227420|Experimental|Anakinra|Anakinra 100mg s.c. x 5
3346210|NCT02227433|Experimental|brentuximab vedotin (BV)|
3346211|NCT02227459|Experimental|Experimental: Arm A|Once a week dosing
3346212|NCT02227459|Experimental|Experimental: Arm B|Twice a week dosing
3239984|NCT01284738|Active Comparator|TM patients|thalassemia major (TM) Need transfusion for survive
3239985|NCT01284738|Active Comparator|TI patients|thalassemia intermedia (TI) Patients with TI have a milder clinical phenotype than those with TM
3239986|NCT01284751||Breast cancer patients|Patients aged 30-70 years having a lumpectomy or mastectomy at the Department of Breast Surgery at Herlev Hospital, Copenhagen, Denmark.
3239987|NCT01284764|No Intervention|midnight fasting|The patients in this group will have midnight fasting the day before endoscopic examination
3239988|NCT01284764|Active Comparator|Mosapride, low volume of water|The patients in this group will take mosapride and a 500mL water at evening of the day before endoscopic examination.
3239989|NCT01284777||patients|
3239990|NCT01284790|Experimental|Cochlear implants|
3346213|NCT02227472||Sickle Cell Disease|All participants who meet eligibility requirements and consent to the study will complete evaluation of cognitive and pre-academic skills, and parent questionnaires.
3346214|NCT02227498|Experimental|Effect of Argus II on Functional Vision|All subjects enrolled in the study will be implanted with the Argus II Retinal Prosthesis. To evaluate safety and effectiveness of Argus II on visual function.
3346215|NCT02227511|Active Comparator|fruit|Participants are given +7kCal/kg body weight of fruit to be eaten as snack in between regular meals
3346216|NCT02227511|Active Comparator|nuts|Participants are given +7kCal/kg body weight of nuts to be eaten as snack in between regular meals
3346217|NCT02227524|Experimental|No Device|Assistive device conditions
3346218|NCT02227524|Experimental|Single Point Cane|Assistive device condition
3346219|NCT02227524|Experimental|Four-Point Cane|Assistive device condition
3346220|NCT02227524|Experimental|Trekking Pole|Assistive device condition
3346221|NCT02227537||Adolescence idiopathic scoliosis|Patients must be at least 10 years of age with a risser score of 0, 1, or 2
3346222|NCT02227550|Experimental|Apixaban|Xa group: factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose)
3346223|NCT02227550|Active Comparator|Vitamin K antagonist|VKA group: any Vitamin K antagonist (VKA), INR 2-3 , min. 30 days prescribed as in clinical routine
3346224|NCT02227563|Experimental|Active tDCS|active tDCS
3346225|NCT02227563|Sham Comparator|control|sham (placebo) tDCS condition
3346226|NCT02227576|Experimental|Romiplostim|Romiplostim lyophilized formulation is a white, solide cake that is reconstituted with sterile water for injection.
3346227|NCT02227589|Experimental|MET/CBT-12 plus CBT-D|CBT-D is an integrated cognitive behavior therapy targeting depression, delivered by the same study therapist who delivers MET/CBT-12 to the adolescent. All adolescents receiving CBT-D remain in MET/CBT-12 with their study provider.
3346228|NCT02227589|Active Comparator|MET/CBT-12 plus D-TAU|D-TAU (Depression Treatment as Usual) consists of referral to a depression treatment provider in the community. In this study D-TAU will be enhanced by assistance from the study team in locating providers and, with consent, an assessment report about the adolescent from the study team to the provider. All adolescents receiving TAU for depression remain in MET/CBT-12 with their study provider.
3346229|NCT02227589|Active Comparator|MET/CBT-12 alone|MET/CBT-12 consists of two sessions of motivation enhancement therapy and 10 sessions of cognitive behavior therapy, targeting alcohol or cannabis abuse. All adolescents in the study receive MET/CBT-12 over 12 to 14 weeks.
3346230|NCT02227602|Experimental|Mango|Mango polyphenolics
3346231|NCT02227615|Placebo Comparator|Sugary beverage|Sugary beverage
3239991|NCT01284803|Experimental|experimental arm|
3239992|NCT01284816|Other|severely obese patients|35 patients addressed for severe obesity in the Endocrinology department of Marseille North Hospital before (V1) and 6 months (V2) after bariatric surgery
3239993|NCT01284829|Experimental|adrenal tumors|adrenal tumors
3239994|NCT01284855|Active Comparator|Low initial dose|This arms corresponds to Nepal national protocol and involves the initial administration of 2 vials of antivenom over one hour followed by the slow infusion of 4 vials over 4 hours
3239995|NCT01284855|Experimental|High initial dose|This arms corresponds to Indian national protocol and involves the initial administration of 10 vials of antivenom over one hour followed by the slow infusion of saline over 4 hours
3239996|NCT01284868|Experimental|Mirabegron|
3239997|NCT01284881||OSAHS|
3239998|NCT01284894|Other|Conventional manometry|
3239999|NCT01284894|Experimental|High resolution manometry|
3240000|NCT01284907|Active Comparator|Vit D|
3240001|NCT01284907|Placebo Comparator|Placebo drops|
3240002|NCT01284920|Experimental|dose-escalation cohort-1|MDV3100 low dose arm
3240003|NCT01284920|Experimental|dose-escalation cohort-2|MDV3100 middle dose arm
3240004|NCT01284920|Experimental|dose-escalation cohort-3|MDV3100 high dose arm
3240005|NCT01284920|Experimental|dose-expansion cohort|dose expansion with MDV3100 middle dose
3240006|NCT01284933||Acute Ischemic Stroke, TIA|Patients admitted to a specialized stroke service because of an acute ischemic stroke or a transient ischemic attack (TIA).
3240007|NCT01284946|Experimental|Exjade|Safety and efficacy
3346232|NCT02227615|Experimental|Mango beverage|Mango polyphenolics
3346233|NCT02227628|Placebo Comparator|Sugary Beverage|Sugary Beverage
3346234|NCT02227628|Experimental|Acai beverage|Acai Polyphenolics
3346235|NCT02227641|Experimental|Adoptive transfer of CMV/EBV specific T-cells|Repetitive adoptive T-cell transfer starting at day 30 after allogeneic stem cell transplantation.
3346236|NCT02227641|No Intervention|Control|Observation only.
3346237|NCT02227654|Experimental|Abnormal Ovarian Ultrasound|Abnormal Ovarian Ultrasound
3346238|NCT02227680|Active Comparator|Music Therapy|Patients randomized to the music therapy group will receive 1-3 10-40 minute music therapy sessions during each of the days of their stay on the inpatient unit. Each participant randomized to the music therapy intervention will be given a personalized CD and one portable CD player with headphones which they may keep after the study has ended.
3346239|NCT02227680|Active Comparator|Massage Therapy|Patients randomized to the massage therapy group will receive 1-3 10-40 minute massage treatments during each of the days of their stay on the inpatient unit.
3346240|NCT02227680|No Intervention|Usual Care|The control group will continue to receive usual care while on the Family Medicine Inpatient Unit.
3346241|NCT02227719|Experimental|Test: CTI|CTI is titanium mesh
3240008|NCT01284972||HINTEGRA|Patient Implanted with the HINTEGRA Total Ankle Prosthesis more than 2 years ago
3346242|NCT02227719|Active Comparator|Control: Collagen membrane|Collagen membrane is used for ridge augmentation
3346243|NCT02227732|Other|New Indwelling Pleural Catheter|
3346244|NCT02227745||Dorzolamide hydrochloride (2%)|dorzolamide: diabetic patients with clinical significally macular edema with treatment photocoagulation dorzolamide (2%) application 1 drop every 8 hours for 4 weeks
3346245|NCT02227745||Placebo Sodium hyaluronate4mg|placebo: diabetic patients with clinically significant macular edema(focal), with photocoagulation sodium hyaluronate (0.5%) application 1 drop every 8 hours for 4 weeks
3346246|NCT02227771||Patient with chronic total occlusion|
3346247|NCT02227797|Experimental|Voriconazole|
3346248|NCT02227823|Experimental|significant decrement|Patients with significant decrement at electromyogram will be treated by pyridostigmine bromide 60mg 3 times a day for patients older than 18 and 1.5mg/kg 3 times a day for children less than 40kg
3346249|NCT02227823|No Intervention|no decrement|Patient without significant decrement will not receive any treatment and will be the control group
3346250|NCT02227888|Experimental|N91115|Every 12 hour oral dosing of 50 mg N91115 for 14 days
3346251|NCT02227901|Experimental|Treatment (tipifarnib, EBRT, temozolomide)|"TIPIFARNIB: Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~CONCURRENT CHEMOTHERAPY DURING RADIATION THERAPY: Within 5-9 days after starting tipifarnib, patients undergo EBRT daily and receive temozolomide PO daily for 6 weeks.~POST-RADIATION CHEMOTHERAPY: Beginning at week 10 post-radiation therapy, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for 1 year or 12 complete courses in the absence of disease progression or unacceptable toxicity."
3240009|NCT01284985||METIS|Patient who has an indication of : Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis and for which surgeon has recommended that a METIS® prosthesis be implanted.
3240010|NCT01284998||B-BOP lock|Subjects who needs a fixation of osteotomy of the basis of the first metatarsal and for whose surgeon has recommended that a B-BOP® Lock plate from INTEGRA be implanted can be enrolled in this study
3240011|NCT01285011||Ipp-On|Patient implanted with the Ipp-On
3346252|NCT02227914|Experimental|Oprozomib with Sorafenib|"Phase 1b:~Oprozomib doses will be escalated in sequential groups of at least 2 subjects. Study subjects will receive oprozomib at dose levels of 90, 120, 150, 180, 210, or 240 mg + sorafenib to reach the dose levels of 600 or 800 mg total daily dose until the maximum tolerated dose (MTD) is reached.~Phase 2:~Study subjects who meet the entry criteria will receive oprozomib + sorafenib at the RP2D (recommended Phase 2 dose) established in the Phase 1b portion of the study."
3346253|NCT02227914|Active Comparator|Sorafenib|"Phase 2:~Study subjects who meet the entry criteria will receive sorafenib 400 mg twice a day (800 mg total daily dose)."
3346254|NCT02227940|Experimental|Arm 1 (ceritinib MTD then with gemcitabine alone)|"Dose Escalation Cohort 1: Patients with advanced solid tumors for whom gemcitabine hydrochloride-based therapy is clinically appropriate receive ceritinib PO (QD on days 1-28 and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 1E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors who previously progressed on gemcitabine hydrochloride-based therapy receive ceritinib and gemcitabine hydrochloride as in the dose escalation cohort 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3346255|NCT02227940|Experimental|Arm 2 (ceritinib MTD then with gemcitabine and nab-paclitaxel)|"Dose Escalation Cohort 2: Patients with advanced pancreatic cancer receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15, and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 2E: Once the MTD of ceritinib has been determined, patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation as in the dose escalation cohort 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3346256|NCT02227940|Experimental|Arm 3 (ceritinib MTD then with gemcitabine and cisplatin)|"Dose Escalation Cohort 3: Patients with advanced solid tumors for whom gemcitabine hydrochloride and cisplatin-based therapy is clinically appropriate receive ceritinib PO QD on days 1-28, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Expansion Cohort 3E: Once the MTD of ceritinib has been determined, an additional 10 patients with ALK-positive advanced solid tumors receive ceritinib, gemcitabine hydrochloride, and cisplatin as in the dose escalation cohort 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity."
3346257|NCT02227953|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
3240012|NCT01285037|Experimental|LY2801653|"This study consists of a dose escalation of LY2801653 (Part A) followed by dose confirmation cohorts in four tumor types (adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma, uveal melanoma with liver metastasis, and cholangiocarcinoma) (Part B).~Part C consists of dose determination for LY2801653 in combination with cetuximab in participants with head and neck squamous cell carcinoma followed by an expansion cohort.~Part D consists of dose determination for LY2801653 in combination with cisplatin in participants with cholangiocarcinoma followed by an expansion cohort.~Part E consists of dose determination for LY2801653 in combination with gemcitabine and cisplatin.~Part F consists of dose determination for LY2801653 in combination with ramicirumab."
3240013|NCT01285063|Experimental|physical activiy & nutrition|"25 kindergarten children in the ages of 4-6 who defined as suffering from overweigh (BMI percentage 85-95) or obesity (above BMI percentage 95).~Non-generalization criteria: children who suffer from obesity due to organic disease or children who take medicine which may influence body weight (e.g., steroids) will be excluded from the research."
3346258|NCT02227953|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
3346259|NCT02227966|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 7 days a week for 12 weeks (total of 84 applications)
3240014|NCT01285089||A|
3346260|NCT02227966|Sham Comparator|sham-YBand (YDT-201N)|sham-tDCS application 7 days a week for 12 weeks (total of 84 applications)
3346261|NCT02227979|Experimental|Group I|The PURPLE Cry Intervention group will get an 11-page booklet and 12-minute DVD to review.
3346262|NCT02227979|Active Comparator|Group II|The control intervention group will get 1 brochure and a DVD on infant safety to review.
3346263|NCT02227992|Experimental|EVARREST™ Sealant Matrix|EVARREST™ Sealant Matrix/Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
3346264|NCT02227992|Active Comparator|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
3346265|NCT02228005|Experimental|Depression|Sertraline 50- 200mg
3346266|NCT02228005|No Intervention|Comparison group (non-depressed)|No intervention
3346267|NCT02228018|Experimental|CALSA and FRI repeatability|CT-Scan No medication used
3346268|NCT02228031|Experimental|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session.
3346269|NCT02228031|Placebo Comparator|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
3346270|NCT02228044|Experimental|Prevention Program|This is a cognitive-behavioral substance abuse, suicide, and HIV prevention program delivered in a workshop format to adolescent participants and their parents/legal guardians.
3346271|NCT02228044|No Intervention|Assessment Only|
3346272|NCT02228057||operated group|all patients who had upper extremity artery surgery at least 6 months ago
3346273|NCT02228070|Experimental|strabismus video goggles|
3346274|NCT02228083|Active Comparator|Safety of dental anesthesia|Application of local dental anesthesia with two cartridges (5,6 mL) of the lidocaine 2% with epinephrine 1:100.000 in heart failure patients in functional class III or IV.
3346275|NCT02228083|Other|Oral health profile|An oral health profile of patients with heart failure will be described based in oral clinical examination.
3346276|NCT02228109|Experimental|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
3346277|NCT02228109|Experimental|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
3346278|NCT02228109|Experimental|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
3346279|NCT02228122|Experimental|Aquacel® Ag+ Extra|
3346280|NCT02228135||Non post-tonsillectomy hemorrhage|Children who do not have post-tonsillectomy hemorrhage.
3346281|NCT02228135||Post-tonsillectomy hemorrhage|Children return to the hospital after surgery with post-tonsillectomy hemorrhage.
3346282|NCT02228148|Experimental|NFS|Cochlear Nucleus Fitting Software
3346283|NCT02228148|Active Comparator|CSS|Cochlear Nucleus Custom SoundTM Suite
3346284|NCT02228161|Experimental|Yoga exercise|Participatants will receive regular 60-minutes yoga classes twice a week for 3 months.
3346285|NCT02228161|No Intervention|Regular schedule of daily living|Participants will maintain regular schedule as usual.
3346286|NCT02228187|Active Comparator|BCI Intervention|Subjects will undergo the Brain-Computer Interface Intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the intervention in the first 8 weeks of the trial.
3346287|NCT02228187|No Intervention|Waitlist Control Group|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
3346288|NCT02228200|Experimental|Nurse-led care|Subjects in the nurse-led care arm received nurse-led care and routine care.
3346289|NCT02228200|Active Comparator|Routine care|Subjects in the routine care arm received routine care provided by the study hospital.
3346290|NCT02228213|Experimental|Treatment|500 mcg MIS416 500 at 0.2 mg/mL administered i.v. once weekly for 52 weeks
3346291|NCT02228213|Placebo Comparator|Saline|Saline administered i.v. once weekly for 52 weeks
3346292|NCT02228226||MG-1treated group|MG-1treated group: Patients those who underwent arthroscopic Bankart repair for glenohumeral instability using MG-1
3346293|NCT02228239|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (esketamine 84 milligram (mg) intranasally and 1 placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3240016|NCT01285115|Placebo Comparator|Placebo; corn flour,|"raw material total contents(500㎎) cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: for each sack 7.67g~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
3346294|NCT02228239|Experimental|Sequence 2 (BCA)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3346295|NCT02228239|Experimental|Sequence 3 (CAB)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3346296|NCT02228239|Experimental|Sequence 4 (CBA)|Participants will receive Treatment C (placebo intranasally and placebo capsule) in Period 1, Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 2 and Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3346297|NCT02228239|Experimental|Sequence 5 (ACB)|Participants will receive Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 1, Treatment C (placebo intranasally and placebo capsule) in Period 2 and Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3346298|NCT02228239|Experimental|Sequence 6 (BAC)|Participants will receive Treatment B (placebo intranasally and 1 mirtazapine 30 mg capsule) in Period 1, Treatment A (esketamine 84 mg intranasally and 1 placebo capsule) in Period 2 and Treatment C (placebo intranasally and placebo capsule) in Period 3 with a washout interval of at least 6 days between treatment periods.
3346299|NCT02228252|Experimental|20 g whey protein (-15 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3346300|NCT02228252|Experimental|20 g whey protein (-30 min)|20 g whey protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 30 min prior to the main meal.
3346301|NCT02228252|Experimental|20 g casein|20 g casein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3346302|NCT02228252|Experimental|20 g gluten protein|21.5 g gluten protein dissolved in 200 milliliter (mL) Water. Consumed as a pre-meal 15 min prior to the main meal.
3346303|NCT02228265||Ancillary-Correlative (genetic analysis)|Patients undergo collection of blood and tissue samples at baseline, during administration of enzalutamide and after the time of disease progression for analysis via immunohistochemistry, comparative genome hybridization, and sequencing.
3346304|NCT02228278|Experimental|Group A|Group A will receive the typical clinic visits plus daily text messages
3346305|NCT02228278|Other|Group B|Group B will act as the control and will receive the typical clinic visits.
3346306|NCT02228291|Placebo Comparator|Placebo|Cellulose
3346307|NCT02228291|Experimental|Citric flavonoid|Citric flavonoid
3346308|NCT02228304|Experimental|NT-503-3 ECT implantation|
3346309|NCT02228304|Active Comparator|Eylea® injected intravitreally every 8 weeks|Eylea® injected intravitreally every 8 weeks
3346310|NCT02228317|Experimental|Telemedicine consultation|EMTs will systematically establish teleconsultation by either telephone or video with the EMDC-physician in all cases of non-critical illness
3346311|NCT02228330|Experimental|uni-lateral obturator nerve block|"Patients scheduled for TUR for bladder tumor Intervention: uni-lateral obturator nerve block.~non-blocked obtorator side of each patient will be used as control"
3346312|NCT02228343|Experimental|Ayurveda|Ayurvedic therapy
3346313|NCT02228369|Experimental|Daily dose of AZD3759|Daily oral dose of AZD3759
3346314|NCT02228369|Experimental|Daily Dose of AZD9291|Daily oral dose of AZD9291
3240017|NCT01285115|Active Comparator|Gamisoyosan extract|"name of product: KyungBangn-Gamisoyosan-x-gwarip~standard code for item : 200005799~shape, type: extract(grayish brown)~usage, content : adults;three times a day , each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature expiration date : after manufacture 36 month macufacturing company: KyungBangnShinYak inc."
3346316|NCT02228434|Experimental|Tailored intervention group|"For the monitoring session, physical activity was assessed by accelerometer and dietary was assessed by diary. Based on the monitoring information, the individual tailored prescription, including the normative feedback and process feedback, were formed and delivered to children and parents. Children were encouraged to modify the behaviors according to the prescription.~Then, next monitoring circle was followed. In total, 7 monitoring round were completed."
3346317|NCT02228434|Experimental|Happy 10 exercise group|All the schools participating in this group were encouraged to take two Happy 10 sessions on each school day.
3346318|NCT02228434|Experimental|Nutrition education group|The nutrition intervention was mainly conducted based on the nutrition knowledge through health education lectures given by researchers. The lectures were given for eight times to students and twice to parents. Each lecture session lasted no less than 40 min.
3346319|NCT02228434|No Intervention|Control group|Receive no intervention
3375900|NCT03555149|Experimental|Atezolizumab + Isatuximab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
3240018|NCT01285115|Active Comparator|Gamisoyosan extract powder|"name of product: KyungBangn Gamisoyosan~standard code for item: 200005591~shape, type: powder(brown)~usage, content: adults;three times a day each sack taken before or between meals~dose, standard: 7.67g for each sack~storage : airtight container, stored in room temperature~expiration date : after manufacture 36 month~macufacturing company: KyungBangnShinYak inc."
3240019|NCT01285141|Experimental|Vaginal immunisation|CN54gp140 glycoprotein-hsp70 conjugate vaccine
3240020|NCT01285154||Traditional Steel Triple Osteotomy|Traditional technique
3240021|NCT01285154||Modified Triple Osteotomy|Modified technique
3240022|NCT01285167||DACOTA|
3240023|NCT01285180||DINO|
3346320|NCT02228447|No Intervention|No intervention group|The control group will not receive any intervention during the one year of this study. Only the baseline, 6-12 months assessments (anthropometrics, PA, dietary intake, social cognitive mediators and sedentary behaviors). To prevent compensatory rivalry and resentful demoralization, the control school will be provided with a condensed version of the following 12-month assessments. The condensed version of the program will include the professional learning workshops for intervention schools and the intervention materials (i.e., nutrition and PA handbooks and PA leadership handbook).
3346321|NCT02228447|Experimental|Healthy habits, healthy girls group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
3346322|NCT02228473|Experimental|Glycopyrrolate|Glycopyrrolate will be administered as the adjuncts of neuromuscular blocker reversal agent.
3346323|NCT02228473|Active Comparator|Atropine|Atropine will be administered as the adjuncts of neuromuscular blocker reversal agent.
3346324|NCT02228486|Active Comparator|Cue Exposure Therapy and verum tDCS|During alcohol cue exposure, an active tDCS with a duration of 15 minutes and 2 mA is applied to the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2).
3346325|NCT02228486|Placebo Comparator|Cue Exposure Therapy and sham tDCS|During alcohol cue exposure, a placebo tDCS is used with electrodes placed over the left dorsolateral prefrontal cortex (F3, anode) and a reference electrode placed over Fp2 (electrode positions determined by the international 10-20 system). The electrodes are rectangular (35cm2). There is a 20 second ramp going up until 2 mA and back to 0 again at the beginning and the end of the placebo stimulation with no active stimulation during the cue exposure.
3346326|NCT02228486|No Intervention|Waiting list control group|The Cue-Reactivity of patients assigned to this arm will be measured twice with an interval of 5 weeks. Afterwards, patients will take part in the cue exposure therapy like subjects assigned to the active arms of the study
3346327|NCT02228512|Active Comparator|1|Treatment naive PEL (main cohort)
3240024|NCT01285193|Experimental|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
3346328|NCT02228512|Active Comparator|2|Treatment na(SqrRoot) ve large cell lymphoma arising in KSHV-MCD
3346329|NCT02228512|Active Comparator|3|Previously treated KSHV-NHL
3240025|NCT01285206|Experimental|Routine practice|
3240026|NCT01285219|Active Comparator|AOB,pegylated filgrastim to filgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
3240027|NCT01285219|Active Comparator|BOA,ﬁlgrastim to pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
3346330|NCT02228525|Experimental|selinexor (KPT-330)|Patients with myelodysplastic syndromes who are refractory to hypomethylating agents (decitabine or 5-azacytidine) will receive oral selinexor at a starting dose of 60 mg twice weekly for 2 weeks, followed by 1 week of no therapy. Dose reductions are permitted for patients who are benefiting from selinexor but have poor tolerance. After discontinuation from treatment, patients will be followed by the study staff for survival status approximately every three months.
3346331|NCT02228538||Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system and off-the-shelf knee implant systems from various manufacturers
3346332|NCT02228551|Other|ARC PPS|Augmented renal clearance Point prevalence study
3346333|NCT02228603|Experimental|high-intensity exercise|community-based group program: weekly supervised high-intensity exercise training during 8 weeks, followed by group counselling every third month for 12 months
3346334|NCT02228603|Active Comparator|web-based follow-up|web-based follow-up program: home-based group will be followed up by mail and telephone calls the first 8 weeks, then every third month for 12 months
3346335|NCT02228603|Other|control|control group will receive usual care: information about recommended physical activity and healthy lifestyle
3346336|NCT02228616|Experimental|Prucalopride plus Polyethylene glycol or lactulose|
3240028|NCT01285232|Experimental|Anakinra|Anakinra 150 mg/day during four weeks
3240029|NCT01285232|Placebo Comparator|Placebo|Placebo during four weeks
3346337|NCT02228629|Experimental|Typical house shoe|Subject's typical shoes worn in and around home
3346338|NCT02228655|Other|FMX-8|FMX-8 for injection, 15mg/kg, twice weekly, 29 days
3346339|NCT02228707|Experimental|BIIB061|Participants receive BIIB061
3346340|NCT02228707|Placebo Comparator|Placebo|Participants receive matched placebo
3346341|NCT02228733|Experimental|KBP-5074: Cohort 1|Healthy Volunteers will receive one dose of KBP-5074
3346342|NCT02228733|Experimental|KBP-5074: Cohort 2|Healthy Volunteers will receive one dose of KBP-5074
3346343|NCT02228733|Experimental|KBP-5074: Cohort 3|Healthy Volunteers will receive one dose of KBP-5074
3346344|NCT02228733|Experimental|KBP-5074: Cohort 4|Healthy Volunteers will receive one dose of KBP-5074
3240030|NCT01285245|Experimental|kineret|
3240031|NCT01285258|Other|peripartum|patients whom underwent peripartum hysterectomy
3240032|NCT01285271|Experimental|Xenon|Xenon will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
3240033|NCT01285271|Active Comparator|Sevoflurane|Sevoflurane will be administered for balanced general anesthesia for CABG surgery before and after the extracorporal circulation.
3240034|NCT01285284|Experimental|Music|A previously defined list of songs will be administered by headphones to these patients during the colonoscopy.
3240035|NCT01285284|Sham Comparator|Control|These patients will receive an MP3 device (and headphones) which will be functioning but without volume.
3240036|NCT01285297|Experimental|TMR plus BMAC injection|Injection of bone marrow aspirate concentrate into reversibly ischemic myocardium with transmyocardial revascularization during the same open procedure.
3346345|NCT02228733|Experimental|KBP-5074: Cohort 5|Healthy Volunteers will receive one dose of KBP-5074
3346346|NCT02228733|Experimental|KBP-5074: Fed Group|Healthy Volunteers will receive one dose of KBP-5074
3346347|NCT02228746|Experimental|Alpha-galacto-oliosaccharides|
3240037|NCT01285336|Experimental|The genetic and the functional study|
3240038|NCT01285362|Active Comparator|Fish Oil Supplementation (Group A)|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
3240039|NCT01285362|Placebo Comparator|Placebo Supplementation (Group B)|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
3240040|NCT01285375|Active Comparator|CDC graft perfusion|Flushing of kidney allografts prior to transplantation with UW-solution containing CDC
3346348|NCT02228746|Placebo Comparator|Placebo|
3346349|NCT02228759|Experimental|Adductor canal block|The study is an open label pilot study to determine the feasibility of same day discharge following total knee arthroplasty with the use of a fast track regimen employing motor sparing knee blocks. The study will be performed on 25 American Society of Anesthesiologists class (ASA) 1-2 patients satisfying the inclusion criteria and undergoing unilateral primary total knee arthroplasty. First and second patients of the day undergoing surgery between Monday to Thursday in a week will be accessed for the study.
3346350|NCT02228772|Experimental|MLN 9708|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~MLN 9708 will be given with standard multi-drug regimen for ALL . MLN 9708 will be administered on determined days during Induction therapy cycle and Consolidation cycle. If remission occurs and if eligible, the next stage with be either Stem Cell or Bone Marrow Transplant.~If not eligible to receive a transplant, the participant will continue on this study for the next 3 stages.~CNS Therapy~Consolidation 2~Continuation Therapy~No further MLN9708, the investigational drug, will be given after Consolidation 1 Standard chemotherapy -Vincristine, Cytarabine, Doxorubicin, Mercaptopurine, Cyclophosphamide, Methotrexate"
3346351|NCT02228785|Experimental|100µg dose of G17DT|Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
3346352|NCT02228785|Experimental|200µg dose of G17DT|Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
3346353|NCT02228785|Experimental|500µg dose of G17DT|Patients in this arm received a 500µg dose of G17DT via intramuscular injection.
3346354|NCT02228798||Rivaroxaban|Patients currently taking rivaroxaban that have atrial fibrillation and require surgery or a procedure.
3346355|NCT02228798||Dabigatran|Patients currently taking dabigatran that have atrial fibrillation and require surgery or a procedure.
3346356|NCT02228798||Apixaban|Patients currently taking apixaban that have atrial fibrillation and require surgery or a procedure.
3346357|NCT02228811|Experimental|DCC-2701 tablet|DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
3346358|NCT02228837|Placebo Comparator|Placebo|12 weeks of consuming 50 g pear-flavored placebo powder mixed with 480 ml per day (1/2 in the morning and 1/2 in the evening at least 6-8 hours apart).
3346359|NCT02228837|Experimental|Pear|12 weeks of consuming 2 medium-sized pears per day (1 in the morning and 1 in the evening at least 6-8 hours apart).
3346360|NCT02228850|Experimental|Alprostadil Cream (300mcg)|300 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
3346361|NCT02228850|Experimental|Alprostadil Cream (1000mcg)|1000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, one dispenser for each administration
3346362|NCT02228850|Experimental|Alprostadil Cream (3000mcg)|3000 micrograms/.42% Alprostadil Cream with 2.5% Dodecyl-2-N,N-dimethylaminopropionate hydrochloride (DDAIP-HCl) and Placebo, two dispensers for each administration
3346363|NCT02228863|Experimental|Early Inmotion and Botox|Concomitant use of Inmotion and botulinum toxin from the baseline
3346364|NCT02228863|Active Comparator|Botox, then Inmotion|Inmotion training 4 weeks after botulinum toxin injection
3346365|NCT02228863|Active Comparator|Inmotion, then Botox|From the baseline Inmotion, then Botox injection at 4 weeks after baseline
3346366|NCT02228863|Active Comparator|Late Inmotion and Botox|No intervention, then Inmotion and Botox injection at 4 weeks from the baseline
3240041|NCT01285375|Sham Comparator|Sham perfusion|
3240042|NCT01285388|Experimental|MB12066 10mg|
3240043|NCT01285388|Active Comparator|MB12066 30mg|
3240044|NCT01285388|Active Comparator|MB12066 100mg|
3240045|NCT01285388|Active Comparator|MB12066 150mg|
3240046|NCT01285388|Active Comparator|MB12066 200mg|
3240047|NCT01285388|Placebo Comparator|placebo|
3240048|NCT01285414|Experimental|Verubulin & standard of care (RT & TMZ)|Verubulin, at the dose selected in Part A, plus standard of care Radiation Therapy and Temozolomide
3240049|NCT01285414|Active Comparator|Standard of care (RT & TMZ)|Standard of care Radiation Therapy and Temozolomide
3240050|NCT01285440||Diagnostic Imaging|
3240051|NCT01285453|Experimental|ASA404|
3240052|NCT01285466|Experimental|BEZ235 + paclitaxel|
3240053|NCT01285466|Experimental|BKM120 + paclitaxel|
3240054|NCT01285466|Experimental|BEZ235 + paclitaxel + trastuzumab|
3240055|NCT01285466|Experimental|BKM120 + paclitaxel + trastuzumab|
3240056|NCT01285479||prescribed fingolimod 0.5 mg/day|
3240057|NCT01285505|Active Comparator|Alprazolam commercial sublingual tablet|
3240058|NCT01285505|Experimental|Alprazolam test sublingual tablet|
3240059|NCT01285531|No Intervention|Lumbar puncture|The participants randomly assigned to this arm will receive a lumbar puncture using standard procedures and equipment
3240060|NCT01285531|Experimental|Lumbar puncture with the Compass device|The participants randomly assigned to this group will receive a lumbar puncture with the use of the Compass device.
3240061|NCT01285544|Experimental|Lipinon-test formulation of atrovastain - 20mg|
3240062|NCT01285544|Active Comparator|Lipitor- branded formuation of atorvastatin-20mg|
3240063|NCT01285557|Experimental|S-1/cisplatin|
3240064|NCT01285557|Active Comparator|5-FU/cisplatin|
3240065|NCT01285570|Experimental|Experimental 2|
3240066|NCT01285570|Experimental|experimental 1|
3240067|NCT01285570|Placebo Comparator|Placebo|Placebo comparator daily (QD)
3346367|NCT02228889|Experimental|Strattice|Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
3346368|NCT02228889|Experimental|XenMatrix|Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
3346369|NCT02228902|Active Comparator|ferrous fumarate|12 patients receive ferrous fumarate, 12 patients receive ferrous gluconate
3346370|NCT02228902|Active Comparator|ferrous gluconate|12 patients receive ferrous fumarate and 12 patients receive ferrous gluconate
3346371|NCT02228928|Experimental|CAPNP, 50 ug/cm2 capsaicin patch|50 ug/cm2 capsaicin patch, 49cm2, 1patch/4days
3346372|NCT02228928|Experimental|CAPNP, 100 ug/cm2 capsaicin patch|100ug/cm2 capsaicin patch, 49cm2, 1patch/4days
3240068|NCT01285583|Other|Olesoxime|All patients will receive the IMP as add-on to riluzole 50 mg bid orally, 50 mg morning and evening on an empty stomach ie at least 20 min before the meal.
3240069|NCT01285622||Gynecology patients|female subjects scheduled for elective robotic gynecological surgery under general anesthesia.
3346373|NCT02228928|Active Comparator|0.075% capsaicin cream|capsaicin cream qc/day
3240070|NCT01285648|Other|Cpap|This group joined chest physiotherapy with CPAP via nasal masks for two hours.CPAP was continued from the immediate postoperative day until the second postoperative day, twice a day.
3346374|NCT02228928|Placebo Comparator|Placebo patch|
3346375|NCT02228941||gene mutation|
3346377|NCT02228993||Awake Craniotomy|
3346378|NCT02228993||General Anesthesia Craniotomy|
3346379|NCT02229006||Aneurysm surveillance|Radiation: 18F-NaF PET-CT
3346380|NCT02229006||Control patients|Radiation: 18F-NaF PET-CT
3346381|NCT02229019|Experimental|Volunteer mealtime assistance|Trained volunteers will provide mealtime assistance to older hospital inpatients at one mealtime each weekday.
3346382|NCT02229032||Dravet Sydrome|Patients with Dravet Syndrome who are self-seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy
3346383|NCT02229045|Experimental|Albumin Bound Paclitaxel With 5-FU/CF|Albumin Bound Paclitaxel 150 mg/m2 (on day 1),5FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
3346384|NCT02229058|Experimental|Albumin Bound Paclitaxel plus S-1|Abraxane 120 mg/m2, D1,D8;S-1 40~60mg QD D1-D14,every 3 weeks until disease progress or intolerable toxicity.
3346385|NCT02229071|Experimental|Donafenib(200mg)|Donafenib 200 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
3240071|NCT01285648|Other|Chest Physiotherapy|Chest Physiotherapy consisted of bronchial hygiene techniques and pulmonary expansion, in addition to exercises, and received oxygen supplementation to maintain the pulse oxymetry saturations > 90%.
3240072|NCT01285661|Experimental|Proximal DVT|Patients whose veins have recanalized (either at the recruitment or later on during the follow-up) will receive the D-dimer determination before discontinuing sodium warfarin. Veins are defined as recanalized when the vein diameter under maximum compressibility is lower than 4 mm both at the common femoral and at the popliteal vein. In those with negative D-dimer sodium warfarin will be discontinued. These patients will have two further determinations of D-dimer (after 1 and 3 months, respectively). While patients with persistently negative D-dimer will no longer receive sodium warfarin, those in whom D-dimer is positive or reverts to positive values in the following determinations will have their sodium warfarin resumed and no longer discontinued.
3346386|NCT02229071|Active Comparator|Donafenib(300mg)|Donafenib 300 mg orally twice daily,each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
3346387|NCT02229084|Experimental|Part 1 - Chemovax Schedule A|Feasibility - Chemovax schedule A: Subjects will receive the first cycle of chemotherapy along with the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 1, the subsequent two injections of the vaccine one week apart (week 2 and 3), second cycle of chemotherapy on week 4, and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
3240073|NCT01285674|Experimental|Intra-tympanic steroid injection|
3240074|NCT01285687|No Intervention|Standard Analgesic Treatment|
3240075|NCT01285687|Experimental|Standard Analgesic Treatment with Acupuncture|Patients will receive standard analgesic treatment and in addition acupuncture.
3240076|NCT01285700|Active Comparator|Lamazym 25|25 U/kg
3240077|NCT01285700|Active Comparator|Lamazym 50|50 U/kg
3240078|NCT01285739||NIMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged with tracheostomy but in domiciliary non invasive ventilation
3240079|NCT01285739||IMV COPD|Patients with chronic obstructive pulmonary disease (COPD), who underwent tracheostomy for acute respiratory failure and who were discharged in domiciliary invasive mechanical ventilation (IMV)
3240080|NCT01285752|Experimental|1|
3240081|NCT01285752|Experimental|2|
3346388|NCT02229084|Experimental|Part 1 - Chemovax Schedule B|Feasibility - Chemovax Schedule B: Subjects will receive the first cycle of chemotherapy on week 1, the first injection of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine on week 2, the subsequent two injections of the vaccine one week apart (week 3 and 4), second cycle of chemotherapy on week 4 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22).
3346389|NCT02229084|Experimental|Part 1 - Chemovax Schedule C|Feasibility - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
3240082|NCT01285752|Active Comparator|3|
3346390|NCT02229084|Experimental|Part 1 - Chemovax Schedule D|Feasibility - Chemovax Schedule D: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 2 (along with second vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 5,8,11,14,17,20,23).
3346391|NCT02229084|Experimental|Part 1 - Chemovax Schedule E|Feasibility - Chemovax Schedule E: Subjects will receive the first injection of vaccine on week 1, the subsequent two injections of the P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine one week apart (week 2 and 3), the first cycle of chemotherapy on week 3 (along with third vaccine injection) and subsequent cycles of chemotherapy every 21 days (week 6,9,12,15,18,21,24).
3346392|NCT02229084|Experimental|Part 2 - Chemovax Schedule C|Primary Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
3346393|NCT02229084|Experimental|Part 3 - Chemovax Schedule C|Expanded Efficacy - Chemovax Schedule C: Subjects will receive three weekly injections of P10s-PADRE/MONTANIDE™ ISA 51 VG vaccine (week 1,2,3), then first cycle of chemotherapy (week 4), and subsequent cycles of chemotherapy every 21 days (week 7,10,13,16,19,22,25).
3346394|NCT02229097|Experimental|Normal then Coordinated|normal bolus during 2 weeks then coordinated bolus during 2 weeks
3346395|NCT02229097|Experimental|Coordinated then Normal|coordinated bolus during 2 weeks then normal bolus during 2 weeks
3346396|NCT02229110|Active Comparator|Signal|In addition to usual care, there will be an automatic signal in the electronic medical record (EMR) upon opening that will show the reader that the patient is currently not treated in the correct treatment setting and it simultaneously will give advice to which treatment allocation this patient should be transferred to.
3346397|NCT02229110|No Intervention|No signal|Patients receive usual care, consisting of 4 office visits yearly
3346398|NCT02229123|Experimental|Intravenous levetiracetam|1 loading dose of 30, 40 or 50 mg/kg administered intra-venously. Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment. Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
3240083|NCT01285765|Experimental|Early-PET-result-adapted treatment|4 to 6 RCHOP21
3240084|NCT01285765|Active Comparator|standard treatment|6 RCHOP21
3240085|NCT01285778|Experimental|Panitumumab, mytomicin C, 5-FU, radiation|
3346403|NCT02229162||90 seconds DCC|the initial 15-20 subjects (15 enrolled subjects who complete study) will have cord clamped at 90 seconds. Then data will be analyzed and evaluated by DSMB
3346404|NCT02229162||Two minutes DCC|If Data Safety Monitoring Board (DSMB) concurs, DCC will then be practiced for 2 minutes for second group, which is the minimum amount of time recommended to be defined as DCC.
3346405|NCT02229175|Experimental|IVB + laser|Intravitreal bevacizumab (IVB) will be administered at baseline, month 1, and month 2, consistent with previous DME trials. Subvisible laser treatment will be administered at baseline. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB and laser therapy every 3 months if defined retreatment criteria are met, as described below.
3346406|NCT02229175|Active Comparator|IVB only|IVB monthly at baseline, month 1, and month 2. Patients will then undergo monthly surveillance, as they would with standard of care treatment, allowing for retreatment with monthly IVB if defined retreatment criteria are met, as described below. Patients will also undergo sham laser treatment (patient will be placed in front of laser but no laser will be activated) to mask the patient to the treatment.
3240086|NCT01285804|Active Comparator|Cuffed ETT|
3346407|NCT02229188|Active Comparator|Problem Solving Therapy|Problem Solving Therapy is an evidence-based behavioral treatment for late life depression proven effective with different geriatric groups including ambulatory; medically ill; older adults with executive dysfunctions; and more recently, low-income, disabled older adults.
3240087|NCT01285804|Active Comparator|Uncuffed ETT|
3240088|NCT01285817|Experimental|traetment|
3240089|NCT01285830|Placebo Comparator|Placebo|
3240090|NCT01285830|Active Comparator|Lactobacillus reuteri|
3346408|NCT02229188|Experimental|Evolution|Evolution is a plasticity intervention in the form of a video driving game that targets the cognitive conflict network.
3346409|NCT02229188|Placebo Comparator|Words|Words is a challenging crosswords type of game that will serve as the placebo comparator to Evo.
3346410|NCT02229201|Experimental|Propofol|intravenous anaesthetic
3346411|NCT02229201|Active Comparator|Sevoflurane|volatile anaesthetic
3346412|NCT02229240|Experimental|Albiglutide|Subjects will receive once-weekly subcutaneous injections of albiglutide 30 mg (with forced uptitration to albiglutide 50 mg at Week 4) in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms.
3346413|NCT02229240|Placebo Comparator|Matching albiglutide placebo|Subjects will receive once-weekly subcutaneous injections of matching albiglutide placebo in addition to intensification of background basal-bolus insulin therapy (with or without metformin) according to predefined titration algorithms
3346414|NCT02229253||Degarelix|Treatment according to standard clinical practice.
3346415|NCT02229266|Experimental|NK cells|Infusion of haploidentical NK cells after immunosuppression with cyclophosphamide and fludarabine, followed by immunostimulatory treatment with interleukin-2
3346416|NCT02229266|Active Comparator|Control Intervention|1 cycle of consolidation chemotherapy with high-dose cytarabine
3346417|NCT02229279|Active Comparator|Teleconsulting|Teleconsulting
3346418|NCT02229279|No Intervention|No Teleconsulting|
3346419|NCT02229292|Active Comparator|Tranexamic acid|The active comparator consists of an intravenously administered bolus injection of 10ml of 100mg/ml tranexamic (1g in total) given as a single dose, after the onset of anesthesia, prior to surgery.
3346420|NCT02229292|Placebo Comparator|Saline|The placebo consists of an intravenously administered bolus injection of 10 ml of 9mg/ml sodium chloride given as a single dose after the onset of anesthesia, prior to surgery.
3240091|NCT01285856|Active Comparator|buprenorphine|populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
3240092|NCT01285856|Active Comparator|methadone|populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment. One hundred and ten patients will be included. Written informed consent will be obtained from each patient. Anonymity will be respected at inclusion and throughout. Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales. Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
3240093|NCT01285869|Experimental|Multidisciplinar intervention|Patients that will receive the multidimensional intervention during the ambulatory follow-up.
3346421|NCT02229305|Active Comparator|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
3346422|NCT02229305|Experimental|Modular Approach to Therapy for Children|Therapists used a modular manual (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2010) to help children with primary problems of anxiety, depression, trauma, and conduct.
3240094|NCT01285869|No Intervention|Conventional follow up|This is an observation only group and outpatient follow up will be indicated in accordance with usual and customary practices.
3240095|NCT01285882||Representations|
3346423|NCT02229331||gait analysis|gait analysis
3346424|NCT02229357|Experimental|OrniFlu® inactivated vaccine|
3346425|NCT02229370||ECAA|all patients diagnosed with an extracranial carotid artery aneurysm
3346426|NCT02229409|No Intervention|Control|Observation only, no behavioral intervention
3346427|NCT02229409|Experimental|Intervention|Intervention Walkadoo.
3240096|NCT01285921|Experimental|hippocampal surgery|"Vestibular test before and after hippocampal surgery~Principal criterion:~Research for an asymmetry of the vestibular responses (Caloric test, Vestibular Evoked Myogenic potentials: VEMp, Head Impulse Test: HIT, Eye Rotational Test: ERI). Investigator performs a blind vestibular test (single blind)"
3240097|NCT01285934|Experimental|Hematopoietic Stem Cell Transplantation|Patients who meet eligibility and have completed pre-HSCT testing in section 7.0 (study parameters) may be enrolled in the transplant arm and will undergo an Autologous Hematopoietic Stem Cell Transplantation
3346428|NCT02229422|Experimental|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
3240098|NCT01285934|Other|control arm of intensive insulin therapy|The control arm of intensive insulin therapy (IIT) will enroll all patients who meet eligibility but decline HSCT or whose insurance does not approve payment for HSCT before expiration of eligibility (within 5 months of disease onset)
3346429|NCT02229435||eGFR <60ml/min|Patients with CKD with eGFR <60 ml/min (CKD-EPI or MDRD) 12/2004-08/2014 of Medical Laboratory, Prof. Schenk / Dr. Ansorge and Colleagues, GbR, Am Neustädter Feld 47, 39124 Magdeburg, Germany.
3346430|NCT02229448||IgG4 UKN diagnosis|who ever been found with IgG4 sub class in blood sample or in his byposy
3346431|NCT02229500|Active Comparator|Control|Inulin control, 10g/d for 7 days. Isotope and appetite measurements on day 7
3346432|NCT02229500|Experimental|Delivery system 1|Delivery system, 28.5% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
3346433|NCT02229500|Experimental|Delivery system 2|Delivery system, 54% w/w propionate, 10g/d for 7 days. Isotope and appetite measurements on day 7.
3346434|NCT02229526|Active Comparator|Low dose fish oil|
3346435|NCT02229526|Placebo Comparator|Low dose olive oil|
3240099|NCT01285986|Experimental|Vein collar at distal anastomosis|Vein collar at the distal anastomosis
3240100|NCT01285986|Experimental|No vein collar at the distal anastomosis|No vein collar at the distal anastomosis
3240101|NCT01285999|Experimental|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)
3346436|NCT02229526|Experimental|High dose fish oil|
3346437|NCT02229526|Placebo Comparator|High dose olive oil|
3346438|NCT02229565||Caucasian|Caucasian subjects having a biopsy or prostatectomy.
3240102|NCT01285999|Active Comparator|TAXUS Liberté|TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)
3240103|NCT01286025|Active Comparator|Video modality|
3346439|NCT02229565||African American|African American subjects having a biopsy or prostatectomy.
3346440|NCT02229578||Lidocaine Treatment Group|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
3346441|NCT02229578||Placebo Treatment Group|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
3346442|NCT02229591||EFL patients|Patients with Expiratory Flow Limitation undergoing surgery
3346443|NCT02229591||Control group|Patients withouth Expiratory Flow Limitation undergoing surgery
3240104|NCT01286025|Active Comparator|Text modality|
3346444|NCT02229604|Experimental|EA group|Patients choose this group will receive EA as a combination. Beside of EA, participants could receive oral medicine as the same as that of the drug group. The EA regimen has two point formulae, i.e. A (BL33) and B (ST25, EX-CA1 and RN4). The two formulae will be used alternatively. One session will last for 20 minutes, 5 sessions per week for the first 4 weeks and 3 sessions per week later (44 sessions in all).
3346445|NCT02229604|Active Comparator|drug group|Hormone replacement therapy (HRT), DHEA and herb decoction are allowed to be used for this group. Treatment course is not fixed. Immunosuppressive agents are not allowed.
3346446|NCT02229617|Active Comparator|Injectable testosterone|We will take a group of transgender males, already on a stable dosage of intramuscular testosterone, and then using their same type and dosage, switch them to the subcutaneous injection route. Weekly trough (just before their weekly injection) levels of total serum testosterone will be taken to compare the steady states of those two injection routes.
3346447|NCT02229630|Experimental|Pregnant women|Foetuses with intra-uterine growth restriction, between 28 and 32 weeks of gestation, with an estimated foetal weight < 5th percentile (Hadlock calculator)
3346448|NCT02229643||Traumatic brain injury|Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
3346449|NCT02229656|Experimental|radiotherapy and olaparib|Radiotherapy will be given with accelerated fractionation following the DAHANCA schedule Olaparib: dose escalation
3346450|NCT02229669|Experimental|Horizontal incisions|Coronally advanced flap was performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted extending beyond the mucogingival junction, to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed.
3346451|NCT02229669|Experimental|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
3346452|NCT02229682|Experimental|Mild-dose IMRT|"Experimental: Mild-dose of 46Gy with IMRT~Drug:~gemcitabine：1250mg/m2 (iv drip) on days 1, oxaliplatin: 85 mg/m2 (iv drip) on day 1, and pegaspargase: 2500 IU/m2 (intramuscular injection) on day 1. Cycle is repeated every 14 days~IMRT： IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions."
3240106|NCT01286051|Active Comparator|Follistim|standard treatment
3240107|NCT01286051|Experimental|Follistim plus single ganirelix injection|
3240108|NCT01286064|Experimental|patient with colo-rectal cancer|fluorescence spectra will be mainly characterized by the presence of an emission peaking at 620-630 nm
3240109|NCT01286064|Active Comparator|patient without colo-rectal cancer|fluorescence spectra will be characterized by the absence of an emission peaking at 620-630 nm
3240110|NCT01286090|Experimental|001|Cisapride One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
3346453|NCT02229708|No Intervention|Usual Care|The Usual Obstetric Care group will receive usual advice about nutrition and activity during pregnancy from their obstetrician along with some additional information about pregnancy and childbirth through readings from The American College of Obstetricians and Gynecologists. In addition, participants will receive weekly text messages to maintain contact and ensure follow-up.
3346454|NCT02229708|Experimental|Healthy Lifestlye Group|The Healthy Lifestyle Group will take part in an individual, technology-based behavioral intervention program which will include specific information about nutrition and physical activity, and strategies for helping them make changes to their diet, physical activity, and weight-related behaviors during pregnancy. Participants will receive information through print materials, text messages, a private Facebook group, and in-person visits and phone calls from a health coach who is part of our research team.
3346455|NCT02229721|Active Comparator|Syntocinon Nasalspray 32 IU|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
3346456|NCT02229721|Placebo Comparator|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
3346457|NCT02229734|Experimental|Radiation plus Androgen Supression|Radiation plus Androgen Suppression give as stereotactic radiation 7gray (Gy) per week x 5 weeks and leuprolide 45mg every 6 months for 18 months
3346458|NCT02229747|Experimental|Meloxicam suspension|
3346459|NCT02229747|Active Comparator|Diclofenac suspension|
3346460|NCT02229747|Active Comparator|Nimesulide suspension|
3346461|NCT02229760|Experimental|TPV/r (Tipranavir co-administered with low dose ritonavir)|
3346462|NCT02229773|Experimental|BIBB 1464 MS low dose|
3346463|NCT02229773|Placebo Comparator|Placebo|
3346464|NCT02229773|Active Comparator|Pravastatin|
3346465|NCT02229773|Experimental|BIBB 1464 MS medium dose|
3346466|NCT02229773|Experimental|BIBB 1464 MS high dose|
3346467|NCT02229786|Experimental|Buscopan® plus|
3346468|NCT02229786|Active Comparator|Buscopan®|
3240111|NCT01286090|Experimental|002|Placebo One tablet taken orally 4 times a day for up to 8 weeks.
3346469|NCT02229786|Active Comparator|Paracetamol|
3346470|NCT02229786|Placebo Comparator|Placebo|
3346471|NCT02229799||Stroke patients|
3346472|NCT02229812||thrombolytic therapy in stroke|
3346473|NCT02229825|Experimental|Duloxetine low|
3346474|NCT02229825|Experimental|Duloxetine high|
3346475|NCT02229838|Experimental|BIBB 1464 MS single rising dose fed|
3346476|NCT02229838|Experimental|BIBB 1464 MS tablet fasted|
3346477|NCT02229838|Active Comparator|BIBB 1464 MS solution fasted|
3346478|NCT02229838|Placebo Comparator|BIBB 1464 MS placebo|
3346479|NCT02229877|Experimental|Gefapixant + Omeprazole|"Gefapixant oral tablets (25mg, 50 mg, 150 mg) administered twice daily for 18 days~+ Omeprazole oral capsules (40 mg) administered twice daily for 8.5 days"
3346480|NCT02229890||Acute ischemic stroke within three hours after symptom onset|
3346481|NCT02229903|Active Comparator|Active DTMS Treatment|Active DTMS Treatment constitutes the Deep Transcranial Magnetci Stimulation (DTMS) which is a new form of TMS which allows direct stimulation of deeper neruonal pathways than the standard TMS. The DTMS coil is designed to allow deeper brain stimulation without significant increase of electric fields included in superficial cortical regions.
3240112|NCT01286103|Experimental|001|Canagliflozin 300 mg once daily and 150 mg twice daily Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
3240113|NCT01286103|Experimental|002|Canagliflozin 100 mg once daily and 50 mg twice daily Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
3240114|NCT01286116|Experimental|Treatment|Parachute implant
3346482|NCT02229903|Sham Comparator|Sham Treatment|The Sham Treatment consists of an electrical field which cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
3346483|NCT02229929|Placebo Comparator|Part A: Placebo|Intravenous matched placebo
3346484|NCT02229929|Experimental|Part A: CR845 0.5 mcg/kg|Intravenous CR845, 0.5 mcg/kg
3346485|NCT02229929|Experimental|Part A: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
3346486|NCT02229929|Experimental|Part A: CR845 2.5 mcg/kg|Intravenous CR845, 2.5 mcg/kg
3346487|NCT02229929|Placebo Comparator|Part B: Placebo|Intravenous matched placebo
3346488|NCT02229929|Experimental|Part B: CR845 1.0 mcg/kg|Intravenous CR845, 1.0 mcg/kg
3346489|NCT02229942|Experimental|Rituximab|Rituximab induction (two infusions two weeks apart) and maintenance (infusions at 3, 6, 9 and 12 months)
3346490|NCT02229942|Placebo Comparator|Placebo|Saline (with added albumin), two infusions two weeks apart, followed by infusions at 3, 6, 9 and 12 months.
3346491|NCT02229955|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3346492|NCT02229955|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3346493|NCT02229968|Experimental|Amicar (ε-aminocaproic acid)|Treatment group 1: Amicar 100 mg/kg (0.4 mL/kg) IV loading dose, followed by an intraoperative continuous infusion at 40 mg/kg/hr (0.16 mL/kg/hr) to be continued until skin closure.
3346494|NCT02229968|Placebo Comparator|normal saline|Treatment group 2: Equal volume of normal saline (placebo control) at the same rate as treatment group 1.
3346495|NCT02229981|Experimental|ABC294640|Patients will receive ABC294640 orally in gelatin capsules BID.
3346496|NCT02229994||Adults patients with chronic respiratory diseases|"- 200 adult patients with chronic respiratory diseases will be studied longitudinally and transversely (follow-up: 6 months) in 12 centres.~Sample 1 (n=110 patients) with COPD~Sample 2 (n=30 patients) with Diffuse interstitial lung diseases~Sample 3 (n=30 patients) with Pulmonary Arterial Hypertension primary or secondary (post embolic .....).~Sample 4 (n=30 patients) Adult with Cystic fibrosis"
3346497|NCT02230007|Experimental|MEOPA|ENTONOX (MEOPA)gas Duration of treatment of a subject according to the protocol: 60 MINUTES Inhalation use
3346498|NCT02230007|No Intervention|Without MEOPA|Physiotherapit care without MEOPA
3346499|NCT02230020||Nasal High Flow|All subjects are in this group
3346500|NCT02230033|Experimental|Treatment A|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1.
3346501|NCT02230033|Experimental|Treatment B|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
3346502|NCT02230033|Experimental|Treatment C|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32, along with single oral dose of JNJ-56021927 240 mg capsule on Day 4.
3346503|NCT02230046|Experimental|Sequence 1 (ABC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
3346504|NCT02230046|Experimental|Sequence 2 (BCA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
3346505|NCT02230046|Experimental|Sequence 3 (CAB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
3346506|NCT02230046|Experimental|Sequence 4 (ACB)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 3.
3346507|NCT02230046|Experimental|Sequence 5 (BAC)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2*500 mg coated tablets) in Period 3.
3346508|NCT02230046|Experimental|Sequence 6 (CBA)|Participants will receive a single oral 1000 milligram [mg] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4*250 mg uncoated tablets) in Period 3.
3346509|NCT02230059||Metastatic Castration-resistant Prostate Cancer|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
3346510|NCT02230072|Experimental|fetoscopic surgical repair|Single arm study. All patients will receive the fetoscopic repair.
3240115|NCT01286142||Influenza treatment with oseltamivir|Patients 24 months of age and younger initially presenting with confirmed or presumed influenza A or B infection treated with oseltamivir.
3240116|NCT01286142||Influenza prophylaxis with oseltamivir|Patients 24 months of age and younger prescribed oseltamivir for influenza prophylaxis
3346511|NCT02230098|Experimental|Remote Ischemic Conditioning|By use of short-term obstruction of the blood supply to the arm
3346512|NCT02230098|No Intervention|Before Remote Ischemic Conditioning|
3346513|NCT02230111|Experimental|Energy restriction plus CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. They will be told that they are on a low-calorie diet and strategies to increase CDR will be used.
3346514|NCT02230111|Experimental|Energy restriction without CDR group|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. To have a condition of energy restriction without CDR, they will not be told that they are on a low-calorie diet and non-restrictive messages will be used.
3346515|NCT02230124|Experimental|MRE|
3346516|NCT02230137|Experimental|Text message arm|
3346517|NCT02230137|No Intervention|No text message arm|
3346518|NCT02230176|Experimental|177Lu-DOTA0-Tyr3-Octreotate or OCLU|7.4 GBq per injection (max: 4 injections)
3346519|NCT02230176|Active Comparator|Sunitinib|37.5 mg/day
3346523|NCT02230202||Healthy control|Healthy control that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3346524|NCT02230202||Stage III or IV CKD patients|Stage III or IV CKD patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3240117|NCT01286142||Influenza patients with no antiviral treatment|A comparator group of patients 24 months of age and younger presenting with confirmed or presumed influenza A or B and not treated with any influenza antiviral.
3240118|NCT01286155||with gastroesophageal reflux disease(GERD)|Subjects with gastroesophageal reflux disease (GERD)
3240119|NCT01286155||Non-GERD|Subjects with no history of gastroesophageal reflux disease (GERD)
3346525|NCT02230202||Post-transplant patients|Stage III or IV CKD Post-transplant patients that meets inclusion/exclusion criteria. Single blood draw and flow-mediated dilation (FMD).
3346526|NCT02230215|Experimental|Patient-Specific Instrumentation|Patients to have a total knee replacement surgery completed using Patient-Specific Instrumentation
3346527|NCT02230215|No Intervention|Traditional Instrumentation|Patients to have a total knee replacement surgery done using traditional instrumentation.
3346528|NCT02230228|Experimental|ALK-001 capsules|
3346529|NCT02230241||Cohort 1|Subjects of either gender and any race, aged ≥ 18 years, at moderate to very high CV risk, on lipid-lowering pharmacotherapy for at least 3 months (90 days), with no dose change for a minimum of 8 weeks (56 days). Before starting any study-related activities, the investigator should obtain written informed consent personally signed and dated by the subject.
3346530|NCT02230254|Experimental|PROMUS POREMIER stent|Single-arm treatment group receiving interventional PROMUS PRIMIER study stent
3346531|NCT02230267|Experimental|High intensity boot camp|Each of the two HIBCs will have 10 participants (20 total) with a 1:5 physical therapist-to-patient ratio. Each HIBC session will last 1.5 hours and will be held on 4 days of the week. Participants will be required to attend 3 of those 4 days but may attend all. Because this is a pragmatic trial, therapists will have some leeway to control the intensity and the modality of the exercise. However, the basic format of the HIBC will consist of the following exercise components: A. 30 minutes of moderate-high intensity aerobic exercise at 70%+ of estimated maximum heart rate; B. 15 minutes of strengthening the major muscle groups of the trunk and upper/lower extremities; C. 15 minutes of balance training; and, D. 15 minutes of rest and stretching. Participants will rotate through these four different exercise components in a circuit fashion.
3346532|NCT02230267|Active Comparator|Usual care arm|The low intensity exercise group will participate in the Fitness Counts Exercise Program (FCEP) which is a basic low intensity, sitting and standing exercise program (10 minutes of stretching, 10 minutes of aerobic exercise (60% of heart rate maximum), and 10 minutes of strengthening). This exercise program was developed by the National Parkinson Foundation and is commonly used in PD exercise classes. The physical therapist-to-patient ratio will be 1:5. As there are two clinical sites, there will be 10 participants in each of the two boot camps (20 total). The FCEP will be 1 hour daily on four days of the week. Participants will be required to attend 3 days per week but may attend more if they are able.
3240120|NCT01286155||Barrett's esophagus|Subjects with confirmed barrett's esophagus in Olmsted county
3346533|NCT02230280|Other|The intervention cohort.|A community transition and rehabilitation intervention that includes a mobile health solution
3346534|NCT02230293|Active Comparator|Conventional Group|Conventional treatment and follow up
3346535|NCT02230293|Experimental|Multidisciplinary Group|Multidisciplinary assistance
3240121|NCT01286181|Experimental|Device-guided slow breathing|
3240122|NCT01286194||Experimental 1|
3346536|NCT02230319|Experimental|Cryotherapy|Each patient will receive cryotherapy administered during weekly paclitaxel treatments by Elasto gel™ Hypothermia mitts and slippers. Patients will wear the mitts and slippers for 15 minutes prior to treatment start, for 60 minutes during treatment, and for 15 minutes following treatment completion, for a total of 90 minutes.
3346537|NCT02230345|Experimental|Probiotic yogurt|Daily administration, during two weeks, of two probiotic yogurts (200 mL each)
3346538|NCT02230345|Active Comparator|Acidified milk|Daily administration, over two consecutive weeks, of an isocaloric dose (compared to probiotics) of unfermented acidified milk
3346539|NCT02230358|Other|Regional anesthesia (RA)|Regional anesthesia (RA) for a carotid endarterectomy Interventions: Regional anesthesia (RA), blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, Near-infrared spectroscopy (NIRS) monitoring, oxygen supply (not invasive 'Vigileo')
3346540|NCT02230358|Other|General anesthesia (GA)|General anesthesia (GA) for a carotid endarterectomy Interventions: General anesthesia, blood gas analysis, 'Transcranieller Doppler' (Transcranial Doppler ultrasonography), invasive arterial blood pressure measurement, arterial blood gas measurement, neurological control, NIRS monitoring, oxygen supply (not invasive 'Vigileo')
3346541|NCT02230371|Experimental|Granisetron|Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is0.5 mL, hence the maximum dose of granisetron a patient can receive is 3 mg per treatment. This is repeated after one and two weeks.
3346542|NCT02230371|Placebo Comparator|Control (placebo)|Placebo (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden) is injected into a maximum of six muscle sites in each patient. The most painful sites to palpation of the masticatory muscles is chosen, either in the same muscle (maximum 3 sites per muscle) or in a different. The injected volume into each site is 0.5 mL. This is repeated after one and two weeks.
3346543|NCT02230397|Other|plantaricin a (active product)|Volunteers applied the active product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage.
3346544|NCT02230397|Other|placebo product|Volunteers applied the placebo product for an uninterrupted period of 8 weeks (on the right or on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
3346545|NCT02230410|Experimental|focal cryo ablation|in this pilot study 10 subjects with residual barrett's esophagus (less than 3 cm) post ablation will under go one CryoBalloon Focal Ablation treatment
3240123|NCT01286220|Active Comparator|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
3240124|NCT01286220|Placebo Comparator|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
3240125|NCT01286233||Group 1: Metformin|850 mg orally twice a day for 5 years
3240126|NCT01286233||Group 2: Placebo|One caplet orally twice a day for 5 years
3240127|NCT01286246|Experimental|Vaginal progesterone|
3240128|NCT01286246|Placebo Comparator|Placebo|
3240129|NCT01286298|Experimental|Laser gingivectomy|
3346546|NCT02230423|Experimental|Patients receiving nose surgery|"Patients in need of nose surgery, before and after surgery; or only after successful surgery, then with or without Empty Nose Syndrome."
3346547|NCT02230436|Experimental|Early drain removal|Removing drain(s) on postoperative day 3 (n = 72)
3346548|NCT02230436|Experimental|Late drain removal|Removing drain(s) on postoperative day 4 or later (n = 72)
3346549|NCT02230462|Experimental|Viewing of cancer excision defect|Patients in this arm of the study will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
3346550|NCT02230462|No Intervention|No viewing of cancer excision defect|Patients in this arm of the study will not be invited to view their cancer excision defect prior to its reconstruction.
3346551|NCT02230488|Active Comparator|Intensive Diabetes Case Management|Intensive Case Diabetes Management : A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
3346552|NCT02230488|No Intervention|Control :Standard/ usual care|
3346553|NCT02230501|Experimental|moderate diet regimen|"Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
3240130|NCT01286337|Experimental|vessel sealing|axilla dissection using this device
3240131|NCT01286337|Active Comparator|control|standard surgical technique
3240132|NCT01286350|No Intervention|Control|Participants randomized control will continue with usual clinical care.
3346554|NCT02230501|Experimental|stringent diet regimen|"Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner~For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned."
3346555|NCT02230514|Experimental|XCEL-MT-OSTEO-ALPHA and surgery|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue"
3346556|NCT02230514|Other|Autologous iliac crest and surgery|Standard treatment
3346557|NCT02230553|Experimental|lapatinib + trametinib|lapatinib: oral tablets, once daily trametinib: oral tablets, once daily
3346558|NCT02230605|Experimental|Cognitive Exercise|The cognitive exercises will consist of a series of computer games focusing on five categories: memory, speed, attention, flexibility and problem-solving. Participants will be expected to complete 1 hour of Lumosity exercise daily for a minimum of 8 days prior to surgery. Participants will be instructed to complete no less than 15 minutes of exercise at a time throughout each day. Each hour of exercise, participants will work through at least 1 game under each category. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
3346559|NCT02230605|Placebo Comparator|Normal Activity|Participants randomized into the Normal Activity group will be encouraged to maintain their normal activity level prior to surgery. These participants are asked not to alter their normal daily routine of mental exertion (i.e. watching television, reading, puzzles, etc.) and not permitted to subscribe to Lumosity while in the research study. Research assessments will include Mini-Mental State Examination, Self-Administered Gerocognitive Examination, Geriatric Depression Scale, Charlson Comorbidity Index, Short Form 36 Health Survey, Confusion Assessment Method, Memorial Delirium Assessment Scale and Postoperative Quality of Recovery Scale.
3346560|NCT02230618||Ryzodeg™|
3346561|NCT02230631||Part 1 (retrospective cross-sectional evaluation)|
3346562|NCT02230631||Part 2 (prospective observational evaluation)|
3346563|NCT02230644|Experimental|Audio enhanced|Enhanced Clinical Environment: participants wait for their operation in the enhanced audio-visual booth.
3346564|NCT02230644|Active Comparator|Other distraction method|Participants wait for their operation in a booth with another distraction such as the news on television
3346565|NCT02230644|No Intervention|Ordinary|Participants wait for their operation in an ordinary, unenhanced booth
3346566|NCT02230657|Active Comparator|Same day Discharge|
3346567|NCT02230657|Active Comparator|Next day discharge|
3240133|NCT01286350|Experimental|Intervention|"Participants randomized to intervention will receive the FL3X Flexible Lifestyle Empowering Change intervention. Adolescents will be paired with a health coach to help learn strategies for improving diabetes control"
3346568|NCT02230709|Experimental|Dry needling|Dry needling treatment on the trigger point number 2 of the trapezius muscle.
3346569|NCT02230709|Active Comparator|"TENS and dry needling"|Application of TENS current after dry needling treatment.
3240134|NCT01286363||Brachyfacial|Subjects with a horizontal facial growth pattern
3346570|NCT02230722|Active Comparator|Attention Control|The neutral 10-15 minute visit with the Care Manager will consist of a brief review of ATHENA-OT safety education and the patient's Pain Care Plan. The CM will answer patient questions, but will avoid using Motivational Interviewing communication. The Care Manager will review upcoming telephone check-in and assessment sessions.
3240135|NCT01286363||Mesofacial|Subjects with a balanced facial growth pattern
3240136|NCT01286363||Dolichofacial|Subjects with a vertical facial growth pattern
3240137|NCT01286376|Active Comparator|symbiotic|
3240138|NCT01286376|Placebo Comparator|placebo|
3346571|NCT02230722|Experimental|Collaborative Care|Collaborative Care intervention in which one of two Care Managers delivering both interventions will assist primary care providers (PCPs) by using Motivational Interviewing to communicate computer-based ATHENA-OT (opioid therapy) decision support guidelines to veterans with chronic pain.
3346572|NCT02230735|Experimental|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
3346573|NCT02230735|Placebo Comparator|Normal Saline|Total of 14 ml of normal saline, 7ml into the right uterosacral ligament and 7ml into the left uterosacral ligament
3346574|NCT02230774||medical staff|Nurses and doctors oncall
3346575|NCT02230787|Active Comparator|Recession coverage without Emdogain|
3346576|NCT02230787|Experimental|Recession coverage with Emdogain|
3240139|NCT01286389|Active Comparator|Conventional medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
3346577|NCT02230800|Experimental|Tocovid SupraBio plus pentoxifylline (PTX)|Tocovid SupraBio* 200mg po bd plus pentoxifylline (PTX) 400mg po bd for 12 months.
3346578|NCT02230800|Placebo Comparator|Matching placebos|Matching placebos bd for 12 months.
3346579|NCT02230813||Oral antibiotic therapy|Consecutive adult patients attending the study Emergency Departments with cellulitis will be considered eligible for recruitment to the study. Only those patients deemed suitable for oral antibiotic therapy and planned for discharge will be recruited to the study. Oral antibiotic therapy prescribed will be dependent on local institutional prescribing guidelines. For the purposes of the sites enrolling participants, the antibiotic of choice is oral flucloxacillin 500 milligrams four times daily for seven days. We will be assessing the treatment failure rate for this cohort of patients; namely, the number of patients requiring the primary outcome (change from oral to intravenous antibiotic therapy). We will also assess this group of patient for the secondary outcomes listed above.
3346580|NCT02230826||Patients with Hip arthroplasty|Patients with Hip implants.
3346581|NCT02230839|Experimental|Exercise training protocol|
3346582|NCT02230839|Experimental|Energy restriction-induced weight loss|
3346583|NCT02230839|No Intervention|Health Education|
3346584|NCT02230865||Surgery|Minimally invasive repair of pectus excavatum
3240140|NCT01286389|Experimental|caloric restriction +medical care|Nutritional counseling individually and in groups, aiming to promote weight loss (10% of body weight) through caloric restriction, +Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise)
3346585|NCT02230878|Experimental|JNJ-42847922, 5 milligram (mg) and Placebo|Participants will be receive either 5 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3346586|NCT02230878|Experimental|JNJ-42847922, 10 mg and Placebo|Participants will be receive either 10 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3346587|NCT02230878|Experimental|JNJ-42847922, 20 mg and Placebo|Participants will be receive either 20 mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3346588|NCT02230878|Experimental|JNJ-42847922, 40 mg and Placebo|Participants will be receive either 40mg of JNJ-42847922 from Day 1 up to Day 10 or matching placebo from Day 1 up to Day 10.
3346592|NCT02230917|Experimental|Sotatercept|Sotatercept 0.2 mg/kg will be administered every 21 days for 12 doses subcutaneously into the upper arm, abdomen or thigh.
3346593|NCT02230917|Placebo Comparator|Placebo|0.2 mg/kg of normal saline will be administered subcutaneously in the upper arm, abdomen or thigh for 21 days for 12 doses.
3346594|NCT02230930|Active Comparator|Massage with a spiky ball|Subjects are instructed to massage the apomorphine-induced skin reactions with a spiky ball 3 times a day for 2 minutes for 14 days.
3240141|NCT01286415|Experimental|Group Cognitive Processing Therapy-Cognitive Only|
3240142|NCT01286415|Active Comparator|Group Present Centered Therapy|
3240143|NCT01286467|Experimental|1|
3240144|NCT01286506||Mechanically ventilated patients|
3240145|NCT01286506||Non-mechanically ventilated patients|
3240146|NCT01286532||1|Children (male or female) aged 5 to 11 years inclusive on step 3 asthma combination therapy with ICS(inhalation glucocorticosteroids) and LABA ( long-acting b2-agonist) who have completed at least one valid CACT assessment after the study entry
3346595|NCT02230930|Active Comparator|Hydrocortisone cream 1%|Subjects are instructed to apply hydrocortisone cream 1% once daily for 14 days.
3346596|NCT02230930|Active Comparator|Subcutaneous hydrocortisone 10mg|Subjects are instructed to administer subcutaneous hydrocortisone (Solu-Cortef 10mg) prior to apomorphine via the subcutaneous infusion line which is used for administration of apomorphine, for 14 days.
3346597|NCT02230930|Active Comparator|Apomorphine 0.25% (2.5mg/ml)|Subjects are instructed to dilute apomorphine 0.5% (5mg/ml) with the same volume of physiologic saline (NaCl 0.9%) to 0.25% (2.5mg/ml). Apomorphine will be infused subcutaneously for 14 days.
3346598|NCT02230969||peginterferon beta-1a|Plegridy will not be supplied for this study. The study will collect data in an observational manner from participants who are prescribed Plegridy by physicians, according to the approved label in the respective country.
3346599|NCT02231008|Experimental|Tasimelteon|Single dose oral capsule, daily dosage, for 21 weeks
3346600|NCT02231008|Placebo Comparator|Placebo|Placebo comparator
3346601|NCT02231021|Experimental|alogliptin + pioglitazone|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3346602|NCT02231021|Active Comparator|alogliptin|alogliptin 25 mg 1 tablet daily for 24 weeks pioglitazone matching placebo 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3346603|NCT02231021|Active Comparator|Pioglitazone|alogliptin matching placebo 1 tablet daily for 24 weeks pioglitazone 30 mg 1 tablet daily for 24 weeks metformin for 24 weeks as the same dose and frequency as before enroll
3346604|NCT02231047|Experimental|64N Nutraceutical|Powdered 64N Nutraceutical 40 mg/kg/day mixed in 12 ounces of a culturally appropriate warm drink for 1 week (7 days).
3346605|NCT02231047|Sham Comparator|No 64N Nutraceutical|Culturally appropriate 12 ounce warm drink daily for 1 week (7 days).
3346606|NCT02231060||AIE after Cardiac Arrest|Male and female patients with AIE following CA.
3346607|NCT02231073|Experimental|Exercise: Agility Boot Camp-Cognitive|Subjects will participate in an 80-minute, group (6 per group) exercise session led by a certified exercise trainer knowledgeable in the Agility Boot Camp-Cognitive (ABC-C) program for 3x/week for 6 weeks. The exercise protocol is an adaptation of our Agility Boot Camp (ABC) exercise program for PD. The exercises are designed as a circuit to challenge movement-skills known to be impaired in PD. Stations will include: Gait training, PWR Moves ©, Agility course, Lunges, Boxing and Tai Chi. Each activity was chosen for its inherent focus on multi-directional movements, dynamic postural transitions, axial mobility, big movements and whole body motor sequencing. Each station (10-20 minutes) has 3 possible progression levels, based on: (1) divided attention with secondary cognitive tasks, (2) response inhibition, (3) limiting external sensory cues, and (4) increasing speed and resistance.
3346608|NCT02231073|Active Comparator|Education: Living with Parkinson's disease|The Education arm is a chronic disease education program to teach patients how to live better with their chronic condition. It was developed by our research team to be specific for people with Parkinson's disease. It will include content and discussion of topics such as sleep, nutrition, and medication management. Classes will consist of a group of subjects (up to 6) meeting with the trainer for 90-minute session, once a week for six weeks. In order to match dose of the education intervention with the exercise intervention, participants will be provided relaxation tapes to be used at home 5 times per week for 30 minutes for an overall education dose of 240 minutes; similar to the exercise dose.
3346609|NCT02231099|Experimental|prolift + m|surgery with mesh (prolift+M)
3346610|NCT02231099|Active Comparator|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery; anterior colporrhaphy or posterior colporrhaphy or spinal ligament fixation
3346611|NCT02231112|Experimental|Prone position whole breast RT|
3346612|NCT02231125|Experimental|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huangkui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
3346613|NCT02231125|Experimental|Losartan|Losartan potassium (Hangzhou MSD Pharmaceutical Co., Ltd.), 100 mg × 7 capsules/box.
3346614|NCT02231138|Experimental|Abelmoschus manihot (AM)|"age above 12 years old (including 12)：huangkui capsule are given orally at 2.5 g three times per day~age between 6-12 years old(including 6):huangkui capsule are given orally at 1.5 g three times per day~age under 6 years old：huangkui capsule are given orally at 1.0 g three times per day"
3346615|NCT02231151|Experimental|Pediatric Acute Care Professionals|Individuals must work in ER or ICU setting regularly or rotate through this setting with up to date BLS/PALS/ACLS certification. The participants will be required to rate the CPR based on accuracy for each video shown. The type of CPR error(s) shown to the individuals will be randomized.
3346616|NCT02231190|Experimental|GSK1278863|Subjects will be given five oral doses of GSK1278863 100 mg (5mg if a low dose is elected for subjects enrolled after interim analysis). The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
3346617|NCT02231190|Placebo Comparator|Placebo|Subjects will be given five oral doses of Placebo. The first dose will be administered immediately after completion of eccentric exercise, and then at 4, 8, 24, and 48 hours
3346618|NCT02231203|Placebo Comparator|Placebo|2 infusions of NaCl, 2 ml/kg, one the night before operation and one the day after operation.
3346619|NCT02231203|Active Comparator|Omegaven|2 infusions of 2ml/kg, one the night before surgery and one the day after surgery
3346620|NCT02231216|Experimental|Rhinoseptoplasty and turbinectomy|Patients submitted to rhinoseptoplasty associated to Endoscopic partial turbinectomy.
3346621|NCT02231216|Active Comparator|Rhinoseptoplasty|Patients submitted only to rhinoseptoplasty, without turbinectomy procedure.
3346622|NCT02231229|Experimental|PCR-based strategy|PCR-based strategy: after testing for isoniazid and rifampin resistance using a molecular testing with PCR (GenoType ®MTB DR plus), patients will receive HRZ combination therapy (INH , RIF, PZA) if no resistance is detected
3346623|NCT02231229|Active Comparator|conventional therapy|Conventional therapy: based on the standard of care in France: initiation of the standard 4 drug regimen INH, RIF, PZA, and EMB, until drug susceptibility testing (DST) results are available.
3346624|NCT02231242|Experimental|Intrathecal Autologous Bone Marrow TNC|Procedure/Surgery: Intrathecal Autologous Bone Marrow TNC. Other Names: Autologous Stem Cell Transplantation Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) (10mcgr/kg of body weight) for 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the autologous TNC concentrate of 10 mL will be infused intrathecally.
3346625|NCT02231242|No Intervention|Control group|"Patients will be evaluated with the Gross Motor Functional Classification System initially, at one, three and six months, and then cross to the intervention arm."
3346626|NCT02231255||Idiopathic Parkinson's disease patients|
3346627|NCT02231268||Depressive patients|
3346628|NCT02231281|Experimental|cART(TDF/AZT+3TC+LPV/r)|cART(TDF/AZT+3TC+LPV/r)
3346629|NCT02231281|Experimental|CTL infusion|cART plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
3240147|NCT01286545||Ankylosing spondylitis, long term treatment with infliximab|Patients with ankylosing spondylitis under long term treatment with infliximab within the open label clinical trials EASIC and DIKAS are now followed up in a registration study. No intervention is planned. Patients will be followed up for clinical outcome parameters and for radiographic progression.
3240148|NCT01286571|Experimental|BI 135585 (T)|single dose per subject as tablet formulation after high fat, high caloric meal
3240149|NCT01286571|Experimental|BI 135585 (R)|single dose per subject as tablet formulation after an overnight fast
3346630|NCT02231294||Idiopathic Parkinson's Disease Patients|
3346631|NCT02231307|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
3346632|NCT02231307|Experimental|SUBLIVAC FIX Birch 40,000 AUN/ml|
3240150|NCT01286584|Active Comparator|varenicline group|
3240151|NCT01286584|Placebo Comparator|placebo group|
3240152|NCT01286597|Experimental|dietary|
3346633|NCT02231320||Chronic Obstructive Pulmonary Disease patients|
3346634|NCT02231333|Experimental|S-adenosylmethionine (SAMe)|
3346635|NCT02231333|Active Comparator|pentoxiphylline (PTX)|
3346636|NCT02231346||chronic obstructive pulmonary disease patients|
3240153|NCT01286610|Other|vibration therapy and electrical muscle stimulation|
3240154|NCT01286636|Experimental|artificial neural network|
3240155|NCT01286636|Active Comparator|Polysomnogram|
3346637|NCT02231359||chronic obstructive airways disease patients|
3346638|NCT02231372||chronic obstructive airways disease patients|
3346639|NCT02231385|Experimental|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
3346640|NCT02231385|No Intervention|Control Group|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
3346641|NCT02231398||Women who participated in nuMoM2b|
3346642|NCT02231411|Active Comparator|Ventilation during DCC (V-DCC)|Measuring the volume of placental transfusion with ventilation (CPAP 5 cm H2O between inflations) in infants born by C/S or VG using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
3346643|NCT02231411|Active Comparator|DCC plus dry and stimulate|Measuring the volume of placental transfusions with delayed cord clamping alone (DCC) in infants born by C/S or VD using, as an initial surrogate marker, Hematocrits at 12 hours of life (HOL)
3346644|NCT02231424||chronic obstructive respiratory tract disease patients|
3346645|NCT02231437||chronic obstructive respiratory tract disease patients|
3240156|NCT01286649|Other|Injection of verum and control|Patients will receive randomized, blinded, injections of BOTH autologous hair follicle cells in medium (verum) and of medium alone (control) into two separate pre-defined treatment areas on their scalp.
3240157|NCT01286675|Experimental|Eltrombopag|0 mg Eltrombopag
3346646|NCT02231450|Experimental|Patients with mild hepatic impairment (Group1)|8 patients with mild hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054
3346647|NCT02231450|Experimental|Patients with moderate hepatic impairment (Group 2)|8 patients with moderate hepatic impairment will be administered a single oral dose of 60 mg Lu AE58054.
3240158|NCT01286688|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
3240159|NCT01286688|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
3346648|NCT02231450|Experimental|Healthy subjects (Group 3)|8 healthy subjects will be administered a single oral dose of 60 mg Lu AE58054.
3346649|NCT02231463||ultrasound measurement|"measuring subclavian vein Diameter in six Groups:~neutral positioning, PEEP 0 cm H2O, neutral positioning, PEEP 5cm H2O, neutral positioning, PEEP 10cm H2O, Trendelenburg positioning -20°, PEEP 0 cmH2O, Trendelenburg positioning -20°, PEEP 5 cmH2O, Trendelenburg positioning -20°, PEEP 10 cmH2O After these measurements a central venous catheter is used to measure the central venous pressure."
3346650|NCT02231489|Experimental|Treatment Sequence AB|Participants will receive treatment A (JNJ-42756493 tablet 10 milligram [mg] as single oral dose) along with JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 tablet on Day 1 in Treatment Period 1. Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) on Day 1 of Treatment Period 2.
3346651|NCT02231489|Experimental|Treatment Sequence BA|Participants will receive treatment B (JNJ-42756493 capsule 10 mg as single oral dose) along with 100 microgram (mcg) intravenous infusion over 5 minutes, 2 hours after administration of JNJ-42756493 capsule on Day 1 in Treatment Period 1. Participants will receive treatment A (JNJ-42756493 tablet as single oral dose) on Day 1 of Treatment Period 2.
3346652|NCT02231502|Experimental|Vegetable-based convenience food|"One time ingestion of a vegetable-based convenience product. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
3346653|NCT02231502|Active Comparator|Vegetable meal|"One time ingestion of a minimally processed vegetable meal. Dietary restrictions will be observed (i.e. avoidance of some vegetables) for 3 days prior to the bioavailability assessment (a list of foods to avoid will be provided).~At least 7 days wash-out between each assessment visit."
3346654|NCT02231515|Experimental|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty
3346655|NCT02231515|Active Comparator|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty (SLT)
3346656|NCT02231528|Experimental|Use of ultrasound with active GPS|
3346657|NCT02231528|Active Comparator|Use of ultrasound with inactive GPS|
3240160|NCT01286701|Experimental|Terbinafine Hydrochloride|Terbinafine Hydrochloride Tablets, 250 mg of Dr.Reddy's Laboratories Limited
3240161|NCT01286701|Active Comparator|Lamisil® 250 mg Tablets|Lamisil® 250 mg Tablets of Novartis
3240162|NCT01286714|Experimental|clips OST|
3240163|NCT01286727|Placebo Comparator|Normal Saline|Placebo
3240164|NCT01286727|Active Comparator|BB3|
3240165|NCT01286766|Active Comparator|DCS|DCS: docetaxel with cisplatin with TS-1
3240166|NCT01286766|Active Comparator|DCF|DCF : docetaxel with cisplatin with 5-FU
3240167|NCT01286831|Experimental|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
3240168|NCT01286844|Experimental|Cohort 1|Subjects ≥4 and< 12 years. First 6 subjects included, ≥8 and< 12 yrs and weigh ≥21kg, receive 1 SD (10mg) and an 8 day RD period (100mg). Remaining subjects in cohort: Subjects < 21kg receive 2 SD periods (10mg and 50mg), Subjects > 21kg receive 2 SD periods (10mg and 50mg) and an 8 day RD (100mg)
3240169|NCT01286844|Experimental|Cohort 2|Subjects ≥1 and< 4 years, receive 2 SD (5mg and 25mg)
3240170|NCT01286883||Blood draws|Laboratory studies will be performed at baseline; Cycle 1, Day 1; Cycle 1, Day 7; Cycle 2, Day 1; Cycle 3, Day 1; Cycle 4, Day 1; Cycle 6, Day 1; Cycle 12, Day 1.
3240171|NCT01286896|Experimental|Sunitinib|Sunitinib is administered in oral capsules of 12.5 mg. Patients will start with a continuous once-daily dose of 37.5 mg.
3240172|NCT01286909|Experimental|LaFlavon|
3240173|NCT01286909|No Intervention|Placebo|
3240174|NCT01286922|Experimental|Interval Training|"The target intensity for the INT group is 2 min at about 95% of baseline VO2max followed by 2 min of recovery at 40-50% of VO2max. Regardless of the training method each participant will be locked into a weekly energy expenditure of 12 kilocalories per kilogram of body weight per week (KKW)."
3240175|NCT01286922|Placebo Comparator|Aerobic Conditioning|During the first AER training condition, we will train all participants at an energy expenditure of 12 kcal/kg/wk (KKW). The target exercise intensity for the AER group will be 50%-70% of baseline V02max.
3240176|NCT01286935|Experimental|Low Dose (50mg/day)|
3240177|NCT01286935|Experimental|High Dose (100mg/day)|
3346658|NCT02231541|Experimental|Very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
3346659|NCT02231541|Placebo Comparator|Turned off very low frequency magnetic fields|The very low frequency magnetic fields (ELF) are magnetic fields already use for orthopedics pathology that have shown to be able to repair, to reduce pain, inflammation and edema in the damaged tissues.
3346660|NCT02231554|Experimental|Feldenkrais|The Feldenkrais method is a self education method that uses the somatic sensory-motor learning to enhance the functions of people in daily life activities through the awareness of their motor habits and the experience of more efficient alternatives.
3346661|NCT02231554|Active Comparator|Back School|The Back School teaches the patient, with theoretical and practical knowledge, how to defend his own back from the pain and how to prevent their disease, considering awareness and education as important parts of the therapeutic process .
3346662|NCT02231567|Experimental|Neurocognitive Rehabilitation|Rehabilitative approach based on exercises proposed as sensory-motor problems, whose solution involves the use of higher cognitive functions (attention, memory, language).
3346663|NCT02231567|Active Comparator|Traditional Rehabilitation|It is a rehabilitative approach based on exercises for the recovery of hip's range of motion, muscle strengthening exercises, stretching exercises of the hamstring muscles, adductor and iliopsoas and proprioceptive exercises.
3346664|NCT02231593||Acromegalic patients|
3346665|NCT02231606|No Intervention|Group 1: Pure Control|Provision of glasses prescription only
3346666|NCT02231606|Experimental|Group 2: Free Glasses|Free glasses for all, no upgrade glasses offered
3346667|NCT02231606|Experimental|Group 3: Free + Upgrade Glasses 1|Free glasses for all, optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
3346668|NCT02231606|Experimental|Group 4: Free + Upgrade Glasses 2|Free glasses for all, optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
3346669|NCT02231619|No Intervention|Demonstration of LSUPT at baseline|This group conduct a LSUPT on their own urine sample at baseline with assistance from a fieldworker.
3346670|NCT02231619|Active Comparator|Baseline verbal instruction of LSUPT|Verbal instruction on how to do LSUPT at baseline
3346671|NCT02231632|Experimental|Live attenuated Poliomyelitis vaccine (human diploid cell)|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
3240178|NCT01286935|Placebo Comparator|Placebo|
3346672|NCT02231632|Experimental|Poliomyelitis（Live）Vaccine(Monkey Kidney Cell),Oral|6.15 lgCCID50(containing typeⅠattenuated poliomyelitis not lower than 6.0 lgCCID50，typeⅡnot lower than 5.0 lgCCID50，type Ⅲ not lower than 5.5 lgCCID50).
3346673|NCT02231645|Experimental|STN DBS group|Experimental protocol is executed in PD patients with STN DBS implant in STN DBS ON and OFF conditions
3346674|NCT02231645|No Intervention|Control group|Experimental protocol is executed in PD patients without STN DBS implant twice without experimental variable manipulation.
3346675|NCT02231658|Experimental|Liraglutide|The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
3346676|NCT02231658|Experimental|Lixisenatide|The highest injected once daily dose will be 20µg s.c. for lixisenatide.
3346677|NCT02231671|Experimental|Part 1: Absolute Bioavilability|Part 1 of this study is an absolute bioavailability study where the IV (intravenous) microtracer dose of ALS-008112 is administered 15-30 minutes after the oral dose to determine the bioavailability of the oral dose compared to the IV dose. The maximum microtracer IV dose administered in Part 1 of this study will not exceed a single dose of 100 μg [14C]-ALS-008112 containing NMT (not more than) 37.0 kBq (1000 nCi) 14C. Based upon previous clinical observations, it is anticipated that the single oral dose and IV microdose to be utilised in Part 1 will provide acceptable PK data and will be safe and well tolerated.
3375901|NCT03555149|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
3240179|NCT01286948|Active Comparator|Levonorgestrel (LNG) gel (Levogel)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
3240180|NCT01286948|Active Comparator|oral LNG (1.5mg)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
3240181|NCT01286961||outpatient colonoscopy, bowel preparation, split dose PEG|adult outpatients who undergo colonoscopy
3240182|NCT01286974|Experimental|ADME|[14C]linifanib
3240183|NCT01286974|Experimental|Extension|linifanib
3240184|NCT01287026|Experimental|1|Open Label
3240185|NCT01287052|Experimental|Nitrous Oxide|
3240186|NCT01287091|Experimental|Part 1|
3240187|NCT01287091|Experimental|Part 2|
3240188|NCT01287091|Experimental|Part 3: Group A|
3346678|NCT02231671|Experimental|Part 2: Mass Balance|Part 2 of this study is an absorption, metabolism and excretion study, for which a single 375 mg [14C]-ALS-008176 (containing NMT 6.85 MBq (megabecquerel) (185 μCi) 14C) dose has been selected for evaluation based upon data from prior studies. Based upon previous clinical observations, it is anticipated that the dose to be utilised in Part 2 will provide acceptable PK data, will be safe and well tolerated and is within the therapeutic range.
3346679|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
3346680|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3346681|NCT02231684|Experimental|s.c. 0.5 mg (3 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
3346682|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (3 mg/ml)|
3346683|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by s.c. 0.5 mg (10 mg/ml)|
3346684|NCT02231684|Experimental|s.c. 0.5 mg (10 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3346685|NCT02231684|Experimental|i.v. 0.25 mg (1 mg/ml) followed by s.c. 0.5 mg (1 mg/ml)|
3346686|NCT02231684|Experimental|s.c. 0.5 mg (1 mg/ml) followed by i.v. 0.25 mg (1 mg/ml)|
3346687|NCT02231697||XLMTM patients - deceased|Non-interventional, retrospective medical chart review
3346688|NCT02231697||XLMTM patients - living|Non-interventional, retrospective medical chart review
3346689|NCT02231710|Experimental|BPX-501 and Rimiducid|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by Rimiducid infusion on day 7
3346690|NCT02231723|Experimental|A: BBI608 in combination with Gemcitabine and nab-Paclitaxel|
3346691|NCT02231723|Experimental|B: BBI608 in combination with modified FOLFIRINOX|
3346692|NCT02231723|Experimental|C: BBI608 in combination with FOLFIRI|
3346693|NCT02231723|Experimental|D: BBI608 in combination with MM-398, 5-FU and leucovorin|
3346694|NCT02231736||Type 2 diabetes, HbA1c>7.5|
3346695|NCT02231736||Type 2 diabetes, HbA1c<7.5|
3346696|NCT02231762|Experimental|Lanreotide Autogel 120mg & Temozolomide|"Combination phase for first 6 months: Lanreotide Autogel 120 mg and Temozolomide.~Followed by either 6 months Lanreotide Autogel 120 mg maintenance or 6 months of no treatment."
3346697|NCT02231775|Experimental|Treatment (dabrafenib, trametinib, surgery)|Patients receive dabrafenib PO BID and trametinib PO QD for 8 weeks. After completion of 8 weeks of dabrafenib and trametinib, patients undergo surgery. Approximately 1 week after surgery, patients receive dabrafenib PO BID and trametinib PO QD for 44 additional weeks in the absence of disease progression or unacceptable toxicity.
3346698|NCT02231788|Experimental|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab.(Telmisartan/S-Amlodipine) 40/2.5mg
3346699|NCT02231788|Active Comparator|Telmitrend®Tab. 80mg|Telmitrend®Tab.(Telmisartan) 80mg
3346700|NCT02231801||Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
3346701|NCT02231814|Experimental|Group 1|Crohn's Disease Exclusion Diet+Partial Enteral Nutrition (PEN): Crohns Disease Exclusion Diet + PEN
3346702|NCT02231814|Experimental|Group 2|Crohn's Disease Exclusion Diet alone with a calcium supplement
3346703|NCT02231827|Experimental|Gait analysis|
3240189|NCT01287091|Experimental|Part 3: Group B|
3240190|NCT01287130|Experimental|DL 1|AZD6244 once daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
3346706|NCT02231853|Experimental|-1|1x10e4 MVST/kg infusion
3346707|NCT02231853|Experimental|1|1x10e5 MVST/kg infusion
3346708|NCT02231853|Experimental|2|5x10e5 MVST/kg infusion
3346709|NCT02231853|Experimental|3|1x10e6 MVST/kg infusion
3346710|NCT02231853|Experimental|3B|1x10e6 MVSTr/kg infusion
3240191|NCT01287130|Experimental|DL 2|AZD6244 twice daily on days 1, 8, 15 and 22. Cetuximab 400 mg/m2 IV loading dose over 120minutes on day 1 and cetuximab 250 mg/m2 IV loading dose over 60 minutes on days 8, 15,22
3240192|NCT01287182|Placebo Comparator|Placebo|
3346711|NCT02231853|Experimental|4|5x10e6 MVSTr/kg infusion
3346712|NCT02231866|Experimental|Group 1|cAd3-EBO at 2x10(10)PU IM
3346713|NCT02231866|Experimental|Group 2|cAd3-EBO at 2x10(11)PU IM
3346714|NCT02231866|Experimental|Group 3|cAd3-EBO at 2x10(11)PU IM boost of Ebola DNA WT vaccine (VRC 206 participants)
3346715|NCT02231866|Experimental|Group 4A|cAd3-EBOZ at 1x10(10)PU IM
3346716|NCT02231866|Experimental|Group 4B|cAd3-EBOZ at 1x10(11)PU IM
3346717|NCT02231866|Experimental|Group 5|cAd3-EBO at 2x10(11)PU IM
3346718|NCT02231879|Active Comparator|Year 1 crossover|G-CSF or plerixafor, blinded
3346719|NCT02231879|Active Comparator|Year 2 crossover|G-CSF or plerixafor, blinded
3346720|NCT02231905|Experimental|BI-Sifrol®|Tablets were administrated after switching from prior treatment of dopamine agonist (talipexole), treatment period consisted of an ascending period and a maintenance period, total duration was 4 to 12 weeks.
3346721|NCT02231931|Experimental|A (Reference 1) Digoxin|1 tablet as single dose, fasted
3346722|NCT02231931|Experimental|B (Reference 2) Furosemide|oral solution, as single dose, fasted
3346723|NCT02231931|Experimental|C (Reference 3) Metformin hydrochloride|1 film-coated tablet as single dose, fasted
3346724|NCT02231931|Experimental|D (Reference 4) Rosuvastatin|1 film-coated tablet as single dose, fasted
3346725|NCT02231931|Experimental|E (Test) 1|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
3346726|NCT02231931|Experimental|F (Test 2)|Digoxin (1 tablet), Furosemide (0.5 mL oral solution), Metformin hydrochloride (2 film-coated tablets), Rosuvastatin (1 film-coated tablet), fasted
3346727|NCT02231931|Experimental|G (Test 3)|Digoxin (1 tablet), Furosemide (2.0 mL oral solution), Metformin hydrochloride (1 film-coated tablet), Rosuvastatin (1 film-coated tablet), fasted
3346728|NCT02231944|Experimental|Replenine®-VF|
3346729|NCT02231957|Experimental|educational text message reminders|receipt of education-embedded text message vaccine reminders
3346730|NCT02231957|Active Comparator|conventional text message reminders|receipt of conventional text message vaccine reminders
3346731|NCT02231970|Experimental|Endoscopic sleeve gastroplasty|The intervention is an endoscopic procedure: to perform endoscopic sleeve gastroplasty we used a cap-based flexible endoscopic suturing system (OverStitch™, Apollo, Inc. Austin, Texas) mounted on a double-channel endoscope (GIF-2T160; Olympus Medical Systems Corporation, Tokyo, Japan) to achieve full-thickness, running sutures through the gastric wall from antrum to fundus.
3346732|NCT02231983||Severe Combined Immunodeficiency|Case histories were analyzed to grasp important characteristics of the diseases. Distribution of lymphocyte subsets from peripheral blood were examined by flow cytometry. Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
3346733|NCT02231996||gene mutation|
3346734|NCT02232035|Placebo Comparator|normal saline, active phase of labor|A single dose intravenous injection of normal saline (2ml) at the beginning of active phase of labor in the group.
3240193|NCT01287182|Active Comparator|Ateronon|
3240194|NCT01287234|Other|All Patients|All patients will have an echocardiogram and SonR sensor readings completed.
3346735|NCT02232035|Experimental|diazepam, active phase of labor|A single dose intravenous injection of diazepam (10mg, 2ml) at the beginning of active phase of labor in the group.
3346736|NCT02232048||Corticosteroid Treatment|Patients in the internal medicine department who are being treated with corticosteroids will undergo Transthoracic Echocardiogram to determine change in heart function.
3346737|NCT02232100|Experimental|10AMG|Attentional bias modification group - 10 training sessions
3346738|NCT02232100|Placebo Comparator|10ACG|Attentional control group - 10 placebo sessions
3346739|NCT02232100|Experimental|18AMG|Attentional bias modification group - 18 training sessions
3240195|NCT01287247||Cervical Dystonia|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.
3240196|NCT01287247||Blepharospasm|The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.
3240197|NCT01287260|Experimental|Arm1|
3240198|NCT01287260|Active Comparator|Arm 2|
3240199|NCT01287273||Group A|Transfer at the day of embryo thawing
3346740|NCT02232100|Placebo Comparator|18ACG|Attentional control group - 18 placebo sessions
3346741|NCT02232113|Experimental|CERA|We included HD patients with stable hematocrit (between 30~36%) under intravenous administration of CERA 100 μg once monthly for two months. Then they were shifted to receive CERA 50μg twice monthly for anther two months and finally they were shifted back to receive CERA 100 μg once monthly again for additional two months. Then we compared the hematocrit, nutrition status and inflammation markers every two months for 6 months totally. Those who had bleeding or received surgery or blood transfusion were excluded.
3240200|NCT01287273||Group B|Transfer of thawed embryos 24-72 hours post thawing
3240201|NCT01287286|Experimental|AC-Can|Antrodia cinnamomea and concomitant chemotherapy
3346742|NCT02232139|No Intervention|Standard therapy group|Participant who will not receive midazolam for pharmacological anxiolytic premedication before general surgery
3346743|NCT02232139|Experimental|Midazolam group|Participant who will receive midazolam for pharmacological anxiolytic premedication before general surgery
3346744|NCT02232152|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid, fluorouracil)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-4 and fluorouracil IV over 46 hours on days 2-4. Courses repeat every 2 weeks for 6 months in the absence of disease progression or unacceptable toxicity.
3240202|NCT01287286|Placebo Comparator|control|Placebo and concomitant chemotherapy
3240203|NCT01287299|Experimental|Low Glycemic Load Diet|Counseled to consume a diet with a low or higher intake of carbohydrate sources that cause rapid or significant intakes in blood glucose. The average glycemic load of the diet should be less than 55 per 1000 calories or greater than 55 per 1000 calories.
3240204|NCT01287299|Experimental|Low Fat Diet|Pregnant women were counseled to consume a diet providing less that 25% of the energy as fat.
3240205|NCT01287325|Experimental|DNK333|
3240206|NCT01287325|Placebo Comparator|Placebo|
3346745|NCT02232165|Experimental|Hypotension avoidance (MAP >= 65 mmHg)|Mean arterial blood pressure is maintained >= 65 mmHg for 7 days following acute SCI.
3346746|NCT02232165|Active Comparator|Induced hypertension (MAP >= 85 mmHg)|Induced hypertension with mean arterial blood pressure >= 85 mmHg for 7 days following acute SCI.
3240207|NCT01287338|Experimental|Lower Puncta Delivery|
3240208|NCT01287338|Experimental|Double Puncta Delivery|
3240209|NCT01287351||IPDI: Qvar|ICS initiation as Qvar
3240210|NCT01287351||IPDI FP|ICS initiation as fluticasone
3240211|NCT01287351||IPDA Qvar|ICS step-up as Qvar
3240212|NCT01287351||IPDA FP|ICS step-up as fluticasone
3240213|NCT01287390|Active Comparator|standard radiotherapy treatment|These patients receive the normal standard treatment.
3240214|NCT01287390|Experimental|adaptive radiotherapy|These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.
3240215|NCT01287429||acute dyspnea|
3240216|NCT01287455|Active Comparator|vitamin D|vitamin D deficient asthmatic patients receiving vitamin D supplement
3240217|NCT01287455|Placebo Comparator|placebo|vitamin D deficient asthmatic patients receiving placebo
3240218|NCT01287468||Experimental Group|
3240219|NCT01287468||Control Group|
3240220|NCT01287481|Experimental|Stress and Emotions|Seeks to reduce stress and physical symptoms by helping individual become aware of their emotions, express them, and resolve emotional difficulties. It will use techniques such as writing about stress, role playing how to handle difficult relationships, recognizing and expressing anger and other feelings, and being more open with others.
3240221|NCT01287481|Active Comparator|Thoughts and Behaviors|Seeks to help individuals function better and improve symptoms by teaching various cognitive and behavioral skills to manage symptoms of fibromyalgia. It will use techniques such as relaxation training, engaging in pleasant activities, pacing yourself, and changing unhelpful ways of thinking.
3240222|NCT01287481|Active Comparator|Brain and Body|Seeks to help individuals improve health by educating about fibromyalgia so that one can better understand and more effectively communicate about their health. It will explain the latest scientific information about fibromyalgia, including its causes, the role of the nervous system and body, various medical and alternative treatments, and how to understand research findings.
3346750|NCT02232204|Active Comparator|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
3346751|NCT02232204|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive CBT-I-ICD.
3240223|NCT01287494|Experimental|Depression Care Management|"DCM Intervention for Depressed Elders in Primary Care~Treatment guidelines (TG): Eight weeks treatment with Sertraline, another 8 weeks treatment augmentation with Bupropion if patients fail to respond in the initial trial, For more complicated cases, the transfer to psychiatrists is indicated.~Care managers: Screening, Adherence support, psychoeducation and communication.~Psychiatric Consultation"
3240224|NCT01287494|No Intervention|Care as Usual|
3240225|NCT01287507|Placebo Comparator|Placebo|In born VLBW infants with parental consent form signed will be given oral saline daily as placebo until discharge
3240226|NCT01287507|Experimental|Lactoferrin|In born VLBW infants with parental consent form signed will be given oral bovine lactoferrin daily until discharge
3240227|NCT01287533|Experimental|Ibandronate treatment|Ibandronate 150mg PO once every 4 weeks
3346752|NCT02232217|Experimental|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
3346753|NCT02232217|Active Comparator|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
3346754|NCT02232256|Experimental|CALPXT96|"1st treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)~2 week wash out period~2nd treatment period: 4 weeks placebo (two capsules hs at bedtime)"
3346755|NCT02232256|Placebo Comparator|Placebo|"1st treatment period: 4 weeks placebo (two capsules hs at bedtime)~2 week wash 'out' period~2nd treatment period: 4 weeks CALPXT96 (two capsules hs at bedtime)"
3346756|NCT02232269|Placebo Comparator|Water plus Felodipine|Felodipine extended-release tablet ,10 mg, single dose, 8 hours
3240228|NCT01287533|Placebo Comparator|Placebo arm|Placebo PO once every 4 weeks
3240229|NCT01287546|Experimental|LY2875358|
3346757|NCT02232269|Active Comparator|Black Coffee|Black Coffee, 300 ml, 0 and 1 hour
3346758|NCT02232269|Experimental|Black Coffee plus Felodipine|"Black Coffee, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
3346759|NCT02232269|Active Comparator|Grapefruit Juice plus Felodipine|"Grapefruit Juice, 300 ml, 0 and 1 hour~Felodipine extended-release tablet ,10 mg, single dose, 8 hours"
3346760|NCT02232295|Active Comparator|Conventional group|Conventional group consist of Upper extremity task oriented functional exercises. Components of Task oriented training include weight bearing, supportive reactions, and reaching, grasping, holding and release activities.
3240230|NCT01287546|Experimental|LY2875358 + erlotinib|
3240231|NCT01287546|Experimental|LY2875358 at Part A highest dose|
3346761|NCT02232295|Experimental|Graded Motor imagery group and Conventional group|"Graded Motor imagery is a three stage process, was performed five days a week for six weeks of one hour duration. It comprises of:~Left Right discrimination training (Implicit Motor Imagery) - 2 weeks~Explicit Motor Imagery (Imagined movements) - 2 weeks~Mirror Therapy - 2 weeks"
3346762|NCT02232308|Experimental|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3346763|NCT02232308|Experimental|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3346764|NCT02232308|Experimental|Nizatidine plus Lisinopril|Nizatidine (150 mg) and Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3346765|NCT02232308|Placebo Comparator|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
3346766|NCT02232321|Other|PsA MDA|
3346767|NCT02232334|Experimental|Osteopathic manual treatment|Global Osteopathic Manual treatment: each subject will be treated according to what restrictions or areas of poor mobility are found individually. No two subjects will receive the same overall treatment.
3346768|NCT02232334|No Intervention|Control--no change in current treatment of subject|The population will act as their own control prior to intervention of osteopathy, their will be a control period where the subject maintains current treatment of their gastroparesis. During that period they will fill out the GCSI measuring tool at the beginning of the control period and at the end. Those measurements will be compared to the GSCI results during the intervention period.
3346769|NCT02232347|Experimental|ketamine|ketamine 5 mg/kg/h, continuous infusion for 48 hours
3240232|NCT01287546|Experimental|LY2875358 at Part A highest dose + trametinib|
3240233|NCT01287559||Subjects with NEC|Infants in which a possible diagnosis of NEC is suspected
3240234|NCT01287559||Control Infants|Age-matched and illness-severity matched to NEC subjects, controls are infants NOT suspected of having NEC.
3346770|NCT02232347|Active Comparator|sufentanil|sufentanil 0,5 mcg/kg/h, continuous infusion for 48 hours
3346771|NCT02232360|Experimental|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
3240235|NCT01287572||Conscious sedation group|Pediatric patients 0 to 18 years requiring conscious sedation for procedures done in the pediatric ICU excluding burned patients or patients with severe eczema or other skin disease.
3240236|NCT01287585|Experimental|ADI-PEG 20|Arginine deiminase formulated with polyethylene glycol.
3346772|NCT02232360|Active Comparator|Rosuvastatin alone|Rosuvastatin 10 mg per day
3240237|NCT01287585|Placebo Comparator|Placebo|an inert treatment with no therapeutic value.
3240238|NCT01287598|Experimental|Arm 1|Regorafenib (Stivarga, BAY73-4506) + warfarin + omeprazole + midazolam
3346773|NCT02232373|Sham Comparator|Normal FODMAP arm|Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
3346774|NCT02232373|Experimental|Low FODMAP arm|Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
3346775|NCT02232386|Experimental|Treatment|"Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Treatment duration with Ibrutinib will be based on what comes first of the following three options:~Treatment until progression or toxicity~Treatment until MRD negativity for 6 months~Treatment for 6 years. Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1."
3346776|NCT02232399|Active Comparator|Milrinone|In this arm the patients will receive Milrinone as an inotrope agent. Concentration: 0.2 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.4 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 48 μg / kg
3346777|NCT02232399|Experimental|Levosimendan|In this arm the patients will receive Levosimendan as an inotrope agent. Concentration: 0.05 mg/mL Infusion rate: 0.12 mL / kg / hr = Dose delivered 0.1 μg / kg / min --- Bolus dose: 1.44 ml / kg / hr in ten minutes (a maximum volume 0.24 ml / kg) = 12 μg/kg
3346778|NCT02232438|Experimental|Behavioral activation therapy|Patients treated with Behavioral activation therapy will improve in mood and anxiety symptoms and psychosocial functioning at the end of the 6 weeks of treatment.
3346779|NCT02232451|Experimental|ERCP with loop tip wire|ERCP with loop tip wire is an endoscopic procedure to treat biliary disease. Wire guide cannulation with loop-tip is a new procedure to improve rate of biliary cannulation and reduce complication, as post-procedure pancreatitis.
3346780|NCT02232451|Active Comparator|ERCP for cannulation|ERCP for cannulation of CBD with traditional technique
3240239|NCT01287598|Experimental|Arm 2|Regorafenib (Stivarga, BAY73-4506) + rosiglitazone
3240240|NCT01287624|Experimental|Gemcitabine,cisplatin|GP (gemcitabine and cisplatin)
3346781|NCT02232464||ADHD group|Adults with clinical diagnosis of ADHD according to the DSM-IV criteria
3346782|NCT02232464||Control group|Age-, sex-, and IQ-matched healthy controls without lifetime diagnosis with ADHD
3346783|NCT02232477|Experimental|Open-label treatment|laronidase 1.74 mg IT q 3 months for five years
3346784|NCT02232490|Experimental|hepcortespenlisimut-L|Experimental placebo-controlled clinical of hepcortespenlisimut-L (V5) therapeutic vaccine against HCC
3346785|NCT02232490|Placebo Comparator|placebo|placebo
3346786|NCT02232516|Experimental|Treatment (romidepsin, lenalidomide)|Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3346787|NCT02232529|Experimental|Part 1: MIN-101|"MIN-101~modified release formulation (MR),single oral dose between 16 and 64 mg"
3346788|NCT02232529|Experimental|Part 2: MIN-101 low dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
3346789|NCT02232529|Placebo Comparator|Part 2: placebo|"placebo MIN-101~daily oral dose from Day 1 to Day 7"
3346790|NCT02232529|Experimental|Part 2: MIN-101 high dose|"MIN-101~single daily oral dose, low dose MR formulation, from Day 1 to Day 7"
3346791|NCT02232542|Experimental|Duloxetine - low dose|
3240241|NCT01287624|Active Comparator|Gemcitabine, Paclitaxel|GT (gemcitabine and paclitaxel combination)
3240242|NCT01287637|Experimental|Early reversal group|Early reversal of temporary ileostomy
3240243|NCT01287637|Active Comparator|Control group|Standard reversal of temporary ileostomy
3240244|NCT01287663|Placebo Comparator|no permethrin|
3240245|NCT01287663|Experimental|permethrin|
3240246|NCT01287689||Patient treated with any IgG|Any marketed SC or IV IgG can be documented
3240247|NCT01287702|Experimental|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
3240248|NCT01287702|Active Comparator|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL.
3240249|NCT01287715|Experimental|STOP-arm|Discontinuation of etanercept
3240250|NCT01287715|No Intervention|CONTROL-arm|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
3240251|NCT01287728|Experimental|treatment BY METROMIDAZOLE|
3240252|NCT01287741|Active Comparator|Rituximab+Chemotherapy|Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
3346792|NCT02232542|Experimental|Duloxetine - high dose|
3346793|NCT02232542|Placebo Comparator|Placebo|
3346794|NCT02232555|Experimental|Duloxetine|
3346795|NCT02232555|Placebo Comparator|Placebo|
3240253|NCT01287741|Experimental|Obinutuzumab+Chemotherapy|Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
3240254|NCT01287767|No Intervention|Control group, ordinary support|Home care as usual.
3240255|NCT01287767|Experimental|A multidimensjonalt support program|•Behavioral (e.g., Psychotherapy, Lifestyle Counseling) The family will receive individual consulting, teaching and problem solving in support groups.
3240256|NCT01287780|Active Comparator|Collagen-gentamicin sponges|Two sponges of collagen-gentamicin will be inserted into the hip immediately before closure of the wound. Each sponge (10 by 10 cm) contains 280 mg of collagen and 130 mg of gentamicin.
3346796|NCT02232568|Experimental|Feedback Arm|Orthopedic surgeons in the Feedback Arm will receive monthly reports providing individualized data on compliance with the FOCUS trial RBC transfusion guideline (pretransfusion Hb <8 g/dL for hip surgery patients in the postoperative period.) Feedback data will be anonymized, but surgeons will be able to see their own data in comparison with their peers.
3346797|NCT02232568|No Intervention|Control Arm|Orthopedic surgeons in the Control Arm will not receive any feedback on their use of RBC transfusion in hip surgery patients.
3346798|NCT02232581|Experimental|Alovudine - low|
3346799|NCT02232581|Experimental|Alovudine - medium|
3346800|NCT02232581|Experimental|Alovudine - high|
3346801|NCT02232581|Placebo Comparator|Placebo|
3346802|NCT02232594||chronic obstructive respiratory tract disease patients|
3346803|NCT02232607|Experimental|Lacidipine, low dose|
3346804|NCT02232607|Experimental|Lacidipine, medium dose|
3240257|NCT01287780|No Intervention|No intervention|
3240258|NCT01287793|Experimental|high dose tigecycline|
3346805|NCT02232607|Experimental|Lacidipine, high dose|
3346806|NCT02232607|Active Comparator|Placebo|
3346807|NCT02232620|Experimental|BBI503|
3240259|NCT01287793|Experimental|regular dose tigecycline|
3240260|NCT01287793|Active Comparator|moxifloxacin|
3240261|NCT01287793|Placebo Comparator|placebo|
3240262|NCT01287806|Sham Comparator|blank control group|
3346808|NCT02232633|Experimental|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily
3346809|NCT02232646|Experimental|BBI503|
3346810|NCT02232659|Experimental|Primary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy to support an HDE Application.
3346811|NCT02232659|Experimental|Secondary Arm|Use of the SynCardia 70cc TAH-t for Destination Therapy in a less-restrictive patient population to further characterize the use of the 70cc TAH-t for DT.
3346812|NCT02232672|Experimental|MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
3346813|NCT02232685|Experimental|Choline PET/CT|18F-Choline PET/CT
3346814|NCT02232724|Experimental|Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
3346815|NCT02232737|Experimental|0.8 mg nicotine|0.8 mg nicotine cigarettes
3240263|NCT01287806|Experimental|ulinastatin group|ulinastatin is a multivalent kunitz-type serine protease inhibitor refined from human urine
3346816|NCT02232737|Experimental|0.12 mg nicotine|0.12 mg nicotine cigarettes
3346817|NCT02232737|Experimental|0.03 mg nicotine|0.03 mg nicotine cigarettes
3346818|NCT02232763|Experimental|Losartan|12 weeks of losartan or placebo with crossover to the other
3346819|NCT02232763|Experimental|Placebo|12 weeks of losartan or placebo with crossover to the other
3346820|NCT02232776|Experimental|Losartan treatement|All patients had received losartan treatment for 24 weeks.
3346821|NCT02232789|Experimental|Mephedrone|Mephedrone 200 mg, single dose, oral administration
3346822|NCT02232789|Active Comparator|3,4-methylenedioxymethamphetamine|3,4-methylenedioxymethamphetamine (MDMA) 100 mg, single dose, oral administration
3346823|NCT02232789|Placebo Comparator|Lactose|Placebo, single dose, oral administration
3346824|NCT02232828|Experimental|Selective removal|
3346825|NCT02232828|Active Comparator|Stepwise removal|
3346826|NCT02232841||Mechanical ventilation|Hospitalized adult patients with lung injury receiving mechanical ventilation and who also have received or will receive a CT scan as part of their standard care
3346827|NCT02232854|Experimental|Depression training/supervision program|"A complex intervention, which will include:~Primary Health Care team training in depression~A focus group, after training~Telephone monitoring of patients~Web-based supervision of clinicians"
3346828|NCT02232854|No Intervention|Usual Care|Patients in the control group will receive all the interventions that are guaranteed for persons with depression in Chile: treatment in Primary Health Care clinics with the Primary Health Care team and referral to the regional specialized psychiatric service.
3346829|NCT02232867|Experimental|Arm and Leg Cycling Exercise Program|Multiple baseline test sessions will be used for the same participant to establish a meaningful baseline thus confirming consistency of all outcome measures prior to the intervention.
3346830|NCT02232906|Experimental|intravenous ferric carboxymaltose|
3346831|NCT02232919|Experimental|Deep Brain Stimulation|The design of this translation trial is a single-center, single cohort, open-label and non-masked study. The aim is to evaluate tolerability of chronic low-frequency electrical stimulation of the VMH, while achieving weight loss in morbidly obese subjects. The subjects must have a body-mass index [BMI] greater than 40, and no obesity co-morbidities, such as diabetes or cardiopulmonary abnormalities. Up to six subjects will be implanted in this protocol.
3346832|NCT02232932|Experimental|CAPECITABINE-Radiotherapy -Liver Transplantation|Neoadjuvant Radio-Chemotherapy (RC) and Liver Transplantation (LT)
3346833|NCT02232932|Active Comparator|RESECTION|Liver resection
3346834|NCT02232945|Placebo Comparator|placebo|placebo of oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules.
3346835|NCT02232945|Experimental|Banlangen granules & placebo|Banlangen(Radix Isatidis) granules and placebo of oseltamivir phosphate
3346836|NCT02232945|Active Comparator|oseltamivir phosphate & placebo|oseltamivir phosphate and placebo of Banlangen(Radix Isatidis) granules
3346837|NCT02232958|Experimental|Hyperbaric Oxygen treatment|administration of 100% Oxygen at 2 Atmospheres Absolute for 1 hour 1 daily, 5 days a week for 2 weeks
3346838|NCT02232971|Placebo Comparator|Placebo|Isotonic Saline
3346839|NCT02232971|Experimental|Glucagon 0.1 mg|GlucaGen(r) 0.1 mg administration
3346840|NCT02232971|Experimental|Glucagon 0.2 mg|GlucaGen(r) 0.2 mg administration
3240264|NCT01287819||APOE4 (+) and APE4 (-)|APOE4 (+) 10 people APOE4 (-) 20 people from 200 participants
3240265|NCT01287845|Experimental|Arm 1|
3240266|NCT01287845|Experimental|Arm 2|
3240267|NCT01287858|Placebo Comparator|Placebo|Placebo
3240268|NCT01287858|Active Comparator|AC430|AC430
3346841|NCT02232971|Experimental|Glucagon 0.3 mg|GlucaGen(r) 0.3 mg administration
3346842|NCT02232997|Active Comparator|Long Hydration|Long term hydration at routine speed(12h before and after procedure)
3346843|NCT02232997|Active Comparator|Short Hydration|Short term hydration at high speed(1h before and 4h after procedure)
3346844|NCT02233010||kidney function normal group|kidney function normal group : defined by the normal level of NGAL after post operation 4hrs
3346845|NCT02233010||kidney function decreased group|kidney function decreased group : defined by the increased level of NGAL after post operation 4hrs
3346846|NCT02233023|Experimental|Pramixpexole|
3346847|NCT02233023|Active Comparator|Bromocriptine and other dopamine agonists|
3346848|NCT02233049|Experimental|R1: erlotinib versus dasatinib|EGFR+ only Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3346849|NCT02233049|Experimental|R2: everolimus versus dasatinib|PTEN-loss only Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3240269|NCT01287871||Social media intervention|Women between the ages of 18-70 who have not been diagnosed with any type of cancer and are of African descent or Latina
3346850|NCT02233049|Experimental|R3: erlotinib versus everolimus versus dasatinib|EGFR+ and PTEN-loss or inconclusive biopsy Tarceva® (erlotinib): 25 mg and 100 mg tablets. The prescribed dose is 125 mg/m²/day orally, once daily. Votubia® (everolimus): 2.5 mg tablets. The prescribed dose is 5 mg/m²/day, orally, once daily. Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day.
3240270|NCT01287884|No Intervention|Venous Blood Gas|All subjects have an ABG and VBG drawn. No intervention.
3240271|NCT01287910|Other|All Patients|All patients undergo the same study procedures
3240272|NCT01287923||DLBCL|DLBCL patients included 075-GOELAMS trial or 075-like patient.
3240273|NCT01287923||Healthy controls|Blood donors from the EFS (French Blood Bank) of Rennes.
3240274|NCT01287923||Septic patients|septic patients included at the Rennes University Hospital.
3240275|NCT01287923||DLBCL in completed remission|DLBCL patients from the 075 GOELAMS study in completed remission.
3240276|NCT01287936|Experimental|SB623|Administration of modified stem cells, SB623
3240277|NCT01287949|Experimental|REPEVAX followed by REVAXIS administration|
3240278|NCT01287962|Experimental|Apatinib|750 mg，po，QD； 28 days every cycle
3240279|NCT01287962|Placebo Comparator|Placebo|
3240280|NCT01287975|Active Comparator|Standard Occupational Therapy|Standard Occupational Therapy for Wrist and Hand Training
3240281|NCT01287975|Experimental|BCI Haptic Knob|BCI controlled robotic-assisted training for wrist and hand
3240282|NCT01287975|Experimental|Haptic Knob|Robotic-assisted training for wrist and hand
3240283|NCT01287988||Ocriplasmin|Subjects who were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study (TG-MV-006 or TG-MV-007)
3240284|NCT01287988||Placebo|Subjects who were exposed to a single intravitreal injection of placebo in a previous phase III study (TG-MV-006 or TG-MV-007)
3240285|NCT01288001|Experimental|Ostenil plus|Patient will get Ostenil plus injection and standard treatment of Osteoarthritis
3240286|NCT01288014||Edlerly Recipients of Zoster Vaccine|Blood samples are collected before and after vaccination in people age 60 or more, who are getting the zoster vaccine as part of their routine health care.
3240287|NCT01288040|Experimental|Treadmill exercise|Split-belt treadmill training
3240288|NCT01288066|Other|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system.
3346851|NCT02233049|Experimental|Cohort Dasatinib|Neither EGFR overexpression nor loss of PTEN expression Sprycel® (dasatinib): 20 mg and 50 mg tablets. The prescribed dose is 85 mg/m²/dose, orally, twice daily, i.e. 170 mg/m2/day
3346852|NCT02233062|Experimental|Semen quality|
3346853|NCT02233075|Experimental|REP 2139-Ca + Pegasys (TM)|REP 2139-Ca 500 mg QW for 15 weeks followed by REP 2139-Ca 250mg QW + Pegasys(TM) 180ug QW for 15 weeks followed by Pegasys(TM) 180ug QW for 33 weeks.
3346854|NCT02233088|Experimental|ELM Group|A 6-month group lifestyle intervention, consisting of 12 weekly and 6 bi-weekly 2-hour sessions. The sessions consist of 30-min physical activity, 30-min meal demonstration, and 60-min group behavioral intervention, with a focus on experiential learning in naturalistic setting. Sessions are facilitated by dietitian/personal trainer and behavioral specialist.
3346855|NCT02233088|Other|ELM Classes|A 6-month health education, consisting of 12 weekly and 6 bi-weekly 30-45 min sessions. The sessions consist of didactic classes, with a focus on health education curriculum. Sessions are facilitated by a health educator and medical providers.
3346856|NCT02233088|Active Comparator|ELM Individual|A 6-month intervention, that consists of educational manuals on physical activity, diet and stress reduction and recommended 3 medical visits every 3 months for medical counseling and feedback using 5A (Ask, Advise, Assess, Assist, and Arrange) framework . These Metabolic syndrome care materials and provider documentation will be embedded in electronic medical record system, and will be accessible to medical providers by usual means. This enhanced usual care by participant's usual health care provider focuses on metabolic syndrome and lifestyle modifications to reduce the risk of chronic disease.
3346857|NCT02233114|Experimental|Yogic exercises|Yogic exercises for lung disorders
3346858|NCT02233114|Active Comparator|physiotherapy|Physiotherapy during the yogic exercises
3346859|NCT02233127||Birth Cohort|The cohort will comprise approximately 3000 pregnant women and their unborn babies, enrolled to participate in the control arm of a cluster-randomized controlled intervention trial (NCT02130856).
3346860|NCT02233140|Experimental|Shockwave with manual manipulation|A shockwave (EPAT) therapy with two supervised manual manipulation per week
3346861|NCT02233140|Active Comparator|Manual manipulation|A Placebo (no) shockwave with two supervised manual manipulations per week
3346862|NCT02233153||Pre-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
3346863|NCT02233153||Post-Elder Friendly Surgical Intervention Group|Elder Acute Care and Emergency Surgery patients
3346864|NCT02233153||Pre-Elder Friendly Surgical Control Group|Elder Acute Care and Emergency Surgery patients
3346865|NCT02233153||Post-Elder Friendly Surgical Control Group|
3346866|NCT02233179|Experimental|Removable Cast Walker|An offloading device that can be removed by the patients
3346867|NCT02233179|Active Comparator|Irremovable Cast Walker|A removable cast rendered irremovable using instant total contact cast, so patients cannot remove offloading device.
3346868|NCT02233205|Experimental|microbubbles & platinum and gemcitabine|In 30min after chemotherapy, inject ultrasonic microbubbles 1 ml once and inject 5 times in 20min and locate the ultrasonic probe on the lesion The chemotherapy of pancreatic is gemcitabine.The chemotherapy of liver metastases is oxaliplatin with taxol.
3346869|NCT02233218|Experimental|telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 40 subjects. Telmisartan80mg + Amlodipine 10mg 9 days, Telmisartan80mg + Amlodipine 10mg , Rosuvastatin 20mg 5days Total 14days administration of investigational products to healthy male volunteers
3346870|NCT02233218|Experimental|Telmisartan, Amlodipine, Rosuvastatin|This arm is consist of 20 subjects. Rosuvastatin 20mg 5 days, Rosuvastatin 20mg , Telmisartan80mg + Amlodipine 10mg 9days, Total 14days administration of investigational products to healthy male volunteers
3346871|NCT02233231|Active Comparator|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
3240289|NCT01288066|Other|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system.
3240290|NCT01288092|Experimental|BEZ235|
3240291|NCT01288105|Experimental|Optical Coherence Tomography|Patients enrolled in the study will undergo optical coherence tomography to evaluate the extent of stent strut coverage.
3240292|NCT01288131|Active Comparator|CSA+MMF|Cyclosporine 100 mg BID combine with Mycophenolate mofetil 750 mg BID for 24 weeks
3346872|NCT02233231|Placebo Comparator|Placebo|Placebo tablets equivalent to IMP.
3240293|NCT01288131|Active Comparator|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD and prednisolone 1.0 mg/kg/day
3240294|NCT01288144|Experimental|Intervention|Quality improvement initiative using computerized decision support
3240295|NCT01288144|No Intervention|Usual care|In control clinics, women will continue to receive usual care.
3240296|NCT01288157|Experimental|001|Golimumab Single dose of 50 mg subcutaneously
3240297|NCT01288157|Experimental|002|Golimumab Single dose of 100 mg subcutaneously
3240298|NCT01288170|Other|Nebcinal Tobi|crossover design
3240299|NCT01288170|Other|Tobi Nebcinal|crossover design
3346873|NCT02233244|Other|CTX-4430 and midazolam|Midazolam 2 mg solution once, CTX-4430 100 mg tablet once per day for 7 days, Midazolam 2 mg solution once
3346874|NCT02233283|Active Comparator|Hypercaloric diet and basal|Volunteers fed a hypercaloric diet for one month will be submitted to a fasting period of ten hours duration
3346875|NCT02233283|Experimental|Hypercaloric diet and clamp|Volunteers fed a hypercaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
3346876|NCT02233283|Active Comparator|Isocaloric diet and basal|Volunteers fed a isocaloric diet for one month will be submitted to a fasting period of ten hours duration
3346877|NCT02233283|Experimental|Isocaloric diet and clamp|Volunteers fed a isocaloric diet for one month will be submitted to a hyperinsulinemic and euglycemic clamp of ten hours duration
3346878|NCT02233322|Experimental|iron supplements|all subjects will receive iron supplementation based on iron levels in blood
3346879|NCT02233348||ASD group|Subjects with DSM-IV ASD diagnosis
3346880|NCT02233348||Control group|Controls without lifetime ASD or a family history of ASD
3346881|NCT02233361|Experimental|Counseling|The intervention group will be informed in advance of a follow-up appointment six month after they have received their hearing aid. They will know that support will be given and time-use of the hearing aid will be checked out. Counseling on hearing aid use will be given.
3346882|NCT02233361|No Intervention|Counselling|The control group will not receive any information of a follow-up appointment. However, they will receive a notice on this after six month.
3346883|NCT02233374|Experimental|Assessing response with MRI + PET.|"Pre-operative chemo/RT as per standard treatment. Intensity Modulated Radiotherapy (IMRT) / Volumetric Arc Therapy (VMAT) 45Gray/25 fractions with simultaneous integrated Boost of 50Gray/25 fractions + concurrent capecitabine chemotherapy.~Intervention 1 'Early MRI and PET/CT - 2 weeks after commencing chemo/RT' involves additional Multiparametric MRI + PET/CT 2 weeks into chemo/RT Intervention 2 :\'Late MRI and PET/CT 6 weeks post chemo/RT' involves additional Multiparametric MRI + PET/CT 6 weeks post chemo/RT"
3240300|NCT01288183|Sham Comparator|sham tDCS|sham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
3240301|NCT01288183|Active Comparator|active tDCS|active anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
3346884|NCT02233387|Experimental|[18F] HX4 PET imaging|injection with [18F] HX4 and PET imaging at baseline and after 20 Gy radiotherapy
3240302|NCT01288196|Experimental|001|CNTO 6785 1 mg/kg IV A single 30-minute IV infusion of CNTO 6785 1 mg/kg
3240303|NCT01288196|Experimental|002|CNTO 6785 3 mg/kg IV A single 30-minute IV infusion of CNTO 6785 3 mg/kg
3240304|NCT01288196|Experimental|003|CNTO 6785 10 mg/kg IV A single 30-minute IV infusion of CNTO 6785 10 mg/kg
3346885|NCT02233400|Experimental|Treatment|Group 1 (treatment) will receive IV acetaminophen (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
3346886|NCT02233400|No Intervention|Control|Group 2 (control) will receive IV normal saline (100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
3346887|NCT02233439|Placebo Comparator|Placebo|a placebo identical in appearance to the galactagogue product
3240305|NCT01288196|Placebo Comparator|004|Placebo IV A single 30-minute IV infusion of placebo
3240306|NCT01288196|Experimental|005|CNTO 6785 SC A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
3240307|NCT01288196|Placebo Comparator|006|Placebo SC A single SC dose of placebo administered in up to 3 SC injections
3346888|NCT02233439|No Intervention|No treatment|Usual care and breastfeeding support
3346889|NCT02233439|Experimental|Herbal galactagogue|A commercially available product containing a combination of Silybum marianum 400 mg and Galega officinalis 150 mg, once a day for 6 weeks
3346890|NCT02233452|Active Comparator|Methadone|Group treated with methadone solution.
3346891|NCT02233452|Active Comparator|Ketamine|Group treated with ketamine solution
3346892|NCT02233452|Active Comparator|Methadone plus ketamine|Group treated with methadone plus ketamine solution
3240308|NCT01288222|Experimental|Unrelated Donor Transplant Patients|Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.
3240309|NCT01288235|Experimental|Proton Radiotherapy|Proton Radiotherapy
3346893|NCT02233465|Experimental|IPOM Mesh-repair parastomal hernia|Mesh-repair of para-stomal hernia. Patients with para-stomal hernia requiring surgery are offererd enrollment in the study. Preoperatively a CT-scan of the abdomen and or a 3D ultrasonography of the stoma is performed. All patients in the stydy are operated with IPOM-mesh designed for treatment of parastomal hernia.
3346894|NCT02233465|No Intervention|No mesh-repair|Patients not attending the study
3346895|NCT02233491|Placebo Comparator|Control|This group will be counselled in clinic by clinicians about the risks of glucose intolerance and will receive leaflets outlining lifestyle modification advice. The leaflets include advice on healthy eating, exercise and the importance of weight loss. However there will be no dietician referral, psychosocial intervention or focused exercise and weight loss monitoring programme. Follow up will be at routine clinic visits only where lifestyle modification advice will be reinforced as per usual clinical practise.
3346896|NCT02233491|Active Comparator|Active intervention|This group will receive active lifestyle modification intervention and will consist of dietician referral, graded exercise programme and weight loss advice. The dietician will be supported by Clinical Psychology services and our collaboration with a recognised expert in behavioural change therapy. The dietician will be trained with motivational interviewing skills and psychological tools will be utilised to support the active lifestyle intervention.
3346897|NCT02233556|Experimental|Memantine|This study has only one arm. i.e. Single dose of memantine 20mg
3346898|NCT02233569|Active Comparator|PH|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.
3346899|NCT02233569|Active Comparator|VS|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.
3346900|NCT02233582|Experimental|ibuprofen plus ascent to high altitude|subjects randomized to this arm will take ibuprofen 200 mg 3 times daily during ascent and at altitude.
3346901|NCT02233582|Placebo Comparator|sugar pill plus ascent to high altitude|subjects randomized to this arm will receive the placebo
3346902|NCT02233595||Adjuvant chemotherapy|
3346903|NCT02233608|No Intervention|Usual Care|The usual care group will receive generic pelvic floor muscle exercise (PMFX) instructions and demonstrations by the research coordinator at the initial post-operative time point. This will include instruction on how to engage the pelvic floor and specific PFMX prescription. Repetition volume will start at 20 repetitions per day during weeks 1-2; 60/day during weeks 3-4; and 90/day during weeks 5-6, and 100+/day for weeks 7-26. The total number of repetitions will be divided equally between rhythmic (contract and relaxed over one second) and sustained contractions (contract and hold for up to 10 seconds).
3346904|NCT02233608|Experimental|Advanced Pelvic Floor Exercise (APFX)|Participants in this group will receive detailed week-by-week description of the program. The program progresses participants through stages of training every two weeks, starting the introduction of basic PFMX, and slowly incorporates Pfilates and Hypopressives exercises until week 8, where patients will maintain the final stage of training until week 26 or urinary incontinence is completely resolved.
3346905|NCT02233621|Experimental|PET with [18F]-FES|PET with [18F]-FES compared to histological analysis performed at least on one biopsy done during coelioscopy.
3346906|NCT02233634|Active Comparator|CAD Patients|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
3346907|NCT02233634|Active Comparator|Healthy Volunteers (Control Group)|Administration of Oxygen via a mask, Hyperventilation, Combination of Oxygen administration and Hyperventilation, long breath-holds
3240310|NCT01288248|Experimental|Airway laryngeal mask classic|Ventilation with Airway laryngeal mask classic during surgery
3240311|NCT01288248|Active Comparator|endotracheal tube|Ventilation with endotracheal tube during surgery
3240312|NCT01288261|Experimental|Treatment|Paclitaxel, bavituximab, laboratory biomarker analysis and pharmacological study
3240313|NCT01288274|Active Comparator|Injection by Health Extension Worker|Women who receive injectable contraceptive from clinic based health extension workers (HEWs) during the study period
3240314|NCT01288274|Active Comparator|Injection by Community Health Worker|Women who receive injectable contraceptive through community based distributors from community based reproductive health agents (CBRHAs) during the study period
3240315|NCT01288300|Active Comparator|Comprehensive diabetes self-management intervention|Diabetes education, self-empowerment training, exercise, patient navigator
3346908|NCT02233660|Experimental|Physical Therapy Group.|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
3346909|NCT02233660|Active Comparator|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3346910|NCT02233673|Experimental|Behavioral, incentives|Participants receive behavioral intervention and financial incentives for meeting gestational weight gain goals
3240316|NCT01288300|Other|Control|Diabetes self-management lecture
3240317|NCT01288313|Experimental|rapeseed oil|
3346911|NCT02233673|No Intervention|Standard care|Participants receive standard obstetrical care from their provider
3346912|NCT02233686|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
3240318|NCT01288313|Experimental|n-3 margarine and rapeseed oil|
3240319|NCT01288313|Experimental|n-3 margarine|
3346913|NCT02233686|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
3346914|NCT02233699|Experimental|XEN-D0501|4mg BID Days 1-13, 4mg once daily (OD) Day 14
3346915|NCT02233699|Placebo Comparator|Placebo to Match|BID Days 1-13, once daily (OD) Day 14
3346916|NCT02233712|Experimental|Group 1|G17DT; 250 µg dose administered at 0, 1, and 3 weeks.
3240320|NCT01288313|Active Comparator|Olive oil|
3346917|NCT02233712|Experimental|Group 2|G17DT; 100 µg dose administered at 0, 1, and 3 weeks.
3346918|NCT02233712|Experimental|Group 3|G17DT; 500 µg dose administered at 0, 1, and 3 weeks.
3240321|NCT01288326||A|
3240322|NCT01288339|Experimental|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP (MMP7+/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
3240323|NCT01288339|Experimental|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
3240324|NCT01288352|No Intervention|Usual care|Usual care closely follows the suggestions laid out in the current European Society of Cardiology (ESC) guidelines for AF treatment. In addition to antithrombotic therapy and therapy of underlying heart disease, usual care usually consists of an initial attempt to control symptoms by rate control therapy. Rhythm control interventions are recommended when symptoms can not be controlled by optimal rate control therapy in the usual care group.
3346919|NCT02233712|Experimental|Group 4|G17DT; 500 µg dose administered at 0, 2, and 6 weeks.
3346920|NCT02233725|Active Comparator|Definity Perflutren Suspension|Injection of Definity Perflutren Injectable Suspension- which travels in the bloodstream throughout the body. These microbubbles are identifiable on ultrasound imaging, and studies of the liver and kidney have identified it as a useful adjunct to identifying vascular lesions. Areas of regular blood flow will not have as large a concentration of the microbubble agent as will areas that have increased blood flow and neovascularisation. It has been well documented that cancerous solid lesions undergo neovascularisation and have increased blood flow to the area.
3346921|NCT02233764|Experimental|FeZnPM|The FeZnPM arm will consume iron- and zinc-biofortified pearl millet (ICTP8203-Fe).
3346922|NCT02233764|Active Comparator|CtrlPM|The CtrlPM arm will consume conventional pearl millet three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
3346923|NCT02233777|Experimental|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg pregabalin.
3259288|NCT01469494|Active Comparator|DIEP flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
3346924|NCT02233777|Active Comparator|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg pregabalin.
3346925|NCT02233790|Experimental|Ticagrelor|
3346926|NCT02233790|Active Comparator|Clopidogrel|
3346927|NCT02233816|Experimental|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
3346928|NCT02233816|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
3346929|NCT02233816|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
3346930|NCT02233816|Placebo Comparator|Placebo|A single dose of Placebo
3346935|NCT02233881||Chronic obstructive pulmonary disease patients|
3240325|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy (Dronedarone, Amiodarone, Flecainide, Propafenone),~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
3346936|NCT02233894||Chronic obstructive pulmonary disease patients|
3346937|NCT02233907||Chronic obstructive pulmonary disease patients|
3346938|NCT02233920||Chronic obstructive bronchitis patients|
3346939|NCT02233933|Active Comparator|argon plasma coagulation|argon plasma coagulation of radiation proctitis
3346940|NCT02233933|Experimental|argon plasma coagulator and hemospray|treatment of radiation proctitis with argon plasma coagulator followed by application of hemospray
3346941|NCT02233959||Healthy Adults|
3346942|NCT02233972|Experimental|Midazolam and Ginkgolides Meglumine Injection|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Ginkgolides Meglumine Injection: 25mg, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
3346943|NCT02233972|Placebo Comparator|Midazolam and placebo|Midazolam: tablet, 7.5 mg. Midazolam will be taken on Day 1 and Day 22. Placebo: Sodium Chloride Injection, 250 ml, intravenous drip, once a day. It will be used on Day 8 -Day 21, 14 days totally.
3346944|NCT02234024|Experimental|Supplementation of gangliosides|Supplementation of dairy-derived concentrated gangliosides
3346945|NCT02234037|Experimental|Decitabine and Exercise|8-week program of physical conditioning and decitabine treatment in newly diagnosed AML patients ≥ 60 years of age who are not candidates for standard induction chemotherapy.
3346946|NCT02234050|Experimental|Trabectedin|Patient will be treated with trabectedin
3346947|NCT02234050|Other|Local standard of care|Treatment in the control arm is left to the discretion of the investigator, according to the local standard of care.
3346948|NCT02234076|Experimental|VRET|"Virtual Reality Exposure Therapy (VRET)~The experimental treatment VRET is offered with the Multi-Modal Memory Restructuring System (3MR system) and a therapy manual. Participants can use this system at home. Note: The 3MR system is offered via a computer screen, no head-mounted display (HMD) equipment is used in this study."
3240326|NCT01288365|Experimental|Exercise training|Protocol of 3 month exercise training program.
3240327|NCT01288365|No Intervention|Control|Control group
3346949|NCT02234076|Active Comparator|TAU|Treatment As Usual
3346950|NCT02234089||Degarelix|
3240328|NCT01288378|Active Comparator|Empirical|Empirical approach (fever driven) for starting antifungal therapy
3346951|NCT02234089||LHRH agonist|
3346952|NCT02234102|Active Comparator|Paroxysmal Atrial Fibrillation (PAF)|Endoscopically guided laser ablation
3346953|NCT02234102|Active Comparator|Persistent Atrial Fibrillation|Endoscopically guided laser ablation
3346954|NCT02234154|Other|TOPS System|Post Marketing Study
3346955|NCT02234167|Other|Risk behaviour and infectious diseases|.(among IDU)
3346956|NCT02234193|Active Comparator|Micro biopsies 2mm x control|2 mm diameter micro biopsies will be performed on all subjects.
3346957|NCT02234193|Active Comparator|Micro biopsies 1mm x control|1 mm diameter micro biopsies will be performed on all subjects.
3346958|NCT02234193|Active Comparator|Micro biopsies 0.8 mm x control|0.8 mm diameter micro biopsies will be performed on all subjects.
3346959|NCT02234193|Active Comparator|Micro biopsies 0.6 mm x control|0.6 mm diameter micro biopsies will be performed on all subjects.
3346960|NCT02234193|Active Comparator|Micro biopsies 0.5 mm x control|0.5 mm diameter micro biopsies will be performed on all subjects.
3346961|NCT02234193|Active Comparator|Micro biopsies 0.40 mm x control|0.4 mm diameter micro biopsies will be performed on all subjects.
3346962|NCT02234193|Active Comparator|Micro biopsies 0.20 mm x control|0.2 mm diameter micro biopsies will be performed on all subjects.
3346963|NCT02234206|Experimental|Chandrakanthi choornam|"Chandrakanthi Choornam (CKC) - 12gm in milk~OD dose; Oral route~3 Months - duration~Intervention Drug: Chandrakanthi Choornam (CKC)"
3346964|NCT02234219|Active Comparator|Circular Anastomosis|
3346965|NCT02234219|Active Comparator|Heart-shaped Anastomosis|
3346966|NCT02234232|Experimental|Aerobic exercise|"Cycling-participants will exercise for 15 minutes at the initial session followed by a weekly increase of 2 min and 3 seconds over 12 weeks. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
3346967|NCT02234232|Experimental|Resistance|"Resistance training of lower limbs using ankle weights. Participants will complete 10-15 repetitions of 4 lower limb exercises: knee extension, straight leg raise, hip abduction, and hip flexion. Exercises will progress from 1 set of each exercise up to 3 sets of each exercise and with weight. Participants will exercise 3 times per week and an intensity of somewhat hard (12-14 on the Borg scale). All exercises will be performed during hemodialysis."
3346968|NCT02234232|Experimental|Combined aerobic and resistance|Participants will complete both the aerobic (cycling) and resistance (ankle weights) exercise prescriptions.
3346969|NCT02234232|Active Comparator|Flexibility|"A non-progressive flexibility regimen using a stretch band. Participants will perform 2 sets of the following exercises: seated pelvic tilt, seated calf stretch, supine hamstring stretch, and supine gluteal stretch. Participants will exercise 3 times per week and an intensity of very light (9 on the Borg scale). All exercises will be performed during hemodialysis."
3346970|NCT02234245|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
3346971|NCT02234245|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
3375902|NCT03555149|Experimental|Atezolizumab + Idasanutlin|"Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.~Enrollment closed."
3346972|NCT02234258|Experimental|Cognitive behavioral social skills|In Cognitive behavioral social skills training (CBSST), skills-based CBT is used to teach individuals how to correct inaccurate dysfunctional thoughts that interfere with goal-directed activities, including defeatist expectancies, low self-efficacy beliefs, and anomalous beliefs. SST focuses on behaviorally-based instruction of interpersonal social skills, utilizing role-modeling, rehearsal, corrective feedback, and positive reinforcement to facilitate learning. In the modified version of CBSST used in this project: 1) we will strengthen the focus on corrective feedback from successful social interactions; 2) focus on normalization and destigmatization of attenuated psychotic symptoms; 3) add motivational interviewing techniques to promote treatment engagement; and 4) use examples and role plays. CBSST will be delivered in three 6-session modules (i.e., Cognitive Skills, Social Skills, and Problem Solving Skills), a total of 18 90-minute group sessions.
3346973|NCT02234258|Active Comparator|Psychoeducation|The purpose of this alternative treatment is to match CBSST for the nonspecific effects of therapist contact and interest, social interaction and support. Common factors include client expectancy, providing a rationale for change, therapist factors and therapeutic alliance. The psychoeducation group will meet weekly, for a total of 18 90-minute sessions. Therapists will follow brief guidelines as to what they can and cannot do. In each session the therapists will ask how the previous week had been. Any crises will be dealt with, and advice will be offered to help with any immediate problems. No active CBT or SST techniques will be taught or used. Psychoeducational information about high risk for psychosis will be offered. There will be a focus on listening, reflecting and empathizing, and demonstrating uncritical acceptance and genuineness. Social exchanges amongst participants will be encouraged.
3346974|NCT02234271|Active Comparator|Health Educator Arm|Health Educator for contraception information
3346975|NCT02234271|Experimental|Mobile Health Application Arm|Plan A Birth Control - iPad based application for contraception information
3346976|NCT02234297|Experimental|BLZ-100|
3346977|NCT02234336||Subjects with HCM|All subjects will undergo noncontrast echocardiography, contrast echocardiography and cardiac MRI.
3240329|NCT01288378|Experimental|Pre-emptive|Pre-emptive approach (diagnostic driven) for starting antifungal therapy
3240330|NCT01288391|Experimental|100 mcg/kg|
3346978|NCT02234349|Experimental|pancreas kidney transplant|Patients with pancreas kidney transplantation
3346979|NCT02234349|Experimental|kidney transplant subjects|Patients with kidney transplantation
3346980|NCT02234349|No Intervention|Control|
3346981|NCT02234375|Experimental|Gadolinium enhancement|Gadolinium enhancement will be performed using intravenous Dotarem[recommended dose of 0.2 mL/kg (0.1 mmol Gd/kg )]
3346982|NCT02234388||Registry Participants|All patients who participate in the UCTD Registry will be put into this cohort and observed over approximately 3 years.
3346983|NCT02234401|Experimental|Non invasive ventilation (NIV)|Non invasive ventilation used for the first 7 days of study
3346984|NCT02234401|Active Comparator|Standard Care|High Flow Controlled Oxygen Therapy
3346985|NCT02234440|Experimental|Metformin|Metformin- 500 mg once daily as a starting dose, can be escalated to 2 g/day to control diabetes
3346986|NCT02234440|Active Comparator|Insulin|
3346987|NCT02234453|Experimental|Cancer patients|Adult patients with solid tumours receiving systemic anti-cancer therapy who are able to use the Minicare H-2000.
3346988|NCT02234466|Active Comparator|Oral Dexamethasone|"Oral dexamethasone- two 4mg tabs and one 2mg tab contained within a gelatin capsule Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
3240331|NCT01288391|Experimental|200 mcg/kg|
3240332|NCT01288404|Placebo Comparator|Control|topical 0.1% fluorometholone eye drops
3240333|NCT01288404|Active Comparator|Bevacizumab group 1|Bevacizumab 1.25 mg/0.05mL
3240334|NCT01288404|Active Comparator|Bevacizumab group 2|Bevacizumab 2.5 mg/0.1mL
3240335|NCT01288404|Active Comparator|bevacizumab group 3|bevacizumab 3.75 mg/0.15mL
3240336|NCT01288417|Experimental|boceprevir + raltegravir|9 days of boceprevir 800mg TID; day 10 two doses of boceprevir 800mg and one dose of raltegravir 400mg
3240337|NCT01288417|Active Comparator|raltegravir alone|single dose of raltegravir 400mg
3240338|NCT01288482|Experimental|Asthma Subjects|
3240339|NCT01288495|Experimental|L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
3240340|NCT01288495|Placebo Comparator|Placebo|Subjects will consume the placebo prior to eating fructose-containing foods.
3240341|NCT01288508|Active Comparator|Supra Fiber|
3240342|NCT01288508|Active Comparator|Psyllium|
3240343|NCT01288547|Active Comparator|theobromine|theobromine (700 mg) in capsule
3240344|NCT01288547|Active Comparator|caffeine|caffeine (120 mg) in capsule
3240345|NCT01288547|Placebo Comparator|Placebo capsule|no theobromine or caffeine
3240346|NCT01288547|Active Comparator|theobromine + caffeine|Combined theobromine and caffeine treatment, consisting of 700 mg theobromine and 120 mg caffeine
3240347|NCT01288560|Active Comparator|Advanced cardiac imaging (PET/CT or CMR)|Patients will undergo cardiac imaging as evaluation of heart failure using 1 of the following alternate/advanced imaging modalities: Positron Emission Tomography (PET/CT), Cardiac Magnetic Resonance (CMR)
3240348|NCT01288560|Active Comparator|Standard cardiac imaging (SPECT)|Patients will undergo standard cardiac imaging procedures for evaluation of heart failure such as single photon emission computed tomography (SPECT).
3240349|NCT01288573|Experimental|Plerixafor 160 μg/kg|Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3240350|NCT01288573|Experimental|Plerixafor 240 μg/kg|Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3240351|NCT01288573|Experimental|Plerixafor 320 μg/kg|Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
3240352|NCT01288586||Device|Scandinavian Total Ankle Replacement System (STAR Ankle)
3346989|NCT02234466|Placebo Comparator|Gelatin pill|"Gelatin capsule contained within second gelatin capsule. Administered a single time, 2 hours pre-induction~Ondansetron 6mg IV will be administered at skin closure"
3346990|NCT02234492|Active Comparator|Rosuvastatin|Rosuvastatin 10mg once daily for 6 months.
3346991|NCT02234492|No Intervention|No rosuvastatin|No rosuvastatin- this group will continue with their current medical therapy for 6 months.
3240353|NCT01288599|Experimental|Single port access laparoscopy|Single port access laparoscopy for benign adnexal disease.
3240354|NCT01288599|Active Comparator|Conventional laparoscopy|Conventional laparoscopy for benign adnexal disease.
3240355|NCT01288638|Experimental|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
3346992|NCT02234505|Experimental|Trans-tibial prosthesis users|prosthetic alignment perturbation
3346993|NCT02234518|Experimental|High quantity fiber food product|
3240356|NCT01288638|Placebo Comparator|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
3346994|NCT02234518|Experimental|Low quantity fiber food product|
3346995|NCT02234518|Placebo Comparator|Placebo|
3240357|NCT01288664|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase for 6 months
3240358|NCT01288677|Experimental|001|TMC649128 Escalated doses
3240359|NCT01288690|No Intervention|Wait List Control|This condition is a wait-list control and receives no intervention during the study period, but is offered treatment after the final assessment.
3240360|NCT01288690|Experimental|Narrative Exposure Therapy|Patients in this condition receive 3 sessions of Narrative Exposure Therapy
3240361|NCT01288716|Placebo Comparator|Placebo|
3240362|NCT01288716|Active Comparator|Arbaclofen|
3346996|NCT02234531|Experimental|EVER TEACHER|"In EVER TEACHER group a specific feedback called virtual teacher will be displayed. The virtual teacher perform the correct movement to emulate, that is supposed to stimulate the motor adaptation exploiting a supervised learning mechanism. This feedback will give an on-line information on motor performance quality, allowing a real time visual comparison between patient's own execution and teacher one. During the experiment, patients will receive 1 hour of virtual reality-based therapy and the treatment will last 1 hour a day, five days weekly for four weeks."
3346997|NCT02234531|Other|NEVER TEACHER|In NEVER TEACHER group the subjects will be asked to perform the same exercises with the upper limb without the virtual teacher assistance. The treatment will last four weeks with daily sessions of 60 minutes, five times per week.
3346998|NCT02234544|Placebo Comparator|Placebo + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
3240363|NCT01288742|Experimental|001|TMC435 One 150-mg capsule once daily for 7 days (Trts B and D).
3240364|NCT01288742|Experimental|002|Digoxin One 0.25-mg tablet for 1 day (Trt A)
3240365|NCT01288742|Experimental|003|Digoxin One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
3240366|NCT01288742|Experimental|004|Rosuvastatin One 10-mg tablet for 1 day (Trt C).
3240367|NCT01288742|Experimental|005|Rosuvastatin One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
3346999|NCT02234544|Active Comparator|Ezetimibe + Cholecalciferol|The groups will be randomized to ezetimibe or placebo. All participants will receive orally a cholecalciferol capsule.
3347000|NCT02234609|Other|adults with incisor dental caries lesion|modified ART class IV with glass ionomer cement
3347001|NCT02234635|Other|monofocal IOLs group|monofocal IOLs group were implantation with Tecnis® ZCB00
3347002|NCT02234635|Active Comparator|Diffractive multifocal IOLs group|Diffractive multifocal IOLs group were implantation with Tecnis® ZMB00
3347003|NCT02234648|Placebo Comparator|Placebo|The PLA supplement consisted of a commercially available, less than 5% fruit, cordial (Protein - Trace, Carbohydrate 260 mg•mL-1, Sodium 0.02 mg•mL-1, Fibre-Trace and Anthocyanins-Trace for colour), mixed with water, whey protein isolate (Arla Foods Ltd., Leeds, UK) and maltodextrin (MyProtein Ltd., Northwich, UK) until matched for carbohydrate and calorie content of the MC.
3240368|NCT01288755|Experimental|001|TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
3240369|NCT01288755|Experimental|002|Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
3240370|NCT01288768|Active Comparator|Arthroscopy|Knee arthroscopy + Exercise therapy
3240371|NCT01288768|No Intervention|Exercise therapy|Exercise therapy alone
3347004|NCT02234648|Active Comparator|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency cherry (MC) juice mixed with 100mL of water. Independent analysis of MC (Atlas Biosciences, 2010) provided the following compositional data; Fat 0.028 mg•mL-1, Protein 31.47 mg•mL-1, Carbohydrate 669.4 mg•mL-1, Cholesterol < 0.01 mg•mL-1, Sodium 0.691 mg•mL-1, Calcium 0.137 mg•mL-1 and Iron 0.026 mg•mL-1. Additionally, according to the manufacturers guidelines (Cherry Active, Hanworth, UK),
3347005|NCT02234661|Experimental|CareerAdvance®|CareerAdvance® provides education, career coaching, and soft-skills training for parents while their children attend Head Start programs.
3347006|NCT02234661|No Intervention|Control Standard of CAP|Control participants access to CAP array of service
3347007|NCT02234674|Active Comparator|Standard intensive CDP|This arm is the controlled group ; patients in that group will undergo a current practice performed in the lymphology unit.
3240372|NCT01288794|Active Comparator|Standard medical treatment plus albumin|The patients will receive standard medical treatment (diuretics) plus weekly albumin infusion
3240373|NCT01288794|Other|Standard medical treatment|The patients will receive the standard medical treatment (diuretics), but non albumin for the therapy of ascites
3240374|NCT01288820|Experimental|DHP+PQ|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
3240375|NCT01288820|Active Comparator|AS-AQ +PQ|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
3240376|NCT01288846||Acutly ill, Medical ward, consent|group of acutely ill patient who uses three or more drugs, must be able to give consent.
3347008|NCT02234674|Experimental|Stendo group|This arm contitutes the group where the Stendo pulsating suit sessions are investigated in the frame of the CDP in replacement of the pressotherapy sessions.
3347009|NCT02234726|Experimental|Early Childhood Development Program|"Treatment clusters will be assigned a trained Child Development Agent (CDA) who will have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases including malaria, diarrhea, and pneumonia and referral for diagnosis and treatment; and 4) organization and mentoring of biweekly caregiver meetings to discuss parenting and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
3347010|NCT02234726|No Intervention|Control|Children residing in comparison health zones will only receive baseline and end line evaluations of their health and developmental status. There will be no active intervention in the comparison areas during the course of the study.
3347011|NCT02234739|Experimental|active treatment|Chinese patients with invasive pulmonary aspergillosis treated by voriconazole, who has COPD as underlying condition
3347012|NCT02234765|Active Comparator|Sleep Unit|Patients diagnosed and followed up in the Sleep Unit.
3347013|NCT02234765|Experimental|Primary Care|Patients diagnosed and followed up in the Primary Care.
3347014|NCT02234778|Experimental|Study Treatment|Each subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period. TGI SVF material injection will be completed within 4 hours of cell separation.
3347015|NCT02234791||gene mutation|
3347016|NCT02234804|Experimental|Medtronic Resolute Integrity stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
3347017|NCT02234804|Experimental|OCT|OCT to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
3347018|NCT02234804|Active Comparator|Angiography|Angiography to guide wire recrossing and reduce stent strut malapposition after kissing balloon dilatation.
3240377|NCT01288872|Experimental|Praziquantel|45 women in 3 cohorts (15 early pregnancy: 12-16 weeks gestation; 15 late pregnancy: 30-36 weeks gestation; and 15 lactating nonpregnant women who are 5-7 months (inclusive) postpartum) given praziquantel (PZQ), 60 mg/kg orally in split dose (30 mg/kg each) separated by 3 hours.
3240378|NCT01288924|Active Comparator|Parecoxib|Parecoxib 2 ml intravenous
3240379|NCT01288924|Placebo Comparator|Control|0.9% sodium chloride 2 ml intravenous
3240380|NCT01288950|Experimental|Vitamin D3|
3240381|NCT01288950|No Intervention|Placebo|
3240382|NCT01288963||IL-2 subjects|Subjects receiving IL-2 for advanced melanoma
3347019|NCT02234804|Active Comparator|Xience Prime stent|Comparing Medtronic Resolute Integrity and Xience Prime for stent strut apposition in the SB ostium
3347020|NCT02234830|Experimental|Exoseal closure device|Closure device for femoral artery access closure
3347021|NCT02234830|Active Comparator|Angio-Seal closure device|Closure device for femoral artery access closure
3347022|NCT02234843|Experimental|BAY59-7939|Rivaroxaban (tablets and oral suspension) Dose: Age and body weight-adjusted dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban.
3347023|NCT02234843|Experimental|Standard of Care|Subcutaneous low molecular weight heparin (LMWH), subcutaneous fondaparinux and/or oral vitamin K antagonist (VKA) Dose : as per standard of care
3347024|NCT02234856|No Intervention|conventional residency training|no intervention
3347025|NCT02234856|Experimental|Laparoscopic Hysterectomy trainer|Intervention: An educational video and web-based e-module will be created. The final product will be reviewed by the expert contributors. Once approved, these tools will be showcased to a voluntary focus group of Obstetrics and Gynecology residents at the University of Toronto. A quantitative assessment of effectiveness of this tool will be performed through the use of pre- and post-tests of knowledge. A qualitative needs assessment will also be performed using post-viewing surveys. If found to be effective, this educational tool will be incorporated in the University of Toronto Obstetrics and Gynecology residency curriculum.
3347026|NCT02234869|Experimental|Peginterferon beta-1a|Participants will receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks during the 6-month comparator period of the study and during the 12-month extension period.
3347027|NCT02234869|Active Comparator|Interferon-β|Participants will continue to receive their standard-of-care interferon beta treatment for the first six months. During the 12-month extension period participants will switch to receive peginterferon beta-1a, 125 µg subcutaneously once every 2 weeks.
3347028|NCT02234882|Experimental|Rosuvastatin and BMS-663068|Treatment A: Rosuvastatin, single dose (SD) Treatment B: BMS-663068 administered on specified days Treatment C: Combination BMS-663068 and Rosuvastatin administered on specified days
3375903|NCT03555149|Experimental|Atezolizumab + Regorafenib|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
3240383|NCT01289054||Cohort 1 - Pregnancy/Fetal Exposure|
3240384|NCT01289054||Cohort 2 - Interrupted TKI|
3240385|NCT01289093||laparoscopic ingunal herniotomy|
3240386|NCT01289093||laparoscopic incisional herniotomy|
3240387|NCT01289093||Lichtenstein inguinal herniotomy|
3240388|NCT01289093||laparoscopic umbilical hernia repair|
3240389|NCT01289106|Active Comparator|Arm A|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
3240390|NCT01289106|Experimental|Arm B|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
3240391|NCT01289106|Experimental|Arm C|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
3240392|NCT01289132|Placebo Comparator|Placebo|
3240393|NCT01289132|Experimental|Azilsartan 5 mg QD|
3347029|NCT02234895|Experimental|Lateral wedge plus medial arch support|The lateral wedge plus medial support orthotic will be custom-made and designed using a 3D volumetric cast of the foot with the participant's foot in a subtalar joint neutral position. The cast will be balanced so that it rests in a neutral position then smoothed to address any irregularities and to allow for soft tissue splay. Polypropylene sheets of 3mm or 4mm thickness will be vacuum formed or milled directly to produce a ¾ length shell. An ethyl-vinyl-acetone (EVA) lateral post in the heel and forefoot of 5 degrees will be incorporated into the orthotic. The orthotic will be finished with a neoprene cover for improved comfort and patient compliance.
3347030|NCT02234895|Experimental|Lateral wedge|The lateral wedge only orthotic will be constructed of EVA, made to full length of the subject's footwear and incorporate a 5 degree posting. The wedge will be finished with a neoprene cover for improved comfort and patient compliance.
3347031|NCT02234908|Experimental|Contacts|Contacts are the household contacts of confirmed TB and drug-resistant TB patients.
3347032|NCT02234908|Other|Index|Index subjects are confirmed TB and drug-resistant TB patients who distribute referral cards to their household contacts.
3347033|NCT02234921|Experimental|DRibble Vaccine|Patients will receive cyclophosphamide 3 days prior to the first of 9 planned DRibble vaccine injections. Imiquimod will be applied following 6 injections. Patients will receive 2 HPV vaccinations (Human papillomavirus).
3347034|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part A|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after myeloreductive conditioning
3240394|NCT01289132|Experimental|Azilsartan 10 mg QD|
3240395|NCT01289132|Experimental|Azilsartan 20 mg QD|
3240396|NCT01289132|Experimental|Azilsartan 40 mg QD|
3347035|NCT02234934|Experimental|Lentiviral G1XCGD Gene Therapy, Part B|Transplantation with autologous CD34+ stem cells corrected with X1XCGD lentiviral vector after modified myeloreductive conditioning including increased monitoring and rescue treatment
3347036|NCT02234947||New onset of Type 1 Diabetes|The subjects with new onset of Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3347037|NCT02234947||Antibody Positive Risk for Diabetes|The subjects with single or double antibody positive risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3347038|NCT02234947||Antibody Negative Risk for Diabetes|The subjects with antibody negative risk for Type 1 Diabetes will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3347039|NCT02234947||Healthy Control|The subjects has no family history for Type 1 Diabetes. They will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and biochemical testing. These test will be compared to the testing from the other groups.
3347040|NCT02234960||Cohort of RA Participants|Participants with RA treated with tocilizumab at a dose and duration at the discretion of physician in accordance with the summary of product characteristics as per routine clinical practice were observed for a period of 6 months with the length of entire study for 24 months.
3347041|NCT02234973||11 First Nations Community and Clinical Teams|11 Community & Clinical Teams in each First Nation community participated in the intervention.
3240397|NCT01289132|Experimental|Azilsartan 80 mg QD|
3240398|NCT01289132|Active Comparator|Candesartan Cilexetil 8 mg titrated to12 mg QD|
3240399|NCT01289145|Experimental|Intervention|"Participants will be allocated to a motivational intervention, a volitional intervention or the active control group.~The motivational intervention promotes positive outcome expectancies on physical activity. The volitional intervention promotes the formulation of action plans for physical activity. Participants in the active control group, receive a quiz on physical activity and sports."
3240400|NCT01289158||non-classical CMAMMA, classical CMAMMA|
3240401|NCT01289171|Experimental|Glycolic acid|All who met the study criteria commenced once daily use of 15% glycolic acid lotion.
3240402|NCT01289184||control|
3240403|NCT01289184||exposure 2-3 years|
3240404|NCT01289184||exposure 3-5 years|
3240405|NCT01289184||exposure 5-10 years|
3240406|NCT01289184||exposure >15 years|
3240407|NCT01289197|No Intervention|No Feedback or services offered.|The Family Check-Up is not offered.
3240408|NCT01289197|Other|Intervention|Family Check Up is offered.
3240409|NCT01289223|Active Comparator|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
3240410|NCT01289223|Experimental|Bendamustine IV|Up to 8 cycles of Bendamustine (120mg/m2 Days 1 and 2, every 21 days (+ 3 days).
3240411|NCT01289236|Placebo Comparator|Placebo|Placebo BID (twice daily, approximately 12 hours apart)
3240412|NCT01289236|Active Comparator|milnacipran 200 mg|200mg- 1 100mg tablet BID (twice daily, approximately 12 hours apart)
3240413|NCT01289236|Active Comparator|milnacipran 100 mg|100mg- 1 50mg tablet BID (twice daily, approximately 12 hours apart)
3240414|NCT01289249||Children receiving meropenem|Children aged from 3 months to 18 years that receive treatment with meropenem.
3240415|NCT01289262|Active Comparator|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture.
3240416|NCT01289262|Active Comparator|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked closure technique.
3240417|NCT01289288|Experimental|Mailed printed materials and in-office training|
3240418|NCT01289288|No Intervention|Control|Usual care
3240419|NCT01289301|Experimental|mTOR-receiving arm|switching from calcineurin-inhibitor-based immunosuppression to mTOR-based immunosuppression
3240420|NCT01289301|Active Comparator|calcineurin-inhibitor keeping arm|continuing calcineurin-inhibitor based immunosuppression
3240421|NCT01289314|Active Comparator|Total laparoscopic hysterectomy|
3240422|NCT01289314|Active Comparator|Laparoscopic supracervical hysterectomy|
3347042|NCT02234986|Experimental|ENMD-2076|ENMD-2076, oral capsule Once daily dose 250 mg/day
3347043|NCT02234999|Experimental|3mg [14C]-CC-122 (Single Dose)|Single oral capsule of 3mg [14C]-CC-122. given as a suspension under fasting conditions on Day 1
3347044|NCT02235012|Experimental|Ketamine then placebo|Infusion of low dose Ketamine then infusion of a saline solution
3347045|NCT02235012|Experimental|Placebo then ketamin|Infusion of a saline solution then infusion of low dose Ketamine
3347046|NCT02235025|Other|Asymptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score equal to zero and are free of respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze.
3347047|NCT02235025|Other|Symptomatic mild COPD|Subjects of this group have GOLD grade I COPD (post-bronchodilator FEV1 > 80% predicted and FEV1/FVC < 0.7). They also have a modified Medical Research Council (mMRC) score > 0.
3347048|NCT02235025|Other|Healthy controls|Healthy controls have normal baseline spirometry (FEV1 > 80% predicted, FEV1/FVC > 0.7). They don't have any health problems, including cardiovascular, metabolic, neuromuscular, musculoskeletal, or respiratory diseases that could contribute to breathlessness or exercise limitation. They have a mMRC score equal to zero and do not complain any respiratory symptoms including chronic cough and/or chronic expectoration and/or chronic wheeze and/or chronic respiratory related medication.
3240423|NCT01289327|Active Comparator|propofol|
3240424|NCT01289327|Active Comparator|midazolam+alfentanil|
3347049|NCT02235038|Active Comparator|Low carbohydrate diet|
3347050|NCT02235038|Active Comparator|Moderate carbohydrate diet|
3347051|NCT02235038|Active Comparator|High carbohydrate diet|
3347052|NCT02235051|Experimental|Arm I (exercise intervention)|Patients participate in a supervised Curves exercise program three days a week for 16 weeks. The circuit-style workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing muscle groups in a concentric-only fashion. Each session at Curves will include two complete circuits which correspond to exercising for approximately 30 minutes followed by a standardized stretching routine.
3347053|NCT02235051|No Intervention|Arm II (no formal exercise intervention)|Patients do not participate in a formal exercise program for 16 weeks. Patients are then offered the Curves exercise intervention.
3347054|NCT02235090|Sham Comparator|Zero-strength of direct current stimulation|Sham transdermal direct current stimulation of cervical spinal cord
3347055|NCT02235090|Experimental|100 microamperes direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
3347056|NCT02235090|Experimental|1 milliampere direct current stimulation|Transdermal direct current stimulation of cervical spinal cord
3347057|NCT02235103||Clinical Pregnancy|Patients who are clinically pregnant after first treatment cycle with intra-uterine insemination.
3347058|NCT02235103||No Clinical Pregnancy|Patients who are not clinically pregnant after first treatment cycle with intra-uterine insemination.
3347059|NCT02235116||Patients who responded to the survey|
3347060|NCT02235129|Experimental|6 minutes walking test|
3347061|NCT02235155||Pregnant women of 13-22 weeks gestation|Pregnant women of 13-22 weeks gestation will receive 200 mg mifepristone followed 24-48 hours later by 400 mcg sublingual misoprostol every three hours until complete expulsion.
3240425|NCT01289340||Polymem (R)|superficial burns treated with Polymem wound dressing until complete wound healing
3240426|NCT01289340||Biaten IBU|burns treated with Biaten IBU until complete wound healing.
3347062|NCT02235168|Experimental|With rollator|Six minutes walking test with rollator
3347063|NCT02235168|Active Comparator|Without rolator|Six minutes walking test without rollator
3347064|NCT02235181|No Intervention|Standard Treatment|Women will be allocated to standard treatment, currently this is no treatment.
3347065|NCT02235181|Active Comparator|Arabin pessary|The Arabin cervical pessary will be inserted between 18 and 20+6 days gestation and removed between 35 and 36+6 weeks gestation unless Labour occurs sooner.
3347066|NCT02235194|Active Comparator|Amino Acids, Chromium - Picolinate|Verum drink containing the dietary supplements is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
3347067|NCT02235194|Placebo Comparator|Placebo Drink|Placebo Drink containing aroma only is taken with a test meal. INsulin and glucose response is documented for 180 minutes.
3347068|NCT02235207|Experimental|Neuromuscular exercise|The exercise group will participate in Fustra20 Neck & Back neuromuscular exercise program.
3240427|NCT01289340||Hartmen dressing|burns treated with hartman or saline wet dressing until wound healing
3240428|NCT01289366||Patients with IBD|
3347069|NCT02235207|No Intervention|Control group|Participants are encouraged to continue there usual physical activity and exercise
3347070|NCT02235220|Experimental|Composite resin restoration|A canine guidance is reestablished by additive composite resin restorations of the canine cusp.
3347071|NCT02235233|Experimental|Patients with NASH|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
3347072|NCT02235233|Active Comparator|Healthy Normal Volunteers|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
3347073|NCT02235246|Experimental|normal saline|
3347074|NCT02235246|Active Comparator|magnesium sulfate|
3240429|NCT01289379|Experimental|HFJV|
3240430|NCT01289405|Placebo Comparator|placebo exercices|relaxation exercises and stretching neck, without therapeutic purpose.
3240431|NCT01289405|Active Comparator|phonoaudiologic therapy|isometric and isotonic exercises to improve posture, mobility and muscle tone of the soft palate, pharyngeal constrictor muscles, tip and base of tongue, cheeks and lips.
3347075|NCT02235259|Experimental|XG-104 low dose|
3347076|NCT02235259|Experimental|XG-104 intermediate dose|
3347077|NCT02235259|Experimental|XG-104 high dose|
3347078|NCT02235259|Placebo Comparator|Placebo|Placebo
3347079|NCT02235272|Experimental|XG-102|
3347080|NCT02235272|Placebo Comparator|Placebo|
3375904|NCT03555149|Experimental|Atezolizumab + Regorafenib + AB928|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
3240432|NCT01289444|Active Comparator|Healthy Living Control|"Session 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered, with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~Session 3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides. The Administered by the trained RA-Control to prevent contamination with the FACE condition."
3240433|NCT01289444|Experimental|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
3240434|NCT01289483|Active Comparator|fospropofol 6.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.
3240435|NCT01289483|Active Comparator|fospropofol 5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.
3240436|NCT01289483|Active Comparator|fospropofol 3.5 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.
3240437|NCT01289483|Active Comparator|fospropofol 2 mg/kg.|Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.
3240438|NCT01289496|Experimental|Peg-interferon alpha-2a, Ribavirin|"Adult patients with chronic hepatitis C and failure of prior treatment with peginterferon plus ribavirin(non-response or relapse).~This is a pilot study with no control group."
3240439|NCT01289509|Experimental|Experimental 1|Drug: E5501
3240440|NCT01289509|Experimental|Experimental 2|Drug: E5501
3240441|NCT01289535|Experimental|antibody rates|
3240442|NCT01289561|Experimental|Alcohol self-administration|All participants will participate in seven sessions. In three sessions, each participant will consume a beverage containing alcohol and caffeine. In three separate sessions, participants will consume a beverage containing alcohol and caffeine-placebo. In the final session, all participants may choose which beverage they consume. Participants and research assistants will be blinded to inclusion of caffeine/caffeine-placebo in beverage, but each beverage will be labeled for identification (e.g., A or B).
3347081|NCT02235324|Experimental|Treatment (ziv-aflibercept, leucovorin calcium, fluorouracil)|"PHASE I:~Patients receive ziv-aflibercept IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients proceed to Phase II.~PHASE II:~Patients receive ziv-aflibercept IV over 1 hour, leucovorin calcium IV over 1 minute, and fluorouracil IV over 46 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity."
3347082|NCT02235337|Experimental|Riboflavin|
3240443|NCT01289587|Experimental|Alternative frequency variant|An alternative variant of the DIAfit program (progressive increase of the number of administered PA sessions per week, namely one PA session per week during 4 weeks and then twice a week over a period of 16 weeks)
3240444|NCT01289587|Active Comparator|Standard frequency program|Standard usual program (3 times per week over a period of 12 weeks)
3240445|NCT01289600|Active Comparator|Pressure support ventilation, ARDSnet|"Mechanical ventilator is set to pressure support ventilation (6 ml/kg) for 30 min with positive end expiratory pressure (PEEP) set according to the higher arm of the ARDS network consensus."
3240446|NCT01289600|Active Comparator|Pressure control ventilation, ARDSnet|"Mechanical ventilator is set to pressure control ventilation (6 ml/kg) for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
3240447|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, ARDSnet|"Mechanical ventilator is set to NAVA for 30 min with PEEP set according to the higher arm of the ARDS network consensus."
3347083|NCT02235350|Experimental|Action Observation Treatment (AOT)|Conventional physiotherapy + Action Observation Treatment
3240448|NCT01289600|Active Comparator|Neurally adjusted ventilatory assist, titrated|Mechanical ventilator is set to NAVA for 30 min with PEEP titrated using the diaphragm EMG signal.
3240449|NCT01289613||Children|Children
3240450|NCT01289613||Adults|Adults
3347084|NCT02235350|Sham Comparator|Observation of videos with no motor content (MNO)|Conventional physiotherapy + Observation of videos with no motor content (MNO)
3347085|NCT02235363|Experimental|facelift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
3347086|NCT02235376||critical care|
3347087|NCT02235389||Administration of thrombolytic treatment with PHARAOH|Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)
3240451|NCT01289652||HCV + HIV|
3240452|NCT01289652||HCV|
3347088|NCT02235389||Standard therapy with thrombolytic treatment in Hospital|
3347089|NCT02235402|Experimental|Lacidipine|
3347090|NCT02235402|Active Comparator|Bendrofluazide|
3347091|NCT02235402|Placebo Comparator|Placebo|
3240453|NCT01289691|Experimental|Air/Oxygen Mixture|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
3240454|NCT01289691|Active Comparator|Oxygen|Patients in this group will be ventilated with only oxygen during one lung ventilation.
3347092|NCT02235415||Motens|
3347093|NCT02235428|Experimental|Ipratropium bromide|
3347094|NCT02235428|Active Comparator|Salbutamol|
3347095|NCT02235441|Experimental|Cardiopulmonary Fitness|All eligible subjects will participate in treadmill exercise to measure cardiopulmonary fitness during chemoradiation therapy.
3240455|NCT01289704|Experimental|TreSPE|Treatment with treadmill, proprioceptive and stretching exercises
3240456|NCT01289704|Active Comparator|SPE|Proprioceptive and stretching exercises
3240457|NCT01289730|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice a week
3240458|NCT01289743|Experimental|Etanercept 25 mg|Etanercept 25 mg subcutaneously twice weekly
3347096|NCT02235467|Active Comparator|ABA parent training|Applied Behavior Analysis parent training using videomodeling in 21 sessions
3347097|NCT02235467|No Intervention|ABA parent training control|
3347098|NCT02235480|Experimental|Tazarotene Gel|once daily
3347099|NCT02235480|Placebo Comparator|Placebo Gel|once daily
3347100|NCT02235506|Experimental|epidural infusion|In epidural infusion group, a lumbar epidural catheter was placed at the L3-4 level using loss-ofresistance procedure. ropivacaine 0.2% and fentayl 2mcg/ml were infused at a rate of 5ml/hr from the end of operation,
3347101|NCT02235506|Experimental|femoral sciatic|In femoral sciatic group, the femoral and sciatic nerve are located using ultrasound and 0.2% ropivacain is injected. A catheter is inserted to femoral nerve. From the end of operation, 0.2% ropivacaine was infused through the femoral catheter at a rate of 5ml/hr.
3240459|NCT01289756|Experimental|CYP2D6 EM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3347102|NCT02235519|Active Comparator|Azilsartan low dosage|Patients will take azilsartan 40 mg during 12 weeks
3347103|NCT02235519|Active Comparator|Azilsartan high dosage|Patients will take azilsartan 80 mg during 12 weeks
3347104|NCT02235532|Experimental|Foramen Herbal Aloe toothpaste|test group was asked to brush the teeth with Foramen Herbal Aloe toothpaste for 30 days once a day.
3347105|NCT02235532|Active Comparator|use of fluoride toothpaste (signal)|use of a fluoride toothpaste (signal) in control group once a day for 30 days .
3347106|NCT02235545||St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
3347107|NCT02235558|Experimental|Verapamil|Super-selective intra-arterial administration of 10 mg verapamil immediately following successful intra-arterial thrombolysis
3347108|NCT02235571|No Intervention|Control|These subjects are receiving standard patient education
3347109|NCT02235571|Experimental|iChoose Kidney Decision Aid|These subjects receive iChoose Kidney Decision Aid along with standard patient education
3347110|NCT02235584|Experimental|Dexamethasone|This is a before-after study. All subjects are administered dexamethasone 2mg BID for 5 days.
3347111|NCT02235597||Patients and Staff of Community Clinics|Patients and Staff of Community Clinics who shared strategies and solutions to overcome barriers to accessing health care
3347112|NCT02235610|No Intervention|Standard Group|"Recipients receive standard donor lungs as per current clinical practice.~No experimental procedures will be carried out."
3347113|NCT02235610|Experimental|EVLP Group|Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.
3347114|NCT02235623|Other|Stage 1- Single-stage Fowler-Stephens orchidopexy (FSO)|Stage 1 single surgery to clip the vessels to the testis, divide the spermatic vessels and bring the testis into the scrotum.
3347115|NCT02235623|Other|Stage 2- Two-stage Fowler-Stephens orchidopexy (FSO)|Stage 2 2 surgeries: 1st surgery-Clip vessels to testis. 2nd surgery done 6-12 months later, divide the spermatic vessels and bring the testis into the scrotum.
3347116|NCT02235636||Laparoscopic group|
3347117|NCT02235636||Robotic group|
3347118|NCT02235649|No Intervention|TAU|Treatment as usual
3347119|NCT02235649|Active Comparator|SOC+TAU|Social Cognition intervention + Treatment as Usual
3347120|NCT02235662|Experimental|TFV IVR|TFV IVR is an intravaginal ring 55.0 mm in diameter, consisting of single segment of polyurethane tubing with an outer diameter of 5.5 mm and filled with white TFV-containing paste. Used for one month, the IVR delivers 8-10 mg/day TFV.
3347121|NCT02235662|Experimental|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm: a longer segment containing white TFV paste and a shorter one (20 mm) with a white LNG core. Used for one month, the IVR delivers 8-10 mg/day TFV and 20 μg/day LNG.
3347122|NCT02235662|Placebo Comparator|Placebo Intravaginal Ring|Intravaginal ring 55.0 mm in diameter, consisting of two segments of polyurethane tubing with an outer diameter of 5.5 mm containing no active experimental ingredients. Used for one month.
3240460|NCT01289756|Experimental|CYP2D6 IM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3240461|NCT01289756|Experimental|CYP2D6 PM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3240462|NCT01289756|Experimental|CYP2D6 UM|clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
3240463|NCT01289769|Active Comparator|dexmedetomidine|
3240464|NCT01289769|Placebo Comparator|control|
3240465|NCT01289795||first-ever ischemic stroke|first-ever ischemic stroke according to the WHO definition
3240466|NCT01289808|Experimental|glucose 25%|"180 healthy babies born term in the Baruch Padeh Medical Center, Poriya.~There will be three study groups:~Study Group: 60 newborn infants who will receive 1cc 25% Glucose, 2-3 minutes prior red-reflex examination.~Base line (control) Group 1: 60 newborn infants who will receive 1cc Water for Injection (WFI), 2-3 minutes prior red-reflex examination.~Base line (control ) Group 2: 60 newborn infants who will not receive neither glucose nor Water for Injection (WFI), 2-3 minutes prior red-reflex examination"
3240467|NCT01289834|Active Comparator|Hi-Fatigue Bone Cement|CPT femoral stems fixed with Hi-Fatigue Bone Cement
3240468|NCT01289834|Active Comparator|Palacos Bone Cement|CPT femoral stems fixed with Palacos Bone Cement
3347123|NCT02235675|Experimental|Tack-It|Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
3347124|NCT02235688|Experimental|aldoxorubicin|
3347125|NCT02235701|Experimental|aldoxorubicin|
3347126|NCT02235714||Tetraplegia|Individuals with chronic tetraplegia
3347127|NCT02235714||Asthma|Individuals with mild asthma
3347128|NCT02235714||Able-bodied controls|Age matched able-bodied (AB) controls with no history of lung disease
3347129|NCT02235727|Experimental|GBR 900|Test treatment GBR 900
3347130|NCT02235727|Placebo Comparator|Placebo|Placebo Treatment
3240469|NCT01289860|Active Comparator|Blueberry drink|30g of blueberry powder (equivalent to 200g fresh blueberries) and 300ml of semi-skimmed milk
3240470|NCT01289860|Placebo Comparator|Control drink|29g of powder consisting of sugars and vitamin C, values of which were matched to that of the blueberry drink, with 1 g of citric acid to match for taste.
3240471|NCT01289886|Other|Arm A|BR-A-657 20mg or placebo
3347131|NCT02235740|Experimental|Afuresertib 125 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive Afuresertib 125 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg (increased dosage of 27 mg/meter (m)^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3347132|NCT02235740|Experimental|Afuresertib 150 mg+ Carfilzomib (Part 1)|Approximately 8 subjects will receive oral Afuresertib 150 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3347133|NCT02235740|Experimental|Afuresertib 100 mg+ Carfilzomib (Part 1)|An additional arm with 100 mg of afuresertib may be evaluated if the other 2 arms are not tolerated. Approximately 8 subjects will receive Afuresertib 100 mg daily starting Cycle 1 Day 2 + Carfilzomib 20 mg/m^2: on Cycle 1, Day 1, 2; Cycle 2, Day 1. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15, and 16; Cycle 2, Days 2, 8, 9, 15, and 16; Cycle 3 and onwards, Days 1, 2, 8, 9, 15, and 16 of each cycle
3347134|NCT02235740|Experimental|Afuresertib/carfilzomib (Part 2)|Approximately 50 subjects will receive Afuresertib Recommended Phase 2 Dose (RP2D) daily starting Cycle 1 Day 1 + Carfilzomib 20 mg/m^2 Cycle 1, Day 1, 2. Carfilzomib 27 mg (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9, 15 and 16; Cycle Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9 and 15 and 16 of each cycle.
3347135|NCT02235740|Active Comparator|Carfilzomib (Part 2)|Approximately 50 subjects will receive Carfilzomib 20 mg/m^2: Cycle 1, Day 1, 2. Carfilzomib 27 mg/m^2 (increased dosage of 27 mg/m^2 will be administered only if tolerated): Cycle 1, Days 8, 9 15, and 16; Cycle 2, Days 1, 2, 8, 9, 15 and 16 of each cycle; Cycle 3 and onwards, Days 1, 2, 8, 9, 15 and 16 of each cycle.
3347136|NCT02235753|Experimental|High-intensity interval training, HIT-S|High-intensity aerobic interval training, short interval (HIT-S)
3347137|NCT02235753|Experimental|High-intensity interval training, HIT-L|High-intensity aerobic interval training, long interval (HIT-L)
3347138|NCT02235753|No Intervention|Usual care|control group
3347139|NCT02235766||CRT candidates patients|In accordance with the current ESC/ACCF/AHA indications for CRT in sinus rhythm, all patients in NYHA class II, III and IV with QRS complex greater than 120 msec and ejection fraction equal or less than 35% will be considered eligible to participate in this observational study.
3347140|NCT02235779|Other|Cryobiopsy|
3347141|NCT02235792|Experimental|Deep Brain Stimulation 37604 Activa PC+S|All subjects will undergo DBS using the 37604 Activa PC+S device (single arm study).
3347142|NCT02235805|Experimental|Magnesium Citrate|
3347143|NCT02235805|Placebo Comparator|Placebo|
3347144|NCT02235818|Active Comparator|Kinesiotape (KT)|Kinesiotape was used only on the affected side as per the manufacturer instructions. With the elbow extended, wrist fully flexed and fingers pointed down 24, KT was applied with slight stretch (10-15%) and paper off tension to the lateral arm beginning just above the bony portion of lateral epicondyle. Once the top strand was anchored, KT was applied along the side of elbow such that hole in the tape was over lateral epicondyle of the elbow. Two strands of tape followed the lateral forearm and ended at around beginning of the distal one third of forearm. Once the support was applied, KT was gently rubbed to activate the glue.
3347145|NCT02235818|Active Comparator|Counterforce elbow brace|The counterforce brace was approximately 5cm wide with velcro attachment for adjustable girth. It had gel pack for extra support on extensor muscle mass. With the elbow extended, brace was applied 2.5cms below the lateral epicondyle. A feeling of comfortable compression, as reported by the patients was used to adjust the brace.
3347146|NCT02235844|Experimental|Mesenchymal Stem Cells|Umbilical Cord Mesenchymal Stem Cells
3347147|NCT02235857|Experimental|Liposorber® LA-15 System|All study patients who meet the study eligibility criteria will undergo the extracorporeal treatment using Liposorber® LA-15 System. The participants are to be treated with the system twice weekly for the 3weeks and then once weekly for the following 6 weeks.
3240472|NCT01289886|Other|Arm B|BR-A-657 60mg or placebo
3240473|NCT01289886|Other|Arm C|BR-A-657 120mg or placebo
3240474|NCT01289886|Other|Arm D|BR-A-657 240mg or placebo
3240475|NCT01289886|Other|Arm E|BR-A-657 480mg or placebo
3240476|NCT01289899|Experimental|Arm A|BR-A-657 120mg or placebo
3240477|NCT01289899|Experimental|Arm B|BR-A-657 360mg or placebo
3240478|NCT01289925|Experimental|Selenium|
3240479|NCT01289925|Placebo Comparator|Sugar Pill|
3240480|NCT01289938|Active Comparator|Metoclopramide|Metoclopramide treatment
3240481|NCT01289938|Active Comparator|Diphenhydramine|Diphenhydramine treatment
3240482|NCT01289951|Experimental|Patients with Child-Pugh C hepatic-cirrhosis.|VIH/VHC coinfected patients with advanced (Child-Pugh C) hepatic cirrhosis.
3240483|NCT01289951|Active Comparator|VIH/VHC coinfected patients without liver damage.|
3240484|NCT01289964|No Intervention|Waiting list control group|No treatment within the study period, were allowed to continue physiotherapy and medication. Were offered the treatment after finishing the study
3240485|NCT01289964|Active Comparator|Treatment group|Received the 5 cupping treatments, application twice a week, non standardised application - individual determinations of trigger points
3240486|NCT01289977||Phlebotomus group|Those in the Phlebotomus group will have exposure to P. duboscqui sand fly
3240487|NCT01289977||Lutzomyia group|Those placed in this group will receive exposure to L. longipalpis sand fly bites.
3240488|NCT01290003|Experimental|Antibiotic Group|Neonates randomized to intervention Group(Antibiotic group)will receive the first line antibiotics (Piperacillin-Tazobactam and Amikacin) as per the unit policy for 72 hours. These neonates will also be monitored by performing sepsis screens and blood culture for development of sepsis.
3347148|NCT02235896|Other|Education/Behavior Modification|Education/Behavior modification program
3347149|NCT02235909|Experimental|Double blind phase: Azilsartan Medoxomil|Double blind phase; Randomized 1:1:1:1. Once a day dosing. Azilsartan medoxomil at 10 mg, or 20 mg, or 40 mg force-titrated to 80 mg
3347150|NCT02235909|Active Comparator|Double blind phase: Losartan 25 or 50 mg|Double blind phase: Double blind phase; Randomized 1:1:1:1. Once a day dosing
3347151|NCT02235909|Active Comparator|Withdrawal Phase: Azilsartan medoxomil dose taken in Double blind phase|Experimental Arm in the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
3347152|NCT02235909|Placebo Comparator|Withdrawal Phase: Placebo to match azilsartan medoxomil|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
3347153|NCT02235909|Experimental|Open Label Phase: Azilsartan Medoxomil|Azilsartan Medoxomil 10 mg which can be titrated to higher dose(s) (up to 40 mg for subjects <50 kg or up to 80 mg for subjects ≥50 kg)
3347154|NCT02235909|Other|"Open Label Phase: Other"|Additional antihypertension medication, as needed. Name and dose as determined by PI
3347155|NCT02235909|Active Comparator|Withdrawal Phase: Losartan 25 or 50 mg|Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
3347156|NCT02235909|Placebo Comparator|Withdrawal Phase: Placebo to Losartan|Placebo Arm In the Withdrawal Phase, subjects will be randomized (1:1) to continue taking their previously assigned active treatment or to be switched to placebo.
3347157|NCT02235922|Experimental|Dual task training|Dual task training
3347158|NCT02235922|Experimental|Conventional training|Conventional training
3347159|NCT02235935||diabetic patients, hyperbaric chamber, diabetic retinopathy|
3240489|NCT01290003|No Intervention|No Antibiotic Group|Neonates randomized to 'No antibiotic group' will receive supportive treatment as per standard unit protocol. These neonates will be monitored by performing sepsis screens and blood culture for development of sepsis.
3240490|NCT01290016|Active Comparator|Control 6-8 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention till the end of the study protocol.
3347160|NCT02235948|Experimental|folic acid|folic acid supplementation placebo controlled
3347161|NCT02235961|Experimental|Part 1|
3347162|NCT02235961|Experimental|Part 2|
3347163|NCT02235974|Experimental|Acute/Early|Intervention: A 20-hour dose of early intensive upper extremity motor training therapy will be initiated within 30 days post-stroke.
3347164|NCT02235974|Experimental|Sub-acute/Outpatient|Intervention: A 20-hour dose of sub-acute intensive upper extremity motor training therapy will be initiated within 2 to 3 months post-stroke.
3347165|NCT02235974|Experimental|Chronic|Intervention: A 20-hour dose of chronic intensive upper extremity motor training therapy will be initiated 6 to 9 months post-stroke
3347166|NCT02235974|Placebo Comparator|Control|Intervention: Usual and customary care. No additional therapy will be initiated during the 1-year study.
3347167|NCT02236000|Experimental|Neratinib and T-DM1|
3347168|NCT02236013|Experimental|ASP2215 Dose Escalation (Part 1)|Successive dose escalation cohorts will determine the maximum tolerated dose (MTD)
3240491|NCT01290016|Experimental|2 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
3240492|NCT01290016|Experimental|4 servings dairy + exercise 6-8 yrs|Subjects in this group will receive family based counselling to maintain the intake of 4 servings of dairy per day and also receive instruction on how to improve their physical activity.
3240493|NCT01290016|Experimental|4 servings dairy + exercise 9-12 yrs|Subjects in this group will receive family based counselling to maintain the standard recommended intake of 4 servings of dairy per day for 9-14 year olds according to the Canada's Food Guide and also receive instruction on how to improve their physical activity.
3347169|NCT02236013|Experimental|ASP2215 Dose Expansion (Part 2)|Once the MTD has been established in Part 1, up to 20 subjects will be enrolled into an expansion cohort
3347170|NCT02236013|Experimental|Alternative Anthracycline and Schedule (Part 3)|In Part 3, two cohorts will be enrolled to evaluate an alternative anthracycline and ASP2215 schedule
3347171|NCT02236013|Experimental|Continuous ASP2215 Exposure during Consolidation (Part 4)|During Consolidation, ASP2215 will be given daily on day 1 up to day 56.
3347172|NCT02236026|Experimental|Supratherapeutic dose of Nestorone|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3347173|NCT02236026|Placebo Comparator|Placebo|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3347174|NCT02236026|Experimental|Moxifloxacin|Subjects will be randomized to a treatment sequence on Day 1 of Treatment Period 1, prior to administration of investigational product, according to a randomization schedule provided by the Sponsor
3347175|NCT02236039|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by a bronchoscopy 24 hours post exposure.
3347176|NCT02236039|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by a bronchoscopy 24 hours post exposure.
3347177|NCT02236052|Experimental|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
3347178|NCT02236052|Experimental|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
3347179|NCT02236052|Experimental|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
3347180|NCT02236052|Experimental|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
3347181|NCT02236052|Experimental|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
3347182|NCT02236052|Placebo Comparator|Placebo|A single dose of Placebo
3347183|NCT02236065|Experimental|UCB + G-CSF|UCB + G-CSF
3347184|NCT02236078|Experimental|High dose isoniazid|INH 900 mg daily to be administered orally for 6 days (600 mg for patients weighing <45 kg)
3347185|NCT02236091||Inpatients|
3240494|NCT01290016|Active Comparator|Control 9-12 yrs|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
3240495|NCT01290042|Active Comparator|Placebo arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
3347186|NCT02236104|Experimental|cough assist session|Mechanical insufflation-exsufflation contains 15 cycles durea 2-3 seconds. pressure level fixed +/-30 cm H2O.
3347187|NCT02236117|Experimental|Intervention: Aerobic Training|The children included in the experimental group will make 10 weeks of aerobic training. The intensity of the race will be based on individual speed obtained in the last stage completed the progressive test, known as the maximal aerobic speed (MAV) in km/h. The running speed of the exercise protocol will be minimum 80% of the MAV in the protocol of continuous training. The intermittent progressive training is n * (10*15 s) to 100% MAV, and n from 2 to 6 series between the first and tenth week. The training protocol was adapted from previously described (Mandigout et al, 2002, Gamelin et al, 2009.). Acceptance of the exercise in a pediatric population has been previously observed by pilot study.
3347188|NCT02236117|No Intervention|physical education classes|
3347189|NCT02236143||MRI|Subjects undergoing MRI
3347190|NCT02236156|Experimental|1% SPL7013 Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3240496|NCT01290042|Active Comparator|Active arm|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
3240497|NCT01290055|Experimental|Group 1|In group 1, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 2 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
3347191|NCT02236156|Placebo Comparator|Placebo Gel|Inserted in to the vagina on alternate days (i.e. every other day) for 16 weeks
3347192|NCT02236169|Experimental|Ipratropium bromide|
3347193|NCT02236169|Active Comparator|ATROVENT|
3347194|NCT02236182|Experimental|Ipratropium Bromide low|delivered via RESPIMAT®
3240498|NCT01290055|Experimental|Group 2|In group 2, participants will receive the Yellow fever vaccine or YFV-17D and will be asked to drink Deuterium (70% enriched 2H2O) labeled water for 3 weeks. They will undergo phlebotomy on Day 0, 14, 28 and 3 to 6 months, 1-2 years and >5 years after vaccination.
3240499|NCT01290081|Active Comparator|Active referral|Case management intervention group - study personnel scheduled the TB doctor appointment for the participant, reminded to keep it, and transportation to the clinic was organized when needed.
3347195|NCT02236182|Experimental|Ipratropium Bromide high|delivered via RESPIMAT®
3347196|NCT02236182|Placebo Comparator|Placebo|delivered via RESPIMAT®
3347197|NCT02236195|Experimental|Mocetinostat|Mocetinostat (MGCD0103) oral capsules three times weekly, 70 mg doses in first month, with increase to 90 mg doses if tolerated
3347198|NCT02236234|Experimental|Vaccine|one group with HPV vaccine
3347199|NCT02236247|Experimental|ivabradine|I(f) inhibitor, heart rate controller
3347200|NCT02236247|Placebo Comparator|placebo|placebo pill will be administered orally twice daily
3347201|NCT02236260|Active Comparator|Local anesthesia alone|
3347202|NCT02236260|Experimental|Local Anesthesia + Electroacupuncture|
3347203|NCT02236273|Experimental|Conventional Text Message|Conventional text message reminder
3347204|NCT02236273|Experimental|Enhanced reminders|Enhanced text message reminders
3347205|NCT02236286|Experimental|Exercise|Subjects will participate in a 90-minute, group (6 per group) exercise session 3 days per week for 6 weeks (18 sessions). The theoretical basis for our novel Agility Boot Camp (ABC) exercise program is based on research that identified the primary neurophysiological and cognitive constraints that limits balance and mobility in PD. The exercises are designed as a circuit with several types of movement-skills specifically focused on improving different postural domains with cognitive challenges such as memorized sequences and dual tasking.
3347206|NCT02236286|Active Comparator|Chronic Disease Management Education|Subjects will also receive (cross-over) six weeks of educational classes. The Education program will teach subjects, chronic disease self-management - how to live better with their parkinsonism. Classes will consist of 6 subjects per group meeting for 90 minute sessions, once a week for six weeks. Subject will do an additional 120 minutes of relaxation at home/week.
3347207|NCT02236299|Placebo Comparator|saline placebo infusion|30 minute infusion of a saline placebo Right coronary artery percutaneous coronary intervention
3347208|NCT02236299|Experimental|GLP-1 infusion|30 minute infusion of GLP-1 Right coronary artery percutaneous coronary intervention
3240500|NCT01290081|No Intervention|Passive referral|Participants were instructed to schedule an appointment with TB services themselves.
3347209|NCT02236312|Experimental|Botulinum Toxin 30 units|I.M. injection
3347210|NCT02236312|Experimental|Botulinum Toxin 45 units|I.M. injection
3347211|NCT02236312|Experimental|Botulinum Toxin 60 units|I.M. injection
3347212|NCT02236312|Placebo Comparator|Placebo|I.M. injection
3347213|NCT02236325|Experimental|DBT Brief Suicide Intervention|
3347214|NCT02236325|Active Comparator|Relaxation Training|
3347215|NCT02236351|Placebo Comparator|Control|Patients assigned to the Control Arm will be taught to apply their patches using the standard technique -- applying the patch evenly and flatly around the orbit.
3347216|NCT02236351|Experimental|Pinched Patch|Patients assigned to the Pinched Patch Arm will be taught to apply their patches after pinching the middle of the superior and inferior edges of the patch so that the patch is convex and the center is raised above the eye.
3347217|NCT02236364|Experimental|New device for OPTICAL determination of blood glucose level|
3347218|NCT02236377|Active Comparator|ERRT - Enhanced Exposure|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced exposure techniques
3347219|NCT02236377|Active Comparator|ERRT - Sleep and Relaxation|Exposure, Relaxation, and Rescripting Therapy protocol, 5 sessions, focused on sleep and relaxation
3347220|NCT02236377|Active Comparator|ERRT-Rescription|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with rescription but no exposure
3347221|NCT02236377|Active Comparator|ERRT-Sleep|Exposure, Relaxation, and Rescripting Therapy, 5 sessions, with enhanced sleep techniques
3347222|NCT02236390|Active Comparator|Cognitive Processing Therapy-Cognitive|12 sessions of cognitive processing therapy-Cognitive
3347223|NCT02236390|Active Comparator|ERRT + CPT-C|5 sessions of Exposure, Relaxation, and Rescripting Therapy, followed by 12 sessions of Cognitive Processing Therapy- Cognitive
3347224|NCT02236390|Active Comparator|CPT-C + ERRT|12 sessions of Cognitive Processing Therapy - Cognitive, followed by 5 sessions of Exposure, Relaxation, and Rescripting Therapy
3347225|NCT02236403|Experimental|Ivermectin 0.1% Metronidazole 1%|30 patients will receive the treatment and at 15 days a second visit will be done and changes in mite counts will be determinated and correlated with symtoms and signs.
3347226|NCT02236403|Placebo Comparator|Control|30 volunters with no signs of blepharitis and with eyelashes with no demodex .None intervention. Symptoms and signs will be compared with experimental group
3347227|NCT02236416|Experimental|Intervention group|Physical exercise
3347228|NCT02236416|Other|Control group|Posture Education/Unchanged condition
3347229|NCT02236429|Experimental|recurrent bacterial vaginitis|
3240501|NCT01290133|Experimental|Active Drug|
3240502|NCT01290133|Placebo Comparator|Placebo|
3347230|NCT02236442|No Intervention|Usual care|First arm : Passive recording head pain, linked symptoms, treatment used and diagnosis.
3347231|NCT02236442|Experimental|After protocol recommendation care|Recording head pain, linked symptoms, treatment used and diagnosis after intervention that is recommendation to use global headache treatment protocol
3347232|NCT02236455|Experimental|Audio Relaxation technique|Relaxation is a process that decreases the effects of stress on your mind and body. Relaxation techniques can help you cope with everyday stress and with stress related to various health problems, such as cancer and pain.
3240503|NCT01290146|Active Comparator|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
3347233|NCT02236455|Experimental|Medical Music Intervention|Music intervention is use to assist with relaxation and reduce stress levels in patients.
3347234|NCT02236455|Experimental|Nature Therapy without Music|Ecotherapy is the use of nature to reduce stress and to increase levels of well-being in patients.
3347235|NCT02236455|Experimental|Nature Therapy with Music|Nature therapy videos were produced with and without music for surgical patients.
3347236|NCT02236468|Experimental|new EHFP|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
3347237|NCT02236468|Experimental|old EHFP+WASH|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication since 2014
3347238|NCT02236468|Other|new EHFP+WASH|Group newly participating in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014 + WASH/malaria behavior change communication since 2014
3347239|NCT02236468|Other|old EHFP+WASH+LNS distribution|Group participating in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010 + WASH/malaria behavior change communication and distribution of LNS since 2014
3240504|NCT01290146|Experimental|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
3240505|NCT01290159||post heat stroke heat tolerant|
3347240|NCT02236481|Experimental|Anakinra|100 mg of anakinra once daily by subcutaneous injection for 24 months
3347241|NCT02236481|Active Comparator|TNF alpha inhibitors|treatment with TNF-alpha inhibitors according to the relative summary of product charateristics
3347242|NCT02236494|Active Comparator|General Health Information Pamphlet|This group will not receive a brief intervention in the ED. They will receive a pamphlet with general health information for older adults, as well as contact information for an outpatient alcohol treatment center where they have the option to follow-up for alcohol treatment at their discretion. The patient's readiness to change their alcohol habits will be measured using a 1-10 scale with a visual cue.
3347243|NCT02236494|Experimental|Brief Negotiated Interview|The BNI will follow standard steps (7, 63): 1. The research assistant (RA) will ask permission to discuss the patient's alcohol use with them. 2. They will provide feedback regarding the patient's alcohol use, and will review guidelines drinking in older adults. Where relevant, the RA will discuss how the patient's current visit may relate to their alcohol use. 3. The RA will assess the patient's readiness to change using a 1-10 scale, and will enhance motivation. 4. The RA will negotiate a goal for the patient's drinking and give advice. The patient will be asked to sign a drinking agreement.
3347244|NCT02236507|Other|children without anorectal disorders|All children will be investigated by 3D high resolution anorectal manometry procedure
3347245|NCT02236533|Placebo Comparator|Control pasta|Volunteers were fed with control pasta, without B-glucans and spores of B. coagulans once a day for 12 weeks.
3240506|NCT01290159||post heat stroke heat intolerant|
3240507|NCT01290159||healthy controls|
3240508|NCT01290172|Experimental|Somatostatin|Patients in this group receive treatment with Somatostatin for 5 days.
3240509|NCT01290172|Placebo Comparator|Placebo|Patients in this group receive a placebo for 5 days.
3347246|NCT02236533|Experimental|Probiotic Whole Grain Pasta|Volunteers were fed with probiotic fortified pasta, including B-glucans and spores of B. coagulans once a day for 12 weeks.
3347247|NCT02236572|Experimental|Aromatase Inhibitor plus Everolimus|Aromatase inhibitor plus everolimus by mouth daily for 26 weeks
3347248|NCT02236585|Active Comparator|Patient-controlled epidural analgesia|Patient-controlled epidural analgesia
3347249|NCT02236585|Placebo Comparator|Continuous epidural analgesia|Continuous epidural analgesia
3347250|NCT02236624|Experimental|Aerobic Exercise|
3347251|NCT02236637||mCRPC patients|Patients with metastatic castration-resistant prostate cancer treated according to routine clinical practice
3347252|NCT02236650|Experimental|Primary Care Stepping Stones Triple P|Primary Care Stepping Stones Triple P program (PC-SS Triple P) - a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
3347253|NCT02236650|Active Comparator|Wait List Control (WLC)|Wait List Control - Participants who will have access to treatment as usual services during the 4 weeks between baseline and 4 week assessment time points and then will have the opportunity to receive PC-SS Triple P.
3347254|NCT02236663|Experimental|App Based Safety Decision Aid|Personalized App-Based Safety Decision Aid
3347255|NCT02236663|Active Comparator|Control App|Usual Care Safety Plan
3347256|NCT02236676|Active Comparator|Nap after rehearsal trials|A 30-minute daytime nap after training
3347257|NCT02236676|Placebo Comparator|Resting while awake|Placebo condition of 30 minutes between training and retesting in which the half hour is spent resting awake in bed.
3347258|NCT02236689|Active Comparator|Arthroscopic tennis elbow release|This group will have arthroscopic tennis elbow release through a standard, two-portal technique,
3347259|NCT02236689|Placebo Comparator|Non Operative|control group will not undergo a second portal or muscle release.
3240510|NCT01290185|Experimental|Coiled Catheter|Placement of the coiled catheter for continuous infusion of local anesthetics close to the femoral nerve: To place coiled catheters ab 18-gauge Tuohy needle (Sonoline Curl Catheter Set, Pajunk® Medizintechnologie GmbH, Geisingen, Germany) of 8 cm length is placed adjacent to the nerve by ultrasound guidance and nerve stimulator control. At this position and after injection of 5 ml dextrose 5% in water to dilate the space the coiled catheter is blindly advanced 2 cm through the needle and the final position verified with ultrasound.
3240511|NCT01290185|Active Comparator|Conventional stimulating Catheter|For the control group a conventional stimulating catheter is placed adjacent to the femoral nerve as follows: To place the simulating catheter an 18-gauge Tuhoy needle s placed adjacenit to the nerve by ultrasound guidance. At this position a stimulation catheter is introduced through the needle and stimulated with a decreasing current from 1 mA to 0.4 mA, with a pulse width 0.1ms to verify the appropriate motor response of the quadriceps muscle. The catheter is slowly advanced 3 cm beyond the needle tip under continuous electric stimulation using a current that is subsequently adapted according to the motor response achieved. If muscles twitches disappear during catheter placement at a current above 1 mA, either the catheter or the needle are manipulated until muscle twitches reappear.
3347260|NCT02236702||Asymptomatic control|Asymptomatic control
3347261|NCT02236702||Mildly symptomatic with depressive symptoms|Mildly symptomatic with depressive symptoms
3240512|NCT01290198|Placebo Comparator|Vehicle without ANESDERM (lidocaine, prilocaine)|
3240513|NCT01290198|Active Comparator|Vehicle with ANESDERM (lidocaine, prilocaine)|
3240514|NCT01290198|Active Comparator|Fluconazole without ANESDERM (lidocaine, prilocaine)|
3347262|NCT02236702||Moderately symptomatic with depressive symptoms|Moderately symptomatic with depressive symptoms
3347263|NCT02236702||Severely symptomatic with depressive symptoms|Severely symptomatic with depressive symptoms
3347264|NCT02236715||Chronic Obstructive Airways Disease|
3347265|NCT02236728||Parkinson's disease patients|
3347266|NCT02236741||users of anti-parkinsonian drugs|
3347267|NCT02236754|Other|Healthy Controls|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in healthy controls: subjects with predicted normal BCM (healthy, normal weight, non-diabetic individuals who have stimulated insulin and c-peptide levels within the normal range).
3347268|NCT02236754|Other|Patients with T1D|Pancreatic 18F-FP-DTBZ uptake will be measured with PET scanning in patients with longstanding T1D: subjects with predicted reduced beta cell mass (subjects with established T1DM who have low or no measurable stimulated insulin and c-peptide levels).
3347269|NCT02236793|Experimental|BioChaperone PDGF-BB|BioChaperone PDGF-BB administered every other day at the dose of 4µg/cm² for 20 weeks or until wound closure, associated with Standard of Care
3347270|NCT02236793|Placebo Comparator|Standard of Care|Normal saline solution applied every other day at the same volume for up to 20 weeks, associated with standard wound care
3347271|NCT02236806|Experimental|Arm 1|bisoprolol plus ramipril
3347272|NCT02236806|Active Comparator|Arm 2|Bisoprolol plus placebo
3240515|NCT01290198|Active Comparator|Fluconazole with ANESDERM (lidocaine, prilocaine)|
3240516|NCT01290211|Experimental|Cohort 1|Twice daily regimen
3347273|NCT02236806|Active Comparator|Arm 3|Ramipril plus placebo
3240517|NCT01290211|Experimental|Cohort 2|Once daily regimen
3347274|NCT02236806|Placebo Comparator|Arm 4|Placebo
3347275|NCT02236832|Experimental|FTD (frontotemporal dementia) patients|fronto-temporal demential patients
3347276|NCT02236832|Experimental|PSP patients|progressive supra nuclear palsy patients
3347277|NCT02236832|Active Comparator|healthy controls|healthy control education matched, age matched and sex matched with PSP and FTD patients
3347278|NCT02236832|Experimental|healthy participants|healthy participants that will participate to the TMS study.
3347279|NCT02236832|Experimental|healthy young participants|Healthy participants will be included for an EEG study
3347280|NCT02236845|Experimental|Lacrima medical active device|
3347281|NCT02236845|Sham Comparator|Lacrima medical sham device|
3347282|NCT02236858|Sham Comparator|Sham HEPA Air Cleaner|Sham HEPA Air Cleaner and Delayed Intervention. Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
3347283|NCT02236858|Active Comparator|HEPA Air Cleaner|HEPA Air Cleaner also containing carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time. These air cleaners are suitably sized to provide clean air delivery rates for the rooms in which they will be placed. Participants will be instructed to run the air cleaners continually during the course of the study and the units will be modified to prevent them from being turned off by the participants.
3347284|NCT02236871|No Intervention|Control|Maintain current milk and milk product intakes.
3347285|NCT02236871|Active Comparator|2 servings|Participants will be asked to consume 1 milk (250 ml) plus a yogurt (100-175 g) or cheese (up to 50 g) to reach an average of 2 servings of milk or milk products/d.
3347286|NCT02236871|Active Comparator|4 servings|Participants will be asked to consume recommended servings of milk or milk products/d for their age, so they will receive 1 milk (250 ml), a yogurt (175 g) and cheese (50 g) or more. This would provide ≥ 3 servings/d.
3347287|NCT02236884|Experimental|no-scar transanal TME|no-scar transanal total mesorectal excision(TME) of rectal cancer
3347288|NCT02236897|Experimental|PET Scanning|Imaging of mGluR5 using PET scanning
3347289|NCT02236910|Experimental|Primary Therapy with Lu-DOTA-TATE|Lu-DOTA-TATE (Lutetium-177 Octreotate) will be administered by intravenous infusion to participants who have not been previously treated with Lu-DOTA-TATE
3347290|NCT02236910|Experimental|Secondary Therapy with Lu-DOTA-TATE|Patients who have received previous treatment with Lu-DOTA-TATE (Lutetium-177 Octreotate) under the special access program are eligible to be treated in this study. Patients will receive Lu-DOTA-TATE by intravenous infusion.
3347291|NCT02236923||Group A: Single procedure|Group A consists of patients recorded as having only had an ascending aortic dissection repair procedure.
3347292|NCT02236923||Group B: Multiple procedures|Group B consists of patients who had an ascending aortic dissection repair procedure together with any other surgical intervention.
3347293|NCT02236936|Active Comparator|Arm A - Standard of care|"Standard care of parenteral nutrition (with or without parenteral nutrition during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
3347294|NCT02236936|Experimental|Arm B - Parenteral over night nutrition|"Parenteral over night nutrition with ZentroOLIMEL 5.7% parenteral over night with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) 15 ml/kg body weight/day (weight loss >5% from baseline; parenteral nutrition increased up to 25 ml/kg body weight per day) during radio-chemotherapy or radio-immunotherapy in combination with Cetuximab or Cisplatin.~Concomitant radiotherapy and immunotherapy (radio-immunotherapy) with Cetuximab or concomitant radiotherapy and chemotherapy (radio-chemotherapy) with Cisplatin"
3347295|NCT02236949|Experimental|Pain Practice Change Booster|Pain Practice Change Booster Intervention: 12 months after the EPIQ intervention, and every 4 months for 2 years, a 30-60 minute standardized booster session was delivered to a small group of champions in each hospital unit randomized to the intervention group. Two co-facilitators familiar with the EPIQ intervention conducted all booster sessions via teleconference. Booster sessions included reviewing the effectiveness knowledge translation strategies champions implemented over the past four months to sustain and improve targeted pain practices; determining the sustainability of the pain practice changes, developing a commitment to change plan of action for the next four months.
3347296|NCT02236949|No Intervention|Usual Care Group|No interventions associated with the study were conducted on these units.
3347297|NCT02236962|Placebo Comparator|Placebo|lactose powder in equivalent capsule
3347298|NCT02236962|Experimental|Drug treatment|sympathetic agonist and thiazolidinedione
3347299|NCT02236975|Experimental|BuMA Supreme Biodegradable drug coating coronary stent system|Implant BuMA Supreme stent only
3347300|NCT02236975|Active Comparator|Resolute Integrity durable polymer stent system|Implant Resolute stent
3240518|NCT01290250|Experimental|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
3240519|NCT01290250|Placebo Comparator|Orange juice with low levels of polyphenols|2 daily doses (250 ml each) during 3 months
3240520|NCT01290276|Experimental|Ond-PR1 followed by (Ond-PR1 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
3240521|NCT01290276|Experimental|Ond-PR2 followed by (Ond-PR2 + MPh-IR)|Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 followed by Oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
3347301|NCT02237027|Experimental|TasP group|HIV positive female sex workers receiving TasP using ART regimen as per Benin guidelines
3347302|NCT02237027|Experimental|PrEP group|HIV negative female sex workers receiving PrEP using Truvada
3347303|NCT02237040|Experimental|treatment group|Patients are treated with the mandibular manipulation technique termly and mouth opening training
3347304|NCT02237053|Active Comparator|Glucagon with Octreotide and insulin|Overnight (10 hours) infusion of glucagon, then 3 hours infusion of glucagon with concurrent infusions of Octreotide and insulin.
3347305|NCT02237053|Placebo Comparator|Placebo, Glucagon with Octreotide and Insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of glucagon with concurrent infusions of Octreotide and insulin.
3347306|NCT02237053|Placebo Comparator|Placebo, with Octreotide and insulin|Overnight (10 hours) infusion of saline, then 3 hour infusion of saline with concurrent infusions of Octreotide and insulin.
3347307|NCT02237066|Experimental|Chocolate PTA Balloon|Chocolate PTA Balloon Angioplasty
3347308|NCT02237066|Active Comparator|Standard PTA Balloon|Standard PTA Balloon Angioplasty
3240522|NCT01290289|Active Comparator|Epidura, combined spinal epidura & IV|"Gp 1: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.5% lidocaine injected epidurally.~Gp 2: received CSE analgesia, 25µg of fentanyl injected intrathecally & a bolus of 10 ml of 0.0625% bupivacaine injected epidurally.~Gp 3: received 50µg of E fentanyl analgesia, injected intrathecally & a bolus of 10 ml of 0.5% lidocaine, followed by lidocaine E top-ups.~Gp 4: received 50µg of E fentanyl injected intrathecally and a bolus dose of 10 ml of 0.125% bupivacaine, followed by E bupivacaine top-ups.~Gp 5: 50mg of IV pethidine was administered as a loading dose, followed by 0.5 mg/kg."
3240523|NCT01290302|Experimental|Luitpold Azacitidine|
3240524|NCT01290302|Active Comparator|Vidaza®|
3240525|NCT01290328|No Intervention|Standard of care|
3240526|NCT01290328|Experimental|Epoetin alfa|150 units/kg/week
3375905|NCT03555149|Experimental|Atezolizumab + LOAd703|Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.
3375906|NCT03543813|Experimental|CX-2029 Escalation|Dose Escalation and Determination
3375907|NCT03543813|Experimental|CX-2029 Biomarker|Characterization of CX-2029 in the tumor microenvironment in subjects with select tumor types
3375908|NCT03543813|Experimental|CX-2029 Expansion|Evaluate antitumor activity of CX-2029
3347309|NCT02237079|Experimental|Bazedoxifene/Conjugated Estrogens (BZA/CE)|"Participants assigned to BZA/CE will receive a daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg. BZA/CE (bazedoxifene/conjugated estrogens) tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. The recommended and only FDA approved dosage is one BZA/CE tablet daily, taken without regard to meals. Tablets should be swallowed whole. If a dose of BZA/CE is missed, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications."
3347310|NCT02237079|Placebo Comparator|Placebo|"Participants assigned to placebo will receive a daily tablet that matches the BZA/CE to maintain the blind. Placebo tablets, 0.45 mg/20 mg are oval, biconvex, pink tablets, branded with 0.45/20 in black ink on one side. Also to assure the blind is maintain, participants in the placebo group will be given the same instructions for taking the study medication.Tablets should be swallowed whole. If a dose, participants will be instructed to take it as soon as remembered unless it is almost time for the next scheduled dose. They should not take two doses at the same time. The dose is one tablet per day independent of weight and fat mass. Participants will be provided with information about BZA/CE and its potential side effects and contraindications, again to maintain the blind."
3347311|NCT02237105|Experimental|Cognitive Behavioral Therapy Group|This group will undergo Cognitive Behavioral Therapy (CBT) before having spinal surgery
3347312|NCT02237105|No Intervention|control group|This group will not undergo any psychological intervention before the spinal surgery.
3347313|NCT02237131|Experimental|Oral contraceptives cyclic|Oral contraceptives containing 0.03 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for 21 days followed by 7 days pill free. The regimen will be repeated for the duration of the trial.
3240527|NCT01290354|Experimental|lapatinib|unlabelled, administered orally
3240528|NCT01290367|Experimental|High Dose MPCs|Injection of High Dose MPCs with Hyaluronic Acid
3240529|NCT01290367|Experimental|Low Dose MPCs|Injection of Low Dose MPCs with Hyaluronic Acid
3240530|NCT01290367|Sham Comparator|Saline injection|Injection of saline solution.
3240531|NCT01290367|Placebo Comparator|Hyaluronic acid injection|Injection of hyaluronic acid solution
3240532|NCT01290380|Experimental|ASA 404 + standard chemotherapy|ASA 404 in combination with in combination with standard chemotherapy (paclitaxel + carboplatin or docetaxel) and a cocktail of caffeine, diclofenac, simvastatin and omeprazole
3347314|NCT02237131|Active Comparator|Oral contraceptives continuous|Oral contraceptives containing 0.030 mg ethinyl estradiol and 3mg drospirenone will be administered. One tablet a day for the duration of the trial.
3347315|NCT02237144|Experimental|Cash transfer|1500 taka ($18.75) per household distributed monthly
3347316|NCT02237144|Experimental|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
3347317|NCT02237144|Experimental|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
3347318|NCT02237144|Experimental|Cash transfer + BCC|1500 taka ($18.75) per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
3347319|NCT02237144|Experimental|Food transfer + BCC|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
3347320|NCT02237170||Castration Resistant Metastatic Prostate Cancer|Castration Resistant Metastatic Prostate Cancer with no history of prior systemic chemotherapy
3240533|NCT01290393||Exposed vaccinated cohort|Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.
3347321|NCT02237183|Experimental|Arm I (iloprost QID)|Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
3347322|NCT02237183|Placebo Comparator|Arm II (placebo QID)|Patients receive placebo via inhalation using a nebulizer QID for 60 days.
3347323|NCT02237183|Experimental|Arm III (iloprost BID)|Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
3347324|NCT02237183|Placebo Comparator|Arm IV (placebo BID)|Patients receive placebo via inhalation using a nebulizer BID for 60 days.
3240534|NCT01290393||Non-exposed vaccinated cohort|Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.
3240535|NCT01290406|Experimental|BEZ235|
3347325|NCT02237209|Experimental|RSV LID ΔM2-2 Vaccine|Participants will receive one dose of the RSV LID ΔM2-2 vaccine at study entry, delivered as nose drops.
3347326|NCT02237209|Placebo Comparator|Placebo Vaccine|Participants will receive one dose of placebo at study entry, delivered as nose drops.
3347327|NCT02237222||Gait rehabilitation|"Multi-modal therapy program including physiotherapy with the aim of gait improvement, Lokomat or treadmill training, strength training, sports therapy.~Frequency and intensity are individually assigned."
3347328|NCT02237235|Experimental|MMFS-202 -302|"MMFS-202: evening dose~MMFS-302: morning dose"
3347329|NCT02237235|Placebo Comparator|Placebo|Placebo
3375909|NCT03542773|Experimental|18F-DCFPyL|A bolus of less than or equal to 9 mCi (331 MBq) of IV injection of 18F-DCFPyL
3240536|NCT01290419|Experimental|A: Dose 1 + adjuvant|
3240537|NCT01290419|Experimental|B: Dose 2 + adjuvant|
3240538|NCT01290419|Experimental|C: Dose 3 + adjuvant|
3240539|NCT01290419|Experimental|D: Dose 3 alone|
3240540|NCT01290419|Placebo Comparator|E: Placebo control|
3240541|NCT01290419|Experimental|F: Dose 4 alone|
3240542|NCT01290419|Experimental|G: Dose 4 +adjuvant|
3240543|NCT01290432|Experimental|Inofolic Plus|Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
3240544|NCT01290458|Experimental|Vitamin|
3240545|NCT01290458|Placebo Comparator|Control|
3347330|NCT02237261|Experimental|Bendamustine, Bortezomib, Prednisone|Induction: Bortezomib: 1.3 mg/m2 subcutaneous for 7 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison: : 60 mg/m2 per os for 4 days Consolidation: Bortezomib: 1.3 mg/m2 subcutaneous for 4 days and Bendamustine: 90 mg/m2 intravenous for 2 days and in addition Prednison 60 mg/m2 per os for 4 days
3347331|NCT02237274|Experimental|Patients with Fontan circulation|High altitude exposition
3347332|NCT02237274|Other|Age and gender-matched healthy volunteers|High altitude exposition
3240546|NCT01290471|Experimental|Part 1 Dose Escalation|Dose escalation of U3 1565 will follow a modified 3+3 study design with a starting intravenous (IV) dose of 2 mg/kg. A maximum of 2 new subjects will receive their first dose of U3-1565 per 24-hour period during the dose-escalation phase. Subsequent escalating doses of 8, 16, and 24 mg/kg are planned. Three to 6 subjects will be enrolled in 4 sequential dose level cohorts.
3240547|NCT01290471|Experimental|Part 2a Dose Expansion|For Part 2a, 6 or 12 subjects with advanced solid malignant tumors will be enrolled and treated at the MTD or MAD to further define the safety and tolerability of U3-1565. These additional subjects are expected to permit the detection of relatively rare toxicities that would not likely be observed during the dose escalation part of the study, whose 3+3 design implies a maximum of 6 subjects only will be treated at the MTD or MAD. Six subjects will be treated; however, if toxicities meeting the definition of DLT are observed during the first cycle of treatment, 6 more subjects will be treated for a total of 12 subjects.
3347333|NCT02237287|Sham Comparator|wound dressing with VAC|After wound debridement wounds are treated for 2 weeks with VAC dressing alone
3347334|NCT02237287|Other|wound dressing with VAC and sNAG under Antiaggregation|In patients being under antiaggregation with Aspirin® 100mg daily, after wound debridement wounds are treated with VAC and sNAG
3347335|NCT02237287|Experimental|wound dressing with VAC and sNAG without antiaggregation|In patients NOT being under antiaggregation, after wound debridement wounds are treated with VAC and sNAG
3347336|NCT02237300|Experimental|VR based cue-exposure therapy|Throughout the six sessions, participants (n=30) will be exposed to different VR environments related to binge behavior, according to a previously constructed hierarchy. During exposure, patients will face high risk situations to diminish or to extinguish the conditioned response of anxiety when exposed to food related cues. In each session, the patient will be exposed to the corresponding step of the hierarchy. During the exposure session, the patient can handle the virtual foods using the laptop's mouse but cannot eat the foods (exposure with response prevention). Exposure will end when the anxiety level decreased by 40% in relation to the level registered at the initiation of the exposure session or after 60 minutes of exposure.
3347337|NCT02237300|Active Comparator|Additional Cognitive-behavioral treatment|Participants (n=30) in this condition will receive six CBT booster sessions (two sessions per week) over the course of three weeks to improve the output of treatment. CBT sessions are based on the approach described by by Eldredge and colleagues (Eldredge et al.,1997). In this treatment program, patients are trained to self-monitor their food patterns and to identify and manage thoughts, emotions, and environmental factors related to disrupted eating behaviors.
3347338|NCT02237313|Experimental|prevalent cases|"40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease.~8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program"
3347339|NCT02237326|Active Comparator|Visual Inspection with Lugol's Iodine|Participants underwent colposcopic exam, followed by Visual Inspection with Lugol's Iodine (VILI) by a second, blinded clinician (the order of exams was reversed to eliminate potential interference with exam results due to iodine staining). Biopsy was done after the VILI.
3347340|NCT02237326|Active Comparator|Visual Inspection with Acetic Acid|Participants underwent Visual Inspection with Acetic Acid followed by colposcopy by a second clinician who was blinded to the screening test result.
3347341|NCT02237339|Active Comparator|Allopurinol|Patients treated with Allopurinol 300mg daily for first month then 300mg twice daily for remainder trial.
3347342|NCT02237339|Placebo Comparator|Placebo tablet|Microcrystalline cellulose one tablet daily for first month then twice daily for remainder of trial.
3347343|NCT02237352||Control|Subjects without diabetic nephropathy
3347344|NCT02237352||Diabetic nephropathy|Subjects with diabetic nephropathy
3347345|NCT02237365|Experimental|81mg aspirin|Aspirin 81mg daily for 60 days
3347346|NCT02237365|Experimental|1000mg aspirin|Aspirin 1000mg daily for 60 days
3347347|NCT02237365|Placebo Comparator|Placebo|Visually matched placebo daily for 60 days
3347348|NCT02237378|Experimental|FDG PET scan|A PET scan using F-18 FDG, N-13 Ammonia will be performed
3347349|NCT02237391|Experimental|CIPAP Program|Complex Interdisciplinary Pain Assessment Program
3347350|NCT02237391|Other|Treatment as Usual (TAU)|Treatment as usual control group
3347351|NCT02237404|No Intervention|Hospital monitoring of pacemakers|Patients have to go to the hospital to be monitorized
3347352|NCT02237404|Experimental|Remote monitoring of pacemakers|"Telemedicine System:~Patients have not to go to the hospital to be monitorized"
3347353|NCT02237430|Active Comparator|Manuel compression|Conventional manual compression
3347354|NCT02237430|Experimental|MynxGrip closure device|Closure device for femoral artery access closure
3347355|NCT02237443|Other|Post-induction|Anesthesia is induced with propofol and mask ventilation is commenced after patient is unresponsive to a jaw thrust prior to administration of rocuronium, vecuronium bromide, or succinylcholine
3347356|NCT02237469||Prone and supine simulation|Women with breast cancer receiving simulation in prone and in supine position for adjuvant radiation treatment.
3347357|NCT02237482|Experimental|Small periacetabular bone defects|Patients with cup loosening and small periacetabular bone defects
3347358|NCT02237482|Experimental|Large periacetabular bone defects|Patients with cup loosening and large periacetabular bone defects
3347359|NCT02237495|Placebo Comparator|Saline|Normal saline as placebo is continuously infused right after anesthesia induction and lasts for 12 hrs with the same infusion rate as the comparator dexmedetomidine
3347360|NCT02237495|Experimental|dexmedetomidine|dexmedetomidine intravenous infusion starts right after anesthesia induction in the operating room and last for 12 hours into ICU with a infusion dose of 0.4 ug/kg/h. To avoid potential cause of bradycardia, no dexmedetomidine bolus is given.
3347361|NCT02237508|Experimental|Z7200|single dose (two inhalations)
3347362|NCT02237508|Active Comparator|Symbicort Turbohaler|single dose (two inhalations)
3347363|NCT02237508|Experimental|Z7200 with charcoal|single dose (two inhalations)
3347364|NCT02237508|Active Comparator|Symbicort Turbohaler with charcoal|single dose (two inhalations)
3347365|NCT02237508|Active Comparator|Symbicort Turbohaler replicate|single dose (two inhalations)
3347366|NCT02237521||End-stage renal disease|Patients with normal glucose tolerance and end-stage renal disease
3347367|NCT02237521||Controls|Healthy controls with normal kidney function and normal glucose tolerance
3347368|NCT02237534|Active Comparator|Calcium carbonate|Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.
3347369|NCT02237534|Experimental|Lanthanum carbonate|Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.
3347370|NCT02237547|Experimental|IV and IT UC-MSC and BMMC|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
3347371|NCT02237560|Experimental|Cybercycle-Game|Combined aerobic & cognitive exercise for 6 months, 3-5x/week.
3347372|NCT02237560|Active Comparator|Cybercyle-Tour|Aerobic exercise only for 6 months, 3-5x/week.
3347373|NCT02237560|Active Comparator|Game Only|Cognitive exercise only 6 months, 3-5x/week.
3347374|NCT02237573|Experimental|Intervention|Written medical report and standardized medical advices
3347375|NCT02237573|Active Comparator|Control|Standardized medical advice only
3347376|NCT02237586|Experimental|Group IA|"Adults with naturally acquired immunity and HbAA (Group IA, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3347377|NCT02237586|Experimental|Group IS|"Adults with naturally acquired immunity and HbAS (Group IS, n=10)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge will be administered once intravenously. If 50% or less of volunteers become parasitemic in Groups IA or IS, 10 additional volunteers will be enrolled and challenged with 12,800 PfSPZ. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3347378|NCT02237586|Experimental|Group NI|"Adults without previous exposure to malaria and HbAA (Group NI, n=5)~As any parasitemia other than PfSPZ will interfere with results, volunteers will undergo a treatment course against P. falciparum with a five-day course of 12-hourly 5 mg/kg clindamycin (corresponds to a 300 mg tablet of clindamycin base administered twice daily). This will be completed no less than three days prior to CHMI. The initial challenge dose of 3,200 PfSPZ Challenge administered once intravenously should lead to consistent infection in naïve adults (15/15 in prior studies) and thus should infect all volunteers in Group NI. Effective treatment will be initiated immediately upon development of parasitemia together with the presence of symptoms associated with malaria."
3347379|NCT02237612|Experimental|Diagnostic (diffusion-weighted MRI)|Patients undergo diffusion-weighted MRI of the pelvis.
3347380|NCT02237625||Medical History of HPP Patients|Patient clinical data will be collected related to the diagnosis, onset, progression, treatment course and outcome for patients with HPP.
3347381|NCT02237638|Experimental|hVEGF26-104/RFASE vaccination|hVEGF26-104/RFASE is investigated in dose escalation in which hVEGF26-104 is escalated from 62.5 ug to 500 ug and RFASE is given in a fixed dose of 20 mg. Three patients are treated at each dose level. If 0 of the 3 patients are observed to have DLT, the dose level is escalated one step for the next cohort. If 1 of the 3 patients shows DLT, 3 additional patients are treated at that dose level. If none of these show DLT, the dose level is escalated for the next cohort; otherwise, the prior dose level is defined as the MTD. At the highest dose level 6 patients will be treated. The recommended dose for a phase II trial will be the lowest dose that results in the most effective VEGF neutralization, together with acceptable safety and toxicity.
3240548|NCT01290471|Experimental|Part 2b Dose Expansion and Anti-tumor Impact|For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
3240549|NCT01290497|Active Comparator|Hyaluronic acid 5 x 2.5 ml|
3240550|NCT01290497|Experimental|Hyaluronic acid 1 X 5 ml|
3240551|NCT01290497|Experimental|Hyaluronic acid 2 x 5 ml|
3240552|NCT01290510|Experimental|hyaluronic acid sodium salt|
3347382|NCT02237651||topical anesthesia multi-use device|anesthesia with multi-use device (Laryngeal atomizer, Karl Storz, Tuttlingen, Germany
3347383|NCT02237651||topical anesthesia Intranasal Mucosal Atomization|single-use product (LMA® MAD Nasal™ Intranasal Mucosal Atomization Device, Teleflex medical, Kernen Germany) for topical anesthesia
3347384|NCT02237664|Active Comparator|Patient-controlled paravertebral analgesia (PC-PVB)|Patient-controlled paravertebral analgesia
3347385|NCT02237664|Placebo Comparator|Continuous paravertebral analgesia (C-PVB)|Continuous paravertebral analgesia
3347386|NCT02237677||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
3347387|NCT02237677||Healthy Controls (HC)|Healthy Controls (HC)
3347388|NCT02237690|Experimental|doxorubicin hydrochloride liposome（Libaoduo）|Use the test drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang ),then use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma) after at least 4-weeks.
3347389|NCT02237690|Active Comparator|doxorubicin hydrochloride liposome|Use the reference drug(doxorubicin hydrochloride liposome，from Sunpharma),then use the test drug drug(doxorubicin hydrochloride liposome-Libaoduo,from Fudan-Zhangjiang) after at least 4-weeks.
3347390|NCT02237703||Post-traumatic stress disorder (PTSD)|Post-traumatic stress disorder (PTSD)
3347391|NCT02237703||Trauma Control (TC)|Trauma Control (TC)
3347392|NCT02237703||Healthy Control (HC)|Healthy Control (HC)
3347393|NCT02237729|Experimental|PF-06410293|
3240553|NCT01290549|Experimental|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by an IV infusion of escalating doses (starting dose of 0.1 mg/kg, potentially to be followed by 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, and 4.0 mg/kg doses) every 3 weeks (q3w) (Day 1 of each 21 day cycle).
3240554|NCT01290549|Experimental|Polatuzumab Vedotin + Rituximab|Polatuzumab vedotin will be administered by an IV infusion q3w (Day 1 of each 21 day cycle). Rituximab was administered by an IV infusion at 375 milligrams per square meter (mg/m^2) body surface area dose q3w.
3347394|NCT02237729|Active Comparator|Adalimumab-US|
3347395|NCT02237729|Active Comparator|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
3347396|NCT02237742|Experimental|PF-06427878|
3347397|NCT02237755|Active Comparator|Clomiphene citrate|Administration of Clomiphene citrate in combination with gonadotropins according to a short stimulation GnRH antagonists protocol.
3240555|NCT01290562|Experimental|Stereotactic Body Radiotherapy (SBRT)|Cohort 1: Patients with spinal metastases and no prior radiation Cohort 2: Patients with spinal metastases in a previously radiated field Cohort 3: Post-operative patients with spinal metastases
3240556|NCT01290575|Active Comparator|Arm 1 BMS-820132 or placebo|
3347398|NCT02237755|Active Comparator|Gonadotropins|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists.
3347399|NCT02237768|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3347400|NCT02237768|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3347401|NCT02237781|Experimental|AMH levels|Patients in this group will be stimulated according to a short stimulation protocol with gonadotropins and GnRH antagonists. Levels of AMH will be measured prior and during the ovarian stimulation.
3347402|NCT02237794||Patients Without Acute Heart Conditions|Patients without acute heart conditions who were hospitalized for other medical indications.
3347403|NCT02237807|Experimental|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey one tablet, once
3347404|NCT02237807|Experimental|DYNABAC 250 MG ENTERIC COATED TABLET|DYNABAC 250 MG ENTERIC COATED TABLET of Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey, two tablets, once
3347405|NCT02237820|Experimental|Dexamethasone|
3347406|NCT02237820|Active Comparator|Prednisone|
3347407|NCT02237833||Septic shock and vasopressor|Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.
3347408|NCT02237846|Active Comparator|Intra-articular knee injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered into the knee joint once
3347409|NCT02237846|Active Comparator|IV injection of UC-MSC|Human umbilical cord tissue-derived mesenchymal stem cells administered once per day for 3 consecutive days
3347410|NCT02237859|Experimental|Vancomycin|Vancomycin 125 mg PO QD vs Placebo
3347411|NCT02237885|Experimental|Neurofeedback|
3347412|NCT02237924|Experimental|endostar + IMRT|
3347413|NCT02237924|Active Comparator|DDP + IMRT|
3347414|NCT02237937|Experimental|Normal dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 40 mg/d~sertraline < 100 mg/d~citalopram < 40 mg/d~escitalopram < 20 mg/d~venlafaxine < 225 mg/d~amitriptyline < 150 mg/d~amitriptylinoxide < 150 mg/d~nortriptyline < 150 mg/d~trimipramine < 150 mg/d"
3347415|NCT02237937|Experimental|High dosage|"Selected antidepressants that are substrates of the P-glycoprotein:~Dosage:~paroxetine < 80 mg/d~sertraline < 200 mg/d~citalopram < 80 mg/d~escitalopram < 40 mg/d~venlafaxine < 450 mg/d~amitriptyline < 300 mg/d~amitriptylinoxide < 300 mg/d~nortriptyline < 300 mg/d~trimipramine < 300 mg/d"
3347416|NCT02237963||Posterolateral thoracotomy|Surgeons perform a posterolateral thoracotomy
3347417|NCT02237963||Axillary thoracotomy|Surgeons perform an axillary thoracotomy
3347418|NCT02237976|Experimental|Self-hypnosis|Patients are trained to practice self-hypnosis wen they are listed for lung transplantation. They are encourage to practice it before and after transplantation.
3240557|NCT01290575|Active Comparator|Arm 2 BMS-820132 or placebo|
3240558|NCT01290575|Active Comparator|Arm 3 BMS-820132 or placebo|
3240559|NCT01290575|Active Comparator|Arm 4 BMS-820132 or placebo|
3240560|NCT01290575|Active Comparator|Arm 5 BMS-820132 or placebo|
3347419|NCT02237976|Active Comparator|Routine practice|No specific intervention
3347420|NCT02238002||normal angle|normal anterior chamber and open angle eyes underwent cataract surgery
3347421|NCT02238002||narrow angle|shallow anterior chamber and narrow angle eyes underwent cataract surgery
3347422|NCT02238015||surgery group|patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
3347423|NCT02238015||control group|patients' other eye that did not have surgery
3347424|NCT02238041||GlucoClear System|
3347425|NCT02238054||ABSORB BVS|All patients with a coronary angioplasty procedure and the implantation of at least one ABSORB BVS
3347426|NCT02238093||Dialysis Patients|End-stage renal disease patients undergoing dialysis at the Hillel Yaffe Medical Center.
3347427|NCT02238106|Experimental|Salmeterol inhalation powder, medium dose|administered via HandiHaler®
3347428|NCT02238106|Active Comparator|Salmeterol inhalation powder, low dose|administered via HandiHaler®
3240561|NCT01290575|Active Comparator|Arm 6 BMS-820132 or placebo|
3347429|NCT02238106|Active Comparator|Salmeterol inhalation powder, high dose|administered via HandiHaler®
3347430|NCT02238106|Active Comparator|Serevent® Diskus®|administered via Diskus®
3240562|NCT01290575|Active Comparator|Arm 7 BMS-820132 or placebo|
3240563|NCT01290575|Active Comparator|Arm 8 BMS-820132 or placebo|
3240564|NCT01290575|Active Comparator|Arm 9 BMS-820132 or placebo|
3347431|NCT02238106|Placebo Comparator|Placebo|administered via Diskus® or HandiHaler®
3347432|NCT02238119|Experimental|tiotropium + formoterol|
3240565|NCT01290588||Children of Caucasian descent|Healthy children of Caucasian descent.
3347433|NCT02238119|Active Comparator|tiotropium|
3347434|NCT02238119|Active Comparator|formoterol|
3347435|NCT02238132||Chronic Obstructive Airways Disease|
3347436|NCT02238145||Chronic Obstructive Airways Disease|
3347437|NCT02238158||Chronic Obstructive Pulmonary Disease|
3347438|NCT02238171||Chronic Obstructive Pulmonary Disease|
3347439|NCT02238184||Chronic Obstructive Pulmonary Disease|patients receiving Atrovent®
3347440|NCT02238184||Cronic Obstructive Pulmonary Disease|patients receiving Ventilat®
3240566|NCT01290588||Adults of Caucasian descent|Healthy adult eyes of Caucasian descent.
3240567|NCT01290588||Children of African-American descent|Healthy children of African-American descent.
3347441|NCT02238197||Chronic Obstructive Pulmonary Disease|
3347442|NCT02238210|Experimental|Atrovent® - common cold group|Treatment duration for common cold group - three time daily for 4 days
3347443|NCT02238210|Experimental|Experimental: Atrovent® - allergy group|Treatment duration for allergy group - three time daily for 14 days
3347444|NCT02238223||Patients without experience in treatment with epinastine|
3347445|NCT02238236||Patients with allergic rhinitis, eczema/dermatitis, urticaria|
3347446|NCT02238249||paediatric patients with urticaria|
3347447|NCT02238262||essential hypertension patients|
3240568|NCT01290588||Adults of African-American descent|Healthy adults of African-American descent.
3240569|NCT01290653|Experimental|Dry Needling of trigger point|Deep dry needling will be applied on the upper trapezius myofascial trigger point
3347448|NCT02238275||Patients with hypertension|
3347449|NCT02238288|Active Comparator|aminocaproic acid|Crushed tablets inserted in the dental socket post-extraction
3347450|NCT02238288|Other|Routine care after dental extraction|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
3347451|NCT02238301|Other|"Patients test (pregnant women with a eutrophic fetus)"|Test the type of mask, oxygen flow and duration of oxygenation, adjustment of MRI machine Adjustment of MRI machine (choice of antenna calibration, verifying Settings of each sequence, adaptation of the number of cuts for the duration of each sequence, checking the correct execution of the succession of sequences, settings of total examination time)
3240570|NCT01290653|Experimental|Strain-counterstraing technique|This manual technique will be applied at the upper trapezius.
3240571|NCT01290653|Placebo Comparator|Placebo manual technique|A technique simulating strain-counterstrain, but without any therapeutic manoeuvre will be applied at the upper trapezius site.
3240572|NCT01290692|Experimental|TVI-Brain-1|All patients will receive the full TVI-Brain-1 treatment.
3240573|NCT01290705|Experimental|high exercise|High dose, high repetition exercise therapy, 3 times weekly in 12 weeks
3240574|NCT01290705|Experimental|low exercise|low dose, low repetition exercise therapy, 3 times weekly in 12 weeks
3240575|NCT01290744|Placebo Comparator|Placebo group|These patients will receive placebo for 12 months after completion of MDT.
3240576|NCT01290744|Experimental|Clofazimine for 12 months after MDT|Patients will be given clofazimine (100mg daily) for 12 months after completion of MDT.
3347452|NCT02238301|Active Comparator|Pregnant women with a diagnosis of IUGR fetuses|Measure of the BOLD effect in the feto-placental units of IUGR fetuses
3347453|NCT02238301|Active Comparator|Pregnant women with eutrophic fetuses|Measure of BOLD effects of fetal-placental unit eutrophic fetuses
3347454|NCT02238314|Experimental|Tipranavir low dose|
3347455|NCT02238314|Experimental|Tipranavir high dose|
3347456|NCT02238327||HIV positive normal pulmonary function|HIV positive DLCO percent predicted >=.80 FEV1/FVC percent predicted >=0.70
3347457|NCT02238327||HIV positive with pulmonary dysfuntion|HIV positive DLco percent predicted <=0.80% FEV1/FVC percent predicted<=0.70%
3347458|NCT02238340|Experimental|Extended-release oxycodone 10mgr|Extended-release oxycodone 10 mgrs , started 12 hours before orthopaedic surgery
3347459|NCT02238340|Experimental|Extended-release oxycodone 20 mgr|Extended-release oxycodone 20 mgr , started 12 hours before orthopaedic surgery
3347460|NCT02238353|Experimental|azelastine + fluticasone|azelastine 137 µg + fluticasone 50 µg combined applied twice daily one puff in each nostril duration: 4 weeks
3347461|NCT02238353|Placebo Comparator|placebo|twice daily one puff in each nostril duration: 4 weeks
3347462|NCT02238366||Prostate cancer patients|Patients recently diagnosed with prostate cancer requiring ADT.
3347463|NCT02238392|Active Comparator|Group A|Adenosine testing after PVI and elimination of dormant conduction
3347464|NCT02238392|Active Comparator|Group B - Termination of AF|Termination of atrial fibrillation by catheter ablation
3347465|NCT02238405|Experimental|Counseling|Intensive anti-smoking counseling
3347466|NCT02238405|No Intervention|Standard Care|Control group will receive current standard of care.
3347467|NCT02238418|Experimental|Usual vitamin D supplementation|
3347468|NCT02238431|Experimental|Lucrin depot, artificial cycle start|intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval
3347469|NCT02238431|Active Comparator|OCP active, artificial cycle start|to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days
3347470|NCT02238431|Experimental|Natural, menstrual period|to wait for the second bleed to commence the artificial FET cycle
3375910|NCT03538041|Experimental|Cohort 1|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period, with a dose-increase option at Week 6 for participants who fulfill dose increase criteria.
3240577|NCT01290770||obese men|obese men with chest pain like angina
3240578|NCT01290783|Active Comparator|FOLFIRI|
3240579|NCT01290783|Experimental|FOLF(HA)iri|
3240580|NCT01290809||Prophylactic Cranial Irradiation|NSCLC patients treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
3240581|NCT01290809||no Prophylactic Cranial Irradiation|NSCLC patients not treated with whole brain PCI: cognitive functioning as assessed by neuropsychological tests?
3347471|NCT02238444|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
3347472|NCT02238444|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
3240582|NCT01290835|Experimental|Stereotactic radiotherapy|Accelerated stereotactic radiotherapy as an adjuvant treatment for early stage breast cancer.
3240583|NCT01290848|Experimental|Township of Uxbridge|The Take TIME for Your Child's Health campaign will target parents and caregivers of children up to 8 years of age.
3240584|NCT01290848|No Intervention|Township of Guelph/Ermosa|For a control group the investigators have selected a community that is similar in size, household composition, population density, distance from Toronto and economic status to the Township of Uxbridge.
3347473|NCT02238457|Active Comparator|Low dose losartan|Low dose losartan
3347474|NCT02238457|Active Comparator|High dose losartan|High dose losartan
3347475|NCT02238470||Oral anticoagulants|Patients who will receive oral anticoagulants indefinitely for the secondary prevention of cardioembolic stroke
3347476|NCT02238496|Other|Surgical Cohort - cytoreductive surgery|Cytoreductive surgery planned (surgical cohort). After post-operative standard evaluations, patients will resume therapy. After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose after recovery from surgery. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
3347477|NCT02238496|Other|Medical Cohort - no cytoreductive surgery|No-Cytoreductive surgery planned (medical cohort). After anti-emetic prophylaxis, patients will receive the first divided dose of the perifosine loading dose. Patients will be observed for at least 30 minutes to ensure there has been adequate anti-emetic prophylaxis, and then patients will receive temsirolimus administered over 30-60 minutes IV. The remaining divided doses of the perifosine loading dose will then be administered. Patients will then return weekly for infusion of temsirolimus over 30-60 minutes IV. Dosing will be continuous although for the purposes of evaluation, a cycle will be defined as 4 weeks (28 days).
3347478|NCT02238509|Experimental|lapatinib and trastuzumab|ARM A: Lapatinib and trastuzumab (experimental arm). Patients with hormone receptor (HR) positive breast cancer will also receive endocrine therapy at the physician's discretion (preferred choice with fulvestrant).
3347479|NCT02238509|Experimental|trastuzumab plus chemotherapy|ARM B: Trastuzumab plus chemotherapy (control arm). Any type of chemotherapy in combination with trastuzumab will be allowed at the physician's discretion.
3347480|NCT02238522|Experimental|Dose Escalation Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
3347481|NCT02238522|Experimental|Dose Expansion Stage - ZEN003365|ZEN003365 will be administered orally as a single agent, enrolling LPM patients and AML patients
3347482|NCT02238535|Active Comparator|Ventavis + Warfarin|Patients in this group will receive drug treatment - ventavis (2,0 ml - 6 time per day - during 5 days). Warfarin - INR=2,0-3,0
3347483|NCT02238535|Active Comparator|Warfarin|Patients in this group will receive drug treatment according to up-to-date guidelines (Warfarin - INR=2,0-3,0)
3347484|NCT02238548|Placebo Comparator|Control group|Regular cholera vaccination
3347485|NCT02238548|Experimental|Milk bolus|Cholera vaccination - raw milk - bolus
3347486|NCT02238548|Experimental|Milk controlled|Cholera vaccination - raw milk - controlled intake
3347487|NCT02238561||Elective major abdominal surgery|Patients undergoing elective major open or laparoscopic abdominal surgery at Plymouth Hospitals National Health Service (NHS) Trust (PHNT)
3347488|NCT02238574|Experimental|follow up & surgery|CIN positive with surgery and intensified follow up
3347489|NCT02238574|Active Comparator|follow up|CIN positive, only intensified outpatient follow up
3347490|NCT02238587|Placebo Comparator|Placebo/Ganoderma|In control group, oral placebos for 6 weeks. Then the patients in control groups are switched, Ganoderma Spores Powder Capsules are given for 6 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
3375911|NCT03538041|Experimental|Cohort 2|Parsaclisib at the protocol-defined dose for 12 weeks followed by extension period.
3240585|NCT01290861||pre-manifest HD|
3240586|NCT01290861||early manifest HD|
3240587|NCT01290861||healthy controls|
3240588|NCT01290900|Experimental|CXL104|2000 mg NXL104 + 1500 mg Ceftaroline (IV)
3240589|NCT01290900|Experimental|CAZ104|Placebo Infusion (saline) + 2000 mg NXL104 + 3000 mg Ceftazidime (IV)
3240590|NCT01290900|Active Comparator|Moxifloxacin|Moxifloxacin 400mg (1 tablet)
3240591|NCT01290900|Placebo Comparator|Placebo|Placebo Infusion (saline)
3240592|NCT01290926|Experimental|Capecitabine & Sorafenib|Sorafenib 200mg in the morning,400mg in the evening; escalation to 400mg twice daily after 1 cycle, Oral, Continuous dosing Capecitabine 850mg/m2 twice daily, Oral Days 1-14, weeks 1-2
3347491|NCT02238587|Experimental|Ganoderma|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks. The data pertaining to their life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
3347492|NCT02238613|Experimental|radioactive stent|The radioactive stent carrying seeds iodine 125 is made of Polytetrafluoroethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the irradiation group patients.
3347493|NCT02238613|Other|plastic stent|The plastic stent is made of polyethylene. It will be implanted in the common bile duct by ERCP(endoscopic retrograde cholangiopancreatography) of the conventional group patients.
3347494|NCT02238639|Experimental|Active search for pulmonary embolism|All included patients will undergo D-dimer testing. A negative plasma highly sensitive D-dimer value (defined as a D-dimer level below the manufacturers assay threshold) will rule out pulmonary embolism, and no further examination will be performed. For patients with a positive D-dimer value, a multidetector computed tomographic pulmonary angiography (MDCT) will be performed.
3347495|NCT02238639|No Intervention|Standard management|All included patients will undergo standard clinical management of their exacerbations, as deemed appropriate by the attending physician.
3347496|NCT02238652|No Intervention|Control|
3240593|NCT01290939|Experimental|Arm 1|Lomustine 90 mg/m² every 6 weeks (cap. 160 mg) + bevacizumab 10 mg/kg every 2 weeks (at further progression treatment will be according to investigators discretion). In the absence of hematological toxicity > grade 1 during the first cycle the dose of lomustine can be escalated to 110 mg/m² (cap 200 mg) in their second cycle.
3347497|NCT02238652|Active Comparator|Intervention|Communication Systematic Pain Assessment and Treatment Medication Review Occupational therapy Safety
3347498|NCT02238665||Ulcerative colitis|
3347499|NCT02238665||Crohn's disease|
3347500|NCT02238678||Deep endometriosis patients|
3347501|NCT02238691|Experimental|Mask ventilation with PEEP|15 subjects will undergo anesthetic induction with application of PEEP of 10 cm H2O during mask ventilation.
3240594|NCT01290939|Active Comparator|Arm 2|Lomustine single agent 110 mg/m² every 6 weeks (cap. 200 mg) (at further progression treatment will be according to investigators discretion).
3347502|NCT02238691|No Intervention|Mask ventilation without PEEP|15 subjects will undergo anesthetic induction without PEEP during mask ventilation.
3347503|NCT02238704|Experimental|Regimen A|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 2 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
3347504|NCT02238704|Active Comparator|Regimen B|500mg elemental calcium (as CaCO3) + 200 microgram Vit D per administration, administered 3 times a day, at least 2hours apart with one administration of 60mg elemental iron (as FeSO4) at any time of the day
3347505|NCT02238717|Experimental|PF-06372865 (65mg)|
3240595|NCT01290965|Placebo Comparator|Placebo comparator|
3240596|NCT01290965|Active Comparator|SCY-635 30 mg once daily|
3347506|NCT02238717|Experimental|PF-06372865 (15mg)|
3347507|NCT02238717|Active Comparator|Pregabalin|
3347508|NCT02238717|Placebo Comparator|Placebo|
3347509|NCT02238730|Active Comparator|Ultrabrief Right Unilateral|Ultrabrief (0.25 ms) Right Unilateral Electroconvulsive Therapy
3347510|NCT02238730|Active Comparator|Brief Pulse Bitemporal|Brief Pulse (0.5 ms) Bitemporal Electroconvulsive Therapy
3347511|NCT02238756|Experimental|CV8102|
3347512|NCT02238756|Active Comparator|Rabipur|
3347513|NCT02238756|Experimental|CV8102 + Rabipur|
3347514|NCT02238769||Hepatocellular Carcinoma|18F-FluoroethylCholine PET will show the difference between HCC lesions and normal liver tissue
3347515|NCT02238795||Purpura fulminans|Patients diagnosed with Purpura fulminans in association with sepsis
3347516|NCT02238808|Experimental|Estradiol treatment|Estradiol 6 mg daily for 7-14 days
3347517|NCT02238821||resectable colorectal cancer|
3347518|NCT02238834|Experimental|SAD Cohorts 1-8 Experimental Arm|
3347519|NCT02238834|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3347520|NCT02238834|Experimental|MAD Cohorts 1 through 4 Experimental Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
3347521|NCT02238834|Placebo Comparator|MAD Cohorts 1 through 4 Placebo Arm|Note: The planned MAD portion of the study was not conducted. Evaluation of FP-025 MAD is being conducted under a separate protocol (Study No. FP02C-17-001).
3240597|NCT01290965|Active Comparator|SCY-635 100 mg once daily|
3240598|NCT01290965|Active Comparator|SCY-635 300 mg once daily|
3347522|NCT02238860|Active Comparator|Entacavir|Entacavir 0.5 mg (OD) for 48 weeks
3347523|NCT02238860|Active Comparator|Tenofovir|Tenofovir 300 mg ,OD for 48 weeks
3347524|NCT02238873|Active Comparator|Pegfilgrastim +1|Pegfilgrastim will be given 24 hours (day +1) after completion of salvage chemotherapy
3347525|NCT02238873|Experimental|Pegfilgrastim +3|Pegfilgrastim will be given 72 hours (day +3) after completion of salvage chemotherapy
3347526|NCT02238886|Experimental|Parenteral nutrition|Patients receives a goal-directed nutritional intervention combining oral intake and parenteral nutrition
3240599|NCT01290965|Active Comparator|SCY-635 100 mg three times daily|
3240600|NCT01290965|Active Comparator|SCY-635 200 mg three times daily|
3240601|NCT01290965|Active Comparator|SCY-635 300 mg three times daily|
3347527|NCT02238886|No Intervention|Standard treatment|patients receives a standard nutritional strategy of resting the bowel till clear signs of bowel recovery and feeding orally after bowel recovery
3347528|NCT02238912|Experimental|Kandhaga Rasayanam- single arm|Kandhaga Rasayanam- 2grams twice a day for 45 days
3347529|NCT02238938|Experimental|en-bloc resection|En- bloc resection is done after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily. Since the aim of this method is the total resection basally and laterally, only one session is intended.
3240602|NCT01290991|Other|Bone Graft|Single Arm.. Augment Bone Graft for Osteochondral Defects
3240606|NCT01291030|Experimental|hypomagnesemic + magnesium supplement|The patient group of hypomagnesesemic renal transplant recipients randomized to magnesium supplementation (number = 30). The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
3240607|NCT01291030|No Intervention|hypomagnesemic without magnesium supplement|The patient group of hypomagnesesemic renal transplantation recipients, randomized to no magnesium supplementation (number = 30). During 6 months, no magnesium supplementation is started, provided that the serum magnesium level remains > 1,2 milligram/deciliter. In case of cramps, intermittent supplementation is allowed, but will be recorded. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion,which are repeated after 6 months.
3240608|NCT01291030|No Intervention|normomagnesemic without magnesium supplement|In the control group of normomagnesemic renal transplantation recipients (number = 10), only a baseline assessment will be performed. The assessments are a baseline fasting assessment of insulin resistance and an Oral Glucose Tolerance Test with derived indices of insulin secretion.
3347530|NCT02238938|Active Comparator|piecemeal resection|"Piecemeal resection will be done by snare following marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps. High resolution endoscopes are mandatory.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done. This second session can be done by sigmoidoscopy."
3347531|NCT02238951|Experimental|Mobile Health (mHealth)|Care coordination using mHealth technology enhancements
3240609|NCT01291043|Experimental|Shiatsu Group|
3240610|NCT01291043|No Intervention|Control Group|
3240611|NCT01291069|Experimental|Tadalafil Citrate|The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
3240612|NCT01291069|Placebo Comparator|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.
3347532|NCT02238951|Active Comparator|No mHealth|Care coordination without mHealth enhancements
3240613|NCT01291082||Breast cancer patients|Breast cancer patients
3240614|NCT01291095|Active Comparator|CONCURRENT CHEMO-RADIOTHERAPY ARM|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy).
3347533|NCT02238964|Active Comparator|Strattice™ Reconstructive Tissue Matrix|Strattice(TM) Reconstructive Tissue Matrix will be placed intra-peritoneally fashion. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl).
3347534|NCT02238964|Active Comparator|Standard closure|"Fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The technique recommended is the fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. This technique can include either interrupted or continuous sutures.~Closure of the muscle, soft tissues and skin is up to the discretion of the operating surgeon."
3347535|NCT02239003|Experimental|DAOIB|250-1500 mg/day, oral, for 24 weeks
3347536|NCT02239003|Placebo Comparator|Placebo|placebo, oral, for 24 weeks
3347537|NCT02239029|Active Comparator|Platelet rich plasma|"Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.~Patients with bilaetral knee osteoarthritis randomized receive on dose of PRP in one knee and placebo with normal saline in the other side."
3347538|NCT02239029|Placebo Comparator|normal saline|Normal saline was injected into the other side of knee as the control group.
3240615|NCT01291095|Experimental|ACCELERATED FRACTIONATION RADIOTHERAPY ARM|Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
3240616|NCT01291121|Active Comparator|group 1|Intravitreal ranibizumab 0.5mg only group
3240617|NCT01291134||Cervical Degenerative Disc Disease|
3240618|NCT01291147|Active Comparator|Levobupivicaine|
3240619|NCT01291147|Placebo Comparator|0.9% Saline|
3347539|NCT02239042|Sham Comparator|Low-level laser therapy (LLLT) Sham|LLLT Sham on the palatal donor site of connective tissue graft
3347540|NCT02239042|Experimental|Low-level laser therapy (LLLT)|LLLT on the palatal donor site of connective tissue graft
3347541|NCT02239055||Focus Group 1|Staff Perceptions
3347542|NCT02239055||Focus Group 2|Staff Perceptions
3347543|NCT02239081|Experimental|CTP-730, 5 mg|oral suspension, once daily.
3347544|NCT02239081|Experimental|CTP-730, 10 mg|Oral Suspension, once daily.
3347545|NCT02239081|Experimental|CTP-730, 20 mg|Oral Suspension, once daily.
3347546|NCT02239081|Experimental|CTP-730, 30 mg|Oral Suspension, once daily.
3347547|NCT02239081|Experimental|CTP-730, 40 mg|Oral Suspension, once daily.
3347548|NCT02239081|Experimental|CTP-730, 50 mg|Oral Suspension, once daily.
3347549|NCT02239081|Experimental|CTP-730, 60 mg|Oral Suspension, once daily.
3347550|NCT02239107|Experimental|N-Acetyl cysteine|Laparoscopic ovarian drilling followed by NAC 1200mg daily in two divided doses for five days starting cycle day 2 for 6 month
3240620|NCT01291186|Experimental|BPV6NO|
3240621|NCT01291186|Experimental|BPV7NO|
3240622|NCT01291186|Experimental|BPV8NO|
3240623|NCT01291186|Experimental|BPV9NO|
3240624|NCT01291186|Experimental|BPV10NO|
3347551|NCT02239107|Active Comparator|laparoscopic drilling group|laparoscopic drilling only will be done
3240625|NCT01291186|Experimental|BPV11NO|
3240626|NCT01291186|Active Comparator|BPV6O|
3240627|NCT01291186|Active Comparator|BPV7O|
3240628|NCT01291186|Active Comparator|BPV8O|
3240629|NCT01291186|Active Comparator|BPV9O|
3240630|NCT01291186|Active Comparator|BPV10O|
3240631|NCT01291186|Active Comparator|BPV11O|
3240632|NCT01291199|Experimental|Vardenafil 10 mg bid|
3240633|NCT01291199|Placebo Comparator|Placebo|
3240634|NCT01291212|Active Comparator|Testosterone and FSHr|
3240635|NCT01291212|Active Comparator|testosterone and FSHr-LHr|
3240636|NCT01291238|Experimental|Healthy lifestyle habits|Increased physical activity and healthy food with decreased sugar and fat content
3347552|NCT02239133|Experimental|ProVATE vaginal pessary|"The ProVATE device is a disposable, single-use, vaginal pessary for the management of Pelvic Organ Prolapse (POP). The ProVATE device is similar to other ring pessaries currently on the market. Its features allow for easy and comfortable insertion and removal by the user herself at her home environment. The ProVATE device is provided in six (6) different sizes and is intended for prescription use only."
3347553|NCT02239146|Experimental|rFXIII|
3347554|NCT02239146|Placebo Comparator|Placebo|
3347555|NCT02239159|No Intervention|Control|Electrodes will be attached, but stimulation will not be given
3347556|NCT02239159|Sham Comparator|Non-acupoint TES|TES is for transcutaneous electric stimulation.Stimulation will be given through electrodes attached to non-acupoints
3347557|NCT02239159|Experimental|Acupoint TES|Transcutaneous stimulation will be given through acupoints
3347558|NCT02239172|Experimental|12.5 µg + Alhydrogel|vaccine
3347559|NCT02239172|Experimental|25 µg + Alhydrogel|vaccine
3347560|NCT02239172|Experimental|50 µg + Alhydrogel|vaccine
3347561|NCT02239172|Experimental|100 µg + Alhydrogel|vaccine
3347562|NCT02239185|Other|Hernial sac ligation in continuity|laparoscopic closure of hernia sac in continuity using 3 - 0 non-absorbable purse-string suture. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying.
3347563|NCT02239185|Other|Hernial sac disconnection|circumferential incision on the peritoneum at internal inguinal ring (IIR) with separation of hernia sac from the peritoneum. The proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
3347564|NCT02239198|Experimental|C|Nutrition bar without omega-3 fatty acids
3347565|NCT02239198|Experimental|B|Nutrition bar without added minerals and vitamins
3347566|NCT02239198|Active Comparator|A|Complete nutrition bar
3347567|NCT02239211|Experimental|BTT1023|BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
3347568|NCT02239237||Compound Kuh-seng Injection|Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
3347569|NCT02239250|Experimental|Water filter and cookstove|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 72 sectors randomised as intervention sectors will be eligible to receive one free water filtering device and one free cookstove. All households will be given instructions of how to use the intervention.
3347570|NCT02239250|No Intervention|Control|All household that appear on Government approved lists as belonging to ubudehe 1 & 2 categories in the 24 sectors randomised as control sectors will continue with their traditional cooking methods and drinking practices.
3240637|NCT01291290|No Intervention|Control treatment|Usual transfusion regime to patients with rAAA
3240638|NCT01291290|Experimental|Thrombocyte|Early thrombocyte administration to patients with rAAA
3240639|NCT01291303|Experimental|1- optimized ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
3240640|NCT01291303|Experimental|2-standard setting of ventilation|35 COPD patients ventilated for acute exacerbations in NIV with pressure support mode.
3240641|NCT01291316|Experimental|clobazam|
3240642|NCT01291316|Active Comparator|clonazepam|
3240643|NCT01291316|Placebo Comparator|tolterodine|
3240644|NCT01291329|Experimental|WJ-MSC|Wharton's jelly- Derived Mesenchymal Stem Cells Transfer
3240645|NCT01291342||Preeclampsia|30 preeclamptic pregnant women with gestational age >24 weeks and no chronic medical disorders who are not in labor and their fetus is alive.
3240646|NCT01291342||Normal pregnancy|30 normotensive pregnant women with gestational age >24 weeks and no chronic medical disorders who has no obstetrical problems, not in labor and their fetus is alive.
3240647|NCT01291342||Healthy non-pregnant|30 healthy non-pregnant control women not on medications and has not delivered a baby or conceived during the year before the breath collection
3240648|NCT01291355|Experimental|Specific maternal position|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts. According to Dr de Gasquet, author of the description of this posture, the effect on the variety of presentation would be almost immediate."
3240649|NCT01291355|No Intervention|Control|Not specific intervention for this group- Only usual care
3240650|NCT01291381|Active Comparator|Dermatophagoides pteronyssinus extract|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
3240651|NCT01291381|Active Comparator|Pharmacotherapy|Persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
3240652|NCT01291407|Experimental|S-1,peroral BID,capsule|
3240653|NCT01291433|Experimental|PENTOCLO|Association pentoxifylline, tocopherol and clodronate
3240654|NCT01291433|Placebo Comparator|Placebo|Triple placebo
3240655|NCT01291446|Sham Comparator|High flatulogenic diet|3-day diet containing fermentable residues
3240656|NCT01291459|Experimental|single arm|Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks
3240657|NCT01291472|Other|ketorolac|Ketorolac will be given to all patients as a part of routine medical care
3347571|NCT02239315|Experimental|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
3347572|NCT02239341|Active Comparator|Music Intervention (M)|The M intervention will be 30 minutes (same amount of time as E group), but the participants will simply be listening to the same music in bed with no exercise component. They will be wearing the heart rate monitor as in the E group. The M group will act as a control group for the E group.
3347573|NCT02239341|Experimental|Muscle Conditioning Intervention (E)|E (exercise) is 30 minutes in length and will consist of 5 minutes of warm-up, 20 minutes of light strengthening exercises using a theraband, and 5 minutes of cool-down. All exercises will be completed in bed. Each participant will be listening to the same music (as the M group) during exercise. A heart rate monitor will be worn throughout each session. The first session for each participant will be used to complete baseline measurements and to assess initial muscle strength. Difficulty level will be adjusted by using different strength therabands.
3347576|NCT02239367|Experimental|Depression Decision Aid protocol|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention. Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower the elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
3347577|NCT02239393|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
3347578|NCT02239393|Experimental|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1 to 2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0.
3347579|NCT02239406||Metal-on-Metal Revision|Patients who have a failed metal on metal total hip implant and are presenting for revision surgery
3347580|NCT02239419|Experimental|CO2-Enriched Tap Water (Carbothera)|CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C. Tap water will be enriched with CO2 by the investigational Carbothera device.
3347581|NCT02239419|Placebo Comparator|Non-CO2-Enriched Tap Water|Non-CO2-enriched tap water (i.e. normal tap water) maintained at a temperature of 37˚C.
3347582|NCT02239432||Suspected Adenocarcinoma of the Lung|Patients with suspected adenocarcinoma of the lung referred for surgical lung biopsy after multi-disciplinary team recommendation.
3347583|NCT02239432||Healthy Control|Age and sex-matched patients with no known lung disease or other chronic inflammatory disease or malignancy
3347584|NCT02239432||Age-matched controls with proven solid lung malignancy|Patients with biopsy-proven advanced solid malignancy of the lung
3347585|NCT02239445|Active Comparator|chloral hydrate group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
3347586|NCT02239445|Experimental|low dose dexmedetomidine Group|"Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
3347587|NCT02239445|Experimental|high dose dexmedetomidine group|"Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup~Undiluted preservative-free dexmedetomidine (AiBeiNing; Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) was prepared in a concentration of 100mcg/ml and dripped into both nostrils using a 1 mL syringe with the child in the Supine position."
3347588|NCT02239458|Placebo Comparator|Placebo|Placebo intake during 3 months
3240658|NCT01291485|Experimental|Lifestyle counseling|Intervention includes education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve HIV medication adherence and clinical outcomes.
3240659|NCT01291485|No Intervention|Treatment as Usual|
3259289|NCT01469494|Active Comparator|SIEA flap group|The standard of care for the patient population is the DIEP or SIEA flap breast reconstruction. Currently the single operating surgeon in the study will always try to perform a SIEA flap reconstruction. If the anatomy does not allow it he will convert to a DIEP flap. The majority of breast surgeons in North America will generally perform a DIEP flap initially. The proposed study does not alter the standard of care received.
3347589|NCT02239458|Active Comparator|Saxagliptin 5mg|Saxagliptin dose of 5mg for 3 months
3347590|NCT02239484|Experimental|Sequence 1|Tadalafil→Tamsulosin→Tadalafil+Tamsulosin
3347591|NCT02239484|Experimental|Sequence 2|Tadalafil+Tamsulosin→Tadalafil→Tamsulosin
3347592|NCT02239484|Experimental|Sequence 3|Tamsulosin→Tadalafil+Tamsulosin→Tadalafil
3347593|NCT02239497|Experimental|femoral block by US and NE and intravenous analgesia|preincisional femoral block by ultrasound and neurostimulation, with 20 ml bupivacaine 0,5% and epinephrine. ketoprofen, dipyrone and dexamethasone IV. Morphine IV to rescue analgesia
3347594|NCT02239497|Experimental|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and morphine. IV morphine to rescue analgesia
3347595|NCT02239523|Active Comparator|Letter Group|Patients will be given discharge letter that includes recommendation to discuss further testing and treatment with their primary care physician.
3347596|NCT02239523|Experimental|Intervention Group|Patients will be given a pamphlet about osteoporosis and importance of treatment, have a bone density test (DEXA) arranged, be given a specific medication recommendation and monthly followup phone calls.
3259290|NCT01469507|Experimental|V0220|
3347597|NCT02239549|Experimental|Jumbo cold forceps polypectomy group|Polypectomy conducted with jumbo cold forceps
3347598|NCT02239549|Experimental|Cold snare polypectomy group|Polypectomy conducted with cold snare
3347599|NCT02239588|Experimental|Pure Canterbury milk powder|Oral consumption of infant formula (0-6 months) milk powder
3347600|NCT02239588|Active Comparator|Other infant formula milk powder|"Oral consumption of milk powder (other than the experimental product) selected by subjects' parents. The products including:~Yashili Ambery Infant Formula Milk Powder (Stage 1: 0-6 months)~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
3347601|NCT02239588|Placebo Comparator|Breast milk|Oral consumption of breast milk
3240660|NCT01291511|Experimental|Iloperidone|After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.
3240661|NCT01291511|Placebo Comparator|Iloperidone (including Placebo)|Post-randomization matching placebo is administered orally bid during the double-blind period.
3240662|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 400-500 calorie|
3240663|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
3240664|NCT01291524|Experimental|Pregabalin controlled release, 330 mg, bedtime|
3240665|NCT01291524|Other|Pregabalin immediate release, 300 mg|Reference Treatment
3240666|NCT01291537|Experimental|Duodopa|
3240667|NCT01291537|Active Comparator|Best medical treatment|
3240668|NCT01291550||Nerodegenerative diseases|Patients with parkinsonism and patients with dementia
3240669|NCT01291550||Controls|
3240670|NCT01291550||ADHD|Subjects diagnosed with ADHD
3347602|NCT02239614|Experimental|Group 1: LAV (T=0), PIV (T=28)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 28 of the study."
3347603|NCT02239614|Experimental|Group 2: PIV (T=0), LAV (T=28)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 28 of the study."
3347604|NCT02239614|Experimental|Group 3: LAV (T=0), PIV (T=180)|"Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 0 of the study.~Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 180 of the study."
3347605|NCT02239614|Experimental|Group 4: PIV (T=0), LAV (T=180)|"Tetravalent dengue purified inactivated vaccine 4 μg/serotype with alum adjuvant (TDENV-PIV 4 µg + alum adjuvant) administered intramuscularly on day 0 of the study.~Tetravalent live-attenuated dengue virus vaccine formulation 17 (TDENV-LAV) reconstituted with 0.7 mL of water-for-injection; administered subcutaneously on day 180 of the study."
3347606|NCT02239653|Experimental|Physician communication|"The Milk. Water. Period intervention comprises brochures, posters, and key talking points for use by primary pediatricians to use in discussion with the parent about the child's beverages consumption."
3347607|NCT02239653|No Intervention|Usual care|
3347608|NCT02239666||Moderate to Severe Plaque Psoriasis|Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
3347609|NCT02239705||Fluid challenge|Patients whose clinical conditions require bolus of fluids infusion to correct blood pressure and cardiac output
3347610|NCT02239705||Inotropic infusion|Patient whose clinical conditions require inotropic agents infusion to correct blood pressure and cardiac output
3347611|NCT02239718|Experimental|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
3240671|NCT01291563|Experimental|001|TMC207 8 tablets of TMC207 (100 mg/tablet) on Day 1
3240672|NCT01291563|Placebo Comparator|002|TMC207 placebo 8 tablets of TMC207 placebo on Day 1
3240673|NCT01291563|Active Comparator|003|Moxifloxacin 1 capsule of moxifloxacin (400 mg/capsule) on Day 2
3240674|NCT01291563|Placebo Comparator|004|Moxifloxacin placebo 1 capsule of moxifloxacin placebo on Day 2
3240675|NCT01291576|Active Comparator|Rectal/colorectal segmental resection|
3240676|NCT01291576|Active Comparator|Rectal nodule excision|
3240677|NCT01291589|Experimental|Cognitive-behavioral counseling|
3240678|NCT01291602|Experimental|NXL104|Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104
3240679|NCT01291602|Placebo Comparator|Placebo|Three Japanese subjects to receive placebo IV doses
3240680|NCT01291602|Experimental|Ceftazidime NXL104 (CAZ104)|Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime
3240681|NCT01291615|Experimental|Gemcitabine group|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
3240682|NCT01291615|Experimental|S-1 group|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks
3240683|NCT01291628|Experimental|socks containing copper-oxide fibers|
3240684|NCT01291641|Placebo Comparator|Group A|HMGCoA reductase inhibitor continued
3259291|NCT01469507|Active Comparator|Hyaluronan|
3347612|NCT02239718|Active Comparator|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
3240685|NCT01291641|Active Comparator|Group B|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID
3240686|NCT01291641|Active Comparator|Group C|HMGCoA reductase inhibitor continued + Probucol 250 mg PO, BID + Cilostazol 100 mg PO, BID
3347613|NCT02239731|Experimental|FDX104 (4% Doxycycline)|Active ingredient: Doxycycline Concentration: 4% Route: Topical Dosage schedule: Twice daily, morning and evening. Prophylactic treatment to prevent the rash associated with EGFRI treatment. patients will apply a thin layer of the drug twice daily for five weeks to one half of face
3240687|NCT01291654|Experimental|Paracetamol|Babies with hsPDA will be treated with paracetamol 15 mg/kg/dose x 4/day for three days
3347614|NCT02239731|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Twice daily, morning and evening. Patients will apply a thin layer of the placebo twice daily for five weeks to the opposite half of the face of which they received active treatment.
3347615|NCT02239757|Experimental|Right radial approach|Primary PCI performed through right radial approach.
3347616|NCT02239757|Experimental|Left radial approach|Primary PCI performed through left radial approach.
3347617|NCT02239783||Total Hip Arthroplasty|Single group previously implanted with the following combination of components: PROFEMUR® TL modular femoral stem, MicroPort Orthopedics acetabular shell, MicroPort Orthopedics polyethylene or ceramic liner, MicroPort Orthopedics metal or ceramic femoral head.
3347618|NCT02239796|Experimental|TPTNS|"12 stimulation sessions of 30 minutes duration, delivered twice weekly over a 6 week period using a NeuroTrac continence stimulator.~Two surface electrodes are applied to the non-hemiparetic ankle, where appropriate, or the right ankle where no hemiparesis exists. The electrical stimulator is pre-programmed to safely deliver 30 minutes of continuous stimulation with a pulse frequency of 10 hertz and pulse width 200µs22. The intensity of the current will depend on the stroke survivor's perception threshold and individual comfort and is self-adjusted at each session, but will normally range between 15 and 40 milliamps."
3240688|NCT01291654|Experimental|NSAID|Babies with hsPDA will be randomized to treatment with IV indomethacin 17 mcg/kg/hr x 36 hr
3240689|NCT01291680||Pre - delivery pregnant women|Participants in the study will be pregnant women attending the obstetric ER for routine term followup. This evaluation is generally conducted at week 39-41 of pregnancy. The current study will focus on women attending a regular followup, not considered to be at high risk.
3240690|NCT01291693|Experimental|Personal counseling|
3347619|NCT02239796|Sham Comparator|Sham TPTNS|"The sham stimulation group will self- or carer-deliver a similar programme of twelve, 30 minute sessions twice weekly for 6 weeks NeuroTrac continence stimulator.~The surface electrodes will be positioned on the lateral malleolar area of the ankle, not the medial aspect, to avoid the posterior tibial nerve.~The stimulation intensity will be increased until sensation is reported, then turned down to 4mA for the 30 minute session, ensuring that despite avoiding the posterior tibial nerve, there is no therapeutic stimulation provided."
3347620|NCT02239809|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
3347621|NCT02239809|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
3347622|NCT02239822|Active Comparator|Active Stimulation|Patients assigned to active stimulation arm will receive electrical stimulation during the study.
3240691|NCT01291693|Experimental|Computer generated feedback letters|
3347623|NCT02239822|Placebo Comparator|Placebo Stimulation|Patients assigned to the placebo arm did not receive stimulation electrical stimulation for 24 weeks. After this period the participants randomized to sham stimulation will be moved to the active stimulation and will be followed until study completion.
3347624|NCT02239835|Experimental|TPV low dose + RTV low dose|
3347625|NCT02239835|Experimental|TPV high dose + RTV low dose|
3347626|NCT02239835|Active Comparator|SQV + RTV high dose|
3240692|NCT01291693|No Intervention|Control group|Treatment as usual
3240693|NCT01291706||Mild TBI with mild lesions on CT scan|Negative predictive value of transcranial doppler for patients with mild to moderate traumatic brain injury and mild brain lesions on initial CT scan (TCDB II)
3347627|NCT02239861|Experimental|TAA-Specific CTLs|"4 different dosing schedules will be evaluated. 2 to 4 patients will be evaluated on each dosing schedule. The first 2 patients on each dose level will be staggered by 4 weeks (which starts when the first infusion is given, Day 0). No subjects between the ages of 2-18 will be enrolled to a dose level on this protocol, until an adult has been enrolled to and treated on that dose level on one of the protocols being conducted under this same IND. Each patient will receive 2 injections at the same dose,14 days apart: The expected volume of infusion will be 1 to 10 cc.~Dose Level One:~Day 0 and 14: 5 x 10^6 cells/m^2~Dose Level Two:~Day 0 and 14: 1 x 10^7 cells/m^2~Dose Level Three:~Day 0 and 14: 2 x 10^7 cells/m^2~Dose Level Four:~Day 0 and 14: 4 x 10^7 cells/m^2"
3347628|NCT02239874|Placebo Comparator|Vitamin D placebo and fish oil placebo|vitamin D placebo + fish oil placebo
3347629|NCT02239874|Active Comparator|Fish oil and vitamin D placebo|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3347630|NCT02239874|Active Comparator|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
3240694|NCT01291719|Experimental|insulin and glucose infusion|trial of experimental technique in outpatient setting; the group under study will be comprised of type 1 and type 2 diabetic individuals ; they will have automated treatment using algorithm which regulates balancing infusions of glucose and/or insulin intravenously without manual intervention; blood glucose target of 80-180 mg/dl will be guide for the automated system
3347631|NCT02239874|Active Comparator|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3347632|NCT02239887||WaveCrest LAA occlusion device|Left Atrial Occlusion
3240695|NCT01291732|Experimental|BI 135585 XX|single dose of BI 135585
3240696|NCT01291732|Placebo Comparator|matching placebo|single dose of matching placebo
3240697|NCT01291745||Patients with MYELODYSPLASTIC SYNDROMES|Patients diagnosed with MDS according to FAB, WHO and IPSS classifications. Patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine).
3240698|NCT01291758||GWI|Veterans of the 1990-1991 Persian Gulf War who have autonomic, neurological and other symptoms
3347633|NCT02239900|Experimental|Group 1 Liver: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 1: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
3347634|NCT02239900|Experimental|Group 2 Liver: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 liver metastasis - Treatment Group 2: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
3240699|NCT01291758||HC|Healthy veterans of the 1990-1991 Persian Gulf War
3240700|NCT01291771|Other|comparator|One group of patients with no myocardial ischemia on non invasive testing will be followed up for 2 years
3240701|NCT01291771|Experimental|coronary angiography group|One group of patients with myocardial ischemia on non invasive testing will undergo coronary angiography and measure of FFR + CFR to detect myocardial microvascular disease
3347635|NCT02239900|Experimental|Group 3 Lung: Concurrent (early) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 1 - 4 of Cycle 1.
3347636|NCT02239900|Experimental|Group 4 Lung: Sequential (late) Ipilimumab and SBRT|Participants with at least 1 lung metastasis - Treatment Group 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4. Each cycle is 21 days. SBRT 50 Gy in 4 fractions to 1 - 4 lung lesion(s) on Days 29 - 33 of each 21 day cycle.
3347637|NCT02239900|Experimental|Group 5 Liver/Lung Metastasis: (late) Ipilimumab and SBRT|Participants with 1 liver or lung metastasis - Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2 - 4. Each cycle is 21 days. SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1.
3347638|NCT02239900|Experimental|Thyroid Expansion Cohort|"Participants enrolled in this arm treated to a total dose of 50 Gy in 4 fractions, 60 Gy in 10 fractions, or 20 Gy in 5 fractions with stereotactic radiotherapy to a liver or lung lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist.~Participants receive Ipilimumab every 21 days for a total of 4 doses."
3347639|NCT02239913|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Subjects will be maintained on placebo and phentermine during placebo maintenance. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3347640|NCT02239913|Experimental|Topiramate Dose 1|Subjects will be maintained on the low topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the low dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3347641|NCT02239913|Experimental|Topiramate Dose 2|Subjects will be maintained on the high topiramate dose. Subjects will be maintained on placebo and phentermine during maintenance on the high dose of topiramate. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3347642|NCT02239952|Experimental|sunitinib|
3347643|NCT02239952|Experimental|vandetanib|
3347644|NCT02239952|Experimental|Erlotinib|
3240702|NCT01291797||Neonates with congenital heart disease|The case group will consist of newborns born between 32 and 41 weeks gestation diagnosed with a congenital cardiac anomaly requiring surgical repair during their hospitalization and managed in the Mount Sinai Neonatal Intensive Care Unit. The control arm will include newborns born between 32 and 41 weeks without congenital cardiac anomalies. Both groups will undergo a neurological screening assessment and receive an AEEG to look at sleep wake cycles.
3240703|NCT01291810|Experimental|TNF Kinoid|
3347645|NCT02239965||Anaesthesia personnel|Anaesthesiologists and nurse anaesthetists
3347646|NCT02239991|No Intervention|Historical control|Group of patients that had their coagulopathy secondary to the liver transplant treated based on conventional laboratory tests. Before the implementation of thromboelastometry.
3347647|NCT02239991|Experimental|Intervention|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
3347648|NCT02240017|Active Comparator|Carboplatin/Gemcitabine|
3347649|NCT02240017|Experimental|Fractionated Cisplatin/Gemcitabine|
3347650|NCT02240043|Other|growth hormone secretion|The elderly had common morbidities peculiar to their age, such as systemic arterial hypertension, diabetes mellitus, Parkinson's disease, initial stages of senile dementia, and osteoporosis.
3347651|NCT02240056||TTC|postmenopausal women with acute Takotsubo cardiomyopathy (TTC), diagnosis by coronary angiography within 24 hours of symptom onset
3347652|NCT02240056||NSTEMI / STEMI|postmenopausal women with acute ST elevation myocardial infarction (NSTEMI / STEMI), diagnosis by coronary angiography within 24 hours of symptom onset
3347653|NCT02240056||healthy subjects|healthy postmenopausal women without coronary artery disease
3240704|NCT01291810|Placebo Comparator|Placebo|
3240705|NCT01291823|Experimental|Concomitant Gefitinib and radiotherapy|Patients received Gefitinib and radiation therapy
3347654|NCT02240069|Experimental|Education (Tx1)|Education on best burn practices
3240706|NCT01291849|Experimental|remifentanil for intranasal surgery|
3347655|NCT02240069|Active Comparator|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove."
3240707|NCT01291875|Experimental|Intensive periodontal treatment|
3240708|NCT01291875|Active Comparator|Supragingival biofilm control|
3240709|NCT01291901|Experimental|Active NP2|Single intradermal dose of active NP2. An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
3347656|NCT02240069|Sham Comparator|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
3347657|NCT02240082|Experimental|Web-based COPing with Shiftwork Program|Participants in this condition will use the web-based COPing with Shiftwork web-based program for three months
3347658|NCT02240082|No Intervention|Wait List Control|Participants in the wait list control group will not receive any intervention during the study period, but will have access to any program offered by the police department.
3347659|NCT02240095|Experimental|Interventions: A + B + C|"See Interventions Description. In this arm, students will be offered all 3 online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3347660|NCT02240095|Experimental|Interventions A + B|"See Interventions Description. In this arm, students will be offered the 2 following interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention B - Online Evidence Retrieval Coach"
3347661|NCT02240095|Experimental|Interventions A + C|"In this arm, students will be offered the 2 following online interventions combined:~Intervention A - Online Clinical Questions Recorder~Intervention C - Online Audit and Feedback"
3347662|NCT02240095|Experimental|Interventions B + C|"See Interventions Description. In this arm, students will be offered the 2 following online interventions combined:~Intervention B - Online Evidence Retrieval Coach~Intervention C - Online Audit and Feedback"
3347663|NCT02240095|Experimental|Intervention A alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention A - Online Clinical Questions Recorder"
3347664|NCT02240095|Experimental|Intervention B alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention B - Online Evidence Retrieval Coach"
3347665|NCT02240095|Experimental|Intervention C alone|"See Interventions Description. In this arm, students will be offered only the following intervention:~* Intervention C - Online Audit and Feedback"
3347666|NCT02240095|No Intervention|No intervention|In this arm, students will be offered none of the 3 online interventions, but will just be using the usual features of the search engine available to all users.
3347667|NCT02240134|Experimental|Education Intervention (Tx1)|The education components for this intervention are based on recent observations and recommendations from tribal, local, state and federal agencies. The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
3347668|NCT02240134|Active Comparator|Air Filtration Unit Treatment (Tx2)|"Within each randomly assigned home, a 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove."
3347669|NCT02240134|Sham Comparator|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
3347670|NCT02240147|Experimental|home-based exercise training|
3347671|NCT02240147|No Intervention|Control group|
3347672|NCT02240160|Experimental|Sativex: acidic oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with Coca-Cola (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3347673|NCT02240160|Experimental|Sativex: neutral oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with tap water (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3347674|NCT02240160|Experimental|Sativex: alkaline oral pH|Four sprays of Sativex taken within two minutes of pH measurement immediately following oral pre-treatment with milk of magnesia (30 mL held in the mouth for 45-60 seconds then spat out, repeated three times).
3347675|NCT02240173|Experimental|Jobelyn + Haloperidol|Combination of the conventional drugs and Jobelyn
3240710|NCT01291901|Placebo Comparator|Placebo|Single intradermal dose of placebo (vehicle). An open label study extension will offer up to two additional doses of active NP2 between weeks 4-10 following the previous dose.
3240711|NCT01291914|Experimental|FX005|
3347676|NCT02240173|Active Comparator|Haloperidol + Placebo|Combination of the conventional drug + Placebo
3347677|NCT02240199|Experimental|Pregabalin/Lidocaine|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Infusion
3347678|NCT02240199|Active Comparator|Pregabalin Placebo/Lidocaine|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Infusion
3347679|NCT02240199|Active Comparator|Pregabalin/Lidocaine Placebo|Perioperative Pregabalin, Intraoperative Intravenous Lidocaine Placebo Infusion
3347680|NCT02240199|Placebo Comparator|Pregabalin Placebo/Lidocaine Placebo|Perioperative Pregabalin Placebo, Intraoperative Intravenous Lidocaine Placebo Infusion
3240712|NCT01291914|Placebo Comparator|Placebo 1 (Carrier)|
3240713|NCT01291914|Placebo Comparator|Placebo 2 (Diluent)|
3240714|NCT01291927|Experimental|Pancreas-sparing duodenectomy|
3347681|NCT02240212|Experimental|Part 1: Dose-escalation (weekly paclitaxel)|The dose escalation will be started from Cohort A (afuresertib combined with weekly paclitaxel regimen at 80 mg/m^2 d1, 8,15, q4w). The starting dose in Cohort A will be 125 mg afuresertib QD to indentify MTD
3347682|NCT02240212|Experimental|Part 1: Dose-escalation (3 weeks Paclitaxel)|Once its MTD is identified, and then the study will move to dosing Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w. Cohort B (afuresertib combined with 3 weekly paclitaxel regimen at 175 mg/m^2 d1, q3w). The starting daily dose of Cohort B will be 25 mg less than the MTD dose from Cohort A for afuresertib. If it is tolerated, then the dose escalation schedule will be followed in Cohort B until the MTD in this Cohort is reached. If the starting dose is not tolerated, then dose de-escalation will be explored until the MTD in this Cohort is reached. Once two dimensions of the MTD are achieved, then the optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be identified
3347683|NCT02240212|Experimental|Part 2: Experimental Cohort|The optimal regimen for paclitaxel and MTD for afuresertib combined with paclitaxel based on the toxicity profile will be administered
3347684|NCT02240238|Experimental|NC-6004 and Gemcitabine|
3347685|NCT02240251||Patients undergoing IVC filter removal using the excimer laser|Laser Assisted IVC Filter Removal
3240715|NCT01291927|Active Comparator|Pancreaticoduodenectomy|
3240716|NCT01291940|Experimental|Pediatric Moisturizer Intervention|Apply one of four moisturizers to one arm daily for four weeks.
3240717|NCT01291940|Experimental|Adult Moisturizer Intervention|Apply moisturizer to one arm once a day for four weeks.
3347686|NCT02240264|Active Comparator|Krill oil capsules|"Capsules containing krill oil rich in omega-3 fatty acid's.~Dietary supplements (krill oil) are provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.~Addendum 25-4-2016: In the Original protocol a dose adjustment after 3 months according to Omega-3 Index was to be executed. As no participant achieved the target Omega-3 Index the dosage was adjusted to 800mg DHA + EPA per day for all participants. The also led to the decision to increase the starting dosage of cohort II to 800mg DHA+ EPA."
3347687|NCT02240264|Placebo Comparator|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
3347688|NCT02240290|Experimental|tozadenant|A single dose of 240 mg tozadenant (four 60 mg tablets) and a 74 kBq (2 μCi) 14C-labeled tozadenant capsule will be administered with 240 mL of water.
3347689|NCT02240303||Chronic Pain Group|Participants that experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
3240718|NCT01291940|No Intervention|Adult Control|No intervention.
3347690|NCT02240303||No Chronic Pain Group|Participants that do not experience chronic pain will have the following procedures performed: A sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin; Pressure sense will be produced by a device that will be pressed against the skin for several seconds; Pinprick pressure will be applied to determine if the pain can be rated; a Physical Performance test will be performed; and an magnetic resonance imaging (MRI) will be done. In addition, blood sample, blood pressure, heart rate, and skin temperature will be taken during the procedures.
3347691|NCT02240316||Follicular NHL Cohort|
3347692|NCT02240316||DLBCL Cohort|
3347693|NCT02240342|Experimental|Poor ovarian reserve women|
3347694|NCT02240355|Experimental|Part 1|Up to 2 cohorts of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
3347695|NCT02240355|Experimental|Part 2|1 cohort of patients, within each cohort patients will receive either RO6885247 or placebo once daily for 12 weeks
3347696|NCT02240355|Experimental|Part 3|1 cohort of patients, within each cohort patients will receive RO6885247 once daily for 12 weeks or 20 weeks
3347697|NCT02240381|Experimental|Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)|Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
3347698|NCT02240407|Experimental|rAAV9-DES-hGAA vector|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase injection.
3375912|NCT03529383|Experimental|Connected device|"Women randomized to the connected device arm will follow a 6-month exercise program using a connected device that includes an activity tracker and subscription to an exercise and physical activity management program through a smartphone application and a website. They will also receive international recommendations on physical activity."
3240719|NCT01291953|Experimental|Screening|Opportunist Screening asymptomatic patients. Taking the arterial pulse. Will invite patient to realize an ECG, if pulse is irregular
3240720|NCT01291953|Active Comparator|Control|Case finding of patient whith symptoms of atrial fibrilation. Taking the arterial pulse. ECG if pulse is irregular
3240721|NCT01291966|Experimental|Motivational interview|
3240722|NCT01291979|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3240723|NCT01291979|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3240724|NCT01291992||Continuous EEG Monitoring|Immediately after surgery, while still sedated and in the cardiac surgery recovery unit, 9 sticker electrodes applied to the skin just below the hairline, which record brain activity onto a computer. The EEG will be recorded for 24 hours. This brain activity (EEG) will later be interpreted by a neurologist who will be looking for evidence of seizure activity in the brain waves. Other relevant information: age, sex, the nature of other health problems, drugs used, complications and whether or not seizures are found will be stored on our computer for further evaluation.
3240725|NCT01292031|Experimental|Colistin|Colistin 4.5 MU/iv.plus Colistin 3 MU/iv./8 h. 30 minutes infusion
3240726|NCT01292031|Active Comparator|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
3240727|NCT01292044|Experimental|The study population|The study population consists of patients for whom an echo-guided fine-needle aspiration was performed for one or more thyroid nodes, and for whom surgical node excision is required.
3240728|NCT01292083|Experimental|Treatment|See Detailed Description
3240729|NCT01292109||PICOPREP®|
3240730|NCT01292122|Experimental|VCT-01-treated STSG donor site wound|Application of VCT-01 to STSG donor site wound at Day 0
3240731|NCT01292161|Other|Silymarin|Silymarin drived from Silybum marianum (milk thistle), a flowering member of the daisy family, may benefit liver function in people infected with the hepatitis C virus.
3347699|NCT02240407|Sham Comparator|Excipient|Each subject will receive Rituxan and Rapamycin prior to the initial exposure to the study agent in one leg and the subsequent exposure of the same vector to the contralateral leg after four months. Diphenhydramine and acetaminophen will be provided before each Rituxan dose. Immune Globulin will be administered to each subject every other month after first exposure to Rituxan and as clinical necessary. Lidocaine will be administered through percutaneous infiltration before injection of the study agent. Side of administration will be randomized at first saline injection.
3240732|NCT01292174|Experimental|Group 1 - lowest dosage|120 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3347700|NCT02240420|Active Comparator|Life Style counseling (Star-Mama)|Star-Mama intervention group will receive during 6 months weekly phone calls with queries and narratives about health habits. The participant's answers will be sent to a health coach who will follow up with the participant, and develop a plan with the participant to address her needs.
3347701|NCT02240420|No Intervention|Educational Resource Support|Participants in the control group of the study will receive a set of educational materials with information about their health and the health of their babies.
3347702|NCT02240433|Experimental|LY2157299 + Sorafenib|LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.
3347703|NCT02240446|Experimental|Active tDCS|Active tDCS
3347704|NCT02240446|Placebo Comparator|Sham tDCS|Sham tDCS
3240733|NCT01292174|Experimental|Group 2 - middle dosage level|240 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3240734|NCT01292174|Experimental|Group 3 - highest dosage level|480 mg ibalizumab administered by subcutaneous injection weekly for 4 weeks, randomized 6:2 with placebo
3347705|NCT02240459|Experimental|Fesoterodine 4mg daily|fesoterodine 4mg oral
3240735|NCT01292200|Experimental|watch DVD and small group discussion|Participants will watch the video in a group and discuss the video.
3240736|NCT01292200|Placebo Comparator|watch video only|watch a 22 minutes long video at home by herself.
3240737|NCT01292213||Cases|Subjects diagnosed with chronic cough who are undergoing general anaesthesia and bronchoscopy/BAL as part of the diagnostic process for chronic cough.
3240738|NCT01292213||Controls|Subjects without respiratory symptoms who are undergoing general anaesthesia for elective surgery or endoscopy of non-respiratory-related conditions.
3347706|NCT02240459|Experimental|Fesoterodine 8mg|Fesoterodine 8mg in form of 2, 4mg tablets
3347707|NCT02240459|Active Comparator|oxybutynin|oxybutynin immediate release, encapsulated 2, 5mg capsules daily
3347708|NCT02240459|Placebo Comparator|placebo capsule|placebo capsule, 2 per day
3347711|NCT02240485|Experimental|Behavioral Couple Therapy|"Already described in the Intervention Description section"
3347712|NCT02240485|Active Comparator|Usual individual/group treatment|Well described in the Intervention section
3347713|NCT02240498|Experimental|MB-PDT, 5 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 5 minutes.
3347714|NCT02240498|Experimental|MB-PDT, 10 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 10 minutes.
3240739|NCT01292278||aSAH|consecutive patients with spontaneous or aneurysmal subarachnoid hemorrhage
3240740|NCT01292278||control group|no neurological disease but spinal anesthesia
3240741|NCT01292317|Active Comparator|intravenous hydration|intravenous application of 0.9% saline
3240742|NCT01292317|Active Comparator|oral hydration only|
3240743|NCT01292356|Experimental|cetuximab|
3240744|NCT01292369||Breast cancer|Women diagnosed with breast cancer by a positive biopsy test after mammography.
3240745|NCT01292369||Breast control|Women with negative biopsy result done due to a suspicious mammography exam.
3240746|NCT01292369||Colon cancer|Men and women diagnosed with colon cancer by a positive colonoscopy and biopsy.
3240747|NCT01292369||Colon control|Men and women with negative colonoscopy and biopsy tested due to complaints indicating the possibility of colon cancer.
3240748|NCT01292382|Sham Comparator|rTMS versus Sham|rTMS: active coil Sham: inactive coil
3347715|NCT02240498|Experimental|MB-PDT, 15 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 15 minutes.
3347716|NCT02240498|Experimental|MB-PDT, 20 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 20 minutes.
3347717|NCT02240498|Experimental|MB-PDT, 25 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 25 minutes.
3347718|NCT02240498|Experimental|MB-PDT, 30 min illumination|Each subject in this group will receive methylene blue, 20% I.V. fat emulsion, insertion of optical fiber, and laser illumination, 30 minutes.
3347719|NCT02240511|Active Comparator|Resistance Exercise|"Resistance Exercise (RE) therapy was divided in four parts: stretching: arms, hands, wrists, legs, knees and ankles, each one for 10 - 20 seconds with resting intervals of 5 seconds (4 series), warming and flexion: the same muscle groups, making small circles forward and backward for 5 - 10 seconds with resting intervals of 5 seconds (4 series), resistance exercises: flexion, contractions and twisting of the same muscle groups worked in the two previous sections. In this part resistance was increased with the aid of dumbbells (500 g - 1500 g), barbells and bands, and patients performed the same exercises with 15 - 20 repetitions with resting intervals of 10 seconds. (4 series), relaxation: involved the same exercises as stretching to rest all muscle groups worked."
3347720|NCT02240511|Experimental|RE and BCAA Supplementation|"RE: Resistance Exercise Resistance Exercise therapy was the same as in the Active Comparator~Branched Chain Aminoacids Amino 2000 BCAA (PRONAT® laboratory) supplementation group received 180 packets of 5 grams (g)and ingested 10 g/day (5 g after breakfast and 5 g before RE)"
3240749|NCT01292382|Active Comparator|rTMS versus sham|rTMS group: active coil Sham group: inactive coil
3240750|NCT01292395|Experimental|Protein level 1|
3347721|NCT02240524|Experimental|D2 lymphadenectomy and HIPEC and Systemic chemotherapy|"Intraoperative and postoperative hyperthermic intraperitoneal chemotherapy (twice HIPEC) were performed after radical gastrectomy with D2 lymphadenectomy, followed by 8 cycles of systemic chemotherapy.~HIPEC was conducted within 48 h after surgery: Normal saline 3000ml-4000ml, Paclitaxel 75mg/m^2, 43°C, 60min.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
3347722|NCT02240524|Placebo Comparator|D2 lymphadenectomy+Systemic chemotherapy|"8 cycles of systemic chemotherapy were performed after radical gastrectomy with D2 lymphadenectomy.~Systemic chemotherapy (XELOX):~Oxaliplatin: 130mg/m^2, d1, Intravenous infusion, every 3 weeks. Capecitabine: 1g/m^2 bid, days 1-14, every 3 weeks and maximum 8 cycles, or progression/intolerance."
3347723|NCT02240537|Experimental|Open Label Treatment Arm|BB-MPI-03 peptides plus montanide plus sargramostim
3347724|NCT02240550|Active Comparator|ProFlor Hernia Repair System|A 3-D hernia mesh
3347725|NCT02240550|Active Comparator|Lichtenstein Hernia Repair|Using flat polypropylene mesh
3347726|NCT02240563|Experimental|Low-level laser therapy|This group of patients was treated with a continuous wave diode laser device (830 nanometer, infrared) with a beam area of 0.002827 cm2 using the punctual method on the continuous emission mode at an output power of 50 milliwatts and a fluence of 707 Joules/cm2 six years before.
3347727|NCT02240563|Placebo Comparator|Non laser ordinary red light|This group of patients was treated using the same method and equipment, except that a non laser ordinary red light, an output power of 0.1 Watt and a fluence of 1.41 Joules/cm2 and an irradiance value of 0.0002827 Watts/cm2 (the placebo), indistinguishable from the laser beam, was used. Therefore, the patients were blinded to which treatment they received.
3347728|NCT02240602|Experimental|Oxycodone, 1.00 mg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 1.00 mg with lock out time of 10 min without basal infusion.
3347729|NCT02240602|Experimental|Oxycodone, 0.03 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.03 mg/kg with lock out time of 10 min without basal infusion.
3240751|NCT01292395|Experimental|Protein level 2|
3240752|NCT01292395|Experimental|Protein level 3|
3240753|NCT01292408|Experimental|Daily HCQ|Between tumor biopsy and surgery, during 2-3 weeks, breast cancer patients will take daily HCQ, an anti-malaria and anti-rheumatic drug that precludes tumor cells from surviving hypoxia by inhibiting the process of autophagy in these cells
3240754|NCT01292421|Placebo Comparator|Arm I|Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
3347730|NCT02240602|Experimental|Oxycodone, 0.02 mg/kg dose|Regimen of intravenous patient-controlled analgesia consists of bolus dose of oxycodone 0.02 mg/kg with lock out time of 10 min without basal infusion.
3347731|NCT02240615|Experimental|Sinopsys Lacrimal Stent|All enrolled patients will receive a Sinopsys Lacrimal Stent inserted from the caruncle to the ethmoid sinus. Discharge instructions will include administration of sterile saline and ophthalmic drops as well as assessments for device patency.
3347732|NCT02240641||hypertension treatment strategies|
3347733|NCT02240719|Experimental|Everolimus + Bendamustine|Patients receive bendamustine hydrochloride IV over 30 minutes on days 1 and 2 and everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3240755|NCT01292421|Experimental|Arm II|Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
3240756|NCT01292421|Experimental|Arm III|Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
3347734|NCT02240732||Total knee replacement patients|"Patients who are due to have a total knee replacement will be studied to look for the presence of Emboli.~Observational with imaging."
3240757|NCT01292421|Experimental|Arm IV|Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
3240758|NCT01292434|Experimental|Lunch in the Bag Intervention|Lunch is in the Bag behavioral intervention: Parents receive a behavioral intervention that includes handouts/newsletters sent to parents from the early care and education (ECE) center, classroom activities and projects, an implementation support calendar, and teacher training.
3240759|NCT01292434|No Intervention|Control|Parents received no specific nutrition education intervention at the ECE center, other than usual practice.
3240760|NCT01292460|Active Comparator|Preservative-free timolol|
3240761|NCT01292460|Experimental|Preservative-free FDC and placebo|
3240762|NCT01292460|Active Comparator|Preservative-free tafluprost|
3240763|NCT01292460|Experimental|Preservative-free FDC|
3240764|NCT01292499|No Intervention|Pharmacological treatment|Pharmacological treatment consists of the administration of a single antidepressant drug. The treatment will be administered as currently done by the mental health center, taking into due account patient's age, general health, previous response to antidepressant drugs, comorbidity, and potential side effects of drugs.
3240765|NCT01292499|Experimental|Psychotherapy|Will receive psychotherapy as well (10 sessions). Psychoterapy will consist of 10 weekly sessions, lasting about 50 minutes each. Psychotherapy will begin after 4-6 weeks from the beginning of the pharmacological treatment, to allow drugs to be effective. The overall list of visits scheduled for the patients is defined during the second psychiatric visit, to allow a reasonable planning of all of the appointments required for that particular patient. Psychotherapists will be free to follow the approach they were trained.
3240766|NCT01292499|Experimental|Psychoeducation|Will receive psychoeducation as well, with phone monitoring and regular follow-ups. Psychoeducation does not simply mean making the patient aware of depression etiology and drugs effect. In fact, patients should receive additional counselling about how to integrate the pharmacological treatment in their daily routine and to solve possible problems, in order to allow them to be actively and constantly involved in the treatment they are going to receive. Patients will receive 7 sessions of psychoeducation and 7 phone calls during the first 5 months. In addition, all of the patients will receive a brochure explaining the most important aspects of their disorder.
3240767|NCT01292499|Experimental|Psychoeducation and psychotherapy|Will receive both psychoeducation and psychotherapy sessions.
3240768|NCT01292512|Experimental|Intervention group|"A) Professional level. B) Patient level.~Intervention~Professional level:~General Practitioners (GP) receive updated information on bereavement related symptoms, how to identify complicated grief, and the Dual Process Model (DPM) of coping.~GPs receive suggestions on how to provide psycho-educational support for the patient.~GPs are informed about the results of the initial assessment of their patient prognostic screening for complicated grief.~Patient level:~Patients receive updated information on bereavement related symptoms, the DPM of coping and suggestions on when to seek professional help.~Patients are informed of the results of their initial assessment of their prognostic grief screening.~Patients are encouraged to contact their GP if they worry about handling their bereavement reaction."
3347735|NCT02240745||All patients|Patients with a suspicion of coronary heart disease
3347736|NCT02240758|Experimental|surgical removal of the tumors+stereotaxic biopsy|
3347737|NCT02240771|Active Comparator|Transarterial chemotherapy|Doxorubicin 50mg, Cisplatin 100mg
3347738|NCT02240771|Placebo Comparator|Oral chemotherapy|Thalidomide---50-300mg once a day Capecitabine---- 500-1500mg once a day
3347739|NCT02240784||Acute Hepatic Porphyria|
3347740|NCT02240797||Anorexia Nervosa - Recovered (AN-REC)|Anorexia Nervosa - Recovered (AN-REC)
3347741|NCT02240797||Healthy Control (HC)|Healthy Control (HC)
3347742|NCT02240823|Experimental|adipose derived stem cells|
3347743|NCT02240836|Experimental|Intervention. Exercise|The intervention starts 3-4 weeks after surgical treatment. The exercise program is performed in parallel with standard breast cancer treatment, and take place in supervised exercise groups by experienced physiotherapists. The duration of the intervention exercise program is 12 months, and the participants will attend the exercise groups for training 60 minutes twice a week. Additionally, they will exercise at home for at least 120 minutes a week, aiming to perform a total of 240 minutes of exercise per week
3347744|NCT02240836|No Intervention|Control group|Control group, standard treatment regimen
3347745|NCT02240849|Experimental|Functional pillow|cervical pillow, designed functionally to decrease neck pain and help to ensure the right support of the cervical curve, was applied to patients' posterior neck area.
3240769|NCT01292512|Other|Control group|Treatment as usual (in the Danish health care system).
3240770|NCT01292525|Active Comparator|Tacrolimus|
3347746|NCT02240849|Placebo Comparator|General pillow|Applicants Randomly allocated to this group were issued by placebo-general pillow. There is not any specific intervention for their neck discomfort except for that.
3347747|NCT02240862||Carotid Artery Disease|Patients undergoing carotid artery stenting for high grade carotid artery stenosis with or without neurologic symptoms and with or without a high risk for carotid endarterectomy.
3347748|NCT02240875|Experimental|Group 1|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly
3347749|NCT02240875|Experimental|Group 1b|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3347750|NCT02240875|Experimental|Group 1c|Single dose of cAd3-EBO Z at 1 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3347751|NCT02240875|Experimental|Group 2|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly
3347752|NCT02240875|Experimental|Group 2b|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3240771|NCT01292525|Experimental|Withdrawal of Tacrolimus|
3240772|NCT01292551|Active Comparator|Bosentan|
3240773|NCT01292551|Placebo Comparator|Placebo|
3240774|NCT01292564|Active Comparator|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
3347753|NCT02240875|Experimental|Group 2c|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3347754|NCT02240875|Experimental|Group 3|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly
3347755|NCT02240875|Experimental|Group 3b|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 4.4x10^8 TCID50s MVA-BN® Filo
3347756|NCT02240875|Experimental|Group 3c|Single dose of cAd3-EBO Z at 5 x 10^10 vp intramuscularly, followed by 2.2x10^8 TCID50s MVA-BN® Filo
3347757|NCT02240875|Experimental|Group 4|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 7
3347758|NCT02240875|Experimental|Group 5|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 2.2 x 10^8 TCID50s MVA-BN® Filo at day 14
3240775|NCT01292564|Placebo Comparator|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
3240776|NCT01292577|Experimental|CET/PT|Behavioral Intervention: Participants will receive adapted Cognitive Enhancement Therapy/Personal Therapy.
3240777|NCT01292577|Active Comparator|Treatment as Usual|Behavioral Intervention: Participants will receive treatment as usual.
3347759|NCT02240875|Experimental|Group 6|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 7
3347760|NCT02240875|Experimental|Group 7|Single dose of cAd3-EBO Z at 2.5 x 10^10 vp intramuscularly at day 0, followed by 4.4 x 10^7 TCID50s MVA-BN® Filo at day 14
3347761|NCT02240888|Active Comparator|vaccinated patients|patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
3240778|NCT01292590|Experimental|High fat meal|
3240779|NCT01292655|Experimental|Arm A1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
3240780|NCT01292655|Experimental|Arm A2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
3240781|NCT01292655|Experimental|Arm B1 (Escalation): BMS-906024|BMS-906024 solution intravenously as specified
3347762|NCT02240888|Active Comparator|vaccinated controls|healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
3347763|NCT02240888|Active Comparator|seasonal influenza vaccine|patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
3347764|NCT02240888|Active Comparator|non-vaccinated controls|healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.
3347765|NCT02240901|Experimental|Laryngeal mask airway|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
3347766|NCT02240901|Experimental|Endotracheal intubation group（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
3240782|NCT01292655|Experimental|Arm B2 (Expansion): BMS-906024|BMS-906024 solution intravenously as specified
3240783|NCT01292668|Experimental|Group I|Patients apply methyl-5-aminolevulinate hydrochloride (MAL) cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo laser light treatment for 3-5 minutes.
3347767|NCT02240914||Vascular USG and IVUS imaging diagnosis|
3347768|NCT02240927|Active Comparator|Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
3347769|NCT02240927|Active Comparator|Enoxaparine and 2.5 mg warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1.0). Full dose warfarin is continued after first trimester and dose is regulated according to INR (between 2.5-4)
3347770|NCT02240927|Active Comparator|Enoxaparine and 4 mg warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
3347771|NCT02240927|Active Comparator|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
3347772|NCT02240940|Experimental|Parachute Implant|Appropriate patients meeting inclusion / exclusion will be implanted with the Parachute device after screening with transthoracic echocardiography (TTE) and cardiac CT or MRI.
3347773|NCT02240953|Active Comparator|Warfarin|In the first arm only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
3347774|NCT02240953|Active Comparator|Warfarin + ASA 100 mg + PPI|In the second arm 100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
3347775|NCT02240953|Active Comparator|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
3347776|NCT02240953|Active Comparator|Observational Warfarin|This arm is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
3240784|NCT01292668|Experimental|Group II|Patients apply MAL cream on the lesions and the surrounding normal skin. Beginning 3 hours later, patients undergo light emitting diode treatment for 5-10 minutes.
3347777|NCT02240979||Adults able to undergo cardiac MRI exam|Adults able to undergo cardiac MRI
3347778|NCT02240992|Experimental|MSCs&PBSC|PBSC will be intravenously infused at a dose of 2×10^8/kg. MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until complete response(CR) . If the patients do not achieve CR or partial remission (PR) within 4 weeks, they will swithed to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
3347779|NCT02240992|Experimental|MSCs|MSCs will be intravenously infused at a dose of 1×10^6 cells/kg once per week or until CR. If the patients have no response (NR) within 4 weeks, they will switch to other therapy. If the patients achieve PR within 4 weeks, a second course of the same treatment will be given.
3240785|NCT01292681|Other|Multi-modality imaging|
3240786|NCT01292694|Experimental|Losartan|Angiotensin II AT1 receptor antagonist which blocks the actions of angiotensin II
3347780|NCT02241005|Active Comparator|Theraworx™|Participants are randomized to use the Theraworx™ bath wipes.
3347781|NCT02241005|Active Comparator|Standard|Participants are randomized to use standard bath wipes.
3347782|NCT02241018|Experimental|Mesenchymal stem cells|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 dose (as 1 cycle) or until CR. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given. Besides, CD25 monoclonal antibody (20mg/kg) will be administered at day 1,4,8,15, 21 and calcineurin inhibitors will also be used.
3347783|NCT02241018|Experimental|CD25 Mc Ab & calcineurin inhibitors|CD25 monoclonal antibody (20mg/kg, day 1,4,8,15,21) will be administered combined with calcineurin inhibitors. The response should be evaluated at 3 and 4 weeks. If symptoms of aGVHD progress at 3 weeks or the patients have NR at 4 weeks, these patients will switch to other therapy. If patients achieved PR at 4 weeks, another cycle will be given.
3347784|NCT02241031|Experimental|MPs|MPs will be intravenously infused within 48 hours after chemotherapy. During the study period, patients can receive platelet infusion but can not receive platelet stimulating factors.
3347785|NCT02241031|Active Comparator|Non-MPs|Patients can receive platelet infusion but can not receive platelet stimulating factors.
3375913|NCT03529383|Experimental|Therapeutic education|"Women randomized to the therapeutic education arm will follow a 6-month program of therapeutic patient education. They will also receive international recommendations on physical activity."
3240787|NCT01292694|Experimental|Captopril|ACE inhibitor which blocks the formation of angiotensin II
3240788|NCT01292694|Placebo Comparator|Placebo Tablet|A placebo tablet will be provided by the Vanderbilt Investigational Drug Service for these studies.
3240789|NCT01292707|Active Comparator|Control|Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania
3240790|NCT01292707|Active Comparator|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.
3259292|NCT01469520|Active Comparator|Reference|Co-administered liquid mixture of Epivir® (lamivudine) solution, Retrovir® (zidovudine)and Viramune® (nevirapine)
3240791|NCT01292707|Active Comparator|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
3240792|NCT01292720|Placebo Comparator|Placebo|Placebo (herbal oil)
3347786|NCT02241044|Active Comparator|the Combined group|The Combined group patients received Argon plasma coagulation therapy, PSD-60/Endoplasma (Olympus Corporation, Tokyo, Japan), following distilled water injection at index endoscopy. Then participants were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
3347787|NCT02241044|Placebo Comparator|the Injection group|Injection group patients underwent distilled water alone at index endoscopy. Then patients were treated with intravenous pantoprazole (Pantoloc i.v., Nycomed GmbH, Singen, Germany) 40 mg every 12 hours during the first 3 days, followed by oral pantoprazole (Pantoloc, Takeda GmbH, Oranienburg, Germany) 40 mg daily until the end of 56-day study period.
3347788|NCT02241057|Experimental|Temperature|Evaluate the temperature profile of the air activated 3-cell patch during 8 hours of wear
3347789|NCT02241057|Experimental|Adhesion|Evaluate the adhesion with and without the presence of a temperature probe
3240793|NCT01292720|Experimental|Vitamin D|
3240794|NCT01292733|Experimental|Ovarian Cancer Screening|CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires
3240795|NCT01292785||Transsexual|Female-to-Male and Male-to-Female Transsexuals receiving hormonal therapy
3240796|NCT01292785||Healthy control subjects|receiving no hormonal therapy
3240797|NCT01292811|Experimental|Functional electrical Stimulation|The functional electrical stimulation for the treatment group will begin by designing a stimulation protocol that can generate the palmar and/or the lateral grasp on demand. In other words, the stimulation sequence (protocol) will be developed for each patient individually using either Compex Motion or HEWHS stimulator; this will allow the patient, who otherwise cannot grasp, to do so with the system. Both stimulators will be used to deliver the same FES therapy. Stimulation parameters are: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from 250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
3347790|NCT02241070|Experimental|mindulness-based intervention|Mindulness-based intervention was eight weeks of mindfulness training with forty-five minutes of homework practice every day during the training course. A leader and a professional facilitator led the group. The leader was a long-term mindfulness and vipassana meditation trainer who had practiced both types of meditation for more than two decades and had completed mindfulness trainer education; the professional facilitator was a mindfulness practitioner and a psychiatrist. The group met weekly for two hours in-session at the workplace.
3347791|NCT02241070|No Intervention|waiting-list control|passive control group
3347792|NCT02241083|Active Comparator|dopamine group|vasopressor dosage individually titred according to the mean arterial pressure
3347793|NCT02241083|Active Comparator|norepinephrine group|vasopressor dosage individually titred according to the mean arterial pressure
3347794|NCT02241083|Active Comparator|control group|no medication
3347795|NCT02241096|Experimental|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
3240798|NCT01292811|Other|Control Group|"The Control group will receive conventional occupational therapy pertaining to hand function [15].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
3347796|NCT02241109|Other|All patients|Compare patients with high calcification propensity do have faster valve-stenosis progression
3347797|NCT02241122|Experimental|MRI guided prostate biopsy|prostate biopsy after MR-imaging
3347798|NCT02241135|Experimental|80 µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
3347799|NCT02241135|Experimental|160µg CV7201 mRNA short|Vaccination by injection on days 0, 7, 28.
3347800|NCT02241135|Experimental|80 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3347801|NCT02241135|Experimental|160 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3347802|NCT02241135|Experimental|320 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3347803|NCT02241135|Experimental|640 µg CV7201 mRNA long|Vaccination by injection on days 0, 28.
3347804|NCT02241135|Experimental|200 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3347805|NCT02241135|Experimental|400 µg CV7201 mRNA long|Vaccination by injection on days 0, 28, 56.
3347806|NCT02241148|Active Comparator|Acetaminophen 500mg|The control group will receive treatment with acetaminophen 500mg and physical therapy rehabilitation
3347807|NCT02241148|Experimental|Kinesio taping|The experimental treatment group will receive acetaminophen 500mg and physical therapy rehabilitation, plus the application of the technique NUCAP Medical Upper Knee Spider ® Kinesio taping
3347808|NCT02241161|Active Comparator|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3347809|NCT02241161|Active Comparator|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3347810|NCT02241161|Active Comparator|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3347811|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream +rejuvenating serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3347812|NCT02241161|Active Comparator|plantaricin a (rejuvenating cream + antioxidant serum)|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
3347813|NCT02241174|Experimental|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water.
3347814|NCT02241174|Placebo Comparator|Placebo|100ml distilled water will be used as a placebo and will be stored on amber bottles identical with the treatment group
3347815|NCT02241200|Experimental|IV Administration|The iv solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
3347816|NCT02241200|Experimental|SC Administration|The sc solutions containing DA-3880 and Aranesp will be indistinguishable in appearance.
3347817|NCT02241213|Active Comparator|Active Transcranial Magnetic Stimulation TMS- r|Application of single stimulation pulses and regularly repeated ones, the frequency may be divided into high frequency EMT (> 1 Hz), low frequency (<1 Hz) This classification is based on physiological effects (stimulation or inhibition neuronal respectively). In this particular case, we will use low frequency <1 Hz with repetitive pulses.
3347818|NCT02241213|Placebo Comparator|Placebo Transcranial Magnetic Stimulation|Placebo coil that will simulate the sound of the pulses.
3347819|NCT02241226|Experimental|Perfect health course|Perfect health course at the Chopra Center for Wellbeing
3347820|NCT02241226|No Intervention|Resort group|Resort group at the La Costa resort
3347821|NCT02241239||participants|healthy adults without stroke and coronary heart disease
3347822|NCT02241252|Other|iPhone ECG QT recording|iPhone ECG
3240799|NCT01292824|No Intervention|Standard liver transplant care|Liver Transplantation as per Standard of Care
3347823|NCT02241265||Past Bronchial Thermoplasty data|Data will be collected from records of patients who, in the past, have undergone bronchial thermoplasty.
3347824|NCT02241278|Placebo Comparator|Control|In the operating room, the anesthesiologist administered 50 mL of 0.9% saline intravenously to patients in the control group 30 minutes before surgical incision.
3347825|NCT02241278|Experimental|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision. (a single dose).
3347826|NCT02241291||All patients|Patients undergoing PCI at Bern University Hospital
3240800|NCT01292824|Experimental|ITX 5061|Liver Transplantation as per Standard of Care + ITX5061
3240801|NCT01292850||Healthy Volunteers|15 healthy volunteers were recruited
3240802|NCT01292863|Active Comparator|Conventional peritoneal dialysis solution|Subjects will be randomized to perform dialysis with the conventional peritoneal dialysis solution for 3 months. At the end of three months mesothelial cell shedding and apoptosis will be measured.
3240803|NCT01292863|Experimental|Novel biocompatible dialysis solution Delflex neutral pH|
3347827|NCT02241304||Elective surgery with muscle relaxation|ASA I-II-III patients. Fentanyl (2-3 ug/kg) - Propofol (2 mg/kg) induction, sevoflurane anesthesia, type and dose of muscle relaxant up to the decision of attending anesthetist. Neuromuscular stimulation with TetraGraph (30mA current intensity, 0.2 msce pulse duration, 20 sec intervals)
3347828|NCT02241330|Placebo Comparator|Control|Control wheat used for meal, level of zinc is usual
3347829|NCT02241330|Active Comparator|fortification|Fortification Wheat is fortified before testmeal administration. Zinc level is comparable to WHO recommendation
3347830|NCT02241330|Active Comparator|Biofortified|Biofortification Biofortified wheat is used for testmeal administration. Zinc concentration is around 30% higher than control
3347831|NCT02241356|Active Comparator|single vision glasses|single vision glasses
3347832|NCT02241356|Experimental|bifocals|bifocal glasses
3240804|NCT01292889||Seasonal Affective Disorder|Consists of Individuals with Seasonal Affective Disorder
3347833|NCT02241369|Experimental|Cohort I|3 mg of INO-3106 (D0); 6 mg of INO-3106 (Wk3); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk6); 6 mg of INO-3106 + 1 mg of INO-9012 (Wk9);
3347834|NCT02241369|Experimental|Cohort II|6 mg of INO-3106 in combination with 1 mg of INO-9012, or at the MTD determined above at D0, Wk3, Wk6, Wk9
3240805|NCT01292889||Subsyndromal Seasonal Affective Disorder|Consists of individuals who do not meet SAD criteria,but present more symptoms for the disorder than do controls.
3240806|NCT01292889||Major Depressive Disorder|Consists of individuals who have MDD.
3347835|NCT02241382|Active Comparator|External Electrocardioversion|"Cardioversion with an external cardioverter-defibrillator with a step-up energy protocol (100, 150, 200, 360 J biphasic) in antero-posterior orientation, maintaining a > 8 cm distance between shock electrodes and device and complying with a cool-down phase of 2 minute between shocks, if more than one shock is required."
3240807|NCT01292889||Controls|Consists of individuals who do not present symptoms of SAD or MDD.
3240808|NCT01292902|Active Comparator|healthy volunteers|
3240809|NCT01292902|Other|chronic heart failure|
3240810|NCT01292915||1|
3240811|NCT01292941|Active Comparator|Active comparator/Yellow catheter|SpeediCath coated catheter
3240812|NCT01292941|Experimental|NonCE marked intermittent catheter/red|
3240813|NCT01292941|Experimental|NonCE marked intermittent catheter/green|
3240814|NCT01292941|Experimental|NonCE marked intermittent catheter/Blue|
3240815|NCT01292954|Active Comparator|Low dose blueberry|
3240816|NCT01292954|Active Comparator|medium dose blueberry|
3240817|NCT01292954|Active Comparator|high dose blueberry|
3240818|NCT01292954|Placebo Comparator|control|
3240819|NCT01292967|Placebo Comparator|Low flavanol|Low-flavanol chocolate contained 48 mg of cocoa flavanols. macro- and micro-nutrient matched with active comparator
3240820|NCT01292967|Active Comparator|High-flavanol with sugar|High-flavanol chocolate made with added sugar containing 251 mg of cocoa flavanols
3240821|NCT01292967|Active Comparator|High flavanol Maltitol|High-flavanol chocolate made with the sugar substitute maltitol containing 266 mg cocoa flavanols
3240822|NCT01292993|Experimental|Treatment A|400 mg LX4211
3240823|NCT01292993|Experimental|Treatment B|1000 mg metformin
3347836|NCT02241382|Experimental|Internal Electrocardioversion|Cardioversion via the implanted ICD with a maximum energy synchronized shock (41 J, with a RV -> SVC+can shock orientation in pts with SVC leads). After 1 ineffective internal shock, the patient will be counted as internal CV failure and cardioverted externally, following the same protocol as the external CV group.
3347837|NCT02241395|Experimental|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
3347838|NCT02241421|Placebo Comparator|Placebo|No intervention: Placebo 3x2 capsules per day during 7 consecutive days.
3347839|NCT02241421|Experimental|Treatment Antibiotics: Amoxicillin|Experimental: Amoxicillin (broad spectrum antibiotics) 1500 mg/day (3x2 capsules of 250 mg) during 7 consecutive days.
3347840|NCT02241421|Experimental|Treatment Antibiotics: Vancomycin|Experimental: Vancomycin (small spectrum antibiotics) 1500mg/day (3x2 capsules of 250 mg) during 7 consecutive days
3347841|NCT02241434|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
3347842|NCT02241447||Observation|the nurse identifies cases with severe AS and collects their data. Baseline data for each patient will be collected and a follow-up will be done after three months for each patient to determine his/her outcome and the treatment that was decided on
3347843|NCT02241447||Early information|in this arm, the physician referring a patient for echocardiography will be notified of a finding of severe aortic stenosis: the nurse brings cases with severe AS to the attention of the referring physician within a week (via phone, e-mail or letter) to make them aware of the diagnosis.
3347844|NCT02241460|Active Comparator|Promescent Lidocaine Spray|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
3347845|NCT02241460|Placebo Comparator|Placebo|Double-Blind Treatment Period: 3 cycles (3 weeks each); 1 week wash-out between each cycle Open-Label Treatment Period: 4 cycles (1 week each); no wash-out
3240824|NCT01292993|Experimental|Treatment C|400 mg LX4211 + 1000 mg metformin
3240825|NCT01293019|Experimental|Experimental|Osteopathic treatment
3240826|NCT01293019|Placebo Comparator|Placebo|Sham osteopathic treatment
3240827|NCT01293019|Active Comparator|Usual care|Classic treatment of cystic fibrosis patients
3240828|NCT01293045|Experimental|HC Group|Group of volunteers fed with Hydrolyzed Collagen
3240829|NCT01293045|Active Comparator|CT Group|Group of volunteers fed with wheat proteins
3240830|NCT01293058|Other|Intravenous|The investigators administered intravenous naloxone for our opioid overdose patients
3240831|NCT01293058|Other|Intranasal|The investigators administered intranasal naloxone for treatment of our patients
3347846|NCT02241473|Experimental|CH training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single-blind fashion.
3347847|NCT02241473|Active Comparator|CN training group|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) condition in a single-blind fashion.
3240832|NCT01293071|Active Comparator|Mixing arm|Antibiotic rotation, each consecutive initiated antibiotic treatment a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems)
3240833|NCT01293071|Active Comparator|Cycling|Antibiotic rotation, every 1.5 month a different preferred antibiotic treatment from a different class (one of 3 classes: cephalosporins, piperacillin-tazobactam, carbapenems) is used for empiric treatment.
3240834|NCT01293097|Active Comparator|Intensive statin therapy|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
3347848|NCT02241499|Experimental|Radiotherapy and chemotherapy (oxaliplatin and fluorouracil).|Radiotherapy (5 x 4 Gy) will be given. After completion of radiotherapy, 4 cycles of chemotherapy will be administered, cycle length 14 days. Each patient will receive oxaliplatin as infusion at a dose of 85 mg/m2, followed by a bolus injection of fluorouracil at a dose of 400 mg/m2, and a long time infusion (44 hours) of fluorouracil at a dose of 2 400 mg/m2.
3347849|NCT02241525||Prospective|Twenty patients will be enrolled and scanned with the RESEARCH procedures
3347850|NCT02241525||Retrospective|Patients with matching age and BMI will be selected from existing patients with a CLINICAL STANDARD of Care CTPA scan.
3347851|NCT02241538|Experimental|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3240835|NCT01293097|Other|Usual care|Usual care, but statin dose should not be higher than that described in exclusion criteria.
3240836|NCT01293136||intravenous opioids|
3240837|NCT01293136||femoral nerve block|
3240838|NCT01293149|Experimental|Ropivacaine plus clonidine|Ropivacaine plus clonidine for femoral block
3240839|NCT01293149|Active Comparator|Ropivacaine|Ropivacaine alone for femoral block
3240840|NCT01293162||placebo|
3240841|NCT01293175|Experimental|Whole grains|Subjects will consume whole grains every day for two months
3240842|NCT01293175|No Intervention|Control|Subjects will consume their habitual diet
3240843|NCT01293188||Biopresthetic aortic valve replacement.|
3240844|NCT01293201|Experimental|STAHIST Investigational Medical Product|STAHIST Tablet, dosed one tablet BID
3240845|NCT01293201|Placebo Comparator|Placebo|Placebo tablet, identical appearance to IMP, dosed one tablet BID
3240846|NCT01293214|Experimental|Transplantation|Subjects will undergo single or multiple limb transplantation
3240847|NCT01293253|Experimental|Stair walking|Participants of this group is encouraged to use the stairs for 10 minutes a day at the workplace
3240848|NCT01293253|Active Comparator|Control|Receives a health examination before and after the intervention period, and are advised to stay active
3240849|NCT01293266|Active Comparator|Propofol|Anesthesia is changed from Sevoflurane to Propofol after obtaining baseline blood gas analysis from the heart catheterisation sheath.
3240850|NCT01293266|No Intervention|Sevoflurane|Sevoflurane anesthesia is maintained after obtaining a baseline blood gas analysis.
3347852|NCT02241538|Experimental|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3347853|NCT02241538|Experimental|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
3347854|NCT02241538|Active Comparator|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group will not receive additional exercise.
3347855|NCT02241564||Malignancy post transplantation|
3240851|NCT01293279||HCV Patients who are treatment naive|Han ethnic Chinese male or female ≥ 18 years old with recent a confirmation of anti-HCV-antibody positive and HCV RNA positive but antiviral or interferon treatment naive at the time this study starts from 28 university affiliated hospital throughout China.
3240852|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine sulfate|Pharmaceutical form capsule.
3347856|NCT02241577|Experimental|Surgical treatment|Surgical access for scaling and disinfection of dental implant
3347857|NCT02241577|Experimental|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of dental implant
3347858|NCT02241590|Placebo Comparator|Entecavir + Placebo|Tablet with Entrcavir+ Tablet with starch
3347859|NCT02241590|Experimental|Entecavir + Fuzheng Huayu Tablet|Tablet with Entrcavir+ Tablet with Fuzheng Huayu
3347860|NCT02241603|Experimental|Weight loss|Obese Veterans will aim to lose 5-10% body weight
3347861|NCT02241603|No Intervention|Baseline comparator|Obese Veterans similar to Aim 1 in BMI, age, gender but not insulin sensitivity will not undergo weight loss
3347862|NCT02241616|Experimental|Entecavir+Fuzheng Huayu+TCM Granule|Tablet with Entecavir+ Tablet with Fuzheng Huayu+ Granule with TCM
3347863|NCT02241629|Experimental|levo phencynonate hydrochloride 1mg|levo phencynonate hydrochloride tablet 1mg
3347864|NCT02241629|Placebo Comparator|placebo|Placebo
3347865|NCT02241629|Experimental|levo phencynonate hydrochloride 2mg|levo phencynonate hydrochloride 2mg
3347866|NCT02241642|Experimental|Treatment|VIVASURE CLOSURE DEVICE™
3347867|NCT02241668|Experimental|FLT PET Scan + 3'-Deoxy-3'-18f-Fluorothymidine|After a magnetic resonance imaging (MRI) scan of brain performed, an FLT PET scan using 3'-Deoxy-3'-18f-Fluorothymidine solution performed. After solution is injected into a vein, the PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. The entire procedure should last about 60-70 minutes.
3240853|NCT01293305|Experimental|Chondroitin Sulfate + Glucosamine Sulfate|Oral powder.
3240854|NCT01293305|Active Comparator|Condroflex®|Pharmaceutical form capsule.
3240855|NCT01293305|Active Comparator|CONDROFLEX®|Oral powder
3240856|NCT01293318||Acute pancreatitis|
3347868|NCT02241681|Other|Peptamen 1.5|500 mL of Peptamen 1.5
3347869|NCT02241694||survey|
3347870|NCT02241746||malnutrition|
3347871|NCT02241759|Experimental|TA-8995|Single oral dose of 150mg TA-8995
3347872|NCT02241759|Experimental|Placebo|Single oral dose of placebo to TA-8995
3240857|NCT01293331||Study Cohort (Case )|Participants will be examined for fever in dengue endemic regions
3240858|NCT01293344|Experimental|Men and Mediterranean diet|Men who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
3240859|NCT01293344|Experimental|Women and Mediterranean diet|Women who are assigned to a 4 weeks experimental diet formulated to be concordant with characteristics of the traditional Mediterranean diet.
3347873|NCT02241759|Active Comparator|Moxifloxacin|Single open-label oral dose of 400mg moxifloxacin
3347874|NCT02241772|Experimental|10mg TA-8995|10mg TA-8995 once daily
3347875|NCT02241772|Experimental|2.5mg TA-8995|2.5mg TA-8995 once daily
3347876|NCT02241772|Placebo Comparator|Placebo to TA-8995|Placebo to TA-8995 once daily.
3347877|NCT02241798|Experimental|Pre-oxygenation first|"st, 3rd, 5th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated~nd, 4th, 6th, etc seizure: Standard practice (O2 only in post-ictal period)."
3347878|NCT02241798|Experimental|Standard practice first|"st, 3rd, 5th, etc seizure: Standard practice (O2 only in post-ictal period).~nd, 4th, 6th, etc seizure: continuous 'pre-oxygenation' up to 4L O2 nasal prongs, as tolerated"
3347879|NCT02241811|Placebo Comparator|Control|After wound dressing we applied hydrogel without any active ingredient everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
3347880|NCT02241811|Experimental|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
3240860|NCT01293357|Experimental|Patches|
3240861|NCT01293370||vocational rehabilitation|Admitted and discharged psychiatric patients receiving vocational rehabilitation
3240862|NCT01293383|Other|LEO 90105|
3240863|NCT01293383|Other|Vehicle|
3240864|NCT01293409|Placebo Comparator|Placebo|The amount of photic energy of light is considered to be non-therapeutical
3240865|NCT01293409|Experimental|Intermediate dose|"The amount of photic energy of bright light is considered to be intermediate"
3240866|NCT01293409|Experimental|High dose bright light|The amount of photic energy of bright light is considered to be fully therapeutic
3240867|NCT01293422|Experimental|Rifampicin|
3240868|NCT01293435||1|
3240869|NCT01293448|Experimental|Intervention|CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
3240870|NCT01293461|Experimental|CBX129801|
3240871|NCT01293461|Placebo Comparator|Placebo|
3240872|NCT01293474||glaucoma patients|patients with diagnosis of primary open angle glaucoma
3347881|NCT02241824|Active Comparator|Elastic abdominal binder|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an elastic abdominal binder.
3347882|NCT02241824|No Intervention|No brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen with no brace (control).
3347883|NCT02241824|Experimental|In-elastic lumbar brace|To evaluate the opioid consumption in chronic low back pain patients on a stable opioid regimen after an intervention of an in-elastic lumbar brace.
3240873|NCT01293474||control group|age matched healthy controls
3347884|NCT02241850|Other|High intensity training|9 weeks of supervised training
3347885|NCT02241863|Experimental|Multifaceted intervention|Patients, their caregivers and family members will received the educational and motivational interventions
3347886|NCT02241863|Active Comparator|Active Comparator|Usual Care The usual care group received routine counseling performed by the psychiatrist and nurses.
3347887|NCT02241876|Placebo Comparator|Placebo|The patients will be treated with placebo as follows: 15 mL (0 mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
3347888|NCT02241876|Experimental|N-Acetylcysteine|The patients will be treated with n-acetylcysteine as follows: 15 mL (600mg of drug), once a day, during 7 days in each cycle (2 days before chemotherapy with cisplatin, on the day of chemotherapy and more 4 days after chemotherapy).
3347889|NCT02241902||No pyuria|
3347890|NCT02241902||Persistent pyuria|
3347891|NCT02241915|Active Comparator|Microbial Sealant|Integuseal (Kimberly Clark)
3347892|NCT02241915|Sham Comparator|Control|No microbial sealant
3347893|NCT02241928|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3347894|NCT02241941|Experimental|Daptomycin|
3347895|NCT02241954||Expansion Thoracoplasty|The rib prosthesis is lengthened periodically to correct the concavity of the deformity, expanding the volume of the hypoplastic thorax and improving associated spinal deformity. This device has been FDA approved by a Humanitarian Device Exemption and is described as a Vertical Expandable Prosthetic Titanium Rib (VEPTR). An updated version of the VEPTR, the VEPTR II, may be used instead depending on the physician's preference and the patient's anatomy. The VEPTR II device has greater size range and modularity of implants than the original VEPTR.
3347896|NCT02241980||Medicare Part D patients|Survey
3347897|NCT02241980||Physician Providers|Survey
3347898|NCT02241993||Type 1 diabetic|
3347899|NCT02242006||piperacillin/tazobactam|Serial serum sampling of patients receiving piperacillin/tazobactam and SLED simultaneously
3240874|NCT01293487|Experimental|Arm 1|
3240875|NCT01293526|Experimental|Experimental 1|Patients who respond will have their leads placed based on study measurements.
3240876|NCT01293526|Experimental|Control|Leads will be placed using standard procedures.
3240877|NCT01293526|Experimental|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
3347900|NCT02242006||meropenem|Serial serum sampling of patients receiving meropenem and SLED simultaneously
3347901|NCT02242006||vancomycin|Serial serum sampling of patients receiving vancomycin and SLED simultaneously
3347902|NCT02242032|Experimental|P-321|P-321 Ophthalmic Solution
3347903|NCT02242032|Placebo Comparator|P-321 Ophthalmic Solution Placebo|P-321 Ophthalmic Solution Placebo
3347904|NCT02242058||High frequency pain group|39 pediatric or adult patients with high pain frequency (greater than or equal to 3 ER visits and/or hospitalizations for pain per year over the last two years)
3240878|NCT01293552|Placebo Comparator|Control|blank vehicle formulation
3240879|NCT01293552|Experimental|Dose 1|Dose 1
3240880|NCT01293552|Experimental|Dose 2|Dose 2
3240881|NCT01293552|Experimental|Dose 3|Dose 3
3347905|NCT02242058||Low Pain Frequency group|39 pediatric or adult patients with low pain frequency (less than or equal to 1 severe pain episode for the last two years)
3347906|NCT02242058||Healthy control group|39 pediatric or adult relatives of sickle cell disease patients, who do not have the sickle cell trait of SCD.
3347907|NCT02242058||Pain Crisis group|30 patients with sickle cell disease with severe phenotype (HbSS, HbSβ0 thalassemia, HbSOArab)
3347908|NCT02242058||Pain Service group|10 patients without sickle cell disease admitted to the pain service.
3347909|NCT02242071|Experimental|Stem Cell|bone marrow mononuclear cell transplantation
3347910|NCT02242084|Experimental|Alteplase treatment|All subject who enter the trial will receive treatment with Alteplase along with questionnaire.
3347911|NCT02242097|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib orally PO QD on days 1-28. Courses repeat every 28 days for up to 4 years in the absence of disease progression, unacceptable toxicity, or patient preference.
3347912|NCT02242110|Experimental|Nightmare Treatment|The nightmare treatment, Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder (ERRT-Bipolar Disorder), is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
3347913|NCT02242123||Study group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of mild intestinal histology damage (grade 1-2) at first evaluation.
3347914|NCT02242123||Control group|Symptomatic patients, with weakly positive serum anti-tTG and evidence of intestinal villous atrophy (intestinal histology damage grade 3) at first evaluation.
3347915|NCT02242136|Experimental|FORNET|During FORNET, the client, with the assistance of the therapist, constructs a chronological narrative of his or her entire life with a focus on exposure to traumatic stress and committed violence. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior. The therapist asks in detail for the client's emotions, cognitions, physiological reactions, and sensory informations during traumatic and aggressive events to link them to an autobiographical context, namely time and place. In total the individuals receive 8 sessions of FORNET, every session lasting between 1,5 and 2 hrs depending on the needs of the participant.
3347916|NCT02242136|No Intervention|Waiting list|
3347917|NCT02242149|Placebo Comparator|Placebo|All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
3347918|NCT02242149|Experimental|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
3347919|NCT02242162||neuromuscular diseases|
3347920|NCT02242175|Other|normal group|
3347921|NCT02242175|Other|irritable bowel syndrome group|
3347922|NCT02242188|Experimental|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
3347923|NCT02242188|Placebo Comparator|Placebo|"Maltodextrin prepared in sachets. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
3347924|NCT02242214||Misoprostol 200 µg VDS|At the discretion of the investigator in accordance with their usual practice and consistent with the Dutch prescribing information.
3240882|NCT01293552|Experimental|Dose 4|Dose 4
3240883|NCT01293565||HED Affected Males|
3240884|NCT01293565||Male Controls|
3240885|NCT01293578|No Intervention|Usual Care|Clinicians will present diabetes medication options to patients, in their usual way.
3240886|NCT01293578|Experimental|Diabetes Medication Decision Aid|In the decision aid arm, clinicians will use the diabetes medication decision aid cards (if they choose) when discussing diabetes medication options with their patients.
3347925|NCT02242227|Experimental|Salmeterol xinafoate|25 μg Salmeterol inhalation powder administered via HandiHaler®
3347926|NCT02242227|Active Comparator|Serevent® Diskus®|50 μg Salmeterol (dry powder inhaler) administered via Diskus®
3347927|NCT02242227|Placebo Comparator|Placebo|
3347928|NCT02242240|Experimental|Tiotropium with single dose of formoterol|
3347929|NCT02242240|Experimental|Tiotropium with double dose of formoterol|
3347930|NCT02242240|Experimental|Tiotropium with Placebo|
3347931|NCT02242253|Experimental|Tiotropium+salmeterol QD|free combination of tiotropium and salmeterol
3347932|NCT02242253|Active Comparator|Tiotropium+salmeterol BID|free combination of tiotropium and salmeterol
3347933|NCT02242253|Active Comparator|Tiotropium QD|
3347934|NCT02242253|Active Comparator|Salmeterol BID|
3347935|NCT02242266|Experimental|Tiotropium low dose|oral inhalation via the blue HandiHaler®
3347936|NCT02242266|Experimental|Tiotropium medium dose|oral inhalation via the blue HandiHaler®
3347937|NCT02242266|Active Comparator|Spiriva® HandiHaler® high dose|oral inhalation via the grey HandiHaler®
3347938|NCT02242266|Placebo Comparator|Placebo|
3347939|NCT02242279|Experimental|BEA 2180 - low dose|
3347940|NCT02242279|Experimental|BEA 2180 - medium dose|
3347941|NCT02242279|Experimental|BEA 2180 - high dose|
3347942|NCT02242279|Active Comparator|Tiotropium|
3347943|NCT02242279|Placebo Comparator|Placebo|
3347944|NCT02242292|Experimental|Hyoscine butylbromide|"5 tablets taken in a 24-hour period/each episode:~for up to 7 episodes, or~over a period of up to 6 weeks"
3347945|NCT02242292|Placebo Comparator|Placebo|
3347946|NCT02242318|Experimental|Telmisartan|low dose for two weeks, then up titration to high dose, once daily
3347947|NCT02242318|Active Comparator|Valsartan|low dose for two weeks, then up titration to high dose, once daily
3240887|NCT01293591|Other|Control|270 kcal White bread with 15 g margarine
3240888|NCT01293591|Other|Garlic Treatment|270 kcal white bread with 15 g margarine and 5 g crushed garlic
3240889|NCT01293604|Experimental|Whole Grain Barley Diet|A controlled diet containing at least 4 daily servings of whole grain barley.
3240890|NCT01293604|Active Comparator|Whole Grain Oats Diet|A diet containing at least 4 servings of whole grain oats.
3240891|NCT01293604|Other|Low Whole Grain Diet|A control diet containing 0.7 daily servings of whole grain.
3240892|NCT01293617|Placebo Comparator|Gelatin|
3240893|NCT01293617|Experimental|Blackberries|
3347948|NCT02242318|Placebo Comparator|Placebo|
3347949|NCT02242331||essential hypertension patients|
3347950|NCT02242344|Experimental|telmisartan - low dose|
3347951|NCT02242344|Experimental|telmisartan - high dose|
3347952|NCT02242344|Placebo Comparator|Placebo|
3347953|NCT02242357||Patients with hypertension|
3347954|NCT02242370|Experimental|Telmisartan low dose|
3347955|NCT02242370|Experimental|Telmisartan high dose|
3347956|NCT02242383||Essential hypertension|
3347957|NCT02242396||Hypertensive patients|
3347958|NCT02242409|Experimental|Gemcitabine/abraxane|Gemcitabine and Abraxane
3347959|NCT02242422||transobturator tape|
3347960|NCT02242435|Experimental|Ampion 4ml|4 mL intra-articular injection of Ampion
3347961|NCT02242435|Placebo Comparator|Placebo Solution|4 mL placebo intra-articular injection
3347962|NCT02242461|Placebo Comparator|Rhodiola placebo capsules|starch
3347963|NCT02242461|Experimental|Rhodiola Crenulata|Rhodiola Crenulata
3347964|NCT02242474|Active Comparator|Anti-TNF suspended perioperatively|Patients randomized to Group B will have their anti-TNFα therapy interrupted before surgery. Different authors suggested that anti-TNFα therapies should be suspended between two and five half-lives prior to surgery. In the current trial, anti-TNFα will be suspended three half-lives (± seven days) prior to surgery. All other medications used in the treatment of the disease (methotrexate, hydroxychloroquine, corticosteroid, etc.) will be documented and continued in the perioperative period. Non-steroidal anti-inflammatory drugs (NSAID) will be suspended seven days prior to surgery and will be restarted postoperatively. Anti-TNFα will be restarted once wound healing is completed.
3375914|NCT03529383|Experimental|Combined|"Women will benefit from both the connected device intervention and the therapeutic education intervention and receive international recommendations on physical activity."
3347965|NCT02242474|Experimental|Anti-TNFα continued perioperatively|Patients randomized to Group A will continue their anti-TNFα treatment unaltered during the whole perioperative period. Surgery will be performed without consideration in regards to the timing of the treatment. The time elapsed between the last anti-TNFα administration and the surgery will nonetheless be documented.
3240894|NCT01293630|Experimental|Cohort - 1 through 5|AVE8062 combined with paclitaxel and carboplatin will be administered once every 3 weeks
3240895|NCT01293643|Experimental|clindamycin/ketoconazole combination|
3347966|NCT02242500|Experimental|Coronally advanced flap + Mucograft|coronally advanced flap associated with a porcine collagen matrix graft as a subepithelial graft
3347967|NCT02242500|Other|Coronally advanced flap|Coronally advanced flap procedure alone
3240896|NCT01293643|Active Comparator|tetracycline hydrochloride/amphotericin B combination|
3347968|NCT02242513|Active Comparator|pulsed mode radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. One dose of PRF was given in tibial nerve behine the medial ankle in intervention group.
3347969|NCT02242513|Placebo Comparator|Xylocaine|2 c.c xylocaine was given in tibial nerve behind the medial ankle in control group.
3347970|NCT02242526|Active Comparator|Parietex™ Composite Hiatal Mesh, North Haven, CT|Synthetic prosthetic mesh Parietex™ Composite Hiatal (PCO 2H) Mesh (Covidien, North Haven, CT) designed for hiatal hernia repair.
3347971|NCT02242526|Active Comparator|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biologic mesh Biodesign™ Surgisis® Graft Reinforcement in Hiatal, Cook Medical, Bloomington, IN which will be placed for repair of hiatal hernia
3347972|NCT02242539|Experimental|Height measurement poster|
3347973|NCT02242539|Experimental|Community-based monitoring|
3240897|NCT01293656||CD and UC participants|All participants with CD or UC visiting their physician over a period of one year, newly and already diagnosed, regardless of treatment pattern.
3240898|NCT01293669|Experimental|TC-6987|
3347974|NCT02242539|No Intervention|Control|
3347975|NCT02242565|Other|Control: all-sizes of ShangRing|All-sizes of ShangRings will be available.
3347976|NCT02242565|Active Comparator|Reduced-sizes|7 adult sizes of ShangRings will be available
3347977|NCT02242591|Active Comparator|ACB_active/placebo|"Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
3240899|NCT01293669|Placebo Comparator|Placebo|
3240900|NCT01293708||Hospital Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed until hospital d/c
3347978|NCT02242591|Placebo Comparator|ACB_placebo/active|"Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0).~The measurements for baseline and outcome will be made in following order:~VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test"
3347979|NCT02242604||Not treatment|Patients with the age of 70 years or above, that have a serum sodium of below 130 mmol/L on admission. All patients will be routinely evaluated at admission with a standardized multidimensional geriatric assessment (MGA) consisting of a battery of validated assays.
3347980|NCT02242617|Active Comparator|MAS-PAP|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep; followed by positive airway pressure (PAP)
3347981|NCT02242617|Active Comparator|PAP-MAS|Positive airway pressure (PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open; followed by mandibular advancement splints (MAS)
3347982|NCT02242656|Experimental|Group 1|Assigned to receive Treatment A (Period 1), Treatment B (Period 2), Treatment C (Period 3)
3347983|NCT02242656|Experimental|Group 2|Assigned to receive Treatment B (Period 1), Treatment A (Period 2), Treatment C (Period 3)
3240901|NCT01293708||Longitudinal Cohort|All 80+ year old that had had an ICU stay of >=24 hrs. Followed for 12 months
3240902|NCT01293721|No Intervention|control|
3240903|NCT01293721|Experimental|Treatment|Receive vibration therapy
3240904|NCT01293734|Experimental|cold type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in cold type
3240905|NCT01293734|Experimental|heat type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in heat type.
3240906|NCT01293734|Experimental|Asthenia type|To comply with the diagnostic standard of bronchial asthma in western medicine and TCM syndrome in Asthenia type.
3240907|NCT01293734|Active Comparator|Western medicine control group|
3240908|NCT01293747|Experimental|Estradiol 0.5 mg/Progesterone 15 mg microspheres|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension
3240909|NCT01293747|Experimental|Estradiol 1 mg/Progesterone 20 mg microspheres|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension
3240910|NCT01293760|Other|6 weeks interval insertion|IUD is inserted 6 weeks following c-section delivery of baby and placenta
3240911|NCT01293760|Experimental|Immediate insertion|IUD is inserted immediately following c-section delivery of baby and placenta
3240912|NCT01293773|Active Comparator|Taxus Element|Patients treated with paclitaxel-eluting stent (Taxus Element, Boston Scientific, MN)
3240913|NCT01293773|Active Comparator|Xience Prime|Patients treated with Everolimus-eluting stent (Xience Prime, Abbott, IL)
3240914|NCT01293773|Active Comparator|Integrity Resolute|Patients treated with ABT 578-eluting stent (Integrity Resolute, Medtronic, MA)
3240915|NCT01293786||Kidney transplant recipients|
3240916|NCT01293786||Chronic kidney disease|
3347984|NCT02242669||AIM 1|200 current DBSA participants.
3240917|NCT01293799|Experimental|The follow-up group|The intervention in the follow-up group consists of regular tests of the patients´ theoretical and practical skills regarding peritoneal dialysis. The test goals should be passed. If not, retraining will be given if needed til the goals are reached. The peritonitis rate in this group will be compared with that of the control group.
3240918|NCT01293799|No Intervention|Control group|Patients randomised to the control group will be treated according to the routines of the clinic.
3240919|NCT01293812|Experimental|sucrose po|"88% sucrose solution (Syrup B.P.). The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution."
3240920|NCT01293812|Placebo Comparator|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
3347985|NCT02242669||AIM 2|60 new DBSA attendees with mood disorders who have attended their first meeting in the past month.
3347986|NCT02242669||AIM 3|100 matched control group individuals with mood disorders with no current or prior exposure to DBSA.
3347987|NCT02242682|No Intervention|Control|This group of subjects will not be exposed to a video during their time in the ED waiting room
3347988|NCT02242682|Experimental|Child passenger safety video|This group of subjects will be exposed to a video during their time in the ED waiting room
3347989|NCT02242695|Experimental|Fluomizin vaginal tablets|Fluomizin vaginal tablets containing 10mg dequalinium chloride once daily for 6 days and one placebo vaginal tablet on day 7
3347990|NCT02242695|Active Comparator|Canesten vaginal tablets|Canesten vaginal tablets containing 100mg clotrimazole once daily for 7 days
3240921|NCT01293877|Other|LGP|Patient underwent surgery for morbid obesity treatment between 18 to 60 years, and BMI of 40 ore more will divided in two groups, one hundred will be schedule for laparoscopic gastric plication. Our theory for this arm is that the procedure can offer the same results than the second arm with less cost and safety, reversibility included.
3240922|NCT01293877|Other|LSG|The patients in a total of one hundred will be schedule for laparoscopic sleeve gastrectomy. The is our control for development of the study.
3347991|NCT02242708|No Intervention|Normal breathing|The control group will do normal breathing.
3347992|NCT02242708|Experimental|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
3347993|NCT02242721||Intensive care unit patients needing renal replacement therapy|Male and female patients in the intensive care unit (ICU), needing renal replacement therapy due to renal dysfunction and are treated with antiinfective drugs.
3347994|NCT02242734|Experimental|Mild Hepatic Impairment|20 mg HC-ER
3240923|NCT01293890||COPD patients with hospital admission for exacerbation|
3240924|NCT01293903|Experimental|Qiliqiangxin capsule|
3347995|NCT02242734|Experimental|Moderate Hepatic Impairment|20 mg HC-ER
3347996|NCT02242734|Experimental|No Hepatic Impairment|20 mg HC-ER
3347997|NCT02242747|Other|ingenol mebutate|Patients assigned to ingenol mebutate gel received an application a day for three consecutive days in a pre-determined area
3240925|NCT01293903|Placebo Comparator|Placebo|
3347998|NCT02242747|Other|5% 5-FU|Patients assigned to 5% 5-FU received two applications a day for four weeks in a pre-determined area
3347999|NCT02242760|Experimental|SB204 2% Twice daily|Twice daily SB204 2%
3348000|NCT02242760|Experimental|SB204 4% daily|Once daily SB204 4%
3348001|NCT02242760|Placebo Comparator|Vehicle Gel Daily|Vehicle Gel Daily
3348002|NCT02242760|Placebo Comparator|Vehicle Gel Twice Daily|Twice daily Vehicle Gel
3348003|NCT02242760|Experimental|SB204 4% Twice Daily|Twice daily SB204 4%
3348004|NCT02242773|Experimental|Active Surveillance|Participants in this group will receive a Multi-Parametric Magnetic Resonance Imaging (MP-MRI) of the prostate/pelvis and MRI-guided prostate biopsy at baseline (0-3 months from enrollment) and at the 12th, 24th and 36th month follow up.
3240926|NCT01293916|Active Comparator|Double leg spica cast|The current accepted treatment is the double leg spica cast in the treatment of pediatric diaphyseal femur fractures.
3240927|NCT01293916|Experimental|Single leg spica casts|The study group is the single leg spica cast group
3348005|NCT02242786|Experimental|EBRT|
3348006|NCT02242799|Experimental|Study A Sequence 1|Artemether-lumefantrine combination alone for 3 days with PK sampling at steady state, then 21 day washout period followed by Dolutegravir 50mg od dosing to steady state (7 days) with PK sampling then a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, with PK sampling at steady state.
3348007|NCT02242799|Experimental|Study A Sequence 2|Dolutegravir 50mg od given for 7 days with PK sampling at steady state, followed immediately by a further 3 days where Artemether-lumefantrine combination and Dolutegravir 50mg od are given together, again with PK sampling at steady state. Following a 21 day washout period, the subject will then receive Artemether-lumefantrine combination alone for 3 days, with PK sampling at steady state.
3348008|NCT02242799|Experimental|Study B Sequence 1|Administration of artesunate-amodiaquine for 3 days with PK sampling at steady state
3348009|NCT02242799|Experimental|Study B Sequence 2|Dolutegravir alone for 7 days with PK sampling at steady state, followed immediately by administration of both artesunate-amodiaquine and dolutegravir together for a further 3 days with PK sampling at steady state
3348010|NCT02242812|Experimental|Telmisartan|MICARDIS®
3348011|NCT02242812|Active Comparator|Metoprolol succinate|BELOC ZOK®
3348012|NCT02242825||Patients with hypertension and diabetes mellitus|
3348013|NCT02242838||Hypertensive patients|
3348014|NCT02242851||Hypertensive patients|
3348015|NCT02242864||Patients with hypertension and diabetes mellitus|
3348016|NCT02242877||Isolated systolic hypertension|
3348017|NCT02242877||Systolic and diastolic hypertension|
3348018|NCT02242890|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
3348019|NCT02242916||Patients with recurrent HN tumors|Patients with recurrent Head and Neck tumors
3240928|NCT01293929||Non- obese group|
3240929|NCT01293929||Obese group|
3240930|NCT01293942|Experimental|IXO+A|IXO regimen with Avastin
3240931|NCT01293955|Experimental|JOINS 200mg|One tablet of JOINS 200mg is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
3240932|NCT01293955|Placebo Comparator|Placebo|One tablet of Placebo is administered three times a day for 1 year. The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
3240933|NCT01293981||Lumbar Degenerative Disc Disease|
3240934|NCT01294007|Experimental|Study Graft Composite|
3348020|NCT02242929|Active Comparator|Standard surgical excision|"Standard surgical elliptical excision including a 3-mm clinically tumour-free margin according to the current local hospital arrangements."
3240935|NCT01294007|Active Comparator|Control Graft Composite|
3348021|NCT02242929|Experimental|Imiquimod 5% cream with prior curettage|Tumours will be partially debulked under local anaesthesia by removing all tumour tissue until normal dermis remains with a blunt curette. After curettage patients will receive an instruction sheet to apply imiquimod 5% cream once daily, 5 days a week, during 6 weeks, starting one week after the curettage procedure. Patients will be instructed to apply a thin layer to the tumour including 5-10mm of the surrounding skin at least 1 hour before going to bed at night. The lesion will not be covered (unless needed because of weeping or bleeding). Participants will be asked to wash their hands after applying the cream, and to wipe the cream off after 8 hours (in the morning).
3240937|NCT01294033|Placebo Comparator|Fractional inspired oxygen 0.21|Cardiopulmonary exercise test performed by subject on Fractional inspired oxygen 0.21
3240938|NCT01294033|Active Comparator|Fractional inspired oxygen 0.28|Cardiopulmonary exercise test performed on supplemental oxygen (Fractional inspired oxygen 0.28)
3240939|NCT01294059|Placebo Comparator|Sugar pill|One sugar pill twice daily over 6 weeks
3240940|NCT01294059|Active Comparator|Milnacipran|Milnacipran 50 mg bid over 6 weeks
3348022|NCT02242955|Active Comparator|"AD = as-usual diazepam"|Diazepam treatment duration will not exceed 10 days (commonly recommended duration for alcohol detoxification).
3348023|NCT02242955|Experimental|"PD = prolonged diazepam"|Diazepam will be slowly tapered to be stopped at day 30
3348024|NCT02243033||Visualase|MR-guided laser focal therapy
3348025|NCT02243059|Experimental|GDF-MRI|"In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.~Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset)."
3348026|NCT02243072|Experimental|Fit Familes plus Standard Medical Care|Participants will receive the intervention Fit Families plus Standard Medical Care which is an adaptation of Multisystemic Therapy for Type 1 Diabetes delivered by Community Health Workers (CHWs) in addition to standard medical care.
3348027|NCT02243072|No Intervention|Standard Medical Care|Standard medical care is provided at Children's Hospital of Michigan consistent with the standards for the care of children with T1D outlined by the American Diabetes Association.
3348028|NCT02243085||photoselective vaporization|
3348029|NCT02243098|Experimental|Semaglutide|
3348030|NCT02243111|Experimental|Doppler ultrasound|Recording Doppler signals from the lungs
3348031|NCT02243124|Active Comparator|Group 1|cenersen IV infusion 0.3 mg/kg/day (0.1 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no Hematologic Improvement (HI) is observed.
3348032|NCT02243124|Active Comparator|Group 2|cenersen IV infusion 0.6 mg/kg/day (0.2 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
3348033|NCT02243124|Active Comparator|Group 3|cenersen IV infusion 1.2 mg/kg/day (0.4 mg/kg/h x 3 h x 4 days) for 6 cycles Administration of study drug will be over 4 consecutive days at the outset of each 28 day cycle for a total of 6 cycles for each patient. Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
3348034|NCT02243137|Active Comparator|prasugrel and acetylsalicylic|single dose of prasugrel 60 mg orally and 300 mg acetylsalicylic acid orally
3348035|NCT02243137|Experimental|lysine acetylsalicylate and prasugrel|single dose of prasugrel 60 mg oral and lysine acetylsalicylate 450 mg intravenous
3348036|NCT02243150|Experimental|Cohort 1|6mg/m2 of G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion
3240941|NCT01294072|Experimental|Arm 1: Curcumin alone|Subjects take curcumin orally.
3240942|NCT01294072|Experimental|Arm 2: Curcumin with plant exosomes|Subjects take curcumin conjugated with plant exosomes.
3240943|NCT01294072|Experimental|Arm 3: no treatment|
3240944|NCT01294111|Experimental|Tai Chi training|Participation in a group of 15 patients, completing a 60 minutes tai chi training programme twice-weekly for 16 weeks.
3240945|NCT01294111|No Intervention|Control|Living as usual, following ordinary care plans and personal activities. Participants will be called to hospital for data collection. Participants are asked not to start any of the activities Tai Chi, Qui Gong or Yoga during the study period.
3240946|NCT01294124||No Tinnitus|The absence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
3240947|NCT01294124||Tinnitus|The presence of tinnitus will be based on the participants' responses to questions 8a, 9c, and 9d of the Post-Deployment Health Assessment (PDHA).
3240948|NCT01294137|Active Comparator|ventilatory polygraphy|
3348037|NCT02243150|Experimental|Cohort 2|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 1; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3348038|NCT02243150|Experimental|Cohort 3|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 2; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3348039|NCT02243150|Experimental|Cohort 4|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 3; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion.
3240949|NCT01294176|Active Comparator|Oral Lipoic Acid|Lipoic acid is a natural antioxidant available as an oral dietary supplement. A higher than average dose of 1200mg will be administered in this trial.
3348040|NCT02243150|Experimental|Cohort 5|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 4; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
3348041|NCT02243150|Experimental|Cohort 6|Dose of G1T28-1 or placebo will be determined based on the safety and PK data from Cohort 5; G1T28-1 or placebo will be administered in 50mL of 5% dextrose by IV infusion. Subjects from this cohort may be selected to participate in the Whole Blood Ex-Vivo Stimulation group.
3348042|NCT02243150|Experimental|Cohort 7 - Bone Marrow Cohort|All subjects in this cohort will receive active drug, G1T28-1. Dose of G1T28-1 will be determined based on the safety and PK data from previous cohorts. G1T28-1 will be administered in 50mL of 5% dextrose by IV infusion. Subjects in this cohort will be selected for the Ex-Vivo Stimulation group and will have a one time bone marrow aspirate at one of the following time points: pre dose, 12 or 24 hours post dose.
3348043|NCT02243163|Experimental|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
3240950|NCT01294176|Placebo Comparator|Avicel™|The placebo is Avicel™ (microcellulose crystal) and 4.3 mg quercetin (a bioflavanoid).
3240951|NCT01294189||ICU-patients that died on the ICU|ICU-patients (post-operative and non operative patients) will be enrolled in the study. All patients are followed until their death on the ICU.
3348044|NCT02243189|Experimental|JNJ-43260295 (Healthy Participants)|Participants will receive a single nasal dose of JNJ-43260295, 6400 microgram, equally spread over the two nostrils.
3348045|NCT02243189|Placebo Comparator|Placebo (Healthy Participants)|Participants will receive a single nasal dose of placebo matching to JNJ-43260295.
3348046|NCT02243189|Experimental|JNJ-43260295 (Asthmatic Participants)|Participants will participate in 3 consecutive treatment periods (Periods 1, 2, and 3). In Period 1, each participant will receive a single nasal dose of JNJ-43260295 without prior nasal allergen challenge. In Period 2, each participant will receive a single nasal dose of JNJ-43260295, preceded by a nasal allergen challenge approximately 15 hours prior to the dosing. In Period 3, each participant will receive single nasal allergen challenge without JNJ-43260295. There will be a washout period of at least 21 days between 3 consecutive treatment periods.
3348047|NCT02243215|Experimental|Offsite training|Access to a portable trainer for laparoscopic skills
3348048|NCT02243215|No Intervention|Onsite training|Will be able practice on-site at Center of Clinical Education and at their local hospital.
3348049|NCT02243228|Experimental|GM-CSF, nebulizer|After the patients were randomly divided into two groups, they will be treated by GM-CSF (using nebulizer, 150ug bid) every other week for 6 months.
3348050|NCT02243241|Experimental|HYD|
3348051|NCT02243241|Other|Moxifloxacin|Moxifloxacin is the positive control.
3348052|NCT02243241|Placebo Comparator|Placebo|Placebo for HYD and placebo for moxifloxacin
3348053|NCT02243254|Placebo Comparator|high dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml normal saline before surgical incision
3348054|NCT02243254|Placebo Comparator|low dose remifentanil without ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml normal saline before surgical incision
3348055|NCT02243254|Active Comparator|high dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 4 ng/ml Intravenous ibuprofen 800 mg before surgical incision
3348056|NCT02243254|Active Comparator|low dose remifentanil with ibuprofen|remifentanil target-controlled infusion effect-site concentration 1 ng/ml Intravenous ibuprofen 800 mg before surgical incision
3240952|NCT01294202|Experimental|AT13387 and imatinib|AT13387 administered on days 1, 8 and 15, imatinib administered daily
3240953|NCT01294215|Experimental|Arm 1|
3348057|NCT02243306|Experimental|Cohort 1|Subjects on continuous ambulatory peritoneal dialysis (CAPD) will receive 5 mg of GSK1278863 orally, once daily for 14 days.
3348058|NCT02243306|Experimental|Cohort 2|Subjects on automated peritoneal dialysis (APD) will receive 5 mg of GSK1278863 orally, once daily for 14 days
3348059|NCT02243319|Experimental|Group 1|"A → B → C~A: HGP1201 for 9 days B: HGP0904 for 9 days C: HGP1201+ HGP0904 for 9 days"
3348060|NCT02243319|Experimental|Group 2|C → A → B
3348061|NCT02243319|Experimental|Group 3|B → C → A
3240954|NCT01294254|Experimental|experimantal: wound site will be treated with Oleogel-S10|"The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.~Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg~Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg~Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)~Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site"
3240955|NCT01294254|Active Comparator|Moist wound healing dressing alone|Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site
3348062|NCT02243319|Experimental|Group 4|C → B → A
3348063|NCT02243319|Experimental|Group 5|B → A → C
3348064|NCT02243319|Experimental|Group 6|A → C → B
3348065|NCT02243332|Experimental|Device (rehabilitation assistance)|Device: KneeStim mobile rehabilitation assistance device
3348066|NCT02243345||Delayed|Time from surfacing to recompression >=48 hours
3348067|NCT02243345||Early|Time from surfacing to recompression <48 hours
3348068|NCT02243384|Experimental|Laparoscopic Hepatectomy|Laparoscopic Hepatectomy
3348069|NCT02243384|Active Comparator|Radiofrequency Ablation|Radiofrequency Ablation
3348070|NCT02243423|Experimental|SUPINE group|The surgical table will remain horizontal after intrathecal (spinal) anesthesia injection for cesarean section. Choosing to position the patient supine is the intervention.
3348071|NCT02243423|Active Comparator|TILT group|The surgical table will be turned to 15° of left lateral tilt after patients are laid supine after spinal anesthesia injection. The tilted group is the control group.
3348072|NCT02243436|Experimental|BV-ESHAP|"- 3 cycles every 21 days:~Brentuximab Vedotin, on day 1 (BV will be administered at three different doses 0.9mg/kg, 1.2mg/kg, 1.8mg/kg)~Etoposide 40 mg/m2/day, on days 1 to 4~Soludomerin (methylprednisolone) 250 mg/day, on days 1 to 4~Cisplatin 25 mg/m2/day, on days 1 to 4~Ara C (cytarabine) 2 g/m2, on day 5~- A fourth dose of BV will be given 21 days after the third BV dose during the evaluation of response before the transplant.~- Autologous peripheral blood stem cell transplant~- A fifth dose of BV (1.8mg/kg) will be given on between day 28 and 35 post-transplant, followed by two additional doses (1.8mg/kg) every 3 weeks, to complete a total of 7 BV infusions."
3348073|NCT02243449|Active Comparator|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3348074|NCT02243449|Experimental|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 06:00 - 08:00 hours and 13:00 - 15:00 hours daily. If a screening period is missed inadvertently or due to an investigation or intervention (operation/procedure) necessitating absence from the ICU, it may be conducted later on the same day and ideally within 6 hours of the scheduled screening period. Additional screening trials in the 'at least twice daily' screening arm will be permitted at the discretion of the clinical team (RTs and physicians). Regardless of group assignment, if the SBT screening assessment is passed, an SBT will be conducted as per protocol.
3348075|NCT02243462|Other|No pre-op warming|No pre-warming in bay before surgery.
3348076|NCT02243462|Active Comparator|Pre-op forced air warming|A forced air warmer device (WarmTouch Convective Warming System) will be used to pre-warm patients in holding bay before surgery
3348077|NCT02243488|Experimental|12 month menstrual hygiene programme|This is the first group to receive the intervention. They will receive the intervention after baseline and be followed up for the following 12 months.
3348078|NCT02243488|Experimental|6 month menstrual hygiene programme|This is the second group to receive the intervention. They will act as a control group for the first 6 months then receive intervention at 6 months.
3348079|NCT02243501|Experimental|Intervention Group|The Intervention Group receives access to the BNBD intervention, and can access alternative resources while enrolled in the study. The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
3348080|NCT02243501|No Intervention|Usual Care Group|The Usual Care Group will receive no treatment until after the 8 month follow-up assessment. The Usual Care Group can access alternative resources and additional programs and services while enrolled in the study.
3348081|NCT02243514||Resistant hypertension|
3348082|NCT02243514||Essential hypertension|
3348083|NCT02243514||Chronic heart failure|
3348084|NCT02243514||Control|
3348085|NCT02243553|Experimental|Treatment A|tipranavir (TPV) capsule + ritonavir (RTV) capsule + cocktail + digoxin oral
3348086|NCT02243553|Experimental|Treatment B|TPV capsule + RTV capsule + cocktail + digoxin injection
3348087|NCT02243553|Experimental|Treatment C|TPV solution + RTV capsule + cocktail + digoxin oral
3348088|NCT02243553|Experimental|Treatment D|TPV solution + RTV capsule + cocktail + digoxin injection
3348089|NCT02243566||Essential hypertension|
3348090|NCT02243592||Ancillary-Correlative (molecular profiling)|Previously collected tissue samples are analyzed via whole exome sequencing and/or targeted NGS assay deep sequencing. Cases for which sufficient nucleic acid amounts are available will undergo additional analyses including whole genome sequencing, mRNA-sequencing, miRNA sequencing, promoter methylation analysis, and SNP analysis.
3348091|NCT02243618|Active Comparator|Rebamipide group|
3348092|NCT02243618|Active Comparator|Polaprezinc group|
3348093|NCT02243631|Experimental|Probenecid|These patients will receive 5 days of probenecid.
3348094|NCT02243631|No Intervention|No intervention|These patients will receive no intervention.
3348095|NCT02243644|Active Comparator|Group A|7 days of albendazole 15 mg/kg/day
3348096|NCT02243644|Active Comparator|Group B|28 days of albendazole 15 mg/kg/day
3348097|NCT02243657|Placebo Comparator|1: Placebo dose level|
3240956|NCT01294280||Ancillary-Correlative (IHC)|Previously collected tissue samples are analyzed by IHC.
3259293|NCT01469520|Active Comparator|Test product|Fixed dose combination of lamivudine, zidovudine and nevirapine reconstitutable suspension
3348098|NCT02243657|Experimental|2: ASP3652 lowest dose level twice daily|
3348099|NCT02243657|Experimental|3:ASP3652 low dose level twice daily|
3348100|NCT02243657|Experimental|4: ASP3652 medium dose level twice daily|
3348101|NCT02243657|Experimental|5: ASP3652 high dose level twice daily|
3348102|NCT02243657|Experimental|6: ASP3652 highest dose level once daily|
3348103|NCT02243670|Experimental|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®.
3348104|NCT02243683|Experimental|Cohort A|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
3348105|NCT02243683|Experimental|Cohort B|Single ascending oral administrations of AX-024.HCl (hydrochloride) and matching placebo
3348106|NCT02243709|Active Comparator|Mifepristone|mifepristone 600-mg/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
3240957|NCT01294293|Experimental|Treatment (TLR8 agonist VTX-2337, PLD, and Paclitaxel)|Patients receive TLR8 agonist VTX-2337 SC on days 3, 10, and 17 and pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 or TLR8 agonist VTX-2337 SC on days 1, 8, and 15 and paclitaxel IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3348107|NCT02243709|Placebo Comparator|Sugar pill|matching placebo/day for a week, in a stress-induced condition triggered by a single dose of 32.4-mg of yohimbine
3348108|NCT02243722||Larynx pharynx and Esophagus Ca with VCP|The cases of laryngopharyngeal and esophageal cancer with endoscopic characters of vocal fold motion impairment (paralysis or fixation)
3348109|NCT02243735|Active Comparator|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
3348110|NCT02243735|Active Comparator|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
3348111|NCT02243748|Active Comparator|Phase I (usual care)|Participants receive usual care. This phase will aid in identifying usual care patterns in each site and provide an audit of system utilization as well as finalization of the educational materials for Phase II.
3348112|NCT02243748|Experimental|Phase II (individualized palliative care)|Participants receive individualized palliative care comprised of tailored educational sessions designed for each patient and FCG that have been modified based on patterns observed in Phase I. The first patient teaching session will cover physical and psychological areas and the second will cover social and spiritual areas. These sessions will be completed within 2 weeks of accrual. A third teaching session is held with the FCG alone to give the FCG the opportunity to discuss their perspectives and focus on their needs. Patients will be asked to identify topics they want included and which if any should be omitted which provides for tailoring of the content to the patient's needs and preferences.
3348113|NCT02243761|Experimental|DBT Based Skills Groups for Families|Family members of youth with concurrent disorder participate in a 12-week DBT based skills group led by therapists and/or peer facilitators.
3240959|NCT01294345||personalized genomics|genetic/genomic syndromes
3240960|NCT01294410|Experimental|Cohort 1: Induction|Placebo or Anti-IP-10 Antibody
3348114|NCT02243774|No Intervention|No letter|Individuals randomized to the control group who will not receive any of the four letters
3348115|NCT02243774|Experimental|Core letter signed by Surgeon General|Individuals randomized to receive only a core letter signed by the Surgeon General
3240961|NCT01294410|Experimental|Cohort 2: Induction|Placebo or Anti-IP-10 Antibody
3240962|NCT01294410|Experimental|Cohort 3: Induction|Placebo or Anti-IP-10 Antibody
3348116|NCT02243774|Experimental|Core letter signed by Director of the National Vaccine Program|Individuals randomized to receive only a core letter signed by the Director of the National Vaccine Program
3348117|NCT02243774|Experimental|Core letter signed by Surgeon General + implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General with an implementation intention prompt added in an appended P.S. tag region below the signature line
3348118|NCT02243774|Experimental|Core letter signed by SG + enhanced implementation prompt|Individuals randomized to receive a core letter signed by the Surgeon General (SG) with an enhanced implementation intention prompt added in an appended P.S. tag region below the signature line
3348119|NCT02243787|Experimental|COVA322|single i.v. infusion
3348120|NCT02243787|Placebo Comparator|Placebo|single i.v. infusion
3348121|NCT02243800|Experimental|cholecalciferol|One group will receive the study treatment: cholecalciferol One group will receive placebo
3348122|NCT02243800|Placebo Comparator|placebo|One group will receive the study treatment: cholecalciferol One group will receive placebo
3348123|NCT02243813|Experimental|Delayed Participation|Participants will begin the psilocybin intervention 6 months after study enrollment.
3348124|NCT02243813|Experimental|Immediate Participation|Participants will begin psilocybin intervention immediately after study enrollment.
3348125|NCT02243826|Experimental|N20|One group will inhale N2O for the 5 minutes before the puncture and during the rest of the procedure.
3348126|NCT02243826|Other|compressed air|The second group will inhale compressed air during the same period of time
3348127|NCT02243839|Active Comparator|Thrombolytic therapy|In the first arm, thrombolytic therapy (TT) is performed to the patients with obstructive prosthetic valve thrombosis. The TT regimen depends on the functional status of the patient. In patients with NYHA class III-IV dyspnea low dose, relatively faster TT regimen (25 mg tPA/6 hours) is performed. In patients with NYHA class I-II dyspnea TT with low dose and ultra-slow infusion of tPA (25 mg tPA/25 hours) is performed. During TT, patients are followed up with transesophageal echocardiography in every 24 hours.
3348128|NCT02243839|Active Comparator|Surgery|In the second arm, redo valve surgery is performed for obstructive valve thrombosis. Intraoperative and postoperative results are recorded
3348129|NCT02243852||Growth Hormone Deficiency (n=16)|16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement) will be compared with 16 healthy controls. Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be assessed in each of cohort to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
3348130|NCT02243852||Healthy Controls (n=16)|16 healthy controls will be compared with 16 asymptomatic GHD patients (who have confirmed GHD but who remain without GH replacement). Participants will be asked to undertake a single fasting blood sample and an MRI scan (whole body MRI and proton- and phosphorus-MR spectroscopy) to determine VAT, SAT and liver fat and muscle mitochondrial function. FGF21, body composition and mitochondrial function will be measured in all cohorts to determine the correlation of FGF21 levels with VAT, SAT and liver fat.
3240963|NCT01294410|Experimental|Maintenance|Placebo or Anti-IP-10 Antibody
3240964|NCT01294410|Other|Open Label|
3348131|NCT02243852||Growth Hormone Replacement Therapy (n=16)|"GHD patients, who are eligible for GH replacement therapy as part of their routine clinical care, according to the National Institute for Clinical Excellence (NICE) recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire score (AGHDA score>11) will be recruited. These patients attend the Joint Endocrine clinic at University Hospital Aintree, Liverpool, and those who are about to commence growth hormone replacement will be asked to participate in this observational study.~Anthropometric, biochemical including measurement of FGF21 and MR evaluation will be carried out in patients who are to be treated with GH as part of their routine clinical care immediately prior to GH therapy and after six months of replacement treatment. The type of GH and dose of treatment will be at the discretion of the treating physician. Standard doses will be used and patients will remain under the care of the supervising"
3348132|NCT02243878|Experimental|Arm A (treatment)|"Participants will receive Stereotactic radiotherapy, a 16 Gy dose of radiation, delivered to the macula.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
3348133|NCT02243878|Sham Comparator|Arm B (control)|"Participants will receive a sham treatment.~Participants will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met."
3348134|NCT02243891|Active Comparator|Control|Atrial fibrillation ablation only
3348135|NCT02243891|Experimental|ROX Coupler|Atrial fibrillation ablation with concurrent ROX Coupler insertion
3348136|NCT02243904||Lead exposure|
3348137|NCT02243917|Experimental|Dose Escalation Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles; subjects who have completed at least one cycle may optionally participate in a food effect week, wherein CB-5083 will be orally administered once daily, on days 1 and 4, and thereafter return to the original dosing schedule
3348138|NCT02243917|Experimental|Dose Expansion Stage - CB-5083|CB-5083 will be orally administered daily, 4 days on and 3 days off, for 28 day cycles
3348139|NCT02243917|Experimental|Food Effect Stage - CB-5083|CB-5083 will be orally administered once daily, on days 1 and 4 of week 1, cycle 1, and orally administered daily, 4 days on and 3 days off, for the remaining 3 weeks of cycle 1; for subsequent 28 day cycles, CB-5083 will be orally administered daily, 4 days on and 3 days off
3348140|NCT02243930|Experimental|Cap|Sigmoidoscopy with cap
3348141|NCT02243930|No Intervention|No cap|Sigmoidoscopy without cap
3348142|NCT02243956|Experimental|Flavanol rich food product|A portion of a common flavanol rich food product is consumed daily for 4 weeks
3348143|NCT02243956|Placebo Comparator|Non-flavanol food product|A portion of a product similar to the experimental Product, but instead contains low amounts of flavanol, is consumed Daily for 4 weeks as a control.
3348144|NCT02243969|Experimental|flaxseed oil (rich in α-linolenic acid )|
3348145|NCT02243969|Placebo Comparator|high oleic sunflower oil|
3348146|NCT02243982|Experimental|[F18]-FDDNP|2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl)amino]-2-naphthyl}-ethylidene)malononitrile. Radiopharmaceutical tracer
3348147|NCT02243995|Experimental|Physical training|
3348148|NCT02244008|Experimental|joint mobilization|Anteroposterior mobilization of the talus (Maitland mobilization grade III)
3348149|NCT02244008|Placebo Comparator|manual contact|
3348150|NCT02244021|Experimental|BRENTUXIMAB VEDOTIN|1 arm for all patients
3348151|NCT02244034||1250 patients who had cardiac surgery wit|
3348152|NCT02244047|Active Comparator|Bifidobacterium breve|Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months
3348153|NCT02244047|Active Comparator|Placebo|Placebo in the same powder packages as Bifidobacterium breve
3348154|NCT02244060|Experimental|Direct comparison|The Direct comparison against vignette (DCV) questionnaire asks subjects to estimate their own vision against vignette situations.Priming effect from vignette is designed in the arm of DCV.
3348155|NCT02244060|No Intervention|Indirect comparison|The Indirect comparison against vignette (ICV) questionnaire asks self-assessed vision and single evaluation of vignettes.
3348156|NCT02244073|Experimental|Individualized blood glucose target|Maintain blood glucose in individualized target based on glycated hemoglobin level (A1c); Blood glucose level is maintained bellow 1.59 × A1c - 1.59 (mmol/l).
3348157|NCT02244073|Active Comparator|Conventional blood glucose target|Maintain blood glucose bellow 10 mmol/l.
3348158|NCT02244086|No Intervention|bupivacaine 0.125%|administrate bupivacaine at 0.125% during initiation of effective labor work
3348159|NCT02244086|Experimental|bupivacaine 0.25%|Administrate bupivacaine at 0.25% during initiation of effective labor work One of the researchers selected from a randomized list containing pages in both groups with numbers ranging from 0001 to 0110 with 55 pages for each group and these selected folios prepared in sterile form and start the day in the morning, the amount of 10 10 ml syringes with foil for each mixture. The remaining samples were discarded if 10 analgesics are not achieved during the day, and the day new preparations were made.
3348160|NCT02244099|Experimental|Controlled Substance|Consenting physicians who care for patients who have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months in Martha Morehouse General Internal Medicine Resident Continuity Clinic.
3240965|NCT01294475|Experimental|Cell Phone Enhanced Parent Training|Cell phones will be provided to mothers participating in Planned Activities Training.
3240966|NCT01294488|Experimental|Phone Consultation|Therapists receive phone consultation for 6 months during the course of the project.
3348161|NCT02244112|Experimental|Part I: Food Effect/QTc|"Subjects will receive a single dose of oprozomib 270 mg in 1 of 3 fasting/fed conditions:~Diet A: Fasted conditions~Diet B: A low-fat breakfast. A low-fat breakfast is defined as having a total caloric value of less than 400 calories, with less than 20% from fat~Diet C: A high-fat breakfast. A high-fat breakfast is defined as having a total caloric value of 800 to 1000 calories, with approximately 50% from fat"
3240967|NCT01294488|Experimental|Remote Real-Time Consultation|Therapists receive consultation for 6 months via polycommunication technology.
3240968|NCT01294501|Experimental|Fever assessment and management|Medication administration educational module for low literacy subjects on how to administer common medications appropriately and safely.
3240969|NCT01294527|Experimental|Implant|Implant of the WiCS-LV system
3240970|NCT01294540|Experimental|Experimental: 1|
3240971|NCT01294540|Placebo Comparator|Placebo Comparator: 2|
3240972|NCT01294566|Experimental|Cohort 1|GSK1322888 (1 mg, 2 mg, 5 mg, 10 mg; 6 subjects) and Placebo (32 subjects)
3348162|NCT02244112|Experimental|Part II: Drug-Drug Interaction (DDI)|"Period 1: Midazolam 2 mg single oral dose on one day between Day -7 and -4~Period 2: Midazolam 2 mg single oral dose 1 hour following oprozomib dose on Day 1 of Cycle 1 and Day 2 of Cycle 2. Oprozomib 300 mg dose on Days 1, 2, 8 and 9 of Cycles 1 and Cycle 2"
3348163|NCT02244112|Experimental|Extension|After subjects complete the Food Effect/QTc or DDI part, subjects may participate in the extension part of the study, where oprozomib treatment will be continued on Days 1, 2, 8, and 9 of each 14-day cycle. During this part of the study, it is recommended that oprozomib be taken with food.
3348164|NCT02244125|Other|Previous IFM/DFCI 2009 arm A|"Patients previously randomized into IFM/DFCI 2009 trial arm A (or if transplantation was not done) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~Melphalan 200mg/m2 followed by ASCT (Autologous Stem Cell Transplantation)~2 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any other reason~Pomalidomide and Dexamethasone"
3348165|NCT02244125|Other|Previous transplantation IFM/DFCI 2009 arm B|"Patients previously randomized into IFM/DFCI 2009 trial arm B (RVD plus Transplant) will receive:~The treatment phase:~4 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The consolidation phase:~5 cycles of PCD (Pomalidomide-Cyclophosphamide-Dexamethasone)~The maintenance phase: Until progression or discontinuation for any oher reason~Pomalidomide and Dexamethasone"
3348166|NCT02244138||Adolescent CDSS|Implementation clinic site for CDDS
3348167|NCT02244151|Experimental|DECAPEPTYL® diario|Group 1: DECAPEPTYL® diario,OPU 24 hours after GnRHa administration.
3348168|NCT02244151|Experimental|Decapeptyl® diaro|Group 2:Decapeptyl® diario OPU 30 hours after GnRHa administration.
3348169|NCT02244151|Experimental|Decapeptyl® diario.|Group 3: Decapeptyl® diario, OPU 40 hours after GnRHa administration.
3348170|NCT02244151|Active Comparator|Decapeptyl® daily|Group 4: Decapeptyl® daily OPU 36 hrs after GnRH administration
3348171|NCT02244164|Active Comparator|Sulfonylurea|Patient will received metformine with sulfonylurea
3348172|NCT02244164|Active Comparator|Incretinomimectics|Patients will received metformin with sulfonylurea with GLP-1 analogue
3240973|NCT01294566|Experimental|Cohort 2|GSK1322888 (20 mg, 40 mg, 80 mg, and dose to be determined; 6 subjects) and Placebot (2 subjects)
3240974|NCT01294605|Experimental|Group A|
3240975|NCT01294605|Experimental|Group B|
3348173|NCT02244164|Active Comparator|DPP-4 inhibitors|Patients will received metformin with DPP-4 inhibitors
3348174|NCT02244177||normotension group|Until 11,March, 2015, 31 cases are collected.
3348175|NCT02244177||hypertension group without treatment|Until 11,March, 2015, 60 cases are collected.
3348176|NCT02244177||hypertension group with antihypertensive treatment|"(ACEI, beta-blocker, Ca blocker, Diuretics) prior to the surgery.~Until 11,March, 2015, 59 cases are collected."
3348177|NCT02244190|Experimental|new Tipranavir + Ritonavir|
3348178|NCT02244190|Active Comparator|current Tipranavir + Ritonavir|
3240976|NCT01294605|Active Comparator|Group C|
3240977|NCT01294618|Experimental|nilotinib + pegylated interferon alpha 2a (PEG-IFN).|
3348179|NCT02244203|Experimental|Single rising doses of BI 60732|
3348180|NCT02244203|Placebo Comparator|Placebo|
3348181|NCT02244216||Chronic Obstructive Respiratory Tract Disease|
3348182|NCT02244229|Experimental|Tamsulosin|
3348183|NCT02244229|Active Comparator|Finasteride|
3240978|NCT01294631|Experimental|001|"Canagliflozin 300 mg once daily and HCTZ 25 mg once daily Period 1: canagliflozin tablets oral 300 mg once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets oral 25 mg once daily for Days 1 to 28 followed by canagliflozin tablets oral 300 mg once daily taken with HCTZ tablets oral 25 mg once daily on Days 29 to 35.."
3240979|NCT01294657||HE Group|Health Education [HE] - Counseling, referrals to resources + self-help materials; 2 HE interventions at Baseline + 6 month visits.
3240980|NCT01294657||MAPS Group|Motivation And Problem Solving (MAPS) - HE + 12 telephone counseling sessions over 1-year period (average 1 call/month).
3240981|NCT01294735|Experimental|Part A, MK-4827 + temozolomide dose escalation cohort|
3240982|NCT01294735|Experimental|Part B, MK-4827 + temozolomide melanoma cohort|
3348184|NCT02244242|Experimental|Tamsulosin hydrochloride|modified release capsules
3348185|NCT02244255|Experimental|FLOMAX®|
3348186|NCT02244255|Active Comparator|HYTRIN®|
3348187|NCT02244268||Patient with symptomatic of benign prostatic hyperplasia|
3348188|NCT02244281|Experimental|FLOMAX®|
3348189|NCT02244281|Placebo Comparator|Placebo|
3348190|NCT02244294|Experimental|FLOMAX®|
3348191|NCT02244294|Placebo Comparator|Placebo|
3348192|NCT02244307||Patients with BPH treated with alpha-andrenergic blockade|
3348193|NCT02244320||functional BPH|patients with functional BPH who switched from phytotherapy to ALNA®
3348194|NCT02244333||Patients with symptomatic BPS|
3348195|NCT02244346||Benign prostatic hyperplasia patients|
3348196|NCT02244359|Experimental|Training|Online tutorial, decision aid and interactive workshop
3348197|NCT02244359|Other|Usual care|Usual care
3348198|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 0.76 g|Cordyceps sinensis mycelium culture extract 0.76 g
3348199|NCT02244372|Experimental|Cordyceps sinensis mycelium culture extract 1.15 g|Cordyceps sinensis mycelium culture extract 1.15 g
3348200|NCT02244372|Placebo Comparator|Placebo|Placebo
3348201|NCT02244385||Observation|No intervention
3375915|NCT03529383|No Intervention|Control|Women will receive standard care, i.e., international recommendations on physical activity, without further intervention.
3375916|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 10g|Suspension administered 10g orally once daily for 28 days after the open label initial phase.
3348202|NCT02244398|Experimental|FP and HTC services|VHTs in the intervention arm provide both family planning and HTC services between May 2012 and September 2013, then return to providing family planning only at the end of the project. Services are made available to all adults in VHTs' communities. HIV testing is done using the national rapid testing algorithm. Clients who test positive for HIV are referred to a health center for care and treatment and receive disclosure support and information on peer support groups.
3348203|NCT02244398|Active Comparator|FP services|VHTs in the control arm only provide family planning services.
3348204|NCT02244411|Experimental|Intervention group|Participants will be assigned an individual diet & physical activity counselor through Healthways at Hopkins. This counselor will stay with the participant for the 24 months. The primary communication with the counselor will be via website & email. Participants will be encouraged to consume a low-calorie, low-salt diet with 7-12 daily servings of fruits, vegetables & low-fat dairy products. Calorie goals are based upon weight at study entry & whether or not the weight loss goal has been met. Participants will gradually build to ≥ 180 minutes of moderate to vigorous physical activity per week, using the activity of their own choosing & gradually adding bouts of ≥ 10 minutes in length. Monitoring & Counselor Contacts: the first 3 months, the participants are encouraged to log into the web hub on a daily basis to record weight, food intake, & physical activity. Participants who decline or drop out of the intervention program will remain on-study doing home visits & questionnaires.
3240983|NCT01294735|Experimental|Part B, MK-4827 + temozolomide glioblastoma multiforme cohort|
3240984|NCT01294761|Experimental|Raltegravir, Darunavir/r|"An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD~to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID"
3240985|NCT01294761|No Intervention|Tenofovir, Emtricitabine, Lopinavir/r|An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
3240986|NCT01294774|Experimental|KRP203 - 1.2 mg|
3348205|NCT02244411|Active Comparator|control group|Participants will receive general information brochures on healthy living and weight loss but will not have access to the Healthways at Hopkins website or counselors.
3348206|NCT02244437|Active Comparator|Ibuprofen|Ibuprofen has been shown to prevent AMS from previous studies.
3348207|NCT02244437|Experimental|Acetaminophen|Acetaminophen has not been tested yet in AMS prevention.
3348208|NCT02244450|Experimental|Screened patients|SCID screening: more drops of blood are placed on a second Guthrie card when current screening (72 hours of life ) is performed after parents' information and consent. The card drawn for the protocol will follow the usual network except that the test for quantifying TRECs will be realized to determine the presence of SCID.
3348209|NCT02244450|No Intervention|Control group|SCID children diagnosed without screening by pediatricians local referents DIP
3348210|NCT02244463|Experimental|MLN0128|Treatment will be administered on an outpatient basis. MLN0128 at fixed dose will be administered orally, daily for treatment cycle. The participant will be requested to maintain a medication diary of medication. The medication diary will be returned to clinic staff at the end of each cycle. Treatment with MLN0128 will continue until progression or withdrawal of consent.
3348211|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine|Participants will receive momelotinib (MMB)+capecitabine at varying dose levels to determine the MTD for momelotinib (MMB) and capecitabine.
3348212|NCT02244489|Experimental|Momelotinib (MMB)+capecitabine+oxaliplatin|Upon reaching the MTD for momelotinib (MMB) and capecitabine or if no MTD is reached, participants will receive momelotinib (MMB)+capecitabine at the MTD plus oxaliplatin at varying dose levels to determine the MTD of combination capecitabine, momelotinib (MMB), and oxaliplatin.
3348213|NCT02244502|Experimental|TTFields in combination with weekly paclitaxel|Patients will be treated continuously with the NovoTTF-100L(O) device, in addition to weekly paclitaxel.
3348214|NCT02244515|Placebo Comparator|Group C|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered 10 ml NaCI 0.9%.
3348215|NCT02244515|Experimental|Group D|Five minutes prior to the commencement of the surgical procedure, Group D participants were administered dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
3348216|NCT02244528|Experimental|Treatment|sildenafil treatment
3348217|NCT02244541|Experimental|Anavex2-73 oral then the Anavex2-73 intravenous formulation|Participants first receive Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days. After a washout period of 11 days they then receive the Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days.
3348218|NCT02244541|Experimental|Anavex2-73 intravenous then the Anavex2-73 oral formulation|Participants first receive Anavex2-73 intravenous formulation each morning with a light breakfast for 11 days. After a washout period of 11 days then they receive the Anavex2-73 hard gelatin capsule each morning with a light breakfast for 11 days.
3348219|NCT02244541|Experimental|Anavex2-73 30 mg oral formulation|Participants will receive the 30 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
3348220|NCT02244541|Experimental|Anavex2-73 50 mg oral formulation|Participants will receive the 50 mg Anavex2-73 hard gelatin capsule orally once daily for 52 weeks.
3348221|NCT02244554|Experimental|enLighten Laser Picosecond Pulse|Picosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
3348222|NCT02244554|Experimental|enLighten Laser Nanosecond Pulse|Nanosecond Pulse-duration with enLighten Q-switched Nd:YAG (1064 nm and 532 nm) laser treatment
3348223|NCT02244567|Active Comparator|Metformin|Cidophage 850 mg twice daily for three months will be given to the patientwith PCOS.
3240987|NCT01294774|Placebo Comparator|Placebo to KRP203 - 1.2 mg|
3259294|NCT01469520|Active Comparator|Test Product|Fixed dose combination combination (Lamivudine, Zidovudine and Nevirapine)tablet
3348224|NCT02244567|Active Comparator|Serum under-carboxylated osteocalcin|Serum uc-oc will be measured before and after 3 months of treatment with cidophage.
3348225|NCT02244567|Active Comparator|Placebo|Other group of patients with high serum UC-OC will be given a placebo.
3259295|NCT01469533|Experimental|experimental group|The experimental group receives the real spinal mechanical manipulation.
3240988|NCT01294813|Experimental|Bronchoscopy-EIT|Patients who routinely undergo bronchoscopy will be measured by EIT directly before, directly after and 10, 30, 60 minutes after bronchoscopy with a rubber belt which is placed around their chest. The EIT measurements will take 1-2 minutes; the total examination will last 1.5 hours.
3240989|NCT01294826|Experimental|AUY922 plus Cetuximab|
3348226|NCT02244593|No Intervention|Mammography screening only|"This group will receive their standard of care mammogram only. Participants in this arm will not receive the FAST MRI.~Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram."
3348227|NCT02244593|Experimental|FAST MRI and mammogram screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram. The intervention is the addition of the FAST Breast MRI.
3348228|NCT02244606|Experimental|SCY-078 500 mg|A single loading dose of SCY-078 1000-mg orally on the first day, followed by SCY-078 500-mg orally once-daily on subsequent days.
3240990|NCT01294839|Experimental|RVOTs|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVOTs arm, the RV lead of this group patients will be implanted in right ventricular outflow tract septum,the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
3240991|NCT01294839|Experimental|AAI|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in AAI arm, the RV lead of this group patients will be implanted in right ventricular apex.
3240992|NCT01294839|Active Comparator|RVA|555 Patients will be randomized to three groups(RVOTs, RVA, AAI) in 1:1:1, 185 patients in RVA arm, the RV lead of this group patients will be implanted in right ventricular apex, the accumulated ventricular pacing percentage should be over 80% by adjusting AV delays.
3240993|NCT01294852|Experimental|immediate bolus surfactant|
3240994|NCT01294852|Experimental|post-resuscitation surfactant|
3348229|NCT02244606|Experimental|SCY-078 750 mg|A single loading dose of SCY-078 1250-mg orally on the first day, followed by SCY-078 750-mg orally once-daily on subsequent days.
3348230|NCT02244606|Active Comparator|Standard-of-care|Oral fluconazole 400 mg daily (with a loading dose of 800 mg on the first day) or IV micafungin 100 mg daily.
3348231|NCT02244632|Experimental|Modufolin / Nordic FLV|Modufolin in combination with 5-Fluorouracil only.
3348232|NCT02244632|Experimental|Modufolin / Nordic FLOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to Nordic FLOX regime
3348233|NCT02244632|Experimental|Modufolin / Nordic FLIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan.
3348234|NCT02244632|Experimental|MOFOX|Modufolin in combination with 5-Fluorouracil and Oxaliplatin according to mFOLFOX-6 regime
3348235|NCT02244632|Experimental|MOFOX / Bevacizumab|Modufolin in combination with 5-Fluorouracil, Oxaliplatin and Bevacizumab
3240995|NCT01294865||septic|Infants having clinical suspected late-onset neonatal sepsis enrolled in the study. Blood samples for suPAR were obtained before initiating antibiotic treatment and at the end of the treatment with other laboratory tests.
3240996|NCT01294865||non-septic|Infants without any clinical or hematological septic signs. Blood samples will be taken only once.
3348236|NCT02244632|Experimental|MOFIRI|Modufolin in combination with 5-Fluorouracil and Irinotecan
3348237|NCT02244645|Other|Passive modality control group|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
3348238|NCT02244645|Experimental|Yoga treatment group|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
3348239|NCT02244658|Experimental|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
3348240|NCT02244658|No Intervention|control|no thrombopoietic agents
3348241|NCT02244671|Experimental|fat, PRP, botulinum toxin|Fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
3348242|NCT02244684||Pregnant women|
3348243|NCT02244697||Experimental: laryngeal ultrasound stridor|Children aged 0-16 years referred for an awake nasolaryngoscopy for stridor or dysphonia at the pediatric Otolaryngology unit at the Tel Aviv Sourasky Medical Centre.
3348244|NCT02244697||Other: laryngeal ultrasound -control|Infants matched for age referred for ANL for reasons other than stridor will undergo US of the larynx.
3240997|NCT01294878|Experimental|treatment with omalizumab|Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used
3240998|NCT01294891||Control|Age matched healthy subjects
3348245|NCT02244710|Experimental|Ticagrelor|180mg initial dose next day 90mg BID
3348246|NCT02244710|Active Comparator|Clopidogrel|600mg po initial dose and 75mg qd starting next day
3240999|NCT01294891||Sickle Cell Patients|Patients with established SCD
3241000|NCT01294891||Paroxysmal Nocturnal Hemoglobinuria patients|Patients with PNH
3241001|NCT01294904||renal transplant patients|Patients undergoing transplantation
3348247|NCT02244723||Patients with suspected VAP|"Only one group is studied : mechanically-ventilated patients with suspected VAP in ICUs.~For each patient a lung ultrasound examination will be performed."
3348248|NCT02244736||Controls|Subjects with no family history of diabetes mellitus and normal OGTT
3348249|NCT02244736||Relatives|First-degree relatives of patients with diabetes mellitus and normal OGTT
3348250|NCT02244736||Diabetics|Subjects with abnormal OGTT
3348251|NCT02244749||skin specimen|skin specimen
3348252|NCT02244762|Experimental|Mild Renal Impairment|20 mg HC-ER
3348253|NCT02244762|Experimental|Moderate Renal Impairment|20 mg HC-ER
3348254|NCT02244762|Experimental|Severe Renal Impairment|20 mg HC-ER
3348255|NCT02244801|Other|Cohort 1|"3 subjects treated with a target dose of 300 million darTreg with the possibility of expanding to 5 patients if safety signals should require additional patients be observed at the 300 million dose.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
3348256|NCT02244801|Other|Cohort 2|"The second cohort will comprise a minimum of 3 and up to 5 subjects treated at a target dose of 900 million darTreg, depending on how many patients were required to be treated in lower dose group.~The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients."
3241002|NCT01294904||dialysis patients|hemodialysis patients and peritoneal dialysis patients. Before and after a dialysis session
3241003|NCT01294904||patients with renal insufficiency|outpatient patients with chronic kidney disease stage 2, 3 and 4
3348257|NCT02244814|Experimental|Choosing Healthy Options in Carbohydrate Energy|60% carbohydrate/25% fat/15% protein diet
3348258|NCT02244814|Active Comparator|Low Carbohydrate/Conventional|40% carbohydrate/45% fat/15% protein
3348259|NCT02244827|Experimental|WCK 2349|Each subject will receive a single oral dose of WCK 2349 1000 mg (i.e., 2 tablets of 400 mg and 1 tablet of 200 mg) with 240 mL water on Day 1 in the morning. Study drug will be administered after a fast of at least 8 hours.
3348260|NCT02244866|Active Comparator|Pergoveris (FSH and LH)|150 IU of recombinant FSH and 75 IU of recombinant LH (Pergoveris) daily subcutaneous injection
3348261|NCT02244866|Active Comparator|Follitropin alpha (FSH)|150 IU of recombinant FSH (follitropin alpha or Gonal-F) daily subcutaneous injection
3348262|NCT02244879|Placebo Comparator|placebo|In this arm, 64 patients will receive a tablet of placebo once/day for 6 months
3348263|NCT02244879|Experimental|resveratrol 40|In this arm, 64 patients will receive a tablet of 40mg resveratrol once/day for 6 months
3348264|NCT02244879|Experimental|resveratrol 500|In this arm, 64 patients will receive a tablet of 500 mg resveratrol once/day for 6 months
3348265|NCT02244905|Experimental|Positive Deviance Intervention Arm|Three hospital wards received Positive Deviance intervention.
3348266|NCT02244905|Other|Control Arm|Three hospital wards randomized to control arm received the Standard-of-Care Infection Control approach.
3348267|NCT02244931|Experimental|Phase 1: Performance evaluation on ergometer|"The 3 devices are experimented in random order to compare them on performance using an ergometer wheelchair:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3348268|NCT02244931|Experimental|Phase 2: Comparison of maneuverability|"The 3 devices are experimented in random order to compare them on maneuverability:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3348269|NCT02244931|Experimental|Phase 3: Comparison of the autonomy|"The 3 devices are experimented in random order to compare them on the autonomy they afford to patients:~Servomatic™ assisting device~E.Motion© assisting device~Standard manual Wheelchair"
3348270|NCT02244970|Experimental|Mindfulness|Subjects are scheduled to receive a 7-week group mindfulness-based intervention (MBI) program.
3348271|NCT02244970|Active Comparator|Psychoeducation|Subjects will receive 7 weeks of group-based psychoeducation as an active comparison group parallel to the mindfulness group.
3241004|NCT01294904||Chronic kidney disease|outpatient cohort. Those with mild renal insufficiency
3348272|NCT02244983||EFAB 65|Patients presenting to the emergency department with falls, above 65 years of age. Patients History will be taken as well as a blood sample
3348273|NCT02245009||Pacemaker patients|Patients with pacemaker, presenting for cardioversion.
3348274|NCT02245009||ICD patients|Patients with ICD, presenting for cardioversion.
3348275|NCT02245009||CRT patients|Patients with CRT device, presenting for cardioversion.
3348276|NCT02245022|Experimental|Dolutegravir 50mg od|30 patients who will receive dolutegravir 50mg once daily plus the same NRTI backbone as the active comparator group (lamivudine and tenofovir)
3348277|NCT02245022|Active Comparator|Standard of Care|Patients randomised to receive antiretroviral therapy as per Uganda national guidelines (Efavirenz 600mg od based plus Tenofovir 300mg od and Lamivudine 300mg od)
3348278|NCT02245035||Low dairy intake|1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall
3348279|NCT02245035||Moderate Dairy Intake|1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
3348280|NCT02245035||Recommended Dairy Intake|Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall
3348281|NCT02245048||Stress Echocardiography (SE)|Subjects will undergo CIMT measurements.
3348282|NCT02245061|Experimental|paired pulses cortical electrical stimulation|
3348283|NCT02245074|Other|Acute exacerbation|Cell profiles Analysis after sputum induction in infants with Acute exacerbation
3348284|NCT02245074|Other|Uncontrolled asthma|Cell profiles Analysis after sputum induction in infants with Uncontrolled asthma
3348285|NCT02245074|Other|controlled asthma|Cell profiles Analysis after sputum induction in infants controlled asthma
3348286|NCT02245087|Experimental|Atorvastatin|Atorvastatin(Lipitor) in addition to the usual guideline based care
3241005|NCT01294930||hip fracture|Patients operated for hip fracture, giving informed consent
3241006|NCT01294943||Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
3241007|NCT01294956|Experimental|FID 115958D|Lubricant Eye Drop
3241008|NCT01294956|Active Comparator|Refresh Liquigel|Lubricant Eye Drop
3241009|NCT01294969|Experimental|AL-4943A|One drop per day in both eyes
3241010|NCT01294982|Experimental|1.6 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
3241011|NCT01294982|Experimental|3.2 g AOBO-001 Group|AOBO-001 400 mg Oral Capsules
3241012|NCT01294982|Placebo Comparator|Placebo|Matching Placebo Capsules
3348287|NCT02245087|No Intervention|Guideline based care|Current guidelines for lipid-management in healthy middle aged men and women only.
3375917|NCT03528681|Experimental|Sodium Zirconium Cyclosilicate 5g|Suspension administered 5g orally once daily for 28 days after the open label initial phase.
3375918|NCT03528681|Placebo Comparator|Matching Placebo|Suspension administered orally placebo once daily for 28 days after the open label initial phase.
3348288|NCT02245100||Predictive value of circulating DNA|Patients undergo blood sample collection within 1 month before surgery, radiation therapy, or chemotherapy; within 1 week after surgical resection (for patients having upfront surgery); within 1 month before beginning of post-operative radiation therapy (for patients having upfront surgery); during the second week of radiation therapy, during the last week of radiation therapy; and at 1 and 3 months after radiation therapy and then every 3 months for up to 18 months. Patients also undergo saliva sample collection within 1 month before surgery, radiation therapy, chemoradiation therapy, or system chemotherapy and tissue collection at the time of surgery (if upfront surgery is indicated). Blood, saliva, and tissue samples are analyzed for tumor mutations via next generation sequencing.
3241013|NCT01294995|Experimental|Tea-flavor Liquor, taken with meal|including 12 males and 11 females
3241014|NCT01294995|Placebo Comparator|Guizhou Meijiao Liquor, taken with meal|including 11 males and 11 females
3241015|NCT01295008||Patients with the classic form|
3348289|NCT02245113|Experimental|Test Fat P|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3348290|NCT02245113|Experimental|Test Fat Q|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3348291|NCT02245113|Experimental|Test Fat R|Test fat, n= 10 (minimum), 6 weeks intervention, Intervention 1, Intervention 2, and Intervention 3.
3241016|NCT01295008||Fabry disease and healthy controls|
3241017|NCT01295047|Active Comparator|ATENOLOL|ATENOLOL 75MG FOR 4 WEEKS
3241018|NCT01295047|Active Comparator|VERAPAMIL|240MG VERAPAML FOR 4 WEEKS
3348292|NCT02245126|Experimental|Lignocaine-bupivacaine lower dosage mix|"Men who received the 3-3-4 local anaesthetic mix( 3 cc of lignocaine 2% , 3cc of bupivacaine 0.5% and 4cc of water for injection)~3-3-4 mix was administered"
3348293|NCT02245126|Active Comparator|Lignocaine-bupivacaine higher dosage mix|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
3348294|NCT02245152|Experimental|PROMIS intervention|"Small group behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly well-baby visits for children 0-17 months of age~Caregivers with children 0-17 months of age that attend the well-baby visit will be provided with a monthly dose of LNS (20g/day)"
3348295|NCT02245152|Active Comparator|control|Monthly well-baby visits as prescribed by national policy This arm is the basic comparison arm. Caregivers are invited to frequent the health center once a month for well-baby visits. During these visits necessary vaccinations are administered, child growth and nutrition status is evaluated and preventive counseling on child nutrition and health is provided in large groups of caregivers.
3348296|NCT02245165|Experimental|Nitric oxide synthase (NOS) inhibition|After a control period of 4 hours, intervention with L-NMMA (10 mg/kg IV) is done and recording continued for 4 hours.
3348297|NCT02245165|Sham Comparator|Saline|After a control period of 4 hours, intervention with saline is done and recording continued for 4 hours.
3348298|NCT02245178||Obervational - CARDIA participants|CARDIA study participants will undergo lung function testing and have existing thoracic CT scans analyzed for lung structure.
3348299|NCT02245191|Experimental|Ephedrine Group|Patients who will receive ephedrine after spinal anesthesia
3241019|NCT01295047|Active Comparator|PERINDOPRIL|4MG PERINDOPRIL FOR 4 WEEKS
3241020|NCT01295060|Experimental|Octreotide Implant|
3241021|NCT01295073|Active Comparator|A|Oral Trientine 1500mg x 1 week before cataract surgery and 3 days post surgery
3241022|NCT01295073|Placebo Comparator|B|Oral Placebo x 1 week before cataract surgery and 3 days post surgery
3348300|NCT02245191|Experimental|Phenylephrine Group|Patients who will receive Phenylephrine after spinal anesthesia
3348301|NCT02245191|Experimental|Metaraminol|Patients who will receive Metaraminol after spinal anesthesia
3348302|NCT02245204|Experimental|Chlorgenic acid, Treatment, powder|Chlorogenic acid for injection(30mg/bottle) is white or off-white freeze-dried lump or powder,it can be easily dissolved in water, which solubility is 20%.
3348305|NCT02245243|Experimental|Delafloxacin|Single Dose 300 mg IV
3348306|NCT02245256|Placebo Comparator|Normal saline|same infusion rate as experimental group (dexmedetomidine)
3348307|NCT02245256|Experimental|dexmedetomidine|0.1mcg/kg/hr of dexmedetomidine infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.
3241023|NCT01295086|Experimental|Her-TEX|
3241024|NCT01295099|Active Comparator|5-Fluorouracil|Patients with small keloidal scars to have intralesional 5FU injected
3241025|NCT01295099|Active Comparator|Radiotherapy|Large keloid scars undergo extralesional excision and radiotherapy
3241026|NCT01295099|Active Comparator|TAC|
3241027|NCT01295125|Experimental|XenMATRIX|Use of XenMATRIX mesh to repair hernia
3241028|NCT01295125|Active Comparator|Native tissue|Repair with participants native tissue
3241029|NCT01295138|Experimental|Lactulose group|Group receives 48 hours of lactulose post Caesarean section.
3241030|NCT01295138|No Intervention|Non-lactulose group|Group receives no lactulose post Caesarean section.
3241031|NCT01295151|Experimental|TNF-blocking drug|
3348308|NCT02245269|Experimental|TPV/r + Atorvastatin followed by TPV/r + antacid|Day 1: first dose of ATV Day 8: single dose of TPV/r Day 13: single dose of TPV/r, followed by a single dose of Maalox Days 14-21: morning and evening doses of TPV/r on Day 20: second dose of ATV
3348309|NCT02245295||EBUS-TBNA|EBUS-TBNA for enlarged mediastinal/hilar lymph nodes
3348310|NCT02245321|Placebo Comparator|Letter Group- No information|Receive a thank you letter after each blood donation.
3348311|NCT02245321|Experimental|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
3348312|NCT02245321|Placebo Comparator|Ferrous gluconate- 0 mg|Receive pills to take daily that contain no iron (a placebo or inert pill).
3348313|NCT02245321|Experimental|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
3348314|NCT02245321|Experimental|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
3348315|NCT02245334|Experimental|Povidone-iodine|povidone iodine pill
3348316|NCT02245334|No Intervention|no intervention|no intervention
3348317|NCT02245347||Patients with expected MDR TB|
3348318|NCT02245373||Antidepressants|Naturalistic assignment: Patients whose physician decides to indicate antidepressants.
3348319|NCT02245373||Active Monitoring|Naturalistic assignment: Patients whose physician considers starting an Active Monitoring intervention.
3348320|NCT02245386||Group 1|(40 women after normal vaginal delivery) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3241032|NCT01295151|Experimental|Abatacept|
3348321|NCT02245386||Group 2|(40 women after urgent cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3348322|NCT02245386||Group 3|(40 women after elective cesarean section) submitted to transperineal pelvic floor ultrasound 48-72 hours postpartum.
3348323|NCT02245399|Experimental|A canola oil enriched mediterranean diet|Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.
3348324|NCT02245399|Active Comparator|A high wheat fiber diet|Participant will be advised to consume a high carbohydrate diet (58% carbohydrate, 16% protein and 25% fat) emphasizing whole wheat/whole grain cereals and increased high fiber alternatives, with fruits and vegetables.
3241033|NCT01295151|Active Comparator|Rituximab|
3241034|NCT01295164|Active Comparator|Group 1|Measurement of aberrations in patients with keratoconus of grade 1
3241035|NCT01295164|Active Comparator|Group 2|patients with keratoconus of grade 2
3241036|NCT01295164|Experimental|Group 3|patients with keratoconus of grade 3
3241037|NCT01295164|Experimental|Group 4|patients with keratoconus of grade 4
3348325|NCT02245425|Active Comparator|Supine Thoracic Spine Manipulation|Supine (lying face-up on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2)
3348326|NCT02245425|Active Comparator|Prone Thoracic Spine Manipulation|Prone (lying face down on the treatment table) thoracic spine thrust manipulation will be given 2 times at 3 treatment sessions (Weeks 0, 1, and 2).
3348327|NCT02245438|Experimental|TPV/RTV low dose|
3348328|NCT02245438|Experimental|TPV/RTV high dose|
3348329|NCT02245451|Experimental|TPV/r with methadone|
3348330|NCT02245464||Patients with essential hypertension|
3348331|NCT02245477||Obstetric Ultrasoud|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
3348332|NCT02245477||Serum Vascular Endothelial Growth Factor|Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat. No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
3348333|NCT02245490|Experimental|Tamsulosin|
3348334|NCT02245490|Placebo Comparator|Placebo|
3348335|NCT02245503||Benign prostatic hyperplasia|Patients with symptomatic BPH to whom ALNA was prescribed
3348336|NCT02245529||Patients with benign prostatic hyperplasia (BPH)|
3241038|NCT01295177|Placebo Comparator|vehicle cream|Intervention: Placebo cream vehicle. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream (cream with the same constitution but without insulin). The placebo cream vehicle was used for 8 weeks.
3241039|NCT01295177|Placebo Comparator|cream insulin|Intervention: insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with insulin cream (cream with the same constitution but with insulin). The insulin cream was used for 8 weeks.
3241040|NCT01295190||Propofol|Patients receiving Propofol during cardiopulmonary bypass.
3241041|NCT01295190||Sevoflurane|Patients receiving sevoflurane during cardiopulmonary bypass
3241042|NCT01295203|No Intervention|Control group|The control group were not given access to the intervention website and received no additional information.
3241043|NCT01295229|Active Comparator|Lifestyle Intervention|
3241044|NCT01295229|Active Comparator|Surgery|
3348337|NCT02245542||BPH patients|
3348338|NCT02245555||Patients with benign prostatic hyperplasia|
3348339|NCT02245581|Active Comparator|SVV-guided fluid management|SVV : Stoke volume variation
3348340|NCT02245581|Active Comparator|CVP-guided fluid management|CVP : Central venous pressure
3348341|NCT02245594||Gl motility and sleep pattern|
3348342|NCT02245607|Experimental|Compensatory Cognitive Training|Compensatory Cognitive Training
3348343|NCT02245607|Active Comparator|Recreational Therapy|Recreational Therapy
3241045|NCT01295268|Active Comparator|Emu Oil|
3241046|NCT01295268|Placebo Comparator|inert oil|
3241047|NCT01295294|Experimental|tranexamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with tranexamic acid
3241048|NCT01295294|Experimental|mefenamic acid + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive treatments with mefenamic acid
3241049|NCT01295294|Placebo Comparator|placebo + Mirena (Levonorgestrel IUS, BAY86-5028)|Subjects with successful MIRENA insertion will receive placebo
3241050|NCT01295307|Experimental|Single Arm|Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
3241051|NCT01295333|Other|conventional approach|conventional traitment
3241052|NCT01295333|Experimental|experimental approach|early and systematic traitment
3348344|NCT02245633||vitamin D levels deficient|Diabetic hemodialysis patients with vitamin D levels deficient
3348345|NCT02245633||vitamin D levels sufficient|Diabetic hemodialysis patients with vitamin D levels sufficient
3348346|NCT02245646||Control group|No indication for stapedotomy
3348347|NCT02245646||Distortion positive|Subjects after stapedotomy perceiving sound distortions
3348348|NCT02245646||Distortion negative|Subjects after stapedotomy not perceiving sound distortions.
3348349|NCT02245659|Experimental|CPAP|
3348350|NCT02245659|Other|Nasal dilator strip|Control
3241053|NCT01295346||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
3241054|NCT01295359|Experimental|Trained Group|This group will receive the usual care of the hospital and a ground walking training program associated with respiratory exercises.
3348351|NCT02245698|Experimental|Stem Cell|Bone marrow mononuclear cells
3348352|NCT02245711|Experimental|Stem Cell|
3348353|NCT02245724|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3348354|NCT02245750|No Intervention|Routine Invistigations|ICSI with long luteal phase protocol
3348355|NCT02245750|Experimental|Hysteroscopy|hysteroscopy will be done prior to the ICSI cycle
3348356|NCT02245776|Experimental|Stem Cell|Bone marrow mononuclear cell transplantation
3348357|NCT02245789|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope. All patients will received propofol and remifentanil anesthesia.
3348358|NCT02245789|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope. All patients will received propofol and remifentanil anesthesia.
3348359|NCT02245802||Low risk group|CU Prediction model < 3
3348360|NCT02245802||High risk group|CU Prediction model >=3
3348361|NCT02245828|Placebo Comparator|Placebo|Placebo comparator
3348362|NCT02245828|Experimental|QCC374|Single and multiple ascending doses of QCC374
3348363|NCT02245841|Experimental|H.P Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
3348364|NCT02245854|Experimental|Colonic polyps|Exacto™
3348365|NCT02245867|Experimental|Phase Ia|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~A 1-patient cohort will be infused with 0.5 mg/m2 of Ch 11-1F4 and, if tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. All individuals will be evaluated prior to treatment, after infusion weekly for four weeks, as well as at 8 weeks."
3348366|NCT02245867|Experimental|Phase Ib|"Administration of Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4:~Subjects will receive four weekly infusions of the monoclonal anti-body at Dose Level 1 (0.5 mg/m2). If tolerated, the doses in the next patients will be increased to 5, 10, 50, 100, 250, and finally, 500 mg/m2. When the highest tolerated dose is reached without toxicity in 2 patients, an additional 4 patients will be enrolled and infused at that dose. Escalation or de-escalation will continue until we have determined the highest dose level at which less than 2 patients experience toxicity. All individuals will be evaluated prior to each course of treatment, as well as at weeks 5, 8, and 12."
3348367|NCT02245880|Active Comparator|Glidescope videolaryngoscope|cervical collar was applied to 47 patients then facemask ventilations were recoded intubated with Glidescope and insertion time: handling of the device till the good glottic visualisation intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device after removal heart rate preinduction heart rate postinduction heart rate postinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation wrere recorded. postoperative minor complications were recorded.
3348368|NCT02245880|Active Comparator|Intubating laryngeal mask airway|cervical collar was applied to 47 patients then facemask ventilations through the collar were recorded and intubated with ILMA insertion time: handling of the device till the good glottic visualisation appears intubation time: handling of the device till the capnography appears mucosal damage: bloodstain on the device heart rate preinduction heart rate postinduction heart rate posinsertion heart rate postintubation mean arterial pressure preinduction mean arterial pressure postinduction mean arterial pressure postinsertion mean arterial pressure postintubation
3241055|NCT01295359|No Intervention|Usual Care Group|This group will only receive the usual care of the hospital, including physical therapy
3241056|NCT01295372|Experimental|Zicronapine|
3241057|NCT01295372|Active Comparator|Risperidone|
3241058|NCT01295385|Experimental|healthy volunteers|
3241059|NCT01295385|Active Comparator|patients with a diabetic cardiomyopathy|
3241060|NCT01295398|Other|conventional jet-nebulizer|(particles diameter of 4-5 µm)
3241061|NCT01295398|Experimental|a jet-nebulizer adapted for infants|(particles diameter of 2-2.5 µm),
3241062|NCT01295398|Experimental|a mesh-nebulizer adapted for infants|(particles diameter of 2-2.5 µm).
3241063|NCT01295411|Other|schizophrenia PATIENTS|
3241064|NCT01295424||Single group study|
3241065|NCT01295437|Active Comparator|Vypro II mesh|A partly absorbable polypropylene-polyglactin mesh (50g/m2).
3241066|NCT01295437|Active Comparator|Premilene LP|A lightweight polypropylene mesh (55 g/m2)
3241067|NCT01295437|Placebo Comparator|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
3259296|NCT01469533|Sham Comparator|control group|The control group receives the sham-manipulation procedure.
3348369|NCT02245893|Active Comparator|Screw|"In the SCREW Group (standard surgery technique), surgical treatment will be by closed reduction utilizing intraoperative fluoroscopy to visualize the reduction and percutaneous syndesmosis screw insertion. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
3348370|NCT02245893|Active Comparator|Anatomic repair technique (ART)|"In the ART group (study group) surgical treatment will be by open reduction and internal fixation. In order to stabilize the syndesmosis, direct visual anatomic alignment will be conducted and a syndesmotic screw inserted. In addition, fixation of the anterior ligament will be performed with use of a 2.7 to 4.0 mm suture anchor. Repair of the intact portion of the ligament will be made using a modified Mason -Allen repair. Intraoperative fluoroscopic stress and non-stress views will be obtained as per standard of care.~'open reduction internal fixation (ORIF)"
3348371|NCT02245906|Placebo Comparator|Control drink|300 ml control drink containing equal amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
3348372|NCT02245906|Experimental|Brazilian fruit peel|300 ml test drink containing Brazilian fruit peel flour, acute study / one time administration
3348373|NCT02245906|Placebo Comparator|Negative control drink|300 ml control drink without containing amount of total fiber and pectine as Brazilian fruit drink, acute study / one time administration
3348374|NCT02245919|Experimental|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
3348375|NCT02245932|Experimental|Resveratrol supplementation|150 mg of resveratrol for 4 weeks (split over two doses of 75 mg/day)
3259297|NCT01469559|Active Comparator|Novolin Toronto insulin|
3348376|NCT02245932|Placebo Comparator|Placebo supplementation|Placebo for 4 weeks (split over two doses per day)
3348377|NCT02245945|Experimental|TFV 1% gel|"Participants will be instructed to use TFV 1% vaginal gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
3348378|NCT02245945|Placebo Comparator|hydroxyethylcellulose (HEC) placebo gel|"Participants will be instructed to use HEC placebo gel according to the BAT 24 regimen (2 gel doses) at least twice per week, regardless of sexual frequency.~The BAT24 dosing regimen when used with sex is defined as one dose of gel within 12 hours before sex and a second dose of gel as soon as possible within 12 hours after sex and no more than two doses in a 24 hour period. Participants who do engage in sexual intercourse should use the BAT24 regimen with each sex act.~If used without sex, the BAT24 dosing regimen is defined as 2 doses of gel administered 2-24 hours apart, with no more than two doses in a 24 hour period."
3348379|NCT02245958||BOTOX®|Retrospective chart review of doses of BOTOX® (onabotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3348380|NCT02245958||Xeomin®|Retrospective chart review of doses of Xeomin® (incobotulinumtoxinA) used as standard of care in clinical practice. No treatment (intervention) was administered.
3348381|NCT02245971|Active Comparator|Whole precutting group|
3348382|NCT02245971|Active Comparator|Partial precutting group|
3348383|NCT02245984|Experimental|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
3348384|NCT02245984|Experimental|electronic nursing process|for two weeks students in this group will be implemented electronic nursing process for patients.
3348385|NCT02245997|Experimental|patients with high-risk neuroblastoma|Patients undergo external beam radiation therapy using IMRT or proton beam RT twice daily for 5-6 weekdays (10-12 treatments). Patients will be evaluated by physical exams, CT scan or MRI of the primary site, and MIBG at, 6, 12, 18 and 24 months (+/- 6 weeks).
3348386|NCT02246023|Active Comparator|Fractionated propofol administration|"Flexible bronchoscopy in moderate sedation with fractionated propofol administrations: Patients receive an initial 20 mg of propofol, followed by a carefully titrated dose of10-20 mg propofol based on the clinical response.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy"
3348387|NCT02246023|Experimental|Propofol-TCI|"Flexible bronchoscopy in moderate sedation with TCI propofol perfusor:~Flexible bronchoscopy is started after reaching the initial targeted effect-site concentration (Ce) of 2.5 μg/mL using the Schnider pharmacokinetic model described elsewhere. Thereafter, Ce is adjusted by increments of 0.2 μg/mL depending on the clinical effect, in order to maintain the required level of sedation.~Continuous measurement of oxygen saturation Measurement of non-invasive blood pressure; Report of dose adjustments und cumulative propofol dosage; Recovery time after bronchoscopy The propofol-TCI perfusor is an active infusion system for fluid management. In the study, the Perfusor® Space of B. Braun AG, Melsungen is used exclusively."
3348388|NCT02246036|Experimental|APD probe|Placement of a duodenal probe during 24 hours.
3348389|NCT02246049|Experimental|FOLFOXIRI plus bevacizumab|"Induction therapy is followed by the maintenance therapy.~[Induction treatment:FOLFOXIRI plus bevacizumab] Administered for a maximum of 12 cycles. BV: 5mg/kg (d.i.v.) L-OHP: 85 mg/sq.m (d.i.v.) CPT-11:165mg/sq.m (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks.~[Maintenance treatment:5-FU / I-LV plus bevacizumab] BV:5mg/kg (d.i.v.) l-LV:200mg/sq.m (d.i.v.) 5-FU:3,200mg/sq.m (c.i.v.) Administered every 2 weeks."
3348390|NCT02246075|Experimental|EVP-6124, low dose|Low dose, Tablet, Once Daily, Day 1 through Day 168
3348391|NCT02246075|Experimental|EVP-6124, high dose|High dose, Tablet, Once Daily, Day 1 through Day 168
3348392|NCT02246075|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 168
3348393|NCT02246088|Experimental|MT + NE|A manual therapy (MT) intervention combined with neuroscience education (NE)
3348394|NCT02246088|Active Comparator|MT + E|Manual therapy (MT) intervention plus an educational program based on a traditional patho-anatomical or biomedical model (E)
3348395|NCT02246101||WTC responders|WTC responders who were enrolled in the WTC-CHEST program.
3241068|NCT01295450|Active Comparator|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
3348396|NCT02246127|Active Comparator|Sequence A, drug: everolimus first|Everolimus (10mg/daily, oral) followed by STZ-5FU (injection/infusion; Moertel or Uppsala regime).
3348397|NCT02246127|Experimental|Sequence B, drug: STZ - 5FU first|STZ-5FU (injection/infusion; Moertel or Uppsala regime) followed by Everolimus (10 mg/ daily, oral)
3348398|NCT02246140|Experimental|Cannabis users|Cerebral MRI and MRA
3241069|NCT01295450|Experimental|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
3241070|NCT01295489||Group A (IP catheter removed)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and blood (for cell, plasma, and serum isolations) is collected before courses two and three for translational research.
3241071|NCT01295489||Group B (IP catheter in place)|Archival formalin-fixed, paraffin-embedded tumor (collected during previous surgery), peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolation) samples are collected before course one and peritoneal fluid, peritoneal wash, and blood (for cell, plasma, and serum isolations) before courses two and three for translational research.
3348399|NCT02246140|Active Comparator|healthy volunteers|Cerebral MRI and MRA
3348400|NCT02246153|Experimental|Laparoscopic gastrectomy|Laparoscopy-assisted distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3348401|NCT02246153|Active Comparator|Open gastrectomy|Open distal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3348402|NCT02246179|Experimental|1: AFXL + AHES|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will be applied at this test region at t1.Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
3348403|NCT02246179|Experimental|2: AFXL + EMLA|This test region will be pretreated with a fractional carbon dioxide laser (ablative fractional laser; AFXL) with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam.
3348404|NCT02246179|Sham Comparator|3: Sham AFXL + AHES|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Articaine hydrochloride 40 mg/ml and epinephrine 10 μg/ml solution (AHES) will then be applied at this test region on the intact skin at t1. Ten minutes after AHES application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
3348405|NCT02246179|Sham Comparator|4: Sham AFXL + EMLA|"A pass with a fractional carbon dioxide laser with a 120 μm spot at 5% density and a pulse energy of 2.5 mJ/microbeam, single pulse will be given at the area right adjacent to this test region (sham AFXL) at t0 in a subject blinded fashion. Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will then be applied at this test region on the intact skin at t1. Ten minutes after EMLA cream application (incubation time; under occlusion), a pain stimulus will be given at t11 to the subject at the test region using AFXL at 5% density and 35 mJ/microbeam."
3348406|NCT02246192|Experimental|control group|sinus pilonidal excision and standard cares
3348407|NCT02246192|Experimental|PRGF group|sinus pilonidal excision+ PRGF
3348408|NCT02246205|Experimental|DPC DN|Roux-en Y reconstruction after pancreaticoduodenectomy
3259298|NCT01469559|Placebo Comparator|Normal saline|
3259299|NCT01469572|Experimental|Sir-sphere radioembolization|Everolimus, Pasireotide and Sir-sphere radioembolization
3259300|NCT01469598|Experimental|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
3348409|NCT02246205|Active Comparator|DPC UN|Child reconstruction after pancreaticoduodenectomy
3348410|NCT02246231|Experimental|NF2 who has an auditory implant|
3348411|NCT02246244|Experimental|Escitalopram|10 mg once per day
3348412|NCT02246244|Placebo Comparator|Placebo|
3348413|NCT02246257|Other|Intervention|"In the intervention group all patients will receive statins according to national guidelines. Stepwise introduction of pharmacological therapy targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria and behaviour modification will be controlled by the project team in an outpatient rheumatology department.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
3348414|NCT02246257|Other|Control|"In the control group patients will be refered to general practice for pharmacological therapy according to national guidelines targeting 1) hyperlipidaemia, 2) hypertension, 3) hyperglycaemia and 4) microalbuminuria.~Hyperlipidaemia: LDL > 2.5 is treated with 40 mg Simvastatin; Hypertension: BT > 140/90 mmHg treated with 100 mg OD Losartan; Diabetes: DM BT > 130/80 mmHg treated with 100 mg OD Losartan; Microalbuminuria: Urinary albumin creatinin ratio > 30 mg treated with 100 mg OD Losartan; Hyperglycaemia: HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks Metformin"
3348415|NCT02246270|Experimental|Intravesical heparin|Recurrent UTI subject receives intravesical heparin once every week for 6 weeks
3348416|NCT02246270|Active Comparator|Placebo|Recurrent UTI subject receives intravesical saline once every week for 6 weeks
3348417|NCT02246296|Active Comparator|Standard F75 Milk|F75 with 63% of total energy from carbohydrates, including 10% of energy from lactose (standard F75).
3348418|NCT02246296|Experimental|Modified F75 Milk|F75 milk with 43% of total energy from carbohydrates, without any lactose, and providing the same amount of energy as standard F75 by increased lipid in the form of medium chain triglycerides.
3348419|NCT02246322|Experimental|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
3241072|NCT01295502|Experimental|Treatment (radiation, cisplatin, paclitaxel, carboplatin)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3241073|NCT01295528||Blood Pressure, Heart Rate, Monitor|
3348420|NCT02246322|Experimental|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
3348421|NCT02246335|Active Comparator|Control group|Hemiarthroplasty
3348422|NCT02246335|Active Comparator|Treatment group|Total hip arthroplasty
3348423|NCT02246348|Experimental|Doppler ultrasound|
3348424|NCT02246361|No Intervention|Phase 1 (without PIL)|No particular intervention during consultation for the patient
3348425|NCT02246361|Experimental|Phase 2|Patient Information Leaflet is given to the patient during the consultation
3348426|NCT02246374|Experimental|ExAblate Treated Arm|ExAblate Transcranial System subthalamotomy for motor symptoms of Parkinson's Disease.
3348427|NCT02246374|Sham Comparator|ExAblate Sham Treated Arm|ExAblate Transcranial System sham subthalamotomy for motor symptoms of Parkinson's Disease. Sham subjects completing the 4 Month visit may be offered the actual ExAblate subthalamotomy.
3348428|NCT02246387||Manchester Operation|Manchester Operation: Native tissue repair
3348429|NCT02246400|Active Comparator|Delayed Intervention|Usual care for first three months. Initiation of the eCMP after the 3-month time point.
3348430|NCT02246400|Experimental|Immediate Intervention|Initiation of the eCMP immediately upon completion of baseline data collection and randomization
3348431|NCT02246426|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
3348432|NCT02246426|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 40 treatment sessions, 3-5 times weekly, 45-60 minutes per session.
3348433|NCT02246465|Experimental|RXI-109|RXI-109 dosed at the site of the revised hypertrophic scar
3241074|NCT01295541||4 months of observation|CVICU
3241075|NCT01295554||Peripheral arterial disease|Peripheral arterial disease
3348434|NCT02246491|Other|iPSCs without gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
3348435|NCT02246491|Other|iPSCs with gene correction|This is not a clinical trial and there is no immediate benefit to the participants. At this time, iPSCs and their derived products are not suitable for administration to patients. However, they are useful for basic and preclinical studies of the disease, such as mechanistic studies of ATM function or screening for small molecules with therapeutic value. As regenerative medicine continues to advance, iPSCs and their products may ultimately be used for clinical studies aimed at replacing damaged tissues in A-T patients.
3348436|NCT02246504|Experimental|HIFU treatment|use of HIFU treatment in patients with non-malignant thyroid nodules
3348437|NCT02246517|Experimental|N2O&Oxygen|70% N2O & 30% Oxygen by Aspiration for 5 min
3348438|NCT02246517|Placebo Comparator|Oxygen|100% Oxygen by Aspiration for 5 min
3348441|NCT02246543|Placebo Comparator|Treatment 1 - Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
3348442|NCT02246543|Active Comparator|Treatment 2 - HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
3348443|NCT02246543|Active Comparator|Treatment 3 - LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
3241076|NCT01295567|Placebo Comparator|placebo|
3241077|NCT01295567|Experimental|dipyridamole|
3348444|NCT02246543|Active Comparator|Treatment 4 - HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
3348445|NCT02246543|Active Comparator|Treatment 5 - LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
3348446|NCT02246556|Active Comparator|Patching therapy|Patching treatment followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3348447|NCT02246556|Active Comparator|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) therapy followed by crossover to dichoptic virtual reality video game treatment arm using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3348448|NCT02246556|Experimental|Dichoptic therapy|Dichoptic virtual reality video game treatment using Diplopia (TM) software developed for the Oculus Rift (R) game system.
3348449|NCT02246595|Active Comparator|CaCP29|dose escalating i.v. administration of CaCP29 (verum)
3348450|NCT02246595|Placebo Comparator|Placebo|dose escalation mimicing i.v. placebo treatment:
3348451|NCT02246621|Experimental|Abemaciclib + NSAI|150 milligrams (mg) Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
3241078|NCT01295593|Experimental|valproic acid combined with CdA|valproic acid, oral daily intake, combined with 2-chlorodeoxyadenosine administered intravenously for 4 cycles
3241079|NCT01295606|No Intervention|Cefazolin, antibiotic prophylaxis|All included patients will received iv cefazolin
3348452|NCT02246621|Placebo Comparator|Placebo + NSAI|Placebo orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
3348453|NCT02246634|Experimental|Diffusion Weighted MRI scan|Patients in the study will get a DW-MRI of the liver in addition to their standard treatment imaging prior to their surgery.
3348454|NCT02246686|Experimental|STW5-II|Half of study population, assigned randomly
3348455|NCT02246686|Placebo Comparator|Placebo|Half of study population, assigned randomly
3348456|NCT02246699|Experimental|KiOnutrime®-Cs|The product is presented as a capsule containing chitosan as ingredient supporting the activity.
3348457|NCT02246699|Placebo Comparator|Placebo|Placebo is presented as a capsule containing inactive ingredients.
3348458|NCT02246712|Active Comparator|Control group|Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for the single nucleotide polymorphism (SNP) 516G>T in CYP2B6 gene (CYP2B6 genotype).
3348459|NCT02246712|Experimental|T2DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 2 DM was performed according to the American Diabetes Association (2010)."
3348460|NCT02246712|Experimental|T1DM group|"Patients received a single oral dose of 100 mg racemic tramadol. Serial blood samples were collected up to 24 h after administration of the drug for pharmacokinetic study and for the analysis of noradrenaline in plasma. Pain was rated on a visual analog pain scale at the same time as blood sampling. CYP2D6 phenotype was evaluated using metoprolol as probe drug. CYP3A phenotype was evaluated using midazolam. Patients were genotyped for SNP 516G>T in CYP2B6 gene (CYP2B6 genotype).~The diagnosis of type 1 DM was performed according to the American Diabetes Association (2010)."
3348461|NCT02246725||Contact with palliative care unit versus contact when needed.|
3348462|NCT02246738||Cohort1|
3348463|NCT02246738||Cohort 2|
3348464|NCT02246738||Cohort 3|
3348465|NCT02246738||Cohort 4|
3348466|NCT02246738||Cohort 5|
3348467|NCT02246738||Cohort 6|
3348468|NCT02246738||Cohort 7|
3241080|NCT01295619|Experimental|I-020805|This was a prospective, open, multi-center, single-arm study to investigate I-020805 in patients following elective cranial surgery. If they met the inclusion/ exclusion criteria, they receive I-020805 after suturing of the dura. If necessary, autologous grafts were to be used to augment dural closure.
3241081|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 90 mg|
3241082|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-2206 135 mg|
3241083|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 90 mg|
3241084|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 135 mg|
3241085|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-2206 200 mg|
3241086|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 135 mg|
3348469|NCT02246738||Cohort 8|
3348470|NCT02246738||Cohort 9|
3348471|NCT02246751|Experimental|Single subject design case series|Targeted Training for trunk control, 5-6 days a week for 9 months, minimum of 20 minutes per day.
3348472|NCT02246790|Active Comparator|Biatrial radiofrequency ablation and CABG|Biatrial radiofrequency ablation during CABG
3348473|NCT02246790|Active Comparator|Left atrial radiofrequency ablation and CABG|Left atrial radiofrequency ablation during CABG
3348474|NCT02246803|Active Comparator|CABG+pulmonary vein isolation|CABG+pulmonary vein isolation procedure
3241087|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-2206 200 mg|
3348475|NCT02246803|Active Comparator|Isolated CABG|Isolated CABG procedure
3241088|NCT01295632|Experimental|Ridaforolimus 20 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3241089|NCT01295632|Experimental|Ridaforolimus 30 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3241090|NCT01295632|Experimental|Ridaforolimus 40 mg + MK-0752 1800 mg|No longer recruiting as of 19 July 2012
3241091|NCT01295645|Experimental|Standard of Care + Cidofovir|Cidofovir 0.5 mg/kg IV 3 x week for 4 weeks
3241092|NCT01295645|Active Comparator|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
3348476|NCT02246816|Experimental|All Subjects|Assigned to receive open-label 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
3348477|NCT02246829|Other|Aflibercept 2mg Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
3348478|NCT02246842|Experimental|D-Gam®|D-Gam® (human anti-D immunoglobulin)
3348479|NCT02246842|Active Comparator|Rhophylac®|Human Anti-D Immunoglobulin
3348480|NCT02246855|Experimental|Vigam® Liquid infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
3348481|NCT02246855|Experimental|Gammaplex® infused at up to 3mL/min|Gammaplex® (Human Normal Immunoglobulin)
3348482|NCT02246855|Experimental|Gammaplex® infused at up to 6mL/min|Gammaplex® (Human Normal Immunoglobulin)
3348483|NCT02246868|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3348484|NCT02246881|Active Comparator|Current Factor VIII|Optivate® (Human Coagulation Factor VIII)
3348485|NCT02246881|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3348486|NCT02246894|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3241093|NCT01295658||Cancer Survivors|"This is a broad observational study conducted online at www.cancerexperienceregistry.org, or via pen and paper survey obtained by calling the cancer support helpline at 888-793-9355~Any individual who has ever received a cancer diagnosis, regardless of disease type, stage, treatment, and time since diagnosis, can take part in this study."
3241094|NCT01295684|Placebo Comparator|placebo|Base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage.
3241095|NCT01295684|Experimental|Cranberry Juice|Base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day.
3241096|NCT01295697|Experimental|EZN-2208|Cytotoxic Agent
3241097|NCT01295723|Experimental|Intraoperative Electron Radiation Therapy|A single dose of electron irradiation given at the surgical site during the operation to remove the cancerous tumor will replace the usual 5-8 days of localized radiation. Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days post operatively.
3241098|NCT01295736|Active Comparator|Actif arm|Sildenafil 20mg TID during 90 days
3348487|NCT02246907|No Intervention|Control Group|The control group will receive standard of care which includes recreational therapy and standard encouragement.
3348488|NCT02246907|Other|Exercise|Participants in this arm will receive standard of care plus exercise for the duration of their inpatient stay for induction chemotherapy.
3241099|NCT01295736|Placebo Comparator|Sugar pill|Placebo pills TID during 90 days
3348489|NCT02246920|Experimental|Investigational Test Product|Fluticasone propionate Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
3241100|NCT01295749|Active Comparator|ventilation by laryngeal tube|ventilation by laryngeal tube and continuous chest compression
3241101|NCT01295749|Sham Comparator|ventilation by bag valve mask|ventilation by bag valve mask and interrupted chest compression
3241102|NCT01295762|Other|Type of neuroblastoma|Neonatal stages I Localized immediately resectable stages Localized immediately unresectable stages High-risk neuroblastoma Relapsed neuroblastoma
3241103|NCT01295775|Active Comparator|Sulodexide group|50 mg of sulodexide a day will be administered by oral route (1+1 capsule/day) for 360 days
3348490|NCT02246920|Active Comparator|Reference Listed Drug|Flonase® (fluticasone propionate) Nasal Spray, 50 mcg/actuation; 200 mcg/day for 14 days
3348491|NCT02246920|Placebo Comparator|Placebo|Saline Placebo Nasal Spray; 4 total sprays/day for 14 days
3348492|NCT02246933|Experimental|PUFA Diet|
3348493|NCT02246933|Placebo Comparator|Control Diet|
3348494|NCT02246946|Experimental|Positive Airway Pressure group|The patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and walking for 100 meters (i.e., the same treatment that will be administered to the Conventional Chest Physiotherapy group). Additionally, this group will receive positive airway pressure breathing with 15 mmHg by a device via a rubber facial mask for 30 minutes in a sitting position.
3348495|NCT02246946|Active Comparator|Conventional Chest Physiotherapy group|"In the sitting position, the patients allocated to this group will undergo bronchial hygiene treatments administered with a high-frequency oscillator for 5 sets of 10 repetitions, lung expansion exercises using flow oriented incentive spirometry for 5 sets of 20 repetitions and positive airway pressure breathing with 4 mmHg via a rubber facial mask for 5 minutes in a sitting position. These patients will also walk for 100 meters.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the equipment in the room and mark the patient's skin."
3348496|NCT02246946|Placebo Comparator|Control group|"The patients allocated to this group will receive positive airway pressure breathing with 4 mmHg (without therapeutic value) via a rubber facial mask for 30 minutes in a sitting position.~The use of positive pressure breathing with 4 mmHg has no therapeutic value, but will help keep the blinding of assessors by the presence of the complete kit of equipment in the room."
3241104|NCT01295775|Placebo Comparator|Placebo group|Sulodexide placebo will be administered at the same schedule (1+1 capsule/day) and for the same lengths of time (for 360 days) as Sulodexide group
3241105|NCT01295788|Experimental|Simultaneous RT-CGM and Pump Initiation|The experimental group will initiate RT-CGM at the same time as they begin insulin pump therapy.
3348497|NCT02246959|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive electronic pill bottles for their statin medication but are not enrolled in the sweepstakes.
3348498|NCT02246959|Experimental|Process Arm|Arm 2 will be a Process incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
3241106|NCT01295788|Active Comparator|Delayed RT-CGM Initiation|The control group will use standard pump therapy until the 6 month study visit at which time RT-CGM will be initiated.
3241107|NCT01295801||Linezolid+vitamin B6|
3241108|NCT01295801||Linezolid|
3241109|NCT01295853|Active Comparator|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
3241110|NCT01295853|Active Comparator|t4 sypathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
3241111|NCT01295866||nasal nitric oxide, atypy status|
3241112|NCT01295892|Placebo Comparator|placebo|placebo (transdermal gel)
3241113|NCT01295892|Experimental|Estrogen|1mg of 17B-estradiol/day (transdermal gel)
3241114|NCT01295918|No Intervention|Placebo, antibiotic, diarrhea|
3348499|NCT02246959|Experimental|Outcome Arm|Arm 3 will be an Outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group may receive incentives if they lower their LDL.
3348500|NCT02246959|Experimental|Process Plus Outcome Arm|Arm 4 will be a process plus outcome incentive arm where participants receive electronic pill bottles for their statin medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication and receive additional incentives for lowering their LDL cholesterol.
3348501|NCT02246972|Experimental|VRET Immediate treatment|Participants will be randomized to receive Virtual Reality Exposure Therapy (VRET) immediately
3348502|NCT02246972|Active Comparator|Waitlist|6 weeks standard of care, then Virtual Reality Exposure Therapy (VRET) treatment.
3348503|NCT02246985|Experimental|Plain bread with plain mayonnaise|Control meal. The bread and mayonnaise in this meal does not have vegetable powders incorporated into them, hence this meal does not contain carotenoids
3241115|NCT01295918|Placebo Comparator|L. reuteri, Antibiotic, diarrhoea|L. reuteri will be ingested by patients on antibiotic therapy, effect of probiotic on AAD will be assessed.
3241116|NCT01295931|Experimental|IC-Green + Imaging|Indocyanine Green (IC-Green) Injections + Imaging
3348504|NCT02246985|Experimental|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids
3348505|NCT02246985|Experimental|Vegetable bread with plain mayonnaise|A vegetable powder (carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread will be standardised to contain a known amount of carotenoids.
3348506|NCT02246985|Experimental|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
3348507|NCT02247037||Triple Negative Breast Cancers|All women eligible for this protocol will fall into this group. These women will have histologically confirmed triple negative breast cancer and be eligible for neoadjuvant chemotherapy or have evidence of metastatic disease.
3348508|NCT02247050|Experimental|Commitment invitation at time 1|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the first clinic will remain in the control period (no intervention) for 2 months and then cross over to the intervention period for 6 months."
3348509|NCT02247050|Experimental|Commitment invitation at time 2|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the second clinic will remain in the control period (no intervention) for 3 months and then cross over to the intervention period for 5 months."
3348510|NCT02247050|Experimental|Commitment invitation at time 3|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the third clinic will remain in the control period (no intervention) for 4 months and then cross over to the intervention period for 4 months."
3348511|NCT02247050|Experimental|Commitment invitation at time 4|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fourth clinic will remain in the control period (no intervention) for 5 months and then cross over to the intervention period for 3 months."
3348512|NCT02247050|Experimental|Commitment invitation at time 5|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the fifth clinic will remain in the control period (no intervention) for 6 months and then cross over to the intervention period for 2 months."
3241118|NCT01295957|Active Comparator|reminiscence therapy, story telling|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. Refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography. Three main variables contributed to successful reminiscing: individuality, evaluation and structure.
3348513|NCT02247050|Experimental|Commitment invitation at time 6|"Intervention: Behavioral: Commitment Invitation~In the stepped wedge cluster randomized design, the sixth clinic will remain in the control period (no intervention) for 7 months and then cross over to the intervention period for 1 month."
3348514|NCT02247076|Placebo Comparator|Grazing|"Participants will eat meals spread over the course of the day (grazing)."
3348515|NCT02247076|Experimental|Time-restricted feeding (early eating)|Participants will eat meals only in the early part of the day (early lunch and very early dinner).
3348516|NCT02247102|Experimental|Isomaltulose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
3348517|NCT02247102|Active Comparator|Sucrose|Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)
3375924|NCT03476369|Experimental|Fentanyl and Crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered crushed (180 mg dose)
3375925|NCT03476369|Active Comparator|Fentanyl and Non-crushed Ticagrelor|Premedicated with Fentanyl (at least 25mcg by IV) followed by Ticagrelor 90mg tablet administered as a whole tablet (180 mg dose)
3241119|NCT01295957|Placebo Comparator|comparison|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, but they didn't participate in reminiscence sessions to rule out the possibility that improvement in quality of life was due only to attention received and social stimulation.
3241120|NCT01295957|No Intervention|control|control group was administered counseling and informal social contacts in bi-weekly sessions of one hour,
3241121|NCT01295970|Active Comparator|Radiosurgery (SRS)|
3241122|NCT01295970|Active Comparator|Surgery|
3241123|NCT01296009|Experimental|traditional Chinese medicine|The pregnancy rate in traditional Chinese medicine group is higher than the control group
3241124|NCT01296022|Active Comparator|Subcutaneous ICD|Subcutaneous Implantable Cardioverter Defibrillator
3241125|NCT01296022|Active Comparator|Transvenous ICD|Transvenous Implantable Cardioverter Defibrillator
3241126|NCT01296048||Body Analysis|
3348518|NCT02247128|Active Comparator|Aspirin + Clopicogrel (Cohort A)|Cohort A: patients will receive clopidogrel (75mg quaque die (qD), 3 months) on top of low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patient in Cohort A doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI.
3348519|NCT02247128|Active Comparator|Aspirin monotherapy (Cohort A)|Cohort A: patients will receive low-dose aspirin (≤100mg qD, at least 1 year but recommended lifelong). When a patients doesn't already takes aspirin, a loading dose of 300mg will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
3348520|NCT02247128|Active Comparator|OAC + Clopicogrel (Cohort B)|Cohort B: patients will receive clopidogrel (75mg qD, 3 months) on top of OAC (according to its indication). The loading dose for clopidogrel is 300mg, and will be given within 24 hours prior to TAVI. It is recommended to omit other antiplatelet therapy (e.g. aspirin) at least 5 days prior to the TAVI procedure.
3348521|NCT02247128|Active Comparator|OAC monotherapy (Cohort B)|Cohort B: patients will receive OAC according to its indication. It is recommended to continue the OAC therapy peri-procedural (International Normalized Ratio aimed at 2.0). It is recommended to omit antiplatelet therapy (e.g. clopidogrel) at least 5 days prior to the TAVI procedure.
3348522|NCT02247141|Experimental|Subgam®|
3348523|NCT02247154|Experimental|Vigam® Liquid|
3348524|NCT02247167|Experimental|adenotonsillectomy (AT)|Children with SDB studied before and after before adenotonsillectomy.
3348525|NCT02247180|Experimental|Cognitive Rehabilitation|cognitive rehabilitation for 12 weeks
3348526|NCT02247180|Active Comparator|Cognitive Training|standardized cognitive training in the domesticity
3348527|NCT02247206|Experimental|Behavior Therapy for Tics (CBIT)|The child 1) learns to become more aware of any sensations, or urges that may trigger tics, and 2) learn some other behavior (competing response) to do every time he/she feels the urge to tic. The child's parent is trained to provide prompts and praise for use of the competing response. The parent and family also receive psychoeducation about tics, and learn ways to reduce the impact of environmental stimuli on tic severity. The child learns relaxation techniques to reduce stress and make it easier for him/her to resist his or her tics. Prior to treatment sessions, the parent and child spend about 10 minutes discussing with the therapist any problematic issues he/she is having. At the end of treatment sessions the child is assigned some tasks to practice prior to the next session.
3348528|NCT02247206|No Intervention|Waitlist-control Group|Participants in the waitlist-control group, do not receive behavior therapy for tics or any other treatment during the 10-week acute treatment period. Instead they child are placed on a waitlist to receive videoconference-delivered treatment following the end of the study period.
3241127|NCT01296061||Failed Kidney Transplant|Adults ≥ 18 years, initiating chronic dialysis
3348529|NCT02247219|Experimental|Intervention|'Counselling and education individually and in groups'
3348530|NCT02247219|Other|Waiting list control|The waiting list group waits 6 months after assessment and allocation and is reassessed after 6 and 12 months. Both groups are reassessed after 24 months, and the second part of the study is a one group longitudinal cohort study.
3348531|NCT02247232|Placebo Comparator|Placebo|
3348532|NCT02247232|Experimental|Z-100|
3348533|NCT02247258|Active Comparator|Systematic azathioprine group|Patients randomized to the systematic azathioprine group received 2.0-2.5 mg/kg azathioprine within 14 days from surgery and throughout 102 weeks.
3348534|NCT02247258|Active Comparator|Endoscopy-driven azathioprine group|Patients randomized to the endoscopy-driven azathioprine group received no Crohn's disease specific treatment for 26 weeks postoperatively. A first ileocolonoscopy was performed at week 26. In case of endoscopic recurrence (Rutgeerts' score i2 or higher), azathioprine was introduced at a dose of 2.0-2.5 mg/kg until week 102. If not, an ileocolonoscopy was repeated at week 52, and azathioprine started in case of endoscopic recurrence. If no endoscopic recurrence was observed, no Crohn's disease-specific treatment was given until week 102.
3348535|NCT02247271|Other|Diabetes health coach support|The intervention is that subjects will receive coach support once a week for 30 minutes for six months. Support is provided by a Diabetes Coach who uses self-management support strategies to assist subjects to achieve their personal health goals.
3348536|NCT02247284|Experimental|group 1|patient with a diagnosis of primary open angle glaucoma will undergo 'RNFL and BMO-MRW SD-OCT' measurements with Heidelberg Spectralis SD-OCT old protocoll and Glaucoma Premium Module (new) protocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
3348537|NCT02247297||Pregnant Women|Healthy pregnant women and women with preeclampsia, HELLP syndrom, amniotic infection syndrome, or preterm premature rupture of membranes
3241128|NCT01296074|Experimental|Corticosteroid|Methylprednisolone will be given during cardiopulmonary bypass.
3241129|NCT01296087|Experimental|TC-6987|
3241130|NCT01296087|Placebo Comparator|Placebo|
3348538|NCT02247310||Cohort 1|Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome and be on treatment with Betaferon using the BETACONNECT auto-injector device.
3241131|NCT01296100|Experimental|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
3241132|NCT01296100|Experimental|Lifestyle counseling (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
3241133|NCT01296113|Experimental|A|
3241134|NCT01296139|Experimental|A|All subjects will receive 7.5 mg/kg Fe
3241135|NCT01296165||Travellers visiting India|People that are older than 18 years and planning to visit India for a period of at least 5 days will be approached by the personal at the travel clinics to participate in the study. Informed consent will be obtained prior to enrolling subjects.
3348539|NCT02247323||premenopausal women|premenopausal women with complex ovarian mass moderate for malignancy by risk of malignancy index score and low CA125.
3348540|NCT02247362|Experimental|Vaccine Dose Group 12 mcg|VAX2012Q, 12 mcg dose
3348541|NCT02247362|Experimental|Vaccine Dose Group 20 mcg|VAX2012Q, 20 mcg dose
3348542|NCT02247362|Experimental|Vaccine Dose Group 16 mcg|VAX2012Q; 16 mcg dose
3348543|NCT02247362|Placebo Comparator|Vaccine Diluent|Vaccine Diluent, F147, as placebo control
3348544|NCT02247375|Experimental|Low dose of BIIL 284 BS|
3348545|NCT02247375|Experimental|High dose of BIIL 284 BS|
3348546|NCT02247375|Placebo Comparator|Placebo|
3348547|NCT02247388|Experimental|AB-CASI|Automated Bilingual Computerized Alcohol Screening and Brief Negotiated Interview(BNI) Intervention
3348548|NCT02247388|No Intervention|Standard Care|Standard Care
3348549|NCT02247414|Experimental|Warfarin with dipyridamole|From postoperative day 3, patients will receive dipyridamole 25mg tid for three months along with subcutaneous Low Molecular Weight Heparin Calcium injection for first five days and Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3. Intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR. After achieving the target INR, this is to be repeated every 4 weeks. The Doppler Ultra Sonography screening will be done every 3 months to assess the occurrence of portal vein thrombus, but the medications will be continue for one year irrespective of the occurrence of portal vein thrombus.
3348550|NCT02247414|Active Comparator|Aspirin with dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months along with subcutaneous injection of Low Molecular Weight Heparin (4100 IU) for first five days and Aspirin Enterie Ccoated Tablets 100mg qd for one year.
3348551|NCT02247427|Experimental|Off-pace group|Deactivated device group
3348552|NCT02247427|No Intervention|On-Pace group|Ongoing device activity group
3348553|NCT02247492||Orsiro|
3348554|NCT02247505|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3348555|NCT02247505|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3241136|NCT01296204|Experimental|BB4 antibody-Iodine 131|
3241137|NCT01296217|Experimental|lymph nod detection|
3241138|NCT01296230|Experimental|Hormone/semen measurements before and after varicocelectomy|We will measure sex-hormone and semen quality in patients both before and after varicocelectomy. The purpose is to asses if preoperative hormone levels are predictive for who will have improved semen quality after surgery.
3241139|NCT01296243|Experimental|Tesetaxel once every 3 weeks|
3241140|NCT01296256|Experimental|Bendamustine-EAM|
3348556|NCT02247518|Other|Group1: Treatment A + Treatment B, PO|Treatment A : Tadarafil 5mg*1t/day for 5days, Treatment B : Tadarafil 5mg*1t/day and Tamsulosin 0.2mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3348557|NCT02247518|Other|Group2: Treatment B + Treatment A, PO|Treatment A : Tamsulosin 0.2mg*1t for 5days, Treatment B : Tamsulosin 0.2mg*1t/day and Tadalafil 5mg*1t/day for 5days, Each treatment period was separated by a washout period of at least 10 days.
3348558|NCT02247544|Experimental|Trabectedin|"Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).~Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response."
3241141|NCT01296269|Experimental|Vasopressin|vasopressin condition
3241142|NCT01296269|Experimental|oxytocin|oxytocin condition (syntocinon)
3348559|NCT02247557|Experimental|Group A: Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
3241143|NCT01296269|Placebo Comparator|placebo|
3241144|NCT01296282||Heart failure patients|
3241145|NCT01296295|Experimental|Spirometry and lifestyle counseling|Intervention group: The intervention is to give brief structured smoking cessation advice combined with a detailed and structured discussion of the spirometric results.
3348560|NCT02247557|Experimental|Group B: BoNT-A 200 U in Normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
3348561|NCT02247557|Placebo Comparator|Group C: Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
3348562|NCT02247570|Experimental|Vestibular Rehabilitation|Vestibular Rehabilitation
3348563|NCT02247583||mRCC patients|Patients with metastatic renal cell carcinoma
3241146|NCT01296295|No Intervention|Lifestyle counseling|No intervention group: the patients of the control group will receive a brief structured smoking cessation advice.
3241147|NCT01296308||type 2 diabetics with neuropathy|
3348564|NCT02247596|Placebo Comparator|Placebo|Sugar pill 1g tds for 2 weeks
3348565|NCT02247596|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum 1g three times a day for 2 weeks
3348566|NCT02247609|Experimental|CAR T cells|Autologous 4th generation anti-CD19-CAR T cells
3348567|NCT02247622||Healthy control|
3348568|NCT02247622||IBD|patients with inflammatory bowel disease, study group
3348569|NCT02247622||PSC|patients with primary sclerosing cholangitis, study group
3348570|NCT02247635|No Intervention|Conventional medical treatment|Based on the clinical guidelines of the Ministry of Health, medical treatment was provided and consisted in counseling for chronic diseases such as obesity, hyperglycemia, hypertension, dyslipidemia
3348571|NCT02247635|Active Comparator|Healthy lifestyle and adherence|1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
3348572|NCT02247648|Experimental|treatment|treatment: tramadol group
3348573|NCT02247648|Placebo Comparator|control|control: placebo group
3348574|NCT02247661||Direct lateral approach|Total or hemiarthroplasty operated with direct-lateral approach.
3348575|NCT02247661||Postero-lateral approach|Total or hemiarthroplasty operated with postero-lateral approach.
3348576|NCT02247674|Placebo Comparator|Education & training consultation|Education and training consultations were provided for subjects in control group during study period.
3348577|NCT02247674|Experimental|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
3348578|NCT02247687|Other|Counseling arm|Counseling without antiretroviral treatment modification
3348579|NCT02247687|Active Comparator|Switch arm for protease inhibitor|Switch arm for protease inhibitor : intervention is the switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.
3241148|NCT01296321|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
3241149|NCT01296321|Active Comparator|Waitlist|Waitlist.
3348580|NCT02247687|Active Comparator|Addition of Isentress® (raltegravir)|"Drug: Addition of Isentress® (raltegravir) arm~• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling"
3348581|NCT02247700||Mechanical Ventilation|Infants and Children requiring mechanical ventilation
3348582|NCT02247713||Retrospective cohort|Participating centers will retrospectively provide demographic, tumor, treatment and follow-up details on at least 25 consecutive patients with stage III NSCLC previously treated with curative intent chemoradiotherapy (concurrent or sequential) in the period between 2010 and 2013.
3348583|NCT02247713||Prospective cohort|Participating centers will provide prospective data on patients with stage III NSCLC treated with curative intent concurrent chemoradiotherapy. Centers will be asked to include at least 25 consecutive cases following the training intervention and the successful local implementation of PET/CT for RTP in NSCLC.
3348584|NCT02247726|Placebo Comparator|Treatment Group A|Saline Placebo (0.5mL injection)
3348585|NCT02247726|Experimental|Treatment Group B|RSV F vaccine with adjuvant (0.5mL injection)
3348586|NCT02247752|Other|Inactive carriers|
3241150|NCT01296334|Experimental|morphine low dose|morphine infusion 10 mg over a 210 min period
3241151|NCT01296334|Experimental|morphine high dose|morphine infusion 20 mg over a 210 min period
3348587|NCT02247778|Active Comparator|conventional plate osteosynthesis|Standard procedure
3348588|NCT02247778|Active Comparator|mini-incision-type osteosynthesis|mini-incision
3241152|NCT01296334|Experimental|buprenorphine low dose|buprenorphine infusion 0.3 mg over a 210 min period
3241153|NCT01296334|Experimental|buprenorphine high dose|buprenorphine infusion 0.6 mg over a 210 min period
3241154|NCT01296334|Placebo Comparator|placebo|placebo (normal saline) infusion 0.6 mg over a 210 min period
3241155|NCT01296373||HIV-1-infected, off ART|HIV-1-infected, antiretroviral naive or off antiretroviral therapy for at least 12 months with CD4+ T-cell counts less than or equal to 350 cells/µL who are about to commence combination antiretroviral therapy
3348589|NCT02247791|Active Comparator|Cemented femoral stem|Patient undergoing total hip arthroplasty surgery
3348590|NCT02247791|Active Comparator|Uncemented femoral stem|Patients undergoing total hip arthroplasty
3348591|NCT02247817|Experimental|HYBRID|Hybrid transvenous/epicardial implantation of a CRT-(D) device.
3241156|NCT01296386|Experimental|IC84, 75 µg w/ Alum|75 µg w/ Alum (microgram with Alum)
3241157|NCT01296386|Experimental|IC84, 75 µg w/o Alum|75 µg w/o Alum (microgram without Alum)
3348592|NCT02247830|Experimental|1 Chamomilla recutita gel|Experimental Group 01: usual care + topical application of the gel recutita chamomile. Such intervention will be characterized by topical application of the gel C. recutita, concomitantly to the initiation of radiotherapy, should be applied on the irradiated three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
3241158|NCT01296386|Experimental|IC84, 200 µg w/ Alum|200 µg w/ Alum (microgram with Alum)
3241159|NCT01296386|Experimental|IC84, 200 µg w/o Alum|200 µg w/o Alum (microgram without Alum)
3348593|NCT02247830|Experimental|2 Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the area irradiated three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
3348594|NCT02247830|No Intervention|Control Group (Usual Care)|The usual care consists of nursing consultation with instructional material (Manual guidelines) that is already done systematically in service. This query is made with all patients starting radiotherapy. Here, guidelines are provided about skin care and hydration, using topical moisturizing soap solution over the bath. Such information is contained in the manual that is provided to the patient during the consultation.
3348595|NCT02247843|Experimental|βAS3-FB vector transduced peripheral blood CD34+ cells|This is a single arm study without randomization. All subjects will receive the intervention of BetaAS3 lentiviral vector-modified autologous peripheral blood stem cell transplant.
3348596|NCT02247856|Active Comparator|Control Group|Noninvasive ventilation+ jet nebulizer
3348597|NCT02247856|Experimental|Experimental Group|Noninvasive ventilation+ Vibrating Mesh Nebulizer (VMN)
3241160|NCT01296399||Bare metal stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary bare metal stent, for de-novo stenosis
3241161|NCT01296399||Drug eluting stent|patients, with a patent previously deployed intra coronary bare metal stent, receiving intra coronary drug eluting stent, for de-novo stenosis
3241162|NCT01296438|Experimental|Treatment sequence 1|
3241163|NCT01296438|Active Comparator|Treatment sequence 2|
3241164|NCT01296451|Experimental|Arm A, group1|Intervention: MVA-NSmut. Administration schedule: 1 dose MVA-NSmut 2 x 10^8 pfu. Subjects: 4 healthy volunteers
3241165|NCT01296451|Experimental|Arm A, group 2|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8.~Subjects: 10 healthy volunteers"
3348598|NCT02247869|Experimental|dose dense ABVD|1 arm for all patients (dose dense ABVD on day 1 and 8 every 21 days)
3241166|NCT01296451|Experimental|Arm B, group 1|"Interventions: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 14 and 1 dose MVA-NSmut 2 x 10^8pfu at week 22, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
3241167|NCT01296451|Experimental|Arm B, group 2|"Interventions: AdCh3NSmut; MVA-NSmut.. Administration schedule: 1 dose AdCh3NSmut 2.5 x 1010vp at week 2 and 1 dose MVA-NSmut 2 x 108pfu at week 10, after starting PEG-IFN and ribavirin therapy.~Subjects: 5 patients"
3241168|NCT01296451|Experimental|Arm C, group 1|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose MVA-NSmut 2 x 10^8pfu at week 8.~Subjects: 4 patients"
3348599|NCT02247882|Experimental|Patient Education|Health Education.
3348600|NCT02247882|Active Comparator|Aquatic Physical Therapy|Protocol of aquatic physical therapy exercises.
3348601|NCT02247895|Sham Comparator|Sham Treatment|Sham stimulation twice daily
3348602|NCT02247895|Active Comparator|Active Treatment|The active treatment group will receive neuromuscular electrical stimulation to both quadriceps muscle for 30 minutes twice daily for a total of 14 treatments.
3348603|NCT02247908|Experimental|Graphic Warning|Graphic warnings that include text and an image depicting a health effect of smoking will be applied on labels that cover the top half of the front and back of participants' cigarette packs each week for 4 weeks. Within the graphic warning condition, participants will be assigned to receive 1 of 4 warnings for 4 weeks. The text for these warnings was selected from the 2009 Family Smoking Prevention and Tobacco Control Act and the images were proposed by the FDA.
3348604|NCT02247908|Active Comparator|Surgeon General's Warning|Labels with Surgeon General's Warning text will be applied to the side of participants' cigarette packs each week for 4 weeks, on top of the Surgeon General's Warning printed by the manufacturer.
3241169|NCT01296451|Experimental|Arm A, group 3|"Interventions: AdCh3NSmut; MVA-NSmut Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8pfu at week 8, 1 dose AdCh3NSmut 2.5 x 10^10vp at week 16 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 24.~Subjects: 5 healthy volunteers"
3348605|NCT02247921|Experimental|Rehabilitation|nurse-led caregiver-delivered rehabilitation
3241170|NCT01296451|Experimental|Arm A, group 4|"Intervention: AdCh3NSmut; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut 2.5 x 10^10vp (at least 6 months after they were initially enrolled) and 1 dose MVA-NSmut 2 x 10^8 pfu 8 weeks later.~Subjects: up to 5 healthy volunteers who were previously in group A2"
3348606|NCT02247921|No Intervention|Usual care|The patients in the control arm will receive conventional care in terms of access to rehabilitation in hospital, timeliness of discharge and follow-up, without any explicit provision of caregiver training or accelerated discharge.
3348607|NCT02247934||Concept elicitation interviews (Step I)|Approximately 20 participants will be included.
3348608|NCT02247934||Cognitive interviews (Step II)|Approximately 30 participants will be included.
3348609|NCT02247947||dead|Patients dead until day 20 (primary outcome measure)
3348610|NCT02247947||survivors|patients alive after day 20 (primary outcome measure)
3348611|NCT02247973|Experimental|Mesenchymal stem cells|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with severe aplastic anemia.
3241171|NCT01296451|Experimental|Experimental: Arm A, group5|"Intervention: AdCh3NSmut1. MVA-NSmut. Administration schedule:1 dose AdCh3NSmut1 2.5 x 10^10vp at week 0, 1 dose MVA-NSmut 2 x 10^8 pfu at week 8 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 40.~Subjects: 5 healthy volunteers"
3241172|NCT01296451|Experimental|Arm A, group 6|"Interventions: AdCh3NSmut1. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^7 pfu at week 8.~Subjects: 5 healthy volunteers"
3348612|NCT02247999||Cohort|HIV-infected women attending HIV care and treatment clinics in Pune, Chennai, andBelgaum in India.
3348613|NCT02248012|Experimental|Everolimus/temozolomide|Everolimus 10 mg daily, temozolomide 150 mg/m2 for 7 days every 2 weeks.
3241173|NCT01296451|Experimental|Arm A, group 7|"Interventions: AdCh3NSmut1; MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^6 pfu at week 8.~Subjects: 5 healthy volunteers"
3241174|NCT01296464|Experimental|Stalevo|levodopa/carbidopa/entacapone
3348614|NCT02248038|Active Comparator|open surgery|Conventional procedure
3348615|NCT02248038|Experimental|laparoscopic surgery|Minimum invasive procedure
3241175|NCT01296464|Placebo Comparator|Placebo|
3241176|NCT01296477||Asthma IQ Primary Care Tool|
3241177|NCT01296477||Usual Asthma Care in Primary Care|
3241178|NCT01296490|Experimental|Stress test|The men will run on a treadmill for 10 minutes until exhaustion. Blood will be drawn before, 5 minutes after and an hour after the test.
3348616|NCT02248051|Experimental|CXA-10|
3348617|NCT02248064|No Intervention|Fixed flow oxygen|The 6MWT will done on the patients usual fixed flow ambulatory oxygen in this arm.
3348618|NCT02248064|Experimental|Auto-titrating arm|The 6MWT will done using the auto-titrating oxygen system in this arm of the study
3348619|NCT02248077|Active Comparator|AutoloGel|AutoloGel consists of platelet-rich plasma (PRP) gel produced from the patient's own peripheral blood and pharmaceutical additives including calcium chloride, thrombin and ascorbic acid. The AutoloGel product is obtained by processing the patient's own blood using the AutoloGel System. After the final AutoloGel formulation is produced it is used immediately for patient's specific ulcer care.
3241179|NCT01296503|Active Comparator|Dexamethasone (Arm A)|Sixty days (D+60) after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days)
3259301|NCT01469611|Experimental|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
3348620|NCT02248077|Other|Usual and Customary Care (UCC)|Standard of care
3348621|NCT02248090|Experimental|AZD9496|AZD9496 dose escalation and expansion(s)
3348622|NCT02248116|Experimental|Alzheimer|
3348623|NCT02248129||Hypertensive patients|
3348624|NCT02248142||RLS patients|
3348625|NCT02248155||RLS patients|
3348626|NCT02248168||Idiopathic Parkinson's disease patients|
3348627|NCT02248181||Idiopathic PD patients|
3348628|NCT02248194|Experimental|"Group 1Tactile electrosurgical ablation"|Endometrial ablation will be done by Tactile electrosurgical ablation probe.
3241180|NCT01296503|Experimental|Thalidomide and Dexamethasone (Arm B)|"D+60 after ASCT: dexamethasone plus thalidomide 200 mg by mouth daily for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
3241181|NCT01296516|Placebo Comparator|Control Group|A group matched for age and BMI will be selected to serve as control subjects in this study.
3348629|NCT02248194|Active Comparator|"Group 2 Hysteroscopic endometrial ablation"|Hysteroscopic endometrial ablation will be done by trans-cervical resection of endometrium.
3348630|NCT02248207||Parkinson Disease patients|
3348631|NCT02248220||Parkinson's disease patients|
3348632|NCT02248233|Experimental|Saline + citicoline|The control group will receive physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days. Patients will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment.
3241182|NCT01296516|Active Comparator|Face-to-face group|Participants randomized to the face-to-face intervention will attend motivational meetings held once per week in Phase I and biweekly in Phase II. Behavioral sessions will be led by a trained interventionist and will take place at Pennington Biomedical Research Center.
3241183|NCT01296516|Active Comparator|Telehealth Group|Participants randomized to the Telehealth intervention will receive behavioral counseling through Trestletree, phone system.
3348633|NCT02248233|Experimental|Nimodipine|"The treatment group will receive 10 mg of nimodipine in 500 ml of physiological saline via intravenous drip, at a rate of 1-2 drops per minute initially, increasing gradually until systolic pressure decreases by 10 mmHg. Maximum drip speed is 10 drops/minute, administered once a day for 7 consecutive days. The nimodipine must be kept in the dark. Blood pressure and heart rate will be monitored throughout the administration period.~Patients in control group will receive additional drugs to treat dehydration, prevent infection and upper gastrointestinal bleeding, and maintain water and electrolyte balance. Patients with complications will receive symptomatic treatment."
3241184|NCT01296529||HIV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HIV antibodies and/or HIV viral RNA, and a negative antibody test for HCV
3348634|NCT02248259|Experimental|Reference treatment|Single oral dose of BI 409306
3348635|NCT02248259|Experimental|Test treatment|Single oral dose of BI 409306 and Administration of Itraconazole
3241185|NCT01296529||HCV monoinfection|Evidence should include a copy of a laboratory report of testing positive for HCV antibodies and HCV viral RNA, and a negative antibody test for HIV
3241186|NCT01296529||HIV and HCV coinfection|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, and positive tests for HCV antibodies and HCV RNA.
3241187|NCT01296529||HIV/HCV coinfection with HCV clearance|Evidence should include a copy of a laboratory report of testing positive for HIV or HIV viral RNA, a positive tests for HCV antibodies, and undetectable HCV RNA without hepatitis C treatment (spontaneous clearance) or >6 months after hepatitis therapy (sustained virologic response)
3241188|NCT01296555|Experimental|Phase I, Stage 1: GDC-0032 as Single Agent|Participants with locally advanced or metastatic solid tumors will receive increasing doses of GDC-0032 administered orally daily in 28-day cycles. Dose escalation decisions will be based upon the observed incidence of DLTs.
3348636|NCT02248272|Experimental|Polycystic Ovary Syndrome|40 women with PCOS followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (40% carbohydrates, 25% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3348637|NCT02248272|Experimental|Impaired Glucose Tolerance|35 individuals with Impaired Glucose Tolerance (IGT) followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3375927|NCT03440736|Active Comparator|Secukinumab 300 mg s.c.|Patients in arm A receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
3241189|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Fulvestrant|Participants (Cohorts F, J, K, L, and M) will receive GDC-0032 in combination with fulvestrant until disease progression.
3241190|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Letrozole|Participants (Cohorts E, N, P, Q, R, and S) will receive GDC-0032 in combination with letrozole until disease progression.
3241191|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 as Single Agent|Participants (Cohorts A, B, C, D, G, H, T, T2, and X) will receive GDC-0032 until disease progression.
3241192|NCT01296555|Experimental|Phase I, Stage 2: GDC-0032 + Midazolam|Participants (Cohort C) will receive GDC-0032 in combination with midazolam.
3241193|NCT01296555|Experimental|Phase II: GDC-0032 + Fulvestrant|Post-menopausal females with locally advanced or metastatic HER2-negative, hormone receptor-positive breast cancer will receive GDC-0032 in combination with fulvestrant until disease progression.
3241194|NCT01296581|Experimental|X-82|
3241195|NCT01296594|Active Comparator|Usual Care|
3241196|NCT01296594|Experimental|usual care with cell phone monitoring and CM|In the CM condition, patients will carry a cell phone and record and send in time- and date-stamped self videos of medication ingestion.
3241197|NCT01296607|Other|Urocortin 2|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 2 in the presence and absence of a saline washout between incremental doses.
3241198|NCT01296607|Other|Urocortin 3|This arm studies the onset/ offset of action and the reproducibility of effect on forearm blood flow of of intra-arterial Urocortin 3 in the presence and absence of a saline washout between incremental doses.
3348638|NCT02248272|Experimental|Type 2 Diabetes|12 individuals diagnosed with type 2 diabetes followed one of two isocaloric weight maintenance diets (isocaloric diet with 3 meals or isocaloric diet with 6 meals), tailored to individual energy needs, with the same macronutrient composition (45% carbohydrates, 20% protein, 35% fat). The energy and carbohydrate contribution for the 3 meals' diet was 20% at breakfast, 50% at lunch, 30% at dinner, whereas for the 6 meals' diet was 20% at breakfast, 10% at morning snack, 30% at lunch, 10% at afternoon snack, 20% at dinner, 10% at before bedtime snack. Each intervention lasted 12 weeks and there was no wash out period.
3348639|NCT02248298|Experimental|2h-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3348640|NCT02248298|Active Comparator|3hr-AFL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3348641|NCT02248298|Active Comparator|3hr-MAL-PDT|All 440 AK lesions of the 93 patients were randomly assigned to treatment with MAL-PDT (3h-MAL-PDT) or AFL-PDT with 2 hours (2h-AFL-PDT) and 3 hours (3h-AFL-PDT) of incubation time, using restricted randomization, with a computer-generated program.
3348642|NCT02248311||Patients/Control Group|Observational
3348643|NCT02248311||Patients/Group Control|Observational
3348644|NCT02248337|Active Comparator|4 Liter PEG|Colon preparation for colonoscopy: PEG 4 Liter before endoscopy
3348645|NCT02248337|Experimental|2 Liter PEG plus bisacodil|Colon preparation for colonoscopy: PEG 2 L before endoscopy
3348646|NCT02248350|Experimental|Exercise Group|8-weeks of supervised and home based exercise intervention, 3 times a week, 50-minutes a session for a total of 150/minutes a week
3348647|NCT02248350|Active Comparator|Stretching Control group|Informational booklet containing stretching exercises (20-minutes a day)
3348648|NCT02248376|Experimental|Gel +|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
3348649|NCT02248376|No Intervention|Gel -|Patients aged of more than 18 years-old coming for a natural miscarriage who will not have the non-stick gel application at the end of the scraping surgery.
3348650|NCT02248389|Experimental|Ablation arm|Each person in study will receive ablation of their renal tumor followed by standard partial nephrectomy.
3348651|NCT02248402|Experimental|Vax-DC/MM|
3348652|NCT02248415|Experimental|No pump group|Blood cardioplegia administration without roller pump
3348653|NCT02248415|Other|Pump group|Blood cardioplegia administration with roller pump
3348654|NCT02248428|Experimental|BiCTd regimen|"Induction and consolidation therapy: BiCTd regimen for 8 cycles. Patients received Clarithromycin 500 mg orally on days 1-28,thalidomide 100-200mg orally on days d1-28, dexamethasone 40mg orally on days on 1,8,15,22, and cyclophosphamide 300mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,repeated every 28 days) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted."
3348655|NCT02248428|Active Comparator|CTd regimen|"Induction and consolidation therapy: CTd regimen for 8 cycles. Patients received thalidomide 100-200mg orally on days d1-28, dexamethasone 40 mg orally on days on 1,8,15,22, and cyclophosphamide 300 mg/m^2 intravenously on day 1-3. Cycles were repeated every 28 days.~Maintenance therapy:CP regimen (cyclophosphamide 200 mg orally on days 1-14 and prednisone 30mg twice daily orally on days 1-7,28 Days per Cycle) until disease progression.~If efficacy <PR after 4 cycles of induction or disease progression at anytime，patients will be quitted.~If no further reduction in the serum and urine M protein in the next cycle，patients may cross over to BiCTd regimen."
3348656|NCT02248441|Experimental|Daily RIC|Daily ischemic conditioning treatment
3348657|NCT02248454|Experimental|Insulin bolus dose/type|Lispro insulin, dose calculated by modeling analysis
3348658|NCT02248467||eugonadal|50 eugonadal subjects
3348659|NCT02248467||untreated hypogonadal|25 asymptomatic hypogonadal subjects
3348660|NCT02248467||treated hypogonadal|25 symptomatic hypogonadal subjects treated - In the present study, we decided to monitor only sexual symptoms of androgen deficiency due to the fact that testosterone replacement therapy (TRT) should be expected to improve them in the time span until surgery. These patients will be treated with TRT as per clinical practice.
3348661|NCT02248493|Experimental|paracetamol and ketoprofen|"paracetamol 20 mg/kg (1% 2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
3348662|NCT02248493|Placebo Comparator|placebo and ketoprofen|"0.9% sodium chloride (2 ml/kg) IV at the end of surgery 6 and 20 hours thereafter.~ketoprofen 1.5 mg/kg IV at the end of surgery 8 and 16 hours thereafter. tramadol 2 mg/kg IV on patient request up til 4 mg/kg or PCA morphine during 24 hours postoperatively."
3348663|NCT02248506|Other|Clotrimazole|Clotrimazole 500 mg
3348664|NCT02248519|Active Comparator|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
3348665|NCT02248519|Experimental|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy.
3348666|NCT02248532|Active Comparator|Group A|Repetitive stem cell administration
3348667|NCT02248532|Active Comparator|Group B|Single stem cell administration
3241199|NCT01296620|Experimental|Experimental 1|
3241200|NCT01296620|Experimental|Experimental 2|
3241201|NCT01296620|Placebo Comparator|Placebo|
3259302|NCT01469624|Experimental|Test group|This group receives pentoxifylline
3259303|NCT01469624|No Intervention|Control group|
3241202|NCT01296633|Experimental|Medtable|The Medtable is a patient education tool used for collaborative planning. The Medtable focuses patients on how to take their medication and prompts them to anchor this task to familiar routines. The tool serves as an external workspace that helps provider and patient jointly visualize how to integrate constraints from medications (e.g., which can be taken together; dose spacing) and patients' routine (e.g., typical meal times) in order to create an optimal daily schedule. The completed Medtable shows providers how patients are thinking about taking their medications, allowing them to clear up any confusion. It encourages teach-back and teach-to-goal strategies recommended for patients with low health literacy. Completing the Medtable helps patients implement as well as create plans by encouraging them to think about when and where they will actually take their medication. It also provides a template developed with their providers that could help patients load pill organizers at home.
3241203|NCT01296633|Active Comparator|Usual care|Patients in the usual care condition at both research sites will receive the medication counseling and communication that is standard of care at these sites. This includes a medication reconciliation process, where patients are given a card with list of medications that is periodically checked. This provides an opportunity for providers to correct patient knowledge of their medications, and is similar to the process of creating a list for the Medtable. However, the Medtable also encourages patients and providers to collaborate in order to organize this list in terms of the patient's routine to create a patient-specific, concrete plan for taking the medications.
3348668|NCT02248545||Non-celiac Wheat Sensitivity Patients|Consecutive adult patients with irritable bowel syndrome (IBS)-like clinical presentation, according to Rome II criteria, and a definitive diagnosis of NCWS.
3348669|NCT02248545||Celiac Disease Patients|Celiac disease adult patients, sex- and age-matched, diagnosed according to standard criteria, during the same study period, chosen at random and enrolled as first control group.
3348670|NCT02248545||Irritable Bowel Syndrome Patients|"Irritable Bowel Syndrome adult patients, sex- and age-matched, diagnosed according to Rome II criteria, and unrelated to NCWS or other food intolerance, during the same study period, chosen at random and enrolled as second control group."
3241204|NCT01296659|Experimental|AIM Arm|Ridaforolimus combined with doxorubicin/ifosfamide/mesma (AIM)
3241205|NCT01296659|Experimental|TG Arm|Ridaforolimus combined with docetaxel and gemcitabine (TG)
3241206|NCT01296685||oxygenator with arterial filter|
3241207|NCT01296685||arterial filter|
3348671|NCT02248571|Experimental|Arm A|"Bevacizumab plus Capecitabine (1st treatment phase) followed by Everolimus plus Exemestane (2nd treatment phase)~Dosing (treatment cycle: 21days):~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
3348672|NCT02248571|Experimental|Arm B|"Everolimus plus Exemestane (1st treatment phase) followed by Bevacizumab plus Capecitabine (2nd treatment phase)~Dosing (treatment cycle: 21days):~Everolimus: 10 mg/day orally applied tablet --- Exemestane: 25 mg/day orally applied tablet~Capecitabine: 1000 mg/m2 orally applied twice daily as combined 150 mg and 500 mg tablets on days 1 to 14 of each 21-day cycle, followed by a seven day rest period (i.e. off-treatment) --- Bevacizumab: 15 mg/kg intravenously applied once every three weeks (i.e. 5 mg/kg/wk dose equivalent)~Patient questionaires to assess patient reported outcome and patients' preference will be completed at four specific time points during study treatment (two timepoints in each treatment phase)"
3348673|NCT02248584|Experimental|Vitamin E, C and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
3348674|NCT02248584|Placebo Comparator|Placebo|Capsule containing only lactose
3348675|NCT02248597|Experimental|Treatment (stem cell transplant with GVHD prophylaxis)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV QD on days -6 to -2. Patients receiving myeloablative conditioning receive busulfan IV every 6 hours for 16 doses on days -7 to -4 and patients receiving reduced intensity conditioning receive busulfan IV every 6 hours for 8 doses on days -5 to -4. Patients also receive cyclophosphamide IV QD on days -3 and -2~TRANSPLANT: Patients undergo stem cell transplant on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide QD on days 3 and 4, tacrolimus on days 5-180, and mycophenolate mofetil on days 5-35. Allogeneic hematopoietic stem cell transplantation"
3348676|NCT02248610||Rivaroxaban|All participants will be treated with rivaroxaban.
3348677|NCT02248688|Other|Embolic Agent - BeadBlock|Left Gastric Artery Embolization - Embolic Agent - BeadBlock 300 - 500 Micron will be used as the embolic agent to embolize left gastric artery.
3348678|NCT02248701|Experimental|testosterone enanthate, finasteride|Testosterone enanthate via i.m. injection (125 mg/week) and finasteride orally (5 mg/day)
3348679|NCT02248701|Placebo Comparator|placebo treatment|Placebo via i.m. injection (once weekly) and placebo pill orally (daily)
3348680|NCT02248753|Active Comparator|Standard Care|Pharmacological cardioversion and/or electrical cardioversion
3348681|NCT02248753|Experimental|Wait-and-see Approach|Rate control drugs only (metoprolol, verapamil or digoxin)
3348682|NCT02248779||treated < 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
3241208|NCT01296711|Experimental|CDP6038|
3241209|NCT01296724|Other|newborn with digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and digestive pathology
3241210|NCT01296724|Other|Newborn without digestive pathology|Preterm or term newborn admitted in paediatric intensive care unit with an urethral catheter and without digestive pathology
3348683|NCT02248779||treated ≥ 20 years prior to study enrollment|"The following information will be gathered:~A. Height, weight, waist circumference, blood pressure B. Oral glucose tolerance testing (OGTT) where in participants will ingest a standard oral glucose load (75 grams) in liquid formulation after an overnight fast. Blood samples for glucose and insulin concentrations will be taken at 0, 30, 60, 90, and 120 minutes post-glucose load.~C. Glutamic acid decarboxylase (GAD), islet cell (ICA-512), and insulin autoantibody (IAA) titers as well as serum adiponectin and hemoglobin A1c.~All enrolled patients will have a discussion with an LTFU doctor regarding the results of testing. Counseling and referral to a specialist will be provided if indicated."
3348684|NCT02248792|Experimental|Group A|Methotrexate 10mg orally once weekly
3348685|NCT02248792|Active Comparator|Group B|Methotrexate 25mg orally once weekly
3348686|NCT02248805|Experimental|Does Escalation Arm A|MGD007 treatment once weekly
3348687|NCT02248805|Experimental|Dose Escalation Arm B|MGD007 treatment once every 3 weeks
3241211|NCT01296750|Active Comparator|Early Physiotherapy|Physiotherapy to begin within 1 day post op.
3241212|NCT01296750|No Intervention|Late Physiotherapy|Physiotherapy to start 6 weeks post op
3348688|NCT02248805|Experimental|Dose Expansion Arm C|MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
3348689|NCT02248805|Experimental|Dose Expansion Arms|MGD007 2, 3, 6, or 12 doses/cycle
3348690|NCT02248831|Experimental|Doppler ultrasound|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
3348691|NCT02248844||Botulinum Toxin Type A|Subjects who receive botulinum toxin Type A injected into crow's feet line areas per clinical practice.
3241213|NCT01296776|Active Comparator|whole-body electromyostimulation|20 min of whole-body electromyostimulation with sequences of 6 sec of current and 4 sec at 85 Hz performed during low-intensity/low amplitude movements. 3 sessions / 14 days for 12 months
3241214|NCT01296776|Placebo Comparator|wellness control group|Low intensity, low frequency exercise that focus on well being. 1 session/week for 10 weeks. 10 blocks of exercise with intermittent periods of 100 weeks of rest
3241215|NCT01296789|Active Comparator|Tissue perfusion guided protocol|Active comparator group, where parameters of tissue perfusion are used to guide hemodynamic therapy
3348692|NCT02248870|Placebo Comparator|Saline|Bupivacaine with adrenaline with 2 ml. of Saline added
3348693|NCT02248870|Experimental|Dexamethasone|Bupivacaine with adrenaline with 2 ml. of Dexamethasone added
3348694|NCT02248883|Experimental|low TPV/RTV|
3348695|NCT02248883|Experimental|high TPV/RTV|
3348696|NCT02248883|Experimental|Placebo/RTV|
3241216|NCT01296789|Other|Usual Care|Usual Care
3348697|NCT02248896||Hypertensive patients|Hypertensive patients or patients treated with antihypertensive drugs with linked GPRD and hospital episodes statistics database (HES) data
3348698|NCT02248909||Patients with COPD risk factors|Group of subjects with COPD risk factors. This group will include patients aged ≥40 years, with smoking history of ≥10 pack years and long-active (not less than 3 consequent months) respiratory complaints
3348699|NCT02248909||Patients previously diagnosed with COPD|Group of patients who according to the medical records have already been diagnosed with COPD
3348700|NCT02248935||Repair with Alyte or Restorelle Y-Mesh|Women who underwent their index robotic-assisted laparoscopic sacrocolpopexy at Morristown Medical Center or Overlook Medical Center using either the Alyte Y-mesh or Restorelle Y-smartmesh between 1/2007 and 8/2011.
3241217|NCT01296802|Placebo Comparator|Placebo|
3348701|NCT02248948|Placebo Comparator|Medium Chain Triglycerides Supplement|Medium Chain Triglycerides Oil with 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
3348702|NCT02248948|Experimental|Omega-3 Fatty Acids Supplement|The Omega-3 Fatty Acid supplement provides 540 mg of eicosapentaenoic acid (EPA), 340 mg of docosahexaenoic acid (DHA), 60 mg of gamma linolenic acid (GLA/Omega-6), 5 micrograms of Vitamin D and 6 mg of Vitamin E in 4 ml.
3348703|NCT02248987||Clozapine|stable patients treated with clozapine
3348704|NCT02248987||Other antipsychotics|stable patients treated with risperidone or paliperidone or olanzapine
3348705|NCT02248987||Healthy volunteer|healthy controls
3348706|NCT02249000|Experimental|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
3348707|NCT02249013|Experimental|HIPEC|Neoadjuvant Chemotherapy (NACT) followed by Cytoreductive Surgery (CRS) under a Fast-track recovery strategy plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and thus, Adjuvant Chemotherapy
3348708|NCT02249026|Experimental|BZDs + opiate exposure treated with BPN|In-utero opiate and BZD exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
3241218|NCT01296802|Experimental|Dexfenfluramine|Dexfenfluramine HCL
3241219|NCT01296828||MOUTH BREATHING CHILDREN|
3241220|NCT01296854|No Intervention|Standard|The patients randomized into this arm of the study will not have spa therapy.
3348709|NCT02249026|Active Comparator|Opiates exposure treated with BPN|In-utero opiate exposed neonates + Buprenorphine sub-lingual administered in dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed.
3348710|NCT02249039|Experimental|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittentClonidine
3348711|NCT02249078|Experimental|Cohort 1|100 mg subcutaneous once every 2 weeks with initial double dose (200 mg total)
3348712|NCT02249078|Experimental|Cohort 2|200 mg subcutaneous once every 2 weeks with initial double dose (400 mg total)
3348713|NCT02249078|Experimental|Cohort 3|400 mg subcutaneous once every 2 weeks with initial double dose (800 mg total)
3348714|NCT02249078|Experimental|Cohort 4|10 mg/kg IV at Day 1, Day 8, Day 15, and every 2 weeks thereafter
3348715|NCT02249078|Placebo Comparator|Placebo|Placebo 2-mL vial solution for injection
3348716|NCT02249117|Experimental|BIWH 3|single escalating dose
3348717|NCT02249117|Placebo Comparator|Placebo|
3348718|NCT02249130|Experimental|Treatment of HIV- infected patients|14 days treatment with tipranavir, ritonavir, then 46 weeks of triple- treatment with delavirdine, zidovudine and lamivudine (stavudine for patients intolerant of zidovudine)
3348719|NCT02249156||Financial incentive group|Employees of employers who have introduced the Rewards program. Currently there are two employers who have introduced the Rewards program, but there might be others that introduce it in the coming months. All intervention (and control) employers are customers of Castlight and use their price transparency product.
3348720|NCT02249156||Control population|Large employers who have not introduced the Rewards program, but work with Castlight and use their transparency product. It will be ideal if the control population looks similar to the intervention population in key characteristics - age, level of illness, industry of the employer (for example, manufacturing), pre-intervention spending, and geographic distribution. If possible, across a pool of potential control employers, we will identify control employers that look the most similar across these characteristics in the pre-intervention period. Another possible strategy we might use is to weight the individuals in the control population in our analyses by how similar they appear to those in the intervention population.
3348721|NCT02249169||IBS-C|Patients with a clinical diagnosis of constipation-predominant irritable bowel syndrome
3348722|NCT02249169||IBS-D|Patients with a clinical diagnosis of diarrhea-predominant irritable bowel syndrome
3348723|NCT02249169||Healthy subjects|Subjects without a clinical diagnosis of IBS-C or IBS-D
3348724|NCT02249169||Healthy Controls|Subject without a clinical diagnosis of IBS-C or IBS-D and who is either a first-degree relative of an IBS participant or is not genetically related but resides with the IBS participant
3348725|NCT02249208|Active Comparator|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery.
3348726|NCT02249208|Experimental|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery.
3348727|NCT02249208|Experimental|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery.
3348728|NCT02249221|Experimental|Quadrivalent cell-culture based influenza vaccin|Day 1: GC3106, 0.5ml, intramuscular, a single dosing
3241221|NCT01296854|Experimental|Spa Therapy|The patients randomized into this arm of the study will have 3 weeks of spa therapy
3348729|NCT02249221|Active Comparator|Trivalent influenza vaccine|Day 1: GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing
3348730|NCT02249234|Experimental|Botox|Botox 200 units reconstituted in 10ml of normal saline for a one-time injection
3348731|NCT02249234|Placebo Comparator|Saline|Saline 10ml of normal saline for a one-time injection
3348732|NCT02249247|Experimental|Low dose of BIIL 284 BS|
3348733|NCT02249247|Experimental|Medium dose of BIIL 284 BS|
3241222|NCT01296880||LCM group|Patients who are having lacosamide (LCM) added to their anti-epileptic drug regimen
3241223|NCT01296880||control group|Patients who are NOT having lacosamide (LCM) added to their anti-epileptic drug regimen
3348734|NCT02249247|Experimental|High dose of BIIL 284 BS|
3348735|NCT02249247|Placebo Comparator|Placebo|
3348736|NCT02249260|Experimental|Behavioral|Group-based high intensity interval training and lifestyle counseling
3348737|NCT02249286|Experimental|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production.
3348738|NCT02249286|No Intervention|No intervention|
3348739|NCT02249299|Active Comparator|Sativex Oromucosal Spray|Participants will titrate onto Sativex during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
3348740|NCT02249299|Placebo Comparator|Placebo|Participants will titrate onto the placebo during the first two weeks of the study, carried out according to a standardised dosing schedule. After 2 weeks the clinician and participant will decide on the optimal dose for the remainder of the 4 week trial
3348741|NCT02249312|Experimental|BIIIL|
3348742|NCT02249312|Placebo Comparator|Placebo|
3241224|NCT01296893|No Intervention|Delayed exercise control|Participants asked to maintain usual lifestyle and provided with abbreviated version of intervention upon completion of end of study testing.
3241225|NCT01296893|Experimental|Exercise|Aerobic exercise Intervention as per below
3348743|NCT02249325|Experimental|Probiotic dietary supplement|Florajen3 oral probiotic (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum) taken daily beginning at 28 weeks gestation.
3348744|NCT02249325|No Intervention|Placebo|Women in the comparison group did not take a placebo.
3348745|NCT02249338|Experimental|BIIL 284 BS|
3348746|NCT02249338|Placebo Comparator|Placebo|
3348747|NCT02249351|Experimental|Talsaclidine|
3348748|NCT02249351|Placebo Comparator|Placebo|
3348749|NCT02249364|Active Comparator|Control|Standard care without hypnosis session followed by closed-loop administration of propofol for anesthesia induction
3241226|NCT01296906|Experimental|Population-based Reminder/Recall|Recall is performed centrally by public health departments for all children in need of immunizations in a geographic area.
3241227|NCT01296906|Experimental|Practice-based Reminder/Recall|Reminder/Recall is performed by individual private practices for their patients who appear in need of immunizations.
3241228|NCT01296919||Sinus drainage|Adult patients with chronic rhinosinusitis who failed treatment with antibiotics and topical corticosteroids and underwent endoscopic sinus surgery. Preoperative evaluation included paranasal sinus CT scans. The diagnosis was confirmed by endoscopic examination showing purulent and/or mucopurulent discharge in the middle and/or superior meatus.
3241229|NCT01296945|Active Comparator|Kiosk|
3241230|NCT01296945|Active Comparator|Paper|
3241231|NCT01296945|Active Comparator|Kiosk PLUS paper|
3241232|NCT01296945|Active Comparator|kiosk PLUS web|
3348750|NCT02249364|Experimental|Hypnosis|Hypnosis session followed by closed-loop administration of propofol for anesthesia induction
3348751|NCT02249390||Anyone|Any individual may complete this survey
3348752|NCT02249403|Experimental|Talsaclidine, 6 mg tid|
3348753|NCT02249403|Experimental|Talsaclidine, 12 mg tid|
3241233|NCT01296958|Experimental|Targeted screening|Screening for intestinal tapeworm carrier followed by treatment with niclosamide as indicated.
3241234|NCT01296958|Active Comparator|Education|Community education about Taenia solium prevention.
3348754|NCT02249403|Experimental|Talsaclidine, 24 mg tid|
3348755|NCT02249403|Experimental|Talsaclidine, 36 mg tid|
3348756|NCT02249403|Experimental|Talsaclidine, 36 mg bid|
3348757|NCT02249403|Placebo Comparator|Placebo|
3348758|NCT02249416|Experimental|TPV/RTV low + ZDV|
3348759|NCT02249416|Experimental|TPV/RTV high + ZDV|
3348760|NCT02249429|Experimental|bimiralisib (PQR309)|
3241235|NCT01296971|Experimental|A|genotype 1, treatment-naive
3241236|NCT01296971|Experimental|B|genotype 2 and 3, treatment-naive
3348761|NCT02249442|Experimental|Scheme A, mild hepatic subjects|multi-dose
3348762|NCT02249442|Experimental|Scheme B, moderate hepatic subjects|single dose
3348763|NCT02249455|Experimental|Acapella|Acapella is given to the patients twice daily for 20 min.
3348764|NCT02249455|Experimental|ELTGOL|Expiration with open glottis in lateral position is done twice daily for 20 min
3348765|NCT02249455|Active Comparator|conventional physiotherapy|Conventional physiotherapy like breathing exercise, active coughing, chest mobilisation was encouraged twice daily for 20 min.
3241237|NCT01296971|Experimental|C|all genotypes, non-responders or relapses
3241238|NCT01296984||Extralevator APR|The perineal part of the APR is done with the intent to create a cylindrically shaped specimen thus removing part of or the entire levator muscle with the specimen.
3348766|NCT02249468||Mild and Moderate Alzheimer's Disease|
3348767|NCT02249468||Cognitively intact healthy people|
3241239|NCT01296984||Traditional APR|The perineal part of the APR is performed with the intent to remove the tumour with CRM free of tumour and the levator left in place.
3241240|NCT01296997|Experimental|calcium phosphate|
3348768|NCT02249481|Active Comparator|Group F|Femoral nerve catheter delivering 0.0625% L- Bupivacaine: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
3348769|NCT02249481|Experimental|Group A|Adductor canal catheter delivering 0.0625% L- Bupivacaine: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
3348770|NCT02249494|Experimental|Smartphone (mobile app) & telehealth|Participants will install and use a mobile application designed to provide nutritional recommendations for hypertensive patients. These recommendations will be based on the DASH diet guidelines appropriate to patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call center when they have questions about diagnosis and management of their patients.
3348771|NCT02249494|Placebo Comparator|nutritional counseling & telehealth|Physicians who are enrolled for this group will continue performing routine nutritional counseling in their clinical practice. The call service will be offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can use this call service when they have questions about diagnosis and management of their patients.
3348772|NCT02249507|No Intervention|Control|sited rest for 45 minutes
3348773|NCT02249507|Experimental|higher intensity aerobic exercise|45 minutes of aerobic exercise at 75%HRmax
3348774|NCT02249507|Experimental|lower intensity aerobic exercise|45 minutes of aerobic exercise at 50%HRmax
3348775|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Research PET-MR imaging on Biograph mMR scanner will be conducted immediately following administration of FDG for clinically approved scan. No additional radioisotope will be administered for the research scan.
3348776|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo research MR-only imaging on Biograph mMR scanner.
3348777|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo research MR imaging on the Siemens MR scanner
3241241|NCT01296997|Placebo Comparator|placebo|
3241242|NCT01297010|Placebo Comparator|Dexamethasone|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg) at the beginning of the procedure.
3241243|NCT01297010|Placebo Comparator|Dexamethasone and ondasetron|Children randomized to this group received a 10 ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling) and ondansetron (0.1 mg / kg dose of 4mg ceiling)at the beginning of the procedure.
3241244|NCT01297023|Experimental|calcium phosphate|
3241245|NCT01297023|Experimental|vitamin d|
3348778|NCT02249533|Experimental|Spot Light and High School RIO|"A total of 200 youth football teams (100 high school and 100 middle school-aged teams) will be enrolled. Potential participating teams, all high schools eligible to report football data to High School RIO™ as well as all Pop Warner and Middle School sponsored football teams that have a valid e-mail contact, will be e-mailed a letter inviting them to participate (Appendix 3).~Intervention: Certified Athletic Trainers will be given access to report football injuries via High School RIO and will report potential concussions using the Spot Light Concussion app."
3348779|NCT02249533|No Intervention|Control|Control: Certified Athletic Trainers will be given access to report football injuries via High School RIO.
3348780|NCT02249546|Experimental|Acetylcysteine + PPI-amoxicillin-clarithromycin|N-acetylcysteine 600mg bid Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
3348781|NCT02249546|Active Comparator|PPI-amoxicillin-clarithromycin|Dexlansoprazole 60mg qd Amoxicillin 1000mg bid Clarithromycin 500mg bid All for 14 days
3348782|NCT02249559||GK subthalamotomy|Evaluate the safety and efficacy of unilateral GK subthalamotomy for PD in patients deemed poor candidates for DBS.
3348783|NCT02249572|Experimental|gamma knife radiosurgery|Single fraction gamma knife radiosurgery given at 12 Gy to tumor periphery for vestibular schwannoma
3348784|NCT02249572|No Intervention|Expectation|No active treatment given for vestibular schwannoma
3348785|NCT02249598|Experimental|Univeristy of Sheffield|lactamica
3348786|NCT02249598|Placebo Comparator|Hallam University|Phosphate Buffered Saline (PBS)
3241246|NCT01297023|Experimental|calcium phosphate and vitamin d|
3348787|NCT02249611|Experimental|MT and life counseling|To improve physical activity, body composition, physiological parameters and quality of life by using MT (mobile physical activity promotion tool) and lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination will be conducted for 3 months in intervention periods.
3348788|NCT02249611|Active Comparator|Standard care|Lifestyle counseling in diet control, increased physical activity, less smoking and drinking, deal with pressure, and regular health examination based on the booklet of metabolic syndrome prevention which is edited by Health Promotion Administration, Ministry of Health and Welfare in Taiwan only once in this period (3 months).
3348789|NCT02249624||Survivors of TTTS|Infants who have survived TTTS to hospital discharge, have an MRI at term, and return for nursery follow-up clinic.
3348790|NCT02249637||Inguinal Orchidopexy|Patients with diagnosed palpable low inguinal cryptorchidism underwent inguinal approach as originally described by Schuller and Bevan.
3348791|NCT02249637||Novel Technique (Circumcision incision)|Patients with diagnosed palpable low inguinal cryptorchidism underwent novel technique- circumcision incision orchidopexy.
3348792|NCT02249650|Experimental|TSB-9-W1 cohort|TSB-9-W1 200 mg/day (Cohort 1) TSB-9-W1 400 mg/day (Cohort 2) TSB-9-W1 600 mg/day (Cohort 3) TSB-9-W1 800 mg/day (Cohort 4) TSB-9-W1 1000 mg/day (Cohort 5)
3241247|NCT01297023|Placebo Comparator|placebo|
3241248|NCT01297036|Active Comparator|Reference arm|Treated with Reference (Aricept, 10 mg donepezil tablet)
3348793|NCT02249663|Experimental|Investigational Test Product|Azelastine hydrochloride and Fluticasone propionate Nasal Spray, 137/50 mcg
3348794|NCT02249663|Active Comparator|Reference Listed Drug|Dymista™ (azelastine hydrochloride/fluticasone propionate) Nasal Spray, 137/50 mcg
3348795|NCT02249663|Placebo Comparator|Placebo|Placebo Nasal Spray
3348796|NCT02249676|Experimental|Autologous mesenchymal stem cells group|"Generated clinical-grade MSC 10 mg chlorpheniramine Po.;100 mg hydrocortisone iv.;10 mg metoclopramide im.;30 min before administration of the cells .~MSC a day-case 2·0×106 cells/kg i.v. 15min Infused normal saline 500 Ml over 4 h i.v."
3241249|NCT01297036|Experimental|Test arm|Treated with Test (Neuropezil, 10 donepezil ODT, orally disintegrating tablet)
3241250|NCT01297049|Experimental|Lifestyle counseling|
3348797|NCT02249676|Placebo Comparator|Control group|Patients with progressive and refractory NMO treated with regular methods
3348798|NCT02249689|Experimental|Definitive 65|The Test product were the Definitive 65 (Filcon V4) lenses. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
3348799|NCT02249689|Active Comparator|Definitive 74|The Control product was the commercially available Definitive 74 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
3348800|NCT02249702|Experimental|Trabectedin|Trabectedin 1.3 mg/m2 will be administered via a central venous catheter as a 24-hour infusion on day 1 of 21-days treatment cycles. Trabectedin treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician.
3348801|NCT02249702|Active Comparator|gemcitabine + docetaxel|Gemcitabine 900 mg/m2 will be administered via a central venous catheter on days one and eight over 90 min, followed by docetaxel 75 mg/m2 on day eight iv over 1 h. Gemcitabine+docetaxel treatment is planned for six cycles, unless there is evidence of disease progression, unacceptable toxicity or patient's intolerance or unwillingness to continue treatment, or medical decision by the responsible physician. Patients with continued response after six cycles can receive two additional cycles of combination therapy or continue with Gemcitabine alone.
3348802|NCT02249715|Experimental|rDTMS|
3348803|NCT02249741|Experimental|Patients with osteoporosis|Treated with Ibandronic acid as per protocol
3348804|NCT02249754|Active Comparator|Routine health education|Routine health education alone
3348805|NCT02249754|Experimental|Nutrition education package|Nutrition education package and routine health education
3348806|NCT02249780|Experimental|New treatment|In patients with at least one well perfused parathyroid gland on ICG parathyroid angiography, no postoperative parathyroid dosage and supplementation will be done. Calcium and parathormone dosage will be done 10 days after surgery.
3348807|NCT02249780|Active Comparator|Standart treatment|In those patients in whom at least on of the four parathyroid glands is well perused, postoperative parathyroid function test and parathyroid supplementation will be done. Calcium and parathormone dosage will be done at 24 hours and 10 days after surgery. Prophylactic supplementation of calcium and Vitamin D will be given.
3348808|NCT02249806||PH target therapy|Patients receiving PH target therapy
3348809|NCT02249845||dehydration scales|children aged 1 - 36 months for CDS scale; 1 month - 5 years old for WHO scale and Gorelick scale
3348810|NCT02249858||Control Group: Cranial Vault Protocol Group|Cranial vault protocol group will receive cranial vault hold.
3348811|NCT02249858||Experimental Group: HVLA Protocol Group|HVLA protocol group will receive cervical HVLA to the key somatic dysfunction C2-C7 segment.
3348812|NCT02249871|Experimental|Semaglutide|
3259304|NCT01469650|Active Comparator|400 IU/day vitamin D|Subjects will receive 400 IU/day of vitamin D3, as per current unit policy
3348813|NCT02249871|Experimental|Semaglutide + Omeprazole|
3348814|NCT02249884|Experimental|Urea Dose A|Topical application of the urea cream in concentration A. The product should be applied on the skin three times daily over 3 weeks.
3348815|NCT02249884|Experimental|Urea Dose B|Topical application of the urea cream in concentration B. The product should be applied on the skin three times daily over 3 weeks.
3348816|NCT02249884|Experimental|Urea Dose C|Topical application of the urea cream in concentration C. The product should be applied on the skin three times daily over 3 weeks.
3241251|NCT01297075|Experimental|Outreach visits|Practices allocated to outreach visits may receive up to three outreach visits in order to motivate and support general practice clinics in implementing two chronic care programmes for chronic obstructive Pulmonary disease and Type 2 diabetes.
3348817|NCT02249884|Experimental|Chamomile Dose A|Topical application of chamomile recutita gel in concentration A. The product should be applied on the skin three times daily over 3 weeks.
3348818|NCT02249884|Experimental|Chamomile Dose B|Topical application of chamomile recutita gel in concentration B. The product should be applied on the skin three times daily over 3 weeks.
3348819|NCT02249884|Experimental|Chamomile Dose C|Topical application of chamomile recutita gel in concentration C. The product should be applied on the skin three times daily over 3 weeks.
3348820|NCT02249897|Placebo Comparator|PLACEBO|AFTER COMPLETING THE INITIAL EVALUATION (ANTHROPOMETRY, SERUM BIOCHEMISTRY AND CML LEVELS, FUNDUS, MUTIFOCAL ELECTRORETINOGRAM AND OPTIC NERVE CONDUCTION VELOCITY) PATIENTS WILL RECEIVE ORAL PLACEBO CAPSULES 4 PER EACH MEAL/DAY DURING 12 WEEKS
3348821|NCT02249897|Active Comparator|CHOLESTIRAMINE|AFTER COMPLETING THE CONTROL PERIOD (PLACEBO CAPSULES) PATIENTS WILL BE REASSESSED, AND THEN TREATED WITH ORAL CHOLESTYRAMINE 6 G/DAY (500 MG CAPSULES -> 4 CAPSULES PER EACH MEAL/DAY) DURING 12 WEEKS AND E SAME INITIAL EVALUATION WILL BE REPEATED
3348822|NCT02249910|Experimental|Semaglutide|
3241252|NCT01297075|No Intervention|Control (late intervention)|These practices are allocated to outreach visits after the initial evaluation stops at 12 months.
3241253|NCT01297088|Experimental|Arm 1|
3348823|NCT02249923||Pulmonary Arterial Hypertension|
3348824|NCT02249936|Experimental|AZD1722 HCl Capsule|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
3348825|NCT02249936|Experimental|AZD1722 HCl Tablet|15 mg bid AZD1722 HCl and 20 mg bid Omeprazole
3348826|NCT02249936|Experimental|AZD1722 Free-base Tablet|15 mg bid AZD1722 and 20 mg bid Omeprazole
3348827|NCT02249962||Overall cohort: HIV+ women on Option B+ and their infants|Women (n=8000) visiting an antenatal clinic for care who will be followed prospectively for Malawi standard treatment outcomes and pregnancy outcomes as patients on Option B+
3241254|NCT01297114||Participants aged 60-70|Participants age 60-70 will receive Florbetaben PET tracer to identify presence of amyloid burden.
3348828|NCT02249962||Sub-cohort A: first HIV diagnosis|Women (n=300) who present to the antenatal care clinic and are diagnosed for the first time with HIV. These women will be started on Option B+ as anti-retroviral treatment, per Malawi Ministry of Health standard of care.
3348829|NCT02249962||Sub-cohort B: subsequent pregnancies failing 1st line ART|Women (n=150) who have failed first-line treatment (TDF/3TC/EFV) based on HIV RNA levels and CD4 count. These women will be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
3348830|NCT02249962||Sub-cohort C: subsequent pregnancies who default from 1st line|Women (n=150) who are HIV+ and have a subsequent pregnancy who have not been adherent to first-line (Option B+: TDF/3TC/EFV). These women will be re-initiated on first-line treatment for 3 months, then evaluated to assess whether continuation on first-line treatment is sufficient, or if they need to be switched to second-line treatment (AZT/3TC/ATZ/r) per Malawi Ministry of Health standard of care.
3348831|NCT02249975|Experimental|C2 CryoBalloon Focal Ablation System|Cryoballoon ablation will be performed on patients with Barrett's Esophagus.
3241255|NCT01297114||Participants aged 20-30|Younger participants will not undergo PET scanning that will be studied with other methods.
3241256|NCT01297127||Cohort|
3348832|NCT02249988|Experimental|Group 1 - ABX203 therapeutic Hepatitis B vaccine treatment arm|ABX203 therapeutic vaccine in addition to NUCs background therapy
3348833|NCT02249988|No Intervention|Group 2 - Control arm|NUCs background therapy only
3348834|NCT02250001||Treatment with DCV/ASV|Patients who are beginning to receive the treatment with DCV/ASV under the approved indications, dosage, and administration will be included in this study
3348835|NCT02250014|Experimental|Arm I (cryotherapy, sargramostim)|Patients undergo cryotherapy on day 0 and receive sargramostim subcutaneously on days 1, 3, 5, 8, 10, and 12.
3241257|NCT01297140|Experimental|questionary|
3241258|NCT01297153|Active Comparator|Aphakia|"The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. If it is aphakia,IOL will not be implanted.Aphakia will be corrected with aphakic glasses / contact lenses. Bilateral aphakes are given both contact lenses and glasses. So when they do not wear contact lenses they can put on aphakic glasses. Unilateral aphakes are given only contact lenses. Contact lenses should be fitted in the eye in OT immediately after the operation.~Aphakic glasses :~Prescribed within 2 weeks of surgery for both eyes."
3348836|NCT02250014|Active Comparator|Arm II (cryotherapy, standard of care)|Patients undergo cryotherapy on day 0.
3348837|NCT02250027|Experimental|experimental A (0.6g/day)|HL301 0.6g/day: 2 capsules at once, 3 times a day, for 7 days
3348838|NCT02250027|Experimental|experimental B (1.2g/day)|HL301 1.2g/day: 2 capsules at once, 3 times a day, for 7 days
3348839|NCT02250027|Experimental|experimental C (1.8g/day)|HL301 1.8g/day: 2 capsules at once, 3 times a day, for 7 days
3348840|NCT02250027|Placebo Comparator|Placebo|placebo: 2 capsules at once, 3 times a day, for 7 days
3348841|NCT02250040|Active Comparator|Control group|Conventional physiotherapy for stroke.
3348842|NCT02250040|Experimental|Target group|Techniques based on patients' functional level were added.
3348843|NCT02250053|Experimental|exercise|aerobic exercise on soluble intercellular adhesion molecules
3348844|NCT02250066|Other|Study group 1|Received high monounsaturated fat diet
3259305|NCT01469650|Experimental|800 IU/day vitamin D3|Subjects will receive 800 IU/day vitamin D3
3348845|NCT02250066|Other|Study group 2|Received high carbohydrate diet
3348846|NCT02250066|No Intervention|Control Group|Control group was encouraged to follow the Food Guide Pyramid
3375928|NCT03440736|Experimental|Secukinumab 300 mg s.c. and lifestyle intervention|Arm B: Patients in arm B receive therapy with Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24). In addition they participate in a lifestyle intervention program.
3375929|NCT03433404|Experimental|Soft Tissue Mobilization|The arm will utilize a Physical Therapy technique call soft tissue mobilization.
3348847|NCT02250079|Experimental|Polyethilene body bag group|The intervention group infants were provided the same care as control infants, but were dressed with the polyethylene body bag immediately after birth. The bag had an upper opening for the head and a seal at the bottom. The intervention group infants remained in the plastic bag for the first 10 minutes after birth. The same process was done in surgery room in case of cesarean. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process were done in surgery room in case of cesarean
3348848|NCT02250079|Active Comparator|Conventional group|): Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
3348849|NCT02250105|Active Comparator|ARI-3037MO|ARI-3037MO 3g bid orally for 12 weeks
3348850|NCT02250105|Placebo Comparator|Placebo|Matching placebo 3g bid orally for 12 weeks
3348851|NCT02250118|Experimental|Bevacizumab|Intrapleural use: range 0.5 - 5 mg/kg
3348852|NCT02250131|No Intervention|Control|Routine cardiopulmonary bypass technique. Flow adjusted on BSA and temperature
3348853|NCT02250131|Active Comparator|Goal Directed Perfusion|Perfusion targeted at oxygen delivery
3348854|NCT02250144|Experimental|Morpho-specific foot orthoses|"Morpho-specific thermo-molded foot orthoses are designed according to the patient's morphotype.~Orthoses are custom-molded from different materials such as BIOFLUX resin, Covercuir MF, EVA300/60, EVA400/70, PE255/55, ABSORB Dur and CAPITON PU."
3348855|NCT02250144|Placebo Comparator|Placebo foot orthoses|The placebo foot orthoses will be made with the same principle of molding and with the same materials as for the experimental group. The only difference is that they involve no active corrective insert element : they will be made without morphotype correction.
3348856|NCT02250157|Experimental|Part 1|"Part 1 of this study is a 3+3 design to define the MTD of Oratecan in up to 60 evaluable subjects. It will be conducted in 2 parts; 1A will test the oral liquid formulation and 1B will test the oral tablet formulation of irinotecan."
3348857|NCT02250157|Experimental|Part 2|Part 2 will enroll an additional 10 subjects at the Part 1 MTD to further characterize the safety, tolerability, pharmacokinetics, and activity of Oratecan at that dose.
3348858|NCT02250170|Experimental|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
3348859|NCT02250196|Active Comparator|PEG-Asc|group 1 (PEG-Asc, N=100) received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
3348860|NCT02250196|Active Comparator|SPMC 2|group 2 (SPMC 2, N=100) received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
3348861|NCT02250209|Experimental|Trastuzumab,Capecitabine,Oxaliplatin|"Patients receive eight 3-week cycles of oral capecitabine (800-1000 mg/m2 twice daily on days 1-14 of each cycle) ,intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) plus intravenous Trastuzumab (440mg on day 0 of each cycle).~Number of cycle:capecitabine and oxaliplatin --8 cycles; Trastuzumab--14-16 cycles."
3348862|NCT02250222|Experimental|Part 1: LGD-6972 15 mg|15 mg LGD-6972 administered once daily (QD) for 14 days.
3348863|NCT02250222|Placebo Comparator|Part 1: Placebo (Captisol ®)|Placebo administered once daily (QD) for 14 days.
3348864|NCT02250222|Experimental|Part 2: LGD-6972 5 mg|5 mg LGD-6972 administered orally QD for 14 days.
3348865|NCT02250222|Experimental|Part 2: LGD-6972 10 mg|10 mg LGD-6972 administered orally QD for 14 days.
3348866|NCT02250222|Experimental|Part 2: LGD-6972 15 mg|15 mg LGD-6972 administered orally QD for 14 days.
3348867|NCT02250222|Placebo Comparator|Part 2: Placebo (Captisol ®)|Placebo administered orally QD for 14 days.
3348868|NCT02250235|Experimental|Self-affirmation|In the self-affirmation arm, the patients completed a 10 item questionnaire about their past acts of kindness (self-affirmation) prior to reading the health risk information.
3348869|NCT02250235|No Intervention|Control|Control patients completed 10 matched control questions with no self-affirming properties, prior to reading the health risk information.
3348870|NCT02250248|Active Comparator|AttraX Putty|Patient will be treated with AttraX Putty intraoperatively.
3348871|NCT02250248|Active Comparator|Iliac Crest Bone Graft (ICBG)|Patients will be treated with ICBG harvested during surgery.
3348872|NCT02250261|Experimental|KÄPY group|Workplaces, which are supported to promote employees' ACW.
3348873|NCT02250261|No Intervention|Comparison group|Workplaces, which are not supported to promote employees' ACW but will be offered support to do so after the study.
3375930|NCT03433404|Active Comparator|Soft Tissue Massage|This arm will utilize standard soft tissue massage applied to the low back in pregnant patients complaining of third trimester low back pain.
3241259|NCT01297153|Active Comparator|Pseudophakia|The patient is randomly assigned for aphakia / pseudophakia. This is done only after vitrectomy. Hydrophobic Acrysof IOL is implanted.All pseudophakic children will be refracted and given the residual correction within a month of surgery.
3241260|NCT01297166|Experimental|LEO 27989 ointment|
3241261|NCT01297192|Other|Treatment Arm 1|The effect of mirabegron on the pharmacokinetics of solifenacin
3241262|NCT01297192|Other|Treatment Arm 2|The effect of solifenacin on the pharmacokinetics of mirabegron
3241263|NCT01297205|Experimental|PNEUMOSTEM®|
3241264|NCT01297218|Experimental|NEUROSTEM®-AD|
3241265|NCT01297231||Breast cancer|This prospective study will recruit patients with stage 0-3 breast cancer who have had or are scheduled for a breast MRI prior to treatment.
3241266|NCT01297361|Other|Plasma Vitamin B12 and Folic acid levels|Blood sample was drawn
3241267|NCT01297374|Experimental|dietetic counseling|
3348874|NCT02250300|Experimental|MLN9708 Phase II matched sibling|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
3348875|NCT02250300|Experimental|MLN9708 Phase II matched unrelated|Phase II Patients will be enrolled in two independent cohorts of matched sibling and matched unrelated donor transplants. Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 starting on day +60 to +90 post allogeneic HCT.
3348876|NCT02250300|Experimental|MLN9708 Phase I|Phase I Four doses of MLN9708 will be administered on days 1, 8, 15, & 22 orally based on a dose escalation schema.
3348877|NCT02250313||Case|All patients will have the tissue from their previous negative biopsy tested with the assay. Cases are defined as those subjects who receive the ConfirmMDx assay results.
3348878|NCT02250313||Control|All patients will have the tissue from their previous negative biopsy tested with the assay. Controls are defined as subjects who will be blinded to the ConfirmMDx assay results.
3348879|NCT02250339||LAKU family program|Time-limited (12 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). LAKU family program (12 month program) includes 35 family-based meetings. Families are also given an opportunity to attend two separate family weekends. In addition to this, parent group format may include 10 meetings at maximum. A 24-month-program will include 15 additional family-based meetings.
3348880|NCT02250339||Etä-LAKU family program|Time-limited (18 or 24 months) intervention program for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Etä-LAKU family program (18 months) includes 35 family-based meetings and two separate family weekends. A 24-month-program will include 10 additional family-based meetings.
3348881|NCT02250339||Family therapy|Time-limited (12 or 24 months) family therapeutic intervention for children (aged 5-12) with neuropsychiatric/psychiatric disorder(s). Family therapy intervention includes 15 (1-year program) or 30 (2-year program) family meetings.
3348882|NCT02250365|Experimental|Continuous, suprasensory ESS|
3348883|NCT02250365|Active Comparator|Intermittent, suprasensory ESS|
3348884|NCT02250378|Experimental|Treatment (stereotactic radiosurgery, wedge resection)|Patients undergo stereotactic radiosurgery every other day for 3 or 5 fractions (depending on the size tumor and proximity to the chest wall). Within 4-6 weeks after completion of stereotactic radiosurgery, patients undergo wedge resection.
3348885|NCT02250391|Experimental|NPB-06|1,500 unit, 5 days continuous-infusion
3348886|NCT02250391|Placebo Comparator|Placebo|0 unit, 5 days continuous-infusion
3348887|NCT02250404||Ancillary-Correlative (molecular profile)|Previously collected tissue samples are analyzed via RNA sequencing and DNA methylation at baseline. Patients also undergo collection of tissue samples for analysis at relapse.
3348888|NCT02250430|Experimental|Topical SB204|Topical application of SB204 2% and 4% twice daily for 2 days and once on Day 3
3348889|NCT02250456||Turner syndrome patients and vascular abnormalities|
3348890|NCT02250469|Active Comparator|Axium SCS System|Implantation with the Axium Neurostimulator
3348891|NCT02250469|Active Comparator|Medtronic SCS System|Implantation with the Medtronic Prime Advanced Dorsal Column Stimulation System
3348892|NCT02250482|Experimental|Optivate®|Optivate® (Human Coagulation Factor VIII)
3348893|NCT02250495|Experimental|Sympara Therapeutic System|All subjects will wear for the Sympara device for 30 days
3348894|NCT02250508|Experimental|Optivate®|
3241268|NCT01297374|Experimental|physical activities|
3241269|NCT01297374|Experimental|Lifestyle counseling|
3348895|NCT02250508|Active Comparator|Haemate P®|
3348896|NCT02250534|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
3348897|NCT02250534|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
3348898|NCT02250534|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
3348899|NCT02250560|Experimental|Replenine®-VF|
3241270|NCT01297387||Revascularization of limb ischemia|Procedure/Surgery
3241271|NCT01297400|Experimental|Investigational Drug, MW-III|Investigational Drug, MW-III
3348900|NCT02250573|Experimental|Replenine®-VF|
3348901|NCT02250586|Experimental|CBT-CSO|"The CBT-CSO program will be based on concepts from cognitive-behavioral therapy and motivational interviewing, and is specifically developed for use with CSOs of treatment refusing problem gamblers. The program resembles the community reinforcement and family training approach that has been successfully used with CSOs of substance abusers.~The program will be given as guided self-help with guidance given via email and telephone. There are 8 modules, which all contain homework exercises and about 5-10 pages of text."
3348902|NCT02250586|No Intervention|Wait-list|The participants allocated to the control condition will be put on a waiting list and offered the CBT-CSO program after 10 weeks. The CSOs will receive information about available treatment options-in their area and web-based-for the problem gambler.
3348903|NCT02250599|Active Comparator|carboplatin and paclitaxel|carboplatin and paclitaxel :paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
3241272|NCT01297400|Active Comparator|Standard of care|Silvadene® Cream 1% [Silver Sulfadiazine]
3241273|NCT01297413|Experimental|Stem cells|All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
3241274|NCT01297426||Group 1|Lean and obese, diabetic and non diabetics
3241275|NCT01297439|Other|group M|"Normal delivery without pushing maneuver suctioning of fetal nose and mouth during delivery"
3241276|NCT01297439|Experimental|group C|"Pushing maneuver on the fetal head"
3241277|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered with paclitaxel + carboplatin on both a 21-day cycle with growth factor support (Group 1)
3241278|NCT01297452|Experimental|BKM120 (days 1 - 28, ) + paclitaxel + carboplatin|This will be a single institution phase I study. The primary objectives are to determine the maximum tolerated dose of BKM120 administered + paclitaxel with carboplatin on a 28-day cycle with growth factor support and a 28-day cycle (Group 2).
3375931|NCT03433404|No Intervention|No manual treatment|Group will still receive acetaminophen, heating pad application, and/or rest which is standard of care.
3348904|NCT02250599|Experimental|AVASTIN and carboplatin and paclitaxel|AVASTIN and carboplatin and paclitaxel: Bevacizumab(AVASTIN) 7.5 mg/kg intravenously (IV) infusion on Day 1 of each 3-week cycle; paclitaxel 175 mg/m2 IV and carboplatin AUC 6 IV on Day 1 of each 3-week cycle
3348905|NCT02250664|Experimental|0.8 mg nicotine|0.8 mg nicotine very low nicotine content cigarettes
3348906|NCT02250664|Experimental|0.12 mg nicotine|0.12 mg nicotine very low nicotine content cigarettes
3348907|NCT02250664|Experimental|0.03 mg nicotine|0.03 mg nicotine very low nicotine content cigarettes
3348908|NCT02250677||Patients with myalgia|Patients with myalgia as a side effect to treatment with Simvastatin (minimum 20 mg daily)
3348909|NCT02250677||Patients without myalgia|Patients treated with Simvastatin (minimum 20 mg daily) without any side effects to the treatment
3348910|NCT02250677||Control group|Patients with elevated serum cholesterol not treated with cholesterol lowering drugs
3348911|NCT02250690|Experimental|experimental group - tDCS|The tDCS intervention occur at 10 sessions of intervention where electrodes are connected to head specifically in supplementary motor area placed at 2 cm in front of vertex. The clinical stimulator (NeuroConn, Germany) provided the direct current using two silicon-sponge electrodes with a surface area of 35 cm2 (5 × 7cm) embedded in a saline-soaked solution. Immediately after 13 minutes of tDCS application, patient was submitted to gait training three times a week during 4 weeks with visuals cues. The patients were asked to walk along at a 7 meters rubber carpet to at different speed, forward and backward gait, side walk during thirty minutes with three intervals of two minutes. The patient may be at on state of drug administration and the training is applied by another physiotherapist.
3348912|NCT02250690|Sham Comparator|Control group (tDCS sham)|The sham character is ensured by the stimulation time, once the device is programmed to turn off 30 seconds after the beginning of stimulation. The current is switched in ascending ramp mode for 10 seconds until 2 mili ampere and a descending ramp similar also for 10 seconds will be used until the end of stimulation. The sham stimulation is commonly perceived by the patient as the actual treatment and all procedures for the application of the technique should be similar to those adopted for the active stimulation. Immediately after tDCS stimulation, the gait training consisting of a protocol based on sensory cues for 30 minutes is administered three times a week for four weeks. Sham stimulation will be held for 30 seconds in order to mimic the perceived lowering effect of ramp current.
3348913|NCT02250716|Experimental|Arm 1|Immediate treatment with Cryotherapy and 12 month cytology and histology follow-up
3348914|NCT02250716|No Intervention|Arm 2|12 month cytology and histology follow-up
3348915|NCT02250729|Experimental|cases with NMBA anaphylaxis|Patients who experienced NMBA anaphylaxis during anesthesia
3348916|NCT02250729|Other|controls|Patients who underwent anesthesia with NMBA injection but did not experience anaphylaxis
3348917|NCT02250742|Experimental|low back pain group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utielized. The needles will be left in situ for 10 minutes.
3348918|NCT02250742|Active Comparator|healthy group|Dry needling to the lumbar multifidus muscles using a deep insertion technique with 4 needles (2 on each side of the spine) will be utilized. The needles will be left in situ for 10 minutes.
3348919|NCT02250755|Experimental|MRI T1 T2 sequences|comparison of perfusion sequences T1 T2 in patients with brain metastase cancer
3348920|NCT02250768|Experimental|GM-CSF|Injected oocytes were cultured in GM-CSF supplemented media until day of transfer
3348921|NCT02250781|Experimental|Treatment (Oral ONC201)|Patients receive Oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3348922|NCT02250794|Active Comparator|insulin glargine and insulin lispro|insulin glargine 0.3 units per kg and insulin lispro 0.1 units per kg with each meal
3241279|NCT01297452|Experimental|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|EXPANSION COHORT A BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT A.
3348923|NCT02250794|Experimental|metformin and sitagliptin|metformin 750 mg PO twice daily and sitagliptin 100 mg PO once daily
3348924|NCT02250820|Experimental|Nasal Dexmedetomidine and oral placebo|If the patient is assigned to the dexmedetomidine arm, they will receive dexmedetomidine through the nose. In order to keep the assignment blinded, the patient will also receive an oral placebo.
3348925|NCT02250820|Experimental|Nasal placebo and oral pentobarbital|If the patient is assigned to the pentobarbital arm, they will receive pentobarbital through the mouth. In order to keep the assignment blinded, the patient will also receive an nasal placebo.
3348926|NCT02250833|Experimental|CKD-828(Fixed Dose Combination)|FDC tablet consisting of Telmisartan 80mg/S-Amlodipine 5mg
3348927|NCT02250833|Active Comparator|Combination Therapy|Coadministration of Telmisartan 80mg and S-amlodipine 5mg
3348928|NCT02250846|Experimental|arm a|EGFR exon 19 mutation with EGFR-TKI
3348929|NCT02250846|Experimental|arm b|EGFR exon 21 mutation with EGFR-TKI
3348930|NCT02250859|Experimental|FMX101 Minocycline 4% foam|FMX101, 4% applied to the face, upper chest, upper back and shoulders for sixsteen consecutive days in subjects either with acne or with normal skin
3348931|NCT02250872|Active Comparator|Experimental: Gemigliptin and Cisplatin|Gemigliptin 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
3348932|NCT02250872|Placebo Comparator|Control arm|Placebo 100mg daily in two divided doses for 8 days starting from one day before cisplatin-treatment
3348933|NCT02250885|Experimental|Selinexor (KPT-330)|Selinexor will be taken orally at a starting dose of 50mg/m2 twice weekly on weeks 1, 2, and 3 of each 4 week cycle.
3375932|NCT03423355|Active Comparator|Dapagliflozin (Forxiga®)|Treatment with the SGLT2 inhibitor dapagliflozin 10 mg once daily for 28 days.
3375933|NCT03423355|Placebo Comparator|Placebo matching Dapagliflozin|Treatment with the Dapagliflozin matching placebo once daily for 28 days.
3375934|NCT03423355|Other|Hydrochlorothiazide|Treatment with the Hydrochlorothiazide 25 mg once daily for 28 days
3375935|NCT03422822|Experimental|Abrocitinib 100 mg|Abrocitinib 100 mg QD PO
3375936|NCT03422822|Experimental|Abrocitinib 200 mg|Abrocitinib 200 mg QD PO
3241280|NCT01297452|Experimental|BKM120 (days 1 - 21) + paclitaxel + carboplatin exp B|Expansion Cohort B will be restricted to patients with tumors known to harbor PTEN mutation or homozygous deletion. The regimen in Expansion Cohort B will be the same regimen established in Group 1 of the protocol, with BKM120 (now called buparlisib) at 100 mg/day per oral + paclitaxel (175 mg/m2) + carboplatin (AUC 5), both given intravenously (IV) on day 1 of a 21-day cycle
3348934|NCT02250898|Experimental|Experimental/Myofascial|The intervention group will receive Myofascial Massage Therapy specific to breast/chest/shoulder of the affected side(s). These massages will include a variety of techniques specifically aimed at reducing pain, inflammation, and tissue sensitivity while also increasing mobility by breaking up scar tissue and thick fibrosis. The intervention massages will include the following specific techniques: skin glide, j stroking, vertical stroking, strumming, fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage. These massages will be twice a week at 30 minutes per massage for a period of 2 months after study enrollment.
3348935|NCT02250898|Active Comparator|Control/Global Relaxation|The control group will receive a general full body massage referred to as a Global Relaxation massage. The massage technique used here will be relaxation massage, avoiding the breast/chest/arm area. This includes light kneading and stroking in order to restore a sense of well- being. The relaxation massage will also be twice a week at 30 minutes per massage for a period of 2 months, avoiding the area of the affected shoulder/shoulders. In this way they are still being seen and touched by a massage therapist, without receiving the intervention treatment.
3348936|NCT02250911|Experimental|This web-based CCC Workshop|The Care for the Cancer Caregivers (CCC) workshop is composed of six webcasts. The Introductory Webcast is based upon Sessions 1 and 2 of Meaning-Centered Psychotherapy for Cancer Caregivers (MCP-C) and provides participants with an introduction to the CCC Workshop, an overview of the different meaning-centered modules (i.e., legacy, choice, creativity, and connectedness), and a discussion about identity and how caregivers' identities have or have not changed since taking on this role.
3348937|NCT02250911|Active Comparator|Waitlist Control|"Participants randomized to the waitlist control arm will be offered what is considered usual care at the ACS: the provision of the ACS Telephone Hotline number (1-800- 227-2345) and direction to the ACS website (www.cancer.org) where participants can find many resources for caregivers, including links to the ACS Caregiver ToolKit. They will complete assessments at time points that correspond with the completion of assessments in the CCC Workshop arm: after consent as soon as they are able (T1), about 2 months (± 4 weeks) after T1 (T2), and about 2-3 months after T2 (T3). Upon completion of all study assessments the waitlist control arm participants will be offered the opportunity to complete the CCC Workshop."
3348938|NCT02250924|Placebo Comparator|Placebo|Subjects will wear a silicone bracelet for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3348939|NCT02250924|Sham Comparator|Sugar-less Gum|Subjects will chew one stick of sugar-less gum for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3348940|NCT02250924|Experimental|Caffeinated Gum|Subjects will chew one stick of caffeinated gum (100mg caffeine per stick) for 30 minutes 3 times daily at 8 am, 12 pm and 4 pm.
3348941|NCT02250950|Experimental|MI and SDT Exercise Group|Intervention Condition: Participated in 12 weekly meetings led by MI- and SDT-trained exercise instructor.
3348942|NCT02250950|Sham Comparator|Non-MI and SDT Exercise Group|Control Condition: Participated in 12 weekly meetings led by an exercise instructor who was not trained in MI and SDT.
3348943|NCT02250963||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
3348944|NCT02250963||CTCA|Computed tomography coronary angiography is going to perform with a 64-slice system (Brilliance 64, Philips Healthcare, Best, the Netherlands).
3348945|NCT02250976|Experimental|Livasupril Cap.160/2mg|"Fenofibrate pellet ( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg~once a day"
3348946|NCT02250976|Active Comparator|Lipilfen cap.160mg, Livaro tab. 2mg|"Lipilfen cap.160mg : Micronized fenofibrate 160mg , Livaro tab. 2mg : Pitavastatin ca 2mg~Coadministariton of Lipilfen cap.160mg and Livaro tab. 2mg, once a day"
3348947|NCT02250989||Hyperinsulinemia/Euglycaemia|In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3348948|NCT02250989||Hyperinsulinemia/Hyperglycemia|In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3241281|NCT01297530|Experimental|Arm 1|
3241282|NCT01297543|Experimental|Consolidation Group A|Low dose CLT-008 (human myeloid progenitor cells)
3241283|NCT01297543|Experimental|Consolidation Group B|Intermediate dose CLT-008 (human myeloid progenitor cells)
3241284|NCT01297543|Experimental|Consolidation Group C|Intermediate dose CLT-008 (human myeloid progenitor cells), no G-CSF
3241285|NCT01297543|Experimental|Consolidation Group D|High dose CLT-008 (human myeloid progenitor cells)
3241286|NCT01297543|Active Comparator|Induction Group A1 (cytarabine 7+3)|G-CSF
3241287|NCT01297543|Experimental|Induction Group A2 (cytarabine 7+3)|Intermediate dose CLT-008 (human myeloid progenitor cells)
3241288|NCT01297543|Experimental|Induction Group A3 (cytarabine 7+3)|High dose CLT-008 (human myeloid progenitor cells)
3241289|NCT01297543|Active Comparator|Induction Group B1 (cytarabine HIDAC)|G-CSF
3241290|NCT01297543|Experimental|Induction Group B2 (cytarabine HIDAC)|Intermediate dose CLT-008 (human myeloid progenitor cells)
3241291|NCT01297543|Experimental|Induction Group B3 (cytarabine HIDAC)|High dose CLT-008 (human myeloid progenitor cells)
3241292|NCT01297556|No Intervention|Control group|Patients in this group will receive conventional treatment for IBS, including anti-diarrhea agents, laxatives, bulking agents and anti-spasmodic.
3241293|NCT01297556|Experimental|Treatment|Patients in this group will receive conventional treatment for IBS, but in addition will receive 6 weeks of CBT
3241294|NCT01297569|Experimental|Ranibizumab|
3241295|NCT01297582|Experimental|E|
3241296|NCT01297582|Placebo Comparator|P|
3241297|NCT01297608|Experimental|treatment|
3241298|NCT01297608|Placebo Comparator|placebo|
3241299|NCT01297621|Experimental|Breast reduction|Breast hypertrophy women allocated to this arm will undergo reduction mammaplasty
3241300|NCT01297621|Other|Control|Patients in this arm will be assessed twice, without surgical intervention
3241301|NCT01297634|Other|Botulinum Toxin Type-A 1U|
3348949|NCT02250989||Hypoinsulinemia/Hyperglycemia group|In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.
3348950|NCT02251002||Control|no history of TBI or neurologic disorder
3241302|NCT01297634|Other|Botulinum Toxin Type-A 2U|
3241303|NCT01297634|Other|Botulinum Toxin Type-A 3U|
3348951|NCT02251002||mTBI|documented past mild to moderate TBI
3348952|NCT02251015|Active Comparator|therapeutic exercises|13 as control group - The control group got only orientation related to therapeutic exercises.The orientation for therapeutic exercises seek to correctly position the jaw in the resting position. Maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
3241304|NCT01297647|Experimental|Spinal cord injured|Patients with neurogenic lower urinary tract infection (Spinal Cord Injury,MS,M. Parkinson)
3241305|NCT01297660||patients with SCI for at least 5 years|Ages Eligibility: minimum 18 years Genders Eligibility: female and male
3241306|NCT01297673||Spinal cord injury|Patients with neurogenic lower urinary tract dysfunction due to spinal cord injury with regular urodynamic examination
3348953|NCT02251015|Experimental|occlusal plate group|36 getting occlusal splints - the splinted group was subjects that used occlusal plate under the occlusal stability criteria. The patients also received therapeutic exercises too. The plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
3348954|NCT02251028|Active Comparator|Group A|Group A receives value-based cognitive behavior therapy after randomization.
3348955|NCT02251028|Active Comparator|Group B|Group B receives value-based cognitive behavior therapy after 3 months.
3348956|NCT02251041|Active Comparator|cases|the group receives a combination of drugs
3241307|NCT01297686|Experimental|Exercise|Multi-element exercise protocol involving static and dynamic stretches, deep massage, and balance training.
3241308|NCT01297686|Active Comparator|Standard of Care|This arm will consist of a single injection of a corticosteroid, followed by stretching exercises for the calf.
3241309|NCT01297699|Experimental|Tocilizumab|
3241310|NCT01297699|Placebo Comparator|Sterile 0.9% Sodium Chloride|
3241311|NCT01297712|Active Comparator|Hi Line|This arm is examined with latest generation HDTV colonoscopes
3348957|NCT02251041|Placebo Comparator|controles|the group do not receive a combination of drugs, but a placebo (sodium chloride solution)
3348958|NCT02251054|Experimental|Avatar group|"Intervention group viewed two avatar coaches: a generic avatar coach (GAC) and a self-avatar, peer mentor (SAP)."
3348959|NCT02251054|Active Comparator|No Avatar group|The control group version (voice only) observed the identical program, including introductions, question asking, narration of animations, delivery of key points, and summary of each section with identical pre-recorded voices without the avatars.
3348960|NCT02251067|Active Comparator|VPI-2690B low dose|6 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3348961|NCT02251067|Active Comparator|VPI-2690B medium dose|18 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3348962|NCT02251067|Placebo Comparator|Placebo|6 or 18 mg Placebo, administered subcutaneously every 2 weeks for 48 weeks
3348963|NCT02251067|Active Comparator|VPI-2690B high dose|48 mg, VPI-2690B Injection, administered subcutaneously every 2 weeks for 48 weeks
3348964|NCT02251080||Internet-based Survey|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF); and responses to a weekly Internet-based questionnaire of adherence and disease severity.
3241312|NCT01297712|No Intervention|Classic Line|control group undergoing colonoscopy with older generation scope currently in use in most centers
3241313|NCT01297725|Experimental|Right sharp, left blunt|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
3241314|NCT01297725|Experimental|Right blunt, left sharp|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
3241315|NCT01297738|Experimental|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which is high in fat and sugar (Nutridrink®)
3241316|NCT01297738|Experimental|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume this caloric surplus with their meals, which results in an increase in meal size.
3241317|NCT01297738|Experimental|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a liquid meal which has a high fat and sugar content(Nutridrink®). Subjects consume the Nutridrink 3 times a day in between meals. which results in an increase in meal frequency.
3241318|NCT01297738|Experimental|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
3241319|NCT01297738|No Intervention|Control group|Subjects will not follow any diet but their own ad-libitum, healty diet.
3259306|NCT01469663||Healthy Control|Healthy participants without borderline personality or depression
3259307|NCT01469663||Major Depression, No Borderline Personality Disorder|With major depression and no borderline personality
3348965|NCT02251080||Standard-of-Care|Assessments completed over the 2-month study will include: disease severity as measured by DSM-V classification and by several validated measures including the ADHD Rating Scale IV with adult prompts, and Clinical Global Impressions, severity and improvement scales; adherence measures (MEMS® and pill counts); validated medication satisfaction measure (the Treatment Satisfaction Questionnaire for Medication); and quality of life measured using the validated WHO Quality of Life Brief measure (WHOQOL-BREF);
3348966|NCT02251093|Experimental|Lcr Regenerans|
3241320|NCT01297764|Experimental|carfilzomib for MML|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone - This study will be conducted as an open-label Phase I/II, single-center study in which subjects will receive carfilzomib, lenalidomide, vorinostat and dexamethasone, for relapsed and/or refractory multiple myeloma. Study treatment will be administered in sequential cohorts, with 3-6 subjects in each cohort. Treatment will be administered in 28-day cycles, with the fourth week as a rest week, for 12 cycles or until disease progression or unacceptable toxicity develops.
3241321|NCT01297777|Experimental|Imatinib mesylate|Imatinib mesylate 300 or 400 mg daily for 12 months.
3241322|NCT01297790||Asthma|Subjects with asthma more than 18 years old with minimal or no smoking history and evidence of bronchial hyperreactivity
3348967|NCT02251093|Placebo Comparator|Placebo|
3348968|NCT02251106|No Intervention|-LBP/-Brace|Subjects in this arm did not have back pain nor did they wear brace (asymptomatic controls). Subjects had their spine function measured before and after a two week period.
3241323|NCT01297790||Chronic obstructive pulmonary disease|Subjects with diagnosis of COPD who must be ex smokers and have evidence of airflow obstruction on breathing tests.
3348969|NCT02251106|Active Comparator|-LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm did not have back pain but wore a brace for a two week period (asymptomatic intervention). Subjects had their spine function measured before and after a two week period.
3348970|NCT02251106|Experimental|+LBP/+Brace|Intervention = Lumbar corset (Quickdraw, Aspen Medical Products) Subjects in this arm had back pain and wore a brace for a two week period (symptomatic intervention). Subjects had their spine function measured before and after a two week period.
3348971|NCT02251119|Experimental|TPV|"Administration of LOP on days 1, 9 and 22~Administration of TPV on days 4-9~Administration of TPV/RTV on days 12-22"
3348972|NCT02251119|Experimental|RTV|"Administration of LOP on days 1, 9 and 22~Administration of RTV on days 4-9~Administration of TPV/RTV on days 12-22"
3348973|NCT02251132|Experimental|TPV/RTV Low 1|
3348974|NCT02251132|Experimental|TPV/RTV Low 2|
3348975|NCT02251132|Experimental|TPV/RTV Low 3|
3348976|NCT02251132|Experimental|TPV/RTV Medium 1|
3348977|NCT02251132|Experimental|TPV/RTV Medium 2|
3348978|NCT02251132|Experimental|TPV/RTV High 1|
3348979|NCT02251132|Experimental|TPV/RTV High 2|
3241324|NCT01297790||Healthy Volunteers|Healthy non smoking adults.
3348980|NCT02251132|Experimental|TPV/RTV High 3|
3348981|NCT02251145|Experimental|tipranavir/ritonavir low dose|
3348982|NCT02251145|Experimental|tipranavir/ritonavir high dose|
3241325|NCT01297790||Healthy smokers|Current smokers with normal breath tests (spirometry)
3241326|NCT01297790||Chronic cough|Subjects with idiopathic chronic cough.
3348983|NCT02251158|Experimental|TPV/r with food|Tipranavir/Ritonavir paediatric/oral solution
3348984|NCT02251158|Experimental|TPV/r|Tipranavir/Ritonavir paediatric/oral solution
3348985|NCT02251158|Active Comparator|TPV/r capsules|
3348986|NCT02251171|Experimental|TPV/RTV - Rifabutin|"Day 1: single dose Rifabutin~Days 8-20: morning and evening doses of Tipranavir/Ritonavir~Day 15: single dose Rifabutin"
3348987|NCT02251184|Experimental|Aggrenox|extended release
3348988|NCT02251184|Active Comparator|dipyridamole+aspirin|immediate release
3348989|NCT02251197|Experimental|BIII 890 CL|escalating doses
3348990|NCT02251197|Placebo Comparator|Placebo|
3241327|NCT01297803|Active Comparator|Mitomycin_c application before sclera flap dissection|
3241328|NCT01297803|Active Comparator|Mitomycin_c application after sclera flapdissection|
3241329|NCT01297816|Placebo Comparator|placebo|100mg-
3241330|NCT01297816|Placebo Comparator|minocyclin|
3241331|NCT01297829|Active Comparator|IV Caldolor|
3241332|NCT01297829|Placebo Comparator|Placebo|
3241333|NCT01297842|Experimental|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
3241334|NCT01297842|Active Comparator|Meropenem or Imipenem|Meropenem or Imipenem o.5 or 1 gram 3 to 4 times a day for 7 to 14 days
3241335|NCT01297855|Active Comparator|Colistin|Colistate
3241336|NCT01297855|Experimental|Colistin plus Rifampicin|Colistate Rifampin
3348991|NCT02251210|Experimental|BIIL 284 BS low dose|
3348992|NCT02251210|Experimental|BIIL 284 BS medium dose|
3348993|NCT02251210|Experimental|BIIL 284 BS high dose|
3348994|NCT02251210|Placebo Comparator|Placebo|
3348995|NCT02251223|Experimental|TPV/r low dose|
3348996|NCT02251223|Experimental|TPV/r medium dose|
3348997|NCT02251223|Experimental|TPV/r high dose|
3348998|NCT02251249|Experimental|STEMI Group|
3348999|NCT02251249|Other|Stable patient Group|Patient referred for angioplasty for angina or non-ST-segment elevation myocardial infarction (NSTEMI)
3349000|NCT02251262|Experimental|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
3349001|NCT02251288|Experimental|Group 1|12 patients receive Intramuscular (IM) A/H7N9 15 mcg on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of Intranasal (IN) sprayer 10^7 FFU H7 N9 pLAIV on Day 29
3349002|NCT02251288|Experimental|Group 2|12 patients receive A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer10^7 FFU H7 N9 pLAIV on Day 85
3349003|NCT02251288|Experimental|Group 3|12 patients receive S A/H7N9 15 mcg IM on Day 1, 12 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1 and all receive single dose of IN sprayer 10^7 FFU H7 N9 pLAIV on Day 169
3349004|NCT02251288|Experimental|Group 4|8 patients receive A/H7N9 15 mcg IM on Day 1, 8 patients receive A/H7N9 15 mcg plus MF59 adjuvant IM on Day 1
3349005|NCT02251288|Experimental|Group 5|12 patients receive A/H7N9 15 mcg plus MF59 adjuvant on Day 1 and Day 29
3241337|NCT01297868||exercise group|
3349006|NCT02251301|Active Comparator|Macronutrient isoenergetic control|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of macro nutrient matched isoenergetic control (whey/casein protein and dextrose/lactose) consumed immediately and 1 h after each training session
3349007|NCT02251301|Experimental|Skim Milk|Participants will also engage in twelve weeks of High intensity interval training with consumption of one serving (250 mL) of fat-free fluid milk immediately and 1 h after each training session
3349008|NCT02251301|Placebo Comparator|Placebo|Participants will also engage in twelve weeks of high intensity interval training with consumption of one serving (250 mL) of placebo (water) consumed immediately and 1 h after each training session.
3349009|NCT02251327||Case detection group|Suspected or confirmed new pulmonary tuberculosis cases who have received anti-tuberculosis drugs for less than 3 (three) days and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
3349010|NCT02251327||Drug resistance risk group|Confirmed pulmonary tuberculosis cases with documented rifampin resistance, who have received anti-tuberculosis drugs for 31 days or less and/or history of prior tuberculosis PLUS ongoing signs and/or cases with symptoms of pulmonary tuberculosis PLUS suspected drug resistance and provide up to two expectorated sputum specimens. One investigational Xpert DST test and one Xpert MTB/RIF test were performed directly on the same sputum specimen; in addition, one smear microscopy test, one mycobacterial liquid culture, and one solid culture were performed after digestion and decontamination of sputum.
3349011|NCT02251340|Experimental|Intervention|Families in the intervention group will receive an Eczema Care Plan
3349012|NCT02251340|No Intervention|Control|Families in the control group will not receive an Eczema Care Plan
3241338|NCT01297881||Caucasian outpatients with respiratory symptoms|all consecutive new Caucasian outpatients with respiratory symptoms like dyspnoea, cough, sputum but without diagnosis who are being examined for the first time.
3241339|NCT01297894|Active Comparator|colistin|Colistimethate sodium 2.5-5mg/kg iv
3241340|NCT01297894|Active Comparator|colistin plus fosfomycin|colistimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
3349013|NCT02251353||lung and/or hepatic metastasis|intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
3349014|NCT02251366|No Intervention|SOC Examination Based Cohort|Participants in this arm will receive standard of care (SOC) retinal examinations at each study visit.
3349015|NCT02251366|Active Comparator|Physician-Guided Diagnostic|Participants in this arm of the study will only receive the physical standard-of-care retinal examination at the 4-month and -month office visits, unless requested by the Physician-Investigator or study participant. At each standard study visit, the physician will use diagnostic imaging to determine if the participant will receive the anti-VEGF injection.
3349016|NCT02251392|Experimental|Chamomila recutita Gel|Experimental Group 1 - patients will apply the gel since the begging of radiodermatitis, three times a day. The dose is being determined in a Phase II study that is being conducted. Topical application of gel is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3241341|NCT01297907||Crohn's Patients|Random Crohn's Disease Patients that can perform Methacholine Challenge Test (MCT)
3241342|NCT01297907||Negative MCT|Patients evaluated for functional cough who had negative Methacholine Challenge Test (MCT)
3241343|NCT01297946|Placebo Comparator|Open-loop|Conventional continuous subcutaneous insulin infusion (CSII) therapy
3349017|NCT02251392|Experimental|Chamomila recutita Infuse 2,5%|Experimental Group 2 - patients will apply the infuse since the begging of radiodermatitis, three times a day. The dose of 2,5% was determined before in a Phase II study. Radiodermatitis grade and intensity is going to be evaluated. Topical application of the infuse is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3349018|NCT02251392|Active Comparator|Urea cream based|Control Group - usual care to treat radiodermatitis, patients will apply the infuse since the begging of radiodermatitis, three times a day. Radiodermatitis grade and intensity is going to be evaluated. Topical application of urea is going to occur concomitantly to the initiation of radiodermatitis and will be follow up until the cure of it.
3349019|NCT02251405|Placebo Comparator|One big bag, no stainless container|No stainless container
3349020|NCT02251405|Active Comparator|One big bag with two stainless containers|Two stainless containers
3349021|NCT02251418|Experimental|Extracorporeal shockwave therapy|6 times extracorporeal shockwave therapy in 3 weeks. This arm also receives standard care treatment.
3349022|NCT02251418|No Intervention|Control|Standard care treatment
3349023|NCT02251431|Experimental|Exenatide-extended release|Exenatide-extended release (BYDUREON™) 2 mg subcutaneously once per week x 38 weeks
3349024|NCT02251431|Placebo Comparator|Placebo|Matching placebo subcutaneously once per week x 38 weeks
3349025|NCT02251444|Experimental|outpatient rehabilitation program|whole-body resistance training, psychological interventions, sessions for information related to ergonomics and healthy alimentation
3349026|NCT02251444|Active Comparator|physical therapy|prescribed physical therapy
3241344|NCT01297946|Experimental|Dual-hormone closed-loop|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. The infusion rates are based on continuous glucose sensor reading and a control algorithm.
3241345|NCT01297998|Experimental|gemcitabine , cisplatin|
3241346|NCT01298011|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|
3241347|NCT01298024|Experimental|Early neuromusclar exercise|
3241348|NCT01298024|Active Comparator|Treatment as usual (late training)|
3241349|NCT01298050||Extracorporeal Membrane Oxygenation|All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
3241350|NCT01298076|Active Comparator|AVASTIN|intravitreal bevacizumab
3241351|NCT01298076|Active Comparator|OZURDEX|intravitreal dexamethasone
3349027|NCT02251457|Experimental|ranolazine|ranolazine 500mg, twice daily for two weeks; 1000mg twice daily for 2 weeks
3349028|NCT02251470|Experimental|HBE Wii (EG)|Participants receive an introduction of using the Nintendo Wii by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (wii-fit balances games) at home (instruction: min. 3 times a week for each 30 minutes).
3349029|NCT02251470|Active Comparator|HBE Control (CG)|Participants receive an introduction for conventional/traditional balance exercise by an individual mentoring for over 6 weeks (a total of 6 sessions á 60 minutes). During the following 6 weeks the participants perform the balance exercise program (exercises in standing and walking) at home (instruction: min. 3 times a week for each 30 minutes).
3349030|NCT02251483|Other|SBI|Group 1: SBI (N=30) - one packet daily
3349031|NCT02251483|Placebo Comparator|Placebo|Group 2: Placebo (N=30) - one packet daily
3349032|NCT02251509|Experimental|Carvedilol|carvedilol BID for 2 weeks
3349033|NCT02251509|Experimental|Metoprolol tartrate|Metoprolol tartrate BID for 2 weeks
3349034|NCT02251522||ConforMIS iTotal Knee Replacement System|Patients who have had an iTotal knee replacement at least 6 months prior to testing
3349035|NCT02251522||Off-the-Shelf Knee Replacement System|Patients who have had an off-the-shelf knee replacement at least 6 months prior to testing
3349036|NCT02251535|Experimental|test group 1|Retrospective test group 1 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining) with intraoperative high level rollback
3349037|NCT02251535|Experimental|test group 2|Retrospective test group 2 (n=10, ATTUNE® Knee System, rotating platform, cruciate retaining)with intraoperative low level rollback
3349038|NCT02251535|Experimental|control group|Control group (n=10, PFC® SIGMA® Knee System, rotatinq platform, cruciate retaininq)
3349039|NCT02251574|Experimental|Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 1200-1500 calories per day.
3349040|NCT02251574|Experimental|Very Low Calorie Diet|Participants will take part in an experimental weight management program involving a low calorie diet (LCD), about 520-800 calories per day.
3349041|NCT02251574|Active Comparator|Standard Care|Participants will receive normal care.
3349042|NCT02251587|Active Comparator|Standard Weight Management Program|Participants will be given information on diet and exercise. Participants will attend meetings to discuss barriers to exercise and nutrition and ways to solve these problems. Participants will be given healthy snack ideas and planning tools.
3349043|NCT02251587|Experimental|$ensible Weigh Program|Participants will be given information on diet and exercise with an emphasis on food security. Participants will be provided with additional information on community resources such as those for food, transportation, and safe places to exercise. A weekly cooking demonstration will be provided using inexpensive ingredients and common food pantry items.
3241352|NCT01298102|Experimental|influenza vaccine|Pandemrix vaccine (Influenza A/H1N1 2009)to be injected to renal transplant patients, haemodialyzed patients, and controls
3349044|NCT02251600|Experimental|Deflazacort|This is an open label and single period study , dosed with 0.9mg/kg Deflazacort.
3349045|NCT02251626|Experimental|Coenzyme Q10 (ubiquinol)|Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day
3349046|NCT02251626|Placebo Comparator|Placebo for CoQ10 (ubiquinol)|Placebo group will be given placebo only
3349047|NCT02251639|Experimental|Oral Imaging and Cytology|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors. Oral cavity inspected using a standard white light headlamp. Oral cavity then examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device. Exfoliative cells for cytology from an abnormal area (if present) and from a contralateral normal appearing area obtained using a brush.
3349048|NCT02251665||Acute ischemic stroke, acute ICH, TIA|Consecutive patients with acute ischemic stroke, intracerebral hemorrhage, and transient ischemic attack who are emergently managed in the stroke care unit or stroke units in the National Cerebral and Cardiovascular Center
3349049|NCT02251678|Experimental|Elimune capsules|Elimune capsules 2 capsules BID (four total capsules per day)
3349050|NCT02251691|Experimental|Advagraf|Take Advagraf once daily
3349051|NCT02251691|Active Comparator|Prograf|Take tacrolimus twice daily
3349052|NCT02251704|Other|Study Group|Subjects 6 months to <10 years of age enrolled in HDSS catchment areas at the sites participating in the EPI-MAL-002 and EPI-MAL-003 studies of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa.
3349053|NCT02251730|Experimental|Refer for smoking cessation|Refer for smoking cessation
3349054|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 1application|Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
3349055|NCT02251756|Experimental|Actinica, 0.8 mg/cm2, 2 applications|Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
3349056|NCT02251756|Experimental|Actinica, 2 mg/cm2, 1 application|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
3349057|NCT02251756|Experimental|Actinica, 2 mg/cm2, 2 applications|Actinica, 2 mg/cm2, 1 application over one day of sun exposure
3349058|NCT02251769|Experimental|Sequential administration|
3349059|NCT02251782||Epi proColon Group|Subjects assigned to the Epi proColon Group will be offered the Epi proColon test for colorectal cancer screening.
3349060|NCT02251782||FIT Group|Subjects in the FIT Group will be offered a fecal immunochemical test (FIT test) for colorectal cancer screening.
3349061|NCT02251782||Usual Care Group|For the purpose of comparison to usual care, participating health systems will build an anonymized group of patients meeting study eligibility criteria, who do not participate in the study. This group will serve as a passive control and their CRC screening activity will be monitored via Medical Record.
3349062|NCT02251795|Experimental|Tipranavir/Ritonavir|500 mg Tipranavir / 200 mg Ritonavir 10 days BID
3349063|NCT02251795|Active Comparator|Darunavir/Ritonavir|600 mg Darunavir /100 mg Ritonavir 10 days BID
3349064|NCT02251795|Active Comparator|Ritonavir|100 mg Ritonavir 10 days BID
3241353|NCT01298115||Stage 5 chronic kidney disease|Incident patients commencing renal replacement therapy or conservative care
3349066|NCT02251834|Experimental|Community Health Worker|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .
3349067|NCT02251834|Other|Usual Care|usual care and health education brochures every 4 months.
3349068|NCT02251847|Active Comparator|R5|Rosuvastatin 5mg
3349069|NCT02251847|Active Comparator|R10|Rosuvastatin 10mg
3349070|NCT02251847|Active Comparator|R20|Rosuvastatin 20mg
3349071|NCT02251847|Experimental|R5/E10|Rosuvastatin 5mg/ezetimibe 10mg
3349072|NCT02251847|Experimental|R10/E10|Rosuvastatin 10mg/ezetimibe 10mg
3241354|NCT01298154|Experimental|Intact Pea Protein (20 g)|
3241355|NCT01298154|Experimental|Hydrolyzed Pea Protein (20 g)|
3241356|NCT01298154|Experimental|Intact Whey Protein|
3349073|NCT02251847|Experimental|R20/E10|Rosuvastatin 20mg/ezetimibe 10mg
3349074|NCT02251860||Participants with Rheumatoid Arthritis|Participants with active rheumatoid arthritis who are prescribed tocilizumab treatment according to the marketing authorization by their physician will be followed under routine conditions over an observation period of up to 2 years if baseline and disease characteristics data are available.
3349075|NCT02251873|Experimental|TPV + RTV (low dose)+ ddI|
3349076|NCT02251873|Experimental|TPV+ RTV (high dose)+ ddI|
3349077|NCT02251899|Experimental|Disease-Management intervention|Behavioral: Disease-Management intervention The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
3349078|NCT02251899|No Intervention|No Intervention: Control arm|Control group not receiving any in
3241357|NCT01298154|Experimental|Hydrolyzed Whey Protein|
3349079|NCT02251925|Experimental|Natural cycle|In natural cycle without hCG, daily monitoring of urinary LH is started from day eight of the cycle and frozen-thawed embryo transfer is planned 3-5 days after detection of LH surge, observing mature follicles in ultrasound and endometrial thickness over 7mm for cleavage embryos.
3349080|NCT02251925|Experimental|Natural cycle + hCG for ovulation induction|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
3349081|NCT02251925|Experimental|Hormonally controlled cycle with GnRH-a|In this group , injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
3349082|NCT02251925|Experimental|Hormonally controlled cycle without GnRH-a|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
3349083|NCT02251951|Experimental|nab-Paclitaxel|Abraxane
3241358|NCT01298154|Experimental|Water|
3241359|NCT01298180|Experimental|SPW|Children presenting a Prader-Willi Syndrome
3241360|NCT01298180|Experimental|GHD|Patient deficient in Growth Hormone
3241361|NCT01298180|Experimental|SPW-B|Patient with Prader-Willi Syndrome who has Biopsy
3241362|NCT01298180|Experimental|T|Patient Control
3349084|NCT02251964|Other|rituximab|single arm study with Zr-89-rituximab immuno PET/CT
3349085|NCT02251977|Experimental|Adjuvant Chemotherapy plus GM1|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
3349086|NCT02251977|Placebo Comparator|Adjuvant Chemotherapy plus placebo|Patients will receive mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) or XELOX (capecitabine and oxaliplatin) for adjuvant chemotherapy. While placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4).
3349087|NCT02252003|Experimental|Pain scales testing|
3349088|NCT02252055|Experimental|ATDC Treatment|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus, as detailed below :~Prednidolone :~D 0: 500 mg IV~D 1: 125 mg IV~D 2 to 14: 20.0 mg/d~Wk 3 to 4: 15.0 mg/d~Wk 5 to 8: 10.0 mg/d~Wk 9 to 12: 5.0 mg/d~Wk 13 to 14: 2.5 mg/d~Wk 15 to End:Cessation~MMF (or biologic equiv.):~D -7 to -2: 500 mg/d (250mg 2x/d)~D -1 to 14: 2000 mg/d~Wk 3 to 36: 1000 mg/d~Wk 37 to 40: 750 mg/d~Wk 41 to 44: 500 mg/d~Wk 45 to 48: 250 mg/d~Wk 49 to End:Cessation Note : MMF tapering will only happen if the 36-week protocol biopsy shows no signs of subclinical rejection and there is evidence of declining renal function or if the clinician has any other concern about MMF dose reduction.~Tacrolimus :~≤ 48 h pre-Tx to D 14: 3-12 ng/ml~Wk 3 to 12: 3-10 ng/ml~Wk 13 to 36: 3-8 ng/ml~Wk 37 to End: 3-6 ng/ml"
3349089|NCT02252094|Active Comparator|Conventional lung protective ventilation|Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
3349090|NCT02252094|Experimental|Ultra-protective ventilation|Ultra-protective ventilation (</= 3ml/kg predicted body weight) targeting plateau pressure of </= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol
3349091|NCT02252107|Experimental|Decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
3349092|NCT02252120|Active Comparator|Supreme|Supreme LMA
3349093|NCT02252120|Active Comparator|Laryngeal Tube|Laryngeal tube LTSII
3375937|NCT03417544|Experimental|ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB|"Patients will receive the following treatment:~Atezolizumab (IV) every 3 weeks (q3w)]~Pertuzumab (loading dose ), followed q3w thereafter by a predetermined dose in the protocol via IV)~High-dose Trastuzumab weekly for the first 24 weeks, and thereafter trastuzumab q3w)."
3375938|NCT03395184|Experimental|PF-06700841 or placebo|
3241363|NCT01298180|Experimental|SPW-GH-B|Patient with Prader-Willi Syndrome taking growth Hormone and who has biopsy
3241364|NCT01298206||H1N1 not exposed controls|For every enrolled H1N1 case, the study will enroll 2 sex matched controls. On the date of enrollment of a case, 2 sex-matched controls will be located from the same clinic from which the case was enrolled. Enrolled controls will then be verified to be free from influenza infection at the time of enrollment by RT-PCR.
3241365|NCT01298206||H1N1 exposed Cases|A swab will be collected from cases to verify presence of pandemic influenza. Testing positive for influenza A/H1N1 by RT PCR to be enrolled will be confirmed as a case. The participant will be presented with a questionnaire that will capture exposure data through a group of variables assessing underlying health conditions, symptoms, use of influenza vaccine, travel, occupational setting, and other demographic variables. Cases will be contacted once during the study.
3241366|NCT01298232|No Intervention|EMAT-guided therapy|electromechanical activation time (EMAT, obtain by phonocardiogram, Audicor, USA)
3349094|NCT02252159||Cohort A|"Patients with clinically overt PV (and not exhibiting any of the characteristics listed for Cohort B), managed with:~Watchful waiting (with or without aspirin)*, or~Phlebotomy (PHL) alone (with or without aspirin)* - or~HU alone (without concomitant PHL, with or without aspirin).~(*Unless patient has a history of intolerance or clinical resistance/ refractoriness to hydroxyurea [HU] (as assessed by the treating physician) - in which case, s/he belongs to Cohort B)"
3349095|NCT02252159||Cohort B|"Patients with clinically overt PV, with one or more of the following disease characteristics:~Treatment with HU and PHL in combination or~Treatment with any agent other than HU or aspirin (e.g., recombinant interferon (IFN) or pegylated IFN preparations, busulfan, anagrelide) or~A history of thrombosis (venous or arterial) or~A history of intolerance or clinical resistance/ refractoriness to HU (as assessed by the treating physician) or~Presence of documented splenomegaly (clinically assessed by palpation) or~Presence of one or more of the following uncontrolled symptoms related to PV despite therapy (Symptoms deemed uncontrolled as per physician's judgment)~Tiredness~Difficulty sleeping~Itching~Muscle aches and/or bone pain~Night sweats~Sweats while awake~Other"
3349096|NCT02252185|Experimental|China made spine fusion system|patents in this arm will be implanted with Johnson&Johnson Medical Suzhou made Spine Fusion System.
3349097|NCT02252185|Active Comparator|Imported spine fusion system|patents in this arm will be implanted with Imported EXPEDIUM screws and OPAL cage .
3241367|NCT01298232|No Intervention|Symptomatic-guided therapy|HF therapy guided by clinical symptoms
3241368|NCT01298245||Case: diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those with known positive results of diabetic retinopathy
3259308|NCT01469663||Major Depression + Borderline Personality Disorder|With major depression and borderline personality disorder
3349098|NCT02252198||Investigational|• Participants will be asked to provide a total of three sputum samples over Days 1 and 2. The intent is for all samples to be collected before the subject starts any form of TB treatment. The first specimen (S1) should be 2 ml or greater in volume, and the second and third specimens (S2 and S3) should each be 1 ml or greater in volume. On Day 1, each participant will be asked to submit one spot sputum (S1) after enrollment and a second spot sputum after at least 2 hours (S2). Participants will be instructed to come back the following day (Day 2) and provide a third spot sputum (S3). In the event that a participant fails to return on Day 2, S3 may be collected a maximum of 7 days after enrollment, provided that no TB treatment has been initiated.
3349099|NCT02252224||T2DM patients treated with Forxiga|Korean patients who are at least 18 years old, diagnosed with type2 diabetes and treated with Forxiga according to the approved lable
3349100|NCT02252237||Children with glucocorticoids|Children receiving Prednisone or Prednisolone or Methylprednisolone Pharmacokinetic
3349101|NCT02252250|Active Comparator|conventional laparoscopic|conventional laparoscopic total mesentery excision surgery for rectal cancer.
3349102|NCT02252250|Experimental|Transanal hybrid-laparoscopic|Transanal hybrid-laparoscopic total mesentery excision surgery for rectal cancer.
3349103|NCT02252263|Experimental|Arm 1: Elotuzumab + Lirilumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Lirilumab every 4 wks Intravenous solution for Up to 2 yrs, depending on response
3349104|NCT02252263|Experimental|Arm 2: Elotuzumab + Urelumab|Elotuzumab weekly for 8 wks and every 2 wks thereafter + Urelumab every 4 wks Intravenous solution for Up to 26 weeks, depending on response
3349105|NCT02252276|Experimental|Experimental|performed the same exercises and manual therapy during 4 weeks
3349106|NCT02252276|Active Comparator|Control|performed proprioceptive and strengthening exercises during 4 weeks
3349107|NCT02252289||Problematic severe asthmatics|"Approximately 75 Children aged 5 to 17 years with problematic severe asthma (PSA). Two groups of PSA children will be recruited: those who have already been assessed as part of the Difficult Asthma protocol and classified as DA (difficult asthma)/ STRA (severe therapy resistant asthma) (training set) and those newly referred to the protocol (validation set).~Previous enrolment or new referral to the Royal Brompton Hospital Difficult Asthma Protocol."
3349108|NCT02252289||Control group of moderate asthmatics|A control group of 30 children aged 5 to 17 years with mild to moderate asthma.
3349109|NCT02252302|Active Comparator|Resting in diesel exhaust following salbutamol inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of 400ug of salbutamol.
3349110|NCT02252302|Placebo Comparator|Resting in diesel exhaust following placebo inhalation|Participants will be sitting in an air pollution chamber while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1hour following the inhalation of a placebo.
3349111|NCT02252302|Active Comparator|Cycling in diesel exhaust following salbutamol inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of 400ug of salbutamol.
3349112|NCT02252302|Placebo Comparator|Cycling in diesel exhaust following placebo inhalation|Participants will be cycling while being exposed to diesel exhaust (PM2.5 of 300 μg/m3) for a total of 1 hr following the inhalation of a placebo
3349113|NCT02252302|Sham Comparator|Resting in filtered air following salbutamol inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of 400ug of salbutamol.
3375939|NCT03395184|Experimental|PF-06651600 or placebo|
3241369|NCT01298245||Control: no diabetic retinopathy|Patients with diabetes who have received ophthalmic fundus examination within 6 months before the study and those without known positive results of diabetic retinopathy
3349114|NCT02252302|Placebo Comparator|Resting in filtered air following placebo inhalation|Participants will be sitting while being exposed to filtered air for a total of 1hour following the inhalation of a placebo.
3349115|NCT02252302|Sham Comparator|Cycling in filtered air following salbutamol inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of 400ug of salbutamol.
3349116|NCT02252302|Placebo Comparator|Cycling in filtered air following placebo inhalation|Participants will be cycling while being exposed to filtered air for a total of 1 hr following the inhalation of a placebo
3349117|NCT02252315|Active Comparator|Written Education|
3349118|NCT02252315|Active Comparator|Verbal Education|
3349119|NCT02252328|Experimental|Simvastatine|Group of patients receiving simvastatin 80mg once daily in addition to standard care
3349120|NCT02252328|Placebo Comparator|Placebo|Group of patients receiving placebo once daily in addition to standard care
3241370|NCT01298258|Placebo Comparator|placebo|control group
3349121|NCT02252341|Placebo Comparator|placebo|"Dietary Supplement: N-Acetyl-Cysteine Phase 4 Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline, 1, 2, 3 months] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers N-Acetyl-cysteine 1800 mg / day will be taken for 12 weeks versus placebo 12 weeks."
3349122|NCT02252341|Placebo Comparator|N-Acetyl-Cysteine|"Study Type: Interventional Study Design: Treatment, Parallel Assignment, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Randomized, Efficacy Study~Official Title: Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder~Primary Outcome Measure:~Hamilton Depression Rating Scale [Time Frame: baseline] [Designated as safety issue: Yes]~Secondary Outcome Measures:~Carbon Oxide exhalation [Time Frame: basal, 1, 2, 3 months] [Designated as safety issue: Yes]~Other Pre-specified Outcome Measures:~Biological outcome measures [Time Frame: baseline and 3 months] [Designated as safety issue: Yes] inflammatory and oxidative stress biomarkers~Placebo will be taken for 12 weeks."
3349123|NCT02252367|Experimental|Tadalafil|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.
3349124|NCT02252367|Placebo Comparator|Placebo|43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.
3349125|NCT02252380|Experimental|Transcranial ExAblate System|Transcranial ExAblate System (MRgFUS)
3349126|NCT02252393|Experimental|Arm I (RARC with IUD)|Patients undergo RARC with IUD.
3349127|NCT02252393|Experimental|Arm II (RARC with EUD)|Patients undergo RARC with EUD.
3349128|NCT02252419|Active Comparator|Dexamethasone|Dexamethasone will be administered 30 minutes before the anesthetic induction.
3349129|NCT02252419|Experimental|Dexamethasone+ Paracetamol (DP)|Dexamethasone will be administered 30 minutes before the anesthetic induction. Paracetamol will be administered at the end of the surgery.
3349130|NCT02252432|Active Comparator|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min))
3349131|NCT02252432|Active Comparator|Methadone|Will receive a single dose of IV methadone (0.2 mg/kg) preinduction
3349132|NCT02252432|Experimental|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
3349133|NCT02252458|Experimental|Fentanyl high dose|Fentanyl 10mcg/kg of bodyweight
3349134|NCT02252458|Active Comparator|Fentanyl low dose|Fentanyl 1mcg/kg of bodyweight
3349135|NCT02252471|Experimental|Choices-Teen Intervention|A three session intervention with two counseling sessions with a master's level therapist and a counseling session with a physician. The counseling with the master's level therapist utilizes a motivational interviewing approach to encourage changes in alcohol use, contraceptive use, smoking and HIV risk behaviors. This part of the intervention (a) provides norms-based-but personalized-feedback; (b) encourages participating in the smoking cessation program; (c) increases motivation to change each of the target behaviors; (d) decreases temptation to engage in risk behaviors; (e) increases confidence to avoid risk behaviors; and (f) develops a personalized, tailored change plan. The physician session provides individualized contraception and HIV risk reduction counseling.
3349136|NCT02252484|Experimental|Weight loss intervention Group|Participants will receive tailor weight loss program. Participants will complete 8-weeks of the weight loss intervention prior to having their prostatectomy (weight loss phase). Program includes individual weight coaching, tailored diet and exercise plan, weight coaching and tracking of daily activities. Sessions will be held weekly during the weight loss phase. The groups will be facilitated by a registered dietitian with genitourinary (GU) oncology experience.
3349137|NCT02252484|Active Comparator|Comparison Group|All patients who are unwilling or not ready to engage in a weight loss program will be offered entry into the comparison group arm.
3349138|NCT02252497|Active Comparator|Tranexamic acid|"1g Intra Venous just before surgery~Then infusion of 1g of Exacyl over eight hours."
3349139|NCT02252497|Placebo Comparator|Physiologic serum|"1g Intra Venous, just before surgery~Then infusion of 1g of physiologic serum over eight hours."
3349140|NCT02252523|Experimental|DEXMEDETOMIDINE|
3349141|NCT02252549|Active Comparator|A|SPIES+WLI assisted TURB
3349142|NCT02252549|Active Comparator|B|WLI assisted TURB
3349143|NCT02252575|Experimental|Electromagnetic field|Exposure to the elctromagnetic field of an electric motor
3241371|NCT01298258|Experimental|Aliskiren|Aliskiren 150 mh
3241372|NCT01298271|No Intervention|Cyanoacrylate|Endoscopic Cyanoacrylate Injection treatment of primary prevention GVB
3241373|NCT01298271|Active Comparator|Propranolol|Propranolol is used for primary prevention of GVB
3349144|NCT02252601|Experimental|Well patients aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3349145|NCT02252601|Experimental|Acute exacerbation aged 11 and over|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity at the beginning of a course of IV antibiotics and at their convalescent clinic visit.
3349146|NCT02252601|Experimental|Children with CF aged 5-10 years|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3349147|NCT02252601|Active Comparator|Healthy Control Children age 5-10 years.|Will have the HFDT test compared to the gold standard (the Pure tone Audiogram) as well as other tests that have previously been suggested as a screening test for ototoxicity.
3349148|NCT02252614|Active Comparator|Naproxen sodium codein|Preoperative Naproxen sodium codein administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3241374|NCT01298284|No Intervention|EVL\GVS Alone|Endoscopic ligation treatment in the 2nd prevention of gastroesophageal variceal bleeding in patients with HCC
3241375|NCT01298284|Active Comparator|EVL\GVS Combined Propranolol|"Propranolol and endoscopic ligation treatment is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~<EVL\GVS Combined Propranolol>"
3349149|NCT02252614|Experimental|Paracetamol codein|Preoperative paracetamol codein administrered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3349150|NCT02252614|Placebo Comparator|Placebo tablet|Preoperative placebo tablet administered, pain intensity measured by the visual analogue scale, and contramal consumption and related side effects evaluated.
3349151|NCT02252627||Group 1|Healthy volunteers
3349152|NCT02252640|Active Comparator|Group 1|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3241376|NCT01298297|Active Comparator|Buprenorphine + Placebo|
3241377|NCT01298297|Placebo Comparator|Morphine + Placebo|
3349153|NCT02252640|Active Comparator|Group 2|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3349154|NCT02252640|Active Comparator|Group 3|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3349155|NCT02252640|Active Comparator|Group 4|Week 0: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & ChAd63 ME-TRAP (5 x 10^10 vp), Week 4: RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 8: RTS,S/AS01B (10mcg of RTS,S and 1/5 of the standard dose of AS01) & MVA ME-TRAP (2 x 10^8 pfu), Week 11: Controlled Human Malaria Infection (CHMI), Week 31-39: Repeat CHMI of sterilely protected volunteers.
3349156|NCT02252640|No Intervention|Group 5|Week 11: Controlled Human Malaria Infection
3241378|NCT01298310|Active Comparator|Xylocaine_1mg|1 injection of Xylocaine (1 mg/mL)
3349157|NCT02252640|No Intervention|Group 6|Week 31-39: Controlled Human Malaria Infection
3241379|NCT01298310|Active Comparator|Xylocaine_10mg|1 injection of Xylocaine (10 mg/mL)
3241380|NCT01298310|Placebo Comparator|Placebo|1 injection of placebo
3349158|NCT02252653||Familial Amyloidotic Cardiomyopathy (FAC)|
3349159|NCT02252679||Osteoporosis|Postmenopausal women, men > age 50 years, or other patients with well-established causes of secondary osteoporosis (incl. glucocorticoid-induced osteoporosis, transplantation-related osteoporosis, disuse osteoporosis, etc.) N=20 treated with antiresorptive drugs N=10 treated with osteoanabolic drugs (e.g. teriparatide, Forsteo)
3349160|NCT02252679||Calcium malabsorption|N=10 Patients with clinically obvious potential causes of calcium malabsorption (incl. severe vitamin D-deficiency, Scopinaro or other bariatric surgery, exocrine pancreatic insufficiency/steatorrhea, cystic fibrosis, inflammatory bowel disease, celiac disease, anorexia nervosa/eating disorders, malnutrition, etc.), with or without bone pains, muscle weakness and other typical osteomalacia symptoms. Confirmed by 24h urine collection showing calciuria <100 mg/24h.
3241381|NCT01298336|Experimental|Clarithromycin|
3241382|NCT01298336|Experimental|Moxifloxacin|
3241383|NCT01298349||schizophrenic patients|
3241384|NCT01298349||normal population|
3349161|NCT02252679||Various disorders|Exploratory, heterogeneous group of calcium-related disorders (incl.hypercalcemia, hypocalcemia, primary/secondary/tertiary hyperparathyroidism, hypoparathyroidism, vitamin D deficiency, X-linked/autosomal dominant hypophosphatemic rickets, familial hypocalciuric hypocalcemia,etc.) N=20
3349162|NCT02252679||Normal control subjects|N=40 Men and women ≤ 40 years recruited from the population
3349163|NCT02252692|Active Comparator|Enalapril|Renitec® 2 x 5 mg tablets administered at once, to be entirely swallowed with 240 ml water
3241385|NCT01298401|Experimental|Arm A|Dose level -1A (Ganitumab 6 mg/kg, Capecitabine 825mg/m2)
3241386|NCT01298401|Experimental|Arm B|Dose level 1A (Ganitumab 12 mg/kg, Capecitabine 825mg/m2)
3241387|NCT01298401|Experimental|Arm C|Dose level 2A (Ganitumab 20 mg/kg, Capecitabine 825mg/m2)
3241388|NCT01298401|Experimental|Arm D|Dose level -1B (Ganitumab 6 mg/kg, Capecitabine 625mg/m2)
3241389|NCT01298401|Experimental|Arm E|Dose level 1B (Ganitumab 12 mg/kg, Capecitabine 625mg/m2)
3241390|NCT01298401|Experimental|Arm F|Dose level 2B (Ganitumab 20 mg/kg, Capecitabine 625mg/m2)
3241391|NCT01298466|Experimental|Pregabalin|Open label study. All patients fulfilling the protocol inclusion/exclusion criteria will receive pregabalin in a flexible-dosing regimen.
3241392|NCT01298479||Group 1|All subjects
3241393|NCT01298505|Experimental|PF-03654764 2.5mg plus fexofenadine 60mg|
3241394|NCT01298505|Experimental|PF-03654764 5mg plus fexofenadine 60mg|
3241395|NCT01298505|Placebo Comparator|placebo|
3349164|NCT02252692|Experimental|Enalapril ODMT|10 x 1mg of Enalapril ODMT, swallowed entirely with 240ml of water
3349165|NCT02252692|Experimental|Enalapril ODMT dispersed|10 x 1mg of Enalapril ODMT, dispersed on tongue
3349166|NCT02252705||Incident patients|Patients with less than three months from diagnosis to start of the Registry or those who have been diagnosed during the recruitment period.
3349167|NCT02252705||Prevalent patients|Patients who have been diagnosed with more than three months from diagnosis to start of the Registry.
3349168|NCT02252731|Experimental|warfarin and FG-4592|Single dose of warfarin and Multiple doses of FG-4592 in combination with a single dose of warfarin
3349169|NCT02252770|Active Comparator|Nitric oxide supplement arm|During this arm, subjects will receive a lozenge with nitric oxide supplement
3241396|NCT01298557||Traumatic brain injured patients|This group consists of participants who suffered a traumatic brain injury an average of 4 months to 4 years prior to testing. Patients must not have history of prior head injury, substance abuse, psychiatric illness, or contraindications to MRI.
3241397|NCT01298557||Controls (no traumatic brain injury)|This group consists of participants who do not have a history of brain trauma. Furthermore, controls must not suffer from substance abuse, psychiatric illness, or have contraindications to the MRI.
3241398|NCT01298583|Experimental|ankle tracking|subjects track a target with ankle movement
3349170|NCT02252770|Placebo Comparator|Placebo Arm|During this arm, subjects will receive placebo
3349171|NCT02252783|Experimental|BFPET|BFPET will be administered as a single intravenous injection of up to 2 mCi (74 MBq) at rest and a single intravenous injection of up to 8mCi (296 MBq) following a stress protocol. Total amount not to exceed 10mCi (370 MBq).
3349172|NCT02252796|Experimental|Sub-group 1|HySBst to be delivered during week 1 with Chemo-radiation to be delivered weeks 2-7
3349173|NCT02252796|Experimental|Sub-group 2|Chemo-radiation to be delivered weeks 1-6 and HySBst to be delivered week 7
3349174|NCT02252809|Active Comparator|adalimumab|adalimumab 40 mg by subcutaneous way 7 days before endotoxin inhalation
3241399|NCT01298583|No Intervention|ankle movement|
3241400|NCT01298609|Active Comparator|Suprathreshold Stimulation|Patients will be stimulated at supra-sensory threshold levels for two weeks using occipital stimulation
3241401|NCT01298609|Sham Comparator|minimal stimulation|Patients will be stimulated at minimal stimulation for two weeks using occipital stimulation
3241402|NCT01298609|Active Comparator|Subthreshold Stimulation|Patients will be stimulated at sub-sensory threshold stimulation for two weeks using occipital stimulation
3349175|NCT02252809|Active Comparator|methylprednisolone|methylprednisolone 20 mg daily , 7 days before endotoxin inhalation
3349176|NCT02252809|No Intervention|control|no intervention, 7 days before endotoxin inhalation
3349177|NCT02252822|Experimental|The Overcoming Bulimia Online Programme|This treatment incorporates a combination of cognitive-behavioral, motivational and education strategies. The program will be presented in 8 collaborative, multi-media, web based CBT sessions for BN.
3241403|NCT01298622||controls|
3241404|NCT01298622||OCD patients|
3349178|NCT02252835|Experimental|Arhalofenate with febuxostat (PK cohort)|
3349179|NCT02252835|Experimental|Arhalofenate with febuxostat (non-PK cohort)|
3349180|NCT02252861||Left Atrial Appendage Closure|Patients with atrial fibrillation and counter-indication to anticoagulant therapy referred for percutaneous Left Atrial Appendage Closure in routine care
3349181|NCT02252874|Placebo Comparator|Control Group|Receive leisure activities (e.g. reading, web-surfing, playing chess/ Mahjong) Twenty hours (2-3 sessions per week, 1.5 hours per session)
3349182|NCT02252874|Active Comparator|Intervention Group 1|Receive slow motion Nintendo Wii video games Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
3349183|NCT02252874|Active Comparator|Intervention Group 2|Receive fast motion Nintendo Wii video games (e.g. shooting game) Twenty hours ( 2-3 sessions per week, 1.5 hours per session)
3349184|NCT02252887|Experimental|Gemcitabine, Trastuzumab, and Pertuzuma|The regimen will consist of gemcitabine at 1000mg/m^2 IV weekly days 1 + 8 q 3 weeks + trastuzumab every 3 weeks (8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose followed by 420 mg every 3 weeks), all given intravenously (IV). Trastuzumab may be given IV weekly (4 mg/kg loading dose followed by 2 mg/kg weekly) in lieu of the every 3 week schedule. A loading dose of trastuzumab will not be required for patients who have received it < 6 weeks prior to Cycle 1 Day 1.
3349185|NCT02252900|Experimental|cerebral MRI during follow-up of IE|All patients will undergo the diagnostic test specific to the study (Magnetic resonance imaging)
3241405|NCT01298622||OCD parents|
3241406|NCT01298635|Active Comparator|trab|
3241407|NCT01298635|Active Comparator|phacotrab|
3241408|NCT01298687|Experimental|Trav 0.00013%|Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3241409|NCT01298687|Experimental|Trav 0.00033%|Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3241410|NCT01298687|Experimental|Trav 0.001%|Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3241411|NCT01298687|Experimental|Trav 0.00267%|Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3241412|NCT01298687|Active Comparator|TRAVATAN|Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)
3241413|NCT01298687|Placebo Comparator|Vehicle|Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days
3241414|NCT01298713|Active Comparator|A|Tamoxifen 20mg/d
3241415|NCT01298713|Experimental|B|Tamoxifen 20mg/d + RAD001 10mg/d
3241416|NCT01298726|Other|PHARMACEUTICAL CARE|
3241417|NCT01298726|Other|HEALTH USUAL CARE|
3349186|NCT02252913|Experimental|Volitinib+docetaxel|"Dose escalation stage: oral administration, Volitinib 600mg/800 QD + docetaxel 75mg/m2.~If the dose of docetaxel 75mg/m2 is not tolerable, docetaxel dose will be reduced to 60mg/m2 while keep volitinib at 600mg QD as the initial dose. Volitinib dose escalation will be re-started and end at the dose of 800mg QD.~Dose expansion Stage:Volitinib with docetaxel. Use the prefer dose from escalation stage"
3349187|NCT02252926|Active Comparator|Bupivacaine lozenge|The patients can take up to eight 25 mg bupivacaine lozenges (max. every second hour in the awake hours) a day for seven days. The patients can use concomitant systemic pain treatment (e.g. morphine).
3349188|NCT02252926|Other|Standard treatment|The patients will be treated with the currently used standard pain treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin). The anesthetics are being administered at the physician's discretion.
3349189|NCT02252952|Experimental|Sugar Sweetened Beverages|Any beverage from a range of caffeine free, sugar sweetened drinks. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3349190|NCT02252952|Experimental|Diet Beverage|Any beverage from a range of caffeine free drinks sweetened with non-caloric sweetener. One serving =12oz. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3241418|NCT01298791|Experimental|Provider sitting|Providers seated during communication through hospitalization
3241419|NCT01298791|Experimental|Provider standing (control)|Providers standing during communication through hospitalization
3241420|NCT01298804|Experimental|Problem Solving Education|
3241421|NCT01298804|No Intervention|Control|
3241422|NCT01298817|Experimental|Soy, Prepared Meals|Soy-based meal replacement weight loss group with additional meals provided
3349191|NCT02252952|Active Comparator|Water|12 oz of water. Two servings will be consumed daily as part of a structured, weight maintenance diet for 6 months.
3349192|NCT02252978|Experimental|Arm I (ciprofloxacin)|Patients receive ciprofloxacin PO BID for 2 weeks.
3349193|NCT02252978|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 2 weeks.
3349194|NCT02252991|Other|Arm A with physical activity during the treatment|In the arm A, patients will realise physical activity during the treatment. Blood samples will be realised. Questionnaries will be given to the patients.
3349195|NCT02252991|Other|Arm B with physical activity after the treatment|In the arm B, the physical activity will be realised after treatment. Blood samples will be realised. Questionnaries will be given to the patients.
3349196|NCT02253004|Experimental|Active|Cilostazol 200 mg single dose
3349197|NCT02253004|Placebo Comparator|Placebo|Placebo capsule
3349198|NCT02253017||Children operated on for cataract|
3349199|NCT02253030||Newly-diagnosed, untreated wet AMD|This group will be adults newly diagnosed with wet AMD who have not undergone any treatment for the condition. Their data will be gathered only once, prior to treatment.
3349200|NCT02253030||"Wet AMD undergoing as-needed treatment"|This group will be adults undergoing treatment as-needed for wet AMD. They will be followed monthly over the course of 1 year.
3349201|NCT02253030||High-risk eyes|This group will be adults with wet AMD in one eye and findings of dry AMD in the other. The eye with dry AMD will be followed every 6 months for 3 years.
3349202|NCT02253030||"Wet AMD undergoing a treat and extend strategy"|"This group will be adults with wet AMD undergoing treatment under the treat and extend strategy. (The treat and extend strategy increases the intervals between treatments as long as the macula remains dry.) They will be followed over the course of 1 year with extra imaging before extending follow-up intervals."
3349203|NCT02253043|Experimental|Deep Brain Stimulation|DBS Implant and stimulation
3349204|NCT02253056|Experimental|Fasting|Intermittent fasting over 8 weeks (one day per week)
3349205|NCT02253056|Active Comparator|Healthy diet|Regular healthy diet according to current German (DGE) guidelines for healthy nutrition.
3349206|NCT02253069|Experimental|PHMB-based antiseptic|Applying Prontosan antiseptic solution to tie-over dressings
3349207|NCT02253069|Placebo Comparator|Control|Applying water to tie-over dressings
3349208|NCT02253082|Active Comparator|OctaplasLG®|replacement to bleeding
3349209|NCT02253082|Placebo Comparator|Standard fresh frozen plasma|replacement to bleeding
3349210|NCT02253095|Experimental|Multiple Intervention Arm|single dose albendazole, two weeks of zinc, 24 weeks of multiple micronutrients
3349211|NCT02253095|Placebo Comparator|Placebo|three placebos
3349212|NCT02253108|Experimental|SYNERGY drug eluting stent|Everolimus eluting bioresorbable polymer stent
3349213|NCT02253108|Experimental|Biomatrix NeoFlex drug eluting stent|Biolimus eluting bioresorbable polymer stent
3241423|NCT01298817|Active Comparator|Non soy prepared meals|Non-soy based meal replacement weight loss group with additional meals provided
3241424|NCT01298830|Experimental|GLP-1 CellBeads|
3241425|NCT01298843|Other|Study of Blood Levels of Ceftaroline Fosamil|Study of Blood Levels of Ceftaroline Fosamil in Children Who Are Receiving Antibiotic Therapy in the Hospital
3241426|NCT01298856|Active Comparator|hydrotherapy|hydrotherapy and ankle taping and land based exercise
3349214|NCT02253121|Experimental|Dapagliflozin + sliding scale insulin.|Treatment with dapagliflozin 10mg once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
3349215|NCT02253121|Placebo Comparator|Placebo + sliding scale insulin|Treatment with placebo once daily orally. Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days). In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
3349216|NCT02253186|Experimental|Group I|Patients wear, for 90 days, the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
3349217|NCT02253186|No Intervention|Group II|Patients wear, for 30 days, only a usual custom-made compressive armsleeve during Day-time and no garment during night-time. Then, for the next 60 days, patients wear the experimental Auto-Adjustable MOBIDERM® Armsleeve during night-time and a usual custom-made compressive armsleeve during Day-time.
3349218|NCT02253199|Active Comparator|1-6 months (Group 1)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3241427|NCT01298856|Active Comparator|land-based|land-based and ankle taping program
3241428|NCT01298869||Chronic kidney disease|Chronic kidney disease stage IV and V
3349219|NCT02253199|Active Comparator|7-12 months (Group 2)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3349220|NCT02253199|Active Comparator|13-24 months (Group 3)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3349221|NCT02253199|Active Comparator|25-36 months (Group 4)|Subjects stratified into four groups according to age: 1-6 months (Group 1), 7-12 months (Group 2),13-24 months (Group 3), 26-36 months (Group 4).
3349222|NCT02253212|Experimental|SonoCloud + carboplatin|SonoCloud : dose escalation Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
3349223|NCT02253225||Bipolar Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with bipolar disorder (BPAD).
3349224|NCT02253225||Major Depressive Disorder|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 patients with major depression (MDD).
3349225|NCT02253225||Healthy Control|Clinical status will be determined using the Mini International Neuropsychiatric Interview (M.I.N.I) for 20 normal, healthy volunteers.
3241429|NCT01298882|Experimental|Diacerein|
3241430|NCT01298882|Placebo Comparator|Placebo|
3349226|NCT02253238|Other|Standard of Care Group|Surveys administered in person or by telephone interview and are audio-recorded.
3349227|NCT02253238|Experimental|CYCORE Group + Standard of Care|"Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer).~Surveys administered in person or by telephone interview and are audio-recorded."
3349228|NCT02253251||Family Registry|For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
3349229|NCT02253251||KRAS-variant BRCA negative Breast Cancer|Women with breast cancer who are BRCA negative will be tested for the KRAS-variant, to determine the associations as well as the prevalence.
3349230|NCT02253251||Double primary breast cancer|Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
3349231|NCT02253251||Autoimmunity|We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
3349232|NCT02253264|Experimental|Intrathecal rituximab|25 mg of rituximab will be administered intrathecally by direct infusion over 10 minutes at two time points, two weeks apart.
3241431|NCT01298895||PEX group|The first group consisted of 47 eyes with cataract complicated with pseudoexfoliation syndrome (PEX).
3241432|NCT01298895||control group|The control group included 177 eyes with uncomplicated cataract in eyes without other ocular pathology
3349233|NCT02253277|Experimental|Nilotinib and Ruxolitinib|The study included two strata, which were to be treated in parallel. The first stratum consisted of CML-patients in CP, which had been on nilotinib treatment before entering the study. These patients did not optimally respond to the previous treatment. The second stratum consisted of patients with CML in AP or BC and patients with relapsed/refractory Ph+ ALL and Ph+ ALL patients with MRD, with or without previous nilotinib treatment. Patients were treated with 300mg nilotinib BID during the escalation phase (12 months) with increasing doses of ruxolitinib. The dose expansion phase (12 months) began following the determination of the MTD of the combination and the decision to explore the cohort for confirmation of RPIID. In this phase, safety and tolerability of the MTD and/or potential RPIID was to be further evaluated, with the purpose of establishing that this dose is suitable for use in this patient group.
3349234|NCT02253290||Neuromuscular disease|Children and adolescents with Neuromuscular disease children according to neuromuscular convention UZL
3349235|NCT02253303|Experimental|Midline incision|The extraction-site incision in laparoscopic colectomy is middline
3349236|NCT02253303|Active Comparator|off-midline incision|The extraction-site incision in laparoscopic colectomy is off-middline
3241433|NCT01298908|Other|Operative treatment|vein stripping
3241434|NCT01298908|Other|Laser ablation|Ultrasound guided laser ablation
3241435|NCT01298908|Other|Foam sclerotherapy|Ultrasound guided foam sclerotherapy
3241436|NCT01298934|Experimental|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
3241437|NCT01298947|Active Comparator|Laser atherectomy and drug-coated balloon|Laser atherectomy and Paclitaxel-coated balloon angioplasty in treatment of instent lesions of femoropopliteal arteries
3241438|NCT01298947|Active Comparator|Drug eluting Ballon PTA|Paclitaxel-coated balloon angioplasty
3241439|NCT01298960|Experimental|rGH Group|
3241440|NCT01298960|No Intervention|Non rGH group|
3241441|NCT01298973|Experimental|Saline|One group will receive Saline to irrigate the wound
3241442|NCT01298973|Experimental|Viscoat|One group will receive Viscoat to close the surgical wound
3241443|NCT01298986|Active Comparator|Pulmonary Vein Isolation|Patients who have paroxysmal or persistent atrial fibrillation but whose left atrium is < /= 5.0
3241444|NCT01298986|Experimental|Hybrid procedure for patients with a left atrium < /= 5.0 cm|A combined procedure where the cardiac surgeon will place the ablation lesions on top of the heart and the electrophysiologist will place the lesions inside the heart. 3D mapping with be used to guide the procedure. The left atrial appendage will be surgically managed.
3241445|NCT01298986|Active Comparator|Cox Maze Procedure|All lesions of the Cox Maze procedure will be completed as originally described by Dr. James Cox using crypthermia. Patients will be randomized if there left atrium is >5.0 cm but < 6.1 cm and are experiencing paroxysmal or persistent atrial fibrillation
3259309|NCT01469663||No Major Depression, Borderline Personality Disorder|With no major depression, but with borderline personality disorder
3259310|NCT01469676|No Intervention|Control group|In the Control group, a standard arterial line filter was inserted on CPB circuit.
3349237|NCT02253329|Active Comparator|Treatment during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
3241446|NCT01298986|Experimental|Hybrid Procedure|A collaborative approach between electrophysiologist and surgeons for patients with a left atrium <5.0 cm and < 6.1 cm where the surgeon will epicardially place the ablation lesions and the electrophysiologist will place the lesion lines endocardially. 3D mapping will be used and the left atrial appendage will be surgically managed.
3241447|NCT01299051|Active Comparator|Steps to Health|Steps to Health worksite weight management program at Duke.
3349238|NCT02253329|Active Comparator|Treatment prior to sleep|Protein ingestion directly after one-legged NMES, directly prior to sleep
3349239|NCT02253342|Experimental|WCK 2349|Subjects will receive oral doses of WCK 2349 administered twice-daily for five days starting on Day 1
3349240|NCT02253355|Experimental|Deep Brain Stimulation|Stimulation is on
3349241|NCT02253355|Sham Comparator|Placebo|Stimulation is off
3349242|NCT02253368|Active Comparator|Sleep Arm 1|Sleep Arm 1
3349243|NCT02253368|Active Comparator|Sleep Arm 2|Sleep Arm 2
3349244|NCT02253381|Active Comparator|Right lateral decubitus position|Right lateral decubitus position during spinal anesthesia
3349245|NCT02253381|Active Comparator|Left lateral decubitus position|Left lateral decubitus position during spinal anesthesia
3349246|NCT02253407|Experimental|Disposable syringe jet injector|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via Disposable Syringe Jet Injector (Brand Name:Stratis) of Pharmajet Inc.
3349247|NCT02253407|Active Comparator|Needle-Syringe|Subjects in this arm will be given a single subcutaneous 0.5 mL dose of Serum Institute of India Ltd.'s MMR vaccine (Brand name: Tresivac) via conventional needle and Syringe
3349248|NCT02253420|Experimental|Copanlisib with and without concomitant Itraconazole (Arm A)|"To evaluate the effect of Itraconazole on the pharmacokinetics of Copanlisib (BAY80-6946) and safety in patients with advanced solid tumor. Cycle 1 of the study will be conducted in 2 parts: Part 1 and part 2:~Part 1 of Cycle 1: 6 patients will be enrolled and will receive 12 mg of copanlisib on Day 1 and Day 15. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Part 2 of Cycle 1: 20 patients will be enrolled and receive copanlisib doses of either 12 mg, 30 mg or 60 mg on Days 1 and 15 with the same dose administered on both days. Copanlisib dose for Part 2 will be based on safety and copanlisib pharmacokinetics in Part 1. Itraconazole 200 mg will be administered twice a day on Day 12 and then once daily from Days 13 to 21.~Cycle 2 and subsequent cycles: All patients will receive copanlisib doses of 60 mg on Days 1, 8 and 15."
3241448|NCT01299051|Experimental|Steps to Health Plus!|Steps to Health Plus! worksite weight management program at Duke. Also known as Pathways to Change.
3241449|NCT01299051|No Intervention|Observational Comparison|Observational comparison group consisting of employees who are eligible for the study but do not take part will also be used in analyses (approximately 1500 subjects).
3349249|NCT02253420|Experimental|Copanlisib with and without concomitant Rifampin (Arm B)|"To evaluate the effect of Rifampin on the pharmacokinetics of Copanlisib (BAY 80-6946) and safety in patients with advanced solid tumor or non-Hodgkin's lymphoma in Cycle 1. Approximately 30 subjects will receive 60mg of copanlisib on Cycle 1 Day 1 and Cycle 1 Day 15. Rifampin will be administered once a day from Cycle 1 Day 10 to Day 21. Holter monitoring will be performed on Cycle 1 Day -1 and Cycle 1 Day 1 to evaluate the effect of copanlisib on the QT/QTc assessment.~Cycle 2 and subsequent cycles, all patients will receive copanlisib dose of 60 mg on Days 1, 8 and 15. Holter monitoring will be performed on Cycle 3 Day 1 and Cycle 6 Day 1."
3349250|NCT02253446|Experimental|Piroksikam|20 mg of piroxicam (feldene ampoule -Pfizer-France) intramuscularly (IM) was given 200 patients,
3349251|NCT02253446|Experimental|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren drug-ampoule -Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
3349252|NCT02253459|Experimental|UTD1 Injection plus capecitabine|"UTD1 Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle; Capecitabine: 2000 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
3241450|NCT01299064||Buddhist Clergy and Laypersons|
3241451|NCT01299142|Experimental|FGI-101-1A6|Intervention: Drug-FGI-101-1A6
3241452|NCT01299142|Placebo Comparator|Placebo|Intervention: Drug-Placebo
3349253|NCT02253459|Active Comparator|capecitabine|"Capecitabine: 2500 mg/m2/day, oral bid on day 1-day 14 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
3349254|NCT02253472|Experimental|Deep Brain Stimulation|Stimulation is on.
3241453|NCT01299155|Experimental|ReSTOR +3|Bilateral implantation of a ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1
3349255|NCT02253472|Sham Comparator|Placebo|Stimulation is off.
3349256|NCT02253485||telbivudine treated entire pregnancy|mothers in this group were treated with antiviral therapy during entire pregnancy for hepatitis, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
3349257|NCT02253485||telbivudine treated in late pregnancy|mothers with high serum HBV DNA load were treated with antiviral therapy in late pregnancy, and their infants receive standard immunoprophylaxis for preventing MTCT of HBV.
3349258|NCT02253485||HBV DNA positive control|infants in this group born to mother with high serum HBV DNA load and receive standard immunoprophylaxis or additional HBIG injection at 1 month after birth for preventing MTCT of HBV.
3349259|NCT02253485||HBV DNA negative control|infants in this group born to a HBsAg positive and serum HBV DNA negative mothers and receive standard immunoprophylaxis for preventing MTCT of HBV
3349260|NCT02253498|Experimental|Deep Brain Stimulation|Deep Brain Stimulation is on
3349261|NCT02253498|Sham Comparator|Sham Stimulation|placebo
3349262|NCT02253511|Experimental|Cidan capsule|Patients who undergone operation and TACE were administered 1.35 g cidan capsules (Weida Pharmaceutical Co., Ltd., Beijing, China) three times a day for 3 months.
3349263|NCT02253511|No Intervention|Control group|Patients were only accepted operation and TACE.
3349264|NCT02253524|Active Comparator|Dimenhydrinate|50 mg Dimenhydrinate with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
3349265|NCT02253524|Active Comparator|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
3349266|NCT02253550|Experimental|Cirrhosis|Patients with confirmed presence of cirrhosis will received 12 weeks of treatment with Sofosbuvir and Simeprevir
3349267|NCT02253550|Experimental|Non-Cirrhotic|Patients with confirmed absence of cirrhosis will received 8 weeks of treatment with Sofosbuvir and Simeprevir
3349268|NCT02253563|Experimental|Resistance Training|Group performing resistance training.
3241454|NCT01299155|Active Comparator|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) Model
3349269|NCT02253563|Experimental|Balance Training|Group performing balance training.
3349270|NCT02253576|Experimental|inhaled 7% hypertonic saline|Three consecutive 4ml doses of 7% NaCl solution with salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
3349271|NCT02253576|Active Comparator|inhaled nebulized normal saline|Three consecutive 4ml doses of 0.9 NaCl solution added to salbutamol(0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) nebulized over a 1-hour period
3349272|NCT02253589|No Intervention|Waiting list|Participants will assessment only during study, same intervention after posttest
3349273|NCT02253589|Experimental|Intervention|Participants assigned to this arm will receive the modified ASSIST-linked Brief Intervention
3349274|NCT02253602|Experimental|Ferumoxytol Dose optimization|"We will assess three different dose levels of Ferumoxytol (4 mg/kg, 6 mg/kg, 8 mg/kg).~Images will be acquired at baseline (before Ferumoxytol administration), during injection of Ferumoxytol and 24, 48 and 72 hours after Ferumoxytol administration to identify the optimal moment of scanning.To assess whether USPIOs are sufficiently cleared within 12 weeks from lymph nodes, the MRI scans will be repeated in all six volunteers at 12 weeks after Ferumoxytol administration. Thus, volunteers will undergo an MRI scan for five times. Ferumoxytol is administered only once"
3349275|NCT02253602|Experimental|Before Surgery|Twenty patients will be measured directly before surgery. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, depending on the results of the dose optimization study. MR parameters will be correlated with pathology data.
3349276|NCT02253602|Experimental|Before Neoadjucant therapy|Ten patients will be measured before start of neoadjuvant chemoradiation. Patients will be measured at baseline, during injection of Ferumoxytol and 24, 48 or 72 hours after Ferumoxytol administration, based on the dose optimization study. MR parameters will be correlated with pathology data.
3241455|NCT01299168||Kidney Transplant Biopsies for Cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care to determine the cause of their graft dysfunction (deterioration in graft function, delayed graft function, proteinuria).
3241456|NCT01299181|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
3349277|NCT02253615|Active Comparator|Machine resistance training (MRT)|The machine resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
3349278|NCT02253615|Experimental|Elastic resistance training (ERT)|The elastic resistance training will consist of four exercises for lower limbs and four exercises for upper limbs which will be alternately performed with a one-minute interval between them during familiarization and training periods. Lower limb exercises will consist of: hip extension and abduction, and knee flexion and extension. Upper limb exercises will consist of: bench press, rowing, triceps and high pulley exercise.
3349279|NCT02253628|Experimental|Trial 1|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3349280|NCT02253628|Experimental|Trial 2|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3349281|NCT02253628|Experimental|Trial 3|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3349282|NCT02253628|Experimental|Trial 4|Forty healthy men and women, with normal body weight. Volunteers consumed randomly 4 coffee beverages with 160 mg caffeine (hot instant coffee, cold instant coffee, cold espresso, hot filter coffee).
3241457|NCT01299181|Placebo Comparator|Placebo|Placebo
3241458|NCT01299194|Active Comparator|ATORVASTATIN|Atorvastatin 80mg once daily for 3 months, 1.5 month wash out, then Placebo for 3 months
3241459|NCT01299194|Placebo Comparator|PLACEBO|Placebo 3 months, then washout for 1.5 months, then Atorvastatin 80mg once daily
3241460|NCT01299207||CAD treated with Xience stents|Patients with CAD who undergo successful stenting with the Xience drug-eluting stent will represent the patient population.
3241461|NCT01299233||control group|age matched healthy controls
3241462|NCT01299233||Glaucoma|patients with diagnosis of primary open angle glaucoma
3241463|NCT01299246|Experimental|improving self-care|
3241464|NCT01299259|Experimental|Text Message Reminders|Subjects randomized to the the intervention group will receive a total of 4 text messages on days 2 through 5 to remind them to schedule and attend a PCP follow-up appointment
3241465|NCT01299259|No Intervention|Control Group|The control group will not receive any additional reminders to follow-up with PCP.
3241466|NCT01299298|Experimental|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
3241467|NCT01299298|Placebo Comparator|placebo|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose
3241468|NCT01299311|No Intervention|Inactivity|4 days of inactivity, mainly sitting
3349283|NCT02253641|Active Comparator|Standard Weight Loss Intervention|"Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al. (Samuel-Hodge, Carmen D., et al. Randomized Trial of a Behavioral Weight Loss Intervention for Low?income Women: The Weight Wise Program. Obesity 17.10 (2009): 1891-1899). The only modifications to the content (other than some general formatting) will be the combining of sessions 3 and 4 and sessions 6 and 7. These changes will allow us to fit the original 16-session curriculum into the 14-session format of our intervention."
3349284|NCT02253641|Experimental|Stress-Focused Weight Loss Intervention|Participants will take part in a 14 session weight loss/healthy lifestyle intervention. Sessions will be 2 hours in length and will occur weekly for month 1 then bi-weekly for months 2 - 6. The core lifestyle curriculum content for both groups will come from the previously IRB-approved Weight Wise intervention developed by Samuel-Hodge et al.. The participants in this arm will receive all of the content that the comparison group receives (just moderately condensed to allow time for additional components) plus a stress-reduction intervention woven into each of the sessions. The stress-reduction content aims to reduce stress by helping participants: (1) identifying and reducing exposure (to the degree possible) of current stressors, (2) change their perceptions of current stressors and (3) use healthier stress-coping techniques (e.g. yoga, meditation, etc.)
3349285|NCT02253667|Experimental|HFONC|Patient will use HFONC with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
3349286|NCT02253667|Other|Conventional oxygen|Patient will use venturi or reservoir mask with FiO2 enough to achieve SpO2>90%. If needed, morphine is titrated to reduce a patient's dyspnoea score by at least one point on the Borg scale and to achieve at least level 5 or less. Initial dose: 10 mg, repeated every 4h until the desired reduction in dyspnoea is obtained. In the case of refractory dyspnoea, the dose is increased by 50%.
3349287|NCT02253680|No Intervention|Routine care|Wool and crepe bandage for 24 hours post-operatively
3349288|NCT02253680|Experimental|Compression bandage|Actico, inelastic, short-stretch compression bandage worn 24 hours post-operatively
3349289|NCT02253693||Patients with haemophilia|Adult patients with haemophilia A presenting joint disease.
3241469|NCT01299311|Active Comparator|NEAT|4 days of NEAT (everyday activities)
3241470|NCT01299311|Active Comparator|Exercise|4 days of inactivity combined with 1 hour of exercise
3241471|NCT01299324|Experimental|BMAC Infusion|Infusion of autologous bone marrow aspirate concentrated nucleated sells into the coronary sinus
3241472|NCT01299324|No Intervention|Control|Standard of care only. No infusion
3241473|NCT01299337||placebo|Subjects will be randomized either receiving T3 or placebo.
3241474|NCT01299350|No Intervention|Usual|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged according to routine clinical practice based on symptoms, physical examination and other data that the cardiologist deems appropriate, except for Nt-proBNP.
3241475|NCT01299350|Experimental|Nt-proBNP guided|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
3241476|NCT01299363|No Intervention|No dilator use|
3241477|NCT01299363|Active Comparator|Dilator use|Women randomized to vaginal dilators will be given instructions to perform softening exercises from postoperative weeks 4 to 8
3241478|NCT01299402|Experimental|Soulera Herbal Blend|
3241479|NCT01299402|Placebo Comparator|Placebo Blend|
3241480|NCT01299415|Experimental|ASA404 + Fluvoxamine|ASA404 + Fluvoxamine (Core Phase), ASA404 + either paclitaxel or docetaxel or paclitaxel plus carboplain chemotherapy combination (Extension Phase)
3241481|NCT01299428|Active Comparator|cerebral oxygenation|
3241482|NCT01299441||OLT patients intubated with ECOM ETT|Patients undergoing liver transplantation and intubated with ECOM endotracheal tube (ETT).
3241483|NCT01299467|Experimental|Dose 1 (0.5 hours)|
3241484|NCT01299467|Experimental|Dose 1 (8 hours)|
3241485|NCT01299467|Placebo Comparator|Dose 1 (placebo)|
3241486|NCT01299467|Experimental|Dose 2 (0.5 hr)|
3241487|NCT01299467|Experimental|Dose 2 (8 hours)|
3241488|NCT01299467|Placebo Comparator|Dose 2 (placebo)|
3241489|NCT01299493|Experimental|Interventional|Access to systems-level interventions to increase colorectal cancer screening.
3241490|NCT01299493|No Intervention|Usual Care|Practices will receive access to intervention components after outcomes data collection is complete.
3241491|NCT01299506||Trabectedin|The administration of chemotherapy regimen with trabectedin will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
3241492|NCT01299506||Conventional care|This includes other palliative chemotherapy or biological therapy or best supportive care.
3241493|NCT01299519|Experimental|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
3241494|NCT01299519|Active Comparator|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
3241495|NCT01299532|Experimental|Macrolane VRF30|
3241496|NCT01299545||a single group of patients -200 expected|polyarthrite rhumatoid patients
3241497|NCT01299558|Other|Treatment period 1|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder given once daily in the morning on Day 1 of Treatment period 1
3241498|NCT01299558|Other|Treatment Period 2|Single IV dose of FF (250mcg) given over 20 mins on Day 1 of Treatment period 2
3241499|NCT01299558|Other|Treatment Period 3|Single IV dose of GW642444M (55mcg) given over 60 mins on Day 1 of Treatment period 3
3349290|NCT02253706|Active Comparator|Low flow nasal oxygen supplementation|Low flow nasal oxygen supplementation as per routine standard of care(control arm)
3349291|NCT02253706|Experimental|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35
3349292|NCT02253719||HIV positive women|500 HIV women will be recruited from the hospital's current patient base as well as the community
3349293|NCT02253719||HIV negative women|500 HIV women will be recruited from the hospital's current patient base as well as the community
3349294|NCT02253732|Experimental|'3 months exercise intervention program'|all participants will be subjected to 3 months supervised exercise intervention programme
3349295|NCT02253745|Experimental|Placebo:V81444|Placebo followed by a 7 day washout then V81444
3349296|NCT02253745|Experimental|V81444:placebo|V81444 followed by a 7 day washout then Placebo
3349297|NCT02253758|Experimental|Sedation|Volunteers will be sedated to Ramsay score 4-5 with propofol, and data will be recorded during arousal
3241500|NCT01299597|Experimental|Cohort 1: Atorvastatin|single dose session with Atorvastatin with PK samples collected up to 72h post dose, then 14 days repeat dose session with SB649868 with Atorvastatin single dose co-administered on day 8 (same time as SB649868) and on day 12 (2 hours before SB649868).
3241501|NCT01299597|Experimental|Cohort 2: Simvastatin|single dose session with Simvastatin with PK samples collected up to 24h post dose, then 14 days repeat dose session with SB649868 with Simvastatin single dose co-administered on day 12 (same time as SB649868) and on day 14 (2 hours before SB649868).
3241502|NCT01299623|Active Comparator|Evidential Group|Participants in this group will receive education about breast cancer prevention and specific information about African American women and breast cancer risk.
3241503|NCT01299623|Active Comparator|Non-Evidential Group|Participants in this group will receive general information about breast cancer prevention without anything specific to African American women.
3349298|NCT02253771|Experimental|shockwave therapy|shockwave therapy
3349299|NCT02253771|Placebo Comparator|Placebo treatment|sham shockwave therapy by an identically looking device without any function
3349300|NCT02253784|Active Comparator|Group I (ISB-P)|Four nerve blocks with perineural injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
3349301|NCT02253784|Active Comparator|Group II (ISB-S)|Four nerve blocks with systemic injection of dexamethasone 0.1 mg/kg and bupivacaine 0.5% - 45 ml
3349302|NCT02253784|Active Comparator|Group III (ISB-C)|Four nerve blocks without dexamethasone
3349303|NCT02253797|Experimental|TPV/r followed by 14C-radiolabeled TPV|Tipranavir/Ritonavir dosed to steady state followed by single-dose 14C-radiolabeled tipranavir co-administered with Tipranavir/Ritonavir
3349304|NCT02253810|Experimental|Tranexamic Acid|Patients randomized to this arm will receive standard dosing of tranexamic acid intraoperatively.
3349305|NCT02253810|Placebo Comparator|Placebo|Patients randomized to this arm will receive normal saline solution, instead of tranexamic acid, intraoperatively.
3349306|NCT02253823|Experimental|TPV+RTV - low dose|
3349307|NCT02253823|Experimental|TPV+RTV - high dose|
3349308|NCT02253836|Experimental|TAZ/RTV - TPV/RTV - TPV/RTV+TAZ|"Days 1-9: single dose TAZ/RTV~Days 16-23: morning and evening dose TPV/RTV~Days 24-32: TPV/RTV + TAZ"
3349309|NCT02253849|Experimental|CBZ - TPB/r+CBZ|"Days 1-14: carbamazepine (CBZ) twice daily~Days 15-22: CBZ twice daily plus TPV/r twice daily"
3349310|NCT02253862|Experimental|Sequential treatment|
3349311|NCT02253875|Experimental|TPV + RTV + Omeprazole|
3349312|NCT02253888|Experimental|TPV/r - Room condition|
3349313|NCT02253888|Experimental|TPV/r - Refrigerated conditions|
3241504|NCT01299636|Experimental|PM060184|
3241505|NCT01299649||Non-contrast echocardiography|Non-contrast echocardiography
3241506|NCT01299649||Contrast Echocardiography|Contrast Echocardiography
3241507|NCT01299662|Experimental|Poly ICLC|One 1.6 mg subcutaneous injection of the adjuvant, poly ICLC, in the upper arm.
3349314|NCT02253901|Experimental|TRUVADA with BILR 355 BS and ritonavir|
3349315|NCT02253901|Active Comparator|BILR 355 BS in combination with ritonavir|
3349316|NCT02253914|Experimental|BILR 355 BS, solution|escalating doses
3349317|NCT02253914|Experimental|BILR 355 BS, tablet|escalating doses
3349318|NCT02253914|Placebo Comparator|Placebo|
3349319|NCT02253927|Experimental|BILR 355 (dose escalation) + Ritonavir|escalating dose groups, for food effect evaluation lowest dose group (D1) with high fat meal breakfast after wash-out period
3349320|NCT02253940|Experimental|Dose Group 1 - low dose|Treatment sequences ABC / CAB / BCA
3349321|NCT02253940|Experimental|Dose Group 2 - high dose|Treatment sequences DE / ED
3349322|NCT02253953|Experimental|D1|
3349323|NCT02253953|Experimental|D2|
3349324|NCT02253953|Experimental|D3|
3349325|NCT02253953|Experimental|D4|
3349326|NCT02253953|Experimental|D5|
3349327|NCT02253953|Experimental|D6|
3349328|NCT02253953|Experimental|D7|
3349329|NCT02253953|Experimental|D8|
3349330|NCT02253953|Experimental|D10|
3349331|NCT02253953|Placebo Comparator|Placebo|for D3 - D10
3349332|NCT02253966|Active Comparator|Methylprednisoloneacetate|"Administration of:~1 ml methylprednisoloneacetate 40 mg/ml 5 ml lidocaine 20 mg/ml 4 ml sodium chloride 9 mg/ml as a single intraarticular injection 7 days prior to surgery."
3349333|NCT02253966|Placebo Comparator|Sodium chloride|"Administration of:~5 ml lidocaine 20 mg/ml 5 ml sodium chloride 9 mg/ml as a singe intraarticular injection 7 days prior to surgery."
3349334|NCT02253979|Placebo Comparator|standard double lumen tube|Intervention: Standard double lumen tube
3349335|NCT02253979|Experimental|VivaSight double lumen tube|Intervention: VivaSight double lumen tube
3349336|NCT02254005|Experimental|single dose escalation|
3349337|NCT02254018|Experimental|bivatuzumab mertansine|single dose escalation
3349338|NCT02254031|Experimental|bivatuzumab mertansine|dose escalation
3349339|NCT02254044|Experimental|bivatuzumab mertansine|dose escalation
3349340|NCT02254057|Experimental|BIBT 986 BS - single rising dose|
3349341|NCT02254057|Placebo Comparator|Placebo|
3349342|NCT02254070|Experimental|BIBT 986 BS|
3349343|NCT02254083|Experimental|BIBT 986 BS - low|
3349344|NCT02254083|Experimental|BIBT 986 BS - high|
3241508|NCT01299675||Chronic Performance|Subjects enrolled prior to or within 30 days post implant of SureScan pacing system. In office follow-up visits required every 6 months.
3241509|NCT01299675||Multiple MRI Scan Characterization|Subject enrolled into study at the time of MRI Scan indication. Subject followed per clinic standard of care.
3241510|NCT01299701|Experimental|ASA404|
3241511|NCT01299740|Other|Control Group|Treatment as usual
3241512|NCT01299740|Experimental|Research Group|Participation in the DBT skills group
3241513|NCT01299753|Placebo Comparator|Control|
3241514|NCT01299753|Experimental|Beta blockade|
3241515|NCT01299779|Active Comparator|PEG-ELS|
3241516|NCT01299779|Active Comparator|PEG-SD|
3241517|NCT01299792||one arm; neurogenic bladder dysfunction|evaluation of the clinical utility of bladder wall thickness as a diagnostic tool in patients with spinal cord injury
3241518|NCT01299818||spinal surgery|patients who undergo spinal surgery
3241519|NCT01299831|Experimental|72 hour fast|
3241520|NCT01299831|Experimental|12 hours fast|
3241521|NCT01299831|Experimental|12 hour fast, growth hormone bolus|
3241522|NCT01299831|Experimental|72 hour fast, inhibition of lipolysis|
3241523|NCT01299844|No Intervention|Standard Care|
3241524|NCT01299844|Experimental|Diabetes Peer Counseling|
3241525|NCT01299870|Active Comparator|AED treatment plus placebo|
3241526|NCT01299870|Experimental|Keishibukuryogan|
3241527|NCT01299883|Active Comparator|Cancer and CVD Education|Participants receive education about both cancer and CVD risk factors and their relationship to dietary and physical activity health behaviors.
3241528|NCT01299883|Active Comparator|CVD Education|Participants receive education about CVD risk factors and their relationship to dietary and physical activity health behaviors.
3241529|NCT01299922|Experimental|cyclosporine+mycophenolic acid+prednison|Triple therapy
3241530|NCT01299922|Active Comparator|mycophenolic acid + prednison|Mycophenolic acid+prednison 106 weeks
3241531|NCT01299935|Experimental|Stress reduction|Stress reduction program utilizing the Transcendental Meditation (TM) technique
3241532|NCT01299935|Active Comparator|health education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
3241533|NCT01299948|Active Comparator|prednisolone|5 mg prednisolone per os daily administration
3241534|NCT01299948|Placebo Comparator|placebo|The placebo is designed to the equal look like the study medication.
3241535|NCT01299974|Other|Parents and Residents in Session|Parents and Residents in Session
3241536|NCT01299987|Experimental|Intraoperative radiotherapy|single arm with intraoperative radiotherapy
3241537|NCT01300000|Active Comparator|Human Milk|ad lib
3241538|NCT01300000|Active Comparator|Milk based standard infant formula|ad lib
3241539|NCT01300000|Experimental|Milk based investigational infant formula|ad lib
3241540|NCT01300013|Experimental|Omecamtiv mecarbil|
3241541|NCT01300013|Placebo Comparator|Placebo|
3241542|NCT01300026|Experimental|Part II Dose Expansion|Dose selected from Part I dose exploration
3241543|NCT01300026|Experimental|Part I Dose Exploration|The AMG 319 doses proposed for this study are 25, 50, 100, 200, 300 and 400 mg administered by mouth once daily.
3241544|NCT01300039||Antibiotics for H. pylori|Patients who underwent upper endoscopy and were found to have H. pylori, and were then to be treated with antibiotics for eradication of H. pylori
3241545|NCT01300039||Control group, no H. pylori|Patients who underwent upper endoscopy and found to not have H. pylori, and then would not receive antibiotics
3241546|NCT01300078|Experimental|MF101 10 grams/day|
3241547|NCT01300078|Experimental|MF101 15 grams/day|
3241548|NCT01300104|Experimental|Exercise and whole grain rye|
3241549|NCT01300104|Active Comparator|No prescriptions|
3241550|NCT01300117||with extracorporeal circulation|Patients undergoing cardiac surgery with the use of an extracorporeal circulation
3241551|NCT01300117||without extracorporeal circulation|Patients undergoing cardiac surgery without the use of extracorporeal circulation (OPCAB)
3241552|NCT01300130|Experimental|low docosahexaenoic acid formula|
3241553|NCT01300130|Experimental|medium docosahexaenoic acid formula|
3241554|NCT01300130|Experimental|high docosahexaenoic acid formula|
3241555|NCT01300130|Active Comparator|human milk|
3241558|NCT01300156|Experimental|ESHAOx arm|Patients who are planned to be treated with ESHAOx chemotherapy
3241559|NCT01300169|Experimental|CAMS--Collaborative Driver-Treatment|"The Collaborative Assessment and Management of Suicidality (CAMS) is a suicide-specific clinical intervention that targets and treats patient-defined suicidal drivers over the course of clinical care."
3241560|NCT01300169|Active Comparator|Enhanced Care as Usual--E-CAU|This control group treatment will reflect current clinical practices for treating suicidal soldiers in the research site setting. These are providers were on site clinicians who provided care according to their usual and customary practices for working with suicidal risk within outpatient care.
3241561|NCT01300182|Experimental|Whole body vibration therapy|Whole body vibration therapy on top of conventional physiotherapy treatment.
3349345|NCT02254083|Placebo Comparator|Placebo|
3349346|NCT02254096|Experimental|BIRT 1696 BS|single escalating dose phase
3349347|NCT02254096|Experimental|BIRT 1696 BS + GFJ|single dose grapefruit effect arm
3349348|NCT02254096|Experimental|BIRT 1696 BS + HFM|single dose food effect arm
3241562|NCT01300182|Active Comparator|Control|Conventional post-operative physical therapy rehabilitation exercises.
3349349|NCT02254096|Placebo Comparator|Placebo|
3349350|NCT02254109|Experimental|BEA 2180 BR - rising dose|
3349351|NCT02254109|Placebo Comparator|Placebo|
3349352|NCT02254122|Experimental|BEA 2180 BR|
3349353|NCT02254122|Placebo Comparator|Placebo|
3349354|NCT02254135|Experimental|BEA 2180 BR solution - rising dose|
3241563|NCT01300195||lung cancer surgery|Patients undergoing video-assisted thoracic surgery
3349355|NCT02254135|Placebo Comparator|Placebo|
3349356|NCT02254148|Experimental|Treatment|single dose of CYP 450 substrates and a P-gp substrate + multiple doses of BI 187004
3349357|NCT02254161|Experimental|BI 1181181 healthy young|Medium doses as tablets q.d. for 10 days
3349358|NCT02254161|Experimental|BI 1181181 healthy elderly|Medium doses as tablets q.d. for 10 days
3349359|NCT02254161|Placebo Comparator|Matching placebo in healthy young|Matching placebo for 10 days
3349360|NCT02254161|Placebo Comparator|Matching placebo in healthy elderly|Matching placebo for 10 days
3349361|NCT02254174|Experimental|Tiotropium/Salmeterol|
3349362|NCT02254174|Active Comparator|Serevent® Diskus®|
3349363|NCT02254174|Active Comparator|Spiriva®|
3349364|NCT02254174|Active Comparator|Spiriva® and Serevent® Diskus®|
3349365|NCT02254187|Experimental|Salmeterol capsule via Handihaler - low|
3349366|NCT02254187|Experimental|Salmeterol capsule via Handihaler - high|
3349367|NCT02254187|Active Comparator|Salmeterol via Serevent® Diskus®|
3349368|NCT02254200|Experimental|Fatmax group|Group who performed a continuous training program at the intensity eliciting the maximal fat oxidation
3349369|NCT02254200|Experimental|HIIT group|Group who performed a continuous training program with high intensity interval
3241564|NCT01300208|Experimental|Cohort 1|CC-11050 (50 milligrams twice per day and Placebo)
3241565|NCT01300208|Experimental|Cohort 2|CC-11050 (100 milligrams twice per day and Placebo)
3241566|NCT01300208|Experimental|Cohort 3|CC-11050 (200 milligrams twice per day and Placebo)
3241567|NCT01300221||Group 1|Subjects who are healthy normal children.
3241568|NCT01300221||Group 2|Subjects who have congenital heart disease.
3241569|NCT01300221||Group 3|Subjects who have sickle cell disease
3349370|NCT02254226|Experimental|Salmeterol MDI low|
3349371|NCT02254226|Active Comparator|Salmeterol MDI high|
3241570|NCT01300221||Group 4|Subjects who have Duchenne muscular dystrophy
3241571|NCT01300221||Group 5|Patients who have Marfan syndrome and other aortic disease
3349372|NCT02254226|Experimental|Salmeterol Diskus low|
3349373|NCT02254226|Experimental|Salmeterol Diskus high|
3241572|NCT01300273|Experimental|Ketosteril|
3349374|NCT02254239|Experimental|Treatment (everolimus, brentuximab vedotin)|"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or QOD on days 1-21. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity. Patients then receive brentuximab vedotin IV over 30 minutes on day 1 and everolimus PO QD or every other day on days 1-84 for 1 course.~MAINTENANCE THERAPY: Beginning on course 17, patients receive everolimus PO QD, QOD, twice weekly, or thrice weekly on days 1-84. Courses repeat every 84 days in the absence of disease progression and unacceptable toxicity."
3349375|NCT02254317|Placebo Comparator|0 mg placebo|Not containing GSE (Placebo)
3241573|NCT01300299|Experimental|All subjects|Subjects will receive chemotherapy after stereotactic body radiation therapy.
3241574|NCT01300312|Experimental|1|
3241575|NCT01300312|Active Comparator|2|
3241576|NCT01300325|Placebo Comparator|0.9% saline|patients receive every 6 hours the nebulized 0.9% saline (placebo comparator) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
3241577|NCT01300325|No Intervention|3% hypertonic saline|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
3241578|NCT01300364|Placebo Comparator|sugar pill|
3241579|NCT01300364|Active Comparator|reboxetine (NRI)|
3241580|NCT01300364|Active Comparator|citalopram (SSRI)|
3241581|NCT01300377|Active Comparator|Bupivacaine / Lidocaine|Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
3241582|NCT01300377|Active Comparator|Lidocaine|Lidocaine - 10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
3241583|NCT01300390||End-stage liver disease pre-transplant|Patients with end-stage liver disease (non-fulminant) awaiting liver transplant
3349376|NCT02254317|Active Comparator|300 mg GSE|Containing 300 mg of GSE
3349377|NCT02254317|Active Comparator|600 mg GSE|Containing 600 mg of GSE
3349378|NCT02254317|Active Comparator|900 mg GSE|Containing 900 mg of GSE
3349379|NCT02254343|Experimental|proximal robot-assisted therapy|treatment programs will target to shoulder and elbow portions of upper extremity via the InMotion2 robotic system
3349380|NCT02254343|Experimental|distal robot-assisted therapy|the InMotion3 robot system will be used to execute treatment programs focus on wrist movements. It includes three degrees of freedom to allow wrist flexion/extension, abduction/adduction, and pronation/supination.
3349381|NCT02254343|Active Comparator|individualized intensive therapy|individualized occupational therapy which is dose-match to robot-assisted therapy, based on task-oriented principle.
3349382|NCT02254356|Experimental|Zilver|
3349383|NCT02254369|Experimental|Cohort 1- GC021109|single dose, 0.0014 mg/kg GC021109
3349384|NCT02254369|Experimental|Cohort 2- GC021109|single dose, 0.014 mg/kg GC021109
3349385|NCT02254369|Experimental|Cohort 3-GC021109|single dose, 0.14 mg/kg GC021109
3349386|NCT02254369|Experimental|Cohort 4- GC021109|single dose, 1.4 mg/kg GC021109 subjects will receive GC021109 under fasting then under fed conditions separated by a washout of 14 (± 1) days after the first dose.
3349387|NCT02254369|Experimental|Cohort 5- GC021109|single dose, 4.2 mg/kg GC021109
3349388|NCT02254369|Placebo Comparator|Cohort 1- placebo|single dose, 0.0014 mg/kg matching placebo
3349389|NCT02254369|Placebo Comparator|Cohort 2- placebo|single dose, 0.014 mg/kg matching placebo
3349390|NCT02254369|Placebo Comparator|Cohort 3- placebo|single dose, 0.14 mg/kg matching placebo
3349391|NCT02254369|Placebo Comparator|Cohort 4- placebo|single dose, 1.4 mg/kg subjects will receive matching placebo under fasting then under fed conditions separated by a washout of 14 (+/- 1) days after the first dose.
3349392|NCT02254369|Placebo Comparator|Cohort 5- placebo|single dose, 4.2 mg/kg matching placebo
3349393|NCT02254382|Experimental|Adaptive servo ventilation (ASV)|This group will receive ventilation therapy (AutoSet CS, ASV device)
3349394|NCT02254395|Experimental|Deep Brain Stimulation|Stimulation is on.
3349395|NCT02254395|Sham Comparator|Placebo|Sham Stimulation: Stimulation is off.
3349396|NCT02254434|Experimental|Eltrombopag 50 mg|Each volunteer will receive orally, single dose of tablet eltrombopag 50 mg under fasting conditions
3241584|NCT01300403|Experimental|FLUTTER|Since this was a crossover study, all patients performed all interventions in a randomized order.
3241585|NCT01300403|Experimental|ELTGOL|Since this was a crossover study, all patients performed all interventions in a randomized order.
3241586|NCT01300403|Active Comparator|CONTROL|Since this was a crossover study, all patients performed all interventions in a randomized order.
3241587|NCT01300416||With Gastro-Intestinal (GI) symptoms|
3349397|NCT02254447|Experimental|Sequence ABC|Subjects in this arm will receive single dose of treatment A in period 1, treatment B in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3349398|NCT02254447|Experimental|Sequence ACB|Subjects in this arm will receive single dose of treatment A in period 1, treatment C in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3349399|NCT02254447|Experimental|Sequence BAC|Subjects in this arm will receive single dose of treatment B in period 1, treatment A in period 2 and treatment C in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3349400|NCT02254447|Experimental|Sequence BCA|Subjects in this arm will receive single dose of treatment B in period 1, treatment C in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3349401|NCT02254447|Experimental|Sequence CAB|Subjects in this arm will receive single dose of treatment C in period 1, treatment A in period 2 and treatment B in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3349402|NCT02254447|Experimental|Sequence CBA|Subjects in this arm will receive single dose of treatment C in period 1, treatment B in period 2 and treatment A in period 3 (one treatment per period), where treatment A= ATACAND as a reference treatment containing Candesartan cilexetil 16 mg, treatment B= Test formulation 1 containing Candesartan cilexetil 16 mg, and treatment C= Test formulation 2 containing Candesartan cilexetil 16 mg.
3241588|NCT01300416||Without GI symptoms|
3349403|NCT02254525|Experimental|800 mg intravenous ibuprofen|Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours, infused over 15 minutes.
3349404|NCT02254525|Placebo Comparator|200 ml of saline solution|Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours, infused over 15 min.
3349405|NCT02254538|Experimental|BILR 355 BS|escalating doses
3349406|NCT02254538|Placebo Comparator|Placebo|
3349407|NCT02254564||Positive Scrapings|Skin scrapings that are positive for scabies
3349408|NCT02254564||Negative Controls|collect negative controls from patients in whom tinea (superficial fungal infection) was clinically suspected. Samples from patients with demodex folliculitis (a mite that is commonly found in oil glands on the face) are also intended to be used as negative controls as well.
3349409|NCT02254577|Experimental|Endometrin® plus Progesterone in Oil (PIO)|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the Endometrin® plus PIO arm will take progesterone as 2 100mg tablets of Endometrin® inserted vaginally twice daily. In addition, on the first day of Endometrin® therapy, patients randomized to this arm will take a 50mg intramuscular injection (1mL) of PIO and will repeat this injection every third day. Patients in this arm will undergo Frozen Embryo Transfer on the fifth day of Endometrin® therapy.
3375948|NCT03365635|Experimental|Genotype 1a -Rx naive -no NS5A polymorph|Genotype 1a - treatment naive without NS5A polymorphism - Drug Intervention : Oral administration Elbasvir (50mg)/Grazoprevir (100mg) one tablet per day for 12 weeks
3241589|NCT01300429||patients with Non Small Cell Lung cancer|This is a protocol to obtain and/or analyze tissue specimens of patients with NSCLC harboring an activating ALK inversion or translocation that have had a previous clinical response to tyrosine kinase inhibitor therapy and subsequently experience progressive disease. The tissue will be used to identify changes in the ALK gene that are acquired during treatment with an ALK TKI and may account for acquired resistance.
3241590|NCT01300442|Experimental|Control|The transcutaneous electrical diaphragmatic stimulation will be applied in healthy and COPD subjects.
3241591|NCT01300442|Experimental|Chronic Obstructive Pulmonary Disease|The intervention will be the TEDS in patients with Chronic Obstructive Pulmonary Disease (COPD)
3241592|NCT01300468|Experimental|Dose-escalation|
3241593|NCT01300520|No Intervention|Target Tape|Including target tape in the procedure
3241594|NCT01300520|Other|Control|Without target tape in the procedure
3241595|NCT01300585|Other|MRI|All patients on study will undergo an MRI of the breast(s).
3349410|NCT02254577|Active Comparator|Progesterone in Oil (PIO) Alone|Subjects in all arms will undergo the standard monitoring appointments and therapies involved in a frozen embryo transfer cycle. Patients randomized to the PIO Only arm will take progesterone as a daily 50mg intramuscular injection (1mL) of PIO and will undergo Frozen Embryo Transfer on the sixth day of taking this medication.
3349411|NCT02254590|Experimental|IEDL|Endoscopic decompression of spinal stenosis
3349412|NCT02254603|Other|Acupuncture controls|Acupuncture group will receive 30-minutes treatment three times a week for 3 months.
3349413|NCT02254603|Experimental|acupuncture and yoga exercise|Subject will receive a combination of acupuncture and yoga exercise three times a week for 3 months.
3349414|NCT02254616|Experimental|Mirror therapy with tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
3349415|NCT02254616|Active Comparator|Mirror Therapy|The MT only group will receive a 60-minute MT per session followed by a 30-minute functional training. Participant will go through the same protocol as that for the MT+tDCS and MT+sham tDCS groups with no tDCS presented in setting. This group is for evaluating placebo effect of the present of tDCS application.
3349416|NCT02254616|Active Comparator|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training. During the 60-mimute conventional training, interventions will include passive range of movement and muscle tone normalization techniques of the affected arm, and gross motor training (e.g., shoulder ladder activity), fine motor training (e.g., grasping cones), and muscle strength training in a unilateral and bilateral manners. During the 30-minute functional training, the same principles to those in the MT groups will be applied.
3241596|NCT01300611|Experimental|TXA127 300 mcg/kg/day|Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
3241597|NCT01300611|Experimental|TXA127 1000 mcg/kg/day|Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
3349417|NCT02254616|Active Comparator|Mirror Therapy with sham-tDCS|Functional training will consist of unilateral and bilateral functional tasks in daily living, and last for 30 minutes. Some examples are mopping the table by using the affected hand or scooping beans from a bowl with one hand while the other hand stabilizes the bowl. The principles of part-task practice and whole-task practice will be applied based on the participant's performance level.
3349418|NCT02254629|Experimental|laxative-probiotic sequential|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks，immediately after colonoscopy
3349419|NCT02254629|Active Comparator|probiotic|Probiotic：2 tablets/ times, 3 times / day for the first 2 weeks.
3349420|NCT02254629|Active Comparator|Laxative followed by Probiotic 2 weeks later|laxative：2000 ml. Probiotic：2 tablets/ times, 3 times / day for the last 2 weeks with two weeks interval after colonoscopy.
3349421|NCT02254642|Experimental|Ischemic preconditioning arm|Patients will have the ischemic preconditioning protocol 1 hour before the aortic clamping.
3349422|NCT02254642|Other|Control patients|Usual surgery assigned to control patients
3241598|NCT01300637|Active Comparator|metformin|metformin intervention group
3349423|NCT02254655|Experimental|Puerarin injection 400 mg|Patients were administrated with 400 mg intravenously infused puerarin injection once a day. Puerarin injection was prepared in 250 mL 0.9% sodium chloride injection before the use. The treatment course consisted of 2 weeks followed by a 15-day interval for 24 weeks. Furthermore, patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3349424|NCT02254655|Sham Comparator|Control|Patients receive routine anti-rheumatic care only. Patients receive stable treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.
3241599|NCT01300637|Placebo Comparator|placebo|placebo-controlled
3349425|NCT02254668|Experimental|Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
3349426|NCT02254668|Active Comparator|Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)
3349427|NCT02254694|Experimental|high heeled shoes|see detailed description
3349428|NCT02254707|Experimental|BILB 1941 ZW|Escalating Doses
3349429|NCT02254707|Placebo Comparator|Placebo|
3349430|NCT02254720|Experimental|BEA 2180 BR IV|Rising doses
3349431|NCT02254720|Placebo Comparator|Placebo|
3349432|NCT02254720|Experimental|BEA 2180 BR inhalation|
3349433|NCT02254733|Experimental|ACT + CBSST|Implementing Cognitive Behavioral Social Skills Training in an Assertive Community Treatment model
3349434|NCT02254733|Active Comparator|ACT only|Assertive Community Treatment only
3375949|NCT03365635|Experimental|Genotype 1a, Rx naive + NS5A polymorph|Genotype 1a - treatment naiive with NS5A polymorphism - Oral administration of Elbasvir/Grazoprevir one tablet daily and ribavirin (200 mg) daily for 16 weeks weeks
3375950|NCT03365635|Experimental|Genotype 1b - Rx naive|Genotype 1b-treatment naive - Oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
3241600|NCT01300663||post-surgery symptom experience|women with vulvar intraephitelial neoplasia or vulvar cancer
3241601|NCT01300676|Active Comparator|Tualang Honey|Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
3241602|NCT01300676|No Intervention|Group 2|Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia.
3241603|NCT01300702||lung cancer surgery|Patients undergoing thoracotomy for lung cancer
3241604|NCT01300715|Active Comparator|MBRF|
3349435|NCT02254746|Experimental|Phase I (dose escalation)/ Phase II|"Phase I~Prostate tumor: starting dose 9 Gy per fraction in 5 fractions (total 45 Gy) and subsequent dose escalation up to 10 Gy.~Prostate gland: fixed prophylactic tumoricidal dose 7.25 Gy per fraction in 5 fractions (no dose escalation). Total 36.25 Gy.~Phase II~Additional patients will be treated at either the maximum tolerated dose (MTD) or at the highest dose level as determined by the investigators from the Phase I portion of the study."
3349436|NCT02254759|Other|IV Midazolam Alone|A single 1 milligram (mg) dose of IV Midazolam on Day 1.
3349437|NCT02254759|Other|Oral Midazolam Alone|A single 5 mg oral dose of midazolam on Day 2.
3349438|NCT02254759|Experimental|RO5186582 Alone|RO5186582 240 mg oral tablet twice daily (BID) for 14 days from Days 3 to 16.
3349439|NCT02254759|Experimental|RO5186582 Plus IV Midazolam|RO5186582 240 mg BID oral tablet in combination with a single 1 mg IV dose of midazolam on Day 17.
3349440|NCT02254759|Experimental|RO5186582 Plus Oral Midazolam|RO5186582 240 mg BID in combination with a single 5 mg oral dose of midazolam on Day 18.
3349441|NCT02254785|Experimental|Cabazitaxel|
3349442|NCT02254785|Active Comparator|Abiraterone or enzalutamide|
3349443|NCT02254798||Transplanted patients|No intervention Prospective registration of patients receiving an allogeneic hematopoietic stem cell transplant
3349444|NCT02254811|Experimental|Delivery via capsule|Fecal microbiota transplant is delivered by oral capsules
3349445|NCT02254811|Experimental|Delivery via colonoscopy|Fecal microbiota transplant delivered by colonoscopy
3349446|NCT02254824|Active Comparator|Normal-dose statin|Lifestyle modification with Normal-dose statin
3349447|NCT02254824|Active Comparator|Lifestyle modification + Xuezhikang|Lifestyle changes with Xuezhikang
3241605|NCT01300754|Active Comparator|Dextrose|
3349448|NCT02254824|Active Comparator|Lifestyle modification|Lifestyle modification
3349449|NCT02254837|Experimental|Zilver PTX|
3349450|NCT02254850|Experimental|Mesoglycan|"The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml and inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg and Inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
3241606|NCT01300754|Active Comparator|Lidocaine|
3241607|NCT01300754|Active Comparator|Usual Care|
3241608|NCT01300780|Active Comparator|Experimental|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
3241609|NCT01300780|Placebo Comparator|placebo group|The participants from the placebo group received a placebo (Talco pharma SM-200-Henrifarma produtos químicos e farmacêuticos LTDA, São Paulo, SP, Brazil) and participants from the etoricoxib group received a dose of a selective COX- 2 inhibitor etoricoxib 60 mg (Arcoxia, MSD, Campinas, SP, Brazil). All the participants were watched to ensure that they took the drugs or placebo 1 h before treatment. The drugs were similar in appearance. A second dose of placebo or etoricoxib (60 mg) was administered 24 h after the first dose. At the time the participants were required to take the second dose of the medicine, the research auxiliary called him/her and asked him/her to take the medicine.
3241610|NCT01300806||myHERO SBIRT|
3349451|NCT02254850|Placebo Comparator|Placebo|"The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.~Nextly the patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.~Patients also performed Flow Mediated Dilation (FMD)."
3241611|NCT01300806||clinician administered SBIRT|
3241612|NCT01300832|Experimental|Duplex scan|Subjects undergo preoperative and post-operative duplex scanning of the lower extremities
3241613|NCT01300845|Active Comparator|Humidification|
3241614|NCT01300845|Experimental|No Humidification|
3241615|NCT01300858|Experimental|EGEN-001|
3241616|NCT01300871||Postmenopausal Women on Endocrine Therapy|Postmenopausal women with Breast Cancer that undergo Endocrine Therapy.
3241617|NCT01300884||healthy volunteers|
3241618|NCT01300884||patients with fecal incontinence|
3241619|NCT01300884||patients with constipation|
3241620|NCT01300897||Healthy Volunteer|healthy volunteers will serve as controls. In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potentials will be measured.
3259311|NCT01469676|Experimental|Filtering Group|In the Filtering group, a leukocyte filter was inserted in the arterial line circuit.
3241621|NCT01300897||Constipated patients|Patients with chronic constipation and rectal hypersensitivity or hyposensitivity and/or dyssynergic defecation.In each subject the cortical evoked potentials, transcranial motor evoked potentials and translumbosacral motor evoked potential will be measured
3349453|NCT02254876|Active Comparator|Standard physical therapy program|Standard physical therapy program is delivered for four rehabilitation sessions for a period of about 45 minutes each.
3349454|NCT02254876|Experimental|NeuroMuscular Taping (NMT)|"NeuroMuscular Taping is delivered in addiction to the Standard Treatment for four rehabilitation sessions. The sessions were spaced apart about five days to ensure the optimum adhesion of the NMT."
3241622|NCT01300910|Active Comparator|1|One group of men will undergo a circumcision using the Shang Ring and men are to return for regular follow-up visits to evaluate pain and wound healing. . The Shang Ring will be removed at 7 days, and the last scheduled follow-up visit is at 60 days.
3349455|NCT02254889|Active Comparator|pre-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) before ESD.
3349456|NCT02254889|Placebo Comparator|post-ESD group|All subjects were randomly assigned to treatment with intravenous proton pump inhibitor (PPI) after ESD.
3349457|NCT02254902|Experimental|Physical Activity|Participants in the Physical Activity intervention arm of the study receive culturally-modified, materials through participation in 12 weekly 1-.5-hour sessions focused on increasing daily step counts and bouts of moderate intensity physical activity. The group sessions include participation in different forms of physical activity as well as group discussions on the barriers and opportunities for increasing physical activity in daily life.
3349458|NCT02254902|No Intervention|Wait List Control|Participants in the Wait List Control will be offered the program after a 3-month wait period. While waiting for the program, participants are offered to attend monthly sessions on various wellness and prevention topics.
3349459|NCT02254915|Experimental|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy (SHTC) with mitomycin C (RITE) intravesical therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
3349460|NCT02254915|Active Comparator|Bacillus Calmette-Guérin|Intravesical BCG therapy as first-line adjuvant treatment for intermediate and high-risk NMIBC,
3349461|NCT02254928|Other|Group 1|First stimulation cycle with corifollitropin alfa (experimental) Second stimulation cycle with rFSH and HMG (active comparator)
3349462|NCT02254928|Other|Group 2|First stimulation cycle with rFSH and HMG (active comparator) Second stimulation cycle with corifollitropin alfa (experimental)
3349463|NCT02254941||Active comparator: Chemotherapy|Metastatic colon cancer and first line treatment with conventional chemotherapy without monoclonal antibody.
3349464|NCT02254941||Experimental: Chemotherapy plus mAb|Metastatic colon cancer and first line treatment with conventional chemotherapy plus monoclonal antibody
3349465|NCT02254954|Experimental|Macitentan in combination with RT & TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
3349466|NCT02254967|Experimental|Fidaxomicin Extended Pulsed Regimen (EPFX)|Participants receive 200 mg fidaxomicin from day 1 to day 5 twice daily, followed by a 1-day gap (day 6) before starting alternate day dosing of 1 tablet of fidaxomicin 200 mg once daily from day 7 to day 25.
3349467|NCT02254967|Experimental|Vancomycin|Participants receive 125 mg vancomycin from day 1 to day 10, 4 times daily.
3349468|NCT02254980|Experimental|Vitamin-E group|Vitamin-E diffused polyethylene
3349469|NCT02254980|Active Comparator|Control group|Standard polyethylene
3349470|NCT02254993|Experimental|Arm 1- Part A|One 30-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
3349471|NCT02254993|Experimental|Arm 2 - Part A|One 4-hour C16G2 tray gel application (3.2 mg/mL) over the course of five days
3349472|NCT02254993|Experimental|Arm 3- Part A|A single 4-hour C16G2 tray gel application (3.2 mg/mL)
3349473|NCT02254993|Experimental|Arm 4- Part A|One 4-hour C16G2 tray gel application (1.6 mg/mL) over the course of five days
3349474|NCT02254993|Experimental|Arm 5- Part A|One 30-minute C16G2 tray gel application (1.6 mg/mL) over the course of five days
3349475|NCT02254993|Experimental|Arm 6- Part A|One 5-minute C16G2 tray gel application (3.2 mg/mL) over the course of five days
3349476|NCT02254993|Experimental|Arm 1 - Part B|Four manual brush gel applications on Day 0 followed by twice daily manual brush gel applications (Days 1 through 6); total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
3349477|NCT02254993|Experimental|Arm 2 - Part B|Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
3241623|NCT01300910|Active Comparator|2|One group of men will undergo a conventional circumcision using a WHO recommended surgical technique, either the forceps-guided method or the dorsal slit method. Men are to return for regular follow-up visits to evaluate pain and wound healing, with the last scheduled follow-up visit at 60 days.
3241624|NCT01300936||patients with abdominal wall hernias|
3241625|NCT01300962|Experimental|BYL719 ARM B|Treatment with BYL719 and Capecitabine
3241626|NCT01300962|Experimental|BKM120 ARM A|Treatment with BKM120 and capecitabine
3241627|NCT01300962|Experimental|ARM C|BKM 120 plus capecitabine plus trastuzumab
3241628|NCT01300962|Experimental|ARM D|BKM120 plus capecitabine plus lapatinib
3241629|NCT01300975|Experimental|Intralesional antimony|3 intralesional injections of antimony at D1, D3 and D7
3375951|NCT03365635|Experimental|Genotype 1a/1b -prior INF or NS3/4A|Genotype 1a or 1b - prior treatment with INF or HCV NS3/4A protease inhibitor - oral administration of Elbasvir/Grazoprevir and ribavirin each once daily for 12 weeks
3241630|NCT01300975|Active Comparator|Cryotherapy|Liquid nitrogen until freezing at DF1 and D14
3241631|NCT01300975|Placebo Comparator|Topical cream|topical treatment 3 times a day during 21 days with an emollient cream
3241632|NCT01300988|Active Comparator|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
3375952|NCT03365635|Experimental|Genotype4 - treatment naive|(e) Genotype 4 - treatment naive - oral administration of Elbasvir/Grazoprevir one daily for 12 weeks
3375953|NCT03365635|Experimental|Genotype 4- prior treatment|Genotype 4 -prior treatment - oral administration of Elbasvir/Grazoprevir and ribavirin each once per day for 16 weeks
3349478|NCT02254993|Experimental|Arm 3a or 3b or 3c - Part B|"Based on the microbiology review, one of 3 study arms will be conducted:~Arm 3a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL~Arm 3c: Three daily manual brush and/or tray gel applications for 7 days, lower C16G2 concentration of 1.6 mg/mL"
3349479|NCT02254993|Experimental|Arm 4a or 4b - Part B|"Based on the microbiology review, one of 2 study arms will be conducted:~Arm 4a: Four manual brush gel applications on Day 0 followed by twice daily manual brush applications (Days 1 through 6); total of 7-day study drug administration, C16G2 concentration of 1.6 mg/mL and lower gel volume~Arm 4b: Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, lower C16G2 concentration of 1.6 mg/mL and lower gel volume"
3349480|NCT02254993|Experimental|Arm 5 - Part B|Arm 5: Three manual brush gel applications followed by one tray gel application on Day 0, 3.2 mg/mL C16G2 gel concentration.
3349481|NCT02255006|Experimental|active acupuncture|The participants in this group receive real acupuncture treatment at first. Afterwards crossover study is scheduled to be performed.
3349482|NCT02255006|Sham Comparator|Sham acupuncture|The participants in this group receive sham acupuncture treatment at first. afterwards crossover study is scheduled to be performed
3349483|NCT02255006|Experimental|Euglycon|Glibenclamide (Euglucon, Roche Pharma) is administered 3 hours before FMD measurement.
3349484|NCT02255006|Experimental|Celebrex|Celebrex(celecoxib, pfizer) 200mg twice daily is administered for 5 days before FMD measurement.
3349485|NCT02255019||IBD, CD, UC|All patients should either have a known IBD diagnose or suspect of having IBD.
3349486|NCT02255045|Experimental|Dose 1 of meloxicam in vaginal ring|2.4 g of meloxicam in a vaginal ring
3349487|NCT02255045|Experimental|Dose 2 of meloxicam in vaginal ring|3.0 g of meloxicam in a vaginal ring
3349488|NCT02255045|Active Comparator|Oral non-steroidal anti-inflammatory drug|Diclofenac potassium
3349489|NCT02255045|Placebo Comparator|Placebo vaginal ring and oral pill|Placebo vaginal ring and placebo oral pill
3349490|NCT02255071|Experimental|Acupressure|Patients will band a acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
3349491|NCT02255071|Sham Comparator|Sham-Acupressure|Patients will band a sham wristband over wrist but no acupressure for seven days.
3349492|NCT02255084|Experimental|Group 1|"Group 1 remove self sample kit at gp consulting room or perform pap smear :~Study coordinators send mail inviting women to remove a kit for vaginal self-sampling at their general practitioner s consulting room.~Either a pap smear is perform or, at home, women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
3349493|NCT02255084|Experimental|Group 2|"Group 2 perform self sample at home or pap smear :~Kit for vaginal self-sampling sent at women home. Women perform vaginal self sampling. Then women send it to a central laboratory for HPV test (Human papillomaVirus)."
3349494|NCT02255136|Experimental|Individualized homeopathic medicines|Psorinum, Tuberculinum, Medorrhinum, Calcarea carbonica, Natrum sulphuricum etc. as indicated; Rescue medicines, e.g. Aralea racemosa, Arsenicum album, Histamine hydrochloride, House dust, Ipecacuanha, Antimonium tartaricum, Grindelia robusta etc. as indicated; 5 ml dose of indicated homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; administered twice daily for 1 year
3349495|NCT02255136|Placebo Comparator|Intervention placebo|5 ml dose made up of single drop of rectified spirit in 5 ml distilled water, identical in appearance of homeopathic medicine, to be administered twice daily for 1 year
3349496|NCT02255162|Experimental|Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Participants will receive the following:~Cytarabine-intravenous, fixed dosage, given 5 times during cycle~HLA-mismatched stem-cell microtransplantation~Lenalidomide-administered daily per cycle"
3349497|NCT02255188||Graft type - PCL|PCL - polycaprolactone
3349498|NCT02255188||Graft type - PCL/ gelatin|polycaprolactone/ gelatin/poorly permeable layer;
3349499|NCT02255188||Graft type - PLGA/PCL/gelatin|PLGA/PCL/gelatin - polylactide-co-glycolide / polycaprolactone / gelatin/poorly permeable layer
3349500|NCT02255188||Graft type - nylon 6|
3349501|NCT02255201|Active Comparator|Beverage A|Single dose, Pre-Workout Master Performance Blend Dose 1
3349502|NCT02255201|Active Comparator|Beverage B|Single dose, Pre-Workout Master Performance Blend Dose 2
3349503|NCT02255201|Active Comparator|Beverage C|Single dose, Pre-Workout Performance Energy Blend
3241633|NCT01300988|Placebo Comparator|Placebo|Aprepitant (Emend®) placebo for 14 days
3241634|NCT01301040|Active Comparator|Epirubicin/Cyclophosphamide|Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles
3241635|NCT01301040|Active Comparator|docetaxel/cyclophosphamide|Treatment Arm 2: TC - docetaxel (Taxotere) (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
3241636|NCT01301053|Other|Current UVA intensive care insulin protocol without brakes|Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days and uses the current UVA intensive care insulin for insulin management for 12 hours.
3241637|NCT01301053|Active Comparator|Current UVA intensive care insulin protocol with brakes|"Studies the safety and feasibility of the continuous glucose monitor in 10 critically ill patients for 7 days. Uses the current UVA intensive care insulin protocol for insulin management for 12 hours with the addition of brakes that reduce insulin administration based on continuous glucose monitoring data between hourly reference glucose data."
3241638|NCT01301105|Placebo Comparator|Health Enhancement Program (HEP)|Intervention designed to be effective and structurally equivalent to Mindfulness Based Stress Reduction (MBSR) but without a mindfulness component. Designed as an active control for MBSR to isolate mindfulness as an active ingredient.
3349504|NCT02255201|Active Comparator|Beverage D|Single dose, Pre-Workout Energy Blend
3349505|NCT02255201|Placebo Comparator|Beverage E|Single dose, Pre-Workout Placebo
3241639|NCT01301105|Active Comparator|Mindfulness Based Stress Reduction (MBSR)|
3349506|NCT02255214||Surgical Patient|These are the results from the blood samples taken from the study participants.
3349507|NCT02255227|Active Comparator|1 dose Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4
3349508|NCT02255227|Experimental|2 doses Prevenar13 and 1 dose PSV23|one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4
3349509|NCT02255240|Experimental|Physical activity intervention|This arm will receive the physical activity intervention, which consists of three individual meetings, weekly brief counseling phone calls for 6 weeks, and provision of a video game console with three active video games.
3349510|NCT02255253|Experimental|Telmisartan|capsule,40mg per day,2 months
3349511|NCT02255253|Experimental|Hydrochlorothiazide|tablet, 25mg per day, 2 months
3241640|NCT01301131|Experimental|Probiotic|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
3349512|NCT02255266||A|
3349513|NCT02255292|Experimental|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study.
3349514|NCT02255305|Experimental|FMT Group (Intervention Arm)|Patients randomized to the FMT group will have antimicrobials targeting C. difficile discontinued at least 6 hours prior to undergoing an FMT via retention enema. A second FMT via retention enema will be administered at 24 hours if diarrhea persists.
3349515|NCT02255305|Active Comparator|Antimicrobial Group (Control Arm)|Patients randomized to the antimicrobial group will be treated with antibiotics targeting C. difficile according to the Society for Healthcare Epidemiology of America (SHEA) Clinical Practice Guidelines for CDI. FMT will be offered to this group after 90 days if they experience relapsing CDI.
3349516|NCT02255318|Experimental|Taurolock|Patients received Taurolock lock for 3 months administration.
3349517|NCT02255318|Placebo Comparator|Placebo|Patients received placebo lock (physiological serum) for 3 months administration.
3349518|NCT02255331||Retrieval Analysis|"You qualify for this Retrieval Analysis study if you:~Have a total hip replacement with a ceramic component undergoing revision for any reason, including recurrent dislocation.~Have a metal-on-polyethylene total hip replacement and have repeated dislocation, or~Have a metal-on-polyethylene total hip replacement greater than 1 year old, or~Have an infected total hip replacement (any surface bearing)~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Have had a prior revision of your total hip~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
3241641|NCT01301131|No Intervention|control|
3241642|NCT01301157|Experimental|25ug M518101|
3349519|NCT02255331||Longitudinal Evaluation|"You qualify for this arm of the study if you:~Have a total hip replacement with a ceramic component~Have a metal-on-polyethylene total hip replacement.~Have your original or revised total hip replacement.~You do not qualify for this arm of the study if you:~Have occupational exposure to cobalt or chromium~Have cemented components.~Presence of a metal-on-metal (MOM) implant, or a recalled implant~Standard contra-indications to MRI (e.g. cardiac pacemaker, etc.)"
3349520|NCT02255344||ST-Elevation Myocardial Infarction|Consecutive patients of any gender between 18 and 90 years old, diagnosed with ST-Elevation Myocardial Infarction according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
3241643|NCT01301157|Placebo Comparator|Vehicle|
3241644|NCT01301157|Active Comparator|Dovonex|
3349521|NCT02255344||Non ST Segment Elevation|Consecutive patients of any gender between 18 and 90 years old, diagnosed with Non ST Segment Elevation (NSTEMI/ Unstable angina) according to international diagnostic criteria - ACC / AHA / ESC, attended in representative hospitals of tertiary and secondary care in the IMSS will be studied
3349522|NCT02255370|Experimental|CURCUMIN|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
3349523|NCT02255370|Placebo Comparator|PLACEBO|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
3349524|NCT02255383|Other|PERSONA TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
3349525|NCT02255409|Experimental|aQIV|Adjuvanted Quadrivalent Subunit Influenza
3349526|NCT02255409|Active Comparator|QIV|Non-Adjuvanted Quadrivalent Subunit Influenza
3349527|NCT02255448|Other|SV1, SV2|SV1 intervention: stroke volume using transthoracic echo SV2 intervention: stroke volume measured using the esCCO device.
3349528|NCT02255487|Experimental|IrriSept System|IrriSept device used for surgical irrigation in subjects with abdominal trauma or acute surgical abdomen
3349529|NCT02255487|Active Comparator|Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
3349530|NCT02255526||Healthy Volunteers|Healthy volunteers between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
3349531|NCT02255526||Heart Failure|Heart failure patients between the ages of 18 and 80 will wear BodyGuardian remote monitoring system to help validate respiration and activity levels.
3241645|NCT01301157|Experimental|50ug M518101|
3241646|NCT01301196|Experimental|Behaviour change|Attendance at 3-h workshop
3241647|NCT01301209||treatment|patients undergoing treatment
3241648|NCT01301222|Experimental|octreotide|octreotide arm 100mcg for 5 days. control has no octreotide
3241649|NCT01301235||Subjects with mitochondrial disease|
3241650|NCT01301248|Active Comparator|Radiotherapy/Cisplatin(GroupA)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)
3349532|NCT02255539|Experimental|CPAP Nasal Mask|Geelong Prototype Mask
3241651|NCT01301248|Experimental|Radiotherapy/Cisplatin/Cetuximab(GroupB)|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
3241652|NCT01301261|Active Comparator|sugammadex 2 mg/kg|2 mg/kg of sugammadex are given when a response of two counts of train of four are present
3241653|NCT01301261|Active Comparator|4 mg/kg of sugammadex|4 mg/kg of sugammadex are given when a posttetanic count 1-3 appears
3241654|NCT01301261|Active Comparator|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg are given three minutes after the injection of cis-atracurium
3241655|NCT01301287|Experimental|Chlorella|
3241656|NCT01301300|Active Comparator|Glenbrook Hospital|Immediate implementation of the disinfecting cap, no baseline contamination assessment, historical infection data only.
3349533|NCT02255578|Other|IVF treatment|Fertility, as determined by egg quality parameters, as well as metabolic parameters, will be assessed following Endobarrier treatment in PCOS during IVF treatment.
3241657|NCT01301300|Active Comparator|Evanston, Highland Park, Skokie Hospitals|"Phase 1: Assess baseline contamination rate for patients with PICC catheters for 3-12 months.~Phase 2: Implement intervention. Assess contamination 3-12 months. Phase 3: (optional): Remove cap asses contamination rate (3-6 months)"
3241658|NCT01301313|Experimental|Levosimendan|
3349534|NCT02255578|Other|clomiphene citrate treatment|Ovulation rate in response to clomiphen citrate after Endobarrier treatment in PCOS.
3349535|NCT02255591|Experimental|Shamrock|Use of the Shamrock technique to place a lumbar plexus block with injection of 20 mL 2% Lidocaine-adrenaline added gadolinium.
3349536|NCT02255591|Active Comparator|Lumbar Ultrasound Trident|Use of the Lumbar Ultrasound Trident technique to place a lumbar plexus block with injection of 20 mL 2% lidocaine-adrenaline added gadolinium.
3349537|NCT02255617|Experimental|Fecal Microbiota Transplant|Single arm open label FMT administered at Week 0 by colonoscopy and at Weeks 1-4 by enema
3349538|NCT02255630|Experimental|Salbutamol inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
3349539|NCT02255630|Experimental|Placebo inhalation|Study participants will be exposed to 1600ug salbutamol 30min prior to exercise
3349540|NCT02255643|Experimental|-10% of effective PMT|Patients are set to a voltage 10% less than their original PMT at start of study, Changes in PMT settings
3349541|NCT02255643|Active Comparator|former setting (+/- 0% of PMT)|Patients are set to their original PMT at start of study, Changes in PMT settings
3349542|NCT02255643|Experimental|+10% of effective PMT|Patients are set to a voltage 10% more than their original PMT at start of study, Changes in PMT settings
3349543|NCT02255669|Active Comparator|partially covered SEMS|Deployment of Partially covered biliary self expandable metal stent
3349544|NCT02255669|Active Comparator|fully covered SEMS|Deployment of Fully covered biliary self expandable metal stent
3349545|NCT02255682|Placebo Comparator|Simvastatin and Q10-placebo|Simvastatin 40 mg orally administered daily and Q10-placebo for 8 weeks
3349546|NCT02255682|Active Comparator|Simvastatin and Q10|Simvastatin 40 mg orally administered daily for 8 weeks in combination with Q10 supplementation of 400 mg/daily
3241659|NCT01301313|Active Comparator|Conventional intensified inotropic treatment|
3241660|NCT01301326|Experimental|subthreshold laser treatment|
3349547|NCT02255695|No Intervention|Control group|Control group
3349548|NCT02255695|Experimental|School-based exercise program|School-based exercise program
3349549|NCT02255708|Other|Healthy group.|Group formed by healthy patients.
3349550|NCT02255708|Other|Group with demyelinating polyneuropathy|Group formed by patients with demyelinating polyneuropathy.
3241661|NCT01301326|Active Comparator|threshold laser treatment|
3241662|NCT01301339||failed and passed physical fitness test|520 subjects who have failed their Air Force physical fitness test and 520 volunteers who have passed their physical fitness test both within the last 6 months
3241663|NCT01301352|No Intervention|Nasojejunal feeding (control)|
3241664|NCT01301352|Experimental|Nasogastric feeding (intervention)|
3241665|NCT01301378|Active Comparator|KeraSys Tissue Patch Graft|20 patients needing a Molteno 3 glaucoma drainage shunt implant will receive the KeraSys patch graft
3241666|NCT01301378|Active Comparator|Tutoplast tissue patch graft|20 patients need Molteno 3 glaucoma drainage surgery will receive tutoplast patch graft
3241667|NCT01301404|No Intervention|control|patient receive nothing
3241668|NCT01301404|Experimental|carbohydrate drink|10%carbohydrate drink
3241669|NCT01301417||ColonRing™|Adult Patients who underwent a laparoscopic or open colorectal resection with the creation of an anastomosis using the ColonRing™ in routine clinical practice
3241670|NCT01301430|Experimental|H-1 parvovirus (H-1PV)|
3241671|NCT01301443|Experimental|Subretinally Injected RetinoStat|Subretinally injected RetinoStat
3241672|NCT01301469|Experimental|1|6% HES 130/0.42 in plasma adapted Ringer's solution (balanced solution)
3241673|NCT01301469|Active Comparator|2|HES 130/0.4 in a saline solution
3241674|NCT01301482|Experimental|battlefield auricular acupuncture|
3241675|NCT01301482|No Intervention|placebo|
3241676|NCT01301495|Experimental|HANAROSTENT covered Esophageal Stent|
3349551|NCT02255721|Experimental|SHIP Intervention|SHIP is a health behavior change intervention to give parents the knowledge, motivation, and skills necessary to set goals, problem-solve, and improve their child's sleep.
3349552|NCT02255721|Active Comparator|SHIP Control Arm|The active control arm uses the same strategies as the SHIP intervention arm, but for child health topics unrelated to sleep or outcome measures.
3349553|NCT02255734|Active Comparator|Zovirax|
3349554|NCT02255734|Experimental|Virless|
3349555|NCT02255747|Active Comparator|anal dilatation|
3349556|NCT02255747|Active Comparator|Oral Lactulose|
3375954|NCT03363464||patients with T2DM initiating empagliflozin|Type 2 diabetes mellitus
3375955|NCT03363464||patients with T2DM initiating a DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor treated patients
3375956|NCT03363464||patients with T2DM initiating a GLP-1 receptor agonist|Glucagon-like peptide-1 receptor agonist treated patients
3349557|NCT02255773|Other|High-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
3349558|NCT02255773|Other|Low-Fatigue Head and Neck (HNC) Cancer Survivors|Participants undergo assessment with three validated computerized tasks designed to measure the neurobehavioral domains of interest: the Effort Expenditure for Rewards Task (EEfRT), an associative learning task, and a set-switch task. Participants complete questionnaires assessing mood, somatic symptoms, and sleep quality, including the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF), the Checklist Individual Strength (CIS), and others. A 10-mL blood sample drawn for assessment of inflammatory markers and COMT and DAT1 genotype.
3349559|NCT02255786|Experimental|ACT Parent Group|Participants will complete a total of five Acceptance and Commitment Therapy - Parent Group Sessions First four are held weekly, last session held one month from 4th session.
3349560|NCT02255786|No Intervention|Treatment as Usual|Treatment as usual-Control
3349561|NCT02255799|Active Comparator|Donepezil|Donepezil 5 mg capsules daily for 14 days. Donepezil 10 mg capsules daily for 56 days.
3349562|NCT02255799|Placebo Comparator|Placebo|Placebo capsules once daily for 70 days.
3349563|NCT02255812|Placebo Comparator|200 mL tap water|Single intragastric instillation of 200 mL tap water via nasogastric tube
3349564|NCT02255812|Active Comparator|2 g citric acid|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube
3349565|NCT02255812|Active Comparator|2 g salt|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube
3349566|NCT02255812|Active Comparator|0.017 g quinine|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube
3349567|NCT02255812|Active Comparator|1 g monosodium glutamate|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube
3349568|NCT02255812|Active Comparator|25 g glucose|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
3349569|NCT02255825|Active Comparator|Control Group|Amniocentesis will be performed, Whole Genome Sequencing will not be performed, and psychosocial assessment will be performed.
3349570|NCT02255825|Experimental|Intervention Group|Amniocentesis will be performed, Whole Genome Sequencing will be performed if the karyotype is normal, and psychosocial assessment will be performed.
3349571|NCT02255838|Experimental|Bronchoscope disposable, aScope IV|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
3349572|NCT02255838|Active Comparator|Bronchoscope reusable Storz 8402 2x|the bronchoscope will be re-inserted and advanced to the basal segmental bronchi of the right lower lobe. The tip of the bronchoscope will be brought into wedge position in one of the basal segments for broncho-alveolar lavage (BAL). A saline flush of 20 ml will be administered. The flow of saline will be observed at the distal tip of the bronchoscope. After 10 seconds of maintaining a wedge position, gentle suction will be applied to collect the lavage specimen in the collection trap. This step will be repeated 4 more times (total of 80ml) to obtain an adequate specimen.
3349573|NCT02255851||Treatment Group|TAVR + SENTINEL (Cerebral Protection System)
3349574|NCT02255864|Experimental|Coronary Scaffold Implantation|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
3349575|NCT02255877|Active Comparator|Zip Surgical Skin Closure|Subjects randomized to receive one knee (left or right) closed with ZipSurgical Skin Closure and the other knee closed with standard staples
3349576|NCT02255877|Active Comparator|Steel Staples|Subjects randomized to receive one knee (left or right) closed with Staples and the other knee closed with ZipSurgical Skin Closure
3349577|NCT02255903||Group 1(Control Group):|ultrasound and Doppler examination: of 100 pregnant females with gestational age 37-40 weeks.
3349578|NCT02255903||Group 2 (post date Group)|ultrasound and Doppler examination:will be done for 100 pregnant females with gestational age 41 weeks or more
3349579|NCT02255916|No Intervention|Controll|No sound-bed intervention
3349580|NCT02255916|Experimental|Music|live sound-bed music intervention
3349581|NCT02255929|Experimental|Gamma Knife Radiosurgery|Gamma Knife treatment is conducted in one day and takes approximately 70 to 90 minutes.
3241677|NCT01301521|Experimental|Cinnulin PF|Will take (by mouth) 2 gelatin capsules that contains 1 gram (2-500 mg capsules) water-soluble cinnamon extract (Cinnulin PF) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
3241678|NCT01301521|Placebo Comparator|Placebo|Will take (by mouth) 2 placebo capsules (gelatin capsule filled with wheat bran) once a day for 1 year plus 1 year of follow-up plus standard of care aggressive lifestyle therapy.
3349582|NCT02255942|Experimental|Iron fortified rice|Administration of iron fortified rice to all subjects; subjects will act as their own controls and each subject will receive all foreseen treatments/interventions.
3241679|NCT01301534||T-Con|1. Nurse initiated Telephone Consult (T-Con)
3349583|NCT02255955|Experimental|550 mg naproxen sodium and 30mg codeine|Preoperatively patients received oral naproxen sodium codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3349584|NCT02255955|Active Comparator|300 mg paracetamol and 30 mg codeine|Preoperatively patients received oral paracetamol codeine, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3349585|NCT02255955|Placebo Comparator|Placebo|Preoperatively patients received oral placebo tablet, postop contramal infused by PCA, and postoperative contramal consumption, side effects pain intensity measured by VAS.
3349586|NCT02255968|Experimental|EDP-788|Multiple doses with dose escalation to continue in successive cohorts
3241680|NCT01301534||Mail-Out|2. Mail-0ut Letter to the patient
3241681|NCT01301534||Education|3. Provider, Nurse and Technician Education with point-of-care patient referrals , Exam Room Flyer
3349587|NCT02255968|Placebo Comparator|Placebo|Multiple doses with dose escalation to continue in successive cohorts
3349588|NCT02255994|Experimental|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
3241682|NCT01301534||Control group|4. Control group (i.e. usual care)
3241683|NCT01301560|Experimental|Radiosurgery arm|Radiosurgery before palliative chemotherapy
3349589|NCT02255994|Active Comparator|No MESH|Patients in this arm had subvesical plication without reinforcement.
3349590|NCT02256007|Active Comparator|Standardized Assessments|"Standardized Assessments (paper and pencil tests) to be given to each participant. The standardized assessments will be completed in paper and pencil format. These tests include:~Line Bisection Test~Patient Reported Outcomes~Trial Making A and B~Usability Questionnaire"
3349591|NCT02256007|Experimental|Videogame Assessments|"Videogame assessments will be performed by each participant using videogames. The videogame assessments will be performed using videogames on a tabletop platform with touchscreen which includes:~Line Crossing~Patient Reported Outcomes~Trial Making A & B-Asteroid Adventure Game~Usability Questionnaire"
3349592|NCT02256020|Other|Original lifestyle|Original lifestyle, watching TV 50 minutes, three times a week for 6 months.
3349593|NCT02256020|Experimental|Wheel-chair music aerobic exercise|Wheel-chair music aerobic exercise with 3 times of 50-minute session (10 minutes warm up, 30 minutes exercise and 10 minutes cool down) a week for 6 months.
3349594|NCT02256033|Experimental|Istradefylline|One 40-mg tablet of istradefylline administered on Day 1.
3349595|NCT02256046|Experimental|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
3349596|NCT02256059||Plate osteosynthesis|Patients with fracture of the lateral clavicle and indication for surgical treatment
3349597|NCT02256085|Sham Comparator|Sham rTMS|"Daily rTMS with Sham coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with Sham (placebo) coil"
3349598|NCT02256085|Experimental|Active rTMS|"Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
3349599|NCT02256085|Experimental|Open Active rTMS|"Open Label Daily rTMS with Active coil~30 minutes of 1Hz rTMS, 5 days per week, for 6 weeks with active coil"
3349600|NCT02256098|Experimental|ATTUNE™|Total Knee Replacement Surgery with ATTUNE™ Knee Prosthesis by DePuy
3349601|NCT02256098|Active Comparator|PFC Sigma|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
3349602|NCT02256124|Experimental|Lamotrigine|"Lamotrigine during 28 consecutive weeks:~8 weeks dose-increase phase: from 25mg once daily to 100mg twice daily~18 weeks target-dose phase: 100mg twice daily~2 weeks decline-phase: 100mg once daily."
3349603|NCT02256124|Placebo Comparator|Placebo|Placebo tablets during 28 consecutive weeks, with identical appearance to lamotrigine tablets, mimicking the lamotrigine dosing schedule.
3241684|NCT01301560|No Intervention|Observation arm|No radiotherapy or local treatment until specific symptoms or sign developed
3349604|NCT02256137||Childhood Cancer Survivors|This study will evaluate 1493 members of the St. Jude Lifetime Cohort Study (SJLIFE) who have completed a baseline functional assessment six or less years ago when 18-45 years of age.
3349605|NCT02256150|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
3349606|NCT02256150|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
3349607|NCT02256215|Experimental|Vitamin D|• All patients will have their serum vitamin D levels measured at the baseline visit. Those assigned to the treatment arm (group A) will receive either 50,000 international units of vitamin D3 by mouth once or more per week for six to eight weeks, then 800 to 1000 (or more) international units of vitamin D3 daily thereafter, this is according to the recommendations of the Endocrine Society clinical practice guideline 2011. Group B patients will receive placebo supplements identical in appearance to the vitamin D supplements.
3349608|NCT02256215|Placebo Comparator|Placebo|
3349609|NCT02256228|Active Comparator|Group R|Ropivacaine is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Ropivacaine would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Ropivacaine (1mg/mL) would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
3349610|NCT02256228|Placebo Comparator|Group P|Saline is instillated through one multi-hole catheter wich would be inserted percutaneously in all patients and tunnelled about 1-2 cm lateral to the abdominal incision and the tip of the catheter placed in the intra-peritoneal cavity. The catheter would not be ligated and fixed in situ intra-peritoneally. Twenty ml of Saline would be injected subcutaneously along both sides of the incision prior to skin closure. Additionally, 20 ml of Saline would be injected every hour by an automatic pump via the intra-peritoneal catheter into the abdomen.
3349611|NCT02256241||The role of RING ubiquitin ligases in osteogenic progenitors|Bone marrow (BM) will be collected from healthy patients undergoing orthopedic surgery. BM will be collected from disposable tissue that is removed during the normal sequence of the surgery.
3241685|NCT01301573||rAAV-GAD Treated Subjects|rAAV-GAD treated subjects who are being observed for long-term effects of the gene therapy product which they received from participating in a previous clinical study.
3241686|NCT01301586|Active Comparator|Oral antibiotic plus soy extract|
3241687|NCT01301586|Active Comparator|Oral antibiotic|
3241688|NCT01301599|Experimental|combination group|combination therapy of alpha blocker and 5-alpha-reductase inhibitor medication
3241689|NCT01301599|Active Comparator|alpha blocker group|alpha blocker monotherapy
3349612|NCT02256241||The role of RING ubiquitin ligases in musculoskeletal cancer|Collection of connective tissue from patients with tumors of musculoskeletal origin - a part of the resected tumor specimens.
3349613|NCT02256254|Active Comparator|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
3349614|NCT02256254|Placebo Comparator|Placebo|2 placebo capsules every evening for 14 days
3349615|NCT02256280|Experimental|S Group|Sugammadex 2 or 4 mg/kg iv once at the end of surgery
3241690|NCT01301599|Active Comparator|5 ARI group|5 alpha-reductase inhibitor group
3241691|NCT01301612|Active Comparator|Radiation therapy and Cisplatin|Cisplatin, 40 mg/m2, IV - Weekly doses for 6 weeks Pelvic radiation therapy, 45 Gy External, Fractions of 1.8 Gy per day, 5 days a week Dose boosts,15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week Brachytherapy (if indicaed), 40 Gy at spot A(low dose rate), Intracavitary 1 or 2 separate fractions for 1 to 3 weeks. 28 Gy at spot A, (high dose rate) Intracavitary,4 fractions of 7.0 Gy once or twice a week.
3349616|NCT02256280|Active Comparator|N Group|Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery
3349617|NCT02256293|Experimental|Group Therapy|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).
3349618|NCT02256306|Experimental|Young Donor Plasma|Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
3349619|NCT02256319|Experimental|Dexmedetomidine recording|Recording registered through the deep brain stimulation electrodes with dexmedetomidine at 0.2 μg/kg/h.
3349620|NCT02256319|Active Comparator|Propofol recording|Recording registered through the deep brain stimulation electrodes with propofol at plasmatic levels of 0.5, 1, 1.5, 2, 2.5 μg/mL.
3349621|NCT02256319|No Intervention|Basal recording|Recording registered through the deep brain stimulation electrodes with no sedation .
3349622|NCT02256332|Active Comparator|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
3349623|NCT02256332|Active Comparator|High dose plant based ingredient|Reference food with high dose of plant based ingredient
3349624|NCT02256332|Placebo Comparator|Reference food format|Reference food without plant-based ingredient
3349625|NCT02256371|Experimental|Hypnotic analgesia|"Hypnosis sessions:~Hypnosis will consist of 45 minutes hypnosis session with a trained hypnotherapist"
3349626|NCT02256371|Experimental|Relaxation|"Relaxation group:~Relaxation will be conducted in 45 minutes sessions with a trained psychotherapist."
3349627|NCT02256371|No Intervention|Routine care|The patients will receive their usual pain treatments throughout the study
3349628|NCT02256397|Active Comparator|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
3349629|NCT02256397|Experimental|Enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
3241692|NCT01301612|Experimental|Nimotuzumab and|"Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks.~Nimotuzumab, 200 mg, Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes, Weekly doses for 14 weeks.~Pelvic radiation therapy, 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts, 15 Gy ± 5%, External,Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week~Brachytherapy (In case there is indication, should it be performed, not to be longer than the expected 70 days for the entire radiation therapy), 40 Gy at spot A (low dose rate) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks 28 Gy at spot A (high dose rate), Intracavitary, 4 fractions of 7.0 Gy once or twice a week."
3241693|NCT01301651|Experimental|virtual reality balance training|balance board training with virtual reality intervention
3241694|NCT01301651|Experimental|conventional balance training|physical therapy conventional balance training
3241695|NCT01301651|No Intervention|control group|No physical therapy
3349630|NCT02256410|Experimental|Stimulation|Patients will undergo 6 sessions, each including 20 minutes of stimulation. These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance. The frequency of stimulation is 8Hz, at an intensity matched for each patient's tolerance, without inflicting any pain. The location of the stimulations will change in accordance to the changes in the peak pain regions, reflecting changes in tissue physiology possibly linked to clinical improvements.
3349631|NCT02256410|Sham Comparator|sham stimulation|Patients will undergo 6 sessions, each including 20 minutesof sham stimulation (no stimulation). These are given after the Nervomatrix device determines the peak pain regions for each patient, and selects to stimulate the top 10 regions with least skin resistance.
3349632|NCT02256423|Active Comparator|REFERENCE 1: Nurofen® 200 mg tablet|Single group 3-way crossover study
3349633|NCT02256423|Active Comparator|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|Single group 3-way crossover study
3241696|NCT01301677|Active Comparator|Hydrocortisone|
3241697|NCT01301677|Experimental|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
3349634|NCT02256423|Experimental|ibuprofen 200 mg soft gel capsule|single group, 3-way cross
3349635|NCT02256449||BVS patients|Use of bioresorbable coronary device, according to the indications of use, in daily clinical practice, in patients undergoing PCI in de novo coronary artery lesions.
3349636|NCT02256462|Experimental|Interventional|Adalimumab levels and antibodies will be obtained with every laboratory examination (every 2 months, except for the first 2 visits). Dose or interval adjustment will be performed as followed:when trough levels results taken prior to ADA injection are above 5 µg/ml no change in dosing is required. Detectable levels below 5 µg/ml will result in interval decrease to every week. If levels are still below 5 µg/ml dose will be increased to 40 mg (in patients receiving less than 40 mg). Undetectable levels below 0.3µg/ml will be followed by antibodies (ATAs) measurement. If ATAs are persistently above 8 µg/ml the patient will discontinue the study. If ATAs are below 8 µg/ml ADA intervals will be decreased to every week.
3375957|NCT03360500|Experimental|EXERCISE PROTOCOL + CRYOTHERAPY|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
3375958|NCT03360500|Experimental|EXERCISE PROTOCOL|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
3349637|NCT02256462|No Intervention|Clinical|"Adalimumab levels and antibodies will be requested based on physician judgment when there are signs of loss of response (LOR). Dose and interval adjustment will be performed according to clinical measures: Following physician decision trough levels and ATAs will be collected and further adjustment may be considered according to results. Interval adjustment will be performed as described for the interventional arm.~LOR is defined as PCDAI equal or higher than 10 or CRP higher than 0.5 mg/dl (5mg/l) and/or Fecal calprotectin higher than 150 mcg/gr (If lower than 150 at randomization)."
3349638|NCT02256475|Experimental|Adolescents Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days.
3349639|NCT02256475|Experimental|Adolescents Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that maximum tolerated dose (MTD) has not been reached.
3349640|NCT02256475|Experimental|Adolescents Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3349641|NCT02256475|Experimental|Children Dose Group 1|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the adolescent dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3241698|NCT01301677|Experimental|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
3349642|NCT02256475|Experimental|Children Dose Group 2|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 1 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3349643|NCT02256475|Experimental|Children Dose Group 3|Fixed dose of NBI-98854 administered once daily at 0800 for 14 days. Dosing will not commence until all safety and PK results from the children dose group 2 have been reviewed to ensure there are no safety concerns and that MTD has not been reached.
3349644|NCT02256501|Experimental|Mono Nunlear Cell (MNC)|The patients with idiopathic dilated cardiomyopathy who underwent intracoronary injection of autologous bone marrow-derived mononuclear cells .
3241699|NCT01301690||Neck masses|Neck mass received US and US-FNA
3241700|NCT01301703|Active Comparator|Tdap vaccination|Patients and controls will be vaccinated with BOOSTRIX (Tdap vaccine)
3241701|NCT01301716|Experimental|A|
3241702|NCT01301716|Experimental|B|
3241703|NCT01301716|Experimental|C|
3349645|NCT02256501|No Intervention|Control|The patients with cardiomyopathy that are under observe during the study.
3349646|NCT02256514|Experimental|Daily oral dose of hepcortespenlisimut-L|Hepcortespenlisimut-L (V5) (850 mg pill) to be administered once per day for the duration of study
3349647|NCT02256527||Promus Premier|observational data
3349648|NCT02256566|Experimental|emotional memory training exercise|study training exercise - Emotional Faces Memory Task (EFMT)
3349649|NCT02256566|Active Comparator|memory training exercise|an active control exercise (CT)
3349650|NCT02256592|Experimental|Fecal microbiota transplant (FMT)|Donor fecal suspension will be delivered during colonoscopy to HIV+ individuals.
3349651|NCT02256605||Insufficient Group|D-3 Chewable Wafer - 14,000 IU/wafer weekly Vitamin D-3 Caps - 2,000 IU/Cap daily Vitamin D-3 Liquid - 5,000 IU/ml (0.4) ml daily
3349652|NCT02256605||Deficient Group|D-3 Chewable Wafer - 50,000 IU/wafer weekly Vitamin D-3 Liquid - 5,000 IU/ml daily
3349653|NCT02256618|Experimental|Cell therapy|Infants who are born at the study sites, have moderate to severe encephalopathy, and have cord blood available for infusion
3349654|NCT02256644||Million Veteran Program (MVP) participants|Veterans who are currently enrolled in the Million Veteran Program.
3349655|NCT02256657|Experimental|Step 1: Toolkit Implemented in Month 4|Quality Improvement Toolkit
3349656|NCT02256657|Experimental|Step 2: Toolkit Implemented in Month 8|Quality Improvement Toolkit
3349657|NCT02256657|Experimental|Step 3: Toolkit Implemented in Month 12|Quality Improvement Toolkit
3349658|NCT02256657|Experimental|Step 4: Toolkit Implemented in Month 16|Quality Improvement Toolkit
3241704|NCT01301755||1|
3241705|NCT01301768|Experimental|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
3349659|NCT02256657|Experimental|Step 5: Toolkit Implemented in Month 20|Quality Improvement Toolkit
3349660|NCT02256670|Experimental|Text Message Application Intervention|The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
3241706|NCT01301768|No Intervention|Usual care|Women in the control group receive the usual care during the pregnancy
3241707|NCT01301781|Experimental|BLI801 laxative|BLI801 laxative - oral solution
3241708|NCT01301781|Placebo Comparator|Placebo|BLI801 placebo - oral solution
3241709|NCT01301807|Experimental|Treatment (carfilzomib, panobinostat)|Participants receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16 and panobinostat PO QD on days 1, 3, 5, 8, 10, and 12 of each course. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. After 8 courses, participants may continue carfilzomib IV on days 1, 2, 15, and 16, and panobinostat PO on days 1, 3, 5, 8, 10, and 12 of each course. If the disease becomes worse, participants can receive carfilzomib on the original dosing schedule (days 1, 2, 8, 9, 15, and 16 of each course).
3241710|NCT01301820|Other|ARM A|maintenance study treatment: azacitidine sc 75 mg/m²/d (d1- d7) in first cycle: months 1,3,5,7,9 ,11 then lenalidomide 10mg/d (d1- d21) months 2,4,6,8,10,12
3241711|NCT01301820|Other|ARM B|maintenance study treatment: lenalidomide 10mg/d (d1- d21)in first cycle and months 1,3,5,7,9 ,11 then azacitidine sc 75 mg/m²/d (d1- d7) months 2,4,6,8,10,12
3241712|NCT01301846||Wheelchair users|People who have a wheelchair for home and community use.
3349661|NCT02256683|Experimental|Dabigatran|Dabigatran etexilate (Pradaxa®) 150 mg capsule by mouth twice daly for 3 up to 6 weeks depending on treatment response
3349662|NCT02256683|Active Comparator|Phenprocoumon|Phenprocoumon (Marcumar®) 3 mg capsule by mouth according to INR (2-3) for 3 up to 6 weeks depending on treatment response
3349663|NCT02256696|Experimental|Arm 1|PA-824 200 mg once daily (QD),Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3349664|NCT02256696|Experimental|Arm 2|PA-824 200 mg once daily,Rifabutin 300 mg once daily , Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then PA-824 200 mg once daily, Rifabutin 300 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3241713|NCT01301859|Active Comparator|TIP Adherence Intervention|The TIP program is a brief, individualized intervention designed as an adjunct to pharmacotherapy for depression prescribed by a primary care physician. The key to the intervention is the involvement of the older adult in creating an adherence strategy tailored to his/her barriers and needs.
3349665|NCT02256696|Active Comparator|Arm 3|Rifampin 600 mg once daily, Ethambutol 15mg/kg once daily, Isoniazid 5 mg/kg once daily, Pyrazinamide 25 mg/kg once daily x 8 weeks, then Rifampin 600 mg once daily, Isoniazid 5 mg/kg once daily x 4 weeks
3349666|NCT02256709|Experimental|single rising dose BIBP 5371 CL|
3349667|NCT02256709|Experimental|BIBP 5371 CL tablet high dose|to be compared with same daily dose level from single rising dose arm
3349668|NCT02256709|Experimental|BIBP 5371 CL tablet low dose|to be compared with same daily dose level from single rising dose arm
3349669|NCT02256709|Placebo Comparator|Placebo drinking solution|
3349670|NCT02256709|Experimental|BIBP 5371 CL drinking solution|
3349671|NCT02256709|Experimental|BIBP 5371 CL tablet high dose with food|
3349672|NCT02256709|Experimental|BIBP 5371 CL tablet low dose with food|
3349673|NCT02256709|Placebo Comparator|Placebo tablet|
3349674|NCT02256722|Experimental|Treatment A|
3349675|NCT02256722|Experimental|Treatment B|
3349676|NCT02256722|Experimental|Treatment C|
3349677|NCT02256722|Experimental|Treatment D|
3349678|NCT02256722|Active Comparator|Treatment E|
3349679|NCT02256735|Experimental|Treatment A|
3349680|NCT02256735|Experimental|Treatment B|
3349681|NCT02256735|Experimental|Treatment C|
3349682|NCT02256735|Experimental|Treatment D|
3349683|NCT02256735|Placebo Comparator|Placebo|
3349684|NCT02256735|Active Comparator|Moxifloxacin|
3349685|NCT02256748|Experimental|BIRT 2584 XX + Midazolam|"BIRT 2584 XX: Multiple doses for 12 days (bid on days 1 and 2, qd from days 3 to 12)~Midazolam: Administration on days -2, 1, 3, and 12"
3349686|NCT02256761|Experimental|BIRT 2584 XX - single dose|"Part 1 - bioavailability/food effect~two single doses, 30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served"
3349687|NCT02256761|Placebo Comparator|Placebo|Part 2
3349688|NCT02256761|Experimental|BIRT 2584 XX - multiple escalating dose|Part 2 - multiple escalating dose, 14 days and 28 days
3349689|NCT02256774|Experimental|Combivir® plus BILR 355/Ritonavir|
3349690|NCT02256774|Experimental|BILR 355/Ritonavir|
3349691|NCT02256787|Experimental|BILB 1941 ZW - single rising dose|Single rising dose part
3349692|NCT02256787|Placebo Comparator|Placebo|Single rising dose part
3349693|NCT02256787|Experimental|BILB 1941 ZW - tablet - fasted|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3349694|NCT02256787|Experimental|BILB 1941 ZW - solution|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3349695|NCT02256787|Experimental|BILB 1941 ZW - tablet - fed|Relative bioavailability: The oral solution fasted should be compared with the solid form fasted and after a standardized breakfast
3349696|NCT02256813|Experimental|BIRT 2584 XX + PK-cocktail|
3349697|NCT02256826|Experimental|Group A|
3349698|NCT02256826|Experimental|Group B|
3349699|NCT02256852|Experimental|QBKPN SSI|Individualized maintenance dose administered subcutaneously for 12 weeks
3349700|NCT02256865|Placebo Comparator|Placebo and Drug Group 2|Placebo pills and gel is used in place. Placebo for Ketoconazole is taken 4 times a day Placebo for Hydrocortisone is taken 3 times a day Placebo for testosterone gel is applied once a day.
3349701|NCT02256865|Active Comparator|Drug and Placebo Group 1|Ketoconazole is taken 4 times a day Hydrocortisone is taken 3 times a day Testosterone gel is applied once a day
3349702|NCT02256878|Experimental|BIRT 2584 XX + Amitriptyline|"BIRT 2584 XX:~Days 1 and 2: twice daily (bid) Days 3 to 21: once daily (qd)~Amitriptyline:~Single dose on day -8, day 1, and day 15"
3349703|NCT02256904|Experimental|Anatomical|67 subjects will be randomized to receive an Anatomical TKA with the My knee instruments and a GMK sphere device.
3349704|NCT02256904|Active Comparator|Mechanical|67 subjects will be randomized to receive a Mechanical TKA with the My knee instruments and the GMK sphere device.
3349705|NCT02256930|Experimental|M518101|M518101 will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3349706|NCT02256930|Placebo Comparator|M518101 Vehicle|M518101 Vehicle will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3349707|NCT02256930|Active Comparator|Sodium lauryl sulfate|The sodium lauryl sulfate will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3349708|NCT02256930|Sham Comparator|Saline|The saline will be applied 9 times for 21 days on the infrascapular area of the back under occlusive patch conditions.
3349709|NCT02256943|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
3349710|NCT02256943|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
3349711|NCT02256956|Active Comparator|Amitriptyline first, Placebo second|Amitriptyline first, Placebo second
3349712|NCT02256956|Active Comparator|Placebo first, Amitriptyline second|Placebo first, Amitriptyline second
3241714|NCT01301859|Placebo Comparator|Usual Care|Treatment as usual in a primary care setting
3241715|NCT01301872|Other|1|All patients meet ALI/less severe ARDS criteria
3241716|NCT01301885||Endometriosis|Women (19-48 years of age) with surgically confirmed endometriosis.
3241717|NCT01301885||Healthy women|Healthy women (32-48 years of age), symptom free, existence of endometriosis ruled out during laparoscopy for tubal ligation
3349713|NCT02256995||Pregnant Women (>22 weeks gestation)|Biomarkers tracked over 3 antenatal care visits via standard of care (dipstick, manually/visually assessed) and via uChek (automated assessment via computer application)
3349714|NCT02257008|Experimental|Single rising dose of BILR 355 BS with grapefruit juice|
3349715|NCT02257008|Experimental|Single rising dose of BILR 355 BS with nelfinavir|
3349716|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir|
3349717|NCT02257008|Experimental|Single dose of BILR 355 BS with atazanavir, ritonavir|
3241718|NCT01301898|Experimental|GC1111_0.5mg/kg|
3241719|NCT01301898|Experimental|GC1111_1.0mg/kg|
3241720|NCT01301898|Active Comparator|Elaprase_0.5mg/kg|
3349718|NCT02257021|Experimental|Tipranavir and high dose of ritonavir plus BILR 355 BS|
3349719|NCT02257021|Experimental|BILR 355 BS with low dose of ritonavir|
3349720|NCT02257034|Experimental|Taichi|patients exercise with Tai chi
3349721|NCT02257034|Sham Comparator|Control|patients under exercise of dance
3349722|NCT02257047|Experimental|RYR|Patients under the treatment of red yeast rice
3349723|NCT02257047|Sham Comparator|Control|Patients under the treatment of tea
3349724|NCT02257060|Experimental|Endocardial Ablation|
3349725|NCT02257073|Experimental|CBT|Cognitive-behavioral treatment
3349726|NCT02257073|Sham Comparator|WLT|Waiting in list
3349727|NCT02257112|Experimental|Multistage low-energy stimulation|Multistage low-energy electrical pulses as described in Janardhan AH et al. JACC 2014 Jan7-14:63(1):40-8 will be delivered to a patient in atrial fibrillation. The responses to these stimuli will be recorded.
3349728|NCT02257125|Experimental|high incentive|game version including visual effects and monetary rewards
3349729|NCT02257125|Active Comparator|low incentive|game version without visual effects or monetary rewards
3349730|NCT02257138|Experimental|Treatment (ruxolitinib phosphate, decitabine)|Patients receive ruxolitinib phosphate PO BID on days 1-28 and decitabine IV on days 1-5. Treatment repeats every 4-6 weeks for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3349731|NCT02257151|Experimental|Group 1: BMS-986142 or placebo|BMS-986142 or placebo Single dose oral Solution or spray dried dispersion as specified
3349732|NCT02257151|Experimental|Group 2: BMS-986142 or placebo|BMS-986142 or placebo Multiple dose oral Solution as specified
3349733|NCT02257164|Active Comparator|femoral nerve block|20 ml injection of 2 mg/ml ropivacaine in femoral nerve
3349734|NCT02257164|Experimental|obturator nerve block and intraarticular injection|10 ml injection of 2 mg/ml ropivacaine in obturator nerve intraarticular injection : 10 ml of chlorhydrate ropivacaine (2 mg/ml) and 10ml of magnesium sulfate
3349735|NCT02257190|Experimental|Control (Con)|No exercise intervention.
3349736|NCT02257190|Experimental|Interval Walking - 3 min intervals (IW3)|One hour of classical interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking.
3349737|NCT02257190|Experimental|Interval Walking - 1 min intervals (IW1)|One hour of fast alternating interval walking exercise (repeated cycles of 3 min of fast and 3 min of slow walking
3349738|NCT02257203|Experimental|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
3349739|NCT02257203|Active Comparator|Reading Education|Parents will receive an educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
3349740|NCT02257216|Active Comparator|Sequence 1: Treatment/Treatment|Treatment/Treatment- consists of Vayarin® for 8 weeks followed by 8 weeks of additional treatment with Vayarin®
3241721|NCT01301911|Experimental|Cipatinib|Each subject will receive a single dose of cipatinib on treatment day 1, followed by 4-day observation period, and then will receive cipatinib once daily in cycles consisting of 21 days.
3349741|NCT02257216|Active Comparator|Sequence 2: Placebo/Treatment|Placebo/Treatment- consists of Placebo for 8 weeks followed by 8 weeks of treatment with Vayarin®
3349742|NCT02257216|Placebo Comparator|Sequence 3: Placebo/Placebo|Placebo/Placebo- consists of Placebo for 8 weeks followed by 8 weeks of additional treatment with Placebo
3241722|NCT01301924|Active Comparator|High dose|High dose: 20 days of 20 mg/kg/day meglumine antimoniate
3241723|NCT01301924|Experimental|Low dose|Low dose: 30 days of 5 mg/kg/day meglumine antimoniate
3241724|NCT01301937|Active Comparator|High continuous dose|Meglumine antimoniate 20 mg/kg/day for 30 continuous days
3241725|NCT01301937|Active Comparator|Low continuous dose|Meglumine antimoniate 5 mg/kg/day for up to 120 continuous days according to clinical cure
3241726|NCT01301989|Placebo Comparator|Sleep Education Control|"The control group receives a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers (in English and Spanish)."
3259312|NCT01469689|Experimental|Google Adwords only|In these areas,the investigators will display online adverts using Google Adwords, with links to the investigators' project website, and from there to four other websites for depression.
3349743|NCT02257229||Surgical|Corrective Surgery only
3349744|NCT02257229||Non-Surgical|Correction with casting, braces, Physical therapy, other non-surgical methods
3349745|NCT02257229||Non-surgical + surgical|Correction with casting, braces, Physical therapy, other non-surgical methods subsequently followed by Corrective Surgery
3349746|NCT02257242|Experimental|Dose-escalation cohort|Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.
3349747|NCT02257255|Active Comparator|Pfannenstiel cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by Pfannenstiel technique. Pain assessment on postoperative hours 6, 12 and 24.
3241727|NCT01301989|Experimental|Sleep Counselor Intervention|"The sleep counselor visits are to assess the family's understanding of their child's sleep problems; help parents recognize the child's sleep deficiency; discuss how sleep problems affect behavior, learning, and health; and reassure parents that the sleep counselor can help them with these problems.~Additionally, sleep counselors: review parent's sleep goals to monitor changes to the child's bedtime routine and sleep environment; help them solve problems with implementation; provide positive feedback to help the parent recognize success; and help parents set additional goals for improving sleep."
3241728|NCT01302002|Experimental|Metformin Pre-Surgery|Patients will take metformin twice a day for three weeks prior surgery
3241729|NCT01302015|Experimental|RNL-Vascostem®|drug name and ingredients : RNL-Vascostem[Autologous adipose tissue derived mesenchymal stem cells] dosage : Intramuscular infusion, 5 x 10e6 cells/kg
3241730|NCT01302028|Active Comparator|Healthy volunteers with normal renal function|Oral
3241731|NCT01302028|Experimental|T2DM patient with normal renal function|Oral
3241732|NCT01302028|Experimental|T2DM patient with mild renal impairment|Oral
3241733|NCT01302028|Experimental|T2DM patient with moderate renal impairment|Oral
3241734|NCT01302028|Experimental|T2DM patient with severe renal impairment|Oral
3241735|NCT01302093|Experimental|Experimental Tablet|A single 100 mg dose of an experimental Racecadotril Film-Coated Tablet (FCT)
3349748|NCT02257255|Experimental|Misgav-Ladach cesarean section|Women in 36 to 40 weeks of pregnancy undergoing first cesarean section by minimally invasive technique. Pain assessment on postoperative hours 6, 12 and 24.
3349749|NCT02257268|Experimental|Change behavior group|Change behavior group = Group of change behavior including physical activity and healthy habits promotion.
3241736|NCT01302093|Active Comparator|Marketed Capsule|A single 100 mg dose of a marketed Racecadotril capsule
3241737|NCT01302106|Experimental|Arm 1|Clofarabine combined with low dose Ara-C
3349750|NCT02257268|No Intervention|Control group|Control group = Group that will not receive the VAMOS program as intervention.
3241738|NCT01302145|Experimental|ASP1941 + metformin|Oral
3241739|NCT01302145|Placebo Comparator|Placebo + metformin|Oral
3241740|NCT01302171|Experimental|Peripheral|Half the patients will be randomised to the non-interventional part of the trial. In this subgroup of patients will be randomised 1:1 to 5 day course of subcutaneous placebo injections or a 5 day course of G-CSF(Granocyte™) subcutaneous injections
3241741|NCT01302171|Experimental|Interventional arm|In the subgroup of the interventional arm patients will be randomised 1:1 to receive a 5 day course of subcutaneous G-CSF (Granocyte™) injections and bone marrow aspiration at day 5, they will then receive either stem cells or placebo via intracoronary injection
3241742|NCT01302184|Experimental|Experimental Group|Lokomat®
3241743|NCT01302184|Active Comparator|Control Group|Treadmill training
3241744|NCT01302210||Intervention|Active surveillance testing for MRSA and decolonization of positive subjects
3241745|NCT01302210||control|Usual standard of care
3241746|NCT01302223||Minor Burns|Total burn surface area less than 5% of second and third degree.
3241747|NCT01302223||Major Burns.|Total Burn Surface Area more than 25% of second and third degree, and less than 50%.
3241748|NCT01302236|Experimental|Eplerenone|
3241749|NCT01302249|Experimental|AR-12286|AR-12286 Ophthalmic Solution 0.5%
3241750|NCT01302249|Active Comparator|Timolol|Timolol maleate ophthalmic solution 0.5%
3241751|NCT01302262||Healthy smokers|Healthy male and female smokers. Each subject will undergo PET scan (along with craving and anxiety questionnaires) on two conditions - Smoking and Non-smoking - on two separate visits.
3241752|NCT01302275|Experimental|oxcarbazepine|Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
3241753|NCT01302275|Placebo Comparator|placebo|
3241754|NCT01302314|Experimental|cognitive rehabilitation|
3241755|NCT01302327|Experimental|Exenatide|
3241756|NCT01302340|Active Comparator|Delta-THC|THC will be administered twice daily during three consecutive days per treatment block(0.75 or 1.5 mg twice daily)
3241757|NCT01302340|Placebo Comparator|placebo|Placebo will be administered twice daily during three consecutive days per treatment block.
3241758|NCT01302353|Experimental|Arm 1 (0.0024 ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0024ml/kg.
3241759|NCT01302353|Experimental|Arm 2 (0.006ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.006ml/kg.
3241760|NCT01302353|Experimental|Arm 3 (0.012ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.012ml/kg.
3241761|NCT01302353|Experimental|Arm 4 (0.02ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.02ml/kg.
3241762|NCT01302353|Experimental|Arm 5 (0.0301ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0301ml/kg.
3241763|NCT01302353|Experimental|Arm 6 (0.0391ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0391ml/kg.
3241764|NCT01302353|Experimental|Arm 7 (0.0508ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0508ml/kg.
3241765|NCT01302353|Experimental|Arm 8 (0.066ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.066ml/kg.
3241766|NCT01302353|Experimental|Arm 9 (0.0859ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.0859ml/kg.
3241767|NCT01302353|Experimental|Arm 10 (0.1116ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1116ml/kg.
3241768|NCT01302353|Experimental|Arm 11 (0.1451ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1451ml/kg.
3241769|NCT01302353|Experimental|Arm 12 (0.1886ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.1886ml/kg.
3241770|NCT01302353|Experimental|Arm 13 (0.2452ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.2452ml/kg.
3349751|NCT02257281|Experimental|Active Therapeutic Ultrasound|The three inflammatory forearm spots on the same side induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with active therapeutic ultrasound .
3349752|NCT02257281|Placebo Comparator|Non-active Therapeutic Ultrasound|The contralateral three inflammatory forearm spots induce by the experimentally skin model(1%, 0.5%, 0% SLS) treat with non-active therapeutic ultrasound .
3349753|NCT02257294|Placebo Comparator|Control Arm|two placebo vials
3349754|NCT02257294|Active Comparator|Arm A|Alteplase 10mg and placebo vial
3349755|NCT02257294|Active Comparator|Arm B|Alteplase 10mg and alteplase 10mg
3349756|NCT02257320|Other|Feasibility|Assessing EMG activity with Bruxoff(TM) device
3349757|NCT02257346|Active Comparator|Lidocaine|Intravenous lidocaine 1.5 mg/Kg bolus dose and 2mg/Kg/hr infusion
3349758|NCT02257346|Placebo Comparator|Normal Saline|Intravenous normal saline infusion
3349759|NCT02257359|Experimental|Epelsiban Cohort 1|Subjects will receive 300 mg of epelsiban administered orally twice (every 12 hr) on Day 1 (total daily dose of 600 mg)
3349760|NCT02257359|Experimental|Epelsiban Cohort 2|Epelsiban dose for Cohort 2 will be determined based on data from Cohort 1, but will not exceed a total daily dose of 900 mg, administered orally in divided doses (450 mg every 12 hrs or 300 mg every 8 hrs).
3349761|NCT02257359|Experimental|Additional Cohorts TBD (to be decided)|Subjects will be enrolled if determined necessary, based on data collected in Epelsiban Cohort 1 and Cohort 2
3349762|NCT02257398|Experimental|Sequence ABDC|Subjects will be administered treatments in Sequence ABDC where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3349763|NCT02257398|Experimental|Sequence BCAD|Subjects will be administered treatments in Sequence BCAD where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3349764|NCT02257398|Experimental|Sequence CDBA|Subjects will be administered treatments in Sequence CDBA where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3241771|NCT01302353|Experimental|Arm 14 (0.3188ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.3188ml/kg.
3241772|NCT01302353|Experimental|Arm 15 (0.4144ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.4144ml/kg.
3349765|NCT02257398|Experimental|Sequence DACB|Subjects will be administered treatments in Sequence DACB where, A= GSK2140944 1000 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; B= GSK2140944 1800 mg IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning; C= GSK2140944 placebo IV infusion over 120 minutes and single dose of moxifloxacin placebo administered orally in morning and D= Moxifloxacin 400 mg administered orally in morning and GSK2140944 placebo administered as IV infusion over 120 minutes
3349766|NCT02257411|Active Comparator|Ear-sized based and weight based formula|the sizes of the PLMA determined with the ear-based compared with the sizes according to the manufacturer's weight-based formula
3349767|NCT02257424|Other|Phase 1/2|
3349768|NCT02257437|Experimental|LNS + borbor|Lipid-based nutrient supplement (LNS) added to borbor
3349769|NCT02257437|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge
3349770|NCT02257437|Active Comparator|Sprinkles|Sprinkles added to borbor
3241773|NCT01302353|Experimental|Arm 16 (0.5387ml/kg)|In this group, the volunteers receive emulsified isoflurane (120mg/ml) at the dose of 0.5387ml/kg.
3241774|NCT01302405|Experimental|PRI-724|
3241775|NCT01302431|Experimental|Nurse-Led Manualised Telephone support|Participants assigned to this arm of the study will receive 4 nurse-led telephone support calls over a three month time-frame
3241776|NCT01302431|No Intervention|Usual care|Participants randomised to this arm of the study will receive their usual care which comprises caregivers calling nurse specialists when they needs advice and support
3241777|NCT01302457||Healthy Same Subjects|The control group will be 19 years or older and be randomly picked from from volunteer staff at Saint Elizabeth Regional Medical Center. This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects
3349771|NCT02257437|Active Comparator|LNS snack|LNS eaten as snack
3349772|NCT02257463|Active Comparator|Study group (group A)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training) inspiratory muscle training: (at intensity that progressively increased from 30% to 60% of patients' maximal inspiratory pressure)"
3349773|NCT02257463|Active Comparator|control positive group (group B)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations peripheral muscles exercise training: (upper limb and lower limb strength and endurance training)"
3349774|NCT02257463|Active Comparator|control negative group (group C)|"pharmacologic treatment: theophylline uniphyllin, long acting bronchodilators foradil/spiriva or combined LABD and inhaled steroids miflonide according to GOLD recommendations"
3349775|NCT02257476|Experimental|Carfilzomib|Patients will receive single agent carfilzomib on a weekly dosing schedule (days 1, 8, 15) in a 21 day cycle. The initial dose will be 20 mg/m² for cycle 1, day 1. Dose escalation will proceed in a standard 3+3 fashion with the requirement that dose escalation to the next level can only proceed if 0 of 3 or ≤ 1 of 6 patients experience a dose limiting toxicity (DLT). Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
3349776|NCT02257502|Experimental|aflibercept|intravitreal injection of aflibercept (EYLEA)
3349777|NCT02257580|Experimental|E-Aminocaproic acid (EACA)|An EACA loading dose of 100 mg/kg with a max of 4-5 grams will be given up to 1 hour prior to incision. During the case, an EACA infusion of 33 mg/kg/hr (max of 1 gram/hr) will be maintained. The use of EACA will be terminated at the end of the case.
3349778|NCT02257580|Placebo Comparator|Placebo|Equivalent volume of normal saline prepared by the pharmacy.
3349779|NCT02257593|Experimental|10 % Protein|10% Dietary protein energy
3349780|NCT02257593|Experimental|15% Protein|15% Dietary protein energy
3349781|NCT02257593|Experimental|25% Protein|25% Dietary protein energy
3349782|NCT02257606|No Intervention|Control group (persons with MS)|no training
3349783|NCT02257606|Experimental|Experimental group (persons with MS)|Robot-assisted training
3349784|NCT02257619|Experimental|Itacitinib plus docetaxel|
3349785|NCT02257645||Euforvac-Hib vaccine|
3349786|NCT02257658|Experimental|Doxycycline|Subjects in the doxycycyline arm will receive Doxycycline, oral, 100 mg, once daily for 36 weeks.
3241778|NCT01302457||Health Volunteers|"The control group will be 19 years or older and be randomly picked from volunteer staff at Saint Elizabeth Regional Medical Center.~DESIGN This is a prospective study that will look at the similarities and difference of both groups. This will help us determine if there is a need to improve oral hygiene protocol given to burn/intensive care patients. Each group will consist of 25 subjects"
3241779|NCT01302470|Active Comparator|Robotic placement of CS lead|CS leads placed epicardially in the area of increased dyssynchrony as demonstrated by low dose dobutamine stress testing.
3241780|NCT01302470|Active Comparator|Transvenous placement of CS lead|CS lead will be placed transvenously
3241781|NCT01302496|Experimental|TriMix-DC and Ipilimumab|
3241782|NCT01302509|Active Comparator|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3349787|NCT02257658|Active Comparator|Incentive|Subjects in the incentive arm will receive escalating payments for remaining STI free at Weeks 12, 24 and 36.
3349788|NCT02257671|Active Comparator|Oral contraceptive|oral dose of ethinylestradiol 0.03 mg + levonorgestrel 0.15 mg per day during 11 weeks
3349789|NCT02257671|Placebo Comparator|Placebo|Oral placebo capsule daily during 11 weeks
3349790|NCT02257697|Experimental|Mizoribine (MZR)|Oral administration, daily dose of 150mg (50mg/tablet, t.i.d) All study subjects will receive standard steroid therapies during the study.
3241783|NCT01302535|Active Comparator|Yoga group with supervision/trainer|
3241784|NCT01302535|Active Comparator|Yoga at home|
3349791|NCT02257697|Active Comparator|Cyclophosphamide (CTX)|"Intravenous injection with between 0.5 to 1.0 g/m2 body surface area each time (the maximum dose is 1.0 g/day each time).~All study subjects will receive standard steroid therapies during the study."
3349792|NCT02257710||Orsiro|All subjects requiring coronary revascularization with Drug Eluting Stents (DES)
3349793|NCT02257749|Experimental|Active Rehabilitation|Active Rehabilitation Intervention and Comprehensive Education Intervention (Standard Care)
3349794|NCT02257749|Active Comparator|Comprehensive Education Intervention|Comprehensive Education Intervention (Standard Care) only
3349795|NCT02257762|Experimental|Lipid-based nutrient supplement (LNS)|LNS added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
3349796|NCT02257762|Active Comparator|Corn-soy blend ++ (CSB++)|CSB++ porridge, eaten over 6 months, age 6-12 months to age 11-17 months
3349797|NCT02257762|Active Comparator|Sprinkles|Sprinkles added to borbor, eaten over 6 months, age 6-12 months to age 11-17 months
3349798|NCT02257762|No Intervention|Control|Plain borbor and thereafter family foods, eaten over 6 months, age 6-12 months to age 11-17 months
3349799|NCT02257788|Active Comparator|Treatment Arm 1|PRO 140: one SC dose, 350 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3349800|NCT02257788|Active Comparator|Treatment Arm 2|PRO 140: one SC loading dose, 700 mg (day 1), followed by two single SC doses, 350 mg each (days 8 and 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3349801|NCT02257788|Active Comparator|Treatment Arm 3|PRO 140: one SC loading dose, 700 mg (day 1), followed by one single SC dose 350 mg (day 15) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3349802|NCT02257788|Active Comparator|Treatment Arm 4|PRO 140: one SC dose, 700 mg (day 1) Intervention: Drug: PRO 140 (humanized monoclonal antibody to CCR5)
3349803|NCT02257801|Experimental|Nutritional beverage fortified with 6mg lutein/day|
3349804|NCT02257801|Experimental|Nutritional beverage fortified with 12mg lutein/day|
3349805|NCT02257801|Placebo Comparator|Nutritional beverage fortified with 0mg lutein/day|
3349806|NCT02257814|No Intervention|Control Group|Control group
3349807|NCT02257814|Experimental|Incredible Years|incredible years intervention
3349808|NCT02257814|Experimental|Preschool PATHS|Preschool PATHS (Promoting Alternative Thinking Strategies)
3349809|NCT02257814|Experimental|Tools of the Mind|Tools of the Mind
3349810|NCT02257827|Experimental|IMRT- Hypofractionated schedule 70 Gy/25 fx|The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
3349811|NCT02257827|Active Comparator|3DCRT-Hypofractionated schedule 70 Gy/25 fx|The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy. By the linear-quadratic formula, considering an α/β ratio of 1.5 Gy for prostate cancer, 70 Gy/25 fractions is equivalent to 86 Gy in 43 fractions of 2 Gy. All patients were simulated on CT simulator.
3349816|NCT02257879||Sequence A|water - GFJ - supplement
3349817|NCT02257879||Sequence B|GFJ - supplement - water
3349818|NCT02257879||Sequence C|supplement - water - GFJ
3349821|NCT02257905||AL Amyloidosis patients who received allo HSCT|
3349822|NCT02257918|Experimental|Group 1|N = 70 subjects receive single oral dose , 2000 mg of AZD0914
3349823|NCT02257918|Experimental|Group 2|N =70 subjects receive single oral dose , 3000 mg of AZD0914
3349824|NCT02257918|Active Comparator|Group 3|N = 40 subjects receive single intramuscular dose, 500 mg of ceftriaxone
3349825|NCT02257931||HSCT recipient|Allogeneic or autologous HSCT recipients, of all ages, for any indications. From this group we take those with a gram-negative bacteremia within 6 months after HSCT.
3241785|NCT01302535|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention groups.
3241786|NCT01302561|Placebo Comparator|Sugar Pill|
3241787|NCT01302561|Experimental|Galactooligosaccharide 5 g|
3241788|NCT01302574|Placebo Comparator|mixed liquid meal|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate
3349826|NCT02257944|Experimental|Motivational Interviewing|Receive brief hospital-based intervention
3349827|NCT02257944|Other|Treatment as Usual|Treatment as Usual
3349828|NCT02257983|Active Comparator|EPI-743|EPI-743 400 mg P.O. TID
3349829|NCT02257983|Placebo Comparator|Placebo|Sesame Oil, NF in sealed gelatin capsules to match the test product
3349830|NCT02257996|Experimental|Interventional Group|Online Systematic Brief Psychodynamic Psychotherapy
3349831|NCT02257996|No Intervention|Control Group|Waiting list
3349832|NCT02258009|Experimental|Group 1|Monthly intravitreal injections of 0.5 mg ranibizumab
3349833|NCT02258009|Experimental|Group 2|Three monthly intravitreal injections of 2 mg aflibercept followed by three monthly intravitreal injections of 0.5 mg ranibizumab
3349834|NCT02258035||DBP/Gc1f-1f genotype|Human volunteers homozygous for the 1f-1f (fast) genotype of DBP.
3241789|NCT01302574|Active Comparator|mixed liquid meal + lactisole|500 mL mixed liquid meal + 50 mg 13C-sodium-acetate + 450 ppm lactisole
3241790|NCT01302587||Albuterol MDI|All participants in this study will receive an albuterol MDI inhaler.
3349835|NCT02258035||DBP/Gc1s-1s genotype|Human volunteers homozygous for the 1s-1s (slow) genotype of DBP.
3241791|NCT01302600|Experimental|Olesoxime|100 patients in this arm. liquid suspension
3241792|NCT01302600|Placebo Comparator|Placebo|50 patients enrolled in this arm. liquid suspension
3349836|NCT02258035||DBP/Gc 2-2 genotype|Human volunteers homozygous for the 2-2 genotype of DBP.
3349837|NCT02258048||Patients with cirrhosis|
3349838|NCT02258061|Experimental|DDD-80 pacing|To investigate the impact of basal pacing rates of 80-bpm (DDD-80) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) and (iii) self-perceived quality of life (QoL).
3241793|NCT01302613|Other|arm one|RT + Chemo + surgery
3241794|NCT01302626||1: Surgery alone or combined with (chemo)radiotherapy|"Fresh frozen tumor tissue and normal tissue;~Recording of clinical characteristics, imaging, surgery features.~After treatment: FU at 2-3 weeks post surgery, 3,6,12,24 and 36 months post-surgery"
3241795|NCT01302626||2: Radiotherapy alone|"(including stereotactic radiotherapy)~Before start RT (during staging):Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Day 0 (before start RT): Recording of clinical characteristics, imaging, and radiotherapy features;~Day 8-12 (during RT): Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3241796|NCT01302626||3: Sequential chemotherapy and radiotherapy|"Day -30 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3241797|NCT01302626||4: Concurrent chemoradiotherapy with induction chemotherapy|"Day -30 until-18 (before start CT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, and chemotherapy features.~Day 0 (before start RT):~Recording of clinical characteristics, imaging, and radiotherapy features.~Scoring of toxicity.~Day 8-12 (during RT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3241798|NCT01302626||5: Concurrent chemoradiotherapy without induction chemotherapy|"Day 0 (before start CRT):~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, chemotherapy features, and radiotherapy features.~Day 8-12 (during CRT):~Scoring of toxicity.~After treatment: FU at 2-3 weeks post RT, 3,6,12,24 and 36 months post-RT"
3241799|NCT01302626||6: Stage IV lungcancer, any systemic therapy & supportive care|"Day 0:~Optional: Biopsies, frozen or RNA later, of tumor and/or lymph nodes;~Recording of clinical characteristics, imaging, surgery or any systemic (MoAb) features.~After treatment: FU at 2-3 weeks post treatment, 3,6,12,24 and 36 months post-treatment"
3241800|NCT01302639|Experimental|EGCG and resveratrol|
3241801|NCT01302639|Experimental|EGCG, resveratrol and genistein|
3241802|NCT01302639|Placebo Comparator|placebo|
3349839|NCT02258061|Sham Comparator|DDD-60 pacing|To investigate the impact of basal pacing rates of 60-bpm (DDD-60) in CRT patients on: (i) autonomic nerve function; assessed by micro-neurography, and N-terminal pro-brain natriuretic peptide (NT-proBNP) and (ii) peak oxygen consumption (pVO2) self-perceived quality of life (QoL).
3349840|NCT02258087|Active Comparator|LDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with Prostate LDR brachytherapy as monotherapy. 145 Gy is prescribed to the prostate. I-125 radioactive sources are used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
3349841|NCT02258087|Experimental|HDRPBT|Patients with low and selected intermediate risk prostate cancer are treated with prostate HDR brachytherapy as monotherapy. The prescribed dose is 1x19 Gy to the whole prostate. Ir-192 radioactive source is used. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time dose optimization is applied.
3349842|NCT02258100||Paper|Patients receiving care documented via paper anesthesia record.
3349843|NCT02258100||AIMS|Patients receiving care documented via electronic anesthesia record.
3349844|NCT02258113|Other|LEA numbers, Pelli-Robson, Octopus|Comparable generally used method for measuring visual acuity, contrast sensitivity and visual field.
3349845|NCT02258126|Active Comparator|Control group|healthy lifestyle education including healthy lifestyle education, supportive therapy and behavioral advice for both children and parents to improve nutrition and physical activity
3349846|NCT02258126|Experimental|Exercise group|multidisciplinary intervention program including healthy lifestyle education, supportive therapy and behavioral advice for for both children and parents to improve nutrition and physical activity and supervised exercise.
3349847|NCT02258165||Advanced ovarian cancer|gated PET/CT imaging
3349848|NCT02258178||1, Flucelvax|Flucelvax exposure in pregnancy
3349849|NCT02258191|Active Comparator|NIV treatment with telemonitoring|telemonitoring is used to manage NIV treatment
3349850|NCT02258191|Sham Comparator|NIV treatment with sham telemonitoring|sham telemonitoring (data not used for NIV management)
3349851|NCT02258204|Placebo Comparator|tPA-placebo|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Saline infusion : 0.15 mL/kg IV bolus (maximum 15 mL) followed by an IV infusion of 0.15 mL/kg over 60 minutes (maximum 15 mL)."
3349852|NCT02258204|Experimental|tPA-ketamine|"tPA infusion : 0.9 mg/kg (90 mg maximum), 10% of the total dose is administered as an initial IV bolus dose over 1 minute and the remainder of the dose is infused over 60 minutes.~Ketamine infusion : 0.15 mg/kg IV bolus (maximum 15 mg) followed by an IV infusion of 0.15 mg/kg over 60 minutes (maximum 15 mg)."
3349853|NCT02258230|Active Comparator|2D mode LSC|2D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3349854|NCT02258230|Active Comparator|3D mode LSC|3D mode of the 3D Laparoscopic Video System for the Laprascopic Sacral Colpopexy (LSC) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3349855|NCT02258230|Active Comparator|2D mode PVR|2D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3349856|NCT02258230|Active Comparator|3D mode PVR|3D mode of the 3D Laparoscopic Video System for the Paravaginal Repair (PVR) arm. Use of the 3D laparoscopic system can be switched to either 2D or 3D.
3349857|NCT02258269|Experimental|SQ|Patients with rheumatoid arthritis exercise square dance
3349858|NCT02258269|Sham Comparator|Control|Patients with rheumatoid arthritis listen to accompany music of square dance at home
3349859|NCT02258282|Experimental|Etanercept|Patients under the treatment of 50 mg Etanercept
3241803|NCT01302652||GH deficient after acromegaly cure (on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are receiving growth hormone treatment.
3241804|NCT01302652||GH deficient after acromegaly cure (not on GH replacement)|Men and women with growth hormone deficiency following cure of acromegaly who are not receiving growth hormone treatment.
3349860|NCT02258282|Sham Comparator|Control|Patients under the treatment of traditional DMARDs
3349861|NCT02258295|Experimental|Intragel|Intragel (IBSA) has an average size of 800-1200 kDaltons. Intragel will give given with a concentration of 16mg/2cc. Each injection (2cc) injection will be given at baseline, then 2 weeks and 4 weeks from the baseline.
3241805|NCT01302717|Active Comparator|Right ventricular pacing|
3241806|NCT01302717|Experimental|Left ventricular pacing|
3241807|NCT01302769|Experimental|battlefield auricular acupuncture|battlefield auricular acupuncture
3241808|NCT01302769|No Intervention|placebo|
3241809|NCT01302795|Experimental|Canakinumab|Canakinumab s.c. 150-300mg Week 0, (2), 8
3241810|NCT01302821|Experimental|Radiotherapy|AMT positron emission tomography with integrated computed tomography (PET/CT)scanning in metastatic breast cancer patients to identify tumors with increased AMT uptake due to up-regulated IDO expression.
3241811|NCT01302847|Experimental|Cohort I: Adolescents 12 to younger than 18 years of age|DTG film-coated tablets
3241812|NCT01302847|Experimental|Cohort IIA: Children 6 to younger than 12 years of age|DTG film-coated tablets
3241813|NCT01302847|Experimental|Cohort IIB: Children 6 to younger than 12 years of age|DTG granules for suspension or DTG dispersible tablets
3241814|NCT01302847|Experimental|Cohort III: Children 2 to younger than 6 years of age|DTG granules for suspension or DTG dispersible tablets
3241815|NCT01302847|Experimental|Cohort III-DT: Children 2 to younger than 6 years of age|DTG dispersible tablets
3241816|NCT01302847|Experimental|Cohort IV: Children 6 months to younger than 2 years of age|DTG granules for suspension or DTG dispersible tablets
3241817|NCT01302847|Experimental|Cohort IV-DT: Children 6 months to younger than 2 years of age|DTG dispersible tablets
3241818|NCT01302847|Experimental|Cohort V-DT: Infants 4 weeks to younger than 6 months of age|DTG dispersible tablets
3241819|NCT01302873|Experimental|BGG492|
3241820|NCT01302873|Placebo Comparator|Placebo|
3241821|NCT01302886|Experimental|BHQ880|
3241822|NCT01302925|Experimental|PEP005 Gel 0.05%/2 days|Subjects will be exposed to investigational product for 2 consecutive days.
3241823|NCT01302925|Experimental|PEP005 Gel 0.015%/3 days|Subjects will be exposed to investigational product for 3 consecutive days.
3241824|NCT01302951|Experimental|Moxifloxacin|Moxifloxacin 400 mg i.v.
3241825|NCT01302951|No Intervention|No drug|2 Patients were included as controls- no MXF given
3349862|NCT02258295|Active Comparator|Saline|Saline injections will be given similar to the active hyaluronic injections. Each injection (2cc) will be given at baseline, then 2 weeks and 4 weeks from the baseline.
3375959|NCT03360500|Placebo Comparator|EXERCISE PROTOCOL + PLACEBO|Patients with knee osteoarthritis, both sexes, with age between 40 and 75
3375960|NCT03350451|Experimental|Lumasiran (ALN-GO1)|
3375961|NCT03339765|Experimental|Serious game intervention|Participants randomized to the intervention will receive the Strong Together serious game program on a tablet computer. The goal of this serious game is to teach the participant how to advocate for her needs relate to her cancer and treatment. The research team will send participants weekly notifications for 12 weeks to alert them that a new serious game session is available and encourage them to complete one session per week.
3349863|NCT02258308|Experimental|CHW intervention|"The CHW intervention is in-home education and support by a community health worker (CHW). At the first home visit, the CHW assesses the participant's knowledge and skills related to asthma self-management, current status of the child's asthma, and resources and support for asthma self-management using a baseline questionnaire. The CHW will inspect the home environment using an Environmental Home Checklist to identify environmental triggers that can cause asthma symptoms and affect asthma control. The CHW makes up to three follow-up visits and two telephone visits during the year the participant is in the study. Participants receive resources to help them control asthma: vacuum cleaner, dust covers for a pillow and mattress and a green cleaning kit with cleaning supplies."
3349864|NCT02258308|No Intervention|control|The control group receives standard asthma care, as provided by a primary health care provider. When the intervention period is over, the control group receives one visit with a CHW and the resources provided to the intervention group participants.
3241826|NCT01302977|Experimental|Fetal intervention|Composed of fetuses that undergo to fetal tracheal occlusion at 26-28 weeks.
3349865|NCT02258321|Experimental|PPI-668 tablet followed by capsule|On day 1, one 200 mg PPI-668 tablet will be administered. On day 6, two 100 mg PI-668 capsules will be administered.
3349866|NCT02258321|Experimental|PPI-668 capsule followed by tablet|On day 1, two 100 mg PI-668 capsules will be administered. On day 6, one 200 mg PPI-668 tablet will be administered.
3349867|NCT02258347|Experimental|Single arm|
3349868|NCT02258360|Active Comparator|24 hours hypothermia|Therapeutic hypothermia for 24 hours after reaching target temperature
3349869|NCT02258360|Experimental|48 hours hypothermia|Therapeutic hypothermia for 48 hours after reaching target temperature
3349870|NCT02258399|Active Comparator|Breakfast Rest|
3349871|NCT02258399|Active Comparator|Breakfast Exercise|
3349872|NCT02258399|Experimental|Fasted Exercise|
3349873|NCT02258425|Experimental|FEM-CARE|Six specialized nurse case managed and health education sessions and coach-facilitated mentoring
3349874|NCT02258425|Active Comparator|Health Promotion|One brief basic health education session and coach-facilitated mentoring
3349875|NCT02258438|Experimental|Uninterrupted sitting|Patient will refrain from any structured activity and reduce any daily life activity. The patient will spend 24 hours in the calorimeter room. During the 24 hours the patient will remain sedentary for the 24 hours but will be able to watch TV, computer work or read.
3349876|NCT02258438|Experimental|Sitting + 1 bout of activity|The patient will be asked to perform the 45 minutes of moderate-exercise intervention in the morning once per day for two days in their daily life. This bout of exercise will be supervised by study staff on one of the treadmills On day 3 the patient will report at the Clinical and Translational Research Center (CTRC) of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, you will be asked to sit quietly in a chair, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity walking on a treadmill.
3349877|NCT02258438|Experimental|Sitting + microbursts of activity|The patient will be asked to refrain from any structured exercise running, swimming, lifting weights, yoga, dancing, etc.) for two days but to walk for the 5 minute intervention each hour between 1000 and 1800. On day 3, The patient will report at the CTRC of the University Hospital of Colorado and will spend 24hr in the room calorimeter. During the day, the patient will be asked to rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5 min moderate-intensity walking on a treadmill, which represents a total of 45 min.
3349878|NCT02258451|Experimental|Radium-223 dichloride + exemestane/everolimus|Up to 6 cycles of radium-223 dichloride 50kBq/kg body weight (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) (randomized) + All patients will receive exemestane and everolimus
3349879|NCT02258451|Placebo Comparator|Placebo + exemestane/everolimus|Up to 6 cycles of saline injection (placebo) (randomized) + All patients will receive exemestane and everolimus
3241827|NCT01302977|No Intervention|Control|Composed of fetuses that do not undergo fetal intervention
3241828|NCT01302990|Experimental|5 micrograms H1 VLP|
3241829|NCT01302990|Experimental|13 micrograms H1 VLP|
3241830|NCT01302990|Experimental|28 micrograms H1 VLP|
3241831|NCT01302990|Active Comparator|45 micrograms Fluzone|
3241832|NCT01302990|Placebo Comparator|Placebo|
3241833|NCT01303016|Experimental|Nutrition supplement|Receives a month's supply of the nutrition supplement, Chispuditos, in addition to a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month.
3241834|NCT01303016|No Intervention|Control|Receives a voucher for 1lb of powdered milk each month and a voucher for 1lb of sugar every other month. Participants in the control group will receive the nutrition supplement, Chispuditos, for one year after the study is complete.
3241835|NCT01303029|Active Comparator|Control|Gemcitabine+erlotinib
3241836|NCT01303029|Experimental|Experimental|Gemcitabine+erlotinib+capecitabine
3241837|NCT01303042|Experimental|Insulin lispro mix 50/50|
3241838|NCT01303055|Experimental|Alogliptin|Alogliptin 25 mg
3241839|NCT01303055|Active Comparator|Metformin|Metformin 750 mg
3241840|NCT01303081|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
3241841|NCT01303081|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
3241842|NCT01303081|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
3349880|NCT02258503||numerical scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and then taken care according to the usual practice of the emergency department.
3349881|NCT02258503||algoplus scale|Evaluation of the pain of elderly patient admitted in the emergency department by numerical scale and by Algoplus® scale then taken care according to the usual practice of the emergency department.
3349882|NCT02258516|Experimental|behavioral intervention|"Patient education for self-management called CHIME 3-M will be delivered"
3349883|NCT02258516|Active Comparator|control|attention control arm received phone calls to discuss non-heart failure related health topics
3349884|NCT02258542|Experimental|Benralizumab Arm A|Benralizumab administered subcutaneously
3349885|NCT02258542|Experimental|Benralizumab Arm B|Benralizumab administered subcutaneously
3349886|NCT02258555|Experimental|GS-9901|Participants will receive one of 6 escalating doses of GS-9901 once daily until unacceptable toxicity, substantial noncompliance, disease progression, pregnancy, initiation of another anti-cancer or experimental therapy, or other protocol-specified reasons for GS-9901 discontinuation.
3349887|NCT02258568|Experimental|Smoking abstinence counseling|Telephone motivational counseling sessions supporting smoking abstinence
3349888|NCT02258568|No Intervention|Control|Do not receive telephone motivational counseling sessions supporting smoking abstinence
3349889|NCT02258594|No Intervention|Baseline - Usual Care|"Usual Care on two Medical Intensive Care Units units~Usual Care on four Oncology units"
3349890|NCT02258594|Experimental|Post-Implementation - Intervention Units|"PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two MICU units~PROSPECT Intervention (Web-Based Patient Centered Toolkit (PCTK) + The Patient-SatisfActive® Model) on two Oncology units"
3349891|NCT02258594|No Intervention|Post-Implementation - Usual Care|Usual Care on two Oncology Units
3349892|NCT02258607|Experimental|Momelotinib (MMB) dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.
3241843|NCT01303081|Experimental|Chosen Deposits|Same as USUAL CARE, plus financial incentive as follows: participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine or anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
3241844|NCT01303081|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
3349893|NCT02258607|Experimental|Trametinib dose escalation|Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.
3349894|NCT02258607|Experimental|Momelotinib (MMB)+trametinib|Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.
3349895|NCT02258620|Experimental|dinitrate isosorbide (intra venous)|dinitrate isosorbide by continuous intra venous injection (1 à 5 mg/h)
3349896|NCT02258620|Experimental|dinitrate isosorbide (intra arterial)|dinitrate isosorbide 5 mg by direct administration intra arterial
3349897|NCT02258620|Experimental|nitroglycerine (transdermic)|nitroglycerine dermal patch15 mg/24h soit 67,2 mg/21 cm2
3241845|NCT01303094|Other|Continuation of Trabectedin|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle, every 3 weeks until progression/ toxicity
3349898|NCT02258633|Experimental|Intervener Brief Intervention (IBI)|Subjects and parents will complete a Brief Motivational Interview (BMI) incorporating personalized feedback, discussion of choices and changes, and therapist led intervention message relating behavioral change and future goals.
3349899|NCT02258633|No Intervention|Enhanced Usual Care|Subjects and parents will receive standard trauma care, plus complete brief questionnaires and receive general safety information.
3349900|NCT02258646|Experimental|Telerehabilitation|Exercise training at home, telemonitoring, and education/self-management
3349901|NCT02258646|Experimental|Unsupervised exercise training at home|Unsupervised exercise training at home
3349902|NCT02258646|No Intervention|Usual care|Usual care
3349903|NCT02258672|Experimental|Prehabilitation program|Participants will be physically trained before undergoing surgery
3349904|NCT02258672|No Intervention|Control|Patients will follow the normal course of care provided by the hospital
3349905|NCT02258685||Cohort A1|ART-treated HIV-infected individuals with lipodystrophy
3349906|NCT02258685||Cohort A2|ART-treated HIV-infected individuals without lipodystrophy
3349907|NCT02258685||Cohort A3|HIV-1 infected individuals naïve to ART
3241846|NCT01303094|Other|"Drug holiday therapy"|patient receives 6 cycles of trabectedin, then one dose 15 days after the 6th cycle and he stops the drug until progression and re-challenge
3241847|NCT01303107|Active Comparator|bupivacaine S50:R50|3 ml subarachnoid block
3241848|NCT01303107|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
3241849|NCT01303120|Active Comparator|Femoral Nerve Block|
3241850|NCT01303120|Active Comparator|Combined Nerve Blocks|
3241851|NCT01303120|Active Comparator|Patient-controlled analgesia|
3241852|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/-)|We will be recruiting healthy adults with Down syndrome ages 30 and over. Participants cannot have a diagnosis of dementia.
3241853|NCT01303133||Adults with Down Syndrome ages 30+ (PiB-/+)|
3241854|NCT01303133||Adults with Down Syndrome ages 30+ (PiB+/+)|
3241855|NCT01303146|Experimental|Enzyme replacement therapy|intravenous infusion 100U/kg every other week for 18 months
3241856|NCT01303185||Experimental Group|
3241857|NCT01303185||Control Group|
3241858|NCT01303198|Active Comparator|CPAP|Use of CPAP as treatment for sleep apnea
3349908|NCT02258685||Cohort A4|HIV-1 seronegative individuals who are at a high risk for infection
3349909|NCT02258685||Cohort B1|A subset of subjects from Cohort A: ART-treated HIV-infected individuals with HIV-associated dysbiosis
3349910|NCT02258685||Cohort B2|A subset of subjects from Cohort A: ART-treated HIV-infected individuals without HIV-associated dysbiosis
3349911|NCT02258698||Elective on-pump cardiac surgery|Observation of perioperative Insulin resistance in patients undergoing elective on-pump cardiac surgery (CABG and/or valve repair)
3349912|NCT02258711|Experimental|SIMPLe 2.0 plus Treatment as Usual (TAU)|Psychoeducative and self-monitoring smart-phone application plus treatment as usual which includes pharmacological and psychological treatment.
3349913|NCT02258711|No Intervention|Treatment as usual (TAU)|Treatment as usual which includes pharmacological and psychological treatment.
3349914|NCT02258737|Experimental|transitional case management|
3349915|NCT02258737|Active Comparator|standard care|
3349916|NCT02258750|Experimental|Polydextrose|Tomato soup enriched with added polydextrose
3349917|NCT02258750|Placebo Comparator|Control|Tomato soup without added polydextrose
3349918|NCT02258763|Experimental|Amoxicillin-Potassium Clavulanate|Patient will be on amoxicillin-clavulanate 22.5mg/kg/dose bd for 10 days
3349919|NCT02258763|Active Comparator|Placebo|Patient will be on amoxicillin-clavulanate 22.5mg/kg/bd for 3 days followed by another 7 days of placebo medication given at the same dose and frequency
3349920|NCT02258776|Active Comparator|Pomegranate Extract|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate extract on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3349921|NCT02258776|Active Comparator|Pomegranate Juice|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of pomegranate juice on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3349922|NCT02258776|Placebo Comparator|Placebo|15 healthy subjects, ages 30-45 years who meet all the eligibility criteria in the screening phase of the study will be assigned to the Pomx arm of the study to evaluate the clinical efficacy of placebo on skin inflammation and aging. Subjects will be asked to take Pomx 1/day for 12 weeks.
3349923|NCT02258789|Experimental|intervention - control|15 hours ( 3 times a week in 5 weeks) intense visio spatial scanning training Virtual Reality-method
3241859|NCT01303198|Active Comparator|APAP|Use of APAP as treatment for sleep apnea
3349924|NCT02258802|Experimental|Psychoeducational intervention|Participants will be receiving a cooking lesson in their community every 2 weeks for 1 year.
3349925|NCT02258802|No Intervention|Usual food practices|These are participants from the communities where the intervention is active but are not attending the cooking lessons.
3349926|NCT02258815|Experimental|ch14.18|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
3349927|NCT02258828|Experimental|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
3349928|NCT02258828|Placebo Comparator|Placebo|Patient received matched placebo
3349929|NCT02258841|Experimental|Personalized online Safety Decision Aid|Setting priorities for safety; Danger Assessment; Personalized Action Plan
3349930|NCT02258841|Active Comparator|General Online Risk/Safety Information|General Risk and Safety Information; Basic Emergency Safety Plan
3241860|NCT01303211||serogroup A meningococcal disease|Cases of serogroup A meningococcal disease
3349931|NCT02258854|Experimental|Dose 2 gevokizumab|
3349932|NCT02258867|Placebo Comparator|Placebo|
3349933|NCT02258867|Experimental|Gevokizumab|
3349934|NCT02258880|Experimental|SUN13837|Drug: SUN13837 daily for 28 days.
3349935|NCT02258880|Placebo Comparator|Placebo|Placebo: Matching Placebo daily for 28 days
3349936|NCT02258893|Experimental|NO2 Scrubber, then HEPA filter, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then HEPA filter, then Control.
3349937|NCT02258893|Experimental|NO2 Scrubber, then Control, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of NO2 Scrubber, then Control, then HEPA filter
3349938|NCT02258893|Experimental|HEPA filter, then NO2 scrubber, then Control|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then NO2 scrubber, then Control
3349939|NCT02258893|Experimental|HEPA filter, then Control, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of HEPA filter, then Control, then NO2 scrubber
3349940|NCT02258893|Experimental|Control, then HEPA filter, then NO2 scrubber|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then HEPA filter, then NO2 scrubber
3349941|NCT02258893|Experimental|Control, then NO2 scrubber, then HEPA filter|Participants will have 3 periods of 4 weeks with each filter with a 1 week washout between phases in the order of Control, then NO2 scrubber, then HEPA filter
3349942|NCT02258906|Experimental|Ulinastatin group|Patients in the ulinastatin group are given ulinastatin during operation.
3349943|NCT02258906|Placebo Comparator|control group|Patients in the control group receive the same volume of normal saline during operation.
3349944|NCT02258919|Experimental|Decompressive craniectomy and best medical treatment|Decompressive craniectomy and best medical treatment
3349945|NCT02258919|Active Comparator|Best medical treatment|Best medical treatment
3349946|NCT02258932||Continuous subcutaneous insulin infusion|This group will consist of patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
3241861|NCT01303211||Community controls|Healthy members of the community controls matched with cases for age, sex and place of residence
3241862|NCT01303211||Hospital controls|Patients admitted to the hospital with an acute illness other than meningitis or septicemia
3349947|NCT02258945||Continuous Subcutaneous Insulin Infusion|This group will consist of patients with Type 1 diabetes using continuous subcutaneous insulin infusion therapy.
3349948|NCT02258945||Multiple Daily Injections|This group will consist of patients with Type 1 diabetes using multiple daily injection therapy.
3349949|NCT02258971|Experimental|BEA 2180 BR oral|
3349950|NCT02258971|Active Comparator|BEA 2180 BR infusion|
3349951|NCT02258984|Other|Open physician access to Venus 1000 CVP data|
3349952|NCT02258984|Other|No open physician access to Venus 1000 CVP data|
3349953|NCT02258997||HbSS|Subjects are homozygous for the sickle hemoglobin mutation (HbS).
3349954|NCT02258997||HbS-beta thalassemia|Subjects are heterozygous for the HbS mutation and beta thalassemia
3349955|NCT02259023|Experimental|Liquid: Sugar sweetened beverage consumption|Consumption of sugar-sweetened beverages
3349956|NCT02259023|Experimental|Solid: Grain based desserts and candy consumption|Consumption of grain based desserts and/or candy
3349957|NCT02259036|Other|SmartCAT Enhanced Treatment|Cognitive Behavioral Therapy enhanced with an ecological momentary treatment enhancement smartphone app called SmartCAT.
3349958|NCT02259049|Active Comparator|L-Tyrosine|We will administer 1,000 mg of L-tyrosine BID for 24 hours and record BP and HR.
3349959|NCT02259049|Placebo Comparator|Sugar Pill|We will administer a sugar pill BID for 24 hours and record BP and HR.
3349960|NCT02259062|Active Comparator|Music listening|
3349961|NCT02259062|Experimental|Music listening with brief mindfulness|
3349962|NCT02259062|Placebo Comparator|Audio book intervention|
3349963|NCT02259075|Experimental|Botulinum Toxin|The patients will be injected with 25 IU of Botulinum Toxin Type A towards both the right and left sphenopalatine ganglion, a total of 50 IU.
3349964|NCT02259101|Experimental|CBT-I Treatment Condition|The CBT-I treatment condition will be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total CBT-I groups occurring over the course of two years will be implemented, with at total of 40 participants enrolled for the CBT-I condition.
3241863|NCT01303250|Experimental|Group 1|A balanced hydroxyethyl starch 130/0.4 will be used
3241864|NCT01303250|Active Comparator|Group 2|A balanced crystalloid will be used
3241865|NCT01303263|Other|Intervention Group|Residents Randomized to Receive Educational Intervention
3241866|NCT01303263|No Intervention|Control Group|Residents randomized not to receive a teaching intervention.
3349965|NCT02259101|Active Comparator|SH Comparison Condition|The SH comparison condition will also be delivered in a one-hour per week group format (10 participants) occurring over the course of six-weeks. Four total SH groups over the course of two years will be conducted, with a total of 40 participants enrolled for the SH condition.
3349966|NCT02259127|Active Comparator|SOC arm|SOC for ODYSSEY A is defined as a PI or non nucleoside transcriptase inhibitors + 2 or 3 nucleoside transcriptase inhibitor SOC for ODYSSEY B is defined as a PI or non nucleoside transcriptase inhibitor+ 2 nucleoside transcriptase inhibitors
3241867|NCT01303276||Anti-VEGF group|Patients who are clinically indicated for the intravitreal injection of ranibizumab
3241868|NCT01303276||Age-matched controls|Group of healthy participants who will be age and gender matched
3241869|NCT01303289|Experimental|Group 1|The group 1 will receive the experimental product T-Diet plus Standard for 3 months.
3241870|NCT01303289|Active Comparator|Group 2|The group 2 will receive the control product Jevity (Abbott Laboratories) for 3 months.
3241871|NCT01303302|Active Comparator|GCM stimulation|The patient will be implanted with a gastric contractility modulation (GCM) stimulation system using the TANTALUS System for treatment of type 2 diabetic patients.
3241872|NCT01303302|Sham Comparator|Device off|The TANTALUS System is implanted but is off
3241873|NCT01303315|Other|GLP-1 receptor agonist therapy|Group A: Subjects on GLP-1 receptor agonist therapy only. After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c < 7.5 are moved to Group A, continue GLP-1 receptor agonist therapy, and then start the Evaluation Period These patients will not be implanted with the TANTALUS system.
3241874|NCT01303315|Experimental|GLP-1 receptor agonist and TANTALUS|Group B: subjects on GLP-1 receptor agonist therapy and TANTALUS therapy After run in of 12 weeks on GLP-1 receptor agonist therapy, Patients with HbA1c > 7.5 are moved to Group B, continue GLP-1 receptor agonist therapy, implanted with TANTALUS within 4 weeks, and then start the Evaluation Period
3241875|NCT01303315|Active Comparator|Subjects on TANTALUS therapy only|Group C: subjects on TANTALUS therapy only After run in of 12 weeks on GLP-1 receptor agonist therapy, patients intolerant to low dosage of GLP-1 receptor agonist therapy will be implanted with the TANTALUS system
3241876|NCT01303328|Experimental|Treatment group|
3241877|NCT01303328|Placebo Comparator|Placebo group|
3241878|NCT01303354|Experimental|DXM 4 mg|Dexamethasone 4 mg
3241879|NCT01303354|Experimental|DXM 8 mg|Dexamethasone 8 mg
3241880|NCT01303354|Experimental|DXM 12 mg|Dexamethasone 12 mg
3241881|NCT01303367||antipsychotic agents|
3241882|NCT01303367||non-antipsychotic agents|
3241883|NCT01303393||Surgery for colorectal cancer|Patients that had surgery for colorectal cancer without receiving a stoma, and their next of kin.
3241884|NCT01303432|Experimental|Mobilee yogurt|Subjects eating daily on yogurt supplemented with Mobilee
3349967|NCT02259127|Experimental|DTG arm|DTG + 2 nucleoside transcriptase inhibitors
3349968|NCT02259140|Active Comparator|Proximal Femoral Resection Arthroplasty|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The abductors of the hip are detached with sharp dissection. A capsulotomy is performed. The femur is exposed in a supra-periosteal manner (2 cm distal to the lesser trochanter) at the level of the ischium; transverse osteotomy will then be performed. The joint capsule will be sutured to itself. The iliopsoas tendon and the abductor tendons are attached to the capsule. The quadriceps will be brought around the proximal femoral stump and sutured to medial tissues.
3349969|NCT02259140|Experimental|Subtrochanteric Valgus Osteotomy|A 10-12 cm direct lateral incision will be made distally from the greater trochanter. The medial half of the abductors may be incised off the greater trochanter for repair. The femoral head is resected at the base of the neck. The ligamentum teres is incised off the head and preserved. A lateral closing wedge osteotomy is performed below the lesser trochanter. 3.5 or 4.5 5 hole locking/non-locking surgeon-contoured plate ( 45⁰) will be used to stabilize the osteotomy. Femoral torsion will be corrected. The psoas tendon will attach the ligamentum teres to the lesser trochanter. The anterior and posterior capsule is sutured together creating interposition tissue. If the ligamentum teres was sutured to the lesser trochanter, the capsule will not close, but will be covered by the psoas tendon.
3349970|NCT02259153|Active Comparator|Lean red meat diet|Participants were given 350 g per day of lean red meat to incorporate to their usual diet for ten days.
3349971|NCT02259153|Active Comparator|Fat red meat diet|Participants were given 350 g per day of fat red meat to incorporate to their usual diet for ten days.
3349972|NCT02259166|Experimental|EHFP+|Group receiving the intervention EHFP+, in addition to MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
3349973|NCT02259166|No Intervention|Control|MNPs distribution for 2 months and malaria diagnosis and treatment for children enrolled, at baseline and after 12 months
3349974|NCT02259179|Active Comparator|Fed Group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fed state.
3349975|NCT02259179|Active Comparator|Fasted group|Reference and test product naltrexone SR/bupropion SR combination trilayer tablets tested in the fasted state.
3349976|NCT02259192|Experimental|Open-label|Cochlear Implant
3241885|NCT01303432|Placebo Comparator|Placebo yogurt|Subjects receiving daily a standard yogurt
3349977|NCT02259205|Experimental|Enriched Yogurt|150 g yogurt enriched with approximately 0.5 g bioactive lipids extract from olive oil mill provided daily for 8 weeks
3349978|NCT02259205|Placebo Comparator|Plain Yogurt|150 g not enriched yogurt provided daily for 8 weeks
3349979|NCT02259205|No Intervention|Control|No yogurt consumption
3349980|NCT02259218||Ancillary-Correlative|Prospectively collected blood, urine, and tissue samples are analyzed for potential predictive biomarkers via metabolomic and other molecular profiling.
3349981|NCT02259244|Experimental|Mediterranean diet+physical activity|Mediterranean diet based on 1573 kcal/day with the goal of consumption of 30 ml/day of olive oil, 56g/week of nuts, 3-4 servings/week of fish, 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat
3349982|NCT02259244|Active Comparator|Hypolipemic reduction diet+physical activity|Hypolipemic reduction diet based on 1287 kcal/day with the goal of consumption of 3 servings/day of fruits, 2-3 servings/day of vegetables, 3 servings/week legumes and white meat instead of red meat, non-fat or low-fat dairy products
3349983|NCT02259270||ASTRA-1|"All patients discharged from the participating hospitals between July 2012 and July 2013.~Determination of long term use of AST before, during and after hospitalisation based on dispensing data, no record review."
3349984|NCT02259270||ASTRA-2|Random selected subset of patients in ASTRA-1 with startup of AST in the hospital and AST at discharge. Record review for appropriateness of indication of startup of AST.
3349985|NCT02259283|Experimental|Achalasia|Patients (age 18-75 years old) with diagnosis of achalasia, without megaesophagus or colonic esophagus, will undergo POEM with the hybrid knife.
3349986|NCT02259296|Experimental|Lower eGFR for AVF creation|
3349987|NCT02259296|Active Comparator|Higher eGFR for AVF creation|
3241886|NCT01303458|Experimental|Intervention arm|Study subjects will receive the Basic Needs Surveillance (BNS) intervention.
3241887|NCT01303458|No Intervention|Control arm|Study subjects in the control arm will receive the standard of care.
3241888|NCT01303471|Experimental|opioïd|Different levels of remifentanyl of each group during nociceptive stimulation
3241889|NCT01303484|Placebo Comparator|MDn|Maltodextrin
3241890|NCT01303484|Active Comparator|B-GOS|Prebiotic
3241891|NCT01303497|Other|Arm A : Paclitaxel|administration of paclitaxel drug during cycle of 28 days (6 cycles Max) + blood sample on day 1, 8, 15, 29 and 57
3241892|NCT01303497|Other|Arm B : Paclitaxel + Bevacizumab|"administration of paclitaxel drug during per cycle of 28 days (6 cycles Max) + Bevacizumab every two weeks during paclitaxel cycles then every 3 weeks during P cycles until disease progression or inacceptable toxicity~+ blood sample on day 1, 8, 15, 29 and 57"
3241893|NCT01303536|Experimental|obsessive compulsive disorder|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
3241894|NCT01303549|Experimental|Anidulafungin|Anidulafungin IV once a day: initial dose 200 mg/day, following doses 100 mg/day.
3241895|NCT01303549|Active Comparator|Liposomal Amphotericin B|Liposomal amphotericin B once a day: 3 mg/kg/day
3241896|NCT01303562|Placebo Comparator|Placebo muffin made with no whole grains|
3241897|NCT01303562|Active Comparator|Test muffin made with whole oats|
3241898|NCT01303562|Active Comparator|Test muffin made with whole barley|
3241899|NCT01303575|Experimental|HIV, STI, and Pregnancy Prevention Curriculum|
3241900|NCT01303575|Active Comparator|Control curricula: Science Education|No sexual health elements
3241901|NCT01303588|No Intervention|Waiting Group|
3241902|NCT01303588|Active Comparator|Qigong|
3241903|NCT01303588|Active Comparator|Yoga|
3241904|NCT01303601|Experimental|olanzapine|
3241905|NCT01303601|Placebo Comparator|placebo|
3241906|NCT01303614|Active Comparator|Lidocaine-Prilocaine cream|
3241907|NCT01303614|Placebo Comparator|Placebo|purified water, ethylene glycol stearate, palm, palm stearate, polyethylene glycol, liquid paraffin, benzoic acid
3241908|NCT01303640|Active Comparator|Biolimus-eluting stent|Biolimus-eluting stent
3241909|NCT01303640|Active Comparator|Everolimus-eluting stent|Everolimus-eluting stent
3349988|NCT02259309|Experimental|Misoprostol administration - buccal then vaginal|Vaginal or buccal administration
3349989|NCT02259309|Experimental|Misoprostol administration - vaginal then buccal|Vaginal or buccal administration
3349990|NCT02259322|Active Comparator|Standard-of-Care|Standard-of-care is the continuation of any treatment or recommendations participants receive from his/her bariatric surgeon/team.
3349991|NCT02259322|Experimental|Behavioral Weight Loss Treatment|Guided self-help Behavioral Weight Loss Treatment
3349992|NCT02259322|Experimental|Cognitive Behavioral Therapy|Guided self-help Cognitive Behavioral Therapy
3349993|NCT02259335|Experimental|patients under invasive ventilation|those patients failing a T-piece trial beacuse of a PaCO2 rise>20% of baseline and/or a rapid shallow-breathing index >100 will be reconnected to the ventilator Two hours later they will repeat a T-piece trial after connection to the CO2 removal device
3349994|NCT02259361|Active Comparator|Experimental|Intervention: Sustained-release oral dalfampridine, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
3349995|NCT02259361|Placebo Comparator|Placebo|Placebo, one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) for 14 consecutive days.
3349996|NCT02259374|Active Comparator|TAP BLOCK 0.2% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.2% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.2% ropivacaine"
3349997|NCT02259374|Active Comparator|TAP BLOCK 0.4% ROPIVACAINE|"Patients randomised into this group will receive bilateral TAP block (single shot) with 0.4% ropivacaine after hysterectomy.~Intervention: TAP block Dose: 20 ml 0.4% ropivacaine"
3349998|NCT02259387||Cases|Children with migraines will be placed into this group.
3349999|NCT02259387||Controls|Children without migraines or headaches will be placed into this group.
3241910|NCT01303666|Active Comparator|TI of the knee|
3241911|NCT01303666|Active Comparator|Intra-articular CSI|
3350000|NCT02259426|Active Comparator|Dihydroartemisínin-piperaquine (Artekin)|Dihydroartemisínin-piperaquine combination alone
3350001|NCT02259426|Experimental|Dihydroartemisinin-piperaquine, Primaquine|Dihydroartemisinin-piperaquine with single-dose 0.25mg/kg Primaquine
3350002|NCT02259465|Active Comparator|Oligofructose|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with oligofructose, 7grams twice daily
3350003|NCT02259465|Placebo Comparator|Maltodextrin|Participants will be asked to follow the low FODMAP diet for a week, supplementing the diet with maltodextrin, 7grams twice daily
3350004|NCT02259491|Experimental|Manuka Honey Dressing|Patient receive manuka honey dressings on skin graft and free flap donor sites
3350005|NCT02259491|No Intervention|Tegaderm and xeroform gauze|Patient receive standard wound care on skin graft and free flap donor sites which includes a tegaderm over the STSG site and xeroform gauze covered with dry gauze, kerlex and a cast for the STSG recipient site
3350008|NCT02259530|Experimental|Integrated Psychotherapeutic Intervention|Integrated treatment of khat use disorder and PTSD
3350009|NCT02259543|No Intervention|G0|Root decontamination performed by scaling and root planing followed by rinsing with saline solution during the treatment of recession defects by subepithelial connective tissue graft (SCTG). Control group.
3350010|NCT02259543|Active Comparator|G90|Root conditioning with citric acid+tetracycline solution (1:1) for 90 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
3350011|NCT02259543|Active Comparator|G180|Root conditioning with citric acid+tetracycline solution (1:1) for 180 seconds after scaling and root planing, followed by rinsing with saline solution for root decontamination during the treatment of recession defects by subepithelial connective tissue graft (SCTG).
3350012|NCT02259556|Experimental|anti-CD30 CAR T cells|Patients receive CART30 cell infusions with an escalation dose.
3350013|NCT02259569|Experimental|PCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in pressure-controlled mode.
3241912|NCT01303679|Active Comparator|paclitaxel-bevacizumab|Paclitaxel, 80mg/m² at d1, d8, d15 bevacizumab, 10 mg/kg at d1, d15
3241913|NCT01303679|Experimental|exemestane-bevacizumab|exemestane, 25 mg daily dose bevacizumab, 15mg/kg every 3 weeks
3241914|NCT01303692||A|Total of 250 prostate cancer patients receiving GnRH agonist
3241915|NCT01303692||B|Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent
3241916|NCT01303705|Experimental|Cyclophosphamide - Cohort 1|Cyclophosphamide 300 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3241917|NCT01303705|Experimental|Cyclophosphamide - Cohort 2|Cyclophosphamide 600 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3350014|NCT02259569|Active Comparator|VCV group|After insertion of I-gel, mechanical ventilation of the lungs was commenced. Mechanical ventilator was set to obtain a tidal volume of 8ml/kg in volume-controlled mode.
3350015|NCT02259595|Experimental|HPN-07 500 mg / Placebo|Single dose of 500mg HPN-07 plus placebo in oral capsules.
3350016|NCT02259595|Experimental|HPN-07 1000 mg / Placebo|Single dose of 1,000mg HPN-07 plus placebo in oral capsules
3350017|NCT02259595|Experimental|HPN-07 1500 mg / Placebo|Single dose of 1,500mg HPN-07 plus placebo in oral capsules
3350018|NCT02259595|Experimental|HPN-07 MTD plus NAC 1200mg|Single dose of maximum tolerated dose of HPN-07 plus 1,200 mg NAC in oral capsules. Dose selection will be determined from safety data of previous cohorts by Data Assessment Committee (DAC).
3350019|NCT02259621|Experimental|Arm B- Nivolumab|"Nivolumab administration:~Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days."
3350020|NCT02259621|Experimental|Arm C- Nivolumab, Carboplatin, & Paclitaxel|Nivolumab 360 mg IV, Carboplatin AUC 5 or 6 IV, and Paclitaxel 175 or 200 mg/m2 IV every 21 days for 3 cycles prior to planned surgery on Day 0.
3241918|NCT01303705|Experimental|Cyclophosphamide - Cohort 3|Cyclophosphamide 900 mg/m2 IV on Day 1; Radiation Therapy 8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment; Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8.
3241919|NCT01303718|Experimental|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
3350021|NCT02259634|Experimental|Patient Navigation|Intensive Patient Navigation with Motivational Interviewing and Health Education for 8 months 18 month follow-up
3350022|NCT02259634|No Intervention|Treatment as Usual|Case Management and Medical Care as provided by the Coming Home Program at Mount Sinai St. Luke's Institute of Advanced Medicine, Morningside Clinic
3350023|NCT02259647|Experimental|Sorafenib +intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
3350024|NCT02259647|Active Comparator|Sorafenib+Placebo|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo daily for 6 days, followed by oral placebo twice daily till 3month
3350025|NCT02259660|Active Comparator|Active Group|Subjects in this arm will train their respiratory muscles at home. The training protocol will use progressively higher pressure threshold training valves to provide respiratory muscle strength training at a pressure threshold greater than 70% maximum inspiratory (MIP) and expiratory (MEP) pressures. The total daily training time should be 20 to 30 minutes in duration.
3350026|NCT02259660|Placebo Comparator|Sham Training|The intervention in the sham training arm will be identical in every way to that of the active arm with the exception of the trainer that is provided. Subjects in the sham training arm will have inspiratory and expiratory muscle strength trainers which have had the pressure threshold spring removed and are therefore unable to provide a load to the muscles being trained.
3350027|NCT02259673|Experimental|Fun exercise|effect of fun physical exercise on sarcopenia
3350028|NCT02259673|Experimental|fun exercise|effect of fun physical exercise on interest in exercise
3350029|NCT02259686|Experimental|Protocol 1. Apelin 1mg doses|5 Healthy volunteers
3350030|NCT02259686|Experimental|Protocol 2. Apelin 5mg doses|5 Healthy volunteers
3350031|NCT02259686|Experimental|Protocol 3. Apelin 10mg single dose|5 Healthy volunteers
3350032|NCT02259712|Active Comparator|Pelviperineal physiotherapy|"The treatment duration is 2 days per week during 8 weks (two months). The aproximate duration of the season is 45 minutes. The protocol consists in:~Anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity).~Hygienic and behavioral advises preventing pelvic floor dysfunctions.~Awareness of the pelvic floor muscles.~Strengthening the pelvic floor muscles and the entire abdominal pelvic cavity. Use of electrostimulation and biofeedback in different positions if deemed necessary.~Treatment the abdominal-pelvic cavity pain if it requires."
3350033|NCT02259712|Experimental|Hiporessive and Pelviperineal PT|The treatment duration is 2 days per week, 8 weeks (two months). The session is about 45 minutes. All women are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle. The participants are also treated by doing Hipopressive exercises and by specific physicaltherapy for the strengthening the pelvic floor muscles.
3375962|NCT03339765|No Intervention|Enhanced care as usual|If randomized to the enhanced care as usual arm, the research team will give participants a paper-based self-advocacy patient brochure published by the National Coalition for Cancer Survivorship. This guide is not a part of usual care, but is freely available on the Internet.
3241920|NCT01303718|Active Comparator|Standard of Care|Usual care (no CardioFit System implant)
3241921|NCT01303731|Active Comparator|Standard dose Marcaine Spinal 0.5% Heavy|Standard group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml).
3241922|NCT01303731|Experimental|Minidose of Marcaine Spinal 0.5% Heavy|Minidose group - will receive spinal anesthesia induced by Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
3241923|NCT01303757|Experimental|Low glycemic load diet|Low glycemic load diet
3241924|NCT01303757|Active Comparator|Low fat diet|Low fat diet
3241925|NCT01303770|Experimental|Cognitive intervention group|Cognitive rehabilitation program designed to be tested in this study
3241926|NCT01303770|Active Comparator|Control group|
3241927|NCT01303783|Experimental|Nifedipine GITS 20 mg|Subjects received 20 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3241928|NCT01303783|Experimental|Nifedipine GITS 30 mg|Subjects received 30 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3241929|NCT01303783|Experimental|Nifedipine GITS 60 mg|Subjects received 60 mg of nifedipine GITS (single tablet) monotherapy once daily for 8 weeks along with 2 placebo tablets and 1 placebo capsule
3241930|NCT01303783|Experimental|Candesartan cilexetil 4 mg|Subjects received 4 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3241931|NCT01303783|Experimental|Candesartan cilexetil 8 mg|Subjects received 8 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3241932|NCT01303783|Experimental|Candesartan cilexetil 16 mg|Subjects received 16 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3241933|NCT01303783|Experimental|Candesartan cilexetil 32 mg|Subjects received 32 mg of candesartan cilexetil (single capsule) monotherapy once daily for 8 weeks along with 3 placebo tablets
3241934|NCT01303783|Experimental|Nifedipine/candesartan 20/4 mg|Subjects received the combination of 20 mg of nifedipine GITS/4 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241935|NCT01303783|Experimental|Nifedipine/candesartan 20/8 mg|Subjects received the combination of 20 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3350034|NCT02259712|Experimental|Hipopressive exercises|The treatment is done 2 times per week for 8 weeks (2 months). The session duration is about 45 minutes. All participants are instructed on hygienic and behavioral advises preventing pelvic floor dysfunctions. They are teach basic anatomy and physiology to understand the importance of these advises and anatomical and physiological explanation of the pelvic girdle (perineal organs bony, ligaments and muscular structures of the entire abdominal and pelvic cavity). The participants are also treated by doing Hipopressive exercises in standing, sitting, and supine fours.
3350036|NCT02259738|Experimental|Human urinary kallidinogenase and Shuxuening injection|Human urinary kallidinogenase 0.15PNA and Shuxuening injection 20mg, every day for 7 days.
3241936|NCT01303783|Experimental|Nifedipine/candesartan 20/16 mg|Subjects received the combination of 20 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3350037|NCT02259751|Experimental|KUC 7483 CL|
3350038|NCT02259751|Placebo Comparator|Placebo|
3350039|NCT02259764|Experimental|KUC 7483 CL - single rising dose|"Treatment 1: KUC 7483 CL - low dose~Treatment 2: KUC 7483 CL - medium dose~Treatment 3: KUC 7483 CL - high dose~In treatment 3 the same subjects as in treatment 2 received drug immediately after the ingestion of a standardized high fat meal"
3350040|NCT02259764|Placebo Comparator|Placebo|
3241937|NCT01303783|Experimental|Nifedipine/candesartan 30/8 mg|Subjects received the combination of 30 mg of nifedipine GITS/8 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241938|NCT01303783|Experimental|Nifedipine/candesartan 30/16 mg|Subjects received the combination of 30 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241939|NCT01303783|Experimental|Nifedipine/candesartan 30/32 mg|Subjects received the combination of 30 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241940|NCT01303783|Experimental|Nifedipine/candesartan 60/16 mg|Subjects received the combination of 60 mg of nifedipine GITS/16 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241941|NCT01303783|Experimental|Nifedipine/candesartan 60/32 mg|Subjects received the combination of 60 mg of nifedipine GITS/32 mg of candesartan cilexetil once daily for 8 weeks along with 2 placebo tablets
3241942|NCT01303783|Placebo Comparator|Placebo|Subjects received placebo (3 tablets and 1 capsule) once daily for 8 weeks
3241943|NCT01303796|Experimental|Sapacitabine-decitabine alternating|Arm A sapacitabine administered in alternating cycles with decitabine
3241944|NCT01303796|Active Comparator|Decitabine|Arm C Decitabine
3241945|NCT01303809|Active Comparator|ERAS|The perioperative management of the patients in this arm will be according to a fast-track protocol designed by the investigators. The preoperative component of this program is the same as routine practice. Intraoperative and postoperative components which are different to routine practice are as described in the intervention section. This protocol is based on current literature regarding Enhanced Recovery After Surgery (ERAS).
3241946|NCT01303809|No Intervention|non ERAS|The perioperative management of patients in this arm will be according to routine practice currently implemented at our institution.
3241947|NCT01303822|Experimental|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
3241948|NCT01303848||Healthy probands|Healthy probands, age between 18 and 40 years
3241949|NCT01303874|Experimental|Combination Therapy|Methotrexate & Etanercept
3241950|NCT01303874|Placebo Comparator|Single-agent therapy|Methotrexate (MTX)
3241951|NCT01303887|Active Comparator|R-CVP|Repeated every 21 days for up to 8 cycles with response assessment after 4 cycles. Responders (PR/CR) after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
3241952|NCT01303887|Experimental|R-FC|Repeated every 21 days for 4 cycles. Responders (PR/CR) after 4 cycles will receive 4 further cycles of Rituximab only. Responders after 8 cycles will receive Rituximab maintenance therapy for 2 years (12 bi-monthly cycles).
3241953|NCT01303913||Walking desaturation group|COPD patients that at the end of 6MWT have SO2 nadir <88-90%
3241954|NCT01303913||Walking No-desaturation group|COPD patients that at the end of 6MWT have SO2 nadir >88-90%
3241955|NCT01303926|Active Comparator|Cisplatin and Pemetrexed|
3241956|NCT01303926|Active Comparator|Carboplatin paclitaxel bevacizumab|
3241957|NCT01303952|Experimental|Eculizumab|
3241958|NCT01303978|Experimental|APD421 starting dose|
3241959|NCT01303991|Experimental|Hexvix PDT|
3241960|NCT01304004|Experimental|Experimental drinking yogurt|
3241961|NCT01304004|Placebo Comparator|Placebo drinking yogurt|
3241962|NCT01304017|Experimental|Virtual Reality Therapy|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing.
3241963|NCT01304017|Active Comparator|Traditional Therapy|The traditional therapy will include exercises for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
3241964|NCT01304030|Experimental|Experimental Group|The experimental group receives Empathy Training. The control Group receives residency training as usual
3241965|NCT01304030|Active Comparator|Control Group|The control group receives residency training as usual
3241966|NCT01304056||Critically ill patients|Patients that are treated in intensive care unit and given ventilatory therapy.
3241967|NCT01304056||Interventional volunteer group|Healthy volunteers
3241968|NCT01304069|Placebo Comparator|Placebo|
3241969|NCT01304069|Active Comparator|Selecoxib|
3241970|NCT01304069|Active Comparator|Etoricoxib|
3241971|NCT01304095|Active Comparator|Ranolazine|Ranolazine in addition to standard of care medical therapy
3241972|NCT01304095|No Intervention|Standard of Care|
3241973|NCT01304108|Experimental|Order Set|"Insertion of VTE-P Order Set tollgate in all active admission and transfer orders."
3241974|NCT01304108|Experimental|Clinical Decision Support Pop-up|Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
3350041|NCT02259777|Experimental|Telmisartan/Amlodipine, fed|
3350042|NCT02259777|Active Comparator|Telmisartan/Amlodipine, fasted|
3350043|NCT02259790|Experimental|Telmisartan/amlodipine fixed-dose combination|
3350044|NCT02259790|Active Comparator|Telmisartan tablet and amlodipine tablet|
3350045|NCT02259803|Experimental|Telmisartan/amlodipine fixed-dose combination|
3350046|NCT02259803|Active Comparator|Telmisartan and amlodipine mono-components|
3350047|NCT02259816|Active Comparator|Telmisartan|
3350048|NCT02259816|Experimental|Telmisartan and amlodipine|
3350049|NCT02259829|Experimental|Telmisartan/Amlodipine fixed dose combination|
3350050|NCT02259829|Active Comparator|Telmisartan and Amlodipine monocomponents|
3350051|NCT02259842|Experimental|BI 34021 FU2 solution|single rising doses, dose groups 3 and 5 double-dosing (fed and fasted)
3350052|NCT02259842|Experimental|BI 34021 FU2 tablet|dose group 4 only
3350053|NCT02259842|Placebo Comparator|Placebo|
3350054|NCT02259855|Experimental|Mild hepatic insufficiency|
3350055|NCT02259855|Experimental|Moderate hepatic insufficiency|
3350056|NCT02259855|Experimental|Healthy subjects|
3350057|NCT02259868|Experimental|Group A|randomized sequence of current low dose formulation (3 tablets) and high dose (1 tablet) BILR 355 BS 1B formulation, separated by 14-day washout
3350058|NCT02259868|Experimental|Group B|randomized sequence of BILR 355 BS (JM) + SDS formulation low dose (2 tablets) ,BILR 355 BS (HM) + SDS formulation low dose (2 tablets), BILR 355 BS high dose 1B formulation (4 low dose tablets), separated by 14-day washout
3350059|NCT02259868|Experimental|Group C|randomized sequence of BILR 355 BS (JM) + SDS formulation high dose (4 tablets) , BILR 355 BS (JM) + SDS formulation mid dose (3 tablets), BILR 355 BS (HM) + SDS formulation high dose (4 tablets), separated by 14-day washout
3350060|NCT02259868|Experimental|Group D|randomized sequence of BILR 355 BS Suspension high dose, BILR 355 BS Suspension low dose, current low dose BILR 355 BS 1B formulation (3 tablets) separated by 14-day washout
3350061|NCT02259881|Experimental|Low dose of BIBT 986 CL|
3241975|NCT01304108|Active Comparator|Usual Care|Usual care, without the experimental additions
3241976|NCT01304121|Experimental|Bioactive glass|Resorbable bioactive glass granules
3241977|NCT01304134|Experimental|Oxycodone i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
3241978|NCT01304134|Active Comparator|Morphine i.v.|To determine the efficacy and safety of oxycodone i.v. patient-controlled analgesia (PCA)
3241979|NCT01304160|Experimental|strereotactic radiotherapy, gemcitabine|stereotactic radiotherapy (30Gray in 5 fractions) followed by gemcitabine
3241980|NCT01304186|Experimental|Tailored Information|Participants in this arm receive the computer-based tailored information application that focuses on improving health literacy related to treatment of HIV infection.
3241981|NCT01304199||Adult Cancer Survivors|"Intervention:~Behavioural:~Questionnaires for patient/family caregiver interview"
3241982|NCT01304212|Active Comparator|femoral block|
3241983|NCT01304212|Experimental|local infiltration + femoral nerve block|Combination of local infiltration with drugs and femoral nerve block
3241984|NCT01304212|Active Comparator|several drugs local infiltration|
3241985|NCT01304225|Active Comparator|100ms single-shot|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
3241986|NCT01304225|Experimental|20ms multiple-shot|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
3241987|NCT01304225|Experimental|20ms multiple-shot, barely visible|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
3241988|NCT01304251|Active Comparator|Short-term fasting|short term fasting (i.e. 24 hours before and 24 hours after administration of chemotherapy) in 20 breast cancer patients
3241989|NCT01304251|Placebo Comparator|Healthy nutrition|20 breast cancer patients eat according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy.
3241990|NCT01304264||combination topical glaucoma treatment|timolol or dorzolamide add on latanoprost monotherapy
3241991|NCT01304290|No Intervention|Control|
3241992|NCT01304290|Experimental|Glucose/Insulin Clamp|
3241993|NCT01304303|Experimental|SPARC1023 I|
3241994|NCT01304303|Experimental|SPARC1023 II|
3241995|NCT01304316|Experimental|Kovacaine Nasal Spray|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%: 6 sprays of 0.1 mL - total of 18 mg tetracaine HCl and 0.3 mg oxymetazoline HCl followed by 12 sprays of 0.1 mL - total of 36 mg tetracaine HCl and 0.6 mg oxymetazoline HCl
3241996|NCT01304342|Active Comparator|Remifentanil|Remifentanil 1 microgram/kg/h along with propofol infusion
3241997|NCT01304342|Active Comparator|Fentanyl|Fentanyl 200 micrograms intranasally
3241998|NCT01304342|Placebo Comparator|Normal saline|Normal saline intravenously and intranasally
3241999|NCT01304355||Controls|Healthy Control Subjects
3242000|NCT01304355||IBS Group|Subjects diagnosed with IBS
3242001|NCT01304368|Active Comparator|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
3242002|NCT01304368|No Intervention|Waiting list|Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
3350062|NCT02259881|Experimental|Medium dose of BIBT 986 CL|
3350063|NCT02259881|Experimental|High dose of BIBT 986 CL|
3350064|NCT02259881|Placebo Comparator|Placebo|
3350065|NCT02259894|Experimental|BIRT 2584|single rising doses
3350066|NCT02259894|Placebo Comparator|Placebo|
3350067|NCT02259907|Experimental|KUC 7483 CL|single rising doses
3350068|NCT02259907|Experimental|KUC 7483 CL, fed|dosing after high fat meal
3350069|NCT02259907|Placebo Comparator|Placebo|
3350070|NCT02259920|Active Comparator|Treatment A|KUC 4783 CL, immediate release tablets
3350071|NCT02259920|Experimental|Treatment B|KUC 4783 CL delivered as a particulate formulation to the distal small bowel
3350072|NCT02259920|Experimental|Treatment C|KUC 4783 CL delivered as a particulate formulation to the ascending colon
3350073|NCT02259920|Experimental|Treatment D|KUC 4783 CL delivered as a solution formulation to the ascending colon
3242003|NCT01304381|Experimental|Integrated care|Multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers in a shared structured person-centred and identity-promoting homecare
3242004|NCT01304381|No Intervention|control|Usual care is performed for the control group
3242005|NCT01304394|Other|parenteral nutrition solution|
3242006|NCT01304433||1|hydroxyethyl starch (HES) 130/0.42
3350074|NCT02259920|Experimental|Treatment E|KUC 4783 CL delivered as a solution formulation to the descending colon
3350075|NCT02259933|Experimental|KUC 7483 CL|increasing repeated oral doses
3350076|NCT02259933|Placebo Comparator|Placebo|
3350077|NCT02259946|Experimental|BI 1744 CL - single rising dose + Tiotropium|Single rising dose of BI 1744 CL (conjointly with Tiotropium bromide)
3350078|NCT02259946|Placebo Comparator|Placebo|
3350079|NCT02259959|Experimental|BI 1744 CL in combination with Tiotropium|
3350080|NCT02259959|Placebo Comparator|Placebo|
3350081|NCT02259972|Experimental|BI 113823 solution|single rising doses, dose group 5 twice (fed and fasted)
3350082|NCT02259972|Experimental|BI 113823 tablet|dose group 5 only
3350083|NCT02259972|Placebo Comparator|Placebo|
3350084|NCT02259985|Experimental|Itasetron tablet fed|
3350085|NCT02259985|Active Comparator|Itasetron tablet fasted|
3242007|NCT01304446|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3242008|NCT01304472|Experimental|Prasugrel|Prasugrel 10mg per day
3242009|NCT01304472|Active Comparator|Clopidogrel|
3242010|NCT01304485|Experimental|Sodium Acetate C11 PET Imaging|
3242011|NCT01304511||Participants Treated|Women undergoing controlled ovarian COH for ART
3242012|NCT01304524|Experimental|VGX 3100|
3242013|NCT01304524|Placebo Comparator|Placebo|
3242014|NCT01304537|Experimental|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 40 mg/kg throughout the study.
3242015|NCT01304537|Experimental|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 60 mg/kg throughout the study.
3242016|NCT01304537|Experimental|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Subjects in this arm will receive a dose of 80 mg/kg throughout the study.
3242017|NCT01304563|Active Comparator|IM15|15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)
3242018|NCT01304563|Active Comparator|ID1|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
3242019|NCT01304563|Active Comparator|ID2|Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)
3242020|NCT01304563|Active Comparator|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device
3242021|NCT01304576|Experimental|patient with right parietal lesions|
3242022|NCT01304576|Active Comparator|patient with left parietal lesions|
3242023|NCT01304602|Experimental|Irinotecan + BKM120|Irinotecan + BKM120 at the assigned cohort dose level.
3242024|NCT01304615|Active Comparator|Web-Based|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a life skills training program. Life skills training topics include stress management, coping with change, time management, and thoughts and emotions in weight control.
3242025|NCT01304615|Experimental|Web-Based plus Culinary Training|Participants will receive a web-based behavioral intervention that decreases dietary energy density and increases physical activity combined with a hands-on culinary skills training program designed to increase food purchasing and meal self-preparation and consumption of meals low in energy density.
3242026|NCT01304628|Experimental|PL-3994 (4 escalating doses)|
3242027|NCT01304628|Placebo Comparator|Placebo|
3242028|NCT01304654||ALI/ARDS oncologic patients|Consecutively admitted patients at GRAACC's PICU with malignancy diagnosis according to IDC-10, in a 24mo consecutive period, under mechanical ventilation for over 24h and with ALI/ARDS criteria, not younger than 29 days or older than 17 years 11 months
3242029|NCT01304719|Experimental|Computer Assisted home visitation|Home visitation with computer modules added
3242030|NCT01304719|Experimental|Home Visitation TAU|Home Visitation Treatment as Usual
3242031|NCT01304719|No Intervention|Community Referral|Community Referral
3242032|NCT01304745|Experimental|Physical traning in group|
3242033|NCT01304745|Experimental|Educational and counselling group|
3242034|NCT01304745|No Intervention|Control group|
3242035|NCT01304758|Experimental|ExAblate Treatment|
3242036|NCT01304771|Active Comparator|Synbiotic AKSB|Participants (healthy > 65 year old persons) will be randomized to take the synbiotic AKSB. All participants will also receive inactivated trivalent Influenza vaccine while being on the AKSB. We will assess safety of the AKSB in this setting. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus and probiotic strain enterococcus. We will also assess influenza vaccine response in patients on AKSB
3350086|NCT02259985|Active Comparator|Itasetron infusion fasted|
3350087|NCT02259998|Experimental|Persantin® new formulation|
3350088|NCT02259998|Active Comparator|Persantin® commercial formulation|
3350089|NCT02260011|Experimental|Ipratropium bromide HFA-134a low|
3350090|NCT02260011|Experimental|Ipratropium bromide HFA-134a high|
3350091|NCT02260011|Active Comparator|Atrovent® CFC low|
3350092|NCT02260011|Active Comparator|Atrovent® CFC high|
3350093|NCT02260011|Placebo Comparator|Placebo|
3350094|NCT02260024|Active Comparator|Pramipexole IR|
3350095|NCT02260024|Experimental|Pramipexole SR C2 in the fasted state|
3350096|NCT02260024|Experimental|Pramipexole SR C2A in the fasted state|
3350097|NCT02260024|Experimental|Pramipexole SR C2B in the fasted state|
3350098|NCT02260024|Experimental|Pramipexole SR C in the fasted state|
3242037|NCT01304771|Placebo Comparator|Talc Placebo|Participants (healthy > 65 year old persons) will be randomized to take the placebo. All participants will also receive inactivated trivalent Influenza vaccine while being on the placebo. We will also assess the stool microbiology in relation to vancomycin-resistant enterococcus. We will also assess influenza vaccine response in patients on placebo.
3350099|NCT02260024|Experimental|Pramipexole SR C2 in the fed state|
3350100|NCT02260037|Experimental|Epinastine nasal|single rising doses
3350101|NCT02260037|Placebo Comparator|Placebo|
3350102|NCT02260050|Experimental|WAL 801 CL new formulation|
3350103|NCT02260050|Active Comparator|WAL 801 CL conventional formulation|
3350104|NCT02260063|Experimental|Epinastine syrup|
3350105|NCT02260063|Active Comparator|Epinastine tablets|
3350106|NCT02260076|Experimental|PEG 400|multiple rising doses
3350107|NCT02260076|Placebo Comparator|Placebo|
3350108|NCT02260089|Experimental|Low dose of telmisartan|4 week placebo run-in phase followed by 6 weeks of treatment with low dose of telmisartan
3350109|NCT02260089|Experimental|High dose of telmisartan|After 6 weeks of treatment with low dose of telmisartan, titration to high dose of telmisartan if blood pressure level is higher than 140/90 mm Hg
3350110|NCT02260102|Active Comparator|urinary tract infections|Children requiring antibiotic treatment for urinary tract infections. Intervention: blood sampling for assay of temocillin
3242038|NCT01304784|Experimental|Arm 1|"Regimen follows a 3-week treatment cycle.~Cisplatin 80mg/m2 given on day 1 by IV infusion over two hours every three weeks.~Capecitabine 1000 mg/m2 given orally twice daily for fourteen days each 3-week cycle.~Up to six 3-week cycles of Cisplatin and Capecitabine to be administered. Trastuzumab given as 8 mg/kg loading dose at week 1 over 90 minutes followed by 6 mg/kg every 3 weeks over 30-90 minutes.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Trastuzumab (every 3 weeks) and MM-111 (weekly) will continue until disease progression, unacceptable toxicity, or withdrawal of consent."
3242039|NCT01304784|Experimental|Arm 2|"Regiment follows a 4-week treatment cycle.~The following Lapatinib and Trastuzumab regimen will be given in combination with MM-111 in the following order:~Trastuzumab 4 mg/kg loading dose week 1 over 90 minutes~Followed by Trastuzumab 2 mg/kg weekly thereafter~Lapatinib 1000 mg by mouth (PO) daily~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3242040|NCT01304784|Experimental|Arm 3|"Regimen follows a 4-week treatment cycle Paclitaxel dosing should begin first dose on cycle 1 day 1. Paclitaxel will be administered at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab will be administered via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 will be administered over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3242041|NCT01304784|Experimental|Arm 4|"4-week treatment cycle. Lapatinib given orally. Paclitaxel dosing on cycle 1 day 1. Paclitaxel given at 80 mg/m2 weekly, as an IV infusion over 60 minutes. The infusion should be prepared as directed in the Paclitaxel package insert. All patients receiving Paclitaxel should be premedicated as per the local institutional guidelines.~Trastuzumab given via IV over 90 minutes at a 4 mg/kg loading dose for the first infusion followed by weekly infusion of 2 mg/kg over 60 minutes thereafter.~MM-111 given over 90 minutes for the first infusion and then weekly over 60 minutes thereafter.~Treatment with this regimen will be continued until disease progression, unacceptable toxicity, or withdrawal of consent."
3259313|NCT01469689|Experimental|Local organisation websites|In these areas, the investigators will try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
3259314|NCT01469689|Experimental|Google Ads and local websites|In these areas, the investigators will place Google Adwords and also try to place adverts on the websites of local organizations, with links to the investigators' project website, and from there to four other websites for depression.
3259315|NCT01469689|No Intervention|Control|Control areas. No Intervention
3350111|NCT02260102|Active Comparator|cholangitis|"Cirrhotic children requiring antibiotic treatment due to suspicion of cholangitis.~Intervention: blood sampling for assay of temocillin"
3350112|NCT02260102|Active Comparator|hepatic transplant|Children requiring antibiotic prophylaxis following a hepatic transplant. Intervention: blood sampling for assay of temocillin
3350113|NCT02260115|Experimental|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
3350114|NCT02260115|Sham Comparator|Surgical Control|Laproscopic Surgery Only
3350115|NCT02260128|Experimental|Gum chewing|"This intervention group will receive chewing gum four times daily following surgery. Each of which they are encouraged to chew for 30 minutes.~Gum chewing is terminated when one of the primary end points occurs."
3350116|NCT02260128|No Intervention|Control group|This group will receive the normal postoperative treatment. Occurence of primary end points are registrered.
3350117|NCT02260141|Experimental|Treatment with d-ribose|Treatment with ribose 5 gm TID
3350118|NCT02260167|Experimental|Treatment with MIND|
3350119|NCT02260193|Experimental|AKB-6548, starting dose 1|
3350120|NCT02260193|Experimental|AKB-6548, starting dose 2|
3350121|NCT02260193|Experimental|AKB-6548, starting dose 3|
3350122|NCT02260206|Experimental|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
3350123|NCT02260206|No Intervention|No intervention|No intervention
3350124|NCT02260219|Active Comparator|S2|Surgically Implant an Ahmed Glaucoma Drainage Device Model S2 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
3350125|NCT02260219|Active Comparator|M4|Surgically Implant an Ahmed Glaucoma Drainage Device Model M4 in Neovascular Glaucoma Patients and evaluate the IOP evolution, complications and need for medication to control IOP
3350126|NCT02260232|Experimental|exercise intervention|Components of the program included supervised moderate to high intensity cardiorespiratory exercise, resistance training, and flexibility.
3350127|NCT02260232|No Intervention|control|
3350128|NCT02260245|Other|Team training|All participating affiliates will undergo team training using the TeamSTEPPS model
3350129|NCT02260271||Database Entry/Biospecimen Collection|Medical information of infants born with HIE entered into RedCap database. In addition, Blood, urine, buccal samples will be collected.
3242042|NCT01304784|Experimental|Arm 5|"Docetaxel, trastuzumab and MM-111 3-week treatment cycles with therapies given in the following order: 1) docetaxel, 2) trastuzumab, and 3) MM-111~Docetaxel given as an IV infusion over 60 minutes every three weeks. The infusion should be prepared as directed in the Docetaxel package insert and any institutional guidelines. All patients receiving Docetaxel should be pre-medicated as per the local institutional guidelines.~The first dose of trastuzumab is a loading dose of 8 mg/kg administered over 90 minutes followed by every three week dosing at 6 mg/kg over 60 minutes via IV infusion.~The first dose of MM-111 given over 90 minutes followed by 3 week dosing over 60 minutes in the absence of infusion-related reactions"
3350130|NCT02260284|Experimental|Yaotong points acupuncture|patients under the treatment of Yaotong ponts penetration mode
3350131|NCT02260284|Active Comparator|standardized acupuncture|patients under the treatment of standardized acupuncture
3350132|NCT02260284|Other|the usual care|In the usual care group, participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS)).
3242043|NCT01304797|Experimental|MM-302|
3350133|NCT02260310|Experimental|Weizhong and Huantiao|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points
3350134|NCT02260310|Active Comparator|A-shi point|Patients with Ankylosing Spondylitis use the Acupuncture Protocol Involving in A-shi points, without including Weizhong (BL4) and Huantiao (GB30) Points
3350135|NCT02260323|Experimental|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
3350136|NCT02260323|Active Comparator|patient-tailored DMARDs|Patients use tailored DMARDs
3242044|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab|
3242045|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab q3w|
3242046|NCT01304797|Experimental|MM-302 in Combination with Trastuzumab and Cyclophosphamide|
3242047|NCT01304810||NicVAX|NicVAX vaccine
3242048|NCT01304810||Placebo vaccine|Placebo vaccine
3242049|NCT01304823|Active Comparator|glucose|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
3242050|NCT01304823|Active Comparator|glucose + lactisole|intraduodenal perfusion of glucose (29.3 g glucose per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
3242051|NCT01304823|Active Comparator|mixed liquid meal|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min)
3242052|NCT01304823|Active Comparator|mixed liquid meal + lactisole|intraduodenal perfusion of a mixed liquid meal (20.20 g carbohydrate, 4.92 g fat and 6.25 g protein per 100 mL; rate: 2.5 mL/min for 180 min; caloric load: 3.0 kcal/min) + 450 ppm lactisole
3242053|NCT01304823|Placebo Comparator|saline + lactisole|saline (0.9 %; rate: 2.5 mL/min for 180 min) + 450 ppm lactisole
3242054|NCT01304836|Active Comparator|10 Days of Steroids|Advagraf + Basiliximab + MMF + Steroids (10 days)
3242055|NCT01304836|Experimental|Optional Steroid bolus only|Advagraf + Basiliximab + MMF + Steroids (bolus only)
3242056|NCT01304849|Experimental|Primary|Patients with aHL will receive 2 cycles of ABVD and undergo interim PET-2 scan- those with positive scans will receive 4 additional cycles of Esc BEACOPP while those with negative scans will receive 4 additional cycles of ABVD.
3242057|NCT01304862|Experimental|Self-management intervention|
3242058|NCT01304862|Active Comparator|Educational Videos about Healthy Living|
3242059|NCT01304888|Experimental|Food basket w/o nutrition education|
3242060|NCT01304888|Experimental|Food basket + nutrition education|
3242061|NCT01304888|Experimental|Control|
3242062|NCT01304888|Experimental|Cash + health and nutrition education|
3242063|NCT01304901|Active Comparator|1-Montelukast|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
3242064|NCT01304901|Placebo Comparator|2- Placebo|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
3242065|NCT01304914||Healthy, term-delivered babies|
3242066|NCT01304927|Active Comparator|Cholecalciferol + calcium|Group of intervention: Each man will receive 300,000 IU (7500 ug) Cholecalciferol (VD3) orally once after blood and semen sampling and performed DXA scan. Thereafter they will receive VD tablets of 1,400 IU (35 ug) + 500 mg calcium daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of 1400 IU VD3 + 500 mg calcium. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
3242067|NCT01304927|Placebo Comparator|placebo|Group receiving placebo: Each man will receive placebo oral mixture once after blood- and semen sampling and performed DXA scan. Thereafter they will receive placebo tablets daily for 3 months. At 3 months a clinical control and blood sampling will be performed, followed by continued daily intake of placebo. At end of treatment at five months after inclusion the men deliver two semen samples, have a blood sample drawn and a DEXA scan performed.
3242068|NCT01304953|Placebo Comparator|P+P|
3242069|NCT01304953|Experimental|P+T|
3242070|NCT01304953|Placebo Comparator|S+P|
3242071|NCT01304953|Experimental|S+T|
3242072|NCT01304979|No Intervention|Usual care alone|Subjects receive usual care alone before and after spine fusion surgery
3242073|NCT01304979|Experimental|Active Intervention|Acupuncture therapies, ear seeds, acupuncture treatment and gua sha, designed to reduce pain and facilitate recovery for low back spine fusion patients.
3242074|NCT01304979|Sham Comparator|Control Arm|Indirect therapies with same encounter time and timing as direct care group.
3350137|NCT02260336|Experimental|Panax Notoginseng Powder 1g|Panax Notoginseng Powder 1g, daily
3350138|NCT02260336|Experimental|Panax Notoginseng Powder 5g|Panax Notoginseng Powder 5g,daily
3350139|NCT02260336|Experimental|Panax Notoginseng Powder 10g|Panax Notoginseng Powder 10g,daily
3350140|NCT02260336|Experimental|Panax Notoginseng Powder 15g|Panax Notoginseng Powder 15g,daily
3350141|NCT02260336|Active Comparator|Celecoxib Capsule 400 mg daily|Celecoxib Capsule 400 mg daily
3350142|NCT02260349|Experimental|patient with Indocyanine green infusion|Infusion of Indocyanine Green 0,25 mg/Kg 24h before prostatic surgery
3350143|NCT02260362||HTAP of Congenital Heart Disease|
3350144|NCT02260375|Experimental|Mesenchymal Stromal Cells (MSC)|A single intravenous infusion (1-2 millions of MSCs per kilogram body weight) of ex-vivo expanded third-party MSC (from healthy donors) will be performed in patients assigned to the MSC procedure in addition to the liver transplantation.
3350145|NCT02260375|No Intervention|No treatment.|
3350146|NCT02260414|Experimental|Patients with multiple myeloma|Patient with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3350147|NCT02260414|Active Comparator|Patients with agressive lymphoma|Patient hospitalized for aggressive lymphoma treated with chemotherapy treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3350148|NCT02260414|Active Comparator|Patients with acute medical condition|Patient older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac treated with one injection of 4500 IU tinzaparin and blood samples taken at hours : 0, 3, 8, 18 and 24 after subcutaneous injection of tinzaparin
3350149|NCT02260427|Experimental|the i-gel group|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
3350150|NCT02260427|Active Comparator|the Air-Q sp group|After induction of general anesthesia, the air-Q sp will be inserted according to randomly allocated group.
3350151|NCT02260453|Active Comparator|A - Coronary angiography|All the patients receive preoperative coronary angiography followed, if needed, by percutaneous intervention (PCI) or bypass (CABG)
3242075|NCT01304992|Experimental|Lupin Protein|Lupin protein (cultivar: Lupinus angustifolius Boregine; incorporated in a drink)
3242076|NCT01304992|Active Comparator|Reference protein|Reference Protein (75% sodium caseinate (EM7; DMV international) and 25% milk protein (Megglosat HP; Meggle), incorporated in a drink)
3242077|NCT01304992|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
3242078|NCT01305005||patients with active-fluidics system|patients who underwent phacoemulsification surgery using active-fluidics system
3242079|NCT01305005||patients with gravity-fluidics system.|patients who underwent phacoemulsification surgery using gravity-fluidics system
3242080|NCT01305018|Experimental|Exercise and BCAA|
3242081|NCT01305018|Experimental|Exercise and Leucine|
3242082|NCT01305018|Placebo Comparator|Exercise and Placebo|
3242083|NCT01305031|Experimental|Room air|Initiation of resuscitation with 21% Oxygen, adjustments to the inspired oxygen concentration (increased 10%) will be made every 60 seconds for infants to achieve a target SpO2 range of 85-92%
3242084|NCT01305031|Active Comparator|100% Oxygen|Initiation of resuscitation with 100% Oxygen and achieve oxygen saturation in the preset limits 85-92%
3242085|NCT01305057|Experimental|Evaluation of P-IP on hydration and barrier function|Effects of P-IP on improvement of skin hydration and TEWL were examined.
3242086|NCT01305070|Active Comparator|Standart balloon angioplasty|Admiral Xtreme, Invatec
3242087|NCT01305070|Active Comparator|Paclitaxel-eluting balloon arm|In.Pact Admiral, Invatec
3242088|NCT01305083|Active Comparator|Udenafil|Active Ingredient
3242089|NCT01305083|Placebo Comparator|Placebo|Placebo
3242090|NCT01305096|Experimental|Yoga group|Participants in this group will take part in six to eight weeks of yoga classes. The classes will be held once a week and each class will be approximately one hour long. The classes will consist of yoga inversions, sun salutations and other yoga postures with deep breathing.
3242091|NCT01305096|No Intervention|Control group|Matched control
3242092|NCT01305109|Experimental|Oral Rotavirus Vaccine 116E (ORV 116E)|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5 mL at 4 week intervals
3242093|NCT01305109|Placebo Comparator|Placebo|3 doses of 0.5 mL at 4 week intervals
3242094|NCT01305122|Other|OMS grade II glioma|neurocognitive tests
3242095|NCT01305135|Experimental|azacitidine 75mg/m²/d + idarubicin 5mg/m²/d|"phase I : palier 1 have 10 patients and palier 2 have to 10 patients.~palier 1: Ida 5mg/m²/d (D8) + AZACITIDINE 75mg/m²/d (D1-D7)"
3350152|NCT02260453|Active Comparator|B - standard cardiac workup|Standard cardiac workup
3350153|NCT02260466|Other|elderly patients with Aortic steNosis valvular replacement|
3350154|NCT02260479|Active Comparator|Preheated chlorhexidine|Preheated skin disinfection with 36ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
3350155|NCT02260479|No Intervention|Room temperature chorhexidine|Room temperature skin disinfection with 20ᵒC Chlorhexidine 5mg/ml in 70% alcohol.
3350156|NCT02260505|Experimental|Imatinib maintenance|Maintenance of Imatinib at the last dose routinely taken by the patient in the 3 years period prior to randomization (either 300 or 400 mg/day). Increase dose up to 800 mg/day if relapse according to RECIST 1.1 criteria. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib Specific Product Characteristics (SPC).
3350157|NCT02260505|No Intervention|Imatinib Interruption|Treatment corresponding to standard practice : interruption of Imatinib from the day of randomization. Reintroduction of Imatinib at 400 mg/day after first relapse according to RECIST 1.1 criteria; Then increase dose to 800 mg/day after 2d relapse. Any relapse/progressive disease at 800 mg/day will lead to Imatinib permanent discontinuation and study discontinuation. In case of toxicity, Imatinib dose will be interrupted or adjusted in accordance with Imatinib SPC.
3350158|NCT02260518|Experimental|Lifestyle Intervention|The intervention will focus on women gaining the recommended amount of weight, increasing physical activity to 150 minutes per week, and meeting healthy eating guidelines.
3350159|NCT02260518|Other|Standard Care|Women in the standard care group will attend their regularly scheduled obstetric (OB) visits with their prenatal care providers and will receive monthly mailings and matched number of podcasts.
3350160|NCT02260544|Experimental|Test Product - T|"doxorubicin hydrochloride liposome ( Dr. Reddy's Lab )~Use the test drug (doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) ; then use the reference drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Sun Pharma ) after at least 4-weeks."
3350161|NCT02260544|Active Comparator|Reference Product - R|"doxorubicin hydrochloride liposome ( Sun Pharma )~Use the reference drug (doxorubicin Hydrochloride Liposome Injection 20mg/10mL i.e. 2mg/mL; from Sun Pharma ) ; then use the test drug ( doxorubicin hydrochloride liposome Injection 20mg/10mL i.e. 2mg/mL from Dr.Reddy's Laboratories Ltd., India) after at least 4 weeks."
3350162|NCT02260557|Experimental|Selexipag|Selexipag is initiated at 200 µg twice daily (b.i.d.) and up-titrated every 3 days in 200 μg b.i.d. increments up to the maximum tolerated dose (MTD) for each individual patient but not above 1600 µg during the 3-week titration phase. This is followed by a 5-week maintenance phase, during which patients continue the treatment at their individual MTD.
3350163|NCT02260557|Experimental|Placebo|Placebo matching selexipag tablets is administered according to the same schedule as selexipag
3350164|NCT02260570|Experimental|Functional MRI Arm|"This cognitive science study consists of a single arm in which all subjects receive both tolcapone and placebo in randomized, double-blind, counterbalanced, crossover fashion"
3350165|NCT02260583|Experimental|extracorporeal CO2 removal device|"the patients will be enroll to start a one shot session of extracorporeal CO2 removal. The patient will be connected to the device via a double lumen catheter inserted in the femoral vein An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used. Blood flow is driven by a roller nonocclusive pump (0-450 mL/min) through a polypropylene oxygenator ; priming volume, 100 mL; contact surface area, 1.35 m2; maximum blood flow rate, 7 L/min) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 L/min. Exiting the oxygenator, blood is driven to a hemofilter."
3350166|NCT02260596||Cohort Population|Pediatric SOT/HSCT recipients
3350167|NCT02260609|Other|Open-Label|Grafix®: Cryopreserved Placental Membrane
3350168|NCT02260661|Experimental|Part A|AZD8835 single agent dose escalation
3242096|NCT01305135|Experimental|Azacitidine 75mg/m²/d + idarubicin 10mg/m²/d|palier 2: Ida 10mg/m²/d (D8)+ Azacitidine 75mg/m²/d (D1-D7)
3242097|NCT01305148|Experimental|Randomized - Genetic|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
3242098|NCT01305148|No Intervention|Randomized - Clinical|Subjects who are randomized to 90 days of follow-up and whose warfarin dose was determined using the genetic information from clinical information alone through the warfarindosing.org website
3242099|NCT01305148|Experimental|Registry|Subjects who are followed 30 days of follow-up and whose warfarin dose was determined using the genetic information from the GenoSTAT test and clinical information through the warfarindosing.org website
3242100|NCT01305174|Active Comparator|Balloon expandable stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the balloon-expandable stent (Visi-Pro™, ev3 Endovascular, Inc., Plymouth, MN, USA), which was premounted on a balloon catheter, was deployed by inflation of the balloon. The nominal stent diameter had to approximate the reference vessel diameter of the target lesion. Postdilation was permitted"
3242101|NCT01305174|Active Comparator|Selfexpanding stent arm|"First placement of the sheath and successful passage of a 0.018 or 0.035 guidewire via the sheath across the target lesion in the iliac arteries was required. Consecutively the the self-expanding stent (Protege™, ev3 Endovascular, Inc., Plymouth, MN, USA), which had to exceed in the nominal diameter the reference vessel diameter at least by 1 mm, was released. Postdilation was mandatory. The inflated postdilation-balloon should approximate the reference vessel diameter."
3242102|NCT01305187|Experimental|Hyaluronic Acid Filler - Medical Device|
3242103|NCT01305226|Experimental|Test - THR-100|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase 60 subjects are to be recruited into Test arm, and administered 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
3242104|NCT01305226|Active Comparator|Streptokinase|120 subjects are to be recruited into the trial, with patients randomized in a 1:1 allocation ratio to THR-100 and Streptokinase Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
3242105|NCT01305278|No Intervention|Control|No Wii balance gaming undertaken
3242106|NCT01305278|Active Comparator|Wii during vestibular rehab only|To start Wii Balance Gaming from the beginning of vestibular rehabilitation.
3242107|NCT01305278|Active Comparator|Wii whilst on waiting list and rehab|Wii Balance Gaming whilst on waiting list for vestibular rehabilitation. To continue with Wii Balance Gaming until end of vestibular rehabilitation.
3242108|NCT01305291|Placebo Comparator|tea only without fibersol-2|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects (11).~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to after the treatments."
3242109|NCT01305291|Active Comparator|tea only with fibersol-2 (10 g)|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling (11).~The beverage will be consumed at 10 am.~Blood samples will be taken at specified time points prior to and after the treatments.~Ingredient only test will be done without the meal to determine independent effects of Fibersol-2."
3350169|NCT02260661|Experimental|Part B|Following the single agent dose escalation (Part A), additional patients with mutations in the PIK3CA gene will be enrolled to a single agent dose expansion phase at the MTD or recommended phase II dose (RP2D) at the selected dose schedule (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part B). Part B will include patients with ER+/HER2 negative breast cancer whose tumours have a mutation of the PIK3CA gene and patients with any solid tumours which have a mutation of the PIK3CA gene.
3350170|NCT02260661|Experimental|Part C|AZD8835 in combination with fulvestrant dose escalation
3375963|NCT03338959|Experimental|Treatment (pembrolizumab, radiation therapy)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for 3 months in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy daily for 5-6 weeks.
3242110|NCT01305291|Placebo Comparator|tea without fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3242111|NCT01305291|Experimental|tea with 5 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3242112|NCT01305291|Experimental|tea with 10 g fibersol-2 and meal|"On the day before the test, subjects need to consume their evening meal before 9 pm, and fast until the start of the test the next day.~The evening meal will be a standardized meal for all subjects.~They are allowed to consume water up until 1 hr before the test.~Before the start of the test a cannula will be inserted into the ante-cubital arm vein for use of repeated blood sampling.~The test meal and beverage will be consumed at 10 am.~The meal will consist of pasta meal (main pasta dish = Carb 64.5%, Fat 17.7%, Protein 17.8%; total kcal 739).~Tea containing test materials will accompany the meal.~Blood samples will be taken at specified time points prior to and after the treatments."
3242113|NCT01305304||1|"15 healthy male veteran runners (marathon, triathlon, orienteering) aged between 40 and 65 years with a history of competitive running at a national level during a period of at least 5 years, implicating normally a runner career with at least 50km per week over more than 10 years"
3242114|NCT01305304||2|15 healthy male volunteers, matched for age and bmi, without a history of competitive physical exercise (i.e. sedentary controls)
3242115|NCT01305317|Experimental|lipitor|atorvastatin 20mg daily
3242116|NCT01305343||Surgical treatment|This observational study is examining the outcomes of standard surgical treatments for adult spinal deformity.
3242117|NCT01305382||Heart Transplant Cohort|This group consist of transplant subjects within 10 years of heart transplant
3242118|NCT01305382||Heart Failure Sub group|Consist of subjects with advanced heart failure (NYHA class III and IV)
3242119|NCT01305382||Healthy Volunteer|This groups consist of healthy individuals
3242120|NCT01305395|Experimental|Early Intervention Arm|Initiate sirolimus within 6 months of heart transplant
3242121|NCT01305395|Experimental|Late Intervention Arm: Group 2A|Initiate sirolimus after CAV is diagnosed by angiogram
3242122|NCT01305395|Experimental|Retrospective Arm: Angiogram group|Start sirolimus after CAV diagnosed is by angiogram
3242123|NCT01305395|Experimental|Late Intervention Arm: Group 2B|Start sirolimus after CAV is diagnosed by IVUS
3242124|NCT01305395|Experimental|Retrospective Arm: Intravascular Ultrasound|Sirolimus after CAV is diagnosed by IVUS
3242125|NCT01305434|Other|Placebo then mulberry leaf|These patients receive placebo for two weeks, then 1 week washout, then two weeks of mulberry leaf extract.
3242126|NCT01305434|Other|Mulberry leaf then placebo|These patients receive mulberry leaf extract for two weeks, then 1 week washout, then two weeks of placebo.
3242127|NCT01305447|Experimental|Exercise Maintenance|"Randomization and Group-Mediated Cognitive Behavioural therapy (GMCB) sessions will begin on week 8 of the program. Topics of self-regulation related to exercise (Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the GMCB principles on how to maintain exercise behavior."
3242128|NCT01305447|Experimental|Ex. Maintenance + relapse prevention|"The same topics of self-regulation related to exercise maintenance(Social cognitive theory of self-regulation, Albert Bandura, 1991) will be discussed: monitoring, scheduling, goal setting, coping, overcoming barriers, rewards, social support.~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) intervention strategies over the phone to continue to enhance the Group-Mediated Cognitive Behavioural therapy (GMCB) principles on how to maintain exercise behavior.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
3242129|NCT01305447|Active Comparator|relapse prevention|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time.~Participants in this arm will also receive the Brandon et al. (2004) Forever Free smoking relapse prevention booklets."
3242130|NCT01305447|Active Comparator|Contact Control|"Randomization and group discussion sessions will begin on week 8 of the program. Topics of women's health, unrelated to exercise will be discussed (control).~Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to continue to maintain contact time."
3242132|NCT01305486||XenMatrix|
3242133|NCT01305499|Experimental|A: 5AC days 1-10 / entinostat days 3, 10|Arm A will be given an overlapping schedule of drugs with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle and entinostat given at a flat dose of 8 mg orally on days 3 and 10.
3242134|NCT01305499|Experimental|B: 5AC days 1-10 / entinostat days 10,17|In Arm B the agents will be administered sequentially with 5AC given at 50mg/m2 subcutaneously daily for 10 days on days 1 - 10 of a 28 day cycle followed by entinostat at a 8 mg flat dose on days 10 and 17.
3242135|NCT01305512|Experimental|SPARC1028|
3350171|NCT02260661|Experimental|Part D|Following the combination dose escalation segment of the study (Part C), additional postmenopausal patients with ER+/HER negative breast cancer and mutations of the PIK3CA gene will be enrolled to a AZD8835 and fulvestrant combination dose expansion phase at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) (as appropriate) to explore further the safety, tolerability, pharmacokinetics and biological activity at the selected dose (Part D).
3350172|NCT02260674|Experimental|Treatment Group 1|Participants will self-administer JNJ-54861911, two tablets of 5 milligram (mg) each for a total of 10 mg, orally, once daily, from Day 1 until Month 6.
3350173|NCT02260674|Experimental|Treatment Group 2|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6.
3242136|NCT01305525||Spinal Cord Stimulation|
3242137|NCT01305538|Other|Arm 1 BMS-954561 40mg or 80mg|"Arm description: BMS-954561 40mg or 80mg three times daily (TID) to Placebo OR Placebo to 40mg or 80mg TID.~Arm type: Active to Placebo or Placebo to Active (cross-over)"
3242138|NCT01305538|Other|Arm 2 BMS-954561 150mg or 300mg|"Arm description: BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Arm type: Active to Placebo or Placebo to Active(cross-over)"
3242139|NCT01305551|Experimental|Treatment A-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fasted state.
3242140|NCT01305551|Experimental|Treatment B-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fasted state.
3242141|NCT01305551|Experimental|Treatment C-Saxagliptin+Metformin XR|5mg Saxagliptin + 500 mg Metformin XR Tablets, once on Day 1 only, administered together in the fed state.
3242142|NCT01305551|Experimental|Treatment D-Saxagliptin/Metformin XR FDC|5mg Saxagliptin / 500 mg Metformin XR FDC tablet, once on Day 1 only, administered in the fed state.
3242143|NCT01305590|Other|Survey|"We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
3242144|NCT01305603|Active Comparator|Dual TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness.
3242145|NCT01305603|Active Comparator|Classical (or single) TAP block|Dual TAP block on one side on the abdomen. Classical (or single) TAP on the contra lateral side of the abdomen; supplemented with a sham injection to ensure double blindness
3242146|NCT01305616|Active Comparator|Group 1, glaucoma and cataract|Group1 were those patients with visually significant cataract (less than grade 2) and mild to moderate open angle glaucoma
3242147|NCT01305616|Sham Comparator|Group2, cataract patients|This group included those patients with visually significant cataract and normal other eye examination.
3242148|NCT01305629|Experimental|Intervention Condition|Twelve sessions of spiritual self schema counseling, adapted to target target medication adherence and substance use.
3242149|NCT01305629|Active Comparator|Education Condition|Eight sessions of education with content designed to mirror the information covered in the intervention condition.
3242150|NCT01305642|Experimental|Individualized fortification of breast milk|
3242151|NCT01305668||Emphysema phenotype|
3242152|NCT01305668||No-Emphysema phenotype|
3242153|NCT01305681|Active Comparator|LoFric® catheters|LoFric® catheters during clean intermittent catheterization will be compared to non-LoFric® catheters during clean intermittent catheterization
3242154|NCT01305694|Experimental|MSC|Intravenous bone marrow derived mesenchymal stem cells infusion from related donor to patients with relapsed/refractory aplastic anemia.
3242155|NCT01305707|Experimental|C-ECT and Pharmacotherapy|Consolidation treatment with ECT will be considered finished after 9 months of being started, at which time patients will stay only on the pharmacological treatment they already had. The study will be completed within 15 months of patient inclusion (six months after the end of C-ECT). Patient assessment and follow-up will be conducted by participant researchers. Blind rater will conduct clinical and adverse effects ratings. A neuropsychologist will conduct neuropsychological assessments.
3242156|NCT01305707|Active Comparator|Pharmacotherapy|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet.
3242157|NCT01305733|Active Comparator|local infiltration analgesia|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
3242158|NCT01305733|Placebo Comparator|saline injection|The normal saline injection are used in the control group in the same manner than in the RKA group.
3242159|NCT01305746|Experimental|A-623 high dose weekly|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3242160|NCT01305746|Experimental|A-623 low dose weekly|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3242161|NCT01305746|Experimental|A-623 high dose every 4 weeks|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
3350174|NCT02260674|Placebo Comparator|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6.
3350175|NCT02260687||Group 1|Decision of treatment is made by attending investigator according to the Japanese Package Insert
3350176|NCT02260700|Experimental|Sequence 1 (ABC)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3242162|NCT01305759||YoungTKA|Adults under 60 years who are having primary TKA
3350177|NCT02260700|Experimental|Sequence 2 (ACB)|Participants will receive Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 1; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment B (single oral dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3242163|NCT01305759||YOUNGTHA|Adults under 60 years who are having primary THA
3242164|NCT01305759||PAOAarhus|Adults under 60 years who are having primary PAO
3242165|NCT01305798|Experimental|Control Arm|The control arm will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment.
3242166|NCT01305798|Experimental|Active Choice and Default Option Arm|The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email.
3242167|NCT01305798|Experimental|Active Choice Only Arm|The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
3242168|NCT01305824|Active Comparator|PRT 201 (10 micrograms)|
3242169|NCT01305824|Placebo Comparator|Placebo|
3242170|NCT01305824|Active Comparator|PRT-201 (30 micrograms)|
3242171|NCT01305837|Experimental|methylprednisolone|all patients will be treated with the active drug methylprednisolone 500 mg in 3 days every month for 60 weeks.
3242172|NCT01305850|Active Comparator|Aliskiren|
3242173|NCT01305850|Active Comparator|Aliskiren plus Losartan|
3242174|NCT01305850|Active Comparator|Enalapril plus Losartan|
3242175|NCT01305850|Placebo Comparator|placebo|
3242176|NCT01305863|Active Comparator|Propaten graft|Untreated Propaten vascular graft
3242177|NCT01305863|Experimental|ASC-Coated ePTFE graft|ASC Coated BARD IMPRA® ePTFE Vascular Graft
3242178|NCT01305876|Experimental|one group with yoga intervention|one group with yoga intervention
3242179|NCT01305889|Experimental|problem solving therapy|subjects will receive 12 weeks of weekly problem solving therapy
3242180|NCT01305889|Experimental|sertraline|12 weeks of sertraline
3242181|NCT01305902|No Intervention|walking recommendations|Participants assigned to this condition will be instructed to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. Each week, they will be congratulated if they walked the target goal on any days, and encouraged to meet the goals for the upcoming week. However, they will not receive any tangible reinforcement for walking. The meetings will be brief (about 15 minutes) and will include discussions and handouts related to the health benefits of walking.
3242182|NCT01305902|Experimental|contingency management for walking|Participants assigned to this condition will be asked to wear a pedometer daily and scheduled for weekly meetings over for the next 12 weeks. The meeting duration and structure will be similar to that in the standard treatment condition including the handouts, with one exception. Participants in this condition will earn tangible reinforcement in the form of prizes for walking the target number of steps per day.
3242183|NCT01305915|No Intervention|Control|participant will receive standard print material
3242184|NCT01305915|Experimental|Intervention|patient will receive standard print material and a single session group psychoeducational intervention (GBOT)
3242185|NCT01305928|Active Comparator|Fax|
3242186|NCT01305928|Experimental|Warm Hand-off|
3242187|NCT01306006|Active Comparator|MV-for-all|Measles vaccine provided to all children aged 9 months -3 years of age
3242188|NCT01306006|No Intervention|National policy|Measles vaccine provided to children aged 9-11 months, if there are sufficient children to open a measles vaccine vial.
3242189|NCT01306097|Experimental|Zinc sulfate|daily zinc supplementation for 3 months. (10mg daily for under 1 years old children and 20mg daily for above 1 years old children)
3242190|NCT01306123|Experimental|Nascobal nasal spray (cyanocobalamin USP)|One single administration of intranasal cyanocobalamin (initially)
3242191|NCT01306123|Active Comparator|Vitamin B12-ratiopharm N, injection solution|One single injection of IM cyanocobalamin (initially)
3242192|NCT01306136|Experimental|Prolonged Exposure|
3242193|NCT01306136|Active Comparator|Usual care|
3242194|NCT01306188||Breast cancer|Metastatic breast cancer
3242195|NCT01306188||Lung cancer|Metastatic lung cancer
3242196|NCT01306227|Placebo Comparator|water|Oral treatment with water for 6 weeks
3242197|NCT01306227|Experimental|L-Thyroxine|Oral treatment with L-Thyroxine for 6 weeks
3242198|NCT01306240|Experimental|Early strategy|Intratracheal poractant alpha (Curosurf®) after tracheal intubation
3242199|NCT01306240|Active Comparator|Delayed strategy|Nasal Continous Positive Airways Pressure. Intratracheal poractant alpha as a rescue treatment if FiO2 > 60%
3242200|NCT01306266|Active Comparator|rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo
3242201|NCT01306266|Placebo Comparator|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg
3242202|NCT01306279||Cystic Fibrosis, infection|Cystic Fibrosis patients with an infective exacerbation
3242203|NCT01306318|Experimental|1|
3242204|NCT01306318|Active Comparator|2|
3350178|NCT02260700|Experimental|Sequence 3 (BAC)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed by Treatment A (single oral dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment C (single oral dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3350179|NCT02260700|Experimental|Sequence 4 (BCA)|Participants will receive Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 1; followed byTreatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3350180|NCT02260700|Experimental|Sequence 5 (CAB)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 2; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3350181|NCT02260700|Experimental|Sequence 6 (CBA)|Participants will receive Treatment C (single dose of JNJ-54861911 25 mg solid formulation under fed conditions) in Period 1; followed by Treatment B (single dose of JNJ-54861911 25 mg solid formulation under fasted conditions) in Period 2; followed by Treatment A (single dose of JNJ-54861911 25 milligram (mg) oral suspension formulation under fasted conditions) in Period 3. A washout period of at least 6 days will be maintained between each treatment period.
3350182|NCT02260713|No Intervention|Control|control subjects with acute complete spinal cord injury who would not receive any bone marrow transplantation.
3350183|NCT02260713|Experimental|Transplantation via intrathecal route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via lumber puncture
3350184|NCT02260713|Experimental|Transplantation via intralesional route|Subjects with acute complete spinal cord injury who receive autologous bone marrow cell transplantation via durotomy and injection at the lesional site .
3375964|NCT03334851|Experimental|Part A, Cohort 1|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration
3242205|NCT01306344||Patients|Heterogeneous groups of patients (age, gender)
3242206|NCT01306344||Nurses|Heterogeneous groups of nurses (age, gender, working experience)
3242207|NCT01306344||Physicians|Heterogeneous groups of physicians (age, gender, working experience)
3242208|NCT01306357||Zomacton® with Zomajet® needle-free device|Zomacton® 4 mg delivered by percutaneous transjection (needle-free) using the Zomajet® 2 Vision device or Zomacton® 10 mg delivered by percutaneous transjection (needle-free) using the Zomajet® Vision X needle-free device.
3242209|NCT01306370|Experimental|Tranexamic acid|Tranexamic acid is a synthetic derivative of the amino acid lysine. It inhibits fibrinolysis by blocking the lysine binding sites on plasminogen and facilitates the coagulation process.
3242210|NCT01306370|Experimental|Fibrin glue BSTC|It is homologous fibrin glue from a single blood donor.
3242211|NCT01306370|Experimental|Tissucol|It is fibrin glue commercialized from multiple donors.
3242212|NCT01306370|Other|Habitual haemostasis|Electrocoagulation of blood vessels was performed during surgery in all patients (routine hemostasis)
3242213|NCT01306383|Active Comparator|SODIS Bottles given|Caregivers in the intervention group were given two 2-litre plastic bottles. Bottle was filled with available water and placed in direct sunlight for a minimum of 6 hours. Water was consumed the next day while second bottle was being consumed.
3242214|NCT01306383|Active Comparator|Usual practices|Caregivers in this group were asked to maintain their usual practices regarding drinking water so that disease rates could be compared with the SODIS arm
3242215|NCT01306396|Other|Intervention group|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake about 50%.
3242216|NCT01306396|No Intervention|Control group|"Families participating in the control group are given only one dietary counseling based on the references of the DGE at the beginning of the study if they wish."
3242217|NCT01306409|Experimental|A|Sequential application of different ESA
3242218|NCT01306422|Placebo Comparator|Stage 2: Placebo|Placebo product, twice-daily, 65 minutes before breakfast and dinner
3242219|NCT01306422|Active Comparator|Stage 2: H.g.PE 1110 mg b.d.|Hoodia gordonii Purified Extract (H.g.PE) formulated product (1110 mg), twice-daily, 65 minutes before breakfast and dinner
3242220|NCT01306422|Placebo Comparator|Stage 1: placebo, breakfast & dinner|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
3242221|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/dinner|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
3242222|NCT01306422|Placebo Comparator|stage 1: Placebo breakfast/lunch|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
3242223|NCT01306422|Active Comparator|Stage 1: H.g.PE 1110 mg breakfast/lunch|Hoodia gordonii purified extract (H.g.PE) formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
3242224|NCT01306435|Experimental|Laser Group|
3242225|NCT01306435|Placebo Comparator|Placebo Group|
3242226|NCT01306448|Experimental|vibrating capsule|
3242227|NCT01306461|Active Comparator|Timolol and Tafluprost|Concomitant administration of preservative-free timolol and tafluprost eye drops
3242228|NCT01306461|Experimental|Fixed Dose Combination of tafluprost and timolol|Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops
3242229|NCT01306474||Prednisone|profess to convinced 1-1.5mg/Kg.d
3242230|NCT01306474||methotrexate to band prednisone|profess to convinced 7.5-15mg/w, concoction prednisone profess to convinced 0.5-1mg/Kg.d
3242231|NCT01306487||Macular hole patients|The patients who underwent vitreous surgery for idiopathic macular hole.
3242232|NCT01306500|Experimental|Gastric lavage Group|In neonates randomized to intervention Group (gastric lavage group) gastric lavage was done in the labor room after initial stabilization
3242233|NCT01306500|No Intervention|No gastric lavage|Neonates randomized to 'No gastric lavage group' will receive supportive treatment as per standard unit protocol.
3242234|NCT01306513|Experimental|cells|
3242235|NCT01306526||Moderate to Severe OSA|
3350185|NCT02260726|Experimental|Surgical group|Subjects already scheduled to undergo surgical correction of a symptomatic cam-type hip impingement deformity. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound investigation prior to surgery.
3350186|NCT02260726|Other|Control|Asymptomatic subjects with normal hip morphometry, as determined by MRI. Subjects will undergo magnetic resonance imaging (MRI) and ultrasound imaging.
3350187|NCT02260739|Other|chronic myelomonocytic leukemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3350188|NCT02260739|Other|essential thrombocytemia|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3350189|NCT02260739|Other|myelofibrosis|Three cohorts will be investigated: ET (essential thrombocythemia), IMF and secondary MF (myelofibrosis) and CMML (chronic myelomonocytic leukemia)
3242236|NCT01306539|Experimental|Deep Brain Stimulation|Parkinson's patients with deep brain stimulation in the subthalamic nucleus.
3242237|NCT01306552|Active Comparator|Student-intervention only group|"Schools randomized to intervention only (arm 1) will agree to visit the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?).~One school class of students will visit the parcours once during a school day. The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
3242238|NCT01306552|Active Comparator|Multi-component intervention|Schools randomized to the student-parent intervention arm also will agree to visit the KARUNA e.V. smoking prevention parcours. In addition, the schools will agree to have one parents' night presented by trained health coaches informing parents about smoking prevention topics in youth during the school year. Trained health coaches will give an evaluated smoking prevention presentation for parents at the parents' nights at the end of the first school year. Also, participating parents will receive information about successful ways to prevent smoking and promote smoking cessation in their children once by mail.
3242239|NCT01306552|Active Comparator|Control Group|Schools randomized to the control school will be offered to participate in the nutrition and exercise prevention program offered by KARUNA e.V. during the 2-year study.
3242240|NCT01306565|Active Comparator|High dose atorvastatin|Three 80mg daily doses of atorvastatin
3242241|NCT01306565|Experimental|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
3242242|NCT01306578|Active Comparator|IVIG group|20 children randomized to receive IVIG for 5 days at a dose of 0.4 g/kg/day
3242243|NCT01306578|Active Comparator|Plasma Exchange|21 children randomized to receive 5 sessions of 1 volume plasma exchange per day for 5 consecutive days
3242244|NCT01306591|Active Comparator|Bevacizumab 1|
3242245|NCT01306591|Active Comparator|Bevacizumab 2|
3242246|NCT01306604||Observation|Patients from the first day of life with Niemann Pick Type C syndrome NPC1/NPC2 or profound suspicion for Niemann Pick Type C syndrome NPC1/NPC2 disease
3242247|NCT01306630|Other|tivozanib + capecitabine|
3242248|NCT01306669|Active Comparator|Trivalent influenza vaccine|Single dose administration of trivalent influenza vaccine prior to onset of influenza season
3242249|NCT01306669|Placebo Comparator|Normal saline|
3242250|NCT01306682|Active Comparator|Trivalent Influenza vaccine|0.5ml of TIV will be administered into deltoid muscle of non dominant arm
3242251|NCT01306682|Placebo Comparator|Normal saline|0.5ml of normal saline administered into deltoid muscle of non dominant arm
3242252|NCT01306695|Experimental|NYUCI|New York University Caregiver Intervention (NYUCI) in addition to community-based case management using community health workers: The first component consists of two individual and four family counseling sessions that include relatives suggested by the caregiver.
3242253|NCT01306695|Other|CHW Intervention|Community-based case management using community health workers (CHWs): The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6.
3242254|NCT01306708|Active Comparator|nimesulide|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral non-steroidal anti-inflammatory (nimesulide 100 mg, twice per day, for 14 days);
3242255|NCT01306721|Active Comparator|FEX 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~1 tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg /pseudoephedrine 60 mg (fixe dose combination)"
3242256|NCT01306721|Experimental|FEX 60 mg/PSE 60 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination~Double-blind treatment period:~1 tablet of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 60 mg / pseudoephedrine 60 mg (fixe dose combination)"
3242257|NCT01306721|Experimental|FEX 60 mg/PSE 120 mg|"Study medications is administered one hour before or two hours after a meal twice a day.~Placebo lead-in period: 1 placebo tablet of fexofenadine 60 mg + 2 placebo tablets of fexofenadine 60 mg/pseudoephedrine 60 mg (fixe dose combination)~Double-blind treatment period:~2 tablets of fexofenadine 30 mg/pseudoephedrine 60 mg (fixe dose combination) + 1 placebo tablet of fexofenadine 30 mg"
3242258|NCT01306734||Gradient cooling group|Study group receiving gradient cooling during the procedure using extracorporeal circulation (ECC). The procedure is used routinely in the department and is not an experimental procedure. A maximum of 10 degrees celsius is allowed between the measured nasopharyngeal body temperature and the heater-cooler unit of the ECC-machine, when cooling or rewarming.
3242259|NCT01306734||Crash cooling group|Study group receiving rapid cooling using extracorporeal circulation. The protocol for rapid cooling is using routinely in the department and is not an experimental procedure. When cooling, the investigators aim for maximal difference in temperature between the heater-cooler unit of the ECC-machine.
3242260|NCT01306747|Experimental|Chronic Pain Self-Management|
3242261|NCT01306747|No Intervention|Control group|
3350190|NCT02260752||Medical|Patients who receive medical therapy only for treatment of their uterine fibroids
3242262|NCT01306760|Experimental|Ketamine|Ketamine used as the anaesthetic during ECT.
3242263|NCT01306760|Active Comparator|Propofol|Propofol, the standard anaesthetic, used during ECT.
3242264|NCT01306773|Active Comparator|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma
3242265|NCT01306773|Active Comparator|Oral Oseltamivir alone|Oseltamivir 75mg bid during ICU hospitalization
3242266|NCT01306786|Active Comparator|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
3242267|NCT01306786|Active Comparator|Triple Therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
3242268|NCT01306799||Barrett's Esophagus, Erosive Esophagitis, GERD|
3242269|NCT01306838|Experimental|Treatment|The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
3242270|NCT01306838|Active Comparator|Control Group|Routine care
3242271|NCT01306851|Active Comparator|Fibrin glue|
3242272|NCT01306864|Experimental|Hemospray Treatment|Hemospray Kit
3242273|NCT01306903|Experimental|MECC|Minimal extracorporeal circuit
3242274|NCT01306903|Placebo Comparator|MOPS|
3242275|NCT01306903|Placebo Comparator|Super MOPS|
3242276|NCT01306916||Group 1 of 1|diagnosis of primary and secondary hyperparathyroidism scheduled to undergo parathyroid resection.
3242277|NCT01306929|Experimental|pridopidine|45mg bid
3242278|NCT01306955|Active Comparator|methylprednisolone|patients who received methylprednisolone
3242279|NCT01306955|Placebo Comparator|dextrose water 5%|patients who received dextrose water 5% as placebo
3242280|NCT01306981|Experimental|Ranibizumab|
3242281|NCT01306981|Placebo Comparator|Saline|
3242282|NCT01306994||Syndrome Group|Individuals with Freeman-Sheldon, Sheldon-Hall, distal arthrogryposis type 1, or distal arthrogryposis type 3
3242283|NCT01306994||Control Group|Healthy individuals
3242284|NCT01307072||Never-treated group|The patients who had no previous ophthalmic examination until the first visit when vitreous surgery was prescribed
3242285|NCT01307072||The non-compliant group|The patients with a history of missing ophthalmic examination over a one year period
3242286|NCT01307072||The compliant group|The patients who had ophthalmic examinations at least once a year
3242287|NCT01307085|Experimental|preconditioning|Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
3242288|NCT01307085|No Intervention|conventional|Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
3242289|NCT01307124|Active Comparator|standard dose|Arm 1:LPV/r Standard dose BW 25-35 kg 300/75 mg BW >35-50 kg 400/100 mg
3242290|NCT01307124|Experimental|low dose|Arm 2:Low dose BW 25-35 kg 200/50 mg BW >35-50 kg 300/75 mg
3242291|NCT01307137|Experimental|Telehealth (TAP)|
3242292|NCT01307137|Experimental|Peer-led care (PC)|
3242293|NCT01307150||Before and after treatment|SCORAD of each patient before and after treatment.
3242294|NCT01307176|Experimental|Home exercise program|Balance and walking exercise program
3242295|NCT01307189|Active Comparator|Tiotropium|
3242296|NCT01307189|Placebo Comparator|Placebo|
3242297|NCT01307202|Experimental|Gabapentin|Gabapentin 600 mg will be given per oral two hours preoperatively and 200 mg three times daily after surgery (600 mg/day).
3242298|NCT01307202|Placebo Comparator|Placebo|Placebo will match the the gabapentin pill and will be given orally.
3242299|NCT01307215|Experimental|20mLs of 0.5% ropivacaine per side|
3242300|NCT01307215|Experimental|30mLs of 0.33% ropivacaine per side|
3242301|NCT01307215|Experimental|40mLs of 0.25% ropivacaine per side|
3242302|NCT01307228|Experimental|Full-serve evidence service|"The full-serve evidence service consists of:~database (Health Systems Evidence) access;~monthly e-mail alerts; and~full-text article availability."
3242303|NCT01307228|Active Comparator|Self-serve evidence service|"Participants allocated to the self-serve evidence service will receive only database access, which is already publicly available at www.healthsystemsevidence.org"
3242304|NCT01307241||one cohort|Adult patients with ALL attending at the Instituto Nacional de Cancerologia Mexico.
3242305|NCT01307254||Non alcoholic fatty liver disease|
3242306|NCT01307254||control|
3242307|NCT01307280|Experimental|Basic HEALTH|Participants received the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
3242308|NCT01307280|Experimental|Interactive Internet|Intervention intensity increased in RCT2, which included bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments.
3242309|NCT01307280|Experimental|Behavioral Counseling|RCT3 included bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
3242310|NCT01307293|Experimental|Cognitive Behavior Therapy|6-12 sessions of Cognitive Behavior Therapy to address PTSD symptoms and parenting issues related to premature infants.
3242311|NCT01307293|No Intervention|Placebo comparison|Education regarding NICU parenting issues.
3350191|NCT02260752||Procedure|Patients who have a hysterectomy, myomectomy, uterine arterial embolization, endometrial ablation, radiofrequency ablation, or magnetic resonance guided focused ultrasound to treat their UF.
3350192|NCT02260765|Active Comparator|HCP dTMS|this arm will receive dTMS treatment
3350193|NCT02260765|No Intervention|HCP TAU|this arm will continue with the same drugs that they are using usually, which mean treatment as usual
3350194|NCT02260778|Experimental|Phase I Intervention|The learning collaborative as designed will be delivered to this arm during phase I, which will last a period of approximately 9 months. After the 9 months, there will be passive follow-up of this arm to see if outcomes following the first 9 months are sustained.
3350195|NCT02260778|No Intervention|Phase II Intervention|This arm will serve as a control for the Phase I intervention arm during the first 9 months of the study for primary analysis. After the first 9 months, the Phase II intervention arm will receive the learning collaborative during the following 9 months.
3242312|NCT01307306|Experimental|Metformin|
3242313|NCT01307306|Experimental|Insulin|
3242314|NCT01307306|No Intervention|Control|
3242315|NCT01307332|Experimental|MabCampath-1h|Single arm, single cohort study, all subjects will be dosed with alemtuzumab.
3242316|NCT01307345|No Intervention|Monitoring Alone|Research assistants will phone or text participants and request videorecordings of breathalyzer samples up to 21 times per week. Participants will receive compensation for each valid videorecording that occurs within the requested one-hour time frame, and bonus compensation each time all requested videorecordings are submitted within the timeframe over a 7-day period, and/or if >90% of prompts are returned over the study period.
3242317|NCT01307345|Experimental|Monitoring plus contingency management for abstinence|Participants assigned to this condition will receive the same monitoring schedule outlined above, plus the same payment for compliance. In addition, they will receive contingent reinforcement for submission of videorecordings that demonstrate negative breath alcohol samples. For each sample submitted that reads below the cut point, participants will receive vouchers for payment.
3242318|NCT01307358|Experimental|Manual Toothbrush + Sonicare Interproximal Cleaning Prototype|Manual Toothbrush + Sonicare Interproximal (IP) Cleaning Prototype
3242319|NCT01307358|Active Comparator|Manual Toothbrush|Manual Toothbrush
3242320|NCT01307358|Active Comparator|Manual Toothbrush + Floss|Manual Toothbrush + Floss
3242321|NCT01307358|Active Comparator|Manual Toothbrush + Waterpik Ultra Water Flosser|Manual Toothbrush + Waterpik Ultra Water Flosser
3242322|NCT01307371||Diabetes|Patients with diabetes.
3242323|NCT01307371||non-diabetes|Patients without diabetes.
3242324|NCT01307384||Continuum Acetabular System|Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System
3242325|NCT01307410||with CAD|Patients with hypertension and dyslipidemia with prior CAD
3242326|NCT01307410||without CAD|Patients with hypertension and dyslipidemia without prior CAD
3242327|NCT01307436|Experimental|Group A|Epaxal + concomitant administration of DTPaHibIPV, MMR, OPV
3242328|NCT01307436|Experimental|Group B|Epaxal, with administration of DTPaHibIPV, MMR, OPV one month later
3242329|NCT01307436|Active Comparator|Group C|Havrix 720 + concomitant administration of DTPaHibIPV, MMR
3242330|NCT01307475||Proband Group|Patients identified with FSS or a related condition
3242331|NCT01307475||Family Group|Persons who are genetically or legally related to a person with FSS or related condition
3242332|NCT01307475||Other Affected Individuals Group|Persons who have had significant and meaningful contact with a person with FSS or related condition but do not qualify for family group enrolment
3242333|NCT01307488|Experimental|ATV/r+3TC|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
3242334|NCT01307488|Active Comparator|ATV/r+2 NRTIs|Subjects will receive ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
3242335|NCT01307540|Experimental|Active light therapy|oral mucosa is exposed to a light source (broad band of wavelengths, 400-800 nm)
3242336|NCT01307540|Placebo Comparator|Inactive light therapy|Oral mucosa is exposed to a extremely low-intensity light which is assumed to have no effect.
3242337|NCT01307553||PCS Group|
3242338|NCT01307566|Experimental|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure (CPAP)
3242339|NCT01307605|Active Comparator|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
3242340|NCT01307605|Active Comparator|Rituximab plus Lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
3242341|NCT01307644|Experimental|Web-based only (WO) weight intervention|A comprehensive lifestyle modification intervention for healthy eating and activity delivered by web only to facilitate Phase I weight loss (weekly messages baseline to 6 months), Phase 2 guided weight loss and weight maintenance (bi-weekly hot topics news, 6-18 months) and Phase 3 self-managed weight maintenance (6 monthly and 3 bi-monthly new content, 18-30 months).
3242342|NCT01307644|Experimental|WO & peer-led discussion board (WD)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with peer-lead discussion board. A peer leader will facilitate the asynchronous discussion group. The primary purpose of this group is to provide support, increase self-efficacy (role modeling by successful women and leader) and discuss progress toward goals.
3242343|NCT01307644|Experimental|WO & professional email counseling (WE)|Includes WO intervention, including all 3 Phases for weight loss and weight maintenance, supplemented with professional email-counseling by experienced counselor who will review women's web-logs of eating, activity, weight and goal-setting on web-site and send e-mail feedback.
3242344|NCT01307657|Other|clopidogrel 600 mg loading dose|
3242345|NCT01307683|Active Comparator|Mindful Moms|Based on the Mindful Motherhood Training (developed by Cassandra Vieten, PhD), Mindfulness-Based-Eating and Awareness Training (MB-EAT) (developed by Jean Kristeller, PhD), and other mindfulness- and acceptance-based interventions
3350196|NCT02260830|Experimental|Treatment Period A|1 reference treatment (2 mg Lu AF11167 immediate release hard capsule) + 5 different test prototype formulations of Lu AF11167
3350197|NCT02260830|Experimental|Treatment Period B|Food interaction and multiple dosing of Lu AF11167
3350198|NCT02260843|No Intervention|Control|Subjects in this group do not received any intervention.
3350199|NCT02260843|Active Comparator|Tai Chi Intervention|Subjects in this group will receive three tai chi lessons in a week while each session last for 1 hour for 12 weeks
3350200|NCT02260843|Placebo Comparator|Generic Fitness Intervention|Subjects in this group will receive three fitness lessons in a week while each session last for 1 hour for 12 weeks
3242346|NCT01307683|No Intervention|Comparison Group|Usual prenatal care
3242347|NCT01307722|Experimental|Patients under LA distensibility-guiding management|The management of guide group will be adjusted by LA distensibility, including the adjustments of inotropic agents, diuretics, beta-blocker, ACEI, and AIIB.
3242348|NCT01307722|No Intervention|patients under conservative monitor and management|This group will be treated by conventional management and traditional echocardiography can be performed as in-charge doctor request. Renal function will be checked 1 time per 3 months.
3242349|NCT01307735||Myocarditis negative on CMR|Patients with suspected myocarditis referred for CMR and not fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
3242350|NCT01307735||Myocarditis positive on CMR|Patients with suspected myocarditis referred for CMR and fulfilling at least 2 of the 3 CMR criteria (Lake Louise Criteria)for myocarditis.Lake Louise Criteria are edema, hyperaemia, and necrosis/fibrosis.
3242351|NCT01307761||Patients with thyroid nodule received US-FNA exam|Patients with thyroid nodules which underwent head and neck ultrasound(US) examination and US-FNA cytology at Department of Otolaryngology, Far Eastern Memorial Hospital, Taipei, Taiwan. No patient included in this series had a previous diagnosis of thyroid malignancy before US exam.
3242352|NCT01307800|Experimental|80 mg LY2140023|40 mg LY2140023 administered orally, twice daily (BID) for up to 7 weeks of treatment.
3242353|NCT01307800|Experimental|40 mg LY2140023|20 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
3242354|NCT01307800|Experimental|10 mg LY2140023|5 mg LY2140023 administered orally, BID for up to 7 weeks of treatment.
3242355|NCT01307800|Placebo Comparator|Placebo|Administered orally, BID for up to 7 weeks of treatment.
3242356|NCT01307813|Experimental|Endoscopic suturing device|Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
3242357|NCT01307826|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
3242358|NCT01307826|Active Comparator|classical massage|In this group of patients 10 classical massage sessions were applied
3242359|NCT01307839|Active Comparator|5% lidocaine patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
3242360|NCT01307839|Placebo Comparator|placebo patch|If the patient chooses to participate, the resident will place the patch over the lower lumbar area of the back.
3242361|NCT01307852|Experimental|In Vivo Dosimetry|Modified endorectal device capable of real-time dose measurement during prostate radiation therapy
3242362|NCT01307865|Experimental|Sculptra Aesthetic|Patients receiving Sculptra Aesthetic
3242363|NCT01307878|Experimental|arm A|chemotherapy ± targeted therapy before resection of primary colorectal cancer
3242364|NCT01307878|No Intervention|arm B|resected the primary colorectal cancer and then given chemotherapy ± targeted therapy
3242365|NCT01307904|Active Comparator|dates|Each healthy and diabetic subjects received 50 grams equivalent of carbohydrates of the tested dates, On five separate days.
3242366|NCT01307904|Active Comparator|sugar|Each healthy and diabetic subjects received 50 grams of glucose
3242367|NCT01307917|Experimental|healthy controls high flavonoid|20 healthy adolescents (12-21 years old) receiving the flavonoid-rich capsule/supplement
3242368|NCT01307917|Active Comparator|healthy controls low flavonoid|20 healthy adolescents (12-21 years old) receiving the placebo
3242369|NCT01307917|Experimental|T1DM or T2DM high flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the capsule/supplement
3242370|NCT01307917|Active Comparator|T1DM or T2DM low flavonoid|20 adolescents (12-21 years old) with Type 1 diabetes mellitus or Type 2 diabetes mellitus receiving the placebo
3242371|NCT01307943|Experimental|Mindfulness Based Stress Reduction|"Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat at the completion of the eight sessions to review and consolidate experience with the various mindfulness practices. The MBSR concepts and techniques will emphasize portability. Participants will be encouraged to find moments throughout their day in which to practice the techniques. The language used to describe mindfulness practices will be accessible to youth. Mindfulness concepts will be linked with tag phrases like breathing break, autopilot, and choice points. Homework will emphasize experiential, concrete tasks (notice five new things today; eat one meal mindfully this week)."
3242372|NCT01307943|Active Comparator|Usual Care|The control group will be youth receiving therapies and programs already used at the site. The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
3242373|NCT01307969|Experimental|Anesthetic efficacy|Local anesthetics were injected at the apex of the maxillary right canine.
3242374|NCT01307982|Active Comparator|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
3375965|NCT03334851|Experimental|Part A, Cohort 2|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3242375|NCT01307982|Active Comparator|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
3242376|NCT01307995||GDM|Patients with Gestational Diabetes Mellitus found during pregnancy by means of 75g OGTT
3375966|NCT03334851|Experimental|Part A, Cohort 3|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3242377|NCT01307995||NGT|Pregnant patients with normal glucose tolerance as observed in 75g OGTT
3242378|NCT01308021|Experimental|gpASIT400|gpASIT+TM 400 µg
3242379|NCT01308021|Experimental|gpASIT800|gpASIT+TM 800 µg
3242380|NCT01308021|Placebo Comparator|Placebo|
3242381|NCT01308034|Experimental|association sunitinib radiotherapy|
3242382|NCT01308047|Experimental|bupivacaine S75:R25|3 ml for subarachnoid block
3242383|NCT01308047|Active Comparator|bupivacaine (S50:R50)|3 ml subarachnoid block
3242384|NCT01308073||EMIC 2 dialysis|Patients on ICU requiring dialysis for acute renal insufficiency
3242385|NCT01308086|Active Comparator|FOLFOX 4 - 6months or XELOX -6months|
3242386|NCT01308086|Experimental|FOLFOX4 -3months or XELOX -3months|
3242387|NCT01308099||POTS & Controls|"Participants will have a physical prior to the study day and collect urine for 24 hours.~On the study day the following procedures take place:~After blood samples taken (about 2 tbsp), the subject will lie down. A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The arm blood pressure cuff will be inflated 60 points above the highest number on your normal blood pressure for five minutes. The blood pressure and forearm blood flow will be recorded. At the end of 5 minutes, the cuff will be released and the measurements of blood pressure and calf blood flow will be repeated. The brachial artery diameter and flow will be measured at baseline, during cuff inflation and for 3 minutes after deflation.~The study lasts about 2 hours."
3242388|NCT01308112|Experimental|Supplemental iron|
3242389|NCT01308112|Placebo Comparator|Placebo|
3242390|NCT01308138|Experimental|ExerciseTr|
3242391|NCT01308138|Experimental|Remote ischemic preconditioning group|
3242392|NCT01308138|No Intervention|Control patient group|
3242393|NCT01308151|Experimental|Experimental Arm|Culturally Adapted Manualised Cognitive Behavioral Therapy (CBT) Sessions will be offered weekly in the first month and then fortnightly.
3242394|NCT01308151|No Intervention|Control|"Patients who will be randomized to the treatment as usual arm will receive routine care"
3242395|NCT01308164|Experimental|MD logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
3242396|NCT01308164|No Intervention|Control Group|Regular treatment, no change will be made in the insulin pump setting during the study (unless there is a medical need or any safety concern) Only segment 2 of the study, which is conducted as RCT (randomized controlled trial) , will include control group
3242397|NCT01308177|Placebo Comparator|PPI+placebo|
3242398|NCT01308177|Active Comparator|PPI+ES|
3242399|NCT01308203|Experimental|Extended release niacin /laropiprant|The patients will be randomized to one of two arms. The intervention is with the extended release niacin laropiprant combination, that is an add on of the usual medication that the primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
3242400|NCT01308203|Placebo Comparator|placebo|The patients will received placebo added to the usual therapy their primary care physician gave them to treat their lipid disorder (statin, ezetimibe or the combination of both).
3242401|NCT01308216|Experimental|Transcranial low level laser therapy|Transcranial laser therapy is applied by automatic scanning over both hemispheres and the patients undergoing also a standard rehabilitation program based on therapeutic exercises.
3242402|NCT01308216|Active Comparator|Control|The patients undergoing only a standard rehabilitation program based on therapeutic exercises.
3242403|NCT01308229|Experimental|Nile PAX®|
3242404|NCT01308242|Experimental|Treatment|Patients enrolled will receive Renvela for a 3 month time frame.
3242405|NCT01308255|Experimental|Infliximab Arm|For those randomised to the infliximab arm, infliximab will be administered at a dose of 3mg/kg according to the standard treatment protocol.
3242406|NCT01308255|Placebo Comparator|Steroid/Placebo Arm|Patients randomised to this arm will receive an IV infusion of 250mg methylprednisolone at week 0 & those without an adequate clinical response after 26 wks will receive additional steroid as IM methylprednisolone 120mg. Patients on this arm will receive an IV placebo infusion of 250ml of 9mg/l NaCl.
3242407|NCT01308281|Experimental|PCI with IVUS guidance|PCI(percutaneous coronary intervention) with IVUS(IntraVascular UltraSound) group
3242408|NCT01308281|Active Comparator|PCI without IVUS guidance|PCI(percutaneous coronary intervention) group
3242409|NCT01308307|Experimental|one arm|
3242410|NCT01308320|Placebo Comparator|saline|control group
3242411|NCT01308320|Active Comparator|F1 group|F1 group : fentanyl 1 mcg/kg
3242412|NCT01308320|Active Comparator|F1.5 group|F1.5 group : fentanyl 1.5 mcg/kg
3242413|NCT01308320|Active Comparator|F2 group|F2 group : fentanyl 2 mcg/kg
3242414|NCT01308333||XLHED children|
3242415|NCT01308333||XLHED adults|
3242416|NCT01308333||Control children|
3242417|NCT01308333||Control adults|
3242418|NCT01308346|Experimental|Bioresorbable Vascular Scaffold (BVS)|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)
3242419|NCT01308346|Active Comparator|XIENCE V® or XIENCE PRIME®|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) or XIENCE PRIME®
3242420|NCT01308359|Experimental|glucose 5%|glucose 5%
3242421|NCT01308359|Active Comparator|saline|saline
3242422|NCT01308372||1|For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;
3242423|NCT01308385||Patients with pectus excavatum|
3242424|NCT01308411|Experimental|50% reduction in ICS dose|All patients will reduce their inhaled corticosteroid dose by 50%
3242425|NCT01308437|Experimental|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
3350201|NCT02260856|Active Comparator|Percutaneous Drill Epiphysiodesis|A 5 mm incision will be made centered over the physis both medially and laterally. A 4.5 mm drill will be passed repeatedly across the physis in a divergent manner. Curettes will then be used to further remove and disrupt the growth plate. Fluoroscopy will be used throughout to ensure proper passage of the drill and curettes. Omnipaque dye will then be inserted to confirm ablation of the physis.
3350202|NCT02260856|Experimental|Percutaneous Screw Epiphysiodesis|In the distal femur, guide wires will be placed in an antegrade fashion, with an 8 mm skin incision proximal to the physis both medially and laterally. The guide wire will be placed with the medial wire crossing the physis at the junction of the middle and medial third of the physis. The lateral guide wire will cross the physis at the junction of the lateral and middle third of the physis. The wires will extend into the epiphysis, but will not enter the joint. The guide wires will be over drilled with a 5 mm drill, and 7.3 mm fully threaded cannulated screws will be placed across the growth plate. For tibias, screw placement will be retrograde, with 8 mm incisions made medially and laterally distal to the physis, with guide wires aiming proximally.
3350203|NCT02260869|Active Comparator|Cooled radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 17 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A cooled radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, cooled genicular nerve radiofrequency ablation is carried out at 60 Celsius for 150 seconds.
3375967|NCT03334851|Experimental|Part A, Cohort 4|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3375968|NCT03334851|Experimental|Part A, Cohort 5|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3242426|NCT01308437|Active Comparator|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
3242427|NCT01308489|Experimental|Arm I (posterior spinal tumor resection)|Patients undergo posterior spinal tumor resection on day 0.
3242428|NCT01308489|Experimental|Arm II (anterior and posterior spinal tumor resection)|Patients undergo anterior and posterior tumor resection on day 0.
3242429|NCT01308502|Experimental|Probe|Children with airway obstruction
3242430|NCT01308515|Other|Posterior Stabilized|Patients who received a PS (Posterior Stabilized) Tibial Bearing.
3242431|NCT01308515|Other|Anterior Stablized|Patients who received an AS (Anterior Stabilized) Tibial Bearing
3242432|NCT01308528|Experimental|Sodium enoxaparin|Endocris - 40 mg/0,4mL
3242433|NCT01308528|Experimental|sodium enoxaparin Clexane|Clexane - 40 mg/ 0,4mL
3242434|NCT01308541|Active Comparator|LUSEDRA (arm 1)|
3242435|NCT01308541|Active Comparator|LUSEDRA (arm 2)|
3242436|NCT01308541|Active Comparator|Propofol (arm 3)|
3242437|NCT01308554|Placebo Comparator|Sterile normal saline|Control group will receive sterile normal saline in the block
3242438|NCT01308554|Active Comparator|Marcaine|Study group will receive a bilateral TAP block using 20 ml of Marcaine 2,5 mg/ml on each side.
3242439|NCT01308593|Active Comparator|Juvederm XC|Juvederm XC
3242440|NCT01308593|Active Comparator|Botox|Medication used to block neuromuscular transmission
3242441|NCT01308606|Experimental|001|TMC435 gelatin capsule Single intake of one 150-mg capsule without food
3242442|NCT01308606|Experimental|002|TMC435 HPMC capsule Single intake of one 150-mg capsule without food
3242443|NCT01308606|Experimental|003|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule without food
3242444|NCT01308606|Experimental|004|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after standardized breakfast
3242445|NCT01308606|Experimental|005|TMC435 HPMC or gelatin capsule Single intake of one 150-mg capsule after high-fat breakfast
3242446|NCT01308632|Experimental|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
3242447|NCT01308658|Experimental|001|Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
3242448|NCT01308658|Experimental|002|ritonavir 100-mg once daily on Day 1 to Day 5
3242449|NCT01308671|Active Comparator|varenicline|On 3 day after received clopidogrel 75mg/day, Varenicline group will be administered with varenicline 0.5mg Qd,after 3 days, 0.5mg Bid,after 7days,1mg Bid .And received counseling and psychosocial support.
3242450|NCT01308671|Other|Blank|Blank group will be only administered with Counseling and psychosocial support,beside antiplatelet etc.conventional therapy for 14 days.
3242451|NCT01308684|Experimental|1|
3242452|NCT01308684|Experimental|2|
3242453|NCT01308697|Active Comparator|Operative|Operative intervention
3242454|NCT01308697|Active Comparator|Non Operative Treatment|Non Operative management
3242455|NCT01308723|Experimental|Part I|
3242456|NCT01308723|Experimental|Part II (A)|
3242457|NCT01308723|Active Comparator|Part II (B)|
3242458|NCT01308775|Active Comparator|SIS.NET, Routine Follow up|
3242459|NCT01308801|Experimental|active rTMS + rehabilitation exercise|14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
3242460|NCT01308801|Placebo Comparator|placebo rTMS + rehabilitation exercise|14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
3242461|NCT01308827||Children with suspected pneumococcal invasive disease|
3242462|NCT01308866|No Intervention|Control|Usual care
3242463|NCT01308866|Experimental|Intervention|Intervention arm using a share-decision tool for cardiovascular patients
3242464|NCT01308879|Experimental|Weekly feedback|After clinical questionnaires are entered into the system (CFStm), an automated online report is available weekly to clinicians in the experimental group that shows current mental health status of youths, alerts, and trends over time based on youth, caregiver, and clinician responses. Reports also show some clinical data on caregivers.
3242465|NCT01308879|Other|No feedback|Clinicians in the control group do not have access to weekly feedback. Instead, they receive reports every 90 days after the youth is enrolled in CFStm. Because the average duration of CFS enrollment was 3.8 months, many youths would have been discharged before the first 90-day report became available three months after treatment start. Thus, we considered the 90-day feedback group to be essentially a no-feedback group.
3242466|NCT01308892|Active Comparator|High flavaonol chocolate|
3242467|NCT01308892|Placebo Comparator|Low flavanol chocolate|
3242468|NCT01308905|Experimental|FLT-PET|"Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment.~Low risk patients: observation only.~Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection.~High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin.~PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection)."
3242469|NCT01308931||Tubal ligation|Patients who elect to have tubal ligation
3242470|NCT01308931||Essure|Group that elects to have Essure placement
3242471|NCT01308931||Levonorgestrel IUD|Patients that elect to have a levonorgestrel intra-uterine device placement
3242472|NCT01308944|Experimental|Arm 1|"Propranolol 40mg po orally twice daily to begin at least 48 hours prior to surgical debulking. This will ideally be titrated in order to maintain a heart rate between 60 and 80 without hypotension.~After surgery, the patient will resume the propranolol once tolerating clear liquids in the hospital and will remain on them until completion of chemotherapy.~After completion of chemotherapy, the patient will be weaned off the medication over the following two weeks."
3242473|NCT01308957|Experimental|Long chain omega-3 fatty acids|
3242474|NCT01308957|Placebo Comparator|Corn oil|
3242475|NCT01308957|No Intervention|Young healthy controls|Young subjects' muscle mass and physical function will be evaluated once (i.e., during baseline testing only). The data in young subjects will be used to determine the magnitude of the aging-induced decline in muscle mass and physical function in the older subjects prior to starting the interventions.
3242476|NCT01308970|Experimental|Stress Management Group 1|
3242477|NCT01308970|Experimental|Stress Management Group 2|
3242478|NCT01308970|Experimental|Stress Management Group 3|
3242479|NCT01308983|Other|Amiloride|
3242480|NCT01308996|Experimental|INFUSE® Bone Graft|
3242481|NCT01308996|Active Comparator|Autogenous bone graft|
3242482|NCT01309009|Experimental|Nepadutant High Dose|
3242483|NCT01309009|Experimental|Nepadutant Low Dose|
3242484|NCT01309009|Placebo Comparator|Placebo|
3242485|NCT01309035|Active Comparator|With Tourniquet|Total Knee Arthroplasty. Surgery performed during use of a tourniquet.
3242486|NCT01309035|Experimental|Without Tourniquet|Total Knee Arthroplasty. Surgery performed without use of a tourniquet.
3242487|NCT01309048|Experimental|Patients with painful bone metastasis|Patients with bone metastasis causing pain
3242488|NCT01309074|Experimental|Pregabalin|Pregabalin is an antiepileptic medication which has been found in double blind placebo controlled trials to be effective and safe in the treatment of primary generalized anxiety disorder. It has an indication for the treatment of this condition in Europe & Canada but not in the US.
3242489|NCT01309074|Active Comparator|Sertraline|Sertraline is an SSRI found to be an effective treatment of generalized anxiety disorder in controlled trials. It does not have an indication for this in this country.
3242490|NCT01309113|Placebo Comparator|Placebo of VAC BNO 1095|1 tablet of placebo in the morning, 1 tablet of placebo in the evening
3242491|NCT01309113|Active Comparator|10 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of placebo in the evening
3242492|NCT01309113|Active Comparator|20 mg VAC BNO 1095|1 tablet of VAC BNO 1095 10 mg in the morning, 1 tablet of VAC BNO 1095 10 mg in the evening
3242493|NCT01309126|Experimental|Arm 1: Imprime PGG + cetuximab|Biological/Vaccine + Drug
3242494|NCT01309126|Active Comparator|Arm 2: cetuximab|Drug
3242495|NCT01309139|Experimental|Treatment A: Tiotropium medium dose|Oral inhalation daily for 21 days
3242496|NCT01309139|Experimental|Treatment A: BI 54903 high dose|Oral inhalation daily for 21 days
3242497|NCT01309139|Experimental|Treatment B: Tiotropium medium dose|Oral inhalation daily for 21 days
3242498|NCT01309139|Experimental|Treatment C: BI 54903 high dose|Oral inhalation daily for 21 days
3242499|NCT01309178|Active Comparator|Amitriptyline|After the experience with the treatment of 18 CF-patients phase IIa study), the medication will be therefore 25 mg daily in two doses (2 x 12,5 mg). Because of a higher rate of side effects (tiredness, dry mucous membrane) the higher dose of 50 mg (2 x 25 mg) is not chosen first, but will be adapted after 2 weeks of treatment.
3242500|NCT01309178|Placebo Comparator|Mannite|The placebo will be given 25 mg daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
3242501|NCT01309191|Experimental|Minoxidil|Patients received Minoxidil (same strength as sold over the counter) twice a day for 8 weeks.
3242502|NCT01309191|Placebo Comparator|Placebo|Placebo arm
3242503|NCT01309217|Active Comparator|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. See below for a complete description.
3259316|NCT01469728|Experimental|Awake VATS|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
3259317|NCT01469728|Active Comparator|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
3259318|NCT01469754||Lymphoma Survivors|
3375969|NCT03334851|Experimental|Part A, Cohort 6|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3242504|NCT01309217|Experimental|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
3242505|NCT01309230|Experimental|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
3242506|NCT01309256||R-robot group|retrospective robot group
3242507|NCT01309256||P-robot group|prospective robot group
3242508|NCT01309256||P-laparoscopic group|prospective laparoscopic group
3242509|NCT01309295||Cohort|
3242510|NCT01309321|Experimental|Perinatal Handwashing Intervention Arm|
3242511|NCT01309321|Active Comparator|Neonatal Health Promotion|
3242512|NCT01309373||001|Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
3242513|NCT01309399|Active Comparator|teriparatide|six weeks of teriparatide
3242514|NCT01309399|Placebo Comparator|placebo|placebo identical in appearance to teriparatide
3242515|NCT01309412|Experimental|Siltuximab|Siltuximab 5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
3242516|NCT01309425|Experimental|001|tapentadol (CG5503) ER 25-mg TRF 25mg TRF single oral dose
3242517|NCT01309425|Experimental|002|tapentadol (CG5503) ER 50-mg TRF 50mg TRF single oral dose
3242518|NCT01309425|Experimental|003|tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose
3242519|NCT01309425|Experimental|004|tapentadol (CG5503) ER two 100-mg TRF 200mg TRF single oral dose
3242520|NCT01309438|Experimental|Normal renal function|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3242521|NCT01309438|Experimental|Mild renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3242522|NCT01309438|Experimental|Moderate renal impairment|Treatment Period 1 (1 dose of 10 mg rivaroxaban on Day 1) followed, up to 14 days later, by Treatment Period 2 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 5 mg rivaroxaban on Day 5) followed, up to 14 days later, by Treatment Period 3 (500 mg erythromycin three times daily on Days 1 to 6 plus 1 dose of 10 mg rivaroxaban on Day 5)
3242523|NCT01309477|Experimental|ADVAGRAF|All subjects in the study will take the Tacrolimus Sustained-release Capsules (ADVAGRAF) orally at the basis of low dose prednisone treatment
3242524|NCT01309490|Experimental|Ribavirin, nucleoside analog|
3242525|NCT01309503||Normal hearing|Children and adults
3242526|NCT01309503||Unilateral hearing loss|
3242527|NCT01309503||Severe hearing loss high frequencies|
3242528|NCT01309503||Adult CI users|Unilateral and bilateral CI
3242529|NCT01309503||Bilateral CI users|"Children and adults~Sequential CIs~Simultaneous CIs"
3242530|NCT01309516|Experimental|Complex Intervention (LTP-TH)|The 12 sessions of complex intervention (LTP-TH) will be delivered to mothers.
3242531|NCT01309516|No Intervention|Control group|Control group will receive standard postnatal follow-up.
3242532|NCT01309529||thoracic surg, epidural, urine retention|
3242533|NCT01309542|Experimental|DVS|
3242534|NCT01309568||Investigational testing|Pending the outcome of culture, the subject may be treated with an approved antiviral medication at the doctors discretion.
3242535|NCT01309594|Experimental|Hematopoietic stem cell transplantation|Extraction of bone marrow cells from HIV positive patients with advanced liver cirrhosis and transplant their bone marrow back into the patients
3242536|NCT01309607|Experimental|Pre-operative Therapy|Neoadjuvant paclitaxel/carboplatin/lapatinib x 12 weeks
3242537|NCT01309620|Placebo Comparator|Placebo|
3242538|NCT01309620|Experimental|Zinc supplement|
3242539|NCT01309633|Experimental|Arm A|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
3242540|NCT01309633|Experimental|Arm B|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
3242541|NCT01309633|Experimental|Arm C|Arm C Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
3242542|NCT01309633|Experimental|Arm D|Arm D Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
3242543|NCT01309698|Experimental|Treatment Sequence 1|
3242544|NCT01309698|Experimental|Treatment Sequence 2|
3242545|NCT01309698|Experimental|Treatment Sequence 3|
3242546|NCT01309698|Experimental|Treatment Sequence 4|
3242547|NCT01309698|Experimental|Treatment Sequence 5|
3242548|NCT01309698|Experimental|Treatment Sequence 6|
3242549|NCT01309711||HIE|Moderate of severe neonatal encephalopathy
3242550|NCT01309724|No Intervention|Control|No measurements are made on the control group.
3242551|NCT01309724|Experimental|USCOM|Patients undergo hemodynamic measurements with the ultrasound cardiac output monitor (USCOM). Fluid resuscitation is guided by USCOM measurements.
3242552|NCT01309750||C. diff|Patients with Clostridium difficile colitis admitted to the intensive care unit will be the study group.
3242553|NCT01309763|Active Comparator|AFFITOPE AD03|s.c. injection
3242554|NCT01309763|Experimental|AFFITOPE AD03 + Alum|s.c. injection
3242555|NCT01309776|Experimental|Tianeptine|
3242556|NCT01309776|Active Comparator|Escitalopram|
3242557|NCT01309789|Experimental|1|Sequential
3242558|NCT01309789|Experimental|2|Combination
3242559|NCT01309789|Experimental|3 Brentuximab vedotin/CH-P|Combination
3242560|NCT01309815||Cancer in elderly people|other
3242561|NCT01309854|Experimental|pioglitazone|
3242562|NCT01309854|Experimental|pioglitazone and fostamatinib|
3242563|NCT01309932|Experimental|A1: pegIFNλ+BMS-790052+Placebo for BMS-650032+Ribavirin|Part A
3242564|NCT01309932|Experimental|A2: pegIFNλ+BMS-650032+Placebo for BMS-790052+Ribavirin|Part A
3242565|NCT01309932|Active Comparator|A3: pegIFNα-2a+PBO for BMS-790052+PBO for BMS-650032+RBV|Part A
3242566|NCT01309932|Experimental|A4: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (24 weeks)|Part B
3242567|NCT01309932|Experimental|A5: pegIFNλ+BMS-790052+BMS-650032+Ribavirin (16 weeks)|Part B
3242568|NCT01309932|Experimental|A6: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (24 weeks)|Part B
3242569|NCT01309932|Experimental|A7: pegIFNλ+BMS-790052+BMS-650032+Placebo for RBV (16 weeks)|Part B
3242570|NCT01309945|Active Comparator|Arm 1: Duloxetine 30mg|
3242571|NCT01309945|Placebo Comparator|Arm 2: BMS-820836 placebo|
3242572|NCT01309945|Experimental|Arm 3: BMS-820836 0.5-2.0 mg/day|
3242573|NCT01309945|Active Comparator|Arm 4: Duloxetine 30mg|
3242574|NCT01309945|Placebo Comparator|Arm 5: Duloxetine placebo|
3242575|NCT01309958||intervention|design instruments and test feasibility of an intervention aimed at increasing the proportion on non-invasive treatment for early caries
3242576|NCT01309971||Questionable occlusal lesions|
3242577|NCT01309984|Active Comparator|arm 1|
3242578|NCT01309984|Active Comparator|arm 2|
3242579|NCT01310010|Experimental|Dasatinib|
3242580|NCT01310023||Static Cohort|HIV-uninfected children < 12 years of age at the time of enrollment, born of HIV-infected mothers
3242581|NCT01310023||Dynamic Cohort|HIV-uninfected children born of HIV-infected mothers enrolled from prior to birth through ≤ 72 hours of age
3242582|NCT01310023||Reference Cohort|HIV-uninfected children born to a mother HIV uninfected at the time of the child's birth enrolled at 1, 3, 5, or 9 years of age(± 3 months) at the time of the study visit
3242583|NCT01310023||Young Adult Cohort|Former Dynamic and Static Cohort participants ≥ 18 years of age.
3242584|NCT01310049|Experimental|LP0058 oral solution (0.050 mg/mL)|LEO 32731
3242585|NCT01310049|Experimental|LP0058 oral solution (0.200 mg/mL)|LEO 32731
3242586|NCT01310049|Placebo Comparator|LP0058 oral solution (placebo)|Placebo
3242587|NCT01310049|Experimental|LP0058 capsule 1-120 mg|LEO 32731
3242588|NCT01310049|Placebo Comparator|LP0058 capsule (placebo)|Placebo
3242589|NCT01310088|Experimental|Lifestyle counseling|Treatment protocol The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
3242590|NCT01310088|No Intervention|Control|Healthy age and gender matched control subjects. Recruited from school visits.
3242591|NCT01310101|Experimental|Ofatumumab plus dexamethasone|
3242592|NCT01310114|Experimental|Cohort 1|1 unit PDA001 [approximately 2 x 108 cells] in 240 mL per infusion on Day 1.
3242593|NCT01310114|Experimental|Cohort 2A - Experimental|1 unit PDA001 [approximately 2 x 108 cells] or placebo in 240 mL per infusion on Day 1
3242594|NCT01310114|Experimental|Cohort 2B - Experimental|4 units PDA001 [approximately 8 x 108 cells] or placebo in 240 mL per infusion on Day 1
3242595|NCT01310140||Major Depressive Disorder|
3242596|NCT01310140||Major Depressive Disorder with Psychotic Features|
3242597|NCT01310153|Active Comparator|Prone Positioning|Newly born infant placed in prone position (face up) for the first 30 60 seconds of life after delivery by Cesarean birth.
3242598|NCT01310153|Active Comparator|Supine Positioning|newly born infant placed in supine position (face down) for the first 30 60 seconds of life after delivery by Cesarean birth.
3242599|NCT01310166|Experimental|Fingolimod|
3242600|NCT01310192|Experimental|1|Investigational Imaging Device
3242601|NCT01310205||Hepatitis C treatment|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
3242602|NCT01310205||non cirrhotic subjects|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
3242603|NCT01310218|Other|extended postoperative dressing|Bulky dressing for 2 weeks
3242604|NCT01310218|Other|short postoperative dressing|2 day bulky dressing followed by bandaid.
3242605|NCT01310244|Experimental|Single arm, open label|"At the study entry each patient will receive a dose level assignment which will include a specific dose level and the dose of IV belinostat in mg/m2 to be administered during the study treatment.~Belinostat will be infused over 30 minutes once daily on Days 1-5 of each 21-day cycle. On Day 3, the infusion of belinostat must be completed at least 1 hour prior to the start of the paclitaxel infusion. Dose of belinostat will be assigned at study entry. The same dose and level will remain throughout the entire study for each patient and no dose adjustment will be allowed, except due to toxicity."
3242606|NCT01310257||Knee osteoarthritis|Patients will have osteoarthritis (OA) of the knee defined and scored radiologically in Study 1. Patients in Study 2 will also have OA of the knee, but a clinical diagnosis will suffice. All patients will report knee pain.
3242607|NCT01310270|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation
3242608|NCT01310270|Placebo Comparator|Placebo|
3350204|NCT02260869|Active Comparator|Monopolar radiofrequency ablation|Patient is placed in supine position on a fluoroscopic table with a pillow under the popliteal fossa. An anterio-posterior fluoroscopic view of the tibio-femoral joint is obtained. Skin and subcutaneous tissues are anesthetized and a 16 g introducer needle is advanced percutaneously towards the junction of shaft with epicondyle until bone contact is made. The needle is then laterally displaced away from the bone. This process is performed at the superior medial and superior lateral aspects of the femur, and the inferior medial aspect of the tibia. The fluoroscope is placed in lateral view to guide the needle depth to be at the medial third of the femur or tibia. A conventional radiofrequency probe from a Pain Management Radiofrequency kit is advanced through the introducer. Following sensory and motor stimulation, genicular nerve radiofrequency ablation will be carried out at 80 Celsius for 90 seconds.
3350205|NCT02260895|No Intervention|Control|Standard 2-hour 75-gram oral glucose tolerance test
3350206|NCT02260895|Experimental|Almond Pre-test snack|1/2 ounce (14 g) almond snack 30 minutes prior to a 2-hour 75-gram oral glucose tolerance test
3350207|NCT02260908|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
3350208|NCT02260908|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo (normal saline) 36-48 hours post-injury until day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting on post-injury day 6.
3242609|NCT01310283|No Intervention|control group|Conventional pediatric dental care.
3350209|NCT02260947|Experimental|1|
3350210|NCT02260947|Experimental|2|
3242610|NCT01310296|Other|Radiolabeled Lofexidine Oral Solution|Participants will receive a radiolabeled lofexidine oral solution followed by safety evaluations, and plasma, urine and fecal sampling for up to 216 hours post dose.
3242611|NCT01310296|Experimental|Lofexidine Intravenous Solution|Participants will receive 200 mcg of lofexidine in an intravenous solution infusion over 200 minutes followed by 72 hours of safety evaluation and plasma sampling.
3350211|NCT02260947|Active Comparator|3|
3242612|NCT01310309||EXecutive Registry|A prospective controlled registry to analyze the clinical efficacy and safety at mid and long-term follow-up in patients with MVD treated with the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS).
3242613|NCT01310322|Experimental|1|AZD5423 iv
3242614|NCT01310322|Experimental|2|AZD5423 inhalation, Spira
3242615|NCT01310322|Experimental|3|AZD5423 inhalation I-neb
3242616|NCT01310322|Experimental|4|AZD5423 oral
3242617|NCT01310335|Experimental|Training|The whole-body vibration (WBV) training
3242618|NCT01310348|Placebo Comparator|Very low magnitude vibration|Very low magnitude vibration
3242619|NCT01310348|Experimental|Training|The whole-body vibration (WBV) training
3350212|NCT02260947|Active Comparator|4|
3242620|NCT01310361|Experimental|Amoxicillin|Once-daily Therapy for Streptococcal Pharyngitis With Amoxicillin
3242621|NCT01310361|Active Comparator|Benzathin Penicillin G|Once-daily Therapy for Streptococcal Pharyngitis With Intramuscular Benzathin Penicillin G
3242622|NCT01310387|Experimental|active pain management|active pain management (APM) by specialized nurses for cancer pain
3350213|NCT02260947|Placebo Comparator|5|
3242623|NCT01310426||anal sphincter damage|After assessing women after vaginal delivery, a comparison will be made between those with anal sphincter damage and those women without.
3350214|NCT02260960|Experimental|Omega-3|Reesterified Triglyceride form omega 3
3350215|NCT02260960|Placebo Comparator|Placebo|safflower oil
3350216|NCT02260973|Active Comparator|Omega-3|re esterified TG omega-3
3350217|NCT02260973|Placebo Comparator|Safflower Oil|vegetable oil
3350218|NCT02260999||healthy|> 18 years old sufficient language knowledge
3350219|NCT02260999||chronic pain patients|
3350220|NCT02260999||patients with injury at the upper etxremity|
3350221|NCT02261012||30 healthy probands|group without the condition of interest
3350222|NCT02261012||30 CRPS patients|group with condition of interest
3242624|NCT01310439||ADHD adolescents and adults|30 adolescents and adults diagnosed with Combined-subtype AD/HD
3242625|NCT01310452|Active Comparator|neutral protamine insulin, metformin|NPH insulin once daily plus oral metformin twice or thrice daily during 26 weeks
3242626|NCT01310452|Experimental|insulin detemir, metformin|Insulin detemir once daily plus oral metformin twice or thrice daily during 26 weeks
3242627|NCT01310465|Experimental|Experimental group|Three days postoperatively, patients in this group are given one infusion of zoledronic acid intravenously.
3242628|NCT01310465|Placebo Comparator|Placebo Comparator|Three days postoperatively, patients in this group are given one infusion of sodium chloride intravenously.
3242629|NCT01310478|Experimental|Endostar combined with mFOLFOX6|
3242630|NCT01310491|No Intervention|Usual Care|
3242631|NCT01310504|Active Comparator|Non peritoneal dialysis patient|
3350223|NCT02261012||30 CTS patients|group with a different type of pain on the upper limbs
3350224|NCT02261025|Experimental|Aspirin group|Aspirin 75-100mg,per day，oral
3350225|NCT02261025|No Intervention|non-aspirin group|No interventions
3350226|NCT02261038|Other|Kanekasu radiographs|No drugs or devices are used in this study. Commonly available radiological techniques such as radiographs and CT are used. All patients undergo a CT of the knee and a special radiograph (Kanekasu technique).
3350227|NCT02261051||Non-concurrent control group|"A group of advanced cancer patients who received care at our Center before implementation of the LCCM model. They will receive current standard of care.~This current study is to collect data on the control group only. After system redesign, we will open an intervention arm study to collect data after implementation of the new care model (about 18-24 months from start of control phase)."
3350228|NCT02261064|Experimental|Telmisartan/Amlodipine low dose, fed|Telmisartan low dose/Amlodipine fixed-dose combination
3350229|NCT02261064|Active Comparator|Telmisartan/Amlodipine low dose, fasted|Telmisartan low dose/Amlodipine fixed-dose combination
3350230|NCT02261064|Experimental|Telmisartan/Amlodipine high dose, fed|Telmisartan high dose/Amlodipine fixed-dose combination
3350231|NCT02261064|Active Comparator|Telmisartan/Amlodipine high dose, fasted|Telmisartan high dose/Amlodipine fixed-dose combination
3350232|NCT02261077|Experimental|Buscopan, single rising doses|
3350233|NCT02261077|Experimental|Buscopan, multiple rising doses|
3350234|NCT02261077|Placebo Comparator|Placebo|
3350235|NCT02261090|Experimental|Formulation B|Slow release (SR) tablet
3350236|NCT02261090|Experimental|Formulation C|SR tablet
3350237|NCT02261090|Experimental|Formulation D|SR tablet
3242632|NCT01310504|Active Comparator|Peritoneal dialysis patient|
3242633|NCT01310517||Radial Coronary Angiography|The subjects enrolled in this study will be adults referred for radial coronary angiography with left ventriculography for clinical indications.
3350238|NCT02261090|Experimental|Formulation E|SR tablet
3350239|NCT02261090|Experimental|Formulation F|SR tablet
3350240|NCT02261090|Experimental|Formulation G|SR tablet
3242634|NCT01310530|Experimental|Partial Breast Proton Therapy|Two weeks of daily proton therapy delivered to the lumpectomy site.
3242635|NCT01310543|Experimental|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
3350241|NCT02261090|Experimental|Formulation H|SR tablet
3350242|NCT02261090|Active Comparator|immediate release (IR) formulation|
3350243|NCT02261103|Active Comparator|Pramipexole IR, fasted|Pramipexole immediate release (IR) tablets
3350244|NCT02261103|Experimental|Pramipexole ER, fasted|Pramipexole extended release (ER) tablets
3350245|NCT02261103|Experimental|Pramipexole ER, fed|Pramipexole extended release tablets with a high-fat meal 30 min before drug administration
3350246|NCT02261116|Experimental|Telmisartan|
3350247|NCT02261116|Active Comparator|Candesartan|
3350248|NCT02261116|Placebo Comparator|Placebo|
3350249|NCT02261129|Experimental|Telmisartan, film-coated tablet|one tablet of telmisartan
3350250|NCT02261129|Active Comparator|Telmisartan, conventional tablet|Two tablets of telmisartan
3350251|NCT02261142|Experimental|Multifocal TENS|Multifocal TENS given in the garment Mollii® (Elektrodress) 1 hour every second day together with individualized training exercises. The steering unit counts down 60 minutes visible for the patient
3242636|NCT01310543|No Intervention|Comparison|Girls in the comparison group will continue with their normal afternoon of schooling, which is missed by girls attending the T&T intervention for the 20 weeks of their attendance.
3350252|NCT02261142|Sham Comparator|Sham treatment|Use of the garment Mollii® (Elektrodress) but without the electrical stimulation combined with the individualized training exercises. The steering unit counts down 60 minutes visible for the patient
3242637|NCT01310556||coronary artery disease|patients with coronary artery disease
3350253|NCT02261155|Other|Hypnosis|hypnotic induction followed by relaxation and pleasant imagery
3350254|NCT02261168|Other|Standardized living protocol|Subjects are kept at the research facility to adhere to a standardized living protocol, mimicking a normal daily living situation. During the study, multiple tests will be performed, including muscle biopsies, blood draws, MRS measurements and indirect calorimetry.
3350255|NCT02261181|Experimental|XONRID|"Patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients.~Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines. The use of other topical medications for the treatment of dermatitis will be not permitted during the study."
3350256|NCT02261194|Experimental|Self-Care Tools|The tool binder includes 3 core tools and 4 supplemental tools. The tools that will be provided include a variety of self-care approaches to manage depression including audio-visual, internet, and paper-based tools that might appeal to individuals with different learning styles. The 3 core tools consist of the Antidepressant Skills Workbook, a Mood Monitoring Tool, and a DVD on depression.
3350257|NCT02261194|No Intervention|Delayed Self-Care Tools|This group will receive the self-care tools at the conclusion of the study.
3350258|NCT02261207|Experimental|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
3350259|NCT02261220|Experimental|MEDI4736 + Tremelimumab|Subjects with multiple tumor types.
3350260|NCT02261233|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
3350261|NCT02261233|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
3350262|NCT02261246|Experimental|Immediate treatment|This arm receives spinal manipulation treatment shortly after enrollment
3350263|NCT02261246|Experimental|Delayed treatment|This arm receives spinal manipulation treatment approximately 4 weeks after enrollment
3350264|NCT02261246|No Intervention|Healthy control (no low back pain)|In this arm, healthy controls are tested at baseline.
3242638|NCT01310595|Experimental|Manual mobilization on cervical spine|Manual mobilization given on cervical spine with infra-red therapy and self exercise and advice pamphlet.
3242639|NCT01310595|Active Comparator|Infra-red radiation therapy|Infra-red radiation therapy with self exercise pamphlet given to patients with chronic mechanical neck pain.
3242640|NCT01310608|Experimental|A-View|
3350265|NCT02261259|Experimental|Immediate treatment|This arm receives osteopathic manipulative treatment shortly after enrollment
3350266|NCT02261259|Experimental|Delayed treatment|This arm receives osteopathic manipulative treatment approximately 4 weeks after enrollment
3350267|NCT02261259|No Intervention|Healthy control (no neck pain)|In this arm, healthy controls are tested at baseline.
3242641|NCT01310608|No Intervention|No A-View|
3350268|NCT02261272|Experimental|CBT for insomnia|Cognitive-behavioral therapy for insomnia
3350269|NCT02261272|Active Comparator|Sleep Hygiene|Psychoeducational intervention based on standard sleep hygiene advices
3242642|NCT01310621|No Intervention|No Lavage|Neonate randomized to this group will be managed as per the standard protocol in the neonatal ward. The evaluation of respiratory distress will be done using Downe's score at hourly intervals till 24 hrs, followed by 2 hourly intervals till 72 hrs and finally 4 hourly intervals till resolution of clinical distress.
3350270|NCT02261298|Experimental|ONO-4538 1mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, 3 times once every 2 weeks in each 6-week cycle
3350271|NCT02261298|Experimental|ONO-4538 3mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, 3 times once every 2 weeks in each 6-week cycle
3350272|NCT02261298|Experimental|ONO-4538 10mg/kg|ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, 3 times once every 2 weeks in each 6-week cycle
3350273|NCT02261311||Quality of Life, tissue collection|All participants will complete the GAD-7 and Cancer Locus of Control Scale - Course of Illness Subscale questionnaires and additional tissue will be collected at the time of the diagnostic biopsy.
3350274|NCT02261350|Experimental|Food Fortification|Food Fortification
3350275|NCT02261350|Experimental|Oral Nutritional Supplements|Oral Nutritional Supplements - Fortisip Compact
3350276|NCT02261350|No Intervention|Usual Care|
3350277|NCT02261363||Ecig group 1|
3242643|NCT01310621|Experimental|Surfactant Lavage|The diluted surfactant is instilled into endotracheal tube over a period of 15 to 20 seconds. Once the instillation is complete, 5 manual breaths will be provided and infant will be repositioned supine. The suction catheter will be inserted and advanced to a position approximately 5mm past the end of endotracheal tube. Suction will be activated for no more than 10 seconds and would be temporarily halted earlier if the oxygen saturation value falls by > 5% of the prelavage value. The same shall be resumed once prelavage oxygen saturation has been restored. The infant's bed will now be moved back to horizontal position. Once the neonate is STABLE, suctioning will be again repeated. The total retrieved volume is measured and recorded.This procedure will be done in both right and left lateral decubitus position
3350278|NCT02261363||Ecig group 2|
3350279|NCT02261376|Experimental|Caucasian men, aged 18-55 years|
3242644|NCT01310634|Experimental|Comprehensive intervention|Parents of hospitalized neonates received Comprehensive intervention program.
3350280|NCT02261376|Experimental|Caucasian men, aged 65 years or older|
3350281|NCT02261376|Experimental|Japanese men, aged 18-55 years|
3242645|NCT01310634|Other|Conventional treatment|Usual educational program
3242646|NCT01310647|Experimental|Testosterone|Transdermal testosterone (20µg/day) from day 24 of the previous cycle until day 2 of the ICSI cycle
3350282|NCT02261376|Experimental|Caucasian women, aged 18-55 years|
3350283|NCT02261389|No Intervention|Arm A, usual follow-up practice|Imaging studies and serum markers (CEA, CA 15.3, others) performed according to local practice
3350284|NCT02261389|Experimental|Arm B, tumor markers assessment|Serum CEA and CA 15.3 performed every 3 months. No imaging studies allowed in asymptomatic patients: imaging studies (18 FDG-PET) performed only in case of critical increase of CEA and /or CA 15.3 serum levels (+100% for CEA and +75% for CA15.3), even if in the normal range.
3350285|NCT02261402|Experimental|Medisinstart|Patients in this arm will receive the service; Medisinstart
3350286|NCT02261402|No Intervention|Current Practice|Patients in this arm will receive the current pharmacy practice of advice and guidance with their new medicine. This involves dispensing the medicine and briefly providing information regarding its use and potential side-effects.
3350287|NCT02261415|Experimental|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
3350288|NCT02261415|Placebo Comparator|Normal saline (0.9% sodium chloride)|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
3350289|NCT02261441||Group 1|Subjects irrespective of the presence of risk factors or cardiovascular disease throughout Spain will be included. This is an observational and non-interventional study
3350290|NCT02261454|No Intervention|No gum chewing|Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.
3350291|NCT02261454|Active Comparator|Gum chewing|"Usual pharmacologic treatment and post-operative care (e.g. daily visits by surgical team, antibiotics where appropriate, mobilization, advancement of diet as tolerated). Analgesia and anti-emetics will be provided (both oral and intravenous) as needed.~Intervention: 1 piece of sugarless gum to be chewed three times daily for 1 hour each."
3350292|NCT02261480||Group A: Documented Prior History|"Pediatric and adult participants with sickle cell disease (SCD) with a documented prior history of parvovirus B19 infection (aplastic crisis).~Group A participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group A."
3350293|NCT02261480||Group B: No Prior History|"Pediatric and adult participants with SCD who have never had a documented parvovirus B19 infection (aplastic crisis).~Group B participants will have blood draw and nasopharyngeal wash on day 1 only. Nasopharyngeal wash will be optional for Group B."
3350294|NCT02261480||Group C: Suspected and/or Confirmed|"Sickle cell disease patients with suspected and/or confirmed acute parvovirus B19 infection, the latter defined as febrile illness with anemia without adequate compensatory reticulocytosis.~Group C participants will have blood draw and nasopharyngeal wash on day 1, day 7±4 days, day 30±7 days, and day 120±14 days."
3350295|NCT02261506|Active Comparator|7 days|Patients in 7 day arm will receive adequate antibiotics until the end of day 7 only
3350296|NCT02261506|Active Comparator|14 days|Patients in 14 day arm will receive adequate antibiotics until the end of day 14 only
3350297|NCT02261519|Experimental|NaBen®|NaBen® is a oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
3350298|NCT02261519|Placebo Comparator|Placebo|The control treatment is placebo.
3350299|NCT02261532|Experimental|TAS-102|
3350300|NCT02261545|Active Comparator|n-3 Fatty Acid Supplemetation|patients with Type II Diabetes who receive 3 cap omega3, 3 times a day, for 10 weeks.
3242647|NCT01310647|Experimental|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
3242648|NCT01310647|Experimental|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI~Estradiol valerate 4 mg/day during 10 days, starting the second day of the cycle prior to the ICSI cycle."
3242649|NCT01310660||Nulliparous|
3242650|NCT01310673|Active Comparator|Allopurinol|
3350301|NCT02261545|Placebo Comparator|Placebo|patients with Type II Diabetes who receive 3 cap of placebo/ for 10 weeks.
3242651|NCT01310673|Placebo Comparator|Placebo|
3242652|NCT01310686||Wet AMD Non-Responders to Anti-VEGF|
3350302|NCT02261558|Experimental|Clinical Improvisation Instrumental Music Therapy|Clinical Music Therapy session, 20 minutes. Focus on instrumental improvisation
3242653|NCT01310712|Experimental|oxybutynin|patients will receive in the end of the treatment, 10 mg of oxybutynin a day
3242654|NCT01310712|Placebo Comparator|Placebo|Placebo
3350303|NCT02261558|Experimental|Clinical Vocal Improvisation|Clinical Music Therapy session, 20 minutes. Focus on vocal improvisation
3350304|NCT02261558|No Intervention|Control Group|Participants enrolled in control group will complete the same study design, without having a clinical music improvisation
3350305|NCT02261571|Experimental|Moxibustion|A series of moxibustion sessions within six weeks from baseline with adjuvant chemotherapy.
3350306|NCT02261571|No Intervention|Waiting|Participants who will be allocated to waitlist will receive no moxibustion treatments throughout the 6 weeks while receiving adjuvant chemotherapy
3350307|NCT02261584|Experimental|Microwave Thermal Coagulation|MW ablation performed either laparoscopically or percutaneously is a safe, effective, and minimally invasive technique for the management of hypersplenism in patients with liver cirrhosis. It may significantly increase platelet count and white blood cell (WBC) count and improve hepatic blood supply with fewer complications. Ablating more than 40% of the splenic parenchyma may yield better long term results. This method may provide a new and promising minimally invasive alternative for treating hypersplenism.
3350308|NCT02261584|Experimental|Partial Splenic Embolization Catheter|Partial splenic embolization (PSE), which was first performed by Spigos et al in 1979, has been considered first-line therapy for hypersplenism in many institutions, and has been proposed as an effective alternative to splenectomy for improving peripheral blood cell counts. However, PSE is associated with many complications, including intermittent fever, abdominal pain, nausea, vomiting, post-embolization syndrome, splenic abscess, splenic rupture, pneumonia, refractory ascites, pleural effusion and gastrointestinal bleeding. To ensure a sustained and long-term increase in platelet and leucocytic counts, the splenic infarction rate needs to be greater than 50% (8). Thus, severe complications can ensue.
3350309|NCT02261610|Experimental|clinical group|In the first group of patients, the use of antibiotics will be guided by clinical (clinical group).
3350310|NCT02261610|Other|PCT group|In the second group, the use of antibiotics will be guided by the algorithm (PCT group).
3350311|NCT02261623||Palliation|Palliative treatment of biliary strictures produced by malignant neoplasms, no intended surgery
3350312|NCT02261623||Curative intent surgery|Palliative treatment of biliary strictures produced by malignant neoplasms, prior to curative intent surgery, with or without neoadjuvant therapy
3350313|NCT02261623||Benign biliary strictures|Treatment of benign biliary strictures
3350314|NCT02261623||Other indication|Other indication
3350315|NCT02261636||Pentasa|Treatment according to standard clinical practice.
3242655|NCT01310738|Active Comparator|Meglumine antimoniate|Antimoniate of N-methylglucamine 20mg/kg/d, I.V. for 20 consecutive days.
3242656|NCT01310738|Experimental|Liposomal Amphotericin B|Liposomal amphotericin B 3mg/kg/d I.V. for 7 consecutive days.
3350316|NCT02261649||Cerebellar Tumor Surgically Removed|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
3350317|NCT02261649||Healthy Volunteer|"Quantitative Sensory Testing and Neuroimaging~Medoc Advanced Medical Systems PATHWAY Model ATS (Contact thermal stimulator)~Cold water bath~MRI scanner~Questionnaires"
3350318|NCT02261662|Experimental|Ribavirin and Betamethasone|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
3350319|NCT02261662|Experimental|Betamethasone alone|Topical steroids alone will be used; Betamethasone.
3350320|NCT02261675|No Intervention|control group|children undergoing selective lower abdominal surgery received saline before induction
3350321|NCT02261675|Experimental|D1 group|children undergoing selective lower abdominal surgery received a bolus dose of 0.5 µg/kg dexmedetomidine followed by a continuous infusion of 0.5 µg/kg /h before induction
3350322|NCT02261675|Experimental|D2 group|children undergoing selective lower abdominal surgery received a bolus dose of 1.0µg/kg dexmedetomidine followed by a continuous infusion of 1.0 µg/kg /h before induction
3350323|NCT02261688|Other|Subjects in study|All subjects in study are in a cross-over study with 3 interventions sequentially (low salt diet, low salt diet + IV normal saline, liberal salt diet)
3350324|NCT02261701|Experimental|Early mobilization|Intervention is early mobilization, four weeks immobilization postsurgery with collar´n cuff only.
3350325|NCT02261701|Other|Post surgery shoulder lock|Post surgery shoulder lock with abduction cushion 3 weeks and after this period collar´n cuff 3 weeks
3350326|NCT02261740|Experimental|Yoga Therapy Group|Participants will attend twice-weekly group yoga classes and be instructed to practice yoga at home one additional hour a week, using a written manual.
3350327|NCT02261753|Active Comparator|A: Classical ketogenic diet|The KD is a high fat, low carbohydrate, low protein diet designed to mimic the effects of fasting on the body. It will be administered by calculation as per local standardised classical KD protocol with utilisation of long chain fat in a ratio of 2:1 to 4:1 carbohydrate and protein.
3242657|NCT01310738|Experimental|Amphotericin B|Amphotericin B deoxycholate 1mg/kg/d I.V. for 14 consecutive days. This arm was suspended in September 19th, 2012, because of a relevant excess of adverse events and serious adverse events associated with this experimental intervention in comparison with the active comparator and the other two experimental arms. The suspension of this study arm was supported by a DSMB statement.
3350328|NCT02261753|No Intervention|B: No pretreatment|Following the decision to proceed to surgery, if randomised to this arm a date will be given for surgery as per routine clinical practice. No KD pre-treatment will be undertaken.
3350329|NCT02261779|Experimental|Tretinoin & Tranylcypromine|Tretinoin started with 45mg/m2 on day 7 for one year, administered orally as soft capsules, Tranylcypromine started with 10mg/d up to a maximum dose of 60mg/d for on year, administered orally as tablets
3350330|NCT02261831|Experimental|obese patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3242658|NCT01310738|Experimental|Combination therapy|Liposomal amphotericin B 10mg/kg/d, I.V. single dose on day 0 plus Antimoniate of N-methylglucamine 20mg/kg/d for 10 consecutive days on days 1 to 10.
3350331|NCT02261831|Experimental|Diabetic patients|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3350332|NCT02261831|Experimental|Patients free of obesity and diabetes|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3350333|NCT02261831|Experimental|patients free type 2 diabetes.|Total blood sample, and 4 biopsies : collection of 2 colonic and 2 ileal biopsies
3350334|NCT02261844|Experimental|resveratrol|Resveratrol 1 g daily for 10 days
3350335|NCT02261844|Placebo Comparator|Placebo|Placebo 1 pill daily for 10 days
3350336|NCT02261857|Experimental|Intervention Arm|Intervention: Subjects will undergo assessment and a personalized CPAP mask device will be manufactured using patient-specific computer-aided design and 3D printing. The subject will use the personalized CPAP mask for 1 month of consistent use and post-intervention data will be collected for compare to historical control (see other arm)
3350337|NCT02261857|No Intervention|Historical Control Arm|Pre-interventional baseline data on subject OSA, CPAP compliance, and quality of life (QoL) measures will be collected to serve as historical controls.
3242659|NCT01310751|Experimental|iloprost nebuliser solusion|50 ng/kg/min
3350338|NCT02261870|Experimental|ALL_patients|MRI T2 quantification : heart transplant patients will have 4-6 MRI exams for T2 quantification during their first year after transplantation.
3350339|NCT02261883|Active Comparator|IV Remodulin|IV Remodulin will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
3350340|NCT02261883|Placebo Comparator|Placebo|Placebo will be initiated at 1 ng/kg/min. The dose will be increased in up to 2 ng/kg/min increments every 2 hrs until the OI is <10 (in the absence of dose-limiting side effects).
3350341|NCT02261896|Experimental|Placebo|1 intravenous dose followed by 1 oral dose each 12 hours (complete 3 days)
3242660|NCT01310751|Placebo Comparator|distilled water|2ml
3242661|NCT01310764|Sham Comparator|Mitomycin C|Those with trabeculectomy and intraoperative application of mitomycin C.
3242662|NCT01310764|Active Comparator|Bevacizumab|Those with trabeculectomy and adjunctive intraoperative subconjunctival injection of bevacizumab.
3242663|NCT01310816|Active Comparator|IPI-926|IPI-926
3242664|NCT01310816|Placebo Comparator|Sugar Pill|Placebo Arm, sugar pill
3350342|NCT02261896|Active Comparator|Antibiotic|Ciprofloxacin 400 mg intravenous one dose followed by ciprofloxacin 500 mg oral each 12 hours (complete 3 days)
3242665|NCT01310829||Virtual Reality|Board-eligible or board-certified genetic counselors and students evaluate a virtual reality-based intervention using questionnaires and physiological measurements.
3242666|NCT01310842||Pilot Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 5 in-person counseling sessions.
3350343|NCT02261909||normal creatinine|pts receiving an iv-contrast enhanced CT with normal baseline renal function
3350344|NCT02261909||elevated creatinine|pts receiving an iv-contrast enhanced CT with abnormal baseline renal function
3350345|NCT02261922|Experimental|ticagrelor|ticagrelor treatment
3350346|NCT02261922|Active Comparator|prasugrel|prasugrel treatment
3242667|NCT01310842||Smoking Cessation|4 weeks nicotine patch therapy, self-help materials, and 7 in-person counseling sessions.
3242668|NCT01310881|Experimental|Dose 1|
3242669|NCT01310881|Experimental|Dose 2|
3242670|NCT01310881|Experimental|Dose 3|
3242671|NCT01310881|Experimental|Dose 4|
3242672|NCT01310881|Experimental|Dose 5|
3350347|NCT02261935|Active Comparator|Existing Home Care Nursing Practice|Home care nurses provide care based on existing home care practice
3350348|NCT02261935|Experimental|Practice Support Tool Intervention|"The practice support tool intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~Update - December 22, 2016 - In some home care offices only, a study nurse will meet with family caregivers who are in the intervention group to deliver the CSNAT intervention. Information arising from the CSNAT about family caregivers' support needs will be communicated by the study nurse to the home care nurse, and incorporated by the home care nurse into the home care plan for the patient and patient's family."
3242673|NCT01310881|Experimental|Dose 6|
3242674|NCT01310881|Experimental|Dose 7|
3242675|NCT01310894|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation, given at a dose of 4mg/Kg.
3242676|NCT01310894|No Intervention|Active Surveillance|Active surveillance is one of the management strategy in men who have low-risk prostate cancer
3242677|NCT01310907||sinus node dysfunction|
3242678|NCT01310907||Atrioventricular block|
3242679|NCT01310907||control|
3242680|NCT01310920||sick sinus syndrome|
3242681|NCT01310920||control|
3242682|NCT01310933||Kikuchi's disease|
3242683|NCT01310933||Malignant lymphoma|
3242684|NCT01310998|Experimental|schizophrenic disorder|
3242685|NCT01310998|Experimental|other psychotic disorder|
3242686|NCT01310998|Experimental|no mental disorder|
3242687|NCT01311076|Experimental|TAK-329 50 mg|
3242688|NCT01311076|Experimental|TAK-329 200 mg|
3242689|NCT01311076|Active Comparator|Insulin 0.2 U/kg|
3242690|NCT01311076|Placebo Comparator|Placebo|
3242691|NCT01311089||Robotic thyroidectomy group|Robotic thyroidectomy group is the patient group who underwent robot-assisted endoscopic thyroid surgery using a gasless, trans-axillary approach.
3350349|NCT02261987|Active Comparator|Autogenic drainage (AD)|Patients will perform the autogenic drainage technique following the Chevallier and Agostini recommendations.
3242692|NCT01311089||conventional open thyroidectomy group|Conventional open thyroidectomy group is th patient group who underwent thyroid surgery via neck incision.
3242693|NCT01311115|Experimental|Group commitment contracts|"In addition to education and counseling, the intervention includes the following components:~Each participant is encouraged to deposit his cigarette money on a weekly basis, to be returned only if the smoker quits successfully within three months.~The project gives a series of two matching contributions of 150 baht each to participants who meet certain deposit requirements.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
3242694|NCT01311115|Active Comparator|Education and counseling|Participants in this group receive educational pamphlets about quitting smoking and one-time, group counseling from a nurse trained in smoking cessation counseling.
3350350|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre (RIM)|Patients will perform the repetitive inspiratory manoeuvers by breathing through a fixed resistance (Power Breathe device, model KH1) . Each session will comprise to cycles of 5 inspiratory breaths (60% of maximal inspiratory pressure). Patients will be stay in both lateral decubitus position (15 min per side).
3350351|NCT02261987|Active Comparator|Resistive inspiratory manoeuvre+autogenic drainage|First, patients will perform the resistive inspiratory manoeuvre during 10 minutes (5 min per side). Right after, patients will perform the autogenic drainage during 20 minutes.The instructions will be similar to described previously.
3242695|NCT01311128||Heart rate and blood pressure determination|All subjects have the same conditions (T-line, blood pressure cuff, and radial artery catheter), in order to compare them within-subjects.
3242696|NCT01311141|Experimental|Doripenem i.v.|no comparator, PK study
3350352|NCT02262013|Active Comparator|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
3350353|NCT02262013|Experimental|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program.
3350354|NCT02262026|Experimental|FHP; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
3350355|NCT02262026|Experimental|FHP; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
3350356|NCT02262026|Experimental|FHP; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History positive for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
3350357|NCT02262026|Experimental|FHP; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
3242697|NCT01311167|Experimental|Dexamethasone|
3242698|NCT01311167|Placebo Comparator|Placebo|
3242699|NCT01311180|Experimental|Sensoril®|
3242700|NCT01311180|Placebo Comparator|Placebo|
3242701|NCT01311193|Experimental|light therapy|Morning bright light treatment (at 8000 lux for 40min, daily during 3 weeks)
3350358|NCT02262026|Experimental|FHP; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
3350359|NCT02262026|Experimental|FHP; placebo, then 125mg AZD0530,then 50mg AZD0530|Family History positive for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
3350360|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then 50mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 125 mg, then 50 mg, then placebo separated by 1 week for each test
3242702|NCT01311206|Experimental|PBFR|Partial Blood Flow Restriction (PBFR) during Low-Intensity Exercise.
3242703|NCT01311206|Active Comparator|PBFR control|Low-Intensity Exercise without partial blood flow restriction.
3242704|NCT01311219|Active Comparator|No surgery|Non-operative Treatment
3242705|NCT01311219|Active Comparator|Plate fixation|Operative Treatment-Plate fixation
3242706|NCT01311219|Active Comparator|Intramedullary pinning|Operative Treatment-Intramedullary Pinning
3242707|NCT01311232||Case|Patients with HBV reactivation
3242708|NCT01311232||Control|Patients without HBV reactivation
3242709|NCT01311245|Experimental|Stage-tailored|At baseline and three months later
3242710|NCT01311245|Experimental|Non-stage-tailored|At baseline and three months later
3242711|NCT01311245|No Intervention|Control group|Assessment only
3242712|NCT01311271|Sham Comparator|Sham rTMS-Sham rTMS|Sham rTMS for 2 weeks
3242713|NCT01311271|Experimental|Sham rTMS-Real rTMS|Sham rTMS in the first week and real rTMS in the second week
3242714|NCT01311271|Experimental|Real rTMS-Real rTMS|Real rTMS for 2 weeks
3242715|NCT01311284|Active Comparator|Macintosh|
3242716|NCT01311284|Active Comparator|Mcgrath|
3242717|NCT01311284|Active Comparator|Airtraq Nasotracheal|
3242718|NCT01311297||Perioperative ovarian cancer patients|
3242719|NCT01311297||Pregnant patients|
3242720|NCT01311297||Female healthy volunteers|
3242721|NCT01311310|Experimental|remote ischemic preconditioning|
3242722|NCT01311323|Experimental|PCI with DES implantation|Percutaneous Coronary Intervention Implantation of Drug-Eluting Stents
3242723|NCT01311323|Active Comparator|CABG|Coronary Artery Bypass Grafting.On-pump or Off-pump CABG
3350361|NCT02262026|Active Comparator|FHN; 125mg AZD0530, then placebo, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 125 mg, then placebo, then 50mg separated by 1 week for each test
3350362|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then 125mg AZD0530, then placebo|Family History negative for alcoholism will take place in blinded testing of 50mg, then 125mg, then placebo separated by 1 week for each test
3350363|NCT02262026|Active Comparator|FHN; 50mg AZD0530, then placebo, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of 50mg, then placebo, then 125mg separated by 1 week for each test
3350364|NCT02262026|Active Comparator|FHN; placebo, then 50mg AZD0530, then 125mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 50 mg, then 125 mg separated by 1 week for each test
3350365|NCT02262026|Active Comparator|FHN; placebo, then 125mg AZD0530, then 50mg AZD0530|Family History negative for alcoholism will take place in blinded testing of placebo, then 125 mg, then 50 mg separated by 1 week for each test
3350366|NCT02262052|Other|Phase 4 cohort study|MRDTI
3350367|NCT02262065||Patients|Patients with suspected arthroplasty intolerance
3350368|NCT02262065||Controls|Patients with well tolerated arthroplasties
3350369|NCT02262091|Placebo Comparator|Placebo group|
3242724|NCT01311336|Active Comparator|Loratadine|Loratadine 10 mg once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
3350370|NCT02262091|Experimental|Food fibers|
3350371|NCT02262104|Experimental|Intensive exercise|Intensive strengthening and balance exercises 1 hour twice a week 12 weeks. Lead by physiotherapists.
3350372|NCT02262104|Placebo Comparator|Control|Control group activities: Social activities one hour twice a week. Light physical activities, reading, conversation, games. Lead by occupational therapist or nursing staff
3350373|NCT02262117|Placebo Comparator|standard care|No specific treatment (standard care)
3350374|NCT02262117|Experimental|specific treatment|As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
3350375|NCT02262143|Experimental|Experimental|Rosuvastatin 10 mg, Fenofibrate 160 mg
3242725|NCT01311336|Placebo Comparator|Placebo|Placebo once a day for 7 days beginning the day of pegfilgrastim treatment in patients with pegfilgrastim-induced back and leg pain during the previous treatment cycle
3242726|NCT01311349||1|A listing of all isolates meeting the inclusion criteria will be maintained.
3242727|NCT01311375|Experimental|w3 supplement + capsule CA-D|Mor DHA :w3 supp will be given to this group + capsule Ca(500 mg)-D(200 micro gram)
3350376|NCT02262143|Active Comparator|Comparator|Rosuvastatin 10 mg
3350377|NCT02262156|Experimental|Cognitive behavioral Therapy|"CBT program to be used in group modality that focused on managing symptoms of depression in patients with epilepsy.~12 CBT sessions, consisting of one weekly 90-minute session for 12 consecutive weeks."
3350378|NCT02262156|Active Comparator|Selective serotonin euptake inhibitor|Patients will receive a SSRI (sertraline or citalopram) for 12 weeks. Dose will be adjusted every 4 weeks according to medical criteria.
3242728|NCT01311375|Placebo Comparator|placebo+ CA-D|placebo in the same color,shape,size
3242729|NCT01311401||Rehania village (Kfar Rehania)|Circassian community
3242730|NCT01311401||Kama village (Kfar Kama )|Circassian community
3350379|NCT02262169|Active Comparator|Treatment I|2 Omeprazole capsules 20 mg once daily and 1 placebo caplet of DLBS2411, twice daily
3350380|NCT02262169|Experimental|Treatment II|1 DLBS2411 caplet 250 mg twice daily and 2 placebo capsules of Omeprazole once daily
3350381|NCT02262182|Experimental|KP group|PEP delivery by EzPAP® device with manual chest physiotherapy .
3350382|NCT02262182|Placebo Comparator|KM group|Manual chest physiotherapy only;
3242731|NCT01311414|Experimental|cafedrine/theodrenalin|
3242732|NCT01311427|Active Comparator|Group education|The control condition received standard group education, which met in small groups two times weekly for 60 minutes over 12 weeks.
3242733|NCT01311427|Experimental|8-form Yang-style Tai chi program|This arm tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in small groups two times weekly for 60 minutes over 12 weeks.
3350383|NCT02262195||Carboxyhemoglobin|Induced carboxyhemoglobin levels up tp 15 percent.
3350384|NCT02262195||Methemoglobin|Induced methemoglobin levels up to 15 percent.
3242734|NCT01311440|Experimental|Modified Atkins diet treatment|12 weeks of Modified Atkins diet treatment, recording seizures
3350385|NCT02262208|Other|Patients with type 2 diabetes|
3350386|NCT02262208|Other|Healthy|
3375970|NCT03334851|Experimental|Part A, Cohort 7|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3375971|NCT03334851|Experimental|Part A, Cohort 8|Subjects will receive a single dose of PF-06835375 or placebo on Day 1 via intravenous administration.
3375972|NCT03334851|Experimental|Part B, Cohort 1|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous administration.
3242735|NCT01311440|No Intervention|No intervention|12 weeks seizure record
3242736|NCT01311466|Experimental|Liver transplantation|The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital
3242737|NCT01311479|Active Comparator|Osteopathic Manipulation|"Patients will be evaluated and examined by an Osteopathic physician. This examination will consist of full osteopathic structural exam, and a focused examination of the sacroiliac joint and the surrounding musculature.~Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction."
3242738|NCT01311479|Active Comparator|Massage Therapy|Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment.
3350387|NCT02262221|No Intervention|ARM A (Non intensive Follow up)|Follow up consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit patients will report all new symptoms and they will receive physical and fiberoptic endoscopic head and neck examination. Laboratory tests will be performed once a year. Quality of life questionnaires will be administered to patients every other visit for the first 2 years and then at each visit. A socio-economic questionnaire will be also administered at each visit. Locoregional imaging will be performed within 6 months after radiotherapy end and recommended only at the occurrence of new signs or symptoms. Patients will be contacted by a phone call between visits in order to monitor patient's reported symptoms potentially related to disease recurrence.
3350388|NCT02262221|Other|ARM B (Intensive Follow up)|Intervention foreseen is scheduled radiologic evaluations (CT or MRI scan) and PET scan if patients ≥ 50 years old and with a smoking history ≥ 20 pack year. Follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment only in patients ≥50 years and with a smoking history of ≥20 pack/years.
3242739|NCT01311492|Placebo Comparator|Healthy Lifestyle Program|The purpose of the healthy lifestyle group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest.
3242740|NCT01311492|Active Comparator|Physical Activity Intervention|The physical activity program includes aerobic, strenth, flexibility and balance training.
3350389|NCT02262234|Experimental|Education Program Type 1|
3350390|NCT02262234|Experimental|Education Program Type 2|
3350391|NCT02262247||Transoral Visualization & Access|Subjects ≥ 22 yrs requiring transoral procedures
3350392|NCT02262273||Serous ovarian cancer:|Women with platinum-sensitive recurrent serous ovarian cancer
3350393|NCT02262286||Brain Injury|Brain Injury
3350394|NCT02262286||Control|Healthy, or Head Trauma, or Orthopedic Trauma, or Poly-Trauma
3350395|NCT02262299|Placebo Comparator|Placebo|Receive placebo tablets
3350396|NCT02262299|Active Comparator|Pirfenidone|Upon enrollment, subjects will be randomized to either the treatment group (Pirfenidone) or to the placebo group (1:1 ratio). The trial medication will be administered as 267-mg oral capsules and titrated to a maintenance dose of 2403 mg/d (3 capsules TID, for a total of 9 capsules/day).
3350397|NCT02262312||Patients with myelodysplastic syndrome|Patients with myelodysplastic syndrome among these include also patients with chronic myelomonocytic leukemia with myelodysplasia, patients with acute myeloid leukemia progressed from myelodysplastic syndrome and patients with myelodysplastic/myeloproliferative neoplasm, unclassifiable
3242741|NCT01311518|Placebo Comparator|Placebo|
3242742|NCT01311518|Active Comparator|Drug: Thymosin Beta 4 injectable|
3242743|NCT01311531|Active Comparator|TriMed fragment-specific fixation|
3350398|NCT02262325|Experimental|Treatment (hypofractionated radiation boost, chemoradiation)|Patients undergo hypofractionated radiation boost over 2 fractions (at least 40 hours apart) during week 1. Beginning week 2, patients receive cisplatin IV on days 8, 15, 36, and 43; and etoposide IV over 60 minutes on days 8-12 and 36-40. Patients also undergo standard 3-D conformal radiation therapy QD 5 days a week for a total of 30 fractions. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
3350399|NCT02262338|Experimental|Treated subjects|AGT-182 solution for infusion will be administered intravenously at doses of 1.0 mg/kg or 3.0 mg/kg weekly for 8-13 weeks.
3350400|NCT02262351|Experimental|Screening|"Subjects will undergo three screening methods for atrial fibrillation:~30 Second Pulse Check Watch BP Home A HeartCheck Hand-held ECG device"
3350401|NCT02262390|Active Comparator|Standard of Care|Partner notification slip is given to the pregnant female participant on the day she receives her syphilis test results to give to their sexual partner encouraging them to come to the STI clinic and be screened for syphilis. The partner notification slip will have a code number, but no identifiable features (no names).
3350402|NCT02262390|Active Comparator|SMS reminders and notification slip for partner screening|Participants will receive weekly SMS reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and on the SMS reminders.
3350403|NCT02262390|Active Comparator|Phone call reminders and notification slip for partner scree|Participants will receive weekly phone call reminders to encourage their partners to attend the STI clinic for syphilis testing for up to 8 weeks after initial positive syphilis test for the participant. The participant ID number will be written on both the notification paper which partners should bring in with them and be given to the participant when the nurse calls.
3242744|NCT01311531|Active Comparator|TriMed volar locking plate|
3242745|NCT01311570|Experimental|Buprenorphine|
3242746|NCT01311583|Active Comparator|usual care plus Teach Back intervention|Trained nurses will provide Teach Back to the intervention group. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
3242747|NCT01311583|No Intervention|usual care|"All participants will experience the current practice of discharge teaching: daily interaction with the interdisciplinary team members via rounds, counseling on diet and medications with a dietician and pharmacist when referred, view the Heart Failure Discharge Video, and receive a Congestive Heart Failure education package which includes the Heart and Stroke Managing Congestive Heart Failure booklet."
3242748|NCT01311596||No icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the first 2 weeks of the study period~Lab -Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the first 2 weeks of the study period"
3242749|NCT01311596||Icons|"Clinic - Children who are established patients, 4-18 years old, and presented to the NeuroDevelopmental Science Center for a follow-up office visit during the last 2 weeks of the study period~Lab - Patients 4-18 years old with a documented diagnosis who were seen in the NeuroDevelopmental Science Center and were given a prescription for lab work during the last 2 weeks of the study period"
3350404|NCT02262403|Experimental|Hookworm infected|The amount, phenotype and function of Treg will be explored at several time points. Cultures with environmental antigen will be subsequently performed.
3350405|NCT02262403|Active Comparator|Non infected (hookworms) healthy subjects|All the tests done in the experimental hookworm infected group will be also done in the comparator non infected group.
3350406|NCT02262416|Placebo Comparator|controls|Normal saline of equivalent volume
3350407|NCT02262416|Active Comparator|case|0.5mg Leuprolide acetate injection
3350408|NCT02262429||ONS QIP|Two (2) hospitals will administer the new rapid, comprehensive oral nutritional supplementation (ONS) QIP.
3350409|NCT02262429||ONS Standard Feeding|"Two (2) hospitals will use their current standard ONS feeding protocol."
3242750|NCT01311609|Experimental|Systane|Systane Lubricant Eye Drops
3350410|NCT02262442|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3350411|NCT02262442|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
3350412|NCT02262455|Experimental|STM 434|
3350413|NCT02262455|Experimental|STM 434 and Liposomal Doxorubicin|
3350414|NCT02262468||MOM total hip replacements|all patients with MOM 36mm hip replacements
3350415|NCT02262481|Active Comparator|Dydrogesterone|tocolytic + corticosteroids + Dydrogesterone 10 mg/tablet prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
3350416|NCT02262481|Placebo Comparator|Placebo|tocolytic + corticosteroids + Placebo prepare in capsule, 1 cap oral every 12 hours, starting form enrollment until gestational age 37 weeks
3242751|NCT01311622|Experimental|warfarin|
3242752|NCT01311622|Experimental|warfarin and fostamatinib|
3242753|NCT01311635|Experimental|Treatment A|
3242754|NCT01311635|Experimental|Treatment B|
3242755|NCT01311635|Experimental|Treatment C|
3242756|NCT01311635|Experimental|Treatment D|
3242757|NCT01311700|Active Comparator|Early metoprolol initiation strategy|
3242758|NCT01311700|No Intervention|Delayed metoprolol initiation strategy|
3242759|NCT01311713|Experimental|(Part 1): CEP-9722|
3242760|NCT01311713|Experimental|(Part 2): CEP-9722|
3242761|NCT01311739|Experimental|10 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as 2 tablets taken with 50 mL of water resulting in a total dose of 10 mg cyanocobalamin and 200 mg SNAC.
3242762|NCT01311739|Experimental|5 mg Eligen® B12 (Cyanocobalamin/SNAC)|A single oral dose of Eligen® B12, cyanocobalamin/SNAC (5 mg cyanocobalamin/100 mg SNAC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin and 100 mg SNAC.
3242763|NCT01311739|Active Comparator|5 mg Oral Cyanocobalamin|A single oral dose of cyanocobalamin alone (5 mg cyanocobalamin, commercial: VITALABS, INC) administered in the fasted state as a tablet taken with 50 mL of water resulting in a total dose of 5 mg cyanocobalamin.
3242764|NCT01311739|Active Comparator|1 mg Intravenous Cyanocobalamin|A single intravenous (IV) dose of cyanocobalamin (1 mg cyanocobalamin) administered in the fasted state. Each subject will receive a 1 mL IV injection of a 1 mg/mL (1000 μg/mL) solution resulting in a total dose of 1 mg cyanocobalamin.
3242765|NCT01311765|Active Comparator|8 day-antibiotherapy|Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit
3350417|NCT02262494|Other|Suspected first episode of DVT|"The study population consists of patients presenting with suspected first episode of DVT at the Nîmes University Hospital.~Intervention: portable venous compression ultrasonography Intervention: venous compress ultrasonography Intervention: Doppler ultrasound of the lower limbs"
3350418|NCT02262520|Experimental|Treatment A: Digoxin|Digoxin tablet by mouth on specified days
3350419|NCT02262520|Experimental|Treatment B: Apixaban and Digoxin|Apixaban and Digoxin tablets by mouth on specified days
3350420|NCT02262533|Experimental|Treatment A: Apixaban|Apixaban tablet by mouth on specified day
3242766|NCT01311765|No Intervention|15 day-antibiotherapy|Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations
3242767|NCT01311778|Placebo Comparator|Placebo|Subjects will receive placebo
3242768|NCT01311778|Experimental|CBD 400 mg|Subjects will receive 400 mg CBD
3242769|NCT01311778|Experimental|CBD 800mg|Subjects will receive 800 mg CBD
3242770|NCT01311791|Experimental|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure.
3242771|NCT01311791|Active Comparator|Standard Medical Therapy|as per protocol
3242772|NCT01311804|Experimental|periarticular parecoxib sodium|patients will be given periarticular parecoxib sodium injection
3242773|NCT01311804|Active Comparator|intravenous parecoxib sodium|intravenous parecoxib sodium will be given during total knee arthroplasty
3242774|NCT01311817|Placebo Comparator|Saline Patch|1mL saline applied to the vaccine patch
3242775|NCT01311817|Experimental|Bacteria plus CT|0.95mL bacterial vector plus 0.05mL cholera toxin
3242776|NCT01311830|Active Comparator|Telephone Counseling|
3242777|NCT01311830|Placebo Comparator|Written Materials|
3242778|NCT01311856||Standard Arm (mail/telephone)|
3242779|NCT01311856||Internet Arm|
3242780|NCT01311869|Active Comparator|EGCG ( Green Tea extract)|40 subjects will receive 800 mg EGCG orally per day for 6 months versus 40 subjects will receive Brown Rice pill for 6 months
3242781|NCT01311869|Placebo Comparator|Brown Rice pills|40 subjects will receive 800 mg brown rice pills orally per day for 6 months versus 40 subjects will receive EGCG capsule for 6 months
3242782|NCT01311882|Experimental|MK-4305 40 mg|Day 1 and Day 8- 4 x 10 mg MK-4305 and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305
3350421|NCT02262533|Experimental|Treatment B: Atenolol|Atenolol tablet by mouth on specified day
3350422|NCT02262533|Experimental|Treatment C: Apixaban and Atenolol|Apixaban and Atenolol tablets by mouth on specified day
3350423|NCT02262546|Experimental|Pramipexole|
3350424|NCT02262546|Active Comparator|Moxifloxacin|
3350425|NCT02262546|Placebo Comparator|Pramipexole Placebo|
3350426|NCT02262546|Placebo Comparator|Moxifloxacin Placebo|
3350427|NCT02262559|Experimental|BIBR 277 tablet|
3350428|NCT02262559|Active Comparator|BIBR 277 capsule|
3242783|NCT01311882|Experimental|MK-4305 20 mg|Day 1 and Day 8- 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 2 x 10 mg MK-4305 and 2 x 10 mg MK-4305 matching placebo
3242784|NCT01311882|Active Comparator|Zopiclone 7.5 mg|Day 1 and Day 8- 1 x 7.5 mg zopiclone and 4 x 10 mg MK-4305 matching placebo; Days 2-7- 4 x 10 mg MK-4305 matching placebo
3242785|NCT01311882|Placebo Comparator|Placebo|Day 1 and Day 8- 4 x 10 mg MK-4305 matching placebo and 1 x 7.5 mg zopiclone grossly matching placebo; Days 2-7 - 4 x 10 mg MK-4305 matching placebo
3350429|NCT02262572|Experimental|Telmisartan /HCTZ - compression tablet (DC)|
3350430|NCT02262572|Experimental|Telmisartan /HCTZ - dry granulation tablet (DG)|
3350431|NCT02262572|Active Comparator|Telmisartan /HCTZ - present commercial formulation|
3350432|NCT02262585|Experimental|BIBR 277 tablet|(Mannitol based)
3350433|NCT02262585|Active Comparator|BIBR 277 capsule|
3242786|NCT01311908||Surgery, Roux-en-Y , reflux esophagitis|Patients with roux-en-Y reconstruction (study group)
3242787|NCT01311908||surgery, traditional gastrojejunostomy|Traditional gastrojejunostomy reconstruction (control group).
3350434|NCT02262598|Experimental|Telmisartan/HCTZ fixed dose|
3350435|NCT02262598|Active Comparator|Telmisartan and HCTZ monocomponents|
3350436|NCT02262611||Hypertension patients - Pneumology|
3350437|NCT02262611||Hypertension patients - Cardiology|
3350438|NCT02262611||Hypertension patients - Nephrology|
3350439|NCT02262611||Hypertension patients - Diabetology|
3350440|NCT02262624|Experimental|Telmisartan/HCTZ fixed combination|
3350441|NCT02262624|Active Comparator|Telmisartan and HCTZ monocomponents|
3242788|NCT01311934||HBV-infected|
3242789|NCT01311934||HCV-infected|
3242790|NCT01311960|Experimental|bevacizumab eye drop|
3350442|NCT02262637||Hypertensive patients - Cardiologists|
3350443|NCT02262637||Hypertensive patients - Nephrologists|
3350444|NCT02262637||Hypertensive patients - Diabetologists|
3350445|NCT02262650|Active Comparator|Telmisartan alone|
3350446|NCT02262650|Experimental|Telmisartan + Clopidogrel (concomitantly)|
3350447|NCT02262650|Experimental|Telmisartan + Clopidogrel (consecutively)|
3350448|NCT02262650|Active Comparator|Clopidogrel alone|
3350449|NCT02262663|Experimental|Vilaprisan [0.5mg]|0.5 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3350450|NCT02262663|Experimental|Vilaprisan [1mg]|1 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3350451|NCT02262663|Experimental|Vilaprisan [2mg]|2 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3350452|NCT02262663|Experimental|Vilaprisan [4mg]|4 mg BAY1002670, oral administration, one tablet to be taken daily, 84 consecutive days
3350453|NCT02262676||Rivaroxaban|Patients with Atrial fibrillation treated with Rivaroxaban
3350454|NCT02262689|Experimental|GSK2256294 15 mg|Randomised subjects will be instructed to take three capsules of GSK2256294 15 mg, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
3350455|NCT02262689|Placebo Comparator|Placebo|Randomised subjects will be instructed to take three capsules of matching placebo, each morning for 7 days. Subjects will undergo echocardiography under normoxic and hypoxic conditions on Day 1 pre-dose and on Day 7 post-dose.
3350456|NCT02262702||Extended Release Paracetamol|Participants prescribed with extended release paracetamol tablet containing 665 mg paracetamol.
3350457|NCT02262702||Standard Paracetamol|Participants prescribed with standard paracetamol tablet containing 500 mg paracetamol.
3350458|NCT02262715|Experimental|Part 1|Participants will receive in random order Treatment A (VX-787, 600 mg tablet 2 times a day on Day 1 to 4, followed by VX 787, 600 mg tablet on Day 5); Treatment B (Oseltamivir, 75 mg capsule 2 times a day on Day 1 to 4, followed by oseltamivir 75 mg capsule in the morning on Day 5) or Treatment C (VX-787, 600 mg tablet, 2 times a day orally + oseltamivir, 75 mg capsule, 2 times a day on Day 1 to 4, followed by a single dose of VX-787, 600 mg + oseltamivir, 75 mg capsule on Day 5). Each participant will receive all three treatments (Treatment A, B and C) in a random sequence.
3350459|NCT02262715|Experimental|Part 2 VX-787|Participants will receive VX-787, 600 mg, tablet 2 times a day, orally on Day 1 to Day 9, followed by single dose of VX-787, 600 mg on Day 10.
3350460|NCT02262715|Experimental|Part 2 Placebo|Participants will receive placebo matching to VX-787, 2 times a day, orally on Day 1 to Day 9, followed by single dose of matching placebo on Day 10.
3350461|NCT02262741|Experimental|MEDI4736 + tremelimumab|
3350462|NCT02262767|Experimental|Single Ascending Doses Cohort 1|Single doses, given by oral solution, starting at 0.75 mg up to a possible maximum of 3.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
3350463|NCT02262767|Experimental|Single Ascending Doses Cohort 2|Single doses, given by oral solution, starting at 4.5 mg up to a possible maximum of 9.0 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator while 6 are given active dose. The subjects will be given concomitant trimethobenzamide hydrochloride for the 3 weeks that the subject is in the CRU. For each of the three periods, subjects will be crossed-over from placebo or PF-06649751. Each PF-06649751 dose is separated by one week.
3350464|NCT02262780|Experimental|Single low dose Telmisartan with HCTZ|
3350465|NCT02262780|Experimental|Single high dose Telmisartan with HCTZ|
3350466|NCT02262780|Experimental|Multiple high dose Telmisartan with HCTZ|
3350467|NCT02262793|Experimental|telmisartan and ASA/ER-DP (concomitant)|
3350468|NCT02262793|Active Comparator|ASA/ER-DP alone|
3350469|NCT02262793|Experimental|telmisartan and ASA/ER-DP (consecutively)|
3350470|NCT02262793|Active Comparator|telmisartan|
3350471|NCT02262806|Other|Leptin therapy|leptin administered via SC injections BID
3350472|NCT02262832|Other|Leptin study drug|Administration of study drug SQ BID
3350473|NCT02262845||Group A: PEP Risk|In subjects deemed at high risk for acute pancreatitis post-endoscopic retrograde cholangiopancreatography (ERCP)
3350474|NCT02262845||Group B: Impaired Pancreatic Duct Drainage|In subjects with a pancreatic duct stricture and/or pancreatic duct stones and/or pancreatic duct sludge or debris, possibly, but not exclusively before or after ESWL or before pancreatic surgery
3350475|NCT02262845||Group C: Pancreatic Duct Leak|In subjects with a pancreatic duct leak
3350476|NCT02262845||Group D: Post Pancreatic Surgery|In subjects at risk of pancreatic duct leak or strictures after resection of a pancreatic lesion close to the main pancreatic duct or at the level of the pancreatico-jejunostomy after pancreatico-duodenectomy
3350477|NCT02262845||Group E: Other|In subjects with other indications
3242791|NCT01311960|Experimental|placebo normal saline eye drop|
3242792|NCT01311973||Renal Function Group #1|Creatinine clearance > 90 mL/min
3350478|NCT02262858|Experimental|Telmisartan and HCTZ (fix dose combination)|
3350479|NCT02262858|Active Comparator|Telmisartan and HCTZ (monocomponent)|
3350480|NCT02262871|Experimental|CF patients HFN|CF patients who meet the eligibility criteria will be randomized to receive HFN and then crossover to other device.
3350481|NCT02262871|Experimental|CF patients NIV|CF patients who meet the eligibility criteria will be randomized to receive NIV and then crossover to other device.
3350482|NCT02262884|Active Comparator|AIS @ 12mmHg pressure|SurgiQuest AirSeal Insufflation System (AIS) set at 12mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
3350483|NCT02262884|Active Comparator|AIS @ 15mmHg pressure|SurgiQuest AirSeal insufflation System (AIS) set at 15 mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephrectomy.
3350484|NCT02262884|Active Comparator|CIS @ 15mmHg pressure|Conventional Insufflation System (CIS) set at 15mmHg pressure for the management of pneumoperitoneum during Robotic Partial Nephectomy.
3350485|NCT02262897|Experimental|Nab-paclitaxel single agent|Nab-paclitaxel single agent, either in 130mg/m2 weekly regimen, d1,8,15 every 4 weeks or in 230mg/m2 d1 every 3 weeks
3350486|NCT02262910|Experimental|ES414|Cohorts 1-3 of the dose escalation stage of the study (Stage 1) will test weekly doses of 0.2 mcg/kg to 2 mcg/kg. Cohorts 4-9 of the dose escalation stage of the study (Stage 1) will test continuous infusion at flat doses of 25 mcg to 300 mcg per day delivered continuously over 24 hours. The maximum tolerated dose from Stage 1 of the study will be further examined in Stage 2. Patients in cohorts 1-3 will receive ES414 weekly via intravenous (IV) infusion during the first three 28-day cycles and then on Day 1 and 15 of each subsequent cycle until disease progression, intolerable toxicity occurs, or the patient withdraws consent. Patients in cohorts 4-9 will receive ES414 as a continuous IV infusion for 6 months until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
3350487|NCT02262923|No Intervention|Control|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the control arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks overall), these patients will receive an oral placebo three times daily."
3242793|NCT01311973||Renal Function Group #2|Creatinine clearance 60-69 mL/min
3242794|NCT01311973||Renal Function Group #3|Creatinine clearance 50-59 mL/min
3242795|NCT01311973||Renal Function Group #4|Creatinine clearance 40-49 mL/min
3375973|NCT03334851|Experimental|Part B, Cohort 2|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
3375974|NCT03334851|Experimental|Part B, Cohort 3|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
3242796|NCT01311973||Renal Function Group #5|Creatinine clearance 30-39 mL/min
3242797|NCT01311973||Renal Function Group #6|Creatinine clearance 20-29 mL/min
3242798|NCT01311973||Renal Function Group #7|Creatinine clearance < 20 mL/min (not on dialysis)
3242799|NCT01311986||Patients with atopic dermatitis|
3242800|NCT01311986||Patients with nummular eczema|
3242801|NCT01311986||Normal control|
3242802|NCT01311999||IGRA-positive group|The subjects who have positive results of interferon-gamma release assay
3242803|NCT01311999||IGRA-negative group|The subjects who have negative results of interferon-gamma release assay
3242804|NCT01312012|Experimental|The effectiveness and feasibility, using antiviral therapy|Experimental: Subjects receive tenofovir disoproxil fumarate (TDF) oral use prior to delivery in pregnant women with positive serum HBeAg and HBsAg and high HBV DNA levels > 10^8copies / mL, to reduce the rate of mother to infant transmission of HBV infection, and also to monitor the safety of the therapy.
3242805|NCT01312012|No Intervention|Control|Subjects receive no intervention, but with blood tests for mothers and infants before and after delivery, as a comparative group to experimental arm.
3242806|NCT01312025|Placebo Comparator|conventional laparoscopic cholecystectomy|
3242807|NCT01312025|Active Comparator|modified laparoscopic cholecystectomy|
3242808|NCT01312051||Protocol 1|Healthy, overweight 11 to 17 year old black and white adolescents
3242809|NCT01312051||Protocol 2|Healthy, normal-weight 11 to 17 year old black and white adolescents
3242810|NCT01312051||Protocol 3|Healthy, normal-weight 8 to 12 year old black and white adolescents
3242811|NCT01312051||Protocol 4|Healthy, overweight 11 to 17 year old black and white adolescents
3242812|NCT01312064|Active Comparator|rituximab and everolimus|Patients of the study arm will receive rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus will be given with an initial dose of 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
3242813|NCT01312064|Active Comparator|thymoglobulin and tacrolimus|The control arm will receive thymoglobulin induction and tacrolimus-based immunosuppressive therapy. The dose of thymoglobulin would be 1.0mg/kg/d for 3 days25. The first dose of thymoglobulin will be administered before graft kidney reperfusion, and so is rituximab. All patients will receive corticosteroid therapy as usual. The initial daily dose of tacrolimus will be 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation. The doses of tacrolimus will be adjusted to target the whole blood trough levels between 8 to 12 ng/ml during the first 30 days after transplantation, and tapered to 6 to 10 ng/ml at 6 months.
3350488|NCT02262923|Experimental|Experimental|"Poor responders will be defined as women who have undergone a previous IVF cycle with fewer than 4 oocytes retrieved and at least one of the following two criteria: (1) advanced age (≥40 years) or any other risk factor for poor ovarian response and (2) abnormal ovarian reserve testing (antral follicle count (AFC) < 5-7 or anti-mullerian hormone (AMH) level < 3.6-7.9 pmol/L). Poor responders who will be undergoing a repeat IVF cycle will be recruited for the study with informed consent.~In the experimental arm, patients will undergo the same ovarian stimulation protocol as the previous IVF cycle in which they experienced a poor response. Starting 3 weeks prior to the first day of stimulation until the time of ovulation trigger (approximately 5 weeks in total), these patients will receive oral metoclopramide 5mg three times daily.."
3350489|NCT02262936|Active Comparator|Desmopressin|Patients randomized to receive Desmopressin will be given 0.1mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 0.2mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
3350490|NCT02262936|Active Comparator|Fesoterodine|Patients randomized to receive Fesoterodine will be given 4mg daily by mouth at bedtime. After 4 weeks, patients will have the option to increase their dose to 8mg daily by mouth at bedtime. Total time of drug administration will be 12 weeks.
3350491|NCT02262949|Experimental|LifeStent Vascular Stent|This is a single arm study and all subjects receive PTA and implantation of one Life Stent Vascular Stent.
3350492|NCT02262962|No Intervention|Usual Well-Child Care|No change in Well-Child Visits.
3350493|NCT02262962|Experimental|Redesigned Well-Child Care|The Redesigned Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and text messaging services (HealthyTxt).
3350494|NCT02262975||donepezil (Aricept)|
3350495|NCT02262988|Experimental|Autologous cells and knee arthroplasty|Regenerative cells recovered from the patient's infrapatellar fat pad will be processed using the Transpose RTTM system (InGeneron, Inc., Houston, TX, USA). The processed cells are injected into the knee as adjuvant treatment for total knee arthroplasty (TKA).
3350496|NCT02262988|Placebo Comparator|Control|Standard total knee arthroplasty (no fat cells harvested).
3350497|NCT02263001|Experimental|Auricular Acupuncture Plus Usual Care|Auricular acupuncture therapy for treatment of musculoskeletal pain, plus usual care therapy consisting of over-the-counter and prescribed pharmacotherapy.
3242814|NCT01312077|Experimental|Levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine, and will receive peri- and intraarticular surgical site infiltration during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure and this will be left in situ in the wound. The catheter will be sited under the fascia lata exiting antero-superior to the incision. A bacterial filter will be attached and it will be connected to an elastomeric pump which will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
3242815|NCT01312077|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.2 mg).
3242816|NCT01312090|Active Comparator|Conventional weight loss treatment group|Eating and physical activity counseling and behavioral therapy for weight loss.
3350498|NCT02263001|Active Comparator|Usual Care Only|Usual care therapy for treatment of musculoskeletal pain. Usual care therapy consists of over-the-counter and prescribed pharmacotherapy.
3350499|NCT02263027|Experimental|Vaccine, then placebo|1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment followed by 1 injection of normal saline placebo, 0.5mL/dose, 28 days later
3350500|NCT02263027|Experimental|Placebo, then vaccine|1 injection of normal saline placebo, 0.5mL/dose followed by 1 injection of trivalent inactivated influenza vaccine, 0.5mL/dose, as approved for use in Canada for season of enrolment, 28 days later
3350501|NCT02263053|Active Comparator|Posterior Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
3350502|NCT02263053|Active Comparator|Caudal Mobilization|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
3350503|NCT02263066||Group 1|Chinese hemophilia A pediatric patients with medical records who had accepted regular prophylaxis, totally/partially with rFⅧ between Nov. 1st 2007 and May 31st 2013
3350504|NCT02263092|Experimental|15 minutes of physical exercise|the subjects will do physical exercise on a treadmill with 64 to 74% of maxHR
3350505|NCT02263092|Experimental|10 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 77 to 95% of maxHR.
3350506|NCT02263092|Experimental|30 minutes of physical exercise|- the subjects will do physical exercise on a treadmill with 57 to 63% of maxHR.
3350507|NCT02263092|Experimental|Rest/control|the subjects will be on 15 or 30 minutes seat without move the legs.
3350508|NCT02263092|Experimental|Anodal tDCS + physical exercise 1|the subjects will be undergo to anodal tDCS + physical exercise 1
3242817|NCT01312090|Experimental|Cryo group|"Eating and physical activity counseling and behavioral therapy for weight loss will be provided to all subjects.~The subjects in the cryo group will be given whole-body cryotherapy 1-3 times a week for the 4-month-treatment period"
3242818|NCT01312103|Experimental|Internet Based Safety Decision Aid|
3242819|NCT01312103|Active Comparator|Control Website|
3350509|NCT02263092|Experimental|Anodal tDCS + physical exercise 2|the subjects will be undergo to anodal tDCS + physical exercise 2
3350510|NCT02263092|Experimental|Cathodal tDCS + physical exercise 1|the subjects will be undergo to cathodal tDCS + physical exercise 1
3350511|NCT02263092|Experimental|Cathodal tDCS + physical exercise 2|- the subjects will be undergo to cathodal tDCS + physical exercise 2
3350512|NCT02263092|Experimental|Sham tDCS + physical exercise 1|the subjects will be undergo to sham tDCS + physical exercise 1
3350513|NCT02263092|Experimental|Sham tDCS + physical exercise 2|the subjects will be undergo to sham tDCS + physical exercise 2
3350514|NCT02263105|Experimental|CDDP plus Temozolomide|"Patients were treated with CDDP and TMZ. CDDP was administered iv from Day 1 to 3 with everyday dose of 30mg. TMZ was orally administered from Day 1 to 7 and Day 15 to 21, with everyday dose of 125mg/m2 (Level 2). The period of one chemotherapy cycle is 28 days. TMZ dose levels were listed in Table 1.~Table 1 TMZ dose levels Dose levels Daily TMZ dose( mg/m2/d ) TMZ dose per cycle(mg/m2)~150 2100~125 1750~100 1400~75 1050"
3350515|NCT02263144||histologically-verified <10mm polyps|histologically-verified <10mm polyps, analyzed by virtual chromo-endoscopy using FICE Fujifilm Technology
3350516|NCT02263157||BSI group with thrombocytopenia|BSI patients with thrombocytopenia
3350517|NCT02263157||Non-BSI group with thrombocytopenia|Non-BSI patients with thrombocytopenia
3242820|NCT01312116|Experimental|Internet-delivered CBT|Active treatment: Internet-delivered Cognitive Behavior Therapy, 8 weeks treatment, guided self-help
3350518|NCT02263157||BSI group without thrombocytopenia|BSI patients without thrombocytopenia
3350519|NCT02263157||Non-BSI group without thrombocytopenia|Non-BSI patients without thrombocytopenia
3350520|NCT02263170||All study participants|Healthy (m/f), normal weighted
3350521|NCT02263183|Active Comparator|red palm olein(labelled A)|red palm olein (labelled A)
3242821|NCT01312116|Experimental|Internet-delivered PDT|Active treatment: Internet-delivered Psychodynamic Therapy Active treatment: Internet-delivered Psychodynamic Therapy, 8 weeks treatment, guided self-help
3350522|NCT02263183|Placebo Comparator|palm olein(labelled B)(control)|palm olein(labelled B)(control)
3350523|NCT02263196|Experimental|alcohol and povidone iodine|the efficacy of combination of alcohol and povidone iodine on inflammation related to vascular access
3350524|NCT02263196|Experimental|combination of alcohol and betadin|the efficacy of combination of alcohol and povidone iodine on infection related to vascular access
3350525|NCT02263209|Experimental|Bioguard Group|Randomised study to either Bioguard or control stock
3242822|NCT01312116|No Intervention|Control condition|Wait-list condition, received treatment 3 months after initial treatment period
3242823|NCT01312142||patients with difficult weaning|
3242824|NCT01312155||Patients undergoing general anesthesia|
3350526|NCT02263209|Active Comparator|Control Group|Randomised study to either Bioguard or control stock
3350527|NCT02263222|Experimental|MDT-10013|Subjects will receive MDT-10013.
3350531|NCT02263248|Experimental|venlafaxine XR plus buprenorphine|Drug Intervention: venlafaxine XR plus buprenorphine Dosage varies. Subject remains on antidepressant throughout the 32 week study. Will be randomized to buprenorphine or placebo for up to 16 weeks.
3242825|NCT01312168|No Intervention|Healthy non-OSA control|
3350532|NCT02263248|Placebo Comparator|venlafaxine XR plus placebo|Drug Intervention: venlafaxine XR plus placebo Dosage varies . Subject remains on antidepressant throughout the 32 weeks study. Will be randomized to buprenorphine or placebo for up to 16 weeks
3350533|NCT02263261|Other|Flex HD Pliable Perforated HADM|Single Arm
3350534|NCT02263274|Experimental|Direct Cortical Measurement|Consented subjects will also have transcranial electrodes applied at four extracranial sites, below the sterile dressing and distant from the surgical skull defect. The four electrodes will be placed in uniform positions based on the standard 10-10 electrode system, at the temples bilaterally (positions F9 and F10) and at the occiput bilaterally (positions PO9 and PO10). Subjects will be stimulated according to a predetermined set of parameters which fall well within empirically and computationally determined safety thresholds, as discussed above. The entire stimulation protocol is described in detail in section 5, and is anticipated to last no longer than 30 minutes.
3350535|NCT02263287|Other|Alzheimer disease (AD)|Patients with AD according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) criteria Intervention: LeSCoD scale
3242826|NCT01312168|Experimental|OSA receiving therapeutic CPAP|
3242827|NCT01312168|Sham Comparator|OSA receiving subtherapeutic CPAP|
3242828|NCT01312194|Experimental|One vist group|All patients included in this treatment group will receive the complete endodontic treatment in a single visit.
3242829|NCT01312194|Active Comparator|Two-vist group|All patients included in this treatment group will receive treatment in two visits. The first will be done chemo mechanical root canal preparation, the placement of the intracanal medication the basis of calcium hydroxide and coronal sealing. Ten to twelve days later, this medication is removed and the root canal will be permanently filled.
3242830|NCT01312259|Active Comparator|Interstim Parameter Frequency 14 HZ|Subjects in this arm will receive 14 Hx as their frequency for the first three months. For the second 3 months, these patients will receive 40 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
3350536|NCT02263287|Other|Dementia with Lewy Bodies (DLB)|Patients with probable DLB according to McKeith criteria. Intervention: LeSCoD scale
3242831|NCT01312259|Experimental|Interstim Parameter Frequency 40 HZ|Subjects in this arm will receive 40 Hz as their frequency for the first three months. For the second 3 months, these patients will receive 14 Hz. Six months after the devise has been implanted, the patient has the option to choose which frequency they feel allows for better symptom control, and this is how the devise will be programmed.
3242832|NCT01312285|Placebo Comparator|Placebo|
3242833|NCT01312285|Experimental|Resonator Device|
3242834|NCT01312298|Experimental|General Anesthesia|Patients allocated to this arm will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml in a Target Controlled Infusion (TCI)
3242835|NCT01312298|Active Comparator|Regional anesthesia|Patients will receive intrathecal anesthesia
3242836|NCT01312311|Experimental|weekly docetaxel and cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles
3350537|NCT02263287|Other|Probable AD and possible DLB|Patients with clinical criteria for possible or probable AD and possible DLB Intervention: LeSCoD scale
3350538|NCT02263300||Supine- Supine|Group A (supine-supine) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global rating scale and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the supine, then Upright position. At the end of one week,the same medical student will then perform the intubation with the mannequin in both positions.
3350539|NCT02263300||Upright-upright|Group B (upright-upright) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position.At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
3242837|NCT01312324|Experimental|neoadjuvant chemotherapy|3 cycles of docetaxel/cisplatin before operation
3242838|NCT01312337|Experimental|Iressa for EGFR wild group|salvage Iressa therapy for patients with EGFR mutation negative NSCLC patients
3350540|NCT02263300||Supine -upright|Group C( supine -upright) will first practice fiberoptic intubation with the iLarynx oriented in the supine position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright then supine position. At the end of one week, The same medical student will then perform the intubation with the mannequin in both positions.
3350541|NCT02263300||Upright - supine|Group D( upright - supine) will first practice fiberoptic intubation with the iLarynx oriented in the upright position. Learning curves, global assessment score and checklist will then be obtained by a blinded examiner with the medical student using a real fiberoptic on a mannequin oriented in the upright,then supine position. At the end of one week, the same medical student will then perform the intubation with the mannequin in both positions.
3350542|NCT02263313||EGO-COMBO group|Previously enrolled into EGO-COMBO Pilot study and with combo stent
3350543|NCT02263339|Experimental|Aerobic Exercise|
3350544|NCT02263339|Active Comparator|Stretching Program|
3350545|NCT02263339|Active Comparator|Aerobic Exercise, Healthy Subjects|
3350546|NCT02263352|Experimental|Lycored soft gels , Scaling and Rootplaning.|Systemic Lycored soft gels,(Jagsonpal Pharma) was given orally 8mgms/day for 2 months and Scaling and rootplaning (otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline
3350547|NCT02263352|Experimental|Scaling and Rootplaning only.|Scaling and rootplaning(otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus) which was performed at baseline.
3242839|NCT01312350|Active Comparator|CCRT only arm|no neoadjuvant chemotherapy before definitive CCRT
3242840|NCT01312350|Experimental|neoadjuvant chemotherapy arm|2 cycles of TPF chemotherapy before definitive CCRT
3350548|NCT02263378|Experimental|supplement|
3350549|NCT02263378|Placebo Comparator|not intervention|
3350550|NCT02263391|Experimental|Opt-in testing|"Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). The research assistant will say: There is voluntary HIV testing available to all study participants if you wish to do it. It is free, private, it is only a finger stick, and you will learn your HIV results in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
3375975|NCT03334851|Experimental|Part B, Cohort 4|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
3375976|NCT03334851|Experimental|Part B, Cohort 5|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
3375977|NCT03334851|Experimental|Part B, cohort 6|Subjects will receive two doses of PF-06835375 or placebo on Day 1 and Day 29 via subcutaneous or intravenous administration.
3375978|NCT03330405|Experimental|Dose Level 0 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
3242841|NCT01312402|Active Comparator|Topical Brinzolamide (Azopt)|ophthalmic drop given three times a day
3242842|NCT01312402|Placebo Comparator|placebo ophthalmic drop in 5 mL solution|masked non-active eye drop (absence of Brinzolamide)
3242843|NCT01312415|Experimental|levobupivacaine infiltration|Patients will receive spinal anaesthesia with intrathecal bupivacaine (17.5 or 15 mg) without morphine, and will receive peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% at 8am the following morning.
3242844|NCT01312415|Other|Control|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
3242845|NCT01312441|Experimental|Ergocalciferol|Ergocalciferol 50,000 IU by mouth once weekly for 6 months
3350551|NCT02263391|Experimental|Opt-out testing|"Participants will be informed that a routine health test bundle is available on a voluntary basis to study participants, and the participant may elect to decline all or any individual part of the testing. The assistant will say: We are offering a voluntary panel of routine health screening test today for study participants. It includes blood sugar, cholesterol, and HIV. We recommend all of them for everyone, but you can choose to decline any or all of them. This is free, private, it is only a finger stick, and you will learn your results for all the tests in just minutes. Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group."
3350552|NCT02263404|Experimental|Deep Brain Stimulation|DBS Implant and stimulation Intervention: Device: Deep Brain Stimulation
3350553|NCT02263417|Active Comparator|Deep Brain Stimulation|Stimulation is on
3242846|NCT01312441|Placebo Comparator|Placebo|Placebo by mouth once weekly for 6 months
3242847|NCT01312454|Experimental|AL-59412C Concentration 1|AL-59412C injectable solution, single intravitreal injection
3350554|NCT02263417|Sham Comparator|Placebo|Stimulation is off
3350555|NCT02263430|Experimental|Deep Brain Stimulation|Stimulation is on.
3350556|NCT02263430|Sham Comparator|Placebo|Stimulation is off.
3350557|NCT02263443|Experimental|Soap sus enema (S.S.E.)|Patients in S.S.E. group will receive bowel preparation by soap suds enema until clear at night before surgery.
3350558|NCT02263443|Experimental|sodium chloride enema|Patients in unison enema group will receive Unison enema 100 ml per rectal at night before surgery.
3242848|NCT01312454|Experimental|AL-59412C Concentration 2|AL-59412C injectable solution, single intravitreal injection
3242849|NCT01312454|Active Comparator|Travoprost|Travoprost injectable solution, single intravitreal injection
3242850|NCT01312454|Placebo Comparator|Vehicle|AL-59412C Vehicle, single intravitreal injection
3350559|NCT02263443|Placebo Comparator|no enema|Patients will receive none of bowel preparation. NPO after midnight
3350560|NCT02263456|Active Comparator|Current Factor IX|
3350561|NCT02263456|Experimental|Replenine®-VF|
3350562|NCT02263469|Experimental|Replenine®-VF|
3242851|NCT01312480|Other|Intervention Group|The smoking cessation intervention is a Public Health Services-approved intervention based on the 5A's Model, which includes (1) Ask if the patient smokes, (2) Advise every patient to quit, (3) Assess readiness to quit, (4) Assist in quitting and finding services and (5) Arrange for cessation services and follow up. Practitioners will complete a 5A checklist for each patient in this arm.
3242852|NCT01312480|Other|Control Group|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
3242853|NCT01312506||Subjects undergoing a craniotomy|This group will include those subjects who have consented to have either a craniotomy or a laminectomy to resect an intramedullary tumor.
3350563|NCT02263482|Other|Control group|patients awaiting for evaluation to cardiac rehabilitation or transplantation
3350564|NCT02263482|Experimental|moderate-intensity group|Patients will be submitted to a 8-weeks training program, with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with upper and lower exercises (50% of the 1-maximum repetition test).
3350565|NCT02263482|Active Comparator|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) and peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 Kg each).
3350566|NCT02263495|Active Comparator|Paclitaxel & Gemcitabine(PG)|Paclitaxel 175mg/m2 IV , Day1,every 3weeks Gemcitabine 1250mg/m2 IV ,Day1& Day8 every 3weeks
3350567|NCT02263495|Experimental|Eribulin & Gemcitabine(EG)|Eribulin 1.0 mg/m2, 2-5min iv ,Day1& Day8 every 3weeks Gemcitabine 1,000 mg/m2 ,Day1& Day8 every 3weeks
3350568|NCT02263521||physicians|Nationally-representative sample of physicians in all specialties who have direct or indirect patient care responsibilities
3242854|NCT01312506||Metastases, no craniotomy|These subjects have metastases but have either chosen not to undergo removal of the cancer or their neurosurgeon does not recommend surgical approach or they have been diagnosed with metastatic melanoma but do not have CNS metastases.
3242855|NCT01312506||Healthy Volunteers|Subjects who do not have known melanoma or metastases.
3242856|NCT01312532|Other|fixed-bearing|fixed-bearing device is a kind of prosthesis
3242857|NCT01312532|Other|mobile-bearing|mobile-bearing device is a kind of prosthesis
3350569|NCT02263521||resident physicians|Nationally-representative of resident physicians in all specialties
3350570|NCT02263521||medical students|Nationally-representative sample of 4th year medical students in all US allopathic medical schools.
3350571|NCT02263534|Experimental|minisling|patients in this arm will undergo single incision minisling
3350572|NCT02263534|Sham Comparator|tension free vaginal tape|patients in this arm will undergo tension free vaginal tape
3350573|NCT02263560||Post-stroke patients|Patients who experienced stroke and who already recover gait abilities.
3242858|NCT01312545|Experimental|local made implant (3DP)|Enucleation and local made implant (3DP) insertion
3350574|NCT02263560||Control population|Participants matching the criterion (age and gender) of the patients' group.
3350575|NCT02263573|Experimental|PEP'C-R|Subjects will benefit from one preliminary session and 18 sessions of PEP'C-R, (2 sessions per week for 9.5 weeks).
3350576|NCT02263573|Active Comparator|Control group|Subjects do not participate in the program PEP'C-R and continue their usual activities at home for 9.5 weeks.
3350577|NCT02263599||Conservatively treated ventral hernias|
3350578|NCT02263599||Surgically treated ventral hernias|
3350579|NCT02263612||Danish Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3350580|NCT02263638|Experimental|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time by a nurse during a five day period
3350581|NCT02263651|Active Comparator|Closure with conventional technique with drainage|The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
3350582|NCT02263651|Experimental|Quilting suture without drainage|In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle.
3350583|NCT02263677|Experimental|Sitagliptin|60 day supply of 100mg Sitagliptin
3350584|NCT02263690|Active Comparator|Group Drops|"proparacaine 0.5% drops (Group Drops)~Patients from group Drops received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~Patients from Group Drops received a second drop of proparacaine 0.5%, 5 minutes after the drop of povidone iodine 5%."
3350585|NCT02263690|Active Comparator|Group SC|"proparacaine 0.5% drops plus subconjunctival lidocaine (Group SC)~Patients from group SC received a drop of proparacaine 0.5% before receiving a drop of povidone iodine 5%.~For the patients from Group SC, a subconjunctival bleb of anesthesia was created by injecting 0.4 ml of lidocaine 1% into the subconjunctival space, posteriorly to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-ml syringe."
3242859|NCT01312545|Experimental|imported implant (Medpor)|Enucleation and imported implant (Medpor) insertion
3242860|NCT01312558|Experimental|Prudent diet group|Participants follow CPAP therapy, a prudent diet while receiving counselling to increase their physical activity.
3350586|NCT02263690|Active Comparator|Group Gel|"Lidocaine gel 2% on the eye (Group Gel)~Patients from Group Gel received 1 mL of 2% lidocaine gel on the eye before receiving the drop of povidone iodine 5%.~For the patients from Group Gel, 1 mL of 2% lidocaine gel was applied on the eye before receiving the drop of povidone iodine 5%."
3350587|NCT02263703|Experimental|HPV vaccine|Quadrivalent HPV vaccine
3350588|NCT02263716||Accelerometer|Utilize accelerometers to measure activity in a diverse population of patients with medical or surgical critical illness.
3350589|NCT02263729|Active Comparator|losartan|Subjects will taken 50mg of losartan per day for 4 weeks
3350590|NCT02263729|Placebo Comparator|placebo|Subjects will be given placebo to replicate appearance of losartan pills. Placebo pill will be taken once per day.
3350591|NCT02263742|Experimental|Peer whole health|Peer whole health intervention will be compared to the treatment as usual at Wellness Center to assess healthcare choice and outcomes
3350592|NCT02263742|Active Comparator|EBPs at Wellness Center|EBPs at Wellness Center will be the active comparative to measure healthcare choice and outcomes with the peer whole health intervention
3350593|NCT02263755||chronic hepatitis B subjects|Subjects who have been diagnosed with chronic hepatitis B.
3350594|NCT02263768|Other|Group 1 - Recall Interval of 12 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3350595|NCT02263768|Other|Group 2 - Recall Interval of 18 months|"Oral clinical conditions:~Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment"
3350596|NCT02263781|Experimental|Control Blood|Patients on routine postinfectious control, blood draw
3350597|NCT02263781|Experimental|Primary PREPL deficiency Blood|Patients with primary PREPL deficiency, blood draw
3350598|NCT02263781|Experimental|Prader Willi syndrome Blood|Patients with Prader-Willi syndrome, blood draw
3242861|NCT01312558|Experimental|Mediterranean diet group|Participants follow CPAP therapy, Mediterranean diet, while receiving counselling to increase their physical activity.
3242862|NCT01312571|Active Comparator|Cognitive behavior therapy via the internet|Cognitive behavior therapy via the internet with therapist support.
3242863|NCT01312571|Active Comparator|Attentional retraining|Attentional retraining as described by Nader Amir.
3350599|NCT02263781|Experimental|Primary PREPL deficiency like Blood|Patients with symptoms overlapping with primary PREPL deficiency (like hypotonia, growth hormone deficiency, obesity), blood draw
3350600|NCT02263781|Experimental|Control muscle|Patients without hypotonia, growth hormone deficiency, obesity, undergoing elective surgery, muscle biopsy from the surgical site and blood draw
3350601|NCT02263781|Experimental|Prader-Willli syndrome muscle|Patients with Prader-Willi syndrome undergoing elective anesthesia or surgery, muscle biopsy (from surgical site if applicable) and blood draw
3350602|NCT02263794|Experimental|Image guided bronchial thermoplasty|At pre-treatment Visit 3, imaging data will be acquired to generate a patient-specific bronchial thermoplasty treatment plan which will include 15-20 target airways, prioritized in order of importance and grouped by lobe, to be targeted during a single session BT treatment procedure. Airways demonstrating dynamic or static bronchoconstriction will be targeted for BT treatment based on their spacial proximity to ventilation defects.
3350603|NCT02263794|Active Comparator|Conventional bronchial thermoplasty|Patients in this group will undergo conventional 3 stage bronchial thermoplasty (during 3 separate bronchoscopies).
3350604|NCT02263807|Experimental|MPFL group|Arthroscopy and MPFL reconstruction
3350605|NCT02263807|Active Comparator|Control|Arhroscopy and rehabilitation
3350606|NCT02263846||Postmenopausal group|Patients at the age ≥ 60 years with more than one year of menopause, or patients having undergone bilateral oophorectomy.
3350607|NCT02263846||Premenopausal group|Patients with regular menses during recent 3 months and having never received luteinizing hormone-releasing hormone analogue therapy.
3350608|NCT02263859|Experimental|Treatment|The Treatment Group will be implanted with the aura6000 System and have therapy turned ON at the Month 1 follow-up visit.
3350609|NCT02263859|Other|Control|The Control Group will be implanted with the aura6000 System and receive treatment as-usual, (i.e. any non-PAP, non-surgical OSA treatment including oral appliances and positional devices being used prior to enrollment in the study) until 14 days (washout period) prior to the Month 4 visit. At the Month 4 + 1 day follow-up visit, subjects in the Control Group will have therapy turned ON for the duration of the study.
3350610|NCT02263872|Experimental|Minocycline|Minocycline 200mg perday
3350611|NCT02263872|Placebo Comparator|comparison group with placebo|Placebo provide
3350612|NCT02263885|Experimental|ExAblate Transcranial System|Transcranial ExAblate MRgFUS
3350613|NCT02263898|Experimental|Treatment (LGX818, MEK162)|Patients receive LGX818 PO QD and MEK162 PO BID continuously for 8 weeks followed by intermittent dosing in subsequent cycles (3 weeks off therapy, 5 weeks on therapy). Cycles repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.
3350614|NCT02263924|Experimental|Experimental: Tocotrienol|Mixed tocotrienol 200mg twice a day for 6 months
3350615|NCT02263924|Placebo Comparator|Placebo (for tocotrienol)|Placebo capsules, 1 capsule twice a day for 6 months
3350616|NCT02263937|Active Comparator|Bilateral Nucleus Basalis Meynert DBS|6 week period of active NBM DBS
3350617|NCT02263937|Sham Comparator|Sham Nucleus Basalis Meynert DBS|6 week period of Sham DBS
3242864|NCT01312584|Placebo Comparator|Non alkalised High Flavanol|Non-alkalised high flavanol cocoa drink containing 1745 mg of total flavanols
3242865|NCT01312584|Active Comparator|Alkalised high Flavanol|Alkalised high flavanol cocoa drink (medium alkalisation) containing 410 mg of total flavanols
3350618|NCT02263950|Experimental|LON002|(Artemether sublingual spray)
3350619|NCT02263963|Experimental|TAP Block Experal|Patient who randomized to this arm, will be blinded, TAP block will be performed under ultrasound guidance, where 20-30 ml of Exparel will be injected in transversus abdominis plane, bilaterally.
3350620|NCT02263963|No Intervention|No TAP Block|
3350621|NCT02263976|Experimental|BEA 2180 BR|single rising doses
3350622|NCT02263976|Placebo Comparator|Placebo|
3350623|NCT02263976|Experimental|Sub-Study|
3350624|NCT02263989|Experimental|Telmisartan film coated tablet|
3350625|NCT02263989|Active Comparator|Telmisartan conventional tablet|
3350626|NCT02264002|Experimental|Cilobradine low dose 1|
3350627|NCT02264002|Experimental|Cilobradine low dose 2|
3350628|NCT02264002|Experimental|Cilobradine medium dose|
3350629|NCT02264002|Experimental|Cilobradine high dose 1|
3350630|NCT02264002|Experimental|Cilobradine high dose 2|
3350631|NCT02264002|Active Comparator|Metoprolol succinate|1 tablet on day 1, day 2 followed by two tablets from day 3 to day 14
3350632|NCT02264002|Placebo Comparator|Placebo|
3350633|NCT02264015|Experimental|Cilobradine low|
3350634|NCT02264015|Placebo Comparator|Placebo|
3350635|NCT02264015|Active Comparator|Moxifloxacin|
3350636|NCT02264015|Experimental|Cilobradine high|
3350637|NCT02264028|Active Comparator|[14C]-DK-AH 269 CL intravenous|
3242866|NCT01312584|Active Comparator|Alkalised Low Flavanol|Alkalised low flavanol cocoa drink (heavily alkalised) containing 1.26 mg of total flavanols
3242867|NCT01312597|Experimental|Fruit beverage|
3350638|NCT02264028|Experimental|[14C]-DK-AH 269 CL oral|
3350639|NCT02264041|Experimental|Cilobradine, low dose plus itraconazole|Pre-study
3350640|NCT02264041|Active Comparator|Cilobradine, low dose|Pre-study
3350641|NCT02264041|Experimental|Cilobradine, high dose plus itraconazole|main study
3350642|NCT02264041|Active Comparator|Cilobradine, high dose|main study
3350643|NCT02264054|Experimental|[14C]talsaclidine, oral|single dose of 20 mg oral solution
3350644|NCT02264054|Active Comparator|[14C]talsaclidine, iv|single dose of 20 mg intravenous (iv) infusion
3242868|NCT01312597|Experimental|Control beverage|
3242869|NCT01312610|Experimental|High flavonone orange juice drink|
3242870|NCT01312610|Placebo Comparator|Control orange juice drink|Juice drink matched for sugar content
3242871|NCT01312623|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
3350645|NCT02264067|Experimental|Talsaclidine|single rising doses
3350646|NCT02264067|Placebo Comparator|Placebo|
3350647|NCT02264080|Experimental|WAL2014|
3350648|NCT02264080|Placebo Comparator|Placebo|
3350649|NCT02264093|Experimental|Talsaclidine with Propranol|
3350650|NCT02264093|Active Comparator|Propranolol|
3350651|NCT02264093|Active Comparator|Talsaclidine|
3350652|NCT02264106|Experimental|Lefradafiban tablet with pantoprazole|
3350653|NCT02264106|Active Comparator|Lefradafiban tablet|
3350654|NCT02264106|Experimental|Lefradafiban double chamber sachet with pantoprazole|
3350655|NCT02264106|Active Comparator|Lefradafiban double chamber sachet|
3350656|NCT02264119|Experimental|Lefradafiban tablet with Pantoprazole|
3350657|NCT02264119|Active Comparator|Lefradafiban tablet without Pantoprazole|
3350658|NCT02264119|Experimental|Lefradafiban double chamber sachet with Pantoprazole|
3350659|NCT02264119|Active Comparator|Lefradafiban double chamber sachet without Pantoprazole|
3350660|NCT02264132|Experimental|Pramipexole ER tablet versus Pramipexole IR tablet|
3350661|NCT02264132|Experimental|Pramipexole IR tablet versus Pramipexole ER tablet|
3350662|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - low|
3350663|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - medium|
3350664|NCT02264145|Experimental|Ethanolic Solution From HFA134a-MDI - high|
3350665|NCT02264145|Experimental|Ethanolic Solution From Respimat®|
3350666|NCT02264158|Experimental|Telmisartan high|
3350667|NCT02264158|Experimental|Telmisartan low|
3350668|NCT02264158|Active Comparator|Lacidipine high|
3350669|NCT02264158|Active Comparator|Lacidipine low|
3350670|NCT02264158|Experimental|Telmisartan+Lacidipine|
3350671|NCT02264158|Placebo Comparator|Placebo|
3350672|NCT02264171|Experimental|Ketoconazole + Tamsulosin HCl|Ketoconazole given once daily in the morning on days -3 to 2 Tamsulosin HCl given at day 1
3350673|NCT02264171|Active Comparator|Tamsulosin HCl|Tamsulosin HCl given at day 1
3350674|NCT02264184|Experimental|Tamsulosin + Paroxetine|"Tamsulosin: q.d on day 1~Paroxetine: higher dose q.d. on days -7 to 2 q.d., lower dose on days -10 to -8 and 3 to 5"
3350675|NCT02264184|Active Comparator|Tamsulosin|Tamsulosin: q.d on day 1
3350676|NCT02264197|Experimental|BIBX 245 CL - fed|after a light breakfast with 40 g fat
3350677|NCT02264197|Active Comparator|BIBX 245 CL - fasted|
3350678|NCT02264210|Experimental|Intervention group|Icotinib 125 mg three times daily (375 mg per day) orally for 12 months.
3350679|NCT02264210|No Intervention|Observation group|Observation.
3350680|NCT02264223|Active Comparator|Capsule (aglycone)|"single bolus 40mg isoflavone formulation of fermented extract in freeze-dried capsule.~Fermented red clover isoflavones in aglycone form"
3350681|NCT02264223|Active Comparator|Tablet (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in freeze-dried tablet.~Fermented red clover isoflavones in aglycone form"
3350682|NCT02264223|Active Comparator|Yoghurt (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract mixed with yoghurt~Fermented red clover isoflavones in aglycone form"
3350683|NCT02264223|Active Comparator|Liquid extract (aglycone)|"single bolus 40mg isoflavone aglycone formulation of fermented extract in liquid~Fermented red clover isoflavones in aglycone form"
3350684|NCT02264223|Active Comparator|Tablet unfermented (glycoside)|"single bolus 40mg isoflavone aglycone equivalent tablet formulation of unfermented red clover isoflavones~Unfermented glycosides (as aglycone equivalents)"
3350685|NCT02264236|Experimental|P10s-PADRE vaccine|Subjects will be immunized by administration of either three or four doses of P10s-PADRE vaccine over a six-week period at a dose level of 500 micrograms (µg) per injection depending on the slandered of care therapy they receive for their lung cancer.
3350686|NCT02264262|Experimental|Sympathetic nerve activity|Healthy volunteers will undergo microneurography, and non invasive sympathetic nerve activity by EKG analysis at baseline and in response to stress.
3350687|NCT02264275|Experimental|Aerobic Exercise Training|An 8-week Nintendo Wii at-home dancing exergame Intervention
3350688|NCT02264288|Experimental|3 x 10^6 cells|Human Placenta Derived cells (PDA-002) administered intramuscularly (IM) on Study Days 1 and 8
3350689|NCT02264288|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3350690|NCT02264288|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3350691|NCT02264288|Placebo Comparator|Placebo|Identically matching placebo administered IM on Study Days 1 and 8
3350692|NCT02264301|Active Comparator|Puerarin injection 400 mg|Patients under the treatment of Puerarin injection 400 mg,daily,for 24 weeks
3350693|NCT02264301|Experimental|Qingkailing injection 40 ml|Patients under the treatment of Qingkailing injection 40 ml,daily,for 24 weeks
3350694|NCT02264314|Experimental|Intervention|This group received an audiological rehabilitation program with a tele-educative intervention boost
3350695|NCT02264314|Placebo Comparator|Control|This group received no intervention
3350696|NCT02264327|Experimental|MI Training + SIM|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive access and a brief introduction to the Motivational Interviewing Simulator (SIM). Sim is designed to help Service Providers practice, learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3350697|NCT02264327|Active Comparator|MI Training + MI eBook|"Service Providers in all group will receive a free two-day Motivational Interviewing training. Service Providers in this group will also receive a Motivational Interviewing eBook designed to help Service Providers learn, maintain, and implement MI skills.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3350698|NCT02264327|Active Comparator|MI Training Only|"Service Providers in this group will only receive a free two-day Motivational Interviewing training.~Clients of Service Providers from this group will receive no study related intervention. All Clients will receive identical surveys to collect client centered observational data of the interventions effect."
3350699|NCT02264340|Active Comparator|Control|Relaxation technique
3350700|NCT02264340|Experimental|Experimental|Combined treatment
3350701|NCT02264366|Experimental|At Risk Group: ACCELERATION program|"This At Risk Group will include ;People at risk of cancer referred from UHN partners and community practices. Also included in this group are; First Nations population of BC, Asians and South Asian populations from Greater Vancouver and the working population of the City of Richmond employees. At the Montreal site users of the YMCA with risk factors for, or family history of, cancer and other chronic diseases will be targeted. And finally, in Nova Scotia the At Risk Group will be identified as being at risk of cancer and other chronic diseases referred from community practices and from the workplace population of the Capital District Health Authority (CDHA).~Intervention: Motivational Communication for Health Behavior management"
3350702|NCT02264366|Experimental|Friends & Family -ACCELERATION Program|This group includes family and friends of cancer survivors and family and friends of cardiac & COPD rehab patients. The intervention includes Motivational Communication for Health Behavior management
3350703|NCT02264379||normal fractionated irradiation|
3350704|NCT02264379||hypo fractionated irradiation|
3350705|NCT02264392|Active Comparator|Ultrasound Guided|Ultrasound Guided Incision and Drainage- Patients will undergo ultrasound guided drainage of the abscess using bedside ultrasound
3350706|NCT02264392|Active Comparator|Blind I&D|Blind Incision and Drainage- Patients will undergo drainage of the abscess using physical exam.
3350707|NCT02264418|Experimental|ODM 203|Oral capsules given once daily dosage 50-800mg
3350708|NCT02264418|Experimental|ODM-203|Oral tablets given once daily 200-1600mg
3350709|NCT02264444|Experimental|Cholecystectomy visualization|All patients will undergo a standard single site cholecystectomy and will have their operation recorded and scored for visualization.
3350710|NCT02264457|Other|First eye closed loop haptic|subjects implanted with the Closed loop haptic during first eye surgery and the plate haptics toric intraocular lens during second eye surgery
3350711|NCT02264457|Other|First eye plate haptic|subjects implanted with the plate haptic toric during first eye surgery and the closed loop haptic toric intraocular lens during second eye surgery
3350712|NCT02264470||Patients with clinical stroke|All patients with stroke, 18 years or older, are asked for participation.
3350713|NCT02264483||COPD exacerbation|"No intervention.~The subjects will be divided in 2 subgroups according to the image study:~COPD exacerbation with pneumonia~COPD exacerbation without pneumonia"
3350714|NCT02264483||COPD stable patients|
3242872|NCT01312623|No Intervention|Control|No ischemic preconditioning
3242873|NCT01312636||A|
3350715|NCT02264496|No Intervention|Control|Standard pre-operative care
3350716|NCT02264496|Experimental|Exercise|A 2-4 week low volume, moderate intensity, supervised, one to one, individualised exercise programme. '
3242874|NCT01312649|Experimental|Arm 1|Healthy volunteers
3242875|NCT01312649|Experimental|Arm 2|Schizophrenia with history of delusions of control
3350717|NCT02264509||Arterial insufficiency and HIV|Of a cohort of 206 HIV patients will be randomly selected 206 for Ankle-brachial index to identify wich suffer symptomatic or asymptomatic arterial insufficiency
3242876|NCT01312649|Experimental|Arm 3|Schizophrenia without history of delusions of control
3242877|NCT01312649|Experimental|Arm 4|Bipolar disorders
3350718|NCT02264522|Experimental|Single Arm|"All patients will be enrolled in the same intervention arm. Interventions are implemented based in 1-4 event levels on the device. Interventions include: Place dialysis chair into position 3, Decrease dialysate temperature, Decrease ultrafiltration rate by 25%, and Decrease ultrafiltration rate by 50%."
3350719|NCT02264535|Experimental|0.1mg/ml Ginkgolides Meglumine Injection|Injection, 0.1mg/ml.
3350720|NCT02264535|Experimental|1mg/ml Ginkgolides Meglumine Injection|Injection, 1mg/ml.
3350721|NCT02264535|Experimental|5mg/ml Ginkgolides Meglumine Injection|Injection, 5mg/ml.
3350722|NCT02264548|Experimental|Arm 1|Radiation: Radio-Ablation
3350723|NCT02264561|Placebo Comparator|Placebo|Mannitol administered at visit 1 and at visit 2
3242878|NCT01312649|Active Comparator|Arm 5|Matched healthy controls
3242879|NCT01312662||normal ophthalmological status|
3350724|NCT02264561|Active Comparator|caffeine|caffeine administered at visit 1 and at visit 2
3350725|NCT02264587|Experimental|mosapride|mosapride 5mg by mouth, 30 minutes before meals, every times one day for 14days
3242880|NCT01312662||opacity of the refractive media|
3242881|NCT01312662||maculopathy|
3242882|NCT01312662||optic neuropathy|
3242883|NCT01312662||chiasmal and postchiasmal visual pathway pathologies|
3350726|NCT02264587|Active Comparator|domperidone|domperidone 10mg by mouth, 30 minutes before meals, every times one day for 14days
3242884|NCT01312662||amblyopia (deprivation)|
3350727|NCT02264613|Experimental|Dose Regimen A (DR-A)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.
3350728|NCT02264613|Experimental|Dose Regimen B (DR-B)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle
3350729|NCT02264613|Experimental|Dose Regimen C (DR-C)|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle
3350730|NCT02264613|Experimental|Combination with palbociclib|Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle
3350731|NCT02264626|Experimental|acutely ill patients|administration of remifentanil at the infusion rate by 0.025 μg kg-1 min-1 to a maximum of 0.10 μg kg-1 min-1.
3350732|NCT02264652|Experimental|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS approximately 2mA will be delivered through High-Definition electrodes that will be arranged on the skull according to a 4x1-ring configuration with the central cathodal electrode placed over the identified target and surrounding return electrodes forming approximately a 5-cm radius ring.
3350733|NCT02264665||Sunitinib|
3242885|NCT01312662||amblyopia (strabism)|
3242886|NCT01312688|Other|Standard hemodynamic therapy|Standard hemodynamic therapy currently accepted in our ICU
3350734|NCT02264665||Afinitor|
3350735|NCT02264665||other treatment (chémotherapy, SSA..)|
3242887|NCT01312688|Experimental|Early Goal Directed Hemodynamic Therapy|Early Goal Directed Hemodynamic Therapy according to the Surviving Sepsis Campaign Guidelines
3242888|NCT01312701||cancer patients|as described patietns with solid cancer about to be treated with anticancer therapies
3242889|NCT01312701||control group|normal populations who domated blood for further use
3242890|NCT01312714|Active Comparator|Cholecalciferol|
3242891|NCT01312714|Placebo Comparator|Placebo|
3242892|NCT01312727|Other|HTIN|HTIN
3242893|NCT01312792|Experimental|Modified IMCI guideline|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
3242894|NCT01312792|Active Comparator|Current IMCI guideline|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
3242895|NCT01312831|Experimental|Oral Eligen® B12|Eligen® B12 1000 μg oral tablet taken in the fasted state as a single tablet with 50 mL water. Each dose self-administered daily, for 90 days, after an overnight fast and 1 hour before the morning meal.
3242896|NCT01312831|Active Comparator|IM B12|Commercially available 1000 μg cyanocobalamin administered IM as 1 mL from a vial containing 1000 μg/mL drug administered by study personnel, in the research clinic, in the morning, in the fasted state and at least 1 hour prior to the morning meal on study Days 1, 3, 7, 10, 14, 21, 30, 60 and 90.
3242897|NCT01312857|Experimental|Randomization to panitumumab|Patients whose liver metastases have been completely resected will be randomized Arm A will receive Panitumumab in addition to HAI FUDR/Dexamethasone plus systemic CPT-11/5FU/LV
3350736|NCT02264691||Normal (healthy volunteers)|No Research Intervention. Clinically indicated interventions only.
3350737|NCT02264691||Mild Asthmatics|No Research Intervention. Clinically indicated interventions only.
3350738|NCT02264691||Mild to Moderate Asthmatics|No Research Intervention. Clinically indicated interventions only.
3350739|NCT02264691||Severe Asthmatics|No Research Intervention. Clinically indicated interventions only.
3375979|NCT03330405|Experimental|Dose Level -1 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
3242898|NCT01312857|Experimental|Randomization to No Panitumumab|Patients whose liver metastases have been completely resected will be randomized and patients randomized to Arm B will receive HAI FUDR/Dex plus systemic CPT-11/5FU/LV alone.
3350740|NCT02264704|Experimental|High intensity exercise|High intensity exercise Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks.
3350741|NCT02264704|Experimental|Moderate intensity exercise|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks.
3350742|NCT02264704|No Intervention|Usual Care|Participants receive usual medical care.
3350743|NCT02264717|Active Comparator|Cardiac MRi|A minimum of 150 patients will be randomized to Cardiac MRI followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA)
3350744|NCT02264717|Active Comparator|SPECT|A minimum 150 patients will be randomized to SPECT followed by conventional angiography CCA-FFR, after detection of obstructive anatomic coronary artery stenoses on coronary Computed Tomography Angiography (cCTA).
3242899|NCT01312870|Experimental|postoperative nutritional supplements|postoperative nutritional supplements in addition to standard hospital diet
3242900|NCT01312870|Placebo Comparator|standard hospital diet|patients receiving standard hospital diet
3242901|NCT01312883|No Intervention|Treatment as usual|Participants will receive standard postpartum education and discharge materials provided by the hospital and a list of community and Internet resources by mail.
3242902|NCT01312883|Experimental|Behavioral education|Participants will receive behavioral education on postpartum depression and a list of community and Internet resources by mail.
3350745|NCT02264730|Experimental|Clot Foam|Application of Clotfoam
3350746|NCT02264743|Experimental|Femoston Conti 0.5mg/2.5mg|"Ultra low dose, film-coated 17β-estradiol (as hemihydrate) 0.5mg & dydrogesterone 2.5 mg~Once a day~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
3242903|NCT01312922|Experimental|PNB01|oral, once daily administration
3242904|NCT01312922|Active Comparator|citalopram|oral, once daily administration
3242905|NCT01312922|Sham Comparator|pipamperone|oral, once daily administration
3242906|NCT01312935|Experimental|Heparin and PMX-60056|
3350747|NCT02264743|Active Comparator|EVOREL® CONTI transdermal patches|"EVOREL CONTI is a transdermal self adhesive patch which is 0.1 mm in thickness and each patch releases 50mcg of oestradiol and 170mcg of norethisterone acetate over 24 hours .~The Evorel Conti patch is cut in half and applied to the lower part of the body for 3.5 days (delivering approx 25mcg of oestradiol over 24 hours ) this is replaced every 3.5 days .~The duration is six months.~Drug intervention: Estradiol&DydrogesteronevsOestradiol&Norethisterone acetate"
3350748|NCT02264756||Ward CAP|Adult immune-competent patients admitted to ward with clinical diagnosis of community-acquired pneumonia will be potentially exposed to ASP review
3350749|NCT02264769|Active Comparator|Carbetocin 20mcg|Patient is given carbetocin 20 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
3350750|NCT02264769|Active Comparator|Carbetocin 100mcg|Patient is given carbetocin 100 mcg intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
3350751|NCT02264782|Experimental|Group I (PreView)|Patients complete PreView, the Video Doctor plus Provider Alert, over 45 minutes on an iPad in the waiting room before a doctor visit.
3350752|NCT02264782|Active Comparator|Group II (educational video)|Patients watch a video about healthy lifestyles including information about exercise and healthy eating over 45 minutes on an iPad in the waiting room before a doctor visit.
3350753|NCT02264795|Placebo Comparator|Placebo|Intraperitoneal instillation of normal saline.
3350754|NCT02264795|Active Comparator|Lidocaine|Intraperitoneal instillation lidocaine 2% (400mg) with epinephrine 5mcg/ml.
3350755|NCT02264808||Developmental outcomes|A developmental assessment (Bayley-III) of children 18-20 months who already enrolled in Florida Neonatal Neurologic Network. As part of this previous study, these children were born with Hypoxic Ischemic Encephalopathy (HIE) and underwent therapeutic cooling after birth.
3350756|NCT02264834|Active Comparator|Control group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.1% + Sufentanil 0.2 µg/mL
3242907|NCT01312987|Experimental|Nutrition intervention|Receives a month's supply of the nutrition supplement, Plumpy'doz®, in addition to food voucher for each month. Participants were also allowed to attend monthly educational sessions.
3242908|NCT01312987|No Intervention|Control|Receives food vouchers each month.
3242909|NCT01313000||Autologous fat transfer|
3242910|NCT01313013|Experimental|intervention|question prompt sheet
3350757|NCT02264834|Experimental|Ambulatory group|Lumbar epidural analgesia during the labour and end up after delivery Levobupivacaine 0.07% + Sufentanil 0.3 µg/mL
3350758|NCT02264847|Active Comparator|Clomiphene citrate plus hCG|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response could be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size . Women will receive 5,000 IU human chorionic gonadotrophin trigger in the morning between 9 and 10 a.m. and the couple will be advised to have intercourse the following night, about 36 hours later.
3350759|NCT02264847|Active Comparator|Clomiphene Citrate alone|Women will receive clomiphene citrate from day 2 to day 6 of the cycle with a starting dose of 100 mg daily. If no response will be observed, the daily dose of clomiphene citrate in subsequent cycles will be increased by 50 mg until a response will be obtained or a maximum daily dose 200 mg of clomiphene citrate will be used. Once a follicle will reach more than 18 mm in size , the women will be advised to have intercourse frequently over the next few days.
3350760|NCT02264860|Other|Nutritional Supplements Zinc and SAMe|All men subjects will be started on 30 mg/day and women will be started on 25mg of elemental zinc plus 1600 mg/day of SAMe.
3350761|NCT02264873|Other|Decitabine|This is a 3+3 design of dose escalation
3375980|NCT03330405|Experimental|Dose Level -2 Phase 1b|"Drug: Avelumab~Drug: Talazoparib"
3242911|NCT01313013|No Intervention|control|no question prompt sheet
3242912|NCT01313026|Active Comparator|PNE first|patients randomised to start with PNE stimulation over 4 weeks. Then the stimulator will be removed and after a wash out period of 4 weeks they will be trained in transanal irrigation
3242913|NCT01313026|Active Comparator|TAI first|Patients randomised to start with transanal irrigation treatment in 8 weeks, thereafter a wash out period of 4 weeks before being implanted with a neuro stimulator
3242914|NCT01313052|Experimental|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
3242915|NCT01313052|Active Comparator|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
3350762|NCT02264886|Experimental|Arm 1: Stereotactic body radiation therapy|"Radiotherapy will consist of stereotactic body therapy, to be given over five fractions, delivered once daily or once every other day for a period of one to two weeks, for a total of five treatments.~All patients will undergo MRI simulation in positioning appropriate for the specific treatment site. When medically feasible and applicable, patients will be simulated with IV and small bowel contrast (for non-thorax cases)."
3350763|NCT02264899|Experimental|Alzheimer's disease and related disorders|
3350764|NCT02264912||stent-PCI patients|Consecutive patients, who underwent intracoronary stent implantation, have been included regardless of whether percutaneous coronary intervention (PCI) was performed on urgent or elective basis.
3350765|NCT02264925|Experimental|Deep Brain Stimulation|All of included patients will receive a standard deep brain stimulation of the thalamus in order to reduce their essential tremor
3350766|NCT02264938|No Intervention|Observation|Patients with AREDS category 2 and 3 AMD are observed during 1 year
3350767|NCT02264938|Active Comparator|Antioxidant|Patients with AREDS category 2 and 3 AMD are enrolled to take daily oral supplementation with lutein (12mg) + zeaxanthin (2mg) + astaxanthin (8mg) + omega-3 fatty acids (docosahexaenoic acid [DHA] 540mg + eicosapentaenoic acid [EPA] 360mg) + vitamin C (40mg) + vitamin E (20mg) + zinc (16mg) + copper (2mg) during 1 year.
3350768|NCT02264951|Active Comparator|A meal containing carrot and tributyrin|A meal containing 200 g grated carrot and 0.0216 mol tributyrin; blood test taken from 0 - 2 hours postprandial
3350769|NCT02264951|Active Comparator|A meal containing carrot and C8-diet oil|A meal containing 200 g grated carrot and 0.0216 mol of C8-diet oil; blood test taken from 0 - 2 hours postprandial
3350770|NCT02264951|Active Comparator|A meal containing carrot and olive oil|A meal containing 200 g grated carrot and 0.0216 mol of olive oil; blood test taken from 0 - 2 hours postprandial
3350771|NCT02264951|Placebo Comparator|A meal containing carrot|A meal containing 200 g grated carrot; blood test taken from 0 - 2 hours postprandial
3350772|NCT02264964|Experimental|internal jugular vein catheterization|900 patients will be received temporary central vena catheterization in right internal jugular vein with non-cuff GamCath® catheter.They will undergo AVF creation.
3350773|NCT02264964|Experimental|femoral vein catheterization|500 patients will be received temporary central vena catheterization in femoral vein with non-cuff GamCath® catheter, which are unsuitable for right internal jugular vein catheterization.They will undergo AVF creation.
3350774|NCT02265003||Healthy young age|Healthy subjects in age of 18-35 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3350775|NCT02265003||Healthy middle age|Healthy subjects in age of 35-45 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3350776|NCT02265003||Healthy old|Healthy subjects in age of >70 years, without cardiac dysrhythmia, hypertension, diabetes mellitus, acute inflammations and terminal kidney disease
3350777|NCT02265003||Patients|Patients with atherosclerosis
3350778|NCT02265016||Patients with CAD|Patients with stable coronary artery disease
3350779|NCT02265016||Patients with ACS|Patients with acute coronar syndrome, instable Angina pectoris and low-risk NSTEMI
3350780|NCT02265016||healthy control group|healthy control group without clinical apparent arteriosclerosis
3350781|NCT02265029|Active Comparator|Immediate spa treatment|Spa treatment during 18 days soon after randomization : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
3242916|NCT01313065|Experimental|VX15/2503|VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle.
3242917|NCT01313104|Experimental|Screening|See Detailed Description
3350782|NCT02265029|Sham Comparator|Late SPA treatment|Spa treatment during 18 days soon after 6 months visit : the most adapted to the concerned pathology and common to all of spa resorts (whirpool bath with automatic air and water massage cycles, massaging shower,...)
3350783|NCT02265042|Experimental|electrical stimulation|electrical Stimulation using the Stimulette device
3350784|NCT02265055|Active Comparator|transfer early cleavage embryos (EC)|transfer early cleavage embryos
3350785|NCT02265055|Active Comparator|transfer non early cleavage embryo (NEC)|transfer non early cleavage embryos
3242918|NCT01313130||blast-related TBI|100 active duty US military personnel identified clinically as having suffered blast-related TBI
3242919|NCT01313130||non-blast-related TBI|100 active duty US military personnel identified clinically as having suffered non-blast-related TBI. TBI caused by other mechanisms such as motor vehicle crashes, falls, struck by blunt objects etc.
3242920|NCT01313130||other blast-related injuries|100 active duty US military personnel with blast-exposure and other blast-related injuries but no clinical evidence of TBI
3242921|NCT01313130||other non-blast injuries|100 active duty US military personnel with other non-blast injuries and no clinical evidence of TBI
3242922|NCT01313143|Experimental|AOP200704, infusion|
3242923|NCT01313143|Active Comparator|Esmolol, infusion|
3242924|NCT01313169|Experimental|EMR reminder|EMR reminder
3242925|NCT01313169|Experimental|EMR reminder + Panel management|EMR reminder + Panel manager
3242926|NCT01313169|No Intervention|Control|Control
3242927|NCT01313234|Experimental|Education|Educational theory based intervention and systematic daily pain assessment
3242928|NCT01313234|No Intervention|Control|Control group with care as usual
3350786|NCT02265081|Active Comparator|nulliparous women|internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3350787|NCT02265081|Experimental|parous women|those who had vaginal delivery in the past; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3350788|NCT02265081|Experimental|parous women - VBAC|those with previous LSCS and no vaginal births; internal ultrasound in the 3rd trimester uroflow meter in 3rd trimester
3350789|NCT02265094|Experimental|Patients|Electroencephalography and neuropsychological tests in children with autism
3242929|NCT01313247|Placebo Comparator|Placebo pills|Placebo tablets resembling paracetamol 500 mg are given as alternative 2 tablets 4 times daily
3242930|NCT01313247|Active Comparator|oral paracetamol 4 g daily|Patients are given 2 tablets of 500 mg paracetamol on a regular basis 4 times daily
3242931|NCT01313260||Epilepsy patients|Epilepsy patients selected before undergoing intracranial EEG recordings
3242932|NCT01313260||control group|Healthy volunteers
3242933|NCT01313325|Experimental|Treatment group|Children between 5-17 years who have balance deficits related to any movement disorder (preferably neuromuscular)
3350790|NCT02265094|Experimental|Control|Electroencephalography and neuropsychological tests in children without autism
3350791|NCT02265107|Experimental|cardiac rehabilitation|We invited all consecutive patients submitted to CABG alone at Cardiologic Hospital Doctor Pedro Bertoni of the Associação de Caridade Santa Casa do Rio Grande in the period of October, 2011 until October, 2012, who resided in the city of the Rio Grande (RS/Brazil), to participate of the exercise training (ET). All patients were evaluated by cardiologist, and were ranked in Functional Classification of New York Heart Association (NYHA) such class I and II. Initially, twenty-four patients accepted and start to participate of ET, but only nine patients completed the program until the end.
3350792|NCT02265120|Experimental|primary care providers by region|A questionnaire will be given to a randomized sample of primary care providers who care for patients in the 194 federally designated regions of Primary Care provider shortage within California will be studied.
3350793|NCT02265159|Other|Focal Therapy Using High Intensity Focused Ultrasound|
3350794|NCT02265172|Experimental|Physiotherapy screening|"Screening consisted of a 60-min appointment including assessment, diagnosis and management. The patients received advice regarding ergonomics, exercises and/or treatment when needed. Management options were;~Referral for orthopaedic surgeon consultation.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
3350795|NCT02265172|Active Comparator|Standard practice (orthopaedic surgeon)|"Appointment was 15 min, including assessment, diagnosis and management. The patients received advice, prescriptions or injections when needed. Management options were;~Referral for orthopaedic intervention.~Referral back to the patient's General Practitioner.~Referral for further investigation.~Referral to the physiotherapy or the occupational therapy clinic."
3350796|NCT02265185||ED Patients|Children aged 2-10 visiting the Emergency Department.
3350797|NCT02265198||PC Group|patients with Pulmonary Contusion on chest computed tomography (CT)
3350798|NCT02265198||Control Group 1|Uninjured patients undergoing elective surgical procedures that will require intubation and mechanical ventilation
3350799|NCT02265198||Control Group 2|Trauma patients without chest injury who are mechanically ventilated
3350800|NCT02265198||MICU group|Patients in the Medical ICU who are mechanically ventilated with acute respiratory failure
3350801|NCT02265211|Experimental|Self-Help App|Smartphone app designed to teach cognitive defusion.
3350802|NCT02265250||Asymptomatic, CACS <300|"5 asymptomatic subjects with low CVD risk, defined as recent coronary artery calcium score (CACS) <300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers)"
3350803|NCT02265250||Asymptomatic, CACS ≥300|"5 asymptomatic subjects with increased CVD risk, defined as a recent coronary artery calcium score (CACS) ≥300~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3350804|NCT02265250||Stable angina|"5 subjects with stable angina and evidence of coronary atherosclerosis based on a recent invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3350805|NCT02265250||Recent acute MI|"5 subjects with a recent acute myocardial infarction (within 1 month) and evidence of coronary atherosclerosis based on invasive or CT coronary angiogram~Noncontrast MRI of the bilateral carotid, coronary, and superficial femoral arteries; Laboratory blood test (cardiovascular biomarkers); Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries"
3350806|NCT02265263||Surgical patients - 3 Tesla MRI|"A study group of at maximum n= 1200 is collected for measuring 3 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin/Utrecht. They include surgical procedures within body cavity e.g. abdomen or thorax from departments of general surgery, urology, gynecology or thoracic surgery; orthopaedic operations (hip-, knee-, endoprosthesis or spine (including neurosurgical spine operations)); cardiac surgery and operation of extracranial/intracranial head and neck~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within two years after initial hospital stay."
3375981|NCT03330405|Experimental|A1. NSCLC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3242934|NCT01313338||Acute coronary syndrome|
3375982|NCT03330405|Experimental|A2. NSCLC PD-L1 Resistant DDR+ Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3375983|NCT03330405|Experimental|B1. TNBC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3242935|NCT01313364|Experimental|All subjects to self-administer 4 IM injections|Subjects will be recruited and stratified into BMI groups: <18.5 kg/m2, 18.5 to 24.9 kg/m2, 25 to 29.99 kg/m2, and >30 kg/m2 all with 20 subjects. To maintain a balance between sexes that is representative of the MS population, approximately 50 to 70% of subjects within each BMI group should be female.
3242936|NCT01313377|Experimental|ARM A: Gemox 85|Adjuvant chemotherapy for six months with gemcitabine - oxaliplatin 85mg / m² ( GEMOX 85)
3242937|NCT01313377|Other|ARM B:|Observation until progression or death
3242938|NCT01313429|Experimental|1|tumor cell vaccine administered with chemotherapy
3242940|NCT01313468|Experimental|4 x 4 Interval|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
3242941|NCT01313468|Experimental|1 4 minutes interval|1 x 4 minutes intervals at 90-95% of HR max
3242942|NCT01313468|Experimental|Moderate continuous Training|47 minutes of Moderate continuous Training
3350807|NCT02265263||Patients ASA II/III - 3 Tesla MRI|"A control group of at maximum n= 300 ASA II/III- patients is collected for measuring the learning experience during the cognitive testings. They are matched on age, education, and gender to the study patients. The 104 ASA II/III- patients should receive additionally MRI-scan (3 Tesla) at baseline, after 3 months and after 1 year in Utrecht, after 3 months, after 1, 2 years in Berlin.~Data collection from study center Utrecht ist within one year after initial hospital stay. Data collection from study center Berlin is within five years after initial hospital stay."
3350808|NCT02265263||Volunteers ASA I/II - 3 Tesla MRI|To analyze scanner variability we additionally measure at maximum 20 subjects (Age ≥ 65 years) from Utrecht in the MRI scanner (3-Tesla) in Berlin and vice versa.
3350809|NCT02265263||Surgical patients - 7 Tesla MRI|A study Group of at maximum n= 80 should be collected for measuring 7 Tesla MRI at two timepoints (Baseline and 90 days) in Berlin.
3350810|NCT02265276|Active Comparator|Saroglitazar Group|Tab Saroglitazar 4 mg oral daily fixed dose for 24 weeks
3350811|NCT02265276|Placebo Comparator|Pioglitazone Group|Tab Pioglitazone 30 mg daily fixed dose for 24 weeks
3350812|NCT02265289|Experimental|Lefradafiban with clopidogrel|"All patients received the same treatment:~Lefradafiban only (day 1-4)~Lefradafiban in combination with Clopidogrel (day 5-8)~Clopidogrel only (day 9-12)"
3350813|NCT02265302|Experimental|BIIL 284 BS oral solution|
3350814|NCT02265302|Experimental|BIIL 284 BS WIF tablets|
3350815|NCT02265302|Placebo Comparator|Placebo|
3242943|NCT01313481|Experimental|Group exercise|Otago exercise performed in groups
3242944|NCT01313481|Active Comparator|Home exercise|Otago exercise performed as home exercise
3350816|NCT02265315|Sham Comparator|LSVT +sham TMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS)
3350817|NCT02265315|Active Comparator|LSVT +left rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to left side of head
3350818|NCT02265315|Active Comparator|LSVT + right rTMS|Lee Silverman Voice Treatment (LSVT) and Transcranial Magnetic Stimulation (TMS) applied to right side of brain
3350819|NCT02265328|Experimental|Bovine colostrum + prednisolone|"Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.~Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. If Lilli score > 0.45 after 7 days, then GC would be stopped and patients will be counselled for liver transplantation.~Oral Bovine colostrum (200 ml (20 gram) TDS × 2 months."
3350820|NCT02265354|Experimental|Collective-Intelligence computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a collective intelligence recommender systems algorithm for up to 6 months
3350821|NCT02265354|Active Comparator|Rule-based computer tailored health communication|Smokers will have access to all Decide2quit.org website functions and will receive 4 tailored emails per week based on a rule-based algorithm for up to 6 months
3350822|NCT02265367|Experimental|Levomilnacipran|In this three week period, baseline measures are obtained during the first week, levomilnacipran will be started during the second week and effects on smoking behavior will be assessed during the third week
3350823|NCT02265367|Placebo Comparator|Placebo|In this three week period, baseline measures are obtained during the first week, placebo will be started during the second week and effects on smoking behavior will be assessed during the third week
3350824|NCT02265380|Experimental|Treatment with OptiVein|The patient will have an IV catheter placed with the use of OptiVein device.
3350825|NCT02265380|Active Comparator|Treatment with Vasofix Certo|The patient will have an IV catheter placed with the use of Vasofix Certo device.
3350826|NCT02265393|Active Comparator|OTO-104|12 mg OTO-104 (dexamethasone)
3242945|NCT01313533|Active Comparator|Lactated Ringers Solution with Arginine|100 ml of LRS with arginine
3242946|NCT01313533|Placebo Comparator|Lactated Ringers Solution|Lactated ringers solution
3242947|NCT01313546|Active Comparator|quadriceps|quadriceps muscular contraction
3242948|NCT01313546|Active Comparator|sartorius|stimulation of sartorius muscle through femoral nerve
3242949|NCT01313572|Experimental|Apadenoson|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with apadenoson
3242950|NCT01313572|Active Comparator|Adenosine|In period 1, subjects will receive a clinically-indicated rest/stress gated SPECT-MPI with adenosine. In period 2, subjects will receive a rest/stress gated SPECT-MPI with the active comparator: adenosine.
3350827|NCT02265393|Placebo Comparator|Placebo|OTO-104 vehicle
3350828|NCT02265406|Experimental|Ceftriaxone|
3350829|NCT02265406|Placebo Comparator|Sodium Chloride|
3350830|NCT02265419|Experimental|Cytosorb group|Extracorporeal treatment with the Cytosorb adsorber for 24 hours after heart surgical operation.
3375984|NCT03330405|Experimental|B2. HR+BC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3375985|NCT03330405|Experimental|C1. Ovarian CA Recurrent Plat-Sensitive Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3375986|NCT03330405|Experimental|C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3242951|NCT01313585||IPDA salbutamol MDI|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
3242952|NCT01313585||IPDA salbutamol EB|receive a recorded increase in ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
3242953|NCT01313585||IPDI salbutamol EB|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol Easibreathe
3242954|NCT01313585||IPDI salbutamol MDI|initiate ICS therapy as BDP Easibreathe at the index date and also receive salbutamol MDI
3242955|NCT01313598|Experimental|GLPG0187|GLPG0187 for infusion
3242956|NCT01313611|Experimental|Rituximab + bendamustine|
3242957|NCT01313689|Experimental|Ofatumumab|Biological
3242958|NCT01313689|Active Comparator|Physicians' Choice|Physicians' choice of treatment
3242959|NCT01313702|Experimental|polipillV1|poli pill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
3350831|NCT02265432|Experimental|Mobile technology intervention|"General physical activity educational materials~Wearable activity tracking devices to enable the intervention participants to self-monitor their physical activity behavior and receive real-time feedback~Access to an online map of Singapore providing location based information about leisure time physical activity opportunities~Personalized text messages which include, educational information, tailored theory-based motivational messages, as well as compliance enhancing reminders"
3242960|NCT01313702|Experimental|polipillV2|Polipill versão2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
3242961|NCT01313702|Active Comparator|usual care|
3242962|NCT01313715|Experimental|160U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 children aged 13-60 months old on day0,28
3242963|NCT01313715|Experimental|320U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 children aged 13-60 months old on day0,28
3242964|NCT01313715|Experimental|640U /0.5ml in children|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 children aged 13-60 months old on day0,28
3350832|NCT02265432|Other|Control|1.General physical activity educational materials
3242965|NCT01313715|Experimental|160U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 45 infants aged 6-12 months old on day0,28
3242966|NCT01313715|Experimental|320U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 45 infants aged 6-12 months old on day0,28
3350833|NCT02265445|Active Comparator|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
3350834|NCT02265445|Active Comparator|Deescalation therapy|Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE. Deescalation therapy
3350835|NCT02265458|Experimental|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
3350836|NCT02265458|Active Comparator|Sensory isolation|Sensory isolation
3350837|NCT02265458|No Intervention|Standard of care|Standard of care
3350838|NCT02265471||university hospital|university hospital
3350839|NCT02265471||large or small public hospitals|large or small public hospitals
3350840|NCT02265471||private HCFs|private HCFs
3350841|NCT02265471||referral centers for cancer|referral centers for cancer
3350842|NCT02265471||chirurgical facilities, clinic|chirurgical facilities, clinic
3350843|NCT02265471||mixed group|local hospitals, long term care and post-op and rehabilitation facilities, and nursing homes
3350844|NCT02265484|Experimental|Lactulose + Rifaximin + Bromocriptine|
3350845|NCT02265484|Active Comparator|Lactulose+Rifaximin+Placebo|
3350846|NCT02265497||Hodgkin's or non-Hodgkin lymphoma|All patients with diagnoses of Hodgkin's or non-Hodgkin lymphoma with available with available clinical, histopathology and treatment data.
3350847|NCT02265523|No Intervention|Standard Post-op Exercise Group|The standard post-operative exercises are already currently recommended to patients. Briefly, they include deep breathing and coughing, ankle pumping, buttock contractions, and static quadriceps strengthening. These are performed on a daily basis , 2-3 times per day, 30 repetitions.
3242967|NCT01313715|Experimental|640U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 45 infants aged 6-12 months old on day0,28
3242968|NCT01313715|Placebo Comparator|0/0.5ml placebo in children|0/0.5ml placebo in 45 children aged 13-60 months old on day0,28
3242969|NCT01313715|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 45 infants aged 6-12 months old on day0,28
3242970|NCT01313741|Experimental|Single arm shoulder arthroplasty|
3242971|NCT01313754|Other|Vicryl|These patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive the vicryl material on the left.
3242972|NCT01313754|Experimental|Dermabond|The patients will receive the standard monocryl suture on their right sided inguinal incision and then will receive dermabond skin glue on the left
3350848|NCT02265523|Experimental|Viscus Group|The Viscus (intervention) group will complete the standard post-operative exercises and will also have access to a Viscus V1.5 cycle ergometer 24 hours per day in their recovery room to use at their leisure.
3350849|NCT02265536|Experimental|LY3022855 - 1.25 mg/kg Dose A|1.25 milligram per kilogram (mg/kg) LY3022855 administered intravenously (IV), once every two weeks. Treatment is 6 week cycle. Participants may receive multiple cycles if they are deriving clinical benefit.
3350850|NCT02265536|Experimental|LY3022855 - Dose B|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3350851|NCT02265536|Experimental|LY3022855 - Dose C|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3242973|NCT01313793|Experimental|Sequence 1|Subjects will receive clinical formulation (treatment A) followed by commercializable formulation (treatment B).
3242974|NCT01313793|Experimental|Sequence 2|Subjects will receive commercializable formulation (treatment B) followed by clinical formulation (treatment A).
3242975|NCT01313806|Active Comparator|Resonator|Treatment with active Resonator device using low level magnetic fields
3242976|NCT01313806|Placebo Comparator|Placebo|
3242977|NCT01313819|Active Comparator|Group 1|Give IV amantadine first then IV placebo(normal saline) drug
3242978|NCT01313819|Active Comparator|Group 2|Give IV placebo drug first then IV amantadine
3242979|NCT01313832|Experimental|remote ischemic preconditioning|
3242980|NCT01313845|Active Comparator|amantadine|administration of intravenous amantadine sulfate 200mg/500ml/bottle 1 bottle infusion over 3 hours, twice a day for consecutive 5 days
3242981|NCT01313845|Placebo Comparator|placebo|administration of 0.9% sodium chloride 500ml/bottle 1 bottle infusion over 3 hours twice a day for consecutive 5 days
3242982|NCT01313871||All Participants|Adults with a confirmed diagnosis of rheumatoid arthritis
3242983|NCT01313949|No Intervention|Usual Care|A total of 90 patients with diabetes will be recruited. Thirty will be selected for the training course and the other 60 will be compared as controls. These controls will receive their usual diabetes care.
3350852|NCT02265536|Experimental|LY3022855 - Dose D|LY3022855 administered IV. Participants may receive multiple cycles if they are deriving clinical benefit.
3350853|NCT02265562|Experimental|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
3350854|NCT02265562|Placebo Comparator|Placebo|60 minutes before the surgery 2 tablets of placebo tablets inserted rectally
3350855|NCT02265575|Experimental|hyaluronic acid|Rehydration using hyaluronidase-assisted subcutaneous infusion
3350856|NCT02265588|No Intervention|Care as usual|Care as usual means receiving their regular medical care. This consists of the regular follow up visits at the gastroenterologist every 3 months.
3242984|NCT01313949|Experimental|Peer leader training|"Peer leaders are people with diabetes who had volunteered to undertake an extensive program of training. The purpose of this training is to make them effective in the provision of support and advice to their peers on a one-to-one basis via telecommunication.~These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors."
3242985|NCT01313962|Experimental|Flufirvitide-3|
3242986|NCT01313962|Placebo Comparator|Placebo|
3350857|NCT02265588|Experimental|Cognitive Behavioral Therapy|The intervention group receives regular medical care (care as usual) AND a cognitive behavioral therapy program called PASCET-PI. The therapy sessions will be performed by trained psychologist.
3350858|NCT02265601|Experimental|computer-based decision aid|"Making Your Wishes Known: Planning Your Medical Future- Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team."
3242987|NCT01313975||1|Patients with non-traumatic subarachnoid hemorrhage
3242988|NCT01313975||2|Patients with severe traumatic brain injury
3242989|NCT01313988|Active Comparator|Dose 1|Spread that contains plant sterols and fish oil
3350859|NCT02265601|Active Comparator|standard care|paper/pencil living will form
3350860|NCT02265614|Experimental|PGS|blastocyst biopsy and chromosomal analysis
3242990|NCT01313988|Active Comparator|Dose 2|Spread that contains plant sterols and fish oil
3242991|NCT01313988|Active Comparator|Dose 3|Spread that contains plant sterols and fish oil
3242992|NCT01313988|Placebo Comparator|Placebo|Placebo spread
3242993|NCT01313988|Active Comparator|Control|Spread that contains plant sterols
3242994|NCT01314027|Experimental|neoadjuvant + adjuvant chemotherapy|neoadjuvant chemotherapy is based on gemcitabine/oxaliplatin adjuvant therapy is based on gemcitabine
3350861|NCT02265614|No Intervention|control|regular IVF
3350862|NCT02265627|Experimental|BIIL 284 BS, normal hepatic function|
3350863|NCT02265627|Experimental|BIIL 284 BS, mild hepatic impairment|
3350864|NCT02265627|Experimental|BIIL 284 BS, moderate hepatic impairment|
3350865|NCT02265640|Experimental|BIIL 284 BS boli - fasted|
3350866|NCT02265640|Experimental|BIIL 284 BS boli - fed|
3350867|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fasted|
3350868|NCT02265640|Active Comparator|BIIL 284 BS tablet C - fed|
3350869|NCT02265653|Experimental|BIIL 284 BS tablet C|
3242995|NCT01314027|Active Comparator|adjuvant chemotherapy|adjuvant therapy is based on gemcitabine
3242996|NCT01314040|Other|Run in|
3242997|NCT01314040|Experimental|High meat protein diet|
3242998|NCT01314040|Experimental|High dairy protein diet|
3242999|NCT01314040|Experimental|High grain protein diet|
3243000|NCT01314066|Experimental|Bevacizumab 5 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
3243001|NCT01314066|Experimental|Bevacizumab at 10 mg/kg|Receive drug solution as a single dose. Treatment will be given as 90 minute IV infusion.
3243002|NCT01314066|Placebo Comparator|Placebo|In addition to receiving the best standard supportive care for both diagnosis and treatment for individuals diagnosed with severe sepsis, they will receive an IV saline solution.
3243003|NCT01314092|Experimental|Group 1|Low dose group
3243004|NCT01314092|Experimental|Group 2|high dose group
3243005|NCT01314131|Experimental|Intervention group|
3350870|NCT02265653|Experimental|BIIL 284 BS tablet D|
3350871|NCT02265653|Active Comparator|BIIL 284 BS WIF tablet|
3350872|NCT02265666|Experimental|BIIL 284 BS Tablet FF|
3350873|NCT02265666|Active Comparator|BIIL 284 BS tablet C|
3350874|NCT02265679|Experimental|BIIL 284 BS, low dose in pediatric patients|
3350875|NCT02265679|Experimental|BIIL 284 BS, medium dose in pediatric patients|
3350876|NCT02265679|Experimental|BIIL 284 BS, high dose in pediatric patients|
3350877|NCT02265679|Experimental|BIIL 284 BS, low dose in adult patients|
3350878|NCT02265679|Experimental|BIIL 284 BS, medium dose in adult patients|
3350879|NCT02265679|Experimental|BIIL 284 BS, high dose in adult patients|
3350880|NCT02265679|Placebo Comparator|Placebo|
3350881|NCT02265718||(Amyloid Negative)|
3350882|NCT02265718||Amyloid Positive|
3350883|NCT02265731|Experimental|Arm A (Phase 1)|Step-up doses of venetoclax to the designated cohort dose administered in participants with relapsed or refractory (R/R) Non-Hodgkin lymphoma (NHL) or multiple myeloma (MM)
3350884|NCT02265731|Experimental|Arm B (Phase 1)|Step-up doses of venetoclax to the designated dose administered in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
3350885|NCT02265731|Experimental|Arm C (Phase 1)|Step-up doses of venetoclax to the designated dose with the addition of azacitidine administered in participants with acute myeloid leukemia (AML)
3350886|NCT02265731|Experimental|Arm D (Phase 2)|Step-up doses of venetoclax to the designated dose with the addition of rituximab in participants with R/R CLL
3350887|NCT02265757|Experimental|No Cognitive Rehabilitation|Will receive a 10 day intervention program (over 2 weeks) consisting of Computer Brain Fitness Training, Support Group, Wellness Education and Physical Exercise.
3375987|NCT03330405|Experimental|D.Urothelial CA Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3375988|NCT03330405|Experimental|E1. CRPC Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3243006|NCT01314144|Experimental|Bupivacaine|Patients will receive intraoperative wound soakage with 20ml of 0.5% bupivacaine with adrenaline by the surgeon before closure and receive a continuous infusion of 4ml/hr of 0.2% bupivacaine delivered by an elastomeric pump the catheter of which will be placed by the surgeon in the wound before closure. Postoperative anlagesia will be provided with oxycodone, paracetamol and diclofenac.
3243007|NCT01314144|No Intervention|Control|Patients will receive morphine up to 0.1mg/kg intraoperatively. Postoperative analgesia will be provided with oxycodone, paracetamol and diclofenac.
3350888|NCT02265757|Experimental|No Computer Brain Fitness Training|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Support Group, Wellness Education and Physical Exercise
3350889|NCT02265757|Experimental|No Support Group|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Wellness Education and Physical Exercise
3350890|NCT02265757|Experimental|No Wellness Education|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Physical Exercise
3350891|NCT02265757|Experimental|No Physical Exercise|Will receive a 10 day intervention program (over 2 weeks) consisting of Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group, and Wellness Education
3350892|NCT02265770|Experimental|Stratum 1 arm A|Conformal radiotherapy followed by 16 weeks of VEC + CDDP.
3350893|NCT02265770|Active Comparator|Stratum 1 arm B|Conformal radiotherapy.
3350894|NCT02265770|Experimental|Stratum 2 arm A|VEC + HD-MTX followed by conformal radiotherapy +/- boost
3243008|NCT01314157|Experimental|Physiotherapy treatment technique|"Randomized clinical trial controlling and using at the time of allocation, toss with sealed envelopes, sealed and opaque. The study group will be dealt with technical isostretching and the other group is control group."
3243009|NCT01314170|No Intervention|Susanna Implant|Patients with refractory glaucoma neovascular type or that failed in trabeculectomy will undergo surgery to place implants Susana.
3350895|NCT02265770|Active Comparator|Stratum 2 arm B|VEC followed by conformal radiotherapy +/- boost
3243010|NCT01314183|Active Comparator|exercise|Subjects in this arm receive 12 exercise sessions in 9 weeks.
3350896|NCT02265770|Experimental|Stratum 3 arm A|Chemotherapy + Valproate.
3243011|NCT01314183|Active Comparator|exercise + manual therapy|Subjects in this group receive exercise combined with manual therapy techniques for 12 sessions in 9 weeks.
3243012|NCT01314183|Experimental|exercise + booster|subjects in this arm will receive exercise sessions delivered with booster sessions (8 sessions in the first 9 weeks, 2 sessions at 5 months, 1 session at 8 months, and 1 session at 11 months).
3350897|NCT02265770|Active Comparator|Stratum 3 arm B|Chemotherapy
3350898|NCT02265809|Experimental|Aldesleukin|Aldesleukin will be administered subcutaneously at varying doses and frequencies for a period of up to 98 days from first administration depending on the treatment assignment. The maximum dose allowed is 0.6 X 10^6 IU/m2.
3243013|NCT01314183|Experimental|exercise + manual therapy + booster|Subjects in this arm will receive exercise combined with manual therapy techniques and booster sessions.
3243014|NCT01314196|Active Comparator|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers
3350899|NCT02265822|Experimental|melatonin|0.5 mg/kg (max 20 mg) oral melatonin premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding water in a syringe without needle.
3350900|NCT02265822|Active Comparator|midazolam|0.5 mg/kg (max 20 mg) oral midazolam premedication will be administered approximately 40 min before the induction of general anaesthesia with propofol. The melatonin will be prepared in a fixed volume of 5 ml adding 5% dextrose in a syringe without needle.
3350901|NCT02265835||Cases of anastomotic airway complication|Cases of anastomotic airway complication
3350902|NCT02265835||Patients with normal anastomotic healing|Patients with normal anastomotic healing
3350903|NCT02265861|Experimental|Group 1|typical PCOS
3350904|NCT02265861|Experimental|Group 2|PCOS without PCO
3350905|NCT02265861|Experimental|Group 3|PCOS without HA
3350906|NCT02265861|Experimental|Group 4|Control
3350907|NCT02265874|Active Comparator|Treatment|Habitrol Nicotine patch - 7,14,21 mg patches Qd
3243015|NCT01314196|Experimental|progressive resistance training biceps|therapeutic exercises for the shoulder and scapula stabilizers and biceps resistance training.
3243016|NCT01314209|Experimental|dexmedetomidine|
3243017|NCT01314222|Other|Arm 1: BMS-954561 40mg or 80mg|"BMS-954561 40mg or 80mg TID to Placebo OR Placebo to 40mg or 80mg TID~Active to Placebo or Placebo to Active (cross-over)"
3243018|NCT01314222|Other|Arm 2: BMS-954561 150mg or 300mg|"BMS-954561 150mg or 300mg TID to Placebo OR Placebo to 150mg or 300mg TID~Active to Placebo or Placebo to Active (cross-over)"
3350908|NCT02265874|Placebo Comparator|Control|Placebo patch
3350909|NCT02265900|Active Comparator|Exercise 1|One type of exercise
3350910|NCT02265900|Placebo Comparator|Exercise 2|A different type of exercise
3350911|NCT02265926|Experimental|N95|Intervention: N95 mask material
3350912|NCT02265978|Experimental|CopeSmart|
3350913|NCT02265978|No Intervention|Control|
3243019|NCT01314222|Other|Arm 3: Pregabalin 100mg|"Pregabalin 100mg TID to Placebo OR Placebo to 100mg TID~Active to Placebo or Placebo to Active (cross-over)"
3243020|NCT01314248||children weighing 10 to 15 kg|
3243021|NCT01314274|Experimental|bevacizumab|submucosal intranasal bevacizumab on day 0
3350914|NCT02266017|Experimental|Mobile Pain Coping Skills Training|Coping Skills Training for pain will be delivered to participants using video-conferencing via a tablet computer.
3350915|NCT02266017|Active Comparator|In person Pain Coping Skills Training|Participants will be provided with an in-person pain coping skills training intervention
3350916|NCT02266030|Experimental|Cilostazol|Cilostazol 100-200 mg qd
3350917|NCT02266030|Active Comparator|Aspirin|Asprin 100mg qd for active comparator
3350918|NCT02266056|Experimental|Deep neuromuscular relaxation|
3243022|NCT01314274|Placebo Comparator|placebo|0.9% NaCl intranasal submucosal on day 0
3243023|NCT01314300|Experimental|Efficacy of Lidocaine 5% plaster|Treatment of pain by Lidocaine 5% plaster
3350919|NCT02266056|Active Comparator|Moderate neuromuscular relaxation|
3350920|NCT02266069|Other|Research cluster 1: Antwerp|The first Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2014.
3350921|NCT02266069|Other|Research cluster 2: Mons|The first French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from November 2014.
3350922|NCT02266069|Other|Research cluster 3: Brussels|The only bilingual Dutch/French-speaking research cluster in a stepped wedge cluster design. Family doctors are implementing the Care Pathway for Primary Palliative Care and will recruit eligible patients from December 2014.
3350923|NCT02266069|Other|Research cluster 4: Limburg|The second Dutch-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from April 2015.
3350924|NCT02266069|Other|Research cluster 5: ?|A second French-speaking research cluster in a stepped wedge cluster design. Family doctors will implement the Care Pathway for Primary Palliative Care and will recruit eligible patients from October 2015.
3243024|NCT01314326||Perimetric Glaucoma (PG)|Patients with clinically confirmed abnormal VF and glaucomatous ONH or NFL defect
3243025|NCT01314326||Glaucoma Suspects and Pre-Perimetric Glaucoma (GSPPG) Group|Patients who are at high risk to develop perimetric glaucoma
3243026|NCT01314326||Normal Group|Volunteers with healthy eyes
3243027|NCT01314339|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
3350925|NCT02266095|Active Comparator|Oval-8 Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee). Oval-8 splints are not commonly used for treatment of thumb CMC arthritis.~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3350926|NCT02266095|Active Comparator|Tee Pee Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3350927|NCT02266095|Active Comparator|Forearm Based Splint|"Patients will be asked to wear their assigned splint 24 hours per day with removal for hygiene care. Follow-up appointments will occur at week 4 and 12. Each visit will include a clinical examination, splint assessment for continued appropriate fit and evaluation of skin for irritation or breakdown.~Standard non-operative therapy includes activity modification, therapy, NSAIDS, splinting (thumb spica or Tee-Pee).~Procedures will be undertaken to minimize patient discomfort. Participants will be instructed to continue with range of motion exercises to 2-5th digits and elbow to try to avoid stiffness."
3350928|NCT02266121|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the rain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform attentional, working memory and executive tasks"
3350929|NCT02266121|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3350930|NCT02266134|Experimental|Standardized Implementation|Sites randomized to the standardized condition will be expected to use the Patient Health Questionnaire prior to each session with a depressed client and they will work as a team to maximize fidelity. Sites in this arm will receive the standard implementation of measurement based care intervention.
3350931|NCT02266134|Experimental|Tailored Implementation|Sites randomized to the tailored condition will develop a site-specific protocol for use of the Patient Health Questionnaire and they will work as a team to maximize the fit of measurement based care to this clinic. Sites in this arm will receive the tailored implementation of measurement based care intervention.
3350932|NCT02266160|Experimental|1|"71 tinnitus patients treated with 2 gram EMLA 5% cream a day for 4 days, 4 hours a day.~we will compare the questionnaires results before and after 4 days of treatment to see whether EMLA cream changes the degree of suffer from tinnitus"
3350933|NCT02266160|Sham Comparator|2|71 tinnitus patients using cetomacrogol cream (lotion cream, does not contain any drug) for 4 days. these patients will fulfill the questionnaires as the investigational group.
3350934|NCT02266173||Pertuzumab|Participants for whom the treating physician has decided to administer pertuzumab according to standard of care and in line with the current summary of product characteristics (SmPC)/local labeling, will be observed.
3350935|NCT02266186|Experimental|Internet CBT|Intervention:Internet-based cognitive behavioural therapy.
3350936|NCT02266186|Active Comparator|Traditional CBT|Intervention:Traditional CBT given by a therapist following given modules.
3350937|NCT02266186|No Intervention|Care as usual|Childbirth preparation according to local routine
3350938|NCT02266199||conservative patients|in-patients on pneumology, cardiology, neurology, gastroenterology, endocrinology
3350939|NCT02266199||operative patients|inpatient on Traumatology, Plastic Surgery, Cardiothoracic Surgery, Gynecology, Abdominal Surgery
3350940|NCT02266212|Active Comparator|Smoke|Fagerstrom test for nicotine dependence
3350941|NCT02266212|Active Comparator|Pain|pain during post-operation Day1 to Day4
3350942|NCT02266212|Active Comparator|Morphine|Morphine consumption during post-operation Day1 to Day4
3243028|NCT01314339|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
3243029|NCT01314352|Experimental|Desloratadine Tablets, 5 mg|Desloratadine Tablets, 5 mg of Dr. Reddy's Laboratories
3243030|NCT01314352|Active Comparator|Clarinex|Clarinex® 5 mg Tablets of Schering-Plough
3243031|NCT01314378|Active Comparator|Cognitive-Behavioral Therapy|
3243032|NCT01314378|Experimental|Mindfulness Training|
3350943|NCT02266238|Experimental|Group 1|DSA guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
3350944|NCT02266238|Experimental|Group 2|Ultrasound guided percutaneous balloon dilatation to expand the stenosis of arteriovenous fistula
3350945|NCT02266238|Experimental|Group 3|Surgical reconstruction of the stenosis to reconstruction the lumen of arteriovenous fistula
3350946|NCT02266251||Surgical AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the Transcatheter Valve Therapies (TVT) Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS Adult Cardiac Surgical DAtabase (ACSD) (Jan 2011-Dec 2013).
3350947|NCT02266251||Transcatheter AVR|No interventions will be administered. Retrospective data analysis will be completed to compare health outcomes among patients with a similar baseline health satus who are eligible for both procedures (operative transcatheter AVR patients enrolled in the TVT Registry (Nov 2011-Dec 2013) and surgical AVR patients with STS perioperative risk of mortality whose index procedure is included in the STS ACSD (Jan 2011-Dec 2013).
3350948|NCT02266264|Experimental|100 milligrams of hydrocortisone|100 milligrams per day of hydrocortisone is the starting dosage.
3350949|NCT02266264|Active Comparator|200 milligrams of hydrocortisone|200 milligrams per day of hydrocortisone is the starting dosage.
3350950|NCT02266290|Experimental|Kinesio-Tape group|In this study, Sport tex® kinesiotape over lateral ankle (6cm*2.5m) is used.
3350951|NCT02266290|Placebo Comparator|Placebo Tape Group|In the placebo group, Pretape Cramer® (100% cotton, 1.25cm*10m) was used. With patient in the same position described above, horizontal strips were placed covering the sural region with no defined direction.
3350952|NCT02266303|Experimental|With checklist|Doctors will initiate insulin with the aid of a checklist
3350953|NCT02266303|No Intervention|Without checklist|Doctors will initiate insulin without the use of the checklist
3350954|NCT02266316|Experimental|Mask|Using mask that warms air at the mouth by utilising body heat
3350955|NCT02266316|No Intervention|No mask|Not using any mask that warms air at the mouth by utilising body heat
3350956|NCT02266329|Active Comparator|prazosin|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
3350957|NCT02266329|Placebo Comparator|placebo|Subjects will be gradually titrated up to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
3350958|NCT02266355|Experimental|OmalizumabTreatment Group|Omalizumab (Xolair) 300 mg SQ every 2 weeks
3350959|NCT02266368|No Intervention|Control group|This arm will include patients with non-coated stents
3350960|NCT02266368|Active Comparator|Antimicrobeal group|This arm will include patients with antimicrobeal coated stents
3350961|NCT02266394|Active Comparator|Mesenchymal stem cell delivery|To determine hemodynamic and immunologic changes associated with intra-renal delivery of adipose-derived MSC into human subjects with advanced RVD.
3350962|NCT02266394|Active Comparator|Mesenchymal stem cell delivery with stent placement|To test adjunctive delivery of MSC to individuals with advanced RVD undergoing renal artery stenting.
3243033|NCT01314404||KAP/WTP study population|"The participants will range in age from 12 to 50 and will be selected randomly. The study population will be representative of the following categories: men, women, adolescent boys, and adolescent girls.~As our study seeks to take a broad-based view of knowledge related to cervical cancer and HPV, our study population is necessarily wide-ranging. Adolescent boys and girls will be between the ages of 12 and 18; men and women will be older than 18, with at least one child that falls within the adolescent age range."
3243034|NCT01314404||Prevalence study population|"We plan to identify and recruit women diagnosed with cervical cancer who are being treated by a doctor from the department of gynecology of the Hospital Gabriel Touré in Bamako, Mali. These patients will have been previously identified and diagnosed by clinical exam by an obstetrician-gynecologist at Gabriel Touré, and will have been identified as surgical candidates by a doctor.~The subject has expressed a willingness to have a biopsy or other gynecological operation and have a doctor collect tissue samples during a standard medical appointment, has agreed to have blood drawn, was older than 18, and has the capacity to give informed consent."
3243035|NCT01314456|Experimental|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
3243036|NCT01314469||Patients with intermediate uveitis|
3243037|NCT01314482|Experimental|Minocycline|
3243038|NCT01314495|Active Comparator|Abatacept|Abatacept administered as a 30 minute intravenous infusion
3243039|NCT01314495|Placebo Comparator|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
3350963|NCT02266407|Active Comparator|ASEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
3350964|NCT02266407|Active Comparator|SEPTIC Revision TKA & Aquamantys System|Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System. These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
3350965|NCT02266420|Other|TNBC pT1a/b with size < or = 10 mm|Patients with pN0 triple negative breast tumor with size < or = 10 mm (pT1a/b) Study intervention = blood samples collected at initial visit
3350966|NCT02266420|Other|TNBC pT1c T2 with size <or = 30 mm|Patients with pN0 triple negative breast tumor with size < or = 30 mm (pT1c T2) Study intervention = blood samples collected at initial visit
3243040|NCT01314508|Other|All patients will be treated with IGF-1 factors|Patients will serve as their own control.
3243041|NCT01314560|Experimental|1|experimental
3350967|NCT02266446|Experimental|Attention & Interpretation Modification|The final product will be web-delivered, so it may be completed at the clinic or home. Treatment will consist of 8, 30-minute, twice-weekly sessions designed to: a) decrease attention bias to threat and b) extinguish threat interpretations/reinforce benign interpretations of ambiguity. Attention bias will be modified via a dot probe task that increases attentional control by directing attention away from threat faces via probe location. Patients will complete 256 trials per session. Interpretation bias will be modified via a word-sentence association task which provides positive feedback when participants endorse benign interpretations of ambiguous sentences and negative feedback for threat interpretations. Participants will complete 150 training trials per session
3350968|NCT02266485|Experimental|BIBB 515 BS|
3350969|NCT02266485|Active Comparator|Pravastatin|
3243042|NCT01314573|Experimental|Interval maximal exercise|Interval exercise involving repeated Wingate tests (30s durations of maximal exercise on a cycle ergometer).
3350970|NCT02266485|Placebo Comparator|Placebo|
3350971|NCT02266498|Experimental|BIBB 515 BS after a standard breakfast|
3350972|NCT02266498|Active Comparator|BIBB 515 BS|
3350973|NCT02266511|Experimental|Sequence 1|Flomax®, Nishine facility followed by Flomax®, Norman II facility
3350974|NCT02266511|Experimental|Sequence 2|Flomax®, Norman II facility followed by Flomax®, Nishine facility
3350975|NCT02266524|Experimental|Tamsulosin hydrochloride, very low dose|
3350976|NCT02266524|Experimental|Tamsulosin hydrochloride, low dose|
3350977|NCT02266524|Experimental|Tamsulosin hydrochloride, medium dose|
3350978|NCT02266524|Experimental|Tamsulosin hydrochloride, high dose|
3350979|NCT02266537|Experimental|Tamsulosin|
3350980|NCT02266537|Experimental|Alfuzosin|
3350981|NCT02266537|Experimental|Doxazosin|
3350982|NCT02266537|Placebo Comparator|Placebo|
3350983|NCT02266563||Traumatic Brain Injury (TBI) Group|TBI subjects will have a history of one or more concussions and have a memory complaint and objective decline that is considered to be worse than others of the same age (in the absence of an acute medical event). Severity classifications of the subjects selected for past history of TBI will be based upon established criteria used in TBI research (i.e., traumatically induced physiologic disruption of brain function as indicated by at least one of the following: any period of loss of consciousness, any loss of memory for events immediately before or after the accident, any alteration in mental state at the time of the accident, focal neurologic deficits that may or may not be transient). TBI cases will be those with mTBI (single or multiple concussion). Most recent injury must have occurred at least 1 year prior to study enrollment.
3243043|NCT01314573|Experimental|Continuous maximal exercise|Continuous exercise of maximal exertion that has been work matched to an initial bout of interval exercise of 4 x 30s of maximal exercise. This exercise is performed on a cycle ergometer.
3243044|NCT01314586|Placebo Comparator|placebo|placebo pill, diet counseling to comply with NCEP Step I diet
3243045|NCT01314586|Experimental|150 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 150 mg secoisolariciresinol (SDG) per day for 12 weeks
3243046|NCT01314586|Experimental|300 mg/day Beneflax|2 pills taken at breakfast and dinner containing a total of 300 mg secoisolariciresinol (SDG) per day for 12 weeks
3243047|NCT01314599|Experimental|Arm 1|PM01183 will be administered i.v. as a 1-hour infusion through a pump device at escalating doses according to the respective dose level, on Days 1 and 8 of each treatment phase.
3350984|NCT02266563||Mild Cognitive Impairment (MCI) Group|MCI Subjects will have MMSE scores between 24-30 (inclusive), a CDR of 0.5, have no depression, no history of TBI, and no dementia.
3350985|NCT02266563||Healthy Control Group|Healthy control subjects will have no self or informant-reported problems with cognition, no depression, no history of TBI, and no dementia.
3350986|NCT02266589|Experimental|Hydrocortisone|little doses of hydrocortisone
3350987|NCT02266589|No Intervention|Placebo|Placebo
3350988|NCT02266602|Other|Treatment|Patients treated with intraoperative radiation therapy at the time of partial mastectomy.
3350989|NCT02266615||Genetic research in 5 areas.|Cardiogenetics; Intellectual Disability, Multiple Congenital Abnormalities and Rare Diseases; Oncogenetics; Dermatogenetics; Reproductive Genetics.
3350990|NCT02266628|Experimental|Treatmetn Group A|RSV-F vaccine (0.5mL Injection)
3350991|NCT02266628|Placebo Comparator|Treatment Group B|Saline Placebo (0.5mL Injection)
3350992|NCT02266641|Active Comparator|healthy pregnant women|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3350993|NCT02266641|Experimental|healthy pregnant women's lineal relative with cancer|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3243048|NCT01314612|Experimental|Group Intervention|Subjects randomly assigned to this arm of the study will receive the 9-week insomnia and nightmare intervention group once per week for 90 minutes in addition to continuing treatment as usual with medical and mental health providers.
3243049|NCT01314612|No Intervention|Treatment as Usual|This group is randomly assigned to receive only treatment as usual and does not receive the active intervention of the insomnia and nightmare group treatment. This treatment will be made available to these members once the study is completed
3243050|NCT01314625||one arm|
3243051|NCT01314638||Single group|Single group, Identical investigations for all subjects
3243052|NCT01314651|Experimental|Sleep Management|Instructions in stimulus control and sleep restriction.
3243053|NCT01314651|Sham Comparator|Lifestyle Modification|Instructions to change general lifestyle habits (maintain consistent liquid consumption, range of motion exercises, etc.)
3243054|NCT01314677|Experimental|Group A (FDG PET/CT between RT fractions 5-6)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 5-6 (before course 2 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3350994|NCT02266641|Experimental|pregnant women or lineal relative with overweight/obesity|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3350995|NCT02266641|No Intervention|healthy pregnant women's lineal relative with diabetes|Supply nutrition counseling and multivitamin supplement to people with poor nutritional status
3243055|NCT01314677|Experimental|Group B (FDG PET/CT between RT fractions 10-11)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 10-11 (before course 3 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3350996|NCT02266654|Experimental|Prehospital-directed therapy arm|Patients who are hypotensive or whose lactate is ≥ 2.5, prehospital providers will provide a notification to the receiving hospital (Hospital Notification), establish an IV, and provide 1 liter normal saline (NS) bolus of IV fluids. An additional 1 liter normal saline bolus will be given for systolic blood pressure less than 100. Patients who have a history of end-stage renal disease or congestive heart failure would receive only 20 milliliters/kilogram of fluid. If the patient remains hypotensive, Emergency Medical Services will continue providing fluids as is standard of care.
3350997|NCT02266654|Experimental|Control Arm|Prehospital providers will obtain a point of care lactate, establish an IV, and provide IV fluids as judged necessary.
3350998|NCT02266667|Experimental|Progressive scoliosis|Children with progressive scoliosis
3350999|NCT02266667|Experimental|Neuromuscular scoliosis|Children with neuromuscular scoliosis
3351000|NCT02266680|Experimental|Yoga Treatment Group|BFY will be taught by a trained yoga instructor. Group sessions will be offered twice a week for 60 minutes each (i.e., a total of 2 hours per week), for 8 weeks.
3351001|NCT02266680|No Intervention|Waitlist Group|Waitlisted participants will receive BFY at the next available group after their waitlist period is completed
3351002|NCT02266693|Experimental|ICBT Group|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
3351003|NCT02266693|No Intervention|Waitlist Group|Upon completion of the 8-week study wait-list period (i.e. their study participation), the opportunity to participate in iCBT, outside the study framework will be provided.
3351004|NCT02266719|Experimental|Fenestrated CMD cohort|Patients enrolled in this arm will be implanted with the custom made fenestrated device. The device is aimed to treat complex abdominal aortic aneurysms including juxtarenal, suprarenal and type IV thoracoabdominal aneurysms.
3351005|NCT02266719|Experimental|Type I - III TAAA cohort|Patients enrolled in this arm will be implanted with the custom made/ off-the-shelfp branched devices. The device is aimed to treat type I-III TAAAs.
3351006|NCT02266719|Experimental|Arch cohort|Patients enrolled in this arm will be implanted with patient-specific stent-grafts with one to three inner branches or a scallop.
3351007|NCT02266732|Other|Interscalene block|
3351008|NCT02266732|Other|Femoral block|
3351009|NCT02266758|Other|GDM Screening Method 1|GDM Screening Methods
3351010|NCT02266758|Other|GDM Screening Method 2|GDM Screening Methods
3351011|NCT02266771|Active Comparator|NPWT with Instillation|Negative Pressure Wound Therapy with Instillation.
3351012|NCT02266771|Placebo Comparator|NPWT without Instillation|Negative Pressure Wound Therapy without Instillation
3351013|NCT02266784|Experimental|Contingency Management (CM)|ADHD (N=20) & CTRL (N=20). Participants will earn compensation, based upon smoking abstinence via a Contingency Management (CM) system. This level of compensation will increase by the same amount each visit based upon abstinence. In addition, escalating bonus payments will be available for evidence of continued abstinence. The first 10 visits will be daily weekdays. The following 9 visits will be over three weeks. The final 3 treatment visits will occur weekly. The 2nd & 3rd type visits CM payments will be based upon monitoring participants' cotinine levels. A missed visit or elevated CO level will lead to 1) no CM payment for that day; 2) resetting the contingencies such that the next CO sample that is below the criterion will result in payment equal to the first day. If there is a lapse, participants' contingencies will be reinstated at their previous highest level post 3 abstinent days. Also follow-up visits at 3 and 6 months.
3351014|NCT02266784|Other|Treatment as Usual|ADHD (N=20). Transdermal nicotine skin patches (i.e. Habitrol) will be used along with supportive counseling in the treatment as usual groups. Visit schedules will coincide with the visit schedules for the CM groups (daily visits for 1st 2 weeks, 3X weekly visits for weeks 3-5, 1x weekly visit for weeks 6-8). A standard regimen of nicotine replacement with which the study team has experience will be used: four weeks of 21 mg/d beginning on the QD, two weeks of 14 mg/d and two weeks of 7 mg/d. Also follow-up visits at 3 and 6 months.
3351015|NCT02266823|Active Comparator|Intervention: Lifestyle A.|"Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
3351016|NCT02266823|Other|Intervention: Lifestyle B.|"Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above.~Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling."
3375989|NCT03330405|Experimental|E2. CRPC DDR Defect +Assay Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3375990|NCT03330405|Experimental|F: Advanced Solid Tumors with BRCA or ATM defect Phase 2|"Drug: Avelumab~Drug: Talazoparib"
3351017|NCT02266836|Experimental|MyndMove|The MyndMove system is a neuromodulation device that delivers short electrical pulses to stimulate muscle contractions and enhance motor recovery following Stroke or Spinal Cord Injury. MyndMove delivers therapeutic stimulation sequences called protocols, which are coded therapeutic algorithms which assist muscle movement allowing the brain and central nervous system to be retrained restoring voluntary reaching and grasping functions lost following neurological injury. The MyndMove system comprises the hardware device, stimulation electrodes and cables, hand and foot switches, and integrated software.
3351018|NCT02266849|Active Comparator|Loperamide|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
3351019|NCT02266849|Placebo Comparator|Placebo|Patients will take the drug for three days. Day 1 - uploading with the drug Day 2 - collecting output when necessary Day 3 - radiopaque marker and collection of output every two hours
3351020|NCT02266862||Study Group|The purpose of this study is to evaluate the location within the renal artery of maximal angular displacement before and after fenestrated endovascular aortic repair (FEVAR) using CT with end-inspiration and end-expiration CT images before and after repair.
3351021|NCT02266901||Cases (endoscopic drainage)|Septic patients presenting post-bariatric collections related to leaks not adequately drained by percutaneous drain, for whom endoscopic drainage of the collections was performed by transluminal or percutaneous route.
3351022|NCT02266927|Active Comparator|Flovent® HFA 440µg|Flovent® HFA (fluticasone propionate) Inhalation Aerosol 440 µg
3351023|NCT02266927|Experimental|OPTINOSE™ FLUTICASONE 400µg intranasal|OPTINOSE™ FLUTICASONE, single dose of 400 µg intranasally
3351024|NCT02266940|Experimental|200mg DS-1971a oral suspension fasted|200 mg DS 1971a given as oral suspension in fasted condition
3351025|NCT02266940|Experimental|200 mg DS-1971a tablet fasted|single 200 mg DS 1971a oral tablet in fasted condition
3351026|NCT02266940|Experimental|200 mg DS-1971a tablet fed|single 200 mg DS 1971a oral tablet given in fed condition
3351027|NCT02266953|Experimental|Use of communication tool about diet|The children and parents in the intervention group are visiting consultations at the child health centre where the public health nurses use a communication tool about diet in order to promote dialogue about themes concerning food and feeding practices. This intervention is carried out at consultations when the child is 10-, 12- and 15-18 months old.
3351028|NCT02266953|Active Comparator|Treatment as usual|The children and parents in the control group are visiting consultations at the child health centre where the public health nurses will conduct the consultations as usual and without use of the actual communication tool about diet. The consultations are carried out when the child is 10-, 12- and 15-18 months old.
3351029|NCT02266966|Experimental|F2695|Single dose - 2 capsules / Day on Day 1 and Day 8
3351030|NCT02266966|Placebo Comparator|placebo|Single dose - 2 capsules / Day on Day 1 and Day 8
3351031|NCT02266992|Experimental|Fluenz Tetra|Live attenuated influenza vaccine- Fluenz tetra. Intra-nasal administration of 0.2ml (0.1ml in each nostril).
3351032|NCT02267005|Experimental|Treatment|patients on this arm will be treated with creapure supplements
3351033|NCT02267005|Placebo Comparator|Placebo|patients on this arm will be given a placebo glucose tablet supplement
3351034|NCT02267018|Active Comparator|nCPAP|Nasal continuous positive airway pressure is a frequently used modality for non-invasive respiratory support in preterm infants.
3243056|NCT01314677|Experimental|Group C (FDG PET/CT between RT fractions 15-16)|"Patients undergo a baseline FDG PET/CT scan and receive standard radiotherapy (RT) for 28 fractions with concurrent chemotherapy.~Patients undergo a FDG PET/CT scan between RT fractions 15-16 (before course 4 of chemotherapy).~Approximately 6 weeks after completion of CRT, patients undergo a FDG PET/CT scan and undergo standard tumor resection."
3243057|NCT01314729|Active Comparator|Fiber-reinforced-composite retainer|
3243058|NCT01314729|Active Comparator|composite-wire retainer|
3243059|NCT01314755|Experimental|immune-enhancing feed IMPACT|immune-enhancing feed IMPACT
3243060|NCT01314755|Active Comparator|control arm|iso-nitrogenous, iso-caloric control feed
3243061|NCT01314768|Active Comparator|Brief intervention|Behavioural brief intervention delivered by GP
3243062|NCT01314768|Placebo Comparator|Business as usual|Business as usual according to individual GP
3243063|NCT01314768|Other|Chronic headache control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
3243064|NCT01314768|Other|Population control|Screening and outcome control only. Non-intervention Control, screened and followed-up at final time point
3351035|NCT02267018|Active Comparator|NIHFV|Non-invasive high-frequency ventilation is a relatively new modality that is being utilized to support preterm infants and prevent the need for invasive ventilation, but this particular modality is has not been well studied to date.
3351036|NCT02267031|Active Comparator|normoxia and normocapnia|Normoxia PaO2 of 70-140 mm Hg Normocapnia PaCO2 of 35-48 mmHg
3351037|NCT02267031|Active Comparator|hyperoxia and normocapnia|Hyperoxia 150-300 mm Hg Normocapnia PaCO2 of 35-48 mmHg
3351038|NCT02267031|Active Comparator|normoxia and hypocapnia|Normoxia PaO2 of 70-140 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
3351039|NCT02267031|Active Comparator|hyperoxia-hypocapnia|Hyperoxia 150-300 mm Hg Hypocapnia PaCO2 of 25-35 mmHg
3351040|NCT02267044|Active Comparator|Ropivacaine Single Shot Block|Single Shot Interscalene block patients will receive a single shot of 30ml of 0.5% Ropivacaine prior to surgery
3351041|NCT02267044|Active Comparator|Ropivacaine Continuous block|Continuous Interscalene block patients will receive a shot of up to 30ml of 0.5% Ropivacaine and then a catheter is placed. The catheter is secured with Dermabond and Tegaderm. Once surgery is complete, the catheter is connected to a pain ball system which holds 400ml of 0.2% Ropivacaine local anesthetic. The rate is locked in at 8ml/hr. Catheter is pulled once the pain ball is empty.
3351042|NCT02267057|Active Comparator|Paracetamol or buprenorphine treatment|Paracetamol tablets 1 g three times daily or Buprenorphine transdermal system 5 micrograms/hour every 7 days, may be titrated up to 10 micrograms/hour every 7 days if clinically appropriate.
3243065|NCT01314781|Experimental|solifenacin 5mg, PFMT and WBVT|Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
3243066|NCT01314781|Active Comparator|solifenacin 5mg|Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
3243067|NCT01314807||patients with COPD|patients who were defined as COPD, based on post-bronchodilator spirometry (GOLD criteria). Patients will have at least 10 pack years
3243068|NCT01314807||smoking controls|patients with at least 10 pack years who have no COPD (based on post-bronchodilator spirometry)
3243069|NCT01314807||non-smoking controls|patients with < 1 pack year who have no COPD (based on post-bronchodilator spirometry)
3243070|NCT01314820|Active Comparator|normal saline injection|20 cc normal saline injection into the knee joint
3243071|NCT01314820|Sham Comparator|sham injection|knee injection without saline
3243072|NCT01314833|Experimental|TC*6|6 cycles of (Docetaxel 75mg/m2 ivgtt d1+ Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) .
3351043|NCT02267057|Placebo Comparator|Paracetamol placebo or buprenorphine placebo|Paracetamol placebo tablet three times daily or buprenorphine transdermal system placebo every 7 days.
3351044|NCT02267070|Experimental|Cognitive Training and Exercise|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
3351045|NCT02267070|Active Comparator|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations. All members receive individual case management and supportive psychotherapy, and family psychoeducation.
3351046|NCT02267096|Experimental|Telephone Counseling (TC)|The TC arm will receive the list of minimal treatment interventions plus 3-6 sessions of stepped-care, proactive, telephone counseling.
3351047|NCT02267096|Active Comparator|Minimal Treatment|The minimal treatment intervention includes a list of print, online, national telephone quitline phone number, and in-person cessation resources that is sent to participants.
3243073|NCT01314833|Experimental|CEF*3-T*3|3 cycles of CEF (Epirubicin 100 mg/m2 ivgtt d1+Cyclophosphamide 500 mg/m2 iv d1+ 5-fluorouracil 500 mg/m2 iv d1, 21 days per cycle) followed by 3 cycles of Docetaxel (Docetaxel 100mg/m2, ivgtt d1, 21 days per cycle)
3243074|NCT01314833|Experimental|EC*4-wP*12|4 cycles of EC (Epirubicin 90 mg/m2 ivgtt d1+Cyclophosphamide 600 mg/m2 iv d1, 21 days per cycle) followed by 4 cycles of Paclitaxel (Paclitaxel 80mg/m2, ivgtt d1,8,15, 21days per cycle)
3351048|NCT02267109|Experimental|2.5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 2.5 x 10(10):
3243075|NCT01314846||Control Group|sequential culture system
3243076|NCT01314846||Co-culture system|
3243077|NCT01314859|Experimental|Nifedipine|"Oral Treatment with Nifedipine capsules (10 mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
3243078|NCT01314859|Active Comparator|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
3243079|NCT01314885|Experimental|PF-03715455|
3243080|NCT01314885|Experimental|PH-797804|
3243081|NCT01314885|Placebo Comparator|Placebo for PF-03715455|
3243082|NCT01314885|Placebo Comparator|Placebo for PH-797804|
3243083|NCT01314898|Experimental|Treatment|
3243084|NCT01314924|Experimental|Responders|Patients who present an increase in flow-mediated dilation of brachial artery.
3243085|NCT01314924|Experimental|Non responders|Patients who do not present an increase in flow-mediated dilation of brachial artery.
3243086|NCT01314937|Experimental|Deworming at 12 months of age|
3243087|NCT01314937|Experimental|Deworming at 18 months of age|
3243088|NCT01314937|Experimental|Deworming at 12 and 18 months of age|
3243089|NCT01314937|Placebo Comparator|Usual care|
3243090|NCT01314950|Active Comparator|Best practices primary care|Best practices primary care encompasses the collaborative care intervention tested in a prior clinical trial (Callahan CM et al. JAMA 2006).
3243091|NCT01314950|Experimental|Home based occupational therapy|The intervention group receives all of the components of best practice primary care in addition to a home-based intervention designed to slow functional decline.
3243092|NCT01314976|Experimental|Metronidazole|Active treatment.
3243093|NCT01314976|Placebo Comparator|Placebo|Passive treatment.
3243094|NCT01314989|Active Comparator|Cyproheptadine|Cross-over study
3243095|NCT01314989|Placebo Comparator|Sugar pill|Cross-over study
3243096|NCT01315015|Experimental|Contrast enhanced breast MRI|The additional MRI will take place biennially after the regular screening mammogram for a study period of 6 years.
3243097|NCT01315015|No Intervention|Regular breast cancer screening|No further follow-up until next scheduled screening examination two years later (according to the current Dutch guideline).
3243098|NCT01315041|Active Comparator|"Pi medicine"|
3243099|NCT01315041|Placebo Comparator|Placebo|
3243100|NCT01315054|Other|Control arm|Using currently practiced methadone dosage prescription methods
3243101|NCT01315054|Experimental|MMT provider dosage training|Intensive health care provider training on prescribing methadone dosage based on national guidelines
3243102|NCT01315054|Experimental|MMT provider dosage training/counseling|Intensive health care provider training on prescribing methadone dosage, plus providing on-site psychosocial counseling services and peer support to clients .
3243103|NCT01315080||Saline|Percutaneous drainage and saline solution irrigation
3351049|NCT02267109|Experimental|5 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 5 x 10(10):
3243104|NCT01315080||Triamcinolone|Percutaneous drainage and saline solution irrigation plus percutaneous triamcinolone
3243105|NCT01315093|Experimental|Heparin, Low-Molecular-Weight group|LMWH was administered during an IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders. Drug was started at the beginning of the cycle and stopped at the time of pregnancy test if negative, or continued if pregnancy occurred until the 32th weeks of gestation
3351050|NCT02267109|Experimental|1.0 x 10(10) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(10):
3351051|NCT02267109|Experimental|1.0 x 10(11) vp|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z) 1.0 x 10(11):
3243106|NCT01315093|Active Comparator|Non Heparin, Low-Molecular-Weight group|IVF cycle using either the GnRH - agonist or antagonist protocol in poor responders.
3243107|NCT01315171|Experimental|Medium chain supplemented diet|Subjects will have a diet during which all meals are supplemented with 4 tablespoons of medium chain triglyceride oil.
3351052|NCT02267109|Experimental|Booster-MVA-BN® Filo or saline placebo|MVA-BN® Filo or saline placebo
3351053|NCT02267122|Experimental|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound.
3351054|NCT02267122|Experimental|Mupirocin ointment application|After placing the staples, a Mupirocin ointment application was placed covering the wound.
3351055|NCT02267122|No Intervention|Conventional dressing|After placing the staples, a conventional dressing, without application of any special gauze or ointment, was placed covering the wound
3243108|NCT01315171|No Intervention|Standard group|Subjects will continue with a standard western diabetes diet.
3243109|NCT01315184|Experimental|Recovery Line Support System|Patients assigned to the Recovery Line Support System will be trained on the system and provided 24-hr access to the system for a four week period, provided with a Recovery notebook, and given reminder calls to contact the system.
3351056|NCT02267161|Experimental|neuropsycological tests|Psychometric scales for infants at 3 years of age
3351057|NCT02267174|Other|Standardized OR to ICU handoff|A standardized handoff process for conducting OR to ICU handoffs will be implemented in two intensive care units without a standard process.
3243110|NCT01315184|No Intervention|Treatment as Usual|Patients assigned to the TAU condition will receive any services provided by their buprenorphine provider and any additional services that their provider refers or recommends that patients attend. No additional services will be provided by the study.
3351058|NCT02267200||reversible PAH group|reversible PAH was defined as sPAP decreasing to 40 mmHg after follow-up more than 6 months through echocardiography.
3351059|NCT02267200||irreversible PAH group|irreversible PAH was defined as 6 months after surgery through echocardiography ，the sPAP remaining 40 mmHg or up
3351060|NCT02267213|Experimental|Lipotecan|Administer 40mg of Lipotecan at D1, D8, D15 of each cycles.
3351061|NCT02267239|Active Comparator|Essential Oils, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the essential oils antiseptic solution
3351062|NCT02267239|Active Comparator|Chlorhexidine, immersion|Professional oral cleaning Plaster cast IDODS Immersion the disk with the biofilm in the chlorhexidine antiseptic solution
3351063|NCT02267239|Other|baseline|Professional oral cleaning Plaster cast IDODS Disk in basal conditions.
3243111|NCT01315197|Experimental|massage|The massage Anma has Japanese origin and a protocol was used with smoothing, kneading and pressure points on the bladder meridian.
3243112|NCT01315210|Experimental|D-Ribose|
3351064|NCT02267239|Active Comparator|Essential Oils, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the essential oils antiseptic solution
3351065|NCT02267239|Active Comparator|Chlorhexidine, mouthwash|Professional oral cleaning Plaster cast IDODS Active mouthwash with the chlorhexidine antiseptic solution
3351066|NCT02267265|Experimental|Treatment intervention|The treatment group will complete a demographics questionnaire and the knowledge survey before the intervention. Participants will then view the 10 minute TMW-Newborn Intervention video around the time of the newborn hearing screening. Participants whose newborn does not pass the hearing screen will view an additional 3 minute video detailing the importance of following up for an outpatient re-screening. The participant will complete the knowledge survey again before discharge, and after approximately four to six weeks.
3351067|NCT02267265|Active Comparator|Control intervention|The control group will complete a demographics questionnaire and knowledge survey. Participants will subsequently view the 10-minute Safe Sleep for your Baby (SIDS) educational video. It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome. This will be around the time of the newborn hearing screening. Participants will complete the knowledge survey again before discharge, and after approximately four to six weeks.
3351068|NCT02267291|Experimental|All patients|Ventilatory support to alter intrathoracic pressure
3351069|NCT02267304|Experimental|Morphine/placebo/naxolone|
3351070|NCT02267304|Experimental|Naxolone/morphine/placebo|
3351071|NCT02267304|Experimental|placebo/naxolone/morphine|
3351072|NCT02267330||Standard of care, Exposure recording|Patient will undergo fracture surgery as per standard of care, and will have radiation exposure recording.
3351073|NCT02267369|Active Comparator|Basic fitness program|The control condition provides study participants with online tools for enrolling in offline fitness workshops offered by the university's recreation department and recording their progress in the program. All fitness workshops are pre-programmed in an online calendar. Upon clicking a workshop, participants can read a detailed description and register for it directly on the calendar. The registration then triggers a confirmation email sent to the participant immediately and a reminder email 12 hours before the workshop starts. In addition, an online tracking tool is built that participants can use to keep a daily journal of their health activities and fitness status.
3243113|NCT01315210|Placebo Comparator|Placebo|
3243114|NCT01315223|No Intervention|Conventional treatment CHF patients|One hundred and fifty patients with CHF will be treated according to current guidelines (conventional treatment).
3243115|NCT01315223|Experimental|Lung impedence-guided treatment|
3243116|NCT01315262|Active Comparator|Viagra 100 mg daily|
3243117|NCT01315262|Active Comparator|Viagra 100mg on demand|
3243118|NCT01315275|Experimental|Ranibizumab|
3243119|NCT01315288|Other|Video presentation|
3243120|NCT01315301|Active Comparator|Arm-A|Immediate Treatment Group
3243121|NCT01315301|Active Comparator|Arm-B|Deferred Treatment Group-1
3243122|NCT01315301|Active Comparator|Arm-C|Deferred Treatment Group-2
3351074|NCT02267369|Experimental|Media-assisted fitness program|"The media condition evaluates the effects of informational and motivational messages on physical activity by supplementing the basic program tools with promotional media, including: high arousal videos encouraging physical activity, real-time email notifications about upcoming fitness workshops, and informational graphics with exercise tips and motivational messages. In the media condition, participants receive two videos on the website and one informational graphic that encourage physical activity on a weekly basis."
3351075|NCT02267369|Experimental|Social network-assisted fitness program|"The social condition, by contrast, omits the media content. Instead, the basic program is supplemented with a network of four to six anonymous health peers, composed of other participants of the program. Within the program website, each participant is able to see their peers' basic profile information, as well as information about their peers' progress in the program, and real-time notifications about their peers' completion of program activities. These networks do not provide any added incentives or additional content to promote physical activity, nor can participants directly communicate with, or message their peers through the website."
3351076|NCT02267395||(No-PRMSDs)|Group 1 : No Playing Related Musculoskeletal Injury
3243123|NCT01315314|No Intervention|conventional PDF (Stay safe)|
3243124|NCT01315314|Active Comparator|low GDP PDF (Balance)|
3243125|NCT01315327|Experimental|Omega-3 Fatty Acids|Omega-3 Fatty Acids (fish oil), flexibly titrated up to 6000 mg/day.
3243126|NCT01315327|Placebo Comparator|Placebo|Olive oil placebo, looks and tastes identical to active intervention.
3243127|NCT01315340|Experimental|Glaucoma Patients|
3243128|NCT01315340|Active Comparator|Control subjects|
3243129|NCT01315353|Experimental|Arm A: Immediate cryotherapy (HPV test-and-treat)|Participants in Arm A (HPV test-and-treat) had cervical cryotherapy at entry. Post entry, participants in Arm A were seen at regular intervals for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP.
3243130|NCT01315353|Experimental|Arm B: cytology-based strategy|Participants in Arm B followed a cytology-based management plan involving three steps- cytology, colposcopy with directed biopsies, and LEEP (as needed).
3243131|NCT01315353|Experimental|Arm C : Ineligible for randomization to Arm A or B|Participants were eligible for Arm C under the conditions noted in the inclusion criteria. Participants in Arm C had colposcopy and directed biopsies at entry. If CIN2+ was found by biopsy, then LEEP was performed and a follow-up visit 26 weeks after these procedures was scheduled for the collection of cervical specimens, cytology, and as needed, cervical colposcopy, directed biopsies, and LEEP. After the week 26 visit, Arm C participants went off study.
3243132|NCT01315366|Active Comparator|High dose vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a supplement of vitamin D3 EuroD (20,000 IU/wk) for one year.
3243133|NCT01315366|Placebo Comparator|Low dose Vitamin D|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) Ci-Cal D daily, plus a weekly placebo (EURO D Placebo) supplement for one year.
3351077|NCT02267395||(Yes-PRMSDs)|Group 2: Playing Related Musculoskeletal Injury
3243134|NCT01315379||PTSD without TBI|"children and adolescents with a diagnosis of PTSD and without head injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
3243135|NCT01315379||PTSD with m-TBI|"children and adolescents with a diagnosis of PTSD and a diagnosis of mild traumatic brain injury, following a motor vehicle accident.~This group will be treated using the Prolonged Exposure Therapy protocol."
3351078|NCT02267408|Experimental|Fearon algorithm dosing|Warfarin adjustment using the Fearon algorithm
3351079|NCT02267408|Active Comparator|Standard dosing|Warfarin adjustment using standard dosing
3351080|NCT02267421|Experimental|Home based aerobic exercise|Home based aerobic exercise on cycle ergometer. Three times per week, 30-60 minutes per session.
3351081|NCT02267421|No Intervention|Usual Care group|These patients will continue with their normal activities of daily living and will not be provided with equipment or coaching for home based exercise during the study period .
3351082|NCT02267434|Experimental|Low dose AFFITOPE® PD03A + Adjuvant|"4 injections of 15µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3243136|NCT01315392|Active Comparator|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for debridement and definitive closure.
3243137|NCT01315392|Active Comparator|immediate wound closure|traumatic and surgical wounds closed at initial surgical intervention
3243138|NCT01315418|Active Comparator|1 = Tested product|
3243139|NCT01315418|Sham Comparator|2 = Control product|
3243140|NCT01315431|Experimental|Tesetaxel-capecitabine|
3243141|NCT01315444|Active Comparator|PPI abrupt cessation|Abrupt cessation
3243142|NCT01315444|Active Comparator|PPI gradual step down cessation|Gradual cessation
3351083|NCT02267434|Experimental|High dose AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3351084|NCT02267434|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
3243143|NCT01315457||Alemtuzumab|Patients treated with alemtuzumab
3243144|NCT01315470|Experimental|neupogen|
3351085|NCT02267460|Active Comparator|AA4500 with investigator modeling and vacuum therapy|AA4500 with investigator modeling and home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
3351086|NCT02267460|Active Comparator|AA4500 without investigator modeling/with vacuum therapy|AA4500 without investigator modeling but with home use of the ErecAid® Esteem® Manual Vacuum Therapy System.
3351087|NCT02267486||Alzheimer Dementia (AD)|Patients with dementia caused by Alzheimer's disease
3243145|NCT01315470|No Intervention|no intervantion|
3243146|NCT01315483|Experimental|Low fat, high carb weight loss diet|Ornish-like weight loss dietary pattern
3351088|NCT02267486||Non-dementia|Patients with cognitive concern without dementia
3351089|NCT02267499|Experimental|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3351090|NCT02267499|No Intervention|Passive Control|Participants do not receive an intervention serving as passive controls
3351091|NCT02267512|Experimental|ATG-F single dosing group|Intravenous (IV)
3351092|NCT02267512|Experimental|ATG-F continuous dosing group|Intravenous (IV)
3351093|NCT02267525|Experimental|Velusetrag 5mg|Velusetrag 5mg capsules QD (once daily) x 12 weeks
3243147|NCT01315483|Experimental|Low carb, high fat weight loss diet|South-Beach-like weight loss diet pattern
3243148|NCT01315483|No Intervention|Control|Usual care
3243149|NCT01315496|Experimental|Imunoglobulin G|The enrolled patients will be randomized to receive supplementation of IVIG in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
3243150|NCT01315496|Placebo Comparator|Placebo control|The enrolled patients will be randomized to receive supplementation of placebo (0.9% NaCl) in ICU within 48 hours after hospital arrival admission for 3 consecutive days.
3351094|NCT02267525|Experimental|Velusetrag 15mg|Velusetrag 15mg capsules QD x 12 weeks
3351095|NCT02267525|Experimental|Velusetrag 30mg|Velusetrag 30mg capsules QD x 12 weeks
3351096|NCT02267525|Placebo Comparator|Placebo|Placebo capsules QD x 12 weeks
3351097|NCT02267551|Other|Mimic dV-Trainer|
3351098|NCT02267551|Other|daVinci Skills Simulator|
3351099|NCT02267564|Experimental|MPFLR without tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction without tibial tubercle transfer.
3351100|NCT02267564|Active Comparator|MPFLR with tibial tubercle transfer|Patients with patellar instability undergo MPFL reconstruction with tibial tubercle transfer.
3351101|NCT02267590||MCL: 80-100 samples from 60- 70 patients|Mantle Cell lymphoma patients
3351102|NCT02267590||CLL: 15-20 samples from 10-15 patients|Chronic lymphocytic leukaemia patients
3351103|NCT02267616|Experimental|Continued Use Implant Group|Woman randomly assigned to the continued use of their Etonogestrel Implant will continue to use their Etonogestrel Implant for contraception past FDA-approved duration of 36 months.
3351104|NCT02267616|Active Comparator|New Implant Group|Woman randomly assigned to the new Etonogestrel Implant will have their existing Etonogestrel Implant removed and a new implant placed.
3243151|NCT01315522|Active Comparator|ComVi stent|ComVi stent (Niti-S stent, ComVi type, Taewoong Medical Inc, Korea)
3243152|NCT01315522|Active Comparator|Uncovered SEMS|uncovered nitinol metal stent (HANAROSTENT, M.I. Tech Co., Ltd., Korea)
3243153|NCT01315535||Fast Titration|
3243154|NCT01315535||Regular Titration|
3351105|NCT02267616|No Intervention|Observational Continued Use Group|Women who refuse randomization will have an option of continuing to use their existing Etonogestrel Implant beyond the FDA-approved duration (36 months).
3351106|NCT02267642|Experimental|AbGn-168H|Seven (7) intravenous doses of AbGn-168H on D1 (Week 0), Day 8 (Week 1), Day 15 (Week 2), Day D29 (Week 4), D43 (Week 6), Day 57 (Week 8) and Day 71 (Week 10)
3243155|NCT01315535||Fast Tritation Including Mandibular Exercises|
3243156|NCT01315535||Regular Tritation Including Mandibular Exercises|
3243157|NCT01315548||Pancreatic adenocarcinoma|Patients diagnosed with solid pancreatic adenocarcinoma masses, with cytological / histologicalconfirmation
3243158|NCT01315548||Chronic pancreatitis|Patients diagnosed with solid pancreatic tumor masses with all the criteria fulfilled to exclude pancreatic cancer
3243159|NCT01315561|Experimental|acupuncture|MSAT is a treatment method in which the patient is exposed to active or passive movement and exercise during acupuncture, as opposed to conventional acupuncture.
3243160|NCT01315561|Active Comparator|injections of diclofenac|the control group was treated with intramuscular injections of diclofenac(NSAID). All administrations were limited to 1 session
3243161|NCT01315587|Active Comparator|intermittent theta burst stimulation|
3243162|NCT01315587|Active Comparator|repetitive Transcranial Magnetic Stimulation|
3243163|NCT01315587|Placebo Comparator|Sham TMS|
3243164|NCT01315613||Acute pancreatitis|Patients admitted in our institution for an episode of acute pancreatitis
3243165|NCT01315626||Immediately preceding intervention|3 months immediately before the education event. Charts of patients with a primary respiratory complaint will be reviewed so evaluate if they 1) have experienced 3 or more suppurative respiratory infections and 2) have required 3 or more courses of antibiotic therapy for respiratory infection over the period of one year. 4) Whether or not they underwent a HRCT, and if so, and 5) Were the patients diagnosed with BE.
3243166|NCT01315626||3 months after educational event|3 months immediately after the education event. An active assessment will be preformed as per the proposed diagnostic algorithm (attachment B) Patients that meet all criteria in the algorithm are considered at risk for bronchiectasis and based on these criteria, physicians will be encouraged to order HRCT, and the number/ proportion of patients identified with BE will be noted and compared to the other time periods.
3351107|NCT02267655|Active Comparator|inhaled Nitric Oxide 30 mcg/kg IBW/hr|30 mcg/kg IBW/hr of inhaled Nitric Oxide Part 1
3351108|NCT02267655|Active Comparator|inhaled nitric oxide 75 mcg/kg IBW/hr|Part 2: 75mcg/Kg IBW/hr
3351109|NCT02267655|Active Comparator|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|Part 3a: Dose tritration 5, 10 and 15 mcg/Kg IBW/hr Part 3b: continuing on dose determined by PI in 3a for 4 weeks
3351110|NCT02267655|Placebo Comparator|Placebo|Placebo for 75 mcg/kg IBW/hr
3351111|NCT02267668|Experimental|STEP arm|"The Baseline Evaluation Session will include formal neuropsychological evaluation, postural stability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Intervention includes exercise tolerance evaluations, 3 times per week exercise by physical therapist. Self report of symptoms and exertion."
3351112|NCT02267668|Active Comparator|Control|"The Baseline Evaluation Session will include formal neuropsychological evaluation, posturalstability evaluation, and an education session (education about mTBI, mTBI recovery, and expected outcomes from mTBI).~Control protocol includes instructions for stretching, instructions for restricting physically demanding activity during first 3 weeks of study; instructions for light, self-guided daily exercise in last 3 weeks of study. Self report of symptoms and exertion."
3351113|NCT02267681|Experimental|Group A|The patients in Group A will be given 100 mcg/kg/min propofol infusion and 10 mcg/kg loading dose of alfentanil and 5 mcg/kg additional bolus of alfentanil whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
3351114|NCT02267681|Experimental|Group F|The patients in Group F will be given 100 mcg/kg/min propofol infusion and 1 mcg/kg loading dose of fentanyl and 5 mcg/kg additional bolus of fentanyl whenever FPS (Faces Pain Scale) is greater than 3 or the patients can not tolerate the procedure.
3351115|NCT02267681|Active Comparator|Group P|Group P is designated as the control group and the patients will be given 100mcg/kg/min infusion and sedation will be achieved via 1 mg/kg propofol loading dose and 0.5 mg/kg propofol additional bolus will be given whenever the patients can not tolerate the procedure or FPS is greater than 3.
3351116|NCT02267694|Other|Black raspberry powder|Black raspberry powder 25 grams once daily for 4 weeks. If tolerated, will increase to 25 grams twice a day for another 20 weeks. Total length of active treatment 24 weeks.
3243167|NCT01315626||Seasonal prior year|As respiratory illnesses are commonly seasonal, an assessment of rate of Bronchiectasis diagnosis during the months of Period 2 in the year prior to the educational intervention will also be assessed as described in Period 1
3243168|NCT01315652|Experimental|Auto DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
3351117|NCT02267707|Experimental|Cohort 1 - Bilirubin level > 1.5 x ULN to 3 x ULN|4 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
3351118|NCT02267707|Experimental|Cohort 2 - Bilirubin level > 3 x ULN to 5 x ULN|6 dose levels may be given in this arm as follows: nab-paclitaxel 75 mg/m2 nab-paclitaxel 75 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 100 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 600 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 800 mg/m2 nab-paclitaxel 125 mg/m2; gemcitabine 1000 mg/m2
3351119|NCT02267720|Active Comparator|Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
3351120|NCT02267720|Experimental|Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
3351121|NCT02267733|Experimental|Early Disease|Patients not requiring anti-tumor therapy
3351122|NCT02267733|Experimental|Disease Requiring Anti-tumor therapy|Patients that have disease requiring anti-tumor therapy at any time
3351123|NCT02267759|Experimental|McGrath|Nasotracheal intubation was performed with McGrath videolaryngoscopy
3243169|NCT01315652|Active Comparator|Comorbidities treatment|
3351124|NCT02267759|Active Comparator|Macintosh|Nasotracheal intubation was performed with Macintosh direct laryngoscopy
3351125|NCT02267785|Experimental|Skill-Based Exercise|Participants assigned to this arm will complete the Skill-Based Exercise Intervention
3351126|NCT02267785|Experimental|Aerobic Exercise|Participants assigned to this arm will complete the Aerobic Exercise Intervention
3351127|NCT02267785|Experimental|Social Contact Group|Participants assigned to this arm will complete the Social Contact Intervention
3351128|NCT02267798|Experimental|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes and will focus on repetitive tasks that incorporate multidirectional reaching actions. In this robot-assisted therapy a robot manipulator applies forces to the paretic arm during goal-directed movements.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists of a battery powered programmable stimulator and a forearm-wrist-hand orthosis containing 5 electrodes positioned to provide reliable activation of muscles. The intensity of stimulation will be set to a level that provided comfortable and consistent activation of the extensor and flexor muscles to achieve whole hand opening and functional grasping."
3351129|NCT02267798|Active Comparator|conventional therapy|The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence, Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques based on neuro-developmental treatment.
3351130|NCT02267876||BD VIPER LT|
3351131|NCT02267889|Experimental|Image guided GP ablation|Use of cardiac nuclear imaging data to guide GP ablation procedures.
3351132|NCT02267902|Experimental|Part 1|Single oral therapeutic dose of 5mg DA-1229 as a tablet + An IV dose of 20㎍ [14C]-DA-1229
3243170|NCT01315691|Experimental|Arikace™|Liposomal amikacin for inhalation
3351133|NCT02267902|Experimental|Part 2|Single oral therapeutic dose of 5mg [14C]-DA-1229
3243171|NCT01315691|Placebo Comparator|Placebo|Placebo for liposomal amikacin for inhalation
3243172|NCT01315704||Group 1|Patients with Mild Cognitive Impairment
3351134|NCT02267915|Experimental|subcutaneous rituximab|MabThera 1400 mg solution for subcutaneous injection
3351135|NCT02267928|Experimental|Check/Experience|Participants are asked to check the symptoms that they have experienced in the last 6 weeks.
3351136|NCT02267928|Experimental|Un-check/Experience|Participants are asked to un-check the symptoms that they have experienced in the last 6 weeks.
3351137|NCT02267928|Experimental|Check/Not Experienced|Participants are asked to check the symptoms that they have NOT experienced in the last 6 weeks.
3351138|NCT02267928|Experimental|Un-check/Not Experienced|Participants are asked to un-check the symptoms that they have NOT experienced in the last 6 weeks.
3351139|NCT02267941||case|Diagnosis of aortic dissection was based on history and physical examination, and confirmed by imaging, visualization at surgery, and/or postmortem examination. According to the Stanford classification system, type A aortic dissection was defined as any dissection that involves the ascending aorta and type B as any that does not. Acute stage was confined to initial 14 days after symptom onset. Simple aortic aneurysm and pseudoaneurysm were excluded. Surgical and endovascular treatments were the main interventions and performed in the case group.
3375991|NCT03324373|Experimental|Lenvatinib and Everolimus prior to cytoreductive nephrectomy|Eligible patients will start treatment with lenvatinib 18 mg PO daily (administered as one 10 mg capsule and two 4 mg capsules) and everolimus 5 mg PO daily for 4 weeks constituting one cycle. Two cycles of treatment will be administered and after 2 weeks wash out period, the patients will go for nephrectomy.
3375992|NCT03319940|Experimental|Part A or Part B|AMG 757 Monotherapy
3375993|NCT03319940|Experimental|Part C|AMG 757 with Pembrolizumab
3351140|NCT02267941||control|As the control group, 2760 patients without AD were obtained from the hospitalized patients in the same period. Types of disease in the control group included congenital heart disease (632), coronary heart disease (467), adult valve disease (375), pulmonary artery hypertension (292), appendicitis (234), pneumonia (197), fracture (189), intestinal polyps (167), gallstone (156), esophagus cancer (51). Patients in the control group were derived from Department of Cardiovascular Surgery, Department of General Surgery, Department of Thoracic Surgery, and Department of Respiration, respectively.
3351141|NCT02267954|Experimental|50% Prices/50% Calories|"The participant is exposed to the baseline menu, but the prices are edited to be at 50% of the actual price (e.g., a $1 coffee is listed as costing $.50) and the calorie labels are edited to be at 50% of the actual content (e.g., a 500 calorie Large Fries is listed as having 250 calories). In addition, the baseline mistakes are still included.~This is the Menu edited intervention."
3351142|NCT02267967|Experimental|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
3351143|NCT02267980|Active Comparator|Group SK|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.
3351144|NCT02267980|Placebo Comparator|Group SS|Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.
3351145|NCT02267993|Experimental|Arm A|At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment. At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
3351146|NCT02267993|Experimental|Arm B|At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
3351147|NCT02268006|Other|IMRT-SIB|
3351148|NCT02268019|Experimental|Hypospadiasis repair|
3243173|NCT01315704||Group 2|Patients with Mild Alzheimer's disease or related disorders
3243174|NCT01315704||Group 3|Patients with Moderate Alzheimer's disease or related disorders
3351149|NCT02268032|Experimental|Vaginal ring 1 (VRD)|20 women using DHEA (VRD) for 2 menstrual cycles
3351150|NCT02268032|Experimental|Vaginal ring 2 (VRaA)|20 women using another androgenic agent (VRaA) for 2 menstrual cycles
3351151|NCT02268032|Experimental|Vaginal ring 3 (VR2A)|20 women using fixed combination of 2 androgenic agents (VR2A) for 2 menstrual cycles
3351152|NCT02268071|Experimental|Hypertensive patients|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence
3243175|NCT01315717||Group 1|Healthy subjects
3243176|NCT01315717||Group 2|Patients with Mild Cognitive Impairment
3351153|NCT02268097|Experimental|Freehand|Patellar resurfacing with freehand technique:Using freehand technique for patella preparation during total knee arthroplasty.
3351154|NCT02268097|Active Comparator|Resection guide|Patellar resurfacing with resection guide technique: Using patellar resection guide technique for patella preparation during total knee arthroplasty.
3243177|NCT01315717||Group 3|Patients with Mild AD
3351155|NCT02268110|Experimental|Supervised exercise therapy|Participants will receive 12 sessions with a physiotherapist where they will receive instructions on body mechanics, and be given a progressive abdominal exercise program
3243178|NCT01315717||Group 4|Patients with Moderate AD
3259319|NCT01469793|Experimental|DMOT4039A Q3W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with 0.2 milligrams per kilogram (mg/kg), as intravenous infusion every 3 weeks (Q3W) to determine the maximum tolerated dose (MTD) of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3351156|NCT02268110|Experimental|Abdominal binding|Participants will be fitted for an abdominal binder and asked to wear it for a period of 12 weeks.
3351157|NCT02268110|Experimental|Exercise therapy and Abdominal Binding|Participants will attend 12 sessions with a physiotherapist, and receive an abdominal binder
3351158|NCT02268110|No Intervention|Control|Participants will not receive an intervention during the study period
3351159|NCT02268136|Experimental|BIII 890 CL|single increasing doses
3351160|NCT02268136|Placebo Comparator|Placebo|
3351161|NCT02268149|Experimental|BIIL 284 BS + Prednisone|BIIL 284 BS 9 days; prednisone 2 single doses
3351162|NCT02268149|Placebo Comparator|Placebo|
3351163|NCT02268162|No Intervention|Routine Bronchoscopy|Participants in the group will receive routine bronchoscopy.
3351164|NCT02268162|Experimental|Routine Bronchoscopy with a guiding equipment|Participants in the group will receive routine bronchoscopy combined with a guiding equipment. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
3351165|NCT02268162|Experimental|Routine Bronchoscopy with two or more guiding equipments|Participants in the group will receive routine bronchoscopy combined with two or more guiding equipments. These guiding equipments include virtual bronchoscopic navigation(VBN), endobronchial ultrasonography with a guide sheath(EBUS-GS) and fluoroscopy.
3351166|NCT02268188|Experimental|Supportive Care (Harvesting Health program)|Participants undergo a series of 10 education and training sessions over 1 hour every 2 weeks, comprising education on current research, evidence-based health guidelines, application techniques, reference materials specific to extended-stage cancer survivors, and recommendations and personal health goals for survivorship. The guidelines described in class are part of a nutrition intervention and an exercise intervention with personal and group goal setting over the course of the study.
3351167|NCT02268201|Experimental|ADV group|Once daily
3351168|NCT02268201|Experimental|PRG group|Twice daily
3351169|NCT02268240|Experimental|Experimental|Stepped Care
3351170|NCT02268240|No Intervention|Control|Usual Care
3351171|NCT02268253|Experimental|Tagraxofusp (SL-401)|
3351172|NCT02268266|Other|Single-arm study|Early mobilization of patients after stroke or spinal cord injury. Monitoring of vital parameters during mobilization of healthy subjects
3243179|NCT01315730|Experimental|Device: Tactile Stimulation|"A new medical grade device (FDA - category exempt) has been newly designed and built at the University of Mississippi within the departments of Communication Sciences & Disorders, Exercise Science, and Computer and Electrical Engineering. The device records either sound waves (via a small standard microphone) or three dimensional accelerometer data from the throat of a stuttering subject. This data is digitally signal processed, and fed back to the user in the form of a small vibrating disk/film that can be held between the fingers or mounted on the skin. This feedback data does not require the subject to attend to the incoming signal."
3243180|NCT01315743|Experimental|Intervention|
3351173|NCT02268279|Experimental|solithromycin|oral dosing (capsules and powder for suspension) by weight once per day intravenous dosing by weight once per day
3351174|NCT02268292|Experimental|Bicycle Exercise|Bicycle Exercise for 12 weeks
3351175|NCT02268305|Experimental|MSM 1000mg twice a day (6000 mgs)|Group 1 will take by mouth three 1000 mg capsules twice a day (6000 mgs) of MSM plus standard of care naproxen
3351176|NCT02268305|Placebo Comparator|Placebo capsules twice a day|Group 2 will take by mouth three placebo capsules twice a day plus standard of care naproxen
3351177|NCT02268318|Experimental|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 1 bottle of dairy product/day with 1,6g of phytosterols
3351178|NCT02268318|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 1 bottle of dairy product/day with no Phytosterols
3351179|NCT02268331|Experimental|Active Surveillance|"For 60 consecutive pediatric visits, patients will be asked to complete a PRE & POST form to capture adverse events (AEs) that occur up to 1 week after treatment. The PRE-treatment form will be completed prior to the start of the visit. The POST-treatment form will be completed after the treatment visit and mailed directly to the investigative team.~The providers will collect data on the treatment provided on the same 60 pediatric patients. The treatment provided is at the discretion of the doctors. If a moderate, serious, or severe AE occurs, the provider will complete the AE form with detailed information about potential risk factors and patient outcomes."
3351180|NCT02268331|Active Comparator|Passive Surveillance|"All doctors allocated to this arm will be provided with a username and password with an established chiropractic passive surveillance reporting and learning online system (CPiRLS) in the UK. If a patient safety incident occurs in their office or an adverse event (AE), the provider will complete a report on the CPiRLS website. The providers can record events that occur during the time period of 60 pediatric visits.~Treatment provided during these treatments is at the doctor's discretion."
3351181|NCT02268344|Active Comparator|Grass SD9 Stimulator|Brief intraoperative electrical stimulation of the spinal accessory nerve (ESSAN) continuously at 20 Hz, 10-15V for 60 minutes immediately following neck dissection.
3351182|NCT02268344|No Intervention|No Stimulation|No stimulation will be performed in this group, and patients will simply have the neck dissection as planned. No sham stimulation is required, as all outcome measures are performed by individuals not present in the operating room, and therefore, blinded to the treatment arm.
3351183|NCT02268357|Experimental|Propranolol|capsules PROPRANOLOL (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
3351184|NCT02268357|Placebo Comparator|Placebo|capsules MICROCRYSTALLINE CELLULOSE (study medication); 80 mg 1 hour preoperative; 40 mg directly postoperative
3351185|NCT02268370|Other|Dasatinib|"This research is being done because dasatinib has been shown to achieve a deep molecular response in patients as compared to imatinib.~Patients in this study will continue to take their own supply of imatinib for three months to ensure they have achieved a stable response to the drug. Once this has been confirmed, imatinib will be stopped and the patients in this study will then be monitored to see if their CML relapses. This period can last up to 2.5 years.~If the participant has a relapse, they will be started on dasatinib and will continue to receive dasatinib for up to 2 years.~If after one year they achieve a response, they will continue on dasatinib for one more year. If the participant maintains this response, they will have the option of discontinuing dasatinib."
3351186|NCT02268383|Experimental|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection.
3351187|NCT02268409|Experimental|ACE-536 0.8 mg/kg once every 3 weeks SC|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
3351188|NCT02268422|Experimental|7 day patch|Buprenorphine transdermal system (BTDS) 2nd generation
3351189|NCT02268422|Active Comparator|7 Day Patch|1st Generation BTDS: Butrans
3351190|NCT02268435|Experimental|Dovitinib plus Imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
3351191|NCT02268448|Experimental|Clonidine|Clonidine will be given orally as a starting dose of 0.1 mg daily. The drug will be administered orally by the subject at bedtime daily for four weeks.
3351192|NCT02268448|Experimental|Naltrexone|Naltrexone will be given to each subject at an oral dose of 50 mg daily. Subjects will self-administer the drug at bedtime.
3351193|NCT02268461|Active Comparator|rTMS|repetitive Transcranial Magnetic Stimulation (rTMS)
3351194|NCT02268461|Sham Comparator|Sham rTMS|Sham repetitive Transcranial Magnetic Stimulation (Sham rTMS)
3351195|NCT02268474|Experimental|532nm KTP Laser|Cutera® Excel V
3351196|NCT02268474|Active Comparator|595nm Pulse Dye Laser|Candela/Syneron Vbeam
3351197|NCT02268487|Experimental|Sertraline|Patients using Sertraline with any dose will be evaluated about Early Improvement
3351198|NCT02268513||MASALA study|"Mediators of Atherosclerosis in South Asians Living in America (MASALA) study participants will be invited to participate in this ancillary study.~Objective of MASALA study:~The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study is investigating the prevalence, correlates, and outcomes associated with subclinical CVD in a population-based sample of South Asian men and women age 40-79 years at 2 US clinical field centers."
3351199|NCT02268539|Active Comparator|Ablation at 20 watt / 30 seconds|Participants randomised to 20 watt ablation for 30 seconds
3351200|NCT02268539|Active Comparator|Ablation at 20 watt /45 seconds|20 watt ablation for 45 seconds
3351201|NCT02268539|Active Comparator|Ablation at 25 watt / 30 seconds|25 watt ablation for 30 seconds
3351202|NCT02268539|Active Comparator|iAblation at 25 watt / 45 seconds|25 watt ablation for 45 seconds
3351203|NCT02268565|Placebo Comparator|Insomnia symptom induction/placebo|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
3351204|NCT02268565|Experimental|Insomnia symptom induction/aspirin|Daily intake of pill at bedtime over 2-week period prior to and during the 5-day in-hospital stay
3351205|NCT02268578|Active Comparator|Transcranial Direct Current Stimulation|Subjects will receive a total of 5 sessions on consecutive days. During each session, 2 mA of tDCS will be applied for 20 minutes over the left DLPFC (active or sham). The electrodes will have the size of 35cm2 each. Direct current will be transferred by a saline-soaked pair of surface sponge electrodes and delivered b y a specially developed, battery driven, constant current stimulator with a maximum output of 2mA.
3351206|NCT02268578|Sham Comparator|Sham TDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied for only 30 seconds - this is a reliable method of sham stimulation as sensations arising from tDCS treatment occur only at the beginning of application as also demonstrated by a randomized study (Gandiga et al. 2006).
3351207|NCT02268591|Active Comparator|Transcranial Stimulator|We will apply oscillating current at a slow frequency of 0.5-1.5 Hz during early sleep, which is rich in slow waves [ie non-REM sleep]. The peak intensity of stimulation which allows for optimal phase entrainment will be determined in pilot studies. However, peak stimulation intensities will not exceed 2 mA (as discussed above). The current will be applied over the left and right prefrontal cortex (F3, F4), corresponding to the predominant region of slow oscillations, during the onset of deep sleep to the first REM episode (early non-REM-rich sleep).
3351208|NCT02268591|No Intervention|Sham Stimulation|The EEG and stimulation electrodes will be placed as in the stimulation sessions, but stimulation will not be administered.
3351209|NCT02268604|Experimental|BIIB 722 CL|
3351210|NCT02268604|Placebo Comparator|Placebo|
3351211|NCT02268617|Experimental|Treadmill Walking|All subjects will walk on treadmill for a total of 20 minutes.
3351212|NCT02268630||Group A|Patients treated with Warfarin for VTE
3351213|NCT02268630||Grup B|Patients treated with Rivaroxaban for VTE
3351214|NCT02268643||group 1|ultrasound plus clinical breast examination
3351215|NCT02268656|Other|concentration in male|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in male
3351216|NCT02268656|Other|concentraion in female|after infusion of dexmedetomidine dexmedetomidine 0.5 mcg/kgfor 2 min, infusion of propofol as using target controlled infusion pump. Effect site concentration would be changed as the response to i-gel insertion as up and down method in female
3351217|NCT02268669|Active Comparator|Primary angioplasty|Patients assigned to this treatment will undergo cardiac catheterization within the time recommended by current guidelines. Double antiagregation will be used, vascular access wil be obtained and bivalirudin will be used as anticoagulation; all following current guidelines recommendations
3351218|NCT02268669|Active Comparator|Post-thrombolysis angioplasty|Patients will receive tenecteplase, enoxaparin, and double antiagreagation with clopidogrel or aspirin as recommended guidelines. Criteria of no reperfusion after fibrinolysis is defined as absence of ST-segment lowering >50%, 90 minutes after fibrinolysis. If not reperfusion is achieved recue angiplasty will be performed inmmediately if reperfusion is achieved cardiac catheterization will be performed the mornig following the day of randomization
3351219|NCT02268682|No Intervention|Standard of Care (Control)|Patients randomized to the standard of care condition will not receive any educational materials from our program and will only participate in the survey portion of the investigation. Dialysis providers will be asked to continue their current practices throughout the study period without change. While Control patients will be free to ask additional questions or solicit more information from their dialysis educators at any point during the study period, no additional educational interventions will be added to what is currently being done.
3351220|NCT02268682|Experimental|Patient-Guided|Over an 8-month period, patients in the Patient-Guided intervention condition will receive four educational modules and twelve transplant education postcards in the mail. Modules will be mailed once every other month and consist of an introductory letter, a transplant video, and printed resources. Transplant education postcard will be mailed every two weeks following the mailing of each module, for a total of three postcards over the course of 6-weeks.
3243181|NCT01315756|No Intervention|Control group|Treatment as usual.
3243182|NCT01315756|Experimental|Few Touch Application (FTA)|"This arm will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user."
3351221|NCT02268682|Experimental|Educator-Guided|Patients in the Educator-Guided intervention condition will receive the same intervention components as those in the Patient-Guided condition; however, the key difference in this condition is that Educator-Guided patients will also receive telephonic support from an experienced clinical social worker in the role of a Transplant Educator to maximally facilitate learning. Telephonic meetings with the Transplant Educator will occur after the mailing of each study module, for a total of four calls, each lasting 20-minutes, totaling 1 hour and 20 minutes. Finally, Patient-Guided and Educator-Guided patients will have the option of enrolling in an educational text messaging service designed to supplement the ET education they are receiving in the mail.
3351222|NCT02268695|Active Comparator|EXTREME: Cisplatin, 5-FU and Cetuximab|"Chemotherapy: 6 cycles (every 3 weeks) of Cisplatin (100 mg/m² iv on Day1), 5FU (4000 mg/m² total dose starting on day 1 and during 96h in continuous infusion), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If cisplatin is not tolerated and/or when the total cumulative dose of cisplatin (including prior administration) reaches 600 mg/m², cisplatin has to be replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Cetuximab maintenance : cetuximab continuation (250 mg/m² iv weekly) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
3243183|NCT01315756|Experimental|FTA and health counseling|This arm will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via sms from the diabetes nurse which is based on the patient's initiative (via sms). In addition, the diabetes nurse will call the patients three times during this period and discuss progress.
3243184|NCT01315769||non pregnant nulliparous|Group 1
3243185|NCT01315769||primiparous women|Group 2
3243186|NCT01315782||Multi-organ failure|Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
3351223|NCT02268695|Experimental|TPEx: Cisplatin, Docetaxel and Cetuximab|"Chemotherapy: 4 cycles (every 3 weeks) of Cisplatin (75 mg/m² iv on Day1), Docetaxel (75 mg/m² iv on Day1), and Cetuximab (loading dose of 400 mg/m² iv on Day1, then 250 mg/m² iv weekly).~If Cisplatin is not tolerated, cisplatin is replaced by carboplatin, AUC 5 (but not exceeding 750 mg), except in the case of bleeding tumor.~Primary prophylactic administration of GCSF must be administered systematically after each cycle of chemotherapy.~Cetuximab maintenance : cetuximab continuation (500 mg/m² iv every two weeks) will begin only if at least disease stabilization is observed at the end of chemotherapy, and will be continued until PD or unacceptable toxicity."
3351224|NCT02268708||COPD|"Patients:~>18 years old COPD: FEV/FEV1<80% in respiratory evaluation who have un oncological pulmonary resection in Cochin Hospital Paris France"
3351225|NCT02268721|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records before discharge, and at six and twelve weeks, as the intervention group. The control group receives no special treatment or care after discharge.
3351226|NCT02268721|Other|App for food delivery|"Intervention: Tablet Computer~Patients in the intervention group receives a tablet upon discharge from the hospital. The tablet contains an app, which the patients in the intervention group can use for ordering meals for delivery from the kitchen at the hospital three times a week. The app also ask the patients to register their own dietary intake, and give them feedback on their daily energy and protein intake.~Baseline measurements and records are taken at prior to discharge from the hospital, and after six and twelve weeks."
3351227|NCT02268734||Sporadic Medullary Thyroid Cancer|Patients with diagnosis of locally relapsed and or metastatic sporadic MTC surgically treated (total thyroidectomy)
3351228|NCT02268747|Experimental|Dacomitinib|"Patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
3243187|NCT01315795|Experimental|Symptomatic polycystic liver disease (PCLD) patients|Symptomatic polycystic liver disease (PCLD) patients
3243188|NCT01315808||Low risk group|Patients will be stratified based on risk factors significantly contributing to diabetes type 2.
3243189|NCT01315808||Intermediate risk group|
3351229|NCT02268760|Experimental|BILN 2061 ZW single rising doses|
3351230|NCT02268760|Placebo Comparator|Placebo|
3351231|NCT02268760|Experimental|BILN 2061 ZW fixed dose fed|
3351232|NCT02268760|Active Comparator|BILN 2061 ZW fixed dose fasted|
3351233|NCT02268773|Experimental|Acetylsalicylic acid low dose with Asasantin®|
3351234|NCT02268773|Active Comparator|Acetylsalicylic acid high dose|
3351235|NCT02268799||DC Cardioversion|Patients undergoing DC cardioversion
3351236|NCT02268825|Experimental|MK-3475 treatment arm, all patients|
3351237|NCT02268838|Experimental|50 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 1, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3351238|NCT02268838|Experimental|100 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 2, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3243190|NCT01315808||High risk group|
3351239|NCT02268838|Experimental|200 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3351240|NCT02268838|Experimental|400 mg E6007 fasted condition|E6007 50mg or E6007 matching placebo x 8, orally once daily in the morning under fasted condition. Drug administration on 1 day for single dose period (Day 1) and 7 days (Day 5 to 11) for repeated dose period.
3243191|NCT01315821|Experimental|Saccharomyces boulardii|Saccharomyces boulardii 5 million unit/day for 3 months
3243192|NCT01315821|Placebo Comparator|control|Placebo- for 3 months
3351241|NCT02268838|Experimental|200 mg E6007 fed condition|E6007 50mg or E6007 matching placebo x 4, orally once daily in the morning under fed condition. Drug administration on 1 day (Day 1).
3351242|NCT02268890|Experimental|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
3351243|NCT02268903|Active Comparator|Diuretics|
3243193|NCT01315834||Couples coping with CHD|The target group will be 127 male patients and their partners. The couples will be recruited during the patients' first hospitalization for ACS. The participants will complete questionnaires during the hospitalization and again six months later. The patients will also be asked to be weighed and have their blood drawn and at the six-month follow-up for measurement of blood Cholesterol level. Relevant data will be obtained from their medical files.
3243194|NCT01315834||control group|The control group will be 100 couples who are not coping with a life threatening illness. The couples will complete self report questionnaires at one point of time.
3243195|NCT01315860||Pregnant Females|Pregnant females in their second or third trimester that meet the inclusion and exclusion criteria.
3243196|NCT01315886|Experimental|SL Fentanyl conversion|"Baseline period: 7-15 episodes of breakthrough cancer pain treated with prior IR opioid medication~Treatment period: Conversion to SL Fentanyl at a Fentanyl:Prior opioid conversion factor of 1:50 (using the estimated Morphine Sulphate Equivalent dose for the prior opioid). SL Fentanyl use was followed for 8-15 episodes of breakthrough cancer pain. SL Fentanyl dose could be titrated between episodes."
3351244|NCT02268903|Placebo Comparator|Placebo|
3243197|NCT01315899|Experimental|ORM-12471 30mg|
3243198|NCT01315899|Placebo Comparator|placebo|
3243199|NCT01315899|Experimental|ORM-12471 100mg|
3243200|NCT01315925||Newly disgnosed AML|Adult and pediatric patients with newly diagnosed acute myeloid leukemia, both eligible and not eligible for intensive chemotherapy. Since this is a non-interventional study, therapeutic strategies remains related to local guidelines. Will be treated as cases all patients with acute leukemia in first induction developing an Invasive Fungal Infection according to international EORTC criteria for possible/probable/proven infections. Patients who do not develop the infection will be used as a control group.
3351245|NCT02268916|Experimental|Intervention|OT-led counseling based on home activity pattern
3351246|NCT02268916|Placebo Comparator|Wait-listed|Usual activity during the study. At the end of the study, will receive OT-led counseling
3351247|NCT02268929|Other|Control Group|Patients treated by usual customary medical practice (Usual Care)
3351248|NCT02268929|Other|Intervention Group|"Patients treated with Integrated Personalized Diabetes Management"
3351249|NCT02268968|Experimental|Lidocaine|Intervention: Topical lidocaine gel 2% (0.3 ml/kg) will be applied once only to the nostrils and nasal CPAP prong 5 minutes prior to the application of nasal CPAP
3351250|NCT02268968|No Intervention|Control|No topical lidocaine will be used prior to application of nasal CPAP
3351251|NCT02268981|Experimental|Oxymizer® compared to CNC|"From 7am to 7pm oxygen saturation is measured by a pulse oximeter. One day with conventional nasal cannula, one day with Oxymizer®, one day with Oxymizer® and reduced Oxygen flow (-1l/min). The order of these days is randomized in 6 groups.~The intervention will be performed on consecutive days and twice during study period."
3351252|NCT02269007|Experimental|0.5ml influenza vaccine|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
3351253|NCT02269020|Experimental|3 patients cancer of the epi larynx|"3 patients with squamous cell carcinoma of the epi-larynx~Intervention: Neck Dissection"
3351254|NCT02269033|Experimental|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
3351255|NCT02269033|Active Comparator|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
3351256|NCT02269046|Experimental|Acupuncture and moxibustion|"therapeutic lifestyle change~Group I:Juque (RN14), Tianshu (ST25, bilateral), Fenglong (ST40, bilateral), Zusanli (ST 36, bilateral), Sanyinjiao (SP6, bilateral)~Group II: Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)~Group I and II will change alternatively every other week .~Once per day five days per week."
3351257|NCT02269046|Active Comparator|Simvastatin|"therapeutic lifestyle change~simvastatin~oral administration with 10mg per day~seven days per week for 12 weeks."
3351258|NCT02269046|Other|waiting list|- therapeutic lifestyle change
3351259|NCT02269059|Experimental|GT1 Participants|Participants take MK-7680 capsules by mouth once daily (QD) for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
3351260|NCT02269059|Experimental|GT3 Participants|Participants take MK-7680 capsules by mouth QD for 7 days. The starting dose will be 200 mg and the dose will be adjusted in successive panels of participants based on analysis of results of the previous panel.
3351261|NCT02269072|Active Comparator|Testosterone|Testosterone cream applied daily
3351262|NCT02269072|Placebo Comparator|Placebo|Identical placebo cream applied daily
3351263|NCT02269085|Experimental|Ibrutinib + Carfilzomib|"Phase I: Ibrutinib administered by mouth daily at 420 or 560 mg on Days 1 - 28 of a 28-day cycle. Carfilzomib administered by vein 20/27 mg/m^2, 20/36 mg/m^2, 20/45 mg/m^2 or 20/56 mg/m^2 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle for Cycles 1- 12 and on Days 1, 2, 15 and 16 for Cycle 13 and higher.~Phase II: Once the MTD has been established 5 additional patients treated at the MTD to a maximum of 35 patients with MCL.~Study staff calls participant after end-of-dosing visit every 6 months for 5 years."
3351264|NCT02269111|Experimental|Diagnostic (hybrid MRI)|Patients undergo hybrid 3 Tesla MRI examination that includes standard MRI sequences, DW-MRI, CEST, and combined DCE-MRI/DSC-MRI at baseline.
3351265|NCT02269150|Experimental|Fecal microbiota transplantation with pre-transplant feces|Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
3351266|NCT02269150|Active Comparator|No FMT, routine management|Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
3351267|NCT02269176|Experimental|Telmisartan|Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered
3351268|NCT02269176|Active Comparator|Losartan|Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered
3351269|NCT02269189|Experimental|BIIL 284 BS, high dose in adult patients|
3351270|NCT02269189|Experimental|BIIL 284 BS, low dose in pediatric patients|
3351271|NCT02269189|Placebo Comparator|Placebo|
3351272|NCT02269202|Experimental|Midazolam and crobenetine|
3351273|NCT02269202|Placebo Comparator|Midazolam and placebo|
3351274|NCT02269215|Experimental|BIII 890 CL single rising dose|
3351275|NCT02269215|Placebo Comparator|Placebo|
3351276|NCT02269228|Experimental|Asasantin ER|Administered once daily (days 1 to 7), followed by twice daily administration (days 8 to 14)
3351277|NCT02269228|Experimental|Asasantin ER, administered twice daily from day 1 to day 14|
3351278|NCT02269228|Placebo Comparator|Placebo|
3351279|NCT02269254|Experimental|Persona PS|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
3351280|NCT02269254|Active Comparator|NexGen PS|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
3351281|NCT02269267||Discontinuation of TKI medication|Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (> 4 log reduction) molecular response (>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) < 0.01%, for at least two years.
3351282|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 3|Azacitidine (AZA) Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
3351283|NCT02269280|Experimental|Azacitidine (AZA) - Days 1 - 5|Azacitidine (AZA) 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
3351284|NCT02269280|Experimental|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
3351285|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
3351286|NCT02269293|Experimental|Regimen 1|Paclitaxel 175 mg/m^2 IV, Day 1 (administered over approximately 3 hours) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3351287|NCT02269293|Experimental|Regimen 2|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once daily on days 1, 4, 8, 11, 15, and 18 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3243201|NCT01315938|Other|Active treatment|Abatacept will be administered intravenously at a dose based on body weight at the screening visit (baseline): participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
3351288|NCT02269293|Experimental|Regimen 3|Paclitaxel 80 mg/m^2 IV, Days 1, 8, 15 (administered over approximately 1 hour) Carboplatin AUC 5 IV, Day 1 (administered over approximately 30 minutes) Selinexor orally (to be taken orally once weekly on days 1, 8, and 15 of each chemotherapy cycle) The selinexor tablet should not be crushed and/or chewed.
3351289|NCT02269293|Experimental|Regimen 4|Paclitaxel and carboplatin will be delivered intravenously (IV) on day 1 of each cycle. Selinexor will be taken orally once a week on days 1, 8 and 15 of each chemotherapy cycle.
3351290|NCT02269306|Experimental|clomiphen citrate(cc)|Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles.
3351291|NCT02269319|Experimental|MRX-I|MRX-I tablets 800 mg given twice a day for 10 days
3351292|NCT02269319|Active Comparator|Linezolid|Linezolid 600 mg given twice a day for 10 days
3351293|NCT02269332||Screening Colonoscopy|Referred for a screening colonoscopy or polyp surveillance or had one in the last 2 weeks
3351294|NCT02269345|Experimental|Battlefield Acupuncture|BFA at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
3351295|NCT02269345|Placebo Comparator|Standard Treatment|Standard Treatment alone
3351296|NCT02269358|Experimental|Addition of methotrexate|Addition SC methotrexate at 15 mg/m2, not to exceed 25 mg/m2 . Patients in remission after 4 weeks will reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
3351297|NCT02269371|Experimental|Group 1|Group 1: Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
3243202|NCT01315938|Other|Delayed-onset treatment|Abatacept will be administered intravenously at a dose based on body weight at 3 months: participants weighing <60 kg received 500 mg, 60-100 kg received 750 mg and those >100 kg received 1000 mg.
3243203|NCT01315951|Experimental|Petroleum Jelly|Every patient will be applying petroleum jelly to the affected areas per protocol.
3351298|NCT02269371|Sham Comparator|Group 2|Group 2: Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
3351299|NCT02269384|Sham Comparator|No History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
3351300|NCT02269384|Active Comparator|History of Significant Injury|Experimental Noxious Stimulus, Memory of Experimental Noxious Stimulus, Memory of Prior Significant Injury, Mental Challenge Test
3351301|NCT02269397||Individuals with suspected epilepsy|The study will enroll individuals who are attending their first visit at the University of Pennsylvania for suspected epilepsy.
3351302|NCT02269410|Active Comparator|GBP-SPS|GBP Standard PRO-S (0.8g protein/kg ideal body weigh/day)
3351303|NCT02269410|Experimental|GBP-HPS|GBP High PRO-S (1.2g protein/ kg ideal body weight/ day)
3351304|NCT02269410|Active Comparator|VSG-SPS|VSG Standard PRO-S (0.8g protein/kg ideal body weigh/ day)
3351305|NCT02269410|Experimental|VSG-HPS|VSG High PRO-S (1.2g protein/ kg ideal body weight/ day)
3243204|NCT01315964|Active Comparator|plant stanol ester|3 grams of plant stanol esters per day in a margarine product as part of daily diet for 6 months
3243205|NCT01315964|Placebo Comparator|Placebo|a margarine product as part of daily diet, which is not containing plant stanol esters
3243206|NCT01315990|Experimental|FOLFIRI + Cetuximab|
3351306|NCT02269436|Experimental|sNN0029 infusion solution|
3351307|NCT02269449|Experimental|6Fr Glidesheath Slender sheath|TRI will be performed using a new 6Fr sheath (Glidesheath slender: GSS).
3351308|NCT02269449|Active Comparator|5Fr contemporary sheath|TRI will be performed using a contemporary safety of 5Fr sheath.
3351309|NCT02269449|Experimental|Hemostasis with TR band|Hemostasis is achieved by randomization of using TR band (TERUMO) Patent hemostasis.
3351310|NCT02269449|Active Comparator|Any hemostasis procedure|Hemostasis is achieved by randomization of any hemostasis of each hospital's routine procedure.
3351311|NCT02269462||Pregnant women - efavirenz|Pregnant women taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health
3351312|NCT02269462||Nursing mothers - efavirenz|Nursing mothers taking 600 mg efavirenz daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
3351313|NCT02269462||Pregnant women - nevirapine|Pregnant women taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health
3375994|NCT03319940|Experimental|Part D|AMG 757 with additional cytokine release syndrome (CRS) mitigation strategies
3351314|NCT02269462||Nursing mothers - nevirapine|Nursing mothers taking 200 mg nevirapine twice daily as part of combination antiretroviral therapy for PMTCT and for their own health and their breastfed babies
3351315|NCT02269501|Experimental|Exercise treatment|Exercise treatment
3351316|NCT02269501|No Intervention|No treatment|No treatment
3351317|NCT02269514|Active Comparator|Own Brand Cigarette|Own Brand Cigarette
3351318|NCT02269514|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 14mg nicotine)
3351319|NCT02269514|Experimental|Electronic Cigarette #2|VUSE® (original flavor, 29mg nicotine)
3243207|NCT01316003||Normal subjects|Thirty-seven eyes of 37 individuals without eye diseases
3351320|NCT02269514|Experimental|Electronic Cigarette #3|VUSE® (original flavor, 36mg nicotine)
3351321|NCT02269514|Active Comparator|Leading U.S. Nicotine Gum|Leading U.S. Nicotine Gum
3351322|NCT02269527|Other|Live music|1-hour live music 5 days/week
3351323|NCT02269540|Experimental|Sertraline and n-acetylcysteine|Sertraline and n-acetylcysteine for seven weeks of treatment
3351324|NCT02269540|Experimental|Citalopram and n-acetylcysteine|Citalopram and n-acetylcysteine for seven weeks of treatment
3351325|NCT02269540|Experimental|Existing medication treatment & NAC|Existing depression medication treatment and n-acetylcysteine for seven weeks of treatment
3243208|NCT01316016|Experimental|Rose hip|
3243209|NCT01316029||laying-on-of-hands|44,587 Japanese volunteers with/without illness, who were interested in receiving laying-on-of-hands
3243210|NCT01316068|Experimental|sequencial use of sulodexide|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks. Then patients will receive 1000 LSU per day orally for 50 weeks.
3243211|NCT01316068|Active Comparator|oral use of sulodexide|Patients allocated to oral group will received 1000 LSU per day orally for 52 weeks
3243212|NCT01316081|Experimental|Antioxidant Group|500mg Vitamin C 400 I.E. Vitamin E 50 mcg Selenium
3351326|NCT02269553|Active Comparator|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. They are constructed from methacrylate polymers - the same material as has been used in hearing aids. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the individuals' ear canals when the jaw is in the open position and permit full passage of sound into each ear. The device is FDA cleared under a 510(k) with an indication of reducing TMD pain.
3351327|NCT02269553|Active Comparator|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch. Each patient assigned to the occlusal splint treatment group may wear either maxillary or mandibular splints or both, as prescribed by the subject's dentist, during the study. All occlusal splints used in the study will be custom fit to each patient using standard dental processes. All occlusal splints used in the study will be manufactured by Paul O'Neill Dental Lab, Yucaipa , CA, USA using clear ADA approved orthodontic acrylic
3243213|NCT01316081|Placebo Comparator|Placebo Group|identical appearing placebo supplements
3243214|NCT01316094|Experimental|ASP group|oral
3351328|NCT02269566|Active Comparator|Allergen extract|0.1 ml of allergen extracts
3351329|NCT02269566|Placebo Comparator|Placebo|Normal saline, 0.1 ml
3351330|NCT02269579|Experimental|CPX-351|Study Drug CPX-351 will be given intravenously at 100u/m2 on days 1, 3 and 5 by approximately 90 minute infusion.
3351331|NCT02269592||Specimen Collection|Patients' tumor tissue including bone marrow, blood, buccal swab or mouthwash, lymph node, urine or other specimens will be collected from patients who consent to the protocol
3243215|NCT01316094|Placebo Comparator|placebo group|oral
3243216|NCT01316107|Experimental|ASP group|Concomitant administration of ASP1941 and nateglinide
3243217|NCT01316120|Experimental|HPV Dry first|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
3243218|NCT01316120|Experimental|HPV standard transport medium|"Randomization will determine the sequence of the two tests, avoiding potential bias that may advantage the first test. All specimens will be tested for the same pathogens (HR-HPV) using the same diagnostic tests"
3243219|NCT01316133|Experimental|Tacrolimus group|Oral
3243220|NCT01316146|Experimental|CAR.CD30 T cells|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection (IV) according to the dosing schedules: starting with the lowest cell dose (2×10^7 cells/m2) and then escalate the cell dose to the highest cell dose (2×10^8/m2) as per study design.
3243221|NCT01316172|Experimental|5 Cs|Educational intervention
3243222|NCT01316172|No Intervention|Control|
3243223|NCT01316185|Experimental|Group 1|Low Dose for 28 days: n=4
3243224|NCT01316185|Experimental|Group 2|High Dose for 28 days; n=4
3243225|NCT01316198|Experimental|Lutein and zeaxanthin|
3243226|NCT01316198|Experimental|Placebo|
3243227|NCT01316237|Other|Cohort 1|(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2) 50 mg GS-6620 or placebo QD in the morning with food [total daily dose (TDD) = 50 mg] for 5 days
3243228|NCT01316237|Other|Cohort 2|"(N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS-6620 or placebo QD in the morning with food (TDD = 100 mg) for 5 days"
3243229|NCT01316237|Other|Cohort 3|"Cohort 3 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning with food (TDD = 300 mg) for 5 days"
3243230|NCT01316237|Other|Cohort 4|"Cohort 4 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~100 mg GS 6620 or placebo QD in the morning without food (TDD = 100 mg) for 5 days"
3243231|NCT01316237|Other|Cohort 5|"Cohort 5 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~300 mg GS 6620 or placebo QD in the morning without food (TDD = 300 mg) for 5 days"
3243232|NCT01316237|Other|Cohort 6|"Cohort 6 (N = 10, genotype 2 or genotype 3): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo QD in the morning without food (TDD = 900 mg) for 5 days"
3351332|NCT02269605|Placebo Comparator|Group 1|Patients receiving placebo (sodium chloride) at single dose
3351333|NCT02269605|Active Comparator|Group 2|Patients receiving Bryostatin 1 (10ug/m2) at single dose
3351334|NCT02269605|Active Comparator|Group 3|Patients receiving Bryostatin 1 (20ug/m2) at single dose
3243233|NCT01316237|Other|Cohort 7|"Cohort 7 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~450 mg GS 6620 or placebo, administered BID with food (TDD = 900 mg) for 5 days"
3351335|NCT02269618|Active Comparator|Control group (Group A)|The patients will be followed in the usual care manner by GPs and by routine specialist visits, if needed
3351336|NCT02269618|Other|Intervention group (Group B)|"Group B (Home-based intervention): the patients will be followed at home for 4 months by nurse and therapist and will perform an individual rehabilitative program. The interventions will be:~Home-based telehealth program~Home-based rehabilitation"
3351337|NCT02269644|Experimental|Dalbavancin|Dalbavancin randomized subjects will receive one dose of dalbavancin 1500 mg IV over 30 minutes on Day 1 plus azithromycin 500 mg IV on Day 1. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis. All patients in the dalbavancin group will receive placebo linezolid infusions or tablets to maintain the blinding. Dalbavancin dose will be adjusted for subjects with significant renal insufficiency who are not receiving regular hemodialysis
3351338|NCT02269644|Active Comparator|Linezolid|Linezolid randomized subjects will receive linezolid 600 mg every 12 hours for a minimum of 10 days, and a maximum of 14 days. All patients will receive at least one IV dose of linezolid initially plus azithromycin 500 mg IV only on Day 1. Subjects then may then be switched to oral linezolid at the discretion of the investigator, if clinical improvement in the signs and symptoms of pneumonia is observed, to complete the 10-14 day course of therapy,. No dose adjustment is required for renal insufficiency.
3351339|NCT02269644|Other|Linezold Placebo IV and Oral Capsules|Dalbavancin randomized subjects after the 1st dose on Day 1 will receive placebo linezolid every 12 hours for a minimum of 10 days and a maximum of 14 days. Dalbavancin randomized subjects may be switched to oral linezolid placebo therapy to complete the 10-14 day course of therapy.
3351340|NCT02269644|Other|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose will also receive 500 mg of IV azithromycin
3351341|NCT02269670|Experimental|Treatment (everolimus, hormone therapy)|Patients receive everolimus PO daily and a hormone therapy regimen chosen at the discretion of the investigator (anastrozole PO daily; letrozole PO daily; tamoxifen citrate PO daily; fulvestrant IM or PO on days 1, 15, and 29, and then monthly; megestrol acetate PO QID; or other regimen). Treatment continues in the absence of disease progression or unacceptable toxicity.
3351342|NCT02269683|Experimental|Robot-assisted|Distal pancreatectomy via robot-assisted minimally-invasive approach
3351343|NCT02269683|Active Comparator|Laparoscopic|Distal pancreatectomy via a conventional laparoscopic approach
3351344|NCT02269696|Experimental|Metoprolol|Metoprolol infusion
3351345|NCT02269696|Placebo Comparator|Normal saline|Equal volume of saline.
3351346|NCT02269722|Experimental|Short Clamp time|Radial clamp applied at full pressure for 20 minutes. At the end of 20 minutes, the clamp will be loosened ¼ turn every 5 minutes over 20 minutes and then removed.
3351347|NCT02269722|Experimental|Long Clamp Time|Radial clamp applied at full pressure for 60 minutes. At the end of 60 minutes, the clamp is to be loosened and removed under the same instruction as those patients in arm one.
3351348|NCT02269735|Experimental|Part I: MK-2640 (Panel A)|Part I: Lowest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351349|NCT02269735|Experimental|Part I: MK-2640 (Panel B)|Part I: Low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351350|NCT02269735|Experimental|Part I: MK-2640 (Panel C)|Part I: Medium-low dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351351|NCT02269735|Experimental|Part I: MK-2640 (Panel D)|Part I: Medium dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351352|NCT02269735|Experimental|Part I: MK-2640 (Panel E)|Part I: Medium-high dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351353|NCT02269735|Experimental|Part I: MK-2640 (Panel F)|Part I: High dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351354|NCT02269735|Experimental|Part I: MK-2640 (Panel G)|Part 1: Highest dose of MK-2640 infusion (3 approximately three-hour infusions at escalating rates) and dextrose infusion for 9 hours.
3351355|NCT02269735|Experimental|Part II: MK-2640 followed by RHI|Part II: MK-2640 infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
3351356|NCT02269735|Experimental|Part II: RHI followed by MK-2640|Part II: RHI infusion and dextrose infusion for 9 hours during Period 1 of Part II followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 9 hours during Period 2 of Part II. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part II.
3351357|NCT02269735|Experimental|Part III: MK-2640 followed by RHI|Part III: MK-2640 infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by RHI infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
3351358|NCT02269735|Experimental|Part III: RHI followed by MK-2640|Part III: RHI infusion and dextrose infusion for 7 hours during Period 1 of Part III followed by a 7-day wash-out period followed by MK-2640 infusion and dextrose infusion for 7 hours during Period 2 of Part III. Insulin aspart administered approximately 10 hours before Periods 1 and 2 of Part III.
3351359|NCT02269748|Experimental|Root coverage with Tunnel (TT)|The tunnel technique with subepithelial connective tissue graft (TT+SeCTG) will be utilized to cover the denude root surface
3351360|NCT02269748|Active Comparator|Coronally advanced flap (CAF+SeCTG)|The Coronally advanced flap with subepithelial connective tissue graft (CAF+SeCTG) will be utilized to cover the denude root surface
3375995|NCT03319940|Experimental|Part E|AMG 757 administration with 24-hour monitoring
3375996|NCT03319940|Experimental|Part F|AMG 757 administered in outpatient infusion centers with 8-hour monitoring.
3351361|NCT02269774|Other|Pulmonary vein isolation|Intra-thoracic pressure swings induced by breathing manoeuvres during standard catheter-ablation procedure. Catheter-based electrical mapping and pressure in the left atrium and pulmonary veins during standard catheter-ablation procedure. Only patients with an apnea-hypopnea index > 5/h and documented premature atrial beats during the Mueller manoeuvre will be eligible for the catheter-based electrical mapping. Follow-up after 1 year for atrial fibrillation recurrence.
3351362|NCT02269774|No Intervention|No intevention|Intra-thoracic pressure swings induced by breathing manoeuvres during ECG-monitoring. Only patients with an apnea-hypopnea index < 5/h and no premature atrial beats during the Mueller manoeuvre will be assigned to the no intervention arm.
3351363|NCT02269800|Experimental|Benzalkonium chloride solution|Tid, for 7 days.
3351364|NCT02269800|Active Comparator|Normal saline|Tid, for 7 days.
3351365|NCT02269813||ET/GOOD|Endocrine therapy only.
3351366|NCT02269813||CT/POOR|Chemoendocrine therapy according to national guidelines.
3351367|NCT02269826|Experimental|Vagisan® Moisturising Cream|non-hormonal vaginal cream for the treatment of vulvovaginal dryness
3351368|NCT02269826|Active Comparator|Gynomunal® vaginal gel|non-hormonal gel
3351369|NCT02269839|Active Comparator|theta-burst rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
3351370|NCT02269839|Sham Comparator|Control arm|The control (sham) stimulation will consist of stimulating with the rTMS coil held at right angles to the participants' head. This will result in no active stimulation of brain tissue but would feel similar to the patient. Each treatment session will therefore last approximately 20 minutes.
3351371|NCT02269852|Experimental|trivalent seasonal influenza vaccine|"Northern hemisphere 2013-2014 trivalent seasonal influenza vaccine~60 infants: two-dose regimen with a 28-day interval;~60 adults: single-dose regimen;~60 seniors: single-dose regimen;"
3351372|NCT02269878||people with MPM with Thymine/Thymine,Thymine/cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
3351373|NCT02269878||people with MPM, Cytosine/Cytosine genotype|according to Single nucleotide polymorphism analysis of rs 763110, people have one of the following genotypes, Thymine/Thymine,Thymine/Cytosine,Cytosine/Cytosine. we will assign Thymine/Thymine, Thymine/Cytosine to group one and Cytosine/Cytosine to group two. for rs 1800682 people will have one of the following genotypes Adenine/Adenine, Adenine/Guanine or Guanine/Guanine.
3351374|NCT02269891|Experimental|Nu Femme|Two capsules (500mg total) taken once daily in the morning after breakfast for 24 weeks
3351375|NCT02269891|Placebo Comparator|Placebo|Two capsules taken once daily in the morning after breakfast for 24 weeks
3351376|NCT02269904|Active Comparator|Fluorouracil Implants and Xelox regimes|"Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.~Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished."
3351377|NCT02269904|Active Comparator|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
3351378|NCT02269930|Experimental|Group 1|Treatment Sequence 1: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41 Treatment Sequence 2: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29
3351379|NCT02269930|Experimental|Group 2|Treatment Sequence 1: SC doses of Rebif on Days 1, 4, 6, 8, 11, and 13; and a single SC dose of BIIB017 on Day 29 Treatment Sequence 2: Single subcutaneous (SC) dose of BIIB017 on Day 1; and SC doses of Rebif on Days 29, 32, 34, 36, 39, and 41
3351380|NCT02269956|Active Comparator|Intervention|The 2 NH's not used in the focus groups will receive the intervention, a 12-week feasibility study. At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for 3 meals over 2 days at baseline and again at week 6 and 12, and a medical record review will be conducted. After baseline data is collected, the training program will be delivered in 5 weekly modules with group coaching sessions completed the same week.
3243234|NCT01316237|Other|Cohort 9|"Cohort 9 (N = 10, genotype 1): (Active drug: 8, Matching Placebo: 2)~900 mg GS 6620 or placebo BID in the with food (TDD = 1800 mg) for 5 days"
3243235|NCT01316237|Other|Cohort 11|"Cohort 11 (N = 10, genotype 1 : (Active drug: 8, Matching Placebo: 2)~Up to 450 mg GS-6620 or placebo as an oral solution, BID, 12 hours apart in the fasted state, 2 hours after a meal (up to TDD = up to 900 mg) for 5 days."
3243236|NCT01316250|Other|Nilotinib, cytogenetic response|Newly diagnosed CML patients
3243237|NCT01316328||BC patients after SSPBI|breast cancer (BC) patients following single shot partial breast irradiation (SSPBI) after breast conservative surgery
3243238|NCT01316354|Experimental|Beta-glucan|Bread with purified beta-glucan
3243239|NCT01316354|Experimental|Rye kernels|Rye bread with kernels
3243240|NCT01316354|Experimental|White bread|White bread
3243241|NCT01316354|Experimental|Arabinoxylan|Bread with Purified arabinoxylan
3243242|NCT01316367|Active Comparator|Conventional Health Promotion Education (CHPE).|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
3243243|NCT01316367|Experimental|PRECEDE HPE model|
3243244|NCT01316393|Experimental|XER2020|mucoprotective product
3243245|NCT01316393|Active Comparator|Saliva Natura|salivary substitute
3351381|NCT02269956|No Intervention|Focus Groups|Year 1 focus groups will aim to identify how nursing staff feel about usual interventions for feeding behaviors of PWD and staff responses when a PWD displays difficult eating behaviors. Year 2 focus groups will evaluate the revised dementia feeding skills training program, the coaching interventions, and case scenarios, and indicate how realistic and compatible the intervention is with their work environment.
3351382|NCT02269969|Experimental|Once daily aminoglycoside|Once daily dosing of Tobramycin
3351383|NCT02269982||men with mCRPC prior to enzalutamide/abiraterone|
3351384|NCT02269995||E7040|
3351385|NCT02270008|Active Comparator|Pelvic floor training|The intervention group will undergo an in-person standardized training session by a trained nurse practitioner. The intervention is the pelvic floor training session. They will then be asked to continue muscle training at home at regular intervals and asked to log their exercises on a standardized exercise diary that is provided to them.
3351386|NCT02270008|No Intervention|Literature-only group|The literature-only group will receive a pamphlet with instructions for pelvic floor muscle exercises; however, no in-person training will be administered.
3351387|NCT02270021|Experimental|Provider Mobile Application (ProvAPP)|Mobile phone application for providers.
3351388|NCT02270021|Experimental|ProvAPP + Patient Educational Tool (Tab)|Patient educational tool; plus the Mobile phone application for providers.
3243246|NCT01316393|Placebo Comparator|XER2020 placebo|
3243247|NCT01316406|Experimental|ATH008 cream 3%|ATH008 cream 3%
3243248|NCT01316406|Experimental|ATH008 cream 8%|ATH008 cream 8%
3243249|NCT01316406|Placebo Comparator|ATH008 cream placebo|ATH008 cream placebo
3351389|NCT02270021|No Intervention|ProvAPP Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
3351390|NCT02270021|No Intervention|ProvAPP+Tab Control Group|Clinics in this group are those NOT randomized - receiving no intervention. These clinics will be chosen at random for comparison using Family PACT claims data.
3243250|NCT01316432|Experimental|SQ Bolus Cenderitide|
3243251|NCT01316432|Experimental|SQ Infusion Cenderitide|24 hour SQ infusion of cenderitide
3351391|NCT02270034|Experimental|Cohort crizotinib|Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
3351392|NCT02270047|Active Comparator|A|Orange nectar with NAXUS fibre, 5g/100mL
3351393|NCT02270047|Placebo Comparator|B|Orange nectar
3351394|NCT02270073|Experimental|TAU + mindfulness intervention|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together the brief intervention with mindfulness elements. Participants sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The text is standardized and spoken by Dr. Thomas Heidenreich. During the exercise, participants are instructed to observe their breathing and body sensations. After completion of the mindfulness intervention, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
3351395|NCT02270073|Active Comparator|TAU + progressive muscle relaxation|"In the first five minutes of each of 25 therapy sessions (duration: about 25 weeks), both patient and therapist perform together a short version of progressive muscle relaxation (PMR). Both patient and therapist sit upright in their chairs in a comfortable position at a distance about one meter from the audio recorder. The PMR text is standardized and spoken by Dr. Thomas Heidenreich. Wording is as similar as possible to the mindfulness interventions.During the exercise, participants are instructed to tense and relax arms, face, body and legs. After completion of PMR, the regular therapy session begins.~Intervention: Cognitive behavior therapy of trainee therapists"
3351396|NCT02270073|Other|Treatment as usual|"No specific intervention is conducted at the beginning of therapy sessions. Standard cognitive behavior therapy treatment, based on the individualized case conception of the trainee therapist, is conducted during the whole treatment sessions.~Intervention: Cognitive behavior therapy of trainee therapists"
3243252|NCT01316432|Placebo Comparator|Placebo|24 hrs of SQ placebo infusion
3243253|NCT01316445|Experimental|nasal Midazolam|3 mg of the standard IV solution of midazolam (5 mg/mL) was given via a metered-dose nasal sprayer (6 sprays × 0.1 ml/spray, or 6 × 0.5 mg/spray) divided between the two nostrils within 1-2 min. During the EEG, vital signs (blood oxygen saturation, blood pressure, pulse and respiratory rate) were monitored and a nurse and a physician were available at all times. Subjects were monitored for 2 hours after administration of midazolam to ensure adequate recovery from sedation.
3351397|NCT02270086||Sarcoma patient|Patient diagnosed with soft tissue sarcoma and receiving preoperative radiotherapy.
3351398|NCT02270099||Subjects with suspected HSV Lesions|
3243254|NCT01316458|Experimental|imatinib mesylate|
3243255|NCT01316471|Experimental|Online Behavioral Intervention|In addition to standard medical care, children and parents in the online behavioral intervention will receive access to the full web-based program including education about chronic pain, training in behavioral and cognitive coping skills, instruction in increasing activity participation, and education about pain behaviors and parental operant strategies using an engaging, interactive format on the Internet.
3243256|NCT01316471|Active Comparator|Online Patient Education|The Online Patient Education group will serve as an attention control condition. In addition to standard medical care, children and parents will be provided with access to a modified version of the study website that will provide information from publicly available educational websites about pediatric chronic pain management.
3243257|NCT01316484||No Treatment|Adult subjects with diabetes mellitus and a diagnosis of gastroparesis
3243258|NCT01316497|Experimental|Remote ischemic preconditioning (RIPC)|See intervention description
3243259|NCT01316497|Placebo Comparator|Control|
3243260|NCT01316536|Experimental|With Music|This randomized group will receive music
3243261|NCT01316536|Placebo Comparator|Control Arm|Will not receive music but will receive audio loop of recorded ICU sounds
3243262|NCT01316549||Inpatient Pediatric Bone Marrow Transplant Recipients|All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.
3243263|NCT01316562||Group 1|Healthy controls
3351399|NCT02270112||Paroxysmal Af|No Intervention is planned. All patients receive a 5 Minute ECG and have their pulse recordes by an iPhone.
3351400|NCT02270125||Adult patients with chronic rhino sinusitis|Group of adult patients indicated for mucotomy due to chronic hypertrophic rhinosinusitis, with or without polyposis
3351401|NCT02270125||Stillborn children|Control group of stillborn children whose nasal mucosa was not exposed to airborne particles
3351402|NCT02270138|Experimental|Movement-to-music|Three movement-to-music video programs will be used by the participants. First and second videos last about 10 minutes including two songs and their movement preparation. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
3351403|NCT02270138|No Intervention|No movement-to-music|Another group will not receive movement-to-music video during intervention. However, their physical activity will be objectively measured as well.
3351404|NCT02270151|Active Comparator|MyDiagnostick|Everyone aged 65 years or over, who visits the GP practice will be screened for AF with the MyDiagnostick. When the device indicates a positive result, the single lead ECG will be assessed to confirm/reject the diagnosis. Every new case of diagnosed AF will be evaluated for further treatment by the general practitioner.
3351405|NCT02270151|No Intervention|Control|Control arm will perform care as usual with selective screening by feeling the pulse.
3351406|NCT02270164|Experimental|Artichoke Leaf Extract|Pycrinil® 100 mg/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
3351407|NCT02270164|Placebo Comparator|Placebo|Placebo/flaxseed oil 380 mg liquid filled hard plant based capsules (Licaps®) twice daily with food
3351408|NCT02270177|No Intervention|Regular consultation|Regular headache consultations
3351409|NCT02270177|Other|Videoconsultation|Headache consultations through telemedicine technology
3351410|NCT02270190|Other|tenesmus patients|Percutaneous Tibial Nerve Stimulation (PTNS) will be applied to all patients in the study
3351411|NCT02270216|Active Comparator|elderly with isolated systolic hypertension|over 60 years of age with essential isolated systolic hypertension (stage I-II base on recommendation of JNC-VII) for the hypertension group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
3351412|NCT02270216|Active Comparator|healthy elderly|over 60 years of age with normal blood pressure in the healthy group. Good communication, independent physical activity. The healthy subject should be non-smokers, free of any signs or symptoms of disease as revealed by medical history
3243264|NCT01316562||Group 2|Patients with an Alzheimer's disease or related disorders
3351413|NCT02270229||Healthcare providers|
3351414|NCT02270229||PD patients|
3351415|NCT02270229||Primary caregivers of the PD patients|
3351416|NCT02270229||Laboratory personnel|
3351417|NCT02270268|Experimental|pectin|a kind of soluble dietary fiber
3351418|NCT02270268|Placebo Comparator|Placebo|maltodextrin
3351419|NCT02270281|Other|Dexmedetomidine|Before dexmedetomidine infusion
3351420|NCT02270294|Experimental|Thai traditional massage|
3351421|NCT02270294|Sham Comparator|No massage|
3351422|NCT02270307|Experimental|MSC+CY|Cyclophosphamide 50 mg/kg/day at +3, +4 day once daily after BMT Mesenchymal stromal cells 1*10^6/kg at day of recovery
3243265|NCT01316588|Experimental|Plastic adesive drape|Intraoperative: Plastic adhesive drape on the chest and bare skin on the leg
3243266|NCT01316588|Experimental|Microbial Sealant|Intraoperative: Microbial Sealant on the leg and bare skin on the chest
3351423|NCT02270320|No Intervention|Control|Control group will receive a telephone consultation once every two weeks for 12 weeks.
3351424|NCT02270320|Active Comparator|Physical activity|Experimental group will receive a 60-minute 24 forms Yang-style Tai Chi Chuan exercise program, three times per week for 12 weeks.
3243267|NCT01316627|Experimental|Crooked Mirror Externalization Therapy|"Of recent, the crooked mirror externalization therapy, developed by Dr. Eda Gorbis, has been put to use with much success (Gorbis 2004). This method involves the use of crooked or fun house mirrors made from highly reflective surfaces that can be bent in different directions, which distort and exaggerate the patient's perceived defects (Gorbis 2005). In turn, this process externalizes or reverses the patient's internalized distorted body image, and allows the patient to habituate to the reflection of the imagined defect that is even more distorted than the internalized image (Rosen et al. 1995)."
3351425|NCT02270333|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
3351426|NCT02270333|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training using POWERbreathe Classic threshold loading device .
3351427|NCT02270346|Active Comparator|Treatment group|Intervention: Treatment group received inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device.
3351428|NCT02270346|Sham Comparator|Control group|Sham: Control group received sham inspiratory muscle training (IMT) using POWERbreathe Classic threshold loading device .
3351429|NCT02270359|Other|MI without obstructive CAD|MI without obstructive CAD, with OCT and CMR imaging
3351430|NCT02270372|Experimental|Drug Combination|The drug combination of ONT-10 and varilumab
3259320|NCT01469793|Experimental|DMOT4039A Q3W: Dose Expansion|Participants will receive DMOT4039A at recommended phase 2 dose (RP2D) for Q3W dosing schedule as intravenous infusion Q3W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3351431|NCT02270385|Experimental|Experimental group|The experimental group will be implemented a 16-week PU prevention programme. The PU prevention programme includes an intensive training on knowledge and skills ono PU prevention and also a PU prevention protocol. The purpose of the programme is to equip care staff with PU knowledge and skills and to guide especially health workers and personal care workers in PU prevention.
3351432|NCT02270385|Other|control group|The control group will be provided with the usual PU prevention care
3351433|NCT02270398|Experimental|Dual-task training group|Participants in this group will receive dual-task balance and gait training for half hour and relaxation exercise for another half hour in each session. There will be 3 sessions per week for 8 weeks.
3351434|NCT02270398|Active Comparator|Single-task training group|This group of subjects will participate in single-task gait and balance activities for half hour and single-task cognitive training in sitting position for another half hour in each session. There will be 3 sessions per week for 8 weeks.
3351435|NCT02270398|Active Comparator|Flexibility and strength training group|The subjects in this group will engage in flexibility exercises and upper limb strengthening exercises for one hour in each session. There will be 3 sessions per week for 8 weeks.
3351436|NCT02270411||Healthy Subjects|Healthy subjects.
3351437|NCT02270411||Atopic Dermatitis|Patient has a history of atopic dermatitis for at least 6 months. Subject has clinically confirmed diagnosis of active atopic dermatitis, according to Hanifin and Rajka criteria.
3243268|NCT01316627|Active Comparator|Mirror Retraining Method|"In treating BDD, the cognitive-behavioral technique, mirror retraining, uses ordinary and/or magnifying mirrors to amplify the supposed defect, which teaches patients to see their appearance in a more holistic way. Since BDD patients tend to only focus on their perceived flaws when looking in the mirror, and tend to think about their flaws in negative terms, in mirror retraining, patients learn how to change their negative evaluations of their appearance into more objective and nonjudgmental descriptions. Generally, this method is designed to intentionally exaggerate anxiety regarding appearance concerns through exposures with mirrors. However, using exclusively ordinary and/or magnifying mirrors does not address the internal distorted image that many patients with BDD experience (Rosen et al. 1995, Osman et al. 2004, Veale 2004)."
3243269|NCT01316653|Active Comparator|GROW Smarter|Library based program to promote early literacy
3351438|NCT02270411||Acne Rosacea|Patient has a history of acne rosacea for at least 6 months.
3351439|NCT02270411||Acne Vulgaris|Patient has a history of acne vulgaris for at least 6 months.
3351440|NCT02270411||Psoriasis|Patient has a history of psoriasis for at least 6 months.
3351441|NCT02270411||Hidradenitis Suppurativa (HS)|Patient has a history of HS for at least 6 months.
3351442|NCT02270424|Experimental|Conventional medicine+ placebo TCM|Patients in this group will be given conventional medicine, Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three placebo TCM treatment, which are which are placebo Bufeijianpi granule, placebo Bufeiyishen granule and placebo Yiqizishen granule corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
3351443|NCT02270424|Experimental|conventional medicine+ TCM|Patients in this group will receive Salmeterol / fluticasone based on the classes of medications recommended by 2011 GOLD and Chinese Treatment Guidelines for COPD, and three types of TCM treatment, which are Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule. A herbal extract twice daily for 52 weeks for lower dosage. The three granules are corresponding to the three traditional Chinese syndromes in sequence, which are syndrome of deficiency of pulmono-splenic qi, syndrome of insufficiency of qi of the lung and kidney, syndrome of insufficiency of qi and yin of the lung and kidney.
3243270|NCT01316653|Experimental|GROW Healthier|Healthy lifestyle intervention focused on building healthy lifestyle skills for preschool children and participating parents and building new social networks between the intervention group members.
3243271|NCT01316666||Neurogenic Hypotension|Patients with neurogenic hypotension, which includes those with Pure Autonomic Failure (PAF), Multiple System Atrophy (MSA) and Parkinson Disease (PD)
3243272|NCT01316679||group A|Patients with known HCC
3243273|NCT01316679||Group B|Patients with liver disease but no HCC
3243274|NCT01316679||Group C|Control; patients with no known liver disease or HCC
3243275|NCT01316718|Experimental|Mesalazine Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
3351444|NCT02270437|Experimental|cocktail analgesia|The local infiltration mixture of ropivacaine, fentanyl, adrenaline is used intra-articularly during operation. The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
3351445|NCT02270437|No Intervention|no cocktail injection|The patients in the no cocktail injection group received PCIA morphine postoperatively.
3351446|NCT02270463|Experimental|SL-401|
3351447|NCT02270476||Early diagnosed (ED)|Children diagnosed with CF in the first 4 months of life.
3351448|NCT02270476||Late diagnosed (LD)|Children diagnosed with CF after the first 4 months of life.
3243276|NCT01316718|Placebo Comparator|Placebo Granules|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
3243277|NCT01316731|Experimental|Exercise|
3351449|NCT02270489|Experimental|AFFITOPE® PD01A + Adjuvant|"4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3351450|NCT02270489|Experimental|AFFITOPE® PD03A + Adjuvant|"4 injections of 75µg AFFITOPE® PD03A/ adjuvanted, once every 4 weeks~1 boost immunization 36 weeks after first injection"
3351451|NCT02270489|Placebo Comparator|Adjuvant without active component|"4 injections of Placebo once every 4 weeks~1 administration 36 weeks after first injection"
3243278|NCT01316757|Experimental|Treatment|Patients receive cetuximab IV over 60 minutes, paclitaxel IV over 1 hour, and carboplatin IV over 30 minutes on day 1. Beginning in course 2, patients also receive erlotinib hydrochloride PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3243280|NCT01316809|Experimental|A|Surgical arm
3243281|NCT01316809|Experimental|B|Non-surgical arm
3243282|NCT01316822|Experimental|ARRY-382|
3243283|NCT01316835||Type 2 Diabetes Mellitus, No treatment|
3243284|NCT01316848|Experimental|Fasted dosing followed by fed dosing|Dosing in the fasted state followed by fed dosing
3243285|NCT01316848|Experimental|Fed dosing followed by fasted dosing|Dosing in the fed state followed by fasted dosing
3243286|NCT01316861|Experimental|EMS Acarbose|
3243287|NCT01316861|Active Comparator|Bayer Acarbose|
3243288|NCT01316874|Experimental|AD32 (valrubicin)|800mg, once weekly for 6 weeks
3351452|NCT02270502||Adult patients on the SICU|Adult patients on the surgical intensive care unit (SICU), within 72 hours of admission to the SICU and until SICU discharge. Ultrasound Philips CX50, Frailty Index questionnaire and muscle strength tests.
3351453|NCT02270528|Experimental|HIT1|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. The second attempt, prior to the WCST, this group will perform a warm-up and 5-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3351454|NCT02270528|Experimental|HIT2|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt, prior to the WCST, this group will perform a warm-up and a 5-minute stationary period. The second attempt, prior to the WCST, this group will perform a warm-up and the high intensity interval exercise. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3351455|NCT02270528|Other|CON|This group will participate in the Wisconsin Card Sorting Task (WCST) two times. During the first attempt and second attempt, prior to the WCST, this group will participate in a 15-minute stationary period. All measures of independent variables (pH, lactate, RPE, RPP, and FS) will be the same for all groups.
3351456|NCT02270541|No Intervention|Control|Standard pre-hospital emergency care by the Paramedic Intervention Team, in accordance with their standing operating procedures.
3351457|NCT02270541|Experimental|Telemedicine|In-ambulance teleconsultation by a stroke expert aiming to support the Paramedic Intervention Team by focusing on patient identification, obtaining homeostasis (optimal control of blood pressure, blood oxygenation, temperature, heart rate and rhythm, glycemia), assessment of the patient's neurological status, stroke diagnosis, hospital notification, and patient selection for specific stroke treatment.
3351458|NCT02270554|Experimental|Reinforced staple|Endo GIA Reinforced Reload with Tri-Staple technology
3351459|NCT02270580|Experimental|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
3351460|NCT02270580|Active Comparator|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
3351461|NCT02270593||Placenta previa|first; maternal serum, fetal membranes (placenta) and maternal myometrial samples will be investigated for ADAMTS, Proteoglycans and oxidative/antioxidative enzyme status levels in patients with placental invasion anomalies Placenta Previa totalis by ELISA, western blot, immunohystochemistry and PCR (polymerase chain reaction).
3351462|NCT02270606|Experimental|Treatment(IMRT,fluorouracil,chemotherapy,surgery)|"CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours.~PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity.~SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery.~POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity."
3351463|NCT02270619|Placebo Comparator|Uninterrupted sleep & placebo|Uninterrupted sleep followed by placebo
3351464|NCT02270619|Experimental|Uninterrupted sleep & endotoxin|Uninterrupted sleep followed by endotoxin 0.8 ng/kg of body weight IV bolus
3351465|NCT02270619|Experimental|Partial sleep deprivation & placebo|Partial sleep deprivation followed by placebo
3351466|NCT02270619|Experimental|Partial sleep deprivation & endotoxin|Partial sleep deprivation followed by endotoxin 0.8 ng/kg of body weight IV bolus
3351467|NCT02270632|Placebo Comparator|Arm 1|Placebo
3351468|NCT02270632|Experimental|Arm 2|F8IL10, 30 μg/kg
3351469|NCT02270632|Experimental|Arm 3|F8IL10, 160 μg/kg
3351470|NCT02270658|Experimental|Continuous positive airway pressure|Continuous positive airway pressure therapy (CPAP)
3351471|NCT02270658|Placebo Comparator|Nasal strips|Nasal strips applied to the outside surface of the nose with adhesive.
3351472|NCT02270697||Regular Diagnosis|Difficult in regular diagnosis specimens, assistance with array.
3243289|NCT01316952||LabRx database Oct. 1st 2004 to Sep. 30th 2009|The study cohort from which cases and controls are drawn is all subjects in the LabRx database between Oct. 1st 2004 to Sep. 30th 2009.
3243290|NCT01316965|Experimental|multifaceted prevention program|
3243291|NCT01316965|No Intervention|usual care|
3243292|NCT01316978|Experimental|Experimental|Experimental Ibuprofen
3243293|NCT01316978|Active Comparator|Nurofen|Nurofen Meltlets Orodispersible Tablet
3243294|NCT01316978|Active Comparator|Motrin|Junior Strength Motrin Chewable Tablet
3243295|NCT01316991|Active Comparator|Chewing gum|Subject will chew gum at defined intervals
3243296|NCT01316991|Placebo Comparator|No Gum|No chewing gum will be provided to subject
3243297|NCT01317069|Experimental|Fluorouracil implant|
3243298|NCT01317108|No Intervention|A|Low uPA/PAI-1: Observation
3243299|NCT01317108|No Intervention|B2|High uPA/PAI-1: Observation
3243300|NCT01317108|No Intervention|B3|High uPA/PAI-1: refused randomization
3243301|NCT01317108|Active Comparator|B1|High uPA/PAi-1: CMF chemotherapy
3243302|NCT01317121||Subjects at risk for psychosis|Identification and clinical characterization of subjects with prodromal symptoms will be done in the early diagnosis outpatient center of the University Department of Psychiatry in Hamburg, Germany. Subjects At Risk Mental State (ARMS) for psychosis will be identified if they meet the criteria of the Structured Interview for Prodromal Syndromes (SIPS) (McGlashan et al 2001).
3243303|NCT01317121||Patients with a first episode of schizophrenia|Patients with a first episode of schizophrenia will be recruited from inpatients at the Clinic for Psychiatry and Psychotherapy at the University Hospital (UKE) in Hamburg, Germany. All patients have to meet criteria for DSM-IV and ICD-10 diagnosis for schizophrenia.
3243304|NCT01317121||Healthy control subjects|Healthy control subjects will be recruited from the hospital staff and students at the University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany. They have to be free from any neurological or psychiatric disorder, according to DSM-IV and ICD-10 criteria.
3351473|NCT02270710||Healthy Subjects|Overall in good health Provide informed consent Male and females, age 18 years and older Nonsmokers
3243305|NCT01317134|Active Comparator|Therapy-naive|"This group consists of patients with a newly diagnosed PH (Class I or IV). First blood sampling takes place before initiation of PH therapy (0 months), the following measurements will be performed after 3, 6, 9 and 12 months under specific therapy.~Initiation of standard therapy is performed directly after baseline visit / study inclusion. No special study medication will be used.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood Test"
3351474|NCT02270710||SLE Subjects|Enrolled by Hospital for Special Surgery Diagnosed with Systemic Lupus Erythematosus
3351475|NCT02270723|Active Comparator|"Human Albumin  Behring"|Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
3351476|NCT02270723|Placebo Comparator|Lactated Ringer|Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
3351477|NCT02270749|Active Comparator|hydroxocobalamin injection|25 patients receive the standard treatment of a vitamin B12 deficiency: hydroxocobalamin injection
3351478|NCT02270749|Active Comparator|FitForMe vitamin B12 tablets|25 patients receive a daily dose vitamine B12 tablets
3351479|NCT02270762|Experimental|1) Rest in bed|First evaluation of EIT with patient in bed at 30º of head inclination during 5 minutes.
3351480|NCT02270762|Experimental|2) Passive Verticalization|Second evaluation of EIT with patient in tilt table at 60º of verticalization during 10 minutes.
3351481|NCT02270762|Experimental|3) Rest in bed|Last evaluation of EIT with patient in bed at 30º of head inclination during 20 minutes.
3351482|NCT02270775||Fibromyalgia Patients|"The central Sensitization questionnaire will be filled in by each patients included.~After One week, patients will filled it the questionnaire again to study the reliability."
3351483|NCT02270775||Ankle sprain Patients|The central Sensitization questionnaire will be filled in by each patients included.
3351484|NCT02270775||Healthy Volunteers|"The central Sensitization questionnaire will be filled in by each volunteer included.~After One week, volunteers will filled it the questionnaire again to study the reliability."
3351485|NCT02270788|Experimental|Study Participants|"All participants who consent and are enrolled on the study.~Interventions: Crenolanib, sorafenib, triple intrathecal chemotherapy (methotrexate, hydrocortisone and cytarabine with leucovorin)."
3351486|NCT02270801|Experimental|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
3351487|NCT02270814|Experimental|CACTUX: nab-paclitaxel, cisplatin (or carboplatin), cetuximab|"Up to 6 cycles of CACTUX may be given. The CACTUX regimen consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle followed by~cisplatin given intravenously over 60 minutes on an outpatient basis OR carboplatin AUC5 given intravenously over 30 minutes on an outpatient basis on Day 1 of each 21-day cycle followed by~cetuximab given intravenously on an outpatient basis of Days 1, 8, and 15 of each 21-day cycle~Cisplatin or carboplatin may be given at the discretion of the investigator.~After the completion of 6 cycles of CACTUX, maintenance therapy will be given and consists of:~nab-paclitaxel given intravenously over 30 minutes on an outpatient basis on Days 1 and 8 of each 21-day cycle~cetuximab given intravenously on an outpatient basis on Days 1, 8, and 15 of each 21-day cycle"
3351490|NCT02270853|Other|sleep apnea screening with ApneaLinkTM|This is the only group in the present study. Patients with bronchial carcinoma (or reasonable suspicion) perform sleep screening with ApneaLinkTM at home or during the hospitalization.
3351491|NCT02270866|Experimental|TNM(trademark) - thermoneuromodulation|TNM (thermoneuromodulation device). A standardized active thermal neuromodulation waveform will be used for all patients. The device is noninvasive and does not use electrical stimulation.
3351492|NCT02270879||Main group|Patients having performed bilateral consecutive cataract surgery between 1st October 2012 and 24th April 2014 in a single ophthalmological center (Centro Hospitalar Baixo Vouga, Portugal).
3351493|NCT02270892|Active Comparator|Group A|Left side Ulthera treatment
3351494|NCT02270892|Active Comparator|Group B|Right side Ulthera treatment
3351495|NCT02270905|Experimental|dCELL® Meniscus|
3351496|NCT02270918|Active Comparator|Apixaban with Kcentra|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of prothrombin complex concentrate Kcentra at 25 units/Kg
3351497|NCT02270918|Placebo Comparator|Apixaban with placebo|Oral apixaban will be administered to steady state in healthy volunteers followed by a single infusion of saline
3351498|NCT02270970|Active Comparator|Responders to Belimumab|This Arm is defined as patients who complete 6 months of belimumab without and meet the primary endpoint
3351499|NCT02270970|Active Comparator|Non Responders to Belimumab|This Arm is defined as patients who complete 6 months of study and do not meet the primary endpoint
3351500|NCT02270996||NO Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) BEFORE the implementation of the Antimicrobial Stewardship Program.
3351501|NCT02270996||WITH Antimicrobial Stewardship Program|Prospective cohort of children who undergo appendectomy for acute appendicitis (perforated and non-perforated) WITH the implementation of the Antimicrobial Stewardship Program.
3351502|NCT02271009|Placebo Comparator|Placebo without Al(OH)3|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3351503|NCT02271009|Active Comparator|AllerT (10 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3351504|NCT02271009|Active Comparator|AllerT (25 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3351505|NCT02271009|Active Comparator|AllerT (50 µg with Al(OH)3)|"Five (5) SC injections over a two-month (8-week) period, according to the following schedule:~First three SC injections at weekly intervals.~Fourth SC injection two weeks after the third injection.~Fifth SC injection four weeks after the fourth injection."
3243306|NCT01317134|Active Comparator|Under therapy|"This group consists of patients under ERA monotherapy at timepoint of inclusion. Observation period is one year to detect intraindividual changes in endothelial dysfunction measured by L-arginine/NO-metabolites after 0, 3, 6, 9 and 12 months under investigation.~Specific PAH therapy has been started prior to the study for medical reasons and will be continued throughout.~Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood"
3243307|NCT01317134|Active Comparator|Healthy controls|This group consists of healthy individuals. Sex and age matching is intended. Intervention: a) Device: EndoPAT measurement and b) Biological/Vaccine: Blood
3243308|NCT01317147||Gastric bypass patients|
3243309|NCT01317173||Progressive disease|Serum creatinin level rise more than 2 times
3243310|NCT01317173||Non-progressive disease|Serum creatinin level rise less than 2 times
3243311|NCT01317186||Group I|Stage 2 Non-diabetic Chronic Kidney Disease
3243312|NCT01317186||Group II|Stage 3 Non-diabetic Chronic Kidney Disease
3243313|NCT01317186||Group III|Stage 4 Non-diabetic Chronic Kidney Disease
3243314|NCT01317225|Experimental|17 α hydroxyprogesterone caproate|17α-Hydroxyprogesterone caproate.
3243315|NCT01317225|Placebo Comparator|Placebo|Saline solution.
3243316|NCT01317238|Experimental|CJ Vaccination arm|healthy vaccinia-experienced volunteers who received CJ smallpox vaccine
3351506|NCT02271022||Cohort 1|"Patients (≥18 years of age) with a working diagnosis of NSTEMI and treatment with an OAP agent (ticagrelor, clopidogrel, or prasugrel) either in the ED, or in any case within the timeframe that emergency physicians consider to be upstream-within the first 72 hours of care and at least 4 hours before diagnostic angiography. In addition, only those patients who undergo a diagnostic coronary angiography within 72 hours of ED arrival will be eligible for UPSTREAM."
3351507|NCT02271035|Active Comparator|Deflux|In each patient, Deflux will be injected into one of the ureteral orifices using the the HIT technique.
3351508|NCT02271035|Active Comparator|Vantris|Vantris will be injected into the other ureteral orifice using the same technique and the same amount of implant.
3351509|NCT02271048|Experimental|Group I|"The raters in this group one firstly review ultrasound images numbered from one to 50 using LCD monitor of ultrasound machine and after mandatory rests of 20 minutes, review the remaining ultrasound examinations numbered from 51 to 100 using iPhone display with CubeView at their first visit.(Remote ultrasonography interpretation using the smartphone)~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
3351510|NCT02271048|Experimental|Group II|"The raters in this group II firstly review the ultrasound images numbered from one to 50 using iPhone with CubeView (Remote ultrasonography interpretation using the smartphone) and 51 to 100 with the LCD monitor.~They visited twice with an interval of four weeks and reviewed the ultrasound images using revered devices at each session."
3351511|NCT02271061|Experimental|Kinesio Tape|Taping method will be performed in supine position .The taping technique will be started at tibial tuberosity to medial and lateral epicondyles of the femur. The tape will be cut in I shape with 30 cm. The back paper of tape will be removed from the center of tape and both end of the back paper will be placed at each end of tape. Center of the tape will be placed on the tibial tuberosity with no tension. Participants' knee will be bend approximately 20 - 30 degrees. The tape will be pulled at 1/3 of each end with 75% of available tension along the medial and lateral collateral ligaments and the tibia will be pushed to the back. The end of the tape will be placed with no tension toward the medial and lateral aspects of the thigh .
3351512|NCT02271061|Sham Comparator|Control tape|Apply tape in same technique without tension.
3351513|NCT02271074|No Intervention|Standard of Care|The role of this arm is to provide a baseline measure that can be used to assess the effectiveness of the combination interventions in improving the proportion of individuals entering care within 3 months. Participants in this arm only receive standard post-test counselling after they are issued with a positive HIV result. They are counselled on possible emotional resources, and given information on how to reduce risk of HIV transmission, ongoing positive living, nutrition and healthy lifestyles. These clients are given referral letters and referred to health facilities of their choice that offer HIV care/treatment. They are then followed up at the designated study time points to ascertain entry into care.
3351514|NCT02271074|Experimental|Point of care CD4 testing|Participants in this arm will receive point of care (POC) cluster differentiation 4 (CD4) testing using the PIMA™ CD4 test system.
3351515|NCT02271074|Experimental|Care facilitation|Participants receive a combination of POC CD4 testing and care facilitation.
3351516|NCT02271074|Experimental|Transport support|Participants receive a combination of POC CD4 testing and transport support.
3351517|NCT02271100|Placebo Comparator|palpation guidance|placement of spinal or combined spinal epidural needle using palpation to guide entry position
3351518|NCT02271100|Active Comparator|ultrasound guidance|placement of spinal or combined spinal epidural using ultrasound to guide entry position
3351519|NCT02271113|Experimental|GMI-1271|IV GMI-1271
3351520|NCT02271113|Placebo Comparator|Placebo|IV Placebo
3351521|NCT02271113|Active Comparator|Enoxaparin Sodium (Lovenox®)|SC Lovenox®
3351522|NCT02271126|Experimental|TEG|TEG-driven anticoagulation group: Anticoagulation will be monitored by TEG. Target will be a range of R parameter at Kaolin activated-TEG (R K-TEG) is 16 - 24 seconds; frequency of TEG assays may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When TEG value falls well below the desired range an heparin bolus will be administered, when is too high infusion will be stopped for either 30 or 60 minutes.
3351523|NCT02271126|Active Comparator|APTT|APTT-driven anticoagulation group: anticoagulation will be monitored by aPTT. aPTT ratio target is 1.5 - 2.0 as for actual clinical practice; frequency of aPTT measurements may vary from a minimum of 3 times per day to a maximum of 6 depending on the standardized protocol. When aPTT value falls well below the desired range an heparin bolus will be administered. When too high, infusion will be stopped for either 30 or 60 minutes.
3351524|NCT02271152|Experimental|FAST ablation + PVI|FAST mapping and ablation will be performed in addition to PVI
3243317|NCT01317251|Experimental|Control diet|Diet without dairy products
3243318|NCT01317251|Experimental|Milk diet|Diet with a high content of milk
3351525|NCT02271152|Active Comparator|PVI|Pulnonary vein isolation will be performed
3351526|NCT02271165|Active Comparator|IVIg naive|Patients naïve to IVIg who have active disease responding to corticosteroids or are corticosteroid-dependent, will be also included. Before these patients enter the study, they will receive 3 monthly infusions of IVIg starting with the standard dose of 2gram/kg/month and followed with monthly maintenance of 1 or 2gram/kg according to their response.
3351527|NCT02271165|Active Comparator|non-IVIg naive|Participants already on IVIg will be observed for 12 weeks under their existing IVIg regimen and will undergo measurements of their muscle strength, skin changes, assessments of their daily activities and quality of life (QoL) every 4 weeks at scheduled visits for monthly maintenance IVIg infusions (weeks 0,4,8,12).
3351528|NCT02271178|Experimental|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
3351529|NCT02271178|Other|Conventional treatment|Usual therapy
3351530|NCT02271191|Active Comparator|Nicardipine and Remifentanil|intravenous nicardipine and remifentanil during deliberate hypotension
3351531|NCT02271191|Placebo Comparator|Remifentanil|intravenous remifentanil during deliberate hypotension
3351532|NCT02271230|Experimental|Vitamin D and fish oil|2000 IU per day and 1 g per day of fish oil
3351533|NCT02271230|Placebo Comparator|Vitamin D alone|2000 IU Vitamin D and fish oil placebo
3351534|NCT02271230|Experimental|Fish oil (EPA/DHA) alone|1 g per day of fish oil and vitamin D placebo
3351535|NCT02271230|Placebo Comparator|Fish oil and vitamin D placebo|Placebo for both vitamin D and fish oil
3351536|NCT02271243||Subject with suspected MBI|
3351537|NCT02271243||Subjects without suspected MBI|
3351538|NCT02271256|Experimental|Functional intimate apparel|A functional intimate apparel will be provided to patient to wear it 8 hours daily. Monitoring and observation will be provided during the 6-9 months wearing period.
3351539|NCT02271256|No Intervention|Control|Monitoring and observation will be provided during the 6-9 months wearing period.
3351540|NCT02271269|No Intervention|Usual Care (UC)|"Patients receiving Usual Care for Glaucoma comprising:~Education on effective glaucoma treatment~Routine check-ups with an ophthalmologist and prescription of glaucoma eye drops~Glaucoma counselling [Can be recommended by ophthalmologist for non-adherent patients] covering:~Glaucoma risk factors and symptoms~Management and treatment~Medications and optimal dosage windows~Risks of medication non-adherence~Formulation of a dosing schedule that compliments each patient's lifestyle"
3351541|NCT02271269|Experimental|Value Pricing (VP)|Patient receiving Usual Care for Glaucoma and given the opportunity to receive Value Pricing Subsidies.
3351542|NCT02271282|Experimental|Oral Toremifene/Oral Placebo|"Oral toremifene will be given once on Day 1 and continue daily x10 days. A single combined IV injection of growth hormone releasing hormone (GHRH)/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral placebo on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
3351543|NCT02271282|Experimental|Oral Placebo/Oral Toremifene|"Oral placebo will be given once on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit.~After at least 3 weeks, subjects will return to receive oral toremifene on Day 1 and continue daily x10 days. A single combined IV injection of GHRH/ghrelin (both doses 0.3mcg/kg) will be given on the overnight visit."
3351544|NCT02271295|Experimental|Enoxaparine|69 Child Pugh B7-C10, cirrhotic patients receiving anticoagulation treatment (daily subcutaneous injection of enoxaparin 4000UI/day) during 24 months
3351545|NCT02271295|No Intervention|Control|69 Child Pugh B7-C10, cirrhotic patients not receiving anticoagulation treatment
3351546|NCT02271308|No Intervention|Control group|Residents in control group will receive regular activity in nursing homes.
3351547|NCT02271308|Experimental|Experimental group|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
3351548|NCT02271321|No Intervention|control group|The control group will receive usual care
3351549|NCT02271321|Experimental|experimental group|The experimental group will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
3351550|NCT02271334|Experimental|Treatment T1|One inhalation of 110 mcg A006 DPI. Total 110 mcg
3351551|NCT02271334|Experimental|Treatment T2|One inhalation of 220 mcg A006 DPI. Total 220 mcg.
3351552|NCT02271334|Active Comparator|Treatment R1|One inhalation of 90 mcg Proventil® MDI. Total 90 mcg.
3243319|NCT01317251|Experimental|Cheese diet|Diet with a high content of cheese
3351553|NCT02271334|Active Comparator|Treatment R2|Two inhalations of 90 mcg Proventil® MDI. Total 180 mcg
3351554|NCT02271347|Experimental|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
3243320|NCT01317264|Placebo Comparator|Placebo milk drink|
3243321|NCT01317264|Experimental|Millk drink with oat β-glucan|
3243322|NCT01317264|Experimental|Milk drink with barley β-glucan|
3351555|NCT02271360|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
3351556|NCT02271360|Active Comparator|group B|while in group B (Cabergoline group), 1 tab/day Cabergoline(Dostinex)( 0.5 mg) will be givenat day of HCG injection and for 8 days .
3351557|NCT02271373|Experimental|intervention group|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
3351558|NCT02271373|No Intervention|control group|The control school did not have any interventions.
3351559|NCT02271399|Active Comparator|acetylsalicylic acid|aspirin 300mg tablet by mouth, every 24 hours for postoperatively 10 days
3351560|NCT02271399|Experimental|rivaroxaban|xarelto 10mg tablet by mouth, every 24 hours for postoperatively 10 days
3351561|NCT02271412|Experimental|LY03005|LY03005 40, 80, 120, or 160 mg
3351562|NCT02271412|Placebo Comparator|Placebo|Placebo at 40, 80, 120, or 160 mg
3351563|NCT02271438|Experimental|Part 1: Ibrutinib 840 milligram (mg)|Participants will receive ibrutinib 840 mg (6*140 mg capsules) + 6 placebo capsules on Day 1 of Part 1, Period 1.
3243323|NCT01317264|Experimental|Milk drink with mutant-barley β-glucan|
3351564|NCT02271438|Experimental|Part 1: Ibrutinib 1680 mg|Participants will receive ibrutinib 1680 mg (12*140 mg capsules) on Day 1 of Part 1, Period 2.
3351565|NCT02271438|Experimental|Part 2: Treatment A|Participants will receive ibrutinib, 1680 mg (12*140 mg capsules) + 1 moxifloxacin-matching placebo capsule Day 1of Part 2.
3243324|NCT01317290|Experimental|linseed oil; young|ALA rich linseed oil to younger subjects (18-35 years)
3351566|NCT02271438|Experimental|Part 2: Treatment B|Participants will receive ibrutinib, 840 mg (6*140 mg capsules) + 6 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule.
3351567|NCT02271438|Experimental|Part 2: Treatment C|Participants will receive placebo (12 ibrutinib-matching placebo capsules + 1 moxifloxacin-matching placebo capsule) Day 1 of Part 2.
3351568|NCT02271438|Experimental|Part 2: Treatment D|Participants will receive moxifloxacin 400 mg (1 capsule) + 12 ibrutinib-matching placebo capsules Day 1 of Part 2.
3351569|NCT02271464|Experimental|Maintenance:BEVACIZUMAB|Induction: FOLFOXIRI; Manteinance: Bevacizumab
3351570|NCT02271464|Experimental|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|Induction: FOLFOXIRI; Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE(Metronomic Chemotherapy)
3351571|NCT02271490|Active Comparator|micoinjection according to classical protocole|incubation of sperm in incubation medium
3351572|NCT02271490|Experimental|incubation in follicular fluid|incubation of sperm in follicular fluid prior to microinjection
3351573|NCT02271503|Other|Sequence 1|Subject received a single dose of IPX203 180 mg and/or IPX203 270mg in Period 1, a single dose of CD-LD IR in Period 2, and a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 3.
3351574|NCT02271503|Other|Sequence 2|Subject received a single dose of a single dose of CD-LD IR in Period 1, a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 2, and a single dose of IPX203 180 mg and/or IPX203 270mg in Period 3.
3351575|NCT02271503|Other|Sequence 3|Subject received a single dose of a single dose of Rytary 145 mg and/or Rytary 195 mg in Period 1, a single dose of IPX203 180 mg and/or IPX203 270mg in Period 2, and a single dose of CD-LD IR in Period 3.
3351576|NCT02271516|Experimental|188Re-BMEDA-liposome|"Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~0.42±0.04 mCi/kg~0.63±0.06 mCi/kg~0.84±0.08 mCi/kg~1.05±0.11 mCi/kg~1.26±0.13 mCi/kg~1.47±0.15 mCi/kg"
3351577|NCT02271542|Experimental|between 1-10 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3351578|NCT02271542|Experimental|under 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3351579|NCT02271542|Experimental|upper 60 ages|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
3351580|NCT02271555|Active Comparator|sevoflurane-remifentanil (Group SR)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
3351581|NCT02271555|Placebo Comparator|sevoflurane-saline (Group SS)|Sevoflurane will be initiated, at 8% for anesthesia induction until loss of consciousness will achieve, at which point it will be discontinued. Placebo is 0.9% saline. After the loss of consciousness saline will be administered to Group sevoflurane-saline in the form of intravenous bolus.
3351582|NCT02271568||Obese patients|15 Obese patients (BMI>30) having one of comorbidity (type 2 diabetes, dyslipidemia, or hypertension) and morbid obese patients (BMI>35) accepted for bariatric surgery.
3351583|NCT02271568||Control patients|15 matched controls receiving Intensive medical therapy
3351584|NCT02271607|Experimental|moxibustion|A series of moxibustion sessions within four weeks from the baseline followed by observation period of four weeks.
3351585|NCT02271607|No Intervention|waiting|Waiting period of four weeks followed by moxibustion therapy sessions on the same way with moxibustion group.
3351586|NCT02271620|Other|nonallergic rhinitis|nonallergic rhinitis nasal allergen provocation test
3351587|NCT02271633|Active Comparator|Sodium nitrate|Dietary supplement: 800 mg of nitrate in sodium nitrate added with water to get a 140 mL solution (BASF, Ludwigshafen, Germany)
3351588|NCT02271633|Active Comparator|Beetroot juice|Dietary supplement: 800 mg of nitrate in concentrated beetroot juice (Beet-IT)
3243325|NCT01317290|Experimental|linseed oil; older|ALA rich linseed oil to older, normalweight subjects (BMI <25, age 49-69 years)
3351589|NCT02271633|Active Comparator|Spinach|Dietary supplement: 800 mg of nitrate in a spinach based beverage
3243326|NCT01317290|Experimental|linseed oil older, overweight|ALA-rich linseed oil to older, normalweight subjects (BMI >25, age 49-69 years)
3243327|NCT01317290|Experimental|olive oil|n3-PUFA free control oil to normalweight subjects (BMI <25)
3351590|NCT02271633|Active Comparator|Rocket salad|Dietary supplement: 800 mg of nitrate in a rocket salad based beverage
3351591|NCT02271646|Experimental|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral blocks at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
3351592|NCT02271659|Experimental|Brachytherapy boost|Brachytherapy boost with external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds (110Gy) or high dose rate (14Gy) with iridium-192) only to the prostate. Each center will choose the appropriate brachytherapy technique
3351593|NCT02271659|Active Comparator|Exclusive external beam irradiation|Exclusive external beam radiotherapy. External beam radiotherapy of 46 Gy delivered to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
3351594|NCT02271672|Experimental|XP1000 RF group|Subjects in the XP1000 RF group will be treated with the XP1000 RF device.
3351595|NCT02271672|Sham Comparator|Sham group|Subjects in the Sham group will be treated with the sham XP1000 RF device.
3351596|NCT02271685|Experimental|Overestimate Parkinson's|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
3351597|NCT02271685|Experimental|Overestimate Alzheimers|People are told that overestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
3351598|NCT02271685|Experimental|Underestimate Parkinson's|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Parkinson's disease, whereas those who are accurate are more likely to develop the disease later in life.
3351599|NCT02271685|Experimental|Underestimate Alzheimers|People are told that underestimates on the sound estimation task are associated with being healthy and having a low risk of Alzheimers disease, whereas those who are accurate are more likely to develop the disease later in life.
3351600|NCT02271711|Experimental|Treatment (autologous ex vivo-expanded NK cells)|Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
3351601|NCT02271724||CIDP/MMN newly diagnosed (drug naive)|"Patients, who are suspected to suffer from CIDP or MMN, will undergo a lumbar puncture as a part of the diagnostic procedure. We expect to include 5-10 patients.~Lumbar puncture Blood sample"
3351602|NCT02271724||CIDP/MMN treated|"All patients with established CIDP in maintenance treatment with SCIG or IVIG are recruited from local registries at the outpatient clinic at Department of Neurology, Aarhus University Hospital.~We expect that 10-15 patients with CIDP and MMN treated with SCIG or IVIG eligible for inclusion. Furthermore, we expect to include 10 CIDP and MMN patients in maintenance therapy from the outpatient clinics at Department of Neurology, Odense University Hospital and Department of Neurology, Aalborg University Hospital."
3351603|NCT02271724||Other peripheral neuropathies|Patients who are diagnosed with other causes of peripheral neuropathies than CIDP. We expect to include 20 patients
3351604|NCT02271724||Syptomatic controls|Controls include patients with unspecified neurological symptoms or diseases who will undergo a lumbar puncture at the Department of Neurology at Aarhus University Hospital as part of their diagnostic work up irrespective of this study plus healthy controls. We expected to include 40-50 symptomatic controls
3243328|NCT01317303|Experimental|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
3243329|NCT01317303|Experimental|cTBS-PAS|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
3243330|NCT01317303|Experimental|iTBS|190 seconds of intermittent theta-burst stimulation
3243331|NCT01317303|Experimental|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
3243332|NCT01317329|Other|Clinically prescribed CPAP therapy|Clinically prescribed CPAP therapy
3243333|NCT01317342|Active Comparator|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour
3243334|NCT01317342|No Intervention|Control group: no intervention|Conventional cold storage (IGL-1)
3243335|NCT01317355||cancer patients|in and out patients of 5 German university hospitals currently undergoing cancer treatment
3243336|NCT01317368|Active Comparator|TAP block|"TAP block with Ropivacaine~Wound infiltration with Saline"
3243337|NCT01317368|Active Comparator|Wound infiltration|"TAP block with Saline.~Wound infiltration with Ropivacaine."
3243338|NCT01317368|Placebo Comparator|Placebo|"TAP block with Saline.~Wound infiltration with Saline."
3243339|NCT01317381||ICU patients|Admitted patients to the ICU
3243340|NCT01317420|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every three weeks, monotherapy
3243341|NCT01317433|Experimental|Arm A|Intensified FOLFIRI plus Cetuximab + Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks + skin moisturizers (Dexeryl), sun protection.
3243342|NCT01317433|Active Comparator|Arm B|Intensified FOLFIRI plus Cetuximab + skin moisturizers (Dexeryl), sun protection.
3243343|NCT01317446|Experimental|amine fluoride/stannous fluoride|Amine fluoride/stannous fluoride mouthrinse in addition to mechanical oral hygiene
3243344|NCT01317446|No Intervention|No rinsing|Mechanical oral hygiene only
3351605|NCT02271737|Experimental|Experimental|Improve infection control in health centers; improve home hygiene; improve newborn danger signs recognition by the HC staff, VHSG, and mothers; and improve care coordination between community and health facilities. The above improvements will be through the training of health center staff and VHSG; HC staff and VHSG provide health education to mothers at the health centers and at home respectively; and provide supportive supervision to both HC and VHSG. VHSG will conduct three home visits to the mothers/newborns on the first 24 hours, the 3rd day, and the 7th day after delivery.
3351606|NCT02271737|No Intervention|No Intervention|We do not make any interventions.
3351607|NCT02271750||Dementia|
3351608|NCT02271750||controls|
3243345|NCT01317459|Experimental|Lifestyle counselling|
3243346|NCT01317459|Experimental|No intervention|Care as usual
3351609|NCT02271763|Active Comparator|Palpating neck|Subjects will have their neck palpated by an anesthesiologist to locate their cricothyroid membrane
3351610|NCT02271763|Experimental|Ultrasound neck|Subjects will have their neck scanned with ultrasound by an anesthesiologist to locate their cricothyroid membrane
3351611|NCT02271776|Active Comparator|Galactooligosaccharide|5g 3x per day for 12 weeks
3351612|NCT02271776|Placebo Comparator|maltodextrin|3x per day for 12 weeks (isocaloric to intervention)
3351613|NCT02271802|Experimental|Butyrate|Enema containing sodium butyrate
3351614|NCT02271802|Placebo Comparator|Placebo|Enema containing NaCl
3351615|NCT02271815||Oral Hygiene|Oral Hygiene
3351616|NCT02271828|Active Comparator|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
3351617|NCT02271828|No Intervention|No sentinel lymph node procedure|No sentinel lymph node procedure
3351618|NCT02271841||Before introduction of PVI|Physicians' practices
3351619|NCT02271841||After introduction of PVI|Physicians' practices
3351620|NCT02271867|Active Comparator|Levobupivacaine 0,5%|Levobupivacaine 0,5% 15 ml once
3351621|NCT02271867|Active Comparator|Levobupivacaine 0,5% with epinephrine|Levobupivacaine 0,5% with 1/200000 epinephrine 15 ml once
3351622|NCT02271867|Active Comparator|Ropivacaine 0,75%|Ropivacaine 0,75% 15 ml once
3351623|NCT02271893|Experimental|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
3351624|NCT02271893|Placebo Comparator|placebo|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
3351625|NCT02271919|Experimental|Group I (varenicline and placebo)|Patients receive varenicline PO QD or BID, placebo patches QD, and placebo lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
3351626|NCT02271919|Placebo Comparator|Group II (placebo, nicotine patch and lozenge)|Patients receive placebo tablets PO QD or BID, nicotine patches QD, and nicotine lozenges PO QD beginning on day 9 and continue for 6 weeks. Patients that are abstinent at week 6 may continue treatment for an additional 6 weeks. Patients also receive behavioral smoking cessation counseling consisting of 4 in-person visits, 4 phone visits, and 4 brief supportive phone calls lasting 10-15 minutes each over the 12 weeks of treatment.
3351627|NCT02271932||Surgery|Surgical management with appendectomy consists of hospital admission with initiation of intravenous antibiotics and urgent appendectomy .
3351628|NCT02271932||Non-operative|Non-operative management consists of hospital admission for observation with a minimum of 24 hours of intravenous antibiotics and a minimum of 12 hours nil per os (NPO). With clinical improvement, patients are switched to oral antibiotics and discharged home with a prescription for oral antibiotics to complete a total antibiotic course of 7 days (including the duration of intravenous antibiotics).
3243347|NCT01317485|Experimental|Purulent peritonitis|"Patients with purulent peritonitis are randomised at a 2:1:1 ratio between~Laparoscopic lavage and drainage~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
3243348|NCT01317485|Experimental|Fecal peritonitis or overt perforation|"Patients with fecal peritonitis or an overt perforation are randomised between~Sigmoidectomy with primary anastomosis~Sigmoidectomy with end-colostomy"
3351629|NCT02271958|Experimental|Group 1|Oral administration of 2,5 mg of mifepristone daily for 6 months
3351630|NCT02271958|Experimental|Group 2|Oral administration of 5 mg of mifepristone daily for 6 months
3351631|NCT02271958|Experimental|Group 3|Oral administration of 10 mg of mifepristone daily for 6 months
3351632|NCT02271958|Experimental|Group 4|Oral administration of mifepristone placebo daily for 3 months
3243349|NCT01317498|Placebo Comparator|Standard Monitoring|The patients in the standard monitoring arm will receive routine laboratory monitoring as provided to all patients in public HIV clinics in Vietnam, including CD4 count, complete blood count, and liver functions tests every 6 months.
3351633|NCT02271971|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive a daily 5.000 IU vitamin D3 capsule during 6 weeks.
3351634|NCT02271971|Placebo Comparator|Placebo|Subjects in the placebo arm will receive a daily placebo capsule during 6 weeks.
3351635|NCT02271997|Active Comparator|Ferrous fumarate|40 patients receive ferrous fumarate 3 times a day 200mg
3351636|NCT02271997|Active Comparator|Ferrous gluconate|40 patients receive ferrous gluconate 2 times a day 695 mg
3351637|NCT02271997|Active Comparator|Iron(III)carboxymaltose|40 patients receive a single intravenous shot of ferinject
3351638|NCT02272010|Experimental|Experimental diet|Altered n-6 and n-3 fatty acid intake.
3351639|NCT02272010|Active Comparator|Comparator Diet|Diet standardized to usual n-6 and n-3 intake.
3351640|NCT02272023|Experimental|9 sessions of Intensive Motivational Interviewing|Experimental condition will consist of 9 1-hour intensive motivational interviewing sessions.
3351641|NCT02272023|Active Comparator|1 Standard Motivational Interview plus 8 nutrition classes|The standard MI intervention will consist of a commonly used, single session of MI (50 minutes) plus 8 hours of nutrition education to achieve time and attention equivalence of study conditions.
3351642|NCT02272036|Active Comparator|SMS receiving|Study participants of the SMS group receive in total 14 short messages (SMS) containing time adjusted information on colonoscopy preparation starting 4 days before colonoscopy appointment on their mobile phones.
3243350|NCT01317498|Active Comparator|Virological Monitoring|The patients in the virological monitoring arm will have routine laboratory monitoring as in the standard monitoring arm and in addition will have a viral load test performed every 6 months while in treatment. The first test will be done 6 months after initiating ART.
3243351|NCT01317511|Experimental|Protein|Protein drink
3243352|NCT01317511|Placebo Comparator|Placebo|water
3243353|NCT01317524|Experimental|Homogenized Milk|900 mL homogenized milk is consumed within a mixed meal
3243354|NCT01317524|Experimental|Unhomogenized Milk|900 mL unhomogenized milk is consumed within a mixed meal
3351643|NCT02272036|Active Comparator|Non-SMS receiving|Study participants of the Non-SMS-Group do not receive any SMS before colonoscopy. Preparation is done according to regular written information given to the patient.
3351644|NCT02272049|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI (less for children) to optimize acquisition of images for children and adults vs. proton MR imaging
3351645|NCT02272062|No Intervention|Preferences Not Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, but these preferences will NOT be shared with the treating clinicians.
3351646|NCT02272062|Experimental|Preferences Provided|Subjects will complete a shared decision-making tool and express preferences regarding treatment for coronary artery disease, and these preferences WILL be shared with the treating clinicians.
3351647|NCT02272075|No Intervention|mobile colposcope|
3351648|NCT02272088|Experimental|physical activity-moderate|participants will be walking during 60 minutes in a moderate pace
3351649|NCT02272088|Experimental|intense physical activity|participants will be running during 60 minutes in na intense pace.
3351650|NCT02272101|Experimental|Vitamin D|Vitamin D 4,000 I.U. orally
3351651|NCT02272101|Placebo Comparator|Placebo|Placebo orally
3351652|NCT02272127|Experimental|intercalated treatment|Patients will receive 4 cycles treatment: chemotherapy(day 1) plus intercalated icotinib(day 8-21) every 3 weeks, and then oral icotinib continuously for 2 years or until disease progression or unacceptable toxic effects
3351653|NCT02272153|Active Comparator|Egg refined grain|Eggs with white toast
3351654|NCT02272153|Active Comparator|Egg whole grain|Eggs with whole grain toast
3351655|NCT02272153|Active Comparator|Cereal Refined grain|rice cereal with white toast
3351656|NCT02272166|Active Comparator|propofol|Hypnotic used in this arm is exclusively intra-venous propofol.
3351657|NCT02272166|Active Comparator|sevoflurane|Hypnotic used in this arm is exclusively inhaled sevoflurane.
3351658|NCT02272179|Experimental|ASAP Treatment and Brite|Participants in the experimental arm received the ASAP treatment, during their transition from inpatient to outpatient care, as well as the Brite app for distress tolerance/emotion regulation and safety planning.
3351659|NCT02272179|Active Comparator|Treatment as Usual|Participants in this grouping were studied as they proceed from inpatient to outpatient care, per usual treatment protocols at each site. Participants completed paper safety plans as part of their regular treatment, which is a standard of care for suicidal youth.
3351660|NCT02272192|Experimental|ESDM15 hr/week|Children receive 15 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
3351661|NCT02272192|Experimental|ESDM 25 hr/week|Children receive 25 hours a week of 1:1 intervention at home plus parent coaching using the Early Start Denver Model and following its manual
3351662|NCT02272192|Experimental|EIBI 15 hr/week|"Children receive 15 hours per week of 1:1 intervention at home plus parent training using Early Intensive Behavioral Intervention (EIBI) and following the Manual A Work in Progress"
3351663|NCT02272192|Experimental|EIBI 25 hr/week|"Children receive 25 hours per week of 1:1 intervention at home plus parent training using EIBI and following the Manual A Work in Progress"
3351664|NCT02272218|Other|LAGB|There is only one arm for this study, since this study involves a single cohort receiving the same intervention, laparoscopic gastric banding (LAGB) surgery.
3351665|NCT02272257|Experimental|Early Direct Access Physical Therapy|All care will be administered by one or more physical therapists employed by Temple University. This arm will be early, direct access, physical therapy (immediately evaluation following contacting the front desk administrator or reporting a work injury). Intervention will include interventions matched to their stratified risk category incorporating biopsychosocially oriented education, therapeutic exercise, and manual therapy tailored to the patient's needs.
3351666|NCT02272257|Active Comparator|Physician management|All usual care by physician will be administered by one or more employee health physicians employed by Temple University. Recommendations may or may not include referral to physical therapy.
3351667|NCT02272270|Experimental|Treatment with Study Agent Combination|"Radiation Therapy 2.0GyX30fx, 5 days per week for a total of 60 Gy Temozolomide 75mg/m2 daily throughout radiation Minocycline begins one week prior to chemoradiation, and continues twice a day throughout radiation Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID~Followed by 28 day break followed by~Temozolomide 150-200mg/m2 on days 1-5 out of 28 for up to12 cycles~Minocycline taken twice a day throughout each 28 day cycle for up to 12 cycles:~Arm -2:100mg PO BID Arm -1:150mgPO BID Arm 0: 200mg PO BID Arm 1: 400mg PO BID Arm 1a: 300mg PO BID"
3243355|NCT01317524|Experimental|Skimmed Milk|900 mL skimmed milk and 44 g of butter are consumed within a mixed meal
3243356|NCT01317537|Experimental|Received personal health record|received personal health record access
3243357|NCT01317537|No Intervention|No personal health record|did not receive personal health record
3243358|NCT01317563|Active Comparator|Antioxidant arm|Two capsules twice daily (total daily dose = Vitamin A 10000 IU, Vitamin C 1200mg, Vitamin E 400 IU, Selenium 300mcg)
3243359|NCT01317563|Placebo Comparator|Placebo arm|two capsules twice daily (total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose)
3351668|NCT02272283|Active Comparator|Angio-guided PCI|"Patients allocated to angio-guided PCI are having Percutaneous Coronary Intervention (PCI) with stent implantation guided by routine angiography alone.~Documentary (comparator) intravascular imaging with Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) is performed. The PCI-operator is blinded to the image aquisitions, and the analysis is performed offline later."
3351669|NCT02272283|Experimental|OCT-guided PCI|"After obtaining an angiographic optimal result, patients allocated to OCT-guided PCI have guiding Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IVUS) performed. Online image interpretation is performed by a dedicated OCT-analyst and the PCI-operator. If the OCT reveals; 1) under expansion of the stent with a minimal stent area (MSA) <90% of the distal/proximal reference vessel lumen area and/or; 2) significant acute incomplete stent apposition (defined as more than or equal to 3 stent struts detached >140 microns from the underlying vessel wall), and/or; 3) edge dissection(s) causing significant reduction in minimal lumen area(s) (MLA <4 mm2) and/or, 4) significant residual stenosis (MLA <4 mm2) at the proximal and/or distal reference segment(s), additional intervention is encouraged. The degree of optimization based upon OCT findings is left to the judgement of the PCI-operator."
3351670|NCT02272296|Active Comparator|Jet Injector_main study|Administration of insulin or placebo injection in main study
3351671|NCT02272296|Placebo Comparator|conventional pen, NovoPen IV|Administration of insulin or placebo injection in main study
3351672|NCT02272296|Active Comparator|jet injector_sub study|Administration of insulin or placebo injection in sub study
3351673|NCT02272309|Experimental|Healthy volunteers|Healthy volunteers
3351674|NCT02272309|Experimental|Patients with LUTS|Patients with LUTS
3351675|NCT02272309|Experimental|Patients with LUTS and treatment|Patients with LUTS and treatment
3351676|NCT02272335|Experimental|CB Stress Management|The Cognitive-Behavioral Stress Management (CBSM) intervention arm is a closed, structured group intervention that offers 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the Cancer Wellness and Education (CW) condition as well. i.e. Group Sessions
3351677|NCT02272335|Active Comparator|Cancer Wellness (CW)|Enhanced Breast Cancer Wellness and Education (CW). The CW condition consists of 10 weekly sessions that are roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain (e.g., National Cancer Institute, Susan G. Komen Foundation, American Cancer Society).i.e. Group Sessions
3351680|NCT02272361|Other|laparoscopic sacrocolpopexy|laparoscopic sacrocolpopexy
3351681|NCT02272361|Other|vaginal mesh surgery|vaginal mesh surgery
3351682|NCT02272374|Experimental|e-AVF group|120 elderly with end stage renal disease will undergo AVF creation.
3351683|NCT02272374|Experimental|e-TCC group|120 elderly with end stage renal disease will undergo TCC placement.
3351684|NCT02272374|Experimental|e-AVG group|60 elderly with end stage renal disease will undergo AVG creation.
3351685|NCT02272374|Experimental|ve-AVF group|80 very elderly with end stage renal disease will undergo AVF creation.
3351686|NCT02272374|Experimental|ve-TCC group|80 very elderly with end stage renal disease will undergo TCC placement.
3351687|NCT02272374|Experimental|ve-AVG group|40 very elderly with end stage renal disease will undergo AVG creation.
3351688|NCT02272387|Active Comparator|Vitamin D3 (cholecalciferol) treatment|50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
3351689|NCT02272387|Placebo Comparator|Vitamin D placebo|Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)
3351690|NCT02272400|Experimental|IGRT of prone partial breast|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy.
3351691|NCT02272426|Experimental|CARET + CTI|Combined Aerobic and Resistance Exercise Training (CARET) plus Cognitive Training Intervention (CTI)
3351692|NCT02272426|Sham Comparator|Sham CARET + Sham CTI|Control group Sham Combined Aerobic and Resistance Exercise Training (CARET) plus Sham Cognitive Training Intervention (CTI)
3351693|NCT02272439||Unexplained (male)|Men of couples with a diagnosis of Unexplained infertility (n=15)
3351694|NCT02272439||Unexplained (female)|Women of couples with a diagnosis of Unexplained infertility (n=15)
3351695|NCT02272439||male factor (male)|Men of couples with a diagnosis of male factor infertility (n=15)
3351696|NCT02272439||male factor (female/control)|Women of couples with a diagnosis of male factor infertility (n=15)
3351697|NCT02272439||PCOS (female)|Women of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
3351698|NCT02272439||PCOS (male/control)|Men of couples with a diagnosis of Polycystic Ovarian Syndrome-related infertility (n=15)
3351699|NCT02272439||healthy volunteer (male/control)|Men with a history of no reproductive dysfunction and proven fertility (n=15)
3351700|NCT02272439||healthy volunteer (female/control)|Women with a history of no reproductive dysfunction and proven fertility (n=15)
3351701|NCT02272465||Received blood products during transport|There is no intervention as this is an observational study. The first group will be the patients that received blood products during the helicopter transport from the scene of the injury per standard of care guidelines at the participating institutions.
3243360|NCT01317576|Experimental|Healthy control|This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.
3351702|NCT02272465||Received crystalloid during transport|There is no study intervention. The second group will be the patients that did not receive blood products during the helicopter transport because blood products are not available or part of the standard of care during flight.
3351703|NCT02272478|Active Comparator|Arm A|"Patients not known adverse karyotype~Randomise between~Daunorubicin 60mg/m2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 10 inclusive (20 doses) Mylotarg (GO) 3mg/m2 on day 1 of DA chemotherapy~Versus~CPX-351 100 units/m2 on days 1, 3 and 5"
3351704|NCT02272478|Active Comparator|Arm B|"Patients with known adverse karyotype~5 cycles of Vosaroxin and Decitabine therapy"
3351705|NCT02272478|Active Comparator|Arm C|"Prior to Course 2 - Patients receving DA plus GO in course 1 and MRD positive PC1~Randomise between~Daunorubicin 50mg/2 daily by i.v. infusion on days 1, 3 and 5 (3 doses) Cytosine Arabinoside 100mg/m2 12 hourly by i.v.push on days 1 - 8 inclusive (16 doses)~Versus~Daunorubicin 50mg/m2 daily by i.v. infusion on days 1, 3 and 5 Cytosine Arabinoside 100mg/m2 12 hourly by i.v. push on days 1 - 8 inclusive Cladribine 5mg/m2 daily on days 1 - 5 inclusive~Versus Patients aged 60-69 Fludarabine 30mg/m2 daily on i.v. on days 2 - 6 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 6 inclusive~Patients aged 70+ Fludarabine 25mg/m2 daily i.v. on days 2 - 5 inclusive Cytosine Arabinoside 1g/m2 daily over 4 hours Fludarabine on days 2 - 5 inclusive Idarubicin 5mg/m2 i.v. daily on days 3, 4 and 5 (3 doses)~And Randomisation to receive AC220 or not"
3351706|NCT02272478|Active Comparator|Arm D|"Prior to Course 2 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomisation to receive AC220 or not"
3243361|NCT01317576|Experimental|Non-alcoholic fatty liver disease|This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group
3243362|NCT01317576|Experimental|Type 2 diabetes patients|This group will exist of patients that suffer from type 2 diabetes
3243363|NCT01317589|Active Comparator|fentanyl|active pain treatment with fentanyl patch
3243364|NCT01317589|Experimental|methadone|active pain treatment with methadone
3351707|NCT02272478|Active Comparator|Arm E|"Prior to Course 2 for patients receiving CPX in course 1 and MRD positive PC1~Randomisation between~CPX-351 100 units/m2 on days 1, and 3 (CPX 200) versus CPX-351 100 units/m2 on days 1, 3 and 5 (CPX 300)"
3351708|NCT02272478|Active Comparator|Arm F|"Prior to Course 3 - Patients that received DA plus GO in course 1 and MRD negative PC1~Randomise between Daunorubicin 50 mg/m2 daily by i.v. infusion on days 1 and 3 (2 doses) Cytosine Arabinoside 100 mg/m2 12-hourly by i.v. push on days 1 - 5 inclusive (10 doses)~versus~Intermediate dose Cytarabine (IDAC) schedule Cytosine Arabinoside 1g/m2 daily by 4 hour infusion on days 1- 5 inclusive (5 doses)"
3351709|NCT02272491|Experimental|ZrO2|"Straumann CARES Variobase Abutment RN~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
3351710|NCT02272491|Active Comparator|PFM crown|Straumann Gold Abutment RN Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
3351711|NCT02272504||Standard of care arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines.
3351712|NCT02272504||Biomarker Arm|Chronic liver disease patients who are under going standard of care surveillance for the development of HCC as defined by AASLD guidelines plus the addition of biomarker assays (AFP, AFP-L3 and DCP) every 6 months.
3351713|NCT02272517|Active Comparator|Escitalopram 10-20 mg|Encapsulated tablets once daily for 8 weeks
3351714|NCT02272517|Experimental|Vortioxetine 10-20 mg|Encapsulated tablets once daily for 8 weeks
3351715|NCT02272530||Healthy|100 healthy volunteers in age of 20-75 years
3351716|NCT02272530||Patients|100 patients with stable coronary artery disease and accordingly endothelial dysfunction
3243365|NCT01317628|Other|Lifestyle counseling|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
3243366|NCT01317654||Survivors of TBM trial 2001-2005|
3243367|NCT01317680|Active Comparator|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
3243368|NCT01317680|Placebo Comparator|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy.
3243369|NCT01317693|Experimental|Treatment LI-ESWT|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
3243370|NCT01317706|Active Comparator|Bishop score|
3243371|NCT01317706|Active Comparator|transvaginal ultrasound|
3243372|NCT01317719||Distal Biceps Ruptures|
3243373|NCT01317732|Experimental|MOTIONPOD (TM)|
3243374|NCT01317745|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
3243375|NCT01317745|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
3243376|NCT01317745|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus Novartis MF59 adjuvant
3243377|NCT01317745|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus Novartis MF59 adjuvant
3243378|NCT01317745|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus Novartis MF59 adjuvant
3243379|NCT01317745|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
3243380|NCT01317758|Placebo Comparator|Group 6|Two doses of sanofi H5N1 antigen 15 mcg plus PBS diluent
3243381|NCT01317758|Placebo Comparator|Group 5|Two doses of sanofi H5N1 antigen 7.5 mcg plus PBS diluent
3243382|NCT01317758|Placebo Comparator|Group 4|Two doses of sanofi H5N1 antigen 3.75 mcg plus Phosphate Buffered Saline (PBS) diluent
3243383|NCT01317758|Experimental|Group 3|Two doses of sanofi H5N1 antigen 15 mcg plus GSK AS03 adjuvant
3243384|NCT01317758|Experimental|Group 1|Two doses of sanofi H5N1 antigen 3.75 mcg plus GSK AS03 adjuvant
3243385|NCT01317758|Experimental|Group 2|Two doses of sanofi H5N1 antigen 7.5 mcg plus GSK AS03 adjuvant
3351717|NCT02272543|Active Comparator|Fish surimi peptide powder|Fish surimi peptide powder
3351718|NCT02272543|Placebo Comparator|Placebo|Placebo
3351719|NCT02272556|Active Comparator|Subjects with Type 2 Diabetes|Type 2 DM subjects with HbA1C > 7.5% treated with metformin, sulfonylurea, insulin or combination
3351720|NCT02272556|Active Comparator|Non-Diabetic Obese|Age-matched, non-diabetic obese (BMI > 30 kg/m^3) individuals
3243386|NCT01317771||Proximal Biceps Tendon Tenodesis|
3243387|NCT01317784|Experimental|All tests.|Choose from all 16 possible tests.
3351721|NCT02272556|Active Comparator|Lean, healthy control subjects|Age-matched, lean, healthy control subjects (BMI < 25 kkg/m^3)
3351722|NCT02272569|Experimental|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant by an ab-externa technique with connection from the anterior chamber to the suprachoroidal space
3351723|NCT02272582|Experimental|SOMVC001 Vascular Conduit Solution|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
3351724|NCT02272582|Active Comparator|Standard of Care Heparin-dosed saline|Each patient will serve as his/her own control because each patient will have two graft segments with one segment immersed in SOMVC001 and the other in heparin dosed saline (Standard solution). Patients will be randomized using a simple random sample allocation scheme. At the time of randomization, patients will be assigned an allocation number. Each randomized patient will be implanted with two SVGs, alternating Target Region A (Circumflex or Diagonal) and Target Region B (Right Coronary System or Diagonal) and alternating (proximal vs. distal) segments of the harvested SV. A randomization schedule will be developed to ensure appropriate randomization allocation of the harvested vein segment being grafted to the targeted regions.
3243388|NCT01317784|Active Comparator|HIV/HCV|Choice of 10 different HIV and hepatitis C tests in the bundle.
3243389|NCT01317784|Active Comparator|HIV/Syphilis|Choice of 7 different tests for HIV and syphilis.
3243390|NCT01317784|Active Comparator|HIV only|Choice of 4 rapid tests for HIV only.
3243391|NCT01317810||Subjects with Overactive Bladder (OAB)|Combination of new OAB subjects and existing subjects on OAB medication
3351725|NCT02272595||Arm A - Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
3351726|NCT02272595||Arm B - Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
3351727|NCT02272608||control|patients WHO do not have sleep apnea
3351728|NCT02272608||mild OSAS|mild apnea patients (AHI: 5-15)
3351729|NCT02272608||moderate OSAS|moderate apnea patients (AHI: 16-30)
3351730|NCT02272608||severe OSAS|severe OSAS patients (AHI: more than 30)
3351731|NCT02272621|Experimental|Partial upper hemisternotomy aortic valve replacement|Partial upper hemisternotomy AVR will be performed according to current standard of care practices.
3351732|NCT02272621|Experimental|Full sternotomy aortic valve replacement|Full sternotomy AVR through a standard median sternotomy will be performed according to current standard of care practices.
3351733|NCT02272647|Experimental|IM Plac - Oral Plac - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3351734|NCT02272647|Experimental|IM Plac - Oral Prog - Ghrelin|Day 1: IM Saline Placebo (0.25 ml) Day 10: IM Saline Placebo (0.5 ml) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3243392|NCT01317823|Active Comparator|Bishop score|
3243393|NCT01317823|Active Comparator|transvaginal ultrasound|
3243394|NCT01317836||Patients having pancreatic cystic lesion|
3243395|NCT01317849|Experimental|vitamin supplements|
3243396|NCT01317849|Placebo Comparator|Placebo|
3243397|NCT01317862|Active Comparator|Transcervical foley catheter|
3243398|NCT01317862|Active Comparator|Prostaglandins|
3243399|NCT01317875|Experimental|Ruxolitinib|
3243400|NCT01317888|Experimental|Treated with MAB-425|All patients receive the same treatment of MAb-425 +Iodine 125 in a total of three injections.
3243401|NCT01317914|Experimental|Dietary instruction on Gluten Free Diet|
3243402|NCT01317927|Experimental|Warfarin, Belinostat|Warfarin 5 mg po will be given on Day -14 and Day 3. Belinostat 1000 mg/m² will be given as a 30 minute IV infusion on Days 1 - 5
3243403|NCT01317966||rhIL-11Combinating Low-dose Rituximab|"rhIL-11 (interleukin-11, Juheli) 50 mcg/kg subcutaneously daily for 14 days~Rituximab 100mcg weekly for 4 weeks"
3243404|NCT01317979||Diabetes group I|metabolic surgery, laparoscopicly
3243405|NCT01317992|Experimental|Ibudilast|To receive ibudilast 40mg twice daily for 8 weeks.
3243406|NCT01317992|Placebo Comparator|Placebo|To receive placebo twice daily for 8 weeks.
3351735|NCT02272647|Experimental|IM E2 - Oral Plac - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Placebo 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Medroxyprogesterone (5 mg - for 10 days)
3351736|NCT02272647|Experimental|IM E2 - Oral Prog - Ghrelin|Day 1: IM Estradiol (2.5 mg) Day 10: IM Estradiol (5.0 mg) and Oral Micronized Progesterone 3x/day Day 23: IV push of ghrelin (0.3 ug/kg) + Placebo (for 10 days)
3351737|NCT02272660|Experimental|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision.
3351738|NCT02272660|Placebo Comparator|Normal saline injection|The control group received 2 mL normal saline injection at the same time point.
3351739|NCT02272699|Experimental|Nimotuzumab with Chemotherapy|"Patients will receive neoadjuvant chemotherapy of paclitaxel and cisplatin with concurrent nimotuzumab.~Paclitaxel 175mg per square metre on day 1 and cisplatin 30mg per square metre on day 1 and day 2 every 3 weeks for 2 cycles. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
3351740|NCT02272699|Experimental|Nimotuzumab with radiotherapy|"Patients will receive neoadjuvant radiotherapy with concurrent nimotuzumab. Intensity-modulated radiation therapy(IMRT) of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.~After neoadjuvant treatment, patients will be evaluated by a multidisciplinary teams (MDTs) and esophagectomy will be given for patients with resectable disease."
3351741|NCT02272699|Active Comparator|Surgery alone|Patients in this group will be given esophagectomy without any neoadjuvant treatment. Adjuvant radiotherapy is permit for patients with positive lymph nodes metastasis.
3351742|NCT02272712|Experimental|Cognitive Behavioural Therapy|A 6-week online cognitive-behavioural treatment for insomnia. Each week focuses on a different topic consistent with the cognitive-behavioural theory of insomnia.
3351743|NCT02272712|No Intervention|Control Condition|The online attention matched control arm will provide education about sleep without any focus on the active ingredients that constitute the intervention group.
3351744|NCT02272738|Experimental|Gemcitabine, Nab-Paclitaxel|"A conformal phase I study using 3 plus 3 method.~Chemoradiotherapy while Gemcitabine, Nab-Paclitaxel are administered.~Both Gemcitabine and Nab-Paclitaxel are an interventional agents in this arm.~Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.~Radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions."
3351745|NCT02272751|Experimental|Exercise Intervention|"Subjects allocated to the Exercise arm will aim to undertake a personal prescribed home exercise programme for half an hour three times a week.~Exercises will be progressed at 6 weeks as subjects progress. All exercise sessions will be documented in the logbooks provided.~Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
3351746|NCT02272751|Experimental|Relaxation Intervention|"Subjects allocated to the Relaxation arm will aim to undertake a guided relaxation programme on a CD for half an hour three times a week.~All relaxation sessions will be documented in the logbooks provided. Outcome measures will be assessed at baseline, mid-way (6 weeks) and at the end of intervention (12 weeks)."
3351747|NCT02272764|Other|Itraconazole|Itraconazole or placebo
3351748|NCT02272764|Experimental|ALKS 5461|ALKS 5461 or placebo Sublingual tablet
3351749|NCT02272829|Active Comparator|Active|Participants in this arm will receive the study intervention (sessions with the BHC and the PCP).
3351750|NCT02272829|Placebo Comparator|Health Education|Participants in this arm will receive study sessions about various health topics.
3351751|NCT02272855|Experimental|HF10 plus ipilimumab|
3243407|NCT01318005|Active Comparator|Ortho-Novum® 1/35|Ortho-Novum® 1/35 is an oral contraceptive that contains more progestin.
3243408|NCT01318005|Active Comparator|Ovcon® 35|Ovcon® 35 is an oral contraceptive that contains less progestin.
3243409|NCT01318005|Active Comparator|Microgestin Fe® 1/20|is an oral contraceptive that contains less estrogen.
3243410|NCT01318031|Experimental|DDI|
3351752|NCT02272868|Experimental|Fecal microbiome transplant|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Fecal Microbial Transplant
3351753|NCT02272868|Placebo Comparator|Normal saline|Pretransplant(Rifaximin 400mg tid x 10 days + omeprazole 20 mg night before transplant and day of transplant + miralax 17g tid x 2 days) + Normal saline
3351754|NCT02272881|Experimental|immediate surgical intervention|immediate surgical reconstruction of the pressure ulcer via flap closure or comparable procedure
3351755|NCT02272881|Other|wound care|conservative wound management directed by certified wound care experts
3351756|NCT02272894||Group A|D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
3351757|NCT02272894||Group B|D2 Radical Gastrectomy
3243411|NCT01318044|Active Comparator|Propofol group: propofol|
3243412|NCT01318044|Active Comparator|Thiopental group: thiopental|
3243413|NCT01318057||Wild-Type|Wild-Type are those individuals who were non-carriers of any functional (loss-of-function)variant in CYP2C9 and/or VKORC1 genes
3351758|NCT02272907|Experimental|Non-buttressed, non-imbricated oversewing|Along the staple line, the surgical attending will oversew the length of the staple line using a 2-0 Vicryl suture in a continuous fashion.
3351759|NCT02272907|Experimental|Non-buttressed, imbricated suture line|Along the staple line, the surgical attending will oversew the staple line using a 2-0 Vicryl suture in a continuous, imbricating fashion.
3351760|NCT02272907|Experimental|Buttressed stapling|"The specimen will be stapled utilizing the same stapling device, with Seamguard applied as a buttress. We will use the standard methodology to apply Seamguard as illustrated in the company's Instructions for Use."
3243414|NCT01318057||Carriers|Those patients who were identified as having any functional CYP2C9 and/or VKORC1 polymorphism
3243415|NCT01318096|Experimental|A:Raltegravir + tenofovir+lamivudine|
3243416|NCT01318096|Active Comparator|B:Efavirenz+tenofovir+lamivudine|
3243417|NCT01318148|Experimental|Caspofungin|
3243418|NCT01318161|Experimental|Epidural anesthesia and analgesia|
3243419|NCT01318161|Active Comparator|Patient controlled analgesia|
3243420|NCT01318187|Experimental|Paracetamol|
3243421|NCT01318187|Active Comparator|Morphine|
3243422|NCT01318200|Active Comparator|Transarterial Chemoembolization|
3243423|NCT01318200|Active Comparator|CyberKnife SBRT|
3243424|NCT01318213||Intervention Arm|The intervention will consist of wearing gloves and gowns for all patient contact in the ICUs that are randomized to receive the intervention. During the intervention phases of the study, all healthcare workers (nurses, physicians, nurse extenders, respiratory therapists, social workers etc.) in the intervention group will be required to wear gloves and gowns for patient contact and when entering any patient room. In essence, healthcare workers will apply the CDC Contact Precautions guidelines for ALL patients.
3243425|NCT01318213||Non-intervention - Usual Standard of Care|The non-intervention units will follow their present standard of care. For all of these units, this will consist of healthcare workers following Contact Precautions (gloves and gowns) only for patients known to have antibiotic-resistant bacteria such as VRE and MRSA based on previous admission clinical and surveillance cultures or clinical cultures from the present admission. This represents on average 20-25% of patients on Contact Precautions. For the rest of the patients standard precautions will be followed.
3243426|NCT01318226|Placebo Comparator|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
3243427|NCT01318226|Experimental|ATx08-001 2.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg, twice a day approximately every 12 hours over an 8 day period.
3243428|NCT01318226|Experimental|ATx08-001 7.5 mg bid|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
3351761|NCT02272907|Active Comparator|No reinforcement|Data will be collected on staple lines without any reinforcement as a baseline for leak pressure.
3351762|NCT02272920|Experimental|Renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation: Medtronic Symplicity Flex, Medtronic Symplicity Spyral or St Jude EnligHTN.~Renal denervation is performed within seven days after PCI in patients with acute myocardial infarction and hypertension."
3243429|NCT01318239|Experimental|Standard Chemotherapy with Avastin|
3243430|NCT01318239|Active Comparator|Standard Chemotherapy only|
3243431|NCT01318252|Experimental|AL-54478|AL-54478 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
3243432|NCT01318252|Active Comparator|Latanoprost|Latanoprost 0.005%, single dose, followed 7 days later with 14 days of once daily dosing
3243433|NCT01318252|Placebo Comparator|Vehicle|AL-54478 Vehicle, single dose, followed 7 days later with 14 days of once daily dosing
3243434|NCT01318265|Experimental|Arm1|
3351763|NCT02272920|No Intervention|Control: Standard of care|Standard-of-care follow-up after ACS. Including nurse and physician out-patient visits.
3351764|NCT02272933|Experimental|Wireless Body-Worn Sensors|Elderly patients will wear sensors (Smart Slippers and a belt-clip sensor) as they go about their daily life in a geriatric care center.
3351765|NCT02272959|Experimental|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral stimuli.
3351766|NCT02272959|Placebo Comparator|Placebo Group|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns using only neutral stimuli.
3351767|NCT02272972||Retrospective group|One x-ray image per patient is assessed by the surgeon. The surgeon undergoes an educational intervention (video/poster) and applies the achieved knowledge during the second assessment of the same image. The intervention is not administered to patients, only to an image.
3351768|NCT02272972||Prosp.group (Application of knowledge)|No direct intervention at the patient. The surgeon applies the achieved knowledge during the performance of the fluoroscopy in the operating room. This image is assessed.
3351769|NCT02272998|Experimental|Treatment (ponatinib hydrochloride)|Patients receive ponatinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3351770|NCT02273011||single shot spinal anesthesia|single shot spinal anesthesia for caesarean section was executed for anesthesia, oral analgesic medication was applicated for postoperative analgesia.
3351771|NCT02273011||combuned spinal epidural anesthesia|combined spinal epidural anesthesia for caesarean section was executed for anesthesia, epidural and oral analgesic medication was applicated for postoperative analgesia.
3351772|NCT02273024|Experimental|Exercise|Individuals will participate in weekly supervised and unsupervised exercise sessions prior to HSCT, during hospitalization and till 100 days from HSCT. Exercise will consist of endurance and resistance exercise 3-5 days a week.
3351773|NCT02273024|No Intervention|Usual Care|Usual care will have continue with standard of care treatment without any specific exercise instruction or guidance other than what is provided by the patient education team at the cancer centre.
3351774|NCT02273089||OSA w/o EDS|Males with moderate to severe obstructive sleep apnea without excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
3243435|NCT01318291|Placebo Comparator|Control|
3351775|NCT02273089||OSA w EDS|Males with moderate to severe obstructive sleep apnea with excessive daytime sleepiness will be proposed nocturnal CPAP (ResMed S9 AutoSet) for three months
3351776|NCT02273102|Experimental|TCP Dose Level 1|20mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3351777|NCT02273102|Experimental|TCP Dose Level 2|40mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3351778|NCT02273102|Experimental|TCP Dose Level 3|60mg of Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each. 45 mg/m2 of Tretinoin (ATRA) to be administered orally twice a day (12 hours apart) beginning on day 4 of each 21 day cycle, for up to 16 cycles.
3351779|NCT02273128||CTR Gene in Osteoporosis and Periodontitis|Patients aged between 35 - 60 yrs with Osteoporosis (BMD>-2.5) and Chronic Periodontitis (>3mm Pocket Probing Depth)
3351780|NCT02273154|Experimental|paroxetine and buspirone group|receive paroxetine (20-60mg/d) and buspirone(30mg/d)
3351781|NCT02273154|Active Comparator|paroxetine group|receive paroxetine (20-60mg/d)
3243436|NCT01318291|Experimental|CCRI Group|
3243437|NCT01318304||Pregnant, HIV- negative|This cohort has completed accrual as of 12/28/11.
3243438|NCT01318304||Pregnant, HIV-positive|
3243439|NCT01318304||Non-pregnant, HIV-negative|This cohort has completed accrual as of 12/28/11.
3243440|NCT01318304||Non-pregnant, HIV-positive|This cohort has completed accrual as of 12/28/11.
3351782|NCT02273193||Pregnant Women|Pregnant Women in the first trimester (<13 weeks) of pregnancy and the second trimester of pregnancy.
3351783|NCT02273219|Experimental|AEB071 and BYL719|AEB071, oral, 100-400 mg twice daily BYL719, oral, 200-350 mg daily
3351784|NCT02273232|Active Comparator|Supervised Exercise Group|All PVD patients will get the standard advice regarding exercises but this group will have a constructed exercise program under supervision of Dr. Micheál Newell who is qualified Sports and Exercise Scientist with a Doctorate degree in Integrated Biology. This include six minute walk test, Chair Stand Test and symptoms free distance.
3243442|NCT01318343||Treatment Group 1|Eight (8) subjects will receive one (1) treatment with the eZ8 Large Applicator.
3243443|NCT01318343||Treatment Group 2|Eight (8) subjects will receive two (2) treatments two (2) months apart with the eZ8 Large Applicator.
3243444|NCT01318343||Treatment Group 3|Four (4) subjects will receive one (1) treatment, six (6) months after the previous treatment with the eZ App 8 large applicator to the abdomen. This is the same applicator that is being evaluated in this study. These subjects have been treated on-site at the Laser & Skin Surgery Center of New York by the study doctor.
3243445|NCT01318369|Experimental|Namisol|Namisol (dronabinol) single dose 8 mg
3351785|NCT02273232|Active Comparator|RIPC and supervised Exercise Group|This group will have structured intermitting periods of induced remote ischaemic preconditioning using standard blood pressure cuffs. The cuff will be applied for 5 minutes alternatively with 5 minutes rest to the total of 4 cycles, which needs 40 minutes per day. The RIPC group will receive an exercise program identical to the first group. The total number of days for each participant will be 28 days.
3351786|NCT02273232|Active Comparator|RIPC with Standard Care Group|The patients in this group will receive standard care advice regarding exercise in addition to RIPC as in the 2nd group.
3351787|NCT02273232|Sham Comparator|Control Group (Standard Care)|This group will get the standard advice regarding exercise for PVD patients and all the information available in Out patients clinic settings.
3351788|NCT02273245||thoracic aortgram CTs|A retrospective cohort assessment of thoracic aortogram CTs of male and female adult (age>18) patients presenting with symptoms of AAS.
3351789|NCT02273258|Experimental|Test (T)|SAR342434: single dose injection
3351790|NCT02273258|Active Comparator|Reference 1 (R1)|US-approved Humalog®: single dose injection
3351791|NCT02273258|Active Comparator|Reference 2 (R2)|EU-approved Humalog®: single dose injection
3351792|NCT02273271|Experimental|Imaging arm|18F-FLT-PET/CT and DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 4 cycles of chemotherapy
3351793|NCT02273284|Experimental|Buzzy|Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
3351794|NCT02273284|No Intervention|control - no Buzzy|Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy
3351795|NCT02273297||Pregnant women and their offspring|Ethnically diverse pregnant women and their offspring
3351796|NCT02273349|Experimental|Treatment|Patients with Alpha-1-Antitrypsin deficiency treated with endoscopic lung volume reduction using Lung Volume Reduction Coils (PneumRx Inc.)
3351797|NCT02273362|Experimental|Prevention (erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD for 7 days (depending on the date of surgery, treatment range may be 5-14 days).
3351798|NCT02273375|Experimental|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
3351799|NCT02273375|Placebo Comparator|Placebo|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier
3351800|NCT02273388|Experimental|Volasertib|
3351801|NCT02273401|Experimental|BI 11054 CL|
3351802|NCT02273401|Placebo Comparator|Placebo|
3351803|NCT02273414|Experimental|BIIL 284 BS - rising dose|
3351804|NCT02273414|Placebo Comparator|Placebo|
3351805|NCT02273427|Active Comparator|BIIL 284 BS fasted|
3351806|NCT02273427|Experimental|BIIL 284 BS with high fat meal|
3351807|NCT02273427|Experimental|BIIL 284 BS with low fat meal|
3351808|NCT02273440|Experimental|BIIL 284 BS with theophylline|
3351809|NCT02273440|Placebo Comparator|Placebo with theophylline|
3351810|NCT02273453|Experimental|Songha® Night|
3351811|NCT02273453|Active Comparator|Placebo + Oxazepam|
3351812|NCT02273453|Placebo Comparator|Placebo|
3351813|NCT02273466|Active Comparator|Desipramine alone|
3351814|NCT02273466|Experimental|Desipramine with Crobenetine|
3351815|NCT02273479|Experimental|Asasantin®|
3351816|NCT02273479|Placebo Comparator|Placebo|
3351817|NCT02273492|Experimental|Asasantin ER after a standardized breakfast|
3351818|NCT02273492|Active Comparator|Asasantin ER at fasted state|
3351819|NCT02273505|Experimental|Asasantin (ER)|
3351820|NCT02273505|Active Comparator|Combination of Persantin and ASA|
3351821|NCT02273518|Experimental|Asasantin ER, new formulation I|
3351822|NCT02273518|Experimental|Asasantin ER, new formulation II|
3351823|NCT02273518|Active Comparator|Asasantin ER, present commercial formulation|
3351824|NCT02273531|Experimental|Asasantin ER, new formulation|
3351825|NCT02273531|Active Comparator|Asasantin ER, present commercial formulation|
3351826|NCT02273544|Experimental|Asasantin ER (new formulation - low)|
3351827|NCT02273544|Experimental|Asasantin ER (new formulation - medium)|
3351828|NCT02273544|Experimental|Asasantin ER (new formulation- high)|
3351829|NCT02273544|Active Comparator|Asasantin ER - commercial formulation|
3351830|NCT02273557|Experimental|Asasantin ER (new formulation I - low)|
3351831|NCT02273557|Experimental|Asasantin ER (new formulation III - medium)|
3351832|NCT02273557|Experimental|Asasantin ER (new formulation II - high)|
3351833|NCT02273557|Active Comparator|Asasantin ER (present commercial formulation)|
3351834|NCT02273570|Active Comparator|control|Control group: standard care. The iPTH target in this group is 300-540 pg/ml
3351835|NCT02273570|Experimental|Optimal CKD-MBD control|Optimal CKD-MBD control: in this group the PTH target is150-300 pg/ml to be achieved with a therapeutic algorithm
3351836|NCT02273583|Experimental|Maintenance therapy|73 weeks of continuous oral low dose chemotherapy with cyclophosphamide (CPM) and methotrexate (MTX) following 31 weeks of MAP.
3351837|NCT02273583|No Intervention|Control|31 weeks of MAP.
3351838|NCT02273622|Experimental|hydroxytyrosol 5 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3351839|NCT02273622|Experimental|hydroxytyrosol 20 mg|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3351840|NCT02273622|Placebo Comparator|placebo|each participant will alternately by the three arms of the study (hydroxytyrosol 5 mg and 20 mg and placebo
3351841|NCT02273635|Experimental|andrographolides|Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.
3351842|NCT02273635|Placebo Comparator|sugar tablets|Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.
3351843|NCT02273648||Orsiro|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES) as well as Subjects presenting with~Diabetes (all types) at least 300 subjects should be included and analyzed in this segment~Small vessels (≤2.75 mm) approx. 150 subjects~Chronic total occlusion (CTO) approx. 50 subjects~Acute Myocardial Infarction (incl. STEMI and NSTEMI) approx. 100 subjects~Multivessels approx. 250 subjects~In stent restenosis approx. 100 subjects~Different type of DAPT interruption : <3 months, between 3 and 6 months, after 6 months approx. 300 subjects subjects who stopped <3 months"
3351844|NCT02273661|Placebo Comparator|Control|An aerosol of isotonic saline x 1/ week will be administered during 6 months
3351845|NCT02273661|Experimental|Ambisome|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
3351846|NCT02273674|Experimental|Left rTMS 5 Hz|This group receive transcranial magnetic stimulation at 5 Hz of frequency over left dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
3351847|NCT02273674|Experimental|Right r TMS 1 Hz|This group receive transcranial magnetic stimulation at 1 Hz of frequency over right dorsolateral prefrontal cortex. Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
3351848|NCT02273687|Experimental|Prognostic study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Intervention: Diaphragmatic ultrasound"
3243446|NCT01318369|Active Comparator|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
3243447|NCT01318395|Active Comparator|Aliskiren|
3243448|NCT01318395|Placebo Comparator|Placebo|
3351849|NCT02273700||the Study Population|"The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.~Intervention: Rivaroxaban"
3351850|NCT02273713|Experimental|Nab-Paclitaxel|Nab-Paclitaxel added to first line treatment with Oxaliplatin and Capecitabine
3243449|NCT01318421|Experimental|ELND002|ELND002 sc injection
3243450|NCT01318434|Experimental|EB-1010 25 mg BID|Experimental Active
3243451|NCT01318434|Experimental|EB-1010 50 mg BID|Experimental Active
3351851|NCT02273765|Active Comparator|Raltegravir|Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID
3351852|NCT02273765|Experimental|Efavirenz|Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD
3351853|NCT02273778|Other|Routine radiotherapy treatment plus MRI scan and PET-CT scan|
3243452|NCT01318434|Active Comparator|SSRI/SNRI|Active Comparator
3351854|NCT02273778|Other|Routine radiotherapy treatment|
3351855|NCT02273791||HRT group|Women will be subjected to HRT using Estradiol valerate before FET
3243453|NCT01318434|Placebo Comparator|EB-1010 0 mg BID|Placebo comparator
3243454|NCT01318447|Experimental|CyberKnife SBRT|
3243455|NCT01318460|Active Comparator|Levosimendan|Patients treated with prophylactic administration of levosimendan
3243456|NCT01318460|Placebo Comparator|Placebo group|Patients managed with placebo administration
3243457|NCT01318473|Other|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
3243458|NCT01318486|Active Comparator|Heparin free dialysis standard of care|Standard of care: can be either saline flushes or predilution (on-line or bags)
3243459|NCT01318486|Experimental|Heparin free dialysis with Evodial|
3243460|NCT01318525|Experimental|ALF-5755|
3243461|NCT01318525|Placebo Comparator|Saline solution (0.9% NaCl)|
3351856|NCT02273791||MOS group|Women will be subjected to MOS using sequential clomiphene citrate and gonadotropin before FET
3351857|NCT02273804|Experimental|topiramate|pill
3351858|NCT02273804|Placebo Comparator|placebo|Sugar pill
3351859|NCT02273817|Experimental|Ciclesonide Nasal Spray (Apotex, Inc.)|"Ciclesonide nasal spray~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide.~Strength: 50 μg per actuation.~Batch/Lot number (Expiry date): JM6697 (May 2012)~Manufacturer: Apotex, Inc."
3351860|NCT02273817|Active Comparator|Omnaris™ nasal spray|"Omnaris™ Nasal Spray,~Dosage form: contain the aqueous medium of each metered-dose pump spray formulation unit plus the active ingredient, ciclesonide~Strength: 50 μg per actuation~Batch/Lot number (Expiry date): 131657 (03/2012)~Manufacturer: Sepracor, Inc."
3351861|NCT02273817|Placebo Comparator|Placebo|"Placebo~Dosage form: Contain the aqueous medium of each metered-dose pump spray formulation unit minus the active ingredient, ciclesonide.~Batch/Lot number (Expiry date): JR3808 (Nov 2012)~Manufacturer: Apotex, Inc."
3351862|NCT02273830|Active Comparator|oxygen adjusted|oxygen adjusted to get SpO2> 90% during the walking test
3351863|NCT02273830|Placebo Comparator|control group|oxygen at 3L/min
3351864|NCT02273843|Experimental|High-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
3351865|NCT02273843|Active Comparator|Conventional-dose vitamin D|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
3351866|NCT02273856||Treatment naïve patients with CLL|
3351867|NCT02273856||Treatment naïve patients with iNHL|
3351868|NCT02273856||Relapsed/refractory patients with CLL|
3351869|NCT02273856||Relapsed/refractory patients with iNHL|
3351870|NCT02273882||Preterm Infants 29-35 Weeks Gestation <12 months of age|Preterm Infants 29-35 Weeks Gestation <12 months of age
3351871|NCT02273895|Active Comparator|Control|Scopolamine
3351872|NCT02273895|Active Comparator|MCI|Scopolamine
3351873|NCT02273895|Active Comparator|AD|Scopolamine
3351874|NCT02273921|No Intervention|EEG|A non-invasive EEG recording
3351875|NCT02273934|Experimental|Reablement|Reablement is an intensive, multidisciplinary, client-centered, home-based type of rehabilitation, where ordinary activities of daily living are used for rehabilitative purposes. It is a rehabilitation alternative that may be offered to adults, and there is no lower age limit. An occupational therapist and physical therapist, or nurse, constitutes the key personal, while home helpers, assistants and others with lower education, are the ones who work rehabilitative with the person on a daily basis focusing on self-help.
3243462|NCT01318551|Experimental|Arm 1|
3243463|NCT01318551|Experimental|Arm 2|
3243464|NCT01318551|Experimental|Arm 3|
3243465|NCT01318564||Group 1: Unit-dose - Pill Bottle|Unit-dose (blister) packages used first week, followed second week by pill bottles usage.
3351876|NCT02273934|Active Comparator|Standard treatment|This arm consists of the standard treatment home-dwelling elderly persons receive when applying for home-based help. Some elderly may receive home-based nursing or home help services assisting them in daily activities, while others may receive occupational therapy or physical therapy measures for rehabilitative purposes.
3351877|NCT02273947|Experimental|Arm 1 (ABDC): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351878|NCT02273947|Experimental|Arm 2 (BCAD): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351879|NCT02273947|Experimental|Arm 3 (CDBA): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351880|NCT02273947|Experimental|Arm 4 (DACB): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351881|NCT02273947|Experimental|Arm 5 (EFHG): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351882|NCT02273947|Experimental|Arm 6 (FGEH): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3243466|NCT01318564||Group 2: Pill Bottle - Unit Dose|Pill bottle usage the first week followed second week by Unit-dose (blister) packages.
3243467|NCT01318590|Experimental|Celiac bloc|The experimental arm will consist of the fractional injection on both sides of the celiac trunk, via EUS, of a local anesthetic (10 ml of Bupivacaine 0.5% (gr / ml)) and an injection of steroids (Triamcinolone 40 mg). In this group antibiotic prophylaxis will be administered after administration of sedation (Cephazolin 1gr IV or Gentamycin).
3351883|NCT02273947|Experimental|Arm 7 (GHFE): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351884|NCT02273947|Experimental|Arm 8 (HEGF): BMS-955176|BMS-955176 single dose by mouth for each treatment as specified
3351885|NCT02273947|Experimental|Arm 9 (IJK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351886|NCT02273947|Experimental|Arm 10 (JKI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351887|NCT02273947|Experimental|Arm 11 (KIJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351888|NCT02273947|Experimental|Arm 12 (IKJ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351889|NCT02273947|Experimental|Arm 13 (JIK): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351890|NCT02273947|Experimental|Arm 14 (KJI): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351891|NCT02273947|Experimental|Arm 15 (LMN): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351892|NCT02273947|Experimental|Arm 16 (OPQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3243468|NCT01318590|Sham Comparator|Conservative treatment|Subject will undergo standard EUS without any additional interventions.
3351893|NCT02273947|Experimental|Arm 17 (PQO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3243469|NCT01318616|Experimental|Training group|
3243470|NCT01318642|Active Comparator|Placebo + Gemcitabine|Arm 2: AMG479-placebo IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle
3243471|NCT01318642|Experimental|AMG 479 20 mg/kg + Gemcitabine|ARM 1: AMG 479 20mg/kg IV days 1 and 15 plus gemcitabine 1000mg/m2 IV days 1, 8, and 15 of a 28 day cycle.
3243472|NCT01318655|Experimental|NKTR-118|
3243473|NCT01318655|Placebo Comparator|Placebo|
3351894|NCT02273947|Experimental|Arm 18 (QOP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351895|NCT02273947|Experimental|Arm 19 (OQP): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351896|NCT02273947|Experimental|Arm 20 (POQ): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351897|NCT02273947|Experimental|Arm 21 (QPO): BMS-955176|BMS-955176 single dose by mouth for each treatment specified
3351898|NCT02273986|Experimental|Digoxin|Digoxin
3351899|NCT02273986|Experimental|Digoxin with K-877|Digoxin with K-877
3351900|NCT02273999|No Intervention|Control Group (no device)|No devices were delivered after third molar tooth extraction
3351901|NCT02273999|Placebo Comparator|Placebo group (Inactivated device)|Inactivated devices were delivered after third molar tooth extraction
3351902|NCT02273999|Experimental|Test (activated device)|Activated devices were delivered after third molar tooth extraction
3351903|NCT02274012|Experimental|Afatinib and weekly Paclitaxel|In addition to the standard chemotherapy, afatinib 40 mg orally once daily will be administered starting on the first day of paclitaxel. Translational studies to assess circulating tumor cells at the start of therapy and then at several later time points, including at the time of progression. These studies will assess the correlation of circulating tumor cell numbers with radiographic response and pilot studies will also be conducted to assess HER2 expression, HER2 genomic amplification, HER2 pathway activation and secondary genetic changes in the HER2 coding sequence as well as other pathway components.
3351904|NCT02274051|Experimental|Kinetin|"Kinetin titration phase to 30mg/kg dose or individual max dose taken once daily.~Patients will then proceed to steady state long-term phase at maximum individual dose of kinetin over a 3 year period."
3243474|NCT01318668|Experimental|Nicotine vaccination|18 week treatment with Nicvax
3351905|NCT02274064|Experimental|Intervention|Donors randomly assigned to this group will receive a motivational interview and implementation intention intervention telephone call.
3351906|NCT02274064|No Intervention|Control|Donors randomly assigned to this group will receive a standard donor recruitment telephone call.
3351907|NCT02274077|Active Comparator|EXPAREL|Bilateral, one time injections using 30ml of EXPAREL ((bupivacaine liposome injectable suspension) 1.3% ( 13.3mg/ml)) into the transverse abdominal plane at the time of abdominal component separation. A total of 60cc used with a Bupivacaine concentration of 0.44%.
3351908|NCT02274077|Placebo Comparator|Normal Saline|Bilateral, one time injections of 30ml normal saline into the transverse abdominal plane at the time of abdominal component separation.
3351909|NCT02274090|Placebo Comparator|Placebo Group|Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
3351910|NCT02274090|Active Comparator|1% Metformin|1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
3351911|NCT02274103|Active Comparator|Clinic|BFST delivered to youth with poorly controlled diabetes and their families in the clinic, face-to-face.
3351912|NCT02274103|Active Comparator|Skype|BFST delivered to youth with poorly controlled diabetes and their families using Skype.
3351913|NCT02274116|Active Comparator|Intermittent Hypoxia (AIH)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of low oxygen.~Intervention: AIH - Intermittent Hypoxia - hypoxia air mixture Dosage: 10% oxygen Frequency: 1.5 minutes bouts of low oxygen with 1.0 minute intervals of room air Duration: 38 minutes"
3243475|NCT01318681|Experimental|Pollen provocation with systemic treatment|Subjects are treated with Cetirizine 10 mg after a nasal challenge with a pollen solution
3243476|NCT01318681|Experimental|Pollen provocation with topical treatment|treatment with 25ug fluticasone furoate after a nasal pollen challenge
3243477|NCT01318681|Placebo Comparator|placebo treatment after pollen challenge|Placebo treatment after a nasal challenge with pollen solution
3243478|NCT01318681|No Intervention|control condition|A placebo drug is administered after a sham nasal challenge with a pollen solution
3243479|NCT01318720|Experimental|Manipulation|The experimental group is receiving thoracic spine thrust manipulation and cervical spine non-thrust manipulation.
3243480|NCT01318746||Healthy group|15 persons with normal renal function
3351914|NCT02274116|Sham Comparator|Intermittent Room Air (SHAM)|"Subjects with chronic, motor-incomplete SCI will breath mild bouts of room air.~Intervention: SHAM - Intermittent Room Air - room air mixture Dosage: 21% oxygen Frequency: 1.5 minutes bouts of room air with 1.0 minute intervals also of room air Duration: 38 minutes"
3243481|NCT01318746||Renal failure|15 persons with renal failure (GFR < 60 ml/min)
3351915|NCT02274129|Experimental|Use of Healing cap II|Single arm study using a new healing cap as intervention
3351916|NCT02274142|Experimental|Restorations with Encapsulated material|Restorations performed with encapsulated glass ionomer cement (EQUIA - GC Corp). Capsules with glass ionomer will be activated and applied after selective carious tissue removal in primary molars.
3351917|NCT02274142|Active Comparator|Restorations with Hand-Mixed material|Restorations will be performed with hand-mixed glass ionomer cement (Fuji IX - GC Corp) after selective carious tissue removal in primary molars.
3243482|NCT01318772||Fluoroscopy and Angiography Procedure|Patient that have been scheduled for routine diagnostic fluoroscopy and angiography procedures by their physician.
3243483|NCT01318785|Active Comparator|Compression ArmsleevesType A|Product A: armsleeves of type SoraLife KKl. 2 according to RAL GZ 387
3243484|NCT01318785|Active Comparator|Compression Armsleeves Type B|Product B: armsleeves of type Elvarex KKl. 2 according to RAL GZ 387
3243485|NCT01318798||Patients with post-operative ARF|"Patients developing acute renal failure (ARF) following liver surgery~ARF was defined according to the RIFLE criteria as an absolute increase in serum-creatinine of more than 0.3 mg/dl above baseline, or an increase of more than 1.5 times the pre-operative baseline value within 48 hours after surgery, or a reduction of urinary output less than 0.5 ml/kg/h for at least 6 hrs."
3243486|NCT01318798||Patients without post-operative ARF|Patients with normal kidney function (without acute renal failure (ARF)) following liver surgery
3243487|NCT01318824|Placebo Comparator|I=NIPPV|This group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment.
3243488|NCT01318824|Experimental|II=BiPAP|This group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
3243489|NCT01318837|Experimental|sofilenacin group|
3243490|NCT01318837|No Intervention|control group|age and sex matched patients without OAB symptom who will answer demographic questionaire and OABSS once
3243491|NCT01318850|Experimental|Cognitive Remediation Therapy|Cognitive Remediation Therapy -Frontal/Executive Program (Delahunty)- (Wykes and Reeder, 2005)
3243492|NCT01318850|Active Comparator|Psychoeducation|Symptom Management Module from the University of California. Liberman & Kopelowicz (1995)
3351918|NCT02274155|Experimental|Group 1|Anti-OX40 antibody administration 3 weeks prior to surgical resection
3351919|NCT02274155|Experimental|Group 2|Anti-OX40 antibody administration 2 weeks prior to surgical resection
3351920|NCT02274155|Experimental|Group 3|Anti-OX40 antibody administration 1 week prior to surgical resection
3351921|NCT02274168|Other|Conventional RF catheter ablation|Conventional RF ablation will be performed without using ICD-EG information
3351922|NCT02274168|Other|Investigational RF Catheter Ablation using ICD-EG information|RF Catheter Ablation will be performed using ICD-EG information
3351923|NCT02274181|Experimental|25 mg (approximately equivalent to [(~]) 500 nanocurie|A single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal
3351924|NCT02274194|Active Comparator|Nasal CPAP during titration|Group nasal mask: use of CPAP for one night whit wash out of two weeks
3351925|NCT02274194|Experimental|Oronasal CPAP during titration|Group oronasal mask: use of CPAP for one night with wash out of two weeks.
3351926|NCT02274207|Experimental|silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
3351927|NCT02274207|Active Comparator|non-silver dressing|Frequency and duration : 1 change/1day or according to statue of patient Dosage : 1 ea
3351928|NCT02274220|Experimental|Rapid Advancement of Feeds|Postoperative feeds are initiated on first postoperative day and rapidly advanced over 27 hours.
3243493|NCT01318850|Other|Healthy Controls|Healthy controls
3243494|NCT01318889|Experimental|normal saline|mouth wash of normal saline ,three times a day, 10 cc each time
3351929|NCT02274220|Experimental|Average feeding protocol|Postoperative feeds are initiated on first postoperative day and advanced in using a standardized protocol that best-reflects current feeding practice. Maximum feeding volume is reached at 60 hours.
3351930|NCT02274220|No Intervention|Feeds not affected|Postoperative feeds for patients not eligible for randomization are initiated by the treating clinical team and increased as per clinical team's preference.
3351931|NCT02274233|Experimental|1.5 mg/kg|1.5 mg/kg SP-420 once daily for 14 days
3351932|NCT02274233|Experimental|3 mg/kg|3 mg/kg SP-420 once daily for 14 days
3351933|NCT02274233|Experimental|6 mg/kg|6 mg/kg SP-420 once daily for 14 days
3351934|NCT02274233|Experimental|12 mg/kg|12 mg/kg SP-420 once daily for 14 days
3243495|NCT01318928|Placebo Comparator|Periodontal intervention, sugar pill|Group 1: metronidazole + mechanical treatment in one day, Group 2: Placebo + mechanical treatment in one day Group 3: metronidazole + mechanical treatment on day 1 and 21 Group 4: Placebo + mechanical treatment on day 1 and 21
3351935|NCT02274233|Experimental|24 mg/kg|24 mg/kg SP-420 once daily for 28 days
3351936|NCT02274233|Experimental|9 mg/kg|9 mg/kg SP-420 twice daily for 28 days
3351937|NCT02274246|Experimental|Gadobutrol|Gadobutrol in Healthy volunteers
3351938|NCT02274259|Active Comparator|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
3243496|NCT01318941||Ranibizumab|
3243497|NCT01318954||Subjects on allergen immunotherapy|Measurements of Nitric Oxide by NIOX MINO. This device is now FDA approved.
3243498|NCT01318980|Experimental|Period 1 Cohort 1 - GSK2190915 100mg|Period 1 - GSK2190915 100mg tablet.
3351939|NCT02274259|Active Comparator|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
3351940|NCT02274272|Placebo Comparator|Placebo Capsules|
3351941|NCT02274272|Experimental|ADR-1|Lactobacillus reuteri GMNL-89
3351942|NCT02274272|Experimental|GMNL-263|Lactobacillus reuteri GMNL-263
3351943|NCT02274285|Experimental|Group A (SP0204)|Participants will receive DTaP-IPV/Hib vaccine administered subcutaneously
3351944|NCT02274285|Active Comparator|Group B (control)|Participants will be given a co-administration of DTaP-IPV vaccine and Hib vaccine subcutaneously
3351945|NCT02274285|Experimental|Group C|Participants will receive DTaP-IPV/Hib vaccine administered intramuscularly
3351946|NCT02274298|Active Comparator|CKD feedback and tools|Physicians in these clinics/clusters will receive feedback on their performance for screening and managing CKD quality indicators as well as EMR tools to aid in their performance
3351947|NCT02274298|No Intervention|No Intervention|Physicians in these clinics/clusters will not receive CKD feedback or tools
3351948|NCT02274324|Active Comparator|PD patients- Diet B first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet B and then crossover to diet C.
3351949|NCT02274324|Active Comparator|PD patients- Diet C first|Patients treated with Duodopa at least three months and are stable on medical therapy. The intervention cosists of Dietary Change. Patients that will be randomized to this group will start diet C and then crossover to diet B.
3351950|NCT02274337|Experimental|AC0010|patients receiving avitinib treatment Qd, at different dose stages
3351951|NCT02274350||radiation therapy|Patients treated with either external beam radiation therapy or brachie therapy for localized prostate cancer
3351952|NCT02274363||Brazilian Participants with Chronic Plaque-type Psoriasis|Brazilian participants with plaque psoriasis followed up at teaching and non-teaching specialized dermatology centers will be included in this study.
3351953|NCT02274376||Cohort|
3351954|NCT02274389||Bedaquiline Patient Registry (BPR)|
3243499|NCT01318980|Experimental|Period 1 Cohort 2 - GSK2190915 100mg plus microtracer|Period 1 - GSK2190915 100mg tablet plus [14C] radiolabelled GSK2190915 microtracer solution.
3243500|NCT01318980|Experimental|Period 2 GSK2190915 100mg to proximal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the proximal small bowel via Enterion capsule.
3243501|NCT01318980|Experimental|Period 3 GSK2190915 100 mg to distal small bowel|100mg of ground half 200mg GSK2190915 tablet administered to the distal small bowel via Enterion capsule.
3351955|NCT02274402||adults with glucocorticoids|Adults receiving Prednisone
3351956|NCT02274415|Experimental|PCV vaccine following by the PSV vaccine|Group 1: patients will receive a first boost with 13-valent pneumococcal conjugate vaccine (PCV) (one dose at W0) and then one administration of the PSV vaccines (one dose at W4).
3351957|NCT02274415|Active Comparator|vaccine Pneumo 23|Group 2: patients will receive a single administration of 23-valent pneumococcal polysaccharide vaccine (PSV) (one dose at W4)
3351958|NCT02274428|Other|pneumostem group|single arm, pneumostem treated infants
3243502|NCT01318980|Experimental|Period 4 - GSK 100mg enteric-coated tablet|100mg enteric-coated GSK2190915 coated tablet.
3243503|NCT01318993|Experimental|GSK1605786A|500 milligrams twice daily
3351959|NCT02274454|Active Comparator|1.25mM Calcium-NO oxytocin pretreatment|
3351960|NCT02274454|Active Comparator|2.5mM Calcium-NO oxytocin pretreatment|
3351961|NCT02274454|Active Comparator|5.0mM Calcium-NO oxytocin pretreatment|
3351962|NCT02274454|Active Comparator|1.25mM Calcium-WITH oxytocin pretreatment|
3351963|NCT02274454|Active Comparator|2.5mM Calcium-WITH oxytocin pretreatment|
3351964|NCT02274454|Active Comparator|5.0mM Calcium-WITH oxytocin pretreatment|
3351965|NCT02274467|Active Comparator|Uniport catheter|19 gauge uniport epidural catheter
3243504|NCT01319006|Experimental|GSK1278863A 100mg (X90=13um)|single dose
3243505|NCT01319006|Experimental|GSK1278863A 100mg (x90=29Um)|single dose
3351966|NCT02274467|Active Comparator|Multiport catheter|19 gauge multiorifice epidural catheter
3243506|NCT01319006|Experimental|GSK1278863 100mg (X90=41um)|single dose
3351967|NCT02274480||Breast cancer patients with cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
3351968|NCT02274480||Breast cancer patients without cardiotoxicity|Each patient will undergo a cardiac MRI with DWI. The standard of care in patients with declining LVEF is a cardiac MRI. For this study, those patients will also have the added DWI sequence. For patients who are not already scheduled for a cardiac MRI by their referring physician, and therefore do not have an upcoming standard of care cardiac MRI, a research cardiac MRI with DWI will be added. They will not be charged for the DW-MRI of the heart or any additional images taken as part of that scan. Patients unable to tolerate lying flat for this length of time or to tolerate the scan for any reason will be withdrawn and replaced in the study. After their cardiac MRI, their participation in the study is complete.
3351969|NCT02274506|Experimental|T-Cell Administration|"Cyclophosphamide 60 mg/kg by vein for 2 consecutive days, followed by Fludarabine at 25 mg/m2/day by vein for 5 consecutive days. Fludarabine dose calculated per adjusted ideal body weight.~T-cell product divided into 2 portions. Up to 25% of the genetically modified cells given on first day, with plan to infuse up to 75% of the remaining T-cell dose no sooner than 24 hours after completion of first portion. Second portion should not be given later than 72 hours after first portion. First group of 3 participants receive lowest dose of T-cells. Each new group receive a higher dose of T-cells than the group before it, if no intolerable side effects were seen. Up to 6 dose levels of T-cells will be tested."
3351970|NCT02274519|Experimental|Tai Chi|Group randomized to participate in Tai Chi intervention
3351971|NCT02274519|Active Comparator|Educational|Group randomized to participate in educational intervention
3351972|NCT02274532|Experimental|Patient|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 5 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability, with the option with patients for a 1-week period of take-home testing and associated pre- and post-assessments.
3351973|NCT02274532|Other|Control|Testing will include self-report questionnaires, assessments of activities of daily living (ADL) by an occupational therapist, and biomechanical measures of forces applied to objects and motion of the upper limb collected during commonly-performed tasks. Motion will be recorded using sensors that are attached to the arm and SoftHand. During each session, videos will be obtained of the subjects performing tasks. The experimental data collections are organized into 4 Sessions, which will take place over the course of 1 week, scheduled by the subject's availability. Control subjects will participate in two sessions, including a pre- and post-training assessments.
3243507|NCT01319019|Experimental|GSK961081 100 mcg QD|
3243508|NCT01319019|Experimental|GSK961081 100mcg BD|
3243509|NCT01319019|Experimental|GSK961081 200mcg QD|
3243510|NCT01319019|Experimental|GSK961081 400mcg QD|
3243511|NCT01319019|Experimental|GSK961081 400mcg BD|
3243512|NCT01319019|Experimental|GSK961081 800mcg QD|
3243513|NCT01319019|Active Comparator|Salmeterol 50mcg BD|
3243514|NCT01319019|Placebo Comparator|Placebo|
3243515|NCT01319032||I. Top-level swimmers|
3243516|NCT01319032||II. Control|Other swimmers
3243517|NCT01319058|Active Comparator|Electrocautery tonsillectomy|Children undergoing tonsillectomy and adenoidectomy for obstructive sleep apnea
3243518|NCT01319058|Active Comparator|Debrider tonsillotomy|Children undergoing debrider tonsillotomy + adenoidectomy for obstructive sleep apnea.
3243519|NCT01319058|Active Comparator|Laser tonsillotomy|Children undergoing laser tonsillotomy + adenoidectomy for obstructive sleep apnea.
3243520|NCT01319071||Top-level athletes|
3243521|NCT01319071||Control group|
3243522|NCT01319084||ARMES group|Surgeons who watch Tilepro program before da Vinci Robotic Surgery.
3243523|NCT01319084||normal group|Surgeons who do not watch Tilepro program before da Vinci Robotic Surgery.
3243524|NCT01319097|Other|Sorbion Sachet S|Subject will evaluate Sorbion Sachet S dressing for 4 weeks.
3243525|NCT01319123|Other|wound dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers.
3243526|NCT01319149||No treatment|Patient records would be extracted from the electronic health record system of Southwest Regional Wound Care Center and placed in a separate bin.
3243527|NCT01319162||Women with PCOS|All obese women between 18 and 50 years diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
3351974|NCT02274545|Experimental|H7N9 live attenuated vaccine & inactivated subvirion H7N9 vac.|Participants will receive one dose of the H7N9 vaccine at Days 0 and 28. They will receive one dose of the inactivated subvirion H7N9 vaccine on Day 98.
3351975|NCT02274571|Experimental|Drug|TSEC (Duavee™, combination of CE and BZA)
3243528|NCT01319162||Women without PCOS|All obese women between 18 and 50 years not diagnosed with PCOS referred to a weight reduction treatment program at the Sahlgrenska Obesity Center at Sahlgrenska University hospital
3243529|NCT01319175|Experimental|Training group|
3243530|NCT01319188|Active Comparator|0.5 mg of ranibizumab|
3243531|NCT01319188|Active Comparator|injection + photodynamic therapy|
3351976|NCT02274571|Placebo Comparator|Placebo|Non active comparator
3351977|NCT02274584|Experimental|CAR T cells|Autologous 4th generation anti-CD30 CAR T cells
3351978|NCT02274597||Environmental impact on epitympanic temperature measurment|volunteers exposed to different environmental factors to simulate field settings
3351979|NCT02274610|Experimental|Group A|Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
3351980|NCT02274610|Experimental|Group B|Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
3351981|NCT02274623|Experimental|CTAP101 Capsules|CTAP101 Capsules daily
3351982|NCT02274636|No Intervention|Data collection|This first phase will involve having you report to the research coordinator through email the presence or absence of several symptoms associated with GERD that can occur during sleep. Phase 1 will occur over 14 days (and nights).
3351983|NCT02274636|Active Comparator|Intervention|In the second phase of the study, each subject will be given either a gel containing xylitol or discs containing xylitol to use for 14 days (the duration of the second phase of the study). If given the gel, a small amount (specified in the directions) is to be applied to the mouth lining just before bed. If given the discs, one will be placed on the gums beside a molar in each cheek each night just before bed (specified in the directions). Each subject will be asked to continue to provide daily email communication with the research coordinator detailing symptoms suggesting reflux experienced the prior night during product use as was provided during phase 1 of the study.
3351984|NCT02274701|Experimental|Holistic Needs Assessment|Participants (patients) complete a self-reported paper assessment that asks them to indicate whether they have any emotional, practical, financial and/or clinical concerns. The patient then takes this completed assessment into their consultation. It is then given to the clinician where it informs a discussion based on the patient's needs and concerns as identified by them. A care plan is then written based on this assessment.
3351985|NCT02274701|No Intervention|Control|The control group entails standard care - routine consultation between the patient and clinician.
3351986|NCT02274714||Case (with IBD)|Women aged 18-48 years with regular menstrual cycles AND with an established diagnosis of CD or UC involving the small bowel, colon or both
3351987|NCT02274714||Control (without IBD)|Women aged 18-48 years with regular menstrual cycles and without a diagnosis of CD will qualify for the study
3351988|NCT02274740|Experimental|lixisenatide|"Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).~Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period."
3351989|NCT02274740|No Intervention|metformin|Greater than or equal than 1.5 g/day as background therapy for 10 weeks
3351990|NCT02274779|Experimental|Hight dose IMRT, ELIGARD|"PTV1 PTV5 to 66 Gy in 30 fractions of 2.2 Gy~PTV Pelvis: 54 Gy in 30 fractions of 1.8 Gy~PTV Loge 60 Gy in 30 fractions of 2 Gy 6 Gy A complement of 3 in two additional fractions Gy may be delivered across the lodge PTV.~PTV Relapse Lodge: In addition to treating the PTV Lodge, additional radiation of 6 Gy in 3 fractions of 2 Gy may be made to bring the total dose of 72 Gy in 36 fractions of 2 Gy."
3351991|NCT02274805||Adults presenting for surgery in the neck area|
3351992|NCT02274818|No Intervention|Standard Duty Hour Schedule|IM programs randomized to the currently mandated duty 16 hour standards (maximum work duration of 16 hours for interns and 28 hours for PGY2-3); this schedule may involve night float.
3351993|NCT02274818|Experimental|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
3351994|NCT02274831|Experimental|Email Group|Includes receiving standard of care discharge instructions plus an email after being discharged home from the emergency department, reinforcing their discharge instructions. Included in the email is their physician's name and recommended timing of follow-up visit.
3351995|NCT02274831|No Intervention|Standard of Care|Includes standard of care discharge instructions after being discharged from the emergency department. This included receiving paper copies of their discharge instructions.
3243532|NCT01319188|Sham Comparator|Sham injection|
3243533|NCT01319201||Impaired glucose regulation|This group of subjects was diagnosed as impaired glucose regulation using oral glucose tolerance test.
3243534|NCT01319201||Type 2 diabetes|This group of subjects was diagnosed as type 2 diabetes using oral glucose tolerance test.
3351996|NCT02274883|Experimental|Enriched Protein Fractions|This group is given Infant formula with enriched protein fractions.
3351997|NCT02274883|Active Comparator|Protein Fractions|This group is given Infant formula with protein fractions.
3351998|NCT02274896|Experimental|PD catheter group|All patients will receive the Bayston PD catheter
3243535|NCT01319201||Normal glucose regulation|This group of subjects was considered normal regarding glucose metabolism using oral glucose tolerance test.
3243536|NCT01319214|Experimental|Inderal, neutral cues|
3243537|NCT01319214|Experimental|Inderal, drug cues|
3243538|NCT01319214|Experimental|Placebo, neutral cues|
3351999|NCT02274909|No Intervention|control group|The subjects received no intervention and continued with their daily activities.
3243539|NCT01319214|Experimental|Placebo, drug cues|
3243540|NCT01319227|Experimental|Hip Arthroplasty, ultra-short stem, conventional cup|Hip replacement with a hydroxy-apatite covered ultra-short uncemented femoral stem and a conventional uncemented acetabular cup with hydroxy-apatite covered porous coating and a moderately cross-linked polyethylene cup liner
3352000|NCT02274909|Active Comparator|Pilates group|The exercise protocol of Pilates method consisted of muscle stretching of the upper limbs, trunk and lower limbs before the exercises. Then, exercises involving range of motion and strength of upper limbs, trunk and lower limbs were performed, always associated with breathing in different positions and with increasing repetitions and resistance along the weeks of training.
3352001|NCT02274909|Active Comparator|PNF group|The exercises from the PNF method were performed with stretching, associated to hold-relax technique, for upper and lower limbs. Then, subjects carried out exercises with the upper limbs, in a bilaterally symmetrical pattern, and with the lower limbs, in the asymmetric bilateral pattern. Additionally, scapular and pelvic girdle exercises were done with symmetrical and reciprocal combination.
3352002|NCT02274935|Experimental|Gait and balance exercise|Traditional exercises focusing on gait and balance
3352003|NCT02274935|Experimental|Cognitive training and physical exercise|Gait and balance exercises done in combination with cognitive training (i.e. counting backwards by 7s from 98)
3352004|NCT02274961|Experimental|S-pantoprazole 10mg|S-pantoprazole 10mg Tablet once daily for 4 weeks
3352005|NCT02274961|Placebo Comparator|Placebo|Placebo tablet for the test drug
3352006|NCT02274974|Active Comparator|lidocaine|20 ml of 2% lidocaine.
3352007|NCT02274974|Experimental|lidocaine and epinephrine.|20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000. I.e.: by adding 1/4 from ampoule of adrenaline 1mg./1ml to bottle of lidocaine Hydrochloric acid (HCL) 2% 50 ml(20mg/ml).
3352009|NCT02275000|Experimental|Intervention|5 Day physiotherapy programme at the National Hospital for Neurology and Neurosurgery, Queen Square, London UK.
3352010|NCT02275000|Active Comparator|Treatment as usual|Participants are referred to their local neuro-physiotherapy service and if appropriate placed on a waiting list for inpatient rehabilitation.
3352011|NCT02275013||Early|Levosimendan administration within first hour of post-operative ICU admission
3352012|NCT02275013||Late|Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
3352013|NCT02275039|Experimental|Treatment (MVA-p53 vaccine and gemcitabine hydrochloride)|Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
3243541|NCT01319227|Experimental|Hip Arthroplasty, conventional stem, trabecular-titanium cup|Hip replacement with an uncemented tapered femoral stem and an uncemented acetabular cup with trabecular-Titanium backside and E-vitamin-treated polyethylene cup liner
3352014|NCT02275078|Other|Interventional|The program consists of 3 components: 1) COPD self-management using an Action Plan; 2) Telesystem-Phone self-assessment/reporting system; and 3) Nurse case manager support.
3352015|NCT02275091||Diabetes|Children with diabetes type 1 , 12-21 years old
3352016|NCT02275091||Healthy|Healthy children 12-21 years old
3352017|NCT02275104||Ventricular arrhythmias|
3352018|NCT02275104||Persistent atrial fibrillation|
3352019|NCT02275130|Experimental|Calcium Hydroxyapatite|30 patients with glottic insufficiency treated operatively with augmentation of vocal cords with injection technique
3352020|NCT02275143||CT TAP scan|Suitable patients will be identified after consultant radiologists have approved a request for cancer routine CT TAP scan.
3352021|NCT02275169|Experimental|Treated|Urofollitropin 150 IU ampoules three times a week for three months
3352022|NCT02275169|Placebo Comparator|Controls|Placebo ampoules three times a week for three months
3352023|NCT02275182|Experimental|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
3352024|NCT02275182|Placebo Comparator|Controlled|0.5μg/kg Saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
3352025|NCT02275221||Hepatitis B and C|Hepatitis B and C
3352026|NCT02275234||Retrospective|Patients who survived cardiac arrest >3 months prior to the start of the study and a close family/friend,will be invited to attend an outpatient clinic
3352027|NCT02275234||Prospective- psychological intervention|In patients who survived cardiac arrest and a close family/friend,will be invited to attend an outpatient clinic
3352028|NCT02275247|Experimental|Intervention 'Stellate Ganglion Block'|Experimental patients will receive a stellate ganglion block with 0.25% ropivacaine 6-8mL on the right side at the level of the sixth cervical vertebrae (C6) before surgery.Then the catheter will be attached to a single use patient-controlled analgesia pump containing 0.2% ropivacaine 150 mL, which will be infused at 2 mL/h.
3352029|NCT02275247|No Intervention|without 'Stellate Ganglion Block'|In the control group, every thing will be conducted as a matter of routine without intervention.
3352030|NCT02275260|Experimental|All patients|All patients undergo cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI), Transesophageal (or Intracardial) Echocardiography and paperbased neurocognitive testing
3243542|NCT01319240|Experimental|IDegLira|
3243543|NCT01319240|Active Comparator|IDeg|
3243544|NCT01319240|Active Comparator|Lira|
3243545|NCT01319253||Cayston Only Cohort|This cohort will be on a previously established medication regiment of Cayston inhaled antibiotic alternating regimen every other month.
3352031|NCT02275273||Patients with adnexal masses|Every patient that are at least 18 years old with a planned pelvic magnetic resonance imagery and an adnexectomy within the institution.
3352032|NCT02275286|Experimental|Trabectedin+Radiotherapy|Trabectedin 1.3 or 1.5mg/m2 and radiotherapy 30Gy or 45Gy.
3243546|NCT01319253||Tobi Only Cohort|This Cohort will be on a previously established medication regiment that includes Tobi inhaled antibiotic regimen alternating every other month.
3243547|NCT01319253||Cayston and Tobi Cohort|This Cohort will be on a previously established medication regiment that includes Cayston and Tobi inhaled antibiotic alternating every other month
3352033|NCT02275299|Experimental|Iguratimod and MTX combination|Drug:Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid) Drug:MTX 2.5 mg/tablet, taken orally once a week, 4 tablets/week
3352034|NCT02275299|Active Comparator|Leflunomide and MTX combination|Drug: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid) Drug: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week
3352035|NCT02275325|Experimental|Preoperative rehabilitation|Patients that have a preoperative vestibular rehabilitation before vestibular schwannoma surgery in addition to the usual postoperative vestibular rehabilitation
3243548|NCT01319266|Experimental|Normal Renal Function|Subjects with normal renal function
3243549|NCT01319266|Experimental|Mild Renal Impairment|Subjects with mild renal impairment (defined by an estimated creatinine clearance of > 50 and up to 80 mL/min)
3352036|NCT02275325|No Intervention|Usual|Group of patients that solely have a postoperative vestibular rehabilitation after vestibular schwannoma surgery
3352037|NCT02275351|Experimental|Active Arm 1|Topical SM04554 0.15% solution, applied once a day for 90 days
3352038|NCT02275351|Experimental|Active Arm 2|Topical SM04554 0.25% solution, applied once a day for 90 days
3352039|NCT02275351|Placebo Comparator|Vehicle Arm|Topical vehicle solution, applied once a day for 90 days
3352040|NCT02275377|Experimental|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 40% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 8 weeks.
3352041|NCT02275377|Placebo Comparator|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance.
3352042|NCT02275377|No Intervention|Normotensive|The normotensive control group (healthy) will go through the same initial evaluation without performing inspiratory muscle training.
3352043|NCT02275390|Experimental|Nurse-led Psycho-education [SPBB: Self-learning program]|"The Nurse-led Psychoeducation Program is comprised of eight 2-hour sessions held at every two weeks (over 4 months). The program consists of five themes: (a) orientation and engaging and understanding of mental health/illness, its related behaviors and community support resources; (b) working collaboratively and empowering and minimizing resistance and challenges using motivational interviewing approach; (c) effective interpersonal and communication skills; (d) strategies in coping with mental illness, sleep hygiene and allaying anxiety; and (e) self-review and evaluation and establishing a realistic plan for future.~[Note: The participants in the SPBB will complete the self-help and problem-solving manual (5 modules) for caregivers of people with psychotic disorders over 20 weeks, together with an orientation, understanding about psychosis and its care and 4 review sessions.]"
3352044|NCT02275390|Active Comparator|Usual Psychiatric Outpatient Care|"Routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study~[Note: for SPBB trial, routine psychiatric outpatient care provided by two psychiatric outpatient clinics under study]"
3352045|NCT02275403|Experimental|Arm A: Standard care plus acupuncture|Medication taken to manage the symptom burden of CIPN plus acupuncture
3352046|NCT02275403|Active Comparator|Arm B: Standard care alone|Medication taken to manage the symptom burden of CIPN
3352047|NCT02275416|Experimental|Ipilimumab & UV1 vaccine & GM-CSF|Ipilimumab (3 mg/kg) every 3rd week for a total of 4 doses. GM-CSF (75 μg) followed by UV1 vaccine (300 μg) will be injected intradermally in the lower abdomen before and between treatments of ipilimumab and thereafter every 4th week up to 28 weeks, and thereafter at week 36 and 48.
3352048|NCT02275429|Other|Runners|Each year, about 1,200 runners residing on Reunion Island take the start of the Madmen's Diagonal ultramarathon. Among those, 500 runners will be selected at random and will receive a letter informing them of the study and requesting their participation. Those who accept are to contact the study team. Among those volunteers, 100 runners will be selected randomly and included in the study. They will undergo a blood test the day before the race starts (day 0, when they retrieve their race number), upon completion of the race, and upon days 7 and 28.
3352049|NCT02275455|Experimental|Participants with autism|
3352050|NCT02275455|Experimental|Aged-matched controls|
3352051|NCT02275468|Placebo Comparator|Control Group|Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90~110g/L.
3352052|NCT02275468|Experimental|Fu-zheng-qu-zhuo oral liquid Group|Patients of FZQZ Group received Fu-zheng-qu-zhuo (FZQZ) oral liquid 20ml every time, and three times a day combined with integrated therapy. The integrated therapy was same to Control Group.
3352053|NCT02275494||shortening group|Shortening group where the operated leg was more than 5mm shorter compared with the contralateral side
3352054|NCT02275494||Restoration group|the restoration control group where the operated leg was within 5mm shortening and 9mm lengthening compared with the contralateral side
3243550|NCT01319266|Experimental|Moderate Renal Impairment|Subjects with moderate renal impairment (defined by an estimated creatinine clearance of 30-50 mL/min)
3243551|NCT01319266|Experimental|Severe Renal Impairment|Subjects with severe renal impairment (defined by an estimated creatinine clearance of less than 30 mL/min)
3243552|NCT01319266|Experimental|End Stage Renal Disease (ESRD)|Subjects with ESRD (defined as being on hemodialysis for at least 6 months prior to enrollment and be receiving standard in-center dialysis treatments three times a week)
3243553|NCT01319279|Experimental|Normal Hepatic Function|Intervention Drug: Hydrocodone bitartrate extended-release tablet
3243554|NCT01319279|Experimental|Moderate Hepatic Impairment|Intervention Drug: Hydrocodone bitartrate extended-release tablet
3243555|NCT01319292||Asthma children|children with asthma symptoms through screening
3243556|NCT01319292||normal children|children without symptoms of asthma
3243557|NCT01319305||BREATHE I participatants|
3243558|NCT01319331|Experimental|Alpha-1 Antitrypsin (AAT, Aralast NP)|Alpha-1 Antitrypsin (AAT, Aralast NP) as prescribed for study duration
3259321|NCT01469793|Experimental|DMOT4039A Q1W: Dose Escalation|Participants in different cohorts will receive DMOT4039A at various escalating dose levels, starting with a dose 33% of MTD for Q3W dosing schedule, as intravenous infusion every week (Q1W) to determine the MTD of DMOT4039A for until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3352055|NCT02275494||Lengthening group|The lengthening group where the operated leg became more than 9mm longer compared with the contralateral side.
3352056|NCT02275507||Women Undergoing Scheduled Cesarean Delivery|We will be recruiting women who are scheduled for an elective repeat or primary cesarean delivery.
3352057|NCT02275520|Other|IO access|Performed intraosseus access device during simulated cardiopulmonary resuscitation
3352058|NCT02275533|Experimental|Arm I (nivolumab)|Patients receive nivolumab IV over 60 minutes once every 2 weeks. Treatment repeats every 2 weeks for 46 cycles in the absence of disease progression or unacceptable toxicity.
3352059|NCT02275533|Active Comparator|Arm II (observation)|Patients undergo standard of care clinical observation for up to 2 years. Upon disease relapse, patients may cross-over to Arm I.
3352060|NCT02275559|Experimental|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
3352061|NCT02275559|Active Comparator|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
3352062|NCT02275572|Experimental|Pharmacist Intervention|Primary care pharmacist apply the GP-GP algorithm to each drug with the support of STOPP criteria, Beers and / or recommendations CatSalut. The pharmacist submit to doctor his findings and reach a consensus and decide which recommendations will be presented to patient.
3352063|NCT02275572|No Intervention|Control|Usual procedure.
3352064|NCT02275585||Cirrhosis|Patients with cirrhosis will be followed looking about the event of portal vein thrombosis
3259322|NCT01469793|Experimental|DMOT4039A Q1W: Dose Expansion|Participants will receive DMOT4039A at RP2D for Q1W dosing schedule as intravenous infusion Q1W until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (up to approximately 2.5 years).
3259323|NCT01469806||1 - PFJ|Patients who require primary partial knee arthroplasty of the patello-femoral joint.
3352065|NCT02275598|Experimental|BV-ABVD|Treatment will consist of two three-weekly doses of Brentuximab vedotin, followed by standard treatment, ABVD (3 o 6 cycles q4w).
3352066|NCT02275650|Experimental|nbUVB|2 SED dose of nbUVB will be given every other week for this intervention group.
3352067|NCT02275650|No Intervention|control|No nbUVB illumination will be given for the control group.
3352068|NCT02275663|Experimental|Azacytidine plus FLAG|"Azacytidine 75 mg/m2 = mg IV in 100 ml Normal Saline (NS) over 30 minutes on days -5 t0 -1~G-CSF 5 mcg/kg subcut on days 0 to + 6~Fludarabine 30mg/m² in 100ml NS IV daily over 30min., on Days +1 to +5~Cytarabine 2gm/m² = 500ml NS IV daily over 4h, on Days +1 to +5 Start 4h after completion of fludarabine infusion."
3352069|NCT02275676||Inflammatory bowel disease|Patients with active and inactive inflammatory bowel disease
3352070|NCT02275689|Active Comparator|Arthrocopic acromioplasty|Surgical intervention with arthroscopic acromioplasty, bursectomy and subacromial decompression
3352071|NCT02275689|Active Comparator|Radiofrequency microtenotomy|Surgical intervention With arthroscopic radiofrequency microtenotomy
3352072|NCT02275689|No Intervention|Physical therapy|Muscle strength training, home trainings programme
3352073|NCT02275702|Placebo Comparator|Group 1|saline solution IV, bolus
3352074|NCT02275702|Active Comparator|Group 2|0,1mg/kg systemic dose of dexamethasone, bolus
3259324|NCT01469832|Experimental|Subretinal injection of MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3259325|NCT01469845|Active Comparator|hypertonic saline and usual care|
3352075|NCT02275715|Experimental|Parent Training Program (PT-F)|Treatment group
3352076|NCT02275715|No Intervention|Waitlist|Control group in which parents randomized to this group will be offered the PT-F at the end of the 20 week study period to address their child's feeding issues.
3352077|NCT02275728|Experimental|Pelvic Floor Muscle Training(PFMT)|The conducted training by two groups, consisting of phasic contractions (3 sets of 10 repetitions of maximal contraction for two seconds to double or triple rest), endurance (two sets of six repetitions of sustained contractions of 6-10 seconds with the same rest time) and training effort, requesting the anticipated contraction of the abdominal pelvic floor coughing effort. We used the same protocol in the supine position, sitting and standing, as evolution of the patient. Both were treated 2 times per week, 20 minutes, totaling 8 sessions.
3259326|NCT01469845|Active Comparator|usual care (oxygen therapy)|
3259327|NCT01469858|Experimental|study group|fMRI
3352078|NCT02275728|Active Comparator|EMG Biofeedback treatment|In this group, the same protocol of the TMAP will be held, however, emg biofeedback is used during training for 20 minutes, 2 times a week, 8 sessions.
3352079|NCT02275728|No Intervention|no treatment|In this group, will be held only the initial assessment, you will not receive treatment for a month and will be reevaluated after being serviced this period.
3259328|NCT01469871|Active Comparator|Hypafix Transparent dressing|The Hypafix Transparent dressing, a stretchable dressing, will be used to treat the patients in this group
3259329|NCT01469871|Active Comparator|Mepore Pro dressing|The Mepore Pro dressing, a self-adhesive perforated dressing, will be used to treat the patients in this group
3259330|NCT01469871|Active Comparator|Mepilex Border dressing|The Mepilex Border dressing, a self-adherent soft silicone dressing, will be used to treat the patients in this group
3259331|NCT01469884|Experimental|Certican®|Arm1(conversion):Certican®+mycophenolate+prednisone
3259332|NCT01469884|Active Comparator|Tacrolimus or Cyclosporine|Arm2(maintained):Tacrolimus or Cyclosporine+mycophenolate+prednisone
3352080|NCT02275754|Experimental|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
3352081|NCT02275754|Active Comparator|PN only|Patient Navigation ONLY. Participants assigned to this group will be assisted by the patient navigator with their health-related needs. Navigation will occur ONLY on contact with navigators initiated by the study participants.
3352082|NCT02275793||high PH and normal PVR|Group I, diastolic heart failure with high PH and normal PVR
3352083|NCT02275793||high PH and high PVR|Group II, diastolic heart failure with high PH and High PVR
3352084|NCT02275793||normal PH and normal PVR|Group III, no heart failure, normal PH and normal PVR
3352085|NCT02275806|Other|All enrolled patients|"Induction Chemotherapy Cycle 1 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 1 and 8~Concurrent Chemotherapy Cycles 2-4 - Irinotecan 65 mg/m2 and Cisplatin 30 mg/m2 on days 22 and 29, days 43 and 50, and days 64 and 71 along with radiation therapy of 60-70 Gy in 2 GY fractions on days 22 -71."
3352086|NCT02275832|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the beard.
3352087|NCT02275832|Placebo Comparator|Placebo|Placebo is applied twice daily to beard.
3352088|NCT02275845|Experimental|intervention|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg. All the subjects are receiving a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
3352089|NCT02275845|Active Comparator|control diet|a diet which contains a 2000 calories/day diet, with an adequate distribution of carbohydrates during the day.
3352090|NCT02275858|Experimental|Stiffening wire first|This arm will use the stiffening wire first followed by the placebo wire
3243559|NCT01319344|Experimental|Eplerenone|
3243560|NCT01319357|Placebo Comparator|Placebo|Placebo
3243561|NCT01319357|Active Comparator|Saxagliptin|saxagliptin 5 mg/day during 6 weeks
3243562|NCT01319370|Placebo Comparator|vehicle of 5% Minoxidl topical foam|vehicel foam in twice daily application in temple and vertex region
3352091|NCT02275858|Placebo Comparator|Placebo wire first|This arm will use the placebo wire first followed by the stiffening wire
3352092|NCT02275871|Experimental|MRI and CESM|High risk patients will get standard of care screening MRI and study CESM on the same day.
3352093|NCT02275884|Active Comparator|Dark chocolate (85% cocoa)|Patients will initially receive 50 grams of dark chocolate (85% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of white chocolate (0% cocoa) b.i.d. for another week.
3352094|NCT02275884|Sham Comparator|White chocolate (0% cocoa)|Patients will initially receive 50 grams of white chocolate (0% cocoa) b.i.d. for one week. Patients will then cross over to intake of 50 grams of dark chocolate (85% cocoa) b.i.d. for another week.
3352095|NCT02275897|Experimental|Slow Speed|Slow group patients will receive spinal injection over 60 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
3352096|NCT02275897|Experimental|Fast Speed|Fast group patients will receive spinal injection over 15 seconds. Vital signs monitored every minute after injection. Hypotension is treated with IV Phenylephrine or Ephedrine.
3352097|NCT02275910|Experimental|E7090 Arm|Oral, starting dose 1 mg once a day, dose escalation in part 1. Cycle 0 is for 7 days. For Cycle 1 and onward, each cycle is 28 days long. The Cycle 0 is set up for PK analysis of a single dose of E7090. In the following Cycle 1, subjects will be administered E7090 QD, and the PK and safety will be assessed for 28 days. One or two doses may be selected from part 1 for Part 2. E7090 will be administered continuously once a daily. Subjects can continue treatment unless they meet discontinuation criteria.
3352098|NCT02275936|Experimental|Group 1 - 50 mg|Every 12 hour oral dosing of N91115 for 28 days
3352099|NCT02275936|Experimental|Group 2 - 100 mg|Every 12 hour oral dosing of N91115 for 28 days
3352100|NCT02275936|Experimental|Group 3 - 200 mg|Every 12 hour oral dosing of N91115 for 28 days
3352101|NCT02275936|Placebo Comparator|Group 4 - Placebo|Every 12 hour oral dosing of placebo comparator for 28 days
3352102|NCT02275949|Experimental|Study group|acupuncture, electroacupuncture and intradermal acupuncture are done at every session.
3352103|NCT02275949|Sham Comparator|Control group|Mock transcutaneous electrical nerve stimulation(mock TENS) and sham intradermal acupuncture are carried out.
3352104|NCT02275962|Experimental|K-877|K-877
3352105|NCT02275962|Experimental|K-877 with Rifampin|K-877 with Rifampin
3352106|NCT02275975|Experimental|K-877|K-877
3352107|NCT02275975|Experimental|K-877 with Fluconazole|K-877 with Fluconazole
3352108|NCT02275988|Experimental|K-877|K-877
3243563|NCT01319370|Active Comparator|5% Minoxidil topical foam|5% Minoxidil topical in twice daily application in temple and vertex region
3243564|NCT01319409|Experimental|Anatomic Double-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic double-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will be split into 2 strands, 1 to recreate the posterolateral (PL) bundle, the other to recreate the anteromedial (AM) bundle of the ACL. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft will be placed in tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle will be fixed with the knee in full extension and the AM bundle will be fixed with the knee at 45 degrees of flexion.
3243565|NCT01319409|Active Comparator|Anatomic Single-Bundle ACL Reconstruction|Subjects in this arm will undergo anatomic single-bundle ACL reconstruction using an autograft quadriceps tendon with a bone block. The graft will not be split. The bone block will be placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free end of the graft will be placed in single tunnel located in the center of the tibial ACL insertion site. The graft will be fixed with the knee at 10 20 20 degrees of flexion.
3243566|NCT01319435|Other|Pharmacokinetics of ciprofloxacin|Patients receiving ciprofloxacin following clinical decision by attending physician
3243567|NCT01319448|Active Comparator|Daily proguanil|Standard policy of a supply of proguanil tablets to be taken daily
3352109|NCT02275988|Experimental|K-877 with Clarithromycin|K-877 with Clarithromycin
3352110|NCT02276001|Experimental|K-877|K-877
3352111|NCT02276001|Experimental|K-877 with Cyclosporine|K-877 with Cyclosporine
3352112|NCT02276014|Other|Supplement A|Beta-carotene 7mg formulation A
3352113|NCT02276014|Other|Supplement B|Beta-carotene 7mg formulation B
3243568|NCT01319448|Experimental|IPT with MQ+AS bimonthly|Intermittent Preventive Treatment (IPT) consisting of a bimonthly course of treatment with mefloquine-artesunate (MQ+AS)
3243569|NCT01319448|Experimental|IPT with SP+AQ bimonthly|IPT with bimonthly course of treatment with sulfadoxine-pyrimethamine plus amodiaquine (SP+AQ)
3352114|NCT02276014|Other|Supplement C|Beta-carotene 7mg formulation C
3352115|NCT02276079|Experimental|mTBI Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily aerobic exercise intervention lasting 1-week.
3352116|NCT02276079|Experimental|mTBI Non-Aerobic Exercise Group|Participants are two-three weeks post-mild traumatic brain injury are randomized to receive a daily non-aerobic exercise intervention lasting 1-week.
3352117|NCT02276079|No Intervention|Non-injured Reference Group|Non-injured, healthy participants will serve as a reference group for functional outcome measures.
3352118|NCT02276092||intervention|exposure to antimicrobial stewardship intervention
3352119|NCT02276092||control|usual care with no exposure to antimicrobial stewardship
3243570|NCT01319461|Placebo Comparator|sterile normal saline injection|
3243571|NCT01319461|Experimental|Hyalgan injection|
3243572|NCT01319474|Other|Ultrasound for suspected DVT|Enrolled subjects suspected to have deep vein thrombosis undergo whole-leg compression ultrasound. Those with a normal result undergo clinical follow-up for thrombotic outcomes over the following three months.
3243573|NCT01319487|Experimental|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
3243574|NCT01319487|Experimental|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
3243575|NCT01319487|Placebo Comparator|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
3352120|NCT02276118|Experimental|e.motion PS Pro group|the patients who receives total knee arthroplasty with the e.motion PS pro prosthesis
3352121|NCT02276118|Active Comparator|Genesis II group|the patients who receives total knee arthroplasty with the Genesis II prosthesis
3243576|NCT01319513|Experimental|protein feeding|Participants will complete 2 trials in a cross-over fashion in which they will consume whey protein either as a single bolus or as 10 small divided doses
3243579|NCT01319578|Active Comparator|Chewing Arm 1|
3243580|NCT01319578|Placebo Comparator|Chewing Arm 2|
3243581|NCT01319578|Active Comparator|Chewing Arm 3|
3243582|NCT01319578|Active Comparator|Chewing Arm 4|
3243583|NCT01319591||CNS lymphoma patients|
3352122|NCT02276131|Experimental|Usability testing|Patients will participate in summative human factors testing of the Vigilant Diabetes Management Application in a controlled environment and during home use testing. Clinicians will participate in summative human factors testing in a controlled environment.
3352123|NCT02276157||Direct peroral cholangioscopy|Patients with bile duct disease that is eligible to direct peroral cholangioscopy
3352124|NCT02276170||Aminophylline per standard of care|
3243584|NCT01319604|Experimental|Study device during 3 hours|
3243585|NCT01319604|Experimental|Study device during 6 hours|
3243586|NCT01319604|Experimental|Study device during 9 hours|
3243587|NCT01319604|Experimental|Study device during 12 hours|
3243588|NCT01319604|Experimental|Study device during 15 hours|
3243589|NCT01319604|Experimental|Study device during 18 hours|
3243590|NCT01319604|Experimental|Study device during 21 hours|
3243591|NCT01319604|Experimental|Study device during 24 hours|
3243592|NCT01319604|Active Comparator|Tonometric assessment during 24 hours|
3243593|NCT01319630||Normal Saline|patients with severe sepsis/septic shock randomized to receive 1500 cc of Normal saline bolus as the resuscitation fluid.
3243594|NCT01319630||Albumin|patients with severe sepsis/septic shock randomized to receive 500 cc of Albumin 5% bolus as the resuscitation fluid.
3243595|NCT01319630||HES|patients with severe sepsis/septic shock randomized to receive 500 cc of Hydroxyethyl starch (HES 130kD) bolus as the resuscitation fluid.
3243596|NCT01319643|Experimental|Oxygenation, rigorous normal|Patients admitted in intensive care unit for 3 days. Administration of the lowest inspiratory fraction dose of oxygen to maintain oxygen peripheral saturation (SpO2) between 94 and 98% or an arterial partial pressure of oxygen (PaO2) between 70 and 100 mmHg. No oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
3243597|NCT01319643|No Intervention|Oxygen, free conventional|Patients admitted in intensive care units for 3 days. Administration of oxygen inspiratory fractions to maintain SpO2 over 97%, up to a PaO2 of 150 mmHg. Oxygen addition administer for transports or diagnostic manoeuvres. Conventional clinical criteria for airways control and ventilation technique.
3243598|NCT01319656|Active Comparator|Group A|Intervention group(n = 163)
3243599|NCT01319656|Active Comparator|Group B|Delayed intervention (n = 163)
3243600|NCT01319656|No Intervention|Group C|No intervention group (n = 163)
3352125|NCT02276183|Experimental|Arm1, Nutrition intervention, test formula and activity|
3352126|NCT02276196|Experimental|Lixisenatide|Lixisenatide will be administered subcutaneously, once daily for 8 weeks
3352127|NCT02276196|Active Comparator|Insulin glulisine|Insulin glulisine will be administered subcutaneously, once daily for 8 weeks
3352128|NCT02276209|Experimental|Dasotraline 4 mg|Dasotraline 4 mg once daily
3352129|NCT02276209|Experimental|Dasotraline 6 mg|Dasotraline 6 mg once daily
3352130|NCT02276209|Placebo Comparator|Placebo|Placebo once daily
3352131|NCT02276235|Experimental|catgut embedding group|Catgut will be embedding in acupoints as below. Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26) Frequency: one time per week Duration: 6 weeks
3352132|NCT02276235|Sham Comparator|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. All the procedure will be performed as in catgut embedding group.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)~The other procedure were the same as catgut embedding group Frequency: one time per week Duration: 6 weeks"
3243601|NCT01319669|Experimental|Treatment group|rhTPO(recombinant human thrombopoietin) is given on the second, 4th and 9th day of the chemotherapy cycle in a dosage of 15000U once subcutaneously.
3243602|NCT01319669|Active Comparator|Control group|15000U of rhTPO(recombinant human thrombopoietin) is given subcutaneously 6 to 24 hours within the end of chemotherapy cycle, that is, the 8th day for 3 consecutive days (d9 to d11)
3352133|NCT02276248|Experimental|radiotherapy+chemotherapy|Radiotherapy technique: Intensity-modulated radiation therapy total dose: 50 to 56 grays per fraction: 2 grays GDP chemotherapy: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
3352134|NCT02276261|Experimental|Vertical|Vaginal cuff closure performed in a vertical manner.
3352135|NCT02276261|Active Comparator|Horizontal|Vaginal cuff closure performed in a horizontal manner.
3352136|NCT02276300|Experimental|HER2-Peptid-Vakzine, Cyclophosphamide|Her2-peptide vaccination, Sargramostim, Imiquimod, Cyclophosphamide
3352137|NCT02276326|Experimental|VSL#3 sachets|VSL#3 is a mix of lactic acid bacteria and bifidobacteria (original De Simone's formulation)
3352138|NCT02276339|Experimental|Single arm ankle exercise intervention|Chronic Ankle Instability Group assessed pre and post a 6 week eccentric - concentric exercise intervention
3352139|NCT02276352|Experimental|Meloxicam low dose - one tablet|
3352140|NCT02276352|Experimental|Meloxicam high dose - two tablets|
3352141|NCT02276352|Active Comparator|Meloxicam high dose - one tablet|
3352142|NCT02276365|Experimental|Sequence ABC|"Treatment A: 50 mg BI 10773 once daily from day 1 to 5~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7~Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out"
3243603|NCT01319682|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3352143|NCT02276365|Experimental|Sequence CAB|"Treatment C: 45 mg pioglitazone once daily from day 1 to 7~Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out~Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7"
3352144|NCT02276378|Experimental|Telmisartan low / HCTZ fixed-dose combination, fed|
3352145|NCT02276378|Experimental|Telmisartan high / HCTZ fixed-dose combination, fed|
3352146|NCT02276378|Active Comparator|Telmisartan low /HCTZ fixed-dose combination, fasted|
3352147|NCT02276378|Active Comparator|Telmisartan high /HCTZ fixed-dose combination, fasted|
3352148|NCT02276391|Experimental|Telmisartan/HCTZ fixed-dose combination|
3352149|NCT02276391|Active Comparator|Telmisartan|
3352150|NCT02276404|Experimental|relaxation training|Each participant of the experimental group 1 receives 2 one-hour sessions of guided relaxation training prior to surgery.
3352151|NCT02276404|Experimental|acupuncture|Each participant of the experimental group 2 receives 3 acupuncture treatments with a semi-standardized acupoint scheme: once a week over 2 weeks and the day before surgery.
3243604|NCT01319682|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3352152|NCT02276404|Experimental|relaxation training and acupuncture|Each patient of the experimental group 3 receives 3 acupuncture treatments with a semi-standardized acupoint scheme and 2 one-hour sessions of guided relaxation training prior to surgery.
3352153|NCT02276404|No Intervention|usual care|Patients receive usual senological treatment
3352154|NCT02276417||Sepsis|Blood Collection. Urine collection. Bioimpedance analysis. Quality-of-life questionnaires, physical function tests and cognitive function tests.
3352155|NCT02276417||Healthy Controls|Blood Collection.
3352156|NCT02276430||Cases|Patients who developed cardiovascular disease after testicular cancer treatment
3352157|NCT02276430||Subcohort members|A random selection out of the total cohort of testicular cancer patients per participating hospital
3352158|NCT02276443|Experimental|Treatment (predictive results given)|Patients undergo baseline molecular and IHC evaluation of their tumor biopsy, and receive the results. Patients then receive standard anthracycline-based chemotherapy and undergo standard ultrasound at baseline, after 2 courses, and after 4 courses of treatment. Patients and physicians are notified of the results of the molecular evaluation. Patients may then choose to continue with standard taxane +/- platinum-based chemotherapy or participate in an experimental clinical trial designed to match the molecular profile and triple-negative subtype. Patients with tumors predicted to be insensitive to chemotherapy are advised to participate in a clinical trial treating their tumor subtype.
3352159|NCT02276456|Experimental|early follow-up|Follow-up within 7 days after discharge from hospital after having an MI. This will be the early-follow-up or experimental arm.
3352160|NCT02276456|No Intervention|standard follow-up|Follow-up appointment within 14-18 days after discharge from hospital after having an MI
3243605|NCT01319695|Experimental|corifollitropin alfa|
3243606|NCT01319695|Active Comparator|recombinant follicle stimulating hormone (FSH)|150-300 IU of FSH for ovarian stimulation in women undergoing IVF
3243607|NCT01319708|Experimental|mild ovarian stimulation|100 mg CC by day 2 till 6, plus antagonist plus gonadotrophin 150-200IO until HCG triggering
3352161|NCT02276469|Experimental|peer support|peer support is delivered on individual basis for half a year, the frequency depends on the patients requirement, but at least 3 sessions has to occur
3352162|NCT02276469|No Intervention|usual care|usual care was delivered to the patients
3243608|NCT01319708|Active Comparator|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses using a GnRH agonist long protocol
3243609|NCT01319734|Experimental|Vitamin C supplementation plus oral hypoglycemic agents arm|This group will receive vitamin C supplementation 500mg daily for one month and then assessment will done for the patients.
3243610|NCT01319734|Active Comparator|Type 2DM patients receiving oral hypoglycemic agents alone|this group is the control group who receive oral hypoglycemic agents alone
3352163|NCT02276495|Experimental|ACB Control + Local Infiltration|ACB Control - 20 ml saline injection for ACB + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
3243611|NCT01319747|Active Comparator|Percutaneous therapy|
3243612|NCT01319747|Active Comparator|VATS therapy|
3352164|NCT02276495|Experimental|ACB Study + Local infiltration|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block + Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
3352165|NCT02276495|Experimental|ACB Study Only|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block
3352166|NCT02276508|Experimental|Probiotic|Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
3352167|NCT02276521||Zero dose group|Participants that did not received any HPV vaccine previously.
3352168|NCT02276521||One dose group|Participants that received one dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3352169|NCT02276521||Two dose group|Participants that received two dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3352170|NCT02276521||Three dose group|Participants that received three dose of Gardasil® vaccine 5-6 years ago from a vaccination campaign.
3352171|NCT02276534|Experimental|Theatre|The participants will receive 10 sessions of peer-mediated, theatre-based intervention.
3352172|NCT02276534|Experimental|No Intervention then Theatre|The participants will not receive the treatment for a period of time.
3243613|NCT01319786|Other|Low- polyphenol diet|
3243614|NCT01319786|Active Comparator|High-polyphenol diet|
3352173|NCT02276573|Experimental|Oral lichen planus disease|buccal cavity sample
3352174|NCT02276586|Active Comparator|Group 1|Horizontal Tooth preparation
3352175|NCT02276586|Experimental|Group 2|Vertical tooth preparation
3352176|NCT02276599||Cardiac catheterization|Patients with a diagnosis of atrial septal defect who are having a cardiac catheterization.
3352177|NCT02276625|Experimental|A - ID|Intradermal administration. 20% dose in a single visit.
3352178|NCT02276625|Experimental|B - ID|Intradermal administration. 40% dose in a single visit.
3352179|NCT02276625|Experimental|C - ID|Intradermal administration. 60% dose in a single visit.
3352180|NCT02276625|Active Comparator|D - IM|1x IM
3352181|NCT02276664|No Intervention|Study 1 - Focus Groups|Using focus group methodology, investigators will identify and explore new content topics for inclusion in smoking cessation booklets and gather feedback about the existing Stop Smoking for Good booklets regarding tone and message design. Results will be used to modify and adapt the existing cessation intervention.
3352182|NCT02276664|Experimental|Study 2 - Self-Help Intervention (SHI)|The SHI arm will receive the intervention developed in Study I.
3243615|NCT01319838|Experimental|isotretinoin prolongation|Prolonged treatment with isotretinoin, extending standard 6 month duration to 2 years
3352183|NCT02276664|Active Comparator|Study 2 - Usual Care (UC)|The UC arm will receive the existing Clearing the Air smoking-cessation manual.
3352184|NCT02276677|Experimental|Oxytocin|Oxytocin 24 IU x 1
3352185|NCT02276677|Placebo Comparator|Placebo|Placebo 24 IU x 1
3352186|NCT02276690|Experimental|Dosage of hepcidin|In order to assess iron deficiency, patients randomized in this arm will have dosage of hepcidin by mass spectrometry
3352187|NCT02276690|Active Comparator|Usual biomarker dosage|In order to assess iron deficiency, patients randomized in this arm will have usual biomarker dosages (ferritin and transferrin saturation)
3352188|NCT02276716|Experimental|Phosphatidylserine|"Phosphatidylserine titration from 300, 600 and 800 mg/day~duration: 6 months"
3352189|NCT02276729|Experimental|Mirror Box Treatment Group|Participants in the intervention group will be required to perform two 20 minute sessions of Mirror Box Therapy, five days/week for the duration of their in-patient stay carried out under the direction of members of the OT stroke team as well as receiving their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
3243616|NCT01319864|Experimental|Plerixafor, Dose Escalation|Dose escalation of plerixafor administered intravenously in combination with IV cytarabine and IV etoposide in pediatric patients wtih relapsed/refractory AML/ALL.
3243617|NCT01319890||Right Colectomy for colonic tumors|The group of patients enrolled will be patients with biopsy proven right colon tumors, both benign and malignant. These patients will then be subdivided into those having conventional laparoscopic right colectomy and SILS right colectomy
3243618|NCT01319942||Unresectable hepatoma|Unresectable hepatoma, unsuitable for transarterial embolization or local failure after transarterial embolization
3243619|NCT01319955|Experimental|Influenza vaccine (trivalent inactivated vaccine)|
3243620|NCT01319955|Active Comparator|Inactivated polio vaccine|
3243621|NCT01319968||Postpartum patients|100 postpartum women attending the clinic for their postpartum visit will be evaluated for vaginal atrophy, vaginal symptoms and dyspareunia.
3259333|NCT01469910|Experimental|Simotinib|
3259334|NCT01469910|Placebo Comparator|Placebo|
3259335|NCT01469923|Active Comparator|AZD2820|AZD2820 multiple injections
3243622|NCT01319981|Experimental|Hyper-CMAD + Rituximab|Odd Courses 1, 3, 5, 7: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 1 & 3; Imatinib oral 600 mg days 1-14 Course 1 then continuously; Cyclophosphamide 300 mg/m2 IV every; 12 hours for 6 doses; Mesna 600 mg/m2/day IV Days 1-3; Doxorubicin 50 mg/m2 IV CVC Day 4; VSLI 2.25 mg/M2 IV Day 1 & 8; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 µg/kg/day; Dexamethasone 40 mg IV or P.O. daily days 1-4 and days 11-14 +/- 3 days.
3243623|NCT01319981|Experimental|Hyper-CVAD|Courses 2, 4, 6, 8: Rituximab 375 mg/m2 IV Day 1 & 8 Courses 2 & 4; Imatinib oral 600 mg; Methotrexate 200 mg/m2 IV over 2 hours followed by 8-0- mg/m2 over 22 hours on Day 1; Solu-Medrol 40 mg IV hours approximately every 12 hours +/- 2 hours for 6 doses days 1-3 +/- 3 days; Decadron 40 mg IV or orally 4 times Days 1-4; Ara-C 3 gm/m2 IV every 2 hours, 4 doses on Days 2-3; Pegfilgrastim 6 mg/kg after chemotherapy + G-CSF 10 mg/kg/day.
3243624|NCT01320007|Experimental|Group 1: Optivol Group|
3243625|NCT01320007|Active Comparator|Group 2: Optivol alarm muted|
3243626|NCT01320020|Experimental|catumaxomab|
3352190|NCT02276729|No Intervention|Conventional Therapy Control Group|Participants in the control group shall receive their standard OT treatment for upper limb rehabilitation for the duration of their in-patient stay, which is 3-5 sessions per week of approximately 45 minutes duration. This classic rehabilitation treatment is based upon neurodevelopmental theory using the Bobath approach of postural control and repetitive task training.
3352191|NCT02276742|No Intervention|Usual Care (UC)|Participants randomized to UC will receive baseline advice about the value of losing weight, becoming more physically active, and limiting intake of sodium and inorganic phosphates followed by 12 mos of UC. We have elected not to use a control group in which we provide equivalent attention to both study arms. Behaviors are difficult to change and there is no reason to believe that simply giving participants attention would create behavioral changes sufficient to result in weight loss, reduce sodium excretion, or reduce serum phosphorus. Numerous weight loss studies, including Look AHEAD, have used attention control groups that did not demonstrate weight loss.
3352192|NCT02276742|Active Comparator|Social Cognitive Theory (SCT)|Participants will be exposed to a group behavioral intervention that is based on SCT, which focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states. Mastery experiences will include emphasizing past successes; setting incremental, easily achievable goals; identifying modifiable barriers to healthy behavior; receiving positive feedback on goal achievement; and practicing problem solving skills around barriers to adherence.
3243627|NCT01320046||Patients with urinary incontinence|Patients attending the urogynecological clinic for urinary incontinence-100 patients. In this group we will recruit patients with UI, and will assess co-existence of VCD
3243628|NCT01320046||Patients with vulvar contact dermatitis|Patients attending the vulvovaginal clinic with vulvar contact dermatitis (100 patients). In this group we will recruit patients with VCD, and will assess co-existence of UI.
3352193|NCT02276742|Active Comparator|Monitoring|Participants will be taught how to use a lifestyle self-monitoring program to reduce information processing requirements, make readily available the information required to make good self-management decisions, deliver automated, real-time feedback about achievement of behavioral goals, and permit individualized guidance from an interventionist who uses the MyNetDiary® electronic log to provide targeted education and advice. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
3352194|NCT02276742|Active Comparator|Combined|Participants randomized to COMBINED will receive all aspects of the SCT and MONITORING intervention conditions. Social Cognitive Theory based behavioral intervention in complex patients is strengthened when technology is used to manage information complexity, and weakened in its absence. The Monitoring intervention reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling
3352195|NCT02276755|Active Comparator|Intervention: 1|Dietary Supplement: Cholecalciferol (vitamin D3)
3352196|NCT02276755|Placebo Comparator|Placebo Comparator: 2|Dietary Supplement: Placebo
3352197|NCT02276768|Experimental|GIC-1001 mid-dose|GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3352198|NCT02276768|Experimental|GIC-1001 high-dose|GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3243629|NCT01320046||Age matched control group|"Patients attending the general clinic for annual checkup, which will be matched for age with the two other groups (200 patients).~These patients will be evaluated for symptoms of UI and VCD"
3352199|NCT02276768|Active Comparator|GIC-1002 mid-dose|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg) 345 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3352200|NCT02276768|Active Comparator|GIC-1002 high-dose|GIC-1002 460 mg (equimolar to GIC-1001 500 mg) 460 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)
3352201|NCT02276768|Placebo Comparator|Placebo matching GIC-1001 and GIC-1002|"Placebo matching GIC-1001 doses Placebo matching GIC-1002 doses~Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)"
3243630|NCT01320059|Experimental|Imaging with 18F-PEG6-IPQA|Radioactive injection given by vein before multiple (3) PET scans.
3243631|NCT01320098|Experimental|Home-Based Parenting Program|
3352202|NCT02276781||PAD Participants|PAD participants from among consecutive patients with PAD identified from Chicago area non-invasive vascular laboratories
3352203|NCT02276794|Experimental|Thrust manipulation (TM)|"The patients allocated to the TM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive a rotational TM technique. The treating therapist will have up to two attempts to perform the TM in each patient.~There is no need for cavitation in order to consider the TM successful; the occurence of cavitation, however, will be recorded.~A single treatment will be provided."
3243632|NCT01320098|Experimental|Clinic-Based Parenting Program|
3243633|NCT01320098|Other|Wait-List Control Group|
3352204|NCT02276794|Experimental|Non-thrust manipulation (NTM)|"The patients allocated to the NTM group will receive TM aimed at the L4-L5 intervertebral segments. All the patients will be positioned in a standardized position (right side-lying) and will receive 30 oscilations of a grade III rotational NTM.~A single treatment will be provided"
3352205|NCT02276820|Experimental|Viralym-A|"Partially HLA-matched Viralym-A cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-A/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3352206|NCT02276833|Experimental|Single patient group with qualifying OA|intra-articular space injection of SVF Single patient group with pre-operative and post-operative assessments
3352207|NCT02276859|Experimental|Normal/ Dual-wave|"On the first study day, pre-breakfast insulin was given as a normal bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a dual-wave bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
3352208|NCT02276859|Experimental|Dual-wave/Normal|"On the first study day, pre-breakfast insulin was given as a dual-wave bolus 15 minutes before a standardized high-protein meal. On the second day, pre-breakfast insulin was given as a normal bolus before the same high-protein meal.~The carbo-insulin and fat-protein-insulin ratio on both study days were identical to the patient's ratio when entering trial.~Kind of study bolus insulin will be a rapid-acting insulin analog same as previously used by the participant (before entering the trial) - insulin aspart, insulin lispro or insulin glulisine"
3352209|NCT02276885|Experimental|PBI Radiotherapy 6 Gy|Prone partial breast irradiation of 6 Gy x 5 over 5 days, on five consecutive days
3352210|NCT02276885|Experimental|PBI Radiotherapy 8 Gy|Prone partial breast irradiation of 8 Gy x 3 over 5 days, every other day
3352211|NCT02276898|Active Comparator|Hypertonic Saline|The treatment intervention is 1 inhalation of 7% hypertonic saline (4ml)
3352212|NCT02276898|Placebo Comparator|Isotonic Saline|The placebo intervention is 1 inhalation of 0.9% isotonic saline
3352213|NCT02276911|Active Comparator|Intravenous (IV) ibuprofen|800mg IV ibuprofen before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
3243634|NCT01320111|Active Comparator|Arm 1: PA|patient is treated with paclitaxel only
3243635|NCT01320111|Experimental|Arm 2: PASO|patient is treated with paclitaxel AND sorafenib
3352214|NCT02276911|Placebo Comparator|Intravenous (IV) normal saline|800mg normal saline before incision, followed by four total scheduled doses of IV ibuprofen every six hours for 24 hours, in addition to whatever narcotic or other pain control regimens prescribed by the treating physician to control postoperative pain.
3352215|NCT02276924|Experimental|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will follow a laser confocal microscopy procedure.
3352216|NCT02276937|Placebo Comparator|Placebo (0 ciu/limb)|Placebo control
3352217|NCT02276937|Active Comparator|DVC1-0101 low dose (1x10^9 ciu/limb)|Low dose cohort
3352218|NCT02276937|Active Comparator|DVC1-0101 high dose (5x10^9 ciu/limb)|High dose cohort
3243636|NCT01320124||osteoarthritis, total knee arthroplasty|The main cohort will have a total knee arthroplasty and will not develop a contracture post surgery. We will analyze differntial gene expression in all subjects.
3243637|NCT01320124||contracture post arthroplasty|A small group (1.3%) will develop a contracture post total knee arthroplasty. A second sample will be taken at the time of corrective surgery. The 2 samples will be compared for gene expression in the same subject. This group will also be compared to the main cohort for differential gene expression.
3243638|NCT01320176|Experimental|Group A|Subjects received dose A of the investigational HIV vaccine
3352219|NCT02276976||cerebral white matter lesions|patients with MRI confirmed cerebral white matter lesions
3352220|NCT02276976||healthy volunteers|healthy volunteers 1:1 matched by age,sex and education years
3352221|NCT02276989|Experimental|Compliance Intervention|Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
3352222|NCT02277002|Placebo Comparator|Placebo|Participants are exposed to unfiltered cabin air
3352223|NCT02277002|Active Comparator|Cabin Air Filter|Participants are exposed to filtered cabin air
3352224|NCT02277015|Experimental|ETI without chest compressions|Endotracheal intubation during pediatric resuscitation without chest compressions.
3352225|NCT02277015|Experimental|ETI with chest compressions|Endotracheal intubation during pediatric resuscitation with chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control).
3243639|NCT01320176|Experimental|Group B|Subjects received dose B of the investigational HIV vaccine
3243640|NCT01320189|Experimental|Protein intake of 5 energy percent|
3243641|NCT01320189|Experimental|Protein intake of 15 energy percent|
3243642|NCT01320189|Experimental|Protein intake of 30 energy percent|
3243643|NCT01320215|Experimental|Robot arm|The patients in this arm will have a robot-assisted promontofixation.
3243644|NCT01320215|Active Comparator|Non-robot arm|The patients in this arm with have a promotofixation via a laparoscopy, but without robot assistance.
3243645|NCT01320228|Placebo Comparator|Control|Alli treatment plus placebo (rice flour)
3243646|NCT01320228|Experimental|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
3243647|NCT01320228|Experimental|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
3243648|NCT01320228|Experimental|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
3259336|NCT01469923|Placebo Comparator|Placebo for AZD2820|Placebo for AZD2820 multiple injections
3259337|NCT01469936|Experimental|PERMEAPROTECT|
3352226|NCT02277028|Experimental|Bilateral Priming|"Bilateral priming a priming technique which is non-invasive and free of side effects. The technique described in this study uses bilateral, symmetrical, rhythmic movement bilateral priming and its purpose is to ready the motor cortex for functional limb training. A rocker is used so that the less affected limb can drive the affected one in symmetrical wrist flexion and extension. The priming (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total priming for one day is 30 minutes. Total task specific training for one day is 90 minutes"
3352227|NCT02277028|Active Comparator|Health Education|The group with no priming will receive stroke related health education via a website from the American Heart Association (15 minutes). They will use their affected hand (as they are able) This will be followed by 45 minutes of the same task specific arm training protocol described in the bilateral priming group. This group will follow the same schedule as above. The health education (15 minutes) will be following by task specific training (45 minutes). Subjects will then have a break (betw. 30-60 minutes) and then repeat the above. Total time on health education website for one day is 30 minutes. Total task specific training for one day is 90 minutes
3352228|NCT02277041|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3352229|NCT02277041|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
3352230|NCT02277067|Active Comparator|Pabal ( carbetocin)|Pabal (carbetocin which is a long acting oxytocin ) given as 100 mcg slow i.v. injection over 1 minute ( Draxis/Multiph). It will be given to the patients included in the study after delivery of the fetal head.
3352231|NCT02277067|Active Comparator|Misoprostol|Misoprostol ( Misotac, Sigma, Egypt) is a stable, synthetic form of prostaglandin E1 analogue. Patients wil be given 600 microgram of misotac immediately postoperative.
3352232|NCT02277080||Opioid group|These patients should have been treated only with one opioid (morphine, oxycodone, fentanyl, methadone, hydromorphone, tapentadol or tramadol) for more than one month
3352233|NCT02277080||Control group|Chronic non-cancer pain patients not treated with analgesics
3352234|NCT02277106|Experimental|SAGE-547|Intravenous
3352235|NCT02277106|Placebo Comparator|Placebo|Intravenous sterile saline
3352236|NCT02277132|Active Comparator|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery
3243649|NCT01320241|Active Comparator|novel radiation stent|"Patients undergo placement of a novel biliary stent loaded with 125I seeds on day 1.~Intervention: Device: self-expandable 125I radioactive seeds-loaded-stent"
3352237|NCT02277132|Placebo Comparator|Placebo|Placebo tablets three times daily orally from randomization until delivery
3352238|NCT02277145|Experimental|treatment group|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade umbilical cord mesenchymal stem cells (MSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions
3352239|NCT02277158|Experimental|Chemoradiotherapy|There are four dose levels and one arm only. Level 1: S-1, 50 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 2: S-1, 65 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 3: S-1, 80 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks Level 4: S-1, 90 mg/m2, Day 1-14, 22-35; RT Total dose 50.4Gy/28fractions/6 weeks
3352240|NCT02277171|Experimental|Nitric oxide impregnated catheter|
3352241|NCT02277184|Experimental|Ficlatuzumab, Cisplatin and IMRT|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every two weeks beginning the week prior to cisplatin-IMRT (week -1), for a total of 4 doses.~Cisplatin will be administered as an IV infusion over 60 minutes on Monday, Tuesday, or Wednesday of each treatment week beginning concurrent with IMRT during week 1 of study treatment (and one week following the first dose of ficlatuzumab) for a total of 7 doses.~IMRT: Treatment will be delivered once daily, 5 fractions per week, 35 - 37 fractions, no weekends or holidays over 7 - 8 weeks. All targets will be treated sequentially."
3352242|NCT02277197|Experimental|Ficlatuzumab and Cetuximab|"Ficlatuzumab will be administered as an IV infusion over 30-60 minutes, once every 2 weeks. Ficlatuzumab will be administered 30-60 minutes after the completion of the cetuximab infusion.~Cetuximab will be administered as an IV infusion once every 2 weeks. The first dose will be administered over 120 minutes (± 15 minutes). Subsequent doses may be infused over 60 minutes (± 15 minutes). The starting dose of cetuximab (dose tier 1) will be 500 mg/m2. Cetuximab will be administered prior to ficlatuzumab."
3352243|NCT02277210|Placebo Comparator|Non-flushing group|Aspiration alone for all follicular larger than 10mm on both sides. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
3352244|NCT02277210|Active Comparator|Flushing group|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
3243650|NCT01320241|Experimental|conventional stent|"Patients undergo placement of a conventional nitinol SEMS on day1.~Intervention: Device: self-expandable biliary nitinol alloys stent"
3243651|NCT01320254|Experimental|Cisplatin, Gemcitabine and Panitumumab|Experimental Arm with cisplatin 25mg/sq.m. at day 1 + 8, gemcitabine 1000mg/ sq.m.at day 1 + 8 and panitumumab 9mg/kg BW at day 1. Cycle will be repeated every 3 weeks.
3243652|NCT01320254|Active Comparator|Cisplatin and Gemcitabine|Cisplatin 25mg/sq.m. at day 1 + 8 and Gemcitabine 1000 mg/sq.m. at day 1 + 8. Cycle will be repeated every 3 weeks.
3243653|NCT01320267|Experimental|SILS right hemicolectomy|Single arm with intervention only.
3243654|NCT01320280|Experimental|BIBW 2992 (Afatinib)|BIBW 2992 (Afatinib) 50mg daily continuously (oral medication)
3243655|NCT01320306||Subarachnoid hemorrhage|A group of patients suffering aneurismal subarachnoid hemorrhage will participate in a fMRI study.
3259338|NCT01469936|Placebo Comparator|PLACEBO|
3259339|NCT01469949||Kinesthetic Imagery group|Subjects receiving Kinesthetic Imagery
3352245|NCT02277223|Experimental|Interventional|In addition to induction therapy, patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<20kg: 1 gram, twice daily, 20-30 kg: 1.5 grams twice daily, weight>30kg: 2 grams twice daily. For Maintenance, in addition to oral 5-ASA maintenance treatment, responding patients will receive oral capsules of curcumin (Bara Herbs Inc): Weight<30kg: 500 milligram, twice daily, weight>30kg: 1 gram twice daily
3352246|NCT02277223|Placebo Comparator|Control|In addition to induction and maintenance therapy, patients will receive matched oral placebo capsules for induction and maintenance (Bara Herbs Inc), twice daily.
3352247|NCT02277236||Younger Veterans|Male Veterans, 45-64.9 years of age. (Exposures include DXA scanning and CT imaging.)
3352248|NCT02277236||Young-Old Veterans|Male Veterans, 65-84.9 years of age. (Exposures include DXA scanning and CT imaging.)
3352249|NCT02277262|Experimental|Treatment arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed reinforcing the suture with a swine dermis biological prosthesis positioned sublay
3352250|NCT02277262|Active Comparator|Control arm|Patients randomized to this arm will be operated for the primary disease and at the end of the intervention the laparotomy will be closed by emi-continuous monofilament sutures with an intermediate-reabsorbable-time suture
3352251|NCT02277275|Placebo Comparator|Standard protein diet with placebo|Subjects will be provided with standard protein diet for four months and corn starch pills(Placebo) for 6 months
3352252|NCT02277275|Experimental|Standard protein diet with BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months, standard protein diet will be provided for four months
3352253|NCT02277275|Placebo Comparator|High protein diet with placebo|Subjects will be provided with high protein diet for four months and corn starch pills(Placebo) for 6 months
3352254|NCT02277288|No Intervention|Emptied bladder arm|No instillation of fluid into bladder.
3352255|NCT02277288|Experimental|Filled bladder arm|Instilled bladder with fluid.
3352256|NCT02277301|Experimental|Mellow Babies|Mellow Babies is a group day programme, run one day a week over 14 weeks with a joint focus on maternal wellbeing and the parentinfant interaction: transport and crèche facilities are provided.The focus is to: (a) explicitly enhance close mother-infant attunement, using a combination of baby-massage, interaction coaching and infant focussed speech; and (b) offer mothers support for their own distress. Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
3352257|NCT02277301|No Intervention|Care as Usual|Routine care received by mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
3352258|NCT02277314|Other|Low Cost Treatment for Cataracts|Low cost, manual small incision cataract surgery performed in an educational environment. All costs covered by subjects.
3352259|NCT02277327|Experimental|Intervention|"Subjects randomized to the intervention group will participate in a bundled intervention that includes action planning and care transitions (for those hospitalized during the study period)"
3352260|NCT02277327|Placebo Comparator|Routine Care|"Subjects randomized to the routine care group will continue to receive their usual care from the Pediatric Medical Home Program at UCLA"
3352261|NCT02277340|Experimental|EAPA for Pilonidal Disease|The abbrevition EAPA is used to describe the study. The cohort of pilonidal disease patients treated who do not have an acute abscess or other problems like hydradenitis suppurativa, has been treated by endoscopy assisted fulguration of the inner surface and additional crystallized phenol application for further clean up of the remaining tissue as well as preventing bacterial growth.
3352262|NCT02277353||All enrolled patients|This study enrolls patients undergoing elective spine surgery in prone position and all enrolled subjects may receive fluid loading with hemodynamic monitoring by Flotrac/Vigileo and NICOM, but the investigator does not assign specific interventions to the subjects of the study because this is a prospective observational study.
3352263|NCT02277366||Fluorescence/Narrow Band Bronchoscopy|All patients in the group are examined by Fluorescence Bronchoscopy and Narrow Band Bronchoscopy to make a early detection of lung cancer.
3352264|NCT02277366||Routine Bronchoscopy|All patients in this group are examined by routine bronchoscopy to make a early detection of lung cancer.
3352265|NCT02277405|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3352266|NCT02277405|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3352267|NCT02277418|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3243656|NCT01320306||Prophylactic surgical treatment of un-ruptured aneurysms|A retrospective follow-up study of patients who have received prophylactic surgical treatment of un-ruptured aneurysms
3243657|NCT01320306||Conservative treatment|A retrospective follow-up of patients receiving conservative (life stile etc.) treatment of un-ruptured aneurysms.
3352268|NCT02277418|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3352269|NCT02277418|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions.
3352270|NCT02277418|Experimental|Infant ETI without chest compressions|Endotracheal intubation of infant mannikin during resuscitation without chest compressions.
3352271|NCT02277431|Experimental|Probiotic dietary supplement|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
3243658|NCT01320306||Control group of healthy subjects|Control group of healthy subjects
3243659|NCT01320319|Placebo Comparator|Placebo|
3243660|NCT01320319|Experimental|Nutritional Supplementation with EPA|This arm will receive the nutritional supplementation of EPA 960mg Three times a day.
3243661|NCT01320332|Experimental|ASP3291 low dose|
3243662|NCT01320332|Experimental|ASP3291 high dose|
3352272|NCT02277431|Placebo Comparator|Placebo|The placebo capsules utilized in this study will be indistinguishable from the probiotic dietary supplement capsules as they will be identical in appearance, odor, weight, and taste. Furthermore, the same sunflower oil matrix will be in both the probiotic dietary supplement and placebo. The only difference between the dietary supplement and placebo capsules will be the probiotic bacteria.
3352273|NCT02277457|Experimental|EGFR Mutation|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Erlotinib followed by 1 year total of Erlotinib Treatment.
3243663|NCT01320332|Placebo Comparator|Placebo|
3243664|NCT01320345|Experimental|Fenofibrate|145 mg tablet of fenofibrate administered daily for 36 months.
3352274|NCT02277457|Experimental|ALK Rearrangement|Patients with an identified EGFR mutation will receive PET (Positron Emission Tomography) - Adaptive RT (Radiation Therapy) plus concurrent Crizotinib followed by 1 year total ofCrizotinib Treatment.
3243665|NCT01320345|Placebo Comparator|Placebo|Inert lactose tablet (otherwise matching active) administered daily for 36 months.
3352275|NCT02277470||Golimumab|Patients who are eligible for golimumab therapy.
3352276|NCT02277483|Active Comparator|active treatment|LAIS® Mites Sublingual tablets + rescue medication
3352277|NCT02277483|No Intervention|control|Rescue medication
3243666|NCT01320358|Experimental|ECMPS-IEM|
3243667|NCT01320371||Barbed sutures|Barbed sutures are self-anchoring, requiring no knots for wound closure.
3243668|NCT01320371||Knotted sutures|Knotted sutures used for traditional surgical closures.
3243669|NCT01320384|Active Comparator|O2 conventional : standard low flow therapy|in order to obtain a SpO2>92%
3243670|NCT01320384|Experimental|O2-HNF : high flow nasal oxygen therapy|set between 30 to 50 l/min,adjusted in order to obtain a SpO2 >92%.
3243671|NCT01320384|Experimental|O2-HFN/NPPV|cycling of NIV and O2-HDN
3243672|NCT01320397|Experimental|Rostafuroxin 6 micrograms capsules|1 capsule of ROSTAFUROXIN (6 micrograms) once a day before breakfast.
3352278|NCT02277496|Experimental|HC toolkit intervention students|HC students will receiveeExperimental wellness education via a toolkit approach to address the 2010 Dietary Guidelines for reducing obesity in youth. The specific recommendations include: 1) reducing intake of sugary beverages, 2) increasing intake of fruits and vegetables, 3) increasing frequency of eating breakfast, 4) decreasing fast and junk food choices, 5) increasing physical activity to 1 hour/day, and 6) decreasing screen time to 2 hours per day.
3352279|NCT02277496|No Intervention|Comparison Schools|During the 2014-2015 school year, control schools were utilized to compare outcomes.
3352280|NCT02277509|Experimental|Chinese DPP|Our Chinese DPP intervention includes: 1) skills development core adapted from the DPP core curriculum, 2) stress reduction counseling and activities, 3) physical activity sessions, 4) self-monitoring tools for diet and physical activity, 5) barriers assessment linked to tool box, and 6) post-core support intervention.
3352281|NCT02277509|Active Comparator|Minimal Intervention Control|The minimal control intervention will consist of providing patients with publically available materials on diabetes prevention, which are produced in Chinese.
3352282|NCT02277522|Experimental|RNA autologous T cells (anti CD19 CAR T cells)|
3352283|NCT02277535|Experimental|E-mail intervention|"ICU clinicians caring for patients who have not yet been initiated on nutrition 48 hours after ICU admission will receive a reminder email.~ICU clinicians caring for patients who accumulate a caloric deficit greater than 4000 calories or 150 g protein deficit will receive a feedback email"
3243673|NCT01320397|Experimental|Rostafuroxin 50 micrograms capsules|1 capsule of ROSTAFUROXIN (50 micrograms) once a day before breakfast.
3243674|NCT01320397|Experimental|Rostafuroxin 500 micrograms|1 capsule of ROSTAFUROXIN (500 micrograms) once a day before breakfast.
3243675|NCT01320397|Experimental|Losartan 50 mg encapsulated|1 capsule containing one cpr of Losartan 50 mg once a day before breakfast.
3243676|NCT01320423|Other|surgery|
3243677|NCT01320436|Active Comparator|Treatments arm|Patients allocated for this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (total of 820 mg each,containing 500 mg curcumin ) curcumin twice daily after meals.
3243678|NCT01320436|Placebo Comparator|Control arm|Patients allocated to this arm will receive 5ASA medication (as advised by their treating physician) + 3 capsules (820gr each) of placebo twice a day after meals.
3243679|NCT01320449|Placebo Comparator|No training + placebo|10 young men being investigated with 10 weeks apart. The will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3243680|NCT01320449|Active Comparator|No training + EPO|10 young men being investigated with 10 weeks apart. During the 10 weeks participants will receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-mas tests will be obtained during the 10 weeks.
3243681|NCT01320449|Active Comparator|Training + placebo|10 young men will be trained for 10 weeks and investigated before and after. They will receive placebo injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3243682|NCT01320449|Active Comparator|Training + EPO|10 young men will be investigated with 10 weeks apart. During the ten weeks they will train 3 times a week and receive EPO injections twice a week. Blood samples, blood pressures as well as VO2-max tests will be obtained during the 10 weeks.
3243683|NCT01320462|Experimental|Smoking cessation group|Counselling, Pharmacotherapy and Smokers Help Line
3243684|NCT01320462|Other|Control group|Brief informatin about quitting and smokers help line
3243685|NCT01320475|Experimental|iv Ketamine|Epidural infusion of levobupivacaine and saline (placebo for sufentanil)and iv infusion of ketamine Up to the third postoperative day (6 PM)
3352284|NCT02277535|No Intervention|No E-mail intervention|Nutrition status of patients will be assessed but no reminder or feedback emails will be sent
3352285|NCT02277561|Experimental|Diagnostic (VB-DTI, MRI)|Patients undergoing WBRT for a total of 10 fractions also undergo VB-DTI MRI at baseline, 1 week after WBRT initiation, and 7-11 days after completion of WBRT. Patients undergoing SRS without WBRT also undergo VB-DTI MRI at baseline and 7-11 days after completion of SRS.
3352286|NCT02277574|Experimental|Crossover Group 1|Subjects assigned to this arm will receive 1 of 3 escalating doses of AMP-110 once a week for 4 weeks followed by 4 weekly doses of placebo
3352287|NCT02277574|Experimental|Crossover Group 2|Subjects assigned to this arm will receive 4 weekly doses of placebo followed by 1 of 3 escalating doses of AMP-110 once a week for 4 week
3352288|NCT02277587|Experimental|Plenadren|Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state The dose is kept the same as patients had before entering the trial.
3352289|NCT02277587|Active Comparator|Conventional glucocorticoid therapy|"Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study. Cortisone Acetate (dose 25 to 37.5 mg) will be continued as before entering the study. The morning dose will be administered in the fasting state.~The total daily dose and timing is not changed during the study period."
3352290|NCT02277587|No Intervention|Healthy volunteers|Healthy volunteers will be enrolled as control group
3352291|NCT02277600|Experimental|Cohort 1, Treatment A, B|"Treatment A:~BMS-663068 orally twice daily (BID) on Days 1 through 4~Treatment B:~BMS-663068 orally BID plus DRV/COBI orally once daily (QD) on Days 5 through 14"
3352292|NCT02277600|Experimental|Cohort 2, Treatment C, D|"Treatment C:~BMS-663068 orally BID on Days 1 through 4~Treatment D:~BMS-663068 orally BID plus COBI QD on Days 5 through 14"
3352293|NCT02277613|Experimental|AMI MultiStem cells|AMI MultiStem cells is a cell therapy medicinal product originating from adherent stem cells taken from the bone marrow of a non-related donor and expanded ex vivo.
3352294|NCT02277613|Sham Comparator|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
3352295|NCT02277652|Experimental|Scenario 1: Uninterrupted chest compressions|Endotracheal intubation (ETI) during pediatric manikin with uninterrupted chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, USA).
3352296|NCT02277652|Experimental|Scenario 2: Neutral position|ETI performed in neutral mannikin head position
3352297|NCT02277652|Experimental|Scenario 3: Sniffing position|ETI performed in sniffing mannikin head position
3352298|NCT02277652|Experimental|Scenario 4: Pharyngeal swelling|ETI performed during mannikin pharyngeal swelling scenario
3352299|NCT02277652|Experimental|Scenario 5: Swollen tongue|ETI performed during mannikin swollen tongue scenario
3243686|NCT01320475|Active Comparator|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
3243687|NCT01320501|Experimental|Erlotinib|150 mg PO daily
3243688|NCT01320514||Fibrin Sealant (Artiss)|
3243689|NCT01320527|Experimental|Nutriceutical formulation|Nutritional supplement
3243690|NCT01320527|Placebo Comparator|Placebo 1|
3243691|NCT01320527|Placebo Comparator|Placebo 2|
3243692|NCT01320540||Breast Center Patients|Patients newly diagnosed with breast cancer who did or did not have genetic testing (retrospectively and prospectively).
3243693|NCT01320540||Staff from the Lynn Sage Comprehensive Breast Cancer Center|Members of the Northwestern staff to include but not limited the Lynn Sage Comprehensive Breast Cancer Center and/or Breast Cancer Genetics Program provider staff (including physicians, nurses, schedulers, physician assistants and/or genetic counselors).
3243694|NCT01320579|Experimental|Group 2 Cis-UCA 5% emulsion cream|
3243695|NCT01320579|Placebo Comparator|Group 3 Placebo cis-UCA emulsion cream|
3243696|NCT01320579|Active Comparator|Group 4 Protopic® 0.1% ointment|
3243697|NCT01320579|Experimental|Group 1 Cis-UCA 2.5% emulsion cream|
3352300|NCT02277652|Experimental|Scenario 6: Immobilized cervical spine|ETI performed during mannikin immobilized cervical spine scenario
3352301|NCT02277678|Experimental|Oxycodone|Epidural oxycodone 3mg single dose as opioid administration
3352302|NCT02277678|Active Comparator|Morphine|Epidural morphine 3mg single dose as opioid administration
3352303|NCT02277704|Placebo Comparator|Treatment A|"2 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
3352304|NCT02277704|Active Comparator|Treatment B|"1 x TNX-102 SL 2.8mg tablet (TNX-102 SL) and 1 x placebo tablet (placebo) to be taken sublingually once daily at bedtime."
3352305|NCT02277704|Active Comparator|Treatment C|"2 x TNX-102 SL 2.8mg tablets (TNX-102 SL) to be taken sublingually once daily at bedtime."
3352306|NCT02277717|Experimental|SYD985 (trastuzumab vc-seco-DUBA)|HER2-targeting Antibody-Drug Conjugate
3352307|NCT02277730|Experimental|vasopressor delivery automated system|vasopressor delivery automated system administering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
3352308|NCT02277730|Active Comparator|manual vasopressor delivery|manual bolus delivering phenylephrine and ephedrine using a 2 step algorithm vasopressor delivery technique
3352309|NCT02277756|Experimental|high functioning Autism|Thermal stimulation with test thermode Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with high functioning Autism
3352310|NCT02277756|Placebo Comparator|witness|Thermic stimulations (tonic heat pain stimulation and cold-pressor test) are used to test excitatory and inhibitory pain mechanisms with a witness
3352311|NCT02277782|Active Comparator|No Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 0.05 ml of 0.9% normal saline.
3352312|NCT02277782|Experimental|Hydromorphone|1.7 mg bupivacaine + 17 mcg fentanyl + 50 mcg preservative-free hydromorphone (0.05 ml)
3352313|NCT02277795|Experimental|AccuCirc|"The AccuCirc procedure is performed according to manufacturer instructions: http://www.clinicalinnovations.com/site_files/files/AccuCirc_IFUs.pdf~Before the surgery, the mother (and father, if available) will be counseled on benefits and risks of EIMC in their language of choice (English, Kiswahili, DhoLuo). At least one parent/guardian will provide documented informed consent using IRB-approved Consent Form. Providers will record demographic and locator information and EIMC eligibility criteria. If the infant is eligible for EIMC, the provider will perform the procedure and document the outcome of the surgery on a post-operative form. Information recorded will include: amount and type of anesthesia provided, intra-operative adverse event and outcome, and procedure start and end time."
3352314|NCT02277808|Active Comparator|Respirgard II|Determination of pulmonary deposition
3352315|NCT02277808|Active Comparator|Isoneb|Determination of pulmonary deposition
3243698|NCT01320592|Experimental|PD0332991 and Paclitaxel|PD0332991 in combination with weekly paclitaxel at a fixed dose of 80 mg/m2
3352316|NCT02277821|Experimental|Stendo pulsating suit System|One 20 minutes Stendo pulsating suit session will be applied to the patient.
3352317|NCT02277834||pancreatic adenocarcinoma|15 patients receiving Endoscopic Retrograde Cholangiopancreatography with suspected pancreatic adenocarcinoma (localized or metastatic).
3352318|NCT02277834||chronic pancreatitis|15 patients with a history of chronic pancreatitis that are having Endoscopic Retrograde Cholangiopancreatography .
3352319|NCT02277834||non-pancreatic, non-neoplastic disorders|15 patients undergoing an Endoscopic Retrograde Cholangiopancreatography for non-pancreatic, non-neoplastic indications.
3352320|NCT02277847|Experimental|IDA 8mg/M2|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
3243699|NCT01320605|Experimental|Weekly HP802247 treatment|
3243700|NCT01320644||vaginal mesh placement|
3243701|NCT01320657|Active Comparator|InOvation C|Active Self-ligating Bracket
3243702|NCT01320657|Placebo Comparator|Ovation|Conventional Bracket
3352321|NCT02277847|Active Comparator|IDA 10mg/M2|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
3352322|NCT02277860|Experimental|Exercise|Aerobic and strength training using the Wii Fit Plus for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
3352323|NCT02277873||No Treatment|Defined population (pregnant women) compared on a environmental moon luminosity influence
3352324|NCT02277886|Experimental|Alginos plus Nexium|sodium alginate 20ml (50mg/ml) once at bed time, and esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
3352325|NCT02277886|Active Comparator|Nexium alone|esomeprazole (40mg/tablet) 1 tablet once before breakfast, 4 weeks
3243703|NCT01320657|Experimental|Damon Q|Self-ligating bracket
3243704|NCT01320696|Experimental|Cohort 1|50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
3243705|NCT01320696|Experimental|Cohort 2|After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22
3352326|NCT02277899||Overweight school-age children|"Overweight 6-12 year-old children. Weight status will be measured and parents complete surveys at baseline and one year later. Pediatricians will complete surveys at baseline, and after index visit. Visits will be directly video-recorded.~The impact of pediatrician clinical practices and communication strategies on child's weight status will be evaluated at one year. Clinical practices (such as risk-factor screening) that occur during the 1-year interval between well-child visits also will be assessed. Specific clinical practice elements and communication strategies that will be examined include:~Communication regarding child's high weight status~Counseling regarding cardiovascular risk factor screening and assessment~Behavioral counseling~Interval follow-up to readdress weight, and~Patient-centeredness, scored as the ratio of patient to doctor-centered communication regarding weight topics."
3352327|NCT02277912|Experimental|Transcranial Magnetic Stimulation I|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the motor cortex
3352328|NCT02277912|Experimental|Transcranial Magnetic Stimulation II|Intervention: Repetitive navigated Transcranial Magnetic Stimulation of the secondary somatosensory cortex
3352329|NCT02277912|Sham Comparator|Sham Stimulation|Intervention: Repetitive sham Transcranial Magnetic Stimulation with SHAM block of the motor cortex
3352330|NCT02277938||Amantadine|Lung cancer patients being prescribed chemotherapy
3352331|NCT02277951||Participants|The Bonfils Intubation Fibrescope the Video Rigid Flexing Laryngoscope the C-MAC® S Video Laryngoscope the Macintosh Laryngoscope
3352332|NCT02277964||RRMS with treatment change|"All patients with treatment change from natalizumab 300mg iv monthly to fingolimod 0.5mg orally/daily.~16 patients were switched with an interval of 8 weeks until october 2013. After an interims analysis the interval has been changed to 4 weeks (after october 2013)."
3243706|NCT01320709|Experimental|Arm 1|
3243707|NCT01320709|Experimental|Arm 2|
3243708|NCT01320709|Placebo Comparator|Arm 3|
3243709|NCT01320709|Experimental|Arm 4|
3243710|NCT01320748|Experimental|Dual Processing|
3243711|NCT01320748|Active Comparator|Relapse Prevention|
3243712|NCT01320761|Experimental|Group 1A|"Left side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
3243713|NCT01320761|Experimental|Group 1B|"Right side injected first:~Left submental - ATX-101-BA Right submental - ATX-101-BA-free"
3243714|NCT01320761|Experimental|Group 2A|"Left side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
3243715|NCT01320761|Experimental|Group 2B|"Right side injected first:~Left submental - ATX-101-BA-free Right submental - ATX-101-BA"
3243716|NCT01320787|Experimental|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
3259340|NCT01469949||Visual Imagery Group|Subjects receiving visual imagery
3243717|NCT01320800|Active Comparator|Expert-led CBT|Expert SASS is the Skills for Academic and Social Success protocol delivered by a postdoctoral fellows.
3243718|NCT01320800|Experimental|School Counselor-led CBT|"School Counselor SASS is the Skills for Academic and Social Success protocol delivered by School Counselors.~Intervention: Behavioral: Skills for Social and Academic Success"
3243719|NCT01320800|Active Comparator|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors. Intervention: Behavioral: Skills for Life
3352333|NCT02277977|Experimental|Contrast enhanced ultrasound|Contrast enhanced ultrasound during septic shock
3243720|NCT01320813|Experimental|Robot arm|Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
3243721|NCT01320813|Active Comparator|Open surgery|Patients in this arm will have a thyroidectomy using an open surgical technique.
3243722|NCT01320839||Stroke|People who have had a stroke and have an ankle-foot orthosis.
3243723|NCT01320852|Active Comparator|Milan Criteria|Patients meeting the Milan Criteria
3243724|NCT01320852|Other|No Milan Criteria|Patients not meeting the Milan Criteria
3243725|NCT01320865||Subjects with PAH treated with nilotinib|
3243726|NCT01320878|Active Comparator|iloprost low dose group|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
3243727|NCT01320878|Active Comparator|iloprost high dose group|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
3352334|NCT02278029||Concussed|those subjects with a concussion
3352335|NCT02278029||Controls|those subjects without a concussion
3352336|NCT02278042|Active Comparator|9% Fuctose|Milk Sweetened with fructose in an amount that the added fructose contributes 9% of the calories required for weight maintenance.
3352337|NCT02278042|Active Comparator|18% Sucrose|Milk Sweetened with sucrose in an amount that the added sucrose contributes 18% of the calories required for weight maintenance.
3352338|NCT02278042|Active Comparator|18% High fructose corn syrup|Milk Sweetened with High fructose corn syrup (HFCS) in an amount that the added HFCS contributes 18% of the calories required for weight maintenance.
3352339|NCT02278042|Active Comparator|9% Glucose|Milk Sweetened with glucose in an amount that the added glucose contributes 9% of the calories required for weight maintenance.
3243728|NCT01320878|Placebo Comparator|placebo group|distilled water 2 ml per session
3352340|NCT02278042|Active Comparator|Unsweetened Milk|Unsweetened milk consumed in amount the contributes 18% of the calories required for weight maintenance.
3243729|NCT01320891|Experimental|balanced|arm in which the subjects received only balanced solutions
3352341|NCT02278055|Experimental|Radium-223|Radium Ra 223 dichloride will be administered as a bolus intravenous (IV) injection (up to 1 minute) at intervals of every 4 weeks for up to 6 cycles. The dosage of Radium Ra 223 dichloride after implementation of the new 2015 NIST standard is 55kBq/kg body weight.
3352342|NCT02278068|Experimental|Metabolic Neuromodulation System (MNS)|Hepatic sympathetic denervation therapy to aid in glycemic control
3352343|NCT02278081|Experimental|treatment group|The treatment group will receive 30 mg lansoprazole (prevacid) one capsule per day for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
3352344|NCT02278081|Placebo Comparator|placebo group|The placebo group will receive one capsule per day of prevacid placebo for three months and mometasone furonate (nasonex) one puff in each nostril per day for three months.
3352345|NCT02278094|Experimental|Experimental group|Subjects will be in random cluster assign to walking exercise (WE), Threshold Inspiratory Muscle Trainer (TIMT) and Tongue Muscle Trainer (TMT) treatment groups.
3243730|NCT01320891|Experimental|not balanced|arm in which the subjects received only not balanced solutions that means only normal saline and colloid dissolved in normal saline
3243731|NCT01320904|Placebo Comparator|Closed Kinetic Chain and NMES placebo|"During the stimulation period the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.~We used a 10-channel electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings."
3352346|NCT02278094|Active Comparator|Control group|Up to 95% of OSAS cases are treated with continuous positive airway pressure (CPAP), CPAP treatment group will be the control group.
3352347|NCT02278107|Experimental|Tidal Assist Ventilator System|Lightweight, portable, positive pressure ventilator system with proprietary nasal interface. Ventilator is powered by compressed oxygen delivered by cylinder, concentrator, or wall source.
3352348|NCT02278107|Active Comparator|Nasal Cannula Oxygen|Nasal Cannula Oxygen Standard nasal cannula oxygen at 2-5 liters per minute (LPM) based on patient requirement. Oxygen sources includes cylinder, concentrator, or wall source.
3352349|NCT02278133|Experimental|WNT974, LGX818 and cetuximab combo|Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab
3352350|NCT02278159||Peritoneal dialysis only|Patient on PD modality 90 days after renal replacement therapy initiation and not transferred to HHD
3259341|NCT01469949||Control group|Subjects receiving measurement with intervention
3352351|NCT02278159||Home hemodialysis only|Patient on HHD 90 days after renal replacement therapy initiation and not transferred to PD
3352352|NCT02278159||PD and HHD|Patient on PD 90 days after RRT initiation and transferred to HHD less than 90 days after PD failure
3352353|NCT02278159||HHD and PD|Patient on HHD after RRT initiation and transferred to PD less than 90 days after HHD failure
3352354|NCT02278172|Active Comparator|Vitamin D3 3000IU (75μg)|Treatment solution delivered via oral spray once daily for 12-weeks
3352355|NCT02278172|Placebo Comparator|Placebo|Placebo solution delivered via oral spray once daily for 12-weeks
3259342|NCT01469962||obese patients|
3259343|NCT01469975|Experimental|Arm A: Dose level 1|1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y
3352356|NCT02278185|Experimental|Arm I (enzalutamide)|Patients receive enzalutamide PO QD for 12 months in the absence of disease progression or unacceptable toxicity.
3243732|NCT01320904|Other|Closed Kinetic Chain Group|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
3243733|NCT01320917|Active Comparator|LNG-IUS|Insertion of a LNG-IUS device
3243734|NCT01320917|Placebo Comparator|Cu-IUD|Insertion of a Cu-IUD
3243735|NCT01320930|Active Comparator|Pulmonary rehabilitation|A standardized 7 week rehabilitation program, including physical training and education.
3352357|NCT02278185|Active Comparator|Arm II (ADT)|Patients receive standard of care ADT comprising one of the following at the discretion of the treating physician: leuprolide acetate, goserelin acetate, histrelin acetate, triptorelin, or degarelix SC or IM for 12 months in the absence of disease progression or unacceptable toxicity. Patients may also choose to undergo surgical castration as an alternative form of ADT.
3352358|NCT02278198|Experimental|Differentiated Thyroid Cancer|"All patients will receive one extra imaging scan with I-123 in addition to their routine care as described above. This research portion of their care will be similar to the scan that they undergo for the I-123 planning scan that is already a part of their routine care. The research study, which will be performed in the middle of the patient's normal standard of care treatment, will take 4 days.~On days 1 and 2, all patients will receive a intramuscular injection of rhTSH (Thyrogen).~On day 3, all patients will be given 3 mCi of I-123 in the form of a pill to take by mouth.~On day 4, all patients will receive a I-123 Whole Body Imaging Scan and a thyroid camera scan of the neck and thigh."
3352359|NCT02278211||Study Cohort|Patients hospitalised with myocardial infarction and angiographically proven multivessel coronary artery disease
3352360|NCT02278224|Experimental|Rumination Focused CBT|11 sessions of manualised group based Rumination Focused CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
3352361|NCT02278224|Active Comparator|Cognitive Behavioral Therapy|11 sessions of manualised group based CBT for depression. 3 hours sessions are administered once during 11 weeks in groups of approximately 8 patients and two therapist.
3352362|NCT02278250|Experimental|Part A: M4344 BIW|Dose escalation of M4344 administered BIW as a single agent.
3352363|NCT02278250|Experimental|Part A2: M4344 BID or once daily|Dose escalation of M4344 administered BID or once daily as a single agent.
3352364|NCT02278250|Experimental|Part A3: M4344 Drug holiday schedule|Dose escalation of M4344 administered in a drug holiday schedule (different schedule with either 3 days once daily (QD) or BID followed by 4 days of pausing, 5 days of QD or BID followed by 2 days of pausing, 7 days of QD or BID dosing followed by 7 days of pausing or 14 days of QD or BID dosing followed by 7 days of pausing may be explored. Other dosing holiday schedules may be explored if agreed by the sponsor and Investigators).
3352365|NCT02278250|Experimental|Part B1: M4344 + Carboplatin|Dose escalation of M4344 in combination with carboplatin.
3352366|NCT02278250|Experimental|Part C1: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
3352367|NCT02278250|Experimental|Part C2: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
3352368|NCT02278250|Experimental|Part C3: M4344 BID or once daily|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
3352369|NCT02278250|Experimental|Part C4: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ARID1A.
3352370|NCT02278250|Experimental|Part C5: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the genes ATRX and/or DAXX.
3352371|NCT02278250|Experimental|Part C6: M4344 Drug holiday schedule|An expanded cohort study to confirm the potential effect of M4344 in participants whose tumor carry a loss-of-function mutation in the gene ataxia telangiectasia mutated (ATM).
3352372|NCT02278276|Placebo Comparator|0 mg SG1002|Capsules containing 400 mg of placebo will be provided to subjects. Subjects will take two tablets twice each day.
3352373|NCT02278276|Active Comparator|1600 mg SG1002|Capsules containing 400 mg of sodium polysulthionate (SG1002) will be provided to subjects. Subjects will take two tablets twice each day, providing subjects with 1600 mg SG1002 daily.
3352374|NCT02278302|Experimental|Aggrenox®|treatment alone or in combination with Ethanol
3352375|NCT02278302|Placebo Comparator|Placebo|treatment alone or in combination with Ethanol
3243736|NCT01320930|Placebo Comparator|Control|Conventional care
3243737|NCT01320956|Experimental|Hypnosis|"Pre operative nurse consultation and Hypnosis:~will have hypnosis"
3243738|NCT01320956|Active Comparator|Control|"Pre operative nurse consultation:~usual nurse consultation without hypnosis"
3243739|NCT01320969|Experimental|Mindfulness-Based Stress Reduction course|an eight week mindfulness-based stress reduction course
3352376|NCT02278315|Experimental|Single|I-131-CLR1404 with or without concurrent dexamethasone
3243740|NCT01320969|No Intervention|Waitlist group|waitlist group
3243741|NCT01320982|Active Comparator|minocycline|minocycline
3243742|NCT01320982|Active Comparator|pramipexole|pramipexole
3243743|NCT01320982|Active Comparator|acetylsalicylic acid|acetylsalicylic acid
3243744|NCT01320982|Placebo Comparator|Placebo|Placebo
3243745|NCT01320995|Experimental|Experimental arm|In this arm, perineal ultrasound is used directly after delivery in order to hypothetically better detect anal lesions.
3243746|NCT01320995|No Intervention|Standard arm|No perineal ultrasound immediately after delivery.
3243747|NCT01321021|Experimental|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan, Diphenhydramine
3243748|NCT01321034|Other|Niacin/Laropiprant|Subjects with normal Lp(a) will be use as comparative group for the other two groups, so no placebo group is required is this study
3243749|NCT01321047|Active Comparator|Propofol group|the conventional propofol group (P group), sedation was induced by an intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV).
3352377|NCT02278380|Other|Arm 1|"To compare the Glycemic Index value of seven test foods:~Low GI standard Breakfast Medium GI standard Breakfast Nutritional pregnant milk supplement Nutritional product for diabetics Pregnant and lactation women milk powder Nutritional drinks for diabetics Test product"
3243750|NCT01321047|Active Comparator|BPS group|the balanced propofol sedation group (BPS group), both midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) and fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, an initial bolus of propofol (0.5 mg/kg body weight) was given intravenously. Sedation was maintained with repeated doses of 10 to 20 mg propofol.
3243751|NCT01321060|Active Comparator|Conservative treatment|Conservative treatment group with only drugs.
3352378|NCT02278393|Active Comparator|1-Fermented Dairy Product with Phytosterols (test)|one arm active = 3 bottles of test product/day with 1,6g of phytosterols each
3352379|NCT02278393|Placebo Comparator|2-Fermented dairy Product with No Phytosterols (control)|one arm control product= 3 bottles test productl/day with no Phytosterols
3352380|NCT02278406|Experimental|Parkinson's patients with DBS|Patients with Parkinson's Disease who are at least 3-months post subthalamic deep brain stimulator surgery
3352381|NCT02278419|Experimental|Group A1|Participants without cirrhosis will receive simeprevir 150 milligram (mg) capsule along with sofosbuvir 400 mg tablet, orally, once daily for 8 weeks.
3352382|NCT02278419|Experimental|Group A2|Participants without cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
3352383|NCT02278419|Experimental|Group B|Participants with cirrhosis will receive simeprevir 150 mg capsule along with sofosbuvir 400 mg tablet, orally, once daily for 12 weeks.
3352384|NCT02278445|Experimental|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
3352385|NCT02278458|Experimental|icotinib plus gemcitabine|"Three dose of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.~Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks."
3352386|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
3352387|NCT02278510|Experimental|Direct infusion of topotecan|The experimental Cleveland Multiport Catheter will be used to inject a chemotherapy, topotecan, and a contrast agent, gadolinium DTPA, into the high grade brain tumors of study participants
3352388|NCT02278523|Experimental|Inspiratory muscle training group|COPD patient use Inspiratory muscle trainer (Threshold IMT®)
3352389|NCT02278523|Active Comparator|control group|normal volunteers use Inspiratory muscle trainer(Threshold IMT®)
3352390|NCT02278536||Multiple high risk gestation pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
3352391|NCT02278536||Multiple low risk gestation pregnancies|women pregnant with twins or triplets at low risk for aneuploidy
3352392|NCT02278549||Asymptomatic|Individuals between 30 and 50 years old that have had no episode of low back pain in the last two years requiring medical attention
3352393|NCT02278549||Patients with Low Back Pain|Individuals between 30 and 50 years old that present with non-specific low back pain for more than 3 months
3352394|NCT02278575|Other|Consisting of treatment with Atenativ|During two weeks antithrombin concentrate(Atenativ) will be administered in order to maintain normal levels of antithrombin
3352395|NCT02278588||PD-R|Parkinson's disease receiving rasagiline
3352396|NCT02278588||PD-NMAO|Parkinson's disease not receiving any MAO-B inhibitors
3352397|NCT02278588||HC|Healthy Controls
3352398|NCT02278601|Experimental|MPIB modified programmed intermittent bolus|Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system
3352399|NCT02278601|Experimental|CIPCEA|computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system
3352400|NCT02278601|Active Comparator|patient controlled epidural analgesia with basal infusion|patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system
3352401|NCT02278627|Experimental|manual lymphatic drainage|We wish to complete the physiotherapist's support with manual lymphatic drainage (MLD) using a specific method based on pressure of finger splayed (PFS)
3352402|NCT02278627|No Intervention|Usual treatment|
3352403|NCT02278653||Study group|The population will consist of patients, aged 18 years or older, with locally advanced rectal cancer who after chemoradiation have a clinical complete response (ycT0N0) or very good response (ycT1-2N0).
3352404|NCT02278666||upper mini-sternotomy|aortic valve replacement surgery via upper J or T sternotomy (ministernotomy)
3352405|NCT02278666||right mini thoracotomy|aortic valve replacement/repair surgery via right mini thoracotomy
3352406|NCT02278666||conventional sternotomy|aortic valve replacement surgery via conventional full sternotomy
3352407|NCT02278679||Anesthitized patient|First, it will be validated on 120 anesthetized patients undergoing prostate surgery comparing responses on the digital rectal exam clinical tool (DiRECT) from both expert and novice clinicians, with surgical pathology reports.
3352408|NCT02278679||Standardized patients|During a standardized patient exercise focusing on digital rectal exam in the University of Virginia School of Medicine curriculum, 160 second-year medical students will be given the DiRECT to document their examination. An attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students.
3352409|NCT02278679||Clinic patient|The third phase includes 8 residents and up to10 attendings in the Urology clinic, who will independently complete the DiRECT documenting their DRE in the course of usual care.
3352410|NCT02278692|Active Comparator|Vitamin K|Vitamin K1 (phytonadione) 10 mg orally three times a week after dialysis for 12 weeks
3352411|NCT02278692|Placebo Comparator|Placebo|Identical appearing placebo orally three times a week after dialysis for 12 weeks
3352412|NCT02278705||Weight-status improved|"Cases, termed, weight-status improved, are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile decreases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later)."
3352413|NCT02278705||Weight-status unchanged/worse|Controls are defined as children whose BMI percent relative to their age/sex-specific BMI at the 95th percentile remains unchanged or increases from one visit to the next; and from one well-child visit to the next well-child (or primary-care visit approximately 9-18 months later).
3352414|NCT02278718|Experimental|NexoBrid Gel|NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
3243752|NCT01321060|Experimental|Continuous catheter drainage|Once the diameter of the fluid collection is more than 6cm, continuous catheter drainage will be applied.
3352415|NCT02278718|Active Comparator|Standard of Care|Non surgical and Surgical Debridement
3352416|NCT02278731|No Intervention|Control Group|The elderly in Control Group suffered no intervention and continued with their daily activities.
3243753|NCT01321060|Experimental|Repeated aspiration|Once the diameter of the fluid collection is more than 6cm, aspiration is applied and draw the tube out immediately after aspiration.
3243754|NCT01321086|Active Comparator|Motivational Interviewing|Motivational Interviewing (MI) is an effective counseling method in individuals who are less ready to change their behavior. 9 MI sessions will be conducted over the course of the six month intervention.
3352417|NCT02278731|Active Comparator|Pilates Group|Pilates group (PG), which underwent one-month (three times per week) training program with the Pilates method. This protocol consisted of Pilates exercises on the ground.Stretches were performed on upper trunk and lower limbs before the exercises. Subsequently, exercises that included the range of motion and strength of the upper limbs, trunk and lower limbs were performed, always associated with breathing and contraction of transversus abdominis muscles, in different positions, increasing repetitions and resistance in the weeks of the study, using the Swiss ball, thera-band and the magic circle.
3352418|NCT02278731|Active Comparator|PNF Group|PNF group that underwent one-month (three times per week) training program using the propriocptive neuromuscular facilitation method.The selected PNF diagonal patterns were chosen with all the basic procedures to the facilitation and according to three specific principles of PNF: rhythmic initiation, sustain and relax and reversal of antagonists. During the first week, one set of ten repetitions for each diagonal was performed; in the second week, two sets of ten repetitions and in the third and fourth weeks, three sets of ten repetitions were performed.
3243755|NCT01321086|Active Comparator|PACE|Patient-centered Assessment and Counseling for Exercise (PACE) is a protocol that targets known modifiable determinants of behavior change to motivate participants to increase their physical activity (walking).
3243756|NCT01321086|No Intervention|Control|
3352420|NCT02278757|Placebo Comparator|Low protein diet (LPD)|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
3352421|NCT02278757|Experimental|High protein diet (HPD)|HPD received a diet with higher protein content (1.34gr/kg body weight). HPD and LPD diets had equal amount of calories, were equivalent in the type of carbohydrate, and had a caloric restriction of 500 calories less than the resting metabolic rate (RMR). Meal replacements (drinks and bars), and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
3352422|NCT02278796|Experimental|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days -7 and -6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
3352423|NCT02278796|Active Comparator|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day -5 to day-2; etoposide, 200 mg/m2 intravenously daily from day -5 to day -2; and melphalan, 140 mg/m2 intravenously on day -1 before reinfusion of autologous stem cells
3243757|NCT01321099|Experimental|NaFeEDTA|
3243758|NCT01321099|Experimental|Phatase|
3243759|NCT01321099|Experimental|Vitamin C|
3352424|NCT02278809|No Intervention|waitlist control group|The waitlist control group parents received the online videos when the intervention period was over.
3352425|NCT02278809|Experimental|intervention group|
3352426|NCT02278822|Experimental|Low dose oral liposomal glutathione|Intervention: low dose oral liposomal glutathione supplementation. 500 mg oral liposomal glutathione each day for 4 weeks.
3352427|NCT02278822|Experimental|High dose oral liposomal glutathione|Intervention: high dose oral liposomal glutathione supplementation. 1000 mg oral liposomal glutathione each day for 4 weeks.
3352428|NCT02278835|Other|level1|Patients classified in level 1 were randomized in the breathing exercises group or incentive spirometry group
3352429|NCT02278835|Other|level2|Patients classified in level 2 were randomized in the Intermittent Positive Pressure Breathing group or Continuous Positive Airway Pressure group
3259344|NCT01469975|Experimental|Arm B: Dose level 2|1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y
3259345|NCT01469975|Experimental|Arm C: Dose level 3|3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y
3259346|NCT01469988|Experimental|Testosterone|
3259347|NCT01469988|Placebo Comparator|Placebo|
3352430|NCT02278848|Experimental|Diagnosis of ICAH|"One arm: patients with chronic adult hydrocephalus.~All patients have: Computerised gait analysis, Ultrasound measurement of cerebral pulsatility, MRI flow, Urinary incontinence scale"
3243760|NCT01321112|Experimental|Conversion arm|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
3243761|NCT01321125|Experimental|Whole group of 30 volunteers|The arm is composed of 30 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and two controls.
3352431|NCT02278861|Active Comparator|Oral isotretinoin 10mg/day|Oral isotretinoin 10mg/day for 6 months The dose could be reduced if there were any significant laboratory alterations or clinical adverse events, along with sunscreen FPS 60 every 3 hours during the day.
3352432|NCT02278861|Active Comparator|Tretinoin 0,05% cream|"An every other night application of tretinoin 0,05% cream in the face and forearms for 6 months, along with sunscreen FPS 60 every 3 hours during the day.~If there were any clinical adverse events the drug could be reduced to twice a week."
3352433|NCT02278874||Multiple gestation high risk pregnancies|women pregnant with twins or triplets at high risk for aneuploidy
3352434|NCT02278887|Active Comparator|Ipilimumab|4 cycles of ipilimumab treatment, the standard treatment
3352435|NCT02278887|Experimental|TIL treatment|non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2
3352436|NCT02278900|Experimental|Communication aids|Patients in the intervention group will receive the QPL at home in advance of the consultation along with information about the clinic.The consultations will be recorded in both the control and intervention group. The recording will be done on the computer, and the patients in the intervention group will be given the recording immediately after the consultation on a memory stick.
3352437|NCT02278900|No Intervention|Control group|No intervention.
3352438|NCT02278913|Experimental|Basal Bolus (Glargine and Glulisine)|Basal bolus: with Insulin analogs (glargine and glulisine), 50% of total daily dose as glargine given before breakfast and 50% as glulisine insulin given in three equally divided doses before each meal.
3243762|NCT01321125|Experimental|test group of substantivity|The arm is composed of 10 human volunteers to test 2% chlorhexidine gluconate in 70% isopropyl alcohol (ChloraPrep ®, Enturia, Texas, USA ), hypochlorite 10% of electrochemical production (Except 10% ®, Pisa, Guadalajara, Mexico), and 10% povidone-iodine (Isodine Solucion ®, Boehringer-Ingelheim Promeco, Mexico City)
3352439|NCT02278913|Active Comparator|Human Insulin|Human insulin: NPH and regular insulin: 2/3 of total daily dose as NPH and 1/3 as regular insulin. NPH insulin dose given as 2/3 in the morning before breakfast and 1/3 before dinner. Regular insulin given in three equally divided doses before each meal
3352440|NCT02278926||Patients ultrasound lypo-hypertrophy identification|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
3352441|NCT02278926||Control group|Type 1 diabetes patients with visible lypo-hypertrphy attended in outpatient clinic
3352442|NCT02278965|Experimental|Main Arm|Open Label- Metformin and Omega-3 fatty acids for 12 months post baseline data collection.
3352443|NCT02278978|Experimental|FGFR3 mutated|BIBF 1120 in patients with advanced FGFR3 mutated
3352444|NCT02278978|Experimental|FGFR3 overexpressed|BIBF 1120 in patients with advanced FGFR3 overexpressed
3352445|NCT02278978|Experimental|FGFR3 wild type|BIBF 1120 in patients with advanced FGFR3 wild type
3243763|NCT01321138|Active Comparator|Femoral nerve block|Continuous femoral nerve block with bolus of ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2 % 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 30 patients.
3243764|NCT01321138|Placebo Comparator|PCA morphine|Patients with iv morphine with self administration with a PCA-system, associated with paracetamol and ibuprofen.
3352446|NCT02278991||Lutonix Drug Coated Balloon|Paclitaxel coated balloon catheter
3352447|NCT02279004||Newly Diagnosed Patients|Newly diagnosed patients with advanced NSCLC or melanoma with complete or planned tissue genotyping.
3352448|NCT02279004||Acquired Resistance Patients|NSCLC patients with a known EGFR mutation or other targetable mutation and acquired resistance to initial kinase inhibitor therapy.
3352449|NCT02279004||Known Genotype Patients|NSCLC patients with a known genomic alteration detectable by ddPCR-based plasma genotyping and planned to start a new line of therapy.
3352450|NCT02279004||Advanced NSCLC|Advanced NSCLC patients with a biopsy planned for tissue genotyping.
3352451|NCT02279017|Other|Weight Loss|We will send the study participate a daily text message for 2 months to their phone at 8 A.M. and a weekly text message for 6 months asking them to report their weight through a 2-question online survey. After that, a monthly text message for 18 months asking them to report their weight.
3352452|NCT02279056|Experimental|Self-help book|A self-help book for insomnia (written in Norwegian). Earlier proven to be effective among insomnia patients (without OSA co-morbidity).
3352453|NCT02279056|Placebo Comparator|Sleep hygiene advice|A sheet of paper with sleep hygiene advice.
3352454|NCT02279069|Active Comparator|4-point canne|Stroke patients walk with 4-point canne
3352455|NCT02279069|Experimental|4-roll canne|Stroke patients walk with 4-roll canne
3352456|NCT02279095|Experimental|Palovarotene dose level 1 (completed)|Participants received 10 mg palovarotene for 14 days, followed by 5 mg palovarotene for 28 days (or weight-based equivalent) for eligible flare-ups (Part A).
3352457|NCT02279095|Experimental|Palovarotene dose level 2|Participants with at least 90% skeletal maturity received 5 mg palovarotene for up to 24 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
3352458|NCT02279095|Experimental|Palovarotene dose level 3|Participants with less than 90% skeletal maturity received weight-adjusted doses of 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part B).
3243765|NCT01321164|Active Comparator|Fumaric acid esters|Fumaric acid esters monotherapy
3259348|NCT01470014||IVNC|
3259349|NCT01470014||differential diagnosis to IVNC|
3352459|NCT02279095|Experimental|Palovarotene dose level 4|All participants will receive 5 mg palovarotene for up to 48 months and 20 mg palovarotene for 28 days, followed by 10 mg for 56 days for eligible flare-ups (Part C). Skeletally immature participants will receive weight-adjusted doses.
3243766|NCT01321164|Experimental|fumaric acid esters plus narrow band UVB|Combination therapy of fumaric acid esters plus narrow band type B ultraviolet therapy (UVB)
3352460|NCT02279121|Experimental|TauroLock|solution of taurolidine-citrate
3352461|NCT02279121|Other|Control|saline solution
3352462|NCT02279134|No Intervention|Surgery alone|No adjuvant treatment after radical resection is developed in this arm
3352463|NCT02279134|Experimental|Adjuvant Chemoradiation|Adjuvant chemoradiation after radical resection is developed in this arm
3352464|NCT02279134|Active Comparator|Adjuvant Radiation|Adjuvant radiation after radical resection is developed in this arm
3352465|NCT02279147|Experimental|raceanisodamine & neostigmine|Patients receive immediately raceanisodamine（10mg）by intramuscular injection after operation.Then the patients will be receive 50mg raceanisodamine and 0.15mg neostigmine within 24hs by slow injection into vein for three consecutive days.
3352466|NCT02279147|No Intervention|blank|Patients do not receive special treatment after operation.
3352467|NCT02279186|Active Comparator|group A|receiving tranexamic acid
3352468|NCT02279186|No Intervention|group B|does not receive tranexamic acid
3352469|NCT02279199||Control|Normative data from standardized assessment
3352470|NCT02279199||Hemophilia|Persons aged 4-21 with any severity of hemophilia A or B
3352471|NCT02279225|Placebo Comparator|placebo (P)|Intervention without radiation
3352472|NCT02279225|Experimental|phototherapy (FT)|Intervention only with phototherapy radiation
3352473|NCT02279225|Experimental|phototherapy+Physical activity (FT+A)|Intervention associated
3352474|NCT02279225|Experimental|Physical activity (A)|Intervention with physical activity: the gold standard of treatment in fibromyalgia
3352475|NCT02279251|Active Comparator|Brief CBT (VÅG)|This is a brief five session CBT group intervention developed at Uni Research. The intervention include self-help material (Psychological First Aid) for the adolescents to use at home between sessions.
3352476|NCT02279251|Active Comparator|Established CBT program (Cool Kids)|An established, 10 session CBT group program (school version) developed by researchers at Macquarie University, Australia. The intervention has previously not been evaluated with Norwegian adolescents.
3352477|NCT02279251|No Intervention|Waitlist|Waiting period is ten weeks, then participants are randomized to one of the two active interventions
3352478|NCT02279277|No Intervention|No physical therapy|No prescribed, supervised physical therapy prior to total knee replacement
3352479|NCT02279277|Active Comparator|Physical Therapy|Prescribed, supervised physical therapy prior to total knee replacement
3243767|NCT01321190||Low Back Pain|Individuals who experience bothersome low back pain.
3243768|NCT01321190||Headache|Individuals who experience bothersome headaches.
3243769|NCT01321190||Fibromyalgia|Individuals who experience bothersome fibromyalgia-related pain.
3243770|NCT01321203||Group-A, use of air;|
3243771|NCT01321203||Group-B use of CO2|
3352480|NCT02279290|Experimental|Healthy Mind Intervention (HMI)|This intervention will focus on teaching individuals a way to manage acute and chronic stressors more effectively.
3352481|NCT02279290|Active Comparator|Healthy Body Intervention (HBI)|This intervention will focus on important health-related topics.
3352482|NCT02279303|Experimental|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
3352483|NCT02279303|Active Comparator|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
3352484|NCT02279316|Experimental|Jaques-Dalcroze eurhythmics|Jaques-Dalcroze eurhythmics (60min/wk) + 800 IU Vitamin D3
3352485|NCT02279316|Experimental|Home exercise program|Home exercise strength program (3x30min/wk) + 800 IU vitamin D
3352486|NCT02279316|Other|Vitamin D only|800 IU Vi-De 3
3352487|NCT02279329|Other|COPD and Bronchiectasis Patients|All enrolled COPD and Bronchiectasis patients will undergo Pulmonary Function Tests, Hyperpolarized Helium MRI, chest CT, 6-Minute Walk Test, and complete questionnaires at up to 8 visits over 2-3 years.
3352488|NCT02279342|No Intervention|Non febuxostat treatment group|No febuxostat treatment
3352489|NCT02279342|Experimental|Febuxostat treatment group|once daily after breakfast
3352490|NCT02279355||pressure ulcer group|Patient who developing pressure ulcer categorized as stage more than II after surgery
3352491|NCT02279355||Control group|Patients has identical values on the matching factors such as age, sex and surgical procedures of control group
3352492|NCT02279368|Experimental|Intervention Group|Nurses delivered the supportive intervention along with family counselling from last term of pregnancy through three months and then were followed till the first birthday of the child.
3243772|NCT01321216||Hospitalized Gastroenteritis|Children under 5 years of age hospitalized with gastroenteritis
3243773|NCT01321229||With sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission Diagnosis and medical care by a sleeping disorder qualified specialist
3243774|NCT01321229||Without sleep APNEA|Sleeping Apnea Syndrome (SAS) screening usin an APNEA LINK device within the 10 first days following the admission
3352493|NCT02279368|No Intervention|Control Group|Control group families were followed in usual care.
3352494|NCT02279381|Experimental|Intervention group A|"Essential Neonatal Care~Kangaroo mother Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
3352495|NCT02279381|Experimental|Intervention group B|"Essential Neonatal Care~Application of 4% Chlorhexidine~Education and counseling for mothers and care providers"
3352496|NCT02279381|Active Comparator|Control group|"Essential Neonatal Care~Education and counseling for mothers and care providers"
3352497|NCT02279394|Experimental|Elo / Len / Dex|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID~•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8~Other Name: Decadron"
3352498|NCT02279394|Experimental|Elo / Len|"•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8~Other Name: HuLuc63~•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24~Other Name: REVLIMID"
3352499|NCT02279433|Experimental|DS-6051b|DS-6051b is orally administered as 50 mg and 200 mg capsules once daily on Days 1 to 21 of a 21-day cycle. Dose escalation in Part 1 will continue until tentative Recommended Part 2 Dose (RP2D) is determined. In Part 2 participants will receive the RP2D.
3352500|NCT02279446||20/20ND group|This group will have 20/20 visual acuity both in distant and near.
3352501|NCT02279446||20/20D group|This group will have 20/20 distant visual acuity and variable near visual acuity.
3352502|NCT02279446||20/20N group|This group will have 20/20 near visual acuity and variable distant visual acuity.
3352503|NCT02279446||s20/20ND group|This group will have variable near and distant visual acuity (both less than 20/20)
3352504|NCT02279459||Patient|Patients head and neck CT scans performed as standard of care done prior to radiation treatment and approximately 12 weeks following treatment, will be acquired in the dual-energy computed tomography (DECT) mode. Participants will have one additional scan, also in the DECT mode, 2 to 3 weeks after the start of their radiation treatment.
3352505|NCT02279472|Other|laser peripheral iridotomy|Laser peripheral iridotomy (LPI) is widely regarded as the first-line intervention for either acute or chronic types of angle-closure glaucoma in early stage ,which relieves pupil block and thus flattening the iris contour and widening the drainage angle,performd by Nd.YAG LASER
3352506|NCT02279485|Experimental|Perampanel - Group 1|"Treatment A: Single oral dose of a 12-mg perampanel tablet under fasted condition.~Treatment B: Single 12 mg dose of perampanel oral suspension under fasted condition.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment A or Treatment B. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
3243775|NCT01321242||achieving resting HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects achieving resting HR goals, according to ACC/AHA/ACP-ASIM Guidelines
3352507|NCT02279485|Experimental|Perampanel - Group 2|"Treatment C: Single oral dose of a 12-mg perampanel tablet co-administered with high fat meal.~Treatment D: Single 12 mg dose of perampanel oral suspension co-administered with high fat meal.~Subjects will be randomized on Study Day 1 for Treatment Period 1 to Treatment C or Treatment D. On Study Day 43 the subject will then receive the alternate Treatment for Treatment Period 2."
3352508|NCT02279511|Experimental|24 hours infusion of ATP|
3352509|NCT02279511|Experimental|6 hours infusion of ATP|
3352510|NCT02279511|Placebo Comparator|24 hours infusion of placebo|
3352511|NCT02279511|Placebo Comparator|6 hours infusion of placebo|
3352512|NCT02279537||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC)
3375997|NCT03314181|Active Comparator|Arm H: DVd Dose|Daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8: Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg on Cycles 1 - 3: Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) on Cycles 4-8: Days 1,2,4,5,8,9,11 and 12; 20 mg monthly for Cycles 9+: Day 1
3375998|NCT03314181|Experimental|Arm G: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
3243776|NCT01321242||non-achieving HR goals|Patient population will be comprised of typical for cardiological practice sample of patients with Coronary Heart Disease and arterial hypertension administered beta-blockers, subjects non-achieving HR goals, according to ACC/AHA/ACP-ASIM Guidelines
3243777|NCT01321255|Experimental|FDC Fixed Dose Combination|
3243778|NCT01321255|Active Comparator|Conventional treatment|
3375999|NCT03314181|Experimental|Arm F: VenDd Dose Expansion|Venetoclax at a pre-determined dose, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
3376000|NCT03314181|Experimental|Arm E, Part 2b: VenDVd Dose Expansion|Venetoclax at dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection) Cycles 1-8, Days 1, 4, 8 and 11, and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
3243779|NCT01321268|Experimental|dietary supplement for cellulite|PUFA, resveratrol, lycopene, beta carotene, lutein
3243780|NCT01321268|Active Comparator|Control|Vitamin E
3243781|NCT01321281|Experimental|AquaCal|Osteoarthritis and healthy volunteers
3243782|NCT01321281|Active Comparator|AquaPT|Osteoarthritis
3243783|NCT01321294|Active Comparator|Nissen fundoplication|
3243784|NCT01321294|Active Comparator|Toupet fundoplication|
3243785|NCT01321307||Sorend|Group no. 1 shall receive Sorend following diagnosis of aphtostomatitis or mucositis.
3243786|NCT01321307||Sorend placebo|Group no. 2 shall receive Sorend placebo following diagnosis of aphtostomatitis or mucositis.
3243787|NCT01321320|Experimental|Active stimulation|This group will receive active muscle stimulation for 1 week to the quadriceps muscle - the leg will be randomly assigned.
3243788|NCT01321333|Experimental|HuCNS-SC cells|Single dose intramedullary administration of HuCNS-SC cells
3243789|NCT01321346|Experimental|Leukemia Patients|Patients with ALL and AML will be treated in one arm of the study.
3352513|NCT02279550||hip fracture|aged >65 with hip fracture
3352514|NCT02279563|Experimental|Azelastine HCl and Fluticasone Propionate Nasal Spray|"The investigational product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL1981, Expiry Date Mar 2015."
3352515|NCT02279563|Active Comparator|Dymista™ Nasal Spray|"The reference product was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number G30349, Expiry Date Mar 2015."
3352516|NCT02279563|Placebo Comparator|Placebo Nasal Spray|"The placebo was administered via nasal inhalation with one spray in each nostril twice daily.~Batch Number KL0781, Expiry Date Mar 2015."
3352517|NCT02279576|Experimental|Pazopanib plus weekly paclitaxel|Pazopanib 800mg /day continuously administered plus paclitaxel 65 mg/m2 in weekly administration, 3 administrations (D1, D8 and D15) every 4 weeks period.
3352518|NCT02279589|Active Comparator|Group A|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
3352519|NCT02279589|Active Comparator|Group B|"Description 15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,1~Route : Intramuscular vaccination schedule : M0, M2, M12"
3352520|NCT02279589|Active Comparator|Group C|"Description :~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,1 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
3352521|NCT02279589|Active Comparator|Group D|"Description:~15 subjects with : Prevenar13® 0,5 then Pneumo 23® 0,5 then Pneumo 23® 0,5~Route : Intramuscular vaccination schedule : M0, M2, M12"
3352522|NCT02279602|Experimental|Single Arm|Subjects will receive fosbretabulin at the same dose and frequency as in study OX4218s
3352523|NCT02279615|Active Comparator|Treatment Group|(Mirabegron + Tamsulosin)
3352524|NCT02279615|Placebo Comparator|Control Group|(Placebo + Tamsulosin)
3352525|NCT02279628|Experimental|Continuous wound infiltration alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 1 ml sodium chloride 0.9% (without morphine). Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
3352526|NCT02279628|Active Comparator|Intrathecal moprhine alone|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of sodium chloride 0.9% 8 ml/H via a preperitoneal catheter.
3352527|NCT02279628|Experimental|Intrathecal morphine&wound infiltration|Spinal anesthesia will be performed with 10 mg bupivacain 0.5% hyperbaric, 3 μg sufentanil and 0.1mg morphine. Patient will then receive a continuous wound infiltration of ropivacaine 0.2% 8 ml/H via a preperitoneal catheter.
3243790|NCT01321346|Experimental|Lymphoma Patients|Patients with NHL or HD will be treated in one arm of the study.
3243791|NCT01321359|Placebo Comparator|Vehicle|Vehicle
3243792|NCT01321359|Active Comparator|Active|Active NB-001(0.3%)
3352528|NCT02279654||Lenalidomide Population|Patients with transfusion-dependent, low- or intermediate (int)-1risk MDS and isolated del (5q) who receive at least 1 dose of lenalidomide after 15th June 2007 and have been followed up for on the registry for 3 years or until death/consent withdrawal
3352529|NCT02279654||Background Population|All MDS patients who have been diagnosed on 15th June 2007 or later, have never been exposed to lenalidomide and have been followed up on the registry for 3 years or until death/consent withdrawal
3352530|NCT02279680|Other|Patients|Adults between 18 and 30 years old right handing Patients with ASD
3243793|NCT01321398||Critically Ill patients receiving HFO|
3243794|NCT01321411||1. ARDS/COPD|Critically ill patients with either ARDS or COPD weaning from mechanical ventilation.
3243795|NCT01321411||2. Healthy Volunteers|
3352531|NCT02279680|Other|Healthy volunteers|Adults between 18 and 30 years old Right handing Healthy
3352532|NCT02279693|Other|CBCT|cone beam computed tomography (CBCT) repositioning
3352533|NCT02279693|Other|fiducial markers|kV imaging of fiducial marker repositioning
3352535|NCT02279758|Experimental|METFORMIN|850mg of metformin every 12 hours.
3352536|NCT02279771|Active Comparator|transanal anastomotic reinforcement|Low anterior resection with TME plus anastomotic transanal reinforcement without protective ileostomy/colostomy (transanal anastomotic reinforced arm:TAR-LAR)
3352537|NCT02279771|Active Comparator|protective ileostomy group|Standard low anterior resection with TME plus protective ileostomy/colostomy (S-LAR)
3352538|NCT02279784|Experimental|Freeway|angioplasty with Freeway drug-eluting balloon
3243796|NCT01321424||Aqueous Dificiency Dry Eye|20 Participants
3352539|NCT02279784|Experimental|Lutonix|angioplasty with Lutonix drug-eluting balloon
3352540|NCT02279810||Medical students, medical staff|Survey about Knowledge, Attitude and Practice About Organ Transplantation
3352541|NCT02279823|Experimental|CB-03-01 solution|Topical solution applied twice daily for 26 weeks
3243797|NCT01321424||Meibomian Gland Disease Dry Eye|20 Participants
3243798|NCT01321424||Normal Eye|20 Participants
3243799|NCT01321450||Group A|Preparation with Harmonic WAVE
3243800|NCT01321450||Group B|Preparation with conventional modalities
3243801|NCT01321463|Experimental|PH-797804|
3243802|NCT01321463|Placebo Comparator|Placebo|
3243803|NCT01321489|Experimental|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
3243804|NCT01321489|Active Comparator|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
3243805|NCT01321528||IBSR Intervention group|30 nurses in the geriatric departments in TASMC
3243806|NCT01321567||Rabeprazole Sodium|
3243807|NCT01321580|Experimental|Group A|
3352542|NCT02279823|Active Comparator|Minoxidil Solution 5%|Topical solution applied twice daily for 26 weeks
3352543|NCT02279823|Placebo Comparator|Placebo solution|Topical solution applied twice daily for 26 weeks
3243808|NCT01321593||hemoglobin determination|emergency unit patients
3243809|NCT01321619|Experimental|Varicell|Drug A(Varicell) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
3352544|NCT02279836|Other|Single arm post-marketing Study|SC20 Colonoscope and Colonoscopy System For Colonoscopy
3352545|NCT02279849|Experimental|Communications|These 6 stores received the communications intervention. Communications materials were developed for each program phase; 1) Healthier Drinks, 2) Healthier Essentials, and 3) Healthier Snacks. Each phase's materials included posters, recipe cards, educational handouts, shelf talkers, price tags, door signs, educational displays, and promotional giveaways (i.e., drink tumblers, re-usable shopping bags) to encourage healthy food purchasing and consumption. Stores receiving the communications intervention also received either a small refrigerator or freezer to help provide the environmental supports needed to stock perishable fruits and vegetables.
3352546|NCT02279849|No Intervention|Control|These 6 stores received no intervention.
3352547|NCT02279849|Experimental|Pricing|These 6 stores received a pricing intervention. 10-30% with discounts for specific foods contingent on price elasticity of demand, initial wholesale price, and projected store-level sales. Items were given the minimum discount needed to increase store supply and consumer demand. For example, brand name frozen vegetables were discounted 30% at the wholesaler, in order to provide the storeowner with enough incentive to stock the item. The % discount passed from the storeowner to the consumer was ultimately a decision made by the storeowner, but was suggested to be at least 50% in order to increase consumer demand. Discounts were automatically applied at wholesaler registers to stores receiving the pricing intervention.
3352548|NCT02279849|Experimental|Combined (Communications & Pricing)|These 6 stores received communications materials as well as pricing incentives as intervention (see Communications & Pricing Arms Descriptions).
3352549|NCT02279875|Experimental|Linezolid 300 mg once per day|Half of a 600mg (scored) tablet
3352550|NCT02279875|Experimental|Linezolid 300 mg twice per day|Half of a 600mg (scored) tablet
3352551|NCT02279875|Experimental|Linezolid 600 mg once per day (A)|600mg (scored) tablet
3352552|NCT02279875|Experimental|Linezolid 600 mg once per day (B)|600mg (scored) tablet
3352553|NCT02279875|Experimental|Linezolid 600 mg twice per day|600mg (scored) tablet
3352554|NCT02279875|Experimental|Linezolid 1200 mg once per day|Two 600mg (scored) tablets
3352555|NCT02279875|Experimental|Linezolid 1200 mg 3 times per week|Linezolid 1200 mg administered as a single oral dose three times per week (1200 mg: Day 1, 3, 5, 8, 10, and 12)
3352556|NCT02279875|Active Comparator|HRZE once per day|"Treatment will be administered orally once daily for 14 days per the~Subject's weight as follows:~30-37 kg: 2 tablets;~38-54 kg: 3 tablets;~55-70 kg: 4 tablets;~71 kg and over: 5 tablets."
3352557|NCT02279888||CardioMEMS HF System Group|Patients implanted with a CardioMEMS HF System.
3352558|NCT02279901|No Intervention|Traditional|Patients will attend a 1 hour OSA Class where OSA education is provided and home sleep testing is set up. These patients return the next day for individual appointments where study is scored and test results are discussed with patient. If study is consistent with OSA based on AHI4% at least 5/hour, patients undergo a 1 week autoCPAP trial. During this week, wireless remote monitoring is performed and troubleshooting is provided via telephone if problems with CPAP use are identified. The autoCPAP is returned during an individual visit, and CPAP is ordered for long-term use based on trial results and patient feedback. Patients are scheduled a 3 month follow-up appointment but are also instructed to call their sleep center case manager prior to that visit if there are problems with CPAP use.
3352559|NCT02279901|Experimental|Telemedicine Education Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are emailed a link to view the Emmi OSA program within 2 weeks prior to their initial OSA class. If the patient tests positive for OSA and agrees to an autoCPAP trial, the patient is emailed a link to view the Emmi CPAP program. These patients are also scheduled for a 3 month follow-up visit to check CPAP usage.
3352560|NCT02279901|Experimental|Telemedicine IVR Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. Additionally, if CPAP is ordered for long-term therapy, the patient is enrolled into an IVR protocol that automatically analyzes the patient's CPAP use. If specific provider-defined thresholds are met, the platform will automatically deliver feedback messages to the patient (phone call, text messaging, or email) with the intention of encouraging better CPAP use. Patients are instructed to contact the sleep center for any issues with their therapy. This platform also includes a method for patients to track their own usage online. Automated messaging mechanism will be active for 3 months after CPAP is ordered, after which the messaging will stop. These patients are also scheduled for a 3 month follow-up visit.
3352561|NCT02279901|Experimental|Telemedicine Both Pathway|Patients follow our usual workflow as outlined in the Traditional Pathway. In addition, patients are provided both Emmi education programs and IVR follow-up as previously outlined. These patients are also scheduled for a 3 month follow-up.
3352562|NCT02279914|Experimental|400 mcg|receives 400 mcg of misoprostol 3 hours prior to the procedure
3352563|NCT02279914|Experimental|600 mcg|receives 600 mcg of misoprostol 90 minutes prior to the procedure
3352564|NCT02279927|Experimental|Low energy high frequency|Ureteroscopy with laser settings of low energy & high frequency with aim of stone dusting
3243810|NCT01321619|Experimental|Placebo daflon (Drug D)|Drug D (Placebo Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
3243811|NCT01321658|Experimental|Geriatric intervention|
3243812|NCT01321658|No Intervention|Control|
3243813|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, 600- 750 calorie|
3243814|NCT01321671|Experimental|Pregabalin controlled release, 330 mg, fasted|
3243815|NCT01321671|Other|Pregabalin immediate release, 300 mg|
3243816|NCT01321762||1|Pregnant Women with singleton pregnancy
3243817|NCT01321775|Experimental|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|
3243818|NCT01321788||STUDY GROUP|will receive the study drug Innohep ® for 14 days
3352565|NCT02279927|Active Comparator|High energy low frequency|Ureteroscopy with laser settings of low energy high frequency with aim of stone fragmentation and basket extraction of fragments
3352566|NCT02279953|Experimental|Vortioxetine 10-20 mg|daily, encapsulated, orally
3352567|NCT02279953|Experimental|Vortioxetine 10-20 mg + SSRI|daily, encapsulated, orally
3352568|NCT02279953|Experimental|SSRI|licensed doses, encapsulated, orally
3352569|NCT02279966|Experimental|Vortioxetine 10 mg|daily, encapsulated, orally
3352570|NCT02279966|Other|Paroxetine 20 mg (active reference)|daily, encapsulated, orally
3352571|NCT02279966|Placebo Comparator|Placebo|capsules, orally
3352572|NCT02279979|Experimental|Treatment Arm|All enrolled patients will be treated with the HeartMate PHP device
3352573|NCT02279992|Experimental|Vardenafil + Carboplatin|Vardenafil (Levitra®) 20 mg oral administered 1 hour prior to start of craniotomy + Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
3352574|NCT02279992|Active Comparator|Carboplatin Alone|Carboplatin (Paraplatin®) 100 mg IV administered over 30 minutes at the start of craniotomy
3243819|NCT01321788||CONTROL|The group that will receive placebo for 14 days
3243820|NCT01321801|Active Comparator|Pregabalin|Preoperative administration of pregabalin 600mg to patients undergo laparoscopic cholecystectomy.Patients receive oral Pregabalin 300 mg the night before the surgery, and another one dose of 300 mg 1 hour prior to surgery
3243821|NCT01321801|Placebo Comparator|Placebo|Preoperative administration of placebo to patients undergo laparoscopic cholecystectomy.Patients receive oral Placebo the night before the surgery, and another one dose 1 hour prior to surgery.
3352575|NCT02280005|Experimental|WAK Treatment|Use of experimental device.
3352576|NCT02280018|Experimental|JNJ-49122944, 5 milligram (mg)|Single dose of 5 mg JNJ-49122944, administered as a 22.2 milliliter (mL) intravenous (IV) infusion over 45 minutes in the morning following an overnight fast.
3352577|NCT02280018|Placebo Comparator|Placebo|Placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes in the morning following an overnight fast.
3352578|NCT02280031|Active Comparator|Experimental|Acetylsalicylic Acid 80mg administered daily at bedtime
3352579|NCT02280031|Placebo Comparator|Control|Identical placebo administered daily at bedtime
3352580|NCT02280057|Active Comparator|Metformin|Metformin 850 mg x 2 in six months
3352581|NCT02280057|Placebo Comparator|Placebo|Placebo 2 tablets daily for six months
3243822|NCT01321814|Experimental|Cognitive behavioural therapy (CBT)|Patients receiving 6 sessions of CBT conducted by a licensed psychologist. Sessions include psychoeducation, exposure treatment, behavioral activation and applied relaxation.
3243823|NCT01321814|No Intervention|Waiting list|Patient waits for CBT treatment for 6 months.
3243824|NCT01321827|Experimental|Itraconazole group|Itraconazole 200 mg BD for 4 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
3243825|NCT01321827|Active Comparator|Glucocorticoid group|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
3243826|NCT01321840|Experimental|Treatment|This group will be treated with SART.
3352582|NCT02280070|Active Comparator|SOX (S-1 + L-OHP)|"S-1 (80 mg/m2, p.o.) (day1-14）, L-OHP (130 mg/m2)(day 1): repeated every 3 weeks until 4 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
3352583|NCT02280070|Active Comparator|mFOLFOX6|"L-OHP (85 mg/m2) and l-LV (200 mg/m2) by IV infusion drip for 2hr at day 1. 5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards (day 1-2: repeated every 2 weeks until 6 courses or meet discontinuation criteria.~Medical history and physical examination, BW and height, performance status, laboratory test, creatinine clearance, biomarker, contrasting CT, adverse event, HBs antigen and HCV antibody, endoscopy, HBs antibody and HBc antibody"
3352584|NCT02280083|Experimental|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
3243827|NCT01321840|No Intervention|No treatment|This group will not be treated with SART but will regularly be examined by a gynecologist to detect sudden aggravation of the disease.
3243828|NCT01321853|Experimental|Machine and NCC|Medications dispensed to subject via MD2 machine and nurse care coordination used to coordinate care among providers and fill machine at least every 2 weeks.
3352585|NCT02280083|Placebo Comparator|placebo|excipient
3352586|NCT02280109|Active Comparator|Tenofovir Gel|Women will receive a single dose of tenofovir gel (1%;equivalent to 40 mg in 4ml's of gel) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
3352587|NCT02280109|Active Comparator|Tenofovir Film|Women will receive a single dose of tenofovir film (1.3%;40 mg) to determine the pharmacokinetics of tenofovir in the blood, cervical tissue, and cervicovaginal fluid.
3352588|NCT02280135|Experimental|Intravitreal injection of Autologous bone marrow Stem Cell|"Patients included in the trial will receive a pars plana intravitreal injection of autologous mononuclear cells (MNC) of bone marrow (BM) in one eye (experimental group A or group). The eye in which autologous BM MNCs were injected will be determined randomly.~The average dose will be 30 million of cells (5-60 million) diluted in 0.1 ml. of saline."
3352589|NCT02280135|Placebo Comparator|Subconjunctival injection of saline|Patients included in the trial will receive a subconjunctival injection of 0.1 ml of saline (SF) (placebo) in the fellow eye (group B or control group). In this way the patient will receive an injection in the control eye but avoid the risks of intraocular injection.
3243829|NCT01321853|Experimental|Medplanner and NCC|Medications loaded in medplanner by nurse care coordinator who coordinates care among providers and visits subject at least every 2 weeks
3243830|NCT01321853|No Intervention|Usual Care Group|Admitted post home health care with no intervention.
3259350|NCT01470040|Experimental|discontinuation of aspirin therapy|
3352590|NCT02280148|Experimental|Endoscopy of Intravenous Anesthesia|20-70 year-old volunteers who hold legitimate licenses were recruited to have gastroscopy or colonoscopy under intravenous anesthesia with propofol
3352591|NCT02280161||Ancillary-Correlative (germ-line mutation analysis)|Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the investigator for germ-line mutation analysis.
3352592|NCT02280174|Experimental|Drug: linagliptin|linagliptin 5 mg/d for 12 weeks
3352593|NCT02280174|No Intervention|Drug: standard treatment|sulfonylurea treatment for 12 weeks
3352594|NCT02280213|Experimental|Intubation without chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) during resuscitation without chest compressions.
3352595|NCT02280213|Experimental|Intubation with chest compression|Endotracheal intubation of infant mannikin using different laryngoscope blades (MAC, MIL, PHIL, WIS) with uninterrupted chest compressions. Chest compressions with the two thumb-encircling hands technique were performed by the same Basic Life Support (BLS) instructor at a rate of 100 compressions per minute and at a depth of about 1.5 inches according to the European Resuscitation Council guidelines of 2010 year.
3352596|NCT02280239|Placebo Comparator|Control Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time dose of placebo via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
3352597|NCT02280239|Experimental|Acetaminophen Group|This group consists of stable but febrile ICU patients (temp >38.3°C). Participants in this group will receive a one-time does of acetaminophen 650mg via the enteral route (via the gut), after which vital signs (including continuous measures of core temperature, heart rate, and blood pressure) will be monitored for 4 hours.
3352598|NCT02280265|Experimental|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight every 48 ± 6 hours) with Recombinant Human Coagulation Factor VIII for injection(ADVATE) for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
3352599|NCT02280278|Experimental|CIK group|Stage III Colon Cancer patients after radical operation and adjuvant chemotherapy will receive 8 cycles of CIK therapy in this group.
3352600|NCT02280278|Active Comparator|Control group|Stage III Colon Cancer patients will only receive radical operation and adjuvant chemotherapy.
3352601|NCT02280330|Active Comparator|MNP group|The MNP group will receive 60 sachets of MNP in a period of 6 months or 10 sachets per month equivalent to 3-4 sachets in a week.
3352602|NCT02280330|Placebo Comparator|Placebo group|The placebo group will receive 60 sachets of placebo (with same characteristics) as the MNP or 10 sachets per month equivalent to 3-4 sachets in a week.
3352603|NCT02280356|Experimental|radiation therapy in combination with brachytherapy|Patients will undergo low dose rate (LDR) prostate brachytherapy using Pd-103 followed approximately 4 weeks later with hypofractionated image-guided external beam radiation therapy (25Gy in 5 fractions; 5Gy x 5 fractions every other day) to the prostate & seminal vesicles. Both brachytherapy as well as external beam will be performed according to our current standards of practice using the same equipment, techniques, & treatment planning procedures. Pts will be followed post-treatment at 1, 3, 6 (+/- 4 weeks) & every 6 months (+/- 4 weeks) thereafter until 36 months. During the post-treatment followup, pts will be evaluated for urinary, bowel/rectal & sexual toxicity. Baseline measures of these domains will be obtained prior to treatment at the time of enrollment. Serum PSA levels will be drawn on the same schedule as clinical followup. Post-treatment prostate biopsies will be obtained once between 24-36 months post-treatment to evaluate pathologic response to therapy
3352604|NCT02280369||automated abdominal binder|automated abdominal binder with waist and thigh accelerometers, and ActivPAL
3352605|NCT02280382|Other|Femmeze®|Femmeze® will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
3352606|NCT02280395|Experimental|RUT058-60|
3352607|NCT02280395|Placebo Comparator|Sterile Saline for Irrigation|
3352608|NCT02280434|Active Comparator|CBP-307|Participants will receive a single dose or once daily dose of CBP-307 for 28 days.
3352609|NCT02280434|Placebo Comparator|Placebo|Participants will receive a single dose or once daily dose of matching placebo for 28 days.
3352610|NCT02280447|Experimental|1/3 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/3 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3352611|NCT02280447|Experimental|1/5 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/5 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3352612|NCT02280447|Experimental|1/10 IPV-Al SSI|"Reduced dose Al(OH)3 adjuvated IPV SSI with 1/10 of dose in full dose non-adjuvated IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL suspension for injection for intramuscular use"
3352613|NCT02280447|Active Comparator|IPV SSI|"Non-adjuvated full dose IPV SSI (i.e.: Type 1:40 DU; Type 2:8 DU; Type 3:32 DU)~1 X 0.5 mL solution for injection for intramuscular use"
3243831|NCT01321866|Experimental|Experimental arm|Patients in this arm will have angioplasty of a fistula stenosis using a cutting balloon
3352614|NCT02280460||VA ECMO|Patients who are placed on VA ECMO.
3352615|NCT02280460||VV ECMO|Patients who are placed on VV ECMO.
3352616|NCT02280486|Active Comparator|Saxagliptin|The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
3352617|NCT02280486|Active Comparator|Glimepiride|Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
3352618|NCT02280512||elderly with fractures|patients more than 65 years old accepting surgeries for lower extremities fracture
3352619|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #1|"Preferred regimen for CLL and low grade lymphoma~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Days -5 to -3. Cyclophosphamide 200 mg/m2 by vein over 3 hours on Days -5 to -3. Rituximab 375 mg/m2 by vein over 3-6 hours on Day -5 for participants with B-cell cancer.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3352620|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #2|"For all malignancies if able to tolerate higher dose cyclophosphamide per the discretion of the treating physician~Lenalidomide 2.5 mg by mouth once a day on Days -2 through Day +14. Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2. Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3352621|NCT02280525|Experimental|Lymphodepleting Chemotherapy Option #3|"For myeloid malignancies~Lenalidomide 2.5 mg by mouth once a day on Days -2 to Day +14. Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2. Cytarabine 2 mg/m2 by vein on Days -6 to -2.~Dose Escalation Phase Starting Dose Level of NK Cells: 1 x 10^7 NK cells/kg given by vein on Day 0.~Dose Expansion Phase Starting Dose level of NK cells: Maximum tolerated dose from Dose Escalation Phase."
3352622|NCT02280538|Experimental|Intra-Articular Hyaluronic Acid|"hylan G-F 20 (high molecular weight hyaluronic acid):~intra-articular administration~6 mL~administered every 6 months~for 2 years"
3352623|NCT02280538|Placebo Comparator|Placebo|"Saline solution:~intra-articular administration~6 mL~administered every 6 months~for 2 years"
3352624|NCT02280551||Adolescents|1927 Grade 7 high school students
3352625|NCT02280551||Parent|A parent of each of the 1927 Grade 7 high school students
3352626|NCT02280564|No Intervention|Control|Standard diabetes care
3352627|NCT02280564|Experimental|Health coaching with technology support|Behavioral strategies including problem solving skills building, family communication counseling, technology support, motivational interviewing support.
3352628|NCT02280590|Experimental|Cresnon®|Rosuvastatin 10mg, tablet, q.d.
3352629|NCT02280590|Active Comparator|Crestor®|Rosuvastatin 10mg, tablet, q.d.
3352630|NCT02280603|Experimental|DA-4001C|DA-4001C is administered
3352631|NCT02280603|Active Comparator|5% minoxidil|5% minoxidil is administered
3352632|NCT02280616|Experimental|Low dose budesonide tablet|
3352633|NCT02280616|Experimental|High dose budesonide tablet|
3243832|NCT01321866|Active Comparator|Standard arm|Patients in this arm will have angioplasty of a fistula stenosis using a non-cutting balloon.
3243833|NCT01321892||Squamous cell carcinoma|Patients included in this study will be receiving surgical treatment for their biopsy-proven squamous cell carcinoma.
3352634|NCT02280616|Experimental|High dose budesonide suspension|
3352635|NCT02280616|Placebo Comparator|Placebo|
3259351|NCT01470040|Sham Comparator|continuation of aspirin therapy|patients will continue their pre-injury dose of low-dose aspirin therapy per previous medical indication
3352636|NCT02280629|Experimental|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
3352637|NCT02280629|Placebo Comparator|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
3352638|NCT02280629|Active Comparator|Mesalamine|LT-02 PLACEBO twice daily AND 500mg mesalamine PLACEBO three-times daily
3352639|NCT02280642||Both doses on time|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
3352640|NCT02280642||Dose 2 delayed|A delayed dose 2 was defined as > 90 days after dose 1 and an on time dose 3 was defined as ≥ 60 days to ≤ 180 days after dose 2.
3352641|NCT02280642||Dose 3 delayed|An on time dose 2 was defined as ≥ 30 days to ≤ 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
3352642|NCT02280642||Both doses delayed|A delayed dose 2 was defined as > 90 days after dose 1 and a delayed dose 3 was defined as >180 days after dose 2.
3352643|NCT02280668|Active Comparator|Control Group|Will perform the eccentric muscle damage exercise and will not perform any icing interventions post damage. These participants will be the control group.
3352644|NCT02280668|Experimental|Icing Protocol 1|Will perform the eccentric muscle damage exercise and will begin the icing intervention immediately after the muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
3352645|NCT02280668|Experimental|Icing Protocol 2|Will perform the eccentric muscle damage exercise and will begin the icing intervention 6 hours post muscle damage. The icing protocol will be icing the elbow flexor muscles for 10 minutes with a cold pack followed by 10 minutes with no icing and another 10 minutes of elbow flexor muscle icing. The participants will perform this protocol every day at approximately the same time for the duration of the study.
3352646|NCT02280681||Couples with ovarian failure|Heterosexual couples confronted with infertility due to ovarian failure between the age of 18 and 44 years old treated in the K.U.Leuven and
3352647|NCT02280681||Clinicians|Clinicians who indicated an interest in reproductive medicine in their membership of the Belgian Society for Reproductive Medicine (BSRM).
3352648|NCT02280694|Experimental|capecitabine, cyclophosphamide, methotrexate, celecoxib|"The Investigational Product: Route and Dosage Form Ambulatory/oral, continuous but not uniform, DAILY treatment~Tab. CYCLOPHOSPHAMIDE 50mg, 1X1/day ONLY days 1-5 / week; At evening only (at the end of meal)~Tab. CAPECITABINE 500mg, fixed dose of 1500mg/day (1000mg at morning + 500mg at evening) ONLY on days 1-5 / week; At morning AND at evening (at the end of meals)~Tab. METHOTREXATE 2.5mg, 1x2/day ONLY on days 6-7/week; At morning AND evening (one hour before meal)~Tab. CELECOXIB 200 mg, 1x2/day EVERY day (at the end of meal)"
3352649|NCT02280707|Experimental|Intervention|
3352650|NCT02280707|No Intervention|Control|
3259352|NCT01470053|Experimental|mometasone furoate + azelastin HCl|opaque suspension, four times each naris per day
3259353|NCT01470053|Active Comparator|mometasone furoate|opaque suspension, four times each naris per day
3352651|NCT02280720|Active Comparator|CoCr-BAS|Stenting using Optimax™ cobalt-chromium alloy platform with a titanium-nitride-oxide coating
3352652|NCT02280720|Active Comparator|PtCr-EES|Stenting using PROMUS Element™ Plus durable polymer everolimus-eluting stent built on a platinum-chromium platform.
3352653|NCT02280746|Experimental|A - gluten challenge group|Gluten challenge group - recommended daily intake of at least one normal meal containing gluten such as bread, pita, pasta, biscuits.
3243834|NCT01321905|Experimental|Ergocalciferol|"Patients younger than 16 years of age are administered 35,000 IU ergocalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU ergocalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
3243835|NCT01321905|Experimental|Cholecalciferol|"Patients younger than 16 years of age are administered 35,000 IU cholecalciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring.~Patients 16 or more years of age are administered 50,000 IU cholecalciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
3243836|NCT01321905|No Intervention|Control|Patients continue their ordinary vitamin supplementation without getting extra vitamin D supplements.
3352654|NCT02280746|No Intervention|B - gluten-free diet|Continuation of GFD.
3352655|NCT02280759|Active Comparator|Gelatin Tannate|"Gelatin Tannate:~4 times 250 mg/daily for 5 days for children under 3. years old or 4 times 500mg/daily for 5 days for children older then 3. years and under 5 years."
3352656|NCT02280759|Placebo Comparator|Placebo|Placebo consists of an identical formulation, except active substance.
3352657|NCT02280772|Experimental|Glucomannan|Glucomannan orally, 3g/day (in three divided doses), for 12 weeks
3243837|NCT01321918|Other|Case subjects|
3243838|NCT01321918|Other|Control subjects|
3243839|NCT01321931|Experimental|NRT 60|A 6 mg dose of an experimental Nicotine Replacement Therapy (NRT) given every hour for 11 hours, with a 36-hour washout between visits
3352658|NCT02280772|Placebo Comparator|Maltodextrin|Maltodextrin orally, 3g/day (in three divided doses), for 12 weeks
3352659|NCT02280785|Experimental|Brentuximab vedotin|"Brentuximab vedotin administered in 250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.~In the absence of infusion toxicities, the infusion rate for all patients must be calculated in order to achieve a 30-minute (approximate) infusion period.~Brentuximab Vedotin is dosed at 1.8mg/kg (capped at 100kg of body weight). Dosing is based on patients' weight according to the institutional standard; however, doses will be adjusted for patients who experience a ≥ 10% change in weight from baseline. Actual weight will be used except for patients weighing greater than 100 kg; dose will be calculated based on 100 kg for these individuals. The dose will be rounded to the nearest whole number of milligrams."
3352660|NCT02280798||pilot study|"A total of 5 volunteers from our egg donation program were included in the study with 4 endometrial biopsies for each one after 4 diferente protocols~Endometrial biopsy after Stimulated cycle~Endometrial biopsy after Natural Cycle~Endometrial biopsy after Natural modified cycle: the biopsy is taken seven days after the hCG~Endometrial biopsy after Hormone Replacement Therapy Cycle"
3352661|NCT02280824|Experimental|A|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
3352662|NCT02280837||Patients with suspected or diagnosed coronary artery disease|
3243840|NCT01321931|Active Comparator|NFG 60|A 4 mg dose of a marketed Nicotine Fruit Gum (NFG) given every hour for 11 hours, with a 36-hour washout between visits
3243841|NCT01321931|Experimental|NRT 90|A 6 mg dose of NRT given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
3243842|NCT01321931|Active Comparator|NFG 90|A 4 mg dose of NFG given every 90 minutes for 10.5 hours, with a 36-hour washout between visits
3352663|NCT02280850|Experimental|Guanxin Shutong Capsule|3 capsules once, tid, Oral Duration: 4 weeks
3352664|NCT02280850|Placebo Comparator|Placebo Capsule|"Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD.~3 capsules once, tid, Oral Duration: 4 weeks"
3352665|NCT02280876|Active Comparator|1 - Andrographis paniculata p/st extract|1 - Andrographis paniculata extract. Active comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the active test product (Andrographis paniculata p/st extract, oral lozenges, one BID, for 12 months), in addition to base medication (Interferon).
3243843|NCT01321931|Active Comparator|NIQ 60|A 4 mg dose of marketed nicotine mint lozenge (NIQ), given every hour for 11 hours, with a 36-hour washout between visits
3243844|NCT01321944|No Intervention|Usual clinical care|Usual clinical care provided by health care system
3243845|NCT01321944|Experimental|DTS intervention|Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP that encourages the smoker to quit, and offers a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC), free nicotine patches, and referral to additional treatment resources including the state's free telephone quitline.
3243846|NCT01321957|Active Comparator|FOLFOX+Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
3352666|NCT02280876|Placebo Comparator|2 - Excipients|2 - Excipients. Placebo comparator, consists of 15 adult patients with active Recurrent Remitting Multiple Sclerosis, randomly assigned, taking the placebo formulation (Only the excipients of the active test product, in oral lozenges of same shape, one BID, for 12 months), in addition to base medication (Interferon).
3352667|NCT02280902||Patient with immunologic and inflammatory diseases|Patient treated with corticosteroids, immunosuppressive drugs or biotherapy for immunologic and inflammatory diseases
3352668|NCT02280915|Experimental|Fortified savoury food product 1|Savoury food product fortified with iron
3243847|NCT01321957|Experimental|FOLFOX+Bevacizumab+Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
3352669|NCT02280915|Experimental|Fortified savoury food product 2|Savoury food product fortified with iron
3352670|NCT02280915|Experimental|Fortified savoury food product 3|Savoury food product fortified with iron
3352671|NCT02280915|Experimental|Fortified savoury food product 4|Savoury food product fortified with iron
3352672|NCT02280928|Experimental|Single-task motor training group|The participants will receive only balance training which will progress from stance activities, to stance activities plus hand manipulation, then gait activities, and finally gait activities plus hand manipulation.
3352673|NCT02280928|Experimental|Single-task cognitive training group|The participants will receive cognitive training that will involve executive function, attention, and working memory.
3352674|NCT02280928|Experimental|Dual-task motor-cognitive training group|The participants assigned to the dual-task motor-cognitive training group will receive the same exercises as single-task motor training while simultaneously performing secondary tasks as those in the single-task cognitive training group.
3352675|NCT02280928|Experimental|Dual-task cognitive-cognitive training group|The participants in the dual-task cognitive-cognitive trainings group will receive two cognitive tasks at the same time.
3352676|NCT02280941|Experimental|Single photon emission computed tomography|Myocardial blood flow (MBF) measurement will be analyzed using attenuation and scatter corrected dynamic single photon emission computed tomography (SPECT) imaging data. The data will be compared to MBF obtained from positron emission tomography (PET) imaging.
3352677|NCT02280954|Experimental|ICG injection group|This group will receive a single dose of ICG, infused over 40 minutes. During surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
3352678|NCT02280967|Experimental|Education about HPV by school nurse|The educational intervention consists of education about HPV and a special designed leaflet and self-reported questionnaires. The educational intervention is included in the regular health interview with the school nurse (scheduled for about one hour) and includes information about HPV; facts about the virus, transmission, what it can cause and prevention (i.e. safe sex with condom use and HPV vaccination), facts about HPV vaccine and the importance of attending future cervical cancer screening controls. Students complete questionnaires before the health interview at baseline and after three months. A follow-up with parts of the boys will be performed with qualitative interviews. Participants (n=40)
3352679|NCT02280967|No Intervention|Control group 1|Students allocated to control group 1 receives standard treatment, the regular health interview with the school nurse. Students complete questionnaires before the health interview at baseline and after three months (n=400).
3352680|NCT02280980|Experimental|Combined rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department is supplemented with a three weeks home protocol of oculomotor and gaze stability exercises.
3243848|NCT01321970|Other|Severe coronary artery disease|Patients in this group have coronary artery disease with a stenosis of >70%.
3243849|NCT01321970|Other|Coronary artery disease|Patients in this group have coronary artery disease with stenosis < 70%.
3243850|NCT01321996|Other|68Ga-DOTANOC PET/CT in patients with IPF and NSIP|one arm study: all patients were studied by 68Ga-DOTANOC PET/CT
3243851|NCT01322061|Active Comparator|Vitamin C|
3352681|NCT02280980|No Intervention|Usual rehabilitation protocol|The usual rehabilitation protocol in the physiotherapy department for patients after stroke.
3352682|NCT02280993|Experimental|DHAP-BV|Brentuximab Vedotin with DHAP chemotherapy follow by Autologous Peripheral Blood Stem Cell Transplantation
3352683|NCT02281006|Experimental|Treated ear|Trans-tympanic injection of a sodium thiosulfate gel
3243852|NCT01322061|Placebo Comparator|mirinda|
3243853|NCT01322074||Total knee arthroplasty|Patients operated with elective, unilateral total knee arthroplasty.
3352684|NCT02281006|No Intervention|Control ear|No intervention
3352685|NCT02281019||Indeterminate strictures or undefined filling defects|
3352686|NCT02281019||Biliary stone cases|
3352687|NCT02281019||Other indications|
3352688|NCT02281032|Other|interRAI Palliative Care|"15 experimental nursing homes:~Caregivers of 15 participating nursing homes receive a training about the interRAI PC and the BelRAI webapplication~Caregivers of 15 experimental nursing homes fill out the interRAI PC multidisciplinary every three months during one year for all nursing home residents with palliative care needs. Based on the results (Client Assessment Protocols and Scales) of the interRAI PC instrument, care plans are being evaluated, adapted and designed."
3352689|NCT02281032|No Intervention|No interRAI Palliative Care|"15 control nursing homes:~- Caregivers of control nursing homes do not receive the intervention and provide care as usual"
3352690|NCT02281045|Experimental|EVODIAL dialyzer and Selectbag citrate|Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
3352691|NCT02281045|Active Comparator|Regional citrate anticoagulation|Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.
3243854|NCT01322087|Experimental|Nutritional intervention|
3243855|NCT01322113||Na+, K+-ATPase/DLC system in BD|Bipolar patients in the various phases of the disease.
3352692|NCT02281058|Experimental|intervention group|Ten subjects recruited to self-administer abatacept 125mg injected subcutaneously weekly for 24 weeks to determine the impact it has on their vitiligo skin lesions.
3243856|NCT01322126|Experimental|ultrasound ,without ultrasound|ultrasound group will be passed the neuraxial anesthesia with ultrasound,the secoud group will be passed the neuraxial anesthesia without ultrasound .
3243857|NCT01322139|Placebo Comparator|High dose placebo and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3243858|NCT01322139|Active Comparator|Low dose Sativex and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily) + 16 or 28 placebo sprays (8 or 14 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3243859|NCT01322139|Active Comparator|High dose Sativex and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin placebo on Day 5.
3352693|NCT02281071|Experimental|laterally moved coronally advanced flap microsurgical|For the test group (LMCAF-M), the surgical procedures were performed with the aid of a galilean loupe, under 2.5x magnification vision, microsurgical instruments and microsurgical suture material .
3352694|NCT02281071|Active Comparator|laterally moved coronally advanced flap macrosurgical|For the control group (LMCAF), LMCAF was performed with conventional instruments (detaylı) and materials (stur). Loupe magnification, microsurgical instruments and suture material were not used in the control group.
3352695|NCT02281097|Active Comparator|Vagal Stimulation First|"Vagal stimulation to improve upright heart rate modulation and symptoms is given on first tilt study day.~Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on second tilt study."
3352696|NCT02281097|Placebo Comparator|Placebo First|"Placebo stimulation with ineffective low amplitude and frequency (sham intervention) is given on first tilt study day.~Vagal stimulation to improve upright heart rate modulation and symptoms is given on second tilt study day."
3352697|NCT02281110||iFR/FFR assessment|Patients enrolled into this prospective registry will be derived from Stable Coronary Artery disease or Acute Coronary Syndrome (ACS) population undergoing cardiac catheterization. Patients with ACS may be evaluated by functional assessment in the non-culprit stenosis during the index PCI revascularization or in a staged procedure. The registry will enroll patients in whom physiological assessment (iFR/FFR) is particularly helpful in identifying haemodynamically significant stenosis: MVD patients defined by patients with lesions > 40% and <100% in 2 or more vessels.
3352698|NCT02281123||Patient suspected of being infected by chikungunya|Patient (>= 45 ans) suspect d'infection par le virus du chikungunya et présentant des symptomes depuis moins de 10 jours
3352699|NCT02281162||Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
3352700|NCT02281162||No Weight Gain|No intervention. Will evaluate vitamin D levels and other biomarkers affecting weight with venous blood draw.
3352701|NCT02281175|No Intervention|No contact intervention|Informative document that proposes a 12-week self-withdrawal grid
3352702|NCT02281175|Active Comparator|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
3352703|NCT02281175|Experimental|psychosocial intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal + psychosocial intervention (PASSE-65+ program: 12 sessions over 16 weeks)
3352704|NCT02281201|Experimental|BE1116|Single intravenous (I.V.) infusion, dosage depending on baseline INR and body weight
3352705|NCT02281214|Experimental|blood sample, biopsy|
3352706|NCT02281227|Active Comparator|compression group|skin compression with an indicator for determination of needle entry point
3352707|NCT02281227|Active Comparator|non-compression group|non skin compression with an indicator for determination of needle entry point
3352708|NCT02281240||With hemostatic complications|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
3352709|NCT02281253|Experimental|With metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
3243860|NCT01322139|Active Comparator|High dose placebo and single oral moxifloxacin 400 mg tablet|24 or 36 placebo sprays (12 or 18 sprays twice daily) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
3243861|NCT01322152|Experimental|wXELIRI regimen|
3243862|NCT01322191|Experimental|1|Random assignment to a single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
3352710|NCT02281253|Experimental|Without metabolic syndrome|Before dietary therapy was initiated, in order to stabilise dietary patterns prior to intervention, patients were submitted to a 4-weeks run-in period of a caloric restriction of 500 Kcal to their usual diet. After this adaptation period, two intervention groups were evaluated: a calorie-restricted diet plus bread-enriched product that received 15.08 g of dietary fibre (9.49 g of insoluble fibre and 5.59 g of soluble fibre) plus 2325 mg of L-carnitine/day in 130 g of bread (enriched group) and a calorie-restricted diet plus placebo bread group whose diet included 130 g/day of not-enriched bread (placebo group).
3352711|NCT02281266|Experimental|treatment (T)|"The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.~Nucleoside analog plan to give to HBV DNA positive patients."
3352712|NCT02281266|Other|control (C)|"The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.~Nucleoside analog plan to give to HBV DNA positive patients."
3243863|NCT01322204|Experimental|1|Neonates 0-30 days, no more than 2,000 grams, receiving mechanical ventilation.
3243864|NCT01322217||AMTU Clients|All HIV-infected adolescents and young adults engaged in care at sites newly participating in ATN III and their affiliates who are between 12 and 24 years of age, inclusive, are aware of their HIV status and understand written and/or verbal English will be eligible for inclusion in the study. In addition, new patients who have their initial clinic visit within the enrollment period will also be eligible for participation.
3243865|NCT01322230|Experimental|Control|Screen shots with voiceover and no interactivity
3243866|NCT01322230|Experimental|WISEMD Original|Learner control of pacing through multi-media content
3243867|NCT01322230|Experimental|Social Networking|social networking features (Forum and Social Presence)
3243868|NCT01322230|Experimental|Social Networking plus Emotional Design|Social networking features plus user interface enhancements
3243869|NCT01322243|Other|Dietary Intervention: Fasted State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission.
3243870|NCT01322243|Other|Dietary Intervention: Fed State|Participants will be randomized to a dietary intervention of a fasted or fed group upon admission
3352713|NCT02281279|Experimental|Treatment (rituximab, romidepsin, lenalidomide)|Patients receive rituximab IV over 90 minutes on day 1; romidepsin IV over 4 hours on either day 1, days 1 and 8, or days 1, 8, and 15; and lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3352714|NCT02281292|Experimental|LKA651 (Part 1)|LKA651 ophthalmic solution in 1 of 5 concentrations, administered as a single IVT injection in the study eye
3352715|NCT02281292|Placebo Comparator|Sham injection (Part 1)|Sham injection in the study eye
3352716|NCT02281292|Experimental|LKA651 and Lucentis (Part 2)|LKA651 ophthalmic solution in 1 of 3 concentrations, administered as a single IVT injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
3352717|NCT02281292|Placebo Comparator|Sham injection and Lucentis (Part 2)|Sham injection in the study eye, followed by ranibizumab ophthalmic solution, 0.5 mg injection in the same eye 30 minutes later
3352718|NCT02281305|Experimental|Colchicine Active treatment group|Drug: Colchicine 2 mg loading dose; 0.5 mg bid for 5 days
3352719|NCT02281305|Placebo Comparator|Control group|Drug: Placebo
3352720|NCT02281331|Active Comparator|Supplement|Each day, participants in this group will receive a supplement that provides a total of protein, creatine monohydrate, calcium, vitamin D and carbohydrate. This supplement will be provided to participants in beverage format, twice daily.
3352721|NCT02281331|Placebo Comparator|Placebo|The placebo will provide participants with maltodextrin (carbohydrate) and sucrose.
3352722|NCT02281370|Experimental|SEQUENCE D0, D1, D2|Participants will receive treatment D0 in treatment period 1, D1 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 milligram (mg), D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3352723|NCT02281370|Experimental|SEQUENCE D1, D0, D2|Participants will receive treatment D1 in treatment period 1, D0 in treatment period 2 and D2 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3352724|NCT02281370|Experimental|SEQUENCE D1, D2, D0|Participants will receive treatment D1 in treatment period 1, D2 in treatment period 2 and D0 in treatment period 3 (one treatment per period). Where D0=eltrombopag 50 mg, D1= cyclosporine 200 mg + eltrombopag 50 mg, and D2= cyclosporine 600 mg + eltrombopag 50 mg. Treatment periods will be separated by washout periods of 3-10 days
3243871|NCT01322256|Experimental|Included patients|"Patients included in the study according to stated inclusion and exclusion criteria~Intervention: Bone scintigraphy Intervention: Leukoscan Intervention: PET / CT Intervention: Bone biopsy Intervention: Bloodwork"
3243872|NCT01322269|Experimental|HQK-1001 (30 mg/kg)|
3243873|NCT01322269|Experimental|HQK-1001 (40 mg/kg)|
3243874|NCT01322269|Experimental|HQK-1001 (50 mg/kg)|
3352725|NCT02281383|Experimental|Bacillus Calmette-Guérin (BCG)|Patients will be treated with an induction course (6 intravesical instillations) of BCG followed by a second induction course (6 intravesical instillations), with a recovery period between the 2 treatment courses.
3352726|NCT02281396|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
3352727|NCT02281396|Experimental|2.5IU/ml in humans aged 21-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
3352728|NCT02281396|Active Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 10-20 years old on day 0,3,7,14,28
3352729|NCT02281396|Active Comparator|2.5IU/ml in humans(from 21-60 years old)|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml in 20 humans aged 21-60 years old on day 0,3,7,14,28
3243875|NCT01322282|Experimental|ODT with Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken with 240 mL of water
3243876|NCT01322282|Experimental|ODT Without Water|Experimental Cetirizine 10 mg Orodispersible Tablet (ODT) taken without 240 mL of water
3243877|NCT01322282|Active Comparator|FCT with Water|Marketed Cetirizine 10 mg Film-Coated Tablet (FCT) taken with 240 mL of water
3243878|NCT01322308|Placebo Comparator|sugar pill|tablet similar to comparator
3352730|NCT02281435|Experimental|PrePex with Incision|Adult male circumcision by the PrePex™ device using foreskin incision
3352731|NCT02281461|Experimental|Early ifants|Intervention Male circumcision using a non-surgical device
3352732|NCT02281461|Experimental|Cildren|Intervention Male circumcision using a non-surgical device
3352733|NCT02281474|Active Comparator|150mg dosing|This arm will take 150mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
3352734|NCT02281474|Active Comparator|300mg dosing|This arm will take 300mg of Nilotinib by mouth daily for the 6 month drug period to establish a safe and efficacious dose.
3352735|NCT02281487|Active Comparator|Hysterectomy|standard hysterectomy
3352736|NCT02281487|Experimental|Hysterectomy plus tubectomy|Hysterectomy plus tubectomy
3352737|NCT02281513|Other|ANTLER Pilot Cohort|Pilot study participants will be provided the smartphone application, fitbit activity monitor, and coaching sessions.
3243879|NCT01322308|Active Comparator|pioglitazone|30 mg tablets QD (taken once daily)
3243880|NCT01322321|Experimental|ACZ885|
3243881|NCT01322321|Placebo Comparator|Placebo|
3243882|NCT01322334|Experimental|Singing exercises|
3243883|NCT01322373||Healthy control subjects (HC)|Subjects who met criteria as healthy control subjects and completed Orasi Protocol ADG-08-01.
3243884|NCT01322373||Alzheimer's disease subjects (AD)|Subjects with a diagnosis of DAT according to DSM-IV-TR criteria who completed Orasi Protocol ADG-08-01.
3243885|NCT01322399|Experimental|Structural Integration plus usual care|Each subject in this arm will receive ten Structural Integration treatments at intervals of between one and three weeks, and will also receive usual care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
3352738|NCT02281539|Experimental|Treatment using myoelectric signals|Virtual- and augmented reality, are controlled by the patient's phantom limb using muscle (myoelectric) signals from the stump. The patient learns to reactivate areas in the brain related to motor control of the missing limb. The medical device is non-invasive and based on surface electromyography
3352739|NCT02281578|Experimental|Combination prevention|Community-based, combination HIV prevention intervention package
3352740|NCT02281578|Active Comparator|Standard of care|Locally run standard of care HIV prevention, treatment and care services
3352741|NCT02281604||0.2/1.2 microliter filter|Use of 0.2/1.2 microliter filters for intravenous drug administration
3352742|NCT02281604||5 mircroliter filter|Use of 5 microliter filters for intravenous drug administration
3243886|NCT01322399|Active Comparator|Usual care|Each subject in this arm will receive care for chronic low back pain as standard practice at Spaulding Medford Rehabilitation Clinic, which may include pain medication, exercise and physical therapy. Usual care will be provided on average twice weekly for between 3 and 7 weeks, at the discretion of the clinic's medical director
3352743|NCT02281630|Experimental|KWA-0711 High dose|
3352744|NCT02281630|Experimental|KWA-0711 Low dose|
3352745|NCT02281630|Placebo Comparator|Placebo|
3352746|NCT02281643|Experimental|Early doxycycline administered|Early doxycycline administered - volunteers will be treated immediately with 200mg daily doxycycline for 6 weeks
3352747|NCT02281643|Active Comparator|Delayed doxycycline administered|Delayed doxycycline administered-volunteers will be treated six months after the early group has received treatment with 200mg daily doxycycline for 6 weeks
3352748|NCT02281656|Experimental|Reverse End-to-side|"Surgery: a reverse end-to-side AIN to ulnar nerve transfer whereby the motor branch of the ulnar is left intact and the end of the AIN nerve is coapted to the side of the ulnar motor fascicle(5,6). The advantage of this technique is it preserves the continuity of the ulnar motor branch for axons if they do eventually reinnervate the intrinsic muscles while augmenting or babysitting these muscles during the time period until this occurs."
3352749|NCT02281656|Active Comparator|Surgery:standard care|Surgery: the anterior interosseous (AIN) to motor branch of the ulnar nerve transfer has been established as an effective means to reinnervate ulnar innervated intrinsic hand muscles (without loss of function from using the AIN) when nerve injury is too proximal for recovering axons to reach the hand by 18 months. . The procedure (surgery) is presently the standard of care
3352750|NCT02281669||Research group|The study group includes all CL cases for whom the treating physician decides to treat by IL Pentostam. The patients will return to follow up and additional treatment every 3 weeks until full recovery [as our current policy].
3352751|NCT02281682|Active Comparator|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
3352752|NCT02281682|Active Comparator|5-Fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
3352753|NCT02281682|Active Comparator|Ingenol mebutate 0.015%|during 3 (consecutive) days once daily. Prior to treatment: curettage
3352754|NCT02281682|Active Comparator|MAL-PDT|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
3352755|NCT02281695|Active Comparator|Arm A|"Patients that are mechanically ventilated for less than 24 hours until the weaning process can be started.~At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen."
3352756|NCT02281695|Active Comparator|Arm B|Patients that are mechanically ventilated for more than 24 hours until the weaning process can be started. At the beginning of the weaning process the PEEP will be adjusted at a value equal with the PEEP during BiPAP (Group 1) and Pmean during BiPAP (Group 2) During controlled mechanical ventilation all patients will be for 5 minutes with FiO2 - 100% ventilated. The PaO2/FiO2 after 5 minutes ventilation with 100% oxygen will be compared with the PaO2/FiO2 during ventilation with 30% oxygen.
3352757|NCT02281708|No Intervention|low risk|low risk; observation
3352758|NCT02281708|No Intervention|high risk; observation group|high risk: observation
3352759|NCT02281708|Experimental|high risk; adjuvant chemotherapy group|high risk. vinorelbine plus cisplatin
3352760|NCT02281721||Single Group; Surpass Flow Diverter(s)|Individuals using the Surpass Flow Diverter(s)
3259354|NCT01470053|Active Comparator|azelastine HCl|lucidus colorless liquid, two times each naris per day
3352763|NCT02281786|Experimental|Cohort 1|8 volunteers (6 active, 2 placebo)
3352764|NCT02281786|Experimental|Cohort 2|8 volunteers (6 active, 2 placebo)
3352765|NCT02281786|Experimental|Cohort 3|8 volunteers (6 active, 2 placebo)
3352766|NCT02281786|Experimental|Cohort 4|8 volunteers (6 active, 2 placebo)
3352767|NCT02281786|Experimental|Cohort 5|8 volunteers (6 active, 2 placebo)
3352768|NCT02281786|Experimental|Cohort 6|8 volunteers (6 active, 2 placebo)
3352769|NCT02281799|Experimental|Open label|"10 patients diagnosed with IBD, treated previously with thiopurines and ceased treatment due to suspected thiopurine-induced pancreatitis.~Patients will be commenced on an alternative thiopurine to that used initially,. The medications will be commenced at standard dose (ie Azathioprine 2.5mg/kg/day, 6-MP 1.5mg/kg/day)."
3352770|NCT02281812|Experimental|RFA group|A percutaneous (utlrasound-guided) radiofrequency ablation (RFA) of the tumor will be performed by the radiologist under general anesthesia. Immediately after, excision of the tumor with appropriate margin will be accomplished.
3352771|NCT02281812|No Intervention|Control group|Normal excision of the tumor according to the protocol
3352772|NCT02281825||Control|Adolescents without any psychiatric disorder
3352773|NCT02281825||Study|Adolescents with psychiatric disorder of the following: Attention-Deficit and Hyperactivity Disorder, Conduct, Oppositional defiant Disorder, Anxiety, Depression, Disruptive Mood Dysregulation Disorder
3352774|NCT02281838|Experimental|Target systolic BP <140mmHg|Systolic blood pressure will be reduced to <140 mmHg within 1 hour of randomization.
3352775|NCT02281838|Active Comparator|Target systolic BP <180mmHg|Systolic blood pressure will be reduced, to <180 mmHg within 1 hour of randomization.
3352776|NCT02281864|Other|Control Group: Quitline|Quitline referral. If the family is randomized to the control group, the research team will give the parent a brochure for the QuitLine
3243887|NCT01322412||Arm A : physical activity program|Arm A : physical activity program (aerobic and strength training) during the 27 weeks of treatment (chemotherapy and radiotherapy) and conventional follow-up during 27 weeks
3243888|NCT01322412||Arm B : conventional management|Arm B : conventional management during and after treatment
3352777|NCT02281864|Experimental|Intervention Group|Smoking Cessation Intervention Bundle. The Investigator has developed an intervention that bundles the best evidence for tobacco dependence treatment, including the USPHS guidelines, and evidence from parent-specific interventions, to create a sustainable, transferrable intervention specific to using the inpatient stay to help parents quit smoking and reduce their children's exposure. The intervention bundle includes screening for exposure, assessing readiness to quit, providing at least one brief motivational interviewing session in the hospital, dispensing nicotine replacement therapy if appropriate, providing a smoking cessation/reduction starter kit and arranging for follow up after the child is discharged.
3352778|NCT02281877|Experimental|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) 48 hours after TKA, 5x/week, 2x/day, for 45 minutes/session.~Standard Rehabilitation Protocol"
3352779|NCT02281877|Active Comparator|Control|Standard Rehabilitation Protocol
3352780|NCT02281890||Proven sepsis|Children included in the INIS trial in whom pathogenic organisms (i.e. bacteria or fungi) were cultured from blood and/or cerebrospinal fluid during the sepsis period at the time of study inclusion
3352781|NCT02281890||Clinical sepsis|Children included in the INIS trial in whom no pathogenic organisms (i.e. bacteria or fungi) were cultured from blood or cerebrospinal fluid during the sepsis period at the time of study inclusion
3352782|NCT02281903|Experimental|Chest compression of manikins chest|Compression of pediatric manikins chest according European Resuscitation Council 2010 guidelines for cardiopulmonary resuscitation.
3352783|NCT02281916|Experimental|P28GST treatment|P28GST as a parasite enzyme
3243889|NCT01322438|Experimental|Arm 1|
3352784|NCT02281929|Active Comparator|amoxicillin+ prednisolone|Oral antibiotherapy during 30 days using amoxicillin+clavulanic acid at a daily dose of 3 gram (amoxicillin) and 375 mg (clavulanic acid) in three daily doses of 1g/125mg. Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
3352785|NCT02281929|Placebo Comparator|Placebo + prednisolone|Oral placebo of amoxicillin- clavulanic acid in three daily doses during 30 days Oral corticotherapy during 30 days with prednisolone at 40 mg/j in a single daily dose in the morning.
3352786|NCT02281942|Experimental|Yoga|Sequential movements in coordination to the breath cycle followed by seated and supine postures to release muscle tension.
3352787|NCT02281942|Placebo Comparator|Education|A series of 30-minute recordings focused on different aspects of healthy living (e.g. diet, stress).
3352788|NCT02281968|Experimental|NSAID cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.
3352789|NCT02281968|Placebo Comparator|Placebo cohort|Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of placebo twice a day and will have received one intraoperative dose of saline solution. Patients will have a prescription for opioids for pain.
3352790|NCT02281981|Experimental|Curcumin supplement|200 mg, curcuminoids, 7d of supplementation in capsular form
3352791|NCT02281981|Placebo Comparator|Placebo|sucrose, capsular
3352792|NCT02281994|Active Comparator|Active PEMF|Active device emits Pulsed Electromagnetic Field (PEMF)
3352793|NCT02281994|Placebo Comparator|Control/no PEMF|control/placebo device does not emit Pulsed Electromagnetic Field (PEMF)
3352794|NCT02282007|No Intervention|No Intervention:Control group|
3243890|NCT01322451|Experimental|Single oral dose, single capsule|
3243891|NCT01322451|Experimental|Single oral dose, two capsules|
3243892|NCT01322464|Experimental|Group 1 Fasted-Fed|"4 sprays Sativex in fasted state, followed by wash-out followed by 4 sprays Sativex in fed state.~Followed by 4 sprays daily in fasted state."
3243893|NCT01322464|Experimental|Group 1 Fed-Fasted|"4 sprays sativex in fed state followed by wash-out followed by 4 sprays Sativex in fasted state.~Followed by 4 sprays daily in fasted state."
3243894|NCT01322464|Experimental|Group 2|2 sprays Sativex daily in fasted state.
3352795|NCT02282007|Experimental|Individual NPMP to the participants|This arm will receive NPMP for 6 months, individually adjusted to their problems.
3243895|NCT01322464|Experimental|Group 3|8 sprays sativex daily in fasted state.
3243896|NCT01322477||Hepatocellular Carcinoma|Patients with advanced HCC
3243897|NCT01322503|Experimental|Norovirus Challenge|
3243898|NCT01322503|Experimental|Norovirus challenge|
3243899|NCT01322620||A|
3243900|NCT01322646|Active Comparator|Driver Training|Driver Education Program Practice driving on a driving simulator Provision of the CarChipPro to the family
3243901|NCT01322646|Experimental|STEER Program|Driver Education STEER Program
3243902|NCT01322659|Active Comparator|Helmet NPPV|Weaning from mechanical ventilation with noninvasive positive pressure ventilation (NPPV)delivered by means of the helmet
3243903|NCT01322659|Sham Comparator|ETT IMV|Weaning from mechanical ventilation with standard invasive mechanical ventilation (IMV) delivered by means of the endotracheal tube (ETT)
3243904|NCT01322685||Health Group|
3243905|NCT01322685||Tuberculosis Group|Tuberculosis or lung cancer group
3243906|NCT01322698||The study population|The target population includes patients in ICUs at the Nîmes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils > 500/mm3) at risk of developing invasive candidiasis.
3243907|NCT01322711|Active Comparator|Atorvastatin|"Each day accordingly to randomization patients allocated to Atorvastatin received a pill of 40 mg of atorvastatin. In diabetic patients the concomitant aspirin treatment include a previous 30 days treatment with 100 mg daily of aspirin.~All patients followed the diet used in the placebo group."
3352796|NCT02282033|Experimental|Treatment|"This is an unblinded, treatment only study in which each patient serves as his or her own control.~All patients who meet entry criteria will undergo implantation of the Moderato System. During the first month the pacemaker Performance will be evaluated and an additional 3 month period of treatment for studying the Moderato-HTN therapy effect."
3352797|NCT02282046||non-diabetic group|patients without diagnosed type 2 diabetes, having an HbA1c level below 6.0%
3243908|NCT01322711|Placebo Comparator|Diet|Low-fat diet with mean macronutrient profiles that were close to the present Adult Treatment Panel III guidelines (7% energy from saturated fat and, 200 mg dietary cholesterol per day)
3243909|NCT01322724|Active Comparator|Warm water|Body temperature (95-100 degrees F) water
3243910|NCT01322724|Experimental|Cool water|Room temperature (68-73 degrees F) water
3352798|NCT02282046||type 2 diabetes group|patients diagnosed with type 2 diabetes of over 1 year duration.
3352799|NCT02282059||sunitinib group|patients with progressive, unresectable, advanced or metastatic well-differentiated pNET
3352800|NCT02282072|Active Comparator|Deep Brain Stimulation|Stimulator is ON
3243911|NCT01322737|Experimental|SUMO Tissue Access and Resection System|
3243912|NCT01322750||With CTCs|Those individuals whom are identified with CTCs
3243913|NCT01322750||Without CTCs|Those individuals whom present and did not have CTCs
3352801|NCT02282072|Sham Comparator|Placebo|Stimulator is OFF
3352802|NCT02282085|Experimental|Aripiprazole Once-Monthly|Switch to 400 mg aripiprazole once-monthly injection
3352803|NCT02282085|Active Comparator|Standard of Care|Continue current SOC oral antipsychotic medication
3243914|NCT01322776|Experimental|Bortezomib,Fludarabine,Cyclophosphamide|
3243915|NCT01322789|Experimental|Intravenous mesenchymal stem cell|This group wil receive 8 intravenous infusions of mesenchymal stem cells. Four infusions 1 week apart and 4 infusions a month apart
3243916|NCT01322802|Experimental|Treatment (pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine)|Patients receive pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine ID monthly for 3 months.
3243917|NCT01322828|Active Comparator|Single incision repair of distal bicep tendon rupture|In this treatment arm patients will have a single incision technique used to repair their distal bicep tendon rupture
3243918|NCT01322828|Active Comparator|Double incision repair of distal bicep tendon rupture|In this treatment arm, patients will have a double incision technique used to repair their distal bicep tendon rupture.
3243919|NCT01322854|Experimental|IMRT + integrated boost|28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost
3243920|NCT01322854|Other|Conventional RT + sequential boost|Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy
3352804|NCT02282098|Experimental|Active Colchicine|The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months
3243921|NCT01322867|Active Comparator|Reference Drug|
3243922|NCT01322867|Active Comparator|Test Drug|
3243923|NCT01322880|Other|Control Arm|The project, administered by the International Rescue Committee (IRC), involved 25 village savings and loans association (VSLA) groups across the province. The VSLA groups initially formed through local members of the community designated as community based facilitators (CBF).
3352805|NCT02282098|Placebo Comparator|Placebo Colchicine|The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.
3352806|NCT02282124|Experimental|Intervention|"The intensity of the intervention follows a defined algorithm during the first eight months after renal transplantation. Behaviours are classified in three groups:~Group 1: Patients with optimal behaviour in all three behaviours.~Group 2: Patients with slight deviation (defined) from optimal behaviour in one or more behaviours.~Group 3: Patients with larger deviation (defined) from optimal behaviour in one or more behaviours.~All patients (group 1-3) will receive an assessment, education and a monthly reassessment.~Patients from group 2 und 3 will receive additionally behavioral education and peer involvement. Patients from group 3 will receive additionally a consilium of specialized healthcare professionals such as a nutritionist, physiotherapist, or psychologist."
3352807|NCT02282124|Other|Control|
3352808|NCT02282137|Experimental|68Ga-PSMA|Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.
3352809|NCT02282150|Other|Conventional vs modified hydrocortisone;|5 weeks of conventional hydrocortisone followed by 16 weeks of modified-release hydrocortisone (Plenadren)
3352810|NCT02282176|Experimental|Azithromycin|10mg/kg azithromycin IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
3352811|NCT02282176|Placebo Comparator|Placebo|Placebo IV daily (administered over a period of at least one 1 hour) for a period of 10 days.
3352812|NCT02282189|Other|Off/on for 4 weeks followed by on/off for 4 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device or no device for four weeks, then crossover for the following four weeks.
3352813|NCT02282202|Other|Off/on for 3 weeks followed by on/off for 3 weeks|Subjects are randomized to either Oscillating Positive Expiratory Pressure device (Aerobika ®) or no device for three weeks, then crossover for the following three weeks.
3352814|NCT02282215|Experimental|CLT-008 low dose with G-CSF|Dose escalation
3352815|NCT02282215|Experimental|CLT-008 high dose with G-CSF|Dose escalation
3352816|NCT02282215|Experimental|CLT-008 with G-CSF|Randomized
3352817|NCT02282215|Active Comparator|G-CSF|Randomized
3352818|NCT02282241|Placebo Comparator|Placebo|Patients given once daily placebo (cellulose) orally in the evening, for 14 days.
3352819|NCT02282241|Experimental|Melatonin|Patients given once daily melatonin 1.5mg orally in the evening, for 14 days.
3352820|NCT02282254|Active Comparator|Single-hormone closed-loop strategy|
3352821|NCT02282254|Active Comparator|Dual-hormone closed-loop strategy|
3243924|NCT01322880|Experimental|Treatment Group|"Half of the VSLA participants were invited to participate in an additional set of discussion groups to be attended along with their spouse. All participants were informed that due to space constraints, only half of the members would be able to attend. In each VSLA, individuals drew numbers from a bag or hat, and those with winning slips were the ones who entered the discussion groups with spouses."
3243925|NCT01322893||Blood sampling.|Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6.
3243926|NCT01322906|Other|Group A|Thirty of the enrolled patients were assigned to Group A to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
3243927|NCT01322919|Experimental|Myopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a myopic condition of the eye in conjunction with a presbyopic condition
3243928|NCT01322919|Experimental|Hyperopic Treatment Arm|Patients treated in this arm will have preoperative measurements that indicate a hyperopic condition of the eye in conjunction with a presbyopic condition
3352822|NCT02282267|Experimental|Gefitinib|Patients with EGFR mutation in plasma detected by droplet digital PCR could receive Gefitinib 250mg every day until disease progression.
3352823|NCT02282280||Study Group|All patients included in the study
3352824|NCT02282306|Other|TTIP-PRO|"Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the Personal Feedback Report, which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the Personal Risk Factors Report which is mailed to the participant with some other helpful information."
3352825|NCT02282319|Experimental|A chloro|spinal chloroprocaine 40 mg
3243929|NCT01322958||At Risk of Ectopic Pregnancy|Women who present to the emergency department at UCSF who are at risk of ectopic pregnancy.
3243930|NCT01322984|Active Comparator|Normal controls|Normal children and youths
3352826|NCT02282319|Experimental|B chloro+ spin dexdor|Spinal chloroprocaine 40 mg spinal dexmedetomidine 0.5 mcg
3352827|NCT02282319|Experimental|C chloro + IV dexdor|Spinal chloroprocaine 40 mg IV dexmedetomidine 0.5 mcg/kg
3352828|NCT02282345|Experimental|Treatment (talazoparib)|"Patients receive talazoparib PO QD on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then proceed to the standard of care therapy of the treating physician's choice.~This arm was concluded early after 13 patients. An expansion arm of 20 patients was opened in August 2016 to include at least 4 and up to 6 cycles of talazoparib, followed by surgery to estimate residual cancer burden after therapy with single-agent talazoparib."
3352829|NCT02282358|Experimental|Mocetinostat|Patients who harbor mutations for CREBBP and/or EP300 will be started on mocetinostat 70 mg orally three times per week on a 28 day schedule in cycle 1. The dose will be escalated in cycle 2 to 90 mg orally three times per week on a 28 day schedule if there are no grade 3 or higher drug related toxicities. Therapy will continue until disease progression, intolerable toxicities or death.
3352830|NCT02282371|Experimental|Cetuximab + BYL719 + IMRT|Cetuximab loading dose, 400 mg/m2 intravenously (IV). IMRT, 1 fraction/day, up to total of approximately 70 Gy, over approximately 33 treatment days Cetuximab 250 mg/m2 weekly IV X 7 weeks Daily BYL719, according to dose escalation scheme followup clinic visits every 3 months for 2 years,every 6 months for the next 3 years, and annually thereafter.
3352831|NCT02282384|Experimental|oseltamivir|75 mg oseltamivir orally twice daily for 5 days within 72 hours of symptom onset
3352832|NCT02282384|Placebo Comparator|Placebo|75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir
3352833|NCT02282397|No Intervention|Phase 1: SMBG|Type 1 or Type 2 diabetes mellitus subjects using SMBG testing and usual care for diabetes management. No intervention to be administered
3352834|NCT02282397|Other|Phase 1: CGM|Type 1 or Type 2 diabetes mellitus subjects using RT-CGM and SMBG testing for diabetes management. RT-CGM (Continuous Glucose Monitoring) is the intervention.
3352835|NCT02282397|No Intervention|Phase 2: CGM/MDI|Type 1 Diabetes Mellitus subjects using RT-CGM and injections for diabetes management.
3352836|NCT02282397|No Intervention|Phase 2: CGM/CSII|Type 1 Diabetes Mellitus subjects using RT-CGM and CSII for diabetes management.
3352837|NCT02282410|Experimental|ADVATE standard prophylaxis|This study is a prospective, open-label, interventional, multicenter study in a total of 15 PTPs with hemophilia A (FVIII≤2 %).The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year. Subjects must be prescribed ADVATE by the treating physician. Data will be collected over a period of 2 years from the time of study enrollment. Study visits are to coincide with routinely rescheduled and emergency visits. Available data from these visits shall be transcribed onto the case report forms (CRFs).
3352838|NCT02282423|Experimental|Lean Controls|"Lean controls will have BMI of 25 or less, gender specific normal body fat, and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3352839|NCT02282423|Experimental|Obese, Non-diabetic|"Obese nondiabetics will have a BMI between 30-50 and not be taking any medication that affects glucose metabolism.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3352840|NCT02282423|Experimental|Diabetic|"Diabetic patients will have a BMI between 30-50. We will recruit patients with mild or newly diagnosed type 2 diabetes who are treated with diet, sulfonylureas, or other drugs working through enhanced insulin secretion. Patients taking metformin or TZDs will not be recruited due to the effects of those drugs on insulin action.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3243931|NCT01322984|Experimental|ASD|Children and youths diagnosed with autism spectrum disorder (ASD)
3243932|NCT01322997|Experimental|Myomo + RTP|This group will be administered a regimen comprised of repetitive task specific practice (RTP) in conjunction with use of the robotic brace described elsewhere in this record.
3243933|NCT01322997|Active Comparator|Myomo|Patients in this group will only be administered the robotic brace described elsewhere in this record.
3243934|NCT01322997|Active Comparator|RTP only|Patients in this group will be administered repetitive task specific practice (RTP), emphasizing use of their affected arms during performance of valued, functional tasks.
3243935|NCT01323036|Experimental|Krill Oil|
3243936|NCT01323036|Experimental|Fish Oil|
3243937|NCT01323049|Active Comparator|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia in this group
3352841|NCT02282423|Experimental|Non-diabetic|"Patients will be nondiabetic, although we will include patients with impaired glucose tolerance. Patients will meet criteria for treatment with fibrates to lower plasma triglyceride concentrations (triglyceride>300 mg/dl for nondiabetics, 250 mg/dl for patients with impaired glucose tolerance). We will aim at recruiting equal numbers of men and women. All participants will be between the ages of 30 and 59. Patients will have a BMI of 25-50 and not be taking any other medication that affects glucose metabolism. All participants will be sedentary (not reporting more than 10 minutes per day of light to vigorous leisure time physical activity.~Interventions include OGTT, Clamp, VO2 Max, Exercise Test and Muscle Biopsy"
3352842|NCT02282436||COPD exacerbation|No specific intervention for this study
3352843|NCT02282449|Experimental|Power Injectable Port|The subjects randomized to this group will receive the newer, power injectable port.
3243938|NCT01323049|Active Comparator|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia in this group
3243939|NCT01323062|Other|Single-arm trial|Single-arm trial
3243940|NCT01323075||Renal insufficiency group|Patients in this group have renal insufficiency as defined by a creatinine clearance of < 30 ml/min without dialysis. These patients do not have diabetes.
3352844|NCT02282449|Active Comparator|Non-Power Injectable Port|The subjects randomized to this group will receive the older, non-power injectable port.
3352845|NCT02282462|Experimental|Reg pressure, Active suction (Dig)|Regulated pleural pressure with active suction
3243941|NCT01323075||Diabetic group|These patients have diabetes, but not renal insufficiency.
3243942|NCT01323075||Non-exposed group|These patients have neither a neurological nor a metabolic disease and a creatine clearance of > 90 ml/min
3243943|NCT01323088|Other|Control|Standard care control (no-exercise)
3352846|NCT02282462|Experimental|Reg pressure, Passive drainage (Dig)|Regulated pleural pressure with passive drainage
3352847|NCT02282462|Experimental|Unreg pressure, Active suction (Trad)|Unregulated pleural pressure with active suction
3352848|NCT02282462|Experimental|Unreg pressure, Passive drainage (Trad)|Unregulated pleural pressure with passive drainage
3352849|NCT02282475||Cohort study of pregnant women|"Participants will complete the following at 12-16 weeks gestation and again at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat using air displacement technology and MRI;~Ultrasound to measure placental blood flow, visceral fat thickness (12-16 weeks only) and to estimate fetal weight (32-36 weeks only);~24 hour diet recalls~Questionaires regarding activity level"
3352850|NCT02282475||Case-control study Gestational Diabetes|"Participants diagnosed with gestational diabetes (cases) and without gestational diabetes (controls) will complete the following at 32-36 weeks gestation:~Fasting glucose, insulin and insulin sensitivity testing;~Blood tests for cholesterol and fatty acids, liver function, inflammation, and markers of metabolism;~Measurements of body fat by using air displacement technology and MRI;~Ultrasound to measure placental blood flow and to estimate fetal weight;~24 hour diet recalls~Questionaires regarding activity level"
3352851|NCT02282488|Experimental|Group 1: Low protein formula|Low protein formula
3352852|NCT02282488|Experimental|Group 2: high protein formula|High protein formula
3352853|NCT02282488|No Intervention|Group Breastfeeding|Breastfeeding
3243944|NCT01323088|Active Comparator|Aerobic Exercise|
3243945|NCT01323088|Active Comparator|Resistance Exercise|
3243946|NCT01323101|Sham Comparator|Control|No doxycycline
3352854|NCT02282501|Active Comparator|intermittent feeding|Bolus infusion - The total daily feeding period was also 4-6 times a day.
3352855|NCT02282501|Active Comparator|continuous feeding|Continuous infusion - The daily desired amount was offered continuously for 20 hours a day.
3352856|NCT02282540|Experimental|Iodixanol to the Eustachian tube|Iodixanol contrast medium diluted with NaCl to 20% into the tympanostomy tube while the patient lies on his / her back with the head slightly turned to the opposite side. After 10 minutes the CT examination will be conducted using 200 mA and 120 kV.
3352857|NCT02282553|Experimental|Magnetically steerable pill camera|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet. This technique will be compared to conventional gastroscopy which uses a flexible endoscope. Both techniques will be used to diagnose upper gastrointestinal pathology in patients with recurrent/refractory iron deficient anemia.
3352858|NCT02282566|Placebo Comparator|Protein-nutrition beverage - Placebo|: 8 oz protein-nutrition beverage 1
3352859|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 2|8 oz protein-nutrition beverage 2
3352860|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 3|8 oz protein-nutrition beverage 3
3243947|NCT01323101|Experimental|Doxycycline|
3243948|NCT01323114|Active Comparator|Medical Control Group|Control group of patients who will receive conventional medical treatment for type 2 diabetes, along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
3243949|NCT01323114|Experimental|Surgical Treatment Group|Experimental group in which patients will undergo the laparoscopic duodenal bypass procedure along with regular dietary and diabetic education, under the monitoring of the study endocrinologist.
3243950|NCT01323127||Chronic back pain|This group of patients has had chronic back pain for longer than 3 months.
3243951|NCT01323127||Non chronic back pain|This group of patients is hospitalized for cardio physical therapy, and has no lumbar-pelvic complications. Patients are selected from the hospitalized population according to age, sex, and BMI in order to match chronic back pain patients.
3352861|NCT02282566|Experimental|Protein-nutrition beverage - Beverage 4|8 oz protein-nutrition beverage 4
3352862|NCT02282579||Patient with metastatic renal cell carcinoma treated|Patient with metastatic renal cell carcinoma treated with Pazopanib
3243952|NCT01323166||Excision of the levator muscle|The abdominal part of the operation is performed as an TME and the perineal part of the operation is performed with the intent to get a cylindrical specimen thus removing part of or the entire levator muscle with the specimen
3243953|NCT01323166||Traditional perineal operation|The abdominal part of the operation performed as a TME. The perineal operation performed with the intent of removing the tumour with CRM free of tumour and the levator left in place
3243954|NCT01323179||Strong opioids|Patients taking strong opioids preoperatively
3243955|NCT01323179||Weak opioids|Patients taking weak opioids preoperatively
3243956|NCT01323179||Opioid native|Patients not taking opioids preoperatively
3352863|NCT02282592||Cases|newly diagnosed (within 6 months) breast cancer patients, before adjuvant or neoadjuvant treatment.
3352864|NCT02282592||Controls|patients without any malignant disease, matched for age an menopausal status with cases.
3352865|NCT02282618||heart failure with HTEA|Heart failure patients are treated with the world-wide accepted medicine, plus HTEA for 4 weeks.
3352866|NCT02282618||heart failure with medicine|Heart failure patients are treated with the world-wide accepted medicine.
3352867|NCT02282644|Experimental|CellSearch|
3352868|NCT02282657|Experimental|One single arm|Procedure: Baseline ventilator settings will be established per the EXPRESS protocol: VT = 6 mL/kg (ideal body weight); inspiratory flow will be set at 50-70 L/min resulting in an end-inspiratory pause of 0.2-0.5 sec, I:E ratio 1:1 to 1:3, PEEP set so that the plateau pressure (Pplat), measured during the end-inspiratory pause of 0.2 to 0.5 s, will be within the following limits: 28 cm H2O ≤ Pplat ≤ 30 cm H2O; Set RR to 20-35 to maintain approximately the same minute ventilation as before study initiation. Baseline ventilator settings will be maintained for a 2-hour run-in time (time to setup ECCO2R devices). Use heated humidifiers for gas humidification and minimize instrumental dead space. ECCO2R will be initiated during the 2-hour run-in time. Neuromuscular blocking agents (NMBA) will be used. EtCO2 will be monitored. RR will be kept what it was at Baseline. Sweep gas flow will be adapted. Ventilation will be adapted. Respiratory rate will be adapted.
3352869|NCT02282670|Experimental|DA-5204|DA-5204 administered two times daily for two weeks
3352870|NCT02282670|Active Comparator|Stillen tab.|Stillen tab. administered three times daily for two weeks
3352871|NCT02282683|Experimental|Prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months.
3352872|NCT02282683|No Intervention|Control|Maximum tolerated guideline-directed medical therapy
3352873|NCT02282696|Experimental|cancer patients|Questionnaire, focus group participation
3243957|NCT01323205|Experimental|JNJ-40411813 (Part A)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
3352874|NCT02282709|Experimental|Daclatasvir and asunaprevir|daclatasvir 60 mg once daily asunaprevir 100 mg BID
3352875|NCT02282761|Experimental|40 mg ITI-007|40 mg ITI-007 administered orally as formulated capsules once daily for 28 days
3352876|NCT02282761|Experimental|60 mg ITI-007|60 mg ITI-007 administered orally as formulated capsules once daily for 28 days
3352877|NCT02282761|Placebo Comparator|Placebo|Placebo administered orally as formulated capsules once daily for 28 days
3352878|NCT02282774|Experimental|SB|receive subtenon block of 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture
3352879|NCT02282774|Sham Comparator|C|receive subtenon block of 4mL saline
3352880|NCT02282787|Experimental|5 micron dex arm|
3352881|NCT02282787|Experimental|10 micron dex arm|
3243958|NCT01323205|Experimental|JNJ-40411813 (Part B)|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 10 weeks.
3243959|NCT01323205|Experimental|Placebo and JNJ-40411813 (Part B)|Placebo capsule (s) orally twice daily with a meal for 4 weeks followed by JNJ-40411813 according to tolerability dose range increased from 50 mg to 150 mg twice daily with a meal to 6 weeks.
3243960|NCT01323231|Experimental|Communities in Schools Services|Communities in Schools services include case management, mental health services, mentorship services, after school programs, and academic assistance.
3352882|NCT02282800||Case group|Case group include patients with generalized AgP were the tissue samples taken to analyse the number of vitamin D receptor present.
3352883|NCT02282800||Control group|Ethnically matched, systemically and periodontally healthy individuals were included in control group were also gingival tissue taken for analysis of number of receptors present in nucleus and cytoplasm
3352884|NCT02282826|Experimental|Dose 1 IV|GZ402668 dose 1 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352885|NCT02282826|Experimental|Dose 2 IV|GZ402668 dose 2 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352886|NCT02282826|Experimental|Dose 3 IV|GZ402668 dose 3 intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352887|NCT02282826|Experimental|Dose 3 SC|GZ402668 dose 3 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352888|NCT02282826|Experimental|Dose 4 SC|GZ402668 dose 4 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352889|NCT02282826|Experimental|Dose 5 SC|GZ402668 dose 5 subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352890|NCT02282826|Placebo Comparator|Placebo SC|placebo subcutaneous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352891|NCT02282826|Placebo Comparator|Placebo IV|placebo intravenous, single administration. Acyclovir 200 mg twice daily for 28 days as prophylactic therapy
3352892|NCT02282839|Active Comparator|Study group|Oral glutamine 10 g TID (total 30 g/day) one week before radiotherapy till the end of radiotherapy
3352893|NCT02282839|Placebo Comparator|Control group|Placebo (Same ingredients without glutamine) one week before radiotherapy till the end of radiotherapy
3352894|NCT02282852|Experimental|Wireless Capsule Endoscopy|Wireless capsule endoscopy is the investigation modality of choice for suspected diseases of the small bowel. A small pill-sized capsule contianing a camera is swallowed by the patient. The procedure is safe and non-invasive. Normally, the pill camera travels through the gut an exits the bowel via natural means. In a small number of cases the capsule is maintained. If the capsule is still in the stomach, mobilisation is encouraged followed by an intramuscular pro-kinetic injection if this fails.
3352895|NCT02282852|Active Comparator|Magnetically steerable capsule endoscopy|A handheld magnet (manufactured by Intromedic Ltd.) has been developed to allow some control of the pill camera (that contains a small amount of magnetic material) in the upper GI tract. We propose that this could be used, alongside positional changes, to expedite capsule transit through the stomach thus improving completion rates and avoiding the risks of unnecessary medication.
3352896|NCT02282865||Visual analogue scale (VAS) >5|The degree of surgery-related anxiety assessment using VAS
3352897|NCT02282865||Visual analogue scale (VAS) ≤5|The degree of surgery-related anxiety assessment using VAS
3352898|NCT02282878|Experimental|High/Low Sodium Diet|All MS patients will receive 2 weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
3352899|NCT02282878|Active Comparator|High/Low Sodium Diet Control|Age matched controls will receive two weeks of controlled high sodium diet followed by a 1 week washout and 2 weeks of low sodium diet.
3352900|NCT02282891|Active Comparator|Propofol|Induction of general Anesthesia using propofol 2mg/kg
3352901|NCT02282891|Experimental|Propofol/Ketamine (ketofol)|Induction of general anesthesia using a mixture of 1.5mg/kg:0.75mg/kg Propofol/ketamine
3352902|NCT02282917|Experimental|AR-42 Administration|AR-42 will be administered three times per week beginning 3 weeks prior to surgery.
3352903|NCT02282943|Active Comparator|Laser|vapourisation/excision of endometriosis using CO2 laser
3352904|NCT02282943|Experimental|Harmonic scalpel|excision of endometriosis using Harmonic scalpel
3352905|NCT02282956|Experimental|study group|single shot, posterior tibial nerve block with 5 ml of Ropivacaine 0,75% before surgery postoperative PCA pump with morphine and droperidol (DHBP®) for the next 24 hours.
3352906|NCT02282956|Other|controll Group|After surgery: standard analgesic treatment by PCA (patient controlled analgesia) pumps with morphine and Droperidol (DHBP®) for the next 24 hours.
3352907|NCT02282969||Lung Cancer Screening Decision Aids|Participants are asked to look over education materials about lung cancer screening, and interviewed. Some participants will look at a video patient decision aid, with an interview and questionnaire completion. Some participants complete lung cancer screening knowledge questionnaire at first visit, and then again in one month.
3352908|NCT02282995||•FDR-Relatives of FD patients|"Relatives of FD patients. Patients may bring at most two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3243961|NCT01323244|Experimental|TMC435|TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
3243962|NCT01323257|Experimental|001|TMC435 150 mg capsule once daily for 7 days (Trt A C D)
3352909|NCT02282995||•FDC-Healthy control|"Healthy control. Controls who are self-referred to this study will be recruited.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3352910|NCT02282995||•FD-Patients with FD|"Patients with FD. Patients referred for OGD in Endoscopy Center, Prince of Wales Hospital, with symptoms suggestive of FGID will be invited to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Fasting glucose test will be performed for FD patients"
3352911|NCT02282995||•FDCR-Relatives of healthy controls|"Relatives of healthy controls. Each participating control is required to bring at least one and up to two FDRs to participate in this study.~Up to 20 ml of fasting blood sample will be collected~Serology test of Hp status will be performed for healthy volunteers and all FDRs"
3352912|NCT02283008|No Intervention|Standard care|This arm will receive standard care which involves informal education on how to use metered dose inhalers
3352913|NCT02283008|Active Comparator|Structured education|This arm will receive structured education on the use of inhalers. At 6 weeks post education inhaler technique will be re-assessed. Participants who fail to achieve a set level of competence may be chosen for semi structured interview.
3352914|NCT02283021||NSCLC Patients|Sample biopsies from normal and cancerous lung tissue.
3352915|NCT02283021||Patients without NSCLC|Sample biopsies from normal lung tissue.Control group.
3352916|NCT02283034|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
3352917|NCT02283034|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
3352918|NCT02283047|Active Comparator|CONTROL GROUP-DIET|Hypocaloric diet intervention with no supervised exercise intervention
3352919|NCT02283047|Experimental|DIET & MODERATE CONTINUOUS TRAINING|Intervention with hypocaloric diet and supervised moderate continuous exercise training (60-80%HRpeak). High volume training (45 minutes in progression from 20 min)
3352920|NCT02283047|Experimental|DIET & HIGH VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). High volume training (45 minutes in progression from 20 min)
3352921|NCT02283047|Experimental|DIET & LOW VOLUME HIIT|Intervention with hypocaloric diet and supervised high intensity interval training (85-95%HRpeak). Low volume training (20 min)
3352922|NCT02283060|Experimental|Stribild switch arm|Patient to be taken off Atripla and switched to Stribild (co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) -one tablet taken daily with food
3352923|NCT02283060|Active Comparator|Atripla control arm|Patient to continue taking Atripla (co-formulated efavirenz/emtricitabine/ tenofovir disoproxil fumarate) - one tablet taken daily at bedtime on an empty stomach
3352924|NCT02283073||Idiopathic Parkinson's disease|Patient with clinical diagnosis of Idiopathic Parkinson's Disease according to Queen Square Brain Bank Criteria up to one year prior to enrollment in study.
3243963|NCT01323257|Experimental|002|erythromycin 500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
3243964|NCT01323257|Experimental|003|erythromycin 500 mg tablets three times a day for 7 days (Trt C)
3352925|NCT02283073||Differential Diagnosis Group|MSA, PSP, CBD, Lewy body dementia, Essential Tremor, and Healthy Controls
3352926|NCT02283086|No Intervention|Control|
3352927|NCT02283086|Experimental|Intervention|The intervention consisted of quarterly performance feedback reports sent via e-mail.
3352928|NCT02283099|Experimental|rVSVΔ-ZEBOV-GP (BPSC1001)|Subjects will be allocated to three cohorts of 10 subjects each receiving one single vaccine injection administered as an i.m. injection.
3352929|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d). Supplementation of multivitamins and minerals was provided per day.
3352930|NCT02283151|Experimental|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). Carbohydrate-rich foods, such as white rice, steamed bread and tubers, were substituted with fish, poultry and plant oil. All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar (106 Kcal: 2.8 g carbohydrate, 11.2 g protein and 5.6 g fat; Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat (i.e., beef, lean pork, skinned chicken, fish) at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
3352931|NCT02283164|Experimental|Treatment|Hazardous materials online education and study feedback
3352932|NCT02283164|Active Comparator|Control then treatment|Hazardous materials online education and study feedback
3243965|NCT01323257|Experimental|004|TMC435 50 mg capsule once daily for 7 days (Trt F)
3243966|NCT01323257|Experimental|005|Darunavir 2 x 400 mg tablet once daily for 7 days (Trt E F)
3243967|NCT01323257|Experimental|006|Ritonavir 100 mg tablet once daily for 7 days (Trt E F)
3352933|NCT02283177|Experimental|Cohort A|Patients will be given cytarabine and daunorubicin during induction therapy plus crenolanib at 100 mg TID.
3243968|NCT01323283|Active Comparator|Omega-3 supplementation|50 % of all included children will be randomized to this arm and administered capsules containing an omega-3 fatty acid composition.
3243969|NCT01323283|Placebo Comparator|Placebo|50 % of included children will be randomized to this arm and will be administered placebo capsules for the 15 week intervention.
3243970|NCT01323296|Active Comparator|Ferumoxytol|Patients will be administered intravenous ferumoxytol 1 - 3 days following myocardial infarction after baseline cardiac magnetic resonance scanning.
3243971|NCT01323296|No Intervention|Control|Subjects who have suffered myocardial infarction will undergo cardiac magnetic resonance imaging at the same time points as those in the 'ferumoxytol' arm but will not receive ferumoxytol or placebo.
3243972|NCT01323309||Individual Meaning-Centered Psychotherapy (IMCP)|
3243973|NCT01323309||standard Individual Supportive Psychotherapy (ISP)|
3352934|NCT02283177|Experimental|Cohort B|Patients will be given cytarabine and idarubicin during induction therapy plus crenolanib at 100 mg TID.
3352935|NCT02283190|Experimental|Ewwinase|Six doses of Erwinase given three times weekly (Monday-Wednesday-Friday) for two weeks. Possible dose levels used are 20.000 IU/m2/day, 25,000IU/m2/day, and 30,000IU/m2/day.
3243974|NCT01323309||enhanced usual care (EUC)|
3243975|NCT01323348|Experimental|Diabetes Educational Intervention|Study participants in the intervention group will receive a diabetes management educational intervention at baseline and at follow-up visits. For those on an annual follow-up schedule, educational intervention will take place at baseline and 12 months. For those whose standard care involves more frequent, than annual, visits the educational intervention will take place no more than once every 12 weeks.
3243976|NCT01323348|No Intervention|Standard Care|Usual care
3243977|NCT01323361|No Intervention|Non-immunosupressed|Normal population
3243978|NCT01323374|Experimental|Droxidopa 200mg TID|
3243979|NCT01323374|Experimental|Droxidopa 400mg TID|
3243980|NCT01323374|Experimental|Droxidopa 600mg TID|
3243981|NCT01323374|Active Comparator|Carbidopa 25mg TID|
3243982|NCT01323374|Active Comparator|Carbidopa 50 mg TID|
3243983|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/25mg TID|
3243984|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/25mg TID|
3243985|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/25mg TID|
3243986|NCT01323374|Experimental|Droxidopa/carbidopa 200mg/50mg TID|
3243987|NCT01323374|Experimental|Droxidopa/carbidopa 400mg/50mg TID|
3243988|NCT01323374|Experimental|Droxidopa/carbidopa 600mg/50mg TID|
3243989|NCT01323374|Placebo Comparator|Placebo TID|
3243990|NCT01323400|Experimental|Pazopanib|"Pazopanib (800 mg/day) + Best supportive care according to the investigator's judgement.~Pazopanib treatment is started on the day after randomization until radiological progression according to RECIST or until documented toxicity. In case of radiological progression, pazopanib may be continued (if the investigator wishes so) if a clinical benefit (pain reduction, 1 point increase in performance status) is observed."
3243991|NCT01323400|Other|Best supportive care|Best supportive care according to the investigator's judgment. Upon progression, compassionate treatment by pazopanib is possible according to eligibility criteria.
3243992|NCT01323413||stroke|acute ischemic stroke patients
3243993|NCT01323426|Experimental|periurethral injection|Periurethral injection of autologous muscle fibers
3243994|NCT01323439||Axium™ MicroFX™ PGLA Treated Subjects|This observational evaluation will evaluate early experience using the Axium™ MicroFX™ PGLA COILS as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ Bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol
3243995|NCT01323452||Chronic HBV patients|Patients with chronic hepatitis B Treated for at least 3 months No HIV, HCV or HDV.
3352936|NCT02283203|Active Comparator|APOTEL max|Active drug; water for injection at a volume of 100ml with added 1g of paracetamol and inactive ingredients (ΑPOTEL max®), infused within 15 minutes. Available in 100ml bags.
3243996|NCT01323465|Experimental|Sequence 1A|Sativex and rifampicin
3243997|NCT01323465|Experimental|Sequence 1B|Sativex and rifampicin
3352937|NCT02283203|Placebo Comparator|Placebo|Placebo; water for injection at a volume of 100ml with added inactive ingredients, infused within 15 minutes. Available in 100ml bags.
3352938|NCT02283216|Experimental|Acoustic, Body, Cortical|Acoustic corresponds to noise sound stimulation. Body corresponds to body electrical stimulation. Cortical corresponds to transcranial magnetic stimulation. Acoustic is presented together with body and cortical stimulation. Different body locations and timing among acoustic, body, and cortical stimulation are presented across testing sessions.
3352939|NCT02283229|Active Comparator|Active|Newborns with preventive caring advices
3352940|NCT02283229|Placebo Comparator|Surveillance|Newborns with normal caring advices
3352941|NCT02283242|Experimental|Galantamine|"8 mg of Galantamine for 4 weeks~16 mg Galantamine for 8 weeks"
3352942|NCT02283242|Placebo Comparator|Placebo|"8 mg of placebo for 4 weeks~16 mg placebo for 8 weeks"
3352943|NCT02283255|Active Comparator|Physical Activity 1|Aerobic Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months.
3352944|NCT02283255|Active Comparator|Physical Activity 2|Respiratory Training: muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
3352945|NCT02283255|Active Comparator|Physical Activity 3|Aerobic and Respiratory Training: Aerobic training and muscle strength exercise for upper and lower limbs, 3 times a week for 4 months and respiratory muscle training using POWERbreathe device, 7 times a week, 3 series of 30 repetitions per day, for 4 months.
3352946|NCT02283255|No Intervention|Physical Activity 4|No Physical Activity: Control group (usual care)
3352947|NCT02283281|Experimental|Cannabis oil high dose|Single-dose, before anesthetic induction: 21.6 mg tetrahydrocannabinol + 20 mg cannabidiol, Sub-linguistic
3352948|NCT02283281|Experimental|Cannabis oil low dose|Single-dose, before anesthetic induction: 10.8 mg tetrahydrocannabinol + 10 mg cannabidiol, Sub-linguistic.
3352949|NCT02283281|Placebo Comparator|Control|Single-dose, before anesthetic induction: Dummy oromucosal spray containing alcohol vehicle without Cannabis oil .
3352950|NCT02283307|Experimental|Reduced contrast DECT scan|Reduced Contrast Dual Energy CT
3352951|NCT02283320|Experimental|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
3352952|NCT02283346|Experimental|HDR Brachytherapy + EBRT|HDR brachytherapy + hypofractionated EBRT
3352953|NCT02283359|Experimental|Selinexor in Combination with Irinotecan|"The first study drug is called selinexor (KPT-330). This drug is taken by mouth on days 1, 3, 8 and 10 of each cycle. The starting dose of selinexor will be dependent on the cohort in which the patient is enrolled into. Level -1: 25 mg/m^2; Level 1: 40 mg/m^2; Level 2: 50 mg/m^2; Level 3: 65 mg/m^2.~The second drug is called irinotecan. This drug is given as intravenous (IV) infusion on days 1 and 8 of each cycle. Participants will receive the standard recommended dose: 125 mg/m^2."
3352954|NCT02283372|Experimental|nab-Paclitaxel + Gemcitabine + IMRT|"Prior to initiation of chemoradiation, patients will undergo 1 full cycle of gemcitabine and nab-paclitaxel on Days 1, 8, and 15 of a 28-day cycle.~Both gemcitabine and nab-paclitaxel will be given intravenously on an outpatient basis during the one-month lead-in period and during Weeks 1 and 2 (and, if enrolled to Dose Level or 2, Weeks 4 and 5) of radiotherapy. There may be up to 21 days between the last dose of lead-in chemotherapy (given on Day 15) and initiation of chemoradiation (inclusive of the week following Day 15, the fourth week of the lead-in cycle (an off-week), and an additional week following that).~Intensity modulated radiation (IMRT) - the prescribed dose will range from 40-67.5 Gy over 15 to 25 fractions."
3243998|NCT01323465|Experimental|Sequence 2C|Sativex and ketoconazole
3243999|NCT01323465|Experimental|Sequence 2D|Sativex and ketoconazole
3352955|NCT02283385|Experimental|PROTECT Intervention|Participants will receive a brief psychotherapy that builds on Problem Solving Therapy (PST)
3352956|NCT02283398|Experimental|with RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
3352957|NCT02283398|Sham Comparator|without RIPC|the cuff will be placed around the left arm without being inflated
3352958|NCT02283424|Active Comparator|chemotherapy|Carboplatin,350mg/m2,1/3weeks Docetaxel,75mg/m2,1/3weeks
3352959|NCT02283424|Experimental|Icotinib|Icotinib, 125mg,3/D,2years
3352960|NCT02283437|Experimental|Problem-solving Based Bibliotherapy|The Problem-solving Based Bibliotherapy Program (PSBPF) using a self-help manual based on problem-solving therapy defined by D'Zurilla and Nezu (2007) to be 'a self-directed cognitive-behavioral process by which a person attempts to identify/discover effective/adaptive solutions for specific problems encountered in everyday living' (p.11).
3352961|NCT02283437|Active Comparator|Behavioral Management and Education Program|The Behavioral Management and Education group program will be guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) psycho-education and McFarlane et al.'s (2003) family behavioral management programs for schizophrenia.
3352962|NCT02283437|No Intervention|Routine Outpatient Service|Participants in the control group (and 2 treatment groups) will receive routine psychiatric outpatient and family services.
3352963|NCT02283450||the experimental group|The patients in experimental group received the relevant tests and inspections before the beginning of experiment，signed the informed consent. Then we get the venous blood centrifugalization and cryopreservation. The patients take the medicine qiliqiangxin three times per day，four tablets at a time. Afrer a month，we evaluated the symptoms，the function of heart，blood pressure，heart rate and keep blood specimens. Three and six month later，electrocardiogram and echocardiography were taken and the determination of the NT - proBNP was done.
3352964|NCT02283450||the placebo group|The placebo group was followed up in the same way.
3244000|NCT01323465|Experimental|Sequence 3E|Sativex and omeprazole
3244001|NCT01323465|Experimental|Sequence 3F|Sativex and omeprazole
3244002|NCT01323491||routine smokers|would-be non-smokers, no actual nicotine replacement therapy
3244003|NCT01323504|Experimental|Music therapy group|Local care with music
3244004|NCT01323504|No Intervention|control group|Local care without music
3244005|NCT01323543|Experimental|Elaspine™|Impantation of Elaspine™ device
3352965|NCT02283463|Active Comparator|Standard Cervical Tenaculum|Single tooth tenaculum, pierces the tissue of the cervix to allow provider to stabilize and place traction on the cervical cal/uterus
3352966|NCT02283463|Experimental|Bioceptive Cervical Retraction Device|Suction based method for stabilizing the cervix and uterus. Achieves suction 360 degrees around cervical os creating a portal through which instruments can be passed into the cervical canal and uterus. Provider can still place traction on uterus with this device just as with tenaculum.
3352967|NCT02283476|Experimental|Endostar continuous intravenous infusion|Endostar continuous intravenous infusion in combination with Gemcitabine and Cisplatin
3352968|NCT02283476|Active Comparator|Endostar routine intravenous infusion|Endostar routine intravenous infusion in combination with Gemcitabine and Cisplatin
3352969|NCT02283489|Experimental|Combination therapy A|Recombinant human endostatin adenovirus (EDS01), 5.0 × 1011 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3352970|NCT02283489|Experimental|Combination therapy B|Recombinant human endostatin adenovirus (EDS01), 1.0 × 1012 VP intratumorally on days 0 and 7; paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3352971|NCT02283489|Experimental|Chemotherapy|Paclitaxel, 160 mg/m2 intravenously on day 1; cisplatin, 25 mg/m2 intravenously on days 1 to 3.
3352972|NCT02283502|Experimental|Intervention: MRgHIFU, Surgery|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
3352973|NCT02283515|Active Comparator|group I - Rosuvastatin, 1.2 mg|Rosuvastatin- locally placed in intrabony defect sites.
3352974|NCT02283515|Placebo Comparator|group II - placebo|placebo-placed locally in intrabony defects.
3352975|NCT02283541|Experimental|ASTM|Participants in Automatic self-transcending meditation (ASTM) arm will complete a 12 week meditation training program in addition to their existing treatment plan. This involves participating in 120-minute sessions on each of four consecutive days of the first week. Participants will individually be given a mantra on day one, and then be instructed in use of the mantra according to specific criteria over the four session program. This will be followed by weekly 60-minute follow up sessions for the 11 subsequent weeks. In addition, participants will be asked to practice ASTM at home for 20 minutes twice daily over the study period. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12.
3352976|NCT02283541|No Intervention|TAU|Participants in TAU arm will continue with their existing treatment schedule as usual. Assessments of depression severity will be completed at specific times over the 12 week training period: at Weeks 0, 4, 8 and 12. However, no assessments will be done or information collected on the TAU arm from week 12 onwards. After week 12, TAU arm participants will be offered the opportunity to learn ASTM and attend follow up meditation.
3352977|NCT02283554|Placebo Comparator|ARM1- open flap debridement (OFD)|open flap debridement done for 30 subjects. After debridement, Metformin or PRF was not added into the intrabony defect.
3352978|NCT02283554|Experimental|ARM2- open flap debridement plus PRF(Platelet rich fibrin)|"After open flap debridement, PRF( Platelet rich fibrin) was added into the intrabony defect.~No. of subjects= 30"
3352979|NCT02283554|Experimental|ARM3- open flap debridement plus 1%Metformin|After open flap debridement, 1% metformin was added into the intrabony defect No. of subjects= 30
3352980|NCT02283554|Experimental|ARM4- open flap debridement plus PRF plus metformin|"After open flap debridement, PRF and 1% metformin was added into the intrabony defect.~No. of subject- 30"
3244006|NCT01323556|Experimental|Exposure with fear augmentation|exposure-based CBT, including interoceptive exposure and in-vivo exposure with fear augmentation by interoceptive exercises (e.g. hyperventilation)
3244007|NCT01323556|Experimental|Exposure without fear augmentation|exposure-based CBT, including interoceptive and in-vivo exposure without fear augmentation during in-vivo exposure
3244008|NCT01323569|Placebo Comparator|Placebo|
3244009|NCT01323569|Experimental|Sativex 4 sprays|
3244010|NCT01323569|Experimental|Sativex 8 sprays|
3244011|NCT01323569|Experimental|Sativex 16 sprays|
3244012|NCT01323569|Active Comparator|Marinol low dose|
3352981|NCT02283580|Experimental|Single limb resistance training|"Low load, high-repetitive resistance training.~single limb at a time (e.g., one arm or one leg)~elastic bands"
3244013|NCT01323569|Active Comparator|Marinol high dose|
3244014|NCT01323608|Placebo Comparator|Placebo|
3244015|NCT01323608|Experimental|Low Vitamin D Group|Subjects in this group will receive the equivalent of 400 IU/day.
3244016|NCT01323608|Experimental|Intermediate Vitamin D group|
3244017|NCT01323608|Experimental|High Vitamin D Group|
3244018|NCT01323686|Experimental|Imaging guided LV lead placement|
3244019|NCT01323686|No Intervention|Empiric LV lead placement|LV lead placement using standard clinical routine.
3244020|NCT01323699|Experimental|Behavioral Therapy|
3244021|NCT01323712|Placebo Comparator|Placebo|
3244022|NCT01323725|Experimental|Team-based financial incentives|Team-based financial incentives
3244023|NCT01323738|No Intervention|Treatment as Ususal|Patients participate in the Treatment as Usual including a non-specific information group.
3244024|NCT01323738|Experimental|Psychoeducation|Intervention group
3244025|NCT01323751|Experimental|Treat Regimen|ACY-1215 Bortezomib Dexamethasone
3244026|NCT01323764|Active Comparator|Radionuclide SPS|Radionuclide Shunt Patency Study
3244027|NCT01323816||Traditional|ICU staffed by a resident, pulmonary fellow and attending
3244028|NCT01323816||Non-Traditional|ICU staffed by Nurse Practitioners as the direct care deliverer, a pulmonary fellow, and an attending
3244029|NCT01323842||rule in renal colic|ED patients with abdominal/flank pain where a diagnosis of renal colic is being considered and undergoing formal imaging while in the ED
3244030|NCT01323881|Experimental|intermittent theta burst stimulation|
3244031|NCT01323881|Placebo Comparator|sham stimulation|
3244032|NCT01323907|Experimental|Omegaven|Omegaven IV lipid emulsion administration for infants with life threatening parenteral nutrition associated liver disease
3352982|NCT02283580|Active Comparator|Two limb resistance training|"Low load, high-repetitive resistance training.~two limbs at a time (e.g., both arms or both legs)~elastic bands"
3352983|NCT02283619||Patients with LBBB being evaluated for ACS|Patients who present to the emergency department with left bundle branch block on the electrocardiogram, who are being evaluated for acute coronary syndrome, and who qualify based on the inclusion/exclusion criteria listed in the detailed description.
3244033|NCT01323933|Experimental|AB0024|"The starting dose for Part A will be 1 mg/kg. Subsequent doses of 3, 10, and 20 mg/kg are planned. Three to 6 patients will be enrolled using a 3 + 3 design. Doses of AB0024 will be administered on Days 1, 15, 29, and 43 to characterize the safety, tolerability, and PK.~The dose expansion phase of the study will begin upon completion of the dose escalation phase. Up to 20 patients will be enrolled into one or two cohorts of Part B. The first expansion cohort will be dosed up to the MTD defined as the highest dose level with an observed incidence of DLT in <33% of patients enrolled from Part A."
3244034|NCT01323985|Experimental|GSK2315698|Intravenous infusion single dose
3352984|NCT02283632|Experimental|Jejunal Diversion|all subjects who receive jejunal diversion surgery
3352985|NCT02283645|Experimental|Minoxidil|3% Minoxidil lotion is applied twice daily to the chest.
3352986|NCT02283645|Placebo Comparator|Placebo|Placebo lotion is applied twice daily to the chest.
3352987|NCT02283671|Experimental|Tolerogenic dendritic cells|"Somatic-cell therapy medicines: tolerogenic dendritic cells loaded with myelin peptides.~Patients will receive intravenous administration every two weeks (week 0 , 2 and 4 ) representing a total of three administrations per patient.~The dose escalation will occur as expected in the absence of limiting toxicity in the previous dosage level."
3244035|NCT01324011|Experimental|Family-based intervention|Special intervention (20 weekly group-based sessions) to be compared with a delayed intervention control group.
3244036|NCT01324011|Other|Delayed intervention controls|The delayed intervention controls will continue with usual care (if patients with diabetes)and at the end of the experimental period (6 months), they will receive a 6-session weight loss intervention delivered over a 2 month period.
3352988|NCT02283684|Active Comparator|Greenlight laser PVP|Greenlight (532-nm) laser Photoselective vaporization of the prostate using (XPS) 180W system
3352989|NCT02283684|Active Comparator|Bipolar TUVP|Bipolar transurethral vaporization of the prostate using bipolar system
3352990|NCT02283697|Experimental|Dietary Counseling|Apart from standard care, an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the Dietary Approach to Stop Hypertension (DASH) diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
3352991|NCT02283697|Other|Control: Standard Care|A standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
3352992|NCT02283710|Experimental|Pentoxifylline + lifestyle modification|Pentoxifylline for 6 months plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3352993|NCT02283710|Experimental|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3352994|NCT02283723|Experimental|Patient Group 1|This patient group will begin receiving the Health TAPESTRY intervention from time zero.
3244037|NCT01324037|Experimental|clinically suspected upper extremity deep vein thrombosis|Patients with suspected upper extremity DVT
3352995|NCT02283723|Active Comparator|Patient Group 2|Using a step-wedge approach, this patient group will receive the intervention after a six month waiting period where they will be used as a comparable group. In the first six months, they will receive usual care.
3352996|NCT02283736|Experimental|Periodontal treatment, Probitic|Periodontal treatment (scaling and root planning) and one tablet containing Lactobacillus rhamnosus SP1 per day during 3 months.
3352997|NCT02283736|Placebo Comparator|Periodontal treatment, talc powder tab|Periodontal treatment (scaling and root planning) and one tablet containing talc powder per day during 3 months
3352998|NCT02283775|Experimental|PomdeSAR|"Part A: Isatuximab (escalating dose) on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression~Part B: Isatuximab 10 mg/kg on Day 1, 8, 15, and 22, then Day 1 and 15 + pomalidomide 4 mg on Day 1 to 21 + dexamethasone 40 mg (20 mg in patients of 75 years or older) on Day 1, 8, 15, 22 in 28-day cycles up to disease progression"
3244038|NCT01324050|Experimental|Internet-based Psychodynamic Therapy|
3244039|NCT01324050|Active Comparator|Internet-delivered therapist support|
3352999|NCT02283801|Experimental|Group A|"Group A~Pre-treatment: 600 mg once daily dose of eslicarbazepine acetate (ESL) administered for two consecutive days;~Treatment 1: 1200 mg once daily dose of eslicarbazepine acetate (ESL) administered for six consecutive days~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 50 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
3353000|NCT02283801|Experimental|Group B|"Group B~Pre-treatment: 50 mg once daily dose of lamotrige (LMT) administered for two consecutive days;~Treatment: 150 mg once daily dose of lamotrige (LMT) administered for six consecutive days;~Treatment 2: Concomitant doses of eslicarbazepine acetate (ESL) 1600 mg and lamotrigine 150 mg for two consecutive days~Treatment 3: Concomitant doses of eslicarbazepine acetate (ESL) 1200 mg and lamotrigine 150 mg for seventeen consecutive days"
3353001|NCT02283853|Experimental|BG00012|Participants will receive the recommended dose of 240 mg orally, twice a day
3353002|NCT02283853|Active Comparator|IFN β-1a (Avonex)|Participants will receive the recommended dose of 30 μg (weekly)
3353003|NCT02283866|Experimental|Administering desflurane according to the patient's BIS value|The anesthesiologist administers the volatile anesthetic desflurane to set the patient's BIS value at 50 during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
3353004|NCT02283866|Experimental|Administering desflurane at 1 MAC|The anesthesiologist administers the volatile anesthetic desflurane at 1 MAC during balanced anesthesia, and titrate the remifentanil dose to set the patient's systolic arterial blood pressure between 100-140mmHg.
3244040|NCT01324089|Active Comparator|Arm 1|Resveratrol 2.5 grams x 1 dose
3244041|NCT01324089|Experimental|Arm 2|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
3244042|NCT01324089|Other|Arm 3|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
3244043|NCT01324180|Experimental|VLPD Regimen|Induction will consist of vincristine, dexamethasone, doxorubicin and PEG asparaginase (so called VPLD - dexamethasone is substituted for prednisone and PEG asparaginase is substituted for L-asparaginase) in combination with metformin. Eligible patients will receive 24 hours of metformin followed by induction. Intrathecal chemotherapy with standard dose cytarabine will be administered at the start of each cycle, with central nervous system (CNS) therapy afterwards determined by findings on staging lumbar puncture.
3244044|NCT01324193|Other|Pre-diaylsis patients|Chronic Kidney Disease patients not receiving dialysis getting pomegrante Supplementation
3244045|NCT01324193|Other|Dialysis patients|Chronic Kidney Disease patients receiving dialysis getting pomegranate supplementation
3244046|NCT01324219|Active Comparator|Staff|
3244047|NCT01324219|Experimental|Resident|
3353005|NCT02283879|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
3244048|NCT01324245|Experimental|Enalapril|2.5 mg every 12 hours for two doses
3244049|NCT01324258|Experimental|GSK1120212|Part 1-Dose escalation will be conducted to assess PK after single dosing and safety, tolerability, PK and efficacy of GSK1120212 in Japanese subjects with solid tumors using a continuous daily dosing schedule.
3353006|NCT02283892|Experimental|Checklist|2 checklists available for consultation by the attending physician: (1) dyspnea evaluation checklist and (2) cough evaluation checklist. The checklists are available on computers and mobile devices (smartphone, PDA or tablet computer).
3353007|NCT02283892|Active Comparator|Conventional assessment|Evaluation of patients reporting dyspnea or cough made by the attending physician, without the use of the checklists for dyspnea or cough evaluation.
3353008|NCT02283905|Other|Amphotericin-B and Voriconazole|Treatment with a 24 hour continuous infusion of amphotericin B deoxycholate at 1.0 mg/kg/day for a total dose of at least 1 g (i.e. ~ 14 days); and then the patient is stepped down to voriconazole 6 mg/kg i.v. q12h for 2 doses, then 4 mg/kg q12h either i.v. or orally as appropriate. The oral dose will be rounded for convenience to either the 200 mg or 400 mg tablet twice daily.
3353009|NCT02283918||Participants with education less than bachelor's degree|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
3244050|NCT01324258|Experimental|GSK1120212+Gemcitabine|Part 2-Further evaluate the safety, tolerability, PK, and efficacy of GSK1120212 in combination with gemcitabine in subjects with non-small cell lung cancer, pancreatic cancer, biliary cancer, urothelial cancer or other tumor types for which 4-week schedule of gemcitabine has been approved using the recommended dose from Part 1 (single agent).
3244051|NCT01324284|Experimental|Lubiprostone|Lubiprostone with PEG solution versus Placebo with PEG solution
3244052|NCT01324284|Placebo Comparator|lubiprostone versus placebo|
3244053|NCT01324297||Healthy Control|Caucasian males and females between 19 and 30 years of age.
3244054|NCT01324297||First Episode Psychosis|Caucasian males and females between 19 and 30 years of age within twelve months of initial DSM IV TR diagnosis of schizophreniform psychosis, schizophrenia, schizoaffective disorder or psychotic disorder NOS.
3244055|NCT01324336||4-17 years, receiving 6-MP|
3244056|NCT01324362|Active Comparator|Fluticasone propionate|
3244057|NCT01324362|Active Comparator|Fluticasone propionate/salmeterol combination|
3244058|NCT01324375||THA (total hip arthroplasty)|Patients undergoing THA, preoperatively heat tested
3244059|NCT01324427|Experimental|virtual medical visit|"This is a pilot trial involving a maximum of 84 patients undergoing either allogeneic or autologous stem cell transplant aimed at determining the feasibility and acceptance of a virtual medical visit by patients and health care personnel. During this pilot trial we expect to perform 84 virtual medical visits using telemedicine."
3244060|NCT01324466|Placebo Comparator|Vehicle|Vehicle
3244061|NCT01324466|Active Comparator|Active|Active NB-001(0.3%)
3244062|NCT01324479|Experimental|INC280|
3244063|NCT01324492|Experimental|RAD001|
3244064|NCT01324505|Experimental|One-sequence cross-over arm|
3244065|NCT01324531|Active Comparator|Bankart repair|
3244066|NCT01324531|Active Comparator|Bankart repair and remplissage|
3244067|NCT01324544|Experimental|Buprenorphine IV|Buprenorphine IV
3244068|NCT01324557|Experimental|CSII|Optimized subcutaneous insulin infusion by means of continuous subcutaneous insulin infusion (CSII)
3244069|NCT01324557|No Intervention|MDI|MDI: Control Optimized subcutaneous insulin by multiple daily injections (MDI)
3244070|NCT01324583|Experimental|Arm 1|"Patients will receive cabazitaxel as the dose of corresponded level~1-hour intravenous infusion every 3 weeks plus prednisolone 10 mg orally given daily: Dose Level Cabazitaxel Dose Level -1: 15 mg/m², Level 1: 20 mg/m², Level 2: 25 mg/m²"
3244071|NCT01324596|Active Comparator|Arm A: R-CHOP|Participants receive 6 cycles of conventional R-CHOP chemotherapy on a standard 21 day schedule: Rituximab 375mg/m2 intravenous Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous Prednisolone 100mg od orally
3244072|NCT01324596|Experimental|Arm B: RB-CHOP|"Participants in this arm will receive 1 cycle of conventional R-CHOP chemotherapy, followed by 5 cycles of R-CHOP:~Cyclophosphamide 750mg/m2 Intravenous Doxorubicin 50mg/m2 Intravenous Vincristine intravenous bortezomib - Intravenous Prednisolone 100mg od orally~."
3244073|NCT01324635|Experimental|Arm A (panobinostat, multiple fractions of SBRT)|Patients receive panobinostat PO thrice weekly for 2 weeks and undergo 10 fractions of SBRT over 2 weeks (recurrent gliomas) OR 30 fractions of SBRT over 6 weeks (high grade meningiomas).
3244074|NCT01324635|Experimental|Arm B (panobinostat, stereotactic radiosurgery)|Patients receive panobinostat as in Arm A and undergo a single fraction of stereotactic radiosurgery on day 1 of week 1.
3244075|NCT01324648|Experimental|TG + GP TAU|
3244076|NCT01324648|Experimental|UG + GP TAU|
3244077|NCT01324648|Active Comparator|GP TAU|
3244078|NCT01324661|No Intervention|Control|Individuals who receive the ball during a computerized ball tossing game about the same number of times as the other players in the game.
3244079|NCT01324661|Other|Ostracism|Participant would receive the ball of a ball-tossing game once or twice in the beginning and then never again for the duration of the game.
3244080|NCT01324674|Placebo Comparator|Placebo group|Is the group of subjects that will take placebo
3353010|NCT02283918||Participants with bachelor's degree or equivalent|Participants are further divided into three sub-groups based on their age group Group 1: Participants aged between 25 to 34 years Group 2: Participants aged between 35 to 44 years Group 3: Participants aged between 45 to 58 years
3353011|NCT02283931|Active Comparator|One handed uterine displacement|Uterine displacement using one hand
3353012|NCT02283931|Active Comparator|two handed uterine displacement|Uterine displacement using two hands
3353013|NCT02283931|Active Comparator|30 degrees uterine displacement|Uterine displacement using a 30 degrees wedge
3353014|NCT02283944|Experimental|TMS electrochemotherapy|Combined TMS (transcranial magnetic stimulation) and Temozolomide chemotherapy.
3353015|NCT02283957|Experimental|2 mL injection of 200 µg of CNTX-4975|Single dose, 2 mL
3353016|NCT02283957|Experimental|2 mL injection of 600 µg of CNTX-4975|Single dose, 2 mL
3353017|NCT02283957|Placebo Comparator|2 mL injection of placebo|Single dose, 2 mL
3353018|NCT02283957|Experimental|2 mL injection of 25 µg of CNTX-4975|Single dose, 2 mL
3353019|NCT02283970||BAV and aortic regurgitation|BAV Diagnosis, Aortic Regurgitation with surgical indication (according to current clinical guidelines or best clinical practice), normal ascending aorta
3353020|NCT02283970||BAV and Ascending aorta dilatation|BAV diagnosis, no or trivial Aortic Regurgitation, ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice)
3353021|NCT02283970||BAV, aortic regurgitation and dilatation|BAV diagnosis, Aortic Regurgitation and ascending aorta dilatation with surgical indication (according to current clinical guidelines or best clinical practice).
3353022|NCT02283970||BAV with aortic stenosis in pts>60yrs|BAV diagnosis, Aortic stenosis with surgical indication (according to current clinical guidelines or best clinical practice). Normal ascending aorta
3353023|NCT02283983|Active Comparator|Standard cryoprotection|Proposal helmet without mittens and booties
3353024|NCT02283983|Experimental|Cryoprotection with mittens and booties|Standard cryoprotection with mittens and booties
3353025|NCT02283996|Experimental|Physical Therapy with Steroid Injection|Patients will undergo regular physical therapy as defined by the standard of care at Massachusetts General Hospital for Adhesive Capsulitis (Frozen Shoulder). If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
3353026|NCT02283996|Experimental|Watchful Waiting with Steroid Injection|Patients will undergo no therapeutic intervention outside of steroid injection. If they are in the inflammatory phase of the condition, they will receive 40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine.
3353027|NCT02284022||Brain Computer Interface|Patients will test the brain computer interface system
3353028|NCT02284035|Experimental|Group 1 Raltegravir / 3TC (MK0518B|Raltegravir / 3TC (MK0518B ) (50 patients)
3353029|NCT02284035|Active Comparator|Group 2 standard combination therapy|"NNRTI-Based Regimen:~• EFV/TDF/FTC~PI-Based Regimens:~ATV/r + TDF/FTC or DRV/r + TDF/FTC~INSTI-Based Regimens:~DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC~NNRTI-Based Regimens:~EFV plus ABC/3TC or RPV/TDF/FTC~PI-Based Regimen:~ATV/r plus ABC/3TC~PI-Based Regimens:~DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC~INSTI-Based Regimen:~RAL plus ABC/3TC~And other ART regimens"
3353030|NCT02284048|Placebo Comparator|control|nitrate,beta blocker
3353031|NCT02284048|Active Comparator|ticagrelor|ticagrelor 90mg qd
3353032|NCT02284061|Experimental|experimental|Immediate Program : the child follows the physical activity program for a period of 18 months, as soon as his medical condition permits.
3353033|NCT02284061|Other|Control|Delayed Program: the child does not participate to the program during the first 6 months, and he joins the delayed program late after 6 months.
3353034|NCT02284074|Experimental|Nasal LPS spray|"This is a 5-way crossover, randomised, placebo-controlled study.~Arms consists of the following nasal challenges:~placebo, 1, 10, 30 and 100µg LPS."
3244081|NCT01324674|Experimental|experimental group|Is the group of subjects that will take Bach´s Flower remedies
3244082|NCT01324713||Males|
3353035|NCT02284087||V_PAS|Visuomotor paired associative stimulation protocol
3353036|NCT02284087||Sham V_PAS|Placebo group of Visuomotor paired associative stimulation protocol
3353037|NCT02284087||CER_PAS|cerebellar-motor associative stimulation protocol
3353038|NCT02284087||Sham CER_PAS|Placebo group of cerebellar-motor associative stimulation protocol
3244083|NCT01324713||Females|
3353039|NCT02284100|Experimental|animal assisted therapy group|the dog was present during post-operative awakening (2 hours after surgery)
3353040|NCT02284100|No Intervention|standard group|children had standard post-operative medical care
3353041|NCT02284113|Experimental|Treatment|Treatment with focused cold therapy.
3353042|NCT02284113|Sham Comparator|Sham|Sham treatment with focused cold therapy device
3244084|NCT01324739|Active Comparator|B-type natriuretic peptide|the effect of B-type natriuretic peptide on glucose metabolism will be compared with placebo during an intravenous glocose tolerance test
3244085|NCT01324739|Placebo Comparator|Placebo|comparison of the effect of b-type natriuretic peptide on glucose metabolism and placebo
3244086|NCT01324752|Experimental|PA21 and Losartan with food|
3244087|NCT01324752|Experimental|No PA21; Losartan with food|
3244088|NCT01324752|Experimental|PA21 with food and Losartan 2 hrs later|
3244089|NCT01324765|Experimental|TARGET|12-session affect regulation therapy for PTSD
3244090|NCT01324765|Active Comparator|SGT|12 session supportive group therapy
3244091|NCT01324778|Experimental|A|
3244092|NCT01324778|Active Comparator|B|
3244093|NCT01324791|Active Comparator|laparoscopic antireflux surgery|
3244094|NCT01324791|Active Comparator|endoscopic full-thickness-gastroplication|
3244095|NCT01324804||CABG - subjects|only one group
3244096|NCT01324817||Hopitalized|Patients admitted to the hospital
3244097|NCT01324856|Experimental|Pancreaticogastro anastomosis|
3244098|NCT01324856|Active Comparator|Pancreaticojejuno anastomosis|
3353043|NCT02284139|Placebo Comparator|Placebo|Placebo ointment dose not contain EGF.
3353044|NCT02284139|Active Comparator|Arm EGF ointment 1ppm|Arm EGF ointment 1ppm will be treated with EGF ointment of 1 ppm concentration
3353045|NCT02284139|Active Comparator|Arm EGF ointment 20ppm|Arm EGF ointment 20ppm will be treated with EGF ointment of 20 ppm concentration
3244099|NCT01324869|Experimental|Group A|Patients will receive an intravitreal injection of 0.5mg KH902 in the study eye at the first month, following the fixed injection, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
3244100|NCT01324869|Experimental|Group B|Patients will receive continuously monthly intravitreal injections of 0.5 mg KH902 for 3 times in the study eye; following the initial 3-month fixed-dosing phase of the trial, patients will continue to receive injection of KH902 at the same dose on an as needed (PRN) dosing schedule based upon the monthly physician assessment of the need for re-treatment in accordance with pre-specified criteria.
3353046|NCT02284152|Experimental|Typical versus Infant-Led feeding|This is a within-subject study; all infants and mothers will be exposed to both conditions (typical feeding versus infant-led feeding conditions). Order of presentation will be counterbalanced across infant/mother dyads.
3353047|NCT02284191|Active Comparator|CT Coronary Angiogram|CT Coronary Angiogram plus standard care
3353048|NCT02284191|No Intervention|Standard Care|Standard care only
3353049|NCT02284204|Active Comparator|Midazolam and Ketamine|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). This combination of drugs were administered fifteen minutes before the start of treatment sessions.
3353050|NCT02284204|Experimental|Midazolam, Ketamine and Sevoflurane|In this arm, the children received, orally, the combination of midazolam and ketamine. Midazolam, at a dose of 0.5 mg/kg (maximum dose 20 mg) and ketamine, at a dose of 3 mg/kg (maximum dose 50 mg). After fifteen minutes of this drug administration, the investigators start to provide sevoflurane, through a nasal hood, in an initial concentration of 0.1%, with 0.1% increment every 30 seconds, until a final expired concentration between 0.3 and 0.4%.
3353051|NCT02284217|Experimental|Patients with invasive ICP monitor (EVD)|Hospitalized patients who have already been implanted with an invasive ICP monitor. Eligible patients will be enrolled into the study and HS-1000 headset portion of the device will be placed in their ears.
3353052|NCT02284230|Active Comparator|Liraglutide treatment|Subcutaneous, once daily injection of liraglutide, individually dosed up to 1.8 mg/day.
3353053|NCT02284230|Placebo Comparator|Placebo treatment|Subcutaneous, once daily injection of placebo, individually dosed up to 1.8 mg/day.
3353054|NCT02284256|Experimental|Fibrocaps|"Human fibrinogen and thrombin powder. Single application during surgery~Other Names:~Raplixa~PRO-0601~Fibrin sealant~Device: Gelatin sponge. Single application during surgery~Other Name: Spongostan"
3353055|NCT02284256|Active Comparator|TachoSil|Human fibrinogen and thrombin powder. Single application during surgery
3353056|NCT02284282|Active Comparator|Spinal injection|Patients receive spinal injection Bupivacaine/Morphine
3353057|NCT02284282|Placebo Comparator|Subcutaneum injection|Placebo subcutaneum injections
3353058|NCT02284295||occupational COPD|"Consists of 2 subgroups~COPD patients with history of exposure to respirable silica dust~COPD patients with history of exposure to aromatic hydrocarbons"
3353059|NCT02284295||smokers with COPD and healthy control|"patients with COPD, history of tobacco smoke and no history of occupational exposure~healthy subjects"
3353060|NCT02284308|Active Comparator|Concurrent RCHT|"Etoposide (day 1, 2 and 3) and cisplatin (day 1) every 3 weeks, 3 cycles)~Etoposide (day 1, 2 and 3) and carboplatin (every 3 weeks, 3 cycles)~Cisplatin (daily)~Pemetrexed/Alimta and cisplatin (day 1 every 3 weeks, 3 cycles)~Pemetrexed/Alimta and carboplatin (day 1 every 3 weeks, 3 cycles)~Radiation schedule:~Radiotherapy in both arms is delivered to a minimal total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the mininimal TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
3353061|NCT02284308|Active Comparator|Sequential RCHT|"Pemetrexed/Alimta and cisplatin day 1 every 3 weeks, 3 cycles,~Pemetrexed/Alimta and carboplatin (every 3 weeks, 3 cycles),~Gemcitabine (day 1 and 8) and cisplatin (day 1) every 3 weeks, 3 cycles)~Gemcitabine (day 1 and 8) and carboplatin, (day 1 every 3 weeks, 3 cycles)~Radtiation schedule:~Radiotherapy in both treatment arms is delivered to a minimum total tumour dose (TTD) of 66 Gy (biologically equivalent dose (EQD2), corrected for overall treatment time), unless restricted by one of the normal tissue constraints (see below). In the latter case, the minimum TTD (EQD2 corrected for overall treatment time) is 60 Gy. Possible RT schedules include 33*2 Gy (once daily), 24*2.75 Gy (once daily) or RT according to an individualized prescribed maximal tolerated dose protocol (once or twice daily). The maximal allowed TTD (EQD2) is 86 Gy, corrected for overall treatment time. The overall treatment time should be no more than 47 days."
3353062|NCT02284334||Low GI-High GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): low-glycemic index; test meal (Visit 2): high-glycemic index"
3353063|NCT02284334||High GI-Low GI|"Two study visits are separate by around one month.~For this arm, test meal (Visit 1): high-glycemic index; test meal (Visit 2): low-glycemic index"
3244101|NCT01324908|Experimental|Treatment (Treg predictor of response to ECP)|Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.
3353064|NCT02284360|Experimental|Group A: Low dose|"Each volunteer in group A will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 12.5*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
3353065|NCT02284360|Experimental|Group B: High dose|"Each volunteer in group B will receive both Verum and Placebo.~The Verum lyophilized APOSEC™ is derived from 25*10^6 cells/ml irradiated lyophilized PBMC. The lyophilizate will be resuspended in 0.9% 200 µL NaCl and finally formulated in 800 µL Nugel.~As Placebo a cell-free control lyophilisate resuspended in 0.9% 200 µL NaCl and finally formulated with 800 µL Nugel is used. The location of application on the inner upper arm (proximal or distal) of Verum and Placebo will be randomized."
3353066|NCT02284412|Active Comparator|neostigmine|Neostigmine will be dosed as 60 μg/kg, and glycopyrrolate 12 μg/kg (commercially available 5:1 co-formulation), as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
3353067|NCT02284412|Experimental|Sugammadex|Sugammadex will be dosed 15 mg/kg, as a single iv bolus administered over 10sec, for reversal of rocuronium-induced moderate neuromuscular blockade.
3353068|NCT02284412|Placebo Comparator|Water for injection|Water will be dosed arbitrarily as a 1 mL single iv bolus administered over 10sec.
3353069|NCT02284425|Experimental|Part A|Participants in Part A will consist of 4 sequential ascending dose cohorts. Each cohort will receive 1 of 4 ascending dose levels of study drug (REGN1193) or placebo.
3353070|NCT02284425|Experimental|Part B|Participants in Part B will consist of a single cohort and will receive three doses of study drug (REGN1193) or placebo.
3353071|NCT02284438|Other|Biofilm formation on ETT|Three different endotracheal tubes uses on intubated mechanical ventilated patients will after extubation be examined regarding biofilm, structure and presence of microbes on the ETTs The different tubes will be used during consecutive time periods The study does not include any interventions concerning the treatment of these critically ill patients
3353072|NCT02284451|Active Comparator|English HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3353073|NCT02284451|Active Comparator|English LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3353074|NCT02284451|Active Comparator|Spanish HIGH Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3353075|NCT02284451|Active Comparator|Spanish LOW Health Literacy|Using a valid measure of health literacy, 300 participants will be randomized into this group. These participants will receive HIV/AIDS and HIV testing information either by video or pictorial brochure in two equal groups.
3244102|NCT01324921|Placebo Comparator|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3244103|NCT01324921|Active Comparator|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3244104|NCT01324921|Experimental|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
3244105|NCT01324934|Active Comparator|Study Group|immunosuppressive treatment consisting of ATG-Fresenius/TAC/MMF or Myfortic
3244106|NCT01324934|No Intervention|Control Group|immunosuppressive treatment consisting of TAC, MMF or Myfortic, and corticosteroids.
3353076|NCT02284477|Experimental|non- PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in glass bottle for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
3353077|NCT02284477|Experimental|PVC containing packing materials|Participants will be provided food for lunch and dinner with 360mL apple juice which was stored in PVC blood bag for 24 hours in 4 ℃. After 1 week, participant will cross over to other intervention.
3353078|NCT02284477|No Intervention|Only lunch and dinner|Participant received food for lunch and dinner After 1 week, participant get over to each experimental arms.
3353079|NCT02284490|Experimental|Treatment Arm|Pemetrexed 900 mg/m² every 21 days until disease progression.
3353080|NCT02284503|Experimental|40mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 40mg within 12±2h before PCI, follow 20mg post PCI for 30days.
3353081|NCT02284503|Experimental|20mg Rosuvastatin group|The subjects in this group will receive Rosuvastatin 20mg within 12±2h before PCI, follow 20mg post PCI for 30days.
3353082|NCT02284503|Experimental|no statin group|The subjects in this group will not receive Rosuvastatin before PCI, follow 10mg post PCI for 30days.
3244107|NCT01324960|Experimental|Ceplene® / IL2 + Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene (EpiCept Corporation, Tarrytown, NY) at 0.5 mg subcutaneous twice daily and human recombinant IL-2 (aldesleukin; Novartis) 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
3244108|NCT01324960|Active Comparator|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
3244109|NCT01324973|Experimental|eWellness program|A comprehensive program that delivers web-based, evidence-based weight management; and structured peer supports. The program is designed to meet the needs of individuals with mental illness.
3244110|NCT01324973|No Intervention|Control group|Care as usual
3244111|NCT01324986|Active Comparator|Nissen fundoplication|
3244112|NCT01324986|Active Comparator|Toupet fundoplication|
3244113|NCT01325012|Active Comparator|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle.
3244114|NCT01325012|Active Comparator|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation.
3244115|NCT01325025|Other|Patients|Patients with a metachromatic leukodystrophy
3244116|NCT01325025|Other|Control|Epileptic population
3244117|NCT01325038|Active Comparator|extra protein supplement|isometric training with addition of extra protein
3244118|NCT01325038|Active Comparator|extra food supplement|isometric exercise with addition of extra food and calories: one fast food meal/day
3244119|NCT01325051|No Intervention|Raltegravir|To test raltegravir to see if it can be detected in gastrointestinal tissue of healthy men.
3353083|NCT02284529|Experimental|Orectalip® (Oxaliplatin)|High-risk Stage-Ⅱ Colorectal Cancer treatment with Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1 to execute 8~12 cycles
3353084|NCT02284542||Patients with successful trial implant|Patients who have had a successful SCS trial and are indicated for permanent implantation will be approached to participate in this study prior to permanent implantation. Patients will be recruited and enrolled by physicians at any one of the involved sites. Each Investigator will only use one method (awake or non-awake) according to his/her typical practice. Patients will receive treatment from their enrolling physician.
3353085|NCT02284581||Retrospective cohort|All consecutive metastatic breast cancers patients treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from Feb 2014 retrospectively back until 2000.
3353086|NCT02284581||Prospective cohort|All new consecutive metastatic breast cancers patients will be treated in the participating sites with a first-line therapy (chemotherapy or hormonal therapy with or without biological therapy) from March 2014 to December 2016.
3353087|NCT02284594|Experimental|text message|Receipt of series of text messages regarding influenza vaccination
3353088|NCT02284594|No Intervention|usual care|
3353089|NCT02284607|Experimental|MHAA4549A higher dose|
3353090|NCT02284607|Experimental|MHAA4549A lower dose|
3353091|NCT02284607|Placebo Comparator|Placebo|
3353092|NCT02284620|Experimental|CFNB group|Particiants in this group will receive a single injection for femoral nerve block intra-operatively combined continuous femoral nerve block post-operatively. This technique will be guided by ultrasound and nerve stimulator.The regimen is a loading dose of 0.8% ropivacaine 30 ml intra-operatively and 0.15% ropivacaine 300ml in the form of continuous femoral nerve block post-operatively.
3353093|NCT02284620|Active Comparator|LWI group|Particiants in this group will receive a peri-articular injection of suspension (48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone) combined with intravenous patient controlled analgesia post-operatively (tramadol 800 mg and flurbiprofenaxetil 100 mg with saline added up to a volume of 80 ml )
3353094|NCT02284646|Experimental|Personalized physical training|9-week personalized physical training program (ergometric bicycle)
3353095|NCT02284646|No Intervention|Information about physical activity|2 sessions of information on physical activity
3353096|NCT02284659|Sham Comparator|FES-sham|Functional Electro Stimulation (FES-sham)
3353097|NCT02284659|Active Comparator|Intervention (FES)|functional electro stimulation
3353098|NCT02284672|Placebo Comparator|control|"After preoxygenation for 3 minutes, normal saline would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
3353099|NCT02284672|Experimental|dexmedetomidine|"After preoxygenation for 3 minutes, dexmedetomidine would be injected to patient for 10 minute. First, 1% lidocaine 3 ml were given for reducing injection pain of propofol and the settled amount of propofol was injected during 15 seconds.~After 90 seconds, other anesthesiologist who did'nt know the injected drug tried to insert LMA."
3244120|NCT01325077|Experimental|Conventional model, Study model|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
3353100|NCT02284685|Experimental|A (opt-out, loss, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, social norming).
3353101|NCT02284685|Experimental|B (opt-out, gain, social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, social norming).
3244121|NCT01325090|Experimental|BOTOX|Patients will receive in one session multiple intradermal injections of Botox, in order to cover the whole painful area
3244122|NCT01325090|Placebo Comparator|PLACEBO|Patients will receive in one session multiple intradermal injections of placebo , in order to cover the whole painful area
3353102|NCT02284685|Experimental|C (opt-out, loss, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, loss, no social norming).
3244123|NCT01325103|Experimental|Stem Cell Transplantation|Patients with spinal cord injury that will undergo autologous bone marrow stem cell transplantation.
3244124|NCT01325116|Active Comparator|Control|Usual post-STEMI care
3244125|NCT01325116|Experimental|Intervention|Recurrent, personalized, educational reminders sent via post on behalf of the interventional cardiologist to the patient and their family physician urging long-term adherence to secondary prevention medications post-STEMI. A copy of the letter will be provided to the patient to take to their pharmacist.
3244126|NCT01325142||ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has developed ONJ
3244127|NCT01325142||No ONJ|Patient with cancer involving the bone treated with osteoclast inhibitor (bisphosphonate) and has NOT developed ONJ
3244128|NCT01325168|Experimental|study group|32 PTSD patients intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
3244129|NCT01325168|Other|control group|control group - 30 healthy control subjects intervention: Drug: syntocinon nasal spray / placebo nasal spray nasal OT - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
3244130|NCT01325194|Experimental|CNS prophylaxis|
3353103|NCT02284685|Experimental|D (opt-out, gain, no social norming)|Students in this intervention arm must opt-out of receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-out, gain, no social norming).
3353104|NCT02284685|Experimental|E (opt-in, loss, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, social norming).
3353105|NCT02284685|Experimental|F (opt-in, gain, social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, social norming).
3353106|NCT02284685|Experimental|G (opt-in, loss, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the negative consequences (losses) of not seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, loss, no social norming).
3353107|NCT02284685|Experimental|H (opt-in, gain, no social norming)|Students in this intervention arm must opt-in to receiving linkage to eating disorder resources on their campus; messages do not include social norming (statistics comparing their rates of eating disorder symptoms to national averages on widely-used and clinically validated screening tools); and messages frame the benefits of seeking-help for current disordered eating symptoms. The intervention ('A Novel Intervention Promoting Eating Disorder Treatment among College Students') is this version of the email messages (opt-in, gain, no social norming).
3244131|NCT01325220|Active Comparator|STX209 5 mg BID|
3353108|NCT02284698||Study Group|Study Group will have the field workers and active health education with referral mechanism
3353109|NCT02284698||Control Group|Control group will not have field workers and active health education. They will follow routine health care
3353110|NCT02284711|Active Comparator|Bipolar|Coagulation during salpingectomy using conventional bipolar electric energy
3244132|NCT01325220|Active Comparator|STX209 10 mg BID|
3244133|NCT01325220|Active Comparator|STX209 10 mg TID|
3244134|NCT01325220|Placebo Comparator|Placebo|
3244135|NCT01325233|Experimental|PG2 Injection|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
3244136|NCT01325233|Placebo Comparator|Placebo|Powder for Injection, 500 ml normal saline, tiw, 2 weeks
3244137|NCT01325259|Experimental|Alzheimer's disease|30 patients suffering from Alzheimer's disease
3244138|NCT01325259|Experimental|Mild Cognitive Impairment|20 patients suffering from Mild Cognitive Impairment
3244139|NCT01325259|Experimental|Control|15 subjects with no cognitive impairment
3244140|NCT01325272||preterm newborn|
3244141|NCT01325272||term newborn|
3244142|NCT01325298|Active Comparator|20 Minute UV-X Light Treatment Duration|"20 Minute UV-X Light Treatment Duration~Note: UV-X is the trademark of Peschke GmbH"
3244143|NCT01325298|Active Comparator|30 Minute UV-X Light Treatment Duration|30 Minute UV-X Light Treatment Duration
3244144|NCT01325324|Other|Study group|Study group
3244145|NCT01325363|Experimental|Schizophrenia|Schizophrenic patients
3244146|NCT01325363|Experimental|Control|Neurotypical subjects
3244147|NCT01325376|No Intervention|Self directed|
3244148|NCT01325376|Active Comparator|Technology assisted health behavior|The intervention arm will have access to a dynamic online environment with social networking and device data uploads that include activity data, weight data and laboratory data at frequent intervals to nudge optimal health behavior.
3244149|NCT01325389|Experimental|Myo+Mel|Patients are treated with 2g of myo + 3mg of melatonin daily
3244150|NCT01325389|Placebo Comparator|Placebo|
3244151|NCT01325402|Experimental|Part 1 Cohort 1|Patients with mild to moderate Alzheimer's Disease
3244152|NCT01325402|Experimental|Part 1 Cohort 2|Patients with mild to moderate Alzheimer's Disease. To run if Maximum Detective Mass is detected in cohort 1.
3244153|NCT01325402|Experimental|Part 2|Healthy Volunteers
3244154|NCT01325415|Experimental|A|NKTR-118 25 mg (1x25 mg tablet + 5x placebo tablets)
3244155|NCT01325415|Experimental|B|NKTR-118 150 mg (6x25 mg tablet)
3244156|NCT01325415|Placebo Comparator|C|NKTR-118 placebo (6x placebo tablets)
3244157|NCT01325415|Active Comparator|D|Moxifloxacin (1 x 400 mg tablet)
3259355|NCT01470092|Active Comparator|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
3244158|NCT01325441|Experimental|BBI608 and Paclitaxel|Patients will receive BBI608 orally continuously at dose levels specified for their respective dose cohorts. A treatment cycle will be 4 weeks (28 days). BBI608 will be administered twice daily. On days 3, 10, and 17 of each 28 day cycle, patients will receive a 1 hour infusion of paclitaxel. Cycles will be repeated until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, adjustment is permitted.
3353111|NCT02284711|Active Comparator|Ultrasound|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
3353112|NCT02284724|Experimental|Needling|Insertion of solid mono-filament needle into lumbar multifidus muscle at both sides of L4/5 segment
3353113|NCT02284724|Other|Sham|The plastic tube containing the mono-filament needle will be pressed into the skin over the lumbar multifidus muscle at both sides of L4/5 segment - without insertion through the skin
3353114|NCT02284737|Experimental|PADN + sildenafil|Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
3244159|NCT01325454||Patients with parapneumonic effusions|Patients with pleural effusions of unknown causes admitted to Taipei Medical University Hospital were included if parapneumonic effusion was diagnosed as one associated with pneumonia according to the criteria of the American Thoracic Society (ie, patients with newly acquired respiratory symptoms, fever, and abnormal breath sounds, plus a new lung infiltrate seen on a chest radiograph).
3244160|NCT01325480||Patients with heart failure and wide QRS|Patients undergoing a cardiac resynchronization therapy procedure
3353115|NCT02284737|Sham Comparator|sham PADN + sildenafil|The radiofrequency ablation catheter placed, no ablations.
3353116|NCT02284750|Experimental|Two-stenting technique|Percutaneous coronary intervention with DK crush, or culotte technique
3353117|NCT02284750|Active Comparator|Provisional stenting technique|Percutaneous coronary intervention with Provisional stenting technique. Stenting of the side branch was required if TIMI flow was <3, or ≥ type B dissection after kissing balloon inflation.
3353118|NCT02284763|Experimental|Change of EtCO2|Changes of rSO2 after adjustment of EtCO2 between 27-45 mmHg
3353119|NCT02284776|No Intervention|Témoin|No treatment.
3353120|NCT02284776|Experimental|Action|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
3353121|NCT02284789|Other|CAJAS evaluation|
3244161|NCT01325506||Prostatectomy subjects|
3353122|NCT02284802|Experimental|Confocal endomicroscopy|Pts will be submitted to confocal endomicroscopy examination of the area of interest during endoscopy. A presumptive diagnosis will be made. This diagnosis will be compared to the definitive histologic diagnosis provided by endoscopic biopsies of the area of interest.
3353123|NCT02284815|Active Comparator|Glutenfree diet|Self-chosen glutenfree diet
3353124|NCT02284815|Placebo Comparator|Normal diet|Those not following the glutenfree diet
3353125|NCT02284841|Experimental|Hilotherm cooling face mask|Use of Hilotherm cooling face mask post-operatively following surgical wisdom tooth removal to evaluate the incidence of pain and swelling
3353126|NCT02284841|No Intervention|No Hilotherm|No intervention following surgical wisdom tooth removal (same patient), therefore the patient is their own control.
3353127|NCT02284919|Experimental|ISO-1 PET/CT|All subjects will receive an [18F]ISO-1 PET/CT scan
3353128|NCT02284932||COPD patients|Group : COPD patients No specific intervention for this study
3353129|NCT02284932||Healthy controls|Group : healthy volunteers No specific intervention for this study
3353130|NCT02284945|Experimental|Posterior percutaneous instrumentations|
3353131|NCT02284945|Other|Traditional open surgery with pedicle screw fixation|
3353132|NCT02284958|Active Comparator|Standard/Control group|Each participant will receive a one-off individualized educational session regarding the management of chronic low back pain with a Physical Therapist: includes a physical examination, standardized advice & provision of the 'Back Book'.
3353133|NCT02284958|Experimental|Walking group|Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
3244162|NCT01325519|No Intervention|no intervention control group|control subjects
3244163|NCT01325519|Experimental|experimental intervention group|video decision aid viewed by subjects
3244164|NCT01325545||Cryptogenic stroke|Patients with stroke of unknown cause after comprehensive conventional evaluation
3244165|NCT01325545||Stroke of known cause|Patients with stroke of known cause determined by comprehensive conventional evaluation
3244166|NCT01325571|Experimental|tacrolimus group|
3244167|NCT01325571|Placebo Comparator|placebo group|
3244168|NCT01325597|Experimental|Combined training|Training with functional electrical stimulation added by inspiratory muscle training.
3353134|NCT02284971|Experimental|Arm A: CDX1127 & SBRT Concurrent|"SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3376001|NCT03314181|Experimental|Arm D, Part 2a: VenDVd Dose Escalation|Venetoclax at various doses administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information, bortezomib (1.3 mg/m2 subcutaneous injection [preferred] or IV) Cycles 1-8, Days 1, 4, 8 and 11), and dexamethasone (oral or IV) 20 mg Cycles 1 - 3, Days 1, 2, 4, 5, 8, 9, 11,12 and 15; 20 mg Cycles 4-8, Days 1,2,4,5,8,9,11 and 12; 40 mg weekly (or 20 mg weekly, if necessary as described in the protocol) Cycle 9+.
3353135|NCT02284971|Experimental|Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3353136|NCT02284971|Experimental|Arm C: CDX1127 & SBRT Sequential; SBRT upfront|"SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases).~Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight."
3353137|NCT02284984|Experimental|Rituximab with belimumab|Rituximab 1000mg on day 0 and day 14 Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks.
3353138|NCT02284997|Experimental|Treatment|Participants will be instructed to use a warming MGDRx® EyeBag for minimum of 10 minutes, twice a day
3353139|NCT02284997|No Intervention|Control|No treatment
3353140|NCT02285036|Experimental|A newly PPV23|The treatment pneumococcal vaccine was developed by Yunnan Walvax Biotech Co., Ltd (Walvax) China, is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of Streptococcus pneumoniae, including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in China. The dose of vaccine is an individual with a 0.5ml dose contains 23 kinds of pneumococcal polysaccharide serotypes each 25μg, and does not contain any preservatives. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
3353141|NCT02285036|Active Comparator|PNEUMOVAX 23|PNEUMOVAX 23 is an established US-licensed vaccine and manufactured by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
3353142|NCT02285049||Urticaria Control Test|"Evaluation by UAS28, PatGA-LS, PhyGA-LS~Fill the UCT and DLQI questionnaire"
3353143|NCT02285075|Other|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations in patients treated with haemodialysis receiving 1 gram temocillin for a 1 day interval, 2 gram temocillin for a two day interval and 3 gram temocillin for a 3 day interval to the next dialysis session
3353144|NCT02285088|Experimental|GBT440|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
3353145|NCT02285088|Placebo Comparator|Placebo|Subjects randomized 6:2 to receive daily oral dosing of GBT440 or placebo for 1 day (single dose) and up to 118 days (multiple dose)
3353146|NCT02285101|Experimental|Cohort 1|PEG-BCT-100 at 0.5 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 0.5 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 0.5 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 0.5 mg/kg until disease progression at the discretion of the investigator.
3353147|NCT02285101|Experimental|Cohort 2|PEG-BCT-100 at 1.0 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.0 mg/kg on days 22 (week4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.0 mg/kg until disease progression at the discretion of the investigator.
3244169|NCT01325597|Experimental|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
3244170|NCT01325597|Experimental|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
3244171|NCT01325597|No Intervention|Control group|No intervention.
3244172|NCT01325636|Experimental|CD4 and CD8 T cell|Injection of specific CD4 and CD8 T cell
3244173|NCT01325649||advanced rectal cancer|Patients with carcinoma of the middle rectum with positive mrCRM (≤ 1 mm), with cT3 low rectal carcinoma, and with cT4 Tumors Arm 1 Long course radiochemotherapy before total mesorectal excision Arm 2 total mesorectal excision without radiochemotherapy
3244174|NCT01325662||Continuous drip sampling|Sampling at ~0.6 cc / hour (~1.2 cc / 2 hours, or lowest feasible rate given technical requirements and volume requirements for core analytes assays)
3244175|NCT01325662||Intermittent sampling|Sampling at 4 cc every 2 hours (+ 2 cc dead space clearance, total = 6 cc / 2 hours)
3244176|NCT01325675|Experimental|Interval training|Interval training
3244177|NCT01325675|No Intervention|Control|Live as usual
3244178|NCT01325688|Experimental|Group 1|PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
3244179|NCT01325688|Experimental|Group 2|PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
3244180|NCT01325688|Experimental|Group 3|PEP005 0.05% applied with no occlusion for up to three consecutive days
3353148|NCT02285101|Experimental|Cohort 3|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 1.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 1.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 1.7 mg/kg until disease progression at the discretion of the investigator.
3353149|NCT02285101|Experimental|Cohort 4|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 2.7 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 2.7 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 2.7 mg/kg until disease progression at the discretion of the investigator.
3353150|NCT02285101|Experimental|Cohort 5|PEG-BCT-100 at 1.7 mg/kg administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT- 100 will be administered at 4.0 mg/kg on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at 4.0 mg/kg. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at 4.0 mg/kg until disease progression at the discretion of the investigator.
3353151|NCT02285101|Experimental|Cohort 6|PEG-BCT-100 at a dose to be determined administered as a single dose on day 1 (week 1); if not DLTs are observed, PEG-BCT-100 will be administered at at a dose to be determined on days 22 (week 4) and 29 (week 5). Patients responding to treatment or with stable disease may receive 8 additional weekly administrations of PEG-BCT-100 at at a dose to be determined. Beyond week 13, patients responding to treatment or with stable disease may continue to receive weekly PEG-BCT-100 at at a dose to be determined until disease progression at the discretion of the investigator.
3353152|NCT02285127|Active Comparator|Short nail implant|used to treat pertrochanteric fractures
3353153|NCT02285127|Active Comparator|Long nail implant|used to treat pertrochanteric fractures
3353154|NCT02285140|Experimental|Cefazolin monotherapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered
3353155|NCT02285140|Experimental|Cefazolin monotherapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose).
3353156|NCT02285140|Experimental|Combination therapy, short course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered. In addition, one dose of vancomycin 60-90min pre-op will be administered.
3353157|NCT02285140|Experimental|Combination therapy, long course|One pre-op dose of cefazolin 30-60 minutes prior to surgery followed by a second dose either four hours after the first dose or upon wound closure (whatever comes first) will be administered followed by additional five doses every eight hours postoperatively (last dose 44 hours after the first dose). In addition, one dose of vancomycin 60-90min pre-op will be administered followed by 3 post-op doses every 12 hours (last dose 36 hours after first dose)
3353158|NCT02285166||Oral administration of 2 g of omega-3-acid ethyl esters|Oral administration of 2 g of omega-3-acid ethyl esters once daily or twice daily immediately after meals
3353159|NCT02285166||Standard antihyperlipidemic therapy|Standard antihyperlipidemic therapy other than omega-3 fatty acid ethyl esters (Lotriga) administration.
3353160|NCT02285179|Experimental|tamoxifen and GDC-0032|20 mg tamoxifen QD and 4 MG GDC-0032 QOD
3353161|NCT02285179|Placebo Comparator|tamoxifen and placebo|20 mg tamoxifen QD and placebo QOD
3353163|NCT02285205|Experimental|Lobeglitazone|
3353164|NCT02285218||1) Normal control|metabolically healthy with no obesity
3353165|NCT02285218||2) dyslipidemia|high triglyceride levels or LDL-C levels
3353166|NCT02285218||3) type 2 diabetes|defined in 'inclusion criteria'
3353167|NCT02285218||4) non-alcoholic fatty liver disease|defined in 'inclusion criteria'
3353168|NCT02285231|Experimental|TEST|Arginyl-fructose Supplementation
3353169|NCT02285231|Experimental|Placebo|Placebo Supplementation
3353170|NCT02285244|Experimental|Treatment (sotrastaurin acetate)|Patients receive sotrastaurin acetate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3353171|NCT02285296|No Intervention|control arm|usual care
3353172|NCT02285296|Experimental|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
3353173|NCT02285309||Cardiac surgery|
3244181|NCT01325727|Experimental|Brief computerized feedback|Brief computerized feedback
3244182|NCT01325727|Active Comparator|Resources only|
3244183|NCT01325740|Active Comparator|STX107 10 mg|
3244184|NCT01325740|Placebo Comparator|Placebo|
3244185|NCT01325740|Active Comparator|STX107 30 mg|
3244186|NCT01325753|Experimental|Treatment (cryoablation)|Patients undergo CT-guided CA.
3244187|NCT01325766|Active Comparator|Yoga (immediate start) group|This arm will start yoga sessions immediately after screening and will continue sessions for 8 weeks. This group will then continue with home yoga for an additional 8 weeks.
3244188|NCT01325766|Active Comparator|Yoga (waitlist) group|This arm will continue regular CF therapies for 8 weeks and will start yoga sessions at week 9.
3244189|NCT01325779|Active Comparator|subcutaneous heparin|
3244190|NCT01325779|Active Comparator|subcutaneous enoxaparin|
3353174|NCT02285322||BP control reached|Patients diagnosed with high blood pressure who lowered their blood pressure measurements during follow-up to <140/90mmHg if aged less than 60 years old, and <150/90mmHg for those of ≥60 years
3353175|NCT02285322||BP control not reached|Patients diagnosed with high blood pressure who did not lower their blood pressure measurement during follow-up (measurements were ≥140/90mmHg for individuals aged less than 60 years old, and ≥150/90mmHg for those of ≥60 years)
3353176|NCT02285335|Experimental|Low group|GINST15 3g/day
3353177|NCT02285335|Experimental|High group|GINST15 6g/day
3353178|NCT02285348|Other|Ataxia Telangiectasia|20 patients with clinically and/or genetically diagnosed Ataxia telangiectasia will get a lumbar puncture
3353179|NCT02285348|Other|Healthy Control|20 patients without inflammation, infection or any other pathology of the CNS, in that a lumbar puncture is indicated for either diagnostic or therapeutic reason (i.e. for the exclusion of a meningitis, subarachnoid hemorrhage or in therapeutic liquor drain in idiopathic intracranial hypertension)
3353180|NCT02285374|Experimental|Arm 1|Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus Dolutegravir 50mg (one tablet) once daily
3353181|NCT02285374|Experimental|Arm 2|Atripla (efavirenz 600mg, emtricitabine 200mg, tenofovir 245mg) one tablet once daily, or Truvada (tenofovir 245mg/emtricitabine 200mg) or Kivexa (abacavir 600mg/lamivudine 300mg) one tablet once daily plus efavirenz 600mg one tablet once daily for 4 weeks. At week 4, efavirenz is switched to Dolutegravir 50mg (one tablet) once daily
3353182|NCT02285387|Experimental|Rhythm control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
3353183|NCT02285387|Active Comparator|Rate control group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
3353184|NCT02285400|Experimental|Moderate COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
3353185|NCT02285400|Experimental|Severe COPD patients|Patients are connected to the noninvasive ventilator and incremental CPAP level is performed.
3353186|NCT02285413|Experimental|DC vaccination|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase
3353187|NCT02285413|Experimental|DC vaccination with cisplatinum|mature DC injected intradermally and intravenously loaded with mRNA encoding tumor-associated antigens gp100 and tyrosinase. each DC vaccine will be preceded by cisplatin infusion: 50 mg/m2, 1-2h before DC injection.
3353188|NCT02285426||suspected lungcancer|"Patients will undergo a bronchoscopy with the Pentax EB1990i HD-bronchoscope investigating the entire bronchial tree. The HD+ bronchoscopy needs to be performed in a standardized way using 3 different imaging modes:~HD+bronchoscopy~HD+bronchoscopy + i-Scan 1~HD+bronchoscopy + i-Scan 2"
3353189|NCT02285439|Experimental|Phase 1|Patients with non-hematologic malignancies that are recurrent, progressive, or refractory after standard up-front therapy receiving MEK162 will define the MTD, DLT, and toxicity profile.
3353190|NCT02285439|Experimental|Phase 2|Children with recurrent tumors signaling through the Ras/Raf pathway will be treated in 3 strata to define the activity of MEK162. S1: Children with LGG characterized by a BRAF truncated fusion (KIAA1549 and similar translocations). S2: Children with NF1 and LGG. S 3: Children with tumors involving the Ras/Raf pathway not included in strata 1 or 2.
3353191|NCT02285439|Experimental|Target Validation|Patients eligible for phase 2 (any stratum) for whom tumor biopsy or resection is clinically indicated may be enrolled on the target validation arm. Patients will receive MEK162 for 7 to 21 days prior to their surgery. Tumor sample will be analyzed for drug concentration and target inhibition.
3353192|NCT02285452|Active Comparator|Thorax wrap with ginger flour (Zingiberis Rhizoma plv.)|Thorax wrap with ginger flour, duration max. 20 minutes
3353193|NCT02285452|Active Comparator|Thorax wrap with mustard flour (Sinapis nigrea semen)|Thorax wrap with mustard flour, duration max 20 minutes
3353194|NCT02285452|Placebo Comparator|Thorax wrap with warm water (placebo)|Thorax wrap with warm water (placebo), duration: 20 minutes
3353195|NCT02285465|Experimental|ASP3700 multiple ascending dose cohort|
3353196|NCT02285465|Placebo Comparator|Placebo cohort|
3353197|NCT02285491|Experimental|bupivacaine group|This is the group of patients that will receive 10ml of bupivacaine 0.5% injection in both angles of the rectus sheath incision
3353198|NCT02285491|Placebo Comparator|saline group|This group will receive saline injections as placebo into both angles of the rectus sheath incision
3353199|NCT02285491|Experimental|bupivacaine and saline group|This group will receive saline injection in one angle and 10ml of bupivacaine 0.5% injection in the opposite angle.
3353200|NCT02285517|Active Comparator|modified Meek technique|Intervention: modified Meek skin grafting technique. Patients with third degree of burns without infected wounds are included and the modified Meek results are studied , measured and compared to other group which is operated lesions by mesh technique
3353201|NCT02285517|Active Comparator|mesh technique|Intervention: mesh skin grafting technique. patients with third degree of burns without infected wounds are included and the mesh skin grafting technique results are studied , measured and compared to other group which is operated lesions by modified Meek skin grafting technique
3353202|NCT02285530|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin:75 mg/m2 5-Fu:750 mg/m2/day"
3353203|NCT02285530|Other|surgery group|Radical resection of the primary lesion and full neck,radiotherapy was arranged 4 to 6 weeks after surgery
3353204|NCT02285543|Experimental|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
3353205|NCT02285543|Other|Control group|The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.
3353206|NCT02285556|No Intervention|general information|use cross-sectional study to collect 1000 ATS abuse or dependence patients' general information and 5 ml blood,get their blood plasma and DNA sample in order to explore the possible addict mechanism.
3353207|NCT02285556|No Intervention|ATS diagnosis and evaluation for abusers|Use cohort study design to establish ATS abuse induced craving experiment.Do the initial and follow-up assessment from start smoking to stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community . Thus compare with normal group to explore the possible psychological abuse mechanism.
3353208|NCT02285556|Active Comparator|psychological training intervention|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
3244193|NCT01325818|Active Comparator|1:pravastatin, 2:rosuvastatin|"Active Comparator Drug:pravastatin~Active Comparator Drug:rosuvastatin"
3244194|NCT01325831|Experimental|transcranial magnetic stimluation|
3353209|NCT02285556|Active Comparator|brain stimulation intervention|Use randomized, prospective pseudo stimulus controlled clinical trial design, evaluation of repetitive transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
3353210|NCT02285556|No Intervention|ATS diagnosis and evaluation for normal people|Do the same initial and follow-up assessment as ATS abusers who stop smoking after 4 weeks, 12 weeks, 26 weeks, 52 weeks and 26 weeks of returning to the community .
3353211|NCT02285556|Active Comparator|physical and neurological rehabilitation|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
3353212|NCT02285556|Placebo Comparator|fake brain stimulation intervention|fake transcranial magnetic stimulation of the left frontal lobe dorsal lateral effect on ATS dependent induced cognitive dysfunction and other symptoms.
3353213|NCT02285595|Other|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
3353214|NCT02285608|Experimental|PIMM/SAM|Partnership in Medication Management (PIMM): The nurse and the attending physician will meet with the patient and ask how s/he administers medication at home (i.e., blister pack). Initial education session: the nurse will teach the patient about his/her medications, dosage, purpose, when and how to take them. Nurse and patient will establish reminders to take his/her medication. Following the education session, patients will be required to notify the nurse when it is time to take their medications, where their medications are, dosage, purpose and side effects. Self-Administered Medication (SAM): Patients will transition to SAM once the clinical team feels that no further medication changes are required. SAM is also the model that the participants will follow after discharge.
3353215|NCT02285608|No Intervention|Standard Prescribing Practice(SPP)|Standard prescribing practice (SPP): medication administration will proceed as standard practice. Patients will not receive a personalized medication training. The nurse will administer the patient's medications. However, patients are encouraged to ask any questions regarding his/her medications.Patients will not be provided with any tool to help them to remember when to take their medications. The nurse will record the patient's knowledge regarding his/her medications.
3353216|NCT02285647|Experimental|Rolapitant - Oral|Investigational Product: Rolapitant Dose: 200 mg (4 x 50mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
3244195|NCT01325831|Sham Comparator|rTMS_sham|
3244196|NCT01325844|No Intervention|G group|G group = General anesthesia group
3244197|NCT01325844|Experimental|G+E group|G+E group = General anesthesia + epidural anesthesia group
3244198|NCT01325857|Experimental|Group B|Group B = Nerve block group
3353217|NCT02285647|Experimental|Rolapitant - IV|Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
3353218|NCT02285660|Other|Routine CT scan plus 4D PET-CT scan|
3353219|NCT02285660|Other|Routine CT scan|
3353220|NCT02285673|Experimental|Umbilical Cord Mesenchymal Stem Cell|
3353221|NCT02285699|Other|SSRI treatment|The intervention only applies to Phase II of the proposed study. Individuals in the OCD group will be offered 12-weeks of standard SSRI treatment ti determine whether 12-weeks of treatment results in a change of the gut microbiota/inflammatory markers.
3353222|NCT02285712|No Intervention|Classical method of peripheral venous catheterization|Classical method will be applied only on arm and forearm.
3244199|NCT01325857|Placebo Comparator|Group L|Group L = Local wound infiltration group
3244200|NCT01325857|Active Comparator|Group C|Group C = Control group
3244201|NCT01325896|Other|All patients are receiving PEG-Intron|
3244202|NCT01325909|Active Comparator|Exercise|
3244203|NCT01325909|No Intervention|No Exercise|
3244204|NCT01325922|Other|50/50% Tilt|
3244205|NCT01325935|Experimental|Short-term DAPT group|1,200 patients to be newly registered: Undergo 3-month (+ 30 days) DAPT (aspirin and clopidogrel)
3244206|NCT01325935|No Intervention|Long-term DAPT group|1,200 patients to be appropriated from E-Japan post-marketing surveillance who meet all inclusion criteria and do not fall under any exclusion criteria of the present clinical study: Undergo 12-month DAPT (aspirin and clopidogrel)
3244207|NCT01325948||Patients with COPD|
3244208|NCT01325987|Placebo Comparator|sugar pill|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
3244209|NCT01325987|Experimental|vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
3244210|NCT01326000|Experimental|KRAS WT A|
3353223|NCT02285712|Experimental|Ultrasound guided peripheral venous catheterization|Nurse will use a vascular ultrasound system to orient the catheter toward the peripheral vein. Ultrasound method will be applied only on arm and forearm.
3353224|NCT02285725|Experimental|Augmented Microdrilling Surgery|
3353225|NCT02285738|Active Comparator|Aspirin+Asprin/Simvastatin+Observation (ASO)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day with daily dose of Simvastatin with a 2-week washout period, ending with 4 weeks of observation
3353226|NCT02285738|Experimental|Aspirin+Observation+Asprin/Simvastatin (AOS)|Aspirin 81mg/day for 4 weeks followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day with daily dose of Simvastatin
3353227|NCT02285738|Experimental|Aspirin/Simvastatin+Observation+Asprin (SOA)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of observation with 2-week washout, ending with Aspirin 81mg/day
3353228|NCT02285738|Experimental|Aspirin/Simvastatin+Asprin+Observation (SAO)|Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, followed by 4 weeks of Aspirin 81mg/day and a 2-week washout, ending with observation for 4 weeks.
3353229|NCT02285738|Experimental|Observation+Aspirin/Simvastatin+Asprin (OSA)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks.
3353230|NCT02285738|Experimental|Observation+Aspirin+Asprin/Simvastatin (OAS)|Observation for 4 weeks with 2-week washout, followed by Aspirin 81mg/day for 4 weeks followed by 2-week washout, ending with Aspirin 81mg/day for 4 weeks with daily dose of Simvastatin.
3353231|NCT02285751|Experimental|200mg acetylsalicylic acid per os|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 200mg acetylsalicylic acid per os"
3353232|NCT02285751|Experimental|100mg acetylsalicylic acid intravenous|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 100mg acetylsalicylic acid intravenously."
3353233|NCT02285751|Experimental|81 mg chewable acetylsalicylic acid|"patients with high on treatment platelet reactivity to acetylsalicylic acid are randomized to 3 different groups, one group receives 81mg chewable acetylsalicylic acid"
3353234|NCT02285751|Active Comparator|75mg clopidogrel|"control group for patients with high on treatment platelet reactivity to clopidogrel patients continue with standard treatment 75mg clopidogrel/day"
3353235|NCT02285751|Experimental|60mg prasugrel|"Loading dose of prasugrel for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel"
3353236|NCT02285751|Experimental|600mg clopidogrel|"additional loading dose for 24 patients tested with high on treatment platelet reactivity to clopidogrel"
3353237|NCT02285751|Experimental|180mg ticagrelor|"Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity in spite of having received an additional loading dose of 600mg clopidogrel Loading dose of ticagrelor for patients who remain tested with high on treatment platelet reactivity after being treated with 10mg prasugrel daily"
3353238|NCT02285751|Active Comparator|prasugrel 10mg|patients treated with 10mg prasugrel daily
3244211|NCT01326000|Active Comparator|KRAS WT B|
3353239|NCT02285764|Experimental|Nutritional Supplement|One 237 ml oral supplement consumed two times a day; Not commercially available.
3353240|NCT02285764|Other|Standard of Care|As determined by the study site
3353241|NCT02285790|Experimental|RCM-OSS procedure|The Vivascope 1500 will be used (CE certified, Lucid Technologies, Henrietta, NY, USA). Reflectance confocal microscopy (RCM) imaging will be performed for intended use only and interpreted on the Vivascope workstation by two investigators independently at both study locations. The investigators will be blinded to the results of the reference standard. After RCM imaging subjects will receive OSS surgical excision according to subtype. Clinically suspected primary BCCs that are not confirmed by RCM will also receive surgical treatment with a margin of 3mm.
3353242|NCT02285790|Active Comparator|Standard of care procedure|Clinical suspected primary BCCs, of all subtypes, will be diagnosed by conventional 3mm punch biopsy of the most elevated part of the lesion. Punch biopsies will be performed under local anesthetics using 1% xylocaine/adrenaline. HE stained sections of the punch biopsies will be evaluated by an experienced board certified pathologist. Subjects will receive surgical excision according to subtype within 6 weeks after punch biopsy has been performed. Clinically suspected new primary BCCs that are not confirmed by punch biopsy will also receive surgical treatment with a margin of 3mm.
3353243|NCT02285803|Active Comparator|TRT and real tDCS|
3353244|NCT02285803|Sham Comparator|TRT and sham tDCS|
3353245|NCT02285816|Experimental|Arm A (MG1MA3 virus alone)|The starting dose of MG1MA3 will be 1 x 10^10 pfu administered by IV on day 1 and day 4.MG1MA3 dose will be escalated as per protocol.
3353246|NCT02285816|Experimental|Arm B- AdMA3 (vaccine prime) alone|Six patients will receive prime AdMA3 vaccine at a dose of 1x10^10 pfu administered IM on day (-14). No dose escalation is planned.
3353247|NCT02285816|Experimental|Arm C- AdMA3 plus MG1MA3 (prime + boost)|Prime AdMA3 vaccine will be administered as a single dose of 1x10^10 pfu IM at day (-14) followed by dose escalation of MG1MA3 boost, IV administered on days 1 & 4 at a starting dose of 1 log below the recommended phase II dose (RP2D), as determined in Arm A of this study. MG1MA3 dose will be escalated as defined in protocol.
3353248|NCT02285829||T4/T1=0.1-0.25|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium, 0.5 µg/kg/min for Cisatracurium ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.1-0.25, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3353249|NCT02285829||T4/T1=0.25-0.50|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.25-0.50, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3244212|NCT01326000|Experimental|KRAS mutant A|
3353250|NCT02285829||T4/T1=0.50-0.75|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.50-0.75, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3353251|NCT02285829||T4/T1=0.75-0.90|Continuous infusion will commence at the lower dose indicated (0.01mg/kg/min IV for Rocuronium Bromide, 0.5 µg/kg/min for Cisatracurium Besylate ), and TOF ratios will be monitored every 20 seconds. T4/T1 ratio of quantitative TOF test will be measured, prior pedicle screw stimulation test. When TOF ratio ranges 0.75-0.90, values of pedicle screw stimulation test will be then measured and recorded in milliamps (mA) after TOF test is performed.
3353252|NCT02285842||Primary Hip Resurfacings|Single study group previously implanted with CONSERVE® Press-Fit Femoral Components
3353253|NCT02285868||Arm, Shoulder and Hand injuries|Pre- and post-treatment outcomes of care as measured by the DASH (Disabilities of the Arm, Shoulder and Hand) via physical therapy
3353254|NCT02285868||Lumbar spine injuries|Pre- and post-treatment outcomes of care as measured by the Modified Oswestry (lumbar spine) via physical therapy
3353255|NCT02285868||Knee injuries|Pre- and post-treatment outcomes of care as measured by the Knee Outcome Survey via physical therapy
3353256|NCT02285868||Foot and ankle injuries|Pre- and post-treatment outcomes of care as measured by the Foot & Ankle Ability Measure via physical therapy
3353257|NCT02285868||Hip and lower extremity injuries|Pre- and post-treatment outcomes of care as measured by the Lower Extremity Functional Scale via physical therapy
3353258|NCT02285868||Neck injuries|Pre- and post-treatment outcomes of care as measured by the Neck Disability Index Questionnaire via physical therapy
3353259|NCT02285881|Experimental|shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
3353260|NCT02285881|No Intervention|control group|Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
3353261|NCT02285894|Experimental|Inspiratory hold|Mechanical inspiratory pressure held for 10 seconds at a time.
3244213|NCT01326000|Active Comparator|KRAS mutant B|
3244214|NCT01326013||Blinded, Prospective Arm|Diagnostic accuracy for higher prevalence targets will be evaluated in prospectively collected, anonymized, leftover, stool specimens.
3353262|NCT02285933|Experimental|VRT|sitting balance exercises delivered via virtual reality training
3353263|NCT02285933|Active Comparator|control|virtual reality training requiring limited arm movements and no challenge to sitting balance
3353264|NCT02285959|Experimental|Intra Arterial Bevacizumab|Repeated Intra Arterial bevacizumab injections at 15 mg/kg every 3 weeks
3244215|NCT01326013||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
3353265|NCT02285972|Placebo Comparator|saline|
3353266|NCT02285972|Active Comparator|dexketoprofen|
3353267|NCT02285972|Active Comparator|tenoxicam|
3353268|NCT02285985|Experimental|Saxagliptin|Saxagliptin (trade-name ONGLYZA™) is used along with diet and exercise to lower blood sugar levels in patients with Type II diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amount of insulin produced by the body after meals when blood sugar is high As the blood sugar returns towards normal, the medication effect on insulin is decreased.
3353269|NCT02285985|Placebo Comparator|Placebo|Sugar pill
3353270|NCT02286011|Experimental|MNC (Mononuclear cells)|"All patients included in the clinical trial will receive an intramuscular infusion of autologous mononuclear cells (MNC) of Bone Marrow (BM) in TA muscle of one of the lower limb (experimental group). The lower limb on the CMN infuse autologous BM will be determined randomly.~The average dose is 550 millions of cells (100-1200 million) diluted in 2 ml. saline"
3353271|NCT02286011|Placebo Comparator|Saline|All patients included in the clinical trial will receive an intramuscular infusion of 2 mL of saline (placebo) in the TA muscle of the contralateral limb (group control).
3353272|NCT02286050|Experimental|CF Nursing Intervention|
3353273|NCT02286063|Active Comparator|ambulatory oxygen cylinders|Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
3353274|NCT02286063|No Intervention|no oxygen cylinders|Subjects randomised to be on air for the first two weeks of the treatment period.
3353275|NCT02286089|Experimental|OpRegen|Up to 12 legally blind subjects with best corrected visual acuity of 20/200 or less in first three cohorts and 12 subjects with best corrected visual acuity of 20/64 and 20/250 in fourth cohort
3244216|NCT01326039|Active Comparator|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
3244217|NCT01326039|Placebo Comparator|saline|perineural isotonic saline 20 ml
3244218|NCT01326052|Experimental|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
3244219|NCT01326052|Active Comparator|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
3244220|NCT01326078|Experimental|propofol nanoemulsion|3-4 mg/kg of propofol nanoemulsion will be administered by 1mL per 5 seconds, adjustment dose can be given.
3244221|NCT01326078|Active Comparator|propofol lipid emulsion|3-4 mg/kg will be administered by 1 ml per 5 seconds.
3353276|NCT02286115|Experimental|Life-Stress Interview|The Life-Stress Interview is an experiential assessment technique
3353277|NCT02286115|No Intervention|Wait-list Control|Wait-list Control
3353278|NCT02286128||Non-diabetic controls|Age-matched non-diabetic subjects
3353279|NCT02286128||Type 2 diabetes|Type 2 diabetes with metformin monotherapy failure
3353280|NCT02286141||Intervention|Patients receiving care at primary care clinics randomized to receive the supplemental training on stratified care for back pain through the use of the StartBack Tool will be considered to be a part of the intervention group. Randomization is done at the clinic level and not at the individual patient level.
3353281|NCT02286141||Control|Patients receiving care at primary care clinics randomized to receive the standard Group Health training on the updated Guidelines for Back Pain Care will be considered to be a part of the control group. Randomization is done at the clinic level and not at the individual patient level.
3353283|NCT02286167|Other|Single arm diet|Intermittent, modified Atkins diet
3353284|NCT02286206|Experimental|Clozapine bid|"Participants have been taking clozapine once daily and have reached steady-state prior to the start of this study.~Intervention: Days 1-14"
3353285|NCT02286219|Experimental|FS102|Dose escalation of either weekly or Q3W of FS102
3353286|NCT02286232|Experimental|Stretching exercise|A series of 12 standardized, weekly stretching exercise classes will be held at the Wilton Family YMCA, designed for people with chronic low back pain unaccustomed to stretching. Participants will be asked to practice the identical routine of that week's stretching exercise class on off days and will be given handouts and CD's to assist in this.
3353287|NCT02286232|Active Comparator|Self-care book|The Back Pain Helpbook (Moore JE, Lorig K, Von Korff M, Gonzalez VM, Laurent DD. The Back Pain Helpbook. Reading, MA: Perseus Books; 1999)provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
3353288|NCT02286245|Experimental|1: focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board. Patients are invited to recall in case of worsening or onset of new symptoms and to get an appointment with their general practitioner during working hours.
3244222|NCT01326091|No Intervention|Standard Positioning|
3353289|NCT02286245|Active Comparator|2: Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
3353290|NCT02286258|Experimental|Inuline - Calcium EDTA|Calcium EDTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
3353291|NCT02286258|Experimental|Inuline - Gd-DOTA|Gd-DOTA clearance for GFR measurement is compared to inuline clearance in healthy volunteers and CKD patients (stage 1 to 4).
3353292|NCT02286284|Experimental|Apheresis arm|Apheresis for extracorporal removal of sFlt-1
3353293|NCT02286297|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3353294|NCT02286297|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3353295|NCT02286310|Experimental|Group A|Kinetic Chain Exercises
3353296|NCT02286310|Active Comparator|Group B|Traditional Exercises
3353297|NCT02286323|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3353298|NCT02286323|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3353299|NCT02286336|Experimental|middle aged group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
3353300|NCT02286336|Active Comparator|young group|brachial plexus block with ropivacaine 40ml, MEC90 for USG-SCB
3353301|NCT02286349|Experimental|Real rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 blocks of real stimulation intensity of 10 Hz, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average).
3353302|NCT02286349|Sham Comparator|Sham rTMS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 5 stimulation sham blocks, each block containing 15 series of repetitive transcranial magnetic stimulation with 1 second duration and presenting interval of 10 seconds between sets + 20 minutes of neuropsychological reassessment (on average)
3353303|NCT02286349|Experimental|Real tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of real anodal transcranial direct current stimulation with intensity of 1 mA + 20 minutes of neuropsychological reassessment (on average).
3353304|NCT02286349|Sham Comparator|Sham tDCS group|Submitted to 20 minutes of neuropsychological assessment (on average) + 10 minutes of sham transcranial direct current stimulation + 20 minutes of neuropsychological reassessment (on average)
3244223|NCT01326091|Active Comparator|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
3353305|NCT02286362||Cohort|
3353306|NCT02286375|Experimental|Intervention group|Interventions include providing comprehensive assessment from Omaha system, giving information regarding the self-care management, assisting and coordinating self-regulating skills and abilities, and providing social support from health-social care team to community-dwelling older adults for three months
3244224|NCT01326104|Experimental|TTRNA-xALT & TTRNA-DCs|TTRNA-xALT 3 x 10^7/kg by intravenous injection once. TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
3244225|NCT01326117|Experimental|tadalafil|
3244226|NCT01326130|Active Comparator|Chronic care management 1|Content of chronic care model implemented in territory 1 and level of implementation
3353307|NCT02286375|Placebo Comparator|customary care group|Customary care includes receiving community services from the community center in the district, providing monthly social call by a reserch assistant for three months
3353308|NCT02286388|Experimental|Partial excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
3244227|NCT01326130|Active Comparator|Chronic care management 2|Content of chronic care model implemented in territory 2 and level of implementation
3244228|NCT01326130|Active Comparator|Chronic care management 3|Content of chronic care model implemented in territory 3 and level of implementation
3244229|NCT01326130|Active Comparator|Chronic care management 4|Content of chronic care model implemented in territory 4 and level of implementation
3353309|NCT02286388|Active Comparator|Complete excavation|patients receiving after excavation (in case of absence of pulp exposure after excavation necessitating endodontic treatment) antibacterial adhesive or non-antibacterial adhesive
3353310|NCT02286388|Experimental|Antibacterial dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
3353311|NCT02286388|Active Comparator|Conventional dental adhesive|patients with prior partial or complete caries removal (excepted patients with a pulp exposure after excavation necessitating endodontic treatment)
3353312|NCT02286414||Exposed group|Patients recieving direct oral anticoagulants (DOA)
3353313|NCT02286414||Non-exposed group|Patients recieving vitamine K antagonists (VKA)
3353314|NCT02286427|Active Comparator|Standard Dressing|J0 to J42 : once a week, primary dressing with Mepitel®
3353315|NCT02286427|Experimental|Amniotic Membrane|J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
3353316|NCT02286440|Experimental|GeneSight guided treatment|GeneSight guided group will have their research psychiatrist make treatment recommendations based on test results
3353317|NCT02286440|Active Comparator|Treatment as usual group|Treatment as usual group will have treatment recommendations based on clinical judgment
3244230|NCT01326130|Active Comparator|Chronic care management 5|Content of chronic care model implemented in territory 5 and level of implementation
3244231|NCT01326130|Active Comparator|Chronic care management 6|Content of chronic care model implemented in territory 6 and level of implementation
3244232|NCT01326143||ORM Narval MRD|
3244233|NCT01326156|Experimental|Avon patellofemoral replacement|Knee arthroplasty with insertion of patellofemoral joint replacement.
3244234|NCT01326156|Active Comparator|PFC Sigma CR total knee replacement|Knee arthroplasty with total (tricompartmental) knee replacement.
3244235|NCT01326169|Active Comparator|Standard care|No intervention
3244236|NCT01326169|Experimental|Counseling|Telephone-delivered counseling
3244237|NCT01326182|Experimental|MAADRE|Group-based intervention combining asthma education and cognitive behavioral treatment for depressive symptoms
3244238|NCT01326182|Active Comparator|MAAS|Group-based treatment combining asthma education and general information regarding child health
3244239|NCT01326195|Experimental|Skills|Cognitive-Behavioral Dating Violence and HIV Prevention Group
3244240|NCT01326195|Active Comparator|Health Promotion|Psycho-educational Dating Violence and HIV Prevention group
3244241|NCT01326208|Experimental|Acute Lung Injury / ARDS|Patient under mechanical suffering from ALI or ARDS
3244242|NCT01326221||1|Single dose of Truvada
3244243|NCT01326234|Active Comparator|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
3244244|NCT01326234|Sham Comparator|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred.
3244245|NCT01326247|No Intervention|0.9% NaCl solution|
3244246|NCT01326260||THAM Patients|Patients who were managed with the use of THAM
3244247|NCT01326260||Non-THAM Patients|Patients who did not use THAM but were resuscitated with crystalloids and colloids and may have received sodium bicarbonate for the treatment of acidosis
3244248|NCT01326286||Open Radical Prostatectomy|262
3353318|NCT02286453|Experimental|1|Benjakul
3353319|NCT02286453|Active Comparator|2|diclofenac
3353320|NCT02286479|Active Comparator|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
3353321|NCT02286479|Experimental|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
3353322|NCT02286505|Experimental|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
3353323|NCT02286505|Other|Standard radiological assessment.|Standard neuroradiological report of the structural MRI only.
3353324|NCT02286531|Experimental|FET imaging|FET Imaging. Patient 0.1 mCi / kg (maximum 185 MBq) of FET with 'O-(2[18F]FLUOROETHYL)-L-TYROSINE' will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
3353325|NCT02286544|Active Comparator|Salmonella typhi vaccine|0.5 mL Salmonella typhi vaccine
3353326|NCT02286544|Experimental|Salmonella typhi vaccine + oxygen|0.5 mL Salmonella typhi vaccine + 6l/min oxygen
3353327|NCT02286544|Experimental|S. typhi vaccine + oxygen + Atorvastatin|0.5 mL Salmonella typhi vaccine + 6l/min oxygen + 80mg Atorvastatin
3353328|NCT02286557|Experimental|Arm I|Arm 1 will undergo four weeks of treatment with MP extended-release (20 mg/day in the morning). Following the four weeks of treatment, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 1 will undergo four weeks of placebo. This will be followed by a final assessment consisting of measures of fatigue, cognitive functioning, and physical disability.
3353329|NCT02286557|Experimental|Arm II|Arm 2 will undergo four weeks of placebo (in the morning). Following the four weeks of placebo, all assessments performed at baseline will be repeated. To minimize practice effects, alternate versions of the neuropsychological tests will be used wherever available. A 7-day washout period will follow in which no medication will be administered. Following the washout period, Arm 2 will undergo four weeks of treatment with MP extended-release (20mg/day). This will be followed by a final assessment consisting of measures of fatigue, sleep quality, cognitive functioning, and physical disability.
3353330|NCT02286570|Active Comparator|face-to-face intubation of Glidescope|patients were intubated using glidescope by face-to-face approach
3353331|NCT02286570|Active Comparator|face-to-face intubation with Airtraq|patients were intubated using the Airtraq by face-to-face approach
3244249|NCT01326286||Robotic Radical Prostatectomy|1303
3244250|NCT01326286||Intensity-Modulated Radiotherapy|638
3244251|NCT01326286||Interstitial Brachytherapy|171
3244252|NCT01326286||combined EBRT and Brachytherapy|143
3244253|NCT01326286||Active Surveillance|448
3244254|NCT01326286||Various other treatments|300
3353332|NCT02286570|Active Comparator|face-to-face intubation with fastrach|patients were intubated using the Fastrach by face-to-face approach
3353333|NCT02286583|No Intervention|Microwave Thermography RTM-01-RES|Microwave thermography with sensitive probe that can detect skin and up to 8 cm microwave radiation deep tissues
3353334|NCT02286596||heparin-induced extracorporeal LDL precipitation|Lipid apheresis treatment for 3 hours
3353335|NCT02286596||dextran sulfate adsorption|Lipid apheresis treatment for 3 hours
3353336|NCT02286609|Experimental|Hepatic Impairment|Eight (8) subjects with moderate hepatic insufficiency (a score of 7 to 9, on the Child-Pugh scale) will receive one 18 mg dose of deflazacort
3353337|NCT02286609|Experimental|Healthy Volunteer|Eight (8) healthy subjects. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the moderate hepatic impaired cohort; will receive 18 mg dose of deflazacort
3353338|NCT02286622|Experimental|Renal Impairment|Eight (8) subjects with ESRD on HD will receive one 18 mg dose of deflazacort.
3353339|NCT02286622|Experimental|Healthy Volunteers|Eight (8) healthy subjects with estimated creatinine clearance (CLcr) ≥ 90 mL/min. Subjects will be matched for age [± 15 years], BMI [± 15 %], and gender [1:1] to the subjects in the ESRD cohort. Subjects will receive one 18 mg dose of deflazacort.
3353340|NCT02286635|Experimental|Cohort A Deflazacort and Rifampin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
3353341|NCT02286635|Experimental|Cohort B Deflazacort and Clarithromycin|Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 4, period 2; cohort B. Subjects will receive twice daily dosing of clarithromycin on Day 1, Period 2 through Day 4, Period 2.
3353342|NCT02286648|Experimental|Mineral Trioxide Aggregate|pulpotomy with MTA
3353343|NCT02286648|Active Comparator|Formocresol|pulpotomy with FC
3353344|NCT02286661|Active Comparator|Short Arm Cast|Short arm cast below the elbow
3353345|NCT02286661|Active Comparator|Long Arm Cast|Long arm cast above the elbow
3353346|NCT02286674|Experimental|Tablet for watching movie|The study group will receive standard of care in addition to a tablet to watch movies and/or TV
3244255|NCT01326299|Active Comparator|Nutritional ingredient|Dissolve in water and consume with meal
3244256|NCT01326299|Placebo Comparator|Carbohydrate|dissolve in water and consume with meal
3244257|NCT01326299|Experimental|#1 Nutrtitional ingredient + Fiber|Dissolve in water and consume with meal
3244258|NCT01326299|Experimental|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
3353347|NCT02286674|No Intervention|Standard of care - no tablet|The control group will receive standard of care only.
3353348|NCT02286687|Experimental|Treatment (talazoparib)|Patients receive talazoparib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3353349|NCT02286700|Active Comparator|Desonide Group|Group randomly receiving desonide cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
3244259|NCT01326299|Experimental|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
3244260|NCT01326312|Experimental|GTX 758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
3244261|NCT01326312|Experimental|GTx-758|GTx-758/Experimental/ nonsteroidal selective ER alpha agonist
3244262|NCT01326312|Active Comparator|Lupron Depot|Luteinizing Hormone Releasing Hormone Agonist
3244263|NCT01326325|Experimental|Ketamine|Ketamine PANFARMA
3244264|NCT01326325|Placebo Comparator|Not Ketamine|NaCl
3244265|NCT01326338|Experimental|Nitazoxanide Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years
3353350|NCT02286700|Experimental|Amino Acid Group|Group randomly receiving amino acid moisturizing cream as the treatment cream for 3 weeks. Fifteen (15) gram tubes are dispensed at the beginning of each week and will be applied twice daily, by the subject, during the 3 week treatment phase.
3244266|NCT01326338|Placebo Comparator|Placebo Suspension|Placebo Oral Suspension 5 ml for patients aged 1-3 years and Placebo Oral Suspension 10 ml for patients aged 4-11 years
3244267|NCT01326351|Experimental|Regenerative Injection Therapy|
3244268|NCT01326351|Sham Comparator|Dry needle|
3353351|NCT02286739|Sham Comparator|Group A TKA without VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA without the use of VERASENSE to guide rotational alignment and balance.
3353352|NCT02286739|Active Comparator|Group B TKA with VERASENSE|will consist of 250 consecutive patients who will undergo primary PCL-retaining or - sacrificing TKA with the use of VERASENSE to guide rotational alignment and balance.
3353353|NCT02286752|Active Comparator|neostigmine|
3353354|NCT02286752|Active Comparator|sugammadex|
3353355|NCT02286765|Active Comparator|Group A|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 60 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
3353356|NCT02286765|Active Comparator|Group B|Subjects receiving Ulthera System treatment in a 3 x 4 grid, 12 treatment squares, 40 lines of treatment per square, at one treatment depth (2.0mm), at 0.30 J of energy
3353357|NCT02286778|Active Comparator|Acetogenins|Dietary Supplement: Acetogenins BID for 12 months
3353358|NCT02286778|Placebo Comparator|Placebo|Dietary Supplement: No Acetogenins BID for 12 months
3353359|NCT02286778|No Intervention|Control|Control subjects will not receive the Acetogenins or the placebo. They will be evaluated every other month to monitor disease progress.
3353360|NCT02286791|Experimental|Mindful Awareness Program|18 sessions of mindful awareness program teaching the elderly mindful awareness practice techniques
3244269|NCT01326351|Active Comparator|Exercise|
3244270|NCT01326403|Experimental|Group A|Patients will receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
3353361|NCT02286791|Active Comparator|Health Education Program|18 sessions of health education program focusing on healthy living topics
3353362|NCT02286804|Experimental|Ultherapy treatment|Subjects receiving Ultherapy treatment to up to 4 spider veins
3353363|NCT02286817|Experimental|Single arm of 30 subjects|Subjects will be administered single dose of NFC-1 to assess safety, tolerability, and pharmacokinetics, then proceed to continuous, daily administration of NFC-1 for 4 weeks to assess safety, tolerability, and impact on ADHD severity.
3353364|NCT02286830|Active Comparator|zoledronic acid|treatment with zoledronic acid for 4 years
3353365|NCT02286830|Placebo Comparator|no treatment|treatment with zoledronic acid withheld after two years
3353366|NCT02286856|Other|control group|Usual care followed bij diet intervention after 6 months
3353367|NCT02286856|Active Comparator|intervention group|diet intervention
3353368|NCT02286869|Experimental|Pressure Controlled Ventilation|"INTERVENTION: respiratory trial in pressure controlled mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the imposed respiratory rate is the same respiratory rate than baseline.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3353369|NCT02286869|Experimental|Pressure Support Ventilation|"INTERVENTION: respiratory trial in pressure support mode: (i) the inspiratory pressure is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a flow-trigger with medium sensitivity.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3353370|NCT02286869|Experimental|Neurally Adjusted Ventilatory Assist|"INTERVENTION: respiratory trial in Neurally Adjusted Ventilatory Assist (NAVA) mode: (i) NAVA-level (gain) is set up to obtain the same tidal volume than baseline, (ii) the inspiratory trigger is a neural trigger set at 0.5 microVolt.~The positive end expiratory pressure and fractional inspiratory oxygen are unchanged from the baseline. In this ventilatory mode the respiratory rate is not imposed because is driven by the patient's respiratory effort.~After an acclimation period of 10 min, electrocardiographic, arterial pressure and respiratory waves are recorded for 30 min."
3244271|NCT01326403|Experimental|GROUP B|Patients will receive IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
3244272|NCT01326403|Placebo Comparator|GROUP C|A control group will only receive placebo in the emergency room and in the OR.
3353371|NCT02286882|Experimental|Cohort 1: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353372|NCT02286882|Experimental|Cohort 2: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353373|NCT02286882|Experimental|Cohort 3: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3244273|NCT01326416|Active Comparator|S: Nutritional Supplementation alone|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
3244274|NCT01326416|Active Comparator|A: Physical Reconditioning alone|Physical reconditioning sessions led by a trainer three times a week for 6 months.
3244275|NCT01326416|Active Comparator|AS: Physical Reconditioning + Nutritional Supplementation|Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
3244276|NCT01326416|No Intervention|C: Lifestyle counseling|Usual advice given in consultation on the need for a balanced diet and regular physical activity
3244277|NCT01326429||Hypernatremia|Patients admitted to the emergency department with a serum sodium exceeding 145 mmol/L.
3244278|NCT01326429||Hyponatremia|Patients admitted to the emergency room with a serum sodium below 135 mmol/L.
3353374|NCT02286882|Experimental|Cohort 4: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3244279|NCT01326442|Experimental|diet only|low glycemic index diet, calorie restricted with exercise 3 times per week.
3244280|NCT01326442|Active Comparator|supplemented|2000 IU vitamin D3 plus 1.8 g EPA + DHA
3353375|NCT02286882|Experimental|Cohort 5: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353376|NCT02286882|Experimental|Cohort 6: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353377|NCT02286882|Experimental|Cohort 7: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353378|NCT02286882|Experimental|Cohort 8: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353379|NCT02286882|Experimental|Cohort 9: PF-06409577 or placebo|Single ascending doses of PF-06409577 or placebo to investigate the safety, tolerability, and PK.
3353380|NCT02286934|Experimental|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd~Day 4 to 8 : Carvedilol 25 mg qd~Day 9 to 11 : Carvedilol 12.5 mg qd~Isoproterenol Sensitivity Test~Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.~Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.~Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol."
3353381|NCT02286973|Active Comparator|Only Intravenous Group|Only Intravenous Injection During Operation, 10mg/kr
3353382|NCT02286973|Active Comparator|Intravenous + Topical 1g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 1g"
3353383|NCT02286973|Active Comparator|Intravenous + Topical 2g Group|"Intravenous Injection During Operation, 10mg/kr~After Capsule Closure, Tranexamic acid Topical Injection 2g"
3353384|NCT02286973|Active Comparator|No Intravenous, Only Topical 2g Group|Only Topical Injection 2g
3353385|NCT02286986|Other|Cannabidiol|open label administration
3353386|NCT02286999|Experimental|B.infantis|Infants in the experimental arm will have two doses of the probiotic Bifidobacterium longum subsp. infantis (B. infantis) on Day 7 and Day 14 of life.
3244281|NCT01326455|No Intervention|Terumo Control|
3244282|NCT01326455|Active Comparator|Terumo Fast Release|
3244283|NCT01326455|Active Comparator|Clo-Sur P.A.D.|
3244284|NCT01326468|Experimental|Cohort A - Temsirolimus with Cisplatin|Temsirolimus with cisplatin, Erbitux and radiation therapy
3244285|NCT01326468|Experimental|Cohort B - Temsirolimus|Temsirolimus with Erbitux and radiation therapy
3244286|NCT01326494|Active Comparator|Arm 1 Oral Cortico Steroid|A filled prescription will be given to be used upon early onset of symptoms.
3353387|NCT02286999|Placebo Comparator|Placebo|Infants in the experimental arm will have two doses of placebo (powdered maltodextrin) on Day 7 and Day 14 of life.
3353388|NCT02287012||Pre-Plerixafor era|The first era (Pre-Plerixafor era) will be defined as a two year period immediately preceding commercialization of plerixafor in Europe, (e.g., June 1, 2007 through June 1, 2009).
3353389|NCT02287012||Plerixafor era|The second era (Plerixafor era) will be defined as July 1, 2010 through July 1, 2012).
3353390|NCT02287051||colonoscopy population|
3244287|NCT01326494|No Intervention|Usual care for Asthma treatment|monitor the readmission of URTI induced asthma in children over a 12 month period
3244288|NCT01326520|Experimental|Phospholipid enriched dairy product|
3353391|NCT02287064|Experimental|Intravenous Immune Globulin (IVIG)|
3244289|NCT01326520|Placebo Comparator|dairy product|
3244290|NCT01326559|Experimental|Experimental 1|Induction chemotherapy using Docetaxel, Cisplatin and 5-FU for week 1 to week 9 and followed by concurrent chemoradiation plus cetuximab from week 10 to week 16
3244291|NCT01326572||female, male, HIV, lung disease|All participants in the University of Pittsburgh Multicenter AIDS Cohort Study are eligible for this protocol. All participants in the UCSF Women's HIV study are eligible and all Men from the UCLA men's HIV study are eligible
3244292|NCT01326585|Experimental|Dexamethasone|Subjects receive intravenous intraoperative dexamethasone
3244293|NCT01326585|Placebo Comparator|Saline solution|Subjects receive intravenous intraoperative normal saline solution
3244294|NCT01326598||T2DM patients with A1C<7.0%|
3244295|NCT01326611|Active Comparator|Clarithromycine Group: Active Comparator|Drug: Clarithromycin intravenous clarithromycin (10 mg/kg twice a day for 10 days)
3244296|NCT01326611|Placebo Comparator|Placebo Group: Placebo Comparator|Drug: D5W Dose given daily, IV same volume that Clarithromycin would be to equal 10 mg/kg for first 10 days.
3244297|NCT01326624||NYHA class III or IV|"Patients with NYHA class III or IV during the past month and one or more of the following:~Hospitalization for cardiac decongestion and stabilization.~Advanced heart failure receiving intravenous diuretics/inotropics in an outpatient clinic.~Awaiting cardiac transplantation"
3244298|NCT01326624||left ventricular ejection fraction ≤ 35%|"Patients with left ventricular ejection fraction ≤ 35% and either one of the following:~Coronary revascularization within 3 calendar months prior to enrollment.~Heart failure of non-ischemic origin diagnosed within 3 calendar months prior to enrollment."
3244299|NCT01326624||Awaiting ICD re-implantation|
3244300|NCT01326624||Acute myocardial infarction|Patients hospitalized with acute myocardial infarction and Killip Class III/IV.
3244301|NCT01326637|Experimental|intervention|Received the intervention: previsit planning phone call with filled out patient overview document & clinician huddle
3244302|NCT01326637|No Intervention|observation|Received usual care
3244303|NCT01326650|Experimental|Vitamin D|daily vitamin D supplement
3244304|NCT01326650|Placebo Comparator|placebo|daily placebo supplement
3244305|NCT01326663|Active Comparator|divalproex sodium|
3244306|NCT01326663|Placebo Comparator|sugar pill|
3244307|NCT01326676|Experimental|polypill|Red Heart Pill Version 1 and Red Heart Pill Version 2.
3244308|NCT01326676|Active Comparator|usual medication|participants continuing to receive cardiovascular disease medications as separate tablets prescribed by their usual physician
3244309|NCT01326689|Experimental|KW-2246|
3244310|NCT01326689|Placebo Comparator|Placebo|
3244311|NCT01326754|Other|Artemether-lumefantrine|
3353392|NCT02287077|No Intervention|Immediate cord clamping|At birth, neonate will be held at the level of placenta and umbilical cord will be clamped immediately (standard of care for depressed neonates).
3353393|NCT02287077|Experimental|Umbilical cord milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
3244312|NCT01326754|Other|Artesunate-amodiaquine|
3244313|NCT01326754|Other|Dihydroartemisinin-piperaquine|
3244314|NCT01326767|Active Comparator|Paclitaxel dosing according to SmPC|
3244315|NCT01326767|Experimental|Individualized pharmacokinetically driven paclitaxel dosing|In the first treatment cycle, the Paclitaxel dose is adapted depending on the age and the gender of the patient. In the treatment cycles 2-6 the Paclitaxel dose is adapted based on individual PK data and toxicities.
3353394|NCT02287103|Experimental|Skipping Breakfast (NoB)|The patients in No B will omit the breakfast and will continue the overnight fast until lunch. Will eat only lunch and dinner. In YesB will eat all three meals
3353395|NCT02287103|Active Comparator|Eating Breakfast (YesB):|The patients in YesB will eat all three mealswill consume three meals: breakfast, lunch and dinner
3353396|NCT02287116|No Intervention|nasal mask and nasal prongs|
3353397|NCT02287129|Experimental|Non-Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Carboplatin Paclitaxel Radiation Biopsy
3353398|NCT02287129|Active Comparator|Responder|Oxaliplatin Epirubicin Capecitabine 5-FU Biopsy
3353399|NCT02287142|Active Comparator|Interscalene|Single-shot Interscalene Nerve Block with ropivacaine 0.5%
3353400|NCT02287142|Active Comparator|Supraclavicular|Single-shot Supraclavicular Nerve Block with ropivacaine 0.5%
3353401|NCT02287142|Active Comparator|Suprascapular|Single-shot Suprascapular Nerve Block with ropivacaine 0.5%
3353402|NCT02287155|Experimental|occupation based health promotion|"The description of the health promotion intervention is provided in the detailed description of the study. It's a single arm study."
3244316|NCT01326806|Experimental|Sex Education + Standard Care|Participating mothers will receive sex education information while their child is having a physical exam.
3244317|NCT01326806|Active Comparator|Hygiene & Nutrition Education + Standard Care|Participating mothers will receive information on hygiene and nutrition while their child is having a physical exam.
3353403|NCT02287168|Experimental|dissemination of cancer cells|conversion of negative result of pre-gastrectomy peritoneal washing cytology to positive cytology after gastrectomy
3353404|NCT02287168|Experimental|elimination of cancer cells|elimination of peritoneal cancer cells occurred before (pre-gastrectomy peritoneal washing cytology) or after gastrectomy (post-gastrectomy peritoneal washing cytology) by intra operative peritoneal lavage ('post-lavage peritoneal washing cytology)
3353405|NCT02287181|Active Comparator|remifentanil effect site concentration 0ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 0 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
3353406|NCT02287181|Active Comparator|remifentanil effect site concentration 3ng/ml|remifentanil run as an infusion using the minto TCI model, at an effect site concentration of 3 nano grams per millilitre, commenced from start of proposal infusion to point at which patient is anaesthetised and not responding to painful stimuli.
3353407|NCT02287194||SpyGlass Direct Visualization System|Any patient who has undergone SpyGlass Choledochoscopy procedures for diagnosis and/or treatment of biliary tract diseases.
3353408|NCT02287207|Active Comparator|Anodal tDCS|20 minutes, 1.0 mA unilateral-anodal motor cortex (M1) tDCS stimulation
3244318|NCT01326806|No Intervention|No Education + Standard Care|Participating mothers who are passive controls will not receive any additional information while their child is having a physical exam.
3244319|NCT01326832||Primoris|50 patients included in RSA cohort of total of 350 anticipated Primoris cases
3353409|NCT02287207|Sham Comparator|Sham tDCS|20 minutes, sham tDCS stimulation
3353410|NCT02287220||Newborn Infants|0-12 months old Male or female Any ethnicity
3353411|NCT02287233|Experimental|Venetoclax + Low-Dose Cytarabine (LDC)|Participants will receive various doses of Venetoclax
3353412|NCT02287246|Experimental|Extended-Release liposomal bupivacaine|20mL Extended-release liposomal bupivacaine injected into the posterior vaginal wall following surgery
3353413|NCT02287246|Active Comparator|Placebo (normal saline)|20mL normal saline injected into the posterior vaginal wall following surgery
3353414|NCT02287259|Experimental|Olanzapine|PO start with 2.5mg daily once for 7days, since then flexible dose.
3353415|NCT02287259|Active Comparator|Lithium|PO start with 400mg daily twice for 7days, since then flexible dose.
3244320|NCT01326858|Experimental|Olopatadine, 0.7%|Olopatadine hydrochloride ophthalmic solution, 0.7%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic vehicle and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
3244321|NCT01326858|Placebo Comparator|Vehicle|Olopatadine hydrochloride ophthalmic solution vehicle, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and ketotifen fumarate ophthalmic solution, 0.025%, Periods 2 and 3, as randomized
3353416|NCT02287272|Active Comparator|Treatment period R|single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
3353417|NCT02287272|Active Comparator|Treatment period T|Cimetidine plus CHF5993 pMDI: repeated doses of oral cimetidine for 6 days plus a single inhaled dose of CHF 5993 pMDI (BDP/FF/GB fixed dose combination)
3353418|NCT02287285|Experimental|Exendin9|Longitudinal study of insulin secretion and sensitivity in patients with type 2 diabetes before and after gastric bypass surgery.
3353419|NCT02287298||2006 TO 2010 PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY
3353420|NCT02287298||CURRENT PATIENTS|PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN
3244322|NCT01326858|Active Comparator|Zaditor|Ketotifen fumarate ophthalmic solution, 0.025%, 1 drop instilled in each eye, 1 dose, in Period 1, followed by olopatadine hydrochloride ophthalmic solution, 0.7% and olopatadine hydrochloride ophthalmic solution vehicle, Periods 2 and 3, as randomized
3353421|NCT02287311|Experimental|Group A: MABEL CTLs|"Patients with 1st or subsequent relapse.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3353422|NCT02287311|Experimental|Group B: MABEL CTLs|"Patients with persistent active disease despite therapy.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3244323|NCT01326871|Experimental|ALT-801 with Cisplatin and Gemcitabine (Phase Ib and Phase II)|
3244324|NCT01326871|Experimental|ALT-801 and Gemcitabine (Phase II only)|
3244325|NCT01326884|Other|1|Endovascular Repair
3244326|NCT01326897|Active Comparator|Comparison Group|Comparison group participants will be given health education materials.
3353423|NCT02287311|Experimental|Group C: MABEL CTLs|"Patients with active disease if immunosuppressive chemotherapy is contraindicated.~Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. Each patient will receive 2 injections, 14 days apart.~If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs."
3353424|NCT02287324|Active Comparator|Manipulation|High velocity low amplitude thrust joint manipulation to the cervical spine
3353425|NCT02287324|Placebo Comparator|Manual Contact|Manual contact to suboccipital region of the cervical spine for 5 minutes
3353426|NCT02287337|Experimental|Manipulation|Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
3353427|NCT02287337|Other|Exercise|Patients will receive 5 visits of therapeutic exercises
3353428|NCT02287363||TPP group|TPP patients(between episodes of paralysis), the inclusion criteria consisted of a certain history of acute limb muscle weakness, hypokalemia and decreased TSH with elevated free FT4, FT3. Subjects who suffered from hyperthyroid myopathy with long term muscle weakness, family periodic paralysis, renal tubular acidosis, hyperaldosteronism, hemiplegia, paraplegia, or any history of other metabolic or traumatic muscular disease were excluded.
3353429|NCT02287363||hyperthyroidism group|Control group, we included subjects with evidence of aberrant thyroid function (decreased TSH, elevated FT4, FT3) without paralysis. Graves' disease(GD) was preferred which required information concerning either increased thyrotrophin receptor antibody(TRAb) level, ophthalmopathy or diffusively enlarged goiter. Individuals with pure thyroid associated ophthalmopathy, history of thyroidectomy due to malignancy or adenoma as well as subacute thyroiditis and pituitary hyperthyroidism were excluded.
3353430|NCT02287389|Experimental|balloon dilation|give the cases balloon dilation as the intervention
3353431|NCT02287389|Experimental|balloon dilation plus cryotherapy|give the cases balloon dilation plus cryotherapy as the intervention
3353432|NCT02287389|Experimental|BD plus spiculiform electrosurgery|give the cases balloon dilation plus spiculiform electrosurgery as the intervention
3244327|NCT01326897|Experimental|Intervention'|This group will receive the intervention (Healthy Homes/Healthy Families) as described below.
3244328|NCT01326936|Experimental|Unworked VP|Online education using typical virtual patient (VP) approach. Five unworked VPs presented to subjects for study.
3353433|NCT02287389|Experimental|BD plus mitomycin C|give the cases Balloon dilation plus mitomycin C as the intervention
3353434|NCT02287428|Experimental|Coh 1 (Original Cohort): Standard RT Followed by NeoVax|"After the screening procedures confirm participant eligible to participate in the research study (must be registered to within 6 weeks of resection):~~ 6 weeks of standard radiation therapy (RT) followed by an RT-recovery period.~During that time, participant NeoAntigen Vaccine-Preparation is created (process takes ~ 12 weeks)~After participant recovers from RT and vaccine is created, participant will re-screen to confirm participant is eligible to receive study vaccinations. Once registered, participant will proceed to receive study vaccinations:~- NeoAntigen Vaccine: NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases (~ 7 months total: 5 priming followed by 2 boost vaccine administrations)"
3244329|NCT01326936|Experimental|Guided Learning|Online education replaces two unworked VPs in Arm 1 with identical worked example VPs (case studies) for learners to study
3353435|NCT02287428|Experimental|Coh 1a: Pembrolizumab w Std RT Followed by NeoVax + Pembro|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts within 2 weeks of start of RT, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
3353436|NCT02287428|Experimental|Coh 1b: Std RT Followed by NeoVax + Pembrolizumab|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
3353437|NCT02287428|Experimental|Coh 1c: Std RT (+ 1 dose Pembro) Followed by NeoVax & Pembo|"RT: Standard RT (60Gy) over 6 weeks~Pembrolizumab: Single dose of pembrolizumab administered within 2 weeks of start of RT; re-starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years.~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
3244330|NCT01326949|Active Comparator|ET+NSBB|"Endoscopic treatment(ET)- Endoscopic variceal ligation (EVL)~Non-selective beta blocker(NSBB)-Propranolol.~Anticoagulation(AT)- Heparin followed by warfarin."
3244331|NCT01326949|Active Comparator|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS.
3244332|NCT01326975||EAdi 1|babies in this group will first receive CPAP through IF-CPAP for 30 minutes. After another 45 minutes, they will be switched to HFNC for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
3244333|NCT01326975||EAdi 2|babies in this group will first receive CPAP through HFNC for 30 minutes. After another 45 minutes, they will be switched to IF-CPAP for 30 minutes. EAdi will be recorded for the last 15 minutes of each 30 minutes period.
3244334|NCT01326988||Patients requiring spinal anesthesia for lower limb surgery|Patients of at least 18 years of age undergoing spinal anesthesia for elective lower limb surgery will be recruited. Therefore inclusion and exclusion criteria are the same as for traditionally administered spinal anesthesia as below. Additionally we will exclude those patients who are incapable of providing fully informed consent, patients who are currently enrolled in other studies and patients with communication difficulties
3353438|NCT02287428|Experimental|Coh 1d: Std RT+TMZ Followed by 6 Cyc TMZ + NeoVax + Pembro|"• RT: Standard RT (60Gy) + concurrent daily temozolomide (TMZ) over 6 weeks. Concurrent TMZ @ 75 mg/m2/day for 6 weeks.~Followed by:~6 cycles of Adjuvant temozolomide (TMZ): Starts 4-6 weeks after completion of RT. TMZ (150-200 mg/m2/day) on days 1-5 of each 28-day cycle for 6 cycles.~Pembrolizumab: Starts 1-4 weeks after completion of NeoVax priming, and continues every 3 weeks for up to 2 years~NeoVax: Starts in the Adjuvant setting - as soon as available after RT - and is administered on days 1, 4, 8, 15, 22 [priming doses], 78 and 134 [booster doses] o NeoVax Day 1 does not have to coincide with Pembrolizumab dosing"
3353439|NCT02287441|Placebo Comparator|Raw Group|Vegetables Prepared Raw (raw)
3353440|NCT02287441|Experimental|Tomato Group|Tomato Products (tomato)
3353441|NCT02287454|Experimental|Cognitive remediation program: REHACOP|Cognitive rehabilitation program (REHACOP) including intervention in: attention, memory, processing speed, language, executive functioning and social cognition during 3 months, 3 times per week
3353442|NCT02287454|No Intervention|Control group|No intervention was administered.
3353443|NCT02287480|Experimental|VSV-ZEBOV lower dose|"One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.~Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV"
3353444|NCT02287480|Experimental|VSV-ZEBOV higher dose|"One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.~Study amendment (01.2015) : interrupted"
3353445|NCT02287480|Placebo Comparator|Placebo|One intramuscular (deltoid) injection of normal saline (0.5 ml)
3353446|NCT02287506|Experimental|ODS from enrolment|Optimised Diagnostic Strategy used from enrolment to study
3353447|NCT02287506|No Intervention|ODS at end of study|ODS fed back at the end of the participants involvement with the study
3353448|NCT02287519|Experimental|Support Group|"One group educational session will include information on resources, self-help strategies, and relaxation techniques.~One telephone coaching session after the group session Or~Pilot webinar format of the educational session"
3353449|NCT02287532|Experimental|DIABEO software alone|Patient will have an introductory training session in the use of DIABEO by the investigating physician an will return for an on site consultation at 6 mounths (optional), 12 mounths and 24 mounths
3353450|NCT02287532|Experimental|DIABEO+paramedical telemonitoring|"Patient will have an on site introductory training session in the use of DIABEO, by his/her telemedicine nurse from his/her region. The nurse will then follow up the patient according to a delegated tasks protocol written by the investigating physician with the nurse. Patient will be asked to return to see the investigator at 6 mounths (optional), 12 mounths and 24 mounths"
3353451|NCT02287532|No Intervention|Usual Follow up|Patient will continue his/her usual follow up and return to see the investigator at 6 mounths (optional) and at the one year end of follow up for the study
3353452|NCT02287545||Glaucoma, primary|Glaucoma patients undergoing trabeculectomy
3353453|NCT02287558|Experimental|Pomalidomide|Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.
3353454|NCT02287571|Active Comparator|Skin traction|Prior to hip fracture surgery, affected limb was wrapped with a special elastic bandage and pulled from the sole of the foot with a weight of 5-10% of total body weight of the patient (min 2.3 kg, max 4.5 kg).
3244335|NCT01327014|Placebo Comparator|Placebo group|
3244336|NCT01327014|Experimental|1,200 mg/day of XZK group|
3244337|NCT01327014|Experimental|2,400 mg/day of XZK group|
3244338|NCT01327027|Experimental|Vasopressin, Arginine, ADH|We will test how vasopressin affects emotional responses to facial stimuli in healthy men and women.
3244339|NCT01327027|Placebo Comparator|Sterile Salilne|Sterile saline will be administered intranasally and emotional responses to facial stimuli measured.
3244340|NCT01327040|Experimental|sensitization duration 1.375h|This group will experience a 1.375h sensitization duration prior to the 12h light exposure
3244341|NCT01327040|Experimental|sensitization duration 5.5h|This group will experience a 5.5h sensitization duration prior to the 12h light exposure
3244342|NCT01327040|Experimental|sensitization duration 22h|This group will experience a 22h sensitization duration prior to the 12h light exposure
3244343|NCT01327040|Experimental|sensitization duration 0.33h|This group will experience a 0.33h sensitization duration prior to the 12h light exposure
3244344|NCT01327066|Experimental|Droxidopa - Therapeutic|Droxidopa 600 mg
3244345|NCT01327066|Experimental|Droxidopa - Supratherapeutic Dose|Droxidopa 2000 mg
3244346|NCT01327066|Placebo Comparator|Placebo|Placebo
3244347|NCT01327066|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg dose
3244348|NCT01327079|Experimental|Group 1|"Gestational age less than 29 weeks We will substitute for one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
3244349|NCT01327079|Experimental|Group 2|"Gestational age greater then 29 weeks We will substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
3353455|NCT02287571|Experimental|Position splint|Prior to hip fracture surgery, position splint was applied to the affected limb in order to keep the extremity in the proper positon without any weight lifting.
3353456|NCT02287597||Cohort|
3353457|NCT02287649|Other|patients with rituximab treatment|blood sample intake
3353458|NCT02287662|Experimental|Vancouver 3M Clinical Pathway|The Vancouver 3M Clinical Pathway utilizes objective anatomical and functional screening criteria as well as strict peri-procedural guidelines to determine if next day discharge home is appropriate.
3353459|NCT02287701|Experimental|PET/MRI|Patient receives MRI
3353460|NCT02287714|Active Comparator|Instep without Gastrocnemius Recession|Patient will receive an instep plantar fascial release but not a gastrocnemius recession.
3353461|NCT02287714|Experimental|Instep with Gastrocnemius Recession|Patient will receive an instep plantar fascial release as well as a gastrocnemius recession.
3353462|NCT02287727|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3244350|NCT01327092|No Intervention|Literacy Group|Families in the Literacy Group (control group)will receive a program which seeks to promote literacy by providing developmentally appropriate books and other reading-related materials to children and encouraging mothers to develop an interest in reading with their child. After enrollment and randomization, CHIP staff will visit these control group homes, assess the mother's interest in and barriers to reading with her child, council mothers about the importance of literacy and reading books to their child, and children will be given age appropriate books and other materials to promote literacy.
3259356|NCT01470092|No Intervention|Placebo|Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
3353463|NCT02287740|Experimental|Tai Ji Quan: Moving for Better Balance|This protocol involves training 2 times a week for 6 months.
3353464|NCT02287740|Active Comparator|Multimodal Exercise|This protocol involves training 2 times a week for 6 months.
3353465|NCT02287740|Sham Comparator|Stretching|This protocol involves participation of 2 times a week for 6 months.
3353466|NCT02287753|Experimental|Vascular occlusion test (VOT)|Pediatric patients aged under 8 years old are enrolled in this study. VOT is performed in 3 times : after induction of anesthesia, during cardiopulmonary bypass (CPB) for main surgical procedure and after weaning from CPB. The relationship between postoperative outcome variables and the dynamic parameters from VOT, such as desaturation and reoxygenation rate, and reactive hyperemic area, will be evaluated.
3353467|NCT02287766||Control|Men and women ages 21-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following cancer, coronary artery disease or heart attack, renal failure or dialysis, hepatitis, Multiple Sclerosis, or any autoimmune disorder.
3353468|NCT02287766||Metabolic Syndrome Diagnosis Group|Men and women ages 21-85 with at least of at least three of the following (as defined in the protocol) : Elevated waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, elevated fasting glucose.
3353469|NCT02287792|Experimental|18-FDG PET/CT scan|All patients will undergo a whole body PET/CT scan
3353470|NCT02287805||quantitative survey 1|parents of 300 patients with craniosynostosis diagnostic
3353471|NCT02287805||qualitative survey|"parents of 12 newly diagnosed patients, they will be seen 3 times (after the diagnosis, 3 months after surgery, 1 year after surgery~12 patients aged over 15 years, operated more than 10 years before"
3353472|NCT02287805||quantitative survey 2|"100 parents of patients 1 year after surgery~100 parents of patients, 5 years after the operation~100 patients aged over 15 years and operated over 10 years ago"
3353473|NCT02287831|Experimental|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
3353474|NCT02287844|Experimental|XOS group|Subjects consumed 6.64 g of a XOS-enriched compound derived from wheat arabinoxylans (5 g of XOS) everyday for 4 weeks.
3353475|NCT02287844|Experimental|INU-XOS group|Subjects consumed 6.64 g of a mixture containing inulin-type fructans, XOS and maltodextrins (3 g of inulin and 1 g of XOS) everyday for 4 weeks.
3353476|NCT02287844|Active Comparator|Placebo|Subjects consumed 6.64 g of wheat maltodextrins everyday for 4 weeks.
3353477|NCT02287857|Experimental|Domestic Tenofovir Disoproxil Fumarate Tablets|
3353478|NCT02287857|Active Comparator|Tenofovir Disoproxil Fumarate Tablets of Gilead|
3353479|NCT02287870|Experimental|Chloroprocaine Group|Epidural anesthesia with 3% chloroprocaine.
3353480|NCT02287870|Active Comparator|Lidocaine Group|Epidural anesthesia with 2% lidocaine.
3353481|NCT02287935|Active Comparator|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique
3353482|NCT02287935|Active Comparator|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis procedure
3353483|NCT02287948||MS subjects group|Multiple sclerosis subjects wiht mild-moderate gait disability with EDSS score not higher than 5.5
3353484|NCT02287948||Healthy subjects group|Healthy subjects age-matched with multiple sclerosis subjects.
3353485|NCT02287961|Other|Subjects|"Standard proctologic examination with digital rectal examination and 2 anal swabs at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~High resolution anoscopy at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits~Biopsy(ies) during High Resolution Anoscopy only if lesion suggestive of AIN detected during High Resolution Anoscopy~High Resolution Anoscopy biannually only if high-grade lesion (ASC-H, HSIL ou AIN2/3)"
3353486|NCT02287974|Experimental|Autologous mononuclear stem cell from the bone marrow|Autologous mononuclear stem cell from the bone marrow in an unique infusion of 150-250 millions of cells
3353487|NCT02287974|Experimental|Autologous endothelial stem cell from the bone marrow|Autologous endothelial progenitor CD133 stem cell from the bone marrow in an unique infusion of 2 - 7 millions of CD133 cells
3353488|NCT02287974|Experimental|Autologous mesenchymal stem cells from the adiposite tissue|Autologous mesenchymal stem cells from the adipose tissue in an unique infusion of 0.5 millions of cells
3353489|NCT02287974|Active Comparator|Current medication for the disease|Current medication for the disease
3353490|NCT02287987|Active Comparator|Clamp|Laparoscopic robot-assisted partial nephrectomy with clamping the renal pedicle during the resection of the tumor
3353491|NCT02287987|Experimental|Off clamp|Laparoscopic robot-assisted partial nephrectomy without clamping the renal pedicle during the resection of the tumor
3353492|NCT02288000|Active Comparator|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
3353493|NCT02288000|Placebo Comparator|Placebo|The placebo will be presented as capsule comparable to memantine
3353494|NCT02288013|Other|Stratafix Tissue control device|Closure of Uterine incision at C section
3353495|NCT02288013|Other|Vicryl suture|Closure of uterine incision at C section
3353496|NCT02288026||Arm I|Patients undergo lobectomy
3353497|NCT02288026||Arm II|Patients undergo a wedge resection or anatomical segmentectomy
3353498|NCT02288039|Experimental|Social Identity Goal-Based Intervention|Participants will receive collaborative goal-setting
3353499|NCT02288039|No Intervention|Standard Care|Participants will receive usual standard treatment
3353500|NCT02288052|Experimental|Writing program|The program will train participants in maintaining writing amplitude, writing speed, writing fluently and automatization of writing.
3353501|NCT02288052|Placebo Comparator|Stretch & Relaxation program|The program will learn participants to alleviate tension in the upper limbs and will consist of exercises performed while lying down or sitting.
3353502|NCT02288065||responders|amelioration of dyspnea radiological amelioration after sterile talc pleurodesis
3353503|NCT02288065||failed intervention|unchanged symptoms and radiology after sterile talc pleurodesis
3353504|NCT02288078|Active Comparator|Treatment group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), test drug capsule (dexamethasone 2 mg) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medicatiob check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
3353505|NCT02288078|Placebo Comparator|Placebo group|"Treatment with regorafenib (160 mg/day, oral administration, 3 weeks on therapy followed by 1 week off therapy), placebo capsule (lactose) and proton pump inhibitors (PPIs) will be started within 14 days of enrollment. The protocol treatment period is 4 weeks.~Follow-up treatment for the underlying disease after the 4-week protocol treatment is not specified. The physician in charge will decide whether or not to continue treatment with regorafenib. For the prevention of fatigue/malaise, dexamethasone 2 mg can be used.~General condition, blood pressure, Patient Reported Outcome, clinical findings, hematology/blood chemistry, coagulation and fibrinolysis system, urinalysis, medication check, adverse event, thyroid function test, brain MRI, Contrast-enhanced torso CT"
3353506|NCT02288104|Other|needle based confocal endomicroscopy|The patient, scheduled for a standard liver or kidney percutaneous biopsy or ablation will undergo a needle-based confocal laser endomicroscopy procedure during the procedure. The objectives of this study are to demonstrate the technical feasibility and safety of doing endomicroscopic imaging during interventional radiology procedure and determine whether it is technically feasible to obtain images from Cellvizio during an interventional radiology procedure.
3353507|NCT02288130|Active Comparator|GnRHa and placebo tablets|11.25 mg Leuproreline injections at the onset of pretreatment with placebo tablets (once daily)
3244351|NCT01327092|Experimental|Injury Intervention Group|Injury Intervention Group: In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq ft) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1 meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years
3353508|NCT02288130|Active Comparator|Ulipristal|Three months of Ulipristal 5 mg once daily combined with a single saline injection at the onset of pretreatment (produced as placebo of Leuproreline)
3353509|NCT02288130|No Intervention|Control|No pre-treatment prior to laparoscopic myomectomy
3353510|NCT02288143|Experimental|COOL-COS|All women will receive the intervention: Letrozole, Clomiphene, and low-dose hMG for the controlled ovarian stimulation.
3353511|NCT02288169|Experimental|COPE|The experimental group will receive usual care plus the COPE intervention. This group will receive 3 individual intervention sessions. During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom. Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home. Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms. In addition they will get 2 phone calls encouraging them to apply COPE.
3353512|NCT02288169|Sham Comparator|Support|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
3353513|NCT02288169|No Intervention|Control|The control group will receive usual care and no additional attention from our interventionists.
3376002|NCT03314181|Experimental|Arm B, Part 1b: VenDd Dose Expansion|Venetoclax at a dose determined by the dose-escalation phase, administered orally QD in combination with daratumumab (1800 mg subcutaneous injection (preferred) or 16 mg/kg IV) administered in accordance with prescribing information and dexamethasone (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
3244352|NCT01327118|Placebo Comparator|Isoton sodium chloride|
3244353|NCT01327118|Active Comparator|Prostaglandin F2alpha|
3353514|NCT02288195|Experimental|Chemotherapy|Patients receive neoadjuvant chemotherapy comprising oxaliplatin 130mg/m² ivdrip over 2 hours on day 1,capecitabine 2000 mg/m² on days 1-14, treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.Patients without disease progression undergo low-anterior resection (LAR) with total mesorectal excision (TME) and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days). Patients with disease progression undergo chemoradiation as in group chemoradiotherapy before proceeding to LAR with TME.
3353515|NCT02288195|Experimental|Chemoradiotherapy|Patients receive capecitabine 825 mg/m² twice daily concurrently with radiation therapy for 5 days per week. Patients also undergo intensity-modulated radiation therapy 5 days a week for approximately 5.5 weeks. Patients then undergo LAR with TME and 4 cycles of XELOX ( oxaliplatin 130mg/m² day 1，capecitabine 2000mg/m² days 1-14, repeated every 21 days) .
3353516|NCT02288208|Experimental|Antiviral Therapy & Birinapant|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.
3244354|NCT01327144|Experimental|Famciclovir 500mg|1 tablet each 8 hours for 7 days
3244355|NCT01327144|Active Comparator|Aciclovir 400mg|2 tablets of Aciclovir 400 mg each 4 hours for 7 days
3353517|NCT02288208|Placebo Comparator|Antiviral Therapy & Placebo|Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.
3353518|NCT02288221|Experimental|With non pharmacological therapeutic|Installation of ICT at patient's home
3353519|NCT02288221|Active Comparator|Without non pharmacological therapeutic|No change at patient's home
3353520|NCT02288234||Vibativ|This is an observational study for patients who were already prescribed Vibativ.
3353523|NCT02288260||Part A|PATIENTS RECEIVED THE STANDARD MEDICAL CARE AS DETERMINED BY THE TREATING CARDIOLOGIST
3353524|NCT02288260||Part B|Patients on ticagrelor at the time of discharge from hospital
3353525|NCT02288286|Experimental|2.5IU/ml in humans aged 10-20 years old|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
3353526|NCT02288286|Experimental|2.5IU/ml in humans aged 21-50|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
3353527|NCT02288286|Experimental|2.5IU/ml in humans aged 51-60|freeze-dried rabies vaccines(MRC-5 cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
3353528|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 10-20 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 10-20 years old on days 0,3,7,14,28
3353529|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 21-50 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 21-50 years old on days 0,3,7,14,28
3353530|NCT02288286|Placebo Comparator|2.5IU/ml in humans(from 51-60 years old)|freeze-dried rabies vaccines(vero cell) of 2.5IU/ml in 200 humans aged 51-60 years old on days 0,3,7,14,28
3353531|NCT02288299|Experimental|non invasive mechanical ventilation|Patients suffering from neuromuscular disease with NIV indication and cough inefficiency
3353532|NCT02288338|Experimental|1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®)|"Three treatment~atorvastatin calcium 40mg will be administration to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
3353533|NCT02288338|Experimental|2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®)|"Three treatment~ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
3353534|NCT02288338|Experimental|3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®)|"Three treatment~atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
3353535|NCT02288338|Experimental|4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®)|"atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days"
3353536|NCT02288338|Experimental|5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®)|"ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days"
3353537|NCT02288338|Experimental|6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®)|"atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days~after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days"
3353538|NCT02288351|Other|RYGB with mucosal abnormality on EGD|Subjects with Type 2 Diabetes undergoing a Roux-en-Y Gastric Bypass with a diagnosis of gastritis, esophagitis, ulcer, or other mucosal abnormality discovered at routine preoperative upper endoscopy, requiring follow-up endoscopy in the post-operative period.
3244356|NCT01327170|Active Comparator|Subthreshold diode micropulse laser|Subthreshold diode micropulse laser in patients with chronic central serous chorioretinopathy
3244357|NCT01327170|Sham Comparator|Sham|Sham group simulating the laser treatment
3244358|NCT01327183|Experimental|20 mg/kg RO4905417 before PCI|
3244359|NCT01327183|Experimental|5 mg/kg RO4905417 before PCI|
3244360|NCT01327183|Placebo Comparator|Placebo before PCI|
3244361|NCT01327209||Patients with diabetes|
3353539|NCT02288390|Active Comparator|Miswak (Sewak)|Miswak (sewak) oral care applied 4 hourly for oral care in mechanically ventilated patients.
3353540|NCT02288390|Active Comparator|Chlorhexidine/ toothbrush|Chlorhexidine 0.12 % plus toothbrushing oral care applied 4 hourly for oral care in mechanically ventilated patients.
3353541|NCT02288403|Experimental|Aerobic interval training|"Interval exercise at an intensity between 90-95% of maximum heart rate (15x30 s), with recoveries at an equivalent speed to 50-55 % of maximal oxygen consumption at baseline (14x60 s).~24 training sessions, 3x weekly (on alternate days)."
3353542|NCT02288403|Active Comparator|Continuous training|"40 minutes of continuous exercise at an intensity between 65-75% of maximum heart rate.~24 training sessions, 3x weekly (on alternate days)."
3353543|NCT02288416|Active Comparator|Group I (standard of care)|Patients receive standard of care following LCS consisting of routine visits and telephone contact with the LCS program nurse practitioner and coordinator.
3353544|NCT02288416|Experimental|Group II (video-based intervention)|Patients undergo a video-based intervention prior to undergoing LCS. Patients watch a 5-minute video that focuses on preparing patients for LCS by providing information on the following: program team and contact information; reason to be screened; screening eligibility; how screening is performed; what to expect on the day of screening; what to expect after screening; what to expect if result is positive; what to expect if result is negative; and risks of screening. Patients also receive an educational handbook. Patients with positive scans (a Lung-RADS 3 or 4) receive additional brochure and nursing support within 1 week after notification of scan results.
3353545|NCT02288429||Colistin|"Patients ≥ 18 years old receiving intravenous colistimethate sodium for the treatment of infection~Have cystic fibrosis and/or are critically ill (admitted to a critical care unit)"
3353546|NCT02288442|No Intervention|control|
3353547|NCT02288442|Experimental|exercise|exercise intervention during 8 weeks
3353548|NCT02288455|Experimental|RELIEF II - GTU AUS|Prospective, non-randomized multi-center study testing the safety and efficacy of the GTU Artificial Urinary Sphincter device in males with stress urinary incontinence.
3353549|NCT02288468|Experimental|STN|"Deep Brain Stimulation of Nucleus subthalamicus with Vercise™ Deep Brain Stimulation System.~The STN will be typically reached with the most distal contacts of the DBS electrode (8 contact). Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located in the STN. We expect the STN to be typically covered by contacts 1-4 of the Vercise™ DBS lead. Typically, only the most superficial contacts (3,4) will be activated after a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction, reduction of rigidity and bradykinesia. Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
3353550|NCT02288468|Experimental|Vim/DRT|"Deep Brain Stimulation of Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~The thalamic target (Vim/DRT) will be typically reached with the proximal contacts. Imaging studies (postop helical CT and re-fusion to planning MRI data) will allow for the identification of contacts located the thalamic target. We expect the thalamic target to be typically covered by contacts 5-8 of the Vercise™ DBS lead. We will perform a monopolar review of each contact. In this monopolar review the therapeutic widths of each contact will be tested for its effectiveness in tremor reduction and the occurrence of side effects (typically capsular e.g. facial contraction). Typical settings will be: Frequency 130-180 Hz, pulse width 60-90 us, Amplitude 1-7 mA."
3353551|NCT02288468|Experimental|STN+Vim/DRT|"Combined Deep Brain Stimulation of Nucleus subthalamicus and Ventral intermediate nucleus with Vercise™ Deep Brain Stimulation System.~STN+Vim/DRT stimulation is essentially a combination of the previously described procedure."
3353552|NCT02288481|Experimental|Cohort 1 10 mg TBA-354|
3353553|NCT02288481|Placebo Comparator|Cohort 1 placebo|Placebo Suspension
3353554|NCT02288481|Experimental|Cohort 2 25 mg TBA-354|
3353555|NCT02288481|Placebo Comparator|Cohort 2 placebo|Placebo Suspension
3353556|NCT02288481|Experimental|Cohort 3 60 mg TBA-354|
3353557|NCT02288481|Placebo Comparator|Cohort 3 placebo|Placebo Suspension
3353558|NCT02288481|Experimental|Cohort 4 150 mg TBA-354|
3353559|NCT02288481|Placebo Comparator|Cohort 4 placebo|Placebo Suspension
3353560|NCT02288481|Experimental|Cohort 5 400 mg TBA-354|
3353561|NCT02288481|Placebo Comparator|Cohort 5 placebo|Placebo Suspension
3353562|NCT02288481|Experimental|Cohort 6 1000 mg TBA-354|
3259357|NCT01470131|Experimental|Masitinib|Masitinib (6 mg/kg/day) in combination with Bortezomib and Dexamethasone
3353563|NCT02288481|Placebo Comparator|Cohort 6 placebo|Placebo Suspension
3353564|NCT02288494||hypoalbuminemia|The primary purpose was to describe the acid base balance of ICU patients with severe hypoalbuminemia using Stewart's approach for acid base disorders, before and after an human albumin perfusion
3353565|NCT02288507|Experimental|sorafenib & Yttrium-90 radioembolization|Sorafenib dose de-escalation starting at 400mg PO BID starting on Day1 Yttrium-90 radioemoblization on Day 14
3353566|NCT02288533|Experimental|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
3353567|NCT02288546||Vegans|Vegans' data are compared with those of sex-and age-matched non vegetarians
3353568|NCT02288546||Non-vegans|Non-vegans are age and sex-matched controls
3353569|NCT02288572|Active Comparator|Lactobacillus plantarum PCS 26|Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
3353570|NCT02288572|Placebo Comparator|Placebo|Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey
3353571|NCT02288585|Active Comparator|Plant sterols|Plant sterols
3353572|NCT02288585|Placebo Comparator|Placebo product|Placebo product
3353573|NCT02288598|Experimental|Anodal TDCS|Participants will receive anodal TDCS over the left inferior frontal cortex. TDCS will be delivered at 1milliampere (mA) intensity for 20 minutes during speech fluency training (5 consecutive days).
3353574|NCT02288598|Sham Comparator|Sham TDCS|Participants will receive sham TDCS over the left inferior frontal cortex. Sham stimulation will involve 30 seconds stimulation at the beginning of the 20 minutes of speech fluency training (5 consecutive days).
3353575|NCT02288611|Placebo Comparator|Maltodextrin/Dextrose mix|"Twenty-two healthy human individuals were randomly assigned to consume a control (maltodextrin-dextrose, 40.2g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.~P.S. placebo is called control in this study, where the bioactive comparator is a fruit."
3353576|NCT02288611|Active Comparator|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume date fruits (approx. 50g) at one of the arms period. Each arm was 21 days in duration, separated by a 14 days washout period.
3353577|NCT02288624|Placebo Comparator|Control|Water control (240 ml)
3353578|NCT02288624|Experimental|Orange Juice|Orange juice, 240 ml. Commercial orange juice
3353579|NCT02288624|Experimental|Whole orange|Whole orange, 240 ml. Whole orange, blended to include all edible orange material.
3353580|NCT02288624|Experimental|processed orange juice|Processed orange juice, 240 ml. Experimental orange juice processing
3353581|NCT02288637|Experimental|Conventional Olyset LLIN|High coverage (>80% access) of conventional Olyset LLIN The arm is the standard of care from the National Malaria Control Program
3353582|NCT02288637|Experimental|Olyset Plus LLIN|High coverage (>80% access) of Olyset Plus LLIN
3353583|NCT02288637|Experimental|Conventional Olyset LLIN and IRS|High coverage (>80% access) of conventional Olyset LLIN and high coverage IRS (>80% of the household sprayed) with pirimiphos methyl CS
3353584|NCT02288637|Experimental|Olyset Plus LLIN and IRS|High coverage (>80% access) of Olyset Plus LLIN and high coverage Indoor Residual Spraying (>80% of the household sprayed) with pirimiphos methyl CS
3353585|NCT02288650|Experimental|Liberal group|Early refeeding
3353586|NCT02288650|Sham Comparator|Control group|Refeeding in the day case ward (usual practice)
3353587|NCT02288663|Other|Freage group|only one group in this trial. All the participants will follow all the listed interventions.
3353588|NCT02288676||Case Group|Participants must have suspected or confirmed upper genital tract cancer (uterine, tubal and ovarian) and must be scheduled to undergo surgery for tumor removal.
3353589|NCT02288676||Control Group|Participants must not be under investigation for any pre-cancerous or cancerous lesions of the genital tract, and must be scheduled for a hysterectomy, bilateral salpingectomy with/without bilateral oopherectomy for presumed benign condition.
3353590|NCT02288702||Normal|This is the group with no neurological problems or syndrome
3353591|NCT02288702||Down syndrome|This is the group with Down syndrome
3353592|NCT02288715||SAE|patient who develop encephalopathy in the progress of sepsis
3353593|NCT02288715||non-SAE|patient who do not develop encephalopathy in the progress of sepsis
3353594|NCT02288728|Experimental|Group B (double-track anastomosis)|Patients in the Group B will received the double-track anastomosis with proximal gastrectomy.
3353595|NCT02288728|Other|Group A (Gastric tube anastomosis)|Patients in the Group A (Gastric tube anastomosis) will take the gastric tube anastomosis with proximal gastrectomy.
3353596|NCT02288741|Experimental|A1: Induction chemotherapy|Anthracycline/dexamethasone-based induction chemotherapy Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3353597|NCT02288741|Active Comparator|A2: No induction chemotherapy|Dexamethasone for control of symptoms Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3353598|NCT02288741|Other|B: Observation|Tumor-reduction chemotherapy and stem cell mobilization Stem cell apheresis Tandem high-dose chemotherapy Autologous peripheral blood stem cell transplantation
3353599|NCT02288754||Stage II or III curative surgery (closed to accrual)|Patients with stage II or III solid tumors undergoing curative intend surgery enrolled before surgery.
3353600|NCT02288754||Stage II or III neoadjuvant therapy cohort (closed to accrual)|Patients with stage II or III solid tumors undergoing neoadjuvant therapy followed by curative intend surgery enrolled before neoadjuvant therapy.
3353601|NCT02288754||Metastatic disease|Patients with advanced, recurrent and/or metastatic disease requiring systemic therapy with chemotherapy, targeted therapy, immunotherapy or a combination of any before initiation of any therapy or a new line of therapy following documentation of disease progression on prior therapy.
3353602|NCT02288767|Active Comparator|Control group|For the traditional method group, crystalloid and colloid (maximum 50 ml/kg) are provided through the traditional method of assessing the blood pressure, heart rate and urine volume.
3353603|NCT02288767|Experimental|SVV group|The method of fluid administration to be employed (traditional or SVV via a FloTrac/ EV1000™ monitor) is determined based on the group. Fluid administration is performed in accordance with the group; in general, about 10 ml/kg/h is administered although it may vary for each patient depending on the preoperative fasting, fluid loss during surgery (evaporation, emanation, urination, surgical area, etc.), and blood loss. Crystalloid is administered in the SVV-monitored group with a target below SVV 12%, and a 200-300 ml of colloid (maximum 50 ml/kg) is loaded when SVV is above 12%. If the patient shows hypertension even when SVV is below 12%, a vasoconstrictor should be administered intermittently or consistently.
3353604|NCT02288780||Control|BPH patients with normal diastolic function
3353605|NCT02288780||Diastolic dysfunction|BPH patients with preoperative diastolic dysfunction
3353606|NCT02288832|Experimental|Innovative strategy (group A):|these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique; if the test is found to be positive, an appropriate treatment will be prescribed. The POC (point-of-care) test will be considered positive if: A. vaginae is detected at a threshold > 105.copies per ml and/or G. vaginalis > 105 copies per ml. The women with vaginosis will be screened monthly for recurrences through 28 weeks, and recurrence will be treated.
3353607|NCT02288832|Other|Standard strategy (group B):|This group will be followed according to the usual practices of the physicians seeing them.
3353608|NCT02288845|Experimental|ITI-007|ITI-007 formulated capsule will be administered orally once daily for up to 14 days in up to 14 subjects.
3353609|NCT02288858|Active Comparator|Test product|Viviscal Oral Supplement Tablets (as 512mg coated red-brown tablets in unbranded blister packs)
3353610|NCT02288858|Placebo Comparator|Placebo|Placebo Tablets (as 512 coated red-brown tablets in unbranded blister packs)
3353611|NCT02288871|Other|"Sutureless valve"|"Patients who underwent aortic valve replacement with a sutureless aortic valve.~An echocardiogram and a cardiac CT-scan will be conducted."
3353612|NCT02288871|Other|"Sewed-in valve"|"Patients who underwent aortic valve replacement with a sewed-in aortic valve. An echocardiogram and a cardiac CT-scan will be conducted."
3353613|NCT02288884|Active Comparator|Silver containing dressing|Subjects will have a silver containing dressing (Acticoat PostOp) applied at the time of elective cesarean section.
3353614|NCT02288884|Placebo Comparator|Standard dressing|Subjects will have a standard dressing (OpSite PostOp) applied at the time of elective cesarean section.
3353615|NCT02288897|Experimental|PV-10|Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.
3353616|NCT02288897|Active Comparator|Chemotherapy or Oncolytic Viral Therapy|Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.
3353617|NCT02288923|Active Comparator|Femoral nerve block|Femoral nerve block with 20ml 0.375% Levobupivacaine
3353618|NCT02288923|Active Comparator|Local Infiltration Analgesia|Local infiltration of knee joint using 40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve).
3353619|NCT02288936|Experimental|Enzalutamide|Enzalutamide 160 mg/day
3353620|NCT02288949||Prospective cohort|Stratification of patients admitted into a network of Spanish ICUs.
3353621|NCT02288962|Experimental|cabergoline|"Target dose for cabergoline is 2 mg/week.The medication is administered in the evening to minimize side effects. If intolerable side effects occur despite this, it may be necessary to treat with a lower dose than 2 mg per week.~Treatment scheme: 0.5 mg x 1 per week the first 2 weeks, then 0.5 mg x 2 per week the next 2 weeks, then 1 + 0.5 mg per week the next 2 weeks, then 1 mg x 2 per week (target dose) for the rest of the study"
3353622|NCT02288962|No Intervention|observation|visits and controls as usual
3353623|NCT02288975||CytoSorb|Patients with septic shock will get routine ICU care supported by CytoSorb® treatment.
3353624|NCT02288975||Control|Patients with septic shock will get routine ICU care.
3353625|NCT02288988|Other|GERD patients with Short Esophagus|Patients with True Short Esophagus diagnosed intra-operatively: The length of the intra-abdominal portion of the esophagus < 2.5 cm measured intra-operatively using a combined endoscopic-laparoscopic method. Minimally invasive antireflux surgery was performed (Collis gastroplasty + Nissen fundoplication).
3353626|NCT02289001|Experimental|Education on SBAR worksheet|Training in the use of the SBAR worksheet created to structure information exchange between healthcare professionals
3244362|NCT01327222|Experimental|bevacizumab|three-monthly intravitreal bevacizumab, followed by PRN monthly injection on the basis of the detection of any fluid on the optical coherence tomography
3244363|NCT01327222|No Intervention|control|monthly follow-up
3244364|NCT01327235|Active Comparator|Endostar|
3244365|NCT01327235|Active Comparator|Cisplatin|
3353627|NCT02289001|No Intervention|No education on SBAR worksheet|The control group will participate in the simulation without any prior training in teamwork skills beyond those included in the undergraduate nursing degree curriculum, which the intervention group also received.
3353628|NCT02289014|No Intervention|Wait-list control group|Wait-list control group
3353629|NCT02289014|Experimental|Active treatment group|online stress Management program
3353630|NCT02289027|Experimental|Deployed volunteers - Group 1|Low dose cAd3-EBOZ (2.5x10e10 vp)
3353631|NCT02289027|Experimental|Deployed volunteers - Group 2|High dose cAd3-EBOZ (5x10e10 vp)
3353632|NCT02289027|Experimental|Not deployed volunteers - Group 3|Low dose cAd3-EBOZ (2.5x10e10 vp)
3353633|NCT02289027|Experimental|Not deployed volunteers - Group 4|High dose cAd3-EBOZ (5x10e10 vp)
3244366|NCT01327235|Experimental|Endostar and Cisplatin|
3353634|NCT02289027|Placebo Comparator|Not deployed volunteers - Group 5|
3353635|NCT02289040||Children undergoing cardiac surgery|Paediatric patients (<17 years with a body weight >2000g) undergoing cardiac surgery for congenital heart disease with extracorporeal circulation
3353636|NCT02289053||Positive Family History|"Eligible participants with a family history of colorectal cancer or polyps will be grouped into the subjects group."
3353637|NCT02289053||Average Risk Patients|"Eligible participants without a family history of colorectal cancer or polyps will be grouped into the control group."
3353638|NCT02289092|Experimental|Family Check-Up Intervention|Prior to the feedback session, trained clinicians will observe family interactions by reviewing the video-taped observations and questionnaires filled out by parents. Therapists then use this data to inform the intervention process and provide feedback to parents based on norms for this age period. Feedback sessions will include a discussion of goal attainment and plans to achieve goals, with specific attention to the parent's role in supporting positive behavior. Options for obtaining goals are based on the literature about empirically supported interventions for this age group and include (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
3244367|NCT01327248||affected patients|20 Patients suffering from bronchiolitis obliterans
3244368|NCT01327248||non-affected patients|20 matched controls not suffering from bronchiolitis obliterans
3244369|NCT01327261|Experimental|Levodopa + benserazide (test formulation)|A randomized-sequence, open-label, 2-period crossover study assessing relative bioavailability of two drug products containing the association levodopa + benserazide.
3244370|NCT01327261|Active Comparator|Levodopa + benserazide (reference formulation)|
3244371|NCT01327287||Trauma patients eligible to receive thoracic epidural|Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
3353639|NCT02289092|No Intervention|Control|Control families will receive services as usual that are being provided to the families within their school
3353640|NCT02289118||Diagnostic Imaging|[18F]T807 imaging tracer.
3353641|NCT02289131|Experimental|Frequency of Once a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours)
3353642|NCT02289131|Experimental|Frequency of Twice a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours)
3353643|NCT02289131|Experimental|Frequency of Three Times a Day|Tooth Brushing Protocol to be provided at 8:00 am (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 1:00 pm (+/- 1.5 hours) Tooth Brushing Protocol to be provided at 6:00 pm (+/- 1.5 hours)
3353644|NCT02289144|Experimental|Ceritinib|
3353645|NCT02289170|Experimental|Heating and cooling combination therapy|The patients in this group received heating and cooling combination therapy by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. Doctor press 8 acupuncture points which is treated in LBP patients and select the most painful 2 acupuncture points. Device's probe is attached to the acupuncture points in 15 minutes. Probe's temperature is changed 5 cycles from maximum 45℃ to minimum 15℃.
3353646|NCT02289170|Sham Comparator|Sham heating and cooling therapy|The patients in this group received sham heating and cooling combination therapy in same conditions of treatment group except the temperature. Before the treatment begin, caregiver measure the patient's skin temperature. Then probe's temperature is changed 5 cycles from 1℃ over the skin temperature to 1℃ under the skin temperature.
3353647|NCT02289183|Experimental|Totally laparoscopic distal gastrectomy|The totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy will be performed for the treatment of patients with distal gastric cancer assigned to this group.
3353648|NCT02289183|Active Comparator|Laparoscopy-assisted distal gastrectomy|The laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis will be performed for the treatment of patients with distal gastric cancer assigned to this group.
3353649|NCT02289196|Experimental|Vx-006: 0,5mg|Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks
3353650|NCT02289196|Experimental|Vx-006: 1mg|Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks
3353651|NCT02289196|Experimental|Vx-006: 5mg|Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks
3353652|NCT02289196|Experimental|Vx-006: 10mg|Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks
3353653|NCT02289209|Experimental|Reirradiation + MK-3475|Reirradiation 1.2 Gy BID for 5 days a week for 5 weeks with MK-3475 (Keytruda, pembrolizumab) 200mg intravenous every 3 weeks until 3 months post completion of reirradiation.
3353654|NCT02289235|Experimental|Ginger|Ginger powder capsule 500 mg
3353655|NCT02289235|Placebo Comparator|Placebo|Placebo powder capsule
3353656|NCT02289248|Experimental|Ketamine/CBT Group|Subjects will undergo 2 week course of 4 intravenous infusions of ketamine (given twice weekly for two weeks) in combination with twice weekly cognitive behavioral therapy for a total of 8 weeks.
3244372|NCT01327287||Control Arm|Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain
3244373|NCT01327326|Active Comparator|TMD patients|"Intervention:~Drug: Naltrexone~Drug: placebo"
3353657|NCT02289261|Active Comparator|Control|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
3353658|NCT02289261|Active Comparator|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
3353659|NCT02289274|Experimental|NVP-1203|NVP-1203
3353660|NCT02289274|Active Comparator|Eperisone SR tab. + and Airtal tab.|Eperisone HCl and aceclofenac
3353661|NCT02289287|Experimental|Self-Management group-intervention|Participants will receive Self-Management group-intervention + Standard Care
3353662|NCT02289287|Active Comparator|Standard Care|Participants will receive Standard Care only
3353663|NCT02289300|Experimental|DCB-BO1202|
3244374|NCT01327326|Active Comparator|Healthy controls|"Intervention:~Drug: Naltrexone~Drug: placebo"
3244375|NCT01327352|Experimental|Oshadi D|"2 dose levels of Oshadi D in 2 food regimen will be administered as following:~Subjects will receive placebo on the morning of day 1 during fast. Late breakfast will be provided 4 hours following placebo administration.~On day 8 a single dose of 180mg Oshadi D will be administrated during fast. Late breakfast will be provided 4 hours following drug administration~On day 16 subjects will be administered with 360mg of Oshadi D during fast. Late breakfast will be provided 4 hours following drug administration.~On day 24, 180mg of Oshadi D will be administrated immediately after breakfast.~On day 32, subject will be administered with 360mg of Oshadi immediately after breakfast."
3244376|NCT01327365|Experimental|Sheathless group|patient randomized to the sheathless guiding catheter group
3244377|NCT01327365|Active Comparator|Conventional group|patients randomized to the conventional guiding catheter group
3244378|NCT01327378||Dialysis, normal glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min < 7.8 mmol/L
3353664|NCT02289300|Experimental|DCB-BO1202+Placebo|
3353665|NCT02289300|Placebo Comparator|Placebo|
3353667|NCT02289339||TAVI patients|all patients undergoing transcatheter aortic valve prostheses implantation
3353668|NCT02289365|Placebo Comparator|Group I|Totally 3000 mg of PEG-400 per day. 3 capsules of 500 mg PEG-400 per time, twice a day.
3353669|NCT02289365|Experimental|Group II|Totally 2000 mg of JBM-TC4 per day. 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400 per time, twice a day.
3353670|NCT02289365|Experimental|Group III|Totally 3000 mg of JBM-TC4 per day. 3 capsules of 500 mg JBM-TC4 per time, twice a day.
3353671|NCT02289378|Experimental|Docetaxel, Oxaliplatin and 5-Fu|Docetaxel 50mg/m2 Oxaliplatin 85mg/m2 5-Fu 2800mg/m2 Repeated every two weeks
3244379|NCT01327378||Dialysis, impaired glucose tolerance|Chronic dialysis treatment, N=10 OGTT,120 min 7.7<11.1 mmol/L
3244380|NCT01327378||Control, normal glucose tolerance|Healthy Control subjects, N=10 OGTT,120 min <7.8 mmol/L
3353672|NCT02289391|Placebo Comparator|non-asthma group|"Non-asthma history~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
3353673|NCT02289391|Experimental|Dexmedetomidine A|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
3353674|NCT02289391|Experimental|Dexmedetomidine B|"With a history of asthma~Infusion of dexmedetomidine(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of dexmedetomidine at 0.7μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of dexmedetomidine at 10 minutes before the end of surgery."
3353675|NCT02289391|Placebo Comparator|Control group|"With a history of asthma~Infusion of normal saline(1μg/kg) at 10 minutes before anesthesia induction.~Infusion of normal saline at 0.4μg•kg-1•h-1during anesthesia maintenance.~Stop infusion of normal saline at 10 minutes before the end of surgery."
3353676|NCT02289404|Experimental|NVP-1203(fed then fasting)|Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
3353677|NCT02289404|Experimental|NVP-1203(fasting then fed)|Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
3353678|NCT02289430|Experimental|Crestor+Ezetrol|rosuvastatin+ezetimibe
3353679|NCT02289430|Active Comparator|Ezetrol|ezetimibe
3353680|NCT02289430|Active Comparator|Crestor|rosuvastatin
3353681|NCT02289443||Simplified|Complete denture fabricated by simple way than the textbook traditional method.
3353682|NCT02289443||Traditional|Complete denture fabricated by textbook discribed traditional method.
3353683|NCT02289482|Experimental|GSK2838232 Part A: Single Dose Escalation|During Part A, subjects will receive GSK2838232/ placebo (3:1) in 4-period (period 1: GSK2838232 200mg, period 2: GSK2838232 500mg), single dose escalation design. Subjects randomized to placebo will receive placebo in all four periods. Following completion of Period 2 PK assessments at 96hr post-dose, subjects will begin daily dosing of RTV 100mg (period 3: GSK2838232 20 mg + RTV 100 mg, period 4: GSK2838232 50 mg + RTV 100 mg) for a total of 26 days.
3353684|NCT02289482|Experimental|GSK2838232 Part B: Single Dose, 3-Period Crossover, Relative B|During Part B, subjects will receive GSK2838232/ placebo, in an open-label, unbalanced, 3-period, cross-over design; subjects will be randomized (1:1) to each sequence. The relative bioavailability of single 100 mg doses of powder in a bottle (PIB) Active Pharmaceutical Ingredient (API) of GSK2838232 versus PIB Spray-Dried Dispersion (SDD) will be assessed (Period 1: SDD GSK2838232 100 mg vs GSK2838232 API 100 mg; period 2: GSK2838232 API 100 mg Vs SDD GSK2838232 100 mg ). A single dose of GSK2838232 will be co-administered on the 10th day of RTV dosing (period 3:GSK2838232 10 mg + RTV 100 mg); RTV dosing will continue for an additional 4 days (total of 14 days).
3244381|NCT01327391|Active Comparator|On line Hemodiafiltration|Hemodialysis patients treated with on line hemodiafiltration technic
3244382|NCT01327391|Other|hemodialysis|Hemodialysis patients treated with conventional hemodialysis technic using high flux dialyzers
3353685|NCT02289495|Experimental|GSK2838232 without RTV|Subjects will receive 20 mg of GSK2838232/ placebo (3:1) in cohort 1 and 50 mg of GSK2838232/ placebo (3:1) in cohort 2, administered QD for 8 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
3353686|NCT02289495|Experimental|GSK2838232 with RTV|Subjects will receive 10 mg of GSK2838232/ placebo (3:1) in cohort 3, 20 mg of GSK2838232/ placebo (3:1) in cohort 4 and 50 mg of GSK2838232/ placebo (3:1) in cohort 5, co administered with RTV 100 mg, QD for 11 days. There will be a minimum period of 7 days between successive cohorts to establish safety and PK for dose escalation; enrollment into a cohort will commence following review of interim PK and safety data from at least 4 subjects in the preceding cohort
3353687|NCT02289508||acute decompensated heart failure|Patients who fulfill Framingham criteria will be classified as acute decompensated heart failure (adHF). For this study we define this as an acute change in symptoms and signs within the previous 24 hours. When symptoms gradually deteriorate between one day and one month, it is described as gradual decompensated heart failure (gdHF). Some patients may have both.
3244383|NCT01327404||Depressed|Patients with Major Depressive Disorder
3353688|NCT02289508||compensated heart failure|compensated heart failure (cHF) is defined as the existence of heart failure in the absence of any acute exacerbation but which may either include typical chronic symptoms and signs or may be asymptomatic but with evidence of cardiac dysfunction i.e. a reduced ejection fraction.
3353689|NCT02289508||non-heart failure patients|Non-heart failure patients (nHFp) are a patient control group with suspected heart failure but who after further assessment are found not to meet the criteria. Such patients may subsequently be found to have COPD, anaemia, over transfusion. As the purpose of this study is to assess the potential value of USCOM parameters in the assessment of patients with possible heart failure in the clinical setting, it is important to include patients without heart failure.
3353690|NCT02289508||healthy controls|Healthy controls are subjects with not acute or chronic illness.
3353691|NCT02289521|Active Comparator|Anodal Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Anodal (A-tDCS): Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20 min. To decrease current-induced injuries, at the beginning the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out)."
3244384|NCT01327404||Diabetic|Patients with Type 2 Diabetes
3244385|NCT01327404||Diabetic/Depressed|Patients with both diabetes and major depressive disorder
3244386|NCT01327404||Healthy Controls|
3244387|NCT01327417||Depressed|Patients with Major Depressive Disorder
3244388|NCT01327417||Healthy Controls|
3244389|NCT01327430|Experimental|Phospholipid supplementation|Supplementation of milk phospholipid
3244390|NCT01327443|Other|Weight loss|10% weight loss in 24 weeks time period through nutritional counseling.
3244391|NCT01327443|Active Comparator|Exercise without weight loss|24 weeks under direct supervision.
3353692|NCT02289521|Sham Comparator|Sham Transcranial Direct Current Stim.|"Transcranial Direct Current Stimulation~Sham: The parameters mimics the A-tDCS (electrode placement, fade-in and current intensity), except the stimulation duration: the current will reach 1.5mA in 30 sec (fade-in) and lasts only for 30 sec (to give the initial sensation of stimulation).~After the stimulation, language performance and EEG will be recorded. Order of interventions (anodal - sham) will be randomised across subjects."
3353693|NCT02289547|No Intervention|Group A|observational arm
3353694|NCT02289547|Experimental|Group B|arm of capecitabine maintenance treatment
3353695|NCT02289560|Experimental|Transcranial ExAblate|Transcranial ExAblate
3353696|NCT02289573|Experimental|neurally adjusted ventilatory assist|
3353697|NCT02289573|Sham Comparator|pressure support ventilation|
3353698|NCT02289586|Active Comparator|hypoxemia, central airway stenosis.|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
3353699|NCT02289586|Experimental|hypoxemia, central airway stenosis|"Inclusion Criteria:~(a)patients with central airway stenosis need interventional bronchoscopy (b) partial pressure of arterial oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio less than 300;~Exclusion Criteria:~(a) facial deformity sufficient to preclude mask fitting; (b) upper gastrointestinal bleeding; (c) upper airway obstruction; (d) acute coronary syndromes; (e) tracheostomy or endotracheal intubation(ETI) before admission; (f) need for urgent ETI due to cardiac or respiratory arrest."
3353700|NCT02289599|Experimental|Part A: 1 mg E2307 (young cohort)|E2307 (1 x 1 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3353701|NCT02289599|Experimental|Part A: 3 mg E2307 (young cohort)|E2307 (3 x 1 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3353702|NCT02289599|Experimental|Part A: 10 mg E2307 (young cohort)|E2307 (1 x 10 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3353703|NCT02289599|Experimental|Part A: 30 mg E2307 (young cohort)|E2307 (3 x 10 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3353704|NCT02289599|Experimental|Part A: 100 mg E2307 (young cohort)|E2307 (1 x 100 mg E2307 capsule) or placebo (1 x 1 E2307 matching placebo capsule)
3244392|NCT01327443|No Intervention|Control|No change in usual exercise levels or food intake.
3244393|NCT01327456|Experimental|Self-Management Intervention|participants who receive the one-on-one self-management intervention
3244394|NCT01327456|No Intervention|Usual Care|group receives no additional education or intervention then they would as usual care of their COPD
3244395|NCT01327469|Experimental|Albendazole 400mg|albendazole, 1 x 400mg
3244396|NCT01327469|Experimental|Albendazole 2 x 400mg|albendazole, 2 x 400mg
3244397|NCT01327469|Experimental|Mebendazole 500mg|mebendazole, 1 x 500mg
3353705|NCT02289599|Experimental|Part A: 200 mg E2307 (young cohort)|E2307 (2 x 100 mg E2307 capsules) or placebo (2 x 1 E2307 matching placebo capsules)
3353706|NCT02289599|Experimental|Part A: 300 mg E2307 (young cohort)|E2307 (3 x 100 mg E2307 capsules) or placebo (3 x 1 E2307 matching placebo capsules)
3353707|NCT02289599|Experimental|Part B: Elderly cohort|One dose level below MTD from Part A
3353708|NCT02289612|Placebo Comparator|Tapioca Starch - Low-Fibre|Tapoica starch pudding without added fibre
3353709|NCT02289612|Placebo Comparator|High Maltose Corn Syrup - Low-Fibre|High maltose corn syrup pudding without added fibre
3353710|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#1)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at first treatment study visit.
3353711|NCT02289612|Placebo Comparator|Trutol Glucose Beverage (#2)|Trutol Glucose Beverage containing 50 g of glucose without added fibre. Consumed at final treatment study visit.
3353712|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - Tapioca Starch|Yellow mustard gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3244398|NCT01327469|Experimental|Mebendazole 2 x 500mg|mebendazole, 2x 500mg
3244399|NCT01327469|Experimental|Pyrantel-oxantel + mebendazole|pyrantel-oxantel (10mg/kg)+ mebendazole (500mg)
3244400|NCT01327534|Experimental|prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
3244401|NCT01327534|Active Comparator|clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
3244402|NCT01327586|Experimental|ATM|Advisor-Teller Money Manager
3353713|NCT02289612|Active Comparator|Yellow Mustard Gum Fibre - High Maltose Corn Syrup|Yellow mustard gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3353714|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - Tapioca Starch|Soluble flaxseed gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3244403|NCT01327586|Active Comparator|Individual Drug Counseling|
3353715|NCT02289612|Active Comparator|Soluble Flaxseed Gum Fibre - High Maltose Corn Syrup|Soluble flaxseed gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3353716|NCT02289612|Active Comparator|Fenugreek Gum Fibre - Tapioca Starch|Fenugreek gum fibre pudding containing tapioca starch. Fibre-enriched treatment product.
3244404|NCT01327625|Experimental|Azithromycin|Patient who are diagnosed as bronchiolitis obliterans according to the WHO criteria
3244405|NCT01327638||Patients with SpA/AS and etoricoxib treatment|
3244406|NCT01327638||Patients with SpA/AS and other COX-2 inhibitor treatment|
3244407|NCT01327638||Patients with SpA/AS and nsNSAIDs treatment|
3244408|NCT01327664|Experimental|AIN457 300mg s.c every 2 weeks|
3244409|NCT01327690|No Intervention|Wait List|Wait Period corresponding in length to treatment period
3244410|NCT01327690|Experimental|EFT (Emotional Freedom Techniques)|EFT group therapy sessions.
3244411|NCT01327690|Active Comparator|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
3244412|NCT01327729|Active Comparator|YPEG-IFN α-2a one week|this arm will be treated with: YPEG-IFN α-2a 180mcg/ week for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
3353717|NCT02289612|Active Comparator|Fenugreek Gum Fibre - High Maltose Corn Syrup|Fenugreek gum fibre pudding containing high maltose corn syrup. Fibre-enriched treatment product.
3353718|NCT02289625|Active Comparator|Attentional performance in OSA|To investigate the attentional performance and muscle sympathetic nerve activity (MSNA) response during Color Word Stroop Test (CWST) in patients with obstructive sleep apnea (OSA) before and after intervention with exercise training.Individuals with no other comorbidities (age=52±1 years, body mass index=29±0.4) were divided in control (n=15) and untreated OSA (n=20) defined by polysomnography.
3353719|NCT02289625|Active Comparator|metaboreflex in OSA|"To investigate the metaboreflex control of MSNA before and after intervention with exercise training in patients with obstructive sleep apnea.~Methods: Thirty-five patients underwent conventional polysomnography. The MSNA was assessed by microneurography technique. Beat to beat blood pressure was measured during 4 minutes at rest, 3 minutes of isometric exercise at 30% maximal voluntary contraction, followed by 2 minutes of occlusion of the circulation in previously exercised muscle. The metaboreflex sensitivity was calculated during the first and second minutes of circulatory occlusion when metaboreceptors are evaluated independently of central command and muscle mechanoreceptors."
3353720|NCT02289638|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3353721|NCT02289638|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3353722|NCT02289651|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3353723|NCT02289651|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3353724|NCT02289664|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3353725|NCT02289664|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3244413|NCT01327729|Active Comparator|YPEG-IFN α-2a Ten days|this arm will be treated with: YPEG-IFN α-2a 180mcg/10 days for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks
3244414|NCT01327729|Active Comparator|YPEG-IFN α-2a two weeks|"The third group will be treated with:~YPEG-IFN α-2a 180mcg/ 2 weeks for 48 weeks. Ribavirin 15 mg/kg/day for 48 weeks."
3353726|NCT02289677|Experimental|Intubation during chest compression|Intubation during mannequin chest compressions. Chest compression was performed using LUCAS-2 (Physio-Control, Redmond, WA, USA).
3353727|NCT02289703|Experimental|Group A|Participants with end-stage renal disease (ESRD), will receive a single 15-milligram (mg) oral dose of rivaroxaban in Treatment Period 1 on Day 1, administered 2 hours before the start of a 4-hour hemodialysis session followed 7 to 14 days later by Treatment Period 2 wherein a single 15-mg oral dose of rivaroxaban will be given 3 hours after the completion of a 4-hour hemodialysis session on Day 1.
3353728|NCT02289703|Experimental|Group B|Healthy control participants matching to 'Group A' participants, will receive a single 15-mg oral dose of rivaroxaban on Day 1.
3353729|NCT02289716|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase.
3353730|NCT02289716|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase.
3353731|NCT02289716|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase.
3353732|NCT02289768|Experimental|5-fluorouracil/salicylic acid|Actikerall® solution (5-fluorouracil 0.5%, salicylic acid 10.0%) applied to the affected area once-daily for 12 weeks
3353733|NCT02289768|Placebo Comparator|Vehicle|Vehicle solution applied to the affected area once-daily for 12 weeks
3353734|NCT02289794|Active Comparator|E.coli bioconjugate vaccine|E.coli bioconjugate vaccine in saline buffer
3353735|NCT02289794|Placebo Comparator|Placebo|Saline buffer
3353736|NCT02289807|Experimental|RT group|intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone
3353737|NCT02289807|Active Comparator|CCRT group|IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles
3353738|NCT02289846|Placebo Comparator|Placebo BID|Placebo once in the morning and once in the evening.
3353739|NCT02289846|Experimental|IW-9179 QD AM + Placebo QD PM|IW-9179 once in the morning and placebo once in the evening.
3353740|NCT02289846|Experimental|Placebo QD AM + IW-9179 QD PM|Placebo once in the morning and IW-9179 once in the evening.
3353741|NCT02289846|Experimental|IW-9179 BID|IW-9179 once in the morning and once in the evening
3353742|NCT02289859|Active Comparator|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
3353743|NCT02289859|Active Comparator|Wound Closure without Undermining|One side of the wound will remain un-undermined.
3353744|NCT02289872|Experimental|Scenario A|The control scenario, where neither chest compression nor cervical stabilization was applied during intubation.
3353745|NCT02289872|Experimental|Scenario B|The chest compression scenario, where continuous chest compression was applied using chest compression system LUCAS-2 (Physio-Control, Redmond, WA, USA). Chest compression was provided at a rate of 100 min-1 to a depth of 5-6 cm during all intubation procedures.
3244415|NCT01327755|Experimental|Selenium|
3244416|NCT01327755|Placebo Comparator|Placebo|
3244417|NCT01327768|Experimental|OECs, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of Olfactory ensheathing cells(OECs), Antiplatelet Medication, and Rehabilitation.
3353746|NCT02289872|Experimental|Scenario C|The chest compression with cervical stabilization scenario, where both chest compression using Lucas-2 and cervical stabilization were applied. A correctly fitting standard cervical immobilization collar (StifNeck Select, Laerdal, Stavanger, Norway) was applied to the manikin's neck to prevent movement of the cervical spine.
3353747|NCT02289885|Experimental|normal model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
3353748|NCT02289885|Experimental|ascites positive model patient|Images of the ultrasound window were captured to disk and later evaluated by an expert in emergency medicine. In this study, the FAST examination was measured to the perihepatic space (also called Morison's pouch or the hepatorenal recess), perisplenic space, pericardium, and the pelvis.
3353749|NCT02289911|Active Comparator|Class|Traditional learning form
3353750|NCT02289911|Active Comparator|Web|Didactic training using internet
3353751|NCT02289924||Cohort 1|According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy
3244419|NCT01327794||Group 1|Participants in this correlative study (CALGB 151006) were enrolled in CALGB 80303, which was a national, multi-center, double-blind phase III study that randomly assigned patients (1:1) with advanced pancreatic cancer to gemcitabine plus bevacizumab vs gemcitabine plus placebo. Blood samples were collected from consenting participants in CALGB 80303 at the time of study registration at respective institutions and shipped to the CALGB Pathology Coordinating Office for storage (Columbus, OH).Baseline serum 25-hydroxyvitamin D (25[OH]D) levels were measured and examined associations between baseline 25(OH)D levels and progression-free survival and OS using the Cox rank score test.
3353752|NCT02289937|Experimental|Ropivacaine|8 ml of ropivacaine 7,5 mg/ml will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided.
3353753|NCT02289937|Placebo Comparator|Placebo|8 ml of isotonic saline will be injected around nervus cutaneous femoral lateralis. Ultrasound-guided
3353754|NCT02289976|Active Comparator|femoral condyle|Core decompression of the talar avascular necrosis followed by free microvascular femoral condyle grafting
3353755|NCT02289976|Active Comparator|core decompression|Core decompression and nonvascularized autograft from the iliac crest
3353756|NCT02290002|Active Comparator|group A|In group A, (Calcium Dobesilate group), 1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given from at day of HCG injection and for 21 days.
3353757|NCT02290002|Active Comparator|group B|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
3353758|NCT02290015|Experimental|true acupuncture|12 sessions of ACP treatment were performed twice a week. Before ACP was performed, patients were examined based on the diagnostic pattern of TCM. Then, the appropriate acupoints for treatment were selected according to the tinnitus-related syndrome. The experimental group was treated with true ACP (stimulating selected meridian points), and the control group was treated with sham-ACP (stimulating false meridian points). The patients were blinded to the identity of their treatment group. Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used in both groups. Needles were inserted manually at each meridian point, and the retention time was twenty minutes.
3353759|NCT02290015|Sham Comparator|sham acupuncture|The control group was treated with sham-ACP (stimulating false meridian points). Disposable stainless steel ACP needles (0.25 x 30 mm, Dong Bang Acupuncture, Korea) were used. Needles were inserted manually at each false meridian point, and the retention time was twenty minutes.
3244420|NCT01327807||Cystinsosis patients|Those with a diagnosis of cystinosis.
3244421|NCT01327820||Open aortic aneurysm repair|
3244422|NCT01327820||Endovascular aortic aneurysm repair|
3244423|NCT01327820||Infra-inguinal lower limb revascularisation|
3353760|NCT02290041|Experimental|Mesenchymal stem cells|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
3353761|NCT02290041|Placebo Comparator|Placebo|Intravenous infusion of 4 doses of Placebo
3353762|NCT02290054|Sham Comparator|Control|A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
3353763|NCT02290054|Experimental|Treated|"A thoracic epidural catheter is inserted first. Then total intra-venous anesthesia is performed. Auriculotherapy is performed while the patient is sleeping but before thoracic incision.~Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles."
3353764|NCT02290067|Active Comparator|Omnitest 3|Blood glucose monitoring system
3353765|NCT02290067|Experimental|Omnitest 5|Blood glucose monitoring system
3244424|NCT01327833||Cardiac Arrest|
3244425|NCT01327859|Experimental|Prior Donepezil 5mg|
3244426|NCT01327859|Experimental|Prior Donepezil 10mg|
3244427|NCT01327859|Placebo Comparator|Prior Placebo|
3244428|NCT01327872|Experimental|Treatment A|
3244429|NCT01327872|Experimental|Treatment B|
3244430|NCT01327872|Experimental|Treatment C|
3244431|NCT01327872|Experimental|Treatment D|
3244432|NCT01327898|Experimental|1|empowerment theory-based small group discussion
3244433|NCT01327898|Active Comparator|2|single session individual resilience counseling
3244434|NCT01327911|Experimental|Ciliary Neurotrophic Factor (CNTF)/NT-501|Biological/Vaccine:NT-501 implant
3244435|NCT01327924||Norditropin NordiFlex® users|
3244436|NCT01327937|Active Comparator|Apligraf Group|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
3244437|NCT01327937|Placebo Comparator|Standard of Care Dressing Group|Standard of care dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
3353766|NCT02290067|Experimental|Omnitest 5D|Blood glucose monitoring system
3353767|NCT02290080|Experimental|Oxygen|"For patients randomized to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
3353768|NCT02290080|No Intervention|No oxygen|"For patients randomized to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
3353769|NCT02290093|Active Comparator|Standard full-volume PEG|
3353770|NCT02290093|Experimental|Split-dose full-volume PEG|
3353771|NCT02290093|Experimental|Split-dose low-volume PEG|
3353772|NCT02290119|Sham Comparator|Control - Without the use of Verasense|Total Knee Replacement without the use of intraoperative sensors
3353773|NCT02290119|Active Comparator|Sensor-assisted TKR (Verasense)|Total Knee Replacement with the use of intraoperative sensors
3244438|NCT01327950||Superficial Femoral Lesions|Patients undergoing percutaneous treatment of Superficial Femoral Artery lesions
3244439|NCT01328015|Active Comparator|Oxybuynin, hyperhidrosis|
3353774|NCT02290132||highly aggressive T cell tumors|The study is to research the outcome of Rabbit Anti-human Thymocyte Globulin (ATG)based myeloablative conditioning regimen after allo-HSCT in patients with highly aggressive T-cell tumors.
3353775|NCT02290145|Experimental|TPF group|TPF induction chemotherapy followed with surgery and post-operative radiotherapy docetaxel 75mg/m2 cisplatin 75 mg/m2 5-Fu 750 mg/m2/day
3353776|NCT02290145|Other|surgery group|surgery with post-operative radiotherapy
3353777|NCT02290158|Active Comparator|Orthodontic finishing|Patients receiving a complete orthodontic finishing protocol according to the ABO-OGS
3353778|NCT02290158|No Intervention|No orthodontic finishing|Patients receiving orthodontic treatment without the finishing protocol according to the ABO-OGS
3353779|NCT02290171|Active Comparator|Intervention group|The intervention groups start the intervention 6 months ahead of the control group.
3353780|NCT02290171|No Intervention|Delayed intervention group|The control groups will start intervention with 6 months delay
3353781|NCT02290197|Experimental|Hinged External Fixator|Hinged external fixator allows early and aggressive joint mobility in the sagittal plane only. Flexion and extension are permitted, but rotational movements, translations in the anterior-posterior plane, lateral (varus) and medial (valgus) openings are not allowed. Thus protective stability is ensured for ligament reconstruction procedures. Simultaneously we allow immediate joint mobilization, reducing the risk of arthrofibrosis, joint stiffness and postoperative ligament laxity.
3353782|NCT02290197|Active Comparator|Cast Immobilization|In these patients we used cast postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
3353783|NCT02290210|Placebo Comparator|Placebo|Placebo x 2weeks
3353784|NCT02290210|Placebo Comparator|URC102 0.25mg|0.25mg URC102 x 2weeks
3353785|NCT02290210|Experimental|URC102 0.5mg|0.5mg URC102 x 2weeks
3244440|NCT01328015|Placebo Comparator|placebo - sugar pill|
3353786|NCT02290210|Placebo Comparator|URC102 1.0mg|1.0mg URC102 x 2weeks
3244441|NCT01328028||Group A|Subjects diagnosed with invasive cervical cancer
3353787|NCT02290210|Placebo Comparator|URC102 2.0mg|2.0mg URC102 x 2weeks
3244442|NCT01328067|Active Comparator|Treatment|MR guided Focused Ultrasound
3353788|NCT02290249|Active Comparator|normal airway|İntubation with glidescope or airtraq in normal airway
3353789|NCT02290249|Active Comparator|tongue edema|intubation with glidescope or airtraq in tongue edema simulation
3353790|NCT02290249|Active Comparator|face-to-face|intubation with glidescope or airtraq in face-to-face intubation
3244443|NCT01328067|Active Comparator|Surgery|Myomectomy
3244444|NCT01328093|Experimental|LY2140023|Double Blind Phase: 40 mg administered orally, given twice daily for 24 weeks. Dose may be adjusted to a minimum of 20 mg and a maximum of 80 mg. Open Label Phase: 40 mg administered orally, given twice daily for an additional 28 weeks.
3244445|NCT01328093|Active Comparator|Aripiprazole|Double Blind Phase: 15 mg administered orally, given once daily for 24 weeks. Dose can be adjusted to a minimum of 10 mg or a maximum of 30 mg. Open Label Phase: LY2140023, 40 mg administered orally, given twice daily for an additional 28 weeks.
3244446|NCT01328106|Experimental|1|
3244447|NCT01328119|Other|hemodialysis patients|conventional hemodialysis patients
3244448|NCT01328132|Active Comparator|Saline|
3244449|NCT01328132|Experimental|25% albumin|
3244450|NCT01328145|Active Comparator|ASA|
3244451|NCT01328145|Placebo Comparator|Placebo|
3244452|NCT01328171|Experimental|A (FOLFOXIRI + Panitumumab)|FOLFOXIRI + Panitumumab
3244453|NCT01328171|Active Comparator|B (FOLFOXIRI)|FOLFOXIRI
3244454|NCT01328197|Experimental|Treovance|
3244455|NCT01328210|Experimental|blood letting|Blood letting was performed immediately after baseline assessment and after 4 weeks. First blood removal consisted of 400ml, second blood removal was tailored according to subsequent serum ferritin levels between 300- 400 ml.
3353791|NCT02290262|Experimental|Comprehensive phase one rehabilitation|Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education plus usual care.
3353792|NCT02290262|No Intervention|Usual care|The control group will receive usual care alone.
3353793|NCT02290275|Placebo Comparator|Placebo|The subjects in this arm will receive 20 grams of a placebo (maltodextrin) for 1 week and then 5 grams of placebo (maltodextrin) for 11 weeks in addition to their regular diets.
3353794|NCT02290275|Experimental|Creatine|The subjects in this arm will receive 20 grams of creatine for 1 week and then 5 grams of creatine for 11 weeks in addition to their regular diets.
3353795|NCT02290275|Experimental|Walking Exercise|The subjects in this arm will receive a walking exercise program on a motorized treadmill where they will walk for 30 minutes at 3.1 mph, 3 days per week for 12 weeks.
3353796|NCT02290288|Active Comparator|SSF|1. vaginal surgery arm (SSF)
3353797|NCT02290288|Active Comparator|LSC|laparoscopic surgery arm (LSC)
3353798|NCT02290301||Type 2 Diabetes Mellitus|
3353799|NCT02290314|Other|minimally invasive MID-line Lumbar Fusion (MIDLF)|MIDLF surgery involves a minimally invasive midline laminectomy posterior approach to the lumbar spine. An incision that is smaller than the standard incision is made in the midline of the low back directly over the spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed as described in the PLIF procedure.
3353800|NCT02290314|Other|posterior lumbar interbody fusion (PLIF)|PLIF surgery involves a standard incision in the midline of the low back directly over the involved spinal levels. Afterward the pressure on the compressed nerves is released, and the disc between the affected vertebrae is completely removed. A metal cage filled with bone graft is placed in between the vertebral bodies where the disc usually lies. This will allow bone fusion (healing) to occur from one vertebral body to the other.
3353801|NCT02290327|Placebo Comparator|Placebo|50 ml of 0.9% Normal Saline Intravenously once daily
3353802|NCT02290327|Active Comparator|Pantoprazole|Pantoprazole 40 mg in 50 ml 0.9% Normal Saline Intravenously once daily
3353803|NCT02290353|Experimental|Adult (Stroke) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
3353804|NCT02290353|Experimental|Teenagers (Cerebral Palsy) group|This includes early intervention and late intervention sub-groups. Intervention: FEATHERS Device
3244456|NCT01328210|No Intervention|waiting list control|This group received no specific treatment but was offered treatment after termination of the 6-week study phase
3244457|NCT01328223||radiotherapy efficacy|"Concurrent stage with RT: sorafenib 400mg twice daily~Maintenance stage after RT: sorafenib 400mg twice daily Treatment can be continued until the occurrence of clinical or radiologic progression, the occurrence of either unacceptable adverse events, death, or any criteria met for removal from the protocol treatment. Basically, minimum maintenance duration of 6 months is recommended, not mandatory."
3353805|NCT02290366|Experimental|Focal Therapy|
3353806|NCT02290379|Experimental|TNX-201 35 mg|Drug: TNX-201 35 mg
3353807|NCT02290379|Experimental|TNX-201 70 mg|Drug: TNX-201 70 mg
3353808|NCT02290379|Experimental|TNX-201 140 mg|Drug: TNX-201 140 mg
3353809|NCT02290379|Active Comparator|Racemic isometheptene 70 mg|Comparator: Racemic Isometheptene 70 mg
3353810|NCT02290379|Placebo Comparator|Placebo|Drug: Placebo
3353812|NCT02290418|Active Comparator|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass and routine care.
3353813|NCT02290418|Active Comparator|Omega-Loop Gastric Bypass|Laparoscopic Omega-Loop Gastric Bypass and routine care.
3353814|NCT02290431|Experimental|LBH589 + bortezomib + dexamethasone|Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.
3353815|NCT02290457|Experimental|CSTS|core strength training performed on stable surfaces
3353816|NCT02290457|Experimental|CSTU|core strength training performed on unstable surfaces
3353817|NCT02290470|Experimental|olanzapine Days 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
3353818|NCT02290470|Experimental|olanzapine+Dexamethasone d 1-3|"Olanzapine + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as the following anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone (16 mg intravenously on the day of chemotherapy and 4 mg orally days 2, 3 post chemotherapy), plus~Olanzapine (10 mg orally on the day of chemotherapy and 10 mg orally on days 2, 3 post chemotherapy)"
3353819|NCT02290470|Active Comparator|dexamethasone days 1-3|"Dexamethasone + Chemotherapy + Antiemetic treatment~Patients will receive the chemotherapy drugs carboplatin and paclitaxel as well as usual anti-nausea/vomiting drugs:~Palonosetron (0.25 mg intravenously) on the day of chemotherapy, plus~Dexamethasone 16 mg intravenously on the day of chemotherapy (day 1), plus~Dexamethasone 8 mg orally on days 2 and 3 post chemotherapy"
3353820|NCT02290496|Experimental|CBT for Insomnia (CBT-I)|Cognitive behavior therapy to improve sleep and depression.
3353821|NCT02290496|Placebo Comparator|Sleep Hygiene (SH)|Attention control placebo comprising sleep hygiene therapy
3353822|NCT02290522|Experimental|tumor biopsy|Tumor biopsy for targeted treatment according to molecular profile
3353823|NCT02290535||Patients|Children and Teenager of 5-18 years with obstructive pulmonary disease (asthma, cystic fibrosis, immotile-cilia-syndrome, obstructive bronchitis, obstructive pneumonia).
3244458|NCT01328236|Experimental|V-DD single arm|"INDUCTION THERAPY: V-DD induction therapy for 6 cycles，28 Days per Cycle. Bortezomib - 1.3 mg/m2 IV, Days 1, 4, 8 , 11 of every treatment; Liposomal Doxorubicin - 30 mg/m2 IV, Day 4 of every treatment; Dexamethasone - 40 mg/d IV, Days 1 - 4 of every treatment.~Maintenance treatment for 4 cycles,28 Days per Cycle. Thalidomide - 100mg Qn ; Bortezomib - 1.3 mg/m2 IV ,Days 1, 4, 8 and 11 of every treatment; Dexamethasone - 40 mg/d IV ,Days 1 - 4; Interferon - 300 u Qod,（Specially for IgA type）. Interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
3244459|NCT01328262|Experimental|Hemoglobin dose|Intervention: Calculated red blood cell transfusion
3244460|NCT01328262|Active Comparator|Standard treatment|Intervention: Standard red blood cell transfusion
3353824|NCT02290535||Probands|Children and Teenager of 5-18 years without known obstructive pulmonary diseases
3244461|NCT01328275||1|long-term follow-up of HIV-infected patients on ART
3244462|NCT01328288||1|long-term follow-up of HIV-infected children
3244463|NCT01328301|Experimental|Speed-dependent treadmill training (SDT)|Subjects underwent short interval of walking trials with stepwise increases in the treadmill speed
3244464|NCT01328301|Active Comparator|speed-stable treadmill training|Control subjects received gait training on the treadmill with a steady speed.
3259358|NCT01470131|Placebo Comparator|Placebo|Placebo in combination with Bortezomib and Dexamethasone
3259359|NCT01470157|Experimental|Ketamine|Oral Ketamine in addition to oral midazolam
3353825|NCT02290548|Experimental|high flow nasal cannula|High flow nasal cannula immediately use after extubation
3353826|NCT02290548|Placebo Comparator|stanrd oxygen therapy|Oxygen cannula or mask after extubation
3353827|NCT02290587|Experimental|Patient|MS diagnosis according to McDonald criteria (Polman et al., 2005). Relapsing-remitting MS (RRMS) according to Lublin et al. (1996);
3353828|NCT02290587|Experimental|Control|healthy subject
3353829|NCT02290600||type 1 diabetes|type 1 diabetes with continuous glucose monitor (CGM)
3353830|NCT02290626|Experimental|Elemental diet|"Study 1: Elemental diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Elemental diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
3353831|NCT02290626|Active Comparator|Semi-solid diet|"Study 1: Semi-solid diet (300 kcal/300 ml) containing a contrast medium (5 ml) is administered within 15 min using the PEG.~Study 2: Semi-solid diet (200 kcal/200 mL) labeled with 100 mg [13C]sodium acetate is administered within 15 min using the PEG."
3353832|NCT02290639|Experimental|Immediate Treatment|Four 30-minute sessions of Brief Cognitive Behavioral treatment starting immediately upon randomization.
3353833|NCT02290639|Active Comparator|Minimal Contact followed by treatment|6-week Minimal Contact period consisting of weekly phone calls starting immediately upon randomization. Experimental treatment will be provided to all subjects upon completion of Minimal Contact period.
3353834|NCT02290652||Prospective|Prospective - Factors affecting sexual function pre-THR
3353835|NCT02290652||Retrospective|Retrospective- Factors affecting sexual function post-THR
3353836|NCT02290665|Experimental|Thermosensitive gel formulation|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
3353837|NCT02290665|Experimental|Saline enema|Thermosensitive gel rectal formulation or saline (control) enema with crossover to the other.
3353838|NCT02290678|Experimental|Intervention|Participate in a two day Adventure-based Programming retreat and team building exercises.
3353839|NCT02290704||controls|People without eye disease
3353840|NCT02290704||GO patients|patients with Graves' ophthalmopathy
3353841|NCT02290717|Experimental|Laser+fluticason+UVB|The treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser). 5 days after laser therapy topical steroids (fluticasone cream) 4 times a week will be applied on the treatment site until the end of the study.
3353842|NCT02290717|Experimental|Laser+UVB|In one session the treatment site will be superficially abraded using an ablative fractional laser (10,600nm CO2 laser).
3353843|NCT02290717|Active Comparator|UVB|As control site, 1 similar depigmented lesion will be used. This site will receive the same NB-UVB treatment as sites 1 and 2.
3353844|NCT02290730|Experimental|Kinesio tape|Kinesio tape on lower trapezius
3244465|NCT01328340|Active Comparator|High-speed power training|Volunteers randomized into SHPT will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength for leg press (LP) and seated knee extension (KE) exercises.
3353845|NCT02290730|No Intervention|Control|No intervention
3353846|NCT02290743|Experimental|Kinesio tape|Kinesio tape on quadriceps femoris
3353847|NCT02290743|No Intervention|Control|No intervention
3353848|NCT02290756|Active Comparator|Parenting program and toolkit|The intervention arm of the study will have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy and the parenting program delivered to the newborn for 12 months.
3353849|NCT02290756|Other|Control- toolkit|The control arm of the study will only have the low cost evidence based toolkit delivered to the the pregnant women for the duration of their pregnancy.
3353850|NCT02290769|Experimental|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
3353851|NCT02290769|Active Comparator|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
3353852|NCT02290782|Experimental|Intraoperative radiotherapy (IORT)|"IORT (20Gy) as intervention will be given during breast conserving surgery. If risk factors (Tumor > 3.5 cm, lobular cancer, resection margin < 2 mm*, L1, pN+ mulitfocal/multicentric, EIC, negative hormone receptors) are present, external beam radiotherapy will be added.~* In case of positive margins (<2 mm resection margin) a re-resection should be done"
3353853|NCT02290795||healthy subjects|Healthy subjects (not diagnosed with any eye disease affecting the vitreous or optic nerve head).
3353854|NCT02290795||Glaucoma patients|Glaucoma patients visiting the glaucoma consultation.
3353855|NCT02290795||Patients scheduled for trabeculectomy|Glaucoma patients scheduled for filtering surgery (=trabeculectomy)
3353856|NCT02290795||Vitreomacular traction patients|Patients with symptomative vitreomacular adhesion scheduled for treatment with Ocriplasmin
3353857|NCT02290808|Experimental|Theory-based group|The theory-based intervention group will receive strategies based on the Theory of Planned Behaviour to help increase physical activity among couples. Parents will receive materials on how to work together.
3353858|NCT02290808|No Intervention|Information group|The information group will serve as the control group and will receive informational materials on the benefits of physical activity.
3353859|NCT02290834|Active Comparator|ARM 1|"Breast cancer patients treated with chemotherapy~Cognitive, functional and subjective assessments (Pre and Post Treatment)~Imaging (Pre and Post Treatment)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3353860|NCT02290834|Active Comparator|ARM 2|"Non-treated breast cancer patient control~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3353861|NCT02290834|Active Comparator|ARM 3|"Healthy control subjects~Cognitive, functional and subjective assessments (Post enrollment and 6-14 months later~Imaging (Post Enrollment and at 8-14 months later)~Magnetic Resonance Imaging (MRI) Scan~Magnetic Resonance Imaging (MRI) Scan / Positron Emission Tomography (PET) Scan"
3353862|NCT02290847|Active Comparator|In-Home Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in their homes by a certified therapist.
3244466|NCT01328340|Active Comparator|Slow-speed strength training|Volunteers randomized into STR will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
3244467|NCT01328340|No Intervention|Control|Volunteers randomized into CON will undergo a placebo exercise intervention consisting of lower extremity range of motion and flexibility exercises performed 2 times per week with the assistance of the research staff.
3353863|NCT02290847|Active Comparator|In-Office Therapy|Cognitive Processing Therapy (CPT-C) will be delivered to participants face to face in a mental health clinic office setting by a certified therapist.
3353864|NCT02290847|Active Comparator|Telebehavioral Health|Cognitive Processing Therapy (CPT-C) will be delivered to participants over the internet using video conferencing software by a certified therapist.
3353865|NCT02290860|Other|Intervention|Type 2 diabetes diagnosis test.
3353866|NCT02290886|Placebo Comparator|Placebo|Intravenous administration of placebo
3353867|NCT02290886|Experimental|1 million of MSC|Intravenous administration of 1 million of MSC/ kg
3353868|NCT02290886|Experimental|2 million of MSC|Intravenous administration of 2 million of MSC/ kg
3353869|NCT02290886|Experimental|4 million of MSC|Intravenous administration of 4 million of MSC/ kg
3353870|NCT02290912|Experimental|Treatment|Health education program; informational website, experiential classes in various help domains, custom smart phone application, and wearable technology
3353871|NCT02290912|No Intervention|Control|No intervention
3353872|NCT02290938|Active Comparator|Community Wellness Gatherings|All youth will attend a CWG, which is a monthly gathering focused on making healthy choices and learning about Native American culture
3353873|NCT02290938|Experimental|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
3353874|NCT02290951|Experimental|1N Part A|DLBCL post CAR-T
3353875|NCT02290951|Experimental|1N Part B|FL
3353876|NCT02290951|Experimental|2N Part B|DLBCL
3244468|NCT01328353|No Intervention|control group|Control group arm follows usual care
3353877|NCT02290964|No Intervention|Control group|After general anesthesia is applied, surgery is performed. Whenever transfusion is indicated, the patients will received allogenic blood transfusion
3353878|NCT02290964|Active Comparator|ANH group|After general anesthesia is applied, blood from patients in this group were withdrawn. the volume of blood withdrawn was determined based on Gross equation. The blood obtained was then stored in the operating room at temperature between 23 - 25 Celsius degree, and given back to the patient whenever transfusion is indicated.
3353879|NCT02290977|Experimental|Scheduled TACE-RT|RT will be delivered at two weeks after TACE for HCC combined PVTT.
3353880|NCT02290990|Experimental|Multiple Sclerosis patients|Patients with MS
3244469|NCT01328353|Experimental|Intervention group arm 1|Intervention group arm 1 receives aprn/telephone care coordination
3244470|NCT01328353|Experimental|Intervention group arm 2|Intervention group arm 2 receives aprn/telephone/video care coordination
3353881|NCT02290990|Experimental|Insomnia patients|Patients with insomnia
3353882|NCT02290990|Experimental|Health professionists|Health professionists as healthy volunteers
3353883|NCT02290990|Active Comparator|Waiting list MS|pw MS filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
3353884|NCT02290990|Active Comparator|Waiting list arm Insomnia|pw INS Insomnia Subject filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated
3353885|NCT02290990|Active Comparator|Waiting list arm Health professionists|Health professionist filled the self administered questionnaire but they receive any training. They must wait study conclusion to be treated.
3244471|NCT01328418|Other|Achondroplasia lengthening|
3244472|NCT01328470|Active Comparator|clopidogrel 75 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 75 mg/day for 14 days.
3353886|NCT02291003||Healthy controls|Healthy controls -observational, no intervention administered.
3353887|NCT02291042|Experimental|Suppository|Patients will receive a single antispasmodic muscarinic suppository after induction of anesthesia but before insertion of urological scope for surgery. The suppository is composed of Belladonna (16.2 mg) and Opium (30 mg) in a water soluble base manufactured as Belladonna and Opium Supprettes.
3353888|NCT02291042|No Intervention|Control|Patients will be provided with routine care.
3353889|NCT02291055|Experimental|Arm A|ADXS11-001& Medi4736, IV Infusion
3353890|NCT02291055|Experimental|Arm B|Medi4736, IV Infusion vs. ADXS11-001 & Medi4736, IV Infusion
3244473|NCT01328470|Active Comparator|clopidogrel 150 mg/day|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive clopidogrel 150 mg/day for 14 days.
3244474|NCT01328470|Active Comparator|adjunctive cilostazol|CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease will be randomized to receive co-administration of adjunctive cilostazol (100 mg twice daily) and clopidogrel (75 mg/day; [group 3, 20 patients]) for 14 days.
3244475|NCT01328470|Active Comparator|75mg clopidogrel|control group undergoing PCI for stable angina will be also maintained on clopidogrel (75 mg/day for 14 days).
3244476|NCT01328483|No Intervention|No Intrapartum Oropharyngeal (IP-OP) Suction|Neonates randomized to No IP-OP group received supportive treatment as per standard unit protocols. They were also assessed as vigorous or non-vigorous and received care according to NRP 2005.
3244477|NCT01328483|Experimental|Intrapartum Oropharyngeal (IP-OP) suction|The neonates randomized to IP-OP group were provided oropharyngeal suctioning at the delivery of head before the delivery of shoulder, using suction machine at a negative pressure of 100mm of Hg or Dee Lee's suction trap in the event of electricity failure or non availability of suction machine.Subsequently, all the neonates born through MSAF were assessed by pediatrician as vigorous or non vigorous and provided care as per NRP guidelines 2005.
3244478|NCT01328509||Sepsis|Patients with sepsis
3244479|NCT01328509||Control|Patients with no clinical evidence of sepsis, but who are critically ill
3259360|NCT01470157|Placebo Comparator|Placebo|Normal saline (placebo) in addition to oral midazolam
3244480|NCT01328522|Experimental|SAR153191 drug product 1|"SAR153191 drug product 1 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
3244481|NCT01328522|Experimental|SAR153191 drug product 2|"SAR153191 drug product 2 in a single injection.~Methotrexate (stable dose) and folic/folinic acid are continued as background therapy."
3353891|NCT02291068|Other|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy.
3353892|NCT02291094|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
3353893|NCT02291094|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
3353894|NCT02291107|Experimental|Experimental group|Participants received 25 sessions of robotically driven gait orthosis training on the Lokomat. Training occurred approximately 5 days/ week for 5 weeks, and each training session on the Lokomat lasted 30 minutes. All sessions were supervised by a trained research therapist. All participants started with 40% body weight-support and an initial treadmill speed of 1.5 km/h. Body weight-support was used primarily to facilitate an increase in walking speed; therefore, progression of training across subsequent sessions was standardized by preferentially increasing speed and then unloading body weight-support. Speed was increased to a range of 2.2 to 2.5 km/h before body weight-support was decreased. There was an active attempt to enhance the level of training at each session. After every Lokomat session, participants performed also 60 minutes of physiotherapy including general exercise program and a conventional gait training
3353895|NCT02291107|Active Comparator|Control group|Participants received 25 sessions of conventional physiotherapy. Training occurred approximately 5 days/week for 5 weeks, and each training session lasted 1 hour and half. Patients allocated to the Control Group performed the same conventional physiotherapy training of the other group: a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and static/dynamic balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation concept, training in walking on different surfaces with or without appropriate walking aids, exercises for the restoration of a correct gait pattern, implementation of residual compensatory strategies and progressive increase of walking resistance
3353896|NCT02291120|Active Comparator|MTA|ProRoot® MTA is a root canal repair material that is a unique improvement over other materials used for root canal repair. Made up of fine hydrophilic particles that set in the presence of water, ProRoot® MTA seals off all pathways between the root canal system and surrounding tissues, significantly reducing bacterial migration. Its excellent compatibility with the dentinal wall allows for a predictable clinical healing response.
3244482|NCT01328626|Experimental|Arm A (CLL/SLL subjects)|Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) subjects
3353897|NCT02291120|Experimental|MedCem Portland Cement (PC)|MedCem PC is an excellent capping material for cariology on permanent teeth (direct and indirect capping) and in milk tooth endodontics (milk tooth amputation). Is characterized by excellent colour stability and neutrality and does not contain any additional ingredients
3353898|NCT02291146|Experimental|LA Sprouts intervention|"The intervention classes will be taught during a 90-minute session once a week for 12 weeks. Participants will receive a 45-minute gardening lesson, taught by a Master Gardener (supervised by Dr. Gatto). This lesson will include learning how to plant, maintain and harvest various fruits and vegetables. Supplementing the gardening lesson, a USC nutrition educator, with help from various graduate students (supervised by PI Dr. Davis), will lead a 45-minute cooking activity and nutrition education lesson. Every participant will participate in the cooking activity and sample the food. The program will include lessons on growing crops that have cultural significance to Latino youth such as nopales, beans, corn and squash (the latter three crops are commonly referred to as the three sisters)."
3353899|NCT02291146|No Intervention|control|Approximately 200 students in the second region who are enrolled in LA's Best will serve as control participants. After the 12-week intervention is conducted and all post-testing measures are collected on controls, a vegetable/fruit garden will be built at both control schools and the LA Sprouts program will be taught to all 3rd, 4th and 5th graders in LAs Best and their parents at the control school as a delayed intervention.
3353900|NCT02291159|Experimental|Intervention-DNHS technique|Dry needling of Myofascial Trigger Points
3353901|NCT02291159|Sham Comparator|Control-Sham Dry Needling|Sham Dry Needling of Myofascial Trigger Points
3353902|NCT02291172|Experimental|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry. The comprehensive communication intervention: (a) teaches foundational social communicative behaviors, (b) related skills that predict long term language outcomes, (c) a range of communicative functions, (d) spoken language skills, (e) provides children with an immediate mode of communication, (f) incorporates instructional methods, contexts, and partners that increase both the critical skills for spoken language and social use of language. Because parents are essential partners for young children with ASD who are learning to communicate, we (g) include parents
3353903|NCT02291172|No Intervention|Business as Usual Control Group|All children, regardless of group assignment will participate in all assessments. Children randomized to the control group will not receive intervention, but will complete all other research procedures. Other treatments that all children receive in the community will be recorded with bi-monthly surveys.
3244483|NCT01328626|Experimental|Arm B (NHL subjects)|Non-Hodgkin lymphoma (NHL) subjects
3244484|NCT01328639|Active Comparator|Usual Care|Participants in this arm will be actively screened for depression and will receive the usual standard care for diabetes from their family physicians based on available clinical practice guidelines.
3244485|NCT01328639|Experimental|TeamCare Depression Intervention|Participants in this arm will be actively screened for depression, and will receive care for depression and diabetes based on the collaborative teamcare model for the management of diabetes and co-morbid depression.
3353904|NCT02291211|Experimental|S-1 plus cisplatin HIPEC|8 cycles of hyperthermic intraperitoneal chemotherapy (cisplatin) and S-1(oral) were performed after palliative operation gastric cancer of stage IV limited peritoneal metastasis. HIPEC was conducted in d1 and d3: Normal saline 2000ml-5000ml, Cisplatin 60mg/m^2, 43°C, 60min. every 3 weeks. S-1: 40-60mg/m^2 bid, days 1-14, every 3 weeks.Subjects should be given maximum 8 cycles, or progression/intolerance.
3353905|NCT02291224|Other|Control|The control arm receives the clinic standard of care counseling. This includes individual clinical care and counseling consistent with protocols at the Grady Health System Teen Services Clinic, with study visits at enrollment, 6 months, and 12 months, during which any medical care or counseling included in the clinic standard of care will be provided. All control group members will see a provider on the day of enrollment. Control arm participants will get phone calls from clinic staff to update their contact information and remind them of upcoming appointments at 3 weeks and 5 months after both the enrollment visit and the 6 month visit. Participants may visit the clinic at any time and will be encouraged to come into the clinic for any concerns. If they have an interim visit during the study period, they will receive the clinic standard of care.
3353906|NCT02291224|Experimental|Intervention|"Enrollment~Interactive multimedia platform focused on DP strategies.~Intervention arm counseling by a health care provider to select DP strategy.~Intervention arm counseling and skill-building by a nurse educator (NE) on correct, consistent use of DP strategy.~Booster counseling by an NE via phone at 3 weeks and 5 months after both the enrollment visit and the 6 month visit.~6 month visit~Abbreviated version of the interactive multimedia platform on DP strategies and adherence.~Intervention arm counseling by an NE to reinforce skills for correct, consistent use of DP strategy.~Interim visits: Participants may visit the clinic at any time. If intervention group members visit the clinic for STI treatment or to switch birth control method, providers and/or NEs will follow structured counseling guides. If they have an interim visit for another reason, they will receive the clinic standard of care."
3353907|NCT02291250|Experimental|Sugar matched water with polycal OGTT|"Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3353908|NCT02291250|Experimental|Blackcurrants with polycal OGTT|"Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Greencurrants ( 200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3244486|NCT01328652|Experimental|Proton Pump Inhibitor|Treatment with dexlansoprazole 60 mg once daily for 3 months
3244487|NCT01328665|Experimental|Expressive Writing|Affectionate Writing Intervention for 20 minutes per day, 2 times per week, 6 weeks.
3244488|NCT01328665|No Intervention|No writing|Control Group -- No writing
3244489|NCT01328678||Alopecia Areata|Individuals with Alopecia Areata (AA)
3244490|NCT01328704||Triathletes|Group of individuals who are participating in a triathlon training program at the Avera Sports Institute
3244491|NCT01328730|Experimental|Firebird 2 stent group|patients who were implated with Firebird 2 SES
3244492|NCT01328730|Active Comparator|Cypher Stent Group|patients who were implanted with Cypher SES
3244494|NCT01328821|Placebo Comparator|Part A|"Single ascending dose administration of four doses of CTP-499 as tablets under fasting condition.~8 subjects per dose group will be enrolled with a 3:1 randomization of active drug to placebo.~Dose levels: 600mg -> 1200mg -> 1800mg -> 2400mg"
3244495|NCT01328821|Active Comparator|Part B|Part B will consist of a single 400 mg dose of an immediate release capsule of CTP-499 administered under fasting conditions. In Part B 6 subjects will be enrolled.
3244496|NCT01328834|Experimental|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) treatment in induction phase
3244497|NCT01328860|Experimental|Biologic; Stem Cells|
3244498|NCT01328886|Experimental|Omalizumab|
3244499|NCT01328899|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
3244500|NCT01328912|Experimental|Remote ischemic preconditioning stimulus|
3244501|NCT01328912|Placebo Comparator|Control|
3244502|NCT01328925|Experimental|Nitazoxanide Oral Suspension|Nitazoxanide Oral Suspension 100 mg/5 ml
3244503|NCT01328925|Placebo Comparator|Placebo Oral Suspension|Placebo Oral Suspension
3244504|NCT01328938|Experimental|Stage I - Arm I: GCPGC I (3.6mg)|GCPGC 3.6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
3244505|NCT01328938|Experimental|Stage I - Arm II: GCPGC II (6mg)|GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1)
3244506|NCT01328938|Experimental|Stage II - Arm I: GCPGC|"GCPGC 6mg, sc, once at Day 2 per cycle (in patients receiving chemotherapy at Day 1).~The recommended dose in Stage II was determinated as GCPGC 6mg in Stage I."
3244507|NCT01328938|Active Comparator|Stage II - Arm II: Neulasta|Neulasta 6mg, sc, once at Day 3 per cycle (in patients receiving chemotherapy at Day 1)
3244508|NCT01328977|Active Comparator|emails, book|
3244509|NCT01328977|Active Comparator|didactic teaching from experts|
3244510|NCT01328977|Experimental|personal coaching by development profs|
3244511|NCT01329003||exposed workers|At least six months of occupational exposure to Caesar stone
3244512|NCT01329016|Active Comparator|GDM Subjects|Women with GDM requiring treatment
3244513|NCT01329016|No Intervention|Non-pregnant Type 2 Diabetes Milletus Subjects|Non-pregnant women with Type 2 diabetes mellitus who plan to use metformin treatment
3353909|NCT02291250|Experimental|Blackcurrants with glucose OGTT|"Blackcurrants (200grams) with glucose~Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments"
3353910|NCT02291250|Experimental|Greencurrants with polycal OGTT|"Greencurrants (200grams) with polycal~Control: sugar matched (matched to currant sugar content) water with polycal~Blackcurrants (200grams) with polycal~Blackcurrants (200grams) with glucose~Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The OGTT will be carried out with glucose as a simple carbohydrate load or polycal as a complex carbohydrate load as decribed above.~Volunteers will be randomised into four groups (n=4 per group). One week wash out between treatments."
3353911|NCT02291263|Active Comparator|Arm A|Group A will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group A participants will also receive inactivated polio vaccine (IPV) at 6 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3353912|NCT02291263|Active Comparator|Arm B|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group B participants will also receive inactivated polio vaccine (IPV) at 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3353913|NCT02291263|Active Comparator|Arm C|Group C will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. Group C participants will also receive inactivated polio vaccine (IPV) at 6 and 14 weeks of age. An additional dose of IPV will be administered at 18 weeks of age.
3353914|NCT02291276||Female cancer patients with ascites|Primary epithelial ovarian female cancer patients with ascites (> 500 ml ascites in the preoperative sonographic examination)
3353915|NCT02291276||Female cancer patients aged > 70 years|"Primary epithelial ovarian female cancer patients aged > 70 years with at least one of the following secondary diagnoses:~Status Post stent placement due to coronary heart disease respectively Status Post-myocardial infarction~existing arterial Hypertension for more than 5 years~chronic heart failure (New York Heart Association (NYHA) class II-III)~peripheral arterial disease"
3353916|NCT02291315||Test meal ingestion|On the morning of the absorption study, fasted women received 2 mg of 42Ca intravenously (in 5 ml of isotonic saline) over 5 minutes before being randomly assigned to receive either the milk or cassia meal first for breakfast and the milk or cassia meal second for lunch. The milk meal consisted of approximately 100 mg of fresh ultrahigh temperature (UHT) milk to which 2 mg of 44Ca was added and allowed to equilibrate for 12 h prior to ingestion and the cassia meal consisted of 142 g of cooked cassia to which 1 mg of 43Ca was extrinsically added.
3353917|NCT02291328|Experimental|High Brassica|Participants will be asked to consume 3x 84g portions of frozen broccoli, 3x 84g portions of frozen cauliflower, and 3x 300g portions of frozen broccoli and sweet potato soups a week for a total of 2 weeks.
3353918|NCT02291328|Experimental|Low Brassica|Participants will be asked to consume 1x 84g portion of either frozen broccoli or frozen cauliflower in week one, and the remaining 84g portion of Brassica in week two.
3353919|NCT02291341|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|Duloxetine Delayed-Release Capsules, 60 mg of Dr. Reddys Laboratories Limited
3353920|NCT02291341|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
3353921|NCT02291354|Placebo Comparator|FMT + Placebo|Patients allocated to control group will receive standard FMT, followed by placebo for 12 weeks.
3353922|NCT02291354|Experimental|FMT + Pectin|Patients allocated to experiment group will receive standard FMT, followed by 24g pectin each day for 12 weeks.
3353923|NCT02291367|Experimental|Duloxetine Delayed-Release Capsules, 60 mg|
3353924|NCT02291367|Active Comparator|Cymbalta|Cymbalta® 60 mg capsule of Eli Lilly and Company
3353925|NCT02291380|Active Comparator|Botulinum Toxin Type A for Injection|Botulinum Toxin Type A is a specific formulation of a locally injected muscle relaxant whose active ingredient is botulinum toxin type A produced by clostridium botulinum A strain Hall. Excipients contain sucrose, dextran and gelatin.
3353926|NCT02291380|Placebo Comparator|Placebo|The placebo does not include botulinum toxin A ,but includes sucrose, dextran and gelatin.
3353927|NCT02291393|Other|Patient|Patients with previously confirmed Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
3353928|NCT02291393|Other|Healthy volunteers|Aged and gender matched healthy controls.
3353929|NCT02291406|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
3353930|NCT02291406|Active Comparator|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
3353931|NCT02291445|Experimental|Tempocol-ColoPulse®|Tempocol-ColoPulse® is a colon-targeted-delivery peppermint oil capsule that will deliver peppermint oil in the (ileo-) colonic region specifically.
3353932|NCT02291445|Active Comparator|Tempocol®|Tempocol® is an enteric-coated peppermint oil capsule that delivers peppermint oil in the upper small intestine.
3353933|NCT02291458|Experimental|L-arginine|Subjects will receive 9 gram of L-arginine per day in three gifts (3dd 3 gram) during 6 weeks.
3244514|NCT01329016|No Intervention|Healthy Pregnant Women|Healthy pregnant women with normal 1-hour glucose tolerance test
3244515|NCT01329055||Hemodialysis patients|
3244516|NCT01329068|Active Comparator|Individual consult|regular individual consult
3244517|NCT01329068|Active Comparator|group medical consult|regular group medical consult
3244518|NCT01329081|Experimental|Six weeks strength training in teams and patient education|
3244519|NCT01329081|Experimental|Supervised home training with focus on activities|
3353934|NCT02291458|Placebo Comparator|Placebo|Subjects will receive 9 gram of placebo per day in three gifts (3 dd 3 gram) during 6 weeks.
3353935|NCT02291471|Experimental|T0001|
3353936|NCT02291484|Experimental|Comprehensive cardiac CT|"Tiered cardiac CT protocol:~CT calcium scan~CT angiography (if calcium scan positive or high pre-test probability)~CT perfusion (if >50% stenosis on CTA, or cannot be ruled out)"
3353937|NCT02291484|No Intervention|Standard care|Standard diagnostic management of suspected CAD, using stress testing
3353938|NCT02291523|Sham Comparator|Patient Stool Transplant|Arm 1 will get FMT (Fecal Microbial Transplant) placebo and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
3353939|NCT02291523|Active Comparator|Donor Stool Transplant|Arm 2 will get FMT (Fecal Microbial Transplant) with Healthy Donor Stool and high dose 5-ASA (Pentasa). The FMT is done through colonoscopy.
3353940|NCT02291536|Experimental|tetrahydrocannabinol|oral administration of 10mg of tetrahydrocannabinol, once
3353941|NCT02291536|Experimental|cannabidiol|oral administration of cannabidiol, 600mg, once
3244520|NCT01329094||Patients with severe mental illness|In-patients and out-patients with severe mental illness attending treatment at Aarhus University Hospital, Risskov.
3353942|NCT02291536|Placebo Comparator|placebo|oral administration of placebo, once
3353943|NCT02291562|Experimental|Tetrahydrocannabinol|10 mg of Tetrahydrocannabinol as capsule (once)
3353944|NCT02291562|Experimental|Cannabidiol|600 mg Cannabidiol capsule (once)
3353945|NCT02291562|Placebo Comparator|placebo|placebo capsule (once)
3244521|NCT01329094||Healthy controls|Healthy controls recruited from staff members at Aarhus University Hospital, Risskov
3244522|NCT01329107|No Intervention|No intervention|Standard Care
3353946|NCT02291575|Experimental|Training|Of the 304 participants in the study, half will be randomized into the treatment arm in which they will receive training from the Liver Foundation.The objective of the Liver Foundation's training program will be capacity building through information in health sciences, training in referral techniques during emergencies, and maternal and child health care priorities in rural areas. The training will be in the form of two three-hour classes per week and will continue for nine months, with three mid-term exams administered every three. During this time, the evaluation team will only collect the rosters of the attendees of the training classes and conduct sporadic random visits to the sessions to gain a better sense of the training methods and attendance rates.
3353947|NCT02291575|Active Comparator|Control|Half of the sample will be randomized into the control group, for whom there will be no training. They will be phased into training the following year. For the current year, the control group will experience no difference in their routine, aside from some (infrequent) opportunities to participate in other public health activities as provided by the Liver Foundation to any provider involved in their various programs.
3353948|NCT02291588|Experimental|AMG 811|AMG 811 administered as subcutaneous and intravenous doses
3353949|NCT02291588|Placebo Comparator|Placebo|No active drug
3353950|NCT02291627|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
3353951|NCT02291640|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3353952|NCT02291640|Experimental|Child ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3244523|NCT01329107|Experimental|Multimodal intervention|Intervention group will be assigned to specific decribed multimodal intervention
3244524|NCT01329120||Pectus excavatum|Patients who has undergone minimally invasive repair of pectus excavatum
3353953|NCT02291653|Experimental|Intubation without chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3353954|NCT02291653|Experimental|Intubation with uninterrupted chest compressions|Endotracheal intubation of pediatric mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3244525|NCT01329120||Pectus carinatum|Patients who has undergone open surgical repair of pectus carinatum
3244526|NCT01329133|Active Comparator|DBS of subthalamic nucleus|
3244527|NCT01329133|Active Comparator|DBS of ventral striatum|
3244528|NCT01329172|Experimental|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 (PUFA n-3)
3244529|NCT01329172|Placebo Comparator|placebo|sun flower oil
3244530|NCT01329211||Gastroparesis Patients|
3244531|NCT01329211||Gastroparesis Patients' Caregivers|
3244532|NCT01329224||TAM patients|All consecutive patients under chronic ASA treatment (100mg/d) seen at our outpatient clinic.
3244533|NCT01329237|Other|dynamic physical exercise OCT|dynamic physical exercise and optical coherence tomography imaging
3244534|NCT01329250|Experimental|Moxifloxacin|Moxifloxacinin escalating dose
3244535|NCT01329276|Other|Symbicort® forte Turbohaler®|
3244536|NCT01329276|Placebo Comparator|Placebo (lactose)|
3244537|NCT01329289|Experimental|SOM230 with Bortezomib and Dexamethasone|
3244538|NCT01329302|Active Comparator|Group A: Direct aspiration|
3244539|NCT01329302|Active Comparator|Follicular Flushing|
3244540|NCT01329315|Active Comparator|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
3244541|NCT01329315|Active Comparator|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
3244542|NCT01329315|No Intervention|DPB|Drug Prevention Booklet (DPB)- National Institute on Drug Abuse (NIDA)-developed drug prevention booklet to address preventing marijuana initiation, and marijuana use.
3244543|NCT01329354|Experimental|Autologous effector lymphocytes|
3244544|NCT01329367|Active Comparator|Control group|"Control group: Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
3244545|NCT01329367|Experimental|Protein group|"Protein group: Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
3353955|NCT02291666|Experimental|T2D patients with A1C ≤7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3353956|NCT02291666|Experimental|T2D patients with A1C>7.0|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3353957|NCT02291666|Active Comparator|Non T2D subjects|CRCHUM-MT cocktail; a single oral dose of the CRCHUM-MT cocktail will be administered; 100mg caffeine, 75mg bupropion, 150mg tolbutamide, 20mg omeprazole, 30mg dextromethorphan, 2mg midazolam and at night, one oral 250mg dose of chlorzoxazone will be taken separately.
3353958|NCT02291692|Active Comparator|Paravertebral blockade|Paravertebral blockade
3244546|NCT01329367|Experimental|Antioxidant group|"Antioxidant group: Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
3244547|NCT01329393|Experimental|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
3244548|NCT01329393|Active Comparator|Illness Management and Recovery|
3353959|NCT02291692|No Intervention|Paracetamol|The patients was given 15 mg/kg of paracetamol.
3244549|NCT01329406|Experimental|Milnacipran|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
3244550|NCT01329406|Placebo Comparator|Placebo|If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
3244551|NCT01329432|Sham Comparator|take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing
3244552|NCT01329432|Experimental|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration
3353960|NCT02291705|Experimental|rectus sheath block|rectus sheath block
3353961|NCT02291705|Active Comparator|tramadol|tramadol control group
3353962|NCT02291731|Experimental|Continuous use of autologous serum|with continuous use of topical autologous serum for an additional 2 weeks after total re-epithelialization.
3353963|NCT02291744|Experimental|XELOX plus surgery|Eight cycles of XELOX chemotherapy plus surgery:Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle. After 4 cycles, the patients are randomized to surgery group. Then the rest four cycles are administrated.
3244553|NCT01329445||DeNovo NT patient|Patients who have received or who are scheduled to receive a DeNovo NT graft for repair of 1-2 knee cartilage lesions.
3244554|NCT01329458||Focal liver lesions|Focal liver lesions: patients discovered with new, uncharacteristic focal liver lesions at standard ultrasound
3353964|NCT02291744|Active Comparator|XELOX|Eight cycles of XELOX chemotherapy: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
3353965|NCT02291757|Active Comparator|NEM brand eggshell membrane|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits.
3353966|NCT02291757|Placebo Comparator|Placebo|Subjects will be given enough treatment capsules or placebo capsules for 30-days after initial assessment, covering both the 7- and 30-day follow-up visits. At the 30-day evaluation, patients in the placebo group will cross over to the treatment group for the remainder of the study and all patients will be given a 60-day supply of treatment capsules covering the 90-day follow-up visit.
3353967|NCT02291770|Active Comparator|Mesenchymal stem cells (MSC)|"Patients with newly diagnosed cGvHD receive primary treatment plus MSC:~MSC+prednisone+cyclosporine;~MSC+prednisone+tacrolimus;~MSC+prednisone+mycophenolate mofetil."
3353968|NCT02291770|Placebo Comparator|Placebo|"Patients with newly diagnosed cGvHD receive primary treatment:~Placebo+prednisone+cyclosporine;~Placebo+prednisone+tacrolimus;~Placebo+prednisone+mycophenolate mofetil."
3244555|NCT01329471||Umbilical cord blood|
3353969|NCT02291783|Experimental|HTL0009936|HTL0009936 single and multiple ascending oral doses.
3244556|NCT01329484|Experimental|Cognitive training|
3244557|NCT01329484|Experimental|Reminiscence therapy|
3244558|NCT01329484|Other|Control|This group will receive neither of the above interventions or any other similar interventions
3244559|NCT01329497|Experimental|interventional group|
3244560|NCT01329510|Experimental|methylphenidate|
3244561|NCT01329523||Subjects with AD|Subjects with a diagnosis of dementia
3244562|NCT01329523||Family Members|Younger biological family members of the patients with dementia
3353970|NCT02291783|Placebo Comparator|HTL0009936 Placebo|HTL0009936 matching placebo
3353971|NCT02291796|Experimental|Bezafibrate group|Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment
3353972|NCT02291796|No Intervention|Control group|Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment
3353973|NCT02291809|Experimental|REMUNE|Remune vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 10 μg of p24 antigen in approximately 100 μg of total protein.
3353974|NCT02291809|Placebo Comparator|REMUNE Low Dose|Remune low dose vaccine consists of a suspension of killed HIV-1 virus particles that have been emulsified with Incomplete Freund's Adjuvant (IFA, a mixture of mannide mono-oleate and a highly purified mineral oil). Each dose is given by IM injection and contains 2.5 μg of p24 antigen in approximately 25 μg of total protein.
3244563|NCT01329523||Control Group|Individuals without dementia matched in age to the patients with a dementia diagnosis
3244564|NCT01329536||AD Patients with Agitation|Patients with a diagnosis of probable Alzheimer's Disease who show signs of agitation based on the Cohen-Mansfield Agitation Inventory
3353975|NCT02291874|Experimental|Ipragliflozin group|Ipragliflozin treatment
3353976|NCT02291887||Neovascular ARMD Patients|Patients with Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab but Resistant to Aflibercept Treatment
3353977|NCT02291900|Active Comparator|medial femoral condyle|Patients in this arm receive core decompression followed by free vascularized medial femoral condyle graft
3353978|NCT02291900|Active Comparator|core decompression|Patients in this arm receive core decompression followed by osseous autograft from the iliac crest
3353979|NCT02291926|Experimental|hUC-MSC treatment|Patients will receive human umbilical cord mesenchymal stem cells transplantation with a 12 months follow-up.
3353980|NCT02291939||Parotidectomy|Patients with an indication for surgical intervention for a parotidectomy.
3353981|NCT02291952|Experimental|Experimental|During Forced Desynchrony sleep and wake will occur at different circadian phases, while meals are restricted to the biological day.
3353982|NCT02291952|Other|Control|During Forced Desynchrony sleep and wake, as well as meals, will occur at different circadian phases.
3353983|NCT02291978|Experimental|ExAblate 2100 Treatment|The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
3353984|NCT02291991|Experimental|Group A|"Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo~(1 subject : GX-E2, 1 subject : Placebo)~Subjects in group A will be injected drug, So we observe safety. After three days, Subject in group B will be injected drug."
3353985|NCT02291991|Experimental|Group B|Drug : GX-E2 - Intravenously injection once day at dose 8 ug/kg Drug : Placebo (7 subjects : GX-E2, 1 subject : Placebo)
3353986|NCT02292004|Experimental|ACL repair with MIACH scaffold|Patients will undergo ACL repair surgery using the newly developed MIACH scaffold
3353987|NCT02292004|Active Comparator|Standard ACL reconstruction|Patients will undergo a standard ACL reconstruction surgery
3244565|NCT01329536||AD Patients without Agitation|Patients with a diagnosis of probable Alzheimer's Disease who do not show signs of agitation based on the Cohen-Mansfield Agitation Inventory and are matched in both age and gender to the AD Patients with Agitation
3353988|NCT02292017|Experimental|Embolization of intracranial aneurysm|Embolization with Target Coils
3353989|NCT02292030||cardioversion+HTEA|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion+HTEA.
3353990|NCT02292030||only cardioversion|Heart failure patients accompanied by atrial fibrillation receive the treatment of cardioversion, but not with HTEA.
3353991|NCT02292043||idiopathic dilated cardiomyopathy group|idiopathic dilated cardiomyopathy group treated with HTEA
3353992|NCT02292043||post-myocardial infarction group|post-myocardial infarction group treated with TEA
3353993|NCT02292056|Experimental|Counseling Group|Participation in the study will be completed in a single session and will involve a pre-counseling questionnaire, followed by a pre-counseling quiz, individualized counseling session, post-counseling quiz and post-counseling questionnaire.
3353994|NCT02292069|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
3353995|NCT02292069|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
3353996|NCT02292095|Experimental|TAPB group|Participants in this group will receive transverse abdominis plane block combined with patient controlled intravenous analgesia.Transverse abdominis plane block will be guided by ultrasound and 0.75% 20 ml ropivacaine will be injected with the sonographic view at the end of the surgery.Participants in this group will also receive patient controlled intravenous analgesia after surgery,the regimens of patient controlled intravenous analgesia are included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total
3353997|NCT02292095|Active Comparator|PCIA group|Participants in this group will only receive patient controlled intravenous analgesia after surgery.The formula of the PCIA included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
3353998|NCT02292108|Experimental|Hypnosis and dietetic counselling|Patient will benefit of usual dietetic counselling and experimental hypnosis
3353999|NCT02292108|Other|dietetic counselling|Patient will only benefit of usual dietetic counselling
3354000|NCT02292121|Experimental|obese group|40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
3354001|NCT02292121|Active Comparator|non-obese control group (T1)|30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
3354002|NCT02292121|No Intervention|non obese control group undergoing a surgery (T2)|40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins
3354003|NCT02292134|Experimental|earplug and sleep mask|
3354004|NCT02292134|No Intervention|control|
3354005|NCT02292173|Experimental|Trametinib plus Sorafenib|"Dose Escalation Followed by Dose Expansion.~Trametinib: Daily (To start on day 8 during cycle 1 and on day 1 from cycle 2 onwards), according to dose level upon entry.~Sorafenib: Twice daily, according to dose level upon entry.~Each cycle is repeated every 28 days."
3244566|NCT01329588|Placebo Comparator|Sugar pill|
3244567|NCT01329588|Experimental|Treatment arm|
3244568|NCT01329601|Experimental|Cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
3244569|NCT01329601|Active Comparator|Booklet-based training|Home based training of episodic memory using paper-pencil exercizes
3354006|NCT02292199|Experimental|TENS High Frequency 100 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
3354007|NCT02292199|Active Comparator|TENS Low Frequency 4 Hz|TENS was applied for thirty minutes, with the frequency defined according to randomization. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
3354008|NCT02292199|Placebo Comparator|TENS Placebo|The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
3354009|NCT02292225|Experimental|IPI-145 in Combination with Obinutuzumab|
3354010|NCT02292238|Experimental|Benfotiamine|The patients in this arm will be treated with benfotiamine
3354011|NCT02292238|Placebo Comparator|Placebo|The patients in this arm will be treated with placebo
3354012|NCT02292251|Active Comparator|Device-assisted therapy|30 hours of therapy with the ArmeoPower device, a commercially available device for arm rehabilitation
3354013|NCT02292251|Active Comparator|Therapy-based occupational therapy|30 hours of conventional occupational therapy that emphasizes task-oriented training.
3354014|NCT02292264||Surgical treatment of ventral hernia|Adult patients who underwent a ventral hernia Repair at Zealand University hospital
3354015|NCT02292277||NSTEMI patients|Subjects eligible for the study will be ticagrelor naïve patients with NSTEMI presenting at the emergency room. Upon arrival to the emergency room written informed consent will be obtained before the patients receive their 180 mg loading dose of ticagrelor, as prescribed by the responsible physician.
3354016|NCT02292277||SCAD controls|Patients with stable coronary artery disease (SCAD) planned for elective angiography. If PCI is to be performed and if the responsible physician decides to administrate a loading dose of 180 mg ticagrelor, written informed consent will be obtained before loading dose and blood sampling.
3354017|NCT02292290|Active Comparator|Monotherapy 2|addition of Sulfonylurea or Pioglitazone to Metformin
3354018|NCT02292290|Experimental|Dual Therapy 1|Swap Liraglutide for sulfonylurea or pioglitazone taken as second line therapy (Metformin) first line)
3354019|NCT02292290|Active Comparator|Dual therapy 2|Maintain sulfonylurea or pioglitazone as second line therapy (Metformin first line)
3354020|NCT02292290|Experimental|Monotherapy|Addition of Liraglutide to Metformin
3354021|NCT02292303|Experimental|zinc-enriched yeast|zinc-enriched yeast capsules
3244570|NCT01329614|Experimental|Nicotine Replacement Therapy, 7mg dose|
3354022|NCT02292303|Active Comparator|zinc oxide|zinc oxide capsules
3354023|NCT02292303|Active Comparator|zinc gluconate|zinc gluconate capsules
3354024|NCT02292316|Experimental|Fall with fracture|Fall with fracture in the last 6 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
3354025|NCT02292316|Sham Comparator|controls|Fall without fracture in the last 12 months; Interventions : behavioral, biological and other; Behavioral intervention includes gait and cognitive assessments Blood sample Osteodensitometry
3354026|NCT02292329|Active Comparator|150g of acai fruit|150g of acai fruit in fruit smoothie form
3354027|NCT02292329|Placebo Comparator|Placebo control|The control will be a smoothie-like drink matched for major macro- and micro-nutrients
3354028|NCT02292342|Active Comparator|0.1 mg/ kg BW pure (-)-epicatechin|0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3354029|NCT02292342|Active Comparator|0.5 mg/ kg BW pure (-)-epicatechin|0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3354030|NCT02292342|Active Comparator|1.0 mg/ kg BW pure (-)-epicatechin|1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.
3244571|NCT01329614|Experimental|Nicotine Replacement Therapy, 21mg dose|
3244572|NCT01329614|Placebo Comparator|Nicotine Replacement Therapy, Placebo|
3244573|NCT01329614|Experimental|Nicotine Replacement Therapy, 42mg dose|
3244574|NCT01329627|Experimental|Paclitaxel/doxorubicin/cyclophosphamide|
3244575|NCT01329640|Experimental|Paclitaxel, trastuzumab, doxorrubicin, ciclophosphamide|
3244576|NCT01329653|Experimental|aerobic training|12 weeks of aerobic training, 4X/week
3244577|NCT01329653|Placebo Comparator|wait list control|wait list control condition, 12 weeks to parallel the active intervention group
3244578|NCT01329666|Experimental|50,000 IU Vitamin D3|
3244579|NCT01329666|Placebo Comparator|Placebo (inactive Vitamin D3)|
3244580|NCT01329692|Experimental|Lifestyle counseling|"This is a seven-week group education, counseling, nutrition, exercise, and journaling program of the Duke Metabolic and Weight Loss Surgery Center designed to help postoperative bariatric surgery patients who are failing to progressively lose weight resume an expected pattern of weight loss and improved overall outcome.~Weeks 1 and 2 consist primarily of a review of current dietary habits. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed."
3244581|NCT01329692|No Intervention|RYGB regular post-op care|Regular care and follow-up after RYGB surgery
3244582|NCT01329705|Active Comparator|Control|All patients will be treated with the current standard of care including onabotulinum toxin
3244583|NCT01329705|Experimental|Dynasplint|Patients in the experimental Dynasplint group will be treated with the current standard of care, including onabotulinum toxin, and use the Ankle Dorsiflexion Dynasplint
3244584|NCT01329718|Experimental|CRC Group|
3244585|NCT01329731|Active Comparator|Test|1.25% fluoride (elmex® gelée)
3244586|NCT01329731|Placebo Comparator|Control|0% fluoride (negative control)
3244587|NCT01329744|Experimental|Treatment|Recombinant IGF-I
3244588|NCT01329744|Placebo Comparator|Placebo|
3244589|NCT01329757|Active Comparator|GH|Administration of a daily dose of GH (0.4mg)for 1 year
3244590|NCT01329757|Placebo Comparator|Placebo|Administration of a daily dose of placebo for 1 year
3244591|NCT01329770|Experimental|Ascorbic Acid and alpha-tocopherol|Two daily doses of the combination of antioxidants, administered at breakfast and dinner
3244592|NCT01329770|Placebo Comparator|Placebo|Two daily doses of placebo, administered at breakfast and dinner
3244593|NCT01329783||EuroSIDA sub-cohort|HIV infected patients in the EuroSIDA cohort who meet the entry criteria for maraviroc pivotal clinical trials (MOTIVATE 1 and MOTIVATE 2)
3244594|NCT01329796|Experimental|Pertubation with Endole® (lignocaine)|Three treatments were to be given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
3354031|NCT02292342|Placebo Comparator|0.0 mg/ kg BW pure (-)-epicatechin|Water only (3 ml/kg BW)
3354032|NCT02292355|Experimental|Pilates|Intervention group will undergo Pilates sessions in addition to conventional treatment with occlusal splint
3354033|NCT02292355|No Intervention|Occlusal splint|Control group who receive conventional treatment with occlusal splint
3354034|NCT02292368|Experimental|Acupuncture - One Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
3354035|NCT02292368|Experimental|Acupuncture - Different Type|"Participants recruited between weeks 3-5 of radiotherapy. Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.~At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.~Participants also have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes."
3354036|NCT02292381||Glaucoma Patients|Patients with primary open angle glaucoma
3354037|NCT02292381||Healthy controls|age- and sex matched controls
3354038|NCT02292394|Experimental|Multicomponent Cognitive Behavioral Telephone Intervention|In this study, we will apply a telephone intervention that is a modified version of a brief prevention intervention for depressed caregivers that previously was applied in person in a group format during five 90-minute sessions (Vazquez et al., 2014). During the intervention, participants will be trained in various behavioral and cognitive abilities such as increasing pleasant activities, self-reinforcement, relaxation techniques, assertive communication, strategies to increase social contacts and social skills, and strategies to increase positive thoughts and decrease depressive ones.
3354039|NCT02292394|Experimental|Telephone Intervention Pleasant Activities|This intervention is also a modified version of a protocol described by Vazquez et al. (2014). However, in this case, we will specifically focus on the behavioral activation components of the multicomponent cognitive-behavioral telephone intervention. This intervention will also be structured in groups and administered by phone in five 90-minute sessions.
3244595|NCT01329796|Placebo Comparator|Placebo|Pertubation with Ringer solution, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
3354040|NCT02292394|No Intervention|Usual care|Individuals assigned to this group will receive no intervention or material, but they will have unrestricted access to any routine medical or psychological care that they might want to seek to treat depressive symptoms. The use of such treatments will be recorded.
3354041|NCT02292407|Experimental|LigaSure Precise instrument|ALND with use of LigaSure Precise instrument, closure of dead space, omission of a postoperative drain.
3354042|NCT02292459|Experimental|PEG 3350|Participants will receive a 17 g oral dose of 1 sachet of PEG 3350 mixed in 120 to 240 mL of water, once a day, for 7 days.
3354043|NCT02292459|Active Comparator|PEG 4000|Participants will receive a 10 to 20 g oral dose of 1 to 2 sachets of PEG 4000 mixed in 120 to 140 mL of water, once a day, for 7 days.
3354044|NCT02292472|Experimental|Medytoxin®|Botulinum toxin type A
3244596|NCT01329809|Experimental|JX-594 Intravenous infusion|JX-594 will be administered intravenously to patients with measurable intra-hepatic disease who are not eligible for intratumoral injection of JX-594.
3244597|NCT01329809|Experimental|JX-594 Intratumoral Injection|JX-594 will be injected directly into the liver tumor of patients who have at least two measurable intra-hepatic tumors, one of which must be at least 1.5cm in diameter and safety injectable.
3244598|NCT01329822|Experimental|Caloric restriction group|CR group were educated by a dietitian to reduce their usual energy intake to 1400 kcal/day (-500 kcal/day, -26% from baseline) for weight reduction and the recommended macronutrient composition was the 50-55% of energy intake as carbohydrate, 15-20% as protein and 20-25% as fat. Daily energy intake and nutrient composition were determined using a computer-aided nutritional analysis program (CAN-Pro 3.0; Korean Nutrition Society, Seoul, South Korea).
3244599|NCT01329822|No Intervention|Control group|Control group - ad libitum diet
3244600|NCT01329835|Experimental|Written information via brochure|Written information by a brochure
3244601|NCT01329835|No Intervention|standard care|standard prenatal care
3244602|NCT01329835|Experimental|Lifestyle counseling|Psycho-education based on principles of motivational interviewing and positive reinforcement
3244603|NCT01329861|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
3244604|NCT01329861|No Intervention|Control condition|Wait-list condition, received treatment after post-treatment assessment.
3244605|NCT01329874|No Intervention|Gow gates ,conventional block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
3244606|NCT01329874|No Intervention|Buccal infiltration, Lingual infiltration|
3244607|NCT01329887|Other|administration of ketanserin|
3244608|NCT01329913|Experimental|GT1-HCV 200 mg|
3354045|NCT02292472|Placebo Comparator|Normal Saline|Normal Saline
3244609|NCT01329913|Experimental|GT1-HCV 400 mg|
3354046|NCT02292485||Physicians - Texas Academy of Family Physicians|Physicians attending Texas Academy of Family Physicians event asked to fill out an anonymous survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
3354047|NCT02292498|Experimental|FLIR ONE thermal camera|Thermal camera (FLIR ONE)
3354048|NCT02292511|Experimental|Square-Stepping Exercise Intervention|Participants in this group will attend a square-stepping exercise intervention 60 minutes on two days a week at a community location.
3354049|NCT02292511|No Intervention|Usual-care wait-list control|This group will receive standard care and be invited to partake in the intervention after all assessments have been completed.
3354050|NCT02292524|No Intervention|Arm I: Control|Men in this group consumed a tomato free diet for the duration of the study (less than or equal to 5 mg lycopene/day) and, thus, did not consume a tomato intervention product.
3354051|NCT02292524|Experimental|Arm II: Juice|Commercially-available tomato food product: men in this group consumed V8® juice (11-16.5 fl. oz./day).
3354052|NCT02292524|Experimental|Arm III: Soup|Commercially-available tomato food product: men in this group consumed Campbell's® Tomato Soup (2-2 ¾ cups/day).
3354053|NCT02292524|Experimental|Arm IV: Sauce|Commercially-available tomato food product: men in this group consumed Prego® spaghetti sauce (5-7 oz./day).
3354054|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
3244610|NCT01329913|Experimental|GTI-HCV 800 mg|
3244611|NCT01329913|Experimental|GT3-HCV 200 mg|
3354055|NCT02292550|Experimental|Ribociclib 100 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
3354056|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 300 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
3354057|NCT02292550|Experimental|Ribociclib 200 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
3354058|NCT02292550|Experimental|Ribociclib 300 mg + Ceritinib 450 mg|LEE011 capsule for oral use (ribociclib) and Ceritinib for oral use
3354059|NCT02292563|Experimental|endoscopist only|Single inspection by endoscopist during colonoscopy
3354060|NCT02292563|Experimental|nurse participation|Dual inspection by both an endoscopist and an experienced nurse during colonoscopy
3354061|NCT02292576|Experimental|Acute dose/Chronic dose|Acute dose/Chronic dose.
3244612|NCT01329913|Experimental|GT3-HCV 400 mg|
3354062|NCT02292576|Experimental|Chronic dose/Acute dose|Chronic dose/Acute dose.
3354063|NCT02292589|Experimental|Frontal Stimulation|Left dorsolateral prefrontal cortex stimulation
3354064|NCT02292589|Experimental|Temporal Stimulation|Left temporal cortex stimulation
3354065|NCT02292589|Experimental|Sham Stimulation|Sham stimulation
3354066|NCT02292602|Experimental|Family-Based Weight Control Intervention|Families will receive the FBWC
3354067|NCT02292602|No Intervention|Control|Families will continue with standard of care at WIC
3244613|NCT01329913|Experimental|GT3-HCV 800 mg|
3244614|NCT01329926||Neural stem cells|
3354068|NCT02292615||cervical cancer|Group 1: Patients with newly diagnosed gynecologic cancers (including cervical, endometrial, and ovarian cancers).
3354069|NCT02292615||endometrial cancer|Group 2: Patients with suspicious recurrent gynecologic cancers (including cervical, endometrial, and ovarian cancers).
3354070|NCT02292615||ovarian cancer|Group 3: Patients with ovarian cancer who had debulking surgery and are going to receive adjuvant chemotherapy.
3244615|NCT01329952||Current intravenous drug users|Those who were actively injecting drugs at the time of their hepatitis C treatment.
3244616|NCT01329952||Past drug users|Those who stopped injecting drugs intravenously at least 6 months prior to the start of treatment for hepatitis C
3244617|NCT01329965|Experimental|LPS|LPS will be injected at a dose of 0.6 ng/kg body weight through a catheter by a trained GCRC staff member involved with this study.
3244618|NCT01329965|Placebo Comparator|Saline|A saline solution will be injected through a catheter by a trained GCRC staff member involved with this study.
3244619|NCT01329991|Active Comparator|oral dose of 200 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3354071|NCT02292628|Experimental|Mesenchymal stem cells|Autologous mesenchymal stem cells from the adipose tissue in an unique intralesional infusion with a dose of 40 million cells.
3354072|NCT02292628|Placebo Comparator|Ringer lactate solution|Ringer lactate solution
3354073|NCT02292641|Other|Patients with advanced or recurrent rectal cancer|Provide these patients with a compartmentalized radiology report which will provide surgeons with data on optimal exenterative surgery
3354074|NCT02292667|Experimental|TAP BLOCK|"Patients included in the ETAP group will receive the combination of a bilateral ultrasound-guided Transversus Abdominis Plane (TAP) block and a multimodal intravenous analgesia protocol for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The TAP block consists in 2 ultrasound-guided injections of Ropivacaine 0.375% on each side of the abdominal wall between the internal oblique and transversus abdominis muscles: 1 subcostal injection and 1 supra-iliac injection (i.e 10 ml of Ropivacaine 0.375% by injection).~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
3244620|NCT01329991|Active Comparator|oral dose of 400 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3244621|NCT01329991|Active Comparator|oral dose of 800 mg PLX5622|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3354075|NCT02292667|Active Comparator|CONTROL|"Patients included in the CONTROL group will receive a multimodal intravenous analgesia protocol alone for the postoperative pain management after the surgical open repair of an aortic abdominal aneurysm.~The multimodal intravenous analgesia protocol consists in the association of intravenous infusion of 1 g of Acetaminophen every 6 h and intravenous patient-controlled analgesia (PCA) with Chlorhydrate of Morphine 1 mg/ml."
3354076|NCT02292680||NICU Tooth Study Cohort|All study subjects will have been cared for in the Mount Sinai NICU and have had the same hospital environment exposure.
3354077|NCT02292693|Experimental|intubation with immobilized cervical spine|endotracheal intubation with immobilized cervical spine
3354078|NCT02292732|Experimental|Trametinib/ ORTHO-NOVUM® tablet|Subjects in treatment period 1will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 21 days (Days 1 through 21), followed by one placebo tablet once daily at approximately the same time each day for 7 days (Days 22 through 28). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for a total of 17 days (Days 12 through 28). Subjects in treatment period 2 will take one active tablet from the ORTHO-NOVUM® tablet 1/35 dial-pack once daily at approximately the same time each day for 11 days (Days 1 through 11). In addition, subjects will take trametinib 2 mg (1 tablet) once daily at approximately the same time each day for 11 days (Days 1 through 11).
3354079|NCT02292745|Experimental|Stereotactic radiotherapy|Standard of care FOLFIRINOX treatment followed by stereotactic radiotherapy
3244622|NCT01329991|Active Comparator|oral dose of PLX5622-dose to be determined|6 subjects will be randomized to take an oral dose of PLX5622 for 14 days and 2 subjects will be randomized to take placebo.
3354080|NCT02292810|Experimental|Inspiratory muscle exercise|Patients will exercise the inspiratory muscle using a load of 60% of maximum inspiratory mouth pressure (MIP 60%).
3354081|NCT02292810|Placebo Comparator|Inspiratory muscle exercise placebo|Patients will exercise the inspiratory muscle using a load of 2% of maximum inspiratory mouth pressure (MIP 2%).
3244623|NCT01329991|Placebo Comparator|Placebo Comparator|2 patients per cohort will be randomly assigned to take placebo. 8 patients total will be randomized to take placebo in this study.
3244624|NCT01330004||Hemodialysis patients|
3244625|NCT01330056|Active Comparator|FOPS|"Functional organ preservation surgery (FOPS) group as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group"
3244626|NCT01330056|Active Comparator|CRT|"Concurrent chemoradiotherapy or radiotherapy group as a first-line treatment modality~Salvage surgery may be applied for the patients for persistent or recurrent cancers after CRT or RT"
3244627|NCT01330082|Experimental|Photodynamic therapy|will be treated by PDT using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
3244628|NCT01330082|Experimental|Light-emitting diode Irradiation|will be treated only by using Light-emitting diode(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark)
3354082|NCT02292836||rosacea patients|Questionnaire testing on routine dermatologist patient population
3354083|NCT02292836||non-rosacea patients|Questionnaire testing on routine dermatologist patient population
3244629|NCT01330082|Experimental|applying photosensitizer|will be treated only by toluidine blue O
3354084|NCT02292862||MG Main Group|lymph node and blood sampling
3354085|NCT02292875||TG002 Subjects|Subjects previously randomised in study TG002
3354086|NCT02292888|Active Comparator|patients with LVEF >40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
3354087|NCT02292888|Active Comparator|patients with LVEF < or equal to 40%|Correlation between hemodynamic variable : SV and echocardiographic variable : Doppler VTI will be compared before and after Passive Leg Raising (PLR) test.
3354088|NCT02292901|Active Comparator|Macintosh laryngoscope|Tracheal intubation will be performed using a Macintosh laryngoscope
3354089|NCT02292901|Experimental|McGrath Mac videolaryngoscope|Tracheal intubation will be performed using a McGrath Mac videolaryngoscope
3354090|NCT02292914|Experimental|Robot-Assisted Surgery|patients undergoing robot assisted surgery for the treatment of cancer
3354091|NCT02292914|Active Comparator|Conventional Surgery|patients undergoing conventional surgery for the treatment of cancer
3354092|NCT02292966|Experimental|Hepatitis C treatment|12 weeks of DCV/ASV/BCV therapy.
3354093|NCT02292979|Active Comparator|ABVD|Patients in standard arm receive Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine on Day 1 and D14 of each 4-week-cycle during 4 cycles
3354094|NCT02292979|Experimental|AVD+BV|Patients in experimental arm receive Doxorubicin, Vinblastine, Dacarbazine and Brentuximab vedotin on Day 1 and D14 of each 4-week-cycle during 4 cycles
3354095|NCT02292992|Experimental|Nasal pillow CPAP|Nasal pillow CPAP
3354096|NCT02293005|Experimental|Alisertib|Alisertib administered by mouth at 50 mg twice a day for 7 days in each treatment cycle, followed by a 14-day, treatment-free period.
3354097|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 0.75% (w/w) MTC896 Gel
3244630|NCT01330095|Active Comparator|Eearly administration|Administration of Bifidobacterium within 48h after birth
3354098|NCT02293018|Experimental|0.75% (w/w) MTC896 Gel twice daily|Subjects will apply topically twice daily 0.75% (w/w) MTC896 Gel
3354099|NCT02293018|Experimental|1.5% (w/w) MTC896 Gel once daily|Subjects will apply topically daily 1.5% (w/w) MTC896 Gel
3244631|NCT01330095|Active Comparator|Late administration|Administration of Bifidobacterium more than 48h after birth
3259361|NCT01470183||Lupus Nephritis Patients|"Male or female subjects age 18 and older~Must have confirmed diagnosis of Class III or Class IV lupus nephritis by biopsy~Must have stable disease on medication at time of enrollment"
3354100|NCT02293031|Experimental|"Gene-activated matrix Nucleostim"|"Implantation of gene-activated matrix Nucleostim into the bone defects or sites of bone atrophy"
3354101|NCT02293057|Active Comparator|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
3354102|NCT02293057|Placebo Comparator|Girl Health Group (Attention Control)|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
3354103|NCT02293070|Experimental|Repeat Cardiac MRI Post Cryoablation|All subjects in this study receive a follow up delayed enhanced cardiac MRI 2-6 weeks after they undergo a cryoablation procedure.
3354104|NCT02293083|Experimental|Lidocaine|Group L received trigger point injection with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline
3244632|NCT01330121|Active Comparator|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
3354105|NCT02293083|Experimental|Hyaluronidase|Group H received trigger point injection with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L&H Pharm., Seoul, Korea) 600 iu/ml
3354106|NCT02293109|Experimental|Treatment (carfilzomib and hyper-CVAD)|Patients receive carfilzomib IV over 30 minutes on days 0, 1, 7, and 8. Patients also receive hyper-CVAD comprising cyclophosphamide IV over 2 hours every 12 hours for 6 doses beginning on day 1, vincristine sulfate IV on days 4 and 11, doxorubicin hydrochloride IV over 2-24 hours on day 4, and dexamethasone PO on days 1-4 and 11-14 (courses 1 and 3) and methotrexate IV over 24 hours on day 1, cytarabine IV over 2 hours every 12 hours for 4 doses starting on day 2, leucovorin calcium IV or PO every 6 hours beginning 36 hours after the start of methotrexate infusion, and methylprednisolone IV every 12 hours for 6 doses beginning on day 1 (courses 2 and 4). Patients with CD20 positive disease also receive rituximab twice daily on days 1 and 11 of courses 1 and 3 and days 1 and 8 of courses 2 and 4. Treatment repeats every 3-4 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3354107|NCT02293122||Observational|Observational group exposure to three test devices and one comparative device. The test Konan Non-con Robo Pachy F&A Specular Microscope.
3354108|NCT02293135|Experimental|Group 1|Verum Stendo session on V1 and Phantom Stendo session on V2
3354109|NCT02293135|Experimental|Group 2|Phantom Stendo session on V1 and Verum Stendo session on V2
3244633|NCT01330121|No Intervention|Standard therapy|Standard therapy: Nurses distribute a education pamphlet on diabetes
3354110|NCT02293148|Experimental|GSK1278863 (Part A)|All subjects will receive a single, oral 500 mg dose of GSK1278863 on Day 1 administered as 5 x 100 mg tablets of GSK1278863. Additional doses/cohorts may be added depending upon the emerging safety, tolerability, pharmacokinetic and/or pharmacodynamics findings at the 500 mg dose level in Part A
3354111|NCT02293148|Experimental|GSK1278863 (75 mg/500 mg)/Moxifloxacin 400 mg/Placebo (Part B)|Subjects will be assigned to one of four treatment sequences (A-1 x Moxifloxacin placebo tablet, 3 x 25 mg tablets of GSK1278863, 2 x GSK1278863 matched placebo; B-1 x Moxifloxacin placebo tablet, 5 x 100 mg tablets of GSK1278863; C-1 x Moxifloxacin placebo tablet, 5 x GSK1278863 matched placebo tablets; D-1 x 400 mg Moxifloxacin tablet, 5 x GSK1278863 matched placebo tablets) (ABDC, BCAD, CDBA, DACB) in accordance with the randomization schedule
3354112|NCT02293161|Experimental|Cohort A GSK2618960|Subjects will receive GSK2618960 0.6 milligram per kilogram (mg/kg)
3354113|NCT02293161|Placebo Comparator|Cohort A Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
3354114|NCT02293161|Experimental|Cohort B GSK2618960|Subjects will receive GSK2618960,planned dose being 2mg/kg. However, actual dose level for Cohort B may be adjusted based on the emerging data on safety, tolerability, PK and RO from Cohort A. The maximum dose will not exceed 2.4 mg/kg (i.e. a 4-fold dose escalation from 0.6 mg/kg)
3354115|NCT02293161|Placebo Comparator|Cohort B Placebo|Subjects will receive Sodium Chloride Intravenous as placebo
3354117|NCT02293187|Active Comparator|vitamin D3|Vitamin D3, 800 IU will be given initially; after 4 months if D level < 70 nmol/L, increase dose to 1600 IU for remainder of study.
3354118|NCT02293187|Placebo Comparator|Placebo|Placebo, microcrystalline cellulose
3354119|NCT02293200|Experimental|Traditional learning|chest compression group learning without CPR feedback device. After a month of quality control of chest compressions is made also without the device.
3354120|NCT02293200|Experimental|Experimental learning|Training is done using TrueCPR feedback device. After a month of quality control of chest compressions is made without the device. To do this will be indicated on the impact of the use of feedback devices for improving the effectiveness of training in CPR.
3354121|NCT02293213|Active Comparator|Counseling only|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling only will receive: CTIS Counseling, Baseline Questionnaire, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
3354122|NCT02293213|Experimental|Counseling + Contraception Appointment|All participants who receive EMR referral to CTIS because they are taking class D or X medications AND are randomized to counseling + Contraception Appointment will receive: CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow up Questionnaire, and 6 Month Follow up Questionnaire.
3354123|NCT02293226|Experimental|Child ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3244634|NCT01330147||Tonsillectomy|Subjects undergoing tonsillectomy for non-cancer reasons including operations for: recurrent tonsillitis, asymmetric tonsils, snoring surgery or obstructive sleep apnoea.
3244635|NCT01330160||cohort of stroke patients|patients, over 40 years old and without dementia, displaying an hemorrhagic or an ischemic stroke, with a sus-tentorial localization, and included 72h before the onset of symptoms
3354124|NCT02293226|Experimental|Infant ETI with chest compressions|endotracheal intubation (ETI) during infant mannikin resuscitation with uninterrupted chest compressions
3354125|NCT02293239|No Intervention|Control Group|"usual care control group receives individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
3354126|NCT02293239|Experimental|WB-EMS group|"physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)~+ individualized nutritional support (dietary advices: daily protein intake > 1.0 g/kg bodyweight)"
3354127|NCT02293252|Experimental|Interventional group|Remote patient monitoring system (Motiva)
3354128|NCT02293252|No Intervention|Control group|Best medical treatment according to the guidelines of the European Society of Cardiology (ESC)
3354129|NCT02293265|Other|Non-drug interventional group|All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants.
3354130|NCT02293278|Experimental|Physical Activity Intervention|"The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
3354131|NCT02293278|No Intervention|Control Group|"Day cares randomly assigned to the control group will continue with their existing programming. Day care providers will receive the PA intervention upon completion of their involvement in the 6 month trial, including: 2 three hour educational workshops, Healthy Opportunities for Preschoolers manual and program outlining the ideal implementation of activities from the manual.~During the 6 month intervention, Preschoolers Activity Trial staff will visit the day care facilities to conduct baseline, 3 month, and 6 month measurements."
3354132|NCT02293291|Active Comparator|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
3354133|NCT02293291|Placebo Comparator|MIneral water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in reducing violence based on previous research."
3354134|NCT02293304|Experimental|Self-etch approach|Application of universal adhesive as self-etch mode
3354135|NCT02293304|Experimental|Etch-and-rinse approach|Application of universal adhesive as etch-and-rinse mode
3354136|NCT02293317|Experimental|M-001 0.5mg & TIV|M-001 (0.5mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3354137|NCT02293317|Experimental|M-001 1.0mg & TIV|M-001 (1.0mg) administered intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3354138|NCT02293317|Placebo Comparator|Placebo & TIV|0.3ml Saline administered Intramuscular 3 times at 21 days intervals followed by vaccination with Trivalent Influenza Vaccine (TIV)
3354139|NCT02293330|Experimental|C group|continuous infusion of levobupivacaine
3354140|NCT02293330|Experimental|B group|Intermittent bolus infusion of levobupivacaine
3354141|NCT02293343||control group|healthy subjects
3354142|NCT02293343||IgE positive|patients with high IgE level in serum
3354143|NCT02293343||IBS patients|patients with afflictions, but no high IgE level and suspicion on histamine intolerance
3354144|NCT02293356|Experimental|Nimotuzumab Injection|200mg,Once a week，Intravenous infusion over 60 minutes
3244636|NCT01330173|Experimental|Treatment (vismodegib)|Patients receive vismodegib PO QD on days 1-28. Treatment repeats every 28 days for up to 11 courses in the absence of disease progression or unacceptable toxicity.
3244637|NCT01330186||Anal cancer|
3244638|NCT01330199|Experimental|TDF 150mg + MVC 150mg|Subjects will receive a single dose of tenofovir 150 mg and maraviroc 150 mg.
3244639|NCT01330199|Experimental|TDF 300mg + MVC 300mg|Subjects will receive a single dose of tenofovir 300 mg and maraviroc 300 mg.
3244640|NCT01330199|Experimental|TDF 600mg +MVC 600mg|Subjects will receive a single dose of tenofovir 600 mg and maraviroc 600 mg.
3244641|NCT01330199|Experimental|FTC 100mg + RAL 200mg|Subjects will receive a single dose of emtricitabine 100 mg and raltegravir 200 mg.
3244642|NCT01330199|Experimental|FTC 200mg + RAL 400mg|Subjects will receive a single dose of emtricitabine 200 mg and raltegravir 400 mg.
3244643|NCT01330199|Experimental|FTC 400mg + RAL 800mg|Subjects will receive a single dose of emtricitabine 400 mg and raltegravir 800 mg.
3244644|NCT01330238|Active Comparator|Zoledronic acid|Single infusion of 5 mg zoledronic acid I.V.
3244645|NCT01330238|Placebo Comparator|Placebo|Single infusion of 100 ml isotonic NaCl-solution I.V.
3244646|NCT01330251||Patients with diabetes having Roux-en-Y gastric bypass|
3244647|NCT01330251||Patients without diabetes having Roux-en-Y gastric bypass|
3244648|NCT01330251||Control subjects (patients having gastroscopy, no surgery)|
3244649|NCT01330264||Dyad|
3244650|NCT01330277||Participants with Hunter syndrome|Participants diagnosed with Hunter syndrome (Mucopolisaccharidosis type 2) aged between 2 months to 50 years
3354145|NCT02293369|Active Comparator|Cuff closure via vaginal route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. The repair will start at one end of the vaginal cuff, taking care to incorporate the uterosacral ligament into the initial bite and will continue toward the surgeon until the other uterosacral ligament will be incorporated into the repair, using a continuous 0-Vicryl suture in the vaginal route.
3354146|NCT02293369|Active Comparator|Cuff closure via laparoscopic route|For vaginal cuff closure both in laparoscopic approach and vaginal route, we will use the same horizontal method, which can be described as closing the vagina anterior to posterior by leaving a horizontal scar. In the laparoscopic approach, needles will be introduced through the umbilical trocar and removed through the peripheral trocars and intracorporeal knots will be utilized.
3354147|NCT02293408||Component 1|Component 1 involved an evaluation of the clinical characteristics of MPS IIIB in participants based on a retrospective chart review to collect information on demographics, clinical history, diagnostic tests, treatments, clinical chemistry and hematology test results, physical examination findings, anthropometric data, radiology results, and supportive interventions performed over a period of up to 6 weeks.
3354148|NCT02293408||Component 2|Component 2 involved a longitudinal evaluation of the course of disease progression in a subset of participants considered to be at risk of rapid disease progression, who, after completing Component 1, were to be prospectively followed for a period of at least 1 year (Longitudinal Follow-Up) and up to 3 years total (Extended Follow-Up).
3354149|NCT02293421|Other|STOP BANG|STOP BANG screening questionnaire and a snore question
3354150|NCT02293434||All Children (1 month to 18 years)|All children (1 month to 18 years) admitted to all PICUs in France during three one-week periods (February, June, October) in the course of a year
3354151|NCT02293447|No Intervention|Control|The control group will undergo uterine artery embolization according to regular protocol, without the administration of lidocaine.
3354152|NCT02293447|Experimental|Lidocaine per-embolization|This group will receive 10mL of 1% lidocaine in both uterine artery during the embolization; the lidocaine will be mixed with the embolization particles.
3354153|NCT02293447|Experimental|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after embolization endpoint is achieved.
3244651|NCT01330329|Experimental|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention.
3244652|NCT01330329|Experimental|Standard behavioral treatment (SBT)|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program.
3244653|NCT01330342||HIV patients without lymphoma|HIV-infected subjects on cART without a diagnosis of lymphoma
3244654|NCT01330342||HIV patients with lymphoma|HIV seropositive individuals with lymphoma
3244655|NCT01330407|Experimental|gp2|Cultured Epidermal Autografts
3244656|NCT01330407|Active Comparator|gp1|cryopreserved skin allografts.
3244657|NCT01330446|Experimental|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
3244658|NCT01330446|Placebo Comparator|Placebo|1 Placebo by mouth every morning for a 28 day cycle.
3244659|NCT01330472|Active Comparator|Xanax XR tablets 3 mg (sourced from Caugus)|Xanax XR tablets 3 mg (sourced from Caugus), 1 x 3 mg (REFERENCE)
3244660|NCT01330472|Experimental|Xanax XR tablets 3 mg (sourced from Barceloneta),|Xanax XR tablets 3 mg (sourced from Barceloneta), 1 x 3 mg (TEST)
3244661|NCT01330485|Experimental|Affect Regulation Training|Affect Regulation Training as described in Berking & Whitley, 2014.
3244662|NCT01330485|Active Comparator|Common Factor Control Condition (CFC)|Common factor based therapy control condition
3244663|NCT01330485|No Intervention|Waitlist Control Condition|Wait List Control
3244664|NCT01330498||Tysabri (natalizumab) infusing|Patients with relapsing forms of MS who participated in 001-001-TY and are currently still infusing with Tysabri (natalizumab).
3244665|NCT01330511||Bilateral Hydronephrosis Grade I-II|Patients with Bilateral Hydronephrosis Grade I-II
3244666|NCT01330511||Bil. Hydronephrosis Grade III-IV, Other|Patient with Bilateral Hydronephrosis Grade III-IV and others with any hydronephrosis and distended bladder or MCKD
3244667|NCT01330511||Unilateral Hydronephrosis Grade I-II|Patients with Unilateral Hydronephrosis Grades I-II
3244668|NCT01330511||Unilateral Hydronephrosis Grade III-IV|Patients with Unilateral Hydronephrosis Grade III-IV
3244669|NCT01330524|Active Comparator|Avastin and Triamcinolone|
3244670|NCT01330524|Placebo Comparator|Placebo|
3244671|NCT01330550|Experimental|high fiber sugar free biscuit.|High fiber sugar free biscuit will regulate Blood sugars.
3244672|NCT01330563|Experimental|CKD-501|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
3244673|NCT01330563|Experimental|ketoconazole|"Subjects received Ketoconazole 200 mg twice daily for 5 days in one period and in the other period, Subjects don't receive Ketoconazole.~In addition, The CKD-501 is administered on day 5"
3244674|NCT01330576|Placebo Comparator|Standard treatment of care at normothermia|Control group: Standard treatment of care at normothermia
3244675|NCT01330576|Experimental|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
3244676|NCT01330589|Experimental|AB: Placebo (A); St. Johns Wort (B)|Receive placebo for 7 days, 7 days washout and 7 days of St. Johns Wort
3244677|NCT01330589|Experimental|BA: St. Johns Wort (B); Placebo (A)|Receive St. Johns Wort for 7 days, 7 days washout and 7 days of placebo
3244678|NCT01330602|Experimental|Lifestyle counseling|"All participants randomised into the IMPRESS Intervention group will undergo tailored health profiling.This individual assessment will be carried out within the clinic setting.~The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy All the individuals in the intervention group will receive a comprehensive report on their risk status and ideal goals."
3354154|NCT02293473|Experimental|Protocol Group|"Using multimodal monitoring to optimise the patients' haemodynamic status, namely, the use of LiDCO Rapid, BIS-Bispectral Index Monitor and INVOS-Cerebral Oxygenation Monitor monitors to assess and fine tune the patient, as described in the study protocol in detail."
3354155|NCT02293473|Active Comparator|Control Group|Using current standard of care
3354156|NCT02293486|No Intervention|Control|Arm that followed all the protocols with the exception of the pomegranate juice intake.
3354157|NCT02293486|Experimental|Pomegranate Juice|Arm that followed all the protocols and the pomegranate juice intake.
3354158|NCT02293486|Experimental|Pomegranate Juice Dilution|Arm that followed all the protocols and the pomegranate juice dilution (1:1) intake.
3354159|NCT02293525|Active Comparator|Ropivacaine|Continuous 0.2% Ropivacaine infusion until catheter removal (typically 36 hours)
3354160|NCT02293525|Placebo Comparator|Saline|Continuous saline infusion until catheter removal (typically 36 hours)
3354161|NCT02293551|Experimental|Part A: Lispro (A)|Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.
3354162|NCT02293551|Experimental|Part A: Lispro (B)|Formulation B: Single dose of lispro administered SC in one of five periods.
3354163|NCT02293551|Experimental|Part A: Lispro (C)|Formulation C: Single dose of lispro administered SC in one of five periods.
3354164|NCT02293551|Experimental|Part A: Lispro (D)|Formulation D: Single dose of lispro administered SC in one of five periods.
3244679|NCT01330602|No Intervention|Usual care arm|"Usual Care Following the assessment of absolute cardiovascular risk, usual care participants will be provided a report outlining areas in which improvements could be made for the prevention of atherosclerotic burden.~No restrictions will be made in respect to usual care management. As such, the prescription of standard medications for primary prevention of atherosclerotic burden based on individual risk factors is anticipated in 20-30% of usual care participants.~At 18 months and three years those in the usual care arm will be invited to undergo repeat CIMT measurements, pathology, absolute risk score calculation and health-related questionnaires as part of the structured study follow-up"
3244680|NCT01330615|Active Comparator|Cryotherapy with EMLA|EMLA applied before cryotherapy
3354165|NCT02293551|Experimental|Part A: Lispro (Reference)|Reference formulation: Single dose of lispro administered SC in one of five periods.
3354166|NCT02293551|Experimental|Part B: Lispro|Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.
3244681|NCT01330615|Placebo Comparator|Cryotherapy with placebo analgesia|Placebo cream applied instead of EMLA
3244682|NCT01330641|Active Comparator|Anterior injection Route|Group of patients injected with medication using the anterior route
3244683|NCT01330641|Active Comparator|Posterior Injection|Group of patients receiving injection through a posterior route
3244684|NCT01330641|Active Comparator|Lateral Injection|Group of patients receiving subacromial injection through a lateral route
3244685|NCT01330654|Active Comparator|Beta blocker|These patients will be randomized to receive a standard dose of metoprolol (50mg) starting two weeks prior to surgery
3244686|NCT01330654|No Intervention|Control|This arm will receive no additional treatment prior to surgery
3244687|NCT01330667|Experimental|Formula Supplementation|Participants will supplement feedings with early limited formula following nursing.
3244688|NCT01330667|No Intervention|Control|Participants will be instructed to continue exclusively breastfeeding with no formula supplementation.
3244689|NCT01330680|Experimental|Coffee|
3244690|NCT01330680|Active Comparator|Decaffeinated coffee|
3244691|NCT01330693|Active Comparator|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children
3244692|NCT01330693|Placebo Comparator|Placebo|Sugar pill
3244693|NCT01330706|Experimental|Sterile Saline solution|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
3244694|NCT01330719|Experimental|Diseased periodontal treatment|Scaling and root planing along with systemic antibiotics (Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days).
3354167|NCT02293564|Experimental|gevokizumab|
3354168|NCT02293590|Experimental|intensive, adapted treatment strategy|"Experimental: intensive, adapted treatment strategy Certolizumab pegol (CZP, Cimzia (R)): 200mg every 2 weeks after loading d 400mg at Weeks 0, 2 and 4~DMARD:~Patients without sufficient treatment response will be taken to the next step according to the therapeutic algorithm or next drug, for example: 15=>25mg Metoject (R)/week => Leflunomide Gebro (R)20mg/d => Salazopyrine EN(R) 2000mg/d~Glucocorticoids:~At Week, 0 patients will be initiated on Spiricort (R) 20mg/d and tapered every 5 days~Joint injections:~Starting at Week 0 up to 5 joint injections may be conducted into synovitic joints at every visit of the study.~The maximum cumulative Lederlon (R) dose is 100mg/visit. Joints are to be infiltrated with the following doses of triamcinolone and lidocaine"
3354169|NCT02293590|Active Comparator|fixed-dosed program|"Intervention:~Certolizumab pegol (Cimzia (R), CZP) CZP of 400mg at Weeks 0, 2 and 4, followed by 200mg injections from Week 6, every 2 weeks until Week 24.~DMARD:~Patients are to continue to receive their stable weekly dose of DMARD as noted at study entry for the duration of the study (24 weeks)~Glucocorticoids:~Prednisolone (Spiricort (R)) daily dose of ≤ 10 mg~Joint injections:~None"
3354170|NCT02293603|Experimental|Allogeneic Cardiosphere-Derived Cells|"The Phase I study consists of a Phase Ia portion and a Phase Ib portion. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.~The Phase Ia portion is an open-label, dose escalation of Allogeneic Cardiosphere-Derived Cells (CDCs)."
3354171|NCT02293603|Placebo Comparator|Placebo|The placebo study arm only applies to the Phase Ib portion of the study design. The Phase Ia portion (N=14 subjects) consists of an open-label, single-arm, study design. The potentially conducted Phase Ib portion of the study (N=28 subjects) consists of a double-blind, randomized, placebo-controlled study design.
3354172|NCT02293616|Experimental|Nitrate Rich|A nitrate rich beetroot juice supplement (Beet It Shot®, James White Drinks, UK) high in nitrates will be provided to the subjects. Subject's diet will be supplemented once daily while hospitalized up to 14 days with one 70 ml bottle containing 300 mg of dietary nitrate.
3354173|NCT02293616|Placebo Comparator|Nitrate Depleted|This group will consume a beetroot juice supplement (Beet It Shot®, James White Drinks, UK) that has had the nitrate removed from the beverage by the manufacturer. Patient's diet will be supplemented once daily with one 70 ml bottle while hospitalized up to 14 days.
3354174|NCT02293629|Placebo Comparator|A1: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3354175|NCT02293629|Placebo Comparator|A2: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3354176|NCT02293629|Placebo Comparator|A3: BMS-986147 or Placebo matching BMS-986147|Single oral dose as specified
3354177|NCT02293629|Active Comparator|B1: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
3354178|NCT02293629|Active Comparator|B2: BMS-986147 or Placebo matching BMS-986147|Daily oral dose as specified
3354179|NCT02293655|Placebo Comparator|MPH Discontinuation|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will receive placebo (qAM)."
3354180|NCT02293655|Active Comparator|Sustained MPH|"Double-blind (DB) placebo-controlled 4-week methylphenidate (MPH) titration trial. Pts will receive 3 active dosages of MPH (children <25kg: 18mg, 27mg, 36mg; children >25kg: 18mg, 36mg, 54mg for) as well as 1 random week of placebo, given qAM. Pts will begin on the lowest dose (or a randomized placebo week) and proceed through all dose conditions in an incremental fashion.~DB 4-week MPH maintenance phase. The clinician, parent, and teacher ratings of behavior and side effects from the titration trial weeks will be graphed. Two doctors will blindly review the graphs and judge which week was the optimal dose week. Pts will then receive their optimal dose of MPH (qAM) for 4 weeks.~DB 4-week MPH Discontinuation Phase. Pts in this arm will continue their optimal MPH dose (qAM)."
3354181|NCT02293668|Active Comparator|Combined 450|Recombinant FSH 225IU/day and human menopausal gonadotropin (hMG) 225IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3354182|NCT02293668|Active Comparator|Combined 300|Recombinant FSH 150IU/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3354183|NCT02293668|Active Comparator|Letrozole and hMG|Letrozole (Femara; Novartis, East Hanover, NJ) at a dose of 5 mg/day and human menopausal gonadotropin (hMG) 150IU/day will be initiated on the second or third day of spontaneous menstruation and continued until the day of ovulation triggering. Ovulation triggering will be performed with the administration of 10000 IU of human chorionic gonadotropin (hCG) as soon as two-three follicles of 17 mm diameter will be observed by transvaginal ultrasound.
3354184|NCT02293681||Cohort 1: Infliximab and/or NSAIDs and DMRADs|Participants receiving intravenous infusion of infliximab with or without non-steroidal anti-inflammatory drugs (NSAIDs: aspirin, ibuprofen and naproxen) and Disease-modifying anti-rheumatic drugs (DMRADs: methotrexate (MTX), sulfasalazine, and thalidomide) will be observed.
3354185|NCT02293681||Cohort 2: NSAIDs and DMARDs|Participants receiving NSAIDs (aspirin, ibuprofen and naproxen) and DMARDs (MTX, sulfasalazine, and thalidomide) will be observed.
3354186|NCT02293694|Active Comparator|self-injection|Women randomized to this arm will be trained to self-inject Sayana Press at home every three months
3354187|NCT02293694|Active Comparator|provider injection|Women randomized to this arm will received Sayana press from a family planning provider every three months.
3354188|NCT02293707|Experimental|GX301 Regimen A (8 administrations)|Administration time frame: Day 1 to Day 63.
3244695|NCT01330719|Active Comparator|Conventional periodontal treatment|Standard periodontal prophylaxis
3354189|NCT02293707|Experimental|GX301 Regimen B (4 administrations)|Administration time frame: Day 1 to Day 63.
3354190|NCT02293707|Experimental|GX301 Regimen C (2 administrations)|Administration time frame: Day 1 to Day 63.
3354191|NCT02293720|Experimental|EndoBarrier Device|Subjects who participated in the control arm of study #09-1 who are not treatment failures and have completed 12 months of the study. These subjects will have the EndoBarrier device implanted for 12 months.
3354192|NCT02293733||Patients NSCLC EGFR mutated|This is an observational study, there is no intervention.
3354193|NCT02293746|Other|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System.
3354194|NCT02293759|Active Comparator|HoLEP|Holmium laser enucleation of the prostate
3244696|NCT01330732||1|Main group: patients examined in scoliosis clinic for kyphosis with recent lateral spine X-rays.
3244697|NCT01330745|Other|aortic valve replacement|
3244698|NCT01330758|Active Comparator|40 mg AZD8931 wet granulation tablet formulation|
3244699|NCT01330758|Experimental|40 mg AZD8931 roller compacted tablet formulation|
3354195|NCT02293759|Active Comparator|Greenlight laser PVP|Phtoselective vaporization of the prostate
3354196|NCT02293772|Active Comparator|Hypoxic ambulatory|Ambulatory in normobaric hypoxia
3354197|NCT02293772|Experimental|Hypoxic Bedrest|Bedrest in normobaric hypoxia
3244700|NCT01330771||hMG-HP/r-FSH|Patients with a condition
3244701|NCT01330784||hMG-HP|Patients with a condition
3244702|NCT01330797||LOCS III|Cohort is composed of cases with a diagnosis of wet age-related macular degeneration and those that received intravitreal ranibizumab
3244703|NCT01330810|Active Comparator|C3 tablet|4g C3 tablet
3244704|NCT01330810|Active Comparator|Meriva|2g Meriva powder
3244705|NCT01330823|Active Comparator|L-Carnitine|L-Carnitine 4 g daily for Intervention
3244706|NCT01330823|Placebo Comparator|Placebo|Placebo (tartaric acid)
3354198|NCT02293772|Active Comparator|Normoxic bedrest|Bedrest in normobaric normoxia
3244707|NCT01330849|Experimental|Toolkit intervention|
3354199|NCT02293811|Other|biopsy|"We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )~To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:~healthy patients;~patients with colonic Crohn disease in acute phase;~patients with colonic Crohn disease in chronic phase;~patients with ulcerative colitis in acute phase;~patients with ulcerative colitis in chronic phase;~patients with colon cancer"
3354200|NCT02293824||Premature infants|Premature infants <29 weeks birth gestational age receiving caffeine per standard of care for the prevention or treatment of apnea of prematurity.
3354201|NCT02293850|Experimental|single intra-tumoral injection|OBP-301 ; Cohort 1: 1x10 10 viral particle (VP)/ tumor Cohort 2: 1x10 11 viral particle (VP)/ tumor Cohort 3: 1x10 12 viral particle (VP)/ tumor
3354202|NCT02293876|Sham Comparator|Eye drop|Eye drop LACRIBELL® - two drops each eye, three times a day, after eye cleansing.
3354203|NCT02293876|Sham Comparator|Ocular gel|Ocular gel LIPOSIC® applied three times a day at the lower palpebra from medium line to the lateral border.
3354204|NCT02293876|Sham Comparator|Glad wrap|Occlusion of the orbital area with a Glad wrap, turning the area into a moisture chamber.
3354205|NCT02293876|No Intervention|Control group|Ocular cleansing three times a day.
3244708|NCT01330849|No Intervention|Waiting List Control Group|Children eligible for the study according to the inclusion criteria, but randomly allocated to the waiting list control group are promised to receive the intervention AFTER the study is finished.
3354206|NCT02293889|Experimental|Vitamin D|Vitamin D3 2000IU/daily 3 months
3354207|NCT02293889|Experimental|Physical Activity|PA intervention People with Osteoarthritis Walking Programme
3354208|NCT02293889|Experimental|Vitamin D and Physical Activity|Vitamin D3 2000IU/daily 3 months PA intervention People with Osteoarthritis Walking Programme
3354209|NCT02293889|Placebo Comparator|Placebo|Placebo capsule: edible oil
3244709|NCT01330888||Group 1|ARNG Chaplains
3244710|NCT01330901|Experimental|Ustekinumab|Ustekinumab 90 mg subcutaneously at week 0, 4 and 16
3354210|NCT02293915|Experimental|sodium oligo-mannurarate 900mg|
3354211|NCT02293915|Placebo Comparator|Placebo|
3354212|NCT02293928||Elective hybrid coronary revascularization|All patients are treated with non-enteric coated aspirin 75 mg once daily prior to study participation. Aspirin treatment is discontinued 8-10 days prior to surgery and resumed 6-9 hours after surgery. Left internal mammary grafting of the left descendent coronary artery is performed off-pump through an inferior J-hemisternotomy (JOPCAB). All patients receive an oral loading dose of aspirin 300 mg 6-9 hours after surgery followed by daily maintenance doses of 75 mg aspirin. An oral loading dose of clopidogrel 300 mg 12 hours prior to PCI is followed by daily maintenance doses of 75 mg for 12 months. Patients are followed for 1 year.
3354213|NCT02293941|Experimental|JKB-122 5mg|5mg, oral, once daily
3354214|NCT02293941|Experimental|JKB-122 15 mg|15mg, oral, once daily
3354215|NCT02293941|Experimental|JKB-122 35 mg|35mg, oral, once daily
3354216|NCT02293941|Placebo Comparator|placebo|comparable capsule, oral, once daily
3354217|NCT02293954|Experimental|Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)|Patients receive copper Cu 64 anti-CEA monoclonal antibody M5A IV on day 0 and then undergo PET on day 1 and day 2.
3354218|NCT02293967|Experimental|MT-1303|[14C] MT-1303 after a single oral dose
3354219|NCT02293980|Experimental|Part 1: PT2385 Tablets|PART 1: Multiple Dose/Dose-Escalation
3354220|NCT02293980|Experimental|Part 2: PT2385 Tablets and nivolumab|PART 2: PT2385 Tablets in combination with nivolumab
3354221|NCT02293980|Experimental|Part 3: PT2385 and cabozantinib tablets|PART 3: PT2385 Tablets in combination with cabozantinib tablets
3354222|NCT02294006|Experimental|everolimus+octreotide LAR+metformin|everolimus+octreotide LAR+metformin
3244711|NCT01330927|Experimental|VA106483 0.5 mg|
3244712|NCT01330927|Experimental|VA106483 1 mg|
3244713|NCT01330927|Experimental|VA106483 2 mg|
3354223|NCT02294032||Kidney Transplant|Patients who are about to undergo a kidney transplant and are on immunosuppressive agents.
3354224|NCT02294071|Experimental|acetaminophen|acetaminophen 15mg/kg (max 975mg)
3244714|NCT01330927|Experimental|VA106483 4 mg|
3244715|NCT01330927|Placebo Comparator|Sugar pill|
3244716|NCT01330940|Placebo Comparator|Water drinking|32 ounces of water/24 hours
3244717|NCT01330940|Active Comparator|orange soda drinking|32 ounces orange soda
3244718|NCT01330992|Experimental|Ocular Light or Dark Exposure|Ocular Light or Dark Exposure
3259362|NCT01470183||Control Patients|Any patient with an idiopathic glomerular disease who does not have lupus nephritis. This includes patients with minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis, and IgA nephropathy.
3354225|NCT02294071|Experimental|ibuprofen|ibuprofen 10mg/kg (max 600mg)
3354226|NCT02294071|Experimental|combination|acetaminophen 15mg/kg (max 975mg) and ibuprofen 10mg/kg (max 600mg)
3354227|NCT02294084|Experimental|Sitagliptin|Subjects will receive Sitagliptin in a dosage of 100 mg/day p.o. for 12 weeks. The dosage corresponds to 1 gift/day.
3354228|NCT02294084|Placebo Comparator|Placebo|Subjects will receive placebo for 12 weeks. Placebo will be given in 1 gift/day
3354229|NCT02294097|No Intervention|Non-biopsy|Population in this arm will be adjusted immunosuppressive drug only from the result of tough level.
3354230|NCT02294097|Experimental|Protocol biopsy|Population in this arm will be adjusted immunosuppressive drug upon both pathological findings and the result of tough level.
3354231|NCT02294110||diabetes mellitus|spinal anesthesia
3354232|NCT02294123|Experimental|Diabetes (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3354233|NCT02294123|Experimental|Overweight (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3354234|NCT02294123|Experimental|Healthy (3 tortillas and white bread)|"Each participants (n=27) receive in random order the following foods: 1) a whole corn tortilla (white criollo corn= 5.3% fiber), 2) a whole corn tortilla (white hybrid corn= 7.9%), 3) a traditional corn tortilla (3.9% fiber), and 4) white bread (reference food containing 2.2% of fiber)."
3354235|NCT02294136|Experimental|Prep-C|Four session nurse administered behavioral intervention.
3354236|NCT02294136|Active Comparator|Educational Control|Attention Control
3354237|NCT02294149|Placebo Comparator|Placebo|A ineffective placebo drug with the same taste, route of administration and physical appearance as the study drug (omega 3/Vit D 3) that has received approval by health Canada.
3354238|NCT02294149|Experimental|Omega 3 FA/Vitamin D3 sublingual|patients will be allocated randomly to receive Sub-lingual Omega 3 FA and Vitamin D3 supplements for 6 months, twice daily ,1/2 tea spoon with instructions to keep it under the tongue for 45 sec.
3354239|NCT02294162|Experimental|0.5 mg/kg body weight Ketamin|Patients allocated to this arm will receive an iv dose of 0.5 mg/kg body weight ketamine.
3354240|NCT02294162|Placebo Comparator|5 ml normal saline as placebo|Patients allocated to this arm will receive an iv dose of 5ml saline as placebo.
3354241|NCT02294188|Placebo Comparator|Placebo|Spatial Repellent product without active ingredient (SHIELD)
3354242|NCT02294188|Active Comparator|Intervention|Spatial Repellent product with active ingredient (SHIELD)
3244720|NCT01331031||Adolescents|Adolescents between 10 and 20 years of age and enrolled in a municipal school system.
3244721|NCT01331044|Experimental|RUTF|Ready to use Therapeutic Food (RUTF) Plumpy nut.
3244722|NCT01331044|Active Comparator|Khichuri - Halwa|Cereal Legume
3244723|NCT01331057||1:Sri Lankais|Children aged of four to six years old, in the nursery school and if their first language is unique : tamil.
3244724|NCT01331057||2: Algerian|Children aged of four to six years old, in the nursery school and if their first language is unique : arabic.
3244725|NCT01331057||3: Mali|Children aged of four to six years old, in the nursery school and if their first language is unique : SONINKE.
3244726|NCT01331070|Experimental|PATIENT|Patients, half with moderate (GOLD II) and half with severe (GOLD III) COPD
3244727|NCT01331070|Other|Accepts Healthy Volunteers|Control arm with the same intervention
3244728|NCT01331096||Anesthetic drugs manually administrated|
3244729|NCT01331096||Automated anesthesia delivery system|
3244730|NCT01331122|Experimental|droxidopa|Northera (2R,3S)-2-amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid L-DOPS L-threo-dihydroxyphenylserine Droxidopa SM-5688
3244731|NCT01331122|Placebo Comparator|placebo|placebo
3244732|NCT01331135|Experimental|sirolimus treatment|Dose escalation of sirolimus with starting dose at 1 mg/m2 and increasing to a possible 3 mg/m2.
3244733|NCT01331148|Active Comparator|Vitamin D|10,000 IU per caplet, with vitamin D dose based on weight, ranging from 240,000 IU to 600,000 IU. Patients will receive calcium/vitamin D daily soft chew as well.
3244734|NCT01331148|Placebo Comparator|Placebo|placebo only, all patients will receive calcium/vitamin D chew
3244735|NCT01331174|Experimental|High dose PSW groups|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W. These settings were based on the fact that applications with mean power below 20W minimize the thermal effects
3244736|NCT01331174|Placebo Comparator|Placebo|A placebo group was also established, in which the PSW device was turned on but kept in stand-by mode during 19 minutes without any electrical current being applied in the patients
3244737|NCT01331174|No Intervention|Control|The control group was composed of patients that were not submitted to any form of treatment and all patients were instructed to maintain their daily activities
3244738|NCT01331226|Experimental|3 session telephone counseling|
3244739|NCT01331226|Experimental|1 session telephone counseling|
3244740|NCT01331226|Active Comparator|written materials|
3244741|NCT01331252|Experimental|supine body position|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
3244742|NCT01331252|Experimental|semi-recumbent|Consecutive patients admitted with severe tetanus to the tetanus intensive care ward will be eligible to be included in the study. An envelope for the next study number will be opened in which patients will be randomly allocated to either semi-recumbent (30 degree) or supine (0 degree) body position
3244743|NCT01331265||no treatment|
3244744|NCT01331278|Active Comparator|Custom Cutting Blocks|
3244745|NCT01331278|Active Comparator|Computer Assisted Surgery|
3244746|NCT01331317|Other|Paricalcitol|Crossover study between paricalcitol and placebo
3244747|NCT01331330|Active Comparator|Group B|Low Programming
3244748|NCT01331330|Experimental|Group A|Normal Programming
3244749|NCT01331356|Experimental|Injection of botulinum toxin type A|
3259363|NCT01470209|Experimental|Combination of BKM120 and everolimus|
3354243|NCT02294201|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
3244750|NCT01331369|Active Comparator|Control|Usual care. It means routine medical care that include free demand consultation and free medicines.
3244751|NCT01331369|Experimental|Intervention|Intensification of care. Besides routine medical care that include free demand consultation and free medicines, subjects were invited to have 6 structured medical encounters based on a social-psychological approach. Doctors must follow a protocol to conduct the encounter that have around 30 minutes each.
3354244|NCT02294201|Active Comparator|Intervention|Spatial Repellent product with active ingredient
3354245|NCT02294214|Placebo Comparator|Placebo|Placebo Repellent product with no active ingredient
3244752|NCT01331382|Experimental|250mg trans- resveratrol|
3354246|NCT02294214|Active Comparator|Intervention|Spatial Repellent product with active ingredient
3354247|NCT02294240|Experimental|Arm One|Energy dense biscuits will be provided throughout pregnancy after enrolment
3354248|NCT02294240|Placebo Comparator|Arm Two|Wheat Flour,oil, iron and folic acid will be provided fortnightly throughout pregnancy after enrolment
3244753|NCT01331382|Experimental|250mg trans-resveratrol with 20mg piperine|
3354249|NCT02294266|Experimental|Mephedrone and alcohol|"Mephedrone 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
3354250|NCT02294266|Active Comparator|Mephedrone|"Mephedrone 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
3354251|NCT02294266|Active Comparator|Alcohol|"Lactose 200 mg, single dose, oral administration~Alcohol 0.8g/kg diluted in lemon-flavoured water (350 ml), single dose, oral administration"
3354252|NCT02294266|Placebo Comparator|Placebo|"Lactose 200 mg, single dose, oral administration~Lemon-flavoured water (350 ml), single dose, oral administration"
3354253|NCT02294279|Experimental|Active|4 weeks of corticosteroid treatment with QVAR (100mcg), 400 mcg daily; two puffs twice daily
3354254|NCT02294279|No Intervention|Placebo|Blinded placebo inhaler
3354255|NCT02294292|Experimental|Carvedilol + Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~if carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
3354256|NCT02294292|Active Comparator|Endoscopic Variceal Ligation (EVL)|
3354257|NCT02294305|Experimental|Vortioxetine|Vortioxetine 10 to 20 mg PO QD for 12 weeks.
3354258|NCT02294305|Placebo Comparator|Placebo|Placebo PO QD for 12 weeks.
3354259|NCT02294331||Attain Performa™ LV Leads|Patients who meet all Inclusion criteria and no Exclusion criteria and are implanted with an Attain Performa™ LV lead.
3244754|NCT01331382|Placebo Comparator|Placebo|
3354260|NCT02294344|Experimental|DFPP&CTX|double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP&CTX)
3354261|NCT02294344|Active Comparator|cyclophosphamide|cyclophosphamide(CTX) pulse therapy
3354262|NCT02294357|Experimental|Carfilzomib + Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration.
3354263|NCT02294357|Experimental|Carfilzomib + Prednisone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Prednisone (IV or PO) will be given prior to each carfilzomib administration.
3354264|NCT02294357|Experimental|Carfilzomib + Methylprednisolone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Methylprednisolone(IV or PO) will be given prior to each carfilzomib administration.
3354265|NCT02294357|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Lenalidomide will be given at the same dose and schedule as patient was receiving previously.
3354266|NCT02294357|Experimental|Carfilzomib+Pomalidomide+Dexamethasone|Carfilzomib will be administered at 70 mg/m2 as an infusion over 30 minutes on days 1, 8 and 15 of a 28-day cycle. Dexamethasone (IV or PO) will be given prior to each carfilzomib administration. Pomalidomide will be given PO at 4mg daily on days 1-21 of a 28-day cycle
3354267|NCT02294370||subjects at the early stages of diabetes|Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years)
3244755|NCT01331395|No Intervention|IVF-No Acupuncture|IVF with no Traditional Chinese Medicine: Acupuncture
3244756|NCT01331395|Active Comparator|IVF-Acupuncture|IVF with Traditional Chinese Medicine: Acupuncture
3244757|NCT01331460|Experimental|RBT Experimental|
3244758|NCT01331460|Active Comparator|Case-Management: Treatment as Usual|
3244759|NCT01331473|Active Comparator|Carotid Artery Stenting without Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and without embolic protection device
3354268|NCT02294383||Pre/post surgery pelvic floor assessment|
3354269|NCT02294383||Conservative treatmen monitoring|
3354270|NCT02294383||Pelvic floor muscle contrictions|
3354271|NCT02294383||Imaging reproducibility|
3354272|NCT02294409|Experimental|Cognitive-behavioral therapy (CBT)|Manualized group cognitive-behavioral therapy for social anxiety in first episode psychosis
3354273|NCT02294409|Active Comparator|Computer assisted Cognitive Remediation therapy (CACRT)|Group computer assisted cognitive remediation therapy
3354274|NCT02294422|Experimental|2. LOR and aneroid manometer group|after inflating the endotracheal tube (ETT) cuff using a loss of resistance syringe (BD Epillor LOR), the LOR syringe is left attached to the pilot balloon and and any excess pressure will be passively released until the plunger stops drawing back.
3244760|NCT01331473|Active Comparator|Carotid Artery Stenting with Proximal Protection|Subjects will undergo carotid artery angioplasty and stenting with any CE-certificated carotid stent and with a proximal embolic protection device provided by the GORE Neuro Protection System
3244761|NCT01331486|Placebo Comparator|Placebo|Placebo capsule
3244762|NCT01331486|Active Comparator|Low dose|
3244763|NCT01331486|Active Comparator|Mid dose|
3244764|NCT01331486|Active Comparator|High dose|
3244765|NCT01331499|Experimental|Bipolar Sealer|Standard of care blood sparing techniques with bipolar sealer
3244766|NCT01331499|Active Comparator|Control|Standard of care blood sparing techniques without the use of bipolar sealer
3354275|NCT02294422|Placebo Comparator|1. PBP and aneroid manometer group|The anaesthesia care provider shall inflate the ETT cuff via the pilot balloon with small volumes of air as he/she 'feels ' for the pressures in the pilot balloon to a pressure he/she thinks is just enough. An aneroid manometer (VBM, Germany. Accurate in the range 0-120 cmH2O +-2 cmH2O) shall then be attached by the investigator and measurement of the pressure taken.
3354276|NCT02294435|Experimental|Primary Study Arm|The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
3244767|NCT01331525|Experimental|Single stage non-randomised|"Patients will receive Carboplatin and Etoposide. Both Chemotherapy drugs will be delivered as a 21 day cycle (q21) with up to a maximum of 6 cycles delivered according to response unless progressive disease (RECIST Version 1.0) and or excessive toxicity.~Ipilimumab will be administered at a dose of 10mg/kg IV on day 1 of cycles 3-6 of Chemotherapy.~In the absence of immune related progression of disease or unacceptable toxicity, subsequent maintenance doses of Ipilimumab will be delivered every 12 weeks starting at week 30 at a dose of 10 mg/kg until unacceptable toxicity or immune related disease progression"
3244768|NCT01331538||adolescents with TMD|adolescents with temporomandibular dysfunction
3354277|NCT02294435|Experimental|Expanded Selection Arm|The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
3354278|NCT02294448|Experimental|cohort 1|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China） in low dosage(3.75mg)
3354279|NCT02294448|Experimental|cohort 2|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) in medial dosage(7.5mg)
3354280|NCT02294448|Experimental|cohort 3|Qishe Pill（Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China）in high dosage(15mg)
3354281|NCT02294487||Subjects|Individuals over 50 who are going to get the seasonal flu vaccine, pneumococcal, HIB, and/or meningococcal vaccination and either have multiple myeloma or do not have multiple myeloma.
3354282|NCT02294513||AD_HI|This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
3354283|NCT02294513||NC_HI|This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
3354284|NCT02294526|Experimental|Sardine diet|Subjects follow general dietary recommendations for diabetes including a fixed amount of sardine in daily meals (100g per day, 5 days a week) as part of their usual diet.
3354285|NCT02294526|No Intervention|Control diet|Subjects only follow general dietary recommendations for diabetes.
3354286|NCT02294539|Experimental|Losartan 50mg/amlodipine 5mg|Once daily, 1T, PO medication
3354287|NCT02294539|Experimental|Losartan 100mg/amlodipine 5mg|Once daily, 1T, PO medication
3244769|NCT01331538||No TMD|adolescents without temporomandibular dysfunction
3244770|NCT01331551||men with inflammatory bowel disease|Men between the ages of 18-55 with inflammatory bowel disease who are taking mesalamine medication.
3244771|NCT01331564|Experimental|electronic intervention group 2|(e-intervention 2) receives a behavioral intervention through a website during pregnancy and until 18 months postpartum
3354288|NCT02294539|Active Comparator|Losartan50 mg/Hydrochlorothiazide12.5 mg|Once daily, 1T, PO medication
3354289|NCT02294539|Active Comparator|Losartan100 mg/Hydrochlorothiazide25 mg|Once daily, 1T, PO medication
3354290|NCT02294552|Experimental|Matched bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv
3354291|NCT02294552|Experimental|Matched peripheral blood stem cells graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 30 mg/kg/day, maximum 2 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
3354292|NCT02294552|Experimental|Mismatched peripheral blood stem cells or bone marrow graft|Days -8 through -4: Busulfan 1 mg/kg po qid x 4 days Days -3 through -2: Cyclophosphamide 50mg/kg/day iv x 2 days Or Days -7 through -2: Fludarabine 30 mg/m2/day iv x 6 days Days -4 through -3: Busulfan 1 mg/kg po qid x 2 days Day 0: Infusion of unmanipulated graft Day +3 and +4: Cyclophosphamide 50 mg/kg/day iv Days +5 through +35: Mycophenolate mofetil 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days Days +5 through +120: Tacrolimus 0.03 mg/kg/day with further correction by concentration
3244772|NCT01331564|Experimental|electronic intervention group 1|(e-intervention 1) receives a behavioral intervention through a website during pregnancy. During the postpartum period this arm receives the same non-weight-related information as the control arm
3244773|NCT01331564|Placebo Comparator|Control|
3244774|NCT01331577|Experimental|Cognitive behavioural Intervention|
3354293|NCT02294565|Other|VST-1001 & 99mTc-labeled sulfur colloid|"VST-1001 (with medical devices) and 99mTc-labeled sulfur colloid are used together during a SLNB procedure in a single subject. Both drugs are evaluated for lymphatic mapping and localization of lymph nodes. The current standard of care for lymphatic mapping and lymph node localization during a SLNB procedure is a combined-modality technique that employs both a radiotracer (99mTc-labeled sulfur colloid is the radiotracer used in this study) and a vital blue dye (a patient receives both drugs). In this study, the vital blue dye is replaced with VST-1001 and companion medical devices.~VST-1001 is excited by a medical device (blue-light LED illuminator) to fluoresce; the surgeon is wearing blue-light filtering eyewear to improve visualization of the relevant tissue structures."
3354294|NCT02294578||Lung Cancer|Patients with biopsy proven lung cancer
3354295|NCT02294578||Controls|Patients with lung lesions suspicious for the presence of cancer and with cancer excluded after further diagnostic study
3354296|NCT02294591|Active Comparator|NAC group|Receiving N-acetylcysteine as add-on treatment
3354297|NCT02294591|Placebo Comparator|Placebo group|Receiving placebo as add-on treatment
3354298|NCT02294617|Active Comparator|Nicotrol Inhaler|Subjects will use the Nicotine Inhaler for 3 days.
3244775|NCT01331577|Experimental|Integrative Kinesiology Intervention|
3244776|NCT01331577|No Intervention|Waiting-List control group|
3244777|NCT01331590|Experimental|G-CSF + Ifosfamide + Etoposide + Dexamethasone + Mesna|"G-CSF = 10 mcg/kg/d SQ starting on day 1 and continuing until ANC >=1000/mcL x 2 days~Ifosfamide = 3330 mg/m2/d CIVI over 24 hours on Days 4-6~Etoposide = 150 mg/m2 IV over 2 hours BID on Days 4-6~Dexamethasone = 5 mg/m2 PO or IV BID on Days 4-10~Mesna = 2660 mg/m2/d continuous IV infusion over 24 hours on Days 4-6. 2000 mg/m2 continuous IV infusion over 12 hours on Day 7 to be started immediately after completion of ifosfamide."
3244778|NCT01331603||MDS and primary myelofibrosis patients|patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
3244780|NCT01331629|Experimental|ART-THERAPIE|supported in art therapy with other supportive care available in the facility
3244781|NCT01331629|No Intervention|standard group|standard care (supportive care available in each facility)
3244782|NCT01331642||Observation|Patients with Gaucher disease or high-grade suspicion for Gaucher disease
3244783|NCT01331655|Experimental|Arm 1|
3244784|NCT01331655|Experimental|Arm 2|
3354299|NCT02294617|Active Comparator|Electronic Cigarette|Subject will use the electronic cigarette for 3 days.
3354300|NCT02294643|Active Comparator|aspirin, clopidogrel & sarpogrelate|the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (Anplag®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily
3354301|NCT02294643|Placebo Comparator|aspirin, clopidogrel & placebo|the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily
3354302|NCT02294656|Experimental|RANIBIZUMAB|Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
3354303|NCT02294656|Active Comparator|TRIAMCINOLONE ACETONIDE|Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
3354304|NCT02294669|Experimental|Turris Facet Fuser|
3354305|NCT02294695||Appropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
3244785|NCT01331655|Active Comparator|Arm 3|
3244786|NCT01331668||renal allograft donors and recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven
3244787|NCT01331707|Active Comparator|Promus Element|
3244788|NCT01331707|Active Comparator|Resolute Integrity|
3244789|NCT01331720||FSH:LH 1:1 - Treatment Group A|"Patients with a condition~LH (luteinizing hormone)"
3244790|NCT01331720||FSH:LH 3:2 - Treatment Group B|Patients with a condition
3244791|NCT01331720||FSH:LH 3:1 - Treatment Group C|Patients with a condition
3244792|NCT01331720||FSH:LH 3:0 - Treatment Group D|Patients with a condition
3244793|NCT01331720||Initially FSH:LH 3:0 and on S6 FSH:LH 1:1 - Treatment Group E|Patients with a condition
3244794|NCT01331733||hMG-HP|Patients with a condition
3244795|NCT01331733||hMG-HP + GnRH antagonist|Patients with a condition
3244796|NCT01331746|Experimental|APD515|Active APD515 treatment 20 mg qds for 7 days
3244797|NCT01331746|Placebo Comparator|Placebo|
3244798|NCT01331759|Experimental|Immediate Neuropattern™|The experimental group will undergo Neuropattern™ stress diagnostics immediately after inclusion in the study.
3244799|NCT01331759|Placebo Comparator|Later Neuropattern™|The control group will undergo Neuropattern™ stress diagnostics three months after inclusion in the study.
3244800|NCT01331772|Other|Control arm|Dietetic follow-up only
3244801|NCT01331772|Experimental|Intervention arm|Dietetic + adapted physical activity
3244802|NCT01331785|Experimental|Midodrine|
3244803|NCT01331798|Experimental|Test: TissuGlu Adhesive|Patients received the TissuGlu Adhesive Treatment
3244804|NCT01331798|Active Comparator|Control|Control Arm received no TissuGlu- Standard of Care received.
3244805|NCT01331850|Experimental|Previous null responders (Cohort B): Group 4|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3354306|NCT02294695||Inappropriate empiric antibiotic therapy|"Based on the microbiological results patients were grouped post hoc into appropriate and inappropriate groups by two independent experts (intensivist, infectologist) who were blinded for PCT."
3354307|NCT02294708|Experimental|supine|postoperative postures: patients in this arm are assigned to adopt supine position for 24 hours after the surgery
3354308|NCT02294708|Experimental|temporal lateral|postoperative postures: patients in this arm are assigned to adopt temporal lateral position for 24 hours after the surgery
3354309|NCT02294721|Experimental|Without feedback|Participants compress the chest of the manikin without CPR feedback device
3244806|NCT01331850|Experimental|Previous null responders (Cohort B): Group 5|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3244807|NCT01331850|Experimental|Previous null responders (Cohort B): Group 6|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.
3354310|NCT02294721|Experimental|With feedback|Participants compress the chest of the manikin with CPR feedback device.
3354311|NCT02294747|Active Comparator|SHS without TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw without trochanteric stabilization plate.
3244808|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 1|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3244809|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 2|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3244810|NCT01331850|Experimental|Previous partial responders (Cohort A): Group 3|Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
3244811|NCT01331863|Experimental|single arm surgery|Airway and/or pulmonary Vessels Transplantation
3354312|NCT02294747|Active Comparator|SHS with TSP|Patients with AO 31 A2 trochanteric fractures operated with sliding hip screw with trochanteric stabilization plate.
3354313|NCT02294760|Active Comparator|Subsensory, OFF, subsensory|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then turned OFF for the next 4 weeks and finally set subsensory for the last 4 weeks.
3244812|NCT01331876|Experimental|reference therapy|20 OCD patients following 15 sessions of the reference CBT (Bouvard,2006)
3354314|NCT02294760|Active Comparator|Subsensory, subsensory, OFF|The stimulator is set subsensory for the first 4 weeks (90% of sensory threshold), then set subsensory for another 4 weeks and finally turned OFF for the last 4 weeks.
3354315|NCT02294799|Other|Intervention Group|TMD diagnosed sujects that will receive the mobilization treatment
3354316|NCT02294799|Placebo Comparator|Placebo Group|TMD diagnosed sujects that will receive the placebo treatment
3354317|NCT02294812|Active Comparator|Control, cognitive training|Participants in the control arm will receive cognitive training for cognitive abilities not affected by age-related hearing loss.
3354318|NCT02294812|Experimental|Experimental, cognitive training|Participants in the experimental arm will receive cognitive training for cognitive abilities affected by age-related hearing loss.
3354319|NCT02294812|Active Comparator|Active Control, crossword training|Participants in this group will undergo crossword puzzle training. The purpose of this group is control for any effects that may be due to engaging in cognitive training.
3354320|NCT02294838|Experimental|MRI with parotid gland stimulation|All participants will have MRI imaging of the parotid gland with IV Gadovist pre and post parotid stimulation with lemon juice. 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered. Approximately three minutes after scan commencement, the salivary glands will be stimulated by orally administering a small portion (≈5 ml) of Citric acid.
3354321|NCT02294851|Experimental|Single Ascending dose cohorts|Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects.
3354322|NCT02294851|Placebo Comparator|Placebo|BMS-986168 Placebo
3354323|NCT02294864|Experimental|Pulsed Radiofrequency|Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
3354324|NCT02294864|Active Comparator|Physical Therapy|This group will receive standard of care outpatient physical therapy weekly for 3-4 weeks with therapist instructions to reduce knee pain.
3354325|NCT02294890||Fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
3354326|NCT02294890||No fibrosis diathesis|"all patients will be checked for signs of fibrosis diathesis. This will be done by examining their hands for Dupuytren's nodules and contractures and recording risk factors associated with increased severity and risk of recurrence of Dupuytren's contracture. These include family history, bilateral DD, and ectopic lesions, age of onset less than 50 years, male gender, Ledderhose disease, first ray involvement, multiple ray involvement and ectopic fibromatosis.~This way, two groups of patients will be identified: those with and those without signs of fibrosis diathesis."
3354327|NCT02294903|Experimental|ProRAFT|Procedure/Surgery: Coiled Bipolar Radiofrequency Ablation
3354328|NCT02294916|Experimental|Child ETI withoutchest compressions|Endotracheal intubation of pediatric mannikin during resuscitation without chest compressions.
3354329|NCT02294916|Experimental|Child ETI with chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3354330|NCT02294929|Other|Atrial fibrillation ablation|Cryoballoon ablation for pulmonary vein isolation
3354331|NCT02294942|Experimental|RANCAD 500mg|RANCAD 1 tab (500 mg) + Placebo 1 tab, twice daily.
3354332|NCT02294942|Experimental|RANCAD 1000mg|RANCAD 2 tabs (500 mg), twice daily
3354333|NCT02294942|Active Comparator|Placebo|2 tabs, twice daily
3354334|NCT02294955|Active Comparator|Catheterablation|Pulmonary vein isolation with Cryo-energy using a Arctic Front™ Cardiac CryoAblation Catheter or an irrigated radiofrequency ablation catheter, with an optional roof line.
3244813|NCT01331876|Experimental|experimental therapy|20 OCD patients following 15 sessions of reference CBT associated with a new psychopedagogic task developed by our team.
3244814|NCT01331889||Potassium concentration|plasma potassium concentrations in the Fluid Management System (FMS) reservoir, arterial blood, and central venous blood
3244815|NCT01331902|Experimental|Adenosine Followed by Nicorandil|
3244816|NCT01331902|Experimental|Nicorandil Followed by Adenosine|
3244817|NCT01331915|Experimental|Theravac|Theravac® is a recombinant adenylate cyclase toxin from Bordetella pertussis that has been detoxified by mutation of its catalytic domain, and which has been coupled to the Tyrosinase.A2 epitope YMDGTMSQV.
3354335|NCT02294955|Active Comparator|Antiarrhythmic drug Class IC or III.|Serial testing of oral antiarrhythmic drugs; amiodarone 600 mg once daily 7-10 days, then 100-200 mg once daily; sotalol: 80-160 mg twice daily; flecainide 100 to 150 mg twice daily or entire dose as slow-release formula once daily; propafenone 300 mg twice daily; disopyramide 250-375mg twice daily, or dronedarone 400 mg twice Daily.
3354336|NCT02294968|Experimental|Family Startup|Family Startup plus usual pre- and postnatal care
3354337|NCT02294968|No Intervention|Control|Usual pre- and postnatal care
3244818|NCT01331928|Experimental|Capecitabine, Oxaliplatin, Docetaxel , Gastric cancer|
3354338|NCT02294994|Experimental|half dose tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.075 µg per kilogram per minute for 24 to 36 hours.UFH heparin was administered as a bolus of 100 U/kg before PCI.
3354339|NCT02294994|Active Comparator|recommended-dose Tirofiban|Tirofiban was administered once the wire had crossed the lesion during PCI with a bolus dose of 25 µg/kg of bodyweight, followed by an infusion of 0.15 µg per kilogram per minute for 18 to 24 hours. UFH heparin was administered as a bolus of 100 U/kg before PCI.
3354340|NCT02294994|Placebo Comparator|none tirofiban|Tirofiban was not administered ,UFH heparin was administered as a bolus of 100 U/kg before PCI.
3244819|NCT01331941|Experimental|Group 1|Cancer subjects with normal renal function.
3244820|NCT01331941|Experimental|Group 3|Cancer subjects with moderate renal impairment.
3244821|NCT01331941|Experimental|Group 4|Cancer subjects with severe renal impairment.
3244822|NCT01331941|Experimental|Group 2|Cancer subjects with mild renal impairment.
3354341|NCT02295007|Other|text message|all families will receive text messages to which they can respond to report symptoms
3354342|NCT02295033|Experimental|Boost irradiation|
3354343|NCT02295033|No Intervention|No boost irradiation|
3354344|NCT02295046|Experimental|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg|Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
3354345|NCT02295046|Active Comparator|Caduet|Caduet® 10/80 mg tablets of Pfizer, Ireland
3354346|NCT02295059|Experimental|Omega 3 fatty acids - high dose|~5 g EPA+DHA in 5 capsules per day
3354347|NCT02295059|Experimental|Omega 3 fatty acids - low dose|~0.9 g EPA+DHA + fatty acids based on the typical American diet in 5 capsules per day
3354348|NCT02295072|No Intervention|Control group|2 Usual Physical Education sessions/week
3354349|NCT02295072|Experimental|Intervention Group|A 5-months physical exercise-based program (3-5 Physical Education after school sessions/week + 2 Usual Physical Education sessions/week)
3244823|NCT01331954|Experimental|HIFU|
3244824|NCT01331967|Experimental|Pioglitazone, Placebo|
3244825|NCT01331980||cystic fibrosis|children aged 6-12 years of age and Tanner stage 1 with a diagnosis of cystic fibrosis
3354350|NCT02295098|Active Comparator|Thoracic epidural catheter|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
3354351|NCT02295098|Active Comparator|Paracostal catheter|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
3354352|NCT02295111|Active Comparator|EA treatment and TCM health consult|Participants randomized to the EA treatment will receive 2 EA +TCM health consult once a week x 4 weeks (8 total)
3354353|NCT02295111|Experimental|TCM health consult|Participants randomized to TCM health consult will receive 2 TCM health consult once a week x 4 weeks ( 8 total)
3354354|NCT02295111|Active Comparator|Usual care|Participants randomized to usual care will continue with their usual care
3354355|NCT02295124|Active Comparator|Oxycodone|Patients will be prescribed oxycodone 10mg (5mg if > age 65) every 2 hours as needed for post-operative pain management in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
3354356|NCT02295124|Active Comparator|Hydromorphone|Patients will be prescribed hydromorphone 2mg (1mg if > age 65) every 2 hours as needed in addition to tylenol 1000mg every 6 hours and celecoxib 200mg every 12 hours.
3354357|NCT02295137|Experimental|pre-procedure image guidance|
3354358|NCT02295150|Experimental|Nadroparin|patients above 140 kg will receive a dose of 2850 IU nadroparine pre-operatively, anti-Xa factor will be determined 3 days after nadroparin use. After surgery patients receive 5700 IU nadroparin (our standard treatment). Three days after surgery and 4 weeks after surgery anti-Xa factor will be measured again.
3354359|NCT02295163|Sham Comparator|Sham procedure|injection of NACL 0,9% in the stellate ganglion
3354360|NCT02295163|Experimental|Stellate ganglion block|injection of Bupivacaine 0,5% in the stellate ganglion
3354361|NCT02295176|Experimental|Armolipid Plus|Armolipid Plus: 1 tablet daily in the evening after dinner for 24 weeks.
3354362|NCT02295176|Placebo Comparator|Placebo|1 tablet matching Armolipid Plus daily in the evening after dinner for 24 weeks
3354363|NCT02295189|Active Comparator|Visual analogue scale|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
3354364|NCT02295189|Active Comparator|Treatment|visual analogue scale versus triamcinolone acetonide visual analogue scale versus ketorolac tromethamine
3354365|NCT02295202|Experimental|CPAP|CPAP: Continuous Positive Airway Pressure - Device used for treating OSA during sleep.
3354366|NCT02295202|Placebo Comparator|Placebo|Nasal Strips
3354367|NCT02295215|No Intervention|Sedentary Group|The patients will not do exercise training
3354368|NCT02295215|Experimental|Trained Group|The patients will do exercise training for sixteen weeks.
3354369|NCT02295228||Adults undergoing total hip arthroplasty|No intervention will be administered, this is an observational trial. The study population includes adults 50+ who are undergoing elective total hip arthroplasty for osteoarthritis.
3354370|NCT02295254||Research group|The study contain only one group: travelers who intended to travel to tropical destinations. The participants will give a feces sample before and after the travel.
3354371|NCT02295267|Experimental|walnut allergy provocation|inclusion of walnut allergic patients, food provocation with walnut
3244826|NCT01331980||healthy controls|children ages 6-12 years and Tanner stage 1 without cystic fibrosis or other chronic disease that affects bone health
3244827|NCT01331993|Experimental|1|Treatment order : A, B, C
3244828|NCT01331993|Experimental|2|Treatment order : B, C, A
3354372|NCT02295293|Experimental|Rhus|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
3354373|NCT02295293|Placebo Comparator|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
3354374|NCT02295319|Experimental|Individual discharge|Discharge based on the patients individual needs and conditions. The discharge focus on information, communication, follow-up plans and collaboration, as well as the patients understanding and accept of the discharge plan. In addition, it includes a telephone interview 2 days after discharge to home.
3244829|NCT01331993|Experimental|3|Treatment order : C, A, B
3244830|NCT01331993|Experimental|4|Treatment order : A, C, B
3244831|NCT01331993|Experimental|5|Treatment order : B, A, C
3244832|NCT01331993|Experimental|6|Treatment order : C, B, A
3354375|NCT02295319|No Intervention|Control|Usual discharge procedures
3354376|NCT02295332|Experimental|Cohort A|
3354377|NCT02295332|Experimental|Cohort B|
3354378|NCT02295345|Experimental|CBT for Insomnia|Participants attend 5 weekly sessions of Cognitive Behavioural Therapy for Insomnia for pregnant women, administered by licensed clinical psychologist.
3354379|NCT02295371||Patients with an incident|Patients undergoing a safety incident while being treated with drugs
3354380|NCT02295384||Audit Group|"Patients attending HHMP in Darlinghurst, Sydney, New South Wales with documented HIV-1 infection from 1st January 2005 to 31st July 2014, who were considered linked to care (Attendance during the study period for at least 2 visits >3 months and <12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site))."
3354381|NCT02295397|Experimental|food provocation|open and placebo-controlled food challenges
3354382|NCT02295410||Engaged in Home-Based CPT|Home-Based Telemental Health-Patients undergoing Home-Based CPT for PTSD
3354383|NCT02295410||Comparison|Treatment as Usual (TAU) Patients NOT receiving regular CPT or other evidence-based therapy for PTSD.
3354384|NCT02295436|Experimental|1-mg group|Twelve healthy young subjects were administered a single oral dose of 1 mg minodronic acid tablets at day 1 and then received repeated oral doses of minodronic acid (1 mg) once daily for 7 days (day 3 to day 9).
3354385|NCT02295436|Experimental|2-mg group|Twelve healthy young subjects were administered a single oral dose of 2 mg minodronic acid tablets.
3354386|NCT02295436|Experimental|4-mg group|Twelve healthy young subjects were administered a single oral dose of 4 mg minodronic acid tablets under fasting state at period 1.After a washout period of 8 days, they received the same dosage under fed conditions (administrated 30 minutes before high-fat breakfast).
3354387|NCT02295436|Experimental|1-mg elderly group|Twelve healthy elderly subjects were administered a single oral dose of 1 mg minodronic acid tablets.
3354388|NCT02295449|Experimental|1|
3354389|NCT02295462|Experimental|Person-centered Care|Medication Review + Person-centered Care
3354390|NCT02295462|Active Comparator|Optimised Treatment|Medication Review
3354391|NCT02295475|Experimental|Apixaban|Subjects will receive apixaban 5 mg tablets taken twice daily for the duration of the study.
3244833|NCT01332006|Experimental|Intra-bone injection|Intra-bone transplantation of hematopoietic stem cells from cord blood
3244834|NCT01332032||Reminder Letter|"A letter sent to women reminding them that are coming due or overdue for a mammogram. It contains a reminder that their primary care provider (PCP) recommends mammography screening every 1-2 years. It urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. Repeat Booster letters will be sent in subsequent years to those failing to get a mammogram."
3354392|NCT02295475|Active Comparator|Warfarin|Subjects will receive warfarin for the duration of the study, with the dose and frequency adjusted per clinician discretion to achieve an INR (International Normalized Ratio) between 2 and 4.
3354393|NCT02295488|Experimental|Desensitization|Blood intake for biological sampling during validated desensitization protocol (Alyostall®)
3354394|NCT02295501|Experimental|EBOV convalescent donors|EBOV convalescent donors for passive immune therapy in subjects with acute EVD
3354395|NCT02295514|Experimental|PTP1B dosage|PTP1B dosage during sepsis
3354396|NCT02295527|Experimental|Home-based physical exercise|Participants randomized to the Intervention Group (IG) will be submitted to a physical exercise program involving a progressive and challenging balance training and a neuromuscular and functional training of the lower limbs, conducted at home by physiotherapists, once a week, lasting about one hour, in the first, second and third month after randomization and will be oriented to perform exercises, twice a week, through a booklet. Visits to follow up exercises progression will be conducted once a month, from de fourth to the sixth month and each two months until the end of the follow up at the 12th month, summing up 18 sessions. Participants will receive monthly phone calls to increase exercise adherence.
3354397|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and the booklet regarding bone health information.
3354398|NCT02295540|Experimental|Treatment (hypofractionated IMRT, surgery)|Patients undergo hypofractionated IMRT every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment.
3354399|NCT02295566|Active Comparator|Nitric Oxide Group|Inhaled Nitric Oxide delivered via nasal canulae at 10ppm for 8 hours a night for 7 nights.
3354400|NCT02295566|Placebo Comparator|Control Group|Air/oxygen mix (according to clinical need) delivered via nasal canulae for 8 hours a night for 7 nights.
3354401|NCT02295592|Experimental|group A( TSTstarr+ group)|"TSTstarr+ is a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
3354402|NCT02295592|Active Comparator|group B ( PPH group)|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
3354403|NCT02295605|Experimental|Land-based exercises|Land-based muscle strengthening exercises protocol
3354404|NCT02295605|Experimental|Water-based exercises|Water-based muscle strengthening exercises protocol
3244835|NCT01332032||Reminder Call|"A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a mammogram within 2 weeks, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offer to schedule a mammogram for her. Repeat Booster letters will be sent and repeat scheduler calls made in subsequent years to those failing to get a mammogram."
3244836|NCT01332032||Counselor Call|"A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat booster letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes."
3354405|NCT02295618|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3354406|NCT02295618|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3354407|NCT02295631|Experimental|ETI during immobilized spine (oral intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
3354408|NCT02295631|Experimental|ETI during immobilized spine (nasal intubation)|intubation with immobilized cervical spine endotracheal intubation with immobilized cervical spine
3354409|NCT02295657|Experimental|ETI intubation|endotracheal intubation in manikin
3354410|NCT02295670|Experimental|Endotracheal intubation without chest compressions|Endotracheal intubation of mannikin during resuscitation without chest compressions.
3354411|NCT02295670|Experimental|Endotracheal intubation with uninterrupted chest compressions|Endotracheal intubation of mannikin during resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3354412|NCT02295696|Experimental|Intervention group|Intervention arm : EMMA consultations
3354413|NCT02295696|No Intervention|Control group|Control arm: Usual care/consultations
3354414|NCT02295709|Experimental|USNR steroid injection|the patient who are treated with steroid (dexamethasone) injection through selected cervical spinal nerve block approach guided by ultrasound and C arm.
3354415|NCT02295709|Experimental|UCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided by ultrasound and C arm.
3354416|NCT02295709|Experimental|XCTF steroid injection|the patients who are treated with steroid (dexamethasone) injection through cervical transforaminal approach guided only by C arm.
3354417|NCT02295722|Experimental|Gemcitabine/Melphalan Condition + ASCT|"Day -1 -~IV gemcitabine 1.5-2.5 g/m2 (depending on dose level assigned) administered as a loading bolus of 75 mg/m2, followed by a continuous infusion of 10 mg/m2/min.~immediately following gemcitabine - IV melphalan 200 mg/m2 over 5 minutes.~Day 0~•Stem cell infusion~Patients will be assigned a dose level using the continual reassessment method based on the toxicity data available at the time of their enrollment. The dosing will start at 1.5 g/m2 and will increase by 0.5 mg/m2 at each level to a maximum of 2.5 g/m2. Dose-limiting toxicity is defined as grade 3 mucositis or skin toxicity lasting more than 3 days before downgrading, or any grade 4 non-hematological toxicity."
3354418|NCT02295748|Experimental|Deflazacort|0.9 mg/kg oral deflazacort (between 2 to 12 x 6mg tablets based on body weight) will be administered daily.
3354419|NCT02295761|Active Comparator|Lifestyle counseling|12-weeks
3354420|NCT02295761|Active Comparator|Lifestyle counseling + activity watch|12-weeks
3354421|NCT02295787|Experimental|Ketamine|Intranasal Ketamine 50mg administered six times over three weeks.
3354422|NCT02295787|Placebo Comparator|Placebo|Intranasal saline solution administered six times over three weeks.
3354423|NCT02295800||Mothers|HIV Infected mothers
3354424|NCT02295800||Infants|HIV exposed infants
3354425|NCT02295800||Healthcare workers|Facility based healthcare workers
3354426|NCT02295813|Experimental|FBF001|"FBF001 must be administered by intravenous route during 1 hour. The dose must be calculated according to the body weight of the subject and diluted in sodium chloride 0.9%.~FBF001 is administered once during 1 day or once per day during 5 days."
3354427|NCT02295813|Placebo Comparator|Placebo|The placebo must be administered by intravenous route during 1 hour. It administered once during 1 day or once per day during 5 days.
3354428|NCT02295826|Experimental|Dabigatran therapy|150 mg BID for 30 days (dose modification - reduced to 110mg BID in patients >80 years of age and/or an eGFR of 30-50 ml/min)
3354429|NCT02295826|Active Comparator|Acetylsalicylic Acid thereapy|325 mg loading dose then 81 mg/day for 30 days
3354430|NCT02295839|No Intervention|Usual care|
3354431|NCT02295839|Experimental|Sleep Hygiene and Relaxation Education|
3354432|NCT02295852|Experimental|Group A: LOW-SODIUM LOW LIPID CALCIUM RICH DIET|Experimental Group A: patients will change their diet in a diet similar for total daily calories, sodium and macronutrients but enriched in calcium (1200 mg/daily) and will be followed up to 1 year with an intermediate control after the first 3 months;
3354433|NCT02295852|Active Comparator|Group B: LOW-SODIUM LOW LIPID DIET|Experimental Group B: patients will continue the low-lipid, low-sodium diet up to 1 year with an intermediate control after the first 3 months.
3354434|NCT02295865|Experimental|JNJ-38518168 60 mg|Participants will receive two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, together with one 30 mg matching placebo tablet and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3244837|NCT01332045|Sham Comparator|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
3244838|NCT01332045|Active Comparator|Continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
3244839|NCT01332058|Experimental|Motivational Interviewing (MI)|
3244840|NCT01332084|Experimental|hypoallergenic wheat cereals|HA wheat cereal used in a SOTI test
3244841|NCT01332097|Experimental|Treatment A|single 75mg oral dose of BCT197 capsules + single oral dose of prednisone placebo capsules
3244842|NCT01332097|Placebo Comparator|Treatment B|single oral dose of BCT197 placebo capsules + single oral dose of prednisone placebo capsules
3354435|NCT02295865|Experimental|JNJ-38518168 30 mg|Participants will receive one tablet of JNJ-38518168, 30 mg, together with two 30 mg matching placebo tablets and one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3354436|NCT02295865|Experimental|JNJ-38518168 3 mg|Participants will receive one tablet of JNJ-38518168, 3 mg, together with three 30 mg matching placebo tablets, orally, once daily, for 12 Weeks.
3354437|NCT02295865|Experimental|Placebo|Participants will receive three tablets of JNJ-38518168, 30 mg matching placebo, together with one 3 mg matching placebo tablet, orally, once daily, for 12 Weeks.
3354438|NCT02295878|Active Comparator|Treatment|400mg capsule containing seaweed extract (treatment)
3354439|NCT02295878|Placebo Comparator|Placebo|400mg capsule containing maltodextrin (placebo)
3244843|NCT01332097|Active Comparator|Treatment C|single oral dose of BCT 197 placebo capsules + single oral dose of 40mg prednisone capsules
3244844|NCT01332097|Experimental|Treatment D|single oral dose of 20mg dose of BCT197 capsules
3244845|NCT01332097|Placebo Comparator|Treatment E|single oral dose of BCT 197 placebo capsules
3244846|NCT01332097|Experimental|Treatment F|single oral dose of 20 mg dose of BCT197 capsules on Day 1 and Day 6
3354440|NCT02295891|Experimental|MiraDry ® treatment|"MiraDry ® is the trademarked name of a non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface.~Each participant will be scheduled two MiraDry ® treatment appointments approximately three months apart."
3244847|NCT01332097|Placebo Comparator|Treatment G|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
3244848|NCT01332097|Experimental|Treatment H|single oral dose of 75mg dose of BCT197 capsules on Day 1 and Day 6
3354441|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
3376003|NCT03314181|Experimental|Arm A, Part 1a: VenDd Dose Escalation|Venetoclax (Ven) various doses administered orally, once daily (QD) in combination with daratumumab (D) (1800 mg subcutaneous injection (preferred) or 16 mg/kg intravenous [IV]) administered in accordance with prescribing information and dexamethasone (d) (oral or IV) 40 mg weekly (or 20 mg weekly, if necessary, as described in the protocol).
3244849|NCT01332097|Placebo Comparator|Treatment I|single oral dose of BCT 197 placebo capsules on Day 1 and Day 6
3244850|NCT01332110|Experimental|Knee abduction moment-reducing footwear|Footwear that is known to decrease knee abduction moments of force in healthy subjects. May include orthotics, or footwear that allows relative movement between the heel section of the outsole and rest of the shoe.
3244851|NCT01332110|Placebo Comparator|Control footwear|Standard, off-the-shelf running shoes with no mechanical modifications.
3244852|NCT01332136||Endoscopic sinus surgery|Patients electing endoscopic sinus surgery for chronic rhinosinusitis
3244853|NCT01332136||Medical management|Continued medical management for symptoms of chronic rhinosinusitis
3244854|NCT01332162|Experimental|Biventricular pacing|All patients will be pacing during two years
3244855|NCT01332162|Active Comparator|No Pacing during the first year|No Pacing during the first year. In the second year all patients will be pacing
3244856|NCT01332175|Active Comparator|Provent|
3244857|NCT01332175|Placebo Comparator|Placebo-Provent|
3244858|NCT01332175|Active Comparator|CPAP|
3244859|NCT01332201|Experimental|Advagraf|
3244860|NCT01332201|Active Comparator|Prograf|
3244861|NCT01332214|Experimental|AZD2820|
3244862|NCT01332214|Placebo Comparator|Placebo|
3244863|NCT01332240|Experimental|Endosonography|Endoscopic ultrasonography (EBUS-TBNA +/- EUS-FNA) for invasive mediastinal nodal staging
3244866|NCT01332279|Experimental|Treatment (enzyme inhibitor and radiation therapy)|Patients receive RAD001 PO and erlotinib hydrochloride PO QD. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo EBRT BID 5 days a week for 5 weeks.
3244867|NCT01332344||Asthma patients treated with inhaled corticosteroids|Asthma subjects newly prescribed inhaled corticosteriods
3354442|NCT02295930|Experimental|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
3354443|NCT02295943|Other|Positioning measuring device|The supine time during the first postoperative day is measured
3354444|NCT02295956|Experimental|Home Based Exercise and Nutrition Program|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete. Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Exercise instructional booklet given to all participants describing all exercises. Participants to walk 20-30 minutes at least 3 times a week. Nutrition program discussed with participants. Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
3354445|NCT02295982|Placebo Comparator|Laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo laparoscopic nephrectomy within standarized technique
3244868|NCT01332370||Adults with Type 2 Diabetes|Subjects with a diagnosis (ICD-9 code) of diabetes
3244869|NCT01332383||Patients prescribed AMERGE|Patients with migraine disorders prescribed AMERGE during study period
3244870|NCT01332396||Patients prescribed TYKERB|Patients with HER2 overexpressing inoperable or recurrent breast cancer
3354446|NCT02295982|Active Comparator|Hand assisted laparoscopic nephrectomy|Patient with renal cell carcenoma will undergo hand assisted laparoscopic nephrectomy
3354447|NCT02296008|Other|surgery for Hirschsprung's disease|children after surgery for Hirschsprung's disease will undergo 3D high resolution anorectal manometry procedure
3354448|NCT02296008|Other|surgery for anorectal malformation|children after surgery for anorectal malformation will undergo 3D high resolution anorectal manometry procedure
3244871|NCT01332409||Patients prescribed salmeterol and fluticasone|Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
3244872|NCT01332422||Pediatric patients prescribed ADOAIR|Pediatric patients with asthma prescribed ADOAIR during study period
3244873|NCT01332448||Orlistat 120|Orlistat 120mg tid
3244874|NCT01332448||Orlistat 60|Orlistat 60 mg tid
3354449|NCT02296008|Other|surgery for other disorders|children after surgery for other disorders will undergo 3D high resolution anorectal manometry procedure
3354450|NCT02296021|Experimental|berberine quadruple therapy|Berberine 500 mg, esomeprazole 20 mg,amoxicillin 1000 mg, and clarithromycin 500 mg by mouth, twice daily for 14 days.
3354451|NCT02296021|Active Comparator|bismuth quadruple therapy|Bismuth 220 mg, esomeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg by mouth,twice daily for 14 days.
3244875|NCT01332448||Placebo|No active drug
3354452|NCT02296047|Experimental|Group A|The medication order: subjects inhaled placebo,ipratropium bromide 80μg, salbutamol 400μg in sequence.
3354453|NCT02296047|Experimental|Group B|The medication order: subjects inhaled placebo, salbutamol 400μg, ipratropium 80μg in sequence.
3354454|NCT02296060|Experimental|6 minutes walking test|
3354455|NCT02296073|Experimental|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
3354456|NCT02296073|Experimental|Dexmedetomidine1|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
3244876|NCT01332474||JCP|treatment of Equinus Foot due to Lower Limb Spasticity in Juvenile Cerebral Palsy Patients Aged 2-year or Older
3244877|NCT01332513|Experimental|ABFCED sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 milligram (mg) twice daily (BID) dosing of ezogabine modified release (MR) tablet in periods A, B, C, D and E and will receive 200 mg three times daily (TID) dosing of ezogabine immediate release (IR) tablet in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3244878|NCT01332513|Experimental|BCADFE sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3354457|NCT02296073|Experimental|Dexmedetomidine2|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
3354458|NCT02296073|Experimental|Dexmedetomiding3|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
3376006|NCT03287050|Experimental|Pembrolizumab + SBRT|
3244879|NCT01332513|Experimental|CDBEAF sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3244880|NCT01332513|Experimental|DECFBA sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3244881|NCT01332513|Experimental|EFDACB sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3354459|NCT02296086||Group I|"Study sites in which patients perform early mobilization as per local standard of care, which is as follows:~2 days (at the latest) after surgery: Transfer from the bed to a sitting chair for the first time~4 (± 2) days after surgery: Stand up and put both feet on the ground for the first time (walking aids allowed)~5 (± 2) days after surgery: Walking (at least partial weight bearing, walking aids allowed)~The patients are instructed by the investigator at the hospital about a standardized mobilization program to be followed at home"
3354460|NCT02296086||Group II|Study sites in which patients start walking (i.e. partial weight bearing, walking aids allowed) more than 7 days after surgery as per local standard of care
3244882|NCT01332513|Experimental|FAEBDC sequence|Each subject will participate in six study periods in the bioavailability phase, wherein the subjects will receive a 300 mg BID dosing of ezogabine MR in periods A, B, C, D and E and will receive 200 mg TID dosing of ezogabine IR in period F. Following the completion of the crossover phase, subjects will be re-randomized to one of five cohorts receiving 600 mg doses of either G, H, I, J or K for the food effect phase.
3244883|NCT01332526||Patients with BMI> 30 and metabolic syndrome ( ATP III).|Patients with BMI> 30 and metabolic syndrome ( ATP III).
3244884|NCT01332526||Patient with BMI> 30 without metabolic syndrome.|Patient with BMI> 30 without metabolic syndrome.
3244885|NCT01332526||Normal healthy control|healthy persons( without renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).
3244886|NCT01332526||Patients with CKD stage III and uric acid < 7 mg/dl|"Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
3354461|NCT02296151|Placebo Comparator|Group A|Four iliotibial band stretches; to be completed 3 days per week.
3354462|NCT02296151|Active Comparator|Group B|Four conventional hip exercises (Hip abductor, gluteus medius strengthening); to be completed 3 days per week.
3354463|NCT02296151|Experimental|Group C|Four conventional hip exercises progressed during the 8-weeks, totalling 16 exercises over the 8-week period (Hip abductor, gluteus medius strengthening). Exercises to be completed 3 days per week.
3354464|NCT02296177|No Intervention|Control|The control group will receive the standard practice of care related to mammography phone call reminders. If a clinic currently conducts reminders, they will receive that standard call. If no reminders are done, then they will not receive a call during the control period.
3354465|NCT02296177|Active Comparator|Intervention|The intervention group will receive a reminder call about their upcoming appointment that assesses their intent to attend the appointment and counsels them through barriers to attendance. The call is conducted by a trained patient navigator using an adapted NCI RTIP to increase mammography appointment adherence.
3354466|NCT02296203|Experimental|cetuximab and irinotecan|
3354467|NCT02296216|Active Comparator|Exposed patients|Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
3354468|NCT02296216|Placebo Comparator|Unexposed patients|Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
3354469|NCT02296229|Experimental|Treatment (SBRT)|Patients undergo SBRT daily or every other day for a total of 5 fraction not exceeding 14 consecutive days. Patients may also receive androgen deprivation therapy for up to 9 months at the discretion of the treating physician.
3354470|NCT02296255|No Intervention|no HPV vaccine|No delivery of HPV vaccine
3354471|NCT02296255|Experimental|HPV vaccine (Cervarix®, GlaxoSmithKline)|Delivery of HPV vaccine (Cervarix®, GlaxoSmithKline) at 0, 1, 6 months
3354472|NCT02296268||Pre-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC prior to the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
3354473|NCT02296268||Post-Clinic Stroke Group|In- or out-patients with diagnosis of ischemic or hemorrhagic stroke who have been referred to the NSRC after the establishment of the Clinic and are willing/able to provide written informed consent and have no contraindications to exercise testing. Each patient will undergo an assessment in the Aerobics Clinic and will receive a prescription for aerobic training based on the assessment findings. Utilization of aerobic exercise will be monitored during their physiotherapy sessions (Aim 3).
3354474|NCT02296268||Stroke Rehabilitation Physiotherapists|Physiotherapists whose current practice involves working full-time or part-time on in- or out-patient stroke service at the NSRC. Their self-efficacy regarding the clinical utilization of aerobic exercise post-stroke will be conducted prior to, and after, implementation of the Aerobics Clinic.
3354475|NCT02296281|Experimental|treatment group|
3354476|NCT02296294|Active Comparator|Fluid Therapy|"Intravenous isotonic fluid therapy of Elo-mel® (Fresenius Kabi Austria) at a rate of 0,50ml/kg/min for one hour.~Body Composition Monitoring every 10 minutes for 6hours."
3354477|NCT02296294|Placebo Comparator|Zero Therapy|Body Composition Monitoring every 10 minutes for 6hours. No intravenous fluid therapy
3244887|NCT01332526||Patients with CKD stage III and uric acid > 7 mg/dl|"Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl~without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents, ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)"
3244888|NCT01332526||Patient with asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
3244889|NCT01332526||Hemodialysis patients|"Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function Hemodialysis patients.~CKD: nondiabetic nephropathy~duration hemodialysis 3-48 months~Hb-11-13 g/dl~well controlled hypertension ( < 140/90 mmHg)~without ACEi, ARB, allopurinol treatment~residual diuresis will be estimated for last 48 hours-between mid and next dialysis"
3354478|NCT02296307||DOvEE Participants|"All symptomatic women who are eligible for participation in the DOvEE trial receive the same interventions:~Blood test: CA-125 biomarker at day 1 and week 6-8. Second Test: Transvaginal Ultrasound at day 1. Follow-up Phone Call: Confirms continuing health 6 months after last visit."
3244890|NCT01332539||drug-resistant partial epilepsy|
3244891|NCT01332539||controlled partial epilepsy|
3354479|NCT02296333|Active Comparator|ondansetron|ondansetron iv, 8 mg, skin closure time
3354480|NCT02296333|Placebo Comparator|isotonic|isotonic 2ml, once, skin closure time
3354481|NCT02296359||Asthma Discordant Monozygotic Twins|This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
3354482|NCT02296359||Non-Asthma Concordant Monozygotic Twins|This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.
3354483|NCT02296372|Other|SOFA <7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score < 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
3354484|NCT02296372|Other|SOFA >7|"Critically ill patients with a Sequential Organ Failure Assessment (SOFA) score > 7 at first day of measurement.~Intervention: Measuring continuous glucose monitoring."
3354485|NCT02296385|Experimental|Supplementation|Supplementation
3354486|NCT02296398||Romidepsin therapy|Patients who received romidepsin per standard of care practice or included in other clinical trials (when receiving romidepsin therapy).
3354487|NCT02296411|Experimental|CHF 5259 12.5 µg|CHF 5259 12.5 µg: 2 inhalations bid (50µg daily dose)
3354488|NCT02296411|Placebo Comparator|CHF 5259 placebo|CHF 5259 placebo: 2 inhalations bid
3244892|NCT01332552|Experimental|Part 1: Single dose escalation|GSK2485852 planned single doses are placebo, 70 mg, 420 mg, 70 mg with food
3244893|NCT01332552|Experimental|Part 2: Repeat dose escalation|GSK2485852 planned repeat doses are placebo, 420mg BID, 420mg TID, 630mg BID
3244894|NCT01332552|Experimental|Part 3: GSK2485852 + Ritonavir|GSK2485852 single dose 70mg, 210 mg +Ritonavir 100mg x 1 day; GSK2485852 210mg + Ritonavir 100mg single dose x 3 days;
3244895|NCT01332565|Experimental|Single Arm|All subjects will receive a 50 mg single dose of GSK1349572
3244896|NCT01332591|Active Comparator|Complete revascularization|"Percutaneous coronary intervention of non-infarct coronary arteries"
3244897|NCT01332591|No Intervention|Conservative management|standard guideline-based medical therapy
3244898|NCT01332604|Experimental|A|
3244899|NCT01332604|Experimental|B|
3244900|NCT01332617|Experimental|Treatment with combination therapy|Treatment with combination therapy of Simvastatin, Zoledronic Acid, Bortezomib, Bendamustine, and Methylprednisolone.
3354489|NCT02296437|Experimental|tDCS + CT|
3354490|NCT02296463|Experimental|Treatment Group A|Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant
3354491|NCT02296463|Experimental|Treatment Group B|Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine
3354492|NCT02296463|Experimental|Treatment Group C|Day 0: RSV F Vaccine, Day 28: RSV F Vaccine
3354493|NCT02296463|Experimental|Treatment Group D|Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine
3354494|NCT02296463|Placebo Comparator|Treatment Group E|Day 0: Placebo, Day 28: Hepatitis A Vaccine
3354495|NCT02296489||Healthy volunteers|
3354496|NCT02296489||Asthma patients|
3354497|NCT02296528|Other|Swallowing Expansion Device|Titanium swallowing expansion device
3354498|NCT02296541|Experimental|Group 1: DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3244901|NCT01332643|Active Comparator|Test|The test group will consist of patients undergoing blastocyst biopsy followed by vitrification (embryo freezing), and in which the biopsied cells will be analyzed with a comprehensive chromosome analysis technique (array Comparative Genome hybridization or aCGH) and only one chromosomally normal embryo will be replaced in a thawed cycle.
3244902|NCT01332643|No Intervention|control|The control group will consist of patients in which one embryo will be replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patient does not become pregnant, successive embryo transfers of frozen embryos will be performed, but not as part of the study.
3244903|NCT01332656|Experimental|Arm A|Ombrabulin, Paclitaxel and Carboplatin
3244904|NCT01332656|Placebo Comparator|Arm B|Placebo, Paclitaxel and Carboplatin
3244905|NCT01332669|Active Comparator|chemoembolization|HCC patients received chemoembolization
3244906|NCT01332669|Other|Historical use of c-TACE using Lipiodiol and doxorubicin|The control arm will be of the patients that have been treated historically in the centers with conventional TACE (that is Lipiodiol plus doxorubicin).
3244907|NCT01332682|Experimental|Resistance Training and Nutrition Counseling|
3244908|NCT01332682|Other|Nutrition Counseling|
3354499|NCT02296541|Placebo Comparator|Group 1: Placebo vaccines for DNA Nat-B env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Nat-B env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3354500|NCT02296541|Experimental|Group 2: DNA CON-S env and MVA-CMDR|Participants will receive a single injection of DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3354501|NCT02296541|Placebo Comparator|Group 2: Placebo vaccines for DNA CON-S env and MVA-CMDR|Participants will receive a single injection of placebo for DNA CON-S env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3354502|NCT02296541|Experimental|Group 3: DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of MVA-CMDR at Months 4 and 8.
3354503|NCT02296541|Placebo Comparator|Group 3: Placebo vaccines for DNA Mosaic env and MVA-CMDR|Participants will receive a single injection of placebo for DNA Mosaic env at Months 0, 1, and 2. They will receive a single injection of placebo for MVA-CMDR at Months 4 and 8.
3354504|NCT02296554|Experimental|SLAP Repair|Patient will receive SLAP repair for their SLAP tear.
3354505|NCT02296554|Experimental|Biceps Tenodesis Repair|Patient will receive biceps tenodesis repair for their SLAP tear.
3354506|NCT02296567|Active Comparator|Group 1 Lucentis 4 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3354507|NCT02296567|Active Comparator|Group 2 Avastin 4 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3354508|NCT02296567|Active Comparator|Group 3 Eylea 4 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3354509|NCT02296567|Active Comparator|Group 4 Lucentis 6 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3354510|NCT02296567|Active Comparator|Group 5 Avastin 6 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3354511|NCT02296567|Active Comparator|Group 6 Eylea 6 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3354512|NCT02296567|Active Comparator|Group 7 Lucentis 8 weeks|Blood samples will be collected from patients receiving ranibizumab following the first dose of standard care therapy.
3354513|NCT02296567|Active Comparator|Group 8 Avastin 8 weeks|Blood samples will be collected from patients receiving bevacizumab following the first dose of standard care therapy.
3354514|NCT02296567|Active Comparator|Group 9 Eylea 8 weeks|Blood samples will be collected from patients receiving aflibercept following the first dose of standard care therapy.
3244909|NCT01332695|Experimental|ST101|ST101 oval tablets
3244910|NCT01332695|Placebo Comparator|Placebo|oval tablets to match ST101 tablet
3354515|NCT02296567|Active Comparator|Group 10 Control Group no treatment|Blood samples will be collected from patients who are not receiving anti-VEGF treatment.
3244911|NCT01332708|Experimental|Obese and overweight subjects|The participants are overweight and obese people with and without metabolic syndrome that will participate in diet groups.
3244912|NCT01332734||severe sepsis and septic shock|
3244913|NCT01332747|Experimental|Safoof e Muhazzil in its conventional powder form|safoof e muhazzil in its conventional powder form 5 gms twice daily given orally
3244914|NCT01332747|Experimental|compressed tablet of safoof e muhazzil|compressed tablet of safoof e muhazzil is given in equivalent dose orally
3244915|NCT01332747|Active Comparator|atorvastatin|atorvastatin 10mg daily as a standard control
3244916|NCT01332760|Active Comparator|narrow diameter heavy dental tool|periodontal tools for dental scaling and cleaning provided that have a narrow diameter (8mm) made of heavy material (steel).
3244917|NCT01332760|Experimental|light large diameter dental tool|periodontal tools for scaling and tooth cleaning provided with large diameter (11mm) handle made of light weight material
3244918|NCT01332773|Experimental|Artery first group|"The basic principle of the artery first approach is the early identification of the SMA at its origin at the aorta with the further resection then being guided by its anatomic course.~The dissection is carried cephalad along the aorta until the origin of the SMA is reached. The posterior and right aspect of the SMA is then dissected over a few centimeters. On the right side of the SMA a replaced or accessory right hepatic artery, if present, will be identified and preserved. This maneuver should be done, if infiltration of the SMA is suspected as the procedure can be terminated at this point. Once the situation at the SMA is assessed and resectability is confirmed resection will be done."
3244919|NCT01332773|Active Comparator|Conventional Group|A wide Kocher manoeuver is performed to fully mobilize the duodenum and the head of the pancreas. The colonic mesentery on the right side is separated from the anterior surface of the duodenum and the head of the pancreas. The size of the tumor and its relation to the superior mesenteric artery, the celiac trunk, the mesentery, the portal vein, and the superior mesenteric vein is assessed. If resectability is given a Kausch-Whipple's resection is performed.
3244920|NCT01332786|Experimental|Tigecycline|
3244921|NCT01332812|Experimental|Dexamethasone, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
3244922|NCT01332812|Sham Comparator|Control, POCD, psycological tests|"Subjects will be randomly assigned in two groups: For the Dexamethasone group, 8mg of dexamethasone will be administered intravenously before the induction of general anesthesia. For Control Group, no Dexamethasone will be administered.~Tests for evaluation of quality of life, depressive symptoms and neuropsychological battery to assess general mental status, learning, attention, visuospatial perception, immediate memory, operational and executive skills and recall, including processing speed. This assessment will be applied before surgery, and 3, 7, 21, 90 and 180 days after surgery."
3244923|NCT01332825|No Intervention|olfactory dysfunction|subjects diagnosed with olfactory dysfunction
3244924|NCT01332825|No Intervention|normal olfaction, no saline|no smell dysfunction, not randomized to saline nasal irrigation for 7 days
3244925|NCT01332825|Other|normal olfaction|normal olfaction, randomized to saline nasal irrigation for 7 days
3354516|NCT02296580|Experimental|Nativis Voyager RFE Therapy|Subjects will be treated with Nativis Voyager therapy until tumor progression.
3354517|NCT02296619|Experimental|TAP Block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
3354518|NCT02296619|Sham Comparator|Control|A sham band-aid will be applied to the abdomen of subjects who are randomized to the no intervention group.
3354519|NCT02296645|Experimental|ZuraPrep|Isopropyl alcohol (IPA) (70%)
3354520|NCT02296645|Active Comparator|ChloraPrep|Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
3354521|NCT02296658|Experimental|S-1 based chemoradiotherapy|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy in a standard manner.
3354522|NCT02296671|Experimental|PEMOX|"Pemetrexed will be given intravenously (IV) on an outpatient basis on Day 1 of each 14-day cycle over 10 minutes. Oxaliplatin will be given (IV) on an outpatient basis on Day 1 of each 14-day cycle at a dose over 120 minutes. Drugs may be given in either order.~-Oxaliplatin will be administered on Day 2 for Cycle 1 only. **"
3354523|NCT02296671|Experimental|FOLFOX|"The modified FOLFOX-6 regimen is the following drugs given every 14 days:~Oxaliplatin on Day 1 of each cycle~Leucovorin over 120 minutes on Day 1 of each cycle~5-FU bolus and continuous infusion over 46 hours beginning on Day 1 of each cycle~Oxaliplatin will be administered on Day 2 for Cycle 1 only and the 5-FU infusion will be interrupted at 20 hours so that the FLT-PET scan can be performed (only for FLT-PET scan eligible patients)."
3354524|NCT02296684|Experimental|Cohort 1: Neoadjuvant MK-3475 and Adjuvant MK-3475|"MK-3475 will be given intravenously once approximately 2-3 weeks prior to standard of care surgery.~Adjuvant therapy will be dictated by surgical pathology and occurs after standard of care surgery and will consist of:~risk-based intensity modulated radiation therapy consisting of 60 Gy in 2 Gy once-daily fraction size (total of 30 fractions)once-daily fraction size (total of 30 fractions)~optional image-guided radiation therapy~risk-based cisplatin administered intravenously on Days 1, 22, and 43 of treatment course~MK-3475 will be given intravenously once every 3 weeks for a maximum of 6 doses if participant is considered high-risk based on 's surgical pathology from standard of care surgery shows high risk features (positive margins or extracapsular extension). These doses of MK-3475 will be given after surgery and after all acute toxicities of post-operative standard of care chemotherapy and radiation have resolved to grade 1 or less."
3354525|NCT02296684|Experimental|Cohort 2: Neoadjuvant MK-3475|-MK-3475 will be given once intravenously and then given again 21 days after dose 1 (14-24 days before standard of care surgery
3354526|NCT02296697|Active Comparator|Low-level laser therapy AlGaInP|AlGaInP 660 nm laser and dose of 6 J / cm 2 with point application on the edges of the lesion and sweep up application in the center.
3354527|NCT02296697|Active Comparator|High-frequency therapy with O3 formation|High frequency generator, spherical electrode. Direct spark technique will be used, in which the electrode is positioned millimeters away from the skin of the patient, causing the formation of sparks, with increasing intensity up to 80 to 100% for ozone formation.
3354528|NCT02296697|Placebo Comparator|Wound dressing with saline solution|Wound dressing with hygiene of the pressure ulcer with warm saline and after applying the bandage will be held will be held.
3354529|NCT02296710|Experimental|Echocardiographic and sleep apnea test|Echocardiographic Evaluation of systolic and diastolic function of both ventricles and evaluation of apnea-hypopnea index and type of apnea
3244926|NCT01332838|Experimental|Sigvaris special compression stocking|
3354530|NCT02296723|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
3354531|NCT02296723|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., Sanfrancisco
3354532|NCT02296736||Pancreatic malignancy|All patients who have undergone surgery for presumed pancreatic malignancy in Derriford Hospital between Jan 2006 and Jan 14 and had a Computerised tomography (CT) scan.
3354533|NCT02296749|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
3354534|NCT02296749|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
3354535|NCT02296762|Experimental|Sirolimus tablets 2 mg|Sirolimus tablets 2 mg of Dr. Reddys Laboratories Limited
3354536|NCT02296762|Active Comparator|Rapamune|Rapamune® 2 mg tablets of Wyeth Laboratories, Philadelphia
3354537|NCT02296788|No Intervention|No Exercise Control|Healthy Living Control Group
3354538|NCT02296788|Experimental|Aerobic Exercise Group|8 kcal/kg of body weight/week (KKW) (~900 kcal/wk)
3354539|NCT02296788|Experimental|Aerobic Exercise Group 2|20 KKW (~2250 kcal/wk)
3354540|NCT02296801|Active Comparator|A: letrozole|letrozole 2.5 mg tablet orally daily for 14 weeks
3354541|NCT02296801|Experimental|B: letrozole then letrozole + palbociclib|letrozole 2.5 mg orally daily plus beginning 2 weeks after starting letrozole, palbociclib 125 mg capsule orally daily for 1 week then 1 week off, then a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of letrozole therapy
3244927|NCT01332838|Active Comparator|Standard Compression|
3244928|NCT01332864|Active Comparator|OMT to the head and rest of body|OMT is the intervention that will be applied to areas of somatic dysfunction as well as to the head using a compression of the fourth ventricle (CV4) technique.
3244929|NCT01332864|Placebo Comparator|Light touch|Light touch will be applied to the head region for 10 minutes with the patient at rest in the supine position.
3354542|NCT02296801|Experimental|C: palbociclib then letrozole + palbociclib|palbociclib 125 mg capsule orally daily (for a 3 weeks on and 1 week off cycle for a total of 14 weeks from start of palbociclib) plus beginning 2 weeks after starting palbociclib, letrozole 2.5 mg tablet orally daily for a total of 12 weeks from start of letrozole therapy
3354543|NCT02296801|Experimental|D: letrozole + palbociclib|letrozole 2.5 mg tablet orally daily for a total of 14 weeks plus palbociclib 125 mg capsule orally daily for a 3 weeks on and 1 week off cycle, for a total of 14 weeks from start of therapy
3354544|NCT02296814|Active Comparator|Sinusitis Hevert SL Tablet|two weeks treatment
3354545|NCT02296814|Placebo Comparator|Placebo for Sinusitis Hevert SL Tablet|two weeks treatment
3354546|NCT02296879|Experimental|SAIT301|"For Stage 1, subjects will be sequentially assigned to 1 of approximately 8 cohorts comprised of 3 to 6 subjects each. SAIT301 will be administered according to a modified Fibonacci sequence and following a 3 + 3 design.~For Stage 2, the MTD or (RP2D) determined in the Stage 1 will be administered to additional subjects with selected diagnoses, 15 subjects per selected diagnosis. After completion of Stage 1 the SRC may elect to increase the interval between doses (i.e., increase cycle length to 28 days) based on the emerging PK data from the lower SAIT301 dose levels."
3354547|NCT02296905|Experimental|Group I|Subjects with mild hepatic impairment
3354548|NCT02296905|Experimental|Group II|Subjects with moderate hepatic impairment
3354549|NCT02296905|Experimental|Group III|Subjects with severe hepatic impairment
3354550|NCT02296905|Experimental|Group IV|Subjects with normal hepatic function
3354555|NCT02296944||Children aged under 7 years old when tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3354556|NCT02296944||Children aged 7 to 10 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3354557|NCT02296944||Children aged 11 to 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3354558|NCT02296944||Children aged over 14 years at the tympanoplatie|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery
3354559|NCT02296957|Experimental|Intervention|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
3354560|NCT02296957|No Intervention|Control|Usual Care
3354561|NCT02296983|Experimental|Low dose arm|The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.
3354562|NCT02296983|Experimental|Full dose arm|The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.
3354563|NCT02296996|Experimental|Dabrafenib + trametinib|Single arm study with dabrafenib + trametinib combination therapy
3354564|NCT02297009||Volunteers|30 volunteers, half men and half women Buccal swab
3354565|NCT02297022|Experimental|Deep Brain Stimulation|Patients with Prader-Willi syndrome to receive DBS.
3354566|NCT02297035|Experimental|PPA patients|Experimental (Patients responding to current diagnostic criteria for Primary Progressive Aphasia (PPA) patients) : Behavioural testing, Brain imaging (MRI, PET), Genetic screening (APOE, Progranulin)
3354567|NCT02297035|Experimental|healthy controls|Healthy controls : Behavioural testing, Brain imaging (MRI, PET).
3354568|NCT02297048|Experimental|RU 486 (mifepristone)|Subjects will receive 400 mg once a day of RU486
3354569|NCT02297048|Placebo Comparator|Placebo|Subjects will receive placebo once a day
3354570|NCT02297061||TEG group|200 consecutive hip fracture patients, Thrombelastography is performed on admission.
3354571|NCT02297074|Experimental|Ordinary White Bread|Ordinary white bread bread is characterised by a white crumb with regular soft alveoli and a slightly soft thin crust.
3354572|NCT02297074|Experimental|Precooked-Frozen White Bread|Precooked-Frozen white bread is characterized by white crumb with regular soft alveoli and bright crusty crust
3354573|NCT02297074|Experimental|Candeal-flour White Bread|Candeal-flour white bread has a thick crust of between one and two millimetres, which is smooth and crisp, golden to light brown in colour and which tastes of toasted cereal. The crumb of the bread is white and its texture is smooth, spongy and consistent, with little regular alveolus and with an intense cereal aroma with a pleasant and slightly sweet taste
3354574|NCT02297074|Experimental|Alfacar White Bread|Alfacar white bread is made according to its protected designation of origin and protected geographical indication (D.O. Alfacar, Granada, Spain). The bread has a creamy white, flexible and soft crumb, with many randomly scattered holes. The crust is medium-thick to thick, golden, slightly shiny and quite smooth
3354575|NCT02297074|Experimental|Organic Wholemeal Bread|The Organic wholemeal bread only includes organic whole grain flours as the unique difference compared with the Ordinary bread. The resulting dark brown bread is characterized by compact crumb free of alveoli and hard thin crust
3354576|NCT02297074|Active Comparator|Glucose|Glucose is used to calculate glycemic index, glycemic load and insulinemic index
3354577|NCT02297087|Other|Pilot|Obtain the necessary tumor biopsies to yield sufficient DNA and RNA for Genome-Wide Sequencing (GWS).
3354578|NCT02297113|Active Comparator|conventional endotracheal intubation|Patients assigned to this group will be intubated using conventional Macintosh blade in adequate size.
3354579|NCT02297113|Active Comparator|C-MAC|Patients assigned to this group will be intubated using C-MAC videolaryngoscope in adequate size.
3354580|NCT02297126|No Intervention|Control Arm|4,000 patients receiving a new prescription for targeted medication(s) randomized into the control arm receive standard care (no intervention affecting drug selection, dosage, dosage form, frequency and duration of therapy). Healthcare costs and adverse events data collected and analyzed for 12 months from time of entry into study. List of targeted medications: codeine, amitriptyline, aripiprazole, atazanavir, atomoxetine, azathioprine, citalopram, clopidogrel, cyclophosphamide, doxepin, efavirenz, escitalopram, esomeprazole, fluconazole, simvastatin, fluorouracil, phenytoin, quetiapine, glyburide, lansoprazole, mercaptopurine, methadone, methotrexate, nortriptyline, omeprazole, pantoprazole, rasburicase, tacrolimus, thioguanine, tramadol, venlafaxine, voriconazole and warfarin
3354581|NCT02297126|Experimental|Pharmacogenetic Intervention Arm|2,000 patients receiving new prescription for targeted medication(s) identified in the control arm will be randomized to the intervention arm, consented and a tests will be performed from a blood sample. The treating physicians will be provided with the pharmacogenetic information and will determine if intervention is appropriate. Physician may elect to stay the course of therapy or alter drug selection, dosage, dosage form, frequency or duration of therapy based on the pharmacogenetic test results and input from clinical pharmacology consultations (if requested). Patients in the intervention arm will have their overall healthcare costs and clinical outcomes (specifically adverse events) followed and analyzed for a 1 year period from the time that they are entered into the study
3354583|NCT02297152|Other|FLIP HOLE|The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation
3354584|NCT02297165|Experimental|Program|olfactory stimulation program
3354585|NCT02297165|No Intervention|Control|normal follow-up
3244930|NCT01332864|Experimental|OMT with CV4 to head|OMT is the intervention using the CV4 technique to the head region for 10 minutes with patient at rest.
3244931|NCT01332864|Active Comparator|OMT to the body except the head region|OMT is the intervention that will be applied to areas of somatic dysfunction in any region except the head.
3244932|NCT01332877|Experimental|enriched breakfast|high carbohydrate, high protein breakfast providing 600 kcal, 50% carbohydrate, 20% protein, 30% fat
3354586|NCT02297178||Cystoscopy Alone|Patients who received cystoscopy only for treatment of OAB and voiding dysfunction.
3354587|NCT02297178||Cystoscopy & Urethral Dilatation|Patients who received urethral dilatation and cystoscopy for treatment of OAB and voiding dysfunction.
3354588|NCT02297191|Experimental|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle, evaluate for spread of local anesthesia and to minimize the risk of Ropivicaine being injected intravascularly.~a. Ultrasound images will be saved using the nomenclature TLIP Anat"
3354589|NCT02297204|Experimental|aflibercept|"2mg, as needed, intravitreal administration. All subjects will be treated with intravitreal (IVT) aflibercept injections as needed in the presence of clinically relevant diabetic macular edema (CR-DME). If CR-DME is not present the subject will not receive an IVT aflibercept injection and will be observed.~If a subject has recurrent CR-DME they will receive an IVT aflibercept 2.0 mg injection and interval between visits will be reduced to 4 weeks.~At week 12 through end of study, all subjects will be evaluated for focal laser treatment."
3354590|NCT02297217|Experimental|Chemotherapy with Concurrent Radiation|Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered
3354591|NCT02297243|Experimental|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
3354592|NCT02297256|Active Comparator|BMAC & Allograft|Subjects will be treated with bone marrow aspirate concentrate (BMAC) and allograft during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, 12 teaspoons of bone marrow will be taken (aspirated) from one side of hip bone. This may be repeated on the other side of hip bone for a total of 12, 24, or 36 teaspoons of bone marrow total taken from your hip bone depending on the decision made by the surgeon. The bone marrow will then be concentrated with a machine for 15 minutes to a final volume of 2, 4, or 6 teaspoons of BMAC. BMAC will be combined with packed allograft bone chips using another machine to produce two or three constructed bone logs. The bone logs will be laid along the backside of the spine and between each vertebral body.
3354593|NCT02297256|Active Comparator|Iliac Crest Bone Graft|Subjects who are in the Iliac Crest Bone Graft arm will be treated with Iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion. During lumbar spine surgery, the surgeon will make an incision to expose the iliac crest (hip bone), and cutting out the segments of the bone that will be needed, based on the decision of the surgeon. The bone chips will be laid along the backside of the spine and also between each vertebral body where the bone will fuse into place. When the bone becomes solid/fused, there is no movement in the fused spine.
3354594|NCT02297269||group laparoscopic surgery|Participants undergo laparoscopic gastrointestinal malignancy surgery will be included in this group. The pressure of pneumoperitoneum maintain in 10-12mmHg.
3354595|NCT02297269||group open surgery|Participants undergo open gastrointestinal malignancy surgery will be included in this group.
3354596|NCT02297282|Experimental|Behavioural Activation|Originally a component of Cognitive Therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. Behavioural Activation involves the use of activities to improve life situations or depressed mood.
3354597|NCT02297282|No Intervention|Wait List (Control Group)|The Control group (waitlist) will receive treatment as usual while they are waiting to start the BA intervention at the end of the Intervention Group Therapy time (28 sessions over an 18 week period). In addition to usual care, the control group will be assessed by clinical staff that offers treatment as usual for mood symptoms and quality of life measures during the waiting time.
3354598|NCT02297295|Experimental|Physiotherapy|Comparing the patients to themselves (spontaneus evolution) before intervention.
3354599|NCT02297321|Experimental|DeScribe patch|Comparison of the number of passes achieved using the Describe patch plus laser compared to laser along
3354600|NCT02297334|Active Comparator|With CytoSorb device|Patients randomised to this arm are treated with the CytoSorb device during bypass.
3354601|NCT02297334|No Intervention|Withouot device|Patients randomised to this arm are treated without the CytoSorb device during bypass.
3354602|NCT02297360|Active Comparator|Viviscal Extra-Strength Supplement|Viviscal Extra-strength tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
3354603|NCT02297360|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 90 days.
3244933|NCT01332890|Experimental|Sequence 1|
3244934|NCT01332890|Experimental|Sequence 2|
3244935|NCT01332890|Experimental|Sequence 3|
3244936|NCT01332890|Experimental|Sequence 4|
3244937|NCT01332890|Experimental|Sequence 5|
3244938|NCT01332890|Experimental|Sequence 6|
3244939|NCT01332903|Experimental|1|[14C] AZD5069
3244940|NCT01332916|Experimental|patients aged 45 and over group|patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
3244941|NCT01332916|Active Comparator|healthy volunteers (controls) aged 45 and over|healthy volunteers (controls) aged 45 and over
3244942|NCT01332929|Experimental|Bevacizumab|first level dose : 5 mg/kg Second level dose : 10 mg/kg Third level dose : 15 mg/kg
3244943|NCT01332942|Placebo Comparator|Placebo|
3244944|NCT01332942|Experimental|Molidustat (BAY85-3934) 5 mg|
3244945|NCT01332942|Experimental|Molidustat (BAY85-3934) 10 mg|
3244946|NCT01332942|Experimental|Molidustat (BAY85-3934) 25 mg|
3354604|NCT02297386|Experimental|[18F] DIHYDRO-TESTOSTERONE PET|"The diagnostic intervention of this study is the use of FDHT PET in localized prostate cancer. Patients will undergo a 30 minute dynamic scan of the pelvis followed by a whole body scan of approximately 30-minutes duration. The dynamic scan will be optional, but strongly encouraged. PET scanning will preferably be done on the GE Discovery STE PET/CT scanner or the equivalent generation of scanner. The PET scans are routinely quantitative, that is corrected for attenuation and scatter and adjusted for system sensitivity and providing parametric images in terms of standardized uptake values (SUV) (= μCi found/gm tissue / μCi injected/gm body mass)."
3354605|NCT02297399|Experimental|PEG-ascorbate 2L|Subjects will take 2 liters of a polyethylene glycol 3500 (sodium sulphate, sodium chloride, postassium chloride), ascorbic acid and sodium ascorbate solution.
3354606|NCT02297399|Active Comparator|PEG 4L|Subjects will take 4 liters of a polyethylene glycol 4000 (sodium sulphate, sodium chloride, postassium chloride and sodium bicarbonate) solution.
3244947|NCT01332942|Experimental|Molidustat (BAY85-3934) 50 mg|
3354607|NCT02297425|Experimental|Single agent - study drug|The study will evaluate single-agent PF-06459988
3354608|NCT02297451|No Intervention|Brachial artery inflow|Elbow fistula created with brachial artery as inflow (ie. either brachiocephalic or brachiobasilic fistulas)
3354609|NCT02297451|Active Comparator|Proximal radial/ulnar artery as inflow|Elbow fistula created with either proximal radial or ulnar artery as inflow
3354610|NCT02297464|Experimental|Eggs - 2 per day for breakfast|Participants will consume 2 eggs per day for breakfast for 4 weeks of the study.
3354611|NCT02297464|Experimental|Oatmeal - 1 packet per day for breakfast|Participants will consume 1 packet of oatmeal per day for breakfast for 4 weeks of the study.
3354612|NCT02297477|Active Comparator|atovaquone-proguanil (AP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) for treatment of uncomplicated P. falciparum malaria.
3354613|NCT02297477|Active Comparator|artesunate-atovaquone-proguanil (ASAP)|A standard fixed-dose 3 day regimen of Atovaquone-proguanil (AP) plus 3 days of artesunate (200mg per day) for treatment of uncomplicated P. falciparum malaria.
3354614|NCT02297490|Placebo Comparator|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
3354615|NCT02297490|Experimental|Allergovit 6-grasses immunotherapy|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
3354616|NCT02297542|Active Comparator|Flu Vaccine SD|Fluzone Standard Dose Influenza Vaccine
3354617|NCT02297542|Active Comparator|Flu Vaccine HD|Fluzone High Dose Influenza Vaccine
3354618|NCT02297555|No Intervention|Conventional medical therapy|Conventional medical therapy is defined as the use of the latest lifestyle guidelines to optimize weight loss and glycaemic management, frequent home monitoring/titration strategies, use of latest approved drug therapy for treatment of hyperglycaemia and restoration of pancreatic B cell function, also for dyslipidemia and hypertension in addition to regular follow-up visits to a medical doctor from a multidisciplinary team
3354619|NCT02297555|Experimental|ENDOBARRIER®|The interventional therapy will be the device ENDOBARRIER® over conventional medical therapy
3354620|NCT02297568|Active Comparator|Calciferol,1800 IU/d supplement|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to 1,800 IU/d .
3354621|NCT02297568|Placebo Comparator|Placebo|The lactating mothers and their breastfed infants with maternal 25 Hydroxy-vitamin D (25OHD) levels of 10-30 ng/ml in third trimester were randomly assigned to receive placebo.
3354622|NCT02297581||GFC: Geriatric Fracture Center|"Patient treatment in a geriatric fracture center~A GFC is defined as follows:~General geriatrician or ortho-geriatrician available in trauma/orthopaedic department~Geriatrician sees the patient prior to surgery (except if the patient is admitted over night or during weekends)~Local medical guidelines, consented by orthopedic surgeons and geriatrician~Pre-defined order set for assessing laboratory values~Pre-defined patient pathway to guarantee a fast track in the emergency room~Daily communication among involved specialists~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~Daily patient visit by geriatrician~Daily patient visit by orthopedic surgeon in combination with nurse~Daily therapy by physiotherapists, except for weekends~Access to social workers, if required"
3354623|NCT02297581||UCC: Usual Care Center|"Patient treatment in an usual care center~A UCC is defined as follows:~No geriatrician available in trauma/orthopaedic department~No pre-operative visit by a geriatrician as a standard~No pre-defined medical guidelines for geriatric fracture patients~Postoperative phase up to discharge from orthopaedic / trauma department (i.e. Discharge 1):~No daily patient visits by a geriatrician as a standard"
3354624|NCT02297594|Experimental|AK0529|Generic name: AK0529 Dosage Form: capsule
3354625|NCT02297594|Placebo Comparator|Placebo|Sugar placebo
3354626|NCT02297607|Experimental|Tube Feeding|Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
3354627|NCT02297607|No Intervention|Standard of Care|Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,
3354628|NCT02297620||Suglat group|
3354629|NCT02297633||Stability in patients with COPD|Those patients diagnosed COPD according to the GOLD guideline and without acute exacerbation within one month.
3244948|NCT01332942|Experimental|Molidustat (BAY85-3934) 75 mg|
3244949|NCT01332955|Experimental|Telaprevir-pegIFN alfa-2a-ribavirine|Single Group Assignment
3244950|NCT01333007||Cohort|
3244951|NCT01333020|Experimental|transglutaminase cross-linking of emulsion|The impact of enzyme cross linking of the protein stabilising the test emulsion on gastric emptying rate will be assessed. In this crossover study the subjects will also consume ( on a separate day)an emulsion of the same formulation but not cross-linked.
3244952|NCT01333046|Experimental|Antigen-Escalation Stage|"The first stage will be an antigen-escalation stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix."
3354630|NCT02297633||AECOPD|the diagnosis of an exacerbation relies exclusively on the clinical presentation of the patient complaining of an acute change of symptoms (baseline dyspnea, cough, and/or sputum production) that is beyond normal day-to-day variation.
3354631|NCT02297633||Healthy persons without smoking|The healthy people who do not smoke
3244953|NCT01333046|Experimental|Dose-Escalation Study Stage|"In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:~Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.~Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant."
3244954|NCT01333046|Experimental|azacytidine and multiTAA T cells Stage|This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).
3244955|NCT01333046|Experimental|Pediatric multiTAA T cells Stage|This phase will give patients < 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.
3354632|NCT02297633||Healthy persons with smoking|Healthy persons who smoke
3354633|NCT02297646|Experimental|Carbohydrates|50 grams of carbohydrates 4 times a week for each training session
3354634|NCT02297646|Placebo Comparator|Control|no carbohydrate intake
3354635|NCT02297659|Active Comparator|Crystalloid resuscitation|Patients to receive normal saline resuscitation at a rate of 30cc/hr.
3354636|NCT02297659|Active Comparator|Hypertonic saline resuscitation|Patients to receive 3% hypertonic saline resuscitation at a rate of 30cc/hr.
3354637|NCT02297672|Experimental|Breast seed implant|Stranded palladium seed interstitial radioactive seed implant to seroma with margin with 3 dimensional ultrasound and CT guidance
3244956|NCT01333085|Experimental|RAD001-paclitaxel-carboplatin|RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles
3354638|NCT02297685|Sham Comparator|Sham Transcutaneous nerve stimulation|The group with sham TENS did not receive any current. Four surface electrodes (5×5 cm Prim-Trode®, Spain) were symmetrically placed over the L1 and L5 transverse processes with respect to the spine. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
3354639|NCT02297685|Experimental|Transcutaneous nerve stimulation|The group with TENS received current at a frequency of 80 Hz and with a pulse width of 150 μs with two channels, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
3244957|NCT01333124|Experimental|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
3244958|NCT01333137|Active Comparator|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
3354640|NCT02297685|Experimental|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode, for 30 minutes over a period of 4 weeks, including a total of 12 sessions.
3354641|NCT02297711|Experimental|Total ExtraPeritoneal|Total ExtraPeritoneal (TEP) technique in general anesthesiacanal from behind
3354642|NCT02297711|Active Comparator|Open minimal suture repair|Open minimal repair (OMR) technique in local or spinal anesthesia
3354643|NCT02297724||all subjects|For all subjects, administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan. Data collection will start about 10 min before the administration of oxygen, and last throughout the oxygen exposure, then continue for about 10 min after oxygen exposure for each subject.
3354644|NCT02297737|Experimental|Tai Chi|A manual consisting of 8 movements learned over a period of 12 weeks will be used to teach participants in the Tai Chi condition. Classes will include around 5-6 subjects, each class lasting one hour, including a 10-minute warm-up and cool-down, and meet twice per week. Patients will be told to practice Tai Chi three times/week at home. After 12 weeks of training patients will be told to practice at home five times/week for 8 more weeks, until the 8-week follow-up visit. Subjects will be asked to rate their perceived exertion/work intensity during each session using the Borg's perceived exertion scale and asked to increase the size of their movements to reach 12-13 (moderate difficulty), which consistently matches with 65-70% of HR max.
3354645|NCT02297737|Active Comparator|Health Education|Participants in the Health Education condition will also meet for one hour, twice per week for 12 weeks for a total of 24 hours. Sessions will be highly structured and will emphasize key concepts in the presentations. Medical and allied health experts will provide twelve didactic videotaped presentations on a series of health-related themes and a group leader will be present to answer questions. Themes will include: Epidemiology of Cardiovascular Disease, Patient/Physician Communication, Medication Adherence, Nutrition and Exercise, The Nature and Structure of Sleep, and Navigating the Health Care System.
3354646|NCT02297750|Active Comparator|single wire technique|single wire technique in patients undergoing ERCP with biliary cannulation
3354647|NCT02297750|Active Comparator|Double wire technique|double-wire technique in patients undergoing ERCP with biliary cannulation
3354648|NCT02297763|Active Comparator|quetiapine|quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
3354649|NCT02297763|Placebo Comparator|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
3244959|NCT01333137|Experimental|P276-00 along with Gemcitabine and carboplatin|P276-00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days.In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
3354650|NCT02297776||CPC score 1 to 2|The patients with CPC score 1 to 2 judged half a year after cardiac arrest
3354651|NCT02297776||CPC scores 3 to 5|The patients with CPC score 3 to 5 judged half a year after cardiac arrest
3354652|NCT02297789|Experimental|Headgear 1|Full Face Mask with Headgear 1
3354653|NCT02297789|Experimental|Headgear 2|Full Face Mask with Headgear 2
3354654|NCT02297828|Experimental|Boussignac CPAP|"Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
3354655|NCT02297828|Active Comparator|Ventury face mask|"Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).~Arterial blood samples to measure PaO2 and PaO2/FiO2 ratio are collected before surgery and at 1, 2 and 24 hours after extubation. Spirometry is performed at the same intervals measuring FEV1 and FVC."
3354656|NCT02297854|Experimental|Valganciclovir Hydrochloride Tablets 450 mg|Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited
3354657|NCT02297854|Active Comparator|Valcyte|Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco
3244960|NCT01333150|Experimental|Propranolol|
3244961|NCT01333150|Experimental|Placebo|
3354658|NCT02297867|Experimental|ADSCs|One milliliter of cell suspension will be injected intrahepatically under sonographic guidance using a gauge-18 needle.
3354659|NCT02297880|Experimental|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners (flavour)
3354660|NCT02297880|Active Comparator|Still water|Still water (no flavour)
3354661|NCT02297893|Experimental|Dexterity training program (HOMEDEXT)|This program is a a high intensity training program adapted from a previously published arm ability training program
3354662|NCT02297893|Active Comparator|Theraband training program|7 different Theraband exercises. Total duration is 30 minutes, trained 5 times a week over a period of 4 weeks
3354663|NCT02297906|Experimental|Intranasal ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intranasal route using a mucosal atomization device.
3354664|NCT02297906|Active Comparator|Intravenous ketorolac|Ketorolac 0.5 mg/kg, maximum single dose = 30 mg. Administered once by intravenous route.
3354665|NCT02297919|Experimental|web based intervention|Web based intervention: Students will have access to the educational content through the learning management system on the web site (genc-e-saglik) created for this project.
3354666|NCT02297919|Active Comparator|classic preprepared lesson|Training at the control group,lectures will be presented on the basis of the classic preprepared lesson by educator and at the end of the training, will be answered student's questions.
3354667|NCT02297932|Experimental|Strength training|The intervention will consist of a Home-based Resistant Training Intervention. Participants randomized to the home-based progressive resistance training (PRT) condition and will be provided with a training manual, an exercise log book, and resistance training equipment. The training manual will consist of a detailed description of the exercises to be performed and how to progress over 4-months. The exercise logbook will allow participants to provide a detailed recording of each training session. Home-based PRT equipment will consist of elastic bands (Thera-Band®, Hygenic Corporation, Akron, OH) and weighted vests.
3354668|NCT02297932|Active Comparator|Stretching|Individuals in the comparator group will participate in a four month home-based stretching program developed by the National Multiple Sclerosis Society (NMSS). They will be provided text-based materials and asked to provide a weekly log book. In efforts to equate the attention received, individuals will come to KF at the same frequency as those receiving the PRT intervention and will also engage in the same number of sessions to assess their adherence to the program.
3354669|NCT02297945|Experimental|Metyrapone|Metyrapone will be administered orally in an open-label fashion. Two possible initiation doses will be used depending on the severity of hypercortisolism, dose will then be adjusted (up or down-titrated) during the first month on an individual basis according to clinical tolerance and cortisol levels achieved.
3244962|NCT01333163|Active Comparator|GLP-1|
3244963|NCT01333163|Placebo Comparator|Placebo|
3354670|NCT02297984||Acute ischemic stroke|Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.
3244964|NCT01333176|Experimental|All volunteers have HbA1c test|All candidates receive same procedure
3244965|NCT01333202|Experimental|Fresh lime|Those who were randomly assigned to receive fresh lime were instructed to use it every time they began to crave cigarettes and as often as they needed. Fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible. All participants in this group had to report the number of fresh lime slices used per day in the self-report card.
3244966|NCT01333202|Active Comparator|Nicotine gum|"The dosage of nicotine gum used in this group was primarily based on the participants' FTND scores. Those with FTND score of 4 or above were given 4-mg nicotine gum. The 2-mg gum was assigned only to light smokers. Appropriate gum use by chew and park technique was instructed to all subjects in this group. They were advised to use the gum whenever they began to crave a cigarette but not to exceed more than 20 pieces per day. All participants in this group also had to report the total number pieces of gum used per day in the self-report card. Like the lime use group, phone calls were also made every 2-3 days during the initial month of study to remind them of technique and record keeping."
3244967|NCT01333215||Group 1|Depressed older suicide non-attempters
3244968|NCT01333215||Group 2|Depressed older suicide attempters
3244969|NCT01333228|Experimental|Endothelial Progenitors Cells|Autologous bone marrow-derived endothelial progenitor cells
3244970|NCT01333241|Experimental|Lifestyle behavior intervention group|The 6-month lifestyle behavior intervention includes group education and individual teaching and coaching.
3354671|NCT02297997|Experimental|1.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 1.5mg will be taken daily for two weeks.
3354672|NCT02297997|Experimental|3mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 3mg will be taken daily for two weeks.
3244971|NCT01333241|Sham Comparator|Control group|Disaster Preparedness/Home Safety group education and teaching
3244972|NCT01333254|No Intervention|Indwelling urinary catheter|Patients in this group with hip fracture will get an indwelling catheter at arrival to the orthopaedic ward. The patients with arthrosis get the indwelling catheter in the morning at the day of surgery. In both cases the indwelling catheter is inserted after shower with skin disinfectant. The catheter system is kept close. The catheter will be removed in the morning on day 2 after surgery. The patients are bladder-scanned every four-hour until normal bladder function is recaptured. If the bladder volume exceeds 400ml and the patient is unable to urinate, the patient will be re-catheterised. The procedure of the patients in this arm is in accordance with common practice in the Orthopaedic clinic.
3244973|NCT01333254|Experimental|Intermittent urinary catheterisation|Patients randomised to this arm will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 400 ml urine in the bladder, the patient will be intermittent catheterised.
3354673|NCT02297997|Experimental|4.5mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 4.5mg will be taken daily for two weeks.
3354674|NCT02297997|Experimental|6mg Cetylpyridinium Chloride|Cetylpyridinium chloride of 6mg will be taken daily for two weeks.
3354675|NCT02297997|Placebo Comparator|Control|Placebo will be taken daily for two weeks.
3244974|NCT01333267|Experimental|PTHrP group|Subjects receive PTHrP(1-36) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTHrP doses.
3244975|NCT01333267|Experimental|PTH dosing group|Subjects receive PTH(1-34) starting with doses of 2 picomoles (pmols)/kg/hr for one week. Subsequent dosing groups are determined by the response to PTH doses.
3244976|NCT01333280|Experimental|Double Trouble (DTR) group|Double Trouble in Recovery groups
3354676|NCT02298010||Adjuvant chemotherapy group|Research subjects who were enrolled in CLASSIC trial and underwent adjuvant chemotherapy.
3244977|NCT01333280|Active Comparator|Treatment as usual|Treatment as usual while on a waiting list for DTR groups
3244978|NCT01333293|Experimental|Omalizumab|
3354677|NCT02298010||Only surgery group|Research subjects who were enrolled in CLASSIC trial and did not undergo adjuvant chemotherapy
3354678|NCT02298036|Experimental|Remote Therapy Offered|Participants randomised to this arm receive 6-10 sessions of remote CBT
3244979|NCT01333293|Placebo Comparator|Placebo|
3244980|NCT01333306|Experimental|tDCS and cognitive training|
3244981|NCT01333332|Experimental|Capecitabine, Radiation|
3244982|NCT01333371|Active Comparator|closed reduction with percutaneous k-wire fixation and casted|
3244983|NCT01333371|Active Comparator|open reduction internal fixation with a volar locked plate|
3244984|NCT01333410|Active Comparator|0.1% tacrolimus ointment|
3244985|NCT01333410|Active Comparator|0.1% mometasone furoate cream|
3354679|NCT02298036|No Intervention|Treatment as Usual|Participants do not receive remote therapy and remain in usual care
3354680|NCT02298049|Other|Scanning|"Repeated measures:~Satiation scan + Pre-meal scan~All participants undertook both scans"
3354681|NCT02298062|Experimental|Infliximab|For one group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them infliximab (5mg/kg) once.
3354682|NCT02298062|Active Comparator|IVIG|For the other group of patients with resistance to intravenous immunoglobulin in Kawasaki disease , we will give them IVIG (2g/kg) once.
3354683|NCT02298088|Active Comparator|Ticagrelor 180 mg|Patients assigned to Ticagrelor will receive oral Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
3354684|NCT02298088|Active Comparator|Clopidogrel|"Patients will take the 300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
3354685|NCT02298101|Active Comparator|Aeroneb Solo Adapter|Subjects inhaled radiolabelled aerosol via the Aeroneb Solo Adapter
3354686|NCT02298101|Active Comparator|Standard Jet Nebulizer|Subjects inhaled radiolabelled aerosol via a standard jet nebulizer, the Opti-Mist Plus Nebulizer
3376008|NCT03263559|Experimental|Haploidentical Transplantation|A conditioning regimen with Hydroxyurea, rabbit-ATG, Thiotepa, Fludarabine, Cyclophosphamide, Total Body Irradiation, and Mesna will be administered prior to Haploidentical Bone Marrow Transplantation.
3376009|NCT03254667||Brodalumad exposed|1500 subjects exposes to brodalumab
3376010|NCT03254667||Comparator Subjects|2000 comparator subjects
3244986|NCT01333423|Experimental|Doxil + Seliciclib|Doxil (Liposomal doxorubicin) 40 mg/m2 intravenous (IV) over 2 -3 hours on Day 4 and Seliciclib starting dose 200 mg orally twice a day on Days 1 - 3 of 28 day cycle
3244987|NCT01333449|Experimental|Single Arm|Decitabine 20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
3244988|NCT01333462|Placebo Comparator|Phosphate Buffered Saline (PBS) IN|
3244989|NCT01333462|Active Comparator|Fluzone 4 mcg HA IN|
3244990|NCT01333462|Active Comparator|Fluzone 15 mcg HA IM|
3244991|NCT01333462|Experimental|NB-1008 4 mcg HA 5% W805EC|
3244992|NCT01333462|Experimental|NB-1008 4 mcg HA 10% W805EC|
3244993|NCT01333462|Experimental|NB-1008 4 mcg HA 15% W805EC|
3244994|NCT01333462|Experimental|NB-1008 4 mcg HA 20% W805EC|
3244995|NCT01333462|Active Comparator|Fluzone 10 mcg HA IN|
3244996|NCT01333462|Experimental|NB-1008 10 mcg HA 5% W805EC|
3244997|NCT01333462|Experimental|NB-1008 10 mcg HA 10% W805EC|
3354687|NCT02298114|Experimental|neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine. The electrodes will be placed over the motor points of the following muscles: pectoral muscles (fibres of the pectoralis major muscle) and rectus abdominis muscles (bilaterally) The first training session will have a duration of 30 minutes , which will then be extended by 1 minute for every 2 days of administration. The intensity will be increased until muscle contraction is visible or palpable or, intensity will be adjusted according to tolerance associated conventional physiotherapy. Neuromuscular electrical stimulation will be applied held until extubation end conventional respiratory and motor physiotherapy until discharge from the ICU.
3354688|NCT02298114|Sham Comparator|Conventional physiotherapy|Conventional physiotherapy will be administered by professionals from the physiotherapy department twice a day, for 30 minutes. The protocol will include upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method (two series of 10 repetitions for each bilateral diagonal), manual bronchial hygiene exercises, such as thoracic vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary. Associated will receive placebo electrical stimulation, in this case the procedure is the same, but intensity is set to a sensory level, not high enough to provoke either visible or palpable muscle contractions.
3354689|NCT02298127|Experimental|Shenmen, mouth, lung & stomach|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the shenmen, mouth, lung and stomach.
3354690|NCT02298127|Experimental|Subcortex,endocrine&sympathetic systems|Participants in this group will receive 4 weekly treatment sessions of auricular acupressure via the subcortex, endocrine and sympathetic systems.
3354691|NCT02298127|Sham Comparator|Elbow, shoulder & knee|Participants in this group will receive 4 weekly treatment sessions of sham-controlled acupressure on the elbow, shoulder and knee acupoints on the auricle that is non-specific to smoking cessation.
3354692|NCT02298140|Experimental|SMS reminders|This arm will receive automated mobile phone text message reminders for health workers in outpatient departments of public and private health facilities on issues related to care of malaria patients and suspected patients.
3354693|NCT02298153|Experimental|atezolizumab (MPDL3280A) + epacadostat (INCB024360)|atezolizumab (MPDL3280A) 1200 mg given every 3 weeks + epacadostat (INCB024360) 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified
3354694|NCT02298166|Placebo Comparator|Standard arm|chemotherapy (MC) in combination with placebo
3354695|NCT02298166|Experimental|Experimental arm|chemotherapy (MC) in combination with crenolanib
3354696|NCT02298205|Other|Provider-based adjustment|Primary care provider will adjust the dose of asthma controller medication based on asthma control at each encounter
3354697|NCT02298205|Active Comparator|Symptom-based adjustment|The dose of asthma controller medication is adjusted based on the symptoms
3354698|NCT02298218|Experimental|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
3244998|NCT01333462|Experimental|NB-1008 10 mcg HA 15% W805EC|
3244999|NCT01333462|Experimental|NB-1008 10 mcg HA 20% W805EC|
3354699|NCT02298218|No Intervention|No intervention|During 6 months, without meloxicam, the maintenance will be decided by the comparison of liver stiffness score comparing the intervention group.
3354700|NCT02298231|Experimental|Group 1|Standard of Care Balance (SCB) Treatment
3354701|NCT02298231|Experimental|Group 2|Mystic Isle (MI) Balance Training
3354702|NCT02298231|Experimental|Group 3|Mystic Isle (MI) Dual Task Training
3354703|NCT02298244|Active Comparator|PV isolation + GP Ablation|
3354704|NCT02298244|Active Comparator|PV isolation + GP ablation + Pulmonary GP ablation|
3354706|NCT02298270|Experimental|Relaxation Response Resiliency Program|Participants will receive an 8-week behavioral intervention which teaches stress management and psychological resiliency-enhancing skills.
3245000|NCT01333514|Experimental|Carbohydrate based prandial insulin dosing|Subjects will received prandial insulin based on the amount of carbohydrates consumed.
3245001|NCT01333514|Active Comparator|Usual Care Prandial insulin dosing|Subjects will received prandial insulin if they consume 50% or more of their meal-tray as is the usual care.
3245002|NCT01333540|Experimental|Active|Escalating Doses of TD-1211
3354707|NCT02298270|Placebo Comparator|Health Education|Participants will receive and 8-week general stress and health education program, with none of the active relaxation and resiliency-based components being tested in the experimental condition.
3245003|NCT01333540|Placebo Comparator|Placebo|
3245004|NCT01333553||Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
3245005|NCT01333566|Experimental|Intervention Group|
3245006|NCT01333566|Placebo Comparator|Control Group|
3245007|NCT01333579|Active Comparator|Active rTMS|1Hz active rTMS delivered to the unaffected hemisphere
3245008|NCT01333579|Placebo Comparator|Placebo rTMS|1Hz placebo rTMS delivered to the vertex
3245009|NCT01333605|Experimental|IGEV regimen|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles
3245010|NCT01333618|Experimental|curving introducer|
3245011|NCT01333618|Placebo Comparator|straight introducer|
3354708|NCT02298283|Experimental|study treatment|"induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks~radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks~Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg"
3354709|NCT02298296||No treatment|
3354710|NCT02298309|No Intervention|Usual Care|Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa
3354711|NCT02298309|Active Comparator|Test-and-Treat Intervention|Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.
3245012|NCT01333631|Experimental|Valporoic acid + chemoradiotherapy|
3245013|NCT01333644||HIV-Infection|Treated HIV-infected individuals with an undetectable HIV RNA level (< 75 copies RNA/mL, untreated HIV-infected individuals, and HIV-uninfected individuals.
3245014|NCT01333657||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3354712|NCT02298335|Experimental|prednisone|First,full-dose induction period, then protracted tapering period.
3354713|NCT02298348|Other|Sorafenib and Cyclophosphamide/Topotecan|Sorafenib and Cyclophosphamide/Topotecan with growth factor support.
3354714|NCT02298374|Experimental|Homecare reablement|Receives comprehensive assessment and individualized follow-up according to a plan with short and longterm goals.
3354715|NCT02298374|Active Comparator|Usual care|Receives normal care
3354716|NCT02298387|Experimental|OMP-305B83|The dose levels of OMP-305B83 will be 0.5, 1.0, 2.5, 5 and 10 mg/kg administered IV once every 3 weeks.
3354717|NCT02298400|Active Comparator|Acuvue®Oasys® Lenses(senofilcon A)|Acuvue® Oasys® Lenses (senofilcon A) contact lenses
3354718|NCT02298400|Active Comparator|Bausch + Lomb PureVision (balafilcon A)|30-Day Bausch + Lomb PureVision (balafilcon A) contact lenses
3354719|NCT02298400|Active Comparator|Clariti® 1-Day (Somofilcon A)|Clariti® 1-Day (Somofilcon A) contact lenses
3354720|NCT02298426|Experimental|health management and product|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
3354721|NCT02298426|Experimental|general management and product|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use dietary supplement products of SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS® to help balance the constitution of participants."
3354722|NCT02298426|Experimental|health management and placebo|"We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.~Meanwhile, we use placebo to replace the dietary supplement products."
3354723|NCT02298426|Placebo Comparator|general management and placebo|"We provide general information about health. Information is provided through telephones and materials.~Meanwhile, we use placebo to replace the dietary supplement products."
3354724|NCT02298452|Other|Hearing aid|172 subjects with a mild hearing loss. 140 subjects with a moderate hearing loss. 70 subjects with a severe/ profound hearing loss.
3354725|NCT02298465|Active Comparator|Prone ESWL|ESWL for distal ureteric stone is performed in the traditional prone position
3354726|NCT02298465|Experimental|Supine ESWL|ESWL for distal ureteric stone is performed in the supine position, with the shockwave generator head placed at a 30 degree angle to the vertical at the patient's gluteal muscles. Thus, the shockwaves will travel via the greater and lesser sciatic foramina to reach the stone
3245015|NCT01333657||Sepsis|"sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3245016|NCT01333670|Experimental|Prontosan wound irrigation solution|
3354727|NCT02298478|Experimental|Group without support by the therapist|"Intervention group that do the NO-FEAR Airlines program and does not receive support by the therapist."
3354728|NCT02298478|Experimental|Group with support by the therapist|"Intervention group that do the NO-FEAR Airlines program and receives support by the therapist (a brief weekly five-minutes call)."
3354729|NCT02298478|Other|Waiting list control group|"Control group that could access the NO-FEAR Airlines program after waiting for 6 weeks.~After that time, those participants still interested were randomly assigned to one of two intervention conditions (with or without support by the therapist)."
3354730|NCT02298504|Experimental|Indirect pulp cap|IDP will be performed for this group
3354731|NCT02298504|Experimental|MTA pulpotomy|MTA pulpotomy will be performed for this group
3354732|NCT02298504|Experimental|Biodentin pulpotomy|Biodentin pulpotomy will be performed for this group
3354733|NCT02298517|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3354734|NCT02298517|Experimental|Incentive spirometry to flow|Was determined for this study that the flow of inspired air will be sufficient to raise up to three spheres. In addition to direct them to do explosive, fast and deep, lifting the ball explosively breaths. Every fifteen inspirations volunteers will be invited to rest for intervals of 30-60 seconds and repeat six times. The use of incentive spirometry was adapted from the recommendations of the American Association for Respiratory Care (1991).
3354735|NCT02298517|Experimental|incentive spirometry to volume|Use of this incentive spirometry will be done as follows: the participants will be instructed to inhale deeply through the mouthpiece, to total lung capacity, starting from functional residual capacity. Will be performed 6 sets of 15 breaths each (deep, slow and sustained) intervals with 30-60 seconds between each series.
3245017|NCT01333670|Active Comparator|Standard care|
3245018|NCT01333683||Control|Normal subjects
3354736|NCT02298517|Experimental|inspiratory load equipment-Threshold|This group will use the device Threshold™. Where adjustment is considered 40% of PNSN achieved by the patient evaluation. The volunteer will be instructed to remain in a supine position with 45 ° fowler comfortably with arms and shoulders relaxed and perform an inspiration with enough force to overcome the linear load of the device, then make a normal expiration. This study was determined to carry six sets of 15 repetitions. The rest will be about one to two minutes in each intervention.
3354737|NCT02298517|Experimental|inspiratory load equipment-Power breathe|To exercise inspiratory muscle in this group will be used device Power breathe ® K2 have the same resistance setting, allowing us to tailor your level of inspiratory muscles. Such adjustment will be made considering 40% of PNSN achieved by the patient in the assessment sniff. For its implementation, the patient will be lying with a tilt of the head of the litter at 45 °, the patient will be asked to inspire to overcome the resistance of the linear unit and after performing a normal expiration. This group will also be achieved 6 series with 15 repetitions each, with an interval of one to two minutes between sets.
3245019|NCT01333683||AH|Arterial hypertension patients
3245020|NCT01333696|Experimental|Pemetrexed|500 mg/m2, repeated every 3 weeks until disease progression or intolerable toxicity
3354738|NCT02298530|Experimental|Combination of caffeine and theanine|250 mg caffeine + 200 mg theanine
3354739|NCT02298530|Placebo Comparator|Caffeine|250 mg caffeine
3354740|NCT02298543||coronary spasm|
3354741|NCT02298556||Hypertensive patients|Hypertensive patients with elevated heart rate and type 2 diabetes mellitus
3354742|NCT02298569|No Intervention|Phase 1 (before multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of a French perinatal network consecutively, whatever the duration of their hospital stay
3354743|NCT02298569|Experimental|Phase 2 (after multi-pronged program)|400 low-risk mothers having given birth without any complication to a healthy newborn are to be recruited in the 5 maternity wards of the same French perinatal network 3 months after the intervention (introduction of the multi-pronged program) consecutively, whatever the duration of their hospital stay
3354744|NCT02298582|Experimental|Intranasal fentanyl|
3245021|NCT01333709|Experimental|Arm A: immediate rectal surgery|"Very good responder patients will be randomly assigned to proctectomy within 2-4 weeks after the end of the induction chemotherapy."
3245022|NCT01333709|Other|Arm B: RCT Cap 50 and then rectal surgery|"Very good responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
3245023|NCT01333709|Other|Arm C: RCT Cap 50 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 50 grays (2Gy/day, 5 days a week, 5 weeks, boost 6 Gy)."
3245024|NCT01333709|Experimental|Bras D: RCT Cap 60 and then rectal surgery|"Good or poor responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg/m2/day, BID) and radiotherapy at a total dose of 60 grays (2Gy/day, 5 days a week, 6 weeks, boost 14 Gy)."
3245025|NCT01333735||Patients with chemotherapy group|Patients with breast or colon cancer must beginning a chemotherapy (colon group was ended)
3245026|NCT01333735||Patients without chemotherapy group|patient with breast or colon cancer should not receive chemotherapy (colon group was ended)
3245027|NCT01333748|Experimental|patients group|Patients with ovarian and/or breast cancer
3245028|NCT01333748|Other|control population|control population without history of breast and/or ovarian cancer
3245029|NCT01333761|Experimental|TCD/Cardiox FDS/TEE testing|All patients enrolled will be evaluated with TCD and Cardiox FDS and TEE for the presence of RTLS.
3245030|NCT01333774||Group 1|
3245031|NCT01333787|Active Comparator|Dietary Fiber Mixture|The dietary fiber mixture was composed of six different types of fibers. It was used for treatment of chronic constipation in children.
3245032|NCT01333787|Placebo Comparator|Maltodextrine|Blinded control group
3245033|NCT01333800|Active Comparator|Ciclesonide|
3354745|NCT02298595|Experimental|1: Low risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then observation.
3354746|NCT02298595|Experimental|2: Intermediate risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT).
3354747|NCT02298595|Experimental|3: High risk|3 cycles (3 weeks) of induction chemotherapy (cisplatin+paclitaxel+BYL719) followed by transoral resection (TORS or TLM) and then Intensity Modulated Radiation Therapy (IMRT) + cisplatin.
3354748|NCT02298608|Experimental|Irreversible Electroporation|Percutaneous, CT guided, Irreversible Electroporation of renal mass
3354749|NCT02298621|Experimental|pomegranate juice|pomegranate juice: 500 ml
3354750|NCT02298621|Placebo Comparator|placebo|sugar + aroma+ color: 500ml
3354751|NCT02298634||Observation|Patients with Farber disease or high-grade suspicion for Farber disease
3245034|NCT01333800|Placebo Comparator|Beclomethasone|
3245035|NCT01333826|Experimental|Unconditional cash transfers|Monthly cash transfers given to households with school aged girls with no strings attached. Transfer amounts randomized within this arm.
3245036|NCT01333826|Experimental|Conditional Cash Transfer|Monthly cash transfers given to households with school aged girls conditional on regular school attendance (80%). Transfer amounts randomized within this arm.
3245037|NCT01333826|No Intervention|Control Group|No cash transfer program implemented in this group.
3245038|NCT01333839|Active Comparator|standard exercise intervention|12 weeks of endurance exercise training
3245039|NCT01333839|Active Comparator|modified exercise intervention|combined endurance + strength exercise training
3245040|NCT01333839|Active Comparator|modified 2 exercise intervention|combined endurance + strength exercise training + oral protein supplements
3245041|NCT01333852|Active Comparator|Paclitaxel, placebo|Paclitaxel 175mg/m² q21d until disease progression, unacceptable toxicity or consent withdrawal
3245042|NCT01333852|Experimental|Paclitaxel plus metformin|Paclitaxel 175mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
3354752|NCT02298647||Observation|Patients with GM1/GM2-Gangliosidosis or high-grade suspicion for GM1/GM2-Gangliosidosis
3354753|NCT02298660|Experimental|BOTOX|BOTOX® Total dose per patient: 200U Number of cycles:1 cycle Treatments will be conducted according to established protocol, 200 BOTOX® units with intradetrusor injections under cystoscopic guided injections into 20 sites, trigone sparing. One month later, urodynamics with continuous arterial blood pressure and electrocardiogram measurements will be repeated, as well as 24 hour ambulatory blood pressure monitoring. AD- HR QoL and I-QOL questionnaires will be administered to evaluate the effect of Botox on AD HR-QoL and bladder-related QoL.
3354754|NCT02298673||Observation|Patients with Mucolipidosis Disorder type I,II,III or IV or high-grade suspicion for Mucolipidosis Disorder type I,II,III or IV
3354755|NCT02298686||Observation|Patients with Sanfilippo Type A-B-C-D disease or high-grade suspicion for Sanfilippo Type A-B-C-D disease
3354756|NCT02298699||Observation|Patients with Sly disease or high-grade suspicion for Sly disease
3354757|NCT02298712||Observation|Patients with Hurler disease or high-grade suspicion for Hurler disease
3245043|NCT01333878|Experimental|Open-Label Subcutaneous Abatacept|Open-Label Subcutaneous Abatacept
3354758|NCT02298725|Experimental|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans. All foods and beverages will be provided to enrolled subjects during the intervention period.
3354759|NCT02298725|Experimental|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet plan will be closely aligned with the NHANES What We Eat In America report. All foods and beverages will be provided to enrolled subjects during the intervention period."
3354760|NCT02298738||New onset Atrial fibrillation|New-onset AF was defined as patients with hypertension and atrial fibrillation which was identified for the first time by an electrocardiogram or ambulatory holter monitoring.
3354761|NCT02298738||control|Hypertensive patients without atrial fibrillation.
3354762|NCT02298751|Experimental|CET via smartphone|Cue Exposure Treatment
3354763|NCT02298751|Experimental|CET via group sessions|Cue Exposure Treatment
3354764|NCT02298751|No Intervention|Aftercare as usual|
3354765|NCT02298764|Active Comparator|standard + 10 psychotherapeutic sessions|- standard back pain treatment plus 10 psychotherapeutic sessions, that will include the shock-trauma method 'Somatic Experiencing'.
3354766|NCT02298764|Active Comparator|Standard back pain treatment|Standard back pain treatment
3354767|NCT02298777||Scleroderma (SSc) patients (beginners and established forms).|"Patients with the ACR / EULAR (2012) and / or criteria of Leroy and Medsger (2001)~Biological samples (skin, urine and blood):~1st point at patient's inclusion visit~2nd point (optional) at SSc patient's visceral complication (assessed during 3 years)"
3245044|NCT01333891|Active Comparator|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
3245045|NCT01333891|Active Comparator|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
3245046|NCT01333891|Active Comparator|Suction Cup|suction force of 25, 50, 75, and 100 mmHg
3245047|NCT01333904|Experimental|PUR118|
3245048|NCT01333917|Experimental|Curcumin|4g Curcumin C3 tablet daily
3245049|NCT01333930|Experimental|Test product (Active O2)|
3245050|NCT01333930|Placebo Comparator|Placebo (Adelholzener Mineralwasser)|
3354768|NCT02298777||Undifferentiated Connective Tissue Disease (UCDT) patients|"Patients with criteria proposed by Mosca et al. (1998)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3245051|NCT01333969|Active Comparator|Ishcemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components).
3245052|NCT01333969|No Intervention|Control|In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
3245053|NCT01333982|Experimental|Referral compliance|Health workers will receive a basic maternal, newborn and child health training under the MNCS programme. Newborn sepsis management training will be organised for the study. The Bangladesh Perinatal Society (BPS) will take the lead in developing and implementing the training programme with support from Saving Newborn Lives (SNL) and other partners.Referral slips will be used in the intervention unions for all the sick newborns identified so that they seek care on a timely fashion.
3245054|NCT01333982|Experimental|Neonatal sepsis|Existing health delivery systems in the community level in managing neonatal sepsis.
3245055|NCT01333995|No Intervention|Usual Health Message|No intervention mothers will recieve standard maternal and child care education
3245056|NCT01333995|Sham Comparator|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
3245057|NCT01334008|Other|Blood sampling|
3245058|NCT01334021|Experimental|Diagnostic (biopsy, surgery, genetic testing)|Patients undergo biopsy or surgery to obtain tumor sample for genetic testing. Patients are then assigned to 4 treatment cohorts as determined by genetic test results.
3245059|NCT01334034|Experimental|Dose levels 1-7|
3245060|NCT01334047|Experimental|DC vaccine|Dendritic cells loaded with amplified ovarian cancer stem cell mRNA, hTERT and Survivin.
3245061|NCT01334060|No Intervention|CML HLA A2-|
3245062|NCT01334060|No Intervention|AML HLA A2-|
3245063|NCT01334060|Experimental|AML HLA A2+|
3245064|NCT01334060|Experimental|CML HLA A2+|
3245065|NCT01334073|Experimental|Axitinib plus everolimus|
3245066|NCT01334099|Experimental|Radiation combined with CP-675,206|
3354769|NCT02298777||Raynaud disease patients|"Patients with primary and isolated Raynaud disease~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3245067|NCT01334112|Experimental|Axitinib|Oral Axitinib (5mg, twice daily) will be administered to all patients
3245068|NCT01334138|Experimental|4-week diet, low in sodium|The study subjects go on a 4-week diet, low in sodium.
3245069|NCT01334151|Active Comparator|Humalog®|Humalog®, administered subcutaneously on 1 occasion
3354770|NCT02298777||Vascular disease patients|"Patients with vascular disease (type 2 diabetes, occlusive vascular disease, history of myocardial infarction or ischemic stroke)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3354771|NCT02298777||Healthy control subjects|"Healthy subjects (no sign of connective tissue disease, no Raynaud, no vascular disease)~Biological samples (skin, urine and blood):~- 1single point at patient's inclusion visit"
3354772|NCT02298790|Experimental|Early Meals|Meals are eaten early in the wake episode
3354773|NCT02298790|Experimental|Late Meals|Meals are eaten late in the wake episode
3354774|NCT02298816||new B-Cell Hematologic Malignancy diagnosis|All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).
3245070|NCT01334151|Experimental|BIOD- 105|BIOD- 105 administered subcutaneously on 1 occasion
3245071|NCT01334151|Experimental|BIOD-107|BIOD-107 administered subcutaneously on 1 occasion
3354775|NCT02298829||No Treatment|Subjects who received AA4500 in a 12-month double blind placebo-controlled study (AUX CC 803 or AUX-CC-804) or in a 9-month open label study (AUX-CC-802 or AUX-CC-806) sponsored by Auxilium Pharmaceuticals, Inc.
3354776|NCT02298855|No Intervention|Conventional follow-up|Treatment as usual will involve: one post treatment appointment then 3 monthly appointments with a Dr. At appointments: medical history; investigations to monitor disease progression including CA125 tumour marker blood test if this were raised at diagnosis. A physical examination may be performed.
3354777|NCT02298855|Experimental|Individualised follow-up|Follow-up is delivered by a nurse and frequency and type (telephone or face-to-face) is negotiated to suit their individual situation. Assessment by holistic guide. The intervention is informed by a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to help patients manage symptoms and psychological discomfort.
3354778|NCT02298881||Dry eye group|People with dry eye symptoms
3354779|NCT02298881||Non-dry eye group|People with no dry eye symptoms
3354780|NCT02298920|Experimental|Single Group|Open Label ADME Study
3245072|NCT01334164|Experimental|Recovery Management Checkup (RMC)|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
3245073|NCT01334164|Active Comparator|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own.
3245074|NCT01334177|Experimental|Treatment (immunotherapy and monoclonal antibody therapy)|Patients receive cetuximab IV over 60-120 minutes on days -28, -21, -14, -7 of weeks -4 to -1. Patients then receive cetuximab IV on days 1, 8, 15, and 22 and TLR8 agonist VTX-2337 SC on days 1, 8, 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3245075|NCT01334203|Experimental|Ranolazine|
3354781|NCT02298972|No Intervention|Comparison group|The comparison group will receive standard care.
3354782|NCT02298972|Active Comparator|Intervention group|After completion of the comparison group, new patients starting chemotherapy treatment will be offered this study. Study participants will receive the nurse support and selfmanagement intervention.
3354783|NCT02298985|Active Comparator|curcumin|curcumin 3 g/day for 6 months
3354784|NCT02298985|Placebo Comparator|placebo|curcumin 3 g/day for 6 months
3354785|NCT02298998||Intervention|The intervention group refers to surveillance based on the EAU guidelines.
3354786|NCT02298998||Control|The control group refers to surveillance based on the AUA guidelines.
3354787|NCT02299011|Experimental|Orsiro drug eluting stent|Orsiro drug eluting stent
3354788|NCT02299011|Active Comparator|Biomatrix drug eluting stent|Biomatrix drug eluting stent
3354789|NCT02299024|No Intervention|Control|Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
3354790|NCT02299024|Experimental|Dual Modality Educational Intervention|"Patients in this arm are discharged from the ED with an additional information sheet about their prescribed opioid pain medication, via the intervention titled Additional Opioid Information. The sheet is read aloud to them by a research assistant. They are called 4-7 days later for a follow up survey."
3354791|NCT02299063|Placebo Comparator|Placebo (0.9% Saline)|0.9% Saline: bolus dose of 0.125mL/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.15mL/kg/hr for the duration of surgery.
3354792|NCT02299063|Experimental|Dexmedetomidine|Dexmedetomidine: bolus dose of 0.5 mcg/kg infused over 10 minutes, followed by a continuous infusion (CI) dose at 0.6 mcg/kg/hr for the duration of surgery.
3354793|NCT02299102|Other|Jamshidi Manual Standard Device|The Jamshidi manual standard device will be randomized for use on the right or left iliac crest
3354794|NCT02299102|Other|OnControl Powered Ported Device|The OnControl power ported device will be used on the opposite iliac crest
3354795|NCT02299115|Experimental|Prednisolone|Single center, prospective, observational, open trial using high-dose oral prednisolone as first-line treatment for newly diagnosed Infantile Spasms (non-Tuberous Sclerosis)
3354796|NCT02299115|Active Comparator|Vigabatrin|Retrospective controls composed of our cohort of non-Tuberous Sclerosis Infantile Spasms patients from January 2010- September 2013 who received Vigabatrin as first-line treatment.
3354797|NCT02299128|Sham Comparator|Minimally Therapeutic Treatment|Non-differential, prescriptive protocol of physical therapy treatment with minimal to no therapeutic benefit.
3354798|NCT02299128|Experimental|Skilled Treatment|Differential treatment based on the results from the assessment. Physical Therapy treatment in this arm will be pragmatically designed and modified by the treating therapist. Treatments will include manual therapy to the cervical spine, neuromotor retraining (position sense and movement sense), habituation and adaptation exercises.
3245076|NCT01334203|Placebo Comparator|Placebo|
3354799|NCT02299154|Experimental|Patient with memory disorders|psychological questionnaires
3354800|NCT02299154|Experimental|Accompanier|psychological questionnaires
3245077|NCT01334242|Experimental|LX4211|400 mg of LX4211 administered orally
3245078|NCT01334242|Placebo Comparator|Placebo|Nonidentical placebo administered orally
3245079|NCT01334255|Experimental|0.5 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
3354801|NCT02299180|No Intervention|Control arm|The control arm patients will not take part in ACP discussions and documentation, but will continue to receive usual care.
3354802|NCT02299180|Experimental|Intervention (ACP) arm|The patient and his/her family members will be referred to an ACP facilitator and will undergo ACP as an ongoing process, integrated with patient's care, from the facilitator, in coordination with a coordinator/nurse, and treating physician. The ACP facilitator will be certified in providing ACP and will possess sufficient knowledge of the risks, benefits, and harms of treatments and procedures available to the patient. The ACP facilitator will be supported by the physician with the specialized knowledge of treatment options, especially with regards to prognosis. Family members will be encouraged to be present during the ACP discussion so that the whole family unit will be able to explore goals, values and beliefs towards the patient's medical care.
3354803|NCT02299193|Experimental|Cognitive Behavioral Therapy|online sessions on how behaviors and thoughts that can affect sleep.
3354804|NCT02299193|Sham Comparator|Healthy Sleep Habits|online sessions about healthy sleep practices
3354805|NCT02299219|Experimental|Taking Charge Experimental Group|
3354806|NCT02299219|Active Comparator|Control Group|
3245080|NCT01334255|Experimental|2.0 mg of iSONEP (sonepcizumab/LT1009)|iSONEP (sonepcizumab/LT1009) is a humanized murine monoclonal antibody to sphingosine 1-phosphate
3354807|NCT02299232|Active Comparator|dexmedetomidine 3mcg/kg|dexmedetomidine 3 mcg/kg intranasal 50 minutes before MRI
3354808|NCT02299232|Active Comparator|dexmedetomidine 4mcg/kg|dexmedetomidine 4 mcg/kg intranasal 50 minutes before MRI
3354809|NCT02299245|Experimental|randomised to rosuvastatin (20mg/d)|randomised to rosuvastatin (20mg/d)
3354810|NCT02299245|Active Comparator|randomised to rosuvastatin (10mg/d)|randomised to rosuvastatin (10mg/d)
3354811|NCT02299271|Active Comparator|ropivacaine block|Ropivacaine 0.375% as a one-time 60 milliliter injection.
3354812|NCT02299271|Placebo Comparator|saline block|Sodium chloride 0.9% as a one-time 60 milliliter injection.
3354813|NCT02299284|Experimental|Hand-Arm Bimanual Intensive Therapy (HABIT)|HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
3354814|NCT02299284|Experimental|Intensive Functional Lower-Limb Training|lower-limb function, strength training, balance, PT, OT, rehab
3354815|NCT02299310|Experimental|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
3354816|NCT02299310|Active Comparator|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
3354817|NCT02299401|Experimental|Buccal|Women randomized to receive three 800 mcg doses of misoprostol taken buccally in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
3354818|NCT02299401|Experimental|Sublingual|Women randomized to receive three 800 mcg doses of misoprostol taken sublingually in three hour intervals. All women receive a semi-quantitative pregnancy test for at-home follow up.
3354819|NCT02299414|Experimental|Anti-hypertensive therapy to goal <140/90 mmHg|Labetalol or Nifedipine ER will be used as first-line to achieve goal; if necessary Nifedipine ER or Labetalol will be second-line antihypertensive. Rarely, other antihypertensive medications may also be used
3354820|NCT02299414|Active Comparator|No anti-hypertensive unless BP is severe (≥160/105 mmHg|Antihypertensive therapy given only if BP becomes severe (defined as BP ≥160/105). The lowest dose of anti-hypertensive needed to keep blood pressure below this threshold will be given (1st-line - Labetalol or Nifedipine ER and 2nd-line - Labetalol or Nifedipine ER). Rarely other medications may be used
3245081|NCT01334268|Active Comparator|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Subjects will be randomized to be treated with Taxus Liberte Paclitaxel-Eluting Coronary Stent System by an interactive voice response system (IVRS).
3245082|NCT01334268|Experimental|Medtronic Resolute (Zotarolimus-eluting stent)|Subjects will be randomized to be treated with Medtronic Resolute (Zotarolimus-eluting stent) by an interactive voice response system (IVRS).
3245083|NCT01334281||Blood: Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
3245084|NCT01334281||Blood: NOT Undergoing Desensitization|Transplant subjects give blood at specified time points. Sensitization to HLA antigens is a barrier to transplant. Several U.S. institutions have protocols for desensitization where patients are treated with IV immunoglobulins (IVIg) and plasmapheresis (PP) to reduce circulating HLA-directed antibody levels. Labs provide doctors information on circulating donor-specific antibody (DSA) levels. These results are the main indicator whether to proceed with transplant. However, no information is given on the fate of the B cells that produce the DSA.
3354821|NCT02299440|Experimental|Ketamine|"Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions"
3354822|NCT02299440|Placebo Comparator|Placebo/Control|"Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions"
3354823|NCT02299453|Experimental|Experimental|Participants receive 9 sessions of telephone-administered PT and have access to standard community-based services. As part of the 9 sessions, participants discuss the extent to which interpersonal issues such as bereavements, role transitions, interpersonal disputes, and relationship difficulties may be related to their depression.
3354824|NCT02299453|No Intervention|Standard of Care|Participants receive no active intervention but do have access to standard community-based services, such as individual therapy, support groups, 12-step programs, and other social serves.
3245085|NCT01334294||1. Received therapy for CNV|
3245086|NCT01334307|Experimental|Lung Volume Reduction Coil (LVRC)|Lung Volume Reduction Coil (LVRC)
3354825|NCT02299492|Experimental|Person-Centered Care Planning|Arm will receive provider level training in Person Centered Care Planning
3354826|NCT02299492|No Intervention|Treatment as Usual|Arm will receive treatment as usual in community mental health clinic
3245087|NCT01334307|Placebo Comparator|Control|Standard of Care
3354827|NCT02299505|Experimental|ceritinib 450 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 450 mg (3×150 mg/capsule) administered in the morning immediately (within 30 minutes)following a low-fat meal.
3354828|NCT02299505|Experimental|ceritinib 600 mg with a low-fat meal|Oral ceritinib QD (21 days/ cycle) at a dose of 600 mg (4×150 mg/capsule) administered in the morning immediately (within 30 minutes) following a low-fat meal.
3354829|NCT02299505|Active Comparator|ceritinib 750 mg on an empty stomach|Oral ceritinib QD (21 days/ cycle) at a dose of 750 mg (5×150 mg/capsule) administered in the morning on an empty stomach (i.e., fasted from food and drink except water)
3354830|NCT02299518|Experimental|Cohort A (mitoxantrone, etoposide, cytarabine, selinexor)|Patients receive mitoxantrone hydrochloride IV, etoposide IV, and cytarabine IV QD on days 1-6 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment continues for 1 course (28 days). Further treatment is based on disease response. Patients achieving CR/CRi are evaluated for stem cell transplant; patients who do not proceed to transplant may receive selinexor as monotherapy in the absence of disease progression or unacceptable toxicity.
3354831|NCT02299518|Experimental|Cohort B (etoposide, selinexor)|Patients receive etoposide PO QD on days 1-5 and selinexor PO on days 1, 3, 8, 10, 15, and 17. Treatment may repeat every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving response after 4 courses discontinue treatment; patients achieving response may receive up to 4 courses of maintenance therapy every 8 weeks. Patients may then continue selinexor as monotherapy at the discretion of the principal investigator.
3354832|NCT02299531|Experimental|Low Energy Density, Small Portions|Low meal energy density and small portion sizes
3354833|NCT02299531|Experimental|Low Energy Density, Medium Portions|Low meal energy density and medium portion sizes
3354834|NCT02299531|Experimental|Low Energy Density, Large Portions|Low meal energy density and large portion sizes
3354835|NCT02299531|Experimental|High Energy Density, Small Portions|High meal energy density and small portion sizes
3354836|NCT02299531|Experimental|High Energy Density, Medium Portions|High meal energy density and medium portion sizes
3354837|NCT02299531|Experimental|High Energy Density, Large Portions|High meal energy density and large portion sizes
3245088|NCT01334320|Experimental|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
3245089|NCT01334320|No Intervention|wait and see|patient underwent primary tumor excision transorally as initial treatment, and without a cervical intervention
3354838|NCT02299544|Experimental|OAB|"Patients with overactive bladder (OAB) with or without urge incontinence.~Two patient populations will be enrolled in the study:~Patients with no previous treatment with percutaneous tibial nerve stimulation (PTNS) [de novo patient group] and Patients with a documented success on PTNS therapy [prior-PTNS group]. Documented success on PTNS is defined by a ≥50% reduction in urinary frequency, and/or ≥50% fewer incontinence episodes, or a return to normal voiding frequency [<8 voids/day], based on retrospective diary review.~All patients will be treated with BlueWind Medical System."
3354839|NCT02299557|Experimental|Treatment|Intra-anal Oxymetazoline gel once daily
3354840|NCT02299557|Placebo Comparator|Placebo|Intra-anal Placebo gel once daily
3354841|NCT02299583|Experimental|Preventive intervention|In this arm HCPs will conduct a trauma-informed early intervention with children and families after exposure to potentially traumatic events (PTE).
3354842|NCT02299583|No Intervention|Control group|There will be no intervention in this arm. The outcome will show the efficiency of usual care.
3245090|NCT01334333|Active Comparator|Prograf®|Prograf® is a twice daily formulation of tacrolimus
3245091|NCT01334333|Experimental|Advagraf®|Advagraf® is a once daily formulation of tacrolimus
3245092|NCT01334346|Active Comparator|Neutral Shoe|Conventional, non-minimalist, footwear.
3245093|NCT01334346|Experimental|Partial minimalist shoe|
3245094|NCT01334346|Experimental|Full minimalist|
3245095|NCT01334359|Experimental|Treatment Group|Participants randomized to the afterschool intervention
3245096|NCT01334359|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
3245097|NCT01334372|No Intervention|Treatment as Usual|Treatment as usual (TAU) outpatient care will consist of existing outpatient clinical practices utilized in the Mental Health Clinic.
3354843|NCT02299596|Experimental|Pre and postoperative exercise|"The intervention is prehabilitation preoperatively and physical training postoperatively. During the hospital stay both groups will be treated in the same manner.~Preoperative intervention:~One half hour of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Inspiratory muscle training. Thirty breaths x two twice daily. Postoperative intervention is mainly the same as preoperatively."
3354844|NCT02299596|No Intervention|Control|Standard treatment with one exception, patients will fill in a physical activity diary
3354845|NCT02299609|Active Comparator|Beam Receiver|Philips HD11 XE® 30 min qid x 4 days
3354846|NCT02299609|Sham Comparator|Beam Non-Receiver|Philips HD11 XE® (ultrasound turned-off) 30 min qid x 4 days
3354847|NCT02299648|Other|Single arm|molecular profiling, patient derived cells
3354848|NCT02299661|Experimental|7.5mg DS-1093a|DS-1093a, single oral dose of 7.5 mg
3354849|NCT02299661|Experimental|25mg DS-1093a|DS-1093a, single oral dose of 25 mg
3354850|NCT02299661|Experimental|50mg DS-1093a|DS-1093a, single oral dose of 50 mg
3354851|NCT02299674||Persons with unilateral transfemoral amputation|
3354852|NCT02299687|Experimental|CYP2C19 EM|CYP2C19 EM
3354853|NCT02299687|Experimental|CYP2C19 IM|CYP2C19 IM
3354854|NCT02299687|Experimental|CYP2C19 PM|CYP2C19 PM
3354855|NCT02299700||Autism Spectrum Disorder (ASD) Participants (6-9 years)|Participants with ASD aged 6 to 9 years will be observed for the usability of the Janssen Autism Knowledge Engine (JAKE) personal healthcare record (pHR) and biosensors in stage 1 and stage 2 (at laboratory sites).
3245098|NCT01334372|Experimental|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
3245099|NCT01334385||OEF/OIF Veterans through VA ECHCS|
3354856|NCT02299700||ASD Participants (13-17 years)|Participants with ASD aged 13 to 17 years will be observed for the usability of the JAKE pHR and biosensors in stage 1 and stage 2 (at laboratory sites).
3354857|NCT02299700||ASD Participants (3 or greater than 3 years)|Participants with ASD aged 3 or greater than 3 years will be observed for the usability of the JAKE pHR and biosensors in stage 2 (at clinical sites).
3245100|NCT01334398||Initial Treatment Group|
3245101|NCT01334398||Deferred Treatment Group|
3354858|NCT02299713|Sham Comparator|placebo/sham acupuncture|There are different types of controls used in acupuncture trials. We used the control described as sham and by some as minimal acupuncture. This group had the same schedule as the electro-acupuncture group. Sham acupuncture was administered, with the same duration and frequency and by the same specialist who performed the non-sham acupuncture. Retractable needles were placed into small adhesive cylinders, so that the needles were supported but did not perforate the skin. The acupuncturist placed the needles at the same points as the non-sham group and used the same pairs of electrodes to simulate the electrical connection.
3354859|NCT02299713|Active Comparator|Electroacupuncture|The electro-acupuncture device was a biphasic pulse generator. It was used with maximum tolerable intensity of current and a frequency of 3 Hz. The points were selected according to the Traditional Chinese Medicine meridian theory to treat knee pain. The points selected were local points St 34, St 35, St 36,Liv 8, Sp 10. One distal point St 44.A total of six needles were inserted into each leg by the acupuncturist (the out come measures were not specifically targeted to whether the patient had one or both knees involved). All patients belonging to this group experienced a De Qi sensation, which is a tingling and numbness sensation upon needling of specific points.
3354860|NCT02299726|Experimental|Active|spironolactone
3354861|NCT02299726|Placebo Comparator|Placebo|matching placebo to active study drug
3354862|NCT02299752|Experimental|Catheterization|Blood vessel Catheterization during resuscitation with single and double - gloving system. Catheterization was performed using simulation mannikin
3354863|NCT02299765|Experimental|Arm A|"Four cycles gemcitabine(d1,8 ) + carboplatin (d1) + gefitinib (15-25), gefitinib 250mg/d from d15 of last cycle until disease progression.~Gemcitabine=1000mg/m2;Carboplatin 5×AUC ; One cycle is 28 days"
3354864|NCT02299765|Active Comparator|Arm B|Gefitinib 250mg/d until disease progression
3354865|NCT02299778|Experimental|1mg of 13C6-p-aminobenzoic acid|
3354866|NCT02299804|Experimental|High dose arm|Have included the Levophencynonate Hydrochloric 1.5mg bid.
3354867|NCT02299804|Experimental|Low dose arm|Have included the Levophencynonate Hydrochloric 1.0mg bid.
3245102|NCT01334424|Placebo Comparator|no propofol|induction anesthesia with midazolam 0.2 - 0.3 mg/kg
3354868|NCT02299804|Placebo Comparator|Placebo arm|Have no any active component
3354869|NCT02299817|Active Comparator|Denosumab|Patients will receive a dose of 60 mg denosumab (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
3354870|NCT02299817|Placebo Comparator|Placebo|Patients will receive a dose of placebo (1 ml solution) for a total of 6 doses with start on day one and every 6 months with last treatment at 30 months.
3354871|NCT02299830|Experimental|cryotherapy|give the cases whose central airway stricture were caused by soft neoplasm tissues cryotherapy
3245103|NCT01334424|Experimental|propofol induction|induction anesthesia with propofol 2 - 2.5 mg/kg
3245104|NCT01334424|Experimental|propofol maintenance|induction anesthesia with midazolam 0.2 - 0.3 mg/kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
3245105|NCT01334424|Experimental|propofol induction and maintenance|induction anesthesia with propofol 2 - 2.5 mg/ kg and maintain anesthesia with propofol 2 mg/kg.h (maintenance dose)
3245106|NCT01334450|Active Comparator|High Frequency TMS to prefrontal cortex|
3245107|NCT01334450|Active Comparator|Low Frequency TMS to Prefrontal cortex|
3245108|NCT01334450|Sham Comparator|Sham TMS on Prefrontal Cortex|
3245109|NCT01334463||mTBI+PTSD|History of active duty-related mild TBI and history of active duty-related PTSD
3245110|NCT01334463||mTBI Only|History of active duty-related mild TBI and no history of active duty-related PTSD
3245111|NCT01334463||PTSD Only|No history of active duty-related mild TBI and history of active duty-related PTSD
3354872|NCT02299830|Experimental|argon plasma coagulation|give the cases whose central airway stricture were caused by hard neoplasm tissues argon plasma coagulation
3354873|NCT02299830|Experimental|stent|give the cases whose central airway stricture were caused by neoplasm compression stent placement
3354874|NCT02299830|Experimental|snare|give the cases whose central airway stricture were caused by polypoid neoplasm tissues snare
3354875|NCT02299843|Active Comparator|ALPPS|Using ALPPS for the the treatment of hepatocellular carcinoma.
3354876|NCT02299843|Experimental|RALPPS|Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I（RALPPS）.Habib 4X was used in RFA.
3245112|NCT01334463||No mTBI, No PTSD|No history of active duty-related mild TBI and no history of active duty-related PTSD
3245113|NCT01334489|No Intervention|Usual management|Usual management of monochorionic pregnancy without the pessary placement
3245114|NCT01334489|Other|Arabin Cervical Pessary|"The pessary will be inserted 24 hours after fetal surgery in the exploration room. This procedure does not need anaesthesia and it does not need to be done in a surgery room. During the following explorations the correct placement of the pessary is assessed, and if it does not, it can be easily adjusted.~The pessary will be removed at 37 weeks of gestation, or before if any unexpected event occurs."
3354877|NCT02299856||Myocarditis|Patients with strong clinical evidence for acute myocarditis (recent infection, elevated troponin and white blood cell count).
3354878|NCT02299856||Healthy Controls|Healthy volunteers without any signs of cardiac disease.
3354879|NCT02299882|Experimental|Vancomycin|Patient will receive Vancomycin powder to the incision just before skin closure
3354880|NCT02299882|No Intervention|no vancomycin|Patient will be randomized to either vancomycin powder or no vancomycin powder. This arm the patient will not have the powder placed in the incision before skin closure.
3354881|NCT02299908|Experimental|TAP block with Bupivacaine at 0.25%|Intervention: Injection of local anesthetics in the transverses abdominal plane
3354882|NCT02299908|Placebo Comparator|Placebo saline solution|Placebo: Injection of saline solution in the transverses abdominal plane
3354883|NCT02299921||Adult ICU patients with respiratory problem|Adult medical ICU patients admitted to the University of Colorado Hospital for a primary respiratory problem, and who are expected to require ICU care ≥48 hrs.
3354884|NCT02299921||Intubated Adult ICU patients with respiratory failure|A subset of subjects, adult medical ICU patients with respiratory failure (due to underlying lung pathology) and who require endotracheal intubation and mechanical ventilation.
3354885|NCT02299947|Experimental|Haemocomplettan P|Study patients that receive Haemocomplettan P
3354886|NCT02299947|Placebo Comparator|NaCl 0.9%|Study patients that receive NaCl 0.9%
3354887|NCT02299960||HFpEF|patients with heart failure with preserved ejection fraction
3354888|NCT02299960||HFrEF|patients with heart failure with reduced ejection fraction
3354889|NCT02299960||AH|patients with hypertension
3354890|NCT02299960||Nephropathy|patients with diabetic nephropathy
3354891|NCT02299973|Placebo Comparator|Placebo group (FMT with own stool)|Fecal microbiota transplantation with patient's own stool
3354892|NCT02299973|Experimental|Treatment group (FMT with donor stool)|Fecal microbiota transplantation with healthy donor stool
3245115|NCT01334502|Experimental|everolimus and RCHOP|Patients registered to the study will receive an assigned dose of everolimus by mouth and RCHOP for a maximum of six cycles. Each cycle is a total of 21 days. RCHOP consists of 375 mg/m2 IV rituximab, 750 mg/m2 IV cyclophosphamide, 50 mg/m2 IV doxorubicin, 1.4 mg/m2 IV vincristine and 100 mg/m2 by mouth QD prednisone. The study includes a Phase I component to determine the maximum tolerated dose of everolimus and the second component determines the feasibility of therapy administered to lymphoma patients.
3245116|NCT01334528||OEF/OIF Veterans mTBI|Operation Iraqi Freedom (OIF)/Operation Enduring Freedom (OEF) Veterans with a history of mild traumatic brain injury (mTBI) with persistent self-reported symptoms.
3245117|NCT01334541||SAFE VET|
3354893|NCT02299986||Single arm Ultrasound measurement|Ultrasound measurement
3354894|NCT02299999|Experimental|Substudy 1: targeted agent|Arm A1 / Targeted Arm : targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, AZD2014 tablet per os 50 mg bd, continuous dosing, AZD4547 tablet per os 80 mg bd, 2 weeks on/1 week off, AZD5363 capsule per os 480 mg bd, 4 days on/3 days off, AZD8931 tablet per os 40 mg bd, continuous dosing, selumetinib capsule per os 75 mg bd, continuous dosing, vandetanib tablet per os 300 mg od, continuous dosing, bicalutamide tablet per os 150 od, continuous dosing, olaparib tablet per os 300 mg bd, continuous dosing
3354895|NCT02299999|Active Comparator|Substudy 1: standard maintenance therapy|Arm B1/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
3354896|NCT02299999|Experimental|Substudy 2: Immunotherapy|Arm A2/ Immunotherapy arm: maintenance with MEDI4736 for patient without actionable genomic alterations or non eligible to Targeted substudy 1, MEDI4736 Intra-venous 10 mg/kg, Q2W
3354897|NCT02299999|Active Comparator|Substudy 2: standard maintenance therapy|Arm B2/ maintenance Standard Chemotherapy Arm : such as Anthracyclines (Doxorubicin or Epirubicin or Liposomal Doxorubicine), Taxanes (Paclitaxel, Docetaxel), Cyclophosphamide, DNA Intercalators (Capecitabine, 5-FU, gemcitabine), Methotrexate, Vinca alkaloids (Vinorelbine, Vinblastine, Vincristine), Platinum based chemotherapies (Carboplatin, Cisplatin), Bevacizumab, Mitomycin C, Eribulin
3354898|NCT02300012|No Intervention|Operation - No PBI|Patients requiring operation - baseline PBI data not seen by surgeon
3354899|NCT02300012|Experimental|Operation - PBI available|Patients requiring operation - baseline PBI data seen by surgeon pre-operatively
3354900|NCT02300012|No Intervention|Non-operation|Patients with ACL rupture not requiring operation
3354901|NCT02300012|No Intervention|Control|Healthy age matched volunteers - No operation
3245118|NCT01334541||E-CARE|
3245119|NCT01334567|Experimental|Tenofovir DF|
3245120|NCT01334580|Active Comparator|Methadone Drug Counseling|Methadone Drug Counseling is provided by skilled drug counselors over a 12 week period and focuses on cessation of illicit drugs
3245121|NCT01334580|Experimental|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
3245122|NCT01334593||Rectal Cancer|
3245123|NCT01334619|Other|ropivacaine volume titration|
3245124|NCT01334632|Active Comparator|Continuous interscalene block|Continuous interscalene block with bolus ropivacaine 0.5% and then continuous infusion of ropivacaine 0.2% 4 - 6 ml/h, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
3245125|NCT01334632|Placebo Comparator|PCA morphine|Patients with iv self-administration of morphine, associated with paracetamol and ibuprofen. Each group will contain 60 patients.
3245126|NCT01334658|Active Comparator|Balanced Salt Solution (BSS®)|Subjects who received Balanced Salt Solution.
3245127|NCT01334658|Active Comparator|Glucose-bicarbonate-Ringer Lactate (GBRL)|Subjects who received glucose-bicarbonate-Ringer Lactate.
3245128|NCT01334671|Experimental|group 1, Atorvastatin|STEMI patients will be randomly divided into three groups Group 1 which has been give 80mg atorvastatin before PCI will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
3354902|NCT02300038|Active Comparator|Lidocaine (Xylocaine) 0.5%|Injection of 1ml after mixing Lidocaine 10 mg/ml 1 ml +1 ml NaCl was administrated perineuromally
3354903|NCT02300038|Placebo Comparator|Lidocaine (Xylocaine) 10 mg/ml 0.01%|Injection of 1 ml from 10 mg/ml 1 ml lidocaine Xylocaine +10 ml Nacl was adminsitrated perineuromally
3354904|NCT02300051|Experimental|STPGP and RPGT|16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT)
3354905|NCT02300051|Active Comparator|TAU|Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
3354906|NCT02300051|Experimental|STPGP and RPGT + TAU|Participants undergo both interventions: 1) 16 weekly sessions of 90 minutes of Short-Term Psychodynamic Group Psychotherapy (STPGP) followed by 8 weekly sessions of 90 minutes of Relapse Prevention Group Therapy (RPGT); 2)Treatment as usual (TAU) will be introduced through psychiatric follow up, in which the three first visits will occur at intervals of 30 days and the followings will occur with an interval of 60 days. The medication protocol includes serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day) or mood stabilizers (topiramate 25 - 200 mg/day, divalproex sodium (500 - 1500 mg/day, oxcarbazepine (300 - 1200 mg/day, and lamotrigine 50 - 200 mg/day).
3354907|NCT02300064|Experimental|Healthy volunteers|Healthy volunteers will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
3354908|NCT02300064|Experimental|COPD patients|Patients with Chronic Obstructive Pulmonary Disease (COPD) will undergo one or more exercise interventions: knee-extensor exercise test; exercise test with restricting/releasing blood flow; exercise test with variable oxygen concentration and MRI; or exercise test with oral antioxidant or placebo cocktail.
3354909|NCT02300090||Intervention group|This group of patients (n=250) will receive the digital service (smart phone application and bluetooth inhaler device) in addition to current best care from their healthcare professional.
3354910|NCT02300090||Control group|This group of patients (n=250) will receive current best care alone. Control patients will not have access to the digital service.
3354911|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M 25μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354912|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 50μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354913|NCT02300142|Experimental|GEN-003 Vaccine 30μg / Matrix-M2 75μg|GEN-003 Vaccine (30 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354914|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 25μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (25 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354915|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 50μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (50 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354916|NCT02300142|Experimental|GEN-003 Vaccine 60μg / Matrix-M2 75μg|GEN-003 Vaccine (60 μg of each antigen) with Matrix-M2 adjuvant (75 μg), administered as a 0.5 mL intramuscular (IM) injection.
3354917|NCT02300155|Experimental|PregVit®|Women will be randomized to the '35 mg' group, who will start supplementation with PregVit® (low iron content, small size)
3354918|NCT02300155|Active Comparator|Orifer F®|Women will be randomized to the '60 mg' group, who will start supplementation with Orifer F® (high iron content, small size).
3245129|NCT01334671|Experimental|group 2 , Atorvastatin|Group 2 will be administered with atorvastatin 40mg per day for one month,then 20mg per day until the end of the trial
3245130|NCT01334671|Experimental|group 3 , Atorvastatin|Group 3 will be administered with atorvastatin 20mg per day until the end of the trial
3354919|NCT02300181|Placebo Comparator|Placebo (flour)|5 placebo capsules for each test (4.88 kcal/5 cap)
3354920|NCT02300181|Experimental|Bacillus subtilis var natto DC-15|5 experimental capsules for each test (4.96 kcal/5 cap) Extract powder of the flour fermented with Bacillus subtilis var natto DC-15
3354921|NCT02300194|Active Comparator|Topic Morphine|Use of topic morphine for treatment of procedure associated pain
3354922|NCT02300194|Placebo Comparator|Placebo|Use of topic hydrogel (placebo) for treatment of procedure associated pain
3354923|NCT02300207|No Intervention|Control group|Subjects were in a resting, flat, head-down position -6° from the horizontal. The entire bed rest period was composed of the 4-day head-down bed rest and 2-day period of data collection (before and after the bed rest period). During all of these periods, there was intensive care monitoring. All dining, washing, urination, and defecation were carried out in the bedridden state. Changing position around the body axis was permitted. Dietary intake was 2300-2500 kcal/day, and water intake was 1.0-1.5 L/day. Urine samples (24 h) were collected every day throughout the study. Body weight, heart rate (HR), and blood pressure (BP) were measured in the morning before breakfast.
3354924|NCT02300207|Experimental|Electroacupuncture group|During the bed rest phase, subjects in the Electroacupuncture(EA) groups received 30 min of EA treatment, while subjects in the Con group did not receive any treatment.EA was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms. The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
3354925|NCT02300233|Active Comparator|volanesorsen|
3354926|NCT02300233|Placebo Comparator|Placebo|
3354927|NCT02300246|Experimental|Test Group|Alveolar socket post-extraction covered with PRF
3354928|NCT02300246|No Intervention|Control Group|Only clot (spontaneous healing)
3354929|NCT02300272||Typically healthy older adults|Adults 65 years and older with only common late-life medical conditions who will complete a screening that includes a Polysomnograph and assessment that includes Actiwatch.
3354930|NCT02300324|Experimental|Standard v Beneforte v Beneforte Extra|This is a randomized, double-blinded, three-phase crossover trial investigating the bioavailability of SF following consumption of three types of broccoli + stilton soup containing different concentrations of glucoraphanin. The three types of soup are standard broccoli and stilton soup, beneforte broccoli and stilton soup, and beneforte extra broccoli and stilton soup.
3354931|NCT02300337|Experimental|Reduce Cuff Pressure|Cuff Pressure difference between inspiration and expiration is measured.
3354932|NCT02300350|Experimental|Treatment A|0.5 mg single-dose oral digoxin administration
3354933|NCT02300350|Experimental|Treatment B|400 mg oral LX4211 qd administration
3245131|NCT01334684|Other|Metformin|"At study entry, all oral hypoglycemic agents will be discontinued for 5 days and then metformin (2,550 mg/daily) will be given for 3 months. Fasting plasma glucose will be measured at baseline and 3 months after metformin treatment. Patients will be stratified according to the median value of metformin efficacy as indicated by fasting glucose change after metformin treatment (i.e. baseline fasting glucose minus 3-month fasting glucose).~So, two subgroups of patients will be obtained, defined as relatively high responders (individual fasting glucose change > median value) or relatively low responders (individual fasting glucose change < median value) to metformin monotherapy."
3245132|NCT01334697|Experimental|Cardiotrophin-1|
3354934|NCT02300350|Experimental|Treatment C|0.5 mg single-dose oral digoxin administration + 400 mg oral LX4211 qd administration
3354935|NCT02300363|Experimental|Treatment A|10 mg oral rosuvastatin administration
3354936|NCT02300363|Experimental|Treatment B|400 mg oral LX4211 qd administration
3354937|NCT02300363|Experimental|Treatment C|10 mg oral rosuvastatin administration + 400 mg oral LX4211 qd administration
3245133|NCT01334697|Placebo Comparator|Placebo|
3245134|NCT01334736|Placebo Comparator|Usual care|
3245135|NCT01334736|Active Comparator|Lung Age|
3245136|NCT01334736|Active Comparator|Contingency Management|
3245137|NCT01334736|Active Comparator|Lung age + Contingency Management|
3245138|NCT01334749||Acute Stroke|Patients over 18 years and without pre-stroke dementia, displaying an ischemic or hemorrhagic stroke, onset within the last 72 hours, language German
3245139|NCT01334762|Experimental|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
3245140|NCT01334762|Active Comparator|CC/IUI|Patients received 100 mg CC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
3245141|NCT01334775|Experimental|Experimental - Cousin Biotech Adhesix|Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
3354938|NCT02300376|Experimental|Calcium edetate de sodium versus inulin|The designing a Bayesian model of the plasma clearance of Calcium edetate de sodium is compared to the renal clearance of Inulin.
3354939|NCT02300389|Experimental|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
3245142|NCT01334775|Active Comparator|Conventional - Cousin Biotech Biomesh P8|Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair
3245143|NCT01334788|Experimental|sleep deprivation|These are subjects who are randomized to undergo sleep deprivation.
3245144|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
3245145|NCT01334801||Aortic Stenosis|Restricted aortic valve motion and a peak Doppler aortic velocity > 2.5 m/sec blood draw
3245146|NCT01334801||Aortic regurgitation|Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume
3245147|NCT01334801||Aortic valve replacement|Mechanical or biological aortic valve replacement
3245148|NCT01334801||Mitral regurgitation|Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume
3245149|NCT01334801||Mitral valve replacement|Mechanical or biological mitral valve replacement
3354940|NCT02300389|Active Comparator|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
3354941|NCT02300415||patient with sepsis|Patients admitted to the emergency department and with criteria of sepsis.
3354942|NCT02300428||1-year cohort|"Patients with at least 1 prescription of any oral iron preparation in the last 2 years and who have at least 1 year of follow up data post-prescription.~It is anticipated that ca. 123,000 patients in CPRD fulfil this criteria."
3245150|NCT01334801||Hypertrophic cardiomyopathy|Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography
3245151|NCT01334801||Severe TR with pacemaker / ICD lead|Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography
3354943|NCT02300428||10-year cohort|"All pre-menopausal women (18-45 years old) with at least 1 prescription of one ferrous iron salt (i.e. sulphate, fumarate and gluconate) since January 2000.~It is anticipated that ca. 299,000 patients in CPRD fulfil this criteria."
3354944|NCT02300454|Active Comparator|Non-slip element balloon (NSE)|Lacrosse® NSE dilatation before use of SeQuent® Please drug coated balloon (DCB)
3354945|NCT02300454|Placebo Comparator|Balloon|Non-compliant balloon dilatation before use of SeQuent® Please drug coated balloon (DCB)
3354946|NCT02300467|Experimental|NOV120401 (CKD-516 Tablet)|5 to 45 mg/day PO for 5 consecutive days and 2 days off
3245152|NCT01334801||Prosthetic valve dysfunction|Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.
3245153|NCT01334801||Normal controls|Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy
3245154|NCT01334801||Left ventricular assist device patients|Patients with previously implanted LVAD
3354947|NCT02300480|Experimental|CTB group|Participants in this group will receive a single injection for calot's triangle block combined with PCIA post-operatively. CTB will be conducted by bile duct needle and 1.0% 10 ml ropivacaine will be injection in calot's triangle when before surgical dissection.Participants in this group will also receive PCIA after surgery,the regimens of PCIA are included tramadol 800 mg, flurbiprofenaxetil 100 mg with normal saline added up to a volume of 80 ml in total.
3354948|NCT02300480|Active Comparator|PCIA group|Participants in this group will receive PCIA post-operatively (tramadol 800 mg and flurbiprofen axetil 100mg with normal saline added up to a volume of 80ml in total ) .The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
3354949|NCT02300493|Experimental|Experimental|weigh themselves daily
3354950|NCT02300493|Active Comparator|Control|Weigh themselves every six months
3354951|NCT02300506||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg, and enrolled in study GLI01S.
3354952|NCT02300519||Volunteers|Blood sampling : 1 blood punction of 36.5 ml for each volunteer
3245155|NCT01334801||Renal dialysis patients|Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.
3354953|NCT02300532||Cohort 1|Patients with diagnosed malignant glioma treated by surgery, implanted Gliadel wafers 7.7mg
3354954|NCT02300584|Experimental|Prototype Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
3245156|NCT01334840|Experimental|BW|Bicarbonated mineral water without meal
3245157|NCT01334840|Experimental|BW with meal|Bicarbonated mineral water with meal
3245158|NCT01334840|Active Comparator|CW|Mineral water low in mineral content (control) without meal
3245159|NCT01334840|Active Comparator|CW with meal|Mineral water low in mineral content (control) with a meal
3354955|NCT02300584|Experimental|Field Program|The Savvy Caregiver (Savvy) - program delivered on an iPad (a tablet computer with an internet connection) extends over a six week period. Caregivers are asked to view brief daily videos (8-12 minutes) on the iPad. Based on the feedback from the prototype program, the videos may vary. Once each week, a group of caregivers joins in a videoconference (an hour) with one or two trained leaders to review material from the week and to learn new material.
3354956|NCT02300597|Experimental|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
3354957|NCT02300597|No Intervention|Treatment as usual (TAU)|A comparison group matched for age, gender and neuropsychiatric diagnosis is offered treatment as usual and is assessed at the same time points as the intervention group.
3354958|NCT02300623|Active Comparator|Control|Antiretroviral therapy alone
3354959|NCT02300623|Experimental|Treatment|Antiretroviral therapy plus Interleukin-2'
3245160|NCT01334853||Cohort 1|50 eosinophilic subjects to be evaluated
3245161|NCT01334853||Cohort 2|50 non-eosinophilic subjects to be evaluated
3245162|NCT01334879|Active Comparator|With Loading Doses|5 patients will receive intravitreal injections every 30 days (+/- 7 days) for the first 4 months and every month thereafter until month 12 (maximum of 12 injections)
3245163|NCT01334879|Active Comparator|Physician Discretion|5 patients will receive intravitreal ranibizumab every 30 days (+/- 7 days) on as needed basis based on the criteria defined in the study.
3245164|NCT01334892|Active Comparator|L-CsA|Twice daily inhalation of 2.5 ml/10 mg L-CsA for 96 weeks
3245165|NCT01334892|Placebo Comparator|L-CsA placebo|Twice daily inhalation of 2.5 ml aerosolised placebo (carrier) for 96 weeks (24 months)
3354960|NCT02300636|Experimental|Training: open kinetic|"Co-contraction training in open kinetic chain position~8 weeks, 3 days in a week"
3245166|NCT01334905|Experimental|Part A group|fasted condition then fed condition
3354961|NCT02300636|Experimental|Training: closed kinetic|"Co-contraction training in closed kinetic chain position~8 weeks, 3 days in a week"
3354962|NCT02300636|Active Comparator|Training: Standard ACL rehabilitation|"Standard ACL rehabilitation~8 weeks, 3 days in a week"
3354963|NCT02300649|Experimental|Dexmedetomidine group|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
3354964|NCT02300649|Placebo Comparator|Control group|Saline will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
3354965|NCT02300662|Experimental|Cycle Ergometer|Conventional physiotherapy and cycle ergometer 20 minutes, at 20 cycles per minute, once per day for as long as they remain on invasive mechanical ventilation
3354966|NCT02300662|Sham Comparator|Conventional Physiotherapy|Upper and lower extremity functional diagonals from the proprioceptive neuromuscular facilitation method and manual bronchial hygiene exercises.
3354967|NCT02300675|No Intervention|control arm|Patients follow the classic support prescription of hormonotherapy
3354968|NCT02300675|Experimental|therapeutic education program|Patients follow the 4 sessions of PEP hormonotherapy. The therapeutic education prgram is led by a trained educational team, inside a prevention center : Hygée centre.
3354969|NCT02300688|Experimental|Arm 1|Period 1 (Treatment A) - Wash out - Period 2 (Treatment B)
3354970|NCT02300688|Experimental|Arm 2|Period 1 (Treatment B) - Wash out - Period 2 (Treatment A)
3354971|NCT02300701|Experimental|Xolair/Omalizumab|
3354972|NCT02300701|Placebo Comparator|Placebo|
3245167|NCT01334905|Experimental|Part B group|fed condition then fasted condition
3354973|NCT02300714|Active Comparator|AP group|oblique view approach during transforaminal epidural block
3354974|NCT02300714|Active Comparator|OB group|oblique view approach during transforaminal epidural block
3245168|NCT01334931|Experimental|Large field of view|Patients will have coronary angiography performed with large field of view lens
3245169|NCT01334931|Active Comparator|Medium field of view|Patients will have coronary angiography performed with medium field of view lens
3245170|NCT01334983|Experimental|REST|Participants instructed in individualized Rapid Easy Strength Training and pedometer-based walking programs
3354975|NCT02300740|Experimental|low dose|500 mg nicotinamide riboside oral
3354976|NCT02300740|Experimental|high dose|1000 mg nicotinamide riboside oral
3354977|NCT02300766||Posterior fossa tumor patients|Children (0-18 years) with a tumour in the posterior fossa (cerebellum/4th ventricle/brainstem ) requiring surgery or open biopsy at one of the participating centres.
3354978|NCT02300779|Experimental|Low-residue diet|Subjects will follow a low-residue diet for 4 days. Their usual treatment for diabetes will be adjusted to the degree of glycemic control.
3354979|NCT02300779|Active Comparator|Usual care|Subjects will follow a low-residue diet for 3 days (from 4 to 2 days before the procedure) and a liquid diet on the following day (the one before the procedure). No changes in their treatment for diabetes will be made
3354980|NCT02300792|Active Comparator|honey|Each patient in the honey group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
3245171|NCT01334983|No Intervention|Wait list control|Participants instructed in REST after completing week 8 outcome measures
3354981|NCT02300792|Placebo Comparator|molasses|Each patient in the molasses (placebo) group (group 1) took molasses in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
3354982|NCT02300818|Active Comparator|Pulsed Electromagnetic Field Therapy|"Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.~PEMF has also proved to be beneficial in vision acuity of patients with low vision. In 50 per cent of the cases, values improved. Patients with vision acuity of 0.2 diopters showed improvement from 46 before treatment to 75 after treatment.~Different studies on varied diseases have proved that Pulsed Electromagnetic Field Therapy (PEMF) treatment is a safe, non-invasive and effective option for curing ocular conditions."
3354983|NCT02300818|Active Comparator|Seawater eyedrops|instantly soothes and clears the eye irritation caused by pollution, pollen, smoke, etc. It is a very practical system for eye daily hygiene · enables efficient therapeutic help in basic eye conditions such as: · · internal and external stye blepharitis and keratoconjunctivitis · · Conjuntiviti Episcleritis and scleritis
3354984|NCT02300831||NSCLC|The eligible patient population of this study will comprise of advanced 2nd line NSCLC patients who are screened for two randomised clinical trials (RCTs) sponsored by AstraZeneca (AZ): SELECT-1 and SELECT-2 trials, but who do not meet eligibility criteria for those trials
3245172|NCT01335022|Experimental|Cardiovascular Disease Education|6 lectures on cardiovascular disease were given over a 2 month time period
3245173|NCT01335035|Experimental|ICL670|
3354985|NCT02300844|Experimental|NNC0174-0833 10 mg/mL|
3245174|NCT01335048|Experimental|Atorvastatin-Clopidogrel group|Patients who receive Atorvastatin 80 mg/day and Clopidogrel 150 mg/day
3245175|NCT01335048|Active Comparator|Clopidogrel group|Patients who receive clopidogrel 150 mg daily
3245176|NCT01335074|Experimental|Temsirolimus + Sorafenib|
3245177|NCT01335087|Active Comparator|Lifestyle|Standard care for OSA: lifestyle, and sleep hygiene counselling
3245178|NCT01335087|Experimental|Continuous positive airway pressure CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
3245179|NCT01335087|No Intervention|Reference|This group will be followed according to cardiovascular protocols and will be evaluated as a reference group.
3245180|NCT01335100||ambulatory CP|ambulatory children with cerebral palsy undergoing Botulinum toxin injections to lower limbs
3245181|NCT01335100||controls|age and gender matched sibilings
3354986|NCT02300844|Placebo Comparator|Placebo|
3354987|NCT02300857|Active Comparator|Low carbohydrate diet|
3354988|NCT02300857|Active Comparator|Moderate carbohydrate diet|
3354989|NCT02300857|Active Comparator|High carbohydrate diet|
3354990|NCT02300870||Heart Transplant Rejection|Patients presenting with acute cellular rejection
3354991|NCT02300870||Heart Transplant Control|Patients presenting for routine office visit
3354992|NCT02300883||no treatment|no treatment
3354993|NCT02300896|Experimental|Intervention|Group-based exercise training during hospitalization Procedure: Exercise training. Individual program training 5 days a week during hospitalization
3245182|NCT01335126|Experimental|Test|
3245183|NCT01335139|Experimental|SCIT + Placebo|Subcutaneous immunotherapy (SCIT) + sublingual immunotherapy (SLIT) placebo
3245184|NCT01335139|Experimental|SLIT + Placebo|Sublingual immunotherapy (SLIT) + subcutaneous immunotherapy (SCIT) placebo
3354994|NCT02300896|No Intervention|Control|Usual care including rehabilitation when necessary
3354995|NCT02300909|Experimental|dHACM|Lumbar Decompression Surgery or Microdiscectomy Surgery with Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
3354996|NCT02300909|Other|Surgery without dHACM|Control Group - Lumbar Decompression Surgery or Microdiscectomy Surgery without application of dHACM
3354997|NCT02300922|Experimental|several cohorts|"All patients will receive 3 injections of TF2 (the first: 14 mg/m², the second and the third:75 mg/m²). One day after each injection of TF2, the patient will receive a radiolabelled peptide (IMP-288) with Yttrium for therapeutic injectionThe First cohort will receive 555 MBq/m2 X 2 of 90-Y-IMP-288.:~All patient will receive 180 MBq of 111-In-IMP-288 for dosimetry analysis"
3354998|NCT02300935|Experimental|trametinib and nab-paclitaxel|Trametinib will be dosed at 1mg, 1.5mg, and 2mg orally (PO) daily based on Phase I data of this drug as a single agent. All patients entering this study will receive intravenous (IV) nab-paclitaxel on Day 1, 8, and 15. Dose levels will be assigned to each patient, and dose escalation decisions will be based on the evaluation of safety data from the prior cohort.
3354999|NCT02300948|Experimental|PregVit-Folic 5®-5 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit-folic 5® contains 5 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
3355000|NCT02300948|Active Comparator|PregVit®-1.1 mg folic acid|Prenatal multivitamin-mineral supplement called PregVit® contains 1.1 mg of folic acid. All other vitamin and mineral doses are identical between the 2 supplements, except for folic acid. Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation.
3355001|NCT02300961|Experimental|Cognitive rehabilitation arm|Cognitive rehabilitation program
3355002|NCT02301000|Experimental|Intestinal microbiota therapy|The patients allocated to this group will receive 60 ml of the anaerobically cultivated human intestinal microbiota through a rectal catheter.
3355003|NCT02301000|Active Comparator|Metronidazole|The patients allocated to this group will receive metronidazole 400 mg t.i.d. for 10 days
3355004|NCT02301013|Experimental|Urinary incontience surgery|Patients who is between 25 to 70 years old and positive stress test and have TVT or TOT operations with diagnoses of stress urinary incontinence and mixed urinary incontinence .
3355005|NCT02301052|Placebo Comparator|placebo|placebo topical cream 2 cc twice daily for 3 weeks
3355006|NCT02301052|Active Comparator|Anti-hemorrhoid topical cream drug|Anti hemorrhoid topical cream as a standard drug 2 cc twice daily for 3 week
3355007|NCT02301052|Active Comparator|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
3355008|NCT02301065||Stem Cell Donors|Allogeneic hematopoietic stem cell transplant (HSCT) donors. Blood samples for phenotypes research will be collected once from donors, prior to apheresis for collection of donor stem cells.
3355009|NCT02301065||Stem Cell Recipients|Allogeneic hematopoietic stem cell transplant (HSCT) recipients. Blood samples will be drawn prior to transplantation and every two weeks, up to day 100 post-transplantation.
3355010|NCT02301078||Percutaneous Needle Aponeurotomy|Patients who choose to undergo percutaneous needle aponeurotomy (PNA) for primary treatment of Dupuytren's disease
3355011|NCT02301078||Xiaflex|Patients who choose to receive Collagenase clostridium histolyticum injection (drug name Xiaflex) for primary treatment of Dupuytren's disease.
3355012|NCT02301091|Experimental|TACE-RFA|2 times TACE first, RFA for residual viable tumors and PVTT within 1 month.
3355013|NCT02301091|Active Comparator|TACE alone|repeated TACE and 1 to 2 months interval between two sessions of TACE.
3355014|NCT02301104|Experimental|Mild Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3355015|NCT02301104|Experimental|Moderate Hepatic Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3245185|NCT01335139|Placebo Comparator|Placebo + Placebo|Sublingual immunotherapy (SLIT) placebo + subcutaneous immunotherapy (SCIT) placebo
3245186|NCT01335152|Experimental|Web-based workbook|Participants will use one chapter of the web-based workbook each week for 10 weeks. The workbook consists of stress management education, cognitive behavioral interventions and relaxation training exercises.
3355016|NCT02301104|Experimental|Severe Hepatic Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort, if enrolled, will be determined based on the Interim Assessment of mild and moderate cohorts."
3355017|NCT02301104|Experimental|Normal Hepatic Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3355018|NCT02301117|Experimental|Mild Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3355019|NCT02301117|Experimental|Moderate Renal Impairment|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3355020|NCT02301117|Experimental|Severe Renal Impairment|"35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.~The dose level of severe cohort will be determined based on the Interim Assessment of mild and moderate cohorts"
3245187|NCT01335152|No Intervention|Waitlist control group|Participants will no intervention for the first 10 weeks of the study and then will receive the web-based intervention.
3245188|NCT01335165|Experimental|TT30 (ALXN1102 Formulation)|IV: 0.1, 0.3, and 1.0 mg/kg
3245189|NCT01335165|Experimental|TT30 (ALXN1103 Formulation)|"IV: 3.0, 6.0, and 10.0 mg/kg~SC: 1.0 and 3.0 mg/kg"
3245190|NCT01335178|Experimental|Intervention|Participants received the behavioral intervention, which was designed to motivate parents to protect their children from tobacco smoke exposure
3245191|NCT01335217|Other|Open-label TNS treatment|There is only one arm in this open label treatment of MDD co-occuring with PTSD.
3245192|NCT01335243|Experimental|TLIF surgery|
3245193|NCT01335256|Experimental|Arm 1|
3355021|NCT02301117|Experimental|Normal Renal Function|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28 day cycle. Number of cycles: approximately 4 or until discontinuation criteria is met.
3355022|NCT02301130|Experimental|mogamulizumab + MEDI4736 (Durvalumab)|"During Parts 1 and 2, mogamulizumab and MEDI4736 (Durvalumab) are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1A to 4A, increased doses of mogamulizumab and MEDI4736 (Durvalumab) are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
3355023|NCT02301130|Experimental|mogamulizumab + tremelimumab|"During Parts 1 and 2, mogamulizumab and tremelimumab are administered at appropriate intervals.~Part 1 (Dose Escalation Phase)~- During Cohort 1B to 4B, increased doses of mogamulizumab and tremelimumab are administered.~Part 2 (Cohort Expansion Phase)~Patients will be treated with maximum tolerated dose established in the Dose Escalation Phase for each combination."
3355024|NCT02301182|Active Comparator|ADM X3-MoP Cup|THA: ADM dual-mobility hydroxyapatite coated cups with X3TM HXLPE liners on 28mm BIOLOX® delta femoral heads (Stryker) with femoral stems being 2nd generation Accolade stems of the taper lock type, proximal circumferential coated with a 50µm plasma-spray PureFix HA coating to aid the mechanical engagement in bone coating (Stryker)
3355025|NCT02301182|Active Comparator|CoC Cup|THA: CoC BIOLOX® delta-delta large-head single-mobility cementless fiber-mesh titanium coated acetabular system from Zimmer (Zimmer TrilogyIT cup/CLS spotorno stem) with a grit-blasted osteophilic titanium alloy CLS® Spotorno femoral stems (Zimmer) that has a three-dimensional wedge shape and sharpened ribs in the proximal region
3355026|NCT02301195|Experimental|Therapeutic Horseback Riding|Ten-weekly one-hour manualized small group Therapeutic Horseback Riding intervention led by certified THR instructor.THR intervention taught riding and horsemanship skills.
3355027|NCT02301195|Active Comparator|Barn Activity Intervention|Ten-weekly one-hour manualized small group Barn Activity Intervention led by THR instructor, teaching horsemanship skills without horses present.
3355028|NCT02301208|Active Comparator|Low dose cisplatin arm|concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
3245194|NCT01335269|Experimental|Treatment arm|BI 853520 once daily in a dose escalation schedule
3245195|NCT01335321|Active Comparator|Hylan GF-20 alone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 only
3355029|NCT02301208|Active Comparator|High dose cisplatin arm|concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
3355030|NCT02301208|Experimental|Low dose nedaplatin arm|concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
3355031|NCT02301208|Experimental|High dose nedaplatin arm|concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
3355032|NCT02301221|Experimental|Fecal microbiota transplantation (FMT)|Patients included will receive standard FMT, and then will be followed up for 24 weeks.
3355033|NCT02301234|Placebo Comparator|Placebo|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of placebo during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib 100 mg orally (by mouth) twice daily for up to 16 weeks.
3355034|NCT02301234|Experimental|Fulranumab 1 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 1 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
3355035|NCT02301234|Experimental|Fulranumab 3 mg|Participants will receive 4 subcutaneous (SC) injections (one injection every 4 weeks) of fulranumab 3 mg during the double-blind treatment phase. In addition, participants may take adjunctive therapy with celecoxib placebo orally twice daily for up to 16 weeks.
3355036|NCT02301247|Experimental|Experimental Group|The experimental group will receive memory retraining exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3245196|NCT01335321|Experimental|Triamcinolone|This arm will receive a knee infiltration with 6ml of Hylan GF-20 associated with 1ml of triamcinolone
3245197|NCT01335347|Experimental|Experimental Low Dose|Biological: One dose of a live replication incompetent adenovirus given in a capsule
3245198|NCT01335347|Experimental|Experimental Medium Dose|"Biological: One or two doses of replication incompetent adenovirus given in a capsule~Other: Placebo capsules of the same size and shape"
3245199|NCT01335347|Experimental|Experimental High Dose|Biological: One dose of replication incompetent adenovirus in a capsule
3245200|NCT01335347|Placebo Comparator|Placebo Control|Capsules of the same size and shape as the experimental
3245201|NCT01335360||Subjects >80kg|As above
3245202|NCT01335360||Subjects <70kg|As above
3245203|NCT01335360||Subjects 70-80kg|As above
3245204|NCT01335373||Group 1|
3245205|NCT01335386|Experimental|KLYX|
3245206|NCT01335386|Active Comparator|Glycerine|
3245207|NCT01335412||IXIARO exposed group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of IXIARO
3245208|NCT01335412||Comparison group|Male and female active duty U.S. military personnel ≥ 17 years of age who either received at least one dose of JE-VAX
3245209|NCT01335438|Experimental|Cementless Nexgen CR|Cementless fixation of Nexgen CR TKR
3355037|NCT02301247|Placebo Comparator|Placebo|The placebo group will receive placebo control memory exercises administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3355038|NCT02301260|Experimental|Speed of Processing Training (SPT)|SPT will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
3355039|NCT02301260|Placebo Comparator|Placebo control group|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 sessions)
3355040|NCT02301273|Active Comparator|Usual Physiotherapy|Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
3355041|NCT02301273|Experimental|Enhanced Physiotherapy|Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
3355042|NCT02301286|Experimental|Aspirin|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.
3245210|NCT01335438|Active Comparator|Cemented Nexgen CR|Cemented fixation of Nexgen CR TKR
3355043|NCT02301286|Placebo Comparator|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
3355044|NCT02301312|Experimental|POSS-PCU graft|POSS-PCU vascular graft will be used to create vascular access for dialysis.
3355045|NCT02301325|Other|0.03 mg Nicotine Cigarette|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes
3355046|NCT02301325|Other|0.03 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.03 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
3355047|NCT02301325|Other|0.80 mg Nicotine Cigarette|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes.
3355048|NCT02301325|Other|0.80 mg Nicotine Cigarette and NRT|Participants will be assigned to smoke 0.80 mg nicotine Spectrum cigarettes and use nicotine replacement patches.
3245211|NCT01335451|Experimental|Active|Each cohort will have 6 subjects that will receive AZD5213
3245212|NCT01335451|Placebo Comparator|Placebo|Each cohort will have 2 subjects that will receive placebo
3245213|NCT01335490|Experimental|Biolite Cook Stove|Provision of two cook stoves to each subject. Each stove burns wood fuel, but more efficiently than a traditional three stone fire.
3245214|NCT01335490|Experimental|LPG Cook Stove|Provision of a two-burner liquified petroleum gas stove to each subject, along with fuel needed for the family during the follow up period.
3245215|NCT01335490|No Intervention|Control|
3245216|NCT01335503|Active Comparator|AN-PEP with low caloric meal|
3245217|NCT01335503|Active Comparator|AN-PEP with high caloric meal|
3245218|NCT01335503|Placebo Comparator|Placebo with low caloric meal|
3355049|NCT02301338||Usual Care|"The patient will get instructions on: - Follow-up appointment date/time with your surgeon - Proper diet - Medications - Communicating concerning symptoms with the surgeon~The patient will answer questions on:~Social support~Quality of life"
3355050|NCT02301338||Phone Calls|"In addition to what the usual care group gets, the patient will also receive weekly phone calls by a geriatrics RN following hospital discharge.~The patient will answer questions on:~Social support~Quality of life"
3355051|NCT02301351|Other|Graphic Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with FDA-approved graphic warning labels.
3355052|NCT02301351|Other|Text Warning Label|Days 5-50: Participants will receive cigarette packs as per the study randomization schema (e.g. three15-day periods of red, gold, and plain packs; order counterbalanced within subject) with standard text warning labels.
3355053|NCT02301442|Experimental|Exercise + behaviour change intervention|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + behaviour change intervention will be delivered by physiotherapists between weeks 1 and 11.
3355054|NCT02301442|Active Comparator|Exercise + control education|This arm of the trial includes assessments at weeks 0, 12, 24 and 36. A 10-week exercise + control education intervention will be delivered by physiotherapists between weeks 1 and 11.
3355055|NCT02301455|No Intervention|Control, Not hypertensive|Participants who after 3 weeks do not have high blood pressure or are not responsive to text messages.
3355056|NCT02301455|Experimental|Text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to receive text messages.
3355057|NCT02301455|No Intervention|No text messages, hypertensive|Participants who after 3 weeks have high blood pressure and are responsive to text messages, who are then randomized to not receive text messages.
3355058|NCT02301468|Experimental|Dry needling|Dry needling (experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained
3355059|NCT02301468|Experimental|Ischemic compression|Ischemic compression (experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
3245219|NCT01335503|Placebo Comparator|Placebo with high caloric meal|
3245220|NCT01335529|Experimental|Boceprevir, PegIFN alfa 2b, Ribavirin|"Standard Treatment :~Peg-Interferon (PegIFN) alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories (< 65 kg: 800 mg ; 65-80 kg: 1000 mg; 81-105 kg: 1200mg; > 105 kg: 1400mg)~Three-drug-regimen:~Peg-Interferon alfa 2b by subcutaneous injection 1,5 µg/kg/week~Ribavirin capsules 200mg: dosage delivered in weight categories like in standard treatment~Boceprevir tablets 200mg: 800 mg 3 times a day (2400 mg/j) with food"
3245221|NCT01335555||Patients Pre and Post-chemotherapy|
3355060|NCT02301481|Experimental|Neoadjuvant Chemoradiotherapy (NCRT)|NCRT arm receives intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) (45.1Gy and 40.04Gy in 22 fractions) concurrently with oral S-1(40mg/m2, orally twice daily every weekday) followed by surgery and four to six cycles of SOX at the same dosage with NCT arm.
3355061|NCT02301481|Active Comparator|Neoadjuvant Chemotherapy (NCT)|NCT arm consists of neoadjuvant three cycles of SOX(S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle followed by radical surgery and another postoperative three cycles of SOX.
3355062|NCT02301494|Experimental|Fluocinonide (Vanos) cream 0.1%|Fluocinonide (Vanos) cream 0.1% will be applied as currently approved by the FDA for treatment of corticosteroid responsive disorders of the skin. Treatment will continue for 4 months with a follow up at 6 and 12 months.
3355063|NCT02301494|Experimental|3.75% Imiquimod (Zyclara) Cream|3.75% Imiquimod (Zyclara) Cream will be used as currently labeled by the FDA for treatment of actinic keratoses. Treatment will continue for 4 months with follow up at 6 and 12 months.
3355064|NCT02301507|Experimental|SMS (texting) Arm|texts received
3355065|NCT02301533|Experimental|Shikamana Intervention|The Shikamana Intervention consists of provider support (modified Next Step Counseling) and peer support (trained peer navigator) to promote adherence to antiretroviral therapy
3355066|NCT02301533|Other|Standard Care|The standard care arm will receive adherence counseling per standard Kenyan Ministry of Health guidelines, along with the recommendation to disclose to a family member or friend in order to obtain support
3355067|NCT02301559|Experimental|Pilates Group|Pilates Group, Pilates exercises, 20 sessions, lasting 40 minutes each, 3 times per week. Soil and ball exercises, with emphasis on the pelvic region. The program began with the work of breathing and postural correction, with warm-up exercises or preparatory, followed by the framework of classical movements of the method.
3355068|NCT02301572||Aggressive onset MS|Two or more relapses in the preceding year and 2 or more gadolinium enhancing lesions on brain MRI scan or a significant T 2 lesion burden or One relapse if it results in sustained EDSS of 3.0 along with 2 or more gadolinium enhancing lesions or significant T2 lesion burden ( T2 lesion burden being determined by factoring the number of lesions, the size of the lesions and lesion location)
3355069|NCT02301585|Experimental|Passive Leg Raising|Before decision on fluid administration a passive leg raising test is performed. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
3355070|NCT02301585|Active Comparator|Standard of care|Patients are treated according to Surviving Sepsis Guidelines. Fluid is administered according to the choice of the clinician.
3245222|NCT01335568|Experimental|surgery|chronic liver insufficiency, cirrhosis
3245223|NCT01335607|Active Comparator|Part A: Samatasvir cap→tab→tab; Part B: cap|Part A: Samatasvir capsule as a single dose on Day 1 (fasting state) followed by samatasvir tablet as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
3245224|NCT01335607|Active Comparator|Part A: Samatasvir tab→cap→tab; Part B: cap|Part A: Samatasvir tablet as a single dose on Day 1 (fasting state) followed by samatasvir capsule as a single dose on Day 8 (fasting state) followed by samatasvir tablet as a single dose on Day 15 (fed state); Part B: samatasvir capsule as a single dose on Day 1 (fed state)
3355071|NCT02301598|Experimental|FS-ALK|Femtosecond laser-assisted maximum thickness anterior lamellar keratoplasty (FS-ALK) was performed for 11 eyes of 11 patients with advanced keratoconus and 2 eyes of 2 patients with superficial corneal scattering.
3245225|NCT01335646|Active Comparator|Surgery|
3245226|NCT01335646|Active Comparator|Non-operative|
3355072|NCT02301650||group A|The one year old children born in Beijing Ditan hospital and whose mothers had taken Lamivudine in late pregnancy
3355073|NCT02301650||group B|The one year old children born in Beijing Ditan hospital and whose mothers had taken Telbivudine in late pregnancy
3245227|NCT01335659||ostial lesion|ostial lesion will be evaluated by IVUS and FFR
3245228|NCT01335672||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3355074|NCT02301650||group C|The one year old children born in Beijing Ditan hospital and whose mothers had taken Tenofovir in late pregnancy
3355075|NCT02301650||group D|The one year old children born in Beijing Ditan hospital and whose mothers untreated in late pregnancy
3355076|NCT02301663|Experimental|Women w/microvascular disease|10 women with microvascular disease
3355077|NCT02301663|Experimental|Normal controls|10 age-matched women with no evidence of microvascular disease
3355078|NCT02301663|Experimental|calibration|10 healthy individuals who will help to synchronize our imaging and stress testing maneuvers.
3355079|NCT02301676|Active Comparator|General anesthesia & Control|"After the surgery, the patients are discharged from the hospital, investigators will check the postoperative cognitive function 4 times: 1weak, 3months, 6months, 1 year later using the intervention Korean version of telephone interview for cognitive status (TICS). The test will be administered to spouse simultaneously by telephone."
3245229|NCT01335685|Experimental|Arm A: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle for up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 23 maintenance cycles; overall up to 32 cycles [34 months]).
3355080|NCT02301676|Active Comparator|Sevoflurane & Propofol & Dexmedetomidine|The anesthetic methods are divided into the following 3 kinds: Sevoflurane, Propofol, Dexmedetomidine. These anesthetic drugs are used in general anesthesia generally.
3355081|NCT02301689||Heart Failure patients|
3245230|NCT01335685|Experimental|Arm A: Ixazomib 3.7 mg|Ixazomib 3.7 mg, capsules, orally, on Days 1, 4, 8, 11, 22, 25, 29, 32 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 10 maintenance cycles; overall up to 19 cycles [21 months]).
3245231|NCT01335685|Experimental|Arm B: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 15 maintenance cycles; overall up to 27 cycles [25 months]).
3245232|NCT01335685|Experimental|Arm B: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 cycle plus melphalan 6 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 49 maintenance cycles; overall up to 61 cycles [58 months]).
3245233|NCT01335685|Experimental|Arm B: Ixazomib 5.5 mg|Ixazomib 5.5 mg, capsules, orally, on Days 1, 8, 15 plus melphalan 6 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1-4 in 28-day cycle for up to 13 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 24 cycles [24 months]).
3245234|NCT01335685|Experimental|Arm C: Ixazomib 3.0 mg|Ixazomib 3.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 30 maintenance cycles; overall up to 39 cycles [40 months]).
3245235|NCT01335685|Experimental|Arm C: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 12 maintenance cycles; overall up to 21 cycles [24 months]).
3355082|NCT02301702|Experimental|Tdap Vaccine|Combination Tetnus Toxoid, Reduced Diptheria Toxoid and Acellular Pertusis (Tdap)
3355083|NCT02301702|Active Comparator|Td Vaccine|Tetanus toxoid and reduced diphtheria toxoid vaccine (Td)
3355084|NCT02301715|Active Comparator|Oxytocin|24 IU Oxytocin, 3 puffs per nostril, each with 4 IU OXT, intranasal application 45 min prior to the experiment
3355085|NCT02301715|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril, 45 min prior to the experiment
3355086|NCT02301741|Experimental|Game Condition|Participants in the GAME condition will complete laboratory sessions on five consecutive days. Session 1 (baseline) and Session 5 (post-test) will be used to assess lumbar spine motion and expectations of pain and harm during standardized reaching tasks. In sessions 2 through 4 they will play the virtual dodge ball game.
3355087|NCT02301741|No Intervention|Control Condition|Participants in the CONTROL condition will complete baseline and post-test standardized reaching tasks, but will not play the game in the intervening three days.
3355088|NCT02301754|Experimental|INVAC-1|"INVAC-1 at escalating doses of 100, 400 and 800 µg will be given as a single agent by intradermal injection (Q 4 weeks x 3 cycles), always combined with electroporation.~Each patient will receive 3 cycles, unless motivated treatment interruption."
3355089|NCT02301767||women that are diagnosed with breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
3355090|NCT02301767||women at high risk of breast cancer|To complete the study women need to have undergone their scheduled contrast-enhanced MRI, completed the study questionnaire, and provided written consent to release MRIs/mammograms. Although attempts will be made to obtain written consent from all women, the questionnaire data captured from the women who only provide verbal consent may be used in analysis. Optional saliva samples will also be collected for future use.
3355091|NCT02301780|Placebo Comparator|Control Group|Placebo
3355092|NCT02301780|Active Comparator|Intervention Group|Aspirin
3355093|NCT02301806|Experimental|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
3355094|NCT02301806|Active Comparator|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
3355095|NCT02301819|Active Comparator|Invasive|Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)
3355096|NCT02301819|Active Comparator|Conservative|Early conservative therapy according to standard practice
3355097|NCT02301845|Experimental|Suspended Diatoms|Suspended diatom shells (10 mg/ 10 ml of saline) will be instilled in the oral cavity of the study subject every 12 hours for the first three study days. The total amount of amorphous silica administered will be 20 mg/day, which is the average daily intake of amorphous silica in normal human diet (0.3 mg/kg body weight/day)
3355098|NCT02301858|Other|Study arm|Genome analysis of tissue samples.
3355099|NCT02301871|Active Comparator|Conventional group|The treatment was given for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
3355100|NCT02301871|Experimental|DNF Group|"DNF training along with conventional treatment. In this programme, emphasis was placed on first attaining the correct craniocervical flexion action, with minimal activity of the superficial cervical flexor muscles. The craniocervical flexion action involves a specific craniocervical movement (nodding - yes movement) of head such that it remains in contact with the supporting surface. Once the correct action had been achieved, participants were instructed in the use of the sphygmomanometer to guide the training of the CCF muscle contraction at the various incremental levels of pressure (22 to 30 mmHg, progressively inner range positions)."
3355101|NCT02301871|Experimental|MET Group|MET in additional to conventional treatment. MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
3355102|NCT02301884|Experimental|Allergen extract|"Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.~Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection"
3355103|NCT02301910|Experimental|Recombinant staphylokinase|Lyophilizate for solution making for intravenous injection, 5 mg (745000 ME). 15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
3355104|NCT02301910|Active Comparator|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~55 to <60 30 mg 6 ml~60 to <70 35 mg 7 ml~70 to <80 40 mg 8 ml~80 to <90 45 mg 9 ml~90 50 mg 10 ml"
3355105|NCT02301923||CPAP compliant (C)|Patients confirmed with obstructive sleep apnea and succeeded to pursue treatment with CPAP
3355106|NCT02301923||CPAP noncompliant (NC)|Patients confirmed with obstructive sleep apnea but did not succeed to pursue treatment with CPAP
3355107|NCT02301949|Active Comparator|Thalidomide Retreatment Group|
3355108|NCT02301949|Placebo Comparator|Placebo Group|
3355109|NCT02301962|Experimental|Panitumumab arm|Subjects will receive panitumumab 6 mg/kg intravenously as monotherapy every 14 days until disease progression, intolerability, withdrawal of consent, or death.
3355110|NCT02302001|Experimental|Primary Breast Augmentation|
3355111|NCT02302014|Experimental|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
3355112|NCT02302014|No Intervention|Usual Care|Usual Care
3355113|NCT02302027|Experimental|platinium IRC9LXO2AWQ|Normobaric oxygen therapy with high flow concentrator to treat headaches attacks, 30 minutes of oxygene inhalation with mask, 9l/minute, no frequency limitation
3355114|NCT02302040|Experimental|AIM2ACT|AIM2ACT uses existing mHealth technology developed by the study team to elucidate tailored intervention targets for each family. AIM2ACT then facilitates collaborative caregiver/adolescent asthma management by automatically guiding dyads through a structured process that includes the supportive behavioral management strategies of goal setting, contingency management, and problem solving communication. Skills-training videos for adolescents and caregivers provide guidance on how to complete each collaborative asthma management component.
3355115|NCT02302040|Active Comparator|Self-Guided|Participants in the self-guided control condition will be given general information on supportive behavioral management techniques they can use to target improvement in asthma self-management behaviors. The control condition will serve as an attention control and is designed to optimize recruitment and sustain interest while concurrently having a minimal impact on asthma management.
3355116|NCT02302053|Active Comparator|New Viviscal Professional Supplement|New Viviscal Professional Strength Supplements. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
3355117|NCT02302053|Placebo Comparator|Placebo Tablet|Placebo tablets. One tablet taken by mouth in the morning and one tablet in the evening with food for 180 days.
3355118|NCT02302079|Experimental|ASP8232 + sham intravitreal (IVT) injections|ASP8232 will be given orally once daily and sham injections 3 times with 1 month intervals
3355119|NCT02302079|Experimental|ASP8232 + ranibizumab intravitreal (IVT) injections|ASP8232 will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
3355120|NCT02302079|Active Comparator|Placebo + ranibizumab intravitreal (IVT) injections|Placebo will be given orally once daily and ranibizumab injections 3 times with 1 month intervals
3355121|NCT02302118||Surgical approach|Group A: Esophagogastrectomy Group B: Extended gastrectomy
3355122|NCT02302131||pulmonary valve replacement|SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
3355123|NCT02302144|Experimental|Early Multi-Ex-PD|Immediately following enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
3355124|NCT02302144|Experimental|Late Multi-Ex-PD|Three months after enrollment, subjects will participate in a group balance and strengthening program (Multi-Ex-PD) 2x/week for 90 minutes over 3 months within the Center for Neurorehabilitation at Sargent College. Each of the exercises consists of a progression which ranges from less challenging to more challenging. The program will be individualized to the subject to appropriately match their abilities. Each subject will be progressed to a more challenging exercise once specific criteria are met. Resistance for the strengthening exercises will be applied using weighted vests.
3355125|NCT02302170|Experimental|H. pylori vaccine in children|H. pylori vaccine (15mg/dose) in children between 6-15 years of age
3355126|NCT02302170|Placebo Comparator|placebo in children|placebo (0mg/dose) in children between 6-15 years of age
3355127|NCT02302183|Experimental|Experimental: device FreeO.|Automatic adjustment of oxygen
3355128|NCT02302183|Active Comparator|Manual oxygenation|Manual adjustment of oxygen
3355129|NCT02302196||Autologous Fat Grafting of the breast|Approximately 100 women who have had a lumpectomy and qualify, will be offered Autologous Fat Grafting (AFG) procedure. Patients will be assessed 3 months post grafting for safety and efficacy by Breast-Q survey, mammography BIRADS scoring and physical assessment. The AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. Repeat mammogram will be done 1 year post AFG.
3245236|NCT01335685|Experimental|Arm D: Ixazomib 4.0 mg|Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 22, and 29 plus melphalan 9 mg/m^2, tablets, orally on Days 1 to 4 and prednisone 60 mg/m^2, tablets, orally, on Days 1 to 4 in 42-day cycle for up to 9 cycles in induction phase followed by ixazomib at dose last tolerated in induction, orally, on Days 1, 8, 15 in 28-day cycle up to 12 cycles or until disease progression or unacceptable toxicity if deriving benefit in maintenance phase (up to 28 maintenance cycles; overall up to 37 cycles [38 months]).
3245237|NCT01335711|Experimental|IMP_C/C IL28B|C/C IL28B subjects to whom IMP will be administrated prior to SOC
3245238|NCT01335711|Active Comparator|SOC_C/C IL28B|C/C IL28B subjects to whom only SOC will be administrated
3245239|NCT01335711|Experimental|IMP_non-C/C IL28B|non-C/C IL28B subjects to whom IMP will be administrated prior to SOC
3355130|NCT02302196||Control arm standard treatment|Retrospective chart review will be done in 100 women who have undergone standard treatment for breast contour defect after lumpectomy.The control group will be measured by compiling BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy.
3355131|NCT02302209|Experimental|Oxytocin|40 IU Oxytocin Intranasal
3355132|NCT02302209|Placebo Comparator|Placebo|Saline Nasal Spray
3355133|NCT02302235|Active Comparator|Ketogenic Diet|Treatment will consist of ketogenic diet. KGD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. Diet will be started at the time of initiation of radiation treatment.
3355134|NCT02302235|Other|Standardized diet|The subjects will be taken standard diet in a 1:1 ratio.
3355135|NCT02302248|Experimental|Crowdsourced Reappraisal|Participants received the web-based crowdsourcing reappraisal intervention.
3245240|NCT01335711|Active Comparator|SOC_non-C/C IL28B|non-C/C IL28B subjects to whom only SOC will be administrated
3245241|NCT01335737|Experimental|aerobic training|12 weeks of aerobic training, 4 times/week
3355136|NCT02302248|Active Comparator|Expressive Writing|Participants received the web-based expressive writing intervention.
3355137|NCT02302261||Status Asthmaticus|Any patient presenting to the ED with status asthmaticus.
3355138|NCT02302274||flecainide infusion test|Patients with suspect Brugada Syndrome will be asked to undergo flecainide infusion (2 mg/Kg up to 150 mg maximum dose) over 10 minutes and their ECG will be continuously monitored. The objective of the study is to investigate if they show conversion from type 2 or type 3 ECG to a diagnostic type 1 ECG.
3355139|NCT02302287|Experimental|Group A|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day~Mediterranean diet and ketoacids for 6 months"
3355140|NCT02302287|Experimental|Group B|"Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;~Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day;~Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day~Mediterranean diet and ketoacids for 6 months"
3355141|NCT02302287|Other|Group control|Free diet: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day
3355142|NCT02302300|Experimental|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
3355143|NCT02302300|No Intervention|Control Group|Standard preparation
3245242|NCT01335737|Placebo Comparator|wait list control|wait list control condition, 12 weeks + 4 to parallel the deconditioning protocol in active intervention group
3245243|NCT01335763|Other|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
3245244|NCT01335776|Experimental|Cognitive Behavior Therapy|Cognitive Behavior Therapy for insomnia consists of stimulus control therapy, sleep restriction therapy, cognitive therapy and relaxation.
3245245|NCT01335776|Experimental|Mindfulness-Based Stress Reduction|The program consists of three primary components: theoretical material related to relaxation, meditation, and the mind-body connection; experiential practice of meditation and yoga and home based practice; group process focused on problem solving and support.
3245246|NCT01335802||Subclinical hypothyroidim|Women having subclinical hypothyroidism and/or TPOab-positive.
3355144|NCT02302313|Other|painful stimuli|"No drug and no placebo will be used in this study. The study participants will only rate their pain on a numerical scale (EN) following cutaneous painful stimulation (6 for each phase) of variable intensity, delivered by a CO2 laser. ANI (Analgesia Nociception Index) will be raised simultaneously by the ANI monitor. This sequence will be performed on subjects at rest and in a state of hypnosis by the technique of remembering a pleasant memory and the ideo-sensory technique of protective glove."
3355145|NCT02302326|Experimental|Metformin|PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.
3355146|NCT02302326|Experimental|Myo-inositol + folic acid|PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks
3355147|NCT02302326|No Intervention|Healthy women|Healthy untreated women adjusted for age and body mass index
3355148|NCT02302352|Active Comparator|Probiotic|Oral probiotic 1g, once/day, containing: Lactobacillus paracasei, 10x9 CFU; Lactobacillus rhamnosus,10x9 CFU; Lactobacillus acidophillus, 10x9 CFU; Bifidobacterium lactis 10x9 CFU per sachet
3355149|NCT02302352|Placebo Comparator|Placebo|Maltodextrin 1g per sachet, once/day
3245247|NCT01335802||Controls|Women having normal levels of TSH and TPOab-negative.
3245248|NCT01335815||elective knee and limb endoprothesis|
3355150|NCT02302378|Active Comparator|Taylor's approach|This arm will have the procedure of spinal anesthetic performed via 'Taylor's approach' which is a paramedian approach to interspace L5 - S1. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
3355151|NCT02302378|Active Comparator|Lumbar approach|This arm will have the procedure of spinal anesthetic performed via a paramedian 'Lumbar approach' at interspace L3-L4. A single dose of 12.5mg of 0.5% bupivacaine (preservative free) will be used for the spinal anesthetic, the effects of this will last approximately 2 hours.
3355152|NCT02302391||Midazolam/fentanyl: PK analysis|Pediatric intensive care patients under analgosedation with midazolam and fentanyl.
3245249|NCT01335828|Other|echography/elastography|
3355153|NCT02302404|Experimental|Cohort 1: GSK2982772 Single Ascending Dose (Part A) (0.1-10mg)|Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through approximately 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 0.1, 0.5, 2.5, and 10mg. A sequential design will be used including approximately weekly dose escalations while allowing for a sufficient washout period. The proposed doses may be adjusted based on emerging safety and PK
3355154|NCT02302404|Experimental|Cohort 2: GSK2982772 Single Ascending Dose (Part A) (40-240mg)|Eight subjects will be randomized equally to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having 4 dose periods (3 active dose of GSK2982772 +1 placebo dose). The subjects will fast overnight from Day -1 to Day 1 of the treatment period. Two of the 8 subjects will be randomized to the dosing on Day 1 as sentinel dosing. Assuming adequate safety in the judgment of the Principal Investigator (e.g., vital signs, ECGs, and adverse events) through 24 hours; the remaining 6 subjects may be randomized to dosing on the following day. Subjects will receive single planned doses of GSK2982772 as 40, 100, 180, and 240 mg. A sequential design with weekly dose escalations and sufficient washout period will be used. The proposed doses may be adjusted based on emerging safety and PK. After the completion of the fasted treatment periods, subjects will receive a high fat meal within 30 minutes of dosing with GSK2982772 during a final treatment period.
3355155|NCT02302404|Experimental|Cohort 3: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A data
3355156|NCT02302404|Experimental|Cohort 4: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in Part A or any preceding repeat dose cohorts in Part B
3245250|NCT01335841|Experimental|3D fluoroscopy and navigation station|
3245251|NCT01335841|Active Comparator|2D and anatomical landmarks|
3245252|NCT01335854|No Intervention|Usual Care|Usual care for 3 months. This consists of a phone call after one week of treatment, and clinic appointments at the sleep center following one month and three months of CPAP treatment.
3245253|NCT01335854|Experimental|Web-Access to CPAP Data|Usual care and web-based access to CPAP adherence data for 3 months. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website.
3245254|NCT01335854|Experimental|Web-Access to CPAP Data & Incentive|Usual care and web-based access to CPAP data for 3 months with financial incentives. Participants in this group will be asked to review their CPAP use daily in the first week of treatment and as desired over the next 3 months by accessing a password protected website. Financial incentive terminated after 1 week.
3245255|NCT01335880|Active Comparator|Promotion I|Three month time horizon
3245256|NCT01335880|Experimental|Promotion II|One week time horizon
3245257|NCT01335893|Experimental|ICG injection group|This group will receive a single dose of ICG, diluted in saline solution, prior to surgery. Then, during their surgery, they will be imaged with the camera and imaging probe we have developed.
3355157|NCT02302404|Experimental|Cohort 5: GSK2982772 Repeat Dose (Part B)|Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The subjects will fast overnight from Day -1 to Day 1 and overnight from Day 13 to Day 14. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B. Once-daily dosing is planned, but twice-daily dosing may be considered based upon the exposure observed in the Part A or any preceding repeat dose cohorts in Part B.
3355158|NCT02302404|Experimental|Cohort 6: GSK2982772 Single Ascending Dose (Part A)|This additional cohort in Part A of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied. Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Eight subjects will be randomized equally (1:1:1:1) to one of the 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2982772 + 1 placebo dose). The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
3355159|NCT02302404|Experimental|Cohort 7: GSK2982772 Repeat Dose (Part B)|This additional cohort in Part B of the study will only be conducted to allow for evaluation of additional dose levels or repeated evaluation of a dose level already studied Doses will be selected based on the safety, tolerability, and PK data from Part A and/or previous Part B cohorts. Twelve subjects will be randomized to repeat doses of GSK2982772 or placebo in a 3:1 ratio. The selection of appropriate daily doses will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts in Part B.
3355160|NCT02302417|Other|All Subjects|Approximately 1000 subjects with clinical diagnoses of asthma and/or COPD or clinical presentations suggestive of either or both will be included. Subjects will undergo spirometry assessments and also will be asked a series of questions by a qualified health care practitioner using a questionnaire containing 41 questions concerning their respiratory condition.
3355161|NCT02302430|Experimental|Treatment|Treatment group will receive either 20IU or 40IU intranasal oxytocin
3355162|NCT02302430|Placebo Comparator|Placebo|Placebo group will receive a saline nasal spray
3355163|NCT02302443|Experimental|Cohort 1|Very low dose of HM12470 (single dose, subcutaneous injection)
3355164|NCT02302443|Experimental|Cohort 2|Low dose of HM12470 (single dose, subcutaneous injection)
3355165|NCT02302443|Experimental|Cohort 3|Intermediate dose of HM12470 (single dose, subcutaneous injection)
3355166|NCT02302443|Experimental|Cohort 4|High dose of HM12470 (single dose, subcutaneous injection)
3355167|NCT02302443|Experimental|Cohort 5|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
3355168|NCT02302443|Experimental|Cohort 6|Active comparator and a selected dose of HM12470 (single dose, subcutaneous injection)
3355169|NCT02302456|Experimental|TXA|Intravenous administration of 1g of tranexamic acid within 2 minutes after birth and prophylactic oxytocin administration
3355170|NCT02302456|Placebo Comparator|Placebo|Intravenous administration of placebo within 2 minutes after birth and prophylactic oxytocin administration
3355171|NCT02302469|Other|revlimid|a dose-escalation of revlimid
3355172|NCT02302482|Experimental|Functional autonomy level collection|Collection of the Functional autonomy level every 6 - 12 months by phone
3355173|NCT02302495|Other|Carfilzomib weekly+Melphalan+Prednisone|one arm, two steps and two parts.In the first step of the study: 5 cohorts of 6 patients with Carfilzomib weekly administrated at different dose regimen will be opened one after the other to determine Maximum tolerated dose of Carfilzomib based on definition of Dose-limiting toxicities.In the second step of the study:expanded Cohort, 50 patients received Carfilzomib at the MTD. In Part 1. Induction.Nine 5 weeks cycles of weekly CMP are plannedCarfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route . Patients will start the first cycle day 1 with 20mg/m². In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.Part 2. Maintenance.Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year.
3245258|NCT01335906|Experimental|Evidence-based informed consent|
3245259|NCT01335906|No Intervention|Usual information|
3355174|NCT02302508|Experimental|T2D patients with A1C ≤7.0|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3355175|NCT02302508|Experimental|T2D patients with A1C>7.5|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3245260|NCT01335919||Neonate|Subjects admitted for surgery or to the pediatric intensive care unit (PICU) or neonatal intensive care unit (NICU) who require daily and/or multiple blood samples for hemoglobin measurement.
3245261|NCT01335945|Other|Cryoablation|Freezing of the celiac plexus
3355176|NCT02302508|Experimental|Insulino-treated|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3245262|NCT01335958|Experimental|A|
3245263|NCT01335984|Experimental|Telemonitoring group|The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
3355177|NCT02302508|Active Comparator|Non-diabetic healthy subjects|Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)
3355178|NCT02302521||Healthy Younger Adults|Age: 20-30. Gender: male or female. No neurological conditions.
3355179|NCT02302521||Healthy Older Adults|Age: 50-70. Gender: male or female. No neurological conditions.
3355180|NCT02302521||Parkinson's disease|Gender: male or female. Tremor dominant Parkinson's disease.
3355181|NCT02302521||Healthy Children|Age: 4-8. Gender:male or female. No neurological conditions.
3245264|NCT01335984|Experimental|Telemonitoring & Telemedicine group|The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
3245265|NCT01335984|Other|Control group|The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
3355182|NCT02302534|Experimental|patients|"2 groups with MRI :~- 8 right thoracic AIS participants (Cobb angle between 20 and 40°)"
3355183|NCT02302534|Experimental|controls subjects|- 8 healthy controls (no clinical scoliosis)
3355184|NCT02302547|Active Comparator|triple therapy|Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease inhibitor or unboosted protease inhibitor or integrase inhibitor or celsentri or non-nucleoside reverse transcriptase inhibitor).
3355185|NCT02302547|Experimental|dual therapy|"Truvada®245mg:oral administration Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor)"
3355186|NCT02302560||Patients with elective hip surgery|Patients with elective hip surgery (implementation or replacement of hip joint endoprotheses).
3355187|NCT02302573|Experimental|placenta accreta|contast-enhanced ultrasound with sonovue
3355188|NCT02302586|Active Comparator|Patient Controlled Analgesia (IV PCA)|Postoperative intravenous (IV) morphine PCA is being used for acute pain control: Basal infusion: 0.3 mg/kg/h Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
3355189|NCT02302586|Active Comparator|Thoracic Paravertebral Block (TPVB)|Preoperative thoracic paravertebral block (TPVB) at 4 levels from T4 to T8 is being performed and total of 20 mL Bupivacaine 0.5% is deposited (5 mL per level by using landmark technique)
3355190|NCT02302599|Experimental|Umbilical cord mesenchymal stem cells|Patients receive Umbilical cord mesenchymal stem cells intravenous infusion for three times with an interval of 4 weeks in the absence of disease progression or unacceptable toxicity
3355191|NCT02302599|Experimental|Controlled suspension liquid|Patients receive Controlled suspension liquid
3355192|NCT02302612|Experimental|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE disease management program.
3355193|NCT02302612|Active Comparator|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
3355194|NCT02302625|Experimental|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
3355195|NCT02302638|Active Comparator|Sage 1-step|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in Sage 1-step medium for up to six days following oocyte retrieval."
3355196|NCT02302638|Active Comparator|CSCM|"Embryo culture in different single-step media:~Half of each patient's oocytes will be randomly allocated to be cultured in CSC medium for up to six days following oocyte retrieval."
3355197|NCT02302651|Other|Osteoid Osteoma|MR guided High Intensity focused ultrasound
3355198|NCT02302664|Active Comparator|PRP Injection|Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
3355199|NCT02302664|Sham Comparator|Imitation Injection|Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
3355200|NCT02302703|Active Comparator|the low FODMAP diet|
3245266|NCT01336010|Experimental|Group A - 8 weeks therapy|8 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 2 weeks of therapy.
3245267|NCT01336010|Experimental|Group B - 16 weeks therapy|16 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 4 weeks of therapy.
3245268|NCT01336010|Experimental|Group C - 24 weeks therapy|24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 6 weeks of therapy.
3245269|NCT01336010|Experimental|Group D - 32 weeks (gt1) or 24 weeks (gt 2/3)|32 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 8 weeks of therapy.
3245270|NCT01336010|Experimental|Group E - 48 weeks (gt 1) or 24 weeks (gt 2/3)|48 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 1) or 24 weeks total of Pegylated interferon and ribavirin if undetectable HCV RNA after 12 weeks of therapy (genotype 2/3).
3355201|NCT02302703|Active Comparator|Gluten free diet|
3355202|NCT02302729|Experimental|Micronutrients No responsive feeding|Micronutrient powder and no responsive feeding
3355203|NCT02302729|Placebo Comparator|Placebo and Responsive Feeding|Placebo (vitamin B2) and Responsive Feeding
3355204|NCT02302729|Experimental|Micronutrients and Responsive caregiving|Micronutrients and Responsive feeding intervention
3355205|NCT02302729|Placebo Comparator|Placebo and No responsive caregiving|Placebo and No responsive caregiving
3355206|NCT02302742||Triple Negative Breast Cancer patients|No intervention
3355207|NCT02302742||Germline HBOC Mutation Carriers|No intervention
3355208|NCT02302755|Experimental|Screening/ Active Treatment Arm|"Screening Period: This includes diagnosis confirmation, consent, required tests and vaccinations.~Treatment Period: All patients will be enrolled through the University of Iowa. This study will follow a patient-specific TP10 dose-escalation scheme during the Induction Period and subsequent dose adjustments based on complement levels during the Maintenance Period"
3355209|NCT02302768|Placebo Comparator|Placebo|Patients randomized to receive same pharmaceutical form (capsule) used for the two Semet groups, with the same excipients but the active drug.
3245271|NCT01336010|No Intervention|Untreated Group|Observation only. No treatment for hepatitis C administered. Subjects who have undetectable HCV RNA at baseline, do not wish to commence treatment or are ineligible for treatment.
3245272|NCT01336049|Experimental|Nimotuzumab|
3355210|NCT02302768|Active Comparator|80-Semet|Patients randomized to receive selenomethionine at 80 mcg per day.
3355211|NCT02302768|Active Comparator|160-Semet|Patients randomized to receive selenomethionine at 160 mcg per day.
3355212|NCT02302781||Subfertile couples|Couples referred to one of the four participating hospitals with any type of subfertility for work up and/ or treatment will be screened for inclusion. Couples have not visited only other clinic yet.
3355213|NCT02302794|Active Comparator|open surgery|Conventional procedure
3355214|NCT02302794|Experimental|laparoscopic surgery|Minimum invasive procedure
3355215|NCT02302820|Active Comparator|Make Your Wishes Known|"A Decision Aid that uses interactions, videos, vignettes.~A formatted Advance Directive; saved data that may be revisited to produce a revised Advance Directive"
3355216|NCT02302820|Active Comparator|Mayo Clinic-Advance Health Care Planning|"Not an online decision aid~Written instructions, worksheets, and Advance Directive to complete"
3355217|NCT02302820|Active Comparator|Mydirectives.com|"Online decision aid that uses interactions, videos, and vignettes.~An electronically stored Advance Directive that may be printed."
3355218|NCT02302820|Active Comparator|Prepare|"An online decision aid that uses interactions, videos and vignettes.~A printed summary useful for transposing values and treatment wishes into an Advance Directive; a list of action steps."
3355219|NCT02302833|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3355220|NCT02302872|Experimental|ARTO system|
3355221|NCT02302898||Wt maintenance|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
3355222|NCT02302898||Wt Regain|Eating Behavior Evaluation Measurement of Functional gastric volume Measurement of gastric pouch and GJ sizes
3355223|NCT02302911||Early intensive behavioral intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive behavioral Intervention at one of the participating centres.
3355224|NCT02302911||Early intensive eclectic intervention|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving early intensive eclectic Intervention at the participating centre.
3245273|NCT01336062|Experimental|Nanoparticle Albumin-Bound Paclitaxel|The study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
3245274|NCT01336075|Active Comparator|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic radiofrequency ablation
3245275|NCT01336075|Active Comparator|Percutaneous ablation|Percutaneous radiofrequency catheter ablation
3355225|NCT02302911||Control group|Children with a diagnosis of Autism Spectrum Disorder under the age of 5 years that are receiving treatment as usual or no treatment at all.
3355226|NCT02302937|Active Comparator|group A: Standard TEP|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
3355227|NCT02302937|Active Comparator|Group B: LESS Port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port (12 to 15 mm transumbilical).
3355228|NCT02302950||women that picked up raltegravir 2013|minority women that picked up raltegravir at Thomas street Health Center 2013
3355229|NCT02302963|Experimental|AP System (DiAs or inControl) with USS Virginia|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then proceed through 7 weeks of training and use of the AP System with USS Virginia and study pump. The inpatient testing will be repeated after wearing the AP System at home.
3355230|NCT02302963|Placebo Comparator|Sensor-Augmented Pump Therapy|Subject will complete an 8-hour inpatient assessment of hypoglycemia counterregulation. Subject will then wear a continuous glucose monitor and their own insulin pump at home for 5 weeks. The inpatient testing will be repeated at the completion of the 5 weeks at home.
3245276|NCT01336088|Experimental|ADX48621|
3245277|NCT01336088|Placebo Comparator|ADX48621 Matching Placebo|
3245278|NCT01336101|Other|SFA stenting|
3245279|NCT01336127|Experimental|occupational therapy|10 weeks occupational therapy according to a protocol (OTiP protocol) based on the Dutch guidelines of occupational therapy in Parkinson's disease
3245280|NCT01336127|No Intervention|No occupational therapy|Patients and their caregivers in the control group will have no occupational therapy intervention until their last measurement has taken place (6 months).
3245281|NCT01336153|Experimental|MLC601|MLC601 (NeuroAideTM) is a TCM which is used extensively in China to improve recovery after stroke. It combines several herbal and animal components.
3245282|NCT01336153|Placebo Comparator|Placebo|
3245283|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
3245284|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 30 μg|split-virion, non-adjuvanted H1N1 vaccine of 30 μg.
3245285|NCT01336166|Experimental|split-virion, non-adjuvanted vaccine of 45 μg|split-virion, non-adjuvanted H1N1 vaccine of 45 μg.
3245286|NCT01336166|Placebo Comparator|Placebo control|Placebo control
3245287|NCT01336179|Experimental|Miswak, dental plaque and gingivitis|
3245288|NCT01336179|Active Comparator|Toothbrush, dental plaque and gingivitis|
3245289|NCT01336192|No Intervention|Best supportive care|Best supportive care
3245290|NCT01336192|Experimental|Maintenance gemcitabine|Maintenance therapy of gemcitabine alone
3245291|NCT01336218|Experimental|1|Fostamatinib
3245292|NCT01336218|Experimental|2|Rifampicin
3355231|NCT02302976|Experimental|acute pre-treatment with exenatide|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
3355232|NCT02302976|Experimental|sub-chronic (5 day) treatment with exenatide|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
3355233|NCT02302976|Placebo Comparator|acute pre-treatment with placebo|This arm plans to explore the effects of acute pre-treatment with the glucagon like peptide-1 (GLP-1) agonist, exenatide vs. placebo, on the subjective (e.g., euphoric) and behavioral effects (e.g., self-administration) of cocaine in experienced, non-treatment seeking users of the drug. We propose to study 24 subjects in a within-subject (two-day, randomized, placebo-controlled) human laboratory study of self-regulated cocaine administration. We hypothesize that acute treatment with exenatide will reduce cocaine-induced euphoria and self-regulated cocaine administration as compared to placebo
3355234|NCT02302976|Placebo Comparator|sub-chronic (5 day) treatment with placebo|This arm plans to explore the effects of sub-chronic (5-day) treatment with exenatide as compared to placebo on the subjective (e.g., euphoric) and behavioral (self-administration) effects of cocaine in experienced, non-treatment seeking users of the drug. Upon completion of arm 1, subjects may opt to be randomized to five days of treatment with either exenatide or placebo, followed by a one-day human laboratory study of self-regulated cocaine administration. We hypothesize that subjects treated with exenatide (up to N=12) will demonstrate decreased self-regulated cocaine administration as compared to subjects treated with placebo (up to N=12).
3355235|NCT02302989|No Intervention|Observation|No treatment. Observation only
3355236|NCT02302989|Active Comparator|Quarterly Ranibizumab 0.5|Quarterly intravitreal injection of 0.5mg Ranibizumab Intervention: Drug: Ranibizumab 0.5mg
3355237|NCT02303002|Experimental|Dose A|Dose A: Botulinum Toxin Type A
3355238|NCT02303002|Experimental|Dose B|Dose B: Botulinum Toxin Type A
3355239|NCT02303002|Experimental|Dose C|Dose C: Botulinum Toxin Type A
3355240|NCT02303002|Active Comparator|Dose D|Dose D: Botulinum Toxin Type A
3245293|NCT01336231||patients group|Patients with a metastatic kidney cancer and must beginning a treatment by antiangiogenic
3245294|NCT01336244|Experimental|GLPG0778 ascending doses|Multiple ascending doses for 13 days, ranging from 50 mg twice daily upto a maximum to be determined during escalation.
3355241|NCT02303002|Placebo Comparator|Dose E|Dose E: Placebo
3355242|NCT02303015||Danish germ cell cancer patients|Danish patients with germ cell cancer diagnosed from 1984 to 2007.
3355243|NCT02303028|Experimental|Topotecan and Pazopanib|Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
3355244|NCT02303054|Experimental|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on an Prostatic multi-parametric MRI (mpMRI) of the prostate will be considered for enrollment. If followed by a positive MRI-US targeted biopsy of the prostate, men who be offered enrollment into the study. All men enrolled in the study will undergo bipolar radiofrequency ablation. Efficacy will be assessed through MRI-US biopsy after focal bipolar RFA.
3355245|NCT02303080|Placebo Comparator|Control (WPM 0)|400 mL beverage with 85.0% maltodextrine, 15.0% fat and 0% of whey protein micelles Product given once after 1 hour of monitoring for baseline
3355246|NCT02303080|Active Comparator|WPM 30|400 mL beverage with 43.7% of maltodextrine, 15.2 % fat and 41.1% (30 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
3355247|NCT02303080|Active Comparator|WPM 50|400 mL beverage with 16.3% of maltodextrine, 15.2 % fat and 68.5% (50 g) of whey protein micelles Product given once after 1 hour of monitoring for baseline
3355248|NCT02303080|Active Comparator|MC 50|400 mL beverage with 16.7% of maltodextrine, 15.0 % fat and 68.2% (50 g) of whey protein micelles 50 g of micellar casein Product given once after 1 hour of monitoring for baseline
3355249|NCT02303106|Active Comparator|lamotrigine|lamotrigine alone
3355250|NCT02303106|Experimental|Lamotrigine + paracetamol|Lamotrigine + paracetamol
3355251|NCT02303119|Active Comparator|Am A : Rituximab IV|4 infusions of intravenous rituximab (375mg/m²) at Day 1, Day 8, Day 15 and D22
3355252|NCT02303119|Experimental|Arm B: Rituximab SC|1 infusion of intravenous rituximab (375mg/m²) at Day 1, and 7 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
3355253|NCT02303119|Experimental|Arm C : Rituximab SC first cycle|8 administrations of sub-cutaneous rituximab (1400mg) at Day 8, Day15, Day 22, Month 3, Month 5, Month 7 and Month 9.
3355254|NCT02303132|Other|Active MC|Patients with active MC will be included
3355255|NCT02303132|Other|MC in remission|Patients with MC in remission will be included
3355256|NCT02303132|Other|Controls|Patients without MC will be included
3355257|NCT02303145||Breast cancer survivor Group|Breast Cancer Survivor Group includes: women between the ages of 18 to 69 who have received a stage I-III diagnosis of breast cancer in the past and completed primary treatment and finished with treatment for at least 6 months; currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
3245295|NCT01336244|Placebo Comparator|Placebo|Twice daily for 13 days, matching the scheme of the multiple ascending dose.
3245296|NCT01336257|Experimental|Electronic Reminder|alert from SEBASTIAN decision support system
3245297|NCT01336257|No Intervention|control|
3245298|NCT01336270||MELANOMA 10mm|patients with a melanoma larger than 10mm or with cutaneous metastasis
3245299|NCT01336270||STAGE III MELANOMA|stage III melanoma patients who shall undergo a regional lymph node dissection
3355258|NCT02303145||Control Group|Control Group includes: women between the ages of 18 to 60 who are healthy with no diagnosis of cancer, currently employed working part-time or full-time at the time of assessment. Participants working between 1 to 34 hours a week will be considered part-time employees.
3355259|NCT02303171|Active Comparator|Enoxaparin group|Women will be subjected to anticoagulant therapy by Enoxaparin throughout pregnancy
3355260|NCT02303171|Active Comparator|Warfarin group|Women will be subjected to anticoagulant therapy by Enoxaparin in the first trimester then Warfarin after the first trimester
3355261|NCT02303197|Experimental|ChiNing decoction|60ml ChiNing decoction by mouth，three times a day for 46 days.
3245300|NCT01336270||SENTINEL NODE PROCEDURE|retrospective study of patients who underwent a sentinel node procedure
3245301|NCT01336270||STAGE IV MELANOMA|stage IV patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment(processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
3355262|NCT02303197|No Intervention|rhEGF spray|The rhEGF spray spray on the oral mucosal surface irradiated area, 3 times a day for 46 days.
3355263|NCT02303210|Other|hearing aid NaidaUP|Within subject design: compare frequency lowering one with frequency lowering two.
3355264|NCT02303210|Other|hearing aid NaidaSP|Within subject design: compare frequency lowering one with frequency lowering two.
3355265|NCT02303223|Other|Propofol|Single intravenous bolus dose of Propofol 2.5mg/kg for induction of anesthesia
3355266|NCT02303249|Experimental|Intervention|Review of discharges and cross-sectoral video conferencing immediately after discharge
3355267|NCT02303249|No Intervention|Control|Standard health care services
3355268|NCT02303275|Other|Lifestyle Change|Lifestyle Change
3355269|NCT02303301|Active Comparator|Probiotics|Patients gurgle twice a day with a suspension of two probiotic strains of bacteria- Contains also a filling material - maltodextrin
3355270|NCT02303301|Placebo Comparator|Control|Patients gurgle twice a day with a suspension of the filling material - maltodextrin
3355271|NCT02303314|Other|Drug: Trigonella Foenum-graecum|in this group patients use Trigonella Foenum-graecum seed extract twice daily.
3245302|NCT01336283|Active Comparator|COPD with emphysema|Analyze what type of training is more appropriate and beneficial as the patient characteristics that apply to you.
3245303|NCT01336283|Active Comparator|COPD non-emphysema|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
3355272|NCT02303314|Other|Drug: Placebo|in this group patients use placebo twice daily.
3355273|NCT02303327|Other|ADT+EBRT+ HDR brachytherapy boost|Standard fractionation radiotherapy: 46 Gy in 23 fractions (EBRT) and a 15-Gy HDRB boost in conjunction with 28 months of androgen deprivation therapy (ADT).
3355274|NCT02303327|Active Comparator|ADT+Hypofractionated Dose Escalation RT|Hypofractionated dose escalation radiotherapy: 68 Gy in 25 fractions in conjunction with 28 months of androgen deprivation therapy (ADT).
3355275|NCT02303340||Study Group|Any patient who enrolled and signed informed consent will be sent to bone mineral density DEXA Scan, and for blood testing for PTH, Phosphor, Calcium ,Vitamin D and Creatinine levels. Density measurements will be done in specific sites on the CBCT's of the jaws.
3355276|NCT02303353||Cancer patients|Patients suffering from a carcinoma (either breast, ovarian, lung, colon, stomach, pancreas, rectum or plasmacytoma)
3355277|NCT02303366|Experimental|SABR + MK-3475|SABR treatment (20Gy in 1 fraction) to at least one metastases (to a maximum of 5 metastases) followed by 8 cycles of 3 weekly treatment with MK-3475 (200mg IV per dose).
3355278|NCT02303379|Active Comparator|Continuous Endurance training|Endurance training with constant work load 31min at 65-75% maximal heart rate (HRmax)
3355279|NCT02303379|Experimental|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
3355280|NCT02303379|Experimental|High-intensity intervall training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
3355281|NCT02303392|Experimental|Treatment (selinexor, ibrutinib)|Patients receive ibrutinib PO on days 8-28 of course 1 and on days 1-28 on subsequent courses and selinexor PO BID weekly on day 1 or bi-weekly on days 1 and 3. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3355282|NCT02303405|Experimental|Hydroxychloroquine|Treatment with hydroxychloroquine 400 mg (2 x 200 mg tablets) po once daily x 4 months
3355283|NCT02303405|Active Comparator|Pioglitazone|Treatment with pioglitazone 45 mg po (1 tablet) once daily x 4 months
3355284|NCT02303418|Active Comparator|Carbetocin|100 µgm of Carbetocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
3355285|NCT02303418|Active Comparator|Oxytocin|5 mg of oxytocin will be diluted in 10ml saline and will be given by the anesthesist slowly intravenously after delivery of the baby. The uterine tone and amount of bleeding will be noted and the need for further uterotonic agents will be determined 2 minutes after giving the drug.
3355286|NCT02303431|Experimental|Cohort 1a|12 to < 18 years of age: edoxaban low dose group
3355287|NCT02303431|Experimental|Cohort 1b|12 to < 18 years of age: edoxaban high dose group
3355288|NCT02303431|Experimental|Cohort 2a|6 to < 12 years of age: edoxaban low dose group
3355289|NCT02303431|Experimental|Cohort 2b|6 to < 12 years of age: edoxaban high dose group
3355290|NCT02303431|Experimental|Cohort 3a|2 to < 6 years of age: edoxaban low dose group
3355291|NCT02303431|Experimental|Cohort 3b|2 to < 6 years of age: edoxaban high dose group
3355292|NCT02303431|Experimental|Cohort 4a|6 months to <2 years of age: edoxaban low dose group
3355293|NCT02303431|Experimental|Cohort 4b|6 months to <2 years of age: edoxaban high dose group
3355294|NCT02303431|Experimental|Cohort 5a|0 to 6 months of age: edoxaban low dose group
3355295|NCT02303431|Experimental|Cohort 5b|0 to 6 months: edoxaban high dose group
3355296|NCT02303444||MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
3355297|NCT02303444||non-MKI patients|Asymptomatic patients with RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study entry. For patients on sorafenib, treatment start and stop dates will be collected along with any adverse events observed.
3355298|NCT02303457|Experimental|CO2 laser surgery|CO2 Laser surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved. All patients, under general anesthesia, underwent endoscopic excision of the lesion using a carbon dioxide (CO2) laser (Sharplan 100) coupled with a microscope (Zeiss) set to an output power of between 5 and 12 W in superpulse mode. The lesion's resection was accomplished in a radical fashion, with a free margin of 2 mm. For lesions which involved the anterior commissure, the excision plane always uncovered the cartilage.
3355299|NCT02303457|Other|Open surgery|"Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved.~open surgery :Frontolateral Vertical Partial Laryngectomy or laryngofissure with cordectomy was accomplished in a radical fashion, with a free margin of 2 mm."
3355300|NCT02303470|Experimental|Vigorous Exercise|High-intensity interval training for 15 minutes daily, 5 days per week for 8 weeks
3245304|NCT01336309||Focus Group|We conducted three focus groups per site, at three sites, with around eight people each. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We will administer the Yoga Research Tool.
3245305|NCT01336309||Cognitive Interviews|We conducted cognitive interviews at three different sites, with about ten in each group. These data were used to guide refinement and selection of the items we developed for Phase III data collection. We collected this data via a large, online survey and administered the Yoga Research Tool.
3245306|NCT01336309||Survey Prototype Administration|We administered a prototype of the study measure to a large group of yoga students, with about 450 total participants. These data were used to further inform the refinement and selection of items to be used in the final measure.
3245307|NCT01336309||Reliability and Validity Testing|We are conducting yoga classes at community partner facilities near each site, with about ten participants in each class. Participants at each class will complete the study measure and related questionnaires, in order to test the reliability and validity of the study measure.
3245308|NCT01336322|Active Comparator|Metformin|Metformin 850 mg bid
3245309|NCT01336322|Active Comparator|Sitagliptin|Sitagliptin 100 mg qd
3355301|NCT02303470|Experimental|Moderate Exercise|Brisk walking for 30 minutes daily, 5 days per week for 8 weeks
3355302|NCT02303483|Placebo Comparator|Placebo|lime tablets
3245310|NCT01336322|Active Comparator|Sitagliptin+Metformin|Sitagliptin 100 mg qd plus Metformin 850 mg bid
3355303|NCT02303483|Experimental|Nicotinamide riboside (NR, Vit B3)|NIAGEN (ChromaDex) 1 g x 2 orally per day
3355304|NCT02303496|Experimental|PRP Cream Application|Application of Cream Containing Platelet Rich Plasma and Oleaginous Base
3355305|NCT02303496|Active Comparator|SW Cream Application - Placebo|Application of Cream Containing Sterile Water and Oleaginous Base
3355306|NCT02303509|Experimental|UCB5857 Part 1|Part 1: Subjects assigned to UCB5857 or placebo single dose.
3355307|NCT02303509|Experimental|UCB5857 Part 2|Part 2: Subjects assigned to UCB5857 or placebo multiple doses.
3355308|NCT02303522||All subjects|All subjects will be included in a unique cohort
3355309|NCT02303535||Congenital|"All patients with congential and acquired heart disease treated by cardiac surgery and therapeutic cardiac catheterisations procedures .~For acquired heart disease, the audit covers all arrhythmias & cardiomyopathies in patients less than 16 years old only.~For congenital heart disease, the audit collects data on both children and adult patients."
3355310|NCT02303561|Experimental|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
3355311|NCT02303561|Active Comparator|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
3245311|NCT01336335|Experimental|CPAP|OSA treatment with CPAP
3355312|NCT02303587|Experimental|low dose group|methylprednisolone 2mg-4mg/Kg
3355313|NCT02303587|Experimental|high dose group|methylprednisolone 10mg/Kg
3355314|NCT02303600|Experimental|biomarker treatment arm|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate).
3355315|NCT02303600|Active Comparator|standard treatment arm|Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
3355316|NCT02303626|Experimental|BCX4161 300 mg three times daily|Three BCX4161 capsules (100 mg) and two placebo capsules to be taken three times daily by mouth
3355317|NCT02303626|Experimental|BCX4161 500 mg three times daily|Five BCX4161 capsules (100 mg) to be taken three times daily by mouth
3355318|NCT02303626|Placebo Comparator|Placebo three times daily|Five placebo capsules to be taken three times daily by mouth
3245312|NCT01336335|No Intervention|control|no intervention
3245313|NCT01336348|Experimental|prasugrel|Prasugrel 60 mg loading dose
3245314|NCT01336348|Active Comparator|Tirofiban|Tirofiban will be at a bolus only of 25uM or followed by 2 hour infusion
3245315|NCT01336361||Physical Therapists|Physical Therapists who are members of the American Physical Therapy Association (APTA) and live in the United States .
3245316|NCT01336374||Greened Vacant Lot|A cluster of vacant lots is greened. People living around this area make up this cohort.
3245317|NCT01336374||Control Site|The control site is a cluster of vacant lots that will not be greened. The people living around these lots make up the control group.
3245318|NCT01336387|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30* PO on days 1-28.
3245319|NCT01336387|Placebo Comparator|Arm II (placebo)|Participants receive placebo* PO on days 1-28.
3245320|NCT01336400||PGD-FISH|"Following couples opting for preimplantation genetic diagnosis on the basis of FISH:~couples suffering a complex chromosomal rearrangement (CCR)~couples with X-linked recessive disorders~couples that carry a balanced chromosomal rearrangement"
3355319|NCT02303639|Experimental|Radiofrequency catheter ablation|Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping
3355320|NCT02303639|Active Comparator|Antiarrhythmic drug therapy|Amiodarone (or sotalol) tablet by mouth for the duration of the study
3355321|NCT02303665|No Intervention|The control group|No Intervention
3355322|NCT02303665|Experimental|The dual therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy.
3355323|NCT02303665|Experimental|The triple therapy group|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM.
3355324|NCT02303678|Experimental|D2C7-IT|Recurrent malignant glioma patients will receive D2C7-IT, delivered intratumorally by CED following confirmatory diagnostic biopsy.
3355325|NCT02303691|Experimental|Computerized Attention Bias Modification|
3355326|NCT02303691|Sham Comparator|Computerized Neutral Training|
3355327|NCT02303717|Active Comparator|Xience|Percutaneous coronary intervention utilising a cobalt chromium everolimus eluting stent with durable polymer (Xience) plus oral dual antiplatelet therapy (DAPT) for 12 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
3355328|NCT02303717|Experimental|Synergy|Percutaneous coronary intervention utilising a platinum chromium everolimus eluting stent with bioresorbable polymer (Synergy) plus oral dual antiplatelet therapy (DAPT) for 4 months. DAPT will be aspirin 75-100mg daily plus either clopidogrel 75mg daily or prasugrel 5-10mg daily or ticagrelor 90mg twice daily.
3355329|NCT02303730|Experimental|Exenatide|Exenatide 5 ug twice daily 1 hour before meal subcutaneously for 4 weeks, then add to 10 ug twice daily 1 hour before meal subcutaneously for another 20 weeks
3355330|NCT02303730|Active Comparator|Insulin glargine|Insulin glargine subcutaneously, once daily, for 24 weeks
3355331|NCT02303756|Experimental|Pillcam® COLON Capsule|Detection of neoplastic lesions in colon and rectum compared to colonoscopy
3355332|NCT02303769|Active Comparator|Tamsulosin HCL 0.2mg|Harnal-D tablet (Tamsulosin HCL 0.2mg)
3355333|NCT02303769|Experimental|Tamsulosin HCL 0.4mg|GL2702 GLARS-NF1 tablet (Tamsulosin HCL 0.4mg)
3355334|NCT02303782|Experimental|OTX015 + azacitidine|
3355335|NCT02303782|Experimental|Azacitidine|
3355336|NCT02303795|Active Comparator|Rivaroxaban 20mg|Oral Rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
3355337|NCT02303795|Active Comparator|Warfarin|Warfarin Warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
3355338|NCT02303808|No Intervention|USUAL CARE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
3355339|NCT02303808|Active Comparator|INHALATION WITH PEP DEVICE|Patients will perform the inhalation of the 7% hypertonic saline (following the gold standard recomendation) combined with a PEP device (Acapella Duet) during 15 minutes. Right after, patients will perform independently their usual session of autogenic drainage during 30 minutes.
3355344|NCT02303834|No Intervention|Control|The control group will not be fitted with CPAP.
3355345|NCT02303834|Experimental|CPAP group|The group will wear a CPAP device throughout the night. The mask fits comfortably over the nose and delivers a steady stream of air under slight pressure (auto-set).
3245321|NCT01336400||PGD-PCR|"Following couples opting for preimplantation genetic diagnosis on the basis of PCR:~-couples at risk for the transmission of monogenic diseases"
3245322|NCT01336439|Active Comparator|M group|A total of 25U of botulinum toxin type A was injected into each side masseter muscle in this arm.
3355346|NCT02303847|Active Comparator|Active Drug|ketamine 16 mg in flavored syrup by mouth twice daily for 1 week, then ketaming 32 mg in flavored syrup by mouth twice daily for 1 week
3355347|NCT02303847|Placebo Comparator|Placebo|Flavored syrup (without ketamine) by mouth twice daily for 2 weeks
3355348|NCT02303860|Experimental|Panel 1|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
3355349|NCT02303860|Experimental|Panel 2|Adaptive design: Each subject will receive MR A or MR B formulation of ORM-12741 or a combination of these once or twice daily for one week either combined with IR formulation or not.
3355350|NCT02303873|Experimental|an open label, prospective, self-controlled study|Children or adolescents under the age of 18 years old with minor trauma fracture were recruited from 30 provinces of China. The diagnosis of OI was made by endocrinology department of Peking Union Medical College Hospital(PUMCH).
3355351|NCT02303886|Active Comparator|A Methylene blue 10 mg/ml 2mg/kg|ten patients that recieved MB1 methylene blue 2 mg/kg infusion under 60 min
3355352|NCT02303886|Placebo Comparator|B Methylene blue 10 mg/ml 0.02 mg/kg|Same patients received MB2 Methylene blue 0.02 mg/kg infusion under 60 min
3355353|NCT02303899|Experimental|Gemcitabine & Imatinib mesylate|Gemcitabine 1000 mg/m2, i.v., days 3 and 10 of a 21-days schedule; Imatinib mesylate 400 mg/die orally on days 1-5 and 8-12 of a 21-days schedule.
3355354|NCT02303912|Other|Open label dose escalation|"Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days.~Dose escalation will be done using 3+3 dose escalation design"
3355355|NCT02303925|Experimental|coils|
3355356|NCT02303938|Experimental|physical exercise|Patients will exercise three times per week for 6 months home-based exercise intervention. Session duration will vary between 20 minutes and 45 minutes.
3355357|NCT02303938|No Intervention|Active control group|Patients in the active control group will be advised to walk regularly based on brochures from 30minutenbewegen.nl
3355358|NCT02303951|Experimental|vemurafenib + cobimetinib + atezolizumab|"Run-In (week 1-4):~Day 1-21: vemurafenib 960 mg bid orally + cobimetinib 60 mg od orally~Day 22-28: vemurafenib 720 mg bid orally~Triple-Treatment (week 5 ongoing):~atezolizumab 840 mg Q2W i.v. + vemurafenib 720 mg bid orally + cobimetinib 60 mg od 21/7 orally (vemurafenib: daily intake; cobimetinib: 3 weeks on drug, 1 week off)"
3355359|NCT02303964|Active Comparator|Type A Thawed Plasma|"Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive 2 units of thawed Type A plasma in the pre-hospital setting administered by EMS first responders.~An exception from informed consent under 21CFR 50.24 is required since enrollment will occur (for the majority of subjects) before consent can be obtained."
3355360|NCT02303964|Placebo Comparator|Normal saline|Eligible subjects with polytrauma (PT) and major hemorrhage (MH) will be randomized to receive normal saline in the pre-hospital setting administered by EMS first responders. Normal saline is standard of care
3245323|NCT01336439|Active Comparator|MT group|A total of 25U of botulinum toxin type A was injected into each side masseter and temporal muscle in this arm.
3355361|NCT02304003|Experimental|Structured Physiotherapy regimen|Heavy-slow resistance training of rotator cuff . Scapular exercises. Manual mobilisation of glenohumeral joint . Stretching. Low Level Laser therapy
3355362|NCT02304003|Other|Standard care|Standard care offered in primary care while waiting for surgery , this may be but are not limited to : Wait and see, Drugs ( NSAIDS ), Corticosteroid injections, physiotherapy or other conservative treatment options.
3355363|NCT02304016|Experimental|Pelvic floor physical therapy|
3355364|NCT02304016|No Intervention|Observatoin|
3355365|NCT02304029|Experimental|assessment of a innovative MRI|Sodium MRI will be performed at CEMEREM, CHU Timone, the only site with this technique, with a Siemens Verio 3T MRI using a dedicated coil and a sequence already developed locally, in 90 patients with partial drug -resistant epilepsy
3355366|NCT02304042|Active Comparator|Carbetocin|125 women will receive carbetocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
3355367|NCT02304042|Active Comparator|Oxytocin|125 women will receive carbetocin oxytocin after delivery of the anterior shoulder. The drug will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder
3355368|NCT02304055|Active Comparator|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
3355369|NCT02304055|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 5IU slowly iv.
3355370|NCT02304068|Other|Intra-vitreal injection|
3245324|NCT01336452|Other|CCRTx|consecutive patients who plan to undertake CCRTx due to advanced hepatocellular carcinoma
3245325|NCT01336465|Experimental|rhuMAb Beta7|
3355371|NCT02304081|Active Comparator|Saxagliptin|Metformin and Dapagliflozin background therapy
3245326|NCT01336465|Placebo Comparator|placebo|
3355372|NCT02304081|Placebo Comparator|Placebo|Metformin and Dapagliflozin background therapy
3355373|NCT02304094|Experimental|manipulation|Those in the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique. They will be asked to return once each week for a further five weeks. At each visit the VAS and PTM measurements shall be repeated, as will the manual manipulation. They shall also be asked to return for a review in the sixth week.
3355374|NCT02304094|Active Comparator|Steroid|Those randomised to the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine. They shall then be asked to return for review in six weeks. A second injection may be offered at this point if clinically indicated.
3355375|NCT02304107|Active Comparator|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9 mm the dose will be increased by 37.5 IU every 7 days.
3355376|NCT02304107|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
3245327|NCT01336530|Experimental|Tepilta®|
3355377|NCT02304120|Experimental|Sensorimotor|"The experimental group will receive added PPT to the conventional physiotherapy. PPT will be applied by means of a neuro-orthopaedic medical device (Posturomed®, see section 3.2). The Posturomed allows adaptive oscillation in the horizontal plane. Therapy instructions advise seven stages of difficulty. In all stages the patient is asked to provoke oscillation by stepping on site. After three steps, the patient must stand still on one leg for 2 seconds before he or she repeats the steps. Difficulty is increased by a) decreasing the damping through release of the breaks and b) through added juggling of a ball during the motor task (dual-task and divided attention). The next stage is reached once stabilisation in the previous stage is secured."
3355378|NCT02304120|Active Comparator|Low-intensity activity|Added to conventional therapy, as administered to all participants, the control group will do added treadmill walking. The control intervention will consist of 10 minutes of walking at comfortable pace. The patient will be instructed in treadmill functions and asked to set the speed between 2 and 4 km/h. The speed should be adjusted to the level where the patient would still be able to talk comfortably.
3355379|NCT02304133|Active Comparator|Intervention|participating in a four-hour course in abdominal POC US
3355380|NCT02304133|Placebo Comparator|Control|no training
3355381|NCT02304146||High ligation and stripping (surgery)|6-10 years post classical stripping of the great saphenous vein.
3355382|NCT02304146||Foam sclerotherapy|6-10 years post post ultrasound guided foam sclerotherapy of the great saphenous vein.
3355383|NCT02304172|Active Comparator|Thunderbeat (Group A)|Patients submitted to thyroidectomy with the use of the Thunderbeat device.
3355384|NCT02304172|Active Comparator|Harmonic (Group B)|Patients submitted to thyroidectomy with the use of the Harmonic scalpel device
3355385|NCT02304185|Experimental|gp140, 50 mcg|
3355386|NCT02304185|Experimental|gp140, 50 mcg + Adjuvant|
3245328|NCT01336530|Active Comparator|Oxetacaine|
3245329|NCT01336530|Active Comparator|Antacids|
3355387|NCT02304185|Placebo Comparator|Placebo 1|
3245330|NCT01336530|Placebo Comparator|Placebo|
3245331|NCT01336543|Experimental|Active Treatment|"ACTIVE TREATMENT intervention below:~NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 60 mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
3245332|NCT01336582|Experimental|docetaxel|
3355388|NCT02304185|Experimental|gp140, 250 mcg|
3355389|NCT02304185|Experimental|gp140, 250 mcg + Adjuvant|
3355390|NCT02304185|Placebo Comparator|Placebo 2|
3355391|NCT02304198|Experimental|Udenafil|Udenafil 50mg tablet by mouth, every 12 hours for 1-year(48-weeks)
3355392|NCT02304211|Experimental|Intra-Arterial Microdose Insulin|Healthy volunteers will receive microdose insulin intra-arterially into the radial artery.
3355393|NCT02304211|Active Comparator|Systemic Insulin|Healthy volunteers will receive full-dose insulin intra-venously.
3355394|NCT02304224|No Intervention|Control|the patients with sepsis admitted in the intensive care unit aren't applied with eye masks at night
3355395|NCT02304224|Experimental|Eye masks|the patients with sepsis in the intensive care unit are applied with eye masks at night in the duration of admission
3355396|NCT02304237|Experimental|Vaginal progesterone|Vaginal progesterone(Utrogestan)200mg/day, during 14~21 weeks.
3355397|NCT02304237|Active Comparator|Intramuscular progesterone|Intramuscular progesterone(Progesterone Depot Jenapharm Injection)250mg/week, during 14~21 weeks.
3355398|NCT02304250|Active Comparator|Group D|Group D: dexamethasone group
3355399|NCT02304250|Placebo Comparator|Group S|Group S: saline group
3355400|NCT02304263||Younger (18-35 years old)|iohexol
3355401|NCT02304263||Older (>60 years old)|iohexol
3355402|NCT02304276|Active Comparator|1 (Explanted valves)|"10 subjects who are due to undergo repeat aortic valve replacement surgery~Investigations:~Baseline 18F-Fluoride PET-CT scan~Retrieval of explanted bioprosthetic aortic valve at time of surgery for analysis"
3355403|NCT02304276|Experimental|2 (AVR)|"70 subjects with surgical bioprosthetic AVR, to include 10 subjects who have had a valve replacement < 1 month; 20 at 2 years; 20 at 5 years and 20 at >10 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
3355404|NCT02304276|Experimental|3 (TAVI)|"50 subjects who have undergone TAVI with the COREVALVE and 50 subjects with the SAPIEN valve. In each group this will include 10 subjects who have had TAVI < 1 month; 20 at 2 years and 20 at 5 years.~Investigations:~Baseline 18F-Fluoride PET-CT scan~Repeat CT calcium score of aortic valve at 2 years~Annual clinical follow-up for 5 years (history, examination, blood tests, ECG and echocardiogram)"
3355405|NCT02304289|Experimental|Oral Artesunate|The first patient will receive 200 mg Artesunate once-daily for 14 days. If no dose-limiting toxicity (DLT) is observed after 14 days, the next patient will start at a daily dose of 300 mg Artesunate. If no DLT is observed after 14 days, a cohort of 3 patients will receive 400 mg once-daily for 14 days. For each subsequent cohort of 3 patients 200 mg will be added to the dose, until the maximum tolerated dose (MTD) is determined.
3355406|NCT02304302|Placebo Comparator|Placebo|Identically-looking placebo pills to memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
3355407|NCT02304302|Experimental|Memantine|Memantine will be dispensed in a 66-day supply (56 days plus 10 extra days) by the study coordinator to participants receiving the placebo at the end of visits 2 and 3.
3245333|NCT01336582|Active Comparator|Taxotere|Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)
3245334|NCT01336595|Experimental|Zirconium Femoral Component|Oxidized zirconium femoral component of Genesis II TKR system is used.
3245335|NCT01336595|Active Comparator|Cobalt Chrome|Cobalt-Chromium Femoral component of Genesis II system is used.
3245336|NCT01336621|Experimental|Retigabine IR|Open label flexible dose between 300 mg/day (Minimum) and 1200 mg/day (maximum).
3355408|NCT02304315|Experimental|GC1102 50,000 IU|Anhepatic phase: 50,000 IU intravenous during surgery, Post-transplantation(1st week): 50,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 50,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 50,000 IU intravenous every 4 weeks.
3355409|NCT02304315|Experimental|GC1102 80,000 IU|Anhepatic phase: 80,000 IU intravenous during surgery, Post-transplantation(1st week): 80,000 IU intravenous every day, Post-transplantation(2nd-4th weeks): 80,000 IU intravenous every weeks, Post-transplantation(8th weeks and till 24 weeks): 80,000 IU intravenous every 4 weeks.
3355410|NCT02304328||No clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients without clinical signs of brain herniation syndrome
3245337|NCT01336660|Experimental|Equine F(ab')2 antivenom|Intensive care support and Equine F(ab')2 antivenom
3355411|NCT02304328||Clinical signs of brain herniation syndrome|Poor grade (WFNS IV and V) SAH patients with clinical signs of brain herniation syndrome
3355412|NCT02304341||intermediate units|Children admitted to the paediatric inpatient unit in 7 regional hospitals French
3355413|NCT02304354|Experimental|Rituximab|two intravenous infusions of 1000 mg with a two-week interval between them
3245338|NCT01336660|Placebo Comparator|Placebo|Intensive care support plus placebo
3245339|NCT01336686|Experimental|Arhalofenate 400 mg|
3245340|NCT01336686|Experimental|Arhalofenate 600 mg|
3245341|NCT01336686|Placebo Comparator|Placebo|
3355414|NCT02304393|Experimental|Part IA: Selicrelumab (IV) + Atezolizumab|Selicrelumab at a dose of 16 milligrams (mg) will be administered intravenously (IV) on Day 1 of Cycle 1 (first cycle in this group was of 42 days, and subsequent 21-day cycles); and atezolizumab 1200 mg will be administered IV after 6 weeks on Day 1 of Cycle 2, followed by every 3 weeks during Part IA until disease progression, death, loss of follow-up, or withdrawal of consent.
3355415|NCT02304393|Experimental|Part IA: Selicrelumab(SC) + Atezolizumab|Selicrelumab at a starting dose of 1 mg will be administered subcutaneously (SC) on Day 1 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 2, and followed by every 3 weeks during Part IA as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3355416|NCT02304393|Experimental|Part IB: Selicrelumab + Atezolizumab|Selicrelumab will be administered at a starting dose of 1 mg SC on Day 2 of Cycle 1 (21-day cycle) which will follow escalation in sequential cohorts; and atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks during Part IB as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3355417|NCT02304393|Experimental|Part II: Selicrelumab + Atezolizumab|Atezolizumab 1200 mg will be administered IV on Day 1 of Cycle 1, and followed by every 3 weeks; and Selicrelumab will be administered at the dose defined in Part IB (not exceeding 80 mg SC [unless IV administration in Part IB demonstrates better benefit/risk ratio]) on Day 2 (1 day after atezolizumab administration) of every second cycle from Cycles 1 to 7, and every fourth cycle thereafter during Part II as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
3355418|NCT02304419|Experimental|Galunisertib|150 milligrams galunisertib given orally twice daily (BID) for 14 days followed by 14 days with no study drug (28 day cycles). Treatment is expected to last for 6 cycles. Participants may receive additional cycles if they are deriving clinical benefit.
3355419|NCT02304445|Active Comparator|Transarterial Chemoembolization (TACE)|Subjects will randomized receive one TACE treatment then receive observation or up to 3 additional TACE treatments as clinically indicated.
3355420|NCT02304445|Experimental|TACE+Stereotactic Body Radiotherapy|Subjects will receive one TACE treatment then receive 1-5 Stereotactic Body Radiotherapy treatments.
3355421|NCT02304458|Experimental|Treatment (nivolumab, ipilimumab)|See Detailed Description
3355422|NCT02304471||Control|healthy subjects
3355423|NCT02304471||CKD|chronic kidney disease
3355424|NCT02304471||ESRD|end-stage renal disease
3355425|NCT02304497||DM-CTRL|Diabetes mellitus patients with periodontally healthy Platelet Rich Fibrin obtained
3355426|NCT02304497||DM-CP|Diabetes mellitus patients with chronic periodontitis Platelet Rich Fibrin obtained
3355427|NCT02304497||CP|Chronic periodontitis patients with systemically healthy Platelet Rich Fibrin obtained
3245342|NCT01336699|Experimental|Cohort A|WRSs2 vaccine 1x10^3 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^3 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3245343|NCT01336699|Experimental|Cohort B|WRSs2 vaccine 1x10^4 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^4 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3245344|NCT01336699|Experimental|Cohort C|WRSs2 vaccine 1x10^5 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^5 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3245345|NCT01336699|Experimental|Cohort D|WRSs2 vaccine 1x10^6 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^6 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3355428|NCT02304497||CTRL|Periodontally and systemically healthy subject Platelet Rich Fibrin obtained
3355429|NCT02304510||females|females aged between 18 and 50 years old living in Beijing
3245346|NCT01336699|Experimental|Cohort E|WRSs2 vaccine 1x10^7 colony-forming units (cfu) orally (8 patients), WRSs3 vaccine 1x10^7 cfu orally (8 patients), Placebo 30 ml orally (2 patients)
3245347|NCT01336725||Morbid obesity|All attending learning and mastery courses for persons with morbid obesity
3245348|NCT01336751|Experimental|Insulin glargine|"Lantus (insulin glargine) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by Self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
3245349|NCT01336751|Active Comparator|Lispro mix|"Humalog Mix 75/25 (lispro mix) administered subcutaneously 15 minutes before the evening meal for 24 weeks. The initial dosage was 10 units /day for 7 days. This was followed by titration every 7 days by increasing the dosage until control was established. Insulin dosages were increased according to a subject's glucose values determined by self-monitoring blood glucose (SMBG).~The starting dosage of metformin or sulfonylurea was the dosage the subject was taking when randomized. The dosage was to remain unchanged during the course of the study. The administration schedule was left to the discretion of the investigator."
3245350|NCT01336777||Insulin resistant group|there is no intervention
3245351|NCT01336777||Insulin sensitive group|There is no intervention
3355430|NCT02304523|Experimental|Test 1|"CDFR0612 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3355431|NCT02304523|Experimental|Test 2|"CDFR0613 Solution 150mL will be mixed with water of 350ml to prepare a bowel cleansing preparation solution 500mL. Take it within 30min. After then, take additional water 500ml within 30min.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3355432|NCT02304523|Active Comparator|Comparator|"Coolprep Powder A and B will be mixed with water to prepare a mixture of a bowel cleansing preparation solution 500mL. Repeat it twice. Take these of IL (2 * 500mL) within 1 hour. After then, take additional 500ml water.~These processes will be in evening at one day before colonoscopy and in early morning at the same day of colonoscopy."
3355433|NCT02304536|Active Comparator|FSH|will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day.
3355434|NCT02304536|Active Comparator|Ovarian drilling|70 women will have laparoscopic ovarian drilling in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
3355435|NCT02304549||patients with BPH undergoing TUV-P|patients with Benign Prostatic Hyperplasia undergoing TUV-P
3355436|NCT02304562|Experimental|UCB Mesenchymal Stem Cells|UCB Mesenchymal Stem Cells treatment of patients with skin injury
3355437|NCT02304575||Testicular cancer survivors|Patients treated for testicular cancer, will receive questionnaires and hormonal function measurement.
3355438|NCT02304575||Surgery for benign testicular problems|Patients treated for benign testicular conditions, will receive questionnaires and hormonal function measurement.
3355439|NCT02304575||Healthy males|Healthy volunteers, will receive questionnaires and hormonal function measurement.
3355440|NCT02304588|Experimental|Mesenchymal stem cells|Maximal amount of MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight).
3245352|NCT01336816|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3245353|NCT01336816|Placebo Comparator|Placebo Wintergreen|Subjects allow study placebo lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3245354|NCT01336829|Experimental|001|ETR/telaprevir Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
3245355|NCT01336829|Experimental|002|telaprevir/ETR Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18 and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
3245356|NCT01336829|Experimental|003|TMC278/telaprevir Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
3245357|NCT01336829|Experimental|004|telaprevir/TMC278 Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18 and TMC278 25 mg once daily from Day 8 to Day 18.
3355441|NCT02304601||Comorbid symptoms|
3245358|NCT01336842|Experimental|Phase I dose-escalation|Drug: panobinostat Drug: cisplatin Drug: pemetrexed Other: Biomarker studies
3245359|NCT01336855||HIV Positive|HIV-1 positive subjects
3245360|NCT01336855||HIV negative subjects|HIV-1 seronegative control group
3245361|NCT01336881||Correlative (tissue analysis)|Archived tumor tissue samples are analyzed for hepatoblastoma and other liver tumor biomarkers by microRNA array profiling and exome sequencing. Results are then compared with patients' clinical data.
3355442|NCT02304601||No comorbid symptoms|
3355443|NCT02304614||Group 1|Patients who have undergone Breast conserving Therapy
3355444|NCT02304627|Experimental|Eating meal immediately after dosing|
3355445|NCT02304627|Experimental|Eating meal 30 min after dosing|
3355446|NCT02304627|Experimental|Eating meal 1 hour after dosing|
3355447|NCT02304627|Experimental|Eating meal 6 hour after dosing|
3355448|NCT02304640||Early-stage breast cancer patients|
3355449|NCT02304640||Healthy control|
3355450|NCT02304666|Experimental|Crohn disease's Patients|Patients with Crohn disease or presenting an ulcerative colitis
3245362|NCT01336907||naive CNV subjects|Newly diagnosed CNV, before any treatment (naïve)
3245363|NCT01336907||previously diagnosed CNV subjects|Previously diagnosed CNV if last treatment is older than 4 months (reactivated)
3245364|NCT01336920|Experimental|Treatment (carfilzomib)|Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3355451|NCT02304666|Other|Control patient|Patients with programmed colonoscopy screening for familial colon cancer history, polyps or for irritbale bowel syndrome
3355452|NCT02304679|Experimental|LIESWT arm|"Patients randomized to this arm will have two sequences of Low-Intensity Extracorporeal Shock Wave Therapy (LIESWT).~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
3355453|NCT02304679|Placebo Comparator|Sham arm|"Patients randomized to this arm will have one sequence of sham Low-Intensity Extracorporeal Shock Wave Therapy and then three months later one sequence of Low-Intensity Extracorporeal Shock Wave Therapy.~Interventions: Pre-inclusion questionnaires; 1 month of PDE5i treatment; PDE5i follow-up questionnaires; Inclusion questionnaires; 4 weekly sham LIESWT (Wave 1) with the RENOVA device; Follow-up questionnaires 1 month after Wave 1; Follow-up questionnaires 3 months after Wave 1; 8 bi-weekly LIESWT (Wave 2) with the RENOVA device; Follow-up questionnaires 1 month after Wave 2; Questionnaires via postal mail; Final follow-up questionnaires 12 months after Wave 2."
3355454|NCT02304692|Sham Comparator|Oticon Medical Machined Abutment|A non surface modified abutment is used
3245365|NCT01336946|Experimental|health promotion program|Psycho education and behavioural group sessions and supervised walking sessions will be performed.
3355455|NCT02304692|Experimental|Oticon Medical Modified Abutment|A surface modified abutment is used
3355456|NCT02304718|Experimental|exercise intervention group|Pregnant women randomised to the exercise intervention group will complete three supervised, exercise sessions each week, exercise sessions completed on alternate days, and lasts until they give birth by using a stational bike. And also they will have regular prenatal care.
3245366|NCT01336946|No Intervention|Control group|No intervention will be performed in this control group.
3245367|NCT01337011|Experimental|intra-coronary administration|Application of stem cells using the intra-coronary route.
3355457|NCT02304718|No Intervention|control group|Pregnant women randomised to the control group only have regular prenatal care.
3355458|NCT02304731|Experimental|Exercise and Pollution Groups|Physical Exercise performed in a clean environment and in a polluted environment.
3355459|NCT02304770|Experimental|cervical persistent high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with cervical persistent high risk HPV infection
3355460|NCT02304770|Experimental|CIN 1 with high risk HPV infection|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 1 and high risk HPV infection
3355461|NCT02304770|Experimental|CIN 2/3|Aminolaevulinic acid photodynamic therapy for the treatment of patients with CIN 2/3
3355462|NCT02304783|Active Comparator|Oral Piroxicam|Piroxicam : 20 mg per pill; one pill per day for five days
3355463|NCT02304783|Placebo Comparator|Placebo|Placebo: one pill per day for five days
3355464|NCT02304783|Active Comparator|paracetamol|paracetamol: 1000mg per day for five days
3355465|NCT02304796|Experimental|Unified CBT|Group psychotherapy according to the principles of the Cognitive-Behavioral Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011).
3355466|NCT02304796|Experimental|Combined CBT-DMT|Group psychotherapy combining cognitive-behavioral principles and techniques with dance/movement therapy techniques.
3355467|NCT02304809|Experimental|VEMURAFENIB|"all eligible patients entering the study will receive oral Vemurafenib as monotherapy.~Vemurafenib ZELBORAF 240 mg tablets Per OS 960 mg twice daily, to a total daily dose of 1,920 mg Cycles are defined in 28-day periods Disease response will be assessed every 8 weeks Safety will be assessed continuously~Treatment will be pursed until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal."
3355468|NCT02304822|Active Comparator|Multiple-dose of ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
3355469|NCT02304822|Experimental|Single-dose of ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only
3355470|NCT02304822|Experimental|Zero-dose of ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
3355471|NCT02304848|Experimental|DBS (Deep Brain Stimulation)|DBS ( Deep Brain Stimulation) ( both high and low frequency deep brain stimulation will be applied to the subthalamic nucleus)
3355472|NCT02304861|Active Comparator|Viscoat group|Patients operated using Viscoat OVD
3355473|NCT02304861|Active Comparator|Visthesia group|Patients operated using Visthesia OVD
3355474|NCT02304874|Other|Phlebotomy|Phlebotomies will be performed every 14 days at the Clinical Investigation Unit (CIU) until the value of ferritin level is below 50 µg/mL and/or the value of hemoglobin level is below 12 g/dL.
3355475|NCT02304887||Bisphosphonate|
3355476|NCT02304887||Selective estrogen receptor modulator|
3355477|NCT02304887||Teriparatide|
3355478|NCT02304887||Senosumab|
3245368|NCT01337011|Experimental|intra-myocardial administration|Application of stem cells using the intra-myocardial route.
3245369|NCT01337024||Control group|Healthy volunteers, examined with ECG without any treatment (controls)
3355479|NCT02304900|Experimental|Group 1 : white implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
3355480|NCT02304900|Experimental|Group 2 : yellow implant|Randomization will determine the color of the implant to be used for each patient for interventions in both eyes, white or yellow to know.
3245370|NCT01337024||100 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 100 units BoNT/A
3245371|NCT01337024||300 BoNT/A|patients with neurogenic detrusor overactivity, examined with ECG, injection of 300 units BoNT/A
3245372|NCT01337037||standard VATS group|patients undergo standard VATS lobectomy using non-modified equipments,without limits of staples
3355481|NCT02304913|Experimental|Hypoglossal acupuncture|Single treatment of hypoglossal needle acupuncture during the chemotherapy administration: Treated points will be Jinjin (Golden Liquid/EX-HN12) left beside the lingual frenulum and Yuye (Jade Fluid/EX-HN13) right beside the lingual frenulum. Both points are treated in quick succession with immediate removal of the needle.
3355482|NCT02304913|Sham Comparator|Sham acupuncture|Single treatment of hypoglossal sham acupuncture uring the chemotherapy administration: Treated points will be 1 to 1.5 cun (a cun is defined as the width of the patient's thumb at the knuckle) beside the verum acupuncture points Jinjin and Yuye using the dull side of the needle.
3355483|NCT02304913|Active Comparator|Dietary recommendations|This group adheres to specific dietary recommendations for dysgeusia of the German Cancer Society.
3355484|NCT02304939|Active Comparator|Quick change|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps at the same speed of the first, wait for a first drop at the end of the tubing.~Close the first syringe, disconnect it and connect the second syringe, open the valve on and stop the first syringe."
3355485|NCT02304939|Experimental|Double Pumping|"For this changeover : When the syringe of norepinephrine stops (pre alarm), start the second syringe pumps, open the second syringe while leaving the first syringe open. Wait until the blood pressure rises 5 mmHg (SBP, DBP or MAP).~Once the blood pressure increased or 2 minutes from the start of the relay if no increase in blood pressure is observed, close the first syringe."
3355486|NCT02304939|Experimental|Smart infusion pump|For this automatic changeover : When the syringe of norepinephrine stops (pre alarm), oversee the progress of the automatic relay.
3355487|NCT02304952|Active Comparator|Eccentric exercise|Conservative treatment with eccentric exercise as self-training
3355488|NCT02304952|Active Comparator|Radiofrequency microtenotomy|A minimally invasive surgery (Topaz) and eccentric exercise as postoperative treatment
3355489|NCT02304965|Experimental|Daily physical activity|Eligible subjects will be included in the feasibility study to conduct an individualized and structured training program with defined walking and cycling on a bicycle ergometer for 2 months.
3355490|NCT02304978|Experimental|Group CRC|patient with a colorectal cancer
3245373|NCT01337037||modified equipments group|patients undergo VATS lobectomy with modified VATS lobectomy equipments designed designed according to the experience of chinese lobectomy surgery: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.).
3245374|NCT01337037||less staples group|patients undergo VATS lobectomy with at most 4 staples used.
3245375|NCT01337037||open group|patients undergo lobectomy by thoracotomy approach
3355491|NCT02304978|Experimental|Group control|Control - volunteers
3245376|NCT01337063|No Intervention|Pre-intervention|Usual care regarding medication reconciliation as currently practiced at each participating site.
3245377|NCT01337063|Experimental|Intervention|Improved medication reconciliation process using continuous quality improvement methods, mentored implementation, and an implementation guide.
3355494|NCT02305030|Experimental|BIA 9-1067 / Warfarin|BIA 9-1067 capsules of 25 mg or 50 mg Warfarin capsules of 5 mg
3245378|NCT01337102|Other|Physician to receive results|Arm 1 Physician to receive the results of the Lung QoL scale
3245379|NCT01337102|Other|Physician Does Not Receive Results|Arm 2 Physician does not receive the results of the Lung QoL scale
3355495|NCT02305056|Experimental|C13 N15 Valine|Intervention C13 N15 Valine
3355496|NCT02305069|Placebo Comparator|Placebo|"Placebo tablet taken once daily for 12 weeks.~For study visits performed pre- and post 12-week placebo treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
3245380|NCT01337141|Experimental|Interventional telematic|80 patients will be included in this arm. They will receive 5 telematic visits (Telecare system) and 2 face to face visits.
3355497|NCT02305069|Experimental|Pioglitazone|"30mg pioglitazone encapsulated and taken once daily for 12 weeks.~For study visits performed pre- and post 12-week pioglitazone treatment for the assessment of muscle protein synthesis and leg protein breakdown, the following substances are administered as part of the analytical technique: insulin, octreotide, glucose, mixed amino acids, [2H5]phenylalanine and [1-13C]leucine. The doses administered change as the analytical technique is conducted and for clarity are described in detail in the protocol."
3355498|NCT02305082||Fast-track group|Patients treated according to the enhanced recovery pathway. This group is examined prospectively.
3355499|NCT02305082||Control group|Patients treated according to the historic recovery pathway. This group is examined retrospectively.
3355500|NCT02305095||GNB3 TT|All subjects with the GNB3 TT genotype for the polymorphism at position 825 (T/C). They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
3245381|NCT01337141|Other|Control|80 patients will be included in this arm. They will receive 7 face-to-face visits (not telematic).
3245382|NCT01337154|Experimental|Tamibarotene|Subjects will receive tamibarotene, 6 mg/m2, divided as twice daily orally starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Chemotherapy will include paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6)administered once every 3 weeks for up to 6 cycles.
3245383|NCT01337154|Placebo Comparator|Placebo|Subjects will take an equal number of placebo tablets as the group receiving tamibarotene divided as twice daily orally, starting 1 week before chemotherapy and continuing through all 6 cycles and through the duration of the study. Paclitaxel (IV; 200 mg/m2) and carboplatin (IV; AUC=6) will be administered once every 3 weeks for up to 6 cycles.
3245384|NCT01337180||Main study group|"Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A).~Sputum part of study: nonsmokers."
3245385|NCT01337193|Active Comparator|Pelvic floor muscle exercises|Three pelvic floor muscle exercises will be performed with verbal cueing from the instructor.
3245386|NCT01337193|Experimental|Pelvic floor exercises with biofeedback|Pelvic floor exercises will be performed with biobeedback cueing.
3245387|NCT01337206|Experimental|Stenting Arm|Stenting Arm
3355501|NCT02305095||GNB3 C|All subjects with at least one copy of the GNB3 C allele which includes both subjects homozygous for the 825C allele (GNB3 CC genotype) and subjects who are heterozygous (GNB3 TC genotype).They will be initiated on therapy with FDC I/H, followed for 2 years and response to therapy quantified by a composite score (CS).
3355502|NCT02305108|Experimental|fascial manipolation and standard|
3355503|NCT02305108|Active Comparator|standard treatment|
3355504|NCT02305134|Active Comparator|Tipepidine Hibenzate|Tipepidine is taken orally at 30 mg/day (10 mg after breakfast, 10 mg after supper, and 10 mg before bedtime), for 4 weeks.
3355505|NCT02305134|Placebo Comparator|Placebo|Placebo is taken orally after breakfast, after supper, and before for 4 weeks.
3355506|NCT02305147||Patients with an idiopathic Parkinson Disease,|Patients with recent onset of Parkinson Disease: N=200
3355507|NCT02305147||Subjects at risk of PD|"Subjects at risk to develop Parkinson Disease:~subjects with idiopathic Rem-sleep behavior disorder (iRBD): N=50~subjects related to a patient with genetically confirmed Parkinson Disease: N=30"
3355508|NCT02305147||Controls|Healthy controls: N=50
3355509|NCT02305147||Patients with Parkinson Disease with genetic mutation|Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
3355510|NCT02305160|Experimental|Butantan|The new pulmonary surfactant produced by Butantan Institute. Butantan Surfactant: 100 mg/kg, IT, maximum of 3 doses.
3355511|NCT02305160|Active Comparator|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
3355512|NCT02305173|Active Comparator|dexamethasone group|patients receive one single dose of intravenous dexamethasone 8 mg.
3245388|NCT01337206|Active Comparator|Dilation Arm|Dilation Arm
3245389|NCT01337219|Other|Arm A|experimental treatment (Nebcinal/Aeroneb Idehaler pocket) - 6day-wash out period - standard treatment (Tobi/Pari LC Plus)
3245390|NCT01337219|Other|Arm B|standard treatment (Tobi/Pari LC Plus) - 6day-wash out period - experimental treatment (Nebcinal/Aeroneb Idehaler)
3245391|NCT01337232|Active Comparator|1 session per week|
3245392|NCT01337232|Experimental|2 sessions per week|
3245393|NCT01337245|Experimental|Antivenom|For comparison with historical mortality rate, all patients prospectively enrolled will receive antivenom (Snake [Micrurus] North American immune F(ab')2 Equine) for treatment of coral snake bite.
3245394|NCT01337258||Men at increased risk for Prostate Cancer (PCA)|
3355513|NCT02305173|Placebo Comparator|placebo group|patients receive one single dose of intravenous placebo.
3355514|NCT02305186|Experimental|Neodjuvant CRT + Pembrolizumab|Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
3355515|NCT02305186|Active Comparator|Neoadjuvant CRT|Standard neoadjuvant chemoradiation treatment (CRT) alone
3355516|NCT02305199|Active Comparator|Hartmanns' solution|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of regular insulin (RI) and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200."
3355517|NCT02305199|Active Comparator|Normal saline|"All the participants went on a fast at midnight and 1 L of 5% dextrose fluid containing 10 units of RI and 40 mEq of potassium was administered intravenously.~On participant's arrival to the operation room, fluid from the ward was immediately removed and replaced it with 1 L of unknown fluid completely sealed in black bag. Neither the participant nor the researcher were aware of the type of the fluid.~After the fluid change, general anesthesia was induced. Intraoperative blood glucose was checked every one hours and 20% dextrose was injected if the number was below 100 and RI was injected if the number was checked over 200"
3355518|NCT02305212|Experimental|Cogmed|Cogmed is a cognitive rehabilitation protocol designed to improve working memory. The Cogmed sessions are on a computer at home for 30-40 min per day, 5 days per week for 5 weeks.
3245395|NCT01337271|Active Comparator|PSV|
3355519|NCT02305212|No Intervention|Wait list|
3355520|NCT02305225|Experimental|SDSR|first total then partial Sleep deprivation
3355521|NCT02305225|Experimental|SRSD|first partial then total Sleep deprivation
3355522|NCT02305264|Experimental|PET -18F-DPA-714 and 18F-FDG|"18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mCi(185MBq), will be injected via an arm intravenous catheter."
3245396|NCT01337271|Experimental|NAVA|
3245397|NCT01337310|Experimental|Tesetaxel|Tesetaxel administered orally once every 21 days for at least 2 cycles
3245398|NCT01337323||New prescription for fluticasone furoate nasal spray|patients receiving their first prescription for fluticasone furoate nasal spray and who have active seasonal allergic rhinitis with a history of using another intranasal steriod (INS) and other concomitant allergic rhinitis medications to treat their seasonal allergy symptoms.
3245399|NCT01337349|Placebo Comparator|Sugar Pill|Placebo control Group with sugar pill three times daily for 6 months
3245400|NCT01337349|Experimental|Pentoxifylline|Pentoxifylline 400mg tablets to be taken three times daily for 6 months
3245401|NCT01337362|Active Comparator|Patients with hypoglycemia awareness|Patients who have symptoms when the blood sugar level is low
3245402|NCT01337362|Experimental|patients with hypoglycaemic unawareness.|Patients who do not feel any symptoms when the blood sugar levels are low
3245403|NCT01337375|Experimental|A/B|
3355523|NCT02305290||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Upper Gastrointestinal Lesions will be included in this cohort.
3355524|NCT02305303|Experimental|Diary|Use of diary
3355525|NCT02305303|No Intervention|Without Diary|
3355526|NCT02305342||Urinary Tract Infections (UTIs)|Uncomplicated UTIs
3355527|NCT02305355|Experimental|Omega-3-acids ethylesters 90 4g, any statin|
3355528|NCT02305355|Active Comparator|any statin|
3355529|NCT02305368||Oncogramme|Taking a fragment of colon tumors taken from a specimen. Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
3245404|NCT01337375|Experimental|C/D|
3245405|NCT01337388||Cohort|
3245406|NCT01337401|Experimental|Blinded Cediranib|
3355530|NCT02305394|Experimental|PK group (ketamine and propofol)|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
3355531|NCT02305394|Active Comparator|P group (propofol group)|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.When patients become unconscious, succinylcholine 1 mg/kg (a muscle relaxant) will be administered intravenously. After 1 minute of succinylcholine infused, ECT will be performed with bitemporal electrode placement using a stimulus dose of 1.0-millisecond pulse width, 60-Hz frequency, 6.0-second stimulus duration, and 0.8-A maximal stimulus intensity.
3355532|NCT02305407|Experimental|surgical revascularization|Patients will be assigned to either surgical or conservative treatment depending on their clinical symptoms and radiological assessment.
3355533|NCT02305407|Experimental|conservative treatment|Normal conservative treatment without surgical intervention.
3355534|NCT02305420|Experimental|EmbryoGen/BlastGen|"EmbryoGen and BlasGen media containing GM-CSF 2ng/ml will be used in the experimental arm~The intervention is to use EmbryoGen/BlastGen"
3355535|NCT02305420|Active Comparator|Control|Standard Cook sequential media
3355536|NCT02305433|Experimental|Physiotherapy (physical exercise) for frail elderly|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
3355537|NCT02305433|Experimental|Physiotherapy (physical exercise) for operated hip fracture|Individually tailored, long-term home-based physiotherapy (physical exercise)twice a week for 12 months. The duration of one session is 60 minutes.
3355538|NCT02305433|No Intervention|Usual care for frail elderly|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
3355539|NCT02305433|No Intervention|Usual care for operated hip fracture|Usual care follows the standard care procedures in the South Karelia Social and Health Care District in health care and in assisted home living.
3355540|NCT02305459||Patients treated with Radioembolisation|"All Patients treated with Radioembolisation with yttrium-90 loaded SIR-Spheres microspheres are asked to be enrolled. In no way will participation in the registry influence the way in which the patient is treated or will it influence the quality of the treatment.~In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with the Hepatocellular carcinoma (HCC) Module to measure changes in the quality of life of the patient."
3245407|NCT01337401|Placebo Comparator|Blinded Placebo|
3245408|NCT01337414|Experimental|VMS diary booklet|
3245409|NCT01337414|Active Comparator|Usual Care (e.g. Amsler grid monitoring)|
3355541|NCT02305472|Experimental|NeoVas BCS|The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA-based polymer scaffold and contains the antiproliferative drug sirolimus.
3245410|NCT01337427|Placebo Comparator|Placebo for 48 weeks, BIIB017 for 48 weeks|Placebo every 2 weeks for 48 weeks followed by 125 mcg BIIB017 SC every 2 or 4 weeks for 48 weeks.
3245411|NCT01337427|Experimental|BIIB017 every 2 weeks for 96 weeks|125 mcg BIIB017 SC every 2 weeks for 96 weeks.
3245412|NCT01337427|Experimental|BIIB017 every 4 weeks for 96 weeks|125 mcg BIIB017 SC every 4 weeks for 96 weeks.
3245413|NCT01337440|Active Comparator|UDCA pretreatment|"Ursodeoxycholic Acid (UDCA) for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
3245414|NCT01337440|Active Comparator|Sitagliptin pretreatment|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
3355542|NCT02305485|Experimental|NeoVas|"The NeoVas sirolimus-eluting bioresorbable coronary scaffold system is a PLLA- based polymer scaffold and contains the antiproliferative drug sirolimus.~Intervention: Device: NeoVas BCS"
3245415|NCT01337453||Flu-like symtoms, incidence|The frequency of FLS will be estimated by number of patients and number of Botox treatments.
3245416|NCT01337466|Experimental|[124I]FIAU|single dose study of [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection who will undergo PET-CT scanning
3245417|NCT01337479||Participants of specific phase III entecavir studies|Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections
3245418|NCT01337492|Experimental|Sorafenib|
3245419|NCT01337505|Experimental|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 doxorubicin equivalents of 165, 260, and 325 mg/m2)will be administered as a 30 minute IVI on Day 1 of each cycle.
3245420|NCT01337518|Experimental|EZN-4176|
3245421|NCT01337531|Experimental|gonadotropin|recombinant or highly purified gonadotropin
3245422|NCT01337531|Active Comparator|Gonadotropins|recombinant versus highly purified gonadotropin
3245423|NCT01337544|Experimental|IL-15 STIMULATED NK CELLS|
3245424|NCT01337557|Experimental|Bepotastine|
3245425|NCT01337570|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
3355543|NCT02305485|Active Comparator|XIENCE PRIME|XIENCE PRIME Everolimus Eluting Coronary Stent System is a balloon expandable metallic platform stent manufactured from a flexible cobalt chromium alloy with a multicellular design and coated with a thin nonadhesive, durable, biocompatible acrylic, and fluorinated everolimus-releasing copolymer. Intervention: Device: XIENCE PRIME EECSS
3355544|NCT02305498|Experimental|Vigorous yoga practice|Supervised vigorous yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
3355545|NCT02305498|Active Comparator|Restorative (gentle) yoga practice|Supervised restorative (gentle) yoga practice, 60 minutes/session, 3 sessions/wk for 12 weeks, followed by 12 weeks of home practice.
3245426|NCT01337570|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3245427|NCT01337583|Experimental|Dapivirine|Vaginal ring containing 25mg of dapivirine
3245428|NCT01337583|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3245429|NCT01337622|Experimental|No routine check for gastric residuals|
3245430|NCT01337622|Active Comparator|Routine check for gastric residuals|
3355546|NCT02305511|Experimental|Peripheral venous catheterization|Peripheral venous catheterization during pediatric resuscitation
3355547|NCT02305511|Experimental|intraosseous access|Intraosseus access using intraosseous access devices during resuscitation
3355548|NCT02305524|Experimental|ETI with chest compressions|endotracheal intubation (ETI) during child mannikin resuscitation with uninterrupted chest compressions. In order to simulate the difficulties associated with intubation during uninterrupted chest compressions, CPR was performed by using LUCAS-2 (Physio-Control, Redmond, WA, U.S.).
3355549|NCT02305524|Experimental|ETI without chest compressions|Endotracheal intubation of child mannikin during resuscitation without chest compressions.
3355550|NCT02305537|Experimental|Treatment (Cognitive-Behavioral Therapy)|Participants in the McLean Anxiety Mastery Program
3355551|NCT02305537|No Intervention|Waitlist|Participants on the waitlist for the McLean Anxiety Mastery Program
3355552|NCT02305550|Experimental|electrical synthesis nitric oxide|Participants will breath 20 minutes of electrical pulsed plasma discharge synthesis of nitric oxide at 25 parts per million
3355553|NCT02305602|Experimental|Post Myocardial Infarction|VentriGel will be injected via a MyoStar catheter after NOGA mapping in the 60 day to 3 year window since the first STEMI myocardial infarction
3355554|NCT02305615||Participants with CRC|This is an observational study; thus, no intervention or treatment is required by the protocol. During the study, the treatment will be determined according to the treating physician decision. Eligible participants will be observed for safety and efficacy of continued bevacizumab plus fluoropyrimidine-based doublet chemotherapy treatment in routine clinical practice for 1 year.
3355555|NCT02305628||Cohort|Method of continuous surveillance per standard of care
3355557|NCT02305654|Active Comparator|Arm A - Standard Surgery (ILND)|"Part of randomisation 1.~The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery."
3355558|NCT02305654|Experimental|Arm B - neoadjuvant chemotherapy|"Part of randomisation 1.~Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).~Administration on an outpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5~Administration on an inpatient basis:~Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3"
3355559|NCT02305654|Experimental|Arm C - neoadjuvant chemoradiotherapy|"Part of randomisation 1.~Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.~Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min."
3355560|NCT02305654|Experimental|Arm P - prophylactic PLND|"Part of randomisation 2.~Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.~Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:~Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes~Electively to external iliac nodes in patient with high disease burden~Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone."
3355561|NCT02305654|No Intervention|Arm Q - Surveillance no prophylactic PLND|"no prophylactic PLND Part of randomisation 2.~For patients who have NOT received neoadjuvant chemoradiotherapy:~Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour~Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:~Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden"
3355562|NCT02305667|Placebo Comparator|Macintosh|Double lumen tube intubation using Macintosh laryngoscope
3245431|NCT01337648||TBI prior to stem cell transplantation|
3245432|NCT01337661||COPD subjects|Adult male and female subjects with COPD
3245433|NCT01337713|Experimental|Swedish Massage|
3245434|NCT01337713|Sham Comparator|Light Touch|
3245435|NCT01337726|Active Comparator|Illness Management Only|
3245436|NCT01337726|Experimental|Combined Psychotherapy & Illness Management|
3245437|NCT01337752|Experimental|BHQ880 + bortezomib and dexamethasone|
3245438|NCT01337752|Placebo Comparator|BHQ880 Placebo + bortezomib and dexamethasone|
3245439|NCT01337765|Experimental|BEZ235 + MEK162|
3245440|NCT01337778|Active Comparator|Primary Care for DILs|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced gender-based violence. A comprehensive health examination for mothers-in-law will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
3355563|NCT02305667|Active Comparator|Glidescope®|Double lumen tube intubation using Glidescope® videolaryngoscope
3355564|NCT02305667|Active Comparator|Airtraq®|Double lumen tube intubation using Airtraq® videolaryngoscope
3355565|NCT02305667|Active Comparator|King Vision™|Double lumen tube intubation using King Vision™ videolaryngoscope
3355566|NCT02305693|Active Comparator|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding
3355567|NCT02305693|Active Comparator|Ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary.
3355568|NCT02305706|Experimental|Right|patients will be positioned on the right-lateral position at the start of colonoscopy
3355569|NCT02305706|Active Comparator|Left|patients will be positioned on the left-lateral position at the start of colonoscopy
3355570|NCT02305719||Epidural anesthesia|Patients receiving thoracic epidural anesthesia for thoracoscopic surgery. Standard regimen with 8-20 ml Ropivacaine 0,5% in the epidural catheter. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered.
3355571|NCT02305719||Serratus-anterior-plane-Block|"Patients receiving (ultrasound-guided) Serratus-anterior-plane-Block for thoracoscopic surgery.~Standard regimen up to 20 ml Ropivacaine 0,5%, were installed. Postopertive Ropivacaine 0,2% 6 ml/h via catheter were administered."
3355572|NCT02305719||Local infiltration|Patients receiving local infiltration with up to 20 ml Ropivacaine 0,5% for thoracoscopic surgery (at the site of thoracoscopy)
3355573|NCT02305745||Preeclampsia- observational|45 women with preeclampsia
3355574|NCT02305745||No preeclampsia- observational|10 women without preeclampsia
3355575|NCT02305771|Other|Healthy volunteers|"20 healthy volunteers will undergo an inclusion visit in order to check inclusion and non inclusion criteria.~Then will be performed:~Electroencephalography~MRI"
3355576|NCT02305810|Experimental|Single arm receiving everolimus|single treatment arm receiving everolimus 10 mg daily
3355577|NCT02305823|Active Comparator|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
3355578|NCT02305823|Active Comparator|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
3355579|NCT02305823|Active Comparator|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
3355580|NCT02305836|Experimental|Electroacupuncture combined with donepezil|Every session will last for 30 minuets and will be given every other day. There are 36 sessions for each participant in all (3 session per week, 12 weeks).
3355581|NCT02305836|Active Comparator|donepezil|Donepezil will be given once daily before bed-time for the first 4-6 weeks. Based on the treatment effect, the dosage may be increased to 10 mg once daily before bed-time for the next 6-8 weeks. Donepezil will be taken for continuous 24 weeks. The full course of treatment is 36 weeks.
3355582|NCT02305862|Experimental|low dose group (5mg)|low dose Rosuvastatin
3355583|NCT02305862|Experimental|high dose group (20mg)|high dose Rosuvastatin
3355584|NCT02305875|Experimental|MCN scoring|Scoring of the mcn nerve's position in the axillary sheat using MRI
3355585|NCT02305901|Experimental|Repaglinide + Bupropion + BI 187004|repaglinide tablets and bupropion tablets with and without concomitant administration of BI 187004
3355586|NCT02305914||follow-up visit|Patients who come for follow-up visit will fill in the questionnaire and undergo regular laboratory examination such as liver function test and CRP,faecal elastase-1 as well as CT scanning.Additionally,blood sample of every patient will be collected and sent to the Lab for storage and further experimented.
3355587|NCT02305927|Experimental|Vitamin D3 (cholecalciferol)|
3355588|NCT02305927|Placebo Comparator|Placebo|
3355589|NCT02305940|Active Comparator|Doxycycline|Doxycycline: oral dose of 100 mg once daily, for a total duration of 52 weeks.
3355590|NCT02305940|Placebo Comparator|Placebo|Placebo: an oral dose of one capsule once daily, for a total duration of 52 weeks.
3355591|NCT02305953||Frozen serum|The cohort consists of original subjects from the Inno-6025 Trial who previously consented to measuring protein in the blood involved in skin inflammation.
3355592|NCT02305966|Active Comparator|pressfit humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is -pressfit humerus & non-lateralized glenoid.
3355593|NCT02305966|Active Comparator|pressfit humerus & lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented). Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is - pressfit humerus & lateralized glenoid.
3355594|NCT02305966|Active Comparator|cemented humerus & non-lateralized glenoid|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component. Therefore, 4 randomization groups will be created and one of them is cemented humerus & non-lateralized glenoid
3355595|NCT02305966|Active Comparator|cemented humerus & lateralized glenoid.|All patients will receive a Delta XTEND reverse shoulder implant (DePuy Synthes, Warsaw, IN). At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant, (n = 6 surrounding the glenoid and n = 6 surrounding the proximal humerus). Half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a cemented humeral component, and half will be randomized to receive a press-fit (uncemented).Similarly, half of the patients (n = 20) will be randomized by an opaque envelope intra-operatively to receive a lateralized glenoid component, and half will be randomized to receive a non-lateralized glenoid component.Therefore, 4 randomization groups will be created and one of them is cemented humerus & lateralized glenoid.
3355596|NCT02305979||Treatment with Loratadine|Treatment with Loratadine
3245441|NCT01337778|Experimental|Standard Care plus Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the daughter-in-law's (DILs) pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with mothers-in-law (MILs), and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce gender-based violence (GBV) and protect and promote their family's health.
3245442|NCT01337791|No Intervention|control|
3355597|NCT02305992|Experimental|Axillary Block with 0.5% Ropivicaine|Patients will receive an axillary block using an ultrasound-guided technique. After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the cephalic aspect of the transducer toward the posterior aspect of the axillary artery. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 20 mL solution of 0.5% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
3355598|NCT02305992|Experimental|Stellate Ganglion Block with 0.2% Ropivicaine|Patients will receive stellate ganglion block and local anesthetic using an ultrasound-guided technique.After skin infiltration with 1 mL of 2% lidocaine, a 22-gauge insulated needle is advanced in-plane from the lateral position toward the anterior aspect of longus colli muscle just posterior to the internal jugular vein. Prior to injection, the syringe is aspirated to confirm extra-vascular placement of the needle. 10 mL of 0.2% ropivicaine is then injected slowly, with syringe aspiration after every 5 mL injection to confirm extravascular placement.
3355599|NCT02305992|Active Comparator|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
3355600|NCT02306005||Type 1 diabetic patients|Newly diagnosed diabetes type 1 admitted to the Department of Internal Medicine and Diabetology. Measurement of lipid profile and lipoproteins before and after administration of insulin. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years.
3355601|NCT02306018||EV1000™/volumeView™|
3355602|NCT02306031|Placebo Comparator|placebo (ARTIFICIAL TEAR)|control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations.
3355603|NCT02306031|Active Comparator|diclofenac sodium drop|case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.. Theses drops continued up to 6 weeks with the same dose after operations.
3355604|NCT02306057||Pre BCPC|Children undergoing catheterization before Bidirectional CavoPulmonary Connection (BCPC) procedure
3355605|NCT02306057||BCPC surgery|Children undergoing surgical BCPC procedure
3355606|NCT02306057||Pre TCPC|Children undergoing catheterization before Total CavoPulmonary Connection (TCPC )procedure
3245443|NCT01337791|No Intervention|telbivudine|
3245444|NCT01337804|Experimental|Zegerid-Prilosec|Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.
3245445|NCT01337804|Experimental|Prilosec-Zegerid|Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.
3245446|NCT01337817|Experimental|Ariva Silver Wintergreen|Subjects allow study product lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3245447|NCT01337817|Active Comparator|Ariva Wintergreen|Subjects allow study comparator lozenge to dissolve in mouth, smoke a cigarette, then answer questionnaires about product taste and effect on desire to smoke.
3245448|NCT01337830|Experimental|Ariva® Silver Wintergreen|Subjects allow study product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
3245449|NCT01337830|Active Comparator|Silver Wintergreen|Subjects allow comparator product lozenge to dissolve in the mouth, smoke a cigarette, then answer questionnaires about the effect of the product on both their desire to smoke and on cigarette taste.
3245450|NCT01337843|Active Comparator|Control Group|Control Group participants will receive a well-regarded book for back pain patients.
3245451|NCT01337843|Experimental|Wellnes Workbook|Participants will receive the Wellness Workbook, a web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase their physical activity and manage stress with relaxation and mindfulness training
3355607|NCT02306057||TCPC surgery|Children undergoing surgical TCPC procedure
3245452|NCT01337856|Other|WHO alcohol handrub protocol|handrubbing with alcohol using the standard 7-step technique (WHO alcohol handrub protocol)
3245453|NCT01337856|Other|CDC alcohol handrub protocol|Handrubbing with alcohol covering all hand surfaces in no particular order (CDC alcohol handrub protocol)
3245454|NCT01337856|Other|Chlorhexidine handwashing|chlorhexidine handwashing using the standard 7-step technique (WHO handwashing protocol)
3245455|NCT01337869|Active Comparator|Bascom Cleft Lift Technique|
3245456|NCT01337869|Active Comparator|Limberg Flap Technique|
3245457|NCT01337882|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
3355608|NCT02306070|Experimental|Metformin + lifestyle modification|Metformin + lifestyle modification pre, during and post HCV antiviral therapy
3355609|NCT02306070|Placebo Comparator|No Metformin + Lifestyle modification|No metformin + lifestyle modification pre, during and post HCV antiviral therapy.
3355610|NCT02306083|Placebo Comparator|Administration of the Placebo|Placebo three times a day.
3355611|NCT02306083|Placebo Comparator|Administration of the glucosamine sulfate|glucosamine sulfate 1500 mg three times a day
3355612|NCT02306109|Active Comparator|Standard motor rehabilitation treatment|
3355613|NCT02306109|Experimental|Intensive motor rehabilitation treatment|
3355614|NCT02306122|Experimental|Default patient default doctor|Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
3355615|NCT02306122|Experimental|Information patient default doctor|Patient nonadherence information sent to physician
3355616|NCT02306122|No Intervention|Control patient default doctor|Control - no intervention
3355617|NCT02306122|Experimental|Choice patient choice doctor|Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
3355618|NCT02306122|Experimental|Information patient choice doctor|Patient nonadherence information sent to physician
3355619|NCT02306122|No Intervention|Control patient choice doctor|Control - no intervention
3355620|NCT02306122|Experimental|Information patient information doctor|Patient nonadherence information sent to physician
3355621|NCT02306122|No Intervention|Control patient information doctor|Control - no intervention
3355622|NCT02306122|Experimental|Default patient default doctor status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient unless physician cancels call
3355623|NCT02306122|Experimental|Information patient default doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3355624|NCT02306122|Experimental|Choice patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician; Pharmacist calls patient if physician requests call
3355625|NCT02306122|Experimental|Information patient choice doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3355626|NCT02306122|Experimental|Information patient info doc status|Patient HMO/PPO status revealed to physician; Patient nonadherence information sent to physician
3355627|NCT02306148|Placebo Comparator|Control Group|Group will practice 15 seconds isometric lower limb stretching protocol and must continue practicing running as usual.
3355628|NCT02306148|Experimental|Foot and ankle strengthening|Group will be trained during 2 months by a physiotherapist for foot and ankle strengthening and must continue to exercise at home with a training software supervision. Must continue practicing running as usual.
3355629|NCT02306174|Experimental|Cognitive Rehabilitation and Exposure-based Class for Compulsi|"Cognitive training is to improve thinking by learning new skills and strategies. The class begins with cognitive training to increase ability to carry out the skills learned later in treatment.~Exposure therapy for discarding and acquiring helps to improve ability to make choices about possessions and learn to tolerate anxiety. Participants will face making difficult choices about items and potentially letting them go. Through repeated exposure to decisions about discarding and acquiring, distress about letting go or making choices about items will decrease over time."
3355630|NCT02306187|Experimental|Non-Alfacaocidol|Ahead of Eldecalcitol treatment, this group has not taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
3355631|NCT02306187|Experimental|Alfacalcidol|Ahead of Eldecalcitol treatment, this group has taken Alfacaocidol before. Eldecalcitol: the commercial name is Edirol We prescribe Edirol 0.5 or 0.75ug per day into each patient.
3355632|NCT02306200||Aortic Disease|Patients with a diagnosis of any form of Aortic Disease
3355633|NCT02306200||Controls|Patients without a diagnosis of Aortic Disease
3355634|NCT02306213|Experimental|Hydroxyethylstarch 6% 130/0.4|These patients have received Hydroxyethylstarch 6% 130/0.4 intraoperatively or postoperatively in addition to standard volume therapy.
3355635|NCT02306213|Active Comparator|No Hydroxyethylstarch 6% 130/0.4|These patients have not received Hydroxyethylstarch 6% 130/0.4 at any time point. Only standard volume therapy has been used.
3355636|NCT02306239|Active Comparator|norepinephrine|patients received norepinephrine
3355637|NCT02306239|Experimental|terlipressin|patients received terlipressin
3355638|NCT02306252|Experimental|CARE Intervention|This group will be contacted to make an appointment for outpatient Occupational and Physical therapy. The therapist will determine the type, frequency and length of treatment. Follow up phone calls will be made to ensure appointments are made, kept and rescheduled as needed.
3355639|NCT02306252|No Intervention|CARE Control|Patients randomized to this arm will receive contact information and a brochure outlining the services available within the supportive care program. The study coordinator will provide the information based on their results and assist the patient with contacting the program if desired.
3355640|NCT02306278|Placebo Comparator|vitamin capsules|vitamin capsules orally at the night before operation and 2 hours before surgery,respectively
3355641|NCT02306278|Experimental|gabapentin|gabapentin 600mg orally at the night before operation and 2 hours before surgery,respectively
3355642|NCT02306291|Experimental|Arm A (Phase I)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
3245458|NCT01337882|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (approximate PM10 concentration 300 mcg/m3) during intermittent exercise
3245459|NCT01337895|Active Comparator|Lifestyle counselling|These participants will be assigned to a 500 kcal/day energy-restricted diet that is low in dairy products (no more than 1 serving per day).
3245460|NCT01337895|Experimental|High dairy|These participants will be assigned a 500 kcal/day energy-restricted diet that is high in dairy (4 or more servings per day).
3245461|NCT01337921|Experimental|Multi-strain Synbiotic|Multi-strain probiotic with prebiotics
3245462|NCT01337921|Active Comparator|Multi-strain Probiotic|Multi-strain Probiotic without prebiotics.
3245463|NCT01337934|Placebo Comparator|Lactated Ringer|Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
3245464|NCT01337934|Active Comparator|Albumin|Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
3245465|NCT01337947||exercise training|12 weeks of exercise treatment/program for DM1 subjects
3245466|NCT01337999||HE-4 levels, healthy premenopausal women|
3245467|NCT01338064||exposed workers|At least six months of occupational exposure to Caesar stone
3245468|NCT01338077|Experimental|Sodium alginate|Oral suspension, 50 mg/ml
3245469|NCT01338077|Active Comparator|Omeprazole|20 mg/cap
3245470|NCT01338090||89Zr-bevacizumab|
3245471|NCT01338103|Experimental|Rituximab|
3245472|NCT01338116|Experimental|Management by TREAT/PCR|The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly.
3245473|NCT01338116|No Intervention|Usual management|Patients will be managed by physicians as in regular clinical practice.
3355643|NCT02306291|Experimental|Arm B (Phase II Arm A)|GMI-1271 in combination with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory subjects 18 years and older
3355644|NCT02306291|Experimental|Arm C (Phase II Arm B)|GMI-1271 in combination with cytarabine and idarubicin (7+3 regimen) in newly diagnosed subjects 60 years and older
3355645|NCT02306304|Other|Israeli Arab men|Single arm study. The arm includes all enrolled patients screened by duplex ultra sound for abdominal aortic aneurysms.
3245474|NCT01338129|Experimental|vitamin c|administration of vitamin c for 45 days following ankle fracture operation
3245475|NCT01338129|Placebo Comparator|placebo|placebo pills
3245476|NCT01338142|Placebo Comparator|CCC|Crystalline calcium carbonate (CCC)
3245477|NCT01338142|Experimental|ACC|Amorphous calcium carbonate (ACC)
3355646|NCT02306317|Active Comparator|Control by nursing.|FiO2 adjusted manually by nursing staff. Intervention: Other. Standard procedure
3355647|NCT02306317|Experimental|Control by parents.|FiO2 adjusted manually by parents. Intervention. Other. Experimental procedure
3355648|NCT02306330|Experimental|Malditof|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in Malditof arm will be performed by Malditof instrument to identify the pathogens. It takes 20 minutes for Malditof to identify the pathogens. Then patients will be treated based on these results.
3355649|NCT02306330|Active Comparator|Routine clinical microbiology|Specimens of patients (diagnostic aspirates from normally sterile sites: cerebrospinal fluid (CSF), deep abscesses, joint fluid, peritoneal fluid, and pleural fluid, deep tissue biopsies) in routine clinical microbiology arm will be conducted by the routine clinical microbiologies and followed the treatment process of the hospital.
3245478|NCT01338285||1|Workers exposed to high levels of formaldehyde and unexposed workers in Guangdong Province, China.
3245479|NCT01338311|Active Comparator|salbutamol|
3245480|NCT01338311|Placebo Comparator|placebo|200mcg twice daily for a total of 7 doses
3245481|NCT01338337|No Intervention|Support treatment|Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed.
3245482|NCT01338337|Experimental|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
3245483|NCT01338350|Experimental|1|
3245484|NCT01338350|Placebo Comparator|2|
3245485|NCT01338363||All first time users of esomeprazole|
3245486|NCT01338363||All first time users of other PPIs|
3245487|NCT01338363||All first time users of H2-receptor antagonists|
3245488|NCT01338376|Experimental|Structured Education Group|Subjects received structured diabetes education
3245489|NCT01338376|Active Comparator|Conventional Care Group:|Subjects received conventional diabetes education
3245490|NCT01338389|Experimental|CITICOLINE|Daily oral administration of 800 mg citicoline
3245491|NCT01338389|Placebo Comparator|Placebo|Daily oral administration of placebo
3245492|NCT01338402|Other|AIR OPTIX® AQUA|Lotrafilcon B contact lenses worn in both eyes on a daily wear basis for one week in Phase 1.
3245493|NCT01338402|Experimental|AIR OPTIX® COLORS|Lotrafilcon B contact lens with color randomly assigned to one eye, with phemfilcon A contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
3355650|NCT02306343|Experimental|Test (with the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, the InsuPad device was placed on the abdomen of the subject. The InsuPad device was activated and insulin bolus (0.2 units/kg body weight) was injected right before study start. The injection was given to the subject's abdomen through the injection window of the InsuPad device. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months with the device (test). Subjects were asked to perform at least 3 blood glucose measurements during the day."
3355651|NCT02306343|No Intervention|Control (without the InsuPad device)|"In the Meal Tolerance Test protocol - After overnight fast followed by a pre-study stabilization period, insulin bolus (0.2 units/kg body weight) was injected to the abdomen right before study start. Immediately afterwards the subject was asked to drink a standardized liquid meal within 10 minutes. Blood glucose measurements were taken from a peripheral venous line at a pre-determined time points. Total follow up time was 5 hours post meal.~In the daily life setting - Up to 12 months without the device (control). Subjects were asked to perform at least 3 blood glucose measurements during the day."
3355652|NCT02306356|Experimental|Interventional|Behavioral: Internet-delivered Cognitive Behavior Therapy
3355653|NCT02306369|No Intervention|Treatment as usual|A wait-list control.
3355654|NCT02306369|Experimental|Internetdelivered exposure-based CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
3355655|NCT02306382|Experimental|ultrasonography, abscess|The experimental group will be treated after examination with 3D ultrasonography. Follow up after two months and one year.
3355656|NCT02306382|Other|Control group with clincial inscision|The control group will have drainage of their perianal abscess in the OR without ultrasound. Follow-up after two months and one year.
3355657|NCT02306395|Experimental|Endometrial local injury|Endometrial local injury is carried in the first 3-5 days after menstrual period at the same time of hysteroscopy.
3355658|NCT02306395|No Intervention|The blank group|Any processing does not carry on the endometrium in the first 3-5 days after menstrual period except hysteroscopy.
3355659|NCT02306421|Active Comparator|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
3355660|NCT02306421|Active Comparator|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
3355661|NCT02306421|Active Comparator|R P H|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
3355662|NCT02306421|Active Comparator|P P H|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids-PPH.In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
3355663|NCT02306421|Active Comparator|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
3355664|NCT02306434|Active Comparator|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
3355665|NCT02306434|Other|Standard care-Counselling|Counselling for childbirth fear is given by the antenatal care midwife and by specially trained midwives working in collaboration with obstetricians at approximately 3-5 face to face counselling sessions. Often a visit to the delivery unit is included in the program and a care plan for the coming birth.
3245494|NCT01338402|Active Comparator|FRESHLOOK® COLORBLENDS|Phemfilcon A contact lens with color randomly assigned to one eye, with lotrafilcon B contact lens with color in the fellow eye for contralateral wear. Both products worn on a daily wear basis for 4 weeks in Phase 2. A replacement phemfilcon A lens was dispensed at the Week 2 visit.
3245495|NCT01338428|Active Comparator|Brochure|
3355666|NCT02306447|Experimental|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
3355667|NCT02306460||left atrial catheter ablation|
3355668|NCT02306460||left atrial appendix closure|
3355669|NCT02306460||paroxysmal atrial fibrillation control group|
3355670|NCT02306460||persistent atrial fibrillation control group|
3355671|NCT02306473|Experimental|Asthma|Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.
3355672|NCT02306473|Experimental|Controls|Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.
3355673|NCT02306486|Placebo Comparator|z250 resin composite|(n=31) Treated with distilled water (placebo) and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
3355674|NCT02306486|Active Comparator|z250 resin composite + oxalic acid|(n=31) treated with 0.5% oxalic acid (Desenssiv, SSWhite)(intervention)// and restored with a methacrylate resin-based-composite (Z250, 3M ESPE, shade: A3)
3355675|NCT02306486|Placebo Comparator|p 90 resin composite|(n=31) Treated with distilled water (placebo) and restored with a silorane resin-based-composite.
3355676|NCT02306486|Active Comparator|p 90 resin composite + oxalic acid|(n=31) treated with 0,5% oxalic acid (Desenssiv SSWhite)(Intervention)/ and restored with a silorane resin-based-composite (Filtek Silorane p90, £M ESPE, shade:)
3355677|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH VARICOCELE|ICSI cases using cryopreserved testicular sperm from infertile azoospermic men, with proven diagnosis of varicocele (clinical & sonographic), which will be used for ICSI in an ART program
3355678|NCT02306499|Experimental|ICSI WITH CRYOPRESERVED SPERM FROM NOA WITH NO VARICOCELE|ICSI cases using cryopreserved testicular sperms from infertile azoospermic men due to etiologies other than varicocele
3355679|NCT02306512|Active Comparator|Standard vs. IF MART-1|"Samples removed with MMS within the first 3 mm margin from the tumor will be the first section. They will be processed as a conventional H&E frozen section and section stained with IHC MART-1. Samples removed with MMS within 3-6 mm from tumor margin will be the second section. They will be processed with fluorescent MART-1 antibodies. Based on the pre-defined characteristics MMS surgeon will evaluate each MART-1 immunofluorescent section as no evident melanoma or possible melanoma or present melanoma. Dermatopathologist will secondarily review each section scoring them in the same manner. If standard H&E, IHC, or immunofluorescence is recorded as present melanoma or possible melanoma a third section from 6-9mm will have the same procedure described before."
3355680|NCT02306512|Active Comparator|IF MART-1 versus IF cocktail|In the second arm of the study, assuming that immunofluorescence with MART-1 proves to be superior or at least equivocal to regular MART-1 IHC, the same method will be applied, but the control sections will be stained with fluorescent MART-1 antibodies and compared to a section stained with a cocktail of fluorescent melanocytic antibodies.
3355681|NCT02306525||Ptt. with Femoracetabular Impingement|Enrollment anticipated: 60 Arthroscopic surgery of the hip joint
3355682|NCT02306525||Healthy volunteers|Enrollment anticipated: 30
3245496|NCT01338428|Experimental|Enhanced AAA Sexual Assault Education|
3245497|NCT01338441|Experimental|Erythromycin|
3355683|NCT02306551||Psychotic Disorder|Biological and psycho-social risk and resilience factors
3355684|NCT02306551||Bipolar Disorder|Biological and psycho-social risk and resilience factors
3355685|NCT02306551||Depressive Disorder|Biological and psycho-social risk and resilience factors
3245498|NCT01338441|Placebo Comparator|Placebo|
3245499|NCT01338454|Active Comparator|tranexamic acid|TA administered intravenously over a 5 min period at delivery of the anterior shoulder
3245500|NCT01338454|No Intervention|saline|10 mL of saline was administered intravenously over a 5 min period at delivery of the anterior shoulder
3245501|NCT01338467|Experimental|EYEOP Treatment|Open label, all subject treated by the EYEOP device
3245502|NCT01338480|Experimental|video|Participants in the intervention group watched an educational video illustrating informed consent information
3355686|NCT02306551||Non-psychiatric Control|Biological and psycho-social risk and resilience factors
3245503|NCT01338480|No Intervention|control|Participants in the control group read an informed consent document.
3245504|NCT01338519||PCOS and hirsutism|
3245505|NCT01338532|Active Comparator|Supervised exercise + patient education|
3245506|NCT01338532|Active Comparator|Patient education|
3245507|NCT01338545||Cohort|
3245508|NCT01338558|Experimental|K-RAS mutated|
3245509|NCT01338558|Experimental|K-RAS native A|
3245510|NCT01338558|Active Comparator|K-RAS native B|
3245511|NCT01338571||Healthly children|Children will be given yogurt twice a day for four weeks. The dose for an adult is 8 ounces of yogurt twice a day. The dose will be scaled to the children based upon surface area dosing charts, but will not exceed a resistant starch load of 1 gram per year of age plus 10 grams10.
3245512|NCT01338584|Experimental|Pelvic floor muscle training, post prostatectomy|Pelvic floor muscle training will be taught on the day of admission
3245513|NCT01338597|Experimental|standard|3 trocars are needed. two in the circumareolar region and one in the parasternal region. the dissection area begins from the trocar site and extends to the neck.
3355687|NCT02306564|Experimental|Group A|Group A will include patients at risk of OHSS receiving Cabergoline 0.5mg daily for 8 days (Dostinex®, Pfizer Australia Pty Ltd ) from the day of oocyte pick up for prevention of hyperstimulation
3355688|NCT02306564|No Intervention|Group B|Group B will include patients AT RISK of ovarian hyperstimulation syndrome (OHSS) not receiving Cabergoline.
3245514|NCT01338597|Experimental|limited dissection|the dissection is reduced by creating a long tunnel from the trocar site and the dissection area confined in the upper chest wall and in the neck.
3245515|NCT01338623|Experimental|Tansulosine|
3355689|NCT02306564|No Intervention|Group C|Group C will serve as a control group and will include age & BMI matched patients NOT AT RISK of OHSS, and not receiving cabergoline.
3355690|NCT02306577||Vancouver|HIV infected people who are current of recent illicit drug users and receive Stribild for their HIV treatment at Vancouver Infectious Diseases Centre and Regina General Hospital.
3245516|NCT01338662||Group A-1|"study enroll number 3n+1 (N=0,1,2...)~initial treatment- amantadine~add levodopa when the patient become to need further treatment."
3355691|NCT02306590|Experimental|Study Intervention|High caloric fatty diet for drinking (100% lipids, 4.5 kcal/ml) 405 kcal/90 ml/day in addition to daily food intake and standard of care; corresponding to an additional intake of 45 g fat per day
3355692|NCT02306590|Placebo Comparator|Placebo|Placebo drinking solution 8 kcal/90ml/day in addition to daily food intake and standard of care
3245517|NCT01338662||Group A-2|"study enroll number 3n+2 (N=0,1,2...)~initial treatment: amantadine~add dopamine agonist when the patient become to need further treatment."
3245518|NCT01338662||Group B|"study enroll number 3n+3 (N=0,1,2...)~initial treatment: dopamine agonist~add levodopa when the patient become to need further treatment. but cannot use amantadine"
3245519|NCT01338675|Experimental|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
3245520|NCT01338688||Td ,Td and TIG|
3245521|NCT01338701|Experimental|Auricular (Ear) Acupuncture|Auricular (Ear) Acupuncture is administered in a step-wise, algorithmic acupuncture approach in which needles are inserted at specific auricular landmarks. The sequence and location of needled points is determined by the participant's severity of headache pain at presentation and response to needling. Between six and nine points are needled in each treatment session depending on the individual's response (i.e., a decrease or persistence of headache pain). In-dwelling ASP needles are inserted at the end of each session. Participants are instructed to remove the needles after 3 days, or sooner if pain or redness developed at a needle site. Ten 45-minute acupuncture treatment sessions are administered over 6 weeks.
3355693|NCT02306603||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Duodenal and Ampullary Lesions will be included in this cohort.
3355694|NCT02306629|Experimental|Epratuzumab dose 1 sc|This group of Caucasian and Japanese subjects will receive one single dose 1 of epratuzumab subcutaneous
3355695|NCT02306629|Experimental|Epratuzumab dose 2 sc|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab subcutaneous
3355696|NCT02306629|Experimental|Epratuzumab dose 3 sc|This group of Caucasian subjects will receive one single dose 3 of epratuzumab subcutaneous
3355697|NCT02306629|Active Comparator|Epratuzumab dose 2 iv|This group of Caucasian and Japanese subjects will receive one single dose 2 of epratuzumab as an intra venous infusion
3355698|NCT02306642||Premature Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have experienced acute kidney injury based on the modified KDIGO guidelines for acute kidney injury.
3355699|NCT02306642||Premature No Acute Kidney Injury in NICU|This group of babies born less than 1500 grams will have not experienced acute kidney injury in the NICU.
3355700|NCT02306642||Term No Acute Kidney Injury|This group of babies born at term will have not experienced any acute kidney injury.
3355701|NCT02306668||Ocular surface discomfort|There are no interventions with this observational study
3355702|NCT02306681||SAQ-Self-Assessment Questionnaire|
3355703|NCT02306707||Endoscopic Mucosal Resection|Patients who are referred for Endoscopic Mucosal Resection of Stomach Lesions will be included in this cohort.
3355704|NCT02306733|Active Comparator|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv)
3355705|NCT02306733|Active Comparator|Oxytocin|100 women with atonic PPH will receive oxytocin 10 IU (Syntocinon® Novartis, Switzerland) slowly intravenous.
3355706|NCT02306746|Experimental|TARGET protocol EN 1.5 kcal/mL|Enteral (EN) feed 1.5 kcal/mL. The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
3355707|NCT02306746|Active Comparator|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL The goal rate for administration of TARGET protocol EN is 1ml/kg/hr. To calculate the goal rate, weight is based on ideal body weight.
3355708|NCT02306772|Experimental|Formulation A|TP05 Coating A
3355709|NCT02306772|Experimental|Formulation B|TP05 Coating B
3355710|NCT02306785|Experimental|Formulation D|TP05 Coating D
3355711|NCT02306785|Experimental|Formulation E|TP05 Coating E
3355712|NCT02306785|Experimental|Formulation H|TP05 Coating H
3355713|NCT02306798|Experimental|Formulation D|TP05
3355714|NCT02306811|Experimental|Vatelizumab Dose 1|Vatelizumab dose 1 every 4 weeks (Q4W) for 96 weeks
3355715|NCT02306811|Experimental|Vatelizumab Dose 2|Vatelizumab dose 2 every 4 weeks (Q4W) for 96 weeks
3355716|NCT02306811|Experimental|Vatelizumab Dose 3|Vatelizumab dose 3 every 4 weeks (Q4W) for 96 weeks
3355717|NCT02306811|Experimental|Vatelizumab Dose 4|Vatelizumab dose 4 every 4 weeks (Q4W) for 96 weeks
3355718|NCT02306837|Experimental|Consolidation chemo|Patients recieved 3 cycles of consolidation chemotherapy post-auto-HSCT: mini-Bu-Cy-E regimen
3355719|NCT02306863|Experimental|whole-body vibration|40 Hz Whole-body vibration applied via physioaccoustic method for 12 weeks, 3 times a week
3355720|NCT02306863|Sham Comparator|sham treatment|simulated whole-body vibration applied 3 times a week for 12 weeks
3355721|NCT02306876|Experimental|PF-06412562 3mg|PF-06412562 3mg BID
3355722|NCT02306876|Placebo Comparator|Placebo|Placebo BID
3355723|NCT02306876|Experimental|PF-06412562 15mg|PF-06412562 15mg BID
3355724|NCT02306889|Experimental|Test|Fenofibrate Capsules, USP 130 mg
3355725|NCT02306889|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
3355726|NCT02306902|Experimental|Test|Fenofibrate Capsules, USP 130 mg
3355727|NCT02306902|Active Comparator|Reference|ANTARA® (fenofibrate) Capsules 130 mg
3245522|NCT01338701|Experimental|Traditional Chinese Acupuncture (TCA)|A semi-standardized form of Traditional Chinese Acupuncture (TCA) is administered, incorporating the insertion of up to 22 acupuncture needles associated with each individual participant's: (1) primary headache pattern (up to three pairs of points); (2) secondary headache pattern (up to 2 pairs of points); (3) Ah-Shi or tender points (up to 4 points); (4) constitutional points (source points on two meridians); and, (5) up to 2 pairs of additional points from a selected list. Point selection was reassessed every two weeks per TCM diagnostic and treatment principles. While the majority of points were located on the limbs, points also included local points of tenderness to the head, as well as the front and back of the torso. Ten 60-minute TCA sessions are administered over 6 weeks.
3355728|NCT02306941|Experimental|Internet-delivered CBT|10 sessions of ICBT during 10 weeks for the adolescents. 5 session of parent training during 10 weeks for parents. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
3355729|NCT02306954|Active Comparator|High Dose IL-2|"Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for 14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.~Patients assigned to the IL-2 arm who have disease progression after the first two IL-2 cycles have the option to receive SBRT followed by 2 additional cycles of IL-2."
3355730|NCT02306954|Experimental|High Dose IL-2 and SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before IL-2 starts (the following Monday). Patients will receive IL-2 at 600,000 international units per kg IVB every 8 hours for14 planned doses with an additional cycle 14 days after the first. Responding patients with regressing disease are eligible for up to 6 IL-2 cycles.
3355731|NCT02306967|Active Comparator|Standard Resection|Oral resection will be guided by usual practice. This involves identifying the tumour with white light and then marking surgical margins and resection the primary cancer.
3355732|NCT02306967|Experimental|FV Guided Resection|The oral resection will be guided by fluorescent visualization (FV).
3355733|NCT02306980|Experimental|Colostrum|Colostrum administration
3355734|NCT02306980|No Intervention|Control|Routine care
3355735|NCT02306993||Healthy volunteers without SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years without sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
3355736|NCT02306993||Healthy volunteers with SCT|Includes Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell trait. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell trait affects bone.
3245523|NCT01338701|Other|Usual Care|All study participants continue to receive routine usual care for their TBI, headaches and associated symptoms as determined by their clinical team.
3355737|NCT02306993||Volunteers with SCD|Healthy African American female volunteer between the ages of 18 and 45 years with sickle cell disease. Their blood and bone density x-ray will help researchers gain a better understanding of what might be different about the way having sickle cell disease affects bone.
3355738|NCT02307006|Experimental|Ceftaroline|Experimental comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
3355739|NCT02307006|Active Comparator|Cefazolin / Vancomycin|Standard of care comparator for surgical peri-operative prophylaxis for procedures at increased risk if MRSA infection
3245524|NCT01338714|Experimental|A foumula|Compound Herbal Formula (RHD-1)
3245525|NCT01338714|Placebo Comparator|B formula|dilute Compound Herbal Formula
3355740|NCT02307019|Experimental|Program on specific prevention of health|The caregivers will be randomly assigned to an experimental group, to receive the program on specific prevention of health. The workshop will be performed twice a month, two hours a day, during a 4-week period.
3355741|NCT02307019|Active Comparator|Program on general prevention of health|Control group will receive an intervention by mean of a general health program to manage the common situations when a caregiver is caring for a patient with dependency. The workshop will be performed two a month, two hours a day, during a 4-week period.
3355742|NCT02307045|Active Comparator|varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
3245526|NCT01338727|Experimental|Breastfeeding Peer Counseling|
3355743|NCT02307045|Active Comparator|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
3355744|NCT02307058|Experimental|LEAD RT Group|Participants in this group will receive the Lattice Extreme Ablative Dose (LEAD) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 8 weeks.
3355745|NCT02307058|Experimental|HEIGHT RT Group|Participants in this group will receive the Hypofractionated Extended Image-Guided Highly Targeted (HEIGHT) radiotherapy. Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over approximately 7 and a half weeks.
3355746|NCT02307071|Experimental|Cefaly Kit Arnold|Occipital transcranial stimulation is implemented in occipital region at 16 mA of intensity, for 20 minutes, everyday for 3 months, in 20 chronic migraine patients.
3245527|NCT01338727|No Intervention|Standard Care|
3245528|NCT01338740||Switch from Adalimumab to Infliximab|Moderately to severely active Crohn's disease patients with primary non-response or loss of response to Adalimumab, will switch to Infliximab.
3245529|NCT01338766|Experimental|Surgery|Decompression using the iO-Flex® system
3245530|NCT01338779||Group 1 - kidney tolerant|Renal allograft recipients showing functional tolerance (normal and stable renal function) after discontinuation of immunosuppressive medications for at least 1 year (or based on the investigator's discretion).
3245531|NCT01338779||Group 2 - acceptor|Enrollment for group 2 was closed. Renal transplant recipients with functioning allografts (not on dialysis) who had not received immunosuppressive medications for at least 1 year (or at investigator's discretion) but who had moderately impaired or gradually deteriorating renal function, defined as creatinine clearance (CrCl) < 40 mL/min and/or creatinine > 50% above baseline value, and thus did not qualify for group 1.
3245532|NCT01338779||Group 3 - kidney graft loss|Enrollment for group 3 is closed. These were renal transplant recipients who had subsequently rejected and lost function of their transplanted kidney.
3355747|NCT02307084|Experimental|Pre-operative ultrasound imaging|Subjects that are randomly allocated to this group will have ultrasound imaging assessment of the long saphenous vein in both legs. This will allow assessment of the suitability of the long saphenous vein and marking of the distribution prior to heart bypass surgery to allow targeted harvesting of a bypass conduit.
3355748|NCT02307084|No Intervention|Current protocol|This group will not undergo pre-operative ultrasound imaging of the long saphenous vein in accordance with current Trust protocols.
3355749|NCT02307097|Experimental|CBB|
3355750|NCT02307097|Experimental|CBT|
3245533|NCT01338779||Group 4 - kidney monotherapy|Renal transplant recipients showing stable and normal renal function after receiving only prednisone 10 mg/day for at least 1 year (or based on the investigator's discretion).
3245534|NCT01338779||Group 5 - kidney standard immunotherapy|Enrollment for group 5 is closed. Stable renal transplant recipients currently on standard immunosuppression.
3245535|NCT01338779||Group 6 - kidney chronic rejector|Enrollment for group 6 is closed. Chronic allograft nephropathy group.
3245536|NCT01338779||Group 7 - kidney identical twin|Enrollment for group 7 is closed.
3245537|NCT01338779||Group 8 - living kidney donors|Corresponding to recipients in group 1 or 4.
3245538|NCT01338779||Group 9 - healthy controls|Enrollment for group 9 is closed.
3245539|NCT01338779||Group 10 - liver tolerant|Enrollment for group 10 is closed. Liver allograft recipients with functional tolerance (stable and normal liver function) after cessation of immunosuppressive medications for at least three years (or at investigator's discretion).
3245540|NCT01338779||Group 11 - liver standard immunotherapy|Enrollment for group 11 is closed. Subjects with a liver transplant who never had an attempt made to discontinue gradually their immunosuppression and who are currently taking standard immunosuppressive medications and have stable and normal liver allograft function after at least 1 year of receiving these drugs.
3355751|NCT02307097|Active Comparator|WAIT|
3355752|NCT02307110|Other|1 arm study|cross-sectional observation
3355753|NCT02307149|Experimental|CAVATAK and ipilimumab|CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg
3355754|NCT02307162|Placebo Comparator|Dummy solution|Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C)
3355755|NCT02307162|Experimental|RPL554 suspension|"Nebulised suspension to be administered as either a single dose (Part A) or 11 doses over 6 days (Parts B anc C).~Starting dose in Part A to be 1.5mg/mL with planned up to 2 fold increments. Doses in Part B will be selected from Part A. Doses in Part C to be selected from Part B"
3245541|NCT01338805|Experimental|BGG492|hard gelatin capsule for oral administration at 50 mg TID, 100 mg TID or 150 mg TID
3245542|NCT01338831|Experimental|Breast & Prostate Cancer Group|Dose Escalation
3355756|NCT02307175||Cyclotec|The first 10 consecutively enrolled patients will have thyroid and whole body scan with CycloTec
3355757|NCT02307175||generator produced Tc99m-pertechnetate|20 subsequent case-matched controls will have thyroid and whole body scan with conventional Tc99m-pertechnetate
3355758|NCT02307201|Experimental|Postpartum Magnesium sulfate|The patient will receive magnesium sulfate as usual for 24 hours postpartum
3355759|NCT02307201|No Intervention|No postpartum treatment|The patient did not receive postpartum magnesium sulfate or other anticonvulsant during 24 hours postpartum
3355760|NCT02307214|Other|Coronary X syndrome|BaroReflex Sensitivity, endothelial function measurement
3355761|NCT02307214|Other|Tako-tsubo cardiomyopathy|BaroReflex Sensitivity, endothelial function measurement
3355762|NCT02307214|Other|Healty Volunteers|BaroReflex Sensitivity, endothelial function measurement
3245543|NCT01338831|Experimental|Breast Cancer Group|Dose Expansion
3355763|NCT02307227|Experimental|Locally advanced HER2+ breast cancer pts|"HER2 positive (defined as 3+ at Herceptest or FISH/CISH positive):~treatment with Trastuzumab 4mg/kg first time, then 2 mg/kg weekly with concomitant paclitaxel 80 mg/mq weekly (one cycle corresponding to 4 weeks) for 12 weeks (3 cycles). Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 6 cycles), then surgical excision"
3245544|NCT01338831|Experimental|Prostate Cancer Group|Dose Expansion
3245545|NCT01338831|Experimental|Uterine Leiomyoma Group|Dose Expansion
3245546|NCT01338844|Experimental|D-Chiro-inositol|Patients will receive 1.2g/day of D-chiro-inositol
3245547|NCT01338844|Active Comparator|Myo-inositol|Patients will receive 4g/day of myo-inositol
3355764|NCT02307227|Experimental|Locally advanced HER2- breast cancer pts|"HER2 negative:~treatment with Epirubicin 90 mg/mq and docetaxel 75 mg/mq every 3 weeks for 4 cycles. Clinical and instrumental evaluation, in responding patients continue for additional 12 weeks (total 8 cycles), then surgical excision."
3355765|NCT02307240|Experimental|CUDC-907 - five days on/two days off|60 mg/day CUDC-907, oral administration, five days on/two days off until disease progression or other discontinuation criteria are met.
3355766|NCT02307253|Experimental|patients with solid lesions|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
3355767|NCT02307279|Experimental|Gelesis100|Gelesis100 twice daily
3355768|NCT02307279|Placebo Comparator|Placebo|Matching placebo twice daily
3355769|NCT02307305|Experimental|Duloxetin group|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)~plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)"
3245548|NCT01338883|Experimental|CVC 100 mg + Truvada|
3245549|NCT01338883|Experimental|CVC 200 mg + Truvada|
3355770|NCT02307305|Active Comparator|routine pain control group|"Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)~Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone"
3355771|NCT02307331|Other|Optivac and E1|Sirius stem used with Optivac mixed cement - Exceed Cup - E1 PE
3355772|NCT02307331|Other|Optivac and Arcom|Sirius stem used with Optivac mixed cement - Exceed Cup - Arcom PE
3355773|NCT02307331|Other|Optipac and E1|Sirius stem used with Optipac mixed cement - Exceed Cup - E1 PE
3355774|NCT02307331|Other|Optipac and Arcom|Sirius stem used with Optipac mixed cement - Exceed Cup - Arcom PE
3355775|NCT02307344|Active Comparator|Nigella Sativa Supplement|Fifty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest capsules containing 2 grams of Nigella Sativa divided into 1 grams twice a day.
3355776|NCT02307344|Active Comparator|Patients receiving a placebo tablet|Twenty patients suffering from Nonalcoholic Steatohepatitis or Liver Steatosis will ingest placebo capsules twice a day, that look like the capsules of those receiving the Nigella Sativa.
3355777|NCT02307357|Experimental|newcomball players|active newcomball women players will perform physical fitness tests
3355778|NCT02307357|Experimental|control|not physically active women will perform physical fitness tests
3355779|NCT02307383|Experimental|Lactitol and Lactobacillus|"Lactitol monohydrated 10g (Emportal®), 1 sachet dissolved in water, three times a day for 21 days.~Lactobacillus acidophilus, 1 x 109 UFC and Lactobacillus Biphidus 1 x 109 UFC, (Infloran Berna), 2 tablets by mouth, three times a day for 21 days."
3355780|NCT02307396|Experimental|Intervention|"Intervention group: guided discontinuation or dose-reduction of the current antipsychotic medication. The antipsychotic drug used before study start will be discontinued gradually under medical surveillance. The process of discontinuation depends on the physicians judgement und should be guided be the participants needs and clinical status. This approach was already used before in another study (gradual discontinuation, Wunderink et al., 2007). We assume that the dose can be reduced by approximately 1/6 of the starting dose every two weeks. If long acting antipsychotics are applied, there is no need for a gradual discontinuation due to their long half life."
3355781|NCT02307396|Active Comparator|Control|The participants receive the same antipsychotic drugs, they have received before the start of the study, without changing the dose or the application form. Study medication is, with exception of Clozapin, every oral or depot neuroleptic drug approved for the treatment of schizophrenia in Germany.
3355782|NCT02307409||Decompensated Chronic Liver Disease|Decompensated Chronic Liver Disease patients will be enrol
3355783|NCT02307409||Healthy Controls|Healthy Controls will be enrol
3245550|NCT01338883|Active Comparator|Sustiva + Truvada|
3355784|NCT02307422||Case|Diabetic patients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
3355785|NCT02307422||Control|Non-diabeticpatients undergoing coronary angiography (both sexes), who are age 18-90, and admitted in the Department of Cardiology in the University General Hospital of Ioannina and Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. Presence epicardial vessel stenosis (>50%), and multi-vessel disease will be recorded. Excluded: previous history of revascularization procedure or moderate to severe stenosis. Patient samples will be evaluated for quantitative levels of the biomarkers Lp(a) and OXPL/apoB. IL-1 Genotypes, and other SNPs associated with CAD will be assessed in this group and related to levels of Lp(a) and oxidized phospolipids. No interventions other than the post-hoc DNA testing will be performed.
3355786|NCT02307435|Experimental|implantation group|implantation group will receive MSC and HA-CaSo4
3355787|NCT02307448|Active Comparator|PRP Group|Patients will receive weekly PRP treatments
3355788|NCT02307448|Placebo Comparator|Standard of Care|Patients will receive weekly standard of care.
3355789|NCT02307461|Experimental|Part 1 Cohort 1|IPI-145 test formulation (capsule) high single dose and IPI-145 reference formulation (capsule) high single dose
3355790|NCT02307461|Experimental|Part 1 Cohort 2|IPI-145 test formulation (capsule) low single dose and IPI-145 reference formulation (capsule) low single dose
3355791|NCT02307461|Experimental|Part 2 Cohort 3|IPI-145 test formulation (capsule) high single dose administered under fasted and fed conditions
3245551|NCT01338896|Experimental|Sequence A-B|4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)
3245552|NCT01338896|Experimental|Sequence B-A|4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)
3245553|NCT01338909|Experimental|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
3245554|NCT01338909|Active Comparator|Clopidogrel|Clopidogrel 150mg/day starting from Day 1 until Day 5
3245555|NCT01338922|Experimental|Insulin pump therapy (CSII)|Continuous subcutaneous insulin infusion therapy using different devices with marketing approval and different insulins
3245556|NCT01338922|Active Comparator|Multiple daily injection therapy (MDI)|Multiple daily injection therapy using different devices with marketing approval and different insulin types
3245557|NCT01338935|Experimental|Part I|Ascending dose tolerance, PK, and estimation of ED95 for CW 002
3245558|NCT01338935|Experimental|Part II|Safety, efficacy and PK of increasing bolus doses and infusions of CW 002, and exploration of Neostigmine reversal
3245559|NCT01338935|Experimental|Part III|Intubation with CW 002 and Neostigmine reversal
3355792|NCT02307474|Experimental|Treatment (Stereotactic Radiosurgery, pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO daily for up to 60 days. Patients then continue to receive pazopanib hydrochloride PO daily and undergo stereotactic radiosurgery (SBRT) every other day over days 60-65.
3355793|NCT02307487|Experimental|Cohort A2|120 mg MMC in 90ml gel
3355794|NCT02307487|Experimental|Cohort B2|140 mg MMC in 90ml gel
3355795|NCT02307487|Experimental|Cohort C2|160 mg MMC in 90ml gel
3355796|NCT02307487|Experimental|Cohort A|120 mg MMC in 60ml gel
3355797|NCT02307487|Experimental|Cohort B|140 mg MMC in 60ml gel
3245560|NCT01338961|No Intervention|Normothermic CPB|Standard management. Patients will be kept at normothermia throughout the procedure (>36oC).
3245561|NCT01338961|Active Comparator|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC.
3245562|NCT01339026|Active Comparator|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
3245563|NCT01339026|Active Comparator|Clopidogrel|Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
3245564|NCT01339039|Experimental|Part 1|Maximum Tolerated Dose Determination of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
3245565|NCT01339039|Experimental|Part 2|Surgical Arm: Safety evaluation of Plerixafor (3 weeks on, 1 week off) and Bevacizumab (every 2 weeks)
3355798|NCT02307487|Experimental|Cohort C|160 mg MMC in 60ml gel
3355799|NCT02307500|Experimental|Regorafenib|Regorafenib 160 mg (40 mg tablets), po, every day for 3 weeks of every 4 week cycle
3355800|NCT02307539|Experimental|Supportive care (PCPI intervention)|"Patients receive a handbook titled Supporting You During Cancer Treatment with educational material on QOL issues. Patients undergo 2 education sessions on handbook material in-person or by telephone, with session 1 focusing on physical and social well-being issues and session 2 focusing on psychological and spiritual well-being issues. At the beginning of each session, patients select 3 priority topics from a list, and content is tailored to patient needs."
3355801|NCT02307565|Experimental|Midodrine|Arm 1 last 30 days. Subject will either be given midodrine or placebo to take during Arm 1.
3355802|NCT02307565|Placebo Comparator|Placebo|Arm 2 is followed by a 14 day washout period. Arm 2 last 30 days. Subject will be given a drug (placebo or midodrine) to take during Arm 2.
3355803|NCT02307591|Active Comparator|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
3355804|NCT02307591|Experimental|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
3355805|NCT02307604||Brain cancer|Patients with diagnosis of brain cancer at any stage
3355806|NCT02307617||Group 2|Adolescent participants who plan to start selective serotonin reuptake inhibitor (SSRI) treatment for their depression. Data will be collected prior to the start of the medication and again 6 weeks after the start of the medication.
3355807|NCT02307617||Medication Responders|Adolescent participants who have responded to SSRI treatment for their depression.
3245566|NCT01339039|Experimental|Part 3|Safety and tolerability of Plerixafor (daily) at MTD dose from Part 1 and Bevacizumab (every 2 weeks)
3355808|NCT02307617||Medication Non-Responders|Adolescent participants with depression that has not responded to SSRI treatment.
3355809|NCT02307617||Healthy Controls|Adolescent participants who have no current or past mental health diagnoses.
3355810|NCT02307643|Experimental|Part 1|MT-1303 Low dose+Corticosteroid
3245567|NCT01339065|Active Comparator|Ketamine|will be given low sub-anesthetic doses of Ketamine 0.5mg/kg.
3355811|NCT02307643|Experimental|Part 2-A|MT-1303 High dose+Corticosteroid
3355812|NCT02307643|Experimental|Part 2-B|MT-1303 Low dose+Corticosteroid+Immunosuppressant
3355813|NCT02307656|Other|Atazanavir and Cobicistat|"Stage 1:Taste evaluation using Active Pharmaceutical Ingredient (API)~Stage 2:Taste Optimization using API (flavours and sweeteners)~Stage 3:Prototypes of the API - containing clinical trial materials"
3245568|NCT01339065|Placebo Comparator|Placebo|will get placebo treatment
3245569|NCT01339078|Active Comparator|Plastic stenting|Patients will be randomized towards plastic stenting.
3355814|NCT02307669|Placebo Comparator|Routine inhaler adherence care|"Normal Care group This management is based on the inhaler training recommendations of the BTS/SIGN group (http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012.pdf) and medication management of the GINA management strategy.~The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by GINA management guidelines using a standardised digital script."
3355815|NCT02307669|Active Comparator|INCA feedback|"The patient's treatment goal is established and used as the focus of the conversation.~Data from the INCA device including (1) time of use, (2) handling proficiency and (3) inhalation flow rates are discussed, with three graphs as shown in the appendix and derived as discussed. These are aimed to enhance the value of the inhaler.~Data from the electronic PEF and AQLQ are correlated with digitally recorded adherence so that these can be used to account for improvements or declines in these measures.~In follow up, medication changes in response to the above (adherence, PEF, ACT and exacerbations) are made using a standardised digital script."
3355816|NCT02307695|Experimental|insulin+Saxagliptin|Patients who have diagnosed type 1 diabetes are assigned to receive Saxagliptin tablets 5 mg and insulin for 24-week.
3355817|NCT02307695|Active Comparator|insulin|Patients who have diagnosed type 1 diabetes only use insulin.
3355818|NCT02307708|Experimental|8° incline shoe|"The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
3355819|NCT02307708|Active Comparator|kinesitherapy|The patient performs its home therapy and consults his physiotherapist once a week according to the protocol Stanish
3355820|NCT02307721|Experimental|intranasal naloxone|8 mg/ml naloxone 0,1 mL IN as one puff in one nostril in supine position
3355821|NCT02307721|Active Comparator|Intramuscular naloxone|0,4 mg/ml Naloxone B Braun 2 ML in deltoid muscle
3355822|NCT02307734|Experimental|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately.
3355823|NCT02307734|Active Comparator|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
3245570|NCT01339078|Experimental|Kaffes stenting|Patients will be randomized towards Kaffes stenting.
3245571|NCT01339104|Experimental|Regorafenib|
3355824|NCT02307747|Experimental|trauma patients|Blood samples will be collected every 4 hours during 24 h, between day 2 and day 4 after inclusion
3355825|NCT02307760|Active Comparator|Study Human Milk Fortifier A|Acidified processing method.
3355826|NCT02307760|Experimental|Study Human Milk Fortifier B|Non-acidified processing method.
3355827|NCT02307773||Case Group|Treated with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope before intubation with conventional pharyngeal anesthesia
3355828|NCT02307773||Control Group|Treated with conventional pharyngeal anesthesia without further treatment.
3355829|NCT02307786||Beta-Thalassemiall -Transplantation|
3355830|NCT02307786||Beta-Thalassemia Supportive Care|
3355831|NCT02307825|Active Comparator|Azithromycin|Patients will receive the active study drug, azithromycin, as well as sinus irrigations with budesonide.
3355832|NCT02307825|Placebo Comparator|Placebo|Patients will receive a placebo as well as sinus irrigations with budesonide.
3355833|NCT02307851|Experimental|Group A|Quadrivalent VLP vaccine, low dose, intramuscular injection (0.5mL)
3355834|NCT02307851|Experimental|Group B|Quadrivalent VLP vaccine, high dose, intramuscular injection (0.5mL)
3355835|NCT02307851|Experimental|Group C|Quadrivalent VLP vaccine, medium dose, intramuscular injection (0.5mL)
3355836|NCT02307851|Active Comparator|Group D|Comparator TIV, intramuscular injection (0.5mL)
3355837|NCT02307864|Experimental|Treatment Sequence 1|Participants will receive treatment A (2*50 milligram [mg] tramadol hydrochloride [HCl] immediate release [IR] tablet + 1 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 2*50 mg tramadol HCl IR tablet + 1 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); treatment B (3*50 mg tramadol HCl IR tablet every 6 hours on Days 1, 2, and 3, along with single dose of 3*50 mg tramadol HCl IR tablet + 1 moxifloxacin placebo on Day 4); treatment C (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4); and treatment D (3 tramadol HCl placebo every 6 hours on Days 1, 2, and 3, along with single dose of 3 tramadol HCl placebo + 1 moxifloxacin placebo on Day 4) in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3355838|NCT02307864|Experimental|Treatment Sequence 2|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3355839|NCT02307864|Experimental|Treatment Sequence 3|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3355840|NCT02307864|Experimental|Treatment Sequence 4|Participants will receive treatment A; treatment B; treatment C; and treatment D in 4 treatment periods as per protocol defined sequence. A washout period of 7 to 15 days will be maintained between each treatment period.
3245572|NCT01339117|Experimental|High fermentable substrate diet|High fermentable substrate diet provided for two days
3245573|NCT01339117|Experimental|Low fermentable substrate diet|Low fermentable substrate diet provided for two days
3245574|NCT01339130|Other|behavioral and physiological tests|Computerized tests and Electrophysiological measurements
3245575|NCT01339143|Active Comparator|Pioglitazone|pioglitazone: 15mg, QD, PO, 16 weeks
3245576|NCT01339143|Experimental|vildagliptin|vildagliptin 50mg,BID,PO,16 weeks
3245577|NCT01339156|Experimental|P3914|
3245578|NCT01339156|Placebo Comparator|Placebo|
3245579|NCT01339169|Experimental|YF476 treatment|
3355841|NCT02307877||Fingolimod|Subjects currently taking Fingolimod for a minimum of 2 years
3355842|NCT02307877||glatiramer acetate|Subjects currently taking glatiramer acetate for a minimum of 2 years
3245580|NCT01339182|Experimental|Pegylated-Somatropin, 10mcg/kg|
3245581|NCT01339182|Experimental|Pegylated-Somatropin, 30mcg/kg|
3355843|NCT02307890||Liver transplantation group|Participants will include all deceased adult liver transplant donors (>16 years of age) whose livers are being utilised for transplantation in the Scottish Liver Transplant Unit in the Royal Infirmary of Edinburgh. Exclusion criteria will include paediatric liver transplant donors (<16 years of age).
3355844|NCT02307903||End-stage renal failure (ESRF)|end-stage renal failure (ESRF)
3355845|NCT02307929||Chronic Disease Management|Aging population with the need of Chronic Disease Management
3355846|NCT02307942|Experimental|SURGERY|Patient will be operated for a gastric banding disposal
3245582|NCT01339182|Experimental|Pegylated-Somatropin, 60mcg/kg|
3355847|NCT02307942|No Intervention|STANDARD|Standard of care for obesity
3355848|NCT02307955|Experimental|firefly|participants treated with firefly device
3355849|NCT02307955|Other|Control|Standard of care
3355850|NCT02307968||inner thigh insulin injection|inject insulin at inner thigh site is the intervention arm. So we inject insulin at this site to see if this site is suitable for insulin injection.
3355851|NCT02307968||outer thigh insulin injection|outer thigh site for insulin therapy is the usual site
3355852|NCT02307981||Visual field defect with vision teacher|Patients With occipital ischemic stroke and Visual Field defect that live in a geographical region where training With vision teacher is an available service (vision Teachers are a Limited Resource in Norway)
3245583|NCT01339182|Experimental|Pegylated-Somatropin, 120mcg/kg|
3355853|NCT02307981||Visual field defect without vision teacher|Patients With occipital ischemic stroke and a Visual Field defect, who live in a geographical area where training With vision teacher is not an available service.
3355854|NCT02307994|Experimental|75IU uFSH|75IU uFSH (Livzon Pharm Group Inc., China) being injected into severe oligospermia patients or azoospermia patients every 3 days for 6 months
3355855|NCT02308059||Patients with diabetes mellitus|Group I; the patients with diabetes mellitus who had peripheral neuropathy as diagnosed.
3355856|NCT02308059||Control|Group II; healthy volunteers
3355857|NCT02308072|Experimental|Olaparib + Cisplatin + IMRT|"Olaparib: 50, 100, 150 or 200 mg twice a day for between 3-5 sequential days, depending on cohort allocation, in combination with Cisplatin: 35 mg/m^2 on day 1, and IMRT: 2 Gy radiotherapy given on days 1-5~Treatment will start on day 1 of every week. Patients will receive up to 7 weeks of combination chemotherapy and radiotherapy treatment."
3355858|NCT02308085|Experimental|Endocrine therapy interruption|Endocrine therapy interruption after having completed between ≥ 18 months and ≤ 30 months.
3355859|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh
3355860|NCT02308098|Experimental|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh|Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh
3355861|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 4 inh
3355862|NCT02308098|Experimental|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|Symbicort Turbuhaler 320/9 ug/inhalation 1 inh Placebo Budesonide/formoterol Easyhaler 320/9 ug/inhalation 1 inh
3355865|NCT02308137|Experimental|Domperidone|Treatment: Oral domperidone four times daily Target dose: 40mg per day Duration: 1 year
3355866|NCT02308176|Experimental|intervention group|health advice and app installation in patient's mobile
3355867|NCT02308176|Placebo Comparator|control group|health advice
3355868|NCT02308202|Active Comparator|doxazosin|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive doses of study medication as over-encapsulated doxazosin XL or placebo dosed once in the morning. Study medication will be initiated as one capsule of doxazosin XL 4 mg or placebo given in the morning. The dose will be titrated up to 16 mg/d doxazosin XL or placebo as follows: Days 1-4: 4mg, Days 5-8: 8mg, Day 9-12: 12 mg, Days 13-16: 16 mg.
3245584|NCT01339182|Experimental|Pegylated-Somatropin, 200mcg/kg|
3245585|NCT01339195|Experimental|Behavioral|Behavioral: French adaptation of NINDS-Canadian Stroke Network battery
3245586|NCT01339208|Experimental|Telemedicine Diabetes Intervention|
3245587|NCT01339221||Cohort A|Children confirmed with G1 and/or P[8] cases from the RotaBel study
3245588|NCT01339221||Cohort B|Children hospitalized for severe gastroenteritis in the study hospitals and tested positive for rotavirus
3245589|NCT01339234|Experimental|Body-weight supported treadmill training|
3245590|NCT01339286|Experimental|atomoxetine|
3245591|NCT01339312|Experimental|VRVg Vaccine Group 1|Participants aged 18 years or older will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
3245592|NCT01339312|Experimental|VRVg Vaccine Group 2|Participants aged 10 to 17 years will receive Purified Vero Rabies Vaccine Serum Free (VRVg)
3245593|NCT01339312|Active Comparator|Verorab Vaccine Group 1|Participants aged 18 years or older will receive Verorab Vaccine
3245594|NCT01339312|Active Comparator|Verorab Vaccine Group 2|Participants aged 10 to 17 years will receive Verorab Vaccine
3355869|NCT02308202|Active Comparator|perindopril|Subjects will be randomized to receive either perindopril 16mg or placebo for 8 days. Participants will receive doses of study medication as over-encapsulated perindopril or placebo dosed once in the morning.
3355870|NCT02308202|Placebo Comparator|placebo|Subjects will be randomized to receive either doxazosin XL or placebo. Participants will receive placebo for doxazosin XL for 16 days and placebo for perindopril for 8 days.
3355871|NCT02308241|Experimental|Ribavirin|Study subjects will self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day). All patients will complete pill diaries to document administration of study drug. Cycle length is 28 days with continuous dosing. Clinic visits for safety assessments and routine laboratory studies will occur weekly in Cycle 1, in weeks 1 and 3 of Cycle 2, and on Week 1 of subsequent cycles. Cross sectional imaging (CT or MRI) is obtained at baseline and q2 cycles and at End-of Treatment (EOT). Response assessments will follow RECIST 1.1 criteria.
3355872|NCT02308254|Active Comparator|Lixisenatide|Lixisenatide: 10 mcg, one subcutaneous injection dose
3355873|NCT02308254|Placebo Comparator|Placebo|Matching placebo: one subcutaneous injection dose
3355874|NCT02308267||Cystic fibrosis|Cystic fibrosis patients More than 18 years old DF508/DF508 mutation colonized or not with Pseudomonas aeruginosa
3355875|NCT02308267||Controls|Controls patients More than 18 years old Without CF Smokers or nonsmokers
3355876|NCT02308280|Experimental|Bortezomib post-transplantation|"Non myeloablative allogeneic transplantation followed by Bortezomib for 1 year after a Bortezomib-based induction and autologous stem cell transplantation.~Bortezomib: 1,3 mg/m2 subcutaneously every 2 weeks for 26 injections."
3355877|NCT02308293|Experimental|High intensity exercise|Subjects will preform a high intensity training exercise (3* 30 seconds all out sprint on a cycle ergometer) to raise plasma lactate levels
3355878|NCT02308293|Sham Comparator|Lay down comfortably|As a control conditions, subjects wil lay down comfortably and rest
3355879|NCT02308306||Opioid analgesics|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
3355880|NCT02308319|Active Comparator|PROMPT|Prompt therapy with Tenofovir disoproxil fumarate (Viread(R)) 300mg p.o
3355881|NCT02308319|Other|Watchful monitoring|Wait and treat with Tenofovir disoproxil fumarate (Viread(R)) when active liver disease is present [defined as HBV DNA >2,000 IU/ml and abnormal ALT (>40 IU/ml)]
3355882|NCT02308332|Active Comparator|Intervention|patients switching from Atripla to Eviplera
3355883|NCT02308332|No Intervention|Control|patients remaining on Atripla
3355884|NCT02308345|Experimental|Video summary|Participants in this arm will be given online access to a 5-minute video summary of their pre-chemotherapy visit, recorded by their physician.
3245595|NCT01339325|Active Comparator|LESS cholecystectomy|Laparo-endoscopic single site cholecystectomy, the entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
3245596|NCT01339325|Active Comparator|Standard LAP-CHOLE|Standard laparoscopic cholecystectomy. The entire surface of the patient's abdomen is covered by plaster at the end of the operation. Patient does not know which kind of procedure he underwent before discharge.
3245597|NCT01339325|Active Comparator|LESS Cholecystectomy not blind|Laparo-endoscopic single site cholecystectomy. The patient is aware of the procedure he underwent.
3355885|NCT02308358||Allograft Transplantation|Subjects with femoral condyle osteochondral defects ≥10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for allograft transplantation.
3355886|NCT02308358||Microfracture Treatment|Subjects with femoral condyle osteochondral defects <10mm, as determined by MRI or diagnostic knee arthroscopy, will be recruited for microfracture treatment.
3355887|NCT02308384|No Intervention|Before intervention|GPs in this group have not yet received intervention.
3355888|NCT02308384|Experimental|After intervention|GPs in this group have received the intervention.
3355889|NCT02308397|Experimental|Group 1|Begins with Normal gluten containing bread
3355890|NCT02308397|Experimental|Group 2|Begins with Bread with reduced gliadins content
3245598|NCT01339338|Experimental|warm media|Subjects undergo HSG using a warm media heated with a 37℃ water-bathing
3245599|NCT01339338|No Intervention|cold media|the contrast media under room temperature without heat
3245600|NCT01339351|No Intervention|Usual Psychosocial Care|Participants are free to use any psychosocial care available to cancer patients. No restrictions to participation in other groups or services.
3245601|NCT01339351|Experimental|Therapeutic Group by teleconference|ten 90 minute group sessions by teleconference. Lead by social workers. Sessions focus on information, story sharing and coping.
3355891|NCT02308397|Experimental|Group 3|Begins with Bread with reduced ATIs content
3245602|NCT01339364|Active Comparator|Didactic Lecture|
3245603|NCT01339364|Experimental|Lecture plus Case Disscussion|
3245604|NCT01339364|Experimental|Lecture plus Small Group Education|
3245605|NCT01339377|Experimental|AO-1000 Treatment|Oxygen-ozone treatment with the AO-1000 device
3355892|NCT02308397|Experimental|Group 4|Begins with Bread with reduced overall protein content
3355893|NCT02308410||Tourniquet group|This group received a pneumatic tourniquet during total knee arthroplasty.
3355894|NCT02308410||Non-tourniquet group|This group received no tourniquet during total knee arthroplasty.
3355895|NCT02308436|Experimental|Candida Mouthwash with Curolox™ Peptide|Repeated applications 2.5 ml or 5 ml twice daily
3355896|NCT02308449|Placebo Comparator|Iron-deficient, given placebo|Iron-deficient participants given an infusion of sodium chloride at conclusion of baseline experimental visit
3355897|NCT02308449|Active Comparator|Iron-deficient, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
3355898|NCT02308449|Placebo Comparator|Iron-replete, given placebo|Iron-replete participants given an infusion of sodium chloride at conclusion of baseline experimental visit
3355899|NCT02308449|Active Comparator|Iron-replete, given iron|Iron-deficient participants given an infusion of ferric carboxymaltose at conclusion of baseline experimental visit
3355900|NCT02308462|Experimental|CHIMPs intervention|Family-Intervention
3245606|NCT01339442|Experimental|Dose Level 1 - Phase 1A|"BKM120 80 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3245607|NCT01339442|Experimental|Dose Level 2 - Phase IA|"BKM120 100 mg PO daily.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3245608|NCT01339442|Experimental|Phase IB|"BKM120 (dose to be determined in Phase IA)PO 5 days on/ 2 days off per week.~Fulvestrant 500 mg IM on Days 1 & Day 15 during Cycle 1 then on Day 1 of each subsequent cycle."
3355901|NCT02308462|No Intervention|Control|"The long-term effectiveness of the CHIMPs intervention under conditions of practice will be examined in comparison to a control condition receiving the usual after care (Treatment as usual = TAU); this testing of effectiveness will be performed in due consideration of the health economic aspects.~The treatment as usual implies that families of the control Group receive the Treatment that is customary in regular care. Thus, these families normally don't receive any post-treatment. If, however, a member of a control group family appears to have an urgent need for treatment (every Family receives a comprehensive diagnostic investigation at the beginning of the study), the respective family will be placed in the ambulatory care system."
3355902|NCT02308488|Other|Radiation|The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks. Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions
3245609|NCT01339442|Experimental|Cohort C|"BKM120 (dose determined in Phase IA) PO daily.~Fulvestrant 500 mg IM on Day 1 and Day 15 during Cycle 1 then monthly on Day 1 of subsequent cycles."
3245610|NCT01339455|Experimental|AHSCT|All patients undergo autologous hematopoietic stem cell transplantation in a two stage process.
3355903|NCT02308514|Active Comparator|conservative care|this group of patients will receive the conservative care: myofascial point release and radial head mobilisation
3355904|NCT02308514|Experimental|cryostimulation|this group of patients will receive the conservative care :myofascial point release and radial haed mobilisation and the cryostimulation (30-40 second of cold air application (-70 celsius degree) in order to lower skin temperature around the lateral epicondyle at 4 celsius degree.
3355905|NCT02308527|Active Comparator|Temozolomide|Temozolomide Days 1-5 every 4 weeks
3355906|NCT02308527|Experimental|Bevacizumab + Temozolomide|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 every 4 weeks
3245611|NCT01339468|Experimental|Arm 1|Intravenous Prograf therapy followed by oral Advagraf therapy
3245612|NCT01339468|Active Comparator|Arm 2|Intravenous Prograf therapy followed by oral Prograf therapy
3245613|NCT01339481||Subjects with RA initiating abatacept treatment regimen|Subjects naïve to both abatacept and belatacept
3245614|NCT01339494|Active Comparator|arginine supplementation|Oral L-arginine supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Arginine will be given every 4 hours.
3245615|NCT01339494|Active Comparator|citrulline supplementation|Oral L-citrulline supplementation will be administered to subjects with MELAS for 48 hours at a dose of 10 grams per M2 per day. Citrulline will be given every 4 hours
3245616|NCT01339507||Bepreve|Subjects with a history of allergic conjunctivitis.
3245617|NCT01339507||Lastacaft|Subjects with a history of allergic conjunctivitis.
3245618|NCT01339520|Experimental|Scorecard|Score of points for variables.
3245619|NCT01339520|No Intervention|Control|Standard of care for diabetes subjects
3355907|NCT02308527|Experimental|Irinotecan + Temozolomide|Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
3245620|NCT01339533|Experimental|APRV ls|APRV low stretch will titrate Plow to maintain release volumes between 4 and 8 cc/kg.
3245621|NCT01339533|Active Comparator|AC/VC Conventional Ventilation|Standard volume control ventilation with the ARDS Net protocol.
3245622|NCT01339533|Experimental|APRV h|APRV Habashi protocol which sets Plow equal to 0.
3245623|NCT01339546||Study population|All ambulatory visits for otitis media, myringotomy tube insertion, skin rash or trauma among children age 5 or under during the periods of study
3245624|NCT01339572|Experimental|Plerixafor|All subjects will receive filgrastim as part of their primary mobilization regimen. If a subject does not meet minimum peripheral blood CD34+ cell count levels or fails to adequately collect a threshold number of CD34+ cells, plerixafor will be added to the mobilization regimen.
3245625|NCT01339572|Active Comparator|Observation|All subjects will receive filgrastim as part of their primary mobilization regimen. If the subject meets minimum peripheral blood CD34+ cell count levels or adequately collects a threshold number of CD34+ cells, plerixafor will not be added to the mobilization regimen.
3245626|NCT01339585|Experimental|Timing of tDCS|
3245627|NCT01339585|Experimental|Alternative timing of tDCS|
3245628|NCT01339598|Sham Comparator|Sham transcranial direct current stimulation|
3245629|NCT01339598|Active Comparator|Transcranial direct current stimulation|
3245630|NCT01339598|Active Comparator|Different transcranial direct current stimulation montage|
3245631|NCT01339611|Experimental|Educational Program|Patients who are going to use of oral anticoagulant will participate in an individual orientation, using instructional material (slides and illustrative booklet) during hospitalization period and the telephone follow-up at a week and four weeks after discharge
3245632|NCT01339611|Other|usual care|Patients who are going to use of oral anticoagulant will have usual orientation from the health service (illustrative booklet) during hospitalization time. No telephone follow-up after discharge.
3245633|NCT01339624|Active Comparator|NASAL FENTANYL,|
3245634|NCT01339624|Active Comparator|KETOROLAC + MORPHINE|
3245635|NCT01339637||Diabetes risk factors|Very dark skin subjects with with diabetes risk factors
3355908|NCT02308527|Experimental|Bevacizumab + Irinotecan + Temozolomide|Bevacizumab Day 1 + Irinotecan Days 1-5 + Temozolomide Days 1-5 every 3 weeks
3355909|NCT02308527|Experimental|Temozolomide + Topotecan|Temozolomide Days 1-5+ Topotecan Days 1-5 every 4 weeks
3355910|NCT02308527|Experimental|Bevacizumab + Temozolomide + Topotecan|Bevacizumab Day 1 and 15 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
3355911|NCT02308527|Experimental|Dinutuximab beta + Temozolomide|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 every 4 weeks
3355912|NCT02308527|Experimental|Dinutuximab beta + Temozolomide + Topotecan|Dinutuximab beta Days 1-7 + Temozolomide Days 1-5 + Topotecan Days 1-5 every 4 weeks
3355913|NCT02308527|Other|Dinutuximab beta + Topotecan + Cyclophosphamide|Dinutuximab beta Days 1-7 + Topotecan Days 1-5 + Cyclophosphamide Days 1-5 every 4 weeks
3245636|NCT01339650|Experimental|ABT-767|ABT-767 monotherapy
3245637|NCT01339663|Experimental|Treatment (dose-escalation, T-APC boost, CTL)|"INFUSION I: Patients receive high-dose cyclophosphamide IV on day days -4 and -3 and low-dose IL-2 SC BID on days 0-14. Patients also receive CTL IV on day 0.~INFUSION II: Beginning 6-48 hours later, patients receive high-dose cyclophosphamide, low-dose IL-2, and CTL as in Infusion I. Patients also receive T-APC vaccine IV within 18-36 hours following CTL infusion and in week 4, and IL-2 SC BID on days 0-14 following second T-APC vaccination."
3355914|NCT02308553|Experimental|Nintedanib + Paclitaxel|Nintedanib (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
3245638|NCT01339676|Experimental|1|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
3245639|NCT01339676|Placebo Comparator|2|Identically appearing once weekly peroral capsules
3245640|NCT01339689|Experimental|Ganaxolone|active
3245641|NCT01339689|Placebo Comparator|Placebo|non-active
3245642|NCT01339702||"Pre-implementation cohort (before)"|This cohort is a combination of retrospective and some prospective severe TBI patients cared for in the EMS systems of Arizona BEFORE implementation of the national prehospital TBI management guidelines
3355915|NCT02308553|Placebo Comparator|Nintedanib-Placebo + Paclitaxel|Placebo (150 or 200mg BID) for up to 48 weeks combined with paclitaxel 90mg/m2 BSA day 1, 8, 15 q28 days for a maximum of 6 courses
3355916|NCT02308566|Active Comparator|Conventional Extracorporeal Circulation Technique|Conventional Extracorporeal Circulation Technique
3355917|NCT02308566|Experimental|Minimized Extracorporeal Circulation Technique|Minimized Extracorporeal Circulation Technique
3355918|NCT02308579||Multiple Sclerosis|Patients diagnosed with Multiple Sclerosis (MS), identified in the CTEVD trial
3355919|NCT02308579||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Syndrome (CIS), identified in the CTEVD trial.
3355920|NCT02308579||Other Neurological Disorders|Patients diagnosed with Other Neurological Disorders (OND), identified in the CTEVD trial. ONDs fall into one of four categories: Neurodegenerative, Vascular, Autoimmune, and Neuromuscular; and the following disorders: Acute Disseminated Encephalomyelitis (ADEM); Antiphospholipid Antibody (syndrome; APLA); Atypical, short-lasting neurodegenerative disease; Autoimmune disease not otherwise specified (NOS); Cerebellum Syndrome; Charcot-Marie Tooth Disease; Chiari Malformation; Chronic Fatigue Syndrome; Central Nervous System Vasculitis; Demyelinating Disease; Epilepsy; Headaches; Idiopathic Chronic Neuropathy; Migraines; Mitochondrial Disease; Myelopathy; Neurofibromatosis; Neuropathy; Optic Neuritis; Parasthesia related to Transient Ischemic Attacks (TIA); Parkinson's Disease; Restless legs syndrome; Seizures; Spinal Cerebellum Disease; Spinal Disc Degeneration; Syringomyelia; and Vertigo
3355921|NCT02308579||Healthy Controls|Individuals who are healthy (i.e., free from neurological conditions; HC) , identified in the CTEVD trial.
3355922|NCT02308592|Placebo Comparator|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
3355923|NCT02308592|Active Comparator|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
3355924|NCT02308605||Suspected stroke patients and subset|"Blood samples taken on admission and at 24 hours, MRI scan between 24 and 48 hours~Subset: Blood samples repeated once per hour for six hours"
3355925|NCT02308605||Control participants (relatives)|To donate blood on two occasions, 24 hours apart, to draw comparison with stroke patients
3355926|NCT02308605||Feeding control participants|To donate a baseline blood sample, eat a simple purine rich meal (meat sandwich), then donate 4 more blood samples at 10, 30, 60 and 120 minutes following the meal
3355927|NCT02308618|Experimental|Traditional Immobilization|45 days of plaster cast immobilization After the immobilization period, subjects received instructions on how to perform a home-based exercise program
3245643|NCT01339702||"Post-implementation cohort (after)"|"This cohort is a comprised of prospective severe TBI patients cared for in the EMS systems of Arizona AFTER training EMS providers in the implementation of the national prehospital TBI management guidelines. It is intended that these patients will receive the bundle of care specified in the TBI Guidelines."
3245644|NCT01339741|Active Comparator|Vitamin D|
3355928|NCT02308618|Experimental|Early mobilization|Six weeks of physical therapy program
3355929|NCT02308618|No Intervention|Control|Subjects had no history of lower limb injury, and were matched in age and anthropometric measurements to subjects that performed physical rehabilitation and to subjects that remained immobilized.
3245645|NCT01339741|Placebo Comparator|Placebo|
3245646|NCT01339754|Experimental|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
3245647|NCT01339780|Experimental|Breast Cancer|
3245648|NCT01339780|Experimental|Prostate Cancer|
3245649|NCT01339806|Other|Standard of Care for mTBI Provider Arm|Arm 1: Psychoeducational Control Group. Individuals assigned to arm 1 will receive psychoeducational materials specifically adapted for persistent management of symptoms and routine follow-up with medical providers (every three weeks). Additionally, subjects assigned to this group will receive medical care (e.g., psychopharmacological management of depression) and/or referral for symptom management (e.g., vestibular rehabilitation) of non-cognitive complaints, consistent with the current standard of care treatment model for managing post-concussive symptoms (see Figure below adapted with permission from authors; Brenner et al., 2009).
3355930|NCT02308631|Experimental|Colostomy with colopexy by endoscopy|Colostomy with colopexy by endoscopy. 5 porks underwent endoscopic assisted colostomy with percutaneous colopexy. Animals were evaluated in post-operative days 1, 2, 5 and 7 Procedure/Surgery: ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY
3355931|NCT02308644|Experimental|Bevacizumab|Group 1 - 21 eyes treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0, 6,12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
3355932|NCT02308644|Sham Comparator|Sham|Group 2 - 20 eyes treated with sham injection at weeks 0 and 6; and intravitreal bevacizumab injection(1.25mg) in the weeks 12 and 18 plus standard metabolic control with glycated hemoglobin measured at baseline, week 12 and 18. All patients were followed by expert (endocrinologist)
3355933|NCT02308670||RRMS changing from 20mg to 40mg GA|Relapsing-remitting Multiple Sclerosis patients who are switching from 20mg of glatiramer acetate (GA) to 40mg. The investigator is not influencing this clinical decision, just measuring its impact using MRI metrics.
3245650|NCT01339806|Experimental|Computer Based Therapy Group|"Arm 2: Non-therapist directed computerized cognitive rehabilitation. Individuals assigned to treatment arm 2 will receive ten hours of in-clinic, computerized treatment per week throughout the 6-week treatment trial. Participants will be scheduled for 2 hours per day, proctored by clinic staff (certified recreation therapist or neuropsychology technician) who will be responsible for recording daily performance, providing positive reinforcement of participation, and effort. Computer programs selected for this treatment trial include both skill-specific training (e.g., attention processes) and general cognitive activation. These computer programs are commercially available and advertised as brain fitness or brain training."
3355934|NCT02308683|Experimental|hsCRP, Hgba1c|Pre treatment hsCRP and hgba1c will be initially measured After 12 weeks supplementation of Moringa oleifera, post treatment hsCRP and Hgba1c will be measured
3355935|NCT02308709|Experimental|Ventilation image-guided radiotherapy|Patients will receive 4D CT ventilation image-guided personalized radiotherapy treatment that selectively avoids irradiating highly-functional lung regions
3355936|NCT02308722|Experimental|5-fraction stereotactic body radiation therapy|See intervention
3355937|NCT02308761|Experimental|RO6870810|Participants with RR-AML and HMA-refractory MDS will receive RO6870810, as per schedule described in intervention description.
3355938|NCT02308800|Active Comparator|Quantum™ Therapy/NPWT with Prontosan|Quantum™ Negative Pressure Wound Therapy with Prontosan irrigant.
3355939|NCT02308800|Active Comparator|Quantum™ Therapy|Quantum™ Negative Pressure Wound Therapy without irrigant.
3355940|NCT02308813|Experimental|Braking and functionality with hip osteoarthritis|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with hip osteoarthritis
3355941|NCT02308813|Experimental|Braking and functionality with hip arthroplasty|Cohort testing of driving performance in a drive simulator and correlation with clinical functionality in patients with total hip arthroplasty
3355942|NCT02308826|Experimental|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
3355943|NCT02308826|Active Comparator|Cool Little Kids|A 6-week parent psychoeducation group administered over an 8-week period.
3355944|NCT02308852|Active Comparator|real tDCS|"Patients will receive non-invasive and painless brain stimulation over the brain areas involved in cognitive aptitudes.~tDCS will be applied during 20 minutes while patients will perform motor bimanual tasks"
3355945|NCT02308852|Placebo Comparator|Sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3355946|NCT02308865|No Intervention|Control arm|Patient supported by the onco respiratory service for the treatment of their disease by chemotherapy and for the treatment of complications.
3355947|NCT02308865|Experimental|intervention arm|Multi disciplinary palliative care monthly consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a chaplain in addition to standard onco-pneumologic care.
3355948|NCT02308878|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for opioid dependence syndrome.
3355949|NCT02308878|Experimental|Mobile health cognitive stimulation|Cognitive stimulation using mobile technology with m-Health applications.
3355950|NCT02308891|Experimental|vigorous hydration arm|"Patients will be randomly allocated to vigorous hydration arm. Patients in the vigorous hydration arm will receive fluids via infusion by the following protocol.~Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
3355951|NCT02308891|Active Comparator|standard hydration arm|"Patients will be randomly allocated to standard hydration arm. Patients in the standard hydration arm will receive fluids via infusion by the following protocol.~- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP."
3355952|NCT02308904|Other|Laboratory Studies for Pituitary-Gonadal Function|"Females: We expect to enroll approximately 15 females ages 12 years and older.~Males: We expect to enroll approximately 15 males ages 12 years and older."
3355953|NCT02308904|Other|Data on iron burden and chelation history|"Retrospective data, as listed in this section, will be obtained from chart review and results of relevant clinical data.~Iron burden data~Assay for non-transferrin bound iron (NTBI)~Chelation data~Oxidant stress~History or presence of hypogonadism"
3355954|NCT02308904|Other|Pituitary MRI|MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland.
3355955|NCT02308930|Experimental|Vitamins + DHA supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg algal oil (containing 150mg DHA).
3355956|NCT02308930|Other|Vitamins supplement|2 x 400 mg capsules per day orally for 6 months, each capsule providing 154μg Vitamin A, 2.36μg Vitamin D, 0.4mg Vitamin E and 375mg corn oil (free of omega-3 fatty acids).
3245651|NCT01339806|Experimental|Cognitive Rehab Group|"Arm 3: Therapist-directed individualized cognitive rehabilitation. Individuals assigned to treatment arm 3 will receive 10 hours of individual and group cognitive rehabilitation treatment (including homework assignments) per week conducted by credentialed speech therapists and occupational therapists. The treatment components will include five hours of weekly individual therapy (one-hour sessions; two hours focused on compensatory strategies and three hours focused on restorative strategies), two hours of weekly group therapy (one hour sessions focused on compensatory strategies), and three hours of weekly computer-based homework proctored by clinic staff who will be responsible for recording performance, and providing positive reinforcement of participation and effort."
3355957|NCT02308956|Experimental|Integrated mental health in primary care|Participants in the new intervention arm will receive a task sharing model of locally-delivered mental health care integrated into primary healthcare. General health workers (health officers, nurses and community-based health extension workers) will be given brief training using the WHO's mental health Gap Action Programme and ongoing supervision in order to deliver mental health care to people with severe mental disorders.
3355958|NCT02308956|Active Comparator|Psychiatric nurse-led specialist care|Participants in the active control arm will receive an established model of centralised, specialist mental health care delivered by psychiatric nurses at an out-patient clinic within Butajira general hospital and supported by outreach from project workers.
3355959|NCT02308969|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
3355960|NCT02308982|Active Comparator|Intravenous immunoglobulin|Intravenous immunoglobulin: 1g/kg per day for 2 consecutive days
3355961|NCT02308982|Placebo Comparator|Placebo|Equivalent volume to 1g/kg of IVIG per day for 2 consecutive days
3355962|NCT02308995|Experimental|Cystectomy using barbed sutures|Endometrioma bed is sutured with barbed sutures
3355963|NCT02308995|Active Comparator|Cystectomy using conventional sutures|Endometrioma bed is sutured with conventional sutures
3355964|NCT02309008|Placebo Comparator|placebo|vehicle cream, dermal administration, multiple dosing
3355965|NCT02309008|Experimental|drug|PAC-14028 cream, dermal administration, multiple dosing, dose escalation
3355966|NCT02309021|Other|Sport Group|Participants randomised to the exercise condition will receive 12 weeks of physical exercise training. Once they have been assigned to this group, they will be informed about the training programme and its content. Training will be carried out in groups (two groups of ten or four groups of five, depending on scheduling, sport preferences, available materials) to ensure that individual attention can be paid to each participant.
3355967|NCT02309021|Other|Control Group|The control group will not receive any exercise training. In order to control, as far as possible, for the potentially therapeutic effects of extra contact time with investigators, and the potentially motivational elements of participation in an intervention, the C group will have equal contact time with an investigator and participate in a leisure program without physical activity component. This time will be filled with group mealtimes, games, films, painting, handcrafts, stretching or relaxation exercises.
3355968|NCT02309034|Experimental|Jump exercise|rebound exercises.
3355969|NCT02309034|Experimental|Aquatic exercise|Hydrogimnastic.
3355970|NCT02309034|Active Comparator|Nutritional guidance|Nutritional counseling classes.
3355971|NCT02309047||WHO anovulation|WHO I, II. III anovulation. See inclusion criteria
3355972|NCT02309060|Experimental|Storytelling Video Intervention (sTVi)|"We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~We will add a short, non-narrative, epilogue at the end of each of the 4 episodes that summarizes key messages and provides information on identifying signs of depression and suggestions for efficacious treatments.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
3355973|NCT02309073||women with a regular indication for ART|In the present proposal we are aiming to include all normo-ovulatory women with a regular indication for ART.
3355974|NCT02309073||women undergoing donor insemination treatment|potential normal fertile control group
3355975|NCT02309086|Experimental|Single arm|Autologous dendritic cells transduced with Ad encoding NS3
3355976|NCT02309125|Experimental|implant A|will include implants with immediate progressive loading using gingival formers of different sizes
3355977|NCT02309125|Other|implant B|The implants will remain submerged from surgery time till loading time 2 month.(submerged healing)
3355978|NCT02309151|Experimental|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
3355979|NCT02309151|No Intervention|Not immediate coronary angiography|Coronary angiography with possible coronary intervention may be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice.
3355980|NCT02309164|Active Comparator|Acupuncture|acupuncture
3355981|NCT02309164|Sham Comparator|orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
3355982|NCT02309177|Experimental|nab-Paclitaxel and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28 day cycle.
3355983|NCT02309177|Experimental|nab-Paclitaxel, Gemcitabine and Nivolumab in Pancreatic Cancer|nab-paclitaxel 125 mg/m2 on Days 1, 8 and 15, gemcitabine 1000 mg/m2 on Days 1, 8 and 15, and nivolumab on Days 1 and 15 of each 28-day cycle.
3355984|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 1 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 1.
3355985|NCT02309177|Experimental|nab-Paclitaxel, carboplatin and nivolumab Cycle 3 in NSCLC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 and carboplatin AUC 6 on Day 1 (Cycles 1 to 4 only) of each 21 day cycle; nivolumab on Day 15 of each 21 day cycle starting in Cycle 3.
3245652|NCT01339806|Experimental|Cognitive and Psychological Based Rehab|"Arm 4: Integrated interdisciplinary cognitive rehabilitation combined with cognitive-behavioral psychotherapy. Individuals assigned to treatment arm 4 will receive 10 hours of individual and group treatment per week conducted by credentialed therapists and doctoral-level psychologists. The treatment components will include four hours of weekly 1 hr individual therapy sessions; 2 hrs of cognitive rehabilitation, 1 hr of cognitive rehab & 1 hr of individual psychotherapy targeting anxiety/combat stress symptoms including relaxation training & exposure therapy and cognitive-behavioral principles, 3 hrs of weekly group therapy & three hours of weekly homework including 30-mins relaxation training, 30-mins cognitive-behavioral psychotherapy homework, and 2 hrs of computerized cognitive rehabilitation exercises proctored by clinic staff."
3245653|NCT01339819|Experimental|Arm 1|Dabigatran Therapy
3245654|NCT01339819|Active Comparator|Arm 2|Phenprocoumon Therapy
3355986|NCT02309177|Experimental|nab-Paclitaxel 100 mg/m2 and Nivolumab in MBC|nab-paclitaxel 100 mg/m2 on Days 1, 8 and 15 of each 28 day cycle, plus nivolumab on Days 1 and 15 starting in Cycle 3.
3355987|NCT02309177|Experimental|nab-Paclitaxel 260 mg/m2 and Nivolumab in MBC|nab-paclitaxel 260 mg/m2 on Days 1 of each 21 day cycle, plus nivolumab on Days 15 starting in Cycle 3.
3355988|NCT02309190||transpulmonary pressures|Esophageal balloon to measure transpulmonary pressures. PEEP adjustment as per transpulmonary pressures.
3355989|NCT02309203|Experimental|Flow Re-Direction Endoluminal Device|Flow Re-Direction Endoluminal Device (FRED Device)
3355990|NCT02309229||Cystic fibrosis patients|patients with cystic fibrosis
3355991|NCT02309242|No Intervention|Neuropsychological assessment, MRI|This is a cross-sectional mono-center study examining survivors who were exposed to chemotherapy for bone or soft tissue sarcomas in childhood. Survivors of bone or soft tissue sarcomas will be examined with neuropsychological tests, questionnaires and advanced MR imaging (Neuropsychological assessment, MRI). Results will be compared to a healthy control group matched for age and sex.
3355992|NCT02309255||coronary heart disease patients|
3355993|NCT02309281|Other|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
3355994|NCT02309307|Experimental|Arm 1 Tissue Repair Device|Tissue Repair Device
3355995|NCT02309320|Experimental|ALX-0171|Inhalation of ALX-0171 during 3 consecutive days
3355996|NCT02309320|Placebo Comparator|Placebo|Inhalation of Placebo during 3 consecutive days
3355997|NCT02309346|Experimental|clindamycin once a day|Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day until clinical improvement
3355998|NCT02309346|Active Comparator|clindamycin thrice a day|Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
3355999|NCT02309385|Experimental|8% DSP-Visulex|8% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
3356000|NCT02309385|Experimental|15% DSP-Visulex|15% dexamethasone sodium phosphate - Visulex (DSP- Visulex) and placebo eye drops in the affected eye.
3356001|NCT02309385|Active Comparator|Pred Forte|Prednisolone acetate (1%) eye drops and vehicle - Visulex in the affected eye.
3356002|NCT02309424|Active Comparator|Vinegar|0,50mmol vinegar (6% acetic acid)
3356003|NCT02309424|Placebo Comparator|Placebo|50 ml water
3356004|NCT02309437|Experimental|Mild group|Use oxycodone when pain is mild level. Start from 10 mg every 12 hours and titrate for appropriate dose.
3356005|NCT02309437|Active Comparator|Moderate group|Use oxycodone when pain is moderate or severe level. Start from 10 mg every 12 hours and titrate for appropriate dose.
3356006|NCT02309450|Experimental|Asunaprevir, Daclatasvir and BMS - 791325|
3356007|NCT02309476|Experimental|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3356008|NCT02309476|Experimental|PASCAL Laser, Green Laser 1 burn|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3245655|NCT01339845|Active Comparator|Vaccine arm|Thirty clusters (approximately 80,000 people) will receive cholera vaccine alone
3245656|NCT01339845|Active Comparator|Vaccine plus hygiene and safe water arm|Thirty clusters (approximately 80,000 people)will receive both cholera vaccine and behaviour change
3245657|NCT01339845|No Intervention|Non-intervention arm|30 neighbourhoods(approximately 80,000 people) will continue their standard habits and practices
3245658|NCT01339871|Experimental|Pazopanib + Vorinostat|Starting doses Pazopanib 400 mg orally daily and Vorinostat 100 mg orally daily
3356009|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3356010|NCT02309476|Experimental|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3356011|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
3245659|NCT01339884|Active Comparator|Resveratrol, 1g daily|15 participants will receive resveratrol 1g daily
3245660|NCT01339884|Active Comparator|Resveratrol, 5g daily|15 participants will receive resveratrol, 5g daily
3245661|NCT01339949|Experimental|24 Gy radiation|
3245662|NCT01339949|Sham Comparator|Sham 24 Gy radiation|
3245663|NCT01339962||Non-Interventional Study|Outcomes Research Study
3356012|NCT02309476|Experimental|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 1 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 40% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
3356013|NCT02309502|Experimental|Green Pascal|Single-session Barely Visible Pascal 532nm 3,000 burns 20ms
3356014|NCT02309502|Experimental|Yellow Pascal|Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management:70%
3356015|NCT02309502|No Intervention|Observation|Observation
3356016|NCT02309541|Experimental|Firmware N|New feedback canceller algorithm
3356017|NCT02309541|Active Comparator|Firmware R|Current feedback canceller algorithm (reference)
3356018|NCT02309554|Active Comparator|SILCS Diaphragm alone|Participants will complete a post-coital test cycle with SILCS diaphragm alone.
3356019|NCT02309554|Active Comparator|SILCS Diaphragm with 3% Nonoxynol-9 Gel|Participants will complete a post-coital test cycle with SILCS diaphragm used with 3% nonoxynol-9 gel.
3356020|NCT02309554|Experimental|SILCS Diarphragm with ContraGel|Participants will complete a post-coital test cycle with SILCS diaphragm used with ContraGel.
3245664|NCT01339975||Group A. Surgically treated patients|Patients having a radical or partial nephrectomy.
3245665|NCT01339975||Group B. Patients treated with targeted therapies|Patients treated by RCC-directed targeted therapy
3356021|NCT02309593||PROFEMUR® Xm Femoral Stems|Single study group either previously implanted or will be implanted with the following combination of components: PROFEMUR® Xm Femoral Stems, with any type of Acetabular Shells.
3356022|NCT02309606||Migraine without aura|Migraine patients suffering from migraine 0-4 days per month.
3356023|NCT02309606||Healthy controls|Healthy controls with no history of migraine or other primary headaches.
3356024|NCT02309606||Chronic migraine|Migraine patients with chronic migraine
3356025|NCT02309619|Experimental|trans-substernal group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-substernal path.
3356026|NCT02309619|Experimental|trans-esophageal bed group|Patients who undergo esophagectomy with the gastric tube lifting to the neck through trans-esophageal bed path.
3356027|NCT02309632|Active Comparator|Pathway 1|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 1
3356028|NCT02309632|Active Comparator|Pathway2|Individuals at high risk of pancreatic cancer who will participate in Pancreatic Cancer Screening Pathway 2
3356029|NCT02309645|Experimental|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
3356030|NCT02309645|Other|Sutures Only|Subjects randomized to control will receive additional dural repair sutures as deemed necessary by the surgeon to attempt to achieve a watertight closure.
3356031|NCT02309658|Experimental|Interventional|Treatment consisted of gemcitabine at a dose of 1000 mg/m2, followed by cisplatin 35 mg/m2 administered on day 1 and 8, for two cycles. After that, weekly cisplatin 40mg/m2 is administered concomitant with radiotherapy (45-55Gy) in 1,8-2,0 daily fractions and a 10Gy boost when there was parametrial involvement. Low-dose rate brachytherapy, in 4 fractions of 7Gy, in a total of 28Gy will complete the protocol.
3356032|NCT02309671|Experimental|FE 999049 6 µg|
3356033|NCT02309671|Experimental|FE 999049 9 µg|
3356034|NCT02309671|Experimental|FE 999049 12 µg|
3356035|NCT02309671|Active Comparator|FOLLISTIM 150 IU|follitropin beta
3356036|NCT02309684||Study Population|Study population are subjects at least 18 years old and of any ethnic background with a full thickness diabetic foot ulcer or venous leg ulcer, where the ulcer has been diagnosed/present for greater than 4 weeks duration.
3356037|NCT02309697||Full Term|Children born at full term on or after Jan 1, 2011
3356038|NCT02309697||PreTerm|Children born preterm on or after Jan 1, 2011
3356039|NCT02309710|Experimental|ShangRing|ShangRing administered to men seeking medical male circumcision
3356040|NCT02309749||Naive cohort|
3245666|NCT01339988|Experimental|Busulfan/Cyclophosphamide|
3245667|NCT01340001|Sham Comparator|Sham Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
3245668|NCT01340001|Experimental|Electrical stimulation of the nucleus basalis of Meynert|Deep brain stimulation
3245669|NCT01340040|Experimental|MEDI-573|MEDI-573
3245670|NCT01340079|Experimental|Virtual world|Virtual world delivery method
3245671|NCT01340079|Active Comparator|face to face|face to face method of health education
3245672|NCT01340092|Active Comparator|Family Navigator|Family navigation
3245673|NCT01340092|No Intervention|Standard Care|standard care
3245674|NCT01340105|Experimental|Microwave|
3245675|NCT01340105|Active Comparator|Radiofrequency|
3356041|NCT02309762|Experimental|FB825|6 cohorts of subjects are planned to be dosed by IV injection, with single- ascending doses ranging from 0.003 - 10 mg/kg
3356042|NCT02309762|Placebo Comparator|Placebo|Placebo
3356043|NCT02309775|Active Comparator|Auriculotherapy Group|The placement, points according to Souza (1997), will be: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. The point descriptions are: Shen Men, is located in the vertex of the angle formed by the lower root and the upper root of the antihelix; the Sympathetic is situated in the middle of the lower root below the Helix membrane (located at the lower end of the Lobe); the Kidney point is situated in cymba concha, near its junction with the lower root of the antihelix, in the same line as the Shen Men point; the Subcortex is situated on upward curve towards the apex of the antitragus, on the upper edge of the concha; the Adrenal is located at the apex of the tragus, on its projection towards the concha cava; the Cerebral point is situated above the edge of the antitragus. As sessions will held twice a week for a total of 10 sessions.
3356044|NCT02309775|Placebo Comparator|Placebo Grup|The point stimulated will be the Trachea, which is one millimeter in the direction of the auditory meatus. This point does not cause risk to the research participant. As sessions will held twice a week for a total of 10 sessions.
3356045|NCT02309788||RT|Resectable HCC patients adjuvant RT for PVT or NM
3245676|NCT01340118|Experimental|Budesonide|Patients with FeNO level greater than 25 ppb were randomly allocated to one of two groups. Randomisation was stratified by baseline FeNO. In one group (treatment group), participants were assigned to once daily treatment with 400 µg budesonide. In the other group (non-treatment group), participants did not receive any medication.
3245677|NCT01340118|No Intervention|remain untreated|
3245678|NCT01340131|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 40mg/S-Amlodipine 5mg Intervention
3356046|NCT02309788||No RT|Resectable HCC patients adjuvant other treatment for PVT or NM
3356047|NCT02309801|Experimental|Daidzin and alcohol|"Daidzin 80 mg, single dose, oral administration (4 capsules of Super-Absorbable Soy Isoflavones®).~Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml."
3356048|NCT02309801|Active Comparator|Alcohol|Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
3356049|NCT02309814|Experimental|eyelid motion sensor device|all volunteers will wear the monitor eyelid sensor device (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance.
3356050|NCT02309827|Experimental|Cohort 1: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356051|NCT02309827|Experimental|Cohort 2: PF-06651600 or Placebo|Single ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356052|NCT02309827|Experimental|Cohort 3: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356053|NCT02309827|Experimental|Cohort 4: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356054|NCT02309827|Experimental|Cohort 5: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356055|NCT02309827|Experimental|Cohort 6: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356056|NCT02309827|Experimental|Cohort 7: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356057|NCT02309827|Experimental|Cohort 8: PF-06651600 or Placebo|Single ascending doses and multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356058|NCT02309827|Experimental|Cohort 9: PF-06651600 or Placebo|Multiple ascending doses of PF-06651600 or placebo to evaluate safety, tolerability and PK.
3356059|NCT02309840|No Intervention|control|Students received standard meals in a standard cafeteria environment
3356060|NCT02309840|Experimental|Chef|Students were exposed to chef-enhanced meals
3356061|NCT02309840|Experimental|choice architecture|"Students were exposed to modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
3356062|NCT02309840|Experimental|Chef and choice architecture|"Students were exposed to both chef-enhanced meals and modifications to the physical environment in the cafeteria to nudge students towards healthier choices"
3356063|NCT02309853|Experimental|Visual and tactile scanning training|20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space combined with trunk rotation
3356064|NCT02309853|Active Comparator|Unimodal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training
3245679|NCT01340131|Active Comparator|Free combination Therapy|Co-administration of single oral doses of a 40mg tablet of Telmisatan and a 5 mg tablet of S-Amlodipine
3245680|NCT01340157|Experimental|Fasting|Treatment A: 1200mg fexinidazole administered in fasting conditions by oral route
3245681|NCT01340157|Experimental|Meal 1: Plumpy Nuts|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 1) by oral route
3245682|NCT01340157|Experimental|Meal 2: Rice + beans|Treatment B: 1200mg fexinidazole administered in fed conditions (meal 2) by oral route
3245683|NCT01340170|Experimental|Soft bone drilling protocol|A soft bone drilling protocol will be used in bone quality 3 and 4
3356065|NCT02309866||Genetic Testing|All participants determined eligible for the study will be placed into genetic testing arm.
3245684|NCT01340170|Active Comparator|Standard drilling protocol|A standard drilling protocol will be used in bone quality 1 and 2
3245685|NCT01340183|Experimental|AZD5099|IV Dose
3245686|NCT01340183|Placebo Comparator|Placebo|IV Dose
3245687|NCT01340235|Experimental|Oral erythromycin|Oral erythromycin
3245688|NCT01340248|Experimental|Dilatrend 64mg capsule|"* Randomized, open-label, single dose, two-period, two-way, crossover study~group : Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~group : Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
3245689|NCT01340261||Pediatric Pain Rehab Patients|
3245690|NCT01340274|Active Comparator|Treatment as Usual|"Clients will receive 12 sessions of Treatment as usual , delivered 1 session per week for 12 consecutive weeks."
3356066|NCT02309879|Active Comparator|Remifentanil group|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
3356067|NCT02309879|Active Comparator|Lidocaine group|Patients in lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
3356068|NCT02309879|Active Comparator|Magnesium group|Patients in lidocaine group received an intravenous bolus injection of 50 mg/kg magnesium sulphate followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
3356069|NCT02309879|Active Comparator|Magnesium and Lidocaine group|Patients received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
3356070|NCT02309892|Experimental|Pemetrexed and Carboplatin plus L-DOS47|Patients will be recruited into cohorts of L DOS47 escalating doses, with a minimum of 3 and a maximum of 6 patients per cohort. The starting dose of L DOS47 will be 0.59 µg/kg; further possible dose levels that may be assessed are 0.78, 1.04, 1.38 and 1.84 µg/kg. The standard of care doses of pemetrexed [500 mg/m2] and carboplatin [AUC6], respectively, to be administered in combination with L-DOS47, will remain constant across cohorts.
3356071|NCT02309905||Control group before telemedicine|Inmates of prisons not having telemedicine before implementation of telemedicine in prisons having telemedicine
3356072|NCT02309905||Control group after telemedicine|Inmates of prisons not having telemedicine after implementation of telemedicine in prisons having telemedicine
3356073|NCT02309905||Exposed group, before telemedicine|Inmates of prisons having telemedicine before implementation of telemedicine
3356074|NCT02309905||Exposed group, after telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
3356075|NCT02309918|Other|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
3356076|NCT02309931|Active Comparator|Isoperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a isoperistaltic side-to-side ileocecal anastomosis
3356077|NCT02309931|Active Comparator|Antiperistaltic anastomosis|Patients with right colon cancer who undergo a right laparoscopic hemicolectomy and a antiperistaltic side-to-side ileocecal anastomosis
3356078|NCT02309957||BioMatrix CRD|All patients will receive BioMatrix CRD to repair an articular cartilage lesion or osteochondral defect.
3356079|NCT02309970||Conservative|patient will get treatment with Antiplatelets or Anticoagulant depending on their clinical status/etiology
3356080|NCT02309970||IV tPA|patient will receive intravenous thrombolysis treatment
3245691|NCT01340274|Experimental|CRAFT Treatment|"Clients will receive 12 sessions of CRAFT, delivered 1 session per week for 12 consecutive weeks."
3245692|NCT01340287|Active Comparator|1 = Tested product|
3245693|NCT01340287|Sham Comparator|2 = Control product|
3245694|NCT01340313||Group 1|4 times evaluation according to doses in 1 group
3356081|NCT02309970||Endovascular treatment|patient who will receive endovascular treatment
3356082|NCT02309983|Active Comparator|Electrical Stimulation Alone Group|Group 1 will receive 1hr of electrical stimulation while lying down followed by 15 min of overground training. Electrical stimulation will be applied through leads and self-adhesive electrodes over muscles of both legs. Two electrodes will be used for each muscle. Electrical stimulation will be induced by using the EMPI, Inc., St. Paul, MN [Respond Select Neuromuscular Stimulation]. There will be 60 sessions/3x week for 20 weeks.
3356083|NCT02309983|Placebo Comparator|Stand Retraining Alone with BWS|Group 2 will receive standing retraining with BWS alone on a treadmill without functional electrical stimulation. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. The duration of stand retraining sessions will be up to 1 hour or determined by subject's fatigue. There will be 60 sessions/3x week for 20 weeks.
3356084|NCT02309983|Experimental|Stand Retraining and ES Group|Group 3 will receive standing retraining with BWS with electrical stimulation, followed by 15 min of overground training. Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion. Electrical stimulation will start while participant is seated and before he/she is brought up to full standing. There will be 60 sessions/3x week for 20 weeks.
3356085|NCT02309996|Experimental|Supervisor Training Program|All supervisors from work units randomized to the intervention will receive a supervisor training program, the Supervisor/Manager Accommodation Recognition & Training (SMART) Program. This training program is modeled on a program developed by Shaw and colleagues of the Liberty Mutual Research Institute for Safety (LMRIS). The aim of the training program is to prevent/reduce work disability by improving supervisor communication, response to workplace injury, and problem solving mechanisms. The training program is designed to be administered by two facilitators to groups of 10 to 12 supervisors, during one 4-hour session or two 2-hour sessions. The training program delivery mode includes PowerPoint presentation with supplementary audio or video segments, case studies, and group discussion.
3245695|NCT01340326|Active Comparator|Valsartan,high dose|high dose group (valsartan up to 320 mg/day)
3245696|NCT01340326|Other|Valsartan, usual dose|usual dose group (valsartan 80 mg/day)
3356086|NCT02309996|No Intervention|No Supervisor Training Program|All supervisors from work units randomized to the control group will not receive the supervisor training program.
3245697|NCT01340339|Experimental|BILITRON BED®|Super-LED reverse phototherapy
3245698|NCT01340339|Active Comparator|BILIBERÇO®|Fluorescent Reverse Phototherapy
3245699|NCT01340352||study group: previous preterm labor|
3245700|NCT01340352||control group:previous term delivery|
3245701|NCT01340365|Other|Usual Care|
3245702|NCT01340365|Experimental|Tai Chi|Individuals will take part in community-based Tai Chi classes twice a week for 6 months as well as practice Tai Chi outside of class twice a week for the same 6 month period.
3245703|NCT01340391|Experimental|splinting method|A new splinting method has been invented. This is a study using the splint / cast in treatment of distal radius fractures.
3245704|NCT01340404|Experimental|Stem Cell Transplantation|
3245705|NCT01340404|Active Comparator|Transfusion program|
3245706|NCT01340417|Experimental|one label|Measurements of melatonin levels in urine, blood, milk.
3245707|NCT01340430|Experimental|FEC-paclitaxel-trastuzumab|fluorouracil 600 mg/m2; epirubicin 90 mg/m2; cyclophosphamide 600 mg/m2 for 4 cycles followed by paclitaxel 80 mg/m2/week in combination with trastuzumab for 12 weeks
3245708|NCT01340443||Cohort|
3245709|NCT01340456|Experimental|Rifampicin 10 mg QD|
3245710|NCT01340456|Experimental|Rifampicin 20 mg QD|
3245711|NCT01340456|Experimental|Rifampicin 100 mg QD|
3245712|NCT01340469|Active Comparator|study|Probiotics supplementation .
3245713|NCT01340469|Placebo Comparator|control|The control group received daily placebo liquid .
3356087|NCT02310009|Experimental|Control (CON)|Placebo will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
3356088|NCT02310009|Experimental|Anakinra (AN)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus, the day prior to the repeated measurement of beta-cell function.
3356089|NCT02310009|Experimental|Exercise (EX)|1 hour of cycling exercise will be performed at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
3356090|NCT02310009|Experimental|Anakinra + Exercise (ANEX)|100 mg of Kineret (Anakinra) will be administered as a subcutaneous injectable bolus followed by 1 hour of cycling exercise at 75% VO2max, the day prior to the repeated measurement of beta-cell function.
3356091|NCT02310022|Experimental|Drug Omega 3|4g (4 capsules) once a day, administered with food Other name MAT9001
3356092|NCT02310022|Active Comparator|Drug Omega 3 Comparator|4g (4 capsules) once a day, administered with food Other name Omega 3 Active Comparator
3356093|NCT02310048|Experimental|MT-1303-FormA|MT-1303, Capsule Formulation A
3356094|NCT02310048|Experimental|MT-1303-FormB|MT-1303, Capsule Formulation B
3356095|NCT02310061|Placebo Comparator|Control arm|Standard protocol of fluid management in hemodialysis
3356096|NCT02310061|Experimental|Active arm|Extra-vascular lung water measurements by ultrasound (LW-US)
3356097|NCT02310074|Experimental|Pulsatile Gonadotropin Releasing Hormone|Pulsatile Gonadotropin Releasing Hormone: subjects in the GnRH group initiated a regimen of pulsatile GnRH administered subcutaneously via a portable infusion pump for 18 months.
3356098|NCT02310074|Active Comparator|combination gonadotropin therapy|combined human chorionic gonadotropin (hCG)/urinary Follicle-Stimulating Hormone (uFSH) therapy:HCG treatment was maintained alone for 6 months and then uFSH was added for the next 12 months
3356099|NCT02310087|Active Comparator|astaxanthin with vitamin E|The participants in the study group will be given perorally four tablets of 4 mg astaxanthin with 10 mg vitamin E (Astasan, Sensilab, Slovenia) daily, taken in single daily dose. The total daily dose will be 16 mg astaxanthin with 40 mg vitamin E. The product will be taken for three months continuously.
3356100|NCT02310087|Placebo Comparator|placebo|The participants in the control group will be given perorally four tablets of placebo daily taken in single daily dose. The placebo tablets are of the same size and colour as the study tablets and were produced by manufacturer of Astasan, Sensilab, Slovenia. The placebo will be taken for three months continuously.
3356101|NCT02310113||Hematologic outpatients|Chronic anaemic outpatients who are planed to get transfusion RBC
3356102|NCT02310139||Failed/Difficult Colonoscopy|Patients referred for colonoscopy because of previously failed attempt at complete caecal intubation.
3356103|NCT02310152|Active Comparator|Active Treatment: CBT|Cognitive Behavioral Therapy
3356104|NCT02310152|Experimental|Experimental Treatment: SPACE|Parent-Based Treatment of Childhood and Adolescent Anxiety Disorders
3245714|NCT01340508|Experimental|Intensity modulated Radiotherapy|Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy
3245715|NCT01340534|Experimental|Oxygen 80% FIO2|Group of 181 patients that will receive supplemental oxygen 80% FIO2 during surgery (cesarean) and two hours after the procedure.
3356105|NCT02310165|Other|Z-tract Insertion Technique|For this technique, the skin is pulled 2 cm downward before the paracentesis needle is inserted and advanced.
3356106|NCT02310165|Other|Coaxial Insertion Technique|For this technique, the needle is directly inserted to minimize the distance between he cutaneous tissue and ascites
3356107|NCT02310178|Other|Group/Cohort|all of the current bariatric surgeries are allowed in this prospective cohort study
3356108|NCT02310191||Stenting|Carotid stenting
3356109|NCT02310204|Experimental|multidisciplinary education program|individual and group education sessions over a 6-month period
3356110|NCT02310204|Active Comparator|Standard psoriasis care alone|Standard psoriasis care alone
3356113|NCT02310230|Other|Blinded Group|Data from the ExSpiron Respiratory Variation Monitor (minute ventilation, tidal volume, and respiratory rate) will not be displayed. The anesthesia provider will care for the patient in the usual manner.
3356114|NCT02310230|Experimental|Monitor Group|The ExSpiron Respiratory Variation Monitor will display continuous real-time measurements of minute ventilation, tidal volume, and respiratory rate, and the anesthesia provider will be instructed to utilize this information in the care of the patient as they deem appropriate.
3356115|NCT02310243|Experimental|Palbociclib|"Phase1b: 125 mg palbociclib once daily for 21 days followed by 7 days of rest; this regimen will be chosen for the first dose to be evaluated.~phase IIa: single-agent palbociclib using the tolerable dose defined in the phase Ib part of the study is administered once daily for 21 days followed by 7 days of rest."
3356116|NCT02310256|No Intervention|Usual care|
3356117|NCT02310256|Active Comparator|Five Plus|Exercise training
3356118|NCT02310269||Pasireotide|
3356119|NCT02310282||Telemedicine|In-hospital telemedicine by a stroke expert aiming to assess stroke severity using the Unassisted TeleStroke Scale.
3356120|NCT02310295|Active Comparator|IVB-Laser|Intravitreal Bevacizumab combined with focal laser therapy
3356121|NCT02310295|Active Comparator|IVTA-Laser|Intravitreal Triamcinolone combined with focal laser therapy
3356122|NCT02310295|Active Comparator|Laser|focal laser therapy
3356123|NCT02310308|Active Comparator|xylitol chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3356124|NCT02310308|Experimental|Xylitol-magnolia chewing gum|Intervention chewing gum administration Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3245716|NCT01340534|Placebo Comparator|Use of air (no oxygen during surgery)|Group of 181 patients that will not receive supplemental oxygen during surgery (cesarean).
3245717|NCT01340547|Other|Single Arm|Single Arm, non-blinded, non-randomized
3245718|NCT01340599|Experimental|Arm I (Polyphenon E)|Patients receive defined green tea catechin extract PO once daily QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
3245719|NCT01340599|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD for 4-10 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo radical prostatectomy between days 28-70.
3356125|NCT02310308|Placebo Comparator|Control chewing gum|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
3356126|NCT02310334|Experimental|Unguided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the first visit, the participant will partake in an unguided exercise session.
3356127|NCT02310334|Experimental|Guided Pacing Strategy|Each participant will stay in the calorimeter (~24 hrs) on 2 different occasions. During the second visit, the participant will partake in a guided exercise session.
3356128|NCT02310347|Experimental|Marinol|"generic name: dronabinol~dosage: 0.1 mg/kg~frequency: 2 times a single dose~duration: acute adminstration"
3356129|NCT02310347|Placebo Comparator|Placebo|Empty hard gelatin capsules
3356130|NCT02310360||Healthy volunteers|
3356131|NCT02310373|Experimental|Nicotine free hookah (herbal/steam stones) smoking|Healthy habitual Hookah smokers will undergo microneurography, myocardial contrast echocardiogram or venous occlusion plethysmography before and after nicotine free hookah smoking.
3356132|NCT02310386|Active Comparator|activated BEMER-device|Activated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
3356133|NCT02310386|Sham Comparator|inactivated BEMER-device|Inactivated BEMER electromagnetic field therapy (BEMER, Innomed International, AG, Lichtenstein).
3245720|NCT01340612|Active Comparator|coiling|
3245721|NCT01340612|Active Comparator|coiling plus stenting|
3356134|NCT02310399|Experimental|Pre-lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in prelingiustically deaf children ages 18 months - 5 years
3356135|NCT02310399|Experimental|Post-Lingual Deafness|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant in postlinguistically deaf children < 21 years of age
3356136|NCT02310412|Experimental|Amicus platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 1, apheresis platelets will be collected using the Amicus separator and stored for 7 days in 35% Plasma and 65% InterSol
3356137|NCT02310412|Experimental|Trima platelet components|The two stages of this pilot study consist of the following: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT treatment, storage for 7 days, collection of fresh platelets, radiolabeling, infusion of fresh and stored INTERCEPT treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). In Stage 2, apheresis platelets will be collected using the Trima separator and stored for 7 days in 100% plasma.
3356138|NCT02310425|Active Comparator|The study group|The study group received S. boulardii supplementation, 50 mg/kg twice daily, compared to no intervention in the control group.
3356139|NCT02310425|Placebo Comparator|The control group|A prospective, Placebo Comparator,randomized case-controlled trial was conducted in infants with a gestational age of 30 to 37 weeks and a birth weight between 1500 to 2500 g.
3356140|NCT02310438|Experimental|Early intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home as soon as they have completed statutory NHS community rehabilitation."
3356141|NCT02310438|Active Comparator|Delayed intervention music therapy|"music therapy:~6 stroke patients with hemiparesis begin music therapy treatment in their home 9 weeks after they have been randomised into the wait list group."
3356142|NCT02310451|Experimental|metastatic melanoma|Patients affected by advanced melanoma not resectable (stage IIIc) or metastatic (stage IV)
3245722|NCT01340638|Active Comparator|Cookgas|This group will be assigned to use cookgas mask
3356143|NCT02310464|Experimental|Dose escalation|Each subject will be given a total of 10 doses of OBI-833/OBI-821 subcutaneously at weeks 1,2,3,4,6,8,12,16,20,and 24 (Visits 1,2,3,4,5,6,7,8,9 and 10, respectively). Post treatment, subjects will be continually evaluated for safety and immune response every 4 weeks until the end of study, which is 12 weeks after the last dose, i.e., week 36. Subsequently, subjects will be followed for survival every 8 weeks up to 12 months after the end of study.
3356144|NCT02310464|Experimental|Cohort expansion phase|Each subject will be given OBI-833/OBI-821 at Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and every 8 weeks thereafter (Visits 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and every 8 weeks thereafter) until disease progression. For the subjects discontinued treatment because of disease progression, subjects will be continually evaluated for safety and immune response every 8 weeks until the end of the study, which is 24 weeks after the last dose.
3245723|NCT01340638|Active Comparator|LMA mask|This group will be assigned to use LMA mask
3245724|NCT01340677|Experimental|001|Canagliflozin 100 mg Type=1 unit=mg number=100 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 300 mg Type=1 unit=mg number=300 form=tablet route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.,Canagliflozin 50 mg Type=1 unit=mg number=50 form=tablet route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
3245725|NCT01340690|Active Comparator|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension each day. Each 4ml suspension bag includes 400mg eicosapentaenoic acid (EPA), 40mg docosahexaenoic acid (DHA), 5.4 mg gamma-linolenic acid (GLA), 80 mg magnesium, 5 mg zinc and consists of linseed oil, xylitol, sea fish oil with high portion of omega-3-acids, magnesium citrate, vegetable oil, orange flavour, evening primrose oil, zink gluconate, soya lecithin, citric acid, acesulfame k (E950)
3245726|NCT01340690|Placebo Comparator|placebo suspension|2 bags of Esprico (R) placebo suspension. Includes no ω-3 fatty acids, no ω-6 fatty acids, no magnesium and no zinc, but other vegetable oils, orange flavor, etc.
3245727|NCT01340703|Other|optic disc pit maculopathy|
3356145|NCT02310490|Active Comparator|Right Side DermaVeil, Left Side Sculptra|DermaVeil right with left side Sculptra left side
3356146|NCT02310490|Active Comparator|Left Side DermaVeil, Right Side Sculptra|DermaVeil left with left side Sculptra right side
3356147|NCT02310503||Mohs surgery|Patients treated using Mohs surgery. Other exposures considered include patient characteristics, preoperative care and technical variants.
3356148|NCT02310516|Experimental|Patient with preoperative device|patients undergoing brain awake surgery with adequate explanations which are provided preoperatively. Preoperative device corresponds to a pre/ perioperative coaching involving the provision of a comprehensive information support on the awake surgery (short video and information brochure) and an interview with an operating room nurse
3245728|NCT01340716|Active Comparator|stretching exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style.
3245729|NCT01340716|Experimental|Tai Chi Chuan exercise|patients in this group held weekly classes of two stretching for 12 weeks.
3245730|NCT01340729|Experimental|TPI 287|Starting dose TPI 287 of 125 mg/m2 intravenous (IV) for 3 weeks of 4 week schedule.
3245731|NCT01340742|Active Comparator|1|Arm remote preconditioning
3356149|NCT02310516|Active Comparator|Patient with standard procedure|patients undergoing brain awake surgery with standard procedure (without adequate explanations)
3245732|NCT01340742|Placebo Comparator|2|Control group.
3245733|NCT01340755|Experimental|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
3245734|NCT01340781||Hospitalized medical patients|"Adult age 18-65 years old admitted to the general medical floors at MetroHealth Medical Center who are expected to stay a minimum of 48 hours.~Potential subjects cannot have a known diagnosis of OSA, a tracheostomy, respiratory failure requiring noninvasive ventilation, currently pre or post surgical intervention, or clinically unstable patients with plans for transfer to a higher acuity of care or transferred from intensive care."
3245735|NCT01340807|Experimental|Prosthetic Feet|Randomized to 4 different prosthetic feet (SACH, SAFE, TALUX, and Proprio Foot)
3356150|NCT02310529|Experimental|Interpersonal Psychotherapy|Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group). IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected. Intervention will be delivered by trained clinical psychologists.
3356151|NCT02310529|No Intervention|Treatment as usual|Patients including in this group will be taking only treatment as usual (in Pakistan it means that participants attending in outpatients' clinic at regular intervals and may or may not be taking prescribed medication).
3356152|NCT02310542|Experimental|MARS-SPAD|Patients will receive first the MARS albumin dialysis system and then, in a second time, the SPAD albumin dialysis system.
3356153|NCT02310542|Experimental|SPAD-MARS|Patients will receive first the SPAD albumin dialysis system and then, in a second time, the MARS albumin dialysis system.
3356154|NCT02310555|Active Comparator|Gastric bypass|classic Gastric bypass
3356155|NCT02310555|Active Comparator|Modified gastric bypass.|Modified gastric bypass. Resection body and fundus gastric
3356156|NCT02310555|Active Comparator|Slevee Gastrectomy|Slevee Gastrectomy
3356157|NCT02310594||Ancillary-Correlative (blood banking)|Samples of blood are collected before, during, and within two weeks after radiation therapy and then stored for analysis of anti-tumor immunity.
3356158|NCT02310633|Active Comparator|Memory Strategy Training|This arm involves intervention that teaches participants to use active encoding strategies to learn and remember new information.
3356159|NCT02310633|Active Comparator|Errorless Learning|This arm involves intervention that enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase.
3356160|NCT02310633|Active Comparator|Retrieval Practice|This arm involves intervention that enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue.
3356161|NCT02310659||lower calcificant score group|patients with coronary artery calcificant score <400
3356162|NCT02310659||higher calcificant score group|patients with coronary artery calcificant score ≥400
3356163|NCT02310685|Active Comparator|Intervention|Active Comparator: Intervention The primary focus is CVD risk factors. Subjects will be shown how to update Cardiovascular Age or Cardiometabolic Age on website. Pharmacists will give overview of comprehensive ehealth wellness program. Subjects will complete additional health assessments which include questionnaires considered gold standard. Pharmacists will explain that participants have access to ehealth coaching based educational modules with information relevant to a better understanding of cardiovascular risk factors. The ehealth coaching modules are guides to help understand risk factors and importance of making lifestyle changes. As information alone is often insufficient to promote change, participants will have access to online physical activity challenges.
3245736|NCT01340820|Experimental|AERAS-422 Low dose|>=10^5 to < 10^6 CFU
3245737|NCT01340820|Experimental|AERAS-422 High Dose|>=10^6 CFU
3245738|NCT01340820|Active Comparator|BCG Tice|BCG Tice 1-8 x 10^5 CFU
3245739|NCT01340833|Experimental|Study Medication|GSK2118436
3245740|NCT01340846|Experimental|Part A|Warfarin dosed at 15mg
3245741|NCT01340846|Experimental|Part B|Ketoconazole dosed at 400mg
3245742|NCT01340846|Experimental|Part C|Gemfibrozil dosed at 600mg
3245743|NCT01340846|Experimental|Part D|GSK2118436 dosed alone
3245744|NCT01340859|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
3356164|NCT02310685|No Intervention|No Intervention|Individuals randomized to the non active intervention group will have access to modified version of ehealth website. The pharmacist will show participants how to update Cardiovascular Age or Cardiometabolic Age on website. They will have access to health assessments but not ehealth coaching educational modules or challenges. They will have online support tools including public domain education material on exercise, healthy eating, understanding and managing blood pressure, diabetes and smoking cessation. Participants will return to the pharmacist for follow-up visits at 3, 6 months and one year. The pharmacist will update their cardiovascular risk profile with current information At the first follow up visit and at 1 year participants will be asked to have blood lipids reassessed.
3245745|NCT01340859|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
3245746|NCT01340911|Active Comparator|Part 1A, Cohorts 1-6|"Approximately 48 healthy male subjects will be enrolled into 6 separate cohorts (8 subjects per cohort). Each Cohort of subjects will be dosed sequentially, approximately one week apart, at escalating doses. Within each cohort, 6 subjects will be randomized to receive a single dose of SRT3025, and 2 will be randomized to receive a single dose of placebo.~The following are the planned doses for Cohorts 1-6, with Cohort 1 being the lowest dose and Cohort 6 being the highest dose: 50, 150, 500, 1000, 2000, and 3000mg of SRT3025. Dose level may be altered as appropriate during the study based on real time analysis of the safety, tolerability, and /or PK data. Dose adjustment may involve an increase or decrease in dose or dividing the total daily dose allowing for twice-daily dosing. Total daily dosing will not exceed 3000mg."
3356165|NCT02310698||Breast Cancer Screening Patients|"Women presenting for screening full field digital mammography (FFDM) and WBUS on the same day or within 30 days of one another.~o These women will be offered CEDM instead of the FFDM.~Women that are scheduled for CEDM alone.~o These women will be offered WBUS in addition to the CEDM.~Women scheduled for both CEDM and WBUS on the same day or within 30 days of one another."
3356166|NCT02310724||TODAY cohort|All subjects randomized to the TODAY clinical trial are eligible to participate in T2P2. The study performs long-term observation only and administers no treatment, care, or management.
3356167|NCT02310737|Active Comparator|sharp incision|the patients who were included as the control group (Group 1) with sharp fascia incision
3356168|NCT02310737|Active Comparator|blunt incision|the patients who were included as the another group (Group 2) with blunt fascia incision
3356169|NCT02310802|Experimental|OBE001 dose 1|
3245747|NCT01340911|Active Comparator|Part 1B, Cohorts 7-8|One to two of the doses administered in Part 1A may be selected for administration with food, based on expected changes in SRT3025 exposures with food, as well as safety, tolerability, and PK data from Part 1A. If initiated, the effect of a single dose of SRT3025 with a moderate fat/calorie meal may be initiated concurrently with a cohort in Part 2 of the study. Approximately 6 subjects would be enrolled into each cohort in Part 1B.
3356170|NCT02310802|Experimental|OBE001 dose 2|
3356171|NCT02310802|Experimental|OBE001 dose 3|
3356172|NCT02310802|Placebo Comparator|Placebo|
3356173|NCT02310828|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for one month
3356174|NCT02310828|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for one month
3356175|NCT02310841|Experimental|unilateral transfemoral amputees|
3356176|NCT02310854|Active Comparator|ACL Reconstruction|Primary reconstructive surgery of ACL with hamstring autograft (All-inside, Arthrex, Napels, Florida, USA)
3356177|NCT02310854|Experimental|ACL Repair|Primary augmented suture of ACL using Dynamic Intraligament Stabilization (DIS; Mathys Medical Bettlach, Switzerland)
3356178|NCT02310867|Experimental|Hand transplant with Belatacept|
3356179|NCT02310880||Low vision (virtual street training)|Low vision subjects trained in virtual streets and observed in real streets
3356180|NCT02310880||Low vision (real street training)|Low vision subjects trained in real streets and observed in real streets
3356181|NCT02310893|Active Comparator|Contingency Management only|Participants assigned to this arm will receive payments for attending regular HIV medical appointments at the clinic and filling prescribed HIV medications at the pharmacy
3356182|NCT02310893|Active Comparator|Peer Navigation only|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care
3356183|NCT02310893|Experimental|Combined Contingency Management and Peer Navigation|Participants in this arm will be assigned a peer navigator to assist them in accessing and remaining in HIV care and will be eligible to receive incentives for attending HIV care visits/refilling prescriptions.
3356184|NCT02310893|No Intervention|Usual care|Participants in this arm will receive the care that they would usually get in their clinic in the absence of this study.
3356185|NCT02310919|Experimental|Low dose hCG plus FSH co-trigger|On the day of ovulation trigger the patient will receive hCG 1,500 IU SQ plus FSH 450 IU SQ
3356186|NCT02310919|Active Comparator|Standard dose of hCG alone|On the day of ovulation trigger the patient will receive standard dose of hCG (10,000 or 5,000 IU SQ)
3356187|NCT02310932|Experimental|Healthy Living Intervention|The Healthy Living Intervention group will participate in an intervention designed to improve depression, anxiety, diabetes and CVD outcomes. This will be achieved through a 12 month intervention which consists of participation in healthy living groups and integrated collaborative clinic care at their Primary Health Clinic (PHC).
3356188|NCT02310932|Placebo Comparator|Enhanced Standard Care Model|"Patients in control groups will receive an enhanced standard care model, which includes providing referrals for mental health needs."
3356189|NCT02310945||Knee osteoarthritis|People with moderate/severe symptomatic knee osteoarthritis referred for physiotherapy
3356190|NCT02310958||Children with inguinal hernia|Laparoscopic surgical hernia repair in children aged between 1 day and 16 years
3356191|NCT02310971|Experimental|Biologic/Vaccine|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
3356192|NCT02310997|Experimental|Fludarabine + Cyclophosphamide + TBI|"Patients aged 2-45 years (excluding AML, JMML and MDS patients aged <16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m^2/day day -8 to -6 (total 75mg/m^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions"
3245748|NCT01340911|Active Comparator|Part 2A, Cohorts 9-11|Approximately 16-24 healthy subjects will be enrolled into 2 to 3 cohorts (8 subjects per cohort) in Part 2A. Within each cohort, 6 subjects will be randomized to receive multiple doses of SRT3025, and 2 will be randomized to receive multiple doses of placebo. The repeat dosing component of the study will be initiated, and doses selected, based on the evaluation of safety, tolerability, and PK data from Part 1A. Subjects in Part 2A will be randomized to receive 14 consecutive days of dosing with SRT3025 or matched-placebo. Subjects in these Cohorts will be dosed sequentially (in the fasted state) approximately two weeks apart.
3245749|NCT01340911|Active Comparator|Part 2B, Cohorts 12-13|If initiated, the effect of repeat doses of SRT3025 with moderate fat/calorie meals would occur in Part 2B (Cohorts 12 and 13). Each of these cohorts would enroll approximately 6 subjects.
3356193|NCT02310997|Experimental|Busulfan + Cyclophosphamide + Melphalan|"Patients aged < 2 years and AML, JMML and MDS patients <16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m^2 day -2"
3356194|NCT02311010|No Intervention|CYP 3 A 5 *3/*3 control group|CYP 3 A 5 *3/*3 control group will receive 0,20 mg/kg of Advagraf®
3245750|NCT01340950|Active Comparator|Better-Penetrating ART|zidovudine 300 mg orally every 12 hours lamivudine 300 mg orally daily nevirapine 200 mg orally every 12 hours
3356195|NCT02311010|Active Comparator|CYP 3 A 5 *3/*3|CYP 3 A 5 *3/*3 will receive 0,25 mg/kg of Advagraf®
3245751|NCT01340950|Active Comparator|Worse-Penetrating ART|tenofovir disoproxil fumarate 300 mg orally daily lamivudine 150 mg orally every 12 hours efavirenz 600 mg orally daily
3245752|NCT01340963||Class I|Structurally normal heart, no bundle branch block
3356196|NCT02311010|Active Comparator|CYP 3 A 5 *1/*3|CYP 3 A 5 *1/*3 will receive 0,30 mg/kg of Advagraf®
3356197|NCT02311010|Active Comparator|CYP 3 A 5 *1/*1|CYP 3 A 5 *1/*1 will receive 0,35 mg/kg of Advagraf®
3356198|NCT02311023|Experimental|Intermittent fasting|Patients consume their normal diet for 5 days in the week. On 2 days they only consume 500 Cals if female and 600 Cals if male.
3356199|NCT02311036|Other|Comorbidity_Comprehensive Rehabilitation|Charlson Comorbidity Index contains 19 categories of comorbidity and predicts the ten-year mortality for a patient who may have a range of co-morbid conditions Each condition is assigned with a score of 1,2,3 or 6 depending on the risk of dying associated with this condition. For a physician, it is helpful in knowing how aggressively to treat a condition. Higher scores indicating greater comorbidity (patients with a score > 5 have essentially a 100% risk of dying at one year).
3356200|NCT02311036|Other|MRS_Comprehensive Rehabilitation|The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.
3356201|NCT02311036|Other|MMSE_Comprehensive Rehabilitation|The mini mental state examination (MMSE) is the most commonly used instrument for screening cognitive function. This examination is not suitable for making a diagnosis but can be used to indicate the presence of cognitive impairment, such as in a person with suspected dementia or following a head injury. The examination has been validated in a number of populations. Scores of 25-30 out of 30 are considered normal; the National Institute for Health and Care Excellence (NICE) classifies 21-24 as mild, 10-20 as moderate and <10 as severe impairment. The MMSE may not be an appropriate assessment if the patient has learning, linguistic/communication or other disabilities (eg, sensory impairments).
3245753|NCT01340963||Class II|Mild symptoms, bundle brunch block or hemi-block on resting surface electrocardiogram, normal cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction as relaxation deficit (type I), none or mild global left ventricular systolic dysfunction
3356202|NCT02311036|Other|BSRS_Comprehensive Rehabilitation|Brief Symptom Rating Scale is a rating scale which a clinician or researcher may use to measure psychiatric symptoms such as depression, anxiety, hallucinations and unusual behavior. Each symptom is rated 1-7 and depending on the version between a total of 18-24 symptoms are scored. The scale is the one of the oldest, widely used scales to measure psychotic symptoms and was first published in 1962.
3356203|NCT02311049|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
3245754|NCT01340963||Class III|Overtly symptomatic, enlarged cardiac silhouette on plain chest X-ray film, left ventricular diastolic dysfunction, global systolic dysfunction, ventricular tachycardia, atrio-ventricular block (any degree)
3245755|NCT01340989|Experimental|4% oxygen|addition of 4% oxygen to the CO2 pneumoperitoneum
3356204|NCT02311049|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
3356205|NCT02311062|Experimental|Eccentric hamstring exercises|Three workouts per week on non-consecutive days for 6 weeks. 1)Assisted Nordic Curl: Kneeling on the ground with ankles fixed by a partner, participant lowering the trunk to the ground by eccentrically contracting the hamstrings. 2) Eccentric single stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the support leg knee and raising the other leg until form an straight line with the trunk4 3) Eccentric double stiff-legged dead lift: From standing position with the arm crossing over the chest, participant lowering the body toward the ground by flexing the hip joint without bending the knees until the body parallel with the floor.
3245756|NCT01340989|Experimental|full conditioning|full conditioning of the peritoneal cavity by the laparoscopic gas: 4% oxygen, 10% nitrous oxide, humidification and set temperature of 32°C
3245757|NCT01340989|Active Comparator|CO2 pneumoperitoneum|standard laparoscopy with CO2 pneumoperitoneum
3245758|NCT01341002|Experimental|SCVO2 < 70%|guidelines transfusion + SCVO2 < 70%
3245759|NCT01341002|Active Comparator|currently intervention|guidelines transfusion
3245760|NCT01341015|Experimental|ultrasound for fracture|All patients receive ultrasound for potential ankle fracture.
3245761|NCT01341028|Active Comparator|Roux-en-Y gastric bypass (LRYGBP)|Twelve subjects underwent laparoscopic Roux-en-Y gastric bypass
3245762|NCT01341028|Experimental|LRYGBP plus gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass plus gastric fundus resection
3356206|NCT02311062|Experimental|Unistable exercises|Trained 3 times per week on non-consecutive days for 6 weeks for a total of 18 training sessions. UNS training consisted in the following three exercises: 1) One leg squat: Standing on the floor on one leg only and squat down until knee flexed to 900 and press back up with just that single leg. 2) One leg Squat on Bosu® balance Trainer: Standing on the Bosu® balance Trainer on one leg only and squat down until supported leg knee flexes to 900 and press back up with just that single leg. 3) Forward lunges on a Bosu® balance Trainer: position the forward leg on the Bosu® balance Trainer and squatting with the forward leg.
3356207|NCT02311062|Active Comparator|Control|Participants did not undergo any resistance training and continued with their regular soccer training.
3356208|NCT02311075|Experimental|Patient comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
3356209|NCT02311075|Experimental|Control subjects comparative approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples.
3356210|NCT02311075|Experimental|Healthy volunteers metabolic approach|Assessing the availability of biological markers (NO, EETs, ET-1 and ROS) during endothelial stimulation using blood samples during hyperglycemia or hyperinsulinemia.
3356211|NCT02311088|Experimental|Caffeine|Caffeine capsules. 200 mg twice daily orally for 7-10 days.
3356212|NCT02311088|Placebo Comparator|Placebo|Matching placebo capsules twice daily orally for 7-10 days.
3356213|NCT02311101|Experimental|Therapy Group MMC 10/BCG Half|"Intravesical Mitomycin C and intravesical BCG~First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (half dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The first 3 participants received 10mg of MMC and half dose of BCG. The dose was assigned in order of enrollment."
3356214|NCT02311101|Experimental|Therapy Group MMC 10/BCG Full|First intravesical mitomycin C (10 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The following 3 participants received 10mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3245763|NCT01341041|Experimental|chlorine dioxide|2 arms
3356215|NCT02311101|Experimental|Therapy Group MMC 20/BCG Full|First intravesical mitomycin C (20 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The next 3 participants enrolled received 20mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3356216|NCT02311101|Experimental|Therapy Group MMC 40/BCG Full|First intravesical mitomycin C (40 mg) is instilled for 30 minutes. Then the mitomycin is removed and the bladder is gently hand-irrigated with sterile water for 15 minutes in order to facilitate removal of mitomycin C. Then, intravesical BCG (full dose) is instilled for 2 hours under usual conditions. Full dose BCG corresponds to 1 to 8x10^8 colony-forming units of BCG. This study targets patients with BCG-naive or BCG-refractory high-risk non-muscle invasive bladder cancer. The last 3 participants received 40mg of MMC and full dose BCG. Dose was assigned in order of enrollment.
3356217|NCT02311114||Telehomecare patients|Observational fieldwork, in depth interviews and surveys up to 4 times will be conducted.
3356218|NCT02311114||Health care providers|In-Depth interviews, observational fieldwork and one time survey will be conducted.
3356219|NCT02311114||Telehomecare administrators|In depth interviews will be conducted
3245764|NCT01341041|Active Comparator|saline|one time wash with 50-100cc of normal saline
3245765|NCT01341054|Experimental|mouthwash with Chamomilla extract 1%|The Chamomile recutita mouthwash 1% was administered two times daily for 30 days.
3245766|NCT01341054|Experimental|mouthwash with Chamomilla extract 2%|The Chamomile recutita mouthwash 2% was administered two times daily for 30 days.
3245767|NCT01341054|Active Comparator|standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12%; oral hygiene teaching. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
3245768|NCT01341054|Experimental|mouthwash with Chamomilla extract 0.5%|The Chamomile recutita mouthwash 0.5% was administered two times daily for 30 days, starting on the first day of chemotherapy.
3245769|NCT01341080|Experimental|Varenicline|
3245770|NCT01341080|Placebo Comparator|Sugar pill|
3245771|NCT01341093|Active Comparator|usual care|
3245772|NCT01341093|Experimental|educational program+telephone follow up|
3245773|NCT01341106|Experimental|Treatment Arm|Patients will be treated with entecavir
3245774|NCT01341132||Suspected Liver Disease|"Alpha-feto protein > 400 ng / mL or~prior ultrasound with mass suspicious for hepatic malignancy or.~clinical risk of hepatocellular carcinoma or~prior multi-detector CT with mass suspicious for possible hepatocellular carcinoma"
3245775|NCT01341145|Experimental|Aerobic Exersice|12-week moderate aerobic exercise program
3245776|NCT01341145|Active Comparator|Relaxation|12-week at home progressive muscle relaxation program
3245777|NCT01341158|Experimental|Experimental arm|
3245778|NCT01341171||tamoxifen or aromatase inhibitors|
3245779|NCT01341184|Experimental|Group 1|16 subjects: TMC207 400mg orally on days 1 and 29, rifabutin 300mg orally, every day on day 20-41
3245780|NCT01341184|Experimental|Group 2|16 subjects: TMC207 400mg orally on days 1 and 29, rifampin 600mg orally, every day on day 20-41
3245781|NCT01341197||Subjects undergoing bidirectional endoscopy and fecal tests|Subjects participating in the health check-up at National Taiwan University Hospital (Health Management Center)
3245782|NCT01341197||Patients with screening detected GI tract cancers|Patients with screening detected GI tract cancer, such as throat cancer, esophageal cancer, gastric cancer and colorectal cancers, from other screening sites in Taiwan and were referred to the National Taiwan University Hospital for confirmatory diagnosis and treatment.
3245783|NCT01341236|Active Comparator|continuous nutrition|
3245784|NCT01341236|Active Comparator|bolus nutrition|
3245785|NCT01341249|Experimental|DW224aa|DW224aa given by oral administration
3356220|NCT02311114||Telehomecare technicians|In-depth interviews, observational fieldwork will be conducted.
3356221|NCT02311127|Experimental|SecurAcath|Subcutaneous securement
3356222|NCT02311127|Active Comparator|StatLock|Adhesive securement
3356223|NCT02311140||Cystic Fibrosis patients with G551D mutation|Cohort Description Ten participants (6 Jena/4 Innsbruck) were included, of whom 6 were female and 4 were male. At the start of the study, patients were aged 7-45 years (mean age: 16.55 ± 13.42 years). Results of sweat tests and lung function FEV1 were available only from 8 patients. Lung function at baseline, as obtained from those patients, ranged from 0.96 to 4.07 L (mean FEV1: 99.7 ± 20.3% predicted, median: 103.6% predicted, IQR=20.4% predicted).
3356224|NCT02311179|Active Comparator|Prosthesis, BoneMaster-Exceed cup|Prosthesis, BoneMaster-Exceed cup: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray. The surface is coated with hydroxyapatite deposited electrochemically (BoneMaster)
3356225|NCT02311179|Active Comparator|Prosthesis Exceed cup without HA|Prosthesis Exceed cup without HA: A hemispheric joint cup of the type Exceed cup (Biomet) characterized by a porous surface of titanium plasma spray
3245786|NCT01341249|Active Comparator|DW224a|DW224aa given by oral administration
3245787|NCT01341275|Experimental|birth, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 10 ug dose of hepatitis B vaccine as a booster
3356226|NCT02311192|Experimental|Ultrasonography B-scan|Patients of uveitis who are included in the study will be imaged using ultrasound B-scan
3356227|NCT02311205|Experimental|TACE+sorafenib|Concurrent Conventional Transarterial Chemoembolization (TACE) and Sorafenib
3356228|NCT02311218|Active Comparator|Test group with L. reuteri|Subjects in the test group take one Lactobacillus reuteri DSM 17938 and PTA 5289 containing lozenge in the morning and one in the evening.
3356229|NCT02311218|Placebo Comparator|Placebo group without L. reuteri|Subjects in the placebo group take one placebo lozenges with same look, taste and smell as the test lozenge but lacking the Lactobacillii the morning and one in the evening.
3245788|NCT01341275|Experimental|birth, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or before day 7 of life who received a 20 ug dose of hepatitis B vaccine as a booster
3245789|NCT01341275|Experimental|4 weeks, lower dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 10 ug dose of hepatitis B vaccine as a booster
3356230|NCT02311231|Experimental|bivalirudin|bivalirudin as intravenous bolus of 0,75 mg per kilogram followed by an infusion of 1,75 mg per kilogram per hour
3356231|NCT02311231|Active Comparator|heparin|unfractionated Heparin 5 000 IU/ml as intravenous bolus according to local practice
3356232|NCT02311322||Children with growth disorders|Children with growth disorders
3356233|NCT02311322||Family members of subjects with growth disorders|Family members of subjects with growth disorders
3245790|NCT01341275|Experimental|4 weeks, higher dose booster|Adolescents who received their first dose of hepatitis B vaccine at or after 4 weeks of life who received a 20 ug dose of hepatitis B vaccine as a booster
3245791|NCT01341288|Experimental|Implant|Robotic implantation of brachytherapy seeds to treat prostate cancer
3356235|NCT02311413|Experimental|Cat-PAD|Subjects will be treated with four monthly doses of Cat-PAD, a peptide immunotherapy product consisting of Fel d 1 synthetic peptide immunoregulatory epitopes (SPIRE).
3356236|NCT02311413|Placebo Comparator|Placebo|Subjects will be treated with 4 monthly doses of Placebo.
3356237|NCT02311426||Norway|"500 consecutive patients with stroke from the stroke units at the University Hospital of North Norway located in the cities Narvik, Harstad and Tromsø.~At baseline 155 patients with first ever stroke were registered. At 3 and 12 months follow-up 135-155 patients were enrolled."
3356238|NCT02311426||Denmark|500 consecutive patients from the stroke unit at Århus Hospital in Denmark. At baseline 402 patients with first ever stroke were included. At 3 and 12 months follow-up 318/ 170 patients were enrolled.
3356239|NCT02311439|Experimental|FOLFIRINOX + CRT|FOLFIRINOX regimen, consisted of oxaliplatin, irinotecan, leucovorin and fluorouracil (5-FU), for 4 cycles, followed by consolidation radiotherapy concurrent with capecitabine 625mg/m2 BID in non-progressed cases, in treating patients with locally advanced cancer pancreas.
3356240|NCT02311452||Acute Osteomyelitis|
3356241|NCT02311452||Complicated Pneumonia|
3356242|NCT02311452||Complicated Appendicitis|
3245792|NCT01341327||Left Main disease|Consecutive patients with unprotected LMCA diseases at participating centers will be evaluated for the entry into the study.
3245793|NCT01341340|Experimental|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
3245794|NCT01341353|Active Comparator|Antiarrythmic Drugs|
3245795|NCT01341353|Experimental|ablation|
3245796|NCT01341366|Experimental|Fast-track perioperative program|
3245797|NCT01341366|Active Comparator|Traditional perioperative program|
3245798|NCT01341379|Experimental|N-carbamylglutamate (Carbaglu)|
3245799|NCT01341392|Experimental|CKD-501 0.5mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3356243|NCT02311465|Experimental|Palliative Care + Standard of Care|Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
3356244|NCT02311465|No Intervention|Standard of Care|Patients will receive standard care from their oncologist. An assessment of health related quality of life will be conducted at regular oncology clinic visits at baseline and 3,6,9,and 12 months.
3356245|NCT02311491|Experimental|Ceramic Coated Orthodontic Archwire|Ceramic coated orthodontic archwires will be evaluated in a limited clinical study at the university of North Carolina to test their efficacy in early and intermediate stages of tooth straightening in orthodontic patients.
3356246|NCT02311491|No Intervention|Control|The patients will receive the ordinary archwires. There is no intervention to the standard treatment.
3356247|NCT02311504||DiabCheck ophta OCTplus|persons with diabetes undergoing OCT examination
3356248|NCT02311517|Experimental|ropivacaine group|45 patients will be randomly allocated into ropivacaine group with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia.
3356249|NCT02311517|Placebo Comparator|saline group|40 patients are randomly allocated into saline group with 0.4 ml/kg saline after induction of anesthesia.
3356250|NCT02311530|Experimental|Test|Felodipine Extended Release Tablets USP 10 mg
3356251|NCT02311530|Active Comparator|Reference|Plendil® Extended release tablets 10 mg
3356252|NCT02311543|No Intervention|Arm A: no TachoSil®|After axillary lymph node dissection no surgical sealing patch (TachoSil®) is applied.
3356253|NCT02311543|Active Comparator|Arm B: TachoSil®|After axillary lymph node dissection, 3 large TachoSil® patches in the dissected axilla are positioned to cover as much of the axillary walls as possible.
3356254|NCT02311556|Experimental|DSC-PMR|DSC-PMR (dynamic susceptibility-weighted contrast- enhanced perfusion magnetic resonance imaging) at baseline (screening or time of radiosurgery) and after radiosurgery
3356255|NCT02311569|Experimental|Arm Mirabegron|Mirabegron treatment of at least 24 weeks with an initial dose of 25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
3356256|NCT02311582|Experimental|Phase I: MK-3475 + MLA|-In the phase I portion of this study, MK-3475 will be given every 3 weeks starting no more than 1 week after MLA until progression or unacceptable toxicity.
3356257|NCT02311582|Experimental|Phase II: MK-3475 Only (Arm B)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks beginning 3 weeks after surgical debulking or no more than 1 week after biopsy (if no debulking)~The phase II dose was determined during the Phase I portion of the study. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will only be performed when clinically warranted."
3356258|NCT02311582|Experimental|Phase II: MK-3475 + MLA (Arm A)|"In the phase II portion of this study, MK-3475 will be given every 3 weeks no more than 1 week after MLA, or no more than 1 week after biopsy (if no debulking).~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~--For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
3356259|NCT02311582|Experimental|Phase II (after amendment #12): MK-3475 + MLA|"After amendment 12, all patients will be enrolled in this arm~MK-3475 will be given every 3 weeks no more than 1 week after MLA~The phase II dose will be determined during the phase I portion of this study and is 200 mg. Patients enrolling in phase II will need to have tissue available for diagnostic purpose and for immunological monitoring.~Surgical resection/debulking is per standard of care and optional for the purpose of this study and the performing neurosurgeon will determine whether each patient will undergo surgery.~For those not undergoing surgical resection/debulking, a biopsy for tissue diagnosis and immune monitoring will be performed during MLA~MLA will take place at least 3 weeks but not more than 6 weeks after surgical resection/debulking or if no surgical resection/debulking will start on day 1"
3356260|NCT02311595|Experimental|reduced port|gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
3245800|NCT01341392|Experimental|CKD-501 Amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3245801|NCT01341392|Experimental|Amlodipine 10mg|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
3245802|NCT01341405|Experimental|CG100649 2 mg|capsule, once daily
3245803|NCT01341405|Experimental|CG100649 4 mg|capsule, 4 mg, once daily for 28 days
3245804|NCT01341405|Active Comparator|celecoxib 200 mg|capsule, once daily
3245805|NCT01341418|Active Comparator|Suprapatellar approach|surgical approach for intramedullary nailing of the tibia
3245806|NCT01341418|Active Comparator|Infrapatellar approach|surgical approach for intramedullary nailing of the tibia
3245807|NCT01341431|Experimental|bee venom|
3245808|NCT01341431|Placebo Comparator|saline|
3245809|NCT01341496|Experimental|1|autologous tumor vaccine plus chemotherapy
3245810|NCT01341509|Active Comparator|FHL tendon transferred|Surgical group in which the FHL tendon was transferred
3245811|NCT01341509|Active Comparator|FHL tendon not transferred|
3356261|NCT02311608||High Dose Somatostatin/Octreotide|continuous IV infusion of 500μg/h of Somatostatin or continuous IV infusion of 50μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3356262|NCT02311608||Terlipressin as salvage|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3356263|NCT02311608||Terlipr+usual dose somato/Octreo|an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h together with continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide when usual somatostatin or Octreotide dose fails to achieve hemostasis of acute variceal bleeding patients
3356264|NCT02311608||Control:Usual Dose Somato/Octreo|Hemostasis achieved by continuous IV infusion of 250μg/h of Somatostatin or continuous IV infusion of 25μg/h of Octreotide
3356265|NCT02311608||Control: Initial Terlipressin|Hemostasis achieved by an initial injection of 2mg of Terlipressin followed by an injection of 1mg of Terlipressin per 6h
3356269|NCT02311634|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.0 Hz and a moderate intensity (25~35 mA); 60 minutes three times a week for a total of three weeks
3356270|NCT02311634|Active Comparator|Transvaginal ES|At a current intensity of < 60 mA (in 5% increments from 0 mA to the intensity that is sensed without obvious discomfort) and frequencies of 12.5 to 30 Hz, 45 min three times a week for a total of four weeks.
3356271|NCT02311647||Post Tamoxifen exposure group|Breast cancer patients receiving or formerly received Tamoxifen for at least 1 year.
3356272|NCT02311647||Control group|Breast cancer patients who did not receive endocrine treatment
3356273|NCT02311660|Experimental|vagus nerve stimulation|Patients will have an implanted vagus nerve stimulation device.
3356274|NCT02311673|Active Comparator|RM-493 Once Daily Dose 1|Dose 1 once daily in the morning
3356275|NCT02311673|Active Comparator|RM-493 Once Daily Dose 2|Dose 2 once daily in the morning
3356276|NCT02311673|Placebo Comparator|Placebo|Placebo in the morning
3356277|NCT02311686|Experimental|10 g ethanol|Subjects will be required to drink a dilution of 31 mL of vodka in 369 mL of lemon-flavored water in 15 minutes.
3245812|NCT01341522|Active Comparator|Control|Control
3245813|NCT01341522|Experimental|MRI|experimental
3245814|NCT01341535|Experimental|adaptive DPBN|"This patient group will be treated by adaptive dose-painting-by-numbers, while patients in the control arm will receive standard treatment.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
3245815|NCT01341535|Active Comparator|standard IMRT|"This patient group will be treated by standard intensity-modulated radiotherapy (IMRT), while patients in the experimental arm will receive adaptive dose-painting-by-numbers.~Patients will have a 50 % chance of being allocated to the experimental arm and a 50 % chance of being allocated to the control arm."
3245816|NCT01341548|Active Comparator|Civamide Nasal Solution 0.01%|
3245817|NCT01341548|Placebo Comparator|Vehicle Solution|
3356278|NCT02311686|Experimental|20 g ethanol|Subjects will be required to drink a dilution of 63 mL of vodka in 337 mL of lemon-flavored water in 15 minutes.
3356279|NCT02311686|Experimental|40 g ethanol|Subjects will be required to drink a dilution of 125 mL of vodka in 275 mL of lemon-flavored water in 15 minutes.
3356280|NCT02311686|Experimental|60 g ethanol|Subjects will be required to drink a dilution of 188 mL of vodka in 212 mL of lemon-flavored water in 15 minutes.
3356281|NCT02311686|Experimental|80 g ethanol|Subjects will be required to drink a dilution of 250 mL of vodka in 150 mL of lemon-flavored water in 15 minutes.
3245818|NCT01341561||weaning patients|
3245819|NCT01341613|Experimental|Cardioviva™ supplement capsule|
3245820|NCT01341613|Placebo Comparator|Placebo capsule|
3356282|NCT02311699|Experimental|Women Only|Groups of women will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by female facilitators.
3356283|NCT02311699|Experimental|Men Only|Groups of men will receive the behavioral intervention to reduce IPV and HIV. Sessions will be led by male facilitators.
3356284|NCT02311699|Experimental|Couples|Couples will receive the behavioural intervention to reduce IPV and HIV. Sessions will be led by a male and a female facilitator.
3356285|NCT02311699|No Intervention|Control Group|Community members in the control villages will receive a short informational session on violence reduction.
3356286|NCT02311712|Active Comparator|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
3356287|NCT02311712|No Intervention|Control|No intervention
3245821|NCT01341626|Experimental|Treatment Foster Care Oregon (TFCO)|Youth are placed individually in well-trained and supervised foster homes. Basic components include: (a) daily telephone contact with TFCO parents using the Parent Daily Report; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation.
3356288|NCT02311725|Experimental|aTAU + sTVi|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Storytelling Video Intervention (sTVi): We will develop a series of 4 videos, each episode approximately 30 minutes long, which will illustrate the key principles of Acceptance and Commitment Therapy.~In addition, we will develop an accompanying personal journal for participants that includes a brief self-help guide which encourages participants to write about what they learned in the videos and how they will take similar steps in their own lives to cope with depression."
3356289|NCT02311725|Active Comparator|aTAU + Attention Control Videos|"Antidepressant Treatment as Usual (aTAU): All participants will receive antidepressant treatment as usual provided by their primary care doctor during the study.~Attention Control Videos: Control participants will view videos about general mental health and well-being. Specifically, we plan to give participants 4 30-minute videos on topics including nutrition, stress reduction, movement and recreation, and becoming an educated patient. The series comes with an accompanying course guidebook. We will provide videos on the same schedule as sTVi."
3356290|NCT02311738|Experimental|High intensity training group|"HIE will consist of the following:~10 minute warm up at 70% of maximal heart rate.~4 minute exercise intervals at 90-95% of maximal heart rate.~4 minute interval bouts repeated 4 times.~Between each bouts there will be a 3 minute active recovery at 70% of maximal heart rate~After all four bouts are completed; 5 minute cool-down at 70% of maximal heart rate."
3356291|NCT02311738|Experimental|Moderate intensity training group|"MIE will consist of the following:~10 minute warm up at 50% of maximal heart rate.~35 minutes exercise at 70% of maximal heart rate.~4 minute cool-down at 50% of maximal heart rate."
3356292|NCT02311751|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 simulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left than right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3356293|NCT02311751|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3356294|NCT02311764|Experimental|Carboplatin|Carboplatin will be administered weekly
3356295|NCT02311777|Active Comparator|Pregabalin-ketamine|Pregabalin and ketamine will be given preoperative period
3356296|NCT02311777|Placebo Comparator|Placebo|Placebo will be given preoperative period
3356297|NCT02311790|Experimental|Trans-C16:1 supplement|Volunteers will take trans-C16:1 supplement for 3 weeks
3356298|NCT02311790|Experimental|Cis-C16:1 supplement|Volunteers will take cis-C16:1 supplement for 3 weeks
3356299|NCT02311803|Experimental|Preservation of Denonvilliers Fascia|Preservation of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3356300|NCT02311803|Active Comparator|Excision of Denonvilliers Fascia|Excision of Denonvilliers Fascia in Laparoscopy-assisted pelvic autonomic nerve preservation surgery for male mid-low rectal cancer patients
3356301|NCT02311816||Infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
3356302|NCT02311816||No infection|"Based on the microbiological results and clinical picture patients were grouped post hoc into infection and no infection groups by two independent experts (intensivist, infectologist) who were blinded for procalcitonin."
3356303|NCT02311829|Experimental|Telephone follow-up device (DST)|"An external independent clinical psychologist is responsible for calling regular the patient included in DST-arm.~Telephone follow-up device(DST) consists of telephone calls at 15 day, 2 month and then every 2 months until 12 months. The clinical psychologist is designed to inform the patient about its pathology, promote acceptance of diagnosis, support the patient in his approach to care encouraging psychiatric observation. The device does not replace psychiatric counseling recommended."
3356304|NCT02311829|No Intervention|Group control ; usual care|"- Usual care: After diagnosis of PNES: orientation psychiatric care or CMP liberal and meeting biannually with the neurologist~- For patients in both groups: in addition, quotation questionnaires of quality of life and evaluation by a neuropsychologist biannual for 24 months after the appointment with the neurologist."
3356305|NCT02311855|Other|Influenza vaccination|all patients are vaccinated per protocol
3356306|NCT02311868|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 day
3356307|NCT02311868|Placebo Comparator|Placebo|patients of this group received 5g of placebo 3 times a day for 30 days
3356308|NCT02311920|Experimental|Arm I (temozolomide and ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and then beginning 3 months after course 4 once every 3 months for 4 courses in the absence unacceptable toxicity.
3356309|NCT02311920|Experimental|Arm II (temozolomide and nivolumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 60 minutes once every 2 weeks for 16 weeks and then once every 2 weeks for 48 weeks in the absence unacceptable toxicity.
3356310|NCT02311920|Experimental|Arm III (temozolomide, nivolumab, ipilimumab)|Within 5 weeks after completion of chemoradiation, patients receive temozolomide PO on days 1-5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive ipilimumab IV over 90 minutes once every 4 weeks for 4 courses and nivolumab IV over 60 minutes once every 2 weeks for 64 weeks in the absence unacceptable toxicity.
3356311|NCT02311946|Experimental|Cohort 1|Cohort 1 will receive a 125 mg round yellow palbociclib tablet containing succinic acid
3356312|NCT02311946|Experimental|Cohort 2|Cohort 2 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet containing HMPC E3
3356313|NCT02311946|Experimental|Cohort 3|Cohort 3 will receive a 125 mg oval yellow palbociclib spray-dried dispersion tablet with HMPC E3 and succinic acid.
3356314|NCT02311946|Experimental|Cohort 4|Cohort 4 will receive a 125 mg oval white/yellow palbociclib bilayer tablet with tartaric and succinic acid.
3356315|NCT02311946|Experimental|Cohort 5|Cohort 5 will receive a 125 mg oval yellow palbociclib fluid bed granulation tablet with succinic acid.
3356316|NCT02311946|Experimental|Cohort 6|Cohort 6 will receive a 125 mg palbociclib oral solution
3356317|NCT02311959|Experimental|Invasive or in situ breast carcinoma.|
3356318|NCT02311985|Active Comparator|Coagulogram-based protocol|Arm based on standard coagulation tests protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
3356319|NCT02311985|Experimental|Thromboelastometry-based protocol|Arm based on rotational thromboelastometry (ROTEM(R)) protocol to guide blood transfusion before central venous catheterization. The possible components to be used include fresh frozen plasma, platelets (random or aphaeresis) and or cryoprecipitate.
3356320|NCT02311985|Experimental|Restrictive strategy|Arm based on a restrictive protocol strategy based on INR/PT and platelets count. The possible components to be used include fresh frozen plasma and/or platelets (random or aphaeresis).
3245822|NCT01341626|Active Comparator|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%).
3245823|NCT01341678|Other|Normal Phosphorus Diet|Diet containing 1500mg of phosphorus per day
3356321|NCT02311998|Experimental|Treatment (bosutinib, inotuzumab ozogamicin)|Patients receive bosutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Patients with confirmed CR, CRi, CCyR and/or absence of MRD may receive inotuzumab ozogamicin IV on day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3356322|NCT02312011|Experimental|IONIS-DMPKRx|"IONIS DMPKRx is administered subcutaneously over the course of 6 weeks for dose levels 1, 2, 3, 4, and 5.~IONIS DMPKRx is administered subcutaneously over the course of 12 weeks for dose levels 4 or 5."
3356323|NCT02312011|Placebo Comparator|Placebo|A placebo is administered subcutaneously over the course of 6 weeks. A placebo is administered subcutaneously over the course of 12 weeks.
3356324|NCT02312024||Patients with severe sepsis/septic shock|Use of CytoSorb adsorber in patients with severe sepsis/septic shock
3356325|NCT02312024||Cardiac surgery with CPB: preemptive use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: preemptive use
3245824|NCT01341678|Other|Restricted Phosphorus Diet|Diet containing 750mg of phosphorus per day and administration of a phosphate binder (lanthanum carbonate)
3245825|NCT01341678|Other|High Phosphorus Diet|Diet containing 3000mg of phosphorus per day and phosphorus supplementation (NeutraPhos)
3245826|NCT01341691|Placebo Comparator|Placebo 20mg|
3245827|NCT01341691|Active Comparator|K2CG 60 mg extender|
3245828|NCT01341691|Active Comparator|K2CG 60 mg|
3245829|NCT01341691|Active Comparator|K2CG 20mg extender|
3356326|NCT02312024||Cardiac surgery with CPB: postop. use|Use of CytoSorb adsorber in patients with cardiac surgery with CPB: postoperative use
3356327|NCT02312024||Patients with other indications|Use of CytoSorb adsorber in patients with other indications
3356328|NCT02312050|Experimental|GCS-100 1 mg|Dose level 1 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3356329|NCT02312050|Experimental|GCS-100 3 mg|Dose level 2 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3356330|NCT02312050|Experimental|GCS-100 9 mg|Dose level 3 - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3356331|NCT02312050|Placebo Comparator|Normal Saline Solution 0.9%|Placebo - administered via IV push injection weekly for 2 months, then every other week for an additional 4 months
3356332|NCT02312076|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
3245830|NCT01341691|Active Comparator|K2CG 20mg|
3245831|NCT01341691|Placebo Comparator|Placebo 60mg|
3245832|NCT01341704|Experimental|MSP3-LSP/AlOH|Synthetic polyprotein of 96 amino acids (186-276 in 3D7 strain) manufactured by solid-phase synthesis by SYNPROSIS, France; lyophilized product was formulated extemporaneously with aluminum hydroxide (Reheis). 30 microgram per dose; three dose schedule on study day 0, 28 and 56 for primary series
3245833|NCT01341704|Placebo Comparator|Control|Primary series: Verorab Rabies vaccine; Secondary/Booster series: 0.9% NaCL/Normal Saline
3245834|NCT01341717|Experimental|Sitagliptin along with metformin and insulin|
3245835|NCT01341717|Active Comparator|Glimepiride as an active comparator to Sitagliptin|
3245836|NCT01341743|Active Comparator|A|oral entecavir 1mg daily for 104 weeks
3245837|NCT01341743|Active Comparator|B|oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
3356333|NCT02312076|No Intervention|Control group|No GnRHa administration in luteal phase
3356334|NCT02312089|Active Comparator|GnRHa group|Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
3356335|NCT02312089|No Intervention|Control group|No GnRHa administration in luteal phase
3356336|NCT02312102|Experimental|Velcade and Lenalidomide|"Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.~Each treatment cycle lasts 28 days (4 weeks). The first two cycles are called the induction cycles. If the participant respond to treatment during the first two cycles, they can continue on to the maintenance cycles.~During the induction and maintenance cycles, patients receive up to the MTD of lenalidomide on days 1-21 days only. During days 22-28 (4th week) there is a rest period.~Bortezomib: During the induction cycles, the medication will be given on days 2, 5, 9, and 12 followed by a 17-day rest period. During the maintenance cycles, bortezomib will be given on days 2, and 5 followed by 23-day rest period."
3356337|NCT02312115|Active Comparator|Furosemide|Patients assigned to the furosemide infusion group will receive furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al. (2007) and the SPARK study protocol (Bagshaw et al. 2010). Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline reaching a concentration of 4 mg/mL. All medication and placebo bags will have no identifiers that show what type of drug is being administered, for blinding purposes. Medication and placebo bags will have randomly generated study identifier numbers. The protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the manufacturer.
3356338|NCT02312115|Placebo Comparator|Saline|All patients assigned to the saline group will receive saline that is equal in volume as compared to the treatment group. The amount of saline given to the patients in the placebo arm is so small that its effect on these patients is negligible. All other aspects of care for the enrolled patient will be managed per primary team and any consultants.
3356339|NCT02312128|Active Comparator|Early Mobilisation|"receives a removable plastic cast for one week and is allowed to move the wrist directly postoperative.~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
3356340|NCT02312128|Active Comparator|Cast Group|"receives a non removable cast for 5 weeks~Interventions:~Range of Motion measurement (ROM),~Grip strength measurement,~VAS Score according to the visual analogue scale ().~Questionnaire: PRWE Score, DASH Score and Mayo Wrist Score.~X- Rays in two planes.~Follow-up: 6., 9., 12. postoperative week, a half and one year after surgery"
3356341|NCT02312167|Experimental|confocal laser endomicroscopy|confocal laser endomicroscopy : 10 to 15 minutes endomicroscopy procedure to obtain real time microscopical images of healthy and malignant tissue of the targeted organs
3356342|NCT02312180|Experimental|Cohort 1|low dose group of 2 mg/kg Plasminogen (Human) Intravenous
3356343|NCT02312180|Experimental|Cohort 2|mid-dose group of 6 mg/kg Plasminogen (Human) Intravenous
3356346|NCT02312232|Experimental|Levodopa formulation A|Levodopa formulation A together with ODM-104 100 mg and carbidopa
3356347|NCT02312232|Experimental|levodopa formulation B|levodopa formulation B together with ODM-104 100 mg and carbidopa
3356348|NCT02312232|Experimental|levodopa formulation C|levodopa formulation C together with ODM-104 100 mg and carbidopa
3356349|NCT02312232|Active Comparator|Sinemet IR 100/25 mg|Sinemet IR 100/25 mg together with ODM-104 100 mg
3356350|NCT02312232|Active Comparator|Half Sinemet CR 100/25 mg|Half Sinemet CR 100/25 mg together with ODM-104 100 mg
3356351|NCT02312245|Experimental|Arm A (Avatar-directed paclitaxel)|Patients receive paclitaxel IV over 1-96 hours on days 1, 8, and 15. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
3356352|NCT02312245|Experimental|Arm B (Avatar-directed gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3356353|NCT02312245|Experimental|Arm C (Avatar-directed liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1. Patients may also receive bevacizumab IV over 90 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3356354|NCT02312245|Experimental|Arm D (Avatar-directed topotecan hydrochloride)|Patients receive topotecan hydrochloride IV over 30 minutes on days 1-5 every 21 days or days 1, 8, and 15 every 28 days. Patients may also receive bevacizumab IV over 90 minutes on day 1 every 21 days or days 1 and 15 every 28 days. Courses repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
3356355|NCT02312271||enterally fed adults|adult subjects with established enteral access receiving standard tube feeding formula
3356356|NCT02312284||Radiotherapy/Chemoradiotherapy|Pre- or postoperative or palliative radiotherapy/chemoradiotherapy based on 5-fluorouracil or Capecitabine +/-Oxaliplatin
3356357|NCT02312284||Surgery|Transabdominal resection or transanal excision
3356358|NCT02312284||Chemotherapy|Pre- or postoperative chemotherapy including 5-fluorouracil/leucovorin with oxaliplatin, Capecitabine, etc
3245838|NCT01341743|Active Comparator|C|oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
3245839|NCT01341756|Experimental|Radiotherapy for gastric cancer|Single arm study
3245840|NCT01341769|Placebo Comparator|Control Test Food|Snack base
3245841|NCT01341769|Experimental|Experimental Test Food 1|Snack Base containing ingredient 1
3245842|NCT01341769|Experimental|Experimental Test Food 2|Snack base containing ingredient 2
3245843|NCT01341769|Experimental|Experimental Test Food 3|Snack base containing ingredients 1 and 2
3245844|NCT01341808|Experimental|IBD patients|"Patients diagnosed with IBD~-> receive Epaxal Berna (virosomal hepatitis A vaccine)"
3245845|NCT01341834|Experimental|LBH589-RAD001|LBH589-RAD001, single arm dose finding study
3356359|NCT02312297|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
3245846|NCT01341847|Active Comparator|Water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of the colonoscope during insertion since the scope is inserted into the anus until reach the cecum. Water will be infused as needed under endoscopist judgement through the adaptor on biopsy channel with endoscopic washer pump. The usual air insufflation will be used during colonoscope withdrawal to facilitate mucosal examination and perform any other intervention, such as biopsy
3245847|NCT01341847|Other|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
3245848|NCT01341860||controls|control group with a BMI of less thatn 25kg/m2
3245849|NCT01341860||obese group|Obese patients with BMI 25-30 kg/m2
3356360|NCT02312297|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
3356361|NCT02312323|Experimental|Definitive 65 HPT|The Test product were the Definitive 65 (Filcon V4) lenses with Hydra PEG surface coating. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
3356362|NCT02312323|Active Comparator|Definitive 65|The Control product was the commercially available Definitive 65 (Efrofilcon A) lens. This material is produced by Contamac Ltd. and the contact lenses were manufactured by Appenzeller Kontaktlinsen AG.
3356363|NCT02312336|Placebo Comparator|Cohort A|Cohort A - Room temperature coronary perfusate
3245850|NCT01341873|Experimental|Group I (FCI)|FCs receive 4 sessions of an APN FCI beginning during the admission for transplant and continuing for up to 100 days after transplant.
3245851|NCT01341873|Other|Group II (control)|FCs receive standard supportive care.
3245852|NCT01341886|Active Comparator|metformin|patients who receive metformin in addition to levothyroxine
3245853|NCT01341886|Placebo Comparator|levothyroxine|patients who receive only levothyroxine
3245854|NCT01341899|Experimental|stem cell transplantation|
3356364|NCT02312336|Active Comparator|Cohort B|Cohort B - Cooled coronary perfusate
3356365|NCT02312362|Experimental|Combined sclerotomy ab interno and phaco|Combined sclerotomy ab interno and phacoemulsification with IOL implantation
3356366|NCT02312362|Active Comparator|Phacoemulsification with IOL implantation|Phacoemulsification with IOL implantation
3245855|NCT01341925|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
3245856|NCT01341925|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3245857|NCT01341925|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
3356367|NCT02312375|Experimental|Fimasartan|Expreimental drug is fimasartan.
3356368|NCT02312375|Active Comparator|Amlodipine|Active comparator is amlodipine.
3356369|NCT02312388|Experimental|Catheter-over-the-needle technique|to use the 22G angiocatheter for central venous catheterization
3356370|NCT02312388|Experimental|Thin-wall needle technique|to use the sharp hollow 23G needle for central venous catheterization
3356372|NCT02312414|No Intervention|IVIR|Patients given IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 1 to week 4
3356373|NCT02312414|Experimental|IVIR Carnitine|Patients given Carnitine (20mg/kg, IV) perior to IV iron (Sodium ferric gluconate, [125 mg/100 ml] from week 4 to week 8.
3356374|NCT02312427|Experimental|Outpatient arm|After baseline data collection, DPP-4 inhibitor will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
3245858|NCT01341925|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3356375|NCT02312427|Experimental|Hospitalization arm 1|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
3356376|NCT02312427|Experimental|Hospitalization arm 2|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
3245859|NCT01341938|Active Comparator|Lozenge Self Help: self help materials & lozenge NRT.|Self-help materials + Commit® nicotine lozenges (4 mg)
3245860|NCT01341938|Experimental|Lozenge Assisted Self-help: lozenge NRT, phone counseling, & self help materials|Self-help materials + Commit® nicotine lozenges (4 mg) + Phone counseling
3245861|NCT01341938|Experimental|Assisted Self-Help: self-help materials & phone counseling without lozenges|Self-help materials + Phone counseling
3245862|NCT01341951|Experimental|G-CSF therapy in acute liver failure and alcoholic hepatitis|G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis
3245863|NCT01341964|Experimental|Higher dose aspirin group|Clopidogrel 600 mg plus aspirin 325mg
3245864|NCT01341964|Active Comparator|Low dose aspirin group|Clopidogrel 600mg plus aspirin 81mg
3356377|NCT02312440|Placebo Comparator|Group1|60 Milliliters（ml）Normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
3356378|NCT02312440|Experimental|Group2|two-dose intravenous tranexamic acid will be applied as follow: 10mg/kg of Tranexamic Acid in 100 Milliliters（ml) normal saline (0.9% sodium chloride),the first dose 15' prior to skin incision and the second dose at 180' after the first dosage.
3356379|NCT02312440|Experimental|Group 3|3g Tranexamic Acid diluted to 60 Milliliters（ml） with normal saline (0.9% sodium chloride) will be applied by soaking the hip cavity for at least 3 minutes before wound closure and then sucked away.
3245865|NCT01342003||Subtype 1a|subtype 1a patients treated with peginterferon plus ribavirin
3245866|NCT01342003||subtype 1b|subtype 1b patients treated with peginterferon plus ribavirin
3356380|NCT02312453|Experimental|Posterior approach|All patients were given a single shot ultrasound-guided posterior parasagittal in-plane approach infraclavicular brachial plexus block under aseptic technique. The blocks were performed using a 21G, 100 mm insulated short bevel needle (Stimuplex A, B Braun, Melsungen, Germany) without nerve stimulation. A 25-ml local anaesthetic admixture [Lignocaine 2% (100mg) plus Ropivacaine 0.75% (150mg)] was administered. We used an ultrasound machine (Sonosite M-Turbo; Sonosite®, Bothell, WA, USA) with HFL38x/ 13-6 MHz linear transducer probe.
3356381|NCT02312466||School aged children|
3245867|NCT01342016|Experimental|tacrolimus group|tacrolimus capsule + leflunomide placebo
3245868|NCT01342016|Active Comparator|leflunomide group|tacrolimus placebo + leflunomide tablet
3245869|NCT01342042|Active Comparator|Metformin|
3245870|NCT01342042|Active Comparator|exenatide-4|
3356382|NCT02312466||Pregnant women|
3356383|NCT02312466||Women of reproductive age|
3245871|NCT01342055|Experimental|Group 1 : Megace 800mg - Apetrol ES 650mg - Apetrol ES 675mg|
3356384|NCT02312479|Experimental|Nyxoah SAT therapy|
3356385|NCT02312492|Experimental|18:1 diet|Oleic Diet - volunteers will consume oleic enriched food for a period of 5 weeks.
3356386|NCT02312492|Experimental|16:0 diet|Palmitic diet - Volunteers will consume palmitic enriched food for a period of 5 weeks.
3356387|NCT02312492|Experimental|18:0|Stearic Diet - Volunteers will receive Stearic enriched food for a period of 5 weeks.
3356388|NCT02312505|Other|COPFX|cardiac output by PulsioFlex® Monitoring system (COPFX)
3356389|NCT02312518|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
3356390|NCT02312518|Other|Usual and Customary Practice|usual and customary practice
3356391|NCT02312531|Experimental|HBIG group|Mothers in HBIG group received 'Hepatitis B immunoglobulin' (HBIG 200 IU, S20023028, Hualan Biological Engineering Inc.) injection at gestational weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40.
3356392|NCT02312531|No Intervention|Control group|Mothers in control group had no HBIG injection during pregnancy.
3356393|NCT02312544|Active Comparator|OTX-TP treatment|OTX-TP (sustained release travoprost, 0.36 mg) to be used in this trial with placebo drops administered separately
3356394|NCT02312544|Active Comparator|Timolol control|Timolol Maleate Ophthalmic Solution, 0.5% dosed twice daily (BID) in the presence of a placebo vehicle punctum plug (PV).
3245872|NCT01342055|Experimental|Group 2 : Apetrol ES 650mg - Apetrol ES 675mg -Megace 800mg|
3245873|NCT01342055|Experimental|Group 4: Megace 800mg - Apetrol ES 675mg - Apetrol ES 650mg|
3356395|NCT02312570|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
3245874|NCT01342055|Experimental|Group 5: Apetrol ES 650mg - Megace 800mg - Apetrol ES 675mg|
3356396|NCT02312570|Other|Usual and Customary Practice|Usual and customary practice for non-healing pressure wounds
3356397|NCT02312583|Sham Comparator|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment.
3245875|NCT01342055|Experimental|Group 3: Apetrol ES 675mg - Apetrol ES 650mg - Megace 800mg|
3356398|NCT02312583|Experimental|iFightDepression online programme.|iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
3356399|NCT02312596|Experimental|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix
3356400|NCT02312596|Active Comparator|Usual and customary practice|Usual and customary practice
3245876|NCT01342055|Experimental|Group 6 : Apetrol ES 675mg - Megace 800mg - Apetrol ES 650mg|
3245877|NCT01342120||Quetiapine|Quetipine users
3245878|NCT01342120||All other atypical antipsychotics|All other atypical antipsychotics users
3245879|NCT01342120||Risperidone|Risperidone users
3245880|NCT01342120||Olanzapine|Olanzapine users
3245881|NCT01342133||Newborns|
3245882|NCT01342133||Mothers|
3245883|NCT01342159|Active Comparator|Intravitreal bevacizumab injection|
3245884|NCT01342159|Active Comparator|Intravitreal Triamcinolone injection|
3245885|NCT01342159|Active Comparator|intravitreal bavacizumab with triamcinolone|
3245886|NCT01342185|Experimental|Medical ozone therapy with tianyi|
3245887|NCT01342185|Active Comparator|medical ozone therapy with humares|
3245888|NCT01342185|Placebo Comparator|Diammonium glycyrrhizinate Capsules|
3245889|NCT01342198|Experimental|1|Single Dose Pregabalin Controlled Release
3245890|NCT01342198|Experimental|2|Single Dose Pregabalin Controlled Release with Multiple Doses of Erythromycin
3245891|NCT01342224|Experimental|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine.
3245892|NCT01342237|Experimental|topotecan|
3245893|NCT01342250|Experimental|Conventional plus hUC-MSCs treatment (low dose)|
3245894|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （medium dose）|
3245895|NCT01342250|Experimental|conventional therapy plus hUC-MSCs treatment （high dose）|
3245896|NCT01342263|No Intervention|Usual Care|Does not get to participate in the interactive chronic disease website.
3356401|NCT02312609|Experimental|Test|Minocycline hydrochloride extended release tablets 135 mg
3245897|NCT01342263|Experimental|iCDM|The iCDM will support patient self-management through collaborative planning and goal setting, education and skill development, support for behaviour change, and regular patient monitoring with follow-up. For each chronic condition, we have outlined sample patient signs and symptoms to be monitored, frequency of patient provider contact and frequency of patient prompt questions on their condition. The main premise of the iCDM is that only those patients who generate 'alerts' will be contacted by the iCDM nurse allowing for the potential to manage more patients than through traditional means of required patient follow-up regardless of patient condition . Across these five diseases are the following cross-cutting features: nutrition therapy, exercise therapy, psychological support, medication adherence and smoking cessation.
3245898|NCT01342276|Experimental|vHFC|Patients will get to participate in the interactive heart failure website (vHFC).
3245899|NCT01342276|No Intervention|Usual Care|Patients will not get to participate in the interactive heart failure website (vHFC).
3245900|NCT01342289|Experimental|Tacrolimus 60|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 60 days.
3245901|NCT01342289|Experimental|Tacrolimus 90|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 90 days.
3356402|NCT02312609|Active Comparator|Reference|Solodyn Extended Release Tablets 135 mg
3356403|NCT02312635|Experimental|Cogmed + D-cycloserine|Partifcipants will receive 6 weeks of cogmed working memory training M-F for 45 min each day. Participants in this arm will also take drug Monday, Wednesday, Friday throughout 6 weeks.
3245902|NCT01342289|Experimental|Tacrolimus 120|Non-myeloablative bone marrow transplant with fludarabine, cyclophosphamide, total body irradiation conditioning regimen and cyclophosphamide, mycophenolate mofetil, and tacrolimus prophylaxis for graft-versus-host disease (GVHD). Tacrolimus was given for 120 days.
3245903|NCT01342302|Other|Couples Intervention|Single arm study design
3356404|NCT02312635|Placebo Comparator|Cogmed + Placebo|Participants will receive 6 weeks of cogmed training M-F and also take a placebo pill Monday, Wednesday, Friday throughout 6 week period.
3356405|NCT02312648|Active Comparator|Early mobilization Group|Patients will perform deep breaths (3 sets of 10 repetitions), once a day, for 30 minutes until 7th postoperative day. Non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.Early mobilization protocol consist of upper and lower (cycle ergometer) limb exercises, chair transfer, deambulation for 10 to 20 minutes, step exercise (six times).
3356406|NCT02312648|Other|Control Group - Respiratory exercise|Respiratory exercises with patient sitting in bed with a high headboard 45, the same breathing exercises will be held
3356407|NCT02312661|Experimental|Carboplatin / paclitaxel /metformin|Three-weekly cycles of carboplatin/paclitaxel chemotherapy in combination with metformin treatment
3245904|NCT01342315|Experimental|Active|Product 33525
3245905|NCT01342315|Experimental|Placebo|Product 33525 Placebo
3245906|NCT01342328|Placebo Comparator|Control|For this arm, the volunteer subject will receive a saline infusion during the sleep session.
3245907|NCT01342328|Experimental|Dexmedetomidine (DEX)|For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
3245908|NCT01342328|Experimental|Propofol|For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
3245909|NCT01342354|Experimental|Stereotactic Radiation|Escalating doses of SBRT in three doses over ten days.
3245910|NCT01342380||Seroquel|Participants who received Seroquel
3245911|NCT01342380||Pioglitazone|Participants who received pioglitazone
3245912|NCT01342432|Experimental|Balance reeducation plus exercise|exercises that challenge postural control are performed in addition to general exercises for stretch and strength of abdominal and paraspinal muscles
3245913|NCT01342432|Other|General exercise only|general exercise for stretch and strength of paraspinal and abdominal muscles
3245914|NCT01342497|Experimental|BBR-012|
3245915|NCT01342497|Placebo Comparator|Placebo|
3245916|NCT01342536|Experimental|lifestyle counseling (OHDC)|Oh Happy Day Class (OHDC) is a culturally-specific, 12-week cognitive behavioral group counseling intervention designed for African American adults experiencing depression
3245917|NCT01342536|Active Comparator|lifestyle counseling (CWD)|Coping with Depression Course (CWD) is a 8-week cognitive behavioral group counseling depression intervention
3245918|NCT01342562|Experimental|DXM-bupivacaine|
3245919|NCT01342562|Placebo Comparator|saline-bupivacaine|
3245920|NCT01342575|Experimental|Intra-operative maneuver group|
3245921|NCT01342588|Experimental|Electrical stimulation|Only arm of the study, the experimental
3245922|NCT01342601|Active Comparator|Ectoin products|
3245923|NCT01342601|Placebo Comparator|Placebo products|
3245924|NCT01342614|Active Comparator|Fosinopril group|Fosinopril group received fosinopril, 10mg, once per day.
3245925|NCT01342614|Experimental|Metformin group|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
3245926|NCT01342627|Experimental|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to protocol.~In case of disease progression Sorafenib administration will be discontinued."
3245927|NCT01342653|Experimental|NIPS plus HIPEC plus adjuvant chemotherapy|
3245928|NCT01342679|Experimental|dasatinib|
3245929|NCT01342692|Active Comparator|Azacitidine alone|
3245930|NCT01342692|Experimental|Azacitidine +Valproic acid|
3245931|NCT01342692|Experimental|Azacitidine +Lenalidomide|
3245932|NCT01342692|Experimental|Azacitidine + Idarubicine|
3245933|NCT01342705|Experimental|phlebotomy|
3356408|NCT02312674|Experimental|Intervention|Patient group which takes daily an adjusted amount of oral nutritional supplements through an intervention period of three months
3356409|NCT02312674|No Intervention|Control|Patients group which takes no oral nutritional supplements
3356410|NCT02312700|Experimental|Interactive empowerment (IEm) group|Intervention: Patients fill in the questionnaire online and their profile (obtained from their answers) is immediately sent to the physician
3356411|NCT02312700|Sham Comparator|Control|Intervention: Patients fill in the questionnaire online, but their profile (obtained from their answers) is not sent to the physician
3356412|NCT02312752|Other|Intra-epidermal stimulation|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
3245934|NCT01342705|No Intervention|control|
3245935|NCT01342718|Experimental|GJS/Duolac7S|GJS: Real herbal extract granule/Duolac7S: Real probiotics
3245936|NCT01342718|Placebo Comparator|GJS-P/Duolac7S|GJS-P: Placebo herbal extract granule/Duolac7S: Real probiotics
3245937|NCT01342718|Placebo Comparator|GJS/Duolac7S-P|GJS: Real herbal extract granule/Duolac7S-P: Placebo probiotics
3356413|NCT02312778|Experimental|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation is delivered to the subjects in the side lying position. The more restricted lumbar segment (mobility restriction) will be the target region for the manipulative procedure.
3356414|NCT02312778|No Intervention|Sham Manipulation|Control Group who receives a simulated manipulation.
3245938|NCT01342718|Placebo Comparator|GJS-P/Duolac7S-P|GJS-P: Placebo herbal extract granule/Duolac7S-P: Placebo probiotics
3245939|NCT01342731|Experimental|Tigecycline|Tigecycline 100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 d
3356415|NCT02312791||Palliative Patients|Inpatients evaluated for palliative radiation therapy.
3356416|NCT02312804|Experimental|Dose Escalation|To determine the MTD/RP2D of BGJ398 when combined with carboplatin and paclitaxel in subjects with locally advanced for metastatic solid tumors.
3245940|NCT01342744|Experimental|Metformin|Metformin (850mg) 1 tab oral twice a day
3245941|NCT01342744|Placebo Comparator|Placebo|Placebo 1 tab oral twice a day
3245942|NCT01342809|Experimental|Follow up|Close follow up from written guidelines, supervision provided.
3245943|NCT01342809|No Intervention|Usual Treatment|
3245944|NCT01342822||PROMUS Element™|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987)
3245945|NCT01342822||Xience™ Prime stent|All patients enrolled will be randomized 2:1 to receive the PROMUS Element™ stent (N=1987) versus the Xience™ Prime Stent (N=993).
3245946|NCT01342835|Active Comparator|drug: propofol|Drug:Propofol and sevoflurane The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
3245947|NCT01342835|Active Comparator|Sevoflurane group:sevoflurane|Drug:Sevoflurane and Propofol Mask induction is perform with sevoflurane (4-6%) follow by 1.5-2% sevoflurane in a 50:50 mixture of N2O and O2.
3245948|NCT01342861|Sham Comparator|Observational period|A first period of follow-up on the 400 patients was designed to survey and evaluate current nutrition administration policy
3245949|NCT01342861|Experimental|Intervention period|The second period of follow-up on the 400 patients was designed to evaluate the impacts of adding milky food to the breakfast and of educating health care professionals on the early detection of undernutrition.
3245950|NCT01342874||Inositol group|Inositol dietary exposure 4000 mg/day
3245951|NCT01342874||Control group|folic acid 400 mcg/day
3245952|NCT01342900|No Intervention|standard care|The data from the InSPectra Monitor in the Control group will be inaccessible for the Investigator since this is not a part of their daily medical practice
3245953|NCT01342900|Active Comparator|Treatment group,|The data given by the monitor will be available for the Investigator and used to apply the optimization protocol
3245954|NCT01342939||MODY2|Also called GCK (glucokinase) MODY. They have a specific mutation in the GCK gene.
3245955|NCT01342939||MODY3|Also called HNF1 alfa MODY. They have a specific mutation in the HNF1 alfa gene.
3245956|NCT01342939||Healthy control subjects|
3245957|NCT01342978||oropharyngeal cancer case|208 oropharyngeal cancer cases were enrolled
3245958|NCT01342978||partner or spouse of case|110 partners of patients with oropharyngeal cancer were enrolled
3245959|NCT01342978||control|A convenience group of 106 non-cancer controls were enrolled at some study sites at cancer screening events
3245960|NCT01342991|Active Comparator|Milligan-Morgan Haemorrhoidectomy|Control arm
3245961|NCT01342991|Experimental|Laser Haemorrhoidectomy|This new method of haemorrhoidectomy is being compared to the standard Milligan-Morgan Haemorrhoidectomy.
3245962|NCT01343017|Other|Increased tidal volume (IVT)|In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
3245963|NCT01343017|Other|Normal tidal volume (NVT), with PEEP|In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
3245964|NCT01343030||Patients with implants|Patients with silicone implants and fat grafting.
3245965|NCT01343069|No Intervention|before surgical checklist|
3245966|NCT01343069|Active Comparator|after implementation surgical checklist|
3245967|NCT01343121|Other|sample collection|"This is a single arm study. Patients will be seen on day 1, 8, 15 and 22 and will have the following samples collected:~Pre gemcitabine urine sample~Blood sample 30 minutes post Gemcitabine infusion~Urine and blood sample 2 hours post Gemcitabine infusion"
3245968|NCT01343134||Retinal detachment cohort|
3356417|NCT02312804|Experimental|Expansion Cervical Cancer|To assess the anti-tumor effect of BGJ398 when combined with carboplatin and paclitaxel in cervix cancer.
3356418|NCT02312817|No Intervention|Group 1|Individuals randomized to Group 1 will receive usual medical care and will not be directly contacted at any point of the trial. Study data and outcomes will be abstracted from the EMR.
3356419|NCT02312817|Experimental|Group 2|Individuals randomized to Group 2 will receive mailed outreach invitation.
3356420|NCT02312817|Experimental|Group 3|Individuals randomized to Group 3 will receive mailed outreach invitation and patient navigation.
3356421|NCT02312843|Active Comparator|High-Intensity Program-aerobic exercises|This exercise program will consist of walking or running on a treadmill or elliptical trainer, or spinning on a stationary bicycle. The goal of the program will be for participants to exercise at a moderate to high level of intensity, defined as 70-80% (American College of Sports Medicine guidelines) of heart rate reserve (HRR), for 45-60 minutes 4 days per week. At the start of each training session and following a 5-minute warm-up, subjects will exercise at 50% HRR (0.5[HRmax-HRrest] +HRrest) and intensity will gradually be increased to the individualized target heart rate training zone. Exercise facilitators will use a pre-specified computerized program. This program provides guidelines for the individualized progression of exercise based on age and resting heart rate. Subjects will wear a digital heart rate monitoring device for the duration of the training session to ensure they are exercising safely at the specified level of intensity.
3356422|NCT02312843|Placebo Comparator|Low-intensity Program-Stretching|The low-intensity activity program will consist of an individualized and organized series of stretching and balance activities for the whole body, specifically designed for older adults. Consistent with the high-intensity protocol, subjects will complete the prescribed 45-60 minute stretching routine 4 days per week at the exercise facility. All stretching routines will include warm-up and cool-down activities, and will be within each subject's range of motion. Each stretch will be held for 20-30 s and repeated 5-10 times. Subjects will wear a digital heart rate monitoring device to ensure they are stretching safely and at an intensity below 35% HRR. The activity log completed during each stretching session will include HR, stretching duration, and mean HR during stretching. Subjects will also have the option to participate in structured pre-approved (by the exercise facilitator) stretching classes at the exercise facility when available.
3356423|NCT02312895|Experimental|Dry Needling|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive dry needling, patient education, and a home exercise program.
3356424|NCT02312895|Experimental|Manual Therapy|A total of 30 subjects will be randomized to this experimental arm. If randomized to this arm, subjects will receive manual therapy, patient education, and a home exercise program.
3356425|NCT02312908|Experimental|Clonazepam|Clonazepam 0.5 mg 1 Tablet by mouth, 1/day before sleeping for 4 weeks
3245969|NCT01343147|Other|Deep hyperthermia|Microwave diathermy
3245970|NCT01343147|Other|Superficial hyperthermia|Hot packs
3245971|NCT01343173|Experimental|Patients|
3356426|NCT02312908|Placebo Comparator|Placebo|Placebo 1 Tablet by mouth, 1/day before sleeping for 4 weeks
3356427|NCT02312921||PREDICT|"Delivery system changes where a team of dental providers (dentists, dental hygienists, case managers, community outreach workers and others) within Advantage Dental Services, LLC provide evidence-based screening, risk assessment and primary and secondary preventive care in non-conventional community settings (WIC, Head Start and similar settings) and seamless, timely and appropriate evidence-based care in dental clinics.~Payment plan model based on global budgeting and Alternative Quality Contract (pay-for-performance) for dental providers within Advantage Dental Services, LLC (Advantage) with the goal of incentivizing implementation of delivery system changes aimed at reducing disparities in dental care utilization and oral health for low-income mothers and children.."
3356428|NCT02312921||Control|Usual care
3356429|NCT02312947|Active Comparator|coblation|coblation adenoidectomy
3356430|NCT02312947|Active Comparator|cold dissection|cold dissection adenoidectomy
3356431|NCT02312973|Experimental|Arm 1|Single oral dose of 75 mg molidustat (fasted) in subjects on hemodialysis (at start of hemodialysis and on a hemodialysis free day,respectively)
3245972|NCT01343186|Other|Arm 1|
3245973|NCT01343186|Other|Arm 2|
3245974|NCT01343186|Other|Arm 3|
3356432|NCT02312973|Experimental|Arm 2|Single oral dose of 75 mg molidustat (fasted) in subjects on peritoneal dialysis (after start of peritoneal dialysis intervall and, optionally, after the start of a peritoneal dialysis-free intervall,respectively)
3356433|NCT02312973|Experimental|Arm 3|Single oral dose of 75 mg molidustat (fasted) in healthy subjects
3245975|NCT01343186|Other|Arm 4|
3245976|NCT01343212||newly diagnosed HCC|"Subjects with newly diagnosed untreated hepatocellular carcinoma (HCC) will be enrolled.~Subjects with the following conditions will be excluded:~liver cancer other than HCC, treated HCC, post major abdominal surgery, contraindications to liver tumor biopsy, contraindications to local percutaneous treatment of liver tumors, low quality ARFI measurement"
3245977|NCT01343225|Active Comparator|atripla|comparator
3245978|NCT01343225|Experimental|darunavir ritonavir raltegravir|experimental
3245979|NCT01343238|Experimental|Diet|12 week diet modification intervention by dietician
3245980|NCT01343238|Experimental|Exercise|12 week physical exercise modification intervention by physical therapist
3245981|NCT01343238|Experimental|Diet and Exercise|12 week diet and exercise behavioral modification by dietician and physical therapist
3245982|NCT01343238|No Intervention|Control|Standard procedure
3245983|NCT01343290|Experimental|001|Canagliflozin Type = 1 unit = mg number = 300 form = tablet route = oral use. Single tablet taken with or without a meal during 2 treatment periods
3245984|NCT01343303|Experimental|001|JNJ-39439335 2 x 5 mg tablets once daily for 21 days
3245985|NCT01343303|Experimental|002|JNJ-39439335 2 x 25 mg tablets once daily for 21 days
3245986|NCT01343303|Other|003|Naproxen 500 mg capsule every 12 hours for 21 days
3356434|NCT02312999|Experimental|Volulyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of volulyte.
3356435|NCT02312999|Active Comparator|Plasma-Lyte|A baseline crystalloid infusion (plasmalyte®) will be set by the attending physician at 3 cc/kg/hr (standard patient care) for each of the randomized groups. The patient will receive fluid management via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to standardize the way fluids are administered intra-operatively and eliminate variation between clinical providers. The liquid perfused will be bolus amounts of plasma-lyte.
3356436|NCT02313012|Experimental|Dose Level 1 CC-90003|CC-90003 by mouth (PO) daily on days 1 -21 of every 28 day cycle; Cycle 1, Days 1 to 28 will constitute the dose limiting toxicity (DLT) assessment period for purposes of non-tolerated dose (NTD) and Maximum Tolerated Dose determination.
3356437|NCT02313025|Experimental|Speech sound intervention|This group receives a speech sound and phonemic awareness intervention for four months.
3356438|NCT02313025|Active Comparator|World-project|This group receives the WORLD intervention for four months.
3356439|NCT02313051|Experimental|Everolimus arm|Everolimus+letrozole
3356440|NCT02313051|Active Comparator|Controll arm|letrozole alone, and when progress, followed by everolimus
3356441|NCT02313064|Active Comparator|CXA-10|single dose of CXA-10 oral formulation
3356442|NCT02313064|Placebo Comparator|CXA-10 placebo|single oral doses of CXA-10 placebo
3356443|NCT02313077|Experimental|Group 1|Participants will receive MVA-BN-filo/ Ad26.ZEBOV (Day 1 /Day 29) or Placebo (Day 1/Day 29).
3356444|NCT02313077|Experimental|Group 2|Participants will receive MVA-BN-filo/Ad26.ZEBOV (Day 1 /Day 57) or placebo ( Day 1/Day 57).
3356445|NCT02313077|Experimental|Group 3|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 29) or placebo (Day 1/Day 29).
3356446|NCT02313077|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 57) or placebo (Day 1/Day 57).
3356447|NCT02313077|Experimental|Group 5|Participants will receive Ad26.ZEBOV/ MVA-BN-filo (Day 1/Day 15).
3356448|NCT02313090|Experimental|Welltang|patients using Welltang
3356449|NCT02313090|No Intervention|usual standard care|patients under usual standard of diabetic care
3356450|NCT02313103|Other|Lofexidine HCl|End Stage Renal Disease (ESRD) subjects will be dosed with 400 micrograms of lofexidine HCl with 240 mL water after their hemodialysis session.
3356451|NCT02313103|Other|Matched Control|normal renal function subjects (enrolled to match each End Stage Renal Disease subject) will be dosed with 400 micrograms of lofexidine HCl with 240 mL water at the same clock time as ESRD subjects.
3356452|NCT02313129||Rheumatoid Arthritis|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history and detailed menstrual history. They will also have a physical exam and blood tests.
3356453|NCT02313129||Healthy Controls|This group will complete questionnaires related to prior pregnancies, intentions and goals for childbearing, fertility history detailed menstrual history, and blood tests.
3356454|NCT02313142|Experimental|Subjects|
3245987|NCT01343303|Placebo Comparator|004|Placebo Placebo tablet/capsule every 12 hours for 21 days
3356455|NCT02313168||1|preoperative FRONT score
3356456|NCT02313168||2|intraoperative FRONT score
3245988|NCT01343316||Transgastric tube|Nasogastric (NG tube)
3245989|NCT01343316||Transpyloric tube - Tiger2|Self-propelled by paristaltic waves of the stomach
3356457|NCT02313181|Experimental|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
3356458|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise instructed by a health care provider
3356459|NCT02313207|Active Comparator|FODMAP diet|FODMAP diet for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
3356460|NCT02313207|Active Comparator|Specific bread diet|Specific bread diet eliminating wheat and yeast for 2 weeks, patients will undergo a specific FODMAP diet for a period of 2 weeks.
3245990|NCT01343316||Transpyloric tube - Syncro BlueTube|Magnetically placed
3245991|NCT01343329|Experimental|Subjects Receiving Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment.
3245992|NCT01343329|Active Comparator|Subjects receiving Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
3245993|NCT01343342|Experimental|capsules omega-3|Omega-3 supplementation (3g EPA+DHA/d)
3245994|NCT01343381|Active Comparator|Hepalean Heparin|
3356461|NCT02313220|Experimental|Dapagliflozin and exenatide|Dapagliflozin 10 mg film-coated tablet once daily and exenatide 2 mg once weekly injection combined treatment for 24 weeks
3356462|NCT02313220|Placebo Comparator|Placebo|Placebo film-coated tablet once daily and placebo once weekly injection combined treatment for 24 weeks
3356463|NCT02313246|Experimental|Group Cognitive Behaviour Therapy|Patients will complete an 11-session group cognitive behaviour therapy for IBS that will be led by two clinicians, one of whom will be a registered clinical psychologist, at the Digestive Diseases Clinic at McMaster University Medical Centre. The group cognitive behaviour therapy will include weekly 2-hour sessions for 11 weeks. Sessions will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
3245995|NCT01343381|Active Comparator|PPC Heparin|
3245996|NCT01343394|Experimental|Biologic; Autologous Cell Injection|
3245997|NCT01343420|Active Comparator|Dog Hair Extract, ALK-Abelló, Inc.|
3245998|NCT01343433||Control group|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. Patients in the other two rooms are only exposed to environmental light
3245999|NCT01343433||Treatment group (bright light therapy)|Chamber allocation will determine which patient receives bright light therapy. We selected four patient chambers at the Intensive Care Unit, each with the capacity of two patient beds. In two chambers patients will receive bright light therapy. During our study, light therapy will be applied with instrument 'Litepod' (manufactured by Goodlite, Donker Curtiusstraat 7/407, Amsterdam), which gives an intensity of 10000 lux at a distance of 22 centimetres.Patients will receive bright light therapy for three hours in the morning, from eight o'clock till eleven o'clock.
3246000|NCT01343446||Patients with Diabetes|Patients with diabetes suffer from sleep impairment or not
3356464|NCT02313259||AMD controls|15 patients with early to intermediate AMD (grade 2-8) were enrolled using the Age-Related Eye Disease Study (AREDS) severity scale for AMD.
3356465|NCT02313259||Age-matched controls|15 drivers without ocular disease.
3356466|NCT02313259||Young controls|15 drivers without ocular disease. Between 18 and 25 years old.
3356467|NCT02313259||Glaucoma patients|15 patients having a Humphrey visual field mean deviation between -10 and -12 (better eye).
3356468|NCT02313272|Experimental|HFSRT with Pembrolizumab and Bevacizumab|Hypofractionated Stereotactic Irradiation (HFSRT). Pembrolizumab intravenous (IV) infusion every 3 weeks. Bevacizumab administered intravenously every 2 weeks.
3356469|NCT02313285||GZ402668|Patient who received GZ402668 in prior study (TDU13475 or TDU14981)
3356470|NCT02313285||Placebo|Patient who received placebo in prior study (TDU13475 or TDU14981)
3246002|NCT01343472|Experimental|WISP supervision|Parolee supervised under WISP parole model.
3246003|NCT01343472|Active Comparator|Parole-as-usual|Parolees supervised under Washington State's parole-as-usual
3246004|NCT01343498|Experimental|BEZ235|
3356471|NCT02313298|Experimental|Stereotactic Body Radiotherapy|An extreme hypofractionated regimen of 36.25Gy in 5 fractions over 10-11 days
3356472|NCT02313324|Experimental|ESWT group|The patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
3356473|NCT02313324|Active Comparator|SWD combined IFC group|The patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
3356474|NCT02313337|Experimental|Oral administration|-Oral administration of a mixture at preoperative 30 minutes : ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
3356475|NCT02313337|Experimental|Intramuscular injection|-At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
3356476|NCT02313337|Experimental|Rectal perfusion|-At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
3246005|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs treatment|Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
3246006|NCT01343511|Experimental|Rehabilitation plus hCB-MNCs and hUC-MSCs therapy|Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
3246007|NCT01343524||all subjects|all subjects who are enrolled in an industry-sponsored study that utilizes a sponsor-supplied spirometer.
3356477|NCT02313337|Experimental|Dripping nose|-At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
3356478|NCT02313350|Experimental|Chemonucleolysis with Discogel|Discogel® is a class III medical device (CE0459 mark on 28/09/2007) constituted by a radiopaque jellified ethanol. Discogel® is provided in a kit containing a 2 ml solution for injection with two disposable 1ml syringes. Discogel® chemonucleolysis for herniated disc-related sciatica is performed under local anesthesia. A volume of 0.9 ml of Discogel® is finally slowly injected during 10 to 15 minutes
3356479|NCT02313350|Active Comparator|Open discectomy|surgery : The comparator is open surgical discectomy. The procedure will be performed under general anesthesia. It will consist in removing the disc herniation after exposition and examination of the nerve root
3356480|NCT02313363|Experimental|PSDCS|using the patient-centered smartphone-based diabetes care system (PSDCS) for 12 weeks
3356481|NCT02313376|Experimental|GAP3KO|
3246008|NCT01343537|Experimental|Monitoring|
3246009|NCT01343550|Experimental|Creativity group for persons diagnosed with BPD|
3246010|NCT01343563|Active Comparator|Low frequency to High|For the first six weeks, subjects randomized to this group will receive low frequency stimulation. At the six week point, the low frequency group subjects will be crossed over to high frequency for the remaining six weeks.
3246011|NCT01343563|Active Comparator|High frequency|Subjects randomized to this group will receive high frequency stimulation for the entire 12 weeks of the first phase of this study.
3356482|NCT02313389|Experimental|maintenance chemotherapy|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
3356483|NCT02313389|No Intervention|observation|"Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.~Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months"
3356484|NCT02313402|Experimental|EOL (Eye On Line)|training program allowing a gradual acquisition of the eye-writing
3356485|NCT02313415|Experimental|UC-MSCs therapy|transplant collagen scaffold loaded with UC-MSCs to treat infertility caused by recurrent intrauterine adhesions
3356486|NCT02313428|Experimental|Standard of Care with Topical Oxygen Treatment|patients who have a chronic wound, will receive their receive standard treatment plus Topical Oxygen Therapy (Topical Oxygen Chamber for Extremities).
3356487|NCT02313428|No Intervention|Standard of Care only|patients that have a chronic wound will receive only their standard of care treatment.
3356488|NCT02313441|Active Comparator|RIPC (Remote Ischemic Pre-Conditioning)|Patients used RIPC had a blood pressure cuff placed around their upper arm at < 2 hours before the PCI procedure. The blood pressure cuff was inflated to for 5 minutes, followed by 5 minutes of deflation. This procedure was repeated 3 times
3356489|NCT02313441|Placebo Comparator|Control|Control participants did not experience this procedure of transient upper-limb ischemia.
3356490|NCT02313467|Active Comparator|1.5% Butenyl ALA|Topical application of 1.5% Butenyl ALA per every other day around acne lesions in the face
3356491|NCT02313467|Sham Comparator|Control|Topical application of sham control per every other day around acne lesions in the face
3356492|NCT02313480|Active Comparator|non-massage group|received exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
3356493|NCT02313480|Experimental|massage group|Received massage, exercise, manual therapy and advice over the 30 minute intervention period, in conjunction with an exercise program to perform at home.
3356494|NCT02313493|Experimental|Baby Triple P parent training group|The 8- session program delivered in four group sessions before birth and four telephone sessions after birth is developed for parents at the transition to parenthood or with a baby (up to 12 months of age).
3356495|NCT02313493|No Intervention|Care as usual control group|
3356496|NCT02313519|Placebo Comparator|Placebo|Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
3356497|NCT02313519|Active Comparator|Probiotics|Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
3356498|NCT02313545|Experimental|Experimental - IZN-6NVS Cream|Eligible women of 3 groups will be assigned to receive IZN-6NVS (IP) - 2.5 g of cream/day for the first 14 days, followed by 3 applications per week for the next 4 weeks.
3356499|NCT02313584|Active Comparator|Short Group|The patients taking dabigatran for 1 month after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
3356500|NCT02313584|Placebo Comparator|Conventional Group|The patients taking dabigatran for 2 months after the radiofrequent catheter ablation for paroxysmal atrial fibrillation.
3356501|NCT02313610|Experimental|Qinbudan|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program （2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan table, table, 4, thrice a day, 8 months
3356502|NCT02313610|Placebo Comparator|Control Qinbudan Placebo|the patient will receive 2HRZES/6HRE follow guidelines of the implementation of China tuberculosis control program（2HRZES/6HRE means： Intensive phase: isoniazid（H）, rifampicin（R）, pyrazinamide（Z）, ethambutol（E）, streptomycin（S）, once, for two months（2）；Consolidation: isoniazid（H）, rifampicin（R）, ethambutol（E）, once, for six months（6）.） Intervention: Qinbudan Placebo, table, 4, thrice a day, 8 months
3356503|NCT02313623||Patient Scheduled for Prostate Fusion Biopsies|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
3356504|NCT02313688|Experimental|Group A|Group A: Patients in the Group A will underwent D2 total gastrectomy and with 3±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
3246012|NCT01343602|Experimental|mod. Constraint-Induced Movement Therapy|CIMT at home is applied in the patients' home over the course of four weeks including (i.e. 20 consecutive days) 2 hours of daily training together with an instructed non-professional coach (e.g. family member) applying shaping techniques.
3356505|NCT02313688|Experimental|Group B|Patients in the Group B will underwent D2 total gastrectomy and with 5±0.5 cm lengthen proximal resection margin. Intraoperative frozen section will routinely performed to secure the tumor free resection margin.
3356506|NCT02313701|No Intervention|Vaginal hysterectomy counseling|Standard verbal counseling to consent for vaginal hysterectomy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3246013|NCT01343602|Other|Therapy as usual|Patients in this arm will receive usual care dose-matched to the intervention group (250-300 minutes).
3246014|NCT01343615|Active Comparator|carotid stenting|
3246015|NCT01343615|Active Comparator|carotid endarterectomy|
3246016|NCT01343628|Placebo Comparator|Placebo, Atomoxetine|
3246017|NCT01343628|Active Comparator|Atomoxetine, Placebo|
3246018|NCT01343641|Experimental|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
3246019|NCT01343641|Placebo Comparator|Placebo|Inactive Pill used as a comparator
3246020|NCT01343654|Experimental|Text messaging|Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
3246021|NCT01343654|Active Comparator|Treatment as usual|Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
3246022|NCT01343680|Active Comparator|10U/l heparin|
3246023|NCT01343680|Experimental|normal saline|
3246024|NCT01343706|Experimental|BI 409306 dose 1|Solution for oral administration
3246025|NCT01343706|Experimental|BI 409306 dose 2|Solution for oral administration
3246026|NCT01343706|Experimental|BI 409306 dose 3|Solution for oral administration
3356507|NCT02313701|Experimental|Vaginal hysterectomy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for vaginal hysterectomy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3356508|NCT02313701|No Intervention|Robotic sacrocolpopexy counseling|Standard verbal counseling to consent for robotic sacrocolpopexy in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3356509|NCT02313701|Experimental|Robotic sacrocolpopexy visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for robotic sacrocolpopexy. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3356510|NCT02313701|No Intervention|Sub-urethral sling counseling|Standard verbal counseling to consent for sub-urethral sling in terms of what the procedures involves, other treatment options, risks, benefits, and what to expect in the pre-op and post-op periods. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3356511|NCT02313701|Experimental|Sub-urethral sling visual aid|In addition to standard verbal counseling, intervention will include a standardized visual presentation for sub-urethral sling. Time spent viewing the visual presentation will be recorded to assess for the efficiency of this quality improvement intervention. At the end of the clinic visit, participants will receive a survey to evaluate their understanding of their procedure, pre-operative and post-operative expectations, and satisfaction with their experience. A similar survey will be repeated before their surgery and at their post-operative clinic visit at approximately 1-2 weeks following the surgery.
3356512|NCT02313714|Experimental|Neuromuscular stimulation|The patients will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
3246027|NCT01343706|Experimental|BI 409306 dose 4|Solution for oral administration
3356513|NCT02313714|Placebo Comparator|Sham Group|The patients will receive very low electric muscular stimulation with a no biological or clinical effects
3356514|NCT02313727|Active Comparator|pamidronate|pamidronate
3356515|NCT02313727|Placebo Comparator|placebo|placebo
3356516|NCT02313740||Healthy adults group|Healthy adults aged 18 to 59 years Butantan Fragmented Inactivated Trivalent Influenza Vaccine
3356517|NCT02313740||Elderly group|Elderly aged over than 60 years completed Butantan Fragmented Inactivated Trivalent Influenza Vaccine
3356518|NCT02313753|Active Comparator|SAFE|Safety Assessment and Follow-up Evaluation Protocol
3246028|NCT01343706|Experimental|BI 409306 dose 5|Immediate release solid oral dosage
3356519|NCT02313753|Experimental|CLASP|Coping Long Term with Active Suicide Program Protocol
3356520|NCT02313779|Placebo Comparator|Neutral|Reading passage about brain function which is masked as a news article.
3356521|NCT02313779|Experimental|Lovingkindness Meditation (LKM)|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
3356522|NCT02313779|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
3356523|NCT02313779|Experimental|Positivity|Reading passage about prioritizing positive emotions which is masked as a news article.
3356524|NCT02313792|Active Comparator|Palifermin|The patients belong to this arm will be given palifermin, keratinocyte growth factor, in addition to the conventional supportive care for oral mucositis. Palifermin will be given at a dose of 60 mcg/kg for 3 days before commencement of the preparative regimen and for 3 days after stem cell infusion
3246029|NCT01343706|Experimental|BI 409306 dose 6|Immediate release solid oral dosage
3246030|NCT01343706|Experimental|BI 409306 dose 7|Immediate release solid oral dosage
3246031|NCT01343706|Experimental|BI 409306 dose 8|Immediate release solid oral dosage
3246032|NCT01343706|Experimental|BI 409306 dose 9|Immediate release solid oral dosage
3246033|NCT01343706|Experimental|BI 409306 dose 10|Immediate release solid oral dosage
3246034|NCT01343706|Experimental|BI 409306 dose 11|Immediate release solid oral dosage
3246035|NCT01343706|Experimental|BI 409306 dose 12|Immediate release solid oral dosage
3246036|NCT01343706|Placebo Comparator|Placebo|Solution for oral administration
3246037|NCT01343706|Placebo Comparator|Placebo 2|Immediate release solid oral dosage
3246038|NCT01343719|Experimental|BI 661051 low dose, low|solution for oral administration, single dose
3246039|NCT01343719|Experimental|BI 661051 low dose, medium|solution for oral administration, single dose
3246040|NCT01343719|Experimental|BI 661051 low dose, high|solution for oral administration, single dose
3246041|NCT01343719|Experimental|BI 661051 medium dose, low|solution for oral administration, single dose
3246042|NCT01343719|Experimental|BI 661051 medium dose, medium|solution for oral administration, single dose
3246043|NCT01343719|Experimental|BI 661051 medium dose, high|solution for oral administration, single dose
3356525|NCT02313792|Placebo Comparator|Normal saline|The patients belong to this arm will be given normal saline as placebo plus conventional supportive care for oral mucositis. Normal saline will be given at the same volume and schedule with the study drug.
3356526|NCT02313805|Experimental|With checklist|Students will simulate insulin initiation with the aid of a checklist
3356527|NCT02313805|No Intervention|Without checklist|Students will simulate insulin initiation without the aid of a checklist
3356528|NCT02313818|Experimental|CPT-C|Cognitive Processing Therapy-Cognitive Only (CPT-C) conducted twice weekly for 4-24 sessions based on good end state functioning.
3356529|NCT02313831|Experimental|Exercise training|Patients of this group will be submitted to an interval training
3356530|NCT02313844|Experimental|Viralym-B|"Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-B/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3356531|NCT02313857|Experimental|Viralym-C|"Partially HLA-matched Viralym-C cells will be thawed and given by intravenous injection. Patients will receive 2 x 10^7 partially HLA-matched Viralym-C/m2 as a single infusion.~If a patient has a partial response they are eligible to receive up to 4 additional doses at biweekly intervals. These doses would come from the original infused line if sufficient vials were available but may come from another line if there are insufficient cells in the original line."
3356532|NCT02313870|Experimental|A|Superpotent topical steroids/methotrexate
3356533|NCT02313870|Other|B|Superpotent topical steroids (clobetasol propionate)
3356534|NCT02313883|Placebo Comparator|SRP only|Scaling and root planing only
3356535|NCT02313883|Placebo Comparator|SRP and Placebo|Scaling and root planing followed by placebo drug administration
3356536|NCT02313883|Experimental|SRP and 0.3% PerioSept(r)|Scaling and root planing followed by 0.3% PerioSept(r) drug administration
3356537|NCT02313883|Experimental|SRP and 1 % PerioSept(r)|Scaling and root planing followed by 1% PerioSept(r) drug administration
3356538|NCT02313883|Experimental|SRP and 3% PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) drug administration
3356539|NCT02313896|No Intervention|Standard of Care|Patients recieve standard care. On discharge they receive an information packet about cirrhosis and hepatic encephalopathy. They will continue to follow with their doctor as usual.
3356540|NCT02313896|Experimental|Phone calls|On discharge, patients will receive an information package about cirrhosis and hepatic encephalopathy. In addition to regular visits with the doctor, they will receive phone calls from one of our research providers who will be a nurse practitioner, doctor, or physician assistant. In the first 2 weeks after discharge, they will receive phone calls every other day. For the following 10 weeks, they will receive phone calls once a week.
3246044|NCT01343719|Experimental|BI 661051 high dose, low|solution for oral administration, single dose
3246045|NCT01343719|Experimental|BI 661051 high dose, medium|solution for oral administration, single dose
3246046|NCT01343719|Experimental|BI 661051 low dose|tablet
3356541|NCT02313922|Experimental|etanercept combined with methotrexate|patients treated with etanercept combined with methotrexate
3356542|NCT02313922|Experimental|etanercept as monotherapy|patients treated with etanercept combined with placebo
3356543|NCT02313935|Experimental|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3356544|NCT02313935|Experimental|PTC|Physical training only. Participants use the FitForAll exergaming computer platform as the physical training component (PTC).
3356545|NCT02313935|Experimental|CTC|Cognitive training only. Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
3356546|NCT02313935|No Intervention|Passive|Passive Control Participants do not receive an intervention serving as passive controls
3356547|NCT02313935|Active Comparator|Active|Active Control Participants receive an alternative cognitive training scheme; software was built on purpose by the AUTH team. The software is called VideoGrade and uses YouTube documentaries.
3356548|NCT02313961|Experimental|RIC patients|Subjects submitted to remote ischaemic conditioning (RIC)
3356549|NCT02313961|No Intervention|No RIC patients|Subjects not submitted to remote ischaemic conditioning (RIC)
3356550|NCT02313987||A-Usual care- Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis) and normal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD"
3356551|NCT02313987||B1-Usual Care-Standard care for NOCAD|"Subjects with non obstructive CAD (20-70% luminal diameter stenosis ) and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the standard care usually provided in each facility for patients with NOCAD. (Same care as Group A)"
3356552|NCT02313987||B2- Endothelial function guid care|"Subjects with non obstructive CAD and abnormal Endothelial function as defined by EndoScore.~These subjects will receive the an Endothelial Function-guided Therapy."
3356553|NCT02314013|Active Comparator|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole) and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
3356554|NCT02314013|No Intervention|No antibiotic|bowel rest and then, discharge until tolerable soft diet.
3356555|NCT02314065|Experimental|Conventional CBT|Cognitive Behavioural Therapy delivered in a conventional manner
3246047|NCT01343719|Experimental|BI 661051 medium dose|tablet
3246048|NCT01343719|Placebo Comparator|Placebo|solution for oral administratrion
3356556|NCT02314065|Experimental|Internet-delivered CBT|Cognitive Behavioural Therapy delivered via the Internet
3356557|NCT02314091|Experimental|Onlay|Onlay mesh repair group
3356558|NCT02314091|Experimental|sublay|Sublay mesh repair group
3356559|NCT02314130|Experimental|Dietary therapy Standardized diet|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
3356560|NCT02314130|No Intervention|Dietary therapy Commercial diet group|The study was constituted by sixty-six patients, thirty-three in each group. Patients on not industrialized enteral diet (standardized diet group) entered at random in the study and were matched by gender, age, socioeconomic status and medical diagnosis to patients using commercial diet (commercial group). The evaluation consisted of anthropometric measures of weight, height, arm circumference, triceps skin fold and biochemical índices at baseline and at the end of the intervention.
3356561|NCT02314156|Experimental|Arm I (transdermal telapristone acetate)|Patients receive telapristone acetate transdermally and placebo PO QD for 4 weeks.
3246049|NCT01343732|No Intervention|healthy volunteeres|this arm will undergo only EEG measurement
3246050|NCT01343732|Active Comparator|real - low frequency|this arm will receive DTMS treatment with low frequency
3246051|NCT01343732|Active Comparator|real - high frequency|this arm will receive DTMS treatment with high frequency
3246052|NCT01343732|Sham Comparator|sham - low / high frequency|this arm will receive DTMS sham treatment with low or high frequency
3246053|NCT01343745|Placebo Comparator|Placebo|Placebo pMDI
3246054|NCT01343745|Experimental|Low dose|BDP/formoterol pMDI low dose
3246055|NCT01343745|Experimental|High dose|BDP/Formoterol pMDI high dose
3356562|NCT02314156|Active Comparator|Arm II (oral telapristone acetate)|Patients receive placebo transdermally and telapristone acetate PO QD for 4 weeks.
3356563|NCT02314169|Experimental|Part A (nivolumab)|Patients receive nivolumab IV over 60 minutes once every two weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3356564|NCT02314169|Experimental|Part B Arm I (nivolumab)|Patients receive nivolumab IV over 30 minutes once every 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3356565|NCT02314169|Experimental|Part B Arm II (nivolumab, ipilimumab)|Patients receive nivolumab as in Arm I. Patients also receive ipilimumab IV over 30 minutes once every 8 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3356566|NCT02314182|Experimental|A Primary tumor resection + chemotherapy|PT resection + systemic chemotherapy +/- target therapy
3356567|NCT02314182|Other|B Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|Chemotherapy (+/- target therapy)
3356568|NCT02314195|Active Comparator|Standard treatment + music therapy|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy. Music therapy encompassing 12 half-hour sessions of therapist-supervised receptive music therapy scheduled over four weeks
3356569|NCT02314195|Active Comparator|Standard treatment only|Selective serotonin re-uptake inhibitor plus cognitive behavioral therapy.
3356570|NCT02314208|Active Comparator|Xenbilox|Xenbilox (chenodeoxycholic acid) 1000mg capsule by mouth every day for 2 months
3356571|NCT02314208|Active Comparator|Resveratrol|Resveratrol 80mg capsule by mouth every day for 2 months
3356572|NCT02314208|Active Comparator|Tahor|Tahor (atorvastatin) 40mg tablet by mouth every day for 2 months
3356573|NCT02314221|Experimental|Exoskeletal-Assisted Walking (WALK)|WALK first for 12 weeks (36 sessions)
3356574|NCT02314221|No Intervention|Usual Activities (UA)|Usual activities first for 12 weeks
3246056|NCT01343758|Active Comparator|5% dextrose in normal saline|This group will receive a bolus of normal saline that contains 5% dextrose
3246057|NCT01343758|No Intervention|Normal Saline Bolus|
3356575|NCT02314234||Control group|did not receive muscle relaxant during anesthesia
3356576|NCT02314234||Sugammadex group|received single dose of rocuronium for anesthesia and sugammadex at skin incision
3356577|NCT02314273|Experimental|rhIL-11 group|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80,000/mL
3356578|NCT02314273|No Intervention|control group|control group
3356579|NCT02314286|Placebo Comparator|control|"After signing an informed consent form and filling a demographic and medical questionnaire, a randomization 1:1 will be carried. 50 women will be in the control arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected.~Control group will be treated with placebo."
3356580|NCT02314286|Experimental|treatment|50 women will be in the treatment arm. the group will be treated according to ACOG guidelines (Appendix). After the delivery, a small placenta sample will be collected. In addition, following randomization experimental group will be treated with Rosuvastatin 40mg that will be administrated orally with or without food. Treatment will be carried within the first hour following delivery. Another dose will be given 24 hours after first administration. Control group will be treated with placebo.
3356581|NCT02314299|Experimental|Low Dose Regimen|MTP-131 (Low Dose) sterile topical ophthalmic solution twice a day into the study eye
3356582|NCT02314299|Experimental|High Dose Regimen|MTP-131 (High Dose) sterile topical ophthalmic solution twice a day into the study eye
3356583|NCT02314312|Experimental|A: investigation arm|De novo kidney transplantation form ECD/AKI donor with Everolimus + low dose cyclosporinA + prednisolone as immunosuppressive regimen
3356584|NCT02314312|Other|B: control arm|De novo kidney transplantation form ECD/AKI donor with standard immunosuppressive regimen
3356585|NCT02314325|Active Comparator|Standard prophylaxis|Advate [Antihemophilic Factor(Recombinant)] 20-40 IU/kg 5-7 infusions per 14days
3356586|NCT02314325|Experimental|Pharmacokinetic tailored prophylaxis|Advate [Antihemophilic Factor(Recombinant)] dose determined by individual patient pharmacokinetics and infusions administerd on alternate days
3356587|NCT02314338|Experimental|Pulmonary rehabilitation|Multi-disciplinary pulmonary rehabilitation
3356588|NCT02314351|Active Comparator|Intravenous metoclopramide|Intravenous metoclopramide, 10 mg (2 mL) in 98 mL 0.9% normal saline solution (total 100 mL)
3356589|NCT02314351|Placebo Comparator|Placebo|0.9% normal saline solution (total 100 mL)
3356591|NCT02314377|Experimental|AVM treatment with Bevacizumab|Bevacizumab infusion dose of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
3356592|NCT02314390|Experimental|G-MBCT|Group-Mindfulness-Based Cognitive Therapy
3356593|NCT02314390|Experimental|I-MBCT|Individual-Mindfulness-Based Cognitive Therapy
3356594|NCT02314416|Active Comparator|Standard Treatment|Patients in the Control Arm will receive collagen matrix for wound coverage and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
3356595|NCT02314416|Experimental|Amniotic Stem Cells and Collagen Matrix|Patients will receive amniotic stem cells(NuCel) embedded in collagen matrix for wound coverage, and standard wound care that will include chemical/surgical debridement (using a topical paste to clean the wound or removing bad tissue using a scalpel or scissors) and dressing care. In addition, they may also have imaging studies (such as x-ray, CAT scan, ultrasound) performed if determined to be necessary by the physician.
3356596|NCT02314429|Experimental|Vaginal Ring|A vaginal ring that slowly releases lactic acid (racemic mixture) into the vaginal environment, will be inserted in healthy volunteering women and left in place for 7 days.
3356597|NCT02314442|Active Comparator|ALN-PCSSC|
3356598|NCT02314442|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3356599|NCT02314455|Experimental|D-xylose, water, honey|"25 grams of D-xylose~10 cc of water~2 teaspoons of honey"
3246058|NCT01343784|Active Comparator|Standard Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects will be discharged without a catheter if the voided amount is more than 200ml, or 2/3rds of the infused volume (300ml).
3246059|NCT01343784|Experimental|Force of Stream Voiding Trial|Subjects in this group will undergo backfill-assisted voiding trial that involves infusing 300ml of fluid in the bladder, removing the catheter and allowing the patient to void. All subjects will be asked to use visual analog scale (VAS) to assess their force of stream (FOS) and the voided amount as well as post-void residual (PVR) (measured by the bladder ultrasound) will be measured and recorded. Subjects in the FOS group will be discharged home without a catheter if they are able to void any amount and report an FOS of at least 50% their typical FOS based on a visual analog scale
3356600|NCT02314468|Active Comparator|negative pressure wound therapy (NPWT)|negative pressure wound therapy (NPWT)
3356601|NCT02314468|Active Comparator|Glycerol Preserved Allografts (GPA)|Glycerol Preserved Allografts (GPA)
3356602|NCT02314481|Experimental|No actionable mutation - MPDL3280A|"MPDL3280A 1200mg IV infusion - 3 weekly for 24 cycles monotherapy~Or in combination with chemotherapy:~For non-squamous: Cisplatin or Carboplatin plus pemetrexed & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A and pemetrexed 3 weekly for 20 cycles~For squamous: Carboplatin plus paclitaxel & MPDL3280A - 3 weekly for 4 cycles followed by MPDL3280A 3 weekly for 20 cycles~Until progression, unacceptable toxicity or completion of a total of 24 cycles."
3356603|NCT02314481|Experimental|BRAF V600 - vemurafenib|Vemurafenib 960mg twice daily until PD
3356604|NCT02314481|Experimental|ALK/RET gene rearrangement - alectinib|Alectinib 600mg twice daily until PD
3246060|NCT01343810|Experimental|Meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The experimental arm will be randomly assigned to practice meditation immediately following the emotional stress task in the lab during the post-MBSR lab visit.
3356605|NCT02314481|Experimental|HER2 amplification - T-DM1|Trastuzumab emtansine (T-DM1) 3.6mg/kg - 3 weekly until PD IV infusion
3356606|NCT02314494||Infants at risk|Infants identified as at risk of obesity using the ProAsk intervention
3356607|NCT02314494||Infants not at risk|Infants identified as not at risk of obesity using the ProAsk intervention.
3356608|NCT02314507|Experimental|Gua sha|Paritcipants in this group will receive a single treatment of Gua sha conducted by a well-trained nurse or Chinese practitioner
3356609|NCT02314507|Active Comparator|Hot Pack Therapy|Participants in this group will receive a single treatment of Hot Pack conducted by a well-trained nurse or Physiotherapist
3356610|NCT02314533|Experimental|fenofibrate|Fenofibrate 200mg capsule will be administered orally with breakfast once daily according to the Chinese prescription information of Lipanthyl, while previous type and dose of statin will be administered in the evening.
3356611|NCT02314559|Experimental|Propofol (manual titration)|
3356612|NCT02314559|Active Comparator|Propofol (target controlled infusion)|
3356613|NCT02314572|Other|Single-arm|
3356614|NCT02314585|Other|Education|In the second phase, participants will partake in an instructional class relating to gait, balance, and falls.
3356615|NCT02314585|Other|Exercise|In the second phase,participants will partake in an exercise course relating to gait, balance, and falls.
3356616|NCT02314624|Experimental|PracticeGround|Clinicians have access to PracticeGround's dynamic progress monitoring, clinical decision support, rich visual displays of client outcomes, online training modules in ESTs, just-in-time training for guided real-time assistance in delivering ESTs, educational videos, and a client portal
3356617|NCT02314624|Active Comparator|Care-as-Usual|Usual care without access to PracticeGround.
3356618|NCT02314650|Experimental|Transcutaneous acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at Ximen and Shenmen acupoint during anesthesia
3356619|NCT02314650|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation was given through electrodes attached to skin at shoulder (non-acupoint) during anesthesia
3356620|NCT02314650|Sham Comparator|Control|patients were with electrodes attached but no stimulation was given
3356621|NCT02314663|Experimental|Intervention group|"COMBINED STRATEGY (a + b + c). Participants in the intervention group will be supplied with: a) printed matter; b) mobile-telephone text messages; and, c) self-report cards.~This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk"
3356622|NCT02314663|No Intervention|Control group|This group receive routine recommendations from their GPs, in accordance with current European clinical practice guidelines on the management of hypercholesterolaemia and cardiovascular risk
3356623|NCT02314676|Experimental|PEG-somatropin|
3356624|NCT02314702||Revision Total Hip Arthroplasty|Single study group previously implanted with a PROFEMUR® L Revision Femoral Stem
3356625|NCT02314715||Knee Osteoarthritis|Participants with diagnosed knee osteoarthritis
3356626|NCT02314715||Controls|Participants without knee osteoarthritis
3246061|NCT01343810|Active Comparator|No meditation|Both arms will undergo 8-weeks of Mindfulness-Based Stress Reduction (MBSR) training. The active comparator arm will be randomly assigned to not practice meditation, but rather listen to a non-meditative audio track of equal length, immediately following the emotional stress task in the lab during the post-MBSR lab visit.
3246062|NCT01343836|Experimental|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte implantation) injection with eccentric exercises
3246063|NCT01343836|Placebo Comparator|Saline injection|Intratendinous saline injection with eccentric exercises
3246064|NCT01343849||Suspected Breast cancer subjects|
3356627|NCT02314741|Experimental|POEM Treatment Arm|Patients treated with the POEM (per-oral endoscopic myotomy) procedure.
3356628|NCT02314754|Experimental|71-77 days gestational age|Women whose pregnancies are estimated to have a gestational age of 71-77 days.
3356629|NCT02314754|No Intervention|64-70 days gestational age|Women whose pregnancies are estimated to have a gestational age of 64-70 days.( Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range).
3356630|NCT02314767|Active Comparator|Interpersonal Psychotherapy|Interpersonal Psychotherapy treatment for MDD patients was implemented with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention:Interpersonal psychotherapy as ADD-on method. Outcome was compared with patients in treatment as usual group.
3356631|NCT02314767|Active Comparator|Psychoeducational Group Therapy|Psychoeducational Group Therapy arm for MDD patients with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression. Intervention: Psychoeducational Group Treatment as ADD-on method.
3356632|NCT02314767|No Intervention|Treatment as Usual|Treatment as usual ( consisting of supportive psychodynamic-oriented treatment) with antidepressant pharmacotherapy by national Quidelines for the treatment of Patients with depression
3356633|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fasting)|Young male and female subjects will receive single doses of ASP2205 in a dose escalation format.
3246065|NCT01343862|Experimental|D- Cycloserine|
3246066|NCT01343862|Placebo Comparator|sugar pill|
3356634|NCT02314793|Placebo Comparator|Part 1: Single Ascending Dose Placebo (Fasting)|Young male and female subjects will receive single doses of matching placebo in a dose escalation format.
3356635|NCT02314793|Experimental|Part 1: Single Ascending Dose ASP2205 (Fed)|Young male and female subjects will receive a single dose of ASP2205
3356636|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Young females|Young female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3356637|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Young females|Young female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3356638|NCT02314793|Experimental|Part 2: Multiple Ascending Dose ASP2205, Elderly females|Elderly female subjects will receive multiple dosing of ASP2205 for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3356639|NCT02314793|Placebo Comparator|Part 2: Multiple Ascending Dose Placebo, Elderly females|Elderly female subjects will receive matching placebo for 14 days: single doses on days 1 and 14 and depending on the dosing regimen (based on emerging data from Part 1) either once or twice daily dosing from days 2 to 13.
3356640|NCT02314806|Experimental|Irrigation with Gentamicin solution|The surgical bed is irrigated with a gentamicin solution
3356641|NCT02314806|Experimental|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
3356642|NCT02314806|Placebo Comparator|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
3356643|NCT02314819|Active Comparator|treatment arm|treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3356644|NCT02314819|Placebo Comparator|control arm|control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
3246067|NCT01343875||surgery, biceps tear|
3246068|NCT01343914||Cohort|
3356645|NCT02314832|Active Comparator|Continuous femoral nerve block|patients receiving continuous femoral nerve block for analgesia after total knee arthroplasty
3246069|NCT01343927|Active Comparator|Yoga|12 weeks of weekly yoga classes plus 40 weeks of either drop-in classes or home practice.
3246070|NCT01343927|Active Comparator|Physical Therapy|15 individual physical therapy treatment sessions over 12 weeks plus 40 weeks with either 5 booster sessions or home practice.
3246071|NCT01343927|Active Comparator|Education|"The Back Pain Helpbook which gives exercises and tips for self-care pain management."
3356646|NCT02314832|Active Comparator|adductor canal block|adductor canal block group will receive adductor canal block for analgesia after TKA
3356647|NCT02314845|Experimental|Optimal PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure using Electrical Impedance Tomography (EIT). Patients will be mechanically ventilated during intraoperative period using Optimal PEEP determined by Electrical Impedance and FIO2 of 0.5."
3356648|NCT02314845|Other|Low PEEP|"Patients submitted to general anesthesia and abdominal laparoscopic surgery (number=10) or open surgery (number=10) will be submitted to a recruitment maneuver followed by a PEEP titration procedure EIT. In this arm, the ventilator will be set with a PEEP=4 cmH2O (Low PEEP) and FIO2 of 0.5 during intraoperative period."
3356649|NCT02314858|Experimental|Brief Personalized Video (BPV)|Our BPV intervention focuses on augmenting risk perception and reducing optimistic bias by showing the patient a dramatic video of his/her own apnea (which shows them struggle to breathe), as well as by explaining the physiological processes involved in an apneic event. Specific apneic events are highlighted and associated decreases in blood oxygen levels are demonstrated via oxygen saturation recording superimposed on the video. This group will receive educational information about OSA, its consequences and the need for treatment.
3246072|NCT01343940|Experimental|Dulce family partner intervention|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services."
3246073|NCT01343940|Active Comparator|Safety intervention|Participating family is assigned a safety specialist who will provide the parent with guidance, equipment and instruction to reduce risk of newborn injury during transport (car seat) and while sleeping (Pack-and-Play).
3246074|NCT01343953|Experimental|Cord Blood Transplantation|
3246075|NCT01343966|Experimental|Part 1: Subcutaneous cohort exp|
3246076|NCT01343966|Experimental|Part 2: Intravenous cohort exp|
3246077|NCT01343966|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
3356650|NCT02314858|Active Comparator|Non-Personalized Video (NPV)|NPV will include a video of someone having apnea, but it will not be personalized. This group will receive educational information about OSA, its consequences and the need for treatment.
3356651|NCT02314858|Placebo Comparator|Treatment As Usual (TAU)|The TAU group will receive no special treatment from study interventionist team and will not view a video.
3356652|NCT02314871|Active Comparator|Epidural|Patients will receive perioperative epidural analgesia. Drugs: bupivacaine 1.25 mg/ml and sufentanil 0.5 mcg/ml Form and frequency: continuous infusion Dosage: 4 - 14 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3356653|NCT02314871|Active Comparator|Piritramide|Patients will receive postoperative analgesia with piritramide. Drugs: piritramide 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3356654|NCT02314871|Active Comparator|Morphine|Patients will receive postoperative analgesia with morphine. Drugs: morphine 1.0 mg/ml Form and frequency: continuous infusion Dosage: 0 - 4 ml/h with boluses 2 - 4 ml based on pain assessment Duration: as long as required
3356655|NCT02314884|Experimental|Cafusertib Hydrochloride|Cafusertib Hydrochloride d1q3w
3356656|NCT02314897|Experimental|LV pacing|Left ventricular pacing lead implanted via coronary sinus
3356657|NCT02314897|Active Comparator|RV pacing|Conventional right ventricular pacing lead.
3356658|NCT02314923|Experimental|3x10^3 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
3356659|NCT02314923|Experimental|3x10^4 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^4 pfu in the deltoid on Day 0.
3356660|NCT02314923|Experimental|3x10^5 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^5 pfu in the deltoid on Day 0.
3356661|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 1|Participants will receive a 1-mL intramuscular injection of V920 3x10^6 pfu in the deltoid on Day 0.
3356662|NCT02314923|Experimental|9x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 9x10^6 pfu in the deltoid on Day 0.
3356663|NCT02314923|Experimental|2x10^7 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 2x10^7 pfu in the deltoid on Day 0.
3356664|NCT02314923|Experimental|1x10^8 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 1x10^8 pfu in the deltoid on Day 0.
3356665|NCT02314923|Placebo Comparator|Placebo Cohort 1|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
3356666|NCT02314923|Experimental|3x10^6 pfu Vaccine Cohort 2|Participants will receive a 1-mL intramuscular injection of V920 3x10^3 pfu in the deltoid on Day 0.
3356667|NCT02314923|Placebo Comparator|Placebo Cohort 2|Participants will receive a 1-mL intramuscular injection of placebo in the deltoid on Day 0.
3246078|NCT01343966|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous infusion
3246079|NCT01343979||positive|Patients with clinically suspected H1N1 infection confirmed by positive H1N1 PCR
3246080|NCT01343979||negative|Patients with clinically suspected H1N1 infection and negative H1N1 PCR
3246081|NCT01343992|Active Comparator|Bedrest|Patients will rest in bed ten minutes after the embryo transfer.
3356668|NCT02314949||intestinal transplantation|all performed intestinal transplants underwent the same Leuven intestinal transplant protocol
3246082|NCT01343992|Experimental|No bed rest|Patients will not rest after the embryo transfer.
3246083|NCT01344018|Active Comparator|Surgery alone|En-bloc resection of surrounding tissues and organs when located within 1 to 2 cm from the surface tumor, even when not infiltrated.
3246084|NCT01344018|Experimental|Preoperative radiotherapy followed by en-bloc surgery|3D-CRT or IMRT to a dose of 50.4 Gy/28 daily fractions
3246085|NCT01344031|Experimental|Arm A (anastrozole and Akt inhibitor MK2206)|"Patients receive anastrozole PO on days 1-28. Beginning in course 2, patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3356669|NCT02314975|Experimental|AcceleDent vibrational device|Fixed appliances with supplementary vibrational force
3356670|NCT02314975|Sham Comparator|Sham AcceleDent device|Fixed appliances with supplementary sham device
3356671|NCT02314975|Active Comparator|Fixed appliance only|Fixed appliances only
3356672|NCT02314988|Active Comparator|Intervention|Subjects will receive tranexamic acid on the surgical wound.
3356673|NCT02314988|Placebo Comparator|Placebo control|Subjects will receive placebo (saline solution) on the surgical wound.
3246086|NCT01344031|Experimental|Arm B (Akt inhibitor MK2206 and anastrozole)|"The RPTD of Akt inhibitor MK2206 with anastrozole is determined after 3 courses, administered as in Arm A.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3246087|NCT01344031|Experimental|Arm C (Akt inhibitor MK2206 and fulvestrant)|"Patients receive Akt inhibitor MK2206 PO on days 1, 8, 15, and 22, fulvestrant IM on day 1and day 15 of course 1 and then on day 1 of each course in each subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3356674|NCT02315001|Active Comparator|Liraglutide|"Week 1 Run-In Phase = 0.6 mg (0.1 ml) Liraglutide once daily via subcutaneous injection~Week 2 Low-Dose Phase = 1.2 mg (0.2 ml) Liraglutide once daily via subcutaneous injection~Week 3 High-Dose Phase = 1.8 mg (0.3 ml) Liraglutide once daily via subcutaneous injection"
3356675|NCT02315001|Placebo Comparator|Saline Placebo|"Week 1 Run-In Phase = 0.1 ml normal saline once daily via subcutaneous injection~Week 2 Low-Dose Phase = 0.2 ml normal saline once daily via subcutaneous injection~Week 3 High-Dose Phase = 0.3 ml normal saline once daily via subcutaneous injection"
3356676|NCT02315014|Experimental|whey protein|whey protein micelles
3356677|NCT02315014|Placebo Comparator|placebo|calorie-free placebo
3246088|NCT01344031|Experimental|Arm D (Akt inhibitor MK2206, anastrozole, fulvestrant)|"Patients receive Akt inhibitor MK2206 PO as in Arm A, anastrozole PO on days 1-28 and fulvestrant IM on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: As of 8/19/2015, patients no longer receive Akt inhibitor MK2206."
3246089|NCT01344044|Active Comparator|BCI treatment|BCI treatment will commence during the week of the Baseline.
3246090|NCT01344044|Other|Wait-list control|BCI treatment will commence 8 weeks after Baseline
3356678|NCT02315027|Experimental|1 dose of 1 × 10(7) MSCs|Group 1: Participants will receive a single intrathecal dose of 1 × 10(7) mesenchymal stem cells (MSCs)
3356679|NCT02315027|Experimental|2 doses of 5 × 10(7) MSCs|Group 2: Participants will receive one intrathecal dose of 5 × 10(7) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 5 × 10(7) MSCs approximately one month later
3356680|NCT02315027|Experimental|2 doses of 1 × 10(8) MSCs|Group 3: Participants will receive one intrathecal dose of 1 × 10(8) mesenchymal stem cells (MSCs), followed by a second intrathecal dose of 1 × 10(8) MSCs approximately one month later
3356681|NCT02315027|Experimental|10 doses of 5 x 10(7) (±20%) MSCs|Group 4: Participants will receive up to 10 doses of 5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
3356682|NCT02315027|Experimental|10 doses of 2.5 x 10(7) (±20%) MSCs|Group 5: Participants will receive up to 10 doses of 2.5 x 10(7) (±20%) mesenchymal stem cells (MSCs) approximately 6 months apart.
3356683|NCT02315040|Active Comparator|IUI|standard intrauterine insemination method
3356684|NCT02315040|Experimental|EVIE|Slow release insemination method (SRI)
3356685|NCT02315053|Other|Low dose FDG PET/CT 5x|Stage II/III NSCLC will undergo a Low dose FDG PET/CT 5x during treatment (CCRT).
3356686|NCT02315066|Experimental|PF-04518600|OX40 agonist
3356687|NCT02315066|Experimental|PF-04518600 plus PF-05082566|OX40 (CD134) agonist plus 4-1BB (CD137) agonist
3356688|NCT02315079||Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
3356689|NCT02315079||Without eye inflammation|This group will have a regular eye exam with the collection of tears.
3356690|NCT02315092||Diabetic foot ulcers|Patients who present with diabetic foot ulcers will undergo fluorescence imaging.
3356691|NCT02315105|Experimental|Morbid Obese patients|This purpose of this study is to find out more about the safety and effectiveness of the Laparoscopic Greater Curvature Plication (LGCP) for Morbid Obese Patients with related problems such as diabetes, hypertension, high cholesterol, mild obstructive sleep apnea and joint problems.
3356692|NCT02315118|Experimental|T-cell therapy + Rituximab + IL-2|"Patients will undergo apheresis procedure and T cell expansion will be done in the laboratory. All patients will receive Rituximab on day -2 and IL-2 three times per week for one week starting on day -1 (dose 1 of 3). IL-2 dosing will be continued 3 times per week for one week (3 doses total).~On Day 0, T cell modification in the laboratory and T cell infusion in the patient will be done.~A disease status evaluation will be conducted approximately 4 weeks post-T cell infusion."
3356693|NCT02315157|Experimental|Bendamustine 200 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).
3356694|NCT02315157|Experimental|Bendamustine 250 mg/m2|Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).
3356695|NCT02315196|Experimental|Treatment (doxil, carboplatin, surgery, paclitaxel)|"NEOADJUVANT: Patients receive pegylated liposomal doxorubicin hydrochloride* IV over 90 minutes and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~ADJUVANT: Patients undergo definitive surgery at the discretion of the treating physician. Patients then receive paclitaxel IV over 60 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity.~*NOTE: If there is a shortage of pegylated liposomal doxorubicin hydrochloride, patients receive epirubicin hydrochloride IV over 15-20 minutes on day 1."
3356696|NCT02315222|Active Comparator|Test|Dietary Supplementation
3356697|NCT02315222|Placebo Comparator|Control|Placebo Supplementation
3356698|NCT02315235|Active Comparator|control|The operator inject normal saline(control) to thirty site of the other side leg of active comparator. The volume of one site injection is 0.5 ml. The depth of needle injection would be 1.5cm.
3356699|NCT02315235|Active Comparator|stem cell (mononuclear cell)|The stem cell (mononuclear cell) is injected to thirty site of one side leg in operating room after general anesthesia. The volume of one site injection is 0.5 to 1.0 ml. The depth of needle injection would be 1.5cm.
3356700|NCT02315274|Experimental|Single arm, remote contact.|Between visit remote contact.
3356701|NCT02315287|Active Comparator|Metformin, Sitagliptin, Pioglitazone|Thiazolidinedione
3356702|NCT02315287|Active Comparator|Metformin, Sitagliptin, Lobeglitazone|Thiazolidinedione
3356703|NCT02315300|Experimental|Study Tretament|Long term ECG measurement is performed with the 12-lead ECG system medilog® DARWIN FD12 from Schillermed to detect different ECG parameter. The continuous glucose monitoring (CGM) system G4 from Dexcom use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for 7 days in parallel to the ECG measurement. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor.
3356704|NCT02315313||group1|RHR≤60bpm
3356705|NCT02315313||group2|RHR 61-70bpm
3356706|NCT02315313||group3|RHR 71-80bpm
3356707|NCT02315313||group4|RHR >80bpm
3356708|NCT02315326|Experimental|Arm A: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|This is an open-label, non-randomized, single center, dose escalation, phase I/II study to establish the maximum-tolerated dose (MTD) of ibrutinib as a single agent in patients with refractory/recurrent PCNSL or refractory/recurrent SCNSL (Arm A).
3356709|NCT02315326|Experimental|Arm B: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|The defined MTD from Arm A will then be used in an expansion cohort to further assess toxicity and clinical activity
3356710|NCT02315326|Experimental|Arm C: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|Arm C will investigate the MTD of ibrutinib in combination with HD-MTX and to determine the safety and tolerability of the ibrutinib/HD-MTX combination regimen in PCNSL and SCNSL patients. To minimize drug-drug interaction between HD-MTX and Ibrutinib, Ibrutinib will not be administered concurrently with HD-MTX.
3246091|NCT01344044|Experimental|BCI pilot arm|This is a experimental arm to test out the safety and effectiveness of BCI in improving ADHD symptoms. This pilot arm is necessary as the BCI device, incorporating dry electrode sensors and intervention game, is newly developed and have not been tested out in children with ADHD. This preliminary study will also allow us to test out the treatment protocol (24 sessions of BCI training over 8 weeks) to see if it is efficacious.
3246092|NCT01344070|Active Comparator|Reference formulation of each drug|Innovator formulation
3246093|NCT01344070|Active Comparator|generic formulation a|one of the several generic formulations in the market, randomly selected for each drug
3246094|NCT01344070|Active Comparator|generic formulation b|second of the several generic formulations in the market, randomly selected for each drug
3356711|NCT02315326|Experimental|Arm D: Participants with refractory/recurrent PCNSL or refractory/recurrent SCNSL|THIS IS ONLY ARM RECRUITING In Arm D, patients will be treated with 4 cycles of therapy. Methotrexate (3.5 g/m2) will be given at Dday 1 and Dday 15 of each cycle. Rituximab (500 mg/m2) will be given at Dday 0 and Dday 15 of each cycle. Vincristine (1.4mg/m2) will be given at Dday 1 and 15 of cycle 1 and 2 only. Procarbazine (100mg/m2) will be given of Day 1 of each cycle. Ibrutinib will be dosed at 560 mg daily. Arm D will have a safety lead-in of 6 patients. If more than 1 of 6 subjects develop a dose limiting toxicity (DLT) within the first 28 days of therapy (cycle 1), ibrutinib will be reduced to 420 mg daily dosing, and 6 additional patients will be enrolled. If more than 1 of 6 subjects develop a DLT, additional enrollment will be stopped.
3356712|NCT02315378|Other|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
3356713|NCT02315378|Other|TAU|Treatment as Usual
3356714|NCT02315391|Experimental|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine|20g isolated whey protein + 30g carb, 8,5g fat, 15g glycine
3356715|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine|20g micellar whey protein + 30g carb, 8.5g fat, 15g glycine
3356716|NCT02315391|Experimental|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline|20g micellar whey protein + 30g carb, 8.5g fat, 5g citrulline
3356717|NCT02315404|Placebo Comparator|No cap|enteroscopy performed without a cap
3356718|NCT02315404|Active Comparator|Enteroscopy with a cap|Enteroscopy performed with a CAP fitted to the end of the scope
3246095|NCT01344070|Active Comparator|generic formulation c|third of the several generic formulations in the market, randomly selected for each drug
3246096|NCT01344083|Experimental|T1210|
3246097|NCT01344083|Active Comparator|Olopatadine hydrochloride|
3246098|NCT01344109||Breast cancer patients|Newly diagnosed patients with breast cancer presenting with operable breast tumor prior to initiation of of neoadjuvant chemotherapy (choice of chemotherapy will be the the treating physician's discretion)
3246099|NCT01344109||Healthy volunteers|Adult women without a cancer diagnosis.
3246100|NCT01344122|Active Comparator|KPI training only|Study sites randomized to this arm will receive a knowledge, perceptions and information (KPI) training for community correctional and treatment staff to address knowledge, perceptions, and information regarding local resources about MAT.
3246101|NCT01344122|Experimental|KPI plus OLI|Study sites randomized to this arm will receive the KPI training plus a Organizational Linkage Intervention (OLI) that will: (a) establish a local Pharmacotherapy Exchange Council (PEC) among agencies important for the implementation of MAT in community corrections; (b) facilitate a strategic planning process within the PEC to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole; and (c) identify a community corrections coordinator in one of the local agencies to operationalize and implement the strategic plan.
3246102|NCT01344135|Placebo Comparator|Group 1 (placebo control)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
3246103|NCT01344135|Experimental|Group 2 (nutritional intervention)|60 clinically stable COPD patients with muscle atrophy, eligible for out-patient pulmonary rehabilitation
3246104|NCT01344148|Experimental|Anti- TB therapy HAART|
3356719|NCT02315417|Experimental|gevokizumab|Solution for subcutaneous injection (Part 1, Group B)
3356720|NCT02315417|Placebo Comparator|Placebo|Solution for subcutaneous injection (Part 1, Group A)
3356721|NCT02315417|Experimental|gevokizumab open-label|Solution for subcutaneous injection (Part 2, Open-label)
3246105|NCT01344174|Other|glucocorticoids treatment|
3246106|NCT01344187|Experimental|riboflavin solution and KXL System|Subjects will receive riboflavin solution followed by UVA irradiation for 4 minutes
3246107|NCT01344187|Placebo Comparator|placebo solution and KXL System|Subjects will receive placebo solution followed by UVA irradiation for 4 minutes
3356722|NCT02315443|Experimental|NA-1|2.60 mg/kg of NA-1 (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
3356723|NCT02315443|Placebo Comparator|Placebo|Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.
3246108|NCT01344200|Active Comparator|Phase I: Study drug Group 1 (Celecoxib 7 mg/kg)|Study participants randomized to this group will receive a single 7 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
3246109|NCT01344200|Active Comparator|Phase I: Study drug Group 2 (Celecoxib 14 mg/kg)|Study participants randomized to this group will receive a single 14 mg/kg dose of celecoxib approximately 121-180 minutes before their scheduled LP ± BMA. The study medication will be a liquid and the study participant will be asked to drink it.
3356724|NCT02315456|Other|Capsule centration|Capsulorhexis made with capsule centration
3356725|NCT02315456|Other|Pupil centration|Capsulorhexis made with pupil centration
3356726|NCT02315482|Experimental|Group A|after induction of general anesthesia (i) a pneumoperitoneum is induced then (ii) patient is placed in steep trendelenburg position at 25 degrees head down
3246110|NCT01344200|Placebo Comparator|Phase II: Group A: Placebo|"Study participants will receive a single dose of placebo. Placebo will be liquid. The study participant will drink it.~The timing of when the study participants in this group will take placebo will be determined in a second randomization:~Group A.1: will take placebo 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.2: will take placebo 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.3: will take the placebo 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group A.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group A.5: will take the study medication 0 to 60 minutes prior to having their LP±BMA. The study medication will be taken at the hospital."
3356727|NCT02315482|Experimental|Group B|after induction of general anesthesia (i) the patient is placed in steep trendelenburg position at 25 degrees head down then (ii) a pneumoperitoneum is induced
3356728|NCT02315495|Experimental|5 mg saxagliptin + 100 mg acarbose|"Acute dosing:~5 mg saxagliptin is given with water, 60 min before a test meal 100 mg acarbose is given with a test meal"
3356729|NCT02315495|Experimental|5 mg saxagliptin|"Acute dosing:~5 mg saxagliptin is given 60 min before a test meal,"
3356730|NCT02315495|Experimental|100 mg acarbose|"Acute dosing:~100 mg acarbose is given with a test meal"
3356731|NCT02315495|No Intervention|control|
3356732|NCT02315508|Experimental|AUT00063|4 capsules of 200 mg of the new medicine, AUT00063, to take orally with food for 4 weeks.
3356733|NCT02315508|Placebo Comparator|Placebo|4 capsules of placebo, to take orally with food for 4 weeks.
3356738|NCT02315547|Other|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
3356739|NCT02315573|Experimental|Lidocaine with epinephrine|"Wrist block anesthesia with Lidocaine 1% with epinephrine; 10cc.~Group 1 will receive the same treatment as group 2, except that the wide-awake carpal tunnel release surgery will be performed under Lidocaine anesthesia instead of Bupivacaine anesthesia."
3356740|NCT02315573|Experimental|Bupivacaine with epinephrine|"Wrist block anesthesia with Bupivacaine 0.25% with epinephrine; 10cc.~Group 2 will receive the same treatment as group 1, except that the wide-awake carpal tunnel release surgery will be performed under Bupivacaine anesthesia instead of Lidocaine anesthesia."
3356746|NCT02315638||Dosed subjects|There is no intervention. This is a observational study monitoring subjects that were dosed with TT-034 in the Tacere B2801001 study,
3356747|NCT02315651|Experimental|Coenzyme Q10|30 children aged 6-12 will consume daily a snack containing 60 mg of CoQ10 for 8 weeks.
3356748|NCT02315651|Placebo Comparator|Placebo|30 children aged 6-12 years will consume an identical snack without CoQ10 for 8 weeks
3356749|NCT02315677|Active Comparator|Nasal intubation-Standard RAE ETT|This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
3356750|NCT02315677|Active Comparator|Nasal intubation-Parker Flex-Tip ETT|This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
3246111|NCT01344200|Active Comparator|Phase II: Group B: Study drug (Celecoxib 7 mg/kg)|"Study participants randomized to this group you will receive a single 7 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group B.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group B.4: will take the study medication 1 to 2 hours prior to having their LP±BMA. The study medication will be taken at the hospital.~Group B.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
3356751|NCT02315690|Active Comparator|Reactive case detection (RACD)|Individuals in RACD Target Areas will be tested by RDT (rapid diagnostic test) and if positive, taken to the nearest health facility for treatment with artemether-lumefantrine per national policy.
3356752|NCT02315690|Experimental|Reactive focal mass drug administration (fMDA)|In the fMDA arm, all individuals in the Target Area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
3246112|NCT01344200|Active Comparator|Phase II: Group C: Study drug (Celecoxib 14 mg/kg)|"Study participants randomized to this group you will receive a single 14 mg/kg dose of celecoxib which will be in a liquid form, and the study participant will drink it.~The timing of when the study participant in this group will take this medication will be determined in a second randomization:~Group C.1: will take the study medication 15 to 24 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.2: will take the study medication 5 to 15 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.3: will take the study medication 3 to 5 hours prior to having their LP±BMA. The study medication will be taken at home.~Group C.4: will take the study medication 1 to 2 hours prior to having your LP±BMA. The study medication will be taken at the hospital.~Group C.5: will take the study medication 0 to 60 minutes prior to having your LP±BMA. The study medication will be taken at the hospital."
3246113|NCT01344213|Active Comparator|Pregabalin|Oral single-dose of pregabalin (150 mg) and 1 capsule of placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3356753|NCT02315716|Experimental|Consolidation with 4 cycles of CarCyDex|Patients responding to induction treatment will receive 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone (CarCyDex) treatment followed by 18 months of maintenance carfilzomib
3356754|NCT02315716|Active Comparator|ASCT|Patients responding to induction treatment will receive a melphalan conditioned autologous stem cell transplant followed by 18 months of maintenance carfilzomib
3246114|NCT01344213|Active Comparator|Celecoxib|Oral single-dose of celecoxib (400 mg) and 1 capsule of placebo (C) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3246115|NCT01344213|Active Comparator|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
3356755|NCT02315742|Experimental|Let's Move Program|Patients will take part in a 12-week exercise program.
3356756|NCT02315768|Experimental|GA101+ibrutinib|"Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.~GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:~Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.~Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.~Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.~Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered."
3356757|NCT02315781|Active Comparator|Active tDCS|active tDCS will be used on half of the study participants
3356758|NCT02315781|Sham Comparator|Sham tDCS|Sham tDCS will be used on half of the study participants
3356759|NCT02315794|Experimental|SPI®ART|in test group after a three month healing period a zirconia abutment was connected to the implant to realize the prosthetic restoration
3246116|NCT01344213|Placebo Comparator|Placebo|Oral single-dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
3246117|NCT01344239|Experimental|Limb RIPC|The limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
3356760|NCT02315794|Active Comparator|SPI®EASY|in control group a three month healing period a titanium abutment was connected to the implant for the prosthetic restoration
3356761|NCT02315807|Experimental|dlPFC|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in dorsolateral prefrontal cortex
3246118|NCT01344239|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia
3356762|NCT02315807|Experimental|CON|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in cingulo-opercular network
3356763|NCT02315807|Active Comparator|M1|Participants in the chronic post-stroke stage will receive active transcranial direct current stimulation in motor primary cortex
3356764|NCT02315820|Experimental|Induction of Labor (IOL)|Group I, Induction of Labor group (IOL). Women will be admitted for induction at 38-40+3 weeks when estimated fetal weight 3800-4500 gram.
3356765|NCT02315820|No Intervention|Expectant|Group II. Will be expectantly managed until 40+6 weeks, or an induction indication will appear.
3356766|NCT02315833|Experimental|Acetium|Patient will administer Acetium capsules (100mg l-cysteine) twice a day for three months
3356767|NCT02315833|Placebo Comparator|Placebo|Patient will administer placebo capsules twice a day for three months
3356768|NCT02315859||All patients|All patients
3356769|NCT02315898|Experimental|Treatment-inhaled tPA|All patients with plastic bronchitis enrolled into the study will receive inhaled tPA.
3356770|NCT02315911|No Intervention|expectancy for mild-moderate OSA|6 months expectancy
3356771|NCT02315911|Experimental|ATE for mild-moderate OSA|adeno-tonsillectomy
3246119|NCT01344252|Experimental|Topical|
3356772|NCT02315911|Experimental|ATE for severe OSA|adeno-tonsillectomy
3356773|NCT02315911|Experimental|APP for severe OSA|adeno-pharyngoplasty
3356774|NCT02315924|Experimental|coronary and cerebral stenosis|
3356775|NCT02315924|Active Comparator|coronary or cerebral stenosis|
3246120|NCT01344252|Active Comparator|subtenon|
3246121|NCT01344265||consecutive patients|there is only one group in our study
3356776|NCT02315950|Other|Arm 1|Botulinum toxin and cineMRI-UDS
3356777|NCT02315963|No Intervention|No intervention group|Patients in stroke rehabilitation receiving standard therapy
3356778|NCT02315963|Active Comparator|Intervention group|Patients in stroke rehabilitation receiving standard therapy plus performance feedback
3246122|NCT01344278|Experimental|Lifestyle Counseling|
3246123|NCT01344278|No Intervention|Control|
3356779|NCT02315976|Experimental|Propatyl nitrate|Patients treated with propatyl nitrate 10mg thrice daily
3356780|NCT02316015|Experimental|Intervention group|Children in the intervention group will receive a protein-energy enriched milk (Infatrini®, or in the case of children on a partial or fully hydrolized milk Infatrini Peptisorb®). The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day). The intervention will be carried out during the first 7 days of hospitalisation, or until the day of discharge (if hospitalized for less than 7 days).
3246124|NCT01344304|No Intervention|Standard therapy|The patients are treated with 5HT3-receptor antagonist + dexamethasone during the first course, then treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone
3246125|NCT01344304|Experimental|Aprepitant / Fosaprepitant therapy|The patients are treated with aprepitant / fosaprepitant + 5HT3-receptor antagonist + dexamethasone during first and second courses.
3246126|NCT01344317||Caffeine group|Premature infants below 30 weeks of gestation who receive Caffeine treatment
3246127|NCT01344317||Caffeine and Doxapram group|Premature infants below 30 weeks of gestation who receive Caffeine and Doxapram treatment
3356781|NCT02316015|No Intervention|Control group|Children in the control group will receive their regular milk. The volume of milk offered will be the same quantity as they usually drink at home (within the limits of 120-170 ml/kg/day).
3356782|NCT02316028|Experimental|decitabine|"administration of decitabine by hepatic arterial infusion~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~Proposed dose levels:~10 mg/m2 per course~15 mg/m2 per course~20 mg/m2 per course"
3356783|NCT02316041|Experimental|Small incision lenticule extraction|Small incision lenticule extraction (SMILE) is a form of corneal laser refractive surgery performed using a femtosecond laser
3356784|NCT02316054||diabetes and MPHI|myocardial perfusion heterogeneity imaging
3356785|NCT02316067|Experimental|Rehabilitation|Eight weeks of rehabilitation (CHORDATA® Method)
3356786|NCT02316067|No Intervention|Control|Participants maintained their daily-life activities routine during the same eight weeks period and were tested before and after this control period.
3356787|NCT02316080|Experimental|Desensitizing therapy|14 groups (7 treated with in-office dental bleaching and 7 treated with home-use dental bleaching) . There will be 7 different types of dessensitizing agents that will be used together with the dental bleaching treatment
3356788|NCT02316080|Experimental|Dental Bleaching|2 groups of dental bleaching treatment - 16% carbamide peroxide and 35% peroxide
3356789|NCT02316093||obese-chronic periodontitis patients|
3356790|NCT02316093||obese-gingivitis patients|
3356791|NCT02316093||obese-periodontally healthy controls|
3356792|NCT02316093||normal weight-chronic periodontitis patients|
3246128|NCT01344317||Group with no treatment|Premature infants below 30 weeks of gestation with no stimulating treatment
3246129|NCT01344330||Screening colonoscopy patients|Men and women age 50 to 75 scheduled for screening colonoscopy
3356793|NCT02316093||normal weight-gingivitis patients|
3356794|NCT02316093||normal weight-periodontally healthy controls|
3356795|NCT02316106|Experimental|Arm A (Long Intense)|
3356796|NCT02316106|Experimental|Arm B (Intermediate)|
3356797|NCT02316106|Experimental|Arm C (Short Intense)|
3356798|NCT02316119||Control group|Post-ACS patients without history of IS/TIA previously to the acute coronary and taking aspirin
3356799|NCT02316119||Case group|Post ACS patients with history of IS/TIA previously to the acute coronary event and taking aspirin
3356800|NCT02316132|Active Comparator|Stress|Injection of corticotropin releasing factor
3356801|NCT02316132|Placebo Comparator|Control|Injection of 0.9% saline 10 ml
3356802|NCT02316145|Other|'Habilitation (Internet-based support)|Before the individual started with the internet-based support and coaching (IBSC), a meeting with the coach was compulsory to discuss what specific issues they were going to work with during the period of IBSC. The IBSC was offered at fixed times twice a week during an eight-week period. Two meetings between the individual and the coach were included. Between chat sessions the individuals and the coaches could get in touch using the programme's e-mail. The content of the support and coaching was individualised based on each individual's requirement. Once a fortnight a meeting was held with the head of the project and coaches. Issues regarding ongoing support and coaching were addressed.
3356803|NCT02316158|Experimental|Webb-based support and education|It contains of two parts 1) evidence based information (about mental diseases, early signs, coping strategies, what you can do for your relative or close friend, what you can do for yourself, addresses to networks and web sites, relevant juridical issues, etc), 2) FAQ, where you directly can find answers to common questions.
3246130|NCT01344343|Experimental|Accelerated hip fracture surgery|Arrival in the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair
3246131|NCT01344343|No Intervention|Standard care|Surgical hip fracture repair according to the standard timing
3246132|NCT01344382|Experimental|CRAFT|All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
3356804|NCT02316158|Active Comparator|Available support in society|Available support in society for young persons presented in a brochure
3356805|NCT02316184|Placebo Comparator|Brief Advice|Participants in this arm will receive brief advice about alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
3356806|NCT02316184|Active Comparator|MI|Participants in this arm will receive a talking intervention designed to explore their interest in reducing/eliminating alcohol use. Sessions will occur at the baseline interview and every three months for 18 months.
3246133|NCT01344382|Active Comparator|Al-Anon Facilitation|All parents will be scheduled for 12 individual Alanon/Naranon Facilitation Training (ANF) sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
3246134|NCT01344395|Experimental|RK-group|
3246135|NCT01344395|Active Comparator|K-group|
3246136|NCT01344408|Experimental|Computer-training|The computer-training program, Move it to improve it was installed in the participants homes using an internet-connected computer with a web camera connected to a cloud-based specifically adapted interactive training program.
3246137|NCT01344408|Experimental|Printed instructions|A training program delivered as printed instructions
3246138|NCT01344421||hip dysplasia|Patients with hip dysplasia
3246139|NCT01344421||Healthy people|Enrolled from the patients acquaintance circle
3356807|NCT02316197|Experimental|MSC2490484A 100 mg QD|Participants received MSC2490484A capsules 100 milligram (mg) orally, once daily (QD) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3246140|NCT01344473|Experimental|Casein phosphopeptide in the form of TM|Experimental group will be given TM to use daily for 12 weeks
3246141|NCT01344473|No Intervention|No intervention|Standard oral care
3246142|NCT01344486|Experimental|Full conditioing|Intervention by alteration of laparoscopic gas with addition of oxygen and nitrous oxide, regulation of humidification and temperature (32°C), injection of 5mg Dexamethasone and application of Hyalobarrier Gel Endo (Nordic Pharma) at the surgical wound
3356808|NCT02316197|Experimental|MSC2490484A 200 mg QD|Participants received MSC2490484A capsules 200 mg orally, QD from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356809|NCT02316197|Experimental|MSC2490484A 150 mg BID|Participants received MSC2490484A capsules 150 mg orally, twice daily (BID) from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356810|NCT02316197|Experimental|MSC2490484A 200 mg BID|Participants received MSC2490484A capsules 200 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356811|NCT02316197|Experimental|MSC2490484A 300 mg BID|Participants received MSC2490484A capsules 300 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356812|NCT02316197|Experimental|MSC2490484A 400 mg BID|Participants received MSC2490484A capsules 400 mg orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356813|NCT02316197|Experimental|MSC2490484A 400 mg BID RP2D|Participants received MSC2490484A capsules 400 mg recommended Phase II dose (RP2D) orally, BID from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
3356814|NCT02316210|Experimental|Digitimer stimulation|
3356815|NCT02316236|Experimental|dexmedetomidine loading dose|dexmedetomidine is given at load dose
3356816|NCT02316236|Experimental|dexmedetomidine sustaining dose|dexmedetomidine is given at sustaining dose
3246143|NCT01344486|Active Comparator|carbon dioxide|induction pneumoperitoneum with carbon dioxide 100%
3356817|NCT02316249|Active Comparator|Gellhorn Pessary|Patients who are fitted with a Gellhorn pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
3246144|NCT01344499|Experimental|Adept|1000ml Adept will be left in the abdomen and measured over time
3356818|NCT02316249|Active Comparator|Ring with Support Pessary|Patients who are fitted with a Ring with Support Pessary for reduction of pelvic organ prolapse. Patients will then be randomized based on pessary to either Estradiol vaginal cream or Placebo vaginal cream. Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
3246145|NCT01344499|Active Comparator|Ringer-lactate|1000 ml of Ringer lactate left in the abdomen and measured over time
3246146|NCT01344512|Experimental|Patients treated with Ceftazidime|
3246147|NCT01344512|Experimental|Patients treated with Ciprofloxacin|
3246148|NCT01344512|Experimental|Patients treated with Voriconazole|
3246149|NCT01344525|No Intervention|Control group|Nutritional counselings every 6 months, no further intervention
3246150|NCT01344525|Experimental|"low-calorie-diet (LCD)-based lifestyle intervention"|12 months multidisciplinary weight loss program including three months low-calorie formula diet (800 kcal) (OPTIFAST®52 program)
3246151|NCT01344525|Experimental|Laparoscopic gastric sleeve intervention|
3246152|NCT01344525|Experimental|Conventional bariatric surgery|Gastric Banding and Gastric Bypass
3246153|NCT01344551|Active Comparator|High Flavanol|High Flavanol cocoa drink containing 495mg cocoa
3246154|NCT01344551|Placebo Comparator|Low Flavanol|Low Flavanol cocoa drink (23mg)
3246155|NCT01344564|Other|ADT|All subjects receive ADT, degarelix acetate for 3 months followed by one 3 month leuprolide depot.
3246156|NCT01344577||Group1#|bone graft material used: Apatos Cortical® (porcine cortical bone 600-1000 µm)
3246157|NCT01344577||Group2#|bone graft material used: MP3® (porcine cortic-cancellous collagenated bone mix 600-1000 µm)
3246158|NCT01344577||Group3#|control group
3246159|NCT01344590|Active Comparator|saline lock maintenance|Standard saline lock maintenance
3246160|NCT01344590|Experimental|ethanol maintenance|Instillation of 70% pharmaceutical grade ethanol solution into the central line in a volume calculated to fill the catheter lumen and hub.
3246161|NCT01344603||epidural|
3246162|NCT01344603||standard|
3246163|NCT01344655|Experimental|Formoterol 12 μg pMDI (Atimos®)|
3246164|NCT01344655|Active Comparator|Salmeterol 25 µg pMDI HFA (Serevent™)|
3246165|NCT01344655|Placebo Comparator|Matched Placebo|
3356819|NCT02316262|Experimental|TR|All subjects enrolled in this study will undergo pre-operative evaluation, anesthesia, and dissection to identify the painful residual limb neuroma(s). Gentle traction will be applied to the nerve while excising the neuroma (traction neurectomy) allowing the nerve to retract more proximally.Targeted muscle reinnervation involves transfer of residual nerves to otherwise redundant target muscles. Native motor innervation of the target muscle is cut, and the residual nerves-after excision of end-neuromas-are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle.
3246166|NCT01344668|Other|Standard Diabetes Education|Standard Diabetes Education
3246167|NCT01344668|Other|Enhanced Diabetes Education|Enhanced Diabetes Education
3246168|NCT01344681|Experimental|Arm A|Micafungin sodium
3246169|NCT01344681|Active Comparator|Arm B|Itraconazole
3246170|NCT01344694||patient with liver fat|30 patients with liver fat
3246171|NCT01344694||excess of visceral fat|50 pts. with excess of visceral fat
3246172|NCT01344694||control|30 control subjects
3246173|NCT01344720|Active Comparator|etoricoxib|etoricoxib up to 60mg/day as monotherapy
3246174|NCT01344720|Active Comparator|etoricoxib plus controlled-release oxycodone|combination treatment of etoricoxib (30 mg/day) plus controlled-release oxycodone (10 mg/day)
3246175|NCT01344733||MDD|Patients with treatment resistant major depressive disorder will be evaluated in order to assess the presence of hypomanic symptoms as cause of resistance.
3246176|NCT01344746||Snoring group|"Subjects with snoring and AHI ≥ 20 episodes/h (severe SDB).~Snorers with AHI < 20 episodes/h and ≥ 5 episodes/h (moderate SDB)~Snorers with AHI < 5 episodes/h and ≥ 1 episodes/h (mild SDB)"
3246177|NCT01344746||Non-snoring group|"When testing serum and urinal samples, healthy children without snoring will be chosen as controls.~When testing lymphoid tissue samples, patients with recurrent infectious tonsillitis (at least five tonsillar infections in less than 6 months) but without snoring will be selected as controls before surgery and recruited to the study, because adenotonsillar tissue can't be obtained from normal children for obvious ethical reasons."
3246178|NCT01344772|Active Comparator|Internal fixation|Displaced femoral neck fracture treated with internal fixation using two parallel cannulated screws.
3246179|NCT01344772|Active Comparator|Total hip replacement|Displaced femoral neck fracture treated with total hip replacement through a posterior approach.
3246180|NCT01344785||Patients with a intertrochanteric fracture|Patients with a intertrochanteric fracture, n=100
3246181|NCT01344798|Experimental|Dose level 1|AAV1-gamma-sarcoglycan vector dose level: 3x10e9 vg/100µl
3246182|NCT01344798|Experimental|Dose level 2|AAV1-gamma-sarcoglycan vector dose level: 1.5x10e10 vg/100µl
3246183|NCT01344798|Experimental|Dose level 3|AAV1-gamma-sarcoglycan vector dose level: 4.5x10e10 vg/300µl
3246184|NCT01344811|Experimental|Telemonitoring group|"A Smartphone, body composition analyzer and Pedometer will be provided~transmitting the results to the Smart Care Server via Smartphone~At Smart care Center,care manager will provide remote body weight and activity monitoring and individual obesity case management"
3246185|NCT01344811|Other|Control group|"A weighing scale and Pedometer will be provided~recording in a self diary of body weight and the number of steps"
3246186|NCT01344837||Observational|Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).
3246187|NCT01344863|Experimental|1|
3246188|NCT01344863|Active Comparator|2|
3246189|NCT01344889||Cohort|
3246190|NCT01344902|Experimental|Hexaminolevulinate|
3246191|NCT01344915|Active Comparator|Knee brace|
3246192|NCT01344915|Active Comparator|Locked knee brace|
3246193|NCT01344928|Experimental|HIT training|
3246194|NCT01344928|Active Comparator|Aerobic exercise training|
3246195|NCT01344941||Group 1|The first group will comprise individuals who have received a St. Jude HIV-1 vaccine and who have exhibited sustained immune responses
3246196|NCT01344941||Group 2|Groups 2 will be HIV-1-infected. The first visit of individuals in groups 2 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
3246197|NCT01344941||Group 3|Groups 3 will be HIV-1-uninfected. The first visit of individuals in groups 3 will involve the collection of 120 ml of blood as well as a minimal blood volume required for the specified screening laboratory evaluation for each group.
3246198|NCT01344954|Experimental|25mg TB-402|
3246199|NCT01344954|Experimental|50mg TB-402|
3246200|NCT01344954|Active Comparator|10mg QD Rivaroxaban|
3246201|NCT01344967|Experimental|Zometa, Bone Suppression, Active Ingredient|
3246202|NCT01344980|Experimental|Stainless steel MGH|Patients in this study arm will have their flexor tendon laceration repaired using stainless steel suture (size 3-0) in an MGH repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
3356820|NCT02316275|Active Comparator|Standard post-operative activity restriction|As a traditional method, patients will be restricted from activity for six weeks after sling surgery.
3356821|NCT02316275|Experimental|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery.
3356822|NCT02316288|Experimental|Therapy|Mindfulness and Acceptance Therapy
3356823|NCT02316288|Active Comparator|Education|Health Education
3356824|NCT02316301|Experimental|Long interval misoprostol|A small envelope including two labeled plastic bags (A & B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In long interval misoprostol group, bag (A) contains misoprostol tablets and bag (B) contains placebo tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
3356825|NCT02316301|Active Comparator|Short interval misoprostol|A small envelope including two labeled plastic bags (A& B) (each bag containing either 2 misoprostol tablets(400µg) or 2 identically appearing placebo tablets) will be packaged in sequentially numbered sealed envelopes. In short interval misoprostol group, bag (A) contains placebo tablets and bag (B) contains misoprostol tablets. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 12 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
3356826|NCT02316314||Individuals diagnosed with FRDA|Individuals diagnosed with FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
3356827|NCT02316314||Healthy controls|Individuals without FRDA, to undergo the cardiac magnetic resonance imaging (CMR), exercise-stress test, echocardiogram (ECHO), and cardiac-related blood studies
3356828|NCT02316327|Experimental|gemcitabine, cisplatin and bevacizumab|"Bevacizumab will be given by I.V infusion at the dose of 7.5 mg/kg on days 1 every 21 days~Cisplatin 80 mg/m2 I.V on day 1~Gemcitabine 1250 mg/m2 I.V on day 1 & 8~Treatment cycles will be repeated every three weeks up to 6 cycles~Bevacizumab monotherapy as maintenance allowed in non-progressive tumors"
3356829|NCT02316340|Experimental|Study Arm - VOR with HCQ|Patients will be given vorinostat 400 mg daily and hydroxychloroquine 600 mg daily in 4 week cycles.
3356830|NCT02316340|Active Comparator|Control Arm - Regorafenib|Patients will be given oral RGF 160 mg daily for 3 weeks in 4 week cycles.
3356831|NCT02316379|Experimental|Hyperpolarized 129 Xenon|Administration of up to 1 liter doses of Hyperpolarized Xenon gas during MRI to optimize acquisition of images for adults vs. proton MR imaging. These scans, utilizing volunteers for calibration, may be utilized through this study to optimize the scan details.
3356832|NCT02316392||Post transplant subjects|Hyperpolarized Helium-3 MRI. Subjects who have had or are scheduled to have a lung transplant
3356833|NCT02316405|Experimental|Test Group|5 weeks of arm and leg cycling, 3 times per week for 30 minute of total exercise per session
3356834|NCT02316418|Experimental|Hairstetics™ anchoring system|Prosthetic hair implantation using the Hairstetics™ anchoring system, followed by attachment of hair extensions.
3356835|NCT02316444|Other|HAART exposed|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
3356836|NCT02316444|Other|HAART naive|Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
3356837|NCT02316457|Experimental|ARM1 IVAC_W_bre1_uID|Patients enrolled in ARM1 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient.
3356838|NCT02316457|Experimental|ARM2 IVAC_W_bre1_uID/IVAC_M_uID|Patients enrolled in ARM2 will optionally receive the WAREHOUSE treatment as described above followed by the personalized IVAC® MUTANOME immunotherapy. The mutation selection process constitutes a multi-step process including identification of somatic mutations by NGS, mutation confirmation and prioritization, selection, and on demand manufacturing.
3356839|NCT02316457|Experimental|ARM3 IVAC_W_bre1_uID + RBLTet.1|Patients enrolled in ARM3 will receive a treatment with four RNAs. This includes two to three variant RNAs selected from the WAREHOUSE plus p53 RNA. The selection process of RNAs from the warehouse is based on RT-PCR-based profiling of RNA extracted from patient tumour sample specimens, pre-defined cut-offs and algorithms to select the three relevant RNAs for a given patient. RBLTet.1 RNA will be added to each RNA applied.
3356840|NCT02316483||Group I: T2D and Charcot foot|Individuals with confirmed diagnosis of type 2 diabetes, using the American Diabetes Association guidelines and confirmed diagnosis of Charcot foot, based on clinical and radiological evidence of Charcot foot.
3356841|NCT02316483||Group II: T2D neuropathy, no charcot|Individuals with type 2 diabetes and presence of neuropathy but the absence of Charcot foot.
3356842|NCT02316483||Group III: Control, non-diabetic|Individuals without history of type 2 diabetes.
3356843|NCT02316496|Experimental|open label , single arm|cetuximab - irinotecan until progression or unacceptable toxicity
3356844|NCT02316509|Experimental|Part I: Dose Escalation - GDC-0927|Participants will receive GDC-0927 orally as a single dose on Day -7. Continuous daily dosing will commence on Day 1. Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0927 with use of a standard 3 + 3 design. The starting dose will be 600 milligrams per day (mg/day), followed by dose escalation in 400 milligrams (mg) increments.
3356845|NCT02316509|Experimental|Part II: Dose Expansion - GDC-0927|Participants in the expansion cohorts will receive GDC-0927 at MTD/RP2D starting from Day 1 of Cycle 1 (cycle length: 28 days) up to disease progression, unacceptable toxicity, participant withdrawal of consent or study termination.
3356846|NCT02316522||Group I: T2D nephropathy|Individuals with type 2 diabetes and nephropathy
3246203|NCT01344980|Active Comparator|Polypropylene DOLL|Patients in this study arm will have their flexor tendon laceration repaired using polypropylene suture (size 3-0) in a double-locking loop repair technique. They will then undergo aggressive early active range of motion rehabilitation post-operatively.
3246204|NCT01344993|Experimental|MA09-hRPE|"Experimental: Subretinal injection of MA09-hRPE~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3356847|NCT02316522||Group II: T2D and no nephropathy|Individuals with type 2 diabetes and no nephropathy
3356848|NCT02316522||Group III: Control, non-diabetic|Non-diabetic individuals with normal kidney function
3356849|NCT02316522||Group IV: Controls, non-diabetic|Non-diabetic individuals with hypertensive nephropathy
3356850|NCT02316535|Active Comparator|standard-dose|capecitabine, oral administration, 1,250 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
3356851|NCT02316535|Experimental|reduced-dose|capecitabine, oral administration, 1,000 mg/m2 twice daily on days 1-14, and repeated on day 22; 8 circles in total.
3246205|NCT01345006|Experimental|MA09-hRPE|Patients will undergo subretinal injection of MA09-hRPE
3246206|NCT01345032|Experimental|Home visits|Nutritional follow-up after discharge, conducted as nutritional counselling performed as in-person counselling in the participants homes
3356852|NCT02316561|Experimental|Single dose ablative radiotherapy|Eligible patients for single dose ablative radiotherapy according to inclusion and exclusion criteria
3356853|NCT02316574|Experimental|Cognitive Behavioral Coping Skills|Cognitive Behavioral Coping Skills Therapy is an individual psychotherapy for alcohol use disorders that has been previously shown to reduce drinking. The focus of this treatment is the teaching of coping skills for managing alcohol craving and negative emotions as a way to reduce drinking behavior.
3356854|NCT02316600|No Intervention|Control|30 frail volunteers of the control group in the second phase won't be equipped with the smart insole.
3356855|NCT02316600|Experimental|Intervention|30 frail volunteers of the intervention group in the second phase will be equipped with the smart insole for 3 months, to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
3356856|NCT02316626|Experimental|Subcutaneous progesterone|Luteal phase support cycles will involve once-daily administration of 25 mg of SC P from the day after insemination for 14 days.
3356857|NCT02316626|Active Comparator|Vaginal Progesterone|Luteal phase support cycles will involve once-daily administration of 90 mg vaginal gel from the day after insemination for 14 days.
3356858|NCT02316639|Experimental|Neuromuscular Training - No Exercise|Subjects will participate in 5 weeks of neuromuscular training followed by 5 weeks of no exercise intervention
3356859|NCT02316639|Experimental|No Exercise - Neuromuscular Training|No exercises will be administered for 5 weeks, followed by 5 weeks of neuromuscular Training.
3356860|NCT02316652|No Intervention|Healthy sites|Healthy sites with no inflammation; observational only
3356861|NCT02316652|Placebo Comparator|Scaling and root planing sites|Inflamed pocket receiving mechanical instrumentation
3356862|NCT02316652|Active Comparator|Scaling and root planing with solution|Inflamed pocket receiving mechanical instrumentation with sodium hypochlorite solution
3356863|NCT02316665|Experimental|continuous positive airway pressure|Patients will receive continuous positive airway pressure during three months
3356864|NCT02316665|Sham Comparator|Sham-continuous positive airway pressure|Patients will receive sham-continuous positive airway pressure during 3 months
3356865|NCT02316691||Thyroid Eye Disease|Blood samples will be drawn from subjects diagnosed with Thyroid Eye Disease. This study is observational. No interventions will be given as part of this study.
3246207|NCT01345032|Experimental|Telephone consultation|Nutritional follow-up after discharge, conducted as nutritional counselling performed as telephone consultation
3356866|NCT02316704|Active Comparator|OsseoTi™ G7 large|OsseoTi™ G7 acetabular cup and an E1™ liner holding largest possible femoral head (36mm-44mm)
3356867|NCT02316704|Active Comparator|OsseoTi™ G7 32|OsseoTi™ G7 acetabular cup and an E1™ insert holding a 32mm femoral head
3356868|NCT02316704|Active Comparator|conventional PPS coated G7 large|conventional PPS coated G7 acetabular cup and an E1™ insert holding largest possible femoral head (36mm-44mm)
3356869|NCT02316704|Active Comparator|conventional PPS coated G7 32|conventional PPS coated G7 acetabular cup and an E1™ insert holding a 32mm femoral head
3356870|NCT02316730|Experimental|Sanchi-Tongshu Capsule (Enteric coated pellets)|Sanchi-Tongshu Capsule (Enteric coated pellets) is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.35g/capsule, containing 100mg of panaxatriol saponins (PTS).
3356871|NCT02316730|Active Comparator|Sanchi-Tongshu Capsule|Sanchi-Tongshu Capsule is developed by pharmaceutical factory of Chengdu Huasun Group Inc., 0.2g/capsule, containing 100mg of panaxatriol saponins (PTS).
3356872|NCT02316743|Experimental|Levothyroxine|Levothyroxine supplementation
3356873|NCT02316756|Experimental|Single Ascending Doses Cohort 1|subjects receive 3 active doses and one placebo
3246208|NCT01345032|No Intervention|Control|No follow-up after discharge
3246209|NCT01345045|Experimental|ABT-639|ABT-639 twice daily for 6 weeks
3246210|NCT01345045|Active Comparator|pregabalin|pregabalin starting dose twice daily for week one then titrated up to maintenance dose twice daily for duration of the study
3246211|NCT01345045|Placebo Comparator|Placebo|Placebo twice daily for 6 weeks
3246212|NCT01345071||RA patients|RA patients with active disease or current use of anti-TNF. Treatment is according to treat to target principles.
3356874|NCT02316756|Experimental|Single Ascending Doses Cohort 2|subjects receive 3 doses and one placebo
3356875|NCT02316756|Experimental|Cohort 3|optional cohort
3356876|NCT02316782||Non-blinded IVUS assessment|The non-blinded arm will use the angiogram and IVUS grayscale and VH-IVUS to guide the procedure.
3356877|NCT02316782||Blinded IVUS assessment|After routine coronary angiogram, the physicians in the blinded arm of the study will only use the angiogram to guide the DES stenting procedure;
3246213|NCT01345084|Experimental|Radiation therapy, cisplatin and nimotuzumab|"Nimotuzumab - (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes. Pre-drugs are optional, at the investigator's discretion)- 200 mg, IV, weekly doses during the radiation therapy until completing 6 months.~Radiation therapy- 66 -70 Gy, external,fractions of 2 Gy per day, 5 days a week~Cisplatin - 75 mg/m2, IV, Doses every 3 weeks (a total of three doses)"
3246214|NCT01345084|Active Comparator|Radiation therapy and cisplatin|"Radiation therapy: 66- 70 Gy, fractions of 2 Gy per day, 5 days a week~Cisplatin:75 mg/m2, IV, doses every 3 weeks (a total of three doses)"
3356878|NCT02316795|Experimental|SLN biopsy with ICG injection|"During the SLN biopsy, the patient will undergo injection of ICG around the breast tumor or melanoma per standard techniques. 1.6 mL of 500 micro-molar ICG will be injected periareolarly (for breast cancer) or peri-tumorly (for melanoma). This will be performed after standard of care technetium-colloid injection. Patients will then undergo the standard SLN biopsy procedure.~After gamma-probe identification of the SLN, the surgeon will put on the goggle system to attempt to identify the SLN using fluorescence guidance. After this is performed, the goggle system will be removed and the SLN biopsy will be completed per standard techniques. Findings with the goggles will be recorded but will not change how the SLN biopsy is performed."
3356879|NCT02316808|Placebo Comparator|Placebo smoothie|
3246215|NCT01345097|Experimental|Younger Group|
3246216|NCT01345097|Experimental|Elderly Group|
3356880|NCT02316808|Experimental|Plant stanol ester smoothie|
3356881|NCT02316821|Experimental|bardoxolone methyl|bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks
3356882|NCT02316821|Placebo Comparator|Placebo|Placebo capsules, once daily for 16 weeks
3356883|NCT02316834|Experimental|BMN 673|
3356884|NCT02316860|Other|History of reflex syncope|Passive tilt test in athletes with a history of reflex syncope
3356885|NCT02316860|Other|No history of reflex syncope|Passive tilt test in athletes without history of reflex syncope
3356886|NCT02316873|Experimental|Music training|twice a week one hour for 30 weeks, music training
3356887|NCT02316873|Active Comparator|Visual arts|twice a week one hour for 30 weeks, visual arts training
3246217|NCT01345136|Experimental|RAD001 Treatment|All subjects will be given RAD001 for 1 year (12 months).
3246218|NCT01345149|Experimental|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
3246219|NCT01345149|Experimental|Exercise|Exercise: Individual counselling
3246220|NCT01345149|No Intervention|Control|Standard treatment without intervention.
3246221|NCT01345175|Experimental|Pts receiving Rifaximin|This group will receive rifaximin 400mg bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
3246222|NCT01345175|Placebo Comparator|Pts receiving placebo|This group will receive a placebo bid for 4 weeks. At 1 - 24 months after completion of the phase III portion of the trial, patients will be contacted by phone and given the option of receiving metronidazole in a followup, single arm study in which all patients receive the antibiotic. Patients who wish to participate will be mailed a drug prescription for a 3 week course of metronidazole 500mgs tid as well as the BFI forms and stool diary. Pretreatment and post treatment BFI scores will be collected and analyzed for change in bowel function as was done in the initial Phase III study.
3356888|NCT02316886|Experimental|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
3356889|NCT02316886|Active Comparator|Optimal Medical Treatment|Optimal Medical Treatment
3356890|NCT02316899|Experimental|ASP0456 (Period I)|Up to 12 weeks
3356891|NCT02316899|Placebo Comparator|Placebo (Period I)|Up to 12 weeks
3356892|NCT02316899|Experimental|ASP0456 (Period II)|From 12 weeks to 52 weeks
3356893|NCT02316912|Active Comparator|Single dose level 1 active|Six subjects ATX2417 I mg tablet once.
3246223|NCT01345214|Experimental|E|
3356894|NCT02316912|Active Comparator|Single dose level 2 active|Six subjects ATX2417 2x1 mg tablet once.
3356895|NCT02316912|Active Comparator|Single dose level 3 active|Six subjects ATX2417 5 mg tablet once.
3356896|NCT02316912|Active Comparator|Single dose level 4 active|Six subjects ATX2417 4x5 mg tablets once.
3356897|NCT02316912|Active Comparator|Single dose level 5 active|Six subjects ATX2417 to be determined.
3356898|NCT02316912|Active Comparator|Multiple dose level 1 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
3356899|NCT02316912|Active Comparator|Multiple dose level 2 active|Six subjects ATX2417 dose to be determined once daily for 8 days.
3356900|NCT02316912|Placebo Comparator|Single dose level 1 placebo|Two subjects one placebo tablet once.
3356901|NCT02316912|Placebo Comparator|Single dose level 2 placebo|Two subjects one placebo tablet x2 once.
3356902|NCT02316912|Placebo Comparator|Single dose level 3 placebo|Two subjects one placebo tablet once.
3356903|NCT02316912|Placebo Comparator|Single dose level 4 placebo|Two subjects two placebo tablets once.
3356904|NCT02316912|Placebo Comparator|Single dose level 5 placebo|Two subjects four placebo tablets once.
3356905|NCT02316912|Placebo Comparator|Multiple dose level 1 placebo|Two subjects matching placebo(s) once daily for 8 days
3356906|NCT02316912|Placebo Comparator|Multiple dose level 2 placebo|Two subjects matching placebo(s) once daily for 8 days.
3356907|NCT02316912|Active Comparator|Single dose level 6 active|Six subjects ATX2417 to be determined.
3356908|NCT02316912|Active Comparator|Single dose level 7 active|Six subjects ATX2417 to be determined.
3356909|NCT02316912|Placebo Comparator|Single dose level 6 placebo|Six subjects placeboto be determined.
3356910|NCT02316912|Placebo Comparator|Single dose level 7 placebo|Six subjects placebo to be determined.
3356911|NCT02316925|Placebo Comparator|Crystalline Cellulose|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3246224|NCT01345227|Experimental|Intra BM islet infusion|single intra BM islet infusion at the level of the iliac crest will be performed in patients having contraindications for intraportal infusion
3356912|NCT02316925|Experimental|Glutathione supplement|500 mg/day Setria glutathione supplement
3356913|NCT02316964|Experimental|Treatment (decitabine, allogeneic NK cells, aldesleukin)|Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
3246225|NCT01345240|Experimental|RTS,S Regimen A Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3246226|NCT01345240|Experimental|RTS,S Regimen A Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. In addition, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3356914|NCT02316990||patients ≥18 ,Neurosurgical departments and whose GCS≤10[4]|"The subject population that will be included in the NIS are the consecutive discharged patients ≥18 years old who were hospitalized to Neurosurgical departments and whose GCS≤10[4] within 24 hours of lesion/admission.(GCS: Glasgow Coma Scale NIS: Non-Interventional Study~)"
3356915|NCT02317003|Experimental|Intervention PPIL|Intervention delivered by the family doctor and based on structured information delivery according to cognitive and behavioural theories, a personalised written physical activity prescription in number of steps per day, a pedometer, and a pedometer logbook similar to diabetes logbooks.
3356916|NCT02317003|Active Comparator|Control OR|Oral recommendation of physical exercise delivered by the family doctor.
3356917|NCT02317029|Experimental|"1 (Standard: Oxygen / LIFEPAK 20)"|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Hyperoxia during cardioversion"
3356918|NCT02317029|Active Comparator|2 (room air / LIFEPAK 20)|"Intervention: Cardioversion with a biphasic truncated exponential waveform~Intervention: Normoxia during cardioversion"
3356919|NCT02317029|Active Comparator|3 (Oxygen / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Hyperoxia during cardioversion"
3356920|NCT02317029|Active Comparator|4 (Room air / Schiller Defigard 5000)|"Intervention: Cardioversion with a pulsed biphasic waveform~Intervention: Normoxia during cardioversion"
3356921|NCT02317055|Other|Patient|Imaging
3356922|NCT02317055|Other|healthy subject|Imaging
3356923|NCT02317068|Experimental|High Atrial Base Rate Pacing|The base rate of pacemaker will be determined 75-100 beats/minute in condition that during first step of follow-up, his/her atrial pacing will be more than 80% of atrial high rate/automatic mode switch
3356924|NCT02317068|Active Comparator|Device Default|The base rate of pacemaker will be determined 60 beats/minute
3356925|NCT02317081|Experimental|Axetis Inert Coronary Stents|Axetis Inert Coronary Stents for de novo coronary lesion
3356926|NCT02317094|Other|Control|Participants receive care as usual (various DMARDs, different from patient to patient).
3356927|NCT02317094|Experimental|Blood-flow restricted tranining|Participants will receive care as usual (various DMARDs, different from patient to patient) + 12 wks of low-intensity blood-flow restricted training twice per week.
3246227|NCT01345240|Experimental|RTS,S Regimen A Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen A, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen A included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™, at Weeks 0, 4 and 8, and 2 doses of Rotarix™ vaccine, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3259364|NCT01470222|Experimental|Intervention Group|"Monthly, all-worksite activities will be implemented to raise awareness of healthy nutrition for weight control throughout the worksite. The purpose of the all-worksite activities is: a) to create a supportive worksite-wide atmosphere for the individuals enrolling in the weight loss support group, and b) to provide low-level weight loss support for individuals who wish to prevent weight gain.~Individuals with eligible weight (defined as BMI ≥ 25 kg/m2) without medical contradictions to weight loss, who wish to join a support group to lose weight, may enroll in the worksite weight control support group that will meet weekly for the first 10 weeks and then monthly until the end of the 6-month intervention"
3356928|NCT02317107||Concussion|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they receive a diagnosis of concussion, defined as a complex pathophysiological process affecting the brain, induced by biomechanical forces. If they agree to participate, they will be placed in the concussion group and assessed at each visit to the clinic. No intervention will be administered.
3356929|NCT02317107||Control|Individuals who report to the Division of Sports Medicine at Boston Children's Hospital will be identified for inclusion in the study if they come to the clinic for an injury unrelated to brain function or a lower extremity function (which may affect normal gait patterns). If they agree to participate, they will be placed in the control group and assessed at each visit to the clinic. No intervention will be administered.
3356930|NCT02317133||HSP: acute episode|"Patients in this group are going through an acute episode of Henoch Schönlein Purpura.~Intervention: Blood samples Intervention: Stool samples"
3356931|NCT02317133||HSP: remission|"Patients in this group have had Henoch Schönlein Purpura in the past but currently have no symptoms.~Intervention: Blood samples Intervention: Stool samples"
3356932|NCT02317133||Control group|"Control patients recruited from elective surgery candidates at the participating hospitals.~Intervention: Blood samples Intervention: Stool samples"
3356933|NCT02317146|Experimental|Six Hours Postpartum|The woman received magnesium sulfate for 6 hours after delivery as prophylaxis to eclampsia.
3356934|NCT02317146|Active Comparator|Twenty-four hours Postpartum|The woman received magnesium sulfate for 24 hours after delivery as prophylaxis to eclampsia.
3246228|NCT01345240|Experimental|RTS,S Regimen B Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3356935|NCT02317159|Experimental|imatinib，Capsule|400mg imatinib qd
3356936|NCT02317172|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
3356937|NCT02317198|Experimental|Intervention|Clopidogrel
3356938|NCT02317198|Active Comparator|Control|Ticagrelor/Prasugrel
3356939|NCT02317211|Placebo Comparator|control|placebo 320 mg daily for twelve weeks
3356940|NCT02317211|Experimental|anthocyanins treatment|anthocyanin supplement 320mg daily for twelve weeks
3356941|NCT02317224|Experimental|"3-Hole subxiphorid and subcostal approach"|The patient were in the supine position with legs apart at about 45°, made a 2.0 cm incision below xiphoid process as the observation hole. Then made two 0.5cm operation holes along bilateral rib arch at midclavicular line, two trocars were inserted into the two holes under the guidance of B-ultrasound.After that, carbon dioxide was pumped into the anterior mediastinum, the pressure was maintained at 8 mmH2O, ultrasound scalpel and a grasping forceps were inserted through the operating ports respectively. Retrosternal space including bilateral lower poles of thymus, internal mammary arteries and phrenic nerves were exposed by both blunt and sharp dissection. Then ultrasound scalpel were used to separate the thymus and its surrounding fat tissue, cut off thymic veins by ultrasound scalpel.For patients with myasthenia gravis, bilateral mediastinal pleurae and the affected adipose tissues had been thoroughly removed.
3356942|NCT02317224|Experimental|Trans sternal approach|
3356943|NCT02317224|Experimental|VATS approach|
3356944|NCT02317237|No Intervention|General Anesthesia|The patients, who will receive general anesthesia during intervention
3356945|NCT02317237|Experimental|Local Anesthesia|The patients, who will receive local anesthesia/conscious sedation during intervention
3356946|NCT02317250|Experimental|prompt amyloid imaging, delayed FDG-PET|Subject's managing physicians will be given the results of amyloid imaging scans immediately. FDG-PET results will be released two years after scanning.
3356947|NCT02317250|Experimental|prompt FDG-PET, delayed amyloid imaging|Subject's managing physicians will be given the results of FDG-PET scans immediately. Amyloid imaging results will be released two years after scanning.
3356948|NCT02317250|Experimental|prompt FDG-PET, prompt amyloid imaging|Both FDG-PET and amyloid imaging scan results will be made immediately available to the managing physician.
3356949|NCT02317250|Active Comparator|delayed FDG-PET, delayed amyloid imaging|Neither FDG-PET nor amyloid imaging scan results will be released to the managing physician for 2 years.
3356950|NCT02317263|Active Comparator|Testosterone gel|Apply gel once a day for 96 weeks
3356951|NCT02317263|Placebo Comparator|Placebo gel|Apply gel once a day for 96 weeks
3356953|NCT02317302|Experimental|FDG-PET/CT or FDG-PET/MR|"Standard of care FDG-PET/CT or FDG-PET/MR at baseline~FDG-PET/CT or FDG-PET/MR after the 2nd but before the 3rd brachytherapy treatment~Standard of care 3 month post treatment FDG-PET/CT or FDG-PET/MR~We will perform the research-related FDG-PET on the PET/MR rather than the PET/CT if the patient is safe to undergo MR and agrees to undergo MR.~The standard of care imaging may be performed on the PET/CT scanner or the PET/MR scanner."
3356954|NCT02317315||Preterm labor group|Patients who are admitted for evaluation of preterm labor.
3356957|NCT02317341|Experimental|1|Single intravenous dose given over 40 minutes
3356958|NCT02317341|Active Comparator|2|Single intravenous dose goven over 40 minutes
3356959|NCT02317367||adult women|Women who drink seven or more drinks per week
3356960|NCT02317367||adults a|Individuals who eat fewer than five servings of fruits and vegetables per day, on average, based on an NCI screener for fruit and vegetable consumption.
3356961|NCT02317367||adults b|Individuals who exercise (moderate or vigorous intensity) less than 75 minutes per week.
3356962|NCT02317393|Other|K5-RGD PET + FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy, with a maximal delay from end of chemotherapy of 2 months. Delay between FDG and 18F-K5-RGD PET scans will not exceed 2 weeks.
3246229|NCT01345240|Experimental|RTS,S Regimen B Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3356963|NCT02317406|Active Comparator|Probiotics|Biostime probiotics sachet children's formula, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
3356964|NCT02317406|Placebo Comparator|Probiotics simulation|Biostime probiotics sachet children's formula（placebo）, 1.5g/d/sachet, administrated during the consumption of the first feeding-bottle of the day. Duration: 4 weeks
3356965|NCT02317419|Experimental|Part A MAD Phase RO6927005 Monotherapy|RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
3356966|NCT02317419|Experimental|Part A Extension Phase Group 1|RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
3356967|NCT02317419|Experimental|Part A Extension Phase Group 2|RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
3356968|NCT02317419|Experimental|Part B MAD Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
3356969|NCT02317419|Experimental|Part B Extension Phase|RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA
3356970|NCT02317458|Experimental|Active arm|One arm with standard of care and C3BS-CQR-1 injection (treatment group) using intramyocardial catheter injection.
3356971|NCT02317458|Sham Comparator|Control arm|One arm with standard of care undergoing a sham procedure (control group)using intramyocardial catheter injection. .
3356972|NCT02317471|Experimental|gp96 group|autologous gp96 vaccination + basal treatment for gastric cancer
3356973|NCT02317471|Other|control group|Oxaliplatin+S-1
3356974|NCT02317484||Ipragliflozin (SGLT2 inhibitor)|
3356975|NCT02317497|Experimental|Moderate sedation (M)|1. Moderate sedation defined by target RASS of >= -3. The intervention (M) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of >= -3 (patient responds to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be deepened below the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the intervention group again.
3356976|NCT02317497|Active Comparator|Deep sedation (D)|2. Deep sedation defined by target RASS of < -3. The control (D) is sedation by use of any sedative and/or analgesic medication(s) left at the discretion of the treating physicians targeted at a RASS of < -3 (patient does not respond to verbal stimulus) from randomization for the next 72h. RASS will be assessed once every 8 h (at he beginning of each shift) and measures undertaken to achieve the target level. If safety-limits are violated, sedation may have to be reduced above the target level for 8h and re-assessed at the beginning of the next shift with the aim to approach the target level of the control group again.
3356977|NCT02317523|Experimental|Behavioral Activation|Behavioral Activation (BA) emphasize self-monitoring as an aid for increasing one's engagement in self-reinforcing activities while simultaneously reducing negative avoidant coping responses. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
3356978|NCT02317523|Active Comparator|Information and Support|Information and Support (IS) consists of providing education on Alzheimer's disease, coping with specific stresses prevalent in caregiving, and community-based services available for caregivers. Caregivers choose information most relevant to their current circumstances, and can discuss this with their counselor during the sessions. In addition, the IS condition encompasses elements of supportive therapy including empathy and active listening. The intervention consists of 6 total face-to-face sessions lasting 60 minutes each.
3356979|NCT02317536|Experimental|Carnipure Product 1|Carnitine-based product 1, subjects will take one dose once daily for 56 days.
3356980|NCT02317536|Experimental|Carnipure Product 2|Carnitine-based product 2, subjects will take one dose once daily for 56 days.
3356981|NCT02317536|Placebo Comparator|Placebo|Placebo, subjects will take one dose once daily for 56 days.
3356982|NCT02317588|Active Comparator|Flax Oil|Flax oil 4 grams of ALA per day for 28 days (4 weeks).
3356983|NCT02317588|Active Comparator|Fish Oil|Fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day for 28 days (4 weeks).
3356984|NCT02317601|Active Comparator|Methylprednisolone sodium succinate|125 mg iv, as single dose, preoperative.
3356985|NCT02317601|Placebo Comparator|physiological saline|5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi
3356986|NCT02317640|Active Comparator|Stand Training Alone|Standing training will be prescribed 3 days/week (1.5 hours/sessions) for 60 sessions. All individuals randomized to stand training will train with BWST with manual assistance and will undergo a stand evaluation. During the evaluation the participants will be placed on the treadmill in an upright position and suspended in a harness by an overhead cable (i.e. BWST). A trainer will be positioned to assist the participant while standing and to provide manual assistance if needed. The amount of BWS and level of assistance given for each body segment will be recorded. The BWS level at which the participant can independently support good standing posture will also be recorded. Standing time while on treadmill and overground will be recorded daily as part of the training sessions.
3356987|NCT02317640|Experimental|ST with placebo or testosterone|Stand Training as described above with Placebo or testosterone Gel applied by a pump. After a baseline testing period, TRT will begin in the treatment groups by application of a daily dose of 40.5 mg of testosterone or placebo gel. The gel is to be applied to the upper arms and shoulders and is absorbed and eliminated over the course of a day. To ensure proper dosing serum T concentration will be assessed at screening, baseline, 2 weeks, 1 month and 3 month time points. As such, follow-up with the participant will be necessary to determine the correct replacement dose of TRT, and adjustment of dose if needed, (i.e. 40.5 mg up to 81 mg of gel). If serum T levels are not within normal range at the 2 week time point, the dose will be increased in increments of 20.25 mg up to 81 mg.
3356988|NCT02317640|Experimental|ST with Placebo or Testosterone and ES|"Stand Training described above with Placebo or testosterone gel applied by a pump. Electrical stimulation will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points (both legs) on the following muscles: gluteus maximus (GL), rectus femoris (RF), biceps femoris (BF), gastrocnemei (GC), and anterior tibialis (TA) of both legs. Two electrodes will be used for each muscle. One RT300 portable stimulator (Restorative Therapies, Inc., Baltimore, MD) will be used to induce the electrical stimulation with 10 sets of electrodes for stimulation."
3356989|NCT02317640|Experimental|ST with ES|Stand Training as described above in Stand Training alone and Electrical Stimulation as described above in ST with Placebo or Testosterone and ES.
3356990|NCT02317653||Overweight/Obese|Archive blood, archive breast milk, and clinical assessment data from 15 participants who were considered overweight or obese at enrollment in the Expecting Success study conducted at Pennington Biomedical Research Center (NCT01610752) will be used to represent the overweight and obese sample for study investigations.
3356991|NCT02317653||Normal Weight|Up to 20 pregnant women who were considered normal weight (18.5 ≤ BMI ≤ 24.9 kg/m2) prior to pregnancy will be enrolled in the study.
3356992|NCT02317666|Experimental|Medication Review|Structured 5-step multidisciplinary medication review (STRIP method) performed by the pharmacist in collaboration with the general practitioner.
3356993|NCT02317666|No Intervention|Delayed Medication Review|Patients in the control group will not undergo a medication review during the study period (delayed medication review).
3356994|NCT02317679|Experimental|Bosentan and laser|Patients with PWS resistant to PDL treatment will be included. A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject). The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
3356995|NCT02317705|Experimental|Patients Receiving OTL38|All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
3356996|NCT02317718||Normal vitamin D levels group|MORE THAN 20 NG/ML VITAMIN D LEVELS
3356997|NCT02317718||Deficient Vitamin D GROUP|LESS THAN 20 NG/ML LEVELS
3356998|NCT02317731|No Intervention|Routine|Subjects will ingest the bowel preparation from a cup
3356999|NCT02317731|Experimental|Straw|Subjects will ingest the bowel preparation with a straw
3357000|NCT02317757||cancer patients receiving chemotherapy|Patients who are older than 70 years old receiving chemotherapy
3357001|NCT02317770|Active Comparator|Lidocaine Spray|20 puffs of 10% Lidocaine spray
3357002|NCT02317770|Active Comparator|Nebulized Lidocaine|2.5 mL of 10% Lidocaine
3246230|NCT01345240|Experimental|RTS,S Regimen B Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen B, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen B included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3246231|NCT01345240|Experimental|RTS,S Regimen C Lot 1 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 1 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 1, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3357003|NCT02317783|Experimental|All Participants|All enrolled subjects will complete three imaging sessions on separate days that consist of: 1) [18F]Flutemetamol-PET/CT, 2) FDG-PET/CT, and 3) MRI. The order of the performance of these studies will be based upon subject and radioisotope availability, but they will all be completed within 2 months of each other.
3357004|NCT02317796|Placebo Comparator|Placebo|
3357005|NCT02317796|Active Comparator|100 mg q.d.|
3357006|NCT02317796|Active Comparator|100 mg b.i.d.|
3357007|NCT02317796|Active Comparator|200 mg q.d.|
3357008|NCT02317796|Active Comparator|200 mg b.i.d.|
3357009|NCT02317835|Other|Study in healthy volunteers|Skin foot temperature measurement by DFUPS device
3246232|NCT01345240|Experimental|RTS,S Regimen C Lot 2 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 2 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 2, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3259365|NCT01470222|Experimental|Control Group (delayed intervention)|At the end of the study period, subjects will receive a 2-month structured intervention that will provide all of the resources and materials given to the intervention worksite as well as weight control support groups for employees interested in losing weight.
3259366|NCT01470235||Ovarian Cancer|"Women treated for ovarian cancer at the departments of obstetrics and gynecology, Aarhus University Hospital and Rigshospitalet, Copenhagen.~Expected recruitment: 200"
3357010|NCT02317848|Other|patients with acute heart failure|polygraphy, echocardiography, ECG during hospitalisation for acute heart failure
3357011|NCT02317861|Experimental|Cohort 1|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 10mg, RDEA3170 2.5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
3357012|NCT02317861|Experimental|Cohort 2|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 10mg, RDEA3170 5 mg + Febuxostat 20mg, and Febuxostat 20mg. The other half will be dosed in the reverse order.
3357013|NCT02317861|Experimental|Cohort 3|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 20mg, RDEA3170 5 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
3357014|NCT02317861|Experimental|Cohort 4|The half of patients randomized to this cohort will be dosed in the order of Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 20mg, RDEA3170 10 mg + Febuxostat 40mg, and Febuxostat 40mg. The other half will be dosed in the reverse order.
3357015|NCT02317861|Experimental|Cohort 5|RDEA3170 2.5mg, RDEA3170 5mg, RDEA3170 10mg, RDEA3170 15mg
3357016|NCT02317861|Experimental|Cohort 6|The half of patients randomized to this cohort will be dosed in the order of Benzbromarone 50 mg, Febuxostat 10mg+RDEA3170 2.5 mg, then Febuxostat 20mg+RDEA3170 5 mg. The other half will be dosed in the order of Febuxostat 10mg+RDEA3170 2.5 mg, Febuxostat 20mg+RDEA3170 5 mg, then Benzbromarone 50mg.
3357017|NCT02317874|Experimental|Schedule A (7-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-7, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
3357018|NCT02317874|Experimental|Schedule B (3-day talazoparib, paclitaxel, carboplatin)|"Patients receive talazoparib PO QD on days 1-3, paclitaxel IV over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4-6 cycles in the absence of disease progression or unacceptable toxicity.~At any time after 4-6 cycles of treatment, patients may continue combination study therapy with talazoparib, carboplatin, and paclitaxel, talazoparib and carboplatin, talazoparib alone (continuous dosing), or observation without therapy at the discretion of the treating physician."
3357019|NCT02317887|Experimental|Group 1|1e9 vg/eye
3357020|NCT02317887|Experimental|Group 2|1e10 vg/eye
3357021|NCT02317887|Experimental|Group 3|1e11 vg/eye
3357022|NCT02317887|Experimental|Group 4|1e11 vg/eye
3357023|NCT02317887|Experimental|Group 5|Not to exceed 3e11 vg/eye
3357024|NCT02317887|Experimental|Group 6|Not to exceed 6e11 vg/eye
3357025|NCT02317900|Experimental|TV005 and rDEN2∆30-7169|Participants will receive one injection of TV005 at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
3357026|NCT02317900|Placebo Comparator|Placebo and rDEN2∆30-7169|Participants will receive one injection of placebo at study entry (Day 0). On Day 180, participants will receive one injection of rDEN2∆30-7169.
3357027|NCT02317926|Active Comparator|Levothyroxine Plus Liothyronine Group|Levothyroxine Plus Liothyronine Group
3357028|NCT02317926|Active Comparator|Levothyroxine Group|Levothyroxine Group
3357029|NCT02317926|Active Comparator|Desiccated Thyroid Extract Group|Desiccated Thyroid Extract Group
3357030|NCT02317939|Experimental|online instruction at followup visits|patients in this group will be subjected to view video instructions online prior to performing the follow-up joint scoring at home
3357031|NCT02317939|Active Comparator|standard baseline instruction|after the initial training patients in this group will not be subjected to any subsequent instructions prior to performing the follow-up joint scoring at home
3357032|NCT02317952|Experimental|New Extensively Hydrolyzed Formula|Administered in context of oral food challenge and then for 16 weeks.
3357033|NCT02317952|Active Comparator|Comparator Formula|Administered in context of oral food challenge and then for 16 weeks.
3357034|NCT02317965||Pregnant Women|"Pregnant women who are scheduled to undergo an amniocentesis or chorionic villus sampling (CVS) procedure~Intervention: Single Maternal blood draw of 20mL"
3357035|NCT02317978||Subfertility without polycystic ovarian syndrome|The records of all women with infertility who had IVF/ICSI without polycystic ovarian syndrome (PCO) will be reviewed
3357036|NCT02317991|Experimental|nab-paclitaxel and ramucirumab|"All patients will receive 125 mg/m^2 of nab-Paclitaxel intravenously (IV) on Days 1, 8, and 15 of a 28-day cycle (weekly for 3 weeks, with 1 week of rest).~Patients will receive ramucirumab 8mg/kg IV in combination with nab-paclitaxel on Days 1 and 15 of the 28-day cycle."
3357037|NCT02318004|Experimental|Home monitoring|Home monitoring via the EarlySense non-invasive nocturnal monitoring system. Movement, heart rate and respiratory rates will be monitored while subject is in his bed. The trends of monitored values will be daily reported to a central repository. No intervention will be attempted and care will be coordinated by the family physician and treating cardiologist as usual.
3357038|NCT02318017|Active Comparator|Methylphenidate|Methylphenidate 0.5mg/kg - once
3357039|NCT02318017|Placebo Comparator|Placebo|Placebo - once
3357040|NCT02318030||Solid organ transplant|
3357041|NCT02318030||Hematopoietic Stem Cell Transplant|
3357042|NCT02318043|Active Comparator|AMP-BPT|Methods of AMP-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
3357043|NCT02318043|Active Comparator|His-BPT|Methods of His-BPT, by applying dosimeters, resembled that reported previously [see references 21-25]. Briefly, dilutions were delivered via nebulizers (output: 160 μl/min) using automated APS pro system (JAEGER, Hochburg, Germany). Inhalation challenge with normal saline served as control step. Challenge steps were proceeded if FEV1 fall <15% and restored to <10% within 1 minute. Subsequent inhalation challenges were performed at 1-minute intervals, and ceased when FEV1 fell by ≥20%. Salbutamol was administered via spacer (Volumatic, Allen & Hanbury's, UK). Spirometry was reexamined at minutes 3, 5, 10 and thereafter, to ensure safety, before discharge.
3246233|NCT01345240|Experimental|RTS,S Regimen C Lot 3 Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the RTS,S Vaccination Regimen C, with the RTS,S vaccine administered in its Lot 3 formulation. This RTS,S Vaccination Regimen C included 3 doses of RTS,S vaccine, Lot 3, co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™, at Weeks 6 and 10, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. The RTS,S vaccine and Engerix B™ were administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3246234|NCT01345240|Active Comparator|Engerix B Regimen A Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen A. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib, Polio Sabin™ and Synflorix™ at Weeks 0, 4 and 8, and 2 doses of Rotarix™, at Weeks 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3357044|NCT02318056|Experimental|Aquacel® Ag Burn Glove|Application of Aquacel® Ag Burn Glove burn dressing
3357045|NCT02318056|Active Comparator|Mepilex® Transfer Ag|Application of Mepilex® Transfer Ag burn dressing
3357046|NCT02318056|Active Comparator|Xeroform®/Bacitracin®|Application of Xeroform® burn dressing and Bacitracin® topical antibiotic
3357047|NCT02318069|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
3246235|NCT01345240|Active Comparator|Engerix B Regimen B Group|Subjects, healthy male and female infants between 8 and 12 weeks of age inclusive at the time of first vaccination, received the Engerix-B Vaccination Regimen B. This regimen included 3 doses of Engerix B™ co-administered with Infanrix™-Hib and Polio Sabin™, at Weeks 0, 4 and 8, 2 doses of Rotarix™ vaccine, at Weeks 4 and 8, and 3 doses of Synflorix™ at Weeks 2, 6 and 10. Additionally, subjects also received one dose of vaccine against yellow fever and against measles, at Week 32, and one booster dose of Infanrix™-Hib and Synflorix™, at Month 16, and one booster dose of Engerix B™ vaccine, at Month 50. Engerix B™ was administered intramuscularly (IM) in the left anterolateral thigh, Infanrix™-Hib IM in the right deltoid, Synflorix™ IM in the right anterolateral thigh, and Rotarix™ and Polio Sabin™ orally. The measles and yellow fever vaccines were administered IM in the deltoid.
3357048|NCT02318069|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
3357049|NCT02318069|Active Comparator|TBE vaccine at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
3357050|NCT02318069|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
3357051|NCT02318069|Active Comparator|double dose of vaccine|This group of 50 participants will be given two doses of TBE vaccine 0.5 ml FSME immune at the first day of the study and an additional dose at day 30 as well as one year later
3357052|NCT02318082|Experimental|Interleukin-2 (IL-2)|Interleukin-2: Each participant will receive daily subcutaneous IL-2 for self-administration per cycle. Each participant will start at Dose Level A. In the abscence of DLTs or severe non-DLT adverse events, participants will have daily SC IL-2 dose-escalated at Week 2 (to dose level B) and at Week 4 (to Dose Level C), and continue on their maximum tolerated dose (MTD) IL-2 for 4 weeks total.
3246236|NCT01345266|Other|Inhalation Profiling|All subjects have Inhaltion profiling, there are no other arms.
3246237|NCT01345279||cisplatin|
3357053|NCT02318108|Experimental|Intervention|Mentored organizational change and feedback.
3246238|NCT01345279||cisplatin + topotecan|
3246239|NCT01345279||cisplatin + paclitaxel|
3357054|NCT02318108|Other|Education only|Education and feedback.
3357055|NCT02318121|Active Comparator|Amniotomy first|Will be done with sterile gloves after insurance that is the baby's head fits in the pelvis ( 3\5 or less of fetal head felt by first pelvic grip ) and by vaginal examination the head at station zero . The membranes are then punctured using an a hook during uterine contractions.
3246240|NCT01345331|Experimental|Real Stimulation|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain.
3246241|NCT01345331|Sham Comparator|Sham|The sham treatment will use the same equipment as the real treatment, but the participant will not receive any real stimulation to the ear.
3246242|NCT01345344|Experimental|Cognitive-Behavioral Therapy|8 individual weekly visits with a psychologist for pain-related CBT.
3246243|NCT01345344|Active Comparator|Disease Education|8 individual weekly visits with a psychologist for fibromyalgia education (this is an active comparator arm, matched for provider contact).
3246244|NCT01345344|No Intervention|Healthy Controls|No intervention.
3246245|NCT01345357|Experimental|CEP-9722 in combination with Gemcitabine and Cisplatin|Study drugs will be administered in cycles of 21 days for up to 6 cycles. CEP-9722 treatment will be initiated at cycle 2. After cycle 3, patients may discontinue gemcitabine and/or cisplatin for reasons of tolerability, at the discretion of the investigator.
3246246|NCT01345370||Stupp protocole|All subjects enrolled must be treated according to the Stupp schedule : surgical resection followed by Temozolomide (TMZ) chemotherapy with concomitant radiotherapy, and then 6 cycles of adjuvant Temzolomide.
3357056|NCT02318121|Active Comparator|Oxytocin first|The starting dose will be the low dose rate equal or less than 4 m unit\minute (4 drops\minute doubled every 15 minutes up to 40 drops \minute) as intravenous drip on dextrose ,Ringer's lactate or saline solution.
3357057|NCT02318121|Active Comparator|Amniotomy and oxytocin|Amniotomy will be done (as explained above) and oxytocin (the same regimen mentioned above) at the same time.
3357058|NCT02318147|Experimental|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor，At the same time give patients the traditional treatment of SAP
3357059|NCT02318147|Other|The traditional treatment|The traditional treatment of SAP according to the associated guidelines
3357060|NCT02318186||0 months - 1 year|
3357061|NCT02318186||11-16 years|
3357062|NCT02318186||7-11 years|
3357063|NCT02318186||4-6 years|
3246247|NCT01345383||Current smokers|
3246248|NCT01345396|Experimental|Education|
3246249|NCT01345396|No Intervention|No education|
3246250|NCT01345422|Experimental|Wii Balance Board|Wii Balance Board Training
3357064|NCT02318186||1-3 years|
3357065|NCT02318199||Agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 5-7 during the first 12 hours after surgery.
3246251|NCT01345435|Experimental|Telemonitoring group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management"
3357066|NCT02318199||Non-agitation group|Patient is evaluated by the sedation-agitation scale (SAS) during the anesthesia recovery after intracranial surgery under general anesthesia. SAS equals to 1-4 during the first 12 hours after surgery.
3357067|NCT02318225|Active Comparator|Misoprostol|Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
3357068|NCT02318225|Placebo Comparator|Placebo|Placebo is administered vaginally 12 hours before office hysteroscopy
3357069|NCT02318238|Active Comparator|6 minute walking test|walking during 6 minutes
3246252|NCT01345435|Experimental|Telemonitoring & Telemedicine group|"A Smart Care PC, blood glucose meter and body composition analyzer will be provided~transmitting the results to the Smart Care Server via Smart Care PC~At Smart care Center,care manager will provide remote blood glucose monitoring and individual diabetes case management~taking telemedicine through video telephone instead of visiting hospital"
3246253|NCT01345435|Other|Control group|"Blood glucose meter and body composition analyzer will be provided~Self-monitoring Blood Glucose (SMBG)"
3246254|NCT01345461||Healthy adult volunteers|Twelve healthy adult volunteers (6 men, 6 women)
3246255|NCT01345487|Other|Low Vegetable Protein|Meal with 10 E% protein from fava beans/split peas
3246256|NCT01345487|Experimental|High Vegetable protein|Meal with 20 E% protein from fava beans/split peas
3246257|NCT01345487|Experimental|High Animal Protein|Meal with 20 E% protein from pork/beef
3246258|NCT01345500|Experimental|Higher Carbohydrate/Lower Fat Diet|
3246259|NCT01345500|Experimental|Lower Carbohydrate/Higher Fat Diet|
3246260|NCT01345500|Active Comparator|Individualized Counseling|
3246261|NCT01345526|Experimental|Metastatic colorectal cancer, Doxycycline, Vitamin K1 Cream|
3246262|NCT01345526|Placebo Comparator|Metastatic colorectal cancer, Doxycycline, Cream|
3246263|NCT01345539|Other|SBRT|
3246264|NCT01345552|Other|SBRT|
3246265|NCT01345565|Experimental|Hepatocyte Transplantation|See Below
3246267|NCT01345604|Placebo Comparator|Saline|
3246268|NCT01345604|Active Comparator|Ropivicaine|
3246269|NCT01345617||cystic fibrosis patients|cystic fibrosis patients
3246270|NCT01345617||non-cystic fibrosis patients|non-cystic fibrosis patients
3357070|NCT02318238|Experimental|6 minute step test|stepping during 6 minutes
3357071|NCT02318238|Experimental|4 meter gait speed|walking as fast as possible on 4 meters
3357072|NCT02318251|Experimental|Involuntary muscle contractions|Standard physiotherapy program (focus on involuntary reflexive pelvic floor muscle contractions)
3357073|NCT02318251|Active Comparator|Voluntary muscle contractions|Physiotherapy program (focus on voluntary pelvic floor muscle contractions)
3357074|NCT02318264|Experimental|Distal to Proximal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting distal by knee and ending proximal by hip.
3357075|NCT02318264|Experimental|Proximal to Distal Tape|Quadriceps muscle taped (Using Kinesio Tape) starting proximal by hip and ending distal by knee.
3357076|NCT02318290||Critically ill patients|Mechanically ventilated critically ill patients receiveing opiates for more than 96 hours will be prospectively followed for the emergence of withdrawal symptoms upon weaning of opiates
3357077|NCT02318316||EBC level|Exhaled breath condensate level of allogeneic stem cell transplantation patients
3357078|NCT02318342|Experimental|Pre-existing bioprosthetic aortic valve|Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
3357079|NCT02318355|No Intervention|Control|Control group that receives no intravenous fluid after blood donation
3357080|NCT02318355|Experimental|Lactated Ringers|Experimental group that receives two liters lactated ringers after blood donation.
3246271|NCT01345643|Experimental|Hemoglobin level based on WCPT Score|According to WCPTS, the patient's hemoglobin level will be maintained not less than 7,8,9,or 10g/dL. Determination of whether a patient need red blood cells transfusion is based on WCPT Score.
3246272|NCT01345643|Active Comparator|Hemoglobin level 100g/L|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
3357081|NCT02318355|Experimental|Normal Saline|Experimental group that receives two liters normal saline after blood donation.
3357082|NCT02318381|No Intervention|Control|Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically without release of the superior transverse scapular ligament.
3357083|NCT02318381|Other|Ligament Release|"Patients with suprascapular neuropathy and rotator cuff tear treated arthroscopically with release of the suprascapular nerve.~Arthroscopic dissection of the superior transverse scapular ligament"
3357084|NCT02318394|Experimental|Monotherapy Arm|MEDI0562 monotherapy
3246273|NCT01345656|Experimental|Arm 1|
3357085|NCT02318407|Experimental|AMG 403|AMG 403 administered as subcutaneous doses
3357086|NCT02318407|Placebo Comparator|Placebo|No active drug
3357087|NCT02318420|Experimental|Women in labour|"All women in labour during the study period (4 months baseline and the 9th-12th month of the intervention) will be included for this pre- vs. post-study of the PartoMa intervention.~The following subgroups will be studied in-depth:~All stillbirths~All maternal deaths~All women with severe hypertensive disorders~A randomized selected group of women delivering a the study site, approximately 300-600 each year."
3357088|NCT02318420|Experimental|Health care providers|All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.
3357089|NCT02318433|Experimental|Dexamethasone|Subjects receive dexamethasone (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
3357090|NCT02318433|Placebo Comparator|Saline|Subjects receive sterile saline (4 mg) injection within the radiocarpal joint either in clinic or in the OR.
3357091|NCT02318446|Placebo Comparator|Control group|Will receive Oral saccharine tablet daily for 1month along with their existing antiepileptic therapy
3357092|NCT02318446|Experimental|Test group|Will receive Oral Folic acid 1mg tablet daily for 1month along with their existing antiepileptic therapy
3357093|NCT02318459|Experimental|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
3357094|NCT02318459|Active Comparator|Traditionnal rehabilitation|Traditionnal group rehabilitation 3 times a week, 1 hour duration.
3357095|NCT02318472|Experimental|Early mobilization|Functional mobilization initiated directly post-operative with a weight-bearing VACOped orthosis with adjustable range of motion of the ankle
3246274|NCT01345656|Experimental|Arm 2|
3246275|NCT01345656|Experimental|Arm 3|
3246276|NCT01345656|Experimental|Arm 4|
3357096|NCT02318472|Active Comparator|Immobilization|Treatment as usual using plaster cast immobilization
3357097|NCT02318485|Experimental|Transplant|A limbal epithelial stem cell graft will be transplanted onto the limbal stem cell deficient eye after it has been debrided of fibrovascular pannus
3246277|NCT01345656|Placebo Comparator|Arm 5|
3246278|NCT01345656|Active Comparator|Arm 6|
3246279|NCT01345695||Treatment|Data collected on persons living in the catchment area for a WHP telemedicine center
3246280|NCT01345695||Control|Data collected on persons living in the catchment area where there is not a WHP telemedicine center
3246281|NCT01345734||Liraglutide|
3246282|NCT01345747|Experimental|laryngeal tube|laryngeal tube suction has suction port
3246283|NCT01345747|Experimental|endotracheal tube|
3246284|NCT01345760||Basal Cell Carcinoma|
3246285|NCT01345760||Squamous Cell Carcinoma|
3246286|NCT01345760||Actinic Keratosis|
3246287|NCT01345760||healthy non-lesional skin|
3246288|NCT01345773||Patients receiving gastric cancer surgery|
3246289|NCT01345799|Experimental|TRK-170 Low Dose|
3246290|NCT01345799|Experimental|TRK-170 Middle Dose|
3246291|NCT01345799|Experimental|TRK-170 High Dose|
3246292|NCT01345799|Placebo Comparator|Placebo|
3246293|NCT01345812|Active Comparator|urine-derived FSH|Follicle stimulating hormone
3357098|NCT02318498|Active Comparator|Prospective MINCA patients|Patients with MINCA prospectively investigated with an early CMR with latest technique
3357099|NCT02318498|Placebo Comparator|Historical MINCA patients|Patients with MINCA investigated earlier with a late CMR (median 12 days)
3357100|NCT02318511|Experimental|ReNu amniotic allograft|Knee injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
3357101|NCT02318511|Placebo Comparator|Saline|Knee injection with saline. Injectable saline will be used as the placebo control.
3357102|NCT02318511|Active Comparator|HA injection|Knee injection with HA. HA will be used as a viscosupplementation injection consisting of cross linked HA.
3357103|NCT02318537|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
3246294|NCT01345812|Active Comparator|recombinant FSH|Follicle stimulation hormone
3357104|NCT02318537|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
3357105|NCT02318563|Experimental|Cannabidiol Oral Solution|Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.
3357106|NCT02318563|Placebo Comparator|Placebo Solution|Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.
3357107|NCT02318576|No Intervention|Control|This group will do nothing for the 12 week program.
3246295|NCT01345825|Experimental|resistance training|
3357108|NCT02318576|Experimental|Cognitive Trained Group|This group will train three time a week for one hour on the given computerized cognitive training website for the 12 week program.
3246296|NCT01345838||Dysplasia|Patients with developmental dysplasia of the hip undergoing PAO
3246297|NCT01345851|Experimental|Treatment (dose-escalation of RT)|Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.
3357109|NCT02318615|Experimental|Immediate Axillary Plasty|Immediate Axillary Plasty ：After axillary lymph node dissection, a pedicled flap named Partial Latissimus Dorsi Muscle Flap is filled in the cavity of axilla, and fixed around the axillary vessels.
3357110|NCT02318615|No Intervention|Education|Education：After surgery, education on the prevention of lymphedema. In patients suffering with upper limb lymphedema during follow-up, any treatment except axillary or breast reconstruction can be used.
3246298|NCT01345864|Other|Cohort A|Parallel design with 5 unique treatment groups Donepezil tablets and matching placebo tablets may be overencapsulated as needed.
3357113|NCT02318680|Experimental|Intervention|Review of follow home visits after discharge from Nykøbing Falster Hospital
3357114|NCT02318680|No Intervention|Control|Standard health care and discharge services
3357115|NCT02318745|Experimental|Culturally Informed Family Treatment for Adolescents|CIFTA focuses on improving parenting practices, parent-adolescent attachment, adolescent ability to meet developmental challenges, increasing family support and decreasing family conflict/negativity, increasing knowledge of drug effects and triggers to use. Parents are taught general parenting and how to help a son or daughter with depression, conduct problems, and/or ADHD. Psycho-educational modules complement the family therapy and culturally relevant information is infused throughout the treatment. In family therapy sessions family members practice the skills and psycho-educational material they have learned. Treatment last approximately 4 months and includes approximately 6 session per month. Session may be family therapy sessions, individual sessions, or psycho-educational modules.
3357116|NCT02318745|Active Comparator|Individual Treatment As Usual|The active comparison condition reflects the typical individually-oriented services that behavior problem youth receive in the community. It was designed to isolate the effects of the CIFTA family interventions. A community agency helped us to standardize the individually-oriented services that were normally provided and a therapist trained by that agency was hired to work on the study to provide continuity to the services. The adolescent individual sessions addressed depression, ADHD, and/or conduct disorder through Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, and assertiveness training. The ITAU therapists were expected to hold 6 sessions per month with the youth.
3357117|NCT02318758|Active Comparator|Comparison 1|UT-15C 1 mg alone
3357118|NCT02318758|Active Comparator|Comparison 2|UT-15C 1 mg plus ethanol (simultaneously)
3357119|NCT02318758|Active Comparator|Comparison 3|UT-15C 1 mg administered 1 hour before ethanol
3357120|NCT02318758|Active Comparator|Comparison 4|UT-15C 1 mg administered 1 hour after ethanol
3357121|NCT02318771|Experimental|A1: RT (1 fraction, 8 Gy) + MK-3475|Patients undergo RT on day 1 per standard of care and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 IV over 30 minutes on day 1. Courses of MK-3475 repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3357122|NCT02318771|Experimental|A2: RT (5 fractions, 4 Gy) + MK-3475|Patients undergo RT on days 1-5 and then undergo biopsy 3-10 days later. Beginning 0-7 days after biopsy, patients receive MK-3475 as in Arm A1.
3357123|NCT02318771|Experimental|B1: MK-3475 + RT (1 fraction, 8 Gy) + MK-3475|Patients receive one dose of MK-3475 IV over 30 minutes on day 1 and then undergo 1 fraction of RT. Patients then receive MK-3475 IV over 30 minutes in the absence of disease progression or unacceptable toxicity.
3357124|NCT02318771|Experimental|B2: MK-3475 + RT (5 fractions, 4 Gy) + MK-3475|Patients receive MK-3475 as in Arm B1 and undergo 5 fractions of RT.
3357125|NCT02318784|Experimental|Carfilzomib|"Carfilzomib will be administered as intravenous (IV) infusion over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of each 28-day cycle.~Cycle 1: First two doses of Carfilzomib 20 mg/m2 IV; subsequent doses at 56 mg/m2 IV~Cycle 2 onwards: Carfilzomib 56 mg/m2 IV"
3357126|NCT02318810|Active Comparator|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
3246299|NCT01345877|Other|gender|
3246300|NCT01345890|Experimental|electrical stimulation|stroke patients
3246301|NCT01345903|Experimental|Treatment (surgery)|Patients undergo robotic-assisted surgery using the da Vinci robot
3246302|NCT01345916|Experimental|CHF 1535 100/6 NEXT Dry Powder Inhaler®|CHF1535 100/6 NEXT DPI® 1 inhalation bis in day (b.i.d) (daily dose BDP 200/FF 12 µg)
3246303|NCT01345916|Active Comparator|CHF1535 100/6 pMDI|CHF1535 100/6 pressurisedMeterDoseInhaler 1 inhalation b.i.d (total daily dose BDP 200/FF 12 µg)
3246304|NCT01345916|Active Comparator|beclomethasone dipropionate DPI|beclomethasone dipropionate 100 µg DPI, 1 inhalation b.i.d (total daily dose BDP 200 µg)
3357127|NCT02318810|Active Comparator|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
3357128|NCT02318810|Active Comparator|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
3357129|NCT02318810|Placebo Comparator|Placebo|Patients receive saline
3357130|NCT02318823|Other|Beer (alcoholic) followed by placebo (non-alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
3357131|NCT02318823|Other|Placebo (non-acoholic beer) followed by Beer (alcoholic)|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has two treatment conditions in the same subject.
3357132|NCT02318836|Active Comparator|Normal Hepatic function|
3357133|NCT02318836|Active Comparator|Mild Hepatic Impairment|(Child-Pugh score 5-6)
3357134|NCT02318836|Active Comparator|Moderate Hepatic Impairment|(Child-Pugh score 7-9)
3357135|NCT02318836|Active Comparator|Severe Hepatic Impairment|(Child-Pugh score 10-15)
3357136|NCT02318849|Experimental|Web intervention|Online intervention that uses information, engaging contests, and advocacy drives to encourage college students to become designated organ donor on driver's license
3357137|NCT02318849|No Intervention|Control|No intervention provided
3357138|NCT02318862|Other|GERD|Those who have abnormal pH and abnormal esophageal mucosa and those who have abnormal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
3357139|NCT02318862|Other|non-GERD|Those who have normal pH and normal esophageal mucosa and are scheduled for standard of care esophagogastroduodenoscopy (EGD) with mucosal impedance testing
3357140|NCT02318875|Experimental|Kritech group|Subjects take 1 Kritech capsule per day (dose of 300mg)
3357141|NCT02318875|Placebo Comparator|Placebo group|Subjects take 1 placebo capsule per day
3357142|NCT02318888|Experimental|Surgery and Icodextrin|Icodextrin 4% instilled every 30 minutes during surgery and 1000 ml instilled before closure of abdomen
3357143|NCT02318888|Active Comparator|Surgery|No instillations during surgery
3357144|NCT02318914|Experimental|gevokizumab|Solution for subcutaneous injection
3357145|NCT02318927|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
3357146|NCT02318953|Experimental|Mobile app follow-up care|"The mobile app follow-up group will have no planned in-person follow-up at one- and four weeks postoperative. However, these visits will be replaced with surgical site examination via submitted photos, visual analog scale (VAS) to assess pain, and the quality of recovery-9 (QoR9) questionnaire monitoring. All of this information is submitted via the mobile application (QoC Health Inc. Toronto). Patient will use daily monitoring for two weeks and then weekly monitoring for four weeks. The surgeon will use a wireless interface to access that data and monitor the patient's condition (not in real time). Physicians will summarize the clinical findings recorded by the mobile app at one week and four weeks postoperative using the prototypical SOAP note."
3246305|NCT01345942|Experimental|A food|
3246306|NCT01345942|Experimental|B without food|
3357147|NCT02318953|Active Comparator|Conventional, in-person follow-up care|Patients in the conventional, in-person follow-up group will have a planned clinic follow-up at one- and 4-weeks postoperative. This is the follow-up schedule currently used by both surgeons. At these scheduled follow-ups, patients will be asked to complete the VAS to assess pain and the QoR9 questionnaire.
3357148|NCT02318966|Active Comparator|Glycosade|Participants will be randomised to receive the medical food Glycosade as a starch load with a maximum dose of 100g. Glycosade to be taken as one dose.
3357149|NCT02318966|Placebo Comparator|Uncooked corn starch|Participants will be randomised to receive uncooked corn starch as a starch load with a maximum dose of 100g. Uncooked corn starch to be taken as one dose.
3357150|NCT02319018|Experimental|Treatment (alisertib, mFOLFOX)|Patients receive alisertib PO BID on days 1-3 and mFOLFOX regimen comprising oxaliplatin IV over 2 hours on day 2, leucovorin calcium IV over 2 hours on day 2, and fluorouracil IV continuously over 46 hours on days 2-4. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3357151|NCT02319057|Experimental|Panel 1|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3357152|NCT02319057|Experimental|Panel 2|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3357153|NCT02319057|Experimental|Panel 3|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3246307|NCT01345968|Placebo Comparator|NaCl 0.9%|
3246308|NCT01345968|Experimental|Ferinject|
3246309|NCT01345981|Experimental|lidocaine 20 mg|intravenous lidocaine
3246310|NCT01345981|Experimental|lidocaine 40 mg|intravenous lidocaine 40 mg
3246311|NCT01345981|Placebo Comparator|normal saline|2 ml
3246312|NCT01345994|Experimental|Acupuncture - local|acupuncture on forearm only
3246313|NCT01345994|Experimental|acupuncture - distal|acupuncture on both arm and leg
3357154|NCT02319057|Experimental|Panel 4|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3357155|NCT02319057|Experimental|Panel 5|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3357156|NCT02319057|Experimental|Panel 6|Adaptive design: Each subject will receive 1-4 single doses of ORM-12741 including various dose levels of ORM-12741 MR A, ORM-12741 MR B, ORM-12741 IR or combination of these
3357157|NCT02319070||Cohort 1|Adult patients with severe Hemophilia A.(25 patients on Secondary Prophylaxis treatment)
3357158|NCT02319070||Cohort 2|Adult patients with severe Hemophilia A.(50 patients on On Demand treatment)
3246314|NCT01346007|Active Comparator|patients|Children with idiopathic nephrotic syndrome in remission treated with low-dose prednisolone and/or mycophenolate mofetil and/or cyclosporine A
3246315|NCT01346007|Active Comparator|controls|
3246316|NCT01346020||CLL|
3357159|NCT02319083||Coronary artery bypass surgery|Patients undergoing coronary artery bypass surgery.
3357160|NCT02319096|Experimental|Patients with stress incontinence|Patients who present to urogynaecology clinic with proven stress urinary incontinence who will be offered Whole body vibration therapy.
3357161|NCT02319122|Other|Progressive Resistance Training|"The key for the PRT is the timely progression of load, based on the child's individual level of strength, which ensures progressive overload.~Every training session will consist of a warm up, progressive resistance exercises and a cool down period. During warm up and cool down periods.These exercises will be the same for both training groups.~The strength training exercises have been chosen to strengthen the main lower extremity muscle groups which are important for the gait: sit-to-stand, lateral step-ups, the half knee rise, heel-rises and bridging.~All these exercises are performed loaded according to the individual level. Three sets of 8 to 10 repetitions of each exercise will be practiced on 3 non-consecutive days with moderate velocity."
3357162|NCT02319122|Other|High Intensity Interval Training|The High Intensity Circuit Training is a sub form of High Intensity Interval Training. The key feature is the very little rest between the exercises which causes a consistent elevation of the participant's heart rate and a short duration of the whole exercise session. Every training session consists of a warm-up, a circuit of 5 exercises (the same as these in the PRT group) and a cool-down period. The children will be asked to train 3 times a week on non-consecutive days and to perform 3 sets. Exercise workload is controlled by determination of time intervals (30 seconds). The children will be instructed to perform as many repetitions as possible during the exercise interval and to keep the rest between the exercises short (it must not exceed 30 seconds).
3357163|NCT02319135|Active Comparator|fludarabine cytarabine|"Priming with daily administration of subcutaneous G-CSF (lenograstim or filgrastim 5 mcg /kg / day, days -1, 1 and 2) (not given if hyperleukocytosis> 25 x 109/l), followed by:~Oral fludarabine (40 mg/m2/day, days 1 to 5) and subcutaneous cytarabine (75mg/m2/day, days 1 to 5) (FLUGA scheme) (fludarabine and cytarabine only days 1 to 4 if age ≥75 years), OR~Fludarabine (25 mg/m2/day) and cytarabine (75 mg/m2/day infusion of 6 hours) on their intravenous formulations if the patient is hospitalized (patients with hyperleukocytosis or other unfavourable conditions).~Treatment cycles every 28 days"
3357164|NCT02319135|Experimental|Azacitidine|Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7. Treatment cycles every 28 days.
3357165|NCT02319161||Group I|Group I: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of calcium channel blocker 10 mg was administered by intravenous route.
3357166|NCT02319161||Group II|Group II: the patients with systolic blood pressure above to 150 mmHg following tourniquet inflation and in which bolus dose of beta blocker 0.5mg/kg was administered by intravenous route
3357167|NCT02319187|Active Comparator|Arm A|S1
3246317|NCT01346033||Those with Type 2 diabetes|All subjects have been diagnosed with type 2 diabetes.
3246318|NCT01346046||Those with Type 2 diabetes|270 subjects with Type 2 diabetes
3246319|NCT01346046||Non diabetic|30 healthy subjects
3357168|NCT02319187|Experimental|Arm B|S1 and irinotecan
3357169|NCT02319200|Experimental|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
3357170|NCT02319200|Placebo Comparator|placebo tablet|2 tablets at morning and 2 tablets at afternoon 4 tablets per day
3357171|NCT02319213|No Intervention|Group C|The control group (Group C) was not subjected to laparoscopic intervention
3246320|NCT01346098|Experimental|GROUP B|At the time of surgery the surgeon will directly assess pancreatic consistency and the pancreatic duct size. In the presence of a soft pancreas and a small duct (diameter <3 mm), the patient will be randomly assigned to receive either a pancreaticoduodenectomy with pancreatic anastomosis (group A) or a total pancreatectomy with IAT (group B).
3246321|NCT01346098|Active Comparator|GROUP A|
3357172|NCT02319213|Experimental|Group L|Intraocular pressure measurement with 9 mmHg insufflation
3357173|NCT02319213|Experimental|Group M|Intraocular pressure measurement with 12 mmHg insufflation
3357174|NCT02319213|Experimental|Group H|Intraocular pressure measurement with 15 mmHg insufflation
3357175|NCT02319239|Active Comparator|Conventional fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
3357176|NCT02319239|Experimental|hypofractionated|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.
3246322|NCT01346111||generation cohort|Included 5 hospitals from Buenos Aires, Argentina
3246323|NCT01346124|Experimental|IMPT|High dose IMPT
3246324|NCT01346137|Experimental|meloxicam|15 mg versus 30 mg per day P.O for 15 days, during 3 menstrual cycles
3246325|NCT01346150||Stratum A -Typical SCID|Typical Severe Combined Immunodeficiency (SCID), Adenosine Deaminase-Deficient ADA SCID, and X-linked SCID (XSCID) who received a transplant
3246326|NCT01346150||Stratum B - Atypical SCID|Leaky SCID, Omenn Syndrome, and Reticular Dysgenesis who received a transplant
3246327|NCT01346150||Stratum C - SCID w/Non-HCT Treatments|SCID who received Polyethylene Glycol -Adenosine Deaminase Enzyme Replacement Therapy (PEG-ADA ERT) or gene therapy
3246328|NCT01346163|Active Comparator|PF-03654746|H3 receptor antagonist currently being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS) as well as with Alzheimer's disease.
3357177|NCT02319239|Experimental|Stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.
3357178|NCT02319252|Active Comparator|Gastric tube|A gastric tube is used
3357179|NCT02319252|Active Comparator|Jejunal tube|A jejunal tube is used
3246329|NCT01346163|Placebo Comparator|Placebo|
3246330|NCT01346202||chronic pain|260 consecutive patients with verified chronic pain syndromes
3246331|NCT01346215|Experimental|Actparin® - Laboratorio Bergamo|
3246332|NCT01346215|Active Comparator|Heparin sodium - APP Pharmaceuticals|
3246333|NCT01346254|Experimental|Vildagliptin|16 patients randomized into this arm will receive vildagliptin (Galvus) 50mg orally once daily
3357180|NCT02319265|Experimental|Melatonin|Melatonin at a dose of either 50mg (50ml) or 100mg (100ml) to be decided after an initial PK study to be given at intervals to be decided after PK data is available, for 72h. Oral liquid via nasogastric tube.
3357181|NCT02319265|Placebo Comparator|Placebo|Placebo at a dose of either 50ml or 100ml (to be decided after an initial PK study) to be given at intervals to be decided after PK data, is available for 72h. Oral liquid via nasogastric tube.
3357182|NCT02319278|Active Comparator|Myocarditis|
3357183|NCT02319278|Active Comparator|Cardiac sarcoid|
3357184|NCT02319278|Active Comparator|Cardiac Transplant|
3357185|NCT02319278|Placebo Comparator|Healthy Volunteers|
3246334|NCT01346254|Experimental|Pioglitazone|16 patients randomized into this arm will receive pioglitazone (Actos) 30mg orally once daily
3246335|NCT01346254|Placebo Comparator|Placebo|16 patients randomized into this arm will receive placebo medication orally once daily
3357187|NCT02319330|Experimental|Phone counseling intervention|Treatment as usual (TAU) plus a nurse-delivered mobile phone counseling intervention delivered at weeks 1 to 12, 14, and 16 post-randomization.
3246336|NCT01346306|Experimental|DCS 1|
3246337|NCT01346306|Experimental|DCS 2|
3357188|NCT02319330|Active Comparator|Treatment as Usual|Routine HIV clinic-based counseling
3246338|NCT01346319|Active Comparator|Testosterone undecanoate|
3246339|NCT01346319|Placebo Comparator|Placebo|
3357189|NCT02319343|Active Comparator|Methylprednisolone|Preoperative single high dose of Solu-Medrol 125 mg iv.
3357190|NCT02319343|Placebo Comparator|Isotonic Sodium Chloride|Preoperative single dose of isotonic Sodium Chloride.
3357191|NCT02319356|Active Comparator|Beetroot juice (BRJ)|beetroot juice
3357192|NCT02319356|Placebo Comparator|Placebo (PL)|placebo juice
3357193|NCT02319382|Experimental|2 markers: 18F-DPA-714 and 11C-PE2I|PET with the tracer [18F]DPA-714 and second PET with the tracer [11C]-PE2I. [18F]DPA-714 is a new marker. It allows the macroscopic visualization of active microglia in the brain. [11C]-PE2I allow measures dopaminergic neuronal loss.
3357194|NCT02319395||cases|Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
3246340|NCT01346332||Anesthetization|
3246341|NCT01346358|Experimental|IMC-CS4 Weight Based Dosing|Participants receiving IMC-CS4 intravenously (weight based dosing)
3246342|NCT01346358|Experimental|IMC-CS4 Non-Weight Based Dosing|Participants receiving IMC-CS4 intravenously (non-weight based dosing)
3357195|NCT02319395||controls|Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
3357196|NCT02319408|No Intervention|No radiation|Lobectomy for lung cancer without preoperative radiation
3246343|NCT01346384||intracuff pressure N2O|measured intracuff pressure of LT with N2o during operative period
3357197|NCT02319408|Experimental|Preoperative radiation|Lobectomy for lung cancer with preoperative radiation
3357198|NCT02319421|Experimental|Primary Subjects|"Physicians and nurse practitioners caring for patients in the Pediatric Intensive Care Unit (PICU). An alarm reduction script will be used to help facilitate discussion of alarm data during weekday morning team huddles."
3357199|NCT02319447|No Intervention|Usual Care|After randomization, these study participants will receive the Usual Care received by all listed kidney transplant candidates at our center.
3357200|NCT02319447|Experimental|Additional education|These study participants will be invited to attend a 60-90 minute educational seminar, entitled Destination: Transplant, delivered in a group setting. They will also receive monthly mailings for 9 months and a follow-up phone call from a transplant educator.
3246344|NCT01346423|Experimental|Intervention group|Treatment team with a physician, a physiotherapist, a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The patient meets at the outpatient clinic three times; at baseline, after 2 weeks and after 3 months. One year after baseline the patient has a telephone-follow-up. At baseline, the patient and the team works out a rehabilitation plan and in this process a new visual, educational tool is central.
3246345|NCT01346423|Active Comparator|Controll group|The brief intervention is a standardized intervention based on the studies by Indahl and Hagen. Therapist treatment manuals will be written for the intervention. The essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. Unless symptoms and clinical findings indicate some serious disease, the patients will be informed about the good prognosis, and the importance of staying active to avoid development of muscle dysfunction.
3246346|NCT01346436|Active Comparator|Robotic|Use of daVinci surgical system (Intuitive Surgical Inc, Sunnyvale, CA) for the treatment of complex pelvic floor dysfunction
3246347|NCT01346436|Active Comparator|Laparoscopy|Use of standard laparoscopy for the treatment of complex pelvic floor dysfunction
3246348|NCT01346449|Active Comparator|Visual cue absent|
3357201|NCT02319460||Retrospective|Retrospective cohort of adults hospitalized for major bleeding during 2008 to 2013 who receive plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
3357202|NCT02319460||Prospective|Prospective parallel cohort of adults hospitalized for major bleeding during 2014 to 2020 who either receive Kcentra® or plasma for urgent reversal of acquired coagulation factor deficiency induced by oral VKA therapy
3357203|NCT02319499|Experimental|Zinc Alone|Zinc Sulphate (10 mg Zn/day)
3357204|NCT02319499|Experimental|Iron and Zinc|Ferrous Sulphate and Zinc Sulphate (10 mg/day of each zinc and iron)
3357205|NCT02319499|Experimental|Iron, Zinc and Vitamin A|Ferrous Sulphate, Zinc Sulphate and Vitamin A (10 mg/day of each zinc and iron, plus 1,000 IU vitamin A/day)
3357206|NCT02319499|Placebo Comparator|Placebo|No minerals/vitamin
3357207|NCT02319512|Experimental|Chewing gum|Chewing gum was administered every fourth hour (08.00-12.00, 12.00-16.00 and 16.00-20.00). During each four-hour period, patients chewed two pieces of gum for 30 minutes each. Chewing gum was used during the whole hospital stay.
3357208|NCT02319512|Sham Comparator|Control|Controls received standard care and sips of glucose, in total 3.6g/day in a 12-ml mixture per day, the same amount of glucose per day as the treatment group received via the chewing gum
3357209|NCT02319538|No Intervention|Non-surgical treatment only|Control arm. This arm receives standard medical hormone treatment (Thyroxine substitution) only and no surgical intervention.
3357210|NCT02319538|Active Comparator|Total thyroidectomy performed|Surgical arm.The approach for total thyroidectomy will be a complete removal of all visible, and immunological active thyroid tissue with a high accuracy, with a special focus on three sites; 1) The angle where the recurrent laryngeal nerve enters the cricothyroid membrane, 2) The pyramidal lobe and 3) The hilus where the superior vessels are entering the field. Standard Thyroxine supplementation maintained as in the control group.
3357211|NCT02319564|Active Comparator|beclomethasone|"beclomethasone dipropionate 250mcg per puff per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3357212|NCT02319564|Active Comparator|beclomethasone and salbutamol|"beclomethasone diprionate 250mcg and salbutamol 100mcg per puff (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3357213|NCT02319564|Placebo Comparator|Placebo|"placebo (Chiesi metered dose inhaler) via a masked spacer (Aerochamber Max®, Plattsburgh, NY, USA). One puff BID for 14 days.~Non-identifiable MDI prepared by Chiesi Farmaceutici Inc."
3357214|NCT02319577|Experimental|Gefitinib plus oral vinorelbine|"Arm A (21-days cycles until progressive disease or unacceptable toxicity):~Oral vinorelbine 60 mg/mq on days 1,8 Gefitinib 250 mg daily from day 9 to day 21"
3357215|NCT02319577|Active Comparator|Gefitinib alone|"Arm B (21-days cycles until progressive disease or unacceptable toxicity):~Gefitinib 250 mg daily from day 1 to day 21"
3357216|NCT02319590||heart failure, no CAD, QRS < 150ms|no CAD, QRS < 150ms
3357217|NCT02319590||heart failure, CAD QRS < 150ms|CAD, QRS < 150ms
3357218|NCT02319590||heart failure, CAD > 150ms|CAD, QRS > 150ms
3357219|NCT02319590||heart failure, no CAD, > 150ms|no CAD, QRS > 150ms
3246349|NCT01346449|Experimental|Calorie information present|
3357220|NCT02319603|Active Comparator|Low dose WenXin keli|"Low dose group (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
3357221|NCT02319603|Experimental|High dose WenXin keli|"High dose group(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.~Oral ,1 bag each time, 3 times a day, 4 weeks for 1 course of treatment."
3357222|NCT02319616|Experimental|Clobetasol 0.05% ointment|All patients will have one arm assigned to receive the experimental treatment (topical clobetasol 0.05% ointment) applied daily for a period of fourteen days.
3357223|NCT02319616|Placebo Comparator|Placebo|All patients will have one arm assigned to receive the placebo treatment (topical petrolatum ointment) applied daily for a period of fourteen days.
3357224|NCT02319629|Experimental|URSODIOL - URSODEOXYCHOLIC ACID|300 mg twice a day
3357225|NCT02319629|Placebo Comparator|placebo|placebo twice a day
3357226|NCT02319655|Active Comparator|Air tamponade|Air is injected after vitrectomy/membrane peeling
3357227|NCT02319655|Active Comparator|Balanced salt solution filling|Balances salt solution is injected after vitrectomy/membrane peeling
3357228|NCT02319681|Experimental|Simple Reminiscence (SR) caregiver|Subjects are caregivers for a persons with EAD and will be administered SR intervention and an attention control treatment four times
3246350|NCT01346449|Active Comparator|Calorie information absent|
3246351|NCT01346449|Experimental|Visual cue present|
3246352|NCT01346462|Experimental|PaCT|The Patient-Centered Transition Arm
3246353|NCT01346462|No Intervention|Control|Control group patients will receive routine care from the admitting hospital, including routine patient management, and discharge planning.
3246354|NCT01346527||Type 2 diabetes|"Women will be diagnosed with type 2 DM (pre-gestational, White classification B or C class). Since the majority of women with B or C class DM are on insulin therapy in our clinic, we will recruit only women on insulin therapy (i.e. no oral diabetes medications).~HbA1C ≤ 8 for greater than 3 months32, 33.~All women will have confirmed singleton pregnancies.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Pre-pregnancy BMI is anticipated to be >30 (i.e. obese) from the data regarding the patient population of our clinic. Women with pre-pregnancy BMI between 23-40 will be included."
3246355|NCT01346527||Healthy, obese pregnant controls|"No diagnosis of type 1 or 2 diabetes or previous gestational DM.~Women with pre-pregnancy BMI between 30-45: control participants will be BMI matched to women with DM.~A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.~Receive care at the Women's Health Clinic at Barnes Jewish Hospital.~Patients will have a singleton pregnancy with no fetal abnormalities (as determined by routine standard of care ultrasonography)."
3357229|NCT02319681|Experimental|Simple Reminiscence (SR) EAD|Subjects are persons with EAD and will be administered SR intervention and an attention control treatment four times
3357230|NCT02319707|Experimental|Intramuscular treatment:IV|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
3357231|NCT02319707|Experimental|Combined treatment:IV+IM|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
3246356|NCT01346527||Healthy, Lean Controls|No diagnosis of type 1 or 2 diabetes or previous gestational DM. 2) Women with pre-pregnancy BMI between 21-25.9 3) A normal routine, standard of care 1 hour 50 gram gestational diabetes screen.
3246357|NCT01346553|Experimental|ESVV treatment|using ESVV device
3246358|NCT01346605||CCTA patients|Prior stress SPECT with intermediate to high likelihood to be referred to the cardiac catheterization laboratory for an invasive coronary angiogram or patients presenting with chest pain and clinical indication of Coronary CT Angiography and an initial calcium score above 300
3357232|NCT02319707|Active Comparator|The control group|pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
3246359|NCT01346618||children ages 4-17 years|Participants are children and youth ages 4-17 years (inclusive) who performed or will perform a X-ray of the left hand for bone age assessment as part of any clinical work up, within 2 months of enrollment in this study.
3357233|NCT02319720|Experimental|BMA/Cultured Bone Marrow Cells|The subjects in this arm will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. Part of the aspirate will be cultured. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate and up to three applications of cultured cells derived from that aspirate. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by direct application of fresh bone marrow to the wound and up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
3357234|NCT02319720|Experimental|Cultured Bone Marrow Cells|In this group, the bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound. Up to three applications of cultured cells will be applied to the wound following the bone marrow biopsy. A single treatment cycle will consist of up to three applications of cultured cells derived from a single bone marrow aspiration. If the wound has not healed, up to three additional treatment cycles may be performed. Each bone marrow biopsy will be followed by up to three applications of cultured cells (prepared from the most recent bone marrow biopsy).
3357235|NCT02319720|Experimental|Bone Marrow Aspirate|The subjects in this group will have fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken. A single treatment cycle will consist of one application of a freshly obtained bone marrow aspirate. If the wound has not healed, up to three additional bone marrow biopsies may be performed. If the wound heals at any point during this protocol, no additional bone marrow biopsy procedures will be performed and no additional cells will be applied.
3357236|NCT02319720|Active Comparator|Control|In this arm, subjects will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressing and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
3357237|NCT02319733|Experimental|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
3357238|NCT02319746|Experimental|Experimental group|The subjects of experimental group will receive a cognitive-behavioral treatment program specific for reduce cannabis use composed of 16 weekly sessions (one hour in duration), in addition to regular psychiatric review and pharmacological treatment. The group will consist of 6-8 subjects.
3357239|NCT02319746|Active Comparator|Control group|The control group will receive standard care for psychotic episodes which includes pharmacological treatment and psychoeducation, following the same format as the experimental group. 16 weekly sessions of psychoeducation (one hour in duration) will be conducted, in addition to regular psychiatric review and pharmacological treatment. Like the experimental group the group will consist of 6-8 subjects.
3357240|NCT02319772|Experimental|BCX4430|BCX4430 administered as an IM injection
3357241|NCT02319772|Placebo Comparator|Placebo|Matched placebo administered as an IM injection
3357242|NCT02319785|Experimental|RAT-NMES|The combined treatment of robot-assisted therapy and neuromuscular electrical stimulation.
3357243|NCT02319785|Experimental|RAT-MT|The combined treatment of robot-assisted therapy and mirror therapy.
3357244|NCT02319785|Active Comparator|Mirror therapy|Patients practice motion in a mirror box, and look into mirror while practicing.
3357245|NCT02319785|Experimental|Unilateral RAT|Unilateral robot-assisted therapy provided by InMotion Isokinetic Testing and Evaluation System.
3357246|NCT02319785|Active Comparator|Bilateral RAT|Bilateral robot-assisted therapy provided by Bi-Manu-Track.
3246360|NCT01346631|Experimental|paleolithic diet|Subjects will adhere to a paleolithic diet for the duration of three months
3357247|NCT02319785|Active Comparator|Conventional rehabilitation|Conventional rehabilitation provided by therapist.
3357248|NCT02319798|Active Comparator|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital as usual.
3246361|NCT01346644|Active Comparator|No probiotics|Infant formula with no probiotics
3246362|NCT01346644|Experimental|Probiotic|Infant formula supplemented with probiotic
3246363|NCT01346657|Experimental|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects
3246364|NCT01346670|Experimental|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor Tablet after single oral administration in healthy subjects using a 2x2 crossover design
3357249|NCT02319798|Experimental|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
3357250|NCT02319811||Cryopreserved meniscus transplant|Intervention: Lateral or medial cryopreserved meniscus transplant implanted into appropriately indicated patients.
3357251|NCT02319850||Reference Group|18 - 29 years of age; apparently healthy younger participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
3357252|NCT02319850||Comparison Group|55 - 75 years of age; apparently healthy older participants; 1:1 male and female recruitment ratio (Exposure include DXA scanning).
3357253|NCT02319863|Active Comparator|conventional resection|Perform hepatectomy with conventional method for HCC patients.
3357254|NCT02319863|Experimental|new method|The new technique of rapid ligating the corresponding inflow and outflow vessels without hills dissection before parenchyma transection during hepatectomy.
3357255|NCT02319876||Severe sepsis|Patients with severe sepsis
3246365|NCT01346709||In-patient Adult Non-obstetricSurgical|"Consecutive patients admitted to participating centres undergoing surgery Non-obstetric in-hospital surgical procedure, elective or emergent, under general anaesthesia (alone or in combination with regional/neuraxial anaesthesia), neuraxial anaesthesia or plexus block (with and without sedation).~All eligible patients undergoing surgery within the seven day study period will be recruited wherever possible."
3246366|NCT01346722|Other|Group A|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with conventional rice-based diet (Diet- CR)
3246367|NCT01346722|Other|Group B|zinc biofortified rice-based diet (Diet-ZBfR) will be compared with a rice-based diet plus zinc fortificant (Diet-CR+Z)
3246368|NCT01346735||ICU infections|Infections acquired during the ICU stay
3357256|NCT02319876||SIRS patient|Patients after elective surgeries presented with SIRS but without sepsis
3357257|NCT02319876||Volunteer|Volunteers
3246369|NCT01346748|Experimental|Statin|
3246370|NCT01346761|Experimental|Telephone genetic counseling|Participants randomly assigned to telephone counseling are mailed packets that included a sealed envelope containing an educational brochure about hereditary breast and ovarian cancer (HBOC) genetic counseling with visual aids. At the time of their session, participants open their envelope and counselors use the visual aids to explain breast-ovarian cancer genetics and administer BRCA1/BRCA2 genetic counseling. Women receiving in-person counseling are given these same materials during their session at the community clinic. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
3357258|NCT02319889|Experimental|Treatment (SBRT, carboplatin, Abraxane)|Patients undergo Stereotactic Body Radiotherapy every other day for up to 14 days for a total of 5 fractions. After a break period of about 30 days, patients will then start chemotherapy. Patients will receive carboplatin IV over 30-40 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30-40 minutes on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3357259|NCT02319902|Placebo Comparator|Standard cold carbon dioxide gas|Standard cold carbon dioxide gas
3357260|NCT02319902|Active Comparator|Heated humidified carbon dioxide gas|Heated humidified carbon dioxide gas
3357261|NCT02319915|Experimental|Tranexamic acid|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection.
3357262|NCT02319915|Active Comparator|Tranexamic acid + adrenalin|Study of the pharmacokinetic profile of the plasmatic resorption of tranexamic acid after an intra-articular injection of tranexamic acid with adrenalin 1/200 000.
3357263|NCT02319928|Active Comparator|Short-term surveillance|Short-term surveillance. Colonoscopy at 5+10 years in low-risk adenomas or 3+5 years in high-risk adenomas.
3357264|NCT02319928|Experimental|Long-term surveillance|Long-term surveillance. Colonoscopy at 10 years in low-risk adenomas or 5 years in high-risk adenomas.
3357265|NCT02319941|Experimental|Low dose ticagrelor|60mg bid
3357266|NCT02319941|Active Comparator|standard dose ticagrelor|90mg bid
3357267|NCT02319941|Active Comparator|standard dose clopidogrel|75mg qd
3357268|NCT02319954|Active Comparator|Compression|Each patient will be randomized to receive compression of their nose on either the left or right for 5 continuous minutes after performing a lateral rhinotomy.
3357269|NCT02319954|No Intervention|No compression|Each patient will serve as their own control with the other side not receiving any compression after a lateral rhinotomy.
3357270|NCT02319980|Active Comparator|Surgical intervention|All participants in this group will be assigned to receive extracranial-intracranial arterial bypass surgery.
3357271|NCT02319980|No Intervention|Conservative management(medical management)|All participants in this group will be assigned to receive conservative management or medical management which involves drug therapy as considered appropriate for medical symptoms by the treating investigator.
3357272|NCT02319993|Experimental|TIAN WANG BU XIN DAN|"Drug:TIAN WANG BU XIN DAN CONCENRATED GRANULES CHUANG SONG ZONG"
3357273|NCT02319993|Experimental|Suan Tzao Ren Tang|"Drug:Suan Tzao Ren Tang Granula Subtilae CHUANG SONG ZONG"
3357274|NCT02319993|Placebo Comparator|Placebo|Drug:1/10 TIAN WANG BU XIN DAN
3357275|NCT02320006|Active Comparator|True acupuncture plus hydrotubation|The treatment group will receive true acupuncture and hydrotubation,Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performedwithin 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles. The points (points used for every participant of treatment group) include bilateral RN4、CV6、CV3、EX-CA1、ST36、SP6,All the needles will be keep in positions for 30 min.Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk)
3357276|NCT02320006|Sham Comparator|control acupuncture plus hydrotubation|The control group will receive control acupuncture and hydrotubation.Hydrotubation (80,000 U gentamicin , 400U chymotrypsin , 5mg dexamethasone , 50ml 0.9% saline) will be performed within 3 7 days after the menstruation[12].We use a manometer to measure the pressure and record the number on a card, then calculate the gap of the first and last time,it continues 3 menstrual cycles.Two needles will be inserted in each arm, one in each shoulder and one in each upper arm at nonacupuncture pointsAll the needles will be keep in positions for 30 min. Acupuncture will be performed three times per week,for a total of 36 sessions (12 wk).
3357277|NCT02320019|Placebo Comparator|Placebo group|Placebo
3357278|NCT02320019|Experimental|Group A|YH14618 A mg/disc
3357279|NCT02320019|Experimental|Group B|YH14618 B mg/disc
3246371|NCT01346761|Active Comparator|In-person genetic counseling|In-person BRCA1/BRCA2 genetic counseling is delivered by board-certified genetic counselors using a guide-line-concordant semistructured protocol that allows for personalization of counseling and is similar to that used by others. All sessions are audiotaped for treatment fidelity assessments. In-person and telephone counseling are delivered by the same five board-certified genetic counselors.
3246372|NCT01346787|Experimental|Carfilzomib Cyclophosphamide Dexamethasone|The treatment period includes administration of Carfilzomib Cyclophosphamide Dexamethasone for 9 courses. In order to assess the toxicity of treatment, patients will attend the study centre visits at each scheduled carfilzomib administration. The response will be assessed after each cycle.
3246373|NCT01346800|Experimental|Prasugrel 10mg po|
3246374|NCT01346800|Experimental|Prasugrel 10mg po + ritonavir 100mg po|
3246375|NCT01346826|Active Comparator|2 hours-infusion group|Number of patients: 57 (Standard 2 hours-infusion group)
3246376|NCT01346826|Experimental|1 hour-infusion group|Number of patients: 59 (1 hour-infusion group)
3246377|NCT01346826|Experimental|30 minutes-infusion group|Number of patients: 59 (30 minutes-infusion group)
3246378|NCT01346865|Experimental|cilostazol|cilostazol 100mg
3246379|NCT01346865|Placebo Comparator|dual therapy group|Placebo
3246380|NCT01346891||Hyponatremia Group (Cases)|Patients over 21 years old, with confirmed antecedent of thiazide-induced hyponatremia who required hospitalization with a serum sodium concentration lower than 125 meq/L.
3357280|NCT02320019|Experimental|Group C|YH14618 C mg/disc
3357281|NCT02320019|Experimental|Group D|YH14618 D mg/disc
3357282|NCT02320032|Experimental|Aripiprazole Lauroxil - A|Intramuscular (IM) injection Dose and Dosing Sequence A
3357283|NCT02320032|Experimental|Aripiprazole Lauroxil - B|Intramuscular (IM) injection Dose and Dosing Sequence B
3357284|NCT02320032|Experimental|Aripiprazole Lauroxil - C|Intramuscular (IM) injection Dose and Dosing Sequence C
3246381|NCT01346891||Good Thiazide Tolerance (Controls)|Patients over 21 years old, who have consumed thiazide diuretics for more than 2 years, with a serum sodium concentration persistently over 135 meq/L.
3246382|NCT01346917|Experimental|Lidocaine|
3246383|NCT01346917|Placebo Comparator|Placebo|
3357285|NCT02320032|Experimental|Aripiprazole Lauroxil - D|Intramuscular (IM) injection Dose and Dosing Sequence D
3357286|NCT02320045|Experimental|Group 1: Normal|Normal Subjects estimated creatinine clearance (eGFR) ≥90 mL/min/1.73 m2
3246384|NCT01346930|Experimental|Macitentan|Macitentan tablet, 10 mg, once daily
3246385|NCT01346943|Experimental|AAA Stent Graft System|Altura Medical AAA Stent Graft System
3246386|NCT01346982|Experimental|Silimarine|darunavir + ritonavir + silimarine
3246387|NCT01346995|Experimental|Experimental Knee Pain|Experimental knee pain induced by injections of 1 ml hypertonic saline in to the infrapatellar fat pad
3246388|NCT01346995|Active Comparator|Control|non-painful injections of isotonic saline into the infrapatellar fatpad.
3246389|NCT01347021|Active Comparator|sacrospinous, pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
3357287|NCT02320045|Experimental|Group 2: Mild Renal Dysfunction|Subjects with Mild Renal Dysfunction estimated creatinine clearance (eGFR) 60-89 mL/min/1.73 m2
3357288|NCT02320045|Experimental|Goup 3: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) 45-59 mL/min/1.73 m2
3357289|NCT02320045|Experimental|Group 4: Moderate Renal Dysfunction|Subjects with Moderate Renal Dysfunction estimated creatinine clearance (eGFR) >30-44 mL/min/1.73 m2
3357290|NCT02320071||Patients with incisional hernia|Patients with one or more incisional hernias, combined horizontal fascial defect 3-8 cm, planned for laparoscopic mesh repair. Patients are examined before and one and three months postoperative in regard to abdominal wall function, pain, discomfort, hernia-related quality of life and physical activity level.
3357291|NCT02320084||HT-1 patients on Orfadin treatment|HT-1 patients on Orfadin (nitisinone) treatment
3246390|NCT01347021|Active Comparator|uterosacral , pelvic prolapse.|Women with pelvic prolapse grade III/IV were randomly allocated to the sacrospinous colpopexy (25 women) or high uterosacral (26 women)
3246391|NCT01347099|Experimental|Internet CBT|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks.
3246392|NCT01347099|Placebo Comparator|Support therapy|10 weeks. Therapist support contact through e-mail.
3246393|NCT01347125|Experimental|ImCardia|Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device
3246394|NCT01347125|No Intervention|AVR control group|Aortic stenosis patients candidates for aortic valve replacement
3246395|NCT01347138|Experimental|case management|case management regulary
3246396|NCT01347138|No Intervention|Control|usual care
3246397|NCT01347151|Experimental|Glide scope|
3246398|NCT01347151|Experimental|Pentax airway scope|
3357292|NCT02320097|Other|Foot pressure measurement|"The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
3357293|NCT02320136||epilepsy|epilepsy patients
3357294|NCT02320136||tumor with epilepsy|tumor patients with epileptic seizures
3357295|NCT02320136||tumor without epilepsy|tumor patients without epileptic seizures
3357296|NCT02320162|Experimental|Experiential learning|Oral health education using experiential learning (EL)
3357297|NCT02320162|Placebo Comparator|Traditional lecturing|Oral health education using traditional lecturing (TL)
3357298|NCT02320188|Experimental|Eccentric exercise|Thirty sessions of Eccentric training in twelve weeks. Average of two sessions per week without spacing higher than eight days between two sessions.
3357299|NCT02320188|Experimental|Concentric exercise|Thirty sessions of Concentric training in twelve weeks. Average of three sessions per week without spacing higher than eight days between two sessions.
3357300|NCT02320188|No Intervention|No training (control)|Usual activities. No further training during the observation period
3357301|NCT02320240||SNRI Exposure Group|Patients who received a new prescription for an SNRI (duloxetine, venlafaxine, or desvenlafaxine at any dosage) with no prescriptions for either SNRI or SSRI in the prior year.
3357302|NCT02320240||SSRI Exposure Group|Patients who received a new prescription for an SSRI (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, or sertraline at any dosage) with no prescriptions for either SSRI or SNRI in the prior year.
3246399|NCT01347164|Experimental|Life coaching sessions|6 2-hour counseling session with trained therapist/counselor. The sessions deal with coping and stress reduction as well as sexual health.
3357303|NCT02320266||Parkinson's Disease|Patients diagnosed with Parkinson's Disease undergoing DBS surgery.
3357304|NCT02320266||Control|Age matched controls without Parkinson's Disease and no history of mental illness.
3246400|NCT01347164|Active Comparator|HIV counseling session|One 60-minute counseling session, based on standard HIV counseling content.
3246401|NCT01347177|Experimental|Zirconia-based adhesive bridges|Patients in this group will be treated with the employment of zirconia-based adhesive bridges to replace the missing tooth/teeth.
3357305|NCT02320266||Essential Tremor|Patients diagnosed with Essential Tremor undergoing DBS surgery.
3246402|NCT01347177|Experimental|Metal-based adhesive bridges|Patients in this group will be treated with the employment of metal-based adhesive bridges.
3246403|NCT01347190|Experimental|Liquid API|
3357306|NCT02320266||Dystonia|Patients diagnosed with Dystonia undergoing DBS surgery.
3357307|NCT02320266||Obsessive-Compulsive disorder|Patients diagnosed with Obsessive-Compulsive disorder undergoing DBS surgery.
3357308|NCT02320292|Active Comparator|Arm A (rituximab)|Patients receive rituximab IV on days 1, 8, 15, and 22.
3357309|NCT02320292|Experimental|Arm B (rituximab, yttrium Y-90 ibritumomab tiuxetan)|Patients receive rituximab IV on days 1 and 8 and yttrium Y-90 ibritumomab tiuxetan over 10 minutes on day 8.
3357310|NCT02320305|Experimental|Arm I (MART-1 antigen and TLR4 antagonist GLA-SE)|Patients receive MART-1 antigen and TLR4 antagonist GLA-SE IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3357311|NCT02320305|Experimental|Arm II (MART-1 antigen)|Patients receive MART-1 antigen IM on day 1. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3357312|NCT02320318|Experimental|Ibodutant 10 mg|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the ibodutant 10 mg arm will be re-randomised in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.
3357313|NCT02320318|Placebo Comparator|Placebo|Oral tablet once daily for 12 weeks of treatment. At week 13, patients in the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant 10 mg for additional 4 weeks of treatment.
3246404|NCT01347190|Placebo Comparator|Placebo|
3357314|NCT02320331|Experimental|PILI Lifestyle Program|
3357315|NCT02320344|Experimental|Partners in Care|
3246405|NCT01347203|Experimental|Treatment A|DPOC-4088 prolonged release tablet 100 mg (Formulation A= 16 hr release formulation)
3357316|NCT02320357|Experimental|Clopidogrel|
3357317|NCT02320370|Experimental|Treatment 1|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
3357318|NCT02320370|Experimental|Treatment 2|NeuroConn DC Stimulator Plus tDCS treatment protocol no 1
3357319|NCT02320383|Experimental|B + GA101|"Induction:~Bendamustine + GA101; a maximum of 6 cycles of BG will be administered; each cycle with a duration of 28 days~Maintenance:~GA101 i.v. 1000 mg (flat dose): every 84 days starting on final restaging continued until progression or to a maximum of 2 years"
3357320|NCT02320409|Experimental|Sulfatinib ,after general diet|First cycle, single oral Sulfatinib after general diet intake; Second cycle, Sulfatinib before general diet intake.
3357321|NCT02320409|Experimental|Sulfatinib, before general diet|First cycle, single oral Sulfatinib before general diet intake;Second cycle,single oral Sulfatinib after general diet intake
3357322|NCT02320422|Experimental|Behavioral Telehealth|
3357323|NCT02320448|Experimental|PIPAC|"PIPAC with cisplatin (7.5mg/m2 in 150 ml saline) and doxorubicin (1.5mg/m2 in 50 ml saline) in patients with peritoneal metastases (PM) from any origin besides colorectal/appendiceal cancers in whom oxaliplatin (92mg/m2 in 150 ml dextrose) will be used.~The aerosolised chemotherapy will be nebulized at a flow of 0.5ml/min at a maximum pressure of 200 PSI during a standard laparoscopy with an intraabdominal pressure of 12mmHg. The CO2 will be evacuated 30 minutes after administration of chemotherapy and the patient is closed similar to a standard laparoscopy."
3246406|NCT01347203|Experimental|Treatment B|DPOC-4088 prolonged release tablet 200 mg (Formulation A= 16 hr release formulation)
3246407|NCT01347203|Experimental|Treatment C|DPOC-4088 prolonged release tablet 100 mg (Formulation B= 20 hr release formulation)
3246408|NCT01347203|Experimental|Treatment D|DPOC-4088 prolonged release tablet 200 mg (Formulation B= 20 hr release formulation)
3357324|NCT02320474|Experimental|Aflibercept|
3246409|NCT01347242|Experimental|study treatment|autologous CD34 positive cells transduced with a lentiviral vector containing the human WAS gene
3357325|NCT02320500|Active Comparator|standard physiotherapy|Standard of care physiotherapy for knee osteoarthritis (OA) patients who have been diagnosed with knee OA and may be candidates for total knee replacement (TKA)
3357326|NCT02320500|Experimental|Myofascial-specific therapy|Patient undergo myofascial pain-specific therapy which includes trigger point injections at the same time points as the comparator (1 session every 2 weeks for 8 weeks)
3246410|NCT01347268|Experimental|withdrawing GnRH agonists|
3246411|NCT01347268|Experimental|GnRH antagonist administration|
3246412|NCT01347281|Experimental|[18F]HX4 PET|Injection of [18F]HX4
3246413|NCT01347294|Experimental|Bleomycin + Fibrovein|
3246414|NCT01347294|Active Comparator|Bleomycin|
3357327|NCT02320513||Control Group|Subjects will wear the activity monitoring device to track their activity between dialysis treatments, however, the feedback from the device will not be shared with them.
3357328|NCT02320513||Feedback Group|The feedback from the activity monitoring device will be shared with subjects at each visit.
3357329|NCT02320526|Experimental|Control|Control intervention: Subjects will continue their life unaltered during the 14 days intervention period
3357330|NCT02320526|Experimental|Continuous walking|Training intervention: Subjects will perform continuous walking for one hour per day at every weekday during the 14 days intervention period
3357331|NCT02320526|Experimental|Interval Walking|Training intervention: Subjects will perform interval walking for one hour per day at every weekday during the 14 days intervention period. Interval walking will be performed as repeated cycles of three minutes of slow and hree minutes of fast walking during the entire training session
3357332|NCT02320539||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3357333|NCT02320539||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3357334|NCT02320539||SAH good grade|SAH without external ventricular drainage
3357335|NCT02320539||Healthy controls|Blood sample in healthy donors registered in the National Donor Registry.
3357336|NCT02320552||PD patients|Patients receiving peritoneal dialysis. No intervention
3357337|NCT02320552||HD patients|Patients receiving hemodialysis. No intervention
3357338|NCT02320565|Experimental|3D Laparoscopy|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system"
3357339|NCT02320565|Active Comparator|Standard Laparoscopy|Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
3357340|NCT02320578|Experimental|3D Laparoscopy|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with 3D Laparoscopic technology.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition 3D telescope. Two additional 5 mm ports are placed under direct visualization. One more 5- mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3357341|NCT02320578|Active Comparator|Standard Laparoscopy|Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
3246415|NCT01347294|Experimental|Natrium Tetradecyl Sulphate (Fibrovein )|
3357342|NCT02320591|Experimental|Treatment group|Practices assigned to the treatment group received per member per month care management fees for each Medicare beneficiary attributed to their practice. They also received quarterly feedback reports on their patients' average Medicare expenditures and use of hospital and emergency room services. Practices also had access to regional learning faculties for technical assistance with transformation activities and to share lessons across practices.
3357343|NCT02320591|No Intervention|Comparison group|Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
3357344|NCT02320604|Experimental|Obese Subjects 1mg/kg|8 obese subjects will receive 1mg/kg Ambisome i.v. infused over 45 minutes
3357345|NCT02320604|Experimental|Obese Subjects 2mg/kg|8 obese subjects will receive 2mg/kg Ambisome i.v. infused over 90 minutes
3357346|NCT02320617|Experimental|DW-MRI group|To evaluate the efficacy of chemoradiotherapy in lung cancer patients by DW-MRI when compared with conventional imaging modalities(CT, ultrasound et al.)
3357347|NCT02320630|Experimental|A|Maintenance treatment group
3357348|NCT02320630|Experimental|B|Combination treatment group
3357349|NCT02320630|Experimental|C|Single drug group
3357350|NCT02320643|Experimental|Seratom® PA mesh|Partially absorbable mesh
3246416|NCT01347320|No Intervention|No preoperative MRI|control arm of the study
3246417|NCT01347320|Active Comparator|MRI group|preoperative MRI
3246418|NCT01347359|Experimental|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, either face-to-face or by telephone.
3246419|NCT01347359|Active Comparator|Control - Standard of care|"Standard of care is at the discretion of the treating rheumatologist."
3246420|NCT01347385|Experimental|Barbed suture|
3246421|NCT01347385|Active Comparator|Traditional suture material|
3246422|NCT01347398|Experimental|MicroMESAM|Sleep study made by MicroMESAM system
3246423|NCT01347398|Active Comparator|PSG|Sleep study made by PSG (polysomnography)
3246424|NCT01347411|No Intervention|Control|Usual treatment
3246425|NCT01347411|Experimental|CPAP|Treatment with CPAP
3246426|NCT01347424|Experimental|Test group|
3246427|NCT01347424|Active Comparator|control group|
3246428|NCT01347437|No Intervention|Condition|In the comparison condition, participants will receive MEMS only.
3357351|NCT02320656|Experimental|Acute leukemia/myelodysplastic or myeloproliferative disease|
3246429|NCT01347437|Experimental|Positive STEPS|"Participants will receive one on one Positive STEPS counseling sessions (~1 hour sessions per week for 5 weeks).~Participants will receive motivational reminders to take medications sent via text message to their cell phones.~Participants will receive the Medication Event Monitoring Systems (MEMS) pill cap monitoring device to measure antiretroviral medication adherence."
3246430|NCT01347450|Experimental|Cocoa, Placebo|
3357352|NCT02320669|Experimental|Triostat|Active Medication - Synthetic Thyroid Hormone
3357353|NCT02320669|Placebo Comparator|Placebo|Placebo Control
3357354|NCT02320682|Active Comparator|Exeter femur component and Delta TT acetabular component|
3357355|NCT02320682|Active Comparator|SP-CL femur component and Delta TT acetabular component|
3246431|NCT01347463||Traditional|
3246432|NCT01347476||patients older than 70 years|
3246433|NCT01347476||patients 70 years or younger|
3357356|NCT02320682|Active Comparator|SP-CL femoral component and Delta PF acetabular component|
3246434|NCT01347502||HCPs with smartphone|healthcare providers in MICU who have smart cellular phones
3246435|NCT01347502||HCP with non-smart phones|healthcare providers in MICU who have non-smart cellular phones
3357357|NCT02320682|Active Comparator|Exeter femoral component and Delta PF acetabular component|
3357358|NCT02320708|Experimental|Test Acetaminophen (ACE) (1000 mg) and placebo|
3246436|NCT01347515|Placebo Comparator|FOO250|FOO250 ppm, the standard virgin olive oil
3246437|NCT01347515|Active Comparator|FOO500|Olive oil enriched with its own broad-spectrum phenolic compounds; FOO500 ppm
3357359|NCT02320708|Active Comparator|Commerical ACE (1000 mg) and placebo|
3357360|NCT02320708|Active Comparator|Commerical Ibuprofen (IBU) (400 mg) and placebo|
3357361|NCT02320708|Placebo Comparator|Placebo|
3357362|NCT02320734|Active Comparator|deep neuromuscular relaxation|continuous infusion of rocuronium 0.6 mg/kg/hr (group 1). On demand bolus rocuronium can be given if demanded by anesthesiologist or surgeon
3357363|NCT02320734|No Intervention|on demand neuromuscular relaxation|continuous infusion of NaCl 0.9% 0.06 ml/kg/hr (group 2) On demand bolus of Rocuronium will be given when demanded by anesthesiologist or surgeon.
3357364|NCT02320747|Experimental|Tai Chi Group|Experienced instructor at teaching tai chi delivered in a group setting in the community lasted approximately 40 minutes. Participants in the program served as an active control group that matched to the program and delivered.The class comprised mainly seated exercises including stretching, low-level strength, and low-level cardiovascular exercise. Participants walked (warm-up and cool-down) for 7 min in class, remaining seated or standing with arm support the rest of the time.
3357365|NCT02320747|No Intervention|Control Group|
3246438|NCT01347515|Active Comparator|FOO750|Olive oil enriched with its own broad-spectra phenolic compounds; FOO750 ppm
3357366|NCT02320760|Experimental|Physical activity on prescription|
3357367|NCT02320760|No Intervention|Ordinary care|
3246439|NCT01347528|Experimental|TELEmonitoring intervention|
3246440|NCT01347528|No Intervention|Usual care|
3246441|NCT01347567|Experimental|BNP + Health Management|Subjects will provide information from home regarding weight,signs and symptoms, and will perform BNP self testing. This information including BNP results will be used by the investigator as an aid to treatment decisions. BNP results are blinded to subjects.
3246442|NCT01347567|Active Comparator|Health Management|Subjects will provide information from home regarding weight, signs and symptoms, and will perform BNP self testing . BNP results will be blinded to the investigator and subject; weight, signs and symptoms will be used by the investigator as an aid to treatment decisions
3246443|NCT01347567|Placebo Comparator|Control|Subject will provide information from home regarding weight, signs and symptoms and will perform BNP self testing. All these data will be blinded to the investigator. BNP results will be blinded to the subject.
3246444|NCT01347593|Experimental|ceftizoxime (cefizox) injection|ceftizoxime (cefizox) as single dose of 1 g at the interval of 30-60 minutes before the incision
3246445|NCT01347619|Active Comparator|Arm 1. Toolkit only with Web Access|NHs in this arm will receive the toolkit only and web access to the materials.
3357368|NCT02320773||1. OAB patients taking Betmiga®|OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
3357369|NCT02320786|Experimental|CoPILOT|Experimental group participants will receive structured training in a standard powered wheelchair using the CoPILOT shared control wheelchair technology consisting of 12 hours total training time (one hour, four times per week for three weeks).
3357370|NCT02320786|No Intervention|Standard of Care|Standard of care participants will receive training according to the standard of care in rehabilitation facilities in the Vancouver area in a standard powered wheelchair, consisting of 12 hour protocols in a standard power wheelchair (one hour, four times per week for three weeks).
3357371|NCT02320799|Active Comparator|treatment as usual|Usual Clinic psychosocial treatment
3357372|NCT02320799|Experimental|interpersonal psychotherapy|Interpersonal Psychotherapy is an evidence-based structured, brief psychotherapy which focuses on improving relationships in order to improve mood and reduce anxiety.
3357373|NCT02320851|Experimental|SVD-tailored Integrative Psychotherapy (IPT)|IPT is a short-term psychotherapy aiming to ameliorate both physical and psychosocial distress. It emanates from a multidirectional and dynamic relationship among body, mind, and environment irrespective of causality. In a multi-component approach, other elements are integrated into it, such as cognitive-behavioral and psychodynamic techniques, psychoeducation and body-oriented techniques. The IPT intervention tailored to SVD will be delivered for 16 weeks in a manualised setting with one group session per week (à 90 minutes) and one additional booster session three months after the end of the therapy. The group psychotherapy is on a 6-8:1 basis and will be conducted by a psychotherapist trained on the basis of the manual and under regular clinical supervision.
3246446|NCT01347619|Active Comparator|Arm 2.Toolkit, Audit/Feedback, Education|NHs in the second arm will receive the toolkit, web access, periodic audit and feedback reports of antipsychotic prescribing to NH leadership, and faxed educational messages adapted from the AHRQ atypical antipsychotic CERSG to prescribers.
3246447|NCT01347619|Active Comparator|Arm 3. All above plus academic detailing|NHs in the third arm will receive the previous items plus face-to-face academic detailing.
3246448|NCT01347645|Active Comparator|1|Experimental Irinotecan plus E7820
3246449|NCT01347645|Active Comparator|2|FOLFIRI alone
3357374|NCT02320851|Active Comparator|Self-help group (SHG)|The experimental condition will be compared to moderated self-help groups without the implementation of additional therapeutic interventions. Those can be classified as low-level non-placebo control. Treatment will consist of 16 weekly moderated SHG sessions (one weekly session à 90 minutes) and one additional booster-session at three months after the end of the control intervention to be delivered on a 6-8:1 basis by a trained SHG moderator under clinical supervision.
3357375|NCT02320864||Non-surgical group|Adults who have knee osteoarthritis, but do not elect to have a total knee replacement surgery.
3357376|NCT02320864||Surgical group|Adults who have knee osteoarthritis and elect to have total knee replacement surgery.
3357377|NCT02320877|Experimental|Mandibular Advancement Device|Mandibular advancement Devices are worn intra-orally at night in order to advance the mandible and to reduce the collapsibility of the upper airway.
3357378|NCT02320890|Experimental|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) application 3 days a week for 12 weeks (total of 36 applications)
3357379|NCT02320890|Sham Comparator|sham-Yband (YDT-201N)|sham-tDCS application 3 days a week for 12 weeks (total of 36 applications)
3357380|NCT02320916|Active Comparator|23Gauge|Arterial blood puncture will be performed using a 23Gauge needle
3357381|NCT02320916|Active Comparator|25Gauge|Arterial blood puncture will be performed using a 25Gauge needle
3357382|NCT02320929|Experimental|Intraoperative irrigation only|The infected tendon sheath is irrigated intraoperatively, the catheter is removed, and small rubber srains are left in small incisions.
3357383|NCT02320929|Active Comparator|Intra- and postoperative irrigation|The infected tendon sheath is irrigated intraoperatively, the catheter is kept in place, the irrigation is continued postoperatively 3 times a day for 3 days.
3357384|NCT02320942|Experimental|Exercise Intervention|At discharge from the inpatient unit, participants will receive a practical introduction by an exercise specialist and enrolled in the 12-week exercise intervention
3357385|NCT02320955||Reimplantation of cryoconserved bone flap|All patients who receive reimplantation of a cryoconserved autologous bone flap
3357386|NCT02320968|Experimental|Patients with nocturnal extraesophageal reflux|This is a non-randomized study to evaluate the effectiveness of the MedclineTM Sleep Assist Device on patients who experience nocturnal extraesophageal reflux. All patients will receive the device. Participants will serve as their own controls while undergoing 96-hour pH monitoring. Participants will follow their regular sleep position patterns on Days 1 and 2 of the study and will use the sleep assist device on Days 3 and 4. pH data and patient report of symptoms will be evaluated during the initial 96 hours of the study to capture physiologic results. All participants will use the sleep assist device for the remainder of the study to determine if a reduction in overall reflux symptom index (RSI) is achieved.
3357387|NCT02320981||EGD with Biopsy|Pediatric patients scheduled for standard of care EGD with biopsy also received measurement of mucosal impedance
3357389|NCT02321033|Experimental|low glycemic index|palatinose in soft drinks
3357390|NCT02321033|Experimental|high glycemic index|sucrose plus maltodextrin in soft drinks
3357391|NCT02321059||No incisional hernia group|Healthy volunteers with an intact abdominal wall.
3357392|NCT02321059||Incisional hernia group|Patients with a ventral incisional hernia.
3357393|NCT02321072|Active Comparator|High-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105-135 mmHg (14-18 kPa).
3246450|NCT01347658|Experimental|Etravirine + echinacea|etravirine + root of Echinacea purpurea
3357394|NCT02321072|Active Comparator|Low-normal PaO2|In patients requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60-90 mmHg (8-18 kPa).
3357395|NCT02321085|Active Comparator|Sinus Rhythm Control group|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
3357396|NCT02321085|Active Comparator|Pulse Rate Control Group|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, diffraction of rate control, the subject will be drop out for study."
3357397|NCT02321124|Active Comparator|intervention|we will apply connective tissue manipulation and life style advice.
3357398|NCT02321124|Other|control group|We will apply only life style advice.
3357399|NCT02321137|Active Comparator|BioAVR with surgical closure of LAA|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage
3246451|NCT01347671|Active Comparator|25 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 25 µg GRT6005 per day
3246452|NCT01347671|Active Comparator|75 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 75 µg GRT6005 per day
3246453|NCT01347671|Active Comparator|200 µg GRT6005|Participants allocated to this treatment arm will receive a daily dose of 200 µg GRT6005 per day
3246454|NCT01347671|Placebo Comparator|Matching Placebo|Participants allocated to this treatment arm will receive a dose of matched placebo once a day.
3246455|NCT01347684|Active Comparator|Standard care using current drugs|Standard care with drug intervention
3246456|NCT01347684|Experimental|Behavioral therapy, splint therapy and physical therapy|Using rehabilitation for comparing use of drug
3246457|NCT01347697|Experimental|Porcine collagen implant (biological mesh)|Reconstruction with an acellular porcine dermal collagen implant (biological mesh).
3357400|NCT02321137|Placebo Comparator|BioAVR alone|Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
3246458|NCT01347697|Active Comparator|Gluteus maximus flap|Reconstruction with a gluteus maximus myocutaneous flap.
3246459|NCT01347723||Supportive care (pain therapy)|Patients undergo scrambler therapy for 30 minutes daily for up to 10 consecutive days. Treatment continues in the absence of unacceptable toxicity.
3246460|NCT01347736|Experimental|Treatment (pain therapy)|Patients undergo scrambler therapy for approximately 30 minutes. Treatment continues for 10 days in the absence of pain progression or unacceptable toxicity.
3357401|NCT02321150|Active Comparator|Sutures|After pterygium removal the conjunctival graft to cover bare sclera will be secured with interrupted 8.0 polyglactin sutures.
3357402|NCT02321150|Experimental|Cautery|After pterygium removal the conjunctival graft to cover bare sclera will be secured with bipolar electrocautery, power set at 25 until whitening of tissue observed.
3357403|NCT02321163|Experimental|NMES new paradigm|For the NMES new paradigm, A portable electrical stimulator will be used to produce simultaneous stimulation to both the quadriceps and calf muscles. The stimulator delivers a biphasic, asymmetrical square wave at a pulse width of 250 μs and duty cycle 5:10 sec with 2 Hz frequencies of stimulation. To disperse current intensity and enhance the comfort of the stimulation, large rectangular electrodes (80 × 100 mm) will be positioned at the best motor points of the quadriceps and calf muscles. The electrodes will be secured by tight short and sock at the respective positions. The stimulation intensity will be set to just visible muscle contractions. Stimuli will be applied twice a day for 3 h (with a 2 h rest between treatments), 5 days a week for 8 weeks.
3246461|NCT01347749|Experimental|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
3357404|NCT02321163|Active Comparator|NMES conventional|For NMES conventional, the experimental protocol will be the conventional electrical stimulation protocol i.e frequency: 50 Hz; intensity: maximum intensity tolerated by the subject; duration: 30 min.
3357405|NCT02321163|Sham Comparator|Placebo|For placebo, electrodes will be applied and all conditions will be similar to those in the NMES group, except that the amplitude will be set to 0 mA so that no muscle stimulation occurs.
3357406|NCT02321176|Experimental|pharmacokinetics,trans-resveratrol|tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
3357407|NCT02321189|Placebo Comparator|LONGEVINEX|The Effect of LONGEVINEX on Choroidal Thickness
3357408|NCT02321189|Placebo Comparator|placebo|The Effect of placebo on Choroidal Thickness
3357409|NCT02321202|Active Comparator|Control group|For postoperative parenteral nutrition, only Structolipid applied for 5 consecutive days.
3357410|NCT02321202|Experimental|Trial group|For postoperative parenteral nutrition, Omega-3 Fatty Acid-Based Parenteral Nutrition (20% Structolipid and 10% Omegaven) were applied for 5 consecutive days.
3357411|NCT02321215|No Intervention|Control|Usual care: This group will receive usual care from their physician without any special focus on education. At the end of the study period, patients that were assigned to the control group will receive the booklet at home and be offered two education sessions by phone or in-person if the patient is willing to return to the hospital.
3357412|NCT02321215|Active Comparator|Education Intervention|Introductory disease education: This group will attend two one-on-one education sessions. The educational content will be standardized and a checklist will be used to ensure that all topics are addressed. The sessions will focus on enhancing self-efficacy in areas that are thought to be important to individuals who recently had an AECOPD.
3357413|NCT02321228|Experimental|Salpingectomy with delayed oophorectomy|Female BRCA mutation carriers can opt for early salpingectomy upon completion of childbearing, followed by second stage oophorectomy delayed for five years beyond current guideline ages for risk-reducing salpingo-oophorectomy (i.e. age 40-45 for BRCA1 mutation carriers and 45-50 for BRCA mutation carriers).
3357414|NCT02321228|Active Comparator|Risk-reducing salpingo-oophorectomy|Female BRCA mutation carriers can opt for standard risk-reducing salpingo-oophorectomy at current guideline ages (age 35-40 for BRCA1 mutation carriers and age 40-45 for BRCA2 mutation carriers).
3357415|NCT02321241||Group 1|According to the recommendations of the Summary of Products Characteristics (SmPC) Administration by intravitreal injection
3357416|NCT02321254|Experimental|The RehaARM-Robot|Receive 45 min of robot-assisted therapy for the shoulder and 1 hour of daily standard rehabilitation therapy.
3357417|NCT02321267|Other|Macular disease with adequate treatments|Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.
3357418|NCT02321280|Experimental|Single arm single dose of denosumab|Open label = Single dose administration of single dose Denosumab 120 mg subcutaneously
3357419|NCT02321293|Experimental|1|"CurcuVIVA™ (NPN 80027414) at a single dose of 80 mg PO daily without any dose escalation to be taken in conjunction with an EGFR-TKI therapy.~CurcuVIVA™ is given in capsule forms. Unit strength of CurcuVIVA™ is equal to Turmeric Extract 25:1 348 mg (containing 80mg Longvida® Optimized Curcumin)~Tyrosine Kinase Inhibitors:~Gefitinib is a targeted therapy, given in a capsule form once daily. The daily dose is 250 mg .~Erlotinib is a targeted therapy, given in a capsule form once daily. The daily dose is 150 mg .~Study intervention is 8 weeks, following which the patients will continue taking their EGFR-TKI without curcumin until progression. The side effects of curcumin will be followed for another 8 weeks from the date of stopping curcumin."
3357420|NCT02321306|Experimental|LUM001|LUM001 administered orally once each day.
3357421|NCT02321332|Active Comparator|B-ETS|Bilateral simultaneous endoscopic thoracic sympathectomy: bilateral simultaneous T2-T3 ganglionectomy.
3357422|NCT02321332|Active Comparator|S-ETS|unilateral sequential endoscopic thoracic sympathectomy: unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval
3357423|NCT02321345|Experimental|Palliative Care Support|Palliative care meetings will address the following issues: 1) values and meaning of life 2) greatest hopes and fears 3) communication preferences 4) proxy readiness to make decisions, and patient preferences, if the patient were to become seriously ill, and 5) symptom management strategies.
3357424|NCT02321358|Experimental|Two-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention and a booster again six weeks following.
3357425|NCT02321358|Active Comparator|One-time implementation intention|Group will receive physical activity materials along with the implementation intention intervention.
3357426|NCT02321358|Sham Comparator|Sham Comparator Group|Group will receive Canada's Food Guide which contains a small amount of physical activity information.
3357427|NCT02321371|Experimental|Lactulose + Rifaximin|Continuation of Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route.
3357428|NCT02321371|Active Comparator|Lactulose therapy|
3357429|NCT02321384|Experimental|A: SAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 6 planned SAD cohorts to receive single dose of RO6889678/matching placebo in fasted state as per anticipated dose escalation sequence (30 milligrams [mg], 100 mg, 300 mg, 600 mg, 1000 mg and 1500 mg). Cohort 1 will be split in 2 groups: 2 participants will be dosed 1 day (1 on RO6889678 and 1 on matching placebo) and 3 participants (2 on RO6889678 and 1 on matching placebo) will be dosed at least 24 hours afterward following satisfactory safety assessment for first 2 participants. Cohort 2 & beyond will include 8 healthy participants with 6 participants randomly assigned to RO6889678 & 2 randomly assigned to placebo. Participants who will tolerate fasted dose and agree to continue in food-effect SAD cohort, will receive single dose (dose level, either 300 mg or 600 mg, decided based on PK and safety data of first 2 SAD cohorts) of RO6889678/matching placebo with US FDA recommended high-fat and high-calorie breakfast on Day 16.
3357430|NCT02321384|Experimental|B: MAD Cohorts - RO6889678/Matching Placebo|Healthy participants will be enrolled into 1 of 4 planned MAD cohorts to receive RO6889678 or matching placebo (at a dose that will be decided as per the safety, tolerability and PK data from SAD 4 cohort) twice daily (BID) for 14 days except for Day 14, where only one dose in the morning will be given. Each of the MAD cohorts will include 8 healthy participants with 6 participants randomly assigned to RO6889678 and 2 participants randomly assigned to placebo. All participants enrolled to the MAD cohorts will receive an oral microdose of midazolam (100 micrograms [mcg]) before (Day -1) and after (Day 14) the repeat treatment with RO6889678 or matching placebo.
3357431|NCT02321384|Experimental|C:RTV-Boosted SAD & MAD Cohorts-RO6889678/Matching Placebo+RTV|Healthy participants will be enrolled in up to 3 SAD cohorts (2 compulsory and 1 optional) and up to 3 MAD cohorts (1 compulsory and 2 optional) to receive RO6889678 in combination with RTV in fed state. Participants of the first 2 RTV-boosted SAD cohorts will receive 100 mg RO6889678 + 100 mg RTV and 300 mg RO6889678 + 100 mg RTV respectively. Based on the PK and safety evaluation of the first 2 RTV-boosted SAD cohorts, another SAD cohort may be enrolled to receive a different dose of RO6889678 in combination with RTV. MAD RTV-boosted cohort will start based on the safety, tolerability and PK data of the RTV-boosted SAD cohorts. All participants enrolled to the RTV-boosted MAD cohorts will receive RO6889678 or placebo together with RTV on BID schedule for 14 days, and additionally an oral microdose of midazolam (100 mcg) before (Day -1) and after (Day 14) the treatment.
3357432|NCT02321397|Experimental|OXN PR HST|Prolonged release oxycodone/naloxone higher strength tablets
3357433|NCT02321397|Active Comparator|OXN PR LST|Prolonged release oxycodone/naloxone lower strength tablets
3246462|NCT01347749|Active Comparator|Present Centered Therapy for PTSD|This is a more standard from of group psychotherapy (talk therapy) which focusses on current symptoms and stressors
3246463|NCT01347775|Sham Comparator|Sham inspiratory muscle training|Patients in the sham group used the threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), with the diaphragm removed.
3246464|NCT01347775|Experimental|Inspiratory muscle training|Inspiratory muscle training will be by a threshold trainer (Threshold at IMT device URES HS730, Respironics, New Jersey, Inc, Cedar Grove, NJ, USA), a commercially available spring-loaded inspiratory muscle training device. It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
3246465|NCT01347801|Placebo Comparator|2C - 1|TNF and OGTT and saline
3357434|NCT02321410|Other|Imaging of carotid plaque|Patient undergo contrast enhanced ultrasound of the carotid plaque and dynamic contrast-enhanced carotid plaque MRI
3357435|NCT02321475||Psycho-emotional symptoms, added to cognitive disorders|Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.
3357436|NCT02321501|Experimental|Treatment (ceritinib, everolimus)|Patients receive ceritinib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3357437|NCT02321540|Experimental|Ibrutinib|"Participants in Part 1 receive dose level of Ibrutinib depending on study joined. First group of participants receive lowest dose level of Ibrutinib. Each new group receives a higher dose of Ibrutinib than the group before it, if no intolerable side effects were seen. This continues until highest tolerable dose of Ibrutinib is found.~Participants in Part 2 receive Ibrutinib at highest dose that was tolerated in Part 1 or 840 mg daily.~Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle."
3357438|NCT02321553|Experimental|Brown Rice|Eat 100g of brown rice cake (3 packets) per day for 5 weeks
3357439|NCT02321553|Experimental|White Rice|Eat 100g of white rice cake (3 packets) per day for 5 weeks
3357440|NCT02321566|Experimental|Treatment Arm|A craniotomy will be performed for the placement of an epidural motor cortex stimulation lead in the context of subjects with chronic facial, upper extremity, and throat pain. If the stimulation is successful during a trial period with externalized lead cabling, the system cabling will be internalized and connected to an internal implantable pulse generator to power and control the system for the duration of the trial.
3357441|NCT02321579|Placebo Comparator|Negative control|Dextrins
3357442|NCT02321579|Experimental|Supplement 1|50 mg/d vitamin B-6
3357443|NCT02321579|Experimental|Supplement 2|500 mg/d Glutathione
3357444|NCT02321579|Experimental|Supplement 3|50 mg/d vitamin B-6 plus 500 mg/d Glutathione
3357445|NCT02321592|Active Comparator|Arm A|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 8 consecutive weeks.~Arm A ist closed."
3246466|NCT01347801|Active Comparator|2C - 2|TNF and OGTT and GLP-1
3246467|NCT01347801|Placebo Comparator|2C - 3|TNF and IVGTT and saline
3357446|NCT02321592|Active Comparator|Arm B|"AFM13 is administered three times a week (e.g. monday-wednesday-friday) for 2 consecutive weeks followed by a weekly appication 6 consecutive weeks.~Arm B is closed."
3357447|NCT02321592|Active Comparator|Arm C|AFM13 is administered for five consecutive days a week as continuous infusion for 8 consecutive weeks
3357448|NCT02321605|Experimental|BPS exercise|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
3357449|NCT02321605|Placebo Comparator|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
3357450|NCT02321618|Experimental|BP measurement & pharmacy|BP measurements performed by barber, role model poster exposure in barbershop, and BP medication management visits with study pharmacist
3357451|NCT02321618|Other|BP educational materials|Exposure to hypertension educational materials in barbershop
3357452|NCT02321631|Experimental|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
3357453|NCT02321631|Placebo Comparator|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
3246468|NCT01347801|Active Comparator|2C - 4|TNF and IVGTT and GLP-1
3246469|NCT01347801|Placebo Comparator|2A-1|Saline infusion and OGTT
3246470|NCT01347801|Placebo Comparator|2A-2|Saline and IVGTT
3246471|NCT01347801|Active Comparator|2A-3|TNF and OGTT
3357454|NCT02321644|Experimental|CC-90001|"Part 1: All subjects will receive the following doses of CC-90001 in the fixed sequence below:~Treatment A: 60 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment B: 160 mg CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days Treatment C: 400 mg of CC-90001 as Active-Ingredient-in-Capsule, once daily x 6 days"
3357455|NCT02321644|Experimental|CC-90001 2 X 100mg fasted|Treatment D: 2 x 100 mg CC-90001 as Active-Ingredient-in-Capsule, single oral dose administered under fasted conditions.
3357456|NCT02321644|Experimental|CC-90001 1 X 200mg fasted|Treatment E: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fasted conditions
3357457|NCT02321644|Experimental|CC-90001 1 X 200mg fed|Treatment F: 1 x 200 mg CC-90001 [formulated tablet(s)] single oral dose administered under fed conditions (standard high fat breakfast).
3357458|NCT02321657|Experimental|iPad app containing art, music and games|On entry to the anaesthetic room, children will be given an iPad (the intervention) with art, music and games to distract them. A nurse will help them engage with the iPad whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the iPad will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
3357459|NCT02321657|Active Comparator|Toys, books and games|On entry to the anaesthetic room, children will be given toys or games to distract them. A nurse will help them play whilst the anaesthetists complete the anaesthetic. Once the child falls asleep, the games will be removed. This process is anticipated to last between 3 and 30 minutes depending on the time taken to anaesthetise the child.
3357460|NCT02321670|Active Comparator|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
3357461|NCT02321670|Active Comparator|Graft|Incision of the stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided.
3357462|NCT02321683|Experimental|Bonemaster|Cement-less femoral stems with electrochemical deposition of hydroxyapatite
3246472|NCT01347801|Active Comparator|2A-4|TNF and IVGTT
3246473|NCT01347801|Experimental|1C|OGTT and corresponding IVGTT
3246474|NCT01347827||on pump|Coronary artery bypass grafting (CABG)with with cardiopulmonary bypass
3246475|NCT01347827||off pump|off-pump CABG surgery
3357463|NCT02321683|Active Comparator|Hydroxyapatite|Cement-less femoral stems with plasmasprayed hydroxyapatite
3357464|NCT02321696|Experimental|Acupuncture and eccentric exercise|Treatment will be performed according to traditional Chinese methods (STRICTA: Standards for reporting interventions in controlled trials of acupunc-ture). Therapists will select points frequently recommended for the treatment of LE. As local point, LI11 and LI10 over the muscular origin of the lateral extensor group of the forearm will be used, and LU5 in the cubical region. LI4 and TE5 will be regional points for pain therapy in the upper limb, GB34 will be used as a distal point for treatment of tendinosis in general, and ST36 for treatment of pain. Needles will be inserted down to the musculature and obtaining De Qi sensation and will remain in situ for 20 min. All patients will receive four treatment sessions; this may be extended to eight depending on patient's pain report and the therapists' clinical evaluation. Maximum treatment period is 4 weeks. Patients will also be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
3357465|NCT02321696|Experimental|Physiotherapy and eccentric exercise|"Manual techniques as gliding mobilization of elbow, therapists are spezialised in manual therapy. At least four treatment sessions will be performed, but depending on the patient's perceived intensity of pain and the therapists' clinical evaluation, a maximum of eight treatment session can be given. All treatment session will be performed during a period of maximum 4 weeks.~In addition, patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward."
3357466|NCT02321696|Active Comparator|Watchful waiting and eccentric exercise|Patients will be instructed in eccentric strength exercises for daily home training from enrolment and 12 weeks forward.
3357467|NCT02321709|Experimental|SAR113244 cohort 1|Two administrations of dosage 1 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3357468|NCT02321709|Experimental|SAR113244 cohort 2|Two administrations of dosage 2 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3357469|NCT02321709|Experimental|SAR113244 cohort 3|Two administrations of dosage 3 SAR113244 or placebo subcutaneous dose (Q4 weeks)
3357470|NCT02321735|Other|Long-Term Ovarian Cancer survivors|Genomic, immunologic and psychosocial characterization of Long-Term survivors of ovarian cancer. This will involve a Quality of Life Questionaire.
3246476|NCT01347853|Experimental|Ketorolac tromethamine|
3246477|NCT01347853|Placebo Comparator|Placebo|
3357471|NCT02321761|Experimental|study group|"Dosage (mg) Day days 0-14 no drug will be given days 15-21 dosage is 100 mg days 22-28 dosage is 200mg days 29-42 dosage is 400mg days 43-56 dosage is 200mg~days 57-70 no drug will be given"
3357472|NCT02321787|No Intervention|Traditional Methods of Assessment|The caudal block will be done using traditional means of assessment, not confirmed by ultrasound.
3357473|NCT02321787|Experimental|Ultrasound for Confirmation|The caudal block will be performed utilizing ultrasound as an additional method of assessment for successful block (in addition to all traditional means of assessment).
3357474|NCT02321813|Experimental|intervention group|In the quality of life pathway results of the quality of life (QoL) measure are transferred to a QoL-profile. Three experts with various professional background use the individual patient's QoL-profile and clinical and sociodemographic information in order to generate a QoL-report including therapy recommendation which is sent to the coordinating practitioner. Specific therapeutic options for the treatment of diseased QoL have been identified: pain therapy, psychotherapy, social support, nutrition counseling, stoma care, physiotherapy, fitness. To provide continuous medical education, quality circles for each therapy option haven been founded. Coordinating practitioners receive a list with addresses of all quality circle members.
3357475|NCT02321813|Placebo Comparator|control group|In control group QoL is also measured but the coordinating practitioner neither receives a QoL-profile nor a QoL-report.
3357476|NCT02321826|Experimental|Music|Listening to music for 45 minutes at bedtime
3357477|NCT02321826|Active Comparator|Audiobook|Listening to audiobook for 45 minutes at bedtime
3357478|NCT02321826|No Intervention|Control|No intervention control group
3246478|NCT01347892||DeNovo NT Subject|Subjects who have received or who are scheduled to receive a DeNovo NT Graft for repair of a cartilage lesion in the ankle.
3246479|NCT01347905||Obese women and men|Obese women and men undergoing restrictive bariatric surgery. Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
3246480|NCT01347918||control|Healthy controls
3246481|NCT01347918||IBS|Patients that fulfil the Rome III criteria for irritable bowel syndrome (IBS)
3246482|NCT01347957|Experimental|Nitric Oxide (NO) Gel|
3246483|NCT01347957|Placebo Comparator|Placebo Gel|
3357479|NCT02321839|Experimental|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
3357480|NCT02321852|Experimental|Verum/Placebo|This group will start with triflusal and after washout will receive placebo
3357481|NCT02321852|Experimental|Placebo/Verum|This group will start with placebo and will receive triflusal after washout.
3357482|NCT02321865|Experimental|NPC-02|
3357483|NCT02321878||Liraglutide|
3357484|NCT02321891|Experimental|Treatment 1|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 1
3246484|NCT01347970|Experimental|Arm I (beta-adrenergic/alpha-1 adrenergic blocker)|Patients receive low-dose carvedilol PO QD or BID for 24 months.
3246485|NCT01347970|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD or BID for 24 months.
3357485|NCT02321891|Experimental|Treatment 2|NeuroConn DC Stimulator Plus, tDCS treatment protocol no 2
3357486|NCT02321904||Diabetic cases|Children with Type 1 Diabetes 8 to 18 years old followed at the Alberta Children's Hospital Diabetes Clinic with duration of diabetes for at least 5 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
3246486|NCT01347996|Experimental|histamine dihydrochloride and IL-2|histamine and IL-2 subcutaneous injections
3246487|NCT01348009|Experimental|Tesetaxel-capecitabine-cisplatin|
3357487|NCT02321904||Normal controls|Healthy children aged 8 to 18 years will undergo Corneal Confocal Microscopy, Nerve Conduction Studies, Quantitative sensory testing, Neuropathy Symptom Scoring and Clinical nerve examinations.
3246488|NCT01348022||Xience V stent|unprotected Left Main Coronary Artery stenting treated with Xience V stent
3246489|NCT01348035||Water Load Group|Water load group: 2.5 ~ 3 L water intake daily for 12 months (50ml/Kg body weight/day). When large amount water intake is not sustainable, patients can reduce the amount of water intake to the levels as much as large he or she can sustain.
3246490|NCT01348035||Non-Water Loaded Group|Non-water load group: The patients are free to access water intake, as they like.
3246491|NCT01348048|Experimental|Specialised palliative care (SPC) group|Patients continue with their standard treatment (typically they receive treatment in one or more hospitals departments and from their GP). In addition, they are offered a consultation in the SPC out-patient clinic (or at home if the patient cannot attend the hospital) as soon as possible and no more than one week after randomization. If possible, each patient will have at least two contacts to the SPC in the trial period.
3246492|NCT01348048|No Intervention|Standard care group|Patients continue with their standard treatment. They are instructed to contact either their GP or their hospital department if they feel that additional treatment or care is needed.
3246493|NCT01348061||Elderly Healthy Control (EHV)|No clinically significant deviation from healthy in medical history, physical examination, ECGs, MRI and clinical laboratory determinations for their respective age group.
3259367|NCT01470235||Control patients|"Women referred to the departments of obstetrics and gynecology in Aarhus University Hospital and Rigshospitalet, Copenhagen on benign indication.~Expected recruitment: 200."
3357488|NCT02321917|Active Comparator|Rheoparin coating|MECC system with rheoparin coating
3357489|NCT02321917|No Intervention|No rheoparin coating|MECC system without rheoparin coating
3357490|NCT02321943||Follow-Up Group|"An earlier investigated cohort with first episode psychosis patients from two Norwegian counties. Being between 18 - 65 years old and being consecutive in- or outpatient referred to first adequate treatment for a DSM-IV diagnosis of schizophrenia, bipolar disorder, or other psychosis."
3357491|NCT02321956|Experimental|Ultrasound|Using ultrasound measurement of the subglottic area to choose endotracheal tube size
3357492|NCT02321956|No Intervention|Formula|Using Cole's formula to choose endotracheal tube size
3357493|NCT02321969|No Intervention|Control|Without green tea extract (GTE) supplementation
3357494|NCT02321969|Experimental|GTE group|GTE supplementation for 12 months after polypectomy for colorectal adenomatous polyps
3246494|NCT01348061||Progressive Supranuclear Palsy (PSP)|A diagnosis of possible or probable PSP according to clinical criteria of National Institute of Neurologic Diseases and Stroke - the Society for PSP plus a MRI at screening to exclude other potential causes of parkinsonism as well as a mild-to-moderate stage of disease severity according to a score of 1 to 3 in Golbe Staging System.
3246495|NCT01348061||Alzheimer's Disease (AD)|A diagnosis of probable AD Based on the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association and The Diagnostic and Statistical Manual of Mental Disorders as determined by a mini-mental state examination (MMSE) score of 16 to 26, inclusive.
3357495|NCT02321982|No Intervention|Separate-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation in advance of the day of the procedure.
3357496|NCT02321982|Experimental|Same-day preoperative consultation|Patients referred for Mohs surgery for non-melanoma skin cancer will have a preoperative consultation on the day same day as the procedure.
3357497|NCT02322034|Experimental|Interval Training|Hospital outpatient-based regimen (3 times/week for 24 weeks) exercise program will be performed by cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
3246496|NCT01348074|Experimental|Double dose|Re-initiation with warfarin at twice the usual maintenance dose the first 2 days, then maintenance dose.
3246497|NCT01348074|No Intervention|Usual maintenance dose|Usual maintenance dose from Day 1, i.e. no postoperative loading dose.
3357498|NCT02322034|No Intervention|Controls|CHF patients allocated to the control group (no intervention) will undergo biochemical and hormonal sampling, Doppler-echocardiography, cardiopulmonary exercise stress testing at study enrollment and at 24-week follow-up.
3357499|NCT02322060||Primary ovarian insufficiency|"Primary ovarian insufficiency (POI; also known as premature ovarian failure/dysfunction/insufficiency or premature menopause) is characterised by amenorrhoea, sex hormone (oestrogen, progesterone and testosterone) deficiency and elevated gonadotrophins levels in a woman aged more than two standard deviations below the mean age of menopause estimated for her reference population. POI is defined as a disorder in ovarian function in any woman before the age of 40 years, irrespective of the cause.~In our study, we mainly recruit POI patients who also desire to have a baby of their own."
3357500|NCT02322060||Ovarian resistance syndrome|We currently also include patients diagnosed with Ovarian resistance syndrome, which means that follicles exist, but do not response to FSH.
3246498|NCT01348113|Experimental|Brief Alcohol Intervention|
3246499|NCT01348113|No Intervention|No intervention|
3357501|NCT02322073||Lean healthy controls|Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.
3357502|NCT02322073||Obese|Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status
3357503|NCT02322086|Experimental|PH-10|Active treatment
3357504|NCT02322099|Active Comparator|Alendronate|Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
3357505|NCT02322099|Placebo Comparator|Placebo|Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada®
3357506|NCT02322112|Placebo Comparator|Microcrystalline Cellulose (Control)|Microcrystalline cellulose will be used as a placebo control, as it is known to be an insoluble, non-viscous fiber that is essentially not fermented by the human gut microbiota. However, it is important to note that cellulose does have fermentation potential within the gastrointestinal tract and may be associated with improved health benefits; indicating a role as an active comparator.
3357507|NCT02322112|Experimental|Acacia Gum|Acacia gum is composed largely of arabinogalactan, and is considered to be a relatively non-viscous, soluble fiber this is highly fermented by the gut microbiota and well tolerated.
3357508|NCT02322112|Experimental|Resistant Starch Type 4|Cross-linked phosphorylated resistant starch (type IV) is generally insoluble and with low viscosity; yet it tends to have physiologic properties similar to soluble fibers, such as fermentability.
3357509|NCT02322138|Experimental|Experimental 1 Infant Formula|Milk-based infant formula without prebiotics
3357510|NCT02322138|Experimental|Experimental 2 Infant Formula|Milk-based infant formula with prebiotics
3357511|NCT02322138|Other|Human Milk-Fed Reference Group|Breast fed infants
3246500|NCT01348126|Active Comparator|Single agent docetaxel|
3246501|NCT01348126|Experimental|Combination of ganetespib and docetaxel|
3246502|NCT01348152|Placebo Comparator|Placebo|Placebo TID
3246503|NCT01348152|Experimental|DAIKENCHUTO (TU-100) 15 g/day|TU-100 5g TID
3357513|NCT02322203|Experimental|Niacin ER in healthy participants and its effects on lipoprotein composition and function|Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
3357514|NCT02322255||All Subjects|All subjects enrolled in the study.
3357515|NCT02322268|Experimental|Diabetic Cosmos caudatus treated group|Subjects in this arm will receive Cosmos caudatus for 8 weeks.
3357516|NCT02322268|No Intervention|Diabetic control group|Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.
3246504|NCT01348178||developmental dysplasia of the hip, PAO|All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus
3246505|NCT01348191||Elective caesarean section|"Population: ten pregnant women, scheduled for elective caesarean section with a term pregnancy ( > 37 weeks).~Inclusion criteria~Elective caesarean section~Term pregnancy > 37 weeks~Age > 18 years~Exclusion criteria~Previous caesarean scar~Gestational age < 37 weeks~Maternal temperature > 37.8 degrees Celsius~Meconium stained liquor~Foetal distress~Maternal diabetes~Seropositivity~Use of thyroid medication~Maternal thyroid disease~Age < 18 years"
3246506|NCT01348204|Experimental|quercetin|health food supplement
3246507|NCT01348217|Active Comparator|ARM A|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~Radiotherapy 40 Gy, in 20 fractions / 4 weeks: PTV (1cm in every direction)~Boost 10 Gy in 5 fr: PTV = +1cm.~Chemotherapy FOLFOX 4: 6 treatments in 3 courses concomitant to the radiotherapy (D1, D15, D29)"
3246508|NCT01348217|Experimental|ARM B|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph nodes:~40 Gy in 20 fractions / 4 weeks, PTV (1cm in every direction)~Boost 26 Gy in 13 fr: PTV = +1cm.~Chemotherapy: FOLFOX 4: 6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43)."
3246509|NCT01348230||prior preterm delivery at 24-32 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3246510|NCT01348230||prior preterm delivery at 32-34 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3246511|NCT01348230||prior preterm delivery at 34-36 weeks|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
3357517|NCT02322294|Experimental|Glucodia™|
3357518|NCT02322294|Placebo Comparator|Placebo|
3357519|NCT02322307|Experimental|HealthPROMISE users|These are patients who will receive HealthPROMISE application. Patients will be asked to track their quality of life and quality of care using standardized metrics. A combination of different questionnaires (i.e. Short IBD Questionnaire), symptom updates, and IBD quality indicators will be the collected during this study through the HealthPROMISE application.
3357520|NCT02322307|Placebo Comparator|Control Group|After entering baseline questionnaire, control patients get a link to download education application along with PIN. Once patients install app on their devices and use the PIN, the patient is considered to be enrolled in the trial from intention to treat perspective. This control app allows access to patient education content only. There is not any direct feedback on Quality of Life, quality of care and resource utilization.
3357521|NCT02322346|Placebo Comparator|Group S|Preincisional bilateral peritonsillar infiltration of a total of 6 mL of saline
3357522|NCT02322346|Active Comparator|Group LL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.25% (3 mL to each tonsil).
3357523|NCT02322346|Active Comparator|Group HL|Preincisional bilateral peritonsillar infiltration of levobupivacaine 0.5% (3 mL to each tonsil).
3357524|NCT02322372|Active Comparator|Group F|"Ultrasound-guided femoral blockade with 15 mL of bupivacaine 0.5% diluted in 15 mL saline was performed in supine position. Then the patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 1 mL (5 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.~."
3357525|NCT02322372|Active Comparator|Group S|The patient was turned to lateral decubitus position with the operated extremity on dependant position and intrathecal injection of heavy bupivacaine 2 mL (10 mg) was administered from L3-L4 intervertebral space at a rate of 1 mL/20 second.
3246512|NCT01348243|Experimental|Clodronate 200 mg|
3246513|NCT01348243|Active Comparator|Clodronate 100 mg|
3357526|NCT02322398||Group A|Patients who had been stimulated with a starting dose of 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio.
3357527|NCT02322398||Group B|Patients who had been stimulated with a starting dose of 150-300 IU/d hMG.
3357528|NCT02322424||Patients who undergo pancreaticoduodenectomy|
3246514|NCT01348256|No Intervention|Observation|Observation after standard treatment
3246515|NCT01348256|Experimental|Dendritic cells vaccine|Adjuvant treatment with dendritic cells vaccine after standard treatment
3246516|NCT01348269|Active Comparator|Aclasta|
3246517|NCT01348269|Placebo Comparator|NaCl Solution|
3246518|NCT01348282|Experimental|Lithium|Lithium group: Patients who will initiate therapy with lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
3246519|NCT01348282|Active Comparator|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
3246520|NCT01348282|No Intervention|Control group|Patients who will not initiate treatment
3246521|NCT01348295||Mechanically ventilated children|All children under 16 years of age who are needing mechanical ventilation for any reason.
3246522|NCT01348308|Active Comparator|Maraviroc|Maraviroc 300, 600 or 1200mg per day
3246523|NCT01348308|Placebo Comparator|Placebo|Placebo 300, 600 or 1200mg per day
3246524|NCT01348321|Experimental|Azithromicine plus levamisole|
3246525|NCT01348321|Experimental|Azithromicin|
3246526|NCT01348334|Active Comparator|Vypromesh®(Ethicon,USA)|Vypromesh®(semiabsorbable multiflament mesh;non-absorbable Polypropylene+absorbable Poliglactin)
3246527|NCT01348334|Active Comparator|Ultrapromesh®(Ethicon,USA)|Ultrapromesh®(semiabsorbable monofilament mesh;non-absorbable Polypropylene+absorbable polyglecaprone).
3246528|NCT01348334|Active Comparator|Prolene light mesh®(Johnson&Johnson,USA)|Prolene light mesh®(cpp-Condensed monofilament non absorbable polypropylene mesh)
3246529|NCT01348360||NOBORI stent|
3246530|NCT01348373||GENOUS EPC-coated stent|Patients treated with GENOUS EPC-coated stent
3246531|NCT01348386|Experimental|KOH 10%|Treatment consists of the application of topical 10% KOH in an aqueous solution.
3246532|NCT01348386|Experimental|KOH 15%|Treatment consists of the application of topical 15% KOH in an aqueous solution
3246533|NCT01348386|Placebo Comparator|PLACEBO|100 milliliters of saline solution
3246534|NCT01348399||XIENCE PRIME stents|
3246535|NCT01348412|Experimental|ARM A|Hepatic artery infusion through an implanted arterial catheter of the combination of raltitrexed (3 mg/m ²) and oxaliplatin (100 mg/m ²) every 21 days.
3246536|NCT01348412|Active Comparator|ARM B|Intravenous standard chemotherapy.
3246537|NCT01348438|Other|Single arm study|
3246538|NCT01348451|Experimental|surgery|A sequential design of five groups will be utilized to reduce risk to subjects. The first group (Group A) will include six subjects and the subsequent groups will include three subjects per group. Each group represents both different inclusion criteria and location of surgery.
3357529|NCT02322437|Experimental|Home treatment|Patients in need of acute psychiatric inpatient care are treated at their houses by mobile treatment teams instead of treatment at mental hospitals whenever home treatment is possible and appropriate.
3357530|NCT02322437|Active Comparator|Treatment as usual|Patients in need of acute psychiatric inpatient care are treated at a mental hospital.
3246539|NCT01348464||lifestyle, wound satisfaction|single site access three site access for appendectomy
3246540|NCT01348477|Experimental|Elliptical domed mesh technique|84 adult patients with primary uncomplicated inguinal hernia, treated with an open preperitoneal elliptical mesh technique
3357531|NCT02322450|Experimental|A: P1-QGC001 - Washout-placebo - P2-placebo|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
3357532|NCT02322450|Experimental|B: P1-placebo - Washout-placebo - P2-QGC001|The first period (P1) will correspond either to QGC001 or placebo, the second period (P2) will correspond either to QGC001 or placebo.
3357533|NCT02322463||Arab children (case subjects)|Arab patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
3357534|NCT02322463||Jewish children (controls)|Jewish patients who were admitted to the pediatric ED due to a limb fracture between 01 January 2011 and 31 October 2014, who were treated with Oxycodone
3357535|NCT02322489|Sham Comparator|Sham microcurrent therapy|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but it lasts only for 5 seconds.
3357536|NCT02322489|Experimental|Microcurrent Group|The participant is lying on an examination table for one hour; several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started.
3246541|NCT01348477|Active Comparator|Lichtenstein technique|84 adult patients with primary uncomplicated inguinal hernia treated with the Lichtenstein technique (gold standard)
3246542|NCT01348503|Experimental|Open Label, Single Arm|Dose escalation of lenalidomide in combination with sorafenib at standard doses in patients with advanced, unresectable hepatocellular carcinoma.
3246543|NCT01348516|Experimental|KM-023|
3357537|NCT02322502|Experimental|desflurane|Suprane® Dose: 0.8 MAC / 4-5 vol. % Mode of administration: inhalation with laryngeal mask One application
3357538|NCT02322502|Active Comparator|sevoflurane|"Sevoflurane:~Dose: 0.8 MAC / 1.2-1.4 vol.% Mode of administration: inhalation with laryngeal mask One application"
3357539|NCT02322502|Active Comparator|propofol|Propofol Dose: 5-7 mg kg-1 h-1 to maintain a BIS index value between 40 and 60 Mode of administration: intravenous One application
3357540|NCT02322515|Experimental|Intervention Taping|The experimental group will use a rigid patellar taping (G1, n = 22) for the correction of lateralization of the patella and stabilization of the knee. The lateral stabilization will be made with self-adhesive taping positioned in the lateral border of the patella and tensioned in relation to the medial portion of the femur condyle, which allows an edge of the medial board patella and a stretching of lateral structures of the knee. All procedure will follow the recommendation from McConnell studies with regard to the patellar femoral syndrome.
3357541|NCT02322515|Placebo Comparator|Placebo Taping|The placebo group will use a rigid patellar taping (G2, n = 22), but without no correction of lateralization of the patella and/or stabilization of the knee. The taping will be placed incorrectly such as in the vertical position of knee and without any tension or traction around structures and patella.
3357542|NCT02322541|Experimental|Time Course|Measurement of garlic metabolites over 24 hours following garlic intervention.
3357543|NCT02322554||wounds treated with CTPs|All cellular and tissue based products currently reimbursed in the hospital based outpatient department, administered at intervals as determined in the course of clinical practice
3357544|NCT02322567||LV diastolic dysfunction|
3357545|NCT02322567||No LV diastolic dysfunction|
3357546|NCT02322580||Psoriasis patients who receive Enbrel® therapy|
3357549|NCT02322606|Other|Cohort 1: TAK-137 5 mg, TAK-137 placebo|Single-dose administration in a fasting state
3357550|NCT02322606|Other|Cohort 2: TAK-137 10 mg, TAK-137 placebo tablet|Single-dose administration in a fasting state
3357551|NCT02322606|Other|Cohort 3: TAK-137 20 mg or TAK-137 2 mg + TAK-137 placebo|Single-dose administration in a fasting state
3246544|NCT01348516|Placebo Comparator|Placebo for KM-023|
3357552|NCT02322606|Other|Cohort 4: TAK-137 5mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3357553|NCT02322606|Other|Cohort 5: TAK-137 10 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3357554|NCT02322606|Other|Cohort 6: TAK-137 15 mg, TAK-137 placebo|Once daily for 7 days in a fasting state
3357555|NCT02322619|Experimental|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
3357556|NCT02322619|Active Comparator|Avelox Tablets 400 mg|Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc.
3357557|NCT02322632|Experimental|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
3357558|NCT02322632|Experimental|Zemplar Capsules, 4 mcg|Zemplar Capsules, 4 mcg of Abott Laboratories USA
3357559|NCT02322645|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
3357560|NCT02322645|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
3357561|NCT02322658|Experimental|Eszopiclone Tablets|Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited
3357562|NCT02322658|Active Comparator|Lunesta|Lunesta Tablets 3 mg of Sepracor Inc.
3246545|NCT01348529|Experimental|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
3246546|NCT01348555|Experimental|V0162|
3246547|NCT01348555|Placebo Comparator|Placebo|
3246548|NCT01348568|Experimental|Low glycemic index diet with canola oil bread|Subjects will be given whole wheat bread which includes canola oil, and advised to follow a diabetic diet using low glycemic index foods.
3357563|NCT02322671|Experimental|Sequence ABC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ABC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357564|NCT02322671|Experimental|Sequence ACB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence ACB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357565|NCT02322671|Experimental|Sequence BAC|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BAC, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357566|NCT02322671|Experimental|Sequence BCA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence BCA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357567|NCT02322671|Experimental|Sequence CAB|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CAB, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357568|NCT02322671|Experimental|Sequence CBA|Subjects will be administered a single oral dose of treatment A, B and C in the sequence CBA, where A is Reference Treatment: 5 mg montelukast sodium reference chewable tablets (innovator product); B is Test Formulation 1: 5mg montelukast sodium (GW483100) chewable tablet and C is Test Formulation 2: 5mg montelukast sodium (GW483100) chewable tablet. The treatment periods will be separated by a washout period of 7 to 14 days
3357569|NCT02322684|Active Comparator|Group Q|Blind endotracheal intubation will be performed through the air-Q
3246549|NCT01348568|Active Comparator|high fiber diet|Subjects will be given whole wheat bread, and advised to follow a healthy high fiber diabetic diet.
3246550|NCT01348581|Experimental|Marigen Wound Dressing|
3357570|NCT02322684|Active Comparator|Group B|Blind endotracheal intubation will be performed through the air-Q with bougie assisted
3357571|NCT02322697|Experimental|Carnitine group|Intravenous administration of L-carnitine 1000mg after each hemodialysis session (three times a week) for one year.
3357572|NCT02322697|No Intervention|control group|No intervention
3357573|NCT02322723||Moderately to severely active RA patients|Moderately to severely active RA patients aged 18 years or older, both male and female
3246551|NCT01348594||Vitamin D deficient|
3246552|NCT01348594||Vitamin D sufficient|
3246553|NCT01348620|Experimental|Single port laparoscopic device|
3246554|NCT01348620|Active Comparator|Four-port laparoscopic device|
3246555|NCT01348633||Sub-study 1|The Quantitative, Doppler SD-OCT Blood Flow Technology will be validated and calibrated by manipulating end-tidal blood gases using the computer-controlled gas sequencer (Slessarev et al, 2005) in 15 healthy controls. Homeostatic inner retina blood flow values and the magnitude of vascular reactivity will be compared between Doppler SD-OCT blood flow technology and the Canon Laser Blood Flowmeter, an established standard, at specific locations within the retinal vascular tree.
3259368|NCT01470235||HBOC/HNPCC|"Patients registered in the large Danish Register of HBOC( hereditary breast and ovarian cancer) and HNPCC (hereditary nonpolyposis colorectal cancer).~Expected recruitment: 200."
3357574|NCT02322736||WT RAS mCRC|Wild Type RAS metastatic colorectal cancer patients
3357575|NCT02322762||One single cohort.|One single cohort of patients with type 2 diabetes mellitus initiating their second line anti-diabetic therapy after first line anti-diabetic therapy.
3357576|NCT02322801||Cohort|
3357577|NCT02322827||single tablet regimen|Subjects whose most recent antiretroviral therapy consist of a single tablet regimen
3259369|NCT01470261||ADHD medicated|Children aged 5-17 years with clinical diagnosis of ADHD and not previously treated with methylphenidate who have an agreement with their physician to begin treatment with methylphenidate.
3357578|NCT02322827||multiple tablet regimen|Subjects whose most recent antiretroviral therapy consist of multi tablet regimen
3357579|NCT02322840|Experimental|TMVR Implant|Twelve TMVR Implant
3357580|NCT02322853|Active Comparator|TAMOXIFEN|"Tamoxifen will be administered daily orally~Patients will receive study medication until disease progression or unacceptable toxicity"
3357581|NCT02322853|Experimental|TAMOXIFEN + LY2228820|"Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally~Patients will receive study medication until disease progression or unacceptable toxicity"
3357582|NCT02322905|Experimental|Emotion Regulation Therapy|8 sessions of Emotion Regulation Therapy.
3357583|NCT02322905|No Intervention|Usual Medical Care|No planned psychotherapy.
3357584|NCT02322918||Participants admitted to BCPP|Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
3357585|NCT02322931|Experimental|Imaging interventions|Eligible patients who consent to participate in this study will undergo a combination of 4 different imaging interventions (based on the group they're in, as described in the protocol), intra-operatively, in addition to their standard LDR brachytherapy treatment.
3357586|NCT02322944|Experimental|Intervention group|The intervention group will take the treatment quality improvement strategies and tools into implementation.
3357587|NCT02322944|No Intervention|Control group|The control group will maintain the routine practice pattern.
3357588|NCT02322944|Experimental|Process optimization group|The process optimization group's clinical pathways and team building will be re-organized for the purpose of quality improvement, and develop individualized treatment strategies and process.
3357589|NCT02322957|Experimental|Treatment Regimen A|FV-100 400mg OD as a single dose fasted (>/= 8 hours)
3357590|NCT02322957|Experimental|Treatment Regimen B|FV-100 400 mg OD as a single dose with ritonavir 200mg OD as a single fasted dose (>/= 8 hours)
3357591|NCT02322970||Intracranial Pressure monitoring|Invasive Intracranial Pressure monitoring will be compared to non invasive intracranial monitoring ( through use of transcranial Doppler ).
3357592|NCT02322983|Experimental|Cerebral Palsy Subjects|Use of conscious sedation with nitrous oxide in the control of stress during dental treatment in individuals with Cerebral Palsy
3357593|NCT02322996||open label|After the surgery and the onset of moderate-severe pain, QST and PROMIS questionnaires will be repeated. Throughout these procedures, patients will rate their pain perception using a numeric rating scale. Approximately 2-3 hours after surgery at the onset of moderate pain, the rescue analgesic (toradol) will be administered via intramuscular injection. Again, QST and PROMIS protocols will be repeated after the drug is given and when patients report pain relief. A standard naproxen dose of 500 mg will be given to patients upon leaving the clinic and they will be instructed to take one pill orally each day before returning for evaluation after 48 hours.
3357594|NCT02323009|Active Comparator|Esophageal balloon Arm|Patients in this arm were randomly assigned to have their PEEP adjusted to maintain a positive transpulmonary pressure (0 to 10 cm H20).
3357595|NCT02323009|Active Comparator|Cstat Arm|Patients in this arm had their PEEP adjusted to achieve the best static effective compliance (CStat).
3357596|NCT02323009|No Intervention|Historic Controls|These were historic controls with similar patient characteristics weaned by traditional methods in the 2-year period prior to the start of the study.
3357597|NCT02323022|Experimental|IAC regimen|Patients in this arm will receive an IAC induction therapy
3357598|NCT02323022|Active Comparator|High-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 10mg/msq/d
3357599|NCT02323022|Active Comparator|Intermediate-dose IA regimen|Patients in this arm will receive an IA induction therapy, in which the idarubicin dose should be 12mg/msq/d
3357600|NCT02323035|Experimental|Headgear|Investigative Headgear with CPAP Mask.
3246556|NCT01348633||Sub-study 2|The Quantitative, Hyper-Spectral Imaging Derived Oxygen Saturation Maps of the major retinal vessels and capillary beds will be validated and calibrated in human volunteers using our novel and exact technique that allows the precise control of the partial pressure of oxygen (PO2) to induce controlled and safe levels of hypoxia. Oxygen saturation values will be compared to measured PO2 values (i.e. recognized standard) for various levels of hypoxia and will be used to provide in-sight into the properties of the data output e.g. effective operating range, linearity of response. At the end of the study, subjects will be returned to normoxic conditions to assess reproducibility of oxygen saturation maps.
3246557|NCT01348633||Sub-study 3|Subjects with symptoms of branch and central retinal artery and vein occlusion within the past 2 months will be used to validate the Doppler SD-OCT blood flow technology and the hyperspectral imaging derived oxygen saturation maps. In cases of central retinal vein and artery occlusion, imaging values (i.e. inner retinal and choroidal blood flow, oxygen saturation values of the major retinal vessels and the capillary beds of the retina and ONH) will be compared between the affected and unaffected eyes. In cases of branch occlusion, imaging values will be compared between the affected and unaffected quadrants of the affected eye and between the affected and unaffected eyes. The difference in inner retinal and choroidal blood flow for each eye will be calculated and compared between eyes.
3246558|NCT01348633||Sub-study 4|Calibration for retinal melanin, crystalline lens absorption, macular pigment, morphological variation and pre-retinal autofluorescence in healthy subjects (n=20 per decade, range 40 to 80yrs). Established reflectometric techniques to derive absorption values and autofluorescence techniques will be used to calculate correction values for each parameter that influences the hyper-spectral retinal and ON oxygen saturation imaging data (Keilhauer and Delori, 2006; Delori et al, 2007).
3357601|NCT02323061|Experimental|BCI-robot (I)|EEG guided training based on ipsilesional EEG signals; Training for 20 sessions
3357602|NCT02323061|Experimental|BCI-robot (IC)|EEG guided training based on both ipsilesional and contralesional EEG signals; Training for 20 sessions
3357603|NCT02323061|Placebo Comparator|robot|Training for 20 sessions
3357604|NCT02323074|Experimental|fBCI-robot|focalized BCI-robot hand training
3357605|NCT02323074|Experimental|gBCI-robot|generalized BCI-robot hand training
3357606|NCT02323074|Sham Comparator|sham-BCI|Sham BCI
3357607|NCT02323087|Active Comparator|Culture and susceptibility testing|Urine culture and sensitivity testing will be performed using the FLEXICULT™ SSI-Urinary Kit
3357608|NCT02323087|Active Comparator|Culture|Point of care culture will be performed using ID FlexicultTM
3357609|NCT02323100|Active Comparator|Ravicti low dose|Low dose Ravicti® oral liquid at 6ml (6.6 gm) by mouth or gastrostomy tube at 8 am, 5.5 ml (6.05gm) at 4pm and midnight for 7 days.
3357610|NCT02323100|Active Comparator|Ravicti high dose|Ravicti® oral liquid at 9ml (9.9 gm)at 8 am and 8.25ml (9.08 gm) at 4pm and midnight for 7 days.
3357611|NCT02323100|Placebo Comparator|Placebo|Matching placebo taken at 8am, 4pm and midnight for 7 days.
3357612|NCT02323139|Experimental|Combination of azacitidine and LDE255|Combination of azacitidine at maximum tolerated dose and LDE255 at dose escalation, the starting dose will be 400 mg
3357613|NCT02323152|Experimental|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
3357614|NCT02323152|Active Comparator|Control group|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment.
3357615|NCT02323178|Experimental|eltrombopag|
3357616|NCT02323191|Experimental|Part 1 (Dose-finding): Emactuzumab + Atezolizumab|Participants will receive escalating doses of emactuzumab along with atezolizumab every 3 weeks (q3w).
3357617|NCT02323191|Experimental|Part 2 (Expansion): Emactuzumab + Atezolizumab|Participants will receive emactuzumab at or below the MTDs for the combination treatments that are determined during Part 1 along with atezolizumab.
3357618|NCT02323230|Experimental|DPX-Survivac + low dose cyclophosphamide|
3357619|NCT02323243|Experimental|Allium BUS|Temporary urethral stent
3357620|NCT02323256|Experimental|newly cochlear implanted adult patients|longitudinal group
3357621|NCT02323256|Experimental|newly cochlear implanted children|longitudinal group
3357622|NCT02323256|Active Comparator|cochlear implanted adult patients (CI>1 year)|transversal group
3246559|NCT01348633||Sub-study 5|Establishment of a database of healthy control imaging values (n=20 per decade, range 40 to 80yrs). A database of healthy control values will be established for each technology taking into account extraneous factors such as age (range 40 to 70 years) and gender. The healthy control database will be compared to the results of each individual patient in the prospective study phase of this proposed Research Program (see Prospective Study Phase, 3, Control group). Statistical confidence limits for abnormality at each time point, and for progression overtime, will be established. Measurements will be repeated at separate visits to establish repeatability.
3246560|NCT01348646|Other|Lifestyle counseling|
3246561|NCT01348659|Active Comparator|7.2% NaCl/hydroxyethyl starch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) (Hyperhaes®, Fresenius Kabi)
3246562|NCT01348659|Active Comparator|0.9% NaCl|250 ml of NaCl 0.9% (Natriumklorid Braun 9 mg/ml)
3357623|NCT02323256|Active Comparator|normal hearing adult subjects|transversal group
3357624|NCT02323269||Treatment naive to dimethyl fumarate|Participants who are prescribed dimethyl fumarate as their initial therapy will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
3357625|NCT02323269||Switch to dimethyl fumarate|Participants who are prescribed dimethyl fumarate after suboptimal response to IFN or GA will receive 120 mg tablet administered orally twice a day for 7 days, then switch to maintenance dose of 240 mg tablet twice daily.
3357626|NCT02323282|Other|ropivacine|
3357629|NCT02323308||vaccination|Anti-HBV vaccine injection
3357630|NCT02323321|Experimental|OCS Preservation|OCS Preservation and Assessment
3357631|NCT02323360|Experimental|Stereotactic body radiation therapy|HCC after incomplete TAE or TACE treated by SBRT
3357632|NCT02323360|Active Comparator|TACE/TAE|HCC after incomplete TAE or TACE treated by a new cycle of TAE or TACE
3357633|NCT02323373|Experimental|Topical group|Intervention: Tranexamic Acid - topical. Topical administration of a solution of 1.5 g of tranexamic acid (50 mg/ml, Transamin, Zydus Nikkho) diluted in 50 ml of saline (at 0.9%), sprayed over the operated area, covering it for 5 minutes, before the tourniquet release.
3357634|NCT02323373|Active Comparator|Intravenous group|Intervention: Tranexamic Acid - intravenous Intravenous injection of 20 mg/kg of tranexamic acid, diluted in 100 ml of saline at 0.9%, administered with anesthesia in 10 minutes.
3246563|NCT01348672||1. ARMD Study arm|"The ARMD study arm (n=150) consists of 3 groups. The groups are organised according to established risk criteria for clinical progression (AREDS, 2003).~Group 1A (n=50); Early stage ARMD with low risk of progression; several small drusen, or a few medium-sized drusen, in one or both eyes. One eye will be randomly selected for the study.~Group 2A (n=50); Intermediate ARMD with high risk of progression to advanced ARMD; many medium-sized drusen, or one or more large drusen, in one or both eyes. More severely affected eyewill be selected for the study.~Group 3A (n=50); In one eye only, either a break-down of light-sensitive cells and supporting tissue in the central retinal area (i.e. geographic atrophy), or abnormal and fragile blood vessels under the retina (i.e. choroidal neovascular membrane formation). The fellow eye is at high risk of progression to advanced ARMD. The fellow eye will be selected for the study."
3259370|NCT01470261||ADHD unmedicated controls|Children aged between 5-17 years with clinical diagnosis and not previously treated with methylphenidate who have an agreement with their physician NOT to treat with methylphenidate
3357635|NCT02323373|Placebo Comparator|Placebo|Intervention: intravenous injection of 100 ml of saline solution also administered with anesthesia in 10 minutes.
3357636|NCT02323386|Experimental|ATTUNE knee system|The patients will undergo primary Total Knee Arthroplasty (ATTUNE knee system)
3357637|NCT02323399|Experimental|Phenylephrine|Phenylephrine Hydrochloride Injection, USP (United States Pharmacopeia) 10 mg/mL label claim
3357638|NCT02323412|Experimental|Amoxicillin|Amoxicillin (Amoksicillintrihydrat) tablets 750 mg 1x3 for 100 days (oral intake). The tablets will be encapsulated in Capsugel DB-caps AAel Swedish orange.
3357639|NCT02323412|Placebo Comparator|Placebo|Placebo capsules for 100 days of daily (1x3), oral intake. The placebo tablets will also be encapsulated in Capsugel DB-caps AAel Swedish orange.
3357640|NCT02323425|Experimental|Remote Ischemic Postconditioning|remote ischemic postconditioning（RIPC） treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation twice a day for the total of 180 consecutive days.
3357641|NCT02323425|No Intervention|Control|Patients in control group will receive foundation treatment. Foundation treatment: including blood vessel expansion、free radical elimination etc during acute phase and aspirin (100-300 mg/d), and atorvastatin (20 mg/d) till the end of the study (180 consecutive days).
3357642|NCT02323438|Active Comparator|Usual Brand (UB) Cigarettes|Usual Brand Cigarette
3357643|NCT02323438|Experimental|Electronic Cigarette #1|VUSE® (original flavor, 29 mg nicotine)
3357644|NCT02323438|Experimental|Electronic Cigarette #2|VUSE® (menthol flavor, 26 mg nicotine)
3357645|NCT02323438|Experimental|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
3357646|NCT02323451|Experimental|Medical Chitosan|Medical Chitosan, 2ml/vial (12mg/ml), intra-articular injection with a volume less than 2ml every two weeks, a total of 3 times
3357647|NCT02323451|Active Comparator|Sodium Hyaluronate Injection|Sodium Hyaluronate Injection, 2ml/vial (10mg/ml), intra-articular injection with a volume less than 2ml every one weeks, a total of 5 times.
3357648|NCT02323464||Before surgery|patients scheduled for surgery of colorectal cancer
3246564|NCT01348672||2. POAG study arm|"Patient groups are organised according to established risk criteria for clinical progression (EMGT, 2003).~Group 1P (n=36); Stable, early to moderate, treated patients with POAG. Early to moderate POAG is defined as having an untreated IOP prior to treatment of >21mmHg and a repeatable visual field defect with a Mean Deviation of <12dB and/or documented but stable ONH appearance, consistent with a diagnosis of glaucoma.~Group 2P (n=36); Early to moderate, treated patients with normal tension glaucoma (NTG). Normal Tension Glaucoma is defined using the same criteria as POAG but with an untreated IOP of <21mmHg throughout the day. This group has NTG and is thought to be at increased risk of vascular dysfunction due to loss of ONH perfusion.~Group 3P (n=36); Early to moderate, treated patients with POAG or NTG with recurrent disc hemorrhage (indicative of progression)."
3259371|NCT01470261||Non-ADHD controls|Any child, including siblings of a child in either the ADHD-medicated or ADHD-unmedicated control group, who is 5-17 years old. These children must have a low rating (<1.5) on the clinician-rated Swanson Nolan and Pelham IV Rating scale (SNAP IV) and not be medicated with with either dexamfetamine or atomoxetine.
3357649|NCT02323464||Open surgery for colorectal cancer|investigated after open surgery of colorectal cancer
3357650|NCT02323464||Laparoscopic or robotic surgery|investigated after laparoscopic or robot surgery of colorectal cancer
3357651|NCT02323464||Control subjects|Controls from the population without colorectal cancer
3357652|NCT02323477|Experimental|Allogeneic umbilical cord MSC group|Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
3357653|NCT02323477|Active Comparator|Autologous bone marrow-derived MNC group|Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF<%45)
3357654|NCT02323477|No Intervention|Control group|20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF<%45) whom will not received any further transplantation
3357655|NCT02323490|Experimental|with microfractures|Standardized meniscal repair with bone marrow stimulation techniques (microfractures)
3357656|NCT02323490|Placebo Comparator|without microfractures|Standardized meniscal repair without augmentation
3357657|NCT02323516|Experimental|Acetylsalicylic acid + loperamide|Acetylsalicylic acid + loperamide
3357658|NCT02323516|Active Comparator|diosmectite + loperamide|Acetylsalicylic acid + loperamide
3357659|NCT02323529|Experimental|Nitisinone treatment group|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks.
3357660|NCT02323542|Experimental|High-SDS biscuit|Biscuit with high Slowly Digestible Starch content
3357661|NCT02323542|Active Comparator|Low-SDS cereal product|Cereal product with low Slowly Digestible Starch content
3357662|NCT02323555|Experimental|Paramedic telephone consultation|"Establishment of a paramedic telephone consultation to the doctor to record the virtual early prescription or non-injectable cancer treatment before the arrival of the patient (Feasibility Process Optima), without changing the current practice of prescribing and dispensing of these treatments on the day of the coming of the patient."
3357663|NCT02323568|Other|Gynecological consulation|
3357664|NCT02323581|Experimental|TAAA (thoracoabdominal aortic aneurysm) Study Arm|"Either the TAAA device or the Physician-Specified TAAA Device will be implanted.~The TAAA Device is a standard configuration branched stent graft with a combination of two branches for the mesenteric arteries and two fenestrations for the renal arteries.~The Physician-Specified TAAA Devices are designed on a per patient basis and may include a combination of up to 4 fenestrations and branches for mesenteric and renal arteries. An additional 5th branch or fenestration may be included if there is a large accessory renal artery. Branches will be used for downward-oriented mesenteric and renal arteries and fenestrations for renal arteries that project laterally or upwards."
3357665|NCT02323581|Experimental|Aortic Arch Study Arm|Physician-specified double inner branch stent-graft with or without retrograde left subclavian branch or a physician-specified retrograde left subclavian branch stent-graft with double or triple wide scallop to the left common carotid artery.
3357666|NCT02323594|Experimental|Group 1: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV pediatric chewable tablet
3357667|NCT02323594|Experimental|Group 2: Daclatasvir|Single oral dose of Daclatasvir (DCV) pediatric chewable tablet and single oral dose of DCV pediatric chewable tablet
3357668|NCT02323594|Experimental|Group 3: Asunaprevir|Single oral dose of Asunaprevir (ASV) tablet, single oral dose of ASV pediatric chewable tablet and single oral dose of ASV pediatric chewable tablets
3357669|NCT02323594|Experimental|Group 4: Daclatasvir|Single oral dose of Daclatasvir (DCV) tablet and single oral dose of DCV tablets
3357670|NCT02323607|Experimental|Cohort A (pacritinib, cytarabine, daunorubicin hydrochloride)|INDUCTION: Patients receive pacritinib PO on days 1-21, cytarabine IV every 24 hours on days 5-11, and daunorubicin hydrochloride IV every 24 hours on days 5-7. Treatment repeats every 28 days for 1-2 courses in the absence of disease progression or unacceptable toxicity.
3357671|NCT02323607|Experimental|Cohort B (pacritinib, decitabine)|"INDUCTION: Patients receive pacritinib PO on days 1-21 and decitabine IV every 24 hours on days 5-14. Treatment repeats every 28 days for 2-4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients achieving CR will proceed with transplant evaluation (if appropriate). Transplant-ineligible patients will receive maintenance courses of pacritinib PO on days 1-21 and decitabine IV over 1 hour daily on days 1-5. Maintenance courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3357672|NCT02323620|No Intervention|Standard care|Optimal standard care after myocardial infarction.
3357673|NCT02323620|Experimental|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor autologous cells aspiration and intracoronary infusion of the cells.
3357674|NCT02323633|Active Comparator|tPCS group|Arm in which random noise oscillating frequencies will be produced for the duration of 20 minutes.
3357675|NCT02323633|Sham Comparator|Sham group|Arm in which no random noise oscillating frequencies will be produced for the duration of 20 minutes
3357676|NCT02323659|Active Comparator|Methotrexate arm|Patients assigned to receive methotrexate
3357677|NCT02323659|Active Comparator|Interferon Alfa-2b|Patients assigned to receive Interferon alfa 2b
3246565|NCT01348672||3. DR study arm|"DR patient groups are organised according to established risk factors for the clinical progression of DR (increasing from Groups 1 A to 3 A, ETDRS, 1991). We will recruit 41 patients per group (Klein et al, 1984).~Group 1D (n=41); Type 2 diabetic patients with no, or minimal, clinically visible DR. These patients are at low risk of developing sight-threatening DR.~Group 2D (n=41); Type 2 diabetic patients with microaneurysms and / or hard exudates within 2 disc diameters of the fovea and no clinical evidence of retinal thickening. These patients are at increased risk of developing DME.~Group 3D (n=41); Type 2 diabetic patients with the typical features of moderate-to-severe DR i.e. venous beading, intra-retinal microvascular abnormalities (IRMA) and dark blot intra-retinal haemorrhages. These patients are at a much increased risk of developing proliferative DR and/or ischemic maculopathy."
3246566|NCT01348724|Experimental|[14C] NKTR-118|
3246567|NCT01348737|Experimental|AZD3839|Oral Treatment
3357678|NCT02323672||oral premalignant patients|15 patients suffering from oral premalignant lesions as lichen planus, actinic keratosis, leukoplakia and erythroplakia.
3357679|NCT02323672||oral malignant patients|15 patients suffering from oral malignant lesions
3357680|NCT02323672||control subjects|15 individuals age, gender and periodontal status matched with oral premalignant and malignant patients and not suffering from any oral mucosal lesions or periodontal disease.
3357681|NCT02323685|Experimental|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
3357682|NCT02323698|Active Comparator|Caffeine/AIH|Subjects with chronic, motor-incomplete SCI receive Caffeine then AIH
3357683|NCT02323698|Active Comparator|Placebo/AIH|Subjects with chronic, motor-incomplete SCI receive Placebo then AIH
3357684|NCT02323698|Active Comparator|Caffeine/SHAM|Subjects with chronic, motor-incomplete SCI receive Caffeine then SHAM
3357685|NCT02323711|No Intervention|Control|This group would be receiving the standard of care. The subject would receive the standard dressing applied by a member of the surgical team in the standard fashion as follows: The closed incision will be covered first with a primary dressing consisting of a nonadherent, composite dressing (Telfa), which is covered with a secondary dressing consisting of an Army Battle Dressing (ABD), before removal of the sterile surgical drapes. This dressing is then held in place with an adhesive fabric tape, currently Mefix tape, which is typically applied by the surgical scrub tech.
3246568|NCT01348737|Placebo Comparator|AZD3839 Placebo|Oral Treatment
3246569|NCT01348750|Other|Group A|This group receives 6 Healing Touch & Guided Imagery treatments in addition to standard medical care.
3246570|NCT01348750|No Intervention|Group B|This group receives standard medical care but NO Healing Touch and Guided Imagery.
3246571|NCT01348802|Experimental|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
3357686|NCT02323711|Experimental|2-octyl cyanoacrylate|This group would receive the experimental treatment. If allocated to coverage with glue, no dressing is placed. After closure of the incision with suture or staples, the incision is patted dry under sterile conditions. The incision is then covered longitudinally by a member of the surgical team with a thick layer of skin glue dispensed from 1 tube of surgical skin glue (2-octyl cyanoacrylate, currently using brand: Derma+Flex QS). The glue is then allowed to dry before the sterile surgical drapes are removed.
3357687|NCT02323724||Selected Papillary carcinoma|Cases with histological diagnosis of papillary carcinoma (CP) and previous cytological diagnosis in groups III, IV and V Bethesda, collected between October 1989 and July 2014 in Corporació Parc Taulí.
3357688|NCT02323737|Active Comparator|Irinotecan and cisplatin|The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
3357689|NCT02323737|Active Comparator|Etoposide and Cisplatin|The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
3357690|NCT02323763||Bipolar I or II Disorder|30 currently depressed patients with DSM-IV bipolar I and II disorder who are currently or previously suicidal will receive fMRI.
3357691|NCT02323789|Experimental|Intervention arm|10 patients with RDEB will be selected to receive the intervention - mesenchymal stromal cells.
3357692|NCT02323802|Experimental|educational group intervention|"The group educational food intervention: it provides the delivery of information leaflet and inclusion in groups on a weekly basis for the first 3 meetings, and then, there are other 2 meetings on the third and sixth month by the AMI.~The meetings will cover education to self-nutrition, physical activity and learning techniques for stimulus control and management of high-risk situations."
3357693|NCT02323802|Active Comparator|prescriptive diet|An objectives food scheme elaborated for each patients will provide the reduction in caloric intake (equivalent to 500-600 calories in deficit if compared to the estimated daily requirement, based on the RDAs) and a reduced intake of lipids, which does not exceed 30% of total calories introduced, with a contribution of saturated fat no more than 7-9% .
3357694|NCT02323815|Active Comparator|Control|Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age
3357695|NCT02323815|Experimental|PROMIS intervention|"Behavior change communication (BCC) on Essential Nutrition Actions (ENA), Infant and Young Child Feeding (IYCF) and Water, sanitation and hygiene (WASH) is provided during monthly meetings for children 6-23 months of age~Caregivers with children 6-23 months of age that attend Counselling meetings will be provided with a monthly dose of SQ-LNS (20g/day)"
3246572|NCT01348802|Placebo Comparator|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
3246573|NCT01348841|No Intervention|Control Arm|Usual care is care as currently delivered to clients with chronic wounds in the community.
3259372|NCT01470287|Experimental|Arm 1|
3259373|NCT01470300|Experimental|Standard ED|100% energy density
3259374|NCT01470300|Experimental|Reduced ED - F/V|80% energy density by adding fruit and vegetables
3259375|NCT01470300|Experimental|Reduced ED - Fat|80% energy density by decreasing fat
3259376|NCT01470300|Experimental|Reduced ED - Plain water|80% energy density by adding plain water
3259377|NCT01470313|Experimental|PD-0360324|
3246574|NCT01348841|Experimental|Intervention Arm|"Systematic referral to MDWCT and comprehensive primary care:~Intervention consists of systematic referral to MDWCT in conjunction with comprehensive primary care.Systematic referral to, and follow up, by MDWCTs, co-ordinated by the CM, will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4."
3246575|NCT01348867|No Intervention|Usual Care|These 120 controls will undergo a comprehensive assessment at baseline then again at 12 months, which is similar to the intervention group. However, in between these 2 time points the 'control' patients will receive usual care and hence will not be monitored under the structured care protocol by a diabetes nurse consultant led team.
3246576|NCT01348867|Experimental|Structured Care|"120 patients will be randomised to the structured care group, and these patients will receive repeated follow-ups and contact with the structured care team in between the two comprehensive assessments at week 0 and week 52.~Patients will be seen by Diabetes Nurse Consultant at week 0, 6, 12, 24 38 during the year. At each visit, clinical and laboratory measurements will be performed; treatment compliance and self care will be assessed and medications will be adjusted to optimise metabolic and cardiovascular risk factors control.~Patients will be seen by the doctors in their clinic follow up at week 0, 24 and 52.~Technical service assistance will telephone patient at week 18, 30 and 44 to reinforce patient to take medications, attend clinical follow up."
3246577|NCT01348880|Experimental|Arm1|
3246578|NCT01348880|Placebo Comparator|Arm2|
3246579|NCT01348893|No Intervention|Physical education as usual|High school physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
3246580|NCT01348893|Experimental|Yoga during physical education|
3246581|NCT01348906|Experimental|Intermittent normoxia|Repeated brief normoxic reperfusion during cardioplegia arrest in adult valve replacement
3246582|NCT01348919|Experimental|CEP-18770 in Combination With Lenalidomide and Dexamethasone|
3246583|NCT01348932||Asthma|The relationship between single nucleotide polymorphisms of chitinase 3-like 1 gene, YKL-40 serum levels and adult asthma
3246584|NCT01348945|Experimental|Stump Preserving ACL Surgery|Patients of partial tear ACL injury fulfilling inclusion criteria received stump preserving ACL surgery, entered conventional ACL reconstruction rehabilitation program
3246585|NCT01348945|Active Comparator|ACL Reconstruction|Patients with complete tear ACL injury received ACL reconstruction entered conventional ACL rehabilitation program
3246586|NCT01348958|Experimental|Post-operative knee replacement|Subjects that have had a hemi knee replacement of one knee at least 8 weeks ago had the post-operative knee scanned using the orthopedic hip application and the Lunar orthopedic knee application.
3246587|NCT01348971|Experimental|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
3246588|NCT01348971|Placebo Comparator|Placebo|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
3246589|NCT01348984|Active Comparator|group 1|group 1 = transdermal fentanyl patch
3246590|NCT01348984|Placebo Comparator|group 2|placebo patch
3246591|NCT01348997|Active Comparator|Project Onward website + 16 person social network|
3246592|NCT01348997|Active Comparator|Project Onward website + 8 person social network|
3246593|NCT01349010|Placebo Comparator|Placebo|Placebo Arm: Placebo 1 tablet bid. p.o
3246594|NCT01349010|Active Comparator|Probucol|Probucol Arm: Imported Probucol 250 mg (1 tablet) bid. p.o
3357696|NCT02323828|Experimental|Investigational product|"The investigational products are RS starch cookies (40 g resistant starch) from high amylose maize starch.~Nine young healthy volunteers (males and females) consumed RS rich cookies (40 g RS) in two separate occasions."
3246595|NCT01349023|Experimental|Standard Energy content/Standard ED|
3246596|NCT01349023|Experimental|Standard Energy content/Reduced ED|
3246597|NCT01349023|Experimental|Reduced Energy content/Standard ED|
3246598|NCT01349023|Experimental|Reduced Energy content/Reduced ED|
3246599|NCT01349062|Other|"Kallunk oxide (Immunotherapy)"|"The participants will be received a daily regimen of Kallunk oxide(Immunotherapy) ."
3246600|NCT01349075||TheraSphere|
3246601|NCT01349088|Experimental|Motesanib|Eligible patients will be enrolled to receive ixabepilone, capecitabine, plus motesanib.
3246602|NCT01349101|Experimental|Myeloablative HSCT|Myeloablative Hematopoietic Stem Cell Transplantation (HSCT): Patients will receive myeloablative transplants or nonmyeloablative transplants depending on their disease type.
3246603|NCT01349101|Experimental|Reduced Intensity HSCT|Reduced Intensity Hematopoietic Stem Cell Transplantation (HSCT): Patients who have received a previous transplant, patients who have received dose limiting radiation, and patients with a DLCO <45% will receive the reduced intensity conditioning regimen.
3246604|NCT01349127|Active Comparator|20µg Vitamin D3|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol).
3246605|NCT01349127|Active Comparator|20µg Vitamin D3 + 500 mg Calcium|Arm will receive per day one gelatin capsule containing 20µg (800IU) of vitamin D3 (Cholecalciferol) and one tablet of calcium carbonate containing 500mg of calcium.
3246606|NCT01349127|Placebo Comparator|Placebo|Arm will receive one gelatin capsule containing 0µg (0IU) of vitamin D3 (Cholecalciferol).
3246607|NCT01349153|Active Comparator|Facebook-based Self-help Comparison|Participants will receive a pedometer and twelve weekly messages with links to Internet resources that have educational materials related to exercise and cancer survivorship.
3246608|NCT01349153|Experimental|Facebook-based Messages/Website|Participants will receive a pedometer, twelve weekly messages, and be encouraged to participate in sixteen Facebook group discussions and use a website for exercise goal-setting and tracking activity.
3246609|NCT01349205|Experimental|Caffeine and Sodium Benzoate 10 mg/kg IV|Group 1 of randomized study.
3246610|NCT01349205|Experimental|Caffeine and Sodium Benzoate 20 mg/kg IV|Group 2 of randomized study
3246611|NCT01349205|Placebo Comparator|0.9 NS Saline|Control group of randomized study.
3259378|NCT01470313|Placebo Comparator|Placebo|
3246612|NCT01349218|Experimental|Blood sample drawn from a vein and from a heel stick|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis. A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
3357697|NCT02323828|Placebo Comparator|Placebo|The placebo products are common wheat-maize cookies (2 g RS). Nine young healthy volunteers (males and females) consumed placebo in two separate occasions.
3357698|NCT02323841|Experimental|conservative treatment in cervix cancer|we performed conservative treatment cervix cancer patients with IB FIGO stage without pelvic involvement
3357699|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - total body irradiation (TBI) first|"Alpha Beta Total Body Irradiation - TBI first Day Treatment~11 Anti-thymocyte globulin (ATG)~10 ATG~9 ATG~8 TBI~7 TBI~6 TBI~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 Rest 0 Transplant with alpha beta T cell depleted stem cells"
3246613|NCT01349270|Experimental|immunoglobulin|patient who received monthly 2g/kg cure of intravenous Immunoglobulin during 6 months
3246614|NCT01349270|Active Comparator|prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
3357700|NCT02323867|Experimental|Alpha Beta Total Body Irradiation - TBI last|"Alpha Beta Total Body Irradiation - TBI last Day Treatment~9 ATG~8 ATG~7 Thiotepa + ATG~6 Thiotepa~5 Cyclophosphamide~4 Cyclophosphamide~3 TBI~2 TBI~1 TBI 0 Transplant with alpha beta T cell depleted stem cells"
3357701|NCT02323867|Experimental|Alpha Beta Non-irradiation regimen|"Alpha Beta Non-irradiation regimen Day Treatment~9 Busulfan + ATG~8 Busulfan + ATG~7 Busulfan +ATG~6 Busulfan~5 Thiotepa~4 Thiotepa~3 Cyclophosphamide~2 Cyclophosphamide~1 0 Transplant with alpha beta T cell depleted stem cells"
3357702|NCT02323880|Experimental|Treatment (selinexor)|Patients receive selinexor PO once weekly (days 1, 8, 15, and 22). Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3357703|NCT02323893|Experimental|18F-FAraG|A single dose intravenous injection of 18F-FAraG followed by PET scanning.
3357704|NCT02323906|Experimental|CC-122 + Fixed-dose Sorafenib|"A dose escalation and expansion clinical study of CC-122 in combination with sorafenib in subjects with unresectable HCC who have received no prior systemic therapy for HCC.~The dose escalation part of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part."
3357705|NCT02323919|Active Comparator|SystemCHANGE|consists of self-efficacy enhancement and relapse prevention strategies, but is primarily anchored in a set of behavior change strategies based on System Improvement techniques.
3357706|NCT02323919|Active Comparator|CHANGE+|is based on several cognitive-behavioral theoretical frameworks: Social Problem-solving Model, Self-efficacy theory, Expectancy-value theory and Relapse Prevention theory.
3357707|NCT02323919|Placebo Comparator|Usual Care|Usual Care
3357708|NCT02323932|Active Comparator|Bilateral Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: each of the CI alone and bilateral (CI/CI) conditions.
3357709|NCT02323932|Active Comparator|Bimodal Cochlear implant users|The perception of intonation will be assessed through the use of 2 tests. In the first test, listeners will have to identify statements and yes/no questions that will be presented by male and female talkers in the background of four- talkers-babble noise comprised of two females and two males. In the second test, listeners will be presented with gradual changes in the fundamental frequency of a sentence. They will be required to identify the sentence with each of the changes as a statement or a question. Each of the 2 tests will be presented in three listening conditions: CI alone, HA alone and bimodal (CI/HA) conditions.
3246615|NCT01349283|Experimental|HepavaxGene Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and hepatitis B envelope antigen - HBeAg)
3246616|NCT01349283|Active Comparator|Comparator vaccine Stratum 1a|Subjects of mothers with chronic hepatitis B (positive for both HBsAg and HBeAg)
3357710|NCT02323945|Active Comparator|AIH/Walk|Subjects with chronic, motor-incomplete SCI receive acute intermittent hypoxia (AIH) with walking practice, then AIH with strength practice and compare their efficacy on enhancing strength and/or walking performance.
3357711|NCT02323945|Active Comparator|AIH/Strength|Subjects with chronic, motor-incomplete SCI receive AIH with strength practice, then AIH with walking practice and compare their efficacy on enhancing strength and/or walking performance.
3357712|NCT02323958|Experimental|Acupoint stimulation|Electrical stimulation is given through electrodes attached to acupoints
3357713|NCT02323958|Placebo Comparator|Non-acupoint stimulation|Electrical stimulation is given through electrodes attached to non-acupoints
3246617|NCT01349283|Experimental|HepavaxGene Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
3246618|NCT01349283|Active Comparator|Comparator vaccine Stratum 1b|Subjects of mothers with chronic hepatitis B (positive for HBsAg only)
3357714|NCT02323958|Sham Comparator|Control stimulation|Electrode attached but no stimulation is given
3357715|NCT02323984||Hypoactive Delirium - Delirious|Hypoactive delirious patients presenting with lethargy and sedation and are slow to respond to questions and demonstrate little spontaneous movement. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3357716|NCT02323984||Hyperactive Delirium - Delirious|Hyperactive delirious patients presenting with restlessness, agitation, hyper vigilance, and occaionally hallucinations. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3246619|NCT01349283|Experimental|HepavaxGene Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
3246620|NCT01349283|Active Comparator|Comparator vaccine Stratum 2|Subjects of mothers without chronic hepatitis B (negative for both HBsAg and HBeAg)
3246621|NCT01349296|Experimental|BIBF 1120 + RAD001|
3357717|NCT02323984||No Delirium - Nondelirious|Patients not presenting any symptoms of hypoactive or hyperactive postoperative delirium. miRNA Testing, Microemboli Monitoring, Delirium Assessment will be performed
3357718|NCT02324010|Experimental|Sitaglipltin (100mg)|Active drug (sitagliptin)
3357719|NCT02324010|Placebo Comparator|Placebo (sugar pill)|Inactive drug (placebo)
3259379|NCT01470326||Bazedoxifene Tablets|Subjects taking Bazedoxifene Tablets
3357720|NCT02324023|Experimental|Endoscopic ultrasound and pathology|Endoscopic ultrasound and contrast enhanced endoscopic ultrasound for staging and perfusion (preoperatively) compared to pathological stage and vessel density in the pathological specimen (postoperatively).
3357721|NCT02324036|Experimental|Coached Care+EMPATHy;|EMPATHy Toolkit: Patient coaching with computer assisted preference assessment
3357722|NCT02324036|Active Comparator|Routine Coached Care|Patient coaching only
3357723|NCT02324062||Pathogenic group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a mutation in a gene not commonly tested for prior to the advent of multiplex panel testing. This excludes BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH unless a patient tested positive for one of these 9 genes but did not meet clinical criteria for the underlying syndrome (n = 124). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3357724|NCT02324062||VUS group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients identified with a variant of unknown significance of any gene of any nonBRCA (BRCA1 and BRCA2) or non-Lynch syndrome gene (MLH1, MSH2, MSH6, PMS2 and EPCAM).~Target accrual is 100. These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3357725|NCT02324062||Negative Group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~Patients who test negative for all the genes tested. Target goal is 50 for Stanford (100 for the study). These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months."
3357726|NCT02324062||No follow-up intervention group|"Blood Draw and Baseline Questionnaire: Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.~All other participants who do not meet any of the above criteria or fall into one of these groups after the target goal is met for that group."
3357727|NCT02324088|Active Comparator|Arm A|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy
3357728|NCT02324088|Experimental|Arm B|4 cycles of high-dose EC (E150 mg/m² and C 4000 mg/m² every 3 weeks) then mastectomy with axillary lymph node dissection and radiotherapy followed by 4 cycles of D-5FU (D 85 mg/m², day 1 and 5FU 2500 mg/m²/day continuous infusion, days 1-5 every 3 weeks)
3357729|NCT02324101|Experimental|Breast cancer|Detect plasma Hsp90α concentration of breast cancer patients
3357730|NCT02324114|Experimental|Rectal cancer|Detect plasma Hsp90α concentration of patients,
3357731|NCT02324127|Experimental|liver cancer|Detect plasma Hsp90α concentration of liver cancer patients
3357732|NCT02324140||Minimized extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the minimized extracorporeal circulation (MECC, group 1)
3357733|NCT02324140||Conventional extracorporeal circulation|Patients with severe aortic valve stenosis undergoing surgical aortic valve replacement using the conventional extracorporeal circulation (CECC, group 2)
3357734|NCT02324140||Transcatheter aortic valve implantation, transfemoral access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transfemoral access route
3357735|NCT02324140||Transcatheter aortic valve implantation, transapical access|Patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation using the transapical access route
3357736|NCT02324166|Active Comparator|Cefazolin|For the control group, cefazolin will be drawn into a 1 mL syringe and 0.5 mL will be injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery.
3357737|NCT02324166|Active Comparator|Cefazolin + Lidocaine|For the comparator group, the cefazolin and 0.2 mL lidocaine 2% will be mixed together in the same 1 mL syringe and 0.5 mL of the mixed solution injected with a 30-gauge needle into the subconjunctival space. This will be performed at the end of the retinal surgery surgery.
3357738|NCT02324179||HIV positive|people with HIV diagnosis
3357739|NCT02324179||Control (HIV negative)|people without HIV
3357740|NCT02324192|Other|Normal ultrasonography|Patients with normal ultrasonography findings
3357741|NCT02324192|Other|Inflammatory ultrasonography|Patients with inflammatory ultrasonography findings
3357742|NCT02324218||Diabetes mellitus Group|All the subjects with diabetes mellitus diagnosed with hepatitis B, reported in the CPRD database of UK, from the Year 2000 to 2012.
3357743|NCT02324218||Non-Diabetes mellitus Group|All the subjects with hepatitis B who are diagnosed negative diabetes mellitus, reported in the CPRD database of UK, from the Year 2000 to 2012.
3357744|NCT02324231|Other|39.0°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=39.0°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
3357745|NCT02324231|Other|38.5°C temperature limit defining fever|Temperature limit defining fever, for definition of fever in neutropenia (FN), is single temperature >=38.5°C measured in the ear by infrared tympanic thermometry. If clinically indicated, the treating physician is allowed to make the diagnosis of FN at lower temperatures.
3357746|NCT02324244||immunocompetent patients underwent heart surgery|
3259380|NCT01470339|Placebo Comparator|placebo|migraine patients to receive placebo treatment
3357747|NCT02324257|Experimental|Part I: RO6958688|Participants will receive single dose of RO6958688 starting from a dose of 0.05, 0.15, 0.45, 1.3, and 2.5 mg in Part I of the study.
3357748|NCT02324257|Experimental|Part II: RO6958688 With/Without Obinutuzumab Pretreatment|Participants will receive RO6958688 with or without obinutuzumab pretreatment QW, Q3W, or according to a combined QW/Q3W step up dosing schedule. Doses will start at 40mg and increase with each administration up to the MTD or 1200mg, whichever is lower.
3357749|NCT02324283|Active Comparator|Desflurane|Desflurane group: this group of patients receives desflurane as the main anesthetic agent in addition to remifentanil infusion at 0.1~0.3 mcg/kg/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
3357750|NCT02324283|Active Comparator|Propofol|Propofol group: this group of patients receives propofol as the main anesthetic agent in addition to remifentanil infusion at the rate of 0.1~0.3 mcg./g/min during one-lung anesthesia. Bispectral index will be maintained between 45 and 50. Arterial blood gases and pulmonary blood flow by using tansesphageal echocardiogrphy will be measured.
3357751|NCT02324309|Experimental|BIOD-531 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3357752|NCT02324309|Active Comparator|Humalog Mix 75/25 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3357753|NCT02324309|Active Comparator|Humulin R U-500 pre-meal|Subcutaneous injections of 1.2 U/kg before the start of a standardized breakfast and 0.8 U/kg before the start of a standardized dinner.
3357754|NCT02324309|Experimental|BIOD-531 post-meal|Subcutaneous injections of 1.2 U/kg 20 minutes after the start of a standardized breakfast and 0.8 U/kg 20 minutes after the start of a standardized dinner.
3357755|NCT02324322|Experimental|Exoskeleton training|"To examine the effectiveness of robotic exoskeleton-assisted over ground walking (5 hrs. p/wk, 100 sessions, 20 wks = 100 hrs) to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI. Combined with our current training protocol where people step 1500-2000/session we predict that the 2,000 lower extremity muscle contractions will be sufficient in our proposed exoskeletal study.~MRI's will be performed to accurately assess muscle CSA of each lower limb to determine individual's muscle thigh and shank volume.~Muscle Biopsies for the quadricep muscle will be performed to determine changes in BMD and bone structure due to intensive exoskeleton assisted walking."
3357756|NCT02324348|Placebo Comparator|Immediate coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, stent implantation is done on the initial procedure in immediate coronary stenting group
3357757|NCT02324348|Active Comparator|Deferred coronary stenting|Within enrolled patients who agreed to participate in the study, signed informed consent and being satisfied with inclusion and exclusion criteria, only TIMI Ⅲ flow achievement is done on the initial procedure and stent implantation is deferred after 5-7 days admission in the deferred coronary stenting group.
3357758|NCT02324374|Experimental|Endocytoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
3246622|NCT01349309|Experimental|Swallowing Exercise Group|Swallowing Exercise Group: This arm will undergo the protocol that involves intensive swallowing exercises to begin at the start of the cancer treatment. Those patients randomized to the intensive therapy protocol will be required to participate in weekly swallowing therapy sessions either in person or over the phone and perform the learned swallowing exercises three times a day. In addition, these patients will document their swallowing practice on a daily basis.
3246623|NCT01349309|No Intervention|Control|Control Arm: This arm will receive the standard of care which provides swallowing evaluation and treatment once symptoms of swallowing dysfunction are experienced by the patient.
3357759|NCT02324387|Experimental|Molecular Breast Imaging (MBI) + Tc99m sestamibi|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled chemotherapy treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
3357760|NCT02324400|Active Comparator|Treatment|
3357761|NCT02324400|Sham Comparator|Control|
3357762|NCT02324413|Active Comparator|clonidine|Clonidine intravenous 1 or 2 micrograms / kg
3357763|NCT02324413|Placebo Comparator|Placebo|
3357764|NCT02324426|Experimental|Reduced Glutathione|The study medication is packaged in sterile 1 ml pre-filled syringes, each containing 200 mg/ ml of reduced glutathione (GSH), which will be delivered intranasally.
3357765|NCT02324439|Experimental|Omega Nutrition cold-milled flaxseeds|All subjects will receive a 20g daily dose of cold-milled flaxseeds for 24 months.
3357766|NCT02324452|Experimental|heterozygous carrier of DPYD variant|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be heterozygous for one of these SNPs
3246624|NCT01349322|Active Comparator|Arm I|Patients undergo standard whole-breast radiotherapy (WBI) comprising intensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for 1-1½ weeks in the absence of disease progression or unacceptable toxicity.
3259381|NCT01470339|Active Comparator|duloxetine|migraine patients to receive duloxetine
3357767|NCT02324452|Experimental|wild type for DPYD|Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A>T, c.1236G>A/HapB3 and DPYD*13) that are found to be wild type for these SNPs
3357768|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.2mg)|ZGN-440 for Injectable Suspension
3246625|NCT01349322|Experimental|Arm II|Patients undergo accelerated hypofractionated WBI comprising IMRT or 3D-CRT with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression or unacceptable toxicity.
3246626|NCT01349335|Experimental|1. tolvaptan|15 mg, P.O., Qd, for 7 days,
3246627|NCT01349335|Experimental|2 tolvaptan|30 mg, P.O., Qd, for 7 days,
3246628|NCT01349335|Experimental|3. Placebo|30mg,P.O.,Qd, for 7 days.
3246629|NCT01349348|Experimental|Tolvaptan 15mg|Tablet;15mg/tab
3246630|NCT01349348|Experimental|Tolvaptan 7.5mg|Tablet;7.5mg/tab
3246631|NCT01349348|Placebo Comparator|Placebo|Tolvaptan 0mg/tab
3357769|NCT02324491|Experimental|ZGN-440 Injectable Suspension (1.8mg)|ZGN-440 for Injectable Suspension
3357770|NCT02324491|Placebo Comparator|Placebo|ZGN-440 Placebo for Injectable Suspension
3357771|NCT02324517||Hemophilia|Patients with Hemophilia A OR B
3357772|NCT02324517||inhibitor patients|Hemophilia or FXI def with inhibitors
3357773|NCT02324517||anticoagulants|patients under therapy with various anticoagulant drugs
3246632|NCT01349361|Experimental|Daylight-PDT|
3246633|NCT01349374|Experimental|Group1|healthy volunteers
3246634|NCT01349374|Experimental|group2|Unaffected siblings of MODY patients
3246635|NCT01349374|Experimental|Group3|Type2 Diabetic patients
3357774|NCT02324517||thrombocytopenia|patients with ITP, chronic thrombocytopenia, chemotherapy induced thrombocytopenia
3357775|NCT02324517||platelet function disorders|Glanzmann, Bernard Soulier, antiplatelet therapy
3357776|NCT02324517||Fibrinogen disordsers|hyperfibrinogenemia, hypofibrinogenemia, dysfibrinogenemia
3357777|NCT02324517||acquired hemophilia|patients with autoimmune Ab's to FVIII
3357778|NCT02324517||RBD|FXIII DEF, FV+FVIII DEF, FVII DEF, FV DEF
3357779|NCT02324517||THROMBOLYTICS|Patients treated by thrombolytic agents
3357780|NCT02324517||Hypercoag|thrombophilias, thrombosis- inc under therapy, acquired high thrombotic risk (eg: cancer)
3357781|NCT02324530|Experimental|Lung tumors|Patients with > 1 cm tumor motion simulated using 4DCT with and without CPAP
3246636|NCT01349374|Experimental|Group4|MODY patients
3246637|NCT01349387|Experimental|Arm1|"During their visit of consultation on the follow-up to the type 2 diabetes, les patients will be selected on the basis of active metformin treatment at a dose greater than or equal to 1400 mg/day. Patients will have to achieve a 10 ml blood sample. The blood will be processed by Ficoll gradient centrifugation to remove the red cells and isolate circulating leukocytes: this stage will be conducted in the CERITD. Analysis on circulating leukocytes and in particular the quantification of expressions of isoforms A and B of the INSR1 by quantitative RT - PCR gene will be conducted in the laboratory of the Professor Marc Peschanski (unit INSERM 861 I - STEM of Evry).~After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31."
3357782|NCT02324530|Experimental|Left sided Breast cancer|Patients with heart abutting chest wall will be simulated using 4DCT with and without CPAP
3357783|NCT02324530|Experimental|Abdominal tumors|Patient with liver metastases for SBRT or pancreatic tumors will be simulated using 4DCT with and without CPAP
3357784|NCT02324556||Laparoscopic total mesorectal excision|Patients operated with laparoscopic total mesorectal surgery for rectal cancer
3357785|NCT02324556||transanal total mesorectal excision|Patients operated with a combined transanal and laparosocopic total mesorectal surgery for rectal cancer
3246638|NCT01349400|Experimental|watchful waiting|"After informed consent and randomization into the watchful waiting group patients will receive standardized verbal information and written instructions on symptoms of acute incarceration. In case of acute symptoms they will be told to visit a physician immediately. On follow-up visits at 1 month, 12 months and 24 months the hernia size will be determined by physical examination, and the pain/ discomfort and the functional status will be monitored.~Control intervention/ reference test:~Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented."
3259382|NCT01470352|Placebo Comparator|Placebo|
3357786|NCT02324582|Experimental|Intravenous MK-3475/ Intravesical BCG|3 subjects will be treated at a dose of 100 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses 12 subjects will be treated at a dose of 200 mg MK-3475 at 100 mg every 3 weeks (Q3W) intravenously (IV) for 6 doses and 1 vial intravesicular BCG suspended in 50 ml preservative-free saline once per week of 6 weekly doses
3357787|NCT02324595|Experimental|Laparoscopic Interval Debulking Surgery|Patients affected by advanced epithelial ovarian cancer already submitted to neoadjuvant chemotherapy with evidence of complete/partial response
3259383|NCT01470352|Active Comparator|treatment|Duloxetine will be given in a daily dose of 30 mg for 5 weeks
3357788|NCT02324608|Experimental|Treatment (cetuximab)|Patients receive cetuximab IV over 60-120 minutes once weekly for 8 weeks.
3357789|NCT02324621|Experimental|Treatment (oral ONC201)|Patients receive oral ONC201 PO on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3357790|NCT02324634|Experimental|ES intervention|Electrical stimulation (ES) twice a day, 5 days a week, for 3 months
3357791|NCT02324634|No Intervention|Control|Usual care only
3357792|NCT02324686|Other|Vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
3357793|NCT02324712|Active Comparator|Acupuncture|Acupuncture treatment for TMD
3357794|NCT02324712|Sham Comparator|Sham Acupuncture|Acupuncture treatment for TMD using the non-penetrating Park Sham Acupuncture Device
3357795|NCT02324725|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
3357796|NCT02324738|Experimental|Healthy Volunteer|All subjects will receive Mefloquine and Dihydroartemisinin-piperaquine, wash out then will receive Mefloquine
3357797|NCT02324751|Experimental|Vi-TCV|Single intramuscular injection
3246639|NCT01349400|Active Comparator|Hernia repair|Intervention: Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided. Divergent types of repair are permitted but have to be documented.
3246640|NCT01349413|Placebo Comparator|Placebo|Identical looking placebo (once daily)
3246641|NCT01349413|Experimental|Esomeprazole 20mg daily|Esomeprazole 20mg daily Oral for 8 weeks
3357798|NCT02324751|Active Comparator|Vi-PS Vaccine|Single intramuscular injection
3357799|NCT02324751|Other|Control (Men ACWY)|Single intramuscular injection
3357800|NCT02324764|Experimental|Glidesheath Slender|The transradial procedure will be performed using the glidesheath slender (studied sheath)
3357801|NCT02324764|Active Comparator|Standard sheath|The transradial procedure will be performed using the standard 6- French radial sheath (comparator sheath)
3246642|NCT01349426|Experimental|LigaSure|"Arm 1~Patients undergoing lung surgery"
3357802|NCT02324777|Experimental|CanniMed™ DPF-I Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation (DPF) with a potency specification similar to CanniMed™ 22·1 product, of 21.9% w/w total THC and 0.8% w/w total CBD is vapourized and inhaled by study subjects.
3357803|NCT02324777|Experimental|CanniMed™ DPF-II Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as the CanniMed™ 15·5 product, of 15.0% w/w total THC and 5.0% w/w total CBD is vapourized and inhaled by study subjects.
3357804|NCT02324777|Experimental|CanniMed™ DPF-III Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification the same as CanniMed™ 9·9 product, of 9.0% w/w total THC and 9.5% w/w total CBD is vapourized and inhaled by study subjects.
3357805|NCT02324777|Experimental|CanniMed™ DPF-IV Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 4·10 product, of 3.8% w/w total THC and 10.0% w/w total CBD is vapourized and inhaled by study subjects.
3357806|NCT02324777|Experimental|CanniMed™ DPF-V Volcano® Vapourization|Using the Volcano® Medic, a dose of 100 mg of finely ground herbal cannabis drug product formulation with a potency specification similar to CanniMed™ 1·13 product profile of 0.6% w/w total THC and 13.0% w/w total CBD is vapourized and inhaled by study subjects.
3246643|NCT01349426|Active Comparator|Automatic Staplers|"Arm 2~Patients undergoing lung surgery"
3357807|NCT02324777|Placebo Comparator|CanniMed™ DPF-P Volcano® Vapourization|"Using the Volcano® Medic, a dose of 100 mg of ethanol extracted DPF-V, reducing the potency profile to <0.3% w/w total THC and <0.3% w/w total CBD (comparable to the threshold levels described for industrial hemp, as per the Canadian Industrial Hemp Regulations (SOR/98-156), is vapourized and inhaled by study subjects."
3357808|NCT02324790|Experimental|Treatment|Treated with iNAP® Sleep Therapy System on the treatment PSG night.
3357809|NCT02324803|Experimental|pazopanib once daily|Patients received continuous treatment of 800 mg pazopanib once daily until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Dose reductions by 400 mg to a lowest dose of 200 mg daily were allowed on the basis of tolerability and according to protocol-defined guidelines.
3357810|NCT02324829||Total joint replacement|Patients who has undergone lower body total joint replacement surgery.
3357811|NCT02324855|No Intervention|Usual care|Subjects will receive the usual medical care in accordance with Spanish non cystic fibrosis bronchiectasis guidelines. In addition they will receive educational sessions about their disease and their pharmacology treatment.
3357812|NCT02324855|Experimental|Chest physiotherapy plus usual care|Subjects will introduce chest physiotherapy as part of their daily treatment
3357813|NCT02324868|Experimental|Shower patch IV catheter protection|Newly developed waterproof catheter dressing may be used for bathing activities
3357814|NCT02324868|Other|Conventional IV catheter protection|No specific dressing will be provided to the patient to protect the catheter entry site during bathing activities.
3246644|NCT01349439|Experimental|Propranolol + Memory Reactivation|This arm involves recalling the traumatic event after administration of propranolol
3246645|NCT01349439|Experimental|Placebo + Memory reactivation|This arm involves recalling the traumatic event after administration of a placebo
3246646|NCT01349439|Experimental|Placebo + No Memory Reactivation|This arm involves administration of a placebo without recalling the traumatic event
3246647|NCT01349439|Experimental|Propranolol + No Memory Reactivation|This arm involves administration of propranolol without recalling the traumatic event
3246648|NCT01349439|Other|Open-label Propranolol + Memory Reactivation|All participants terminating the double-blind phase of the study will receive open-label reconsolidation blockade treatment with propranolol combined with recall of the traumatic event for six weeks.
3246649|NCT01349452|Experimental|Ganciclovir|
3246650|NCT01349452|Sham Comparator|Artificial tear|
3246651|NCT01349478|Experimental|study arm|
3246652|NCT01349504||Mesalmine|
3246653|NCT01349517|Other|MIE Group|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
3246654|NCT01349517|Other|Three-incision esophagectomy group|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
3246655|NCT01349517|Other|Ivor-Lewis esophagectomy group|The patients in this group would underwent Ivor-Lewis esophagectomy
3246656|NCT01349517|Other|Sweet esophagectomy group|The patients in this group would underwent Sweet esophagectomy.
3246657|NCT01349530|Experimental|Anticoagulation clinic care|Monitoring by CREATIF
3246658|NCT01349530|Active Comparator|Usual care|Monitoring by GP.
3246659|NCT01349543|Experimental|Viral Challenge|
3357815|NCT02324881|Experimental|Health Services Research (PMSA)|"Patients/caregivers are instructed to download the PMSA and are demonstrated how to properly use the application. Beginning on the first day of radiation therapy (day 1), patients are instructed to use the PMSA for the duration of their radiation therapy (up to day 50). The patient will fill out a satisfaction questionnaire at the completion of their treatment (Questionnaire administration). The timing of use may change depending on the availability of the app. The use of the app is classified as the telephone-based intervention per NCI."
3357816|NCT02324894|Other|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
3357817|NCT02324907||Tibiotalocalcaneal arthrodesis with DynaNail|Procedure/Surgery: Tibiotalocalcaneal arthrodesis with a novel dynamic compression intramedullary nail
3357818|NCT02324933|Experimental|Fentanyl Challenge Dosing|"In the operating room a fentanyl infusion will be started at 2 mcg/kg/min. The time from start of the infusion to respiratory depression(rate < 5 breaths/minute) will be used to calculate the effect-site concentration (Ce).Using the pharmacodynamic model calculated by the Stanpump PCA software, the infusion will continue intraoperatively to achieve a fentanyl Ce of 30%. In the Post Anesthesia Care Unit (PACU), the rate would be changed with the following parameters:~50% of the hourly dose is given as a basal infusion~The remainder of the hourly dose is ordered as a demand dose q 15 minutes. Post-operatively, the basal rate is adjusted according to the average demand dose use. In patients using < 1 demand dose per hour, the basal rate is decreased by 20%. In patients using > 3 demand doses per hour, the basal rate is increased by 20%. Patients whose pain cannot be managed by this protocol will be removed from the study and pain management will revert to the primary service."
3246660|NCT01349556|Experimental|Tretinoin pre-treatment|
3246661|NCT01349582|Active Comparator|flow diversion|
3246662|NCT01349582|Active Comparator|Best standard treatment|
3246663|NCT01349582|Other|Registry for flow diversion|Flow diversion when randomization between flow diversion and best standard treatment is not possible and the only alternative is flow diversion for compassionate use. In this case there will be no random allocation but the patient will be entered into a registry
3246664|NCT01349608|Experimental|Health coaching|
3246665|NCT01349621||Standard and polarized light colposcopy|Standard and polarized light colposcopy
3357819|NCT02324933|Active Comparator|Standard of Care (Control)|"Patients in the best practice arm would receive pre-operative sedation in the operating room comparable to the dose normally given in the Ambulatory Surgery Unit as a simulated fentanyl challenge. Best practice (control) patients will be followed by the Pain & Palliative Care team in order to make adjustments in pain management as required by the patients."
3357820|NCT02324946||Study Group|Mass Screening
3357821|NCT02324959|Active Comparator|Acupuncture|Needling of affected meridian groups in line with Traditional Chinese Medicine procedures (Baihui and Shenting).
3357822|NCT02324959|Active Comparator|Computer-based|Computer-based attention training (RehaCom).
3357823|NCT02324959|Experimental|ACoTrain|A combination of computer-based attention training with acupuncture.
3246666|NCT01349634|No Intervention|Comparison group|This arm will use the salt that is on the open market, which is primarily non-iodized salt. Iodized salt may enter in these communities through the normal trade route. No active interference with salt trade will occur in these communities.
3246667|NCT01349634|Experimental|Early delivery of iodized salt|Iodized salt that is produced nationally for the open market (which meets only about 10% of national needs) will be directed to these communities through the normal trade system or by direct delivery to the communities.
3357824|NCT02324985|Active Comparator|Active Arm|S-Ibuprofen Topical Gel 5%
3357825|NCT02324985|Placebo Comparator|Placebo Arm|Vehicle Topical Gel
3357826|NCT02324998|Experimental|Group A|Olaparib Monotherapy
3246668|NCT01349647|Experimental|Vaccine and Chemotherapy|This is a pilot trial evaluating the safety and immunogenicity of a pentavalent vaccine for patients with small cell lung cancer (SCLC). Patients with SCLC who have completed all planned initial therapy and have maintained a partial or complete response will be enrolled.
3246669|NCT01349647|Experimental|Vaccine Alone|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
3246670|NCT01349686|Experimental|Oral intake of fluids|Intake of oral fluids during labour.
3357827|NCT02324998|Experimental|Group B|Olaparib in combination with degarelix
3357828|NCT02325011|Experimental|Treatment Sequence 1|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 1 is as follows;~Visit 2 (Treatment A)~Visit 3 (Treatment B)~Visit 4 (Treatment A)~Visit 5 (Treatment B)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
3357829|NCT02325011|Experimental|Treatment Sequence 2|"During each of the four Inpatient Periods (Visit 2 to Visit 5 inclusive), healthy subjects with a history of cannabis use will either receive a single dose of Sativex® alone (Treatment A) or a single-dose of Sativex coadministered with the interaction drug, fluconazole (Treatment B) on a repeated, cross-over basis.~Subjects will be randomly assigned to one of two treatment sequences. Treatment sequence 2 is as follows;~Visit 2 (Treatment B)~Visit 3 (Treatment A)~Visit 4 (Treatment B)~Visit 5 (Treatment A)~The crossover treatments will be separated by a washout period of at least 10 days, but no more than 12 days, between each Sativex® dose."
3246671|NCT01349686|Placebo Comparator|Fasting|No intake of oral fluids during labour.
3357830|NCT02325024|Experimental|Renally Impaired Subjects|"Treatment group consists of subjects with severe renal impairment or ESRD and in accordance with the following criteria;~Clinically significantly abnormal creatinine and creatinine clearance (CLcr <30 mL/min) and not requiring dialysis.~Onset of renal impairment must have been documented at least 3 months prior to study start."
3246672|NCT01349699|Active Comparator|Iron loading|Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.
3246673|NCT01349699|Active Comparator|Iron chelation|Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.
3357831|NCT02325024|Experimental|Matched subjects with Normal Renal Function|Group consists of healthy subjects (as determined by medical history, physical examination, biochemistry, hematology, urinalysis, hepatitis B and C, and HIV testing) who demonstrate normal renal function (CLcr > 80 mL/min) and are individually matched to renally impaired subjects with respect to age (within the decile or five years, whichever is less), gender, and Body Mass Index (BMI) (+/- 10% BMI).
3357832|NCT02325037|Experimental|GLPG1837 single dose|Single oral dose of GLPG1837 suspension - ascending doses
3357833|NCT02325037|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
3357834|NCT02325037|Experimental|GLPG1837 muliple doses|Multiple oral doses of GLPG1837 suspension - ascending doses
3357835|NCT02325037|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3357836|NCT02325050|Experimental|Group 1|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3246674|NCT01349699|Placebo Comparator|Placebo|Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration
3246675|NCT01349712||Coumadin (warfarin)|Subjects are required to be currently receiving coumadin (warfarin) treatment.
3357837|NCT02325050|Experimental|Group 2|Participants will receive MVA-BN-Filo/Ad26.ZEBOV (Day 1 /Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3357838|NCT02325050|Experimental|Group 3|Participants will receive MVA-BN-Filo /Ad26.ZEBOV/ (Day 1/Day 57) or placebo (Day 1/Day 57). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3357839|NCT02325050|Experimental|Group 4|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 29) or placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3357840|NCT02325050|Experimental|Group 5|Participants will receive MVA-BN-Filo (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3357841|NCT02325050|Experimental|Group 6|Participants will receive Ad26.ZEBOV (Day 1 and Day 15) or placebo (Day 1 and Day 15). Participants will receive MVA-BN-Filo (1*10^8 TCID50) on Day 360.
3357842|NCT02325050|Experimental|Group 7|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1/Day 15) or Placebo (Day 1/Day 15). Participants will receive Ad26.ZEBOV (5x10^10 vp) on Day 360.
3357843|NCT02325050|Experimental|Group 8|Participants will receive Ad26.ZEBOV/ MVA-BN-Filo (Day 1 /Day 29) or Placebo (Day 1/Day 29). Participants will receive Ad26.ZEBOV (1x10^11 vp) on Day 360.
3357844|NCT02325050|Experimental|Group 9|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 8) or Placebo (Day 1/Day 8).
3357845|NCT02325050|Experimental|Group 10|Participants will receive MVA-BN-Filo/ Ad26.ZEBOV (Day 1 /Day 15) or Placebo (Day 1/Day 15).
3357846|NCT02325063|Experimental|PRP-L Group|"Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).~Intervention: PRP-L Injection"
3357847|NCT02325063|Active Comparator|Botox Group|"Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).~Intervention: Botox injection"
3246676|NCT01349725|Experimental|ARRY-502|
3246677|NCT01349725|Placebo Comparator|Placebo|
3246678|NCT01349738||Positive Group|Positive for ASB
3246679|NCT01349738||Negative Group|Negative for ASB
3246680|NCT01349751|Active Comparator|isobaric levobupivacaine|spinal isobaric levobupivacaine
3246681|NCT01349751|Active Comparator|hyperbaric levobupivacaine|hyperbaric levobupivacaine
3246682|NCT01349764||No vitamin D replacement|The control arm will not receive vitamin D replacement, but patients in both study arms will receive care consistent with best care practices for stone disease. All patients will be evaluated by the stone clinic clinical nutritionist and full nutritional evaluation will be performed. All patients will be advised to maintain adequate hydration (>2L/day), no-added salt diet (Na 80-100mmol/day), low protein diet (1 g/kg/day). Patients with hyperoxaluria will be advised to follow low-oxalate diet. All patients will be advised to maintain moderate calcium intake; 800-1200mg/day.
3246683|NCT01349764||Vitamin D3 tabs|The active arm of randomization will receive vitamin D repletion in the form of oral vitamin D3 tablets 10 000 IU twice/ week for 8 consecutive weeks, followed by a maintenance dose of 1 000 IU daily for further 22 months.
3246684|NCT01349777|Experimental|Pregrel®|clopidogrel
3246685|NCT01349777|Active Comparator|Plavix®|clopidogrel
3246686|NCT01349842|Experimental|Circulating Tumor Cells|Centralized determination of CTC by CellSearch® technology (Veridex), the only technology currently validated in clinical practice for the early evaluation of response to chemotherapy of breast cancers. This evaluation is performed by blood sampling comparing the CTC level before the first injection of each new line of chemotherapy. Chemotherapy can only be continued in the case of a positive CTC response. Discontinuation of chemotherapy can also be decided by the clinician on the basis of other clinical or radiological arguments.
3246687|NCT01349842|Other|Clinical and radiological criteria|Management of chemotherapy according to the usual clinical and radiological criteria adopted by the patient's attending physician.
3246688|NCT01349855|Experimental|Cohort 1|Dose Level 1
3246689|NCT01349855|Experimental|Cohort 2|Dose Level 2
3246690|NCT01349868|Experimental|PT005 MDI (Dose 1)|PT005 MDI (Dose 1)
3246691|NCT01349868|Experimental|PT005 MDI (Dose 2)|PT005 MDI (Dose 2)
3246692|NCT01349868|Experimental|PT005 MDI (Dose 3)|PT005 MDI (Dose 3)
3246693|NCT01349868|Placebo Comparator|Placebo MDI|Placebo MDI
3246694|NCT01349868|Active Comparator|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 12 μg
3246695|NCT01349868|Active Comparator|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Formoterol fumarate inhalation powder 24 μg
3246696|NCT01349894||SNaP® Wound Care System|
3246697|NCT01349985|Experimental|AGATE|To evaluate whether AGATE, a smartphone medication reminder and assessment system, effectively measures and enhances medication adherence in the context of naltrexone treatment for problem drinking.
3246698|NCT01349985|Active Comparator|SASED|The control condition for the proposed study is a smartphone alcohol and side-effects diary (SASED, a smartphone alcohol and side effects diary).
3246699|NCT01349998|Experimental|Safety Population|
3246700|NCT01350011|Active Comparator|Innovative System (IS)|The innovative intervention uses the treatment system to support motivational counseling treatment entrance and treatment utilization. It has two components, a Motivational Intervention component via Expert System Counseling, and a Treatment Component that incorporates both pharmacological and behavioral long-term components. An innovative aspect of the IS is the use of the pharmacist as an intervention agent, who queries participants on their readiness to quit smoking, encourages involvement in the motivational intervention and in treatment, and who, along with the counselors, is available to answer medication questions.
3246701|NCT01350011|Active Comparator|Standard Treatment Control|After a baseline interview, patients in this condition will be given a packet of brochures on quitting, including descriptions of self-quitting and help-lines. Participants in this condition will continue to have access to their primary care providers, and through that system have access to pharmacotherapy for smoking cessation, if they wish to receive it. They will receive written instructions on how to approach their primary care provider about smoking cessation medication, and a written description of the medications used in smoking cessation and a list of those that are available to them through the public health system. At each assessment, patients will be queried about their use of these resources.
3246702|NCT01350024|Active Comparator|Frontal Nerve Block|Patients will receive a frontal nerve block for anesthesia
3357848|NCT02325063|Active Comparator|Corticoid Group|"Patients randomized to this group will be treated with an injection of Corticoids.~Intervention: Corticoid injection"
3357849|NCT02325076|Experimental|Spirodoc|One time during examination at the outpatient unit
3357850|NCT02325089|Experimental|Mandibular advancement device|Mandibular advancement device titrated to reduce or eliminate snoring and sleep apnea
3357851|NCT02325089|Placebo Comparator|Placebo|Oral appliance identical to the mandibular advancement device without mandibular advancement
3357852|NCT02325115||students (STUD)|The STUD population was a convenient sample of 75 first year students (51 females and 24 males); with 45 from a School of Business Management and 30 from a medical university.
3357853|NCT02325115||working adults (WORK)|The WORK population was also a convenient sample of 113 (63 females and 256 males) working adults including 217 soldiers from Paris Fire Brigade, 93 nurses and 9 individuals from a research laboratory.
3357854|NCT02325115||remitted schizophrenia (PRS)|The PRS population was comprised of 121 remitted schizophrenia patients (39 females and 82 males) who were all clients of the rehabilitation centre for psychotic disorders (Le Vinatier hospital),
3357855|NCT02325128|Experimental|Post-Exposure Nap|Sleep-enhancement of extinction memory: At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be given a 2-hour sleep opportunity with polysomnographic (PSG) monitoring.
3357856|NCT02325128|Active Comparator|Post-Exposure Wake|At the end of the third and fourth of 5 exposure therapy sessions, all participants deliver a speech designed to elicit significant social anxiety. Following this speech, this arm will be instrumented for PSG but, instead of napping, will undergo 2 hours of quiet wakefulness. Therefore, this arm will not undergo sleep-enhancement of extinction memory.
3357857|NCT02325141|Active Comparator|LSG|patients undergoing laparoscopic sleeve gastrectomy without BTX-A injection into the pyloric sphincter
3357858|NCT02325141|Active Comparator|BTX-LSG|patients undergoing laparoscopic sleeve gastrectomy with BTX-A injection into the pyloric sphincter
3357859|NCT02325154||THA Patients|Patients undergoing unilateral total hip arthroplasty
3357860|NCT02325167|Experimental|EBT|
3246703|NCT01350024|Active Comparator|Subconjucntival Injection|Patients will receive a subconjunctival injection for anesthesia
3357861|NCT02325167|Experimental|Treatment-as-usual|
3357862|NCT02325180|Experimental|DHA-PQ|One tablet of dihydroartemisinin-piperaquine consists of 40 mg of dihydroartemisinin and 320 mg of piperaquine. DHA-PQ is administered once daily for 3 days (at enrolment, hour 24 and you 48). Dosing should be given based on body weight. Daily dose for dihydroartemisinin is 2.25 mg/kg (total 6.75 mg/kg) and for piperaquine is 18 mg/kg (total 54 mg/kg).
3357863|NCT02325180|Active Comparator|AL|Half a tablet of artemether-lumefantrine consists of 20 mg of artemether and 120 mg of lumefantrine is given per 5 kg body weight. AL is administered as 6-dose regimens given twice daily for 3 days (at enrolment, hour 8, hour 24, hour 36, hour 48 and hour 60).
3357864|NCT02325206|Experimental|dapafliflozin|one administration of 10mg dapagliflozin as tablet
3357865|NCT02325206|Placebo Comparator|placebo|one administration as tablet identical to the experimental drug
3357866|NCT02325232|Experimental|Enteroscopy|Capsule endoscopy, double balloon enteroscopy sequential use
3357867|NCT02325245|Experimental|Metformin|Metformin tablet 500 mg three times a day for 16 weeks.
3357868|NCT02325245|Placebo Comparator|Placebo|Placebo tablet three times a day for 16 weeks.
3357869|NCT02325258|Experimental|Telephone call|Telephone call to physicians in charge of patients who have just had blood cultures drawn. Diagnostic and therapeutic recommendations to physicians in charge.
3357870|NCT02325258|No Intervention|No telephone call|control arm: no intervention
3357871|NCT02325271||Control group|Subjects with normal glucose tolerance
3357872|NCT02325271||Diabetes group|Patients with type 2 diabetes
3246704|NCT01350037|Active Comparator|remifentanil|sedative mixture for PCS consisting of propofol 10mg/ml 20 ml and remifentanil 50 mkg/ml 5 ml
3246705|NCT01350037|Active Comparator|alfentanil 0.04 mg/ml|sedative mixture for PCS consisting of propofol10 mg/ml 20 ml,alfentanil 0.5 mg/ml 2 ml, NaCL 9 mg/ml 3 ml
3357873|NCT02325284||Healthy adults|
3357874|NCT02325297|Experimental|Letter of condolence|Letter of condolence 15 days after the death of the relative.
3357875|NCT02325297|No Intervention|No letter of condolence|No letter of condolence
3357876|NCT02325310|Experimental|Breastfeeding women|70 breastfeeding women meeting all the inclusion criteria and none of the exclusion criteria will be immunized with MMR vaccine in postpartum (before the exit of the maternity)
3357877|NCT02325336|Experimental|bar-code-assisted administration|during administration rounds, nurses will use the BCMA system to help preventing administration errors
3246706|NCT01350037|Active Comparator|alfentanil 0.08 mg/ml|sedative mixture for PCS consisting of propofol 10 mg/ml 20 ml, alfentanil 0.5 mg/ml 4 ml,NaCl 9mg/ml 1ml
3357878|NCT02325336|No Intervention|control|during administration rounds, nurses will administer drugs as usual
3357879|NCT02325349|Experimental|radiopharmaceutical|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
3357880|NCT02325362|Experimental|Miglustat then placebo|10 patients will received Miglustat then the placebo
3357881|NCT02325362|Experimental|Placebo then Miglustat|10 patients will received Placebo then Miglustat
3357882|NCT02325375||ALS newly diagnosed|
3357883|NCT02325375||ALS treated|
3357884|NCT02325375||controls|
3357885|NCT02325388|Experimental|Treatment group with ForeSite PT™ system|Inpatients assigned to the treatment group with the ForeSite PT™ system will have its LCD monitor turned on (i.e., real-time images of interface pressure will be displayed on the monitor) during their enrolment in the trial.
3246707|NCT01350050|Active Comparator|articaine|Pharyngeal anesthesia with articaine 4% or placebo should randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of Articaine 4%solution or placebo (NaCl 0,9%) will be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with articaine (or placebo) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
3246708|NCT01350050|Placebo Comparator|placebo|Pharyngeal anesthesia with placebo or articaine 4% should be randomly and double-blindly applied in turns for every volunteer. In details: 3 ml of placebo or Articaine 4% solution should be sprayed into the pharynx 5 minutes before beginning of gastroscopy. Also gastroscope will be lubricated with placebo(or articaine) gel(prepared by adding 4% articaine or 0,9%NaCl in placebo grope to Endopurin® endoscopic lubricant at the day of study).
3246709|NCT01350063|Experimental|Aquatabs and Safe Storage Vessel|Households in this group will receive Aquatabs for water purification, a safe water storage container to prevent contamination during storage in the home, and training and encouragement to treat and safely store their water using the provided products.
3246710|NCT01350063|Experimental|Safe Storage Vessel|Households in this group will receive a safe water storage container, and training and encouragement to safely store their water using the provided products. If our study shows that treatment of tubewell water at the household level is effective in protecting children's health, they will receive a six-month supply of water treatment tablets at the end of the study.
3246711|NCT01350063|Other|Standard practice|Households in this group will not receive any water treatment or storage intervention during the study. They will continue their usual water collection and storage practices. If our study shows that treatment and safe storage of tubewell water at the household level is effective in protecting children's health, they will receive the same safe water storage container as Groups 1 and 2 as well as a six-month supply of water treatment tablets at the end of the study.
3246712|NCT01350076|Active Comparator|control group|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
3246713|NCT01350076|Experimental|study group|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
3246714|NCT01350089|Placebo Comparator|Placebo|
3246715|NCT01350089|Active Comparator|Comparator 1 (with alcohol)|
3246716|NCT01350089|Active Comparator|Comparator 2 (with alcohol and coffeine)|
3246717|NCT01350089|Experimental|Comparator 3 (with alcohol and energy drink)|
3357886|NCT02325388|No Intervention|Control group|Inpatients assigned to the control group will have the ForeSite PT™ system's LCD monitor turned off and hidden (i.e., real-time images of interface pressure will not be displayed on the monitor). As the ForeSite PT™ system will continue to record interface pressure with the display turned off, this enables patients enrolled in the control group to undergo silent monitoring.
3357887|NCT02325427|Experimental|real tDCS|Subjects will receive tDCS stimulation at the intensity of 1 mA and last for 20 minutes. The anode will be placed over the affected primary motor cortex (M1) of cortical representation of the hand, while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
3357888|NCT02325427|Sham Comparator|sham tDCS|Subjects will receive sham tDCS stimulation. The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
3357889|NCT02325427|No Intervention|no stimulation|Subjects will not received any intervention.
3357890|NCT02325440|Experimental|Natalizumab - Washout - Fingolimod|One experimental arm: Patients receive one final dose of natalizumab 300mg followed by an 8-week washout Phase and subsequent 32-week treatment Phase with fingolimod 0.5mg o.i.d.
3357891|NCT02325453||Robotic Surgery|Patients underwent gastric surgery through the use of a robotic system.
3357892|NCT02325453||Laparoscopic Surgery|Patients underwent gastric surgery with laparoscopic procedures.
3357893|NCT02325453||Open Surgery|Patients underwent gastric surgery with open approach.
3357894|NCT02325466|Placebo Comparator|Aspirin/Ticagrelor placebo|aspirin 81 mg daily and ticagrelor placebo twice daily
3357895|NCT02325466|Active Comparator|Aspirin/Ticagrelor|aspirin 81 mg daily and ticagrelor 90 mg twice daily
3357896|NCT02325466|Active Comparator|Aspirin Placebo/Ticagrelor|aspirin placebo daily and ticagrelor 90 mg twice daily
3357897|NCT02325479|Experimental|Group A|After scheduled oocyte pick up, a mock embryo transfer will be done using labotec catheter (Labotec, Gottingen Germany), and an injection of Enaoxaprin sodium (LMWH) (Clexane® Sanofi S.A Paris, France) will be given intrauterine in group A patients, 500 IU of LMWH which is 5mg, in 0.05 ml.
3357898|NCT02325479|Placebo Comparator|Group B|The control arm (group B) will be injected intrauterine with similar volume of tissue culture media (G.2 plus ref. 10132, Vitrolife)
3357899|NCT02325492|Experimental|Aramchol 400 mg|• One tablet of Aramchol 400 mg and one tablet of Placebo
3357900|NCT02325492|Experimental|Aramchol 600 mg|• One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
3357901|NCT02325492|Placebo Comparator|Placebo|• Two tablet of Aramchol matching placebo.
3357902|NCT02325505||Tuberous sclerosis complex|All patients with TSC, LAM or AML followed at Hospital das Clínicas, University of São Paulo Medical School will be included in the proposed study. Patients of all ages will participate in the study.
3357903|NCT02325531|Other|Low support|EHR-based toolkit Basic webinar
3357904|NCT02325531|Other|Medium support|Support provided to the low support arm, PLUS Staff training Adaptive webinars
3357905|NCT02325531|Other|High support|Support provided to the low and medium support arms, PLUS Practice facilitation
3357906|NCT02325544|Experimental|CBT+SMC|12 sessions of Cognitive Behavioural Therapy adapted for DS (plus one booster session) plus standardised medical care
3246718|NCT01350154|Experimental|Sildenafil (Revation) 20 mg|This arm will receive sildenafil for 4 weeks followed by 2 weeks washout and 4 weeks placebo.
3246719|NCT01350154|Experimental|Placebo|This arm will receive placebo for 4 weeks followed by 2 weeks washout and 4 weeks sildenafil
3246720|NCT01350167|Active Comparator|Triphasic CT|Triphasic CT of the abdomen with and without contrast every 12 months with alpha-fetoprotein every 6 months.
3246721|NCT01350167|Active Comparator|Ultrasound|Ultrasound of the upper left quadrant with alpha-fetoprotein testing every 6 months.
3357907|NCT02325544|Active Comparator|SMC|Standardised medical care provide by neurologist and/or psychiatrist
3357908|NCT02325557|Experimental|Part A|Patients will receive ADXS31-142 monotherapy. Dosing will start at 1 x 10^9 cfu IV and escalate to 1 x 10^10 if appropriate.
3357909|NCT02325557|Experimental|Part B/Expansion|Patients will receive ADXS31-142 and pembrolizumab (MK-3475) in combination. Dosing of ADXS31-142 will start at one dose level less that appropriate in Part A in combination with 200 mg of pembrolizumab. Dosing of ADXS31-142 will be escalated if appropriate
3357910|NCT02325570|Experimental|KLOX BioPhotonic OraLum Gel + SRP|Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
3357911|NCT02325570|Other|Scaling and Root Planing (SRP)|The second half-mouth will be treated with SRP alone.
3357912|NCT02325583|Experimental|Intraoral 30% Glucose in Newborns|0.5-1 mL 30% glucose solution was administered orally and the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added. After 2 consecutive oral glucose administration the newborns who did not keep motionless or sleep and had motion artefacts sedated with midazolam. The routine blood glucose level measurement was also performed in ICU.
3357913|NCT02325596||control|Patients with only nasal septum deviation
3357914|NCT02325596||CRS sNP|Chronic Rhinosinusitis patients without nasal polyps
3357915|NCT02325596||atopic CRS wNP|Chronic Rhinosinusitis patients with allergic constitution and nasal polyps
3357916|NCT02325596||non-atopic CRS wNP|Chronic Rhinosinusitis patients with nasal polyps but not allergic constitution
3357917|NCT02325635|Experimental|Training of Endoscopist|A series of 1 hour classes with ongoing monitoring and feedback to endoscopist only.
3357918|NCT02325635|No Intervention|Deferred Training of Endoscopist|No intervention during the data collection period. Training will be deferred to end of study.
3357919|NCT02325648||HIPEC cytoreductive surgery|
3357920|NCT02325661|Other|cognitive interviewing|individual cognitive interviewing, 30 minutes per patient
3357921|NCT02325674||Metreleptin|Generalised lipodystrophy patients treated with Metreleptin
3357922|NCT02325700||Open aortic repair|145 patients with open aortic repair for abdominal aortic aneurysmal disease (n=139) or abdominal aortic occlusive disease (n=89)
3357923|NCT02325700||Laparoscopic aortic repair|83 patients with Laparoscopic aortic repair for abdominal aortic aneurysmal disease (n=30) or abdominal aortic occlusive disease (n=53)
3357924|NCT02325726||Renal Resistive Index/Nephrocheck test|Patients undergoing elective cardiac surgery with extracorporeal circulation and who are at risk to develop postoperative Acute Kidney Injury.
3357925|NCT02325752|No Intervention|Control|Patients in the control group received usual care by the hospital. There was no contact between the patients in the control group and the study team throughout the 3 months interval. A scheduled telephone call was made at the end of 3 months when they were invited to participate in a telephone survey.
3357926|NCT02325752|Active Comparator|Intervention|Intervention
3246722|NCT01350193|Active Comparator|Saline Nasal Irrigation|Saline Nasal Irrigation is actively being used as the standard of care. It does not contain any active ingredients.
3246723|NCT01350193|Experimental|Manuka Honey Irrigation|Manuka Honey Irrigation involves the experimental treatment of manuka honey nasal irrigation.
3357927|NCT02325765||category of RACHS-2 for cardiac surgery|ASD & VSD repair; VSD repair; Tetralogy repair; Tetralogy repair
3357928|NCT02325765||category of RACHS-3 for cardiac surgery|DORV repair with or without RV obstruction; AVSD (complete or transitional) repair with or without valve replacement; Coarctation & VSD repair
3357929|NCT02325778|Experimental|CTI First|CTI ablation prior to left atrial ablation
3357930|NCT02325778|Experimental|CTI second|CTI ablation after left atrial ablation
3357931|NCT02325804|Active Comparator|Conventional lifestyle counseling|Randomized, open label study to assess effect of 8 weeks of Conventional lifestyle counseling (low calorie diet and exercise) on body composition, physical fitness, and metabolic parameters
3357932|NCT02325804|Active Comparator|Unconventional lifestyle counseling|"Randomized, open label study to assess effect of 8 weeks of unconventional lifestyle counseling (low calorie metabolic stairs diet and circuit-based exercise) on body composition, physical fitness, and metabolic parameters"
3357933|NCT02325817|Experimental|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
3357934|NCT02325817|Active Comparator|Uncoated balloon|Treat the side branch of bifurcation lesion with uncoated balloon
3259384|NCT01470365|Experimental|Treatment (radiation therapy)|Patients undergo 3-dimensional CRT or IMRT QD, 5 days a week for 10-30 days. Treatment continues in the absence of disease progression or unacceptable toxicity.
3357935|NCT02325830|Experimental|Treatment Group|Implantation of the CARILLON Mitral Contour System
3357936|NCT02325830|No Intervention|Control Group|Optimized stable medical therapy
3246724|NCT01350206|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
3357937|NCT02325843|Experimental|human bone marrow MSC|5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
3357938|NCT02325869|Experimental|Bell Balloon Catheter|The Bell Balloon Catheter is designed to help the physician capture some of this material that may have broken off.
3357939|NCT02325882|Active Comparator|Conventional fentanyl-based epidural PCA|
3357940|NCT02325882|Experimental|dexmedetomidine to fentanyl-based intravenous PCA|
3357941|NCT02325882|Active Comparator|Conventional fentanyl-based intravenous PCA|
3357942|NCT02325895|No Intervention|Control (0 g Dried plum/day)|Participants only received 400IU of vitamin D and 500mg of calcium daily for 6 months.
3357943|NCT02325895|Experimental|50 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 50g of dried plum daily for 6 months.
3357944|NCT02325895|Experimental|100 g Dried plum/day|Participants received 400IU of vitamin D and 500mg of calcium and 100g of dried plum daily for 6 months.
3357945|NCT02325908||Hemodialysis patients|Dialysis patients will have their estimated dry weight measured with calf segmental bioimpedance. Based on these measurements, their dry weight will be adjusted and the amount of fluid removed during subsequent dialysis treatments will be increased by 200-300mL. The additional fluid removal will occur during 3 consecutive hemodialysis sessions. In addition, these subjects will also use VStim during these treatments. to prevent common intradialytic symptoms by promoting vascular refilling.
3357946|NCT02325908||Healthy Controls|No Intervention was administered. Both groups had their hydration status measured with segmental bioimpedance The group of healthy subjects was studied in order to obtain a range of values for normal hydration status.
3357947|NCT02325921||Renal tumor.|Patients >18 years of age with histopathologically confirmed renal tumor diagnosis.
3357948|NCT02325934|Active Comparator|Reference|Stribild Standardized breakfast followed by a single dose of STB (whole tablet).
3357949|NCT02325934|Experimental|Intervention I|Stribild, crushed Standardized breakfast followed by a single dose of crushed and suspended STB.
3357950|NCT02325934|Experimental|Intervention II|Stribild, crushed 350 mL of drip feed (type) followed by a single dose of crushed and suspended STB.
3357951|NCT02325947|Experimental|Study group|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
3357952|NCT02325947|Sham Comparator|Placebo group|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
3376011|NCT03238534|Active Comparator|Omeprazole 20mg|"Patients will be provided with enough amount of 20 mg omeprazole [30' before meal] and Neobianacid® placebo [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole + Neobianacid® placebo Lunch: Neobianacid® placebo Midafternoon: Neobianacid® placebo Dinner: Neobianacid® placebo Before going to bed: Neobianacid® placebo~Day14-27 Breakfast: Omeprazole+ Neobianacid® placebo (both on demand) Lunch: Neobianacid® placebo on demand Dinner: Neobianacid® placebo on demand Any other time: Neobianacid® placebo on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
3376012|NCT03238534|Experimental|Neobianacid®|"Patients will be provided with enough amount of Omeprazole placebo [30' before meal] and Neobianacid® [30' after meal] (both per os) to complete the first phase of the treatment (day 1-27). Then, at day 28, the patients will be provided with Neobianacid® that can be administered on demand until the study end (day 56). Malgradate will be also provided as rescue medication.~Treatment regimen:~Day 0-13 Breakfast: Omeprazole placebo + Neobianacid® Lunch: Neobianacid® Midafternoon: Neobianacid® Dinner: Neobianacid® Before going to bed: Neobianacid®~Day14-27 Breakfast: Omeprazole placebo + Neobianacid® (both on demand) Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed~Day28-55 Breakfast: Neobianacid® on demand Lunch: Neobianacid® on demand Dinner: Neobianacid® on demand Any other time: Neobianacid® on demand, if needed"
3376014|NCT03224767|Experimental|Treatment (vemurafenib, cobimetinib)|Patients receive vemurafenib PO BID on day 1-28 and cobimetinib PO QD on days 1-21. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity. Patients may then receive radiation therapy, surgery, or continued treatment with vemurafenib and cobimetinib at the discretion of the treating physician.
3376015|NCT03223350|Experimental|Capsaicin|0.1% capsaicin cream, one application
3376016|NCT03223350|Placebo Comparator|Placebo|Topical cream with no active drug
3376017|NCT03217396||multiple sclerosis patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
3376018|NCT03217396||neurodegenerative disease patients|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
3376019|NCT03217396||control subjects|lumbar puncture, microRNAs quantification in blood and CSF samples, SNPs analysis
3376020|NCT03208010|Experimental|Diabetes Prevention Intervention|The intervention is 12 weeks of education on diet and physical activity, followed by 15 bi-weekly support groups for problem solving. Then, 3 booster sessions are scheduled, each one at 6-month intervals. Further, motivational interviewing is integrated into all group sessions.
3246725|NCT01350206|Experimental|TACE group|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
3259385|NCT01470378|Active Comparator|Control Group|This group will not be undergoing to manual lymphatic drainage
3259386|NCT01470378|Active Comparator|Study Group|This group will be undergoing to manual lymphatic drainage
3357954|NCT05144919|No Intervention|Control|The control group will continue to receive routine health check and nutrition education from health staff at commune health facilities. Access to agriculture extension services as offered by provincial staff will also continue as normal.
3357955|NCT05144919|Experimental|Intervention|The intervention group will receive capacity building sessions on both Agriculture and Nutrition, in addition to access to routine health and nutrition checks, and agriculture extension as offered by commune and provincial staff as normal.
3357956|NCT05144906||Blind women|The blind women group will include women who are congenitally blind or that were blinded early in life (up to the age of 7).
3246726|NCT01350219|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations.
3246727|NCT01350284|Experimental|Dietary supplementation|3g of cinnamon or placebo control were added to a test-meal.
3246728|NCT01350297|Experimental|Patients|Patients
3357957|NCT05144906||Sighted women|Women with normal or corrected-to-normal eye sight.
3357958|NCT05144893|Experimental|Virtual Mindfullness-Based Support Group|The virtual mindfulness-based intervention with social support groups will meet once a week for 4 weeks, each session will be 60 minutes. Each group will have 3-8 participants. The groups will be closed, meaning the same group of participants meet with the same instructor (unless a backup instructor is needed due to unavoidable reasons). Groups will be completed using the video conferencing application.
3357959|NCT05144880|Experimental|electroacupuncture with 2Hz group|
3357960|NCT05144880|Experimental|electroacupuncture with 100Hz group|
3357961|NCT05144867|Active Comparator|Arm 1|The WBRT dosage schedule will be 30 Gy in 10 fractions over 2 weeks. For Arm 1, Treatment planning is to be done using CT simulation or conventional simulation (fluoroscopy). Simple beam arrangements, such as parallel opposed beams, will be favoured wherever possible.
3357962|NCT05144867|Experimental|Arm 2|Metastases with a maximum diameter of up to 2 cm will be treated with doses of 22 to 25 Gy and those larger than 2 cm will be treated with doses of 18 to 20 Gy.
3357963|NCT05144854|Experimental|ONO-4538 + ipilimumab + chemotherapy|
3357964|NCT05144854|Active Comparator|Chemotherapy|
3357966|NCT05144828|Experimental|Intercostal Nerve Cryoablation plus Standard of Care (SOC) Pain Control|Intercostal nerve cryoablation using the CryoICE® CRYO2 cryoablation probe plus prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
3357967|NCT05144828|Active Comparator|Standard of Care (SOC) Pain Control|Prescribed post-operative pain medication, including tramadol, tylenol, and robaxin
3357968|NCT05144815|Experimental|Exercise protocol + IPC group|Patients in this group (n=20) will undergo an endurance training protocol. Prior to this training (8-12 minutes before) they will undergo ischaemic preconditioning.
3357969|NCT05144815|Sham Comparator|Exercise protocol + Sham IPC group|Patients in this group (n=20) will undergo the same training as the previous group and with the same frequency and duration, but the pressure cuff will be inflated by only 10 mmHg, so that it will act as a placebo.
3357970|NCT05144815|No Intervention|Control group|Patients in this group (n=20) will not perform any exercise during the 6 week-treatment period.
3357971|NCT05144802|Experimental|group 1 : FreeStyle Libre 2 on right arm and Dexcom G6 on left arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : FreeStyle Libre 2 will be applied on right arm and Dexcom G6 will be applied on left arm.
3357972|NCT05144802|Active Comparator|group 2 : 2 FreeStyle Libre 2 on left arm and Dexcom G6 on right arm|In this group, participants will be continuously monitored for their interstitial glucose level with 2 CGM devices : Dexcom G6 will be applied on right arm and FreeStyle Libre 2 will be applied on left arm.
3357973|NCT05144789|Active Comparator|Active TBS-DLPFC|The active group will receive theta-burst TMS stimulation.
3357974|NCT05144789|Active Comparator|Active TBS-DMPFC|The active group will receive theta-burst TMS stimulation.
3357975|NCT05144789|Sham Comparator|Sham TBS-DLPFC or DMPFC|The sham group will receive sham theta-burst TMS stimulation.
3357976|NCT05144776||Chronic hepatitis B|300 patients diagnosed with chronic hepatitis B will be enrolled. A fingerstick HBV DNA test will be performed using the Xpert HBV Viral Load assay, and a dried blood spot sample will be collected which will be tested using a gold standard HBV DNA viral load assay. Both results will be compared against the HBV DNA viral load from standard of care venous blood using the gold standard HBV DNA viral load assy. Enrolment of HBV DNA undetectable participants will be capped at 100.
3246729|NCT01350310|Experimental|Intramyocardial Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
3246730|NCT01350310|Active Comparator|Intracoronary Injections|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Patients will undergo myocardial perfusion scintigraphy and CD34+ cells will be injected intracoronary in the artery supplying segments of reduced viability. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure.
3246731|NCT01350310|Active Comparator|Ischemic heart disease|Peripheral blood stem cells will be mobilised by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labelled with technetium. Electromechanical mapping will be used to identify viable myocardium and intramyocardial injections in the target areas will be performed with NOGA catheter. Nuclear imaging for quantitation of myocardial retention rates of labeled cells will be performed at 2 and 18 hours after the procedure
3357977|NCT05144763|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
3357978|NCT05144763|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
3357981|NCT05144724|Experimental|Volume Targeted Ventilation|Positive pressure ventilation will be provided using a set tidal volume
3357982|NCT05144724|Active Comparator|Pressure guided Ventilation|Positive pressure ventilation will be provided using a set peak inflation pressure
3357983|NCT05144711|Active Comparator|Selective excavation|Cries will be removed from the peripheries of the cavity, while only soft caries will be removed from the plural side leaving stained leathery dentine that can not be removed by hand instruments. Biodentine will be placed and the cavity will be restored.
3357984|NCT05144711|Active Comparator|Non selective excavation|Caries will be cleaned form all cavity peripheries and floor. Biodentine will be placed and the toothy will be restored.
3357986|NCT05144685|Experimental|ABC + Treatment as Usual|This intervention will be for the treatment group
3357987|NCT05144685|Sham Comparator|STEPS + Treatment as Usual|This intervention will be for the control group
3357988|NCT05144672||Patient Group|The patient group will include 60 patients with type II DM. They will be subdivided into three groups according to albumin-creatinine ratio ,normoalbuminuric group(less than 30mg/g),which will include 20 patients, microalbuminuric group (ACR =30-300 mg/), which will include 20 patients, and macroalbuminuric group (ACR more than 300mg/g),which will include 20 patients.
3357989|NCT05144672||Control Group|control group will include 30 apparently healthy age-matched and sex-matched individuals.
3357992|NCT05144646|Experimental|HEALTHY SUBJECTS|With healthy subjects in a randomised, open experimental design, in an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 1
3357993|NCT05144646|Experimental|PATIENTS|With hospitalised patients and patients from social and health centers an experimental, randomised, open design, also with an intrasubject control group (application of HFA / EVOO on one heel, using the contralateral heel as a control and evaluating oxygenation and tissue perfusion in both cases). This intervention would correspond to phase 2.
3357994|NCT05144633||Acute Respiratory failure|Patients presenting to the Emergency Department in acute respiratory failure. These patients may or may not have a diagnosis of chronic lung disease.
3357998|NCT05144594||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County between 2013-2017, identified by ICD-code K.58.
3357999|NCT05144581||Patients diagnosed with IBS|Patients diagnosed with IBS within primary care in Region Örebro County 2013-2017, identified by ICD-code K.58.
3358000|NCT05144568|Experimental|experimental group|Nutrition education will be given to participants with PMS in the experimental group.
3358001|NCT05144568|No Intervention|Control group|
3358006|NCT05144529|Active Comparator|Ipilimumab/nivolumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks.
3358007|NCT05144529|Experimental|ipilimumab/nivolumab/evolucumab|Subjects receive ipilimumab 1 mg/kg IV every 6 weeks and nivolumab 240 mg IV every 2 weeks plus evolocumab 140 mg SC every 2 weeks
3358008|NCT05144516|Experimental|Patient Caregiver Dyad|Participants who are 65 years or older with cancer and mild cognitive impairment with their caregiver.
3358009|NCT05144503|Experimental|SpherePVI™ Catheter|Subjects treated with the SpherePVI™ Catheter
3358014|NCT05144464|Experimental|Quadrivalent influenza vaccine|Subjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.
3358015|NCT05144451|Experimental|TCD arm|All patients will be evaluated with TCD for prediction of the post-transplant neurological complications
3358016|NCT05144438||Pregnant women or woman in desire for conception|Towseek test : hair taking different questionnaires : environmental questionnaire, compliance questionnaire
3358017|NCT05144425|Active Comparator|group A|underwent TKA with using pneumatic tourniquet
3358018|NCT05144425|Placebo Comparator|group B|underwent TKA without using pneumatic tourniquet
3358019|NCT05144399|Experimental|Accelerated antibiotic treatment|Patients are treated shorter than usual
3358020|NCT05144399|Other|Standard length of antibiotic treatment|Patients are receiving the standard length of antibiotic treatment
3246732|NCT01350323|Active Comparator|Type 3 NV|Wet-AMD related type 3 neovascularization
3246733|NCT01350323|Active Comparator|Type 2 NV|Wet-AMD related type 2 neovascularization
3246734|NCT01350323|Active Comparator|Type 1 NV|Wet-AMD related type 1 neovascularization
3246735|NCT01350323|Other|Controls|Aqueous sample (0.1ml) in patients undergoing cataract extraction
3358021|NCT05144386|Experimental|EBT-101 Dose-Level 1|Cohort A: Participants will be administered dose-level 1 of EBT-101
3358022|NCT05144386|Experimental|EBT-101 Dose-Level 2|Cohort B: Participants will be administered dose-level 2 of EBT-101
3358023|NCT05144386|Experimental|EBT-101 Dose-Level 3|Cohort C: Participants will be administered dose-level 3 of EBT-101
3358024|NCT05144373|Experimental|Gross motor intervention|Participants will receive a home-based, parent-administered body-weight supported treadmill intervention from about 10 months of age until walking onset.
3358025|NCT05144373|Experimental|Gross and fine motor intervention|"Besides the body-weight supported treadmill intervention as illustrated above, participants will receive additional fine motor intervention using sticky mittens from about 10 months of age for five months."
3358026|NCT05144373|No Intervention|Control|Participants will not receive specific intervention.
3358027|NCT05144360|Experimental|Atenas|"The study is triple-dummy. The patient must take 3 tablets once a day, as follows:~1 tablet Atenas, oral;~1 tablet empagliflozin placebo, oral;~1 tablet telmisartan + amlodipine placebo, oral."
3358028|NCT05144360|Active Comparator|Empagliflozin + telmisartan + amlodipine|"The patient must take 3 tablets once a day, as follows:~1 tablet Atenas placebo, oral;~1 tablet empagliflozin, oral;~1 tablet telmisartan + amlodipine, oral."
3358031|NCT05144334|Experimental|BTX-1188 Dose Cohort 1|Starting dose of BTX-1188 administered orally per dosing schedule
3358032|NCT05144334|Experimental|BTX-1188 Dose Cohort 2|First dose escalation of BTX-1188 administered orally per dosing schedule
3358033|NCT05144334|Experimental|BTX-1188 Dose Cohort 3|Second dose escalation of BTX-1188 administered orally per dosing schedule
3358034|NCT05144334|Experimental|BTX-1188 Dose Cohort 4|Third dose escalation of BTX-1188 administered orally per dosing schedule
3358035|NCT05144334|Experimental|BTX-1188 Dose Cohort 5|Fourth dose escalation of BTX-1188 administered orally per dosing schedule
3358036|NCT05144334|Experimental|BTX-1188 Dose Cohort 6|Fifth dose escalation of BTX-1188 administered orally per dosing schedule
3246736|NCT01350349|Experimental|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
3358037|NCT05144334|Experimental|BTX-1188 Dose Cohort 7|Sixth dose escalation of BTX-1188 administered orally per dosing schedule
3358038|NCT05144321||All pregnant women delivering a twin pregnancy|All pregnant women delivering a twin pregnancy
3358039|NCT05144308|Experimental|Patients operated with a TECNIS® Eyhance Toric II 1-piece posterior chamber lens|For at least one eye : Planned cataract surgery with placement of a TECNIS® Eyhance Toric II 1-piece posterior chamber lens
3246737|NCT01350349|Active Comparator|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
3246738|NCT01350362|Experimental|Tideglusib 1000 mg Q.D.|Group dosed with 1000 mg once daily for 26 weeks/extension
3259387|NCT01470391|Experimental|Adductor-Canal-Blockade|
3246739|NCT01350362|Experimental|Tideglusib 1000 mg Q.O.D.|Group dosed with 1000 mg once every other day for 26 weeks/extension
3246740|NCT01350362|Experimental|Tideglusib 500 mg Q.D.|Group dosed with 500 mg once daily for 26 weeks/extension
3246741|NCT01350362|Placebo Comparator|Placebo|Once daily administration for 26 weeks/extension
3246742|NCT01350375|Placebo Comparator|Saline|
3358042|NCT05144282||premature baby without ROP (Group 1)|ROP: retinopathy of prematurity
3358043|NCT05144282||ROP without treatment (Group 2)|ROP: retinopathy of prematurity
3358044|NCT05144282||ROP with anti-VEGF treatment (Group 3)|ROP: retinopathy of prematurity
3358045|NCT05144282||ROP with laser photocoagulation treatment (Group 4)|ROP: retinopathy of prematurity
3358046|NCT05144269|Experimental|Multimodal exercises group|Multimodal exercise-based telerehabilitation will be implemented with video conference method. For telerehabilitation, a program including pilates, breathing, progressive relaxation training, posture and pelvic floor strengthening exercises was created. Sessions consist of 45 minutes. Telerehabilitation will take place 2 days a week for 8 weeks.
3246743|NCT01350375|Active Comparator|Botox|
3246744|NCT01350427|Experimental|Leucine|
3358047|NCT05144269|No Intervention|Education group|30 minutes of training will be given about postpartum and exercises. As exercise, only aerobic walking exercise, which can be started for 15 minutes a day and 3 days a week according to the guide, gradually increasing, up to 30 minutes and up to 4 days a week will be applied. There will also be a warm-up and a cool-down period before the walking exercise. *Exercise intensity is determined in the 12-14 score range according to the Borg Scale, and how to apply it will be explained.
3246745|NCT01350427|Experimental|BCAA|
3246746|NCT01350427|Placebo Comparator|Placebo|
3246747|NCT01350440|Experimental|IVIG|Intravenous Immune Globulin
3358051|NCT05144243|Experimental|Venetoclax in Combination with Azacitidine|Participants will receive oral tablet venetoclax dose ramp-up only in Cycle 1 Days 1-3 until target dose is reached. Particpants will then receive oral tablet venetoclax at the target dose every day (QD) on Cycle Days 1 - 28 plus Azacitidine through subcutaneous injection (SC) QD on Cycle Days 1 - 7 (28-day cycle).
3358052|NCT05144217|Placebo Comparator|Placebo|1 capsule twice per day
3246748|NCT01350466||FESS patients|
3246749|NCT01350466||Controls|
3246750|NCT01350518|Placebo Comparator|Study prepared meals and placebo|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will not receive any fiber (Benefiber) supplementation in their TrueLemon mixture.
3358053|NCT05144217|Active Comparator|oral administration of 2x 140 mg per day|1 capsule twice per day
3358054|NCT05144217|Active Comparator|oral administration of 3x 280 mg per day|2 capsules three times a day
3246751|NCT01350518|Active Comparator|Nutritional Counseling with fiber|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions will focus on knowledge, self-regulation, motivation, experience and environment. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture .
3246752|NCT01350518|Placebo Comparator|Nutrition counseling and placebo|Participants receiving nutritional education will have two individual sessions (spaced approx. 2 weeks apart). The nutritional sessions (interventions) will focus on knowledge, self-regulation, motivation, experience and environment.Participants will receive no fiber supplementation in their TrueLemon mixture .
3358055|NCT05144217|Active Comparator|oral administration of 1x 1120 mg per day|8 capsules once per day
3358056|NCT05144204|Experimental|Irritable Bowel Syndrome Patients|
3246753|NCT01350518|Active Comparator|Study prepared meals and fiber|Participants will have meals designed specifically for them based on their caloric needs. Participants will choose a weeks worth of meals (from a menu) and pick them up from the Clinical Research Unit twice a week. Participants will receive fiber (Benefiber) supplementation as the fiber intervention in their TrueLemon mixture.
3246754|NCT01350531|Experimental|Skills training|
3246755|NCT01350531|Experimental|Contingency Management|
3246756|NCT01350557|No Intervention|Control group|Patients receive only usual hospital care
3246757|NCT01350557|Other|Subacute care group|Patients receive hospital usual care and subacute care. Subacute care consisted of geriatric consultation, a rehabilitation program, and early discharge planning.
3246758|NCT01350557|Experimental|Comprehensive care group|Patients receive not only the subacute care (geriatric consultation, rehabilitation program, and discharge planning), but also health-maintenance interventions to prevent falls, consult on nutrition, and manage depression.
3358057|NCT05144191|Other|Insignia uncemented Hip Stem|"The Insignia™ Hip Stem is a collared stem that features a plasma-sprayed Hydroxyapatite (HA) coating over plasma-sprayed titanium in the proximal region and a plasma-sprayed HA coating over grit blast in the distal region and collar underside.~Insignia™ Hip Stems are intended for 'cement less' use only and are intended for total arthroplasty procedures."
3246759|NCT01350570|Experimental|acupuncture group 1|Acupoints ST25 and BL25 will be used in the group. ST25 locate at the abdomen, while BL25 locate at the back.
3246760|NCT01350570|Experimental|acupuncture group 2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
3246761|NCT01350570|Experimental|acupuncture group 3|All acupoints used in acupuncture group1 and acupuncture group2 will be used in this group.
3246762|NCT01350570|Active Comparator|Loperamide|Loperamide will be used as an active comparator to the acupuncture groups.
3246763|NCT01350596|Active Comparator|Reference Drug|
3246764|NCT01350596|Active Comparator|Test Drug|
3246765|NCT01350609|Experimental|Nifedipine/Candesartan (fixed dose)|
3246766|NCT01350609|Active Comparator|Nifedipine/Candesartan (loose)|
3246767|NCT01350622|Experimental|Pennsaid|Active Pennsaid and oral placebo
3246768|NCT01350622|Active Comparator|Oral Diclofenac|Oral diclofenac and placebo lotion (2.3% DMSO solution)
3358060|NCT05144139|Experimental|Low dose group with mRNA vaccine|25μg with COVID-19 mRNA vaccine
3358061|NCT05144139|Placebo Comparator|Low dose group with placebo|Low dose group with placebo
3358062|NCT05144139|Experimental|High dose group with mRNA vaccine|45μg with COVID-19 mRNA vaccine
3358063|NCT05144139|Placebo Comparator|High dose group with placebo|High dose group with placebo
3358064|NCT05144126|Experimental|i-Factor Arm|All patients undergoing spine fusion surgery will be treated with i-FACTOR
3358065|NCT05144113||Current FES-Row Subjects|To determine user needs we will survey 10 subjects that are currently participating in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
3358066|NCT05144113||Non-FES-Row Subjects|To determine user needs we will survey 10 subjects that have never participated in FES-row training to discover their motivations, preferences and challenges pertaining to participation in physical activity in general and FES-rowing.
3358067|NCT05144100|Experimental|Arm 1 - Surgery +/- Neck Dissection|Patients would undergo appropriate surgery via open, endoscopic, TLM, TORS or a combination. The primary and the neck would be addressed. For N0 neck, clearance of levels II-IV will be required, with levels I and/or V electively dissected at the discretion of the operating surgeon and based on extension of nodal disease. For N+ neck and tumors approaching to within 1cm of the midline, we recommend a contralateral neck dissection be performed as well of levels II-IV but to be done as per operating team's discretion. For lateralized lesions of the BOT and tonsil, ipsilateral neck dissection will be performed. A minimum of 18 lymph nodes per dissected side of the neck is required and will be subject to quality assurance review
3358068|NCT05144100|Experimental|Arm 2 - Chemoradiation|"Patients will receive IMRT with normal tissue sparing techniques (70Gy/35# or 66Gy/ 30#) along with concurrent weekly cisplatin. Weekly cisplatin will be administered during IMRT at a dose of 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36, and 43 for a total of up to 7 weekly doses, administered during the course of IMRT.~For patients with T1-2 lateralized tonsil tumors with <1 cm invasion into the soft palate, no invasion of BOT, and N1 neck involvement, unilateral neck will be irradiated. The contralateral neck will be addressed for some BOT tumors<1cm or at the midline and may be considered in patients with N2 and N3status. For patients with residual neck disease after CCRT, a formal neck dissection will be performed. For patients with residual primary disease after CCRT, surgery for the primary will be performed if feasible."
3358069|NCT05144074||Non-filtered platelet concentrates (NF-PC group).|In NF-PC group, 90 whole blood units were collected with Tripple blood bags, Six NF-PCs were pooled together and stored in a horizonal shaker at 20 ± 2C for 5 days .
3358070|NCT05144074||leukocyte-depleted platelet concentrates (LD-PC group).|In LD-PC group, another 90 whole blood units were collected using Whole Blood Filter Saving Platelets (WB-SP) bags with an integrated leukoreduction filter
3358072|NCT05144048|Active Comparator|Induction of labour with oral misoprostol, inpatient setting|These women receive all treatment in the maternity unit.
3246775|NCT01350661||Asthma control level assessment|
3246776|NCT01350674|Experimental|EBUS|patients undergoing EBUS
3246777|NCT01350700||Patients that were treated in MW2004-011-02 study with Debrase|
3246778|NCT01350700||Patients that were treated in MW2004-011-02 with SOC|
3246779|NCT01350713|Experimental|povidone iodine|
3246780|NCT01350713|Active Comparator|cold water|treatment by cold water after burn
3246781|NCT01350726||Normal control|Subjects without liver cirrhosis and normal volunteers.
3246782|NCT01350726||Cirrhosis group|Subjects with liver cirrhosis.
3246783|NCT01350739|Other|intraumbilical incision|an intraumbilical vertical incision is made
3246784|NCT01350739|Other|infraumbilical incision|incision is done in circular fashion at the inferior boarder of umbilicus
3246785|NCT01350752|No Intervention|Control|"In Cameroon: Existing practice (with microscopy widely available)~In Nigeria: Expected practice (RDTs will be provided with basic instructions)"
3259388|NCT01470391|Active Comparator|Femoral Nerve Block|
3358073|NCT05144048|Experimental|Induction of labour with oral misoprostol, outpatient setting|These women are observed 2 hours after they receive one dose of oral misoprostol before they leave the maternity unit.
3358076|NCT05144022|Experimental|Interventions group: High stress condition (bungee jump)|25-30 healthy male volunteers participating in a bungee jump
3358077|NCT05144022|Placebo Comparator|Control group: No stress condition|10-15 healthy males serving as a control group without undergoing a stress event/intervention
3358078|NCT05144009|Experimental|Cohort A, Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are unfit (per sGA) will receive Lonca-R for 3 cycles. Participants who achieve a complete response (CR) will receive Lonca-R for 1 additional cycle. Participants who achieve a partial response (PR) will receive Lonca-R for 3 additional cycles.~Lonca-R will be administered as rituximab 375 mg/m^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab* 375 mg/m^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m^2 and loncastuximab tesirine 75 µg/kg on Day 1.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
3358079|NCT05144009|Experimental|Cohort B, Part 1 and Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Participants who are frail (per sGA) or participants with cardiac comorbidities will receive Lonca-R for 3 cycles. Participants who achieve a CR will receive Lonca-R for 1 additional cycle. Participants who achieve a PR will receive Lonca-R for 3 additional cycles for a total of up to 6 cycles. Participants enrolled in Cohort B only, who achieve stable disease (SD) and deriving clinical benefit per the treating physician, may also receive Lonca-R for an additional 3 cycles.~Lonca-R will be administered as rituximab 375 mg/m^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab* 375 mg/m^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m^2 and loncastuximab tesirine 75 µg/kg on Day 1.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
3358080|NCT05144009|Active Comparator|Cohort A, Part 2: R-mini-CHOP|"Randomized participants who are unfit (per sGA) will receive standard R-mini-CHOP for 3 cycles. Participants who achieve a CR will receive R-mini-CHOP for 1 additional cycle. Participants who achieve a PR will receive R-mini-CHOP for 3 additional cycles.~Participants will receive R-mini-CHOP consisting of 375 mg/m^2 rituximab*, 400 mg/ m^2 cyclophosphamide, 25 mg/m^2 doxorubicin and 1 mg vincristine on Day 1 of each cycle. Participants will also receive 40 mg/m^2 prednisone daily (QD) on Days 1 to 5 of each cycle.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
3358081|NCT05144009|Experimental|Cohort A, Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Randomized participants who are unfit (per sGA) will receive Lonca-R for 3 cycles. If participants achieve a CR, they will receive Lonca-R for 1 additional cycle. If participants achieve a PR, they will receive Lonca-R for 3 additional cycles.~Lonca-R will be administered as rituximab 375 mg/m^2 on Day 1 of Cycle 1 and loncastuximab tesirine 150 µg/kg on Day 2 of Cycle 1. During Cycle 2, Lonca-R will be administered as rituximab* 375 mg/m^2 and loncastuximab tesirine 150 µg/kg on Day 1. For cycles 3 and beyond, Lonca-R will be administered as rituximab 375 mg/m^2 and loncastuximab tesirine 75 µg/kg on Day 1.~*subcutaneous rituximab 1400mg/dose may be used during Cycle 2 and beyond"
3358082|NCT05143996|Experimental|Single Ascending Dose (SAD)|A single dose of CLN-049 in patients with Relapsed/Refractory AML
3358083|NCT05143983|Active Comparator|depressed subjects, positive valence music listening at first|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to positive musical excepts (3 minutes)
3358084|NCT05143983|Other|depressed subjects, neutral valence music listening|patients with major depressive disorder will be recruited and will complete 3 cognitive tasks after listening to neutral valence musical excepts (3 minutes)
3358085|NCT05143983|Other|healthy controls, positive valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to positive valence musical excepts (3 minutes)
3358086|NCT05143983|Other|healthy controls, neutral valence music listening|healthy individuals will be recruited and will complete 3 cognitive task after listening to neutral valence musical excepts (3 minutes)
3358087|NCT05143970|Experimental|IPH5301 administration|"Part I- Dose escalation:~Escalating dose levels of IPH5301 will be evaluated.~Part II-Cohort Expansion:~IPH5301 will be administrated in combination with trastuzumab and paclitaxel"
3358088|NCT05143957|Experimental|IONIS-TMPRSS6-LRx Dose Level 1|IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks.
3358089|NCT05143957|Experimental|IONIS-TMPRSS6-LRx Dose Level 2|IONIS-TMPRSS6-LRx will be administered by SC injection every 4 weeks
3358090|NCT05143944||Nice clinical guidelines for intrapartum care for healthy women and babies|define gold standards in intrapartum care for healthy women and babies
3358091|NCT05143944||performance in the care provided to patients in periods of audit|measure performance in the care provided to the patients in the period of audit
3358092|NCT05143931|Active Comparator|WW Only|WW is commercially-available weight management program focusing on diet, physical activity and mindset skills.
3358093|NCT05143931|Experimental|WW + Home modification and grocery delivery (AVOID)|WW + modification of home food environment + online grocery shopping and delivery
3358094|NCT05143931|Experimental|WW + Inhibitory control training (RESIST)|WW + daily gamified inhibitory control training
3358095|NCT05143931|Experimental|WW + Home food modification and grocery delivery (AVOID) + Inhibitory control training (RESIST)|WW + modification of home food environment + online grocery shopping and delivery + daily gamified inhibitory control training
3358110|NCT05143892|Experimental|Avatrombopag|In the 4-weeks' core study,the initial dose of avatrombopag is 20 mg/d. If the patient's PLT count remains less than 20*109/L after one week, the maximum dose was increased to 40 mg/d. Avatrombopag will be taken orally with food;in the 4-weeks' extended study,participants in the avatrombopag group who does not meet the withdrawal indication can be enrolled in the extended study and continue the avatrombopag treatment with a maximum dose of 60 mg/d.
3358111|NCT05143892|Active Comparator|rhTPO|In the 4-weeks' core study,the rhTPO will be subcutaneously injected with dosage of 300 U/kg/d.
3358112|NCT05143879|Placebo Comparator|Placebo|8 subjects took 3 g/kg/day of placebo during 9 weeks
3358113|NCT05143879|Active Comparator|Nitrate|8 subjects took 3 g/kg/day of nitrate during 9 weeks
3358114|NCT05143879|Active Comparator|Citrulline|8 subjects took 3 g/kg/day of citrulline during 9 weeks
3246786|NCT01350752|Active Comparator|Provider Intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment. This involved 1-day training on: 1) Malaria Diagnosis; 2) Rapid Diagnostic Testing; 3) Malaria Treatment. These modules explain that all febrile patients should be tested for malaria; procedures for using an RDT; that confirmed cases of uncomplicated malaria should be treated with an ACT; and test-negative patients should not be given an antimalarial.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment. This involved a 2-day training workshop and support visits. The training covered the following topics: causes and symptoms of malaria; demonstration on how to use an RDT; updated malaria guidelines; and communications skills. The training used a combination of seminars and facilitated small-group work, such as a treatment algorithm game, problem-solving exercises, self-developed participatory drama and role-playing."
3246787|NCT01350752|Active Comparator|Extended intervention|"Cameroon: Introduce malaria RDTs with basic provider training and job aids on malaria diagnosis and treatment AND enhanced provider training on improving quality of care. Clinicians received 3-days of training: the first day was identical to the basic intervention, while the remainder of the course covered three additional modules targeting improvements in quality of care: 4) Adapting to Change; 5) Professionalism; 6) Communicating Effectively.~Nigeria: Introduce malaria RDTs with provider training and job aids on malaria diagnosis and treatment AND School-based malaria education intervention (with drama, peer-health education and distribution of health education materials). In addition, teachers and Peer Health Educators were offered support to hold malaria events in which parents, guardians, and other community members could participate in the same types of activities."
3246788|NCT01350765|Experimental|Intervention|This would be the interventional arm of the study, where the LHWs would receive additional training for identification and management of birth asphyxia, lbw, and sepsis.
3358115|NCT05143879|Active Comparator|Nitrate plus Citrulline|8 subjects took 3 g/kg/day of nitrate plus citrulline during 9 weeks
3358116|NCT05143866|Experimental|Self-help CBT|Evidence based book detailing self-help program to follow plus Telephone support from a non specialist guide
3358117|NCT05143853|Active Comparator|group with tape augmentation of acromioclavicular (AC) joint|patients randomised in this group will have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
3358118|NCT05143853|Sham Comparator|group without tape augmentation of AC joint|patients randomised in this group will not have additional tape fixation around AC joint. Both groups will however have fixation in CC area.
3358119|NCT05143840|Experimental|Asciminib|Asciminib 40mg taken orally twice a day starting cycle 1 day 1 for up to 24 months.
3358120|NCT05143827|Experimental|Senatore Cappelli pasta|
3358121|NCT05143827|Experimental|Korasan pasta|
3358122|NCT05143827|Active Comparator|Claudio pasta|
3358123|NCT05143801|Active Comparator|No mask temperate|Participant exercised in room temperature environment not wearing a surgical face mask
3358124|NCT05143801|Experimental|Mask temperate|Participant exercised in room temperature environment while wearing a surgical face mask
3358125|NCT05143801|Active Comparator|No mask hot|Participant exercised in a hot environmental temperature not wearing a surgical face mask
3358126|NCT05143801|Experimental|Mask hot|Participant exercised in a hot environmental temperature while wearing a surgical face mask
3358131|NCT05143762|Active Comparator|group (A)|will receive intravenous paracetamol 30mg/kg (max 90 mg/kg/day).
3358132|NCT05143762|Active Comparator|group (B)|will receive dexamethasone 0.5mg/kg IV.
3358133|NCT05143762|Placebo Comparator|group(C)|will received placebo 10 ml normal saline IV.
3358134|NCT05143749|Experimental|10 assistant doctors who received video training|10 assistant doctors who receive video training will be the intervention arm
3358135|NCT05143749|No Intervention|10 assistant doctors who did not receive video training|10 assistant doctors who did not receive video training will be the control arm
3358136|NCT05143736||Modeling cohort|The population enrolled at the intensive care unit of Zhujiang Hospital of Southern Medical University in Guangdong Province, China will be used as a modeling cohort.For the patients in this cohort, the nasal and fecal specimens and related clinical information will collected to construct the prediction model.
3358137|NCT05143736||validation cohort|The population enrolled at the intensive care unit of Dongguan People's Hospital in Guangdong Province, China will be used as a validation cohort.
3358138|NCT05143723|Experimental|agonist group|Patients of the first group received GNRH-a for LPS at a dose of 0.2 mg, subdermally, daily from the second day after TVOP till 8 weeks of pregnancy.
3358139|NCT05143723|Active Comparator|group of progesterone and estradiol|The second group of patients received progesterone as LPS at a dosage of 30 mg per day, per os, and estradiol at a dosage of 3 mg per day, transdermally starting from the second day after TVOP till 8 weeks of pregnancy
3246789|NCT01350765|Active Comparator|Control|This would be the comparative group of the study in which the LHWs would perform the usual routine tasks assigned to them by their program.
3246790|NCT01350778||Biomatrix stent|patients treated with Biomatrix stent
3358141|NCT05143697|Other|Wellness Coaching for Families and Kids|For clinics assigned to mBMI2Kids intervention, Pediatricians will be trained in Motivational Interviewing (MI) and behavioral intervention. Pediatricians will conduct up to 3 sessions with each parent (3 x 10 min) and refer patients electronically to experienced MI-trained lifestyle coaches. With full access to the electronic medical record coaches will call referred families (child's BMI-for-age ≥85th percentile) and deliver a telephonic MI counseling over two years (6 x 45 min) simultaneous with pediatricians. 36 clinics will be selected with 18 participating in the intervention and 18 providing patients with usual care.
3358142|NCT05143671||Hybrid coronary revascularization strategy (HCR)|Patients who undergo a combination of coronary artery bypass grafting and PCI.
3358143|NCT05143671||Hybrid valve and coronary disease correction|Patients who undergo a combination of surgical valve replacement and PCI.
3246791|NCT01350791||Promus Element stent|Patients receiving Promus Element stents
3246792|NCT01350817|Active Comparator|Docetaxel|
3246793|NCT01350817|Experimental|Erlotinib|
3246794|NCT01350830|Active Comparator|pre-trasversalis mesh repair group|
3358144|NCT05143671||Hybrid coronary and carotid artery disease treatment|Patients who undergo a combination of coronary artery bypass grafting and carotid stenting.
3358145|NCT05143658|Active Comparator|Laparoscopic Lateral Suspension Group (LLS)|Anterior and apical prolapse repair via LLS
3358146|NCT05143658|Experimental|Laparoscopic Pectopexy (LP)|Anterior and apical prolapse repair via LP
3358147|NCT05143632|No Intervention|Intermittent NIBP monitoring|Oscillometric intermittent (3 mins) noninvasive blood pressure monitoring
3358148|NCT05143632|Experimental|ClearSight|Continuous non invasive hemodynamic monitoring
3358149|NCT05143619||Observational (surveys)|Participants complete surveys immediately after completion of a HCC diagnostic guideline webinar, monthly thereafter, and again at 6 months.
3358150|NCT05143606|Experimental|3D printed simulator|"The participants in this arm will undergo two self-directed training sessions on a custom-made 3D-printed airway simulator. The participants will use a standard intubating fiberoptic bronchoscope to practice fiberoptic-assisted nasal intubation.~The sessions will be one week apart. Each session is 30 minutes per participant."
3246795|NCT01350830|Active Comparator|trans-inguinal preperitoneal patch group|
3246796|NCT01350843|Experimental|Orange Juice|Juice high in flavonoids
3246797|NCT01350843|Placebo Comparator|Orange Drink|Sugars matched, low flavonoids orange drink
3246798|NCT01350856|Active Comparator|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
3246799|NCT01350856|Experimental|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
3246800|NCT01350869||Xience stent|Real world patients treated with XIENCE stents
3246801|NCT01350882|Experimental|A|Patients randomized into the arm blind A. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3259389|NCT01470404||adjuvant chemotherapy|Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
3259390|NCT01470430||ROP infants treated with intravitreal anti-VEGF agents|
3259391|NCT01470430||ROP infants treated with retinal laser photocoagulation|
3358151|NCT05143606|Experimental|Virtual reality software|"The participants in this arm will practice fiberoptic-assisted nasal intubation using the free virtual reality software (AirwayEX) on their mobile phones or computer tablets. Two practice sessions are required by the investigators. The sessions will be one week apart. Each session is 30 minutes per participant.~The participants in this arm will have the opportunity to practice on the software as often as they feel necessary. All the additional practice data will be recorded."
3358154|NCT05143580|Experimental|Cognitive Therapy Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education.~Provide post-operative care and environmental imaging materials, explain the importance of intensive care unit routines and related equipment, indwelling pipelines, related nursing staff, post-operative care methods, and provide imaging and health education manuals for explanation.~Use gamification to evaluate: pain relief skills, lung expansion skills."
3246802|NCT01350882|Placebo Comparator|B|Patients randomized into the arm blind B. Rituximab is allowed as additional treatment from J12, within the limit of 2 infusions of rituximab. In case of insufficient efficacy of the treatment of acute humoral rejection, investigators may propose an additional infusion of rituximab from J12, without patient withdrawn. In this case (2nd infusion effective in group A and 1st infusion effective group B), a additional consultation (CS) will be provided as part of the study 7 days after infusion. In case of insufficient efficacy of the treatment,in fairness to care for patients between the 2 treatment groups, the investigators may propose to a 3rd infusion patients in group B (2nd infusion effective for this group). To prevent patients from group A will receive a 3rd infusion of rituximab, unblinding will be applied in this case by the investigator before the administration of additional treatment with rituximab.
3358155|NCT05143580|Placebo Comparator|Routine Care Group|"The anesthesiologist will provide the patient with instructions for preoperative anesthesia.~The operating room nurses will introduce the operating room environment and surgical care instructions to the patient.~Provide a manual for disease health education."
3358159|NCT05143554|Active Comparator|Active percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
3358160|NCT05143554|Sham Comparator|Sham percutaneous neurostimulation|Subject randomized to maximum of 5 days of active vs sham neurostimulation therapy with moderate to severe emetogenic chemotherapy admission . With the next scheduled identical chemotherapy cycle, each subject will cross over to the other one (active vs sham)
3246803|NCT01350895||Experimental Group|
3246804|NCT01350895||Control Group|
3358161|NCT05143541||AEON Endostapler|Stapling performed with AEON Endostapler
3358162|NCT05143528|Placebo Comparator|Arm A: Placebo|425 subjects will be randomized to the placebo group.
3246805|NCT01350908|Other|Blood sampling|
3246806|NCT01350960|Placebo Comparator|saline 0.9%|
3246807|NCT01350960|Experimental|Cohort 1|0.5 mg/kg in Healthy Subjects
3246808|NCT01350960|Experimental|Cohort 2|1.5 mg/kg in Healthy subjects
3246809|NCT01350960|Experimental|Cohort 3|5.0 mg/kg in Healthy subjects
3246810|NCT01350960|Experimental|Cohort 4|10 mg/kg in Healthy subjects
3358163|NCT05143528|Active Comparator|Arm B: Experimental Low Dose|425 subjects to each of the Nilotinib BE, 84mg.
3358164|NCT05143528|Active Comparator|Arm C: Experimental High Dose|425 subjects to each of the Nilotinib BE, 112mg.
3358165|NCT05143515|Experimental|PACE Label group|This group used the PACE label plus calorie label to help participants to know about the number of minutes of walking or running required to burn off the calories in food and drinks.
3246811|NCT01350960|Experimental|Cohort 5|TBD mg/kg in FH subjects
3246812|NCT01350986|Experimental|Directive|
3358166|NCT05143515|No Intervention|Calorie Label group|This group used only calorie labels to show the number of calories in food and drinks.
3246813|NCT01350986|Active Comparator|Non-Directive|
3246814|NCT01351012|Placebo Comparator|Corn and safflower oil|
3358167|NCT05143502|Experimental|Montelukast Group|Patients in group A (interventional group) will be treated with fluticasone furoate nasal: (50 micrograms /spray ) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast (montelukast 10 mg, once a day) for 3 monthes and oral Prednisolone 40 mg/day for two weeks.
3358168|NCT05143502|Active Comparator|Control Group|Subjects in treatment group B will receive topical and systemic steroids in an identical regimen only.
3246815|NCT01351012|Active Comparator|Canola oil|
3246816|NCT01351012|Active Comparator|High oleic acid canola oil|
3246817|NCT01351012|Active Comparator|DHA enriched high oleic acid canola oil|
3246818|NCT01351012|Active Comparator|Flax and safflower oil|
3358171|NCT05143463|Experimental|Sequential SAD - NS101|A staggered dosing schedule will be used for each dose level administered under fasting conditions.
3358172|NCT05143463|Placebo Comparator|Sequential SAD - NS101 Placebo|Volume of matching placebo will be determined based on subject weight and NS101 concentration per cohort.
3358175|NCT05143437|Experimental|Writing Intervention|Couples will take part in three 7-minute online writing sessions over the course of four weeks.
3358176|NCT05143424|Active Comparator|CBD (350 mg)|CBD 350 mg twice per day for 3 days
3358177|NCT05143424|Active Comparator|CBD (700 mg)|CBD 700 mg twice per day for 3 days
3358178|NCT05143411|Experimental|Use of mobile application|Single arm: At the first time, the researcher will collect all glycemic levels before using the mobile application. Then, all the participants will receive the mobile application to select their main meals, breakfast, lunch, and dinner. Then, the application must calculate the insulin bolus according to their initial profile and the food before being eaten.
3358179|NCT05143398|Active Comparator|Diet Arm|low-calorie diet normoproteic with an energy deficit of 15% compared to what emerged from the calorimetric value (basal REE)
3246819|NCT01351038|Experimental|treatment|3 cycles(repeated q21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Capecitabine 500mg/m² bid d1-d21 Panitumumab 9mg/kg i.v. d1
3358180|NCT05143398|Active Comparator|Protein Arm|low-calorie diet normoproteic + an integration of 8.72 g of protein in the form of a nutritional supplement (18-20% protein)
3358181|NCT05143398|Active Comparator|EAA Arm|low-calorie diet normoproteic + amino acid supplement (2 sachet/daily; 1 sachet contains protein 0 gr, carbohydrates 6.69 gr , lipids 0 gr, i-leucine 1,2 gr, i-isoleucine 0,6 gr, i-valine 0,6 gr).
3358182|NCT05143398|Active Comparator|EAA + TCA|low-calorie diet normoproteic + an amino acid supplement (2 stick/daily; 1 stick pack contains protein 0 gr, carbohydrates 1,046 gr, lipids 0.074 gr, i-leucine 1.2 gr, i-isoleucine 0.6 gr, i-valine 0.6 gr, citric acid, succinic acid and malic acid)
3358183|NCT05143385|No Intervention|Control|"The variables to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: Mississippi Aphasia Screening test, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfreiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16., Will be performed on all patients who are part of the trial.~Those patients where conventional rehabilitative treatment is performed will be:~Physiotherapy sessions~Speech therapy sessions~Neuropsychology sessions~Occupational therapy sessions"
3246820|NCT01351051||No endometriosis|
3246821|NCT01351051||Superficial endometriosis|
3246822|NCT01351051||Endometrioma|
3246823|NCT01351051||Deep infiltrating endometriosis|
3358184|NCT05143385|Experimental|Intervention Group|The variables are to be filled in upon admission are: age, sex, reason for admission and main caregiver. The variables that will be collected on admission and discharge are: MAST, Canadian scale, Duke-UNK-11 subjective support scale, UCLA loneliness scale, oropharyngeal dysphagia screening test, Pfeiffer scale, State assessment mood, Hamilton Rating for Depression and Hospital Anxiety Depression Scale and HLS-EU Q16.The beginning of the intervention will be once you have completed 15 calendar days from your admission.The intervention will be carried out once a week with a duration of 20 min with one of the games chosen by the patient together with the physiotherapist.The completion of the intervention will be until the patient is discharged from hospital, with a minimum of four sessions carried out in order to participate in the study.A registration table will be executed where the number of sessions of each patient and the type of session are quantified like a control group.
3358185|NCT05143372|Active Comparator|SaO2 (oxygen status)|Measurment 4 times per day, ABA (acid-bases analyses)
3358186|NCT05143372|Active Comparator|PaO2/FiO2 (respiratory index)|Measurment 4 times per day, ABA (acid-bases analyses)
3358187|NCT05143359|Experimental|Wharfe and Pederson difficulty index|Assessment of Difficulty in third molar extraction using Wharfe and Pederson difficulty index
3358188|NCT05143359|Active Comparator|Winters difficulty index|Assessment of Difficulty in third molar extraction using Winters difficulty index
3358189|NCT05143346|Other|Group A|Group A will include 168 patients and will be intubated by the use of video stylet.
3358190|NCT05143346|Other|Group B|Group B will include 168 patients and will intubated by the use of video laryngoscope
3246826|NCT01351116|Experimental|EBR plus HDRIB|External Beam Radiation (EBR) plus High Dose Rate Intraluminal Brachytherapy (HDRIB)
3246827|NCT01351116|Active Comparator|EBR|External Beam Radiation (EBR)
3246828|NCT01351129|Experimental|Formulation 1|
3246829|NCT01351129|Experimental|Formulation 2|
3246830|NCT01351129|Experimental|Formulation 3|
3246831|NCT01351155|Active Comparator|polyurethane foam (Allewyn adesive)|Polyurethane foam is applied as skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3246832|NCT01351155|Active Comparator|polyurethane film (Tegaderm)|The polyurethane film is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3259392|NCT01470443|Active Comparator|GEMOX|"Gemcitabine 1,000 mg/㎡, day 1 and 8, every 3 weeks~Oxaliplatin 100 mg/㎡, day 1, every 3 weeks"
3246833|NCT01351155|Active Comparator|Hydrocolloid (Duoderm)|Hydrocolloid is applied ss skin protective dressing device before NIV and kept on site till the 7th day of treatment Intervention: active prophilactic barrier against skin breakdown
3246834|NCT01351155|No Intervention|Control|In this no-intervention arm, any skin protective dressing devices is applied before NIV starting
3246835|NCT01351168|Placebo Comparator|Sugar pill|
3358192|NCT05143320||Covid+|
3358193|NCT05143320||Covid-|
3358194|NCT05143307|Experimental|Long Term Follow Up|Participants who received EBT-101 in a previous intervention study will undergo long term follow up
3246836|NCT01351168|Active Comparator|Levodopa|
3246837|NCT01351168|Experimental|Zolpidam second dose|
3246838|NCT01351168|Experimental|Zolpidam first dose|
3246839|NCT01351181|Experimental|Exercise advice|Behavioural
3358195|NCT05143294|Experimental|Modern board and card games group|The program consisted of 12 one-hour intervention sessions. The sessions were biweekly with a total duration of 6 weeks. The modern board and card games used in the program were Bee Alert (Knizia, 2012), Monster Match (Gruhl & Weir, 2018), Kaleidos Junior (Albertarelli, 1997), Sherlock Express (Kermarrec, 2019), Alles Kanone! (Knizia, 2007), Halli Galli (Shafir, 1990), Bananazul (Warsch, 2019), Blurble (Bernard, 2013), La Morada Maldita (Ortiz, 2020), Dice Academy (Gobert, 2019) and Streams (Itsubaki, 2011). Play sessions will be held in subgroups of 3-5 children within the class group. In each session, each subgroup will play two games. The games used in the program have an average duration of approximately 20-30 minutes (filler games). All subgroups will play all games in the program the same number of times with the same rules. The game program will be the same in all participating centers to guarantee the homogeneity of its implementation.
3358196|NCT05143294|No Intervention|Wait-list group|Wait-list. They will do the usual classes without modern board games. At the end of the post-intervention evaluation, the Conectar Jugando game program will be implemented under the same conditions as the experimental group.
3358197|NCT05143281|Experimental|Dexamethasone Ophthalmic Insert|Day of surgery, in OR placement vs. Day 1 Post-Op, In-office (HOPD)
3358198|NCT05143268||A|In the experimental arm (arm A), a total of 11 sessions of acupuncture will be performed on a weekly basis, spanning from 2 weeks before Radiotherapy start throughout 7 weeks of treatment, to 2 weeks after its completion. Patients randomized to the experimental arm will receive acupuncture in addition to standard of care treatment, chosen by the treating multidisciplinary team in accordance with international guidelines.
3358199|NCT05143268||B|In the standard arm (arm B), patients will be treated with standard of care treatment.
3358200|NCT05143255|Experimental|KNOW Intervention|
3358201|NCT05143242|Active Comparator|Guided bone regeneration: Control|Deproteinized bovine derived xenograft (Geistlich Bio-Oss® 0.25 - 1 mm, Geistlich Pharma AG, Wolhusen, Switzerland)
3358202|NCT05143242|Active Comparator|Connective tissue graft: Test|Connective tissue graft harvested from the palate
3246840|NCT01351181|Other|Normal Care|Normal care
3246841|NCT01351194|Experimental|RFA group|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3246842|NCT01351194|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
3246843|NCT01351207|Active Comparator|pork sausages and hash brown potatoes plus eggs|
3246844|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes plus egg-free pudding|
3246845|NCT01351207|Placebo Comparator|pork sausages and hash brown potatoes|
3246846|NCT01351220|Active Comparator|Basic dissemination|
3358203|NCT05143229|Experimental|Dose level 1: alpelisib 250 mg plus sacituzumab govitecan 8 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 8 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
3358204|NCT05143229|Experimental|Dose level 2: alpelisib 250 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 250 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
3358205|NCT05143229|Experimental|Dose level 3: alpelisib 300 mg plus sacituzumab govitecan 10 mg/kg|Alpelisib: 300 mg by mouth daily Sacituzumab govitecan: 10 mg/kg intravenous on days 1 and 8 of each 21 (+/-2) day cycle
3358206|NCT05143216||Chronic subdural haematoma post burr-hole drainage|Chronic subdural haematoma post burr-hole drainage
3358207|NCT05143203||Staff trained in October 2021|22 nursing staff will follow two days of Self-Hypnosis training in October 2021
3358208|NCT05143203||Staff trained in May 2021|22 nursing staff will follow two days of Self-Hypnosis training in May 2021
3246847|NCT01351220|Active Comparator|Organizational dissemination|
3246848|NCT01351246|Experimental|Intervention|
3246849|NCT01351259|Experimental|Pneumatic device, tapered cuff|Intervention: continuous control of cuff pressure using a pneumatic device, tapered polyurethane cuff
3246850|NCT01351259|Experimental|Pneumatic device, cylindrical cuff|Continuous control of cuff pressure using a pneumatic device in patients intubated with cylindrical polyurethane cuffed tracheal tubes
3246851|NCT01351259|Active Comparator|Routine care, tapered cuff|Routine care of cuff pressure using a manometer, tapered polyurethane cuff
3246852|NCT01351259|Active Comparator|Routine care, cylindrical cuff|Routine care of cuff pressure using a manometer, cylindrical polyurethane tracheal cuff
3246853|NCT01351272|Experimental|methylphenidate, non-retard|
3246854|NCT01351285|Experimental|Sevo group|undergoing sevoflurane-remifentanil anesthesia
3246855|NCT01351285|Active Comparator|Des group|undergoing desflurane-remifentanil anesthesia
3246856|NCT01351285|Active Comparator|Pro group|undergoing propofol-remifentanil anesthesia
3246857|NCT01351298|Placebo Comparator|Saline spray|
3246858|NCT01351298|Experimental|Decongestant|
3246859|NCT01351298|Experimental|Decongestant and local anesthetic|
3358209|NCT05143203||Control staff without training|22 nursing staff will not follow any training
3358210|NCT05143190|Experimental|PTR-01|All patients will receive a PTR-01 dose of 3.0 mg/kg once weekly every week for a total of 4 doses, followed by a dose of 3.0 mg/kg once monthly for a total of 5 doses.
3246860|NCT01351311|Experimental|Exercise Group|Resistance exercise with swiss ball and drug treatment
3246861|NCT01351311|Other|Control Group|Drug treatment
3246862|NCT01351324|Experimental|SFA|Oral dose of palmitic acid (SFA) given as a chocolate-flavoured drink every 30 min (0-390 min) with a continuous infusion of heparin (60-390 min).
3246863|NCT01351324|Experimental|SFA + LC n-3 PUFA|Oral dose of palmitic acid and DHA-rich fish oil (SFA + LC n-3 PUFA) given as a chocolate-flavoured drink every 30 min (0-390 min) together with a continuous infusion of heparin (60-390 min).
3246864|NCT01351363|Experimental|Electrical pain threshold measrement patients|
3246865|NCT01351389|Active Comparator|Brief Motivational Intervention (BMI)|
3358211|NCT05143177|Placebo Comparator|Placebo|
3358212|NCT05143177|Active Comparator|DA-1229 5mg|
3246866|NCT01351389|Active Comparator|Brief Advice|
3246867|NCT01351428|Experimental|NICOM group|Vasodilator therapy begins when SVR increases by 20% or greater than baseline. Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
3358213|NCT05143177|Active Comparator|DA-1229 10 mg|
3358214|NCT05143164|Experimental|Hydrocolloid dressing|The intervention group will use the weekly hydrocolloid dressing (Duoderm Extra Thin CGF dressing,10 x 10 cm) for peritoneal dialysis exit-site care
3358215|NCT05143164|Active Comparator|Gentamicin cream|The control group will apply topical gentamicin cream to catheter exit site daily and cover with normal dressing
3358216|NCT05143151|Experimental|Treatment group|CD276 targeted chimeric antigen receptor cells treatment
3246868|NCT01351441|Other|Age 65 years or over AND at least 5 chronic medications|
3246869|NCT01351454|Active Comparator|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
3246870|NCT01351454|Placebo Comparator|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
3246871|NCT01351467||Parkinson's disease patients|People diagnosed with Parkinson's disease by a physician
3246872|NCT01351493|Active Comparator|Nitric oxide gel|
3246873|NCT01351493|Placebo Comparator|placebo|
3358217|NCT05143138||fEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a fenestrated stent graft to allow endovascular aneurysm repair
3358218|NCT05143138||bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched stent graft to allow endovascular aneurysm repair
3358219|NCT05143138||fEVAR and bEVAR|Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent in conjunction with a branched and fenestrated stent graft to allow endovascular aneurysm repair
3358220|NCT05143125|Experimental|Treatment group|Decitabine combined with NK cell infusion as post-remission therapy
3358221|NCT05143112|Experimental|Treatment group|Allogeneic CD19 CR-T cell infusion
3246874|NCT01351519|Experimental|Aminolevulinic Acid (AL)|
3246875|NCT01351532|Experimental|Lifestyle counseling, smoking cessation drug|
3246876|NCT01351532|Active Comparator|Lifestyle counseling|
3246878|NCT01351558|No Intervention|Control|No intervention for 12 weeks
3246879|NCT01351558|Active Comparator|Knee muscle strengthening exercises|
3246880|NCT01351558|Active Comparator|Upper extremity strengthening exercises|
3246881|NCT01351558|Active Comparator|Cardiovascular fitness exercises|
3246882|NCT01351571||Cohort|
3246883|NCT01351597|Experimental|docetaxel/ oxaliplatin|All the patients are recurrent or metastatic breast cancer. Patients with a measurable lesion.
3246884|NCT01351610|Experimental|Group B|
3246885|NCT01351610|Experimental|Group A|
3246886|NCT01351636|Experimental|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride
3246887|NCT01351636|Placebo Comparator|Non arotinolol group|Antihypertensive medications without arotinolol hydrochloride
3246888|NCT01351649|Other|attention control|Sessions with school nurse to discuss health-promoting topics and after-school health-promoting workshop. Physical activity and healthy eating were not addressed.
3246889|NCT01351649|Experimental|physical activity|
3246890|NCT01351662|Experimental|Self management program|"The Arthritis Self-Management Program (ASMP) will be administered to 15 African American lupus patients participating in an ongoing SLE Clinic Database Project at the Medical University of South Carolina (MUSC). Fifteen other patients will serve as controls and receive usual care."
3246891|NCT01351675|Placebo Comparator|Placebo|
3358222|NCT05143099|Experimental|1|tirelizumab combined with cetuximab and irinotecan
3358223|NCT05143086|Placebo Comparator|Placebo|Mouthwash without fluoride.
3358224|NCT05143086|Active Comparator|Mouthwash standard|Mouthwash with 225ppm sodium fluoride (NaF). Positive control.
3358225|NCT05143086|Experimental|Mouthwash 50% Nano-F|Mouthwash experimental with Fluoride being half of fluoride Nanoencapsulated and other half freeform of NaF.
3358226|NCT05143086|Experimental|Mouthwash 100% Nano-F|Mouthwash experimental with fluoride 100% Nanoencapsulated.
3358230|NCT05143060|Experimental|Cereal fiber powder|Cereal fiber powder
3358231|NCT05143060|Placebo Comparator|Pure glucose powder|Pure glucose powder
3358232|NCT05143047|No Intervention|Control|Participants in the usual care group will receive standard-of-care discharge communications per unit routine, including counseling regarding prescribed medications and post-discharge instructions, return precautions, and follow-up appointments by the pediatric nursing staff.
3358233|NCT05143047|Experimental|Intervention|Participants in the intervention group will receive supplementary medication discharge instructions in addition to the standard communications. They will receive instructions on how to submit information and complete study surveys securely through their cellphones during their child's home treatment period.
3358237|NCT05143008|Experimental|SMART Intervention|Counseling sessions will be completed with a toolbox approach so that clinicians can work on topics that are of interest and relevant to each participant. SMART will focus on weight, physical activity, eating and psychosocial issues. Intervention goals will emphasize adherence to healthy behaviors rather than absolute weight goals. Specifically, women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
3358238|NCT05142982|Experimental|Radiotherapy|Patients randomized to the test arm will undergo radiotherapy to the residual mass. Patients will be stratified by the size of the residual mass in shortest dimension being <3 cm or > 3 cm.A dose of 30-36 Gy in conventional fractionation of 1.8-2.0 Gy per fraction using 3-dimensional conformal technique. Radiotherapy will be delivered five days a week.
3358239|NCT05142982|No Intervention|Observation|Patients randomized to the standard arm will be observed and the status of residual mass monitored with an FDG PETCT scan done at three to six monthly intervals.
3246892|NCT01351675|Experimental|Bardoxolone Methyl|
3246893|NCT01351688|Experimental|AZD3514|Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
3246894|NCT01351714|Other|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
3246895|NCT01351727||Seniors with Seizures|Seniors aged 65 or older with newly diagnosed seizures (consistent with epilepsy) or epilepsy as of October, 2010.
3246896|NCT01351779||Progressive glaucoma|Patients with primary open angle glaucoma identified to have an optic disc hemorrhage
3246897|NCT01351792|Experimental|Foster®|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
3246898|NCT01351792|Active Comparator|Symbicort® Turbohaler®|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
3358242|NCT05142956||Smokers|Current smokers are defined as cigarettes smoking within one year before surgery.
3358243|NCT05142943|Experimental|Visual Illusion (VI and therapeutic exercise program (EP)|"the patient will be seated in a chair with a table in front of it. The front part of the trunk will be covered with a black blanket that will be attached to the table. On the table, you will see arms and hands projected performing different types of functional manual activities that will include mobility and strength tasks. The projected arms will be adapted to the dimensions of each subject so that the patient can recognize the projected arms as theirs. This program will last 10 minutes. Then a physical exercise program for the upper extremities will be carried out:~General mobility and warm-up: flexion-extension joint movements, rotations, deviations, abduction-adduction, etc.~Gross mobility and coordination: ball games.~Fine mobility and coordination: writing tasks, puzzles, abacus ...~Strength exercises: shoulder, elbow, wrist, fingers.~Stretching."
3358244|NCT05142943|Sham Comparator|VI sham and EP|the configuration of the work table will be the same as in real IV, although videos of landscapes will be projected on them without any type of human or animal movement appearing on them. This program will last 10 minutes. Afterwards, a physical exercise program for the upper extremities will be carried out, detailed in Arm I.
3358245|NCT05142943|Experimental|VI|only the visual illusion program will be carried out, detailed in Arm I.
3358246|NCT05142943|Sham Comparator|VI sham|
3246899|NCT01351818||Growth hormone|Patients with a condition
3246900|NCT01351831|Experimental|Rehabilitation with strength training|
3246901|NCT01351831|Active Comparator|Rehabilitation without strength training|
3259393|NCT01470443|Experimental|XELOX|Xeloda, 1000mg/㎡ bid, day 1-15, every 3 weeks Oxaliplatin 130mg/㎡, day 1, every 3 weeks
3358247|NCT05142930|Active Comparator|Intermittent ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Intermittent ultrasound will be used as a physical therapy agent. Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
3358248|NCT05142930|Active Comparator|Continuous ultrasound|Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Continuous ultrasound will be used as a physical therapy agent. Continuous ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
3358249|NCT05142917|Experimental|fNIRS based hand motor area real stimulation|Real stimulation is applied to functional brain image-based hand function area (20 minutes) and then hand motor task (18 minutes).
3358250|NCT05142917|Active Comparator|Traditional hand motor area real stimulation|Real stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (18 minutes).
3358251|NCT05142917|Sham Comparator|Traditional hand motor area sham stimulation|Sham stimulation is applied to the traditional hand function area (20 minutes) and then hand motor task (18 minutes).
3358252|NCT05142904|Experimental|Radiofrequency ablation|Patients allocated to the radiofrequency ablation (RFA) arm will undergo RFA under local anaesthesia with the moving-shot technique.
3358253|NCT05142904|Active Comparator|Radioactive iodine, study protocol|Patients allocated to this arm will undergo treatment with radioactive iodine (I-131) according to a standardized dose-calculation.
3358254|NCT05142904|Other|Radioactive iodine, cohort|This group contains patients who are not randomized and have given informed consent undergo treatment with radioactive iodine (I-131) according to local standard (e.g. fixed dose or dose-calculation based on iodine uptake and thyroid nodule mass).
3358256|NCT05142865|Experimental|Camrelizumab+ Chemotherapy+Apatinib|Induction stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 +Etoposide (100mg/m2 IV continuously on Day 1, 2 and 3）+Carboplatin（AUC 5 mg/mL/min IV on Day 1) or Cisplatin(25mg/m2，continuously on Day 1, 2 and 3) Q3W for 4-6 cycles; Maintenance stage：Camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally, once daily in 21-day cycle .
3358257|NCT05142852|Experimental|Extracorporeal shock wave therapy|The participants in the experiment group received 5 consecutive sessions of ESWT for 5 minutes. Treatment parameters for the shock wave therapy group were set similar to a previous study (Devrimsel et al., 2013) 2000 shock waves with 1.6 bar intensity and 16 Hz frequency were applied for five sessions using the Swiss DolorClast Master (EMS, Nyon, Switzerland). All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
3358258|NCT05142852|Active Comparator|Conventional physiotherapy|The participants in the control group received 5 sessions of conventional physical therapy intervention for 5 minutes. The control group intervention consists of a 1-minute friction massage over the common extensor tendon of the elbow, followed by 3 minutes therapeutic ultrasound with a frequency of 1.5 Hz, and a 1-minute ice massage over the common extensor tendon of the elbow. All participants used 10-cm lateral epicondyle bandages in the treatment period, while none of them received analgesic or anti-inflammatory drugs and received exercise programs.
3358259|NCT05142839|Experimental|EUS-CD|EUS-guided choledochoduodenostomy
3358260|NCT05142839|Experimental|EUS-GEA|EUS-guided gastroenterostomy
3358261|NCT05142826|Active Comparator|School as Usual|
3358262|NCT05142826|Experimental|Immediate Relative Age Effect Intervention|
3358263|NCT05142826|Experimental|Delayed Relative Age Effect Intervention|
3358264|NCT05142800||Target Therapy Drug-Stand Care|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
3358265|NCT05142800||Target Therapy-Early or Metastatic Breast Cancer|"Screening procedures confirm participation in the research study.~Participants limb volume is measured prior to treatment start date.~Participant is provided informational brochure about risk of lymphedema and Lymphedema Screening Program Card.~Perometer and SOZO measurements will be incorporated as a part of the follow-up visits throughout the course of their trial and for at least 6 months beyond their last dose of trial medication"
3246902|NCT01351844|Active Comparator|Education and exercise intervention|"The intervention module will contain a brief series of slides with a voice-over. An occupational therapist will review recommended exercises."
3246903|NCT01351844|Placebo Comparator|Education and general exercise|"The control module will contain a brief series of slides with a voice-over. A physical therapist with experience in treating breast cancer patients will demonstrate a series of 4-5 general stretching and toning exercises."
3246904|NCT01351857|Other|Transition Coordinator|A Transition Coordinator, a Certified Diabetes Educator, will provide transition support and the link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
3246905|NCT01351857|No Intervention|Current Standard of Care|Subjects in the control group will transition to adult care equal to the intervention group and will differ only by exclusion of Transition Coordinator. Control group will receive the current standard of diabetes care otherwise unchanged. Three months following randomization, subjects in the control group will be referred to the adult endocrinologist in the same way as subjects in the intervention group
3246906|NCT01351870|Active Comparator|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
3358266|NCT05142787|Other|axillary lymph nodes requiring localisation prior to surgical excision|"The Magseed Pro® marker is intended to be placed percutaneously in suspicious/biopsy proven positive axillary lymph nodes under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
3358267|NCT05142787|Other|breast lesions requiring localisation|"The Magseed Pro® marker is intended to be placed percutaneously in breast lesions under imaging guidance to mark tissue intended for selective surgical removal.~The Magseed Pro® marker is localised using the Sentimag® Gen3 system handheld probes and surgically removed within/from the target tissue."
3358268|NCT05142774|Experimental|tapinarof cream|Tapinarof 1%, cream
3246907|NCT01351870|Experimental|Hyperfractionated radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
3246908|NCT01351883|No Intervention|Standard enteral nutrition supplement|regular standard enteral nutrition(SEN) was made by hospital for patient
3259394|NCT01470456|Experimental|SAR3419 + Rituximab|Combined therapy will be administered intravenously for 8 doses in the absence of unacceptable toxicity, disease progression or withdrawal of consent.
3358270|NCT05142735|Experimental|Experimental|N-Acetylcysteine 2000 mg (4 x 500-mg tablets) orally every morning for 8 weeks
3358271|NCT05142735|Placebo Comparator|Placebo Comparator|N-Acetylcysteine Placebo tablet matching N-Acetylcysteine orally every morning for 8 weeks
3358272|NCT05142722|Placebo Comparator|Placebo|one placebo tablet once daily
3358273|NCT05142722|Experimental|obicetrapib 10mg|one 10mg obicetrapib tablet once daily
3358274|NCT05142709||ESCC patients treated with anti-PD-1 immunotherapy as 1st line treatment.|
3358275|NCT05142592|Experimental|Cohort 1|1~6 subjects in this cohort will receive IPG7236 50 mg bid orally.
3358276|NCT05142592|Experimental|Cohort 2|3~6 subjects in this cohort will receive IPG7236 100 mg bid orally.
3358277|NCT05142592|Experimental|Cohort 3|3~6 subjects in this cohort will receive IPG7236 150 mg bid orally.
3358278|NCT05142592|Experimental|Cohort 4|3~6 subjects in this cohort will receive IPG7236 200 mg bid orally.
3358279|NCT05142592|Experimental|Cohort 5|3~6 subjects in this cohort will receive IPG7236 250 mg bid orally.
3358280|NCT05142592|Experimental|Cohort 6|3~6 subjects in this cohort will receive IPG7236 300 mg bid orally.
3358281|NCT05141331|Experimental|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges|Piezoelectric split-crest technique in treatment of Maxillary Narrow Ridges
3358282|NCT05141331|Active Comparator|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges|Hand Driven Ridge Expanders in treatment of Maxillary Narrow Ridges
3358284|NCT05139303|Experimental|MAD therapy|
3358285|NCT05139225|Experimental|TTI-621 + Daratumumab Hyaluronidase-fihj|
3358286|NCT05139225|Experimental|TTI-622 + Daratumumab Hyaluronidase-fihj|
3358287|NCT05135377||Children with Anaphylaxis|Patients under 18 years of age presenting to the Emergency Department (ED) with an allergic reaction that matches diagnostic criteria for anaphylaxis.
3358288|NCT05134675||Consumption|Patients consuming homemade beer
3358289|NCT05134675||Not consumption|Patients are not consuming homemade beer
3358290|NCT05131412||mesenchymal stromal cell|Patients treated with mesenchymal stromal cell
3358291|NCT05131412||non-mesenchymal stromal cell|Patients treated without mesenchymal stromal cell
3358294|NCT05129839|Experimental|Lightened and Musical Baby Mobile Group|The children in the study group were applied a lightened and musical baby mobile before sleeping at night.
3358295|NCT05129839|No Intervention|Control Group|The children in the control group were not given lightened and musical baby mobile, and their routine sleep patterns were continued.
3358296|NCT05129761||• Patient with a clinical history of cough|Syrup Hydryllin ( Syrup Hydryllin & Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan & Diphenhydramine) in the symptomatic management of cough in routine practice by physicians. Subjects will be observed for overall safety and effectiveness of study drug from visit 1 (baseline visit, screening, and start of treatment), to visit 2 (Week 1-2, end of treatment) in the routine practice.
3358297|NCT05129384|Active Comparator|Treatment|B. infantis EVC001 infant probiotic
3358298|NCT05129384|Placebo Comparator|Placebo|Lactose
3358299|NCT05129202||Chemotherapy alone or chemotherapy combined with anti-angiogenesis|patients with Chemotherapy
3358300|NCT05129202||immuntherapy|patients with immune checkpoint inhibitor
3358301|NCT05129163|Placebo Comparator|Exercise|The control group received weekly one-hour group exercise training for 3 months.
3358302|NCT05129163|Experimental|Exercise and nutrition|The intervention group had weekly one-hour group exercise training the same as the control and an additional weekly one-hour group nutrition session for 3 months.
3358303|NCT05128682|Other|Urodynamic testing with and without pudendal nerve stimulation|"The neuromodulation settings of the implanted device will be adjusted to deliver acute simulation. Urodynamic testing (UDT) will be completed by filling the bladder and observing for urinary leakage. The assessment will be completed with the stimulation sets turned off and then turned on. At the end of the UDT the settings will be returned to the previously set therapeutic values. The neuromodulation settings constitute the dose and can include the voltage/current amplitude, frequency, pulse width, on time/off time duration and electrode polarity assignments. These parameters are limited by the available ranges of the approved neurostimulation device and will be adjusted during the study by the principal investigator to stay within the safe and comfortable levels for each individual study subject."
3358304|NCT05128266||Endodontical Retreatment|non-surgical retreatment of teeth with broken file instrument into the canal using ultrasounds, microscope and a modified spinal needle
3358305|NCT05127954|Experimental|Adolescents Ubrogepant Dose A|Participants aged 12 to 17 will receive oral tablets of ubrogepant Dose A for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
3358306|NCT05127954|Experimental|Children Ubrogepant Dose B|Participants aged 6 to 11 will receive the highest dose of oral tablets of ubrogepant tested in Study 3110-305-002 for qualifying migraine attack. Participants have the option to take a second dose of ubrogepant or rescue medication, 2 to 24 hours after initial dose for headache of any intensity.
3358307|NCT05127538|Active Comparator|Individuals diagnosed with neuropathic pain due to type 2 diabetes|"Individuals between the ages of 40-65~Individuals who take 4 points or more from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points or more from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
3358308|NCT05127538|Active Comparator|Individuals with type 2 diabetes but no neuropathic pain|"Individuals between the ages of 40-65~Individuals who take 4 points from the Douleur Neuropathique en 4 questions (DN4) questionnaire~Individuals who take 12 points from the Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) scale"
3358309|NCT05127538|Active Comparator|Healthy control group|"Individuals between the ages of 40-65~Individuals who have no pain (Taking 1 point or less according to the Visual Pain Scale)"
3358312|NCT05127382||untreated patients with advanced EGFR positive non-small cell lung cancer|
3358313|NCT05126056|Active Comparator|Active Comparator|Products that contain plant stanol ester. Product with active ingredient
3358314|NCT05126056|Placebo Comparator|Placebo comparator|Placebo product. Product without active ingredient
3358315|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fasted (Without Food)|Oral Dose
3358316|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 1 x 25 mg tablet, Fed (With food)|Oral Dose
3358317|NCT05123079|Experimental|Single Oral Dose of 25 mg administered as 2 x 7.5 and 2 x 5.0 mg tablets, Fasted (Without Food)|Oral Dose
3358318|NCT05122689|Experimental|Nitrate|Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
3358319|NCT05122689|Placebo Comparator|Control|Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
3246909|NCT01351896|Experimental|Arm A (Concurrent PCV13 and lenalidomide)|Patients receive low-dose lenalidomide PO once daily on days 1-28. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive PCV13 IM on day 1 of courses 3 and 5.
3358324|NCT05122052||Women with cancer|Patients with cancer of any site and stage defined as feminine both from the biological (female sex) and psychosocial point of view (feminine gender)
3358325|NCT05122052||Men with cancer|Patients with cancer of any site and stage defined as masculine both from the biological (male sex) and psychosocial point of view (masculine gender)
3358326|NCT05121740|Experimental|Arm A: Experimental 1|In the APLICOV-PC study, patients of arm A received 1.5 mg of plitidepsin / day for 3 consecutive days (total dose 4.5 mg).
3358327|NCT05121740|Experimental|Arm B: Experimental 2|In the APLICOV-PC study, patients of arm B received 2.0 mg of plitidepsin / day for 3 consecutive days (total dose 6.0 mg).
3358328|NCT05121740|Experimental|Arm C: Experimental 3|In the APLICOV-PC study, patients of arm C received 2.5 mg of plitidepsin / day for 3 consecutive days (total dose 7.5 mg).
3358329|NCT05119335|Experimental|Phase 1 dose escalation|Phase 1 is designed to determine the maximum tolerated dose and/or identify the recommended Phase 2 dose of NKT2152 as a single agent administered orally once daily in ccRCC patients
3358330|NCT05119335|Experimental|Phase 2 dose expansion|Phase 2 will evaluate the safety, pharmacokinetics and antitumor efficacy of NKT2152 as a single agent administered orally once daily in ccRCC patients
3358331|NCT05119192||Veterans with Dysvascular Lower Limb Amputation|Self-report assessments, performance-based assessments, and optional individual interview with Veterans with dysvascular lower limb amputation.
3358332|NCT05118737|Active Comparator|colchicine|Intervention arm: colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab
3358333|NCT05118737|Placebo Comparator|Control|COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab according to local protocol
3358334|NCT05118685|Active Comparator|the first group estrogen group|they will receive estrogen conjugate vaginal cream one tube every night for 14 nights; then, one tube 2 nights in 1 week (two tubes every week) for 10 weeks.
3358335|NCT05118685|Experimental|the second group PRP group|they will receive a Platelet-rich plasma injection every 3 weeks for 4 times. PRP will be administered to the anterior vaginal wall using 27-G needles o and it is mainly injected into the anterior wall of the vagina to increase the tactile sensitivity of the injection site.
3246910|NCT01351896|Experimental|Arm B (Sequential PCV13 and lenalidomide)|Patients receive PCV13 IM on days 1 and 78 (cycles 1 and 3). Patients also receive low-dose lenalidomide as in arm 1 beginning on day 1 of course 4. Treatment repeats every 28 days for at least 24 cycles in the absence of disease progression or unacceptable toxicity.
3246911|NCT01351909|Experimental|Treatment (veliparib, cyclophosphamide)|Patients receive veliparib orally PO QD and cyclophosphamide PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3246912|NCT01351922||A|
3246913|NCT01351935|Experimental|AVL-292|
3246914|NCT01351948|Experimental|Group 1|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
3246915|NCT01351948|Experimental|Group 2|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909
3246916|NCT01351948|Experimental|Group 3|AdCh63 AMA1 + AMA1-C1/Alhydrogel®
3358345|NCT05113641|Experimental|Alkalizing Fruit and Vegetables|Participants randomized to fruit and vegetables (F+V) will receive weekly supplementation of alkalizing fruits and vegetables via home delivery in a box format. Participants will receive a 1-hour dietary counseling session in the first week from a registered dietitian (RD), either in person or via videoconference, depending on regional coronavirus disease (COVID) 19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the F+V into the participant's current diet. Intervention will last 12 months.
3358346|NCT05113641|Active Comparator|Sodium Bicarbonate|Participants randomized to the alkali therapy will receive oral sodium bicarbonate 500mg tablets three times a day, reflecting a common starting dose at clinical practice. Thereafter, decisions around dose titration for the sodium bicarbonate will then be transferred to the participant's nephrologist who will be responsible for monitoring the participants serum bicarbonate concentration with a goal of maintaining a serum bicarbonate level >22 mEq/L. Participants will receive counselling from a registered dietician (RD) as part of the standard care. Intervention will last 12 months.
3358348|NCT05111626|Experimental|Part 1 Safety Lead-in: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at different doses with mFOLFOX6 and nivolumab to determine the recommended phase 3 dose (RP3D) based on occurence of dose-limiting toxicities (DLTs), and on an evaluation of the overall safety, tolerability, and pharmacokinetics (PK).
3358349|NCT05111626|Experimental|Part 2: Bemarituzumab with mFOLFOX6 and Nivolumab|Participants will be administered bemarituzumab at the RP3D determined from Part 1 in combination with mFOLFOX6 and nivolumab.
3358350|NCT05111626|Placebo Comparator|Part 2: Placebo with mFOLFOX6 and Nivolumab|Participants will be administered placebo comparator in combination with mFOLFOX6 and nivolumab.
3358351|NCT05111301|Experimental|Basal Insulin Only (Group A)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
3358352|NCT05111301|Experimental|Multiple Daily Injections (Group B)|"2 to 4 week CGM run-in~2 to 4 week pump run-in~6 weeks Control-IQ technology use"
3358355|NCT05109442|Experimental|Escalation Phase|The Escalation phase will determine the MTD/RP2D of AFM24 in combination with atezolizumab. A traditional 3+3 design will be used to determine the RP2D.
3246917|NCT01351948|Experimental|Group 4|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909
3246918|NCT01351948|Experimental|Group 5|AdCh63 AMA1 + MVA AMA1
3246919|NCT01351961|Other|Elderly hypertensive patients with mnemonic subjective|"Elderly hypertensive patients with mnemonic subjective without dementia. Interventions :~blood sampling brain MRI Assessment of cognitive functions brain MRI and TEP cerebral Electrocardiogram and blood pressure Pulse wave velocity Quality of life questionnaire Urine sample Vascular explorations"
3246920|NCT01352000|Active Comparator|Usual Care (UC)|Receive Quitline services
3246921|NCT01352000|Active Comparator|Repeated Mailings (RM)|Receive the 8 Forever Free booklets sent by mail at regular intervals over a period of 12 months
3246922|NCT01352000|Active Comparator|Massed Mailings (MM)|Receive all 8 booklets in a single mailing
3246923|NCT01352013|Placebo Comparator|Colored olive oil|
3246924|NCT01352013|Active Comparator|Omega-3 (oil)|
3246925|NCT01352026|Experimental|Metformin|
3246926|NCT01352039|Experimental|Heparin Sodium - Eurofarma|
3246927|NCT01352039|Active Comparator|Heparin Sodium - APP Pharmaceuticals|
3246928|NCT01352052|No Intervention|waiting list assignment|6 months waiting list assignment followed by the 2-week interdisciplinary rehabilitation programme
3259395|NCT01470482|Other|No Tourniquet|We compare tourniquet or not in knee surgery
3358356|NCT05109442|Experimental|Expansion Phase|The expansion phase will collect preliminary evidence of efficacy and further confirm the safety of AFM24 in combination with atezolizumab.
3358357|NCT05109416|Active Comparator|Group A|Children will receive bupivacaine by infiltration through anterior and posterior approaches to block glossopharyngeal nerve
3358358|NCT05109416|Other|Group B|Children will receive paracetamol as analgesic post operative 10-15 mg /kg
3358359|NCT05109364|Experimental|terazosin therapy extension|Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin medication. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the alpha1- adrenergic receptor antagonist terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
3358360|NCT05107973|Experimental|intervention|in this arm of participants will be receiving the Baduajin intervention.
3358361|NCT05107973|No Intervention|control|in this arm of participants will not receive any intervention
3358362|NCT05107492|Experimental|Cohort 1|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 450mg and placebo arms.
3358363|NCT05107492|Experimental|Cohort 2|12 participants will be randomly assigned at an allocation ratio of 3:1 to the active treatment 150mg and placebo arms.
3246929|NCT01352052|Active Comparator|Intervention: interdisciplinary rehabilitation programme|A two-weeks non-residential, group-based, psycho-educative treatment course conducted by an interdisciplinary team.
3246930|NCT01352065|Experimental|BOSENTAN|
3246931|NCT01352065|Experimental|AMBRISENTAN|
3246932|NCT01352065|Placebo Comparator|PLACEBO|
3246933|NCT01352091|Experimental|Switch to Zoladex + AI for 3-2 years|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
3246934|NCT01352091|Experimental|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
3246935|NCT01352104|Experimental|waiting-intervention-course|
3358368|NCT05104671|Active Comparator|Scapular stabilization exercises|Group I (control group) will receive scapular stabilization exercises.
3358369|NCT05104671|Experimental|Thoracic manipulation.|Group II will receive scapular stabilization exercises and thoracic manipulation.
3358370|NCT05104671|Experimental|Myofascial release|Group III will receive scapular stabilization exercises and myofascial release by instrument assisted soft tissue mobilization techniques.
3246936|NCT01352130|Active Comparator|Ondansetron|Patients given Ondansetron
3246937|NCT01352130|Active Comparator|Granisetron|Patients given Granisetron
3358376|NCT05099159|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
3358377|NCT05099159|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
3246941|NCT01352208|Experimental|ASP9521|
3246942|NCT01352234|Experimental|Group A|Acetylsalicylic Acid 160mg administered at bedtime
3246943|NCT01352234|Active Comparator|Group B|Acetylsalicylic Acid 80mg administered at bedtime
3246944|NCT01352247|Experimental|Unicompartmental Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure."
3246945|NCT01352247|Experimental|Total Knee Replacement|"TOPKAT will be pragmatic in terms of implant selection for the knee replacement operation. Providing the inclusion criteria are met, surgeons will be entirely free to use an implant of their choice or will use the current implants used at their institution. Implant type used on each patient will be recorded.~A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position."
3246946|NCT01352260||Cardiac Disease|Total Aortic Arch Replacement
3358378|NCT05096429|Experimental|Intervention|Within these cities/towns, the health department will work with stakeholders to prioritize overdose prevention interventions to neighborhoods with the highest probability of future overdose deaths, as predicted by the PROVIDENT model.
3358379|NCT05096429|No Intervention|Control|Cities/towns assigned to the control arm will continue to work with the health department and distribute these interventions at existing resource levels, but without receiving information on predicted probability of overdose risk for specific neighborhoods.
3358381|NCT05093972|Experimental|Panel A: Mild HI|Participants with mild HI receive a single oral dose of MK-8507 400 mg on Day 1.
3358382|NCT05093972|Experimental|Panel B: Moderate HI|Participants with moderate HI receive a single oral dose of MK-8507 400 mg on Day 1.
3358383|NCT05093972|Active Comparator|Panel C: Healthy Controls|Healthy matched control participants receive a single oral dose of MK-8507 400 mg on Day 1.
3358386|NCT05091736|Experimental|Subject glucometer measurement|
3358387|NCT05086978||Heart Failure out-patients|Subjects with heart failure of any etiology
3358388|NCT05086978||Heart Failure in-patients|Subjects with heart failure of any etiology
3358395|NCT05086263|No Intervention|Standard of Care (No VR) Randomization|Participants would take the same questionnaires as the VR interventional group except the RT questionnaire. Then they will proceed with their MRI.
3358396|NCT05086263|Experimental|VR Randomization|The virtual reality MRI training will be conducted immediately after completion of the questionnaires in a distraction free room. The training explains the procedure to the viewer and addresses common questions that individuals often have regarding an MRI. Using audio/visual cues and biofeedback training is aimed to mimic the experience of the MRI with real audio recordings of image acquisition, in order to adequately train the view to stay still in an MRI procedure. The research subject will continue with their regularly scheduled MRI. The modified Yale Preoperative Anxiety Scale (mYPAS) is an observational measure and will be completed by research staff.
3246947|NCT01352273|Experimental|MEK162 + RAF265|
3246948|NCT01352299|Active Comparator|Macintosh|Laryngoscopy performed with Macintosh Laryngoscope
3358405|NCT05073952|Active Comparator|Connective tissue graft|patient in this group will be treated with a flap and a connective tissue graft at the moment of implant placement.
3358406|NCT05073952|Active Comparator|Flapess|patient in this group will be treated with a flapless approach at the moment of implant placement.
3358411|NCT05070728|Sham Comparator|Sham Comparator|sham injection
3358412|NCT05070728|Active Comparator|FAI insert (0.05 mg fluocinolone acetonide)|FAI insert (0.05 mg fluocinolone acetonide)
3358413|NCT05064644|Active Comparator|Plant stanol ester comparator|Product that contains plant stanol ester
3358414|NCT05064644|Placebo Comparator|Placebo comparator|Placebo product
3358415|NCT05063734|Experimental|Part A, THR-687 dose level 1|
3246949|NCT01352299|Active Comparator|McCoy|Laryngoscopy performed with MacCoy Laryngoscope
3358416|NCT05063734|Experimental|Part A, THR-687 dose level 2|
3358417|NCT05063734|Experimental|Part B, treatment naïve subjects, THR-687 selected dose level|
3358418|NCT05063734|Active Comparator|Part B, treatment naïve subjects, aflibercept|
3358419|NCT05063734|Experimental|Part B, previously treated subjects, THR-687 selected dose level|
3358420|NCT05063734|Active Comparator|Part B, previously treated subjects, aflibercept|
3358422|NCT05061966|Active Comparator|Online Resource website|The comparator is a website that includes a list of freely available web-based resources for sexual and gender minority youth.
3358423|NCT05061966|Experimental|immi|The intervention is a novel and scalable web application designed to provide sexual and gender minority youth with tools for affirming their identity and coping with minority stress.
3246950|NCT01352299|Active Comparator|Miller|Laryngoscopy performed with Miller Laryngoscope
3246951|NCT01352299|Active Comparator|TrueView|Laryngoscopy performed with TrueView Laryngoscope
3246952|NCT01352312|Experimental|Treatment (pentostatin, bendamustine, ofatumumab)|Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, pentostatin IV on day 1, and ofatumumab IV on day 2. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3246953|NCT01352325|Experimental|system constellations seminar (exp. group)|Study participants randomized to this group receive the intervention (system constellation seminar) 4 months prior to the control group
3246954|NCT01352325|Experimental|system constellations seminar (control group)|Study participants randomized to this group receive the intervention (system constellations seminar) 4 months after the experimental group.
3246955|NCT01352338|Experimental|lenalidomide, endoxan, prednisone|"lenalidomide 25mg, oral therapy, once a day, 4 weeks cycles. Lenalidomide is used 3 of the 4 weeks.~Lenalidomide is combined with endoxan and prednisone"
3246956|NCT01352351|Experimental|Breastfeeding promotion intervention|"Intervention:~Group breastfeeding counseling during monthly microcredit borrower group meetings~Weekly cell phone messages about breastfeeding"
3358432|NCT05055024|Experimental|NLS-2 (mazindol extended release)|NLS-2 (mazindol extended release) administered once a day.
3358433|NCT05052801|Experimental|Bemarituzumab with mFOLFOX6|
3358434|NCT05052801|Active Comparator|Placebo with mFOLFOX6|
3246957|NCT01352351|No Intervention|No intervention|The no intervention group will participate in their regular microcredit borrower group meetings, but will not receive breastfeeding counseling or cell phone messages.
3246958|NCT01352364|Experimental|deaf children|
3246959|NCT01352390|Active Comparator|Control Condition|A basic reminder mailing will prompt each subject to receive a health test as specified on the mailing
3246960|NCT01352390|Experimental|Artwork Prompt Condition|A basic reminder mailing will prompt each subject to give their child a reminder postcard to color
3246961|NCT01352403|Other|intensive life style intrvention|intensive life style intervention over 18 months including movement, psychological meetings and change in food intake
3246962|NCT01352403|Other|gastric bypass|
3246963|NCT01352429||Phase 1 Feasibility|
3246964|NCT01352429||Phase 2 Registration|
3246965|NCT01352455|Experimental|5 days per week hemodialysis|5 days per week, 2 hours 20 minutes per session versus 3 days per week, 4 hours per session
3358446|NCT05048264|Active Comparator|Kenalog 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Kenalog in the index shoulder.
3358447|NCT05048264|Active Comparator|Dexamethasone 4 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 4 mg corticosteroid injection of Dexamethasone in the index shoulder.
3246966|NCT01352481|Experimental|Intervention group|
3246967|NCT01352481|No Intervention|Control group|
3246968|NCT01352494|Experimental|docetaxel/gemcitabine|All the patients are locally advanced breast cancer. Patients with a measurable lesion at chest CT. (at least 1 measurable lesion)
3358448|NCT05048264|Active Comparator|Celestone 6 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 6 mg corticosteroid injection of Celestone in the index shoulder.
3358449|NCT05048264|Active Comparator|Depo-medrol 40 mg|Thirty-one subjects will be randomized to this arm. Each subject randomized to this arm will receive one 40 mg corticosteroid injection of Depo-Medrol in the index shoulder.
3358450|NCT05046847|Experimental|TQB3811|The initial dose is 2.5mg, once a day (QD), and the medication stage is divided into single administration and continuous administration. The single administration is given once a day, and the continuous administration is entered 4 days after drug withdrawal. The drug is administered continuously until the disease progresses.
3358451|NCT05045313|Experimental|The DDI of DBPR108 and Warfarin Sodium Tablets|Subjects will receive a single dose of Warfarin sodium 5 mg on Day 1, then take DBPR108 100 mg once-daily on Day 15 through Day 26 and a single dose of Warfarin sodium 5 mg on Day 19.
3358452|NCT05045313|Experimental|The DDI of DBPR108 and Digoxin Tablets|Subjects will receive a single dose of Digoxin 0.25 mg on Day 1, then take DBPR108 100 mg once-daily on Day 6 through Day 15 and a single dose of Digoxin 0.25 mg on Day 10.
3358453|NCT05045313|Experimental|The DDI of DBPR108 and Probenecid Tablets|Subjects will receive a single dose of DBPR108 100 mg on Day 1, then take Probenecid 500 mg twice-daily on Day 5 through Day 9 and a single dose of DBPR108 100 mg on Day 7.
3358456|NCT05042466|Experimental|Plant Medicine On Boarding|The participant will partner with psychiatrist to reduce SSRI's and on-board psilocybin, every other day dose of 1 gram to 1.5 grams .Study Status, Oversight, Study Design, Outcome Measures, Eligibility, and informed consent will all be metrics of this study.
3358457|NCT05042466|Experimental|Participant|1gram to 1.5 grams psilocybin
3246972|NCT01352559|Experimental|responders|50 ≤ Decrease rate(%) of HAM-D score
3358458|NCT05042466|Experimental|Psychiatrist|Psychiatrist QC scaling back SSRI's replacing with psilocybin.
3358459|NCT05042466|Experimental|On-Boarding Plant Medicine Specialist|The On-Boarding Provider will control dosage of the plant medicine.
3358462|NCT05041023||Relative volunteers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been discussed with the relatives, a relative can be included after information and acceptance of the study. One relative per situation can be included : the most involved personn in the relationship with the resuscitation team.
3358463|NCT05041023||Caregivers|For each situation of death of a patient in ICU following a decision to withdraw LST and for which OD has been considered, 2 to 3 caregivers who are present at the time the WLST is initiated can be included (1 physician and 1 or 2 paramedics).
3358464|NCT05040048||Parkinson's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Motor and non motor assessments for Parkinson's disease group only.
3358465|NCT05040048||Alzheimer's disease Group|Blood, cerebrospinal fluid (CSF) and skin biopsy samples. Neuropsychological assessment. Brain MRI for Alzheimer's disease group only.
3358466|NCT05038163|No Intervention|Control Arm|In Part II of the experiment, subjects are not presented with nutrition or warning labels when choosing between beverages.
3246973|NCT01352559|Active Comparator|non-responders|nonresponders is a patients having 50 > Decrease rate(%) of HAM-D score
3358467|NCT05038163|Experimental|Nutrition Labels Arm|In Part II of the experiment, subjects are shown enlarged nutrition labels when choosing between beverages.
3358468|NCT05038163|Experimental|Text Warning Labels Arm|In Part II of the experiment, subjects are shown a warning message about the health risks of sugary beverages when choosing between beverages.
3358469|NCT05038163|Experimental|Graphic Warning Labels Arm|In Part II of the experiment, subjects are shown a graphic warning message about the health risks of sugary beverages when choosing between beverages. The message, for example, could include photos of tooth decay and other negative health outcomes.
3246974|NCT01352572|Experimental|antidepressant response|antidepressant response are refered the patients having a 50 ≤ Decrease rate(%) of HAM-D score
3246975|NCT01352572|Active Comparator|antidepressant non-response|antidepressant non-response are refered the patients having a 50 > Decrease rate(%) of HAM-D score
3246976|NCT01352611|Experimental|baclofen, intrathecal|A single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
3246977|NCT01352624|Experimental|Experimental|$teps for Achieving Financial Empowerment ($AFE)
3246978|NCT01352624|No Intervention|Usual Care|Veterans in control arm will receive usual care at VA
3246979|NCT01352650|Active Comparator|Cohort 1A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5
3259396|NCT01470482|Active Comparator|Tourniquet|We compare tourniquet or not in knee surgery
3358470|NCT05037552|Active Comparator|BIPOLAR FORCEPS|The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room.
3358471|NCT05037552|Experimental|FLOSEAL|"FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective.~During this study, it will be used in 1st intention."
3358472|NCT05036980|Experimental|0.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 0.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
3358473|NCT05036980|Experimental|1.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 1.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
3246980|NCT01352650|Active Comparator|Cohort 1B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 320 mcg/kg IV on days 1-5 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
3246981|NCT01352650|Active Comparator|Cohort 2A|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5
3358474|NCT05036980|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC. Subjects will also receive a single IV dose of normal saline as placebo, thereby serving as their own control.
3358475|NCT05036096|Experimental|CBBCT Imaging Screening Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of screening mammography.
3358476|NCT05036096|Experimental|CBBCT Imaging Diagnostic Patients|Patient undergo bilateral CBBCT imaging (or unilateral CBBCT imaging if the patient had mastectomy) within 4 weeks of diagnostic mammography.
3246982|NCT01352650|Active Comparator|Cohort 2B|Cycle 1: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 2 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 540 mcg/kg IV on days 1-5 Cycle 4 decitabine 20 mg/m2 IV daily for a 1-hour infusion on days 1-10
3358486|NCT05032274|Experimental|Single group|The study will include one group and each participant will perform home-based exercise for 8-weeks.
3358488|NCT05029427|Experimental|Study period 1: β-glucan Oat ; Study period 2: Wheat|For the first period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan. For the second period, the participant will receive food products made from wheat.
3358489|NCT05029427|Experimental|Study period 1: Wheat ; Study period 2: β-glucan Oat|For the first period, the participant will receive food products made from wheat. For the second period, the participant will receive food products made from oats containing a total of 4 grams per day HMW oat β-glucan.
3246983|NCT01352650|Active Comparator|Cohort 3A|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5
3246984|NCT01352650|Active Comparator|Cohort 3B|Cycle 1: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 2: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 Cycle 3: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10 + plerixafor 810 mcg/kg IV on days 1-5 Cycle 4: decitabine 20mg/m2 IV daily for a 1-hour infusion on days 1-10
3358502|NCT05025956|Experimental|Fisetin group (investigational group)|"20mg/kg of Fisetin per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
3358503|NCT05025956|Placebo Comparator|Placebo group (control group)|"20mg/kg of Placebo per day for days 1 and 2 prior to surgery and days 33, 34, 63, 64, 93, and 94 post surgery.~(The pills are 100mg each. For example, if a participant weighs 160 pounds (about 73 kg), the participant will need to take 15 pills per day)"
3358504|NCT05023551|Experimental|Single arm DSP-0390|Arm Description [*] DSP-0390 by oral administration
3358505|NCT05022849|Experimental|Part 1: Dose Escalation|Participants will receive a conditioning regimen of cyclophosphamide and fludarabine intravenously (IV) followed by JNJ-75229414 IV infusion escalated sequentially with a targeted dose consistent with the dose required by the cohort being enrolled to determine recommended Phase 2 dose (RP2D) regimen(s). Additional, intermediate dose levels may be implemented based on the review of all available data including, but not limited to, safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) by the study evaluation team (SET). Participants may receive bridging therapy (anti-androgen receptor agents [example, abiraterone, enzalutamide] and radiotherapy, or chemotherapy [example, docetaxel]) if clinically indicated to maintain disease stability.
3358506|NCT05022849|Experimental|Part 2: Dose Expansion|Participants will receive JNJ-75229414 for each RP2D regimen determined in Part 1.
3358508|NCT05022355||scapulothoracic arthrodesis|"Individuals diagnosed with FSHD who have undergone unilateral or bilateral surgery who meet the inclusion criteria.~application of determined outcome scales on patients"
3358509|NCT05022355||non-operative|"Participants diagnosed with FSHD who have not undergone any surgery, who meet the inclusion criteria.~application of determined outcome scales on patients"
3358510|NCT05021926|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 26
3358511|NCT05021926|Experimental|Comparator product|Juvéderm Voluma™ with lidocaine (Allergan, Inc)
3358512|NCT05021913|Experimental|Investigational device|DKL crosslinked sodium hyaluronate 23
3358513|NCT05021913|Active Comparator|Comparator product|Juvéderm Volift™ with lidocaine (Allergan, Inc)
3358514|NCT05020743||Patients with ALSP|
3358515|NCT05020743||Asymptomatic carriers of the CSF1R gene mutation|
3358516|NCT05020587|Other|Open Pilot Trial|Open pilot trial of a group therapy manual.
3246985|NCT01352663|Experimental|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
3246986|NCT01352663|Active Comparator|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
3246987|NCT01352689|Experimental|CKD-828(Fixed Dose Combination)|Single oral dose of a FDC tablet consisting of Telmisatan 80mg/S-Amlodipine 2.5mg
3246988|NCT01352689|Experimental|Free combination Therapy|Co-administration of single oral doses of a 80mg tablet of Telmisatan and a 2.5 mg tablet of S-Amlodipine
3246989|NCT01352702|Experimental|Arm 1|Dabigatran Therapy
3246990|NCT01352702|Active Comparator|Arm 2|Phenprocoumon Therapy
3246991|NCT01352728|Experimental|TACE+Axitinib|
3246992|NCT01352767|Experimental|InsuPad Device|Use of the InsuPad which heats the injection site.
3358530|NCT05006885|Experimental|ALT-801 Dose Level 1|Administered once a week for 12 weeks
3358531|NCT05006885|Experimental|ALT-801 Dose Level 2|Administered once a week for 12 weeks
3358532|NCT05006885|Experimental|ALT-801 Dose Level 3|Administered once a week for 12 weeks
3358533|NCT05006885|Placebo Comparator|Placebo|Administered once a week for 12 weeks
3358534|NCT05005975|Experimental|Dersimelagon 100mg|
3358537|NCT05003622|Experimental|encorafenib|Encorafenib hard capsule will be orally self-administered. A fixed-flat dose of 300 mg (4 x 75 mg) Per Oral (PO) encorafenib will be administered once-daily (QD).
3358538|NCT05001373|Experimental|Study Group 1|eOD-GT8 60mer mRNA Vaccine (100µg)
3246993|NCT01352767|No Intervention|CONTROL|no treatment
3358539|NCT05001373|Experimental|Study Group 2|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
3358540|NCT05001373|Experimental|Study Group 3|eOD-GT8 60mer mRNA Vaccine (100µg) and Core-g28v2 60mer mRNA Vaccine (100µg)
3358541|NCT05001373|Experimental|Study Group 4|Core-g28v2 60mer mRNA Vaccine (100µg)
3358542|NCT05001282|Experimental|ELU001|Dose Escalation: Escalating doses of ELU001 Dose Expansion: Recommended Dose for Expansion (or RP2D)
3358544|NCT04995796|Experimental|Enrolled Participants|Study participation will involve 2 visits. The first visit will take approximately 90 minutes, but may be longer if participant desires longer interaction with the DSI/DA. The second visit will take approximately 5 minutes.
3358549|NCT04993755|Experimental|TPN-101, 400 mg/day|
3246994|NCT01352780|No Intervention|usual care|Motivational interviewing
3246995|NCT01352806|Experimental|fluoroscopy, palpation, ultrasound|in the same subject we will compare the accuracy of identifying the intralaminar space by three technique, fluoroscopy, ultrasound, palpation.
3246996|NCT01352832|Experimental|Interactive DVD|"Patients randomized to this arm will receive a DVD DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
3246997|NCT01352832|Placebo Comparator|Usual Care|Patients randomized to this arm receive their usual care.
3358550|NCT04993755|Placebo Comparator|Placebo|
3246998|NCT01352858|Experimental|TolDC|Experimental arm - TolDC administered arthroscopically
3246999|NCT01352858|Placebo Comparator|Control|Arthroscopy & saline irrigation alone
3247000|NCT01352871||Concentration / meditation|The subject will try to influence the innate immune response by concentration / meditation in advance of and during endotoxemia
3247001|NCT01352884|Experimental|Stage 1|Stage 1 will identify the recommended Stage 2 dose using a dose-escalation process. Dose-escalation will continue until either a maximum tolerated dose is established, or a therapeutic dose is reached.
3247002|NCT01352884|Experimental|Stage 2|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood specimens will be evaluated for pharmacodynamic markers/activity at specified timepoints throughout the study.
3247003|NCT01352910|Experimental|effective rTMS|
3247004|NCT01352910|Sham Comparator|Sham rTMS|
3247005|NCT01352923|Experimental|peripheral blood|healthy voluntary donors
3247006|NCT01352936||Experimental Group|
3247007|NCT01352936||Control Group|
3358560|NCT04987931||Primary population: Talazoparib-treated patients with HER2- ABC with gBRCA1/2m|HER2-negative ABC patients with gBRCA1/2 mutations treated with talazoparib monotherapy initiated on or after October 16, 2018 and ≥18 years of age at initiation of talazoparib.
3358562|NCT04980326|Experimental|Stepped-care program (Step 1: DWM; Step 2: PM+)|"The treatment group will receive the stepped-care program consisting of Doing What Matters (DWM) (step 1) and Problem Management Plus (PM+) (step 2) in addition to Psychological First Aid (PFA) and care-as-usual (CAU). Step 2 will only be provided if the participant still has elevated levels of psychological distress at 2 weeks after DWM, i.e. during the second quantitative assessment at 2 weeks after DWM.~Participants allocated to the experimental arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria."
3358563|NCT04980326|Active Comparator|Psychological First Aid (PFA)|Participants allocated to the control arm will also receive training in PFA, which consists of a 30-min call that covers basic aspects about peer support in times of stress. Participants will also be allowed to continue with their mental health interventions (CAU), as long as they meet eligibility criteria.
3358571|NCT04973956|Active Comparator|Relaxation group|This group will perform the APMR
3247013|NCT01352988|Experimental|Fumaric acid esters|
3247014|NCT01353001|Experimental|Diet Only|
3247015|NCT01353001|Experimental|Diet plus Aerobic Training|
3247016|NCT01353001|Experimental|Diet plus Resistance Training|
3247017|NCT01353014|Experimental|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genetic information.
3358572|NCT04973956|Active Comparator|Control group|This group will perform the control intervention
3247018|NCT01353014|Active Comparator|General dietary recommendations|This group will receive general dietary recommendations for caffeine, vitamin C, sugar and sodium from recognized health institutions (caffeine: Health Canada; sugar: the World Health Organization; vitamin C and sodium: the Institute of Medicine).
3247019|NCT01353027|Placebo Comparator|Placebo|
3247020|NCT01353027|Experimental|AVI-6002|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3247021|NCT01353040|Experimental|AVI-6003|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3247022|NCT01353040|Placebo Comparator|Placebo|Normal saline
3247023|NCT01353053||Tacrolimus, Everolimus|Immunosuppression is the same for all patients in the study until the period between the 3rd and 5th weeks, when patients will be randomized to initial regimen and remain or be converted to everolimus tacrolimus.
3247024|NCT01353066|Active Comparator|Intensive Medical Treatment|
3247025|NCT01353066|Experimental|Intensive medical treatment (IMM)+RYGBP|
3247026|NCT01353092|Experimental|Active PEMF twice daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
3247027|NCT01353092|Active Comparator|Active PEMF once daily|"Re5 treatment helmet using Pulsating ElectroMagnetic Field:~Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
3247028|NCT01353105|Experimental|Ex vivo lung transplantation|single-group studies
3247029|NCT01353118|No Intervention|gastric bypass|Group A: Patients will undergo gastric bypass surgery within 3 months after randomisation without any pre operative optimisation of glycaemic control.
3259397|NCT01470495|Experimental|RFA+Sorafenib|to treat recurrent HCC both with RFA and Sorafenib
3259398|NCT01470495|Active Comparator|RFA group|To treat recurrent HCC with RFA
3247030|NCT01353118|Active Comparator|Gastric bypass 2|Gastric bypass 2 (Group B):Patients will undergo gastric bypass 3-6 months after randomisation. During this period the group will receive modern best medical care based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines. Glycaemic optimisation will be achieved in a gradual manner with particular attention to the avoidance of hypoglycaemia
3247031|NCT01353118|No Intervention|Best medical care|Group C: Obese patients with T2DM (who choose not to have surgery) will be treated with best medical care based on the ADA/EASD guidelines including anti-diabetes/obesity pharmacotherapy, access to a trained dietician and exercise programme.
3247032|NCT01353131||ECG Screening|1000 patients with moderate to high risk determined by stratification algorithm based on the electronic analysis of 69,088 routine 12-lead ECGs performed in a large medical institution during a 6 month period by combining previously established indices of abnormal repolarization (wide QRS-T angle) with validated measures of myocardial damage (Selvester QRS score) excluding those > 70 years of age or with LV ejection fraction ≤ 35%, or at a high risk of dying within 3 years from cancer, end stage cardiac, pulmonary, renal, immunologic or neurologic diseases excluded on clinical data obtained through medical record.
3247033|NCT01353157||patients with elective cardiac surgery|
3358580|NCT04967092|Active Comparator|Modified Xiao-Feng Powder|Modified Xiao-Feng Powder granules will be taken twice daily for 12 weeks
3358581|NCT04967092|Placebo Comparator|Placebo|Placebo granules will be taken twice daily for 12 weeks
3247034|NCT01353170|Experimental|Prevalent hd patients|Patients undergoing three consecutive cross-over hd session with 3 different dialysate calcium concentrations
3247035|NCT01353183|Experimental|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
3247036|NCT01353209|Experimental|Letrozole|
3358585|NCT04962178|Experimental|Early Invasive Strategy|Procedure: Primary PCI
3358586|NCT04962178|Active Comparator|Conservative Strategy|Procedure: Optimal medical therapy with primary PCI not performed.
3358587|NCT04961957|Active Comparator|Waterproof padding|Waterproof, short leg walking cast for 3-7 weeks
3358588|NCT04961957|Active Comparator|Non-waterproof padding|Non-waterproof, short leg walking cast for 3-7 weeks
3358589|NCT04961190|Active Comparator|Prolonged Exposure Therapy|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders
3358590|NCT04961190|Active Comparator|Pharmacotherapy|20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
3358591|NCT04961190|Active Comparator|Combined treatment (Prolonged Exposure and Pharmacotherapy)|8-14 sessions of psychotherapy, each lasting 60-90 minutes, focused on imaginal exposure to trauma memories and in vivo exposure to trauma reminders AND 20-60mg of paroxetine daily, or 75-300mg of venlafaxine XR daily
3358596|NCT04958811|Experimental|Tiragolumab plus atezolizumab and bevacizumab|Tiragolumab 600mg IV will be administered together with atezolizumab 1200mg IV and bevacizumab 15mg/kg IV every 3 weeks (q3w) until progressive disease or unacceptable toxicity.
3358597|NCT04958265|Experimental|Crovalimab|Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.
3358598|NCT04956627|Experimental|BMS-986166|
3358599|NCT04956627|Experimental|BMS-986166 + Itraconazole|
3247037|NCT01353209|Placebo Comparator|Placebo|
3247038|NCT01353235|Sham Comparator|usual care|
3247039|NCT01353235|Active Comparator|Prednisolone|1mg/kg/day prednisolone for the entire ICU stay and a maximum of 10 days
3247040|NCT01353248|Active Comparator|Arm 1|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 24 weeks.
3247041|NCT01353248|Active Comparator|Arm 2|GS-5885, GS-9451 and Tegobuvir in combination with ribavirin (Copegus®) for 12 or 24 weeks.
3247042|NCT01353261||Elective Cases|Patients with stable CAD undergoing PCI
3358600|NCT04956627|Experimental|BMS-986166 + Phenytoin|
3358601|NCT04956627|Experimental|BMS-986166 + Gemfibrozil|
3358603|NCT04949854|Active Comparator|Control Arm B.Braun 6.35 cm 20 Gauge catheter|Device 6.35 cm 20 Gauge B. Braun catheter without guidewire
3358604|NCT04949854|Experimental|Experimental Arm B.D. Accucath 5.71 cm 20 Gauge catheter|Device BD 5.71 cm Accucath IV catheter with guidewire
3247043|NCT01353261||AMI Cases treated with clopidogrel|Patient with AMI undergoing PCI
3247044|NCT01353261||AMI Cases treated with prasugrel|Patients with AMI undergoing PCI
3358607|NCT04946435|Experimental|Drug: Antibiotic Irrigation, and Procedure/Surgery: Nasal Packing|Experimental group will receive nasal packing with antibiotic irrigation.
3358608|NCT04946435|Active Comparator|Procedure/Surgery: Nasal Packing|Patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group.
3358609|NCT04941339|Experimental|MRG002|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG002 on Day 1 of every 3 weeks (21-day cycle).
3247045|NCT01353287||TAVI live case or video-taped transmission|
3358610|NCT04939701|Experimental|Phase 1 ASP0739 Monotherapy Dose Escalation|Participants with R/R solid tumors known to express NY-ESO-1 will receive ASP0739 on day 1 of each 28-day cycle for up to 6 doses, to determine the RP2D.
3358611|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Safety Lead-in|Participants with R/R SS, MRCL or ovarian cancer will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses in combination with receiving 4 doses of pembrolizumab every 6 weeks starting on Cycle 1 Day 1 to determine the RP2D of ASP0739 with pembrolizumab. An additional 13 doses of pembrolizumab may be available for qualifying participants.
3358612|NCT04939701|Experimental|Phase 2 ASP0739 Monotherapy Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer and other solid tumors known to express NY-ESO-1 (melanoma, NSCLC-adenocarcinoma, squamous cell, and ESCC) will receive RP2D of ASP0739 on day 1 of each 28-day cycle for up to 6 doses.
3247046|NCT01353287||TAVI without transmission|
3247047|NCT01353313|Placebo Comparator|Placebo|Saline placebo
3247048|NCT01353313|Experimental|Hydrocortisone|hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents)
3247049|NCT01353326|Active Comparator|Cementless Hip Resurfacing|Patients randomized into the Cementless Hip Resurfacing Group will have their hip resurfaced with the cementless Cormet / Corin Hip Resurfacing System.
3247050|NCT01353326|Active Comparator|Cemented Hip Resurfacing|Patients randomized into the Cemented Hip Resurfacing Group will have their hip resurfaced with the cemented Conserve Plus Total Resurfacing Hip System.
3358613|NCT04939701|Experimental|Phase 2 ASP0739 + Pembrolizumab Dose Expansion|Participants with R/R SS, MRCL, or ovarian cancer will receive RP2D of ASP0739 with pembrolizumab on day 1 of each 28-day cycle for up to 6 doses, in combination with 4 doses of Pembrolizumab administered every 6 weeks. An additional 13 doses of Pembrolizumab may be available for qualifying participants.
3247051|NCT01353339|Placebo Comparator|sugar pill|
3247052|NCT01353339|Active Comparator|levofloxacin|
3358619|NCT04937296|Placebo Comparator|Usual care|
3358620|NCT04937296|Experimental|Physical activity|
3247053|NCT01353352|Other|Cervical spine injury|We enrolled consecutive alert adults who were in stable condition and who presented with potential cervical spine injury after acute blunt trauma, including patients with posterior neck pain and those presenting by ambulance with immobilization of the cervical spine.
3247054|NCT01353378|Experimental|dexmedetomidine|intravenously injecting 0.125microgram/kg and 0.25microgram/kg within 10 minutes as soon as the operation begins respectively.
3247055|NCT01353391|Active Comparator|Metformin|
3247056|NCT01353391|Placebo Comparator|Placebo|
3247057|NCT01353404|Experimental|fenofibrate 65mg, fed condition, per oral|
3247058|NCT01353404|Experimental|fenofibrate 65mg, fasting condition, per oral|
3247059|NCT01353404|Active Comparator|fenofibrate 160mg, fed condition, per oral|
3247060|NCT01353417||Renal allograft|
3247061|NCT01353430||VCP families|Patients with a personal or family history of VCP associated disease.
3358621|NCT04937127||Experimental Group|The experimental group will be made up of patients from nursing homes whose carers have received I-Learn training.
3358622|NCT04937127||Control Group|The control group will consist of nursing homes patients whose caregivers have not received I-Learn training and will continue their usual care, regardless of the practices already implemented.
3358626|NCT04935697|Experimental|nVNS|nVNS treatment will be applied three times daily. One treatment is defined as 2 consecutive doses. One dose is applied to the left side of the neck and one is applied to the right side, three times a day (in the morning 30 minutes prior to breakfast, mid-day 30 minutes prior to lunch, and 30 minutes prior to the evening meal). Will also receive SOC for TBI
3358627|NCT04935697|Other|SOC only|Patients will be managed according to the institutional best practices and SOC for TBI.
3358631|NCT04933448|Experimental|Prospective Intervention Group|Participants will receive standard of care for acute management of moderate to severe traumatic brain injury, together with a weight-based ketogenic diet added for up to fourteen days.
3358632|NCT04933448|No Intervention|Historical Control Group|Medical records of past TBI patients will be used as controls matched for age, gender, socioeconomic status (type of health care coverage including private insurance vs. government-funded coverage), lowest first 24 hour post-injury Glasgow Coma Score (GCS) (<8 or 8-12), and pre-injury school program (regular or special education).
3358633|NCT04929847|Experimental|Group 1|All patients will receive the experimental emollient during 3 weeks.
3358634|NCT04929834|Experimental|Experimental group|All patients will receive the experimental emollients during 3 weeks.
3358635|NCT04929210|Experimental|Group 1: Guselkumab and Placebo|Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.
3247062|NCT01353443|No Intervention|Group A|Monofilament absorbable MonoPlus® suture material will be used for closing of the midline incision.
3247063|NCT01353443|Other|Group B|Abdominal wall closure with monofilament absorbable MonoPlus® suture material and onlay placement of Optilene® Mesh Elastic fixed by sutures.
3247064|NCT01353443|No Intervention|Group C|Monofilament, absorbable MonoMax suture material will be used for the closure of the abdominal cavity.
3358636|NCT04929210|Experimental|Group 2: Guselkumab|Participants will receive guselkumab SC.
3358637|NCT04929210|Experimental|Group 3: Placebo followed by Guselkumab|Participants will receive matching placebo and will cross over to receive guselkumab SC.
3358638|NCT04929184|Experimental|Adults who stutter (AWS)|Participants will have 2 visits.
3358639|NCT04929184|Other|Healthy Adults|Participants will have 2 visits.
3247065|NCT01353456|Active Comparator|Dexmedetomidine|
3247066|NCT01353456|Placebo Comparator|Normal saline|
3247067|NCT01353469|Experimental|Insuman Comb 25|Insuman Comb 25 will be self-injected subcutaneously twice daily 30-45 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline.
3247068|NCT01353469|Active Comparator|Novolin® 30R|Novolin® 30R will be self-injected subcutaneously twice daily within 30 minutes before breakfast and dinner. The dose will be adjusted individually by monitoring the blood glucose values and symptoms, and following China guideline and the package insert of Novolin® 30R
3247069|NCT01353482|Active Comparator|Phase II only - Arm I|If the patient is randomised into the Vorinostat arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle plus the dose of Vorinostat determined in the phase I study.
3247070|NCT01353482|Placebo Comparator|Phase II only - Arm 2|If the patient is randomised into the placebo arm they will be given Pemetrexed (500mg/m2 iv) and Cisplatin (75mg/m2 iv) on day one of a 21 day cycle with the placebo for the same number of days as in the vorinostat arm.
3247072|NCT01353534|Experimental|Group 1|3.8 mcg with AS03 adjuvant at D0 and 21
3247073|NCT01353534|Experimental|Group 2|15 mcg at D0 and 21
3247074|NCT01353534|Experimental|Group 3|15 mcg + 50 mcg VEP at D0 and 21
3247075|NCT01353534|Experimental|Group 4|30 mcg + 50 mcg VEP at D0
3358640|NCT04929184|Experimental|Children who Stutter|Participants will have 1 visit.
3358641|NCT04929184|Other|Healthy Children|Participants will have 1 visit.
3247076|NCT01353547||Received anti-TNFa therapy|Received anti-TNFa therapy
3247077|NCT01353547||First-degree relative of MS patients|"First-degree relative (child, parent or sibling) of a diagnosed MS patient~A subgroup will be asked to undergo magnetic resonance imaging (MRI). Participants may be asked to donate a stool sample for gut flora analysis and a blood sample for ribonucleic acid (RNA) sequencing."
3247078|NCT01353547||Referred by the Partners MS Center|Referred by the Partners MS Center
3247079|NCT01353560||New patients of Osher Clinical Center|
3247080|NCT01353573|Active Comparator|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a Fixed Gantry Linear Accelerator
3358642|NCT04928534||Athletes with rmTBI history|50 active or retired athletes from the Weightlifting, Wrestling, Judo, Boxing and Taekwondo Sports Management Center of Tianjin Sports Bureau
3358643|NCT04928534||Patients with rmTBI history|50 patients with multiple (≥2 times) exposure to brain trauma attending Tianjin Medical Insurance designated hospitals such as Tianjin Medical University General Hospital
3358644|NCT04928534||Healthy volunteer|20 healthy volunteers
3247081|NCT01353573|Experimental|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic linear accelerator
3247082|NCT01353599|Experimental|Asmanex|Study participants will receive inhaled Mometasone Furoate (Asmanex) 220mcg once daily for 8 weeks.
3247083|NCT01353625|Experimental|CC-115|
3247084|NCT01353638|Other|Arm A|Arm A includes 14 patients. In treatment period 1, arm A receives standard PDF with the interventional drug alanyl-glutamine-dipeptide as add-on. As it is a cross-over study design, in treatment period 2, group A receives standard PDF without add-on.
3247085|NCT01353638|Other|Arm B|Arm B includes 14 patients who in treatment period 1 receive standard PDF without the investigational drug. As it is a cross-over study design, in treatment period 2 arm B receives standard PDF with alanyl-glutamine-dipeptide as add-on.
3247086|NCT01353651|Experimental|Endovascular treatment|
3247087|NCT01353651|Active Comparator|Open repair treatment|
3247088|NCT01353677||HSCT recipients|"Adult (≥ 18 years), or pediatric (≥ 2 years and < 18 years) allogeneic HCT recipient (related, unrelated, or CBU) at participating pilot study transplant centers.~Signed informed consent form from adult patient or parent/guardian of pediatric patient.~Patient must have a valid mailing address within the United States to receive QOL surveys.~Ability to speak and read English.~Patients with access to a telephone."
3247089|NCT01353690|Experimental|AMDC|
3247090|NCT01353716|Experimental|Cohort 1|Healthy subjects matched to the renal impaired subjects by gender, age and body mass index to the renal impaired subjects. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
3247091|NCT01353716|Experimental|Cohort 2|Subjects with severe renal impairment. There will be a screening visit within 30 days of dose, a single dose of study drug and a follow-up visit 7-10 days after the dose of study drug.
3247092|NCT01353729|Experimental|Treatment A|Treatment A will include combination of zanamivir 600 mg IV plus placebo for moxifloxacin
3247093|NCT01353729|Experimental|Treatment B|Treatment A will include combination of zanamivir 1200 mg IV plus placebo for moxifloxacin
3247094|NCT01353729|Experimental|Treatment C|Treatment C will include zanamivir placebo plus placebo for moxifloxacin
3247095|NCT01353729|Experimental|Treatment D|Treatment D will include moxifloxacin plus zanamivir placebo
3247096|NCT01353742|Active Comparator|Lamivudine and Adefovir dipivoxil|One 100mg Lamivudine tablet and One 10mg Adefovir dipivoxil tablet
3247097|NCT01353742|Experimental|Fixed dose combination|One capsule (100mg lamivudine and 10mg adefovir dipivoxil)
3247098|NCT01353755|Experimental|recombinant Phleum (rPhleum) allergen cocktail|The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate. The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities. The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
3358660|NCT04920578|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts (Double-blind)|Healthy male participants will receive JNJ-69095897 or matching placebo orally in Cohorts 1-7.
3358661|NCT04920578|Experimental|Part 2: Single Dose Cohort (Open-label)|Healthy male participants will receive JNJ-69095897 orally in Cohort 8.
3358662|NCT04920578|Experimental|Part 3: Single Dose Cohort (Double-blind)|Healthy male participants and women of non-childbearing potential (WONCBP) will receive JNJ-69095897 or matching placebo orally in Cohort 9.
3247099|NCT01353755|Placebo Comparator|Placebo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
3247100|NCT01353768||No treatment|zanamivir aqueous solution administered previously as part of the Compassionate Use Program
3247101|NCT01353781|Experimental|AZD5363|Ascending doses of AZD5363 administered orally to patients to define the maximum tolerated dose (MTD)
3358673|NCT04912427|Experimental|Isatuximab + Boretezomib + Dexamethasone|"Each cycle is 28 days~Cycle 1~Days 1, 8, 15, and 22: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Cycles 2-8~Days 1 and 15: Dexamethasone at start time, Bortezomib at 30 minutes after start time, and Isatuximab at 60 minutes after start time~Days 8 and 22: Dexamethasone at start time and Bortezomib at 30 minutes after start time~Cycles 9+~Days 1 and 15: Dexamethasone at start time and Isatuximab at 30-60 minutes after start time"
3358674|NCT04904588|Experimental|Regimen A (MAC: busulfan and fludarabine, PBSC HCT)|"Patients receive:~Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0."
3247102|NCT01353794||Group 1|
3247103|NCT01353807|Active Comparator|Fish oil supplementation|These women received 4 1-g capsules of fish oil per day providing 2,7 grams long chain n-3 fatty acids per day, from gestation week 30 until delivery
3247104|NCT01353807|Placebo Comparator|Olive oil|These women received 4 1-g capsules with olive oil per day from gestational week 30 until delivery
3247105|NCT01353807|No Intervention|No oil supplement|These women received no capsules with oil
3247106|NCT01353820|Active Comparator|1 = Tested product|
3358675|NCT04904588|Experimental|Regimen B (MAC: Fludarabine and TBI; PBSC HCT)|"Patients receive:~Fludarabine (90 mg/m2 total dose) IV on days -7 to -5~Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
3358676|NCT04904588|Experimental|Regimen C (RIC: Fludarabine and Busulfan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -6 to -2~Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
3247107|NCT01353820|Sham Comparator|2 = Control product|
3247108|NCT01353833|Placebo Comparator|IL2-4|
3247109|NCT01353833|Experimental|IL2-2|1 millions IU of IL-2 per day
3247110|NCT01353833|Experimental|IL2-3|3 millions IU of IL-2 per day
3247111|NCT01353833|Experimental|IL2-1|0.33 millions IU of IL-2 per day
3247112|NCT01353846|Active Comparator|Natural cycle|
3247113|NCT01353846|Active Comparator|Artificial cycle|"Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.~Natural micronized progesterone, 400 mg/12 hours vaginal administration"
3247114|NCT01353872|Experimental|Sports Drinks|3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match)
3247115|NCT01353872|Placebo Comparator|Placebo|3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match)
3247116|NCT01353885||Anterior Approach THA|500 Patients will be included who have received a total hip arthroplasty using the Anterior Approach. The anterior approach to total hip arthroplasty refers to an internervous approach to the hip, where the incision is made from the middle of the iliac crest, then curved distally and laterally to the anterior superior iliac spine (Kelmanovich et al., 2003). To optimize feasibility and applicability of our results, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size. Surgeons will use the manufacturer specific guides for insertion of the total hip arthroplasty.
3358677|NCT04904588|Experimental|Regimen D (RIC: Fludarabine and Melphalan; PBSC HCT)|"Patients receive:~Fludarabine (120-180 mg/m2 total dose) IV on days -7 to -3~Melphalan (100-140 mg/m2) IV on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
3358678|NCT04904588|Experimental|Regimen E (NMA: Fludarabine, Cyclophosphamide, TBI; PBSC HCT)|"Patients receive:~Fludarabine (150 mg/m2 total dose) IV on days -6 to -2~Cyclophosphamide (29-50 mg/kg) IV on days -6 and -5~TBI (200 cGy) on day -1~Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0."
3358679|NCT04904588|Experimental|Regimen F (MAC: Busulfan and Cyclophosphamide; BM HCT)|"Patients receive:~Busulfan (dosed by age and weight per institutional standards to target goal pharmacokinetic (PK) in range noted in protocol.) on days -6 to -3~Cyclophosphamide (100 mg/kg total dose) IV on days -2 and -1~Patients receive a bone marrow (BM) graft infusion from a mismatched unrelated donor on Day 0."
3247117|NCT01353885||Posterior Approach THA|100 patients will be enrolled who have received a total hip arthroplasty using the posterior approach. The posterior approach is performed by making a curved incision posteriorly on the greater trochanter (Jolles & Bogoch, 2004). The fascia lata is then incised and the fibers of the gluteus maximus split using dissection (Jolles & Bogoch, 2004). To ensure the feasibility and applicability of our findings, we will not standardize the use of cemented components, the implant manufacturer, or the femoral head size used in the posterior approach.
3358680|NCT04904588|Experimental|Regimen G (MAC: Cyclophosphamide and TBI; BM HCT)|"Patients receive:~Cyclophosphamide (100 mg/kg total dose) IV on days -5 and -4~TBI (1200 cGy total dose) on days -3, -2 and -1~Patients receive a BM graft infusion from a mismatched unrelated donor on Day 0."
3358687|NCT04898634|Experimental|JNJ-78278343|Participants will receive JNJ-78278343 subcutaneously (SC). The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by the study evaluation team (SET) in Part 1 (dose escalation). In Part 2 (dose expansion), participants will receive JNJ-78278343 SC at recommended phase 2 dose (RP2D) as determined in Part 1.
3358693|NCT04894019|Experimental|Continuous monitoring group|In patients randomized to the continuous monitoring group, continuous invasive arterial blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist will be blinded to intermittent blood pressure monitoring using upper-arm cuff oscillometry.
3358694|NCT04894019|Active Comparator|Intermittent monitoring group|In patients randomized to the intermittent monitoring group, intermittent blood pressure monitoring will be displayed on the patient monitor. The treating anesthesiologist is blinded to continuous invasive arterial blood pressure monitoring.
3358695|NCT04891978|Experimental|AIRQ, Asthma Checklist, and PRECISION Program|All participants in the trial will be given the behavioral interventions which include the AIRQ tool, the Asthma Checklist tool, and the PRECISION program educational resources.
3358702|NCT04884971|Experimental|Microbiota Treatment Arm|Participants will receive the encapsulated microbiota intervention daily for seven days and will be subsequently monitored for six months.
3358705|NCT04883424|Experimental|Diabetes Education Program Based on Health Belief Model|Experimental group After the diabetic patients were determined according to the research criteria, they were randomly divided into intervention and control groups. First, pre-tests were applied to diabetics and family members in the experimental group. Diabetes Education Program Based on Health Belief Model It will be administered in two sessions to people with diabetes and their family members. This program; definition of diabetes, the importance of healthy nutrition in diabetes, the importance of exercise, the importance of regular medication, fingertip blood glucose measurement, acute and chronic problems that may develop in diabetic patients, diabetic foot care, personal self-care and family support. A reminder text message will be sent twice a week to diabetics and family members in the intervention group to manage their diabetes well. Once a month, both the diabetic patient and their family member will be called by phone for counseling.
3358706|NCT04883424|No Intervention|Control Group|First of all, pre-tests will be applied to diabetic patients in the control group. Diabetics in this group will not be intervened and their final tests will be made 3 months after the pre-test.
3247118|NCT01353885||Anterolateral Approach THA|100 patients will be enrolled who have had a total hip arthroplasty using the anterolateral approach. An anterolateral approach to THA utilizes an intermuscular approach by incising the patient posteriorly and distally to the anterior superior iliac spine, extending distally to the greater trochanter along the shaft of the femur (Kelmanovich et al., 2003). To optimize the feasibility and applicability of our results, the implant manufacturer, femoral head size or the use of cemented components will not be standardized in this study.
3247119|NCT01353924|Active Comparator|Bet v 1aF1 + Bet v 1aF2 -Alum|
3247120|NCT01353924|Placebo Comparator|Alum-Placebo|
3358712|NCT04881955|Experimental|[14C]-Ecopipam|Single oral capsule dose of 200 mg ecopipam HCl containing approximately 88.5 µCi of [14C]-ecopipam HCl
3358713|NCT04881903|Experimental|MIST intervention followed by MIRA intervention|These are both mobile interventions that use interpretation bias modification (IBM) techniques to reduce cognitive biases. The MIST app targets suicidal cognitions and the MIRA app targets hostile interpretation bias (which contributes to anger). The MIRA application has already been developed, but the MIST application is newly developed based on the same procedures. All participants will complete the MIST intervention and provide feedback so that we can refine it. We will also be collecting EMA data on to examine how changes to suicide cognitions and hostile interpretation bias (by use of the two apps) affects suicidal ideation and functioning.
3358718|NCT04876092|Experimental|JNJ-67856633 and Ibrutinib|Participants in Part A (dose escalation) will receive JNJ-67856633 together with Ibrutinib orally on a 21-day cycle. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) has been identified. Participants in Part B (cohort expansion) will receive JNJ-67856633 together with Ibrutinib orally at one of the RP2D(s) determined in Part A.
3247121|NCT01353937|No Intervention|Standard of Care|All patients will be receiving the Standard of Care treatments regardless of whether or not they are receiving study drug.
3247122|NCT01353937|Active Comparator|Novel Combination Therapy|AMD3100 (Plerixafor) injection with Regranex Gel topical application
3247123|NCT01353937|Active Comparator|Becaplermin (Regranex Gel)|Topical application
3358722|NCT04860713|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin
3358723|NCT04860713|Active Comparator|Nurtec (Rimegepant) Group|Drug: 75 mg of ODT
3247124|NCT01353950||Adult Cystic Fibrosis Patients|Adults with Cystic Fibrosis will be followed longitudinally for 2 years
3247125|NCT01353989||>60 years|
3247126|NCT01353989||< 40 years|
3247127|NCT01354002||Protocol Participants|All participants enrolled on protocols
3247128|NCT01354041|No Intervention|Treatment-as-usual|Participants in the Treatment as usual (TAU) arm will not receive any specific Fear of Cancer Recurrence (FCR) intervention during the study period. However, they will be offered an optional full-day workshop at the end of the study.
3247129|NCT01354041|Experimental|Acceptance and Commitment Therapy|"Participants in the intervention arm will receive seven sessions of a mindfulness and values-based living intervention, led by a trained licensed facilitator, conducted in groups of 10-12 participants and include components specifically designed to reduce FCR. The intervention arm will include six weekly 90 minute group sessions and one followup 90 minute group session booster session held three weeks later. The group sessions will be interactive and experiential and include homework practice for generalizing skills."
3358726|NCT04857619||Retrospective: Cohort 1|All patients recruited outside China, including Australia, Brazil, Singapore, Taiwan, Korea, and Hong Kong special administrative region (SAR) and who are diagnosed with HER2-positive unresectable or mBC since either the date of T-DM1 (Kadcyla) availability through reimbursement or patient access programme that makes it a valid local treatment option for patients or 01 January 2017 and have received at least 2 LOTs in the advanced setting will be included.
3358727|NCT04857619||Retrospective: Cohort 2|Patients from all countries, including China who are diagnosed with HER2-positive unresectable or mBC, since either the date of T-DM1 (Kadcyla) availability through reimbursement or patient access programme that makes it a valid local treatment option for patients or 01 January 2017 and have received at least 2 LOTs in the advanced setting will be included.
3358728|NCT04856358|Experimental|GLPG3121 SAD|Single doses of GLPG3121 at up to 3 dose levels in ascending order
3358729|NCT04856358|Placebo Comparator|Placebo SAD|Single doses of placebo
3358730|NCT04856358|Experimental|GLPG3121 MAD|Multiple doses of GLPG3121 at up to 3 dose levels in ascending order
3247130|NCT01354054|Experimental|High frrequency TENS|100 Hz TENS, 100 usec
3358731|NCT04856358|Placebo Comparator|Placebo MAD|Multiple doses of placebo
3358732|NCT04856358|Experimental|GLPG3121 FE fed|Single dose of GLPG3121 in fed state
3247131|NCT01354054|Experimental|Low frequency TENS|4 Hz, 100 usec TENS
3247132|NCT01354054|Experimental|Placebo TENS|100 Hz, 100 usec, set at motor minus 10% then ramps to off in 45 sec, 40 minutes
3358733|NCT04856358|Experimental|GLPG3121 FE fasted|Single dose of GLPG3121 in fasted state
3358734|NCT04852692||Part A: Retrospective Phase|Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.
3247133|NCT01354054|No Intervention|Control|Age matched controls, no intervention
3247134|NCT01354067|Active Comparator|Control group|The control group will receive standardized patient education four times, once every two weeks, during the eight week intervention period.
3358735|NCT04852692||Part B: Prospective Phase|Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.
3358740|NCT04850222|Experimental|Subjects randomized to get Fluoxetine therapy|Subjects will be randomized to take Fluoxetine (10mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
3247135|NCT01354067|Experimental|High-repetitive single limb training|The experimental group will receive a high-repetitive single limb exercise regime, three times a week for two months. In addition, the exercise group will receive patient education at four occasions during the intervention period.
3247136|NCT01354080|Experimental|tensegrity massage|In this group of patients massage sessions based on the tensegrity method were applied.
3358741|NCT04850222|Active Comparator|Subjects randomized to get Calcium Supplmentation|Subjects will be randomized to take Calcium supplementation (1000mg by mouth per day). The randomized drug will be prescribed by the orthopedic team on the day randomization so that the patient may be monitored for side effects during the remainder of their hospitalization. The patient will be prescribed the randomized medication on the day of discharge and a 90 day supply will be provided by the inpatient research pharmacy.
3247137|NCT01354080|Active Comparator|classical massage|In this group of patients classical massage sessions were applied
3247138|NCT01354093||MacTel Type 2 20 mg/day dose group|Participants will have macular telangiectasis type 2 as confirmed by the reading center. Participants will take 20 mg of zeaxanthin per day.
3247139|NCT01354093||MacTel Type 2 10 mg/day dose group|Participants will have macular telangiectasia type 2 as confirmed by the reading center. Participants will take 10 mg of zeaxanthin per day.
3247140|NCT01354119|Active Comparator|Early intervention|Early intervention: stent-graft just after acute phase
3247141|NCT01354119|No Intervention|Conservative|Conservative: medial follow-up without early intervention
3247142|NCT01354158|Experimental|Droxidopa|The dose-titration response to ascending doses of Droxidopa (placebo, 100mg, 200mg, 400mg) will be measured four separate days.
3247143|NCT01354171|No Intervention|TRUS guided biopsy|
3247144|NCT01354171|Experimental|MRI Assisted TRUS guided biopsy|
3358749|NCT04842045|Experimental|Single Arm|Medically and psychiatrically healthy adults ages 21 to 60 years will receive a single 25 mg dose of psilocybin combined with repeated boluses of midazolam administered in a clinically supportive setting.
3358750|NCT04839991|Experimental|Multi center open label Dose Escalation followed by cohort expansion|
3358751|NCT04839601|Experimental|Evaluation Group (stimulation ON)|Group of participants that have an RNS System implanted and are being treated with responsive stimulation.
3358752|NCT04836897|Experimental|Treatment|Transcatheter aortic valve replacement
3358753|NCT04836195|Experimental|PCLX-001 intervention|"The Dose-Escalation phase will follow a standard 3+3 cohort design. Three patients will be treated at each dose level. If 0/3 patients experience DLT, 3 patients will be treated at the next dose level. Escalation will terminate as soon as two or more patients experience any DLT attributable to study drugs, at a given dose level.~Oral PCLX-001 will be provided as continuous daily dosing on a 28-day cycle. The starting dose of PCLX-001 will be 20 mg daily Expansion Cohort Once the MTD has been defined, preliminary activity will be further evaluated in the expansion part of the study. The RP2D may be the MTD but not necessarily as not only safety data will be taken into account prior to its determination."
3247145|NCT01354184|Experimental|CRD007 10 mg tablet|
3358759|NCT04831697|Experimental|Multi-Caregiving Intervention|The multi-caregiving intervention consists of group-based, peer support, and nurse-facilitation and includes: a. Storytelling/shared experiences (30 minutes); Peer support and problem solving (30 minutes); Coping strategies (30 minutes); and Structured Diabetes Education and Skills Training (30 minutes).
3358760|NCT04831697|Active Comparator|Diabetes Enhanced Usual Care Intervention|This is composed of group-based, nurse-facilitated diabetes education and skills training and general health education and will receive structured diabetes education and skills training as described above (30 minutes) and an additional discussion on general health topics (i.e., back pain, dyspepsia, etc.) (30 minutes).
3358761|NCT04831307|Experimental|[68Ga]Ga-HTK03149 PET/CT|200 MBq/m2 of body surface area, with a 200 MBq minimum adult administered activity will be injected intravenously prior to perform the PET/CT
3358762|NCT04830306|Active Comparator|6MST|Six minute step test
3358763|NCT04830306|Active Comparator|6MWT|Six minute walk test
3358764|NCT04830306|Active Comparator|CPET|Cardiopulmonary exercise test
3247146|NCT01354184|Experimental|CRD007 25 mg tablet|
3247147|NCT01354184|Experimental|CRD007 40 mg tablet|
3247148|NCT01354184|Placebo Comparator|CRD007 matching placebo tablet|
3247149|NCT01354236||School dropouts|Students who quit school without graduation
3247150|NCT01354236||Controls|Normally enrolled students matched for age, gender, school and educational level
3247151|NCT01354249|Placebo Comparator|water|Patients will receive water 3h before operation in the same volume of the study group
3358765|NCT04830033|Experimental|ENO Breathe group|Participation in the online ENO Breathe programme for 6 weeks.
3358766|NCT04830033|No Intervention|Usual Care Group|Participants continue with usual care.
3358767|NCT04826341|Experimental|1/Phase I|Dose escalated Sacituzumab Govitecan and Berzosertib
3358768|NCT04826341|Experimental|2/Phase II|Sacituzumab Govitecan and Berzosertib treatment with identified MTD based on phase I.
3358770|NCT04822155||Children|Children between 11-17 years of age will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect their physical, emotional, or mental well-being (BRIEF-II and CBCL questionnaires). The child will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality.
3358771|NCT04822155||Adults|Adults, 18 years and older will be asked to participate in a home visit, where they respond to questions about certain actions or behaviors that affect your physical, emotional, or mental well-being (BRIEF-A and ABCL questionnaires). The adult will also be asked to wear an actigraphy device on their wrist for 14 days while he/she sleeps to track their sleep quality. Additionally, the adult will need to take their blood pressure 3 times per day for 14 days and record measurements.
3358772|NCT04821674|Experimental|Cohort A1: DS-5670a 10 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
3247152|NCT01354249|Experimental|whey protein plus carbohydrate|The CHO-P group will receive 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
3247153|NCT01354262|Experimental|Lower dose vitamin D|Fixed daily doses of 600 IU vitamin D oral supplementation.
3247154|NCT01354262|Experimental|Higher dose vitamin D|50,000 IU supplementation bi-monthly.
3247155|NCT01354262|No Intervention|Control Group|Patients will be followed from baseline to 12 and 24 week follow up. Patients do not receive any research treatment or intervention beyond the standard care of their diabetes. This group are patients with normal levels of Vitamin D.
3247156|NCT01354275|Active Comparator|GnRH Agonist|oral contraceptive pill and GnRH Agonist IVF/ICSI cycle
3358773|NCT04821674|Experimental|Cohort A2: DS-5670a 30 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
3358774|NCT04821674|Experimental|Cohort A3: DS-5670a 60 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
3358775|NCT04821674|Experimental|Cohort A4: DS-5670a 100 µg|Healthy adults participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
3358776|NCT04821674|Placebo Comparator|Cohort A: Placebo|Healthy adults participants will be randomized to receive a intramuscular injection of placebo.
3358777|NCT04821674|Experimental|Cohort B1: DS-5670a 10 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 10 µg.
3358778|NCT04821674|Experimental|Cohort B2: DS-5670a 30 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 30 µg.
3247157|NCT01354275|Active Comparator|GnRH Agonist Arm|Oral contraceptive pill and day 21 GnRH agonist began, Day 3 of menstruation 150 IU FSH will be started. If 3 or more follicle reach >17 mm hCG will be administered.
3247158|NCT01354288|Experimental|Therapeutic education|
3247159|NCT01354288|No Intervention|Classical management|
3358779|NCT04821674|Experimental|Cohort B3: DS-5670a 60 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 60 µg.
3358780|NCT04821674|Experimental|Cohort B4: DS-5670a 100 µg|Healthy elderly participants will be randomized to receive a intramuscular injection of DS-5670a 100 µg.
3358781|NCT04821674|Placebo Comparator|Cohort B: Placebo|Healthy elderly participants will be randomized to receive a intramuscular injection of placebo.
3358782|NCT04821362|No Intervention|Standard technique group|In this group, peripheral intravenous catheter insertion will be performed routinely.
3358783|NCT04821362|Active Comparator|Ultrasound group|In this group, peripheral intravenous catheter insertion will be performed with ultrasound. A linear probe will be used for procedures.
3358784|NCT04821362|Active Comparator|Near Infrared Device Group|In this group, peripheral intravenous catheter insertion will be performed with AccuVein AV 400.
3358785|NCT04819841|Experimental|GPH101 Drug Product|GPH101 Drug Product is a human autologous CRISPR-Cas9 edited and sickle mutation-corrected HSPC product.
3247160|NCT01354301|Experimental|Thymoglobulin and everolimus|single dose antithymocyte globulin, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
3247161|NCT01354301|Experimental|Basiliximabe and everolimus|basiliximab, reduced concentration tacrolimus, everolimus starting at day 2 posttransplant and prednisone
3358793|NCT04807400|Experimental|Background Therapy + Behavioural Support|Participants will continue to receive their background lipid lowering therapy plus behavioural support.
3358794|NCT04807400|Experimental|Backgroud Therapy + Inclisiran|Participants will continue to receive their background lipid lowering therapy plus inclisiran for injection.
3358795|NCT04807400|Experimental|Background Therapy + Inclisiran + Behavioral Support|Participants will continue to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.
3247162|NCT01354301|Active Comparator|Basiliximabe and mycophenolate|basiliximab, reduced concentration tacrolimus, mycophenolate and prednisone.
3247163|NCT01354327|Experimental|Limicol|
3247164|NCT01354327|Placebo Comparator|Placebo|
3247165|NCT01354340|Experimental|Limicol simple dose|
3247166|NCT01354340|Experimental|Limicol double doses|
3247167|NCT01354340|Placebo Comparator|Placebo|
3358803|NCT04800315|Experimental|Dose 1: CC-93538 SC QW|Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.
3358804|NCT04800315|Experimental|Dose 2: CC-93538 and Placebo SC Q2W|Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.
3358805|NCT04800315|Experimental|Dose 3: CC-93538 and Placebo SC Q2W|"Starting at the baseline visit, active IP and matching placebo will be administered.~On the alternate weeks, placebo will be administered weekly to maintain the blind."
3358806|NCT04800315|Placebo Comparator|Placebo SC QW|Administration of placebo each week.
3358810|NCT04798833|Experimental|Integrated Newborn Care Kit|"The integrated newborn care kit will contain a clean birth kit to be used at the time of delivery either at home or in a facility, three misoprostol tablets (200ug each), 4% chlorhexidine solution, sunflower oil emollient, temperature monitoring strip or sticker, a fleece blanket, a reusable, non-electric, heating device, and a pictorial instruction guide. Lady Health Workers will be equipped with a hand-held electronic scale to identify low birth weight newborns.~Participants in this arm will receive the same local standard of care as the no intervention arm."
3358811|NCT04798833|No Intervention|Control (Local Standard of Care)|"In the control arm, LHWs will deliver the local standard of care, which entails both anti-natal and post-natal LHW home visits. As part of standard practice, LHWs visit pregnant women in their homes during the 3rd trimester, at which time these health workers:~Provide instructions regarding proper nutrition during pregnancy~Encourage that delivery take place in a facility~Discuss the fundamentals of safe water, sanitation, and hygiene behavior~Encourage exclusive breastfeeding~These community health workers will identify early danger signs in newborns such as infections and teach caregivers to identify the same symptoms, so that early interventions can be made. If danger signs are identified, the LHW will refer newborns to the appropriate level of health care."
3358812|NCT04797000|Experimental|Eltrombopag Arm|Participants randomized to a 1: 1 ratio will take eltrombopag.
3358813|NCT04797000|Placebo Comparator|Placebo Arm|Participants randomized to a 1: 1 ratio will take Placebo.
3247168|NCT01354366||Control|Marketed hypoallergenic infant formula containing a probiotic
3247169|NCT01354366||Experimental 1|An investigational hypoallergenic infant formula with a different protein content, containing the same probiotic as the control
3358817|NCT04790916|Experimental|RO7049665 3.5 mg|Participants will receive RO7049665 3.5 mg, administered as subcutaneous (SC) injection, every 2 weeks (Q2W) until participants experience relapse or the study is closed.
3358818|NCT04790916|Experimental|RO7049665 7.5 mg|Participants will receive RO7049665 7.5 mg, administered as SC injection, Q2W until participants experience relapse or the study is closed.
3358819|NCT04790916|Placebo Comparator|Placebo|Participants will receive RO7049665-matching placebo, administered as SC injection, Q2W until participants experience relapse or the study is closed.
3247170|NCT01354366||Experimental 2|An investigational hypoallergenic infant formula with a different protein content, without a probiotic
3247171|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Pipette|
3358820|NCT04785339|Experimental|one-arm, pre-post design|This study will test an intervention in adult Latinx immigrants. There will be no control condition or other comparators. One condition will only provide data at pre (baseline) and post. The only comparison will be across time, but not across conditions as this will be the only condition and all participants will receive the same intervention.
3247172|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Pipette|
3247173|NCT01354379|Active Comparator|Fluzone 15 mcg HA 200 mcl IN by Nasal Spray|
3247174|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 200 mcl IN by Nasal Spray|
3247175|NCT01354379|Experimental|NB-1008 15 mcg HA 20% W805EC 400 mcl IN by Nasal Spray|
3247176|NCT01354392|Experimental|AZD1152|
3247177|NCT01354405||Lanreotide|
3247178|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fasted|Single dose phenylephrine HCl extended release tablet administered under fasted conditions on Day 1 in one of four study periods
3247179|NCT01354418|Experimental|Phenylephrine HCl Extended Release - Fed|Single dose phenylephrine HCl extended release tablet administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
3247180|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fasted|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered under fasted conditions on Day 1 in one of four study periods
3358833|NCT04776317|Experimental|Stage 1 (Naïve) Group 1|5 x 10^10 viral particles of ChAdV68-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=4
3358834|NCT04776317|Experimental|Stage 1 (Naïve) Group 3A|30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 30 mcg of SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 29 in participants from 18 to 60 years of age. N=3
3358835|NCT04776317|Experimental|Stage 1 (Naïve) Group 3B|30 mcg SAM-LNP-S administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-LNP-S administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=7
3358836|NCT04776317|Experimental|Stage 1 (Naïve) Group 4|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on or after Day 85 and no later than Day 130 in participants from 18 to 60 years of age. N=3
3358837|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 13|5 x 10^10 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and on or after Day 113 in participants older than 60 years of age. N=10
3358838|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 14|1 x 10^11 viral particles of ChAdV68-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
3358839|NCT04776317|Experimental|Stage 2 (ChAd-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 15|5 x 10^11 viral particles of ChAdV68-S-TCE administered through 1.0 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
3358840|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after Ad26 COVID-19 EUA Vaccinated) Group 8|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants from 18 to 60 years of age. N=10
3247181|NCT01354418|Active Comparator|Phenylephrine HCl Immediate Release - Fed|Three single doses of phenylephrine HCl immediate release tablet four hours apart, with the first dose administered after a high-fat, high-calorie breakfast on Day 1 in one of four study periods
3247182|NCT01354457|Experimental|Epratuzumab and 90Y-Epratuzumab|Escalating dose schedule with 5 cohort. For each cohort 3 patients will receive Radio-immunotherapy (RIT ) at Day 1 and Day 8 ± 2 First cohort : 92,5 MBq/m² of 90Y-DOTA-hLL2 associated with hLL2 Second cohort : 185 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Third cohort : 277,5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fourth cohort : 370 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2 Fifth cohort : 462.5 MBq/m² d'90Y-DOTA-hLL2 associated with hLL2
3247183|NCT01354470|Experimental|Modafinil|
3247184|NCT01354470|Placebo Comparator|placebo (cornstarch)|
3358841|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after Ad26 COVID-19 EUA Vaccines) Group 12|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 and 10 mcg SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 57 in participants older than 60 years of age. N=10
3358842|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 5|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
3358843|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 6|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
3247185|NCT01354483|Experimental|Treatment Group A|Umbilical cord blood mononuclear cell, 1.6 million
3247186|NCT01354483|Experimental|Treatment Group B|Umbilical cord blood mononuclear cell, 3.2 million
3247187|NCT01354483|Experimental|Treatment Group C|Umbilical cord blood mononuclear cell, 6.4 million
3247188|NCT01354483|Experimental|Treatment Group D|Umbilical cord blood mononuclear cell, 6.4 million; mehtylprednisolone
3247189|NCT01354483|Experimental|Treatment Group E|Umbilical cord blood mononuclear cell, 6.4 million; methylprednisolone; 6 week course of lithium carbonate tablet
3247190|NCT01354509||Current protocol group|Patients treated with current standards based on physician discretion.
3247191|NCT01354509||Normothermia group|Normothermia protocol, using Hydrogel cooling Pads(Arctic Sun) applied for 96 hrs starting upon admission to the ICU
3247192|NCT01354522|Active Comparator|TAC|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
3247193|NCT01354522|Experimental|TCX|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
3247194|NCT01354535|Active Comparator|Cable plating with strut|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
3247195|NCT01354535|Active Comparator|isolated plating|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
3247196|NCT01354548|Experimental|TheraBite grupp|
3247197|NCT01354548|No Intervention|Conventional treatment|
3358844|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccinated) Group 7|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
3358845|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 10|6 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
3358846|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 11|10 mcg of SAM-S-TCE administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10.
3358847|NCT04776317|Experimental|Stage 2 (SAM-S-TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 9|3 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
3358848|NCT04776317|Experimental|Stage 2 Dose de-escalation (SAM-S TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 16|1 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants from 18 to 60 years of age. N=10
3358849|NCT04776317|Experimental|Stage 2 Dose de-escalation (SAM-S TCE Boosts after mRNA COVID-19 EUA Vaccines) Group 17|1 mcg of SAM-S-TCE administered through 0.25 mL intramuscular injection in the deltoid muscle on Day 1 in participants older than 60 years of age. N=10
3358850|NCT04776252|Experimental|MK-8591A|Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for 48 weeks.
3358853|NCT04769648|Placebo Comparator|Vehicle|
3358854|NCT04769648|Experimental|Pro-ocular™ Topical Gel 1%|
3358855|NCT04767854|Experimental|OA school + Virtual Training mobile health application|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The intervention group will receive an individually tailored exercise program through the Virtual Training mobile health application. After each exercise the patient score his/her execution of the exercise on a Likert-scale of 1 to 5, judging their effort from very poor to very good. After the session, patients rate their pain on a Numeric Rating Scale from 0 to 10. The patients in the intervention group will be instructed to exercise 3 times per week for 6 weeks. If the patients want to exercise more than 3 times per week, the exercise program will be available in the app once every day."
3358856|NCT04767854|Active Comparator|OA school + usual care|"After a clinical examination by the physiotherapist, all patients will receive a 1-2-hour group session of patient education according to guidelines.~The control group will receive individually tailored supervised exercise therapy by a physiotherapist individually or in a group setting, twice a week for 6 weeks. Additionally, the patients will be motivated to perform one session of home exercise a week, a total of 3 sessions per week"
3358859|NCT04765657|Experimental|inclisiran sodium 300 mg|Subcutaneous injection
3358860|NCT04765657|Placebo Comparator|Placebo|Subcutaneous injection
3358861|NCT04764253|Experimental|Modified Sodium Watcher Program + Digital Self-Monitoring|
3358862|NCT04764253|Active Comparator|Usual care + Digital Self-Monitoring|
3358863|NCT04763330|Active Comparator|Enhanced Usual Care (EUC)|Active comparator (EUC only).
3358864|NCT04763330|Experimental|Active treatment plus EUC|Veterans randomized to this condition received the treatment plus EUC.
3247198|NCT01354561|Sham Comparator|control group|Physiotherapy in the control group were also done at hospital, in dorsal decubitus position at 30-degree elevation, all receiving the same treatment given for the paediatric inpatients, except nasotracheal suction, which was not performed due to ethical reasons.
3247199|NCT01354561|Active Comparator|respiratory disease group|Respiratory disease group consisting of hospitalized children with acute viral bronchiolitis
3358884|NCT04748445||All participants|
3358885|NCT04747054|Experimental|Radiotherapy added to pembrolizumab|"Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.~Loco-regional radiotherapy will start at D8 after the first administration of pembrolizumab (D1) with 54 Gy/18 fractions in the head and neck region."
3358886|NCT04747054|Active Comparator|pembrolizumab alone|Pembrolizumab 200 mg every 3 weeks until disease progression or unacceptable toxicity.
3358889|NCT04743804|Experimental|Ravulizumab|
3358890|NCT04743804|Placebo Comparator|Placebo|
3358893|NCT04732117|Experimental|Secukinumab Arm|Secukinumab 150 mg PFS s.c.
3358894|NCT04732117|Placebo Comparator|Placebo Arm|Placebo 150mg PFS s.c.
3358895|NCT04729959|Experimental|Group I (tocilizumab, atezolizumab, FSRT)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes (dependent upon the results of the Safety Run-In) on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days in the absence of disease progression or unacceptable toxicity. Starting 4 weeks from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3358896|NCT04729959|Experimental|Group II, Arm I (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes (dependent upon the results of the Safety Run-In) on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3358897|NCT04729959|Experimental|Group II, Arm II (tocilizumab, atezolizumab, FSRT, surgery)|Patients receive systemic treatment with atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3-5 fractions over 3-5 days. Within 7-14 days after FSRT, patients undergo surgery. Within 21-24 days from the first dose of systemic treatment, patients resume treatment with tocilizumab IV over 60 minutes with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3358898|NCT04727528|Experimental|Open-label correction phase (up to 48 hours)|"All eligible patients will receive SZC 10 g TID for up to 48 hours. Patients with POCT (Point-of-Care-Test) K+ ≥5.1 mmol/L after 24 hours will continue on SZC 10 g TID for another 24 hours. Patients who achieve normokalemia (defined as POCT K+ between 3.5 and 5.0 mmol/L inclusive) after receiving SZC 10 g TID for up to 48 hours will proceed to randomization.~Patients with POCT K+ <3.5mmol/L at any time during the open-label phase will be withdrawn from study treatment and will be followed per protocol."
3247200|NCT01354574|Experimental|High Glycemic Index meals|Three days of run-in diet with meals containing high glycemic index carbohydrates followed by test day with breakfast meal containing high glycemic index carbohydrates.
3247201|NCT01354574|Experimental|Low Glycemic Index meals|Three days of run-in diet with meals containing low glycemic index carbohydrates followed by test day with breakfast meal containing low glycemic index carbohydrates.
3247202|NCT01354587|Active Comparator|Hizentra|Compare IgG levels and site reaction in subjects transitioning from Vivaglobin to Hizentra
3247203|NCT01354600|Other|Energy Balance|
3247204|NCT01354600|Other|Positive Energy Balance|
3358899|NCT04727528|Experimental|Randomized, placebo controlled phase (Day 2 or 3 to Day 29)|Patients will be randomized to SZC 10 g QD or placebo 10 g QD. The dose of SZC/placebo will be titrated by increasing or decreasing the dose by 5 g increments at 1-week intervals to between 5 g every other day (QOD) and 15 g QD of the randomized phase to maintain normokalemia by POCT K+.
3358900|NCT04727151|Experimental|TAC01-HER2|Lymphodepletion followed by TAC01-HER2 as a single IV infusion.
3358901|NCT04724967|Experimental|CeraVe Group|Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.
3358902|NCT04724746|Experimental|Written Exposure and Cognitive Behavioral Therapy|Participants receive 5 to 6, 60 minute, sessions of written exposure therapy for posttraumatic stress disorder combined with cognitive behavioral therapy for substance use disorder.
3358903|NCT04722952|Experimental|Anti-PD-1 mAb Combined With Azacytidine and HAG regimen|Anti-PD-1 mAb combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen
3247205|NCT01354613|Experimental|HFpEF|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will receive amlodipine, oral administration for a period of 12 weeks.
3247206|NCT01354613|Experimental|Pulmonary Disease|20 patients with pulmonary disease and no clinical evidence of cardiovascular disease
3247207|NCT01354613|Experimental|LVH/HTN|20 subjects with known left ventricular hypertrophy and clinically diagnosed hypertension without the diagnosis of heart failure.
3358909|NCT04720664|Experimental|oral SM-88|SM-88 taken with three conditioning agents: methoxsalen, phenytoin, and sirolimus
3358910|NCT04716933|Experimental|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib|Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily for up to 2 years.
3358911|NCT04716933|Placebo Comparator|Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo|In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily for up to 2 years.
3358912|NCT04715191|Experimental|CARE T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 plus IL21 (CARE T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
3358915|NCT04713722||MDD/childhood adversity group|subjects with current MDD who experienced childhood adversity
3358916|NCT04713722||rMDD/ childhood adversity|subjects with a history of MDD who experienced childhood adversity
3358917|NCT04713722||MDD|subjects in a current episode of MDD, with no history of childhood adversity
3358918|NCT04713722||Healthy Control|healthy control subjects, with no history of childhood adversity
3358919|NCT04713618||Supportive Care (pelvic exam, survey)|Patients undergo standard of care pelvic exam at baseline and 1, 3, 6, 12, and 24 month follow ups. Patients also complete patient reported outcome measures at baseline and 1, 3, 6, 12, 18, and 12 month follow ups.
3358920|NCT04711902|Active Comparator|Arm 1|Arm 1 - Secukinumab Dose level 1
3358921|NCT04711902|Placebo Comparator|Arm 2|Arm 2 Secukinumab Placebo
3247208|NCT01354613|Placebo Comparator|HFpEF placebo|25 patients with clinically diagnosed heart failure with preserved ejection fraction, confirmed by Framingham criteria, with EF > 50% and without evidence of active ischemia or known severe CAD, valvular or pericardial disease, infiltrative or hypertrophic cardiomyopathy, cor pulmonale, severe pulmonary disease, or primary renal disease. Subjects will be administered a placebo for a period of 12 weeks.
3247209|NCT01354626|Experimental|High fat diets|High-fat-Low-protein or High-fat-high-protein
3358922|NCT04711902|Active Comparator|Arm 3|Arm 3 Secukinumab Dose level 1 and Placebo
3358923|NCT04711902|Active Comparator|Arm 4|Arm 4 Secukinumab Dose level 2
3358928|NCT04708418|Experimental|Arm A (pembrolizumab)|"NEOADJUVANT PHASE: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity."
3358929|NCT04708418|Experimental|Arm B (CMP-001, pembrolizumab)|"NEOADJUVANT PHASE: Patients receive CMP-001 SC on day 1 of cycle 1 and then intratumorally on days 8 and 15 of cycle 1, days 1, 8, and 15 of cycle 2, and day 1 of cycle 3. Patients also receive pembrolizumab IV over 30 minutes on day 8 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.~SURGERY: Patients undergo surgery 1-2 weeks after completion of neoadjuvant phase.~ADJUVANT PHASE: After recovery from surgery, patients receive pembrolizumab IV over 30 minutes on day 1 of every other cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity."
3358930|NCT04707664|Experimental|Sargramostim Arm|Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
3358931|NCT04707664|Placebo Comparator|Placebo Arm|Day 1 - 5: Placebo treatment in addition to standard of care for COVID-19
3358934|NCT04703361|Experimental|Niacin|12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.
3358935|NCT04703361|Experimental|Na-3-OHB|"12 patients with Heart failure with reduced ejection fraction (HFrEF) investigated with echocardiography and right heart catheterization.~All patients will receive Aspirin before intervention and randomization."
3358936|NCT04703192|Experimental|Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible peripheral T-cell lymphoma subtype that was confirmed by independent hematopathology central review.
3358937|NCT04703192|Experimental|Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma|Participants who will receive 200 mg/day valemetostat tosylate and had an eligible adult T-cell leukemia/lymphoma subtype that was confirmed by the local pathologist/investigators and by documented positive anti-human T-cell leukemia virus type 1 (HTLV-1) antibody.
3358938|NCT04701957|Experimental|Modified Atkins 2 :1 Ketogenic diet|The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
3358939|NCT04701957|No Intervention|Control diet|
3358940|NCT04701684|Experimental|Direct tot Angiography Suite (DTAS) triage workflow|
3358941|NCT04701684|Active Comparator|Conventional CT/MR triage workflow|
3358942|NCT04696809|Experimental|Japanese Participants with Relapsed or Refractory Multiple Myeloma (MM)|Japanese participants with relapsed or refractory MM will receive Teclistamab subcutaneously (SC) at three dose levels. Cohort 1 will receive Teclistamab at Dose 1 and Dose 2 (step-up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 3 on Days 1,8, and 15 of a 21-day cycle. Cohort 2 will receive Teclistamab at Dose 1 and Dose 4 (step up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 5 on Days 1,8, and 15 of a 21-day cycle. Cohort 3 will receive Teclistamab at Dose 1, Dose 4, and Dose 5 (step up doses) up to 10 days prior to the first treatment dose on Day 1 followed by Dose 6 on Days 1,8, and 15 of a 21-day cycle.
3358944|NCT04692584|Experimental|The Lullaby Group|In this group, their mothers sang a lullaby during the vaccination process. Each mother touched her baby's hands and body while singing a lullaby and hugged her baby after the procedure.
3358945|NCT04692584|No Intervention|Control Group|"In this group, their mothers did not sing a lullaby during the vaccination process.~Mothers touched their infant's hands and body and talk to their infants during and after vaccination. Mothers hugged their infant after the procedure."
3358949|NCT04687696|Experimental|Post Isometric Relaxation Group|The participants in this group will perform post isometric relaxation stretching in modified cross body position for 6 weeks.
3358950|NCT04687696|Experimental|Isolytic Stretching Group|The participants in this group will perform isolytic stretching in modified cross body position for 6 weeks..
3247210|NCT01354626|Other|Control group|Low-protein-low-fat (according to healthy eating guidelines)
3247211|NCT01354639||Group 1|Group 1 : conventional open thyroidectomy group (papillary thyroid carcinoma patient who underwent conventional open bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
3247212|NCT01354639||Group 2|Group 2 : robotic thyroidectomy group (papillary thyroid carcinoma patient who underwent robotic bilateral total thyroidectomy procedure and postoperative low dose RAI therapy)
3247213|NCT01354665||Group 1|
3247214|NCT01354678|Active Comparator|group of bone marrow cell therapy|
3247215|NCT01354678|Sham Comparator|group of sham therapy|
3247216|NCT01354704|Active Comparator|lovenox|patient under lovenox 4000 IU
3247217|NCT01354704|Active Comparator|enoxa|patients under Enoxa 4000 IU
3247218|NCT01354704|No Intervention|total knee replacement|patients undergoing total knee replacement
3247219|NCT01354704|No Intervention|total hip replacement|patient undergoing total knee replacement
3247220|NCT01354717|Active Comparator|Brand Carac|Treatment of actinic keratosis with active ingredient
3247221|NCT01354717|Active Comparator|Generic 0.5% 5-fluorouracil cream|Treatment of actinic keratosis with active ingredient
3247222|NCT01354717|Placebo Comparator|Placebo|treatment of actinic keratosis with placebo cream
3358951|NCT04687696|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position for 6 weeks.
3247223|NCT01354730||Exposed cohort|The woman received AdimFlu-S (A/H1N1) vaccination between 2009/10 and 2010/02. The woman was pregnant at the time of vaccination.
3247224|NCT01354730||Unexposed cohort|The woman was gestation after April 2009.
3247225|NCT01354743|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass
3358952|NCT04687683|Experimental|Post Isometric Relaxation Group|The participants in this group will receive post isometric relaxation stretching in modified cross body position.
3358953|NCT04687683|Experimental|Isolytic Stretching Group|The participants in this group will receive isolytic stretching in modified cross body position.
3358954|NCT04687683|Experimental|Static Stretching Group Group|The participants in this group will receive static stretching in modified cross body position.
3358957|NCT04684914|Experimental|HepTcell|Dose administered at intervals of 4 weeks for 6 doses
3358958|NCT04684914|Placebo Comparator|Placebo|Dose administered at intervals of 4 weeks for 6 doses
3247226|NCT01354756||bariatric population|obese patients in whom a bariatric surgery is planified
3247227|NCT01354769||Non-intubated patients|
3247228|NCT01354769||Intubated patients|
3247229|NCT01354782|Experimental|Roflumilast|(This is a pharmacokinetic study)
3358961|NCT04676698|Experimental|Three Good Things|"Three times weekly for three weeks, participants will receive a text-based survey asking them to type or dictate three good things."
3358962|NCT04676698|Active Comparator|Waitlist Control Arm then Three Good Things|Participants will have surveys in the waiting period for 3 months and then be crossed over to the treatment arm Three Good Things.
3358963|NCT04674241|Active Comparator|DEX group|The DEX group will receives dexmedetomidine intraoperative.
3358964|NCT04674241|Placebo Comparator|Placebo group|The placebo group will receives 0.9% saline intraoperative.
3358968|NCT04670068|Experimental|CAR.B7-H3 T cell product|Up to 12 patients will receive three weekly CAR.B7-H3 T cell product infusions at the same dose. To determine the recommended phase 2 dose (RP2D), a modified 3+3 dose escalation design will be used to evaluate two dose levels: Dose Level 1 (7.5x10^7 cells/infusion), Dose Level 2 (2x10^8 cells/infusion). If this dose is not tolerated, then a lower dose of 3.75 × 10^6 cells/infusion will be explored. Up to 3 dose levels of CAR.B7-H3 cells will be tested with at least 3 patients enrolled at each dose cohort before dose escalation is considered based on the incidence of dose limiting toxicity (DLT). An expansion cohort will enroll up to 9 patients at the recommended phase 2 dose. Prior to receiving the infusions, patients will undergo lymphodepletion with fludarabine and cyclophosphamide.
3247230|NCT01354795|Experimental|1.EUS-FNA with or without suction|During EUS FNA is performed, with or without self-retracting 10-mL syringe
3247231|NCT01354795|Experimental|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet into the needle or injecting air
3247232|NCT01354808|Active Comparator|DAPT|
3247233|NCT01354808|Experimental|TAPT|
3247234|NCT01354821|Active Comparator|Endovascular therapy branched|Endovascular therapy branched or fenestrated stent-graft
3247235|NCT01354821|Other|Open surgical repair|Open surgical repair or aortic replacement with revascularization of visceral arteries
3247236|NCT01354834||hMG|
3247237|NCT01354847||cardiac surgery patients|cardiac surgery patients scheduled for elective complex cardiac surgery
3247238|NCT01354860|Experimental|Moxibustion treatment plus usual care|
3247239|NCT01354860|No Intervention|usual care alone|
3247240|NCT01354886|Experimental|FSH-GEX 25 IU|25 IU single dose
3247241|NCT01354886|Experimental|FSH-GEX 75 IU|75 IU single dose
3247242|NCT01354886|Experimental|FSH-GEX 150 IU|150 IU single dose
3247243|NCT01354886|Experimental|FSH-GEX 300 IU|300 IU single dose
3358981|NCT04662931|Experimental|Crizanlizumab|Participants will receive Crizanlizumab at a dose of 5.0 mg/kg.
3358986|NCT04658888|Experimental|Modified letter with self-sampling request card|This group will receive a modified letter telling the participant they are out of date with their cervical cancer screening. They will also receive information on the self-sampling kit and will be provided a card that they can send back to the study team in order to have a kit sent to their house. The kit will include a pre-paid mailer so that it can be sent back to the lab for testing. The result will then be shared with the participant.
3358987|NCT04658888|No Intervention|Standard letter|Participants will receive a standard of care letter that tells the participant they are out of date with their cervical cancer screening and should contact their primary care provider to schedule an appointment.
3358988|NCT04658771|Experimental|All patients|"Patients will undergo MR-HIFU ablation procedure of OO under general anesthesia. Patients will be monitored for disease status and adverse events for 12 months following procedure. Patients with incomplete or partial response at 28 days after MR-HIFU will be permitted a second MR-HIFU procedure.~If there is still incomplete pain relief without medication use by 28 days following the second MR-HIFU treatment, patients will be offered standard of care treatment with RFA and followed for one year."
3358990|NCT04657224|Experimental|Part A: Dose escalation: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 will be administered together until disease progression, intolerable toxicity, withdrawal of consent, or the investigator.
3358991|NCT04657224|Experimental|Part B: Cohort Expansion: JNJ-64264681 and JNJ-67856633|Participants will receive JNJ-64264681 and JNJ-67856633 at the recommended Phase 2 dose (RP2D) determined in Part 1.
3358992|NCT04656730|Experimental|Study 1: Experimental: Study 2: Experimental|Iberogast® (STW5) or Iberogast® N (STW5-II) 20 drops TID per 14 days
3358993|NCT04656730|Placebo Comparator|Study 1: Comparator Study 2: Comparator|Placebo 20 drops TID per 14 days
3358994|NCT04656418|Experimental|CSL312|Subjects with C1-INH HAE receiving CSL312
3358995|NCT04656418|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
3247244|NCT01354886|Active Comparator|Gonal-f|150 IU single dose
3247245|NCT01354886|Active Comparator|Bravelle|150 IU single dose
3247246|NCT01354886|Placebo Comparator|Placebo|single dose
3247247|NCT01354925|Active Comparator|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. .
3247248|NCT01354925|Active Comparator|Standard treatment during Ramadan|Standard of care according to physicians choice
3247249|NCT01354977|Experimental|Resveratrol|Each participant will receive a 28 days' supply of resveratrol capsules on day 0.
3247250|NCT01355003||All Participants|Participants who were vaccinated with GARDASIL™ by their physician
3247251|NCT01355016|Experimental|MDT-637|Active formulation
3247252|NCT01355016|Placebo Comparator|Placebo|Matched Placebo Comparator
3247253|NCT01355042||Severe Sepsis and Septic Shock|
3247254|NCT01355042||Other Critical Ill with or without Shock|Severe Trauma, Neurological Injury, Other Shock (not Septic)
3247255|NCT01355094|Active Comparator|"Stampede VAC"|"Calgary-home-made Stampede VAC system with only closed drain bulb suction"
3247256|NCT01355094|Experimental|KCI AbThera|commercial AbThera vacuum assisted abdominal closure at 125 mmHg suction
3247257|NCT01355107||chronic hcv, no liver cirrhosis, no HCC|patients with chronic hepatitis c- infection: no cirrhosis of the liver (= Desmet IV), no HCC - suspected lesion in the liver
3247258|NCT01355107||chronic hcv, liver cirrhosis, no HCC|patients with hcv- associated cirrhosis of the liver, but with no HCC - suspected lesions in the liver
3247259|NCT01355107||hcv-infection, HCC|patients with hcv- associated HCC
3358996|NCT04652557|Experimental|Fampridine SR|"Active study medication consists of 7 tablets of fampridine SR 10 mg formulated for oral administration taken in the morning and evening 12 h apart without food. Tablets must be administered whole.~There will be a washout period of at least 8 days equaling over 30 half-lives of the active substance fampridine (t½ = 6 h) between experimental and control intervention and up to 26 days depending on the individual scheduling of each subject."
3247260|NCT01355120|Experimental|a human immunoglobulin|Four infusions (i.v.) of 3mg/kg Ipilimumab in week 1, week 4, week 7 and week 10
3247261|NCT01355146||Fabry's Disease under Replagal|
3247262|NCT01355198|Experimental|Cysteine/glycine|Subjects will be studied before and after receiving oral cysteine (as n-acetylcysteine) and glycine for 2 weeks
3247263|NCT01355237||OCC Patients|Patients being treated for chronic low back pain at the Osher Clinical Center of Brigham and Women's Hospital
3247264|NCT01355237||Comparison|Patients being treated for chronic low back pain at Brigham and Women's Hospital, other than at Osher Clinical Center
3247265|NCT01355263|Experimental|iron tablet, vitamin a capsule|children in Group I received a 200,000 IU vitamin A capsule just one time initially; Group II received ferrous sulfate (element Fe 1-2 mg/kg•day) once a day for 6 months;.
3247266|NCT01355276|Experimental|1|
3247267|NCT01355276|Active Comparator|2|
3247268|NCT01355328|Experimental|laser|
3358997|NCT04652557|Placebo Comparator|Placebo|Identically looking placebo tablets consisting of widely identical additives formulated for oral administration.
3358998|NCT04650295|Experimental|Household Remedy|
3358999|NCT04650295|Placebo Comparator|Tap Water|
3359000|NCT04650204|Experimental|Arm A (perampanel)|Patients receive perampanel PO daily 40 weeks in the absence of disease progression or unacceptable toxicity.
3359001|NCT04650204|Active Comparator|Arm B (ASD)|Patients receive ASD per standard of care for 40 weeks in the absence of disease progression or unacceptable toxicity.
3359002|NCT04649736|Experimental|Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support|"Participants in the intervention arm will receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.~Additionally, these participants will receive the intervention program that involves home-based respiratory physiotherapy and telephone-based psychological support for 6 weeks."
3359003|NCT04649736|No Intervention|Control|Participants in the control arm will only receive the conventional care given by the hospital that consists of discharged recommendations and a follow-up plan through telephone calls to verify treatment compliance. Discharged recommendations include performing respiratory exercises at home and medication. There is no plan for diagnosing mental illness or a strategy for respiratory o psychological rehabilitation at the hospital.
3247269|NCT01355328|No Intervention|control|
3247270|NCT01355341|Experimental|HERBMED PLUS|Herbal formulation of four constituents i.e.Varuna,Yav,Aghada,Kadali as per ayurvedic literature.
3247271|NCT01355354|Experimental|1|Digoxin
3247272|NCT01355354|Experimental|2|Fostamatinib
3359004|NCT04649359|Experimental|Elranatamab (cohort A)|BCMA-CD3 bispecific antibody
3359005|NCT04649359|Experimental|Elranatamab (cohort B)|BCMA-CD3 bispecific antibody
3359006|NCT04649112|Experimental|Dose Level 1|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
3247273|NCT01355367|Experimental|Arm 1|
3247274|NCT01355380||Group 1|Drug (incl. Placebo)
3247275|NCT01355393|Experimental|Stage I, Arm 1 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 1: HER2 peptide vaccine + 4 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
3247276|NCT01355393|Active Comparator|Stage II, Arm I (HER-2/neu peptide vaccine and sargramostim)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF ID.
3247277|NCT01355393|Experimental|Stage II, Arm II (HER-2 vaccine, sargramostim, rintatolimod)|Patients receive synthetic HER-2/neu peptide vaccine admixed with GM-CSF and rintatolimod ID
3247278|NCT01355393|Experimental|Stage I, Arm 2 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 2: HER2 peptide vaccine + 20 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
3247279|NCT01355393|Experimental|Stage I, Arm 3 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 3: HER2 peptide vaccine + 79 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
3247280|NCT01355393|Experimental|Stage I, Arm 4 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 4: HER2 peptide vaccine + 495 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
3247281|NCT01355393|Experimental|Stage I; Arm 5 (HER-2/neu peptide vaccine and rintatolimod)|"Arm 5: HER2 peptide vaccine + 2000 mcg Ampligen®~Five groups of randomized patients with each group receiving the synthetic HER-2/neu peptide vaccine admixed with rintatolimod (different doses)."
3359007|NCT04649112|Experimental|Dose Level 2|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
3359008|NCT04649112|Experimental|Dose Level 3|"In this study, PBCAR19B, allogeneic anti-CD19 CAR T Cells, is used to treat participants with relapsed or refractory (r/r) Non-Hodgkin Lymphoma (NHL).~Route of Administration: Intravenous injection/infusion."
3359012|NCT04644770|Experimental|Part 1: Dose Escalation|Participants will receive intravenous (IV) injection of JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
3359013|NCT04644770|Experimental|Part 2: Dose Expansion|Participants will receive intravenous (IV) injection of JNJ-69086420 at one of the RP2D(s) determined in Part 1.
3359016|NCT04641728|Experimental|pembrolizumab plus olaparib|Until RECIST-based confirmation of progressive disease (PD), death, manifestation of intolerable toxicity, or participant withdrawal from the study, study participants will continue intravenous infusion of pembrolizumab 200 mg every three weeks (Q3W) in combination with oral olaparib 300 mg twice daily (BID) (combination therapy)
3359022|NCT04639102|Experimental|PATH Intervention|Patients in the treatment arm will receive a personalized plan of care upon discharge from the emergency department.
3359023|NCT04639102|No Intervention|Routine Care|Patients in the control arm will receive standard-of-care services (the care plan that the emergency physician would normally offer if PATH were not available) without PATH enrollment.
3247282|NCT01355406|Other|PAD|This is a prospective single-arm multi-center clinical trial designed to evaluate the safety and efficacy of the Flexible Stenting Solutions Flext Stent® Femoropopliteal stenting system in subjects with lower limb peripheral arterial desease (PAD). Subjects targeted for enrollment must have a single de-novo lesion located in the superficial femoral artery and/or proximal popliteal artery with at > 70% stenosis. Subjects must meet all enrollment criteria and provide written informed consent prior to participation in the study.
3247283|NCT01355432||Propofol|
3247284|NCT01355445|Active Comparator|Vincristine / Irinotecan|Vincristine, Irinotecan Vincristine :1.5 mg/m² (max 2mg), IV Irinotecan : Irinotecan 50 mg/m²/d, IV
3247285|NCT01355445|Experimental|Vincristine / Irinotecan / Temozolomide|Vincristine, Irinotecan, Temozolomide
3247286|NCT01355536||Preterm birth group|Women with prior preterm birth
3247287|NCT01355536||Term birth group|Women with prior term birth
3247288|NCT01355549|Experimental|Platelet-rich plasma therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
3359029|NCT04634019|No Intervention|Control arm|Providers in control facilities will not receive any additional training or knowledge assessments.
3359030|NCT04634019|Experimental|Financial incentive arm|Providers in treatment facilities will be visited once a quarter for a knowledge assessment using vignettes. Facilities performing well in this assessment will receive a quarterly bonus payment, which will be distributed among providers.
3247289|NCT01355601|Experimental|Group 1 - Control A|Nutritional beverage containing varying types and levels of carbohydrates
3247290|NCT01355601|Experimental|Group 2 - Experimental A|Nutritional Beverage with varying types and levels of carbohydrates
3359033|NCT04632927|Experimental|Secukinumab|AIN457
3359034|NCT04632927|Experimental|Ustekinumab|
3247291|NCT01355614|Experimental|QAX576|
3359038|NCT04628039|Other|Rehabilitation-focused program|Subjects will receive multiple services in a rehabilitation-focused program
3359039|NCT04625205|Experimental|NEO-PTC-01 Part 1 dose finding phase|
3359040|NCT04625205|Experimental|NEO-PTC-01 Part 2 dose expansion phase|
3359041|NCT04622774|Experimental|IMGC936|Single-arm. IMGC936 administered every 3 weeks.
3359042|NCT04620005||ECMO|The first group will include practitioners who work in intensive care unit with ECMO services
3359043|NCT04620005||Non-ECMO|The second group will include practitioners who work in non-ECMO inventive care unit
3247292|NCT01355614|Other|Infliximab|
3247293|NCT01355640|Experimental|breast-feeding group|Mothers console their babies by breast-feeding during heel lance.
3247294|NCT01355640|Experimental|non-nutritive sucking|"Every mother was given a vacuum pacifier( the brand is Goodbaby) to console her baby during heel lance."
3247295|NCT01355640|No Intervention|control group|A research nurse also explained the study to the control group parents. Standard clinic procedure for infant injection was also implemented. Mothers in control group also lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed.
3247296|NCT01355653|Experimental|Treatment A|thermal therapy
3247297|NCT01355653|Active Comparator|Treatment B|ThermaCare Lower Back/Hip heatwrap
3247298|NCT01355666|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
3247299|NCT01355692|Experimental|Laser therapy|
3247300|NCT01355718||Repaglinide|
3247301|NCT01355731||Registered Nurse|This is quality improvement study that is descriptive and is utilizing a convenience sample of direct care registered nurses employed full-time for at least one year at St. Jude Children's Research Hospital.Participants will take a onetime researcher generated therapeutic boundaries questionnaire which will describe behaviors and attitudes regarding therapeutic boundaries.
3247302|NCT01355744||Spider bite patients|All patients treated for an actual spider bite by a Swiss physician during study period.
3247303|NCT01355757|Experimental|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
3247304|NCT01355757|Active Comparator|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
3247305|NCT01355783|Active Comparator|E7777 + CHOP Chemotherapy|
3247306|NCT01355783|Active Comparator|CHOP alone|
3247307|NCT01355809|Active Comparator|Inhalation Nitrogen/Oxygen|Nitrogen/Oxygen (65%/35%)
3247308|NCT01355809|Experimental|Inhalation Helium/Oxygen|Helium/Oxygen (65%/35%)
3247309|NCT01355809|Experimental|Inhalation gas|Medicinal oxygen 100% via NIV with FiO2 of 0.35
3247310|NCT01355822|Placebo Comparator|Placebo|
3247311|NCT01355822|Experimental|PETN|Pentalong, Actavis Germay: 80 mg twice a day
3247312|NCT01355835|Active Comparator|[STNmono]|Conventional stimulation on subthalamic contacts
3247313|NCT01355835|Experimental|[STN+SNr]|Combined subthalamic and nigral stimulation
3247314|NCT01355848|Experimental|Brief Intervention|The brief intervention consists of stepped care protocol, including building rapport, functional analysis of suicidal behavior, and crisis planning
3247315|NCT01355848|No Intervention|care as usual|Patients randomized to the care as usual arm will not receive the brief intervention.
3359044|NCT04612335|Experimental|Watchful waiting|the watchful-waiting approach consists of administration of rate control medication to obtain relief of symptoms and a heart rate <110 beats per minute, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
3359045|NCT04612335|Other|Routine care|Routine care consists of the standard treatment for an acute episode of recent-onset symptomatic atrial fibrillation, namely acute or delayed cardioversion, followed by a telemetric rhythm monitoring period of four weeks to guide rate control therapy.
3359046|NCT04610866|Experimental|1|Subjects will be treated with a maintenance dose of mitapivat previously assessed for safety and tolerability in the Phase I study for an initial 48 weeks and undergo safety monitoring, evaluation of pharmacokinetics and pharmacodynamics, and assessment of secondary laboratory and clinical endpoints at pre-specified intervals during the study period.
3359047|NCT04609826|Experimental|Arm A: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. The dose levels will be escalated based on the decisions of the Study Evaluation Team (SET) until a recommended Phase 2 dose (RP2D) has been identified.
3359048|NCT04609826|Experimental|Arm B: JNJ-74856665 + Azacitidine (AZA)|Participants will receive JNJ-74856665 orally in combination with AZA administered intravenously (IV) or subcutaneously (SC) in a 28-day cycle.
3359049|NCT04609826|Experimental|Arm C: JNJ-74856665 + Venetoclax (VEN)|Participants will receive JNJ-74856665 orally in combination with VEN in a 28-day cycle.
3359050|NCT04609826|Experimental|Arm D: JNJ-74856665|Participants will receive JNJ-74856665 orally in a 21-day cycle. Participants with transfusion dependent relapsed/refractory Myelodysplastic Syndrome (MDS) will be included.
3359053|NCT04600895|Experimental|Favipiravir|Favipiravir 200mg tablet
3359054|NCT04600895|Placebo Comparator|Placebo|Placebo 200mg tablet
3247316|NCT01355861|Experimental|1|Exercise group 1: Negative work exercise
3247317|NCT01355861|Other|2|Exercise group 2: Negative work exercise (delayed start for single-arm crossover trial)
3247318|NCT01355874|Experimental|Iferanserin|
3247319|NCT01355874|Experimental|Placebo|
3247320|NCT01355874|Experimental|Iferanserin + Placebo|
3247321|NCT01355900|Other|I tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after bone cement set.
3247322|NCT01355900|Other|II tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
3247323|NCT01355900|Other|III tourniquet tactic|Use volume loading test twice (before surgery and 24hrs postoperatively). Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before incision, deflation- after wound closure
3247324|NCT01355900|Other|IV control group|Do not use volume loading test. Total knee arthroplasty performed under tourniquet. Lower limb tourniquet inflation- before cement application, deflation- after bone cement set.
3247325|NCT01355926|Experimental|Flexible Fiber-based CO2 Laser|In the CO2 excised group, the resection will be performed at 15W, at a distance of 1cm from the tissue. Here too, if required, the bipolar will be used to achieve hemostasis The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
3247326|NCT01355926|Experimental|electrocautery resection|In the electrocautery excised group, the cut and coagulation modes used will be each at 25 Malis power setting. First, cut mode will be used to mark out the lesion. Subsequently, coagulation mode will be used for excision. Bipolar cautery will then be used at 25 Malis for hemostasis. The study will focus on post operative pain and quality of life outcomes for both surgical interventions.
3247327|NCT01355939||Abdominal surgery after prior VHR with barrier-coated mesh|
3247328|NCT01355939||Abdominal surgery after prior VHR with nonbarrier-coated mesh|
3247329|NCT01355939||Lap adhesiolysis during abdominal surgery after prior VHR|
3247330|NCT01355939||Open adhesioloysis during abdominal surgery after prior VHR|
3247331|NCT01355952|Experimental|Alpha Lipoic Acid|taking 1800mg daily (600mg 3 times per day) Alpha Lipoic Acid (ALA) open-label for 10 weeks.
3247332|NCT01355965|Experimental|Cohort 1 - One dose of cells|Subjects receive one dose of 1x108 cells on day 0 followed by one dose of 1x109 autologous transfected anti-mesothelin CAR T cells on day 7.
3247333|NCT01355965|Experimental|Cohort 2 - three doses of cells|receive three doses of 1x108 cells on day 0, 2, 4 (Monday-Wednesday-Friday (MWF) of Cycle 1) followed by three doses of 1x109 T cells on day 7, 9, 11 (MWF of Cycle 2). Total target dose for Cohort 2 is 3.3x109 cells.
3247334|NCT01355991|Active Comparator|Anticholinergic Agent|
3247335|NCT01355991|Active Comparator|Long Acting Beta 2 Agonist|
3247336|NCT01356004|Experimental|chicken pox vaccine, efficacy|
3247337|NCT01356004|Placebo Comparator|saline, efficacy|
3247338|NCT01356017|Experimental|Free combination of Telmisartan and S-amlodipine|Subjects received Telmisartan 80mg and S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3359064|NCT04589663|Experimental|Mometasone furoate followed by QMF149|Single inhaled dose of mometasone furoate on Day 1 followed by a single inhaled dose of QMF149 on Day 6
3247339|NCT01356017|Active Comparator|Telmisartan monotherapy|Subjects received Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3247340|NCT01356030|Active Comparator|EUS-FNA|
3247341|NCT01356030|Active Comparator|ERCP Brushing and Biopsy|
3247342|NCT01356043|Experimental|Free combination of S-amlodipine and Telmisartan|Subjects received S-amlodipine 5mg and Telmisartan 80mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3359065|NCT04588207|Experimental|On Urea, Then Off Urea|Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
3359066|NCT04588207|Experimental|Off Urea, Then On Urea|Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)
3359067|NCT04587622|Experimental|Group 1 - Healthy subjects with normal hepatic function|Healthy subjects with normal hepatic function - Control
3359068|NCT04587622|Experimental|Group 2 - Mild Hepatic Impairment|Mild hepatic impairment: Child-Pugh A (Score 5-6)
3247343|NCT01356043|Active Comparator|S-amlodipine monotherapy|Subjects received S-amlodipine 5mg once a day for 9 days. And subjects doesn't take any medications for 19 days.
3359069|NCT04587622|Experimental|Group 3 - Moderate Hepatic Impairment|Moderate hepatic impairment: Child-Pugh B (Score 7-9)
3359070|NCT04587622|Experimental|Group 4 - Severe Hepatic Impairment|Severe hepatic impairment: Child-Pugh C (Score 10-15)
3247344|NCT01356056||Kinesia HomeView Monitoring|Uses Kinesia HomeView at home once per week
3247345|NCT01356056||Control|Assessed in the clinic every 4 weeks using traditional methods
3247346|NCT01356069|Experimental|SB-APP Psychotherapy|Patients, who signed the informed consent, were randomly assigned to SB-APP in addition to TAU (n=18) or to TAU alone (n=17) groups. The SB-APP group received the usual treatment plus SB-APP (40 weekly sessions) for 10 or 11 months. At the term of the first year (T12) the TAU group continued with the TAU management with supportive weekly session whilst the SB-APP group was carried on with the psychiatric, nurse, educational management without any individual psychological support. The number of sessions performed by the two groups in the first year (T0-T12) was programmed to be almost the same to reduce the number of sessions bias comparing the specific quality of treatments.
3359071|NCT04586660|Experimental|Surgically unsalvageable disease|Participants with surgically unsalvageable disease (eg, sacral, spinal Giant cell tumor of bone [GCTB], or multiple lesions including pulmonary metastases).
3359072|NCT04586660|Experimental|Surgically salvageable disease|Participants with surgically salvageable disease whose planned on-study surgery is associated with severe morbidity (eg, joint resection, limb amputation, or hemipelvectomy).
3359073|NCT04586270|Experimental|TAS0612 Escalation|TAS0612 administered orally
3359074|NCT04586270|Experimental|TAS0612 Expansion|TAS0612 administered orally
3359075|NCT04584554|Experimental|Intervention|
3247347|NCT01356069|Active Comparator|TAU treatment|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators. The medication was administered according to the APA guidelines [18] for good clinical practice with regard to BPD.
3247348|NCT01356082||Arterial blood pressure line|Patients receiving an arterial blood pressure line
3247349|NCT01356095|Active Comparator|PALM-Plus control|Health centers randomized to Palm-Plus intervention in larger trial this trial is embedded in, but not receiving the adherence intervention.
3247350|NCT01356095|Experimental|Adherence intervention|Intervention arm.
3247351|NCT01356095|No Intervention|Control|
3247352|NCT01356121|Active Comparator|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
3247353|NCT01356121|Active Comparator|Propofol|Propofol will be initiated with a 0.5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
3247354|NCT01356121|No Intervention|No Sedation|No sedation given in this group
3247355|NCT01356134||Multiple sclerosis and or Ehlers-Danlos|Patients with suspected or confirmed cases of Ehlers Danlos Syndrome and or Multiple Sclerosis
3247356|NCT01356134||Age matched normals|Age matched normals
3247357|NCT01356160|Active Comparator|Arm 1|RGT with GS-5885 30 mg QD + GS-9451 200 mg QD + PEG/RBV
3247358|NCT01356160|Placebo Comparator|Arm 2|RGT with GS-5885 30 mg QD + GS-9451 placebo QD + PEG/RBV
3359080|NCT04577547|Experimental|Dietary Guidelines (DGA) diet with weight loss (WL) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with Physical Activity Guidelines for Americans (PAGA)-recommended exercise
3359081|NCT04577547|Experimental|DGA diet with WL & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight loss with no exercise
3359082|NCT04577547|Experimental|DGA diet weight maintenance (WM) & exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with PAGA-recommended exercise
3359083|NCT04577547|Experimental|DGA diet WM & no exercise|Menu to provide DGA-recommended food group amounts at a calorie level to promote weight maintenance with no exercise
3359084|NCT04577547|Experimental|Western diet with WL & exercise|Western-type menu to provide a calorie level to promote weight loss with PAGA-recommended exercise
3359085|NCT04577547|Experimental|Western diet with WL & no exercise|Western-type menu to provide a calorie level to promote weight loss with no exercise
3359086|NCT04577547|Experimental|Western diet WM exercise|Western-type menu to provide a calorie level to promote weight maintenance with PAGA-recommended exercise
3359087|NCT04577547|Experimental|Western diet WM no exercise|Western-type menu to provide a calorie level to promote weight maintenance with no exercise
3247359|NCT01356173|Experimental|A|
3247360|NCT01356186|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Sessions of Post Admission Cognitive Therapy Delivered Preferably Over 3 Consecutive Days of Inpatient Stay
3359088|NCT04576247|Experimental|Combined aerobic and resistance exercise|12 weeks of supervised resistance exercise and unsupervised aerobic exercise.
3359092|NCT04569734|Experimental|Experimental: Treatment Group|Determination for participation in the study is based on institutional standard of care practice for assessment of WATCHMAN eligibility. Patients that are being considered for LAA Closure with WATCHMAN device implant based on a history of non-valvular atrial fibrillation who are at increased risk for stroke and systemic embolism based on CHADS2VASc score >2 but have an appropriate rationale to seek a non-pharmacologic alternative to anti-thrombotic therapy due to risks of anti-thrombotic therapy. Patients should be able to tolerate the WATCHMAN device implant procedure without the need for general anesthesia.
3359099|NCT04564833|Experimental|Low Dose RBT-1|45 mg SnPP/240 mg FeS
3359100|NCT04564833|Experimental|High Dose RBT-1|90 mg SnPP/240 mg FeS
3359101|NCT04564833|Placebo Comparator|Placebo|Normal saline
3359102|NCT04558359|Active Comparator|Standard of Care Cohort|Patients in this group will receive standard of care treatment.
3247361|NCT01356186|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services
3247362|NCT01356199|Experimental|ARTRONAT|
3247363|NCT01356199|Placebo Comparator|PLACEBO|
3247364|NCT01356212|Experimental|Regimen A: Ketorolac tromethamine (Gentle Sniff - Upright)|Gentle sniff-inhalation with the volunteer upright for dosing and imaging
3247365|NCT01356212|Experimental|Regimen B: Ketorolac tromethamine (Vigorous Sniff - Upright)|Vigorous sniff-inhalation with the volunteer upright for dosing and imaging
3247366|NCT01356212|Experimental|Regimen C: Ketorolac tromethamine (Gentle Sniff - Semi-supine)|Gentle sniff-inhalation with the volunteer semi-supine for dosing and imaging
3247367|NCT01356225|Experimental|Intranasal Ketorolac tromethamine|
3247368|NCT01356225|Placebo Comparator|Intranasal placebo|
3247369|NCT01356238|Experimental|MRC media|Use MRC media in the human IVF-ET program
3247370|NCT01356238|Active Comparator|Sydney IVF media|Use Sydney IVF media in the human IVF-ET program
3359103|NCT04558359|Experimental|Angiotensin II Cohort|Patients in this group will receive angiotensin II.
3247371|NCT01356251|Experimental|Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group.
3247372|NCT01356251|Experimental|Non Surgical group with mesothelioma|The study proposed here has two parts: part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life through a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. In part 2, patients are invited to participate in an Internet-based discussion group
3247373|NCT01356264|Experimental|multimodal prehabilitation begun preop|The prehabilitation program will begin several weeks preop and continue in the postoperative period
3247374|NCT01356264|Active Comparator|Multimodal prehabilitation begun postop|The prehabilitation program will begin after the surgery.
3247375|NCT01356303|Experimental|Cisplatin, Docetaxel|Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of D5W or NS administered as a 1-hour intravenous infusion, followed by cisplatin at dose of 75 mg/m2administered as a 2-hour intravenous infusion every 3 weeks per cycle for 4-6 cycles
3247376|NCT01356316|Experimental|AdimFlu-S Influenza Vaccine|
3247377|NCT01356329|Experimental|Lovenox|Group A : Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin)
3247378|NCT01356329|Experimental|Heparin|Group B:HeparinTM (Unfractionated Heparin)
3359108|NCT04551898|Experimental|BGB-DXP593 Low Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
3359109|NCT04551898|Experimental|BGB-DXP593 Medium Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
3359110|NCT04551898|Experimental|BGB-DXP593 High Dose|Participants will receive BGB-DXP593 on Day 1, and followed up for safety for up to 85 days
3359111|NCT04551898|Placebo Comparator|Placebo|Participants will receive placebo on Day 1, and followed up for safety for up to 85 days
3247379|NCT01356342|Experimental|AdimFlu-S 2010-2011, 6 months~<3 years|
3247380|NCT01356342|Experimental|AdimFlu-S 2010-2011,3~<9 years|
3359112|NCT04551144||Transmen|Subjects starting testosterone therapy as part of standard of care for gender incongruence
3247381|NCT01356342|Experimental|AdimFlu-S 2010-2011,9~<18 years|
3247382|NCT01356355|Experimental|Herbmed plus|One capsule twice a day daily till ureteral stent in situ
3359113|NCT04551144||transwomen|Subjects starting estradiol therapy as part of standard of care for gender incongruence
3359114|NCT04548128||Treatment Arm|The treatment arm will have the HM3 LVAS implanted utilizing a technique other than full median sternotomy (e.g. thoracotomy).
3359115|NCT04545021||Cognitive Behavioral Stress Management (CBSM) - PC Survivor|Participant receives standard cognitive behavioral stress management from the Parent study NCT03344757.
3359116|NCT04545021||CBSM - PC Survivor Partner|The survivor partner does not receive any intervention.
3359117|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor|Participant receives culturally adapted cognitive behavioral stress management from the Parent study NCT03344757.
3359118|NCT04545021||Cultural CBSM (C-CBSM) - PC Survivor Partner|The survivor partner does not receive any intervention.
3359119|NCT04541589|Active Comparator|Arm 1|Arm 1 - Iscalimab Dose 1
3359120|NCT04541589|Active Comparator|Arm 2|Arm 2 - Iscalimab Dose 2 and Placebo
3247383|NCT01356355|Placebo Comparator|Placebo|One capsule twice a day daily till ureteral stent in situ
3247384|NCT01356355|Active Comparator|Tolterodine|One capsule twice a day daily till ureteral stent in situ
3247385|NCT01356368|Experimental|Cisplatin,Docetaxel,Gemzar, Premetrexed|Patients will receive treatment for up to six cycles of the assigned regimen unless there is disease progression or unacceptable toxicities. After treatment, the patients will be seen every 2 months for the first year, then every 3 months for the second year and every 6 months afterwards.
3247386|NCT01356381|Experimental|vildagliptin|
3247387|NCT01356381|Experimental|Placebo|
3247388|NCT01356420|Experimental|Cholesterol supplementation|All new subjects will come to their first visit with an least 3 weeks of stable cholesterol intake. Typically and preferably this will include egg yolk as cholesterol supplement, but in some instances e.g. intolerance to egg yolk it may include a new encapsulated cholesterol preparation, Sloesterol.
3247389|NCT01356433|Other|arm1, vitamin C treated first|Arm 1(50cases): intervention with oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
3359121|NCT04540796|Experimental|Part A: Dose Escalation|Participants will receive once weekly dose or may receive every 2 weeks (Q2W) administration of JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.
3359122|NCT04540796|Experimental|Part B: Cohort Expansion|Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.
3359127|NCT04535011|No Intervention|Usual Care|No prevention or educational information verbally or written coinciding with current usual care
3359128|NCT04535011|Experimental|PPKAY|One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use
3359129|NCT04535011|Experimental|PPKAY with Standard Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use.~Weekly standard text booster until final follow-up (e.g., Reducing your alcohol intake to less than 4 drinks per day reduces your risk of alcohol-related consequences)"
3359130|NCT04535011|Experimental|PPKAY with Personalized Booster|"One-time, 15-minute, nurse-led motivational interview discussing safe drinking behaviors, and negotiating change in alcohol use Weekly personalized text booster until final follow-up (e.g., Remember to reduce your alcohol less than 4 drinks to achieve your goal of… [being a better husband].)"
3247390|NCT01356433|Other|Arm 2 control first|
3247391|NCT01356446|No Intervention|before surgical checklist|
3359131|NCT04534881|Active Comparator|progesterone|subjects on active drug (progesterone)
3359132|NCT04534881|Placebo Comparator|placebo|subjects on placebo
3359133|NCT04532502||Study group|All female assistants in anesthesia
3359134|NCT04532463||Amphotericin B,Flucytosine, Fluconazole|Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
3247392|NCT01356446|Active Comparator|after implementation surgical checklist|
3359141|NCT04526106|Experimental|Part 1: Dose Escalation|Multiple doses of RLY-4008 for oral administration.
3247393|NCT01356459|Experimental|Intervention|Patients in this arm will have Mepilex dressings applied to their sacrum and heels
3247394|NCT01356459|No Intervention|Control|Patients in this arm will have standard care
3359142|NCT04526106|Experimental|Part 2: Dose Expansion|Oral dose of RLY-4008 as determined during Part 1 Dose Escalation.
3359143|NCT04524507|Experimental|High-Titer (CCP1)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive high-titer ABO-compatible convalescent COVID-19 plasma (CCP1) within 24 hours following random assignment.
3247395|NCT01356472|No Intervention|Linezolid alone|the control group is designed for linezolid alone treated MRSA VAP (standard treatment).
3247396|NCT01356485|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
3247397|NCT01356485|Placebo Comparator|Saline|Normal saline (0.9% sodium chloride solution)
3359144|NCT04524507|Active Comparator|Standard-Titer (CCP2)|Within 8 days of COVID symptom onset and no more than 48 hours following hospitalization, participants will be randomized to and receive standard-titer ABO-compatible convalescent COVID-19 plasma (CCP2) within 24 hours following random assignment.
3247398|NCT01356511|Experimental|Prednisone group|Patients in the PDN arm received PDNorally at 1.0mg/kg body weight daily for 4 consecutive weeks.
3247399|NCT01356511|Experimental|Dexamethasone group|DXM was administered orally at 40 mg daily for 4 consecutive days and then stopped
3247400|NCT01356524|Active Comparator|Supplementary progesterone|Women with mid-luteal progesterone levels that are less than 15 ng/dl will receive higher doses of supplementary progesterone
3247401|NCT01356524|No Intervention|No additional progesterone|No additional progesterone given to women with mid-luteal progesterone levels below 15 ng/dl
3359146|NCT04520750|Experimental|Open label treatment arm|PTX-022 QTORIN
3247402|NCT01356537||Gaucher's Disease under VPRIV|
3359147|NCT04519645|Experimental|Lacosamide|Study participants randomized to this arm will receive lacosamide (LCM) as an intravenous infusion in the Treatment Period and may continue to receive lacosamide in the Extension Period. Participants should be switched to oral dosing of LCM as soon as medically possible during the Extension Period.
3359148|NCT04519645|Active Comparator|Active Comparator|Study participants randomized to this arm will receive Active Comparator chosen based on standard of care (StOC) in the Clinical Practice in the Treatment Period and may continue to receive in the Extension Period.
3359149|NCT04518943|Experimental|F1M1P1R1|Financial Reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
3359150|NCT04518943|Experimental|N1M1P1R1|Non-financial reward, mixed lottery, pre-commitment postcard reminders, request physical activity advice
3359151|NCT04518943|Experimental|N1M1P1R0|Non-financial reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
3359152|NCT04518943|Experimental|N1M1P0R0|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
3359153|NCT04518943|Experimental|N1M1P0R1|Non-financial reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
3359154|NCT04518943|Experimental|N1L1P1R1|Non-financial reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
3247403|NCT01356550|Experimental|Healthy subjects|
3359155|NCT04518943|Experimental|N1L1P1R0|Non-financial reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
3359156|NCT04518943|Experimental|N1L1P0R0|Non-financial reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
3359157|NCT04518943|Experimental|N1L1P0R1|Non-financial reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
3359158|NCT04518943|Experimental|F1M1P1R0|Financial Reward, mixed lottery, pre-commitment postcard reminders, no request physical activity advice
3359159|NCT04518943|Experimental|F1M1P0R0|Financial Reward, mixed lottery, no pre-commitment postcard reminders, no request physical activity advice
3359160|NCT04518943|Experimental|F1M1P0R1|Financial Reward, mixed lottery, no pre-commitment postcard reminders, request physical activity advice
3359161|NCT04518943|Experimental|F1L1P1R1|Financial Reward, loss incentive, pre-commitment postcard reminders, request physical activity advice
3359162|NCT04518943|Experimental|F1L1P1R0|Financial Reward, loss incentive, pre-commitment postcard reminders, no request physical activity advice
3359163|NCT04518943|Experimental|F1L1P0R0|Financial Reward, loss incentive, no pre-commitment postcard reminders, no request physical activity advice
3359164|NCT04518943|Experimental|F1L1P0R1|Financial Reward, loss incentive, no pre-commitment postcard reminders, request physical activity advice
3359165|NCT04517383|Experimental|POS group|Patients in the POS group will undergo ET under general anesthesia. After the surgery is done, patients will keep being intubated and mechanically ventilated for 6hrs, during which period the patients will be sedated with sedatives to maintain a BIS value of 50~70 and Ramsay sedation score of 5 ~ 6. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs. After 6hs, the patients will be recovered and extubated.
3359166|NCT04517383|Active Comparator|Con group|Patients in the Con group will undergo ET under general anesthesia and will be routinely recovered and extubated immediately after the surgery is done. The SBP will be controlled between 120 ~ 180mmHg with vasoactive drugs for at least 7hrs after the surgery.
3359168|NCT04513548|Experimental|Ligelizumab|
3359169|NCT04513548|Placebo Comparator|Placebo|
3247404|NCT01356550|Experimental|Hepatic impairment|
3247405|NCT01356563|Experimental|clinical pharmacist intervention|
3247406|NCT01356563|No Intervention|usual care|Patients randomized to usual care group will receive routine review of medication by outpatient department pharmacists and nurse.
3247407|NCT01356615|Experimental|enoxaparin|enoxaparin sodium (Clexane) (40 mg) followed prospectively for 3 months (36 dialyses)
3247408|NCT01356615|Active Comparator|standard unfractionated heparin|standard unfractionated heparin followed prospectively for 3 months (36 dialyses)
3247409|NCT01356641|Experimental|Antibiotic treatment alone|"Intravenous administration:~Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7mg/kg once daily~Oral administration of:~Amoxicillin/clavulanic acid 50/12.5 mg/kg/day (in three doses)"
3247410|NCT01356641|Active Comparator|Appendectomy|Routine appendectomy either laparoscopic or open depending on the surgeon's preference
3247411|NCT01356654|Sham Comparator|SHAM TDCS|
3359181|NCT04499729|Active Comparator|Treatment as Usual (TAU)|TAU will be the treatment that is provided through the Rush Collaborative Care program as part of their service
3247412|NCT01356654|Active Comparator|True TDCS|
3247413|NCT01356680|Active Comparator|Arm A|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IF-RT irrespective of FDG-PET results after chemotherapy
3359182|NCT04499729|Experimental|IntelliCare|Patients will be offered IntelliCare as part of their care in the Rush Collaborative Care service. Patients who agree will download the IntelliCare app, which provides self management and collects symptom self-report data. Symptom severity scores are displayed to the care manager, allowing them to manage the patient's care. The app also provides a secure messaging service for communication between the care manager and the patient.
3247414|NCT01356680|Experimental|Arm B|2 cycles BEACOPPescalated plus 2 cycles ABVD followed by 30Gy IN-RT if FDG-PET is positive after chemotherapy; 2 cycles BEACOPPescalated plus 2 cycles ABVD and treatment stop if FDG-PET is negative after chemotherapy
3247415|NCT01356693|Experimental|Active drug|Bromelin. Extract from Ananas comosus, 3,3g on vehicle (methylparaben, propylparaben, honey from apis mellifera, sodium benzoate, ethylic alcohol, water) 5ml.
3359185|NCT04496986||Cardiovascular Surgical Patients Preoperative Exam|All enrolled participants will undergo a baseline Fiberoptic Endoscopic Evaluation of Swallowing (FEES) before their surgery to determine baseline / preoperative swallowing function. Those with confirmed dysphagia will not be asked to complete the postoperative swallowing exam, given our desire to examine contributing risk factors for dysphagia development and mechanisms within cardiovascular surgical patients. In addition to the instrumental exam, systematic collection of demographic, medical, surgical, and intubation-related candidate predictor variables will be conducted over the entire perioperative period.
3359186|NCT04496986||Cardiovascular Surgical Patients Postoperative Exam|All remaining participants without preoperative dysphagia will be seen for a postoperative exam performed within 48 hours of extubation. Simultaneous imaging using FEES and videofluoroscopy will be performed at the bedside, as well as a battery of clinical tests. Completion of these postoperative tests will indicate study completion for participants without evidence of dysphagia, while participants who demonstrate acute-phase postoperative dysphagia will continue to participate if they desire. During their standard of care one-month follow-up appointment, a third research evaluation will be offered for participants with previously identified postoperative dysphagia. During this exam, the same imaging and clinical tests from the previous research exam will be performed. Finally, participants with persisting dysphagia will be offered the opportunity to continue to be studied for a fourth and final research exam during their standard of care six-month follow up clinic visit.
3359187|NCT04496908|Active Comparator|Early Amniotomy|Women in the Early AROM group will under amniotomy one hour from Foley Catheter expulsion. Labor augmentation will continue per study protocol. Refer to Appendix A for protocol regimen.
3247416|NCT01356693|Placebo Comparator|Placebo|Placebo comparator with the same characteristics of experimental drug, 5ml, single dose.
3247417|NCT01356706||CRLM|patients with colorectal liver metastases (CRLM) who undergo their primary surgery at UZ. Leuven (single-center academic study)
3247418|NCT01356732|Experimental|Sufentanil|
3247419|NCT01356745|Experimental|premixed 50% nitrous oxide and oxygen|
3247420|NCT01356745|Placebo Comparator|medical air|
3247421|NCT01356758||Psoriasis topical treatment|Psoriasis topical treatment. No systemic drugs.
3247422|NCT01356758||Psoriasis biological treatment|Psoriasis biological treatment. Anti-Tnf and anti-il12/23.
3247423|NCT01356758||Severe atopic dermatitis|Severe atopic dermatitis
3247424|NCT01356758||Control|No intervention. No inflammatory skin disease.
3247425|NCT01356771|Other|Control Group|
3247426|NCT01356771|Other|Tailored Intervention|We will mail three separate pamphlets created specifically for the participant. The information in the pamphlets will be based on answers from the first survey.
3247427|NCT01356784|Experimental|Tailored Physical Activity|
3247428|NCT01356784|Active Comparator|"Chronic Pain Self-management Programme"|
3247429|NCT01356784|Other|Health Counselling|
3247430|NCT01356797|Active Comparator|hyperbaric bupivacaine|
3247431|NCT01356797|Experimental|hypobaric levobupivacaine with fentanyl|
3247432|NCT01356810|Placebo Comparator|Standard Care|Delirium management defined by the attending physician.
3247433|NCT01356810|Experimental|Environmental Intervention|
3247434|NCT01356823|Experimental|30μg HPV|Participants in this arm would receive 30μg HPV vaccines which contains 20μg HPV 16 antigen and 10μg HPV 18 antigen
3247435|NCT01356823|Experimental|60μg HPV|Participants in this arm would receive 60μg HPV vaccines which contains 40μg HPV 16 antigen and 20μg HPV 18 antigen
3359188|NCT04496908|Active Comparator|Delayed Amniotomy|Women in the Delayed AROM group will undergo amniotomy at the discretion of the obstetrician or labor provider. No specific instructions will be given.
3359189|NCT04488393||Pregnancies with multiple gestations|
3247436|NCT01356823|Experimental|90μg HPV|Participants in this arm would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
3247437|NCT01356823|Placebo Comparator|hepatitis B vaccine|Participants in this arm would receive hepatitis B vaccine.
3359194|NCT04472702|Experimental|Subjects with knee OA using ultrasound for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to ultrasound (N=45) cRFA treatment arm.
3359195|NCT04472702|Experimental|Subjects with knee OA using fluoroscopy for cRFA intervention|Knee osteoarthritis patients (Kellegren-Lawrence Scale 2-4) that have been refractory to conservative treatments and report at least 80% pain relief with diagnostic geniculate nerve blocks will be enrolled and randomized to fluoroscopic (N=45) cRFA treatment arm.
3359196|NCT04464785||Treatment|Subjects who receive the CentriMag Circulatory Support System
3359198|NCT04459130|Experimental|Child Obesity Program|"Firstly, overweight and obese students will be determined by measuring their height and weight. While selecting children for the experimental group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Experiment group. Child Obesity Program (COP) will be applied to students in the experimental group for 10 weeks. Before the program is implemented, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~- Children's Dietary Self- Efficacy Scale-CDSS~- Food Behavior Scale~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~-Daily Food Consumption Form~-Drink Consumption Form~Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
3376021|NCT03208010|Active Comparator|Enhanced Usual Care|"The comparator is an enhanced usual care control group that receives health care from personal physicians plus has access to: a) data collection sessions; b) individualized exit interviews with program staff after each data collection session to receive immediate feedback on lab results and trends in personal health indicators (e.g., BMI, A1C) and to ask questions; c) referral to a local physician or clinic, if needed; and d) Spanish-language materials on diabetes prevention."
3247438|NCT01356836||Good-poor collateral|Patients who had good and poor collaterals formed 2 groups
3247439|NCT01356836||Good collateral, Poor collateral|
3247440|NCT01356849|Placebo Comparator|Group A - Placebo QD|
3247441|NCT01356849|Active Comparator|Group B - Low dose Atrasentan QD|
3247442|NCT01356849|Active Comparator|Group C - High dose Atrasentan QD|
3247443|NCT01356862|Experimental|PASIREOTIDE|INTRAMUSCULAR INJECTION OF PASIREOTIDE 60 MG
3247444|NCT01356862|Placebo Comparator|PLACEBO|INTRAMUSCULAR INJECTION OF PLACEBO
3247445|NCT01356875|Experimental|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycles of hydralazine and valproic acid.
3247446|NCT01356875|Active Comparator|best supportive care (BSC)|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
3247447|NCT01356888|Active Comparator|Abbott Laboratories - Xience Prime DES|
3247448|NCT01356888|Experimental|Biotronik - Orsiro DES|
3247449|NCT01356901||Treatment naïve and pre-treated CHB patients|subanalysis with migrant and non-migrant patients
3247450|NCT01356914|Experimental|Treatment A: BMS-914392|
3247451|NCT01356914|Experimental|Treatment B: BMS-914392|
3247452|NCT01356914|Experimental|Treatment C: BMS-914392|
3247453|NCT01356914|Placebo Comparator|Treatment D: Placebo|
3247454|NCT01356927||DMPA|DMPA given at the time of mifepristone for medical abortion
3247455|NCT01356927||Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone for medical abortion
3247456|NCT01356953|Experimental|Aerobic Exercise|
3247457|NCT01356979||Patients underwent medical thoracoscopy|Patients who require medical thoracoscopy for undiagnosed exudative pleural effusion by other clinical or radiological investigations.
3247458|NCT01356992|Active Comparator|Clexane® (enoxaparin - Sanofi)|
3359199|NCT04459130|No Intervention|Control Grup|"Firstly, overweight and obese students will be determined by measuring their height and weight. When selecting children for the control group, random numbers table will be used. As a result of statistical analysis, 33 students will be selected to the Control group. First, children's height, weight, subcutaneous adipose tissue measurements will be made. The pedometer wristband will be distributed. The control group will be trained for a daily healthy diet and physical activity.~Pretest: BMI, weight average, subcutaneous adipose tissue measurement and application of scales~- Children's Dietary Self- Efficacy Scale-CDSS~- Food Behavior Scale~- Child Heart Health Development Attitude Scale (exercise, stress, nutrition subscales)~-Daily Food Consumption Form~-Drink Consumption Form~Health Perception Form~Follow-ups will be performed in the 6th and 9th months after the intervention"
3359200|NCT04456517|Experimental|Ranolazine, Then Placebo|- Participants first receive a Ranolazine 500 mg tablet twice daily for 12 weeks, they then receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
3359201|NCT04456517|Experimental|Placebo, Then Ranolazine|- Participants first receive a Placebo tablet (matching Ranolazine 500 mg tablets) twice daily for 12 weeks, they then receive a Ranolazine 500mg tablet twice daily for 12 weeks. This treatment will be given to participants with either active CD or patients with CD that is in remission but who experience continued symptoms
3247459|NCT01356992|Experimental|Versa® (enoxaparin - Eurofarma)|
3247460|NCT01357005||Schizophrenia Family|
3359202|NCT04452747|Active Comparator|Dino-first|Labour will be induced by the use of the vaginal Dinoprostone system (Propess®) first.
3359203|NCT04452747|Active Comparator|Balloon-first|Labour will be induced by the use of a cervix dilatation balloon first.
3247461|NCT01357018||patients with rheumatoid arthritis|
3247462|NCT01357018||patients with ankylosing spondylitis|
3359204|NCT04445987|Experimental|Long-term safety of ARQ-154|Open-label, Long-term Safety of ARQ-154
3359205|NCT04443907|Experimental|OTQ923 or HIX763|Single intravenous infusion of either OTQ923 or HIX763, Part A - Adults treated with OTQ923; Part B - Adults treated with HIX763 Part C - Children age 2-17 - either OTQ923 or HIX763 based on review of data from Part A and/or Part B by Health agency after a formal interim analysis.
3247463|NCT01357031|Experimental|Melatonin|Melatonin 3 mg at bedtime
3247464|NCT01357031|Placebo Comparator|Placebo|Placebo
3359211|NCT04441125||case group|The mothers in the case group will receive oxytocin induction before and after delivery(n:44).
3359212|NCT04441125||control group|The mothers in the control group will not receive any oxytocin induction before delivery, and will receive oxytocin induction in the end of delivery(n:44)
3359213|NCT04439526||Participants with Facial Psoriasis|Participants with moderate facial psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
3359214|NCT04439526||Participants with Genital Psoriasis|Participants with moderate genital psoriasis who are being treated with guselkumab in real world practice will be observed in this study.
3359218|NCT04430452|Experimental|Arm I (hypofractionated RT, durvalumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive durvalumab IV over 1 hour on day 1. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3247465|NCT01357031|Active Comparator|Amitriptyline|Amitriptyline 25 mg
3247466|NCT01357044|Active Comparator|Plant extracts|
3247467|NCT01357044|Placebo Comparator|Placebo|
3247468|NCT01357057||Derivation cohort|Arm 1: Derivation cohort (from 2003 to 2007)
3247469|NCT01357057||Validation cohort|Arm 2: Validation cohort (from 2008 to 2009)
3247470|NCT01357070|Active Comparator|Brocco-sprout homogenate|
3247471|NCT01357070|Sham Comparator|Alfalfa sprout homogenate|
3259399|NCT01470508|Experimental|Family Enhancement|PAS is a 27-week program consisting of 25 sessions, 50 minutes in length, between an individual and a therapist. During six (6) family sessions, a family member will accompany the individual to therapy and will take an active role during the session. In this program, individuals and their family members will learn about ways to communicate about their relationship in the context of experiencing an eating disorder. PAS focuses on family-specific skills such as communication skills and problem solving skills while also incorporating eating disorders psychoeducation.
3359219|NCT04430452|Experimental|Arm II (hypofractionated RT, durvalumab, tremelimumab)|Patients undergo standard of care hypofractionated RT over 5 fractions QD for 5 days in the absence of disease progression or unacceptable toxicity. Within 3-10 days after completion of RT, patients receive tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with durvalumab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients who complete the first dose of tremelimumab and demonstrate clinical benefit based upon radiographic tumor regression and/or other clinical response without progression for at least 6 cycles or 6 months on treatment, whichever is shorter, and subsequently have evidence of progressive disease during the durvalumab monotherapy portion may receive a repeat dose of tremelimumab at the next scheduled cycle of treatment with durvalumab per physician discretion.
3359220|NCT04428307|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
3247472|NCT01357083||Major Depression Disorder|This study is analytical cross-sectional and randomized. Two groups of depressed patients and healthy subjects were selected.The individual were submitted to a medical examination, and responded to the Beck depression inventory (BDII-II). Those, who got a score above 20, were included in the depressed group. Among this group, 50 patients were chosen randomly. those who obtained a depressive score below 9, 50 of them were chosen and they were included in the healthy group. The control group was chosen to match to the depressed patients for education, social occasion, occupational and economical situation. All of the subjects were interviewed psychiatrically, and the depression disorder was confirmed on the basis of the DSM criteria. eight out of 50 depressed patients were excluded from the study due to suffering from other psychiatric disorders .
3247473|NCT01357096|No Intervention|Comparison group|
3359221|NCT04428307|Experimental|Arm 2 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
3359222|NCT04428307|Experimental|Arm 3 (client-directed and provider-directed intervention)|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
3247474|NCT01357096|Experimental|Integrated health care team|
3247475|NCT01357109|Experimental|Bosentan|
3247476|NCT01357109|Placebo Comparator|Placebo|
3247477|NCT01357122|Experimental|NCI Insertion|
3247478|NCT01357122|Active Comparator|Standard Forceps Insertion|
3247479|NCT01357174||All Participants|Infants who were vaccinated with ROTATEQ™
3247480|NCT01357187|Other|Control|
3247481|NCT01357187|Experimental|Treatment|
3247482|NCT01357200||critically ill obese adults|Age ≥ 18 years, body mass index (BMI) ≥ 30, in intensive care unit (ICU) requiring tube feeding ≥ 3 days
3247483|NCT01357213|Placebo Comparator|Arm 2|Placebo in all three cohorts
3247484|NCT01357213|Experimental|Arm 1|XOMA 3AB in 3 dose levels/cohorts A, B or C.
3247485|NCT01357226||All patients over the age of 18|
3247486|NCT01357252|Experimental|vildagliptin|
3247487|NCT01357252|Placebo Comparator|placebo|
3247488|NCT01357265|Other|1|No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit
3247489|NCT01357278|Experimental|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
3247490|NCT01357278|No Intervention|Patient education|Patient education will be offered every eight week.
3247491|NCT01357291|Experimental|Recidivism Reduction Program|Inmates who were assigned to the RRP intervention.
3247492|NCT01357291|Active Comparator|Business-as-usual|Business-as-usual are those inmates not assigned to RRP and who receive standard inmate programming.
3247493|NCT01357304|Experimental|Group treatment and PAR|
3359223|NCT04425538|Experimental|Infliximab|All patients enrolled into this trial will be assigned to the Infliximab arm. Patients will be treated with infliximab on Day 1, and may be re-treated per protocol and at the discretion of the investigator.
3359224|NCT04415931|Experimental|Local infiltration analgesia group|This group of patients will receive local infiltration analgesia
3359225|NCT04415931|Active Comparator|Interscalene block group|This group of patients will receive interscalene block
3247494|NCT01357304|No Intervention|Usual care|
3247495|NCT01357317|Active Comparator|Lanthanum Carbonate|Lanthanum Carbonate: initial dose 500 mg TID with meals, titrated at monthly intervals in 500 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis (serum phosphorus, PTH or TRP). Normality for this marker will be defined as serum phosphorus of 2.6-4.6 mg/dl, PTH of 10-65pg/ml and TRP>=80%.
3247496|NCT01357317|Active Comparator|Calcium Acetate|Calcium Acetate: initial dose 667 mg TID with meals, titrated at monthly intervals in 667 mg increments or decrements, with goal of returning to normal the level of the abnormal baseline marker(s) of phosphorus homeostasis. The maximum daily intake of elemental calcium should not exceed 1500 mg in order to comply w/recommendations from K-DOQI [5](this is approximately equal to three 667mg tablets of calcium acetate TID).
3247497|NCT01357317|Active Comparator|Dietary instructions|Dietary instructions consisting of pamphlets describing foods high in phosphorus and consultation with a renal dietitian if necessary, with the goal of return to normal the level of the abnormal marker of phosphorus homeostasis. Rescue therapy with a phosphorus binder of the treating physician's choice will be allowed in patients who fail to normalize elevated baseline serum phosphorus levels after 3 months following dietary instructions.
3247498|NCT01357330|Experimental|Dose Escalation|Dose escalation phase The starting dose of SAR245408 will be 25-mg once daily (up to 200-mg). The starting dose of MSC1936369B will be 15- mg once daily (up to 90-mg)
3247499|NCT01357343|Active Comparator|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping
3247500|NCT01357343|Active Comparator|Chiropractic care|Chiropractic adjustments and active and passive physical modalities.
3247501|NCT01357343|Active Comparator|Integrated Chiropractic and Acupuncture|
3247502|NCT01357369||Ondansetron/Cefazolin treatment|Pregnant women undergoing uncomplicated cesarean section deliveries who have consented to participate, and will receive Ondansetron and Cefazolin in the course of their clinical care will have PK blood samples drawn.
3247503|NCT01357382|No Intervention|low fat diet|replace high fat, energy dense foods with foods rich in whole grains, fruits and vegetables. The macronutrient distribution of this diet will be approximately 55% carbohydrate, 15% protein and 30% fat. Individuals will also be instructed to reduce sodium intake to < 2300 mg / day and in individuals with hypertension, < 1500 mg / day.
3247504|NCT01357382|Experimental|low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' to increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
3359228|NCT04404595|Experimental|anti-claudin18.2 chimeric antigen receptor T-cell therapy|Phase 1 will include two parts, a dose escalation part to determine the recommended dose for the expansion part. During expansion patients will be treated with the recommended dose determined in the expansion part.
3359229|NCT04397276|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
3359230|NCT04397276|Experimental|Part 2: Dose Expansion|Participants with mCRPC will receive JNJ-70218902 at the RP2D determined in Part 1.
3359231|NCT04397263|Experimental|Guselkumab|Participants will receive guselkumab by intravenous (IV) infusion, followed by guselkumab by subcutaneous (SC) injection. Participants who are eligible and willing to continue guselkumab may enter the Long-term extension (LTE) phase and continue to receive guselkumab.
3359232|NCT04387773|Experimental|GOCOVRI Treatment|All participants will have gait, balance, dyskinesia assessed before and after receiving GOCOVRI (274 mg/day).
3359233|NCT04385732|Experimental|Standard of Care plus Melanoma Surveillance Photography|Clinical surveillance standard of care with addition of 2D or 3D Melanoma Surveillance Photography and digital dermoscopy.
3359234|NCT04385732|No Intervention|Standard of Care|Clinical surveillance standard of care without Melanoma Surveillance Photography.
3359235|NCT04384497|Experimental|Convalescent plasma treatment|Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 7 CP infusions. CP will be given as a slow infusion over 1 hour. Patients will be monitored for adverse events, especially allergic reactions.
3359236|NCT04384107|Experimental|V114|Participants will receive a single 0.5 mL subcutaneous injection of V114 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
3359237|NCT04384107|Experimental|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|Participants will receive a single 0.5 mL subcutaneous injection of PCV13 administered at 2 to 6 months of age, and second and third dose is administered at an interval of ≥27 days from the prior dose. The fourth dose is administered at 12 to 15 months.
3359238|NCT04384055||Covid-19 Positive Patients|This group includes individuals who were diagnosed with Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx
3359239|NCT04384055||Covid-19 Negative Patients|This group includes individuals who did NOT have a positive test for Covid-19 based on reverse transcriptase polymerase chain reaction (RT-PCR) of the nasopharynx.
3359240|NCT04382924|Experimental|Treatment Arm A|NP-120 (Ifenprodil) 20 mg TID + Standard of Care
3359241|NCT04382924|No Intervention|Control Arm|Standard of Care only
3359242|NCT04382924|Experimental|Treatment Arm B|NP-120 (Ifenprodil) 40 mg TID + Standard of Care
3359243|NCT04377932|Experimental|AGAR T cells + Fludarabine and Cytoxan|GPC3-CAR and the IL15 (AGAR T cells) along with lymphodepleting chemotherapy (Cytoxan and Fludarabine) will be administered to patients with GPC3-positive solid tumors.
3359246|NCT04371640|Active Comparator|Sirolimus|Sirolimus + standard medical care Day 1: 10mg Days 2-7: 5mg
3359247|NCT04371640|Placebo Comparator|Placebo|Placebo + standard medical care Day 1: 10mL Days 2-7: 5mL
3359250|NCT04364997|Experimental|Desvenlafaxine Succinate Sustained-Release|
3359251|NCT04364997|Active Comparator|Duloxetine Hydrochloride Enteric-coated|
3247505|NCT01357395|Experimental|Amuvatinib|Amuvatinib 300 mg PO TID + standard-of-care platinum-etoposide
3247506|NCT01357408||REVEAL XT device|Subjects implanted at time of admission for HF or to be implanted within 14 days of discharge from HF hospitalization for clinical indications>
3247507|NCT01357421|Experimental|TT301|Investigational drug TT301
3247508|NCT01357421|Placebo Comparator|Placebo|Normal saline
3359253|NCT04356196|Experimental|Verapamil group|45 patients will receive 80 mg oral verapamil 3 hours pre-operative
3359254|NCT04356196|Experimental|Bisoprolol group|45 patients will receive Bisoprolol 5mg PO 3 hours preoperative
3359255|NCT04356196|Experimental|placebo group|45 patients will receive placebo tablet PO 3 hours preoperative .
3247509|NCT01357434||Adolescents|Participants 12-21 years old.
3247510|NCT01357447|Experimental|Dornase alfa (Pulmozyme)|Dornase alfa is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.
3247511|NCT01357447|Placebo Comparator|Saline|Normal saline 0.9% solution
3247512|NCT01357486|Experimental|A|patients receiving sorafenib 400 mg - twice a day
3247513|NCT01357486|Experimental|B|patients receiving pravastatin 40 mg - once a day
3247514|NCT01357486|Experimental|C|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
3359259|NCT04338178|Experimental|Experimental intervention|Standard outpatient program, with additional group sessions integrating the experimental intervention : Cognitive Remediation Therapy (CRT), Emotional Skills Training (EST), and Cognitive Behavioral Therapy focused on craving and food addiction (CBT), delivered once a week during 10 weeks.
3359260|NCT04338178|Active Comparator|Standard intervention|Standard outpatient program, with additional group sessions integrating control intervention : multidisciplinary outpatient program including several consultations with endocrinologists, dietitians, psychologists, nutritionists and/or physical activity coaches, delivered once a week during 10 weeks.
3359261|NCT04336969|Other|T1D Patients|Participants will wear a Continuous Glucose Monitor (CGM) with remote data monitoring
3359262|NCT04335032|Experimental|Eicosapentaenoic acid gastro-resistant capsules|"Eicosapentaenoic acid free fatty acid (EPA-FFA) 500mg gastro-resistant capsules 2g daily (two capsules twice daily).~One capsule of EPA-FFA gastro-resistant capsules contains 500mg EPA-FFA in a capsule containing gelatin, glycerol, sorbitol, titanium dioxide, FD&C blue No. 1, hypromellose phthalate, dibutyl sebacate."
3359263|NCT04335032|Placebo Comparator|Placebo|Placebo capsules that cannot be visually differentiated from the active treatment
3359266|NCT04325828|Experimental|Apalutamide plus GnRH Agonist|Participants will receive apalutamide 240 milligram (mg) in combination with a gonadotropin-releasing hormone (GnRH) agonist until disease progression, unacceptable toxicity, death, or the end of the study and each treatment cycle will be of 28 days.
3359274|NCT04306315|Experimental|Brodalumab 210 mg + brodalumab 70 mg add-on* (adjusted brodalumab dosing regimen)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any visit with efficacy assessments after Week 16 will receive a dose adjustment to 280 mg brodalumab every 2 weeks.
3247515|NCT01357486|Other|D|patients receiving best supportive care
3247516|NCT01357499||control group|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg but without inflating the cuff and without stimulating the muscle. Now 25 minutes will have to pass by before beginning the coronary angioplasty.
3247517|NCT01357499||intervention group 1|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. There will be no electrical muscle stimulation in this group.
3247518|NCT01357499||intervention group 2|A Blood pressure cuff and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle
3247519|NCT01357538|Active Comparator|Posiformin 2 %|Eye ointment applied to the eye lid
3247520|NCT01357538|Placebo Comparator|Placebo|corresponding vehicle, eye ointment applied to the eye lid
3247521|NCT01357603|Experimental|Glaritus arm|Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
3247522|NCT01357603|Active Comparator|Lantus arm|Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
3247523|NCT01357642|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of E004, QID, with 4-6 hr intervals
3359275|NCT04306315|Placebo Comparator|Brodalumab 210 mg + placebo add-on* (standard brodalumab treatment)|Participants will receive 210 mg brodalumab subcutaneously at Week 0, Week 1, and Week 2, and then once every 2 weeks. *Participants not fulfilling a predefined response at any time visit with efficacy assessments Week 16 will receive a dose adjustment to 210 mg brodalumab + placebo every 2 weeks.
3359276|NCT04300478|Other|Sedentary Control/REx|Subjects will complete the Sedentary control testing sessions, have a 7-14 day washout period, and then complete the REx
3359277|NCT04300478|Other|REx/Sedentary Control|Subjects will complete the REx testing sessions, have a 7-14 day washout period, and then complete the Sedentary control
3359279|NCT04289493|Experimental|Group 1: first to receive therapy|27 patients that will receive study specific speech therapy in the first 3 months since study inclusion. From months 3-6 they will be group 2 controls.
3359280|NCT04289493|Experimental|Group 2: second to receive therapy|27 patients that will receive study specific speech therapy during months 3-6 since study inclusion. During the first 3 months of the study period, they will be group 1 controls.
3359281|NCT04289428||A|Not currently on antiviral therapy for HBV and HBV DNA detectable
3359282|NCT04289428||B|Stable on HBV antiviral therapy for at least 3 months with HBV DNA < 20 IU/ml
3359283|NCT04288570|Active Comparator|Bone socket formation with a punch|suture anchor socket creation with punch
3359284|NCT04288570|Active Comparator|Bone socket formation with a drill|suture anchor socket creation with drill
3359285|NCT04284436|Experimental|High Intensity Exercise|Treadmill exercise 4x per week at 80-85% HRmax.
3359286|NCT04284436|Active Comparator|Moderate Intensity Exercise|Treadmill exercise 4x per week at 60-65% HRmax.
3359287|NCT04283461|Experimental|Arm 1|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)
3359288|NCT04283461|Experimental|Arm 10|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
3359289|NCT04283461|Experimental|Arm 11|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
3359290|NCT04283461|Experimental|Arm 12|50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
3359291|NCT04283461|Experimental|Arm 13|10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.
3247524|NCT01357642|Placebo Comparator|Arm P|Placebo comparator as 2×Placebo QID, with 4-6 hr intervals
3359292|NCT04283461|Experimental|Arm 14|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle after Day 209 in participants from Arm 1,4,7,10, 11, and 12 from 18 years of age or older. N=70.
3359293|NCT04283461|Experimental|Arm 15|Optional third mRNA-1273 vaccination sub-study. 100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle no later than Day 394 in participants from Arm 2,3,5 and 8 from 18 years of age or older. N=50.
3359294|NCT04283461|Experimental|Arm 2|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
3359295|NCT04283461|Experimental|Arm 3|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).
3359296|NCT04283461|Experimental|Arm 4|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
3359297|NCT04283461|Experimental|Arm 5|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
3359298|NCT04283461|Experimental|Arm 6|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.
3359299|NCT04283461|Experimental|Arm 7|25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
3359300|NCT04283461|Experimental|Arm 8|100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
3359301|NCT04283461|Experimental|Arm 9|250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.
3247525|NCT01357642|Active Comparator|Arm A|Active comparator, Primatene Mist, 2×220 mcg/inhalation, QID, with 4-6 hr intervals
3247526|NCT01357668||Patients with JIA who are treated with Abatacept|Patients with JIA who are treated with Abatacept according to physicians'/families' decisions
3247527|NCT01357681|Experimental|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) p.o. Month 02:800 mg /day (400-0-400) p.o. Month 03 -12: 1200 mg /day (600-0-600) p.o.
3247528|NCT01357681|Placebo Comparator|Placebo|Placebo
3247529|NCT01357694|Experimental|psychotherapeutic contacts|
3247530|NCT01357694|No Intervention|control group|
3247531|NCT01357707||West Syndrome (idiopathic)|Patients with idiopathic infantile seizures
3247532|NCT01357733|Other|Interim FDG PET/CT|Single arm study with diagnostic imaging study as the intervention.
3247533|NCT01357759|Experimental|Escalating doses of MORAb-022|Subjects with RA will be randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
3247534|NCT01357759|Placebo Comparator|Placebo|Subjects with RA will be also randomized into Cohorts 8 to 11, with each cohort consisting of five RA subjects per cohort (four active and one placebo).
3247535|NCT01357772|Experimental|Tamoxifen|tamoxifen at daily dose of 5 mg for a total treatment time of 3 years
3247536|NCT01357772|Placebo Comparator|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
3247537|NCT01357798|Active Comparator|Btx-A: Active Comparator|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
3247538|NCT01357798|Placebo Comparator|Placebo Comparator|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
3359306|NCT04258488|Experimental|Oral Factor Xa inhibitor|
3359307|NCT04258488|Active Comparator|Vitamin K antagonist|
3359308|NCT04258410|Placebo Comparator|Placebo|Blinded subjects in this arm will receive 2 placebo (blank) soft chews, twice daily, orally for 20 weeks.
3247539|NCT01357811|Active Comparator|digoxin|
3247540|NCT01357811|Experimental|eliglustat with digoxin|
3247541|NCT01357824||Patients admitted for elective surgery|The patient admitted for elective surgery can be included, and will both the case and control, as we intubate the same patient twice, with and without Sellick´s maneuver.
3247542|NCT01357837|Placebo Comparator|Matching Placebo|Once daily oral administration of matching placebo for 4 weeks.
3247543|NCT01357837|Experimental|75 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3247544|NCT01357837|Experimental|200 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3359309|NCT04258410|Experimental|Active Drug|Blinded subjects in this arm will receive 1 g/day of Quercetin delivered in 2 soft chews (250 mg/chew), twice daily, orally, for 20 weeks.
3359313|NCT04252742|Experimental|Erenumab|"The 4-month DBTP has 2 phases:~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
3359314|NCT04252742|Experimental|Placebo|"The 4-month DBTP has 2 phases:~Main DBTP (M-DBTP, months 1 to 3) that will assess the effect of erenumab on metrics such as time spent in at least moderate pain, peak migraine severity, and functional impairment.~Exploratory DBTP (E-DBTP, month 4) that will assess the impact of erenumab on the acute response to treatment with oral triptans as well as non-ictal burden."
3359315|NCT04249739|Experimental|CapeOx+Pembrolizumab(HER2 negative)|"<Cohort A>: HER2 negative patients CapeOx+Pembrolizumab therapy (N=78)~Cycle 1 CapeOX~Cycle 2 up to Cycle 8 CapeOX + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + pembrolizumab therapy~CapeOx + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
3359316|NCT04249739|Experimental|Cape/Cis+Trastuzumab+Pembrolizumab (HER2 positive )|"Cape/Cis+Trastuzumab+Pembrolizumab therapy (N=15)~Cycle 1 Capecitabine + cisplatin (Cape/Cis)~Cycle 2 up to Cycle 8 Cape/Cis + Trastuzumab + pembrolizumab therapy~Cycle 9 up to Cycle 35 Capecitabine + Trastuzumab + pembrolizumab therapy~Cape/Cis + Trastuzumab + Pembrolizumab administered until disease progression, unacceptable toxicity or patient's refusal.~Cycle: Day 1 through Day 21)"
3359317|NCT04247438|Other|Biofilm formation|Biofilm formation after 12 and 36 h on PMMA (polymethyl methacrylate) dentures and the number of brushing cycles needed to remove it.
3247545|NCT01357837|Experimental|400 µg GRT6005|Once daily oral administration of GRT6005 for 4 weeks.
3247546|NCT01357863||Patients on second line treatment|Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
3247547|NCT01357863||Patients on third or more lines treatment|Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
3247548|NCT01357876|Other|Type two diabetics|Type two diabetics
3247549|NCT01357902|Experimental|Lamictal|Chinese healthy male subjects were randomized to receive single dose of either 5 mg lamotrigine dispersible/chewable tablets or 25mg compressed/standard tablets.
3247550|NCT01357928||Healthy Volunteers|
3247551|NCT01357941||Prior VTE minor transient risk factor|Pregnant women with a single prior VTE episode that was either unprovoked or associated with a minor transient risk factor - Prophylaxis with fixed-dose LMWH
3247552|NCT01357941||Prior VTE major transient risk factor|Pregnant women with a single prior VTE episode that was provoked by a major transient risk factor - Surveillance
3247553|NCT01357954|Experimental|Targeted Training|
3247554|NCT01357954|Other|Control|
3359331|NCT04239027|Experimental|RTH258/Brolucizumab|This is a single-arm study in which all patients will be treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment from Week 16/Week 20 up to Week 40/Week 44.
3359332|NCT04233801|Experimental|Empagliflozin low dose|
3359333|NCT04233801|Experimental|Empagliflozin high dose|
3359334|NCT04233801|Placebo Comparator|Placebo|
3359342|NCT04227899|Experimental|Esprit BTK|Participants who receives Esprit BTK device will be included in this arm
3359343|NCT04227899|Active Comparator|Percutaneous Transluminal Angioplasty (PTA)|Participants who receives PTA treatment will be included in this arm
3359344|NCT04224688|Experimental|Rozanolixizumab|Study participants randomized to this arm will receive fixed-unit doses of rozanolixizumab across body weight tiers at pre-specified time points during the Treatment Period. Doses will be adjusted based on platelet count values or medical needs.
3359345|NCT04224688|Placebo Comparator|Placebo|Study participants randomized to this arm receive placebo at pre-specified time points during the Treatment Period.
3359346|NCT04218123|Experimental|Venlafaxine Arm|
3359347|NCT04218123|Placebo Comparator|Placebo|
3247555|NCT01357967|Experimental|Seroquel XR adjunctive|"The quetiapine XR adjunct group will be titrated up to 300mg. Initial dosing will begin at 50mg on Day 1 and 2, increased to 150mg on Day 3 and 4. Further adjustments will be able to be made upwards or downwards within the recommended dose range of 50mg to 300mg depending upon the clinical response and tolerance of the patient. Seroquel XR will be administered daily in the evening.~The dosage of SSRIs will be maintained as low (es-citalopram 5mg, paxil CR 6.25mg, fluoxetine 10mg, and sertraline 25mg)."
3247556|NCT01357967|Active Comparator|SSRI monotherapy|active comparator
3247557|NCT01357993|Experimental|001|JNS001 18 mg 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
3247558|NCT01358006|Experimental|001|JNJ-40411813 Cohort 1: Type=2 to 3 unit=mg number=200 to 300 form=capsule route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.,JNJ-40411813 Cohort 2: Type=up to 7 unit=mg number=up to 700 mg form=capsule route=oral use. Capsule(s) taken in the fed state.
3247559|NCT01358019|Experimental|LY2523355|
3247560|NCT01358032|Experimental|Cognitive behavioral program|an in-home cognitive behavioral program on managing concerns about falling and associated activity avoidance in frail community-dwelling older people facilitated by trained community nurses.
3247561|NCT01358032|No Intervention|Control group|no program, only care as usual
3247562|NCT01358045|Active Comparator|Solaraze|
3359348|NCT04217590|Experimental|Sodium Zirconium Cyclosilicate (SZC)|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
3359349|NCT04217590|Placebo Comparator|Placebo|Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
3359352|NCT04210947|Experimental|Foam-roller I-II-III|Participants will use foam roller in following order of 30RPM(I), 15RPM(II) and self-determined(III)
3359353|NCT04210947|Experimental|Foam-roller I-III-II|Participants will use foam roller in following order of 30RPM(I), self-determined(III) and 15RPM(II)
3359354|NCT04210947|Experimental|Foam-roller II-I-III|Participants will use foam roller in following order of 15RPM(II), 30RPM(I) and self-determined(III)
3359355|NCT04210947|Experimental|Foam-roller II-III-I|Participants will use foam roller in following order of 15RPM(II), self-determined(III) and 30RPM(I)
3359356|NCT04210947|Experimental|Foam-roller III-I-II|Participants will use foam roller in following order of self-determined(III), 30RPM(I) and 15RPM(II)
3359357|NCT04210947|Experimental|Foam-roller III-II-I|Participants will use foam roller in following order of self-determined(III), 15RPM(II) and 30RPM(I)
3247563|NCT01358045|Active Comparator|Solaraze + Silkis|
3359359|NCT04209205|Experimental|Secukinumab|Secukinumab intravenous (i.v.) regimen
3359360|NCT04209205|Placebo Comparator|Placebo|Placebo intravenous (i.v.) regimen
3359361|NCT04202679|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
3359362|NCT04202679|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
3247564|NCT01358045|Active Comparator|Silkis|
3247565|NCT01358045|No Intervention|No treatment|
3247566|NCT01358058|Experimental|Proton radiation therapy|Single arm study delivering fractionated proton therapy over 6 week (54-59.4 Gy(RBE))
3247567|NCT01358071|Experimental|Arm A: NGR-hTNF+ anthracycline|NGR-hTNF+Pegylated Liposomal Doxorubicin or Doxorubicin
3247568|NCT01358071|Active Comparator|Arm B: anthracycline|Pegylated Liposomal Doxorubicin or Doxorubicin
3247569|NCT01358084|Experimental|Arm A: NGR-hTNF + Best Supportive Care|NGR-hTNF + Best Supportive Care
3359365|NCT04199728|Experimental|Investigational group|Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention. Liraglutide will be administered by injection pen.
3359366|NCT04199728|Placebo Comparator|Control group|Participants in the control group will have placebo administered by injection pen following the same low dose titration to 3.0 mg once per day.
3359367|NCT04194476|Experimental|120 neonates less than 28 days old|Each neonate will be tested for blood glucose level twice on the same heel stick site using two glucose meters. additional 200-300 ul blood will be collected and centrifuged. Plasma will be tested blood glucose in the lab analyzer in the clinical laboratory.
3247570|NCT01358084|Placebo Comparator|Arm B: Placebo + Best Supportive Care|Placebo + Best Supportive Care
3247571|NCT01358097||Patients with HPV positive tumors|
3247572|NCT01358097||Patients with HPV negative tumors|
3247573|NCT01358097||Control|
3247574|NCT01358110|Experimental|Early palliative care consultation|Early palliative care consultation for ED patients with advanced cancer.
3247575|NCT01358110|Other|Care as usual|Care as usual, may or may not receive palliative care consultation
3247576|NCT01358136||Hemithyroidectomy|Patients with benign nontoxic goiter who have an indication for hemithyroidectomy
3247577|NCT01358149|Placebo Comparator|placebo|cocoa-based food 1
3247578|NCT01358149|Active Comparator|Treatment 1|cocoa-based food 2
3247579|NCT01358162|Experimental|SQ109|300 mg of SQ109, orally, given daily for 14 consecutive days
3247580|NCT01358162|Placebo Comparator|Placebo|Placebo given orally, daily for 14 consecutive days
3247581|NCT01358188||Gaucher disease group|Subjects will include individuals with GD
3359368|NCT04192760|Active Comparator|Culotte Technique|Both vessels have to be wired. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference. After lesion preparation, the side branch has to be stented first. The first stent is placed from main branch into the side branch, covering the entire diseased segment with a wire jailed in the main vessel. The main vessel is rewired through the stent struts, and after removal of the jailed wire, is dilated with a balloon to separate stent struts. The side branch wire is then removed and the main vessel is stented covering the proximal and distal segment. The side-branch is re-wired and high pressure individual inflations are made in each vessel at the bifurcation point to ensure good stent strut separation. Afterwards, a lower pressure kissing inflation is made. Balloon sizing should be in accordance with the diameter of the vessel itself. Finally, a proximal optimization (POT) procedure is performed.
3359369|NCT04192760|Active Comparator|DK-Crush Technique|"Both vessels have to be wired first. Lesion preparation in the main vessel and side branch may be undertaken according to operator preference (rotablation, if needed).~After lesion preparation, the side branch is stented first. Side branch stent should have a small protrusion into the main branch. Before stent implantation in the side branch, an adequately sized balloon should be placed in the main branch, just opposite to the side branch ostium. After stent implantation in the side branch, stent balloon and wire are removed and the balloon in the main branch must be inflated, to crush the struts into the vessel wall. In next step, the new wire should be crossed into the ostium of the side branch and first kissing balloon dilatation will follow. The next step is to implant the second stent into the main branch, followed by second re-wiring, a second kissing balloon-dilatation and final proximal optimization (POT) procedure (single short balloon inflation in proximal segment)."
3247582|NCT01358188||Control group|Controls will include healthy individuals and individuals with primary immune dysfunction
3247583|NCT01358214||Patients treated with a surgical mesh|This arm of study patients is defined by patients treated with a TiLOOP® Tape mesh between 2007 and 2009 at the Franziskus Krankenhaus, Berlin. The sample of the treated population represents the patient population for which the medical device is intended. To minimize selection bias without compromising patients' rights and welfare, all treated patients will be invited. These patients will be asked to participate in the validation of the questionnaire on quality of life. In addition to this safety and effectiveness of the surgical mesh implantation will be collected
3247584|NCT01358214||Intended to be treated with a mesh|This arm of the study populations is defined by patients in whom a clinical anamnesis independent of the requirements of this study suggests that a sub-urethral sling operation is indicated. These patients will be asked to participate in the validation of the questionnaire on quality of life.
3247585|NCT01358214||Non-symptomatic Population|This arm of the study population is defined by women that show no symptoms of incontinence. They will be asked to participate in the validation of the questionnaire on quality of life.
3359371|NCT04191616|Experimental|Carfilzomib combined with pomalidomide and dexamethasone|Carfilzomib, pomalidomide, and dexamethasone (KPd)
3359372|NCT04190225|Experimental|Multi-technology physical activity intervention|Digital/social media
3359373|NCT04190225|No Intervention|Control|Control group receives a Fitbit but none of the intervention components.
3359374|NCT04188041|No Intervention|Qualitative|"Specific Aim 1: Explore the specific knowledge, attitudinal, and skills gaps to TB infection testing and treatment among primary care team members in RI through qualitative key informant interviews.~In Aim 1, 30 primary care team members from the Brown Family Medicine and Care New England networks will be purposively sampled to undergo key informant interviews regarding TB infection testing and treatment knowledge, attitudinal, and skill gaps. Questions will be asked to ascertain gaps throughout the entire latent TB infection care cascade. The results from Aim 1 will be used to design the survey instrument and the curriculum for an innovative, telementoring program (TB infection ECHO)."
3359375|NCT04188041|Other|Quantitative|Specific Aim 2: Design and evaluate an evidence-based telementoring intervention (ECHO model) that addresses the identified TB infection gaps in Aim 1, and evaluate this model for feasibility as well as its impact on primary care team member knowledge and TB infection testing and treatment in RI. 20 primary care team members will be recruited to participate in a virtual six-month TB infection ECHO course. Participants will complete quantitative surveys before and after the course as well as post-session surveys following each session. Survey questions will assess feasibility measures related to process, resources, and management and impact measures related to learning and performance. Paired data from pre- and post-course surveys will be analyzed accordingly depending on the distribution of results.
3359376|NCT04188041|Other|Retrospective chart review|Pilot a retrospective electronic medical record (EMR) data review to examine RI primary care providers' testing and treatment before and after ECHO implementation and evaluate the model's reach. In Aim 3, data will be retrospectively extracted from two participants' clinics to research RI primary care providers' testing and treatment patterns before and after the ECHO course. The two clinics will be identified once Aim 2 is completed.
3359379|NCT04184622|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3359380|NCT04184622|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3247586|NCT01358227|Experimental|PR104|
3247587|NCT01358240|Experimental|Econazole Nitrate Foam 1%|Study medication
3247588|NCT01358240|Placebo Comparator|Vehicle Foam|Placebo medication
3247589|NCT01358240|Active Comparator|Econazole Nitrate Cream 1%|Econazole Nitrate Cream 1%
3247590|NCT01358240|Sham Comparator|Placebo Cream|Placebo Cream
3247591|NCT01358253|Active Comparator|HyperCVAD|"Consolidation:~HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9."
3259400|NCT01470508|Active Comparator|Cognitive Behavioral Therapy|Individuals meet their therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy.
3247592|NCT01358253|Experimental|R-HyperCVAD|"Consolidation:~R-HyperCVAD(odd courses) alternated with high-dose methotrexate + cytarabine (even courses) every 21 days or later to allow for myelosuppression recovery, for total of 8 courses.~Maintenance:~6-Mercaptopurine+Methotrexate for 24 months. Vincristine+Prednisone for the first 12 months. L-asparaginase in month 3 and 9. Rituximab in month 6 and 12."
3247593|NCT01358279|Experimental|migraine|
3359381|NCT04184622|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3359382|NCT04184622|Placebo Comparator|Placebo|Placebo administered SC once a week.
3247594|NCT01358292|Experimental|Semi-extended surgical technique|The experimental technique for implanting an intramedullary tibia nail is with the knee in 10-20 degrees of flexion.
3359383|NCT04181827|Experimental|Arm A: PVd or DPd (Standard Therapy)|Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.
3359384|NCT04181827|Experimental|Arm B: JNJ-68284528 (Ciltacabtagene Autoleucel [Cilta-cel])|Participants will receive at least one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 (cilta-cel) along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 (cilta-cel) infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).
3359385|NCT04181762|Experimental|secukinumab|secukinumab 300 mg s.c.
3359386|NCT04181762|Placebo Comparator|placebo|secukinumab placebo s.c.
3359389|NCT04179175|Active Comparator|secukinumab 1 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 2 weeks
3247595|NCT01358292|Active Comparator|Standard Surgical Technique|The standard surgical technique in intramedullary tibia nailing is with the knee in almost 90 degrees of flexion.
3247596|NCT01358305|Active Comparator|Whey Protein Isolate|
3359390|NCT04179175|Active Comparator|secukinumab 2 HiSCR Responder|HiSCR responder in core trial, secukinumab 300mg every 4 weeks
3359391|NCT04179175|Placebo Comparator|placebo 1 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300mg every 2 weeks
3359392|NCT04179175|Placebo Comparator|placebo 2 HiSCR Responder|HiSCR responder in core trial, placebo to secukinumab 300 mg every 4 weeks
3359393|NCT04179175|Active Comparator|HiSCR non-responders|non-responder to core trial treatment; secukinumab 300mg every 2 weeks
3359394|NCT04173260|Experimental|Intervention arm - Oral Deutetrabenazine|This is the only arm for this trial. All subjects will receive oral Deutetrabanazine.
3247597|NCT01358305|Experimental|Protein Blend (soy, whey and casein)|
3247598|NCT01358318|Placebo Comparator|Control|
3247599|NCT01358318|Experimental|Soy Protein|
3247600|NCT01358318|Experimental|Soy Fiber|
3247601|NCT01358318|Experimental|Soy Protein and Soy Fiber|
3247602|NCT01358344|Experimental|Standard Percentage|
3247603|NCT01358344|Experimental|High Percentage|
3247604|NCT01358396||HBA1c|
3247605|NCT01358409|Experimental|Nebivolol|Nebivolol (Bystolic® by Forest/Mylan) is a third-generation beta-blocker; it selectively blocks β1-adrenergic receptors and increases peripheral vasodilation.
3247606|NCT01358422||In Patients|
3247607|NCT01358435|Experimental|Wosulin 70/30|Wosulin 70N /30R is a recombinant Human Insulin with 30 % Regular Insulin Human Neutral and 70% Isophane Insulin, 600 nmol/ml, 100 IU/ml.
3247608|NCT01358435|Active Comparator|Novolin 70/30|Novolin 70/30 is a Recombinant Human Insulin with 70% NPH, Human Insulin Isophane Suspension and 30% Regular, Human Insulin Injection
3247609|NCT01358448|No Intervention|Newsletter|
3247610|NCT01358448|Experimental|Growth Monitoring|
3247611|NCT01358448|Experimental|Growth Monitoring plus Family-based Behavioral Counseling|
3247612|NCT01358461||Patients with vagal syncopes|Patients with vagal syncopes (n=120 : 60 adults & 60 children)
3247613|NCT01358461||Subjects controls without vagal syncopes|Subjects controls without vagal syncopes (n=120:60 adults & 60 children
3247614|NCT01358474||PD Subjects|Subjects diagnosed with Parkinson's disease (PD)
3247615|NCT01358474||At-risk for PD|Subjects at-risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations)
3247616|NCT01358474||Healthy Controls|Healthy volunteers
3359399|NCT04170543|Experimental|Group 1|MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).
3359400|NCT04170543|Experimental|Group 2|MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).
3359401|NCT04170543|Experimental|Group 3|MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).
3359402|NCT04170543|Experimental|Group 4|MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).
3359403|NCT04170543|Placebo Comparator|Group 5|Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).
3359404|NCT04166214|Experimental|Dental Providers|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
3359405|NCT04166214|Experimental|Dental Patients|The tele-mentoring intervention involves training dental faculty members and residents to use intraoral cameras to take photographs of oral lesions and place them in the Dentrix electronic health record (EHR), along with descriptions of the lesions.
3247617|NCT01358487|Active Comparator|Online self-help mood management course|Online self-help mood management course based on cognitive behavioral therapy and social cognitive theory, plus automated online follow ups using email reminders and incentives for completing follow-ups
3359407|NCT04154774|Experimental|Group 1: Participants with Severe Hepatic Impairment|Participants with severe hepatic impairment will receive single oral dose of apalutamide on Day 1 under fasted condition.
3359408|NCT04154774|Experimental|Group 2: Participants with Normal Hepatic Function|Participants with normal hepatic function will receive single oral dose of apalutamide on Day 1 under fasted condition.
3247618|NCT01358487|Experimental|Online self-help course plus live follow-up if needed|Intervention and automated follow ups with incentives as in the active comparator condition. The experimental procedure is adding live phone follow-ups if participant does not complete online assessment surveys at 1, 3, and 6 months in response to automated emails.
3247619|NCT01358500|Experimental|Fentanyl|
3359413|NCT04147338|Experimental|Reference Device: Guselkumab|Participants will receive subcutaneous (SC) injections of guselkumab in reference device.
3359414|NCT04147338|Experimental|Test Device 1: Guselkumab|Participants will receive SC injections of guselkumab in test device 1.
3359415|NCT04147338|Experimental|Test Device 2: Guselkumab|Participants will receive SC injections of guselkumab in test device 2.
3359416|NCT04146051|Experimental|Phase 1b Dose-Escalation|Generalized Myasthenia Gravis
3359417|NCT04146051|Experimental|Phase IIa Expansion|Generalized Myasthenia Gravis
3247620|NCT01358513||Control Patients|Patients with normal aortic valves
3247621|NCT01358513||Aortic sclerosis|To undergo PET imaging and follow up with CT and echo for 2 years
3247622|NCT01358513||Mild Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3247623|NCT01358513||Moderate Aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3247624|NCT01358513||Severe aortic stenosis|To undergo PET imaging and follow up with CT and echo for 2 years
3247625|NCT01358539|Experimental|Pain education|Patients receiving pain education
3247626|NCT01358539|No Intervention|No Pain education|Control group, patients receiving no pain education
3247627|NCT01358552||Néevo®/NéevoDHA®|Subjects who have been prescribed Néevo/NéevoDHA® daily.
3247628|NCT01358565|Active Comparator|Mild and Moderate Hepatic Dysfunction|Patients with mild and moderate hepatic dysfunction
3359428|NCT04137224|Experimental|IgPro20|20% liquid formulation of human immunoglobulin for subcutaneous use
3359429|NCT04137224|Experimental|IgPro10|10% liquid formulation of human immunoglobulin for intravenous use
3247629|NCT01358565|Active Comparator|Healthy Volunteers|Healthy volunteers
3359431|NCT04133636|Experimental|JNJ-68284528|Single group assignment-After lymphodepletion, JNJ-68284528 will be administered as single infusion to participants in cohort A (Progressive disease after 1-3 prior lines of therapy), cohort B (Early relapse after front-line), cohort C (Relapsed/refractory multiple myeloma after PI, IMiD, anti-CD38, and anti- BCMA therapy), cohort D (Less than CR after ASCT front-line therapy; some participants will be administered JNJ-68284528 followed by lenalidomide), cohort F (Newly diagnosed multiple myeloma [NDMM] with standard risk [international staging system {ISS} Stage I and II] and after initiation of therapy). Participants in cohort E (NDMM, transplant not planned, high risk disease) will first be administered with quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd), followed by lymphodepletion and JNJ-68284528, followed by consolidation regimen of daratumumab and lenalidomide (D+R).
3359432|NCT04133168|Experimental|Cryoablation|Subjects undergoing cardiac ablation procedure with the POLARx™ Cardiac Cryoablation System
3359433|NCT04129775|Experimental|OTO-413|
3359434|NCT04129775|Placebo Comparator|Placebo|
3359437|NCT04121260|Experimental|Daratumumab|Participants will receive daratumumab dose 1 subcutaneously (SC) with recombinant human hyaluronidase [rHuPH20] 30,000 units [U] that is 2,000 U/milliliter (U/mL) SC injection once weekly for the first 8 weeks Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks Cycles 3 to 6 (Days 1 and 15) or the following 16 weeks and then every 4 weeks from Cycle 7 [Day 1] in subsequent cycles, until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
3359438|NCT04120454|Experimental|Treatment (ramucirumab, pembrolizumab)|Patients receive ramucirumab IV over 60 minutes and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
3359439|NCT04108208|Experimental|Apalutamide 240 milligram (mg) plus ADT|Participants will receive apalutamide 240 mg orally daily from Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study along with androgen-deprivation therapy (ADT). Each treatment cycle will consist of 28 days.
3359440|NCT04108208|Placebo Comparator|Placebo plus ADT|Participants will receive matching placebo daily along with ADT from Cycle 1 Day 1 until disease progression, unacceptable toxicity, withdrawal of consent, death or termination of the study. Participants who do not have distant metastasis will switch to treatment with apalutamide after completion of 5 cycles of placebo treatment. Participants who have prostate-specific antigen (PSA) progression prior to completion of 5 cycles of study treatment, will cross over to apalutamide at the time of PSA progression. Each treatment cycle will consist of 28 days.
3359441|NCT04108195|Experimental|Part 1: Dose Escalation|Participants will be assigned to either a combination of 1) daratumumab plus teclistamab or 2) daratumumab plus talquetamab or 3) daratumumab plus talquetamab plus pomalidomide or 4) daratumumab plus teclistamab plus pomalidomide.
3359442|NCT04108195|Experimental|Part 2: Dose Expansion|Participants will be treated with the RP2D(s) for selected treatment combinations determined in Part 1 until disease progression, unacceptable toxicity, withdrawal of consent, otherwise deemed necessary by the investigator or the sponsor, or end of study.
3359443|NCT04107168||Cohort 1|"Disease: Unresectable AJCC (American Joint Committee on Cancer) stage 3 or 4 melanoma.~Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted."
3359444|NCT04107168||Cohort 2|Disease: Unresectable AJCC stage 3 or 4 melanoma. Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359445|NCT04107168||Cohort 3|Disease: Advanced renal cell carcinoma. Anti-PD-(L)1 + kinase inhibitor. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3247630|NCT01358591|Sham Comparator|Control Breakfast|Normal calcium breakfast.
3247631|NCT01358591|Experimental|High calcium breakfast|High calcium breakfast.
3247632|NCT01358617||Biomarker analysis|Archived tissue microarray samples are analyzed for ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) expression by UCHL1 monoclonal antibody and peroxidase technique.
3247633|NCT01358643|Other|P90X + Sparkpeople|"For six weeks of the study participants will use the P90X tools and for the other six weeks participants will use Sparkpeople tools.~Sparkpeople is a web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight.~P90X is A DVD based home exercise program that guides the participant through a daily exercise routine."
3247634|NCT01358643|Other|P90X + BodyMedia Fit|"For six weeks participants will use the P90X tools and for the other six weeks participants will use the BodyMedia Fit Device.~P90X is a DVD based home exercise program that guides the participant through a daily exercise routine.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress."
3259401|NCT01470521|Experimental|Hookworm larvae (Necator americanus)|Participants will receive 25 live hookworm larvae
3359446|NCT04107168||Cohort 4|Disease: Advanced renal cell carcinoma Nivolumab + Ipilimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359447|NCT04107168||Cohort 5|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) monotherapy in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359448|NCT04107168||Cohort 6|Disease: Advanced NSCLC Anti-PD-(L)1 (Nivolumab, Pembrolizumab or Atezolizumab) + chemotherapy +/- antiangiogenic (Bevacizumab) in the first line setting. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359449|NCT04107168||Cohort 7|Disease: Resected AJCC stage 3 or 4 melanoma. Anti-PD-1 monotherapy (Nivolumab or Pembrolizumab). Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359450|NCT04107168||Cohort 8|Disease: Resected renal cancer Durvalumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359451|NCT04107168||Cohort 9|Disease: Resected renal cancer Durvalumab + Tremelimumab. Dosage form, dosage, frequency and duration will be either standard of care and accessed via normal commissioning arrangements, or will be part of an ethics-approved clinical trial, where co-enrollment into an observational study is permitted.
3359452|NCT04098237|Experimental|Standard of care treatment with Pancreaze (pancrelipase)|Pancrelipase capsules; 84,000 IU lipase units per main meal and 42,000 IU lipase units per snack; for 24 weeks
3247635|NCT01358643|Other|BodyMedia Fit + Sparkpeople|"For six weeks participants will use the BodyMedia Fit devise and for the other six weeks participants will use the Sparkpeople program.~BodyMedia Fit is a program in which the participants wears a small device on their arm that measures their physical activity and allows you to upload detailed physical activity data to a web site to help them track your progress.~Sparkpeople is A web based diet and exercise program in which the participant can track their diet and exercise progress and read and post messages to a large online community of others who are also trying to lose weight"
3247636|NCT01358656|Active Comparator|Single Bundle Reconstruction|Subjects will undergo single bundle acl reconstruction
3359453|NCT04098016|Experimental|Intervention|Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, and 3) skills training.
3359454|NCT04097730|Placebo Comparator|Standard Therapy|Participants in this arm will receive topical 0.5% moxifloxacin plus topical placebo plus sham corneal cross-linking.
3247637|NCT01358656|Active Comparator|Double bundle reconstruction|Subjects will undergo double bundle acl reconstruction
3359455|NCT04097730|Experimental|Early Steroids|Participants in this arm will receive topical 0.5% moxifloxacin plus topical steroids plus sham corneal cross-linking.
3359456|NCT04097730|Experimental|Cross-Linking plus Early Steroids|Participants in this group will receive topical 0.5% moxifloxacin plus topical steroids plus corneal cross-linking.
3359461|NCT04087720|Experimental|Pegloticase|Participants will receive 8 mg pegloticase by IV infusion every 2 weeks from Day 1 through Week 22
3247638|NCT01358669|Active Comparator|Denosumab|In this study we explore the potential for giving a medication (denosumab) that may prevent the loss of bone around the hip replacement implant
3247639|NCT01358669|Placebo Comparator|Placebo|Placebo
3247640|NCT01358695|Placebo Comparator|Placebo Comparator|
3247641|NCT01358695|Experimental|Dose 1|Dose 1
3359464|NCT04083976|Experimental|Erdafitinib|Participants with fibroblast growth factor receptor (FGFR) mutations and FGFR gene fusions will receive a dose of erdafitinib oral tablets until disease progression, intolerable toxicity, withdrawal of consent, or decision by the investigator to discontinue treatment.
3247642|NCT01358695|Experimental|Dose 2|Dose 2
3247643|NCT01358695|Experimental|Dose 3|Dose 3
3247644|NCT01358695|Experimental|Dose 4|Dose 4
3247645|NCT01358695|Experimental|Dose 5|Dose 5
3247646|NCT01358747|Active Comparator|Standard arm|Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 4 cycles. A PET will be performed after 2 cycles of chemotherapy (PET2) with no decisional value, and after 4 cycles with decisional value. Consolidation treatment: depends on the reviewed PET4 result. In case of PET4 negative result, patient will received 2 additional cycles of BEACOPPesc, whatever the result of the PET2. In case of PET4 positive, the patient will be considered in treatment failure and proposed to a salvage therapy after pathologic confirmation of failure by biopsy of the hypermetabolic residual mass when possible.
3247647|NCT01358747|Experimental|Experimental arm|"Induction treatment: Patients will be treated by a BEACOPPesc regimen every 3 weeks for 2 cycles followed by a PET scan (PET2).~After PET2 central review:~In case of positive PET2, the induction treatment will be completed by 2 additional cycles of BEACOPPesc~In case of negative PET2, the induction treatment will be completed by 2 cycles of ABVD delivered every 4 weeks. The first cycle of ABVD will start at day 21 of the second cycle of BEACOPPesc.~Consolidation treatment: depends on the reviewed PET4 result In case of PET4 negative result, consolidation treatment will depends on PET2 results:~If PET2 was positive, patient will received 2 additional cycles of BEACOPPesc delivered every 3 weeks~If PET2 was negative, patient will received 2 additional cycles of ABVD delivered every 4 weeks In case of PET4 positive, the patient will be considered as treatment failure."
3247648|NCT01358773|Other|Lifestyle counseling|Obese adolescents are encouraged to improve their lifestyle
3247649|NCT01358786|No Intervention|no quilting sutures but drains|
3247650|NCT01358786|Experimental|quilting sutures and drains|
3247651|NCT01358786|Experimental|quilting sutures but no drains|
3247652|NCT01358812|Experimental|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
3247653|NCT01358838|Active Comparator|laser|
3247654|NCT01358838|No Intervention|no laser|
3247655|NCT01358851|Experimental|1|Drug Las41005
3247656|NCT01358851|Other|2|Cryotherapy
3247657|NCT01358890|Experimental|B|Subjects will be supplied with low carbohydrate diet for 12 weeks.
3247658|NCT01358890|Experimental|A|Subjects will be supplied with calories restricted diet for 12 weeks
3247659|NCT01358903|Experimental|A|
3247660|NCT01358903|Experimental|B|
3247661|NCT01358916|No Intervention|Usual information policy|No specific intervention
3247662|NCT01358916|Other|Antibiotic therapy guidelines|
3247663|NCT01358929|Experimental|1|
3247664|NCT01358929|Placebo Comparator|2|
3247665|NCT01358942||Cohort|
3247666|NCT01358955|Active Comparator|Group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
3247667|NCT01358955|Active Comparator|Home-based cognitive intervention|The participants will do their homework for 30 minutes every business days for 12 weeks.
3247668|NCT01358955|No Intervention|Wait list Control|They will participate in cognitive intervention after ending this study.
3247669|NCT01359020|Experimental|Ibuprofen|10 milligram per kilo, oral administration
3247670|NCT01359020|Active Comparator|Acetaminophen|10 milligram per kilo, oral administration
3247671|NCT01359020|Active Comparator|Dipyrone|10 milligram per kilo, oral administration
3247672|NCT01359033||MINAP cohort|The Myocardial Ischaemia National Audit Project (MINAP) was established in 1999, in response to the national service framework (NSF) for coronary heart disease, to examine the quality of management of heart attacks (myocardial infarction) in hospitals in England and Wales.
3259402|NCT01470521|Placebo Comparator|Placebo|Participant will receive pharmacopoeial grade water
3259403|NCT01470534|Experimental|Normal body weight|
3359473|NCT04065841|Experimental|Arm A: combination therapy|tropifexor + licogliflozin
3359474|NCT04065841|Experimental|Arm B: tropifexor monotherapy|tropifexor (+ licogliflozin placebo)
3359475|NCT04065841|Experimental|Arm C: licogliflozin monotherapy|licogliflozin (+ tropifexor placebo)
3359476|NCT04065841|Placebo Comparator|Arm D: Placebo|licogliflozin placebo + tropifexor placebo
3359477|NCT04062448|Experimental|Ibrutinib + Rituximab|Participants will receive ibrutinib 420 milligram (mg) orally, once daily, from Day 1 of Week 1 until disease progression or unacceptable toxicity in combination with rituximab 375 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 of Weeks 1 to 4 and Weeks 17 to 20.
3359483|NCT04050540|Experimental|dPEP Intervention Arm|Participants assigned to dPEP will be instructed to take doxycycline 200 mg (two 100mg capsules) orally within 24 hours and up to 72 hours after each condomless sex act
3359484|NCT04050540|No Intervention|Standard of Care Arm|Participants assigned to Standard of Care
3359487|NCT04042376|Experimental|Ibrutinib 420 milligram (mg)|Participants will receive ibrutinib 420 mg once daily, continuously starting at Day 1 of Week 1 until disease progression or unacceptable toxicity, whichever occurs first.
3359488|NCT04040244|Experimental|Exhaled Breath Analysis|Exhaled breathe condensate will be collected using R-tube and ReCIVA device over 5-10 minutes.
3359491|NCT04036058|Experimental|Intervention|Enact universal gloving practices
3359492|NCT04036058|No Intervention|Control|Continue standard of care gloving practices
3359493|NCT04035226||Relapsed/refractory Multiple Myeloma|Patients with relapsed/refractory multiple myeloma who received at least 3 prior lines of therapy including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody treatment will be observed.
3359494|NCT04034459|Active Comparator|FOLFOXIRI plus bevacizumab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1 *1st administration 90 min.; in case of good tolerability, second administration 60 min.; further administrations 30 min.~Repeat administration every 2 weeks for a maximum of 12 cycles~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with fluoropyrimidine and bevacizumab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
3247673|NCT01359033||RIKS-HIA cohort|The Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) has been established to record clinical and treatment information for all patients admitted to the coronary care units in Sweden from 1995.
3247674|NCT01359059|Active Comparator|IV-PCA (Patient-controlled analgesia) morphine|
3247675|NCT01359059|Active Comparator|Patient controlled epidural analgesia (PCEA) fentanyl|
3247676|NCT01359072|Experimental|Immediate Intervention Treatment|
3247677|NCT01359072|Experimental|Wait list|
3247678|NCT01359085|Active Comparator|Pregabalin|
3247679|NCT01359085|Active Comparator|ISBPB|Interscalene brachial plexus block
3247680|NCT01359098|Active Comparator|Ciprodex Otic Suspension|Ciprodex Sterile Otic Solution (Alcon, Inc.)
3247681|NCT01359098|Experimental|Ciprodexa Otic Foam|Ciprodexa Otic Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone otic foam)
3247682|NCT01359124||Water Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a water-based treadmill.
3247683|NCT01359124||Land Treadmill|These subjects will participate in three monitored exercise sessions per week for 8 weeks using a land-based treadmill.
3247684|NCT01359124||Exercise Cycle|These subjects will participate in three monitored exercise sessions per week for 8 weeks using an upright exercise cycle.
3247685|NCT01359137|Experimental|Probation as usual|Routine supervision with no deferred jail condition.
3247686|NCT01359137|Experimental|Deferred jail|Discretionary deferred jail in response to violations of probation conditions.
3247687|NCT01359137|Experimental|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) which uses non-discretionary brief jail sanctions for probation violations.
3359495|NCT04034459|Experimental|FOLFOXIRI plus cetuximab|"One cycle (cycle duration 14 days) consists of:~Irinotecan 150 mg/m² iv, 30 - 90 min. day 1~Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1~Oxaliplatin 85mg/m² day 1~5-FU 3000 mg/m² iv over 48 h days 1-2~Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8~Repeat administration every two weeks up to a maximum of 12 cycles.~Dose adaptation at the treating physician's discretion.~Switch to the recommended maintenance treatment with 5-FU and cetuximab or irinotecan and cetuximab after the 8th cycle (following 2nd staging after baseline) is possible at the treating physician's discretion if response according to RECIST 1.1 (CR or PR) has been achieved."
3359506|NCT04030052|Experimental|Untreated/minimally treated moderate HA no inhibitors|Previously untreated patients (PUPs) and minimally treated patients (MTPs) <3 years of age with moderately severe (≤2% FVIII) HA and no inhibitors.
3359507|NCT04030052|Experimental|Treated any moderate HA with existing inhibitors|Children <21 years of age with moderately severe (≤2% FVIII) HA and with already existing inhibitors (LTI or HTI).
3247688|NCT01359163|Active Comparator|Femulen commercial tablets|
3359515|NCT04015180|Experimental|Aflibercept arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
3359516|NCT04015180|Active Comparator|Laser photocoagulation arm|No study treatment will be administered. The treatments to be evaluated in this study were administered in Study 20090.
3359518|NCT04008706|Experimental|Acalabrutinib|Participants will be enrolled into 3 cohorts. In the treatment-naive (TN) cohort, a minimum of 300 participants with treatment-naïve chronic lymphocytic leukemia will be enrolled. In the relapsed/refractory (R/R) cohort, approximately 200 participants with relapsed/refractory chronic lymphocytic leukemia will be enrolled. In the prior Bruton tyrosine kinase inhibitor (BTKi) therapy cohort, up to 70 to 100 participants with Prior BTKi therapy will be enrolled.
3376024|NCT03197467|Experimental|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
3376025|NCT03193931|Experimental|Arm A|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
3247689|NCT01359163|Experimental|Femulen reformulated tablets|
3247690|NCT01359176||Healthy volunteers|
3376026|NCT03193931|Active Comparator|Arm B|Arm B: Methotrexate (MTX) 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
3376027|NCT03185026|Active Comparator|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
3376028|NCT03185026|Experimental|Psychoeducational group|The patients will experiment the last innovating psychological skills in order to acquire the ability to engage in behaviors to manage their disease.
3376029|NCT03181828|Experimental|Acetohydroxamic Acid Oral Tablet then No Intervention|Participants receive a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg) in the fasted state on the morning of the study. After completion of the 4-h study, participants then enter a wash-out period of 3 days. Participants then completed an identical 4-h study in the fasted state without acetohydroxamic acid.
3259404|NCT01470534|Experimental|Obese|
3259405|NCT01470534|Placebo Comparator|Normal Body Weight placebo|Participants of mormal body weight given placebo
3259406|NCT01470534|Placebo Comparator|Obese placebo|Participants who are obese given placebo
3359519|NCT04005729|Experimental|Cangrelor + Ticagrelor|Bolus of cangrelor (30 mcg/kg) and immediately afterwards a continuous intravenous infusion of 4 mcg/kg/min at the start of the primary percutaneous coronary intervention. Crushed and dissolved ticagrelor tablets (180 mg) will be given via inserted enteral tube.
3359520|NCT04005729|No Intervention|Ticagrelor|Crushed and dissolved ticagrelor tablets (180 mg) will be given via enteral tube (standard care).
3359521|NCT04000737|Experimental|Sorafenib + YIV-906|Patients in the study arm will be treated orally for 28-day courses with YIV-906 + sorafenib
3359522|NCT04000737|Active Comparator|Sorafenib + Placebo|Patients in the placebo arm will be given sorafenib with placebo
3359525|NCT03980314|Experimental|Arm A (Process C)|"Participants will receive nivolumab specified dose on specified days"
3247691|NCT01359189|Experimental|Suspected Primary Prostate Cancer|Patients with suspected prostate cancer will be evaluated for initial proof of concept and feasibility of a scintigraphic rectal probe (ProxiScanTM) utilizing a PSMA receptor radiopharmaceutical (ProstaScint®). To explore the adjunctive benefit/feasibility of PSMA distribution in the normal prostate versus prostate cancer gland utilizing TRUS and CT/SPECT hybrid imaging, biopsy negative patients will be considered as normal controls. This is an exploratory, open label trial and randomization is not required. Subject blinding is not needed and investigator blinding in not possible.
3247692|NCT01359202|Active Comparator|Niastase RT|Niastase RT 80ug/kg IV bolus
3359526|NCT03980314|Experimental|Arm B (Process D)|"Participants will receive nivolumab specified dose on specified days"
3247693|NCT01359202|Placebo Comparator|Placebo|saline IV bolus
3247694|NCT01359215||Treatment|Children who received an anesthetic prior to age 2
3359530|NCT03955900||Participants with Multiple Myeloma (MM)|Participants with MM will be observed in real-world clinical practice settings. The primary data source for this study will be the medical records of each participant.
3359535|NCT03950076|Experimental|Edoxaban 60/30mg daily|Edoxaban 60/30 mg daily (lower dose depending on clinical criteria)
3359536|NCT03950076|Active Comparator|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy: no antithrombotic therapy or antiplatelet monotherapy (at discretion of local investigator)
3359537|NCT03947788|Experimental|Interventional Practices|These clinics, including physicians, clinical and administrative staff, will receive the One Key Question training program, delivered by Power to Decide, via an in-person group training session.
3359538|NCT03947788|No Intervention|Control Practices|These clinics will not receive the OKQ training program during the study period. They will have the opportunity to receive the training after the study period is over.
3359539|NCT03944798|Active Comparator|Surveillance Arm I|Clinical assessment and chest radiograph (CXR) every six months for two years
3359540|NCT03944798|Experimental|Surveillance Arm II|Clinical assessment and CXR every three months for two years
3247695|NCT01359215||Control|Children who have never been anesthetized
3247696|NCT01359228|Experimental|Rifaximin|rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
3247697|NCT01359228|Placebo Comparator|sugar pill|Placebo 1 tablet three times a day for 14 days.
3247698|NCT01359241|Experimental|closed-loop insulin delivery|Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
3247699|NCT01359241|Active Comparator|Usual diabetes treatment regimen|Usual non-insulin glucose-lowering medications
3247700|NCT01359267|Experimental|Imaging|
3247701|NCT01359280|Experimental|Adherence Counseling + Text Messages|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
3359541|NCT03944798|Experimental|Surveillance Arm III|Clinical assessment and chest computed tomography (CT) every six months for two years
3359542|NCT03944798|Experimental|Surveillance Arm IV|Clinical assessment and chest CT every three months for two years
3359544|NCT03938402|Experimental|PEEP 5|
3359545|NCT03938402|Experimental|PEEP 10|
3359546|NCT03938402|Experimental|PEEP 15|
3247702|NCT01359280|Experimental|Adherence Counseling Only|Participants receive one office-based adherence counseling session and 4 phone-delivered counseling sessions focused on antiretroviral adherence strategies using a model of behavioral self regulation skills building.
3247703|NCT01359280|Placebo Comparator|General Health Counseling Only|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building.
3247704|NCT01359280|Placebo Comparator|General Health Messages + Text Messages|Participants receive one office-based counseling session and 4 phone-delivered counseling sessions focused on general health and nutrition strategies using a model of behavioral self regulation skills building. Participants also receive follow-up medication reminder text messages delivered by cell phone.
3359551|NCT03928743|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
3359552|NCT03928743|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
3359556|NCT03927690|Experimental|LKA651|LKA651 IVT
3359557|NCT03927690|Experimental|LKA651/Lucentis|LKA651/Lucentis IVT
3359558|NCT03927690|Active Comparator|Lucentis|Lucentis IVT
3359559|NCT03927638||Normal Weight|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
3359560|NCT03927638||Overweight/Obese|Group is determined based upon subjects weight status. Subjects will preform computer work in the seated and standing position in a counterbalanced manner while metabolic and cardiovascular measurements are made.
3359561|NCT03926013|Experimental|Part 1: Dose Escalation|Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-63898081. Ascending dose levels will be sequentially tested.
3359562|NCT03926013|Experimental|Part 2: Dose Expansion|Participants with mCRPC or renal cell carcinoma (RCC) will receive JNJ-63898081 at the recommended Phase 2 dose (RP2D) determined in Part 1.
3247705|NCT01359319|Experimental|650 mg (single dose only)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3247706|NCT01359319|Experimental|1,950 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3359570|NCT03918447|Experimental|Maximum bardoxolone methyl dose of 20 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR less than or equal to 300 mg/g will be titrated to a maximum dose of 20 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2 and 20 mg at Week 4.~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.~Patients will be assessed at an in-person follow-up visit at Week 104."
3359571|NCT03918447|Experimental|Maximum bardoxolone methyl dose 30 mg|"Patients randomized to receive bardoxolone methyl with a baseline ACR greater than 300 mg/g will be titrated to a maximum dose of 30 mg. Patients will begin once-daily dosing with bardoxolone methyl capsules at 5 mg and will dose escalate to 10 mg at Week 2, 20 mg at Week 4 and 30 mg at Week 6.~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive study drug during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 at the same dose they received at Week 48 and will continue study drug treatment through Week 100.~Patients will be assessed at an in-person follow-up visit at Week 104."
3376030|NCT03181828|Experimental|No Intervention then Acetohydroxamic Acid Oral Tablet|Participants completed a 4-h study in the fasted state without acetohydroxamic acid. 3 days later, participants then completed an identical 4-h study in the fasted state, after having received a single oral dose of 60 mg/kg acetohydroxamic acid (rounded to the nearest 250 mg).
3376031|NCT03181529|Experimental|Immediate Treatment|Participants will begin psilocybin intervention immediately after study enrollment.
3376032|NCT03181529|Experimental|Delayed Treatment|Participants will begin the psilocybin intervention 8 weeks after study enrollment.
3376033|NCT03178370||Diabetic Gastroparesis|
3376034|NCT03178370||Idiopathic Gastroparesis|
3376035|NCT03170557|Active Comparator|Traditional chinese acupuncture|Traditional chinese acupuncture. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
3376036|NCT03170557|Sham Comparator|Aspecific needle skin stimulation|Aspecific needle skin stimulation. Administration of 12 sessions (2 per week for 6 weeks). Each session lasts 20-30 minutes.
3376037|NCT03165526||First Cohort|All available Emergency and Compassionate PIVSD Occluder subject data from 2011 until the end of 2016 will be utilized to determine technical success and acute survival. All subjects belonging to this cohort must have undergone an attempt to close a post-infarct VSD using the AMPLATZER™ PIVSD Occluder.
3359572|NCT03918447|Placebo Comparator|Placebo|"Patients randomized to placebo will remain on placebo capsules throughout the study, undergoing sham titration.~Patients will be scheduled to be assessed during treatment at Weeks 1, 2, 4, 6, 8, 12, 24, 36, 48, 52, 64, 76, 88, 100, and 104 by telephone contact on Days 3, 10, 21, 31, 38, and 45. Patients will not receive placebo during a 4-week withdrawal period between Weeks 48 and 52. They will re-start treatment at Week 52 and will continue treatment through Week 100.~Patients will be assessed at an in-person follow-up visit at Week 104"
3359577|NCT03913741|Experimental|Experimental tisotumab vedotin|Open label, single arm trial where tisotumab vedotin will be administered
3359578|NCT03913273|Experimental|Intervention group|Intervention: AMI transtibial amputation
3359579|NCT03913273|Active Comparator|Control group|Intervention: Standard transtibial amputation
3359580|NCT03911869|Experimental|Standard Dose Arm|"Patients in the standard-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~450 mg encorafenib orally once a day (QD)~45 mg binimetinib orally twice a day (BID)~Patients who are able to tolerate the standard dose during the first 4 weeks of treatment (Cycle 1) should be dose-escalated to 600 mg encorafenib QD plus 45 mg binimetinib BID provided they meet protocol-defined criteria."
3359581|NCT03911869|Experimental|High Dose Arm|"Patients in the high-dose treatment arm will receive encorafenib and binimetinib in 28-day cycles.~300 mg encorafenib orally twice a day (BID)~45 mg binimetinib orally twice a day (BID)"
3247707|NCT01359319|Experimental|2,925 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3247708|NCT01359319|Experimental|4,875 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3359582|NCT03911492|Other|SCP Pressure Management|Active management of Spinal Cord Perfusion Pressure (SCPP) at or above 65 mmHg.
3247709|NCT01359319|Experimental|6,000 mg (single and repeat dose)|Each patient will be sequentially assigned to a specific dose level and will receive two single-dose exposures at that same dose level (fasted and fed). The low-dose cohorts will be filled before assigning higher-dose cohorts. The patient will then be assigned to receive one repeat-dose regimen. The lower-dose repeat-dose cohorts will be filled before proceeding to higher repeat-dose levels.
3247710|NCT01359332|Experimental|hypothermia|
3247711|NCT01359332|No Intervention|control|
3247712|NCT01359345|Experimental|A|The patients with renal failure in whom Gadollinume has being used
3247713|NCT01359384||affected patients|25 patients suffering from severe immune deficiency under immunoglobulin therapy
3247714|NCT01359384||non-affected patients|25 matched controls not suffering from severe immune deficiency
3247715|NCT01359397|Active Comparator|Herceptin -|
3247716|NCT01359397|Experimental|Herceptin +|
3247717|NCT01359423|Experimental|long coverage|Primary long full coverage stenting
3247718|NCT01359423|Active Comparator|short spot|primary short spot stenting
3247719|NCT01359436|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
3247720|NCT01359462|Experimental|Tolvaptan 15mg tablet|
3359587|NCT03905525|Experimental|Cohort 1 /Arm A|CFZ533 dose 1
3359588|NCT03905525|Experimental|Cohort 1/Arm B|CFZ533 dose 2
3359589|NCT03905525|Experimental|Cohort 1/Arm C|CFZ533 dose 3
3359590|NCT03905525|Placebo Comparator|Cohort 1/Arm D|Placebo dose (up to week 24)
3359591|NCT03905525|Experimental|Cohort 1/Arm D1|CFZ533 dose 1 (from week 24)
3359592|NCT03905525|Experimental|Cohort 2/Arm E|CFZ533 dose 1
3359593|NCT03905525|Placebo Comparator|Cohort 2/Arm F|Placebo dose (up to week 24)
3359594|NCT03905525|Experimental|Cphort 2/Arm F1|CFZ533 dose 2 (from week 24)
3359595|NCT03904134|Other|Donor Search Prognosis: MUD Very Likely|Patients who are Very Likely to find a matched unrelated donor (MUD), defined as having a >90% chance of finding an 8/8 HLA-matched unrelated donor, for whom a fully matched unrelated donor will be pursued.
3359596|NCT03904134|Other|Donor Search Prognosis: MUD Very Unlikely|Patients who are Very Unlikely to find a MUD, defined as having a <10% chance of finding an 8/8 HLA-matched unrelated donor, for whom a haploidentical, cord blood, or mismatched unrelated donor transplant will be pursued.
3359597|NCT03904134|Other|Donor Search Prognosis: MUD Less Likely|Patients with a Less Likely chance of finding a MUD, i.e., those not falling into the other two groups (a 26% chance), will be enrolled onto the observational component of the study and analyzed for all relevant endpoints but will not be included in the primary comparison.
3247721|NCT01359475|Experimental|Acetal crown|Clinical performance of acetal crowns for treatment of primary molars
3359616|NCT03885089||Infliximab [infliximab biosimilar 3]|Patients with Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, or Erythrodermic Psoriasis treated by Infliximab BS
3359617|NCT03875235|Experimental|Treatment Arm|Durvalumab + Gemcitabine + Cisplatin
3359618|NCT03875235|Placebo Comparator|Placebo Arm|Placebo + Gemcitabine + Cisplatin
3359619|NCT03873402|Experimental|Nivolumab + ipilimumab|
3359620|NCT03873402|Experimental|Nivolumab + ipilimumab placebo|
3376038|NCT03165526||Second Cohort|"This cohort will consist of subjects over the age of 18 years who have previously been successfully implanted with the PIVSD Occluder and~For living subjects, the subject or subject's legally authorized representative has provided consent to participate in this study.~Subject's post-procedure echocardiogram is evaluable and can be sent to the echocardiography core laboratory for residual shunt assessment.~Therefore, this cohort will be composed of retrospectively enrolled subjects. This cohort will be utilized to determine acute and chronic closure and chronic survival."
3376039|NCT03164928|Other|Placebo|SC Q6M placebo
3376040|NCT03164928|Experimental|Denosumab|1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
3376041|NCT03150693|Active Comparator|Arm I (frontline chemotherapy)|See detailed description.
3376042|NCT03150693|Experimental|Arm II (frontline chemotherapy, inotuzumab ozogamicin)|Patients receive inotuzumab ozogamicin IV on days 1, 8, and 15 and undergo bone marrow aspirate and biopsy on day 28. Treatment repeats every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients also receive remission consolidated chemotherapy, interim maintenance chemotherapy, delayed intensification, and maintenance therapy as in Arm I.
3376043|NCT03138096|Experimental|Group 1 - five Pb(PfCS@UIS4)-infected mosquitoes|(Group 1) will be exposed to bites of five Pb(PfCS@UIS4)-infected mosquitoes
3376044|NCT03138096|Experimental|Group 2 - 25 Pb(PfCS@UIS4)-infected mosquito bites|(group 2) will be exposed to 25 Pb(PfCS@UIS4)-infected mosquito bites
3376045|NCT03138096|Experimental|Group 3 - 75 Pb(PfCS@UIS4)-infected mosquito bites|(group 3) will be exposed to 75 Pb(PfCS@UIS4)-infected mosquito bites
3376046|NCT03138096|Other|Group 4 - Infectivity control group of Phase 1|Infectivity control group of Phase 1
3376047|NCT03138096|Other|Group 5 - Infectivity control group of Phase 2|Infectivity control group of Phase 2
3376048|NCT03113929||Alcoholic Liver Disease Patients|
3247722|NCT01359488|Experimental|VRS-317 Safety Arm 1|"VRS-317 Single injection SC of dose level 1 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3247723|NCT01359488|Experimental|VRS-317 Safety Arm 2|"VRS-317 Single injection SC of dose level 2 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3247724|NCT01359488|Experimental|VRS-317 Safety Arm 3|"VRS-317 Single injection SC of dose level 3 (based on 90 kg patient)~Placebo Single SC injection Dose Volume matched to active treatment volume"
3359626|NCT03866239|Experimental|Obinutuzumab Pretreatment (OpT) + Cibisatamab + Atezolizumab|Participants will receive obinutuzumab approximately 2 weeks before receiving atezolizumab and cibisatamab on Day 1 of each treatment cycle (cycle = 21 days).
3359627|NCT03854474|Experimental|Treatment (tazemetostat, pembrolizumab)|Patients receive tazemetostat PO BID on days 1-21 and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3359628|NCT03842436|Experimental|Digital Pills|Digital Pills containing Truvada ingested once daily as PrEP
3359629|NCT03838549|Experimental|implant for breast reconstruction|20 patients female with genetic risk for breast cancer and who ask for prophylactic mastectomy. They will have a prophylactic mastectomy with immediate breast reconstruction
3359630|NCT03834064|Experimental|Intervention|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the intervention arm. Caregivers working in that home will receive the oral health promotion strategy/intervention over the course of a year.
3247725|NCT01359488|Experimental|VRS-317 Safety Arm 4|"VRS-317 Two injections SC of dose level 4 (based on 90 kg patient)~Placebo Two SC injection Dose matched to treatment volume"
3247726|NCT01359488|Experimental|VRS-317 Safety Arm 5|"VRS-317 Two injections SC of dose level 5 (based on 90 kg patient)~Placebo Two SC injections Dose Volume matched to active treatment volume"
3359631|NCT03834064|No Intervention|Control|Homes where participants with intellectual/developmental disabilities reside will be randomly assigned to the control arm. Caregivers in that home will not receive the oral health promotion strategy/intervention over the course of a year but will be offered a compressed intervention after a year.
3359632|NCT03832998|Experimental|Dose Level 1|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
3359633|NCT03832998|Experimental|Dose Level 2|Subjects will be randomized to one of two doses determined by their body weight at Day 1.
3359634|NCT03832998|Placebo Comparator|Placebo|
3359635|NCT03829540|Experimental|Treatment|"Redirected autologous T cells transduced with the anti-CD4 lentiviral vector (referred to as CD4CAR cells)"
3376049|NCT03106987|Experimental|Active Comparator: Olaparib|Olaparib 300mg tablets administered orally twice daily continuously.
3247727|NCT01359501|Experimental|Chinese medical treatment|
3247728|NCT01359501|Placebo Comparator|Placebo|
3247729|NCT01359514|Active Comparator|Duloxetine|
3376050|NCT03106987|Placebo Comparator|Placebo Comparator: Placebo|Matching placebo 300mg tablets administered orally twice daily continuously.
3247730|NCT01359514|Active Comparator|Pregabalin|
3247731|NCT01359527||Hip Resurfacing|
3247732|NCT01359527||Total Hip Arthroplasty|
3247733|NCT01359540||APEX Modular|APEX Modular Stem group
3247734|NCT01359540||ARC Stem|ARC Stem group
3247735|NCT01359553||Knee pain|Group with knee pain problems referred to an arthroscopy.
3247736|NCT01359566|Active Comparator|Arbaclofen placarbil 15 mg BID|Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening
3247737|NCT01359566|Active Comparator|Arbaclofen placarbil 30 mg BID|Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening
3247738|NCT01359566|Active Comparator|Arbaclofen placarbil 45 mg BID|Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening
3247739|NCT01359566|Placebo Comparator|Placebo|Placebo every morning and every evening
3247740|NCT01359579|Experimental|Subjects with mild renal impairment|
3247741|NCT01359579|Experimental|Subjects with moderate renal impairment|
3247742|NCT01359579|Experimental|Subjects with normal renal function|
3247743|NCT01359579|Experimental|Subjects with severe renal impairment|
3247744|NCT01359605|Experimental|varespladib methyl|
3247745|NCT01359618|Experimental|Part A 1|TC-5214
3247746|NCT01359618|Experimental|Part A 2|TC-5214 placebo
3376051|NCT03089606|Other|C11-AMT PET|"Whole body FDG PET/CT scan with IV contrast will be performed at least 24 hours before C11-AMT PET scanning, as per standard of care.~C11-AMT PET will be performed at least 24 hours before pembrolizumab treatment and at least 24 hours after FDG PET/CT scan.~Pembrolizumab 200mg by IV flat dose will be administered over 30 minutes on Day 1; Pembrolizumab dosing will be repeated every 3 weeks until progression or subject withdrawal for other reasons.~Whole body FDG PET/CT scan with IV contrast at end of treatment."
3376052|NCT03059264||CDM|Children with Congenital Myotonic Dystrophy
3376053|NCT03059264||Control|Healthy Children
3376054|NCT03056001|Experimental|Pembrolizumab + doxorubicin|Participants receive pembrolizumab IV infusion and doxorubicin IV injection on Day 1 of each cycle.
3247747|NCT01359618|Experimental|Part B 1|TC-5214 8 mg + moxifloxacin placebo
3359636|NCT03823534|Experimental|Experimental Arm|For the first 24 hours following surgery, patients younger than 65 years old will be administered a maximum of 120 mg/day bolus IV ketorolac (30 mg every 6 hours). Patients older than 65 years old or with history of advanced renal impairment will receive a maximum of 60 mg/day bolus IV ketorolac (15 mg every 6 hours). All patients may also be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate- severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. At discharge, they will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours, quantity 50. Those with preexisting liver disease will be prescribed the equivalent in oxycodone and will not receive acetaminophen for mild pain.
3359637|NCT03823534|Placebo Comparator|Control|Following surgery, patients will be given acetaminophen 500 mg PO Q4 hours PRN for mild pain, oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate-severe pain, and morphine IV PRN (or other opioid) for severe breakthrough pain while hospitalized. They will also be given a placebo injection of normal saline every 6 hours for the first 24 hours following surgery. At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours PRN quantity 50, unless they have preexisting liver disease, in which case they will be prescribed the equivalent in oxycodone. They will not receive a nerve block.
3359645|NCT03812991|No Intervention|Non-Treatment Group|This is the Non-Treatment Arm of the study. No intervention is to be administered.
3359646|NCT03812991|Experimental|Miacalcin Calcitonin Salmon Nasal Spray|1 spray (200 IU) qDay, alternate nostrils daily
3247748|NCT01359618|Experimental|Part B 2|TC-5214 supratherapeutic dose + moxifloxacin placebo
3359652|NCT03803228|Experimental|DUOSTIM|(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; oocyte freezing; (stim 2) resumption of stimulation only by Fertistratkit® 300 IU / day from the day after the puncture; introduction of Progestan® 7 days later to avoid menstruation during the second puncture; triggering with rHCG and second puncture at 36h associated with the devitrification of stim 1 oocytes, with sperm collection and embryonic vitrification. Transfer of frozen embryos to the subsequent cycle in the natural cycle (without HCG) and until the frozen embryos are exhausted.
3376055|NCT03049189|Experimental|177Lu-edotreotide PRRT|"177Lu-edotreotide (177Lu-DOTATOC)~A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each.~Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)"
3376056|NCT03049189|Active Comparator|Everolimus|"Everolimus (Afinitor ®)~Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)"
3376057|NCT03047031||Group A|Patients who started treatment with nintedanib after 23rd January, 2017 and have permanently discontinued the drug (as decided by the investigator) at the time of participation in the active surveillance.
3376058|NCT03047031||Group B|Patients who started treatment with nintedanib after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance.
3376059|NCT03047031||Group C|Patients who have been newly prescribed nintedanib at the time of participation in the active surveillance
3247749|NCT01359618|Active Comparator|Part B 3|TC-5214 placebo + moxifloxacin 400 mg
3376060|NCT03043729|Active Comparator|Arm A|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
3247750|NCT01359618|Placebo Comparator|Part B 4|TC-5214 placebo + moxifloxacin placebo
3247751|NCT01359657|Experimental|Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone|
3359653|NCT03803228|Active Comparator|Conventional stimuli|"(stim 1) flexible antagonist protocol with pre-treatment with estrogen (S1 between J1 and J8 under E2) and stimulation with Fertistartkit® 300 IU / d; triggering by rHCG (Ovitrelle®250μg) and puncture at 36h; fresh embryonic transfer if satisfactory endometrial conditions with luteal phase support by vaginal micronized progesterone Progestan® 600 mg / d; otherwise embryonic freezing and transfer of frozen embryos to the subsequent cycle in the natural cycle until the frozen embryos are exhausted.~(stim 2) ditto starting on the next cycle if possible or the next one. Hormonal Controls + Ultrasound During Stimulation: Blocking / S1 - S5 / S6 - S8 / S9 - SHCG / SHCG-1"
3359654|NCT03796065|Experimental|FSI-R Treatment|Families randomized into the FSI-R Treatment arm will receive the 10-module Family Strengthening Intervention in addition to any outside services or programs they are participating in.
3247752|NCT01359657|Experimental|Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone|
3247753|NCT01359670|Experimental|Tadalafil|
3359655|NCT03796065|No Intervention|FSI-R Control|Families randomized into the FSI-R Control arm will not receive the FSI-R treatment. Instead, they will continue with their usual care, referred to as Treatment as Usual (TAU).
3359656|NCT03793478|Experimental|All Participants|All participants will receive re-induction therapy that includes fludarabine and cytarabine in combination with experimental drug quizartinib. For prophylaxis, IT chemotherapy with cytarabine, methotrexate and prednisolone/hydrocortisone will be given prior to or between re-induction cycles. After completing re-induction therapy, eligible participants may also receive optional consolidation chemotherapy which includes cytarabine, etoposide and quizartinib, if HSCT is not available immediately. After completing re-induction or HSCT successfully, eligible participants can go on to receive continuation therapy with quizartinib.
3247754|NCT01359670|Experimental|Sildenafil|
3247755|NCT01359683|Other|A|This is a prospective observational study. 100 patients in one arm scheduled for cardiac surgery will be enrolled. ECG tracings will be obtained when subject is at rest, in supine position, before induction of anesthesia (within 24 hours prior to induction), after induction of general anesthesia, right before emergence from anesthesia (or before transportation to the ICU if the subject remains intubated), and within 24 hours post-operatively; additional ECG readings may be obtained during the surgery if deemed necessary.
3359661|NCT03785678|Experimental|Tenecteplase|Patients in this arm will receive Tenecteplase (0.25 mg/kg, maximum 25 mg) administered as a single bolus injection over 5 seconds.
3359662|NCT03785678|Placebo Comparator|Placebo|Patients in this arm will receive placebo administered as a single bolus injection over 5 seconds.
3359663|NCT03779243|Experimental|5mg Melatonin and Sleep Education|Participants will take 5mg Melatonin nightly, 1 hour before bedtime and be provided educational materials to improve sleep hygiene. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits.
3247756|NCT01359696|Experimental|A|
3247757|NCT01359709|Experimental|Contingency Management|
3247758|NCT01359709|Placebo Comparator|Noncontingent control|
3247759|NCT01359722|Experimental|N-Acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
3247760|NCT01359722|Placebo Comparator|Control|This group will receive only the infusion of saline in the same doses and infusion rate.
3247761|NCT01359761|Experimental|Post Admission Cognitive Therapy (PACT)|Six (6) 60-90 Minutes Post Admission Cognitive Therapy Individual Sessions; Up to Two (2) Inpatient Booster Sessions; Up to Four (4) Telephone Booster Sessions Following Psychiatric Discharge; 12-Months Case Management
3247762|NCT01359761|No Intervention|Enhanced Usual Care (EUC)|Treatment As Usual and Study Assessment Services; 12-Months Case Management
3247763|NCT01359774|Other|Healthy volunteers|
3247764|NCT01359774|Other|Huntington patients|
3247765|NCT01359787|Active Comparator|Mapracorat 0.01% Ointment|Lowest concentration
3247766|NCT01359787|Active Comparator|Mapracorat 0.03% Ointment|Middle concentration
3247767|NCT01359787|Active Comparator|Mapracorat 0.1% Ointment|Highest concentration
3359664|NCT03779243|Placebo Comparator|Placebo Control|"Participants will be given placebo pills to be taken daily 1 hour before bedtime and are a sleep aid. Participants will not receive any sleep education materials. They will have study visits in clinic as part of standard-of-care at 6 weeks and 12 weeks. They will complete Pittsburgh Sleep Quality Index and SF-36 Quality of Life questionnaires at enrollment and at their clinic visits."
3247768|NCT01359787|Placebo Comparator|Vehicle without active|
3359665|NCT03774082|Experimental|INC424 (ruxolitinib)|Subjects who will be administered 5mg ruxolitinib tablet or ruxolitinib oral pediatric formulation twice a day.
3359666|NCT03770598|Active Comparator|Distressed|Study participants who do indicate distress or who do meet criteria for depression or anxiety will be randomized to receive either treatment as usual (referral to Psychiatry or Psychology for evaluation and further treatment) or team based care model.
3359667|NCT03770598|Active Comparator|Non-Distressed|Study participants who do not indicate distress or who do not meet criteria for depression or anxiety will be randomize to monitoring only or to receive psycho-education regarding subjects that when used can promote wellness.
3359668|NCT03768960|Experimental|Daratumumab|Participants will receive 16 milligram per kilogram (mg/kg) of daratumumab as intravenous (IV) infusion every week (QW) in Cycles 1 and 2 (Days 1, 8, 15 and 22) and every 2 weeks (Q2W) in Cycle 3 to 6 (Days 1 and 15) each cycle is of 28 days.
3359671|NCT03757013||Patients treated with Apremilast|Patients with moderate to severe chronic plaque psoriasis after failure or contra-indication or intolerance to other systemic therapy including ciclosporin, methotrexate, or phototherapy UVA + psoralen (PUVA therapy).
3359672|NCT03750825|Experimental|Vapers|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
3359673|NCT03750825|No Intervention|Smokers|Smokers will continue to smoke.
3359674|NCT03750825|No Intervention|Nonsmokers non-vapers|Control nonsmokers non-vapers will continue to refrain from smoking or vaping.
3359675|NCT03749746|Active Comparator|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
3359676|NCT03749746|Experimental|Home Blood Pressure Monitoring|In addition to usual care outlined above, each participant will receive a Bluetooth-enabled blood pressure cuff along with a checklist of proper technique and instructions on use. Women will be prompted to measure their BP across the first week of each month during the intervention. Based on guidelines, participants will take their blood pressure in the morning and evening, each time taking two readings separated by one minute.
3359677|NCT03749746|Experimental|Heart Health 4 New Moms|Participants randomized to this group will receive instruction on the use of Heart Health 4 New Moms internet-based lifestyle intervention and home blood pressure monitoring. The internet-based intervention is comprised of four key components: an online curriculum with modules on healthy eating and physical activity, a self-monitoring and tracking program, a registered dietitian will act as a lifestyle coach for participants and a customized online toolbox.
3359681|NCT03738228|Experimental|Arm A (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.
3359682|NCT03738228|Experimental|Arm B (atezolizumab, standard cisplatin and radiation therapy)|Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.
3247769|NCT01359800||Treatment-naive HIV+ subjects|
3247770|NCT01359800||HAART-treated HIV+ subjects|
3247771|NCT01359813|No Intervention|Usual treatment|intravenous injection of Human Albumin. 1,5g/kg on first day and 1g/kg on third day
3247772|NCT01359813|Experimental|Human Albumin|1,5g/kg on first day and 1g/kg on third day.
3247773|NCT01359826|Experimental|Milnacipran|Patients administered milnacipran will receive a dose escalation to 50 mg twice a day over 12 days and continued at this dose until week 6. If tolerated and a 15% improvement in fatigue from baseline is achieved by assessment on the FSS, then patients will continue taking 50 mg twice a day until the end of the study on day 98 (week 14). Otherwise, the dose of milnacipran will be titrated upward to 100 mg twice a day over 12 days and continued at this dose until day 98 (week 14).
3247774|NCT01359826|Placebo Comparator|Placebo|Placebo tablets administered orally twice a day for 14 weeks.
3247775|NCT01359839|Experimental|Relaxation Response Mind Body Intervention|The Relaxation Response (RR) Mind Body Intervention Arm receives the Behavioral: Relaxation Response and Cognitive Behavioral Therapy Intervention which is a RR based Mind Body Group consisting of 1½ hour group classes held weekly for 8 weeks, in a conference room at the health center.
3247776|NCT01359852|Experimental|001|"[11C] JNJ-42491293 + JNJ-40411813 Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan,[11C] JNJ-42491293 + JNJ-40411813 Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain,[11C] JNJ-42491293 Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.,[11C] JNJ-42491293 Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection have a 90 minute PET scan and have arterial and venous blood sampling."
3247777|NCT01359865|No Intervention|Lumbar plexus Block|This group will recieve pre-operative lumbar plexus block plus general anesthesia
3247778|NCT01359878|Experimental|Fibrinogen Concentrate|
3247779|NCT01359878|Placebo Comparator|Placebo|Isotonic Saline
3359686|NCT03729271|Experimental|Rifaximin and breath tests|Rifaximin 550mg three times a day for 14 days. Breath tests (glucose and lactulose) will be completed prior to Rifaximin treatment and at week 13 of the study.
3359687|NCT03724747|Experimental|BAY2315497 dose escalation|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. The total antibody dose of 50 mg will be evaluated first; on the basis of emerging clinical data, doses within the range of 20-100 mg may be investigated.
3359688|NCT03724747|Experimental|BAY2315497 dose escalation in combination with darolutamide|The thorium-227 dose will be escalated in a step-wise fashion to the MTD, according to a predefined dose escalation scheme. In addition, Darolutamide oral dosing at the approved dose of twice daily 600 mg will be initiated 14 days prior to the first BAY2315497 Injection dose on Day 1 of the first cycle. Daily darolutamide dosing will continue throughout the entire BAY2315497 Injection treatment period until withdrawal criteria from study treatment period are met.
3359689|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 1|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
3359690|NCT03724747|Experimental|BAY2315497 dose expansion:Dose regimen 2|The thorium-227 and total antibody doses, as well as the treatment regimen, will be selected for expansion on the basis of the safety, PK and overall benefit risk profile of BAY2315497 Injection, observed in the course of the dose escalation.
3359691|NCT03721068|Experimental|iC9.GD2.CAR.IL-15 T-cells|The continuous reassessment method (CRM) will be used to estimate the maximum-tolerated dose (MTD) of cells that to be given in dose escalation cohorts comprised of 2-6 subjects. The final MTD will be the dose with estimated probability of dose limiting toxicity (DLT) closest to the target toxicity rate of 20%. Three cell doses will be evaluated: 0.5 x 10^6 cells/kg, 1.0 x 10^6 cells/kg, 1.5 x 10^6 cells/kg. Cohort enrollment will be staggered and each subject must complete at least 2 weeks of the cell treatment without incident of DLT before another subject can be enrolled at that dose level. A minimum of two subjects must complete the 4-week post-infusion DLT period before enrollment at the next higher dose level will be considered. If dose level 1 is determined to be above a tolerable dose, de-escalation would occur to dose level -1 where subjects would receive 0.25 x 10^6 cells/kg.
3359694|NCT03712228|Placebo Comparator|Placebo|Subjects with C1-INH HAE receiving buffer only
3359695|NCT03712228|Active Comparator|CSL312 (low)|Subjects with C1-INH HAE receiving low dose CSL312
3359696|NCT03712228|Active Comparator|CSL312 (med)|Subjects with C1-INH HAE receiving medium dose CSL312
3359697|NCT03712228|Active Comparator|CSL312 (high)|Subjects with C1-INH HAE receiving high dose CSL312
3247780|NCT01359891||Cohort 1|"All patients >18 years admitted to the University Hospital Graz, Austria, with positive blood cultures tested in the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz, or the Institute for Hygiene, Microbiology and Environmental Medicine, Medical University Graz, are screened for study inclusion. Patients eligible for the study have to have Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Klebsiella pneumoniae or medically relevant fungi / viral pathogens identified as causative pathogen.~The estimated total number of patients included in this first study cohort will be 500."
3359698|NCT03712228|Active Comparator|CSL312 (med/high)|Subjects with C1-INH HAE receiving medium/high dose CSL312
3359699|NCT03712228|Active Comparator|CSL312-F|Subjects with FXII or plasminogen mutation (FXII/PLG) HAE receiving CSL312
3247781|NCT01359891||Cohort 2|"All patients >18 years admitted to the University Hospital Graz, Austria, will be screened for study inclusion if the attending emergency department physicians on the very first visit suspects bacteremia/fungemia/sepsis and consecutively orders blood cultures. Patients will be included in this second cohort if these initially taken blood culture turns positive (n=200) or stays negative (n=50) at the Microbiology Laboratory, Department of Internal Medicine, Medical University Graz. As soon as the number of 50 is reached for the control group enrollment will be stopped for this group.~As soon as the proposed number of 250 patients is reached enrolment for this second cohort will be stopped. Patients enrolled in cohort 2 may also be consecutively enrolled in cohort 1."
3247782|NCT01359891||Validation Cohort|To verify the employed Presage™ST2 assay established in our study laboratory for its intended use, a total number of 70 left over plasma samples obtained from septic patients which have prior been tested for sST2 with the same assay at the Department of Laboratory Medicine, Barmherzige Brueder Linz, Austria, will be retested. This cohort therefore serves as a validation cohort.
3247783|NCT01359917||autologous fat transfer|patients received fat transfer for HIV lipodystrophy
3247784|NCT01359917||polylactic acid|treatment with polylactic acid (PLA) for HIV lipodystrophy
3247785|NCT01359917||bio-alcamid|bio-alcamid injections
3247786|NCT01359930|Active Comparator|Naltrexone and Bupropion SR|
3247787|NCT01359930|Placebo Comparator|Placebo|
3247788|NCT01359969|Experimental|Recombinant Human C1 Inhibitor|Patients presented to the clinic within 5 hours of onset received rhC1INH 50 U/kg body weight up to a maximum of 4200 U.
3247789|NCT01359982|Experimental|RRx-001|
3247790|NCT01360008||Cryo ablation|Patients with first Ablation of atrial fibrillation treated by cryo ablation
3247791|NCT01360008||RF ablation|Patients with first Ablation of atrial fibrillation treated by Radio frequency ablation
3359710|NCT03696784|Experimental|Single Arm iC9.CAR19 T cells|"The safety of iC9-CAR19 cells will be investigated using the 3+3 design. Dose level (DL) Dose (#transduced cells/kg)~-1 1 x 10^5~1 x 10^6~2 x 10^6 DL1 will enroll 3 subjects. If no toxicity within 4 weeks, then DL 2 will enroll 3 subjects. If toxicity in 1/3 subjects in DL 1, 3 more subjects will be enrolled. If DL 1 is not tolerable, a de-escalation to DL -1 will enroll 3 subjects. If 3 subjects at the higher dose do not have DLTs more will be enrolled at that dose to get more information about toxicity.~Lymphodepleting chemotherapy of IV bendamustine 70 mg/m2 and IV fludarabine 30 mg/m2/day for 3 consecutive days will be given within 2-14 days prior to cell infusion.~AP1903 (0.4 mg/kg), a dimerizing agent to engage and activate the caspase 9 safety switch to trigger iC9-CAR19 T cell death by apoptosis will be given to subjects who develop severe cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS)."
3359711|NCT03696784|Experimental|Expansion Cohort iC9-CAR19 cells|After the tolerable cell dose (TCD) has been determined in adults, up to 18 additional subjects may be enrolled in an expansion cohort at the TCD. A TCD is defined as the dose at which approximately 0.20 of subjects experience dose limiting toxicity (0 - 1 out of 6 subjects).
3359712|NCT03696550|Experimental|Cohort 1|"Eravacycline (TP-434) intravenous formulation Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 12 to <18 (Cohort 1) 1.50"
3247792|NCT01360034|Experimental|Nifedipine|108 patients will receive nifedipine as tocolytic for 48 hours.
3247793|NCT01360034|Experimental|Indomethacin|108 patients will receive indomethacin as tocolytic for 48 hours.
3359713|NCT03696550|Experimental|Cohort 2|"Eravacycline will be administered as a single 60 minute IV infusion according to age.~Age group (years) Dose (mg/kg) 8 to <12 (Cohort 2) 1.75"
3359714|NCT03693846|Experimental|Nivolumab and Ipilimumab|Treatment will consist of nivolumab 480mg every 4 weeks and ipilimumab 1mg/kg every 8 weeks.
3359717|NCT03669497|Experimental|Hypo fractionated radiotherapy|Hypo fractionated whole breast radiotherapy with simultaneous integrated boost to the tumour
3247794|NCT01360047||Cases|Cases with nonfatal MI or coronary death
3247795|NCT01360047||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
3247796|NCT01360060||Group N|parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia
3247797|NCT01360060||Group P|parturients who had undergone Cesarean section under the diagnosis of preeclampsia
3247798|NCT01360073||Cases|Cases with nonfatal MI or coronary death
3247799|NCT01360073||Controls|Age, sex, and calendar-year matched controls sampled from the original study cohort to be a round number of at least four times the number of cases
3247800|NCT01360086|Experimental|Perioperative CT with 5FU-Cisplatine-Cetuximab|6 cycles of intravenous Cetuximab (500mg/m²), Cisplatine (50mg/m²) and LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks. Surgery was planned 3-4 weeks after the end of neaodjuvant CT and postoperative CT, with the same regimen, planned for 6-8 weeks after surgery.
3247801|NCT01360138|Active Comparator|midline approach|cervical epidural steroid injection with 18G Touhy epidural needle by midline approach
3247802|NCT01360138|Active Comparator|paramedian approach|cervical epidural steroid injection with 18G Touhy epidural needle by paramedian approach
3247803|NCT01360151|Experimental|experimental|Arm 1 : combination treatment of ranibizumab(Lucentis) and verteporfin(Visudyne) injection
3247804|NCT01360151|Active Comparator|active comparator|Arm 2 : Treatment of verteporfin(Visudyne)
3247805|NCT01360151|No Intervention|normal control group|Arm 3 : normal control group
3247806|NCT01360164|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Participants will be given umbilical cord mesenchymal stem cells transplantation with a 1 year follow-up.
3247807|NCT01360177|Experimental|Radioactive Iodide and PET/CT|
3247808|NCT01360190|Active Comparator|fluoxetine|
3247809|NCT01360190|Placebo Comparator|placebo|
3247810|NCT01360203|No Intervention|Current Care|Patients will receive the current care provided to heart failure patients at each of the study sites
3247811|NCT01360203|Experimental|Care Transition Intervention|Care transition intervention beginning prior to discharge and through six months post-discharge.
3247812|NCT01360216|Experimental|LARC education and training|Clinicians and contraceptive educators practicing in clinics assigned to this arm receive a special half-day Continuing Medical Education (CME/CEU) accredited LARC education and training session.
3247813|NCT01360216|No Intervention|Standard practice- control|Clinicians and contraceptive educators practicing in clinics assigned to this arm do not receive special LARC training and education session. Standard practice will be followed at clinics assigned to the control arm.
3247814|NCT01360242|Active Comparator|MIMI procedure (two-step strategy)|Thrombus aspiration is performed to achieve TIMI-3 flow. Once TIMI-3 flow is restored and sustained for > 10 minutes, the initial procedure is stopped regardless of the presence of any residual stenosis. A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
3359732|NCT03646604|Experimental|Part 1; Cohort 1|Participants, 6 to <12 years of age, will receive low dose of upadacitinib.
3359733|NCT03646604|Experimental|Part 1; Cohort 2|Participants, 6 to <12 years of age, will receive high dose of upadacitinib.
3359734|NCT03646604|Experimental|Part 1; Cohort 3|Participants, 2 to <6 years of age, will receive low dose of upadacitinib.
3359735|NCT03646604|Experimental|Part 1; Cohort 4|Participants, 2 to <6 years of age, will receive high dose of upadacitinib.
3359736|NCT03646604|Experimental|Part 1; Cohort 5|Participants, 6 months to <2 years of age, will receive low dose of upadacitinib.
3359737|NCT03646604|Experimental|Part 1; Cohort 6|Participants, 6 months to <2 years of age, will receive high dose of upadacitinib.
3247815|NCT01360242|Sham Comparator|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
3247816|NCT01360255||Patients treated with TACE|Patients treated with transarterial chemoembolisation (TACE) are included in this clinical trial
3359738|NCT03646162|Experimental|Veru-944 10 mg|Veru-944 10 mg daily
3359739|NCT03646162|Experimental|Veru-944 50 mg|Veru-944 50 mg daily
3359740|NCT03646162|Placebo Comparator|Placebo|Placebo daily
3247817|NCT01360281|Experimental|ECR|
3247818|NCT01360281|No Intervention|Control|
3247819|NCT01360281|Experimental|NMES|
3247820|NCT01360294||Asthma with small airway disease|
3359743|NCT03635788|Experimental|Arm A: LA ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 3, participants will receive a RPV-LA maintenance dose and a CAB-LA maintenance dose every 4 weeks for 52 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
3359744|NCT03635788|Active Comparator|Arm B: SOC Oral ART|In Step 1, participants will receive SOC oral ART regimen for 24 weeks. In Step 2, participants will continue SOC oral ART regimen for 52 weeks. In Step 3, participants will receive oral RPV once daily and oral CAB once daily for 4 weeks, followed by a RPV-LA loading dose and a CAB-LA loading dose, followed in 4 weeks by a RPV-LA maintenance dose and CAB-LA maintenance dose every 4 weeks for 44 weeks. In Step 4, eligible participants will be followed until they complete 52 weeks on locally sourced oral ART.
3359745|NCT03619213|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo.
3359746|NCT03619213|Placebo Comparator|Placebo|Placebo matching dapagliflozin.
3359747|NCT03617445|Active Comparator|FMT oral capsules/ oral vancomycin placebo|FMT plus placebo vancomycin
3359748|NCT03617445|Active Comparator|Placebo FMT capsules/ Active oral vancomycin|Vancomycin plus FMT enema placebo
3359751|NCT03611868|Experimental|APG-115+Pembrolizumab open label, two-part phase Ib/II|single arm dose escalation and dose expansion
3359752|NCT03611751|Experimental|BMS-986165|BMS-986165 oral administration
3359753|NCT03611751|Placebo Comparator|Placebo|Placebo oral administration
3359754|NCT03611751|Active Comparator|Active comparator|Active comparator oral administration
3359757|NCT03604172|Experimental|Cognitive behavioral therapy|16-week cognitive behavioral therapy intervention for binge eating disorder
3359758|NCT03604172|Other|Waitlist control|16-weeks on waitlist then participants will be provided with 16-weeks of cognitive behavioral therapy
3359759|NCT03603288|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meal)
3359760|NCT03602157|Experimental|ATLCAR.CD30.CCR4 & ATLCAR.CD30|A 3+3 design in adult subjects. Subjects in the first dose level will receive ATLCAR.CD30.CCR4 cells alone, once safety has been established, the initial dose of ATLCAR.CD30.CCR4 will be combined with a fixed dose of ATLCAR.CD30 cells in the next dose level. Every time the dose of ATLCAR.CD30.CCR4 is escalated, subjects in that dose level will receive ATLCAR.CD30.CCR4 alone prior to subsequent dose level enrolling subjects to receive a combination of fixed dose ATLCAR.CD30 and the selected dose level of ATLCAR.CD30.CCR4. The six dose levels will consist of: dose level 1 = 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 2 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 2 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 3 = 5 × 10^7/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 4 = 1 × 10^8 ATLCAR.CD30 cells/m2 and 5 × 10^7 ATLCAR.CD30.CCR4 cells/m2; dose level 5 = 1 × 10^8/m2 ATLCAR.CD30.CCR4 cells/m2; dose level 6 = 1 × 108 ATLCAR.CD30 cells/m2 and 1 × 108 ATLCAR.CD30.CCR4 cells/m2.
3359761|NCT03601455|Experimental|Regimen A (radiation therapy and durvalumab)|Participants receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity. Participants also undergo EBRT for 5 fractions beginning on day 8 of course 1.
3359762|NCT03601455|Experimental|Regimen B (radiation therapy, durvalumab, tremelimumab)|Participants receive tremelimumab IV over 60 minutes on day 1 for up to 2 courses and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression of unacceptable toxicity. Participants also receive undergo EBRT for 5 fractions beginning on day 8 of course 1.
3359765|NCT03584737||Symptomatic for bacterial sinusitis|Samples from participants showing symptoms of bacterial sinusitis tested by rapid in vitro diagnostic test, bacterial culture, and PCR assay
3247821|NCT01360294||Asthma without small airway disease|
3247822|NCT01360307||Major Depressive Disorder Patients|
3247823|NCT01360320|Experimental|Green tea extract|Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG, bid for 3 years
3247824|NCT01360320|Placebo Comparator|Placebo|Placebo, packed in hard gelatine capsules, bid for 3 years
3359768|NCT03581006||Intervention Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This intervention group will undergo technology based monitoring and behavioral participation in a dietary and exercise program with the intent of weight loss and compliance with a low-calorie Mediterranean diet."
3359769|NCT03581006||Control (Usual care) Group|"This observational cohort study will follow firefighters enrolled in Monitoring and Treatment Program. Investigators will include firefighters in the validation cohort who were present at the WTC site within 3 days of 9/11, have consent, and have abnormal post-9/11 lung function.~This group will receive no dietary or behavioral intervention. They will continue usual care with their home physicians."
3247825|NCT01360333|Other|Tap water, sodium chloride, carbohydrate rich fluid|
3247826|NCT01360346|Experimental|Enteral Sedation (EN)|Melatonin, Hydroxyzine, and Lorazepam. At every work shift, it will be checked the possibility to decrease the Lorazepam and then the Hydroxyzine dosage to quickly obtain and continuously maintain a RASS level = 0
3359774|NCT03578224|Experimental|Diagnostic (EUS, FNA, perflubutane microbubble)|Participants undergo standard of care unenhanced endoscopic ultrasound (EUS) and fine needle aspiration (FNA) of identified lymph nodes. Participants then receive perflubutane microbubble peri- or intratumorally and undergo contrast-enhanced EUS followed by FNA of identified lymph nodes.
3359775|NCT03574545|Active Comparator|Reference VAY736 Drug Product|Powder for solution for injection / infusion
3359776|NCT03574545|Experimental|Test VAY736 Drug Product|Solution for injection
3359777|NCT03574207|Other|Arm A: Stimulation then Sham|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm A, transcranial magnetic stimulation (TMS) will be applied in the first week of participation, and sham stimulation will be applied in the second week of participation.
3359778|NCT03574207|Other|Arm B: Sham then Stimulation|All procedures are identical in both arms with the exception of the order of stimulation administration. In Arm B, sham stimulation will be applied in the first week of participation, and transcranial magnetic stimulation (TMS) will be applied in the second week of participation.
3247827|NCT01360346|Active Comparator|Intravenous Sedation (IV)|Intravenous propofol or midazolam administration at the ICU admission to discharge at the compatible lowest level with harsh ICU environment. At every shift nurses are requested to give intravenous lowest dosage to obtain RASS=0
3247828|NCT01360359|Experimental|Core Stabilization|"8-week core stabilization program in 3 stage that emphasizes use of specific local trunk stabilizing muscles to restore active control and stability to the trunk.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
3247829|NCT01360359|Active Comparator|Trunk Motion and Fitness|"8-week exercise program in 3 stages emphasizing spine motion, general trunk flexibility and strengthening and cardiovascular fitness.~8-week exercise program, 1-2 sessions/ week, 30-60 minute sessions"
3247830|NCT01360372|Active Comparator|Methylnaltrexone|
3247831|NCT01360372|Placebo Comparator|saline placebo injection|
3247832|NCT01360385||Central Retinal Vein Occlusion|CRVO-patients with planned treatment with intravitreal injections of ranibizumab, who receive three monthly injections of ranibizumab and a 3 month follow-up period, during which ranibizumab injections are provided as needed.
3247833|NCT01360411||Pancreatic lesions|"Any patient with a solid pancreatic lesion of unknown histology may be recruited. Cystic lesions are not included.~Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively."
3247834|NCT01360411||Intramural upper GI-lesions|Patients with intramural lesions discovered by endoscopy or other imaging modalities are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
3247835|NCT01360411||Lymph nodes|Patients with visible mediastinal lymph nodes or retroperitoneal lymph nodes in patients with inflammatory or malignant diseases are recruited. Elastography findings are classified and compared to cytology or histology if the standard procedures or treatment provide this. In other cases the patients are being followed up conservatively.
3247836|NCT01360424|Experimental|teriparatide|
3247837|NCT01360437|Active Comparator|Prasugrel|
3247838|NCT01360437|Experimental|Ticagrelor|
3247839|NCT01360463|Experimental|Behavioral and Drug Risk Counseling|Participants assigned to this arm will receive bi weekly Behavioral and Drug Risk Counseling (BDRC) counseling for six months.
3247840|NCT01360463|Active Comparator|Treatment as Usual|Participants assigned to this arm will receive methadone treatment without and alterations.
3247841|NCT01360476|Active Comparator|Vitamin D|
3247842|NCT01360476|Placebo Comparator|placebo|
3247843|NCT01360528||Extremely low birth weight|Extremely low birth weight under 1000 gram
3247844|NCT01360528||Very low birth weight|Between 1000-1500 gram babies
3247845|NCT01360528||Low birth weight|Between 1500-2500 gram
3247846|NCT01360541|Experimental|Radiofrequency ablation|Endoscopic radiofrequency ablation of BE
3247847|NCT01360541|Active Comparator|Surveillance|Endoscopic surveillance and PPI treatment
3247848|NCT01360567|Placebo Comparator|B formula|placebo
3247849|NCT01360567|Experimental|A formula|Green tea extract
3247850|NCT01360593|Other|Gem, Xeloda, SBRT|
3247851|NCT01360606|Other|SBRT|
3359785|NCT03551782|Experimental|Cohort 1|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not treatment-emergent small-cell neuroendocrine prostate cancer [t-SCNC]) who progressed on abiraterone acetate plus prednisone/prednisolone (AA-P) will be enrolled in this cohort. Participants will receive cetrelimab 480 milligram (mg) plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
3359786|NCT03551782|Experimental|Cohort 2|Biomarker-negative or biomarker-unknown participants with adenocarcinoma (and not t-SCNC) who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1.
3359787|NCT03551782|Experimental|Cohort 3|Biomarker-positive participants who progressed on AA-P will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
3359788|NCT03551782|Experimental|Cohort 4|Biomarker-positive participants who progressed on apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
3359789|NCT03551782|Experimental|Cohort 5|Biomarker-negative participants with t-SCNC who progressed on treatment with AA-P, apalutamide, darolutamide, or enzalutamide will be enrolled in this cohort. Participants will receive cetrelimab 480 mg plus apalutamide 240 mg daily starting Cycle 1 (each cycle of 28 days).
3359790|NCT03548207|Experimental|JNJ-68284528|After lymphodepletion JNJ-68284528 will be administered as a single infusion.
3359791|NCT03547037|Experimental|Phase 1a: JNJ-63723283 (Monotherapy)|Participants will receive monotherapy of JNJ-63723283 intravenously. The subsequent dose levels of JNJ-63723283 will be escalated using Bayesian logistic regression model (BLRM).
3359792|NCT03547037|Experimental|Phase 1b: Erdafitinib Combination|Participants will receive erdafitinib in combination with JNJ-63723283 which will be escalated using BLRM.
3359794|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 1)|
3247852|NCT01360658|Experimental|Intravenous immunoglobulins|Intravenous immunoglobulins
3247853|NCT01360671|Experimental|Sildenafil|iv sildenafil
3359795|NCT03538301|Experimental|ND-L02-s0201 (Dose Level 2)|
3359796|NCT03538301|Placebo Comparator|Placebo|
3359797|NCT03523442|Experimental|Apalutamide|Participants will receive a single oral dose of apalutamide 240 milligram (mg) during pharmacokinetics (PK) Week Day 1 and will be monitored for one week (that is; PK Week) to assess PK and safety of drug. Subsequently, participants will further receive daily treatment of apalutamide from Cycle 1 Day 1 onwards until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. Each treatment cycle consists of 28 days.
3359798|NCT03519997|Experimental|Pembro + Bavi|Pembrolizumab 200 mg IV every 3 weeks plus, Bavituximab 3mg/kg IV weekly
3359799|NCT03510468|Experimental|1|(1) TAF once daily alone (days 1-14) and (2) TAFonce daily + weight-based RPT + INH (withpyridoxine) once weekly (days 15-31)
3247854|NCT01360697|Experimental|JADE- JA|Use the JADE portal to monitor the delivery of structured care.
3247855|NCT01360697|Active Comparator|Usual care|Patients will receive usual care in between two annual comprehensive assessments.
3247856|NCT01360710|Experimental|Moxonidine|
3247857|NCT01360710|Active Comparator|Irbesartan|
3247858|NCT01360723||urothelial carcinoma|Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
3247859|NCT01360723||Healthy controls group|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
3247860|NCT01360736|Experimental|Safety Planning - Military (SAFE-MIL)|Brief Safety Planning Using Stanley and Brown (2012) Model
3247861|NCT01360736|No Intervention|E-CARE|Treatment As Usual and Assessment Services of Study; Control Condition
3247862|NCT01360749|Experimental|Lambdalina and placebo|Eligible patients will receive lambdaline (lidocaine cream 40 mg/g) in Left Lower Extremity and placebo in Right Lower Extremity.
3247863|NCT01360749|Experimental|Placebo and lambdalina|Eligible patients will receive placebo in Left Lower Extremity and lambdaline (lidocaine cream 40 mg/g) in Right Lower Extremity.
3247864|NCT01360775|Experimental|nutritional counseling|Supervision and monitoring of nutritional status of patients in the home care program, after making nutritional advice
3247865|NCT01360775|No Intervention|Not nutritional counseling|
3247866|NCT01360788||Healthy control subjects|Subjects with a significant smoking history (more than 10 pack-years) and a normal lung function.
3359800|NCT03503357|Experimental|IFT Testing 1|Participants will be fitted with and IFT cuff and randomized to command list A intra-operatively to assess awareness.
3359801|NCT03503357|Experimental|IFT Testing 2|Participants will be fitted with and IFT cuff and randomized to command list B intra-operatively to assess awareness.
3359802|NCT03503357|Experimental|IFT Testing 3|Participants will be fitted with and IFT cuff and randomized to command list C intra-operatively to assess awareness.
3359803|NCT03503357|Experimental|IFT Testing 4|Participants will be fitted with and IFT cuff and randomized to command list D intra-operatively to assess awareness.
3359804|NCT03501173||Metastatic Castrate-Sensitive Prostate Cancer (mCSPC)|Participants will be defined as having mCSPC if there is a new mCSPC diagnosis in the past 6 months, documented metastatic prostate cancer, no more than 12 months of androgen deprivation therapy (ADT) in any setting and no more than 6 months of systemic treatment for mCSPC (example, next generation androgen receptor targeted therapy or chemotherapy).
3359805|NCT03501173||Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|Participants will be defined as having mCRPC if there is mCRPC diagnosis at any time, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated prostate specific antigen [PSA] despite testosterone less than [<]50 nanogram per deciliter [ng/dL] [<1.7 nano moles per liter{nmol/L}]), the first treatment for mCRPC was started in the past 6 months or is scheduled to begin.
3359806|NCT03501173||NonMetastatic Castrate-Resistant Prostate Cancer (nmCRPC)|Participants will be defined as having nmCRPC if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 3 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7 nmol/L]). nmCRPC, defined as a prostate specific antigen doubling time (PSADT) of less than or equal to 12 months, or beginning next generation ARAT for nmCRPC.
3359807|NCT03501173||mCRPC (Treatment-experienced in the nmCRPC or mCSPC Setting)|Participants will be defined as having mCRPC (treatment-experienced in the nmCRPC or mCSPC setting) if there is nmCRPC diagnosis at any time, documented non-metastatic prostate cancer, documented metastatic prostate cancer, documented castration resistance per Prostate Cancer Working Group 2 criteria (elevated PSA despite testosterone <50 ng/dL [<1.7nmol/L]), the first treatment for mCRPC clinical state was started in the past 6months or is scheduled to begin, disease progression occurred while receiving active treatment (ARAT or chemotherapy) in the prior nmCRPC or mCSPC clinical state.
3359810|NCT03489434|Experimental|Intervention Group|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
3359811|NCT03489434|No Intervention|Control|Assessment only control.
3247867|NCT01360788||Asymptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea). Concretely, this group did not present any respiratory symptoms, with a MRC dyspnea score of 1/5.
3247868|NCT01360788||Symptomatic GOLD stage I COPD patients|GOLD stage I COPD (post-bronchodilator forced expiratory volume in 1 second [FEV1] > 80% predicted and FEV1/ forced vital capacity [FVC] < 0.7 and a smoking history > 10 pack-years) were recruited. A Medical Research Council (MRC) dyspnea score ≥ 2 was used to define the presence of symptoms (dyspnea) in this group.
3359815|NCT03474471|Experimental|Group 1:PR-EBV treatment|Follow a Pulmonary rehabilitation program PRIOR to the EBV treatment
3359816|NCT03474471|Experimental|Group 2: EBV treatment-PR|Follow a Pulmonary rehabilitation program AFTER the EBV treatment
3359817|NCT03474471|Active Comparator|Group 3: EBV treatment|Only EBV treatment
3359818|NCT03474107|Experimental|Arm A: Enfortumab Vedotin 1.25 mg/kg|Participants received 1.25 milligrams per kilogram (mg/kg) of body weight enfortumab vedotin by intravenous infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
3359819|NCT03474107|Active Comparator|Arm B: Chemotherapy|Participants received either 75 milligrams per square meter (mg/m^2) docetaxel by IV infusion over approximately 1 hour or 320 mg/m^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m^2 paclitaxel by IV infusion over approximately 1 hour on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first.
3247869|NCT01360814||GROUP A (multidisciplinary intervention)|Patients receive six 90-minute sessions of a multidisciplinary structured intervention comprising physical therapy, education, a cognitive-behavioral intervention, discussion and support, spiritual reflection, and a relaxation exercise over 2-4 weeks. Caregivers are invited to sessions 1, 3, 4, and 6. Patients may also receive brief telephone contact during the 6 month follow-up period.
3247870|NCT01360814||GROUP B (standard medical care)|Patients receive standard medical care only. Patients may also receive brief telephone contact during the 6 month follow-up period.
3359822|NCT03464110|No Intervention|Standard of Care|Investigator will compare patients randomized into the intervention group to those who receive standard of care.
3359823|NCT03464110|Experimental|Communication Intervention|The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
3359824|NCT03462719|Experimental|Treatment Arm A: Ibrutinib and Venetoclax (I+VEN)|Participants will initially receive ibrutinib (420 mg [milligrams]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
3247871|NCT01360827|Experimental|Arm 1 (Part 1)|
3359825|NCT03462719|Active Comparator|Treatment Arm B: Chlorambucil and Obinutuzumab (G-Clb)|Participants will receive chlorambucil and obinutuzumab (G-Clb) for 6 cycles. Participants will receive obinutuzumab, 1000 mg intravenously (IV) on Days 1, 8 and 15 of Cycle 1, and on Day 1 of Cycles 2 to 6 and chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight, on Days 1 and 15 of Cycles 1 to 6. Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
3359826|NCT03462030|Experimental|Baked Milk Immunotherapy|Subjects will receive baked milk oral immunotherapy with baked non-fat cow's milk powder as the intervention. Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
3359827|NCT03462030|Placebo Comparator|Placebo|Subjects will receive oral immunotherapy with the placebo control (tapioca powder). Subjects will undergo an initial dose escalation, build-up, and then a maintenance period.
3247872|NCT01360827|Experimental|Arm 2 (Expansion cohorts -Part 2 and Part 2a)|
3247873|NCT01360853|Experimental|Arm A: Combination|Arm A: Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle, + ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
3247874|NCT01360853|Active Comparator|Arm B: Gemcitabine only|Arm B: Gemcitabine only, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
3247875|NCT01360918|Active Comparator|Usual care|
3247876|NCT01360918|Active Comparator|Pulmonary vein isolation|
3247877|NCT01360931||Lung Cancer group|Subject with histological confirmation of lung cancer
3247878|NCT01360931||Control group|Subjects with no diagnosis of lung cancer
3247879|NCT01360944|Experimental|LAS 41004, variant 1, once daily|variant 1, once daily
3247880|NCT01360944|Experimental|LAS41004, variant 2, once daily|variant 2, once daily
3247881|NCT01360944|Experimental|LAS41004, variant 3, once daily|variant 3, once daily
3247882|NCT01360944|Experimental|LAS41004, variant 4, once daily|variant 4, once daily
3247883|NCT01360944|Experimental|LAS41004, variant 5, once daily|variant 5, once daily
3247884|NCT01360944|Experimental|LAS41004, variant 6, once daily|variant 6, once daily
3247885|NCT01360944|Placebo Comparator|reference|once daily, 100microgram
3247886|NCT01360944|Active Comparator|reference, once daily|once daily
3247887|NCT01360957|Placebo Comparator|Water flavored placebo|to be given orally in a dosage of 30 ml trice daily for 60 days
3247888|NCT01360957|Experimental|Black cumin water extract as a traditional medicine|Black cumin water extract as a traditional medicine to be given orally in a dosage of 30 ml trice daily for 60 days
3247889|NCT01361022|Active Comparator|Brotizolam tablet|Brotizolam tablets 250mcg : at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
3247890|NCT01361022|Experimental|Lendormin tablet|Lendormin tablets 250mcg: at least 6 and 24 subjects will be enrolled in the pre-study and main study, respectively
3247891|NCT01361035|No Intervention|No communication training|Physicians enrolled in the control arm do not undergo training in health literacy, cancer screening and shared decision making
3247892|NCT01361035|Other|Cancer risk ommunication skills training|Physicians enrolled in the intervention arm undergo training in health literacy, cancer screening and shared decision making
3247893|NCT01361061||patients with liver cirrhosis|
3247894|NCT01361074|Experimental|In Vivo Exposure|
3247895|NCT01361074|Experimental|Augmented Reality Exposure|
3247896|NCT01361100|Experimental|Oncoral test|
3247897|NCT01361152|Experimental|Fixed-bearing group|Fixed-bearing group
3247898|NCT01361152|Experimental|Mobile-bearing group|Mobile-bearing group
3247899|NCT01361204|Experimental|Theanine|Experimental Comparator, theanine Taking 4 tablets of theanine two times daily for 16 days Placebo Comparator, sucrose Taking 4 tablets of sucrose two times daily for 16 days
3247900|NCT01361230|Experimental|Protocol|Using sedation monitoring and protocol
3247901|NCT01361230|No Intervention|Control|Standard practice
3247902|NCT01361243|Experimental|NOURISH+|Participants will receive a 6-week face-to-face intervention, NOURISH+. Weekly topics teach parents skills to role model and encourage healthy lifestyle behaviors for their children.
3247903|NCT01361243|Placebo Comparator|Wellness Group|"Participants will receive an in-person Family Wellness Night followed by 6 mailings of information regarding pediatric overweight and obesity."
3359835|NCT03446768|Active Comparator|Reactive Care (RC)|Participants in the RC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support.
3359836|NCT03446768|Active Comparator|Proactive Care (PC)|Participants in the PC arm of the study will be provided access to the COPD Information Line if they feel they would benefit from the support of a peer health coach. Peer health coaches working the information line are patients also living with COPD who can offer peer level support. Additionally, the PC group will also receive access to an online study portal which houses an educational health curriculum covering topics related to COPD and OSA. The portal allows participants to send online messages to peer coaches and respiratory therapist coaches. PC group will also receive weekly updates.
3359837|NCT03437330|Experimental|Empagliflozin (Jardiance®)|Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral
3359838|NCT03437330|Active Comparator|Insulin Glargine (Lantus®)|"Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU FBG 7-8 mmol/L: +3 IU FBG > 8 mmol/L: +5 IU"
3359839|NCT03431350|Experimental|Combination 1:Dose Selection: Niraparib + cetrelimab (Part 1)|Dose regimen 1: The participants will receive niraparib 200 milligram (mg) orally once daily in combination with cetrelimab 240 mg intravenously (IV) once every 2 weeks. Dose regimen 2: The participants will receive niraparib 200 mg orally once daily in combination with cetrelimab 480 mg IV once every 4 weeks in 28-day treatment cycles until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. The safety evaluation team (SET) will determine if an additional cohort is necessary, based on the data from dose regimens 1 and 2. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
3247904|NCT01361256|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD (Age-related Macular Degeneration)
3247905|NCT01361269|Experimental|Fosmidomycin and clindamycin treatment|All the subject will be given fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
3247906|NCT01361282||Triple Procedure|All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
3247907|NCT01361295|Active Comparator|PVI with PVAC gold|Patient for pulmonal vein isolation using the PVAC Gold Catheter. Intervention.
3247908|NCT01361295|Active Comparator|PVI with Cooled-RF|Patient for pulmonal vein isolation using the Cooled-RF catheter.
3359840|NCT03431350|Experimental|Combination 1:Dose Expansion: Niraparib + cetrelimab (Part 2)|Participants will be assigned to either Cohort 1A (Biomarker [BM] positive [+]) or Cohort 1B (BM negative [-]) and will receive established RP2D of cetrelimab and niraparib, in Part 2 until disease progression, unacceptable toxicity, death, or the sponsor terminates the study. A futility analysis will be performed for the Cohort 1B after 10 BM- participants are enrolled in Part 2. This cohort will be closed if the response is less than predetermined response rate as outlined in the protocol. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
3359841|NCT03431350|Experimental|Combination 2: Dose Expansion: Niraparib + AA-P (Part 2)|Participants will be assigned to one of 4 cohorts based on biomarker status - Cohort 2A (BRCA biallelic loss), 2B (other DRD biallelic loss), 2C (BRCA monoallelic loss), or 2D (other DRD monoallelic loss), and will receive niraparib 200 mg once daily in combination with abiraterone acetate 1000 mg (4*250 mg) plus 10 mg prednisone (5 mg twice daily) throughout treatment phase. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
3359842|NCT03431350|Experimental|Combination 3: Niraparib + AA-P|Participants will be assigned to one of three cohorts to receive AA-P with or without niraparib. Participants in the Treatment Phase of this combination will be offered the option to enter the Long-term Extension Phase of the study.
3359843|NCT03425591||Cohort 1: Chronic Lymphocytic Leukemia (CLL) Participants|Participants with confirmed diagnosis of CLL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 1. The primary data source for this observational study will be the medical records of each enrolled participant.
3359844|NCT03425591||Cohort 2: Mantle-Cell Lymphoma (MCL) Participants|Participants with confirmed diagnosis of MCL will be observed to collect data on ibrutinib therapy to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy in Cohort 2. The primary data source for this observational study will be the medical records of each enrolled participant.
3359845|NCT03424122|Experimental|Treatment A|Parsaclisib + Rituximab
3359846|NCT03424122|Experimental|Treatment B|Parsaclisib + Bendamustine + Rituximab
3359847|NCT03424122|Experimental|Treatment C|Parsaclisib + Ibrutinib
3359848|NCT03416283|Experimental|Remote Monitoring (RM)|Remote Monitoring subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence.
3359849|NCT03416283|Experimental|Remote Monitoring + Social Support (RM+SS)|Remote Monitoring + Social Support subjects will receive a blood pressure cuff and bidirectional text messaging regarding blood pressure and medication adherence, as well as a social support partner to provide additional feedback to the participant on their monitoring and adherence practices.
3359850|NCT03416283|No Intervention|Usual Care|Usual care subjects will not receive a blood pressure cuff or bidirectional text messaging. They will be asked to take their medication and monitor BP as usual with no additional contact from study staff until the 4 month study follow-up.
3359851|NCT03414515||Patients with peripheral artery disease|located in the common and external iliac artery, the common and superficial femoral artery, the popliteal artery and/or the below-the-knee (BTK) arteries (anterior tibial artery, posterior tibial artery or peroneal artery).
3247909|NCT01361321||patients after GBR procedure|The study will comprise of patients who already underwent a routine Guided Bone Regeneration (GBR) procedure in order to augment a bony ridge before dental implant insertion. The patients will be followed up in order to determine bone quality and quantity formed after the usage of routinely used bone substitutes during GBR procedure.
3247910|NCT01361334|Experimental|Pazopanib|Pazopanib treatment
3247911|NCT01361347|Placebo Comparator|placebo|"rice/soy/oat milkdrink, masked"
3359852|NCT03412565|Experimental|Daratumumab(D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)|Participants will receive daratumumab 1800 milligram (mg) by subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligram per square meter (mg/m^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.
3359853|NCT03412565|Experimental|D + Bortezomib + Melphalan + Prednisone (D-VMP)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1 then on Days 1 and 22 in Cycles 2 to 9 and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; bortezomib 1.3 mg/m^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m^2 orally on Days 1 to 4 of cycles 1 to 9.
3359854|NCT03412565|Experimental|Daratumumab + Lenalidomide + Dexamethasone (D-Rd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or end of study.
3247912|NCT01361347|Experimental|milk|cow's milk
3247913|NCT01361360||control|
3247914|NCT01361360||hypercapnia|
3247915|NCT01361373|Active Comparator|DOPAMINE|Sinemet up to 10 mg/kg/day
3247916|NCT01361373|Placebo Comparator|Placebo|placebo
3247917|NCT01361386||1|
3247918|NCT01361399|Experimental|Arm 1|
3247919|NCT01361399|Active Comparator|Arm 2|
3247920|NCT01361399|Active Comparator|Arm 3|
3247921|NCT01361399|Placebo Comparator|Arm 4|
3247922|NCT01361412|Experimental|ToleroMune Ragweed 4|
3247923|NCT01361412|Experimental|ToleroMune Ragweed Regimen 3|
3247924|NCT01361412|Experimental|ToleroMune Ragweed Regimen 2|
3247925|NCT01361412|Placebo Comparator|Placebo|Placebo
3247926|NCT01361412|Experimental|ToleroMune Ragweed Regimen 1|
3247927|NCT01361425|Experimental|methildopa|pregnant women with stable severe pre-eclampsia will use methildopa (1,5g/day)
3359855|NCT03412565|Experimental|Daratumumab + Carfilzomib + Dexamethasone (D-Kd)|Participants will receive daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days) then on Day 1 and 15 of Cycles 3 to 6 and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or end of study; Carfilzomib 20 mg/m^2 intravenously (IV) on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or IV weekly for Cycles 1-9 then on Days 1, 8, 15 of each cycle for Cycles 10 and thereafter until documented progression of disease, unacceptable toxicity, or end of study.
3359856|NCT03410706||Rivaroxaban|Anticoagulation with rivaroxaban
3359857|NCT03405714|Experimental|Brivaracetam|Brivaracetam will be administered to various age-based cohorts. Cohort 1: Subjects >=12 to <16 years; Cohort 2: Subjects >=6 to <12 years; Cohort 3: Subjects >=2 to <6 years; Cohort 4: Subjects 1 month to <2 years. Enrollment will be sequential by descending age beginning with Cohort 1. For each cohort, the first half will receive a 15-minute iv infusion. The Data Monitoring Committee (DMC) will then review safety and, as available, PK data to make the following recommendations: the progression of the current cohort (up to 2-minute iv bolus infusion) and progression to initiate enrollment in the preceding cohort.
3359858|NCT03404791|Experimental|Participants Ineligible for Radical Cystectomy|Participants will receive the TAR-200 transuretherally on Day 0 in to the bladder through an Inserter and gradually releases gemcitabine during the 21-day indwelling period before being removed on Day 21 via flexible or rigid cystoscopy. Participants will undergo an 84-day induction period comprised of four consecutive 21-day dosing cycles. Participants may undergo 21 day cycle every 3 months for a maximum of 3 cycles as maintenance (Up to 14 months). Each TAR-200 system will be removed at 21 days after insertion.
3359859|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Intravenous (IV)|Participants will receive IV infusion of Talquetamab at minimum anticipated biologic effect level (MABEL)-based starting dose until the completion of the end of treatment visit. Subsequent dose levels will be selected based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and preliminary antitumor activity data.
3359860|NCT03399799|Experimental|Part 1: Dose Escalation (Talquetamab) - Subcutaneous (SC)|Participants will receive Talquetamab SC. The dose levels will be selected to identify safe and tolerable putative RP2D(s).
3247928|NCT01361425|Placebo Comparator|placebo|stable pregnant women with severe preeclampsia will use placebo
3247929|NCT01361477||patient|"Prolonged ICU stay~Unplanned ICU admission~Complication/adversel during ICU admission~Result of intraoperative complications and admission to ICU 5 Result of early postoperative (within 7 days) and ICU admission"
3247930|NCT01361503||Autism Spectrum Disorder (ASD)|
3247931|NCT01361503||Controls|
3359861|NCT03399799|Experimental|Part 2: Dose Expansion (Talquetamab)|Participants will receive IV infusion or SC injection of Talquetamab at each putative recommended Phase 2 dose(s) (RP2D[s]) as determined in Part 1.
3247932|NCT01361516|Experimental|Intravenous sedation, General anaesthesia|IV sedation-ESWL under spontaneous respiration GA - ESWL under controlled respiration
3247933|NCT01361529|Experimental|safty test|FLP,dose escalation,MTD
3247934|NCT01361542|Experimental|Anti TNF|Anti TNF alpha therapy including either infliximab or etanercept with data obtained before and after the study duration.
3247935|NCT01361555|Experimental|Arm 1: Placebo + BMS-820836 (0.5 mg/day)|
3247936|NCT01361555|Experimental|Arm 2: Placebo + BMS-820836 (1 mg/day)|
3247937|NCT01361555|Experimental|Arm 3: Placebo + BMS-820836 (2 mg/day)|
3247938|NCT01361581||ACD (acid-citrate-dextrose)|
3247939|NCT01361581||4% trisodium citrate|
3247940|NCT01361581||unfractionated heparin (UFH)|
3247941|NCT01361646|Experimental|LC350189|
3247942|NCT01361646|Active Comparator|Febuxostat|
3247943|NCT01361646|Placebo Comparator|Placebo|
3247944|NCT01361698|Experimental|IMR program|The program is organised into 11 curriculum topic areas: recovery strategies, practical facts about mental illness, the stress-vulnerability model, building social support, using medication effectively, drug and alcohol use, reducing relapses, healthy lifestyle, coping with stress, coping with problems and symptoms, and getting your needs met in the mental health system. In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
3247945|NCT01361698|No Intervention|Treatment as usual|Patients randomised to the control group will get 'treatment as usual' only. This means individual adapted interdisciplinary treatment including medication, individual support, occupational therapy, psycho-education and group therapy.
3247946|NCT01361724|Other|One on one with a PT|The participant will work one-on-one with a trained for PT for 3 days a week for four weeks.
3247947|NCT01361724|Other|Group exercise class|The participant will be in a group exercise class. That will meet 3 days a week for 4 weeks.
3247948|NCT01361724|Other|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
3247949|NCT01361737||preeclampsia|"Control group: 86 healthy women not developing preeclampsia (PE)~Case group: 43 women developing PE"
3247950|NCT01361750|Experimental|gastirc tube group|conduit will be perfomed by narrowed gastric tube
3247951|NCT01361750|No Intervention|control group|conduit will be traditional subtotal stomach without any surgical modification
3247952|NCT01361763|Experimental|Dabigatran|
3247953|NCT01361763|Active Comparator|Antiplatelets|
3247954|NCT01361776|Active Comparator|TBE vaccine at 0+30 days|This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
3247955|NCT01361776|Active Comparator|TBE vaccine at 0+7+21 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
3247956|NCT01361776|Active Comparator|TBE vaccinte at 0+30+90 days|This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
3247957|NCT01361776|Active Comparator|younger participants|This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later
3359880|NCT03348514|Experimental|CPX-POM - 30 mg/m^2|
3359881|NCT03348514|Experimental|CPX-POM - 60 mg/m^2|
3359882|NCT03348514|Experimental|CPX-POM - 120 mg/m^2|
3359883|NCT03348514|Experimental|CPX-POM - 240 mg/m^2|
3359884|NCT03348514|Experimental|CPX-POM - 360 mg/m^2|
3359885|NCT03348514|Experimental|CPX-POM - 600 mg/m^2|
3359886|NCT03348514|Experimental|CPX-POM - 900 mg/m^2|
3359887|NCT03348514|Experimental|CPX-POM - 1200 mg/m^2|
3359892|NCT03320304||Vagal Nerve Simulation (VNS) Therapy|"The aim of this study is to include patients with difficult to treat depression from a global real world (standard of care) population who are referred for treatment with VNS Therapy."
3359893|NCT03317392|Experimental|Arm I (radium Ra 223 dichloride, olaparib)|Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3247958|NCT01361789|Active Comparator|COXIB|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
3247959|NCT01361789|Active Comparator|Dexamethasone|dexamethasone 8 mg iv
3247960|NCT01361789|Active Comparator|COXIB and dexamethasone|combination of coxib AND dexamethasone
3247961|NCT01361802|Active Comparator|Ambroxol Spray 2.5mg|Ambroxol Spray Low Dose
3247962|NCT01361802|Active Comparator|Ambroxol Spray 5mg|Ambroxol Spray Medium Dose
3247963|NCT01361802|Active Comparator|Ambroxol Spray 10mg|Ambroxol Spray High dose
3247964|NCT01361802|Placebo Comparator|Placebo Spray|Placebo Spray
3247965|NCT01361815|Other|H-Coil Deep TMS Treatment|
3247966|NCT01361828||Patients with choroidal neovascularization|CNV due to Age-Related Macular Degenerations and Myopia were included.
3247967|NCT01361841|Other|ophtalmic solution,|Travoprost, latanoprost and bimatoprost, ophthalmic solution are topical medications used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. they are synthetic prostaglandin F 2α analogue (and prodrug for bimatoprost) that works by increasing the outflow of aqueous fluid from the eyes.
3247968|NCT01361880|Other|Reduce infant mortality|The overall purpose of this study is to develop and evaluate a systematic approach to improve African-American parental behaviors specifically with regards to the infant sleep environment
3247969|NCT01361893|Other|Lifestyle Counseling|Parents who qualify for the study will be asked to participate in the survey portion of the study. informed consent will be obtained. After completing the survey each parent will be asked if they would be willing to participate in and additional interview (focus group or semi-structured in-debth interview) at a later date.
3247970|NCT01361906|No Intervention|Untreated control|Untreated control
3247971|NCT01361906|Experimental|Sensomotoric training|Treatment with Sensomotoric training
3359894|NCT03317392|Experimental|Arm II (radium Ra 223 dichloride)|Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib.
3359897|NCT03304639|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3359898|NCT03304639|Experimental|Group II (pembrolizumab, SBRT)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo SBRT for 3 doses during cycle 1.
3359900|NCT03301220|No Intervention|Arm A: Active Monitoring|Participants randomized to active monitoring will receive no study medication, but will undergo the same disease evaluations at the same frequency as participants randomized to daratumumab.
3359901|NCT03301220|Experimental|Arm B: Daratumumab SC|Participants will receive 1800 milligram (mg) of daratumumab co-formulated with 2000 units per milliliter (U/mL) of recombinant human hyaluronidase (rHuPH20) by subcutaneous (SC) injection until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion.
3376061|NCT03043729|Experimental|Arm B|6 cycles chemotherapy with Oxaliplatin 85 mg/m^2 and Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 and 5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusionq2w + Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (6th cycle without Aflibercept) followed by surgery 4 weeks after last neoadjuvant chemotherapy treatment
3376063|NCT03018080|Experimental|Cohort A|Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. Starting with cycle 3 and subsequent cycles, pembrolizumab will be given as an IV infusion over 30 minutes before paclitaxel on day 1 every 21 (+/- 3) days.
3247972|NCT01361932|Experimental|Video of ED Discharge Instructions|
3247973|NCT01361932|No Intervention|Control (usual standard of care)|
3247974|NCT01361945|Experimental|AUY922|Single Arm
3247975|NCT01361958|Experimental|T1 received 0.625 mg NOMAC + 1.5 mg E2|
3247976|NCT01361958|Experimental|T2 received 1.25 mg NOMAC + 1.5 mg E2|
3247977|NCT01361958|Experimental|T3 received 2.5 mg NOMAC + 1.5 mg E2|
3247978|NCT01361958|Experimental|T4 received 2.5 mg NOMAC + Lactose|
3247979|NCT01361984|Experimental|Brovana (nebulized arformoterol)|Brovana (nebulized arformoterol) treatment for 2 weeks
3247980|NCT01361984|Experimental|Serevent (Salmeterol dry powder inhaler)|Serevent (Salmeterol dry powder inhaler) treatment for 2 weeks
3247981|NCT01361997|Experimental|Chlorhexidine in isopropyl alcohol|This arm is composed of 545 hospitalized patients with suspected blood stream infection, to test 2% chlorhexidine gluconate in 70% isopropyl alcohol.
3247982|NCT01361997|Experimental|Isopropyl alcohol|This arm is composed of 572 hospitalized patients with suspected blood stream infection, to test 70% isopropyl alcohol.
3247983|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 4%|Active ingredient: Minocycline Concentration: 4% Route: Topical Dosage schedule: Once daily, evening.
3247984|NCT01362010|Experimental|Topical Minocycline Foam FXFM244 - 1%|Active ingredient: Minocycline Concentration: 1% Route: Topical Dosage schedule: Once daily, evening.
3247985|NCT01362010|Placebo Comparator|Placebo foam|Active ingredient: None Route: Topical Dosage schedule: Once daily, evening
3359907|NCT03261830|Active Comparator|Pre-operative Antibiotics|Patients randomized to preoperative antibiotics will receive 25mg/kg cefazolin IV up to 1g or clindamycin 10mg/kg up to 600mg IV in cases of documented allergy to cefazolin.
3359908|NCT03261830|Placebo Comparator|Saline Placebo|Patients randomized to the no-antibiotic group will receive a saline placebo. This placebo will consist of a 10 mL pre-filled syringe of normal saline.
3359909|NCT03253393|Experimental|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging|Silicone hydrogel (with EDTA) in Smart Touch vs. in conventional packaging
3247986|NCT01362023|No Intervention|control|Control pupils follow their usual activities
3359910|NCT03253393|Experimental|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging|Hydrogel (no EDTA) in Smart Touch vs. in conventional packaging
3359911|NCT03253393|Experimental|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch|Silicone hydrogel (no EDTA) vs. hydrogel (with EDTA) in Smart Touch
3359915|NCT03242889|Experimental|DARA SC|Participants will receive DARA SC (daratumumab 1800 milligram [mg] with Recombinant Human Hyaluronidase [rHuPH20] 30,000 units [U] that is 2000 U/milliliter [U/mL]) subcutaneous (SC) injection once weekly for the first 8 weeks in Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks in Cycles 3 to 6 (Days 1 and 15) for the following 16 weeks and then every 4 weeks (from Cycle 7 [Day 1]) in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation. Each cycle is 28 days in duration.
3359916|NCT03242174||Traditional Obstetrical Prenatal Care|Pregnant women receiving traditional obstetrical prenatal care and delivering in a hospital will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
3359917|NCT03242174||Prenatal Care from Midwife|Pregnant women receiving prenatal care from a midwife and delivering at the birth center will be offered the Health Behavior questionnaire packet at third trimester prenatal appointment
3359918|NCT03235544|Experimental|Cohort 1- Parsaclisib|Participants who have previously received ibrutinib.
3359919|NCT03235544|Experimental|Cohort 2 - Parsaclisib|Participants who have not previously received a BTK inhibitor.
3359922|NCT03219528|Active Comparator|Rifaximin|Rifaximin 550 mg three times daily for 14 days
3359923|NCT03219528|Active Comparator|Low FODMAP Group|Low FODMAP diet for 4 weeks
3359924|NCT03217812|Active Comparator|Treatment A: VMP Alone|Participants will receive Velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous (SC) injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is greater than [>]2 milligram per deciliter [mg/dL] at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2) orally, once daily (on Days 1 to 4) and prednisone 60 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
3359925|NCT03217812|Experimental|Treatment B: D-VMP|Participants will receive Velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 milligram per kilogram (mg/kg) as intravenous (IV) infusion or daratumumab Subcutaneously (SC) at the discretion of the investigator, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycles 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study. Participants will receive pre-infusion medications before each daratumumab infusion.
3247987|NCT01362023|Experimental|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
3247988|NCT01362036|Experimental|TXA127 sc injectable|All cohorts will recieve TXA127; Cohorts receive either 300, 600, or 900 ug/kg daily
3359926|NCT03201965|Active Comparator|CyBorD alone (cyclophosphamide/bortezomib/dexamethasone)|Participants will receive dexamethasone (40 milligrams [mg] orally or intravenous [IV] dose), followed by cyclophosphamide (300 milligram per meter square [mg/m^2] orally or IV dose), then bortezomib (1.3 mg/m^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
3359927|NCT03201965|Experimental|CyBorD plus Daratumumab|Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m^2 orally or IV dose weekly) and bortezomib (1.3 mg/m^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
3359928|NCT03190330|Experimental|Ibrutinib|Participants will receive ibrutinib 420 milligram (mg) (three 140 mg capsules) as a single daily dose for chronic lymphocytic leukemia (CLL) and 560 mg (four 140 mg capsules) as a single daily dose for mantle cell lymphoma (MCL) for up to 12 months or till disease progression, whichever is earlier.
3359929|NCT03188822|Experimental|Bioabsorbable steroid releasing sinus implant & nasal dressing impregnated with steroid|Patients will undergo bilateral endoscopic sinus surgery which will include bilateral frontal sinusotomy of Draf 2a or 2b type as previously described in the literature. At the conclusion of the procedure, if the patient still meets all inclusion criteria, one frontal sinus will be randomly assigned using the envelop method to receive a bioabsorbable steroid releasing implant and the other frontal sinus will receive a bioabsorbable nasal dressing impregnated with steroid
3247989|NCT01362075|Experimental|Local infiltration analgesia|
3247990|NCT01362075|Active Comparator|Interscalene catheter|
3359933|NCT03145181|Experimental|Part 1: Dose Escalation (IV)|Participants will receive Teclistamab intravenously (IV).
3359934|NCT03145181|Experimental|Part 2: Dose Expansion (IV)|Participants will receive Teclistamab IV.
3359935|NCT03145181|Experimental|Part 1: Dose Escalation (SC)|Participants will receive Teclistamab subcutaneously (SC).
3359936|NCT03145181|Experimental|Part 2: Dose Expansion (SC)|Participants will receive Teclistamab SC.
3247991|NCT01362088||CVVH patients|
3247992|NCT01362101|Active Comparator|Traditional behavioral intervention|
3247993|NCT01362101|Active Comparator|Mindfulness behavioral intervention|
3359937|NCT03144674|Experimental|Cohort 1- Closed to Further enrollment|Participants who have received prior ibrutinib.
3359938|NCT03144674|Experimental|Cohort 2|Participants who have not received a prior BTK inhibitor.
3359939|NCT03141684|Experimental|Arm I (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3247994|NCT01362114|Experimental|Sihogayonggolmoryeo-tang extract|"name of product: 'SIHOGAYONGGOLMORYU TANG EXTRACT GRAN'~standard code for item: 200005676~shape, type: extract(brown)~usage, content: adults;three times a day, each taken before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36months after manufacture~macufacturing company: KyungBangnShinYak inc."
3247995|NCT01362114|Placebo Comparator|Placebo; corn flour,|"raw material: total contents(500㎎); cornstarch 50.0%(250.0㎎), 당수화물 49.45%(247.25㎎), caramel pigment 0.5%(2.5㎎), SsangHwa fragrance 0.05%(0.25㎎)~shape, type: extract(brown)~usage, dose: adults: three times a day, 1 sack before or between meals~dose, standard: 2.5g for each sack, capsulated~storage : airtight container, stored in room temperature~expiration date : 36 months after manufacture~manufacturing company: KyungBangnShinYak inc."
3247996|NCT01362153|Experimental|001|Golimumab IV infusions of 2 mg/kg golimumab on Days 1 and 85.
3359940|NCT03141684|Experimental|Arm II (atezolizumab, bevacizumab)|Patients receive atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3359941|NCT03128671|Experimental|FAVoR Intervention Group|In the intervention group, scripted audio messages recorded by the patient's family (FAVoR intervention) will be played for the patient at hourly intervals during daytime hours. These messages will be personalized, delivered automatically, and provide information about the ICU environment. The FAVoR intervention, a standardized protocol developed and tested in preliminary work, will be delivered by audio recording for 5 consecutive days (120 hours), or until ICU discharge if discharge occurs within the first 5 days. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
3359942|NCT03128671|No Intervention|Control Group|The control group will not receive the FAVoR intervention. The number of episodes of delirium during ICU stay is the primary outcome measure. Data will also be collected at 1 month and 6 months following hospital discharge for secondary aim 3.
3359943|NCT03126630|Active Comparator|Group I (pembrolizumab)|Patients receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Upon radiologic documentation of disease progression, patients may cross over to Group II.
3359944|NCT03126630|Experimental|Group II (anetumab ravtansine, pembrolizumab)|Patients receive anetumab ravtansine IV over 1 hour and pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 21 days for up to 12 months for anetumab ravtansine and up to 24 months for pembrolizumab in the absence of disease progression or unacceptable toxicity.
3359945|NCT03126019|Experimental|Group A|Parsaclisib once daily (QD) for 8 weeks followed by Parsaclisib once weekly
3359946|NCT03126019|Experimental|Group B|Parsaclisib QD
3359951|NCT03121534|Experimental|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab.~Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment."
3359952|NCT03111732|Experimental|1/Arm 1|Pembrolizumab plus Oxaliplatin plus Capecitabine
3359955|NCT03092635|Experimental|OPC|During weeks 1- 12, subjects will take one OPC tablet in the morning and in the evening, about 12 hours apart.
3359956|NCT03088059|Experimental|Patient Cohort B1|Patients who are p16 negative and have an EGFR amplification/mutation or PTEN high or HER2 mutation/amplification will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care).
3247997|NCT01362153|Experimental|002|Golimumab SC injection of 100 mg every 4 weeks through Week 20
3359957|NCT03088059|Experimental|Patient Cohort B2|Patients who are p16 negative and cetuximab naïve will be randomized between afatinib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
3359958|NCT03088059|Experimental|Patient Cohort B3|Patients who are p16 negative and have an amplification of CCND1 will be randomized between palbociclib or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
3359959|NCT03088059|Experimental|Patient Cohort B4|Patients who are p16 negative and 'platinum sensitive' SCCHN will receive niraparib
3359960|NCT03088059|Experimental|Patient Cohort B5|Patients whith oropharyngeal cancer and which are p16 positive will receive niraparib
3247998|NCT01362179||unstimulated BM donors|Observational (non-interventional) study.
3247999|NCT01362179||filgrastim-mobilized PBSC donors|Observational (non-interventional) study.
3359961|NCT03088059|Experimental|Patient Cohort I1|Patients who are anti-PD(L)1-naïeve or resistant (primary or secondary resistance) will receive IPH2201 antibody (monalizumab).
3248000|NCT01362218|Experimental|Fixed Dose Combination Pill|A fixed dose combination of acetylsalicylic acid, simvastatin, and ramipril Intervention: Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)
3248001|NCT01362218|Active Comparator|Simvastatin|Simvastatin given together with the reference drugs ramipril and acetylsalicylic acid
3248002|NCT01362231|Experimental|GS-6624 125mg|
3359962|NCT03088059|Experimental|Patient Cohort I2|Patient who are PD(L)1 pretreated will be randomized between monalizumab + durvalumab or the standard of care (Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care)
3359963|NCT03088059|Experimental|Patient Cohort I3|Patient who are progressing prior PD(L)1 after having received at least 2 months of anti-PD(L)-1 will receive INCAGN01876.
3359966|NCT03065244|Active Comparator|IVIG|Patient will be randomly assigned to receive a second IVIG infusion: 2 g/kg IV over 8-10 hours single infusion
3248003|NCT01362231|Experimental|Experimental: GS-6624 200mg|
3248004|NCT01362257|Experimental|14C-GSK573719 Oral Solution|single dose of 1000µg
3248005|NCT01362257|Experimental|14C-GSK573719 IV Solution|single dose of 65µg
3248006|NCT01362283||Hypertension|Subject who meet eligible criteria
3248007|NCT01362309|Placebo Comparator|Placebo|Inert filler in matched pill.
3359967|NCT03065244|Active Comparator|Infliximab|Patient will be randomly assigned to receive Infliximab 10 mg/kg IV over 2 hours
3359968|NCT03037671||CGM Monitored Cohort|The continuous glucose monitor (CGM) used during this study will be the Abbot Freestyle Libre Professional Continuous Glucose Monitoring System.
3376064|NCT03018080|Experimental|Cohort B|Pembrolizumab will be given as an IV infusion on day 1 before paclitaxel every 21 (+/- 3) days. Paclitaxel will be given as an IV infusion over 60 minutes, on days 1 and 8 every 21 (+/- 3) days.
3248008|NCT01362309|Active Comparator|d-cycloserine 50 mg|50 mg d-cycloserine.
3248009|NCT01362335||patients, that are having a routine surgical procedure.|
3248010|NCT01362361|Experimental|Arm A|mFOLFOX6 + BIBF 1120
3248011|NCT01362361|Placebo Comparator|Arm B|mFOLFOX6+placebo
3248012|NCT01362374|Experimental|Arm A (Ipatasertib + Docetaxel)|Participants will receive ipatasertib at a starting dose of 100 milligrams (mg) once daily for 14 consecutive days (beginning on Day 2) in combination with docetaxel on Day 1, in 21-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3248013|NCT01362374|Experimental|Arm B (Ipatasertib + mFOLFOX6)|Participants will receive ipatasertib at a starting dose of 100 mg once daily for 7 consecutive days (beginning on Day 1) in combination with mFOLFOX6 chemotherapy (comprising of oxaliplatin, leucovorin, and 5-FU) on Day 1, in 14-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3359969|NCT03030612|Experimental|ARGX-110 with Azacytidine (AZA)|Phase 1: Participants will receive loading dose of ARGX-110 1 milligram per kilogram (mg/kg) body weight (cohort 1), 3 mg/kg body weight (cohort 2), 10 mg/kg body weight (cohort 3) or 20 mg/kg body weight (cohort 4) administered intravenously (IV) in combination with AZA standard dose of 75 milligram per meter square (mg/m^2) body surface area (BSA) administered subcutaneously (SC) / intravenously (IV). Phase 2: Participants will receive loading dose of ARGX-110 IV at a recommended dose for Phase 2 (RP2D) level from phase 1 in combination with AZA standard dose of 75 mg/m^2 BSA, administered SC/IV as per local practice.
3359971|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
3248014|NCT01362374|Experimental|Arm C (Ipatasertib + Paclitaxel)|Participants will receive ipatasertib at a dose of 600 mg once daily for 21 consecutive days (beginning on Day 1) in combination with paclitaxel on Days 1, 8, and 15, in 28-day continuous cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first.
3359972|NCT03007732|Experimental|Cohort 1: Prostate Only Sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
3359973|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
3359974|NCT03007732|Experimental|Cohort 2: Prostate and Oligometastatic sites (ADT, SBRT, Pembrolizumab, SD-101)|"Three month androgen deprivation therapy (ADT) run-in followed by leuprolide injected intramuscularly every 3 months for 3 doses (or another FDA approved gonadotropin-releasing hormone agent for 9 months) + abiraterone by mouth daily with prednisone by mouth daily (or equivalent medication per local standard practice) for 9 months starting on Day 1.~TLR9 agonist SD-101: Injected into the dominant prostatic tumor lesion at time of fiducial marker placement (1-5weeks prior to Cycle 1 Day 1) and 1-3 weeks after Cycle 1 Day 1~Pembrolizumab: Given IV every 21 days for up to 13 doses~Radiotherapy: Given every other day over 10-14 days delivered to the whole prostate gland and oligometastatic sites via stereotactic body radiation therapy (SBRT) starting 1-2 weeks after marker placement."
3359975|NCT02988544|Experimental|Artificial shrinkage (AS) group|The Artificial shrinkage group where blastocoelic cavity is artificially reduced by a laser pulse prior to transfer
3359976|NCT02988544|No Intervention|Control group|No intervention on blastocoelic
3248015|NCT01362374|Experimental|Arm D (Ipatasertib + Enzalutamide)|Participants will receive ipatasertib at a dose of 400 mg once daily alone for 8 days, then from Day 9, ipatasertib will be administered in combination with enzalutamide once daily for 27 days (Cycle 1 duration = 35 days). Participants will receive both ipatasertib and enzalutamide once daily continuously in subsequent 28-days cycles, until disease progression, unacceptable toxicity, or use of another anti-cancer therapy, whichever occurs first. Higher (up to 600 mg) or lower dose of ipatasertib may be evaluated in subsequent cycles depending upon safety, tolerability, and pharmacokinetics of the first cycle.
3248016|NCT01362387|No Intervention|Group 1|Women assigned to Group 1 will receive the standard post-abortion follow-up currently used at bpas and will be undertaken as usual by staff at the treating clinic
3248017|NCT01362387|Experimental|Group 2|Follow-up after medical abortion using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test.
3359984|NCT02980731|Experimental|Venetoclax|Venetoclax will be administered orally 20 mg once daily (QD) beginning with a dose-titration phase, and then escalated up to 400 mg QD.
3359987|NCT02965716|Experimental|Treatment (talimogene laherparepvec, pembrolizumab)|Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
3359988|NCT02965638|Active Comparator|Oxygen Group|The mothers will be asked to be on 4 liter of oxygen through nasal cannula up to 24 hours a day. The subjects will be blinded to their treatment.
3359989|NCT02965638|No Intervention|Control Group|These mothers will not undergo CMH therapy
3359990|NCT02964780||Gastric Bypass Surgery|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
3359991|NCT02964780||Conservative weight loss|Solid mixed meal tolerance test, MRI, CT, anthropometrics, liver biopsies, fat biopsies, muscle biopsies
3248018|NCT01362400|Active Comparator|ARM 1: IPI 504 + Docetaxel|Drug: IPI-504 plus Docetaxel
3248019|NCT01362400|Placebo Comparator|Placebo + Docetaxel|Placebo plus Docetaxel
3248020|NCT01362426||001|paliperidone palmitate Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
3248021|NCT01362452|Experimental|Double Umbilical Cord Blood (UCB)|"Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation."
3248022|NCT01362452|Experimental|Single Umbilical Cord Blood (UCB)|"Single UCB unit arm does not start enrollment until Dose Level A2 in the double UCB unit arm has been deemed safe.~Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.~Starting dose level of T-cells not to exceed 106/m2.~The investigational component of the treatment plan of this study is the infusion of CD19-specific T cells derived from cord blood (CB) to be infused Day +42 to Day +100 following stem cell transplantation. The transplant component of the treatment plan will include CB transplant regimens that are commonly use for CB transplantation"
3248023|NCT01362465|Experimental|Cardiac Resynchronization Therapy (CRT)|Implanting device to measure delays between paced chambers in heart failure patients.
3359992|NCT02952924|Placebo Comparator|Parts 1a and 1b: SAD in Healthy Volunteers (Placebo)|In Part 1a, participants will receive a single oral dose of placebo matching to RO7049389 film coated tablet on Day 1. In Part 1b, minimum 8 participants from Part 1a will be selected and 2 of whom will receive another single dose of placebo matching to RO7049389 on Day 16 after eating the standard United States - Food and Drug Administration (US FDA)-recommended high-fat and high-calorie breakfast.
3359993|NCT02952924|Experimental|Parts 1a and 1b: SAD in Healthy Volunteers (RO7049389)|In Part 1a, participants will receive a single oral dose of RO7049389 film coated tablet on Day 1 in dose-escalation cohorts with a starting dose of 150 milligrams (mg). The doses for subsequent cohorts will be defined by an adaptive approach based on the safety and PK data in previously-dosed healthy volunteers. In Part 1b, minimum 8 participants from Part 1a will be selected and 6 of whom will receive another single dose of RO7049389 on Day 16 after eating the standard US FDA-recommended high-fat and high-calorie breakfast.
3359994|NCT02952924|Placebo Comparator|Part 1c: MAD in Healthy Volunteers (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 13 (either once a day [QD] or twice a day [BID]) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 micrograms [mcg]) on Day -1 and Day 14.
3359995|NCT02952924|Experimental|Part 1c: MAD in Healthy Volunteers (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 13 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 14. Participants will also receive a single dose of midazolam solution (100 mcg) on Day -1 and Day 14.
3359996|NCT02952924|Placebo Comparator|Part 2: POM in Chronic HBV Participants (Placebo)|Participants will receive placebo matching to RO7049389 film coated tablet from Days 1 to 27 (either QD or BID) and a single dose of placebo matching to RO7049389 film coated tablet in the morning of Day 28.
3359997|NCT02952924|Experimental|Part 2: POM in Chronic HBV Participants (RO7049389)|Participants will receive RO7049389 film coated tablet from Days 1 to 27 (either QD or BID; dose and regimen will be decided based on the available PK and safety data) and a single dose of RO7049389 film coated tablet in the morning of Day 28.
3248024|NCT01362478||Case group|
3359998|NCT02952924|Experimental|Part 3: POM in NUC-Suppressed CHB Participants (Cohort A)|Participants will receive RO7049389 on top of a NUC for 48 weeks at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
3248025|NCT01362478||Control group|
3248026|NCT01362504||Clinical sepsis|
3248027|NCT01362504||Proven sepsis|
3248028|NCT01362504||Control group|healthy neonates
3248029|NCT01362543|Active Comparator|Stress Management|
3248030|NCT01362543|Active Comparator|Cognitive restructuring|
3248031|NCT01362556|Placebo Comparator|Sodium Chloride|Group receiving sodium chloride 0.9% after arterial blood gas analysis in cardiac arrest.
3248032|NCT01362556|Active Comparator|Sodium Bicarbonate|Group receiving targeted sodium bicarbonate 8% therapy after arterial blood gas analysis in cardiac arrest.
3248033|NCT01362569||predialytic renal insufficiency|Patents without renal replacement therapy
3248034|NCT01362569||hemodialysis/hemofiltration patients|patients undergoing regular hemodialysis/hemofiltration
3248035|NCT01362569||peritoneal dialysis patients|patients undergoing peritoneal dialysis
3248036|NCT01362569||acute renal failure|patients with acute renal failure
3248037|NCT01362569||post renal transplantation|patients after renal transplantation
3248038|NCT01362569||healthy controls|control group
3359999|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort B)|Participants will receive RO7049389 for 4 weeks, followed by RO7049389 with an added NUC for 44 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC therapy will be administered per local label or guidelines.
3360000|NCT02952924|Experimental|Part 3: POM in Treatment-Naive CHB Participants (Cohort C)|Participants will receive RO7049389 + NUC + Pegylated-Interferon (Peg-IFN) for 48 weeks. RO7049389 will be administered at a dose determined from Part 2. NUC and Peg-IFN therapy will be administered per local label or guidelines.
3360002|NCT02948400|Experimental|Google Cardboard virtual environment|pedestrian safety training using the Google Cardboard device and delivery of a pedestrian virtual environment by mobile smartphone. Note that children in this arm will be trained using an immersive virtual environment delivered by smartphone, which is different from the other arm that is trained using a semi-immersive virtual environment delivered in a kiosk. The intervention is pedestrian safety training for both arms.
3360003|NCT02948400|Active Comparator|semi-immersive virtual environment|pedestrian safety training using a semi-immersive virtual pedestrian environment kiosk. Note that children in this arm will be trained using a semi-immersive virtual environment delivered in a kiosk, which is different from the other arm that is trained using an immersive virtual environment delivered by smartphone. The intervention is pedestrian safety training for both arms.
3360004|NCT02946996|Experimental|OPC|Subjects will take one OPC capsule at the same time each morning and evening, approximately 12 hours apart during weeks 1-12.
3360005|NCT02934529|Active Comparator|A1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every two weeks until progression in first-line or emergence of unacceptable toxicity.~De-escalation (e.g. to irinotecan plus cetuximab or FUFA plus cetuximab) is allowed, but cetuximab should be administered until progression if safety is adequate."
3360006|NCT02934529|Experimental|B1|"FOLFIRI plus cetuximab: one cycle (cycle duration 14 days) consists of Irinotecan, Folinic acid 5-FU, cetuximab~Administration every 2 weeks for a maximum of 12 cycles~Treatment may be de-escalated to irinotecan plus cetuximab or FUFA plus cetuximab, prior to 12 cycles, for toxicity if necessary, if the best response has been SD,~Treatment may undergo 'switchover' to a fluoropyrimidine and bevacizumab, between 8 and 12 cycles, for toxicity if necessary, if the best response has been CR or PR,"
3360007|NCT02934529|Experimental|B1 Switchover regimens|"Switchover to FUFA plus bevacizumab every three weeks (cycle duration 21 days) until progression in first-line or emergence of unacceptable toxicity.~Folinic acid, 5-FU, Bevacizumab~1st administration 90 min. in case of good safety, the second 60 min. further administration 30 min.~Or alternatively Switchover to capecitabine plus bevacizumab every three weeks (cycle duration 21 days) until progression in the first-line or emergence of unacceptable toxicity."
3360008|NCT02934529|Active Comparator|A2 (third line)|"Treatment at the treating physician's discretion depending on the patient's general condition, with the exclusion of any anti-EGFR treatment whatsoever (such as for example cetuximab, panitumumab). Recommendations include Regorafenib in line with Grothey A et al, Lancet. 2013~or alternatively another anti-EGFR-free treatment according to the investigating physician's choice~Administration until progression occurs in the third line or unacceptable toxicity"
3360009|NCT02934529|Experimental|B2 (third line)|"one cycle (cycle duration 14 days) consists of Irinotecan 125mg, Folinic acid, 5-FU, cetuximab wkly~Administration every 2 weeks until progression occurs in the third line or unacceptable toxicity~or depending on the patient's general condition and the study physician's decision~Irinotecan plus cetuximab in line with Cunningham D et al, N Engl J Med. 2004"
3360010|NCT02908906|Experimental|JNJ-63723283|In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), IV every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4 to evaluate additional doses.
3248039|NCT01362582|No Intervention|Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Subjects in the control group receive Best Supportive Nutritional Care. BSNC is defined as nutritional consultation and recommendation by experienced ecotrophologists."
3248040|NCT01362582|Experimental|PN, Chemotherapy, Nutritional Care|"5-Fluorouracil (5-FU) 2000mg/m2 IV (24-hour)/folinic acid (FA) 200mg/m2 IV (30 min) will be administered weekly over four weeks with additional oxaliplatin 85 mg/m2 IV (2-hour) on days 8 and 22. Therapy will be interrupted between days 23 to 42. The next cycle will be started on day 43.~Patients receive also Best Supportive Nutritional Care defined as nutritional consultation and recommendation by experienced ecotrophologists.~Intervention: Supportive Parenteral Nutrition"
3248041|NCT01362595|Other|Leucine|No alternative treatment arm
3248042|NCT01362621||Children 6 to less than 12 years of age|
3248043|NCT01362634|Experimental|CAPI Intervention|an interviewer-administered comprehensive health and social risk assessment intervention
3360011|NCT02879305|Experimental|Daprodustat|Participants will receive oral daprodustat once daily.
3248044|NCT01362634|Experimental|ACASI Intervention|self-administered comprehensive health and social risk assessment intervention
3248045|NCT01362634|No Intervention|Control|waitlist control condition
3248046|NCT01362660||Infants with potential exposure in utero|
3248047|NCT01362673|Experimental|Single dose|
3248048|NCT01362673|Experimental|Multiple dose|
3248049|NCT01362699|Experimental|JNJ-31001074|
3248050|NCT01362699|Placebo Comparator|Placebo|
3248051|NCT01362725|Experimental|Spinal cord stimulation|
3248052|NCT01362738|Active Comparator|Ablation of PV and extra-PV triggers|Conventional approach which includes pulmonary vein isolation (PVI) and ablation of extra-pulmonary triggers
3248053|NCT01362738|Active Comparator|LAA isolation along with the conventional ablation strategy|LAA isolation along with the conventional ablation strategy
3248054|NCT01362751||Nursing home residents|In this study, patients from both the somatic and the psychogeriatric department are included. For the primary endpoint 'successful rehabilitation' only the patients from the somatic departments are included.
3360012|NCT02879305|Active Comparator|rhEPO|Participants on peritoneal dialysis (PD) will be administered darbepoetin alfa subcutaneously (SC) and participants on hemodialysis (HD) will be administered epoetin alfa intravenously (IV).
3360013|NCT02874742|Experimental|Daratumumab+Lenalidomide+Bortezomib+Dexamethasone (D-RVd)|Participants will receive lenalidomide, bortezomib, dexamethasone and daratumumab.
3360014|NCT02874742|Experimental|Lenalidomide+Bortezomib+Dexamethasone (RVd)|Participants will receive lenalidomide, bortezomib and dexamethasone.
3360017|NCT02845323|Experimental|Nivolumab in combination with Urelumab|"Nivolumab and Urelumab combination:~Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles~Urelumab 8mg will be administered by 1 hour intravenous infusion on day 1 for two cycles"
3360018|NCT02845323|Active Comparator|Nivolumab monotherapy|Nivolumab 240 mg will be administered by 1 hour intravenous infusion on day 1 and day 15 for two cycles
3360019|NCT02834884||RP-1828 IMMUcan|"The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions.~Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary"
3360020|NCT02834884||RP-1759 AYA/TYA|"The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials.~Tumor type: CNS"
3360021|NCT02834884||RP-1843 Arcagen|"This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population.~Tumor types: all 10 EURACAN domains"
3360022|NCT02825160||Ventavis|Ventavis treatment group
3248055|NCT01362764|Other|001|Abiraterone acetate tablets Type=exact unit=mg number= 250 form=tablet route=oral use as a single dose
3248056|NCT01362764|Other|002|Abiraterone acetate suspension Formulation 1 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
3248057|NCT01362764|Other|003|Abiraterone acetate suspension Formulation 2 Type=exact unit=mg/mL number=25 form=oral suspension route=oral use as a single dose of 10 mL
3360026|NCT02816736|Active Comparator|LCZ696 (Entresto) + placebo|LCZ696 50 mg, 100 mg, or 200 mg orally twice daily for 24 weeks, plus valsartan placebo (to match 40 mg, 80 mg, or 160 mg) orally twice daily for 24 weeks
3360027|NCT02816736|Active Comparator|valsartan + placebo|valsartan 40 mg, 80 mg, or 160 mg orally twice daily for 24 weeks, plus LCZ696 placebo (to match 50 mg, 100 mg, or 200 mg) orally twice daily for 24 weeks
3248058|NCT01362777|Experimental|In-Patient Rehabilitation|"Sessions of rehabilitation contains :~Individualized exercise training~Educational activities~Dietary advices"
3248059|NCT01362777|Active Comparator|Educational activities alone|"Out-patient control arm contains only :~-Educational activities"
3360028|NCT02814019|Experimental|idebenone 150 mg film-coated tablets|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
3360029|NCT02814019|Placebo Comparator|placebo|matching placebo tablets
3360030|NCT02787850|Experimental|CoolSculpting Treatment Cohort A|"Cohort A will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 60 minutes using the CoolMax applicator without the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with the Crown Cooling Insert at a second protocol-defined temperature for 45 minutes.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
3360031|NCT02787850|Active Comparator|CoolSculpting Treatment Cohort B|"Cohort B will be treated on one side of the abdomen (Abdominal side 1) at a protocol-defined temperature for 45 minutes using the CoolMax applicator with the Crown Cooling Insert. The contralateral side (Abdominal side 2) will be treated with a second protocol-defined temperature for 60 minutes with the Crown Cooling Insert.~Each half of the abdominal area will be treated once, for a total of two treatments per subject."
3360032|NCT02774421|Experimental|IT trastuzumab after subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab following 5-day course of subQ GM-CSF. Surgical resection should be planned (based on institutional surgical scheduling standards) for ideally 2-7 days after IT trastuzumab dosage.
3360033|NCT02774421|Experimental|IT trastuzumab in combination with subQ GM-CSF|Patients with localized recurrent PFEPN will be treated with IT trastuzumab in combination with GM-CSF to establish a maximum tolerated dosage. GM-CSF will be administered at 250 mcg/m2/dose subQ daily for three (3) days prior to the IT trastuzumab dose.
3360035|NCT02736968|Experimental|E. histolytica- Active|N=34, 6mg auranofin daily x 7 days
3360036|NCT02736968|Placebo Comparator|E. histolytica- Placebo|N=34, 6mg placebo daily x 7 days
3360037|NCT02736968|Experimental|Giardia- Active|N=34, 6mg auranofin daily x 5 days
3360038|NCT02736968|Placebo Comparator|Giardia- Placebo|N=34, 6mg placebo daily x 5 days
3376068|NCT02994446|Experimental|SERF Catheter Ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
3360039|NCT02725619|Experimental|Cognitive-Behavioral Therapy (CBT)|CBT is dedicated to developing coping skills for managing anxiety such as emotion regulation and cognitive reappraisal. Children first learn and practice these skills during one-on-one, weekly sessions with experienced therapists and then apply this skills to navigate anxiety-producing situations as home, school and community. A key component of CBT involves exposure exercises, facing feared situations repeatedly while using the emotion regulation skills and remaining in the situations until anxiety is substantially reduced or become easy to tolerate. The feared situations are ordered from least to most distressing during therapy sessions in collaboration with the child and their parent. The unique combination of anxiety and ASD symptoms of social impairment and restricted/repetitive behavior is addressed in dedicated child and parent modules.
3360040|NCT02725619|Active Comparator|Psychoeducation and Supportive Therapy (PST)|"Psychoeducation and Supportive Therapy includes learning about and discussing issues of diagnosis, treatment and educational services can also benefit children with ASD and their families. Each PST session starts with a review of events of the past week and include queries of topics such as school, interests, and family with an overarching goal of enhancing subjective well-being. The clinician, through the use of supportive, empathic and nondirective actions, will provide the participant with a sounding-board so that they can voice their concerns regarding specific problems that may require discussion and assistance. A major objective is to provide a clinical contact that enables participants to think through and discuss their concerns with a sympathetic adult. Subjects randomized to PST will be offered CBT after completion of the endpoint assessments."
3360041|NCT02725567|Experimental|Part A|"Group 1: Participants 12 to < 24 months~Group 2: Participants 6 to < 12 months (enrollment begins after an assessment of data from Group 1)~Group 3: Participants 3 to < 6 months (enrollment begins after an assessment of data from Group 2)"
3360042|NCT02725567|Experimental|Part B|"Group 5: Participants 12 to < 24 months (enrollment begins after an assessment of data from Part A, Group 1)~Group 6: Participants 6 to < 12 months (enrollment begins after an assessment of data from Part A, Group 2)~Group 7: Participants 4 to < 6 months (enrollment begins after an assessment of data from Part A, Group 3)"
3360043|NCT02725567|Experimental|Part A/B|- Group 8: Participants 1 to < 4 months of age
3360044|NCT02719613|Experimental|Elotuzumab|This is a continuation roll-over study for patients receiving benefit from prior elotuzumab protocols. All participants will receive elotuzumab and/or other study drugs as per previous protocol.
3360045|NCT02713373|Experimental|Arm I (cetuximab and pembrolizumab)|Patients receive cetuximab IV over 120 minutes on day 1 (days 1, 7, and 14 of course 1 only) and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 24 months in the absence of disease progression or unacceptable toxicity. Patients may continue pembrolizumab treatment for up to 1 year if they experience disease progression.
3248060|NCT01362816||Palliative care cancer patients|"Inclusion criteria are:~Patient has a cancer diagnosis (radiological, histological, cytological or operative evidence), local, loco-regional or metastatic disease, defined as a palliative care patient; enrolled in a palliative care programme, age 18 years or older, able to provide written informed consent, able to complete the data collection tool, preferably without help, available for follow up registration"
3360046|NCT02702869||uCL(A)|Children with unilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
3360047|NCT02702869||uCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, or Veau-III).
3360048|NCT02702869||bCL(A)|Children with bilateral cleft lip with/without cleft alveolus but intact secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form).
3360049|NCT02702869||bCL(A)P|Children with unilateral cleft lip with/without cleft alveolus and with cleft secondary palate. Subgroup analysis by severity of lip (complete, incomplete, or lesser-form) and severity of palate (submucous, Veau-I, Veau-II, Veau-III, or Veau-IV).
3360050|NCT02702869||CP|Children with cleft secondary palate only, but intact lip and alveolus. Subgroup analysis by severity (submucous, Veau-I, or Veau-II).
3360051|NCT02701829|Experimental|Health Fairs (HF)|Drivers will undergo U&C Health Fair follow-up either Regular or Urgent Follow-up: Timeline is determined by health status, with regular follow-up continuing for at least two weeks and urgent follow-up continuing for at least a month
3360052|NCT02701829|Experimental|HF + text messaging + home BP monitoring|Drivers will receive: U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months A home BP monitoring equipment with instructions to self-monitor BP for nine months
3360053|NCT02701829|Experimental|HF +Tech + social network support (SNS).|"Drivers will receive:~U&C HF follow-up, Mobile text messaging intervention w/ interactive 2- way messaging to encourage BP management for nine months and home BP monitoring equipment with instructions to self-monitor BP for nine months A social network support intervention in which selected family/peers encourage drivers to maintain healthy behaviors for nine months"
3360055|NCT02690545|Experimental|ATLCAR.CD30 cells|"Phase Ib: In adults, and separately, in children, two doses will be investigated 1x10^8 cells/m2 and 2x10^8 cells/m^2. The study team will run two independent dose-escalation sequences, one for adults and another one for children. The study team plans to use the 3+3 design and start with a low dose of 1x10^8 cells/m2. If there are no DLT in first 3 patients, the study team will go up to the dose of 2 x 10^8 cells/m2. If there is toxicity in 1/3 patients in the initial cohort, the study team would expand to enroll up to 6 patients. If there are dose limiting toxicities (DLT) at the dose of 2 x 10^8 cells/m^2, the study team will initially decrease the dose to an intermediate dose of 1.5 x 10^8 cells/m^.~Phase II: The study team planning to enroll 31 patients to contribute data. Sequential boundary will be used to monitor DLT rate."
3360056|NCT02683473||Infants|Infants aged 1-3 months
3248061|NCT01362829||Patients with severe sepsis|Patients who are admitted to medical ICU with severe sepsis
3248062|NCT01362920||Sepsis or Septic shock cohort|
3248063|NCT01362920||Non-sepsis or non-Septic shock cohort|
3360057|NCT02681302|Experimental|All Participants|"Ipilimumab 1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22~Nivolumab 3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26"
3360058|NCT02676284|Experimental|Durolane SJ|single dose injection. One infiltration of the study product in the trapeziometacarpal (TMC) joint. The study treatment contains sodium hyaluronate 20 mg/mL, in a 1 mL prefilled syringe.
3360059|NCT02663297|Experimental|ATLCAR.CD30 cells|"Three dose levels of ATLCAR.CD30 cells will be evaluated. Using the modified continual reassessment method (CRM), initial cohort of size two will be enrolled at each dose level after that subjects are enrolled one at a time until a minimum of 12 patients is treated. Each patient will receive one injection according to the dosing schedules listed below. Investigators will start with the lowest cell dose (2X10^7 cells/m^2) given to patients in one of our previous trials employing CAR-T cells including the CD28 costimulatory endodomain, and investigators will escalate the cell dose to the highest cell dose (2X10^8/m^2) given in the same trial.~Note: Initially, only adults will be enrolled during the dose escalation phase of the study. Once a dose level has been tested in at least 2 adults without the occurrence of dose limiting toxicities (DLTs), children may then be enrolled on that dose level according to the CRM."
3360064|NCT02632409|Experimental|Nivolumab|Nivolumab dose as specified
3248064|NCT01362933||VTE treatment in cancer patient|All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
3248065|NCT01362972||plerixafor + granulocyte colony stimulating factor (G-CSF)|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF) for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3360065|NCT02632409|Placebo Comparator|Placebo|Placebo dose as specified
3360066|NCT02627443|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, VX-970)|Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and berzosertib IV over 60 minutes on days 2 and 9. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3360069|NCT02608359||Abiraterone Acetate (Zytiga) Post-marketing Surveillance (PMS)|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
3360072|NCT02592317|Experimental|JNJ 56021927|Participants will receive drug cocktail (comprising of midazolam [2 milligram {mg}], warfarin [10 mg], vitamin K (10 mg), omeprazole (40 mg), and fexofenadine [30 mg]) orally on Study Day 1 and 43 (Cycle 2 Day 1). On Study Day 8 and 50, pioglitazone 15 mg will be administered orally and on Study Day 9 and 51, rosuvastatin 10 mg will be administered orally. JNJ 56021927, 240 mg once daily will be administered on Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
3360073|NCT02590094|Active Comparator|A|Study Group A: Subjects receive 2.5 mg intravitreal bevacizumab 1-3 days prior to vitrectomy.
3360074|NCT02590094|Active Comparator|B|Study Group B: Subjects receive 2.5 mg intravitreal bevacizumab 5-10 days prior to vitrectomy.
3248066|NCT01362972||plerixafor + G-CSF + chemotherapy|Patients who receive plerixafor+granulocyte colony stimulating factor (G-CSF)+chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3248067|NCT01362972||granulocyte colony stimulating factor (G-CSF) + chemotherapy|Patients who receive granulocyte colony stimulating factor (G-CSF) + chemotherapy for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3248068|NCT01362972||granulocyte colony stimulating factor (G-CSF) alone|Patients who receive granulocyte colony stimulating factor (G-CSF) alone for the mobilisation of peripheral blood (PB) CD34+ cells and who have undergone autologous haematopoietic stem cell (HSC) transplantation.
3360075|NCT02590094|Active Comparator|C|Study Group C: Subjects receive 1.25 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
3360076|NCT02590094|Active Comparator|D|Study Group D: Subjects receive 0.625 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
3360077|NCT02590094|Active Comparator|E|Study Group E: Subjects receive 2.5 mg intravitreal bevacizumab 1-10 days prior to vitrectomy.
3360078|NCT02590094|Active Comparator|F|Study Group F: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy.
3360079|NCT02590094|Active Comparator|G|Study Group G: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-3 days prior to vitrectomy.
3360080|NCT02590094|Active Comparator|H|Study Group H: Subjects receive 1.25 mg intravitreal ziv-aflibercept 5-10 days prior to vitrectomy.
3360081|NCT02590094|Active Comparator|I|Study Group I: Subjects receive 1.25 mg intravitreal ziv-aflibercept 1-10 days prior to vitrectomy, and then receive 1.25 mg intravitreal ziv-aflibercept at the completion of the vitrectomy.
3360082|NCT02578797|Experimental|Apalutamide|Prostate Cancer participants will receive the study drug on an outpatient basis except for Cycle 1 (Day 1 and Day 2) and Cycle 3 (Day 1), when intake must occur at study site under overnight fasted conditions.
3248069|NCT01362998|Active Comparator|Preservative free morphine|This group will receive 3mg of preservative free morphine epidurally during the procedure.
3248070|NCT01362998|Active Comparator|Fentanyl infusion|This group will receive an epidural infusion of fentanyl (60 micrograms per hour), which will be started during the Cesarean section and which will continue for the next two days.
3360083|NCT02564848|Experimental|Lumpectomy without sentinel node biopsy|Subjects will undergo standard of care lumpectomy. A biopsy of the sentinel node will not be performed. After surgery, subjects will receive standard of care radiation on the affected breast and hormonal therapy.
3360086|NCT02519452|Experimental|Part 1: Cohort 1|Participants will receive 1200 mg (daratumumab 1200 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 30,000 U) via mixing immediately before Subcutaneous (SC) infusion once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
3360087|NCT02519452|Experimental|Part 1: Cohort 2|Participants will receive 1800 mg (daratumumab 1800 milligram (mg) with Recombinant Human Hyaluronidase [rHuPH20] 45,000 U) via mixing immediately before SC infusion once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression.
3360088|NCT02519452|Experimental|Part 1: Cohort 3|Participants will receive mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery at a dose which will be decided by Study Evaluation Team (SET) once weekly by SC infusion in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles until disease progression. Also up to three additional optional cohorts (Cohorts 3b, 3c, and 3d) may be enrolled to repeat a dose level of daratumumab.
3248071|NCT01363024|Experimental|A|
3248072|NCT01363037|Experimental|Dapivirine-Maraviroc Vaginal Ring|
3248073|NCT01363037|Placebo Comparator|Placebo Vaginal Ring|
3248074|NCT01363037|Active Comparator|Maraviroc Vaginal Ring|
3248075|NCT01363037|Active Comparator|Dapivirine Vaginal Ring|
3248076|NCT01363063|Experimental|Ketorolac tromethamine (Part A)|
3360089|NCT02519452|Experimental|Part 2: Cohort 4|Participants will receive 1800 mg co-formulated daratumumab and rHuPH20 preparation initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles. The dose level and schedule for any additional cohorts would be selected based on the daratumumab pharmacokinetic profile and safety profile (reviewed by the SET) that will be observed in Cohort 4.
3360090|NCT02519452|Experimental|Part 3: Dara-CF 1800 mg|Participants will receive co-formulated daratumumab 1800 mg and rHuPH20 preparation (Dara-CF) initially administered by SC injection once weekly in Cycles 1 and 2, every 2 weeks in Cycles 3-6, and then every 4 weeks in subsequent cycles.
3360091|NCT02516241|Experimental|Combination Therapy|MEDI4736 (Durvalumab) + Tremelimumab
3360092|NCT02516241|Experimental|Monotherapy|MEDI4736 (Durvalumab)
3360093|NCT02516241|Active Comparator|Standard of Care|Standard of Care Chemotherapy Treatment
3360094|NCT02468778|Experimental|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
3360095|NCT02468778|Active Comparator|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® Device approved for use in high-risk PCI.
3248077|NCT01363063|Experimental|Ketorolac tromethamine (Part B)|
3248078|NCT01363089|Experimental|Ketorolac tromethamine|
3248079|NCT01363089|Experimental|Oxymetazoline hydrochloride|
3248080|NCT01363102|No Intervention|Control group|Group will undergo usual mobilization per standard SICU care
3248081|NCT01363102|Experimental|Study Group|Patient mobilization discussed on rounds, SOMS score goal created, specific attempt to mobilize patient and achieve goal throughout day.
3248082|NCT01363115|Experimental|OJ fortified with Ca and VitD|Regular OJ fortified with Calcium (350 mg/8 fluid oz serving) and Vitamin D3 (100 IU/8 fluid oz serving): one 8 fluid oz serving three times/day (treatment) in combination with nutritional counseling
3248083|NCT01363115|Active Comparator|OJ without VitD and Ca|Regular OJ without Calcium or Vitamin D3: one 8 fluid oz serving three times/day (control)
3248084|NCT01363141|Active Comparator|Regular AGE Diet|Regular AGE Diet
3248085|NCT01363141|Active Comparator|Low AGE Diet|One year reduction in dietary AGE intake
3248086|NCT01363154|Active Comparator|Mozart K448|Treatment: music exposure to Mozart K448
3248087|NCT01363154|Placebo Comparator|Beethoven's Für Elise|Placebo: music exposure to Beethoven's Für Elise for piano
3360096|NCT02431702|Active Comparator|Part-1: Oral Antipsychotics (OAP)|All Participants will receive Paliperidone Extended Release (ER) 1.5 to 12 milligram (mg) or risperidone 1 to 6 mg once daily orally for 2 months. Subjects who tolerate paliperidone ER/risperidone but find it inadequately efficacious after treatment for an adequate duration at an adequate dosage (per clinical judgment), may be switched to another protocol-specified OAP at the discretion of the investigator.
3360097|NCT02431702|Experimental|Part-2: Paliperidone Palmitate (PP)|Participants who will complete Part-1 will be randomized to receive oral Paliperidone Palmitate (PP) treatment. Participants will receive 5 doses of PP1M (paliperidone palmitate once-monthly injection). First dose at a starting dose of 234 mg on Day 1 and thereafter second dose in second week and then, every month up to Day 92. Participants will be subsequently switched to PP3M (paliperidone palmitate three-monthly injection) following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
3360098|NCT02431702|Active Comparator|Part-2: OAP|Participants who will complete Part-1 will be randomized to receive Oral Antipsychotics for 9 months.
3360099|NCT02431702|Experimental|Part-3: PP - PP|Participants who will complete Part-2 (with PP treatment) will continue to receive Paliperidone Palmitate for 9 months.
3360100|NCT02431702|Experimental|Part-3: OAP - Delayed Start Paliperidone Palmitate (PP)|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive PP treatment for 9 months. PP treatment includes PP1M and PP3M. Participants will be subsequently switched to PP3M following a minimum of 5 injections of PP1M. Participants receiving PP3M may go back to treatment with PP1M (monthly injections of 78, 117, 156 or 234 mg, flexibly dosed) for further dose adjustment or for the duration of the study with the approval of the medical monitor.
3360101|NCT02431702|Active Comparator|Part-3: OAP - OAP|Participants who will complete Part-2 (with OAP treatment) will be randomized to receive OAP treatment for additional 9 months.
3360106|NCT02420912|Experimental|Cohort I (nivolumab, ibrutinib)|Patients receive nivolumab IV over 1 hour on days 1 and 15 and ibrutinib PO QD on days 1-28 of courses 2-24. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3248088|NCT01363154|No Intervention|No music exposure|Control: no music exposure
3248089|NCT01363167|Active Comparator|400 IU Cholecalciferol - Vitamin D|
3360107|NCT02420912|Experimental|Cohort II (nivolumab, previous ibrutinib)|Patients receive nivolumab as in Cohort I and continue previous ibrutinib treatment.
3360108|NCT02420912|Experimental|Cohort III (nivolumab, ibrutinib)|Patients receive nivolumab and ibrutinib as in cohort I. Ibrutinib may be given earlier than course 2 in case of worsening disease after discussion with study principal investigator. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
3360109|NCT02393248|Experimental|Dose Escalation|"Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.~Dose Expansion~Combination therapy:~Gemcitabine + Cisplatin + Pemigatinib~Pembrolizumab + Pemigatinib~Docetaxel + Pemigatinib~Trastuzumab + Pemigatinib~INCMGA00012 + Pemigatinib"
3360110|NCT02368002|Experimental|Behavioral weight loss therapy|Emphasizes 1) identifying behaviors in need of change, 2) setting goals for change, 3) monitoring progress, 4) modifying environmental cues to facilitate change, and 5) modifying consequences to motivate change.
3360111|NCT02368002|Experimental|Portion-controlled meals|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive portion-controlled meals in addition to standard behavioral weight loss therapy.
3360112|NCT02368002|Experimental|Acceptance-based treatment|Fifty percent of participants who have not lost the expected amount of weight will be re-randomized to receive an enhanced version of behavioral weight loss therapy teaching acceptance-based behavioral skills.
3248090|NCT01363167|Placebo Comparator|Placebo|Placebo contains Fractionated Coconut Oil
3248091|NCT01363180||Control|
3248092|NCT01363180||Trauma-exposed without PTSD|
3248093|NCT01363180||Trauma-exposed with PTSD|
3248094|NCT01363206|Experimental|Single arm open label|GM-CSF and Ipilimumab
3248095|NCT01363232|Experimental|BKM120 + MEK162|
3248096|NCT01363245|Experimental|Hospital phone counseling|multisession telephone counseling by hospital/study's smoking cessation staff
3248097|NCT01363245|Active Comparator|Fax-to-quit|Faxed referral to the state Quitline, which will then perform phone outreach as per Quitline protocol
3248098|NCT01363271||complicated skin and skin structure infections (cSSSI)|Identified through a pre-specified list of ICD-9 codes in study protocol.
3248099|NCT01363271||Pneumonia|Identified through a pre-specified list of ICD-9 codes in study protocol.
3248100|NCT01363284|Experimental|Duloxetine|The first week of the treatment is the placebo treatment. The effect of placebo will be taken into consideration for further evaluation the duloxetine effect on clinical pain and descending pain inhibition capabilities.
3248101|NCT01363310|Active Comparator|Quetiapine XR|
3248102|NCT01363310|Active Comparator|Escitalopram|
3248103|NCT01363323|Experimental|Arm 1|
3360113|NCT02365597|Experimental|Erdafitinib (8 milligram)|Prior to interim analysis 1 (IA1), there were 2 treatment regimens: Regimen 1 (10 milligram [mg] once daily, 7 days on/7 days off); and Regimen 2 (6 mg once daily for 28 days). Following IA1, Regimen 1 is closed for further enrollment and starting dose of Regimen 2 is increased to 8 mg once daily for 28 days on a 28-day cycle (referred to as Regimen 3). Participants who enrolled in DDI substudy will receive pretreatment with single doses of midazolam (Day -2) and metformin (Day -1). Participants will receive 8 mg erdafitinib treatment from Day 1 to Day 15, single doses of midazolam 2.5 mg (Day 13) and metformin 1000 mg (Day 14) and erdafitinib treatment will continued until disease progression.
3360117|NCT02329847|Experimental|Cohort A1|Participants will receive ibrutinib 420 milligram (mg) capsule orally once daily and nivolumab intravenously as 3 milligram/kilogram (mg/kg) every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360118|NCT02329847|Experimental|Cohort A2|Participants will receive ibrutinib 560 mg capsule orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360119|NCT02329847|Experimental|Cohort B1|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360120|NCT02329847|Experimental|Cohort B2|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360121|NCT02329847|Experimental|Cohort B3|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360122|NCT02329847|Experimental|Cohort B4|Participants will receive ibrutinib recommended Phase 2 dose (RP2D) orally once daily and nivolumab intravenously as 3 mg/kg every 2 weeks for 14-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3360123|NCT02298959|Experimental|Treatment (pembrolizumab and ziv-aflibercept)|Patients receive pembrolizumab IV over approximately 30 minutes and ziv-aflibercept IV over 1-2 hours on day 1. Cycles repeat every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3360124|NCT02256631|Experimental|Dose Group 1|Infants in Dose Group 1 received a single VRC01 20 mg/kg injection less than 72 hours after birth.
3360125|NCT02256631|Experimental|Dose Group 2|Infants in Dose Group 2 received a single VRC01 40 mg/kg injection less than 72 hours after birth.
3360126|NCT02256631|Experimental|Dose Group 3|Infants in Dose Group 3 received a VRC01 40 mg/kg injection less than 5 days after birth. They then received a VRC01 20 mg/kg injection monthly for at least 6 months and no more than 18 months while breastfeeding.
3360127|NCT02256631|Experimental|Dose Group 4, Cohort 1|Infants in Cohort 1 received a single VRC01LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
3360128|NCT02256631|Experimental|Dose Group 4, Cohort 2|Infants in Cohort 2 received an initial VRC01LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC01LS was administered at Week 12 if an infant was still breastfeeding.
3248104|NCT01363323|Experimental|Arm 2|
3248105|NCT01363323|Experimental|Arm 3|
3360129|NCT02256631|Experimental|Dose Group 5, Cohort 1|Infants in Cohort 1 received a single VRC07-523LS injection less than 72 hours after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater.
3360130|NCT02256631|Experimental|Dose Group 5, Cohort 2|Infants in Cohort 2 received an initial VRC07-523LS injection no longer than 5 days after birth. Dose was based on weight: 80 mg for infants weighing less than 4.5 kg and 100 mg for infants weighing 4.5 kg or greater. A second dose of 100 mg VRC07-523LS was administered at Week 12 if an infant was still breastfeeding.
3248106|NCT01363323|Placebo Comparator|Arm 4|
3248107|NCT01363323|Active Comparator|Arm 5|
3248108|NCT01363336||Group 1|
3248109|NCT01363362|Experimental|glaucoma patients|Glaucoma patients undergoing selective laser trabeculoplasty for further IOP reduction
3248110|NCT01363375||normal foot|Subjects with normal foot structure
3248111|NCT01363375||flat foot|Subjects with flat foot structure.
3248112|NCT01363375||high arch foot|Subjects with high arch foot structure.
3248113|NCT01363414|Experimental|Artificial tear|One drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
3248114|NCT01363414|Placebo Comparator|Control|one drop of sterile 0.9% sodium chloride solution in the other eye
3248115|NCT01363427||Crohn's disease|Patients with initially diagnosed Crohn's disease
3248116|NCT01363453||Patients with Ulcerative Colitis|
3248117|NCT01363466|Experimental|with hysterectomy|
3248118|NCT01363466|No Intervention|without hysterectomy|
3248119|NCT01363505||Acute CHF patients|Acute CHF patients with BARD Intra-abdominal pressure monitors in ICU
3248120|NCT01363518||Operative|Operative group would have had surgery to treat their broken humerus.
3248121|NCT01363518||Nonoperative|Nonoperative group would have been treated with a brace, no surgery.
3360131|NCT02252172|Active Comparator|Lenalidomide and Dexamethasone (Rd)|Participants will receive Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
3360132|NCT02252172|Active Comparator|Daratumumab + Lenalidomide + Dexamethasone (DRd)|Participants will receive Daratumumab 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks, Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle, Dexamethasone 40 mg orally or intravenously once a week. Following implementation of protocol amendment 8, participants still receiving treatment with daratumumab IV will have the option to switch to daratumumab SC on Day 1 of any cycle, at the discretion of the investigator. Daratumumab subcutaneous (SC) will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or study completion. Study treatment continues until disease progression, unacceptable toxicity, or end of study (maximum up to 7 years after last subject is randomized) whichever comes first.
3360135|NCT02200770|Placebo Comparator|Placebo/Inebilizumab|Aquaporin-4-antibody (AQP4-IgG) sero positive and sero negative participants will receive IV dose of placebo matched to inebilizumab on Day 1 and Day 15 of the RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on both Day 1 and Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
3360136|NCT02200770|Experimental|Inebilizumab/Inebilizumab|AQP4-IgG sero positive and sero negative participants will IV dose of inebilizumab 300 mg on Day 1 and Day 15 of RCP. The participants who enter OLP will receive IV inebilizumab 300 mg on Day 1 and matching placebo on Day 15, followed by a single IV dose of inebilizumab 300 mg every 6 months until maximum of 3 years after the last participant enters the OLP. Participants will have choice to enter in the SFP at any point during RCP or OLP and will be free to pursue other treatment options otherwise prohibited during the RCP and OLP. Participants will continue in the SFP for 12 months from last dose of study drug.
3360137|NCT02195479|Active Comparator|Treatment Arm A (VMP Alone)|Participants will receive velcade (bortezomib) 1.3 milligram per square meter (mg/m^2) as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2 , orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
3360138|NCT02195479|Experimental|Treatment Arm B (D-VMP)|Participants will receive velcade 1.3 mg/m^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
3248122|NCT01363531|Active Comparator|Direct antibiotic treatment|The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.
3248123|NCT01363531|No Intervention|No antibiotic treatment|The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.
3248124|NCT01363531|Experimental|Delayed antibiotic prescription 1|The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.
3248125|NCT01363531|Experimental|Delayed antibiotic prescription 2|The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.
3248126|NCT01363544|Experimental|Neurofeedback|
3248127|NCT01363544|Experimental|Exercise|
3248128|NCT01363544|Active Comparator|methylphenidate|optimum dose of methylphenidate (assessed by a double blind placebo-controlled procedure)
3248129|NCT01363557|Experimental|Arm A : Gefitinib + WBRT|Arm A : WBRT and Concurrent Gefitinib followed by Gefitinib Maintenance
3248130|NCT01363557|Experimental|Arm B : Gefitinib|Arm B : Gefitinib alone
3248131|NCT01363570|Other|Ranibizumab|Ranibizumab is the current gold standard treatment for wet age-related macular degeneration. This intervention is approved by Health Canada, covered by OHIP (Ontario Health Insurance Plan) and used regularly by ophthalmologists in Canada. Participants will receive intravitreal injections of ranibizumab each month for up to 6 months, with ocular testing at each appointment as prescribed by the study protocol.
3248132|NCT01363583|Active Comparator|epoprostenol, Flolan®|Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis
3248133|NCT01363583|Placebo Comparator|normal saline|Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis
3248134|NCT01363596||Natural Procreative Technology (NPT)|Patients who are treated or who consider being treated with Natural Procreative Technology (NPT) for infertility or history of spontaneous abortion.
3248135|NCT01363609|Experimental|Liraglutide|12 week treatment with liraglutide in fixed dosage
3248136|NCT01363609|Active Comparator|Insulin glargine|12 week treatment, once daily, with insulin glargine. Dosage based on fasting blood glucose measurements
3248137|NCT01363609|Other|before start of treatment period|before start of the treatment period, one day with tests will be performed. During this test a GLP-1 receptor antagonist will be administered In the group with obesity and planned gastric bypass surgery, the GLP-1 receptor agonist will be administered during 1 test before and 1 test after the surgery
3248138|NCT01363622||SGA|SGA (small for gestational age)
3248139|NCT01363622||LGA|LGA (large for gestational age)
3248140|NCT01363622||AGA|AGA (appropriate-for-gestational-age)
3248141|NCT01363635||severe sepsis|severe sepsis/septic shock, organ failure, ICU death
3248142|NCT01363648|Experimental|Choline alfoscerate|choline alfoscerate 400mg, 3 times a day, for 12 weeks.
3248143|NCT01363648|Placebo Comparator|placebo (for choline alfoscerate )|placebo tablet, 3 times a day, for 12 weeks.
3360150|NCT02136134|Experimental|Daratumumab+VELCADE+dexamethasone|Daratumumab, VELCADE and dexamethasone
3248144|NCT01363687|Experimental|Remote ischemic postconditioning group|Recipients receive remote ischemic postconditioning after declamping of renal artery during kidney transplantation
3248145|NCT01363687|No Intervention|Control group|Patients who have a deflated cuff placed on the upper limb free of arteriovenous fistula during the surgery
3248146|NCT01363726||2|Jewish and Bedouin children < 5 years of age in southern Israel
3360151|NCT02136134|Active Comparator|VELCADE+dexamethasone|VELCADE and dexamethasone.
3360152|NCT02136069|Experimental|Etrolizumab + Placebo (IV)|Participants will receive ertolizumab (SC) Q4W until Week 52 along with placebo matched to infliximab as IV infusion until Week 46.
3360153|NCT02136069|Active Comparator|Infliximab + Placebo (Injection)|Participants will receive IV infusion of infliximab at Weeks 0,2, and 6, then every 8 weeks until Week 46 partnered with placebo matched to etrolizumab by SC injection Q4W until Week 52.
3248147|NCT01363752|Active Comparator|Advagraf + MMF + Steroids|Without sirolimus
3248148|NCT01363752|Experimental|Advagraf + MMF + Steroids + Sirolimus|With sirolimus; MMF withdrawn on Day 28; Sirolimus introduced on Day 28
3248149|NCT01363778|Experimental|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
3248150|NCT01363804|Experimental|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
3248151|NCT01363817|Experimental|Escalation Phase: BMS-906024|BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity
3248152|NCT01363817|Experimental|Expansion Phase: BMS-906024 + Dexamethasone|BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity
3248153|NCT01363830|Experimental|Two-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for two-weeks following discectomy.
3248154|NCT01363830|Active Comparator|Six-Week Post-Operative Restriction|Restrict bending, lifting, and twisting for six-weeks following discectomy.
3248155|NCT01363856||First ever acute stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
3248156|NCT01363869|Experimental|Green tea extracts 2 gm/day|Green tea extracts 2 gm/day for 14 days
3248157|NCT01363869|Experimental|Green tea extracts 4 gm/day|Green tea extracts 4 gm/day for 14 days
3248158|NCT01363869|Experimental|Green tea extracts 6 gm/day|Green tea extracts 6 gm/day for 14 days
3360157|NCT02096874|Other|Bevacizumab|Each study subject will recieve Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month.
3360158|NCT02086552|Experimental|Treatment (sonidegib, lenalidomide)|Patients receive sonidegib PO QD on days 1-28 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve sCR, CR, VGPR, PR, MR, or SD (or usCR, uCR, uVGPR, uPR, uMR) continue treatment in the absence of disease progression or unacceptable toxicity.
3360161|NCT02019706|Experimental|Imaging|All subjects will be imaged
3360162|NCT01946204|Experimental|Treatment Arm A: Apalutamide|
3360163|NCT01946204|Placebo Comparator|Treatment Arm B: Placebo|
3360164|NCT01900574|Experimental|Golimumab|
3360165|NCT01839396|Active Comparator|Medium continuous dose of stimulation|Subjects in this arm will receive stimulation settings at a medium continuous dose of Deep Brain stimulation that may have been effective in previous DBS patients.
3360166|NCT01839396|Sham Comparator|Low intermittent dose of stimulation|Subjects in this arm will receive stimulation settings at a lower intermittent dose of Deep Brain stimulation which is less likely to be effective.
3360169|NCT01615029|Experimental|Daratumumab|Participants will receive daratumumab along with Lenalidomide and dexamethasone.
3360170|NCT01517659|Experimental|Fat Reduction|The Zeltiq CoolSculpting System will be used to treat subcutaneous fat on each inner thigh.
3360174|NCT01482195|Experimental|Subretinal Injection of rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus|Single arm of 6 patients undergoing subretinal injection of Gene Therapy using rAAV2-VMD2-hMERTKRecombinant Adeno-Associated Virus. Each patient received the injection in one eye.
3360175|NCT01482195|No Intervention|fellow eye without intervention|fellow eye without intervention
3360176|NCT01443468||1|Patients within a family with a known TP53 mutation who are positive for that mutation.
3360177|NCT01443468||2|Patients within a family with a known TP53 mutation who are negative for that mutation.
3360178|NCT01443468||3|Unaffected family members.
3360179|NCT01443468||4|Patients who meet clinical LFS criteria but haven't had TP53 testing.
3360180|NCT01443468||5|Patients within a family with an negative/unknown TP53 mutation.
3360185|NCT01314118|Experimental|001|abiraterone acetate in combination with prednisone Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
3360192|NCT01209767|Experimental|cryolipolysis|
3360193|NCT01209767|Active Comparator|subcision|
3360194|NCT01209767|Active Comparator|Control|Areas with cellulite that had no treatment performed were considered the control arm.
3360197|NCT01186848|Active Comparator|1550-nm erbium-doped fractionated laser|
3360198|NCT01186848|Active Comparator|Combination treatment|"micro-focused ultrasound and 1550nm-fractionated laser"
3360199|NCT01171898|Experimental|Dose Escalation Cohort (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily. Once Recommended Phase 2 Dose (RP2D) has been selected, Phase 1 participants being treated at the lower dose levels will be allowed to escalate to the RP2D level at the discretion of the primary investigator.
3360200|NCT01171898|Experimental|Non-metastatic CRPC (Phase 2)|Participants with non-metastatic, treatment-naive Castration-Resistant Prostate Cancer (CRPC) with rapidly rising Prostate Specific Antigen (PSA) will be enrolled. ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
3360201|NCT01171898|Experimental|Treatment-naive metastatic CRPC (Phase 2)|Participants with treatment-naive metastatic CRPC will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
3360202|NCT01171898|Experimental|Post-abiraterone metastatic CRPC (Phase 2)|Participants with metastatic CRPC that are chemotherapy-naive, but have been previously treated with abiraterone will be enrolled. ARN-509 will be administered at MTD and/or RP2D, determined in Phase 1.
3360204|NCT01040624|Experimental|High-risk arm A (HR-A)|< 15% risk of + lymph nodes (LN)
3360205|NCT01040624|Experimental|HR-B|> 15% risk of + LN
3360206|NCT01024608|Experimental|BDP HFA 320 µg/day|During the 2-week double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
3360207|NCT01024608|Placebo Comparator|Placebo|During the 2-week double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
3360208|NCT00988247|Experimental|BDP HFA 320 µg/day|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning.
3360209|NCT00988247|Placebo Comparator|Placebo|During the 30-week (or 52-week, depending upon investigator site) double-blind Treatment Period participants self-administered four actuations (two per nostril) of placebo HFA once daily each morning.
3248159|NCT01363882|Active Comparator|Standard NIV|Noninvasive ventilation (NIV) will be initiated and managed as per current standard of practice guided by the American Academy of Neurology (AAN) Practice Parameters (updated in 2009), in all subjects with amyotrophic lateral sclerosis (ALS) and a forced vital capacity of <50% predicted. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months, but will not influence management of the NIV.
3360213|NCT00838981|Active Comparator|Modafinil Plus Contingency Magagement|Modafinil from 200mg up to 400mg plus Contingency Management
3360214|NCT00838981|Placebo Comparator|Sugar Pill Plus Contingency Management|Placebo: sugar pill
3360215|NCT00838981|Active Comparator|Modafinil Plus Voucher Control|
3360216|NCT00838981|Placebo Comparator|Sugar Pill Plus Voucher Control|
3360219|NCT00730639|Experimental|Melanoma - BMS-936558 (MDX-1106)|
3360220|NCT00730639|Experimental|RCC - BMS-936558 (MDX-1106)|
3360221|NCT00730639|Experimental|mCRPC - BMS-936558 (MDX-1106)|
3360222|NCT00730639|Experimental|NSCLC - BMS-936558 (MDX-1106)|
3248160|NCT01363882|Experimental|Sleep study titrated NIV|ALS subjects in this arm, who are offered NIV for Forced Vital Capacity (FVC) <50% as per AAN Practice Parameters, will have their initial level of NIV determined polysomnographically. They will be followed with sleep studies at 1 month, 3 months and 6 months to reassess NIV efficacy and NIV will be adjusted as necessary to optimize parameters of oxygenation and ventilation.
3360223|NCT00730639|Experimental|CRC - BMS-936558 (MDX-1106)|
3360224|NCT00693238|Experimental|Low Risk Proton Radiation|70 Gy/CGE in 28 fractions of 2.5 Gy/CGE/fx
3360225|NCT00693238|Experimental|Intermediate Risk Proton Radiation|72.5 GY/CGE in 29 fractions of 2.5 Gy/CGE/fx
3360231|NCT00363038|Experimental|Bruising|Bruises at three time points: immediate after bruise creating, and at 1 and 2 weeks.
3248161|NCT01363895|Active Comparator|Percutaneous closure of LAA|Percutaneous closure of LAA
3248162|NCT01363895|Active Comparator|Catheter ablation of AF|Catheter ablation of AF
3248163|NCT01363921|Experimental|Dialysis treatment with HCO1100|
3248164|NCT01363934|Experimental|Group A|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3248165|NCT01363934|Experimental|Group B|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3248166|NCT01363934|Experimental|Group C|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3248167|NCT01363934|Experimental|Group D|GC1113 or Placebo: GC1113 0.3ug/kg to 5ug/kg once intravenously
3248168|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by IV|Darbepoetin alfa 30ug/kg once intravenously
3376069|NCT02993107|Other|Group 1 (Placebo Crossovers)|Subjects who complete the placebo arm of ARC003 and consent to enroll in ARC004 (Group-1) will cross over to active treatment with AR101 using the same dosing regimen used in ARC003 in open-label fashion. Group 1 subjects may also be assigned to cohorts which test the gradual lengthening of dosing intervals. Following the completion of their longest tested dosing interval, Group 1 subjects will undergo an exit double-blinded placebo-controlled food challenge (DBPCFC).
3376070|NCT02993107|Other|Group 2 (Active Rollovers)|Subjects who successfully complete the active arm of ARC003 and consent to enroll in ARC004 (Group-2) will consecutively enter treatment with AR101 in one of three cohorts which will test alternate dosing intervals. There will be a DBPCFC at the completion of the subject's longest tested dosing interval.
3376075|NCT02973789|Experimental|NovoTTF-200T|Patients receive TTFields using the NovoTTF-200T device together with immune checkpoint inhibitors or docetaxel
3376076|NCT02973789|Active Comparator|Best Standard of Care|Patients receive best standard of care with immune checkpoint inhibitors or docetaxel
3376077|NCT02969915|Active Comparator|Integrated care centers|Participants in the active comparator arm have access to integrated care centers (ICCs)
3376078|NCT02969915|Experimental|ICC + incentives|Participants in the experimental arm have access to the ICC intervention and the incentive intervention
3376079|NCT02946931||Prizbind® for Intravenous Solution|Patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.
3376080|NCT02932475|Active Comparator|Treatment|Metformin 1000 mg twice a day
3248169|NCT01363934|Experimental|Group H|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3248170|NCT01363934|Experimental|Group I|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3248171|NCT01363934|Experimental|Group J|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3248172|NCT01363934|Experimental|Group K|GC1113 or Placebo: GC1113 1ug/kg to 8ug/kg once subcutaneously
3248173|NCT01363934|Active Comparator|Darbepoetin alfa 30ug/kg by SC|Darbepoetin alfa 30ug/kg once subcutaneously
3376081|NCT02932475|Sham Comparator|Placebo|Placebo, identical to Metformin
3376082|NCT02918890|Experimental|CIMT|Procedure: Constraint-Induced Movement Therapy 90 hours Other Name: CIT, CI Therapy, restraint therapy, PT, OT, rehab
3376083|NCT02918890|Experimental|HABIT|Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) 90 hours Other Name: HABIT, bimanual training, bilateral training, restraint therapy, PT, OT, rehab
3376084|NCT02914938|Experimental|ME-401 Alone|This arm is an open-label, dose escalation study to determine the safety, efficacy and pharmacokinetics of ME-401 along with the mBED, MTD, and DLTs. There are 4 planned cohorts which may enroll up to 61 subjects.
3376085|NCT02914938|Experimental|ME-401 in Combination with Rituximab|The second arm is an open label study to evaluate the safety, efficacy, and pharmacokinetics of ME-401 in combination with rituximab in subjects with various B-cell malignancies. There are two planned cohorts which may enroll up to 30 subjects.
3376086|NCT02914938|Experimental|ME-401 in Combination with Zanubrutinib|The third arm is an open label study evaluating the safety, efficacy, MTD, DLT and pharmacokinetics of ME-401 in combination with zanubrutinib in subjects with various B-cell malignancies. This arm will include 2 stages: a safety evaluation stage (cohort of 6-12 subjects) and a disease-specific expansion cohort stage (up to 74 subjects).
3376089|NCT02905318|Experimental|Palbociclib|125mg orally days 1-21 every 28 day cycle
3360271|NCT05146557||Group Obese adolescents|BMI above the 97th percentile + 2.17 to+2.18 SDS
3360272|NCT05146557||Group Normal weight adolescents|BMI between the 10th and 90th percentile -1.64 to +1.64 SDS
3360273|NCT05146544||No limitation of exercise performance capacities|normal maximal oxygen uptake (greater than or equal to 80% of the reference value)
3360274|NCT05146544||Limitation of exercise performance capacities|reduced maximal oxygen uptake (less than 80% of the reference value).
3360275|NCT05146531|Active Comparator|McCoy group|Patients were intubated with McCoy laryngoscope.
3248174|NCT01363947|Experimental|Dose Escalation Cohort (DNIB0600A)|Participants will receive IV infusions of DNIB0600A at doses ranging from 0.2 milligrams/kilogram (mg/kg) to 2.8 mg/kg q3w until dose-limiting toxicity (DLT) is reached, or up to 28 cycles.
3248175|NCT01363947|Experimental|Expansion Cohort (DNIB0600A)|Participants will receive 2.4 mg/kg, by IV infusion, of DNIB0600A q3w for up to 26 cycles.
3360276|NCT05146531|Experimental|C-MAC group|Patients were intubated with C-MAC D-blade video laryngoscope.
3360277|NCT05146518|Experimental|Single-arm, pre-post|Maternity staff of health public health facilities will exposed to the intervention package (capacity building and systemic changes in the health facilities).
3248176|NCT01363960||neonates with retinopathy of prematurity|"all neonates meet the criteria:~a BW of less than 1501 gram (g)~born at a GA of 34 weeks (wk) or less and~selected infants with an unstable clinical course were included"
3248177|NCT01363973|Experimental|Sensory stimulation|Transcutaneous electrical stimulation at 75% of motor threshold
3360278|NCT05146492|Active Comparator|Patient with acute myocardial infarction without pericardial effusion|
3360279|NCT05146492|Experimental|Patient with acute myocardial infarction and pericardial effusion|
3248178|NCT01363973|Experimental|Motor stimulation|Transcutaneous electrical stimulation at motor threshold
3248179|NCT01364012|Experimental|Bevacizumab + Paclitaxel/Carboplatin|Participants will receive bevacizumab on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3248180|NCT01364012|Active Comparator|Placebo + Paclitaxel/Carboplatin|Participants will receive bevacizumab matching placebo on Day 1 of each 3-week cycle in combination with paclitaxel and carboplatin for the first 6 treatment cycles (cycle length = 21 days). Participants will continue to receive bevacizumab matching placebo on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
3360282|NCT05146466|Other|E-MATVR (intervention)|
3248181|NCT01364025|Experimental|uterosacral ligament suspension|uterosacral ligament suspension colpopexy sutures will be placed bilaterally at the time of hysterectomy
3248182|NCT01364025|No Intervention|hysterectomy alone|
3248183|NCT01364051|Experimental|Treatment (cediranib maleate, selumetinib)|Patients receive cediranib maleate PO QD and selumetinib sulfate PO QD or BID on days 1-28 (days 8-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cycles may be extended to 12 weeks after 1 year of study treatment.
3248184|NCT01364064|Active Comparator|Conventional adjuvant Temozolomide|TMZ d 1-5 of 28-d cycle 6 cycles
3248185|NCT01364064|Experimental|Dose intensive Temozolomide|TMZ d 1-21 of 28-d cycle 6 cycles
3360283|NCT05146466|Other|E-MATEE (control)|
3360284|NCT05146453|Experimental|Intervention|This group of patients will undergo placement of US guided pectointercostal fascia blocks.
3360285|NCT05146453|Placebo Comparator|Placebo|The control group patients will receive the same intraoperative analgesia management. A PIF block will not be performed, instead, a peripheral nerve block catheter will be secured to the skin surface and connected to a CADD™ pump. As the catheter is taped to the skin surface the control group patients will not be exposed to the risks of peripheral nerve block placement.
3360287|NCT05146427|Experimental|Active Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will play auditory tones to selectively enhance slow-wave activity.
3360288|NCT05146427|Sham Comparator|Sham Slow-wave enhancement|Participants will wear the Philips SmartSleep Deep Sleep Headband which will not be programmed to enhance slow-wave activity
3360289|NCT05146401||Gestational diabetes mellitus|"Gestational diabetes mellitus (GDM) was diagnosed according to the American Diabetes Association criteria, which is based on the one-step approach recommended by the International Association of Diabetes and Pregnancy Study Groups. All women underwent a 75g OGTT in the morning after an overnight fast, with plasma glucose measurement fasting and at 1 and 2 hours. The criteria for GDM diagnosis was to have at least one abnormal value: Fasting glucose ≥ 5.1 mmol/L (92 mg/dL), 1 h glucose ≥ 10.0 mmol/L (180 mg/dL), 2 h glucose ≥ 8.5 mmol/L (153 mg/dL)."
3360290|NCT05146401||Healthy pregnant women|Pregnant women with fasting glucose < 5.1 mmol/L (92 mg/dL), 1 h glucose < 10.0 mmol/L (180 mg/dL) and 2 h glucose < 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
3248186|NCT01364077|Active Comparator|Ivabradine|
3248187|NCT01364077|Placebo Comparator|Control|
3248188|NCT01364129|Experimental|Telemedicine|Participants in this group have digital images of their retina captured with a non-mydriatic camera and are encouraged to see an eye care provider yearly.
3360293|NCT05146375||MSF1|Each member of the MSF1 family who consents to participate to the study will be included.
3360294|NCT05146362|Experimental|RETAIN Programming|
3248189|NCT01364129|No Intervention|Traditional Surveillance|Participants in this group are encouraged to see an eye care provider each year for a diabetic eye exam.
3248190|NCT01364142||thoracic surgery|Patients undergoing thoracic surgery in which one lung ventilation is needed.
3360295|NCT05146362|No Intervention|Control|This arm receives information about American Job Center services and assistance with opening a JobLink account if an individual doesn't have one. Medical providers at all practices will receive training on how to identify early and then manage the risk of work disability to help prevent long-term unemployment
3360296|NCT05146349|Experimental|RETAIN Programming|
3360297|NCT05146349|No Intervention|Control|
3360298|NCT05146310|Experimental|Treated eye|Eye is treated at Baseline visit (V1)
3360299|NCT05146297|Active Comparator|Patient Participants|Patients with invasive breast, prostate or liver cancer, who face a treatment decision
3360300|NCT05146297|Active Comparator|Physician Participants|Oncologists, and advanced practitioners caring for patients with breast, prostate, liver cancer including medical, surgical, radiation oncologists, interventional radiologists, urologists & hepatologists
3360301|NCT05146284|Experimental|PXL770 500 mg QD|
3360302|NCT05146284|Experimental|PXL770 250 mg BID|
3360303|NCT05146245|Experimental|Therapeutic Drug Monitoring|Physicians receive dosing advice based on measured blood levels of risperidone and 9-OH-risperidone.
3360304|NCT05146245|Active Comparator|Care As Usual|Physician decides on possible dosing changes without receiving advice based on blood levels.
3360307|NCT05146219|Experimental|TY-9591 Tablets|TY-9591 Tablets 160mg/d
3360308|NCT05146206||Patients on RYALTRIS|Patients who are currently using RYALTRIS nasal spray.
3360309|NCT05146206||Patients on DYMISTA|Patients who are currently using DYMISTA nasal spray.
3360310|NCT05146193||All subjects are diagnosed of having a spinal deformity|Routine care of patients with spinal deformities
3360311|NCT05146180|Experimental|Parametric positron emission computed tomography|
3248191|NCT01364155|Experimental|600 mg LIM-0705 BID for 28 days|
3248192|NCT01364155|Placebo Comparator|Placebo LIM-0705 for 28 days|
3248193|NCT01364168||First ever acute ischemic stroke|Patients over 18 years and without prior stroke according to WHO criteria, displaying an ischemic stroke, onset within the last 7 days, language German
3248194|NCT01364181|Experimental|Udenafil|Udenafil 50mg qd po
3360312|NCT05146167|Experimental|Bodhi AIM|Participants randomized to the intervention group will receive the Bodhi AIM app
3360313|NCT05146167|Active Comparator|HIB|Participants randomized to the health promotion control group will receive the HIB app
3360314|NCT05146154|Experimental|Pharmacokinetic cohort|After at least 2 doses of study drug, serial blood samples will be collected from 12 non-infected, obese ICU patients to evaluate the pharmacokinetics of imipenem and relebactam in this population.
3360315|NCT05146154|Experimental|Safety cohort|After at least 2 doses of study drug, safety will be monitored closely during study drug dosing and through 72 hours after the last dose is administered in the same 12 non-infected, obese ICU patients from the PK arm
3248195|NCT01364194|Active Comparator|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
3248196|NCT01364194|Placebo Comparator|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
3248197|NCT01364220|Experimental|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
3248198|NCT01364220|Placebo Comparator|Placebo|Placebo tablet, once daily, for 14 days
3248199|NCT01364246|Experimental|Human umbilical cord mesenchymal stem cells transplantation|Intervention group
3248200|NCT01364324||Gastrectomy|Twenty gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
3248201|NCT01364324||Non-gastrectomy|Twenty non-gastrectomized patients with pulmonary TB, treated with standard first line anti-TB drugs(isoniazid/rifampicin/ethambutol/pyrazinamide), administered daily, orally
3360316|NCT05146141|Experimental|Intervention Group|The participants will have to perform a bent-arm throw program 5 minutes before each training session
3360317|NCT05146141|Sham Comparator|Control group|No intervention. They will perform their usual warm-up.
3360318|NCT05146128|Experimental|Analytic group|The participants had to perform analytic exercices for shoulder rotators and scapular stabilizing muscles
3360319|NCT05146128|Experimental|Functional group|The participants had to perform functional exercices for shoulder rotators and scapular stabilizing muscles
3360320|NCT05146128|Experimental|Mixed group|The participants had to perform both analytic and functional exercices for shoulder rotators and scapular stabilizing muscles
3360321|NCT05146102|Experimental|"ethics communication in group, in line with the one to five-step method"|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They will continue by going through an education program for facilitating ethics communication in group, in line with the one to five-step method~The education program has a theoretical and practical approach, which includes the theoretical base of the ethical communication in groups and practicing the one to five method~Thereafter, each ethical representative will facilitate interprofessional sessions at a clinical ward, once a month, for six months at their workplace. Gathering meetings for feedback will be offered for the ethical representatives once a month."
3248202|NCT01364337|Active Comparator|DASH diet|
3360322|NCT05146102|No Intervention|No organized ethics communication in group|"Healthcare professionals working as ethical representatives at the current ward (n=5) have recently gone through a basic ethics program. They have not being educated in the one to five-step method and organized interprofessional sessions are not planned at the wards."
3360323|NCT05146089|Experimental|Hypoxia Exposure|Men and women will be exposed to acute intermittent hypoxic episodes.
3360324|NCT05146076|Experimental|telemedicine supervised group|physical training supervised by telemonitoring
3360325|NCT05146076|Active Comparator|institutional training|institutional training supervised by physiotherapist
3360326|NCT05146063||Polycystic ovary syndrome patients with insulin resistance|
3360327|NCT05146063||Polycystic ovary syndrome patients without insulin resistance|
3360328|NCT05146037|Active Comparator|Saline flushing|TAVI valves will be prepared according to instruction for use(IFU) with saline flushing only.
3360329|NCT05146037|Experimental|CO2 and saline flushing|TAVI valves will be flushed with CO2 and then saline as per IFU
3360330|NCT05146024||Formative Research|Alcohol-serving establishment owners, managers, and servers in New Mexico and Washington State.
3360331|NCT05146011||Single stage pathway|
3360332|NCT05146011||Two stage pathway|
3248203|NCT01364337|Active Comparator|lower carbohydrate DASH diet|
3248204|NCT01364350||TODAY cohort|The cohort of participants diagnosed with type 2 diabetes ages 10 to <18 and obese at time of diagnosis who participated in the TODAY clinical trial are recruited, consented and followed.
3360333|NCT05145998|Active Comparator|Control - Glucola|Glucola control beverage
3360334|NCT05145998|Experimental|Whole peas|Whole cooked peas in a 50 gram carbohydrate meal dose
3360335|NCT05145998|Experimental|Pea Flour|Pea flour in a 50 gram carbohydrate meal dose
3248205|NCT01364363|Other|Total Body Irradiation/VP16|Acute Leukemias, Myelodysplastic syndromes
3248206|NCT01364363|Other|Cytoxan/Total Body Irradiation|Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease
3360336|NCT05145998|Experimental|Whole lentils|Whole cooked lentils in a 50 gram carbohydrate meal dose
3360337|NCT05145998|Experimental|Lentil flour|Lentil flour in a 50 gram carbohydrate meal dose
3248207|NCT01364363|Other|Busulfan/Cytoxan|Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states
3248208|NCT01364363|Other|BEAM (BCNU, etoposide, Ara-C, melphalan)|Lymphomas, Hodgkin's Disease
3360341|NCT05145946|Experimental|Video Game Training Group 1 - High Frequency Hearing Loss|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
3360342|NCT05145946|Active Comparator|Video Game Training Group 1 - Normal Hearing|Closed-loop audiomotor game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
3360343|NCT05145946|Sham Comparator|Video Game Training Group 2 - High Frequency Hearing Loss|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have high frequency hearing loss.
3360344|NCT05145946|Sham Comparator|Video Game Training Group 2 - Normal Hearing|Auditory memory game. Home-based training sessions for 3.5 hours per week over an 8-week. Participants will have normal hearing.
3360345|NCT05145920|Experimental|Pilot testing of an education program promoting effective parenting habit|Parents will receive a series of 5 short videos via Whatsapp
3248209|NCT01364363|Other|Total Lymphoid Irradiation|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
3248210|NCT01364363|Other|Cladribine/Melphalan|For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55
3248211|NCT01364363|Other|FLAG (fludarabine, Ara-C, G-CSF)|For patients undergoing a second allogeneic transplant
3360346|NCT05145907|Experimental|TJ107+Pembrolizumab|TJ107 1200ug/Kg,Q12W + Pembrolizumab 200mg Q3W
3360347|NCT05145894||Asthma|Asthma patients aged 3 years and older with confirmed asthma diagnosis treated by a monotherapy ICS or ICS plus LABA or other controllers and presenting with moderate or severe disease exacerbation
3360348|NCT05145894||COPD|COPD patients aged 40 years and older with confirmed COPD diagnosis treated by a monotherapy long-acting muscarinic antagonist (LAMA), or LAMA plus long acting beta2-agonist (LABA), or inhaled corticosteroid (ICS) plus LABA, or LAMA plus LABA plus ICS and presenting with moderate or severe disease exacerbation
3248212|NCT01364376|Active Comparator|FOLFOX|
3248213|NCT01364376|Experimental|SOX|
3248214|NCT01364402|Experimental|Erythropoietin|
3248215|NCT01364402|Placebo Comparator|Placebo|
3248216|NCT01364415|Experimental|Pasireotide LAR|
3248217|NCT01364441|Placebo Comparator|P|
3248218|NCT01364441|Experimental|E|
3248219|NCT01364454|Experimental|Eligible patients' paper-based reminder|
3248220|NCT01364454|No Intervention|Control group|
3248221|NCT01364480|Experimental|Brain-Machine Interface Users|All participants enrolled in the study will undergo Implantation of NeuroPort Arrays in the motor cortex. There is no control group.
3248222|NCT01364493|Experimental|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
3360349|NCT05145881|Active Comparator|Low dose probiotics|
3360350|NCT05145881|Experimental|Normal dose probiotics|
3360351|NCT05145868|Experimental|Intervention|
3360352|NCT05145868|Sham Comparator|Attention Control|
3248223|NCT01364506|Experimental|Water exercise|
3248224|NCT01364506|No Intervention|Control|
3360358|NCT05145816|Experimental|Cohort (DL 0) for Part 1|Cohort (DL 0) for Starting Dose : Belantamab mafodotin 2.5 mg/kg on Day 1 every 6 weeks
3360359|NCT05145816|Experimental|Cohort (DL +1) for Part 1|Cohort (DL +1) for Dose Escalation: Belantamab mafodotin 2.5 mg/kg on Day 1 every 4 weeks
3248225|NCT01364519|Experimental|Arm 1|
3248226|NCT01364519|Placebo Comparator|Arm 2|
3248227|NCT01364532|Experimental|Transulnar arterial access|Transulnar arterial access for coronary angiography, ad-hoc or elective PCI
3248228|NCT01364532|Active Comparator|Transradial arterial access|Transradial arterial access for coronary angiography, ad-hoc or elective PCI
3248229|NCT01364545|Other|Ketone ester drink Vs placebo drink|Ketone ester drink Vs placebo drink (cross over study - all patients will recieve both)
3360360|NCT05145816|Experimental|Cohort (DL -1) for Part 1|Cohort (DL -1) for Dose De-escalation : Belantamab mafodotin 2.5 mg/kg on Day 1 every 8 weeks
3360361|NCT05145816|Experimental|Cohort (DL -2) for Part 1|Cohort (DL -2) for Dose De-escalation: Belantamab mafodotin 1.9 mg/kg on Day 1 every 8 weeks
3248230|NCT01364571|Experimental|1|SA4Ag vaccine low dose
3248231|NCT01364571|Experimental|2|SA4Ag vaccine mid dose
3248232|NCT01364571|Experimental|3|SA4Ag vaccine high dose
3360362|NCT05145816|Experimental|Cohort Dose Expansion for Part 2|Cohort Dose expansion for Part 2: Belantamab mafodotin Dose 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosage calculations.
3248233|NCT01364571|Placebo Comparator|4|Placebo
3248234|NCT01364610|Active Comparator|Standard Care|Group 1 will have standard catheter based pH-metry. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour monitoring period.
3360364|NCT05145764|Experimental|Suvorexant|Nightly dosing of suvorexant
3360365|NCT05145764|Placebo Comparator|Placebo|Nightly dosing of placebo
3248235|NCT01364610|Active Comparator|Bravo pH Monitoring System|Group 2 will undergo unsedated peroral placement of the Bravo capsule. All participants will answer a questionnaire assessing tolerance and satisfaction of both the siting and placement methods and the 24 hour pH monitoring period.
3248236|NCT01364636||Acute Heart Failure|Patients admitted to emergency room in Acute Heart Failure at Hospital PróCardíaco and Hospital Universitario Antonio Pedro
3360369|NCT05145725||Idiopathic scoliosis in adolescents requiring surgery|
3360370|NCT05145712|Experimental|Bowel readiness|
3360371|NCT05145699|Experimental|Right hemispheric stroke with hemineglect|
3360372|NCT05145699|Active Comparator|Right hemispheric stroke without hemineglect|
3360373|NCT05145699|Other|Normal people|
3248237|NCT01364662|Experimental|1|
3248238|NCT01364662|Experimental|2|
3248239|NCT01364662|Experimental|3|
3248240|NCT01364662|Experimental|4|
3248241|NCT01364675|Experimental|Metformin+Enalapril+Simvastatin|
3248242|NCT01364675|Placebo Comparator|Placebo tablet|
3248243|NCT01364688|Experimental|Treatment|oral alfacalcidol
3248244|NCT01364688|No Intervention|Control|No drug
3248245|NCT01364701|Active Comparator|Maximal dose sildenafil|4 tablets of sildenafil 100mg are given for on demand use
3248246|NCT01364701|Active Comparator|Tadalafil 20mg maximal dose|4 tablets of tadalafil 20mg are given for on demand use
3248247|NCT01364701|Active Comparator|Combination half dose|4 tablets of sildenafil 50mg and tadalafil 10mg are given for on demand use
3248248|NCT01364714||ICU survivors|Male ICU survivors 12 month after discharge
3248249|NCT01364714||Controls|Age and gender matched controls
3248250|NCT01364753||Pilots|No intervention; observational study
3248251|NCT01364792|Experimental|Valaciclovir|The patients in the experimental group will be treated with 4 times 2 grams valaciclovir per day for seven days.
3248252|NCT01364792|Placebo Comparator|Placebo|Patient receives placebo four times a day for seven days.
3259407|NCT01470560|Sham Comparator|Sham Yoga Group Treatment|Sham yoga group (control group) will attend 8 weekly sessions for 1-2 hours and will be lead by a certified yoga instructor. The yoga class will be based on Pantajali's Eight Fold Path which is the basis of Yoga. Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
3360376|NCT05145673|Placebo Comparator|Placebo (OGTT)|The control group was given an glucose solution to oral glucose tolerance test (OGTT) .
3360377|NCT05145673|Experimental|Cinnamon (OGTT plus aqueous cinnamon extract)|The Experimental group was given an glucose solution to oral glucose tolerance test (OGTT) followed by aqueous cinnamon extract.
3360378|NCT05145660|Experimental|Experimental: involved site irradiation|CTVn1=GTVnd+10mm expansion
3360379|NCT05145660|Active Comparator|elective region irradiation|CTVn1= the whole levels where positive lymph nodes are located （the involved levels）+ plus at least ipsilateral one level below the involved levels
3360380|NCT05145647|Experimental|Add-on Brachytherapy|The evaluation for feasibility of surgery takes place 5-6 weeks after CCRT. Any subject whose tumor status is resectable at evaluation but declines surgical proposal will be eligible to be enrolled in the following study phase.
3360381|NCT05145634|Experimental|Educational group|The interventions administered to the experimental group were one-on-one instruction and Health Brief Model (HBM)-driven strategies, health information technology system, monthly telephone follow-ups, and providing medication cards.
3360382|NCT05145634|No Intervention|Control group|Patients in the control group only received brochure and medication cards.
3360387|NCT05145595|Experimental|Psychophysical assessments of experimental pain|"At baseline, participants will complete a 2.5-hours study session. In the study session, psychophysical assessments of thermal and pressure stimuli will be performed and sex hormone levels will be analyzed. In addition, demographic, social, pubertal maturation, behavioral and psychological factors will be collected via questionnaires.~In the optional follow-up portion, participants can complete short surveys every 3 months and/or return for study visits every year depending on the participant's availability. The study visits will include the same procedures as the baseline study visit. Additional surveys regarding new symptoms of pain will be completed. In some cases, participants will meet a pediatric physician who will determine if they meet the criteria for any pain syndrome (for research purposes only)."
3360388|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD.
3360389|NCT05145582|Experimental|Unguided, Transdiagnostic ICBT Tailored for PSP + Online Discussion Forum|An 8-week, unguided, transdiagnostic ICBT program tailored specifically for public safety personnel and designed to treat depression, anxiety, and PTSD plus a built-in online discussion forum.
3360390|NCT05145569|Experimental|Carboplatin/paclitaxel + Bintrafusp alfa (M7824)|Bintrafusp alfa (M7824) (2400 mg flat dose IV), in combination with chemotherapy including carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
3360391|NCT05145569|Active Comparator|Carboplatin/paclitaxel|Carboplatin AUC 5 and paclitaxel 175 mg/m2 on Day 1 of the 21-day cycle
3360392|NCT05145556|Experimental|Videolaryngoscopy (McGrath Macintosh)|First pass success rate using the videolaryngoscopy
3360393|NCT05145556|Experimental|conventional direct laryngoscopy|First pass success rate using the conventional direct laryngoscopy
3360394|NCT05145543|Placebo Comparator|Group C|0.9 NaCl % (Saline) (5 ml)
3360395|NCT05145543|Active Comparator|Group L|0.25 % levobupivacaine (5 ml) will be applied.
3360396|NCT05145543|Experimental|Group LF|fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
3360397|NCT05145543|Experimental|Group LD|dexamethasone plus levobupivacaine (5 ml) will be applied.
3360400|NCT05145504||20 obese patients, with BMI ≥ 30|
3360401|NCT05145504||20 normal weight patients with BMI between 18.5 - 24.9 inclusive|
3360402|NCT05145491|Active Comparator|Immediate Vitrectomy|
3360403|NCT05145491|Other|Deferred Vitrectomy|
3360404|NCT05145478||Shockwave Intravascular Lithotripsy (IVL)|Patients with calcified common-femoral artery disease, who are eligible to receive IVL per the FDA indications.
3360405|NCT05145465|Experimental|Telerehabilitation group|"Participants will undertake the first training session in the University of Thessaly under the supervision of a specialized physiotherapist in order to precept the exercises. All the other sessions will proceed via telerehabilitation program at their home. Participants will undergo an exercise home based program 3 times/week.~The program will start with 10 minutes warm up exercise , 20 minutes continuous aerobic exercise ( 60-80% of target heart rate), 20 minutes resistance training exercise ( 30-50% 1RM), 5 minutes cool down and breathing exercises. For their safety patients will monitor glucose, blood pressure, pulse-oxygen and heart rate via, blood pressure monitor, pulse oximeter and smart-watch devices. They will be assessed at the beginning of the study and after the intervention ( at 6 weeks)"
3360406|NCT05145465|No Intervention|control group|The participants in this group will just receive the education session and they will continue their current medical therapies.They will be assessed at the beginning of the study and after the intervention ( at 6 weeks).
3360407|NCT05145452|Experimental|Intervention Group|Subjects randomized to n-3 PUFA will receive a total of 4.2 g/d of fish oil.
3360408|NCT05145452|Placebo Comparator|Placebo Group|Subjects randomized to placebo will receive 4.2 g/d sunflower oil.
3360409|NCT05145452|No Intervention|Control group|Subjects assigned to the control group will be tested once
3360410|NCT05145439|Experimental|VibratoSleeve TUS|In this single arm study, there is only one group/arm, all of whom will be given 3 levels of treatment with the VibratoSleeve TUS device.
3360411|NCT05145426|Experimental|Pain Trials|Multi visit - LIFU/Sham application, with quantitative sensory testing (using peltier device).
3248253|NCT01364805|Experimental|PK Intravenous Vitamin C and Gemcitabine|Week 1: 2 visits for escalating doses of intravenous ascorbic acid (IV C). First dose 25 gm followed by 50 gm 2nd visit. Week 2: 3 visits escalating doses of IV C, 75 grams, 100 grams, and 125 grams. Week 3: 2 visits pharmacokinetic evaluation of intravenous ascorbic acid alone at 125 grams; return to the infusion clinic the following morning for a 24 hour blood draw; 2nd visit receive the first infusion of gemcitabine chemotherapy for PK evaluation of gemcitabine alone. Week-4: gemcitabine and IV C co-administered for pharmacokinetics of both drugs to assess for PK variability related to drug-drug interactions. Subjects will return to the infusion clinic the following morning for 24 hour blood draw.
3248254|NCT01364818||Placebo Comparator: Placebo|No treatment/ performance of somatosensory task (cortical metrics) without any intervention. The somatosory task will be performed before any intervention/at the midpoint/ and finally at the end.
3360415|NCT05145387|Experimental|TEAMSS Intervention in the RCT|Students randomly assigned to the TEAMSS intervention will receive the 5th and 6th grade components.
3360416|NCT05145387|No Intervention|Enhanced Usual Care in the RCT|Enhanced Usual Care (EUC) will serve as the comparison group. EUC will be comprised of written materials (given all at once after randomization by study team) for parents and children that include: 1) a specialty mental health referral list; 2) a list of websites and books on child anxiety; and 3) tip sheets on successful transitions to MS. Families in this condition will not be prohibited from seeking treatment (though this will be monitored) for their children. These students will visit and meet with the 6th grade clinician in the spring of 5th grade.
3360417|NCT05145374||Stressful Stimuli|Participation in meal, exercise, sleep activities alone or in combination with stressful stimuli.
3360424|NCT05145335|Experimental|Autoregulated cuff|two sessions in which an autoregulated cuff will be used to adapt the pressure in order to keep the total pressure given constant. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
3360425|NCT05145335|Active Comparator|non-autoregulated cuff|two sessions in which an non-autoregulated cuff will be used. In these two sessions, the pressure will not be adapted. Consequently, during each muscle contraction the pressure will rise because the cuff is not autoregulated. First session will be within a 30-15-15-15 reps protocol, the second session will be performed until max fatigue.
3248255|NCT01364818||Active Comparator: Active Medication|Treatment (memantine, lurasidone)/ performance of somatosensory task (cortical metrics) with intervention. The somatosory task will be performed before any intervention has started/at the midpoint/ and finally at the end.
3248256|NCT01364844|Experimental|DS7423|
3360428|NCT05145309|Experimental|Potassium Magnesium Citrate (KMgCit) first then Placebo|Patients will be asked to take KMgCit ( Sterling Pharmaceutical Services) first for 4 weeks. The content of each sachet will be dissolved in 250 ml water and will be drunk with breakfast and again with dinner during the KMgCit Phase, to deliver 40 meq K, 20 meq Mg and 74 meq citrate per day. Then, subjects will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
3360429|NCT05145309|Experimental|Placebo first then KMgCit|Patients will be asked to take Placebo packaged in an identical sachet by dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks. Then, subjects will be asked to take KMgCit (Sterling Pharmaceutical Services, Dupo, IL) after dissolving in 250 ml water and drink it with breakfast and again with dinner for 4 weeks
3248257|NCT01364857|Other|PWS cohort|search for polymorphisms of RASA1 gene
3248258|NCT01364883|Experimental|Group 1|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
3248259|NCT01364883|Experimental|Group 2|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
3248260|NCT01364883|Experimental|Group 3|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W4, MVA ME-TRAP boost W8, MVA ME-TRAP boost W12
3360430|NCT05145296|Other|Patients with cPRA ≥99%|This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
3360431|NCT05145283|Active Comparator|Conestat alfa (Ruconest®) intervention group|The intervention group will receive conestat alfa (Ruconest®) as a 10-minute slow intravenous injection (up to 56 ml) once during the TAVI procedure followed by a second administration (up to 28 ml) again three hours later. The first administration will include a dosage of 100 U/kg (maximum 8400 U) conestat alfa. The dosing of the second administration will be 50 U/kg (maximum 4200 U).
3360432|NCT05145283|Placebo Comparator|saline injection placebo group|Subjects randomized into the placebo group will receive an intravenous normal saline injection with corresponding volume over 10 minutes during the TAVI procedure and three hours later after the first administration.
3360433|NCT05145270|Active Comparator|Escitalopram|The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.
3360434|NCT05145270|Experimental|Escitalopram plus Sulforaphane|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
3360435|NCT05145270|Experimental|Escitalopram plus rTMS|"The dose of Escitalopram based on treatment guidelines for major depressive disorder and drug prescription manual is 10-20mg/day, once per day.~rTMS is delivered to the left dorsolateral prefrontal lobe position. Stimulation parameters are set to be 80 stimulation strings of 10Hz with an interval of 12 seconds. Each stimulation string includes 30 stimulations lasting for 3 seconds. One session includes 2400 stimulation strings lasting for 19 minutes and 40 seconds. The course of rTMS treatment includes 20 sessions, once a day or twice a day."
3360436|NCT05145257|Other|Elix Cycle Balance|Elix Cycle Balance supplement
3360437|NCT05145244||Patients with newly diagnosed non-small cell lung cancer|"Approximately 1800 patients who are initiating~Standard of care, including targeted therapy based on PD-L1 status, EGFR, ALK or ROS1 (routine biomarkers)~Active clinical trials in the clinics after informed consent"
3360438|NCT05145244||Patients with metastatic breast cancer|"Approximately 600 patients who are initiating~Standard of care, including targeted therapy based on HER2 status and ER status (routine biomarkers)~Active clinical trials in the clinics after informed consent"
3360439|NCT05145231||grup 1|GMFCS PEDİ ABİLOCO-KİDS FMS
3360442|NCT05145205||LSG|
3248261|NCT01364883|Experimental|Group 4|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, MVA ME-TRAP boost W16, MVA ME-TRAP boost W24
3248262|NCT01364883|Experimental|Group 5|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W16
3360443|NCT05145205||RYGB|
3360444|NCT05145192|Experimental|COSMED K5 CPET|Participants in this arm will complete the CPET using the COSMED K5 wearable metabolic system at first visit and the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at second visit.
3360445|NCT05145192|Active Comparator|ParvoMedics CPET|Participants in this arm will complete the CPET using the ParvoMedics TrueOne® 2400 automated metabolic gas analysis system at first visit and the COSMED K5 wearable metabolic system at second visit.
3360446|NCT05145179|Experimental|HER2-expressing Solid Tumors|SSGJ-705 Administered via intravenous (IV) infusion
3360447|NCT05145140|Active Comparator|Standardized Western Medicine Treatment Group|All participants undergo a similar treatment protocol for the diabetic foot, based on the Infectious Diseases Society of America (IDSA).
3360448|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet+TNTL cream Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day. Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
3360449|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL tablet Group|Treatment with TNTL tablets:the oral administration of TNTL tablets, 4 tablets each time, 3 times a day.
3360450|NCT05145140|Experimental|Standardized Western Medicine Treatment +TNTL cream Group|Treatment with TNTL cream: topical application of sterile TNTL cream on the wound surface, the dressing is continuously changed according to the wound healing.
3360452|NCT05145114|Experimental|Supine Group (SG)|
3360453|NCT05145114|Experimental|Prone Group (PG)|
3360454|NCT05145114|Experimental|Lateral Decubitus Group (LDG)|
3360455|NCT05145088|No Intervention|Control Group|The participants in this group are under control and not perfoming any exercise, and their life style is NOT consistent with any kind of submaximal exercise training designed as per protocol.
3248263|NCT01364883|Experimental|Group 6|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W4, AdCh63 ME-TRAP boost W8, MVA ME-TRAP boost W12
3248264|NCT01364883|Experimental|Group 7|AdCh63 ME-TRAP prime D0, MVA ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
3248265|NCT01364909|Placebo Comparator|Control (usual practice)|
3248266|NCT01364909|Experimental|Exercise|
3248267|NCT01364948|Experimental|Coconut oil application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day starting at 12 hrs of life. Four ml of coconut oil was applied using both hands of the caregiver in four strokes. First stroke was from the clavicles over the chest and abdomen till the groin, second from the front of thighs over the knee and leg upto the sole, the third one from the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back, starting from the upper back, continuing over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life).
3360456|NCT05145088|Experimental|Experimental group|"the particpants are made to perform submaximal exercise testing according to ACSM guidelines for 03 weeks.~For Moderate-intensity exercises includes either 30 min a day for five days a week or a total of two hours and 30 min per week using 50% to 70% of maximum heart rate.~The data will be calculated at two times in the form of pre and post testing."
3360457|NCT05145075|Experimental|Survey group|Patients are asked to fill in a survey.
3360460|NCT05145036|Active Comparator|Tai Chi exercise|In addition to standard of care participants will be asked to apply Tai Chi. There are 8 movements. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: Ward-off, Rollback, Push, Press, Grab, Split, Elbow strike, and shoulder strike.
3360461|NCT05145036|Active Comparator|Comprehensive training|In addition to standard of care participants will be asked to apply Comprehensive training. There are 3 exercises. Each session consisted of 10 minutes of warm-up, 40 minutes of Tai Chi, and 10 minutes of cool down. The 8 movements are: stretch exercise, strengthening exercise, and balance exercise.
3360462|NCT05145023||Development of the CARD-SARC (n=20)|"Interviews: 6-20 participants (depending of data saturation) will be recruited using a convenience sampling strategy.~Field-testing: 20 participants using a convenience/consecutive sampling strategy."
3360463|NCT05145023||Validation of the CARD-SARC (n=100)|The CS-specialist centres (Barts Health NHS Trust and Royal Papworth Hospital NHS Foundation Trust) have a cohort of 60-70 potential candidates in each site. The estimated sample size for the Pilot-testing is 100 study participants, considering previous sarcoidosis studies including PROMs, with less than 10% population declining participation or failing to complete their questionnaires.
3360464|NCT05145010|Experimental|Arm 1|Children who have completed under QED-sponsored interventional study with infigratinib
3360465|NCT05145010|Experimental|Arm 2|Children naïve to infigratinib
3360466|NCT05144997|Experimental|Lorlatinib|Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
3360477|NCT05144958||Totally thoracoscopic LAAO - ATRICLIP|In this group, LAA will be sealed using the epicardial thoracoscopic approach with the ATRICLIP device.
3360478|NCT05144958||Percutaneous LAAO - WATCHMAN|In this population, LAA will be occluded using an endocardial totally-percutaneous approach with the WATCHMAN device.
3360479|NCT05144958||Hybrid- minimally invasive LAAO - LARIAT|In these patients, LAA will be closed using a hybrid, combined endo- and epicardial approach using the LARIAT system.
3248268|NCT01364948|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
3248269|NCT01364961|Placebo Comparator|Cellulose capsules|
3360482|NCT05138393|Experimental|Active self-corrective exercises|An active self-correction tailored to the individual type of curve and clinical presentation will be applied with the aim to correct the scoliosis in all three planes. Patients will also be informed and educated in task oriented activities of daily living. Training goals are directed towards postural control, spinal stability, muscular stabilization and endurance in corrective postures. Patients will have outpatient sessions once every two weeks the first 3 months and perform the exercises at home in 30-minutes sessions three times per week. Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily. Compliance will be monitored through a mobile application (Physitrack) where the patients record their sessions and can have contact with the research personnel. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
3360483|NCT05138393|Active Comparator|Observation|Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
3360486|NCT05136430|Experimental|Self-Regulation strategies + large changes (SR)|This arm will receive the Self-Regulation strategies + large changes (SR) intervention followed by smoking cessation treatment
3248270|NCT01364961|Experimental|Resveratrol capsules|
3248271|NCT01364974|Experimental|Group A|low dose, all male
3360487|NCT05136430|Active Comparator|Healthy Lifestyle Education (LE)|This arm will receive the healthy Lifestyle Education (LE) intervention followed by smoking cessation treatment
3360488|NCT05136196|Experimental|Treatment (nivolumab and cabozantinib)|Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cabozantinib PO BID. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
3360491|NCT05132556|Experimental|Nitrate-rich beetroot juice (~12.8 mmol)|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the nitrate-rich beetroot juice (~12.8 mmol).
3248272|NCT01364974|Experimental|Group B|medium dose, all male
3248273|NCT01364974|Experimental|Group C|high dose, all male
3360492|NCT05132556|Placebo Comparator|Beetroot juice with nitrate removed|Participants will have blood pressure, arterial stiffness, and blood samples (from venipuncture) assessed before and after the beetroot juice with nitrate removed.
3360493|NCT05132543|Experimental|Wireless µECoG Prosthesis for Speech|
3360498|NCT05131386|Experimental|Multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas|"Premedication~4 mg oral dexamethasone 24h and 12h before trabectedin administration, 20 mg IV dexamethasone 30 minutes before treatment. Ondansetron or analogue will also be given prior to trabectedin.~Medication~Trabectedin at 1.5 mg/m2 24-h IV CI along with radiation therapy (30 Gy, 3 Gy/day for 10 days for non-extremity location and 45 Gy, 1.8 Gy/day for 25 days for extremity location of target lesion(s)), starting within 1 hour after the first trabectedin infusion withdrawal (day 2)) will be given every 3 weeks up to progression or intolerance."
3360499|NCT05131165|No Intervention|Control|This arm will receive care as usual, including the adherence support mechanisms that are part of usual care practices. At recruitment participant will be explained the importance of pill-taking. All participants (including in the control group) will receive a leaflet containing detailed information on how to establish healthy pill-taking routines. Finally, clinic staff will counsel participants on how to select an already regularly routine behavior that occurs at roughly the same time each day that forms the basis of their implementation plan.
3248274|NCT01364974|Experimental|Group D|medium dose, all female
3248275|NCT01364974|Placebo Comparator|Placebo|
3248276|NCT01364987|Experimental|ASP015K and Mycophenolate Mofetil|
3248277|NCT01365000|Experimental|NKTR118 Formulation 1|Fasted
3248278|NCT01365000|Experimental|NKTR118 Formulation 2|Fasted
3248279|NCT01365000|Experimental|NKTR118 Formulation 3|Fasted
3248280|NCT01365000|Experimental|NKTR118 Formulation 1a|Fed
3248281|NCT01365000|Experimental|NKTR118 Formulation 3a|FED
3248282|NCT01365013|Experimental|Lifestyle counseling|
3248283|NCT01365013|Active Comparator|control group|
3248284|NCT01365026|Experimental|PVS intervention|
3248285|NCT01365026|No Intervention|Control group|
3248286|NCT01365065|Experimental|Vorinostat|Vorinostat 400mg ( 4 X 100mg ) orally daily for 14 days
3248287|NCT01365078|Experimental|Echium oil (SDA-rich oil)|
3248288|NCT01365078|Placebo Comparator|High-oleic acid sunflower oil (HOSO)|low in SDA
3360500|NCT05131165|Experimental|Intervention group receiving messages (Messages Group)|"Participants will receive the same information as those in the Control Group, but in addition, receive the Daily Text Message Intervention."
3360501|NCT05131165|Experimental|Intervention group receiving messages and incentives (Incentives Group)|"Participants will receive the same information as the Control group. Additionally, they will receive the Daily Text Message Intervention and will be eligible for prize drawings."
3360503|NCT05130021|Experimental|Part 1;50mg|
3360504|NCT05130021|Experimental|Part 1;70mg|
3360505|NCT05130021|Experimental|Part 2;MAX-40279-01|
3360506|NCT05130021|Experimental|Part 2;regorafenib|
3360507|NCT05129917|Placebo Comparator|Placebo|consume 1 sachet per day for 14 day
3360508|NCT05129917|Experimental|Gojinsen® drinks|consume 1 sachet per day for 14 day
3360509|NCT05129696|No Intervention|Control (C): Status quo health and nutrition program|
3360510|NCT05129696|Experimental|Treatment (T): adaption of Reach Up and Learn home visiting program to a group setting|
3360511|NCT05129696|Experimental|Treatment + (T+): Enhanced play materials/activities package|
3360512|NCT05129540|Experimental|Custom-made foot orthoses group|Custom-made foot orthoses will be applied to participants in this arm. The orthoses will consist on a 3-mm thick polypropylene layer from heel to just proximal to the metatarsal heads, and a cover layer of polyethylene foam from heel to toe tips. Both materials will be adapted to the foot positive casts that will be obtained from all participants.
3360513|NCT05129540|Placebo Comparator|Placebo group|The placebo orthoses will consist on a 3-mm thick polyethylene foam layer from heel to toe tips and a 0.8-mm thick resin layer from heel to just proximal to the metatarsal heads. None of the materials will be adapted to the foot positive casts.
3360514|NCT05129111|Active Comparator|STIMULATOR OF THE SALIVARY EXCRETION BASED ON PHYSICAL VIBRATION|Measurement of salivary secretion at rest and stimulated conditions.
3360515|NCT05129111|Placebo Comparator|STIMULATOR OF THE SALIVARY EXCRETION PLACEBO|Measurement of salivary secretion at rest and stimulated conditions.
3360516|NCT05128617||Epirubicin-cyclophosphamide|Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide
3248289|NCT01365104|Experimental|Healthy young|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
3248290|NCT01365104|Experimental|healthy old|Each subject comes for 2 visits. There is a randomized, double-blind, crossover design so each subject will receive active drug during one visit and placebo during the other.
3360517|NCT05128617||Paclitaxel|Woman with early breast cancer receiving a first cycle of paclitaxel
3360518|NCT05127122|Placebo Comparator|Placebo Saline|Saline
3360519|NCT05127122|Experimental|10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
3360520|NCT05127122|Experimental|15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles|ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
3360521|NCT05123534|Experimental|Cohort 1|5 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
3360522|NCT05123534|Experimental|Cohort 2|5 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
3360523|NCT05123534|Experimental|Cohort 3|5 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
3360524|NCT05123534|Experimental|Cohort 4|10 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
3360525|NCT05123534|Experimental|Cohort 5|10 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
3360526|NCT05123534|Experimental|Cohort 6|10 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
3360527|NCT05123534|Experimental|Cohort 7|15 mg/kg iv SONALA-001 (ALA) and 200J MR-guided Focused Ultrasound (MRgFUS)
3360528|NCT05123534|Experimental|Cohort 8|15 mg/kg iv SONALA-001 (ALA) and 400J MR-guided Focused Ultrasound (MRgFUS)
3360529|NCT05123534|Experimental|Cohort 9|15 mg/kg iv SONALA-001 (ALA) and 800J MR-guided Focused Ultrasound (MRgFUS)
3360530|NCT05116761|Placebo Comparator|Treatment Arm 1|Normal Saline 100 mL
3360531|NCT05116761|Experimental|Treatment Arm 2|Normal saline 85 mL and ExoFlo 15 mL, which is 10.5 x 10^8 EV
3360534|NCT05114629||Active|Individuals in the active group will meet or exceed the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
3360535|NCT05114629||Inactive|Individuals in the inactive group are those who do not meet the American College of Sports Medicine's Guidelines for Physical Activity in Adults with Chronic Health Conditions and Disabilities. ACMS recommends individuals participate in at least 150 to 300 minutes of moderate-intensity aerobic exercise, 75 to 150 minutes of vigorous-intensity activity.(health.gov/ PAGuidelines)
3360536|NCT05114512|Experimental|RAPTOR Physical Therapy Intervention|RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis
3360537|NCT05113095||Darvadstrocel|Darvadstrocel, 24 mL suspension of 120 million cells as a perilesional injection, once. Participants received interventions as part of routine medical care.
3248291|NCT01365117|Experimental|Cohort 1|
3248292|NCT01365117|Experimental|Cohort 2|
3360538|NCT05111964|Experimental|HIFU Treatment of STS or Intra-abdominal Desmoid Tumour|All participants receive HIFU to their target tumour, hence this is a single arm study with 4 recruitment pathways.
3360539|NCT05110261|Experimental|Nirsevimab|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
3360540|NCT05110261|Placebo Comparator|Placebo|Subjects will be randomized 2:1 to receive a single IM dose of nirsevimab or placebo.
3360541|NCT05110157|Placebo Comparator|Placebo|Placebo once daily.
3360542|NCT05110157|Experimental|Vesicular monoamine transporter 2 (VMAT2) inhibitor|Valbenazine once daily
3360543|NCT05105555||Healthy controls|In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.
3360544|NCT05105555||Vaping teenagers|Vaping teenagers will be recruited independently from the BILD study through advertisements and visits to Bernese schools.
3360547|NCT05104476|Experimental|Lu AF82422|Participants will receive Lu AF82422 intravenous (IV) infusion every 4 weeks (Q4W) from Baseline for a minimum 48 weeks up to a maximum 72 weeks.
3248293|NCT01365143|Active Comparator|Open Radical Prostatectomy|
3248294|NCT01365143|Active Comparator|Robotic radical prostatectomy|
3248295|NCT01365169|Experimental|Arm I (colorectal cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a heart rate monitor, a GPS device, and a smart phone that prompts patients to electronically answer questions about exercise and health-related symptoms and feelings. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
3248296|NCT01365169|Experimental|Arm II (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use two accelerometers, a blood pressure monitor, a weight scale, and a smart phone that prompts patients to electronically answer questions about diet and health-related symptoms. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
3248297|NCT01365169|Experimental|Arm III (head and neck cancer patients)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a smart phone that prompts patients to electronically answer questions about diet, health-related symptoms, and swallowing exercises. Patients also take video recordings of their neck while performing swallowing exercises. The device is used for 5 consecutive days. After a 2 week period, patients resume use of the device for an additional 5 days.
3248298|NCT01365169|Experimental|Arm IV (cancer survivors that are current/former smokers)|(CLOSED TO ACCRUAL AS OF 01/30/14) Patients use a CO monitor and a smart phone that prompts patients to electronically answer questions about smoking. Patients also take video recordings of themselves while exhaling into the CO monitor. The devices are used for 5 consecutive days. After a 2 week period, patients resume use of the devices for an additional 5 days.
3248299|NCT01365169|Experimental|PCS (pancreatic surgery patients)|Patients receive post-surgical wellness program consisting of physical activity, nutrition counseling, and daily monitoring (physical activity, weight, and self-reported data) for up to 7 months post-op.
3360548|NCT05104476|Experimental|Placebo|Participants will receive Lu AF82422 matching placebo IV infusion Q4W from Baseline for a minimum 48 weeks up to a maximum 72 weeks.
3360549|NCT05101070|Experimental|Part A-1: S-531011 Monotherapy|Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
3360550|NCT05101070|Experimental|Part A-2: S-531011 + Pembrolizumab|Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
3360551|NCT05101070|Experimental|Part B: S-531011 Monotherapy|Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
3360552|NCT05101070|Experimental|Part C: S-531011 + Pembrolizumab|Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
3360555|NCT05099757|Experimental|20 µg at month 0, months 0, 1 or 0, 1, and 6|20 µg recombinant hepatitis B vaccine with one, two or three injections at month 0, months 0, 1 or 0, 1, and 6
3360556|NCT05098730|Experimental|Stroke survivors with pets|Stroke survivors with pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
3360557|NCT05098730|Active Comparator|Stroke survivors without pets|Stroke survivors without pets will receive strategy training for 10-15 sessions, 45 minutes each session, delivered by a trained occupational therapist in the home.
3360561|NCT05090904|Experimental|Brensocatib 10 mg|Participants will be administered brensocatib at a dose of 10 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered cystic fibrosis transmembrane conductance regulators (CFTRs) during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
3248300|NCT01365169|Experimental|TAPS (Technological Approach to Performance Status)|Patients use two Physical Activity monitor devices, the wrist-worn device (Fitbit) continuously and the Actigraph during waking hours. Patients use the devices for 7 consecutive days.
3360562|NCT05090904|Experimental|Brensocatib 25 mg|Participants will be administered brensocatib at a dose of 25 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
3360563|NCT05090904|Experimental|Brensocatib 40 mg|Participants will be administered brensocatib at a dose of 40 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
3360564|NCT05090904|Experimental|Brensocatib 65 mg|Following review of safety and pharmacokinetic data by the safety review committee, an additional cohort of participants may be administered brensocatib at a dose of 65 mg once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
3360565|NCT05090904|Placebo Comparator|Placebo|Participants will be administered a placebo matching brensocatib once per day for 28 days. Half of the participants in the arm will have previously received and will continue to be administered CFTRs during the study. The other half of participants in the arm will have not previously received and will not be administered CFTRs during the study.
3360570|NCT05079620|Experimental|Antibiotics|"5 days of empiric antibiotics selected from a guideline-appropriate regimen. Alternate agents may be selected by the treating team if allergies or other patient factors mandate, but are still recommended for a 5 day course. Supportive care including oxygen and ventilation can be offered ad libitum.~Options include ceftriaxone, Augmentin, cefepime, vancomycin, levofloxacin."
3360571|NCT05079620|No Intervention|Control|No initial antibiotic therapy unless clinical picture changes or worsens. Supportive care including oxygen and ventilation can be offered ad libitum.
3360576|NCT05072808|Active Comparator|Intervention Group|ED Providers randomized to the Intervention Group will be able to view the results of the parent-completed questionnaire, the Pediatric Asthma Control and Communication Instrument for the Emergency Department (PACCI-ED), and outpatient referral recommendations aligned with asthma severity.
3360577|NCT05072808|No Intervention|Control Group|ED providers randomized to the Control Group will neither receive the results of the parent-completed PACCI-ED or specific recommendations for outpatient referrals. Patients randomized to the control group will receive usual care.
3248301|NCT01365182|Other|BF+SUPPORT|
3248302|NCT01365182|Other|BF+PHONE|
3248303|NCT01365182|No Intervention|Usual Care|
3248304|NCT01365195|Placebo Comparator|Control|"Loading and Infusion:~Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate"
3248305|NCT01365195|Active Comparator|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
3248306|NCT01365195|Active Comparator|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
3248307|NCT01365208||advanced nasopharyngeal carcinoma|
3248308|NCT01365221|Experimental|Patients who have received loading dose of clopidogrel|
3248309|NCT01365221|Active Comparator|Patients who have not received loading dose of clopidogrel|
3248310|NCT01365234|Experimental|20066 Lead|Non-randomized study. Intervention: Device: Pacing Lead
3248311|NCT01365247|Experimental|COPE|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure
3248312|NCT01365247|Active Comparator|RPT|Relapse Prevention Therapy
3248313|NCT01365247|Active Comparator|Active Monitoring Control Group|
3248314|NCT01365260|Experimental|MM-II|
3248315|NCT01365260|Active Comparator|DurolaneTM|hyaluronic acid
3248316|NCT01365286|Active Comparator|Ivabradine-Placebo|
3248317|NCT01365286|Active Comparator|Placebo-Ivabradine|
3248318|NCT01365312|Experimental|Ethanol|Assigned intervention is a 70% ethanol lock, placed every 72 hours for 15 minutes, for the duration of the PICC line.
3248319|NCT01365312|Placebo Comparator|Heparinized saline|Intervention is to place a heparinized saline lock every 72 hours for 15 minutes, for the duration of the line.
3248320|NCT01365325|Experimental|handled echocardiography|home monitoring care program based on clinical and electrocardiographic evaluations and periodical handled echocardiographic examinations
3248321|NCT01365325|Active Comparator|home monitoring program|home monitoring care program based on clinical and electrocardiographic evaluations
3248322|NCT01365338|Placebo Comparator|Placebo|Participants will receive placebo as a single oral dose.
3248323|NCT01365338|Experimental|Cohort 1|Participants will receive 0.075 milligrams (mg) of PF-04958242 as a single oral dose.
3248324|NCT01365338|Experimental|Cohort 2|Participants will receive 0.15 mg of PF-04958242 as a single oral dose.
3248325|NCT01365351||Growth hormone|Children with growth hormone deficiency
3248326|NCT01365364|Active Comparator|PLM group|Individuals with increased periodic leg movement index (>5)
3248327|NCT01365364|Active Comparator|Non-PLM group|Individuals with PLM index <5
3248328|NCT01365377|Experimental|Booklet|Referent member of the family is designated to receive a written detailed information on Critical care.
3248329|NCT01365377|No Intervention|No booklet|daily information to the family is given as usual.
3248330|NCT01365390||Cohort A|Subjects aged < 6 years who are registered in primary care clinics of any of the participating countries (Estonia, Lithuania, Poland, Romania and Slovenia).
3248331|NCT01365403|Experimental|Single Arm|
3360594|NCT05059600|Experimental|ZULRESSO®|Participants will administer ZULRESSO® in a home setting as a single, continuous, intravenous (IV) infusion for 60-hours (hrs) starting on Day 1.
3360595|NCT05053451|Experimental|dlPFC/TPJ Stimulation + Rest|20 minutes of 2 mA direct current stimulation during rest.
3248332|NCT01365429|Experimental|EVLP Group|EVLP Group are those recipient lung transplant patients that received donor lungs that had been placed on the XPS™ with Steen Solution™ and undergone ex-vivo lung perfusion before being transplanted.
3248333|NCT01365429|No Intervention|Control Group|Control Group are those recipient lung transplant patients that receive donor lungs via conventional transplant.
3248334|NCT01365442||Consenting, eligible participants|All consenting eligible participants in the study area will receive the oral cholera vaccine
3248335|NCT01365520|Experimental|N8|
3248336|NCT01365533|Active Comparator|Roflumilast|
3248337|NCT01365533|Placebo Comparator|Placebo|
3248338|NCT01365559|Experimental|Group A: Carfilzomib & Non-IMiD containing regimen|Bortezomib is replaced with carfilzomib in a combined regimen identical to the patient's previous regimen. Regimen cannot include thalidomide or lenalidomide.
3248339|NCT01365559|Experimental|Group B: Carfilzomib & IMiD containing regimen.|Bortezomib is replaced with carfilzomib in a regimen that includes IMiDs (lenalidomide or thalidomide). Thus, the regimen is carfilzomib in an IMiD-containing regimen.
3248340|NCT01365572|Active Comparator|Xience V, drug-eluting stent|randomized implantation for DES restenotic lesion
3248341|NCT01365572|Active Comparator|Endeavor Resolute, drug-eluting stent|randomized implantation for DES restenotic lesion
3248342|NCT01365598|Placebo Comparator|Placebo|Non-active drug
3248343|NCT01365598|Experimental|Low dose primaquine (PQ1)|Lowest experimental dose of primaquine base: 0.1mg/kg
3248344|NCT01365598|Experimental|Intermediate dose primaquine (PQ2)|Intermediate experimental dose of primaquine base: 0.4mg/kg
3360612|NCT05051033|Active Comparator|Surgical mitral valve repair|Patients who are randomized to the surgical arm will undergo mitral surgery.
3360613|NCT05051033|Active Comparator|Transcatheter edge-to-edge repair|In the transcatheter edge-to-edge repair arm, patients will be treated with a commercially-approved edge-to-edge mitral repair device.
3360617|NCT05047185|Other|Low dose|BID low dose of PHA-022121
3360618|NCT05047185|Other|High dose|BID high dose of PHA-022121
3360619|NCT05047185|Other|Placebo|BID placebo
3248345|NCT01365598|Active Comparator|Reference dose primaquine (PQ-R)|WHO-recommended dose of primaquine base: 0.75mg/kg
3360625|NCT05043805|Active Comparator|Dextromethorphan|add on therapy
3360626|NCT05043805|Placebo Comparator|placebo|add on therapy
3360629|NCT05035615||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria, are leftover from routine flow cytometry testing, and are from subjects having or suspected of having a hematological or non-hematological disorder.
3360632|NCT05032339||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for plasma cell disorders
3360633|NCT05032313||Remnant/ Leftover specimens|Specimens that meet inclusion/exclusions criteria and are leftover from routine flow cytometry testing for hematological disorders.
3248346|NCT01365637|Experimental|Cohort 1 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3248347|NCT01365637|Experimental|Cohort 2 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3248348|NCT01365637|Experimental|Cohort 3 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3360646|NCT05027802|Experimental|Palovarotene Chronic/Flare-Up Regimen|"Chronic treatment: participants will receive 5 mg palovarotene or the dose received during participation in the parent study at the time of transition to Study CLIN-60120-452 or prior to interrupting/stopping palovarotene treatment.~Flare-up treatment: at the time of a flare-up (or substantial high-risk traumatic event likely to lead to a flare-up) participants will receive 20 mg palovarotene for 28 days, followed by 10 mg palovarotene for 56 days."
3360651|NCT05026320|Experimental|Naproxen Topical Gel (BAYH006689)|UI Number: 1614000-268; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
3360652|NCT05026320|Active Comparator|Diclofenac Diethylamine Gel|UI Number: Not applicable; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
3360653|NCT05026320|Placebo Comparator|Placebo Gel|UI Number: 1614000-272; Subjects will be randomized into one of the three treatment groups in a 2:2:1 (active:active:placebo) allocation. Treatment consists of a twice daily (bid) application (approximately 12 hours apart) of the assigned topical gel over 5 consecutive days, beginning on the evening of Day 1 and ending (last application) on the morning of Day 6 (total of 10 applications). In order to assure adequate representation of different types of soft tissue injuries, at least 25 randomized subjects must enter the study with a lower extremity sprain/strain injury (cohort) and at least 50 randomized subjects with a lower extremity contusion injury (cohort).
3360654|NCT05026177|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks
3360655|NCT05026177|Experimental|Simufilam 50 mg|Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
3360656|NCT05026177|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks
3360659|NCT05026008|Experimental|SR1375 Capsule|Ascending single and multiple doses of SR1375 capsules orally
3360660|NCT05026008|Experimental|Matching placebo|Ascending single and multiple doses of placebo capsules orally
3360661|NCT05025267|Other|Enteral Tube-fed Adults|Adults being fed an enteral formula with a feeding tube
3360662|NCT05024058|Experimental|Ligelizumab low dose, symptomatic dermographism group|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
3360663|NCT05024058|Experimental|Ligelizumab high dose, symptomatic dermographism|Ligelizumab high dose subcutaneous injection every 4 weeks in participants with symptomatic dermographism
3360664|NCT05024058|Placebo Comparator|Placebo SC q4W, symptomatic dermographism|Placebo subcutaneous injection every 4 weeks in participants with symptomatic dermographism
3360665|NCT05024058|Experimental|Ligelizumab low dose, cold urticaria|Ligelizumab low dose subcutaneous injection every 4 weeks in participants with cold urticaria
3360666|NCT05024058|Experimental|Ligelizumab high dose, cold urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cold urticaria
3360667|NCT05024058|Placebo Comparator|Placebo SC q4w, cold urticaria|Placebo subcutaneous injection every 4 weeks in participants with cold urticaria
3360668|NCT05024058|Experimental|Ligelizumab high dose, cholinergic urticaria|Ligelizumab high dose subcutaneous injections every 4 weeks in participants with cholinergic urticaria
3360669|NCT05024058|Placebo Comparator|Placebo SC q4w, cholinergic urticaria|Placebo subcutaneous injections every 4 weeks in participants with cholinergic urticaria
3360672|NCT05022758||Participants treated with rivaroxaban|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on rivaroxaban (defined as the index date) during the enrollment period from January 2015 to December 2017.
3360673|NCT05022758||Participants treated with warfarin|NVAF patients who were OAC-naïve (Have no record of Oral anticoagulation [OAC] therapy use in the January 2013 to December 2014) and newly initiated on warfarin (defined as the index date) during the enrollment period from January 2015 to December 2017.
3360674|NCT05022693|Experimental|BIO89-100 30 mg, Open Lable, Single Dose|
3360675|NCT05021991|Experimental|PRAX-944 (120 mg)|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
3360676|NCT05021991|Experimental|PRAX-944 (60 mg)|Once daily, oral dosing with titration to 60 mg: 3 days of 20 mg, 4 days of 40 mg, 49 days of 60 mg
3360677|NCT05021991|Experimental|PRAX-944 (20 mg)|Once daily, oral dosing: 56 days of 20 mg
3360678|NCT05021991|Placebo Comparator|Placebo|Once daily, oral dosing: 56 days of placebo
3360679|NCT05021978|Experimental|Part A: Open-label 20 and 40 mg PRAX-944|Once daily, oral dosing with 7 days of 20 mg and 7 days of 40 mg
3360680|NCT05021978|Experimental|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded PRAX-944|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 28 days of 120 mg
3360681|NCT05021978|Active Comparator|Part B: Open-label titration PRAX-944 (120 mg) followed by blinded placebo|Once daily, oral dosing with titration to 120 mg: 3 days of 20 mg, 4 days of 40 mg, 7 days of 60 mg, 7 days of 80 mg, 7 days of 100 mg, 14 days of 120 mg, 14 days placebo
3248349|NCT01365637|Experimental|Cohort 4 PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo either twice or thrice daily to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
3248350|NCT01365663|Experimental|Cohort 1|0.25 mg/kg in Healthy Subjects
3360692|NCT05019430|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3360693|NCT05019430|Experimental|Zolmitriptan Dose 1|Subjects will be maintained on oral zolmitriptan dose 1. Cocaine will be administered acutely during zolmitriptan dose 1 maintenance. Placebo will be administered acutely during zolmitriptan dose 1 maintenance.
3360694|NCT05019430|Experimental|Zolmitriptan Dose 2|Subjects will be maintained on oral zolmitriptan dose 2. Cocaine will be administered acutely during zolmitriptan dose 2 maintenance. Placebo will be administered acutely during zolmitriptan dose 2 maintenance.
3360695|NCT05019430|Experimental|Zolmitriptan Dose 3|Subjects will be maintained on oral zolmitriptan dose 3. Cocaine will be administered acutely during zolmitriptan dose 3 maintenance. Placebo will be administered acutely during zolmitriptan dose 3 maintenance.
3360696|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc1 + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc1 [dose level 1 {DL1}] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab intravenously (IV) on Day 1 of Cycles 2 and 4 to 18, with or without background standard of care (SOC) chemotherapy as appropriate for the indication. A cycle is 42 days.
3360697|NCT05017012|Experimental|MK-3475A (Pembrolizumab Conc2 + MK-5180)|Participants receive MK-3475A (pembrolizumab Conc2 [DL1] + MK-5180) SC on Day 1 of Cycles 1 and 3 plus 400 mg pembrolizumab IV on Day 1 of Cycles 2 and 4 to 18, with or without background SOC chemotherapy as appropriate for the indication. A cycle is 42 days.
3248351|NCT01365663|Experimental|Cohort 2|0.5 mg/kg in Healthy Subjects
3248352|NCT01365663|Experimental|Cohort 3|1.0 mg/kg in Healthy Subjects
3248353|NCT01365663|Experimental|Cohort 4|1.5 mg/kg in Healthy Subjects
3248354|NCT01365663|Experimental|Cohort 5|2.0 mg/kg in Healthy Subjects
3248355|NCT01365663|Placebo Comparator|Saline 0.9%|
3248356|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
3248357|NCT01365676|Active Comparator|GAMALINE® 25-44 years old|Fertile women 24-44 years old with PMS symptoms
3248358|NCT01365676|Experimental|GAMALINE® + HIPERICIN® 45-55 years old|Climacteric women with PMS symptoms
3248359|NCT01365676|Active Comparator|GAMALINE® 45-55 years old|Climacteric women with PMS symptoms
3248360|NCT01365702||Tiotropium in TB destroyed lung|
3248361|NCT01365715|Experimental|Preoperative embolization|32 patients with spinal metastasis/metastases will undergo arteriography and receive transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
3248362|NCT01365715|Active Comparator|Control group|32 patients with spinal metastasis/metastases will undergo arteriography of spinal metastasis/metastases without receiving transcatheter arterial embolization prior to surgery.
3248363|NCT01365741|No Intervention|Standard administration of Efient|The test person will ingest Efient in supine position, and remain supine during 2 hours, mimicing the way Efient is used for pre-PCI treatment today
3248364|NCT01365741|Active Comparator|Upright administration of Efient|The test person will ingest Efient in an upright position, and remain supine during 2 hours.
3248365|NCT01365754|Active Comparator|A|A - Fusion
3248366|NCT01365754|Active Comparator|B|B - Dynamic (new)
3248367|NCT01365767||Crohn Disease|Patients with Crohns Disease referred to referred to a Magnetic Resonance Imaging Scan.
3248368|NCT01365780|Active Comparator|With HBOT|Patients, who receive hyperbaric Oxygen Therapy after their surgical treatment
3248369|NCT01365780|No Intervention|Without HBOT|"Patients who receive the same surgical treatment of their radius fracture than the patients of the group with HBOT, but no hyperbaric oxygen therapy (comparison group)"
3248370|NCT01365832|Experimental|Sleep apnea|"Participants with Obstructive Sleep Apnea (OSA).This arm will undergo a pre-treatment blood draw, six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and a post-treatment blood draw 3 and 6 months later.~Intervention: Procedure: Continuous Positive Airway Pressure (CPAP)"
3248371|NCT01365858|Experimental|Virtual reality-based cognitive training|
3248372|NCT01365858|Active Comparator|Cognitive rehabilitation (without extra computer training)|
3248373|NCT01365871|Active Comparator|basal injection|basal injection of anesthetics
3248374|NCT01365871|Active Comparator|basal + apical injection|basal + apical injection of anesthetics
3248375|NCT01365897|Placebo Comparator|Placebo|Control Group
3248376|NCT01365897|Experimental|Modafinil 200mg|Modafinil 200mg taken orally.
3248377|NCT01365923|Active Comparator|Remifentanil group|Remifentanil group : remifentanil effect site-TCI 2-4ng/ml
3248378|NCT01365923|Active Comparator|Dexmedetimidine group|Dexmedetomidine group: remifentanil effect site-TCI 2-4ng/ml + dexmedetomidine 0.5mcg/kg
3248379|NCT01365936|Active Comparator|menotrophin|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
3248380|NCT01365936|Active Comparator|recombinant FSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
3360706|NCT05000645|No Intervention|Women, Infants, and Children (WIC)|Usual WIC counseling and food benefits for use in person at approved grocery stores.
3360707|NCT05000645|Experimental|WIC + grocery delivery|Usual WIC counseling and food benefits, as well as twice-monthly home deliveries of WIC-approved foods.
3360708|NCT05000645|Experimental|WIC + grocery delivery + unsweetened beverage delivery|Usual WIC counseling and food benefits as well as twice-monthly home deliveries of WIC-approved foods PLUS unsweetened beverages to replace their current sugar-sweetened beverages (SSB) intake.
3360709|NCT04996628|Experimental|Pancreatic Quantitative Sensory Testing (P-QST)|Definite Chronic Pancreatitis patients undergoing decompressive invasive treatments (endoscopic therapy or surgery) to relieve main pancreatic duct obstruction due to stones and/or stricture for management of pain will undergo P-QST prior to clinically-indicated invasive treatment.
3360710|NCT04995523|Experimental|Dose Escalation Part A: Checkpoint inhibitor (CPI) experienced NSCLC|AZD2936 Intravenous (IV) monotherapy
3360711|NCT04995523|Experimental|Dose Expansion Part B: CPI experienced NSCLC|AZD2936 IV monotherapy
3248381|NCT01365975||Community Intervention Program Population: The Chinese Childre|Community sample of mothers, fathers and offspring from 2 provinces in China who participated in a community public health study in 1994-1996.
3360712|NCT04995523|Experimental|Dose Expansion Part C: CPI Naive NSCLC|AZD2936 IV monotherapy
3360713|NCT04995523|Experimental|Dose Expansion Part D: To be confirmed through a protocol amendment|AZD2936 IV monotherapy
3360714|NCT04994483|Placebo Comparator|Placebo|Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
3248382|NCT01366001|Experimental|ALKS 33-BUP|
3248383|NCT01366001|Experimental|ALKS 33|
3248384|NCT01366001|Placebo Comparator|Placebo|
3248385|NCT01366014|Experimental|ARRY-371797|
3248386|NCT01366014|Active Comparator|Oxycodone HCl ER|
3360715|NCT04994483|Experimental|Simufilam 100 mg|Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
3360716|NCT04991480|Experimental|Part A1|Part A1 will evaluate ART4215 monotherapy administered in 21 day cycles. Up to 36 participants will participate in this dose escalation arm.
3360717|NCT04991480|Experimental|Part A2|Part A2 will evaluate ART4215 given in combination with talazoparib in 21 day cycles. Up to 30 participants will participate in this dose escalation arm.
3360718|NCT04991480|Experimental|Part B1|In Part B1 dose expansion, up to 30 participants with solid cancers that have been treated with a PARP inhibitor for an approved indication will receive ART4215.
3248387|NCT01366014|Placebo Comparator|Placebo|
3360719|NCT04991480|Experimental|Part B2|In Part B2 dose expansion, up to 20 participants with solid cancers with characteristics indicative of sensitivity to pol theta inhibition will receive ART4215.
3360720|NCT04991480|Experimental|Part B3|In Part B3, approximately 90 participants with HER2 negative BRCA breast cancers will be randomized 1:1 to either ART4215 in combination with talazoparib or talazoparib alone.
3248388|NCT01366053||Prostate Cancer|Males who have been diagnosed with Prostate Cancer and are experiencing PSA rise, while taking androgen agonist therapy.
3248389|NCT01366066|Active Comparator|TMNS treatment - Stress incontinence|Women with stress incontinence treated with active TMNS (vibration)
3248390|NCT01366066|No Intervention|No treatment - stress incontinence|Women with stress incontinence NOT treated with TMNS (vibration)
3248391|NCT01366066|Active Comparator|TMNS treatment - Urge incontinence|Women with stress incontinence treated with TMNS (vibration)
3248392|NCT01366066|No Intervention|No treatment - urge incontinence|Women with urge incontinence NOT treated with TMNS (vibration)
3248393|NCT01366079|Experimental|Position change|Position change group
3248394|NCT01366079|Active Comparator|Left lateral|Left lateral position
3248395|NCT01366105|No Intervention|Dry Dressing|Incisions that were dressed with a sterile dry dressing at end of operation.
3248396|NCT01366105|Experimental|Negative Pressure Wound Therapy|Incisions dressed with a V.A.C. (NPWT) postoperatively.
3248397|NCT01366118|Experimental|TT tailored Ch plus IMRT|
3248398|NCT01366131|Experimental|A|
3248399|NCT01366131|Experimental|B|
3248400|NCT01366183||Observational (quality of life questionnaire)|"Patients receive chemotherapy comprising carboplatin, paclitaxel, and filgrastim (regimen 1) or carboplatin alone (regimen 2) every 21 days for 4 courses according to their physicians and/or patients' choice. Patients may undergo surgery and/or further chemotherapy at the discretion of treating physician. Patients undergo blood sample collection at baseline and periodically during course 1 for pharmacokinetic studies.~Patients' quality of life is assessed by the FACT-O, the FACT-Ntx subscale, the IADL, and the Ability to Complete Social Activity questionnaires at baseline, prior to courses 1 and 3, and then 3-6 weeks after completion of course 4. Nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment are also assessed."
3248401|NCT01366222|Placebo Comparator|Placebo|
3248402|NCT01366222|Active Comparator|Food concentrates (FC)|Food concentrates (FC) was including fruit and vegetable, fish and probiotics.
3360730|NCT04987307|Experimental|Efavaleukin alfa|
3360731|NCT04987307|Placebo Comparator|Placebo|
3360732|NCT04987294|Experimental|ALLN-346 (Engineered Urate Oxidase)|ALLN-346 is novel urate oxidase provided as capsules for oral administration. ALLN-346 will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
3248403|NCT01366235|Experimental|Southeast Asians|
3248404|NCT01366235|Experimental|Korean|
3248405|NCT01366235|Experimental|Caucasians|
3248406|NCT01366235|Experimental|Africans|
3248407|NCT01366248||IO Clinic Breast Cancer Patients|Includes patients who are receiving care for their breast cancer at participating Seattle area IO clinics.
3248408|NCT01366248||CSS Match-Control Patients|For each IO clinic patient, an average of two (up to four) matched comparison cases will be recruited from the Washington State Cancer Surveillance System (CSS). Matched comparison cases from CSS will be identified by CSS and confirmed by the FHCRC investigator.
3248409|NCT01366261|Experimental|semirigid thoracoscopy|Semirigid instrument which we compare was autoclavable Olympus LTF-160 (Olympus Tokyo, Japan). Handle and its controls were similar to flexible fiberoptic bronchoscope, with the insertion portion composed of 22 cm long rigid part and distal 5 cm flexible tip with angulation range 1600 up / 1300 down. The external diameter of insertion portion was 7 mm with 2,8 mm inner channel diameter. The instrument was compatible with Olympus EVIS Exera 160 and 145 and EVIS 100 and 140 video processors and light sources, otherwise employed in video-bronchoscopy. Forceps, which we used was flexible FB-55CD-1 Olympus forceps with 5 mm long cusps and diameter, which fitted the diameter of inner channel of semirigid thoracoscope.
3248410|NCT01366261|Active Comparator|rigid thoracoscopy|The rigid instrument was autoclavable OP EndoEYE WA50120A (Olympus Tokyo, Japan) video thoracoscope. The length of the instrument was 29 cm with 00 direction of view and 700 field of view. The external diameter of the instrument was 10 mm with 5,2 mm inner channel diameter. The instrument was compatible with Olympus Visera OTV-S7V and EVIS Exera II CV-180 video processors. Cusps of rigid forceps had outer diameter 5 mm and length 10 mm.
3360733|NCT04987294|Placebo Comparator|Placebo|Matching placebo capsules for oral administration. Placebo capsules will be administered as 5 capsules thrice daily (15 capsules per day total) to each of two subject cohorts based on estimated glomerular filtration rate (eGFR). Treatment Period is 14 Days.
3248411|NCT01366274|Active Comparator|Usual method of MHI|
3248412|NCT01366274|Experimental|Protective MHI|
3248413|NCT01366287|Experimental|Suspension/fasted|
3248414|NCT01366287|Experimental|Tablet/fasted|
3248415|NCT01366287|Experimental|Tablet/fed|
3248416|NCT01366300|Active Comparator|Intravenous lidocaine infusion|Intravenous lidocaine infusion during total intravenous anesthesia with propofol administered by target controlled infusion
3248417|NCT01366300|Placebo Comparator|Intravenous 0.9% saline infusion|Intravenous 0.9% saline infusion during total intravenous anesthesia with propofol administered by target controlled infusion
3248418|NCT01366313|Experimental|Paracetamol|initial doses was 1.5g g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
3360750|NCT04968834||GENOMIC PROFILING AND SPECIMEN BANKING REGISTRATION ARM|The research study procedures include screening for eligibility, reviewing and signing this consent form, collecting patient information and clinical data, obtaining previously collected bone marrow and blood samples, and completing a brief optional Household Survey. Bone marrow and blood samples may also be collected in the future as part of your routine clinical procedures
3360754|NCT04961541|Experimental|Group A - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
3360755|NCT04961541|Experimental|Group B -ICC Vaccine Formulation|2 doses of Formulation 2. 1 dose each on Days 0 and Day 56.
3360756|NCT04961541|Experimental|Group C - ICC Vaccine Formulation|2 doses of Formulation 1. 1 dose each on Days 0 and Day 56.
3360757|NCT04961541|Experimental|Group D - ICC Vaccine Formulation|2 doses of Formulation 3. 1 dose each on Days 0 and Day 56.
3360758|NCT04961541|Experimental|Group E - ICC Vaccine Formulation|2 doses of Formulation 4. 1 dose each on Days 0 and Day 56.
3360759|NCT04961541|Experimental|Group F- ICC Vaccine Formulation|2 doses of Formulation 5. 1 dose each on Days 0 and Day 56.
3360760|NCT04961541|Experimental|Group G- ICC Vaccine Formulation|2 doses of Formulation 6. 1 dose each on Days 0 and Day 56.
3360761|NCT04961541|Experimental|Group H- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
3360762|NCT04961541|Experimental|Group I- ICC Vaccine Formulation|2 doses of Formulation 8. 1 dose each on Days 0 and Day 56.
3360763|NCT04961541|Experimental|Group J -ICC Vaccine Formulation|2 doses of Formulation 9. 1 dose each on Days 0 and Day 56.
3360764|NCT04961541|Experimental|Group K - ICC Vaccine Formulation|2 doses of Formulation 10. 1 dose each on Days 0 and Day 56.
3248419|NCT01366313|Experimental|Morphine|Initial doses of morphine was 5mg, with dose adjustment intervals of 1 mg .
3360765|NCT04961541|Experimental|Group L - ICC Vaccine Formulation|2 doses of Formulation 11. 1 dose each on Days 0 and Day 56.
3360766|NCT04961541|Experimental|Group M -ICC Vaccine Formulation|2 doses of Formulation 12. 1 dose each on Days 0 and Day 56.
3360767|NCT04961541|Experimental|Group N- ICC Vaccine Formulation|2 doses of Formulation 7. 1 dose each on Days 0 and Day 56.
3360768|NCT04961541|Experimental|Group O - qNIV with Matrix-M1 adjuvant|2 doses of Formulation 13. 1 dose each on Days 0 and Day 56 and an additional dose of 5 µg SARS-CoV-2 rS+50 µg Matrix-M1 at Day 70.
3360769|NCT04961541|Experimental|Group P- SARS-CoV-2 rS with Matrix-M1 adjuvant|2 doses of Formulation 14. 1 dose each on Days 0 and Day 56.
3360770|NCT04961164|Experimental|Resistant Potato Starch|15g RPS mixed with water will be consumed twice per day during intervention
3360771|NCT04961164|Placebo Comparator|Corn Starch|15 g corn starch mixed with water will be consumed twice per day during intervention
3360775|NCT04957537|Other|6 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 6 weeks (i.e. 18 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
3360776|NCT04957537|Other|8 weeks phase A|"According to SCED methodology design :~Phase A, which constitutes the control period of semantic therapy, will be composed of lexico-phonological training exercises (Piroux-Davous, 2018). This phase will last 8 weeks (i.e. 24 sessions), at the rate of 3 speech therapy sessions of 45 minutes per week."
3360777|NCT04957082|Active Comparator|White Flint Registry: General|"White participants receive general consumption video information about SARS-CoV-2 antibody testing."
3360778|NCT04957082|Active Comparator|African American Registry: General|"African American participants receive general consumption video information about SARS-CoV-2 antibody testing."
3360779|NCT04957082|Experimental|African American Registry: Culturally Targeted|African American participants receive culturally targeted video information about SARS-CoV-2 antibody testing.
3360782|NCT04956302|Experimental|Treatment (panobinostat, daratumumab, bortezomib, dexa)|Patients receive panobinostat PO QD on days 1, 3, 5, 15, 17, 19, daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of subsequent cycles, bortezomib SC on days 1, 8, 15, 22 and dexamethasone PO (IV on days of daratumumab and hyaluronidase-fihj administration) QD on days 1, 8, 15, 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3360784|NCT04948333|Experimental|ABL001|Participants will be treated with 80 mg of ABL001 (40 mg BID or 80mg QD). In patients not achieving MMR at 48 weeks or losing the response after the week 48 assessment up to week 108, asciminib dose may be escalated to 200 mg q.d. if in the investigator's opinion the patient may benefit from the escalation.
3360785|NCT04946253|Active Comparator|DOCC with standard implementation (No TEAM or LEAD)|Practices in this arm will receive DOCC materials/training and technical support, but will not receive care team coaching/consultation (TEAM) or practice leadership facilitation (LEAD) after the training phase.
3360786|NCT04946253|Experimental|DOCC with TEAM implementation|Practices in this arm will receive DOCC training and materials and one type of implementation support after the training: coaching/consultation for the provider care team (TEAM).
3248420|NCT01366313|Experimental|Paracetamol-morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
3248421|NCT01366326|Experimental|Arm 1|Methylnaltrexone bromide
3248422|NCT01366339|Experimental|Arm 1|Oral methylnaltrexone
3248423|NCT01366339|Experimental|Arm 2|Oral methylnaltrexone
3248424|NCT01366339|Experimental|Arm 3|Oral methylnaltrexone
3248425|NCT01366339|Placebo Comparator|Arm 4|Oral placebo
3248426|NCT01366352|Experimental|Arm 1|MNTX tablet
3248427|NCT01366352|Experimental|Arm 2|MNTX tablet
3248428|NCT01366365|Experimental|Arm 1|IV methylnaltrexone (MNTX)
3248429|NCT01366365|Placebo Comparator|Arm 2|placebo
3248430|NCT01366378|Experimental|Arm 1|methylnaltrexone (MNTX)
3248431|NCT01366391|Other|Metformin|study parallel with one arm only.
3248432|NCT01366404||FFR|Patients who had FFR measurement
3248433|NCT01366430|Active Comparator|Gefoni manenuver|Gefoni manenuver for Geotropic HC-BPPV
3248434|NCT01366430|Active Comparator|sham maneuver|sham maneuver for geotropic HC-BPPV
3248435|NCT01366430|Active Comparator|barbecue maneuver|barbecue maneuver for geotropic HC-BPPV
3248436|NCT01366456|Active Comparator|Shingigu|Treat with Shingigu
3248437|NCT01366456|Active Comparator|Charcoal|Treat with Charcoal
3248438|NCT01366482|Experimental|Drug-eluting balloon|Subjects are randomized to have a lesion treated with a paclitaxel-coated balloon Intervention: Cotavance Drug-Eluting Balloon
3248439|NCT01366482|Experimental|Plaque excision + drug-eluting balloon|Subjects are randomized to have a lesion treated with plaque excision (PE) followed by treatment with a paclitaxel-coated balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
3360787|NCT04946253|Experimental|DOCC with LEAD implementation|Practices in this arm will receive DOCC training and materials and only one type of implementation support after the training: facilitation for practice leadership (LEAD).
3360788|NCT04946253|Experimental|DOCC with TEAM + LEAD implementation|Practices in this arm will receive DOCC training and materials and both types of implementation support after the training: coaching/consultation for the provider care team (TEAM) and facilitation for practice leadership (LEAD).
3360791|NCT04944654|Experimental|Assigned intervention|Biktarvy OD for 96 weeks
3248440|NCT01366482|Experimental|Severely Ca++ Group|Subjects with a severely calcified lesion will be assigned to a non-randomized arm and treated with plaque excision followed by a drug-eluting balloon Intervention: SilverHawk/TurboHawk + Cotavance Drug-Eluting Balloon
3248441|NCT01366508|Other|Visit B|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
3248442|NCT01366508|Other|Visit A|At approximately 13:00 the subject will be given a standard high calorie lunch that the subject is required to finish
3259408|NCT01470560|Active Comparator|MBSR Group Treatment|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
3360792|NCT04942964|Experimental|ASP0367: Mild Hepatic Impairment|Participants with mild hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
3360793|NCT04942964|Experimental|ASP0367: Moderate Hepatic Impairment|Participants with moderate hepatic impairment will receive a single dose of ASP0367 under fasting conditions on day 1.
3360794|NCT04942964|Experimental|ASP0367: Normal Hepatic Function|Participants with normal hepatic function will receive a single dose of ASP0367 under fasting conditions on day 1.
3360803|NCT04938245||Observed Cohort|Participants with chronic pain scheduled to undergo externalized trial for assessment of spinal cord stimulation will undergo intraoperative stimulation and up to three postoperative visits where already externalized electrodes (used clinically for stimulation) will be used to record and stimulate using evoked complex action potentials (ECAPs) while also measuring other electrophysiological responses.
3360804|NCT04936230|Experimental|Arm A (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
3360805|NCT04936230|Experimental|Arm B (atezolizumab, SBRT)|Patients receive atezolizumab as in Arm A. Patients also undergo SBRT for 3 fractions over 2 weeks in the absence of disease progression or unacceptable toxicity.
3360809|NCT04930094|Experimental|Secukinumab 300 mg|AIN457
3360810|NCT04930094|Placebo Comparator|Placebo|Placebo
3360815|NCT04926272|Experimental|18F-92, PET/CT|PET/CT perform after injecting 18F-92
3248443|NCT01366547|Experimental|Single Arm|Subjects will be randomized in a three-way crossover design to receive a single dose of each of two different tablet formulations of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg or dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg). There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3248444|NCT01366560|Experimental|GSK962040|The subjects will be administered GSK962040 125 mg tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
3248445|NCT01366560|Placebo Comparator|Placebo|The subjects will be administered placebo tablet as a single dose on Day 1 of study treatment visit. After 2 hours, the subjects will be administered wireless motility capsule. The subjects will be observed for expulsion of WMC in stool. Each subject will attend the clinical unit for two study treatment visits which will be separated by at least one week.
3248446|NCT01366573|Experimental|GSK1521498 &amp; alcohol|GSK1521498 20 mg and alcohol (0.5g/kg ethanol mixed with orange juice)
3360825|NCT04915118||Patients with HFrEF|Patients with HFrEF (Heart failure with reduced ejection fraction) who had a previous decompensation event.
3360826|NCT04911153||Aim 1: Physical Activity|250 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of physical activity on cardiometabolic health among veterans with and without PTSD.
3248447|NCT01366573|Experimental|GSK1521498 & orange juice|GSK1521498 20 mg and orange juice approximately matching alcoholic beverage for volume and colour
3248448|NCT01366573|Experimental|Placebo &amp; alcohol|Placebo and alcohol (0.5g/kg ethanol mixed with orange juice)
3360827|NCT04911153||Aim 2: Diet Quality|200 participants will be identified from the Translational Research Center for TBI and Stress Disorders (TRACTS) data repository to examine the longitudinal impact of diet quality on cardiometabolic health among veterans with and without PTSD.
3360828|NCT04911153||Supplemental Aim: Instrument Validation|100 participants will be recruited to examine the validity of a self-report clinical measure of physical activity against objectively measured physical activity obtained via accelerometry.
3360834|NCT04907032|Experimental|Posterior Tibial Nerve Stimulation with Mirabegron|One arm of the study will receive PTNS combined with mirabegron. In the PTNS with mirabegron arm, the patient will take a 50 mg dose daily for 12 weeks of the trial. This arm of the study will have 27 patients randomized to this arm of the study. The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
3360835|NCT04907032|Placebo Comparator|Posterior Tibial Nerve Stimulation Plus Placebo|The other arm of the study will receive PTNS with placebo. In the PTNS with placebo arm, the patient will receive a placebo daily during the 12-week trial. PTNS will be performed as described: The percutaneous approach entails insertion of a 36-gauge needle electrode at a 60 degree angle approximately 5 cm or 3 finger breadths cephalad to the medial malleolus and posterior to the tibia. A portable electrical stimulator delivers an adjustable current in the range of 0.5-9 mA. The generators commonly are set for a pulse frequency of 20 Hz with a goal of creating a motor and/or sensory response in the foot. The stimulation sessions last for 30 min once per week for 12 continuous weeks.
3248449|NCT01366573|Placebo Comparator|Placebo &amp; orange juice|Placebo and orange juice approximately matching alcoholic beverage for volume and colour
3248450|NCT01366599||Patients enrolled in IHCIS in 2006|Patients enrolled in IHCIS in 2006
3248451|NCT01366612|Active Comparator|Group 1|FLUDARABINE AND BUSULFAN
3360840|NCT04901377||Combined oral contraception: Estradiol valerate / Dienogest|Young women (18-35 years of age) using estradiol valerate / dienogest in real clinical practice.
3248452|NCT01366612|Experimental|Group 2|FLUDARABINE, BUSULFAN AND LOW DOSE TOTAL BODY IRRADIATION
3248453|NCT01366625|Experimental|Renal Denervation|Renal Denervation and maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
3248454|NCT01366625|No Intervention|Maintenance of Medications|Maintenance of anti-hypertensive medications and continuous positive airway pressure therapy
3248455|NCT01366651|Experimental|Doripenem|Doripenem Type=exact number unit=mg/kg number=10 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.,Doripenem Type=exact number unit=mg/kg number=30 form=solution for injection route=intravenous use every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age. Doripenem 500-mg sterile powder will be supplied for the study in single use glass vials.
3248456|NCT01366664|Experimental|001|Treatment sequence 1 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days)
3248457|NCT01366664|Experimental|002|Treatment sequence 2 Treatment Period 1 (stable dose of terazosin [2 to 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2 to 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
3360865|NCT04882696|No Intervention|usual care with bare feet|patients will be treated barefoot during their stay
3360866|NCT04882696|Experimental|specific care with anti-slip socks|Patients in this group will wear non-slip socks
3360867|NCT04882085|Experimental|CAZ-AVI|ceftazidime 2g plus avibactam 0.5g
3360868|NCT04882085|Active Comparator|Best Available Treatment|Based on investigative site practice and local epidemiology and guideline
3360871|NCT04873934|Experimental|Inclisiran with Usual Care|Inclisiran sodium 300 mg / 1.5 ml (equivalent to 284 mg of inclisiran)
3360872|NCT04873934|No Intervention|Usual Care|Usual Care Alone
3248458|NCT01366677|Experimental|Yoga Therapy|
3248459|NCT01366690|Experimental|Peer Support|Peer supporter assigned to participant.
3248460|NCT01366690|No Intervention|Standard of Care|No peer assigned. Current standard of care.
3248461|NCT01366703||heart failure patients|stable heart failure patients, NYHA 1-2, EF > 35%, no AF, No OAC, CHADS score >2
3248462|NCT01366716|Experimental|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
3360877|NCT04855786|Experimental|Thoracic Duct Drainage|This is the main study group of patients with thoracic duct drainage
3360878|NCT04852978|Experimental|Wave 1 Dose 1|
3360879|NCT04852978|Experimental|Wave 1 Dose 2|
3360880|NCT04852978|Experimental|Wave 1 Dose 3|
3360881|NCT04852978|Experimental|Wave 1 Vaccine only|
3360882|NCT04852978|Experimental|Wave 2 Dose 1|
3360883|NCT04852978|Experimental|Wave 2 Dose 2|
3360884|NCT04852978|Experimental|Wave 2 Vaccine only|
3360885|NCT04852978|Experimental|Wave 3 Dose 1|
3248463|NCT01366716|Experimental|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
3248464|NCT01366716|No Intervention|Non-CM Control|Participants in the non-CM control condition will provide urine specimens during the 12-week period as do the two experimental conditions, but will receive no contingent rewards other than praise from the RAs.
3360886|NCT04852978|Experimental|Wave 3 Dose 2|
3360887|NCT04852978|Experimental|Wave 3 Vaccine only|
3360888|NCT04852978|Experimental|Wave 4 Dose 1|
3360889|NCT04852978|Experimental|Wave 4 Vaccine only|
3248465|NCT01366729|Experimental|TheraTogs|
3248466|NCT01366729|Active Comparator|Cane walking|
3360896|NCT04844970|Experimental|Anamorelin|Patients randomized to anamorelin HCL will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
3360897|NCT04844970|Placebo Comparator|Placebo|Patients randomized to placebo will take it daily for 24 weeks starting 3-5 days prior to chemotherapy
3248467|NCT01366742||HPV Cohort|Sexually active young women aged 12 to 22 years of age without a previous history of CIN. Women are not eligible for entry if pregnant or known immunosuppression.
3360903|NCT04836455|Experimental|The Real Cost vaping prevention ads - Health effects theme|
3360904|NCT04836455|Experimental|The Real Cost vaping prevention ads - Addiction theme|
3360905|NCT04836455|Other|Neutral vaping ads|
3248468|NCT01366768|Experimental|Oral amino acid mixture|Oral administration of amino acid mixture in healthy volunteers
3360906|NCT04834362|Experimental|Analog insulin arm|Patients treated with insulin analog regimen will receive 50% of total daily dose as basal insulin glargine at the same time of day and 50% as insulin aspart given in 3 equally divided doses at 6 am, 12 pm and 6 pm.
3360907|NCT04834362|Active Comparator|Human insulin arm|Patients treated with human insulin regimen will receive 50% of total daily dose as NPH insulin at around 6 am and 6 pm, while the rest 50% regular human insulin three times a day in 3 equally divided doses at around 6 am, 12 pm and 6 pm
3248469|NCT01366768|Experimental|Intravenous amino acid administration|Intravenous infusion of amino acid mixture in healthy volunteers
3248470|NCT01366781|Experimental|Healthy males|Meal ingestion in healthy males
3248471|NCT01366781|Experimental|Healthy females|Meal ingestion in healthy females
3248472|NCT01366794|Experimental|Type 2 diabetes|Administration of macronutrients in type 2 diabetes
3248473|NCT01366794|Experimental|Healthy volunteers|Administration of macronutrients in healthy volunteers
3248474|NCT01366820|Experimental|NNZ-2566|20 mg/kg intravenous bolus infusion of NNZ-2566 over 10 minutes followed by a continuous intravenous infusion of 6 mg/kg/h (n=133) intravenous infusion of NNZ-2566 for a total of 72 consecutive hours.
3248475|NCT01366820|Placebo Comparator|Sodium Chloride (0.9%) for Injection|Intravenous bolus infusion of Sodium Chloride (0.9%) for Injection over 10 minutes followed by a continuous intravenous infusion of Sodium Chloride (0.9%) for Injection for a total of 72 consecutive hours.
3248476|NCT01366833|Active Comparator|Self-expanding stent alone|All patients in Arm A will receive self-expanding stent alone
3248477|NCT01366833|Experimental|Brachytherapy and Stent therapy|
3248478|NCT01366859|Experimental|Whey Protein (Immunocal®)|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
3248479|NCT01366859|Placebo Comparator|Placebo: Rice Protein|The control or placebo study arm will consist of thirty children who will receive a dose of 0.5 g/kg of weight a day up to 18 kg of weight a day or a dose of 10 g/day for those over 18 kg for three months.
3248480|NCT01366898|Experimental|Chemotherapy|
3360918|NCT04829630|Other|subjects who received three vs. four ID PEP at least two, five or 10 years earlier|"30 subjects who received three ID PEP at least two years earlier in Cambodia~30 subjects who received three ID PEP at least five years earlier in Cambodia~30 subjects who received three ID PEP at least 10 years earlier in Cambodia~30 subjects who received four ID PEP at least two years earlier in Madagascar~30 subjects who received four ID PEP at least five years earlier in Madagascar~30 subjects who received four ID PEP at least 10 years earlier in Madagascar"
3360921|NCT04829136|Experimental|Arm I (enteral nutrition)|Patients receive enteral nutrition via nasoenteric feeding tube starting on day 1 until hospital discharge.
3360922|NCT04829136|Active Comparator|Arm II (standard of care)|Patients receive standard of care nutritional support.
3360923|NCT04826354|Experimental|Rosuvastatin|Rosuvastatin 20mg
3360924|NCT04826354|Active Comparator|Rosuvamibe|Rosuvastatin plus ezetimibe 10/5
3248481|NCT01366911||stem cell QCT testing|
3248482|NCT01366924|No Intervention|Muscle protein turnover and intracellular signaling at rest|Muscle protein turnover and intracellular signaling are measured at rest for comparison to post-exercise muscle metabolism.
3360926|NCT04820530|Experimental|LNP023|Participants will receive LNP023 at a dose of 200 mg orally b.i.d
3360929|NCT04817618|Experimental|iptacopan 200mg b.i.d.|
3360930|NCT04817618|Placebo Comparator|Placebo to iptacopan 200mg b.i.d.|
3360933|NCT04816214|Experimental|Combination of capmatinib + osimertinib (run-in part)|For run-in part: Up to 2 dose levels of capmatinib in combination with osimertinib may be investigated. The starting dose of combination is capmatinib 400 mg orally twice daily (b.i.d) and osimertinib 80 mg orally once per day (q.d). If a dose de-escalation is required, a lower dose level is defined as capmatinib 400 mg orally twice a day (b.i.d) and osimertinib 40 mg orally once per day (q.d.)
3248483|NCT01366924|Active Comparator|Muscle metabolism after endurance exercise|Post-exercise muscle protein metabolism was measured to determine if endurance exercise affects muscle metabolism compared to rest.
3248484|NCT01366924|Experimental|Muscle Metabolism after endurance exercise|Muscle metabolism response to endurance exercise with essential amino acid supplementation
3248485|NCT01366924|Experimental|Muscle anabolism after endurance exercise|Muscle anabolism after endurance exercise with essential amino acid supplementation.
3248486|NCT01366950|Experimental|Excercise group|
3360934|NCT04816214|Experimental|Combination of capmatinib + osimertinib (randomized part)|For randomized part: capmatinib in combination with osimertinib administered at the recommended Phase III regimen (defined in the safety run-in part).
3360935|NCT04816214|Active Comparator|platinum + pemetrexed based doublet chemotherapy|For randomized part: following local guidelines as per standard of care and products labels
3360936|NCT04815551|Experimental|AV-380 IV 4 mg/kg|IV infusion of AV-380 at dose level 4 mg/kg
3360937|NCT04815551|Experimental|AV-380 IV 8 mg/kg|IV infusion of AV-380 at dose level 8 mg/kg
3360938|NCT04815551|Experimental|AV-380 IV 13 mg/kg|IV infusion of AV-380 at dose level 13 mg/kg
3360939|NCT04815551|Experimental|AV-380 IV 20 mg/kg|IV infusion of AV-380 at dose level 20 mg/kg
3360940|NCT04815551|Experimental|AV-380 SC 4 mg/kg|Subcutaneous injection of AV-380 at dose level 4 mg/kg
3360941|NCT04815551|Experimental|AV-380 SC 2 mg/kg|Subcutaneous injection of AV-380 at dose level 2 mg/kg
3248487|NCT01366950|No Intervention|Reference|
3248488|NCT01366963||Normal Controls / Healthy Volunteers|Age and gender matched individuals without postural orthostatic tachycardia syndrome
3248489|NCT01366963||Patients with Postural Tachycardia Syndrome (POTS)|Individuals with Postural Tachycardia Syndrome
3360942|NCT04815551|Experimental|AV-380 SC 1 mg/kg|Subcutaneous injection of AV-380 at dose level 1 mg/kg
3360943|NCT04815551|Placebo Comparator|Placebo|
3248490|NCT01366989||Total Ankle Arthroplasty with calcaneal stem|Patients received the TAA with calcaneal stem between 12/6/05 & 11/13/07 at approximately 28 sites.
3248491|NCT01367015|Experimental|Early Feeding|Early feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours after randomization followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
3248492|NCT01367015|Active Comparator|Late feeding|Late feeding group was kept NPO for a period of 48 hours after randomization followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
3360946|NCT04814264|Experimental|Sex-matched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is matched to their sex (donor and recipient sex are the same). Patients in this arm will receive RBCs matched to their sex until discharge from hospital or death.
3360947|NCT04814264|Experimental|Sex-mismatched red blood cell transfusion|All patients will receive red blood cells (RBCs) that are ABO and Rh compatible as per routine blood bank practices. In addition to routine compatibility, subjects in this arm will receive blood that is not matched to their sex (donor and recipient sex are not the same). Patients in this arm will receive RBCs mismatched to their sex until discharge from hospital or death.
3360948|NCT04811027|Experimental|(CPS ≥1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
3360949|NCT04811027|Active Comparator|(CPS ≥1): Pembro|Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks).
3360950|NCT04811027|Experimental|(CPS <1): Pembro + Efti|"Eftilagimod alpha: 30 mg every 2 weeks for the first 4 cycles;thereafter every 3 weeks for up to 18 cycles(1 cycle = 6 weeks).~Pembrolizumab: 400 mg every 6 weeks for up to 18 cycles (1 cycle = 6 weeks)."
3360951|NCT04810611|Experimental|Arm 1: MBG453 single agent|Treatment with MBG453 single agent Q4W to confirm safety and tolerability of RD.
3360952|NCT04810611|Experimental|Arm 2: NIS793 single agent|Treatment with NIS793 single agent Q3W to establish RD in this indication and confirm safety and tolerability.
3360953|NCT04810611|Experimental|Arm 3: canakinumab single agent|Treatment with single agent canakinumab Q4W to confirm safety and tolerability of RD.
3360954|NCT04810611|Experimental|Arm 4: MBG453 + NIS793 combination|Treatment with combination of MBG453 and NIS793 Q3W to confirm safety and tolerability of combination RD.
3360955|NCT04810611|Experimental|Arm 5: MBG453 + canakinumab combination|Treatment with MBG453 + canakinumab combination Q4W to confirm safety and tolerability of combination RD.
3360957|NCT04806451|Experimental|Crinecerfont|Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.
3248493|NCT01367028|Other|A: Trastuzumab+Docetaxel|
3248494|NCT01367028|Experimental|B: Trastuzumab+Docetaxel+Bevacizumab|
3248495|NCT01367028|Experimental|C: Trastuzumab+Docetaxel+NPLD|
3248496|NCT01367028|Experimental|D: Trastuzumab+Docetaxel+NPLD+Bevacizumab|
3360958|NCT04806451|Placebo Comparator|Placebo|Solution or capsule, administered orally, twice daily for 28 weeks, followed by active treatment for 24 weeks.
3360959|NCT04802356|Experimental|Multiple Myeloma experimental arm|Combination of belantamab mafodotin + the combination treatment VRd (bortezomib, lenalidomide, dexamethasone)
3248497|NCT01367041|Experimental|Bone loss|Postmenopausal women with osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
3360960|NCT04800237|Experimental|VQW-765|
3360961|NCT04800237|Placebo Comparator|Placebo|
3248498|NCT01367041|Experimental|Normal|Postmenopausal women without osteoporosis, whole body vibration will be applied at 40 Hz, 2mm amplitude, 30+30s
3360965|NCT04795908|Experimental|Active rTMS Group|Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
3248499|NCT01367054|Experimental|Metformin|500 mg
3248500|NCT01367067||Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and have filled out a psychometric questionnaire
3259409|NCT01470573|Experimental|Progenitor Autologous Cells|Progenitor Autologous Cells of Sclerocorneal Limbus Amplified ex Vivo
3360970|NCT04789213||Patients with Living Donor Liver Transplantation|
3360971|NCT04789213||Patients with Deceased Donor Liver Transplantation|
3248501|NCT01367067||No Psychometric Questionnaire|Adult inpatients and outpatients with a clinical indication of any part of the body who have been referred to Charité for MR imaging and did not fill out a psychometric questionnaire
3248502|NCT01367093||ICU patients admitted for severe illness|
3248503|NCT01367106|Experimental|exposed offspring|
3360975|NCT04785261|Active Comparator|conventional treatment|Patients in this group will be given conventional treatment including Artelac® Eye Drops (1-2 drips each time, every 4 hours) and Vidisic® Gel (1 drip each time, at bedtime) for 12 weeks.
3360976|NCT04785261|Experimental|conventional treatment + TCM|Patients in this group will be given conventional treatment and traditional Chinese medicine (6.0g twice daily) for 12 weeks.
3360978|NCT04777084|Experimental|IBI318|IBI318, 300mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 20mg, orally
3360979|NCT04777006|Experimental|Cluster 1 (First Cluster of Clinics Randomized to Receive Care)|Arm 1 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 3 of the trial
3360980|NCT04777006|Experimental|Cluster 2 (Second Cluster of Clinics Randomized to Receive Care)|Arm 2 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 6 of the trial
3360981|NCT04777006|Experimental|Cluster 3 (Third Cluster of Clinics Randomized to Receive Care)|Arm 3 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 9 of the trial
3360982|NCT04777006|Experimental|Cluster 4 (Fourth Cluster of Clinics Randomized to Receive Care)|Arm 4 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 12 of the trial
3360983|NCT04777006|Experimental|Cluster 5 (Fifth Cluster of Clinics Randomized to Receive Care)|Arm 5 represents a cluster of 2-3 clinics randomized to begin delivering the intervention at month 15 of the trial
3360985|NCT04774003|Experimental|300 mg inclisiran sodium (equivalent to 284 mg inclisiran)|300 mg inclisiran sodium (equivalent to 284 mg inclisiran) x 1 dose (n=15) at Day 1
3360986|NCT04774003|Experimental|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)|100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran) x 1 dose (n=15) at Day 1
3360987|NCT04774003|Placebo Comparator|Placebo|Placebo x 1 dose (n=10) at Day 1
3360988|NCT04772755|No Intervention|Usual Care|Participants will receive usual care that follows administration of a vaccine and will have a 20 minute post vaccination observation period.
3360989|NCT04772755|Experimental|Buzzy ® and Electronic Game|Buzzy® will be applied to arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants will be instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then play that game for a specified amount of time before, during and after the vaccination administration.
3248504|NCT01367106|Other|controls|
3248505|NCT01367145|Active Comparator|Omacor|
3248506|NCT01367145|Placebo Comparator|Placebo|
3360991|NCT04764799||Patients that need emergency rapid sequence inductions|"Patients of all ages who need emergency rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~We defined emergency as a non scheduled intervention with immediate (or maximum up to 6 hours after announcement) need of general anaesthesia (e.g. trauma patients with need for emergency surgery) and therefore appropriate fastening is not possible."
3360992|NCT04764799||Patients that need scheduled rapid sequence inductions|"Patients of all ages who need scheduled rapid sequence inductions due to their medical condition performed by the staff of the Department of Anaesthesiology and Pain Medicine at the Bern University Hospital.~Patients of this cohort have a scheduled intervention and therefore can fasten meals for at least 6 hours before induction of general anaesthesia."
3360993|NCT04764656||Brolucizumab|Naïve (Patients being the first time treated) and pre-treated patients
3248507|NCT01367197|No Intervention|No intervention|Observation only
3248508|NCT01367197|Experimental|Exercise training group|Group exercise training, three times weekly high-intensity
3248509|NCT01367210|Experimental|MARAVIROC, DARUNAVIR/r|"Treatment simplification from a standard combined antiretroviral therapy including 3 drugs to Maraviroc plus Darunavir with Ritonavir. Treatment simplification from three-drugs- to two-drugs-based antiretroviral therapy"
3248510|NCT01367210|Sham Comparator|current ART with 3 drugs|Patients on HAART with three drugs and HIV RNA below 50 copies/mL
3361002|NCT04758247|Active Comparator|Active|
3361003|NCT04758247|Sham Comparator|Sham|
3361005|NCT04744207|Experimental|GS-248|GS-248, capsule, 120 mg, once daily for 4 weeks
3361006|NCT04744207|Placebo Comparator|Placebo|placebo, capsule, once daily for 4 weeks
3361007|NCT04743791|Active Comparator|Dupilumab|Two injections of Dupilumab will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of Dupilumab will be given every 2 weeks ± 3 days at home by the patient. The doses of investigational product must be separated by ≥11 days to avoid an overdose.
3361008|NCT04743791|Placebo Comparator|Placebo|Two injections of placebo will be administered at Week 0/Visit 3 as a loading dose. Subsequently one injection of placebo will be given every 2 weeks ± 3 days at home by the patient. The doses must be separated by ≥11 day.
3361009|NCT04743570|Placebo Comparator|Placebo treatment|Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
3361010|NCT04743570|Active Comparator|Methylnaltrexone treatment|0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump.
3248511|NCT01367223|Experimental|solution of amino acids with glutamine|Group 1 as the experimental group who will be administered a solution of amino acids supplemented with glutamine
3248512|NCT01367223|Other|amino acids solution without glutamine|Group 2:control group will be administered a solution of amino acids (Aminoven Infant® or Vamin®) not supplemented with glutamine
3248513|NCT01367288|Experimental|A (Neoadjuvant therapy + Zometa)|Patients will be treated every 3 weeks (+/- 2 days ) for 8 cycles in total. The 4 first cycles : Zometa 4 mg (in a 15 min. infusion) + doxorubicin (60 mg/m²) + cyclophosphamide (600 mg/m²). The 4 last cycles with Zometa 4 mg (in a 15 min. infusion) + docetaxel (100 mg/m²)
3248514|NCT01367288|Active Comparator|B (Neoadjuvant therapy)|Patients will be treated every 3 weeks (+/- 2 days) for 8 cycles in total. The 4 first cycles : doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²). The 4 last cycles with docetaxel (100 mg/m²)
3248515|NCT01367301|Experimental|Treatment (paclitaxel, carboplatin, radiotherapy)|"CHEMOTHERAPY (weeks 1-9, 14-22): Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 3 courses during weeks 1-9 and 14-22.~RADIATION THERAPY (weeks 8-16): Patients undergo external beam pelvic radiation therapy once a day, 5 days a week for 5 weeks during weeks 8-13. Patients then undergo HDR brachytherapy or IMRT once weekly during weeks 14-16."
3248516|NCT01367314|Experimental|NVC-422 Dermal Gel, 1.5%|
3248517|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.5%|
3248518|NCT01367314|Experimental|NVC-422 Dermal Gel, 0.1%|
3248519|NCT01367327|Experimental|Exercise with music|Loaded sit-to-stand exercise with music for 6 weeks
3248520|NCT01367327|Active Comparator|Exercise without music|Loaded sit-to-stand exercise without music for 6 weeks
3248521|NCT01367340|Experimental|Exercise and physical activity|
3248522|NCT01367340|Active Comparator|Exercise only|
3248523|NCT01367353|Experimental|ovarian cancer|
3248524|NCT01367366||Mediastinal malignant lymphadenopathy|
3248525|NCT01367379||Physician of internal medicine in Taipei city hospital|
3248526|NCT01367392|Experimental|interventional procedure|The patients undergo the required interventional procedure, biopsy or ablation
3248527|NCT01367405|Experimental|surgical decompression|surgical decompression within 24 hours post-injury
3361022|NCT04739293|Experimental|ON 123300|ON 123300 capsules at increasing doses per cohort, starting at 40 mg
3248528|NCT01367405|Active Comparator|Conservative treatment|Normal conservative treatment without surgical intervention
3248529|NCT01367418|Experimental|Thoracic Epidural Analgesia (TEA)|TEA is used for perioperative pain management, having been used both intra- and postoperatively, up to 48 h.
3248530|NCT01367418|Active Comparator|Patient controlled analgesia (PCA)|PCA is the standard of pain management and is usually used for up to 48 h postoperative for pain management following radical prostatectomy.
3248531|NCT01367431||20 mg|Single dose 20 mg Xanthohumol
3248532|NCT01367431||60 mg|Single dose 60 mg Xanthohumol
3248533|NCT01367431||180 mg|Single dose 180 mg Xanthohumol
3248534|NCT01367470|Active Comparator|VSL#3 probiotic preparation|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) 1 sachet per day of probiotics (VSL#3) during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet before meal).
3361028|NCT04735718|Experimental|Cerviron vaginal ovules|Since Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device.
3361029|NCT04734275|Experimental|Treatment A (Test Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A), in fasted condition.
3248535|NCT01367470|Placebo Comparator|Placebo VSL#3|30 mothers in the last 4 weeks of gestation and in the first month of breastfeeding will be given (after obtaining their informed consent) a placebo comparable to VSL#3 during the last four weeks of pregnancy and the first month of breastfeeding for four weeks under the usual fasting dosage scheme (1 sachet/day, before meal)
3248536|NCT01367483|Experimental|Arm1|MNTX active treatment
3248537|NCT01367496|Experimental|Arm 1|
3248538|NCT01367496|Experimental|Arm 2|
3248539|NCT01367496|Experimental|Arm 3|
3248540|NCT01367496|Experimental|Arm 4|
3248541|NCT01367509|Experimental|Arm 1|SC Methylnaltrexone (MNTX)
3248542|NCT01367522|Experimental|Arm 1|
3248543|NCT01367535|Experimental|Arm 1|
3248544|NCT01367535|Experimental|Arm 2|
3248545|NCT01367535|Active Comparator|Arm 3|
3361030|NCT04734275|Experimental|Treatment B (Test Formulation): AZD5718 Dose A, fed|Subjects will receive single dose of AZD5718 (Dose A) in fed condition
3361031|NCT04734275|Active Comparator|Treatment C (Reference Formulation): AZD5718 Dose A, fasted|Subjects will receive single dose of AZD5718 (Dose A) in fasted condition
3248546|NCT01367535|Placebo Comparator|Arm 4|
3361038|NCT04729387|Experimental|Alpelisib+olaparib|Alpelisib 200 mg orally once daily and olaparib 200 mg orally twice daily on a continuous dosing schedule.
3361039|NCT04729387|Active Comparator|Paclitaxel or PLD|Investigator's choice of one of 2 single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician discretion) intravenously every 28 days.
3248547|NCT01367548|Experimental|Arm 1|
3248548|NCT01367548|Placebo Comparator|Arm 2|
3248549|NCT01367561|Experimental|Arm 1|
3361042|NCT04717414|Experimental|Experimental Arm: Luspatercept (ACE-536)|Luspatercept will be given to participants via subcutaneous injection (administered on Day 1 of each 21-day treatment cycle)
3361043|NCT04717414|Placebo Comparator|Control Arm: Placebo|Placebo starting dose with volume equivalent to experimental arm subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
3361046|NCT04714437|Active Comparator|F-R/L-A1/A3/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5)
3361047|NCT04714437|Active Comparator|F-R/L-A1/A5/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3)
3361048|NCT04714437|Active Comparator|F-R/L-A3/A1/A5 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5)
3361049|NCT04714437|Active Comparator|F-R/L-A3/A5/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A3-A5-A1-A1-A5-A3-A3-A5-A1-A1-A5-A3-A3-A5-A1)
3361050|NCT04714437|Active Comparator|F-R/L-A5/A1/A3 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A1-A3-A3-A1-A5-A5-A1-A3-A3-A1-A5-A5-A1-A3)
3361051|NCT04714437|Active Comparator|F-R/L-A5/A3/A1 Sequence|First, 5 freestyle masticatory assays (F). Second, 5 only-right (R) and 5 only-left (L) masticatory assays in the following order (R-L-L-R-R-L-L-R-R-L) Third, 15 masticatory assays changing the side once (A1), three times (A3) or 5 times (A5) in the following order (A5-A3-A1-A1-A3-A5-A5-A3-A1-A1-A3-A5-A5-A3-A1)
3361052|NCT04714151|Experimental|Treatment A|K-877 ER 0.2 mg/day (once daily)
3361053|NCT04714151|Experimental|Treatment B|K-877 ER 0.4 mg/day (once daily)
3248550|NCT01367561|Experimental|Arm 2|
3361054|NCT04714151|Active Comparator|Control A|K-877 IR 0.2 mg/day (twice daily)
3248551|NCT01367561|Placebo Comparator|Arm 3|
3248552|NCT01367574|Experimental|Arm 1|
3248553|NCT01367574|Experimental|Arm 2|
3248554|NCT01367574|Experimental|Arm 3|
3248555|NCT01367587|Experimental|Arm 1|
3248556|NCT01367600|Experimental|Arm 1|
3248557|NCT01367613|Experimental|Arm 1|
3248558|NCT01367626|Active Comparator|letrozole|2.5 mg tablet
3248559|NCT01367626|Active Comparator|Fermara|2.5 mg tablet
3248560|NCT01367639|Experimental|intervention|Inquiry Based Stress Reduction (IBSR) program
3248561|NCT01367652|Active Comparator|Letrozole|2.5 mg tablet
3248562|NCT01367652|Active Comparator|Femara|2.5 mg tablet
3248563|NCT01367678|Experimental|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
3248564|NCT01367678|Experimental|i-Gel|Directly measured mucosal pressures
3248565|NCT01367717|Active Comparator|Creatine Monohydrate|Each of the 25 subjects took Creatine Monohydrate.
3248566|NCT01367717|Active Comparator|Creatine Ethyl Ester|Each of the 25 subjects took Creatine Ethyl Ester.
3248567|NCT01367730||osteoporosis and osteopenia|Subjects will be stratified based on DXA BMD T-scores.
3248568|NCT01367743|Active Comparator|epinephrine|
3248569|NCT01367743|Active Comparator|norepinephrine|
3248570|NCT01367756|Experimental|1|
3248571|NCT01367756|Placebo Comparator|2|
3259410|NCT01470586|Other|Surgery for colorectal cancer|Colorectal cancer patients
3259411|NCT01470586|No Intervention|Controls|Controls
3248572|NCT01367769||Thrombosis|"Patients with acute, idiopathic or provoked, unilateral proximal DVT (involving the popliteal vein or further proximal veins) and SVT of the lower-extremity detected with duplex ultrasound.~Age and sex matched controls (volunteers)"
3248573|NCT01367782|Active Comparator|Active repetitive Transcranial Stimulation|Each patient will be given 12 stimulation sessions, over a period of 4 weeks, and then a maintenance phase consisting of 8 stimulation sessions for the first 4 weeks and additional 4 stimulation sessions during the following 4 weeks.
3361055|NCT04709783|Experimental|Implementation Arm|Participants will receive the 3-Step Workout for Life program and other rehabilitation services based on the plan of care.
3361056|NCT04708613||Former Professional Football Players|Former professional football players who played in at least 3 professional seasons, with at least 3 games each season.
3361057|NCT04708613||Control Groups|Friends and brothers of the Former Professional Football Player group.
3361058|NCT04707625|Other|Aflibercept|All subjects will receive aflibercept every 4 weeks. Once vascular endothelial growth factor levels become normal and macular edema improves treatment windows will be extended up to every 12 weeks.
3248574|NCT01367782|Sham Comparator|Sham Stimulation|The control arm group will receive sham stimulations in identical treatment and maintenance schedules.
3248575|NCT01367795||palliative tumor disease|Patients in a known palliative setting with symptoms due to tumor growth.
3248576|NCT01367808|Placebo Comparator|Placebo|
3361059|NCT04706221|Experimental|Blood Volume Monitoring|
3361061|NCT04703504|Experimental|multi-intervention|"Automatic creation of discharge prescription (personalized checklist of possible therapeutic optimizations generated from clinical data entered into the platform. This checklist will comply with the recommendations on altered left ventricular ejection fraction from European Society of Cardiology 2016.~Automatic creation of documents for patient:~Reminder letter to make an appointment with his general practitioner (at 7 days) and cardiologist (1 month) and to report the prescribed blood test.~Drug prescription.~Prescription for blood tests (5 days and 25 days before seeing the general practitioner and cardiologist).~Therapeutic education documents~Patients will receive numerous messages (SMS / e-mail) in order to 1 / not forget their medical appointments, 2 / not to forget to make and bring back their blood test for the consultation, 3 / to perfect the therapeutic education advice provided previously"
3361062|NCT04703504|No Intervention|Control|Discharge prescription according to the investigator's habits.
3248577|NCT01367808|Active Comparator|Vorikonazole|
3248578|NCT01367808|Active Comparator|Posakonazole|
3248579|NCT01367821||Patients with obstructive jaundice|Patients with obstructive jaundice
3248580|NCT01367821||Healthy volunteers|Healthy volunteers
3361063|NCT04702217|Experimental|POTS patients|All POTS patients in the study will perform a 16 week-training program. The present study will be using longitudinal comparisons, meaning that the 100 POTS patients are their own controls. The questionnaires and exercise capacity will be compared before and after the 16-weeks training program.
3361064|NCT04694950||Group feasibility|Adults undergoing elective urologic laparoscopic robotic surgery.
3248581|NCT01367873|Placebo Comparator|Placebo|
3248582|NCT01367873|Experimental|VIA-3196|Multiple, single-dose, ascending dosing groups (cohorts) will be evaluated.
3361071|NCT04688398|Experimental|Seal oil|Daily intake of 15 ml of seal oil containing 534 mg of EPA + 1129 mg of DHA + 530 mg of DPA during 12 weeks
3361072|NCT04688398|Active Comparator|Control|Daily intake of vegetable oil during 12 weeks
3361073|NCT04687072|Experimental|Efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
3361074|NCT04687072|Placebo Comparator|Placebo PH20 SC|Patients receiving placebo PH20 SC treatment
3361075|NCT04685408|Experimental|TargEted MAnageMent Intervention (TEAM)|This arm will receive the experimental intervention, TargEted MAnageMent Intervention (TEAM)
3361076|NCT04685408|Active Comparator|Enhanced treatment as usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
3248583|NCT01367873|Experimental|VIA-3196 with Food|Second, single dose administered after a standard high-fat breakfast.
3248584|NCT01367873|Placebo Comparator|Placebo with Food|
3248585|NCT01367899||CONSERVE® Plus hip resurfacing|Recipients/C Plus (IDE)study
3248586|NCT01367912|No Intervention|Progesterone only group|received a single daily application of vaginal progesterone gel beginning from the day of OPU and continued at least until pregnancy was ruled out by a negative serum ß-hCG measurement performed on the 14th day after embryo transfer with no E2 added
3248587|NCT01367912|Active Comparator|Progesterone+Early Estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
3259412|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
3259413|NCT01470664|Experimental|FST-100|
3248588|NCT01367912|Active Comparator|Progesterone+Late estradiol group|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel
3361079|NCT04683588|Experimental|intervention arm|"Polyclinic: Pre-tests (pain, anxiety, self-care and daily living activities), General coaching, 60 minutes~Before Surgery: Nursing coaching, 30-45 minutes~Surgery Day: Nursing coaching, 30-45 minutes~Postoperative 1st Day: Nursing coaching, 30-45 minutes~Postoperative 2nd Day: Nursing coaching practice, 30-45 minutes~Day of discharge: Nursing coaching, 30-45 minutes.~15 days after discharge: Nursing coaching, 60 minutes~45 days after the operation: Nursing coaching, 60 minutes.~90 days after surgery: Nursing coaching, 60 minutes."
3361080|NCT04683588|No Intervention|Control arm|Patients in the control group will receive routine postoperative nursing care.
3248589|NCT01367925||Cruciate Substituting Tibial Insert|
3248590|NCT01367925||Posterior Stabilized Tibial Insert|
3361083|NCT04681482||Apixaban Group|The cohort prescribed apixaban and diagnosed with Atrial Fibrillation
3361084|NCT04681482||Warfarin Group|patients prescribed warfarin only diagnosed with Atrial Fibrillation.
3248591|NCT01367938||OMNI Apex Ultracongruent Knee Device|
3361085|NCT04672941||COPD patients|COPD patients switching from Tiotropium monotherapy to dual therapy with Tiotropium bromide plus Olodaterol
3361086|NCT04669665|Experimental|SLS-002 + Standard of care|Participants will receive SLS-002 (intranasal racemic ketamine) 90 milligram (mg) two times per week for 2 weeks with standard of care treatment
3361087|NCT04669665|Placebo Comparator|Placebo + Standard of care|Participants will receive intranasal placebo two times per week for 2 weeks with standard of care treatment
3248592|NCT01367951|Experimental|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
3248593|NCT01367951|No Intervention|non-operative|"Mechanical ventilation: Patients in respiratory distress will receive endotracheal intubation, and placed on mechanical ventilation. PEEP will be utilized as needed, at the discretion of the ICU and respiratory therapy team.~Other conservative means/Pulmonary toilet:Patients will receive aggressive pulmonary toilet (suctioning of ET tube as needed), chest physiotherapy (as per standard local protocol), and will have the head of the bed elevated to 30° unless contraindicated (ie unstable C-spine injury).~Pain control:Epidural catheters, intercostal nerve block, PCA, IV/PO pain medication"
3361088|NCT04666584|Active Comparator|ScoreFlex balloon|Pre-dilatation with a ScoreFlex balloon before implantation with a Magmaris bioresorbable scaffold
3361089|NCT04666584|Active Comparator|Standard non-compliant balloon|Pre-dilatation with a non-compliant balloon before implantation with a Magmaris bioresorbable scaffold
3361090|NCT04665570||Treatment|The decision to prescribe Acarbose/Metformin fixed dose combination (FDC) will be solely at the discretion of the Investigator and in accordance with his/her experience. Patients can only be enrolled in the study if the decision to treat with Acarbose/Metformin fixed dose combination has been made by the treating physician in advance and independent of study inclusion.
3361091|NCT04663321|Experimental|MK-1942 Daily Dose Group|Participants receive a total daily dose titrated from 5 mg to 20 mg of MK-1942 twice daily (BID), orally, over 4 weeks of treatment duration: 5 mg in Week 1, 10 mg in Week 2, and 20 mg in Weeks 3 and 4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
3361092|NCT04663321|Experimental|MK-1942 Intermittent Dose Group|Participants receive a total daily dose of 10 mg of MK-1942 twice weekly (BIW), orally, for Weeks 1-4. Participants receive MK-1942 and matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
3361093|NCT04663321|Placebo Comparator|Placebo|Participants receive a dose-matched placebo BID, orally, for 4 weeks. Participants receive matching placebo packaged in blister cards with an equal number of capsules administered in the morning and evening regardless of treatment assignment.
3361094|NCT04654013|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
3248594|NCT01367964|Experimental|ACTH treatment|Infants with a Type 3 EEG (pre-hypsarhythmia) will be treated with ACTH for 2 weeks.
3361095|NCT04654013|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (18 months).
3361096|NCT04652804|Active Comparator|Arm 1: Low Intensity Intervention|4 weeks dispensation + standard adherence counseling
3361097|NCT04652804|Active Comparator|Arm 2: Medium Intensity Intervention|4 weeks dispensation + support from patient navigator
3361098|NCT04652804|Active Comparator|Arm 3: High Intensity Intervention|Directly Observed Therapy with flexible dispensing and support from patient navigator
3248595|NCT01367977||Ehlers-Danlos patients|Patients with diagnosed or suspected Classic or Hypermobile Ehlers-Danlos Syndrome
3248596|NCT01367990|Experimental|Norepinephrine|
3248597|NCT01368003|Experimental|STA9090 with Dutasteride|STA9090 with Dutasteride
3361099|NCT04651400||COVID-19 patients who had received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
3248598|NCT01368003|Experimental|STA9090|STA9090
3248599|NCT01368016|Experimental|Experimental NRT|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits.
3248600|NCT01368016|Active Comparator|Nicotine GUM|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits.
3248601|NCT01368029|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to volunteers with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
3248602|NCT01368029|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
3248603|NCT01368055|Experimental|Low Risk|70 Gy/CGE
3361100|NCT04651400||COVID-19 patients who had not received treatment with ATIII|Patient records of patients hospitalised for severe COVID-19 infection until 01.06.2020 that required oxygen therapy will be used to retrospectively gather baseline demographic data (age, gender, height, weight, ethnicity/race, blood group, rhesus factor) and comorbidities. Records will also be used to retrospectively gather information on routine coagulation and laboratory parameters measured as per local protocols (including where available: AT, aPTT, PT, Quick, INR, , fibrinogen, D-dimers, haemoglobin levels, and platelet count), and thromboembolic complications and bleeding events that occurred during the individual observational treatment period. Patients will be grouped into 2 cohorts; those that received treatment with ATIII and those that did not. ATIII was administered as per local guidelines at each institute.
3248604|NCT01368055|Experimental|Intermediate Risk|72.5 Gy/CGE
3361101|NCT04651400||Non-COVID-19 patients who had received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
3361102|NCT04651400||Non-COVID-19 patients who had not received treatment with ATIII|"A control group will be used to gather comparative data in non-COVID-19 patients.~Data will be gathered retrospectively from patient records for severely ill patients who received oxygen therapy for non-COVID-19 infection until end 2019 (31.12.2019). Control group will also be grouped into 2 cohorts for those having received/ having not received ATIII treatment."
3248605|NCT01368068|Experimental|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial.
3248606|NCT01368068|Active Comparator|Escitalopram|10mg of escitalopram will be taken by participants daily for the duration of the 12 week trial period.
3248607|NCT01368068|Placebo Comparator|Placebo|Placebo arm containing sweetener has been approved and will be used as placebo arm.
3248608|NCT01368094|Active Comparator|Standard drainage|
3248609|NCT01368094|Experimental|Short drainage|
3248610|NCT01368107|Placebo Comparator|Placebo Arm|the patients will receive Placebo before the 1st and during the 3rd CT cycle (N=6)
3248611|NCT01368107|Experimental|CYT107 treatment before CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and the placebo during the 3rd CT cycle (N=6)
3248612|NCT01368107|Experimental|CYT107 treatment during CT|patients will receive the placebo before the 1st CT cycle and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6)
3248613|NCT01368107|Experimental|CYT107 treatment before and during CT|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (N=6).
3248614|NCT01368120|Experimental|IV Clear™|
3248615|NCT01368120|Active Comparator|Tegaderm CHG™|
3248616|NCT01368120|Placebo Comparator|Vehicle Control Dressing|
3248617|NCT01368146|Experimental|IV Clear™|
3248618|NCT01368146|Active Comparator|Tegaderm CHG™|
3248619|NCT01368146|Placebo Comparator|Control Vehicle Dressing|
3248620|NCT01368159|Active Comparator|pressure centred at 25 mm Hg|
3248621|NCT01368159|Active Comparator|pressure between 20 and 36 mm Hg|
3248622|NCT01368159|Placebo Comparator|pressure between 10 and 15 mm Hg|
3248623|NCT01368172|Experimental|Physical Activity Guidelines|Participants randomized to this arm received training/guidance on following the physical activity guidelines for adults with spinal cord injury
3248624|NCT01368172|No Intervention|Control|
3248625|NCT01368198|Active Comparator|Ocular Emulsion|An Ocular Emulsion
3248626|NCT01368198|Active Comparator|OPTIVE™|An OPTIVE™
3248627|NCT01368224|Placebo Comparator|Maltodextrin|
3248628|NCT01368224|Experimental|Lactobacillus paracasei NCC 2461 (ST 11)|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11)
3248629|NCT01368224|Experimental|Lactobacillus paracasei+ Bifidobacterium longum|1x1010 CFU of Lactobacillus paracasei NCC 2461 (ST 11) + 1x1010 CFU of Bifidobacterium longum (NCC3001)
3248630|NCT01368237||Patients|Patients awaiting invasive coronary angiography
3248631|NCT01368250||1|Patients with native aortic stenosis undergoing TAVI
3248632|NCT01368250||2|Patients with native aortic regurgitation undergoing TAVI
3248633|NCT01368250||3|Patients with degenerative surgical bioprosthesis undergoing TAV-in-SAV
3248634|NCT01368289||Colonic Polyps|Patients who present with colonic polyps >20mm
3248635|NCT01368302|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to normalize threat-related attention biases.
3248636|NCT01368302|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
3248637|NCT01368315|Experimental|CT327|Cream
3248638|NCT01368315|Placebo Comparator|Placebo|Cream (Vehicle only)
3248639|NCT01368315|Active Comparator|Active comparator|Cream
3248640|NCT01368315|No Intervention|No intervention|
3361108|NCT04635943|Active Comparator|Ivermectin|Participants on this arm will receive orally one (1) daily dose of ivermectin 300 mcg/kg for three (3) consecutive days, starting at the enrolment visit.
3361109|NCT04635943|Placebo Comparator|Placebo|Participants on this arm will receive orally one (1) daily dose of placebo for three (3) consecutive days, starting at the enrolment visit.
3361112|NCT04633239|Experimental|Treatment (abemaciclib, olaparib)|Patients receive olaparib PO BID on days 1-28 and abemaciclib PO BID on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3361114|NCT04629820|Experimental|Intervention|Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
3248641|NCT01368328|Placebo Comparator|Placebo|
3248642|NCT01368328|Active Comparator|Chromium nicotinate 50 mcg|
3248643|NCT01368328|Active Comparator|Chromium nicotinate 200 mcg|
3248644|NCT01368341|Active Comparator|Doxycycline|Doxycycline, 100 mg, tablets, b.i.d., 14 days
3248645|NCT01368341|Active Comparator|Penicillin|Phenoxymethylpenicillin tablets 650 mg. 2 tablets t.i.d. 14 days
3248646|NCT01368341|Active Comparator|Amoxicillin|Amoxicillin 500 mg capsula, t.i.d., 14 days
3248647|NCT01368354|Active Comparator|CLTS Arm|To induce behavioural changes by confronting the community with their open defecation behaviour. This will lead to voluntary construction and use of latrines and improved hygiene behaviour. CLTS involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination.
3248648|NCT01368354|No Intervention|Control arm|
3248649|NCT01368367|Active Comparator|Intensive exercise group|
3248650|NCT01368367|Placebo Comparator|Stretch exercise only|
3248651|NCT01368380|Experimental|Psychological Intervention|
3248652|NCT01368380|No Intervention|Usual care|
3248653|NCT01368393|Experimental|Electroacupuncture|
3248654|NCT01368393|Active Comparator|Sham acupuncture|
3248655|NCT01368419|Experimental|Treatment|
3248656|NCT01368445|Active Comparator|MP03-36 Nasal Spray|azelastine hydrochloride 0.15%
3361115|NCT04629820|No Intervention|Control|Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).
3361116|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-Cell Lymphoma|FT819 single-dose monotherapy in adult subjects with r/r B-cell Lymphoma
3361117|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-Cell Lymphoma|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-cell Lymphoma
3361118|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-Cell Lymphoma|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-cell Lymphoma
3248657|NCT01368445|Active Comparator|MP03-36 and Placebo Nasal Spray|azelastine hydrochloride 0.15% and Placebo
3248658|NCT01368445|Active Comparator|Azelastine 0.1%, Nasal Spray|Azelastine 0.1%, Nasal Spray
3248659|NCT01368445|Placebo Comparator|Placebo Nasal Sapray|0mg, 2 sprays per nostril twice daily AM & PM)
3361119|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, CLL|FT819 single-dose monotherapy in adult subjects with r/r CLL
3361120|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, CLL|FT819 single-dose in combination with IL-2 in adult subjects with r/r CLL
3361121|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, CLL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r CLL
3361122|NCT04629729|Experimental|FT819 Single-Dose Monotherapy, B-ALL|FT819 single-dose monotherapy in adult subjects with r/r B-ALL
3248660|NCT01368458|Experimental|Conversion to mono therapy|Conversion from 2 to 1 antipsychotic
3248661|NCT01368458|No Intervention|control|No change in antipsychotics
3248662|NCT01368471|Experimental|MGuard|MGuard stent will be deployed
3361123|NCT04629729|Experimental|FT819 Single-Dose in Combination with IL-2, B-ALL|FT819 single-dose in combination with IL-2 in adult subjects with r/r B-ALL
3361124|NCT04629729|Experimental|FT819 Step Fractionated Monotherapy, B-ALL|FT819 monotherapy administered as step-fractionated dosing in adult subjects with r/r B-ALL
3361127|NCT04625101|Experimental|NBI-827104|NBI-827104 administered orally for 13 weeks.
3361128|NCT04625101|Placebo Comparator|Placebo|Placebo administered orally for 13 weeks.
3361129|NCT04615949|Experimental|Cannabidiol, pharmaceutically produced with < 5 ppm THC|CardiolRx
3361130|NCT04615949|Placebo Comparator|Placebo|Placebo
3361131|NCT04615650|Active Comparator|Surgical treatment|Patients randomised to operative treatment will have their surgery performed by an orthopaedic surgeon or by orthopaedic trainees under the supervision of a consultant, when fit for surgery. The surgical technique and choice of implants will be decided by the surgeon in order to closely resemble everyday clinical practice. The syndesmosis must be reduced (closed or open) and fixed. Postoperatively, the patients will be treated with an ankle orthosis for six weeks with weight-bearing as tolerated.
3248663|NCT01368471|Active Comparator|BMS or DES|A regular bare metal stent or drug-eluting stent will be deployed
3248664|NCT01368484|Placebo Comparator|Sunflower oil|
3248665|NCT01368484|Experimental|Docosahexanoic acid|
3361132|NCT04615650|Experimental|Non-surgical treatment|Patients randomised to non-operative treatment are treated with an ankle orthosis for six weeks with weight-bearing as tolerated. Other types of casts can be used if preferred by the treating orthopaedic surgeon, but the cast must allow full weight-bearing and must prevent equinus position.
3248666|NCT01368510|Experimental|OCD Active CBT|Adults with obsessive-compulsive disorder (OCD) will be treated with cognitive-behavioral therapy (CBT) from the time of enrollment.
3361133|NCT04611789|Experimental|LY3832479|Participants received single subcutaneous dose of 350 milligrams (mg) and 1000 mg LY3832479.
3361134|NCT04611789|Placebo Comparator|Placebo|Participants received single subcutaneous dose of Placebo.
3248667|NCT01368510|Active Comparator|OCD Waitlist|Adults with OCD will receive waitlist treatment at enrollment. Nonresponders will cross over to CBT.
3248668|NCT01368510|No Intervention|Healthy Control|Healthy control adults will be given no intervention.
3248669|NCT01368523|Experimental|nilotinib|
3248670|NCT01368549||Metanx®|Subjects with Diabetic Peripheral Neuropathy who have been prescribed Metanx® daily.
3248671|NCT01368575|Active Comparator|subgroup B1|subgroup B1 will receive CABG combined with MV repair with annuloplasty rigid ring
3248672|NCT01368575|Active Comparator|subgroup B2|B2 - CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus
3248673|NCT01368575|Active Comparator|subgroup A2|CABG combined with MV repair with remodeling annuloplasty rigid ring
3248674|NCT01368575|Active Comparator|subgroup A1|only CABG
3248675|NCT01368575|Active Comparator|subgroup B3|patients in subgroup B3 will be performed CABG and MV replacement with preservation of subvalvular apparatus
3248676|NCT01368588|Active Comparator|Arm I|Patients undergo high-dose radiotherapy of the prostate and seminal vesicles using intensity-modulated radiotherapy (IMRT)* or 3D-conformal radiation therapy (3D-CRT)* once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo permanent prostate implant (PPI) brachytherapy or high-dose rate brachytherapy (I 125 or Pd 103 may be used as the radioisotope).
3248677|NCT01368588|Experimental|Arm II|Patients undergo whole-pelvic radiotherapy (WPRT)* (3D-CRT or IMRT) once daily, 5 days a week, for approximately 9 weeks. Patients may also undergo brachytherapy as in arm I.
3248678|NCT01368601|Active Comparator|CPAP (positive airway pressure)|To evaluate if continuous positive airway pressure(CPAP) on the lung undergoing lobectomy can decrease the inflammatory response PPC (postoperative pulmonary complications).
3248679|NCT01368601|No Intervention|Control without CPAP|
3248680|NCT01368627|Experimental|Supralimus® Sirolimus-Eluting Coronary Stent|
3361141|NCT04594707|Experimental|PRM-151|"Corhort A: Participants entering, following participation in study PRM-151-202.~Cohort B: Participants entering, following participation in study WA42293."
3361142|NCT04592484|Experimental|CDK-002|
3361143|NCT04592341|Experimental|Gantenerumab|Participants will receive gantenerumab by subcutaneous (SC) injection at a dose of 120 mg every 4 weeks (Q4W) for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg every 2 weeks (Q2W) for another 12 weeks, followed by the target dose 255 mg once weekly (Q1W) for up to Week 103.
3361145|NCT04589650|Experimental|Adult cohort (group 1)- Alpelisib|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive alpelisib (125 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
3361146|NCT04589650|Placebo Comparator|Adult cohort (group 1)- Placebo|During double-blind randomized study period (from baseline up to Week 16), adult participants will be randomized to receive placebo (125 mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
3361147|NCT04589650|Experimental|Pediatric cohort (group 2: 6 to 17 years old) -Alpelisib|During double-blind randomized study period (from baseline up to Week 16, pediatric participants (6 to 17 years old) will be randomized to receive alpelisib (50 mg, oral, once daily). After Week 16, participants will continue their active treatment at the same dose level.
3361148|NCT04589650|Placebo Comparator|Pediatric cohort (group 2: 6 to 17 years old)-Placebo|During double-blind randomized study period (from baseline up to Week 16), pediatric participants (6 to 17 years old) will be randomized to receive Placebo (50mg, oral, once daily). After Week 16, participants will be switched to active treatment with alpelisib at the placebo dose level received at the end of the placebo period.
3361149|NCT04589650|Experimental|Pediatric cohort (group 3: 2 to 5 years old)- Alpelisib|Pediatric participants (2 to 5 years old) will receive alpelisib at dose determined based on the primary analysis for efficacy, safety and PK of alpelisib in Groups 1 and 2. An extrapolation approach will be used for dose selection for this group.
3248681|NCT01368640||healthy adults|The study will cover 130 healthy adults. 65 men and 65 women in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3361152|NCT04583995|Experimental|Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
3361153|NCT04583995|Placebo Comparator|Cohort 1: Placebo|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
3361154|NCT04583995|Experimental|Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine|2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
3361155|NCT04583995|Placebo Comparator|Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
3248682|NCT01368666|Experimental|Perceval S Valve Prosthesis|Patients who underwent replacement of diseased or malfunctioning native aortic valve with the Perceval S Valve prosthesis
3248683|NCT01368679|Experimental|Endoprothesis Scitech|"The endoprothesis of SCITECH is a self-expandable stent mixed (laser cut and wire plotted) covered with polyester fabric. The delivery system has lower profile than the existing market and this approach allows the passage of the delivery system through the femoral artery with ease and without dissection. Fixation has proximal and distal securing lower rates of leakage and displacement.~The delivery system is done by linear drive or screw diameters greater than 30mm"
3361162|NCT04578834|Experimental|LNP023 200mg b.i.d|
3361163|NCT04578834|Placebo Comparator|Placebo to LNP023 200mg b.i.d|
3361164|NCT04577482||Participants treated with Glecaprevir/Pibrentasvir|Participants will receive glecaprevir/pibrentasvir (GLE/PIB) as prescribed by physician in accordance with local clinical practice.
3361165|NCT04576156|Experimental|Imetelstat|Participants will receive imetelstat at 9.4 mg/kg intravenous (IV) every 21 days (±3 days), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
3361166|NCT04576156|Active Comparator|Best Available Therapy (BAT)|Participants will receive BAT (investigator-selected non-JAK-inhibitor treatment), until disease progression or unacceptable toxicity, treatment discontinuation or study end.
3361173|NCT04574518|Experimental|TeaM OUT Intervention|The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
3248684|NCT01368692|Active Comparator|neutral shoulder|neutral shoulder position during subclavian vein catheterization
3361174|NCT04574518|Other|Enhanced Usual Care|The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
3248685|NCT01368692|Experimental|shoulder retraction|position of shoulder retraction during subclavian vein catheterization
3248686|NCT01368705|Active Comparator|Control Group|
3248687|NCT01368705|Experimental|Intervention Group 1|
3361179|NCT04563793||Superion IDS|All patients to receive IDS for the treatment of their moderate Lumbar Spinal Stenosis Symptoms.
3361180|NCT04553068|Experimental|EVO100 gel|EVO100 vaginal gel, 5 g
3361181|NCT04553068|Placebo Comparator|Placebo gel|Placebo vaginal gel, 5 g
3361182|NCT04552899|Experimental|PRM-151|Participants will receive intravenous (IV) infusions of PRM-151 over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48.
3361183|NCT04552899|Placebo Comparator|Placebo|Participants will receive IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
3248688|NCT01368705|Experimental|Intervention Group 2|
3248689|NCT01368718|Other|Active/Sham CPAP|
3248690|NCT01368731|No Intervention|nil prophylactic coagulation|
3248691|NCT01368731|Active Comparator|Prophylactic coagulation|
3248692|NCT01368744||OSNA Breast Cancer System|
3248693|NCT01368770|Experimental|Coronary CTA|Coronary CTA using standard protocols
3361186|NCT04546633|Experimental|KAF156 and LUM-SDF QD for 2 days in fasted condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fasted condition
3248694|NCT01368770|Active Comparator|Stress MPI SPECT|Stress-rest MPI SPECT using standard protocols
3248695|NCT01368783|Experimental|atazanavir|400 mg/day for 2 days
3248696|NCT01368783|Experimental|Atazanavir and Tenofovir|
3248697|NCT01368783|Experimental|Atazanavir and Ritonavir|
3248698|NCT01368783|Experimental|Atazanavir + tenofovir + ritonavir|
3248699|NCT01368796|Active Comparator|Trivalent Influenza vaccine subunit|The seasonal vaccine (Agriflu, Novartis) contains egg-derived, inactivated and detergent split versions of the 3 influenza strains (tri-valent). It is given into the muscle of the upper arm at a dose of 0.5 mL.
3361187|NCT04546633|Experimental|KAF156 and LUM-SDF QD for 2 days in fed condition|KAF156 and LUM-SDF QD (once daily) for 2 days in fed condition
3248700|NCT01368796|Active Comparator|Adjuvanted Tri-valent Influenza Vaccine|The adjuvanted vaccine (Fluad, Novartis) is made with an immune-stimulator (MF59) that contains squalene oil microdroplets and two surfactants, Tween 80 and Span 65. It is given into the muscle of the upper arm at a dose of 0.5 mL.
3248701|NCT01368796|Active Comparator|Intradermal Tri-valent Influenza vaccine|(Intanza 15ug, Sanofi Pasteur) is an inactivated, split-virion influenza vaccine. Strains are grown in fertilized hen's eggs, inactivated with formalin and split using Triton X-100 detergent, as for TIV. The syringe is attached to a micro-needle injection system (Beckton Dickinson) that limits the depth of injection to just under the skin. It is given into the skin over the upper arm at a dose of 0.1 mL.
3248702|NCT01368796|Active Comparator|Trivalent Split-virion Influenza vaccine|Vaxigrip, Sanofi Pasteur is an inactivated, split-virion Influenza vaccine. The 3 influenza strains are grown on fertilized eggs, concentrated, purified in a sugar-like solution, detergent split, and inactivated by formaldehyde, then diluted in phosphate buffered salt solution. A dose of 0.5 mL is given into the muscle of the arm.
3248703|NCT01368861||control|water and normal physical comfort provided by mom
3248704|NCT01368861||sucrose|sugar and normal physical comfort provided by mom
3248705|NCT01368861||physical intervention|physical intervention using the 5 S's and water
3361188|NCT04546126|Experimental|Dexamethasone (Group 2)|"Participants will undergo an FNP-59 scan on day 0 in the am. Participants will then take~1 mg dexamethasone 2x a day for 3 days to suppress cortisol production. Participants will then have a second FNP-59 scan on day 4 in the am."
3361189|NCT04546126|Experimental|Cosyntropin (Group 3)|Participants will undergo an FNP-59 scan on day 0 in the am. On day 4 the participant will arrive for imaging. Cosyntropin, 250 micro-gm will be administered IV. Five minutes following administration FNP-59 will be given. Following uptake of FNP-59 imaging will occur.
3248706|NCT01368861||physical intervention and sucrose|Physical intervention using the 5 S's and sugar water
3248707|NCT01368887|Experimental|1|DPS-102
3361190|NCT04546126|Experimental|Adrenal pathology (Group 4)|Whole-body PET/CT scans will be done on 4 patients at 1 hr and the other 4 patients at 6 hours. All the patients will have a whole-body PET/CT scan at 3 hours.
3361191|NCT04544189|Experimental|Alpelisib+Fulvestrant (randomized cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
3361192|NCT04544189|Placebo Comparator|Placebo+Fulvestrant (randomized cohort)|Placebo (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
3361193|NCT04544189|Experimental|PK cohort (open label cohort)|Alpelisib (300 mg by mouth once daily, in a 28-day cycle) plus fulvestrant (500 mg intramuscular [as two 250mg/5 ml injections] on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter)
3361194|NCT04541381|No Intervention|Control Group (No PGx Test)|Participants assigned to the control group will not take a genotyping/PGx test during the start of treatment and will instead receive standard chemotherapy without their doctors receiving any genetic information based on the participants' PGx test results. Blood samples for participants in this group will be stored and tested for genotyping six months later after treatment (or earlier if the participant experiences side effects).
3361195|NCT04541381|Experimental|Pharmacogenomics (PGx Testing) Group|Participants enrolled in the pharmacogenomics (PgX) testing group will give a blood sample for immediate genotyping/PGx testing. Once the results from these tests are in, cancer doctors caring for each participant will have immediate access to the participant's genetic test results and can make dosing decisions/changes to the participant's chemotherapy prescription based on genetic information found in their PGx test results.
3361196|NCT04540952|Experimental|Total Capture Drape|Surgical drape created by Principal Investigator to adequately collect fluid during hysteroscopy procedure
3361197|NCT04540952|Active Comparator|Control|Standard surgical drape used to adequately collect fluid during hysteroscopy procedure
3248708|NCT01368887|Placebo Comparator|2|Vehicle
3361198|NCT04537910|Experimental|LY3819253|Participants received single subcutaneous (SC) doses of 150 milligram (mg), 350 mg or 700 mg LY3819253.
3361199|NCT04537910|Placebo Comparator|Placebo|Participants received a single SC dose of Placebo.
3361202|NCT04535323|Experimental|Treatment Group|Platelet rich plasma will be administered in an array of 6 locations inside the vagina. Each array will receive 5 injections of 0.2 ml PRP. An additional 5 injections of 0.2 ml PRP will be injected at the entrance of the vagina for a total of 7 ml PRP.
3248709|NCT01368887|Active Comparator|3|Calcipotriol Monotherapy
3248710|NCT01368887|Active Comparator|4|Nicotinamide Monotherapy
3248711|NCT01368913||Patients treated with orally disintegrating tablet|
3248712|NCT01368913||Patients treated with tablets|
3248713|NCT01368926|Experimental|Part 1|
3248714|NCT01368926|Experimental|Part 2|
3248715|NCT01368952|Active Comparator|Pure Prone Positioning|Sleeping in prone position by pure prone positioning device, which consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
3248716|NCT01368952|No Intervention|Baseline|No intervention for sleep position
3248717|NCT01368978|Experimental|Test (with the InsuPatch device)|Device use
3248718|NCT01368978|No Intervention|Control (without the InsuPatch device)|
3248719|NCT01368991|Active Comparator|Kryptonite|Sternal closure with stainless steel and kryptonite
3248720|NCT01368991|Active Comparator|Conventional Closure|Sternal closure with stainless steel wires
3248721|NCT01369004|Experimental|Daily self-weighing + feedback/lessons|Participants will be instructed to weigh daily and they will receive a smart scale for daily monitoring of weighing via the website bodytrace.com. They will also receive weekly emailed lessons with content related to behavioral weight control (e.g., How to control portion sizes, How to develop an exercise routine) as well as weekly emailed feedback from a registered dietitian on their daily weighing and weight loss progress.
3248722|NCT01369004|No Intervention|Delayed Intervention Control Group|Participants will receive the same components of the experimental group with the exception of the weekly feedback after the 6-month study period is complete.
3248723|NCT01369017|Active Comparator|Anakinra|All subjects will undergo 2 CCRE challenges. Each subject will be given either anakinra or placebo prior to CCRE challenge
3248724|NCT01369017|Placebo Comparator|Placebo|Normal saline injection
3248725|NCT01369043|Active Comparator|Vitamin E and Vitamin C|4 weeks with Vitamin E and Vitamin C supplementation with no exercise and 4 weeks of supplementation with prescribed exercise.
3248726|NCT01369043|No Intervention|Placebo|Placebos instead of the Vitamin E and Vitamin C supplements
3361215|NCT04513834|Experimental|Multi-faceted intervention|Patient education material on PPI deprescribing will be sent to the patients and their general practitioner (GP) will receive an educational outreach visit by a Delegue d'Assurance Maladie (DAM, healthcare representative )
3361216|NCT04513834|Active Comparator|Educational outreach visit to GPs|GP will receive the educational outreach visit by a DAM (healthcare representative). Their patients will not receive any patient education material.
3248727|NCT01369056|Experimental|Advanced Adherence Counseling (AdvAdh)|Please see the Intervention Description section
3248728|NCT01369056|No Intervention|Control|Standard of care (including counseling regarding antiretroviral treatment adherence) received by HIV/AIDS patients at the study clinic
3248729|NCT01369082||CIT Islet Transplantation Recipients|"Subjects who received an islet-cell transplant for Type 1 Diabetes (T1D) while enrolled in one of the Clinical Islet Transplantation (CIT) parent studies and continue to have islet graft function. All subjects will continue immunosuppressive medications under CIT08. Detailed follow-up evaluations including but not limited to islet function will occur on an annual basis.~The immunosuppressive medications (e.g., tacrolimus, sirolimus, cyclosporine, mycophenolate mofetil [MMF], mycophenolic sodium) in this study are obtained by prescription unless provided by the study through the drug distributor. Generic brands are allowed, when available. Antibacterial, antifungal, and antiviral prophylaxis, insulin therapy, and other standard therapies will be provided per site-specific practices."
3248730|NCT01369095|Active Comparator|Arm 1: Duloxetine / Escitalopram + BMS-820836 placebo|
3248731|NCT01369095|Experimental|Arm 2: BMS-820836 (0.25 mg) + BMS-820836 placebo|
3248732|NCT01369095|Experimental|Arm 3: BMS-820836 (0.50 mg) + BMS-820836 placebo|
3248733|NCT01369095|Experimental|Arm 4: BMS-820836 (1.0 mg) + BMS-820836 placebo|
3248734|NCT01369095|Experimental|Arm 5: BMS-820836 (2.0 mg) + BMS-820836 placebo|
3361217|NCT04513834|No Intervention|Control|Neither the patients nor their GP will receive any information.
3361218|NCT04512534|Experimental|Sinitilimab+Chidamide|Anti-PD-1 antibody Sintilimab 200mg intravenously every 3 weeks; HDAC inhibitor Chidamide 30mg orally twice every week
3361219|NCT04512040|Experimental|Yoga Dyads AD patients and Caregivers|Initially Yoga will be delivered in 1-on-1 format between the yoga therapist and the AD/caregiver dyad. Five outpatient adults, with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver, will receive at-home teleyoga classes via video conferencing. Later, yoga will be delivered in a group format. Ten outpatient adults with chronic musculoskeletal pain and a diagnosis of mild AD and their Caregiver will receive group at-home teleyoga classes via video conferencing.
3361220|NCT04510506|Experimental|Artificial Pancreas Therapy|Participants will use a study assigned Tandem t:slim X2 with Control-IQ Technology.for two years.
3361221|NCT04510506|No Intervention|Usual Care + CGM|Participant will use their usual diabetes care along with a study CGM.
3361222|NCT04502186|Experimental|Raising Our Spirits Together Intervention|
3361223|NCT04502186|Other|Enhanced Control Condition|
3361230|NCT04495179|Experimental|Arm A: AZD4635 + durvalumab|AZD4635 plus durvalumab (Arm A) will consist of participants with mCRPC previously treated with one or more approved NHAs (eg, abiraterone acetate, enzalutamide, apalutamide and/or darolutamide), and one or more taxanes, or participants who are taxane ineligible.
3361231|NCT04495179|Experimental|Arm B: AZD4635 + durvalumab + cabazitaxel|AZD4635 plus durvalumab plus cabazitaxel (Arm B) will consist of participants with mCRPC previously treated with docetaxel and one prior NHA (either abiraterone acetate or enzalutamide but not both (prior apalutamide is not allowed in Arm B).
3361232|NCT04493853|Experimental|Capivasertib + Abiraterone|Participants receive capivasertib in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
3361233|NCT04493853|Placebo Comparator|Placebo + Abiraterone|Participants receive placebo in combination with abiraterone (prednisone/prednisolone) on a background of ADT.
3361234|NCT04493242|Placebo Comparator|Placebo|Normal saline 100 mL
3361235|NCT04493242|Experimental|Experimental Dose 1|Normal saline 90 mL and ExoFlo 10 mL, which is 800 Billion Extracellular Vesicles.
3361236|NCT04493242|Experimental|Experimental Dose 2|Normal saline 85 mL and ExoFlo 15 mL, which is 1.2 Trillion Extracellular Vesicles.
3361237|NCT04491422|Active Comparator|Integrated Next Steps Counseling using poi|At quarterly visits, intervention arm participants will receive iNSC Support Level 1 to address PrEP adherence and sexual health needs. Those with urine TFV levels <1000 ng/mL will receive iNSC Support Level 2, in which participant responses to two 7-item questionnaires on PrEP adherence and sexual health will guide problem solving on improved dosing.
3361238|NCT04491422|No Intervention|Standard adherence counseling|Control arm participants will receive standard adherence counseling.
3361239|NCT04491136|Experimental|ACEI/ARB treatment in 6 months/ARNI treatment in next 6 months|"Angiotensin-converting enzyme inhibitor/Angiotensin receptor blockers treatment in the first 6 months~Angiotensin receptor neprilysin inhibitor treatment in next 6 months"
3361240|NCT04490915|Experimental|Crinecerfont|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
3361241|NCT04490915|Placebo Comparator|Placebo|Capsule, administered orally, twice daily for 24 weeks, followed by active treatment for 1 year.
3361242|NCT04488419|Experimental|Low Dose|Daily subcutaneous (SC) injection of Low Dose ATH-1017
3361243|NCT04488419|Experimental|High Dose|Daily subcutaneous (SC) injection of High Dose ATH-1017
3361244|NCT04488419|Placebo Comparator|Placebo|Daily subcutaneous (SC) injection of Placebo
3361245|NCT04488133|Experimental|Nusinersen 12 mg|Participants will receive Nusinersen 12 milligrams (mg) via intrathecal (IT) injection as loading doses on Days 1, 15, 29, and 64 followed by maintenance doses, every 4 months, on Days 183, 302, 421, 540 and 659.
3361246|NCT04485858|Experimental|CorNeat KPro|Intraocular implantation of the CorNeat KPro
3361247|NCT04478695|Experimental|Cohort 1|
3361248|NCT04478695|Experimental|Cohort 2|
3361249|NCT04477486|Experimental|Ibrutinib + Venetoclax|Participants will receive Ibrutinib Dose A + Venetoclax in various doses until a target dose is reached, for up to 104 weeks, followed by Ibrutinib monotherapy.
3248735|NCT01369121|Experimental|Xerecept|All patients will receive hCRF (XERECEPT)
3248736|NCT01369147|Experimental|Parenteral nutrition energy dose at 0.6x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 0.6 x resting energy expenditure (REE).
3259414|NCT01470664|Experimental|FST-100 (Component #1)|
3259415|NCT01470664|Placebo Comparator|FST-100 Vehicle|
3361252|NCT04455620|Experimental|Part 1: BNT151|Monotherapy dose escalation in patients with advanced solid malignancies until the maximum tolerated dose (MTD) and/or RP2D
3361253|NCT04441931|Experimental|LY3832479|Participants received single Intravenous (IV) doses of 700, 2800 and 7000 milligrams (mg) LY3832479.
3361254|NCT04441931|Placebo Comparator|Placebo|Participants received single IV dose of Placebo.
3361255|NCT04437602|Experimental|CEM|Patients in experimental arm will go through additional preoperative staging with contrast enhanced mammography
3361256|NCT04437602|No Intervention|No CEM|Patients in No intervention arm will go through no additional preoperative imaging
3361257|NCT04429243||GORE® VIABAHN® Stent Graft|Participants will be examined 1, 3, 6, 12 and 24 months following the GORE® VIABAHN® Stent Graft installation.
3361258|NCT04425447|Active Comparator|Group C|30 patients will receive bilateral tumescent local anesthesia as a control group
3361259|NCT04425447|Experimental|Group TPVB|30 patients will receive bilateral US guided thoracic paravertebral block.
3361260|NCT04425447|Experimental|Group TIPB|30 patients will receive bilateral US guided thoracic interfascial plane block
3361261|NCT04419480|Experimental|CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge implantation of the CardioMEMS device will receive that device ≤14 days following discharge from the index hospitalization for Cardiogenic Shock, in addition to local standard of care medical therapy.
3361262|NCT04419480|No Intervention|Non-CardioMEMS Implant Group|Following enrollment, patients randomized 1:1 to post-discharge standard of care will be treated according to local standard of care medical therapy following their index hospitalization for Cardiogenic Shock.
3361263|NCT04414527|Other|Standard counseling|Pregnant women in the control group will receive the standard education package as per the Ethiopian guidelines. In the standard health care, pregnant women receive a minimum of four ante-natal care visits at the health centers during which they also receive iron and folic acid supplementation. They participate in monthly forums facilitated by nurses to answer questions and concerns regarding nutritional care.
3361264|NCT04414527|Experimental|Health-Video|Women in the Health-Video group will receive home visits for delivery of healthy nutrition messages using prepared video-based messages every two weeks. They will also participate in monthly forums facilitated by nurses using also videos for demonstration of nutritional care. During the monthly forums (six in total during the pregnancy and the post-partum periods), the messages will all be given as a video show coordinated by a nurse/ health professional for any questions. During postnatal period, two counseling sessions will be delivered within two weeks of birth, and 12 sessions or twice every month till 6 months.
3361267|NCT04404257|Experimental|ControlRad System|Participant will undergo Cardiac catheterization or electrophysiology implant procedures with the ControlRad system installed in Cath lab room 5
3361268|NCT04404257|Active Comparator|Without ControlRad System|Participant will undergo the cardiac catheterization or electrophysiology implant procedures per standard of care. Meaning, without the ControlRad system installed in Cath lab room 5.
3361271|NCT04398355|No Intervention|control|basic treatment+Swallowing rehabilitation training
3361272|NCT04398355|Experimental|treatment|basic treatment+Swallowing rehabilitation training+Chinese traditional rehabilitation
3361277|NCT04368988|Placebo Comparator|Placebo - Phase 1|2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
3361278|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.
3361279|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
3361280|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.
3361281|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.
3361282|NCT04368988|Placebo Comparator|Placebo - Phase 2|3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.
3361283|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
3361284|NCT04368988|Experimental|SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.
3361285|NCT04368988|Experimental|SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2|2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.
3361286|NCT04368988|Experimental|SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
3248737|NCT01369147|Active Comparator|Parenteral nutrition energy dose at 1.0 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.0 x resting energy expenditure (REE).
3248738|NCT01369147|Experimental|Parenteral nutrition energy dose at 1.3 x measured REE|Participants in this study arm will be provided a total daily calorie (kcal) intake [from parenteral nutrition (PN) + dextrose-containing IV fluids (> 500 mL/day) + propofol/clevidipine + any enteral feedings) at 1.3 x resting energy expenditure (REE).
3248739|NCT01369160||1|Chronic Transfusion
3361287|NCT04368988|Experimental|SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2|3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.
3361288|NCT04368988|Experimental|SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2|1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.
3361289|NCT04364087||Infertile PCOS women|All Vietnamese, infertile women, diagnosed with PCOS according to the Rotterdam criteria (2003) at IVFMD Tan Binh and IVFMD Phu Nhuan will be enrolled to the study.
3361290|NCT04362436|Experimental|TheraSpheres Selective Internal Radiation Therapy (SIRT)|Radiation therapy
3361291|NCT04358185|Experimental|Itacitinib|Itacitinib (INCB039110) - novel and small molecule selective inhibitor of JAK1
3361292|NCT04355728|Experimental|UC-MSCs Group|Participants in this group will be treated with two infusions of UC-MCSs along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
3248740|NCT01369160||2|hydroxyurea
3248741|NCT01369160||3|matched sibling donor stem cell transplantation (MSD-SCT)
3248742|NCT01369160||4|standard comprehensive care (SCC, control)
3248743|NCT01369173|Active Comparator|Mexican Menu|24 days, all foods and drinks provided, menu consists of traditional mexican meals
3361293|NCT04355728|Placebo Comparator|Control Group|Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
3361294|NCT04350775|Experimental|RE-IADL group|Reablement
3361295|NCT04350775|Placebo Comparator|Control group|General community rehabilitation
3361296|NCT04347161|Experimental|Intervention Arm|Participants in the intervention arm will be tracked and able to engage with the intervention (conversational agent) on their mobile telephone for 12 weeks.
3361297|NCT04347161|Active Comparator|Control Arm|Patients in the control arm will receive usual care, which includes clinician-driven education on medication management and self-monitoring of symptoms.
3361298|NCT04344535|Active Comparator|Convalescent Donor Plasma|
3361299|NCT04344535|Placebo Comparator|Standard Donor Plasma|
3248744|NCT01369173|Active Comparator|US diet|24 days, all foods and drinks provided, menu consists of foods commonly eaten in contemporary United States
3248745|NCT01369186|Active Comparator|Morphine|Vendal 5 mg i.v. bolus injection
3248746|NCT01369186|Placebo Comparator|Placebo|Sodium chloride 0.9% i.v. bolus injection
3361300|NCT04340843|Experimental|Treatment (belinostat, guadecitabine, ASTX727)|Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy at baseline (within 21 days of the first cycle) and during cycle 2 (on day 3, 4, or 5). In addition, patients undergo MRI or CT scans every 2 cycles (8 weeks) while receiving guadecitabine or ASTX727 and belinostat.
3361305|NCT04329065|Experimental|Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab)|Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15, and trastuzumab IV and pertuzumab IV on day 1. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
3361306|NCT04328714|Experimental|Adult Population|Study participants aged 18 or older who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
3361307|NCT04328714|Experimental|Pediatric Population|Study participants under 18 years of age who are having an allogeneic blood and marrow transplant (BMT), to treat leukemia, lymphoma or other cancer of the blood will receive an infusion of mesenchymal stromal cells (MSCs).
3361308|NCT04328623|Active Comparator|Infiltration|Ultrasound-guided hand infiltration
3361309|NCT04328623|Experimental|Hypnosis|Hypnosis before Ultrasound-guided hand infiltration
3248747|NCT01369212|Experimental|Tenofovir|Tenofovir 192 weeks
3248748|NCT01369212|Experimental|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a plus tenofovir for 24 weeks and then tenofovir only for 168 weeks
3248749|NCT01369238|Experimental|Bee Venom Acupuncture & zaltoprofen|
3248750|NCT01369238|Active Comparator|zaltoprofen|
3248751|NCT01369238|Active Comparator|Bee Venom Acupuncture|
3248752|NCT01369251|Experimental|Hygiene with water and soap|
3248753|NCT01369251|Active Comparator|Usual alcohol care|
3361318|NCT04305925|Experimental|Focal Laser Ablation|The Orion system will be used to deploy and monitor thermal energy in cancerous regions of the prostate, identified by MRI and confirmed by targeted biopsy.
3361319|NCT04304508|Experimental|BAY2433334 high dose|
3361320|NCT04304508|Experimental|BAY2433334 medium dose|
3361321|NCT04304508|Experimental|BAY2433334 low dose|
3361322|NCT04304508|Placebo Comparator|BAY2433334 matching placebo|
3361323|NCT04303780|Experimental|AMG 510|
3361324|NCT04303780|Active Comparator|Docetaxel|
3361325|NCT04300309|Experimental|artemether lumefantrine (2.5 mg:30 mg)|artemether lumefantrine (2.5 mg:30 mg) bid over 3 days, from 1-4 tablets per dose
3361326|NCT04298567||Treatment|Female and male patients with a diagnosis of CAD or symptomatic PAD will be enrolled within 4 weeks after the decision for treatment with rivaroxaban 2.5mg [BID] plus ASA 75mg [OD] has been made by the investigator.
3361327|NCT04297592|Active Comparator|Group A - antibiotic group|Patients will be given 7-days of an oral antibiotic (either cephalexin or doxycycline) to be started after completion of standard perioperative intravenous antibiotics following primary hip or knee arthroplasty
3361328|NCT04297592|No Intervention|Group B - no additional antibiotic|No antibiotics will be prescribed following standard perioperative IV antibiotics following primary hip or knee arthroplasty.
3248754|NCT01369264|Experimental|True Left High Frequency|True left high frequency repetitive transcranial magnetic stimulation
3248755|NCT01369264|Placebo Comparator|Passive sham left high frequency|Passive sham left high frequency repetitive transcranial magnetic stimulation
3248756|NCT01369277|Experimental|Japanese cohort|A total of 12 Japanese healthy subjects will be allocated to receive 3 ascending single doses (100 mg, 300 mg and 750 mg) of PF-04991532 or placebo through 3 dosing periods in a randomization ratio of 3:1.
3361329|NCT04293094|Experimental|Dose Exploration Phase|Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.
3361330|NCT04293094|Experimental|Dose Expansion Phase Group 1: TNBC|Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
3361331|NCT04293094|Experimental|Dose Expansion Phase Group 2: HGSOC|Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.
3248757|NCT01369277|Experimental|Weterner Cohort|9 western healthy subjects will be enrolled to receive 2 single ascending doses (300 mg and 750 mg) of PF-04991532 through 2 dosing periods.
3248758|NCT01369290||Drug 1|Venlafaxine
3248759|NCT01369290||Drug 2|Bupropion
3248760|NCT01369290||Drug 3|Escitalopram
3248761|NCT01369290||Drug 4|Duloxetine
3248762|NCT01369290||Psychotherapy|Cognitive behaviour therapy
3361332|NCT04292275|Experimental|Digital Health Tools + Standard of Care|
3361333|NCT04292275|Other|Standard of Care|
3361335|NCT04283656|Other|Period I|Sequence E, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone Sequence F, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone
3361336|NCT04283656|Other|Period II|Sequence E and F, Treatment B: Single-dose estradiol and spironolactone co-administered with placebo
3361337|NCT04283656|Other|Period III|Sequence E, Treatment C: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate co-administered with estradiol and spironolactone Sequence F, Treatment A: Single-dose oral Doravirine/lamivudine/tenofovir disoproxil fumarate alone
3248763|NCT01369303|Experimental|Daily dosing|Tenofovir 1% gel will be inserted each day or evening at about the same time with the last study-sex 12 hours after the final dose
3248764|NCT01369303|Experimental|BAT24 dosing|Tenofovir 1% gel will be inserted 1 hour before and 1 hour after sex
3248765|NCT01369303|Experimental|Pericoital dosing|Tenofovir 1% gel will be inserted either 1 hour before sex OR 1 hour after sex
3361344|NCT04269070|Active Comparator|Move, Stand|Usual behavior condition, followed by the standing condition, followed by the LPA condition.
3361345|NCT04269070|Active Comparator|Stand, Move|Usual behavior condition, followed by the LPA condition, followed by the standing condition.
3361349|NCT04267562|Other|Single-Arm, Open-Label Treatment with the Minitouch System|Eligible participants will undergo a single treatment (endometrial ablation) with the Minitouch System
3248766|NCT01369316|Experimental|Circumferential Submucosal Incision Resection|
3248767|NCT01369316|Active Comparator|Endoscopic Mucosal Resection|Patients randomised into this arm will receive the conventional treatment Endoscopic Mucosal Resection in which the sessile lesion is injected and snared by piecemeal technique.
3248768|NCT01369368|Experimental|1|Azacitidine, valproic acid, all-trans retinoic acid, hydroxyurea, eventually donor leukocyte infusions
3248769|NCT01369381|Experimental|Airtraq laryngoscope|The Airtraq is an alternative indirect laryngoscope that appears to cause less cervical spine motion during intubation that conventional direct laryngoscopy (Macintosh blade)
3248770|NCT01369381|Active Comparator|Macintosh laryngoscope|This arm constitutes intubation with a conventional direct laryngoscopy with a Macintosh blade which has been shown to result in cervical spine extension, particularly in the upper cervical segments.
3248771|NCT01369394|Experimental|Tailored information|Individuals assigned to the experimental group will receive individually-tailored educational messages.
3248772|NCT01369394|Active Comparator|Untailored information|Individuals assigned to the control group will receive generic, untailored educational messages.
3248773|NCT01369407||Enrolled Subjects|Enrolled subjects participate for up to 2 years
3248774|NCT01369446||Women undergoing IVF treatment|
3248775|NCT01369459|Experimental|Family Counseling with MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
3248776|NCT01369459|No Intervention|Historical Control|
3248777|NCT01369472|Experimental|Dilatrend SR capsule 8mg|
3248778|NCT01369472|Experimental|Dilatrend SR capsule 16mg|
3248779|NCT01369472|Experimental|Dilatrend SR capsule 32mg|
3361353|NCT04261439|Experimental|Arm 1|Single agent arm. NIZ985 is administered as a single agent (subjects may be treated with the NIZ985-Spartalizumab combination after their first disease re-evaluation)
3361354|NCT04261439|Experimental|Arm 2|Combination arm. NIZ985 and Spartalizumab combination is administered starting at Cycle 1 Day 1
3361356|NCT04255823|Experimental|Multi-faceted intervention|"A patient education material on PPI deprescribing will be send to patients with long-term treatment with PPI (>300DDD/patient/year).~Their general practitioner (GP) will receive a dear doctor letter with an algorithm related to PPI deprescribing."
3361357|NCT04255823|Experimental|"Dear doctor letter of the GP"|"Only the GP will receive the dear doctor letter with the algorithm.~Their patients will not receive any patient education material."
3361358|NCT04255823|No Intervention|Control|Neither the patients nor their GP will receive information.
3361359|NCT04254809|Experimental|Re-Evaluating Suicidal Thoughts|Participants in this condition will complete the experimental intervention at the baseline appointment.
3248780|NCT01369472|Experimental|Dilatrend SR capsule 64mg|
3248781|NCT01369472|Experimental|Dilatrend SR capsule 128mg|
3248782|NCT01369524||ICUpatient with need of fluid|age > 18 - haemodynamic monitoring - informed consent - admission on ICU
3248783|NCT01369537||adults > 65 yrs undergoing noncardiac surgery|
3248784|NCT01369550|Placebo Comparator|High-oleic sunflower oil-containing foods|Subjects will consume 3 servings of foods containing high-oleic sunflower oil plus 3x500 mg high-oleic sunflower oils softgels per day.
3248785|NCT01369550|Active Comparator|Eicosapentaenoic acid|Subjects will consume 3 x 500 mg eicosapentaenoic acid ethyl ester in softgels plus 3 servings of high-oleic sunflower oil-containing foods per day
3248786|NCT01369550|Experimental|SDA soybean oil-containing foods|Subjects in this arm will consume 3 servings of SDA soybean oil-containing foods plus 3 x 500 mg high-oleic sunflower oil softgels per day.
3248787|NCT01369576|Placebo Comparator|Placebo|Usual sleep apnea and CPAP care Sleep apnea OSR Medical Treatment Plan©
3248788|NCT01369576|Experimental|zopiclone|Sleep apnea OSR Medical Treatment plan ©
3248789|NCT01369589|Experimental|P-552 on Day 1 and Placebo on Day 2|Randomly assigned subjects will receive a single dose of P-552 on Day 1 followed by a single dose of Placebo on Day 2
3361360|NCT04254809|Sham Comparator|Healthy Social Living|Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.
3248790|NCT01369589|Experimental|Placebo on Day 1 and P-552 on Day 2|Randomly assigned subjects will receive a single dose of Placebo on Day 1 followed by a single dose of P-52 on Day 2
3248791|NCT01369602|Experimental|healthy controls|healthy subjects (creatinine clearance > 90 mL/min)
3248792|NCT01369602|Experimental|ESRD / severe renal insufficiency|Severe (creatinine clearance 15 to 29 mL/min) OR ESRD (creatinine clearnace <15 mL/min OR requiring dialysis)
3361361|NCT04254484|Experimental|SIESTA Rehab|"Stroke floor on which nurses will be receiving training (SIESTA Rehab Education) on how to minimize nighttime disruptions and batching overnight tasks to preserve sleep for patients hospitalized on that floor. Stroke patients admitted to the SIESTA Rehab Unit will be screening for sleep disordered breathing using ApneaLink.~Patients hospitalized on this unit will be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
3361362|NCT04254484|No Intervention|Control Unit|"Patients on this unit will receive usual care for stroke patients as outlined by SRALab. including routine nursing care without any intervention to promote sleep like SIESTA and routing sleep disorders screenings based on clinician judgement.~Patients hospitalized on this unit will also be approached for consent to wear sensors and actigraphy watches during the hospital stay and after discharge."
3361363|NCT04253314||Venetoclax Participants|Participants treated with Venetoclax in accordance with approved local label. Decision to treat with Venetoclax was made prior to offering participation in this study.
3361364|NCT04251533|Experimental|alpelisib + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Single arm Open label in Study Part B1
3361365|NCT04251533|Placebo Comparator|placebo + nab-paclitaxel|Double-blinded, Randomized in a 1:1 ratio in Study Parts A and B2 Not applicable in Study Part B1
3361366|NCT04248933|Experimental|"Peer-Delivered Behavioral Activation (Peer Activate)"|Participants in the Peer Activate intervention will receive a PRC-delivered behavioral activation intervention to address barriers to retention in methadone treatment and increase substance-free, positive reinforcement to support retention.
3361370|NCT04240704|Experimental|JBH492 single agent|
3361371|NCT04233164|Experimental|1 mg/kg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
3361372|NCT04233164|Experimental|250 mg|The study agent solution will be administered as an IV infusion over 30 minutes, for a total single dose of 1 mg/kg or 250 mg of methylprednisolone.
3361373|NCT04230122|Experimental|10 milligram (mg) LY3478006 - Intravenous (IV)|Participants received single dose of 10 mg LY3478006 administered IV. Due to early termination of the study Cohort 2 to 6 (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg LY3478006 IV) were not explored for safety reasons following dosing of the first 4 participants in Cohort 1.
3361374|NCT04230122|Placebo Comparator|Placebo - IV|Participants received single dose of placebo administered IV. Placebo IV Cohorts 2 through 6 were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
3361375|NCT04230122|Experimental|100 mg LY3478006 - Subcutaneous (SC) (Cohort 7)|100 mg LY3478006 cohort 7 SC dose was not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
3361376|NCT04230122|Placebo Comparator|Placebo - SC (Cohort 7)|Placebo cohort 7 SC dose were not explored as study was terminated for safety reasons following dosing of the first 4 participants in cohort 1.
3361377|NCT04227288|Experimental|Enstilar Foam|Eligible subjects will be provided twice daily daily Enstilar Foam (calcipotriene and betamethasone dipropionate).
3361378|NCT04225156|Experimental|efgartigimod|patients receiving efgartigimod
3361379|NCT04223024|Experimental|CCRT + Nimotuzumab|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)
3248793|NCT01369602|Experimental|Moderate renal impairment|Moderate (creatinine clearance = 30 to 59 mL/min)
3248794|NCT01369602|Experimental|Mild renal impairment|Mild (creatinine clearance = 60 to 89 mL/min)
3361380|NCT04223024|Active Comparator|CCRT alone|Patients whose plasma EBV DNA> 0 copy/mL or SD/PD according to RECIST after two cycle induction chemotherapy( TPF :Paclitaxel liposome135mg/m2 d1+DDP 25mg/m2 d1-d3+ 5-fu 5-fu 750mg /m2/day civ120h, every 3 weeks for 2 courses) will have concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) )
3248795|NCT01369628|Experimental|Arm 1|"1 arm with the 3 following dose regimens:~Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
3248796|NCT01369654|Experimental|Computerized decision aid|
3248797|NCT01369667|Active Comparator|vitamin D|Capsule, one taken daily
3248798|NCT01369667|Placebo Comparator|Placebo|Capsule, one taken daily
3248799|NCT01369693|Active Comparator|General Portion 1 g pouch|
3248800|NCT01369693|Active Comparator|Catch Licorice Portion 1 g pouch|
3248801|NCT01369693|Active Comparator|Catch Licorice Portion Mini 0.5 g pouch|
3248802|NCT01369693|Active Comparator|Catch Licorice Portion Dry Mini 0.3 g pouch|
3361383|NCT04221542|Experimental|Dose exploration phase|"The dose exploration phase of the study will estimate the MTD of AMG 509 using a Bayesian logistic regression model (BLRM; Neuenschwander et al, 2008).~Recommended phase 2 dose (RP2D) may be identified based on emerging safety, efficacy, PK, and PD data, as well as patient experience prior to reaching an MTD. Alternative dosing schedule(s) (including a third step dose) may be explored based on emerging efficacy, safety, PK data and patient experience."
3361384|NCT04221542|Experimental|Dose expansion phase|A dose expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and correlative biomarker analysis.
3361385|NCT04221451|Experimental|GZ402671|"Primary population: participant will receive venglustat dose 1 once daily during 104 weeks.~Secondary population: participant will receive venglustat at various doses once daily during 104 weeks (open label period)."
3361386|NCT04221451|Placebo Comparator|Placebo|Primary population: participants will receive placebo once daily during 104 weeks.
3248803|NCT01369719|Experimental|Osveral|20 mg/kg oral osveral daily
3361396|NCT04204538||Urban|Young adults living in urban communities of Rwanda
3361397|NCT04204538||Rural|Young adults living in rural communities of Rwanda
3361398|NCT04202354|Experimental|ARO-HSD|
3361399|NCT04202354|Placebo Comparator|Placebo|
3361400|NCT04202107||Urban|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
3361401|NCT04202107||Rural|"Men and women between 18 and 49 years of age living in the selected urban communities in Rwanda and who are familiar with the diet.~Participants in this study should be acquainted with cooking practices to be able to cite all the ingredients that are used in the preparation of the dishes/ meals"
3248804|NCT01369719|Active Comparator|desferal|40mg/kg desferal for 6 nights in a week subcutaneously
3248805|NCT01369771|Experimental|Tafluprost 0.0015%|Open, one arm study. Patients who have been using latanoprost 0.005% eye drops (Xalatan®) as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost to the assigned preservative-free tafluprost 0.0015% (Taflotan®)eye drops for twelve (12) months.
3248806|NCT01369797|No Intervention|reference|"reference group, where every patient will benefit: of the same GGA at home as those of the  specific intervention  group. The GGA results will not be supplied to the family practioner."
3361404|NCT04194554|Experimental|Niraparid Dose Escalation|"Dose Level 1: 100 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 2: 200 mg PO daily of Niraparib but held for 5 days (+/- 2 days) prior to RT, during SBRT, and 5 days (+/- 2 days) after last fraction of SBRT~Dose Level 3: 200 mg PO daily of Niraparib without breaks during SBRT until completion of 6 cycles."
3361405|NCT04192591|Experimental|Superion® IDS device|Superion® Indirect Decompression System (IDS)
3361412|NCT04186429||traumatic brain injury|Children with traumatic brain injury
3361413|NCT04186429||orthopedic injury|Children with orthopedic injury
3361414|NCT04182997|Placebo Comparator|Placebo Group|Patients in this group will be given the placebo (sterile saline).
3361415|NCT04182997|Active Comparator|Dexamethasone Group|Patients in this group will be given the study drug (dexamethasone).
3361416|NCT04167423||Healthy|No thyroid disease in pregnancy defined as plasma TSH (thyrotropin), TPOAb (thyroperoxidase auto antibodies) or FT4 (free thyroxin) out of the ranges proposed by 2017 American Thyroid Association Guideline.
3361417|NCT04167423||hyperthyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
3361418|NCT04167423||hypothyroidism|Thyroid disease in pregnancy defined as plasma TSH, or FT4 out of the ranges proposed by 2017 American Thyroid Association Guideline.
3361419|NCT04167423||thyroid autoimmunity|Thyroid disease in pregnancy defined as plasma TPOAb out of the ranges proposed by 2017 American Thyroid Association Guideline.
3361421|NCT04154956|Experimental|SAR408701 (tusamitamab ravtansine)|Administered intravenously once every 2 weeks
3361422|NCT04154956|Active Comparator|Docetaxel|Administered intravenously once every 3 weeks
3361425|NCT04137731|Experimental|IFC Treatment|The IFC treatment will be used for 30 minutes, twice a day for two days after the total knee arthroplasty
3361426|NCT04137731|Placebo Comparator|Placebo|One set of device is programmed to be used as Placebo, the subject will feel the vibration but will not receive a therapeutic signal.
3361427|NCT04137354|Placebo Comparator|Control Iron&Vitamin A Placebo|Children randomly assigned to the placebo iron & vitamin A control group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months).
3361428|NCT04137354|Experimental|Vitamin A & Placebo Iron Supplements|Children is this group will receive weekly three placebo tablets that are identical to the iron tablets (blinded) for the whole duration of the study (9 months of the school year). They will also receive a high dose vitamin A capsule (200,000IU) at baseline and after 4.5 months (at mid-line)
3361429|NCT04137354|Experimental|Intermittent Iron Supplements & Placebo Vitamin A|"Children is this group will receive weekly three tablets of iron (42mg of elemental iron once a week) for 9 months (equivalent to a one school year).~They will also receive placebo vitamin A at baseline and at mid-line (after 4.5 months)."
3361430|NCT04137354|Experimental|Intermittent Iron Supplements & High dose Vitamin A|Combined weekly iron supplementation (42mg of elemental iron once a week) for 9 months and high dose vitamin A (200,000IU) at baseline and after 4.5 months (mid-line).
3361431|NCT04126395||Controls|"This groups consists of children now aged 6-12y:~Without a medical diagnosis possibly influencing motor development~Without motor problems (M-ABC-2 and DCD-Q)~Without social reponsiveness problems (SRS-2)"
3361432|NCT04126395||Developmental Coordination Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)~Without social responsiveness problems (SRS-2)"
3361433|NCT04126395||Developmental Coordination Disorder + Autism Spectrum Disorder|"This groups consists of children now aged 6-12y:~With a multidisciplinary diagnosis of DCD~With motor problems (M-ABC-2 and DCD-Q)~With social responsiveness problems (SRS-2)"
3248807|NCT01369797|Experimental|specific intervention|"specific intervention group, where every patient will benefit: of an GGA at home. According to the frailties or the detected morbidity, a specific plan of intervention will be established for the person. all the preventive actions will be coordinated by UPSAV."
3248808|NCT01369810||1|All patients who was on treatment with fixed combination asthma or COPD therapy by January 1 2010
3248809|NCT01369836|Experimental|20 mg soft gelatin capsule|
3248810|NCT01369836|Experimental|40 mg (20 mg*2) soft gelatin capsule|
3248811|NCT01369836|Active Comparator|Placebo|
3248812|NCT01369862|Placebo Comparator|SPGNH buffer|SPGNH buffer administration by liquid nasal spray
3248813|NCT01369862|Experimental|GHB16L2|Dose level ~7.0 log10 fTCID50/strain/person
3248814|NCT01369901|Experimental|Group A|Functional exercise
3248815|NCT01369901|Active Comparator|Group B|Stretching exercise
3361436|NCT04125836|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, 12 months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
3361437|NCT04124653|Experimental|PF-06842874/Placebo|Single dose administration of PF-06842874 or placebo
3361438|NCT04124653|Experimental|Relative Bioavailability|Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation
3361439|NCT04123418|Experimental|WVT078 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
3361440|NCT04123418|Experimental|WVT078 in combination with WHG626 in Multiple Myeloma (MM) patients|Dose escalation study to determine Maximum Tolerated Dose (MTD)/ Recommended Dose (RD) in adult patients with relapsed and/or refractory Multiple Myeloma (MM)
3361441|NCT04112641|Placebo Comparator|Placebo capsules|Subjects will take 2 capsules in the a.m. and 2 capsules in the p.m. daily for 84 days.
3361442|NCT04112641|Experimental|Nicotinamide Riboside (NIAGEN)|Subjects will take 2 250-mg capsules in the a.m. and 2 250- mg capsules in the p.m. daily (total daily dose is 1 g) for 84 days.
3248816|NCT01369940||NICHD Fetal Growth Study - Twin Gestations|"Women with dichorionic twin gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2012-2013) in this prospective cohort study.~Intervention: No intervention"
3248817|NCT01369979||Patients with chronic liver disease|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
3361443|NCT04110366|Experimental|Live attenuated influenza vaccine|Participants receiving live attenuated influenza vaccine (LAIV)
3361444|NCT04110366|Experimental|Mucosal immune stability cohort|Participants receiving a vehicle control nasal challenge
3361447|NCT04102865|Other|single use NPWT dressing|single use NPWT dressing
3361453|NCT04090411|Experimental|450 mg|PF-06480605
3361454|NCT04090411|Experimental|150 mg|PF-06480605
3361455|NCT04090411|Experimental|50 mg|PF-06480605
3361456|NCT04090411|Placebo Comparator|0 mg|
3361457|NCT04086693|Active Comparator|Standard IV dressing|Polyurethane dressing with clear tape
3248818|NCT01369979||Healthy subjects|"Inclusion criteria~Age between 40 and 70 years~BMI between 20 and 26~Exclusion Criteria~Diabetes mellitus~Glucose intolerance~Medical treatment of portal hypertension~People who have undergone surgery for obesity~Pregnancy"
3361458|NCT04086693|Experimental|Standard IV dressing plus Adhezion SecurePortIV|Polyurethane dressing with clear tape plus Adhezion Biomedical SecurePortIV (a tissue adhesive peripheral IV securement device).
3361461|NCT04084470|Active Comparator|Bread types 1, 2 and 3|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
3361462|NCT04084470|Active Comparator|Bread types 4, 5 and 6|Daily consumption of 5 slices of allocated bread type for three intervention days (separated by a wash-out period of at least 7 days).
3361463|NCT04080167|Other|Arm 1 (InCharge Health app)|Patient receives the InCharge Health app for 6 months
3361464|NCT04080167|Other|Arm 2 (HU Toolbox app)|Provider receives the HU Toolbox app for 9 months
3248819|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® administered via AeroChamber Plus™ spacer
3248820|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™|Clenil® Modulite® administered via Volumatic™ spacer
3248821|NCT01370031|Experimental|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® administered via AeroChamber Plus™ spacer plus charcoal block
3361465|NCT04077619|Experimental|Modern pain neuroscience approach|Behavioral: Modern pain neuroscience approach
3361466|NCT04077619|Active Comparator|Usual care evidence-based physiotherapy|Behavioral: Usual care evidence-based physiotherapy
3361467|NCT04077541|Experimental|The experimental group|The trauma care bundles combined with the internet platform.
3361468|NCT04077541|No Intervention|The control group|Only trauma care bundles.
3248822|NCT01370031|Active Comparator|Clenil® Modulite® via Volumatic™ plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
3248823|NCT01370044|Experimental|Verum|Verum arm receiving Carbogen
3248824|NCT01370044|Placebo Comparator|Placebo|Placebo arm receiving oxygen
3248825|NCT01370057|Experimental|Treatment Group|Treatment with bracing
3248826|NCT01370057|No Intervention|Control Group|Watchful waiting without bracing
3361469|NCT04077086|Experimental|Intervention|Children at Intervention schools will receive free spectacles of a design they select, based on the child's measured refractive power and dispensed at school by the study optometrist. Additionally, teachers (but not children) in eligible classes will be informed that if 80% spectacle compliance as measured across three separate unannounced inspections was achieved, they will be given an incentive of an conditional cash transfer. The cash transfer will be deposited into the teacher's bank accounts directly.
3248827|NCT01370070|Experimental|MK-2206|
3248828|NCT01370109||Penn Site|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks, with additional follow-up at 1 and 2 years.
3361470|NCT04077086|No Intervention|Control|Children at Control schools will receive a glasses prescription and letter to the parents informing them of the refractive status of their child, with free glasses provided only at the end of the trial. No teacher incentive will be offered. Service offered to the Control group exceeds standard care, in that no school-based programs of vision screening and refraction currently exist in the study area, or in most of rural China.
3361471|NCT04076644|Active Comparator|TMS Treatment Arm|Subjects will receive either a 20min 10hz TMS treatment, or a 3min theta-burst TMS treatment at certain monthly intervals. The TMS treatment protocol they receive depends on what they received in their acute clinical treatment. Subjects in the arm will be tapered off antidepressant medication before TMS treatment begins. Subjects will be assessed monthly for depression using QIDS and PHQ9.
3248829|NCT01370109||Vanderbilt University Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3248830|NCT01370109||Case Medical Center|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3361472|NCT04076644|No Intervention|No TMS Arm|Subjects will be followed and assessed for depressive symptoms at monthly time intervals similar to the active treatment arm using QIDS and PHQ9. This group does not receive TMS treatment.
3361473|NCT04076462|Experimental|CAM2029 (octreotide subcutaneous depot)|CAM2029 (octreotide subcutaneous depot) 20mg/1.0 mL for 20 mg dose, subcutaneous injection once monthly, six months treatment. If down-titration is required, 10mg/0.5 mL for 10 mg dose is available.
3248831|NCT01370109||University of Wisconsin at Madison|Patients with renal cell cancer newly undergoing therapy with the oral tyrosine kinase inhibitor sunitinib will be recrutied and observed over a period of approximately 33 weeks.
3248832|NCT01370122||Subjects exposed to radiation|
3361474|NCT04076462|Placebo Comparator|Matching placebo|Placebo (subcutaneous depot) 1.0 mL, subcutaneous injection once monthly, six months treatment. If down-titration is required, 0.5 mL dose is available.
3361475|NCT04070313|Experimental|S-1|single-arm
3248833|NCT01370122||Subjects not exposed to radiation|
3248834|NCT01370135|Experimental|Lucentis (Ranibizumab)|
3248835|NCT01370148|Experimental|Subjects with severe hepatic impairment|
3361476|NCT04069026|Experimental|Dose escalation of BAY2416964|Approximately 8 dose levels of BAY2416964 are planned
3361477|NCT04069026|Experimental|Dose expansion of BAY2416964 in tumor type specific|Patients with NSCLC, HNSCC, Urothelial cancer and Colorectal cancer MSS
3248836|NCT01370148|Active Comparator|Subjects with normal hepatic function|
3248837|NCT01370161|Experimental|TIPS treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
3361480|NCT04068181|Experimental|Talimogene Laherparepvec and Pembrolizumab|To evaluate the efficacy and safety of talimogene laherparepvec in combination with pembrolizumab following disease progression on prior anti-PD-1 therapy in unresectable/metastatic melanoma (stage IIIB-IVM1d) or prior anti-PD-1 therapy in the adjuvant setting.
3248838|NCT01370161|Active Comparator|Medical treatment|Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.
3248839|NCT01370187|No Intervention|Control|Control group
3248840|NCT01370187|Experimental|Montelukast|4mg Montelukast daily for 2 months
3248841|NCT01370200|Active Comparator|4% citrate|4% trisodium citrate, starting infusion rate 180 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
3248842|NCT01370200|Active Comparator|15% citrate|15% trisodium citrate, starting infusion rate 50 ml/h Interventions according to postfilter ionized calcium, change in 10 ml/h step
3248843|NCT01370226|Active Comparator|CBI|Computer delivered Brief Intervention
3361486|NCT04052555|Experimental|Treatment (berzosertib, radiation therapy)|Patients receive berzosertib IV over 60 minutes BIW for 5 weeks in the absence of disease progression or unacceptable toxicity. Patients also undergo RT 5 days a week for 5-6 weeks depending on the type of surgery undergone.
3248844|NCT01370226|Active Comparator|TBI|Therapist delivered Brief Intervention
3248845|NCT01370226|No Intervention|EUC|Enhanced Usual Care
3248846|NCT01370239|Experimental|Hu3S193|Single arm
3361487|NCT04051229|Experimental|Exercise Training Group|All 20 participants will be assigned to this arm. These individuals will participate in 6 weeks of a moderate supervised aerobic exercise training program.
3361488|NCT04045145|Experimental|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
3361489|NCT04039841|Other|Motor imagery evaluation|cohort study
3361490|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccinations (high dose)|14 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and day 28
3361491|NCT04033068|Experimental|Two MV-ZIKA-RSP vaccination (low dose)|14 Participants will receive MV-ZIKA-RSP 2,5 x10E4 /dose on day 0 and day 28
3361492|NCT04033068|Experimental|One MV-ZIKA-RSP vaccination (high dose) and one placebo|12 Participants will receive MV-ZIKA-RSP 1 x10E5/dose on day 0 and placebo on day 28
3248847|NCT01370252||scope technique|
3248848|NCT01370252||open technique|
3248849|NCT01370278|Active Comparator|Normal Saline|Normal saline sprayed into stent/airway tubes then suctioned out through bronchoscope.
3361493|NCT04033068|Placebo Comparator|Two placebo injection|8 Participants will receive placebo on day 0 and placebo on day 28
3248850|NCT01370278|Active Comparator|Sodium Bicarbonate|Sodium bicarbonate sprayed into stent/airway tubes then suctioned out through bronchoscope.
3248851|NCT01370291|Active Comparator|active Risperidone and active rTMS|active Risperidone and active rTMS for the first-episode schizophrenia patients
3248852|NCT01370291|Experimental|active rTMS and sham Risperidone|active rTMS and sham Risperidone for the first-episode schizophrenia
3248853|NCT01370291|Sham Comparator|sham rTMS and active Risperidone|sham rTMS and active Risperidone for the first-episode schizophrenia patients
3248854|NCT01370304|Experimental|active rTMS and active Venlafaxine|
3248855|NCT01370304|Experimental|active rTMS and sham Venlafaxine|
3248856|NCT01370304|Sham Comparator|sham rTMS and active Venlafaxine|
3248857|NCT01370343|Experimental|PF-04991532 alone|
3248858|NCT01370343|Experimental|PF-04991532 + cyclosporine|
3248859|NCT01370382||Time interval|"Patients are divided according to the interval between the onset of chest pain symptoms and presentation at the hospital in an early(<4 hours) and late(> = 4 hours) group."
3248860|NCT01370395||Left ventricular function|According to the result of the echocardiographic exam, the patients will be divided into subgroups with (LV-EF>=55%) and without preserved ejection fraction (LV-EF<55%).
3248861|NCT01370421||Knee OA patients undergoing Total Knee Arthroplasty (TKA)|Participants will be 45 years or older, diagnosed with Osteoarthritis of the knee and be scheduled for a unilateral total knee replacement surgery.
3248862|NCT01370434|No Intervention|VAD combination|"vincristine 0.4mg iv on D1-4~doxorubicin 9mg/m2 iv on D1-4~dexamethasone 40mg/d po on D1-4,9-12,17-20~Many physicians use vincristine, doxorubicin, and dexamethasone (VAD) for three to four months as induction therapy (Alexandrian et al, 1990). VAD produces partial response (PR) in about 50% patients, with complete response (CR) observed in 5%-10% patients (Kyle et al, 2004)."
3248864|NCT01370486|Active Comparator|melatonin|
3248865|NCT01370486|Placebo Comparator|placebo|
3248866|NCT01370512|Active Comparator|Droxidopa / Pyridostigmine|
3248867|NCT01370512|Placebo Comparator|Droxidopa|
3248868|NCT01370512|Placebo Comparator|Pyridostigmine|
3248869|NCT01370551|Experimental|Gynoflor|This study consists only of this arm.
3248870|NCT01370577||1|Total 300 subjects who was diagnosed with asthma
3248871|NCT01370668|Experimental|Functional remediation|"Patients assigned to the experimental treatment will receive standard psychiatric care and will be enrolled in the neurocognitive intervention program composed of 21 sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 8-to-10 patient group conducted by 2 experienced neuropsychologists. with previous experience with bipolar patients (at least 3 years) and specific training on patients' group management."
3361505|NCT04023227|Experimental|Sacubitril/valsartan|"Sacubitril/valsartan 200 mg b.i.d.~Following randomization, patients will receive sacubitril/valsartan in titrated doses from level 1 up to level 3 (50, 100 and 200 mg twice daily).~Participants taking ACEIs who are randomized to sacubitril/valsartan will do a 36-hour ACEI washout before they start taking the study drug~Sacubitril/valsartan in dose levels of 50 mg, 100 mg, and 200 mg are equivalent to sacubitril/valsartan 24/26 mg, 49/51 mg and 97/103 mg, respectively"
3361506|NCT04023227|Active Comparator|Enalapril|"Enalapril 10 mg b.i.d.~Following randomization, patients will receive the enalapril in titrated doses from level 1 up to level 3 (2.5, 5 and 10 mg twice daily)."
3361507|NCT04020198||Parkinson's Disease|Subjects who have a PD diagnosis
3361508|NCT04020198||Multiple System Atrophy|Subjects who have an MSA diagnosis
3361509|NCT04020198||Age-matched controls|Subjects who do not have a diagnosed parkinsonian disorder
3361510|NCT04020198||Rapid Eye Movement Sleep Behavior Disorder (RBD)|Subjects who have a diagnosis of RBD
3361511|NCT04020198||Normal Pressure Hydrocephalus|Subjects who are prescribed a lumbar puncture to treat normal pressure hydrocephalus
3361512|NCT04019275|Experimental|ENGAGE|The intervention blends social learning, guided discovery, and skill training to promote community participation after stroke. The intervention is delivered in a group format and comprises group learning activities and individual action planning activities that address barriers to community participation after stroke.
3361513|NCT04006405||Cohort 1|140 patients with a minimum follow-up of 12 months
3361514|NCT04006405||Cohort 2|up to 140 patients with a minimum follow-up of 12 months
3361515|NCT04004767||TRC-PAD Cohort|Individuals identified as being at an increased risk for memory loss caused by Alzheimer's disease dementia. Determination of risk based on a number of factors including family history, performance on memory tests, genetic tests and biomarker tests.
3361516|NCT04002037|Active Comparator|Triamcinolone 40mg/mL|A corticosteroid injection of Triamcinolone 40mg/mL will be given to subjects to treat their symptoms of trigger finger.
3361517|NCT04002037|Active Comparator|Triamcinolone 10mg/mL|A corticosteroid injection of Triamcinolone 10mg/mL will be given to subjects to treat their symptoms of trigger finger.
3361518|NCT04002037|Active Comparator|Soluble dexamethasone 4mg/mL|A corticosteroid injection of Soluble Dexamethasone 4mg/mL will be given to subjects to treat their symptoms of trigger finger.
3248872|NCT01370668|Active Comparator|Psychoeducation|The group psychoeducation is a tested (Colom et al, 2003) and manualized intervention (Vieta and Colom, 2006) consisting on 21 sessions of 90 minutes, aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences and lifestyle regularity. The program will be performed in an 8-10 patient group conducted by 2 experienced psychologists with previous experience with bipolar patients and specific training on patients' group management. The structure of each session consists of a 30 to 40 minute speech on the topic of the day, followed by an exercise related to the issue (eg. drawing a life chart, writing a list of potential triggering factors) and a discussion.
3248873|NCT01370668|Active Comparator|Treatment as Usual|This arm will not receive any sort of add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
3361519|NCT04001062|Active Comparator|Non-operatively|"Adults 18 and older~Native English-speaker~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
3361520|NCT04001062|Active Comparator|Surgical|"Adults 18 and older~Native English-speaker~Non-thumb isolated single metacarpal shaft closed fracture (both scissoring and non-scissoring injuries)"
3248874|NCT01370681|Experimental|Group1|
3361521|NCT04000529|Experimental|TNO155 in combination with spartalizumab|TNO155 in combination with spartalizumab
3361522|NCT04000529|Experimental|TNO155 in combination with ribociclib|TNO155 in combination with ribociclib
3248875|NCT01370681|Experimental|Group2|
3248876|NCT01370707|Active Comparator|Metformin|
3248877|NCT01370707|Experimental|CJ-30001/CJ-30002|
3248878|NCT01370720|Active Comparator|Recoclix (CM&D Pharma Limited)|Recoclix: two tablets per day for 12 weeks
3248879|NCT01370720|Placebo Comparator|Placebo|IBS patients
3361525|NCT03988634|Experimental|sacubitril/valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose for patients randomized to sacubitril/valsartan (LCZ696) will be determined by patient's previous dose of ACEi/ARB immediately prior to hospital admission for acute decompensated heart failure. Study treatment will be titrated to the target dose of sacubitril/valsartan (LCZ696) 97/103 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active sacubitril/valsartan and one tablet of valsartan matching placebo pack)."
3361526|NCT03988634|Active Comparator|valsartan|"randomized in a 1:1 ratio: sacubitril/valsartan to valsartan for up to approximately 20 months of double-blind treatment.~Initial dose at randomization will be based on patient's previous dose of or lack of ACEi/ARB immediately prior to current hospital admission for ADHF, or at the time of out-of-hospital randomization.~Study treatment will be titrated to the target dose of valsartan 160 mg twice daily (Dose Level 3).~Patients will be required to take a total of two tablets twice daily (one tablet of active valsartan and one tablet of sacubitril/valsartan (LCZ696) matching placebo pack)."
3248880|NCT01370746||Cross-Sectional Study Group|Cross-sectional comparison of perceived barriers to adherence to post-transplant immunosuppressant regimens in parents/legal guardians of children 0-11 years versus adolescents 12-21 years
3361527|NCT03986034|Experimental|Relapsed/Refractory CLL pts|Ages 18 and older
3361528|NCT03985384|Active Comparator|Semaglutide|Semaglutide 2mg/1.5 ml (1.34 mg/ml) Prefilled pen for SQ injection
3361529|NCT03985384|Placebo Comparator|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
3361530|NCT03968419|Experimental|canakinumab monotherapy|All patients will receive canakinumab (ACZ885) prior to surgery
3361531|NCT03968419|Experimental|canakinumab + pembrolizumab|All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery
3361532|NCT03968419|Experimental|pembrolizumab monotherapy|All patients will receive 2 doses of pembrolizumab prior to surgery
3361533|NCT03963427|Other|Irradiated women|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap.
3361534|NCT03963427|Other|Non-irradiated women|Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
3361535|NCT03961516||Cystic Fibrosis, Pancreatic Sufficient|CF patients with exocrine pancreatic sufficiency
3361536|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, No Insulin|CF patients with exocrine pancreatic insufficiency but not treated with insulin therapy
3361537|NCT03961516||Cystic Fibrosis, Pancreatic Insufficient, Treated with Insulin|CF patients with exocrine pancreatic insufficiency who are treated with insulin therapy for CFRD
3361538|NCT03955445|Experimental|Open Label LNP023|LNP023 capsules formulation
3361539|NCT03954938|Sham Comparator|Neutral-Look|Subjects will be instructed to look at cocaine associated images and respond naturally.
3361540|NCT03954938|Experimental|Positive|Subjects will be instructed to look at cocaine associated images and anticipate the positive aspects of engaging with the items shown.
3248881|NCT01370746||Longitudinal Study Group|Subset of Cross-Sectional Study Group to evaluate whether perceived barriers to adherence increase with time during the first year following transplantation
3248882|NCT01370759|Experimental|Colon-targeted cleaning capsule|
3361541|NCT03954938|Active Comparator|Negative|Subjects will be instructed to look at cocaine associated images and anticipate the negative aspects of engaging with the items shown.
3361542|NCT03951480|Experimental|Manual medicine|
3361543|NCT03951480|Active Comparator|Corticosteroids infiltration|
3361544|NCT03940352|Experimental|treatment arm1: HDM201+MBG453|Phase Ib (escalation)
3361545|NCT03940352|Experimental|treatment arm2: HDM201+venetoclax|Phase Ib (escalation)
3361546|NCT03940157|Experimental|Oh Happy Day Class - Still I Rise|The Oh Happy Day Class-Still I Rise (OHDC-SIR) is a one-time, 4-hour class focused on awareness of depression and healthy self-management strategies ( a workbook is created with the class content). The class is offered in non clinical setting, but will be delivered in a classroom setting at the University. The class will be taught by the PI Dr. Ward, who is an associate professor and licensed psychologist, and Dr. Ward's research program manager, Lucretia Sullivan-Wade.
3361547|NCT03937986|Placebo Comparator|Placebo|Subjects will be maintained on oral placebo. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
3361548|NCT03937986|Experimental|Suvorexant Dose 1|Subjects will be maintained on oral suvorexant dose 1. Cocaine will be administered acutely during suvorexant dose 1 maintenance. Placebo will be administered acutely during suvorexant dose 1 maintenance.
3361549|NCT03937986|Experimental|Suvorexant Dose 2|Subjects will be maintained on oral suvorexant dose 2. Cocaine will be administered acutely during suvorexant dose 2 maintenance. Placebo will be administered acutely during suvorexant dose 2 maintenance.
3361550|NCT03937986|Experimental|Suvorexant Dose 3|Subjects will be maintained on oral suvorexant dose 3. Cocaine will be administered acutely during suvorexant dose 3 maintenance. Placebo will be administered acutely during suvorexant dose 3 maintenance.
3259416|NCT01470677|Experimental|application of Tachosil fibrin patches|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group.
3259417|NCT01470677|No Intervention|Control group|In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
3361555|NCT03935854|Experimental|Ketogenic Diet 16 Week Group|Patients follow ketogenic diet for 16 weeks, with monitoring of physical and psychological health and coaching support
3361556|NCT03931681|Experimental|Experimental: Phase 1 - Dose Escalation|Dose escalation trial evaluating OKI-179 given orally on a daily basis. Patients will take OKI-179 orally (PO) on Days 1 - 4, 8 - 11 and 15 - 18 in 21-day cycles (± 3 days), under fasted conditions. The design is a modified 3+3 design to determine the maximum tolerated dose and allows for additional cohorts enrolling subjects with an alternative dosing schedule such as OKI-179 orally (PO) daily on Days 1 - 5, 8 - 12 and 15 - 19 per 21-day cycles or Days 1 - 21 per 21-day cycles to determine the maximum tolerated dose for continuous daily dosing.
3248883|NCT01370772|Active Comparator|Standard R-FC arm|"Standard R-FC arm 6 cycles every 28 days~Cycle 1:~Rituximab : 375 mg/m² i.v on day 1~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days For patients with Leucocyte count > 25* G/L : rituximab in two equal doses at D1, D2~Cycle 2-6:~Rituximab: 500 mg/m² i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
3248884|NCT01370772|Experimental|DenseR-FC arm|"DenseR-FC arm =1 prephase R Dense course +6 R-FC courses~Prephase:~- Rituximab: 500 mg on day 0, 2000 mg on days 1, 8, and D15 For patients with Leucocyte count > 25* G/L : rituximab 250 mg D-1, D0 prephase~Cycle 1-6 (cycle 1 beginning at D22):~Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days~Fludarabine : 40 mg/m² per os, days 2-4, repeated every 28 days~Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days"
3248885|NCT01370798|Experimental|promestriene|Children with severe hypospadias treated with promestriene 1%
3248886|NCT01370798|Placebo Comparator|Placebo|Control group, children with severe hypospadias treated with Placebo.
3248887|NCT01370811|Placebo Comparator|OC oral solution treatment D|Placebo
3248888|NCT01370811|Experimental|OC oral solution treatment C|High dose oxybutynin and clonidine
3248889|NCT01370811|Experimental|OC oral solution treatment A|Low dose oxybutynin and clonidine
3248890|NCT01370811|Experimental|OC oral solution treatment B|Intermediate dose oxybutynin and clonidine
3248891|NCT01370824||Basal cell carcinoma|"- Population: Eligible are patients (men and women) ≥18 years of age who visit the outpatient department of dermatology of the Maastricht University Medical Centre because of a clinically suspected BCC.~- Inclusion criteria: All patients aged 18 years or older, otherwise healthy, with ≤ three primary (no previous treatment) clinically determined BCC.~- Exclusion criteria: Patients using immunosuppressive drugs. Genetic skin cancer disorders. Earlier treatments at the same site. Age under 18 years. More than 3 clinical suspected BCCs. Not capable of informed consent."
3361581|NCT03871348|Experimental|SAR441000 Dose Escalation Phase|SAR441000 will be administered as intratumoral injection as monotherapy in patients with solid tumors over a 28-day cycle
3361582|NCT03871348|Experimental|SAR441000 + cemiplimab - Dose Escalation Phase|SAR441000 will be administered as intratumoral injection in patients with solid tumors in combination with cemiplimab over a 21-day cycle
3361583|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 failure|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced melanoma who have failed anti-PD-1/PD-L1 therapy. Treatment is administered over a 21-day cycle
3361584|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion Melanoma, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve melanoma over a 21-day cycle
3361585|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion CSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Cutaneous Squamous Cell Carcinoma (CSCC) over a 21-day cycle
3361586|NCT03871348|Experimental|SAR441000 + cemiplimab Expansion HNSCC, anti-PD-1 naive|SAR441000 will be administered intratumorally at the determined recommended dose in combination with cemiplimab to patients with advanced anti-PD-1/PD-L1 naïve Head and Neck Squamous Cell Cancer (HNSCC) over a 21-day cycle
3361592|NCT03844750|Experimental|Treatment (vactosertib, pembrolizumab, surgery)|"Neoadjuvant pembrolizumab will be administered at a fixed dose of 200 mg (IV) for 1 cycle plus 200 mg vactosertib (PO QD, 5 days per week x 2 weeks).~Adjuvant pembrolizumab (400 mg IV) + vactosertib (200 mg PO QD Cycle 1, 5 days per week, Cycles 2 and beyond (200 mg BID, 5 days per week) will be administered for up to eight 6-week cycles"
3248892|NCT01370850||Normal|Normal results from the clinical exam and free of ocular pathology.
3361593|NCT03839823|Active Comparator|Comparator arm|Combination chemotherapies of docetaxel/capecitabine, paclitaxel/gemcitabine or capecitabine/vinorelbine will be administer to patients enrolled in the control group. The chemotherapy regimen will be decided by the treating physician.
3361594|NCT03839823|Experimental|Ribociclib arm|"Combination of non-steroidal aromatase inhibitor: NSAI (letrozole or anastrozole) + goserelin + ribociclib.~Ribociclib (600 mg) is dosed orally for the first 21 days out of a 28 day cycle.~Letrozole (2.5 mg) or anastrozole (1 mg) are dosed orally daily (28 days out of the 28 day cycle).~Goserelin (3.6 mg) is continuously released via a subcutaneous implant injected on Day 1 of each 28 day cycle (regardless of ribociclib treatment cycle) with an administration window of + 3 days."
3361597|NCT03833713|Experimental|SMS Intervention|Once-weekly automated SMS dialogue sessions or micro-interventions and use behavior change techniques including self-monitoring with performance feedback and goal support
3361598|NCT03833713|Active Comparator|SMS Assessments|Once-weekly SMS assessments related to their target risk behavior without receiving any feedback or goal support
3361599|NCT03829501|Experimental|KY1044 monotherapy phase 1|KY1044 monotherapy dose escalation
3361600|NCT03829501|Experimental|KY1044 and atezolizumab phase 1|KY1044 and atezolizumab combination dose escalation
3361601|NCT03829501|Experimental|KY1044 monotherapy phase 2|KY1044 monotherapy
3361602|NCT03829501|Experimental|KY1044 and atezolizumab phase 2|KY1044 and atezolizumab combination
3361603|NCT03822897|Other|Two Treatment Options|"Option #1 - Radiotherapy 35 fractions, 5/wk, 7 wks 70Gy/56Gy Cisplatin 100mg/m2 on day 1, 22 and 43 or 40mg mg/m2/wk for 7 wks~Option #2 - Radiation only-35 fraction, 6/wk, 6wks 70Gy/56Gy"
3361604|NCT03822468|Experimental|Ribociclib 400 mg|Ribociclib 400 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+goserelin in premenopausal women)
3361605|NCT03822468|Active Comparator|Ribociclib 600 mg|Ribociclib 600 mg QD 3 weeks on/1 week off + letrozole or anastrozole (+ goserelin in premenopausal women)
3248893|NCT01370850||Glaucoma|Clinical exam results consistent with glaucoma; visual field defects consistent with glaucoma and/or structural damage consistent with glaucoma.
3361606|NCT03806491|Experimental|CBT-I + AUD-TAU|Individual Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered once a week for five (5) weeks.
3361607|NCT03806491|Active Comparator|Sleep Hygiene + AUD-TAU|Sleep hygiene education delivered once to all participants
3361608|NCT03799146|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
3361609|NCT03799146|Experimental|Waiting List control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
3361610|NCT03799003|Experimental|ASP1951 Monotherapy Escalation|The monotherapy escalation cohort will evaluate escalating dose levels of ASP1951.Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
3361611|NCT03799003|Experimental|ASP1951 Monotherapy Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in a monotherapy or combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable.
3248894|NCT01370850||Retina|Clinical exam results consistent with retina pathology.
3248895|NCT01370876|Experimental|Oxaliplatin/5-FU|
3248896|NCT01370889|Experimental|Basic Science (resveratrol)|Patients receive resveratrol PO QD for 12 weeks.
3248897|NCT01370902|Experimental|Single-dose (SD) trial part (i.v.)|
3248898|NCT01370902|Experimental|Single-dose (SD) trial part (s.c.)|
3361612|NCT03799003|Experimental|ASP1951 Optional Monotherapy Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
3248899|NCT01370902|Experimental|Multiple-dose (MD) trial part (s.c.)|
3248900|NCT01370915|Experimental|Pregabalin|Patients receive oral placebo 150 mg 1hour prior to septal surgery, and 12 hours later
3361613|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Escalation|The combination escalation cohort will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab. Dose escalation to the next level will be made based on the Bayesian Continual Reassessment Method (CRM).
3361614|NCT03799003|Experimental|ASP1951 plus pembrolizumab Combination Expansion|If a confirmed response (partial Response (PR) or complete response (CR)) occurs in the combination escalation cohort, a tumor-specific expansion cohort may be opened in that tumor type, at the dose level in which the confirmed response was observed and at all subsequent dose levels once each dose level has been deemed tolerable. Once the high dose RP2D and schedule of ASP1951 in combination with pembrolizumab has been determined, expansion cohorts may be opened to enroll participants with NSCLC (all PD-L1 status), NSCLC PD-L1 high, SCCHN and cervical cancer (if any of these tumor specific expansion cohorts are not already opened). Also, low dose cohorts of ASP1951 in combination will be opened in NSCLC (all PD-L1 status), SCCHN and cervical cancer for further evaluation of response and safety and establishing a possible low dose RP2D based on clinical and biomarker activity.
3361615|NCT03799003|Experimental|ASP1951 plus pembrolizumab Optional Retreatment Period|Participants may reinitiate study drug treatment after confirmation that the participant meets all the re-treatment eligibility criteria.
3248901|NCT01370915|Placebo Comparator|Placebo|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
3248902|NCT01370928|Experimental|Prototype colonoscope|The new colonoscope to be tested
3248903|NCT01370928|Active Comparator|Standard colonoscope|The standard colonoscope used world-wide today.
3248904|NCT01370941|Active Comparator|Drug A: Chymosin|A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
3248905|NCT01370941|Placebo Comparator|Drug B: Placebo|B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
3248906|NCT01370954||CerefolinNAC®|Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
3248907|NCT01370967||Study formula-fed only|
3248908|NCT01370967||Human milk-fed only|
3248909|NCT01370967||Mixed-fed using study formula only|
3248910|NCT01370980||Study population|Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
3248911|NCT01371019||Women with preterm delivery|
3248912|NCT01371019||Women without preterm delivery|
3248913|NCT01371045||Acromegaly|Patients carrying the diagnosis of acromegaly who are on long-acting somatostatin for at least 3 months prior to study enrollment.
3248914|NCT01371045||Carcinoid Syndrome|Patients carrying a diagnosis of carcinoid syndrome who are taking long-acting somatostatin for at least 3 months prior to study enrollment.
3248915|NCT01371045||Healthy Controls|
3248916|NCT01371058|Active Comparator|routine dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically； clopidogrel 75mg/d for 1year.
3248917|NCT01371058|Experimental|high maintenance clopidogrel|aspirin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 150mg/d for 1 month followed by 75mg/d for at least 1 year.
3361622|NCT03789188||Healthy Volunteers|CC Registered Nurses
3248918|NCT01371058|Experimental|policosanol plus dual antiplatelet|asprin 300mg/d for 1 month followed by 100mg/d chronically; clopidogrel 75mg/d for at least 1 year; Policosanol 40mg/d for 6months.
3248919|NCT01371071||CIS or early relapsing-remitting MS|
3248920|NCT01371084|Experimental|Physical activity treatment group|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
3248921|NCT01371084|Placebo Comparator|Wait List Control|
3248922|NCT01371097|No Intervention|Control Group|
3361623|NCT03785405|Experimental|sacubitril/valsartan|single arm, open label sacubitril/valsartan
3361624|NCT03781414|Active Comparator|Arm 1|Control/Standard of Care: TAC + MMF + Corticosteroids
3361625|NCT03781414|Experimental|Arm 2|CFZ533 dose A + MMF + Corticosteroids
3248923|NCT01371097|Experimental|Treatment group|
3248924|NCT01371123||On long-term PN|
3248925|NCT01371123||Never been on TPN|
3248926|NCT01371136|Experimental|Curricular Trained|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
3248927|NCT01371136|No Intervention|conventional residency training|These residents proceed through surgical residency training as usual
3248928|NCT01371149|No Intervention|Physician led ventilator set up|Patients will be set up on non-invasive ventilation as per the current gold standard physician led approach
3361626|NCT03781414|Experimental|Arm 3|CFZ533 dose B + MMF + Corticosteroids
3248929|NCT01371149|Experimental|parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
3248930|NCT01371162|Experimental|A1 Healthy Volunteers|
3248931|NCT01371162|Placebo Comparator|A2|
3248932|NCT01371162|Experimental|B1 HCV Infection|
3248933|NCT01371162|Placebo Comparator|B2|
3361627|NCT03770390|Other|The study population|"Patients included in this study have pectus excavatum. The have either already undergone corrective surgery during the four years prior to the inclusion period, or are scheduled for surgery during the inclusion period.~Intervention: Surgical correction of pectus excavatum"
3361630|NCT03763149|Experimental|IBI188|"Part 1: Accelerated Titration Phase 0.1 mg/kg IV; QW 0.3 mg/kg IV QW; 1 mg/kg IV QW~Part 2 : Dose Escalation Phase with initial fixed priming dose Priming dose of 1mg/kg on C1D1 followed by 3 mg/kg IV QW; 10 mg/kg IV QW; 20 mg/kg IV QW; 30 mg/kg IV QW."
3248934|NCT01371175|Experimental|Group A|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3248935|NCT01371175|Experimental|Group B|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3361636|NCT03761108|Experimental|REGN5458|Phase 1: Cohorts of multiple REGN5458 dose levels Phase 2: Until disease progression or other discontinuation criterion is met
3361637|NCT03759873|Experimental|Incentives|Patient earns incentives for completing cardiac rehabilitation sessions.
3361638|NCT03759873|Experimental|Case Management|Patient is assigned a case manager while in hospital.
3361639|NCT03759873|Experimental|Incentives and Case Management|Patient receives both the Incentives and Case Management interventions.
3361640|NCT03759873|No Intervention|Usual care|This control condition does not receive either intervention.
3361641|NCT03759522|Experimental|Healthy Controls|
3361642|NCT03759522|Experimental|Fibromyalgia Subjects|
3361643|NCT03759522|Experimental|Chronic Fatigue Syndrome Subjets|
3361644|NCT03759522|Experimental|Multiple Sclerosis Subjects|
3361645|NCT03756688|No Intervention|Group 1: Control|No treatment will be administered for the entirety of the study (6 months)
3248936|NCT01371175|Experimental|Group C|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intradermally. Vaccine:Placebo =18/3
3248937|NCT01371175|Experimental|Group D|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3248938|NCT01371175|Experimental|Group E|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3248939|NCT01371175|Experimental|Group F|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered subcutaneously. Vaccine:Placebo =12/3
3361646|NCT03756688|Experimental|Group 2: Treatment|PTT for 30 min 2x/ day x 3 months, followed by no treatment x 3 months
3361647|NCT03756688|Experimental|Group 3: Treatment|PTT for 30 min 2x/day x 3 months, followed by once weekly (30 minutes) x 3 months
3361648|NCT03756688|Experimental|Group 4: Treatment|PTT for 30 min 2x day x 6 months
3248940|NCT01371175|Experimental|Group G|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and 8 delivered intramuscularly. Vaccine:Placebo =12/3
3259418|NCT01470690|Active Comparator|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC alone)
3259419|NCT01470690|Active Comparator|omeprazole|Omeprazole 40 mg QD for 5 consecutive days (OME alone)
3361649|NCT03749616|Active Comparator|Non-operative Acetaminophen|Acetaminophen will be given to participants for pain control following their injury.
3361650|NCT03749616|Active Comparator|Operative Acetaminophen|Acetaminophen will be given to participants for pain control following their surgery for arm fracture.
3361651|NCT03749616|Experimental|Non-operative NSAID|Ibuprofen will be given to participants for pain control following their injury.
3361652|NCT03749616|Experimental|Operative NSAID|Ibuprofen will be given to participants following their surgery for arm fracture.
3361653|NCT03742349|Experimental|1: spartalizumab + LAG525 + NIR178|phase Ib (escalation and expansion)
3361654|NCT03742349|Experimental|2: spartalizumab +LAG525 +capmatinib|phase Ib (escalation and expansion)
3361655|NCT03742349|Experimental|3: spartalizumab + LAG525 + MCS110|phase Ib (escalation and expansion)
3361656|NCT03742349|Experimental|4: spartalizumab +LAG525 +canakinumab|phase Ib (escalation and expansion)
3361657|NCT03734016|Experimental|Zanubrutinib|Zanubrutinib will be orally administered until disease progression or unacceptable toxicity.
3361658|NCT03734016|Active Comparator|Ibrutinib|Ibrutinib will be orally administered until disease progression or unacceptable toxicity.
3361661|NCT03732352|Experimental|Treatment (18F-FDG PET, osimertinib)|Within days -28 to -4, patients receive fludeoxyglucose F-18 IV and after 60 minutes undergo PET scan over 15 minutes. After 18-54 hours, patients undergo a second fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days -3 to -1 and after 24-72 hours, undergo a third fludeoxyglucose F-18 PET scan. Patients then receive osimertinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3248941|NCT01371175|Experimental|Groups C2/D2/E2 (Subgroups of C,D,E)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered ID, SC, or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in C2/D2/E2 = 16.
3248942|NCT01371175|Experimental|Group F2/G2 (Subgroup of F and G)|DNA or Placebo delivered intramuscularly at Months 0 and 1 followed by MVA or Placebo at Months 5 and Month 12+ (volunteers offered second MVA/placebo more than 12 months (late boost) after their enrollment into their original treatment assignment) delivered either SC or IM according to original randomization. Vaccine:Placebo = blinded ratio, maximum in F/G= 29.
3361662|NCT03729739|Experimental|QFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by Quantitative flow ratio (QFR).~Revascularization is indicated if QFR≤0.80. Treatment is performed according to standard clinical practice."
3361663|NCT03729739|Active Comparator|FFR-based diagnostic strategy|"Intermediate stenosis with indication for evaluation are diagnosed by fractional flow reserve (FFR).~Revascularization is indicated if FFR≤0.80. Treatment is performed according to standard clinical practice."
3361671|NCT03703128||Informants of suicide victims|Partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who received a definitive verdict of suicide in the Dutch-speaking part of Belgium (Flanders). The suicide should have taken place more than 3 months ago and less than 5 years ago.
3248943|NCT01371188||Controls|Healthy male volunteers, non-smokers, 20-40yo, living in the city of Mendonça, São Paulo-Brazil.
3248944|NCT01371188||Sugarcane Workers|Healthy male volunteers, non-smokers, 20-40yo, sugarcane workers, living in the city of Mendonça, São Paulo-Brazil.
3361672|NCT03703128||Control group|Informants i.e., partners, children, parents, siblings, other relatives, peers or other informants of adults (aged 45-60 years) who have mental health problems.
3361673|NCT03694756|Other|Pre-biopsy patients|Patients identified by a radiologist at the time of diagnostic evaluation. Once consent is obtained, the TMEM-MRI will be scheduled. After TMEM-MRI, the patient will undergo core biopsy as per usual radiology procedure, with additional FNA at the time of core biopsy (preceding the core biopsy). MenaINV and MenaCalc will be calculated from the FNA material. After the breast biopsy confirms the suspected diagnosis of invasive breast carcinoma, the patient will be referred to breast surgery and a treatment plan devised, as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be also calculated from the specimen obtained at the time of definitive surgery. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
3248945|NCT01371201|Experimental|Sunitinib|sunitinib 37.5 mg per day
3248946|NCT01371201|Placebo Comparator|Placebo|Placebo 37.5 mg per day
3361674|NCT03694756|Other|Post-biopsy patients|Patients after breast biopsy. Once consent is obtained, patients will undergo TMEM-MRI. The patients will undergo definitive breast surgery and will receive adjuvant treatments as per NCCN/ASCO guidelines. TMEM density, MenaCalc and MenaINV will be evaluated in final surgical specimen. Uth qTPERM will be correlated with TMEM density, MenaCalc and MenaINV.
3248947|NCT01371214|Experimental|Group 1|PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
3248948|NCT01371214|Active Comparator|Group 2|Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
3361677|NCT03676465|Experimental|Experimental Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will receive a weekly CloudConnect Report based on analysis of the weekly data gathered for each participant. The report will be sent via email once a week to both the subject and their parent(s). Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~the communication within the family about the information shared in this report~how subjects feel when blood sugar is high or low~who takes responsibility of how diabetes care is managed"
3361678|NCT03676465|Active Comparator|Control Group|"Subjects will wear their personal pump (if appropriate), use a study insulin pen (if appropriate), a study CGM and study activity tracker (i.e. Fitbit). Participants will not receive a CloudConnect Report. Subjects and parents will have weekly contact with the study team. Subjects will complete questionnaires at the beginning and end of the study. These questionnaires will ask subjects about:~the communication within the family about the information shared in this report~how subjects feel when blood sugar is high or low~who takes responsibility of how diabetes care is managed"
3361683|NCT03664609||Parkinson's Disease|Subjects with Parkinson's disease, implanted with a Boston Scientific Deep Brain Stimulation System
3248949|NCT01371227|Experimental|JNS002|JNS002 30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
3248950|NCT01371253|Experimental|Nintendo Wii traning|Balance training
3361684|NCT03664609||Essential Tremor|Subjects with Essential Tremor, implanted with a Boston Scientific Deep Brain Stimulation System
3361685|NCT03664609||Dystonia|Subjects with dystonia, implanted with a Boston Scientific Deep Brain Stimulation System
3361696|NCT03626662|Placebo Comparator|Placebo|Single Ascending Dose Cohorts
3361697|NCT03626662|Experimental|AMG 890|Single Ascending Dose Cohorts
3361698|NCT03612466|Experimental|Dose Escalation Arm|"Dose Levels 1-3 will consist of treatment with radiopharmaceutical (153Sm-DOTMP) alone. If the maximally tolerated dose (MTD) has not been reached at Level 3, external beam radiotherapy will be added to each of Levels 4-6. Participants enrolled on Dose Levels 4-6 will be treated with external beam radiotherapy to all radiographically evident sites of disease. If an MTD has not been determined at Level 6, the study will end and Dose Level 6 will be declared the Recommended Phase 2 Dose.~Participants will be given prophylactic / supportive treatment protocols including Calcium Carbonate, mozobil, and neupogen injectable product."
3361703|NCT03604835||Patients with MPS VII receiving vestronidase-alfa|via prescription, or early access/ compassionate use program
3248951|NCT01371253|Placebo Comparator|EVA-soles|
3248952|NCT01371266|Active Comparator|Honey|60.7 grams daily orally times 14 days
3248953|NCT01371266|Active Comparator|CHO|50 grams daily orally times 14 days
3248954|NCT01371266|Active Comparator|High Fructose Corn Syrup|65.7 grams daily orally times 14 days
3248955|NCT01371292|Experimental|Transformational teaching condition|Teachers allocated to this condition will receive the transformational teaching intervention.
3361704|NCT03604835||Patients with MPS VII not receiving vestronidase-alfa|no treatment or treatment other than vestronidase alfa
3361705|NCT03599635|Experimental|liposomal bupivacaine|These patients will receive liposomal bupivacaine for a pectoralis block infiltration by the anesthesiologist.
3248956|NCT01371292|Active Comparator|Standard practice control condition|Teachers allocated to this condition will not receive the transformational teaching intervention. Instead they will take part in a parallel workshop offered by their respective school board (unrelated to transformational leadership training).
3248957|NCT01371305|Experimental|BG00011|Participants will receive 8 consecutive weekly doses of BG00011
3361706|NCT03599635|Active Comparator|bupivacaine|These patients will receive incisional bupivacaine infiltration by the surgeon.
3361707|NCT03598608|Experimental|Part A: Favezelimab Dose A+pembrolizumab|Participants receive 200 mg pembrolizumab by intravenous (IV) infusion followed by favezelimab Dose A by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3361708|NCT03598608|Experimental|Part A: Favezelimab Dose B+pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose B by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3361709|NCT03598608|Experimental|Part A: Favezelimab Dose C+Pembrolizumab|Participants receive 200 mg pembrolizumab by IV infusion followed by favezelimab Dose C by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3248958|NCT01371305|Placebo Comparator|Placebo|Participants will receive 8 consecutive weekly doses of placebo.
3248959|NCT01371318|Experimental|OWEMR|Medical centers will be randomized to use the Online Wound Electronic Medical Record to enhance care of patients with diabetic foot ulcers
3248960|NCT01371318|No Intervention|Standard of Care|Medical/wound centers will be randomized to continue routine care of patients with diabetic foot ulcers
3248961|NCT01371331|Experimental|Tacrolimus granules|oral
3248962|NCT01371344|Experimental|Part A: Heart Transplant (Tacrolimus granules)|In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3248963|NCT01371344|Experimental|Part A: Liver Transplant (Tacrolimus granules)|In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3361710|NCT03598608|Experimental|Part B: cHL|Participants with cHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3361711|NCT03598608|Experimental|Part B: DLBCL|Participants with DLBCL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3361712|NCT03598608|Experimental|Part B: iNHL|Participants with iNHL receive 200 mg pembrolizumab by IV infusion followed by the RPTD of favezelimab by IV infusion on Day 1 of each 3-week cycle for up to 35 cycles.
3361713|NCT03598530||Tibial Shaft Fracture|Patients sustaining a tibial shaft fracture (AO/OTA type 42) that requires surgery
3361717|NCT03586128||HIV serodiscordant couples|
3361718|NCT03580369|Experimental|Ligelizumab Dose A|Ligelizumab Dose A q4w
3361719|NCT03580369|Experimental|Ligelizumab Dose B|Ligelizumab Dose B q4w
3361720|NCT03580369|Active Comparator|Omalizumab 300 mg|Omalizumab 300 mg q4w
3361721|NCT03580369|Placebo Comparator|Placebo|Placebo q4w from randomization to week 20. Ligelizumab Dose B from week 24 to week 48.
3361722|NCT03580044|Experimental|ATM- AVI Aztreonam- Avibactam (ATM-AVI) Active Treatment Arm|
3361723|NCT03580044|Active Comparator|Best Available Therapy (BAT) Comparator Treatment Arm|
3361724|NCT03570632|No Intervention|Usual care|
3361725|NCT03570632|Experimental|Metformin|
3361726|NCT03565835|Experimental|Abiraterone and Prednisone without a GnRH Analogue|Abiraterone (1000 mg daily) with Prednisone (5 mg) with Discontinuation of GnRH Analogue Injection
3361727|NCT03561597|Experimental|Mobile health application|Participants will undergo Kurbo program, a Mobile health application, for more detailed dietary and physical activity recommendations and implementation of behavioural changes. The patient's progress will be reviewed by the nurse clinician at one month post intervention to determine whether the BMI percentile has shown a reduction through the Kurbo Program. Patients that declined Kurbo intervention, has a BMI of more than 99th percentile or continue to have increase in their BMI percentile in Kurbo program, will be offered the high risk weight management clinic appointment for a more detailed multidisciplinary evaluation for targeted intervention. Patients that are able to engage with Kurbo intervention and showed a decrease in BMI percentile over 4 sessions of Kurbo will be offered the low risk weight management clinic (WMC). There will be a month 3 and month 6 visit for study measurements in this study.
3361728|NCT03546829|Experimental|Arm 1 - Experimental|
3361729|NCT03546829|Active Comparator|Arm 2 - Control Arm|
3361730|NCT03543839|Active Comparator|Belimumab|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 2 years
3361731|NCT03543839|Experimental|Belimumab/Placebo|Subjects in this arm will receive 200mg belimumab for self administration subcutaneously weekly for 1 year and then placebo injections subcutaneously for 1 year.
3361732|NCT03543839|Placebo Comparator|Placebo|Subjects in this arm will receive placebo for self administration subcutaneously weekly for 2 years
3361734|NCT03529292|Experimental|Matrix and Cells obtained by the AmeaCell® device|
3361736|NCT03524612|Other|eltrombopag|Participants will be treated with eltrombopagto to induce sustained remission to reach a target platelet count of ≥ 100×109/L (CR), after 1st line steroids have failed.
3248964|NCT01371344|Experimental|Part A: Kidney Transplant (Tacrolimus granules)|In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
3361745|NCT03508557|Experimental|Advance care planning tools|Advance care planning education and structured conversation using tools
3361748|NCT03499119|Other|Cohort 1|Subjects with a body weight at Day 1 of less than weight threshold.
3361749|NCT03499119|Other|Cohort 2|Subjects with a body weight at Day 1 of weight threshold or more.
3361753|NCT03490058||Young women|Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
3248965|NCT01371344|Experimental|Part B: All Participants (Tacrolimus capsules)|In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.
3248966|NCT01371357|Experimental|TEST1|2.4 g/day of guanidinoacetic acid
3361754|NCT03486067|Experimental|Administration of CC-93269|CC-93269 will be administered to each patient on a 28-day cycle
3361757|NCT03481114|Active Comparator|Standard chemoradiotherapy|Patients receiving standard radiotherapy will receive a total dose of 60 Gy in 30 fractions over 6 weeks, delivered to all involved lesions (tumors and lymph nodes).
3361758|NCT03481114|Experimental|PET-based, dose-painted, accelerated chemoradiotherapy,|For patients receiving PET-based, dose-painted, accelerated chemoradiotherapy, lesions with MTV exceeding 20 cc will be treated with 55 Gy in 20 fractions over 4 weeks, while lesions with MTV below 20 cc will receive 44 Gy in 20 fractions over the same 4 weeks.
3361759|NCT03456843|Experimental|Arm I (ADT, docetaxel)|Participants receive antiandrogen therapy with or without docetaxel at the discretion of the treating physician.
3248967|NCT01371357|Experimental|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogen citrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3248968|NCT01371357|Experimental|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3361760|NCT03456843|Experimental|Arm II (ADT, radical prostatectomy, docetaxel)|Participants receive antiandrogen therapy for at least 1 month, then undergo cytoreductive radical prostatectomy. Participants continue antiandrogen therapy and may receive docetaxel prior to surgery at the discretion of the treating physician.
3361761|NCT03451825|Experimental|Phase 1: Avelumab|
3361762|NCT03451825|Experimental|Phase 2, Cohort 1: Avelumab|
3248969|NCT01371357|Experimental|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
3248970|NCT01371370|Experimental|Resistance exercise training|Lower-body exercises 3 times per wk for 12 wk
3248971|NCT01371370|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
3361763|NCT03451825|Experimental|Phase 2, Cohort 2: Avelumab|
3361764|NCT03451422|Experimental|Efavaleukin Alfa|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
3361765|NCT03451422|Placebo Comparator|Placebo|Approximately 29 participants will be randomized in a 5:2 ratio (cohorts 1, 2, and 3) or in a 3:1 ratio (cohorts 4 and 5) to Efavaleukin Alfa or placebo in addition to standard of care therapy. Efavaleukin Alfa or placebo will be administered either weekly (QW) or biweekly (Q2W).
3361768|NCT03447769|Experimental|canakinumab|Participants will be administered receive canakinumab for 18 cycles (approximately 54 weeks).
3361769|NCT03447769|Placebo Comparator|Placebo|Participants will be administered receive canakinumab placebo for 18 cycles (approximately 54 weeks).
3361770|NCT03446573|Experimental|DTG + 3TC 50 mg/300 mg|Subjects will receive a single tablet of a two-drug regimen of DTG 50 mg + 3TC 300 mg once daily from Day 1 through Week 200 (Early and Late Switch Phase).
3361771|NCT03446573|Active Comparator|TAF based regimen (TBR)|Subjects will continue their TBR from Day 1 to Week 148 (Early Switch Phase), and eligible subjects will switch to DTG + 3TC once daily from Week 148 to 200 (Late Switch Phase).
3361772|NCT03439046|Experimental|ribociclib+letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
3361773|NCT03439046|Experimental|alpelisib+fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
3361775|NCT03421184|Experimental|Patient with Systemic Lupus Erythematosus|30 women with SLE
3361776|NCT03421184|Active Comparator|Patients with other autoimmune diseases|20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia
3361777|NCT03421184|Active Comparator|Healthy control|30 healthy control women
3361778|NCT03420118|Experimental|Tumor tissue and blood samples collection|
3361781|NCT03406897|Active Comparator|Omega-3 and Vitamin D Combination|The treatment arm A includes Omega-3 Fatty Acids and Cholecalciferol (Vitamin D) supplement.
3361782|NCT03406897|Active Comparator|Vitamin D Only|The treatment arm B (control group) will receive only Cholecalciferol (Vitamin D) supplement.
3361783|NCT03402607|Active Comparator|Percutaneous Local Abalation (PLA)|A PLA procedure uses high-energy radio waves to treat liver tumors. Using CT and ultrasound guidance the doctor inserts a thin, needle-like probe into the liver tumor A high-frequency current is then passed through the tip of the probe, which heats the tumor with the goal to destroy the cancer cells. This may be done as an outpatient procedure or a short (1-2 day) hospital stay. PLA is the standard treatment for patients with liver cancer who cannot undergo liver surgery.
3361784|NCT03402607|Active Comparator|Hypofractionated Image-Guided Radiation Therapy (HIGRT)|HIGRT is an emerging treatment option for patients with HCC; it utilizes external radiation where multiple beams enter the body from multiple angles to treat the liver cancer over typically 5-10 treatments while minimizing radiation to normal tissues. You will receive between 5-10 fractions (treatments) of radiation. Fraction size will be either 5 or 10 Gy (pronounced Gray, a standard unit of radiation measurement) depending on your tumor size and location or underlying liver function. The total dose of radiation is 50 Gy.
3361785|NCT03400176|Experimental|Dose Escalation|Increasing doses of VAY736 in combination with a fixed dose of ibrutinib.
3361786|NCT03400176|Experimental|Dose expansion|Evaluation of the MTD/RD of the combination of VAY736 and ibrutinib that was identified in dose escalation.
3248972|NCT01371370|Experimental|Resistance exercise training & diet|Lower-body exercise training and diet
3248973|NCT01371370|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
3248974|NCT01371383|Experimental|omega-3 fatty acids|
3248975|NCT01371383|Placebo Comparator|Placebo|
3248976|NCT01371396|Other|Hispanic subjects|Subjects will identify as Hispanic ethnicity.
3248977|NCT01371396|Other|African American subjects|Subjects will self-identify as African American in origin.
3248978|NCT01371409|Experimental|active cTBS|
3248979|NCT01371409|Sham Comparator|Sham cTBS|
3248980|NCT01371422|Experimental|A1 (PVB)|PVB technique will be utilized for injection of the anaesthetic under the skin before the procedure.
3361806|NCT03395197|Experimental|Combination arm|Talazoparib plus enzalutamide
3361807|NCT03395197|Active Comparator|Monotherapy arm|Ezalutamide plus placebo
3248981|NCT01371422|Placebo Comparator|A2 (Placebo)|The placebo is an inactive substance that looks identical to the test intervention but contains no active ingredients and will be administered the same as the PVB by a local skin injection, but no advancement of the needle to the paravertebral space will be made to avoid unnecessary risks.
3248982|NCT01371435||Patients prescribed PAXIL|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
3248983|NCT01371448||Patients prescribed PAXIL for long-term use|Patients with depression/depressed state or panic disorder prescribed PAXIL during study period
3248984|NCT01371461||Patients prescribed PAXIL|Patients with depression or depressed state prescribed PAXIL during study period
3248985|NCT01371474||Patients prescribed PAXIL|Patients with depression or in a depressed state starting PAXIL at 20 mg/day during study period
3248986|NCT01371487|Experimental|Treatment A|GSK1120212 Dose /Treatment 2.0 mg/Fasted
3248987|NCT01371487|Experimental|Treatment B|GSK1120212 Dose /Treatment 2.0 mg/high fat, high calorie meal
3248988|NCT01371513||PSA level|more than 2.5ng/ml
3248989|NCT01371526|Experimental|Synacthen|active treatment
3248990|NCT01371578|Experimental|Arm 2|"AM Dosing: One GS-5885 30 mg tablet, two GS-9451 100 mg tablets, orally with RBV and with food.~PM Dosing: RBV with food.~PEG, 180 µg, will be administered weekly by subcutaneous injection for the specified period of time (see Study Design). Pegasys® prefilled syringes (Hoffman-La Roche) will be supplied by Gilead Sciences."
3361810|NCT03350984|Experimental|NPH insulin group|Patients receiving NPH twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL. If subjects were not eating, they shouldn't receive dose of NPH insulin. Intervention Drug: NPH insulin
3361811|NCT03350984|Active Comparator|Glargine and Lispro insulin group|"Half of the total of Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose will be given as Lispro; doses were divided equally for breakfast, lunch, and dinner. An additional correctional dose of Lispro will be given for any blood glucose >180 mg/dL. If subjects were not eating, they received glargine once daily and they shouldn't receive doses of lispro.~Intervention drug: Glargine and Lispro"
3361812|NCT03340506|Experimental|dabrafenib monotherapy|"Patients in this study may receive:~- monotherapy of dabrafenib"
3361813|NCT03340506|Experimental|trametinib monotherapy|"Patients in this study may receive:~- monotherapy of trametinib"
3361814|NCT03340506|Experimental|Combination therapy (dabrafenib & trametinib)|"Patients in this study may receive:~- the combination of dabrafenib and trametinib"
3361824|NCT03331341|Experimental|Treatment (APVD)|"PART A: Patients receive doxorubicin hydrochloride intravenously (IV), vinblastine IV, and dacarbazine IV on days 1 and 15. Patients also receive pembrolizumab IV over 30 minutes on days 1 and 22 of cycle 1 and on day 15 of cycle 2. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.~PART B: Patients receive doxorubicin hydrochloride IV, vinblastine IV, dacarbazine IV, and pembrolizumab IV as in part A, but undergo a total of 6 treatment cycles."
3361825|NCT03328845|Other|Tresiba & NovoRapid|Patients treated with Tresiba insulin and NovoRapid insulin
3361826|NCT03328845|Other|Toujeo SoloStar & NovoRapid|Patients treated with Toujeo SoloStar insulin and NovoRapid insulin
3361827|NCT03328845|Other|Tresiba & Humalog Kwikpen|Patients treated with Tresiba insulin and Humalog kwikpen insulin
3361828|NCT03328845|Other|Toujeo SoloStar & Humalog Kwikpen|Patients treated with Toujeo SoloStar insulin and Humalog kwikpen insulin
3361829|NCT03328845|Other|Tresiba & Apidra|Patients treated with Tresiba insulin and Apidra insulin
3361830|NCT03328845|Other|Toujeo SoloStar & Apidra|Patients treated with Toujeo SoloStar insulin and Apidra insulin
3248993|NCT01371604|Experimental|IDX184 50 mg + Peg-IFN/RBV|IDX184 50 mg and matching placebo once daily plus peginterferon alfa-2a (Peg-IFN) weekly and ribavirin (RBV) daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
3248994|NCT01371604|Experimental|IDX184 100 mg + Peg-IFN/RBV|IDX184 100 mg once daily plus Peg-IFN weekly and RBV daily for 12 weeks followed by Peg-IFN weekly and RBV daily for an additional 12 or 36 weeks.
3248995|NCT01371617|Experimental|IPI-926|Single Arm, Phase 2 trial evaluating the safety and efficacy of IPI-926 in patients with myelofibrosis
3248996|NCT01371630|Experimental|Treatment (inotuzumab ozogamicin, combination chemotherapy)|See Detailed Description
3248997|NCT01371669||IPAH or CPEPH|Idiopathic pulmonary arterial hypertension (IPAH) or pulmonary hypertension associated with chronic post-embolic pulmonary hypertension (CPEPH)
3248998|NCT01371682|Other|Session 1|Ropinirole manufactued at Crawley will be compared to that manufactured at Aranda
3248999|NCT01371682|Other|Session 2|Ropinirole manufactured at Crawley will be compared to that manufactured at Aranda.
3249000|NCT01371760|Experimental|Intervention|The patients will undergo PTA of the extracranial cerebral veins
3249001|NCT01371760|Sham Comparator|Controls|The patients will undergo sham procedure
3249002|NCT01371773|Experimental|Left-sided double lumen tube|
3249003|NCT01371799|Experimental|Study drug at 4mg|GSK1034702 at 4mg
3249004|NCT01371799|Experimental|Study drug at 8mg|GSK1034702 at 8mg
3249005|NCT01371799|Placebo Comparator|Placebo|Placebo
3249006|NCT01371812|Experimental|Cohort 1|Interlocking design with Cohort 2. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 150mg, to 600mg, to 1200mg and 1200mg with a FDA high fat/high calorie meal, will be administered over the 13 week long study allowing adequate washout period between doses.
3249007|NCT01371812|Experimental|Cohort 2|Interlocking design with Cohort 1. Single dose; treatment period over 2 days such that one subject will receive GSK2239633 and one subject will receive placebo on Day 1. The remaining subjects will be dosed on day 2 of each treatment period assuming adequate safety from Day 1. Placebo and an escalation of GSK2239633 from 300mg, to 900mg, and 1500mg, will be administered over the 13 week long study allowing adequate washout period between doses.
3361838|NCT03305341|Experimental|Assess for therapeutic biologics activity (proof-of-concept)|"0.1mg Spike-GM-CSF Protein~0.5 ml Lactated Ringer's Injection, USP"
3361841|NCT03300427|Experimental|sacubitril/valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. Two strengths of sacubitril/valsartan will be available for use after randomization, 49 mg sacubitril/51 mg valsartan and 97 mg sacubitril/103 mg valsartan. After randomization, subjects in this arm will receive sacubitril/valsartan 100 mg orally twice daily (BID). The dose will be then up-titrated to 200 mg BID (or maintained at the starting dose level, if up-titration is not possible). Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate the 100 mg BID dose at the minimum. In total, participants will be on sacubitril/valsartan for a minimum of 8 weeks and a maximum of 10 weeks.
3361842|NCT03300427|Active Comparator|valsartan|Participants will be randomized to two treatment arms in a 1:1, double blinded fashion. In this arm, Valsartan 80 mg and 160 mg will be used as comparative drug, taken orally BID at home. Depending on the screening/run-in dose the subjects in this arm will get either valsartan 80 mg BID or valsartan 160 mg BID. During the treatment period the dose of valsartan will be up-titrated to the highest tolerated dose (160 mg BID) or maintained at 80 mg BID if up-titration is not possible. Dose modifications are allowed until week 4 after the randomization. In order to be eligible for the final assessments, the subject has to tolerate at least 80 mg BID dose of valsartan. The treatment phase will be a minimum of 8 weeks, and a maximum of 10 weeks.
3361843|NCT03298867|Active Comparator|Teprotumumab 20 mg/kg|Approximately 38 participants will receive 8 infusions of teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
3249008|NCT01371864||Pediatric Cardiothoracic Team|This group consists of members of the cardiothoracic surgery team: The attending physician, the fellow physician, the nurses, and the physician assistants.
3249009|NCT01371864||Critical Care Team|This group consists of the nurses and physicians who work in the pediatric intensive care unit and the neonatal intensive care unit caring for patients who require cardiothoracic surgery.
3249010|NCT01371864||Subspecialty Team|This group consists of physicians and nurses from pediatric cardiology and pediatric anesthesiology who care for children who require cardiothoracic surgery.
3249011|NCT01371864||Parent|This group consists of the parent or legal guardian of the pediatric patient who requires cardiothoracic surgery.
3249012|NCT01371890||Intradialytic hypertension|Patients with systolic blood pressure increases > 10 mmHg during 4/6 hemodialysis sessions
3249013|NCT01371916||ESAT-6 positive|
3249014|NCT01371916||ESAT-6 negative|
3249015|NCT01371929||ICU patients who become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected to develop sepsis, severe sepsis, or septic shock.
3249016|NCT01371929||ICU patients who do not become septic|Patients considered to be at risk of becoming septic based upon his/her clinical presentation during admittance or transfer to an ICU will be tested for the presence of plasma iNOS using our PliNOSa test on the day of ICU entry and their sepsis status will be followed for three days to determine if they develop sepsis, severe sepsis, or septic shock. Approximately, 50% of the enrolled patients are expected NOT to develop sepsis, severe sepsis, or septic shock.
3249017|NCT01371955||diabetic nephropathy group|patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
3249018|NCT01371955||diabetic retinopathy group|patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
3361844|NCT03298867|Placebo Comparator|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
3361845|NCT03291171|Experimental|Intervention group|Participants will receive the e- and mHealth intervention 'MyPlan 2.0'.
3361846|NCT03291171|No Intervention|Waiting-list control group|Participants will not receive the e- and mHealth intervention 'MyPlan 2.0', but will be given access to the intervention after all testing phases.
3361847|NCT03288324|Experimental|Tofacitinib Arm|open-label study
3361849|NCT03284047|Experimental|2.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
3361850|NCT03284047|Experimental|5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
3361851|NCT03284047|Experimental|7.5 U dose|"Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:~2.5 U~5 U~7.5 U"
3249019|NCT01371955||no complication group|patient without diabetic nephropathy or retinopathy
3249020|NCT01371968|Experimental|alfentanil|patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods
3361852|NCT03284021|Other|Fraxel laser|
3361853|NCT03277261|Experimental|Ublituximab + Oral Placebo|Participants were administered ublituximab 150 milligrams (mg), intravenous (IV) infusion over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo once daily (QD) from Day 1 up to the last day of Week 95.
3361854|NCT03277261|Active Comparator|Teriflunomide + IV Placebo|Participants were administered teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
3361855|NCT03277248|Experimental|Ublituximab + Oral Placebo|Participants received ublituximab intravenous (IV) infusion, 150 milligrams (mg) over 4 hours (h) on Day 1 followed by 450 mg over 1 h on Days 15, 168, 336 and 504 (Week 72) along with the oral placebo tablet, once daily (QD) from Day 1 up to the last day of Week 95.
3361856|NCT03277248|Active Comparator|Teriflunomide + IV Placebo|Participants received teriflunomide 14 mg tablet, orally, QD from Day 1 up to the last day of Week 95 along with the placebo IV infusion on Days 1, 15, 168, 336 and 504 (Week 72).
3361857|NCT03274271|Experimental|AP+CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with all three behaviour change techniques of interest: action planning (AP), coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361858|NCT03274271|Experimental|AP+CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361859|NCT03274271|Experimental|AP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: action planning (AP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361860|NCT03274271|Experimental|CP+M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with two of the behaviour change techniques of interest: coping planning (CP) and self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361861|NCT03274271|Experimental|M|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: self-monitoring (M).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3249021|NCT01372007|Experimental|Lanreotide Autogel 120mg|
3249022|NCT01372007|Placebo Comparator|Placebo|
3249023|NCT01372020|Sham Comparator|control group|
3249024|NCT01372020|Experimental|neuromuscular electrical therapy|
3249025|NCT01372033|Experimental|CBT|Use of cognitive behavioral therapy focused on social skill development and interpersonal relationships
3249026|NCT01372046|Experimental|Enhanced|A external consultant works with the team to develop skills and trains an in-house coach
3249027|NCT01372046|Experimental|Trainer|External consultant provides booster session
3249028|NCT01372046|Experimental|Standard|Receive agency training
3249029|NCT01372059|Experimental|Rhythm and music therapy|Since 1993 The RGRM Method is a concept launched in both health and medical care. The method is mainly designed to help people with injuries and diseases of the central nervous system.
3361862|NCT03274271|Experimental|CP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: coping planning (CP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361863|NCT03274271|Experimental|AP|"Participants will receive the e- and mHealth intervention 'MyPlan 2.0' with only one of the behaviour change techniques of interest: action planning (AP).~They will also receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support."
3361864|NCT03274271|Active Comparator|Control|Participants will receive the e- and mHealth intervention 'MyPlan 2.0' without the three behaviour change techniques of interest (action planning, coping planning, self-monitoring). They will receive general tips and tricks and other behaviour change techniques included in the intervention: tailored feedback and eliciting social support.
3361865|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Triple Negative Breast Cancer (TNBC)|Participants with TNBC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 plaque-forming units/milliliter (PFU/mL) on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
3361866|NCT03256344|Experimental|Talimogene Laherparepvec with Atezolizumab: Colorectal Cancer (CRC)|Participants with CRC with liver metastases administered intrahepatic injection of talimogene laherparepvec into liver metastases via guided injection (either ultrasound or computerized tomography) on Day 1 of each cycle for a maximum of 12 cycles, where each cycle is 21 days. Participants administered 10^6 PFU/mL on Day 1 of Cycle 1 and 10^8 PFU/mL on Day 1 of each cycle thereafter. Participants also administered 1200 mg atezolizumab via intravenous injection on Day 1 of each cycle.
3361867|NCT03243734|Experimental|trūFreeze® System spray cryotherapy|trūFreeze® System spray cryotherapy as clinically indicated for symptom relief
3361868|NCT03229499|Experimental|Anastrozole|1mg (1 tablet)taken by mouth once a day for one year
3361869|NCT03229499|Placebo Comparator|Placebo|1 tablet taken by mouth once a day for one year
3361870|NCT03224546|No Intervention|Control Group|This group will receive payment for providing urine samples throughout the trial.
3361871|NCT03224546|Experimental|Low Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
3361872|NCT03224546|Experimental|High Value Alternative Reinforcer Group|This group will receive payment for providing cocaine negative urine samples throughout the trial.
3249030|NCT01372059|Active Comparator|Therapeutic riding|Therapeutic riding can be useful for individuals with neurological and muscular impairments. The goal of therapeutic riding as professional treatment is to improve neurological functioning and to achieve functional gains and enhance life skills.
3249031|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
3249032|NCT01372072|Active Comparator|Humidification|Patients in this arm of the trial will receive humidification with the non-invasive ventilation.
3361875|NCT03203850|Experimental|Deferasirox FCT Arm|randomized in a 2:1 ratio: Deferasirox to surgery
3361876|NCT03203850|Experimental|phlebotomy|randomized in a 2:1 ratio: Deferasirox to surgery
3249033|NCT01372072|No Intervention|NIV without humidifivation|As per usual practice patients in this arm will not have humidification with their NIV
3361879|NCT03190174|Experimental|Arm 1|"This is an open label, dose-seeking phase 1b study using a defined dose of nivolumab and escalating doses of Nab-Rapamycin (ABI-009) given intravenously.~I. Dose Escalation Phase 1 Part of Study: The study will employ the standard cohort of three design. No intra-patient dose escalation will take place.~II. Expansion Phase 1b Part of Study: Following dose escalation, an additional 22-28 patients will receive ABI-009 at the MTD and defined doses of nivolumab to assess overall safety and potential efficacy in a greater number of patients. Patients in the expansion phase of the study may continue treatment up to 18 three-week cycles or until significant disease progression or unacceptable toxicity occurs."
3361880|NCT03187353|Active Comparator|Lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.
3361881|NCT03187353|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
3361885|NCT03180034|Experimental|Arm I (Gardasil, DTaP)|Participants receive Gardasil IM at month 0 and DTaP IM at month 6.
3361886|NCT03180034|Experimental|Arm II (Cervarix, DTaP)|Participants receive Cervarix IM at month 0 and DTaP IM at month 6.
3361887|NCT03180034|Active Comparator|Arm III (Gardasil)|Participants receive Gardasil IM at month 0 and 6.
3361888|NCT03180034|Active Comparator|Arm IV (Cervarix)|Participants receive Cervarix IM at month 0 and 6.
3361889|NCT03180034|No Intervention|Arm V (epidemiologic survey)|A concurrent epidemiologic survey for HPV status among unvaccinated women. Survey participants are followed for two study visits six months apart to determine their HPV DNA status, with no further follow-up. These women will be offered HPV vaccination (Cervarix) at the two study visits.
3361890|NCT03179462|Experimental|Pork intake|Subjects will consume 2 ounces of cooked lean pork following diet normalization for 3 days.
3361891|NCT03179462|Experimental|Mixed nuts intake|Subjects will consume 1 ounce of mixed nuts following diet normalization for 3 days.
3361892|NCT03179462|Experimental|Tofu intake|Subjects will consume 2 ounces of tofu following diet normalization for 3 days.
3361893|NCT03173976|Experimental|Zoledronic Acid|1 cycle of Zoledronic Acid (ZA) at 4mg IVP prior to surgery and a second cycle of ZA at 4 mg IVP 3 weeks after surgery
3361894|NCT03173521|Experimental|open label|"Adeno-associated viral vector serotype 8 with liver-specific thyroxine-binding globulin (TBG) promoter driving the expression of the human ARSB gene diluted in its final formulation medium [Drug product (DP) diluted in 0.9% saline solution and 0.25% of human serum albumin].~Four dose levels are available:~'Starting dose' is 6x1011 gc of vector per kg of body weight.~'High dose' is 2x1012 gc of vector per kg of body weight.~'Very high dose' is 6x1012 gc of vector per kg of body weight.~'Low dose' is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein (e.g. median cubital vein) over 2-4 hours using an infusion pump. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
3361895|NCT03167203|Experimental|hESC-RPE cells|Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
3361896|NCT03148899|Experimental|Visit 1 Randomization|At visit 1 (PSG 1) subjects will receive one of two interventions: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
3361897|NCT03148899|Experimental|Visit 2: Crossover Randomization|At visit 2 (PSG 2) subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal Spray (40 IU) or Placebo Intranasal Spray. Subjects will be blinded as to which drug they are receiving.
3249034|NCT01372098|Experimental|NFP + IPV intervention|The protocol for number and timing of visits will be the same for both NFP+IPVI and Standard Care, as follows: weekly for the first four visits, every other week for the remainder of the pregnancy, every week for six weeks in the postpartum and every other week until the infant is 21 months old after which it is once a month for the last three months. We recognize that the intervention might prompt the nurse and mother to alter the regular visit schedule if IPV is present.
3361903|NCT03136627|Experimental|Tivozanib (AV-951) plus Nivolumab|Tivozanib plus Nivolumab:Tivozanib will be administered once daily for 3 weeks followed by 1 week off. Nivolumab will be administered every 2 weeks starting on Day 1.
3361904|NCT03127722|Experimental|ESSURE (BAY1454032)|Subjects selecting hysteroscopic sterilization who are not contraindicated for the Essure procedure according to the most current approved version of the Essure IFU. Subject willing to use alternative contraception for at least 3 months post-Essure placement procedure, until a satisfactory Essure Confirmation Test is documented.
3361905|NCT03127722|Active Comparator|Laparoscopic tubal sterilization|Subjects selecting laparoscopic sterilization who are not contraindicated for laparoscopic tubal sterilization according to common clinical practice standard of care
3361906|NCT03115632||Obese asthmatic & lean asthmatic|men and women with asthma and either obese or lean BMI
3361907|NCT03115632||Obese non-asthmatic & lean non-asthmatic|men and women without asthma and either obese or lean BMI
3361908|NCT03115632||Asthmatic undergoing bariatric surgery|Obese asthmatic men and women undergoing bariatric surgery
3361909|NCT03115632||Non-asthmatic undergoing bariatric surgery|Obese men and women undergoing bariatric surgery
3361910|NCT03114319|Experimental|TNO155|TNO155 for oral administration
3361911|NCT03114319|Experimental|TNO155 in combination with EGF816 (nazartinib)|TNO155 in combination with EGF816 (nazartinib) in patients with advanced EGFR mutant NSCLC
3361912|NCT03099707|No Intervention|Standard of Care|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200 Rand to complete all three surveys) only. This group will not receive any additional engagement to care intervention. Investigators intend to follow their clinical outcomes through medical registries, pharmacy data, and the National Health Laboratory Service (a national database for all individuals living with HIV in South Africa regarding engagement in care).
3361913|NCT03099707|Active Comparator|Treatment Ambassador Intervention|Participants are administered baseline, 3 month, and 6 month questionnaires and provided with study incentive (100 Rand per survey plus an additional 200R to complete all three surveys). For participants randomized to the intervention arm, they will immediately meet with a Treatment Ambassador to begin the 8 session intervention, which has components of motivational interviewing, peer-support, and peer navigation. The protocol is detailed in a study manual that has been reviewed and undergone multiple iterative revisions to ensure cultural acceptability.
3361914|NCT03096834|Placebo Comparator|Placebo DB|Matching placebo subcutaneous injections administered every 4 weeks during Double-Blind Epoch
3361915|NCT03096834|Experimental|AMG334 140 mg DB|AMG334 140 mg subcutaneous injections administered every 4 weeks during Double-Blind Epoch
3249035|NCT01372098|No Intervention|NFP (standard care)|"The NFP nurses currently receive some training regarding IPV, but it is minimal. Between intake and when the child is 3 months and 12 months old, there is a brief instruction that the nurse assess for IPV. If the client acknowledges current abuse when completing the Abuse Assessment Screen, the nurse should assist her to evaluate threats to personal safety and make referrals as needed. There is a prompt to be mindful of client safety, and to make referrals as needed."
3361916|NCT03096834|Experimental|AMG334 140 mg DB cont on AMG334 140 mg|AMG334 140 mg subcutaneous injections during DB continued on AMG334 140 mg in Open-Label Epoch
3361917|NCT03096834|Experimental|Placebo in DB to AMG334 140 mg|Placebo in Double-Blind Epoch (DB) switched to AMG334 140 mg in Open-Label Epoch
3361918|NCT03084549|Experimental|Ropivacaïne|
3361919|NCT03084549|Placebo Comparator|Placebo|
3361920|NCT03077425|Experimental|Intervention|An RCT will enroll 360 mothers (total) of children 4-6 month olds from New York City (n=3) and New Jersey (n=2) pediatric practices. Half (180) will be assigned to the Community Health Worker intervention comprised of: a) home visits with mothers/families (n=6 visits over one year) and follow up telephone support; b) patient navigation to make/keep timely dental visits (2x by 18 months).
3361921|NCT03077425|Placebo Comparator|Enhanced Usual Care (EUC)|"Community Health Workers (CHWs)- will deliver the EUC to all study participants at their 6 month well-child visit, which will occur just after their T0 Baseline Interview, just prior to randomization. EUC Components: 1) Pamphlet- CHWs will hand out and review deliver and review a pamphlet with basic ECC and Obesity prevention messages for parents of 6-18 month olds; and 2) Dental Referral List of dentists who will see 12 month olds, and who accept most insurance plans in the pediatric practices we are recruiting from.~Thus, the EUC will be delivered to n=180 families in the EUC Control and n=180 families in the Intervention group."
3361925|NCT03064763|Experimental|Talimogene laherparepvec|"Participants will receive talimogene laherparepvec administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance.~On Day 1 (Week 0), the initial dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 Plaque forming units per millilitre (PFU/mL). Subsequent doses of talimogene laherparepvec will be up to 4.0 mL of 10^8 or 10^7 PFU/mL. The second dose is to be administered 3 weeks (+ 5 days) after the initial dose, and subsequent doses were to be given every 2 weeks (+ 3 days)."
3361926|NCT03049813|Experimental|Virtual Reality Job Interview Training|Virtual Reality Job Interview Training
3361927|NCT03049813|Other|Supported Employment (Services as Usual)|Supported Employment (Services as Usual)
3361928|NCT03036267|Experimental|BREATHE|7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach
3361929|NCT03036267|Active Comparator|Attention Control Condition|7-minute diet and exercise discussion
3361930|NCT03030378|Experimental|Treatment (recombinant interleukin-12, pembrolizumab)|Patients receive recombinant interleukin-12 SC on days 2, 5, 9, and 12 and pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of subsequent cycles. Treatment continues for 28 days for cycle 1 and repeats every 21 days for subsequent cycles for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patient then receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 8 additional cycles in the absence of disease progression or unacceptable toxicity.
3361931|NCT03026348|Active Comparator|Treatment Group A|Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
3361932|NCT03026348|Active Comparator|Treatment Group B|Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
3249036|NCT01372124|Experimental|NOX-E36|All subjects included in this study will receive the same dose of NOX E36.
3249037|NCT01372137|Experimental|NOX-H94|Group A: single 15 minutes IV infusion of 0.3 mg/kg NOX-H94 Group B: single 15 minutes IV infusion of 0.6 mg/kg NOX-H94 Group C: single 15 minutes IV infusion of 1.2 mg/kg NOX-H94 Group D: single 15 minutes IV infusion of 2.4 mg/kg NOX-H94 Group E: single 15 minutes IV infusion of 4.8 mg/kg NOX-H94 Group F: single / repeated SC injection of NOX-H94 over a treatment period of 2 weeks Group G: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks Group H: multiple doses of NOX-H94 as a 15 minutes IV infusion over a treatment period of 2 weeks
3249038|NCT01372137|Placebo Comparator|Glucose 5%|Group A to Group H get NOX-H94 or Placebo
3249039|NCT01372163|Experimental|2 mg PF-05190457 or Placebo BID|
3249040|NCT01372163|Experimental|10 mg PF-05190457 or Placebo BID|
3249041|NCT01372163|Experimental|40 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3249042|NCT01372163|Experimental|150 mg PF-05190457 or Placebo BID|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3249043|NCT01372163|Experimental|5 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3249044|NCT01372163|Experimental|50 mg PF-05190457 or Placebo QD|Dose and dose frequency may be adjusted based on emerging safety and PK data.
3361933|NCT03026348|Active Comparator|Treatment Group C|Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
3361934|NCT03026348|Active Comparator|Treatment Group D|Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
3361935|NCT03026348|Active Comparator|Treatment Group E|Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
3361936|NCT03026348|Active Comparator|Treatment Group F|Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
3361937|NCT03026348|Active Comparator|Treatment Group G|Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
3249045|NCT01372163|Experimental|xxx mg PF-05190457 or Placebo|Dose and dose frequency to be determined based on emerging safety and PK data.
3361938|NCT03026348|Active Comparator|Treatment Group H|Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
3361939|NCT03026348|Active Comparator|Treatment Group J|Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
3361940|NCT03026348|Active Comparator|Treatment Group K|Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
3361941|NCT03026348|Active Comparator|Treatment Group L|Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
3361942|NCT03026348|Placebo Comparator|Treatment Group M|Day 0 Phosphate Buffer Day 21 Phosphate Buffer
3361943|NCT03006172|Experimental|Stage I Arm A: Inavolisib Single Agent|Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361944|NCT03006172|Experimental|Stage I Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361945|NCT03006172|Experimental|Stage I Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361946|NCT03006172|Experimental|Stage II Arm B: Inavolisib + Palbociclib + Letrozole|Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361947|NCT03006172|Experimental|Stage II Arm C: Inavolisib + Letrozole|Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3249046|NCT01372176|Experimental|Early Goal-Directed Nutrition|
3249047|NCT01372176|Active Comparator|ASPEN-guidelines|
3249048|NCT01372189||colorectal cancer|Patients with colorectal carcinoma during conventional endoscopic imaging.
3249049|NCT01372189||colorectal adenoma|Patients with colorectal adenoma during conventional endoscopic imaging.
3361948|NCT03006172|Experimental|Stage II Arm D: Inavolisib + Fulvestrant|Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361949|NCT03006172|Experimental|Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361950|NCT03006172|Experimental|Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin|Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3249050|NCT01372228|Experimental|Inherited Metabolic Disorder Patients|Recipients are treated with hematopoietic stem cell infusion from living donors
3249051|NCT01372241|Experimental|Early Intervention|This group served as the treatment group for analysis of the primary outcome.
3249052|NCT01372241|No Intervention|Delayed Intervention|This group served as a wait-list control group, eventually receiving the intervention after the treatment group completed the intervention and the primary outcomes were assessed for both groups.
3249053|NCT01372267|Experimental|CBT for pain|
3249054|NCT01372267|Active Comparator|Psychoeducational control group|This group is designed to be an active control which provides detailed information about substance us and chronic pain without providing any CBT or other specific therapy.
3249055|NCT01372280|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
3249056|NCT01372280|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
3249057|NCT01372306|Experimental|Galantamine|Galantamine Hydrobromide Tablets of Dr. Reddy's
3249058|NCT01372306|Active Comparator|Reminyl|Reminyl 4 mg tablets of Janssen Pharmaceutical Products
3249059|NCT01372319||Glaucoma Patients (OAG, Aulhorn stages II - IV)|Manifest glaucoma (OAG, Aulhorn stages II - IV) with advanced binocular visual loss, as obtained by semi-automated kinetic perimetry (SKP), no study medication
3249060|NCT01372319||Normal subjects|male+female > 18 years
3361951|NCT03006172|Experimental|Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab|Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
3361955|NCT02989402|Experimental|Rivastigmine patch|15 cm2 patch sizes loaded with 27 mg of rivastigmine
3249061|NCT01372332||Normal subjects|Age-related (+ 5 years of age) and gender-matched normal subjects.
3249062|NCT01372332||Patients with homonymous hemianopia|Patients with homonymous visual field defects
3361956|NCT02974725|Experimental|LXH254+LTT462|
3361957|NCT02974725|Experimental|LXH254+Trametinib|
3361958|NCT02974725|Experimental|LXH254+Ribociclib|
3249063|NCT01372345|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
3249064|NCT01372345|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
3361959|NCT02966548|Experimental|Monotherapy|Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
3361960|NCT02966548|Experimental|Combination Therapy|Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation
3361961|NCT02962414|Experimental|everolimus|everolimus, 2mg dispersible tablets
3249065|NCT01372358|Experimental|Ciprofloxacin|Ciprofloxacin Extended Release Tablets of Dr. Reddy's Laboratories Limited
3249066|NCT01372358|Active Comparator|CIPRO®XR|CIPRO® XR (Bayer Health Care, Bayer Pharmaceuticals Corporation) Tablets
3249067|NCT01372371|Active Comparator|Vancomycin|
3249068|NCT01372371|Active Comparator|Vancomycin and Gentamycin|
3249069|NCT01372371|Active Comparator|Intravenous Antibiotic|
3249070|NCT01372423|Active Comparator|AMITIZA|Manufactured by Sucampo Pharmaceuticals (24 mcg administered for 7 days)
3361962|NCT02959164|Experimental|Decitabine and Gemcitabine|"Decitabine, Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Gemcitabine fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle."
3361963|NCT02957149|Experimental|Platelet Rich Plasma (PRP) Treatment|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The Autologous Platelet-Rich Plasma is concentrated in a device (Angel Concentrated Platelet Rich Plasma System) to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
3361964|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 1b Dose Escalation|Participants with B-cell non-Hodgkin's lymphoma will receive 1 mg/kg magrolimab priming dose on Day 1 of Cycle 1 followed by weekly maintenance doses of 10, 20, 30, or 45 mg/kg on Days 8, 15, 22 for Cycle 1 and Days 1, 8, 15, and 22 for each cycle to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose and schedule (RP2DS) in combination with rituxumab 375 mg/m^2. Cycle length is 28 days.
3361965|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Indolent Lymphoma|Participants with indolent lymphoma will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
3361966|NCT02953509|Experimental|Magrolimab + Rituximab, Phase 2 Diffuse Large B-Cell lymphoma|Participants with diffuse large B-cell lymphoma (DLBCL) will receive magrolimab based on RP2DS from Phase 1b portion of the study in combination with rituxumab 375 mg/m^2.
3361967|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Safety Dose Escalation Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive 1 mg/kg magrolimab priming dose on Day 1 for Cyle 1 followed by maintenance doses of 30 or 45 mg/kg on Days 8, 11, 15, 22, and 29 for Cycle 1, every week for Cycle 2, and every 2 weeks for each cycle to determine maximum tolerated dose (MTD) + rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2. Cycle length is 28 days.
3361968|NCT02953509|Experimental|Magrolimab + R-GemOx, Phase 1b Dose Expansion Phase|Autologous stem cell transplant (or transplantation) ineligible DLBCL participants will receive magrolimab at a dose determined from Phase 1b Safety Dose-Escalation Phase in combination with rituxumab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2.
3361969|NCT02941146|Experimental|Zeltiq Dual Sculpting Treatment Group|All subjects treated with CoolSculpting System using the CoolAdvantage and CoolAdvantage Plus applicators simultaneously on the abdomen.
3249071|NCT01372423|Placebo Comparator|Placebo|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
3361970|NCT02934568|Experimental|LEE011|All patients in all combinations with LEE011 will be entered in one arm.
3249072|NCT01372423|Experimental|Lubiprostone|Manufactured by Anchen Pharmaceuticals (24 mcg administered for 7 days)
3249073|NCT01372436||1|children in high-school
3249074|NCT01372436||2|children in primary school
3249075|NCT01372449|Active Comparator|Memantine|
3249076|NCT01372449|Placebo Comparator|Placebo|Placebo Comparator
3361971|NCT02928224|Experimental|Safety Lead-in, Triplet Arm|Encorafenib + binimetinib + cetuximab.
3361972|NCT02928224|Experimental|Doublet Arm|Encorafenib + cetuximab.
3361973|NCT02928224|Active Comparator|Control Arm|Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab.
3361974|NCT02923778|Experimental|Treatment (talimogene laherparepvec, radiation therapy)|Patients receive talimogene laherparepvec IT at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy at weeks 2-6.
3249077|NCT01372475|Active Comparator|Hymovis Viscoelastic Hydrogel|Intra-articular Injection
3249078|NCT01372475|Placebo Comparator|Placebo|Phosphate Buffered Saline Intra-articular Injection
3249079|NCT01372488|Active Comparator|Study group|Study group will be provided with suture removal instructions and suture removal kit and asked to consider removing their own sutures
3249080|NCT01372488|Placebo Comparator|Control group|Control group will be asked to have their sutures removed as they normally would (see family doctor or clinic)
3361975|NCT02923726|Active Comparator|ATP and Shock|Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
3361976|NCT02923726|Experimental|Shock only|Once tachycardia has been detected and duration met, this group would receive shock therapy only.
3361977|NCT02922985|Placebo Comparator|Placebo Control Group|Patients will receive a placebo dose of all three study medications: Patients will receive the pre-operative dose of IV normal saline placebo within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of 20 mL of subcutaneous normal saline placebo after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive an IM dose of normal saline placebo.
3361978|NCT02922985|Active Comparator|Multimodal Pain Regimen Group|Patients will receive the actual study medication for all three study medications: Patients will receive the pre-operative dose of IV acetaminophen 1 g within 30 minutes of going to the OR for CD. The patient will receive the subcutaneous infiltration of either 20 mL of bupivacaine 0.25% after positioning and preparation but prior to skin incision. At the time of fascial closure, the patient will receive 60 mg of IM ketorolac.
3249081|NCT01372514||suspected thromboembolic disease|Patients with thromboembolic disease according to diagnostic tests (MDTC with angiography, scintigraphy V/Q, dimer d, ecografia doppler, etc. ) required by the physician.
3361979|NCT02918500|No Intervention|Placebo|Participants will receive 3 weeks of inactive NRT patches.
3361980|NCT02918500|Active Comparator|Active|Participants will receive 3 weeks of active NRT patches
3361981|NCT02906033|Experimental|Intervention group|New perioperative practice model.
3361982|NCT02906033|No Intervention|Control group|Traditional practice model.
3361983|NCT02869789|Experimental|Nivolumab in combination with Ipilimumab|Specified dose on specified days
3361984|NCT02849496|Experimental|Arm I (olaparib)|Patients receive olaparib PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may cross-over to Arm II.
3361985|NCT02849496|Experimental|Arm II (olaparib, atezolizumab)|Patients receive olaparib as Arm I and atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3361986|NCT02837783|Experimental|290 μg linaclotide|Linaclotide Oral, once daily
3361987|NCT02837783|Placebo Comparator|Matching Placebo|Matching Placebo Oral, once daily
3361988|NCT02831673|Experimental|DTG + 3TC (50 mg+300 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the subject no longer derives clinical benefit, or (iv) the subject meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.
3361989|NCT02831673|Active Comparator|DTG + TDF/FTC FDC (50 mg+300/200 mg)|Eligible subjects will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).
3361990|NCT02827201|Experimental|nab-paclitaxel + gemcitabine/FOLFIRI.3|"Alternance of :~2 months with nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m², 30 min in IV, 3 injections follow by 1 week free)~follow by 2 months with FOLFIRI.3 (irinotecan: 90 mg/m² at D1, acid folinic 400 mg/m², 5Fu continus: 2000 mg/m² IV 46 hours, and irinotecan at D3, 90 mg/m²) This alternance continus until progression"
3361991|NCT02827201|Active Comparator|nab-paclitaxel + gemcitabine|nab-paclitaxel (125 g/m² - 30 min in IV) + gemcitabine (1000 mg/m² - 30 min in IV) 3 injections follow by 1 week free, until progression
3361992|NCT02816996|Experimental|Hand-holding|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
3361993|NCT02816996|Experimental|Stress Ball|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
3249082|NCT01372527|Experimental|TopCare Intervention|"The TOP-CARE intervention will be based on a medical informatics platform that:~Identifies all patients eligible for any of the three cancer screening programs~Links patients with a specific clinician~Offers a visit-independent method for clinicians to review panels of their eligible patients~For patients due for one or more cancer screenings, clinicians will access a web-based informatics tool to:~Screen their panel based upon risk~Defer patients, document exclusions, and update the EHR~Order a screening test with patient information material based upon the patient's risk profile and automatically initiate the process of:~Informing the patient by letter of the need to schedule a test, educating the patient with respect to the benefits of cancer screening, and properly documenting the transaction in the patient's EHR, or~Referral to a patient navigator for patients most likely to benefit from this more intensive approach"
3259420|NCT01470690|Experimental|boceprevir+omeprazole|Omeprazole 40 mg QD for 5 consecutive days combined with boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5 (BOC+OME)
3361994|NCT02816996|No Intervention|Nothing|Subjects will be randomized to be in the handholding, stress ball, or control study arms. The randomization will be 1:1:1.
3249083|NCT01372527|Active Comparator|Augmented Standard Care|In augmented standard care control practices, we will implement a system that includes: 1) a population-based perspective to identify all eligible patients overdue for screening, 2) an automated, centralized process to contact selected patients by letter, 3) a result management system that automatically tracks test scheduling and completion, 4) a web-based, easily accessible tool allowing practice personnel to contact patients not completing testing, and 5) use of patient navigators for high risk patients not responding to initial outreach. In the control arm, the process of escalating the reminder intervention from a letter, to contact by phone call, to a patient navigator, will occur in a standard algorithmic fashion without provider input.
3249084|NCT01372540|Experimental|Treatment (filanesib and carfilzomib)|Patients receive filanesib IV over 1 hour on days 1, 2, 15, and 16 and carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 8 courses of therapy, patients may continue with dosing of carfilzomib on days 1, 2, 15, and 16 and filanesib as tolerated. If patient progresses on carfilzomib maintenance with administration on days 1, 2, 15, and 16 they may increase the intensity and add in days 8 and 9 dosing.
3249085|NCT01372553||Family history risk stratification|primary care patients who receive risk stratification and clinical decision support based upon the family health history they entered in to MeTree
3361995|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir) with RBV|Patients received 1 EBR/GZR (elbasvir/grazoprevir) (Zepatier) tablet (50/100mg) once daily for 12 to 16 weeks (provider discretion) with Ribavirin (RBV) 200 mg/tablet, 1-3/day, taken 1-2 times per day (dosage at discretion of provider).
3361996|NCT02786537|Active Comparator|EBR/GZR (elbasvir/grazoprevir)|Patients received 1 EBR/GZR (elbasvir/grazoprevir) tablet (50/100 mg) once daily for 12 to 16 weeks (provider discretion) (without Ribavirin)
3249088|NCT01372579|Experimental|Treatment (neoadjuvant chemotherapy)|Patients receive eribulin mesylate IV over 2-5 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3249089|NCT01372592||Degenerative|Patients being treated for degenerative spine conditions.
3249090|NCT01372592||Deformity|Patients being treated for a deformity spine condition.
3361997|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir) with RBV|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) (Harvoni) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks with ribavirin (RBV) (at discretion of provider). RBV taken as 200 mg/tablet(capsule), 1-3 pills/day, 1-2 times/day.
3361998|NCT02786537|Active Comparator|SOF/LDV (sofosbuvir/ledipasvir)|Patients received 1 SOF/LDV (sofosbuvir/ledipasvir) tablet (400/90 mg) orally once daily with or without food 12 to 24 weeks without ribavirin (RBV) (per discretion of provider)
3361999|NCT02786537|Active Comparator|PrOD (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) with RBV (Phase 1 only)|"Patients received Pr0D (Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir) orally daily with food for 12 to 24 weeks with RBV (Ribavirin). Ombitasvir/Paritaprevir/Ritonavir (12.5/75/50 mg/tablet) -2 tablets once daily with food for 12 to 24 weeks and 1 dasabuvir tablet (250 mg) twice daily with food for 12 to 24 weeks.~RBV (200 mg/pill) 1-3 pills/day, 1-2 times/day (use and dosage at provider discretion). Total daily RBV dosage ranged from 200 to 1200 mg."
3362000|NCT02786537|Active Comparator|PrOD (ombitasvir/paritaprevir/ritonavir and dasabuvir)|Patients received 2 ombitasvir/paritaprevir/ritonavir tablets (12.5/75/50 mg) once daily and 1 dasabuvir (250 mg) tablet twice daily with food for 12 to 24 weeks without Ribavirin (as per provider instructions)
3362001|NCT02775851|Experimental|Cohort A (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles. Patients with potentially resectable disease undergo surgery. Patients with tumor progression and unresectable disease may receive one additional cycle of pembrolizumab.
3362002|NCT02775851|Active Comparator|Cohort B (pembrolizumab)|Patients with unresectable disease receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 34 cycles in the absence of disease progression or toxicity.
3362003|NCT02765191|Experimental|Study group|Subjects investigated according to protocol after administration of bolus of Ringer's Acetate
3362004|NCT02759419|Experimental|BAY63-2521|Single-arm, uncontrolled
3362005|NCT02756845|Experimental|Talimogene Laherparepvec (TVEC)|The first dose of talimogene laherparepvec will be administered at a dose of up to 4.0 mL of 10ᶺ6 PFU/mL followed by a dose of up to 4.0 mL of 10ᶺ8 PFU/mL 21 days (+3 days) later. Subsequent doses of up to 4.0 mL of 10ᶺ8 PFU/mL will be administered every 14 days (± 3 days) thereafter. Cohorts will be assigned as follows: Cohort A1 (age 12 to ≤ 21 years). Cohort B1 (age 2 to < 12 years). The DLRT will review the safety data of the first 3 subjects in the older age cohort A1 to decide if the younger age cohort B1 can be opened for enrollment. If dose de-escalation is needed and if permissible based on the incidence of DLTs, additional DLT-evaluable subjects will be enrolled and treated at a lower dose level of talimogene laherparepvec. Dose de-escalation cohorts will be assigned as follows and the same DLT rules will be applied: Cohort A2 (age 12 to ≤ 21 years), Cohort B2 (age 2 to < 12 years).
3362006|NCT02740231|Active Comparator|Reference product|Hylan G-F 20
3362007|NCT02740231|Experimental|JTA-004 50 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
3362008|NCT02740231|Experimental|JTA-004 50 (4 ml)|Sodium hyaluronate, plasma proteins and clonidine
3362009|NCT02740231|Experimental|JTA-004 100 (2 ml)|Sodium hyaluronate, plasma proteins and clonidine
3362010|NCT02733601||Breast Cancer Patients|Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
3362011|NCT02710084|Experimental|Oxytocin|The first phase of the study will follow a double-blind, placebo-controlled design. Participants randomized to the experimental group will receive intranasal oxytocin in doses of 24 IU, two times daily, for a total of 48 IU. Doses may be reduced by 8 IU/day if safety concerns emerge. During the second phase of the study, all participants will receive oxytocin, in identical doses.
3362012|NCT02710084|Placebo Comparator|Saline|During the first phase, patients randomized to the placebo group will receive intranasal saline solution in doses of 24 IU two times daily, for a total of 48 IU. During the second phase of the study, all participants will receive oxytocin, in identical doses.
3249091|NCT01372592||Trauma|Patients being treated for a trauma related spine condition.
3249092|NCT01372631|Experimental|Pressure assessment|30 patients undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled to assess the ideal pressure that should be applied when taking optical measurements.
3249093|NCT01372631|Experimental|Random and Systematic Errors|40 patients undergoing lumpectomy or mastectomy will be enrolled to assess the random and systematic errors of the miniature spectral imaging system.
3362013|NCT02699697|Experimental|ARM I (palliative radiation therapy)|Patients undergo 1 fraction of EBRT over 30 minutes.
3362014|NCT02699697|Experimental|ARM II (palliative radiation therapy)|Patients undergo 2 fractions of EBRT over 30 minutes. The 2 fractions will be separated by 3-7 days.
3362015|NCT02684058|Experimental|HGG cohort: Dabrafenib and trametinib|HGG cohort: All patients in the HGG cohort will receive DRB+TMT
3362016|NCT02684058|Active Comparator|LGG cohort: Carboplatin with vincristine|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
3362017|NCT02684058|Experimental|LGG cohort: Dabrafenib and trametinib|LGG cohort: Patients randomized 2:1 to either DRB+TMT or active comparator chemotherapy.
3362018|NCT02683239|Experimental|Fasinumab dosing regimen 1|
3362019|NCT02683239|Experimental|Fasinumab dosing regimen 2|
3362020|NCT02683239|Experimental|Placebo|
3362021|NCT02678312|Experimental|Part 1: LCZ696 open label|LCZ696 open label either 1) 0.8 mg/kg or 2) 3.1 mg/kg or both. After LCZ696 PK assessment, patients will be maintained on open-label Enalapril or standard of care for heart failure treatment, if patient consents to participate in Part 2.
3362022|NCT02678312|Active Comparator|Part 2: Enalapril|The target dose for enalapril is 0.2 mg/kg bid (0.4 mg/kg total daily dose) with a maximum dose of 10 mg bid (20 mg total daily dose).
3362023|NCT02678312|Experimental|Part 2:LCZ696|LCZ696 3.125 mg granules and adult formulation (50, 100, 200 mg) can be given based on patient weight.
3249094|NCT01372631|Experimental|Sensitivity and Specificity Assessment|150 patient undergoing lumpectomy, mastectomy or reduction mammoplasty will be enrolled in order to determine the sensitivity and specificity of the miniature spectral imaging system.
3249095|NCT01372644|Experimental|ADH, ALH, LCIS, SOM 230|Women who meet eligibility criteria.
3249096|NCT01372657||cataract patients|cataract patients
3362024|NCT02672215|Experimental|tailored group|Received a web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting.
3362025|NCT02672215|Active Comparator|generic group|Received a web-based intervention containing generic information and tips to reduce and/or interrupt workplace sitting.
3362026|NCT02672215|No Intervention|control group|A waitlist control condition and received the generic intervention after completing all measurements
3362029|NCT02660034|Experimental|Part A: Dose Escalation Phase|Participants received tislelizumab and pamiparib (dose escalation) until determination of the maximum tolerated dose/recommended Phase 2 dose.
3362030|NCT02660034|Experimental|Part B: Dose Expansion Phase|Participants received tislelizumab and pamiparib (dose expansion).
3362031|NCT02645474|Active Comparator|Paravertebral block with ropivacaine|Patients are treated with an older technique (paravertebral block with ropivacaine), somehow established in treating pain after breast surgery. This technique has been shown to be effective but has an intrinsic risk of iatrogenic pneumothorax and is considered technically demanding.
3362032|NCT02645474|Experimental|PECS block with ropivacaine|Patients are treated with PECS block, which has been already adopted in common clinical practice as an alternative to paravertebral block for postoperative pain treatment after breast surgery. This technique is thought to be somehow simpler to perform and safer with regard to pneumothorax, however no studies have been done yet to statistically compare the two blocks with regard to safety and effectiveness.
3362033|NCT02640625|Experimental|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
3362034|NCT02617277|Experimental|Dose Schedule A|In Schedule A, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 1-5 and Days 15-19 of a 28-day cycle. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib).
3362035|NCT02617277|Experimental|Dose Schedule B|In Schedule B, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 15-17 and Days 22-24 of a 28-day cycle. In Schedule B there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
3362036|NCT02617277|Experimental|Dose Schedule C|In Schedule C, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) twice daily orally on Days 8-10, Days 15-17, and Days 22-24 of a 28-day cycle. In Schedule C there will be a 7-day AZD1775 (adavosertib) lead-in to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
3362037|NCT02617277|Experimental|Dose Schedule D|In Schedule D, patients will receive MEDI4736 (durvalumab) by intravenous on Day 1, and AZD1775 (adavosertib) one time per day orally on Days 15-19, and Days 22-26 of a 28-day cycle. In Schedule D there will be a 9-day lead-in period with AZD1775 (adavosertib) being dosed on Days -9 to -5 to enable serial PK measurements prior to initiating MEDI4736 (durvalumab) on Day 1. In all dose schedules, dexamethasone will be administered as an anti-emetic on the first day of the AZD1775 (adavosertib) consecutive dosing day blocks including the lead-in portion of Schedules B, C, and D. Additional alternative dose levels and/or schedules may also be explored if emerging data suggest these would be more appropriate.
3362039|NCT02586519|Experimental|Active SurroSense Rx System + RCW|Patients randomized to the experimental group will be fitted with an active (alerting) version of the SurroSense R® smart insole System. This device will be placed in the RCW, underneath the liner. The device tab will be fed up the instep, through a hole in the liner, and affixed to the dorsum of the RCW by way of a tie.
3362040|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + RCW|Patients randomized to this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion.
3249097|NCT01372670|Experimental|Hydroxyzine|Hydroxyzine given TID
3362041|NCT02586519|Sham Comparator|Inactive SurroSense Rx System + iTCC|Patients in this group will be fitted with an inactive (non-alerting) version of the device in an identical fashion. The RCW will be further secured using a device specific tie such that it acts as an iTCC.
3362045|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose A|Participants were administered AMG 224 Dose A as an intravenous (IV) infusion once every 3 weeks (Q3W) on Day 1 of each cycle, where each cycle is 3 weeks.
3362046|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose B|Participants were administered AMG 224 Dose B as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3249098|NCT01372670|Placebo Comparator|Sugar Pill|Placebo given 3 times per day
3249099|NCT01372683|Experimental|Test cereal 1|Oat based breakfast cereal
3249100|NCT01372683|Experimental|Test cereal 2|2nd Oat based breakfast cereal
3249101|NCT01372683|Experimental|Leading oat based RTE cereal|3rd oat based breakfast cereal
3249102|NCT01372696|Other|Tissue sample|Patients who consent to participate in this study will have a small sample of their polyp and normal tissue sent for molecular testing.
3249103|NCT01372709||Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients will be consecutively screened for the study. Eligible patients must meet all of the inclusion criteria and none of the exclusion criteria.
3249104|NCT01372722|Experimental|Sham then Stimulation|
3249105|NCT01372722|Experimental|Stimulation then Sham|
3249106|NCT01372761|Placebo Comparator|Normal Saline|
3249107|NCT01372761|Experimental|ZGN-433|
3249108|NCT01372787||Arm I|
3249109|NCT01372800||volunteer|
3249110|NCT01372826|Experimental|NKTR118 Group1|Normal Renal Function
3362047|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose C|Participants were administered AMG 224 Dose C as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3249111|NCT01372826|Experimental|NKTR118 Group 2|Moderate Renal Function
3362048|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose D|Participants were administered AMG 224 Dose D as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3362049|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose E|Participants were administered AMG 224 Dose E as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3362050|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose F|Participants were administered AMG 224 Dose F as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3249112|NCT01372826|Experimental|NKTR118 Group 3|Severe Renal Impairment
3249113|NCT01372826|Experimental|NKTR118 Group 4|End-Stage Renal Disease
3362051|NCT02561962|Experimental|Dose Exploration: AMG 224 Dose G|Participants were administered AMG 224 Dose G as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3362052|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + prior CD38 targeting antibody treatment|Participants who had prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the maximum tolerated dose [MTD] based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3249114|NCT01372839|Active Comparator|Atorvastatin|80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
3249115|NCT01372839|Other|Usual care|statin dose should not be higher than that described in exclusion criteria.
3249116|NCT01372852||T2DM patients|newly diagnosed T2DM patients and untreated with any drugs.
3362053|NCT02561962|Experimental|Dose Expansion: AMG 224 Dose H + no prior CD38 targeting antibody treatment|Participants who had no prior treatment with CD38-targeting antibody were administered AMG 224 Dose H (the MTD based on the dose exploration phase) as an IV infusion Q3W on Day 1 of each cycle, where each cycle is 3 weeks.
3362054|NCT02530034|Experimental|Treatment (Hu8F4)|Patients receive anti-PR1/HLA-A2 monoclonal antibody Hu8F4 IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3362055|NCT02519348|Experimental|Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants in Part 1A (safety run-in cohort) and Part 1 B (efficacy-gating cohort) will receive tremelimumab 1 mg/kg every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362056|NCT02519348|Experimental|Parts 2 and 3: Durvalumab 1500 mg|Participants will receive durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362057|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 300 mg 1 dose and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow, or development of other reason for treatment discontinuation, whichever occurs first.
3249117|NCT01372852||Non-diabetic Control Group|
3249118|NCT01372865|Experimental|Mometasone|
3249119|NCT01372865|Active Comparator|Nasonex®|
3362058|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 750 mg|Participants will receive tremelimumab 750 mg Q4W 7 doses followed by every 12 weeks (Q12W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3249120|NCT01372891||Patients underging PCI|
3249121|NCT01372904|Experimental|Dexamethasone|
3249122|NCT01372917||Allomax|The cohort consists of immediate breast reconstruction patients who have AlloMax placed at the time of their tissue expander based immediate breast reconstruction.
3249123|NCT01372930|Experimental|Etanercept|
3249124|NCT01372930|Placebo Comparator|saline|
3249125|NCT01372943|Experimental|synthetic stool|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
3249126|NCT01372956||Dyslipidemia|
3249127|NCT01372969|Experimental|Cx601|
3249128|NCT01372982|Active Comparator|Femara|
3249129|NCT01372982|Experimental|Letrozole|
3249130|NCT01373008|Experimental|Inhaled QVAR|Inhaled QVAR 100 mic via aerochamber twice daily until 3 month post discharge
3249131|NCT01373008|Placebo Comparator|Inhaled placebo|Inhaled nonmedicated MDI [metered dose inhaler] in a similarly marked aerosol chamber using the same delivery technique, obtained from the drug manufacturer
3249132|NCT01373021|Placebo Comparator|F|Fentanyl+Normal saline
3249133|NCT01373021|Experimental|D|Fentanyl+Dexmedetomidine
3249134|NCT01373034|Experimental|Soy Dietary Fiber|
3249135|NCT01373034|Placebo Comparator|Rice powder|
3249136|NCT01373047|Experimental|Intrahepatic anti-CEA designer T cells|
3249137|NCT01373060|Experimental|ASP1941 group|
3249138|NCT01373060|Placebo Comparator|placebo group|
3249139|NCT01373073|Experimental|Experimental Human Milk Fortifier|Experimental human milk fortifier to be added to human milk
3249140|NCT01373073|Active Comparator|Control Human Milk Fortifier|Control human milk fortifier to be added to human milk
3249141|NCT01373086|Experimental|LFF269 low dose|LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period
3249142|NCT01373086|Experimental|LFF269 high dose|LFF269 high dose + Matching Placebo to Eplerenone 50mg
3249143|NCT01373086|Active Comparator|Eplerenone|Eplerenone 50mg twice daily + matching placebo of LFF269
3249144|NCT01373086|Placebo Comparator|Placebo|Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg
3249145|NCT01373099|Experimental|Static Spacer|Patients in this group will be randomized to a static, nonarticulating, antibiotic-impregnated cement spacer.
3249146|NCT01373099|Experimental|Articulating spacer|Patients in this group will be randomized to an articulating antibiotic-impregnated cement spacer.
3259421|NCT01470703|Experimental|ECMO arm|
3259422|NCT01470703|Active Comparator|conventional arm|
3259423|NCT01470716|Experimental|Study arm|Neo-adjuvant Erlotinib treatment arm.
3362059|NCT02519348|Experimental|Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg|Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362060|NCT02519348|Experimental|Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg|Participants will receive durvalumab 1120 mg and bevacizumab 15 mg/kg every 3 weeks (Q3W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first
3362061|NCT02519348|Experimental|China Cohort: Durvalumab 20 mg/kg|Participants will receive durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362062|NCT02519348|Experimental|China Cohort: Tremelimumab 10 mg/kg|Participants will receive tremelimumab 10 mg/kg Q4W 7 doses followed by Q12W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362063|NCT02519348|Experimental|China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg|Participants will receive tremelimumab 1 mg/kg Q4W 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
3362064|NCT02516553|Experimental|arm A|once daily continuous oral intake in 3-week cycles
3362065|NCT02516553|Experimental|arm B|once daily intermittent oral intake with two weeks on treatment followed by one week off in 3-week cycles
3362066|NCT02516553|Experimental|arm C|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
3249147|NCT01373112|Experimental|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
3249148|NCT01373112|Experimental|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
3249149|NCT01373125||Radiofrequency Ablation (RFA)|Participants in this group are greater than or equal to 12 months status post radiofrequency ablation (RFA).
3249150|NCT01373125||Radiofrequency Ablation Longitudinal (RFAL)|Participants in this group are part of a longitudinal portion of the study and are enrolled prior to their first radiofrequency ablation procedure and followed at 6 and 12 months after completion of RFA.
3362067|NCT02512172|Experimental|Oral CC-486 & MK-3475|Oral CC-486 300 mg days 1-14 or 21 every 28 days + IV MK-3475 200 mg days 1 and 15 every 28 days
3362068|NCT02512172|Experimental|Romidepsin & MK-3475|Romidepsin 14 mg/m2 days 1, 8 and 15 + IV MK-3475 200 mg days 1 and 15 every 28 days
3362069|NCT02512172|Experimental|Oral CC-486 & Romidepsin & MK-3475|Oral CC-486 300 mg days 1-14 or 21 + romidepsin 7 mg/m2 (days 1, 8 and 15) + IV MK-3475 200 mg days 1 and 15 every 28 days.
3362070|NCT02501096|Experimental|Lenvatinib + Pembrolizumab|Participants with one of the tumors: non-small cell lung cancer, renal cell carcinoma, endometrial cancer, urothelial cancer, squamous cell carcinoma of the head and neck, or melanoma.
3362071|NCT02500589|Experimental|Mood management enhancement|In the SMK-MM enhanced arm, behavioral mood management will be integrated into the evidence-based smoking cessation counseling.
3362072|NCT02500589|Other|Health education control|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with personal health care. Participants also will receive chronic-disease-specific self-management information."
3249151|NCT01373125||Gastroesophageal Reflux Disease (GERD)|Participants in this group have been diagnosed with gastroesophageal reflux disease.
3249152|NCT01373125||Asymptomatic Controls (AC)|Participants in this group are asymptomatic controls and enrolled as part of the comparison group.
3249153|NCT01373138|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
3249154|NCT01373138|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
3362075|NCT02494258|Experimental|Oral Azacitidine (CC-486)|This study is an open-label, single-arm study and is divided into the screening period, treatment period and follow-up period. It is intended to evaluate the long-term safety of CC-486 and is to be taken at the same dose, schedule and frequency used from the last dose of CC-486 given in the parent study.
3362077|NCT02474329||Cohort 1|"Dutch Parkinson's patients resident in the region of Noord-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3362078|NCT02474329||Cohort 2|"Dutch Parkinson's patients resident in the region of Zuid-Holland whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3362079|NCT02474329||Cohort 3|"Dutch Parkinson's patients resident in the region of Gelderland and Utrecht whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3362080|NCT02474329||Cohort 4|"Dutch Parkinson's patients resident in the region of Groningen, Friesland, Drenthe and Overijssel whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3362081|NCT02474329||Cohort 5|"Dutch Parkinson's patients resident in the region of Zeeland, Noord-Brabant and Limburg whose fulfill the eligibility criteria.~Interventions/Exposures to be administered:~PPMI (Parkinson's Progression Markers Initiative) protocol Trained physiotherapists will perform once a standardized clinical assessment to every included patient. This assessment will last for 60 minutes, and it will be done once.~Fox Insight self-monitoring android app and falls detector Patients will wear a smartwatch and a pendant movement sensor during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling."
3362082|NCT02471339|Experimental|1/Acceptance and Commitment Therapy (ACT) Group|2 Acceptance and Commitment Therapy (ACT) Training Sessions followed by weekly emails and video chats.
3362083|NCT02471339|Active Comparator|2/Waitlist (WL) Group|Waitlist group - no intervention for first 8 weeks (then will receive Acceptance and Commitment Therapy (ACT) intervention as Arm 1)
3362084|NCT02450890|Placebo Comparator|Placebo First, then ORADUR®|Placebo once daily for 2 weeks in Period 1 and ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in period 2. (No washout period between two treatment periods)
3362085|NCT02450890|Experimental|ORADUR® First, then Placebo|ORADUR®-Methylphenidate oral capsule at the optimal dose once daily for 2 weeks in Period 1 and Placebo once daily for 2 weeks in period 2. (No washout period between two treatment periods)
3249162|NCT01373177|Active Comparator|BSID-II, then Bayley-III|Receive BSID-II testing 4-8 weeks before Bayley-III testing
3249163|NCT01373177|Active Comparator|Bayley-III, then BSID-II|Receive Bayley-III testing 4-8 weeks before BSID-II testing
3249164|NCT01373190||Epilepsy Group|Individuals diagnosed with Partial/Focal Onset Epilepsy ICD9CM 345.4 and/or 345.5
3249165|NCT01373190||Control Group|Individuals who do not have the diagnosis of Epilepsy and have no history of seizure disorders
3259424|NCT01470729||Spinocerebellar Ataxia type 1 (SCA1)|Spinocerebellar Ataxia type 1 (SCA1)
3362089|NCT02422355||Femoral Neck Fractures AO/OTA 31-B1:3|Fixation using the implant FNS.
3249166|NCT01373216|Experimental|Exenatide|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving perioperatively i.v. exenatide on top of standard treatment
3362090|NCT02414139|Experimental|cMET GCN ≥ 6|Pre-treated patients with cMET GCN ≥ 6 treated with INC280 at 400mg BID as second or third line
3249167|NCT01373216|No Intervention|Control|Patients with decreased left ventricular function undergoing elective coronary artery by-pass grafting receiving standard treatment
3249168|NCT01373255|Experimental|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
3249169|NCT01373255|No Intervention|No intervention|no intervention prior to cesarean
3249170|NCT01373307|Experimental|Early Intervention|Participants are nested in churches which were randomly assigned to receive the intervention first.
3362091|NCT02414139|Experimental|cMET GCN ≥ 4 and < 6|Pre-treated patients with cMET GCN ≥ 4 and < 6 treated with INC280 at 400 mg BID as second or third line
3362092|NCT02414139|Experimental|cMET GCN < 4|Pre-treated patients with cMET GCN < 4 treated with INC280 at 400mg BID as second or third line
3362093|NCT02414139|Experimental|cMET mutations|Pre-treated patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID as second or third line
3362094|NCT02414139|Experimental|cMET dysregulation - treatment-naïve|Treatment-naïve patients with cMET dysregulation treated with INC280 at 400mg BID
3249171|NCT01373307|No Intervention|Delayed Intervention|Wait-list control group. Participants are nested in churches which were randomly assigned to receive the intervention at a later date. Delayed Intervention participants receive an educational luncheon addressing stress reduction during the window of no intervention.
3362095|NCT02414139|Experimental|cMET dysregulation - second line|Pre-treated patients with cMET deregulation treated with INC280 at 400 mg BID as second line
3362096|NCT02414139|Experimental|cMET mutations treatment-naïve|Treatment-naïve patients with cMET mutations regardless of cMET GCN treated with INC280 at 400mg BID
3249172|NCT01373320|Experimental|Early Intervention|Participants in this group are nested in churches which were randomly assigned to the treatment group.
3362097|NCT02384993|Experimental|Enhanced Physical Activity|Those assigned to the enhanced physical activity group will train 3-4 days per week with the goal of attaining current public health recommendations of 150 minutes of moderate intensity exercise by the 7th week of training, and maintaining this level of exercise for the remainder of the 26-week intervention. A gradual increase in exercise intensity and duration will be used throughout this twenty-six week exercise intervention, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Training will occur in individual sessions supervised by exercise specialists with the appropriate education and experience. Each training session will begin with an appropriate warm-up, slowly build up, and end with an appropriate cool down period.
3362098|NCT02384993|No Intervention|Usual Physical Activity|"All study participants randomized to the usual physical activity group will receive education from study staff about the importance of maintaining a healthy and active lifestyle. They will receive standardized literature such as Exercise & Physical Activity: Your Everyday Guide from the National Institute on Aging. These booklets provide vetted and reliable information for older adults on how to exercise. Participants assigned to the usual physical activity group will not be provided additional support or guidance with an exercise program."
3249173|NCT01373320|No Intervention|Delayed Intervention|Participants in this group are nested in churches which were randomly assigned to the wait-list control group. They receive an educational luncheon focused on stress reduction during the intervention window for the Early Intervention group, and subsequently receive the intervention(s) for their selected target health behaviors at a later date.
3249174|NCT01373359|Experimental|Sublingual misoprostol|400 µg powdered misoprostol administered sublingually; IM placebo
3249175|NCT01373359|Active Comparator|Oxytocin|10 IU IM oxytocin; placebo powder
3249176|NCT01373372|Experimental|Functional Dyspepsia cohort|Cohort of subjects with functional dyspepsia
3249177|NCT01373372|Other|Control cohort|Control group of subjects with no functional dyspepsia
3249178|NCT01373385||Surgical|Patients receiving a surgical procedure for vesicoureteral reflux at Connecticut Children's Medical Center.
3362099|NCT02366559|Active Comparator|electrocautery|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
3249179|NCT01373411|Placebo Comparator|Placebo|Placebo twice daily. Study drug will be started within 48 hours of CABG.
3249180|NCT01373411|Active Comparator|ticagrelor 90 mg|Taken twice daily. Study drug will be started within 48 hours of CABG.
3249181|NCT01373424||Cervical dystonia|People diagnosed with cervical dystonia
3249182|NCT01373424||Laryngeal dystonia|People diagnosed with laryngeal dystonia
3249183|NCT01373424||Other voice disorders|People diagnosed with a voice disorder other than laryngeal dystonia - enrollment for this group is complete
3249184|NCT01373424||Craniofacial dystonia|People diagnosed with craniofacial dystonia (including blepharospasm, meige syndrome, and oromandibular dystonia)
3249185|NCT01373424||Limb dystonia|People diagnosed with limb dystonia
3249186|NCT01373424||All other isolated dystonias|People diagnosed with any isolated dystonia not listed in descriptions of other cohorts
3249187|NCT01373424||Myoclonus dystonia|People diagnosed with myoclonus dystonia
3249188|NCT01373424||Dopa-responsive dystonia|People diagnosed with dopa-responsive dystonia
3249189|NCT01373437||Intubate|
3249190|NCT01373463|Experimental|Arm A|"Patients will be given the drugs pemetrexed and carboplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
3362100|NCT02366559|Active Comparator|532 nm Nd:YAG laser|Blocks of subjects' lesions will be randomized 1:1 to receive electrocautery or 532 nm Nd:YAG laser. Prior to treatment with either electrocautery or 532nm Q-switched Nd:YAG laser, a topical EMLA cream will be applied to the lesions for at least 60 minutes under occlusion at the area of treatment.
3362101|NCT02352337|Active Comparator|FOLFIRINOX|Every two weeks (maximum of 12 cycles) : Oxaliplatin 85 mg / m2 Day1 in 2 hours - then Irinotecan 180 mg / m2 Day1 in 90 minutes - Folinic acid 400 mg / m2 Day1 in 2 h (during the irinotecan infusion) - 5-FU bolus 400 mg / m² Day1 followed by continuous 5-FU 2400 mg / m2 total over 46 hours
3362102|NCT02352337|Experimental|FOLFIRINOX + LV5FU2 in maintenance|"Folfirinox during 4 months followed by LV5FU2 maintenance until progression:~Folfirinox (as described in arm FOLFIRINOX) LV5FU2 : Folinic acid 400 mg/m² (200 mg/m² if Elvorine), in perfusion over 2 hours the 5FU 400 mg/m² in bolus over 10 mn followed by 5FU 2400 mg/m² in perfusion over 46 hours."
3362103|NCT02352337|Experimental|FIRGEM|"Alternance of 2 months of FOLFIRI.3 with 2 months of GEMCITABINE:~Folfiri.3: Irinotécan 90 mg/m² at day 1 in perfusion over 60 minutes in parralel of folinic acid Folinic acid 400 mg/m² (or 200 mg/m² Elvorine) at day 1 in perfusion over 2 hours 5FU continue 2000 mg/m² over 46 heures then irinotécan at 90 mg/m² (1h) at day 3 when 5U perfusion is over~Gemcitabine: 1000 mg/m² in perfusion over 30 mn at day 1,8,15,29,36 and 43 over (1 injection per week during 3 weeks followed with 7 days of rest )"
3362104|NCT02338609|Experimental|Everolimus|All patients will have been previously treated with everolimus as part of CRAD001M2301. Continued treatment with everolimus is allowed but not required for participation in this study. However, the physician may choose to place the patient on another treatment.
3362105|NCT02338609|Experimental|Physician Choice|
3362108|NCT02246530|Active Comparator|PRP injection into PTRCT|Treatment - PRP injection
3362109|NCT02246530|Active Comparator|Subacromial steroid bursal injection|Current standard of care for treatment of resistant partial thickness rotator cuff tears
3362110|NCT02239354|Experimental|Cohort 1|2 VC-01™ Combination Product implants
3362111|NCT02239354|Experimental|Cohort 2|4 or 6 VC-01™ Combination Product implants
3362112|NCT02229149|Experimental|Triple Therapy|"Physician's choice of chemotherapy plus trastuzumab plus pertuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off.~AND pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks."
3362113|NCT02229149|Active Comparator|Double Therapy|"Physician's choice of chemotherapy plus trastuzumab~trastuzumab, given as a loading dose of 8 mg/kg intravenously (IV, or through the vein) on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter, AND~physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg PO BID 14 days on and then 7 days off."
3249191|NCT01373463|Experimental|Arm B|"Patients will be given the drugs pemetrexed and cisplatin~Radiation~Participants evaluated for response~Lobectomy surgery"
3249192|NCT01373476|Experimental|Qideng Mingmu capsule|High dosage group,Middle dosage group,Low dosage group.
3249193|NCT01373476|Placebo Comparator|Placebo|Placebo group
3249194|NCT01373502|Experimental|DES Limus Carbostent Coronary Stent|
3249195|NCT01373502|Active Comparator|Taxus Liberté Coronary Stent|
3249196|NCT01373515|Experimental|Cohort 1; 1x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 1x10E7 DCP-001.
3249197|NCT01373515|Experimental|Cohort 2; 2.5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 2.5x10E7 DCP-001.
3249198|NCT01373515|Experimental|Cohort 3; 5x10E7 DCP-001|n=3; patients receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001.
3249199|NCT01373515|Experimental|Cohort 4; 5x10E7 DCP-001|n=3; patients, matched for HLA-A2, receiving 4 bi-weekly vaccinations of 5x10E7 DCP-001. Or, in case this turned out toxic, this group will receive the Maximum Tolerated Dose.
3249200|NCT01373528|Experimental|Budesonide|
3249201|NCT01373541|Active Comparator|InFat group|Infant formula with structured triglycerides (high palmitic acid content at the sn-2 position)
3249202|NCT01373541|Active Comparator|Control group|Infant formula with standard vegetable blend (low palmitic acid content at the sn-2 position)
3249203|NCT01373541|No Intervention|Referance group|Human milk breastfeeding
3249204|NCT01373554|Placebo Comparator|Placebo|
3249205|NCT01373554|Experimental|Oltipraz|
3249206|NCT01373567|Experimental|TINEFCON|Tablets of 700 mg.
3249207|NCT01373593|Experimental|lidocaine|lidocaine block
3249208|NCT01373593|Placebo Comparator|Placebo|
3249209|NCT01373606|Experimental|Terlipressin|
3259425|NCT01470729||Spinocerebellar Ataxia type 2 (SCA2)|Spinocerebellar Ataxia type 2 (SCA2)
3259426|NCT01470729||Spinocerebellar Ataxia type 3 (SCA3)|Spinocerebellar Ataxia type 3 (SCA3)
3249210|NCT01373619|Experimental|IVABRADINE, HEART FAILURE WITH NORMAL EF|Patient on hemodialysis with Heart failure with normal ejection fraction treated with ivabradine titrated to 7.5 mg BID to assess changes in echocardiography diastolic function and NYHA class and 6-minutes walking test
3362125|NCT02187991|Active Comparator|ER+/HER2- Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
3362126|NCT02187991|Experimental|ER+/HER2- Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
3362127|NCT02187991|Active Comparator|Triple Negative Paclitaxel Alone|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
3362128|NCT02187991|Experimental|Triple Negative Paclitaxel plus Alisertib|Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
3362129|NCT02184416||Observational Arm|"Patients will be enrolled when they start a treatment with Sutent in 1st line or Inlyta in 2nd line post Sutent treatment. The possible sequences of treatment under investigation will be:~Sutent (prospective) - Inlyta~Sutent (retrospective) - Inlyta~Sutent - not further active treatment (supportive care)~Sutent - other second line treatment (Nexavar (sorafenib), Votrient (pazopanib), Afinitor (everolimus), Torisel (temsirolimus), other))"
3362130|NCT02182687|Other|Arm A|Stereotactic Body Radiation Therapy (SBRT)
3362131|NCT02182687|Other|Arm B|Trans-Arterial Chemoembolization (TACE) Drug: Doxorubin
3362132|NCT02163525|Active Comparator|Ablation vs Embolization|Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)
3362133|NCT02163525|Active Comparator|Ablation vs Myomectomy|Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)
3362134|NCT02159742||Cohort 1|
3362140|NCT01981174|Active Comparator|30-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
3249211|NCT01373632|Experimental|Firebird 2 stent group|the patients who receive Firebird 2 stent
3249212|NCT01373632|Active Comparator|Excel stent group|the patients who receive Excel stent
3249213|NCT01373645|Experimental|Yinyi stent|subjects with Yinyi stent implantation
3249214|NCT01373658|Experimental|Yinyi stent|
3249215|NCT01373684|Experimental|Peginterferon alfa-2a add on|All patients are all currently being treated with long-term NA treatment. PEG-IFN will be given in a dose of 180 μg per week s.c. for a total duration of 48 weeks starting at week 0.
3249216|NCT01373684|Active Comparator|Nucleoside analogue|All patients are all currently being treated with long-term Nucleos(t)ide analogue treatment and will continue using this medication during the duration of the study.
3362141|NCT01981174|Active Comparator|32-gauge needle|Subjects will be screened, assessed, and randomized to be injected with onabotulinum toxin A using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit. All needles would be luer lock, ½ inch length, and attached to separate 1cc syringes. Injection depth would be 1-2mm, dermal, and the angle of incidence would be perpendicular.
3362142|NCT01976273|Active Comparator|1064nm Q-switch Laser|The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
3362143|NCT01976273|Active Comparator|Glycolic Acid Peels|A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
3362144|NCT01950390|Active Comparator|Arm A (ipilimumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Beginning cycle 8, patients receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
3362145|NCT01950390|Experimental|Arm B (ipilimumab and bevacizumab)|"INDUCTION THERAPY: Patients receive ipilimumab IV over 90 minutes and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive bevacizumab as in Induction Therapy. Beginning cycle 8, patients also receive ipilimumab IV over 90 minutes on day 1. Cycles repeat every 12 weeks in the absence of disease progression or unacceptable toxicity."
3362146|NCT01948882|Experimental|ESS505|All subjects that sign the informed consent and meet the eligibility criteria will be scheduled for an implant procedure.
3362147|NCT01918683|Other|A -Tace alone|A - TACE alone (control group, current practice and treatment)
3362148|NCT01918683|Experimental|B - Tace combined with SBRT|B- TACE combined with SBRT (experimental group).
3362153|NCT01802203||truFreeze spray cryotherapy|truFreeze Spray Cryotherapy administered as routine clinical care
3362154|NCT01802086|Active Comparator|Emla-cream|Dose: 1 g Emla-cream, 1 hour.
3362155|NCT01802086|Placebo Comparator|Miniderm cream|Dose: 1 g Miniderm-cream, 1 hour.
3249217|NCT01373697|Active Comparator|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
3249218|NCT01373697|Active Comparator|Ibuprofen|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
3362156|NCT01742143||ICCAN|For those randomized into the ICCAN arm, the core of the intervention will be three ICCAN Access Facilitators who will assess needs and synchronize for each patient an individualized set of transdisciplinary services.
3362157|NCT01742143||Usual and Customary Group (U&C)|Participants in this group will receive the same written materials on social and economic resources as ICCAN group.
3362158|NCT01735942|Experimental|Ingenol Mebutate|Ingenol Mebutate applied to one side of face with skin lesions
3362159|NCT01735942|Active Comparator|Cryotherapy|Cryotherapy applied to other side of face with skin lesions
3362160|NCT01735929|Experimental|Neck Liposuction and Ultrasound Treatment|Subject will receive neck liposuction and ultrasound treatment.
3362161|NCT01735929|Sham Comparator|Sham|Subject will receive sham treatment
3362162|NCT01722929|Experimental|Skin sensor on surgery side|Skin sensor will be placed on the side that had surgery. This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
3362163|NCT01722929|Active Comparator|Skin sensor on non-surgery side|Skin sensor will be placed on the contralateral side from surgery site.This is split-body, interventional, parallel-design study. All participants will have the skin sensor measured twice on their bodies: on the side with surgery and a contralateral, control site of the body.
3362164|NCT01704209|Experimental|Fibroblast Treatment|The fibroblast treatment will be randomly injected into one side of the face.
3362165|NCT01704209|Placebo Comparator|Vehicle|The vehicle will be injected randomly to the other side of the face.
3362166|NCT01689012|Experimental|Facial Exercise|
3362167|NCT01632644||Physicians|Physicians performing skin biopsies
3362168|NCT01632644||Patients|Patients who have had skin biopsies
3362169|NCT01563783|Active Comparator|Woman Suitable for Myomectomy or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or Myomectomy (laparoscopic or abdominal).
3362170|NCT01563783|Active Comparator|Woman Suitable for UAE or GFA|This group will consist of women who desire uterine preservation. Women will be randomized 1:1 to GFA or uterine artery embolization (UAE).
3362171|NCT01535131|Active Comparator|Furlow palatoplasty|standard procedure
3362172|NCT01535131|Experimental|modified Furlow palatoplasty|standard procedure plus modification
3362173|NCT01525316|Experimental|Bovine Lactoferrin|Lactoferrin is a freeze-dried protein purified directly from fresh bovine milk.
3362174|NCT01525316|Placebo Comparator|Maltodextrin|Maltodextrin is an inert sugar.
3362177|NCT01500733|Experimental|Elderly greater than 65|
3362178|NCT01500733|Experimental|17p Deletioin|
3362179|NCT01436656|Experimental|LGX818 - Dose escalation|
3362180|NCT01436656|Experimental|LGX818 - Dose Expansion at MTD or RP2D|
3249219|NCT01373710|Experimental|Trastuzumab intrathecal|
3249220|NCT01373723|Experimental|invitation letter|to participate in the screening
3249221|NCT01373723|Experimental|Invitation letter, informative leaflet and phone call reminder|to participate in the screening
3249222|NCT01373723|Experimental|Invitation letter and informative leaflet|to participate in the screening
3362185|NCT01388491|Experimental|Treatment I: (DR-102)|21 days of combination active pills (containing 150 mcg desogestrel [DSG]/20 mcg ethinyl estradiol [EE]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
3362186|NCT01388491|Active Comparator|Treatment II|21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
3362187|NCT01373151|Placebo Comparator|Arm 1|BMS-945429 Placebo/BMS-945429+Methotrexate+Adalimumab Placebo
3362188|NCT01373151|Experimental|Arm 2|BMS-945429 + Methotrexate + Adalimumab Placebo
3362189|NCT01373151|Experimental|Arm 3|BMS-945429 + Methotrexate + Adalimumab Placebo
3362190|NCT01373151|Experimental|Arm 4|BMS-945429 + Methotrexate + Adalimumab Placebo
3362191|NCT01373151|Experimental|Arm 5|BMS-945429 + Methotrexate/Methotrexate Placebo + Adalimumab Placebo
3362192|NCT01373151|Experimental|Arm 6|BMS-945429 + Methotrexate/Methotrexate Placebo+Adalimumab Placebo
3362193|NCT01373151|Active Comparator|Arm 7|Adalimumab + Methotrexate
3362194|NCT01352533|Active Comparator|Running polypropylene closure|Half of every linear wound will be closed with running polypropylene sutures. This technique is Standard of Care.
3362195|NCT01352533|Experimental|Tissue Adhesive (Derma-Bond)|The experimental half of the wound will be randomized to receive closure with tissue adhesive alone.
3362196|NCT01352533|Experimental|Subcuticular polyglactin-910 combined with tissue adhesive|The experimental half of the wound will be randomized to receive closure with running subcuticular polyglactin-910 combined with tissue adhesive.
3362197|NCT01351103|Experimental|LGK974|LGK974
3362198|NCT01351103|Experimental|LGK974 in combination with PDR001|LGK in combination with PDR001
3362199|NCT01328587|Experimental|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 50mg/day (East Asian ancestry 25mg/day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
3362200|NCT01294020|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B of the study.
3362202|NCT01285947|Other|Naive Subjects|Subjects who have not previously undergone energy-based dermatologic procedures in the past.
3362203|NCT01285947|Other|Non-Naive Subjects|Subjects who have previously undergone energy-based dermatologic procedures in the past.
3362204|NCT01281644|No Intervention|No Laser Treatment|
3362205|NCT01281644|Active Comparator|45-60 J Diode Laser Therapy|Diode laser therapy will be initiated at 45-60 J for 30 ms to 100 ms.
3362206|NCT01274611|Active Comparator|Suction-Curettage|
3362207|NCT01274611|Experimental|Botox|
3249223|NCT01373749|Experimental|NOS|NO inhalation was performed in the first stage(<48h) of PPHN, NO inhalation was replaced by sildenafil in the second stage(>48h).
3249224|NCT01373749|Placebo Comparator|NO|NO inhalation was performed during the whole treatment procedure of PPHN. There is no other methods given to treat PPHN during the therapy course.
3249225|NCT01373762|Experimental|Exercise Videogame Bike|Families in this group will receive an interactive exercise videogame bike (ie. the Active Cycle) to keep in their home for three months.
3259427|NCT01470729||Spinocerebellar Ataxia type 7 (SCA7)|Spinocerebellar Ataxia type 7 (SCA7)
3259428|NCT01470742|Active Comparator|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
3362209|NCT01196390|Experimental|Arm I (radiotherapy, chemotherapy, trastuzumab)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive trastuzumab IV over 30-90 minutes on days 1, 8, 15, 22, 29, 36, and 57 and paclitaxel intravenously IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Beginning 21-56 days after surgery, patients receive trastuzumab IV over 30-90 minutes. Treatment repeats every 21 days for 13 courses in the absence of disease progression or unacceptable toxicity.
3362210|NCT01196390|Experimental|Arm II (radiotherapy and chemotherapy)|Patients undergo radiotherapy once daily 5 days a week for 5.5 weeks. Patients also receive paclitaxel IV over 60 minutes and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
3362211|NCT00960297|Experimental|Carboplatin/Paclitaxel/Bevacizumab|Preoperative chemotherapy and bevacizumab
3249226|NCT01373762|Other|Stationary Bike|Families will receive a stationary bike to keep in their home for three months. It is required that the family places the stationary bike (Active Cycle without video game controllers) in front of a television.
3249227|NCT01373775||Revisit|HF patients who revisit the emergency department before the next appointment date.
3249228|NCT01373775||Non-revisit|HF patients who follow up on the appointment date.
3362214|NCT00910650|Experimental|F5 TCR transgenic cells|F5 TCR transgenic cell adoptive transfer therapy
3362215|NCT00793169||lidocane|Patients undergoing Mohs micrographic surgery of the face or neck will have their blood drawn before, during, and after the procedure.
3362216|NCT00756288|Experimental|1|Topical retinoid and Light therapy with photosensitizing agent
3362217|NCT00756288|Active Comparator|2|Light therapy with photosensitizing agent
3362218|NCT00703326|Experimental|ramucirumab (IMC-1121B) + docetaxel|
3362219|NCT00703326|Placebo Comparator|placebo + docetaxel|
3362220|NCT00700258||1|Patients treated with Temsirolimus for metastatic renal cell carcinoma (mRCC) under usual care settings.
3362221|NCT00700258||2|Patients treated with Temsirolimus for mantle cell lymphoma (MCL) under usual care setting
3249229|NCT01373801|Active Comparator|Control|
3249230|NCT01373801|Experimental|GuardaCare|
3249231|NCT01373827||MC1 Subjects|
3249232|NCT01373840||healthy controls|
3249233|NCT01373840||patients with focal dystonias|
3249234|NCT01373853|Experimental|Femtec Groupe A|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery
3362222|NCT00700258||3|Patients treated with Sunitinib for metastatic renal cell carcinoma (mRCC) under usual care setting
3362223|NCT00700258||4|Patients treated with Sunitinib for gastro-intestinal stroma tumor (GIST) under usual care setting
3249235|NCT01373853|Active Comparator|Manual Group B|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
3249236|NCT01373866|Experimental|Multimodal MRI-guided rTMS|
3362224|NCT00700258||5|Patients treated with Axitinib after treatment with Sunitinib or Cytokine for metastatic renal cell carcinoma (mRCC)
3362225|NCT00602667|Experimental|Low-Risk Patients|"Patients with GTR/M0 medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.~Note: Accrual to the low-risk medulloblastoma cohort is closed as of 12/2/2015. Accrual to the low-risk high grade glioma remains open."
3362226|NCT00602667|Experimental|High-Risk Patients|Patients with CNS metastatic disease will receive induction chemotherapy and high-risk therapy.
3362227|NCT00602667|Experimental|Intermediate-Risk Therapy|Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.
3362228|NCT00558688|Experimental|1|Light Therapy
3249237|NCT01373866|Active Comparator|Conventional T3-P3 rTMS|
3249238|NCT01373879|Experimental|Group 1A|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3249239|NCT01373879|Experimental|Group 1B|Adults (18-50 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME TRAP
3249240|NCT01373879|Experimental|Group 2A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3362229|NCT00558688|Experimental|2|Light Therapy
3362230|NCT00518037||1|nonmelanoma skin cancer patients
3362231|NCT00472186|Experimental|1|Post-operative administration of Lansoprazole
3362232|NCT00472186|Placebo Comparator|2|Placebo
3249241|NCT01373879|Experimental|Group 2B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3249242|NCT01373879|Active Comparator|Group 2C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
3249243|NCT01373879|Experimental|Group 3A|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3249244|NCT01373879|Experimental|Group 3B|Children (2-6 years old) vaccinated with AdCh63 ME-TRAP followed with MVA ME-TRAP
3249245|NCT01373879|Active Comparator|Group 3C|Children (2-6 years old) vaccinated with human diploid cell rabies vaccine
3249246|NCT01373892|Active Comparator|Surgery|Slevve vs. Roux-Y
3249247|NCT01373892|No Intervention|Healthy lean volunteers|
3249248|NCT01373905|Active Comparator|Sustained lung inflation|recruitment was done using CPAP of 30 Cm/ H2o for 30 seconds
3249249|NCT01373905|Active Comparator|Stepwise PEEP elevation|Recruitment was done using stepwise elevation of PEEP followed by determination of the alveolar collapsing pressure
3249250|NCT01373944||Stress Only SPECT MPI with Anger Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the traditional Anger camera
3362236|NCT00004847|Experimental|Adults or children with suspected PHEO/PGL|Patients are adults or children of any age with known, sporadic or familial PHEO/PGL
3376090|NCT02899052|Experimental|Venetoclax + Carfilzomib + Dexamethasone|"Part 1: Evaluate the safety and pharmacokinetic profiles while providing information to determine the appropriate doses of venetoclax and carfilzomib (VenKd) to be used in the VenKd combination in approximately 18 participants. The dose levels are Venetoclax 400 mg or 800 mg; Carfilzomib 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; Dexamethasone 40 mg~Part 2: Further evaluate the safety and efficacy profile of the VenKd combination selected after completion of Part 1 in approximately 22 additional participants. Participants may discontinue Kd but may continue receiving venetoclax once daily (QD) as monotherapy.~Part 3: Further evaluation of the efficacy of the VenKd combination after completion of Part 1 and Part 2 in 7 additional participants.~Part 4, An additional 65 participants t(11;14) positive will receive varying doses of the VenKd combination or carfilzomib and dexamethasone"
3376091|NCT02891538|Experimental|epigallocatechin gallate (EGCG)|Patients randomized to the EGCG arm, will start EGCG within 4-12 weeks of surgery and take EGCG 450 mg PO twice a day.
3376092|NCT02891538|No Intervention|Observation Only|Standard of care surgical resection followed by standard of care colonoscopy at year.
3362242|NCT05148000|Experimental|QM1114-DP, a Botulinum Toxin Type A (BoNT-A)|QM1114-DP, a Botulinum Toxin Type A (BoNT-A); Intramuscular injection single dose
3249251|NCT01373944||Stress Only SPECT MPI with SD Camera|Patients undergoing clinically-indicated stress-only sestamibi studies who are imaged on the Spectrum Dynamics camera system.
3362243|NCT05147987|Experimental|Intervention Group|Will be provided a discreet, hands-free, wearable breast pump with an associated App
3362244|NCT05147987|No Intervention|Standard care group|Will be provided a standard mechanical breast pump with no associated App.
3249252|NCT01373957||1|Patients hospitalized and diagnosed with UA, STEMI or NSTEMI
3249253|NCT01373970|Placebo Comparator|Placebo|
3362245|NCT05147974|Experimental|Intervention arm|A cohort of YAC patients to be studied, pre & post-intervention, prospectively. All participants will be assigned to the intervention (complete DOZE app: Sleep diary and DOZE modules).
3362246|NCT05147961|Experimental|mHealth|A mHealth automated behavioral intervention via E-mail, web, and mobile phone will be developed and tested in the intervention trial trial (phase 4 of the project)
3249254|NCT01373970|Active Comparator|PPI + Placebo|PPI followed by cross over to placebo
3249255|NCT01373983|Other|ziconotide|
3362247|NCT05147961|Active Comparator|Standard care|Traditional recommendations (lifestyle modification) (phase 4 of the project)
3362248|NCT05147948|Experimental|Treatment|Internet delivered Acceptance and Commitment Therapy for PTSD and Chronic Pain, supported by a psychologist
3362249|NCT05147948|No Intervention|Waitlist|Waitlist for 12 weeks.
3362250|NCT05147935|Experimental|Specialist Palliative Care|All patients will be assigned to receive the intervention, consisting of two outpatient palliative care visits at Vanderbilt University Medical Center (VUMC).
3362253|NCT05147909|Experimental|Sodium Phosphate (NaPO4) then sodium chloride (NaCl)|Participants will be asked to take 2 capsules daily of Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) ) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d). Then, participants will be asked to take 2 capsules of Sodium Chloride (NaCl, containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).
3362254|NCT05147909|Experimental|NaCl then NaPO4|Participants will be asked to take 2 capsules daily of Sodium Chloride (NaCl, containing a total of 372mg of sodium) for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d). Then, participants will be asked to take 2 capsules of Sodium Phosphate daily for 4 weeks Sodium Phosphate (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks during the high Pi phase (total Pi intake 1,200 mg/d).
3362255|NCT05147896|Active Comparator|Interventional Arm|Beside metformin and sulphonyl urea treatment, the active, interventional arm, will be receiving Semaglutide Oral Tablets as per protocol, 3 mg for the first month, 7 mg in the second month and 14 mg form the third month onwards.
3362256|NCT05147896|No Intervention|Comparative Arm|This group will not be receiving the additional therapy besides metformin and sulphonyl urea treatment. After 6 months a revaluation of glycemic control will be performed, if needed, rescue therapy with basal insulin will be implemented.
3249256|NCT01373996||Wireless|Measuring of invasive arterial blood pressure through HMW10 Wireless System.
3249257|NCT01373996||Wired|Measuring of invasive arterial blood pressure through conventional wired technology.
3249258|NCT01374022|Experimental|ART Strategy|maximum alveolar recruitment plus PEEP titration
3249259|NCT01374022|Active Comparator|ARDSNet Strategy|standard strategy (ARDSNet)
3259429|NCT01470742|Experimental|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
3362259|NCT05147870||Irrigation group|
3362260|NCT05147870||Suction only group|
3362261|NCT05147857|Active Comparator|Mesotac in mid trimester|Prostaglandin
3362262|NCT05147857|Active Comparator|Dilapan s in mid trimester|"is an osmotic hygroscopic dilator produced from a patented Aquacryl® hydrogel that guarantees consistency of action.~It is a rigid gel rod that increases in volume by absorbing fluids from the cervical canal, so it gradually dilates the cervix The thin 4 mm rod can expand up to 15 mm over a 12-24 hours period. This allows it to dilate and soften the cervix gradually."
3362263|NCT05147844|Experimental|Toripalimab +Radiotherapy|
3362266|NCT05147818||Cases|"200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition & Staging. KDIGO definition of AKI: Increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 h, or Increase in serum creatinine to ≥1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume <0.5 mL/kg/h for 6 h.~KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or ≥0.3 mg/dL (≥26.5 µmol/L) increase / Urine output <0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output <0.5 mL/kg/h for ≥12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to ≥4.0 mg/dL (≥353.6 µmol/L), initiation of renal replacement therapy, or, in patients <18 years, decrease in eGFR to <35 mL/min per 1.73 m2 / Urine output <0.3 mL/kg/h for ≥24 h or anuria for ≥12 h ."
3249260|NCT01374035|Experimental|Participating GPs|GPs working at randomly selected GP centers/offices within the region that are invited to participate and signs a written informed consent to participate. (N=30-40)
3362267|NCT05147818||Controls|200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Matched to controls in age ,sex
3362268|NCT05147805|Experimental|Treprostinil Palmitil Inhalation Powder|Participants will be administered TPIP once per day at a starting dose of 80 micrograms (μg). Participants will be up-titrated to the highest tolerated dose for each individual participant of between 80 μg and 640 μg during the initial 3 weeks of treatment. The overall treatment period will be 16 weeks.
3249261|NCT01374035|No Intervention|Control group|GPs working at randomly selected GP centers/office within the region that are not invited to participate, will form the control group. (N=30-40)
3249262|NCT01374061|Active Comparator|1: Classical intubation|
3249263|NCT01374061|Experimental|2: Glidescope intubation|
3249264|NCT01374074||White GERD|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with gastroesophageal reflux disease and do not have Barrett's esophagus."
3249265|NCT01374074||African American GERD|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with gastroesophageal reflux disease and do no have Barrett's esophagus."
3362269|NCT05147805|Placebo Comparator|Placebo|Participants will be administered a placebo matching TPIP once per day for 16 weeks.
3362272|NCT05147779|Experimental|Treatment Group (AlloRx)|intravenous and intracavernosal or interstitial delivery (total dose of 100 million cells)
3362273|NCT05147766|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3362274|NCT05147753|Experimental|Group|0.6 mg moxonidine daily
3362275|NCT05147740|Experimental|B/F/TAF|B/F/TAF for 48 weeks
3362276|NCT05147727|Experimental|Fluconazole and Famitinib interaction|
3362277|NCT05147701|Experimental|Treatment Group (AlloRx)|intravenous and sub-tenon delivery (total dose of 100 million cells)
3249266|NCT01374074||White BE|"Participants who self-identify as not-Hispanic or Latino and White and have been diagnosed by a physician with Barrett's Esophagus."
3249267|NCT01374074||African American BE|"Participants who self-identify as not-Hispanic or Latino and African American and have been diagnosed by a physician with Barrett's Esophagus."
3362278|NCT05147688|Experimental|Treatment Group|Single intravenous infusion of 100 million cells
3362279|NCT05147675|Experimental|Treatment Group (AlloRx)|Intravenous infusion and intraarticular injection (total dose of 100 million cells)
3362281|NCT05147649|Active Comparator|non-OSAS patients|Patients without OSAS (Apnea-Hypopnea Index (AHI) < 15/h and absence of excessive daytime sleepiness with Epworth score <11)
3362282|NCT05147649|Experimental|OSAS patients|Patients with severe OSAS with an Apnea-Hypopnea Index (AHI) > 30/h
3362283|NCT05147636|Experimental|PEEP|
3362284|NCT05147636|Active Comparator|Aspiration|
3249268|NCT01374100|Active Comparator|Standard Exercise|See methods below - standard strength and endurance training
3362285|NCT05147623||Principal cohort|All patients recruited in one week who underwent to any surgical procedure that meet inclusion criteria of the study.
3362286|NCT05147610|Experimental|patients requiring an IOP (intra-Ocular Pression) measurement|group representing adults patients in ophthalmologic consultation requiring an IOP measurement
3362287|NCT05147584|Experimental|Interventional/Observational|The internal and external oxygen sensors will be used to record fetal oxygen during active labor and these will be be compared to the CTG retrospectively.
3362288|NCT05147571|Active Comparator|Active Group (responsive stimulation ON)|Participants are implanted with the RNS System and are receiving treatment with responsive stimulation.
3362289|NCT05147571|Sham Comparator|Sham Group (responsive stimulation OFF)|Participants are implanted with the RNS System and are not receiving treatment with responsive stimulation.
3362291|NCT05147545|Experimental|Subjects free of malignancy|Moderate intensity physical effort and meal (once)
3362292|NCT05147545|Experimental|Patients with colon cancer|Low intensity physical effort and meal (visit 1, day of cycle 1 chemotherapy) and low intensity physical effort (visit 2, day of cycle 2 chemotherapy)
3362293|NCT05147532|Other|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714|PET-MRI with [18F]-Florbetaben and PET-MRI with [18F]-DPA-714
3362294|NCT05147519||Step 1|Step 1 will enroll participants aged 15-55 years who are vulnerable to contracting HIV. They will be evaluated every 12 weeks for HIV and other sexually transmitted infections (STIs).
3362295|NCT05147519||Step 2|Participants who are diagnosed with HIV will proceed to Step 2, with evaluation of viral load and other HIV-related tests every four weeks for 12 weeks and then every 12 weeks for a total of 48 weeks.
3362296|NCT05147519||Step 3|Participants who achieve and maintain viral suppression in Step 2 will proceed to Step 3 for continued HIV monitoring every 24 weeks to document maintenance of viral suppression and maintain engagement with the study site for potential future recruitment into interventional studies, including clinical trials of novel strategies to achieve HIV remission.
3362297|NCT05147506|Experimental|CBT DTx|Participants randomized to active intervention will access a structured, cognitive behavioral therapy (CBT) intervention.
3362298|NCT05147506|Active Comparator|Psychoeducations DTx|Participants randomized to the comparison group will access an unstructured educational DTx.
3362299|NCT05147493|Experimental|Single-arm|"Eligible patients will initially receive an induction phase of six 28-day cycles of Isatuximab in combination with Bortezomib, Cyclophosphamide, and Dexamethasone, followed by a maintenance phase with isatuximab and lenalidomide until disease progression, death, unacceptable adverse events (AEs), lost to follow up, or consent withdrawal, whichever occurs first.~Isatuximab will be given at a dose of 10 mg/kg once weekly (QW) on Days 1, 8, 15, and 22 in Cycle 1, on Days 1 and 15 during Cycles 2-6 and on Day 1 from Cycle 7 onwards.~Bortezomib will be given at 1.3 mg/m2 on Days 1, 4, 8, 11 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Cyclophosphamide will be given at 300 mg/m2 on Days 1, 8, 15 of Cycle 1 and days 1, 8, 15, 22 of Cycles 2-6.~Dexamethasone will be given at 40 mg (20 mg for ≥75 years old) on Days 1-4 and 9-12 of Cycle 1 and Days 1, 8, 15 and 22 of Cycles 2-6.~Lenalidomide will be given at 10 mg (or according to renal function) daily from Cycle 7 onwards."
3362300|NCT05147480|Active Comparator|yoga group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers intervention: 6-week, once a week internet-based mother and baby yoga
3362301|NCT05147480|No Intervention|control group|infants whose gestational ages are between 32-37 weeks and completed the corrected age of the 6th week, and their mothers the standardized follow-up without intervention
3362303|NCT05147454||Trigeminal Neuralgia|Patients with a definite diagnosis of Classical or Idiopathic Trigeminal Neuralgia
3362304|NCT05147454||Persistent Idiopathic Facial Pain|Patients with a definite diagnosis of Persistent Idiopathic Facial Pain
3362312|NCT05147402|Active Comparator|Fasted Treatments with 3,4-methylenedioxymethamphetamine (MDMA)|10 hours of fasting followed by IMP administration with 240 mL water
3362313|NCT05147402|Active Comparator|Fed Treatments with 3,4-methylenedioxymethamphetamine (MDMA)|A high-fat (approximately 50 percent of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal will be consumed within 30 minutes of IMP administration
3362316|NCT05147376|Experimental|Curcumin mouthwash|The curcumin mouthwash contains the final concentration of 1 μM curcumin, water, xylitol, and food coloring agent.
3362317|NCT05147376|Sham Comparator|Placebo mouthwash|The placebo mouthwash contains water, xylitol, and food coloring agent.
3362318|NCT05147350|Experimental|Phase 1: RP-6306 in combination with FOLFIRI Dose Escalation|RP-6306 will be administered as oral capsules Multiple dose levels of RP-6306 (oral) and FOLFIRI (IV)
3249269|NCT01374100|Experimental|Qigong exercise|See methods below - medical QiGong therapy session
3249270|NCT01374113|Experimental|Group 1|Subjects with moderate renal impairment
3249271|NCT01374113|Experimental|Group 2|Subjects with severe renal impairment
3362328|NCT05147311|Experimental|PATH Intervention|"Participants in the PATH Intervention arm will receive psychosocial support phone calls during week 1 through 9 following enrollment.~At approximately 100-days post-HSCT, participants will begin an 9-week positive-psychology program involving weekly calls with an interventionist and exercises (i.e. writing a letter of gratitude, identifying personal strengths, planning meaningful and enjoyable activities).~-Self-assessment questionnaires to measure positive affect, health behaviors, and overall function before and after completing the Positive Psychology Intervention."
3249272|NCT01374113|Experimental|Group 3|Matched subjects with normal renal function
3249273|NCT01374126|Experimental|Azithromycin-Artesunate|
3249274|NCT01374126|Active Comparator|Control (artesunate alone)|
3249275|NCT01374139|Experimental|Cohort 1|
3249276|NCT01374139|Experimental|Cohort 2|
3249277|NCT01374152|Experimental|Perfetti|Cognitive sensory motor training method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
3249278|NCT01374152|No Intervention|conventional rehabilitation|conventional occupational therapy method for upper extremities rehabilitation every working day, totally training not less than 600 minutes within 4 weeks.
3249279|NCT01374165||Low dose SANGUINATE™|"160 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
3249280|NCT01374165||High dose of SANGUINATE™|"320 mg/kg of SANGUINATE™.~SANGUINATE™ (PEG-bHb-CO) an OTA is composed of three moieties, polyethylene glycol, bHb and carbon monoxide that act in a specific manner to promote the delivery of oxygen to tissue. SANGUINATE™ was not developed to be used as a blood substitute. It is instead an oxygen transfer agent intended to functionally deliver and release oxygen to hypoxic tissues."
3249281|NCT01374191|Active Comparator|onabotulinum toxin type-A|1 injection of Btx-A, or up to 4 injections of Btx-A during the 1-year study period if pain recurs
3362329|NCT05147311|No Intervention|Usual Care Control|Participants in the Usual Care Control arm will receive regular social work assessments as part of HSCT recovery and work does not focus on PPWB skill building or cognitive strategies.
3362334|NCT05147285|Experimental|Stabilization group|Only stabilization exercises in patients with cystic fibrosis
3362335|NCT05147285|Experimental|combined group|stabilization exercise and aerobic exercise training in patients with cystic fibrosis
3362336|NCT05147285|Experimental|control group|physical activity recommendations in patients with cystic fibrosis
3362337|NCT05147272|Experimental|Phase 1 Dose Escalation|Multiple dose levels of RP-6306 and gemcitabine
3249282|NCT01374191|Placebo Comparator|placebo|saline
3249283|NCT01374191|Active Comparator|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
3362338|NCT05147259|Experimental|Cohort one: Low dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
3362339|NCT05147259|Experimental|Cohort two: Medium dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
3362340|NCT05147259|Experimental|Cohort three: high dose|Subjects will be randomized to a treatment sequence consisting of two treatment periods: received two formulation HR011408 injections successively
3249284|NCT01374230|Experimental|E1 Tibial bearing|All patients undergoing primary total knee replacement surgery will receive a tibial bearing made of E1 polyethylene, which is the material being monitored in this study.
3249285|NCT01374256||Combination therapy|Patients with Acinetobacter baumannii bacteremia treated with combination therapy of imipenem and sulbactam
3249286|NCT01374256||Not combination therapy|Patients with Acinetobacter baumannii bacteremia not treated with combination therapy of imipenem and sulbactam
3249287|NCT01374295|Experimental|video|If randomized to this arm patient watches a 3 minute video
3249288|NCT01374295|Active Comparator|standard education|If randomized to this arm patient receives standard verbal education from healthcare provider.
3362345|NCT05147233|Experimental|Active Treatment Arm|OCS-01 (Ophthalmic Suspension) - topical use
3362346|NCT05147233|Placebo Comparator|Vehicle Placebo Arm|Vehicle
3249289|NCT01374308|Experimental|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
3362351|NCT05147207|Experimental|Superpath|This is a minimally invasive surgical approach.
3362352|NCT05147207|No Intervention|Posterior Approach|This is the traditional THA surgical approach used.
3362353|NCT05147194|No Intervention|Control group|Blank group
3362354|NCT05147194|Experimental|Trimetazidine group|The participates received treatments of trimetazidine
3362356|NCT05147155||Severe asthma patients|The sample will consist of 40 patients between 18 and 82 years of age with uncontrolled severe eosinophilic asthma despite receiving high dose ICS/LABA combination therapy who will receive mepolizumab, which will be administered as a 100-mg subcutaneous dose every four weeks
3362357|NCT05147155||Control group 1|Control group 1 will be a set of 50 healthy individuals matched for age and gender
3362358|NCT05147155||Control group 2|Control group 2 will be a set of 40 patients with severe well-controlled asthma requiring high dose ICS/LABA combination therapy from becoming uncontrolled, as previously defined, matched for age and gender.
3362359|NCT05147142|Experimental|Target Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the target region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
3362360|NCT05147142|Active Comparator|Control Site Low Intensity Focused Ultrasound|Low Intensity focused ultrasound of the control region. These are at a fundamental frequency = 650kHz, PRF = 10Hz, pulse width = 5ms, duty cycle = 5%; ISPTA.3 of 720 mW/cm2. As in prior studies, each sonication includes 10 pulsations, each lasting 30s, followed by 30s pause intervals; two 10-minute administrations provided per LIFU session.
3362361|NCT05147129||Postmenopausal with vulvar lichen sclerosus|Includes postmenopausal patients with clinically-active vulvar lichen sclerosus, as determined by biopsy or examination by a vulvar specialist
3362362|NCT05147129||Postmenopausal without vulvar lichen sclerosus|Includes postmenopausal patients without vulvar lichen sclerosus
3362365|NCT05147103|Experimental|Duration Trials|Six different durations (three intermittent and three continuous) of LIFU application will be tested across six study sessions. Response recorded using TMS and EMG.
3362366|NCT05147090|Active Comparator|Empagliflozin group|Empagliflozin 10mg daily for 156 weeks
3362367|NCT05147090|Placebo Comparator|Placebo group|Placebo pills (identical in appearance to empagliflozin 10mg) daily for 156 weeks
3362368|NCT05147077|Experimental|Integrated rehabilitation group|This group will include 94 patients. On the basis of standard care, patients in this group will receive acupuncture, traditional Chinese medicine, repetitive transcranial magnetic stimulation.
3362369|NCT05147077|Active Comparator|Standard care group|The patients were recommended to take one oral tablet of escitalopram oxalate (10 mg) every morning after a meal for 4 weeks. Internal medicine includes lipid regulation, blood sugar control, anti-hypertension, anticoagulation, and other drugs. Moreover, general duty nursing and motor therapy are also needed.
3362370|NCT05147064|Experimental|group A|randomly allocated
3362371|NCT05147064|Experimental|group B|randomly allocated
3362372|NCT05147051|Experimental|Reamberin group|Patients receive the investigational treatment (meglumine sodium succinate), 500 ml intravenously every 8 hours (up to 6 infusions).
3362373|NCT05147051|Placebo Comparator|Placebo|Patients receive a Placebo (Ringer's solution), 500 ml intravenously every 8 hours (up to 6 infusions).
3362374|NCT05147038|Experimental|Intervention group|Participants allocated into the intervention group will be coached for 12 weeks by a tele-coaching mobile App containing tips for PA increase and for number of steps recording (visual feedback for the patient).
3362375|NCT05147038|No Intervention|Control group|Participants in the control group will receive usual care (including regular visits) together with the educational information.
3362376|NCT05147025|Experimental|Revasularization|Revascularization of failed previously revascularized younge permenant inciors
3362377|NCT05147012||control group|
3362378|NCT05147012||focus group|
3362379|NCT05146999|Active Comparator|Active arm - QM1114-DP|a Botulinum Toxin Type A (BoNT-A)
3249290|NCT01374308|Active Comparator|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
3362380|NCT05146999|Placebo Comparator|Inactive arm - Placebo|A buffered solution,
3362381|NCT05146986||Non-surgical group|Patients will receive analgesia and symptomatic management treatment
3362382|NCT05146986||Surgical group|Patients will receive surgical treatment using RibFix Blu Thoracic Fixation System
3362383|NCT05146973|Experimental|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart.
3249291|NCT01374321|Placebo Comparator|Placebo|
3249292|NCT01374321|Experimental|TRO40303|
3249293|NCT01374347||One dose, Repeat doses|First group recives one dose Second group receives several doses
3362384|NCT05146960|Experimental|Temporal summation|"Temporal summation will be evoked in ECRL muscle origin, ECRB muscle belly, Brachioradialis. Pressure pain thresholds (PPTs) will be identified two times with a 30 s interval for each predetermined area. The average of two measurements will be used as a PPTs value. Temporal summation was induced two minutes after last PPTs was recorded. To evoke temporal summation at the lateral elbow, the probe will be applied with the pressure of the predefined PPT threshold at the rate of approximately 2 kg/s where it will be maintained for 1 s before being released with a 1 s interstimulus interval (ISI). This procedure will be repeated 10 times in each predetermined area. Pain intensity will be asked to participants at first, fifth and tenth pulse using a Visual Analog Scale range from 0 indicate no pain to 10 most painful"
3362385|NCT05146960|Placebo Comparator|Placebo|pressure pain threshold will be evaluated once in each predetermined region with a 30 second interval.
3362386|NCT05146934||Hormone sensitive group|Prednisone, 0.5mg/kgqd, 3-6months
3362387|NCT05146934||Hormone insensitivity group|Prednisone, 0.5mg/kgqd, 3-6months
3362388|NCT05146921|Active Comparator|food supplement: multi-strain probiotic (Symprove)|70 ml daily for 12 weeks
3362389|NCT05146921|Placebo Comparator|Placebo|70 ml daily for 12 weeks
3249294|NCT01374347||One dose, several doses|15 patients will take one dose of 20 mg cialis, and will have a second brain SPECT 24 hours after cialis administration. 15 other patients (age and risk factor matched) will be prescribed 5 mg of cialis once daily for 7 days, and a second SPECT study will be performed 24 hours after the last dose.
3362391|NCT05146895|Experimental|Local Hyperthermia at 44℃ for falt warts|Local hyperthermia at 44℃ for 30 mins on one lesion region, at days of 1,2,3, 15, 16, 21 and 28.
3362392|NCT05146895|Active Comparator|Imiquimod for Flat Warts|Miquimod treatment: 3 times a week for 1 month
3362395|NCT05146869|Experimental|50 mg DBPR108 tablets|10 patients will be randomized to receive 50 mg DBPR108 tablets.
3362396|NCT05146869|Experimental|100 mg DBPR108 tablets|10 patients will be randomized to receive 100 mg DBPR108 tablets.
3249297|NCT01374373|Other|Open Label|One arm open label
3249298|NCT01374386|No Intervention|Usual Physical Activity|Participants in this arm are do not have access to Exergames, only usual physical activity at the gym
3362397|NCT05146869|Experimental|200 mg DBPR108 tablets|10 patients will be randomized to receive 200 mg DBPR108 tablets.
3362398|NCT05146856||Control|Residents in control group have a usual day with clinical activity before night shift
3362399|NCT05146856||Intervention|Residents in intervention group have a day off clinic before night shift (i.e day off or day with university activity)
3362400|NCT05146843|Experimental|Mitoquinone|MitoQ, 20 mg per day for three months
3249299|NCT01374386|Experimental|Exergaming|Participants in this arm will have access to usual physical activity at the gym as well as access to Exergaming equipment (video games that require physical activity)
3249300|NCT01374399|Experimental|resistance and endurance exercise|
3362401|NCT05146843|Placebo Comparator|Placebo|Placebo, 20 mg per day for three months
3362402|NCT05146830||Participants with Cystinosis Disease|This is a long-term follow-up study of participants who previously received AVR-RD-04 (single dose administration). No investigational product will be administered in this study.
3362403|NCT05146817|Active Comparator|Traditional oral care in long-term mechanical ventilation ICU patients|Control group - traditional protocol of oral care ( traditional tooth brushing 1 time a day + chlorhexidine rinsing
3362404|NCT05146817|Experimental|Original oral care protocol in long-term mechanical ventilation ICU patients|Treatment group - original protocol of oral care: special device for tooth brushing 3 times a day with chlorhexidine .
3362405|NCT05146804|Other|BroccoCress/Affilla Cress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
3362406|NCT05146804|Other|Affilla Cress/Broccocress|Potential participants will be screened after showing their interest to participate to the study. When they are considered eligible to participate (after a phone call with the executing researcher), participants will be randomized into one of the two groups in this study: either consuming the broccoli sprouts on day one (visit 1) and the placebo product in the second visit, or the other way around (placebo product on day 1 and the intervention during the second visit). Both days, participants will consume the PhenFlex, the challenge product with the high caloric load. This will allow for analyzing the effectiveness of the intervention on different biomarkers of chronic, low-grade inflammation, with the main objective being on endothelial activation.
3362407|NCT05146791||Inlay Bristow Group|Inlay Bristow procedure
3362408|NCT05146791||Onlay Bristow Group|Onlay Bristow procedure
3362409|NCT05146778|Active Comparator|Opioid-free anesthesia group|OFA group will be sedated using dexmedetomidine and lidocaine during mastectomy.
3249301|NCT01374399|Active Comparator|relaxation|
3249302|NCT01374412||osteoporosis|patients with benign osteoporosis
3249303|NCT01374464|Active Comparator|High Volume, High Concentration|
3249304|NCT01374464|Active Comparator|High Volume, Low Concentration|
3249305|NCT01374464|Active Comparator|Low Volume, High Concentration|
3249306|NCT01374464|Active Comparator|Low Volume, Low Concentration|
3249307|NCT01374477||Adolescent with preeclampsia|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) that developed a hypertensive disorder of pregnancy.
3249308|NCT01374477||Normal adolescent|Patients < 19 years old who delivered in our institution (vaginal birth or cesarean) without developing a hypertensive disorder of pregnancy.
3362410|NCT05146778|Active Comparator|Conventional anesthesia group with opioid|Conventional opioid anesthesia group will be sedated using remi-fentanyl during mastectomy.
3362411|NCT05146765|Experimental|Intervention group|The intervention group will receive treatment as usual and use the smart phone app for speech therapy.
3362412|NCT05146765|No Intervention|Control group|The control group will receive treatment as usual only.
3362413|NCT05146752|Experimental|Extremely low frequency electromagnetic fields|After parental permission for participation was obtained, the preterm newborns were enrolled and divided into the experimental group, which received ELF-EMF therapy after a pretest in addition to regular medical care, and the control group, which received regular medical care only, using a random number table.
3362414|NCT05146752|Other|control group|routine care
3249309|NCT01374503|Experimental|ALX-0651|
3249310|NCT01374503|Placebo Comparator|Placebo|
3249311|NCT01374542||Respiratory endoscopy patients|Patients undergoing respiratory endoscopy at Singapore General Hospital
3249312|NCT01374581|Experimental|Artemether/Lumefantrine|Tablets 20 mg/120 of Artemether/Lumefantrine will be given to 124 trial patients
3249313|NCT01374581|Experimental|Artesunate/Amodiaquine|Tablets 25mg/67,5 mg of Artesunate/Amodiaquine will be given to 124 trial patients.
3249314|NCT01374581|Active Comparator|Quinine + Clindamycin|Quinine tablet 125mg + Clindamycin syrup 75mg/5ml will be given to 60 children.
3362415|NCT05146739|Experimental|Experimental: Treatment (uproleselan, fludarabine, cytarabine)|Patients receive uproleselan intravenously (IV) once daily (QD) over 20 minutes on day 1 and IV over 20 minutes twice daily (BID) on days 2-8, fludarabine IV QD over 30 minutes on days 2-6, and high dose cytarabine IV QD over 1-3 hours on days 2-6. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
3362416|NCT05146726||BARMER insured patients|"Group I: BARMER insured patients with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10%.~Central measures in this group are the IV contract for the creation of an organizational and financing structure for the guideline-compliant detection, diagnosis and treatment of preoperative anemia and the evaluation of the machine autotransfusion as part of the preoperative premedication visit in anesthesiology (implementation is the responsibility of the patient blood management (PBM) service)."
3362417|NCT05146726||Patients insured with another statutory health insurer than BARMER|Group II: Patients not insured with BARMER and with preoperative anemia and an elective (N5) surgical intervention with a probability of transfusion > 10% and receive early anemia detection.
3362418|NCT05146713|Experimental|Propolis nanoparticles extract solution|
3362419|NCT05146713|Active Comparator|sodium hypochlorite|
3249315|NCT01374594||Healthy adults|
3376093|NCT02884206|Experimental|LCZ696|Patients will receive LCZ696 at 100 mg twice daily during a single-blind treatment run-in period to ensure patients tolerate this medication before they are randomized. Down-titration is not allowed during this period. Patients who are able to tolerate LCZ696 100 mg twice daily are eligible to enter the randomized treatment period. Patients randomized to receive LCZ696 will be given LCZ696 at 200 mg twice daily. Patients will receive randomized study drug for three years.
3376094|NCT02884206|Active Comparator|Valsartan|Patients will receive valsartan at 40mg and/or 80mg twice daily during a single-blind treatment run-in period. Following the run-in period, patients randomized to receive valsartan will be given valsartan at 160 mg twice daily for three years.
3249316|NCT01374594||Type 2 diabetes|
3249317|NCT01374620|Experimental|Paclitaxel Dose escalation|"A standard dose escalation strategy will be used including 3 to 6 patients at each dose level (Paclitaxel dose escalation + fixed dose of cyclophosphamide)~+ blood collection"
3249318|NCT01374620|Experimental|Cohort extension|"An additional 10 patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose~+ blood collection"
3376095|NCT02860741|Experimental|Intervention|Churches in the REJOICE intervention arm will provide the REJOICE intervention over an 8 week period
3376096|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about both identifying depressive symptoms and managing depressive symptoms. This is consistent with self-management interventions commonly utilized for individuals experiencing subclinical levels of depressive symptoms.
3376097|NCT02856646||Population with Condition|Community Sample
3376098|NCT02840136|Experimental|Standard of care|Sputum is collected from patients receiving standard of care therapy with IV piperacillin-tazobactam, ceftazidime or meropenem
3249319|NCT01374633|Experimental|1:patient with severe traumatic brain|
3249320|NCT01374659||Study patients|Study patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy. After the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/ml) after TSH stimulation (TSH > 30 mU/l). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [131I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology or positive fine-needle aspiration cytology (FNAC) were excluded from the study. The work was approved by our Institutional Review Board and written informed consent was obtained from each patient.
3249321|NCT01374672||Correlative studies|DNA and RNA extracted from biopsy samples are analyzed for methylation changes and transcription changes by ligation-mediated PCR and mass-array genotyping.
3259430|NCT01470755|Other|salbutamol - dose 1|Metered dose inhaler, 100µg+300µg per puff, administered one day
3362426|NCT05146674|Active Comparator|Tadalafil group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
3362427|NCT05146674|No Intervention|Control group|"Our prospective, randomized, study will consist of a 1-week baseline period and 12-week double-blind treatment period During the baseline period, patients' characteristics, including medical and sexual history, physical examination results, vital signs, HPMDQ score, IPSS, International Index of Erectile Function (IIEF) score, PMD volume, and uroflowmetry results; and laboratory results, including urine analysis results, will be recorded.~After the baseline period, patients will be randomly assigned, 1:1, to the treatment or control groups using a computer-generated system. Both study groups will be advised to do bulbar urethral massage in addition to pelvic floor muscle exercise (explained later) during the study period, treatment group will be given tadalafil 5 mg (treatment group) daily or no medication (control group)."
3362428|NCT05146661|Experimental|Treatment|The NEURESCUE device will be used as an adjunct to ALS.
3362429|NCT05146648|Active Comparator|Real AMPS|AMPS therapy consists of mechanical stimulations applied to two specific points on both feet: the tip of the big toe (hallux) and the first metatarsal joint.
3362430|NCT05146648|Sham Comparator|Sham AMPS|AMPS therapy applied to two non-specific points on both feet.
3362431|NCT05146635|Active Comparator|Intravesical immunotherapy (BCG) group|
3362432|NCT05146635|Active Comparator|Intravesical chemotherapy (Epirubicin) group|
3362433|NCT05146622||Formative Research|Outdoor workers in the United States.
3362434|NCT05146609|Experimental|HR-HOSPITAL|Patients assigned to the strategy HR-HOSPITAL, who are high risk population (HR), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
3362435|NCT05146609|Experimental|HR-DDP|Patients assigned to the strategy HR-DDP, who are high risk population, will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the drug dependence center (DDP) the participants used to attend.
3362436|NCT05146609|Experimental|GP-HOSPITAL|Patients assigned to the strategy GP-HOSPITAL, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the referral hospital.
3362437|NCT05146609|Experimental|GP-PCC|Patients assigned to the strategy GP-PCC, who are general population (GP), will receive an invitation letter for HCV screening with DBS to be performed by themselves or at the primary care center (PCC) to be performed by the general practitioner.
3249322|NCT01374698|Active Comparator|Aspirin|All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
3249323|NCT01374698|No Intervention|No intervention|No intervention
3249324|NCT01374711|Placebo Comparator|placebo|LPS will be administered twice on days 1 and 7. In between placebo will be administered on days 2, 4 and 6 subcutaneously.
3362440|NCT05146570|Experimental|Aseptic Meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~native vial for conventional culture (agar plate & broth)~EDTA vial for the determination of leukocyte count and differential~pediatric blood culture bottle (BacTec PedsPlus/F)~native vial for biomarker detection (D-Lactate)"
3249325|NCT01374711|Active Comparator|GM-CSF|LPS will be administered twice on days 1 and 7. In between GM-CSF will be administered on days 2, 4 and 6 subcutaneously.
3249326|NCT01374711|Active Comparator|IFN-y|LPS will be administered twice on days 1 and 7. In between IFN-Y will be administered on days 2, 4 and 6 subcutaneously.
3249327|NCT01374724|Experimental|Ban & Informational Pamphlet|Following 8.5 weeks of cessation subjects are given an informational pamphlet on tobacco cessation and relapse prevention.
3249328|NCT01374724|Experimental|Ban & Tailored Pamphlet|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force
3249329|NCT01374724|Experimental|Ban & Tailored Pamphlet & Intervention|After 8.5 weeks of tobacco use cessation during Basic Military Training subjects are provided a tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force. In addition they are given a face to face relapse prevention intervention.
3249330|NCT01374737|Other|dexmedetomidine, children|
3249331|NCT01374750|Active Comparator|m-TOR inhibitor free|Immunosuppressive drug
3249332|NCT01374750|Experimental|Sirolimus|Immunosuppressive drug
3249333|NCT01374763|Active Comparator|Oxycodone|Drug: prolonged-release oxycodone
3249334|NCT01374763|Active Comparator|Oxycodone/naloxone|Prolonged-release oxycodone/naloxone
3249335|NCT01374776|Experimental|intravenous iron carboxymaltose|intravenous iron carboxymaltose infusion
3249336|NCT01374789|Experimental|Arm A (GemCis + Panitumumab)|gemcitabine + cisplatin + panitumumab
3249337|NCT01374789|Active Comparator|Arm B (GemCis)|gemcitabine + cisplatin
3249338|NCT01374815|Experimental|The Online Advocate|
3362441|NCT05146570|Experimental|Infective meningitis|"In all patients cerebrospinal (CSF) fluid will be aspirated following the routine diagnostic procedure. After aspiration CSF will be tested with standard diagnostic tests and experimental diagnostic test (D-lactate).~Immediately after aspiration, 0.5-1 ml of cerebrospinal fluid will be transferred into each of the following vials:~native vial for conventional culture (agar plate & broth)~EDTA vial for the determination of leukocyte count and differential~pediatric blood culture bottle (BacTec PedsPlus/F)~native vial for biomarker detection (D-Lactate)"
3362442|NCT05145608|Active Comparator|Test- Lamotrigine ER Tablets USP 50mg|Single dose of Test- Lamotrigine ER Tablets USP 50mg will be administered
3362443|NCT05145608|Active Comparator|Reference- Lamictal® XRTM ER tablet 50mg|Single dose of Reference- Lamictal® XRTM (Lamotrigine) ER tablet 50mg will be administered
3249339|NCT01374828|Experimental|Ketolorac|
3249340|NCT01374841|Experimental|Stem Cell Transplant+Cyclophosphamide|patients with high-risk hematologic malignancies will receive hematopoietic stem cell transplantation from haploidentical donors after treatment with cyclophosphamide
3249341|NCT01374854|Experimental|Stem Cell Infusion|
3249342|NCT01374854|Active Comparator|traditional therapy control|
3249343|NCT01374880||Dyspnea cohort|Dyspnea cohort
3249344|NCT01374880||Stable chronic heart failure|Stable chronic heart failure
3362454|NCT05143034|Experimental|TCI66207 Essence|Essence
3362455|NCT05143034|Placebo Comparator|Placebo Essence|
3362458|NCT05139316|Experimental|DTX401, Then Placebo|Participants receive single peripheral intravenous (IV) infusion of DTX401 in solution. At week 48 participants receive single peripheral IV infusion of Placebo.
3362459|NCT05139316|Placebo Comparator|Placebo, Then DTX401|Participants receive single peripheral IV infusion of Placebo. At week 48 eligible participants receive single peripheral IV infusion of DTX401 solution.
3362460|NCT05138679||Acute lower limb ischemia|Patients with acute lower limb ischemia (older than 18 years)
3362461|NCT05137730|Experimental|Part I: Sequence AB|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation A) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation B) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
3249345|NCT01374880||Valvular heart disease|Valvular heart disease
3249346|NCT01374880||Ventricular assist device|Ventricular assist device
3249347|NCT01374880||Cardiac arrest|Cardiac arrest
3249348|NCT01374880||Cardiac rehabilitation|Cardiac rehabilitation
3249349|NCT01374893|Active Comparator|Exercise|
3249350|NCT01374893|Placebo Comparator|Control group|Usual care
3249351|NCT01374932|Experimental|CPAP (see below)|Adult patients with asthma who require treatment with CPAP because of OSAS (RDI> = 20 events per hour). CPAP will be administered according to SEPAR guidelines and tailored to individual characteristics
3249352|NCT01374945|No Intervention|SOC preparation and colonoscopy|
3249353|NCT01374945|Experimental|Miniprep and Clearpath|
3249354|NCT01374984||Subjects treated with VIGIV.|"Subjects treated with VIGIV deployed from the US Strategic National Stockpile for any of the following conditions:~Eczema vaccinatum.~Progressive vaccinia.~Severe generalized vaccinia.~Vaccinia infections in individuals who have skin conditions.~Aberrant infections induced by vaccinia virus (except in cases of isolated keratitis)."
3249355|NCT01374997|Other|patients with Fabry disease|detection of this disease in end-stage renal failure patients, transplant or hemodialysis
3249356|NCT01375023|Experimental|Anti-Thymocyte Globulin+radiotherapy|triple negative breast cancer patients treated with radiation and Anti-Thymocyte Globulin iv
3249357|NCT01375062|No Intervention|tissue from biopsies|
3249358|NCT01375088|Placebo Comparator|placebo mouth wash|10 patients swish & swallow 15 ml placebo mouth wash for at least 5 min from the first session of radiotherapy until the last session
3362462|NCT05137730|Experimental|Part I: Sequence BA|Participants will receive a single SC injection of 100 microgram (mcg) rhPTH(1-84) (Formulation B) on Day 1 of treatment period 1 followed by 100 mcg rhPTH(1-84) (Formulation A) on Day 1 of treatment period 2. A washout period of 96 hours will be maintained between each treatment period.
3362463|NCT05137730|Experimental|Part II: Sequence cdef|Participants will receive a single SC injection of 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 1 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 2 followed by 75 mcg (dose e ) rhPTH(1-84) on Day 1 of treatment period 3 followed 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
3362464|NCT05137730|Experimental|Part II: Sequence dfce|Participants will receive a single SC injection of 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 1 followed by 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 2 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 3 followed by 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
3362465|NCT05137730|Experimental|Part II: Sequence ecfd|Participants will receive a single SC injection of 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 1 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 2 followed by 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 3 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
3362466|NCT05137730|Experimental|Part II: Sequence fedc|Participants will receive a single SC injection of 200 mcg (dose f) rhPTH(1-84) on Day 1 of treatment period 1 followed by 75 mcg (dose e) rhPTH(1-84) on Day 1 of treatment period 2 followed by 50 mcg (dose d) rhPTH(1-84) on Day 1 of treatment period 3 followed by 25 mcg (dose c) rhPTH(1-84) on Day 1 of treatment period 4. A washout period of 48 hours will be maintained between each treatment period 1,2,3 and 4.
3362467|NCT05137158|Experimental|iTBS stimulation|The patients in iTBS stimulation group will receive iTBS stimulation on the target of the bilateral dorsolateral prefrontal cortex for 10 consecutive days and 4 times per day.There will have at least 30 minutes interval between each intervention.
3362468|NCT05137158|Sham Comparator|Sham stimulation|The participants in sham stimulation will receive sham stimulation, as the coil vertical to the brain surface, for 10 consecutive days and 4 times per day.There will have at least 30 minutes interval between each intervention.
3362469|NCT05135052|Experimental|Treatment arm|Treatment with Rhenium-SCT, Single treatment.
3362470|NCT05134987|Experimental|NNC0363-0845 followed by insulin detemir|Participants will get subcutaneous (under the skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of insulin detemir up to 6 times daily for 3 days.
3362471|NCT05134987|Experimental|Insulin detemir followed by NNC0363-0845|Participants will get subcutaneous (under the skin) injections of insulin detemir up to 6 times daily for 3 days. After a 4-21 days wash-out period with no injections they will get subcutaneous injections of NNC0363-0845 (study medicine) up to 6 times daily for 3 days.
3362472|NCT05132673||Participants|Those who meet the Eligibility Criteria will be asked to complete online questionnaires and wear a device on your wrist for two weeks that measures your heart rate, physical activity, and sleep. A WHOOP® wrist monitor and charging equipment will be used.
3362475|NCT05131373|Experimental|Experimental 1|C. acnes vaccine in adjuvanted formulation will be administered in double-blind fashion in 3 single increasing doses given i.m.
3362476|NCT05131373|Placebo Comparator|Placebo 1|Placebo in adjuvanted formulation will be administered in double-blind fashion in single i.m. injections
3362477|NCT05131373|Experimental|Experimental 2|C. acnes vaccine in non-adjuvanted formulation will be administered in double-blind fashion and as a single i.m. or i.d. injection
3362478|NCT05131373|Placebo Comparator|Placebo 2|Placebo in non-adjuvanted formulation will be administered in double-blind fashion and as a single i.m. or i.d. injection
3362479|NCT05131347|Experimental|motor intervention|Children in the motor intervention group will receive a 8-week motor intervention program. Each week will be of 1.5-hour duration.
3362480|NCT05131347|Active Comparator|cognitive intervention|Children in the cognitive intervention group will receive a 8-week cognitive training program. Each week will be of 1.5-hour duration.
3362481|NCT05131191||patients with coronary metal stents implantation|
3362482|NCT05130840|Experimental|Stage IV HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
3362483|NCT05130840|Experimental|Stage II-III HER2+ breast cancer|Once enrolled on study, patients will undergo screening MRI Brain (unless already done as standard of care within 2 months on enrollment to evaluate for CNS disease) as well as lumbar puncture to evaluate for CNS disease. Once on study, patients will undergo LP and MRI Brain at 2 timepoints 6 months apart (+/- 8 weeks). LP will be performed to analyze cerebrospinal fluid for: cytology, circulating tumor cells and cell-free DNA. 6-month intervals for investigations have been based on feedback from patient advocates as well as clinical determination.
3249359|NCT01375088|Active Comparator|propolis|10 patients swish & swallow 15 ml propolis mouth wash for at least 5 min from the first session of radiotherapy until the last session
3249360|NCT01375101|Active Comparator|quercetin|quercetin is one of flavonoids , and having therapeutical anti-inflammatory and antioxidant action
3249361|NCT01375101|Placebo Comparator|placebo|placebo capsul is produced with lactose for using in placebo/ control group.
3259431|NCT01470755|Other|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
3259432|NCT01470755|Other|Salbutamol - dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
3249362|NCT01375114|Experimental|Panax Ginseng|Panax ginseng 400 mg by mouth twice a day from Day 1-29 for first 30 participants in Part 1. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3249363|NCT01375114|Experimental|Ginseng (Part 2)|Panax ginseng 400 mg by mouth twice a day from Day 1-29. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3362486|NCT05129254|Experimental|Thulium laser (1927nm) and post-treatment topically administered platelet rich plasma (PRP)|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with LaseMD, a 1927nm Fractionated Thulium laser and post-treatment topically applied autologous platelet rich plasma at monthly intervals for a total of 4 treatment. The total duration of laser application, venipuncture, PRP preparation, and topical administration will take approximately 30 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
3362487|NCT05129254|Experimental|Platelet rich plasma injection|All participating subjects will serve as their own baseline control and will receive treatment of their androgenetic alopecia with autologous platelet rich plasma injection at monthly intervals for a total of 4 treatment. The total duration of venipuncture, PRP preparation, and injection will take approximately 15 minutes. Post-treatment surveillance: The subject will be observed in the clinic under direct supervision of the treating physician for any post-treatment side-effects for up to 15 minutes.
3362490|NCT05127421|Experimental|Double-blind Period: vehicle cream or Ruxolitinib cream 1.5% BID|Participants will be treated with ruxolitinib cream 1.5% or vehicle cream twice a day (BID) in a double-blind fashion.
3362491|NCT05127421|Experimental|Open Label Extension: Ruxolitiib cream 1.5%|Patients will be treated with Ruxoltinib cream 1.5% twice per day (BID) during the open label extension period. Participants who complete the double-blind period will continue into this open-label extension period for an additional 4 weeks of treatment.
3362492|NCT05125848|Experimental|Hemodialysis Single Group Assignment|All enrolled subjects will be connected to the CM-1500 for monitoring during their hemodialysis session
3362493|NCT05123027|Experimental|Peer Intervention to Link Overdose Survivors to Treatment (PILOT) Peer|
3362494|NCT05123027|Active Comparator|Treatment As Usual Peer|
3362495|NCT05122182|Experimental|Interventional Arm|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + fixed dose repagermanium one x 120mg immediate release capsule twice daily (total daily dose 240mg). Treatment will continue for 28 days.
3249364|NCT01375114|Placebo Comparator|Placebo (Part 2)|Oral placebo twice daily for 4 weeks. Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
3249365|NCT01375153|Placebo Comparator|Placebo|0,9% NaCl administered as a continuous intravenous infusion during four hours.
3362496|NCT05122182|Placebo Comparator|Control Arm #1|Titratable candesartan with commencing dose 4mg tablets twice daily (daily dose 8 mg) + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
3362497|NCT05122182|Placebo Comparator|Control Arm #2|Titratable matched placebo candesartan one tablet twice daily + matched placebo repagermanium one capsule twice daily. Treatment will continue for 28 days.
3362498|NCT05121506|Experimental|CBD and THC with GT4 technology|
3362499|NCT05119790|Experimental|Cohort A|
3362500|NCT05118308|Experimental|Transjugular approach|Transjugular hepatic venous pressure gradient measurement with liver biopsy (HVPG-LB).
3362501|NCT05118308|Experimental|Endoscopic ultrasound approach|Endoscopic ultrasound portal pressure gradient measurement with liver biopsy (EUS-PPG-LB)
3249366|NCT01375153|Active Comparator|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours.
3249367|NCT01375166||Diabetic retinopathy|Patients with early insulin dependent diabetes and no or mild non-proliferative retinopathy
3249368|NCT01375166||healthy|healthy control subjects
3249369|NCT01375179|Experimental|KRP203|"Experimental~Edit~Experimental"
3249370|NCT01375179|Placebo Comparator|Placebo|Placebo
3362510|NCT05116800|Experimental|Stratum A: Soft Tissue Sarcoma|Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3362511|NCT05116800|Experimental|Stratum B: Bone Sarcoma|Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3362512|NCT05116787|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions~In Part 2, all participants receive open-label BCX9930 monotherapy"
3362513|NCT05116787|Placebo Comparator|Placebo|In Part 1, participants are randomized to 2:1 to receive BCX9930 monotherapy or placebo under double-blind conditions
3362514|NCT05116774|Experimental|BCX9930 monotherapy|"In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor~In Part 2, all subjects receive BCX9930 monotherapy"
3362515|NCT05116774|Active Comparator|Continued C5 inhibitor therapy|In Part 1, participants are randomized 2:1 to receive BCX9930 monotherapy or continue with current C5 inhibitor
3362516|NCT05116709|Experimental|BAT6005 single drug dose escalation study|"The whole is divided into two phases.The first stage: 10mg group, 30mg group, 100mg group using accelerated titration method to increase the dose.The second stage: 300mg group, 600mg group, 900mg group according to the standard 3+3 rule dose increase study."
3249371|NCT01375218|Active Comparator|Plastizote Brace|
3249372|NCT01375218|Active Comparator|Pavlik Brace|
3362517|NCT05114993|Experimental|Effects of donning a disposable surgical mask|"Participants will be observed and monitored without wearing a mask for a 5-minute control period. Measurements will include End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute without a mask x 5 minutes.~After 5 minutes, all study subjects will don the same model of disposable surgical mask. The same measurements will be taken, including End Tidal CO2, Inspired CO2, Pulse Oximetry, Respiratory Rate, and Heart Rate each minute with a mask x 15 minutes."
3362518|NCT05114655|Experimental|Intervention 1|Participants apply an herbaceous, earthy based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
3249373|NCT01375231|Active Comparator|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
3249374|NCT01375231|Active Comparator|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
3249375|NCT01375244|Experimental|A|Subjects received the Par formulated product.
3249376|NCT01375244|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3249377|NCT01375257|Active Comparator|Guideline treatment with parenteral antibiotics|Guideline treatment with parenteral antibiotics
3249378|NCT01375257|Experimental|Oral treatment with antibiotics|Oral treatment with antibiotics based on resistens pattern
3362519|NCT05114655|Experimental|Intervention 2|Participants apply a light, citrus-based essential oil blend diluted in fractionated coconut oil to the jawline three times each day for 7 days.
3362520|NCT05114655|Placebo Comparator|Placebo|Participants apply an inert blend including fractionated coconut oil to the jawline three times each day for 7 days.
3362521|NCT05114616|Experimental|Sleep Study and Daytime MWT|Health volunteers completing one overnight sleep study followed by daytime MWT. The sleep study will include standard surface electrodes as well as EEGBuds. Participants will be asked to wear Ellcie Healthy glasses, concurrent with the EEGBuds, during each MWT trial.
3362522|NCT05113251|Experimental|Arm A|Trastuzumab deruxtecan
3362523|NCT05113251|Experimental|Arm B|T-DXd, followed by THP
3362524|NCT05113251|Active Comparator|Arm C|doxorubicin and cyclophosphamide, followed by THP
3362525|NCT05112861|Experimental|Biological: bevacizumab|
3362526|NCT05111288|Experimental|Pulsed electromagnetic field (PEMF) therapy|A portable PEMF device will be utilized. For the PEMF group, the device includes adjustable magnetic field strength range (X-axis: 0.22±0.05 mT, Y-axis: 0.20±0.05 mT and Z-axis: 0.06±0.02 mT) and working frequency (30±3Hz). This magnetic strength range and frequency will be maintained during 180 days of the study period. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
3362527|NCT05111288|Sham Comparator|Sham PEMF therapy|The sham PEMF devices are modified to deliver no micromagnetic field when turned on. The subjects will be instructed to use their device three times per day: providing micromagnetic emitting on both hands (palms) during morning, afternoon and evening/night sessions. Each session takes 16 min (both hands, 8 min per hand) and thus subjects are exposed to therapy for 48 min per day. Subjects will use the device as outlined continuously up through the final days of testing.
3362528|NCT05106231|Experimental|PICC arm|Participants assigned to the intervention group will attend the PICC program, which will take four-month and each session 2.5 hours.
3362529|NCT05106231|Active Comparator|Control arm|Participants assigned to the control group will receive a normal lecturer with the same syllabus with PICC and end up with quizzes.
3249379|NCT01375270|Experimental|Glucotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood glucose."
3249380|NCT01375270|No Intervention|Control Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest and isocaloric meal feeding."
3259433|NCT01470755|Other|salbutamol - dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
3362534|NCT05102929|Experimental|active, then sham Intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive active iTBS stimulation and then sham iTBS over the left dorsolateral prefrontal cortex (DLPFC).
3362535|NCT05102929|Experimental|sham, then active intermittent Theta Burst Stimulation (iTBS) over DLPFC|This arm will first receive sham iTBS (i.e., with the TMS coil in the placebo orientation) and then active iTBS stimulation over the left dorsolateral prefrontal cortex (DLPFC).
3362536|NCT05102071||Treatment with empagliflozin|as add-on therapy with metformin
3362537|NCT05102071||Treatment with a sulfonylurea|as add-on therapy with metformin
3362538|NCT05101057||Treated|Patients who underwent ACDF surgery and who received post surgical therapy with the SpinalogicTM Non-Invasive Bone Graft Stimulation Device.
3362539|NCT05101057||Control|Patients who underwent ACDF surgery and did not receive post surgical Bone Graft Stimulation.
3249381|NCT01375270|Experimental|Lipotoxicity Trial|"Insulin secretion will be assessed using a hyperglycemic clamp combined with GLP-1, GIP, and arginine infusions.~The clamp will be performed before and after 24 hours of bed rest, isocaloric meal feeding, and experimental elevation of blood free fatty acids."
3362540|NCT05100212|Active Comparator|Adult-RBC transfusions|Adult-red blood cell concentrate transfusions
3362541|NCT05100212|Experimental|CB-RBC transfusions|Cord blood-red blood cell concentrate transfusions
3362544|NCT05099029|Experimental|EV71 Vaccine|
3362545|NCT05099029|Placebo Comparator|Placebo|
3249382|NCT01375283||lung cancer surgery|
3249383|NCT01375296|Experimental|SES|including two types of China-made SES, i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
3249384|NCT01375296|Other|medicine|
3249385|NCT01375309|Active Comparator|Active|Bifidobacterium bifidum
3362548|NCT05097196|Experimental|Step Aerobic Group|Step aerobic exercise
3249386|NCT01375309|Placebo Comparator|Placebo|Dextrin without Bifidobacterium bifidum
3249387|NCT01375322|Active Comparator|Co-Diovan® Group|The starting dose of Co-Diovan® was 1 capsule (contains 1/2 tablet) (valsartan/ hydrochlorothiazide 40 mg/ 6.25 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (valsartan/ hydrochlorothiazide 160 mg/ 25.0 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
3249388|NCT01375322|Experimental|Amtrel® Group|The starting dose of Amtrel® was 1 capsule (contains 1/2 tablet) (amlodipine / benazepril hydrochloride 2.5 mg/ 5 mg) every morning and could be adjusted up to 2 capsules (contains 1 tablet per capsule) (amlodipine / benazepril hydrochloride 10 mg/ 20 mg) every morning if patients did not achieve the criteria of SBP<130 mmHg and DBP< 80 mmHg during treatment period
3249389|NCT01375335|Experimental|Dobutamine|
3249390|NCT01375348|Active Comparator|Remifentanil|"Investigate the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle pain induced by the tourniquet pain model~cognitive tests~recording of brain activity by use of 64 channel cap"
3259434|NCT01470768|Other|Arm 1 - AA Formula with DHA and ARA|Marketed AA formula with Docosahexanoic Acid (DHA) and Arachidonic Acid (ARA)
3259435|NCT01470768|Other|Arm 2 - AA Formula with alternative levels of DHA and ARA|
3362553|NCT05091307|Experimental|Group 1: Ad26.COV2.S + Quadrivalent (Q) Standard-dose (SD) Influenza Vaccine and Placebo|Participants aged greater than or equal to (>=) 18 years and less than or equal to (<=) 64 years will receive a single intramuscular (IM) injection of Ad26.COV2.S and a seasonal Q SD influenza vaccine on Day 1 and placebo on Day 29.
3362554|NCT05091307|Placebo Comparator|Group 2: Placebo + Q SD Influenza Vaccine and Ad26.COV2.S|Participants aged >=18 years and <=64 years will receive a single IM injection of placebo and a seasonal Q SD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
3362555|NCT05091307|Experimental|Group 3: Ad26.COV2.S + Q High-dose (HD) Influenza Vaccine and Placebo|Participants aged >=65 years will receive a single IM injection of Ad26.COV2.S and a seasonal Q HD influenza vaccine on Day 1 followed by placebo on Day 29.
3362556|NCT05091307|Placebo Comparator|Group 4: Placebo + Q HD Influenza Vaccine and Ad26.COV2.S|Participants aged >=65 years will receive a single IM injection of placebo and a seasonal Q HD influenza vaccine on Day 1 followed by Ad26.COV2.S on Day 29.
3362557|NCT05089669|Experimental|interactive e-book|The experimental group will read an interactive e-book for 90 minutes to learn nasogastric tube feeding.
3362558|NCT05089669|Active Comparator|comparison group|The comparison group will read a paper textbook for 90 minutes to learn nasogastric tube feeding.
3362559|NCT05089565||Sarcoidosis, not on treatment|Sarcoidosis patients, 18 years of age or older, not currently being treated with immunosuppressive medications
3362560|NCT05089565||Sarcoidosis, on treatment|Sarcoidosis patients, 18 years of age or older, currently being treated with immunosuppressive medications
3362561|NCT05089565||Healthy controls|Healthy individuals, matched for age and sex with those in the two sarcoidosis cohorts
3362563|NCT05085327|Experimental|ChapStick Lip Moisturizer Original|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3362564|NCT05085327|Experimental|ChapStick Lip Moisturizer Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3362565|NCT05085327|Experimental|ChapStick Lip Moisturizer Black Cherry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of ChapStick Lip Moisturizer Black Cherry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3249391|NCT01375348|Placebo Comparator|Placebo infusion|"To blind the study and use as comparator in the investigation of the effect of remifentanil on cognitive function in healthy volunteers by use of experimental pain models:~tonic muscle induced pain by the tourniquet pain model~cognitive tests~brain activity by use of a 64 channel cap"
3249392|NCT01375361|Experimental|Inhaled Albuterol|Patients identified to have Cardiogenic Pulmonary Edema, will receive 2.5mg of Albuterol nebulizer on enrollment in the study and again at 4 hours. Patients will be monitored on telemetry in the emergency department during and after study drug administration. Although study drug administration will cease after 4 hours, we will continue to record ongoing data during the patient's hospitalization.
3249393|NCT01375361|Placebo Comparator|Inhaled Placebo.|Patients identified to have Cardiogenic Pulmonary Edema will receive 2.5mg Normal saline inhaled (Placebo) on enrollment and at 4 hours in the emergency department. Patient will be monitor on telemetry in the emergency department during and after placebo administration.
3249394|NCT01375387|Experimental|Lacosamide 100 mg, Japanese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
3249395|NCT01375387|Experimental|Lacosamide 100 mg, Chinese|1 Lacosamide 100 mg tablet plus 3 placebo tablets
3249396|NCT01375387|Experimental|Lacosamide 200 mg, Japanese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
3362566|NCT05085327|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3362567|NCT05083975|Experimental|Buzzy System|Maxillary anesthetic infiltration injection with (Mepecaine - L 1.8ml Carpule) after activating the buzzy device over the area/cheek where the local anaesthetic solution is to be delivered.
3362568|NCT05083975|Active Comparator|Control|Maxillary anesthetic infiltration injection with (Mepecaine - L 1.8ml Carpule) after topical application with 20% Benzocaine topical gel only.
3362569|NCT05082545|Experimental|Dose escalation:SHR-2002+SHR-1316|SHR-2002 +SHR-1316 C1D1 SHR-2002,C1D22 SHR-2002+SHR-1316, C2 SHR-2002+SHR-1316
3249397|NCT01375387|Experimental|Lacosamide 200 mg, Chinese|2 Lacosamide 100 mg tablets plus 2 placebo tablets
3249398|NCT01375387|Experimental|Lacosamide 400 mg, Japanese|4 Lacosamide 100 mg tablets
3249399|NCT01375387|Experimental|Lacosamide 400 mg, Chinese|4 Lacosamide 100 mg tablets
3249400|NCT01375387|Placebo Comparator|Placebo Comparator, Japanese|4 placebo tablets
3362570|NCT05082545|Experimental|Dose expansion stage: SHR-2002+SHR-1316|Dose expansion of SHR-2002 will be decided after finishing few cohorts in Dose escalation part.
3362571|NCT05082545|Experimental|Indication expansion stage：SHR-2002+SHR-1316|Indication expansion of SHR-2002 will be decided after finishing few cohorts in Dose expansion part.
3362573|NCT05079139|Other|surgical technique of Musset|
3362577|NCT05078463|Experimental|Intervention A: Microneedle with 1 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 1 Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
3362578|NCT05078463|Experimental|Intervention B: Microneedle with 0.5 Finger Tip Unit (FTU) EMLA for 30 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with 1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. 0.5 Finger Tip Unit (FTU) of EMLA cream containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5% (dose: approximately 0.369 g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
3249401|NCT01375387|Placebo Comparator|Placebo Comparator, Chinese|4 placebo tablets
3249402|NCT01375413|Experimental|Integrated dual task training|Integrated dual task training delivered by a physiotherapist. In this training mode walking practice will be combined with simultaneously carrying out cognitive discrimination, verbal fluency and memory tasks.
3249403|NCT01375413|Active Comparator|Consecutive task training|Consecutive task gait training delivered by a physical therapist. In this training mode, walking practice will be conducted separately, focusing on the motor task only. Training of cognitive discrimination, verbal fluency and memory tasks will be done consecutively while the subjects are sitting.
3259436|NCT01470794|Experimental|Single Arm|Toca 511 vector/Toca FC prodrug
3259437|NCT01470807|Experimental|portable artificial pancreas system with CTR algorithms|This is the only arm of the study and concerns all patients.
3259438|NCT01470820|Active Comparator|Distance 20 cm|The infants were randomized by sealed and opaque envelopes to one of four phototherapy regimens. Either with distance from the phototherapy device to the mattress of 20, 29, 38 or 47 cm measured by a wood stick for each infant, corresponding to the distances to the infants of averagely 12, 21, 30 and 39 cm, respectively.
3362579|NCT05078463|Experimental|Intervention C: Microneedle with 1 Finger Tip Units (FTUs) EMLA for 15 minutes|A Maltose Microneedle array patch (size: 1 cm x 1 cm) containing 36 microneedles (the height, base width and tip radius of each microneedle are 400 μm, 100 μm and 3 μm, respectively) with1 mm needle gap in between will be firmly applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 15 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
3362580|NCT05078463|Sham Comparator|Intervention D: 1 Finger Tip Unit (FTUs) EMLA only and PVA-containing PET Sham Patch|A Polyvinyl Alcohol (PVA)-containing Polyethylene Terephthalate (PET) Sham Patch of 1 cm x 1cm size will be applied for 5 seconds against the pre-specified 1 cm x 1 cm grid (which will be the ideal site for intravenous cannulation for blood transfusion) on the dorsal surface of the hand. One (1) Finger Tip Unit (FTU) of EMLA cream (containing an equal amount (25 mg) of lidocaine 2.5% and prilocaine 2.5%) (approximately 0.68g/cm2) will then be topically applied for 30 minutes on the same site of microneedle application. Intravenous cannulation will subsequently be carried out.
3362581|NCT05077176|Active Comparator|CoronaVac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
3259439|NCT01470820|Active Comparator|Distance 29 cm|
3259440|NCT01470820|Active Comparator|Distance 38 cm|
3259441|NCT01470820|Active Comparator|Distance 47 cm|
3362582|NCT05077176|Experimental|Turkovac|Inactivated SARS-CoV-2 virus antigen, single intramuscular injection for boosting dose.
3362597|NCT05068596|Experimental|study groip|received the designed physical therapy program as the control group. In addition, they received progressive resistive functional strength training in the plantigrade foot position.
3362598|NCT05068596|Other|control group|received a designed physical therapy program
3362599|NCT05067478||Cohort A Vibegron|Participants with previous anticholinergic therapy experience will receive vibegron as per the United States (U.S.) label.
3362600|NCT05067478||Cohort B Vibegron|Participants with previous mirabegron monotherapy or mirabegron plus solifenacin or mirabegron and anticholinergic therapy experience will receive vibegron as per the U.S. label.
3362601|NCT05064553||Ultrasound Surveillance Group|Subjects will undergo standard of care ultrasound surveillance imaging. Subjects with positive ultrasound are anticipated to have standard of care imaging follow-up with CT or MRI as well as other procedures as needed. Subjects with negative ultrasound will be sent for a study CT/MRI.
3362602|NCT05064553||CT/MRI Surveillance Group|Subjects will undergo standard of care CT/MRI surveillance imaging.
3362603|NCT05062577|Experimental|ASP8062 in combination with buprenorphine/naloxone|Participants will receive ASP8062 once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
3362604|NCT05062577|Placebo Comparator|Placebo ASP8062 in combination with buprenorphine/naloxone|Participants will receive matching placebo once daily at bedtime (QHS) and buprenorphine/naloxone once daily every morning (QAM) for 12 weeks.
3362606|NCT05056324|Experimental|Intervention group|
3362607|NCT05056324|Active Comparator|Control group|
3362608|NCT05055297|Experimental|SELUTION SLR™ DEB 014|
3362609|NCT05055297|Active Comparator|Plain (Uncoated) Balloon Angioplasty (PTA)|
3362620|NCT05045196|Experimental|Patient and family member of patient undergoing elective open heart surgery- Intervention|Family randomized to the intervention group receiving Health-promoting conversation intervention
3362621|NCT05045196|No Intervention|Patient and family member of patient undergoing elective open heart surgery- Control|Family of a patient undergoing elective open-heart surgery randomized to the intervention group receiving standard care
3362624|NCT05043064|Active Comparator|Experienced robotic cardiac surgeons|
3362625|NCT05043064|Active Comparator|Cardiac surgeons with limited robotic experience|
3249404|NCT01375439|Other|Active search of lower genital tract infections|"Active search of lower genital tract infections~Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome."
3249405|NCT01375452|Active Comparator|Femara|
3249406|NCT01375452|Experimental|Letrozole|
3362626|NCT05043064|Active Comparator|Non-cardiac surgeons with limited robotic experience|
3362627|NCT05042440|Experimental|efanesoctocog alfa (BIVV001)|Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001
3362630|NCT05039268|Active Comparator|15mg Dose Group|Participants will receive a fixed dose regimen of five doses of 15mg.
3362631|NCT05039268|Active Comparator|30mg Dose Group|Participants will receive a fixed dose regimen of five doses of 30mg.
3362632|NCT05039112|Other|P1fA, then MyDay Toric|Verofilcon A toric contact lenses worn first, with stenfilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
3362633|NCT05039112|Other|MyDay Toric, then P1fA|Stenfilcon A toric contact lenses worn first, with verofilcon A toric contact lenses worn second, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days in a daily disposable modality.
3362634|NCT05036668|Experimental|ABO809|Participants will receive ABO809 at a single oral dose of 1x10^4 oocysts. Other doses such as 1x10^6 oocysts may be considered to optimize the model
3362637|NCT05033847|Experimental|Subject last vaccination time is within 30-90 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
3362638|NCT05033847|Experimental|Subject last vaccination time is within 91-180 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
3362639|NCT05033847|Experimental|Subject last vaccination time more than 181 days|Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
3249407|NCT01375465|Other|Dior|One arm observational registry using the Dior paclitaxel eluting balloon for the treatment of de novo ostial bifurcated lesions.
3362647|NCT05031130|No Intervention|Control Group|For the control group, the researcher will provide routine care to pregnant adolescents.
3362648|NCT05031130|Experimental|Experimental group|For the experimental group, the researcher will provide the empowered program integrated with family support plus routine care.
3362656|NCT05027139|Experimental|Zanidatamab plus evorpacept (ALX148)|
3362661|NCT05019339|Experimental|Healthy HomeStyles|Six-week virtual, group nutrition education series using the HomeStyles-2 experimental curriculum administered through SNAP-Ed. This curriculum addresses factors affecting school-aged children's health and nutritional status: inadequate intake of fruits and vegetables, infrequent family meals, excessive consumption of sugar-sweetened beverages, large portion sizes, and irregular breakfast consumption.
3362662|NCT05019339|Active Comparator|Eat Healthy Be Active|Six-week virtual, group nutrition education series using the Eat Healthy Be Active attention control curriculum administered through SNAP-Ed. This curriculum addresses factors affecting overall health and nutritional status: limiting nutrients of concern (saturated fat, sodium, and added sugars), eating healthy while dining out, eating healthy on a budget, losing weight and keeping it off, understanding nutrition facts labels, and being physically active.
3249408|NCT01375478||Cohort|
3249409|NCT01375504|Active Comparator|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
3362677|NCT05013294|Experimental|Intervention|The intervention group will receive a total of 43 text messages. Text messages were developed using the Behavior Chang Wheel (BCW) through a systematic process linked to specific behavior change techniques. The text messages will provide practical information or guidance to influence selection and eating healthy diet for type 2 diabetes care. The text messages were either loss- or gain-framed to increase influence on behavioral decisions. Additionally, the participants will receive a text message to rate their ability on selection of food and eating of healthy diet based on the messages received in the month. The combination of the one-way and two-way messages in this group are designed to increase engagement of the participants.
3362678|NCT05013294|Placebo Comparator|Control Arm|The control group will continue receiving standard care in the hospitals. The control group shall also receive a reminder text messages one day prior the routine clinic appointment. The clinic appointment dates shall be derived from the hospital where the participant receives routine diabetes care.
3249410|NCT01375504|Other|Mindfulness Training Program|The mindfulness training program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
3249411|NCT01375543||Enrollees|Enrolled study participants in whom genetic sequencing was done
3249412|NCT01375582|Experimental|Drop Administration|
3249413|NCT01375621||AHS cohort|population of S. aureus asymptomatic rural Iowans
3249414|NCT01375621||Non-AHS group|symptomatic S. aureus infections in rural Iowans.
3249415|NCT01375634|Placebo Comparator|Placebo|Normal saline
3249416|NCT01375634|Experimental|Midazolam|Midazolam
3249417|NCT01375647|Experimental|Rotarix + No IPV|Randomized to receive rotarix vaccine but no IPV boost
3249418|NCT01375647|Experimental|Rotarix + with IPV boost|Randomized to receive both rotarix vaccine and IPV boost
3362688|NCT05007782|Experimental|Phase 1a, Part A - GS-1811 Dose Escalation|Participants will receive escalating dose levels of GS-1811 for up to 12 months to determine maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of GS-1811.
3362689|NCT05007782|Experimental|Phase 1a, Part B - Mandatory Paired Tumor Biopsy|Participants with select tumor types will receive GS-1811 at the dose deemed safe in Part A for up to 12 months.
3362690|NCT05007782|Experimental|Phase 1b, Part C: GS-1811 + Pembrolizumab|Participants will receive GS-1811 at dose levels deemed safe in Part A in combination with pembrolizumab for up to 24 months.
3362691|NCT05007275|Experimental|Single arm, dose escalation|Experimental: Healthy Volunteers Biological/Vaccine: AZD1222 (1x10^9 vp, 5x10^9 vp and 1x10^10 vp)
3362692|NCT05006794|Experimental|Part A: GS-9716 Dose-Escalation|Participants will receive escalating doses of GS-9716 to establish MTD.
3362693|NCT05006794|Experimental|Part A: GS-9716 Dose-Expansion|Participants will receive the MTD or below MTD of GS-9716.
3362694|NCT05006794|Experimental|Part B (Cohort B1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
3249419|NCT01375647|No Intervention|No Rotarix + No IPV|Randomized to receive neither rotarix vaccine nor IPV boost
3249420|NCT01375647|Experimental|No Rotarix + with IPV boost|Randomized to receive no rotarix vaccine but to receive IPV boost
3249421|NCT01375686||Those at Risk for Type 2 diabetes|All subjects will be at risk for diabetes based on the American Diabetes Association (ADA) Standard of Care Guidelines.
3249422|NCT01375699|Experimental|Sildenafil + doxorubicin|"Patients receive sildenafil citrate PO QD* beginning at least 2 days prior to scheduled first dose of doxorubicin hydrochloride and continuing until 2 weeks after last scheduled dose of doxorubicin hydrochloride. Patients also receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.~NOTE: *Patients receive sildenafil citrate PO TID on days that doxorubicin hydrochloride is also administered."
3249423|NCT01375699|Active Comparator|Doxorubicin-based chemotherapy|Patients receive doxorubicin hydrochloride IV as clinically indicated and as prescribed by treating provider.
3362695|NCT05006794|Experimental|Part B (Cohort B2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
3362696|NCT05006794|Experimental|Part B (Cohort B3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
3249424|NCT01375712|Active Comparator|Fermented milk|Fermented milk containing Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
3249425|NCT01375712|Placebo Comparator|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml in a bottle, consume 1 bottle per day.
3249426|NCT01375725||Coumadin (warfarin)|Subjects currently receiving coumadin (warfarin) treatment.
3249427|NCT01375738|Active Comparator|Gastroduodenostomy|Arm 1: undergo gastroduodenostomy after distal gastrectomy for gastric cancer
3249428|NCT01375738|Experimental|Roux-en Y gastrojejunostomy|Arm 2: undergo Roux-en Y gastrojejunostomy after distal gastrectomy for gastric cancer
3249429|NCT01375790|Experimental|Exercise with Whole-body vibration platform|Exercise with Whole-body vibration (WBV) platform (Power Plate®). The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm). Training volume and intensity we will increase systematically over six weeks according to the overload principle.
3249430|NCT01375790|Active Comparator|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli, during a six weeks training period (3sessions/week). Training volume and intensity we will increase systematically over six weeks according to the overload principle
3249431|NCT01375803|Experimental|1|3g/day
3249432|NCT01375803|Experimental|2|6g/day
3249433|NCT01375803|Placebo Comparator|Placebo beverage|0g/day
3249434|NCT01375816|Active Comparator|FOLFIRI 1 or m FOLFIRI3-Bevacizumab|"FOLFIRI 1-Bevacizumab:~Day 1 H0 : Bevacizumab 5 mg/kg, 30-90 min infusion H+1: Irinotecan 180 mg/m² in 250 ml NaCl 0.9%, 1h infusion Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) over 2h H + 3: 5-FU bolus 400 mg/m², 15 min infusion H + 3.5: 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14~modified FOLFIRI3-Bevacizumab H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H+1:Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion H+1: Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) 2-h infusion H + 3: 5-FU continuous infusion 2400 mg/m² 46-h infusion Day 3 (H+49) H0 Irinotecan 90 mg/m² in 250 ml NaCl 0.9%, 1h infusion End of cycle: day 14"
3249435|NCT01375816|Experimental|FUPEP-Bevacizumab|"Day 1 H0 :Bevacizumab 5 mg/kg, 30-90 min infusion H +1 :PEP02 80 mg/m² , 1h30 infusion. The infusion time could be reduced to 1h from cycle 2 if no acute infusion reaction has occured in cycle 1.~H +1 : Folinic Acid 400 mg/m² (l + d racemic form, or l form 200 mg/m²) , 2-h infusion H +3 : 5-FU continuous infusion 2400 mg/m² 46-h infusion End of cycle: day 14"
3249436|NCT01375829|Experimental|Treatment (ixabepilone, temsirolimus)|Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3249437|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.01 mg/kg|Participants will receive intravenous (IV) infusion of atezolizumab 0.01 milligrams per kilogram (mg/kg) every 3 weeks (q3w) until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3362697|NCT05006794|Experimental|Part B (Cohort B4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
3362698|NCT05006794|Experimental|Part B (Cohort B5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
3249438|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.03 mg/kg|Participants will receive IV infusion of atezolizumab 0.03 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3249439|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.1 mg/kg|Participants will receive IV infusion of atezolizumab 0.1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3362699|NCT05006794|Experimental|Part C (Cohort C1): GS-9716 + Docetaxel|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and docetaxel.
3362700|NCT05006794|Experimental|Part C (Cohort C2): GS-9716 + Sacituzumab Govitecan-hziy|Participants with non-squamous metastatic NSCLC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
3362701|NCT05006794|Experimental|Part C (Cohort C3): GS-9716 + Docetaxel|Participants with metastatic TNBC will receive combination of GS-9716 and docetaxel.
3362702|NCT05006794|Experimental|Part C (Cohort C4): GS-9716 + Sacituzumab Govitecan-hziy|Participants with metastatic TNBC will receive combination of GS-9716 and sacituzumab govitecan-hziy.
3362703|NCT05006794|Experimental|Part C (Cohort C5): GS-9716 + Docetaxel + Gemcitabine|Participants with metastatic STS with nonspecific histologies will receive combination of GS-9716, docetaxel and gemcitabine.
3362704|NCT05006482|Active Comparator|Arm I (usual care)|Patients and caregivers receive routine survivorship follow-up care at their doctor's office for 5 visits over 12 months.
3249440|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 0.3 mg/kg|Participants will receive IV infusion of atezolizumab 0.3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3362705|NCT05006482|Experimental|Arm II (GEMS intervention)|Patients and caregivers participate in GEMS consultation over 1 hour that includes discussion of results and recommendations from geriatric assessment. Patients also participate in survivorship health education sessions over 75 minutes twice weekly for 4 weeks. Patients also participate in EXCAP program, which includes daily walking and resistance exercises.
3362706|NCT05004389||Acute Stroke|Persons ≥ 18 years of age with acute (≤ 7 days) ischemic or intracerebral hemorrhagic stroke.
3362715|NCT05003778|Active Comparator|Traditional equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using traditional equipment (i.e., power racks, barbells, dumbbells, etc.)
3362716|NCT05003778|Experimental|Minimal equipment resistance and endurance training|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.)
3362717|NCT05003778|Experimental|Minimal equipment resistance and endurance training with blood flow restriction|Participants in this group undergo 6 weeks of concurrent resistance and endurance training using minimal equipment (i.e., sandbags, resistance bands, suspension trainers, weight vests, etc.) while wearing upper- and lower-body blood-flow restriction cuffs
3249441|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 1 mg/kg|Participants will receive IV infusion of atezolizumab 1 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3249442|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 3 mg/kg|Participants will receive IV infusion of atezolizumab 3 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3362718|NCT05003089|Experimental|BAY1834845 arm|BAY1834845 will be administered twice daily for 7 consecutive days (Days 1 - 7).
3362719|NCT05003089|Experimental|BAY1830839 arm|BAY1830839 will be administered twice daily for 7 consecutive days (Days 1 - 7).
3362720|NCT05003089|Active Comparator|Prednisolone arm|Prednisolone will be administered twice daily for 7 consecutive days (Days 1 - 7).
3362721|NCT05003089|Placebo Comparator|Placebo arm|Placebo will be administered twice daily for 7 consecutive days (Days 1 - 7).
3362722|NCT05002829|Experimental|Restricted Post-Operative Antibiotics Group|"Participants undergoing standard of care (SOC) with simple appendicitis will not receive post-operative antibiotics.~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive up to 24 hours of SOC post-operative antibiotics."
3362723|NCT05002829|Active Comparator|Liberal Post-Operative Antibiotics Group|"Participants undergoing standard of care with simple appendicitis will receive 24 hours of post-operative SOC antibiotics~Participants undergoing standard of care with complicated (gangrenous or perforated) appendicitis will receive 4 days of post-operative SOC antibiotics."
3362724|NCT04999202|Experimental|Dose escalation of BAY2416964|Two dose levels of BAY2416964 (as determined in the first in human mono-therapy study of BAY2416964) will be given in combination with standard dose Pembrolizumab.
3362725|NCT04999202|Experimental|Dose expansion of BAY2416964 in tumor type specific cohort|To determine the RP2D of BAY2416964 in combination therapy with pembrolizumab. Participants will be enrolled in up to 3 tumor type-specific cohorts including relapsed/refractory non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and urothelial cancer.
3362726|NCT04998201|Experimental|ARO-APOC3|2 doses of ARO-APOC3 by subcutaneous (sc) injection
3362727|NCT04998201|Placebo Comparator|Placebo|calculated volume to match active treatment by sc injection
3249443|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 10 mg/kg|Participants will receive IV infusion of atezolizumab 10 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3249444|NCT01375842|Experimental|Dose Escalation Cohort: Atezolizumab 20 mg/kg|Participants will receive IV infusion of atezolizumab 20 mg/kg q3w until DLT is reached or up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first.
3362734|NCT04994002|Experimental|Cohort 1: CERC-006 (0.5 mg)|Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
3362735|NCT04994002|Experimental|Cohort 2: CERC-006 (1 mg)|Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
3362736|NCT04991025|Experimental|Participants with resectable stage II-III lung cancers.|This is a single arm phase II study of neoadjuvant platinum-based chemotherapy + certolizumab in participants with resectable stage II-III lung cancers. There will be separate adenocarcinoma and squamous cell carcinoma cohorts.
3362737|NCT04988464|Experimental|Sleep Scholar|Sleep Scholar is a fully automated, single-session, self-guided, internet-based CBT-I intervention that participants will read from a web browser on their electronic device. Sleep Scholar's content was adapted from Ellis and colleague's, Morin's, and Perlis and colleague's protocols for therapist-guided CBT-I interventions. Sleep Scholar will be completed in approximately 30 minutes and consists of three successive text-based modules: Sleep Education, Initiating Sleep, and Enhancing Sleep Quality. New content (e.g., vignettes and quizzes) was created to tailor the intervention to college students. For example, after each module, short multiple choice and/or true-false question will be administered to assess participants' understanding of Sleep Scholar's strategies. Participants will be automatically provided feedback on their responses to ensure their understanding of Sleep Scholar's strategies.
3362738|NCT04988464|Placebo Comparator|Building Healthy Habits|Building Healthy Habits will be used as the control condition. It combines two modules being utilized as the control condition in an ongoing randomized controlled trial. It is a single-session, self-guided, internet-based intervention that participants will read from a web browser on their electronic device. Building Healthy Habits was piloted by undergraduate research assistants to ensure that it was approximately the same duration as Sleep Scholar (i.e., 30 minutes). It consists of two successive text-based modules focused on healthy movement and healthy eating.
3362739|NCT04987489|Experimental|Etavopivat 400 mg daily - SCD with transfusions|Patients with sickle cell disease on chronic red blood cell transfusions
3362740|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia with transfusions|Patients with thalassemia on chronic red blood cell transfusions
3362741|NCT04987489|Experimental|Etavopivat 400 mg daily - Thalassemia|Patients with thalassemia not on chronic red blood cell transfusions
3362742|NCT04984889|Experimental|TAK-662 80 IU/kg|TAK-662 80 international unit (IU)/kg, single intravenous infusion over 15 minutes on Day 1. In the extension part, dose of TAK-662 will be modified per participants. TAK-662 is Protein C Concentrate, which is a lyophilized, sterile concentrate of human protein C.
3362743|NCT04984837|Experimental|Lacutamab|Lacutamab 750 mg/IV + GEmOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase Lacutamab 750 mg/IV for a maximum of 20 additional cycles of 4 weeks during the maintenance phase
3362744|NCT04984837|Active Comparator|Standard of care|GemOx (1000 mg/m² / 100 mg/m²) 6 cycles of 3 weeks (4,5 months) during the induction phase
3362745|NCT04983368|Experimental|Xanamem® 5 mg|Oral Xanamem® capsules 5 mg, to be administered once daily
3249445|NCT01375842|Experimental|Expansion Cohort (Atezolizumab)|Participants will receive IV infusion of atezolizumab q3w up to end of study or treatment discontinuation or death or until initiation of another anti cancer therapy, whichever occurs first. The dose which result in total drug exposure less than or equal to (</=) exposures achieved at the MTD or maximum administered dose (MAD), will be selected for expansion cohort.
3249446|NCT01375855|Active Comparator|Polimeric-PES|Arm receiving polimeric stent (Taxus)
3362746|NCT04983368|Experimental|Xanamem® 10 mg|Oral Xanamem® capsules 10 mg, to be administered once daily
3249447|NCT01375855|Active Comparator|Non-Polimeric PES|Arm receiving non-polimeric PES (axxion)
3249448|NCT01375868|Experimental|Vaccine Silgard|vaccination with tetravalent antiviral vaccine, 3 doses
3362747|NCT04983368|Placebo Comparator|Placebo|Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily.
3362749|NCT04981821|Experimental|GO-EXCAP|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
3362750|NCT04981821|Active Comparator|Behavioral Placebo Control|Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
3362751|NCT04980456|Other|TOTAL30, then Biofinity|Lehfilcon A contact lenses worn first, followed by comfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.
3362752|NCT04980456|Other|Biofinity, then TOTAL30|Comfilcon A contact lenses worn first, followed by lehfilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for at least 10 hours per day during waking hours only. CLEAR CARE will be used for nightly cleaning and disinfection.
3362759|NCT04974216|Experimental|R-Lena-Tafa|"12 cycles of 28 days. From C1 to C6 : rituximab + tafasitamab + lenalidomide and from C7 to C12: tafasitamab and lenalidomide~Patients with Progressive Disease or Stable Disease after 3 cycles should start a conventional chemotherapy (rituximab + cyclophosphamide + adriamycine + vincristine + prednisone R-miniCHOP) at Investigator's discretion according to local practices"
3249449|NCT01375881||001|darunavir/ritonavir plus background regimen darunavir/ritonavir oral use in naive and experienced patients at approved dosages
3362773|NCT04969510|Experimental|PRAX-114 (10 mg)|10 mg PRAX-114 once daily
3362774|NCT04969510|Experimental|PRAX-114 (20 mg)|20 mg PRAX-114 once daily
3362775|NCT04969510|Experimental|PRAX-114 (40 mg)|40 mg PRAX-114 once daily
3362776|NCT04969510|Experimental|PRAX-114 (60 mg)|60 mg PRAX-114 once daily
3362777|NCT04969510|Placebo Comparator|Placebo|Placebo once daily
3249450|NCT01375894|Active Comparator|depresive patients|30 patients suffering from depression
3249451|NCT01375894|Experimental|Schizophrenia patients|30 Schizophrenia patients
3249452|NCT01375907|Experimental|Rotavin|Rotavin-M1 vaccine, 10e6.3FFU/dose, 2 doses, 1 month between doses
3249453|NCT01375920|Active Comparator|Metyrapone, daily medication|500 milligrams Metyrapone to be taken orally twice daily for 3 weeks.
3249454|NCT01375920|Placebo Comparator|placebo|a matched placebo will be given for patients to take twice daily
3249455|NCT01375933|Active Comparator|NicVAX - Phase 3 Lot|NicVAX - Phase 3 Lot
3249456|NCT01375933|Active Comparator|NicVAX - Commercial Lot|NicVAX - Commercial Lot
3249457|NCT01375972|Experimental|SP treatment|S-1 plus cisplatin combination chemotherapy
3249458|NCT01375972|Active Comparator|GP treatment|Gemcitabine plus Cisplatin combination chemotherapy
3362778|NCT04968106|Other|Standard Arm A: treatment by neoadjuvant chemotherapy|Treatment by doxorubicin and ifosfamide followed by surgery
3362779|NCT04968106|Experimental|Experimental Arm B: treatement by neoadjuvant chemotherapy and retifanlimab|Treatment by doxorubicin, ifosfamide and retifanlimab followed by surgery
3249459|NCT01375985|Experimental|AVI-7100|Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™)
3249460|NCT01375985|Experimental|Placebo|Vehicle
3249461|NCT01375998||Group 1|
3249462|NCT01376011|Experimental|healthy young|
3249463|NCT01376011|Experimental|healthy old|
3249464|NCT01376063|Experimental|FG-4592|
3362788|NCT04952753|Experimental|Safety run-in: NIS793+SOC (Investigational arm 1)|In the safety run-in part for investigational arm 1, participants will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 to confirm the RP2D of the NIS793
3362789|NCT04952753|Experimental|Expansion: NIS793+SOC (Investigational arm 1)|In the expansion part, participants in the investigational arm 1 will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI) and NIS793 at the RP2D defined in the safety run-in
3362790|NCT04952753|Active Comparator|Expansion: SOC (control arm)|In the expansion part, participants in the control arm will be treated with a combination of SOC anti-cancer therapy (bevacizumab with either modified FOLFOX6 or FOLFIRI)
3249465|NCT01376076|Experimental|1|Sequential, Multiple Dose, titration from 1.5mg to 18mg once daily dose of cariprazine
3249466|NCT01376076|Placebo Comparator|2A|Double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35
3362794|NCT04948463|Experimental|Early Stopping|Stopping empiric FN antibiotics after resolution of fever for 48 hours, irrespective of absolute neutrophil count (ANC)
3362795|NCT04948463|Active Comparator|Standard of care|Continuing empiric FN antibiotics until resolution of fever for 48 hours and recovery of ANC as defined by the treating clinician but usually to ≥200-500/mm3
3362796|NCT04941261|Experimental|18-59 years old group A|
3249467|NCT01376076|Placebo Comparator|2B|Double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35
3249468|NCT01376102||BONVIVA(ibandronate)|Patients administrated ibandronate injection with postmenopausal osteoporosis
3249469|NCT01376115||Subjects administered nelarabine|Subjects with T-cell acute lymphocytic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) prescribed nelarabine during study period
3249470|NCT01376128||Subjects prescribed PAXIL|Pediatric subjects with panic disorder prescribed PAXIL during study period
3249471|NCT01376141||Subjects prescribed IMIGRAN|Subjects with migraine disorders prescribed IMIGRAN during study period
3249472|NCT01376154||Subjects prescribed lamivudine tablet|Subjects with hepatitis B virus-induced liver cirrhosis prescribed lamivudine tablet during study period
3249473|NCT01376180||Subjects prescribed lamotrigine tablet|Subjects with epilepsy prescribed lamotrigine tablet during study period
3249474|NCT01376193||Subjects prescribed naratriptan tablets|Subjects with migraine headache prescribed naratriptan tablets during study period
3362797|NCT04941261|Experimental|18-59 years old group B|
3249475|NCT01376206||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
3249476|NCT01376219||All patients|All patients entered in the study
3249477|NCT01376232|Experimental|GSK1278863|100 mg of GSK1278863
3249478|NCT01376232|Experimental|GSK1278863 + food|100 mg of GSK1278863 given with a high fat meal
3249479|NCT01376232|Experimental|GSK1278863 + Gemfibrozil|GSK1278863A 100mg + Gemfibrozil 600mg steady state
3249480|NCT01376258||Patients adherent to 5-alpha reductase inhibitor (5ARI)|Patients with benign prostate hyperplasia (BPH) who are adherent (as measured by a medication possession ratio (MPR)) based on 3 MPR threshold values of 70%, 75% and 80%
3249481|NCT01376258||Patients who are non-adherent to 5ARI therapy|Patients with BPH who are not adherent to 5ARI therapy as measured by 3 MPR threshold values of 70%, 75%, and 80%
3249482|NCT01376271||Subjects prescribed paroxetine tablets|Subjects with SAD prescribed paroxetine tablets during study period
3249483|NCT01376284||Subjects prescribed dutasteride capsules|Subjects with BPH prescribed dutasteride capsules during study period
3249484|NCT01376323|Experimental|GSK256073 1mg bid|GSK256073 1mg capsule taken orally twice a day
3249485|NCT01376323|Experimental|GSK256073 2mg qd|GSK256073 2 x 1mg capsule taken orally once a day
3249486|NCT01376323|Experimental|GSK256073 5mg bid|GSK256073 5mg capsule taken orally twice a day
3362798|NCT04941261|Placebo Comparator|18-59 years old group C|
3362799|NCT04941261|Experimental|6-17 years old group A|
3362800|NCT04941261|Experimental|6-17 years old group B|
3362801|NCT04941261|Placebo Comparator|6-17 years old group C|
3362802|NCT04941261|Experimental|3-5 years old group A|
3362803|NCT04941261|Experimental|3-5 years old group B|
3362804|NCT04941261|Placebo Comparator|3-5 years old group C|
3362805|NCT04941261|Experimental|6-35 months old group A|
3362806|NCT04941261|Experimental|6-35 months old group B|
3362807|NCT04941261|Placebo Comparator|6-35 months old group C|
3362808|NCT04941261|Experimental|6-35 months old group D|
3362809|NCT04941261|Experimental|6-35 months old group E|
3362810|NCT04941261|Placebo Comparator|6-35 months old group F|
3362811|NCT04939363|Experimental|combination of Ibrutinib, Venetoclax and Obinutuzumab|"Obinutuzumab intravenous infusion:~Cycles 1: Day 1: Obinutuzumab 100 mg Day 1 (or 2): Obinutuzumab 900 mg Day 8: Obinutuzumab 1000 mg Day 15: Obinutuzumab 1000 mg Cycles 2-6: Day 1: Obinutuzumab 1000 mg The first infusion of Obinutuzumab may be administered at the full dose (1000 mg) on day 1 of cycle 1, if the infusion of a test-dosage of 100 mg is well tolerated by the patient. Alternatively, if the first 100 mg infusion on day 1 is not well tolerated, the remaining 900 mg of the first dose should be administered on day 2.~Ibrutinib PO 560mg daily starting on cycle 1 day 1 for 12 cycles.~Venetoclax with an accelerated ramp-up and close inpatient TLS monitoring starts on cycle 1 day 15 to the target dose of 400mg daily for a total of 12 cycles:~Cycle 1: Day 15: Venetoclax 20 mg Days 16-17: Venetoclax 50 mg Days 18-21: Venetoclax 100 mg Days: 22-28: Venetoclax 200 mg Cycles 2-12: Days 1-28: Venetoclax 400 mg"
3362817|NCT04935359|Experimental|Safety run-in part: NIS793+gemcitabine+nab-paclitaxel|In the safety run-in part, participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel.
3362818|NCT04935359|Experimental|Randomized part: NIS793+gemcitabine+nab-paclitaxel|Participants will receive a combination of NIS793, gemcitabine and nab-paclitaxel
3362819|NCT04935359|Placebo Comparator|Randomized part: placebo+gemcitabine+nab-paclitaxel|Participants will receive a combination of placebo, gemcitabine and nab-paclitaxel
3362823|NCT04928326||Patients with heart failure undergoing right heart catheterization|Subjects with a diagnosis of NYHA class II-IV heart failure who meet the inclusion and exclusion criteria will be eligible for participation in this study.
3249487|NCT01376323|Experimental|GSK256073 10mg qd|GSK256073 2 x 5mg capsule taken orally once a day
3249488|NCT01376323|Experimental|GSK256073 10mg bid|GSK256073 10mg capsule taken orally twice a day
3362836|NCT04921865||Patients treated with the DPS VA-LCP® Clavicle Plate 2.7 System or Hook Plate 2.7 System|Any patient undergoing surgical treatment for the fixation of clavicle bone fragments and acromioclavicular joint dislocations using the DPS VA-LCP® Clavicle Plate 2.7 System or DPS VA-LCP® Clavicle Clavicle Hook Plate 2.7 .
3362837|NCT04920435||training population|patients from which we will develop the prediction model
3362838|NCT04920435||testing population|patients on whom we will test the prediction model
3362839|NCT04915313|Experimental|Intervention group|Subjects in the intervention group will recieve remote ischemic conditioning (RIC) treatment twice a day for 4 weeks.
3362840|NCT04915313|Sham Comparator|Sham control group|Subject in the sham control group will recieve sham remote ischemic conditioning (Sham-RIC) treatment twice a day for 4 weeks..
3362845|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
3362846|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
3362847|NCT04912063|Experimental|Lemzoparlimab + Azacitidine in MDS (Escalation)|Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
3249489|NCT01376323|Experimental|GSK256073 20mg qd|GSK256073 2x 10mg capsule taken orally once a day
3362848|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
3362849|NCT04912063|Experimental|Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)|Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
3362850|NCT04908826|Active Comparator|Group A (standard cholangiography during surgery)|All patients will undergo laparoscopic cholecystectomy. In this group standard cholangiography will be performed during surgery. Standard cholangiography will be performed with selective catheterization of the cystic duct and infusion of a radiolucent substance (non-ionic low osmotic iodine). The category includes drugs such as iohexol, iopamidol, iopromide, ioversol, iobitriol, iomeprol and iodixanol. In our study we will use Xenetix (iobitriol) and perform cholangiography with C-ARM recording.
3362851|NCT04908826|Active Comparator|Group B (cholangiography with iv administration of icg prior to surgery)|All patients will undergo laparoscopic cholecystectomy. In this group intravenous fluorescent cholangiography with indocyanine green will be given at a dose of 0.3 mg / mL / Kg 6 (six) hours before the start of surgery.The bile duct system will be recorded with a special camera (Karl Storz NIR / ICG).
3362852|NCT04908826|Active Comparator|Group C (cholangiography with direct administration of icg to the bile duct system during surgery)|All patients will undergo laparoscopic cholecystectomy. In the third group intraoperative cholangiography will be performed with direct administration of indocyanine green at a dose of 0.03 mg / ml / Kg to the bile duct cyst.
3362855|NCT04899999|Experimental|Financial reward graphic message|
3362856|NCT04899999|Experimental|Health reward graphic message|
3362857|NCT04899999|Experimental|Self-efficacy graphic message|
3362858|NCT04899999|Experimental|Social norms graphic message|
3362859|NCT04899349|Experimental|Alpelisib + Fulvestrant + Dapagliflozin + Metformin XR|Alpelisib 300mg orally once daily starting at Cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive a combination treatment of dapagliflozin+metformin XR (as a single tablet or as two separate tablets, at the discretion of the investigator) at a starting dose of 5 mg dapagliflozin + 500 mg metformin XR orally once daily which can be titrated to a maximum dose of 10 mg dapagliflozin + 2000 mg metformin XR once daily.
3362860|NCT04899349|Active Comparator|Alpelisib + Fulvestrant + Metformin XR|Alpelisib 300mg orally once daily starting at cycle 1 Day 8 in combination with fulvestrant 500mg intramuscular at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle. Participants will receive metformin XR 500mg orally once daily which can be titrated to a maximum dose of 2000 mg once daily.
3362865|NCT04894721|Experimental|Experimental Group|The EG receives ivermectin 0,6mg/kg of weight orally on days 1 (one) and 7 (seven) plus standard biosecurity care
3362866|NCT04894721|Placebo Comparator|Control Group|The CG receives a placebo on days 1 (one) and 7 (seven) plus standard biosecurity care
3249490|NCT01376323|Experimental|GSK256073 25mg bid|GSK256073 25mg capsule taken orally twice a day
3249491|NCT01376323|Experimental|GSK256073 50mg qd|GSK256073 2x 25mg capsule taken orally once a day
3249492|NCT01376323|Placebo Comparator|Placebo|Matching placebo capsules taken orally either once a day or twice a day
3249493|NCT01376323|Active Comparator|Sitagliptin 100mg qd|Commercially available Sitagliptin 100mg capsules taken once a day
3249494|NCT01376336|Experimental|Safe storage device|This arm will be assigned a safe water storage device.
3249495|NCT01376336|No Intervention|Control|This arm of the trial will receive nothing until the end of the trial.
3249496|NCT01376414||Non specific upper abdominal pain|Cohort is patients who present to the Emergency Department with primary complaint of upper abdominal pain without obvious cause.
3249497|NCT01376440|Experimental|Household water treatment|household water treatment with 1.25% sodium hypochlorite
3362867|NCT04892901||c-ESPB group|Postoperative analgesia ensured by continuous ultrasound-guided ESPB performed at the end of surgery.
3249498|NCT01376440|No Intervention|control|"Usual practice (the use of Jerrican for water storage, which is considered as safe storage)"
3362868|NCT04892901||c-SAPB group|Postoperative analgesia ensured by continuous SAPB performed by surgeons at the end of surgery.
3362869|NCT04892901||ICNB-group|"Postoperative analgesia ensured by one-shot ICNB + continuous intravenous administration of tramadol by elastomeric pump."
3362877|NCT04881760|Experimental|LY3437943 Dose 1|LY3437943 administered subcutaneously (SC)
3362878|NCT04881760|Experimental|LY3437943 Dose 2|LY3437943 administered SC
3362879|NCT04881760|Experimental|LY3437943 Dose 3|LY3437943 administered SC
3362880|NCT04881760|Experimental|LY3437943 Dose 4|LY3437943 administered SC
3362881|NCT04881760|Placebo Comparator|Placebo|Placebo administered SC
3362887|NCT04878367|Experimental|COPD_E|COPD patients with intervention
3249499|NCT01376453|Experimental|Sorafenib Dose Escalation|Pre-operative Continuous 5-FU, and Sorafenib with External Radiation Therapy. Dose level -1 will only be evaluated if dose level 1 exceeds MTD. The sorafenib and infusional 5-FU will only be given Day 1-5(Monday-Friday) with radiation only.
3249500|NCT01376466||patients with acute appendicitis|Patients who have been clinically diagnosed to have acute appendicitis
3362888|NCT04878367|No Intervention|COPD_C|COPD patients without intervention
3362889|NCT04878289|Experimental|TOTAL Intervention|TOTAL video and participate in three one-on-one, 30-minute motivational sessions via VVC at 1-week, 6-months, and 12-months
3362893|NCT04876352|Experimental|VR-training|Upper limb/handwriting exercises in an immersive virtual reality setting
3362894|NCT04876352|Active Comparator|RS-training|The same upper limb/handwriting exercises in a real setting
3249501|NCT01376479|Experimental|INV21 Low Dose|
3249502|NCT01376479|Experimental|INV21 High Dose|
3362895|NCT04876352|Other|Healthy subjects|Age- and sex-matched healthy subjects recruited to compare clinical and fMRI characteristics at baseline.
3362896|NCT04874623|Experimental|CDI|
3362897|NCT04874311|Experimental|Experimental Arm A: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
3362898|NCT04874311|Other|Standard Arm B: treatment by doxorubicin|Soft-tissue sarcoma patients with an inflammed tumor will be treated with doxorubicin for 6 cycles
3362899|NCT04874311|Experimental|Experimental Arm C: treatment by bintrafusp alfa combined with doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with bintrafusp alfa combined with doxorubicin for 6 cycles, followed by bintrafusp alfa maintenance
3362900|NCT04874311|Other|Standard Arm D: treatment by doxorubicin|Soft-tissue sarcoma patients with a cold tumor will be treated with doxorubicin for 6 cycles
3362902|NCT04868968|Experimental|DFV890|DFV890
3249503|NCT01376492||001|Functioning assessment The functioning will be assessed with 2 scales (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
3249504|NCT01376492||002|Quality of sleep assessment The quality of sleep will be assessed with 2 scales (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
3249505|NCT01376505|Experimental|HER-2 Vaccine|"combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720~This escalation arm has completed. The trial has moved on to the extension arm"
3249506|NCT01376505|Experimental|EXTENSION HER-2 Vaccine at OBD|"Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with nor-MDP and ISA 720 at dose level cohort 2~This extension arm is ongoing"
3362905|NCT04866160|Experimental|BI 1291583 low dose|
3362906|NCT04866160|Experimental|BI 1291583 high dose|
3362907|NCT04866160|Placebo Comparator|Placebo|
3362908|NCT04865809|Experimental|Trial Group|Patients from this group will use Peribioma Toothpaste and Mousse for home oral care.
3362909|NCT04865809|Active Comparator|Control Group|Patients from this group will use standard toothpastes for home oral care.
3249507|NCT01376518||respiratory failure|patients with respiratory failure and need of high positive end-expiratory pressure ventilation.
3249508|NCT01376531||acute renal failure|patients at intensive care unit with definition of acute renal failure and the need for continuous veno-venous hemodialysis
3362910|NCT04861454||surgical|internal browbexy and brassier suture were done after blepharoplasty
3362911|NCT04860804|Active Comparator|AOK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
3362912|NCT04860804|Active Comparator|OK Group|Drug: Proprietary oral formulation of 0.5mg/kg of ketamine
3362913|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody Low Dose|
3249509|NCT01376544|Active Comparator|Assist control ventilation|Assist control ventilation
3249510|NCT01376544|Active Comparator|Pressure support ventilation|
3249511|NCT01376570|Experimental|Contingency Management arm|The Contingency Management arm will receive the abstinence-reinforcing contingency management intervention.
3249512|NCT01376570|Active Comparator|Control arm|The Control arm will receive the performance feedback intervention.
3362914|NCT04856930|Experimental|ANB019 Biological Humanized Monoclonal Antibody High Dose|
3362915|NCT04856930|Placebo Comparator|Placebo Solution|
3249513|NCT01376596|Experimental|CBT-based Intervention|Contrast the impact of a CBT intervention for the treatment of social anxiety in schizophrenia with standard care (care as usual)
3249514|NCT01376596|Active Comparator|Treatment as usual|Usual care received by patients at clinic/hospital - randomized to a wait list to receive the CBT intervention at the end of the group that received the intervention immediately
3249515|NCT01376622||Chronically Transfusion Patients|Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
3249516|NCT01376622||Controls|Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.
3249517|NCT01376661||Active Surveillance/ Prostate Cancer|
3249518|NCT01376687||Pain free|No pain in the cervical spine
3362916|NCT04855929|Experimental|ANV419 single agent, Q2W|
3362917|NCT04855929|Experimental|ANV419 in combination with CPI or Immunostimulatory agent, Q2W|
3362918|NCT04855656|Experimental|Phase 1: RP-6306 Single-Agent, Dose Escalation and Food-effect Study|Patients receive RP-6306 orally until disease progression, unacceptable toxicity, or investigator/patient decision. Dose escalation will proceed until a maximum tolerated dose is identified.
3249519|NCT01376687||Pain|Pain of 3 or greater on a VAS scale for the cervical spine
3362939|NCT04848220|Experimental|Stage A (Dose Cohort 1) and Stage B (Dose Group 1)|
3362940|NCT04848220|Experimental|Stage A (Dose Cohort 2) and Stage B (Dose Group 2)|
3362941|NCT04848220|Placebo Comparator|Stage A (Dose Cohort 1 and Dose Cohort 2) and Stage B (Dose Group 1 and Dose Group 2)|
3362942|NCT04847726|Experimental|CEUS with perfluorobutane and sulfur hexafluoride|Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.
3362947|NCT04842643|Experimental|Epoch 2 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 50 and 200 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once a week until the study drug becomes commercially available (approximately 2 years). All participants of this arm will have assigned Epoch 2 of previous study (TAK-664-3001). The dose of IGSC will be established in previous study.
3362948|NCT04842643|Experimental|Epoch 3 in previous study: Immune Globulin Subcutaneous 20% Solution (IGSC)|Participants will receive between 100 and 400 mg/kg of Immunoglobulin Globulin subcutaneous (IGSC) infusion, 20 percent (%) once every 2 weeks until the study drug becomes commercially available (approximately 2 years). All participants of this arm will have assigned Epoch 3 of previous study (TAK-664-3001).The dose of IGSC will be established in previous study (TAK-664-3001).
3362949|NCT04839393|Experimental|Part A - Sequence 1|Treatment A - PF-06882961 single dose followed by Treatment B - PF-06882961 single dose and PF-06865571 single dose
3362950|NCT04839393|Experimental|Part A - Sequence 2|Treatment B - PF-06882961 single dose and PF-06865571 single dose followed by Treatment A - PF-06882961 single dose
3362951|NCT04839393|Experimental|Part B|Period 1: PF-06865571 single dose, Period 2: PF-06882961 twice daily dose titration, Period 3: PF-06865571 single dose and PF-06882961 twice daily dosing, Period 4: PF-06865571 twice daily dosing and PF-06882961 twice daily dosing
3249520|NCT01376713|Experimental|Ofatumumab alone|Patients with melanoma unresectable stage III B (T1- 4a, N2b-c), stage III C or stage IV (AJCC 2009) will be included in this study. Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks. Tumor imaging is performed at wk 4 (screening for rapid disease progression), 8, 16 and 24. In case of PD, patients will have the opportunity to receive at least 3 cycles of ofatumumab q4w in combination with DTIC (1000 mg/m2) q4w (see Arm2).
3249521|NCT01376713|Experimental|Ofatumumab plus Dacarbazine|Patients will be treated with a combination of DTIC (1000 mg/m2) q4w plus ofatumumab (1000mg) qw for 8 wks, and thereafter q4w.Tumor imaging is performed at wk 8, 16 and 24.
3249522|NCT01376726|Experimental|Previous HIV Vaccine Trial Participants (Group 1)|"Participants will receive the study vaccine administered as one 0.5 mL intramuscular injection (IM) in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
3249523|NCT01376726|Experimental|No Previous HIV Vaccine Trial (Group 2)|"Participants will receive the study vaccine administered as one 0.5 mL IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
3249524|NCT01376739||Group 1|
3249525|NCT01376752|Active Comparator|maximal cytoreductive surgery without HIPEC|The participant will have a regular cytoreductive surgery without the adjunction of HIPEC.
3249526|NCT01376752|Experimental|maximal cytoreductive surgery with HIPEC|The participant will have a regular cytoreductive surgery, then the adjunction of HIPEC: hyperthermic cisplatin will be used at 75mg/m²
3249527|NCT01376765|Experimental|Cohort 1|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine received with aluminum hydroxide adjuvant (Alhydrogel®), without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 5 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine {(SARS vaccine with aluminum hydroxide adjuvant (Alhydrogel®)}; 4 subjects receive placebo.
3249528|NCT01376765|Experimental|Cohort 3|SARS vaccine with adjuvant, without adjuvant, or placebo; l in 2 intramuscular doses, 28 days apart, at 45 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant); 4 subjects receive placebo.
3362959|NCT04835805|Experimental|Belvarafenib Monotherapy|Twice daily (BID), continuous dosing.
3362960|NCT04835805|Experimental|Belvarafenib Plus cobimetinib|Recommended dose (RD) and schedule of belvarafenib and cobimetinib selected based on the safety data, tolerability, pharmacokinetics, and anti-tumor activity tested in dose-finding phase followed by an expansion phase.
3362961|NCT04835805|Experimental|Belvarafenib Plus Cobimetinib Plus Atezolizumab|Recommended dose (RD) and schedule of belvarafenib and cobimetinib plus atezolizumab IV infusion every 4 weeks (Q4W) followed by an expansion phase
3362963|NCT04833140|Active Comparator|Estradiol|"Estradiol in the form of a transdermal patch 100 mcg daily (Vivelle-Dot generic).~Women with an intact uterus will also receive progesterone (100 mg) in the form of a vaginal tablet (Endometrin, Ferring Pharmaceuticals, Inc.) inserted daily for endometrial protection"
3362964|NCT04833140|Placebo Comparator|Placebo|Placebo patch (containing no estradiol) Women with an intact uterus will also receive vaginal placebo capsules (containing no progesterone)
3362965|NCT04832425|Experimental|PRAX-114|40 mg PRAX-114 once daily
3362966|NCT04832425|Placebo Comparator|Placebo|Placebo once daily
3362967|NCT04827992|Experimental|Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment|This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.
3362968|NCT04827992|Active Comparator|Prescription Opioid Taper Support (POTS) treatment alone|This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.
3362969|NCT04825288|Active Comparator|Arm 1|"XB2001 + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 1 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: XB2001 MTD as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-Fluorouracil 2400mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
3362970|NCT04825288|Placebo Comparator|Arm 2|"Placebo + ONIVYDE + 5-FU + LV combination therapy administered for 12 cycles of treatment~• Arm 2 Treatment Cycle: Patients randomized to this arm will receive the following treatments every 2 weeks: Placebo as an intravenous infusion over up to 60 minutes, followed by ONIVYDE 70 mg/m2 intravenously over 90 minutes, followed by leucovorin l + d racemic 400 mg/m2 intravenously over 30 minutes, followed by 5-fluorouracil 2400 mg/m2 intravenously over 46 hours. Therapy will be administered every 2 weeks (2 weeks = 1 cycle)."
3362971|NCT04825197|Experimental|LRS Group|This arm will receive up to 4 doses (100 mg Kg) of Poractant alfa (Curosurf, Chiesi) every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV. Optimal recruitment is defined as adequate oxygenation using a fraction of inspired oxygen (FiO2) of 0.30 or less. The continuous distending pressure (CDP) will be increased stepwise (1 cmH2O every 2-3 min) as long as pulse oximetry (SpO2) improves. The FiO2 will be reduced stepwise, keeping SpO2 within the target range (87-94 %). The recruitment procedure will be stopped if oxygenation no longer improves or if the FiO2 is equal to or less than 0.30. The corresponding CDP will be called the opening pressure (CDPO). Next, the CDP will be reduced stepwise (1-2 cmH2O every 2-3 min) until the SpO2 deteriorates (by at least 2-3 points). The corresponding CDP will be called the closing pressure (CDPC). After a second recruitment maneuver at CDPO for 5 min, the optimal CDP (CDPOPT) will be set 2 cmH2O above the CDPC for at least 3 min.
3362972|NCT04825197|No Intervention|Standard Group|This arm will be managed following the ward standard ventilatory protocol which does not contemplate neither surfactant administration nor recruitment manoeuvre.
3249529|NCT01376765|Experimental|Cohort 2|SARS vaccine with adjuvant, without adjuvant, or placebo in 2 intramuscular doses, 28 days apart, at 15 micrograms per dose; 12 subjects receive unadjuvanted vaccine (SARS vaccine alone); 12 subjects receive adjuvanted vaccine (SARS vaccine with adjuvant) 4 subjects receive placebo.
3249530|NCT01376778|Active Comparator|CMV hyperimmune globulin - Cytogam®|Infusion of Cytogam®, Cytomegalovirus Immune Globulin Intravenous (Human) (CMV-IGIV)
3362976|NCT04822168|Active Comparator|Standard Care|Standard Care through detox-based opioid treatment with B/N and weekly urine toxicology screening
3362977|NCT04822168|Experimental|MySafeRx™ Intervention|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of B/N medication within a secure medication storage device, and a standardized protocol for supervising self-administration of medication via videoconferencing.
3362980|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 1|TAK-994 dose 1, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
3362981|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 2|TAK-994 dose 2, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
3362982|NCT04820842|Experimental|Active Drug Extension Period: TAK-994 Dose 3|TAK-994 dose 3, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56.
3362983|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 1|Following the Active Drug Extension Period, participants randomized to active treatment Dose 1 will continue to receive same dose (TAK-994, dose 1, tablets, orally) from Day 57 to Day 84.
3362984|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 2|Following the Active Drug Extension Period, participants randomized to active treatment Dose 2 will continue to receive same dose (TAK-994, dose 2, tablets, orally) from Day 57 to Day 84.
3362985|NCT04820842|Experimental|Double-blind Randomized Withdrawal Period: TAK-994 Dose 3|Following the Active Drug Extension Period, participants randomized to active treatment Dose 3 will continue to receive same dose (TAK-994, dose 3, tablets, orally) from Day 57 to Day 84.
3362986|NCT04820842|Placebo Comparator|Double-blind Randomized Withdrawal Period: Placebo|Following the Active Drug Extension Period participants will receive placebo-matching tablets for 4 weeks (from Day 57 to Day 84).
3362987|NCT04817956|Experimental|Atezolizumab|Atezolizumab used outside of current indication, based on biomarkers
3362988|NCT04817956|Experimental|Atezilizumab combined with bevacizumab|Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers
3362989|NCT04817956|Experimental|Phesgo (trastuzumab og pertuzumab)|Phesgo used outside of indication, based on biomarkers.
3362990|NCT04817956|Experimental|Alectinib|Alectinib used outside of indication, based on biomarker
3362991|NCT04817956|Experimental|vismodegib|vismodegib used outside of indication, based on biomarker
3249531|NCT01376778|Placebo Comparator|Placebo|IV 5% albumin diluted 1 to 9 with 5% Dextrose in water (D5W)
3362992|NCT04817956|Experimental|entrectinib|entrectinib used outside of indication, based on biomarker
3362993|NCT04817956|Experimental|Zelboraf + Cotellic|Zelboraf + Cotellic used outside of indication, based on biomarker
3362996|NCT04816630||CBC-Diff Monocyte Volume Width Distribution|Monocyte Distribution Width [MDW] is part of the CBC with Differential. No intervention
3362999|NCT04814134|Experimental|CPNS Therapy|Treatment with CPNS system: Endovascular stimulation of the cardiac autonomic nerves in addition to standard of care
3363000|NCT04814134|Other|Standard of Care|Available standard treatment
3249532|NCT01376817|Experimental|Omega 3|
3249533|NCT01376817|Active Comparator|MCT / LCT|
3249534|NCT01376830||COPD patients|
3249535|NCT01376843||Health care workers|health care workers who performed TST or Quantiferon-TB Gold In tube assay before
3249536|NCT01376856||PET/CT and surgical biopsy group|person who performed PET/CT and surgical biopsy of mediastinal lymph node for diagnosis of primary lung cancer of metastatic lung cancer
3249537|NCT01376869|Active Comparator|102mg extract 1 hops|Equivalent to 0.5g dry weight
3249538|NCT01376869|Active Comparator|410mg extract 1 hops|Equivalent to 2g dry weight
3249539|NCT01376869|Active Comparator|79mg extract 2 hops|Equivalent to 0.5g dry weight
3249540|NCT01376869|Active Comparator|316mg extract 2 hops|Equivalent to 2g dry weight
3249541|NCT01376869|Placebo Comparator|Placebo|
3249542|NCT01376882|Experimental|Acute withdrawal|Chronic intervention 100 mg caffeine capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
3363006|NCT04802590|Experimental|Arm A|Ibrutinib (+ CD20Ab)
3363007|NCT04802590|Experimental|Arm B|Ibrutinib + Venetoclax (+CD20Ab)
3363008|NCT04802174|Experimental|1/ Phase I|Dose escalation of Berzosertib + lurbinectedin
3363009|NCT04802174|Experimental|2/ Phase II|Berzosertib + lurbinectedin at MTD
3249543|NCT01376882|Experimental|Acute caffeine-independent of withdrawal|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
3249544|NCT01376882|Experimental|Chronic abstinence|Chronic intervention of placebo capsules 3 times per day for 14 days. Acute intervention of placebo capsule on day 15.
3363016|NCT04797208|Experimental|Real-Time CGM|This group will have a subcutaneous RT-CGM inserted by a member of the research team. CGM's low and high glucose alerts will be activated. The treating clinical team will be able to remotely monitor glucose data and be notified of low glucose alerts through the linked handset. Hyper- and hypo-glycemia management including insulin dose adjustments by the treating clinical team, will be guided by sensor glucose levels and trends according to written guidelines during the study. Glucose level during and post-hypoglycaemia treatment will be confirmed by capillary blood glucose (CBG) measurements (using the NovaStat® glucometer or similar CE-marked glucose meter).
3363017|NCT04797208|Active Comparator|Capillary blood glucose with masked CGM|This group will have their glucose monitored in hospital using the NovaStat® glucometer or similar CE-marked glucose meter) and insulin dose adjusted by the treating clinical team as per usual hospital guidelines. A masked subcutaneous CGM will be inserted by a member of the research team to collect glucose values (glucose values will not be displayed and no glucose alerts will be available). This will removed at the end of the study by the research team.
3363018|NCT04796922|Experimental|Treatment Group A|Participants will be administered with parsaclisib in combination with investigator choice of rituximab or obinutuzumab.
3363019|NCT04796922|Placebo Comparator|Treatment Group B|Participants will be administered with placebo in combination with investigator choice of rituximab or obinutuzumab
3363022|NCT04794335||Patients undergoing resection of intestine for therapeutic purposes|Tissue will be accepted from all eligible donors who consent to having their intestine removed for therapeutic purposes. This tissue would normally be disposed of as medical waste, used for research purposes. The tissue will be studied in the lab in a series of experiments involving GABA agonists and antagonists. Each GABA agonist and/or agonists/antagonist combination will be studied on intestine tissue randomly assigned to one of four groups defined by patient sex (m/f) and the application of inflammatory mediators (+/-). Thus, four groups are needed per GABA agonist and agonist/antagonist combination and seven agonist/antagonist combinations will be tested for a total of 28 experimental groups. But all of these groups will be generated from all patients recruited for the study.
3363023|NCT04793659|Experimental|Oral Fasudil 90 mg/day|Subjects will receive a daily dose of 90 mg Fasudil for 42 days (open-label period 1). After Period 1 is complete, if the subject is a responder to Fasudil 90 mg/day, they will be randomized to either Fasudil 90 mg/day or a placebo for 6 weeks (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
3363024|NCT04793659|Experimental|Oral Fasudil 180 mg/day|If the subject is a not a responder in the open-label period 1 but tolerated Fasudil 90 mg/day, they will be escalated to Fasudil 180 mg/day (open-label period 2) for 42 days. If the subject is a responder to Fasudil 180 mg/day, they are randomized to either Fasudil 180 mg/day for 42 days or a placebo (double-blind period 1), then crossover to the other arm for 6 weeks (double-blind period 2).
3363025|NCT04793659|Placebo Comparator|Oral Placebo|Placebo comparator arm to investigational drug (Fasudil 90 mg/day or 180 mg/day).
3363026|NCT04789148|Experimental|4 IU oxytocin - 24 IU oxytocin - placebo|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: intranasal placebo
3363027|NCT04789148|Experimental|4 IU oxytocin - placebo - 24 IU oxytocin|Main visit 1: 4 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 24 IU intranasal oxytocin
3363028|NCT04789148|Experimental|24 IU oxytocin - 4 IU oxytocin - placebo|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: intranasal placebo
3249545|NCT01376882|Experimental|Acute caffeine-in state of withdrawal|Chronic intervention of 100 mg caffeine capsule 3 times per day for 14 days. Acute intervention of 100 mg caffeine capsule on day 15.
3249546|NCT01376895|Experimental|POWER|Power is a 3 session intervention delivered through the internet in real time by a trained health educator. It focuses on reducing HIV risk. Each session last from 1 to 2 hours.
3249547|NCT01376895|Active Comparator|Power Health|Power Health is a 1 session general health promotion program designed to be delivered via the internet in real time by a trained health educator. The sessions focus on healthy life styles, cardiovascular health, and prostate health. Participants also receive information regarding safe sex.
3249548|NCT01376947||Nulliparous|Nulliparous women who were submitted to IUD device insertion
3249549|NCT01376947||Multiparous with no cesaraen section|Multiparous women with no cesarean sections that were submitted to IUD device insertion
3249550|NCT01376947||Mulitparous with cesarean section|multiparous women with a cesarean section that were submitted to IUD insertion
3249551|NCT01376960|Active Comparator|single shot popliteal fossa block|
3249552|NCT01376960|Active Comparator|ankle blocks|
3249553|NCT01376973||group A|Not received any oral device (Control)
3249554|NCT01376973||Group B and Group C|Group B - Used Michigan Occlusal Splint (MOS); Group C - Used Planas Oral Appliance (POA).
3249555|NCT01376986|Experimental|Activation|All those determined fit for service or who are granted postponement will be included in the activation intervention. The physical activation intervention will be implemented between the call-up and start of military service. The activation group utilises an ICT platform that will be developed.
3249556|NCT01376986|No Intervention|control|no access to the activation platform
3249557|NCT01376999|Experimental|Step Down|Step Down: We begin the COS (controlled ovarian stimulation) with 150 IU of FSH-r until 7th day of stimulation. This day we make an adjustment reducing the dose if necessary.
3249558|NCT01376999|Active Comparator|Step Up|Step up: We begin the COS (controlled ovarian stimulation) with 75 IU of FSH-r until 7th day of stimulation.This day we make an adjustment increasing the dose if necessary.
3249559|NCT01377025|Experimental|Sorafenib blinded Phase|400 mg Sorafenib bid until PD
3363029|NCT04789148|Experimental|24 IU oxytocin - placebo - 4 IU oxytocin|Main visit 1: 24 IU intranasal oxytocin; Main visit 2: intranasal placebo; Main visit 3: 4 IU intranasal oxytocin
3363030|NCT04789148|Experimental|Placebo - 4 IU oxytocin - 24 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 4 IU intranasal oxytocin; Main visit 3: 24 IU intranasal oxytocin
3363031|NCT04789148|Experimental|Placebo - 24 IU oxytocin - 4 IU oxytocin|Main visit 1: intranasal placebo; Main visit 2: 24 IU intranasal oxytocin; Main visit 3: 4 IU intranasal oxytocin
3249560|NCT01377025|Placebo Comparator|Placebo blinded Phase|Two tbl. in the morning and two tbl. in teh evening until PD
3249561|NCT01377025|Experimental|Sorafenib Open Phase|400 mg Sorafenib bid until PD
3363032|NCT04783675|Experimental|Intervention/treatment|
3363033|NCT04777656|Experimental|CDED/Modulen™IBD®|Strategy combining CD exclusion diet plus Modulen™IBD® on top of ongoing maintenance therapy.
3363034|NCT04777656|Active Comparator|Unrestricted food access|Stop CDED and Modulen™IBD®, but continue maintenance therapy with unrestricted food access.
3363035|NCT04777656|Other|Not randomized|Patient not in remission at M2 or refusing randomisation
3363036|NCT04776148|Experimental|lenvatinib+pembrolizumab|Participants receive pembrolizumab 400 mg via intravenous (IV) infusion on Day 1 of each 6-week (Q6W) Cycle for up to 18 cycles (up to approximately 2 years) PLUS lenvatinib 20 mg via oral capsule once daily until progressive disease.
3363037|NCT04776148|Active Comparator|standard of care treatment (regorafenib OR TAS-102)|Participants receive regorafenib 160 mg via oral tablet once daily on Days 1 through 21 of each 4-week cycle OR TAS-102 (trifluridine and tipiracil hydrochloride) 35 mg/m^2 via oral tablet twice a day on Days 1 through 5 and Days 8-12 of each 4-week cycle until progressive disease.
3249562|NCT01377038|Active Comparator|Duloxetine|Phenotype assessment prior to and after treatement with duloxetine 20-30 mg oral daily for eight weeks.
3249563|NCT01377038|Active Comparator|Diclofenac|Phenotype assessment prior to and after treatment with topical diclofenac four times daily
3363039|NCT04772989|Experimental|Dose Escalation Q3W Cohorts|Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
3363040|NCT04772989|Experimental|Dose Escalation Q4W Cohorts|Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
3363041|NCT04772989|Experimental|Dose Expansion Cohort 1|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
3363042|NCT04772989|Experimental|Dose Expansion Cohort 2|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
3363043|NCT04772989|Experimental|Dose Expansion Cohort 3|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
3363044|NCT04772989|Experimental|Dose Expansion Cohort 4|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
3363045|NCT04772989|Experimental|Dose Expansion Cohort 5|AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
3249564|NCT01377051|Active Comparator|Bronchodilator|Indacaterol maleate 300 mcg will be administered by a third independent investigator following a randomization list.
3249565|NCT01377051|Placebo Comparator|Placebo|Will be administered with the same device by a third independent investigator
3249566|NCT01377064|Experimental|Physical activity group|Subjects will participant in physical activity program
3249567|NCT01377064|Active Comparator|Standard care group|This group will not receive a physical activity intervention
3249568|NCT01377077|Experimental|epidermal 1mm grafting|Epidermal skin biopsies of 1mm diameter
3249569|NCT01377077|Experimental|dermal 1mm grafting|dermal skinbiopsies of 1mm diameter
3249570|NCT01377077|Experimental|dermal 1,5mm grafting|dermal skinbiopsies of 1,5mm diameter
3363049|NCT04770246|Experimental|TAS-117 Dose Escalation Daily Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
3363050|NCT04770246|Experimental|TAS-117 Dose Escalation Intermittent Dose Regimen (Part A: safety lead-in)|Advanced or metastatic solid tumors irrespective of gene alterations
3363051|NCT04770246|Experimental|TAS-117 Dose and Regimen Confirmation (Part A: safety lead-in)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
3363052|NCT04770246|Experimental|TAS-117 Phase 2 (Part B)|Advanced or metastatic solid tumors with germline PTEN inactivating mutations
3249571|NCT01377077|Active Comparator|epidermal 1,5mm grafting|epidermal skinbiopsies of 1,5mm diameter
3249572|NCT01377090||SSc DU-history subgroup|Systemic sclerosis patients with history of digital ulcers
3363063|NCT04756700|Experimental|Healthy Participants|Healthy participants matched with PwMS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
3363064|NCT04756700|Experimental|PwMS: Participants with MS|Participants with MS will have their cognitive and motor functions assessed using the DigiCog (BCCAMS app) tablet once in clinic and Konectom smartphone-based application for 2 days in clinic and at least 15 days at home.
3363065|NCT04756037|Experimental|Relugolix/E2/NETA|Participants will receive relugolix combination therapy for 1 year (13 consecutive 28-day treatment cycles).
3249573|NCT01377090||SSc with No-DU-history subgroup|Systemic sclerosis patients with no history of digital ulcers
3249574|NCT01377103|Placebo Comparator|Placebo|Placebo Gel
3249575|NCT01377103|Active Comparator|Testosterone Supplementation|Testosterone Gel
3249576|NCT01377129|Active Comparator|Single Bundle|These patients are operated using a single bundle technique.
3249577|NCT01377129|Experimental|Double bundle|These patients are operated using a double bundle technique.
3363067|NCT04752696|Experimental|Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU|The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
3363068|NCT04752696|Experimental|Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU|Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
3363069|NCT04745832|Experimental|Rituximab plus Zandelisib|Rituximab plus Zandelisib for 6 cycles followed by Zandelisib for 20 cycles
3249578|NCT01377142||Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
3363070|NCT04745832|Experimental|Rituximab plus chemotherapy|Rituximab and Bendamustine or Rituximab with (CHOP) for 6 cycles
3363071|NCT04745689|Experimental|AZD2811 + Durvalumab|"Induction:~Durvalumab + Platinum Chemotherapy (Carboplatin or cisplatin & Etoposide)~Maintenance:~AZD2811 + Durvalumab"
3363072|NCT04742140|Active Comparator|group I|each patient injected 0.5ml in each TrPs of saline by the same operator
3363073|NCT04742140|Experimental|group II|each patient injected 0.5ml in each TrPs of magnesium sulphate by the same operator
3249579|NCT01377142||Vaginal mesh hysteropexy|Vaginal Mesh Hysteropexy using the Uphold device which includes Sacrospinous Ligament Fixation
3363076|NCT04740723|Experimental|Renal denervation|Renal denervation with the iRF system
3363077|NCT04740606||Treatment Group|The patients whose chest CT images show that the pulmonary nodules are highly suspected of malignant and scheduled to be diagnosed by bronchoscopy under the guidance of the Augmented Reality Navigation System.
3363078|NCT04737135||Patients|Patients with Tetralogy of Fallot
3363079|NCT04736173|Active Comparator|Arm A (Platinum-based Chemotherapy)|Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion.
3363080|NCT04736173|Experimental|Arm B (Zimberelimab Monotherapy)|Participants will receive zimberelimab monotherapy by IV infusion.
3249580|NCT01377155|Other|Insulin determir|
3249581|NCT01377168|Placebo Comparator|Placebo pill|Daily oral placebo.
3363081|NCT04736173|Active Comparator|Arm C (Zimberelimab + AB154 Combination Therapy)|Participants will receive zimberelimab in combination with AB154 by IV infusion.
3363082|NCT04721808||Patients with Rheumatoid Arthritis (RA)|Patients receiving tofacitinib from the Corrona RA Registry from November 2012 onward
3363084|NCT04715230|Experimental|IXT-m200|IXT-m200 is a high-affinity chimeric anti-METH monoclonal antibody that is well-tolerated in healthy volunteers and in non-intoxicated people with METH use disorder. The total dose will be given over 10 min for the 0.5-g dose and over 20 min for the 1-, 1.5-, and 2-g doses.
3249582|NCT01377168|Active Comparator|NTX|Daily oral naltrexone.
3249583|NCT01377181||group A|the patients were accepted laparoscopic purse-string knot closing the internal hernia opening only
3363085|NCT04715230|Active Comparator|Treatment as Usual (TAU)|Lorazepam is a benzodiazepine that is safe and commonly used to treat agitation and dysphoria in the emergency setting. Haloperidol is commonly used to treat agitation due to psychosis.
3249584|NCT01377181||group B|the patients were accepted the lateral umbilicus ligament covering the internal hernia opening region after the laparoscopic purse-string knot
3363088|NCT04709926||Paramedics that were eligible to take part in the PRESTO study|Paramedics that are employed by one of the four Ambulance Services involved in the PRESTO study and were eligible to complete the training provided by Manchester University NHS Foundation Trust to take part in the PRESTO study.
3249585|NCT01377207|Experimental|Female Arm|Female gender diagnosed with ST segment Elevation Myocardial Infarction (STEMI)
3249586|NCT01377207|Active Comparator|Male Arm|Male Gender diagnosed with ST segment Elevation Acute Myocardial Infarction (STEMI)
3249587|NCT01377246|Placebo Comparator|Saline solution.|
3249588|NCT01377246|Experimental|Octrotide-LAR|
3249589|NCT01377259||1Tissue oxygenation change|Spinal anesthesia may result different changes of tissue oxygenation in blocked area ( upper extrimities ) and non-blocked area ( lower extrimities). The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for orthopedic surgery
3249590|NCT01377259||2Tissue oxygenation change|The changes of tissue oxygenation saturation between upper and lower extremities in patients under spinal anesthesia for cesarean section
3363093|NCT04706273||GORE® VIABAHN® Endoprosthesis|Participants with symptomatic peripheral arterial disease in superficial femoral artery lesions.
3363094|NCT04699786|Active Comparator|Arm A|Participants randomized to Arm A will receive their research results two weeks after they review educational materials provided by the study and sign the informed consent document.
3363095|NCT04699786|Active Comparator|Arm B|Participants randomized to Arm B will receive their research results one year after they review the educational materials provided by the study and sign the informed consent document.
3249591|NCT01377285|Experimental|ARB & Pentoxifylline|angiotensin receptor blockers(ARB)and Pentoxifylline 400mg tablet (If CKD3 1# BID(Bi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
3249592|NCT01377285|Active Comparator|ARB & Placebo|angiotensin receptor blockers(ARB) and Placebo tablet(If CKD3 1# BIDBi in die=two times a day); CKD4 1# QD(quaque die=one time a day); CKD5(estimated Glomerular filtration rate,eGFR<15ml/min/1.73 m2) 1# QOD(Every other day).
3249593|NCT01377298|Experimental|Pazopanib|Single arm study, pazopanib
3249594|NCT01377311|Experimental|1|Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
3249595|NCT01377324|Experimental|Single arm|Fluoroestradiol-PET is performed at baseline, after 1 month, and 3 months
3249596|NCT01377337|Active Comparator|Sodium bicarbonate|1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
3249597|NCT01377337|Placebo Comparator|0.9% NaCl|1 ml/kg of 0.9% NaCl (Blinded label)
3363105|NCT04681170|Other|Age 5-10 years|Age 5-10 years Lomitapide dosing will commence with 2mg at week 1 for 8 Weeks,then increase to 5mg Week 8±3 days, 10 mg at Week 12±3 days to the maximum allowable dose of 20 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
3363106|NCT04681170|Other|Age11-15years|Lomitapide dosing will commence with 2mg at week 1 for 4 Weeks, then increase to 5mg Week 4±3 days, 10 mg at Week 8±3 days,20mgs at week, 12±3 days to the maximum allowable dose of 40 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
3363107|NCT04681170|Other|16 to ≤17 years|Lomitapide dosing will commence with 5mg at week 1 for 4 Weeks, then increase to 10mg Week 4±3 days,20 mg at Week 8±3 days,40mgs at week, 12±3 days to the maximum allowable dose of 60 mg by Week 16±3 days or the MTD by Week 20±3 days based upon acceptable safety and tolerability criteria in addition to LDL C values
3363108|NCT04680156||EN3835|Previously treated with EN3835 in EN3835-210 or the pivotal phase 3 studies
3363109|NCT04680156||Placebo|Previously treated Placebo in EN3835-210 or the pivotal phase 3 studies
3363110|NCT04677387|Placebo Comparator|Prescribe to Prevent Naloxone Training Module|This a 55-minute online module that covers basic information about naloxone that is relevant to community pharmacists.
3363111|NCT04677387|Experimental|Nalox-Comm|This is a newly developed 30-60 minute online module focused on teaching pharmacists how to overcome naloxone communication barriers.
3363112|NCT04674683|Experimental|Test Arm|HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
3363113|NCT04674683|Placebo Comparator|Control Arm|Placebo oral BIW + nivolumab IV at specific doses on specific days
3363114|NCT04674397||Test group|Living kidney donors
3249598|NCT01377350|Experimental|"Pneumedicares monitoring system"|"Single arm study - Pneumedicares monitoring system is used for monitoring heart failure patients"
3249599|NCT01377363||Not treatment|Locally recurrent breast carcinoma or metastatic
3363119|NCT04669548||Accuryn Monitoring System|Observational only (no intervention). Patients undergoing cardiovascular surgical intervention(s) monitored with the Accuryn Monitoring System (per standard of care) during their hospital stay
3363120|NCT04665037|Experimental|Panel A: POS IV|Posaconazole 6 mg/kg body weight administered in a single dose by IV infusion on Day 1.
3363121|NCT04665037|Experimental|Panel B: POS IV/PFS|Posaconazole at a dose to be determined administered twice daily by IV infusion on Day 1, and then once daily from Day 2 to a maximum 84 days. Following a minimum of 7 days IV dosing, participants as clinically able will be transitioned from POS IV to POS PFS on Day 8, once daily to a maximum 84 days.
3249600|NCT01377376|Experimental|ARQ 197|ARQ 197 and Erlotinib
3249601|NCT01377376|Placebo Comparator|Placebo|Placebo and Erlotinib
3249602|NCT01377415|Active Comparator|bupivacaine|a continuous flow of 5 mg/ml bupivacaine 2 ml/h 48 h
3249603|NCT01377415|Placebo Comparator|saline|saline 9 mg/ml infusion 2 ml/h 48 h
3249604|NCT01377428|Experimental|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
3363127|NCT04643379|Experimental|Olaparib + Pembrolizumab + Carboplatin AUC|"-Patients enrolled in this study will receive olaparib, pembrolizumab and carboplatin in three-week cycles for six cycles, followed by maintenance therapy with three-week cycles of olaparib and pembrolizumab. Treatment will continue until disease progression, intolerable toxicity, patient or physician decision to stop therapy, or after 35 cycles, whichever occurs first. Drug dosing for each cycle is as follows:~Olaparib 200 mg twice per day (bid) by mouth (po) Days 1-10 for the first six cycles (when given with carboplatin), followed by 400 mg bid po Days 1-21 of subsequent cycles.~Pembrolizumab 200 mg intravenous (IV) Day 1.~Carboplatin AUC 5 IV on Day 1 for up to six cycles."
3363128|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 1|Randomised participants will receive oral inhalation of AZD1402 Dose 1 via DPI.
3363129|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 2|Randomised participants will receive oral inhalation of AZD1402 Dose 2 via DPI.
3363130|NCT04643158|Experimental|Part 1 and Part 2: AZD1402 Dose 3|Randomised participants will receive oral inhalation of AZD1402 Dose 3 via DPI.
3363131|NCT04643158|Placebo Comparator|Part 1 and Part 2: Placebo|Randomised participants will receive oral inhalation of matching placebo via DPI.
3363132|NCT04640077|Other|Part A Validation of Remote Scale Assessments|"Alternating at-home and on-site cognitive and functional scale assessments~Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site"
3363133|NCT04640077|Other|Part B Donanemab|Donanemab administered intravenously (IV)
3363137|NCT04629833|Experimental|MC0518|Participants will receive MC0518 1-2 million cells/ kilogram infusions (based on body weight at the Screening Visit) once a week for 4 weeks (Visit Day 1, 8, 15, and 22). Participants with partial response (PR) on Day 28 will have 2 additional MC0518 infusions administered on Day 29 and 36.
3363138|NCT04629833|Active Comparator|Best Available Therapy (BAT)|Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP), anti-thymocyte globulin (ATG), everolimus, and ruxolitinib (RUX).
3363141|NCT04624659|Experimental|Double blind etavopivat Low Dose|Double blind etavopivat Low Dose
3363142|NCT04624659|Experimental|Double blind etavopivat High Dose|Double blind etavopivat High Dose
3363143|NCT04624659|Experimental|Double blind placebo|Double blind placebo
3363144|NCT04624659|Experimental|Open label etavopivat|Open label etavopivat
3249605|NCT01377428|Active Comparator|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
3249606|NCT01377493|Placebo Comparator|placebo|
3249607|NCT01377493|Active Comparator|POs-Ca|
3363149|NCT04615715|Experimental|CMV Risk-Reduction Intervention|One-on-one CMV prevention and education visit followed by 12 weeks of CMV prevention and education text messages
3363150|NCT04615715|Placebo Comparator|Stress Reduction Messaging|One-on-one stress reduction messaging visit followed by 12 weeks of reducing stress text messages
3363151|NCT04615325|Experimental|Single ascending dose stage|Patients will receive a single dose of RO7303359, in multiple escalating cohorts (A-D)
3363152|NCT04615325|Experimental|Expansion cohort stage|Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.
3363153|NCT04615325|Experimental|Optional cohort E|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
3363154|NCT04615325|Experimental|Optional cohort F|An optional additional cohort maybe added with the dose not exceed the MTD or MTeD
3249608|NCT01377493|Active Comparator|POs-Ca+F|
3249609|NCT01377506|Experimental|Lifestyle counseling|Diabetes Prevention Program Lifestyle Balance Intervention delivered by lay health educator
3363156|NCT04607681|Experimental|1 GROUP|"Patients who agree to participate in the study will be informed about the study and their written and verbal consent will be obtained. At this stage, which will last 6 weeks for each patient;~On the first day, the patients will be evaluated first by filling the Individual Descriptive Features Form, Information Need Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices,~In order for the patients in the intervention group to use the web-based asthma education program, a web-based asthma education program will be introduced by giving their username and password.~After 6 weeks of training, second data will be collected on the web in the intervention group."
3363157|NCT04607681|No Intervention|2 GROUP|"Written and verbal consents will be obtained from patients who agree to participate in the study by providing information about the study.~At this stage, which will take 6 weeks for each patient; On the first day, the patients will first be evaluated by filling the Individual Descriptive Characteristics Form, Information Requirement Determination Question Form, COPD and Asthma Fatigue Scale, Medication Compliance Notification Scale, Asthma Control Test (ACT), Form for evaluation of the skills of using inhalation devices, Second data after 6 weeks will be collected in the control group via Google form or phone call"
3363160|NCT04604067|Experimental|Arm with 4 cohorts|"Cohort A: MYD88 L265P and/or CD79A/B mutations at baseline Treatment: Acalabrutinib-R-CHOP for a total number of 6 cycles.~Cohort B, C D: Without MYD88 L265P and CD79A/B mutations at baseline:~Assignment of cohort B, C and D after 2 cycles of R-CHOP according to PET (Deauville score (DS)) and molecular response (MR) (>2log10 reduction of ctDNA)) results:~Cohort B: DS 4 and No MR Treatment: 2 cycles of acalabrutinib-R-CHOP. After PET3/ctDNA3: patients with DS 1-3 and no MR OR DS4 with MR will receive 2 additional cycles of acalabrutinb-R-CHOP and 2 cycles of acalabrutinib single agent.~Cohort C: DS 1-3 and MR Treatment: 2 additional cycles of R-CHOP (4x RCHOP in total) followed by 2 cycles of rituximab single agent.~Cohort D: DS 4 and no MR OR DS 1-3 and MR Treatment: 4 additional cycles of RCHOP (6 cycles in total).~Follow up: Patients off treatment will be followed for 5 years."
3363161|NCT04601818|Experimental|Interventional arm|During our study period, transplants with a planned recipient anesthesia starting time between 10:00pm-6:00am will be allowed to move to a 6:00-8:00am start at the earliest. To be eligible, donor lungs cross clamp time have to occur between 6pm and 4am and lungs need to be suitable for transplantation without the need for ex vivo lung evaluation. Lungs meeting criteria for direct transplantation will be transported in the usual fashion in a cooler of ice at 4oC and upon arrival to Shands UF Health they will immediately be transferred to cold static preservation at 10oC within a specific refrigerator placed in the Shands UF Health OR. The maximum preservation time from donor cold flush (cross clamp) to recipient anesthesia start should be 12 hours and the recipient procedure should not start before 6am.
3363162|NCT04601818|No Intervention|Retrospective arm|Outcomes will be compared to conventional transplant patients matched by age, medical diagnosis, BMI, lung allocation score and donor type ( DCD vs. NDD) using a 1:2 matching.
3363163|NCT04600804||All patients registered in the MCL0208 trial|"About 200 patients enrolled in the MCL0208 trial who performed the PET exams within the clinical trial and who consent to the present study: all PETs available at each center participating in this study will be collected and analyzed.~In the clinical trial PET was optional at baseline (b-PET), before ASCT (i-PET) and after- ASCT (eot-PET). All the PETs available per patient will be collected and considered for analysis, both in the case PET are available at all the 3 time points above listed and in case of availability of PET at 1 or 2 time points only."
3249610|NCT01377506|Active Comparator|Cognitive Training|Adaptation of SeniorWise Memory Training program for delivery by lay health educator, matched in duration and contact to the other study arm
3249611|NCT01377519|Active Comparator|MR Guided Focused Ultrasound|
3249612|NCT01377519|Placebo Comparator|Placebo MR Guided Focused Ultrasound|
3249613|NCT01377545|Active Comparator|Local Anesthetic Via Catheter|30mL of Lidocaine (local Anesthetic) will be injected via a perineural catheter at hour 0.
3249614|NCT01377545|Active Comparator|Local Anesthetic Via Needle|30mL of Lidocaine (local Anesthetic) will be injected via a needle at hour 0.
3249615|NCT01377558|Experimental|Aerobic endurance training intervention|Aerobic endurance training
3249616|NCT01377558|Experimental|Strength endurance training intervention|Strength endurance training
3249617|NCT01377558|Experimental|Combined training intervention|Combined aerobic endurance training and strength endurance training intervention
3249618|NCT01377558|No Intervention|Control group|control group
3249619|NCT01377571|Experimental|Rotavin2H|2 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 2-month separation between doses
3363168|NCT04599270|Experimental|Intervention group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the intensivity of dependance of substance use and the patient will be randomized.~If he is randomized in intervention group, the patient will follow PREVENTURE program (2 session of 90 min by videoconference), within 3 months after inclusion and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after sessions to answer the same tests and scales."
3249620|NCT01377571|Experimental|Rotavin2L|2 doses of Rotavin-M1 vaccine, 106.0FFU/dose, 2-month interval between doses
3363169|NCT04599270|Active Comparator|Control group|"Teenager encounter psychologist for conduct a Substance Use risk Personality Scale (SURPS) assessment to identify personality characteristics that represent a risk for the development of problematic substance use. Only adolescents with at-risk personality traits according to the SURPS will be randomized for further assessment.~If adolescent have not risk personality traits, the patient will go out of the study.~If adolescent have risk personality traits, other tests and scales will be performed to study the severity of substance use disorders and the patient will be randomized.~If he is randomized in control group, the patient will follow routine care and will be contacted by phone by the psychologist at 1, 3, 6 and 12 month after inclusion to answer the same tests and scales."
3249621|NCT01377571|Experimental|Rotavin3H|3 doses of Rotavin-M1 vaccine, 106.3FFU/dose, 1-month interval between doses
3249622|NCT01377571|Experimental|Rotavin3L|3 doses of Rotavin-M1, 106.0FFU/dose, 1-month interval between doses
3249623|NCT01377597|Experimental|ranibizumab intravitreal injection|
3249624|NCT01377610|Active Comparator|Buprenorphine|Standard 7-day buprenorphine induction and gradual taper from 8 mg to 0 mg followed on day 15 by Vivitrol injection
3249625|NCT01377610|Active Comparator|Oral naltrexone|The naltrexone arm is a modification of our current inpatient naltrexone induction procedure, consisting of a single day of buprenorphine followed by a washout day and 4 days of ascending oral naltrexone doses. Followed on day 8 by Vivitrol injection.
3249626|NCT01377649||Control|Age matched control subjects without PAD
3249627|NCT01377649||Patients with PAD|
3249628|NCT01377662|Placebo Comparator|Placebo|
3363170|NCT04594369|Experimental|Brensocatib 10 mg|Participants will receive brensocatib 10 mg once daily, for 52 weeks.
3363171|NCT04594369|Experimental|Brensocatib 25 mg|Participants will receive brensocatib 25 mg once daily, for 52 weeks.
3363172|NCT04594369|Placebo Comparator|Placebo|Participants will receive a brensocatib-matching placebo once daily.
3363174|NCT04590274|Experimental|Regimen|0-400 mg Hydroxychloroquine 0-500 mg Azithromycin 0-50 mg elemental Zinc 0-3,000 mg Vitamin C 0-5,000 IU Vitamin D3 0-1200 mg N-acetylcysteine 0-600 mg Elderberry 0-600 mg Quercetin
3363175|NCT04581863|Active Comparator|COVID Watch|COVID Watch provides text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately. This service is provided free of charge to patients, a benefit to patients without insurance or established primary care. UPHS already offers a version of COVID Watch with pulse oximetry to patients with COVID-19 being discharged from the ED who meet specific criteria: a discharge pulse ox less than 95%, an infiltrate on chest x-ray, are or age of 60 years or older, or who are deemed by the ED clinician to have significant comorbid conditions.
3363176|NCT04581863|Experimental|PCORI Pulse|This arm is COVID Watch + pulse oximeter device. Patients sent a pulse oximeter will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is >3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .
3363177|NCT04580914|Experimental|Treatment with Ablation Catheter|Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation
3363179|NCT04574908|Active Comparator|Blinded Ward 1|Continuous ward monitoring with hallway monitor screens covered. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
3249629|NCT01377662|Experimental|OND-PR002 and MPh-IR|
3249630|NCT01377675||Usual curriculum education program|Third year internal medicine residents
3249631|NCT01377688||Diabetics with PKD|Diagnoses of diabetes type 2 with progressive kidney disease (slope of eGFR decline between -15 to -3 ml/min/1.73m2 per year, estimated by calculating an eGFR for each creatinine using the 4-variable Modification of Diet in Renal Disease Study [MDRD] equation and conducting a simple ordinary least squares regression from these values to evaluate changes over time to derive each individuals' slope of eGFR, annualized using test dates)
3363180|NCT04574908|Experimental|Unblinded Ward 2|Continuous ward monitoring with hallway monitor screens accessible for viewing but with alarm limits more narrow. When an alarm goes off (limits based on the stratification of that month) the nursing staff will still be notified via their Ascom phone as per standard of care. Nursing staff will be able to view the hallway monitors showing the vital signs in all of the rooms and/or log in to WakeOne to verify the vital sign and/or go to the patient room to check on the patient. To ensure patient safety, factory alarm limits at extremes of physiological vital signs will stay on in the blinded arm. Every 4 hourly checks by nursing teams unless otherwise ordered.
3363181|NCT04574908|Active Comparator|Blinded Ward 2|Continuous monitoring accessible to clinicians with pre-specified alerts at Systolic Blood Pressure alert <70, no Mean Arterial Pressure alert, heart rate >150 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <80%. Every 4 hourly checks by nursing teams unless otherwise ordered. These alarms are consistent with current standard of care.
3363182|NCT04574908|Experimental|Unblinded Ward 1|Continuous monitoring accessible to clinicians with pre-specified alerts at Mean Arterial Pressure (MAP) <65 mmHg, heart rate >110 beats per minute (b/m), and peripheral capillary oxygen saturation (SpO2) <90%. Every 4 hourly checks by nursing teams unless otherwise ordered.
3363188|NCT04569032|Experimental|CD30-negative Cohort|Participants with CD30 expression level < 1%
3363189|NCT04569032|Experimental|CD30-positive Cohort|Participants with CD30 expression level ≥1% to < 10%
3249632|NCT01377753|Experimental|1|Eligible subjects will undergo MRthermal image guided laser ablation of all biopsy proven areas of prostate cancer using one or multiple laser probes during a single procedure lasting approximately two hours in duration.
3363190|NCT04568395|Experimental|PLWH smoker|PLWH who smoke will undergo 3 interventions : acute TCIG use, acute ECIG use and acute sham control
3363191|NCT04567784|Placebo Comparator|Control|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
3363192|NCT04567784|Experimental|CBD 800mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
3363193|NCT04566159|Experimental|CBI + CHW|2 Session Computer Delivered Intervention with use of Nicotine Replacement Therapy and Community Health Worker Follow Up
3363194|NCT04566159|Other|Routine Care|Routine Tobacco Cessation Advice to Stop Smoking and Nicotine Replacement Therapy as offered by the inpatient team
3249633|NCT01377779|Experimental|Intercoat treatment|women treated by Intercoat gel following hysteroscopy for retained products of conception
3249634|NCT01377779|Placebo Comparator|Control group|No additional treatment following hysteroscopy was performed
3249635|NCT01377792|Active Comparator|5 ml|
3249636|NCT01377792|Active Comparator|10 ml|
3249637|NCT01377805||Multiple Sclerosis patients|Multiple sclerosis patients
3249638|NCT01377818|Experimental|ventilation|Group program of positive pressure ventilation noninvasive
3249639|NCT01377818|Experimental|exercise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~d. 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~e. Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
3249640|NCT01377818|Experimental|exercise training and ventilation|Group of exercise training program and noninvasive positive pressure ventilation
3249641|NCT01377857|Experimental|Opt-In|Opt-in refers to a default of no test - patients must ask for the test in order to receive it. Patients are informed of the availability of rapid testing. They are tested only if they request the test.
3249642|NCT01377857|Experimental|Opt-Out|Opt-out has a default to test - patients are informed that they will receive a rapid HIV screening test unless they decline it. Patients will be tested unless they decline.
3249643|NCT01377857|Experimental|Active Choice|In the active choice treatment, there is no default; patients must actively accept or actively decline the test.
3249644|NCT01377857|Experimental|$1 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3249645|NCT01377857|Experimental|$5 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3249646|NCT01377857|Experimental|$10 Incentive|When offering the HIV test, study staff will inform subjects that the ED is offering cash incentives to promote HIV testing (and that the test is also free), and will inform them of that day's value.
3363200|NCT04560166|Experimental|Naxitamab and GM-CSF in combination with irinotecan and temozolomide|"A treatment cycle is 21 days. The patients will receive irinotecan 50 mg/m2/day IV and temozolomide 100 mg/m2/day orally (both on Days 1-5) in combination with naxitamab 2.25 mg/kg/day IV (Days 2, 4, 8 and 10) (total 9 mg/kg per cycle), and GM-CSF 250 ug/m2/day sc, (Days 6-10).~Patients will receive up to 18 IT cycles after enrollment. Naxitamab and GM-CSF will be given for at least 8 cycles."
3363201|NCT04559815||Patients with type 2 diabetes|Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.
3363202|NCT04558775||Observational Cohort|
3363203|NCT04558489|Experimental|IPR + GMI|Participants receiving IPR + GMI will complete a 30-minute on-line intervention via qualtrics that covers the following topics: (1) Educate youth and caregiver that thoughts and emotions are not fixed but are malleable and subject to change; (2) provide youth and families with a brief intervention that instills hopefulness through an action plan for managing internalizing symptoms; (3) assist with developing system of support to access during times of distress; and (4) educate the caregiver on the importance of these interventions.
3363204|NCT04542291|Experimental|Dapagliflozin|"Dapagliflozin is an oral drug which will be administered on an outpatient basis. Dosing will start at 5 mg daily and will increase to 10 mg daily after 2 weeks (after consulation with a study endrocrinologist) if the patient is tolerating the 5 mg dose. Dapagliflozin will be given for a total of 8 weeks (2 weeks at 5 mg and 6 weeks at 10 mg)~Treatment with dapagliflozin will be initiated on Cycle 1 Day 1 of standard of care chemotherapy.~Participants will use the BIOSENSE meter once daily"
3363205|NCT04538989|Experimental|RZ358 Cohort 1|
3363206|NCT04538989|Experimental|RZ358 Cohort 2|
3363207|NCT04538989|Experimental|RZ358 Cohort 3|
3363208|NCT04538989|Experimental|RZ358 Cohort 4|
3363211|NCT04530344|Experimental|Cohort A : ruxolitinib cream|Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream.
3249647|NCT01377857|Experimental|Early Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
3249648|NCT01377857|Experimental|Late Questionnaire|At a time that does not interfere with patients' medical care, patients will be approached by a member of the research team to consent to and complete a short (3 minutes) questionnaire. The questionnaire is designed to elicit two things: subjective risk of infection (e.g., What are the chances you have HIV? [Not possible, Unlikely, Possible, Likely, Certain]) and objective risk of infection (e.g., In the past year, have you given anyone drugs or money for sex?). The questionnaire will be administered as one of two timing treatments - a) at the beginning of care, before the patient is offered an HIV test (Early questionnaire) or b) after the patient has been offered an HIV test (Late questionnaire).
3363212|NCT04530344|Placebo Comparator|Cohort A : Vehicle|Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream.
3363213|NCT04530344|Experimental|Cohort B : roxolitinib cream|Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream.
3363214|NCT04526899|Experimental|BNT111 + cemiplimab|
3249649|NCT01377857|Experimental|FITD Questionnaire|"There will be two versions of the early questionnaire: one standard Early questionnaire, and one with an additional question: If you were offered an HIV test as part of your routine health care at no cost, would you get tested? The two questionnaires will be otherwise identical."
3249650|NCT01377857|Experimental|Free|When offering the HIV test, study staff will inform subjects that the ED is offering HIV testing (and that the test is also free); no monetary incentive will be offered.
3363215|NCT04526899|Experimental|BNT111 monotherapy|
3363216|NCT04526899|Experimental|Cemiplimab monotherapy|
3363217|NCT04526691|Experimental|Datopotamab deruxtecan (Dato-DXd)|Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy in participants with advanced or metastatic NSCLC
3363224|NCT04524455|Experimental|Blinatumomab and AMG 404|
3363225|NCT04522713|Experimental|Large-group transdiagnostic course|6 weekly structured transdiagnostic large-group course sessions which focus on evidence-based strategies to reduce psychiatric symptoms and increase wellbeing
3363226|NCT04520763|Experimental|Respiratory Muscle Exercises|Two respiratory muscle exercises
3363227|NCT04520763|No Intervention|Control|The control intervention consists of quiet sitting for 15 min
3249651|NCT01377870|Placebo Comparator|cell free media|15 patients with relapsing remitting multiple sclerosis who receive cell free media
3249652|NCT01377870|Experimental|mesenchymal stem cell reciepiants|Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells
3249653|NCT01377883|Sham Comparator|Standard intervention|"Preparation and information: the doctor and nurse explained the steps of the procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Memory change and positive reinforcement: medical staff present spoke to the child positively and offered prizes, among which the child could choose.~Volunteer attendance: as part of the control session, receiving no particular instructions in relation to the child's potential pain during the procedure."
3249654|NCT01377883|Experimental|clown care|Cognitive coping: encouraging a child to cope with the challenge. Imagery: a cognitive technique used to encourage the child to cope with the pain and distress of the procedure by imagining a pleasant object or experience Empowerment: the child is made to feel empowered by controlling the actions of the clown Reflecting emotions: the clown, sensing the state of the child, plays it out in an exaggerated fashion.
3249655|NCT01377909|Experimental|statin|
3249656|NCT01377935||Patients exposed to Saxagliptin|
3363243|NCT04515147|Experimental|Part 1, Group 1: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
3363244|NCT04515147|Experimental|Part 1, Group 2: CVnCoV 6 μg|Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
3363245|NCT04515147|Experimental|Part 1, Group 3: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be between the ages of 18 to 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 180 in a sub-group of participants."
3363246|NCT04515147|Experimental|Part 1, Group 4: CVnCoV 12 μg|"Participants will be vaccinated with CVnCoV on Day 1 and Day 29. Participants in this group will be aged over 60 years old.~CVnCoV will be administered again as a booster vaccination on Day 57 or Day 180 in a sub-group of participants."
3363247|NCT04515147|Active Comparator|Part 1, Group 5: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
3363248|NCT04515147|Active Comparator|Part 1, Group 6: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
3363249|NCT04515147|Experimental|Part 2, Group 1: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
3363250|NCT04515147|Active Comparator|Part 2, Group 2: Hepatitis A vaccine|Participants will be vaccinated with a hepatitis A vaccine on Day 1 and Day 29. Participants in this group will be aged between 18 and 60 years old.
3363251|NCT04515147|Experimental|Part 2, Group 3: CVnCoV 12 µg|Participants will be vaccinated with CVnCoV 12 µg on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
3363252|NCT04515147|Active Comparator|Part 2, Group 4: Pneumococcal vaccine|Participants will be vaccinated with a pneumococcal vaccine on Day 1 and Day 29. Participants in this group will be aged over 60 years old.
3363254|NCT04512235|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
3363255|NCT04512235|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 77 deaths have been observed.
3363256|NCT04512235|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) according to institutional SoC. Patients will have a planned first-line PCD treatment with a CyBorD regimen according to institutional SoC. The patient's PCD treatment may be initiated during the Screening period in consultation with the Medical Monitor and after screening laboratory samples are obtained. The patient may receive a maximum of 2 weeks of PCD treatment prior to randomization. For patients who receive the first dose of study drug prior to starting their PCD treatment, their PCD treatment must be initiated no later than 7 days after receiving the first dose of study drug. Patients can refer to the package insert or Summary of Product Characteristics (SmPC) for contraindications, warnings and precautions for anti-PCD medications.
3249657|NCT01377935||Patients exposed to OAD in classes other than DPP4 inhibitors|OAD - Oral Antidiabetic Drug
3249658|NCT01377948|Other|ACT with RAGE-Control|all subjects are assigned to this arm. This is an open feasability proof of concept trail with a single experimental group with all subjects receiving the intervention being studied.
3363257|NCT04512001|Experimental|MSB11456|
3363258|NCT04512001|Active Comparator|RoActemra®|
3249659|NCT01377961|Active Comparator|Arm1: Metabolic Syndrome Volunteers|
3249660|NCT01377961|Active Comparator|Arm 2:Previously Diagnosed diabetic patients|
3363259|NCT04504825|Experimental|CAEL-101 combined with SoC plasma cell dyscrasia|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
3363260|NCT04504825|Placebo Comparator|Placebo combined with SoC plasma cell dyscrasia|Patients randomized to receive placebo will receive 0.9% normal saline in an equivalent volume to a CAEL-101 infusion (approximately 250 cc). The minimum planned treatment time for each patient will be at least 50 weeks or until the patient's death. It is planned that all patients will continue their double-blind treatment until the last patient completes at least 50 weeks of treatment. As this is an event driven study, the study will continue, and all patients will continue to receive study treatment until at least 54 deaths have been observed.
3363261|NCT04504825|Other|Concurrent Plasma Cell Dyscrasia Treatment|All patients will also receive concurrent treatment for Plasma Cell Dyscrasia (PCD) according to institutional SoC. Patients will have a planned first-line PCD treatment with a CyBorD regimen according to institutional SoC. The patient's PCD treatment may be initiated during the Screening period in consultation with the Medical Monitor and after screening laboratory samples are obtained. The patient may receive a maximum of 2 weeks of PCD treatment prior to randomization. For patients who receive the first dose of study drug prior to starting their PCD treatment, their PCD treatment must be initiated no later than 7 days after receiving the first dose of study drug. Patients can refer to the package insert or Summary of Product Characteristics (SmPC) for contraindications, warnings and precautions for PCD medications.
3363266|NCT04497116|Experimental|RP-3500 alone|"Phase 1:~Multiple doses of RP-3500 for oral administration alone"
3363267|NCT04497116|Experimental|Expansion cohorts with RP-3500|"Phase 2:~Expansion cohorts with RP-3500"
3363268|NCT04497116|Experimental|RP-3500 with Talazoparib or Gemcitabine|"Phase 1:~Multiple doses of RP-3500 for oral administration in combination with talazoparib or gemcitabine"
3249661|NCT01377974|Active Comparator|Standard Treatment|Meglumine antimoniate as recommended by the Brazilian Ministry of Health
3249662|NCT01377974|Experimental|Tested Intervention|Miltefosine as the tested intervention
3249663|NCT01378000||UFH,once a day|
3249664|NCT01378000||heparin Calcium,every 12 hours|
3249665|NCT01378000||dextran,Salviae,once a day|
3249666|NCT01378000||UFH,continuous intravenous infusion,|
3249667|NCT01378013||Elective sugery|"Patients entering into elective surgery. These will be divided into three subgroups:~A. Patients with cancer. This will include patients with malignancy of the gastrointestinal and colorectal tract (including those excised by microsurgery) cancer of the breast or solid tumours of the kidney.~B. Patients with benign diseases of the bowel requiring surgery e.g. inflammatory bowel disease C. Benign surgical conditions, usually operated on in a day surgery setting. These will specifically be of the biliary tree (gall stones) and the anterior abdominal wall (e.g. Hernia surgery)"
3249668|NCT01378013||Acute (emergency) surgery|"Patients presenting to Accident and emergency under the care of the general surgery on call team will be recruited into this study group. This study group will have the following subgroups:~A. Acute abdominal pain, as per the previous ethical clearance B. Patients with acute sepsis thought to be of surgical origin. C. Patients suffering major trauma with an Injury severity score of >15, multiple injuries, who require surgery or who have >1 organ system that is failed or who are admitted to the intensive care department."
3363269|NCT04497116|Experimental|RP-3500 in children|"Phase 1:~Multiple doses of RP-3500 for oral administration alone given in children"
3363271|NCT04474470|Experimental|Dose escalation of NT219 as a single agent|
3249669|NCT01378039|Other|Budesonide|patients who gave their agreement were randomised to 3 months treatment with either inhaled budesonide (400 µg BD) or placebo
3249670|NCT01378052||urothelial carcinoma pateints|
3249671|NCT01378052||healthy controls|Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
3363272|NCT04474470|Experimental|Dose escalation of NT219 in combination with ERBITUX®|
3363273|NCT04474470|Experimental|Expansion cohort of NT219 in combination with ERBITUX®|
3249672|NCT01378078|Sham Comparator|sham|patients receive sham tDCS stimulation
3249673|NCT01378078|Active Comparator|active|active transcranial direct current stimulation
3249674|NCT01378091|Experimental|Lenalidomide, Docetaxel, Prednisone|Subjects will receive this drug combination during a treatment phase and an extension phase.
3249675|NCT01378143|Experimental|OCZ103-OS, mFOLFOX6 or FOLFIRI|OCZ103-OS in combination with mFOLFOX6 or FOLFIRI as standard of care
3363276|NCT04466891|Experimental|ZW25 (Zanidatamab) Monotherapy|
3363277|NCT04464473|Experimental|FPl-TMS|Transcranial magnetic stimulation to the lateral frontal pole. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold.
3363278|NCT04464473|Experimental|MFG-TMS|Transcranial magnetic stimulation to the middle frontal gyrus. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
3363279|NCT04464473|Active Comparator|S1-TMS|Transcranial magnetic stimulation to primary somatosensory cortex. 600 pulses delivered in 50 Hz bursts every 5 Hz for 40 seconds at 80% of active motor threshold..
3363280|NCT04458194|Active Comparator|Standard Care|Cancer survivor-caregiver dyads receive their standard care
3363281|NCT04458194|Experimental|Partnered yoga|Cancer survivor-caregiver duads receive 8 virtual Zoom yoga sessions (75 minutes/session, 2 times a week for 4 weeks) together
3363282|NCT04458194|Experimental|Non-partnered yoga|Cancer survivors receive 8 virtual Zoom yoga sessions (75 minutes/session, 2 times a week for 4 weeks) along; caregivers do not receive virtual Zoom yoga sessions.
3363283|NCT04449549|Experimental|1|Nilotinib will be administered at 300 mg orally BID; Paclitaxel will be administered IV at 80 mg/m2 on Days 1, 8, and 15 in 28- day cycles.
3363284|NCT04448483|Experimental|Group A|Patients belonging to group A will start intervention I, immediately after baseline. We will recruit about 25 for group A (randomization will take into account the two to one study design) in order to have about 20 patients in Group A that will complete the study.
3363285|NCT04448483|Experimental|Group B|Patients belonging to group B will follow an observation period (max. 3 months) before starting intervention I. We will recruit about 15 patients for group B (randomization will take into account the two to one study design) in order to have about 10 patients in Group B that will complete the study.
3363286|NCT04447820|Experimental|K-877-ER Dose A|K-877-ER dose A administered once daily
3363287|NCT04447820|Experimental|K-877-ER Dose B|K-877-ER dose B administered once daily
3363288|NCT04447820|Experimental|K-877-IR|K-877-IR administered twice daily.
3363291|NCT04440358|Experimental|Exablate BBBD with carboplatin|Carboplatin will be administered via IV infusion about every 4 weeks for up to 6 cycles. The dosage will be calculated based on subject's creatinine level. On the day of planned carboplatin therapy, subjects will undergo Exablate procedure to open the blood-brain-barrier in the targeted cancerous brain areas prior to carboplatin administration.
3363292|NCT04427072|Experimental|Capmatinib|400mg of capmatinib tablets, administered orally twice daily
3363293|NCT04427072|Active Comparator|Docetaxel|Docetaxel 75 mg/m2 solution administered by intravenous infusion on Day 1 of every 21-day cycle
3363296|NCT04414423|Experimental|Bone marrow concentrate|Bone marrow concentrate combined with Autogenous bone graft
3249676|NCT01378156|Experimental|JS7 plasmid DNA and MVA62B vaccines|All subjects receive JS7 plasmid DNA (at 1 and 9 weeks) and MVA62B vaccines (17 and 25 weeks), followed (in 2 months after last vaccination) by a 12-week treatment interruption phase. Subjects reinstitute therapy after the treatment interruption and are followed for 6 months.
3249677|NCT01378169||SIRS patients|Every patient, without exclusion criteria, presenting with SIRS during an hospitalization in ICU.
3249678|NCT01378208|Experimental|Normal weight|Body Mass Index between 18-25 kg/m2 Age between 18-35 years male
3363297|NCT04414423|Active Comparator|autogenous bone graft|grafting with autogenous bone graft
3363308|NCT04401826|Experimental|The conventional approach|Conventionnal ECL using piezosurgery and microsurgical tools
3363309|NCT04401826|Active Comparator|The intervention approach:|Conventionnal ECL with tunneling using piezosurgery and microsurgical tools
3363314|NCT04392232|Experimental|Convalescent Plasma|
3363315|NCT04389632|Experimental|SGN-B6A|SGN-B6A monotherapy
3363316|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + enzalutamide|Participants will receive oral etrumadenant in combination with intravenous (IV) zimberelimab and standard oral enzalutamide
3363317|NCT04381832|Active Comparator|Stage 2: enzalutamide|Participants will receive standard oral enzalutamide
3363318|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + docetaxel|Participants will receive oral etrumadenant in combination with IV zimberelimab and standard IV docetaxel
3363319|NCT04381832|Active Comparator|Stage 2: docetaxel|Participants will receive standard dose of IV docetaxel
3363320|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab|Oral etrumadenant in combination IV zimberelimab
3363321|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + zimberelimab + AB680|Participants will receive oral etrumadenant in combination with IV zimberelimab and IV AB680
3363322|NCT04381832|Experimental|Stage 1 and 2: Etrumadenant + AB680|Participants will receive oral etrumadenant in combination with IV AB680
3363323|NCT04381832|Experimental|Stage 1: Etrumadenant + zimberelimab PK Sub-Study|Participants will receive oral etrumadenant in combination with IV zimberelimab
3363324|NCT04379050|Experimental|ABBV-951|Participants will receive ABBV-951 solution by continuous subcutaneous infusion (CSCI), at the discretion of the investigator, for 96 weeks.
3363327|NCT04370730|Other|prospective cohort|prospective monitoring of children and adolescents with schizophrenia and related psychotic disorders
3249679|NCT01378234|Experimental|EDPP Intervention|Receive EDPP transitional care intervention from social worker upon hospital discharge
3363328|NCT04364646|Active Comparator|Usual Care|Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
3363329|NCT04364646|Experimental|Personalize Integrated Chronotherapy|Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
3363330|NCT04351555|Placebo Comparator|Arm 1: Placebo with platinum-based chemotherapy|Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
3363331|NCT04351555|Experimental|Arm 2: Osimertinib with platinum-based chemotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
3363332|NCT04351555|Experimental|Arm 3: Osimertinib monotherapy|Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)
3363333|NCT04347135|Experimental|F-18 FES PET/MRI|16α-(18)F-fluoro-17β-estradiol ([F-18] FES)
3249680|NCT01378234|No Intervention|Usual Care|Receive usual care upon hospital discharge
3249681|NCT01378247|No Intervention|Treatment as usual|Pharmacological treatment, patient information and counselling according to international and national guidelines by health professionals specialized in heart failure.
3249682|NCT01378247|Experimental|Family Focused Nursing|Family Focused Nursing and treatment as usual
3363334|NCT04343989|Experimental|Clazakizumab 25 mg|
3363335|NCT04343989|Experimental|Clazakizumab 12.5 mg|
3363336|NCT04343989|Placebo Comparator|Placebo|
3249683|NCT01378260||Surgical Bypass|use of synthetic or endogenous (vein) or composite graft to treat lesions in the superficial femoral, common femoral, or popliteal artery
3249684|NCT01378260||Endovascular Therapy|angioplasty and/or stent to treat lesions in the superficial femoral or popliteal artery
3249685|NCT01378260||Medical Management|"Documentation of the following in the medical record:~i. Walking/physical therapy to improve endurance was recommended; ii. For tobacco users, tobacco cessation was recommended; iii. Prescribing pentoxifylline (Trental) or cilostazol (pletal) iv. Ongoing care by physician for treatment of claudication"
3249686|NCT01378286|Experimental|artesunate/amodiaquine|"artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment"
3249687|NCT01378286|Active Comparator|chloroquine|150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment
3249688|NCT01378312|Placebo Comparator|Placebo Arm|
3249689|NCT01378312|Active Comparator|AERAS 402 Arm|
3249690|NCT01378338||Typical reflux symptom by EGD|Total 2000 subjects who has Typical reflux symptom by EGD
3249691|NCT01378364|Experimental|AbGn-168H very low dose i.v.|subject to receive a single very low dose of AbGn-168H intravenously (i.v.) or placebo
3249692|NCT01378364|Experimental|AbGn-168H low dose i.v.|subject to receive a single low dose of AbGn-168H intravenously (i.v.) or placebo
3249693|NCT01378364|Experimental|AbGn-168H medium dose i.v.|subject to receive a single medium dose of AbGn-168H intravenously (i.v.) or placebo
3249694|NCT01378364|Experimental|AbGn-168H high dose i.v.|subject to receive a single high dose of AbGn-168H intravenously (i.v.) or placebo
3249695|NCT01378364|Experimental|AbGn-168H very low dose s.c.|subject to receive a single very low dose of AbGn-168H subcutaneously (s.c.) or placebo
3363338|NCT04339140|Experimental|Zafirlukast|Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
3363339|NCT04336098|Experimental|Monotherapy Dose Escalation|The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of SRF617 as monotherapy in up to 36 patients with advanced solid tumors.
3363340|NCT04336098|Experimental|Monotherapy Tumor Biopsy Expansion|The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy in up to 20 patients at cleared and recommended phase 2 dose levels.
3363341|NCT04336098|Experimental|Combination Therapy - SRF617 with Gemcitabine + Albumin-bound Paclitaxel|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel in patients with locally advanced or metastatic solid tumors. Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with advanced pancreatic ductal adenocarcinoma (PDAC) to further evaluate safety with SRF617 and gemcitabine + albumin-bound paclitaxel combination therapy.
3363342|NCT04336098|Experimental|Combination Therapy - SRF617 with Pembrolizumab|This portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with pembrolizumab (Keytruda®) in patients with locally advanced or metastatic solid tumors. Enrollment at the recommended phase 2 combination dose may be expanded to include approximately 10 additional patients with HER2 negative gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma to further evaluate safety with SRF617 and pembrolizumab combination therapy.
3363343|NCT04329728|Experimental|DLBCL and high-grade B-cell lymphoma|Diffuse Large Cell B-Lymphoma High-grade B-cell Lymphoma
3363344|NCT04329728|Experimental|MCL (Chronic Lymphoid Leukemia)|Chronic Lymphoid Leukemia
3249696|NCT01378364|Experimental|AbGn-168H medium dose s.c.|subject to receive a single medium dose dose of AbGn-168H subcutaneously (s.c.) or placebo
3249697|NCT01378390|Experimental|ASCs|Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million cells in case of incomplete fistula closure following week 12 assessment.
3249698|NCT01378390|Sham Comparator|Placebo|Instillation of saline solution into the fistulous tract, following identical tract preparation process as for the investigational treatment group.
3249699|NCT01378442|Experimental|high level training group|receive high frequency fitness training program(Frequency: three times a week, Duration: 40 minutes).
3363345|NCT04329728|Experimental|Primary Mediastinal Large B-cell lymphoma|Primary mediastinal large B-cell lymphoma
3363346|NCT04329728|Experimental|Burkitt or Burkitt-like lymphoma/leukemia|Burkitt or Burkitt-like lymphoma/leukemia
3363347|NCT04329728|Experimental|CLL/SLL|Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
3363348|NCT04329728|Experimental|B- or T-ALL|B-lymphoblastic leukemia/lymphoma, T-lymphoblastic leukemia/lymphoma, acute leukemia/lymphoma, acute leukemias of ambiguous lineage, or natural killer (NK) cell lymphoblastic leukemia/lymphoma
3363349|NCT04321343|Experimental|Group 1|PXL065 Dose 1
3363350|NCT04321343|Experimental|Group 2|PXL065 Dose 2
3363351|NCT04321343|Experimental|Group 3|PXL065 Dose 3
3363352|NCT04321343|Placebo Comparator|Group 4|Placebo oral tablet
3249700|NCT01378442|Experimental|low level training group|will receive low frequency fitness training program(Frequency: 1-2 times a week, Duration: 40 minutes).
3249701|NCT01378442|No Intervention|control|No intervention, but maintain usual physical activities
3363354|NCT04318886|No Intervention|Usual Care|
3249702|NCT01378455|Experimental|ICHTP group|In ICHTP (interactive computerized handwriting training program) group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software
3363355|NCT04318886|Experimental|Project ENABLE Cornerstone|
3363356|NCT04317534|Experimental|Arm A- Pembrolizumab|Pembrolizumab 400mg IV every 6 weeks x 9 cycles
3363357|NCT04317534|No Intervention|Arm B - Observation|Observation only
3363364|NCT04308135||vascular parkinsonism|the investigators will recruit 30 patients diagnosed as Vascular Parkisonism ,
3363365|NCT04308135||Parkinson's disease|50 patients diagnosed as Parkinson Disease
3363366|NCT04308135||Controls|30 healthy controls.
3363367|NCT04304144|Experimental|Part A: CAEL-101 combined with SoC CyBorD|CAEL-101 is administered as an intravenous (IV) infusion over approximately 2 hours. The initial cohort dose assignments of CAEL-101 will be: Cohort 1 - 500 mg/m^2 Cohort 2 - 750 mg/m^2 Cohort 3 - 1000 mg/m^2. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
3363368|NCT04304144|Experimental|Part B: CAEL-101 combined with SoC CyBorD and daratumumab|CAEL-101 is administered as an intravenous (IV) infusion at the RP3D dose level. CAEL-101 will be administered weekly for the first 4 weeks, and then every other week until end of study, in combination with the SoC CyBorD chemotherapy and daratumumab. Patients will be treated until death, unacceptable toxicity, symptomatic deterioration, Investigator decision, patient decision or Sponsor decision to terminate the study.
3363369|NCT04299464|Placebo Comparator|Placebo|Participants will receive placebo matched to RO7017773 for approximately 12 weeks.
3363370|NCT04299464|Experimental|RO7017773 Low Dose|Participants will receive a fixed low dose of RO7017773 for approximately 12 weeks.
3363371|NCT04299464|Experimental|RO7017773 High Dose|Participants will receive a fixed high dose of RO7017773 for approximately 12 weeks.
3363372|NCT04294810|Experimental|Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
3363373|NCT04294810|Placebo Comparator|Placebo + Atezolizumab|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
3363375|NCT04287478|Experimental|Intravenous (IV)|Phage administered via the intravenous route.
3363376|NCT04287478|Experimental|Intravesical (IVS)|Phage administered via the intravesical route.
3363377|NCT04287478|Experimental|Subcohort A|Selected phage for E. coli administered via selected route based on previous Arms.
3363378|NCT04287478|Experimental|Subcohort B|Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
3363379|NCT04287478|Experimental|Subcohort C|Selected phage for E. coli administered via selected route based on previous Arms.
3363380|NCT04287478|Experimental|Subcohort D|Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
3363382|NCT04285554|Experimental|Hepatic Denervation|
3363383|NCT04283617|Experimental|Diabetic with short duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes < 5 years
3363384|NCT04283617|Experimental|Diabetic with long duration|Type 2 diabetics with HbA1c > 7.5 % with short duration of diabetes > 5 years
3363385|NCT04272294|Experimental|Use of Optical Spectroscopy|Optical spectroscopy used to characterize treatment response
3363386|NCT04268277|Experimental|Rituximab & Pembrolizumab|"Cycle 1 (21 days cycle):~Rituximab: 375 mg/m2 day 1, 8, 15 Pembrolizumab: 200 mg IV fixed dose day 2~Cycle 2-18 (21 days cycle) or until progression or non-tolerable toxicity:~Rituximab: 375 mg/m2 day 1 every second cycle Pembrolizumab: 200 mg IV fixed dose day 1"
3363388|NCT04266704|Experimental|Intervention|Along with providing education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence, the intervention arm is designed to promote information sharing and stimulate broad cortical neural networks, the default mode (DMN), which focuses on emotion-management and self-awareness.
3249703|NCT01378455|Active Comparator|THTP group|The THTP (traditional handwriting training program)group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
3363389|NCT04266704|Active Comparator|Control|education on a low sodium diet (Dietary Approaches to Stop Hypertension or DASH), exercise, and medication adherence
3363392|NCT04255511|Experimental|Twin block|Removable Functional appliance
3363393|NCT04255511|Active Comparator|Fixed appliance|Preadjusted fixed appliance
3249704|NCT01378468||Patients with first ischemic stroke|
3249705|NCT01378481|Experimental|Treatment (vorinostat, surgery, FSRT)|Patients receive high-dose vorinostat PO at 48, 27, and 3 hours prior to surgery. Beginning 2-6 weeks later, patients receive vorinostat PO QD on days 1-3 in weeks 1-2and undergo fractionated stereotactic body radiation therapy on days 1-5 in weeks 1-2. Treatment continues in the absence of disease progression or unacceptable toxicity.
3249706|NCT01378494||HIV+|HIV+ patients that entered the 1917 Clinic at UAB as naive to ART
3249707|NCT01378507|Experimental|Endoscopic Submucosal Dissection|Single-arm for ESD procedure and retrospective surgical procedure(Laparoscopy, Open surgery)data collection
3249708|NCT01378533|Experimental|AC-T（dose-dense）|AC-T(dose-dense) EPI（Pharmorubicin） CTX（cyclophosphamide） PTX（Paclitaxel） G-CSF
3249709|NCT01378533|Experimental|chemotherapy:PC|PTX（Paclitaxel） CBP（carboplatin）
3249710|NCT01378559||Penis prosthesis cohort|
3249711|NCT01378585|Experimental|Treatment 1|Test drug treatment: 3 x 490 mg DLBS1033 daily
3249712|NCT01378585|Placebo Comparator|Treatment 2|Placebo treatment: 3 x 1 tablet daily
3363400|NCT04246372|Experimental|On Treatment|Tofacitinib 5mg oral tablets twice daily for 16 weeks
3363401|NCT04228965|Other|Co-Use Group|Cannabis and tobacco co-use group.
3363402|NCT04228965|Active Comparator|Tobacco Only Group|Tobacco only group.
3363403|NCT04228367|Experimental|Meniscal repair|Patients in need of meniscal repair
3363404|NCT04216342|Experimental|1|subjects entered into the trial may go thru a 0-4 weeks screening (Screening Phase). On the Intervention phase, subjects will be followed for 7 days which includes: entry criteria assessments and settling at the inpatient unit on Day 0, a single-dose I.V. infusion with data collection on Day 1 followed by 24 hours monitoring (Day 2), a 7-day and 28-day outpatient follow-up visit (Follow-Up Phase).
3363405|NCT04213807|Experimental|MAA868|Subcutaneous injection on Day 1 with two subsequent monthly injections
3363406|NCT04213807|Placebo Comparator|Placebo|Subcutaneous injection: Placebo on Day 1 with two subsequent monthly injections
3249713|NCT01378611|Placebo Comparator|active control group|The active control group is stimulated with: Output current 0.25 milliampere, Pulse width 0.1 milliseconds, Frequency 1 Hz, Duty cycle: 14 sec on 60 min off (duty cycle <0.5%)
3249714|NCT01378611|Experimental|treatment group|The high stimulation group is stimulated with output current 0.25 milliampere, Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off in the treatment group the current was stepwise increased with two week intervals to the maximally tolerated output current (maximum 1.75 mA).
3249715|NCT01378624|Experimental|Bronchoscopy|
3363408|NCT04192994|Active Comparator|Group 1: Antibiotic injection|A total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected with a 30-gauge needle into the vitreous cavity of the affected eyes in the randomized group, as soon as the diagnosis is confirmed.
3363409|NCT04192994|Active Comparator|Group 2: Pars Plana Vitrectomy|Randomized patients will undergo PPV. Briefly, a blepharostat will be placed followed by instillation of a drop of 5% iodine-povidone over the eye. Under a surgical microscope, three 23-gauge or 25-gauge sclerotomies will be performed. Vitreous core vitrectomy will be performed, and a fluid-gas exchange with balanced saline solution (BSS) or 5,000 grams of silicone oil as a vitreous substitute. At the end of surgery, all sclerotomies will be sutured with Vicryl 7.0 and a total of 0.05 ml of vancomycin 1 mg and 0.05 ml of ceftazidime 2.25 mg will be injected into the vitreous cavity. As soon as the diagnosis is confirmed.
3363410|NCT04184635|Experimental|Experimental ECMO + IABP Arm|"VA-ECMO will be instituted percutaneously under echo guidance via the femoral route as soon as possible.~An IABP will be systematically inserted in the contralateral femoral artery (unless technically not possible)."
3249716|NCT01378637|Experimental|AMES Leg treatment|An investigational device flexes and extends the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the foot. The subject's task is to assist the motion of the device by pulling or pushing with the foot. Feedback of ankle torque or the electrical signal produced by the muscles (EMG) while the subject is assisting the motion is provided during the 30 treatment sessions.
3249717|NCT01378650|Experimental|Cilostazol group|Administration of Cilostazol 100mg twice a day for 4 weeks
3249718|NCT01378650|Placebo Comparator|Placebo group|placebo drug twice a day for 4 weeks.
3363411|NCT04184635|No Intervention|Control Conventional Treatment Arm|Standard management of cardiogenic shock due to myocardial infarction according to the current ESC guidelines. It is not recommended to use IABP support and no other TCS device (e.g., ECMO, Impella, Thoratec PHP, TandemHeart) will be permitted in the control group.
3363412|NCT04184284||Primary Study Cohort - Anti-IL5/IL5R naïve patients|Severe eosinophilic asthma patients who have never received anti-Interleukin-5 / anti-Interleukin-5-receptor (anti-IL-5/anti-IL-5R) biologic treatment for severe eosinophilic asthma, for whom the investigator had decided to initiate benralizumab biologic treatment.
3363413|NCT04184284||Secondary Study Cohort - Biologic experienced patients|Patients that previously received a biologic treatment for severe asthma (at least one dose).
3363414|NCT04182321|Experimental|Combination Therapy|Metformin as add-on to entecavir therapy in patients with chronic hepatitis B
3363415|NCT04182321|Placebo Comparator|Standard Therapy|Entecavir monotherapy in patients with chronic hepatitis B
3363416|NCT04167917|Experimental|NTX-301|
3363417|NCT04164316|Sham Comparator|Kinesio Tape No Tension|Kinesio Tape No Tension
3363418|NCT04164316|Active Comparator|Kinesio Tape with Tension|Kinesio Tape with Tension
3363419|NCT04163926|Experimental|Intervention group - Post op follow up by trained optometrist|Intervention group will have cataract follow up conducted by a trained optometrist 4-6 weeks after surgery in community clinic
3363420|NCT04163926|Active Comparator|Usual care group - Consultant led post op follow up|Follow-up at 4-6 weeks after surgery led by consultant ophthalmologist
3363421|NCT04158258||Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3363422|NCT04158258||Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3363423|NCT04158258||Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3249719|NCT01378663||Post congenital cardiac surgery pain management|All patients that underwent congenital cardiac surgery from 2004 till 2010 and required PCA or NCA.
3249720|NCT01378676|Placebo Comparator|Matching Placebo|
3249721|NCT01378676|Experimental|Active Drug Low Dose (CK-2017357 125 mg)|
3249722|NCT01378676|Experimental|Active Drug Mid Dose (CK-2017357 250 mg)|
3249723|NCT01378676|Experimental|Active Drug High Dose (CK-2017357 375 mg)|
3249724|NCT01378689|Experimental|Online video|Participants in this arm are shown a brief video (~5 minutes) after ordering a refill for their glucocorticoid use. The video includes real patients telling their own story about the possible side effects of prolonged use of glucocorticoids.
3249725|NCT01378689|No Intervention|No video|
3249726|NCT01378702|Experimental|Iscucin populi strength F, G and H|1 ampoule two times/week subcutaneously. Week 1-4: strength F. Week 5-8: strength G. Week 9-12: strength H.
3249727|NCT01378702|Experimental|Viscum Mali e planta tota D3, D2, 2%|1 ampoule two times a week subcutaneously. Week 1-4: D3. Week 4-8: D2. Week 9-12: 2%.
3249728|NCT01378702|Placebo Comparator|Placebo|1 ampoule two times a week subcutaneously
3363424|NCT04158258||Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3249729|NCT01378715|Active Comparator|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
3249730|NCT01378715|No Intervention|Control|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to no-pretreatment with rosuvastatin.
3249731|NCT01378728||Patients with chronic or acute wounds.|Patients with chronic or acute wounds.
3363425|NCT04158258||Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3363426|NCT04158258||Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
3363427|NCT04155034|Active Comparator|Arm I (PCI, MRI)|Patients undergo conventional or hippocampal avoidance PCI over 20 minutes 5 days per week for 2 weeks. Patients also undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
3363428|NCT04155034|Experimental|Arm II (MRI)|Patients undergo MRI scan at 3, 6, 9, 12, 18, and 24 months.
3363429|NCT04153396|Experimental|The Treatment Group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine.
3249732|NCT01378741|Active Comparator|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
3249733|NCT01378741|Active Comparator|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
3249734|NCT01378754|Experimental|6.5 milligram per kilogram of Fospropofol (Lusedra®)|
3363430|NCT04153396|Active Comparator|The Control group|The local infiltration solution in the control group will consist of ropivacaine.
3249735|NCT01378754|Experimental|10 milligram per kilogram of Fospropofol (Lusedra®)|
3363432|NCT04146142|Active Comparator|Transperineal prostate biopsy with antibiotic profylaxis|Cefuroxim 1.5 g will be applied intramuscularly before prostate biopsy
3363433|NCT04146142|Experimental|Transperineal prostate biopsy without antibiotic profylaxis|No antibiotics will be used before or after prostate biopsy
3363434|NCT04145414|Experimental|Cerebral magnetic resonance imaging x2|Cerebral MRI performed at enrolment visit and at +6 weeks (maximum)
3363435|NCT04143282|Experimental|Metformin group|Non Diabetic metastatic breast cancer Patients will take metformin 1 gm. twice daily (Nathan 2009) along with standard chemotherapy
3363436|NCT04143282|Other|control group|Non Diabetic metastatic breast cancer Patients will take standard chemotherapy only
3363437|NCT04140305|Experimental|Administration of RPC-1063|Patients with relapsing MS will receive RPC-1063 orally:
3363438|NCT04135495|Experimental|ELX-02|Eukaryotic ribosomal selective glycoside (ERSG)
3363439|NCT04133038||Children consulting|Children consulting in the expert center for food difficulties.
3363440|NCT04133038||Pierre Robin sequence|Children with Pierre Robin sequence following for food difficulties.
3363441|NCT04133038||Cardiac malformations|Children with cardiac malformations followed for food difficulties.
3363442|NCT04133038||Oesophageal atresia|Children with oesophageal atresia followed for food difficulties.
3363443|NCT04133038||Cleft lip and palate|Children with cleft lip and palate followed for food difficulties.
3363444|NCT04133038||Autism spectrum disorders|Children followed for congenital pathology that cause food difficulties.
3363445|NCT04133038||Ex-prematurity < 32 AG|Children born premature followed for food difficulties.
3363446|NCT04133038||Chromosomal anomalies|Children with chromosomal anomalies followed for food difficulties.
3249736|NCT01378754|Experimental|12 milligram per kilogram of Fospropofol (Lusedra®)|
3249737|NCT01378767|Active Comparator|Krill oil capsules|Two grams per day daily for 21 days
3249738|NCT01378767|Placebo Comparator|Coconut oil capsules|Two grams per day for 21 days
3249739|NCT01378780|Active Comparator|Intervention for diet, exercise|This group will receive the educational intervention for healthy diet and increased physical activity
3249740|NCT01378780|Other|Control|This group will get a skin cancer awareness educational message. At the end of the study this group will also receive the diet and exercise intervention but outcomes will not be measured after the crossover.
3249741|NCT01378793|No Intervention|Standard of Care|Participants will be asked to continue doing whatever their healthcare providers advise for their insomnia, but not to start any new treatments during the study. They will also be given a sleep hygiene handout as a standard of care. After six weeks, they will be reassessed and then provided the opportunity to engage in the web-based acupressure intervention.
3363449|NCT04127656|Experimental|Amino Acid-Based Experimental Study Formula|Not commercially available amino acid-based study formula
3363450|NCT04125173|Active Comparator|1. Pneumoperitoneum pressure = 15mmHg|1. Pneumoperitoneum will be set at 15mmHg
3363451|NCT04125173|Active Comparator|2. Pneumoperitoneum pressure = 12mmHg|2.Pneumoperitoneum will be set at 12mmHg
3363452|NCT04125173|Active Comparator|3. Pneumoperitoneum set at 10mmHg|3. Pneumoperitoneum will be set at 10mmHg
3363453|NCT04124588|Experimental|Test group|"After achieving initial hemostasis only with the standard-of-care, endoscopic hemostatic therapie(s)"
3363454|NCT04124588|Active Comparator|Control gruop|"After achieving initial hemostasis only with the standard-of-care, Wrap up the first endoscopy without adding an additional procedure."
3363455|NCT04120233|Placebo Comparator|Placebo|Participants will receive placebo.
3363456|NCT04120233|Experimental|Dose 1|Participants will receive 10 mg of MW151.
3249742|NCT01378793|Active Comparator|Relaxation Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 5 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 9 points to stimulate. Each of the 9 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 27 minutes done once daily.
3249743|NCT01378793|Active Comparator|Stimulating Acupressure|In addition to being given a sleep hygiene handout as a standard of care, participants will be asked to apply pressure on each of following points (bilaterally where indicated). There are 6 acupoints with 4 of the acupoints performed on both the left and the right sides of the body giving a total of 10 points to stimulate. Each of the 10 acupoints will be stimulated for 3 minutes per point giving a total treatment time of 30 minutes done once daily.
3363457|NCT04120233|Experimental|Dose 2|Participants will receive 20mg of MW151.
3363458|NCT04120233|Experimental|Dose 3|Participants will receive 40mg of MW151.
3363459|NCT04120233|Experimental|Dose 4|Participants will receive 80mg of MW151.
3363460|NCT04120233|Experimental|Dose 5|Participants will receive 160mg of MW151.
3363461|NCT04114669|Experimental|Regret lottery|"Will receive a lottery incentive (regret lottery) for 6 months"
3363462|NCT04114669|Placebo Comparator|Control Condition|Will complete a total of 3 in-person study visits, approximately one hour each.
3363465|NCT04104672|Experimental|Dose Escalation|Dose escalation is a 3+3 design, including a Dose Limiting Toxicity (DLT) evaluation period. The dose expansion dose level will be determined in this part with escalating doses of AB680 in combination with Zimberelimab at the recommended phase 2 dose (RP2D) and the standard nab-paclitaxel and gemcitabine chemotherapy regimen in participants with advanced pancreatic cancer.
3363466|NCT04104672|Experimental|Dose Expansion (AB680 + Zimberelimab + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with Zimberelimab at the RP2D and the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
3363467|NCT04104672|Experimental|Dose Expansion (AB680 + NP/Gem)|The AB680 dose given in dose expansion will be determined from the dose escalation part. AB680 will be given at the recommended phase 2 dose (RP2D) in combination with the standard nab-paclitaxel (NP) and gemcitabine (Gem) chemotherapy regimen in participants with advanced pancreatic cancer.
3363468|NCT04094519|Experimental|digoxin plus rosuvastatin and enzalutamide|Participants will receive a single oral dose cocktail containing 0.25 mg digoxin and 10 mg rosuvastatin on Day 1 and 64. A single oral dose of placebo to match enzalutamide will be given on Day 1 and 160 mg enzalutamide once daily on Days 8 through 71.
3363469|NCT04093310|Experimental|Word catheter|The abscess is incised and the Word catheter is inserted into the residual cavity to create a neo-channel to prevent recurrence. The catheter is removed after 4 weeks during a consultation
3363470|NCT04093310|Active Comparator|Incision-drainage|This procedure performed under general or loco-regional anaesthesia consists in incising the abscess, draining the pus build-up and placing a wick in the residual cavity to promote progressive healing from the inside out.
3363475|NCT04076813||STEMI/NSTEMI|Patients in the registry will be 18 years of age or older and underwent coronary angiography for a ST-elevation myocardial infarction (STEMI) or NSTEMI Non-ST-elevation myocardial infarction
3363478|NCT04062279||case group|patients diagnosed with idiopathic paaarkinson's disease according to the clinical criteria.
3363479|NCT04060446||Observational (smoke cigarettes)|Patients smoke 5 cigarettes separated by 30 minute washout periods. Between 48 hours and 1 week later, patients smoke another 5 cigarettes separated by 30 minute washout period with CReSSMicro topography measurement device and BioRadio device for recording inhalation patterns.
3363483|NCT04044469|Experimental|Immunization-enhancement|This group receives an immunization-promoting manipulation aimed at triggering negative appraisals of the medical information received and questioning the validity of the medical reassurance. For this purpose, a standardized information text is presented to the participants after receipt of the doctor's report, in which it is stated that the standard medical diagnosis in gastroenterology is often not particularly accurate and that serious diseases are from times to times overlooked. As a further factor contributing to the non-detection of diseases, it is mentioned that doctors are often under time pressure and thus do not have sufficient time to ask patients for all important information. It is believed that communicating this information will result in participants continuing to report high probabilities of serious illness despite the previously received findings report.
3363484|NCT04044469|Experimental|Immunization-inhibition|The aim of the immunization-inhibiting manipulation is to increase the probability that the normal test results obtained will be used to reduce worries about a serious illness. The participants of this group receive - analogous to the immunization-promoting group - a standardized information text which states that the standard medical diagnosis in gastroenterology is very accurate and that the physicians are very often correct in their initial diagnostic assessment, especially with regard to the assessment of a serious organic disease. This is supported by two scientific publications. The aim of this information is to increase the value of the results obtained, so that the participants are more reassured as a result of the inconspicuous test results and use them to correct their health-related concerns.
3363485|NCT04044469|Experimental|Control group|This group does not receive additional information after the doctor's report.
3363486|NCT04042480|Experimental|SGN-CD228A|SGN-CD228A administered intravenously
3363487|NCT04035278|Experimental|Dengusiil|
3363488|NCT04035278|Placebo Comparator|Placebo|
3363489|NCT04029688|Experimental|Dose Escalation: Solid Tumors: Idasanutlin Single Agent|
3363490|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Venetoclax|
3363491|NCT04029688|Experimental|Neuroblastoma: Idasanutlin + Cyclophosphamide + Topotecan|
3363492|NCT04029688|Experimental|AML: Idasanutlin + Venetoclax|
3249744|NCT01378806|Experimental|Intervention|A 12-week intensive intervention on nutrition and exercise education and coping skills training (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
3249745|NCT01378845|Placebo Comparator|Prostavasin|
3249746|NCT01378845|Active Comparator|Prostavasin + Bosentan|
3363493|NCT04029688|Experimental|AML: Idasanutlin + Fludarabine + Cytarabine|
3363494|NCT04029688|Experimental|ALL: Idasanutlin + Venetoclax|
3363495|NCT04023162|Experimental|Biomedical group|Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
3363496|NCT04023162|Experimental|Biopsychosocial group|Operant Conditioning implement in physiotherapy, Therapy Exercises and Back School by month, 2 times a week for 60 minutes.
3363497|NCT04023162|No Intervention|Usual care|Usual care and written instructions on Therapeutic Exercises and Back School for home work.
3363498|NCT04017871|Experimental|Interventional|10 days of intensive and structured motor therapy, 5 hours a day = 50h
3363499|NCT04017871|Placebo Comparator|Control|10 days of care and classic activities
3363500|NCT04015739|Experimental|Bevacizumab, Olaparib and Durvalumab|Single arm study
3249747|NCT01378871|Experimental|Anitbody Therapy|Treatment with Imtox-25 intravenously over 4 hours every other day for 4 doses. Hospital admission is required during this treatment.
3249748|NCT01378884|Experimental|Domeperidone|Patients to receive Domperidone for treatment of Gastroparesis
3249749|NCT01378910|Experimental|Change of 3rd drug to maraviroc|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
3249750|NCT01378923|Experimental|Values-based mindfulness group|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
3249751|NCT01378923|Other|Treatment as usual|has access to standard jail interventions and programs
3363501|NCT04015336|Experimental|Arm 1|Up to 3x1010 E7 TCR T cells (based on the number of cells that can be generated in the shortened manufacturing process) will be administered intravenously over 20 to 30 minutes on day 0.
3363502|NCT04006652|Experimental|Recipient|"Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy which will be administered at the discretion of the treating physician~Recipients will undergo a single fresh ApoGraft transplant as per standard clinical site guidelines"
3363503|NCT04006652|No Intervention|Donor|-Donors will undergo apheresis from peripheral blood after daily G-CSF administration (for up to 5 days prior to Day -1)
3249752|NCT01378936|Experimental|MI plus IOC group intervention|
3363507|NCT04000594|Experimental|Dose level 1 of RO7234292 (RG6042)|Participants will receive dose level 1 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
3363508|NCT04000594|Experimental|Dose level 2 of RO7234292 (RG6042)|Participants will receive dose level 2 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
3363509|NCT04000594|Experimental|Dose level 3 of RO7234292 (RG6042)|Participants will receive dose level 3 of RO7234292 (RG6042) intrathecally on Day 1 and Day 29.
3363510|NCT03999333|Experimental|Virtual Reality|Every participant is provided with a VR headset
3363511|NCT03996876|Active Comparator|Threat ABM Training|Attention Bias Modification Training with threatening words
3249753|NCT01378936|Experimental|Motivational Interview only|
3249754|NCT01378949|Active Comparator|PsCB Group|Ultrasound-Guided Psoas Compartment Block will be used in patients for pain relief after THA
3249755|NCT01378949|Active Comparator|FICB Group|Ultrasound-Guided Fascia Iliaca Compartment Block will be used in patients for pain relief after THA
3363512|NCT03996876|Placebo Comparator|Neutral Attention Training|Non-active version of ABM Training
3249756|NCT01378949|Active Comparator|Patient-Controlled Analgesia|Patient-controlled analgesia will be used for pain relief after THA
3363513|NCT03989882|Experimental|Wheat germ|Wheat germ energy balls containing 30 g of wheat germ, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
3363514|NCT03989882|Placebo Comparator|Control|Control energy ball containing 30 g of cornmeal, peanut butter, and honey to form 2 energy balls that is approximately 200 kcal. Two energy balls will be consumed daily for 30 days.
3363515|NCT03989414|Experimental|Cohort A: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at specified cohort A dose administered over a 21-day cycle~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8"
3363516|NCT03989414|Experimental|Cohort C: CC-92480 with carfilzomib and dexamethasone|"Oral CC-92480 at specified cohort C dose administered over a 28-day cycle~Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle~Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle"
3363517|NCT03989414|Experimental|Cohort H: CC-92480 with elotuzumab and dexamathasone|"Oral CC-92480 at specified cohort H dose administered over a 28-day cycle~Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle~Oral (28 mg) and IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg] and IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle"
3363518|NCT03989414|Experimental|Cohort I: CC-92480 with isatuximab and dexamathasone|"Oral CC-92480 at specified cohort I dose administered over a 28-day cycle~Intravenous ISA 10 mg/kg administered over a 28-day cycle~Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)"
3363519|NCT03989414|Experimental|Cohort D: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle in the first 8 cycles and on days 1, 2, 8 and 9 after Cycle 8"
3363520|NCT03989414|Experimental|Cohort F: CC-92480 with carfilzomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle~Intravenous (IV) carfilzomib 20 mg/m2 then 56 mg/m2 administered over a 28-day cycle~Oral/IV dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) administered over a 28-day cycle"
3363521|NCT03989414|Experimental|Cohort J: CC-92480 with elotuzumab and dexamathasone|"Oral CC-92480 at RP2D administered over a 28-day cycle~Intravenous ELO 10 mg/kg then 20 mg/kg administered over a 28-day cycle~Oral (28 mg)/IV (8 mg) dexamethasone for total 36 mg/day (oral [8 mg]/IV [8 mg] dexamethasone for total 16 mg/day for subjects > 75 years old) on ELO dosing days, and oral dexamethasone 40 mg/day (20 mg/day for subjects > 75 years old) on non-ELO dosing days, administered over a 28-day cycle"
3363522|NCT03989414|Experimental|Cohort K: CC-92480 with isatuximab and dexamathasone|"Oral CC-92480 at RP2D administered over a 28-day cycle~Intravenous ISA 10 mg/kg administered over a 28-day cycle~Oral/IV dexamethasone 40 mg weekly (20 mg weekly for subjects > 75 years old)"
3363523|NCT03989414|Experimental|Cohort G: CC-92480 with bortezomib and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle~Subcutaneous bortezomib 1.3 mg/m2 administered over a 21-day cycle up to Cycle 6~Oral dexamethasone 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle up to Cycle 6"
3363524|NCT03989414|Experimental|Subcohort B1: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort dose administered over a 28-day cycle~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
3363525|NCT03989414|Experimental|Subcohort B2: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort dose administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards"
3363526|NCT03989414|Experimental|Subcohort B3: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at specified cohort B dose administered over a 28-day cycle~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
3363527|NCT03989414|Experimental|Subcohort E1: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle~Either IV DARA administered at a dose of 16 mg/kg or SC DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
3363528|NCT03989414|Experimental|Subcohort E2: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight, administered over a 21-day cycle from Cycle 1 to Cycle 8 and over a 28-day cycle from Cycle 9 onwards"
3363529|NCT03989414|Experimental|Subcohort E3: CC-92480 with daratumumab and dexamethasone|"Oral CC-92480 at RP2D administered over a 28-day cycle~Either Intravenous (IV) DARA administered at a dose of 16 mg/kg or Subcutaneous (SC) DARA administered at a dose of 1800 mg over 3 to 5 minutes~Oral/IV dexamethasone 40 mg weekly or 20 mg weekly for subjects older than 75 years or underweight administered over a 28-day cycle"
3363530|NCT03979313|Experimental|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
3363531|NCT03979313|Placebo Comparator|Placebo|Commercially available 0.9% (w/v) saline
3363532|NCT03978936|Experimental|MTM-EAM|Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management [MTM-EAM]
3363533|NCT03978936|Active Comparator|EAM only|Electronic Adherence Self-Management [EAM] only
3249757|NCT01379001|Experimental|Young|Young healthy controls, aged 21-35
3249758|NCT01379001|Experimental|Older|Older healthy controls, aged 65-80
3363534|NCT03978754||Patients who visit clinic|Postoperative patients who have undergone axillary surgery for breast cancer and went to clinic due to complaints of upper limb discomfort.（The expected number of subjects in this group is 300）
3249759|NCT01379014|Experimental|Decision Aid Tool|Intervention group - receives the decision aid tool in booklet form and is introduced to it by an investigator.
3363535|NCT03978754||Preoperative breast cancer patients|Preoperative subjects diagnosed with breast cancer were enrolled as non-lymphedema group. （The expected number of subjects in this group is 1300）
3363536|NCT03978546|Experimental|Non-Glaucoma Patient Arm|All participants will complete the same assessments
3363537|NCT03978546|Experimental|Glaucoma Patient Arm|All participants will complete the same assessments
3249760|NCT01379014|No Intervention|Control|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
3249761|NCT01379027|No Intervention|a treatment as usual (TAU) control condition|Participants will receive recruitment information, go on the study website to enroll and complete assessments over the study web site but will not receive the study intervention.
3363540|NCT03965728|Experimental|BAY1830839 arm|Period 1: Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6, single dose. Period 2: Dose 1, Dose 2 and Dose 3, once daily over 10 days. Dose 4 and Dose 5, twice daily over 10 days. Dose 6, single dose on Day 1, three times daily (TID) for 9 days (Days 2-10).
3363541|NCT03965728|Placebo Comparator|Placebo arm|Placebo tablets matching BAY1830839
3363542|NCT03964402||Control|Control arm, i.e., as per standard procedures
3363543|NCT03964402||Experimental|Experimental arm, i.e. investigational product
3249762|NCT01379027|Experimental|Pure self-help Internet CBT for depression|Participants will receive TAU plus access to the study website for the self-help Internet CBT for depression, consisting of access to the Internet site without any contact with therapist
3249763|NCT01379027|Experimental|Guided self-help Internet CBT|Participants will receive TAU plus Guided self-help Internet CBT, consisting of access to the Internet site plus brief, periodic telephone contacts with therapists
3363544|NCT03964207|Experimental|T1 followed by T2|
3363545|NCT03964207|Experimental|T2 followed by T1|
3363546|NCT03959930|Experimental|Interventional arm|Total and segmental body fluid volumes (total water, extracellular water and interstitial water) will be measured by Segmental Bioelectrical Impedance Spectroscopy (as per manufacturer instructions of use). Areas with most significant oedema and skin in a suitable condition shall be selected for the TFR application. Moisture Meter shall be used at the selected site to measure the skin water content at 4 depths (0.5mm, 1.5mm, 2.5mm and 5mm).
3363547|NCT03958929|Experimental|Education group|Subjects will be asked to watch a 5-10 min education film two times (pre-op one day and post-op one day).
3363548|NCT03958929|No Intervention|Control group|Standard patient procedure that includes a pre-operative discussion with an ophthalmologist about glaucoma surgery, during which the surgeon gains the patient's informed consent. Subjects will not be asked to watch education film..
3249764|NCT01379027|Experimental|Stepped-Care Internet CBT condition|This consists of a Stepped-Care Internet CBT condition, starting with TAU + Pure self-help CBT and progressing to Guided self-help CBT if adequate progress is not observed early on
3249765|NCT01379040||Cystic Fibrosis Patients|Patients with Cystic Fibrosis, some having Pseudomonas aeruginosa, some not.
3249766|NCT01379040||Control|Healthy volunteers
3249767|NCT01379053||Staphylococcus Patients|Patients suspected of having Methicillin-resistant and/or methicillin-susceptible staphylococcus aureus.
3249768|NCT01379053||Control|Healthy volunteer
3249769|NCT01379066||Tuberculosis Patients|Suspected Tuberculosis patients
3249770|NCT01379066||Control|Healthy volunteers
3249771|NCT01379079|Experimental|aspirin at bedtime|
3249772|NCT01379079|Active Comparator|aspirin on awakening|
3249773|NCT01379092|Experimental|Breast biopsy specimen imaging & comparison of image quality|Each subject's explanted tissue will serve as both the control (standard analysis) and the experimental analysis of the quality of the images.
3249774|NCT01379105|Other|electromyography|The electrical activity of the femoral bicep muscle of the right thigh was recorded by a four channel EMG system with using superficial bipolar active electrodes (pre-amplified) with acquisition software and signal processing. The sampling frequency was 2,000 Hz, and the amplifier had a high-pass filter at 20 Hz and a low-pass filter at 500 Hz; a 12-bit analogical converter and computer completed the system
3249775|NCT01379131||GPRD patients|"All patients included in up to standard GPRD practices that agreed to the linkage with the MINAP database are included in this cohort."
3249776|NCT01379144|Experimental|latanoprost 75 ug|
3249777|NCT01379144|Experimental|latanoprost 100 ug|
3249778|NCT01379144|Experimental|latanoprost 125 ug|
3363562|NCT03937830|Experimental|1/Arm 1|Durvalumab, bevacizumab and tremelimumab
3363563|NCT03937830|Experimental|2/Arm 2|Durvalumab, bevacizumab, tremelimumab and TACE
3249779|NCT01379144|Active Comparator|latanoprost 50 ug|
3249780|NCT01379157|Active Comparator|Conventional arm|Infusion of 0.5 g of imipenem for 0.5 hr every 6 hr for 3-5 days
3363567|NCT03916341|Experimental|Non-user|Non- users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
3363568|NCT03916341|Experimental|Chronic EC user|Chronic EC users will use, in a randomized, crossover fashion with a 4 week washout, an 1) EC with nicotine, 2) EC without nicotine, and 3) an empty EC (control)
3363569|NCT03916341|Experimental|Chronic TC smoker|Chronic TC smokers will use, in a randomized, crossover fashion with a 4 week washout, a 1) TC with nicotine (own brand), 2) research TC with very low level nicotine, and 3) a straw (control)
3363570|NCT03912350|Experimental|Test group|Participants with moderate hepatic impairment.
3363571|NCT03912350|Active Comparator|Reference group|Healthy pariticipants with normal hepatic function.
3363574|NCT03895996|Experimental|AVT001 (Treatment)|Infusion of AVT001 (treatment)
3363575|NCT03895996|Placebo Comparator|Matched placebo|Infusion of AVT001-matched placebo
3249781|NCT01379157|Experimental|Extended infusion arm|Infusion of 1 g of imipenem for 4 hr every 8 hr for 3-5 days
3249782|NCT01379170|Experimental|Type 2 diabetes, de novo hypothyrodism treatment|Type 2 diabetic patients with de novo hypothyroidism will be included in this arm and will receive 3 months of treatment with Euthyrox (standard protocol).
3363580|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in study 192024-093|Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment.
3249783|NCT01379196|Experimental|Azithromycin PO three times weekly|Tablets Azithromycin 500 mg PO three times weekly for three months
3249784|NCT01379209|Experimental|RGI-2001 0.001 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Dose escalation cohort 1 in part 1 of this study will include 2-6 patients"
3249785|NCT01379209|Experimental|RGI-2001 0.01 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 2 in part 1 of this study will include 2-6 patients"
3249786|NCT01379209|Experimental|RGI-2001 0.1 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 3 in part 1 of this study will include 2-6 patients"
3249787|NCT01379209|Experimental|RGI-2001 1.0 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 4 in part 1 of this study will include 2-6 patients"
3249788|NCT01379209|Experimental|RGI-2001 10 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 5 in part 1 of this study will include 2-6 patients"
3363581|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-093/-095|Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment.
3363582|NCT03891446|Experimental|Bimatoprost SR 10mcg; Lead-in studies 192024-091/-092|Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment.
3249789|NCT01379209|Experimental|RGI-2001 100 μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 6 in part 1 of this study will include 2-6 patients"
3249790|NCT01379209|Experimental|RGI-2001 250μg/kg + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~Cohort 7 in part 1 of this study will include 2-6 patients (optional)"
3249791|NCT01379209|Experimental|RGI-2001 + Standard of Care GVHD Prophylaxis|"RGI-2001 will be add to standard treatment with a calcineurin inhibitor, in combination with either methotrexate, mycophenolate mofetil, or sirolimus all at doses as per the institutional protocols~In part 2 of this study the best dose or doses determined from part 1 will be administered in up to 30 persons."
3249792|NCT01379235|Experimental|Intervention group|Intervention group: will receive 12 weeks of pilatis exercise 3 times a week.
3249793|NCT01379235|Other|control group|The control group will be offered the same intervention (pilatis exercise) at the end of the study period.
3249794|NCT01379248|Experimental|thrombus aspiration|Manual thrombus aspiration with dedicated catheter (Export, Medtronic Inc. Minneapolis, Minnesota, USA)
3249795|NCT01379248|No Intervention|no thrombus aspiration|
3249796|NCT01379261|Active Comparator|Hypothermia treatment|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
3249797|NCT01379261|No Intervention|Standard treatment|Standard treatment
3249798|NCT01379287|Experimental|Patients with Advanced Solid Tumors|The trial was initially designed as a 3 hour IV infusion of iso-fludelone every 3 weeks with three dose-escalation stages (12 patients), however it has been amended to study iso-fludelone administered over 6 hours (+/- 30 minutes) every 3 weeks schedule.
3249799|NCT01379300|Experimental|Dabigatran|Single 150-mg dose of dabigatran etexilate
3363583|NCT03891446|Experimental|Bimatoprost SR 15mcg; Lead-in studies 192024-091/-092|Study eye: Eye that received Bimatoprost SR in the lead-in study. Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye Fellow eye: Eye that did not receive Bimatoprost SR in the lead-in study. Fellow eye will receive only standard of care for intraocular pressure (IOP) lowering, based on the investigator's judgment.
3363584|NCT03881020|Experimental|SMART|Silver modified atraumatic restorative treatment group in which advantage Arrest Silver diamine Fluoride 38% (Elevate oral Care, USA ) will be applied to carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
3363585|NCT03881020|Active Comparator|Conventional ART|Conventional atraumatic restorative treatment group in which a sharp excavator will be used to remove caries from carious molars then teeth will be restored with GC Fuji IX GP® FAST FAST Packable Posterior Restorative glass ionomer fillings (GC corporation, Tokyo, Japan)
3363586|NCT03872427|Experimental|Treatment (telaglenastat hydrochloride)|Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3363587|NCT03872401|Placebo Comparator|Placebo|Participants will receive placebo subcutaneous injection once every 2 weeks (Q2W) for a minimum of 4 years.
3363588|NCT03872401|Experimental|Evolocumab 140 mg Q2W|Participants will receive 140 mg evolocumab by subcutaneous injection once every 2 weeks for a minimum of 4 years.
3249800|NCT01379300|Experimental|Rivaroxaban|Single 20-mg dose of rivaroxaban
3249801|NCT01379300|No Intervention|No intervention|No study drug will be administered
3249802|NCT01379313|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
3249803|NCT01379313|Experimental|1:1 group|1:1 I:E ratio group, inspiratory time : expiratory time = 1:1
3249804|NCT01379313|Experimental|2:1 group|inverse ratio group, inspiratory time : expiratory time = 2:1
3249805|NCT01379313|Active Comparator|1:2 PEEP group|I:E ratio of 1:2 with external PEEP of 5 cm H2O
3249806|NCT01379326|Experimental|Mebendazole|
3249807|NCT01379339|Experimental|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3363592|NCT03841708|Active Comparator|Pleth Variability Index|In the experimental group patients will be hemodynamically resuscitated in the early phases after ROSC based on the pleth variability index on top of standard non invasive monitoring
3249808|NCT01379339|Experimental|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3249809|NCT01379339|Experimental|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3249810|NCT01379339|Experimental|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3249811|NCT01379339|Experimental|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
3249812|NCT01379352||High MELD group|Preoperative MELD score greater than 20
3249813|NCT01379352||Low MELD group|Preoperative MELD score lesser than 20
3249814|NCT01379365|Experimental|Treatment|
3249815|NCT01379391|Active Comparator|TPO|Patients received myeloablative Allo-HSCT with platelet lower than 20G/L on +14d post-transplantation. Patient enrolled in TPO arm will recieved Recombinant Human Thrombopoietin (rHTPO) treatment fro 14 days.
3363593|NCT03841708|Placebo Comparator|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG.
3363594|NCT03841448|Experimental|Cemdisiran|Participants will receive cemdisiran during the Treatment and optional Open-Label Extension (OLE) Periods in combination with standard of care.
3363595|NCT03841448|Placebo Comparator|Placebo|Participants will receive matching placebo during the Treatment Period in combination with standard of care. During the optional OLE Period participants will receive cemdisiran in combination with standard of care.
3363596|NCT03837639|Experimental|Arm crank ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
3363597|NCT03837639|Experimental|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
3249816|NCT01379391|No Intervention|TPO-Free Arm|No TPO intervention
3249817|NCT01379417|Placebo Comparator|Maltodextrin|Maltodextrin
3249818|NCT01379417|Active Comparator|Probiotic B lactis/B longum|Bifidobacterium lactis + Bifidobacterium longum
3249819|NCT01379417|Active Comparator|Probiotic B longum|Bifidobacterium longum
3249820|NCT01379417|Active Comparator|Probiotic B lactis|Bifidobacterium lactis
3249821|NCT01379430|Experimental|Group 1|Intramuscular arm
3249822|NCT01379430|Experimental|Group 2|Intradermal arm
3249823|NCT01379443|Active Comparator|Parental reports of their children|Parental report of family-centered processes of care (MPOC) Parent mental health Parent perceived social support
3249824|NCT01379443|No Intervention|Integration of service provider teams|Network co-alition teams were measured using the Integration of Human Services Measure, the Partnership Synergy Measure and a Network Capacity Measure were employed at the CEO level.
3249825|NCT01379456|Experimental|physiotherapy|exercises
3249826|NCT01379456|No Intervention|conventional treatment|care as usual
3363598|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
3363599|NCT03832946|Experimental|A. GB0139 3 mg once a day|Inhalation of GB0139
3363600|NCT03832946|Placebo Comparator|B. Placebo once a day|Inhalation of Placebo
3363601|NCT03825783|Experimental|RP-L201|RP-L201 is a gene therapy product containing autologous genetically modified CD34+ hematopoietic stem cells transduced with Chim-CD18-WPRE lentiviral vector administered as a single infusion in subjects with severe LAD-I
3249827|NCT01379482|Experimental|Multimodal treatment|Neoadjuvant systemic chemotherapy followed by cytoreductive surgery, hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
3249828|NCT01379495|No Intervention|Usual Care|Burns victims will receive information according to the service routine
3363602|NCT03823885|Experimental|E-cig|One time exposure to e-cig
3363603|NCT03823885|Experimental|sham|One time exposure to empty e-cig
3363604|NCT03821233|Experimental|ZW49|
3363605|NCT03819153|Experimental|Semaglutide|Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
3363606|NCT03819153|Placebo Comparator|Placebo|Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
3249829|NCT01379495|Experimental|educational program+telephone follow up|Burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
3249830|NCT01379547|Active Comparator|Conventional Treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice
3363607|NCT03815006|Experimental|Free Style Libre device|At the start, a blood sample will be taken for the measurement of HbA1c. Training and education on the use of FSL will be provided by the research team. Participants will be advised to use flash glucose monitoring continuously for the next 24 weeks.
3363608|NCT03815006|No Intervention|Self-monitoring of blood glucose|At the start, a blood sample will be taken for the measurement of HbA1c. Masked FSL will be applied for two weeks, during the last two weeks of control period. Education will focus on using fingerstick measurement for treatment optimisation.
3363609|NCT03812614|Experimental|FAM ACT|"Patient and Support Person (dyad) will be included together as much as possible. The dyad will:~Take part in a one-hour introductory session and review of the patient's Diabetes Complications Risk Assessment profile.~Be invited to 4-6 Support Person-focused, group diabetes self-management education (DSME) sessions lasting 1-2 ½ hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
3363610|NCT03812614|Active Comparator|I-DSME + CM|"This arm will focus on the patient only. The Support Person assigned to this arm will not be invited to the introduction sessions, care management contacts, or diabetes self-management education sessions. Patients assigned to this arm will:~Take part in a one-hour introductory session and review of patient's diabetes management risk assessment.~Be invited to 4-6 group diabetes self-management education (DSME) sessions lasting 45 min to 2 hours each.~Receive case management contacts with a Community Health Worker (CHW) once every 2-4 weeks, subject to participant availability. Successful contacts will last approximately 20 minutes."
3249831|NCT01379547|Experimental|procalcitonin-guided antibiotics treatment|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin-guided algorithm.
3249832|NCT01379560|Experimental|unoprostone isopropyl (2 drop)|
3249833|NCT01379560|Experimental|unoprostone isopropyl (3 drop)|
3249834|NCT01379586|Experimental|E|ONO-4053
3249835|NCT01379586|Placebo Comparator|P|Placebo
3249836|NCT01379599|Experimental|Brief motivation intervention|Brief motivation intervention was implemented with enrollees identified with heroin and cocaine use who were allocated to the experimental group. The aim was to test the ability of a peer-delivered intervention to reduce risk of HIV and STIs related to sexual behaviors (condom use and sex while high on drugs.
3249837|NCT01379599|No Intervention|control group|Care as usual.
3249838|NCT01379612||Rectal cancer patients in chemoradiation|
3249839|NCT01379638||cardiac output|Adult patients undergoing cardiac surgery with normothermic cardiopulmonary bypass
3249840|NCT01379677|Other|Single arm|This is an Head to Head Comparison between Rubidium-82 PET and Tc-99m-MIBI SPET with CTA as gold standard. All the patients will undergo the three imaging protocols.
3249841|NCT01379690||Control|Controls were selected from patients with diabetes on consultation during the year 2005-2010 in specialist clinic, without a previous hip fracture. There was no followup period for these patients. Instead the A1C value upon the point of consultation was used to reflect glycaemic control at the point of consultation
3249842|NCT01379690||Case|All patients with treated diabetes admitted with primary diagnosis hip fractures from 2005-2010 to Changi General Hospital was included in the study. The A1C at the point of admission was used to reflect the glycaemic control at that point in time. This was a retrospective study and there was no subsequent follow up on patients after the point of admission
3249843|NCT01379729|Active Comparator|Group A|Patients with loss of long-term function after intraportal implantation
3249844|NCT01379729|Active Comparator|Group B|Patients that are candidates for islet cell transplantation
3249845|NCT01379742|Active Comparator|Iodine-125 standard 18 g needle|Rapidstrand
3249846|NCT01379742|Active Comparator|20 g needle|Thin Strand
3249847|NCT01379807|Experimental|panitumumab + docetaxel + cisplatino|
3363615|NCT03797261|Experimental|Venetoclax + AMG 176|Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
3249848|NCT01379833||Subjects|Subjects are patients with CIDP
3249849|NCT01379833||Controls|Controls are age-matched people without CIDP
3363616|NCT03789617|Experimental|EBViNT Cell|
3363618|NCT03776188||no groups - observational study|no groups - observational study
3249850|NCT01379846|Experimental|TAK-816|
3249851|NCT01379846|Active Comparator|ActHIB|
3363619|NCT03775954||1) Fetal Congenital Heart Disease|Pregnancy with major fetal congenital heart disease, after 20 weeks gestation, and as neonate following delivery. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
3363620|NCT03775954||2) History of fetal demise (Stillbirth)|Pregnancy with a history of an unexplained fetal demise (stillbirth at 20 -40 weeks gestation) during any prior pregnancy. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
3363621|NCT03775954||3) Fetal hydrops, immune or non-immune|Pregnancy with fetal hydrops, immune or non-immune, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
3363622|NCT03775954||4) Fetal gastroschisis|Pregnancy with fetal gastroschisis, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (nECG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
3363623|NCT03775954||5) Twin pregnancy, monochorionic|Twin pregnancy, monochorionic, with or without twin-twin transfusion syndrome, at or after 20 weeks gestation. Two fetal magnetocardiograms (fMCG) and 1 neonatal electrocardiogram (fMCG) will be obtained and heart rate, rhythm, and conduction patterns will be compared.
3363625|NCT03773666|Experimental|Durvalumab|-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
3363626|NCT03773666|Experimental|Durvalumab + Oleclumab|"Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle~Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle"
3363627|NCT03769116|Experimental|SRP-9001 in Part 1 Followed by Placebo in Part 2|Patient will receive SRP-9001 at Part 1 followed by matching Placebo at Part 2 followed by an open-label extension at Part 3.
3363628|NCT03769116|Experimental|Placebo in Part 1 Followed by SRP-9001 in Part 2|Patient will receive matching Placebo at Part 1 followed by SRP-9001 at Part 2 followed by an open-label extension at Part 3.
3363633|NCT03761849|Experimental|RO7234292 Q8W|RO4234292 is administered intrathecally every 8 weeks.
3363634|NCT03761849|Experimental|RO7234292 Q16W|RO7234292 is administered intrathecally every 16 weeks. Participants in this arm will also receive placebo at alternate weeks to keep the blind.
3363635|NCT03761849|Placebo Comparator|Placebo|Placebo will be administered every 8 weeks by IT injection.
3249852|NCT01379872||Study Protocol A - IMRT Post Prostatectomy|"Prospective TROG 08.03 (RAVES) Participants~Prospective Participants (NOT participating in TROG 08.03 (RAVES))~Retrospective TROG 08.03 (RAVES) Participants~Participating in dosimetric evaluation and toxicity/QoL study~Participating in dosimetric evaluation only"
3249853|NCT01379872||Study Protocol B - IMRT Anal Cancer|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)"
3249854|NCT01379872||Study Protocol C - IMRT Nasopharynx|"Retrospective Patient Datasets~Prospective Participants (dosimetric evaluation and toxicity/QoL study)~Post-Treatment Prospective Participants (toxicity/QoL and cost study)"
3363638|NCT03751124|Experimental|Relugolix plus E2/NETA|Relugolix 40 mg co-administered with estradiol (1.0 mg) and norethindrone acetate (0.5 mg) for up to 52 weeks.
3363639|NCT03751124|Placebo Comparator|Placebo tablets and capsules|"Placebo for relugolix co-administered with placebo for E2/NETA for up to 52 weeks or until heavy menstrual bleeding returns.~Retreatment with open-label relugolix with E2/NETA will be offered if heavy menstrual bleeding returns."
3363641|NCT03742102|Experimental|Arm 1|durvalumab + paclitaxel
3363642|NCT03742102|Experimental|Arm 2|durvalumab + paclitaxel + capivasertib
3363643|NCT03742102|Experimental|Arm 5|durvalumab + paclitaxel + oleclumab
3363644|NCT03742102|Experimental|Arm 6|durvalumab + trastuzumab deruxtecan
3249855|NCT01379872||Study Protocol D - IGRT Intact Prostate|"Patients with prostate cancer~- A sample of 30 patients from at least 10 centres that are to be treated for intermediate risk prostate cancer will be enrolled. The sample will be selected to comprise at least 10 patients that will undergo non-IGRT, 10 that will undergo IGRT with fiducials and planar imaging, and 10 that will undergo IGRT with volumetric imaging."
3249856|NCT01379885|Active Comparator|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
3249857|NCT01379885|Experimental|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
3249858|NCT01379898|Active Comparator|Phenoxybezamine|Phenoxybenzamine (capsules 10 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
3249859|NCT01379898|Active Comparator|Doxazosin|Phenoxybenzamine (slow release tablets 4 or 8 mg, once to twice daily) is administered orally, starting 2-3 weeks before planned resection of PCC.
3249860|NCT01379911|Active Comparator|Yogurt with added inulin|Yogurt with 6g of added inulin
3249861|NCT01379911|Placebo Comparator|Regular yogurt|Regular yogurt without added inulin
3249862|NCT01379950||periodontitis|patients diagnosed with periodontal disease
3249863|NCT01379976|Placebo Comparator|CHT cisplatin containing + placebo|
3249864|NCT01379976|Experimental|CHT cisplatin containing + acetyl-L-carnitina|
3249865|NCT01379989|Active Comparator|Carboplatin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/ m2 followed by carboplatin AUC 5.
3249866|NCT01379989|Experimental|Trabectedin plus PLD|Pegylated Lipoxomal Doxorubicin (PLD) 30 mg/m2 infusion followed by trabectedin 1.1 mg/m2 infusion.
3249867|NCT01380015|Placebo Comparator|Placebo Control|Participants will consume two cups of commercial spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 20 mg of rosmarinic acid per day) for a total of 4 months.
3249868|NCT01380015|Experimental|Experimental|Participants will consume two cups of a high rosmarinic acid spearmint tea per day (300 mL in the morning and 300 mL in the evening, providing a total of approximately 300 mg of rosmarinic acid per day) for a total of 4 months.
3249871|NCT01380054||patients with pulmonary hypertension|
3249872|NCT01380067||Group A|the patients were subjected laparoscopic purse-string knot for closing the internal hernia opening
3249873|NCT01380067||Group B|the lateral umbilicus ligament was used to cover the internal hernia opening after the laparoscopic purse-string knot
3249874|NCT01380119|Experimental|V7|Oral pill containing heat-killed Mycobacterium vaccae
3249875|NCT01380119|Placebo Comparator|Placebo pill|Identically appearing placebo pills
3249876|NCT01380132|Experimental|Anal injection of Nasha Dx|
3249877|NCT01380158|Experimental|Pessary use during pregnancy|Device: Cup pessary
3249878|NCT01380158|No Intervention|Expectant management|Expectant Management + weekly intramuscular progesterone injections
3249879|NCT01380171||Cleft lip/palate|Patients who have had surgical intervention for cleft lip/palate since 1998 at Children's Healthcare of Atlanta at the Center for Craniofacial Disorders
3249880|NCT01380223|Experimental|Dose-escalation Cohort 1|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3249881|NCT01380223|Experimental|Dose-escalation Cohort 2|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3249882|NCT01380223|Experimental|Dose-escalation Cohort 3|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3249883|NCT01380223|Experimental|Dose-escalation Cohort 4|4 treatment periods consisting of a 2 hour placebo infusion (single blind) followed by a 6 hour infusion of study drug or placebo. Each subject will receive 3 active ascending doses of study drug and 1 dose of placebo randomized into the sequence of escalating doses in a double-blind manner. Treatment periods occur at least 7 days apart.
3363645|NCT03742102|Experimental|Arm 7|durvalumab + datopotamab deruxtecan
3363650|NCT03737851|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
3363651|NCT03737851|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
3363652|NCT03737851|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
3363653|NCT03735667|Experimental|ACURATE Valve - Randomized|"Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.~*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy."
3249884|NCT01380249|Experimental|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12 mg, 2.24 mg, 3.5 mg and 14 mg, 28 mg and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or the patient is refractory to it.
3363654|NCT03735667|Experimental|ACURATE Valve - Single-arm Roll-in|Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.
3363655|NCT03735667|Active Comparator|Commercial Valve - Randomized|"Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System~Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.~*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy."
3363658|NCT03731247|Experimental|OCTAV Patient|The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
3363659|NCT03731247|Experimental|OCTAV Control group|Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
3363660|NCT03731234|Experimental|Ibrutinib+R-CHOP|Screening phase for selection of Activated-B-Cell (ABC)-DLBCL Induction phase: R-CHOP21 x 5 cycles in combination with ibrutinib Maintenance phase: maintenance with Ibrutinib for 18 months for patients responding to the induction phase (CR or PR)
3363663|NCT03720730|Experimental|Study participants|Patients with a recent history of suicidal crisis (within the last 7 days) will use a smartphone application to evaluate sleep, appetite and social parameters.
3363664|NCT03719924|Experimental|arm A: ONIVYDE|ONIVYDE ONIVYDE will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14 ONIVYDE: 80 mg/m² intravenous over 90 minutes Folinic acid: 400 mg/m² intravenous over 30 minutes or L-folinic acid (racemic form L) 200 mg/m² over 30 minutes 5-FU: 2400 mg/m² over 46 hours
3363665|NCT03719924|Active Comparator|Arm B: TAXOL|TAXOL Premedication consists of corticosteroids, H1 antihistamines and H2 antagonists during 30 minutes at time 1 hour before chemotherapy One cycle every 28 days (D1=D28) 80 mg/m2 IV over 60 minutes at D1, D8 and D15
3363668|NCT03717402|Other|Intervention Participants|Patients with advances cancer using opioids for chronic pain will be enrolled and asked to use the STAMP cancer pain management app for 4 weeks.
3363675|NCT03686306|Experimental|Experimental group|Sildenafil citrate 140 mg/day (single morning oral dose of 140 mg) for a total duration of 24 weeks.
3363676|NCT03686306|Placebo Comparator|Control group|Placebo (single morning oral dose) for a total duration of 24 weeks.
3363679|NCT03661840|Experimental|Acceptance and Commitment Therapy|Participants will receive both the ACT intervention and medication management that is given as usual treatment.
3363680|NCT03661840|Active Comparator|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management.
3363681|NCT03661138|Experimental|Arm A|Upadacitinib Dose A is administered once daily along with Topical Corticosteroids (TCS).
3363682|NCT03661138|Experimental|Arm B|Upadacitinib Dose B is administered once daily along with Topical Corticosteroids (TCS).
3363683|NCT03661138|Experimental|Arm C|Placebo administered once daily and TCS followed by Upadacitinib Dose A once daily along with TCS.
3363684|NCT03661138|Experimental|Arm D|Placebo administered once daily and TCS followed by Upadacitinib Dose B once daily along with TCS.
3363685|NCT03655782|Experimental|PATH neurotraining|Subject looks at computer screen to determine whether dim gray stripes in fish-shaped window move left or right relative to stationary background stripes. The subject reports which way center stripes move by pushing left or right arrow key, receiving brief tone if incorrect. Program adaptively changes contrast of test pattern in order to keep subject at 79% correct. There are levels of difficulty introduced by making the background pattern more similar to that in fish, by increasing pattern's complexity level, and by increasing number of directions of movement from one to two directions of motion. Intervention will be trained for one training cycle, 15 minutes, 3 times each week for 16 weeks. Fifteen minutes of working memory practice, recalling the correct sequence of digits, each presented for 500 msec, from 5 digits up to 10 digits will be completed for 15 minutes following PATH training.
3363686|NCT03655782|Sham Comparator|Orientation Discrimination training|The sham treatment will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings, see patterns in Fig. 4 below. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key component of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
3363687|NCT03655782|Experimental|N-Back Working Memory Task|Participants are required to compare each item on a computer screen to the item that they saw n-items back in the sequence. The participant plays a simple game where they control the movement of an astronaut that needs to collect correct gems, avoid incorrect gems, and also obstacles, to succeed at the game. If the participants performs well then they can be advanced to the 2-back, 3-back, 4-back, etc where they make similar matches but to earlier items in the sequence. This gamified task consists of a color n-back with 6 colors (a new color every 3 seconds, requiring subjects respond to targets by tapping the screen and navigating the astronaut to the targets, and avoiding the distractors) with 30% targets, and where the n-level will change every 2 minutes depending on performance (increase if performance is >85% and decrease if <75%). Sessions consist of 10 ~2 minute blocks, each with n-level as determined by the adaptive procedure and with user paced breaks between blocks.
3249885|NCT01380262||Low Dose Doxycycline|Patients with metastatic colorectal cancer, qualified to either cetuximab or panitumumab based systemic treatment (either monotherapy or with chemotherapy) receiving a 100 mg of doxycycline daily
3259442|NCT01470833|No Intervention|Non-weight-bearing|"The group of non-weightbearing is instructed as follows:~Week 1 to 6 No weightbearing. Crutches are obligatory. Week 7 to 8 Full weightbearing is allowed.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
3363689|NCT03646123|Experimental|Part A: A+AVD|Brentuximab vedotin (A) plus doxorubicin (+A), vinblastine (V), and dacarbazine (D) administered by intravenous (IV) infusion in participants with advanced stage classical Hodgkin lymphoma (cHL) during each treatment cycle.
3363690|NCT03646123|Experimental|Part B: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage II bulky mediastinal disease and Stage III or IV cHL during each treatment cycle.
3363691|NCT03646123|Experimental|Part C: AN+AD|Brentuximab vedotin (A) plus nivolumab (N), doxorubicin (+A), and dacarbazine (D) administered separately by IV infusion in participants with Stage I or II cHL with non-bulky mediastinal disease during each treatment cycle.
3363692|NCT03641560|Experimental|Enzalutamide group|Participants will receive Enzalutamide once daily in addition to continued androgen deprivation therapy until discontinuation criteria is met
3363693|NCT03631199|Experimental|canakinumab|canakinumab in combination with pembrolizumab and platinum-based doublet chemotherapy
3363694|NCT03631199|Other|canakinumab matching-placebo|canakinumab matching-placebo in combination with pembrolizumab and platinum-based doublet chemotherapy
3363697|NCT03621774|Experimental|Mobile-assisted CBT-informed Skills Training|Psychosocial intervention combining in-person and smartphone-based CBT-informed skills training for experiential negative symptoms in schizophrenia, called Mobile-assisted Cognitive-Behavioral Therapy for Negative symptoms (mCBTn).
3363698|NCT03621774|Placebo Comparator|Supportive Contact|An active group leader- and device-contact control group.
3363699|NCT03621397|Experimental|Cognitive Intervention Group|Research participants in the cognitive intervention group will undergo a baseline neuropsychological evaluation. One week later, they will receive the online training program (brainHQ by Posit Science) three times a week for 45 minutes for a total of 12 weeks. This group will return one week after completing the online intervention program for their follow-up neuropsychological evaluation. They will then return again one year later for another follow-up neuropsychological evaluation.
3363700|NCT03621397|No Intervention|Control Group|Research participants in the control group will undergo a baseline neuropsychological evaluation. They will then return 13 weeks after their baseline neuropsychological evaluation for a follow-up neuropsychological evaluation and again one year later.
3363701|NCT03620903|Experimental|Bortezomib-Rituximab-Ibrutinib|"Cycle 1:~Rituximab: 375 mg/m2 intravenously (i.v) day 1; Bortezomib:1.6 mg/ m2 subcutanously (SC) day 1,8,15; Ibrutinib: 420 mg orally (p.o.) day 1-28;~Cycle 2-6 Rituximab: 1400 mg absolute SC day 1; Bortezomib:1.6 mg/ m2 SC day 1,8,15; Ibrutinib: 420 mg p.o. day 1-28;~Maintenance I (1 cycle = 56 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years); Rituximab 1400 mg absolute SC day 1, every second month for 24 months (month 7-30);~Maintenance II (1 cycle = 84 days):~Ibrutinib 420 mg p.o. daily, until evidence of progressive disease or no longer tolerated by the subject (for a maximum of 10 years);"
3363702|NCT03602521|Experimental|BPD|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of patients with a BPD
3363703|NCT03602521|Active Comparator|HC|Blood sample After simulating an interpersonal stress, the evolution of plasma neuropeptides level (OXT, vasopressin and opioid) of healthy controls (HC) patients .without any history of psychopathology
3363704|NCT03598114|Experimental|Program Sustainability Training|"Selected publicly funded tobacco control programs receive the intervention in the form of custom training curricula designed to identify and enable sustainable tobacco control programming at a state-organizational level. Sustainability is assessed at t=12 months and 1=24 months to capture potential impact of the training and curricula.~The intervention group will receive a follow-up survey inviting them to evaluate the training and their progress on executing their sustainability plan. The intervention group will also receive a follow-up survey inviting them to evaluate the technical assistance they have received from the research team. Responses on neither follow-up survey impact participants standing in the study"
3363705|NCT03598114|No Intervention|Control Condition|"In this condition, publicly funded tobacco control programs do not receive the designated program sustainability training and proceed with standard operations. Sustainability is assessed at t=12 months and t=24 months to compare against tobacco control programs receiving sustainability training~The control group will receive a follow-up survey inviting them to evaluate their progress on creating their sustainability plan. Responses on the follow-up survey do not impact participants' standing in the study"
3363706|NCT03589976|Experimental|Sirolimus|2 mg/day (one 2-mg tablet/day). The dose of sirolimus will be adjusted throughout the trial based on sirolimus plasma levels and the presence of drug-related adverse events. The maximum dose of sirolimus will be6 mg/day (three 2-mg tablets/day).
3363707|NCT03589976|Placebo Comparator|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
3363708|NCT03586596|Experimental|The Decídetext program|Participants will receive a tablet-based interactive educational session, 6 months of text-messaging based counseling, which includes prompts to access free pharmacotherapy.
3363709|NCT03586596|Active Comparator|Standard Care Control|Participants will receive an adapted version of standard printed smoking cessation educational materials from the American Cancer Society and, the National Cancer Institute, which include information about the health risks of smoking, benefits & strategies for quitting and access to free pharmacotherapy by calling a free number.
3249886|NCT01380275|Experimental|Docetaxel and Irinotecan (DI)|"Combination chemotherapy of Docetaxel and Irinotecan (DI) in recurrent or refractory bone and soft tissue sarcomas.~Docetaxel and Irinotecan (DI) have different biologic targets, mode of action and mechanism of resistance. Preclinical studies have demonstrated an additive or synergistic effect of irinotecan and taxanes when used in combination in human.~Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1 Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8 Therapy consists of 3-week cycles comprising weekly treatment for 2 weeks (docetaxel on D1 and irinotecan on D1 and D8) followed by 1-week rest, and will be continued in the absence of disease progression or unacceptable toxicity."
3249887|NCT01380288|Active Comparator|without white matter change|
3363710|NCT03579615|Experimental|FIASP + closed loop device|Subjects randomised to FIASP and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using FIASP + closed loop intervention for 24 hours. Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
3363711|NCT03579615|Active Comparator|Insulin aspart (standard of care insulin) + closed loop device|Subjects randomised to insulin aspart (standard of care insulin) and closed loop device will be invited to have blood samples taken at baseline, CGM training, competency assessment, and optimisation of treatment. This is followed by inpatient stay where patients will be using insulin aspart (standard of care insulin) + closed loop intervention for 24 hours.Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
3363712|NCT03555422|Experimental|Selinexor|Participants will receive fixed dose of selinexor 80 mg (or 60 mg for participants with a body mass index [BMI] less than [<] 20 kilogram per meter square [kg/m^2]) oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
3363713|NCT03555422|Placebo Comparator|Matching placebo for selinexor|Participants will receive matching placebo for selinexor oral tablets QW on Days 1, 8, 15, and 22 of each 28-day cycle.
3249888|NCT01380288|Active Comparator|with white matter change group|
3249889|NCT01380301|Experimental|Miltefosine and Antimony|Miltefosine 1,5 to 2,5 mg x k x d during 14 days simultaneously with meglumine antimoniate 20 mg x kg x d during 10 days
3249890|NCT01380301|Active Comparator|Miltefosine alone|Miltefosine 1,5 to 2,5 mg x kg x d during 14 days
3363714|NCT03541369|Experimental|Dose Escalation Phase|AMG 427 Dose-finding phase of the study
3363715|NCT03541369|Experimental|Dose Expansion Phase|AMG 427 MTD identified in dose escalation phase (or lower) will be administered to subjects.
3363716|NCT03539744|Experimental|Arm 1 VenDex|Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
3249891|NCT01380314|Experimental|1|Miltefosine 150 mg x day + Imiquimod 5%
3249892|NCT01380314|Placebo Comparator|2|Miltefosine 150 mg x day + Placebo
3363717|NCT03539744|Active Comparator|Arm 2 PomDex|Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.
3363718|NCT03532256||Treated Patients|This prospective, observational study includes adult patients (age ≥18) undergoing elective surgical procedures within the departments of orthopedics, sports medicine, and neurosurgery, as well as patients treated for an acute injury and prescribed an opioid from the ED who own a mobile phone and can receive SMS text messaging at the University of Pennsylvania or Penn Presbyterian Medical Center.
3363719|NCT03532256||Treated patients randomized to receive survey|A subset of patients (described above) will receive an automated SMS text message with a link to an online survey. This survey contains the script questions about pain management and opioid use.
3363720|NCT03532256||Treated patients randomized to receive text script|A subset of patients (described above) will receive an automated questionnaire conducted via text message. Questions will be about pain management and opioid use.
3363721|NCT03532139|Experimental|Enoxaparin|-Enoxaparin is administered subcutaneous daily
3363722|NCT03532139|Experimental|Enoxaparin + Rosuvastatin|"Enoxaparin is administered subcutaneous daily.~Rosuvastatin is administered daily orally starting on day 15"
3363723|NCT03532139|Experimental|Thromboprophylaxis|-Thromboprophylaxis is administered per clinician discretion
3363724|NCT03517449|Experimental|Lenvatinib 20 mg + Pembrolizumab 200 mg|Participants will receive pembrolizumab 200 milligram (mg) administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus lenvatinib 20 mg administered orally (PO) once daily (QD) during each 21-day cycle for up to 35 cycles.
3363725|NCT03517449|Active Comparator|Treatment of Physician's Choice|Participants will receive either of the following treatments: doxorubicin 60 milligram per square meter (mg/m^2) administered by IV on Day 1 of each 21-day cycle for up to a maximum cumulative dose of 500 mg/m^2 OR paclitaxel 80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
3363726|NCT03504826|Experimental|Locomotor training using adaptive robot|The intervention will consist of 60 sessions of locomotor training using the HAL adaptive robot. The training sessions will be scheduled 5 days per week for 12 weeks. A physical therapist with expertise in SCI walking rehabilitation and use of the HAL will oversee all intervention sessions. The intervention sessions will include up to a total of 40 minutes of stepping time, which may take up to 2 hours to complete due to set up time and rest breaks.
3249893|NCT01380340|Experimental|Seniors early intervention driving group|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
3249894|NCT01380340|No Intervention|Matched comparison group|The subjects will be recruited from a parallel service and will be paired with similar subjects in the experimental group.
3249895|NCT01380353|Experimental|Breast Group|Diclofenac epolamine patch applied to the breast
3249896|NCT01380353|Experimental|Abdomen Group|Diclofenac epolamine patch applied to the abdomen
3249897|NCT01380405|No Intervention|without health education|the normal practices without specific intervention
3249898|NCT01380405|Experimental|individual health education|"The study intervention is an individual education in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. The lesson included inhalation devices, explanatory leaflets"
3363730|NCT03496012|Experimental|BIIB111 High Dose|Participants will receive a single administration of high dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
3363731|NCT03496012|Experimental|BIIB111 Low Dose|Participants will receive a single administration of low dose BIIB111 in one eye through sub-retinal injection after vitrectomy.
3363732|NCT03496012|No Intervention|Untreated Control Group|Participants will receive no sham surgery or study medication.
3259443|NCT01470833|Experimental|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weightbearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weightbearing is allowed. Week 5 to 8 Full weightbearing is allowed. Crutches should be avoided."
3259444|NCT01470846|Experimental|APD|patient with epidural analgesia
3259445|NCT01470846|Active Comparator|PCA|Patient with morphine analgesia
3259446|NCT01470885||glucose value|glucose value
3249899|NCT01380405|Experimental|health education group|"The study intervention is education in group in the correct use of inhalers and it will be carried out in so-called inhalation workshops. The room in which the inhalation workshop will be located has to meet the necessary comfort conditions for the patient to feel relaxed and be able to carry out learning. In addition to the necessary furniture and teaching material that will be required (slide projector, over-head-projector, projection screen, video, etc.), the physical space given over to this purpose should consist of an area in which material can be left which will be used to complete the teaching and patient information (inhalation devices, explanatory leaflets, small monographs, slides, etc.)."
3363742|NCT03475953|Experimental|Phase 1 : Regorafenib + Avelumab|Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363743|NCT03475953|Experimental|Phase 2 : cohort A Regorafenib + Avelumab|Treatment by Avelumab + Regorafenib Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363744|NCT03475953|Experimental|Phase 2 : cohort B Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363745|NCT03475953|Experimental|Phase 2 : cohort C Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363746|NCT03475953|Experimental|Phase 2 : cohort D Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363747|NCT03475953|Experimental|Phase 2 : cohort E Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363748|NCT03475953|Experimental|Phase 2 : cohort F Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363749|NCT03475953|Experimental|Phase 2 : cohort G Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363750|NCT03475953|Experimental|Phase 2 : cohort H Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363751|NCT03475953|Experimental|Phase 2 : cohort I Regorafenib + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363752|NCT03475953|Experimental|Phase 2 : cohort A' Regorafenib low-dose + Avelumab|Treatment by Avelumab will be administrated by intravenous 1-hour infusion every 2 weeks starting at Cycle 1 Day 15. Regorafenib will be taken orally once daily for three weeks on/ one week off.
3363754|NCT03464045||type 2 diabetes patients|
3249900|NCT01380418||Study group|Obese BMI>30 18-85 years old
3249901|NCT01380431|Experimental|A|Subjects received the Par formulated product.
3249902|NCT01380431|Active Comparator|B|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3249903|NCT01380431|Active Comparator|C|Subjects received the IPR (Zeneca Pharmaceuticals) formulated product.
3249904|NCT01380444|Active Comparator|1|Gamma3 Intramedullary Nails
3249905|NCT01380444|Active Comparator|2|Sliding Hip Screws
3249906|NCT01380457|Experimental|A|Subjects received the test formulated product manufactured by Pharmaceutics International, Inc. and marketed by Par Pharmaceutical, Inc. under fasting conditions
3249907|NCT01380457|Active Comparator|B|Subjects received the reference listed drug manufactured by Banner Pharmacaps, Inc. and marketed by Unimed Pharmaceutical, Inc.
3249908|NCT01380470||Chronic Obstructive Pulmonary Disease|Group of patients seen in consultation not previously diagnosed with COPD, both sexes, aged between 40 and 70 years.
3249909|NCT01380483|Experimental|A|Subjects received the Par formulated product
3249910|NCT01380483|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals formulated product.
3249911|NCT01380496|Active Comparator|B|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
3249912|NCT01380496|Active Comparator|C|Subjects received the Oclassen Pharmaceuticals Inc. formulated product.
3249913|NCT01380496|Experimental|A|Subjects received the Par formulated product
3249914|NCT01380509|Experimental|A|Subjects received kali product under fasting conditions
3249915|NCT01380509|Active Comparator|B|Subjects received Searle product under fasting conditions
3249916|NCT01380522|Experimental|A|Subjects received kali product under fed conditions
3249917|NCT01380522|Active Comparator|B|Subjects received Searle product under fed conditions
3249918|NCT01380548|Placebo Comparator|Placebo|
3249919|NCT01380548|Placebo Comparator|Iron alone|
3249920|NCT01380548|Experimental|Low-dose 5-aminolevulinic acid|
3249921|NCT01380548|Experimental|Medium-dose 5-aminolevulinic acid|
3363755|NCT03447574|Experimental|Aim 1|The ethanol dilution is, in essence, a non-invasive dilution method. It is of interest because of how ethanol readily dissolves itself exclusively into the water space of the body[4], is non-toxic in reasonable concentrations, is metabolized in a 0th order reaction above concentrations of 0.015 g/dL[4], and there are non-invasive methods for determining blood alcohol concentration[5, 6]. Thus, by drinking a known amount of ethanol, total body water can be calculated after a few hours of periodic breathalyzer analyses. Ethanol has been validated against deuterium oxide, the invasive gold standard for determining total body water[4]. The ethanol dose will be 0.5g/kg body weight.
3249922|NCT01380548|Experimental|High-dose 5-aminolevulinic acid|
3363756|NCT03447574|Active Comparator|Aim 2|30mL/kg body weight of saline will be rapidly infused after the baseline measurements completed in Aim 1. Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated. To determine if non-invasive fluid volume techniques can accurately determine fluid changes in healthy participants.Non-invasive methods for fluid volume determination (CO-pulse-oximetry, ethanol breathalyzer, BIS) will be conducted and change from baseline calculated.
3363757|NCT03447041||the keratoplasty group|Patients with limbal dermoid who accepted cornea transplantation surgery after 1 year were performed quick CSF from Adaptive Sensory Technology company
3363758|NCT03447041||the normal group|normal children without ocular disease
3363759|NCT03440853|Experimental|TASCCI|Patients randomized to TASCCI will receive a stepped-care approach of pharmaco and/or behavioral therapy for 12 weeks. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference.
3363760|NCT03440853|Other|Technology Delivered Health Education|Patients randomized to the Technology Delivered Health Education Intervention health education group will receive technology delivered health education material on topics relevant to dialysis.
3363761|NCT03434301|Active Comparator|Mesh with absorbable tack fixation|Mesh with absorbable tack (ReliaTack™) fixation
3363762|NCT03434301|Active Comparator|Mesh with non-absorbable fixation|Mesh with non-absorbable (Protack™) fixation
3363763|NCT03421353|Experimental|Arm A1|Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every four weeks (Q4W). There will be a 1 week AZD9150 lead-in prior to durvalumab dosing.
3363764|NCT03421353|Experimental|Arm A2|Patients will receive AZD9150 once weekly (QW) + durvalumab every three weeks (Q3W) + Cisplatin on Day 1 + 5-flourouracil (5-FU) on Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
3363765|NCT03421353|Experimental|Arm A3|Depending on the results of Arm A2, Arm A3 may not be conducted. If Arm A3 is conducted, patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + cisplatin on Day 1 + 5-flourouracil (5-FU) over Days 1 to 4. This regimen will be repeated every 3 weeks for up to 18 weeks. There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
3363766|NCT03421353|Experimental|Arm A4|"Patients will receive AZD9150 every two weeks (Q2W) + durvalumab every three weeks (Q3W) + gemcitabine on Days 1 and 8. This regimen will be repeated every 3 weeks. In addition, the following will be added to the regimen:~For cisplatin-eligible patients: cisplatin on Day 1 (every 3 weeks for up to 12-18 weeks); or~For cisplatin ineligible patients: carboplatin on Day 1 and Day 8 (every 3 weeks for up to 12-18 weeks).~There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing."
3363767|NCT03421353|Experimental|Arm A5|Patients will receive AZD9150 every two weeks (Q2W) plus durvalumab every three weeks (Q3W) plus carboplatin on Day 1 plus nab-paclitaxel on Days 1, 8, and 15 (every 3 weeks for up to 12-18 weeks). There will be a 1 week AZD9150 + chemotherapy lead-in prior to durvalumab dosing.
3363768|NCT03421353|Experimental|Arm D: AZD9150 SC|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
3249923|NCT01380561|Experimental|Single Arm Study|asimadoline
3249924|NCT01380587||Acute Lymphoblastic Leukemia|We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
3363769|NCT03421353|Experimental|Arm D: AZD9150 IV|Part D will compare the single and steady state pharmacokinetics of AZD9150 given subcutaneously (SC) QW to AZD9150 given by IV QW in combination with durvalumab 1500 mg Q4W. Patients will be randomly assigned to either SC or IV AZD9150.
3249925|NCT01380600|Other|single arm; Dose escalation|Dose escalation 1e6 pfu/kg bw, 1e7 pfu/kg bw, 3e7 pfu/kg bw of Recombinant Vaccinia GM-CSF JX-594
3249926|NCT01380613|Active Comparator|Workshop Control|Participants receive HIV/STDs risk reduction information.
3249927|NCT01380613|Experimental|Intervention Workshop|Participants learn skills to cope with depressive symptoms and stress as well as safer sex and injection skills.
3363770|NCT03419871||monitoring sleep effects on toddlers|Monitoring the sleep characteristics of toddlers living in economically stressed communities.
3363771|NCT03418701|Active Comparator|Patient Centered Culturally Sensitive WLM|This program is designed to enable physicians to: (a) talk with their patients about their weight, weight loss goals, goal barriers, strategies for overcoming these barriers, and deliver this talk in patient-centered, culturally sensitive ways, (b) assist their patients with engaging in self-identified strategies for achieving and sustaining their self selected goals for weight loss and overall health, (c) be knowledgeable about health-smart behaviors, (d) use behaviors and display attitudes in physician-patient interactions with patients that are provider cultural sensitivity indicators in published literature, and (e) say and display behaviors and attitudes that patients identified as important when discussing obesity and losing weight.
3249928|NCT01380626|Experimental|exercise training|
3249929|NCT01380652|Experimental|rehabilitation with vibration training|
3249930|NCT01380652|No Intervention|rehabilitation without vibration training|
3249931|NCT01380665|Other|There is one group of 100 patients|50 of these patients will receive a total hip replacement; 50 patients will receive a total knee replacement;
3363772|NCT03418701|Active Comparator|Standard Behavioral WLM|This program is designed to enable physicians to: (a) implement motivational interviewing approaches when talking with their patients about their weight loss goals and behavioral strategies to achieve these goals, (b) become knowledgeable about empirically supported behavioral change principles that have been used to help patients maintain weight loss in previous interventions, (c) communicate how to use these empirically supported behavioral change principles to have patients initiate or maintain their self-selected health-smart goals related to weight loss and/or weight loss maintenance, and (d) use motivational interviewing approaches to communicate empathy and understanding with patients who are struggling to maintain their weight loss and/or accomplish a behavioral goal.
3363773|NCT03413735|Placebo Comparator|Placebo Confection|Confection without green tea extract consumed daily for 4 weeks
3363774|NCT03413735|Experimental|Green Tea Extract-Confection|Confection with green tea extract consumed daily for 4 weeks
3363778|NCT03401190|Experimental|Low Dose Group|Phase 1: Cohorts 1 & 2 will consist of 4 female and 4 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 1.0 mg/kg on Days 1 and 1.4 mg/kg on Days 2-4.
3363779|NCT03401190|Experimental|High Dose Group|Phase 2: Cohorts 3 & 4 will consist of 8 female and 8 male patients enrolled concurrently who will be randomized 3:1 to receive CM4620-IE plus standard of care versus standard of care alone. Planned doses for patients who are randomized to receive CM4620-IE are 2.08 mg/kg of CM4620-IE on Days 1 and 2, and 1.6 mg/kg on Days 3 and 4.
3363780|NCT03401190|No Intervention|Standard of Care|For all cohorts, patients will be randomized 3:1 to CM4620-IE plus standard of care versus standard of care alone.
3249932|NCT01380678|Active Comparator|bevacizumab|intralesional bevacizumab injection
3249933|NCT01380678|Active Comparator|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
3363796|NCT03392753|Active Comparator|Mechanochemical ablation (MOCA)|Mechanochemical ablation using the ClariVein® mechanochemical ablation (MOCA) device (Vascular Insights, Madison, CT, USA).
3363797|NCT03392753|Active Comparator|Cyanoacrylate adhesive (CAE)|Cyanoacrylate using the VenaSealTM Closure System (Medtronic, Minneapolis, Minnesota, USA).
3249934|NCT01380704|Experimental|Active|
3249935|NCT01380704|Placebo Comparator|Placebo|
3363798|NCT03380273|No Intervention|pre-intervention|The number of SSI are collected in this phase. Patients with fractures are enrolled and their standard of care treatment is observed.
3363799|NCT03380273|Other|post-intervention|Here the same observations are made as in the first arm, however this is after the hospital staff was thought the prevention measures (all by themselves approved) and enforced to be applied.
3363800|NCT03373084||hamstring muscle lesions|Patients with hamstring muscle lesions in sport will be included. As usual practice they will have Magnetic Resonance Imaging (MRI) or ultrasound, and will answer to self-questionnaire
3363801|NCT03368729|Experimental|Phase 1: Niraparib 200 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this first arm will receive 200 mg Niraparib in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
3363802|NCT03368729|Experimental|Phase 1: Niraparib 100 mg + Trastuzumab 6 mg/kg|In phase 1 patients in this second arm will receive Niraparib 100 mg in combination with 6 mg/kg Trastuzumab given IV every 3 weeks.
3249936|NCT01380717|Active Comparator|Standard treatment|Patients with CKD 3-4, hypertension, treated for 18 months with beta-blocker and if needed ACE-inhibitor or ARB.
3249937|NCT01380717|Active Comparator|Intensive vasodilation|Patients with CKD 3-4 and hypertension, randomized to treatment with calcium channel blocker and if needed ACE-inhibitor or ARB for 18 months
3363803|NCT03368729|Experimental|Phase 2: Niraparib 200 mg or 100 mg + Trastuzumab 6 mg/kg|The dosage of Niraparib in phase 2 will be determined by the response of patients in Phase 1. A dosage of Niraparib 200 mg will be given along with Trastuzumab 6 mg/kg IV unless a dose limiting toxicity occurs in Phase 1. If so, Niraparib 100 mg will be given with Trastuzumab 6 mg/kg (instead of Niraparib 200 mg).
3249938|NCT01380756|Experimental|Arm 1- Dose Escalation|The dose escalation will be conducted in 2 parts. Group 1 will consist of 8 cohorts and Group 2 will consist of 5 cohorts. The dose escalation is aimed at determining the maximum tolerated dose (MTD) of AMG 900.
3249939|NCT01380756|Experimental|Arm 2- Dose Expansion|The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 20 subjects with acute myelogenous leukemia.
3249940|NCT01380795|Other|Circulating Tumor Cell|blood sample CTC monitoring and CTC EGFR/K-ras status determination
3249941|NCT01380808|Experimental|experimental arm|capecitabine and pseudomonas aeruginosa combination
3363808|NCT03356106|Experimental|CPAP|Nocturnal administration of continuous positive airway pressure treatment (CPAP) until delivery
3363809|NCT03356106|No Intervention|Control|Usual antenatal care for high risk pregnancy
3363810|NCT03344341|Experimental|Dapagliflozin|Dapagliflozin is started from 5 mg once a day, taken orally in the morning, before or after breakfast. From the third week, the dose will be increased to 10 mg once a day and last to the end of the study.
3249942|NCT01380821||SPECT|Patients clinically indicated to undergo myocardial SPECT in our institution.
3249943|NCT01380847||Renal allograft nephropathy|To evaluate urine from KTRs during the first year post-transplantation to assess whether mRNA levels of genes involved in EMT/fibrogenesis can diagnose and predict CAN, and identify patients at risk of chronic allograft dysfunction
3363811|NCT03344341|Active Comparator|Acarbose|Acarbose is started from 50 mg once a day at dinner during the first week, titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
3363812|NCT03336931||High-risk childhood cancers|Expected survival < 30%
3363813|NCT03336216|Active Comparator|Arm A|"Investigator choice of chemotherapy:~Gemcitabine/Nab-Paclitaxel (Abraxane®) or 5-Fluorouracil/Leucovorin/Irinotecan Liposome (ONIVYDE)"
3363814|NCT03336216|Experimental|Arm B|Cabiralizumab Q2W + Nivolumab Q4W
3363815|NCT03336216|Experimental|Arm C|Cabiralizumab Q2W + Nivolumab Q4W and Gemcitabine + Nab-Paclitaxel (Abraxane®) D1, 8 and 15 Q4W
3249944|NCT01380860|Experimental|Mesh|The patients allocated to this arm of the study will have mesh (Covidien France: mono filament polyester bidimensional knit) implanted in association with their colostomy.
3249945|NCT01380860|Active Comparator|No mesh|The patients allocated to this arm of the protocol will not receive mesh implantation with their colostomy.
3249946|NCT01380873|Experimental|Group1|
3249947|NCT01380873|Experimental|Group2|
3249948|NCT01380873|Experimental|Group3|
3249949|NCT01380886|Experimental|Infant formula, alternate protein source|Experimental infant formula with alternate protein source
3249950|NCT01380886|Active Comparator|Infant formula powder|Infant formula powder
3249951|NCT01380912||breast cancer|"Patients operated with mastectomy and axillary dissection, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and axillary dissection, who are randomised to injection of saline solution in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of methylprednisoloneacetate in the cavity~Patients operated with mastectomy and Sentinel Node Operation, who are randomised to injection of saline solution in the cavity"
3363816|NCT03336216|Experimental|Arm D|Cabiralizumab Q2W + Nivolumab Q4W and Oxaliplatin/5-Flurouracil/Leucovorin (FOLFOX) Q2W
3363817|NCT03334435|Experimental|Baricitinib High Dose Nonresponders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363818|NCT03334435|Experimental|Baricitinib High Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363819|NCT03334435|Experimental|Baricitinib Mid Dose Nonresponders Rescued|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363820|NCT03334435|Experimental|Baricitinib High Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363821|NCT03334435|Experimental|Baricitinib Mid Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363822|NCT03334435|Experimental|Baricitinib Low Dose Responders|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3363823|NCT03334435|Placebo Comparator|Placebo Responders|Placebo administered orally.
3363824|NCT03334435|Experimental|Baricitinib Open Label Extension|Baricitinib administered orally.
3363825|NCT03331731|Experimental|Single arm|Single Arm
3249952|NCT01380938|No Intervention|Arm C. Standard duration|"Patients will be randomly assigned in 3:3:1 ratio to three treatment arms. In the standard treatment group (Arm C), patients will be treated for 24 weeks independently of the HCV RNA status at week 4 with Peginterferon alpha-2a at a dose of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients enrolled in Arm C will be treated for standard 24 weeks duration of treatment."
3249953|NCT01380938|Experimental|Arm A|"Patients enrolled in Arm A will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 1000 mg/day for patients with a body weight < 75 kg or 1200 mg/day for those with a body weight > 75 kg.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm A), whereas those without RVR will be treated for 24 weeks (Arm A)"
3363831|NCT03289702|Experimental|CORETOX®|
3363832|NCT03289702|Active Comparator|BOTOX®|
3363833|NCT03285152|Experimental|Ketogenic Diet (KD)|The KD cohort will receive a rotating 7 day meal plan prepared by the Clinical Translational Science Center (CTSC) at Weill Cornell Medical Center (WCMC) with weekly food pick-up. The meal plan will provide a 3:1 fat to net carbohydrate ratio and calories for weight maintenance (30kcals /kg for a BMI< 30kg/ m2 and 25 kcal/kg for a BMI.30 kg/ m2.
3249954|NCT01380938|Experimental|Arm B|"Patients enrolled in Arm B will receive Peginterferon alpha-2a at a dosage of 180 mcg weekly in combination with oral ribavirin administered at a dosage of 800 mg/day.~Patients with week 4 viral clearance (labelled as rapid virological responders, RVR) will be allocated to 12 week treatment duration (Arm B), whereas those without RVR will be treated for 48 weeks (Arm B)"
3249955|NCT01380951|Experimental|telbivudine|
3363834|NCT03285152|Active Comparator|Standard Diet (SD)|Patients randomized to the SD group will consume their normal diet plan. They will meet with the dietitian from the CTSC at WCMC weekly and receive standard nutritional counseling from the CTSC. Average intake will be documented through analyzing a 3 day intake pre and post the 4 week period.
3363835|NCT03276468|Experimental|Experimental|Combination of venetoclax, atezolizumab and obinutuzumab
3363836|NCT03260881|Active Comparator|L-group|• L-group will be started on liraglutide. Liraglutide will be started and administered for from a minimum of 4 weeks up to 12 weeks prior to CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). The dose of 1.8 mg daily will be maintained until the end of the 12-week study. Other and current diabetes treatment will be continued
3363837|NCT03260881|Placebo Comparator|D-group|placebo will be administered in addition to current treatment prior to the CABG with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). D-group will be started on a supervised low calorie diet (LCD) to achieve approximately 5% of weight loss after from a minimum of 4 weeks up to 12 weeks.
3363840|NCT03238495|Active Comparator|Chemotherapy Only|Taxotere, Carboplatin, Herceptin + Pertuzumab (TCH+P)
3363841|NCT03238495|Experimental|Chemotherapy plus Metformin|TCH+P plus metformin
3363842|NCT03232138|Experimental|Sulforaphane (Study Drug)|Sulforaphane four tablets 2 times per day with breakfast and dinner each dose contains approximately 120 micromole of Sulforaphane
3363843|NCT03232138|Placebo Comparator|Placebo|Placebo (containing no active drug) four tablets 2 times per day with breakfast and dinner
3249956|NCT01380964||DMD patients|DMD Patients
3363844|NCT03231306|Experimental|Open label study of Binimetinib (MEK162)|"Subjects (≥ 18 years) (Stratum A) will receive a course of binimetinib by mouth twice a day (12 hours apart) of 45 mg/dose. Duration of each course is 4 weeks. After 8 courses, subjects will receive additional courses if MRI results showed at least 15% reduction in volume of the target tumor. Subjects can continue on therapy and will be evaluated at the end of 12 courses. Subjects who have ≥ 20% reduction in volume of the target tumor according to the MRI results can continue therapy up to an additional year (maximum of 24 total courses). Subjects who have not met the tumor reduction at the specified times will be removed from the study therapy. Subjects will be carefully monitored for toxicities associated with binimetinib.~Recruitment of subjects 1 - 17 years of age (Stratum B) is currently available. The pediatric maximum tolerated dose (MTD) of binimetinib the pediatric patients (Statum B) was established by a phase 1 study (NCT022)."
3249957|NCT01380964||Control patients|Control patients
3249958|NCT01380977|Experimental|Impact of Crime group intervention|
3249959|NCT01380977|Active Comparator|Treatment as usual|
3249960|NCT01381003|Experimental|pCCLchimGp91s lentiviral vector transduced CD34+ cells|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
3249961|NCT01381029||HIV positive|HIV positive, receiving Influenza vaccine as standard of care.
3249962|NCT01381055|Experimental|Pentoxifylline plus antimony|
3249963|NCT01381055|Placebo Comparator|Placebo plus antimony|
3249964|NCT01381081|Experimental|platelet-rich plasma intra-articular knee injections|a single intra-articular injection of PRP in knee osteoarthritis
3363845|NCT03220711|Experimental|Subjects with abnormal colon tissue|The study subjects will be high-risk for colonic adenomas (i.e. strong family history of adenomas/adenocarcinoma or personal history of adenomas/adenocarcinoma), known adenoma scheduled for endoscopic resection, or in subjects with suspected dysplasia in inflammatory bowel disease (IBD). Fluorescein will be sprayed on the area of interest to provide imaging contrast for the images taken with the confocal endomicroscope.
3249965|NCT01381081|Active Comparator|Corticosteroid intra-articular knee injections|a betamethasone and bupivacaine intra-articular injection
3249966|NCT01381094|Experimental|AKB-6548 240 mg|
3249967|NCT01381094|Experimental|AKB-6548 370 mg|
3249968|NCT01381094|Experimental|AKB-6548 500 mg|
3249969|NCT01381094|Experimental|AKB-6548 630 mg|
3363846|NCT03212963|Experimental|Halobetasol lotion treatment arm|All subjects will receive Halobetasol Topical Lotion, 0.05%.
3363847|NCT03207594||Arm 1|Current smokers with cancer who are planning to get radiation therapy at MUSC.
3363848|NCT03194256|Active Comparator|Normal Nicotine Content Cigarettes|Spectrum Research Cigarettes: 15.8 mg nicotine/g tobacco, 9 mg of tar
3363849|NCT03194256|Experimental|Very Low Nicotine Content Cigarettes|Spectrum Research Cigarettes: 0.4 mg nicotine/g tobacco, 9 mg of tar
3363850|NCT03168971|Experimental|Managing Anxiety from Cancer (MAC)|Older adults with cancer and their primary informal caregiver will receive a seven-session cognitive-behavior therapy intervention administered over the telephone by a trained study interventionist. The intervention is administered weekly and each session is 45-50 minutes in length. Patients and caregivers will receive the intervention independently and from separate therapists.
3363851|NCT03168971|No Intervention|Usual Care|Older adults with cancer and their primary informal caregiver will receive standard care provided by their medical team. These participants will not receive any intervention from the research team.
3363852|NCT03135262|Experimental|Dose-Escalation Cohort: FL|Induction Treatment: Participants will receive either Regimen A or Regimen B. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax (both at maximum tolerated dose [MTD] established from Regimen A) in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
3363853|NCT03135262|Experimental|Dose-Escalation Cohort: DLBCL|Induction Treatment: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. In bridging cohort, participants will receive rituximab on Day 1 of Cycles 1 to 6 and idasanutlin and venetoclax (both at MTD) in Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive obinutuzumab or rituximab (according to study treatment received in the induction) every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
3363854|NCT03135262|Experimental|Expansion Cohort: FL|Induction Treatment: Participants will receive idasanutlin and venetoclax at the RP2D of the selected regimen (Regimen A or B) identified during the dose-escalation phase in combination with obinutuzumab. Regimen A: Participants will receive either obinutuzumab on Days 1, 8, 15 of Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin and venetoclax on Days 1 to 5 of Cycles 1 to 6 or obinutuzumab on Days 1, 8, 15 on Cycle 1 and then on Day 1 of Cycles 2 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Regimen B (in bridging cohort): Participants will receive obinutuzumab alone in Cycle 1 and obinutuzumab with idasanutlin and venetoclax in Cycles 2 to 6. Post-Induction Treatment (Maintenance Treatment): Participants will receive obinutuzumab every 2 months for 24 months; idasanutlin and venetoclax for 6 months.
3363855|NCT03135262|Experimental|Expansion Cohort: DLBCL|Induction Treatment: Participants will receive rituximab on Day 1 of Cycles 1 to 6; idasanutlin and venetoclax (both at RP2D) on Days 1 to 5 of Cycles 1 to 6 or rituximab on Day 1 of Cycles 1 to 6; idasanutlin on Days 1 to 5 and venetoclax on Days 1 to 10 of Cycles 1 to 6. Post-Induction Treatment (Consolidation Treatment): Participants will receive rituximab every 2 months for 6 months; idasanutlin and venetoclax for 6 months.
3249970|NCT01381094|Placebo Comparator|Placebo|
3249971|NCT01381107|Experimental|ALKS 5461 (ALKS 33 and buprenorphine)|
3249972|NCT01381107|Placebo Comparator|Placebo|
3249973|NCT01381133|Experimental|CBOP without ACC|
3249974|NCT01381133|Experimental|CBOP with ACC|
3249975|NCT01381133|Experimental|MET/CBT 7 without ACC|
3249976|NCT01381133|Experimental|MET/CBT 7 with ACC|
3249977|NCT01381146|Experimental|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
3249978|NCT01381146|Other|TAU|treatment as usual -- participants have access to all other jail programs and services
3249979|NCT01381159|Experimental|Motivational Communication|Up to 3 x 30 minute brief MC sessions within 4-6 week period
3249980|NCT01381159|Placebo Comparator|Control|Usual care
3249981|NCT01381185|No Intervention|Standard therapy|standard dose of 100mg aspirin qd and 1x75mg Clopidogrel will be given
3249982|NCT01381185|Active Comparator|ASA/CLP increase|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd
3249983|NCT01381198|Active Comparator|Distal rectus femoris transfer|Single-event multilevel surgery with a concomitant distal rectus femoris transfer
3249984|NCT01381198|No Intervention|No distal rectus femoris transfer|Single-event multilevel surgery without distal rectus femoris transfer
3249985|NCT01381211|Active Comparator|Yttrium-90 radioembolization (90Y-RE)|
3249986|NCT01381211|Active Comparator|Transarterial chemoembolization with drug eluting beads|Transarterial chemoembolization is performed with drug eluting beads, polyvinyl alcohol-based microspheres (DC Beads, Biocompatibles) loaded with the chemotherapeutic agent doxorubicin.
3249987|NCT01381224||Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection.
3363856|NCT03134833|Experimental|Automated Messaging & Monitoring|"Youth randomized to the Automated Messaging and Monitoring Intervention (AMMI) arm will receive daily texts to motivate, inform, and refer youth to health care and HIV services. Message banks will focus on the HIV Prevention Continuum, with libraries of text messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for young men-who-have-sex-with-men (MSM) and non-MSM.~Youth will also receive a weekly monitoring survey that covers seven domains, including: use of PrEP/PEP, condomless sex, potential symptoms of acute HIV infection, potential symptoms of STI, excessive use of alcohol and/or drugs, feelings of sadness or depression, and housing or food insecurity."
3363857|NCT03134833|Experimental|Peer Support|Youth randomized to the Peer Support arm will be enrolled in private, online peer support groups, where they can post information and have discussions with other participants, guided broadly by topics relevant to the HIV Prevention Continuum. Peer Supporters will post to encourage and broadly guide discussion, while Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content. All youth will also receive AMMI messages.
3363858|NCT03134833|Experimental|Coaching|Youth randomized to the Coaching arm will have access to a dedicated Coach for crisis management, problem-solving, linkage to HIV and related services, and care coordination. The Coach's primary means of contact with youth will be electronic - using e-mail, social media, text messages - and phone calls. In person contacts may also occur. AMMI is also provided to all youth.
3363859|NCT03134833|Experimental|Coaching + Peer Support|Youth randomized to the Coach + Peer Support arm will be enrolled in online, private peer support groups and have access to a Coach. As well as AMMI messages.
3363860|NCT03117881|Experimental|DirectCAM|The DirectCAM arm receives the intervention content via therapists at participating clinics.
3363861|NCT03117881|Experimental|TeleCAM|The TeleCAM arm receives the intervention content at home using pre-loaded tablets and Interactive Voice Response (IVR) system technology.
3363862|NCT03117881|Experimental|rDirectCAM|The rDirectCAM arm is being implemented in response to Covid-19. The rDirectCAM arm receives the intervention content delivered remotely in real-time by therapists via videoconferencing technology.
3363863|NCT03104075|Active Comparator|Prevnar 13|Prevnar 13 (Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein) will be administered at the single 0.5 ml dose, by intramuscular injection with routine clinical care.
3363864|NCT03104075|Active Comparator|Pneumovax 23|Pneumovax 23 (Pneumococcal Vaccine Polyvalent) will be administered at the single 0.5ml dose, by intramuscular injection with routine clinical care.
3363865|NCT03103750|Experimental|Calcitriol then placebo|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
3363866|NCT03103750|Experimental|Placebo then Calcitriol|Healthy volunteers will receive a baseline MRI. On the night before, and day of testing subjects will receive two doses of calcitriol or placebo, followed by PHNO injection & PET Scan #1. A minimum of six days later, subjects will receive a Dexedrine Dose followed by a second PHNO injection and PET scan #2.
3249988|NCT01381250|Experimental|Treatment|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
3249989|NCT01381263|Experimental|Behavioural medicine|
3249990|NCT01381263|Active Comparator|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
3363867|NCT03093922|Experimental|Atezolizumab alone with Gemcitabine and Cisplatin|Atezolizumab alone for 2 cycles. One treatment cycle equals 21 days. Then patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 6 cycles. All 8 treatment cycles will take approximately 24 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator. This cohort is NO LONGER ACCRUING patients since 5/22/2018.
3363868|NCT03093922|Experimental|Atezolizumab with Gemcitabine and Cisplatin|Gemcitabine and Cisplatin for 2 cycles. One treatment cycle equals 21 days. After 2 cycles of Gemcitabine and Cisplatin patient will receive combined atezolizumab and Gemcitabine and Cisplatin for 4 cycles. All 6 treatment cycles will take approximately 18 weeks. If carboplatin is substituted for cisplatin, eGFR for dosing may be calculated by institutional standard formulas, at the discretion of the treating investigator.
3363869|NCT03093922|Experimental|Atezolizumab alone for 1 cycle prior to gemcitabine, cisplatin|"Atezolizumab alone for 1 cycle. One treatment cycle equals 21 days. After 1 cycle of atezolizumab the patients will receive combined atezolizumab and gemcitabine, cisplatin for 4 cycles. All 5 treatment cycles will take approximately 15 weeks. Cisplatin dose can be given on day 1 or split over days 1 and 8 at the investigators discretion. Once the split-dose cisplatin is used, it should be used for the remainder of the chemotherapy treatment course."
3363870|NCT03092843||No functional capacity testing|6 minute walk Quality of life Questionaire
3363871|NCT03092843||Functional Capacity Testing|6 minute walk Quality of Life Questionnaire Metabolic stress test
3363873|NCT03092427|Experimental|Probiotic VSL#3|
3363874|NCT03092427|Placebo Comparator|Placebo|
3363875|NCT03080935|Experimental|Evolocumab|Single arm study administering Evolocumab.
3363876|NCT03077620|Experimental|Poor sleep group treatment 1|10mg Suvorexant tablet h.s. for two consecutive nights
3249991|NCT01381276|Experimental|Cassava Treatment 1|Single meal containing bio-fortified, high carotenoid cassava without oil.
3363877|NCT03077620|Placebo Comparator|Poor sleep group control|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
3363878|NCT03077620|Placebo Comparator|Good sleep group|Participant will receive placebo for two consecutive nights and sleep as normal under the same controlled conditions in a clinical research unit.
3363879|NCT03077620|Experimental|Poor sleep group treatment 2|20mg Suvorexant tablet h.s. for two consecutive nights
3363880|NCT03076554|Experimental|Arm 1 Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
3363881|NCT03072628|Experimental|Nicotine: use e-cig with nicotine|One time exposure to e-cig with nicotine
3363882|NCT03072628|Experimental|no nicotine: use e-cig without nicotine|One time exposure to e-cig without nicotine
3249992|NCT01381276|Experimental|Cassava Treatment 2|Single meal containing bio-fortified, high carotenoid cassava with oil.
3249993|NCT01381276|Active Comparator|Cassava Treatment 3|Single meal containing low carotenoid cassava with oil and retinyl palmitate.
3249994|NCT01381302||Parkinson|Early onset of disease
3249995|NCT01381315|Other|Sentinel lymph node biopsy|During surgery, 1.0 mCi of technetium-99m sulfur colloid will be injected into sub-dermal subareolar aspect of the affected breast. The KUMC Nuclear Medicine Department will be responsible for performing the injection of the isotope and dilution of the isotope using saline to a final volume of 4.0 ml or less.
3249996|NCT01381315|Other|Axillary lymph node biopsy|
3363883|NCT03072628|Experimental|Nicotine inhaler: use a nictoine inhaler|One time exposure to nicotine inhaler
3363884|NCT03072628|Sham Comparator|Sham control|Use an empty e-cigarette
3363885|NCT03064126|Experimental|RANGER™ Paclitaxel Coated Balloon|"RANGER™ Paclitaxel Coated Balloon Catheter angioplasty in the SFA/PPA at the index procedure.~Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon."
3363886|NCT03064126|Active Comparator|Standard Balloon Angioplasty|Standard Balloon Catheter angioplasty in the SFA/PPA at the index procedure. Subjects will be randomized 3:1 to the drug coated or standard angioplasty balloon.
3363887|NCT03043313|Experimental|Cohort A: Tucatinib + Trastuzumab|Non-randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
3363888|NCT03043313|Experimental|Cohort B: Tucatinib + Trastuzumab|Randomized cohort. Participants take tucatinib twice per day orally on Days 1-21 and trastuzumab intravenously (into the vein; IV) on Day 1. Cycles repeat every 21 days.
3249997|NCT01381328||RAL Group|HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen
3363889|NCT03043313|Experimental|Cohort C: Tucatinib Monotherapy|Randomized cohort. Participants take tucatinib twice per orally every day. Participants who do not respond to therapy may have the option to receive tucatinib and trastuzumab.
3363890|NCT03043209||Genomic sequencing|Perform Genomic sequencing in peripheral blood DNA and discarded myocardium from cardiac procedures
3363891|NCT03038087|Experimental|SENSE Device Monitoring in ICH Patients|"The SENSE device transmits a low power tailored electro-magnetic (EM) pulse in the radio-frequency range across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~A molded plastic headpiece containing the antenna array, and~A processing control unit that contains:~The driving electronics for the array;~A spectrum analyzer coupled with a computer; and,~The operating software that controls the device function and data acquisition, processing and archiving.~For this study, the research personnel will place the headset over the subject's head. The headset will be sized to fit snuggly. Each headset is marked with a unique headset identification number. The patient-contacting components of the molded plastic form are made from a medical grade (USP Class VI), biocompatible plastic and foam."
3363892|NCT03034629|Experimental|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
3363894|NCT03015558|Experimental|patients|
3363895|NCT03015558|Active Comparator|healthy subjects|
3363896|NCT02998645|Experimental|Eltrombopag + cyclosporine|Planned duration of treatment with eltrombopag & cyclosporine is 6 months (for all patients); the planned duration of treatment with cyclosporine (cyclosporine tapering) is 18 months (for responder patients only).
3363897|NCT02981472|Experimental|Apixaban|
3363898|NCT02981472|Active Comparator|LMWH/VKA|
3363901|NCT02955966|Experimental|Patient with invasive pulmonary aspergillosis|Blood collection and imaging 18F-FDG-PET/CT
3363902|NCT02941783||BAY81-8973|Hemophilia A patients who require Factor VIII replacement therapy
3363903|NCT02914600|Experimental|Filgotinib 200 mg (blinded dosing)|Filgotinib 200 mg + placebo to match filgotinib 100 mg for up to 432 weeks
3363904|NCT02914600|Experimental|Filgotinib 100 mg (blinded dosing)|Filgotinib 100 mg + placebo to match filgotinib 200 mg for up to 432 weeks
3363905|NCT02914600|Placebo Comparator|Placebo (blinded dosing)|Placebo to match filgotinib 200 mg for up to 432 weeks
3363906|NCT02914600|Experimental|Filgotinib 200 mg (open-label)|Filgotinib 200 mg for up to 432 weeks
3363907|NCT02914600|Experimental|Filgotinib 100 mg (open-label)|Filgotinib 100 mg for up to 432 weeks
3363910|NCT02907983|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivicaine
3363911|NCT02907983|Sham Comparator|Saline|Saline injection
3363912|NCT02880540|Active Comparator|Control Group|Fentanyl 50 micrograms IV every 15 minutes up to 3 doses in postanesthesia recovery room and Morphine 2mg IV every 2 hours for 2days on hospital floor
3249998|NCT01381341|Experimental|linifanib|
3363913|NCT02880540|Experimental|Dexmedetomidine Treated|Dexmedetomidine IV bolus 1.5microgram/kilogram and a continuous infusion starting at 0.1 microgram/kilogram/hour during surgery
3249999|NCT01381354|Experimental|Combined intervention|Combination intervention consisting of the following: structured modified paleolithic diet, Progressive Exercise, Neuromuscular Electrical Stimulation designed to facilitate the adoption of multiple therapeutic lifestyle behaviors associated with superior health outcomes.
3250000|NCT01381367|Experimental|Vaccine|Enrolled COPD patients receiving PPSV23 pneumococcal vaccine
3363914|NCT02859415|Experimental|Phase I|Escalating doses of Mithramycin
3363915|NCT02859415|Experimental|Phase II|Mithramycin administered at MTD
3363916|NCT02848092|Experimental|FOCAL+Training|
3363917|NCT02848092|Sham Comparator|Rules of the Road Training|
3363918|NCT02841215|Experimental|Oral ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
3363919|NCT02841215|Active Comparator|Oral ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)
3363920|NCT02827214||Surgical treatment|"Several surgical treatments exist to treat the fractures included in the study. The following section describes the different surgical treatment modalities in more detail~Approaches:~Open short segment surgical fixation (1 level above and below the fracture level) with or without posterior decompression~Open long segment posterior fixation (2 or more levels above, 2 or more levels below) with or without posterior decompression~Posterior short or long fixation with posterolateral corpectomy and reconstruction~Anterior alone instrumentation~Combined Anterior Posterior (AP) instrumentation~Percutaneous posterior fixation combined with anterior instrumentation~Percutaneous posterior fixation with or without vertebroplasty"
3250001|NCT01381367|Placebo Comparator|Normal saline|Enrolled COPD patient receiving placebo normal saline
3250002|NCT01381380|Other|single-arm studies|Manual therapy for one group
3363921|NCT02827214||Non-surgical treatment|"Non-surgical treatment is defined as bed rest followed by immobilization with:~Custom-molded or prefabricated total body contact thoracolumbosacral orthosis (TLSO)~Thermoplastic removable brace~Jewett hyperextension braces~Anterior hyperextension brace (ASH)~Taylor-Knight brace~Plaster of Paris (POP)"
3250003|NCT01381393||Ibandronate|The subjects with osteoporosis in postmenopausal women
3250004|NCT01381419|Experimental|Part A, Cohort 1|In Cohort 1, four subjects (two on active and two on placebo for first dose, and then three on active and one on placebo for subsequent doses) will be included. Subjects will be dosed at least 30 minutes apart over the dosing day and only doses administered where the predicted plasma concentration will remain below those corresponding to the MABEL.
3363926|NCT02802566|Experimental|Investigative|This arm receives a standard prenatal (provided by the study) and a micronutrient supplement.
3363927|NCT02802566|Active Comparator|Control|Standard prenatal vitamin provided by the study
3363928|NCT02799641|Placebo Comparator|Control|Control arm receives ibuprofen, placebo pill, and placebo injection.
3363929|NCT02799641|Experimental|Treatment|Treatment arm receives ibuprofen, diazepam pill, and lidocaine injection.
3363930|NCT02791230|Experimental|Tafamidis|Active treatment - 61 mg or if not available, tafamidis megulmine 80 mg
3363932|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose A|Open label dose A once daily (QD)
3363933|NCT02782663|Experimental|Upadacitinib (ABT-494) Dose B|Open label dose B QD
3363936|NCT02764489|Experimental|Part 1 Regular then reduced volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA reconstituted in regular volume then FEIBA reconstituted in 50% reduced volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
3363937|NCT02764489|Experimental|Part 1 Reduced then regular volume Part 2 Faster infusion rate|STUDY PART 1- FEIBA Reconstituted in 50% Reduced Volume then FEIBA Reconstituted in Regular Volume; STUDY PART 2- Infusion rate escalation to 4 U/min/kg and reconstituted in 50% reduced volume; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 4 U/min/kg; Followed by FEIBA reconstituted in 50% reduced volume with infusion rate: 10 U/min/kg.
3363938|NCT02755844|Experimental|Olaparib, metformin and metronomic cyclophosphamide|"Phase 1: Dose escalation scheme: a continual reassessment method (CRM) will be used to guide inclusion of patients in drug dose levels pre-specified based on observations of dose-limiting toxicity.~Phase 2 (expansion of cohort): once RP2D will be determined, additional patients will be enrolled, in order to obtain preliminary data about efficacy in a 2 stage Simon's design."
3363942|NCT02741388|Experimental|Selinexor + immunochemotherapy|"Selinexor will be administered orally on Day1, 3, 8 and 10 of each 3-week cycle with an immunochemotherapy, R-DHAOx (Group A: rituximab + dexamethasone + oxaliplatin + cytarabine) or R-GDP (Group B: rituximab + dexamethasone + gemcitabine + cisplatin) for 3 cycles (choice of the immunochemotherapy left at the investigator's decision before patient's inclusion).~Different dose levels of selinexor will be examined sequentially in each group: 20 mg flat (DL-1), 40 mg flat (DL1), 60 mg flat (DL2), 80 mg flat (DL3)."
3363943|NCT02740972|Experimental|NS-065/NCNP-01 40mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 40mg/kg dose once a week for 24 weeks
3250005|NCT01381419|Experimental|Part A, cohort 2|In Cohort 2, 10 subjects will be included (8 active : 2 placebo). Dosing will start once the previous cohort (Cohort 1) has completed the Treatment Phase. For Cohort 2 and any subsequent cohorts, dosing will take place on two different days when a new dose is administered such that no more than one subject receives the agreed ascending dose on the first dosing day. Doses may be split in up to three divided doses given 2 to 3 hours apart. Dosing for the first four sessions in each cohort will be staggered over 2 days. On the first day of each dosing session, only one subject will receive the highest dose for that dosing session and at least one subject each will receive placebo. The remaining subjects in the cohort will be dosed on the second day according to the randomisation plan.
3250006|NCT01381419|Experimental|Part B|Part B of the study will consist of a Screening Visit (up to 30 days before the dosing session), three PET scans (where possible, all three scans may be performed in one visit when subject is admitted overnight) and a Follow-up Visit. Each subject will receive an oral dose of study drug. The dose may be split in up to three divided doses given 2 to 3 hours apart.
3363944|NCT02740972|Experimental|NS-065/NCNP-01 80mg/kg|Six patients with confirmed DMD with genetic deletions amenable to exon 53 skipping will be administered an intravenous infusion of NS-065/NCNP-01 80mg/kg once a week for 24 weeks
3363945|NCT02740972|Placebo Comparator|Placebo|Two patients in each of the dose groups will be administered placebo as an intravenous infusion once a week for 4 weeks followed by 20 weeks of open label treatment
3363946|NCT02702310||Quality of Life/ Grading Skin Findings|Patients' baseline quality of life is established by completion of an initial questionnaire, and skin lesion burden is quantified by physical examination using a recommended system . Following the standard of care radiation therapy, patients' completion of questionnaire, and physical examination is repeated for continued assessment.
3363947|NCT02688855|Experimental|Investigational Group|Standard Rigid Fixation + Active OL1000 device
3250007|NCT01381432||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the lung transplantation
3363948|NCT02688855|Sham Comparator|Control Group|Standard Rigid Fixation + Sham OL1000 device
3363949|NCT02686346|Experimental|BV-ICE|"Phase I:~4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;~Phase II:~4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4"
3363952|NCT02669212|Other|1|MRI RadiofrequencyCoils, TMS
3363953|NCT02662985|Active Comparator|Group 1|"In Treatment Period-1:~Patients in this group were administered secukinumab with 12 weeks of treatment from baseline.~In Treatment Period-2:~Patients continued to receive the same active dose of secukinumab every 4 weeks until Week 24~In Treatment Period 3 (extension period):~the extension period allowed responder patients the possibility to continue open-label secukinumab treatment up to Week 52"
3363954|NCT02662985|Placebo Comparator|Group 2|"In Treatment Period-1:~Patients received placebo at baseline and same time points as secukinumab until Week 8.~In Treatment Period-2:~Patients commenced open-label secukinumab every 4 weeks from Week 12, as follows, based on their clinical characteristics at Week 12~In Treatment Period-3:~Open-label secukinumab continued to be assigned to patients"
3363955|NCT02637947|Experimental|Magnetic navigation|Catheter ablation using magnetic navigation for ventricular tachycardia via remote magnetic navigation of a NaviStar RMT ThermoCool catheter, or other magnetically compatible catheter, via Stereotaxis's Niobe ES system.
3363956|NCT02637947|Active Comparator|Manual navigation|Catheter ablation using manual navigation for ventricular tachycardia via a manually navigated Thermocool catheter, or equivalent catheter.
3363957|NCT02630654||GEP NETs|Patients with a suspected diagnosis of metastatic GEP NETs
3250008|NCT01381445|Experimental|GW870086 0.2% &amp; GW870086 2%|GW870086 0.2%, 2% &amp; placebo each applied to an identified area for 42 days.
3250009|NCT01381445|Experimental|GW870086 2% &amp; Clobetasol Propionate|GW870086 2% &amp; placebo applied to an identified area for 42 days, while Clobetasol Propionate is applied to an area for 21 days
3363958|NCT02630654||Healthy controls|Healthy controls matched by age and gender.
3363959|NCT02606461|Experimental|Phase 2 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 milligrams (mg) selinexor twice weekly on Day 1 and 3 during each 6 Week cycle (42 days) up to 13 months until progressive disease (PD).
3363960|NCT02606461|Experimental|Phase 3 Double-blinded: Selinexor|Participants received a fixed blinding dose of 60 mg selinexor twice weekly on Day 1 and 3 during each 6 Week cycle (42 days) up to 38 months until PD.
3363961|NCT02606461|Placebo Comparator|Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice weekly on Day 1 and 3 during each 6 Week cycle (42 days) up to 13 months until PD in double-blinded treatment period. Participants in the placebo group who had PD during the Phase 2 double-blinded treatment, will be elected to cross over to open-label selinexor.
3363962|NCT02606461|Placebo Comparator|Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor|Participants received a fixed blinding dose of placebo matched to selinexor twice weekly on Day 1 and 3 during each 6 Week cycle (42 days) up to 14 months until PD or development of unacceptable toxicity. Participants in the placebo group who had PD during the Phase 3 double-blinded treatment, will be elected to cross over to open-label selinexor.
3363963|NCT02599558|Experimental|Cytosponge,Diet,EEsAI Pro,Phone call|Patients going through the six food elimination diet (clinically)for EoE, will be asked to participate. We will introduce 1 of the 6 foods previously eliminated for two weeks, than another for two weeks, at the end of 4 weeks the participant will return to swallow the cytosponge to monitor them through the diet, rather than multiple repeat Upper Endoscopies. The cytosponge is a 10 minute procedure done in the office. This will be sent for histology, <15 phf would be considered a responder. Results of the histology will help the investigator to direct the diet, which foods to add or take out of the diet.
3363966|NCT02592291|Experimental|MHealth Group|Participants randomized into this group will use the mHealth system throughout the study in conjunction with their standard of care
3363967|NCT02592291|No Intervention|Control|Participants randomized into this group will not use the mHealth system throughout the study, but will continue with their standard of care.
3363968|NCT02590757|Active Comparator|NIV-NAVA|Noninvasive ventilation in this group is practiced with NIV-NAVA
3363969|NCT02590757|Active Comparator|N-CPAP|Patients in this group will receive nasal continuous positive airway pressure as routinely in neonatal intensive care unit.
3363970|NCT02545673|Experimental|Enhanced Linkage|Participants will receive the enhanced linkage to care Intervention. Behavioral: Enhanced linkage to care Intervention Multiple sessions will focus on providing orientation to the HIV care system, counseling to help clients identify and reduce barriers to engagement in care, assistance disclosing and identifying a treatment supporter, and stigma reduction through increasing social support. The approach is guided by the HIV Stigma Framework.
3363971|NCT02545673|Active Comparator|Standard-of-care plus|Behavioral: Participants will receive the standard-of-care (paper-based referrals) plus return of CD4 test results to their home.
3250010|NCT01381458||COPD patients receiving pharmacotherapy|COPD patients age 40 years and older receiving pharmacotherapy to treat their COPD and an index event of COPD hospitalization or ER visit.
3250011|NCT01381484|No Intervention|Placebo|This group received placebo gel and requested to apply periorbital area and over the face for 3 months.
3250012|NCT01381484|Experimental|Study group|This group received La Jolie Gel and requested to apply periorbital area and over the face for 3 months.
3250013|NCT01381497||Employed migraine sufferers|Diagnosed adult migraine sufferers who are employed at least 30 hours per week during a daytime shift
3250014|NCT01381510||Adherent BPH patients|Patients with benign prostatic hyperplasia (BPH) who are adherent to 5-alpha reductase inhibitor (5ARI) therapy based on a medication possession ratio (MPR). Analyses will be conducted with threshold adherence levels of 70%, 75% and 80%
3363977|NCT02536339|Experimental|Pertuzumab + Trastuzumab|Participants with CNS metastases secondary to HER2-positive MBC will receive pertuzumab in combination with high-dose trastuzumab until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
3250015|NCT01381510||Non-adherent BPH patients|Patients with BPH who are not adherent to 5ARI therapy based on an MPR and threshold levels of less than 70%, less than 75% and less than 80%
3250016|NCT01381523||Study-treatment naive insured adults with migraine|Adult health care plan members with a pharmacy claim for a combination product of sumatriptan and naproxen sodium (SumaRT/Nap) and propensity score matched controls with a pharmacy claim for a single-entity triptan
3250017|NCT01381523||Insured adults with migraine who switch study treatment|Adult health plan members with a pharmacy claim for SumaRT/Nap following at least one single-entity triptan pharmacy claim in the previous 6 months and propensity-score matched controls who switched from one single-entity triptan to another
3250018|NCT01381536|Experimental|GSK1550188 1mg/kg or 10mg/kg|one shot IV
3250019|NCT01381588||Post menopausal women|Post menopausal women between 50 to 80
3250020|NCT01381601||Severe adverse event claims in subjects with metastatic RCC|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurence as reported in product label.
3250021|NCT01381614||Occurance of severe adverse event claims in subjects|Presence or absence of common severe treatment related adverse events (based on existence of claims) in patients with metastatic RCC. Common severe adverse event defined as Grade 3 or higher with >=5% frequency of occurance as reported in product label.
3250022|NCT01381627|Active Comparator|Remifentanil|
3250023|NCT01381627|Experimental|Dexmedetomidine|
3250024|NCT01381640|Active Comparator|Marketed paracetamol|Marketed formulation
3250025|NCT01381640|Experimental|Experimental paracetamol formulation|Experimental formulation
3250026|NCT01381653|Experimental|Motivational Interviewing|Eight 30-minute sessions utilizing Motivational Interviewing will be delivered to reduce substance use and sexual risk in a group of high risk young men who have sex with men.
3250027|NCT01381666|Experimental|INS316|inhalation via nebulizer given for 2 doses for 60 minutes each
3250028|NCT01381666|Placebo Comparator|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
3363987|NCT02527031|Active Comparator|Pre hospital ECMO|ECMO Insertion on pre hospital setting for a refractory cardiac arrest
3250029|NCT01381731|Experimental|Diquafosol tetrasodium ophthalmic solution 2%|topical ophthalmic solution
3250030|NCT01381731|Placebo Comparator|Placebo|saline ophthalmic solution
3363988|NCT02527031|Active Comparator|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
3363989|NCT02523469|Experimental|ALT-803 + Nivolumab dose escalation|"Up to 21 patients will receive ALT-803 + Nivolumab in the dose escalation phase to determine the maximum tolerated dose.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. The starting dose level for ALT-803 is 6 microgram (mcg)/kilogram (kg); the second dose level is 10 mcg/kg; the third dose level is 15 mcg/kg; and the fourth dose level is 20 mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3363990|NCT02523469|Experimental|Arm A: ALT-803 + Nivo naive|"Patients who have not received PD-1 blockade (nivolumab, pembrolizumab, or atezolizumab) will be enrolled to Arm A in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3363991|NCT02523469|Experimental|Arm B: ALT-803 + Nivolumab progressor|"Patients who have had PD-1 blockade (nivolumab, pembrolizumab, or atzolizumab) and progressed will be enrolled to Arm B in the Phase II part of the study.~ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles. During week 6 no study drug will be administered. ALT-803 will be administered at the recommended phase II dose of 20mcg/kg.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3363992|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 1|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 20 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3363993|NCT02523469|Experimental|ALT-803 + Nivolumab Exploratory Arm 2|"All eligible patients will be enrolled into one of two exploratory dosing arms.~For exploratory Arm 1:~The dose level for ALT-803 is 10 mcg/kg. ALT-803 will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5) for up to 4 cycles.~Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).The dose level for Nivolumab is 240mg."
3250031|NCT01381744|Experimental|Group 3: 6 mcg Flagellin/F1/V|12 subjects will receive 6 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3250032|NCT01381744|Experimental|Group 4: 10 mcg Flagellin/F1V|12 subjects will receive 10 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3250033|NCT01381744|Experimental|Group 2: 3 mcg Flagellin/F1/V|12 subjects will receive 3 mcg of Flagellin/F1/V or placebo on Day 0 and Day 28.
3250034|NCT01381744|Experimental|Group 1: 1 mcg Flagellin/F1/V|12 subjects will receive 1 microgram (mcg) of Flagellin/F1/V or placebo on Day 0 and Day 28.
3250035|NCT01381770|Experimental|Platelet-derived repairing factors|
3250036|NCT01381783|Other|Topical anesthesia|
3363994|NCT02514083|Experimental|Ibrutinib and short-course fludarabine|"Ibrutinib 420 mg PO daily for the duration of the study~Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4"
3250037|NCT01381796|Active Comparator|Treatment A - NP101|
3250038|NCT01381796|Active Comparator|Treatment C - oral sumatriptan succinate|
3250039|NCT01381796|Experimental|Treatment B - NP101B|
3250040|NCT01381796|Experimental|Treatment D - NP101D|
3363999|NCT02394704|Experimental|Graded sensory attention training|Sensory stimuli will begin at a maximal tolerable intensity and decrease in intensity throughout the training, to shift from involuntary to voluntary attentional focus.
3364000|NCT02394704|Active Comparator|Non-graded sensory attention training|Sensory stimuli will begin and be maintained at a minimal detectable intensity to maximize voluntary attentional training.
3364007|NCT02368132|No Intervention|Usual Care|Caregivers randomized to UC will be sent general material about VA and community resources for patients with dementia and their CGs. With the exception of this material, individuals in this group will receive usual care and will be contacted again at 3, 6, and 12 months for follow-up research assessments.
3364008|NCT02368132|Active Comparator|Individual Delivered TEP Arm|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
3364009|NCT02368132|Active Comparator|Group Delivered TEP Arm|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
3364010|NCT02352389||Influenza|"Children and young adults identified as having influenza infections by the St. Jude Children's Research Hospital diagnostic microbiology will be approached to participate in the study. Biological samples will be collected on Day 0 within 72 hours of the diagnosis of influenza, and at 7, 14, 21, and 28 days later.~Interventions: Symptom checklist, Blood sample, Nasal swab, Oropharyngeal swab, Stool sample."
3250041|NCT01381809|Experimental|Epoetin alfa|Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
3250042|NCT01381809|Placebo Comparator|No treatment|Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
3364016|NCT02333370|Experimental|LEE011 +Letrozole|LEE011 - 3 weeks on 1 week off Letrozole 2.5mg - Once daily
3364017|NCT02333370|Experimental|LEE011 + Tamoxifen|LEE011 - 3 weeks on 1 week off Tamoxifen 20mg - Once daily
3364018|NCT02333370|Experimental|LEE011 + Fulvestrant|LEE011 - 3 weeks on 1 week off Fulvestrant 500 mg - Dosed every 28 days (Day 1 for each cycle) with 1 additional dose on Day 15 of Cycle 1
3250043|NCT01381822|Experimental|TH-302 Dose escalation|The initial dose of TH-302 will be 240 mg/m2. A Dose Level minus 1 and 2 will be built into the study in the event that subjects experience excessive toxicity at Dose Level 1. Dose escalation will continue with approximately 40% increases from the previous dose level; however lower dose increases of 20-39% may be implemented after consultation between the Investigators, Medical Monitor and Sponsor with the percent increase dependent on the current dose level and the cumulative safety data.
3250044|NCT01381835|Experimental|001|TMC435 150 mg capsule once daily for 7 days
3250045|NCT01381848|Experimental|001|Doripenem Type=exact number unit=mg/kg number=5 form=solution for injection route=intravenous use once on Day 1 for patients <8 weeks CA.,Doripenem Type=exact number unit=mg/kg number=8 form=solution for injection route=intravenous use once on Day 1 for patients >=8 weeks CA.
3250046|NCT01381887|Placebo Comparator|001|Placebo Treatment A: Form=capsule route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
3250047|NCT01381887|Experimental|002|"Canagliflozin 300mg/Placebo Treatment B: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
3250048|NCT01381887|Experimental|003|Canagliflozin 300mg Treatment C: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
3364022|NCT02323295|Experimental|Non Surgical-Radiation Only|Non-surgical candidates receive 72 up to 77.l4 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma
3364023|NCT02323295|Experimental|Malignant Tumor Surgery And Radiation|The standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor. After approximately 6 weeks of recovery, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease). If the wound is not healed or there is another medical reason to delay adjuvant radiation, then radiation may begin later.
3250049|NCT01381887|Experimental|004|"Canagliflozin 300mg/Canagliflozin 150mg Treatment D: Type=1 unit=mg number=300 form=capsule route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1 unit=mg number=150 form=capsule route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
3250050|NCT01381939||Induction of labor in ICP|Induction of laborin women with ICP
3364026|NCT02311374|Sham Comparator|Phase 2|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM-12 PM).
3364027|NCT02311374|Sham Comparator|Phase I|ADC will be measured in the same subject in the wake state (following a night of regular sleep) and during sleep (following a night of sleep deprivation). The MRI scans will be done in the morning (9 AM-12 pm), once while the subject is sleeping (following a night of sleep deprivation) and once while awake (following regular sleep 9 AM 12 PM).
3364028|NCT02308111|Experimental|Obeticholic Acid (OCA) 5 mg to 10 mg|Obeticholic Acid (OCA) 5 mg for a minimum 3 months and then titrating up to a maximum 10 mg for the remainder of the trial (based on tolerability and Child Pugh Score).
3364029|NCT02308111|Placebo Comparator|Placebo|
3250051|NCT01381939||Induction of labor in women with no ICP|No ICP
3250052|NCT01381939||ICP and spontanius delivery|
3250053|NCT01381965|Active Comparator|Eyes with macular hole|
3250054|NCT01381991|Experimental|i-scan-EGD|Examination of GE junction using conventional WL as well as i-scan mode
3250055|NCT01382004|Active Comparator|Penicillin-G-Benzathine|penicillin-G-Benzathine : 50,000 UI/Kg single dose(maximum 2.4 million units IM)
3364030|NCT02305641||Cohort|Method of continuous surveillance per standard of care
3364031|NCT02298257|Experimental|Treatment (BV + combination chemotherapy)|Patients receive doxorubicin hydrochloride given IV , vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3364032|NCT02278120|Experimental|Ribociclib (LEE011) + NSAI/tamoxifen + goserelin|LEE011 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
3364033|NCT02278120|Placebo Comparator|LEE011 placebo+NSAI/tamoxifen+goserelin|LEE011 Placebo 600 mg daily oral (3 weeks on/ 1 week off) in combination with NSAI or tamoxifen (tamoxifen 20 mg daily oral or letrozole 2.5 mg daily oral or anastrozole 1 mg daily oral) and goserelin 3.6 mg subcutaneous injection (once every 28 days)
3364034|NCT02277444|Experimental|Golimumab + Methotrexate|Participants will receive 80 milligram per meter square (mg/m^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m^2 per week for participants with BSA less than [<] 1.67 meter square (m^2), or minimum of 15 mg/week for participants with BSA greater than or equal to [>=] 1.67 m^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m^2 every 8 weeks after completion of the Week 252 assessments.
3364037|NCT02229136|Experimental|Miracle Mouthwash plus Hydrocortisone|Miracle Mouthwash plus Hydrocortisone, swish and expectorate 10cc (10 mLs) 4 times per day, every day for 12 weeks.
3364038|NCT02229136|Active Comparator|Prednisolone|Prednisolone oral solution 15 mg/5 ml; swish and expectorate 10cc (10 mL) 4 times per day, every day for 12 weeks.
3364039|NCT02228954||Renal Cell Cancer|
3364041|NCT02189798|Experimental|Newly Implanted Group|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness. Patients retaining considerable low frequency acoustic hearing after the surgery, will be fitted with the EAS sound processor.
3364042|NCT02189798|Experimental|Existing Implanted Group|Adults unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness will be fitted with the EAS sound processor.
3364043|NCT02189798|Experimental|EAS Extended Use Arm|Adults who are unilaterally implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode with partial deafness and completed the 12 Month visit using the EAS sound processor in either the Newly Implanted Group or Existing Implanted Group.
3250056|NCT01382004|Experimental|Azithromycin|Azithromycin: 30 mg/kg single dose (Maximum: 2.000 mg.)
3250057|NCT01382017|Placebo Comparator|Placebo|Placebo arm
3250058|NCT01382017|Experimental|Lasosamide 200|Lacosamide 200 mg
3250059|NCT01382017|Experimental|Lacosamide 400|Lacosamide 400 mg
3250060|NCT01382017|Active Comparator|Carbamazepine 600|Carbamazepine 600 mg
3364045|NCT02180724|Experimental|Previously Treated/Naive|Previously treated, N=92 Treatment Naïve, N=14
3364051|NCT02108964|Experimental|Phase I part|Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
3364052|NCT02108964|Experimental|Phase II part|Treatment naïve participants with locally advanced or metastatic NSCLC harboring EGFR mutations will be administered with EGF816 at RP2D during Phase II part of the study.
3364053|NCT02098876|Active Comparator|Resolute Integrity DES|Resolute Integrity zotarolimus eluting stent
3364054|NCT02098876|Active Comparator|Xience Xpedition DES|Xience Xpedition everolimus eluting stent
3364055|NCT02088554|Experimental|Model 400 aortic valve bioprosthesis|
3364060|NCT02051218|Active Comparator|Arm A (standard arm)|Denosumab 120mg (XGEVA®) sc. q4w
3364061|NCT02051218|Experimental|Arm B (reduced arm)|Denosumab 120mg (XGEVA®) sc. q4w [weeks 1, 5, 9] followed by Denosumab 120mg (XGEVA®) sc. q12w [weeks 13, 25, …]
3364062|NCT02050347|Experimental|Subgroup A1|Patients with residual or relapsed B-cell ALL and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
3364063|NCT02050347|Experimental|Subgroup B1|Patients with other B-cell malignancies and with an HLA-matched related donor will receive CD19.CAR-CD28Z T Cells - dose escalation 1
3364064|NCT02050347|Experimental|Subgroup A2|Patients with residual or relapsed B-cell ALL and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
3364065|NCT02050347|Experimental|Subgroup B2|Patients with other B cell malignancies and with an unrelated or HLA-mismatched donor will receive CD19.CAR-CD28Z T Cells - dose escalation 2
3364066|NCT02050308|Experimental|Internet-All Nations Breath of Life (I-ANBL)|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to quitting smoking (like: preparing to quit, dealing with cravings, and support systems, etc.) and topics relevant to American Indian culture (like traditional use of tobacco).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
3250061|NCT01382030|Experimental|Treatment Arm|All patients receive 4 cycles of EIA chemotherapy pre- and postoperatively. There is no further observation arm. The study is non-randomized.
3250062|NCT01382043||Endeavor Segment group|
3250063|NCT01382043||Excel Segment Group|
3250064|NCT01382056|Experimental|Mixed beans (higher amount)|Participants may be randomized to foods containing 0.6 cup of mixed beans daily 5 times per week for 8 weeks
3364067|NCT02050308|Active Comparator|Honoring the Gift of Heart Health|"The culturally-tailored program includes 9 individual Internet-based sessions across a 12 week period and an additional individual Internet-based session at 6 months. Web sessions will last about half-an-hour (30 minutes) and will discuss topics that are important to heart health (like: Assessing risk for heart disease, increasing fruit and vegetable consumption, physical activity, etc.).~We plan to give participants in our cessation program a choice of varenicline, bupropion, nicotine replacement therapy or no pharmacotherapy. We choose to give our participants a choice because our experience shows that we would be unlikely to recruit AI participants into a trial that requires pharmacotherapy use."
3364068|NCT02036970|Experimental|Part 1 Dose-Ranging Bardoxolone methyl 2.5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 2.5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
3364069|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 5 mg/Part 2: Open-Label|Participants received bardoxolone methyl 5 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
3250065|NCT01382056|Experimental|Mixed beans (lower aomunt)|Participants may be randomized to foods containing 0.3 cup of mixed beans daily, 5 times per week for 8 weeks.
3250066|NCT01382056|Active Comparator|Control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
3364070|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 10 mg/Part 2: Open-Label|Participants received bardoxolone methyl 10 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
3364071|NCT02036970|Experimental|Part 1: Dose-Ranging Bardoxolone methyl 20 mg/Part 2: Open-Label|Participants received bardoxolone methyl 20 mg once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 continued to receive the same bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
3250067|NCT01382069|Placebo Comparator|Placebo|Placebo
3364072|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone methyl 2.5 mg|Participants received bardoxolone methyl 2.5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 2.5 mg once-daily in Part 2 (Week 16 and onwards)
3364073|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone methyl 5 mg|Participants received bardoxolone methyl 5 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 5 mg once-daily in Part 2 (Week 16 and onwards)
3364074|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants received bardoxolone methyl 10 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 10 mg once-daily in Part 2 (Week 16 and onwards)
3364075|NCT02036970|Placebo Comparator|Part 1: Dose-Ranging Placebo 20 mg/Part 2: Bardoxolone methyl 20 mg|Participants received bardoxolone methyl 20 mg matching placebo capsules once-daily in Part 1 (Day 1 to Week 16). Participants who continued to Part 2 received bardoxolone methyl 20 mg once-daily in Part 2 (Week 16 and onwards)
3364076|NCT02036970|Experimental|Part 1: Dose Titration: Bardoxolone methyl 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 started with bardoxolone methyl 5 mg once-daily from Day 1 and escalated to bardoxolone methyl 10 mg once-daily starting at Week 4 thru Week 16. Participants who continued to Part 2 continued to receive the same bardoxolone methyl dose once-daily in Part 2 (Week 16 and onwards)
3364077|NCT02036970|Placebo Comparator|Part 1: Dose Titration: Placebo 10 mg/Part 2: Bardoxolone methyl 10 mg|Participants in Part 1 received Placebo once-daily from Day 1 thru Week 16. Participants who continued to Part 2 initially received bardoxolone methyl 5 mg once-daily from Week 16 thru Week 20 and bardoxolone methyl 10 mg from week 20 onwards
3364078|NCT02019641|Experimental|AET|AET will consist of a 10-week regimen of supervised treadmill walking three times a week. The duration of the exercise sessions will progress from 30 minutes to 45 minutes per session over the 10 weeks as tolerated. The intensity of the exercise will be between 70 and 80% of the patient's heart rate reserve.
3364079|NCT02019641|Active Comparator|No AET|control will not engage in AET.No AET (education only)
3250068|NCT01382069|Experimental|Dimethandrolone Undecanoate|DMAU group with different doses 100, 200 and 400 groups
3364082|NCT02013167|Experimental|Blinatumomab|"Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.~The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles."
3364083|NCT02013167|Active Comparator|Standard of Care Chemotherapy|"Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.~Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months."
3364084|NCT02000427|Experimental|Blinatumomab|"Participants will receive blinatumomab by continuous intravenous (CIVI) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieve a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.~The initial dose will be 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 for all subsequent cycles of treatment."
3250069|NCT01382082||subjects with breast cancer|
3250070|NCT01382082||subjects with lymphoma|
3364085|NCT01958021|Experimental|LEE011 + letrozole|LEE011 (Ribociclib) oral (3 weeks on/ 1 week off) in combination with oral once daily letrozole. 600mg LEE011 QD + 2.5 mg letrozole QD
3250071|NCT01382082||subjects without cancer|
3250072|NCT01382095|Experimental|Group A|
3364086|NCT01958021|Placebo Comparator|Placebo + letrozole|Matching ribociclib placebo was the control drug and was administered orally once daily.
3364087|NCT01946100|Other|Multifocal Lung Adenocarcinoma|
3364088|NCT01941719|Experimental|enhanced foot care education|In addition to the standard diabetic foot self-care instruction, the importance of daily foot self-care was reinforced at baseline by viewing personal barefoot plantar pressure in gait
3364089|NCT01941719|Active Comparator|Standard Foot Care Education|Reviewed the standard diabetic foot self-care instructions, including daily foot inspection and proper footwear at all times.
3364090|NCT01872260|Experimental|LEE011 + letrozole Arm 1|LEE011 - 28 day cycles (21 days followed by a 7 day break - dose escalating), letrozole - 2.5 mg/day
3250073|NCT01382095|Experimental|Group B-1|
3250074|NCT01382095|Experimental|Group B-2|
3250075|NCT01382095|Experimental|Group C|
3250076|NCT01382121|Experimental|Peer modeling|Participants watch a video geared to increase confidence in ability to preform fitness test. Male participants will watch a video of a male adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of his ability. Female participants will watch a video of a female adolescent completing the fitness test and talking about coping mechanisms used to preform to the best of her ability.
3250077|NCT01382121|Active Comparator|Control|Participants watch a video unrelated to the fitness test and self-efficacy. The video depicts healthy food and nutrition options.
3364091|NCT01872260|Experimental|BYL719 + letrozole Arm 2|BYL719 - daily (dose escalating) letrozole - 2.5 mg/day
3364092|NCT01872260|Experimental|LEE011 + BYL719 + letrozole Arm 3|LEE011 - 28 day cycles (21 days followed by a 7 day break -dose escalating), BYL719 - daily (dose escalating), letrozole 2.5 mg/day
3364093|NCT01872260|Experimental|LEE011+ BYL719+letrozole Arm 4|LEE011-daily (dose escalating), BYL719 -daily (dose escalating), letrozole 2.5 mg/day
3364094|NCT01869361|Placebo Comparator|Placebo|The patient will be given a loading dose of 50mg placebo by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
3250078|NCT01382134|Placebo Comparator|Placebo group|Subjects will be given placebo daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15 microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
3250079|NCT01382134|Active Comparator|Aspirin group|Subjects will be given aspirin 100mg daily for 3 days. On day 4 an early morning urine sample will be collected for detection of aspirin metabolite (11-dehydro thromboxane B2). On day 6 venous blood sample will be collected, 17mls before and 17 mls after injection of DDAVP 15microgram subcutaneously. The blood samples will then be subjected for platelet function analysis.
3364095|NCT01869361|Active Comparator|Indomethacin|The patient will be given a loading dose of 50mg indomethacin by mouth followed by 25mg by mouth every six hours for a total of eight doses over 48 hours.
3364096|NCT01852370|Experimental|BOLT+BMT|All patients will receive a double lung transplant followed by a hematopoietic stem cell transplant. The lungs and stem cells are from the same partially HLA-matched cadaveric donor. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device.
3364098|NCT01829750|Sham Comparator|Control|"(Stage 1) No active intervention after standard surgical treatment~(Stage 2) Rescuing transplantation by cardiac progenitor cell infusion is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1."
3364099|NCT01829750|Active Comparator|Cardiac progenitor cell infusion|(Stage 1) single dose, intracoronary infusion of 0.3 million cells/kg cardiac progenitor cells
3364100|NCT01828099|Experimental|Ceritinib|Ceritinib patients were on continuous oral dosing of ceritinib 750 mg once daily in fasted state.
3364101|NCT01828099|Active Comparator|Chemotherapy|Chemotherapy patients (Induction per Investigator's choice) were on four 21-day cycles of Pemetrexed 500mg/m2 iv + Cisplatin 75 mg/m2 or Pemetrexed 500 mg/m2 iv + Carboplatin AUC 5-6 iv followed by Pemetrexed 500 mg/m2 every 21 days followed by Pemetrexed maintenance in non-progressors, etc (other usual rule to stop treatment).
3364106|NCT01783535|Experimental|Stratum A|"Participants with early bilateral or unilateral (unifocal or multifocal) retinoblastoma (R-E I-III, IC A-B; R-E IV with IC A or B; or IC C with limited sub-retinal seeding), and participants with bilateral disease in whom the advanced eye has been enucleated upfront (without any high risk histopathology) and the remaining eye has early stage disease (as defined above).~Interventions (see detailed description): vincristine, carboplatin, topotecan, filgrastim or PEG-filgrastim, and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
3364107|NCT01783535|Experimental|Stratum B|"Participants considered candidates for conservative management including those:~Participants with bilateral retinoblastoma who have R-E IV-V and IC D in one eye~Participants with advanced unilateral (unifocal or multifocal) retinoblastoma (R-E IV-V and IC D-E) who demonstrate foveal sparing by the tumor during EUA. Due to foveal sparing, these patients have potential for vision preservation.~Interventions (see Detailed Description): vincristine, topotecan, carboplatin, etoposide, filgrastim or PEG-filgrastim and focal therapy, including cryotherapy, laser photocoagulation, thermo-therapy, plaque radiotherapy."
3250080|NCT01382147|Experimental|S-HAM|S-HAM (S-HAMescalated for younger patients and S-HAMbasis for elderly patients)
3250081|NCT01382147|Active Comparator|TAD-HAM (younger) or HAM-HAM (elderly)|is TAD-9 - HAM for younger patients (with 2 mandatory induction cycles) and HAM (- HAM) for the elderly patients with the second HAM cycle only applied in the case of inadequate blast clearance (> 5%) in the day 16 bone marrow aspirate
3250082|NCT01382160|Experimental|adalimumab|40 mg every two weeks, by subcutaneous way
3364108|NCT01783535|Experimental|Stratum C|"Participants with advanced (R-E IV-V and IC D-E) unilateral retinoblastoma who require upfront enucleation. Participants will be assessed and treated by low, intermediate or high risk.~Interventions (see Detailed Description): vincristine, cyclophosphamide, MESNA, doxorubicin, etoposide, carboplatin, filgrastim or PEG-filgrastim, enucleation"
3364109|NCT01783535|Experimental|Stratum D|"Participants with bilateral retinoblastoma who may require upfront enucleation for one eye due to advanced disease (R-E IV-V and IC E).~Interventions (see Detailed Description): vincristine, carboplatin, topotecan, etoposide, enucleation, filgrastim or PEG-filgrastim, focal therapy, including cryotherapy, laser photocoagulation, thermotherapy (and thermo-chemotherapy) and episcleral plaque brachytherapy, and external beam radiation or proton beam radiation in select cases."
3250083|NCT01382199|Experimental|Ven100|Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients
3250084|NCT01382238|Experimental|Single arm|Subjects will have a screening visit within 30 days prior to the first dose of study drug, five treatment periods containing a single dose of study drug, followed by 48 hours of serial PK collection. In the 5 treatment periods subjects will receive DTG granule formulation 1) directly to mouth; 2) with purified water; 3) with Contrex brand water; and 4) with milk-based infant formula. They will also receive the current 50 mg tablet formulation administered with tap water. These treatments will be administered in a random order. Subjects will check out of the unit on Day 3 after the 48 hour PK sample in each period. Study periods will be separated by at least 5 days. Subjects will have a follow-up visit 5-7 days after last dose of DTG given.
3364118|NCT01655784|Active Comparator|Eighteen Coils (0.014-0.0155 inch)|Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
3364119|NCT01655784|Active Comparator|Standard Coils (0.014 inch)|Subjects who randomize to this arm will receive the standard diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target 360 Standard, Target 360 Soft, Target 360 Ultra, Target 360 NANO, Target 360 Helical Ultra, GDC-10 360 Standard SR, GDC-10 360 Soft SR, GDC-10 UltraSoft, GDC-10 3D, GDC-10 2D, GDC-10 Soft 2D SR, GDC-10 Soft SR, GDC-10 Soft, and/or any additional 0.014 inch or less diameter bare platinum intracranial coils.
3250085|NCT01382264|Experimental|CADS|
3250086|NCT01382277|Experimental|Rosuvastatin 20 mg|Rosuvastatin 20 mg for 76 weeks.
3250087|NCT01382316|Experimental|Making Alcoholics Anonymous Easier|Six session, group format intervention, consisting of introductory session, four core sessions (sponsorship, principles not personalities, spirituality, living sober), and return to introductory session as MAAEZ graduate
3250088|NCT01382316|Active Comparator|Usual care|Usual group sessions on education about alcohol and drug problems
3364124|NCT01593254|Active Comparator|Arm 1: Imatinib (≥400 mg)|Imatinib ≥400 mg tablets by mouth once daily (QD) or twice daily (BID) up to 60 months
3364125|NCT01593254|Active Comparator|Arm 2: Dasatinib (100 mg)|Dasatinib 100 mg tablet by mouth QD up to 60 months
3364126|NCT01578967|Other|ABVD followed by Brentuximab vedotin|Single arm trial
3250089|NCT01382329|Experimental|Treatment group I / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose A on Days 1 and 22
3250090|NCT01382329|Experimental|Treatment group II / Intramuscular|85 subjects to receive 2 intramuscular vaccinations at Dose B on Days 1 and 22
3250091|NCT01382329|Experimental|Treatment group III / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose A on Days 1 and 22
3250092|NCT01382329|Experimental|Treatment group IV / Subcutaneous|85 subjects to receive 2 subcutaneous vaccinations at Dose B on Days 1 and 22
3250093|NCT01382342|Experimental|rasagiline|Participants in this arm will receive 1 mg of rasagiline daily for the six month duration of the study.
3250094|NCT01382342|Placebo Comparator|Placebo|Participants in this group will receive 1 mg of placebo daily for the six month duration of the study.
3250095|NCT01382355||Kidney transplant|
3250096|NCT01382368|Experimental|Sildenafil|
3250097|NCT01382394||Sepsis Group, Heart failure group|"The first group will include 60 patients with the diagnosis of acute decompensated heart failure.~The second group will include 60 patients with the diagnosis of sepsis."
3250098|NCT01382407||Cetuximab|All patients who started treatment with ERBITUX® (cetuximab), as a single agent or in combination with chemotherapy.
3364154|NCT01460862||Omalizumab Cohort|
3250099|NCT01382420|Active Comparator|Adrenalectomy group|patients who undergo adrenalectomy
3364161|NCT01364597|Experimental|Brivaracetam|
3250100|NCT01382420|No Intervention|Control group|patients who receive conservative treatment
3250101|NCT01382433|Experimental|Chronic Cannabis Users|
3250102|NCT01382433|Experimental|Control|Neurotypical subjects
3250103|NCT01382459||type 1 DM children- intervention group|will have home visits and trainings at school
3364175|NCT01218854|Experimental|B-NASS|Block assisted needle angle selection system
3364176|NCT01218854|Experimental|L-NASS|laser assisted needle angle selection system
3364177|NCT01218854|Experimental|MD-NASS|mobile-device assisted needle angle selection system
3364180|NCT01186003|No Intervention|Standard insulin drip therapy|
3364181|NCT01186003|Active Comparator|Insulin drip and Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
3364184|NCT01153035|Other|Surgery followed by RFA|
3250104|NCT01382459||type 1 DM children- control group|will receive the standard care at the clinic
3250105|NCT01382472|Experimental|Rosuvastatin|40 mg rosuvastatin pre PCI and daily during hospital stay
3250106|NCT01382472|Other|Historical data (KOMPIS)|Patients from the KOMPIS trial (n=44) will be used as historical controls. They received no statins omn the first day. Low dose simvastatin during hospital stay.
3250107|NCT01382485|Active Comparator|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
3250108|NCT01382485|Experimental|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
3250109|NCT01382498|Placebo Comparator|Placebo|Placebo tablets will be administered to the patients in Placebo arms daily for three months.
3250110|NCT01382498|Experimental|Calcium dobesilate|Calcium dobesilate as 500 mg tablets will be administered once to the patients daily.
3250111|NCT01382524||Stabilization system A|A commercialized stabilization dressing using a winged PIV catheter.
3250112|NCT01382524||Stabilization System B|A commercialized stabilization device using a non-winged PIV catheter
3250113|NCT01382537|Active Comparator|A|
3250114|NCT01382537|Placebo Comparator|B|
3250115|NCT01382550||VTE subjects|"subjects with a recent (<3 months) first VTE event undergoing long-lasting OAT or 12-month OAT~Exclusion criteria: missing data during the follow-up; contraindications to or lack of compliance to oral anticoagulation (OAT), lack of informed consent; history of previous VTE event; indication for continuous oral anticoagulation (e.g., an artificial heart valve or chronic atrial fibrillation); events occurring during pregnancy, malignancy, puerperium, oral contraceptive intake, hormone replacement therapy; deficiencies of Prot. C and Prot S or combined inhibitor deficiencies."
3364205|NCT01036581|Experimental|drug-using|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
3364206|NCT01036581|Active Comparator|Healthy controls|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
3364207|NCT01036581|Experimental|smokers|Subjects must be between the ages of 18-55, be generally healthy and male or non-pregnant female. Smokers, non-smokers, drug using and non-drug using populations will participate in this study.
3364211|NCT00995202|Other|Standard Monitoring CEA/ Standard Imagery|No specific follow-up of CEA and Standard imagery
3364212|NCT00995202|Other|Intensive monitoring CEA/ Standard Imagery|Intensive follow-up CEA and Standard imagery .
3250116|NCT01382576||PCOS patients|
3250117|NCT01382576||PCOS patients and healthy controls|There are two groups in this study. One group is PCOS patients and other group is healthy controls.
3250118|NCT01382589|Experimental|Arm A: Afamelanotide + NB-UVB|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 6 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total)
3250119|NCT01382589|Active Comparator|Arm B: NB-UVB alone|Subjects in this arm B will receive NB-UVB light only (administered thrice weekly, 72 treatments in total)
3250120|NCT01382615||Healthy Volunteers|Healthy volunteers who have agreed to have a bone marrow and/or blood harvest as part of a donation to a transplant recipient.
3250121|NCT01382615||Patients with multiple myeloma|Patients undergoing routine blood draw and bone marrow aspirates as part of their ongoing follow-up care for myeloma at the Norris Cotton Cancer Center of DHMC.
3250122|NCT01382628||Preulcerative plantar foot lesion|An area on the plantar foot, usually at the location of a bony prominence, that presents with erythema, significant hyperkeratosis, or thin, shiny skin.
3364213|NCT00995202|Other|Intensive Monitoring CEA / Intensive Monitoring Imagery|Intensive follow-up CEA and Intensive imagery
3364214|NCT00995202|Other|Standard Monitoring CEA/ Intensive Monitoring Imagery|No specific follow-up of CEA and Intensive Imagery
3250123|NCT01382628||Plantar ulcer no history of amputation|Plantar ulceration without a history of amputation or require an amputation.
3250124|NCT01382628||Plantar ulcer and digital amputation|Plantar ulceration who will be undergoing a digital amputation.
3250125|NCT01382628||Plantar ulcer and transmet amputation|Plantar ulceration who will be undergoing a transmetatarsal amputation.
3250126|NCT01382628||Plantar ulceration and choparts|Plantar ulceration who will be undergoing Chopart's or more proximal amputation.
3250127|NCT01382641|Other|Hoya AF-1 IOL|
3250128|NCT01382641|Other|Revital Vision|
3250129|NCT01382654|Experimental|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
3250130|NCT01382654|Experimental|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
3250131|NCT01382654|Experimental|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
3250132|NCT01382654|Experimental|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
3250133|NCT01382654|Active Comparator|azelastine 0.1%|nasal spray 2 sprays in each nostril for a total of 3 doses
3250134|NCT01382667||GLP-2 and symptom evaluation|Before starting and at the end of the chemotherapy, along with a blood withdrawal for GLP-2 evaluation, a GSRS (gastrointestinal symptom rate scale) questionnaire will be filled by each patient to account for GI symptoms. In addition, minor complaints such as warm sensation after chemotherapy, susceptibility to nausea under specific condition, sweating and weakness will scored by visual analog score (VAS). Lastly, the NCI-CTC score for mucositis will be performed.
3250135|NCT01382680|Active Comparator|Classic guidewires|Conventional guidewires used in combination as preferred by the investigating ERCP specialist
3250136|NCT01382680|Active Comparator|New guidewire (G240)|Primary use of the new guidewire (G240)
3364218|NCT00943618|Active Comparator|Group 1|Varenicline and Bupropion
3364219|NCT00943618|Placebo Comparator|Group 2|Varenicline and Placebo
3364220|NCT00943618|Placebo Comparator|Group 3|Placebo that looks like varenicline and a placebo that looks like bupropion.
3250137|NCT01382693|Experimental|TimeSlips group storytelling program|
3364228|NCT00914823|Experimental|kisspeptin, GnRH|intravenous or subcutaneous administration of kisspeptin 112-121 and/or administration of GnRH
3250138|NCT01382693|Active Comparator|Standard care activity program|
3250139|NCT01382706|Experimental|Treatment|Patients receive docetaxel IV over 1 hour on day 1 and lapatinib ditosylate PO QD on days 1-21. Courses repeat every 21 days until disease progression or unacceptable toxicity.
3250140|NCT01382732|Experimental|Carbetocin|"Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.~Ringer's Lactate 4mL applied to a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr"
3250141|NCT01382732|Active Comparator|Oxytocin|Protocol B (oxytocin + placebo) Ringer's Lactate 11mL directly into the vein in no less than two minutes. Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
3250142|NCT01382745|Experimental|Nimotuzumab|Patients will receive weekly injections of Nimotuzumab (200mg/injection) for 12 weeks and standard external beam radiotherapy
3250143|NCT01382758||Acute kidney injury|The group of patients who develop acute kidney injury as defined by the pediatric RIFLE criteria.
3250144|NCT01382758||No acute kidney injury|The patients who do not develop acute kidney injury
3250145|NCT01382771|Active Comparator|Intra-articular corticosteroid injection|Intra-articular corticosteroid injection in conjunction with confirmatory anesthetic medial branch blocks
3250146|NCT01382771|Placebo Comparator|Intra-articular saline injection|Intra-articular saline injections with confirmatory anesthetic medial branch blocks
3250147|NCT01382797|Placebo Comparator|Placebo|Capsules for oral administration
3250148|NCT01382797|Experimental|ALKS 37|Capsules for oral administration
3250149|NCT01382810|Active Comparator|Altaire Gel forming solution|
3364246|NCT00580515|Experimental|1|6 sessions of Family Focused Group Therapy
3364247|NCT00580515|Experimental|2|10 Sessions of Family Focused Group Therapy
3364248|NCT00580515|Active Comparator|3|Standard Care- Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request
3364249|NCT00529763|Experimental|1|
3250150|NCT01382810|Placebo Comparator|Refresh Tears|
3250151|NCT01382823|Experimental|Femtosecond Laser|
3250152|NCT01382836||Black inner city children with persistent asthma|
3250153|NCT01382836||Black inner city non-atopic healthy children|
3250154|NCT01382849||CAA positive microbleeders|Cerebral amyloid angiopathy (CAA) positive microbleeders
3250155|NCT01382849||probable CAA macrobleeders|
3250156|NCT01382849||CAA negative microbleeders|
3250157|NCT01382862|No Intervention|Regular Care|Regular care for suspected stroke in Berlin consists of an ambulance with paramedics only, and neither computed tomography (CT) nor point-of-care diagnostics. In Berlin, emergency physicians are involved in prehospital care only in cases of special medical emergencies such as severe instability of vital parameters or loss of consciousness.
3250158|NCT01382862|Active Comparator|Stroke Emergency Unit Mobile (STEMO)|The STEMO is equipped with a CT-scanner, a point-of-care laboratory and the infrastructure for tele-radiological as well as videoconferencing support. STEMO is operated by a team of experienced neurologists (n=6, half-time positions, with additional formal training in emergency medicine according to the requirements of the Berlin Medical Board), paramedics of the fire brigade (n=3, two years formal training in emergency care) and radiology technicians (n=3, three years formal training in radiology assistance and three months formal training in emergency care).
3250159|NCT01382875|No Intervention|Conventional care program|
3250160|NCT01382875|Experimental|Multi-disciplinary management program|
3250161|NCT01382888|Active Comparator|Heparin 2,400 IU /ml Cutaneous Spray|Patients are randomized to receive the active comparator heparin 2,400 IU/ml cutaneous spray for 24 weeks
3250162|NCT01382888|Placebo Comparator|Placebo Cutaneous Spray|Patients are randomized to receive placebo cutaneous spray for 24 weeks
3250163|NCT01382914|Experimental|chlorhexidine 0.12 %|
3250164|NCT01382927||General Anesthesia|
3250165|NCT01382927||Spinal Anesthesia|
3250166|NCT01382966||Single group|Maintenance hemodialysis patients of minimal 6 months of hemodialysis duration; free of malignancy, infection and autoimmune disease; age over 18 years
3250167|NCT01382979|Experimental|Alcohol education and prevention|AlcoholEdu is an online course designed to prevent alcohol misuse and related problems among college freshmen.
3250168|NCT01382979|No Intervention|Control|Control group.
3250169|NCT01382992||Early Stage|
3250170|NCT01382992||Late Stage|
3250171|NCT01383031|Active Comparator|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
3250172|NCT01383031|Active Comparator|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC（conventional laparoscopic cholecystetomy）by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
3250173|NCT01383044|Experimental|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
3250174|NCT01383044|Active Comparator|carvedilol|carvedilol 6.25-12.5 mg per day
3250175|NCT01383057|Experimental|Femtosecond Laser|
3250176|NCT01383070|No Intervention|Lactational Conseling|The existing staff of the hospitals will be provided training in IYCF by BPNI. They will be encouraged to set up their own systems to continue counseling during the ante natal period, at delivery and during the immunization visits. The participants will be asked to come for the same schedule of visits as in the intervention group where their data will be collected.
3250177|NCT01383070|Experimental|Lactation Counseling by Cell Phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
3250178|NCT01383083||iloprost|In the adult patient group, iloprost acceptable target dose is 2.5 ug 4-6 times/day according to the patient's compliance. Because of the concern of safety and tolerability, during the first 4 weeks of treatment, patients receive 2.5 ug twice daily. After 4 weeks, this is increased to the target dose, if iloprost is well tolerated.
3250179|NCT01383109|Experimental|Pyronaridine|All subjects will receive a single dose of Pyronaridine
3250180|NCT01383122|Active Comparator|Active device|Functional pulsed electromagnetic field device
3250181|NCT01383122|Placebo Comparator|Placebo - inactive device|Inactive pulsed electromagnetic field device
3250182|NCT01383148|Experimental|Arm 1 - TG4010 + first line therapy|First-line therapy and maintenance therapy
3250183|NCT01383148|Active Comparator|Arm 2 : Placebo + first line therapy|First-line therapy and maintenance therapy
3250184|NCT01383187|Experimental|DE graft and PRP concentrate|Patients enrolled in this arm receive the innovative treatment methods consisting of application of DE graft together with PRP concentrate.
3364300|NCT00065676|Experimental|1 gram quercetin|1 gram quercetin with 6 hour OGTT
3364301|NCT00065676|Experimental|2 grams quercetin|2 gram quercetin with 6 hour OGTT
3364302|NCT00065676|Experimental|placebo|placebo with 6 hour OGTT
3250185|NCT01383187|Active Comparator|Standard treatment group|PAtients included into this arm will receive a standard treatment for deep-burn injuries, i.e. DE graft without the application of the PRP concentrate.
3250186|NCT01383226|Other|Thoracic endosonography|Thoracic endosonography, either endobronchial or esophageal ultrasound controlled needle aspiration, is a minimally invasive diagnostic technique.
3250187|NCT01383239|Active Comparator|Immediate postoperative therapy|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay
3250188|NCT01383239|Active Comparator|postoperative therapy delayed for 6 weeks|Patients will be randomized into one of two groups: immediate postoperative therapy versus 6-week delay.
3250189|NCT01383252|Experimental|Water method|Water infusion in lieu of air insufflation for screening and surveillance colonoscopy
3250190|NCT01383252|Active Comparator|Air method|Air insufflation for screening and surveillance colonoscopy
3250191|NCT01383265|Experimental|Water method and chromoendoscopy|Combined water method with chromoendoscopy using 0.008% IC solution for screening colonoscopy
3250192|NCT01383265|Active Comparator|Water method|Control method will use plain water with the water method for screening colonoscopy
3364314|NCT00044304|Experimental|Imatinib|open label imatinib mesylate treatment
3364315|NCT00044304|Experimental|Ruxolitinib|open label ruxolitinib treatment
3250193|NCT01383278|Experimental|Computer-directed 5 A's intervention for smoking|
3250194|NCT01383278|Active Comparator|Screening and resource provision|
3250195|NCT01383291||Pelvic floor prolapse|Those who underwent prolift and those who underwent IVS
3250196|NCT01383330|Experimental|Megace|800mg
3250197|NCT01383330|Active Comparator|DW-ES(A)|625mg
3250198|NCT01383330|Active Comparator|DW-ES(B)|625mg
3250199|NCT01383343|Experimental|Treatment (FOLFIRI and bevacizumab)|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1, leucovorin calcium IV over 2 hours on day 1, fluorouracil IV continuously over 46 hours on days 1-2, bevacizumab IV over 30-90 minutes on day 1, and sorafenib tosylate PO QD or BID on days 3-6 and 10-13*. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3250200|NCT01383395|Experimental|simvastatin/cilostazol|simvastatin 40 mg on day 1 and 6, cilostazol 100 mg from day 2 to day 6
3250201|NCT01383408|Sham Comparator|healthy individual|healthy individual with no lung disease and no history of cancer including lung cancer
3250202|NCT01383408|Experimental|lung cancer|patients with histologically confirmed lung cancer, but no history of other cancer
3250203|NCT01383408|Experimental|breast cancer|patients with histologically confirmed breast cancer, but no history of other cancer
3250204|NCT01383408|Experimental|ovarian cancer|patients with histologically confirmed ovarian cancer, but no history of other cancer
3364363|NCT00001563|Experimental|1|EPOCH-R every 3 weeks for up to 6 cycle
3250205|NCT01383460|Active Comparator|G-CSF+EPO|
3250206|NCT01383460|Placebo Comparator|Placebo|
3250207|NCT01383473||Leukemia Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
3250208|NCT01383473||Solid Tumor Patients|6-12 year old pediatric oncology patients' perceptions of their school experiences pre and post cancer diagnosis will be done through interviews and drawings.
3250209|NCT01383512|Experimental|Rehabilitation robotics|Subjects will be practicing an Armeo Spring rehabilitation program in addition to their usual care (1.5h/day,5d/week) 1h/day 5d/week 4 weeks.
3250210|NCT01383512|Active Comparator|Self-rehabilitation|Subject will associated to there classical care 1 hours, 5 days per week during 4 weeks, of self rehabilitation.
3250211|NCT01383512|Other|Healthy volunteer|20 healthy volunteer will be recruiting and using ARMEO Spring. All volunteer will repeat 5 times the same program on the medical device.
3250212|NCT01383525|Experimental|Direct Selective Trabeculoplasty|Treatment by an Direct Selective Trabeculoplasty device
3250213|NCT01383538|Experimental|FOLFIRINOX Plus IPI-926|
3376103|NCT02831049|Experimental|1|alcohol retrieval/alcohol extinction
3376104|NCT02831049|Active Comparator|2|soft-drink retrieval/alcohol extinction
3376105|NCT02831049|Active Comparator|3|alcohol retrieval/soft-drink extinction
3376106|NCT02820961|Active Comparator|Cohort 1|Cohort 1 will evaluate exemestane's effect on the PK of entinostat. Each treatment cycle is 28 days.
3250214|NCT01383551|Experimental|"Becoming Parents intervention"|"A Becoming Parents Programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
3250215|NCT01383551|No Intervention|Usual prenatal education|Attend usual prenatal classes which will be provided by the midwives in the hospital.
3250216|NCT01383564|Active Comparator|CPAP group|CPAP group
3250217|NCT01383564|Placebo Comparator|non CPAP group|non CPAP group
3250218|NCT01383577|Experimental|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each session of treatment.
3376107|NCT02820961|Active Comparator|Cohort 2|Cohort 2 will enroll when Cohort 1 enrollment is complete. Cohort 2 will evaluate entinostat's effect on the PK of exemestane. Each treatment cycle is 28 days.
3376108|NCT02804932|Experimental|Beetroot crystals (nitrate)|Participants will receive a nitrate rich beetroot powder (10g/day) for 8 weeks.
3376109|NCT02804932|Placebo Comparator|Placebo (beetroot powder, no nitrate)|Participants will receive a beetroot powder placebo (no nitrate) for 8 weeks.
3376110|NCT02779556|Other|Enhanced Usual Care|ADA Living Well with Diabetes Workbook, 15 minute in-person counseling, follow-up every 3 months
3376111|NCT02779556|Other|Intervention|ACP Living with Diabetes Guide, 15 minute in-person counseling , 15 minute follow-up counseling (3, 6, and 9 months), monthly phone calls after 3 months
3250219|NCT01383577|Experimental|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. The three following monthly appointments of patients of this arm are for sham hemorrhoidal ligations and final revision.
3250220|NCT01383590|Experimental|Cat-PAD|
3250221|NCT01383603|Experimental|Cat-PAD|
3376112|NCT02726009|Experimental|Degarelix|
3376113|NCT02724774|Experimental|Promoting First Relationships® (PFR)|10 week home visiting program
3376114|NCT02724774|No Intervention|Parent Information Packet|A packet is mailed to the families, including handouts related to child development, health, and local resources.
3376115|NCT02722941|Active Comparator|Cohort A: Maintenance Therapy|Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule.
3376116|NCT02722941|Active Comparator|Cohort B: Maintenance Therapy|Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule.
3376117|NCT02721498|Active Comparator|Visit A|Rest period for 30-60 minutes
3376118|NCT02721498|Active Comparator|Visit B|Airway clearance session utilising the Active Cycle of Breathing techniques (ACBT) supervised by a specialist physiotherapist for 30-60 minutes.
3364404|NCT05150171|Experimental|e-self-management intervention|Patients will receive the HAPPY Hands e-self-management intervention delivered through a smartphone app.
3364405|NCT05150145|Experimental|Radiotherpy will be performed to thoracic and liver metastasis.|Radiotherapy for liver metastases and thoracic will be performed in paticipants with liver metastasis who achieved CR or PR after chemotherapy.
3364406|NCT05150145|No Intervention|Radiotherpy will be performed to thoracic.|Radiotherapy performed only on the thoracic after chemotherapy of paticipants with liver metastasis who achieved CR or PR.
3250222|NCT01383629|No Intervention|No counselling|normal preoperative procedures prior to vitrectomy surgery
3250223|NCT01383629|Experimental|Preoperative counselling|Counselling to patient about what to expect during vitrectomy surgery under local anaesthesia
3364410|NCT05150106||Laryngeal dystonia|Patients with laryngeal dystonia (or spasmodic dysphonia)
3364411|NCT05150106||Voice tremor|Patients with voice tremor (essential or dystonic)
3364412|NCT05150106||Healthy controls|Healthy research volunteers
3364414|NCT05150080||cardiotoxicity|subjects with heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
3250224|NCT01383642||individuals age >=70|
3250225|NCT01383655|Experimental|Magnesium|i.v. magnesium infusion 40mg/kg in 20 min
3364415|NCT05150080||non-cardiotoxicity|subjects with on heart failure, coronary artery disease, valvular heart disease, arrhythmia, hypertension, thromboembolic disease, peripheral vascular disease and stroke, pulmonary hypertension and pericardial disease after hematopoietic stem cell transplantation.
3364416|NCT05150067|Experimental|Experimental group|The participants in the experimental group received a blended learning programme with face-to-face training and an online module on handover practice.
3364417|NCT05150067|Active Comparator|waitlist control group|The participants in the waitlist control group received the same face-to-face training workshop as the experimental group. However, these participants were invited to access the online module only after data collection was completed.
3364418|NCT05150041|Active Comparator|iPRo2 only (Control group)|- The Control group will go through target lifestyle coaching including diet and exercise and they will undergo 24 weeks of follow-up period.
3364419|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week treatment (Treatment group 1)|Treatment group 1 will go through target lifestyle coaching including diet and exercise and will have 1 session of RT-CGM after which they will undergo 24 weeks of follow-up period.
3364420|NCT05150041|Experimental|iPRo2 + RT-CGM 1 week on /3 weeks off (2cycles) (Treatment 2)|- Treatment group 2 will go through target life coaching including diet and exercise and will have 2 sessions(CGM 1week, 12week after measuring HbA1c) of RT-CGM after which they will undergo 24 weeks of follow-up period.
3250226|NCT01383655|Placebo Comparator|Placebo|i.v. 0.9 % NaCl
3250227|NCT01383668|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD on days 1-28 and gold sodium thiomalate IM on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3250228|NCT01383694|Experimental|Piperine Dose 1|Piperine 1 mM
3250229|NCT01383694|Experimental|Piperine Dose 2|Piperine 150 microM
3364421|NCT05150028|Experimental|Intervention - Pediatric parent/caregiver|Questionnaires along with instructional video for the use of Medication Event Monitoring System (MEMS)
3364422|NCT05150028|Experimental|Clinicians|Will complete pre and post survey about medication education practices
3364423|NCT05150015|Experimental|Number of consented patients who complete the antibiotics through an elastomeric pump|Flucloxacillin, piperacillin/taozbactam and benzylpenicillin will be use
3250230|NCT01383733|Experimental|Single Arm|
3250231|NCT01383746|Experimental|1|Yttrium microsphere injection
3250232|NCT01383772|Experimental|Visual fields|One arm study. All patients will receive laser treatment following visual field testing.
3250233|NCT01383785|Active Comparator|GROUP A|Intracoronary full bolus dose of abciximab proximal to thrombus occlusion
3250234|NCT01383785|Experimental|GROUP B|Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter
3250235|NCT01383785|Experimental|GROUP C|Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter
3250236|NCT01383798|Placebo Comparator|Placebo|Red capsule (50 mg) lactose
3250237|NCT01383798|Experimental|Ferrous sulfate|
3250238|NCT01383811|Active Comparator|Moderate Intensity Aerobic Exercise|
3250239|NCT01383811|Other|Wait List/Usual Care|The subjects in this group will continue to receive the usual treatment that they were on at the time of enrollment through the wait list period of 12 weeks. Subsequently they will receive the 12 weeks of aerobic exercise program intervention
3364424|NCT05150002|Experimental|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH|Cervical spinal cord stimulation on cerebral vasospasm after aneurysmal SAH
3364425|NCT05149989|Experimental|Proning|Proned on standard and proning pillows
3250240|NCT01383824|Other|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
3364426|NCT05149976|Experimental|Experimental group|Patients scheduled for VFSS testing
3364427|NCT05149963|Experimental|Cognitive Behavioural Therapy (CBT) for Chronic Loneliness|Participants will receive an average of 12 50-minute sessions of CBT aiming to reduce their loneliness. The intervention is modular and has been developed for this study. In total there are 10 treatment modules, 1) Assessment, 2) Formulation and Psychoeducation, 3) Challenging Negative Interpersonal Appraisals and Counterproductive Behaviours, 4) Challenging Negative Thoughts and Cognitive Biases, 5) Challenging Self-focussed Attention, Hypervigilance and Camouflaging, 6) Values-based Social-skills Training, 7) Problem Solving, 8) Findings Friends, 9) Managing Emotions and 10) Relapse Prevention. All participants will complete module 1) Assessment and module 2) Formulation and Psychoeducation. They will then work with the clinician to collaboratively develop a treatment plan based on their formulation. The treatment will be comprised of one or more of the intervention modules. All participants will then complete module 10) Relapse Prevention at the end of their treatment.
3364428|NCT05149963|No Intervention|Baseline Phase 1 (12 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
3364429|NCT05149963|No Intervention|Baseline Phase 2 (19 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
3364430|NCT05149963|No Intervention|Baseline Phase 3 (26 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
3364431|NCT05149963|No Intervention|Baseline Phase 4 (33 days)|The design of the study is a randomised multiple-baseline single-case experimental design (SCED). Participants will be randomised to one of 4 baseline lengths (12 days, 19 days, 26 days or 33 days). The baseline phase will act as the control condition within and between participants.
3376119|NCT02706288|Experimental|Weight loss with diet with exercise|Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after 7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until 7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
3250241|NCT01383837|Experimental|STYLEnS|Multifamily Group HIV/STI Prevention intervention or Single Family Dyad (youth and a parent)
3250242|NCT01383837|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
3250243|NCT01383850|Active Comparator|NCPAP + standard air|
3250244|NCT01383850|Experimental|NCPAP + Heliox|
3250245|NCT01383876|Active Comparator|Collar|Hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
3250246|NCT01383876|Experimental|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
3250247|NCT01383889|Other|Treading mill exercise|Pregnant women in this group will perform treadmill exercise during 20 minutes. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
3250248|NCT01383889|Other|Stationary bicycle exercise|Pregnant women in this group will perform exercise using a stationary bicycle. The intensity of exercise will be maintained between 60% and 80% of maximum heart rate by Karvonen formula, in addition to the subjective perception of exertion on the modified Borg scale (moderate intensity).
3250249|NCT01383902|Other|dessert / chocolate|
3250250|NCT01383915||inpatients|Youth with a clinical diagnosis of a mood disorder or psychosis spectrum disorder
3250251|NCT01383941||Subjects with Mild to Severe Asthma|This is an epidemiologic, multi-center, cross-sectional study to define the phenotypic characteristics of Difficult-to-Treat asthma, among children receiving one year of guidelines-based therapy for asthma and rhinitis/rhinosinusitis.
3250252|NCT01383967|Experimental|LY2979165 Part A, Cohort 1|20 mg LY2979165 administered orally, daily for 14 days
3250253|NCT01383967|Experimental|LY2979165 Part A, Cohort 2|60 mg LY2979165 administered orally, daily for 14 days
3250254|NCT01383967|Experimental|LY2979165 Part A, Cohort 3|100 mg LY2979165 administered, orally daily for 14 days
3250255|NCT01383967|Experimental|LY2979165 Part A, Cohort 4|150 mg LY2979165 administered orally, daily for 14 days
3250256|NCT01383967|Experimental|LY2979165 Part B, Cohort 5|Dose to be determined by safety review of doses administered in Part A, administered, orally daily for 14 days
3250257|NCT01383967|Placebo Comparator|Placebo|Administered orally, daily for 14 days in a ratio of 3:1 in each Cohort of Part A
3250258|NCT01383967|Experimental|LY2979165 Part A, Cohort 6|250 mg LY2979165 administered orally, daily for 14 days
3250259|NCT01383967|Experimental|LY2979165 Part A, Cohort 7|400 mg LY2979165 administered orally, daily for 14 days
3250260|NCT01383980|No Intervention|Control|Tube feeds are held night prior to elective surgery (standard of care)
3250261|NCT01383980|Experimental|Continuous Feeding|Tube feeds are continued up until surgery. Subjects with a nasogastric tube will have their stomach contents emptied prior to surgery.
3250262|NCT01384006||Control|standard pancreas allograft recipients
3250263|NCT01384006||Study|recipients of extended donor criteria pancreas allografts
3250264|NCT01384032|Experimental|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
3364432|NCT05149950|Experimental|Increased therapist contact.|The patient gets access to the internet treatment via a secure login to 1177 The care guide-services on 1177.se. The treatment lasts for six months and includes 12 treatment modules. The patient works with each module for two weeks. The modules have different numbers of sections, but most have 4-5 sections. The modules consist mainly of text but also films and pictures are included. It is also possible to listen to the text. The modules end with one or more exercises to be performed before the next module is activated for the patient. Participants receive feedback on the information from therapists via the email function in the treatment program. The therapist provides individual feedback on completed exercises and answers questions that the patient has.
3364433|NCT05149950|Other|Less therapist contact.|The feedback from the therapist will largely be general and not individually tailored. The general feedback is based on responses to the participants in the previous pilot study. No physical or digital meetings between patient and therapist take place during treatment.
3364434|NCT05149937|Experimental|Interventional group|Implementation of interprof Home measures to improve cooperation between nursing services, general practitioners and members of the therapeutic professions in the care of people living at home with care needs.
3364435|NCT05149924|Experimental|QL1012，Recombinant Human Follicle Stimulating Hormone for Injection|
3364436|NCT05149924|Active Comparator|Gonal-f ®|
3364437|NCT05149911|Experimental|Coaching|Participants randomized to the coaching group will receive a 1-hour initial professional coaching session followed by five 30-minute professional coaching sessions occurring at a goal frequency of every 2 to 3 weeks within 5 months (total of 3.5 coaching hours). All coaching sessions will be conducted individually (i.e. between one coach and one participant). Participants will be able to request coaching on any topic to individualize the intervention, but the general structure of the sessions will be standardized across participants. All coaching sessions will be performed over the phone or virtual web meeting as standard in coaching practices.
3364438|NCT05149911|No Intervention|Control|"Participants randomized to the control group will receive no intervention but will be asked to complete the distress and wellness survey at the same time points as participants in the intervention group. Participants in the control group will receive the life coaching intervention after the statistical analysis is completed."
3364439|NCT05149898|Experimental|Open-label|Open-label
3364440|NCT05149885|Experimental|Investigational SenseGuard Device|"Subjects with suspected diagnosis of Asthma and eligible for MCT will be recruited to the study.~The MCT procedure will be performed as usual, with the addition of SG measurements after each spirometry for each Methacholine dose."
3364441|NCT05149872|Other|TOF ratio 0.9 spontaneous recovery|TOF ratio maintained at 0.9, spontaneous recovery
3364442|NCT05149872|Other|TOF ratio 0.7 spontaneous recovery|TOF ratio maintained at 0.7, spontaneous recovery
3364443|NCT05149872|Other|TOF ratio 0.7 low dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 2 mg/kg
3364444|NCT05149872|Other|TOF ratio 0.7 high dose sugammadex|TOF ratio maintained at 0.7, reversal with sugammadex 4 mg/kg
3250265|NCT01384032|Experimental|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
3250266|NCT01384032|Experimental|High saturated fat plus DHA diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
3250267|NCT01384045|No Intervention|Usual Care|Patients continue to receive usual diabetes care without outreach by health promotions staff.
3250268|NCT01384045|Experimental|Arm 1-Health Promotoin Outreach|Active outreach by health promotion staff to send diabetes report card and schedule services including laboratory testing and visits.
3364445|NCT05149859||BED+ : Participants with obesity and binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 positive score and a Binge Eating Scale score >16
3364446|NCT05149859||BED-: Participants with obesity but without binge eating disorder|Obesity is define by a BMI ≥ 30 kg.m-2 Binge eating disorder is defined by Binge Eating Disorder Screener (BEDS)-7 negative score and a Binge Eating Scale score < 12
3250269|NCT01384058|Active Comparator|Ezetimibe 10mg/d|intake of ezetimibe 10mg per day for six weeks after wash-out
3250270|NCT01384058|Active Comparator|Simvastatin 20 mg per day|intake of simvastatin 20 mg per day for six weeks after wash-out
3364447|NCT05149846|Other|Pre-conditioning|Pre-conditioning by three consecutive 60 seconds balloon inflations, spaced 120 seconds apart followed by 10 minutes rest prior to PCI
3364448|NCT05149846|No Intervention|Controll|No pre-conditioning, standard care
3250271|NCT01384058|Active Comparator|Ezetimibe 10 mg/d and Simvastatin 20mg/d|intake of ezetimibe 10 mg and simvastatin 20 mg per day for six weeks after wash-out
3250272|NCT01384071|Experimental|Unstable shoes (MBT)|MBT shoes (Masai Barefoot Technology, Switzerland)
3250273|NCT01384071|Sham Comparator|Stable shoes (Adidas)|Adidas stable shoes (Adidas Bigroar2)
3250274|NCT01384084|Experimental|POP repair plus mini-sling|Patients affected by urogenital prolapse and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy plus anti-incontinence procedure (mini-sling).
3250275|NCT01384084|Active Comparator|pelvic organ prolapse repair|Patients affected by urogenital prolapsed and urinary incontinence, who are candidates for pelvic organ prolapsed repair using sacropexy, will receive sacropexy alone.
3250276|NCT01384097||Conventional care|patients treated by conventional haemodynamic care intraoperatively
3250277|NCT01384097||Haemodynamic algorithm|patients treated within a goal-directed haemodynamic algorithm intraoperatively
3364449|NCT05149820|Active Comparator|Nudge Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
3250278|NCT01384110|Experimental|Brown Seaweed Lemon Tea|Single administration of lemon tea containing 500 mg of brown seaweed powder and 50 g of sucrose
3364450|NCT05149820|Active Comparator|Nudge Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Nudge design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
3364451|NCT05149820|Active Comparator|Preference Prompt, Liberal Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a liberal magnesium supplementation strategy.
3364452|NCT05149820|Active Comparator|Preference Prompt, Restrictive Magnesium Strategy|This group will be randomised to receive the Preference design of electronic point of care randomisation prompt. The prompt will encourage the clinician to follow a restrictive magnesium supplementation strategy.
3364453|NCT05149807|Experimental|SHR-1701 + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
3250279|NCT01384110|Placebo Comparator|Placebo lemon tea|Single administration of placebo lemon tea containing 50 g of sucrose
3250280|NCT01384136||High risk pregnancy|
3250281|NCT01384136||"|Control - Normal low risk pregnancies"|
3250282|NCT01384149|Active Comparator|standart slt|gonioscopic selective laser trabeculoplasty
3250283|NCT01384149|Experimental|external slt|perilimbal ,above trabecular meshwork 180 degrees ,100 laser dots
3364454|NCT05149807|Placebo Comparator|Placebo + Tegafur Gimeracil Oteracil Potassium and Oxaliplatin|
3364455|NCT05149794|Experimental|Calisthenic Exercises|The participants of this group perform calisthenic exercises.
3364456|NCT05149794|No Intervention|Conventional Training|The participants of this group perform activities of daily routines like playing cricket, taking swings etc
3364459|NCT05149768|Experimental|Administration of Brentuximab vedotin|Maximum duration of treatment: 48 weeks Maximum dose allowed: 0.6 mg/kg Route of administration: intravenous
3364460|NCT05149755|Experimental|Medtronic Evolut PRO+ TAVR System and guideline-directed management and therapy (GDMT)|
3364461|NCT05149755|No Intervention|Clinical site determined guideline-directed management and therapy (GDMT) alone|
3364462|NCT05149742|Experimental|Cases: Patients with severe to profound hearing loss|Patients aged between 45 to 64 years with severe to profound bilateral post-lingual sensorineural hearing loss with a maximum intelligibility of 70% (disyllabic words) in free-field silence with hearing aids at 60 dB SPL
3364463|NCT05149742|Active Comparator|Controls: 90 matched subjects with normal hearing|Healthy controls aged between 45 to 64 years with normal hearing on pure-tone audiometry (as function of ISO 7029 reference)
3364464|NCT05149729|Experimental|Crowe type 3 and 4 patients undergoing shortened hip replacement|Clinical and radiological results of Crowe type 3 and 4 patients who underwent shortened hip prosthesis at 12 and 24 months
3364465|NCT05149716|Experimental|Taurine supplementation|Taurine supplementation composed of capsules of taurine powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
3364466|NCT05149716|Placebo Comparator|Placebo supplementation|Placebo supplementation composed of capsules of starch powder. Dosage: 1.5 gram/day Frequency: 1 time/day Duration: 16 weeks
3364467|NCT05149703|Experimental|Mezieres Group|This intervention includes a total of three postures of the Mézières therapy. Specifically, the postures maintained for 12 weeks consist of: supine dancer; in supine position with the upper extremities abducted 120 °; and dancer in a sitting position.
3364468|NCT05149703|Active Comparator|Isostretching Group|This study aims to follow a total of 6 isostretching postures, the most similar to the Mezieres method. In each of the isostretching positions, if it is symmetric, 3, 6 or 9 repetitions will be performed and if it is asymmetric, 2, 4, or 8 repetitions.
3364469|NCT05149690|Experimental|monopolar dielectric diathermy and supervised therapeutic exercise|The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar musculature by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. Once the application of (MDR) is finished, an exercise program supervised by a physiotherapist will be carried out. The exercise program will consist mainly of three types: stability and lumbo-pelvic motor control, strengthening and stretching of the lumbar muscles (Annex XIV), with a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday, a total of 8 treatment sessions.
3250284|NCT01384162|Experimental|sNN0029, ICV infusion|
3250285|NCT01384175|Active Comparator|intravenous analgesia|Patients received postoperative analgesia by intravenous fentanyl 10 µg/ml 3-8 mL/h.
3250286|NCT01384175|Active Comparator|epiduaral infusion|Patients received epidural analgesia intraoperatively with ropivacaine 0.75% 1 mg/kg and fentanyl 1 µg/kg followed by continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL postoperatively.
3376120|NCT02704390|Experimental|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
3250287|NCT01384175|Active Comparator|patient-controlled epidural analgesia|In addition to epidural anesthesia and epidural infusion, postoperatively patients received patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
3250288|NCT01384188|Experimental|E1|ONO-5334
3250289|NCT01384188|Experimental|E2|ONO-5334
3250290|NCT01384201||Confocal Laser Endomicroscopy|OGD by Confocal Endomicroscopy
3250291|NCT01384201||White light endoscopy|OGD by whitelight endoscopy
3250292|NCT01384214|Experimental|1|botulinum toxin Type A
3250293|NCT01384227|Experimental|Proflavine Hemisulfate|
3250294|NCT01384240|Experimental|Proflavine Hemisulfate|
3364470|NCT05149690|Active Comparator|Supervised therapeutic exercise|The Control Group formed by 30 subjects will be administered a training program consisting of three types of exercises, taking into account: stability and lumbopelvic motor control, strengthening and stretching of the lumbar muscles, exactly the same as the Experimental Group. With a duration of 20 minutes. 2 weekly sessions will be held for 4 weeks, distributed as follows: Monday and Wednesday or Tuesday and Thursday with a total of 8 treatment sessions.
3364471|NCT05149677|No Intervention|Standard of Care for labor pain|Standard of Care of Care for labor pain
3364472|NCT05149677|Experimental|Music therapy intervention + Standard of Care for labor pain|Music therapy intervention + Standard of Care for labor pain
3364473|NCT05149664|Experimental|VibratoSleeve TUS|Subjects will receive 30 TUS treatments, each one lasting 90 minutes on the calf of a leg with peripheral arterial disease.
3364474|NCT05149651|Experimental|Totalfill|Totalfill® Bioceramic Root Repair Material -Fast Set Putty used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
3364475|NCT05149651|Active Comparator|MTA|ProRoot White MTA® used as pulpotomy agent to treat extensive decayed tooth indicated for pulpotomy
3364476|NCT05149638|Active Comparator|Healthy volunteers|Healthy volunteers are those 18 years or older without prior diagnosis of adrenal insufficiency. Study participation by healthy volunteers helps us understand what cortisol levels should be in a healthy population. This information also helps us figure out what levels might be in people with adrenal insufficiency.
3364477|NCT05149638|Active Comparator|Patients with known adrenal insufficiency|This group consists of patients 18 years or older with an established diagnosis of adrenal insufficiency. Study participation by patients with adrenal insufficiency helps us understand what cortisol levels should be, in the new assays, among those with adrenal insufficiency.
3364478|NCT05149638|Active Comparator|Patients suspected to have adrenal insufficiency|This groups consists of patients 18 years or older who are suspected to have adrenal insufficiency. Study participation by this group will help us understand if the cortisol values we get from the new assay accurately diagnose adrenal insufficiency.
3364479|NCT05149625|Experimental|Dexcom G6|
3364480|NCT05149625|No Intervention|Traditional self-blood glucose measurement|
3364481|NCT05149612|Experimental|Heat Therapy Group|The patients in the intervention group will be treated with hot water bags twice, for 20 minutes in the morning and 20 minutes in the evening, to the shoulder area, starting four hours after the operation, until the patient is discharged.
3250295|NCT01384253|Experimental|Phase I: Dose escalation|In preparation for the study, patients screened and eligible will have a peritoneal catheter placed and the evening prior to the injection of the labeled antibody will receive furosemide. Herceptin will be administered IV followed by a single IP infusion of ²¹²Pb-TCMC-Trastuzumab. Serial sampling of blood, urine, and dosimetry will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antitumor effects.
3250296|NCT01384266||Subjects undergoing Cataract Surgery|Subjects undergoing routine cataract surgery
3364482|NCT05149612|No Intervention|Control group|When the individuals in the control group have pain, analgesic drug treatment will be applied at the request of the physician, and no other intervention will be applied.
3250297|NCT01384279|Experimental|metformin, topiramate|
3250298|NCT01384318||Cuffed ETT|Patients intubated with cuffed endotracheal tubes.
3364483|NCT05149599|Experimental|Treated patients|
3364484|NCT05149573|Active Comparator|4-Week Treatment with no Maintenance Period|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
3364485|NCT05149573|Sham Comparator|4-Week Sham Treatment with no Maintenance Period|Participants will be provided with a sham B. Body and B. Pad that appears identical to the active pulsed electromagnetic field (PEMF) device. The participant will lie the sham B. Body mat on any flat surface and lay on the mat with the smaller sham B. Pad placed directly over the pelvic area. The participant will be instructed to administer this sham treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will return the sham device and complete one set of electronic questionnaires during the last week of the month for the following 3 months.
3364486|NCT05149573|Active Comparator|4-Week Treatment with 1-Week-Per-Month Maintenance Period for an Additional 3 Months|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (full body mat) and B. Pad (targeted pelvic pad). The participant will lie the B. Body mat on any flat surface and lay on the mat with the smaller B. Pad placed directly over the pelvic area. The PEMF device (attached to the control unit) has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a 4-week period. After 4 weeks, participants will keep the device and use it for 1 week (7 days) during the last week of the month for the following 3 months. Each participant in this group will be asked to complete a set of electronic questionnaires immediately following their week-long maintenance treatment during the last 3 months of the study.
3250299|NCT01384331|Active Comparator|Group 1 Marvelon ,placebo|"7 days daily intake of oral capsule containing Marvelon ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules containing starch for 21 day treatment Cycle"
3364487|NCT05149560|Experimental|Ticagrelor|Ticagrelor 90 mg twice daily for 12 months
3364488|NCT05149534|Experimental|Active TMS/WET|Active repetitive transcranial magnetic stimulation completed prior to written exposure therapy
3364489|NCT05149534|Sham Comparator|Sham TMS/WET|Sham repetitive transcranial magnetic stimulation completed prior to written exposure therapy
3364490|NCT05149521||Patients who have received radiotherapy|This is a consensus study with no interventions Patients who previously participated in COMFORT study interviews (NCT03984435)
3376121|NCT02702687|Experimental|PEF Feedback|This group will have 9 visits across 15 months.
3364491|NCT05149521||Therapeutic radiographers who deliver radiotherapy|This is a consensus study with no interventions Therapeutic radiographers who previously participated in COMFORT study interviews (NCT03984435)
3364492|NCT05149443|Experimental|Effectiveness of the Move it, Move ID app|All participants will receive the Move it, Move ID app.
3250300|NCT01384331|Active Comparator|Marvelon|"21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~for one cycle of 21 days"
3364493|NCT05149417|Placebo Comparator|Standard group|Patients enrolled in this group were discharged and they didn't undergo any intervention within the treatment period.
3364494|NCT05149417|Active Comparator|SMS group|patients received SMS at day 2 , day 4 and day 7 after emergency departement discharge to remind them to take their treatment .
3364495|NCT05149417|Active Comparator|telemonitoring group|Patients received a phone call on day 2 and day 4 to evaluate the adherence , to detect any problem that can affect the adherence to the treatment and modify the analgesic protocol treatment if needed.
3364496|NCT05149404||ERAS group|
3364497|NCT05149404||Conventional group|
3364498|NCT05149391|Experimental|C-CAR039|Autologous C-CAR039 administered by intravenous (IV) infusion
3364499|NCT05149378|Experimental|Venetclax combined with azacitidine|Relapsed or refractroy acute lymphoblastic leukemia patients reveive venetclax combined with azacitidine regimen treatment.
3364500|NCT05149365|Experimental|Sitagliptin Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will receive Sitagliptin combined with Standard prophylaxis regimen for GVHD of Alternative Donor HSCT.
3364501|NCT05149365|Active Comparator|Standard Group|95 adult patients with hematologic malignancies receiving Alternative Donor HSCT, who will only receive Standard prophylaxis regimen for GVHD of Alternative Donor HSCT
3364502|NCT05149352|Active Comparator|Treatment as usual (TAU)|Participants will receive an evidence-based psychotherapeutic intervention combined with/or pharmacotherapy (TAU)
3364503|NCT05149352|Experimental|Treatment as usual (TAU) + Trauma-focused therapy (TFT)|Participants will receive 6 to 10, 60-90 minute TFT sessions delivered over a period of 12 weeks, in addition to TAU.
3364504|NCT05149339|No Intervention|Case subgroup with deficient Vitamin D|Group with deficient Vitamin D < 20 ng/mL No treatment for the Vitamin D deficiency
3364505|NCT05149339|Experimental|Case subgroup with deficient Vitamin D + Vitamin D supplementation|Group with deficient Vitamin D + Daily oral dose of Cholecalciferol for 28 days for correcting the deficiency
3364506|NCT05149339|No Intervention|Case subgroup with normal Vitamin D|Group with normal Vitamin D level > 20 ng/mL
3250301|NCT01384331|Active Comparator|NuvaRing|21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days Treatment will be for 21 days
3364507|NCT05149326|Experimental|Experimental arm|
3364508|NCT05149326|Placebo Comparator|Control arm|
3364509|NCT05149313|Experimental|Lebrikizumab|Lebrikizumab administered subcutaneously (SC), 250 milligram (mg) dose once every two weeks (Q2W) in the induction period for 16 weeks. Participants achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab 250 mg once every four weeks (Q4W) after Week 20 up to Week 36. Participants not achieving EASI75 at Week 16 will receive 1 injection each of 250 mg lebrikizumab and placebo at Week 16 and 18, followed by 1 injection of lebrikizumab 250 mg Q2W after Week 20 up to Week 52.
3250302|NCT01384331|Placebo Comparator|Starch capsule|21 days daily oral placebo capsules Treatment will be for one 21 day cycle
3250303|NCT01384344|Active Comparator|witness|no mnesic complaint
3250304|NCT01384344|Experimental|Alzheimer disease with apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA with apathy
3364510|NCT05149313|Placebo Comparator|Lebrikizumab-matching Placebo|Lebrikizumab-matching Placebo administered SC, 250 mg dose, Q2W in the induction period for 16 weeks. Participants will receive 2 injections each of 250 mg lebrikizumab-matching placebo at Week 16, no injections at Week 18 followed by 1 injection of lebrikizumab- matching placebo 250 mg Q4W after Week 20 up to Week 36.
3364515|NCT05149287|Experimental|Experimental|The experimental group will receive a single intravenous dose of 1 g of ceftriaxone immediately postoperative in the operating room.
3364516|NCT05149287|Placebo Comparator|Placebo|The placebo group will receive a single intravenous dose of 1% lidocaine and saline immediately postoperative in the operating room.
3364517|NCT05149274|Active Comparator|Part1|DWP14012 Tablet A : single/multiple dose, 1 group, 2 period study
3364518|NCT05149274|Active Comparator|Part2|DWP14012 Tablet A 4T vs DWP14012 Tablet B 1T
3364519|NCT05149261||Acute aortic syndrome|"patients admitted to the Georges Pompidou European Hospital via the SOS aorta network"
3364520|NCT05149248|Other|Group 1: MSM|Arm 1: HPV vaccination in an alternative schedule for MSM of 1 dose (M0). Arm 2: HPV vaccination in an alternative schedule for MSM of 2 doses over a 6-month period (M0,6) Arm 3: a control group will be screened for high-risk HPV and vaccinated at 12 months
3364521|NCT05149248|Other|Group 2: TRANSGENDER WOMEN|Arm 1: Transgender women
3364522|NCT05149248|Other|GROUP 3: WOMEN AND MEN LIVING ON THE STREET|Arm 1: Women and men living on the street
3364523|NCT05149248|Other|GROUP 4: WOMEN AND MEN WHO HAVE SUFFERED RAPE|Women and men who have suffered rape
3364524|NCT05149248|Other|GROUP 5: WOMEN WHO ARE SEX WORKERS|Female sex workers
3364525|NCT05149235|Active Comparator|early mobilization group|this group will perform early mobilization exercises using a cycle ergometer.
3364526|NCT05149235|Experimental|game tech group|this group will use physio adventure device instead of a cycle ergometer
3364527|NCT05149235|Placebo Comparator|placebo group|this group is placebo control and will receive routine respiratory physiotherapy
3376122|NCT02702687|Active Comparator|Control Feedback|This group will have 9 visits across 15 months.
3376123|NCT02675751|Experimental|wavefront-guided PRK with iDesign|wavefront-guided PRK for treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser
3250305|NCT01384344|Experimental|Alzheimer's disease without apathy|Alzheimer's disease according to criteria of NINCDS-ADRDA without apathy
3376124|NCT02659930|Experimental|1/Group 1|Pomalidomide and liposomal doxorubicin given at escalating doses to patients with KS requiring systemic therapy
3364528|NCT05149209|Experimental|Fluoride, calcium and phosphate-releasing new bioactive material (Activa™ Presto, Pulpdent®, USA).|ACTIVA Presto is a novel bioactive material with a mineral-enriched hydrophilic resin base and a patented rubberized component that resists abrasion and wear with high release and recharge of not only fluoride but also calcium and phosphate ions. It doesn't contain BIS-GMA, Bisphenol A, or BPA derivatives.
3364529|NCT05149209|Active Comparator|Fluoride-releasing hybrid restorative material (Giomer, Shofu, Japan).|Giomer is a hybrid restorative material that contains a resin base and pre-reacted glass ionomer. S-PRG (surface reaction type) technology provides some properties of GI such as fluoride release and recharge which helps prevent recurrent caries.
3364530|NCT05149196|Experimental|Targeted blood pressure management|"During anesthesia, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~For patients admitted to intensive care unit after surgery, mean blood pressure is maintained ≥85 mmHg or above baseline by combining fluid challenge and norepinephrine infusion;~In the general ward, systolic blood pressure is maintained ≥110 mmHg or within 10% of baseline by delaying antihypertensive resumption, providing fluid challenge, and/or norepinephrine infusion."
3364531|NCT05149196|Active Comparator|Routine care|"During anesthesia, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~For patients admitted to intensive care unit, mean blood pressure is maintained ≥65 mmHg or within 20% of baseline according to routine practice;~In the general ward, management is performed according to routine practice."
3364532|NCT05149183|Experimental|cervical stability training|cervical stability training will be received three times a week for eight weeks
3364533|NCT05149183|Active Comparator|traditional treatment|traditional treatment will be received three times a week for eight weeks
3364534|NCT05149170|Experimental|Inductive and concurrent anti-PD-1 antibody combined with radiotherapy|All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent anti-PD-1 antibody (Tislelizumab 200mg) every two weeks.
3364536|NCT05149131||mCSPC patients in the province of Alberta|mCSPC patients who initiated and received at least one dose of guideline recommended life-prolonging therapy for mCSPC (docetaxel, abiraterone, enzalutamide, apalutamide, or ADT alone) from 01-Jan-2016 up to 31-Dec-2020 or earlier based on database cutoff, inclusive.
3250306|NCT01384357||ultrasound,lymphadenopathy|
3250307|NCT01384370||AHPV positive and negative subjects|
3250308|NCT01384383|Experimental|Arm 1|Response-Guided Therapy with GS-5885 30 mg plus GS-9451 200 mg, plus PEG and RBV for 6 or 12 weeks.
3250309|NCT01384383|Experimental|Arm 2|Response-Guided Therapy with PEG and RBV for 24 weeks.
3250310|NCT01384396|Experimental|KW-3357|
3364537|NCT05149118|Experimental|PDRN injected group|The participants in treatment group had received two consecutive injections of PDRN one day and two days after the surgery. A total 1mL of PDRN was injected along the suture line at distance of 1cm in each session.
3364538|NCT05149118|No Intervention|Control group|The participants in control group were left untreated.
3364539|NCT05149105|Experimental|APC intervention|"In addition to multidisciplinary care (standard care), patients benefit from an Argon Plasma Coagulation (APC) intervention at D0.~The APC intervention should be repeted at Month 2 and Month 4."
3364540|NCT05149105|No Intervention|Control|Patients are treated according to standard care (multidisciplinary care).
3364541|NCT05149092|Placebo Comparator|Placebo (casein protein supplement)|
3364542|NCT05149092|Active Comparator|Chicken protein hydrolysate supplement|
3364543|NCT05149079|Placebo Comparator|Placebo (whey protein supplement)|Participants will consume 18 g of the placebo whey protein supplement each day for 12 weeks.
3364544|NCT05149079|Active Comparator|Cod protein hydrolysate supplement|Participants will consume 18 g of the cod protein supplement each day for 12 weeks.
3364545|NCT05149066|Experimental|Experimental group|"The experimental group was administered a 9-sessions weekly programme in the school context.~It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up."
3364546|NCT05149066|No Intervention|Control group|The control group did not receive any intervention. It completed three assessment moments: pre-intervention, post-intervention and a 3-months after the intervention follow-up.
3364547|NCT05149053|Experimental|Food Supplement|Food supplement packet taken one per day preferably in the morning for 6 months.
3364548|NCT05149053|Placebo Comparator|Control|Placebo packet taken one per day preferably in the morning for 6 months.
3364549|NCT05149040||very elderly outpatients|outpatients (eyes, ear-nose-and throat, orthopaedic outpatient clinics at Haukeland University Hospital, Bergen, Norway) aged 80 years and older
3364550|NCT05149040||proxy|next of kin who likely would act as a proxy in a medical emergency, identified by the very elderly respondent
3364551|NCT05149027|Experimental|HBM4003+Toripalimap|HBM4003 combined with toripalimab in patients with advanced HCC and other solid tumors
3364552|NCT05148988||AAA patients|The entire cohort consists of patients with an abdominal aortic aneurysm eligible for endovascular repair using an Endurant II device.
3250311|NCT01384409|Experimental|KW-3357|
3250312|NCT01384422|Experimental|GLPG0634 100 mg bid oral capsules|
3250313|NCT01384422|Experimental|GLPG0634 200 mg qd oral capsules|
3250314|NCT01384422|Placebo Comparator|Placebo oral capsules|
3250315|NCT01384435|Experimental|KPS-0373, lowest dose|
3250316|NCT01384435|Experimental|KPS-0373, 2nd lowest dose|
3250317|NCT01384435|Experimental|KPS-0373, 2nd highest dose|
3250318|NCT01384435|Experimental|KPS-0373, highest dose|
3250319|NCT01384435|Placebo Comparator|Placebo|
3250320|NCT01384448|Experimental|Initial Stress Echocardiography|
3250321|NCT01384448|Experimental|Initial Coronary CT Angiography|
3250322|NCT01384461||Cohort|
3250323|NCT01384474||CRM training of surgical teams|CRM : Crew resource Management
3364554|NCT05148962|Experimental|Cohort 1: 2 Doses 10 mcg GRT-R910 after AstraZeneca Standard of Care|Participants (including 2 sentinels) receive 2 doses of 10 mcg GRT-R910 homologous prime-boost (after AstraZeneca standard of care).
3364555|NCT05148962|Experimental|Cohort 2: 2 Doses 30 mcg GRT-R910 after AstraZeneca Standard of Care|Participants (including 2 sentinels) receive 2 doses of 30 mcg GRT-R910 homologous prime-boost (after AstraZeneca standard of care).
3364556|NCT05148962|Experimental|Cohort 3: 2 Doses 10 mcg or 30 mcg GRT-R910 after Adenovirus-Based Vector Vaccine Standard of Care|Participants receive 2 doses of 10 mcg or 30 mcg GRT-R910 homologous prime-boost (after adenovirus-based vector vaccine standard of care).
3364557|NCT05148962|Experimental|Cohort 4: 2 Doses 10 mcg or 30 mcg GRT-R910 after mRNA Vaccine Standard of Care|Participants receive 2 doses of 10 mcg or 30 mcg GRT-R910 homologous prime-boost (after mRNA vaccine standard of care).
3364561|NCT05148936|Experimental|At home testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be provided with COVID-19 testing provided at home by a healthcare worker.
3364562|NCT05148936|Active Comparator|Mobile testing (Aim 1)|High-risk friends and family of contacts exposed to COVID-19 will be referred to study operated mobile testing sites in the community for COVID-19 testing.
3364563|NCT05148936|Other|Mobile testing approach 1 (Aim 2)|Mobile testing utilizing active outreach
3364564|NCT05148936|Other|Mobile testing approach 2 (Aim 2)|Mobile testing utilizing baseline outreach approaches
3364567|NCT05148910|Active Comparator|Copper IUD (TCu380A)|Women receiving an intrauterine device (IUD) containing 380mm² of copper.
3364568|NCT05148910|Experimental|Silver and copper IUD (TCu380Ag)|Women receiving an intrauterine device (IUD) containing 380mm² of copper with a silver core.
3364569|NCT05148897||All Women can participate|among 500 women, over 6 months by random selection and they will be asked to answer the questions of prepared and copied questionnaire sheet.
3364570|NCT05148884|Experimental|NLX-112|Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks.
3364571|NCT05148884|Placebo Comparator|Placebo|Patients will self-administer placebo 2 times each day, once in the morning and once in the evening. Up-titration of number of tablets over 4 weeks, number of tablets equivalent to maximal dose of 2 mg/day NLX-112 during 2 weeks, down-titration over 2 weeks.
3250324|NCT01384474||No CRM training of surgical teams|CRM : Crew resource Management
3250325|NCT01384487||Normal Eyes|Eyes without disease
3250326|NCT01384487||Eyes with Glaucoma|
3364576|NCT05148858||Cases|Patients affected by COVID-19 infection
3364577|NCT05148858||Control|Normal subjects not affected by COVID-19 infection
3364579|NCT05148806||Solid organ transplant patients|Patients who have received a solid organ transplant and who have received 3 doses of Covid-19 vaccine
3364580|NCT05148806||Rare autoimmune diseases|Patients with a rare autoimmune disease who have received 3 doses of Covid-19 vaccine
3250327|NCT01384487||Eyes with Retinal Disease|
3250328|NCT01384487||Eyes with Corneal Disease|Including post keratorefractive surgery
3364581|NCT05148806||Blood cancer|Patients with acute myeloid and lymphoid blood cancers who have received 3 doses of Covid-19 vaccine.
3364583|NCT05148767|Experimental|Neoadjuvant chemoradiotherapy based on irinotecan|Locally advanced rectal cancer patients who were treated with irinotecan-based neoadjuvant chemoradiotherapy regimen can be enrolled in this group.
3250329|NCT01384500|Experimental|Saline in tube cuff|Use of sterile saline to inflate tracheal tube cuff
3364588|NCT05148741||Group 1|implanted with the C-loop haptic intraocular lens
3364589|NCT05148741||Group 2|implanted with the plate haptic intraocular lens
3364590|NCT05148728|No Intervention|Active surveillance|After a recurrence in patient with previous low grade bladder cancer tumor, strict follow up with cystoscopy and cytology, avoiding immediate surgery
3364591|NCT05148728|Active Comparator|endoscopic fulguration|After a recurrence in patient with previous low grade bladder cancer tumor, fulguration under local anesthesia and sedation will be performed using a flexible cystoscope and a monopolar electrode
3364592|NCT05148715|Experimental|Tacrolimus|Tacrolimus 0.02 mg/kg ideal body weight 4-8 hours before organ recovery
3364593|NCT05148715|Placebo Comparator|Placebo|0.9% sodium chloride 4-8 hours before organ recovery
3364594|NCT05148702|Active Comparator|Standard care|Clinician decided antibiotic treatment duration
3364595|NCT05148702|Experimental|Fixed-extended-duration antibiotics|28 day antibiotic treatment duration
3250330|NCT01384500|No Intervention|Air in tube cuff|No intervention (control) - patient cohort, using air to inflate tracheal tube cuff.
3250331|NCT01384513|Experimental|Treatment (Allogeneic PBSCT)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 60 minutes on days -11 to -8 and busulfan IV over 3 hours on days -10 to -9. Patients undergo TBI on day -6. Patients also receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo DLI on day -6 and CD-34+ allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Beginning on day -1, patients receive tacrolimus IV or PO with taper beginning on day 42. Patients also receive mycophenolate mofetil IV BID on days -1 to 28."
3250332|NCT01384526||history of hormone therapy|
3250333|NCT01384526||no history of hormone therapy|
3364596|NCT05148689|Experimental|test product|Oxymetazoline Cream, 1%
3364597|NCT05148689|Active Comparator|reference|Rhofade™ (oxymetazoline) cream, 1%
3364598|NCT05148689|Placebo Comparator|placebo|Vehicle of Test product
3364599|NCT05148663||blood drawing and hemorrhagic events in CCM patients|planned for three blood drawing before surgery
3364600|NCT05148663||blood drawing for age/gender/ethnicity matched controls|Blood draw from Control patients with no inflammation
3364601|NCT05148650|Experimental|Crystalloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of a balanced crystalloid solution (Optilyte®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
3364602|NCT05148650|Experimental|Colloid infusion|Intravenous (IV) transfusions were performed of a 20ml/kg of gelatin 26,500 Da (Geloplasma®, Fresenius Kabi). The infusions were performed through an intravenous cannula (18G) inserted into a vein in the antecubital fossa on the non-dominant limb at 1000 ml/h
3364606|NCT05148624|Experimental|Immediate ambulation|Sub-infertile women will immediately ambulate and empty her bladder after embryo transfer.
3364607|NCT05148624|Active Comparator|short time bed rest|Sub-infertile women will stay in the bed (same bed where embryo transfer was performed) after embryo transfer for a period of 5 minutes without emptying her bladder.
3364608|NCT05148598|Experimental|ADRC Arm|Subjects in the ADRC arm will receive standard care and active treatment (ADRCs)
3364609|NCT05148598|Placebo Comparator|Standard Care Arm|Subjects in the Standard Care arm will receive standard care and Placebo
3364610|NCT05148585|Active Comparator|group 1|"group 1 (get only physiotherapy) After flexor tendon repair patients start getting physiotherapy. They use static dorsal splint.~exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. Then follow-up sixth months."
3364611|NCT05148585|Experimental|group 2|"group 2 (get both physiotherapy and activity-based therapy) After flexor tendon repair patients start getting physiotherapy. They use a static dorsal splint.~Exercises are progressive according to the healing process. Physiotherapy lasts 12 weeks. then follow-up sixth month. Additionally, group 2 gets activity-based therapy once a week about an hour. activities are also progressive according to the patients needs."
3364612|NCT05148559|Experimental|Enhanced Reminder|
3364613|NCT05148559|Other|Standard of Care|
3364614|NCT05148546|Experimental|A: Neoadjuvant nivolumab|Neoadjuvant 2 cycles of nivolumab 360mg every 3 weeks
3364615|NCT05148546|Experimental|B: Neoadjuvant nivolumab + ipilimumab|Neoadjuvant 2 cycles of nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 3 weeks
3364616|NCT05148546|Experimental|C: Neoadjuvant nivolumab + relatlimab|Neoadjuvant 2 cycles of nivolumab 360mg + relatlimab 360mg every 3 weeks
3364617|NCT05148533|Experimental|30mg/kg TJ1133 Injection|
3364618|NCT05148533|Experimental|45mg/kg TJ1133 Injection|
3364619|NCT05148520|Other|5A's model|The practice guideline emphasizes on the use of '5A's' model that contains five major steps in providing smoking cessation counselling. Specifically, our counsellors will take the following steps to provide telephone counselling for youth smokers who are ready to quit smoking
3364620|NCT05148494|Active Comparator|Fleet Enema|Patient is to administer one sodium bisphosphate (Fleet) enema at home 2 hours prior to arrival for surgery and a second enema one hour prior to arrival for surgery. Each 120 mL application of rectally administered enema contains 19g of monobasic sodium phosphate and 9 g of dibasic sodium phosphate. Patient is to follow standard packaging instructions from the manufacturer.
3364621|NCT05148494|Active Comparator|Pico Salax|Patient is to take Pico Salax oral bowel preparation which is a combination product consisting of 10 mg picosulfate sodium, 3.5 g magnesium oxide, and 12 g citric acid per sachet the day prior to surgery. Patient is to take 2 doses of this product, as per standard packaging instructions from the manufacturer. Specifically patient is to take the first packet contents dissolved in 150 mL water at 3pm the day before surgery. Patient is to take the second packet dissolved in 150 mL water at 8pm the day before surgery. Patient should drink 2-3L of clear liquids after each dose, for a total of 4-6L.
3364622|NCT05148481|Experimental|BIIB104: Dose 1|Japanese and non-Japanese participants will receive BIIB104, Dose 1, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
3364623|NCT05148481|Experimental|BIIB104: Dose 2|Japanese and non-Japanese participants will receive BIIB104, Dose 2, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
3250334|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3250335|NCT01384552|Active Comparator|Normal Weight, Restrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3250336|NCT01384552|Active Comparator|Normal Weight, Restrained - Standard|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3250337|NCT01384552|Active Comparator|Overweight, Unrestrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3364624|NCT05148481|Placebo Comparator|Placebo|Japanese and non-Japanese participants will receive BIIB104-matching placebo, oral capsule, BID, from Day 1 through Day 9 with an additional dose on Day 10.
3364625|NCT05148468|Experimental|Active stimulation|
3364626|NCT05148468|Sham Comparator|Sham stimulation|
3364627|NCT05148455||pregnant women|
3364628|NCT05148455||non-pregnant women (control group)|
3364629|NCT05148442|Experimental|IBI322|
3364630|NCT05148442|Experimental|IBI322+HMA|
3364632|NCT05148416|Experimental|Laser group|"1. Experimental group (A) the laser group (n=20) which received~high intensity laser therapy(HILT)~knee osteoarthritis conventional exercises program in form of stretching exercises for both vastus medialis and gastrocnemius muscles , ROM exercises for knee flexion and extension , and isometric strengthening exercise of previously mentioned muscles .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
3364633|NCT05148416|Sham Comparator|the sham group group( B)|"the Sham group (n= 20) which received~sham HILT~knee osteoarthritis conventional exercises program previously mentioned .~all interventions were done under the supervision of physiotherapist for 30 minutes once a day for 3 days per week during a period of 4 weeks."
3364634|NCT05148403|Experimental|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
3364635|NCT05148403|No Intervention|Control group|No glibenclamide treatment
3250338|NCT01384552|Active Comparator|Overweight, Unrestrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3364638|NCT05148338|Experimental|Risk intervention group|Comprehensive risk factor management at specialized AF outpatient clinic concerning blood pressure, cholesterol, glycaemic control, physical inactivity, weight control, smoking, alcohol intake and sleep apnea.
3364639|NCT05148338|Active Comparator|Control group|Standard of care. Treatment by cardiologist conform existing guidelines.
3364640|NCT05148325|Experimental|Single group|First Phase: dose escalation study. It was divided into four dose groups: 0.1mg/kg, 0.3mg/kg, 0.5mg/kg and 1.0mg/kg. The safety, tolerability and pharmacokinetics of bat4706 injection were explored according to the 3 + 3 dose increasing mode. It is expected that 12-24 cases will be included in the group Second Phase: dose expansion study. After the completion of dose increment, 1-2 tolerated doses were selected for extended research on melanoma (20-40 cases), so as to provide recommended doses for subsequent clinical trials
3364641|NCT05148312|Experimental|AQ001S 0.125 mg/2mL single-dose|AQ001S 0.125 mg/2 ml (budesonide 0.125 mg/2 ml inhalation solution) single-dose administered by nebulization.
3364642|NCT05148312|Experimental|AQ001S 0.250 mg/2mL single-dose|AQ001S 0.250 mg/2 ml (budesonide 0.250 mg/2 ml inhalation solution) single-dose administered by nebulization.
3364643|NCT05148312|Experimental|AQ001S 0.500 mg/2mL single-dose|AQ001S 0.500 mg/2 ml (budesonide 0.500 mg/2 ml inhalation solution) single-dose administered by nebulization.
3364644|NCT05148312|Active Comparator|Budesonide inhalation suspension 1.0 mg/2 ml single-dose|Pulmicort Respules® 1.0 mg/2 ml is a budesonide inhalation suspension administered by nebulization.
3364645|NCT05148299|Experimental|Pegcetacoplan|
3364648|NCT05148273||intervention|After the selection process with 1 to 1 randomization method, a personal information form and Beck anxiety scale will be applied to the women selected for the case group on the day of the initiation of treatment with assisted reproductive techniques interview. Then, within an average of 10 days, there is a treatment procedure including planned drug use, messages containing drug doses, drug use, drug administration, follicle count, reminder of the times of operations such as OPU, IUI, ET, and motivational issues. Medication use, time, date, dose, application form and motivational sentences will be sent every day through the WhatsApp application. The Beck anxiety scale will be repeated on the day of IUI and ET procedures, and the effect of telehealth practices on the anxiety levels of women undergoing infertility treatment will be evaluated. During the study, the participants will be able to reach the researcher from their mobile phones whenever they want.
3364649|NCT05148273||control|In the first interview at the beginning of the treatment protocol with assisted reproductive techniques, a personal information questionnaire and beck anxiety scale will be applied to the control group selected by the 1-to-1 randomization method. Afterwards, the Beck anxiety scale will be applied again at the end of the treatment without any intervention.
3376125|NCT02659930|Experimental|2/Group I; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS requiring systemic therapy
3364650|NCT05148260|Experimental|LTP+CaCBT|"Learning Through Play (LTP): Underpinned by Piaget's theory of cognitive development (Piaget, 1952) and Bowlby's theory of attachment (Bowlby, 1980), the central feature of the LTP component of the intervention is a pictorial calendar devised for parents, depicting eight successive stages of child development from birth to 3 years, with illustrations of parent-child play and other activities that promote parental involvement, learning, and mother-child attachment.~Culturally adapted Cognitive Behaviour Therapy (CaCBT): CaCBT is well-grounded in the standard framework of cognitive-behavioural theory (Bernal et al., 2009) and uses techniques of active listening, changing negative thinking, guided discovery."
3364651|NCT05148260|Active Comparator|Psychoeducation|Involve supportive and educational components grounded on the theory and philosophy of group psychotherapy (with relevant topics on maternal mental healthcare advice and discussions), problem-solving techniques that are relevant to addressing maternal depression/anxiety and child-related difficulties, and general parenting discussions that aim at improving child's psychosocial development through mother-child attachment to promote early childhood development.
3364657|NCT05148221|Experimental|A three-week tailored, virtual exercise intervention.|
3364658|NCT05148208|Placebo Comparator|Placebo|Supplementation of water
3364659|NCT05148208|Active Comparator|Creatine 0.5 mM|Supplementation of creatine dissolved in water to a final concentration of 0.5 mM of creatine in the dialysate
3364660|NCT05148208|Active Comparator|Creatine 1 mM|Supplementation of creatine dissolved in water to a final concentration of 1 mM of creatine in the dialysate
3364661|NCT05148208|Active Comparator|Creatine 1.5 mM|Supplementation of creatine dissolved in water to a final concentration of 1.5 mM of creatine in the dialysate
3364662|NCT05148208|Active Comparator|Creatine 2.0 mM|Supplementation of creatine dissolved in water to a final concentration of 2 mM of creatine in the dialysate
3364663|NCT05148195|Experimental|A: Solid tumor|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
3364664|NCT05148195|Experimental|B: HCC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）
3364665|NCT05148195|Experimental|D：NSCLC|Envofolimab（300mg，Q3W）+BD0801（2mg/kg，Q3W）+Docetaxel(75mg/m2，Q3W)
3364666|NCT05148195|Experimental|D：CRC|Envofolimab（200mg，Q2W）+BD0801（2mg/kg，Q2W）+FOLFIRI（Irinotecan 180 mg/m2，Leucovorin 400mg/m2，5-Fluorouridine 2400 mg/m2，Q2W）
3364667|NCT05148182||low risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as low-risk population.
3364668|NCT05148182||medium risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as medium-risk population.
3364669|NCT05148182||high risk|According to the China PAR equations and Chinese guidelines and consensus on cardiovascular risk assessment and management, it is considered as high-risk population.
3364670|NCT05148169|Active Comparator|SSRI group|One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.
3364671|NCT05148169|Experimental|SSRI plus Sulforaphane group|"One SSRI is prescribed based on treatment guidelines for major depressive disorder and drug prescription manual. The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for escitalopram, respectively.~The oral dose of SFN is based on weight. The usage and dosage are as follows: 40-70kg, 4 tablets/day (containing 274μmol of glucosinolates); 70-90kg, 6 tablets/day (containing 411μmol of glucosinolates). Take it once in the morning and evening."
3364672|NCT05148169|No Intervention|Healthy control group|No intervention is given.
3364674|NCT05148143|Experimental|RALOX|Raltitrexed combined with oxaplatin
3364675|NCT05148130||the gestational diabetes pregnant women group|The diagnosis of GDM was established following the International Association of Diabetes and Pregnancy Study Groups (IADPSG) diagnostic criteria. GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l, 1-hour plasma glucose ≥10.0 mmol/l, and 2-hour plasma glucose of 8.5-11.0 mmol/l. Women diagnosed with DM or prediabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
3364676|NCT05148130||the healthy pregnant control group|the control group was pregnant women who delivered a single fetus at full term without complications and complications during pregnancy
3364677|NCT05148117||suspected sepsis group|We will perform a prospective observational study of patients admitted to the intensive care units (ICU) with suspected sepsis or septic shock.
3364678|NCT05148117||control group|This group will be compared to suspected sepsis or sepsis shock patients. The control group will be age matched, gender-matched, and cardiovascular risk-factor matched controls.
3364679|NCT05148104||Patients receiving shoulder arthroplasty|Patients receiving shoulder arthroplasty that have an intact glenoid prior to the procedure. Ideally the glenoid surface should be visible and intact during imaging.
3250339|NCT01384552|Active Comparator|Overweight, Restrained - Single Serving|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3364692|NCT05148078||General Anesthesia Decrease use : PROMISE|To decrease the total number of pediatric patients who require general anesthesia through the use of PROMISE
3364693|NCT05148052|Experimental|Conventional therapy first|Group receiving conventional occupational therapy first and then virtual reality exergames.
3364694|NCT05148052|Experimental|Virtual reality first|Group receiving virtual reality exergames with virtual reality first and then conventional occupational therapy.
3364695|NCT05148039|Active Comparator|Community cohort|Participants from the Ehlers Danlos UK society community who low diet quality
3250340|NCT01384552|Active Comparator|Overweight, Restrained - Standard|Each participant is overweight (BMI: 25-39.9 kg/m2) and is classified as a restrained eater (scoring greater than 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3250341|NCT01384552|Active Comparator|Normal Weight, Unrestrained - Single Serving|Each participant is of normal weight (BMI: 18.5-24.9 kg/m2) and is classified as an unrestrained eater (scoring less than or equal to 12 on the Three Factor Eating Questionnaire - Cognitive Restraint Scale).
3250342|NCT01384565|Active Comparator|G-CSF+EPO|
3250343|NCT01384565|Placebo Comparator|Placebo|
3364696|NCT05148039|Active Comparator|Clinic cohort|Participants from a Tertiary Neurogastroenterology clinic who have low die quality
3364697|NCT05148026|Active Comparator|Anticoagulation sequence 1 (UFH+ RCA)|UFH+ RCA first
3364698|NCT05148026|Active Comparator|Anticoagulation sequence 2 (UFH)|UFH first
3364699|NCT05146908||Patients in intensive care|Ventilated intubated patients for whom enteral nutrition is planned
3364700|NCT05145400|Experimental|Single Arm|All subjects will receive the same treatment on the study, consisting of isatuximab, lenalidomide, and dexamethasone with 28 days cycles.
3250344|NCT01384578|Experimental|pentoxiphylline and Vitamin E|
3250345|NCT01384578|Active Comparator|Vitamin E|
3250346|NCT01384617|Experimental|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
3250347|NCT01384617|Active Comparator|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
3250348|NCT01384630|Other|Single group|
3364701|NCT05145218|Experimental|TQB2450 injection + Anlotinib Hydrochloride capsules|"TQB2450 injection: once every 21 days, 1200mg each time, intravenous infusion. The longest administration time should not exceed 24 months.~Anlotinib Hydrochloride capsules: once a day, 12mg each time, oral administration on an empty stomach before breakfast for 2 weeks, withdrawal for 1 week, i.e. 3 weeks (21 days) as a course of treatment."
3364702|NCT05145218|Active Comparator|Paclitaxel injection|80mg/m2, intravenous drip, once a week (D1, D8, D15 of 21 days), 21 days as a course of treatment.
3250349|NCT01384643|Experimental|Propofol group|
3250350|NCT01384643|Placebo Comparator|Control group|
3250351|NCT01384656|Experimental|GIK group|
3250352|NCT01384656|Placebo Comparator|Control group|
3364704|NCT05140850||PRES group|PE or E with PRES
3250353|NCT01384669||Group 1|papillary thyroid microcarcinoma without lymph node metastasis
3364705|NCT05140850||non-PRES group|PE or E without PRES
3364706|NCT05139173|Experimental|Experimental: Injured Worker Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre for a work-related shoulder injury as part of the Working Condition Program.
3364707|NCT05139173|Active Comparator|Active Comparator: OHIP (funded) Patient Population|Participants that have a confirmed rotator cuff pathology, and are undergoing physiotherapy at the Holland Centre as part of the Shoulder Program.
3364708|NCT05138770|Experimental|VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets 1、5、10、25、50、100mg, qd
3364709|NCT05138770|Placebo Comparator|VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg|VC005 Tablets Placebo 1、5、10、25、50、100mg, qd
3364710|NCT05138770|Experimental|VC005 Tablets food effects group|VC005 Tablets, qd
3364711|NCT05138029|Experimental|Anti-VEGF treatment group|Visual acuity and center thickness of the macula
3364712|NCT05138029|Experimental|Inner limiting membrane stripping group|Visual acuity and center thickness of the macula
3364713|NCT05138029|Experimental|Glucocorticoid treatment group|Visual acuity and center thickness of the macula
3250354|NCT01384669||Group 2|papillary thyroid microcarcinoma with lateral lymph node metastasis
3250355|NCT01384682|No Intervention|No change|continue their current cART regimen
3364714|NCT05136040|Active Comparator|Group İzobarik bupivakain (5 mg) + fentanil|Patients were given a solution containing 5 mg isobaric bupivacaine + 15 µg fentanyl (1.3 ml)
3364715|NCT05136040|Active Comparator|Group İzobarik bupivakain (7 mg) + fentanil|Patients were givena solution containing 7 mg isobaric bupivacaine + 15 µg fentanyl (1.7 ml)
3364716|NCT05135650|Experimental|Prevention (Sotrovimab)|Patients receive sotrovimab IV over 30 minutes within 1-7 days prior to the start of pre-transplant conditioning.
3364717|NCT05135546|Experimental|Experimental|Recombinant nonimmunogenic staphylokinase lyophilisate for preparation of a solution for inhaled administration, 5 mg (745,000 IU) complete with a solvent. 15 mg (2,235,000 IU) - 3 vials, regardless of body weight.
3364718|NCT05135546|Placebo Comparator|Placebo control|Placebo
3250356|NCT01384682|Active Comparator|Replace N(t)RTI drugs with Maraviroc|Replace N(t)RTI drugs with MVC at a dose of 150mg bid (MVC 300mg bid can be used at the discretion of the Investigator if the PI/r is fosamprenavir/r) and continue the PI/r
3250357|NCT01384682|Active Comparator|Replace PI/r drugs with Maraviroc|Replace PI/r drugs with MVC at a dose of 300mg bid and continue 2N(t)RTI.
3250358|NCT01384695|Experimental|Fluorescein|Confocal imaging using contrast agent fluorescein
3250359|NCT01384695|Experimental|Proflavine hemisulfate|confocal imaging using contrast agent proflavine
3364719|NCT05135130||ON101 Cream|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to ON101 Cream arm
3364720|NCT05135130||Aquacel® Hydrofiber® dressing|Patients Who Had Participated in the ON101CLCT02 Diabetic Foot Ulcer Trial and assigned to Aquacel® Hydrofiber® dressing arm
3364721|NCT05134285||control|pregnancy without preeclampsia
3364722|NCT05134285||preeclampsia|pregnancy complicated with preeclampsia at the first delivery or at the second delivery
3364723|NCT05134285||recurrent preeclampsia|pregnancy complicated with preeclampsia at two deliveries
3250360|NCT01384708|Experimental|treatment|imaging with proflavine
3250361|NCT01384747|Experimental|Fimasartan|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
3364727|NCT05132387||Out-of-hospital cardiac arrest|Patients with out-of-hospital cardiac arrest which occured in the predefined area of the city of Wroclaw.
3364728|NCT05132179|Active Comparator|HOCl arm|Dakin´s Solution, with the active substance Hypochlorous Acid, HOCl was first invented 1915 for use on infected war wounds. The DFU will be cleaned with HOCl twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
3364729|NCT05132179|No Intervention|PHMB arm|Prontosan, with the active substance PHMB, is recommended by 19 out of 21 regions in Sweden, for cleaning DFU. The DFU will be cleaned with PHMB twice a week. The treatment will be performed in accordance with instructions for Prontosan, PHMB.
3364730|NCT05131802||Postcholecystectomy group|which included patients that had undergone cholecystectomy.
3364731|NCT05131802||Biliary intervention group|included patients who had undergone at least one of the following procedures for treatment of benign pathology: endoscopic sphincterotomy (ES) and endoscopic stenting.
3364732|NCT05131061||aldosterone-producing adenoma(APA)|PA confirmatory tests was positive; lateralization index in AVS≥4 or lateralization index 3-4in combination with contralateral suppression index≤1
3364733|NCT05131061||bilateral adrenal hyperplasia(BAH)|PA confirmatory tests was positive; lateralization index in AVS<3
3376126|NCT02659930|Experimental|3/Group II|Pomalidomide with liposomal doxorubicin given at escalating doses in to patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS requiring systemic therapy
3250362|NCT01384747|Placebo Comparator|Placebo|Initial dose will be started with 60mg per day. At 4 week follow-up after the procedure, dose titration upto 120 mg per day will be made if the patient is not hypotensive.
3250363|NCT01384812|Placebo Comparator|Isoton sodium chloride|
3250364|NCT01384812|Active Comparator|Prostin E2 (dinoprostone)|
3250365|NCT01384825||MS|Subjects with Multiple Sclerosis
3250366|NCT01384825||HC|Healthy Controls
3250367|NCT01384825||OND|"Subjects with Other Neurodegenerative Diseases, including both other non-inflammatory neurodegenerative diseases (OND) and other inflammatory neurodegenerative diseases (ONDi)"
3250368|NCT01384838|Other|Counseling|Patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.
3250369|NCT01384838|Experimental|Controlled physical activity|"All patients are to receive identical counseling for ideal nutritional, lifestyle, physical activity.~Patients randomized to Arm 2 will additionally undergo a controlled and observed program of physical activity for a period of 6 months. Thereafter the patients are expected to adhere to a comparable, unobserved exercise program at home."
3364734|NCT05130853|Experimental|SoCIAL Group|Subjects will conduct SoCIAL programme once a week, for a total of 10 weeks. Every session consists of two different modules: 1) a training programme that helps patients recognize emotions and important social signals (such as facial expressions and prosody) and develop strategy focused on the Theory of Mind; 2) a training in narrative enhancement. Time of administration for both modules is 30 minutes; the operator, however, can choose to focus the session on one module rather than the other, based on the subject's specific needs.
3364735|NCT05130853|Active Comparator|Control Group - Treatment-as-usual (TAU)|Subjects that will be randomized in this group will receive their treatment as usual for the whole length of the study (10 weeks). TAU includes all the psychiatric therapies (pharmacological, psychological, occupational etc) that subjects may have begun before study's enrollment.
3364736|NCT05130333||Non-cardiac surgery patients under general anesthesia|> 18y/o patients undergoing noncardiac surgery with BIS monitoring under general anesthesia.
3364737|NCT05130047|Experimental|Aldafermin (NGM282)|Aldafermin (NGM282) is an investigational medication. It is an engineered analog of FGF-19 which reduces synthesis of bile acids and diarrhea caused by elevated bile acids. Participants receive aldafermin (NGM282) 1 mg given by subcutaneous injection once daily for 28 days.
3364738|NCT05130047|Placebo Comparator|Placebo|A placebo looks exactly like the study drug but contains no active ingredients. It is used to learn if the effects seen are truly from the study drug. Participants receive placebo solution matching aldafermin (NGM282) given by subcutaneous injection once daily for 28 days.
3364739|NCT05129566|Experimental|IOL Clareon AutonoMe|The first group of patients (39 eyes) who received the monofocal IOL Clareon AutonoMe after the phacoemulsification of cataract.
3364740|NCT05129566|Active Comparator|IOL Hoya iSert 251|the second group of patients (39 eyes) who received the monofocal IOL Hoya iSert 251 after the phacoemulsification of cataract
3364741|NCT05127551|Active Comparator|iStent Infinite|Subjects implanted with iStent Infinite system
3250370|NCT01384851|Experimental|Next Generation Emulsion|Next Generation Emulsion Multi-Dose Eye Drop (9963X) is a sterile, buffered, aqueous and emulsion topical ophthalmic product formulated for the relief of ocular surface irritation and symptoms of dryness. The Next Generation Emulsion 9963X formulation is an oil-in-water aqueous emulsion intended to replenish deficient aqueous and lipid components and stabilising the tear film.
3364742|NCT05127551|Active Comparator|Competitor Device|Subject implanted with competitor device
3364743|NCT05126550||Immunogenicity|First 500 participants will be assigned to group 1 that constitute the immunogenicity group which will be evaluated regarding immunogenicity, safety, and effectiveness of the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm
3364744|NCT05126550||Non-Immunogenicity|The next 500 participants will be assigned to group 2 that constitute the non-immunogenicity group which will be evaluated regarding only safety and effectiveness of the aforementioned vaccine
3364745|NCT05126472|Experimental|anti-CD40 antibody 2141-V11|Eligible subjects will receive the anti-CD40 antibody 2141-V11 administered by intravesical instillation once weekly for 3 consecutive weeks (weeks 1, 2, and 3) for a total of 3 doses.
3364746|NCT05126316|Experimental|Lu AG09222 Low Dose|Participants will receive Lu AG09222 injection at a low dose level 3 times with 4 weeks between each administration.
3364747|NCT05126316|Experimental|Lu AG09222 High Dose|Participants will receive Lu AG09222 injection at a high dose level 3 times with 4 weeks between each administration.
3364748|NCT05126316|Placebo Comparator|Placebo|Participants will receive placebo matching to Lu AG09222 injection 3 times with 4 weeks between each administration.
3364749|NCT05126303|Experimental|RMC-035|"RMC-035 is a concentrate (6.0 mg/mL) for solution for infusion for IV administration.~Dosing will be based on renal function at Day -1: Subjects with eGFR ≥60 mL/min/1.73m2 will receive 1.3 mg/kg (per dose) for the first and second dose, followed by 0.65 mg/kg (per dose) for the third, fourth and fifth dose, while subjects with eGFR >30 and <60 mL/min/1.73m2 will receive 0.65 mg/kg (per dose) for all five doses Dosing occurs at time 0 and then after 6, 12, 24 and 48 hours."
3364750|NCT05126303|Placebo Comparator|Placebo|Identical to RMC-035 arm except that the placebo contains no active ingredient.
3364751|NCT05125939||Screening indication|Screening indication includes asymptomatic patients aged ≥50 years with no prior colonoscopy and at average risk of CRC. Screening indication also includes asymptomatic patients with negative prior colonoscopy.
3364752|NCT05125939||Surveillance indication|Surveillance indication includes patients with prior colon neoplasms, including conventional adenomas and clinically significant serrated polyps.
3364753|NCT05125939||Diagnostic indication|Diagnostic indication includes patients who report symptoms (e.g., abdominal pain, a change in bowel habits, or rectal bleeding) before their first screening examination and undergo evaluation of an abnormality on other image study, unexplained anemia and/or unexplained weight loss.
3364754|NCT05125939||Positive fecal immunochemical test|FIT+ indication includes patients who undergo colonoscopy for positive FIT results in screen-eligible individuals. FIT+ indication also applies to those with a positive FIT result and a recent colonoscopy.
3364755|NCT05125809|Placebo Comparator|Placebo -> Placebo -> Open Label (OL) Setrusumab|Double-blind placebo during phase 2 followed by double-blind placebo in phase 3 followed by open-label setrusumab
3364756|NCT05125809|Experimental|Low Dose Setrusumab -> Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab low dose during phase 2 followed by double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
3364757|NCT05125809|Experimental|High Dose Setrusumab -> Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab high dose during phase 2 followed by double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
3364758|NCT05125809|Experimental|Setrusumab Selected Dose -> OL Setrusumab|Double-blind setrusumab selected dose during phase 3 followed by open-label setrusumab
3376127|NCT02659930|Experimental|4/Group II; Antitumor Assessment Phase|Pomalidomide and liposomal doxorubicin, given at the highest tolerated dose to patients with KS or KS with concurrent KSHV-associated MCD or KICS requiring systemic therapy
3376128|NCT02649959|Experimental|Open Label|CM-AT
3376129|NCT02643381|Experimental|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
3376130|NCT02643381|Experimental|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
3364759|NCT05125029|No Intervention|Placebo|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
3364760|NCT05125029|Active Comparator|10 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
3364761|NCT05125029|Active Comparator|20 units of BT per digit|Prior to injection, patients will wait in a temperature controlled room for 30 minutes in order to allow time for normalization of baseline digital temperature. Once a patient is randomly selected via our randomization process, BT will be reconstituted by clinic nursing staff with sterile saline per manufacturer recommendations such that the investigating hand surgeon who will be performing the injection will be sufficiently blinded. After proper cleansing of the skin with alcohol swabs, BT will be sterilely administered percutaneously via a small-gauge needle and syringe into the base of each digit by the investigating hand surgeons within the Upper Extremity Division. The volar metacarpal head will be used as a standardized anatomic landmark for injection both to lessen the probability and magnitude of risk to deep structures of the hand as well as maximize probability of proper anatomic placement of the drug.
3364762|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, 4%|Pilocarpine Ophthalmic Topical Cream, 4%
3364763|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, 6%|Pilocarpine Ophthalmic Topical Cream, 6%
3364764|NCT05124275|Experimental|Pilocarpine Ophthalmic Topical Cream, 8%|Pilocarpine Ophthalmic Topical Cream, 8%
3364765|NCT05124275|Placebo Comparator|Pilocarpine Ophthalmic Topical Cream, 0%|Pilocarpine Ophthalmic Topical Cream, 0%
3250371|NCT01384851|Active Comparator|Refresh Dry Eye Therapy|A preserved multi-dose formulation for use in treating dry eye symptomatology. The key ingredients are Castor oil, Polysorbate 80, Carbomer 1342 and Glycerin. Refresh Dry Eye Therapy® Lubricant Eye Drops contains emulsified castor oil, which enhances the natural oily superficial tear layer on the ocular surface. By stabilizing and supplementing the lipid layer, castor oil may retard evaporation of surface moisture.
3250372|NCT01384851|Active Comparator|Refresh Contacts|Solution contains carboxymethylcellulose sodium (carmellose), sodium chloride, boric acid, sodium borate, potassium chloride, calcium chloride, magnesium chloride, Purite®, sodium hydroxide, and purified water. This product is registered as a CE Mark medical device. Refresh Contacts Comfort drops providing soothing relief from tired, dry eyes. Although intended for contact lens wearers, the primary indication is for relief of dry eyes as is being studied in this investigation.
3364773|NCT05122650|Experimental|10 milligram (mg) JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.
3364774|NCT05122650|Experimental|20 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.
3364775|NCT05122650|Experimental|30 mg JZP385|Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.
3250373|NCT01384864|Experimental|treatment|fluorescent imaging with proflavine
3250374|NCT01384890|Experimental|VMAT with CBCT|Volumetric modulated arc therapy (VMAT) with cone-beam computed tomography position (CBCT) verification
3250375|NCT01384890|Active Comparator|VMAT with kV-ray|Volumetric modulation arc therapy (VMAT) with kV-ray position verification
3250376|NCT01384903|Experimental|KW-3357|
3364776|NCT05122650|Placebo Comparator|Placebo|Participants will receive placebo from Day 1.
3364777|NCT05121974|Experimental|Tebipenem-pivoxil arm (Pilot study)|Oral Tebipenem-pivoxil in children with shigellosis
3364778|NCT05121974|Active Comparator|Azithromycin arm (Pilot study)|Oral Azithromycin in children with shigellosis
3364779|NCT05121974|Experimental|Tebipenem-pivoxil arm (Main trial)|Oral Tebipenem-pivoxil in children with shigellosis
3364780|NCT05121974|Active Comparator|Ceftriaxone arm (Main trial)|Intravenous Ceftriaxone in children with shigellosis
3364781|NCT05121545|Other|Pro-GRID treatment Arm|Patients enrolled in this study will receive spatially-fractionated radiotherapy or GRID-therapy, which involves delivering a one-time treatment of high dose radiation to small amounts of tumor in a manner that creates alternating regions of high and low dose radiation within the tumor. Patients will receive 2 (lowest dose) to 18 Gy (highest dose) in a single fraction.
3364782|NCT05121441|Experimental|ARD-101|Dose 200 mg of ARD-101, twice daily for 28 days
3250377|NCT01384903|Active Comparator|Plasma-derived antithrombin|
3250378|NCT01384916|Experimental|Yoga|
3364783|NCT05121441|Placebo Comparator|Placebo Comparator|Placebo arm matching active arm ARD-101, 200 mg BID
3364784|NCT05121298|Experimental|Upadacitinib|The administration of upadacitinib 15mg/day
3364785|NCT05120336|Experimental|Non-depressed control participants: sham first, active taVNS second|Non-depressed control participants receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
3364786|NCT05120336|Experimental|Patients with major depressive disorders: sham first, active taVNS second|participants with depression receive sham stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the earlobe (sham) for 1.5 h). In a second identical session, they receive active stimulation with the same parameters (at the cymba conchae).
3364787|NCT05120336|Experimental|Patients with major depressive disorders: active taVNS first, sham second|participants with depression receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
3364788|NCT05120336|Experimental|Non-depressed control participants: active taVNS first, sham second|Non-depressed control participants receive active stimulation in the first session (biphasic stimulation with a frequenyc of 25 Hz, 30s OFF/30s ON at the cymba conchae (active) for 1.5 h). In a second identical session, they receive sham stimulation with the same parameters (at the earlobe).
3250379|NCT01384916|Active Comparator|Health education|
3250380|NCT01384929||ICU patients|All patients present in the ICU on the selected days
3364789|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, 4%|Pilocarpine Ophthalmic Topical Cream, 4%
3364790|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, 6%|Pilocarpine Ophthalmic Topical Cream, 6%
3364791|NCT05119920|Experimental|Pilocarpine Ophthalmic Topical Cream, 8%|Pilocarpine Ophthalmic Topical Cream, 8%
3364792|NCT05119920|Placebo Comparator|Pilocarpine Ophthalmic Topical Cream, 0%|Pilocarpine Ophthalmic Topical Cream, 0%
3250381|NCT01384942|Experimental|Meaning-Based Bereavement Group|
3250382|NCT01384942|Active Comparator|Conventional Bereavement Group|
3250383|NCT01384955||exercise|subjects diagnosed and treated in the Centre of Corrective and Compensatory Gymnastics in Bielsko - Biala, Poland, between 1983 and 1994, with scoliosis - specific exercise program
3364793|NCT05119075|Experimental|Dopaminergic ON-drug state first, dopaminergic OFF-drug state second|"The following examinations and assessments will be performed at visit 3 on regular treatment in dopaminergic ON-drug state and at visit 4 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs):~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
3376131|NCT02621424|Experimental|RTMS|repetitive transcranial magnetic stimulation
3250384|NCT01384955||control|age and condition - matched subjects, who were diagnosed at the same time, in the same clinic, and by the same physician, and prescribed the same method of physiotherapy, but did not start the exercise treatment
3250385|NCT01384968|Experimental|Beetroot juice|beetroot juice (170 mL, 8 mmol nitrate)
3250386|NCT01384968|Placebo Comparator|Nitrate-depleted beetroot juice|140 mL ...0 nitrate. Beetroot juice
3250387|NCT01384981|Active Comparator|pulmonary rehabilitation with NIV|Patients receiving nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
3250388|NCT01384981|Sham Comparator|pulmonary rehabilitation without NIV|Patients receiving no nocturnal non-invasiv Ventilation during a 3-week pulmonary Rehabilitation program.
3250389|NCT01384994|Experimental|FOLFOX + Panitumumab|
3250390|NCT01384994|Active Comparator|FOLFOX|
3250391|NCT01385020|Experimental|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects
3250392|NCT01385046|Experimental|physical activity and nutrition|
3250393|NCT01385059|Experimental|Arm I (neoadjuvant enzyme inhibitor and prostatectomy)|Patients receive axitinib PO BID on days 1-28. Patients then undergo prostatectomy and pelvic lymph node dissection. Treatment continues in the absence of disease progression or unacceptable toxicity.
3250394|NCT01385059|Active Comparator|Arm II (surgery)|Patients undergo prostatectomy and pelvic lymph node dissection at 5-6 weeks after biopsy confirmation of prostate cancer.
3250395|NCT01385072|Experimental|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
3250396|NCT01385085||No natural sunlight|one group works in a basement with no natural sunlight
3250397|NCT01385085||Low level of Natural Sunlight|the second group work in offices with unopenable windows.
3250398|NCT01385085||High level of Natural Sunlight|The third group works outdoors.
3250399|NCT01385111|Active Comparator|Arm A|EBUS centered
3250400|NCT01385111|Experimental|Arm B|EUS centered
3250401|NCT01385124|Experimental|Oral Cannabidiol|Oral Cannabidiol 10 mg twice daily will be given from conditioning starting day and until day +30 after allogeneic transplantation. Dose can be doubled every 7 days if no significant side effects documented.
3250402|NCT01385163|No Intervention|Control - VSLA|the wait control sample for the economic intervention
3250403|NCT01385163|Other|Control - Mental Health|treatment as usual based on standard psychosocial services in the area
3250404|NCT01385163|Experimental|Voluntary Savings/Loans Assoc|
3250405|NCT01385163|Experimental|Cognitive Processing Therapy|
3250406|NCT01385215|Placebo Comparator|Placebo|
3250407|NCT01385215|Placebo Comparator|Nasal Aerosol Immunization|
3250408|NCT01385215|Placebo Comparator|Nasal Droplet Immunization|
3250409|NCT01385215|Placebo Comparator|Intramuscular Immunization|
3250410|NCT01385228|Experimental|"Dose Level Xa"|once daily pazopanib for Days 1-21 in combination with docetaxel given IV on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
3250411|NCT01385228|Experimental|"Dose Level Xb"|once daily oral administration of pazopanib for Days 3-19 in combination with docetaxel given intravenous administration on Day 1 and prednisone daily. Pegfilgrastim (Neulasta) every 21 days on Day 2, 3 or 4 of each cycle.
3250412|NCT01385241|Experimental|Received video intervention|The group of women who received an Ipod Touch with the video loaded onto it and told to view it at least once a week for the first 4 weeks, and as often as desired in weeks 5-12.
3250413|NCT01385241|No Intervention|Did not receive video|This group does not receive the video intervention during the study period, and will complete surveys at baseline, 30 days and 90 days for comparison to the intervention group.
3250414|NCT01385254||siblings and mothers of Very Low Birth Weight infants|50 older siblings (closest in age) and mothers of very low birthweight (VLBW) infants, born at <33 weeks gestation and <1500 grams at birth
3250415|NCT01385254||siblings and mothers of healthy infants|50 siblings (closest in age) and mothers of healthy, full-term infants (between 38-42 weeks gestation and lacking medical conditions that require a hospital stay past the mother's discharge date)
3250416|NCT01385267||Diamniotic twin gestations|
3364794|NCT05119075|Experimental|Dopaminergic OFF-drug state first, dopaminergic ON-drug state second|"The following examinations and assessments will be performed at visit 3 in dopaminergic OFF-drug state (overnight withdrawal of all antiparkinsonian drugs) and at visit 4 on regular treatment in dopaminergic ON-drug state:~MRI assessment,~Cognitive, neuropsychiatric and neurological assessment,~Robot-induced hallucinations through sensorimotor stimulation."
3250417|NCT01385319|Active Comparator|bare metal stent|
3250418|NCT01385319|Experimental|Endeavor sprint stent|
3364795|NCT05116202|Active Comparator|Cohort 1: Nivolumab + Ipilimumab|Cohort 1 participants in the nivolumab plus ipilimumab arm will receive treatment for 2 cycles (6 weeks) on Day 1 of each cycle (cycle length 21 days) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
3364796|NCT05116202|Experimental|Cohort 1: RO7247669|Cohort 1 participants in the RO7247669 arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
3364797|NCT05116202|Experimental|Cohort 1: + Atezolizumab + Tiragolumab|Cohort 1 participants in the atezolizumab plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
3364798|NCT05116202|Experimental|Cohort 1: RO7247669 + Tiragolumab|Cohort 1 participants in the RO7247669 plus tiragolumab arm will receive treatment for 2 cycles (6 weeks) until surgery, or until unacceptable toxicity or loss of clinical benefit, whichever occurs first.
3364799|NCT05116202|Experimental|Cohort 2: RO7247669 + Tiragolumab|Cohort 2 participants in RO7247669 plus tiragolumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3364800|NCT05113719|Experimental|Bridge exercise at knee angle 45 degree|The group will perform the bridge exercise at a 45-degree knee flexion angle.
3364801|NCT05113719|Experimental|Bridge exercise at knee angle 60 degree|The group will perform the bridge exercise at a 60-degree knee flexion angle.
3364802|NCT05113719|Experimental|Bridge exercise at knee angle 90 degree|The group will perform the bridge exercise at a 90-degree knee flexion angle.
3250419|NCT01385332|Active Comparator|Early luteal phase -COH-|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the early luteal phase.
3250420|NCT01385332|Active Comparator|Late folicular phase - COH -|We perform an standard antagonist protocol beginning the second day of the menstrual cycle compared with an antagonist protocol beginning in the late follicular phase.
3364803|NCT05112926|Experimental|Embosphere Microspheres group|Participants in this group who are receiving standard of care (SOC) embolization surgery for the treatment of moderate to severe knee osteoarthritis will receive the Embospheres Microspheres during scheduled SOC surgery.
3364804|NCT05107115|Experimental|Rilzabrutinib dose A|dose A
3364805|NCT05107115|Experimental|Rilzabrutinib dose B|dose B
3364806|NCT05107115|Experimental|Rilzabrutinib dose C|dose C
3364807|NCT05107115|Placebo Comparator|Placebo|Matching placebo
3364810|NCT05103644|Experimental|study|breast cancer patient received Atorvastatin 80 mg
3364811|NCT05103644|Placebo Comparator|control group|breast cancer patient received placebo
3364812|NCT05100264|Experimental|Vaginal washing 5% acetic acid|
3364813|NCT05100264|Placebo Comparator|Vaginal washing 0.9% N/S|
3364814|NCT05100082||Cabozantinib 60 mg|Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 12 months. Participants received interventions as part of routine medical care.
3364815|NCT05098210|Experimental|Treatment (poly ICLC, PNV21 vaccine, nivolumab)|Patients receive poly ICLC IM once weekly in weeks when no vaccine is given. Beginning 2 weeks after starting poly ICLC, patients receive personalized neo-antigen peptide vaccine IM once every 4 weeks and nivolumab every 2 or 4 weeks. Treatment continuous for 25 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab every 2 or 4 weeks for up to 12 months in the absence of disease progression or unacceptable toxicity.
3364823|NCT05093413|Experimental|Fully slept first; Sleep deprived second|Participants will be fully slept during the first experimental visit and sleep deprived during the second experimental visit
3364824|NCT05093413|Experimental|Sleep deprived first; Fully slept second|Participants will be sleep deprived during the first experimental visit and fully slept during the second experimental visit
3364827|NCT05091983||Restrictive eating disorder group|Adolescents between 12 and 18 y.o. Restrictive eating disorders diagnosis (Anorexia Nervosa or ARFID) answering DSM-5 criteria
3364828|NCT05091983||Control group|Adolescents between 12 and 18 y.o. No eating disorders
3250421|NCT01385345|Active Comparator|Vitamin D3 high dose|200,000 units (time 0) followed by (100,000 units) at months 1.5, 3 and 5. Participants will also have daily 1,000 units per day to mirror the control arm and maintain double blinding.
3364829|NCT05091710|Experimental|Follow up care program for HF patients|Discharged HF patients in rural Haiti will be receive a follow-up care program delivered by trained community health workers (CHWs).
3364830|NCT05091710|Other|Standard of care|Historical reference group who received standard of care for HF identified prior to CHW training.
3364831|NCT05088603|Experimental|Clear Mask|Subjects randomized to this group will have a neurologist who wears a clear mask during their procedure and during their interaction with the subject.
3250422|NCT01385345|Placebo Comparator|Vitamin D3|Participants will have a placebo liquid (to mirror the active arm high dose Vitamin D3) and also have daily 1,000 units Vitamin D3.
3364832|NCT05088603|No Intervention|Standard Mask|Subjects randomized to this group will have a neurologist who wears a standard mask during their procedure and during their interaction with the subject.
3364833|NCT05086120|Experimental|Remote Electronically Delivered Integrated Care Pathway (ICP)|The remote electronically-delivered ICP (also known as eCARIBOU) will consist of psychiatry appointments through telemedicine every 4 weeks over 16 weeks, where the youth is at home. Prior to these appointments, measures (i.e., Mood and Feelings Questionnaire - MFQ) will be sent to the youth to be completed. Change in measure scores will be reviewed collaboratively between the psychiatrist and the youth to assist in making treatment decisions. The medication algorithm in the in-person ICP will be used to guide these decisions. The psychiatrist will also administer the Columbia Suicide Severity Rating Scale (C-SSRS) at each telepsychiatry appointment to monitor risk. Concurrently, youth will be offered internet-based Cognitive Behavioural Therapy (iCBT) and health-coaching via text.
3364834|NCT05084521|Experimental|Famotidine|Suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
3364835|NCT05084430|Experimental|Recurrent MG|To determine the safety and tolerability of M032 at the doses examined when given in combinations with pembrolizumab in patients with recurrent MG.
3364836|NCT05084430|Experimental|Newly Diagnosed MG|To determine Overall Survival at 12 and 24 months, and Progression Free Survival at 6 months (PFS-6) in patients with newly diagnosed glioblastoma multiforme of M032 when given in combinations with pembrolizumab (while maintaining safety).
3364837|NCT05082688|Experimental|1: Young adults herpes zoster vaccination|Young adults between 18 and 35 years old will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
3364838|NCT05082688|Experimental|2: Older adults herpes zoster vaccination|Adults older than 60 years of age will receive the herpes zoster vaccine (Shingrix). 60 days later, they will receive a booster dose.
3364839|NCT05082688|Experimental|3: Young adults influenza vaccination|Young adults between 18 and 35 years old will receive the influenza vaccine (Fluarix Tetra).
3364840|NCT05082688|Experimental|4: Older adults influenza vaccination|Adults older than 60 years of age will receive the influenza vaccine (Fluarix Tetra).
3364841|NCT05082688|Placebo Comparator|5: Young adults herpes zoster vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl). 60 days later, they will receive another placebo.
3364842|NCT05082688|Placebo Comparator|6: Young adults influenza vaccination related placebo|Young adults between 18 and 35 years old will receive the placebo injection (0.9% NaCl).
3364843|NCT05082376|Experimental|Test Arm|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg/centimeter^2) of ChapStick Lip Moisturizer Original will be applied to the assigned test site using a fingercot. The test product will be evenly spread over the test site using light pressure.
3364844|NCT05082376|No Intervention|Control Arm|No treatment will be applied to the assigned control site.
3250423|NCT01385358|Experimental|Thoracoscopically Assisted Surgical Ablation|This arm will have an index thoracoscopically assisted surgical ablation.
3250424|NCT01385358|Active Comparator|Catheter Ablation|This is an active comparator arm where study subjects will undergo conventional catheter ablation.
3250425|NCT01385384|Other|NeuRx|
3250426|NCT01385397|Experimental|Preceptorship and virtual community|
3250427|NCT01385410|Active Comparator|CPS, cell phone based peer support|Cell phone base peer mother support for continued exclusive breastfeeding
3250428|NCT01385410|Active Comparator|PSG, group meeting based peer support|Group based peer Cell phone base peer mother support for continued exclusive breastfeeding
3250429|NCT01385410|No Intervention|Control|Current standard of care and support (national health system)
3250430|NCT01385423|Experimental|IL-15 Patients with AML|Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)
3250431|NCT01385436||HPV HSIL cervical carcinoma|
3364845|NCT05081570|Experimental|Intervention group|The participants will receive two tertiary stroke care consultations provided by stroke nurses via telecare in 2 months.
3364846|NCT05080335|Active Comparator|TRANS-gender female instructor, with videos (TV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a TRANS-gender woman with extensive experience as an educator on transgender health
3250432|NCT01385449|Experimental|interscalene block|interscalene block
3364847|NCT05080335|Active Comparator|CIS-gender female instructor, with videos (CV)|Didactic materials use embedded WITH short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
3364848|NCT05080335|Active Comparator|CIS-gender female, with NO videos (CN)|Didactic materials do NOT use short videos of transgender youth; lesson led by a CIS-gender woman with extensive experience as an educator on transgender health
3364849|NCT05078931|Experimental|Pembrolizumab + Lenvatinib in PD-L1 Positive TKI resistant NSCLC patients|The PD-L1 positive patients with TKI-resistant EGFR-mutated advanced NSCLC will receive the combination of pembrolizumab and lenvatinib.
3364853|NCT05078060||VaxigripTetra®|Participant vaccinated with VaxigripTetra® as per routine clinical practice
3364854|NCT05078060||Efluelda®|Participant vaccinated with Efluelda® as per routine clinical practice
3364855|NCT05075824|Experimental|Crovalimab|Participants will receive a loading series of Crovalimab comprised of an intravenous (IV) loading dose on Day 1, followed by weekly Crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance SC dosing will begin at Week 5 and will continue every 4 weeks (Q4W) thereafter for a total of 48 weeks of treatment.
3364856|NCT05075824|Placebo Comparator|Placebo|Participants will receive matching Placebo administered by IV infusion and SC injection over the same duration as Crovalimab, for a total of 48 weeks of treatment.
3364857|NCT05075187||Participants diagnosed with Frontotemporal Dementia|Participants diagnosed with Frontotemporal Dementia
3364858|NCT05074264||Arm I (imaging, biospecimen collection, colposcopy)|Patients undergo collection of cervical images, 3 cervical anal swabs and 3 anal swabs for real-time testing of hrHPV over 90 minutes. Patients with a positive hrHPV test on their cervical swab undergo colposcopy and biopsies of visible lesions. Patients with a negative hrHPV test on their cervical swab may undergo a colposcopy. Patients with a positive hrHPV test on their anal swab undergo high-resolution anoscopy at a later visit within 1 month. Patients with a negative hrHPV on their anal swabs may undergo a high-resolution anoscopy and biopsies of visible lesions, and those with a positive anal cytology for LSIL or worse undergo a high-resolution anoscopy and biopsies within 1 month. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual.
3364859|NCT05074264||Arm II (biospecimen collection, anoscopy, biopsy)|Patients undergo collection of 3 anal swabs for real-time testing of high-risk HPV over 90 minutes. Patients with a positive hrHPV test undergo high-resolution anoscopy with biopsies of visible lesions. Patients with hrHPV negative test may undergo high-resolution anoscopy. Patients may be given a diagnosis and treatment at the second visit. Patients diagnosed with HSIL may undergo SOC treatment or enroll in additional studies when they are open to accrual.
3364860|NCT05072613||Pregnant women|Pregnant women attending Antenatal Care Services
3364861|NCT05072613||School children|Children attending Primary Schools
3364862|NCT05072561|Experimental|Experimental|
3364865|NCT05072041|Experimental|Test group|Degradable embolic microsphere (Nexsphere™)
3364866|NCT05070923|Experimental|HealthyLifetime Group|"HL is an 8-week, personalized health coaching program that includes a comprehensive assessment made through a survey and a virtual' home visit (via video), a goal-directed strengthening action plan developed by the participant with the guidance of the nurse, a tailored daily planning guide to enhance action steps and goal attainment, and six weekly 30 minute nurse coaching sessions with participants the Healthie application technology via their personal home computer, Tablet or Smartphone device. If a participant does not use a personal device or the device cannot support the Healthie platform, the HL program will provide a Tablet to them for their use during the program. All video sessions ( ie, home visit, strengthening plan, and weekly coaching sessions will use a two-way video but only the audio portions of the sessions will be recorded. The HL program, tailored to each participant's need for strong and resilient function, encompasses the following key elements:"
3376132|NCT02621424|Sham Comparator|sham|sham noise to block the sound of treatment
3376133|NCT02611960|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg Q3W for up to 17 cycles (up to approximately 1 additional year).
3376134|NCT02611960|Active Comparator|Standard Treatment|Participants receive capecitabine 1000 mg/m^2 orally (PO) twice each day (BID) on Days 1-14 of each 3-week cycle, or gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle, or docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle until PD or unacceptable toxicity.
3250433|NCT01385449|Experimental|interscalene catheter|interscalene catheter
3250434|NCT01385475|Experimental|Control|
3250435|NCT01385488|Experimental|self-monitoring|participants will use bioelectrical impedance to self-monitor arm volume at home
3250436|NCT01385488|No Intervention|completion of forms|participants will complete self-report forms
3250437|NCT01385501|No Intervention|routine care|
3250438|NCT01385501|Experimental|Educational intervention group|
3250439|NCT01385514||company A-Training Base No.1|
3250440|NCT01385514||company A-Training Base No.2|
3250441|NCT01385514||company A-Training Base No.3|
3250442|NCT01385527|Experimental|Weekly Internet survey w medication|Weekly survey via email plus topical triamcinolone
3250443|NCT01385527|Active Comparator|Topical triamcinolone only|Standard of care
3250444|NCT01385540||Task-based fMRI|
3250445|NCT01385553|Active Comparator|Individual Drug Counseling|
3250446|NCT01385553|Experimental|Fathers for Change|
3250447|NCT01385592|Experimental|AFQ056 100 mg|
3250448|NCT01385592|Placebo Comparator|Placebo|
3364867|NCT05070923|No Intervention|Usual Care Group|Participants randomized to the usual care group will be given information about when to expect reminders on the Healthie platform to complete future surveys at the end of week 8, and after three months that will be available on the Healthie Platform for them to fill out and save on the platform. They will also be reminded how to contact the study coordinator if they should have questions. Participants in this group will have the view to other functions on the platform turned off. They will only be able to view documents as the reminders appear for them to complete.
3364868|NCT05068687|Experimental|intraoperative high-resolution PET-CT imaging of resected malignancy|
3364869|NCT05067582|Placebo Comparator|Placebo Capsules|1 capsule twice daily
3364870|NCT05067582|Experimental|L1-79 200 mg or 300 mg Capsules|1 capsule twice daily
3364871|NCT05066100|Experimental|Pregnant women with FIRN|Women desiring to breastfeed and identified during their pregnancy as having flat, inverted or retracted nipples
3364872|NCT05064267||CKD stage 3|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 3 from a non-inflammatory etiology.
3364873|NCT05064267||CKD stage 4|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 4 from a non-inflammatory etiology.
3364874|NCT05064267||CKD stage 5|Between the ages of 6 months and 17 years currently followed within the hospital system's CKD clinic, and diagnosed with CKD 5 from a non-inflammatory etiology.
3364875|NCT05062109|Experimental|Multimodal geriatric prehabilitation|
3250449|NCT01385605||female patients|ICSI treatment because of male subfertility
3250450|NCT01385618||high responder|females with >15 follicles or E2>3000 after treatment with gonadotropins
3364885|NCT05057221|Experimental|Uproleselan|Uproleselan injection is a sterile solution for IV administration, supplied in single-dose vials at a concentration of 50 mg/mL.
3364888|NCT05054452|Experimental|Echocardiographic assessment|At baseline before standardized volume expansion, a first set of echocardiographic measurements will be performed. Then, we will perform 15-second end-expiratory and end-inspiratory occlusions. Occlusions will be separated by 1 minute to allow the cardiac index to return to its baseline value. A last set of measurements will be performed after fluid administration. Ventilatory settings and other treatments will remain unchanged during the study period.
3364891|NCT05050942|Experimental|CAM2029|
3364892|NCT05050942|Active Comparator|Octreotide LAR or lanreotide ATG|
3364896|NCT05050864|Active Comparator|internal ventricular shunt (neurosurgery)|The internal ventricular shunt consists of the introduction of a catheter from a lateral ventricle into the atrium or peritoneum. It is associated with a valve whose opening pressure is adjustable. The goal is that cerebrospinal fluid can be absorbed extra-cranial
3364897|NCT05050864|Active Comparator|endovacascular stenting (interventional neuroradiology)|The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
3364898|NCT05050162|Experimental|ARM I (high-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
3250451|NCT01385618||low responder|patients with <3 follicles or no response to treatment with gonadotropins
3250452|NCT01385618||control|females with an indication for treatment because of male subfertility
3250453|NCT01385631|Placebo Comparator|Atorvastatin plus Placebo|50/100 patients are randomized to Atorvastatin 80 mg per day plus placebo.
3364899|NCT05050162|Experimental|Arm II (low-dose cisplatin, radiation therapy)|NON-OPC/p16-NEGATIVE OPC: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
3364900|NCT05050162|Experimental|Arm III (high-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive high-dose cisplatin IV Q3W (on days 1, 22, and 43) during radiation therapy in the absence of disease progression or unacceptable toxicity.
3364901|NCT05050162|Experimental|Arm IV (low-dose cisplatin, radiation therapy)|p16-POSITIVE OPC/CUP: Patients undergo radiation therapy over 5 fractions a week for a total of 33-35 fractions in the absence of disease progression or unacceptable toxicity. Patients also receive low-dose cisplatin IV QW during radiation therapy in the absence of disease progression or unacceptable toxicity.
3364902|NCT05048732|Experimental|Cohort 1 = Healthy Volunteers|"Healthy volunteers (N=6, three male, three female) will be recruited to undergo a single 18F-FAT PET/CT imaging session for radiation dosimetry estimates.~18F-FAT administration followed by body imaging at 3 time points~0-60 min = multiple quick body scans~120 min post injection = body scan~240 min post injection = body scan"
3364903|NCT05048732|Experimental|Cohort 2a: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N= 3 : 18F-FAT imaging session at baseline and Day 2 following Cycle 1 RCHOP
3364904|NCT05048732|Experimental|Cohort 2b: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N=3: 18F-FAT imaging session at baseline and Day 4 following Cycle 1 RCHOP
3250454|NCT01385631|Experimental|Atorvastatin plus Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
3250455|NCT01385657|Experimental|Placebo|Placebo (for Dupilumab) as a single subcutaneous (SC) injection on Day 1, 8, 15, and 22
3364905|NCT05048732|Experimental|Cohort 2c: Newly Diagnosed DLBCL patients being treated with R-CHOP|-N=9: 18F-FAT imaging session at baseline and best time point determined from Cohort 2a and 2b. (2 or 4 days post Cycle 1 RCHOP therapy)
3364906|NCT05047640|Experimental|BNT162b2 vaccine|Participants in this arm will receive one booster dose of the BNT162b2.
3250456|NCT01385657|Experimental|Dupilumab 150 mg|Dupilumab 150 mg as a single SC injection on Day 1, 8, 15, and 22
3250457|NCT01385657|Experimental|Dupilumab 300 mg|Dupilumab 300 mg as a single SC injection on Day 1, 8, 15, and 22
3250458|NCT01385683|Active Comparator|Arm A|Dabigatran then dabigatran and clarithromycin
3364907|NCT05047640|Experimental|JNJ-78436735 vaccine|Participants in this arm will receive one booster dose of the JNJ-78436735
3250459|NCT01385683|Active Comparator|Arm B|Clarithromycin and dabigatran and dabigatran
3250460|NCT01385709||Sertraline|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that sertraline is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking either sertraline on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
3364910|NCT05044195|Experimental|aQIV|Adjuvanted QIV containing 2 influenza type A strains and 2 influenza type B strains
3364911|NCT05044195|Active Comparator|Comparator QIV|Non-adjuvanted comparator QIV containing 2 influenza type A strains and 2 influenza type B strains
3364914|NCT05041257|Experimental|Mirvetuximab Soravtansine|Participants will receive MIRV 6.0 mg/kg adjusted by ideal body weight (AIBW)
3364915|NCT05038709|Experimental|Pink Pad|Hip arthroscopy using The Pink Pad Hip Kit Patient Positioning System (Xodus Medical, New Kensington, PA). The pad is placed between the patient and the traction table, using a perineal post.
3364916|NCT05038709|No Intervention|Control (No pad)|Hip arthroscopy in the usual fashion, no pad, using traction table with perineal post.
3364919|NCT05034471|Experimental|Mitral Valve Repair with Novel Device Technologies|All study participants will undergo mitral valve repair by replacing the chordae tendinea with ePTFE single loop sutures using novel suturing devices.
3364920|NCT05032833|Experimental|5-MeO-DMT arm|
3364921|NCT05032833|Placebo Comparator|Placebo arm|
3364923|NCT05029856|Experimental|Group A- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
3364924|NCT05029856|Experimental|Group B- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
3364925|NCT05029856|Experimental|Group C- SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 3 μg SII B.1.351 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
3364926|NCT05029856|Experimental|Group D - SII B.1.351 Vaccine / Matrix-M1 Adjuvant|1 dose of 5 μg SII B.1.351 Vaccine + 50 μg Matrix-M1 adjuvant (co-formulated) .1 dose on Day 0.
3364927|NCT05029856|Experimental|Group E -SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 6 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
3364928|NCT05029856|Experimental|Group F- SII Bivalent Vaccine / Matrix-M1 Adjuvant|2 doses of 10 μg SII Bivalent Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
3364929|NCT05029856|Experimental|Group G- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|2 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose each on Days 0 and Day 21.
3364930|NCT05029856|Experimental|Group H- SII B.1.617.2 Vaccine / Matrix-M1 Adjuvant|1 doses of 5 μg SII B.1.617.2 Vaccine+ 50 μg Matrix-M1 adjuvant (co-formulated) . 1 dose on Days 0.
3250461|NCT01385709||Lithium|Therefore, patients who are already taking psychotropic medications, and therefore are currently in treatment for a psychiatric illness, will be recruited. The specific psychiatric diagnoses anticipated in the subject pool include the conditions that lithium is indicated to treat, including Bipolar Affective Disorders, Cyclothymic Disorder, Schizoaffective Disorder, Major Depressive Disorder, Dysthymic Disorder, Obsessive-Compulsive Disorder, Panic Disorder, Posttraumatic Stress Disorder, Premenstrual Dysphoric Disorder, and Social Anxiety Disorder. Patients must be female, between the ages of 18-40, taking lithium on a daily basis for at least one week. Exclusion criteria include 1) currently pregnant or breastfeeding, 2) concurrent use of any form of hormonal birth control, including oral contraceptive pills, Norplant or Depo-provera, 3) hepatic or renal disease, 4) irregular menstrual cycles.
3364940|NCT05027308|Experimental|Teduglutide 0.05 milligram per kilogram (mg/kg)|Participants will receive teduglutide 0.05 mg/kg (0.025 mg/kg for participants with moderate or greater renal impairment) subcutaneous (SC) injection once daily for 24 weeks followed by no treatment period for 4 weeks.
3364943|NCT05017246|Active Comparator|Epidural bupivacaine with hydromorphone patient-controlled anesthesia (EPCA)|"Standard of care at Washington University School of Medicine/Barnes-Jewish Hospital~Day of surgery: preoperative tylenol, gabapentin, celebrex, and epidural dosing per standard protocol.~Intraoperative: dexamethasone and epidural bupivacaine~Day of surgery postoperative: hydromorphone PCA, toradol, ibuprofen, tylenol, epidural bupivacaine~Postoperative: hydromorphone PCA, ibuprofen, oxycodone"
3364944|NCT05017246|Experimental|Intrathecal morphine with intraoperative lidocaine infusion|"Day or surgery: tylenol, gabapentin, celebrex, and preoperative intrathecal morphine one time injection (150mcg)~Intraoperative: dexamethasone and lidocaine infusion 1 mg/kg ideal body weight~Day of surgery postoperative: toradol, ibuprofen, tylenol~Postoperative: ibuprofen, oxycodone, and hydromorphone prn"
3364945|NCT05016765|Experimental|Active MNS|Active, self-directed electrical stimulation of the right median nerve
3364946|NCT05013008|Experimental|Finerenone (BAY94-8862)|Finerenone tablet
3364947|NCT05013008|Placebo Comparator|Placebo|Matching placebo
3364948|NCT05012631|Experimental|Losartan|Participants will receive oral losartan as tablets or oral solution one time daily. The dosing will depend on age and will be based on drug label and dosing used in studies on patients with SCD.
3250462|NCT01385735|Placebo Comparator|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
3250463|NCT01385735|Active Comparator|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
3250464|NCT01385761||Laryngeal Mask airway (LMA)|children weighing 20 to 30 kg
3250465|NCT01385761||Intubating Laryngeal Airway (ILA-SP)|Children weighing 20-30 kg
3364955|NCT05008809|Experimental|Treatment|Active treatment with mFOLFOXIRI or mFOLFOX6 q2w up to six months followed by structured Follow-up for up to five years after randomization
3364956|NCT05008809|No Intervention|Control|Structured Follow-up for up to five years after randomization
3250466|NCT01385774|Active Comparator|Intervention group: Angioplasty|Angioplasty with or without stent of the iliac artery
3364959|NCT05005806|Active Comparator|Omega 3 soft gel|participants in this group (1)omega 3 fatty acid soft gel 1000 mg will be given to participants twice daily for two months.
3364960|NCT05005806|Placebo Comparator|placebo|placebo group ,placebo soft gel designed same as omega 3 contain Vitamin A 1000 mg twice daily for two months
3250467|NCT01385774|Active Comparator|Control: Supervised Exercise Therapy|Supervised exercise therapy by a physiotherapist
3250468|NCT01385800|Placebo Comparator|Placebo|Intradermal injection, 1 x 8 administrations 2 weeks apart
3364963|NCT05003544|Active Comparator|PENG BLOCK ( Group A)|A regional block will be applied while the patient is in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) will initially be placed in a transverse plane on the AIIS and then rotate the probe approximately 45 degrees counterclockwise to align with the pubic ramus. In this view, IPE, iliopsoas muscle and tendon, femoral artery and pectineus muscle will be observed. A 22 gauge, 80 mm needle will be inserted from lateral to medial in an in-plane approach to place the psoas tendon anteriorly and posteriorly in the musculofacial plane between the pubic ramus. Following negative aspiration, a local anesthetic solution (20ml bupivacaine 0.5%) will be injected.
3364964|NCT05003544|Active Comparator|Intra-articular( Group B)|It will be applied to the intra-articular region by the surgeon at the end of the operation. A volume of 90 ml (30 ml of 0.5% bupivacaine and 60 ml of 0.9% NaCl)
3364965|NCT05003544|Active Comparator|Quadratus lumborum block ( Group C)|The patient will be in the lateral position. A low-frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in-plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.5 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
3364966|NCT05003401|Experimental|HabitAware Keen 2|Participants will receive the wrist device device that alerts the participant when the participant is engaging in hair pulling behavior.
3364967|NCT05002998|Other|Teprotumumab 4 Infusions|"• 4 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 3 infusions) (Cohort 1) followed by 4 infusions of:~Placebo if a participant is a treatment responder at Week 12 or~Teprotumumab 20 mg/kg if a participant is a treatment non-responder at Week 12"
3364968|NCT05002998|Other|Teprotumumab 8 Infusions|8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions) (Cohort 2)
3364969|NCT05002998|Other|Teprotumumab 16 Infusions|16 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the remaining 15 infusions) (Cohort 3)
3364970|NCT05001737|Experimental|Cohort 1 (sJIA and AOSD) and Cohort 2 (SLE)|MAS in the context of systemic juvenile idiopathic arthritis and adult onset Still's disease (sJIA and AOSD) or SLE
3364971|NCT05000866|No Intervention|CHTC as usual|Participants complete the standard Couples HIV Testing and Counseling session (CHTC).
3364972|NCT05000866|Active Comparator|CHTC and communications skills training video|Participants complete the standard Couples HIV Testing and Counseling session and also watch a communication skills training video together.
3250469|NCT01385800|Experimental|ToleroMune Grass Dose 1|Intradermal injection 1 x 8 administrations 2 weeks apart
3250470|NCT01385800|Experimental|ToleroMune Grass Dose 2|Intradermal injection 1 x 8 administrations 2 weeks apart
3250471|NCT01385800|Experimental|ToleroMune Grass Dose 3|Intradermal injection 1 x 8 administrations 2 weeks apart
3250472|NCT01385813||Pregnant women who develop preeclampsia|pregnant women who develop preeclampsia (n =43) compared to pregnant women fulfilling a normotensive pregnancy (n= 86).
3250473|NCT01385826|Experimental|adalimumab|Anti-tumor necrosis factor alpha monoclonal antibody
3364973|NCT05000866|Active Comparator|CHTC and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and also complete a substance use module together.
3364974|NCT05000866|Active Comparator|CHTC, communications skills training and substance use module|Participants complete the standard Couples HIV Testing and Counseling session and watch a communication skills training video and complete a substance use module together.
3364975|NCT04995484|Experimental|Belzutifan in participants with moderate hepatic impairment|Participants with moderate hepatic impairment will receive a single oral 120 mg dose of belzutifan.
3364976|NCT04995484|Experimental|Belzutifan in participants with normal hepatic function|Participants with normal hepatic function will receive a single oral 120 mg dose of belzutifan.
3250474|NCT01385826|Placebo Comparator|placebo|placebo
3250475|NCT01385839|Experimental|alopecia areata|pts will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle
3250476|NCT01385852|Active Comparator|Longitudinal U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, LONGITUDINAL ULTRASOUND
3250477|NCT01385852|Active Comparator|Torsional U/S - low fluidic|ASPIRATION FLOW RATE - 25 CC/MIN, BOTTLE HEIGHT - 90 CMS, TORSIONAL ULTRASOUND
3250478|NCT01385852|Active Comparator|Longitudinal U/S - high fluidic|ASPIRATION FLOW RATE - 40 CC/MIN, BOTTLE HEIGHT - 110 CMS, LONGITUDINAL ULTRASOUND
3376135|NCT02611713||Arm A: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries.
3250479|NCT01385865|Experimental|Mulberry leaf extract|
3250480|NCT01385865|Placebo Comparator|Placebo|
3250481|NCT01385878|Active Comparator|Phacoemulsification with 1.8mm incision|Microcoaxial phacoemulsification was performed using a 1.8mm clear corneal incision
3250482|NCT01385878|Active Comparator|Phacoemulsification with 2.2mm incisi|Microcoaxial phacoemulsificaiton will be performed through 2.2mm incision
3250483|NCT01385891|Experimental|children with advanced leukemia|
3250484|NCT01385930|Experimental|Lifestyle counseling|Lifestyle counseling
3250485|NCT01385930|No Intervention|Control group|Control group
3250486|NCT01385943||Skin Cancer|Patients from dermatology practices throughout Europe that have a skin lesion or tumor requiring a biopsy for diagnosis.
3250487|NCT01385956|Experimental|SOM 230 LAR and Gemcitabine|"Combination Therapy: Dose escalation of SOM 230 LAR and standard treatment with gemcitabine. Treatment will be administered on an outpatient basis. Gemcitabine is administered by IV infusion. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline. The dose of gemcitabine will be given over 30 minutes, weekly every 3 weeks followed by 1 week rest period.~SOM 230 LAR will be administered as an intramuscular dose determined by the dosing schema, every month."
3250488|NCT01385969||Standard Practice|
3364977|NCT04994522|Experimental|Belzutifan in Participants with ESRD|Participants with ESRD will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1), followed by a ≥7 day washout period. Participants receive another single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 2).
3364978|NCT04994522|Experimental|Belzutifan in Healthy Participants|Participants in the healthy matched control group will receive a single dose of belzutifan 120 mg orally on Day 1 of a 4-day treatment period (Period 1).
3364979|NCT04992260|Experimental|Experimental Group|7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of inactivated COVID-19 vaccine on day 0 and day 28.
3364980|NCT04992260|Placebo Comparator|Control Group|7000 subjects (including 100 participants aged 6-35 months ,1900 participants aged 3-5 years ,2500 participants aged 6-11 years and 2500 aged 12-17 years )will receive two doses of placebo on day 0 and day 28.
3364981|NCT04990401|Experimental|Behavioral Activation Teletherapy|All eligible participants will be assigned to receive the behavioral activation teletherapy intervention.
3364982|NCT04989491|Experimental|Experimental group|Prophylactic treatment with Rituximab: one single dose of 375mg/m2 intravenous 7 days before transplantation in case of living donor or at time of transplantation (D0 or D1) in case of transplantation with a deceased donor.
3250489|NCT01385969||Syringe recoil|
3250490|NCT01385969||Pressure Transducer|
3250491|NCT01385982|Other|Actionable Test Results|"Creating standardized policies and procedures around actionable test results (ATR) management, and implementing them network-wide:~Defining the levels of severity and urgency for clinically significant test results~Network-wide policy for test result follow-up by the responsible providers, documentation and escalation processes to assure timely communication.~Standardized policies for the time frames and nature of communication of test result alerts.~Establish criteria for appropriate ATR management by the responsible provider.~Feedback performance including provider, practice and service report cards"
3364983|NCT04989491|Active Comparator|control group|Immunosuppression treatment will be given according to the practice of the centers; use of Thymoglobuline is strongly discouraged because of EBV seronegativity and risk of lymphoma. Basiliximab is recommended for induction therapy. Recommended maintenance immunosuppression consists in a calcineurin inhibitor (tacrolimus or ciclosporine), MMF and Steroids
3364984|NCT04989322|Experimental|Treatment|
3364985|NCT04987476||ATRT|Children affected by an ATRT at time of surgical resection
3364986|NCT04984668|Experimental|GT90001+KN046|"GT90001, 100 mg/10 mL/vial. GT90001 will be administered via intravenous infusion (IV) for around 60 minutes, once every 2 weeks (Q2W) in each 14-day cycle.~KN046, 40 mg/1.6 mL/vial, 300 mg/12 mL/vial KN046 will be administered via intravenous infusion (IV) for at least 120 minutes (up to 4h for the first 6 cycles), once every 2 weeks (Q2W) in each 14-day cycle, after 60 minutes post the GT90001 taken."
3364987|NCT04983472||Observational Group|Individuals diagnosed with Chronic Obstructive Pulmonary Disease by the Department of Pulmonology of the Faculty of Medicine of Bolu Abant Izzet Baysal University will be referred to the Department of Physiotherapy and rehabilitation of the Faculty of Health Sciences of Bolu Abant Izzet Baysal University
3250492|NCT01386021||Prior recipients of allografts for CABG|
3250493|NCT01386034|Experimental|Citrulline/Placebo|
3250494|NCT01386034|Experimental|Placebo/Citrulline|
3365003|NCT04966377|Experimental|Intervention Group|Intervention Group First, pre-tests were applied to the women in the experimental group. A 4-week training program created by taking into account the cultural characteristics of Syrian women; Explaining breast health, Explaining breast structure, Cancer, Breast cancer, Early diagnosis and its importance, BSE application, CBE and mammography, Barriers on breast cancer, Cancer Early Diagnosis, Screening and Education Center. A 'Nurse-directed screening counseling telephone support line' will be established for the women in the experimental group. Then, motivational interviews will be applied to the women in the experimental group by the researcher, who emphasizes the importance of early diagnosis in line with the health belief model. Reminders will be made by phone every week in the 3rd month. The final tests will be held 4 months after the end of the training.
3365004|NCT04966377|No Intervention|Control Group|Pre-tests will be applied to the women in the control group. No intervention will be applied to the women in this group and post-tests will be performed 4 months after the pre-test.
3365005|NCT04965038|Active Comparator|Thrombolysis (interventional study)|Alteplase (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
3365006|NCT04965038|Placebo Comparator|Placebo (interventional study)|Placebo (0.9 mg per kg body weight; 10% as bolus; remaining over one hour) will be administered intravenously within 4.5 hours of symptom onset
3250495|NCT01386047|Experimental|iCPR randomized providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. The iCPR tool will automatically trigger for providers randomized into the iCPR intervention arm when they initiated an encounter for a patient that meets the criteria for possible evaluation of Strep Pharyngitis or Pneumonia.
3250496|NCT01386047|No Intervention|Control providers|The physician population for the proposed study will comprise primary care providers (physicians, internal medicine residents, or licensed nurse practitioners; practicing in the outpatient primary care clinics at Mount Sinai Medical Center. These providers will conduct visits for Strep Pharyngitis and Pneumonia in their manner (usual care).
3365007|NCT04965038|No Intervention|Observational study|The prospective REVISION observational study will enroll patients within 12 hours of symptom onset
3250497|NCT01386060|Experimental|Mindfulness Meditation Training|Participants receive the 6-week meditation training intervention between the 1st and 2nd study visits.
3250498|NCT01386060|No Intervention|Waitlist Control|Participants receive no intervention between the 1st and 2nd study visits. They receive the training between the 2nd and 3rd study visits only.
3250499|NCT01386073|Active Comparator|FreshKote|
3250500|NCT01386073|Placebo Comparator|Systane|
3250501|NCT01386086|Experimental|Aripiprazole|aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
3365021|NCT04939259|Experimental|New Music Program|The new hearing aid contains the new music program will be worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
3365022|NCT04939259|Active Comparator|Standard Listening Program|The new hearing aid also contains the standard listening program worn by all participants at the same time. The participants must switch between the two programs during use to make the comparison.
3365028|NCT04936997|Experimental|3rd COVID-19 vaccine (2nd booster)|Patients who were a part of the non-interventional portion of the study are eligible to receive a third COVID-19 Pfizer vaccine.
3365029|NCT04935177|Experimental|Imlifidase|Imlifidase, is provided as a freeze-dried powder for concentrate for solution for infusion, 11 mg per vial. After reconstitution with sterile water for injection, the concentrate contains 10 mg/mL imlifidase. Imlifidase is administered intravenously as one infusion of 0.25 mg/kg over 15 minutes generally 24 hours prior to transplantation. A second dose of 0.25 mg/kg may be given if the first imlifidase dose is considered not to have had sufficient effect.
3365030|NCT04935177|Other|Best available treatment|Institution-specific desensitization protocol (i.e. any combination of plasma exchange (PLEX), intravenous IVIg, anti-CD20 antibody, and eculizumab) where appropriate OR remain on wait list for a more compatible organ offer
3365031|NCT04935112|Experimental|Group 1 Treatment A (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
3365032|NCT04935112|Experimental|Group 1 Treatment B (sitravatinib and pantoprazole)|Period 2: Oral pantoprazole once daily for 7 days (Days 1 to 7) and a single oral dose of 100 mg sitravatinib on Day 7
3365033|NCT04935112|Experimental|Group 2 Treatment C (sitravatinib only)|Period 1: A single oral dose of 100 mg sitravatinib on Day 1
3365034|NCT04935112|Experimental|Group 2 Treatment D (sitravatinib and famotidine)|Period 2: A single oral dose of 100 mg sitravatinib followed by a single oral dose of famotidine 40 mg approximately 2 hours after sitravatinib dose on Day 1
3365038|NCT04931849|Experimental|Experimental: Avatrombopag|Avatrombopag 40 mg daily by mouth (PO)
3365039|NCT04931511|Experimental|Gluteal muscle injection plus physical therapy group|Gluteal muscle injection (corticosteroid 1ml+normal saline 4ml) + Subacromial Ultrasound Guided injection (sodium chloride 5ml) + Physical therapy
3250502|NCT01386099|Experimental|PSN821|
3250503|NCT01386099|Placebo Comparator|Placebo|
3365040|NCT04931511|Experimental|Subacromial Ultrasound Guided injection plus physical therapy group|Gluteal muscle injection(sodium chloride 5ml)) + Subacromial Ultrasound Guided injection(corticosteroid 1ml+normal saline 4ml) + Physical therapy
3365041|NCT04929028|Experimental|High-risk stratum (nivolumab)|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3365042|NCT04929028|Experimental|Low-risk stratum (mitomycin|Patients receive mitomycin IV on day 1 and either fluorouracil IV on day 1 or capecitabine PO BID on Monday-Friday until the completion of radiation therapy at the discretion of the treating physician. Patients also undergo IMRT QD for 20-23 treatment sessions over 6 weeks.
3250504|NCT01386112|Experimental|EUR-1100 1.5 mg|
3250505|NCT01386112|Experimental|EUR-1100 3.0 mg|
3250506|NCT01386112|Placebo Comparator|placebo|
3250507|NCT01386138|Experimental|RBT+WHIC|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups. The four WHC modules were incorporated into the RBT sessions.
3365047|NCT04925401|Experimental|Information brochure Arm|The experimental group will receive an information brochure on fever in children and how to deal with a febrile episode and usual medical management.
3365048|NCT04925401|No Intervention|Habitual care|The control group will receive the usual medical management
3250508|NCT01386138|Active Comparator|Psycho-education|Participants met in groups for 2 hours thrice weekly (M/W/F). During the first hour, the counselor facilitated discussion of 1 of the 12 RBT module topics, repeated three times during the course of the 12-week intervention (as in RBT). A patient-led group served the purpose of mutual support during the second hour. The counselor facilitated but did not have direct discussion in these latter groups.
3250509|NCT01386151|Active Comparator|Study drug|Keratinocyte growth factor (KGF) will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11.
3365055|NCT04920942|Experimental|Treatment group|Ivermectin 0.4mg/kg/day for 5 days + standard-of-care
3365056|NCT04920942|No Intervention|Control group|Standard-of-care only
3250510|NCT01386151|Placebo Comparator|Placebo|Saline will be used as a placebo comparator
3365059|NCT04913129|No Intervention|Control Group|Standard physician-guided medical care after COVID-19
3365060|NCT04913129|Experimental|Interventional (exercise training) Group|8 week home-based exercise training
3365061|NCT04912869|Experimental|Crovalimab|Participants will receive a single intravenous (IV) infusion of Crovalimab based on body weight.
3365062|NCT04912869|Placebo Comparator|Placebo|Participants will receive a single IV infusion of matching Placebo.
3250511|NCT01386164|Experimental|Gardasil®|
3250512|NCT01386164|Experimental|Cervarix®|
3250513|NCT01386177|Experimental|doxazosin, MDMA, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3365067|NCT04905121|Experimental|Psilocybin|
3250514|NCT01386190|Experimental|Exercise Group|Caregivers will be taught progressive exercises to use with their infants from hospital discharge to 1 year of age.
3250515|NCT01386190|Active Comparator|Control|Both the control and the intervention groups will be guided in implementing structured social interaction.In the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
3365070|NCT04901754|Experimental|Camrelizumab Plus Apatinib|camrelizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus Apatinib capsules 250 mg given orally
3365071|NCT04897763|Experimental|89Zr-TLX250 PET/CT|Pretherapeutic 89Zr-TLX250 PET/CT
3250516|NCT01386203||Lung Cancer|
3250517|NCT01386203||Lung Cancer after therapy|
3250518|NCT01386203||COPD controls|
3250519|NCT01386216|Experimental|Bone Marrow Cell Concentrate|Bone Marrow Cell Concentrate Prepared Using the Magellan System
3250520|NCT01386229|Active Comparator|Ketamine|
3250521|NCT01386229|Active Comparator|Etomidate|
3250522|NCT01386242|Experimental|The first group|Recombinant anti-tumor and anti-virus protein for injection, twice per week
3250523|NCT01386242|Experimental|The second group|Recombinant anti-tumor and anti-virus protein for injection, three times per week
3365085|NCT04889950|Experimental|Tixel Group|Tixel C Group: Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
3250524|NCT01386242|Placebo Comparator|Placebo group|Saline Injection, three times per week
3250525|NCT01386242|Experimental|The third group|High dose of recombinant anti-tumor and anti-virus protein for injection, three times per week
3250526|NCT01386255|Active Comparator|baclofen|Baclofen suspension
3250527|NCT01386255|Placebo Comparator|placebo|Identical palcebo suspension
3250528|NCT01386268||Group 1|
3250529|NCT01386281||Group 1|Drug (incl. Placebo)
3250530|NCT01386294|Experimental|Tenofovir 1% vaginal gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
3250531|NCT01386294|Placebo Comparator|Universal placebo gel|Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
3250532|NCT01386320|Active Comparator|Ultrasound guided ankle block|Subjects in this arm will be given an ultrasound guided ankle block prior to foot surgery.
3250533|NCT01386320|Active Comparator|Medial forefoot block|Subjects in this arm will be given a nerve-stimulator guided forefoot block prior to anaesthesia and forefoot surgery
3250534|NCT01386333|Experimental|Oxytocin 24IU|Oxytocin 24 IU administered intranasally twice daily for 1 week
3250535|NCT01386333|Experimental|Oxytocin 48 IU|48 IU of intranasal oxytocin administered twice daily for 1 week
3250536|NCT01386333|Experimental|72 IU oxytocin|72 IU of intranasal oxytocin administered twice daily for 1 week
3250537|NCT01386333|Placebo Comparator|Saline nasal spray|
3250538|NCT01386346|Experimental|All subjects|"Azacitidine Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.~Oxaliplatin on Day 1 130mg/m2 Epirubicin on Day 1 50mg/m2 Capecitabine 625 mg/m2"
3250539|NCT01386359||Adult de novo EBV-seropositive kidney-transplant recipients|Adult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
3250540|NCT01386372|Experimental|Tolvaptan|
3250541|NCT01386372|Active Comparator|standard therapy|
3250542|NCT01386411||Women with Breast Cancer|The proposed investigation is a prospective cohort study. Women with newly diagnosed breast cancer will decide whether to undergo BRCA testing either before or after completion of local surgical treatment.
3365086|NCT04889950|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits, Treatment- 1 single treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
3365089|NCT04887922|No Intervention|Pre-Surgery: No Incentive Spirometry (IS)|-Will not receive a incentive spirometer prior to surgery
3365090|NCT04887922|Experimental|Pre-Surgery: Standard Incentive Spirometry (IS)|"Will receive a conventional spirometer prior to surgery~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery."
3365091|NCT04887922|Experimental|Pre-Surgery: Digital Incentive Spirometry (IS) + Text Message|"Will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be asked to perform spirometry 10 times per hour, every hour while awake, every day for at least 7 days prior to surgery. Absence of spirometry for 24 hours will trigger a text message reminder to encourage compliance with IS."
3365092|NCT04887922|Active Comparator|Post-Surgery: Standard Incentive Spirometry (IS)|"After surgery, the participants will receive a conventional spirometer.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~The conventional spirometer will be equipped with an accelerometer that will allow the research team to determine whether the spirometer moves throughout the patients' postoperative stay (as a proxy for IS use)"
3365093|NCT04887922|Experimental|Post-Surgery: Digital Incentive Spirometry (IS) + Text Message|"After surgery, the participants will receive the digital incentive spirometer (Spirobank G) that is compatible with health monitoring software developed by ZEPHYRx®. The digital spirometer couples with a HIPAA-compliant mobile application that calculates and stores pulmonary function test (PFT) results.~Will be instructed to perform spirometry 10 times per hour, every hour while awake through postoperative Day 3~Will receive text reminders to perform spirometry if they do not perform spirometry in a 24-hour period."
3365094|NCT04884035|Experimental|Administration of CC-220 with R-CHOP-21|CC-220 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
3365095|NCT04884035|Experimental|Administration of CC-99282 with R-CHOP-21|CC-99282 to be administered orally in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP-21) for 6 cycles of treatment
3365096|NCT04883437|Experimental|Treatment (acalabrutinib, obinutuzumab)|"INDUCTION PHASE: Patients receive acalabrutinib PO BID on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of cycle 3, then on day 1 of cycles 4-8. Treatments repeat every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.~FOLLOW-UP PHASE: After cycle 12, patients who are in CR are randomized to either discontinue acalabrutinib or to continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with PR or SD after cycle 12 continue acalabrutinib monotherapy in the absence of disease progression or unacceptable toxicity. Patients with disease progression after cycle 12 discontinue study treatment. Patients with disease progression at any time prior to the conclusion of cycle 12 may continue study therapy if they are felt to be benefiting by the treating physician, but not past cycle 12."
3365097|NCT04882644|Experimental|Aerobic Exercise Intervention Group|The subjects receive an intensive aerobic exercise for 3 months and a health education content for 12 months.
3365098|NCT04882644|No Intervention|Control Group|The subjects do not change their physical activity routine and receive a health education content for 12 months.
3250545|NCT01386541|Active Comparator|BYK324677|"Dose group I: total daily dose 2 mg (1 mg BID or 2 mg SID)~Dose group II: total daily dose 4 mg (2 mg BID or 4 mg SID)~Dose group III: total daily dose 6 mg (3 mg BID or 6 mg SID)~In each dose group 12 subjects (8 subjects BYK324677, 4 subjects placebo) are planned.~Within each dose group, the subjects will be randomised to either BYK324677 or placebo at a ratio of 2:1.~Within each verum group, the subjects will be randomised to one of the 2 treatment sequences (BID/SID or SID/BID, ratio 1:1) and treated in a cross-over manner."
3250546|NCT01386541|Placebo Comparator|Placebo|
3250547|NCT01386567|Experimental|Androxal|Androxal (enclomiphene citrate)12.5 mg or 25 mg
3250548|NCT01386567|Active Comparator|Testim (topical testosterone)|
3250549|NCT01386580|Experimental|2B3-101 Single Agent Dose Escalation|Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3250550|NCT01386580|Experimental|2B3-101 in combination with trastuzumab|HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.
3250551|NCT01386580|Experimental|2B3-101 solid tumor expansion|Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3250552|NCT01386580|Experimental|2B3-101 glioma expansion|Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.
3250553|NCT01386593|Other|(A) Baseline|
3365099|NCT04881175|Experimental|FlexSure Applicator|The TempSure FlexSure applicator will be used on the abdomen or flanks.
3365102|NCT04877262|Experimental|early time-restricted eating (eTRE)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 6-h window in the morning hours (e.g., 8:00 AM - 2:00 PM)
3365103|NCT04877262|Experimental|control eating schedule (CON)|Participants will be provided a weight-maintenance diet for 9 consecutive days and will consume all meals and snacks in a 12-h window in the morning hours (e.g., 8:00 AM - 8:00 PM)
3365106|NCT04870775|Experimental|Experimental group|The intervention administered to the experimental group will be a mindfulness training program
3365107|NCT04870775|No Intervention|Control group|The control group will not receive any intervention
3365108|NCT04868916||Participants with X-Linked Retinitis Pigmentosa (XLRP)|Participants with confirmed diagnosis of XLRP associated with pathogenic variants in retinitis pigmentosa GTPase regulator (RPGR) in the Japanese population will be enrolled in the study and the data will be collected and observed. The primary data source for this study will be the medical records of each participant.
3250554|NCT01386593|Other|(B) Inhibition|
3250555|NCT01386593|Other|(C) Induction|
3365109|NCT04868799||ATRT|Patients <18 years with an ATRT having frozen samples
3365112|NCT04861844|Experimental|Mindfulness training|
3365113|NCT04861844|Active Comparator|Active listening|
3365114|NCT04860336||Pregnant women less than or equal to 14w0d gestation|
3365115|NCT04859517|Experimental|ADG20|Participants will be dosed on Day 1 with ADG20 IM
3365116|NCT04859517|Placebo Comparator|Placebo|Participants will be dosed on Day 1 with placebo IM
3365117|NCT04856527|Experimental|Experimental Group|Participants will receive physical therapist support to reduce postural sway while completing a precision aiming task in virtual reality, whether or not they require the support.
3365118|NCT04856527|No Intervention|Control Group|Participants will receive no physical therapist support while completing the task.
3365119|NCT04856475|Experimental|HER2 metastatic breast cancer locally pretreated for previous CNS events and currently progressive|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
3365120|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with newly diagnosed brain metastases|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), brain MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
3365121|NCT04856475|Experimental|HER2 positive metastatic breast cancer patients with leptomeningeal carcinomatosis|"Eligible subjects will receive neratinib in combination with capecitabine or with T-DM1 or with paclitaxel or with vinorelbine as per investigator's choice. Trastuzumab can be added as per investigator's choice to those regimens except for T-DM1.~At screening and during the study treatment period (every 9 weeks), contrast-enhanced neuraxis brain and spine MRI and tumour assessment by thoracic and abdomino-pelvic CT scan should be performed. CSF cytological assessment should also be performed.~Additionally, at screening and at each cycle during the study treatment period, subjects must fill quality of life questionnaires: EORTC core questionnaire (QLQ-C30) and brain module (QLQ-BN20)."
3376136|NCT02611713||Arm B: Participants with Advanced Parkinson's Disease|Participants who along with their physicians have elected for treatment with Duodopa/Duopa and are prescribed according to the local product label and reimbursement guidelines for their participating countries. Participants will be evaluated with a wearable device
3250556|NCT01386619|Experimental|NK cell DLI|
3250557|NCT01386658|Experimental|Icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
3250558|NCT01386671|Experimental|Metformin glycinate|Metformin glycinate is a new biguanide, for this study the dose administrated will be 1050.6 mg OD for a month, and 1050.6 mg BID for 11 moths.
3250559|NCT01386671|Active Comparator|Metformin Hydrochloride|Metformin Hydrochloride is the biguanide most used, for this study the dose administrated will be 850 mg OD for a month, and 850 mg BID for 11 months.
3250560|NCT01386684||Patients with Prostate Cancer|Patients with prostate cancer who were receiving treatment with leuprolide acetate (Lupron).
3250561|NCT01386710|Experimental|Arm 2|Drug: Bevacizumab and Carboplatin
3250562|NCT01386710|Experimental|Arm 1|Drug: Bevacizumab and Carboplatin
3250563|NCT01386723||Discontinuation of eltrombopag|ITP subjects who have discontinued the use of eltrombopag
3365122|NCT04852328|Experimental|Schedule A: CUE-101|"In Schedule A, CUE-101 will be administered during the neoadjuvant phase as a single dose given 14 days prior to initiation of standard of care (SOC) therapy.~Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
3365123|NCT04852328|Experimental|Schedule B: CUE-101|"In Schedule B, CUE-101 will be administered during the neoadjuvant phase as two doses: one dose given 14 days and one dose given 7 days prior to initiation of standard of care (SOC) therapy.~Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
3365124|NCT04852328|Experimental|Schedule C: CUE-101|"In Schedule C, CUE-101 will be administered during the neoadjuvant phase as a single dose given 7 days prior to initiation of standard of care (SOC) therapy.~-Standard of care therapy consists of surgery and postoperative adjuvant (cisplatin) and radiation therapy or cisplatin and radiation therapy (definitive-chemoradiation therapy)"
3365129|NCT04849988|Experimental|ABP-450 - Low Dose|ABP-450 Low Dose - Intramuscular injections into affected neck muscles.
3365130|NCT04849988|Experimental|ABP-450 - Medium Dose|ABP-450 Mid Dose - Intramuscular injections into affected neck muscles.
3365131|NCT04849988|Experimental|ABP-450 - High Dose|ABP-450 High Dose - Intramuscular injections into affected neck muscles.
3365132|NCT04849988|Placebo Comparator|Placebo|Placebo (0.9% saline, sterile, unpreserved, USP/Ph.Eur.) - Intramuscular injections into affected neck muscles.
3250564|NCT01386736|Active Comparator|Vitamin D|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
3250565|NCT01386736|Placebo Comparator|Placebo|Subjects will randomly be assigned to Vitamin D drops versus placebo drops.
3250566|NCT01386749|No Intervention|Control|
3250567|NCT01386749|Experimental|Treatment|receive 6 months LMHFV
3250568|NCT01386762|Experimental|Exercise intervention|6 months of intense multimodal training.
3365136|NCT04849273|Experimental|TPX-0131|"The Phase 1 part of the study will determine the safety, tolerability, PK, MTD, and RP2D of TPX-0131.~The Phase 2 part of the study will determine the safety, tolerability, PK and preliminary efficacy of TPX-0131 in specific cohorts."
3365137|NCT04848753|Active Comparator|Experimental Group|Toripalimab combined with cisplatin and paclitaxel
3365138|NCT04848753|Placebo Comparator|Control Group|Placebo combined with cisplatin and paclitaxel
3365139|NCT04848506|Experimental|CK-3773274 up to 15 mg|Patients in this arm take daily dose of CK-3773274. Each patient will start at the lowest prespecified dose and titrate up to their maximum tolerated dose.
3365140|NCT04848480|Experimental|Insulin icodec + insulin aspart|insulin icodec once a week in combination with 2-4 times daily injections of insulin aspart at meal times
3365141|NCT04848480|Active Comparator|Insulin degludec + insulin aspart|insulin degludec once a day in combination with 2-4 times daily injections of insulin aspart at meal times
3365142|NCT04847648|Active Comparator|Control - Mechanical instrumentation of implant surface|The control group will be subjected to non-surgical and surgical mechanical decontamination including the use of hand instruments and polishing cups aiming at the removal of all supra-mucosal soft and hard deposits from the implant surfaces.
3365143|NCT04847648|Experimental|Test - Mechanical instrumentation and air-polishing of implant surface|In the test group the mechanical instrumentation will be supplemented by the use of an air-polishing device, both, during non-surgical and during surgical therapy.
3365147|NCT04844593||Participants With CD|Participants with CD diagnosed with or without CPF will be identified from EMRs through medical language application program interface (API) software. The AI will apply NLP and machine learning to identify and analyse text information in EMRs and thereby, extract medical information. The study will consist of two sequential phases: Phase 1 (validation process) and Phase 2 (data collection and NLP).
3365148|NCT04844450|Experimental|Single Ascending Dose (SAD)|Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.
3365149|NCT04844450|Experimental|Multiple Ascending Dose (MAD)|Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
3365150|NCT04840849|Experimental|Nirsevimab|Nirsevimab single dose IM injection
3365151|NCT04840849|Placebo Comparator|Placebo|Placebo single dose IM injection
3376143|NCT02603900|Experimental|Adductor Canal Catheter|This group will receive ropivacaine 0.5% 15 ml for the adductor canal block under ultrasound guided nerve block. A multi-orifice catheter will be placed in the adductor canal and an infusion of ropivacaine 0.2% at 10 ml/hr will be continued for 72 hours.
3250569|NCT01386775||HED Affected Males|
3250570|NCT01386775||Controls|
3250571|NCT01386801||People with Diabetes Mellitus Type II|500 subjects will have T2D
3250572|NCT01386801||Healthy|500 persons who do not have T2D, hypertension or hypercholesterol
3250573|NCT01386827|Active Comparator|A) primary immunization with MB-JEV|Volunteers immunized with MB-JEV
3250574|NCT01386827|Active Comparator|Primary and booster MBJEV vaccinations|Booster immunization with MB-JEV of vaccinees primed with MB-JEV
3250575|NCT01386827|Active Comparator|C) primary immunizations with Ixiaro|Primary immunization with Ixiaro 2 dose
3250576|NCT01386827|Active Comparator|S) Ixiaro booster to MBJEV primed|Actual study group:Booster immunization with Ixiaro to those primed previously with MB-JEV
3365152|NCT04834297|Experimental|SVS mattress|Infants randomized to the experimental arm will have the SVS mattress placed in their crib within 24 hours of birth and will continue till discharge home after the completion of monitoring phase of NOWS or till determination is made to initiate pharmacotherapy for NOWS.
3365153|NCT04834297|No Intervention|Standard mattress|Infants randomized to the no intervention arm will continue to be cared for using the standard hospital crib mattress throughout their birth hospitalization.
3365155|NCT04830761|Experimental|Habit - Motivation group|First: 2 weeks habit intervention; Second: 2 weeks motivation intervention
3365156|NCT04830761|Experimental|Habit - Social group|First: 2 weeks habit intervention; Second: 2 weeks social intervention
3365157|NCT04830761|Experimental|Habit - Habit group|4 weeks habit intervention
3250577|NCT01386840|No Intervention|Severe Pneumonia - Hospital Management|"Those randomized to hospital management will be monitored by health personnel for at least 48 hours for clinical deterioration and parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, Clinical deterioration, Other signs eg. comorbid conditions, Assessment of adherence, Adverse event.~Mothers, whose children are discharged after 48 hours, will be counseled to continue with oral treatment prescribed for a period of 7 days and will be advised to return to healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card"
3365158|NCT04830761|Experimental|Motivation - Habit group|First: 2 weeks motivation intervention; Second: 2 weeks habit intervention
3365159|NCT04830761|Experimental|Motivation - Social group|First: 2 weeks motivation intervention; Second: 2 weeks social intervention
3365160|NCT04830761|Experimental|Motivation - Motivation group|4 weeks motivation intervention
3365161|NCT04830761|Experimental|Social - Habit group|First: 2 weeks social intervention; Second: 2 weeks habit intervention
3365162|NCT04830761|Experimental|Social - Motivation group|First: 2 weeks social intervention; Second: 2 weeks motivation intervention
3365163|NCT04830761|Experimental|Social - Social group|4 weeks social intervention
3365164|NCT04830124|Experimental|Advanced Cutaneous Melanoma|Patients with unresectable and/or metastatic cutaneous melanoma
3365165|NCT04830124|Experimental|Advanced mucosal melanoma|Patients with unresectable and/or metastatic mucosal melanoma
3365166|NCT04818801|Experimental|Recombinant two-component COVID-19 vaccine (CHO cell)|Participants received Recombinant two-component COVID-19 vaccine (CHO cell) 0.5ml reconstituted by adjuvant solution, 2 shots at a interval 21 days, intramuscular injection
3365167|NCT04818801|Placebo Comparator|Placebo|Participants received placebo of 0.5ml normal saline (0.9% sodium chloride solution), 2 shots at a interval 21 days, intramuscular injection
3365177|NCT04804709|Experimental|FUS using Oral Panobinostat|All patients enrolled in the study will be treated with oral Panobinostat after receiving Focused Ultrasound treatment (FUS) with microbubbles and neuro-navigator-controlled sonication.
3365179|NCT04799665||All Participants|
3365185|NCT04790903|Experimental|Venetoclax (Schedule A)|"Participants enrolled in dosing Schedule A will receive a total of six 21-day cycles of venetoclax treatment for 5 days in combination with Polatuzumab Vedotin + R-CHP (Rituximab, Cyclophosphamide, Doxorubicin and Prednisone) as described below:~Schedule A: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 5 consecutive days as follows:~Cycle 1: 5 consecutive days of dosing on Days 4-8. Cycles 2-6: 5 consecutive days of dosing on Days 1-5."
3250578|NCT01386840|Experimental|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
3250579|NCT01386853|Experimental|Pitavastatin|
3365186|NCT04790903|Experimental|Venetoclax (Schedule B)|"Participants enrolled in dosing Schedule B will receive a total of six 21-day cycles of venetoclax treatment for 10 days in combination with Polatuzumab Vedotin + R-CHP as described below:~Schedule B: Participants will self-administer Venetoclax orally (PO) once daily (QD) at a dose of 800 mg for 10 consecutive days as follows:~Cycle 1: 10 consecutive days of dosing on Days 4-10. Cycles 2-6: 10 consecutive days of dosing on Days 1-10."
3365187|NCT04786847|Experimental|Single administration of 177Lu-DOTA-TLX591|Two single IV infusions of 76 mCi (2.8 GBq) each (equivalent to a 45 mCi/m2 administered activity in a standard 1.7m2 individual) of 177Lu-DOTA-TLX591, given 14 days apart. This therapy will be administered with the current standard of care treatment regimens.
3365188|NCT04783428||Prior TIO Burosumab Clinical Trial Participants|
3365189|NCT04783428||Adults Who Have Not Participated In Prior Burosumab Clinical Trials|
3250580|NCT01386853|Active Comparator|Atorvastatin|
3250581|NCT01386866|Experimental|A|
3250582|NCT01386879|Experimental|TaperGuard Evac ETT|Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
3250583|NCT01386879|Experimental|Teleflex ISIS ETT|Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
3250584|NCT01386879|Active Comparator|Standard ETT|Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)
3250585|NCT01386892||Healthy Volunteer|Healthy Volunteer without lung disease
3250586|NCT01386918|Experimental|Low frequency left (LFL) sided rTMS|LFL rTMS was administered at an intensity of 115% resting motor threshold at 1HZ for 20 minutes. The treatment targeted the left temporoparietal cortex (TPC).
3250587|NCT01386918|Experimental|Priming stimulation|Priming stimulation was administered as follows: 10 minutes of 6 Hz at 90% resting motor threshold (RMT) administered to the left temporoparietal cortex followed by 10 minutes of 1 Hz stimulation at 115% RMT.
3365190|NCT04783428||Pediatrics Who Have Not Participated In Prior Burosumab Clinical Trials|
3365191|NCT04778748||Obstructive Sleep Apnea|Participants will be provided with a Withings sleep monitor and instructed to begin using it. Effective data collection via the Withings unit should be confirmed for at least 7 consecutive nights, and the WatchPAT device will be used during one of those same 7 nights.
3365196|NCT04763772|Experimental|Detailed Report|A detailed body composition profile report that consists of the following elements: basic demographic data, percent body fat, weight to muscle ratio, visceral fat and abdominal subcutaneous fat volume, visceral fat ratio (the fraction of visceral divided by total abdominal fat), muscle fat infiltration and liver fat (%), and thigh muscle volumes (also separated into right and left, anterior and posterior compartments). Each parameter is presented on a visual scale in the context of the individual value, general population defined by reference data (from United Kingdom (UK) Biobank population), a metabolic disease-free population (also from UK Biobank), low/high and very low/very high, corresponding to 15th and 5th percentiles, respectively. There are also descriptions of each biomarker and how they are derived to provide context for the recipient.
3365197|NCT04763772|Placebo Comparator|Basic Weight Information|A simple informational report consisting of weight, BMI, and a visual representation of their BMI. This report also categorizes their BMI into underweight, normal weight, overweight, or obese categories according to the World Health Organization categorization schema.
3365198|NCT04763772|Experimental|Patient Provided|Report provided directly to the patient.
3365199|NCT04763772|Placebo Comparator|Physician Provided|Report provided directly to the provider to translate/counsel the patient.
3250588|NCT01386918|Sham Comparator|Sham Control|Sham stimulation was applied with identical parameters to those for the LFL condition but with the coil angled at 90 degrees off the scalp in a single wing tilt position.
3365202|NCT04760288|Experimental|Arm A (Pralsetinib)|Participants will receive Pralsetinib at a dose of 400mg orally once daily (PO QD) in 28-day cycles.
3365203|NCT04760288|Active Comparator|Arm B (SOC: Cabozantinib/Vandetanib)|Participants will receive either one of the following SOC therapies, as determined by the treating investigator: Cabozantinib: 140mg PO QD in 28-day cycles; Vandetanib: 300mg PO QD in 28-day cycles.
3250589|NCT01386931||Cytopathologist present during EUS-FNA|"Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
3250590|NCT01386931||Cytopathologist absent during EUS-FNA|"In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).~After EUS-FNA is performed all slides will be sent to the pathology department. The slides will be sent for review regardless of which arm the patient is randomized into, and they will be reviewed by experienced cytopathologists for the purpose of determining the final diagnoses."
3250591|NCT01386957||Study group|children aged 6 months - 18 years, diagnosed with an initial episode of INS occurring from the first of July 2011 to the 31st of june 2013.
3250592|NCT01386996|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3250593|NCT01386996|Active Comparator|Charcoal and Symbicort Turbuhaler|
3250594|NCT01386996|Experimental|Budesonide/formoterol Easyhaler|
3250595|NCT01386996|Active Comparator|Symbicort Turbuhaler|
3250596|NCT01387048|Experimental|Skinoren gel 15 %, topical|primary treatment 12 weeks with Skinoren gel®, followed by maintenance therapy with Skinoren gel® for another 24 weeks,
3250597|NCT01387048|Active Comparator|Differin Gel 0.1%|primary 12 weeks therapy with Differin gel®, followed by maintenance therapy with Differin gel® for another 24 weeks.
3250598|NCT01387048|Experimental|Skinoren|primary 12 weeks therapy with Skinoren gel®, followed by observation only for another 24 weeks,
3250599|NCT01387061|Experimental|hepatic resection|
3365214|NCT04750941|Experimental|Follicular Lymphoma (FL)|"The lymphoma study group will enroll 23 patients with FL.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
3250600|NCT01387087|Experimental|Group A|Lowest dose, all males, fasting
3250601|NCT01387087|Experimental|Group B|Second lowest dose, all males, fasting
3250602|NCT01387087|Experimental|Group C|Third lowest dose, all males, fasting
3250603|NCT01387087|Experimental|Group D|Middle dose, all males, fasting
3250604|NCT01387087|Experimental|Group E|Third lowest dose, all females, fasting
3250605|NCT01387087|Experimental|Group F|Third highest dose, all males, fasting then fed
3250606|NCT01387087|Experimental|Group G|Second highest dose, all males, fasting
3250607|NCT01387087|Experimental|Group H|Highest dose, all males, fasting
3250608|NCT01387087|Experimental|Group I|Second highest dose, all females, fasting
3365215|NCT04750941|Experimental|Endometrial Cancer (EC)|"The solid tumor group will enroll 19 patients with EC.~In cycle 1, patients will first start ketogenic diet for 7 days (Day -6 to Day 0). Only patients who demonstrate compliance and tolerance with the ketogenic diet for all 7 days, as confirmed by pertinent blood and urine tests, will be allowed to continue the study and treatment using copanlisib and the ketogenic diet starting on Day 1. In cycle 2 and beyond, patients will start the ketogenic diet and copanlisib on day 1."
3250609|NCT01387087|Placebo Comparator|Placebo Group A|all male, fasting
3250610|NCT01387087|Placebo Comparator|Placebo Group B|all male, fasting then fed
3250611|NCT01387087|Placebo Comparator|Placebo Group C|all female, fasting
3250612|NCT01387100|Experimental|Physical Therapist/Occupational Therapist Intervention|This group will be assigned a physical therapist or occupational therapist to meet with followed by 2 phone consultations.
3365216|NCT04747496||NVAF patients|NVAF adult patients with one or more risk factors treated with edoxaban.
3365217|NCT04745676|Experimental|Experimental|The SICG program consists of the Serious Illness Conversation Guide as well as training and system-level support for physicians to conduct ACP conversations.
3365220|NCT04739527|Experimental|Treatment arm|Patients receiving 4 bi-weekly vaccinations with 25E6 cells/vaccination of DCP-001, and 2 booster vaccinations with 10E6 cells/vaccination
3365221|NCT04733534|Active Comparator|Dasatinib plus Quercetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16^INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 will assess the permanence of change after completion of the trial."
3365222|NCT04733534|Active Comparator|Fisetin|"Day 0 (30 per arm, randomization stratified by sex and age)~At the visit on day 7, blood CD3+ T lymphocyte p16INK4A mRNA and other markers of inflammation and senescence will be accessed to verify that senescent cells have been cleared by the intervention.~Post-treatment follow-up will occur on days 60 for (primary endpoints) and day 150 for secondary evaluation. Day 150 to will assess the permanence of change after completion of the trial."
3365223|NCT04731103|Active Comparator|Abacavir (ABC)|Participants receive Abacavir (ABC) for 6 weeks and 4 weeks of washout.
3365224|NCT04731103|Active Comparator|Lamivudine (3TC)|Participants receive Lamivudine (3TC) for 6 weeks and 4 weeks of washout.
3365225|NCT04731103|Active Comparator|Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)|Participants receive Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) for 6 weeks and 4 weeks of washout.
3365226|NCT04729907|Experimental|BIIB058 28 mg (Prior Maintenance Dose 28 mg)|Participants who received maintenance dose of 28 milligram (mg) nusinersen in study 232SM203 (NCT04089566), will receive maintenance dose of 28 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
3365227|NCT04729907|Experimental|BIIB058 50/28 mg (Prior Maintenance Dose 12 mg)|Participants who received maintenance dose of 12 mg nusinersen in study 232SM203 (NCT04089566), will receive loading dose of 50 mg nusinersen, by intrathecal injection, on Day 1, followed by maintenance dose of 28 mg nusinersen, by intrathecal injection, every 4 months, up to Day 961.
3365228|NCT04728620|Experimental|Intervention|Participants will have access to a new feature within an established patient portal native app on mobile devices. The new feature aims to address diabetes care gaps.
3250613|NCT01387100|No Intervention|Control|This is the control group. This group will not receive the vocational rehabilitation intervention from an occupational or physical therapist. They will receive written information regarding job accommodations and disability advocacy.
3365232|NCT04718961|Experimental|Volixibat 20mg|Participants randomized to this arm will receive volixibat 20mg twice daily.
3365233|NCT04718961|Experimental|Volixibat 80mg|Participants randomized to this arm will receive volixibat 80mg twice daily.
3365234|NCT04718961|Placebo Comparator|Placebo|Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
3365235|NCT04715516|Experimental|alcohol brief intervention + lifestyle health promotion|"The intervention arm will receive 4 minutes of alcohol brief intervention, and 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight), to increase knowledge of how to improve women's health and reduce breast cancer risk. Alcohol and lifestyle information will be delivered by way of an animation on an iPad. Participant responses to questions about current alcohol use will branch to personalised feedback consistent with level of alcohol consumption (i.e. drinking within or above current Australian Alcohol Guidelines).~Take-home pamphlets - a pamphlet summarising the alcohol information presented during the animation, and a pamphlet on nutrition to maintain a healthy weight, will be provided."
3365236|NCT04715516|Other|lifestyle health promotion, not inclusive of alcohol information|"The control arm will receive 3 minutes of lifestyle health promotion (physical activity; maintaining a healthy weight) to increase knowledge of how to improve women's health and reduce breast cancer risk, not inclusive of alcohol information. Lifestyle information will be delivered by way of an animation on an iPad.~Take-home pamphlet - a pamphlet on nutrition to maintain a healthy weight will be provided."
3250614|NCT01387113||Acute ischemic stroke patients|All acute ischemic stroke patients receiving IV rt-PA within 6 hours of symptom onset
3365239|NCT04711148|Placebo Comparator|placebo|"The Core Part：Participants receive placebo~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
3365240|NCT04711148|Experimental|orelabrutinib(low dose)|"The Core Part：Participants receive low dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
3365241|NCT04711148|Experimental|orelabrutinib(medium dose)|"The Core Part ：Participants receive medium dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
3365242|NCT04711148|Experimental|orelabrutinib (high dose)|"The Core Part：Participants receive high dose orelabrutinib~The OLE Part：Participants who have completed the Week 24 visit in the Core Part for continued treatment and collect additional long-term safety and efficacy data receive the low dose of orelabrutinib or any other dose as suggested from the Core part of the study."
3365243|NCT04711135|Experimental|GEP-NET and PPGL|All eligible participants will receive Lutathera (7.4 GBq/200 mCi x 4 administrations every 8 weeks; cumulative dose: 29.6 GBq/800 mCi), with a concomitant administration of 2.5% Lysine - Arginine amino acid solution.
3365244|NCT04708535||Bariatric Cohort|For consenting subjects who are undergoing bariatric surgery, a visceral fat sample will be taken during surgery. In addition to the fat sample, insulin resistance will be measured and determined by a modification of the insulin suppression test.
3250615|NCT01387126|Experimental|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
3250616|NCT01387126|No Intervention|Weight management program|
3365247|NCT04704882|Experimental|omental patchwork group|
3365248|NCT04704882|No Intervention|non-omental patchwork group|
3365249|NCT04700098|Experimental|Internet-based behavioral treatment for insomnia + HBPR|Internet version of cognitive-behavioral treatment for insomnia plus home-based pulmonary rehabilitation
3365250|NCT04700098|Experimental|HBPR only|Home-based pulmonary rehabilitation only
3365251|NCT04697472|Experimental|Functional task practice (FTP) followed by FTP + ARC Therapy|Clinic-based functional task practice (FTP) for two months followed by FTP + ARC Therapy for an additional 2 months.
3365252|NCT04695977|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
3365253|NCT04695977|Experimental|Nivolumab Monotherapy|All enrolled subjects will receive nivolumab monotherapy IV according to the treatment schedule until a reason for treatment discontinuation is reached.
3365254|NCT04694781|Experimental|Monotherapy Dose Escalation|LVGN6051 monotherapy dose escalation
3365255|NCT04694781|Experimental|Monotherapy Dose Expansion|LVGN6051 dose expansion cohorts
3365256|NCT04694781|Experimental|Combination therapy dose escalation|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose escalation
3250617|NCT01387152||Very low dose stress test protocol|Patients admitted to New York Presbyterian Hospital (NYPH)-Columbia University Medical Center with chest pain but normal or nondiagnostic electrocardiograms and at least 3 negative troponins taken 4 or more hours apart, and undergo exercise or pharmacologic stress testing using a very low dose (<6 mCi) of Tc99m tetrofosmin or sestamibi with imaging performed using acquisitions with an Alcyone camera.
3250618|NCT01387165||Patients|males and females between 18 and 75 years of age who been diagnosed with T2DM as defined by the American Diabetes Association
3250619|NCT01387191||Subjects prescribed epoprostenol|Subjects with pulmonary arterial hypertension prescribed epoprostenol injection during study period
3250620|NCT01387204|Experimental|Single-Dose, 2 mg [14C]GSK1120212|A single 2 mg (2 mg/10mL) oral dose of [14C]GSK1120212 containing approximately 79 μCi of radioactivity will be delivered as a solution.
3250621|NCT01387217|Experimental|Part A|Part A will be used to confirm the prediction of GSK2018682 PK, assess its effects on lymphocytes, and monitor its safety profile in a single cohort (Cohort 1). Cohort 1 will consist of 4 subjects and explore 4 doses of GSK2018682 in 4 study sessions. In each session, three subjects will receive GSK2018682 and one subject will receive placebo. Thus, when the cohort completes, each subject will receive placebo and 3 doses of GSK2018682.
3250622|NCT01387217|Experimental|Part B|Part B will explore doses to refine the dose-response curve of GSK2018682 on lymphocyte suppression, as allowed by stopping criteria, in 1 or 2 cohorts of up to 15 subjects (Cohort 2 and Cohort 3). In Part B, up to six single ascending doses of GSK2018682 and one dose of placebo will be investigated in up to 8 sessions.
3250623|NCT01387243||60 mg Orlistat|Purchased by consumer
3365257|NCT04694781|Experimental|Combination therapy dose expansion|LVGN6051 in combination with anti-PD-1 antibody pembrolizumab dose expansion cohorts
3365258|NCT04693767||Patients with ischemic stroke|
3365259|NCT04693767||Patients with intracranial hematoma|
3365264|NCT04690673|Experimental|Study group|All healthy volunteers are in this group. They receive 1g paracetamol orally. Saline-, urine-, venous blood and fingerprick samples will be collected at timely intervals.
3250624|NCT01387256|Other|mifepristone+misoprostol|200 mg mifepristone + 800 mcg buccal misoprostol
3365265|NCT04689646|Experimental|Mind-Body Intervention 1|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 1.
3365266|NCT04689646|Active Comparator|Mind-Body Intervention 2|Participants will receive a mind body educational based intervention to learn the techniques comprising intervention 2.
3365267|NCT04689646|No Intervention|Usual Care|Participants will continue their usual care for 26 weeks
3365268|NCT04685590|Experimental|Treatment|Dasatinib (D) is given as (1) 100mg capsule daily for 2 consecutive days (Sprycel®, Bristol Myers Squibb). Quercetin (Q) will be given as (4) 250 mg capsules daily (total 1000 mg daily) for the same 2 consecutive days (Thorne Research). Both are administered orally.
3365269|NCT04685590|Placebo Comparator|Placebo|Matching placebo capsules following the same administration protocol as the experimental treatment - administered once daily (1st dose of each cycle will be given, supervised, at the clinic visit; the 2nd dose will be taken at home) for 2 consecutive days followed by a 13-day (+/- 2 day) no-drug period for 12 consecutive weeks for 6 rounds of administration.
3250625|NCT01387256|Experimental|buccal misoprostol|2 doses of 800 mcg buccal misoprostol
3250626|NCT01387295|Experimental|chemotherapy|
3250627|NCT01387308|Experimental|A|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
3250628|NCT01387308|Sham Comparator|B|Fostamatinib 50 mg tablet x 3 (Phase 3 batch)
3250629|NCT01387308|Experimental|C|Fostamatinib 100 mg tablet (new formulation)
3250630|NCT01387308|Experimental|D|Fostamatinib 150 mg tablet (new formulation)
3250631|NCT01387308|Experimental|E|Fostamatinib 50 mg tablet x 2 (Phase 3 batch)
3250632|NCT01387321|Experimental|BYL719|
3250633|NCT01387334|Experimental|Resistance Exercise Training Program|
3250634|NCT01387360|Experimental|Supracor|Study arm will consist of patients who have undergone previous cataract surgery with implantation of a monofocal IOL. The Supracor procedure will be performed on the non-dominant pseudophakic eye of these patients.
3250635|NCT01387373|Experimental|chemotherapy|
3365272|NCT04682990|Experimental|Pulmonary TB|"This arm will enroll 80-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with pulmonary TB proved by TB LAMP test.~Interventions:~They will be asked to perform a breath exhalation with a nose clamp.~Medical History: Symptom based Survey, Physical Exam,and HIV status.~Other interventions:~Sputum samples for Ziehl Neelsen smear or Culture in L-J or GeneXpert MTB/RIF;~Chest X-ray Follow Up 5 days after beginning of Tx Follow Up 15 days after beginning of Tx Follow Up 30 days after beginning of Tx"
3365273|NCT04682990|Active Comparator|Non Pulmonary TB|"This arm will enroll 50-100 patients older than 18 years old, from the Center of Respiratory Diseases in Douala, with Negative pulmonary TB status proved by TB LAMP test. These Negative TB patients can be healthy controls or TB suspects.~Interventions:~They will be asked to perform a breath exhalation with a nose clamp. Medical History: Symptom based Survey, and HIV status.~Other interventions:~Sputum samples for Ziehl Neelsen smear or Culture in L-J GeneXpert MTB/RIF;~Chest X-ray."
3365274|NCT04682288|Experimental|Levofloxacin Ocular Implant|Biphasic levofloxacin antibiotic implant
3365275|NCT04681144||Radium-223-dichloride (Xofigo, BAY88-8223)|Patients with metastatic castration-resistant prostate cancer (mCRPC)
3250636|NCT01387399|Experimental|Cisplatin as HIPEC|Phase I dose escalating study of cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion
3365276|NCT04675866|Experimental|camrelizumab+albumin-bound paclitaxel+S-1|camrelizumab+albumin-bound paclitaxel+S-1
3365277|NCT04671797|Experimental|Early Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at an early dinner time (DLMO-3h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
3365278|NCT04671797|Experimental|Late Dinner first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by a sleep study (DLMO+2h). This arm will cross-over to the other 2 arms in random order.
3250637|NCT01387412||Genital warts|Those with and without ano-genital warts
3250638|NCT01387425|Active Comparator|varenicline|varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
3250639|NCT01387425|Placebo Comparator|control group|
3250640|NCT01387477|Experimental|Lactate|infusion of 66 mmol of lactate
3250641|NCT01387477|Active Comparator|glucose|infusion of 33 mmol of glucose
3250642|NCT01387490|Experimental|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
3250643|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
3250644|NCT01387503|Experimental|Group 1 - Transplant strategy|Patients randomized to Group 1 will be enlisted for liver transplantation and will undergo liver transplantation within 8 months unless oncological (i.e. extrahepatic disease) or medical (i.e. cardiac insufficiency) will occur
3250645|NCT01387503|No Intervention|Group 2 - Non-transplant strategy|Patients randomized to Group 2 will continue to receive treatments according to their stage of disease, or will undergo only strict follow-up should a complete response after downstaging treatments have been achieved
3250646|NCT01387555|Experimental|Arm A|Patients on Arm A will receive 1 e9 pfu (plaque forming units) total dose of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) on each of six (6) treatments over 18 weeks.
3250647|NCT01387555|Other|Arm B|Patients on the control arm (Arm B) will have best supportive care over 18 weeks.
3250648|NCT01387568|Active Comparator|group L|Lidocaine group
3250649|NCT01387568|Placebo Comparator|group P|Placebo group
3365279|NCT04671797|Experimental|Late Dinner + Late Sleep first|Participants will be served dinner and a stable isotope of palmitate to measure fat oxidation, at a late dinner time (DLMO+1h) followed by delayed bedtime (DLMO+6h). This arm will cross-over to the other 2 arms in random order.
3365280|NCT04668209|Active Comparator|Silmitasertib|Standard of care / supportive care in combination with Silmitasertib (CX-4945)
3365281|NCT04668209|No Intervention|Standard of Care|Standard of care / supportive care
3365287|NCT04656652|Experimental|DS-1062a 6.0 mg/kg|Participants will be randomized to receive 6.0 mg/kg of DS-1062a.
3365288|NCT04656652|Active Comparator|Docetaxel 75 mg/m^2|Participants will be randomized to receive 75 mg/m^2 docetaxel.
3365289|NCT04653051||Patients who received DVR Plating System|
3365290|NCT04652856|Experimental|Electrical and Sham Electrical Brain Stimulation|Electrical brain stimulation and sham electrical brain stimulation will be administered to all participants.
3365291|NCT04652687||VIA Disc NP|Patients meeting study criteria receiving Vivex VIA Disc NP injection as treatment for discogenic low back pain.
3365292|NCT04652687||Non Surgical Management|Patients receiving non surgical management (i.e., physical therapy, transforaminal epidural steroid injection, lifestyle modification, or surgical intervention)
3365293|NCT04652375|Experimental|Albumin Solution|Participants will receive Albumin solution for fluid resuscitation post-surgery.
3365294|NCT04652375|Experimental|Lactated Ringer's Solution|Participants will receive lactated Ringer's for fluid resuscitation post-surgery
3365295|NCT04649580||Online Survey|
3365296|NCT04649580||One-to-one interviews|
3365302|NCT04642365|Experimental|Part I|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682 with a fixed dose of Atezolizumab, every three weeks (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
3365303|NCT04642365|Experimental|Part II|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I. Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab.
3365304|NCT04642365|Experimental|Part III (Exploratory)|Dose-Expansion: Will start once MTD/RP2D dose of RO7296682 in combination with Atezolizumab is defined in Part I and if clinical activity is seen in this trial or in the single agent study (WP41188). Participants with selected tumor types will receive a fixed dose of RO7296682 in combination with Atezolizumab at the dosing regimen established in Part I.
3250650|NCT01387633|Experimental|Educational intervention through telephone contact|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact
3250651|NCT01387633|Active Comparator|Educational intervention group|Educational intervention group for people with diabetes through Diabetes Conversation Maps.
3250652|NCT01387646|Other|Control Group|Participants in the control arm will be interviewed at baseline, be given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and will receive abuse and enhanced clinical counseling
3250653|NCT01387659|Experimental|Transplant recipients|All subjects receive identical drug treatment
3250654|NCT01387711|Experimental|ingenol mebutate|PEP gel 0.05% once daily exposure
3250655|NCT01387750|Placebo Comparator|Mentholated Cream|
3250656|NCT01387750|Active Comparator|Mentholated Cream with OGT|
3250657|NCT01387763|Active Comparator|PegIntron <= 60 years|In patients <= 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
3365305|NCT04641871|Experimental|Sym021+Sym022 [ARM A]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym022 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
3365306|NCT04641871|Experimental|Sym021+Sym023 [ARM B]|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated.
3365307|NCT04641871|Experimental|Sym021+Sym023+irrinotecan|Sym021 will be infused over approximately 30 minutes (+10 minutes), followed by a 30-minute post-dosing interval before infusion of Sym023 over approximately 30 minutes (+10 minutes). The duration of each infusion may be extended by 30 minutes, or longer, if indicated. After another 30-minute post-dosing interval, irinotecan will be infused over 90 minutes.
3250658|NCT01387763|Active Comparator|Pegasys <= 60 years|In patients <= 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
3250659|NCT01387763|Active Comparator|PegIntron > 60 years|In patients < 60 years PegIntron is started at low-dose 35 micrograms once weekly. Dose escalation to 50 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 50 micrograms weekly at 12 months and 18 months respectively, dose escalation to 96 micrograms weekly.
3365313|NCT04625972|Experimental|AZD7442|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
3365314|NCT04625972|Placebo Comparator|Placebo|Participants will be randomized in a 2:1 ratio to receive a single dose (× 2 IM injections) of either 300 mg of AZD7442 (n = approximately 750) or saline placebo (n = approximately 375) on Day 1.
3250660|NCT01387763|Active Comparator|Pegasys > 60 years|In patients > 60 years Pegasys is started at low-dose 45 micrograms once weekly. Dose escalation to 90 micrograms weekly if lack of complete hematological response at 4 months or lack of at least partial molecular response at 8 months. If complete hematological response or lack of at least partial molecular response is not achieved at 90 micrograms weekly at 12 months and 18 months respectively, dose escalation to 135 micrograms weekly.
3250661|NCT01387763|Active Comparator|Hydroxyurea > 60 years|Capsule Hydrea 500-2000 mg orally QD or BID
3250662|NCT01387776||study group|patients coming to clinique OVO in the 1st trimester of pregnancy to undergo prenatal screening
3250663|NCT01387802||Non-Biologic arm|Patients that have not responded to the current treatment with an NSAID (Nonsteroidal Anti-Inflammatory Drug) and/or non - biologic DMARD (Disease-Modifying Anti Rheumatic Drug) for peripheral joint involvement and switch to or addition of another NSAID /DMARDS
3250664|NCT01387802||Biologic arm|Patients that have not responded to the current treatment with non biologic DMARDS (Disease-Modifying Anti Rheumatic Drug) /NSAID (Nonsteroidal Anti-Inflammatory Drug) and switch to or addition of adalimumab
3250665|NCT01387828|Active Comparator|Laparoscopy|Includes all patient underwent intervention with a laparoscopic approach, even if converted to open surgery during intervention
3365315|NCT04625296||Healthcare professional|Communities Health professionals (doctors, nurses, physiotherapist) Working in the city, In metropolitan France, Having managed patients with COVID-19
3250666|NCT01387828|Active Comparator|Open surgery|Includes all the patients underwent intervention with a laparotomic approach; it does not include patient underwent laparoscopic approach and then converted in laparotomy.
3250667|NCT01387841|Experimental|Yoga group|Yoga intervention with standard antiemetic care
3250668|NCT01387841|Active Comparator|PMRT/Jacobsons Relaxation training|25 minutes of progressive muscle relaxation training will be given to this group with standard antiemetic care
3250669|NCT01387841|No Intervention|Standard antiemetic care|Standard antiemetic care only
3365326|NCT04618744|Placebo Comparator|Placebo|Fish oil
3365327|NCT04618744|Experimental|ORMD-0801 (Insulin) capsule 8 mg BD|ORMD-0801 (insulin) capsule Dose: 8 mg BD Dosage Regimen: 1 capsule twice a day (once in the morning approximately 30 to 45 minutes prior to breakfast and no later than 10 AM, and once at night between 8 PM to Midnight and no sooner than 1 hour after dinner) Mode of Administration: Oral
3365330|NCT04608409|Experimental|Lapatinib - Group 1|Patients in this group will receive Lapatinib (500mg PO BID) and Paclitaxel (80mg/m2).
3250670|NCT01387867|Experimental|Strength training|Strength training three times weekly, i.e.supervised strength training twice weekly and un-supervised strength training once weekly for 4 months.
3250671|NCT01387867|Experimental|Nordic Walking|Nordic walking three times weekly, i.e.Nordic walking twice weekly and un-supervised Nordic walking once weekly for 4 months.
3365331|NCT04608409|Experimental|Lapatinib - Group 2|Patients in this group will receive Lapatinib (750mg PO BID) and Paclitaxel (80mg/m2).
3365332|NCT04608409|Experimental|Lapatinib - Group 3|Patients in this group will receive Lapatinib (1500mg PO BID) and Paclitaxel (80mg/m2).
3365333|NCT04608409|Experimental|Lapatinib - Group 4|Patients in this group will receive Lapatinib (2000mg PO BID) and Paclitaxel (80mg/m2).
3250672|NCT01387867|Active Comparator|Unsupervised home based exercise|The home based unsupervised exercise comprised exercises recommended by the Danish Arthritis Association.
3365343|NCT04606797|Experimental|Nicotine Replacement Therapy|
3365344|NCT04606797|No Intervention|Control|
3365345|NCT04606576|Placebo Comparator|Placebo|Fish Oil
3365346|NCT04606576|Experimental|ORMD-0801 QD|8 mg ORMD-0801 administered QD at night
3365347|NCT04606576|Experimental|ORMD-0801 BID|8 mg ORMD-0801 administered at night and in the morning 45 minutes before breakfast.
3365348|NCT04605718|Experimental|Part 1 (SAD)|Due to mandatory sentinel dosing, participants will be divided into two groups: 2 participants will be dosed on one day (sentinel group with 1 on active treatment and 1 on placebo) and remaining participants of the dose cohort (randomized as 5 on active treatment and 1 on placebo) at the earliest 24 hours after the first dosing occasion.
3365349|NCT04605718|Experimental|Part 2 (MAD)|In each dose cohort, a minimum of 4 participants and a maximum of 12 participants will receive either multiple IV doses of RO72232809 or placebo daily for 10 days (3:1 ratio of active:placebo treatment). Based upon the review of emerging data, there will be the option to adjust the number of participants on active treatment and placebo per dose level.
3250673|NCT01387880|Experimental|Cetuximab, everolimus, irinotecan|
3250674|NCT01387880|Active Comparator|Cetuximab, everolimus and Irinotecan.|"Patients with metastatic colorectal cancer with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan.~Patients with KRAS wildtype colorectal cancer that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, irinotecan and everolimus."
3250675|NCT01387893|Experimental|Immediate & Delayed Instruction|Male patients with mild to moderate lower urinary tract symptoms will alternately be assigned to either immediate intervention or delayed intervention groups. Statistical assessments will be performed to establish comparability of baseline characteristics in the two groups.
3250676|NCT01387906|Experimental|Topical bimatoprost for eyebrows|Topical bimatoprost will be applied to areas of the eyebrow that have diminished eyebrows (hypotrichosis).
3250677|NCT01387919|Experimental|1|healthy young and lean men
3250678|NCT01387945|No Intervention|HBPM only|
3250679|NCT01387945|Experimental|HBPM+website+patient navigator|
3250680|NCT01387958|Experimental|LCQ908|
3250681|NCT01387958|Placebo Comparator|Placebo|
3250682|NCT01387971||ocular surface disorders|various ocular surface disorders
3250683|NCT01387984||Type 2 diabetes mellitus|
3250684|NCT01387997|Experimental|1|
3250685|NCT01388010|Experimental|1 = Test product|Arm 1 - Intervention 1 (probiotics)
3250686|NCT01388010|Other|2 = Control product|Arm 2 - Intervention 2 (control)
3250687|NCT01388023|Active Comparator|smellx|test group- SmellX palatal patch with the herbal formula
3250688|NCT01388023|Placebo Comparator|smellx palatal patch|negative control group- SmellX palatal patch with out the herbal formula
3250689|NCT01388023|Active Comparator|chlorhexidine|poositive control group-mouth wash with chlorhexidine 0.125%
3250690|NCT01388023|Active Comparator|listerine|listerine mouth wash
3250691|NCT01388036|Experimental|esmolol infusion|infusion of esmolol during rest and exercise
3250692|NCT01388049|Experimental|virus detection|
3250693|NCT01388062|Experimental|virus detection|
3250694|NCT01388075|Experimental|Rifampicin|Consecutive treatments with rifampicin and placebo
3365354|NCT04596293|Experimental|BBT-401-1S (800mg)|
3365355|NCT04596293|Experimental|BBT-401-1S (1,600mg)|
3365356|NCT04596293|Placebo Comparator|Placebo|
3365357|NCT04591834||Observational|No Intervention
3365359|NCT04583839|Experimental|Navigation Group|Women who are randomized into SWEET will be assigned to a patient navigator. The navigator will meet women during hospitalization, at postpartum appointments, during primary care appointments, and as needed. At these face-to-face meetings, the navigator will perform education about the postpartum OGTT, post-GDM management plan, diabetes mellitus risks, lifestyle modification, and primary care transition. The navigator will facilitate the development of an individualized GDM Care Plan in conjunction with the patient and the medical team. The navigator will assess individual barriers to T2DM screening and prevention. At appointments, the navigator will also ensure a woman understands her diabetes-related care plan and will perform health education and barrier-reducing tasks as needed.
3365360|NCT04583839|No Intervention|Non-navigation cohort|No navigation will be provided; women will receive usual care.
3365361|NCT04583787|Experimental|Patients with suspected CAD|
3365362|NCT04582201|Experimental|Dosage and Cohorts|"Cohort 1 100 × 10^6 iNKT Cohort 2 300 × 10^6 iNKT Cohort 3 1000 × 10^6 iNKT~Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized patients as a single IV infusion."
3365363|NCT04580992||Ajmaline group|
3365364|NCT04580160|Experimental|Duo Venous Stent System Implantation|
3365365|NCT04576702|Experimental|Investigational aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
3365366|NCT04576702|Active Comparator|licensed IIV type 1 group|IIV will be administered as a single dose intramuscularly on Day 1
3365367|NCT04576702|Active Comparator|licensed aIIV group|aIIV will be administered as a single dose intramuscularly on Day 1
3365368|NCT04576702|Active Comparator|licensed IIV type 2 group|IIV will be administered as a single dose intramuscularly on Day 1
3365369|NCT04576117|Active Comparator|Efficacy Phase Arm II (selumetinib)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.
3365370|NCT04576117|Experimental|Feasibility & Efficacy Phase Arm I (selumetinib, vinblastine)|Patients receive vinblastine sulfate IV over 1 minute or IV infusion on days 1, 8, 15, and 22 and selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days. Patients receive selumetinib and vinblastine for a total duration of 17 cycles followed by 10 additional cycles of selumetinib alone in the absence of disease progression or unacceptable toxicity.
3365371|NCT04572451|Experimental|Nivolumab (Anti-PD-1) + BMS-986253 (Anti-IL-8) + SBRT|480 mg intravenous nivolumab (BMS-936558-01) every 4 weeks + 2,400 mg intravenous BMS-986253 (Anti-IL-8) every 2 weeks + Stereotactic Body Radiotherapy (SBRT)
3365372|NCT04569695|Experimental|Part 1: Cohort A: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 once daily (QD) on Day 1 followed by washout period of 4 days and then Dose 1 of JNJ-70033093 QD from Days 5 to 12.
3250695|NCT01388088|Active Comparator|Spironolactone|Increases the level of potassium
3365373|NCT04569695|Experimental|Part 1: Cohort B: JNJ-70033093|Participants will receive Dose 1 of JNJ-70033093 twice daily (BID) from Days 1 to 8.
3365374|NCT04569695|Experimental|Part 1: Cohort C: JNJ-70033093|Participants will receive Dose 2 of JNJ-70033093 BID from Days 1 to 8.
3250696|NCT01388088|Active Comparator|Amiloride|Increases the level of potassium
3250697|NCT01388088|Placebo Comparator|Placebo|
3250698|NCT01388101|Experimental|LECT2 detection|single-arm study: Electrosensing antibody probing system(e-AB sensor)
3250699|NCT01388114|Experimental|Electrosensing antibody probing system (e- Ab sensing)|
3250700|NCT01388140||psychiatric inpatients, regardless of clinical diagnoses|
3250701|NCT01388153|Experimental|Arm 1|
3250702|NCT01388153|Experimental|Arm 2|
3250703|NCT01388153|Active Comparator|Arm 3|
3250704|NCT01388179|Active Comparator|Real rTMS treatment|low-frequency rTMS to the left DLPFC (Dorsa-Lateral Pre-Frontal Cortex) prior to high-frequency deep rTMS to the FFA (Fusi-Form Area) through the STS(Superior Temporal Sulcus).
3250705|NCT01388179|Sham Comparator|Sham rTMS treatment|Sham coil which simulate the real coil action
3250706|NCT01388192||Receiving pancreaticoduodenectomy|
3250707|NCT01388205|Experimental|Family-based Intervention Arm|
3250708|NCT01388205|No Intervention|Control|
3250709|NCT01388218||Arm 1 - Daily+Clinical|Order of assessment: Daily PRO + Clinical visit PRO
3250710|NCT01388218||Arm 2 - Clinical+Daily|Order of assessment: Clinical visit PRO + Daily PRO
3365375|NCT04569695|Experimental|Part 2: Cohort D: JNJ-70033093|Participants will receive Dose 3 of JNJ-70033093 QD on Day 1 followed by washout period of 4 days and then Dose 3 of JNJ-70033093 BID from Days 5 to 12 in Cohort D. Dose escalation to Part 2: Cohort D will occur only after the safety and tolerability data of the Part 1 are assessed.
3250711|NCT01388231|Active Comparator|Manualized CBT Group|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients after receiving structured clinical training on the treatment of social phobia based on the Clark and Wells (1995) model.
3250712|NCT01388231|Active Comparator|CBT Group -Treatment as Usual|The present group is comprised of clinical practitioners performing cognitive-behavioral therapy (CBT) on social phobic patients, while receiving no structured training in the treatment of social phobia.
3250713|NCT01388244|Active Comparator|Screening|Two-step screening process using FRAX risk score assessment followed by DXA scanning for high risk participants.
3250714|NCT01388244|Other|Control|Control arm - Fracture risk assessment by FRAX without any intervention
3250715|NCT01388257|Experimental|Surgery|Seton drain removal is associated with proctological surgery.
3365377|NCT04567602||Participants with PAH|Participants with confirmed diagnosis of pulmonary arterial hypertension (PAH) will be enrolled in the study and the data will be collected and observed to describe the application of European ESC/ERS guidelines and related 6th WSPH proceedings on risk assessment and related treatment strategy, in clinical practice.
3365378|NCT04567420|Experimental|Arm A|Palbociclib/Fulvestrant Combination
3365379|NCT04567420|Active Comparator|Arm B|Adjuvant Therapy
3250716|NCT01388257|Other|Simple seton drain removal|
3250717|NCT01388270|Active Comparator|Evodial|a pre-heparin-coated hemodialysis filter
3365381|NCT04565990|Experimental|Selexipag|Participants will receive selexipag tablets twice daily with the dose strength corresponding to their individual maximum tolerated dose (iMTD) from the parent study.
3365382|NCT04565275|Experimental|ICP-192|"Dose Escalation Phase ICP-192~Dose Expansion Phase ICP-192"
3365383|NCT04559217|Experimental|Single arm with 68Ga-DOTATATE|all participants will undergo a PET scan with 68Ga-DOTATATE
3365384|NCT04557150|Experimental|Part I: Dose Escalation|Participants will receive RO7425781 as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion.
3365385|NCT04557150|Experimental|Part II: Dose Expansion|Dose Expansion cohorts with IV and/or SC administration will be initiated at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) determined from Part I: Dose Escalation.
3365386|NCT04554732|Experimental|Part 1 - Initial group treatment|For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
3365387|NCT04549025|Experimental|JTX-4104|Drug: JTX-4014
3365388|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 1)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
3250718|NCT01388270|No Intervention|170 H|Conventional filter
3250719|NCT01388296||Morbidly obese patients|BMI 40-50 k/m2
3250720|NCT01388296||Morbidly obese|BMI 50-60 k/m2
3250721|NCT01388296||Morbidly obeses|BMI 60-70 k/m2
3365389|NCT04549025|Experimental|JTX 4014 in combination with vopratelimab (dose level 2)|"Drug: JTX-4014~Drug: Vopratelimab Other Name: JTX-2011"
3365390|NCT04544111|Experimental|Cohort A-BRAF WT tumors|Cohort A (BRAF WT tumors): trametinib (T) 2mg by mouth daily plus PDR001 400mg IV every 4 weeks
3365391|NCT04544111|Experimental|Cohort B-BRAF Mutant|Cohort B (BRAF Mutant, resistant to previous BRAF inhibitors): dabrafenib (D) 150 mg twice daily (OR at dose the patient previously tolerated) plus PDR001 400mg IV every 4 weeks.
3365392|NCT04536467|Other|Goserelin arm|3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
3365393|NCT04536467|Other|control Arm|Standard chemotherapy
3365396|NCT04530981|Experimental|Repaglinide 0.5 mg + Ripretinib 150 mg QD|A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.
3250722|NCT01388309||Cohort|
3250723|NCT01388322|Experimental|Enoxaparin|Subcutaneous administration of one dose daily of enoxaparin
3250724|NCT01388322|No Intervention|expectant management|Usual management
3250725|NCT01388348|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
3250726|NCT01388374|No Intervention|General Practitioners Care|Usual medical care provided by a general practitioner at the Primary Out of Hours Emergency Service.
3250727|NCT01388374|Experimental|Nurse Practitioners Care|Medical care provided by the Nurse Practitioner at the Primary Out of Hours Emergency Service.
3250728|NCT01388387|Experimental|Tacrolimus pharmacokinetics|
3250729|NCT01388400|Experimental|Conventional intervention for upper limb reaching|Reaching or holding cones, cups, etc. in all planes with and without gravity or loading
3250730|NCT01388400|Experimental|VR treatment|The Virtual Reality (VR) therapy group received the treatment in the GestureTek VR environment which focused on reaching movements of the affected upper limb using virtual games and a virtual supermarket.
3250731|NCT01388413|Experimental|Weekly Oral Cyclic Antibiotic programme|
3250732|NCT01388413|No Intervention|Classic care|
3250733|NCT01388426|Experimental|7eye( Panoptx)™ Moisture chamber glasses|7eye( Panoptx)™
3250734|NCT01388439||Oseltamivir exposure|One infant in the Neonatal Intensive Care Unit (NICU) at St. Louis Children's Hospital experienced respiratory decompensation and tested positive for influenza virus type A by fluorescent antibody stain performed on a nasopharyngeal swab. This infant received treatment doses of oseltamivir. Subsequently, 27 other infants received oseltamivir prophylaxis for exposure to influenza virus type A. Exposed infants were those who shared a primary medical team, nursing care, respiratory therapist, physical therapist, or occupational therapist with the influenza A positive infant. Prophylaxis was deemed necessary by the attending neonatologist after consultation with the Infectious Diseases Division of the Department of Pediatrics at the Washington University School of Medicine.
3250735|NCT01388452|Experimental|Point of Care HIV RNA PCR|Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for point of care RNA PCR testing, number the sample, and transport it to the central laboratory for processing. Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an inpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end.
3250736|NCT01388452|No Intervention|Standard of Care|"Patients randomized to this arm will be followed prospectively from the time of clinical evaluation in the hospital until 12 months after returning for outpatient care at the KCH HIV clinic. The counselor will collect infant blood for dried blood spot DNA PCR testing, number the sample, and transport it to the central laboratory for processing. If the patient is PD positive then the patient will be offered ART initiation prior to hospital discharge.~Patients determined to be HIV-uninfected or HIV-exposed uninfected will not continue in the study beyond virologic test result disclosure, which will occur as an outpatient at KCH for this arm. If the patient does not return for outpatient care for three months after hospitalization then the patient's participation in the study will end."
3365403|NCT04524910||mCNV patients|Adult Canadian patients diagnosed with myopic choroidal neovascularization (mCNV) and naïve for anti-VEGF treatment
3365404|NCT04524442|Experimental|GEP-NET|One dose of arginine/lysine solution administered intravenously over a 4-hour period
3250737|NCT01388465|Experimental|Mobile phone text message Intervention|Daily assessments with feedback about (1) filling prescription and (2) number of doses taken
3250738|NCT01388465|No Intervention|Control|No TM queries or feedback
3250739|NCT01388504|Experimental|sodium nitrite|
3365405|NCT04523480|Experimental|Testopel 75mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 10 x 75 mg pellets of Testopel for a total of 750 mg Testopel.
3365406|NCT04523480|Active Comparator|Compounded testosterone pellets 100mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 8 x 100 mg compounded testosterone for a total of 800 mg compounded testosterone.
3365407|NCT04523480|Active Comparator|Compounded Testosterone pellets 200mg Group|Participants in this group will receive a one-time subcutaneous testosterone insertion of 4 x 200 mg compounded testosterone for a total of 800 mg compounded testosterone.
3365408|NCT04522765||Health|Healthy individuals with no known medical condition and taking no regular medication
3365409|NCT04522765||Acute kidney injury|Individuals with acute kidney injury as defined by KDIGO criteria
3365410|NCT04522765||Chronic kidney disease|Individuals with chronic kidney disease as defined by KDIGO criteria
3365411|NCT04522765||Small vessel vasculitis|Individuals with active small vessel vasculitis an diagnosed by a specialist physician
3365412|NCT04522765||Kidney transplant recipient|Individuals who have received a kidney transplant
3365413|NCT04522765||Kidney donor|Individuals who have donated a kidney for transplantation
3365414|NCT04517149|Experimental|4D-125 Dose Exploration|"Dose 1 and Dose 2~4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1."
3365415|NCT04517149|Experimental|4D-125 Dose Expansion|4D-125 will be administered at the assigned dose level as a single dose, uniocular IVT injection on Day 1. The contralateral eye may also be dosed with 4D-125 as a single dose, uniocular IVT injection provided the subject is eligible and provides consent.
3365416|NCT04517149|Other|Observational|Natural History
3365417|NCT04508023|Experimental|Rivaroxaban|Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).
3365418|NCT04508023|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.
3365421|NCT04500548|Experimental|Dose level -1 (nivolumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity."
3365422|NCT04500548|Experimental|Dose level 1 (nivolumab, ipilimumab)|"PART I: Patients undergo collection of tissue samples for TMB level. Patients with elevated TMB may be eligible for Part II.~PART II: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive nivolumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for up to 23 cycles in the absence of disease progression or unacceptable toxicity."
3365423|NCT04494360||Healthy Participants|Healthy participants (men and women) who have, or are likely to have, NAFLD will be enrolled in the study.
3365424|NCT04483245||controls|persons free of hemorrhage or haemostasis disorder
3365425|NCT04483245||Haemorrhagic|Acute hemorrhagic patient
3250740|NCT01388504|Placebo Comparator|placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes
3250741|NCT01388517|Active Comparator|Calcitriol|Repigmentation treatment for the relief of hypopigmented pityriasis alba lesions
3250742|NCT01388517|Active Comparator|Tacrolimus|Treatment for the relief of hypopigmented pityriasis alba lesions
3365426|NCT04483245||ECMO|ECMO surgery patient with hemorrhagic complication
3365427|NCT04483245||polytrauma|
3250743|NCT01388517|Placebo Comparator|Petrolatum|Petrolatum treatment for the relief of hypopigmented pityriasis alba lesions
3250744|NCT01388556|Experimental|Tango|Twice weekly tango dance classes for 12 months.
3365428|NCT04483245||Platelet disorder|Patient with an identified platelet disorder or treated with antiplatelet agents
3365430|NCT04469634|Experimental|antibody response and memory B-cell|Regular blood draws to measure antibody responses and memory B-cell responses Regular swab collection to test for re-infection
3365431|NCT04464434|Experimental|Upfront autologous HSCT|
3250745|NCT01388556|No Intervention|Control Group|
3250746|NCT01388582|Active Comparator|Combined oral contraceptive|10 women will receive COC during breastfeeding
3365432|NCT04464434|Active Comparator|Immunosuppressive therapy|"12 monthly i.v. pulses CYC 750 mg/m2 (= 9 g/m2 cumulative) followed by at least 12 months of oral MMF daily (3 grams as maximum daily dosage) or mycophenolic acid (up to 2.160 grams daily).~Hyperhydration, alkalinisation of the urine and mesna is recommended, and will be given according to local protocols in order to prevent haemorrhagic cystitis."
3365433|NCT04463719|Experimental|Intervention group|Counseling using the electronic conversation aid
3365434|NCT04463719|Active Comparator|Control Group|Routine counseling only
3365435|NCT04463641|Experimental|Axone 4LV Lead|Subjects implanted with the Axone 4LV Lead
3365436|NCT04455178|Experimental|Spironolactone|Spironolactone 20mg once daily
3365437|NCT04455178|Active Comparator|Indapamide|Indapamide 1.5mg once daily
3365438|NCT04454658|Experimental|Segment A: ABBV-744 Dose Identification and Optimization|Participants who have been previously treated with Janus Kinase inhibitor(s) (JAKi) and stopped such therapy, will receive different dosing regimens and schedules of ABBV-744 to identify the safe dosing regimen and schedule.
3365439|NCT04454658|Experimental|Segment A: ABBV-744 Monotherapy|Participants will receive the identified safe dosing regimen of ABBV-744 as monotherapy.
3365440|NCT04454658|Experimental|"Segment B: Ruxolitinib + ABBV-744 Add on Therapy"|"Participants whose disease (myelofibrosis) is inadequately controlled by ongoing ruxolitinib therapy will receive ruxolitinib and ABBV-744 as add-on therapy."
3365441|NCT04454658|Experimental|Segment C: ABBV-744 + Navitoclax|Participants who have previously been exposed to JAKi, and stopped such therapy, will receive ABBV-744 and navitoclax.
3365442|NCT04454658|Experimental|Segment D: ABBV-744 + Ruxolitinib|Participants who have never received JAKi will receive ABBV-744 and ruxolitinib.
3365443|NCT04454424|Experimental|Arm A: Child-Pugh A|Participants with mildly impaired hepatic function (Child-Pugh A)
3365444|NCT04454424|Experimental|Arm B: Child-Pugh B|Participants with moderately impaired hepatic function (Child-Pugh B)
3365445|NCT04454424|Experimental|Arm C: Child-Pugh C|Participants with severely impaired hepatic function (Child-Pugh C)
3250747|NCT01388582|Active Comparator|Levonorgestrel intrauterine system|10 women will receive a LNG-IUS during breastfeeding
3250748|NCT01388582|Active Comparator|Implanon|10 women will receive Implanon during breastfeeding
3250749|NCT01388582|Active Comparator|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding
3250750|NCT01388595|Active Comparator|Fluticasone Proprionate|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3365446|NCT04454424|Experimental|Arm D: Normal hepatic (Matched A and B)|Participants with normal hepatic function matched to Arm A and B
3365447|NCT04454424|Experimental|Arm E: Normal hepatic (Matched to C)|Participants with normal hepatic function matched to Arm C
3365455|NCT04448327|Experimental|Active tVNS|Expiratory-gated transcutaneous vagus nerve stimulation on the left auricle
3365456|NCT04448327|Sham Comparator|Sham tVNS|Sham transcutaneous vagus nerve stimulation on the left auricle
3365457|NCT04439656||Absence Seizures|Participants with absence seizures will have their eye movements compared to the EEG recording.
3365458|NCT04435782|Experimental|JNJ-67896049|Participants will receive JNJ-67896049 tablets at a starting dose of 200 mcg on Day 1. Dose will be up-titrated from Day 1 to the end of Week 12 (Day 84) to determine individual maintenance dose (IMD). Then, participants will receive JNJ-67896049 tablets at their IMD from Week 13 to Week 52.
3365460|NCT04424914|Other|ATTR-CM positive|Participants diagnosed with ATTR-CM by scintigraphy
3365461|NCT04424914|Other|ATTR-CM negative|Participants who are scintigraphy negative for ATTR-CM
3250751|NCT01388595|Active Comparator|Salmeterol|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3365462|NCT04421235|Other|Childbirth Support|Women who enroll in the intervention portion of this study will receive the childbirth support elements for which they are eligible in and elect to participate. Possible program elements include prenatal education classes, support group, lactation program, doula support, and parenting classes.
3250752|NCT01388595|Placebo Comparator|placebo|The participants will be randomised and at each study visit, will receive a single inhaler which can either be active or placebo.
3365469|NCT04404140|Experimental|Ipatasertib + Atezolizumab + Docetaxel|"Part A (Safety Run-In): 12 Participants will be administered Ipatasertib orally once a day [QD] from Day 1 to Day 14 in combination with Atezolizumab administered by intravenous (IV infusion) every 3 weeks (Q3W) on Day 1 of each cycle (a cycle being 21 days) and Docetaxel administered by IV infusion (Q3W) on Day 1 of each cycle. Docetaxel will be administered for a maximum of 10 cycles (approximately 7 months), after which Atezolizumab and Ipatasertib will be administered as a doublet until disease progression. During Part A, a staggered recruitment will be applied to the first and potentially first 6 participants to enrol a participant only once the former one has safely overcome the safety time window (Cycle 1).~Part B (Expansion): 38 Participants will be administered Ipatasertib, Atezolizumab and Docetaxel as described above, though without a staggered enrolment or safety assessment window."
3365470|NCT04401761||CAD/PAD-patients|Adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) who are treated with a combination of rivaroxaban and acetylsalicylic acid.
3365475|NCT04400110|Experimental|Short treatment group|Amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 5 consecutive days
3250753|NCT01388608||RA patients receiving etanercept|Patients with active rheumatoid arthritis (RA) who are eligible to a treatment with etanercept.
3250754|NCT01388621|Experimental|Experimental arm (A):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 Panitumumab 6 mg/kg/KG d1 + 15 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 Panitumumab 9 mg/kg/KG d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
3365476|NCT04400110|Active Comparator|Standard treatment group|amoxicillin and clavulanic acid 50 mg/kg three times daily administered orally for 10 consecutive days
3365477|NCT04399382||Non-radiographic group|Participants with non-radiographic axial SpA
3365478|NCT04399382||Radiographic group|Participants with radiographic axial SpA (a.k.a. ankylosing spondylitis)
3365479|NCT04398628||Hemophilia|"This cohort includes three Arms:~PUPs Arm:~This Arm is for previously untreated patients (PUPs) with congenital hemophilia A or B. This is a longitudinal, observational, prospective and retrospective Arm of PUPs with moderate or severe congenital hemophilia. Participants will be followed to assess inhibitor development within 50 exposure days (ED).~Hemophilia Natural History Arm:~This Arm is investigating a natural history of the safety, effectiveness, and practice of treatment for people with hemophilia. It is a longitudinal, observational, prospective Arm for participants with acquired or congenital hemophilia A or B.~Hemophilia Gene Therapy Outcomes Arm:~This Arm is investigating the safety and effectiveness of gene therapy in people with hemophilia. It is a longitudinal, observational cohort Arm following participants prospectively and retrospective for 15 years after vector infusion."
3365480|NCT04398628||Von Willebrand Disease|The Severe VWD Natural History Arm is investigating the natural history of the safety, effectiveness, and practice of treatment for people with severe von Willebrand disease (VWD). It is a longitudinal, observational cohort Arm following participants every 6 months for at least 2 years.
3250755|NCT01388621|Active Comparator|Standard arm (B):|"Caelyx 30 mg/m² d1 Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles~OR~Gemcitabine 1000 mg/m² d1 + 8 Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles~The backbone chemotherapy (Caelyx or Gemcitabine-based) is specified by the investigator before randomization of a patient."
3250756|NCT01388634||Study cohort|Patients with prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
3250757|NCT01388634||control group|Patients without prolonged length of hospital stay (>5 days) or readmission after ventral hernia repair
3250758|NCT01388660|Experimental|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin
3250759|NCT01388660|Active Comparator|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin)
3365481|NCT04398628||Congenital Platelet Disorders|No Arms or Modules at this time.
3365482|NCT04398628||Rare Bleeding Disorders|No Arms or Modules at this time
3365483|NCT04398628||Bleeding NOS|No Arms or Modules at this time
3365484|NCT04398628||Thrombosis/Thrombophilia|No Arms or Modules at this time
3365485|NCT04398628||Non-Neoplastic Hematologic Conditions|No Arms or Modules at this time
3365488|NCT04392440|Experimental|intervention|
3365489|NCT04392440|Other|control|Usual care
3365490|NCT04389957||Providers|The quantitative surveys will be delivered to the identified local quality stewards (N=73) and providers (N=657) for each enrolled site via the Research Electronic Data Capture (REDCap) platform at baseline (prior to VA-EQuIP) and 12 months following completion of the VA-EQuIP intervention. We will incorporate established methods of maximizing web survey responses, including multiple, carefully-timed, integrated email contacts.
3365491|NCT04389957||Patients|We expect 69 sites with 571 providers seeing 135,517 patients/year, corresponding to 95 providers/wave and 59 patients/provider/quarter. Patient data is retrospective and informs the primary outcome of provider adenoma detection rate. There is not a direct intervention for patients.
3365492|NCT04388501|Experimental|Treatment Sequence ABC|Participants will receive milvexian capsule once daily (qd) for 5 days (Treatment A) in Period 1 followed by Atorvastatin tablets qd for 5 days (Treatment B) in Period 2 followed by milvexian capsules qd and atorvastatin tablets qd for 5 days (Treatment C) in Period 3. Each period is separated by a washout period of 7 days.
3365493|NCT04388501|Experimental|Treatment Sequence BCA|Participants will receive Treatment B in Period 1 followed by Treatment C in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
3365494|NCT04388501|Experimental|Treatment Sequence CAB|Participants will receive Treatment C in Period 1 followed by Treatment A in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
3365495|NCT04388501|Experimental|Treatment Sequence CBA|Participants will receive Treatment C in Period 1 followed by Treatment B in Period 2 and Treatment A in Period 3. Each Period is separated by a washout period of 7 days.
3365496|NCT04388501|Experimental|Treatment Sequence ACB|Participants will receive Treatment A in Period 1 followed by Treatment C in Period 2 and Treatment B in Period 3. Each Period is separated by a washout period of 7 days.
3365497|NCT04388501|Experimental|Treatment Sequence BAC|Participants will receive Treatment B in Period 1 followed by Treatment A in Period 2 and Treatment C in Period 3. Each Period is separated by a washout period of 7 days.
3365499|NCT04383509|Experimental|Cognitive control training|Cognitive Control Training (CCT) makes use of a very basic cognitive task that strongly loads on working memory and cognitive control processes, namely the adaptive Paced Auditory Serial Addition Task (aPASAT) where participants are given a number every 3 seconds and are asked to add the number they just heard with the number they heard before. Task difficulty is modified based on the participants current task performance, allowing training of cognitive control. Participants in the intervention group will start the CCT training after completion of ECT with a maximum time interval of 7 days. Training sessions will be performed on a tablet or computer and participants will complete five sessions per week (20 minutes per session) for a period of two weeks.
3250760|NCT01388673|Experimental|ACE Stapler procedure|ACE Stapler procedure for the treatment of dilated post-surgical gastric anatomy
3250761|NCT01388686||INABBRA|Participating intensive care units of hospitals in the INABBRA alliance.
3250762|NCT01388699||migraine group|female migraineurs with aura
3250763|NCT01388699||control group|healthy women without headache syndrome
3250764|NCT01388712|Placebo Comparator|Placebo|
3250765|NCT01388712|Active Comparator|Probiotics|Lactobacillus reuteri DSM 17938
3250766|NCT01388725||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3250767|NCT01388725||Sepsis|SIRS + infection
3250768|NCT01388738|Active Comparator|cerebrolysin|IV
3250769|NCT01388738|Active Comparator|L-Alpha glycerylphosphorylcholine|IV
3250770|NCT01388738|Active Comparator|citicoline|IV and per os
3250771|NCT01388751|No Intervention|no night splinting|
3250772|NCT01388751|Active Comparator|night splinting|Night Splinting for 4 weeks after removal of initial cast
3250773|NCT01388764|Experimental|L-arginine|
3365500|NCT04383509|Active Comparator|Active Control|Participants in the active control group will start placebo training after completion of ECT with a maximum time interval of 7 days. The placebo task consists of a task similar to the experimental condition but that does not train cognitive control. Prior research confirmed that this condition controls for non-specific effects of the training and motivational issues. Participants will perform the sessions on a tablet or computer and complete five sessions per week (20 minutes per session) for a period of two weeks.
3365501|NCT04373746|Experimental|10-20 kg|Patients undergoing major surgery that weigh between 10-20 kg.
3365502|NCT04373746|Experimental|20-40 kg|Patients undergoing major surgery that weigh between 20-40 kg.
3365503|NCT04373746|Experimental|40-80 kg|Patients undergoing major surgery that weigh between 40-80 kg.
3365506|NCT04370704|Experimental|Phase 1 Part 1|Part 1 will confirm the safety of INCAGN02385 and INCAGN02390 when used in combination. INCAGN02385 will be administered first intravenously followed by INCAGN02390.
3365507|NCT04370704|Experimental|Phase 1 Part 2|Part 2 will confirm the safety of the triple combination of INCAGN02385 + INCAGN02390 + INCMGA00012, following confirmation of the safety of the doublet in Part 1. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012.
3365508|NCT04370704|Experimental|Phase 2|Phase 2 will determine preliminary efficacy and proof of concept for the combination of INCAGN02385 + INCAGN02390 + INCMGA00012. INCAGN02385 will be administered first intravenously followed by INCAGN02390 and INCMGA00012
3365509|NCT04367675|Experimental|INO-5401|Participants receive INO-5401 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
3365510|NCT04367675|Experimental|INO-5401 and INO-9012|Participants receive INO-5401 and INO-09012 vaccine, followed by electroporation, on Day 1, Week 4, Week 8, and Week 12
3365511|NCT04358393|Experimental|APG-115 monotherapy|Monotherapy given in part 1
3365512|NCT04358393|Experimental|APG-115 + 5-azacitidine combination|Combination therapy given in part 2
3365513|NCT04356339||BETASERON|Participants with Multiple Sclerosis treated with BETASERON using BETACONNECT autoinjector and myBETAapp will be enrolled
3365514|NCT04342494|Experimental|Enhanced Feedback + Standard Feedback|Participants will receive enhanced feedback from the MyDataHelps study app in addition to standard feedback from the activity tracker.
3365515|NCT04342494|Experimental|Headspace app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
3365516|NCT04342494|Experimental|Headspace app + Enhanced Feedback + Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback activity tracker.
3365517|NCT04342494|Experimental|SilverCloud app + Standard Feedback|Participants will receive an app-based intervention in addition to standard feedback from the activity tracker.
3365518|NCT04342494|Experimental|SilverCloud app +Enhanced Feedback +Standard Feedback|Participants will receive an app-based intervention, enhanced feedback from the MyDataHelps study app, and standard feedback from the activity tracker.
3365520|NCT04339595|Experimental|Tildrakizumab|
3365521|NCT04337203|Experimental|SHARE-S|Three components consisting of electronic referral, health coaching and tailored text/email messages for patients that have been referred to the cancer survivorship clinic.
3365522|NCT04336722|Experimental|Odevixibat (A4250)|Capsules for oral administration once daily for 104 weeks.
3250774|NCT01388829|Experimental|formulation comparison|formulation comparison
3250775|NCT01388842|Placebo Comparator|Placebo|Controls will receive small pulses of placebo study drug via the INOpulse delivery system. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
3250776|NCT01388842|Experimental|inhaled nitric oxide|Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air using an INOpulse delivery system for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days. Oxygen saturation will be maintained above 94% by adding oxygen to inspired gas via a loose fitting mask when necessary.
3250777|NCT01388855|Experimental|Cholecalciferol|Patients were given two cholecalciferol tablets (10,000 IU each) daily for 30 days.
3250778|NCT01388855|Placebo Comparator|Placebo|Patients were given two cholecalciferol placebo tablets daily for 30 days.
3250779|NCT01388868|Active Comparator|TOF count guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by No. of response to TOF stimulation
3365523|NCT04336722|Placebo Comparator|Placebo|Capsules for oral administration (to match active) once daily for 104 weeks.
3365524|NCT04335539|Experimental|Single Dose Phase: Cefiderocol|Participants will receive a single dose of cefiderocol administered intravenously on Day 1, in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg.
3365525|NCT04335539|Experimental|Multiple Dose Phase: Cefiderocol|Participants will receive cefiderocol administered intravenously every 8 hours for 5 to 14 days in addition to standard of care. Participants weighing less than 34 kg will receive 60 mg/kg cefiderocol and participants ≥ 34 kg will receive 2000 mg. Dosage may be adjusted based on renal function.
3365526|NCT04334577|Experimental|Attenuated Zoster Vaccine, Live|One shot of the vaccine (with live viruses titer >=4.3 LgPFU per dose)
3365527|NCT04334577|Placebo Comparator|Placebo|one shot of placebo with no live virus
3250780|NCT01388868|Experimental|T1/T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T1 twitch height as compared with control (T0)
3250781|NCT01388868|Experimental|T2/ T0 guided group|adjustment of neuromuscular blocking agent infusion dose every 15 minute as guided by T2 twitch height as compared with baseline (T0)
3250782|NCT01388881|Experimental|Music Education|Music education classes take place three times a week, 50 minutes each. These interventional classrooms will make available keyboard and blockflute.
3250783|NCT01388881|No Intervention|Non-intervention|In this arm, children will be not encourage practicing musical activities and will not have musical classes.
3365540|NCT04309370|Experimental|20 Hz rTMS targeting the LDLPFC|
3365541|NCT04309370|Experimental|20 Hz rTMS targeting the LSPC|
3365542|NCT04308837|Experimental|Patients With Local Regional Advanced Gastric Cancer|Patients with local regional advanced gastric cancer after at least 4 weeks post diagnostic laparoscopy and HIPEC, will receive all of the treatments described in the study protocol.
3250784|NCT01388933|Experimental|TU-100|15g TU-100 (oral, daily) for 8 consecutive weeks (administered as 5g three times daily)
3250785|NCT01388933|Placebo Comparator|Matching placebo|Matching placebo given 5g three times daily orally for 8 consecutive weeks
3365545|NCT04303702|Other|Discontinue Oxytocin|
3365546|NCT04303702|Active Comparator|Continue Oxytocin|
3365547|NCT04303000|Experimental|Opioid Overdose Education and Naloxone Distribution|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will be provided with a naloxone nasal spray kit (4mg).
3365548|NCT04303000|Active Comparator|Opioid Overdose Education|Participants will engage in online audiovisual training focused on recognizing the signs of an opioid overdose and the procedural steps for how to administer naloxone. Participants randomized to this arm will receive information about pharmacies in their area where they can purchase a naloxone kit.
3365549|NCT04298034|Experimental|Treatment|The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol or nifedipine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects.
3365550|NCT04298034|No Intervention|No-treatment|
3365553|NCT04288778|Experimental|Canagliflozin + Metformin Hydrochloride Immediate Release (IR)|Participants will receive canagliflozin + metformin hydrochloride IR fixed-dose combination, 50 milligram (mg) + 500 mg or 50 mg + 1000 mg, will be provided as tablets for oral administration.
3365554|NCT04287868|Experimental|Arm 1|Triple Therapy: PDS0101 + NHS-IL12 + M7824; The dose level of NHS-IL12 may decrease depending on DLT events. The dose level of HVP vaccine and M7824 will remain constant.
3365555|NCT04287868|Experimental|Arm 2|Triple Therapy: PDS0101 + NHS-IL12 + M7824; Accrual will be expanded first to 8 participants and then to 20 evaluable participants at the dose level selected in Arm 1 if more than 3 of 8 participants have an objective response.Triple Therapy: PDS0101 + NHS-IL12 + M7824; Reduced doses.
3250786|NCT01388959|Experimental|Single arm|
3365556|NCT04285567|Experimental|VEN + G|Participants will receive 12 cycles of treatment (each cycle is 28 days). Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
3365557|NCT04285567|Active Comparator|FCR/BR|Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
3365558|NCT04285398|Other|Study Group 1|Four years follow up of patients with ophthalmic examination.
3365559|NCT04285398|Other|Study Group 2|Four years follow-up of patients with ophthalmic examination and mobility testing.
3365561|NCT04280744|Experimental|Music therapy|Music listening intervention provided by a board certified music therapist.
3365562|NCT04279613|Experimental|NNC0361-0041|Dosage form: 9 mg/ml Solution for injection Route of administration: Subcutaneous Initial dose/Unit dose strength(s)/Dosage level(s) in cohort 1: 1mg Additional doses in cohorts 2, 3, and 4: 5mg, 12.5mg and 25mg Dosing instructions: Once weekly on site
3365563|NCT04279613|Placebo Comparator|Placebo|Dosage form: Solution for injection Route of administration: Subcutaneous Dosing instructions: Once weekly on site
3250787|NCT01389024|Experimental|Hydroxyurea|treatment with hydroxyurea 20 mg/kg/day increased by 5 mg/kg every 8 weeks to maximum of 35 mg/kg/day or hematologic toxicity or ANC <4000
3250788|NCT01389024|Placebo Comparator|Placebo|Sucrose placebo 0.2 ml/kg/day increased to max of 0.35 ml/kg/day
3250789|NCT01389037|Experimental|Health Literacy-focused Self-help|
3365564|NCT04276441||Non- Atrial Fibrillation (AF) Cohort|Participants without a history of AF will be randomly assigned into the study to either an Apple Watch/iPhone group or an iPhone group only.
3365565|NCT04276441||Atrial Fibrillation (AF) Cohort|Participants with a diagnosis of AF taking a direct oral anti-coagulant (DOAC) for at least 30 days will be randomly assigned to Apple Watch/iPhone group or iPhone group only.
3365566|NCT04273945|Active Comparator|Macitentan 10 milligrams (mg) + Placebo|Participants will receive macitentan 10 mg once daily (qd) orally for 4 weeks in open-label Run-in phase prior to randomization (only for participants who are Endothelin Receptor Antagonist (ERA) treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 10 mg qd and matching placebo of macitentan 37.5 for 4 weeks (Uptitration) and 75 mg thereafter orally up to End of Double-Blind Treatment period (EDBT). Treatment Extension Period: After EDBT, participants will receive macitentan 37.5 mg qd and macitentan 75 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
3365567|NCT04273945|Experimental|Macitentan 75 mg + Placebo|Participants will receive macitentan 10 mg qd orally for 4 weeks in open-label Run-in phase prior to randomization (only for ERA treatment-naive. Other participants will bypass the Run-in period and go directly to randomization). Double-blind Treatment Period: participants will receive macitentan 37.5 for 4 weeks (Uptitration) and 75 mg qd along with matching placebo for macitentan 10 mg orally up to EDBT. Treatment Extension Period: After EDBT, participants will receive macitentan 75 mg qd and macitentan 37.5 mg matching placebo orally for 4 weeks (Uptitration), followed by open-label macitentan 75 mg qd orally for 2 years.
3250790|NCT01389037|Placebo Comparator|Delayed intervention control|
3250791|NCT01389050|No Intervention|Follow-up|Data from these patients will be added to retrospectively gathered data from the PMH radiotherapy data bank (approximately 50 patients). The data collected will be analyzed using descriptive statistics.
3250792|NCT01389050|Experimental|Prospective|
3250793|NCT01389063|Active Comparator|Arm A|HAART of subjects in arm A will be intensified with maraviroc during week 1-8.
3365576|NCT04264143|Experimental|MTX110 and CED|All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered by the CED delivery system directly into the tumor over 9-11 days.
3365577|NCT04263766|Experimental|Healthy Adult Volunteers|The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.
3365578|NCT04262154|Experimental|Metastatic Prostate Cancer|Participants will have untreated metastatic (M1a/b/c) hormone-sensitive prostate cancer documented by positive bone scan or metastatic lesion on CT or MRI; untreated is defined as having never received surgical, radiotherapeutic, or systemic therapy for their prostate cancer.Group 1 and 2. The first 20 patients enrolled will be in Group 1 and the remaining patients (and those who are already on a GnRH analog) will be assigned to Group 2. All study participants will receive treatment with atezolizumab, abiraterone acetate, prednisone, GnRH analog, and SBRT, at the same doses.
3365579|NCT04260776|Experimental|Phase 1|Participants will be randomly assigned to one of the two text message programs that correspond with the web-based intervention (MyWebQuit): 1) standard, 1-way text messages, or 2) interactive, 2-way text messages
3250794|NCT01389063|Active Comparator|Arm B|HAART of subjects enrolled in arm B will be intensified with maraviroc during week 9-16
3250795|NCT01389089|No Intervention|Control group|The Control group received ice gel packs and elevation to reduce edema.
3250796|NCT01389089|Experimental|Multi-layer compression bandage|A multi-layer compression bandage was applied to the lower limb and foot of the patient to reduce edema. Additionally, the limb was constantly elevated.
3250797|NCT01389089|Experimental|A-V Impulse compression|An A-V Impulse compression device was used to reduce edema.
3250798|NCT01389115||Liver Cirrhosis|Patient with liver cirrhosis undergoing liver transplant
3250799|NCT01389115||Liver donors|Subjects eligible for organ explant
3365580|NCT04260776|Experimental|Phase 2|"For the first 5 weeks after randomization, engagement with the website will be monitored. Participants who continue to engage with the website will continue with the same Phase 1 treatment components until the 3-month follow-up.~Participants who disengage with the website will be randomly assigned to receive one of three re-engagement strategies: 1) interactive, re-engagement text messages, 2) re-engagement email, or 3) no re-engagement strategy"
3250800|NCT01389115||Healthy controls|
3250801|NCT01389141||mid-reproductive age|
3365582|NCT04254549|Experimental|Intervention Treatment|Subjects diagnosed with gastroparesis will receive Rifaximin
3365583|NCT04254549|Placebo Comparator|Placebo Group|Subjects diagnosed with gastroparesis will receive a placebo
3365584|NCT04252287|Experimental|Canagliflozin 100 mg|Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.
3365585|NCT04252287|Placebo Comparator|Placebo|Participants will be administered matching placebo capsules orally once daily for 12 weeks.
3365587|NCT04240002|Experimental|Dose Escalation - 2 years to less than 21 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
3250802|NCT01389141||late reproductive age-1|
3250803|NCT01389141||late reproductive age-2|
3250804|NCT01389154|Experimental|Patients recommended for a lung biopsy.|Patients with a positive diagnosis of a peripheral, less than 3.0 centimeter lung lesion, recommended for bronchoscopic biopsy are eligible to be consented into the study.
3250805|NCT01389167|Experimental|Vivitrol + BDRC|
3250806|NCT01389167|Experimental|Vivitrol + Medical Management|
3250807|NCT01389167|Experimental|Naltrexone (oral)+BDRC|
3365588|NCT04240002|Experimental|Dose Escalation - 1 year to less than 2 years of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
3365589|NCT04240002|Experimental|Dose Escalation - 6 months to less than 1 year of age|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
3365590|NCT04240002|Experimental|Dose Expansion|Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the dose determined in dose escalation portion. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
3250808|NCT01389167|Experimental|Naltrexone (oral) + Medical Management|
3250809|NCT01389180|Experimental|BDRC|
3250810|NCT01389180|Experimental|EC|
3250811|NCT01389180|Other|TAU|
3250812|NCT01389193|Experimental|Ibudilast|
3250813|NCT01389193|Placebo Comparator|Placebo|
3250814|NCT01389206||Standard of care|Observational study to improve the management of PAH patients through an evidence-based approach aimed at achieving optimal WHO functional class (FC) treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi.
3250815|NCT01389219|No Intervention|Control|Control arm
3250816|NCT01389219|Other|Intervention clusters|Focus is to increase the number of visits by LHWs to the newborn baby and to ensure that this visit occurs within 48-72 hours of birth. The purpose of this visit was the provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation, cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
3250817|NCT01389271||Group 1|
3250818|NCT01389297|Active Comparator|Face-to-face SMART Recovery meetings|Participants in this arm will be asked to attend face-to-face SMART Recovery meetings.
3250819|NCT01389297|Experimental|Overcoming Addictions web app|Participants in this condition will use the Overcoming Addictions web application and not attend face-to-face SMART Recovery meetings.
3250820|NCT01389297|Experimental|Web app + meetings|Participants in this condition will be asked to use both the Overcoming Addictions web application and attend face-to-face SMART Recovery meetings.
3250821|NCT01389310||HIV-infected children <18 yrs old - exposed to Atazanavir|
3250822|NCT01389336||Add-on Ayurveda - Group|In the Āyurveda add-on-group 20 patients will receive individualized treatment according to the Āyurveda diagnosis which may include manual treatments, massages, dietary advice, specific consideration of selected food items, āyurvedic lifestyle & yoga posture advice and daily self-applied massage on top of standard care.
3250823|NCT01389336||Standard Care|20 Patients will receive the individually adjusted complex conventional standard care according to the current AWMF-guidelines including physiotherapy, occupational therapy, specific pain therapy and psychotherapy.
3365595|NCT04235777|Experimental|Arm 1|Treatment with M7824 and de-escalating doses of M9241 if appropriate
3250824|NCT01389349|Experimental|Acupuncture|
3250825|NCT01389349|Sham Comparator|Sham Control|
3250826|NCT01389362|Active Comparator|Chinese Herbal Medicine|2 sachets of Chinese Herbal Medicine to be taken daily
3365596|NCT04235777|Experimental|Arm 2|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with sequential SBRT
3250827|NCT01389362|Placebo Comparator|Placebo arm|2 sachets to be taken daily
3250828|NCT01389375|Experimental|FemoSeal®|Device: FemoSeal®
3250829|NCT01389375|Experimental|ExoSeal®|Device: ExoSeal®
3365597|NCT04235777|Experimental|Arm 3|Treatment with M7824 and de-escalating doses of M9241 (if appropriate) with concurrent SBRT
3365598|NCT04231318|Experimental|Cingal|
3365599|NCT04231318|Active Comparator|Triamcinolone Hexacetonide (TH) - Lederlon|
3365600|NCT04231318|Placebo Comparator|Placebo|
3250830|NCT01389375|Active Comparator|Manual compression|Other: Manual compression
3250831|NCT01389388|Experimental|Rosuvastatin intervention|Patients > 70 years will be given Rosuvastatin of 5 mg a day, uptitering the dose until the LDL level of 1.6-1.8 mmol/l has been reached. Patient <70 years, strat on Rosuvastatin 20 mg a day, uptitered to 40 mg a day, with the LDL of 1.6-1.8 mmol/l. -1.8 mmol/l. The objective is that all the participants should have reached a LDL level of 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
3365604|NCT04225078|Experimental|Treatment Sequence 1: Treatment ADBC|Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
3365605|NCT04225078|Experimental|Treatment Sequence 2: Treatment BACD|Participants will receive Treatment B on Day 1 of treatment period 1 followed by Treatment A on Day 1 of treatment period 2 then Treatment C on Day 1 of treatment period 3 and then Treatment D on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
3365606|NCT04225078|Experimental|Treatment Sequence 3: Treatment CBDA|Participants will receive Treatment C on Day 1 of treatment period 1 followed by Treatment B on Day 1 of treatment period 2 then Treatment D on Day 1 of treatment period 3 and then Treatment A on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
3365607|NCT04225078|Experimental|Treatment Sequence 1: Treatment DCAB|Participants will receive Treatment D on Day 1 of treatment period 1 followed by Treatment C on Day 1 of treatment period 2 then Treatment A on Day 1 of treatment period 3 and then Treatment B on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
3365608|NCT04217057|Experimental|64Cu-DOTA-ECL1i-PET/CT|-64CU-DOTA-ECL1i-PET/CT imaging consisting of a dynamic scan centered at the level of the known tumor followed by a limited body scan of the head/neck and upper chest will be performed
3250832|NCT01389401||reflux laryngitis group pre-treatment|adults with clinical suspicion of Reflux Laryngitis confirmed by 24-hour double probe esophageal monitoring who have not made use of any treatment in the past 15 days.
3250833|NCT01389401||study group - post treatment|adults with reflux laryngitis after 16 weeks of treatment with proton pump inhibitor (omeprazole 40 mg twice a day)and dietary/lifestyle changes that present improvement in symptoms and video laryngoscopic signs of chronic laryngitis
3250834|NCT01389401||control group|healthy controls paired by gender and age that do not present symptoms and videolaryngoscopic signs suggestive of reflux laryngitis
3250835|NCT01389414|Experimental|Arm A- p-Gemox|"Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once Q2W.~GEMOX chemotherapy will be administered after the administration of panitumumab once Q2W.~Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle."
3250836|NCT01389414|Active Comparator|Arm B-GEMOX|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
3250837|NCT01389427|Experimental|Torisel 15 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 15 mg
3365613|NCT04208464|Experimental|Immediate-start arm|Participants will receive 4mg baracitinib daily for 24 weeks from the baseline visit in week 0. After treatment participants will be followed up for 12 weeks.
3250838|NCT01389427|Experimental|Torisel 25 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 25 mg
3250839|NCT01389427|Experimental|Torisel 50 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 50 mg
3365614|NCT04208464|Experimental|Delayed-start arm|After the baseline visit in week 0, participants will wait for a 12 week treatment delay and will then receive 4mg baracitinib daily from week 12-week 36 (i.e. for 24 weeks). After treatment participants will be followed up for 4 weeks for safety.
3365615|NCT04198649|Experimental|Azithromycin|62 patients Non-surgical periodontal treatment and two 250mg azithromycin tablets one time daily for 3 days
3365616|NCT04198649|Placebo Comparator|Placebo|62 patients Non-surgical periodontal treatment and two 250mg starch tablets one time daily for 3 days
3365618|NCT04194203|Experimental|Treatment A|Participants will receive atezolizumab, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with atezolizumab, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
3365619|NCT04194203|Placebo Comparator|Treatment B|Participants will receive placebo, bevacizumab, paclitaxel or pemetrexed, and carboplatin (in this order) by intravenous (IV) injection on Day 1 of each 21-day cycle for 4 cycles in the induction treatment. In the maintenance phase, participants will be treated with placebo, bevacizumab and pemetrexed (if given in the induction phase) until unacceptable toxicity or loss of clinical benefit.
3365620|NCT04193046|Other|Participants with PH and non-PH|Blood samples will be collected for biomarker analysis from new (incident) and existing (prevalent) participants who undergo right heart catheterization (RHC). Participants will be categorized into non-PH or PH based on the results of the RHC and those who are found to have PH will be further classified into the different groups of PH. A transthoracic echocardiography (TTE) will be performed if not done previously.
3250840|NCT01389427|Experimental|Torisel 75 mg|Chemotherapy (R-CHOP, R-DHA or R-FC) associated to Torisel 75 mg
3250841|NCT01389440|Experimental|Gemcitabine, Erlotinib and radiotherapy|Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy
3250842|NCT01389453|Active Comparator|stem cell transplatation|All experimental group patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7-14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
3250843|NCT01389453|No Intervention|control|The control group gives injection through intravenous and lumbar puncture ways separately in the corresponding time, but the transplantation matter is physiological saline not the stem cell.
3250844|NCT01389466|Experimental|MG1109 - Step 1|
3250845|NCT01389466|Placebo Comparator|Normal Saline - Step 1|
3250846|NCT01389466|Experimental|MG1109 - Step 2|
3250847|NCT01389479|Experimental|Fluviral Group|
3250848|NCT01389479|Active Comparator|Fluzone Group|
3250849|NCT01389492|Other|frozen meat|250 g of frozen meat meal for 4 days
3250850|NCT01389492|Other|frozen meat and wine|250 g of frozen meat and red wine for 4 days
3250851|NCT01389492|Other|fresh meat|250 g of fresh meat meal
3250852|NCT01389492|Other|fresh meat and wine|250 g of fresh meat meal
3250853|NCT01389505|Active Comparator|Panretinal photocoagulation|Group 1: Panretinal photocoagulation treatment (PRP) at month-0 that can be repeated after month-3.
3250854|NCT01389505|Experimental|Bevacizumab + Panretinal Photocoagulation (PRP)|Group 2: Bevacizumab intravitreous injections plus PRP
3250855|NCT01389518|Active Comparator|Paracetamol,Chlorpheniramin,Phenylephrin|
3250856|NCT01389518|Placebo Comparator|Placebo|
3250857|NCT01389531|Other|Stents|All recruited patients will be receiving a stent during a rigid bronchoscopy procedure.
3250858|NCT01389544|Experimental|Single Arm|
3250859|NCT01389570|Experimental|Acupressure wrist band|The group receiving acupressure wrist band
3250860|NCT01389583|Experimental|AUY922|AUY922
3250861|NCT01389609|Experimental|A|Doxazosin 4 mg Japanese marketed IR tablet as a single oral dose under fasted conditions
3250862|NCT01389609|Experimental|B|Doxazosin 4 mg ODT with water as a single oral dose under fasted conditions
3365622|NCT04188769|Sham Comparator|uninflated - rest|splint around the arm is not inflated both arms are in rest during the entire trial
3365623|NCT04188769|Sham Comparator|uninflated - triggered|splint around the arm is not inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
3250863|NCT01389609|Experimental|C|Doxazosin 4 mg ODT without water as a single oral dose under fasted conditions
3250864|NCT01389622|Experimental|Arm 1: NADA points and digital pressure|Arm 1: NADA points and digital pressure with urge.
3365624|NCT04188769|Active Comparator|constantly inflated - rest|splint around the arm is constantly inflated both arms are in rest during the entire trial
3365625|NCT04188769|Active Comparator|constantly inflated - triggered|splint around the arm is constantly inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
3365626|NCT04188769|Experimental|intermittently inflated - rest|splint around the arm is intermittently inflated both arms are in rest during the entire trial
3365627|NCT04188769|Experimental|intermittently inflated - triggered|splint around the arm is intermittently inflated 5x flexion and extension with the contralateral arm (with weight of 5kg in the hands)
3365628|NCT04187404|Experimental|5-cohort study design|"Cohort 1:3-by-3 design of EO2401 in combination with nivolumab at standard dose. Three to 12 evaluable patients with adrenal carcinoma or progressive malignant pheochromocytoma/paraganglioma will be included depending on the safety profile of the administered treatments.~Cohorts 2A (previously treated patients) and 2B (previously untreated patients): evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 2A and 2B) with adrenal carcinoma.~Cohorts 3A (previously treated patients) and 3B (previously untreated patients) : evaluation of EO2401 at the recommended dose found in Cohort 1 in combination with nivolumab in 30 evaluable patients (15 each for Cohorts 3A and 3B) with progressive malignant pheochromocytoma/paraganglioma."
3365629|NCT04183335|Experimental|Dupilumab|Dose regimen 1 on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
3365630|NCT04183335|Placebo Comparator|Matched placebo|Placebo on top of moisturizers and if applicable low to medium potent topical corticosteroids or topical calcineurin inhibitors
3365631|NCT04180813||Subjects with Diabetes Mellitus, Type 2|
3365632|NCT04177654||Cambodia|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365633|NCT04177654||Bangladesh|The group of school-aged children from Cambodia who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3250865|NCT01389622|Experimental|Arm 2: random points + digital pressure with urge|Arm 2 (20 participants): random points + digital pressure with urge
3250866|NCT01389622|No Intervention|Arm 3 (20 participants): NO acupressure, only advice + support|
3250867|NCT01389635||Abdominoplasty patients|All patients who underwent abdominoplasty at our institution without concurrent operations
3250868|NCT01389648|Experimental|Pre Operative|Pre operative chest physiotherapy treatment
3250869|NCT01389648|No Intervention|usual care|
3365634|NCT04177654||Vietnam|The group of school-aged children from Vietnam who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365635|NCT04177654||Lao PDR|The group of school-aged children from Lao PDR who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365636|NCT04177654||Ghana|The group of school-aged children from Ghana who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365637|NCT04177654||Senegal|The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365638|NCT04177654||Rwanda|The group of school-aged children from Rwanda who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365639|NCT04177654||Haiti|The group of school-aged children from Haiti who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
3365640|NCT04176497|Experimental|PMSA-PET/MRI|Patients scheduled to receive PMSA-PET/MRI scan in addition to standard of care CT scan prior to treatment
3365641|NCT04175600|Experimental|Selexipag|Participants will receive selexipag based on the body weight on Day 1 and will continue thereafter with twice daily dosing. Selexipag will be uptitrated during the first 12 weeks until the participants reaches the individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline body-weight category is achieved. Uptitration is followed by a maintenance period after Week 12 until end of treatment (EOT), at the maximum tolerated dose.
3250870|NCT01389661|Experimental|MSV treatment|MSV treatment: Mesenchymal stem cells from bone marrow expanded by GMP-compliant procedure in IBGM cell production unit in autologous plasma scaffold and implanted in maxillary bone cavities after cyst removal
3365642|NCT04175600|Placebo Comparator|Placebo|Participants will receive matching placebo based on the body weight on Day 1 and will continue thereafter with twice daily dosing.
3365643|NCT04172402|Experimental|NGS|"Eligible patients will receive Nivolumab 240mg on day 1, gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.~BSA < 1.25 m2: 80 mg/day~1.25 m2 ≤ BSA < 1.5 m2: 100 mg/day~BSA ≥ 1.5 m2: 120 mg/day The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
3365644|NCT04170062|Experimental|Baseline followed by intervention 1a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
3365645|NCT04170062|Experimental|Baseline followed by intervention 1b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
3365646|NCT04170062|Experimental|Baseline followed by intervention 1c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
3365647|NCT04170062|Experimental|Baseline followed by intervention 1d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
3365648|NCT04170062|Experimental|Baseline followed by intervention 1e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
3250871|NCT01389674|Experimental|2D-strain echo|After myocard vitality diagnostics with MRI follows a stress echocardiography to determine the LV volumes and EF. The received Data are compare with the MRI-Data(reference)to identify the ideal strain-parameters and Cut-Off-Result for an intraprocedural vitality diagnostic of the different films (endocardial, myocardial and epicardial).
3365649|NCT04170062|Experimental|Baseline followed by intervention 1f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
3365650|NCT04170062|Experimental|Baseline followed by intervention 2a|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 20 L/min, 25 L/min).
3365651|NCT04170062|Experimental|Baseline followed by intervention 2b|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 15 L/min, 25 L/min, 20 L/min).
3250872|NCT01389687|Experimental|Study Group|
3250873|NCT01389700|Experimental|SAR279356 dose 1|SAR279356 dose 1, single administration
3250874|NCT01389700|Experimental|SAR279356 dose 2|SAR279356 dose 2, single administration
3250875|NCT01389700|Placebo Comparator|Placebo|Matching placebo, single administration
3365652|NCT04170062|Experimental|Baseline followed by intervention 2c|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 15 L/min, 25 L/min).
3365653|NCT04170062|Experimental|Baseline followed by intervention 2d|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 20 L/min, 25 L/min, 15 L/min).
3365654|NCT04170062|Experimental|Baseline followed by intervention 2e|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 15 L/min, 20 L/min).
3250876|NCT01389713|Active Comparator|High doses|Administration of high doses of gonadotrophins to stimulate ovarian follicular growth
3250877|NCT01389713|Experimental|Clomid|Administration of Clomiphene Citrate to obtain ovarian follicular growth
3250878|NCT01389726|Experimental|Behavioral Parenting Training|Triple-P Parenting Training Program (group level)
3250879|NCT01389726|Experimental|Cognitive Behavioral Therapy|CBT group-level intervention (Designed by Larry Thompson & Dolores Gallagher Thompson)
3250880|NCT01389726|Active Comparator|Psychosocial-Informational Support|Standard of Care informational support group
3250881|NCT01389739|Experimental|Exposed to the intervention|Patients in the intervention arm will be exposed to a multi-faceted intervention to improve continuity of care; the intervention includes 4 components: 1) systematic appointments with FP at 3-month interval during the study period; 2) transmission to FP of a standardized comprehensive summary before each appointment; 3)systematic transmission to the oncology team of patients' information resulting from FP visits; 4) development of a priority access to FP for cancer patients
3250882|NCT01389739|No Intervention|Usual care|
3250883|NCT01389778|Experimental|Metformin|Subjects treated with metformin.
3365655|NCT04170062|Experimental|Baseline followed by intervention 2f|Subjects perform baseline titration with oxygen only first. Subjects are then titrated with six different delivery methods. The subjects will be first delivered Out-of-Phase pulsed high-flow air and oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min) and then Continuous high-flow air with pulsed oxygen (order of high-flow air flow rate: 25 L/min, 20 L/min, 15 L/min).
3365656|NCT04166539||Metallosis Patients|Patients who are being seen by surgeons for metal-related issues in the blood, pain, or revision surgery.
3365657|NCT04166539||Control Group|Patients who have had total hip or knee arthroplasty no less than 5-10 years ago, who have no symptoms.
3365661|NCT04130503|Experimental|PAP treatment- Acute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
3365662|NCT04130503|Active Comparator|Usual Care (HLE)|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur.
3365663|NCT04130503|Experimental|PAP treatment- Subacute|"Acute intervention patients will start PAP within 1-week poststroke symptom onset, and subacute patients will start PAP 1-month post-symptom onset. Both groups will continue PAP therapy through the duration of the study, reinforced with technical assistance and behavioral support.~All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention, as well as interim contacts occurring at 1 week, 1 month, and 3 months, post-randomization, where outcome measures and safety assessments will occur."
3365664|NCT04116658|Experimental|Cohort 1|Multiple dose of EO2041 monotherapy followed by continued EO2401 in combination with nivolumab
3365665|NCT04116658|Experimental|Cohort 2|Multiple dose of EO2041 in combination with nivolumab
3365666|NCT04116658|Experimental|Cohort 3|Multiple dose of EO2041 in combination with nivolumab and bevacizumab (US only)
3365667|NCT04116619||Individuals with Cannabis Use Disorder|Participants who meet criteria for Cannabis Use Disorder will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
3250884|NCT01389791|No Intervention|Roc|Patients in this group receive neither MgSO4 nor priming dose of rocuronium.
3250885|NCT01389791|Active Comparator|priming|patients in this group receive 0.06mg/kg of rocuronium before 0.54mg/kg of rocuronium.
3250886|NCT01389791|Experimental|Mg&priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
3250887|NCT01389791|Active Comparator|MgSO4|Patients in this group receive intravenous MgSO4 before administration of rocuronium.
3250888|NCT01389804||Pediatric Solid Organ Transplant|Parents of pediatric solid organ transplant recipients
3250889|NCT01389830||Older Latinos With Cancer|Monthly Telephone Survey of Cohort with stage III or greater of breast, colorectal, or prostate cancer up until 12 months.
3250890|NCT01389830||Older Latinos Without Cancer|Single Telephone Survey of Cohort without a history of cancer.
3250891|NCT01389843||All consecutive hospitalized adult patients|"All consecutive hospitalized adult patients who have 1 and (2 and/or 3)~Symptom and/or sign of heart failure~Lung congestion~Objective finding of LV systolic dysfunction (LVEF), or structural heart disease."
3250892|NCT01389869|Experimental|Tears|Emotional tears of female volunteers while watching sad video clips
3250893|NCT01389869|Placebo Comparator|Saline|Saline collected after being trickled down women's skin below eyes like tears
3250894|NCT01389869|Placebo Comparator|Fasting|Their own overnight fasting plasma of male volunteers
3365668|NCT04116619||Light Cannabis Users|Participants who are light cannabis users (<1 joint/week) will complete three guided imagery conditions (stress, cannabis, neutral) in an inpatient research unit. During the guided imagery, repeated measurements of subjective (i.e., craving, negative affect), neuroendocrine (i.e., cortisol), and physiological variables (i.e., heart rate variability [HRV]) will be collected.
3365669|NCT04111419|Experimental|Intensive blood pressure and cholesterol control|
3365670|NCT04111419|Active Comparator|Intensive blood pressure and routine cholesterol control|
3365671|NCT04111419|Active Comparator|Routine blood pressure and intensive cholesterol control|
3250895|NCT01389869|Experimental|Prandial|Their own postprandial plasma of male volunteers
3250896|NCT01389895|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
3365672|NCT04111419|Active Comparator|Routine blood pressure and cholesterol control|
3365673|NCT04103970|No Intervention|Control group|"Usual care:~Before surgery all patients are invited to participate in a pre-surgery seminar, where they receive information and advice about the time before, during and after the LSF. The seminar will be guided by nurses, surgeons, anesthesiologist, occupational therapists and physiotherapist.~After the surgery the patient will be hospitalized on an average of 3-4 days. During hospitalization a physiotherapist consults the patients on a daily basis to provide information, guidance on mobilization and instructions in gradually progressing movement. The patients will have no restrictions on movement after surgery and should gradually return to normal activity level.~Three months post-operatively all patients will receive physical rehabilitation delivered by physiotherapists in a community care center."
3250897|NCT01389895|Placebo Comparator|AMG 557 Placebo|All will receive placebo on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99.
3250898|NCT01389908|Experimental|schizophrenia|schizophrenia or schizoaffective patients
3365674|NCT04103970|Experimental|Intervention group: Graded Activity and Pain Education (GAPE)|"Patients in the intervention-group will receive usual care and 9 sessions of GAPE, 4 sessions at the hospital, 2 sessions in the patient's home and 3 sessions by telephone.~Pain education in GAPE is viewed as an approach which target cognitive attitudes and beliefs about pain. The pain education will target 3 overall questions: 1. What is pain and is my pain normal? 2. What can affect my pain? 3. What can I do to relieve my pain? The education will be individually adjusted to each patient, so the patient's context and concerns regarding pain and movement are included.~The aim of Graded activity is to improve the patient's functional ability by positive reinforcement of health behaviors and activity levels. Graded activity will be based on which short-term activity-goals the patient evaluates as the most important for the treatment outcome. In close collaboration with the patient the physiotherapist will set quotas for the selected exercises/activities."
3365677|NCT04101422|No Intervention|Development of Augmented Reality (AR) Application|Investigators will collaborate with an AR software specialist to develop AR stimuli that are embedded within a basic digital application.
3250899|NCT01389921|Experimental|healthy testpersons|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
3250900|NCT01389921|Experimental|patients with non-neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome.
3250901|NCT01389921|Other|patients with neurogenic OAB|Electroencephalography recording during electrical stimulation of different locations of the lower urinary tract as well as during electrical and heat stimulation at the tibial and pudendal nerve and S3 dermatome
3250902|NCT01389934|Placebo Comparator|Control|Women of this group be infused saline 2 ml / h for 48h.
3250903|NCT01389934|Experimental|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.
3250904|NCT01389947||Extracorporeal circulation|Patients who have coronary artery bypass graft performed under extracorporeal circulation
3250905|NCT01389947||Heart beating group|Patients who have a coronary artery bypass graft without extracorporeal circulation
3250906|NCT01389986|Experimental|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3250907|NCT01389986|No Intervention|Conventional|Conventional postoperative feeding schedule
3250908|NCT01389999||Chronic back pain patients|Patients who have had back pain for at least three months.
3250909|NCT01390012|Active Comparator|Dexamethasone oral|
3250910|NCT01390012|Active Comparator|Dexamethasone intravenous|
3250911|NCT01390025|Experimental|TCN-032|
3250912|NCT01390025|Placebo Comparator|Placebo|
3250913|NCT01390051|Active Comparator|Innohep|Tinzaparin 4500 I.U. sub cutaneous once daily until gestational week 37
3250914|NCT01390051|No Intervention|no treatment|
3250915|NCT01390103||Assessment following the hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
3250916|NCT01390116|Placebo Comparator|Sugar pill|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3250917|NCT01390116|Experimental|AGE|Encapsulated aged garlic extract, 4 capsules per day, 2.56 g/day
3250918|NCT01390129|Experimental|Control|
3250919|NCT01390129|Active Comparator|Remote ischemic preconditioning|
3250920|NCT01390142|Experimental|Control|
3250921|NCT01390142|Active Comparator|RIPer|Remote ischemic preconditioning
3250922|NCT01390142|Active Comparator|RIPer + IPost|Remote ischemic preconditioning and Local ischemic postconditioning
3365678|NCT04101422|Experimental|Pilot Testing of AR Application|AR stimuli (smoking, e.g, cigarette, ashtray, lighter; and non-smoking, e.g., pen, notebook, eraser) will be piloted on a small group of smokers to receive feedback and modify as needed. Participants will answer questions from a 10 point Likert scale that will asses urge from 1 (absolutely no urge to smoke) to 10 (strongest urge to smoke) and reality/co-existence (how realistic the item looks, and it's integration into the environment), from 1 (Not at all) to 10 (Very Much). Participants will then be asked additional open-ended questions about the quality of the images following the ratings of the images.
3365679|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 1: Cue Reactivity|142 study participants will attend 1st lab based session that will test cue-reactivity. Participant will be randomized to view either AR images, or in vivo items first. Order of presentation of items will also be randomized within the type (AR or in vivo).Session 1 should last under 1 hour.
3365680|NCT04101422|Experimental|Laboratory Validation of AR Stimuli Session 2: Extinction|Participants will be randomized into either the extinction or control group. 28 trials of AR cues will be presented for each group. Both groups will receive the same neutral cue in Trial 1 (to establish baseline urge) and the same smoking cue in Trial 2 (for pre-test cue-reactivity). The extinction group will receive smoking cues for trials 3-26, whereas the control group will receive neutral cues. Both groups will receive matched smoking cues for trial (27) followed by matched neutral cues for the final trial (28), for post-test cuereactivity. Each cue will be presented for 1 minute and will be shown 4 times in trials 3-26. Following each cue, participants will complete the single-item measure of urge. Following the final trial (28) for both groups, participants will be presented with one of their own cigarettes and asked to take at least one puff. Latency to smoke will later be determined using time stamps on the video recording. Session 2 is expected to last 1.25 hours.
3365681|NCT04101422|Experimental|Testing AR Application|20 Participants will be instructed to use the AR app that presents smoking-related stimuli (cigarette, ashtray, lighter) in locations/situations where they typically smoke with the goal of at least 5 uses per day for 7 days. Usage and rating data will be collected in real-time. Participants will also be asked to rate their urge to smoke on the smartphone app at selected times. Participants will then return to the lab to provide additional feedback on the app, answer questions related to smoking behavior, and receive an in-person interview on their perceptions of the app as a potential cessation tool. Participants will use the smart phone application for 7 days.
3365684|NCT04099823|Other|MR brain|"Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.~Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.~Those who meet eligibility criteria for the study and have agreed to participate will be taken to the MRI suite when MR imaging of the brain will be performed."
3365685|NCT04094506|Experimental|Dose level A of ASP1948|Dose A of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
3365686|NCT04094506|Experimental|Dose level B of ASP1948|Dose B of ASP1948 will be administered intravenously on Day 1 of every 2-week cycle.
3365687|NCT04094506|Experimental|Dose level C of ASP1948|Dose C of ASP1948 will be administered intravenously on Day 1 of every 3-week cycle.
3365690|NCT04079296|Experimental|Phase 1 ASP7517 Dose Escalation|Two single doses of ASP7517 will be administered intravenously at up to 3 dose levels and will be based on the assessment of safety variables, including the occurrence of dose limiting toxicities (DLTs).
3365691|NCT04079296|Experimental|Phase 2 ASP7517 Dose Expansion|Up to six single doses of ASP7517 will be administered intravenously at the dose levels determined from the Dose Escalation phase.
3365692|NCT04076618|Experimental|Weight Loss plus Vest|
3365693|NCT04076618|Active Comparator|Weight Loss Plus Resistance Exercise Training|
3365694|NCT04076618|Active Comparator|Weight Loss|
3365695|NCT04071613|Active Comparator|Intravenous tenecteplase (TNK)|Patients will receive intravenous tenecteplase (0.25mg/kg, maximum 25mg, administered as a bolus over ~10 seconds).
3365696|NCT04071613|Active Comparator|Intravenous tissue plasminogen activator (tPA)|Patients will receive intravenous t-PA at the standard licensed dose of 0.9 mg/kg up to a maximum of 90mg, 10% as bolus and the remainder over 1 hour.
3250923|NCT01390155||1|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left anterior descending coronary artery.
3250924|NCT01390155||2|Patients undergoing temporary myocardial ischemia produced by a one-minute balloon occlusion of the proximal left circumflex artery.
3250925|NCT01390155||3|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the proximal right coronary artery.
3250926|NCT01390155||4|Patients undergoing temporary myocardial ischemia produced by a one-minute occlusion of the target vessel.
3250927|NCT01390168|Experimental|tailored internet-administrated CBT|Behavioral: tailored internet-administrated CBT
3250928|NCT01390168|Active Comparator|waitlist|waitlist
3250929|NCT01390194||subjects with an underlying liver disease|(1)underlying liver disease; (2) have a lesion on a prior imaging study; (3) must be prior standard MR
3250930|NCT01390207|Experimental|16mm follicles|
3250931|NCT01390285|Experimental|TENS|
3250932|NCT01390285|Sham Comparator|Sham TENS|
3250933|NCT01390311|Active Comparator|Control Cohort|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~No Azacitidine will be given"
3365697|NCT04063969||Endovascular team members|"All vascular surgeons, surgical trainees, nurses active in the hybrid angiography suite at one of the participating centers will be invited to participate in the study.~All participating team members complete an online questionnaire containing an assessment of their perceived radiation safety climate (28 items, 5 dimensions), radiation safety behaviors(2 items, 2 dimensions), radiation safety knowledge (single item) and radiation safety motivation (single item). All data will be stored pseudonymized."
3365698|NCT04063969||Vascular surgical patients|"In each center, five patients undergoing primary elective endovascular repair for an infrarenal abdominal aortic aneurysm (EVAR) will be enrolled in the study.~For each participating patient, a set of demographical (BMI, case difficulty, ASA-grade,etc.), procedure-related (procedure duration, contrast use, etc.) and radiation dose parameters (DAP, cumulative air kerma) will be collected and stored in a pseudonymized way.~Participation in this study has no effect on the interventional procedure, or the chosen approach."
3365699|NCT04062708|Experimental|Treatment|Combined neoadjuvant platinum doublet chemotherapy plus durvalumab followed by surgery, postoperative radiation and adjuvant durvalumab for 13 cycles.
3365700|NCT04062630|Active Comparator|Standard care|Multilevel Lumbar Fusion Surgery
3365701|NCT04062630|Experimental|Standard Care + iFuse 3-D|Multilevel Lumbar Fusion Surgery with additional placement of iFuse 3-D in a trajectory parallel to the S2AI screws
3365705|NCT04047056|Placebo Comparator|Ergonomic Guidelines Manual|A manual of ergonomic occupational and daily living guidelines will be given to both control and labor kinesiotherapy groups, which is the only approach for the control group initially.
3365706|NCT04047056|Active Comparator|Labor Kinesiotherapy in group|The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.
3365707|NCT04040231|Experimental|Malignant Pleural Mesothelioma (MPM)|Participants with previously treated Malignant Pleural Mesothelioma/MPM
3365708|NCT04037254|Experimental|Phase I (niraparib, GnRH, IMRT)|Patients receive niraparib PO QD and receive standard of care GnRH agonist androgen suppression therapy. Treatment with niraparib continues for 12 months, and GnRH agonist therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib and GnRH agonist, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks, depending on type of radiation therapy given, in the absence of disease progression or unacceptable toxicity.
3250934|NCT01390311|Experimental|Cohort 1 (Starting Dose)|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 45 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
3250935|NCT01390311|Experimental|Cohort 2|"Pre-DLI Salvage Chemotherapy (at the discretion of the treating physician)~DLI will be administered 2 +/- 1 weeks after pre-DLI chemotherapy. The minimum CD3+ cell counts in DLI product should be 1 x 107 cells/kg for sibling and ~1 x 106/kg for match unrelated donors based on recipient weight~Azacitidine 75 mg/m2 IV on Days 4, 6, 8, and 10 post-DLI."
3250936|NCT01390324|Experimental|Fixed-dose combination of naratriptan+naproxen|Fixed-dose combination of naratriptan+naproxen
3250937|NCT01390324|Active Comparator|Naratriptan|Naratriptan
3250938|NCT01390324|Active Comparator|Naproxen|Naproxen
3250939|NCT01390337|Experimental|AC220|
3250940|NCT01390350|Placebo Comparator|Placebo|
3250941|NCT01390350|Experimental|Canakinumab|
3250942|NCT01390363|No Intervention|control|This study arm will receive usual clinical care, but no specific intervention will be made to inform the parent or adolescent that the adolescents is overdue for a routine vaccine.
3250943|NCT01390363|Experimental|Parent Only Group|Parent Only Phone Call
3250944|NCT01390363|Experimental|Parent and Adolescent Group|Parent and Adolescent Phone Call
3250945|NCT01390376|Experimental|BE 1|DAAOI-1 1g
3250946|NCT01390376|Experimental|BE 2|DAAOI-1 2g
3250947|NCT01390376|Placebo Comparator|starch pill|
3250948|NCT01390454|Experimental|Tennis elbow patients|These patients have tennis elbow, according to stated inclusion criteria.
3250949|NCT01390454|Active Comparator|Healthy volunteers|Healthy volunteers are selected and paired according to age, sex, socio-professional category and left- or right-handedness.
3250950|NCT01390480|Placebo Comparator|Placebo|peanut oil
3250951|NCT01390480|Active Comparator|Vitamin D (Oleovit®)|cholecalciferol
3250952|NCT01390493|Experimental|neurofeedback, alpha power|
3250953|NCT01390506|Active Comparator|Sodium-selenite infusion|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
3250954|NCT01390506|Placebo Comparator|Placebo|0.9% sodium chloride
3250955|NCT01390519||Afinitor|Afinitor
3250956|NCT01390545|Active Comparator|Veltuzumab 80 mg|
3250957|NCT01390545|Active Comparator|Veltuzumab 160 mg|
3250958|NCT01390545|Active Comparator|Veltuzumab 320 mg|
3250959|NCT01390545|Placebo Comparator|Placebo|
3250960|NCT01390558||Persons with Down Syndrome who use orthotics|Orthotic users
3250961|NCT01390558||Persons with Down Syndrome who do not use orthotics|Non orthotic users
3250962|NCT01390636||ED-DMT1 and ED/only|Eating Disorder and Type 1 Diabetes and only an Eating Disorder
3365709|NCT04037254|Active Comparator|Phase II, Arm I (GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months in the absence of disease progression or unacceptable toxicity. Beginning 8-28 weeks after starting GnRH agonist, patients undergo IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
3365710|NCT04037254|Experimental|Phase II, Arm II (niraparib, GnRH, IMRT)|Patients undergo standard of care GnRH agonist androgen suppression therapy for 24 months, and niraparib PO QD for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 8 weeks after starting niraparib, patients undergo standard of care IMRT 5 days per week for about 6-9 weeks depending on type of radiation therapy given in the absence of disease progression or unacceptable toxicity.
3365711|NCT04035499|Experimental|Experimental Arm:single|GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©® is a progressive walking and resistance exercise program
3250963|NCT01390662|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 24 weeks.
3250964|NCT01390662|Placebo Comparator|placebo|one tablet of sugar pill per day for 24 weeks.
3365712|NCT04030026|Active Comparator|Arm 1a: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 1
3365713|NCT04030026|Placebo Comparator|Arm 2a: Placebo|Placebo twice a day for Treatment Period 1
3365714|NCT04030026|Placebo Comparator|Arm 1b: Placebo|Placebo twice a day for Treatment Period 1
3365715|NCT04030026|Active Comparator|Arm 2b: Nalbuphine ER|Active tablets containing the study drug being tested (NAL ER) twice a day for Treatment Period 2
3250965|NCT01390688||Type 2 Diabetes|80 individuals with type 2 Diabetes, confirmed by an OGTT, age 40-65 years, BMI > 18.5 kg/m2 fatsing plasma glucose < 12 mmol/l
3365716|NCT04026191|Other|Orthovisc-T|
3365721|NCT04021784|Experimental|Spring Distraction System (SDS)|The SDS will be placed and fits around a standard rod of 5.5mm.
3365722|NCT04021784|Experimental|Necker Enfants Malade OSTeosynthesis (NEMOST)|The NEMOST is a one-way-rod that uses a ratchet type of locking mechanism. Both NEMOST devices should be placed in parallel, on the two fixator rods that are connected with a cross connector
3365723|NCT04018495|Experimental|Interventional - Fitbit tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
3365724|NCT04007146|Experimental|Cardiac Output Measurement|Subject will have a usual cardiac output
3365725|NCT04006769|Experimental|Entacapone & Imatinib mesylate|"Entacapone 200mg tablet (Orion pharma,Switzerland) by mouth, three times a day and then escalated to final dose of 1.0 grams three times per day within one week, until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first.~And Imatinib mesylate 400mg tablet by mouth, once a day until disease progression, intolerable toxicity, or withdrawal of informed consent, whichever occurs first."
3365726|NCT03993691|Experimental|All Participants|Participants that have undergone standard of care, conventional 2D radiographic imaging of wrist for presumed or known scaphoid, wrist or distal radius fractures will receive the Tomo-E scans within two weeks.
3365727|NCT03993574|Other|Standard Care|The standard care group will receive baseline testing #1, standard care, baseline testing #2 and follow up testing approximately 8 weeks later.
3365728|NCT03993574|Experimental|Experimental|Experimental group will baseline testing #1, standard care, baseline testing #2 however then participate in a 6-week self-management intervention (either generic or vision specific self-management based) and then get 8 week follow up testing.
3250966|NCT01390688||Impaired glucose tolerance|40 individuals with impaired glucose tolerance. age 40 -65 years, BMI > 18. 5 kg/m2
3250967|NCT01390688||Normal glucose tolerance|80 Individuals without type 2 diabetes Age 40-65 years, BMI >18.5 kg/m2.
3365729|NCT03990493|Experimental|PV-001-DV in Combination with PV-001-DC|Intratumoral injection of PV-001-DV (1 injection) and IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
3365730|NCT03989895|Experimental|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
3365731|NCT03989245||Target arm: UCC (Cognitive Behavioural Unit)|Patients receiving care in Cognitive Behavioural Unit (UCC )
3365732|NCT03989245||Control arm: SSR (Geriatric Follow-up and Rehabilitation Unit)|Patients receiving care in Geriatric Follow-up and Rehabilitation Care Unit (SSR)
3365733|NCT03977584|Experimental|[^18F]GTP1 in Mutation Carriers: Crenezumab|Mutation-carrying participants receiving crenezumab in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
3365734|NCT03977584|Placebo Comparator|[^18F]GTP1 in Mutation Carriers: Placebo|Mutation-carrying participants receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
3365735|NCT03977584|Placebo Comparator|[^18F]GTP1 in Non-carriers of Mutation: Placebo|Non-carriers of the mutation receiving placebo in the main study NCT01998841 (GN28352) will receive up to three IV injections of [^18F]GTP1 and will undergo a tau PET scan after each IV injection of [^18F]GTP1.
3250968|NCT01390701|Experimental|transcutaneous electr. nerve stimulation|
3250969|NCT01390701|Active Comparator|felodipin|
3250970|NCT01390714|Experimental|1|
3250971|NCT01390714|Experimental|2|
3250972|NCT01390727|Placebo Comparator|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
3365736|NCT03971253||Peficitinib|Participants will receive peficitinib once daily after meal.
3250973|NCT01390727|Active Comparator|Device-guided breathing|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
3250974|NCT01390740||Echocardiography|patients with echocardiography
3365737|NCT03970746|Experimental|Cohort A1|PDC*lung01 Low Dose
3365738|NCT03970746|Experimental|Cohort A2|PDC*lung01 High Dose
3365739|NCT03970746|Experimental|Cohort B1|PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment
3365740|NCT03970746|Experimental|Cohort B2|PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment
3365741|NCT03969420|Experimental|Stage 1: Arm 1|Refractory (i.e., failed to achieve a CR/CRi or achieved a CR/CRi with duration <90 days)
3365742|NCT03969420|Experimental|Stage 1: Arm 2|Relapsed (i.e., reoccurrence of disease following a CR/CRi with duration ≥90 days).
3365743|NCT03965377|Experimental|Home Safety Hero game play|Home Safety Hero is parental psychoeducational computer game to prevent childhood injuries
3365744|NCT03962894|Experimental|Early Prehospital Systemic Corticosteroids|Children with asthma attacks who receive systemic corticosteroids in the prehospital environment by emergency medical services
3365745|NCT03962894|No Intervention|Usual Care|Children with asthma attacks treated by emergency medical services who receive usual care en route to emergency departments, where in the ED they then receive systemic corticosteroids
3365749|NCT03951103||Hemophili A patients|Patients treated with rFVIIIFc for ITI
3250975|NCT01390753|No Intervention|Preterm formula|
3250976|NCT01390753|Active Comparator|Donor milk + preterm formula|Human milk from a donor bank
3250977|NCT01390753|No Intervention|Breastfeeding + formula|
3250978|NCT01390753|No Intervention|Breasfeeding|
3250979|NCT01390766||Subjects prescribed azathioprine tablet|Subjects prescribed azathioprine tablet during study period after the liver transplantation
3250980|NCT01390792||Subjects prescribed zanamivir|Subjects prescribed zanamivir during study period
3250981|NCT01390805||Subjects with recurrent genital herpes|
3250982|NCT01390831|Experimental|Catheter, Renal Denervation, Ablation|Catheter-based renal denervation and maintenance of anti-hypertensive medications
3250983|NCT01390831|No Intervention|anti-hypertensive medications|Maintenance of anti-hypertensive medications
3250984|NCT01390883||Patients prescribed fondaparinux|Patients undergoing abdominal surgery in urology, obstetrics and gynecology departments prescribed fondaparinux during study period
3250985|NCT01390896||Patients prescribed fondaparinux|Patients undergoing general surgery of the lower limb at high risk for venous thromboembolism
3365757|NCT03943277||patient with infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~A group with an inflammatory syndrome and infection; infection being defined as:~Viral infection confirmed by nasopharynx swab for: influenza, RSV, parainfluenza, rhinovirusses, coronavirusses.~Bacterial infection confirmed with positive blood culture, positive articular punction, positive expectorations, pneumonia on chest radiograph, or infection documented by abdominal imagery (CT or echo), a positive urine culture with a confirmed pyelonephritis with a renal echography or a DMSA scintigraphy or specific clinical symptoms for pyelonephritis and positive hemoculture. A positive urine culture alone is not considered as urine infection because of the high prevalence of asymptomatic bacteriuria in geriatric patients."
3250986|NCT01390922||Subjects prescribed botulinum injection|Subjects prescribed botulinum injection
3250987|NCT01390935||systolic heart failure|EF under 45%
3250988|NCT01390974||Patients treated for ACS|ACS patients who recently underwent stent PCI, who are stable and eligible for prasugrel or clopidogrel therapy.
3250989|NCT01391026|No Intervention|Usual care|
3250990|NCT01391026|Experimental|Enhanced patient-centered care|Patients will be evaluated and treated in the advanced illness management clinic
3250991|NCT01391039|Experimental|Contrast perfusion and elastography arm|Intravenous injection of microbubble contrast agent and elastography
3250992|NCT01391052|Active Comparator|Norethindrone acetate pretreatment|This arm will receive two cycles of norethindrone acetate before LVN IUS insertion.
3250993|NCT01391052|Other|No pretreatment|LVN IUS is placed without norethindrone acetate pretreatment.
3250994|NCT01391065|Other|1|The study arm will undergo baseline multifunctional PET and MRI scans, before brachytherapy and at follow up
3365758|NCT03943277||patient without infection|"Acute inflammation is defined as a CRP ≥ 10 mg/l. We will include 2 groups of participants:~=> B) A group with inflammatory syndrome and inflammatory diseases without infection: defined as:~Confirmed pulmonary embolism (PE) by CT or ventilation-perfusion scintigraphy~Microcrystalline arthritis diagnosed by articular punction~Crush syndrome or rhabdomyolyses defined by history of a fall and raised creatine kinase in blood sample."
3365759|NCT03942211|Experimental|Selexipag 200 micro gram (μg)|Study intervention will be up-titrated to allow each participant to reach their individual maximum tolerated dose (iMTD), in the range of 200 μg to1600 μg (ie, 1 to 8 tablets) bid/qd. Dosing frequency will be bid, except for participants with moderate hepatic impairment (Child-Pugh B) or who are concomitantly taking (a) moderate CYP2C8 inhibitor(s), who receive study intervention qd. The dose will be up-titrated by the investigator/delegate in 200 μg bid/qd increments at weekly intervals during scheduled TCs until reaching the iMTD. If the dose regimen is not well tolerated or symptoms cannot be fully managed with symptomatic treatment, the duration of the titration step can be prolonged to 2 weeks. If needed, the dose can be reduced by 200 μg bid/qd.
3365760|NCT03942211|Placebo Comparator|Placebo|The comparator will be administered similarly to the experimental intervention.
3250995|NCT01391078|Experimental|Sensimed Triggerfish|
3250996|NCT01391078|Active Comparator|Goldmann Applanation Tonometry/Perkins Tonometry|
3365761|NCT03940703|Experimental|Tepotinib and Osimertinib|Participants will receive a combination of tepotinib and osimertinib. The combination will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
3365762|NCT03940703|Experimental|Tepotinib Mono-therapy|Participants will receive once daily dose of tepotinib. The mono therapy will be applied in cycles of 21 days until disease progression, death, adverse event leading to discontinuation, study withdrawal or consent withdrawal.
3365763|NCT03938272|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes Strain HC-1
3365764|NCT03934684|Experimental|Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 56 mg/m2 starting on day 8 of cycle 1 and thereafter.~Dexamethasone 20 mg taken by mouth or intravenously on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle. An individual subject will receive study treatment for a maximum of 3 years if the subject has not yet experienced disease progression"
3365765|NCT03934684|Experimental|Carfilzomib+Lenalidomide+Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib is 20 mg/m2 on days 1 and 2, and if tolerated, escalated to a target dose of 27 mg/m2 starting on day 8 of cycle 1 and thereafter. From cycle 13, the day 8 and day 9 doses of Carfilzomib will be omitted.~Lenalidomide 25 mg is taken orally on days 1 to 21.~Dexamethasone 40 mg on days 1, 8, 15, and 22 of the 28-day cycles. An individual subject will receive study treatment for a maximum of 18 months consistent with the approved use in this combination."
3365767|NCT03925181|Experimental|Intervention|Recovery counselling group.
3365768|NCT03925181|No Intervention|Waitlist control|Waitlist control group. Will receive intervention after arm one is complete.
3365769|NCT03925142|Active Comparator|Controlled healthy vegetarian diet|Subjects will be randomized and assigned to consume the controlled Healthy Vegetarian Eeating Pattern for 5 weeks.
3365770|NCT03925142|Experimental|Controlled beef diet|Subjects will be randomized and assigned to consume the beef diet for 5 weeks, which will substitute predominantly starchy vegetables and refined grains with 6 oz. of lean unprocessed beef/day.
3365773|NCT03917472|Experimental|Brolucizumab 6mg q4w|Brolucizumab 6 mg/0.05 mL every 4 weeks.
3365774|NCT03917472|Active Comparator|Aflibercept 2mg q4w|Aflibercept 2mg/0.05 mL every 4 weeks
3365775|NCT03916627|Experimental|Cohort A1|Cemiplimab prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
3365776|NCT03916627|Experimental|Cohort A2|Cemiplimab and platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC)
3365777|NCT03916627|Experimental|Cohort A3|Platinum doublet prior to surgery; cemiplimab and platinum doublet post surgery (NSCLC) No longer enrolling
3365778|NCT03916627|Experimental|Cohort B|Cemiplimab prior to surgery; cemiplimab post surgery (HCC)
3365779|NCT03916627|Experimental|Cohort C|Cemiplimab prior to surgery; standard of care radiation and/or chemotherapy followed by cemiplimab post surgery (HNSCC) No longer enrolling
3365780|NCT03916627|Experimental|Cohort B2|SBRT 8 Gy X 3 fractions followed by cemiplimab prior to surgery; cemiplimab post surgery (HCC)
3250997|NCT01391091|Active Comparator|Patients without history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
3250998|NCT01391091|Active Comparator|Patients with history of migraine|Incidence and prevalence of migraine episodes in the post-ablation period
3250999|NCT01391104|Experimental|Sildenalfil|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
3251000|NCT01391104|Placebo Comparator|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
3251001|NCT01391117|Experimental|010|TMC649128 panel 4 arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128 administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
3251002|NCT01391117|Experimental|001|TMC649128. panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
3365790|NCT03910621|Experimental|Miglustat|Miglustat is administered three times a day as an oral capsule
3365791|NCT03909685|Experimental|the intervention arm|During the course of the study, the participants in the intervention arm will use the Ask RoSE application daily. Participants will receive weekly in-person psychotherapy for a total of four sessions over four weeks. Licensed therapists will provide the in-person psychotherapy
3365792|NCT03909685|No Intervention|a waitlist control arm|The participants in the waitlist arm will serve as controls unless there is attrition from the intervention group at which time waitlist participants will be offered a spot in the intervention arm
3365795|NCT03904693|Experimental|FDC therapy + Placebo macitentan + Placebo tadalafil|Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.
3365796|NCT03904693|Active Comparator|Macitentan mono-therapy + Placebo tadalafil + Placebo FDC|Subjects to receive macitentan 10 mg plus matching placebos for the two other study treatments.
3365797|NCT03904693|Active Comparator|Tadalafil mono-therapy + Placebo macitentan + Placebo FDC|Subjects to receive tadalafil 40 mg (2 x 20 mg) plus matching placebos for the two other study treatments.
3365798|NCT03897205|Experimental|Imlifidase|Subjects randomized to imlifidase treatment will receive one intravenous dose of imlifidase, 0.25 mg/kg, administered over 15 minutes.
3365799|NCT03897205|Active Comparator|Plasma Exchange|Subjects randomized to plasma exchange (PE) treatment will receive 5-10 sessions of PE, as judged by the investigator. Immunoadsorption (IA) may replace PE, at the discretion of the investigator.
3365806|NCT03893370|Active Comparator|Treatment|RJA MCS
3365807|NCT03893370|Sham Comparator|Sham Control|Sham
3365808|NCT03893318|Experimental|Study Group|will receive intravenous lidocaine during and after posterior spinal fusion for AIS
3251003|NCT01391117|Placebo Comparator|002|placebo. panel 1: 2 participants receive placebo at a q24h regimen.
3251004|NCT01391117|Experimental|003|TMC649128. panel 2 arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
3251005|NCT01391117|Placebo Comparator|004|placebo. panel 2 arm 1: 2 participants receive placebo at a q12h regimen.
3251006|NCT01391117|Experimental|005|TMC649128. panel 2 arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
3251007|NCT01391117|Placebo Comparator|006|placebo. panel 2 arm 2: 2 participants receive placebo at a q24h regimen.
3251008|NCT01391117|Experimental|007|TMC649128 panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
3251009|NCT01391117|Placebo Comparator|008|placebo. panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
3251010|NCT01391117|Placebo Comparator|009|placebo panel 4 arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo administered q12h or q24h for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1 2 and 3.
3251011|NCT01391143|Experimental|MGA271|Fc-optimized, humanized monoclonal antibody
3251012|NCT01391156|Experimental|Minoxidil|
3251013|NCT01391156|Active Comparator|MinoxidilFinasteride|
3251014|NCT01391169|Active Comparator|1sup group|enforcement of the anastomoses with seromuscular flap
3251015|NCT01391169|Placebo Comparator|2nd group|primary anastomosis without enforcement
3365809|NCT03893318|Placebo Comparator|Control Group|will receive saline placebo during and after surgery.
3251016|NCT01391182|Active Comparator|EACA arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
3365812|NCT03865719|Other|Healthy Habits for Life Intervention|Participants will receive the Healthy Habits for Life Intervention
3251017|NCT01391182|Placebo Comparator|Placebo arm|In order to obtain sufficient power, a total of 120 patients will be studied, 60 in each group. The surgeon performing the case, their staff, the anesthesiologist, nurse anesthetist and the patient will be blinded to whether the patient received EACA or placebo. Pharmacy will prepare the EACA dose or the saline. Serum hemoglobin levels with be drawn preoperatively and on post operative days one, two, and three. The first dose will be given in the operating room prior to incision (within 30 minutes of the incision). The second dose will be given four hours after the first dose. Two doses are given due to the short half-life of EACA. The timing of administration of EACA will be recorded.
3251018|NCT01391195|Experimental|Laser therapy and aerobic capacity|Effects of low level laser therapy on aerobic capacity of young women submitted to endurance training
3365819|NCT03851380||Treatment Resistant Major Depression|Patients with treatment resistant major depression
3365820|NCT03851380||COVID Stress|Veterans with COVID-19-related distress
3365825|NCT03842358|Experimental|Phase I - Training Set|"20 patients will be recruited to undergo US-DOT and CEM to allow for training study readers in assessing US-DOT data, intra-observer variability and to assess inter-observer variability in the assessment of US-DOT data~A hand-held hybrid probe will be used for the scans"
3365826|NCT03842358|Experimental|Phase 2: Prospective Trial|"US-DOT (US/NIR) Imaging Exam~Breast biopsy or FNA performed (standard of care)~A hand-held hybrid probe will be used for the scans"
3365827|NCT03840642|Active Comparator|Mirror Me|Parents randomized to the Mirror Me condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then they will be told their condition and to continue to use the website and practice what they have learned with their children.
3365828|NCT03840642|Experimental|Mirror Me Plus Remote Coaching|Parents randomized to the Mirror Me plus remote coaching condition will complete the 4 Mirror Me modules over a period of 5 weeks (~1 per week plus a week to practice). They will be provided with a visual guide for how to access the website. At 5 weeks, they will complete a remote parent-child interaction. Then all parents in this condition will be told about the opportunity to participate in remote video teleconferences once per week for 5 weeks. Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week. Sessions will be recorded for data collection and therapist coaching fidelity. Participants will have access to Mirror Me for the duration of the research study.
3365829|NCT03832010|Active Comparator|Crisaborole|Participants will be instructed to apply emollient, topical steroid, and or crisaborole (blinded) to affected areas with eczema.
3251019|NCT01391208|No Intervention|peptide application|
3365830|NCT03832010|Placebo Comparator|Vehicle|Participants will be instructed to apply emollient, topical steroid, and or vehicle (blinded) to affected areas with eczema.
3365831|NCT03832010|Sham Comparator|Control|Participants will be instructed to apply emollient, topical steroid, and or emollient (blinded) to affected areas with eczema.
3365832|NCT03824223|Other|new/old HCT component order|"new/old hypoxic challenge test (HCT) component order~Where the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen and the old test uses pulse oximetry to titrate supplementary oxygen."
3365833|NCT03824223|Other|old/new HCT component order|"old/new hypoxic challenge test (HCT) component order~Where the old test uses pulse oximetry to titrate supplementary oxygen and the new test uses pulse oximetry and transcutaneous CO2 monitoring to guide use of ventilatory support and if necessary supplementary oxygen."
3365834|NCT03819478|Placebo Comparator|RecProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Lower protein / higher CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Carbohydrate supplement for months 0-6 (blinded). Follow-up months 7-18.
3365835|NCT03819478|Active Comparator|6-mo HiProt|Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643): Higher protein / lower CHO diet for the 6-month weight loss phase. Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Follow-up months 7-18.
3365836|NCT03819478|Active Comparator|18-mo HiProt|"Subjects receiving the following interventions in the parent trial (UPLIFT; NCT03074643):~Higher protein / lower CHO diet for the 6-month weight loss and 12-month follow-up phases.~Exercise intervention months 0-6. Weight loss intervention months 0-6. Protein supplement for months 0-6 (blinded). Protein supplement for follow-up months 7-18."
3365837|NCT03817125|Placebo Comparator|SER-401 Matching Placebo/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic placebo, then matching placebo for SER-401 and nivolumab (480 mg) treatment.
3365838|NCT03817125|Experimental|SER-401/ Nivolumab|Participants will undergo a 4-day lead-in pretreatment with antibiotic (vancomycin) to prime the gut microbiome for engraftment of the oral microbiome study intervention, then SER-401 and nivolumab treatment.
3365839|NCT03816176|Experimental|Isavuconazonium sulfate|Participants will receive a loading dose of isavuconazonium sulfate (via intravenous or oral administration at the investigator's discretion) every 8 hours (± 2 hours) on Days 1 and 2 followed by once-daily maintenance dosing
3365844|NCT03807778|Experimental|TAK-788, Phase 1 Part|TAK-788 40 milligrams (mg) (as the starting dose), capsules, orally, once daily on Days 1-28 of each 28-day treatment cycle for up to disease progression or intolerable toxicity, or another discontinuation criterion, and increasing until 160 mg, once daily (for up to approximately 10-12 cycles).
3365845|NCT03807778|Experimental|TAK-788, Phase 2 Part|TAK-788 160 mg, once daily, for up to approximately 10-12 cycles.
3365846|NCT03803397|Experimental|PV-001-DC alone|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells
3251020|NCT01391221|Experimental|Duloxetine treatment|Subjects with major depression will be entered into the trial and treated with open label duloxetine
3251021|NCT01391234|Experimental|STAT RT planning and delivery workflow|single arm
3251022|NCT01391247||healthy age machted controls|
3251023|NCT01391247||normal tension glaucoma patients|
3251024|NCT01391247||primary open angle glaucoma patients|
3251025|NCT01391260|Experimental|Radiotherapy Combined With Gefitinib|
3251026|NCT01391338|Experimental|Lowest dose ASP3652 twice daily|
3251027|NCT01391338|Experimental|Low dose ASP3652 twice daily|
3251028|NCT01391338|Experimental|Medium dose ASP3652 twice daily|
3251029|NCT01391338|Experimental|High dose ASP3652 once daily|
3251030|NCT01391338|Experimental|High dose ASP3652 twice daily|
3251031|NCT01391338|Placebo Comparator|Placebo|
3251032|NCT01391351|Other|Taxol and carboplatin|blood samples in patients receiving Taxol and carboplatin chemotherapy
3251033|NCT01391351|Other|Taxol, carboplatin and avastin|blood samples in patients receiving Taxol, carboplatin chemotherapy with avastin
3251034|NCT01391377|Active Comparator|Niacin / Laropiprant|
3251035|NCT01391377|Placebo Comparator|Sugar Pill (Placebo)|
3251036|NCT01391390|Experimental|Melatonin, antioxidant, oxidative stress|Melatonin is an active treatment for TD.
3251037|NCT01391390|Placebo Comparator|Placebo|Placebo look like the active drug, and same dose.
3251038|NCT01391403|Experimental|Artemisinin, anti-toxoplasma|Artemisinin
3251039|NCT01391403|Placebo Comparator|Placebo|Placebo looks like the active drug, with the same dose.
3251040|NCT01391416||CKD stage 3-4|CKD stage 3-4 from Thai SEEK study
3251041|NCT01391416||hyperhomocysteine group|CKD stage 3-4 from Thai SEEK study
3365852|NCT03783026|Experimental|Administration of CC-10004|Apremilast 30 mg BID in monotherapy or in combination with Methotrexate
3365853|NCT03775421|Experimental|Open-label treatment period|oral administration of 10 mg macitentan once daily
3365858|NCT03750279|Active Comparator|Exercise therapy + LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.~LLLT applied to the knee 3 times per week for 3 weeks from baseline."
3365859|NCT03750279|Placebo Comparator|Exercise therapy + sham LLLT|"Exercise therapy 3 times per week for 8 weeks from baseline.~Sham LLLT applied to the knee 3 times per week for 3 weeks from baseline."
3365860|NCT03740009|Experimental|Perimenopausal women, depressed|Participants will take Bazedoxifene/Conjugated Estrogen orally for 3 weeks
3365861|NCT03734666|Experimental|Mindfulness Based Relapse Prevention|Participants will receive Mindfulness Based Relapse Prevention (MBRP), an existing substance use treatment, which has been modified to focus explicitly on smoking cessation and reduced alcohol use, creating Mindfulness Based Relapse Prevention - Smoking and Alcohol (MBRP-SA).
3365862|NCT03734666|Active Comparator|Cognitive Behavioral Therapy|Participants will receive Cognitive Behavioral Therapy (CBT) a well-established and commonly used treatment for substance abuse behaviors that utilizes problem solving and coping skills.
3365863|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled prior to July 2020 (Cohort 1)|ACRYSOF IQ RESTOR Multifocal Toric IOL (+3.0 D or +2.5 D) implanted in at least one eye during cataract surgery
3365864|NCT03733730|Experimental|ACRYSOF IQ RESTOR subjects enrolled after July 2020 (Cohort 2)|ACRYSOF IQ RESTOR +3.0 D Multifocal Toric IOL or ACRYSOF IQ RESTOR +2.5 D Multifocal IOL implanted in at least one eye during cataract surgery
3365865|NCT03733132|Placebo Comparator|Placebo|Participants in placebo group will receive Placebo Oral Tablets identical to the metformin tablets for 10 months.
3365866|NCT03733132|Active Comparator|Metformin|Participants in placebo group will receive an escalating dose of Metformin hydrochloride tablets up to a dose of 2500mg for 10 months.
3251042|NCT01391429|Experimental|Video decision support tool|Video decision support tool for goals-of-care options
3365869|NCT03728985|Active Comparator|Primary Study Arm|TAAA requiring only TAMBE System. Crawford Type IV TAAA and Pararenal (n= 102)
3365870|NCT03728985|Experimental|Secondary Study Arm|TAAA requiring TAMBE System and CTAG Device(s). Crawford Type I-III (n= 20 - 100)
3365871|NCT03728088||Surgical Candidates|"Under- and postgraduate candidates applying for surgical training in general surgery, orthopedics, urology or plastic surgery at Ghent University Hospital.~All candidates will complete the rating scales concerning non-technical attributes in the period prior to the surgical selections."
3365872|NCT03728088||Surgical trainees|"Surgical trainees active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital or an affiliated non-academic training hospital.~All trainees will be invited to participate in the study. Trainees who agree to participate will complete the rating scales concerning non-technical attributes."
3365873|NCT03728088||Surgical staff|"Surgical staff members active in general surgery, orthopaedics, urology or plastic surgery, at Ghent University Hospital.~All surgical staff members will be invited to participate in the study. Surgical staff members who agree to participate will complete the rating scales concerning non-technical attributes."
3251043|NCT01391429|No Intervention|Verbal description|Standard verbal description of goals-of-care options provided by an inpatient palliative care team
3251044|NCT01391442|Other|family|each family, composed of 4 characters at least, is studied
3251045|NCT01391455|No Intervention|Spermatic Cord in contact with mesh|Where the spermatic cord has been allowed to remain in contact with the mesh.
3251046|NCT01391455|Experimental|Spermatic Cord is isolated from the mesh|The inguinal ligament is interposed between the cord and the mesh and then repaired. This isolates the cord from the mesh and the splinting function of the overlying inguinal ligament.
3251047|NCT01391481|Experimental|Perfluorocarbon|
3251048|NCT01391481|Placebo Comparator|Sterile Water for Injection|
3251049|NCT01391494|Experimental|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3251050|NCT01391494|Experimental|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3251051|NCT01391494|Experimental|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
3251052|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
3251053|NCT01391494|Placebo Comparator|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
3365877|NCT03724396|Experimental|Novel Executive Function Training - NEXT|Same as BWL with some additional strategies targeted at improving executive function to help adherence to BWL skills.
3365878|NCT03724396|Active Comparator|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
3365879|NCT03721952|Experimental|Facilitator-Based Intervention|The 'Facilitator-Based Intervention' includes patient and family member subjects.
3251054|NCT01391494|Experimental|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3251055|NCT01391494|Experimental|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3365880|NCT03721952|No Intervention|Usual Care|The 'Usual Care' arm includes patient and family member subjects.
3365881|NCT03706690|Experimental|Durvalumab Therapy|Durvalumab (PD-L1 monoclonal antibody)1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/deterioration or confirmed radiological progression)
3251056|NCT01391494|Experimental|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
3251057|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
3251058|NCT01391494|Placebo Comparator|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
3251059|NCT01391494|Experimental|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3365882|NCT03706690|Placebo Comparator|Placebo Therapy|Placebo (matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression)
3365883|NCT03699553|Experimental|Intervention|Participants will receive the online LARKSPUR intervention which lasts about 5-6 weeks, receiving the positive emotions skills through the website, and logging on to the website for about 5-10 minutes each day for that period. Assessments will be taken at baseline, post-intervention (8 weeks after the baseline), and 12 weeks after baseline (1 month post intervention).
3365884|NCT03699553|Active Comparator|Emotion Reporting Control|Participants will report their emotions for 5-6 weeks by logging on to the website for about 5 minutes each day. Assessments will be taken at baseline, 8 weeks after baseline, and 12 weeks after baseline. After 12 weeks, participants will receive access to the LARKSPUR intervention online.
3365885|NCT03691974|Experimental|Fasinumab|
3251060|NCT01391494|Experimental|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3251061|NCT01391494|Experimental|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
3251062|NCT01391494|Experimental|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
3365886|NCT03691974|Placebo Comparator|Placebo|
3251063|NCT01391494|Placebo Comparator|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
3251064|NCT01391520|Experimental|CRMD001-Deferiprone|CRMD001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
3251065|NCT01391520|Placebo Comparator|Placebo|3 placebo tablets matching the appearance of the experimental treatment arm (CRMD001) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
3365890|NCT03689244|Experimental|Selexipag DB|During the double blind treatment period, participants in this group will receive selexipag. Each participant will start with one oral tablet of selexipag 200 µg in the evening of Day 1 and will continue with 200 µg twice daily (b.i.d.) on Day 2. If this dose is well-tolerated, selexipag is up-titrated with weekly increments of 200 µg until reaching the individual maximal tolerated dose (iMTD) in the range of 200 to 1600 µg b.i.d. The up-titration period up to Week 12 is followed by a stable maintenance treatment period from Week 12 to Week 26, at the iMTD. After Week 26, further up-titration can be allowed (but not above 1600 µg b.i.d.).
3251066|NCT01391533|Experimental|Dose Escalation|Dose escalation phase: The starting dose of SAR125844 will be 50 mg/m^2 up to 960 mg/m^2
3251067|NCT01391572|Experimental|A|After esophagectomy, patients in Arm A will receive Large field radiation (tumor bed + ENI (elective nodal irradiation)) + Sequential chemotherapy
3251068|NCT01391572|Active Comparator|B|After esophagectomy, patients in Arm B will receive small field radiation (tumor bed only) + Sequential chemotherapy
3251069|NCT01391585|Experimental|text message recipients|Patients will be recruited to receive text messages
3251070|NCT01391598|Active Comparator|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
3251071|NCT01391598|Placebo Comparator|Saline|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
3365891|NCT03689244|Placebo Comparator|Placebo DB|During the double-blind treatment period, participants in this group will receive the oral matching placebo, twice daily. A (mock) up-titration scheme will be followed.
3365892|NCT03689244|Experimental|Selexipag OL|All participants who completed the double-blind treatment period, whether they received placebo or selexipag during the double-blind period, will receive selexipag during the open-label extension period, using the same up-titration schedule as in the double-blind period.
3365893|NCT03681015||Cohort 1 - Parkinson's Disease Participants|Volunteers will be women and men with early, untreated Parkinson disease.
3365894|NCT03681015||Cohort 2 - Control Participants|Participants will be women and men without PD.
3365895|NCT03672643|Other|single arm|Crizotinib
3365896|NCT03655769|Sham Comparator|sham tDCS|tDCS delivered for only 30 sec to replicate tingling sensation and blind subject
3365897|NCT03655769|Experimental|cathodal tDCS|cathodal tDCS, 2 milliamps (mA), delivered to right parietal region
3365898|NCT03642769|Active Comparator|Lactated Ringer|Patients will receive fluid administration of Lactated Ringer's solution at a pre-determined volume algorithm that is the same for both arms
3365899|NCT03642769|Experimental|Normal Saline|Patients will receive fluid administration of Normal Saline solution at a pre-determined volume algorithm that is the same for both arms
3365900|NCT03641339|Experimental|Cohort A: One vector feeding and three biopsies|Undergo one vector feeding and three biopsies on Day 0
3365901|NCT03641339|Experimental|Cohort B: Four vector feedings and three biopsies|Undergo 4 vector feedings over 8 weeks and 3 biopsy procedures after the 4th and final feeding
3365902|NCT03625466|Experimental|Part 1: Placebo|Participants received placebo matched to LUM/IVA in placebo-controlled period for 48 weeks.
3251072|NCT01391624|Experimental|Omega 3|The group was treated with omega 3 fatty acids for 2 months.
3365903|NCT03625466|Experimental|Part 1: LUM/IVA|Participants weighing less than (<)14 kilograms (kg) at screening received LUM 100 milligrams (mg)/IVA 125 mg fixed-dose combination (FDC) every 12 hours (q12h) in placebo-controlled period for 48 weeks. Participants weighing greater than or equals to (>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h in placebo-controlled period for 48 weeks.
3365904|NCT03625466|Experimental|Part 2: Open Label Period|Participants <6 years of age will receive LUM/IVA as FDC granules dependent upon weight at Day 1. Participants >=6 years of age at or after the Week 48 Visit will receive LUM 200 mg/IVA 250 mg tablets q12h.
3365905|NCT03605719|Experimental|Arm 1|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3365906|NCT03605719|Experimental|Arm 2|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3251073|NCT01391624|Placebo Comparator|Placebo|The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
3365907|NCT03605719|Experimental|Arm 3 (expansion)|Patients receive dexamethasone IV on days 1, 2, 8, 9, 15, and 16, pelareorep IV on days 1, 2, 8, 9, 15, and 16, carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16, and nivolumab IV over 30 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3251074|NCT01391637||HuCNS-SC transplanted subjects in the lead-in phase|Subjects who had HuCNS-SC transplant in the lead-in phase study CL-N01-PMD
3251075|NCT01391650|Experimental|biomechanic of the knee|
3365914|NCT03580824|Experimental|Group 1|Group 1 adults (n=20) will be administered 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the non-dominant arm).
3365915|NCT03580824|Experimental|Group 2|"Group 2A children 1-5 years (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 2B children 1-5 years (n=17) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
3365916|NCT03580824|Experimental|Group 3|"Group 3A infants 5-<12 months (n=3) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3B infants 5-<12 months (n=3) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3C infants 5-<12 months (n=15) will be receiving 5mcg R21/25mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3D infants 5-<12 months (n=15) will be receiving 10mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid).~Group 3E infants 5-<12 months (n=15) will be receiving 5mcg R21/50mcg Matrix-M vaccine through intramuscular route (into the left deltoid)."
3251076|NCT01391676||Trabeculectomy|glaucoma patients undergoing trabeculectomy with mitomycin c 0,02%
3251077|NCT01391689|Experimental|Arm I (antineoplastic therapy)|Patients receive diindolylmethane (BioResponse) PO BID for approximately 18 months.
3365917|NCT03579394|Active Comparator|Interval Debulking Surgery (IDS)|Complete surgery after 3 courses of neoadjuvant chemotherapy (NACT)
3365918|NCT03579394|Experimental|Retarded Interval Debulking Surgery (IDS)|Complete surgery after 6 courses of neoadjuvant chemotherapy (NACT)
3365919|NCT03568461|Experimental|CTL019|tisagenlecleucel infusion
3365920|NCT03564587|Experimental|AWAKE|The AWAKE intervention is an 8 week program including a mobile app and phone-based coaching, focused on improving hope in order to increase quality of life and health-promoting behaviors in young adult cancer survivors.
3365921|NCT03564587|No Intervention|No treatment|Control participants will receive the surveys to complete only; however, they may opt to receive the intervention after the 4-month assessment.
3365923|NCT03554356|Experimental|Cryoballoon Focal Ablation System (CbFAS) Treatment|Subjects undergoing CbFAS treatment as part of their clinical care for their condition.
3365924|NCT03544632|Experimental|Acellular Adipose Tissue (AAT)|This open-label, phase II, dose-escalation study will be conducted in human subjects seeking repair of modest (approx. 5-30cc) soft tissue defects of the trunk (n=15). All participants will be treated via permanent injection of the study intervention (AAT injection) to restore the defect's contour. All study data will be collected in Case Report Forms (CRFs) and entered into a customized study database, created and maintained in HIPAA-compliant Research Electronic Data Capture (REDCap) software (14).
3365925|NCT03535129|No Intervention|Stage 1|Pilot portion to optimize intervention and achievecorrelational research aims
3365926|NCT03535129|Experimental|Stage 2|Main Clinical Trial with random assignment
3251078|NCT01391689|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for approximately 18 months.
3251079|NCT01391702||Labouring woman with epidural in situ|Any healthy English-speaking pregnant woman in labour who has received an epidural for pain relief
3365931|NCT03529890|Experimental|Radio-Immunotherapy before cystectomy|Single arm treatment with Nivolumab during a neoadjuvant radiation therapy of the pelvis before radical cystectomy with standardized pelvic lymphadenectomy
3251080|NCT01391715|Active Comparator|Double dose rabeprazole|Rabeprazole 20m bid per day will be given for 2 weeks
3251081|NCT01391715|Placebo Comparator|standard dose rabeprazole|rabeprazole 20mg per day will bi given for 2 weeks
3251082|NCT01391728|Active Comparator|Lifestyle counseling|
3251083|NCT01391728|No Intervention|Control|
3251084|NCT01391741|Experimental|Walking with visual cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
3251085|NCT01391741|Active Comparator|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4 times a week for 4 weeks.
3251086|NCT01391754|Experimental|SafeCare with Coached Implementation|Home-based services with the SafeCare model, implemented with in vivo provider coaching as quality control
3365934|NCT03523819|Experimental|CS1002|Participants will receive CS1002 intravenously at specified dose on specified days.
3365935|NCT03523819|Experimental|CS1003|Participants will receive CS1003 intravenously at fixed dose on specified days.
3251087|NCT01391754|Experimental|SafeCare without Coaching|Home-based services using the SafeCare model, implemented without in vivo coached implementation quality control
3251088|NCT01391754|Experimental|Services As Usual with Coaching|Usual home based services, with in vivo coached implementation quality control
3365938|NCT03504553|Experimental|Noise reduction|Reduced operating room personnel, low ambient light and soft background music during induction and emergence from anesthesia.
3365939|NCT03504553|No Intervention|Control|Normal operating room environment.
3365940|NCT03499795|Experimental|VGX-3100|Adult participants, who are HIV negative with histologically confirmed anal or anal/peri-anal HSIL associated with HPV-16 and/or 18, will receive VGX-3100 administered by IM injection followed immediately by EP using the CELLECTRA™ 5PSP device. Participants will receive at least 3 doses of VGX-3100 at Day 0, Week 4 and Week 12. For partial responders at Week 36, a fourth dose may be administered at Week 40. All participants are scheduled to be followed to Week 88.
3365948|NCT03492177|Experimental|open label selexipag|The first dose of selexipag (Uptravi) will be administered in the evening of Day 1 and will be based on the body weight. Thereafter selexipag will be administered twice daily (morning and evening). Selexipag will be up-titrated during the first 12 weeks, with weekly increments equal to the starting dose until the participants reach their individual maximum tolerated dose (iMTD) or until a maximum dose corresponding to their baseline weight category is achieved (which will be 8-fold of the corresponding starting dose). Up-titration is followed by a stable maintenance treatment period from Week 12 to Week 16, at the maximum tolerated dose. Thereafter, participants will be treated with selexipag as long as the treatment is beneficial to the participants, as per investigator's decision.
3365951|NCT03476239|Experimental|Blinatumomab|"Treatment consisted of two induction cycles and up to 3 consolidation cycles of treatment for responders.~In the first induction cycle, the initial dose of blinatumomab was 9 μg/day for Days 1-7 and then escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). This is followed by two weeks without blinatumomab treatment.~In subsequent cycles (beginning with the second induction cycle and continuing through consolidation, for applicable participants) 28 μg/day was administered for all 4 weeks of continuous treatment, followed by a treatment-free interval of two weeks."
3251089|NCT01391754|Active Comparator|Services As Usual Without Coaching|Usual home based services without in vivo coached quality control
3251090|NCT01391767||NuOss XC|Bone grafting material used in this group will be NuOss XC.
3365956|NCT03451799|Experimental|Ketogenic diet+radiation+temozolomide|Ketogenic diet in combination with standard-of-care radiation and standard-of-care temozolomide
3365957|NCT03443973|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
3365958|NCT03443973|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
3365959|NCT03438877|Experimental|Intervention group|Intervention group is intensive dosage of PD.
3365960|NCT03438877|Active Comparator|Control group|Control group is regular dosage of PD.
3365961|NCT03436862|Experimental|Nivolumab|Patients will receive Nivolumab 240 mg by intravenous infusion (IV) starting Day 45-120 post-transplant (±10 days) every 2 weeks for up to a maximum of 6 months of treatment.
3365962|NCT03428945|Experimental|Hydroxychloroquine|Hydroxychloroquine compound for oral use
3365963|NCT03428945|Placebo Comparator|Placebo|Placebo tablet matching active drug
3365964|NCT03427411|Experimental|1/Arm 1|M7824 at a flat dose of 1,200 mg IV once every 2 weeks
3365965|NCT03423121|Experimental|TUDCA Treatment|Tauroursodeoxycholic acid (Taurolite) 250 mg four capsules by mouth, twice daily for 16 weeks.
3251091|NCT01391767||NuOss Particulate|Bone grafting material used in this group will be NuOss Particulate.
3365966|NCT03423121|Placebo Comparator|Placebo oral capsule|Placebo oral capsule four capsules by mouth, twice daily for 16 weeks.
3365967|NCT03422328|Experimental|Open-label macitentan 10 mg|10 mg macitentan film coated tablet, administered orally once daily
3251092|NCT01391780||Group 1|Patients with stress urinary incontinence
3251093|NCT01391780||Group 2|Patients with urgency urinary incontinence.
3365968|NCT03417479||1:1 Randomization|Patients will be randomized to either a single dose of 15mg/kg up to 600 mg of gabapentin or a placebo equivalent at a 1:1 ratio. The subjects will be enrolled in the study at the orthopedic surgeon's office with randomization occurring on the day of surgery by the hospital pharmacist. The method for the randomization will be the creation of a sequence of sealed envelopes containing assignment information for a dose of 600 mg of gabapentin or placebo.
3365969|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 1|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: four 100 mg capsules under fasting conditions, followed by one 400-mg tablet under fasting conditions, then one 400 mg tablet under non-fasting conditions.
3365970|NCT03400306|Experimental|Part 2, Extension|Veliparib as monotherapy or in combination with carboplatin and paclitaxel, per investigators' discretion.
3365971|NCT03400306|Experimental|Part 1, Bioequivalence Sequence Group 2|Veliparib 400-mg doses administered orally on Day 1 of each 2-3 day period in Part 1 with the following sequence for the 3 dosing days: one 400-mg tablet under fasting conditions, followed by four 100 mg capsules under fasting conditions, then one 400 mg tablet under non-fasting conditions.
3365974|NCT03374800|Placebo Comparator|Placebo (0.9% saline)|Withholding Stress ulcer prophylaxis (intravenous 0.9% saline as placebo)
3365975|NCT03374800|Active Comparator|Stress Ulcer Prophylaxis (Pantoprazole)|pantoprazole 40mg powder for injection reconstituted with 0.9% saline
3365976|NCT03342716||Main cohort|Patients with a clinical or radiological diagnosis of acute pancreatitis (AP)
3365977|NCT03342716||Nested cohort|Subgroup of patients with a clinical or radiological diagnosis of acute pancreatitis (AP) who will undergo additional assessments and scans
3365978|NCT03317795|Active Comparator|Levonorgestrel IUS|Levonorgestrel-releasing intrauterine system (Mirena) contains 52 mg of levonorgestrel, a progestin, and is intended to provide an initial release of approximately 20 mcg/day. Levonorgestrel intrauterine system is effective immediately upon placement in the uterus and can be kept in place for up to 5 years.
3365979|NCT03317795|Active Comparator|Tranexamic Acid|Tranexamic Acid (Lysteda) is an antifibrinolytic drug. Tranexamic Acid will be dosed at 1300mg by mouth three times a day at the start of menses and used during the days that bleeding is heaviest (not to exceed 5 days per menstrual cycle).
3365980|NCT03315221|Experimental|Test product|Human Milk Fortifier (HMF) with added lipids.
3365981|NCT03315221|Active Comparator|Control product|Commercially available HMF (without lipids).
3365987|NCT03298659|Experimental|Active iFR-guided revascularization|Decision to treat the nonculprit coronary stenosis if there is a significant pressure drop over the stenosis, as measured by intracoronary iFR assessment
3365988|NCT03298659|Active Comparator|Deferred CMR-guided revascularization|Decision to treat the nonculprit coronary stenosis if perfusion defect visible in corresponding coronary territory as visualized on stress perfusion CMR imaging
3365989|NCT03294187|Experimental|Monitoring and Feedback|Subjects will use two wrist-worn wearables over a period of 6 weeks. Patients will receive multimodal (vibrotactile and visual) feedback.
3365990|NCT03294187|Placebo Comparator|Monitoring|Study subjects will use identical devices over a period of 6 weeks. Patients will *not* receive multimodal feedback.
3365991|NCT03287245|Experimental|Idasanutlin|Two cohorts of ruxolitinib-naïve and ruxolitinib-resitant or intolerant participants will be enrolled to receive idasanutlin once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years).
3251094|NCT01391806||Breast cancer|Patients selected for breast-conserving surgery based on conventional radiological methods, following the criteria recommended by the Norwegian Breast Cancer Group
3251095|NCT01391845|Experimental|UPA, 300UI FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
3251096|NCT01391845|Placebo Comparator|No UPA, 300FSH|patients on COS with 300UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
3365992|NCT03284723|Experimental|PF-06804103|Study Treatment
3365993|NCT03284723|Experimental|PF-06804103+Combination Regimen|Study Treatment
3365994|NCT03282656|Experimental|Treatment arm|open-label, non-randomized, single center, pilot and feasibility, single arm cohort study of a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with lentiviral vector containing a short-hairpin RNA targeting BC11A.
3251097|NCT01391845|Experimental|UPA, FSH 225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and ulipristal acetate use
3251098|NCT01391845|Placebo Comparator|no UPA, FSH225|patients on COS with 225UI FSHu/GnRH Antagonist protocol and without ulipristal acetate use
3365997|NCT03249090|Experimental|Patient Self-Reporting of Symptoms|Patients report symptoms weekly via web or automated telephone system. Email alerts to nurses for severe/worsening symptoms; printouts for clinicians at visits. Evidence based symptom management pathways provided to patients and clinicians.
3365998|NCT03249090|Active Comparator|Usual Care Delivery|Evidence-based symptom management pathways provided to patients and clinicians
3251099|NCT01391871||PRO-Kinetic DES|Patients receiving PRO-Kinetic drug-eluting stent
3251100|NCT01391871||Endeavor Resolute DES|Patient receiving Endeavor Resolute zotarolimus-eluting stent
3251101|NCT01391884||Dialysis, Non-diabetic|Hemodialysis
3251102|NCT01391884||Healthy control|
3365999|NCT03245411|No Intervention|Standard of Care (Control Group)|All participants in this group will receive the standard of care intervention provided by the RN.
3366000|NCT03245411|Experimental|Intervention Group|"In addition to the standard of care, the participants randomized to Intervention Group will be invited to a separate room. The following activities will be undertaken, in order to address patients' questions and concerns, and discuss potential solutions to their barriers to care~The patient will be asked to watch brief educational videos on Life with oral cancer treatment. The information contained in the videos will be reinforced with materials written at a 4th grade level, that correspond to each of the brief videos.The patient will receive a brief phone call (from the study coordinator) on the first business day following the baseline interview, and thereafter, two weeks following each visit to the oncology clinic."
3366003|NCT03232073|Experimental|Ponesimod|20 mg administered orally once daily
3366004|NCT03223610|Experimental|Arm 1: Dose Escalation|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
3366005|NCT03223610|Experimental|Arm 2: Dose Escalation|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
3366006|NCT03223610|Experimental|Arm 3: Dose Expansion|ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 1-6
3366007|NCT03223610|Experimental|Arm 4: Dose Expansion|iPOR (ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycle 1; followed by ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide) for cycles 2-6
3366009|NCT03214250|Experimental|Gem/NP/nivolumab|Gemcitabine+Nab-Paclitaxel+nivolumab
3366010|NCT03214250|Experimental|Gem/NP/APX005M|Gemcitabine+Nab-Paclitaxel+APX005M
3366011|NCT03214250|Experimental|Gem/NP/nivolumab/APX005M|Gemcitabine+Nab-Paclitaxel+nivolumab+APX005M
3366016|NCT03209713|Active Comparator|Parental Education|Participants will receive parental education on HPV vaccine and the vaccine's benefits.
3366017|NCT03209713|Experimental|Parental Education + Text Messaging|Participants will receive parental education on HPV vaccine and the vaccine's benefits plus text messaging reminder.
3366022|NCT03194672|Experimental|Intervention Condition|"This experimental condition has three major components:~Individual sessions: Roughly 12 90-minute sessions over 3 months Prenatal sessions covering contraceptive options, including long-acting reversible contraception. Prenatal and postnatal sessions will also cover (a) financial benefits of smoking cessation; (b)financial literacy/budgeting skills based upon selected components of the Money Matters curriculum; (c) establishing concrete steps to reach educational/career goals; (d) healthy eating habits; and (e) importance of HPV vaccinations and getting a medical home.~Transportation assistance for medical home appointments.~Electronic Prompts/Reminders to Encourage Completion of Goals."
3251103|NCT01391897||in- and out-patient psychotherapy patients|All included patients are highly selected in- and outpatients in a department of psychosomatic medicine (Germany) undergoing high dose psychotherapy (e.g. group therapy, creative therapy, cbt and psychodynamic psychotherapy).
3251104|NCT01391910||post endoscopic sinus surgery for chronic rhinosinusitis|Patients who have undergone functional endoscopic sinus surgery for treatment of chronic rhinosinusitis and completed a pre-surgery SNOT-20
3251105|NCT01391936|Other|Tension Band Wiring|Patients in this arm will receive the tension band wiring technique for fixation of their olecranon fracture.
3251106|NCT01391936|Other|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
3251107|NCT01391949|Experimental|Detailed feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
3251108|NCT01391949|Active Comparator|Basic feedback|Subjects will pedal on the UCFit with a goal of 30 total minutes of daily exercise.
3366023|NCT03194672|No Intervention|Treatment as Usual Control Condition|"The comparison group will be a Usual Care control group. The control group will have access to standard medical and behavior health services as part of routine care. Prior to randomization, each enrolled participant will receive a listing of contact information for organizations offering this routine care.~The only interaction the HAT providers will have with control group participants is to have periodic and brief phone conversations in which updated changes in contact information will be collected. The HAT providers will also obtain updated changes in contact information for HAT intervention group participants."
3366025|NCT03185013|Experimental|VGX-3100 + EP|IM injections with VGX-3100 followed by electroporation (EP) using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
3366026|NCT03185013|Placebo Comparator|Placebo + EP|IM injections with matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4 and Week 12.
3366027|NCT03183245|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
3366028|NCT03183245|Active Comparator|Arteriovenous fistula (AVF)|The comparator is an autologous arteriovenous fistula created in the forearm or upper arm on Study Day 0.
3366029|NCT03183141|Experimental|SER-109|Received oral dose of SER-109
3366030|NCT03180684|Experimental|VGX-3100 + EP|Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.
3366031|NCT03180684|Experimental|VGX-3100 + EP + Imiquimod|IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
3366032|NCT03176732||Group 1: Normotensive|Categorized by 24-hr systolic BP (SBP): normotensive (< 125 mm Hg) on no BP medications
3366033|NCT03176732||Group 2: Controlled Hypertensive|Categorized by 24-hr systolic BP (SBP): controlled hypertensive (< 130 mm Hg) on BP medication(s) and/or lifestyle modification
3366034|NCT03176732||Group 3: Uncontrolled Hypertensive|Categorized by 24-hr systolic BP (SBP): uncontrolled hypertensive (≥ 130 mm Hg) on 0-2 BP medications
3366035|NCT03176732||Group 4: Hypertensive|Categorized by 24-hr systolic BP (SBP): hypertensive (≥ 135 mm Hg) resistant to 3 or more BP medications ideally including a diuretic (resistant hypertension)
3366036|NCT03174275|Experimental|Low Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive adjuvant durvalumab (750 mg) once every two weeks x 3 cycles"
3366037|NCT03174275|Experimental|Medium Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- patients receive ipsilateral involved field radiation concurrent with weekly cisplatin 30mg/m2. Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
3366038|NCT03174275|Experimental|High Risk|"Part 1- Patients receive 6 weeks of induction chemotherapy comprised of weekly cycles of carboplatin dosed to an Area Under the Curve (AUC2) and nab-paclitaxel 100 mg/m2 X 6 cycles in combination with durvalumab 750 mg administered once every two weeks for 5 cycles (D1 of weeks 1, 3, 5, 7, and 9).~Part 2- Within a 2-6 week window post induction, tumor imaging will be followed by surgical resection.~Part 3- All patients will be treated with intensity modulation radiation therapy (IMRT) concurrent with weekly cisplatin 30mg/m2 or other standard of care chemoradiotherapy regimen.Once chemoradiotherapy is complete these patients will receive durvalumab 750 mg every two weeks for 3 cycles."
3251111|NCT01391975|Experimental|Surveillance and proactive intervention|
3251112|NCT01391975|No Intervention|Control and reactive intervention|
3251113|NCT01391988|Active Comparator|Electric Scalpel Mastectomy|Radical mastectomy with electric scalpel
3251114|NCT01391988|Experimental|Harmonic scalpel mastectomy|Radical Mastectomy with harmonic scalpel
3251115|NCT01392001||Cohort|
3251116|NCT01392014|Active Comparator|dihydroartemisinin-piperaquine|
3251117|NCT01392014|Active Comparator|Dihydroartemisininpiperaquine primaquine|
3251118|NCT01392040||Patients in oral anticoagulant therapy|Patients taking oral anticoagulant therapy
3251119|NCT01392066||Breast cancer patients and their partners|Patients with breast cancer and their cohabiting partners/spouses
3251120|NCT01392079|Experimental|Alemtuzumab|"30 mg alemtuzumab will be administered subcutaneously 3 times weekly for 4 weeks (total of 12 doses of 30 mg alemtuzumab) with premedication (as needed) and infection prophylaxis; combined with oral dexamethasone 40 mg total dose for 4 days every 2 weeks; evaluation at end of cycle (i.e. after 12 doses of 30 mg alemtuzumab).~If CR is documented after week 4 (12 doses of 30 mg alemtuzumab) or 8 (24 doses of 30 mg alemtuzumab), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted at this time point.~After a maximum of three 4-week cycles (total of 36 doses of 30 mg alemtuzumab, in case of interruptions this may take longer than 12 weeks), maintenance treatment with alemtuzumab or withdrawal from the study and stem cell transplantation will be instituted. Maintenance treatment with alemtuzumab will continue for a maximum of two years, with evaluation every three months, unless there is PD."
3251121|NCT01392105|Active Comparator|Mesenchymal stem cell treatment group|
3366039|NCT03170518|Experimental|Single-blind run-in Period: Placebo|Participants will receive 1 placebo tablet matching canagliflozin 100 milligram (mg) once-daily during the 2-week single-blind placebo run-in period.
3251122|NCT01392105|Placebo Comparator|Control group|All patients were required to have successful revascularization of an infarct-related artery on coronary angiography at the time of randomization. All patients received aspirin (300 mg loading dose, then 100 mg daily) and clopidogrel (600 mg loading dose, then 75 mg daily) with optimal medical therapy according to the American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines for treatment of ST-segment elevation myocardial infarction (STEMI)
3251123|NCT01392131|Active Comparator|Oncoxin will be administered orally|20 patients will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
3251124|NCT01392131|Active Comparator|Supportive treatment|20 patients with hepatocellular carcinoma will receive supportive treatment only
3251125|NCT01392144||Nitric Oxide Breath Analysis|Nitric Oxide Breath Test + Questionnaires
3251126|NCT01392157|Active Comparator|copper intrauterine device|100 women will be allocated to receive a TCu380A intrauterine device
3251127|NCT01392157|Active Comparator|LNG-releasing intrauterine system|100 women were allocated to receive a LNG-IUS
3251128|NCT01392157|Active Comparator|ENG-releasing implant|100 women will receive an LNG-IUS
3251129|NCT01392196|Other|Single arm|Renal Denervation
3251130|NCT01392209|Experimental|Bevacizumab & Stereotactic Radiotherapy|This will be a multicenter (MSKCC and UCSF) phase I dose escalation study to determine the maximum tolerated dose (MTD) of hypofractionated stereotactic radiotherapy when administered in combination with a fixed dose of bevacizumab.
3251131|NCT01392222||patients who have had surgery or have scheduled surgery|In this exploratory study we will conduct focus groups and individual interviews with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
3251132|NCT01392222||who chose to not have immediate surgery|In this exploratory study we will conduct focus groups with two population segments according to the established methodology of Krueger and Casey [13] and Morgan [14]. We will conduct 4-6 focus groups, two to three within each population segment, to evaluate the process of decision-making to manage papillary microcarcinoma, factors that influenced decision-making, understanding of risk for recurrence and other negative outcomes due to thyroid cancer, information needed to make informed decisions, and what could influence thyroid cancer patients who have had surgery or have scheduled to have surgery to remove their papillary microcarcinomas to consider active surveillance. Individual interviews will be offered and conducted as needed for those patients who are unable to attend a focus group due to scheduling conflicts or other reasons.
3251133|NCT01392235|Experimental|Drug: Famitinib|
3366040|NCT03170518|Experimental|Double-blind Treatment Phase: Canagliflozin or Placebo|Canagliflozin 100 mg/matching placebo once-daily during first 12 weeks. At Week 13, participants who have glycated hemoglobin (HbA1c) of greater than or equal to (>=)7.0 percent (%), estimated glomerular filtration rate (eGFR) >=60 milliliter/minute/1.73 meter square (mL/min/1.73 m^2) will be re-randomized to either remain on canagliflozin 100 mg/matching placebo or up-titrate to canagliflozin 300 mg/matching placebo till Week 52.
3366041|NCT03165916|Experimental|Reconstruction with stent placement|Subjects will undergo biliary reconstruction with stent placement at the anastomosis site.
3366042|NCT03165916|No Intervention|Reconstruction without stent placement|Subjects will undergo biliary reconstruction without stent placement.
3366043|NCT03158688|Active Comparator|Kd - Carfilzomib and Dexamethasone|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles."
3251134|NCT01392274||pCLE|This trial will study only one group which will receive a standard ERCP procedure followed by pCLE
3251135|NCT01392287|Experimental|Memantine hydrochloride|Older individuals with DSM IV TR Major Depression, with persistent symptoms of depression despite at least 8 weeks of treatment with standard pharmacotherapy, will be referred for a study of memantine hydrochloride augmentation. Healthy control subjects follow similar study schedule for baseline and endpoint but do not receive memantine hydrochloride.
3366044|NCT03158688|Experimental|KdD - Carfilzomib, Dexamethasone and Daratumumab|"Carfilzomib was administered intravenously (IV) at 20 mg/m^2 in Cycle 1: days 1 and 2; at 56 mg/m^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.~Dexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.~Daratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg was further continued on Cycles 7+: day 1 only."
3366045|NCT03123783|Experimental|Phase 1b escalation|"Non-small cell lung cancer (NSCLC) or metastatic melanoma~APX005M escalated from 0.03 to 0.1 to 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
3366046|NCT03123783|Experimental|Phase 2 expansion Cohort 1|"Immunotherapy naïve, metastatic or locally advanced NSCLC~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
3251136|NCT01392313|Experimental|Carnitine|Participants will be given Creatinine supplements
3251137|NCT01392313|Placebo Comparator|Placebo|participants will be given creatinine placebo
3251138|NCT01392339|Experimental|CPAP|CPAP - Continuous Positive Airway Pressure, gold standard treatment to Obstructive Sleep Apnea
3366047|NCT03123783|Experimental|Phase 2 expansion Cohort 2|"Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
3366048|NCT03123783|Experimental|Phase 2 expansion Cohort 3|"Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:~Group A: best response of progressive disease or with stable disease < 16 weeks~Group B: tumor response or with stable disease ≥ 16 weeks~APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks"
3366049|NCT03122899|Other|SIJ fusion with iFuse 3D with 6 mo CT|These subjects will get pelvic CT at 6 months post-operatively.
3366050|NCT03122899|Other|SIJ fusion with iFuse 3D with 12 mo CT|These subjects will get pelvic CT at 12 months post-operatively.
3366051|NCT03115294|Experimental|Study group|Patients undergo procedure with stepwise measurements and ventilator + volume adjustment + iv theophylline Myocardial movement recording using videoscanning
3366055|NCT03103139|Active Comparator|Transpapillary Stents|Stent placement across the Papilla (with a short plastic stent) for biliary leak
3366056|NCT03103139|Experimental|Stent across bile leak|Stent placement across the bile leak (with a longer stent) for biliary leak
3366057|NCT03101891|Experimental|Serial amnioinfusions with isotonic fluid|Patients will undergo amnioinfusions with isotonic fluid every 2-12 days.. A spinal needle will be used to perform the infusion. The latest infusions will begin is 26 weeks gestation. Standard postnatal care will occur at a RAFT center.
3366058|NCT03101891|No Intervention|Expectant|Patients will be observed serially by ultrasound, fetal echocardiogram and MRI. Standard postnatal care will occur at a RAFT center.
3366059|NCT03092219|Experimental|TEOSYAL RHA Redensity|Injection of TEOSYAL RHA Redensity into the perioral lines (n=150). Up to 6.0 mL (max 3 mL for upper and max 3 mL for lower) injected into the dermis, including the superficial dermis. Touch-up treatment provided at 2 weeks.
3366060|NCT03092219|No Intervention|No Treatment|No treatment control group (n=52).
3366061|NCT03087656|Active Comparator|Antibiotic arm|The drugs ceftriaxone and levofloxacin will be administered to patients in the antibiotic arm.
3366062|NCT03087656|No Intervention|No Antibiotic arm|No prophylactic antibiotics will be administered.
3366065|NCT03085004|Active Comparator|Control Group|Cyst will be lavaged for 3 to 5 minutes with 98% ethanol. Following lavage with 98% ethanol, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
3366066|NCT03085004|Experimental|Study group|Cyst will be lavaged for 3 to 5 minutes with normal saline. Following lavage with normal saline, the cyst will be infused with an admixture of (3mg/ml paclitaxel + 19mg/ml gemcitabine).
3366067|NCT03084640|Experimental|Part 1: Dose-Escalation - CMP-001 (SC) and Pembrolizumab|Participants will receive up to 7 escalating dose levels (5 milligrams [mg], 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, and 20 mg) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
3366068|NCT03084640|Experimental|Part 1: Dose-Expansion - CMP-001 (SC) and Pembrolizumab|Participants will receive RP2D (as determined in Part 1 dose-escalation phase) of CMP-001 via SC injection once a week for 3 weeks and every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule.
3366069|NCT03084640|Experimental|Part 2: CMP-001 (SC and IT) and Pembrolizumab|Participants will receive CMP-001 via SC injection once weekly for 2 weeks, then IT injection once weekly for 4 weeks, and SC injection once weekly for every 3 weeks thereafter until discontinuation of treatment in combination with pembrolizumab at its labelled dose and schedule. CMP-001 planned IT dose level in Part 2 will be up to 10 mg and the SC dose will be the RP2D determined from Part 1 dose-escalation phase of the study.
3366070|NCT03074045|Experimental|Test|LCS16 (Low-dose LNG IUS)
3366071|NCT03074045|Active Comparator|Reference|COC (Yarina)
3366072|NCT03067714|Experimental|Active product: partially hydrolysed formula + synbiotics|
3366073|NCT03067714|Active Comparator|Control product: standard formula (intact protein)|
3366074|NCT03055611||Haemophilia A patients|Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
3366075|NCT03055611||Haemophilia B patients|Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment
3366076|NCT03045289|Experimental|Intervention group|Subjects are provided three meals daily, attend weekly office visits, take a daily multivitamin.
3366077|NCT03045289|No Intervention|Control Group|Women instructed to maintain current intake and take a provided multivitamin.
3366078|NCT03041688|Experimental|Treatment (decitabine, MDM2 inhibitor KRT-232)|"Patients receive decitabine IV over 1 hour on days 1-10 and MDM2 inhibitor KRT-232 PO QD on days 4-10. Treatment repeats every 28 days for up to 4 cycles in patients with evidence of persistent AML.~Starting cycle 2, patients with no morphologic evidence of AML receive decitabine IV over 1 hour on days 1-5 and KRT-232 PO QD on days 4-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3366079|NCT03033069|Experimental|Brexpiprazole + Sertraline|Participants were administered oral brexpiprazole initial dose of 0.5 milligram (mg)/day plus sertraline initial dose of 50 mg/day. The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo based on dose titration/adjustment up to Week 12.
3366080|NCT03033069|Experimental|Brexpiprazole|Participants were administered oral brexpiprazole initial dose of 0.5 mg/day The dose was up titrated to brexpiprazole maximum dose of 3 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received sertraline matching placebo up to Week 12.
3366081|NCT03033069|Active Comparator|Sertraline|Participants were administered oral sertraline initial dose of 50 mg/day. The dose was up titrated to sertraline maximum dose of 200 mg/day and continued thereafter up to Week 12 based on efficacy and tolerability. No dose reductions were allowed after Week 6 and no dose increments were allowed after Week 4. Participants also received brexpiprazole matching placebo and sertraline matching placebo based on dose titration/adjustment up to Week 12.
3366082|NCT03033069|Placebo Comparator|Placebo|Participants received oral brexpiprazole matching placebo tablet and oral sertraline matching placebo capsules up to Week 12.
3366083|NCT03031730|Experimental|Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)|Patients receive MDM2 Inhibitor KRT-232 PO QD on days 1-7, carfilzomib IV over 10-30 minutes on days 1-2, 8-9, and 15-16 of cycles 1-12 and on days 1-2 and 15-16 of cycles 13-18, lenalidomide PO on days 1-21, and dexamethasone PO or dexamethasone sodium phosphate IV on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unexpected toxicity.
3366084|NCT03005418|Experimental|Limb Cohort|Patients with limb-threatening vascular trauma in an extremity will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
3366085|NCT03005418|Experimental|Torso Cohort|Patients with life-threatening vascular trauma in the torso will be implanted with a Humacyte Human Acellular Vessel (HAV) as an interposition vessel or bypass using standard vascular surgical techniques.
3366086|NCT02994134|Active Comparator|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
3366087|NCT02994134|Experimental|High intensity exercise|High intensity aerobic exercise intervention (delivered at 65%-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
3366088|NCT02990793|Active Comparator|Active MeRT Treatment|Active treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
3366089|NCT02990793|Sham Comparator|Sham MeRT Treatment|Sham treatment will consist of 6 seconds a minute for 30 minutes a day, 5 days a week for 5 weeks.
3366092|NCT02976753||Elocta|Elocta will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
3366093|NCT02976753||Conventional factor VIII product|Conventional factor VIII products will be prescribed and administered for prophylactic treatment of patients with haemophilia A according to usual clinical practice
3251139|NCT01392352|Experimental|Pazopanib|Patients will receive 800mg (2 X 400mg tablets) of pazopanib, to be administered once daily orally for 12 weeks or until development of hypertension (defined as VHyp), whichever occurs first.
3251140|NCT01392365||Crohn' disease|The group of patients whose final diagnosis is Crohn's disease
3251141|NCT01392365||Intestinal tuberculosis|The group of patients whose final diagnosis is intestinal tuberculosis
3251142|NCT01392391|Experimental|Exercise|Task-oriented exercise training (aerobic, strength, and balance exercises)
3251143|NCT01392391|Active Comparator|Stroke Care|"Best Medical Care in Jamaica adapted from the American Stroke Association Get with the Guidelines."
3251144|NCT01392430|No Intervention|Arm A|Continuation of prophylaxis of opportunistic infections
3251145|NCT01392430|Experimental|Arm B|Discontinuation of opportunistic infections
3251146|NCT01392456|Active Comparator|Retentive Anchor Group|23 fully edentulous patients will receive Retentive Anchors (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3366094|NCT02956434|Experimental|Brief family intervention|Participants will receive the BFI in this arm of the study. The BFI is a 2-session intervention for family members of Veterans who are beginning PTSD treatment.
3251147|NCT01392456|Active Comparator|Magnet Group|23 fully edentulous patients will receive Magnets (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3366095|NCT02956434|No Intervention|No intervention|Participants will not receive the BFI in this arm of the study. They will be eligible for any usual support or programming for the families of Veterans.
3366096|NCT02946424|Experimental|Simvastatin treatment|Simvastatin for one year time period
3251148|NCT01392456|Active Comparator|Locator Group|23 fully edentulous patients will receive Locator (Institute Straumann AG, Basel Switzerland)as retention system for the two implant overdenture.
3251149|NCT01392482||treatment with antipsychotics|40 LHU covering about 18 millions inhabitants distributed all over Italy with a coverage of nearly 100% of Italian regions. All subjects will be included in the analysis who have received treatment with antipsychotics (typical and / or atypical) between January 1, 2009 and June 30, 2010 and diagnosed with schizophrenia and / or Bipolar Disorder.
3366097|NCT02946424|Placebo Comparator|Placebo treatment|Placebo for one year time period
3366098|NCT02941926|Experimental|Ribociclib + letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
3366099|NCT02926911|Active Comparator|Surgery|DCIS - Surgery +/- radiation choice for endocrine therapy (MMG q 12 months x 5 years usual care for recurrent disease)
3366100|NCT02926911|Experimental|Active Monitoring|DCIS - Choice for endocrine therapy (MMG q 6 months x 5 years GCC for invasive progression)
3366103|NCT02912104|Experimental|hAECs transplantation|To clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of POF patients
3251150|NCT01392521|Experimental|Arm 1|
3251151|NCT01392534||Group 1|
3366104|NCT02891954|Experimental|Single arm|Healthy volunteers will receive canagliflozin to assess pharmacodynamic responses to drug.
3366105|NCT02887859|Experimental|HAV Treatment|Human Acellular Vessel (HAV)
3251152|NCT01392586|Experimental|Upfront surgery|Upfront surgery followed by systemic treatment
3251153|NCT01392586|Other|Systemic therapy|Systemic therapy possibly followed by local treatment of the breast tumor
3366106|NCT02872532|Experimental|Testicular tissue|Children faced with a fertility threatening diagnosis or treatment plan will be offered testicular tissue cryopreservation, particularly if pre-pubescent and without other options to preserve fertility.
3366107|NCT02871297|Experimental|Vortioxetine tablets|Vortioxetine tablets for 26 weeks
3251154|NCT01392599|Experimental|Surgery|Patients with CRPS Type II
3251155|NCT01392612|Other|Erythropoietin|all subjects received epo iv.
3366108|NCT02871297|Experimental|Vortioxetine|Single dose of vortioxetine oral drops (only a subset of patients)
3366109|NCT02870816|Active Comparator|Tissue engineered skin substitute|Application of tissue engineered skin substitute with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of skin substitute will be applied weekly at weeks 2-11.
3251156|NCT01392638|Placebo Comparator|sugar pill|Intervention: sugar pill
3366110|NCT02870816|Experimental|Amnionic membrane graft|Application of amnionic membrane graft with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of amnionic membrane graft will be applied weekly at weeks 2-11
3366111|NCT02863770|Experimental|Contrast EUS|Undergoing EUS for pancreatic indication (cyst, pancreatitis, mass)
3366112|NCT02855268|Experimental|lademirsen (SAR339375)|Eligible participants will receive subcutaneous injection every week for 48 weeks
3366113|NCT02855268|Placebo Comparator|Placebo|Eligible participants will receive subcutaneous injection every week for 48 weeks
3366114|NCT02806336|Experimental|Multi Modal Balance Training & Weight Loss|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes). Weekly nutrition sessions for individual dietary recommendations designed to produce about a 10% weight loss over the first six months of the study.
3366115|NCT02806336|Active Comparator|Multi Modal Balance Training Only|Supervised exercise 3 times per week for about 1 hour. The classes will consist of a group balance class (about 30 minutes), a supervised obstacle course (about 10 minutes), and lower body and core body strength exercises (about 20 minutes).
3366116|NCT02798471|Experimental|Edoxaban|"Edoxaban treatment will be dispensed to the participant on a monthly visit schedule.~Edoxaban will be started orally at the age/weight/renal function appropriate dose, depending on the results of the ongoing U157 study (NCT02303431) for the Treatment Period."
3366117|NCT02798471|Experimental|Standard of Care|Standard of Care (SOC) treatment will be dispensed to the participant on a monthly visit schedule.
3251157|NCT01392638|Active Comparator|sildenafil|Intervention: sildenafil citrate
3251158|NCT01392651||Women with urinary stress incontinence|
3251159|NCT01392690|No Intervention|Waiting list control - no intervention|No intervention. After the post-test they were offered the prevention program.
3251160|NCT01392690|Experimental|Dominique's handy tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
3251161|NCT01392716|Experimental|Single arm|
3251162|NCT01392729||Cohort|
3251163|NCT01392755|Experimental|1|
3251164|NCT01392755|Experimental|2|
3251165|NCT01392768|Experimental|Levetiracetam|
3251166|NCT01392768|Placebo Comparator|Placebo|
3251167|NCT01392781||normoweight PCOS patients|
3251168|NCT01392781||normoweight controls|
3251169|NCT01392781||overweight plus obese PCOS patients|
3251170|NCT01392781||overwqeight plus obese controls|
3251171|NCT01392794|Experimental|orally-disintegrating (OD) tablet precedence group|
3251172|NCT01392794|Experimental|conventional tablet precedence group|
3251173|NCT01392807|Experimental|Group 1|Normal hepatic function, 25 mg NKTR-118 administered orally
3251174|NCT01392807|Experimental|Group 2|Mild hepatic impairment, 25 mg NKTR-118 administered orally
3251175|NCT01392807|Experimental|Group 3|Moderate hepatic impairment, 25 mg NKTR-118 administered orally
3251176|NCT01392820|Experimental|TC-5214|
3251177|NCT01392820|Placebo Comparator|Placebo|
3251178|NCT01392833|Active Comparator|steroids|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day for six months followed by oral prednisone 0.2 mg/kg every other day for a further six months.
3251179|NCT01392833|Experimental|steroids plus azathioprine|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5, and oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further six months.
3251180|NCT01392846||Resolute Integrity|Patients receiving Resolute-Integrity stent
3251181|NCT01392872|Other|sclerosis|
3251182|NCT01392898|Experimental|liraglutide|
3251183|NCT01392898|Active Comparator|insulin|
3251184|NCT01392911|Active Comparator|10 mg/kg rifampicin|7 Days monotherapy with 10 mg/kg rifampicin followed by 7 days standard TB treatment, i.e. Rifafour® e275 once daily including the standard dose of rifampicin.
3251185|NCT01392911|Experimental|20 mg/kg Rifampicin|7 Days monotherapy with 20 mg/kg rifampicin followed by 7 days combination therapy consisting of 20 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251186|NCT01392911|Experimental|25 mg/kg Rifampicin|7 Days monotherapy with 25 mg/kg rifampicin followed by 7 days combination therapy consisting of 25 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3366130|NCT02663622|Experimental|CD24Fc 240 mg|CD24Fc in 240 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
3366131|NCT02663622|Experimental|CD24Fc 480 mg|CD24Fc in 480 mg as intravenous (IV) infusion at Day -1 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
3366132|NCT02663622|Experimental|CD24Fc 960 mg|CD24Fc (480 mg (day -1), 240 mg (day +14) and 240 mg (day +28)) + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
3366133|NCT02663622|Placebo Comparator|Placebo|Placebo to CD24Fc (saline IV injection solution) on day -1 or days -1, 14, and 28 + Tacrolimus (begin on day -3. IV [0.03 mg/kg/day] or PO [0.045 mg/kg/dose] dosing is permitted) + Methotrexate (given intravenously at a dose of 15 mg/square meter/dose once daily on Day 1 after HCT, and at a dose of 10 mg/square meter/dose on days 3, 6, and 11 after HCT)
3366136|NCT02622295|Experimental|Acute gene regulation|Adaptations in gene regulation in response to single-session high-frequency active-resisted stance or single-session low-frequency active-resisted stance
3251187|NCT01392911|Experimental|30 mg/kg Rifampicin|7 Days monotherapy with 30 mg/kg rifampicin followed by 7 days combination therapy consisting of 30 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3366137|NCT02622295|Experimental|3 year Training Study|Adaptations in gene regulation, metabolic markers, and subject-report metrics in response to 3 years of high-frequency active-resisted stance training or 3 years of low-frequency active-resisted stance training
3366138|NCT02609685|Other|Active Surveillance|Active surveillance instead of standard of care immediate surgery. Patients will be closely monitored every six months until disease is stable for a two-year period and then annually thereafter.
3366139|NCT02609685|No Intervention|Immediate Surgery|"Patients who choose to get surgery immediately after diagnosis may choose to enroll in a questionnaire sub-study that will compare quality of life and anxiety scores to patients who enroll in the active surveillance study. This is considered no intervention because the protocol is not directing treatment. Surgery is the standard treatment for papillary thyroid microcarcinoma."
3251188|NCT01392911|Experimental|35 mg/kg Rifampicin|7 Days monotherapy with 35 mg/kg rifampicin followed by 7 days combination therapy consisting of 35 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251189|NCT01392911|Experimental|40 mg/kg Rifampicin|7 Days monotherapy with 40 mg/kg rifampicin followed by 7 days combination therapy consisting of 40 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251190|NCT01392911|Experimental|45 mg/kg Rifampicin|7 Days monotherapy with 45 mg/kg rifampicin followed by 7 days combination therapy consisting of 45mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251191|NCT01392911|Experimental|50 mg/kg rifampicin|7 Days monotherapy with 50 mg/kg rifampicin followed by 7 days combination therapy consisting of 50 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251192|NCT01392911|Experimental|55 mg/kg Rifampicin|7 Days monotherapy with 55 mg/kg rifampicin followed by 7 days combination therapy consisting of 55 mg/kg rifampicin plus the standard doses of isoniazid, ethambutol and pyrazinamide.
3251193|NCT01392924|Experimental|SAR245408|single cohort: SAR245408 administered once daily
3366140|NCT02609503|Experimental|Open label|Pembrolizumab
3366141|NCT02609503|Other|Radiation|Intensity Modulated Radiation Therapy (IMRT)
3251194|NCT01392937|Active Comparator|All-in-One Light multipurpose|Used All in One light multipurpose with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
3366143|NCT02587598|Experimental|Parts 1 and 2: INCB053914 100 mg QD|INCB053914 will be self-administered orally once a day in as a 100mg immediate release tablet as a monotherapy.
3366144|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + Azacitidine|Azacitidine will be administered at a dose of 75 mg/m2 subcutaneously or via IV per day, as a combination therapy with INCB053914.
3366145|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + I-DAC (Intermediate dose cytarabine)|I-DAC (intermediate dose cytarabine) will be administered at a dose of 1 g/m2 per day as an infusion as a combination therapy with INCB053914.
3366146|NCT02587598|Experimental|Parts 3 and 4: INCB053914 + Ruxolitinib|Ruxolitinib will be administered as an oral dose between 5 mg to 25 mg twice per day, as a combination therapy with INCB053914.
3366147|NCT02587598|Experimental|Parts 1 and 2: INCB053914 50 mg|INCB053914 will be self-administered orally twice day in as a 50mg immediate release tablet as a monotherapy.
3366148|NCT02587598|Experimental|Parts 1 and 2: INB053914 65 mg|INCB053914 will be self-administered orally twice day in as a 65mg immediate release tablet as a monotherapy.
3251195|NCT01392937|Active Comparator|Aquify care|Use Aquify care with one of five different lens brands: Air Optix Aqua(Ciba Vision Inc.), PureVision (Bausch + Lomb Inc.), Biofinity (CooperVision Inc.), Acuvue Advance and Acuvue 2 (both Johnson & Johnson).
3251196|NCT01392950|Active Comparator|Air Optix Aqua|Compare safety and efficacy using OptiFree Replenish solution
3251197|NCT01392950|Active Comparator|Clariti|Compare safety and efficacy of the lens using OptiFree Replenish solution
3251198|NCT01392976|Experimental|CO-1.01 Formulation B|
3366149|NCT02587598|Experimental|Parts 1 and 2: INB053914 80 mg|INCB053914 will be self-administered orally twice day in as a 80mg immediate release tablet as a monotherapy.
3366150|NCT02587598|Experimental|Parts 1 and 2: INB053914 100 mg BID|INCB053914 will be self-administered orally twice day in as a 100mg immediate release tablet as a monotherapy.
3366151|NCT02587598|Experimental|Parts 1 and 2: INB053914 115 mg|INCB053914 will be self-administered orally twice day in as a 115mg immediate release tablet as a monotherapy.
3366152|NCT02581306|Other|Exercise session|All subjects will exercise for 1 hour at a moderate intensity. There are no different arms in this study
3366153|NCT02581020||1|Participants who were treated with 2D regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow up from the prior Phase 2 or 3 studies conducted in Japan.
3251199|NCT01392976|Active Comparator|CO-1.01 Formulation A|
3251200|NCT01393002||INABBRA|Participating hospitals in the INABBRA alliance.
3251201|NCT01393015|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
3251202|NCT01393015|Active Comparator|Rotameter (flowmeter)|A rotameter is a device that measures the flow rate of liquid or gas in a closed tube.
3251203|NCT01393028|Experimental|Cardiac CT|Cardiac CT (CT calcium and/or CT angiography), followed by stress testing, invasive angiography or neither depending on the CT scan result
3366157|NCT02533713|Experimental|Immediate gait training|Participants assigned to this arm will begin Exoskeleton assisted gait training right away and will continue training for the first 6 months of the study.
3251204|NCT01393028|Other|Standard care|Standard diagnostic management, including stress testing and/or invasive angiography
3251205|NCT01393041|Other|Angio-Seal VIP|
3251206|NCT01393067|Active Comparator|study group NEPS|implantation of multiple non-expandable plastic stents
3251207|NCT01393067|Active Comparator|group cSEMS|implantation of a self-expandable metal stent (cSEMS)
3251208|NCT01393080|Experimental|Nimotuzumab and TP regimen|"TP Regimen ：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab : 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
3251209|NCT01393080|Placebo Comparator|TP Regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
3366158|NCT02533713|Other|Delayed gait training|Participants assigned to this arm will not gait train for 6 months. They will engage in Exoskeleton assisted gait training for the last 6 months of the study.
3366159|NCT02485574|Experimental|Left cage- auto bone|At the operated segment, left cage was filled with auto bone only. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
3366160|NCT02485574|Experimental|Right cage- auto local bone mixed with β-calcium phosphate + hydroxyapatite|At the operated segment, right cage was filled with auto local bone mixed with β-calcium phosphate + hydroxyapatite. We evaluated bone bridging between inside and outside the cage in transforaminal lumbar interbody arthrodesis.
3366161|NCT02481310|Experimental|Treatment (combination chemotherapy, rituximab, ixazomib)|"INDUCTION:~Patients receive ixazomib citrate PO on day 1 and day 8 or 15; etoposide IV, vincristine sulfate IV, and doxorubicin hydrochloride IV continuously over 96 hours on days 1-4; prednisone PO BID on days 1-5; rituximab IV should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr on day 1; and cyclophosphamide IV over 90 minutes on day 5.~CNS PROPHYLAXIS:~Patients with a negative LP receive methotrexate IT once per course. Patients with a positive LP receive methotrexate IT or intraventricularly OR cytarabine IT or intraventricularly OR methotrexate IT or intraventricularly, cytarabine IT or intraventricularly, and therapeutic hydrocortisone IT or intraventricularly.~MAINTENANCE:~Patients not treated with consolidative SCT, receive ixazomib citrate PO BID on days 1, 8, and 15. Treatment repeats every 28 days for up to one year in the absence of disease progression or unacceptable toxicity."
3251210|NCT01393093|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
3251211|NCT01393093|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
3251212|NCT01393093|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
3251213|NCT01393093|Experimental|TACE-KMG(withou chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
3251214|NCT01393119|Experimental|3000mg GTx-758 daily|loading dose 3000mg GTx-758 daily + maintenance dose of 1000mg
3251215|NCT01393119|Experimental|3000 mg GTx-758 daily|loading dose of 3000mg GTx-758 daily + maintenance dose of 2000mg GTx-758 daily
3251216|NCT01393119|Experimental|1500 mg GTx-758 BID|Loading dose of 1500 mg GTx-758 BID + maintenance dose of 1000mg GTx-758 daily
3251217|NCT01393119|Experimental|1500mg GTx-758 BID|loading dose of 1500mg of GTx-758 BID + maintenance dose of 2000mg GTx-758 daily
3251218|NCT01393145|Experimental|Group 1|
3251219|NCT01393145|Active Comparator|Group 2|
3251220|NCT01393171|Active Comparator|Polypropylene Mesh|Site-specific cystocele repair with polypropylene mesh augmentation
3251221|NCT01393171|Placebo Comparator|Anterior Colporrhaphy|Anterior vaginal prolapse repair with anterior colporrhaphy with no graft.
3251222|NCT01393171|Active Comparator|Porcine Dermis|Site-specific cystocele repair with porcine dermis augmentation
3251223|NCT01393184|Experimental|Radiotherapy + Nimotuzumab|"Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F~Nimotuzumab (Nimo) weekly Nimo (200 mg) × 8, started 1 w before RT"
3251224|NCT01393184|Active Comparator|Radiotherapy (RT)|Radiotherapy (RT) Technique: IMRT, Rapid Arc, Tomotherapy Total dose: GTV 70 Gy & CTV 60 Gy/33F
3251225|NCT01393197|Active Comparator|TACE -oil|embolization agent:Iodinated Oil or /and gelatin sponge Iodinated Oil （5-30ml）with Epirubicin （30-40mg/m2） or and gelatin sponge
3366200|NCT02462421|Active Comparator|Wild type genotype|Research subjects with wild type genotypes at three candidate genes encoding sodium-dependent glucose transporter-3, sodium-dependent glucose transporter-4, and glucose transporter-9 (abbreviated as SLC5A4, SLC5A9, SLC2A9, respectively) will be studied before and after canagliflozin treatment.
3251226|NCT01393197|Experimental|TACE-KMG ( routine dose Chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with routine dose Epirubicin （30-40mg/m2）
3251227|NCT01393197|Experimental|TACE-KMG( low dose Chemo )|embolization agent:KMG microsphere( 150-450µm,0.2-2g) with low dose Epirubicin （5-10mg/m2）
3366201|NCT02462421|Experimental|Nonsense mutation in SLC5A4|Research subjects who are homozygous for nonsense mutation in SLC5A4 (sodium-dependent glucose transporter-3) will be studied before and after canagliflozin treatment.
3366202|NCT02462421|Experimental|Nonsense mutation in SLC5A9|Research subjects who are homozygous for nonsense mutation in SLC5A9 (sodium-dependent glucose transporter-4) will be studied before and after canagliflozin treatment.
3366203|NCT02462421|Experimental|Missense variant in SLC2A9|Research subjects who are homozygous for nonsynonymous variant in glucose transporter-9 (SLC2A9) will be studied before and after canagliflozin treatment.
3366204|NCT02442102|Experimental|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
3366205|NCT02410330||Group I|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with Therapeutic ultrasound with 20 usec: custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 MI designed for the 1.7 MHz S5-1 transducer while waiting for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
3366206|NCT02410330||Group II|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) with therapeutic ultrasound with repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low MI perfusion imaging detected microbubbles within the microvasculature. Treatment will be applied while patient waits for percutaneous coronary intervention. Treatment will continue after procedure untill complete a total of 60 minutes.
3366207|NCT02410330||Group III|Patients with acute STEMI will receive intravenous infusion of microbubbles (3% Definity) while few limited diagnostic high MI impulses (n<5 per patient) will be applied to assess myocardial perfusion before and after percutaneous coronary intervention (PCI).
3366208|NCT02393885|Experimental|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System at day 1 of surgical procedure followed by endocardial catheter ablation procedure to occur at approximately 90 days after day 1 of surgical procedure.
3251228|NCT01393197|Experimental|TACE-KMG(without chemo)|embolization agent:KMG microsphere( 150-450µm,0.2-2g)
3251229|NCT01393210|Active Comparator|low-calorie diet|Intervention was low-calorie diet only for 12 weeks.
3251230|NCT01393210|Active Comparator|low calorie diet plus beta-glucan|Intervention was low-calorie diet plus BETA-GlLUCAN 1.3D-1.6D 500 mg daily for 12 weeks.
3251231|NCT01393223|Active Comparator|LP-08 80mg|4 weekly intravesical administration of LP-08 80mg
3251232|NCT01393223|Active Comparator|LP-08 20mg|4 weekly intravesical administration of LP-08 20mg
3251233|NCT01393223|Placebo Comparator|Normal Saline|Four weekly normal saline intravesical administration
3251234|NCT01393236||patients|patient characteristics are specified in H-2-2010-011
3251235|NCT01393236||controls|age matched to patients described in protocol H-2-2010-011
3366213|NCT02350764|Experimental|Nivolumab|Patients will begin treatment with nivolumab IV 3mg/kg and ipilimumab 1mg/kg. Treatment with nivolumab will continue every 2 weeks (+/- 3 days) thereafter and treatment with ipilimumab will continue every 6 weeks (+/- 3 days) thereafter. Treatment will continue until protocol-defined toxicity, confirmed progression of disease*, withdrawal of consent, or death.
3366214|NCT02337686|Experimental|Treatment (pembrolizumab, surgery)|Patients receive pembrolizumab IV over 30 minutes on day -21 and day -1, and then undergo surgery on day 0. After 2-3 weeks or recovery from surgery, patients continue to receive pembrolizumab IV over 30 minutes every 3 weeks. Courses repeat every 42 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3366215|NCT02328885|Experimental|Experimental|DLI of the 20 fraction of the UCBT
3366216|NCT02266745|Experimental|Arm 1: PT-112 injection|Arm 1: PT-112 Injection, administered by intravenous infusion, 360 mg/m2
3366217|NCT02266745|Experimental|Arm 2: PT-112 injection|Arm 2: PT-112 Injection, administered by intravenous infusion, 250 mg/m2
3366218|NCT02214160|Experimental|UX007|Participants previously treated with UX007 or treatment-naive participants will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
3251236|NCT01393249||ALL, Asparaginase, pancreatitis|Patients that have been scanned and have had blood tests
3251237|NCT01393262||Healthy Escort|
3251238|NCT01393262||Hand Service patient|
3251239|NCT01393275|Active Comparator|Rehabilitation intervention group|The group is performing a strength endurance training intervention in addition with rehabilitation exercise intervention.
3251240|NCT01393275|Placebo Comparator|Placebo rehabilitation|The group is performing a strength endurance training intervention in addition with placebo rehabilitation exercise intervention.
3251241|NCT01393288|Placebo Comparator|Ondansetron|
3251242|NCT01393288|Placebo Comparator|Lorazepam|
3251243|NCT01393288|Placebo Comparator|Aprepitant|
3251244|NCT01393314|Active Comparator|Honeywell HomMed Telemonitor|
3251245|NCT01393314|No Intervention|usual care|
3251246|NCT01393327|Experimental|Respiratory and exercise therapy|Early after PEA postoperative three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks.
3251247|NCT01393340|Placebo Comparator|Placebo|
3251248|NCT01393340|Active Comparator|Omalizumab|
3251249|NCT01393353|Sham Comparator|Computer game|Nintendo Wii
3251250|NCT01393353|Experimental|Cognitive Training with Cogniplus|CogniPlus
3251251|NCT01393366|Other|Without AMA|Patient will be follow only like usual practice
3251252|NCT01393366|Other|With AMA|Patient will be follow like usual practice, plus 'Telephone Intervention' every week with a nurse to evaluate physical conditions.
3251253|NCT01393418||Subjects undergoing cardiac surgery|
3251254|NCT01393431||EBC pH|Observational study
3251255|NCT01393470||Cohort A (Trial Cohort, Vaccinated during HPV-008)|"Cohort A subjects were previously enrolled in the HPV-008 study, and have received at least 1 dose of the HPV vaccine.~Cohort A subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
3251256|NCT01393470||Cohort B1 + B2|"Cohort B1 subjects were previously enrolled in the HPV-008 study and received at least 1 dose of HPV vaccine as cross-over vaccination at the end of the HPV-008 study.~Cohort B1 subjects have provided written informed consent prior to enrolment to allow retrieval of biospecimens for HPV DNA testing and confirmation of diagnosis.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries.~Cohort B2 (Trial Cohort, Non-Vaccinated)"
3366230|NCT02178345||Surgical patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
3366231|NCT02178345||surveillance management patients|The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
3366232|NCT02091934|Active Comparator|Wavefront-guided PRK|Wavefront-guided PRK
3366233|NCT02091934|Active Comparator|Wavefront-optimized PRK|Wavefront-optimized PRK
3366234|NCT02085148|Experimental|Sequential dosing schedule|Expansion phase: Schedule B - Sequential dosing schedule: Of a 21-day cycle, regorafenib will be dosed sequentially, following administration of VI: Vincristine：intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 8 to Day 21.
3366235|NCT02085148|Experimental|Concomitant dosing schedule|Expansion phase: Schedule A - Concomitant dosing schedule: Of a 21-day cycle, regorafenib will be concomitantly administered with vincristine and irinotecan (VI): Vincristine: intravenous bolus, 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg), Day 1 and Day 8. Irinotecan: intravenously over 1 hour, 50 mg/m2/day, Day 1 to Day 5. Regorafenib: orally, at a starting dose level of 72 mg/m2 (subjects 2 to less than 18 years old) or 60 mg/m2 (subjects 6 to less than 24 months old) once daily, Day 1 to Day 14.
3366236|NCT02085148|Experimental|Dose escalation|Dose escalation phase: This phase of the study has been completed
3366237|NCT02060721|Experimental|Macitentan|Macitentan 10mg, oral tablet, once daily
3366238|NCT02032823|Experimental|Olaparib|Olaparib tablets 300mg b.i.d. p.o.
3366239|NCT02032823|Placebo Comparator|Placebo|Placebo tablets b.i.d. p.o.
3366240|NCT02023996|Experimental|PET Imaging With 89Zr-DFO-Trastuzumab|Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
3366241|NCT02003924|Sham Comparator|Placebo|Sugar pill manufactured to mimic enzalutamide 40 mg capsule
3366242|NCT02003924|Experimental|Enzalutamide|160 mg by mouth once daily
3366243|NCT01997697|Experimental|Patients with obesity|behavior change program among patients with obesity
3366244|NCT01987648||All study participants|Included are all patients who 18 years or older, who get an elective craniotomy (no biopsy, no awake surgery, no re-operation) and who are treated at the Department of Neurosurgery
3366245|NCT01899261|Experimental|Treatment (SBRT)|Patients undergo SBRT every other day over 2 weeks (5 fractions total) in the absence of unacceptable toxicity.
3366246|NCT01872208|Experimental|HAVG graft|HAVG graft implantation to study participants.
3366247|NCT01840956|Experimental|HAVG|Surgical placement of HAVG
3366248|NCT01775072||Pts with solid tumors|Patients must have solid or hematologic cancer. for treatment on a . Patients must have undergone pathologic confirmation of their tumor at MSKCC and have either: 1) archival tissue available for analysis, 2) have fresh tissue collection planned as routine standard of care biopsy or part of a research biopsy under another clinical trial(or peripheral blood / bone marrow collection in the case of hematologic cancers) outside of the context of this protocol, or 3)archival tissue .available at an outside facility. For prospective genotyping tissue specimens from the primary site, a metastasis or recurrence will be used based upon the availability and quality of tissue.
3251257|NCT01393470||Cohort C (Referent Cohort, Non-Vaccinated)|"Cohort C subjects have not participated in the HPV-008 study but have been enrolled in the Referent Cohort.~Cohort C subjects have not received any HPV vaccination (neither Cervarix, nor Gardasil, nor any experimental HPV vaccine).~Cohort C subjects are partially matched to HPV-008 in terms of the geographical recruitment area.~Subjects who provided written informed consent prior to enrolment for the use of their personal identifier for linkage purposes to Finnish Registries."
3251258|NCT01393483||patients endoscopically resected|In patients with endoscopically resected T1 disease (40 patients in 2 years) if available, we will stain the initial endoscopic tumor specimen, as well as any subsequent specimen obtained at each routine 3(+/- 2) month interval endoscopy.
3366249|NCT01744418|Experimental|HAVG graft|HAVG graft implantation to study participants.
3251259|NCT01393483||patients treated primarily with surgery|In patients who undergo surgery as their primary therapy, serum will be obtained at the time of surgical resection, and at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months.
3251260|NCT01393483||patients who undergo chemo-radiation prior to surgery|a serum sample will be obtained : 1) prior to initiation of therapy, 2) following the completion of induction chemotherapy, 3) at the time of surgical resection, and 4) at each subsequent long-term disease status follow-up visit every 4 (+/- 2) months. The availability of tissue for staining will determine whether or not patients are evaluable for Group 3.
3251261|NCT01393496|Experimental|"liberal transfusion triggers"|"liberal guidelines for red blood cell transfusions"
3251262|NCT01393496|Active Comparator|"restrictive transfusion triggers"|"restrictive guidelines for red blood cell transfusions"
3251263|NCT01393509|Experimental|PU-H71|This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
3366250|NCT01639690|Experimental|Autologous CD34+ cells transduced with TNS9.3.55|An open label study using a non-myeloablative conditioning regimen of busulfan and 1 or several infusions of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the human ß-globin gene.
3366251|NCT01612351|Experimental|Non-Randomized Single-Arm|All participants will receive induction chemotherapy and transoral surgery. Following surgery, participants will be stratified into a risk category (low, medium, or high). Subjects in the low risk category will receive no further treatment after their transoral surgery. Subjects in the medium risk category will receive ipsilateral radiation concurrent with weekly cisplatin, and subjects in the high risk category will receive cisplatin every three weeks with concurrent bilateral radiation.
3366252|NCT01595503|Experimental|fMRI-based targeting|
3251264|NCT01393522|Active Comparator|Milnacipran|
3251265|NCT01393522|Placebo Comparator|Sugar Pill|
3251266|NCT01393548|Experimental|brompheniramine + phenylephrine|Fixed dose combination of brompheniramine + phenylephrine
3366253|NCT01595503|Active Comparator|landmark-based targeting|
3366254|NCT01547117|Experimental|High Sodium Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The high sodium diet will provide 300 milliequivalents (mEq) sodium/day.
3366255|NCT01547117|Experimental|Low Sodium Dietary Level|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels. The low sodium diet will provide 10 mEq sodium/day.
3366256|NCT01546571|Placebo Comparator|POL-103A without API|
3366257|NCT01546571|Experimental|POL-103A|
3366258|NCT01460160|Experimental|Arm 1: Dasatinib|
3366259|NCT01413399|Active Comparator|Intra-Arrest Therapeutic Hypothermia|
3366260|NCT01413399|Active Comparator|Post-Arrest Therapeutic Hypothermia|
3366261|NCT01291004|Experimental|28-day Desogestrel Oral Contraceptive|
3366262|NCT01291004|Active Comparator|28-day Drospirenone Oral Contraceptive|
3251267|NCT01393548|Active Comparator|brompheniramine + pseudoephedrine|Fixed dose combination of brompheniramine + pseudoephedrine
3366263|NCT01291004|Active Comparator|28-day Levonorgestrel Oral Contraceptive|
3366265|NCT01233960|Experimental|Prochymal|Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
3366266|NCT01226316|Experimental|Part A and B Schedule 1, Continuous dosing|Part A: Ascending doses of AZD5363 administered orally, every day to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A.
3366267|NCT01226316|Experimental|Parts A,B,C,D Schedule 2, Intermittent dosing|Part A: Ascending doses of AZD5363 administered orally, twice daily, on a 7-day repeating regimen (4 days on, 3 days off and 2 days on, 5 days off), to define the maximum tolerated dose. Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A (4 days on, 3 days off and 2 days on, 5 days off). Part C and D: AZD5363 orally, twice daily on an intermittent regimen (4 days on, 3 days off).
3366268|NCT01226316|Experimental|Parts A and B Schedule 3, Intermittent dosing.|"Part A: Ascending doses of AZD5363 administered orally, twice daily, on an alternative weekly regimen. Initiation of Schedule 3 is dependant on emerging clinical data.~Part B: Dose expansion phase, at the defined maximum tolerated dose or recommended dose from Part A"
3366269|NCT01226316|Experimental|Parts E and F, Intermittent dosing with Fulvestrant|Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment to cessation of therapy combined with background therapy of fulvestrant at its licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter to cessation of therapy.
3251268|NCT01393561|Experimental|Group 1|Fixed dose combination of brompheniramine + phenylephrine.
3251269|NCT01393561|Placebo Comparator|Group 2|Placebo
3251270|NCT01393574|Experimental|Melatonin treatment|Treatment with Melatonin before sleep for 1 month - 3 mg for body weight <40kg, 6mg for body weight >40kg
3251271|NCT01393574|Active Comparator|Stimulants treatment|Treatment with Methylphenidate with a formulary and dose as decided by the treating neurologist, for 1 month.
3251272|NCT01393587|Experimental|Experimental|
3251273|NCT01393639|Experimental|PF-04171327 1 mg QD|
3251274|NCT01393639|Experimental|PF-04171327 5 mg QD|
3251275|NCT01393639|Experimental|PF-04171327 10 mg QD|
3251276|NCT01393639|Experimental|PF-04171327 15 mg QD|
3251277|NCT01393639|Active Comparator|prednisone 5 mg QD|
3251278|NCT01393639|Active Comparator|prednisone 10 mg QD|
3251279|NCT01393639|Placebo Comparator|placebo|
3251280|NCT01393652|Experimental|Cohort 1: Experimental intervention: PF-05105679 or placebo|Cohort 1
3251281|NCT01393652|Experimental|Cohort 2: Experimental intervention: PF-05105679 or placebo|Cohort 2
3251282|NCT01393652|Active Comparator|Cohort 3: Experimental intervention PF-05105679 or placebo and|Cohort 3
3251283|NCT01393665|Placebo Comparator|Placebo|
3251284|NCT01393665|Experimental|PENNEL capsule|1cap or 2cap T.I.D
3251285|NCT01393678|Experimental|PENNEL|2cap T.I.D
3251286|NCT01393678|Active Comparator|NISSEL|"NISSEL~BDD (biphenylmethyl dicarboxylate) ................25mg~2cap T.I.D"
3251287|NCT01393691|Experimental|CBT with parent combined play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
3251288|NCT01393691|Active Comparator|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
3251289|NCT01393756|Experimental|Lenalidomide dose 25 mg|
3251290|NCT01393769|Experimental|Melphalan|Intra-arterial chemotherapy with melphalan, via direct administration by catheterization of the ophthalmic artery. Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume: a)3 mg for patients under 10 kg and tumour volume size under 1,5 cm3; b)5 mg for patients over 10 kg and tumour volume over 1,5 cm3; c)4 mg in all other situations(tumour volume over 1,5 cm3 in patients under 10 kg or tumour volume under 1,5 cm3 in patients over 10 kg).
3366270|NCT01170702|Placebo Comparator|Group 1|TAP Block utilizing 15mL of 0.9% normal saline per side
3366271|NCT01170702|Experimental|Group 2|TAP Block utilizing 15ml of 0.2% ropivacaine per side
3366272|NCT01170702|Experimental|Group 3|TAP Block utilizing 15ml of 0.5% ropivacaine per side
3366273|NCT01170702|Experimental|Group 4|TAP Block utilizing 15ml of 0.75% ropivacaine per side
3366277|NCT01093326|Experimental|Ponesimod 10 mg|Ponesimod 10 mg oral use
3366278|NCT01093326|Experimental|Ponesimod 20 mg|Ponesimod 20 mg oral use
3366279|NCT01093326|Experimental|Ponesimod 40 mg|Ponesimod 40 mg oral use
3366280|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 2 mg|Participants received riociguat up to 2 mg three times per day (tid) (increasing from 0.5 to 1 to 2 mg).
3366281|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) up to 1 mg|Participants received riociguat up to 1 mg tid (increasing from 0.5 to 1 mg).
3251291|NCT01393782|Active Comparator|Angiotensin|The angiotensin arm will receive angiotensin II acetate at an initial dose of 20ng/kg/min, titratable during the study (6 hours) for MAP goals as outlined in the protocol.
3251292|NCT01393782|Placebo Comparator|Control|Control patients will receive placebo intravenously equal in duration, color and volume to the intervention arm's angiotensin II.
3366282|NCT01065454|Experimental|Riociguat (Adempas, BAY63-2521) fixed 0.5 mg|Participants received riociguat 0.5 mg tid (fixed dose).
3366283|NCT01065454|Placebo Comparator|Placebo|Participants received placebo tid.
3366284|NCT01018563|Experimental|MORAb-003|Maintenance infusions of MORAb-003 every 3 weeks
3251293|NCT01393795|Placebo Comparator|Tegaderm|
3251294|NCT01393795|Active Comparator|Qutenza|
3366287|NCT00920387|Experimental|Full Dose LSD (200 mcg)|200 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
3366288|NCT00920387|Active Comparator|Active Placebo LSD (20 mcg)|20 mcg LSD administered once during each of two LSD-assisted therapy sessions, scheduled two to four weeks apart.
3366289|NCT00816114||Chronic Myelogenous Leukemia|All CML patients in any phase of the disease that received imatinib treatment outside of MDACC clinical trials and has had at least one MDACC clinic visit.
3366290|NCT00805961|Experimental|Intervention|"Combined Modality Treatment and Systemic Therapy~Combined Modality Therapy - Radiation Therapy: 2 Gy/fraction, single daily fractions Monday-Friday, to total of 60 Gy Temozolomide: 75 mg/m2 by mouth daily Bevacizumab: 10 mg/kg IV every 2 weeks (Weeks 1, 3, 5, and 7)~After the last dose of radiation, patients exhibiting an objective response, stable disease on MRI scan, or have stable/improved tumor-related symptoms will begin systemic therapy~Systemic Therapy - Bevacizumab: 10 mg/kg IV every 2 weeks Everolimus: 10 mg by mouth daily"
3366291|NCT00762866||MDD|Unipolar Major Depressive Disorder, any subtype
3366292|NCT00762866||Bipolar|Bipolar I or II Disorder or Bipolar Disorder NOS
3366293|NCT00762866||Psychosis|Psychotic Disorder including Schizophrenia, Schizoaffective, Schizophreniform, Brief Psychotic Disorder, and Psychotic Disorder NOS
3366294|NCT00750841|Experimental|1|Cediranib alone, followed by cediranib plus rifampicin, followed by cediranib alone.
3366295|NCT00625417|Experimental|Optical spectroscopy on tumor margins|Optical spectroscopy is performed on breast tumor margins obtained from patients undergoing surgery
3366296|NCT00600496|Experimental|1|AZD6244 + docetaxel
3251295|NCT01393808|Experimental|Paricalcitol|
3251296|NCT01393808|Placebo Comparator|placebo|
3251297|NCT01393834|Experimental|Delayed cord clamping|Delayed cord clamping for 30 seconds
3366297|NCT00600496|Experimental|2|AZD6244 + Dacarbazine
3366298|NCT00600496|Experimental|3|AZD6244 + Erlotinib
3366299|NCT00600496|Experimental|4|AZD6244 + Temsirolimus
3366300|NCT00562497|Placebo Comparator|Placebo|Placebo
3366301|NCT00562497|Active Comparator|Prochymal™|Subjects assigned to the active treatment group will receive Prochymal™.
3366302|NCT00374660|Experimental|1|
3376144|NCT02603900|Experimental|Local Infiltration of Analgesia|Local infiltration using 20 ml of free bupivacaine solution (Marcaine 0.25% with epinephrine 1:200000, ) diluted with 40 ml of normal saline following implantation of the knee prosthesis, the solution will be injected into the vastus medialis (5 ml), medial retinaculum (5 ml), origin of MCL (5 ml) and LCL (5 ml), lateral portion of quadriceps tendon (5 ml), vastus lateralis (5 ml), and subcutaneous tissues especially along saphenous nerve distribution (30 ml). Postoperatively, a sham adductor canal catheter will be placed as in the ACC arm following stabilization in the PACU to infuse only normal saline with an initial bolus of 15 ml saline and infusion of saline at 10ml/hr for 72 hours.
3376145|NCT02595905|Active Comparator|Arm I (cisplatin and placebo)|Patients receive cisplatin IV over 1 hour on day 1 and placebo PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3376146|NCT02595905|Experimental|Arm II (cisplatin and veliparib)|Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3376147|NCT02595372|Experimental|High dose omeprazole treatment|Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery.
3376148|NCT02584634|Experimental|Group A|ALK negative Non-Small Cell Lung Cancer
3376149|NCT02584634|Experimental|Group B|ALK positive Non-Small Cell Lung Cancer
3376150|NCT02576496|Experimental|Tinostamustine (EDO-S101)|EDO-S101, IV, 20mg/m2 up to 150mg/m2 Day1 of each 21 day cycle-Stage 1; EDO-S101,IV, 40mg/m2 up to 60mg/m2 on Day 1 and Day 15 of 28 day cycle in multiple myeloma patients and IV, 40mg/m2 up to 100mg/m2 on Day 1 of 21 day cycle in lymphoma patients-Stage 2
3376151|NCT02521844|Experimental|Dose Escalation|ETC-1922159 + pembrolizumab
3376152|NCT02521844|Experimental|Dose Expansion|ETC-1922159 as single agent until disease progression, then in combination with pembrolizumab at the recommended dose (RD) identified in the dose escalation segment
3376153|NCT02510261|Experimental|Patisiran (ALN-TTR02)|
3366314|NCT05152498|Experimental|Fu Zheng Jie Du Hua Yu therapy|
3366315|NCT05152498|Experimental|Routine medical care|
3366316|NCT05152485|Active Comparator|BIIB104 0.5 mg Reference Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release liquid-filled hard-shell capsule, orally, on Day 1 in the fasted state.
3366317|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fasted State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fasted state.
3366318|NCT05152485|Experimental|BIIB104 0.5 mg Test Formulation (Fed State)|Participants will receive BIIB104 0.5 mg, immediate-release softgel capsule, orally, on Day 1 in the fed state.
3251298|NCT01393834|Experimental|Milking of the cord|Milking of the cord 4 times in 10 seconds
3251299|NCT01393834|No Intervention|Immediate cord clamping|Immediate cord clamping after delivery
3251300|NCT01393860||Aliskiren|Diabetic nephropathy
3251301|NCT01393873||Bariatric surgery pts with Type 2 DM|Primary bariatric surgery pts with Type 2 DM
3251302|NCT01393886|Experimental|Laparoscopic Greater Curvature Plication|Only one treatment arm
3251303|NCT01393912|Other|Stratum A Patients|The patients are newly diagnosed Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 3 (170 mg/m^2).
3251304|NCT01393912|Other|Stratum B Patients|The patients are recurrent, refractory or progressive high-grade glioma including Diffuse Intrinsic Pontine Glioma patients. Patients may take crenolanib as an intact tablet or crushed in apple sauce/juice. Currently accruing to dose level 4 (220 mg/m^2).
3251305|NCT01393925|Experimental|parecoxib, normal saline|
3251306|NCT01393938|Other|Mullerian Duct Anomaly|
3251307|NCT01393951|Experimental|sc dose 1|subcutaneous (sc) vaccination of ASP7374 dose-1
3366319|NCT05152472|Experimental|Imatinib + Atezolizumab|Imatinib per os 400 mg daily continuously associated with intravenous administrations of atezolizumab at the fixed dose of 1 200 mg every 3 weeks (up to 12 months)
3366320|NCT05152472|Active Comparator|Imatinib alone|Imatinib alone, per os 400 mg daily continuously (up to 12 months)
3251308|NCT01393951|Experimental|sc dose 2|subcutaneous vaccination of ASP7374 dose-2
3251309|NCT01393951|Experimental|im dose 3|intramuscular (im) vaccination of ASP7374 dose-3
3366321|NCT05152459|Experimental|Treatment (tazemetostat, umbralisib, ublituximab)|Patients receive ublituximab IV on days 1, 8, and 15 of cycle 1, day 1 of cycle 2-6, and day 1 of every 3 cycles thereafter. Patients also receive tazemetostat PO BID umbralisib by PO QD on days 1-28. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity.
3366322|NCT05152446|Experimental|Infusion management scheme|To implement infusion management scheme, then observe the continuous changes.
3366323|NCT05152433|Active Comparator|Conventional therapy|Length of period: 2 weeks
3366324|NCT05152433|Experimental|Therapy assisted by a humanoid robot (E-BRAiN)|Length of period: 2 weeks Fixed dose: 10 therapy sessions with E-BRAiN
3366325|NCT05152420|Experimental|Part 1 - Cohort 1|Single dose cohort
3366326|NCT05152420|Experimental|Part 1 - Cohort 2|Single dose cohort
3366327|NCT05152420|Experimental|Part 1 - Cohort 3|Single dose cohort
3366328|NCT05152420|Experimental|Part 1 - Cohort 4|Single dose cohort
3366329|NCT05152420|Experimental|Part 1 - Cohort 5|Single dose cohort
3366330|NCT05152420|Experimental|Part 1 - Cohort 6|Single dose cohort
3366331|NCT05152420|Experimental|Part 2 - Cohort 1|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
3366332|NCT05152420|Experimental|Part 2 - Cohort 2|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
3366333|NCT05152420|Experimental|Part 2 - Cohort 3|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
3366334|NCT05152420|Experimental|Part 2 - Cohort 4|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
3366335|NCT05152420|Experimental|Part 2 - Cohort 5|Single dose cohort of selected FXa DOAC anticoagulant in combination with VMX-C001
3251310|NCT01393977|No Intervention|control|Outpatient in hospital
3251311|NCT01393977|Active Comparator|rehabilitation|interventions: rehabilitation
3251312|NCT01393977|Experimental|Stem Cell Transplantation|interventions: stem cell transplantation
3251313|NCT01394016|Experimental|LY2835219|
3251314|NCT01394029||deferasirox|
3251315|NCT01394042|No Intervention|No intervention|All consenting patients will be imaged with the Proxiscan and data compared with MRI, ProstaScint and biopsy data
3251316|NCT01394055|Active Comparator|RM-131|
3251317|NCT01394055|Placebo Comparator|Placebo|
3251318|NCT01394094|Experimental|Gum Chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
3251319|NCT01394094|No Intervention|Conventional|Conventional postoperative feeding schedule
3251320|NCT01394107||Pregnant|"50 pregnant women with physiological ongoing pregnancy and undergoing planned caesarean section, without known coagulation disorders, will be included in to the study.~Inclusion criteria: pregnant women undergoing planned caesarean section, 39th-40th week of pregnancy, age 18-40 years, informed consent."
3366338|NCT05152394|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3366339|NCT05152381|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3366340|NCT05152368|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3366341|NCT05152355|Experimental|Budesonide HFA MDI (Treatment A)|Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks
3366342|NCT05152355|Active Comparator|Budesonide DPI (Turbuhaler) (Treatment B)|Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks
3366343|NCT05152342|Experimental|Staff intervention|Half day virtual training for staff focusing on stigma reduction strategies.
3366344|NCT05152342|Experimental|Client intervention|Three session virtual therapy group for clients focusing on behavioral strategies to cope with stigma.
3366345|NCT05152303|Experimental|Remimazolam Tosilate|
3366346|NCT05152303|Active Comparator|Propofol Injection|
3251321|NCT01394107||Control|50 healthy women in fertility age (18-40 years) undergoing elective surgery for other than oncology or inflammatory indication, without known risk factors for coagulation disorders, not using hormonal contraception, informed consent.
3251322|NCT01394120|Experimental|Tarteted Therapy|
3251323|NCT01394120|Active Comparator|Standard Chemotherapy|
3366347|NCT05152290|Experimental|Treatment Group (AlloRx)|intravenous infusion and intrathecal injection (total of 100 million cells)
3366348|NCT05152277|Experimental|Single dose escalation of HRS9531 injection in healthy subjects|
3366349|NCT05152277|Placebo Comparator|Single dose of placebo in healthy adults|
3366350|NCT05152277|Experimental|Multiple dose escalation of HRS9531 injection in healthy subjects|
3366351|NCT05152277|Placebo Comparator|Multiple dose of placebo in healthy adults|
3366352|NCT05152264|Active Comparator|TENS (transcutaneous electrical nerve stimulation)|Patients with endometriosis-related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
3251324|NCT01394133||HIV+ Female|HIV infected women between 21-40 years of age, not receiving oral contraceptives.
3251325|NCT01394146|Experimental|Subjects with healthy kidney function|
3366353|NCT05152264|Active Comparator|Conventional analgesic treatment|Patients with endometriosis related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to conventional analgesic treatment for 8 weeks. After 8 weeks the patients are treated with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
3366354|NCT05152264|Active Comparator|External control group|Patients with endometriosis-related pain that is not frequent or without high pain intensity (< 4 according to Numeric Rating Scale, NRS) constitute an external control group. The patients are treated with transcutaneous electrical nerve stimulation as add-on treatment in addition to conventional analgesic treatment. Treatment with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
3366355|NCT05152251||Study Group|Down Syndrome
3366356|NCT05152251||Control Group|Typically Developing Children
3251326|NCT01394224|Experimental|Levetiracetam IV Infusion (1500 mg)|
3366357|NCT05152225||Infective endocarditis|Infective endocarditis with systematic brain MRI and digital subtraction angiography (DSA) performed routinely.
3366358|NCT05152212|Experimental|LVGN7409|Monotherapy Dose Escalation
3366359|NCT05152199|Other|Cystoscopy with use of obturator sheath|This intervention arm will include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy.
3366360|NCT05152199|Active Comparator|Cystoscopy without use of obturator sheath|This intervention arm will not include the use of the obturator sheath upon entry into the urethra during rigid cystoscopy, but will consist of using the telescope under direct visualization.
3366361|NCT05152186|Active Comparator|tranexamic acid|Topical hemostatics as tranexamic acid or hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
3251327|NCT01394224|Experimental|Levetiracetam tablets (1500 mg)|
3251328|NCT01394237||Operated by laparoscopic sacrocolpopexy|Patients operated at our institution by laparoscopic sacrocolpopexy between 2003 and 2007
3251329|NCT01394263|Active Comparator|Zoladex goserelin implant.|Zoladex goserelin implant: D, L-lactic and glycolic acids copolymer. Injected subcutaneously into the upper abdominal wall.
3251330|NCT01394263|Experimental|Histrelin Acetate implant|Histrelin hydrogel implant, 3 cm x 3.5 mm, containing 50 mg of histrelin acetate, surgically placed subdermally into the inner aspect of the upper arm.
3366362|NCT05152186|Active Comparator|Hydrogen peroxide|Topical hemostatics as hydrogen peroxide in wound before skin closure to decrease perioperative blood loss
3366363|NCT05152186|Placebo Comparator|Normal saline|Hemostasis in spine surgery
3366366|NCT05152160|Experimental|Treatment group|Umbilical Cord Mesenchymal Stem Cell Therapy
3366370|NCT05152134|Experimental|E-ROD|Empowered Relief: On-Demand (E-ROD) will include roughly 60 minutes of interactive and multimedia pain educational content that targets pain and stress self-regulation, pain medication misuse, a personalized plan for relief and a 'relaxation medicine' app.
3366371|NCT05152134|Placebo Comparator|Health Education (HE)|The HE arm is an interactive digital general health education intervention that is devoid of specific content on pain, psychological skills, and has no active strategies or worksheets.
3366373|NCT05152108|Experimental|Stroke patients|Experimental group of stroke survivors for testing the feasibility of a BCI system
3251331|NCT01394289|Experimental|Biological/Vaccine: Lolium allergen extract|Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
3251332|NCT01394328||Persons with Dementia|Persons with Dementia are identified by the Modified Blessed Dementia Rating Scale and the IQCODE
3251333|NCT01394341|Active Comparator|T2D, Dialysis, Liraglutide|Daily liraglutide treatment Chronic dialysis treatment
3251334|NCT01394341|Placebo Comparator|T2D, Dialysis, Placebo|Daily placebo Chronic dialysis treatment
3366378|NCT05152030||hyposmic patients|
3366379|NCT05152030||anosmic patients|
3366380|NCT05152030||normosmic group|
3366381|NCT05152017|Experimental|Flu-M Quadro with preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine with a preservative
3366382|NCT05152017|Experimental|Flu-M Quadro without preservative|25 volunteers were vaccinated with the Flu-M Quadro inactivated split influenza vaccine without a preservative
3366383|NCT05152017|Placebo Comparator|Placebo|25 volunteers were vaccinated with a Placebo
3366384|NCT05152004|Experimental|High dose dual therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 750 mg q.i.d for 14 days
3366385|NCT05152004|Active Comparator|Hybrid therapy|Rabeprazole (Pariet) 20 mg and amoxicillin (Amolin) 1 g b.i.d. for 7 days, followed by rabeprazole (Pariet) 20 mg, amoxicillin(Amolin)1 g, clarithromycin (Klaricid) 500 mg, and metronidazole (Flagyl) 500 mg b.i.d. for 7 days
3366388|NCT05151978||(glasgow coma scale) 9 _15|No Secondary Neurological deterioration
3366389|NCT05151978||(glasgow coma scale) 9_15|Secondary Neurological deterioration
3366392|NCT05151952||Cancer patients receiving proton radiation therapy|Cancer patients receiving proton radiation therapy, Registry of cancer patients who receive proton radiation therapy to crack disease and toxicity outcomes.
3366394|NCT05151926|Experimental|Full weight-bearing|Full immediate weight-bearing postoperatively
3366395|NCT05151926|Active Comparator|Partial-weight bearing|Partial weight-bearing for the first 6 weeks postoperatively.
3366396|NCT05151913||Previous ICP, recurrence|Pregnant women with at least one previously completed parturition with ICP and ICP during the present study
3366397|NCT05151913||Previous ICP, non-recurrence|Pregnant women with at least one previously completed parturition with ICP and no ICP during the present study
3366398|NCT05151913||No previous ICP|Pregnant women with at least one previously completed parturition with no previous ICP and no ICP during the present study
3251335|NCT01394341|Active Comparator|T2D, Normal kidney function, Liraglutide|Daily Liraglutide treatment Normal kidney function
3251336|NCT01394341|Placebo Comparator|T2D, Normal kidney function, Placebo|Daily placebo treatment Normal kidney function
3251337|NCT01394354|Experimental|1|"Vorinostat. To determine the MTD, dose escalation for Vorinostat will be conducted following the 3 + 3 design The first cohort of 3 patients will be given 100mg/d on days 1-4, 8-11, 15-18. The second cohort of 3 new patients will be treated with Vorinostat 200mg/d. The third cohort will be given Vorinostat 300mg/d. Cycles will be repeated every 28 days. Maximum treatment cycles: 6. Bortezomib will be administered intravenously (i.v.) 1.3mg/m2 BSA an days 1, 8, 15.~Doxorubicin will be administered i.v. with a total dose of 18mg/m2 BSA per cycle (9mg/m2 BSA, d1 and 8).~Dexamethasone will be administered per os (p.o.) with 40mg (first cycle) or 20mg (all other cycles) on d1, 8, 15, and 22."
3251338|NCT01394367|Experimental|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
3366399|NCT05151900|Experimental|Stakeholder Perspectives and Virtual Parent-Led Peer Support Group|Qualitative interviews regarding the impact of COVID-19 will be conducted with youth who have an eating disorder (ED), parents of youth who have an ED, ED clinicians and ED program administrators, as well as get their perspectives on parent-led peer support groups. Three parent-led peer support groups will be started, including psychoeducation in a virtual group setting for parents who have a child or adolescent with an eating disorder.
3366400|NCT05151887|Experimental|Meat meal|Minced beef, potato, string beans, apple sauce, and herb butter
3366401|NCT05151887|Experimental|Plant meal|Quinoa, soy beans, chickpeas, broad beans, and soy sauce
3366402|NCT05151874||Range of movement|Change in passive joint mobility (ROM) of the carpus (flexion-extension) affected by spasticity pattern III during a 20-week follow-up.
3251339|NCT01394367|No Intervention|respiratory and exercise therapy|
3251340|NCT01394380|Experimental|artificially sweetened beverages|subjects will be required to consume only artificially-sweetened sodas, water, tea or coffee
3251341|NCT01394380|No Intervention|regular sodas|subjects will continue their usual consumption of sweetened sodas
3251342|NCT01394393|Experimental|ECT|Experiential-Cognitive Therapy for Obesity
3251343|NCT01394393|Active Comparator|BCT|Cognitive behavioral treatment program
3366407|NCT05151835|Experimental|Robotic Surgery|Prospective single arm study to investigate effect of a novel robotic surgical system on safety, efficacy and outcomes for performance of minimally invasive surgery across urology, upper and lower GI surgery.
3251344|NCT01394393|Sham Comparator|NT|Nutritional groups In this condition (NT) the participants enter only 5 weekly nutritional groups held by dietitians.
3251345|NCT01394406|Experimental|Ketamine group|
3251346|NCT01394406|Placebo Comparator|Saline group|
3366409|NCT05151809||PBC population residing in Italy|"All PBC patients living in Italy and aged at least 18 years can be included in the database. According to well-established criteria, PBC is diagnosed in subjects who fulfill two of the three of following criteria:~elevated alkaline phosphatase and /or GGT;~positive anti-mitochondrial autoantibodies (titer ≥ 1:40) or PBC-specific antinuclear antibodies (gp-210 and sp100);~characteristic histological features of florid bile ducts lesions and granulomatous lesion."
3366410|NCT05151796||Aspirin continued within 5 days before surgery|
3366411|NCT05151796||Aspirin discontinued more than 5 days before surgery|
3366412|NCT05151783|Active Comparator|conventional physiotherapy|routine physical therapy for adhesive capsulitis
3366413|NCT05151783|Experimental|PNF techniques|PNF techniques along with conventional physiotherapy
3366414|NCT05151757|Experimental|To test the effectiveness of a training course to improve graders ability to detect glaucoma|"Study design: This is an uncontrolled interventional experimental before and after study in which a minimum of 42 non-physician graders shall be trained to screen for glaucoma using optic nerve photos obtained for diabetic retinopathy (DR) screening in Vietnam.~The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma, obtained from the on-going ORBIS CAFÉ DR screening programme (in which the graders are working), population-based eye studies in the UK (NICOLA) and the standard Glaucomatous Optic Neuropathy Evaluation (GONE) set of images. (https://gone-project.com/newgone/). The test set contains 60 normal and glaucomatous optic disc images."
3366415|NCT05151744|Experimental|Arm A: RO7200220 + Ranibizumab|Participants will receive RO7200220, 1 milligram (mg) administered as intravitreal (IVT) injection in combination with ranibizumab, 0.5 mg IVT, on Day 1 and every fourth week (Q4W) up to Week 20, for a total of 6 injections, followed by an observational period up to Week 48.
3366416|NCT05151744|Active Comparator|Arm B: Ranibizumab|Participants will receive ranibizumab, 0.5 mg IVT, from Day 1 and Q4W in combination with sham up to Week 20, for a total of 6 injections, followed by an observational period up to Week 48.
3366417|NCT05151731|Experimental|Arm A: 0.25 mg RO7200220 Q8W|Participants will receive RO7200220 0.25 milligrams (mg), by Intravitreal (IVT) injection, on Day 1 and every 8th week (Q8W), up to Week 20, for a total of 3 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
3366418|NCT05151731|Experimental|Arm B: 1.0 mg RO7200220 Q8W|Participants will receive RO7200220 1.0 mg, by IVT injection, on Day 1 and Q8W, up to Week 20, for a total of 3 injections. A sham procedure will be administered during study visits at which no study drug is administered to maintain masking between treatment arms.
3366419|NCT05151731|Experimental|Arm C: 1.0 mg RO7200220 Q4W|Participants will receive RO7200220 1.0 mg, by IVT injection, on Day 1 and every 4th week (Q4W), up to Week 20 for a total of 6 injections.
3366420|NCT05151731|Active Comparator|Arm D: 0.5 mg Ranibizumab Q4W|Participants will receive ranibizumab 0.5 mg, by IVT injection, on Day 1 and Q4W, up to Week 20 for a total of 6 injections.
3251347|NCT01394419|Experimental|NAC group|N-acetylcysteine
3251348|NCT01394419|Placebo Comparator|Placebo group|Saline
3251349|NCT01394432|Active Comparator|Group 1 (PCI+SC implantation)|Endocardial Stem cells implantation with Noga system
3251350|NCT01394432|Placebo Comparator|Group 2 (PCI+Placebo)|Placebo
3251351|NCT01394445|Active Comparator|Physostigmine|
3251352|NCT01394445|Placebo Comparator|Placebo|
3251353|NCT01394458|Experimental|30 % ethanol/ 4 % sodium citrate group|For patients randomized to the 30% ethanol /4 % sodium citrate group, the lock solution will be provided in pre-filled syringes for single use only. After each dialysis session, the locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. Any remaining 30% ethanol/4% sodium citrate solution in each syringe will be discarded. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
3251354|NCT01394458|Experimental|Heparin 1000 U/ml|For patients randomized to the heparin group, the heparin will be provided in 10 ml glass vials. Two, 3 ml syringes will be used to draw up the required volume of heparin to fill each lumen. A separate syringe will be used to fill each catheter lumen. The necessary volume should match the lumen volume with no overfill. The locking solution will be instilled into both catheter lumens, the lumens clamped and caps tightly secured to the hubs. The locking solution will be withdrawn from the catheter lumens before the next dialysis session.
3251355|NCT01394471|Experimental|oxytocin|Twice daily treatment of oxytocin will be administered by subjects
3251356|NCT01394471|Placebo Comparator|Control spray|Self administration twice daily of intranasal spray that does not contain oxytocin
3251357|NCT01394484|Experimental|Arm 1|Four servings of dairy foods per day for 42 days, followed by washout for 42 days, followed by dietary supplements for 42 days
3251358|NCT01394484|Experimental|Arm 2|Dietary Supplements for 42 days, followed by washout for 42 days, followed by 4 servings of dairy foods for 42 days.
3251359|NCT01394497|Experimental|NAC procurement protocol|The allocated organ, in addition to the standard procedure, was treated with a systemic NAC infusion before initiating the liver harvesting procedure, and a loco-regional infusion into the portal vein before cross-clamping.
3366421|NCT05151705|Experimental|Treatment group A: HR17031 injection|
3251360|NCT01394497|No Intervention|Standard procurement procedure|Allocated organ was treated according to the centre's standard procurement procedure: a modified double perfusion technique, where donor livers are gravity-perfused in situ via the aorta and portal vein with Celsior solution at 4 °C. After hepatectomy, donor livers were further perfused at the back-table with Celsior solution and then stored in conventional bags containing the same solution at 4 °C until transplantation.
3366422|NCT05151705|Experimental|Treatment group B: HR17031 injection|
3366423|NCT05151705|Experimental|Treatment group C: HR17031 injection|
3366424|NCT05151692|Experimental|Cohort 1: Nipocalimab|Participants will receive a single intravenous (IV) dose of nipocalimab Dose 1 on Day 1.
3366425|NCT05151692|Experimental|Cohort 2: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 2 on Day 1.
3366426|NCT05151692|Experimental|Cohort 3: Nipocalimab|Participants will receive a single IV dose of nipocalimab Dose 3 on Day 1.
3366427|NCT05151666|Experimental|Hemodialysis Patients|
3251361|NCT01394536|Sham Comparator|1|"Sham device - an EAS band placed over the P6 acupoint that will be turned off (inactive)."
3251362|NCT01394536|Active Comparator|2|The second arm will use the ReliefBand (Aeromedix, Jackson, WY), an FDA-approved, reusable, battery-operated electroacustimulation device.
3366431|NCT05151627|Experimental|KINESIO TAPING AND CONVENTIONAL PHYSICAL THERAPY|Application of Kinesio taping following Transcutaneous Electrical Nerve Stimulation and Knee Exercises
3366432|NCT05151627|Experimental|CONVENTIONAL PHYSICAL THERAPY|Application of Transcutaneous Electrical Nerve Stimulation and Knee Exercises
3366433|NCT05151614|Experimental|Colchicine group|Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy
3366434|NCT05151614|No Intervention|Control group|"The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:~Acetaminophen 500mg on need~Vitamin C 1000mg twice/ day~Zinc 75-125 mg/day~Vitamin D3 5000IU/day~Azithromycin 250mg/day for 5 days~Oxygen therapy/ C-Pap if needed~Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~Mechanical ventilation, if needed"
3366435|NCT05151601|Experimental|HMOs + Probiotics|"Dosing: A total daily dose of 2 x sachets (6g/day)~Product Comprised of:~2.5g of a proprietary blend of human milk oligosaccharides combined with~20 billion CFUs of a mixture of Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium animalis spp. lactis, and Bifidobacterium longum.~Mode of administration: oral."
3366436|NCT05151601|Placebo Comparator|Placebo|Dosing: A total daily dose of 2 x sachets (6g/day)u (8 weeks of phase 1A). Product: powdered maltodextrin. Mode of administration: oral.
3366438|NCT05151575|Experimental|group-based walking intervention with professional trainer's supervision|Participants will conduct the intervention in groups under the supervision of a professional fitness trainer.
3366439|NCT05151575|Active Comparator|individual-based walking intervention without professional trainer supervision|Participants will conduct the intervention individually, without the supervision of a professional fitness trainer
3366440|NCT05151575|No Intervention|control group|No intervention will be given to the control group.
3366441|NCT05151562|Experimental|Virtual Music Therapy|Participants will attend two 30 minutes long virtual music therapy sessions per week for 8 weeks using Zoom.
3366442|NCT05151549|Experimental|Camrelizumab , Cisplatin or Carboplatin|Participants will be given intravenous administration of Camrelizumab (200mg) ,Cisplatin(40mg/m²) or Carboplatin(AUC 2) and Radiotherapy. After completing 17 cycles of concurrent chemoradiation, the Participants will continue to use camrelizumab as maintenance therapy until one year.
3366443|NCT05151510|Experimental|Trigger point with 1% Lidocaine|The physician will withdraw 1cc of 1% lidocaine in a 25g needle, sterilely prep the field with a Chloraprep applicator, use index, and middle finger to squeeze the borders of the trigger point and raise the central aspect of the trigger point, insert the needle at 90-degree angle up to 5/8' deep, inject 1cc of the 1% lidocaine after ensuring needle is not in a blood vessel, removing the needle, and then covering the insertion site with a sterile bandage.
3366444|NCT05151510|Active Comparator|5% Lidocaine Patch|5% lidocaine patch will be placed at the point of maximal tenderness upon palpation. Location of placement will be described and instructed by physician and placed by nursing staff.
3251363|NCT01394549||Cardiology|The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study.
3366447|NCT05151484|Active Comparator|Group 1 Low Turnover|Teriparatide (anabolic) For 1 Year
3366448|NCT05151484|Active Comparator|Group 2 Low Turnover|"Standard of Care - Control:~Treated with Alendronate (antiresorber) For 1 Year"
3366449|NCT05151484|Active Comparator|Group 3 Normal-High Turnover|Standard of Care Treatment with Alendronate (antiresorber) For 1 Year
3366450|NCT05151471|Experimental|MT-1186 - Group 1|Oral edaravone administered once daily for up to 48 weeks or until the drug is commercially available in that country.
3251364|NCT01394562|Experimental|Ferinject (ferric carboxymaltose)|
3366451|NCT05151471|Experimental|MT-1186 - Group 2|Oral edaravone administered for 10 days followed by 18-day placebo (regimen denoted as on/off) for up to 48 weeks or until the drug is commercially available in that country.
3366452|NCT05151445||mHealth dietary app + health coaching intervention|A feasibility study will be utilized to establish the recruitment, retention, and adherence with post-kidney transplant recipients using a consumer-based mHealth dietary app + health coaching.
3366453|NCT05151432|Experimental|Pulsed US + Exercise Group|Twenty subjects will receive PUT, plus an exercise program.
3366454|NCT05151432|Experimental|Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PEMF, plus an exercise program.
3366455|NCT05151432|Experimental|Pulsed US + Pulsed Electromagnetic + Exercise Group|Twenty subjects will receive PUT, PEMF, plus an exercise program.
3366456|NCT05151432|Experimental|Sham + Exercise group|Twenty subjects will receive sham PEMF and sham PUT plus exercises program.
3366457|NCT05151419|Other|bronchoscope ,forceps,cryo-biopsy|biopies were taken from the lung mass using forceps and cryo-biopsy to evalute diagnostic yield of cryo-biosy versus forceps in the diagnosis of lung cancer
3366458|NCT05151406|Active Comparator|medical students|5th year undergraduate medical students
3366459|NCT05151406|Active Comparator|nursing students|4th year undergraduate nursing students
3366460|NCT05151393||Cases|Cases with uterine leiomyoma
3366461|NCT05151393||Controls|Cases free of uterine leiomyoma
3366463|NCT05151367|Experimental|Text message reminders|Text message reminders
3366464|NCT05151367|No Intervention|Usual Care|No reminders
3366465|NCT05151341|Experimental|Case|Patient in whom newly diagnosed, or recurring / progressing bladder cancer is strongly suspected after initial fibroscopy
3366466|NCT05151341|Experimental|Control|Patient attending or hospitalized for urolithiasis, urinary infections, superior excretory stones or with non suspect urinary symptomatology
3366467|NCT05151328|Experimental|Plecanatide group(n=320)|The investigational products are administrated orally, each patient will take one table (Plecanatide 3.0mg) Once daily(QD) in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
3366468|NCT05151328|Placebo Comparator|Placebo group (n=320)|The investigational products are administrated orally, each patient will take one table (Placebo 3mg) QD in the day before 18:00 with approximately of water. If the investigational product is not taken in the day before 18:00 then skip the dose on that day and take the next dose on the next regular time. The duration of treatment is 12 weeks.
3366469|NCT05151315|Active Comparator|Evolution Total Knee Arthroplasty system|Patients will undergo total knee arthroplasty with the Evolution Total Knee System
3366470|NCT05151315|Experimental|Evolution with NitrX Total Knee Arthoplasty system|Patients will undergo total knee arthroplasty with the NitrX Evolution Total Knee System which has the specialized protective coating
3366471|NCT05151302|Other|completion of the computer vision symptom scale questionnaire, italian version|video display terminal (VDT) workers completed the questionnaire
3366472|NCT05151289|Experimental|Patients consulting in one of the participating centers for intra uterine growth restriction.|All included patients
3366473|NCT05151276|Experimental|Intervention Group|individuals with odd sequence numbers were assigned to the intervention group (n=46)
3366474|NCT05151276|No Intervention|Control Group|those with even numbers to the control group (n=47).
3251365|NCT01394562|Other|Standard of Care|Standard of care. IV iron is not permitted
3251366|NCT01394575|Experimental|IMRT-SIB|
3251367|NCT01394588||Cardiac Surgery Patients|Competent Adult Patients going for elective cardiac surgery.
3251368|NCT01394640||Healthy Volunteers|Healthy people without any serious comorbidity (no immunosuppressive treatment, no autoimmune disease, no cancer) receiving the same vaccine
3251369|NCT01394640||Onco-hematologic patients|Patients with lymphoma or myeloproliferative diseases or multiple myeloma either receiving chemotherapy or in follow-up or treated with allogeneic hematopoietic stem cell transplant.
3251370|NCT01394653|Experimental|orally-disintegrating (OD) tablet precedence group|
3251371|NCT01394653|Experimental|conventional tablet precedence group|
3251372|NCT01394666||CP-CML patients who have failed Imatinib 400 mg daily|
3366475|NCT05151224||Breast cancer patients eligible to neoadjuvant systemic therapy|Invasive breast cancer, age are 18 years or more, from stage IIB to stage IIIC, all subtypes are included, either HR (ER, PR) positive or negative, HER2 positive or negative, eligible to neoadjuvant systemic therapy.
3366476|NCT05151211||Validity and Reliability Group|In order to evaluate the usability of the 1 MSTS, the validity and reliability of the test will be examined. In order to determine its validity in assessing physical capacity, the correlation of 1 minute sit up and 6 MWT and quadriceps muscle strength; In order to determine its validity in the evaluation of effort-induced desaturation, the correlation between the change in oxygen saturation and heart rate parameters before and after the 6 MWT and the change before and after the 1 MSTS test will be examined. In order to determine the reliability of the 1 MSTS, a re-test will be performed and 1 MSTS will be applied again after 1 week and the intraclass correlation coefficient will be checked.
3366477|NCT05151185|No Intervention|Control group|The dementia case manager in the control group undergo existing training. The family caregiver in the control group receive routine service.
3366478|NCT05151185|Experimental|training program|The dementia case manager in experiment group will undergo training (Competency-based Dementia Case Management Train-the-trainer Program; CDCMTP); The family caregiver in experiment group will receive competency-based Dementia Case Management Service Program.
3251373|NCT01394679|Active Comparator|18-F-FDG Imaging Agent|18 F FDG followed by PET/CT imaging
3251374|NCT01394679|Experimental|99m Tc-EC-DG imaging agent|99m Tc-EC-DG injection followed by SPECT/CT imaging (target of 20-30 mCi of Tc)and < 1 mg EC-DG
3251375|NCT01394731|Experimental|Paracetamol 1|
3251376|NCT01394731|Experimental|Paraceatmol 2|
3251377|NCT01394731|Active Comparator|Meperidine|
3366479|NCT05151172|Placebo Comparator|best medical care|All patients will receive the best standard of medical care according to modern acute stroke care guidelines All patients including the ones in control arm will receive the best standard of medical care according to modern acute stroke care guidelines. The model will be the Canadian best practices guidelines for acute stroke care. These are very similar to the guidelines of the American Stroke Association and the European Stroke Organization. All participants are expected to be admitted to hospital as part of routine standard of care.It is expected that all participants will undergo a routine work-up for the mechanism of their stroke and be treated appropriately and definitively.
3366480|NCT05151172|Experimental|endovascular thrombectomy|All participants will receive the best standard of medical care according to modern acute stroke care guidelines. In the intervention/experimental arm, participants will be treated with endovascular thrombectomy with a Solitaire device (Medtronic) as the first line approach. The trial mandates that the first attempt is performed with a Solitaire X device (3mm, 4mm or 6mm diameter devices; Medtronic). The remaining treatment technique is left to the discretion of the treating neurointerventionalist. Secondary devices may be used if success is not achieved after use of the first device.
3366481|NCT05151159||FIGO group 1A1|20 subjects with tumor invasion depth up to 1 mm
3366482|NCT05151159||FIGO group 1A2|20 subjects with an invasion depth of 1 - 3 mm
3366483|NCT05151159||FIGO group 1B1|20 subjects with invasion depth up to 2 cm
3366484|NCT05151159||FIGO group 1B2|20 subjects with tumor invasion depth> 2 cm 20 subjects with tumor invasion depth> 2 cm
3366488|NCT05151133|Experimental|Group 1|
3366489|NCT05151133|Experimental|Group 2|
3366490|NCT05151133|Experimental|Group 3|
3366491|NCT05151120||Group A: Hyperthyroid|30 patients will be included and divided into three categories: A1: 10 patients with suppressed TSH, around 0.01 milli-international unit/liter (mIU/L) A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L
3366492|NCT05151120||Group B: Euthyroid|30 Patients (under treatment) with TSH values between 0.4 - 4 mIU/L will be included
3366493|NCT05151120||GROUP C: Hypothyroid|40 patients will be included and divided into two categories: C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values > 50 mIU/L up to 100 mIU/L. Even distribution (if possible).
3366494|NCT05151094||Remdesivir exposure|Patients treated with remdesivir due to the COVID-19 infection
3251378|NCT01394770|Experimental|Aliskiren|
3251379|NCT01394770|Active Comparator|Amlodipine|
3366495|NCT05151081||Enuresis, Non-Enuresis|Patients were divided into two gruops according to whether having NE or not during childhood
3366496|NCT05151068|Experimental|Group A,traditional|"The control group is given conventional nursing care: ①Preoperative education, informing patients of the importance of the tube and the adverse effects of unauthorised extubation after the operation on the recovery of the disease. ②Pipe care: The nose wing is fixed with modified human elastic tape, and the same side cheek bridge is fixed to keep the duct unobstructed and pour gastric juice in time. ③Oral care: routinely brush teeth and gargle with mouthwash daily. ④Skin care: Observe the condition of the nose, cheek skin and oral and nasal mucosa. Replace the tape as needed, and clean the skin before fixing. ⑤ Pain care: assess the degree of pain, follow the doctor's prescription for medication, and observe the efficacy of medication. ⑥Psychological care: pay attention to the emotional changes of patients and provide psychological support.This group is planned to enroll 100 patients."
3251380|NCT01394783|Other|Classic laryngoscope|Phase 1 and 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
3251381|NCT01394783|Other|Videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
3366497|NCT05151068|Experimental|Group B,Precise|On the basis of conventional nursing, the experimental group adopted a precision nursing program of acupoint application combined with ear acupoint embedding.This group is planned to enroll 100 patients.
3366498|NCT05151055|Experimental|Lactezin|100 mg lactoferrin, 11 IU vitamin E (as alpha tocopherol), and 5 mg zinc (as zinc gluconate)
3251382|NCT01394796|Active Comparator|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
3251383|NCT01394796|Placebo Comparator|Placebo|No active substance is given.
3366499|NCT05151055|Placebo Comparator|Placebo|
3251384|NCT01394809|Experimental|Mental Practice|During motor imagery practice a person imagines performing a movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of movement performance. The guideline offers therapists structure and a strategy to deliver subject-specific imagery, and is based on principles of motor learning.
3251385|NCT01394809|Experimental|Mirror Therapy|Mirror therapy is thought to work by using vision of the intact or good arm to replace or drive proprioception in the affected arm, and so normalise the afferent segment of the movement process.
3366500|NCT05151042|Experimental|Group I|Distal segments repositioning using osteotomy/plate locating bone-borne surgical guide (wafer-less approach).
3366501|NCT05151042|Active Comparator|Group II|Distal segments repositioning using preoperative and final wafers.
3366502|NCT05151016|Experimental|mifepristone|mifepristone tablets，10mg，One tablet daily, oral treatment
3366503|NCT05151016|Active Comparator|Triptorelin Acetate|dafinil, 3.75 mg, first injection on the third day of menstruation, followed by intramuscular injection every 28 days for 24 weeks.
3251386|NCT01394809|Active Comparator|Relaxation training|The control group will receive therapy as usual. Currently, this means that patients are immobilized during first 3-4 weeks. The control group will receive additional relaxation training during this period to achieve the same total amount of time the therapist spends with the patients of the experimental groups.
3251387|NCT01394822||Ultrasound results reported|
3251388|NCT01394822||Ultrasound results NOT reported|
3366504|NCT05151003||Patients admitted to University Hospital San Martino, Genova, Italy|Adult patients admitted to University Hospital San Martino, Genova, Italy
3366505|NCT05150990|Experimental|Virtual Reality|Weekly activities using virtual reality (Rendever)
3366506|NCT05150990|Active Comparator|Video Chat|Weekly activities using video conference (Zoom)
3366507|NCT05150977||Idiopathic hypersomnia|Observation
3366508|NCT05150964|Experimental|Experimental|One group will be fit with commercially available hearing aids that will have different program settings
3366509|NCT05150951|Experimental|Experimental group|Novel exploration is used before extinction in an attempt to strengthen the extinction consolidation.
3366510|NCT05150951|Experimental|Control group|Participants perform a control task (visual attention) instead of the novel exploration.
3366511|NCT05150938||Cancer patients with VTE|Cancer patients who received anticoagulation treatment.
3366512|NCT05150925|Experimental|Immediate mobilization after distal radius fracture treated with volar locking plate|
3366513|NCT05150925|Active Comparator|2 weeks cast immobilization after distal radius fracture treated with volar locking plate|
3366514|NCT05150912|Active Comparator|Neuro dynamic|Neurodynamic techniques.
3366515|NCT05150912|Active Comparator|desensitization|Desensitization maneuvers
3366516|NCT05150899||Tamsulosin 0.4mg|group A receive Tamsulosin 0.4mg in combination of NSAI drug if patient present with colic, if not in renal colic at bed time Tamsulosin 0.4mg with analgesic on demand.
3366517|NCT05150899||fexofenadine 180 mg in combination of Tamsulosin 0.4mg|group B receive pheniramine maleate 50mg injection every 12hr for 24 hr in combination of Tamsulosin 0.4mg and NSAI drug then fexofenadine 180 mg in combination of Tamsulosin 0.4mg and NSAI drug on demand if patient present with colic. if not in renal colic at bed time fexofenadine 180 mg in combination of Tamsulosin with NSAI on demand.
3366518|NCT05150886||Improved and weaned from HFNC|
3366519|NCT05150886||Intubated after HFNC failure|
3366520|NCT05150873||Patients ttreatted for AAA|Patients affected by AAA and treated att our institution with EVAR and/or Open Repair between 2010 and 2020
3366521|NCT05150860|Active Comparator|At-home testing + household|At-home COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
3366522|NCT05150860|Active Comparator|On-site testing + household|On-site COVID-19 testing model with active encouragement of household member participation in regular COVID-19 testing part way through the trial
3366523|NCT05150860|Active Comparator|On-site testing|On-site COVID-19 testing model, no active encouragement of household member participation in COVID-19 testing
3366524|NCT05150847|Other|Prone Positioning|Patients will be ventilated in volume-controlled mode with Vt at 6 ml/kg of predicted body weight. Prone positioning will be performed over periods of 16 hours when PaO2/FiO2 was persistently lower than 150 mm Hg. Flow, volume, and airway pressure will bw measured by ventilators. Measurements were performed at 5 and 15 cmH20 PEEP levels and will be repeated every season as before first period of prone positioning, before supin positioning, and again before second period of prone positioning. Total PEEP and plateau pressure will be measured by a short end-expiratory and an end-inspiratory occlusion respectively. Complete airway closure will be assessed by performing a low-flow (4 L/min) inflation.9). The potential for lung recruitment will be assessed by means of the R/I ratio (10).
3366525|NCT05150834||ChAdOx1 vaccinated group|From Febrary 25, 2021 to July 16, 2021, healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get ChAdOx1 (Oxford/AstraZeneca) (n=26) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
3366526|NCT05150834||BNT162b2 vaccinated group|From Febrary 25, 2021 to July 16, 2021, 53 healthy healthcare workers were prospectively recruited at a tertiary hospital in Seoul, Republic of Korea, and they were assigned to get BNT162b2 (n=27) vaccines. Participants were excluded if they had history of medication which would affect gut microbiota in the past 1 month, including antibiotics, laxatives, and motility drugs; previous history of positive SARS-CoV-2 test on nasopharyngeal PCR; or positive serum Spike IgG results.
3366527|NCT05150821||experimental|patients during lockdown
3366528|NCT05150821||control group|patients before lockdown
3366529|NCT05150808|Active Comparator|Intervention IRS|Intervention IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
3366530|NCT05150808|Active Comparator|Control IRS|WHO approved IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
3251389|NCT01394835|Experimental|Alpha -1 Antitrypsin|
3251390|NCT01394848|Active Comparator|Genous stent group|Genous stent (Endothelial progenitor cell capture stent) insertion in elderly patients with stable coronary artery disease
3251391|NCT01394848|Active Comparator|Xience stent group|Xience Prime V stent (everolimus eluting stent) insertion in elderly patients with stable coronary artery disease
3251392|NCT01394848|Active Comparator|Atorvastatin 20mg group|
3251393|NCT01394848|Active Comparator|Atorvastatin 80mg group|
3251394|NCT01394861|Experimental|ESD using MASTER Slave Robotic System|
3251395|NCT01394874|Experimental|Telephone-linked Communication (TLC)|This group will receive the computer-based telephone counseling.
3251396|NCT01394874|No Intervention|Control|This is the control group. They will receive the exercise class, however, they will not receive the telephone counseling.
3251397|NCT01394887|Active Comparator|metformin group|this group received 850 mg metformin twice daily, along with recommended diet and exercise
3251398|NCT01394887|Placebo Comparator|placebo group|This group received 850 mg of placebo twice daily, along with a recommended regimen of diet and exercise
3366531|NCT05150795|Active Comparator|Group Pregabalin|Patients will receive oral pregabalin capsule (150 mg) 90 min before induction of anesthesia, and will receive a bolus injection of 10 ml saline at induction of anesthesia
3366532|NCT05150795|Active Comparator|Group Fentanyl|Patients will receive oral placebo capsule identical to the trial drug in size, shape and color, 90 min before induction of anesthesia and will receive a bolus injection of 10 ml of 1µg /kg fentanyl at induction of anesthesia
3366533|NCT05150782|Experimental|Curcumin/Boswellia Serrata/Ascorbic acid mixture|The daily intake of 2x10 drops of a mixture of micellized curcumin(2%), boswellia serrata (1,5%) and ascorbic acid (6%).
3366534|NCT05150756|Active Comparator|Group Lidocaine|At induction of anesthesia, patients will receive a loading dose of intravenous (IV) 1.5mg/kg lidocaine hydrochloride 2% slowly over 3 min followed by IV infusion of 2mg/kg/hr lidocaine hydrochloride 2% via infusion pump. The infusion will be continued till the end of surgery.
3366535|NCT05150756|Active Comparator|Group Morphine|At induction of anesthesia, patients will receive a loading dose of IV 0.1mg/kg morphine sulphate slowly over 3 minutes followed by IV infusion of normal saline via infusion pump. The infusion will be continued till the end of surgery
3366536|NCT05150730|Experimental|Quality-of-Life multidisciplinary care program|Six groups (between 10 -19 participants per group) received a meeting for two hours, the first hour being devoted to physical exercise, stimulating body awareness, improving mobility and muscle strengthening, relaxation and self-care.
3366537|NCT05150717|Experimental|[14C]-Jaktinib|Subjects will receive single dose of [14C]-Jaktinib (Suspension, 100mg/150μCi)
3366540|NCT05150691|Experimental|DB-1303 Dose Level 1|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 1 on Day 1 of each cycle Q3W
3251399|NCT01394900|Experimental|CNU intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of CNU intervention
3251400|NCT01394900|Active Comparator|WP intervention|African American/Black men who have sex with men (MSM) in same sex intimate relationships in which at least one partner is illicitly using psychostimulants and/or psychoactive substances will receive 4 sessions of general wellness promotion (WP) intervention
3251401|NCT01394913|Experimental|Reumatocept 25mg|50mg each week for 30 weeks
3251402|NCT01394913|Active Comparator|Enbrel 25mg|50mg each week for 30 weeks
3251403|NCT01394965|No Intervention|ECG Mapping|
3366541|NCT05150691|Experimental|DB-1303 Dose Level 2|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 2 on Day 1 of each cycle Q3W
3366542|NCT05150691|Experimental|DB-1303 Dose Level 3|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 3 on Day 1 of each cycle Q3W
3366543|NCT05150691|Experimental|DB-1303 Dose Level 4|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 4 on Day 1 of each cycle Q3W
3366544|NCT05150691|Experimental|DB-1303 Dose Level 5|Enrolled Subjects will receive a single-dose of DB-1303 at Dose Level 5 on Day 1 of each cycle Q3W
3366545|NCT05150691|Experimental|DB-1303 Dose Expansion 1|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
3366546|NCT05150691|Experimental|DB-1303 Dose Expansion 2|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
3366547|NCT05150691|Experimental|DB-1303 Dose Expansion 3|Enrolled Subjects will receive a single-dose of DB-1303 on a selected dose level (RP2D) Day 1 of each cycle Q3W
3251404|NCT01395004|Experimental|Active Drug - GSK2110183|This was an open-label study of oral GSK211083 administered at the maximum tolerated dose of 125 mg once daily.
3366550|NCT05150665|Experimental|En-Masse Retraction|Six anterior teeth (en-Masse) retracted using a crimpable hook distal to the upper lateral incisor and a power chain
3366551|NCT05150665|Experimental|two step retraction|Six anterior teeth are retracted by two step technique by canine retraction followed by four anterior teeth retraction using a crimpable hook distal to the upper lateral incisor and a power chain
3366552|NCT05150652|Experimental|Neoadjuvant Endocrine Therapy|Participants will begin treatment with Anastrozole. If not tolerated well, participants will discontinue and begin treatment using Letrozole. If not tolerated well, participants will discontinue and begin treatment using Exemestane. If not tolerated well, participants will discontinue and begin treatment on Tamoxifen.
3366553|NCT05150626|Experimental|Sequence A administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg under fasted condition, following a low-fat meal and a standard meal.
3366554|NCT05150626|Experimental|Sequence B administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a low-fat meal and standard meal, under fasted condition.
3366555|NCT05150626|Experimental|Sequence C administered DBPR108|Subjects will receive a single dose of DBPR108 100 mg following a standard meal, under fasted condition, following a low-fat meal.
3251405|NCT01395069|Active Comparator|Nepafenac 0.1%|
3251406|NCT01395069|Active Comparator|Ketorolac 0.5%|
3251407|NCT01395069|Placebo Comparator|Placebo|
3376156|NCT02470884|Experimental|FAST|Subjects treated with the Boston Scientific Fully Absorbable Scaffold
3251408|NCT01395082||Entire registry group|Participants with potential myopericarditis cases referred to the Registry
3251409|NCT01395095|Experimental|OPTICARE-A|Starts 2 weeks after ending standard cardiac rehabilitation (CR) and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
3251410|NCT01395095|Active Comparator|OPTICARE-B|Standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions)
3251411|NCT01395095|Experimental|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
3251412|NCT01395108|Placebo Comparator|Placebo|Placebo
3251413|NCT01395108|Active Comparator|Nemonoxacin 125mg|Nemonoxacin 125mg
3251414|NCT01395108|Active Comparator|Nemonoxacin 250mg|Nemonoxacin 250mg
3251415|NCT01395108|Active Comparator|Nemonoxacin 500mg|Nemonoxacin 500mg
3251416|NCT01395108|Active Comparator|Nemonoxacin 750mg|Nemonoxacin 750mg
3251417|NCT01395108|Active Comparator|Nemonoxacin 1000mg|Nemonoxacin 1000mg
3251418|NCT01395121|Experimental|nilotinib|nilotinib 400mgs oral tablets
3251419|NCT01395134|No Intervention|Visualization of the EBSLN and RLN|Visual inspection of the nerves.
3251420|NCT01395134|Experimental|Neuromonitoring of the EBSLN and RLN|Electrical stimulation and monitoring of the nerves' function.
3251421|NCT01395147|Experimental|Lu AA21004 group|
3251422|NCT01395160||Adult ADHD|
3251423|NCT01395160||Bipolar Disorder|
3251424|NCT01395160||Healthy control|
3366559|NCT05150600|Experimental|Group Inverse Ratio Ventilation (IRV)|The inspiratory to expiratory (I:E) ratio in this group will be 2:1 with the maximum inspiratory time (Ti) of 1.3 seconds
3366560|NCT05150600|No Intervention|Group Conventional Ratio Ventilation (CRV)|The inspiratory to expiratory (I:E) ratio in this group will be 1:2 with the minimum inspiratory time (Ti) of 0.4 seconds
3366561|NCT05150587|Active Comparator|Rifaximin-Tested dose A|
3366562|NCT05150587|Active Comparator|Rifaximin-Tested dose B|
3366563|NCT05150587|Placebo Comparator|Placebo|
3251425|NCT01395173|Placebo Comparator|Control|Subject will undergo standard colonoscopy.
3251426|NCT01395173|Active Comparator|Position change|Subject will under go standard colonoscopy, but also with position changes during colonoscope withdrawal.
3251427|NCT01395186|Other|varicocelectomy|varicocelectomy for patients complaining of pain
3251428|NCT01395199|Placebo Comparator|Starch pill|Placebo
3251429|NCT01395199|Experimental|Amlodipine|Amlodipine 5mg QD
3251430|NCT01395212||Cardiac stem cell therapy 5 years ago|
3251431|NCT01395225||All Patients|There will be no separate cohorts in this study. All patients will have their specimens processed by conventional means and by the study method. The conventional means will be the control for the study method.
3251432|NCT01395238|No Intervention|Wait-List Group|
3251433|NCT01395238|Experimental|Parenting Group|Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
3251434|NCT01395251|Other|Prednisolone|Patients with suspicious of rheumatoid arthritis will undergo a prednisolone test with 20 mg per day for 3 days after 2 days of therapy with paracetamol 500 mg twice for 2 days.
3251435|NCT01395264||Episodic Migraine.|
3251436|NCT01395264||menstrual migraine|
3251437|NCT01395264||Cluster Headache patients|
3251438|NCT01395264||control (non-headache group)|
3251439|NCT01395290|Experimental|cholecalciferol|cholecalciferol 20.000 IU per week
3251440|NCT01395303||myocardial infarction|subjects with myocardial infarction in the Tromsø study end point registry
3251441|NCT01395303||type 2 diabetes|subjects with type 2 diabetes in the Tromsø study end point registry
3251442|NCT01395303||stroke|subjects with stroke in the Tromsø study end point registry
3251443|NCT01395303||fracture|subjects with fracture in the Tromsø study end point registry
3251444|NCT01395303||cancer|subjects with cancer in the Tromsø study end point registry
3251445|NCT01395303||death|subjects registered as dead in the Tromsø study end point registry
3366580|NCT05150561||Cohort I - Patients newly diagnosed with malignant lymphoma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
3366581|NCT05150561||Cohort II - Patients newly diagnosed with acute leukaemia (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
3366582|NCT05150561||Cohort III - Patients newly diagnosed with multiple myeloma (n=72)|These patients will undergo two assessments: A baseline-assessment prior to treatment for the hematologic cancer disease and a follow-up assessment at 6 months after treatment start
3366583|NCT05150548||Entire Cohort|"Patients undergoing elective colectomy with data that has been collected in the NSQIP® Procedure Targeted Colectomy dataset from 2014-2019 with American Society of Anesthesiologists (ASA) Physical Status I-IV.~Patients will not be included in this cohort with urgent or emergency colectomy or indication for colectomy consisting of Acute diverticulitis, Enterocolitis (e.g. C. Difficile), and Volvulus, patients with disseminated cancer, wound infection, systemic sepsis or ventilator-dependence preoperatively."
3366584|NCT05150535|Active Comparator|Hypofractionation control arm|Patients who will receive 40 Gy in 15 fractions to the entire breast or chest wall over three weeks and have had breast conservation surgery (BCS) or oncoplastic breast surgery(OBS) will receive an additional boost to the tumour site if and will receive sequential dose 12GY\4 fractions or SIB 8GY 15 fractions. The supraclavicular fossa will be treated in patients with node-positive disease or those who had received neoadjuvant chemotherapy . The IMLN will be irradiated in N2and N3 at first presentation.
3366585|NCT05150535|Experimental|. Ultrahypofractionation experimental arm|Patients who will receive 26 Gy in 5 fractions to the entire breast and or chest wall for one week only. The volume of this arm will be the same as the volume of the control arm as regard axillary nodes, supraclavicular and IMLN. Patients who have had breast conservation or oncoplastic breast surgery(OBS) will be given a boost. If a boost is given, SIB of 6 Gy in 5 fractions will be used (or a sequential boost of 12GY\4 fractions).
3366586|NCT05150522|Experimental|BCMA CAR-T|BCMA CAR-T cells infusion
3251446|NCT01395303||aortic stenosis|subjects with aortic stenosis in the Tromsø study end point registry
3251447|NCT01395303||control group|randomly selected controls from the Tromsø study
3366592|NCT05150483||Patients with de novo acute hypoxemic respiratory failure|We will consider for inclusion patients presenting in the emergency department with de novo acute hypoxemic respiratory failure (AHRF). De novo AHRF is defined as the requirement of oxygen flow rate of 5 liters per minute or more to maintain SpO2 of 90% or more in a patient who does not receive long term oxygen therapy.
3366593|NCT05150470|Other|open label|Single Group Assignment
3366594|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 1|"Starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles.~Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles"
3366595|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 2|3 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
3366596|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 3|10 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
3251448|NCT01395342|No Intervention|blood pressure and heart rate data|
3251449|NCT01395355|Experimental|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
3251450|NCT01395355|Active Comparator|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral weight management techniques.
3251451|NCT01395381|Placebo Comparator|Placebo|
3251452|NCT01395381|Experimental|Albendazole|
3251453|NCT01395407|Experimental|Cohort A|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Dose level Cohort A (Gy)~21~23~25"
3251454|NCT01395407|Experimental|Cohort B|"Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter).~Dose level Cohort B (Gy)~18~20~22"
3251455|NCT01395407|Experimental|Cohort C|"Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter).~Dose level Cohort C (Gy)~15~17~19"
3251456|NCT01395420|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
3251457|NCT01395420|Experimental|2|CAZ104 (3000mg Ceftazidime/1000mg Avibactam)
3251458|NCT01395433|Active Comparator|Treatment A|Conventional escitalopram
3366597|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 4|30 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
3366598|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 5|100 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
3366599|NCT05150457|Experimental|Dose Escalation Phase, Dose Level 6|200 times the starting dose level of BNA035 administered as an IV infusion once weekly in 28 day cycles Drug: BNA035 Administered once weekly as an IV infusion at the assigned dose level in 28 day cycles
3366604|NCT05150418|Experimental|Oxygen|Oxygen 15 l/min administered with face mask with reservoir.
3251459|NCT01395433|Experimental|Treatment B|Escitalopram test treatment B
3366605|NCT05150418|Placebo Comparator|Room air|Room air 15 l/min administered with face mask with reservoir.
3366606|NCT05150405|Experimental|QLF31907|single arm with QLF31907 treatment
3366607|NCT05150392|Experimental|Booster immunization 1 year after primary immunization|Subjects C0001-C0400 except C0243 received 1 dose of booster immunization 1 year after primary immunization.
3366608|NCT05150392|Experimental|Booster immunization 2 year after primary immunization|Subjects C0401-C0800 except C0556 received 1 dose of booster immunization 2 years after primary immunization.
3366609|NCT05150392|Experimental|Booster immunization 3 year after primary immunization|Subjects C0801-C1197 received 1 dose of booster immunization 3 years after primary immunization.
3366610|NCT05150379||Dominant side shoulder surgery patients|
3366611|NCT05150379||Patients operated on the shoulder on the non-dominant side|
3366612|NCT05150379||Healthy volunteers|
3366613|NCT05150366|Experimental|Patient scheduled for percutaneous closure of the left auricle by St Jude AMULET device|
3366614|NCT05150353|Experimental|Patients with cardiac amyloidosis|
3251460|NCT01395433|Experimental|Treatment C|Escitalopram test treatment C
3366615|NCT05150353|Placebo Comparator|Healthy volunteers|
3251461|NCT01395446||prolonged neutropenic patients|patients that will undergo treatment for a hematological malignancy expected to result in grade 4 neutropenia of prolonged duration
3251462|NCT01395459|No Intervention|control|Care as usual is given.
3366616|NCT05150340|Experimental|Epoch 1: TAK-771 Ramp up Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution. The dose of 10% IGI will be increased from 1/3 of full dose to full dose in 3 weeks for participants who will receive TAK-771 once every 3 week, or from 1/4 of full dose to full dose in 6 weeks for participants who will receive TAK-771 once every 4 week.
3366617|NCT05150340|Experimental|Epoch 2: TAK-771 Treatment Period|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 3, or 4 weeks for up to Week 24.
3251463|NCT01395459|Experimental|IVR only|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable.
3251464|NCT01395459|Experimental|IVR+PCC|The participants in this study arm receive calls from an Interactive Voice Response (IVR) call system, to remind them that they are in need of breast, cervical and colon cancer screening, as applicable. Furthermore, if remained unscreened, these participants receive person to person follow up telephone calls from a prevention care coordinator (PCC) to address barriers.
3251465|NCT01395472|Experimental|TBI - Experimental Sample|TBI patients will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
3366618|NCT05150288|Experimental|Formula-fed infants|Infants fed exclusively with experimental formula
3366619|NCT05150288|Experimental|Mixed-fed infants|Infants receiving breastmilk and experimental formula
3366620|NCT05150288|No Intervention|Breast-fed infants|Reference group of exclusively breastfed
3366621|NCT05150236|Experimental|Combination 177Lu-PSMA-617, Ipilimumab & Nivolumab|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles in combination with concurrent ipilimumab (3mg/kg Q6W x 4 doses) and nivolumab (1mg/kg Q3W x 8 doses) followed by nivolumab monotherapy (480mg Q4W up to 18 doses) or until disease progression or unacceptable toxicity.
3366622|NCT05150236|Experimental|177Lu-PSMA-617|177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles or until disease progression or unacceptable toxicity.
3366623|NCT05150223|Active Comparator|Traditional strength training group|traditional strength training (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
3251466|NCT01395472|Active Comparator|Healthy Controls|healthy volunteers will be submitted to two acute physical exercise protocols in a cycloergometer with one weak of interval (until voluntary exhaustion and 30 minutes in ventilatory threshold I)
3366624|NCT05150223|Experimental|Power Training group|progressive functional strength training protocol (running, jumping forward over a barrier with one leg and two legs, heel-rise, push up and ball throw with load, bench press, and flexion-abduction-external rotation pattern with theraband)
3251467|NCT01395472|Active Comparator|TBI Controls|Patients will be submitted to a protocol of stretching for 30 minutes
3251468|NCT01395485|Experimental|Cohort 2|Adolescents - Ages 13 to <17
3366625|NCT05150223|No Intervention|Control group|no intervention Typically developing children
3366626|NCT05150210|Experimental|Single Arm|Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.
3251469|NCT01395485|Experimental|Cohort 1|Adolescents - Ages 12 to <13
3251470|NCT01395485|Experimental|Cohort 4|Adults - Ages 18 to <=50
3366627|NCT05150197|Experimental|Patient (pathology) group|This group will perform both the standard of care Humphrey Visual Field (HVF) and the VisuALL Virtual Reality Visual Field.
3366628|NCT05150197|Other|Control group|This group will only perform the VisuALL Virtual Reality Visual Field.
3366630|NCT05148754|Experimental|Elsulfavirin 400 mg.|Cohort I (N = 3). Single oral dose of 400 mg.
3366631|NCT05148754|Experimental|Elsulfavirin 800 mg.|Cohort II (N = 3). Single oral dose of 800 mg.
3366632|NCT05148754|Experimental|Elsulfavirin 1 200 mg.|Cohort III (N = 3). Single oral administration at a dose of 1200 mg.
3366633|NCT05148754|Experimental|Elsulfavirin 1 200 mg*9|Cohort IV (N = 6). A single 1200 mg oral dose followed by 200 mg daily for 9 days.
3251471|NCT01395485|Experimental|Cohort 3|Adolescents - Ages 17 to <18
3251472|NCT01395498||fiberoptic bronchoscopy|patients undergoing fiberoptic bronchoscopy who are not immunocompromized and in whom an opportunistic infection is not suspected.
3251473|NCT01395511|Experimental|Acupuncture|"About ten acupuncture points are selected from the following points to be used. Local Acupoints : SI14, SI15, BL10, BL12, BL13, BL14, TE15, GB20, SI9~Distal Acupoints :~Upper extremities: LU6, LU7, LU9, LI11, HT3, SI2, SI3, SI5, SI7, PC4, PC6, TE5~Lower extremities: SP3, SP4, BL59, BL60, BL61, BL62, BL66, KI3, KI4,KI6, KI7, GB40, GB41, LR4~All Acupuncture points were prepared with 70% alcohol pads, and disposable stainless steel needles were used. Most of acupuncture were inserted vertically 1~1.5cm in depth until patient can feel De-Qi. (No more additional stimulation)"
3251474|NCT01395511|No Intervention|Waiting list group|"No Intervention Comparator~The waiting-list group did not receive acupuncture treatment and participants were permitted to receive usual care including physical therapy and exercise and were not permitted to take analgesics and antiphlogistics during the periods."
3251475|NCT01395563|Experimental|1|pancreatic cancer patients
3251476|NCT01395563|Experimental|2|pancreatic cancer patients
3366638|NCT05146700|Experimental|Restrictive oxygen|"- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants)~and~- Only trial participants receiving an FiO2 = 0.21 can saturate >94%~Pre-oxygenation as usual prior to intubation is permitted"
3366639|NCT05146700|Active Comparator|Liberal oxygen|"- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98%~or~- FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%"
3366640|NCT05140980||"women aged 18 to 25 group"|"women aged 18 to 25 group: women aged 18 to 25 with or without sexual activity"
3251477|NCT01395589|Active Comparator|Injectable + oral vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
3251478|NCT01395589|Active Comparator|Oral-only Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL.
3251479|NCT01395602|Placebo Comparator|placebo|placebo pill
3251480|NCT01395602|Active Comparator|cabergoline|cabergoline pill
3251481|NCT01395615||Cohort|
3251482|NCT01395641|Experimental|Gene therapy|Intracerebral infusion of AAV2-hAADC viral vector will be performed
3251483|NCT01395654|Experimental|Standard rechallenge, Slow rechallenge|
3251484|NCT01395667|Experimental|Bevacizumab + CCRT followed by surgery|Bevacizumab 5 mg/kg every 2 weeks + radiotherapy 45~55 Gy/25 fractions, followed by total mesorectal excision
3251485|NCT01395680||cancer adolescent|
3251486|NCT01395693|Experimental|Salt Lake mask system|
3251487|NCT01395706|Experimental|ICG flourescence technique|This is an uncontrolled, non-randomised, open-label, monocenter clinical trial. A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
3251488|NCT01395719|No Intervention|Non remote ischemic conditionin(non-rIC)|Patients receiving kidney transplantation from a deceased donor. This group does not receive remote ischemic conditioning, but has a tourniquet on the leg (not inflated).
3251489|NCT01395719|Experimental|Remote ischemic conditioning (rIC)|Patients receiving kidney transplantation from a deceased donor. This group receives remote ischemic conditioning by inflating a tourniquet on the leg during surgery, before reperfusion of the kidney.
3251490|NCT01395732|Experimental|1|
3251491|NCT01395745|Experimental|blisibimod weekly dose|
3366646|NCT05137431||High Flow Nasal Oxygenation-HFNO|The current will be adjusted from 50-70 liters. The patient's SpO2 value will be maintained at at least 92%. Arterial blood gas will be checked at the 1st hour
3366647|NCT05137431||Non-Invasive Ventilation-NIV|Tidal volume will be adjusted to be 6-8 ml/kg. The respiratory rate will be <30. The patient's SpO2 value will be maintained at at least 92%. The PEEP value will be 5 cmH2O. At the 1st hour, arterial blood gas will be checked.
3251492|NCT01395745|Placebo Comparator|Placebo|
3366648|NCT05136339|Experimental|Immediate Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions immediately after enrollment.
3366649|NCT05136339|Experimental|Delayed Community-Based Mentoring and Education Sessions|Subjects will receive the intervention of community-based mentoring and education sessions approximately 12 months after enrollment.
3366650|NCT05135923|Active Comparator|Benchmark gluten-free products|Products containing less than 6g fibre per 100g product.
3366651|NCT05135923|Experimental|Optimised gluten-free products|Products containing less than 6g fibre per 100g product.
3251493|NCT01395771|Experimental|Phone call|New cases and old cases will be randomly categorized into two groups,respectively,one is phone call intervention group, the other is no phone call intervention group.
3251494|NCT01395836||Treatment|"The treatment group will be medically managed based on data obtained from monthly transmissions of the implanted Cardiac Monitor."
3251495|NCT01395836||Control Group|"The control group will be managed in the usual standard of care with physicians blinded to their ICM data."
3251496|NCT01395849||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol during study period
3251497|NCT01395862||Patients prescribed fluticasone and salmeterol|Patients with asthma prescribed fluticasone and salmeterol for long-term use during study period
3251498|NCT01395875||COPD patients with moderate exacerbations|COPD patients with COPD-related using ICD-9 codes physician office/outpatient visit with a dispensing for oral corticosteroid (OCS) or antibiotic (ABX) within 5 days of the visit (Phy+Rx)
3366654|NCT05134571|Experimental|Aldurazyme (laronidase)|Aldurazyme (laronidase) treatment at approved dose and regimen, administered every week as an IV infusion
3366655|NCT05133817|Placebo Comparator|Control group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of normal saline by IV infusion.
3251499|NCT01395927|Experimental|001|Canagliflozin Type=1 unit=mg number=300 form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10,Rifampin Type=2 unit=mg number=300 Form=capsule route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
3251500|NCT01395940|Experimental|KLH-2109, lower dose|
3366656|NCT05133817|Experimental|0.025 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.025 μg/kg/min) by IV infusion.
3366657|NCT05133817|Experimental|0.05 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.05 μg/kg/min) by IV infusion.
3366658|NCT05133817|Experimental|0.075 μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.075 μg/kg/min) by IV infusion.
3376157|NCT02457000||Normal, healthy volunteers|Normal, healthy volunteers without any skin pathology will be asked to undergo various procedures to evaluate their sleep and skin health.
3251501|NCT01395940|Experimental|KLH-2109, higher dose|
3251502|NCT01395953|Active Comparator|Buspirone|
3251503|NCT01395953|Placebo Comparator|Placebo|
3251504|NCT01395979|Experimental|Cognitive Processing Therapy for Sexual Risk (CPT-SR)|The CPT-SR condition will be comprised of 10 individual therapy sessions fully integrating sexual risk reduction counseling into cognitive therapy for sexual abuse-related trauma.
3251505|NCT01395979|Active Comparator|Time-Matched Control (TMC)|The TMC will be comprised of sexual risk reduction counseling/education and supportive psychotherapy.
3251506|NCT01395992|Experimental|Asenapine 5 mg|Participants who were randomized to asenapine 5 mg twice per day (BID) during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension study. Participant who were randomized to placebo during the P05691 study will be assigned to receive asenapine 5 mg BID on this extension trial.
3251507|NCT01395992|Experimental|Asenapine 10 mg|Participants who were randomized to asenapine 10 mg BID during the P05691 study will be assigned to receive asenapine 10 mg BID on this extension study.
3251508|NCT01396031|Experimental|Excercise|Cardiovascular exercise Standing Hip Abduction Step-up/Step-down Wall Slide Sit-to-Stand Activity / Exercise Diary 3 times per week x ~1 month
3251509|NCT01396109|Active Comparator|Group I|Intervention: Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System
3251510|NCT01396109|Active Comparator|Group II|Intervention: Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with Mesh
3251511|NCT01396122|Experimental|PROSIMA group|Reconstructive surgeries with GYNECARE PROSIMA* were performed in all patients.
3251512|NCT01396135|Experimental|Single dosing|Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
3251513|NCT01396135|Experimental|Multiple dosing|Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
3251514|NCT01396174|Active Comparator|Standard Online Support Group|
3366659|NCT05133817|Experimental|0.1μg/kg/min group|Simultaneous with spinal anesthesia, 500 mL 6% Hydroxyethyl starch (130/0.4) coload was given and a maintenance dose of norepinephrine (0.1μg/kg/min) by IV infusion.
3366660|NCT05133180|Experimental|Oxervate|one drop of cenegermin 20 mcg/mL will be instilled in both eyes three times daily.
3366661|NCT05133180|Placebo Comparator|Vehicle|vehicle eye one drop will be instilled in both eyes three times daily.
3366662|NCT05131217|Experimental|Acute bout of Continuous Moderate Intensity Exercise|
3366663|NCT05131217|Experimental|Acute bout of High Intensity Interval Training (HIIT)|
3366664|NCT05131217|Experimental|Control|
3366665|NCT05130268|Experimental|Dronedarone|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. As dronedarone has anti-adrenergic rate controlling properties, a low dose of beta-blocker or calcium-channel blocker is recommended in the United States Prescribing Information (USPI) when starting dronedarone. In the dronedarone arm concomitant digoxin use will be contraindicated due to P-gp interaction based upon data from the PALLAS trial. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
3366666|NCT05130268|No Intervention|Usual care|In most patients, the investigators anticipate usual care to include an atrioventricular nodal blocking agent (beta-blocker, non-dihydropyridine calcium channel blocker, or digoxin) without an antiarrhythmic. All patients will receive oral anticoagulation for stroke prevention according to current guideline recommendations.
3366667|NCT05129306||Patients|Patients with moderate to severe Allergic Rhinitis who have been prescribed RYALTRIS® nasal spray by their healthcare professional. Observational.
3366668|NCT05129150||assessment of cognitive functions|Assessment of cognitive disorders with an ultrasound examination performed in routine care during a day hospital.
3366669|NCT05126745||Patients who had an epidural placed for labour|Patients who had an epidural placed for labour may take part. Study procedures will take place after delivery and prior to removal of the epidural catheter.
3366670|NCT05125263|Experimental|group 1|This group receives KinesioTaping along with conventional treatment
3366671|NCT05125263|Experimental|group 2|This group receives mulligan taping along with conventional treatment
3366672|NCT05122715|Other|OMNI PET/CT scan first|
3366673|NCT05122715|Other|DMI PET/CT scan first|
3366674|NCT05122286|Experimental|bailout angioplasty|If the patient is randomized into the bailout angioplasty arm, the choice of balloon dilation or stenting will be left to the discretion of the interventionalist.
3366675|NCT05122286|Active Comparator|thrombectomy alone|"If the patient is randomized into the thrombectomy alone arm, the interventionalist will decide whether to stop the endovascular recanalization procedure or to perform further recanalization attempts using stent-retrievers and/or aspiration catheters.~Balloon dilation and/or stenting procedure after randomization should be avoided in the thrombectomy alone arm."
3366681|NCT05114590|Experimental|Soliqua 100/33|Soliqua 100/33 (Insulin glargine 100 Units/ml /lixisenatide 33 μg/mL) once daily for 16 weeks.
3251515|NCT01396174|Experimental|Prosocial Online Support Group|
3366686|NCT05112276|Active Comparator|Control Diet|Average Swedish diet
3366687|NCT05112276|Experimental|Intervention Diet|The intervention diet will be based on food items that have shown a beneficial effect on gut microbiota associated with cardiometabolic risk factors.
3366688|NCT05111353|Experimental|Arm 1: Vaccine given after neoadjuvant chemotherapy and surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, 22, 50, and 78 beginning approximately 1 month after surgery."
3366689|NCT05111353|Experimental|Arm 2: Vaccine given after neoadjuvant chemotherapy but before surgery|"The neoantigen peptide vaccine will be manufactured during neoadjuvant chemotherapy. Institutional standard of care chemotherapy will be given.~Peptide and poly-ICLC will be administered intramuscularly on Days 1, 4, 8, 15, and 22 during the chemotherapy holiday, and Days 50 and 78 post-operatively."
3366690|NCT05109195||MDD Participants with Insufficient Response to SSRI/SNRI (antidepressant)|Major Depressive Disorder (MDD) participants with insufficient response to a selective serotonin reuptake inhibitor (SSRI)/serotonin-norepinephrine reuptake inhibitor (SNRI) (antidepressant) and starting an adjunctive therapy will be observed to create an external control arm (ECA) based on real world data (RWD) from electronic health records (EHR) data during routine medical care (standard of care [SOC]) combined with scheduled research assessments.
3366695|NCT05097963|Experimental|Subjects undergoing EUS shear wave elastography|Subject who are eligible will undergo EUS for clinical indications. EUS shear wave measurements will be gathered and studied to determine diagnostic accuracy when compared to MR Elastography.
3366696|NCT05096988|Experimental|PKU sphere liquid|PKU sphere liquid will be prescribed by the study dietitian based on the patient's individual requirements.
3251516|NCT01396200|Experimental|Hydroxychloroquine (Cohort B)|Infusional cyclophosphamide 300mg/m2/day for 4 days IV and dexamethasone 40mg/day orally or IV for 4 days on days 1 through 4. Hydroxychloroquine oral will be given on days 5 through 28 of cycle 1 and every day of all subsequent cycles (to be given with milk or food at approximately the same time each day)
3251517|NCT01396200|Experimental|Rapamycin (Cohort A)|Infusional cyclophosphamide 300 mg/m2/day for 4 days IV and dexamethasone 40 mg/day orally or IV for 4 days on days 3 through 6. Rapamycin oral loading dose will be given on day 1 followed by an oral daily dose for an additional 5 days (days 2 through 6) to be given on an empty stomach at approximately the same time each day suggested 11 am)This dosing schedule is the same for all cycles.
3366700|NCT05091697|Experimental|Multicomponent treatment VIRTUAL FIBROWALK + TAU|VIRTUAL FIBROWALK is a multicomponent non-pharmacological program based on Pain Neuroscience Education (PNE), therapeutic exercise, Cognitive Behavioural Therapy (CBT) and Mindfulness Training
3366701|NCT05091697|Active Comparator|Treatment as Usual (TAU)|Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.patient
3251518|NCT01396213|Experimental|Larazotide Acetate 0.5 mg|larazotide acetate 0.5 mg capsules TID
3251519|NCT01396213|Experimental|Larazotide Acetate 1 mg|larazotide acetate 1 mg capsules TID
3366704|NCT05091424|Experimental|R/R CLL|Participants will receive weekly step-up dosing of mosunetuzumab until the target dose is reached, after which mosunetuzumab will be administered once every 21 days for up to 17 cycles (cycle = 21 days) or until objective disease progression or unacceptable toxicity, whichever occurs first.
3366705|NCT05090501|Experimental|Green and Indoor|Green first participants will first exercise in the nature-based condition, followed by the indoor condition.
3366706|NCT05090501|Experimental|Indoor and Green|Indoor and Green participants will first exercise in the indoor condition, followed by the nature-based condition.
3366709|NCT05085574|Experimental|Group 1 (Study Product)|Subjects will receive 80 mg famotidine (PO) QID and 400 mg celecoxib as a first dose, followed by 200 mg (PO) BID celecoxib, for 5 days. Following this 5-day period, subjects will continue their famotidine treatment for an additional 9 days.
3251520|NCT01396213|Experimental|Larazotide Acetate 2 mg|larazotide acetate 2 mg capsules TID
3366710|NCT05085574|Placebo Comparator|Group 2 (Reference Therapy)|Subjects will receive matching placebos QID and BID, for 5 days. Following this 5-day period, subjects will continue to receive matching famotidine placebo, QID, for an additional 9 days.
3251521|NCT01396213|Placebo Comparator|Placebo|placebo capsules TID
3366711|NCT05084586|Active Comparator|Continuous Intravesical Infusion of Epirubicin|Patients who received continuous epirubicin infusion into the bladder in the early postoperative period.
3366712|NCT05084586|Sham Comparator|Single-Dose Instillation of Epirubicin|Patients who received single-dose epirubicin into the bladder in the early postoperative period.
3366720|NCT05077579||metabolically abnormal overweight & obese|
3366721|NCT05077579||metabolically normal overweight|
3366722|NCT05077579||obese and metabolically normal lean|
3366725|NCT05076513|Experimental|Arm A: Presumed Newly-Diagnosed glioblastoma|Participants undergoing resection for a presumed newly-diagnosed glioblastoma (WHO grade 4) will be treated with niraparib for 4 days prior to surgical resection. Participants who proceed to the therapeutic expansion phase of this study will receive niraparib in combination with radiation (60 Gy over 6-7 weeks, as per standard of care). Following radiotherapy, eligible study participants may receive niraparib maintenance treatment.
3366726|NCT05076513|Experimental|Arm B: Recurrent Glioma (Grades II-IV)|Participants undergoing resection of a recurrent WHO Grade II, III, or IV glioma with IDH1 or IDH2 mutation and ATRX loss will be treated with niraparib for 4 days prior to a planned surgical resection. Participants who proceed to the Expansion cohort will receive niraparib in 28d cycles after surgery.
3366727|NCT05074498|Experimental|Part 1: TB006|Participants will be randomized to 1 of 3 ascending dose groups to receive a total of 5 once-weekly doses of TB006, infused over 1 hour.
3366728|NCT05074498|Placebo Comparator|Part 1: Placebo|Participants will be randomized to receive 5 once-weekly doses of matching placebo.
3366729|NCT05074498|Experimental|Part 2: TB006|Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
3366730|NCT05074498|Placebo Comparator|Part 2: Placebo|Participants will be randomized to receive matching placebo. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
3366734|NCT05071729|Experimental|Moderate renal impairment|Participants with estimated glomerular filtration rate (eGFR) of 30 to 59 mL/min/1.73 m^2
3366735|NCT05071729|Experimental|Severe renal impairment|Participants with eGFR < 30 mL/min/ 1.73 m^2
3366736|NCT05071729|Experimental|Normal renal function|Participants with ≥ 90 mL/min/1.73 m^2
3366737|NCT05070702|Experimental|CT-1500 Active (SAD)|6 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of CT-1500 between 5 mg and 120 mg
3366738|NCT05070702|Placebo Comparator|Placebo (SAD)|2 out of 8 participants per cohort (up to 5 cohorts) will be randomized to receive a single oral dose of matching placebo
3366739|NCT05070702|Experimental|CT-1500 Active (MAD)|6 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of CT-1500 between 5 and 45 mg
3366740|NCT05070702|Placebo Comparator|Placebo (MAD)|2 out of 8 participants per cohort (up to 3 cohorts) will be randomized to receive 7 daily oral doses of matching placebo
3366741|NCT05069610|Experimental|Standard of care + AD17002 (3 doses)|Received 3 weekly doses of AD17002 20μg/dose of AD17002 by intranasal route
3366742|NCT05069610|Placebo Comparator|Standard of care + Placebo (3 doses)|Received 3 weekly doses of Placebo 20μg/dose of formulation buffer by intranasal route
3366743|NCT05069610|Experimental|Standard of care + AD17002 (5 doses)|Received 5 doses of AD17002 in 15 days 20μg/dose of AD17002 by intranasal route
3366744|NCT05069610|Placebo Comparator|Standard of care + Placebo (5 doses)|Received 5 doses of Placebo in 15 days 20μg/dose of formulation buffer by intranasal route
3366745|NCT05068219|Active Comparator|Usual technique|Standard rehabilitation
3366746|NCT05068219|Experimental|CR technique|Standard rehabilitation + 3 CR
3366747|NCT05066984|Experimental|structured, multidisciplinary and personalized post-ICU care|structured, multidisciplinary and personalized post-ICU care
3366748|NCT05066984|No Intervention|Ususal care|Usual care
3366749|NCT05065476||Study Group|"Participants signed up for the webinar will be learning and practicing the Isha Kriya practice (meditation for beginners) taught by the Isha Foundation."
3251522|NCT01396252|Experimental|Arm1: BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
3366754|NCT05061823|Experimental|Bintrafusp alfa|
3366757|NCT05051891|Experimental|the experimental group|Orelabrutinib in Combinaion with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP)
3366758|NCT05051891|Experimental|The control group|R-CHOP
3251523|NCT01396252|Placebo Comparator|Arm 2: Placebo matching BMS-820836|Panels 1-4 are fixed dose panels (0.5, 1, 1 and 2 mg respectively), Panels 5-7 are titration dose panels (initiated at 1 mg and dose escalated to the target dose of 2 mg)
3251524|NCT01396278|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
3251525|NCT01396278|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
3251526|NCT01396278|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
3251527|NCT01396278|Active Comparator|Fluticasone propionate 440 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 440 mcg ICS plus placebo matching Respimat inhaler
3366770|NCT05047575|Experimental|REASSURE Cohort 1|Survivors who are enrolled at time of a follow-up visit and who will be offered the REASSURE intervention at the next 6 month visit (including the opportunity to replace a visit with feedback communication).
3366771|NCT05047575|Experimental|REASSURE Cohort 2|Survivors who are enrolled prior to a follow-up visit and who will be offered the REASSURE PRO assessment and feedback communication (but not provided the opportunity to replace a visit with feedback communication).
3366776|NCT05038787|Experimental|LY3473329|LY3473329 administered orally.
3366777|NCT05038787|Placebo Comparator|Placebo|Placebo administered orally.
3251528|NCT01396278|Active Comparator|Fluticasone propioante 88 mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 88 mcg ICS plus placebo matching Respimat inhaler
3251529|NCT01396291|Experimental|Asenapine|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
3251530|NCT01396291|Placebo Comparator|Placebo|All study participants will first receive open-label asenapine and placebo for 12 to 16 weeks before being randomized. After randomization, participants will receive asenapine or placebo (this is the double-blind period) for up to 26 weeks.
3251531|NCT01396304|Experimental|Restore Calcium Alginate Dressing Silver|Restore Calcium Alginate Dressing Silver under compression wrap
3251532|NCT01396304|Active Comparator|Aquacel Ag Wound Dressing|Aquacel Ag Wound Dressing under compression wrap
3366783|NCT05028517|Experimental|FMF Connect Intervention + Coaching|Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
3366784|NCT05028517|Experimental|FMF Connect Intervention (no coaching)|Participants receive the FMF Connect mobile health app. They do not receive coaching.
3366785|NCT05028517|No Intervention|Waitlist comparison group|Participants receive the FMF Connect mobile health app at the conclusion of the study.
3251533|NCT01396330|Other|Stress|
3251534|NCT01396343||Pediatric MS Case|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
3251535|NCT01396343||Pediatric Control|Demographic and Medical History Questionnaire, Environmental Exposure Questionnaire, Food Frequency Questionnaire, Blood Sample Collection
3251536|NCT01396356||ablation procedure|
3251537|NCT01396369|Active Comparator|Birth control|
3251538|NCT01396369|Experimental|Birth control plus Brevail|
3251539|NCT01396408|Active Comparator|Sunitinib|
3251540|NCT01396408|Active Comparator|Temsirolimus|
3251541|NCT01396460||bariatric patients|Bariatric post operative patients were compared with morbid obese population
3251542|NCT01396460||control group|morbid obese population
3251543|NCT01396473|No Intervention|control|
3251544|NCT01396473|Experimental|Policy and Environmental Change|
3251545|NCT01396499|Experimental|BKM120|Oral BKM120 starting dose 80 mg once daily.
3251546|NCT01396564|Active Comparator|Metformin|Randomized patients are given 850 mg of metformin daily, increased to 1700 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
3251547|NCT01396564|Active Comparator|Pioglitazone|Randomized patients are given 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks. Adherence is evaluated and after the first phase, the arm is opened. Fasting plasma glucose concentration, body weight, and blood pressure, fasting plasma lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol), HbA1c are measured during the initial and final week of treatment. Dietary adherence is reinforced.
3251548|NCT01396577|Active Comparator|3 x 2-mg perampanel|
3366798|NCT05026710|Experimental|Silicone (Coloplast Imajin Hydro) ureteral stent|
3366799|NCT05026710|Experimental|Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).|
3251549|NCT01396577|Active Comparator|6mg perampanel|
3251550|NCT01396590|Active Comparator|6 x 2 mg perampanel|
3251551|NCT01396590|Active Comparator|12 mg Perampanel|
3251552|NCT01396616|Experimental|Single Arm|The enrolled subject will be implanted with Toric IOL manufactured by AuroLab
3366802|NCT05021614|Experimental|Treatment|Transcatheter Mitral Valve Repair with Valveclip®
3366803|NCT05019729|Experimental|Group 2|5 mg/kg IV
3366804|NCT05019729|Experimental|Group 3|5 mg/kg SC
3366805|NCT05019729|Experimental|Group 4|20 mg/kg IV
3366806|NCT05019729|No Intervention|Group 5|Nothing
3366807|NCT05019729|Experimental|Group 6|5 mg/kg IM
3251553|NCT01396629||single group|the intra ocular lenses will be loaded in the cartridge.
3251554|NCT01396642|Experimental|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
3366808|NCT05019729|Experimental|Group1|1 mg/kg IV
3251555|NCT01396642|No Intervention|Routine Skin Care|Neonates in this group will receive routine skin care as per unit protocol
3251556|NCT01396655|Experimental|docetaxel + doxorubicin|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks.
3251557|NCT01396694||all|All patients requiring arthroscopy or arthroplasty
3251558|NCT01396707|Experimental|Herceptin+XELOX|
3366811|NCT05018208||Arm 1 (wearable device[s], smartphone app)|Patients undergoing CAR-T therapy use the Biofourmis wearable device(s) and smartphone app to answer a series of questions about health and neurologic symptoms a few times a day for 5 weeks.
3366812|NCT05018208||Arm 2 (wearable device[s], smartphone app, questionnaires)|Patients undergoing radiation therapy (RT) for head and neck, lung, or gastrointestinal cancers use the Biofourmis wearable device(s) for 90 days after completion of RT. Patients also use the smartphone app to answer a series of questions about health and neurologic symptoms before start of RT, after completion of RT, 3 months after completion of RT, and 1 year after completion of RT. In addition, patients complete weekly questionnaires regarding side effects and tolerance of the device.
3251559|NCT01396720|Active Comparator|fluvoxamine|
3251560|NCT01396720|Active Comparator|citalopharm|
3251561|NCT01396733|Active Comparator|Low dose group|Patients who will receive 600 mg/day alpha-lipoic acid
3251562|NCT01396733|Active Comparator|High dose group|Patients who will receive 1,200 mg/day alpha-lipoic acid
3251563|NCT01396746||People with Post Stroke Conditions|(a) having acquired stroke at least 1 year before testing. (b) Chronic weakness and/or spasticity of the affected side. (c) Independent stair-climbers (with hand-rail). (d) With cognitive level sufficient to comprehend instructions. (e) age range between 40-69. (f) Use of walking aid is permitted as long as the participant is able to walk on a treadmill with hand-rail. (g) No heart failure or other medical conditions that preclude participation in the study.
3251564|NCT01396759|Experimental|bubble CPAP|Children will receive bubble CPAP Bubble-CPAP, which requires a source of gas flow (typically 6-8 L/ minute in a neonate), an air-oxygen blender, a humidifier and a T-piece. The expiratory arm is inserted in a bottle of water and the level of CPAP delivered is equivalent to the length of the expiratory tubing that remains under water. Robust equipment is now available at a fraction of the cost of mechanical ventilators. Bubble-CPAP has potential advantages over the mechanical ventilation, such as lower cost, ease of application by nursing staff, lower risk of complications, and has been proposed as an inexpensive method of delivering CPAP in developing countries.
3366823|NCT05015127|Experimental|HBM9161 680 mg qw by q2w from week 13|Subcutaneous injection; HBM9161 680 mg qw from week 13
3366824|NCT05015127|Experimental|HBM9161 680 mg qw by q2w from week 7|Subcutaneous injection; HBM9161 680 mg qw by q2w from week 7
3366825|NCT05015127|Experimental|Placebo|Subcutaneous injection; Placebo
3366826|NCT05015127|Experimental|Placebo qw by HBM9161 680mg qw from week 12|Placebo qw by HBM9161 680mg qw from week 12
3366827|NCT05013255|Active Comparator|Pioglitazone 15mg Dose|Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
3366828|NCT05013255|Active Comparator|Pioglitazone 30mg Dose|Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
3366829|NCT05013255|No Intervention|No Drug|Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.
3366830|NCT05013190||Participants With Multiple Myeloma (MM)|Participants diagnosed with MM (Newly Diagnosed Multiple Myeloma [NDMM]) using IMWG criteria and received a bortezomib-based triple-drug regimens for more than 2 cycles as initial therapy will be treated with ixazomib based regimens strictly following NINLARO® label will be observed prospectively for 24 months.
3366831|NCT05012332|Other|Erector Spinae Plane Block|All volunteers will be given the choice of procedural pain relief in the form of rapifen 0,5-1 mg. All volunteers included will receive an unilateral ESPB at the T7 level with 30 ml of 2,5 mg/ml ropivacaine and a total of 0,3 mmol gadolinium. The intervention will be performed by the PhD candidate connected to the study. The ESPB will be performed under ultrasound guidance, where the needle target is the transverse process of the Th7 vertebra, under the musculus (m.) erector spinae. All volunteers will be tested for cold and pinprick sensation 30 minutes after block completion, and the results plotted on a dermatome map before they undergo an MRI.
3366833|NCT05011721|Experimental|Intervention with activity tracker|Women allocated to the intervention arm will used an activity tracker
3366834|NCT05011123|Experimental|Group 1|1 injection of vYF vaccine at Day 1
3366835|NCT05011123|Active Comparator|Group 2|1 injection of Stamaril vaccine at Day 1
3251565|NCT01396759|Experimental|High flow air/ oxygen mix|High flow air/ oxygen mix is useful in reducing the indication of mechanical ventilation (4); however, there is a lack of randomized studies comparing it with bubble CPAP or with standard flow O2 supplementation by nasal prongs. High flow air/oxygen mix uses flows of 2 litre per kg per minute of blended air / oxygen mix, usually with a low fraction of inspired oxygen (say 25-40%).
3366840|NCT05005182|Experimental|Cohort A (luspatercept)|Patients receive luspatercept SC on day 1. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
3366841|NCT05005182|Experimental|Cohort A (luspatercept, hydroxyurea)|Patients receive luspatercept SC on day 1 and hydroxyurea PO on days 1-21. Cycles repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
3366842|NCT05004740||Lactating birthing persons delivering at Sinai Health System or from the general population|
3366843|NCT05004428||Type 2 Diabetes Mellitus patients with Chronic Kidney Disease|Canadian patients with type 2 diabetes mellitus data will be collected retrospectively.
3366844|NCT05004181|Experimental|Part A - Cohort 1: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
3366845|NCT05004181|Experimental|Part A - Cohort 2: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
3366846|NCT05004181|Experimental|Part A - Cohort 3: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7) of 30 µg.
3366847|NCT05004181|Experimental|Part A - Cohort 4: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
3251566|NCT01396759|Active Comparator|Standard O2 supplementation by nasal prongs|Standard O2 supplementation by nasal prongs @ 0.5-2.0 litre per minute
3366848|NCT05004181|Experimental|Part A - Cohort 5: 18 to 55 years of age|Participants will receive 1 dose of BNT162b2 of 30 µg.
3366849|NCT05004181|Experimental|Part A - Cohort 6: 18 to 55 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
3366850|NCT05004181|Experimental|Part B - Cohort 1: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
3366851|NCT05004181|Experimental|Part B - Cohort 4: 18 to 85 years of age|Participants will receive 1 dose of BNT162b2 (B.1.617.2) of 30 µg.
3366852|NCT05004181|Experimental|Part B - Cohort 6: 18 to 85 years of age|Participants will receive 2 doses of BNT162b2 (B.1.1.7 + B.1.617.2) of 30 µg.
3366855|NCT05003323||High Knee Pain with Osteoarthritis|Adults 45-80 years old who have moderately severe knee osteoarthritis and rate their daily knee pain at >=6 on a 0-10 numeric rating scale
3366856|NCT05003323||Low Knee Pain with Osteoarthritis|Adults 45-80 who have moderately severe knee osteoarthritis and rate their daily knee pain at <=5 on a 0-10 numeric rating scale
3366857|NCT05003323||Healthy Controls|Age matched, BMI matched adults who do not have knee osteoarthritis or chronic pain
3366858|NCT05002777|Experimental|Rilzabrutinib|Oral rilzabrutinib 400 mg BID
3366859|NCT04998981|Experimental|K-877 0.1 mg BID|K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
3366860|NCT04998981|Experimental|K-877 0.2 mg BID|K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
3251567|NCT01396772|Experimental|PREPARE education program|This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
3251568|NCT01396772|Other|Control arm|Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
3251569|NCT01396785|Experimental|Active|Product 33525
3251570|NCT01396785|Placebo Comparator|Placebo|Product 33525 Placebo
3251571|NCT01396798||Children with an acute illness|Children aged 1 month to 16 years of age, which attend the A&E department of UZLeuven with an acute illness episode of maximum 5 days.
3251572|NCT01396811|Experimental|Active|Product 33525
3366861|NCT04998981|Active Comparator|Fenofibrate 200 mg QD|Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
3366862|NCT04998981|Placebo Comparator|Placebo|Placcebo tablet x 2 twice daily, Placebo capsule once daily
3366863|NCT04998604|Experimental|Dupilumab|Dosing every 2 weeks (Q2W)
3366864|NCT04998604|Experimental|Omalizumab|Dosing Q2W or every 4 weeks (Q4W)
3366865|NCT04996654|Experimental|Exergame|Participants will perform a twelve-week training intervention in addition to their usual care as provided by the memory clinics where the patients are recruited. The training intervention will be prescribed according to a newly developed exergame-based intervention concept that consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) perceptual-motor function.
3366866|NCT04996654|Active Comparator|Usual Care|An active control group will proceed with usual care as provided by the memory clinics where the patients are recruited.
3251573|NCT01396811|Placebo Comparator|Placebo|Product 33525 Placebo
3251574|NCT01396824||Heart failure|Heart failure patients attending a HF clinic with depressed LVEF (< 45%) or ≥ 1 hospital admission due to HF decompensation.
3251575|NCT01396850||Psychotic Group|
3251576|NCT01396850||Anxiety|
3251577|NCT01396850||Depressed|
3251578|NCT01396850||Control Group|
3251579|NCT01396863|Active Comparator|First treatment HDF|The patient will receive treatment with pre-dilution hemodiafiltration during the first examination day. During the second examination day the patient will receive treatment with low flux hemodialysis.
3251580|NCT01396863|Active Comparator|First treatment HD|The patient will receive treatment with low flux hemodialysis during the first examination day. During the second examination day the patient will receive treatment with pre-dilution hemodiafiltration.
3366872|NCT04991350|Active Comparator|Ranibizumab Group|Patients will receive monthly ranibizumab injections for 3 months.
3366873|NCT04991350|Active Comparator|Bevacizumab Group|Patients will receive monthly bevacizumab injections for 3 months.
3366874|NCT04990934||Video Telemedicine|20 participants will have used video telemedicine for appointments with their treating oncologist.
3366875|NCT04990934||Telephone Telemedicine|10 participants will have used telephone telemedicine for appointments with their treating oncologist.
3251581|NCT01396876|Active Comparator|Clown|A clown is present during venipuncture
3251582|NCT01396876|No Intervention|No clown|
3366876|NCT04989517|Experimental|AT193|Topical applied daily
3366877|NCT04989517|Placebo Comparator|Placebo|Topical applied daily
3366879|NCT04982991|Experimental|SAR443820|Participants will receive a single sequence of 3 different doses of SAR443820 in a total of 3 treatment periods
3366880|NCT04982666|Experimental|Whole-Food, Plant-Based Diet Group|Subjects with a known diagnosis of Crohn's disease will follow a whole-food, plant-based diet for a total of 12 weeks
3366881|NCT04982666|Active Comparator|FODMAP Diet|Subjects with a known diagnosis of Crohn's disease will follow a FODMAP diet for a total of 12 weeks
3251583|NCT01396889|Experimental|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children2-5 years old for 3 months
3251584|NCT01396889|Placebo Comparator|Placebo|Placebo
3251585|NCT01396902|Active Comparator|Standard of care|
3251586|NCT01396902|Experimental|Text Messaging|
3251587|NCT01396915||High or Normal Dietary Protein Intake|
3366882|NCT04980027|Experimental|Insuline Glargine (U300) (Gla-300)|Insulin glargine (U300) once daily for 24 weeks on top of non-insulin antidiabetic drug. Insulin dose will be adjusted according to the recommended titration algorithm
3366883|NCT04979754||RENAL TRANSPLANT RECIPIENTS|All patients with previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
3251588|NCT01396928||"J pouch"|"Anastomosis coloanal wiht j pouch reservoir"
3251589|NCT01396928||Transverse coloplasty pouch|Coloanal anastomosis with transverse coloplasty pouch reservoir
3366884|NCT04979754||NON RENAL TRANSPLANT RECIPIENTS|All patients without previous renal transplantation undergoing cardiac surgery with cardiopulmonary bypass
3366885|NCT04978142|Experimental|Active|Active tDCS stimulation at 2 mA for 20 minutes, with a 10 seconds of ramp-up and 10 seconds of ramp-down time as used in previous tinnitus studies. The stimulation will be delivered via two rubber electrodes attached using a layer of conductive paste (35 cm2). The anode will be placed over the right dlPFC and cathode over the left dlPFC).
3366886|NCT04978142|Sham Comparator|Sham|Placebo stimulation is performed using the same current intensity, but only applied for 45 seconds in addition to the 10 second ramp-up and 10 second ramp-down periods. The electrode configuration and placement will be identical to the active stimulation.
3366891|NCT04971161|Experimental|allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)|Application of IMP on patients wound
3251590|NCT01396941|Experimental|sleep restriction|The investigators will compare the effects of sleep restriction vs. normal sleep in healthy volunteers, using a randomized crossover study design. Each subject will undergo a period of normal sleep and a period of sleep restriction, separated by a 1-month washout period. Subjects will be randomized to receive either sleep restriction first (later followed by normal sleep) or normal sleep first (later followed by sleep restriction).
3251591|NCT01396980||dialysis patients|dialysis patients, stabil, dialysis dependancy for more than 3 months, with adequate access
3366892|NCT04971161|Placebo Comparator|Placebo|Application of IMP on patients wound
3366893|NCT04971161|Experimental|allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)|Application of IMP on patients wound
3366894|NCT04971161|Experimental|allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)|Application of IMP on patients wound
3366895|NCT04971031|Experimental|Reproxalap Ophthalmic Solution (0.25%) administered 7 times over two consecutive days.|
3366896|NCT04971031|Placebo Comparator|Vehicle Ophthalmic Solution administered 7 times over two consecutive days.|
3251592|NCT01396993||iTOP|Patients undergoing immediate techniques for oncoplastic surgery (level I only parenchmyl rotation and breast undermining as well as level II using complex reduction plastics for nipple-areola-complex movings) and patients with mastectomy and immediate reconstruction
3251593|NCT01396993||BCT|patients undergoing conservative breast surgery
3251594|NCT01397006|Experimental|Pregabalin|
3251595|NCT01397006|Placebo Comparator|Placebo|
3251596|NCT01397019|Experimental|FOLFIRINOX|
3251597|NCT01397032|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3251598|NCT01397032|Placebo Comparator|Placebo|Attention training via repeated trials of a dot-probe task not intended to change threat-related attention patterns.
3251599|NCT01397045|Active Comparator|Video-assisted lung segmentectomy|Patients undergoing VATS segmentectomy
3251600|NCT01397045|Other|Mini thoracotomy|Patients undergoing lung segmentectomy through a mini thoracotomy
3251601|NCT01397097|Experimental|Arm 1|
3251602|NCT01397097|Active Comparator|Arm 2|
3376158|NCT02457000||Volunteers with skin pathology|Volunteers with skin pathology including but not limited to eczema, psoriasis, acne, and other inflammatory dermatoses will be asked to undergo various procedures to evaluate their sleep and skin health.
3376159|NCT02447692|Active Comparator|PSV ventilation strategy|The control is the standard of care PSV ventilation strategy, designed to adjust the level of support according to usual clinical parameters.
3376160|NCT02447692|Active Comparator|PAV+ ventilation strategy|The intervention is a PAV+ ventilation strategy, designed to adjust the level of support (gain) to target a predefined range of respiratory muscle pressure.
3376161|NCT02447133|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Maestro device
3376162|NCT02438306|Experimental|CardiAMP cell therapy|Placement of an introducer guidewire, performance of a left ventriculogram, and treatment with autologous cell therapy.
3376163|NCT02438306|Sham Comparator|Sham Comparator|Placement of an introducer guidewire and performance of a left ventriculogram with no autologous cell therapy treatment.
3376166|NCT02434354|Experimental|neo-adjuvant/adjuvant pembrolizaumab 200 mg IV|All subjects will receive 1 cycle neo-adjuvant pembrolizumab 200mg IV followed by complete surgical resection followed by pembrolizumab Q3weeks for 1 year
3376167|NCT02420977|Experimental|DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
3366901|NCT04966104|Experimental|ODYSSEE-vCHAT|ODYSSEE-vCHAT consists of (a) automated digital counselling resources (information pages, videos, and interactive digital tools and trackers), (b) moderated chatrooms, and (c) weekly 30-minute presentations led by a healthcare professional and/or a patient representative, followed by a 30-minute question-and-answer period. Each aspect of ODYSSEE-vCHAT is informed by a rotating schedule of seven weekly themes on heart failure (HF) self-care behaviours. Our server contacts participants by email on a weekly basis, inviting them to access the resources available to them. Participants login to our server using their password-protected personal accounts. Each participant's total number of logins and login time (with timestamps) are recorded. Assessments occur online at baseline, months 2, 4, 6, 10, and 12, and end of trial (median = 14 months, range = 6 to 22 months).
3366902|NCT04966104|No Intervention|Enhanced usual care (eUC)|eUC provides educational HF self-care resources and COVID-19 prevention guidelines that are available to the public on professional websites (e.g., Heart Failure Society of Canada, American Heart Association, European Society of Cardiology, Health Canada). Patients will have unlimited access to these resources. Subjects are invited by weekly emails to participate in these resources. Self-reported assessments are administered at baseline, at months 2, 4, 6, 10, and 12, and at trial completion (median = 14 months, range = 6 to 22 months).
3251603|NCT01397110|Active Comparator|Respiratory and exercise therapy|Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
3251604|NCT01397110|No Intervention|Control group without exercise training|"patients of the control group continue their sedentary lifestyle without given advice for exercise training.~The time before start of rehabilitation (three months) serves as control group. Afterwards patients take part in the training program as well."
3251605|NCT01397123|Experimental|Lifestyle counseling|
3251606|NCT01397149|Experimental|Eltrombopag|In phase II, patients will be randomized (2:1 eltrombopag : placebo) to receive either eltrombopag or placebo to explore the efficacy and confirm the safety of the identified eltrombopag dose from Phase I.
3251607|NCT01397149|Placebo Comparator|Film coated tablet|
3251608|NCT01397162|Experimental|BI 54903 LD BID|BI 54903 low dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3366903|NCT04965844|Experimental|Oxygen close-loop|Four hours period where the fraction of inspired oxygen delivered will be automatically titrated based on SpO2 values.
3366904|NCT04965844|Active Comparator|Manual FiO2 adjustment|Four hours period where the fraction of inspired oxygen delivered will be manually adjusted by the healthcare personnel based on SpO2 values.
3366905|NCT04963725||Participants Initiating Therapy with Ustekinumab|Data will be collected for participants in Japan who have had an inadequate response, or been intolerant to, conventional or biologic therapies. The treating physician has made the decision to initiate ustekinumab induction therapy in the routine clinical practice - either as a first or subsequent biologic therapy initiating for their moderate to severe ulcerative colitis.
3251609|NCT01397162|Experimental|BI 54903 MD BID|BI 54903 medium dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3251610|NCT01397162|Experimental|BI 54903 HD BID|BI 54903 high dose 2 puffs b.i.d. via Respimat inhaler plus HFA MDI matching placebo 2 puffs b.i.d.
3251611|NCT01397162|Active Comparator|Fluticasone propionate 88 mcg BID|44 mcg Fluticasone propionate 2 puffs BID via HFA MDI plus placebo BI54903 via Respimat inhaler 2 puffs b.i.d.
3251612|NCT01397162|Placebo Comparator|Placebo|Placebo Respimat inhaler 2 puffs b.i.d. and placebo HFA MDI, 2 puffs b.i.d.
3251613|NCT01397175|Active Comparator|Biolimus-eluting stent|Biomatrix stent, Biosensors, USA Biomatrix Flex stent, Biosensors, USA
3251614|NCT01397175|Active Comparator|Everolimus-eluting stent|Xience Prime stent, Abbott, USA Xience V stent, Abbott, USA
3251615|NCT01397175|Active Comparator|Zotarolimus-eluting stent|Endeavor resolute, Medtronic, USA Endeavor resolute integrity, Medtronic, USA
3251616|NCT01397188|Experimental|PiCCO group|Intervention: Device: Picco- thermodilution catheter
3251617|NCT01397188|Sham Comparator|sham group|No PiCCO Intervention
3251618|NCT01397201|Experimental|BI 54903 LD BID|patient to receive Respimat inhaler containing LD BI54903 plus placebo matching HFA MDI inhaler
3251619|NCT01397201|Experimental|BI 54903 MD BID|patient to receive Respimat inhaler containing MD BI54903 plus placebo matching HFA MDI inhaler
3251620|NCT01397201|Experimental|BI 54903 HD BID|patient to receive Respimat inhaler containing HD BI54903 plus placebo matching HFA MDI inhaler
3251621|NCT01397201|Active Comparator|Fluticasone propionate 220mcg BID|patient to receive Fluticasone HFA MDI inhaler containing 220 mcg ICS plus placebo matching Respimat inhaler
3251622|NCT01397201|Placebo Comparator|Placebo|patient to receive placebo matching Respimat inhaler plus placebo matching HFA MDI inhaler
3251623|NCT01397214|Experimental|Megace F|Megace F oral suspension
3251624|NCT01397214|Active Comparator|Megace OS|Megace acetate oral suspension
3251625|NCT01397227|Experimental|Cohort 1 (Low Dose)|Ad35.CS.01/Ad26.CS.01 - 1 x 10^10 vp
3251626|NCT01397227|Experimental|Cohort 2 (High Dose)|Ad35.CS.01/Ad26.CS.01 - 5 x 10^10 vp
3251627|NCT01397227|Placebo Comparator|Cohort 1 - Placebo|
3251628|NCT01397227|Placebo Comparator|Cohort 2 - Placebo|
3251629|NCT01397240|Experimental|Albis|Drug: Albis Tab 2 tab, twice a day
3251630|NCT01397240|Placebo Comparator|Placebo|Placebo 2 tab, twice a day
3251631|NCT01397266|Active Comparator|Active TMS|active rTMS delivered to the left dorsolateral prefrontal cortex
3251632|NCT01397266|Placebo Comparator|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
3251633|NCT01397279|Active Comparator|Botnia clamp|hyperinsulinemic euglycemic clamp following intravenous glucose tolerance test
3251634|NCT01397279|Active Comparator|hyperinsulinemic euglycemic clamp|hyperinsulinemic euglycemic clamp without previous intravenous glucose tolerance test
3251635|NCT01397305|Experimental|Modufolin and Pemetrexed|Modufolin ( [6R] 5,10-methylenetetrahydrofolate) and Pemetrexed
3251636|NCT01397318||Experimental Group|
3251637|NCT01397318||Control Group|
3366909|NCT04960124|Experimental|Part 1: Cohort 1 (JNJ-42847922)|Participants with normal hepatic function will receive Dose 1 of JNJ-42847922 on Day 1.
3366910|NCT04960124|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with mild hepatic impairment will receive Dose 1 of JNJ-42847922 on Day 1.
3251638|NCT01397331|Active Comparator|Inhalational anesthesia|Group of patients undergoing the surgery under anesthesia based on inhalational anesthetic
3251639|NCT01397331|Active Comparator|TIVA|Group of patients undergoing the surgery under total intravenous anesthesia
3251640|NCT01397357||suspected Myocardial Ischemia|Patient with diagnosis of suspected coronary artery disease (CAD) or recurrent ischemic symptoms assessed by under-effort angina symptoms and/or cardiac conventional stress test, and the presence of at least two risk factors.
3251641|NCT01397370|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 14 days, starting from 5 mg/day
3251642|NCT01397370|Placebo Comparator|Placebo oral solution|Once daily dosing for 14 days
3251643|NCT01397383||Vitamin D deficiency|Patients with low serum vitamin D (25-hydroxy vitamin D < 32 ng/ml)
3251644|NCT01397383||Control group|Patients with normal serum vitamin D level (serum 25-hydroxy vitamin D > 32 ng/ml)
3366911|NCT04960124|Experimental|Part 1: Cohort 3 (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 2 of JNJ-42847922 on Day 1.
3366912|NCT04960124|Experimental|Part 2: Cohort 4 (Optional) (JNJ-42847922)|Participants with moderate hepatic impairment will receive Dose 1 (depending on the results of Cohort 3) of JNJ-42847922 on Day 1.
3366913|NCT04960124|Experimental|Part 2: Cohort 5 (Optional) (JNJ-42847922)|Participants with severe hepatic impairment will receive Dose 2 or Dose 3 (depending on the results of Part 1) of JNJ-42847922 on Day 1.
3251645|NCT01397396|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
3366917|NCT04958226|Experimental|Treatment (Midazolam + Capivasertib)|Midazolam will be administered on Cycle 1 Day 1 and Cycle 1 Day 8. Capivasertib will be administrated from Cycle 1 Day 2 as an intermittent schedule (4 days on/3 days off) until discontinuation. On Cycle 1 Day 12, Midazolam will be administrated with Capivasertib.
3366918|NCT04952636|Experimental|Arthroscopic Cuistow|Patients who receive arthroscopic Cuistow procedure
3366919|NCT04952636|Experimental|Open Cuistow|Patients who receive open Cuistow procedure
3366920|NCT04951609|Experimental|Seltorexant|Participants will receive weight based dose of Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6). Participants will continue baseline selective serotonin reuptake inhibitor (SSRI) antidepressant (Fluoxetine and Escitalopram) orally once daily.
3366921|NCT04951609|Placebo Comparator|Placebo|Participants will receive matching placebo tablets to seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
3366922|NCT04951544|Experimental|Intervention Group|This arm will start the intervention using LetSync app v1.0 from T1 to T4, baseline/Month 0 to Month 14.
3251646|NCT01397396|Placebo Comparator|Sham IMT|Sham Inspiratory Muscle Training
3366923|NCT04951544|Active Comparator|Waitlist-Control Group|This arm will wait to begin the intervention using the LetSync app v2.0 from T3 to T4, Month 8 to Month 14.
3251647|NCT01397435||Gaucher|We will enroll 15 children who have a confirmed diagnosis of Gaucher disease.
3251648|NCT01397435||Healthy volunteers|We will enroll 15 age and gender matched controls.
3251649|NCT01397474|No Intervention|Control|The fluid management algorithm of the control group is based on the standard care procedure of our ICU as recommended in guidelines: the patient's fluid status is assessed by performing a fluid challenge with a bolus of 250 ml colloids. When the patients is fluid responsive (i.e. showing an increase in stroke volume > 10% ) he will receive an additional bolus of 250 ml of colloids. After each fluid challenge, patients will be revaluated for fluid responsiveness to access need of further fluid administration.
3376168|NCT02407405|Experimental|1|Selumetinib 50 mg BID daily
3376170|NCT02334722|Experimental|1 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for one week.
3376171|NCT02334722|Active Comparator|6 Week Levetiracetam|Levetiracetam taken by mouth at a daily dose of 1000 mg for six weeks.
3366932|NCT04944862|Experimental|CDX-0159 1.5mg/kg|CDX-0159 1.5mg/kg administered intravenously every four weeks
3366933|NCT04944862|Experimental|CDX-0159 3mg/kg|CDX-0159 3.0 mg/kg administered intravenously once, followed by placebo four weeks later
3366934|NCT04944862|Experimental|CDX-0159 4.5mg/kg|CDX-0159 4.5 mg/kg administered intravenously once, followed by placebo four weeks later
3366935|NCT04944862|Placebo Comparator|Placebo|Normal saline administered intravenously every four weeks
3366936|NCT04943172|Experimental|VenoValve|Subjects who receive VenoValve implant
3366937|NCT04940572|Experimental|Depakine (VPA)|"Depakine Chrono 500 mg (VPA)~VPA will be administered orally:~From D1 to D3: During the first week 10-15 mg sodium valproate/kg bodyweight per day will be taken daily.~From D3 to W156: The dose will be increased every 3 days in steps of 10 mg sodium valproate/kg bodyweight per day with VPA plasma concentration monitoring until the total daily dose corresponding to the optimal plasma level between 40 and 100 mg/l (ie, 300 to 700 micromol/l) is reached, till the 156 weeks corresponding to the end of treatment (EOT) visit.~The total daily dose will be taken in one or two doses during meals."
3366938|NCT04940039|Experimental|Paliperidone Palmitate|Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their usual clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks.
3366948|NCT04936685|Experimental|MenACYW conjugate vaccine|MenACYW conjugate vaccine single injection at Day 01
3366949|NCT04935580|Experimental|GC012F treatment|GC012F will be infused at a dose of 3 x 10^5 CAR+ T cells/kg after receiving lymphodepleting chemotherapy. Lenalidomide maintenance therapy will be given post month 6 at physicians' choice.
3366953|NCT04933253|Experimental|Experimental|this cohort will receive 2 L of warm 37celsius saline irrigation of the mediastinum prior to closure of the chest
3366954|NCT04933253|No Intervention|Control|this cohort will receive the normal standard of care as established by the primary surgeon
3366955|NCT04933240|Active Comparator|Tamoxifen|tamoxifen 10mg daily for 7 days
3366956|NCT04933240|Active Comparator|Estradiol|estradiol 1mg daily for 7 days
3366957|NCT04933240|Placebo Comparator|placebo|placebo daily for 7 days
3366958|NCT04933058|Experimental|Opioid-free anesthesia|"IV propofol 1-1.5 mg/kg~IV acetaminophen 1000mg~IV dipyrone 1000mg~IV lidocaine 1mg/kg~IV dexacort 4mg~PR diclofenac 50 mg"
3366959|NCT04933058|Active Comparator|Opioid-supplemented anesthesia|"IV propofol 1-1.5 mg/kg~IV fentanyl 1.5 mcg/kg~IV dipyrone 1000mg~IV lidocaine 1mg/kg~IV dexacort 4mg~PR diclofenac 50 mg"
3366960|NCT04932694|Experimental|Study group|Core stabilization exercises will be conducted for 8 weeks, 3 sessions per day at home, and exercises will be supervised remotly.
3366961|NCT04932694|No Intervention|Control group|No exercise will be given to the participants in the control group
3366962|NCT04931823|Experimental|Part A: Dose Escalation|"CPO-100 administered intravenously~At Dose Level 1 & 2: 2 patients will be enrolled. Cohort(s) may be expanded up to 6 patients if a Dose Limiting Toxicity (DLT) occurs within the first 4 weeks after first dosing.~At Dose Level 3 - 7: 3-6 patients will be enrolled. Cohort(s) will be expanded up to 6 patients if a DLT occurs within the first 4 weeks after first dosing.~Dose escalation will end once the maximum tolerated dose (MTD) has been reached. Once the MTD is identified, a recommended Phase 2 dose (RP2D) will be chosen based on accumulated PK, safety data, and further assessed in Part B dose expansion cohorts in patients with advanced solid tumors."
3366963|NCT04931823|Experimental|Part B: Cohort 1|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced solid tumors of gastric, head and neck, lung, and ovarian.
3251650|NCT01397474|Experimental|PPTFM|"The fluid management algorithm of the intervention group uses identical therapy (i.e. fluids) yet targeted at different endpoints (i.e. peripheral perfusion parameters). After evaluation of peripheral perfusion, only patients with a bad peripheral perfusion (i.e. 3 out of 4 criteria considered as bad) will receive a fluid challenge, the same way as in the standard care procedure (i.e. bolus of 250 ml of fluid). After each fluid challenge, patients will be re-evaluated for peripheral perfusion to access further need in fluid challenges. To ensure that no hypovolemia will occur in the intervention group, fluid will be administered irrespectively of peripheral perfusion parameters, if cardiac index falls below a value of 2,5 L/min/m2."
3251651|NCT01397487|Other|one single arm|All patients are included to complete a biopsy of half part of the embryos
3251652|NCT01397500|Active Comparator|Genotropin|"6 months Genotropin (open treatment)~Daily dose:~Male < 45 years: 0,4 mg; ≥ 45 years: 0,2 mg Female < 45 years: 0,5 mg; ≥ 45 years: 0,3 mg Starting with half of the dose for the first 4 weeks."
3366964|NCT04931823|Experimental|Part B: Cohort 2|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced breast cancer.
3366965|NCT04931823|Experimental|Part B: Cohort 3|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with taxane naïve advanced prostate cancer.
3366966|NCT04931823|Experimental|Part B: Cohort 4|CPO-100 administered intravenously in cycles of 3 weekly doses with 1 week rest (1 cycle = 4 weeks) at the recommended Phase 2 dose (X mg/m2) in 15 patients with either ovarian or/and breast cancer who have failed prior taxane treatment (ie, either progressed on a taxane regimen or within 6 months of receiving a taxane regimen).
3366977|NCT04924062|Experimental|Arm A (Pembrolizumab+Gemcitabine+Cisplatin)|Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
3366978|NCT04924062|Placebo Comparator|Arm B (Placebo+Gemcitabine+Cisplatin)|Placebo to Pembrolizumab, 200 mg, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS Gemcitabine, 1000 mg/m^2, Q3W, Day 1 and Day 8 of each cycle until progressive disease or unacceptable toxicity PLUS Cisplatin, 25 mg/m^2, Q3W, Day 1 and Day 8 of each cycle for up to 8 cycles.
3366979|NCT04923958|Experimental|Evaluation of various novel TB triage and diagnostic tests.|For the novel TB triage and diagnostic tests, the investigators will conduct large-scale evaluation of design-locked tests in a cohort of adults with presumed TB, with nested feasibility/pilot studies of early and late prototype tests. The investigators aim to enroll 1500 patients, including 300 people living with HIV and 300 people with diabetes, for evaluation of various novel TB triage and diagnostic tests.
3251653|NCT01397500|Active Comparator|Testosterone undecannoate|18 weeks testosterone undecanoate/placebo (double-blind treatment) 1000 mg/4 ml at baseline and after 6 weeks
3251654|NCT01397500|No Intervention|control group|No Intervention.
3251655|NCT01397513|Active Comparator|Aspirin 75mg|
3251656|NCT01397513|Active Comparator|Aspirin 320mg|
3366980|NCT04923958|Experimental|Evaluation of novel rDST assays|Clinicians at participating sites will be asked to refer adult patients with rifampin-resistance identified by routine molecular testing. The investigators aim to enroll 200 patients for evaluation of novel rDST assays.
3251657|NCT01397539|Experimental|BIIB037|A single dose of BIIB037 by intravenous infusion.
3251658|NCT01397539|Placebo Comparator|Placebo|A single dose of placebo matching BIIB037 by intravenous infusion.
3251659|NCT01397565|Active Comparator|Laparoscopic cholecystectomy|Patients in this arm will undergo conventional laparoscopic cholecystectomy
3251660|NCT01397565|Experimental|Minilaparoscopic cholecystectomy|Patients in this arm will undergo laparoscopic cholecystectomy using minilaparoscopic instruments
3251661|NCT01397578|Experimental|Part 1: Subcutaneous cohort exp|
3251662|NCT01397578|Experimental|Part 2: Intravenous cohort exp|
3251663|NCT01397578|Placebo Comparator|Part 1: Subcutaneous cohort|Repeating subcutaneous injection
3251664|NCT01397578|Placebo Comparator|Part 2: Intravenous cohort|Repeating intravenous injection
3366987|NCT04922762|Experimental|Moderate Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, normal volume exercise training
3366988|NCT04922762|Experimental|High Intensity, Normal Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of high intensity, normal volume exercise training
3366989|NCT04922762|Experimental|Moderate Intensity, High Volume Exercise Training|Participants will complete study 1 (HM20020955-1) and then 10 weeks of moderate intensity, high volume exercise training
3366990|NCT04920422||Metastatic colorectal cancer patients.|Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.
3251665|NCT01397604|No Intervention|Saline Placebo|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects."
3251666|NCT01397604|Placebo Comparator|SE Vehicle|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~The SE (squalene) vehicle contains the oil emulsion in which the GLA-SE is solubilized."
3366991|NCT04916340|Experimental|Muscular Strength|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular strength
3251667|NCT01397604|Active Comparator|GLA-AF|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-AF contains the study drug in an aqueous solution."
3366992|NCT04916340|Experimental|Muscular fitness|Participants will complete study 1 (HM20020955-1) and then 10 weeks of resistance training for muscular fitness
3366993|NCT04915833|Experimental|Patients for CRC screening and diagnostic colonoscopy|Consecutive patients >45 years of age submitted for diagnostic colonoscopy
3366996|NCT04910776|Experimental|Avalglucosidase alfa|Administered intravenously every 2 weeks
3366997|NCT04908280|Experimental|Discoid lupus erythematosus|Patients with discoid lupus erythematosus will be given ruxolitinib cream to be used twice daily for 12 weeks.
3367000|NCT04899583|Experimental|Treatment Group|a Sirolimus Coated Balloon
3367001|NCT04899583|Active Comparator|Control Group|a Paclitaxel Coated Balloon Catheter
3367002|NCT04896827||Chronic pain|Patients with chronic pain (n=100)
3367003|NCT04896827||Healthy participants|Healthy participants (n=144)
3367004|NCT04896619|Experimental|Daily dose of Kori-tofu mixed in 3 slices of bread|Kori tofu as part of bread
3367005|NCT04896619|Active Comparator|Daily dose of whey protein, soy oil and maltodextrin mixed in 3 slices of bread|Whey protein, soy oil and maltodextrin as part of bread
3367010|NCT04891991|Active Comparator|Infliximab group|This group will receive 1 mg/0.05 mL of intravitreal infliximab at the end of standard pars plana vitrectomy.
3367011|NCT04891991|Sham Comparator|Standard of care group|This group will undergo standard pars plana vitrectomy.
3367012|NCT04891614|Experimental|Treatment|Subjects diagnosed with PTSD will be recruited from the community and from local clinical programs. All subjects will undergo Prism neurofeedback training.
3367017|NCT04882072|Experimental|Ustekinumab|"Double-blind (DB) Period: Participants will receive weight-ranged based ustekinumab (6 milligrams/kilogram[mg/kg]) as IV infusion at Week 0 followed by ustekinumab 90mg injection SC 8 weeks after initial IV dose, then every 8 weeks (q8w) thereafter until the end of the DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~Open Label Extension (OLE) period: Participants will receive ustekinumab SC injection at Week OL-0, followed by ustekinumab 90mg SC injection with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from first SC administration after end of DB period whichever is later.~Long-term Extension (LTE) Period: Participants who completed OLE period may be eligible to enter LTE and continue to receive ustekinumab 90mg SC injection q8w."
3251668|NCT01397604|Active Comparator|GLA-SE|"The trial will consist of a total of 32 people. An over-enrollment of about 10% (3 volunteers) will be permitted.~Each cohort will be recruited in sequence. Cohort I will include 16 subjects that will receive a subcutaneous injection, randomized equally so that 5 individuals will receive GLA-AF (2µg), 5 individuals will receive GLA-SE, 3 individuals will receive saline placebo and 3 individuals will receive SE vehicle. Cohort II will include 16 subjects that will receive intramuscular injections, randomized equally into 5 GLA-AF (2µg) subjects, 5 GLA-SE (2µg) subjects, 3 saline placebo subjects and 3 SE vehicle control subjects.~GLA-SE contains the study drug in a squalene oil emulsion."
3251669|NCT01397630|Experimental|Accelerated Oxytocin Titration|
3251670|NCT01397630|Active Comparator|Gradual Oxytocin Titration|
3251671|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
3251672|NCT01397643|Other|Operative|Patients in this arm will be managed operatively for their olecranon fracture using either tension band wiring or plate fixation.
3251673|NCT01397669|Other|HIV infection and non HIV infection|
3251674|NCT01397708|Experimental|INXN-1001 in combination with INXN-2001|Intratumoral injections of INXN-2001 (Ad-RTS-hIL-12) at a constant dose in combination with inter-cohort escalating doses of INXN-1001 (activator ligand).
3251675|NCT01397734|Experimental|Cohort 1|Patients who are receiving Imatinib as part of their standard of care therapy for CML.
3251676|NCT01397734|Experimental|Cohort 2|Patients who are receiving Dasatinib as part of their standard of care therapy for CML.
3251677|NCT01397734|Experimental|Cohort 3|Patients who are receiving Nilotinib as part of their standard of care therapy for CML.
3251678|NCT01397773||Hemodialysis group|Patients on chronic hemodialysis program
3367018|NCT04882072|Placebo Comparator|Placebo|"DB period: Participants will receive placebo intravenous (IV) infusion at Week 0 followed by placebo subcutaneous (SC) injection administration, 8 weeks after the initial IV dose, then q8w thereafter until the end of DB period with starting the protocol defined oral GC taper regimen from Week 2 visit.~OLE period: Participants will receive ustekinumab SC at Week OL-0, followed by SC administration of ustekinumab with oral GC taper at investigator's discretion for 52 weeks (Week OL-52) or until 32 weeks from the first SC administration after the end of DB period, whichever is later.~LTE Period: Participants who complete their participation in OLE period may be eligible to enter the LTE and continue to receive 90 mg SC ustekinumab q8w."
3367019|NCT04880148|Experimental|Thyme and Honey-based oral spray|Thyme and Honey-based oral spray
3367020|NCT04880148|Placebo Comparator|Placebo oral spray|Placebo oral spray
3251679|NCT01397773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
3251680|NCT01397773||Pre-dialysis group|Patients with chronic kidney disease stage-4
3251681|NCT01397773||Control group|Healthy subjects
3251682|NCT01397799|Experimental|Treatment|Subjects will be enrolled into a 28-day dose-escalation study. If no DLT's are observed during the first 28 days, subjects are eligible to continue treatment in the Extension Phase and can remain on treatment until toxicity occurs or until disease progression.
3367025|NCT04872101|Experimental|Delgocitinib 20 mg/g|Twice-daily topical application for 16 weeks
3367026|NCT04872101|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
3367027|NCT04870515|Experimental|Group I (diet, physical activity)|Patients attend 10 in-person or virtual sessions with a registered dietician over 6 months to receive diet instructions. Patients also attend 2 one-on-one sessions with an exercise psychologist to receive instruction to complete aerobic physical activity and strength/resistance training. Patients may also complete up to 21 additional supervised exercise sessions.
3251683|NCT01397812||1|"Subjects will comprise of patients who are the recipients of a heart transplant within the previous 12 months and are scheduled for a routine endomyocardial biopsy.~Subjects will provide breath samples for the Heartsbreath test using the BreathScanner 1.0. Optionally subjects will provide breath samples using the BreathLink point of care system."
3251684|NCT01397838|Experimental|Pro-Bone|
3251685|NCT01397864||Hereditary Angioedema|
3251686|NCT01397877|Experimental|stratum 1|Patients with low grade disease (grade 1 or 2) with positive or negative mutational status
3367028|NCT04870515|Active Comparator|Group II (standard lifestyle recommendations)|Patients receive standard lifestyle recommendations and attend an individual session with a dietitian over 20-30 minutes including US dietary guidelines, activity goal of 30 minutes of physical activity 5 days/week; and discussion of the health benefits of weight loss along with general behavior change suggestions for weight loss.
3251687|NCT01397903||Group 1|"Inpatients and outpatients diagnosed with major depressive disorder as per the DSM-IV criteria who had poor disease control during antidepressant treatment and have completed 4 weeks of add-on drug therapy at enrolment in the study.~The percentage of patients with CGI-I score ≤ 2 at study Visit (4 weeks after the commencement of add-on treatment)."
3251688|NCT01397916||CLL-patients|
3251689|NCT01397916||Controls|
3251690|NCT01397929|Experimental|Drug: BAL101553 at MTD|
3251691|NCT01397929|Experimental|Drug: BAL101553 at 50% of MTD|
3251692|NCT01397942|Experimental|Diet intervention - Ancient vegatables|A healthy Nordic diet with high content of bitter strong tasting vegetables and cabbages.
3251693|NCT01397942|No Intervention|Control Nordic diet|A diet habitually consumed in the Nordic countries
3251694|NCT01397942|Experimental|Diet intervention - Modern Vegetables|A healthy Nordic diet with high content of sweet and mild tasting vegetables and cabbages.
3251695|NCT01397955||Group 1|Drug (incl. Placebo)
3251696|NCT01397968|Experimental|YKP3089|
3251697|NCT01397968|Placebo Comparator|Placebo|
3251698|NCT01397981|Experimental|Walking modification|Changing kinematics for walking
3251699|NCT01397994|Active Comparator|Nicorandil test arm|Nicorandil is given with atenolol therapy.
3367037|NCT04863677|Experimental|High Intensity Interval Training(HIIT)|The HIIT sessions include brief, intermittent bouts of high-intensity exercise interspersed with periods of low-intensity exercise (active recovery).HIIT include 20 intervals of high-intensity (30-60s at rating of perceived exertion (RPE; Borg scale of 6-20) of 15 to 17) and low-intensity (1min at RPE <10 or totally rest). The whole exercise cycle takes around 40-50 minutes.
3367038|NCT04863677|Experimental|Moderate Intensity Continuous Training(MICT)|Patients perform 40-50 minutes at a RPE of 12 to 14(a total of 4 groups, each group 5-8 min, interspersed with 2-minute rest)
3367039|NCT04863677|No Intervention|Control Group|No additional rehabilitation treatment or physical exercise was added in Control Group.
3251700|NCT01397994|Active Comparator|Atenolol control arm|Atenolol 50 mg OD is given.
3251701|NCT01398007|No Intervention|Conventional syringe|Conventional syringe
3367040|NCT04857138|Experimental|Part 1: Dose Escalation (RO7300490 Monotherapy)|Participants will receive escalating doses of RO7300490 intravenously (IV) as a single agent for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
3367041|NCT04857138|Experimental|Part 2: Dose Escalation (RO7300490/atezolizumab combination therapy)|Participants will receive escalating doses of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label) for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
3367042|NCT04857138|Experimental|Part 3: Dose Expansion (Disease-specific Expansion(s))|Participants with selected types of advanced and/or metastatic tumors will receive the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) (determined from Parts 1 and 2) of RO7300490 in combination with a fixed dose of atezolizumab IV (as per label). Treatment will be administered for up to 24 months maximum or until progressive disease, unacceptable toxicities, death, or withdrawal of consent.
3367043|NCT04856917|Experimental|High Dose Arm: Imsidolimab Biological humanized antibody|
3367044|NCT04856917|Experimental|Low Dose Arm: Imsidolimab Biological humanized antibody|
3367045|NCT04856917|Placebo Comparator|Placebo|
3367046|NCT04854512|Experimental|Investigational Arm (Metformin DR plus metformin IR placebo)|Group A will receive 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2×placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
3367047|NCT04854512|Placebo Comparator|Placebo Arm (Metformin DR placebo plus metformin IR placebo)|Group B will receive placebo for 1800 mg Metformin DR qAM + placebo for 1500 mg metformin IR in divided doses (2× placebo for metformin IR 500 mg qAM and 1×placebo for metformin IR 500 mg qPM).
3367048|NCT04854512|Active Comparator|Active Control Arm (Metformin DR placebo plus metformin IR)|Group C will receive placebo for 1800 mg Metformin DR qAM + 1500 mg metformin IR in divided doses (2× metformin IR 500 mg qAM and 1× metformin IR 500 mg qPM).
3367054|NCT04849416|Experimental|LOXO-305|LOXO-305 administered orally.
3367058|NCT04847050|Experimental|1|100 mcg (0.5 mL) mRNA-1273 injection (IM) on days 1 and 29; with option for subsequent booster dose, 100 mcg (0.5 mL) mRNA-1273 injection (IM) no less than 4 weeks after day 29
3367059|NCT04847050|Experimental|2|100 micrograms (0.5 mL) mRNA-1273 injection on D1
3367060|NCT04844918|Experimental|Tirzepatide Regimen A|Tirzepatide Regimen A administered subcutaneously (SC)
3367061|NCT04844918|Experimental|Tirzepatide Regimen B|Tirzepatide Regimen B administered subcutaneously (SC)
3367062|NCT04844918|Placebo Comparator|Placebo|Placebo administered SC
3251702|NCT01398007|Experimental|Camouflage syringe|The camouflage syringe is divided into three parts: head, body and tail. Head consists of bristles to apply topical anesthesia. The body holds the normally used conventional syringe and presents with a slot to check the aspiration results. The tail hides the conventional syringe loaded with the local anesthetic solution. This syringe is made up of cold-cure acrylic with a colorful toy-like look.
3367063|NCT04844411|Experimental|Arm A: JNJ-67835989 (Oral Suspension)|Participants will receive a single oral suspension dose of JNJ-67835989 on Day 1 in Part 1 and Part 2.
3367064|NCT04844411|Placebo Comparator|Arm B: Placebo|Participants will receive a single oral solution placebo on Day 1 in Part 1 only (except food effect cohorts).
3367065|NCT04844411|Experimental|Arm C: JNJ-67835989 (Oral Solid Dose)|Participants will receive a single oral solid dose (tablet) of JNJ-67835989 on Day 1 in Part 3.
3367066|NCT04840914|Experimental|LY3461767|LY3461767 administered subcutaneously (SC).
3367067|NCT04840914|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC).
3367068|NCT04839289|Experimental|A-B-A|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument A Hearing instrument B Hearing instrument A"
3367069|NCT04839289|Experimental|B-A-B|"Participants will be fit with hearing instruments A and B in the following order:~Hearing instrument B Hearing instrument A Hearing instrument B"
3367070|NCT04837807|Experimental|Unit Dose|Subjects randomized to this group will apply the unit-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
3251703|NCT01398020|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep prior to colonoscopy.
3251704|NCT01398020|Experimental|2L Bi-Peglyte|Subjects will be asked to take 2L Bi-Peglyte + 15mg bisacodyl for bowel prep the day before colonoscopy.
3367071|NCT04837807|Experimental|Multi Dose|Subjects randomized to this group will apply multi-dose version of Systane Hydration PF to determine if it helps alleviate symptoms associated with digital eye strain.
3367072|NCT04837105|Active Comparator|Control group|"Classic rehab (physio including strength rehab, fitness, motor activity...) + treadmill gait training 3*/week/4weeks:~5 minutes of warm-up with gradual increase in treadmill speed, max 20 minutes of walking at 80% of maximum speed, 5 minutes of active recovery with gradual decrease in treadmill speed.~(protocol from Grecco et al.)"
3367073|NCT04837105|Experimental|Test group|"Classic rehab - same as control group - (physio including strength rehab, fitness, motor activity...) + overground ARROW CP gait training 3*/week/4weeks:~walking sprint session at maximal speed with gradual increase in number of repetitions over the weeks.~(protocol from Verschuren et al.)"
3367074|NCT04836559|Experimental|JNJ-40411813|Participants will receive JNJ-40411813 twice a day (bid) up to 12 weeks. Up to 3 different doses (low, medium, high) of JNJ-40411813 will be administered in this study.
3367075|NCT04836559|Placebo Comparator|Placebo|Participants will receive Placebo bid up to 12 weeks.
3367076|NCT04833894|Experimental|Efgartigimod|Patients receiving efgartigimod intravenous (IV) treatment
3367078|NCT04830592|Experimental|Part A|NG-641 monotherapy
3367079|NCT04830592|Experimental|Part B|NG-641 and pembrolizumab
3367080|NCT04829669||Participants with Major Depressive Disorder (MDD) and Active Suicidal Ideation with Intent|Participants with MDD (moderate or severe) and active suicidal ideation with intent as defined/confirmed by healthcare team will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical chart review, carer and clinician-reported outcome measures records of each participant.
3367082|NCT04829318|Experimental|Esketamine|Participants who were randomly assigned to the esketamine arm in Study 54135419TRD3013 (NCT04338321), had esketamine nasal spray administered through Week 30 (every 2 weeks dosing) or Week 31 (once weekly dosing), completed the maintenance phase at Week 32 will continue to receive esketamine nasal spray once weekly or every 2 weeks along with serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI) in this long-term extension (LTE) study. Participants will receive esketamine nasal spray until it is commercially available in participant's country.
3251705|NCT01398033|Active Comparator|Drug-coated balloon|"pre-dilatation of the target lesion with a non-coated balloon.~treatment of the target lesion with the paclitaxel-coated balloon"
3251706|NCT01398033|Placebo Comparator|non-coated balloon|Treatment of the target lesion with plain balloon angioplasty.
3251707|NCT01398046|Active Comparator|Dasatinib|
3251708|NCT01398046|Experimental|Dasatinib plus Rabeprazole|
3251709|NCT01398046|Experimental|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|
3251710|NCT01398072|Active Comparator|Moxifloxacin|
3251711|NCT01398072|Active Comparator|Azithromycin|
3251712|NCT01398072|Active Comparator|Doxycycline|
3251713|NCT01398072|Placebo Comparator|Placebo|
3251714|NCT01398085|Active Comparator|Radioactive iodine (RAI) ablation Arm|Patients will be randomised to receive Radioactive iodine (RAI) ablation I131 1.1 GBq
3251715|NCT01398085|No Intervention|No Radioactive iodine (No-RAI) ablation|Patients will be randomised to receive No Radioactive iodine (No-RAI) ablation
3251716|NCT01398098|Experimental|COLOKIT®|
3251717|NCT01398111|Active Comparator|Treatment R2|
3251718|NCT01398111|Active Comparator|Treatment R1|
3251719|NCT01398111|Placebo Comparator|Placebo|
3251720|NCT01398111|Experimental|Treatment T|
3251721|NCT01398137||Ragweed allergic subjects|
3251722|NCT01398150|Placebo Comparator|Sweetened Beverage|looks like and is given in the same way as the experimental treatment but contains no active ingredient
3251723|NCT01398150|Experimental|Cranberry Beverage|15 ounce bottle of cranberry beverage consumed daily for 70 days
3251724|NCT01398163|Experimental|1 = Tested product|
3367087|NCT04825223|Experimental|Stage 1: MenB vaccine formulation(s)|Assigned MenB vaccine formulation or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
3367088|NCT04825223|Active Comparator|Stage 1: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine or Placebo single injection in the respective dosing schedule at Day 01, Day 31 and Day 181
3367089|NCT04825223|Experimental|Stage 2: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, MenQuadfi vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of leading MenB vaccine formulation single injection at Day 366
3367090|NCT04825223|Active Comparator|Stage 2: vaccine comparator(s)|Bexsero vaccine or Trumenba vaccine and Placebo single injection in the respective dosing schedule at Day 01, Day 31, Day 61 and Day 181 + booster dose of Bexsero vaccine single injection at Day 366
3251725|NCT01398163|Active Comparator|2 = Control product|
3251726|NCT01398163|No Intervention|3 = No product|
3251727|NCT01398189|Experimental|clozapine|patients with refractory schizophrenia or schizoaffective disorder
3251728|NCT01398202|Active Comparator|Vitamin D3 (20 microgram/day)|
3367091|NCT04825223|Experimental|Stage 3: Men B vaccine formulation(s)|Assigned MenB vaccine formulation and/or MenQuadfi vaccine single injection in the respective dosing schedule at Day 01 and Day 61
3367092|NCT04825223|Active Comparator|Stage 3: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine single injection at Day 01 or Bexsero vaccine single injection at Day 01 and Day 61
3367093|NCT04825223|Experimental|Stage 4: MenB vaccine formulation(s)|Assigned MenB vaccine formulation, Routine Vaccines (RV)s and MenQuadfi vaccine single injection in the respective dosing at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
3367094|NCT04825223|Active Comparator|Stage 4: MenQuadfi vaccine and vaccine comparator|MenQuadfi vaccine or Bexsero vaccine and RVs in the respective dosing schedule at 2 months of ages [moa] (Day 01), 4moa (Day 61) and 12 moa
3251729|NCT01398202|Active Comparator|25-hydroxyvitamin D (7 microgram/day)|
3251730|NCT01398202|Active Comparator|25-hydroxyvitamin D3 (20 micogram/day)|
3367096|NCT04823897|Experimental|Dose Escalation and Expansion|"Dose escalation phase: CCI-001 will be administered at the starting dose to a cohort of patients with recurrent and/or metastatic solid tumours. The dose will be escalated sequentially in subsequent cohorts to determine the maximum tolerated dose, or recommended dose for the dose expansion cohort.~Dose expansion phase: patients with the following tumour types will be permitted to enroll: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined during the dose escalation phase."
3367097|NCT04823208|Experimental|LY3437943|LY3437943 administered subcutaneously (SC)
3367098|NCT04823208|Placebo Comparator|Placebo|Placebo administered SC
3251731|NCT01398202|Placebo Comparator|Placebo|
3367099|NCT04819945|Experimental|GATT-Patch|GATT-Patch will be used to control bleeding during open liver surgery. Each surgery will be performed according to the standard procedures at the hospital, with the exception of the use of GATT-Patch.
3376172|NCT02319837|Experimental|Enzalutamide plus leuprolide|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with leuprolide administered as as a single intramuscular or subcutaneous injection once every 12 weeks
3376173|NCT02319837|Experimental|Enzalutamide monotherapy|Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily
3376174|NCT02319837|Active Comparator|Placebo plus leuprolide|Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with leuprolide administered as a single intramuscular or subcutaneous injection once every 12 weeks
3251732|NCT01398215||transvaginal NOTES|
3251733|NCT01398228|Other|Group 1|Group 1 will receive quality improvement initiatives first, after 6 months of baseline initiation.
3251734|NCT01398228|Other|Group 2|Group 2 will receive quality improvement initiatives second, after 6 months of the intervention initiation for Group 1.
3251735|NCT01398228|Other|Group 3|Group 3 will receive quality improvement initiatives third, after 6 months of the intervention initiation for Group 2.
3251736|NCT01398228|Other|Group 4|Group 4 will receive quality improvement initiatives forth, after 6 months of the intervention initiation for Group 3.
3251737|NCT01398241|Experimental|Active|
3251738|NCT01398241|Placebo Comparator|Placebo|
3251739|NCT01398254|Other|TRA|Transradial Access
3251740|NCT01398254|Other|TFA|Transfemoral Access
3251741|NCT01398267|Experimental|1|
3251742|NCT01398267|Placebo Comparator|2|
3251743|NCT01398293|Experimental|A|
3251744|NCT01398293|Experimental|B|
3251745|NCT01398293|Active Comparator|C|
3251746|NCT01398293|Placebo Comparator|D|
3251747|NCT01398306||Group A|Patients with clear cell renal cell carcinoma with metastases.
3251748|NCT01398306||Group B|Patients with low grade neuro-endocrine tumours with metastases.
3367105|NCT04810143|Experimental|Aim 1|"All patients presenting for routine post-transplant care including, but not limited to: cardiac catheterization, cardiac biopsy, inpatient admission, or outpatient visits. A convenience sample of 25 inpatient samples will be collected for Aim 1. Although the assay developed by the MSCF will be validated for accuracy, the purpose of Aim 1 is to test real world application of the Mitra Microsampler tubes against the gold standard of blood collected by venipuncture in a controlled setting. To accomplish this, consecutive inpatient heart transplant patients will be enrolled. That sample will be collected at the same time (+/- 15 minutes) as a clinically-indicated, appropriately-timed venipuncture for measurement of a tacrolimus trough and prior to the subject taking tacrolimus so as to represent a trough."
3367106|NCT04810143|Experimental|Aim 2|Outpatient. A convenience sample of 25 outpatients collecting 1-2 samples will be collected for Aim 2. For those who agree to participate, the parent/patient will be taught by a member of the team on how to use the Microsampler to collect blood from a finger stick. They will be provided with a kit for collection of up to 2 samples and will also be provided with appropriate shipping materials to return samples to CCHMC. Participants will then be instructed to collect a sample in the Mitra Microsampler via fingerstick. In addition to the process of collecting the sample in Aim 2, appropriately-aged participants and/or families will be asked to fill out a brief survey regarding sample collection. This will include questions about the ease or difficulty of performing the steps and tolerability of the procedure relative to past experiences with values obtained by venipuncture.
3367107|NCT04809220|Experimental|1.5 mg Dulaglutide|"1.5 mg Dulaglutide given subcutaneously (SC).~Dulaglutide will be given alone or in combination with 1 oral antihyperglycemic medications (OAM).~Participants taking DPP-4 inhibitors (DPP-4i) to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
3367108|NCT04809220|Active Comparator|0.75 mg Dulaglutide|"0.75 mg Dulaglutide given SC.~Dulaglutide will be given alone or in combination with 1 OAM.~Participants taking DPP-4i to stop at randomization or if taking other OAM's, then continue taking same dose of OAM during the study period."
3367110|NCT04805307|Experimental|Part A, Dose escalation|CMG901 will be administered in treatment cycles once every 3 weeks (Q3W). Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 2 dose levels (0.3mg/kg and 0.6mg/kg), and then traditional 3+3 dose escalation design will be used for the following levels (1.2mg/kg, 1.8mg/kg, 2.2mg/kg, 2.6mg/kg and 3.0mg/kg).
3367111|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
3367112|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD determined during Dose Escalation."
3367113|NCT04805307|Experimental|Part B, Dose expansion _GC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive GC or GEJ adenocarcinoma with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
3367114|NCT04805307|Experimental|Part B, Dose expansion _PC_ MTD-1 level|"This cohort will comprise subjects with Claudin 18.2 positive pancreatic cancer with prior failure of, progression on, or intolerance to, standard therapy.~The starting dose of CMG901 for Expansion will be derived from the MTD-1 level determined during Dose Escalation."
3367115|NCT04805177|Experimental|hematoma evacuation|Early minimally invasive image guided hematoma evacuation
3367116|NCT04802057|Experimental|BIVV020|Repeat dose of BIVV020
3251749|NCT01398319|Other|Group Brief Alcohol Intervention|The number of alcohol related incidents for the year prior the initiation of the BAI will be compared to the number of alcohol related incidents when Airmen were exposed to the BAI
3251750|NCT01398332||Aortic pathologies|Indication for aortic endovascular stent graft repair
3251751|NCT01398345|Active Comparator|Exercise and Respiratory Training|
3251752|NCT01398371|Active Comparator|Stable digoxin therapy|Participants need to have been receiving digoxin therapy for at least 3 months at a dose that results in digoxin plasma levels of 0.4-0.8 on 2 consecutive blood tests (at least 1 weeks apart) prior to randomisation. The dose of digoxin must remain stable for at least 2 weeks prior to randomisation.
3251753|NCT01398371|Experimental|Digoxin withdrawal|Participants will receive a placebo for 4 weeks.
3251754|NCT01398384|Active Comparator|Nitric Oxide|nitric oxide for inhalation
3251755|NCT01398384|Placebo Comparator|Placebo|inhalation gas
3251756|NCT01398423|Active Comparator|Active control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
3251757|NCT01398423|Experimental|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
3251758|NCT01398436|Experimental|Catheter tip in right atrium|In this group a central venous catheter will be advanced for its entire length unless arrhythmias develop.Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography.
3367124|NCT04793880|Experimental|Medication checklist with cost information|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist with cost information intervention.
3367125|NCT04793880|Active Comparator|Medication checklist|Participants with chronic heart failure with reduced ejection fraction (HFrEF) having a clinic visit at a site randomized to the medication checklist without cost information.
3367126|NCT04782180|Experimental|Rapid PrEP group|Participants will receive PrEP i.e. Descovy for 12 months at the syringe services program.
3367127|NCT04781816|Experimental|SAR443122|SAR443122 for 12 weeks
3367128|NCT04781816|Placebo Comparator|Placebo|Matching placebo
3367129|NCT04777851|Experimental|Regorafenib + Nivolumab|Investigational arm: regorafenib at a dose of 90 mg orally once per day (on days 1 to 21 of a 28-day cycle), in combination with nivolumab 480 mg using 30-minutes intravenous infusion (on day 1 of a 28-day cycle, every 4 weeks).
3367130|NCT04777851|Active Comparator|Transarterial Chemoembolization (TACE)|"Control arm: Patients will be treated with transarterial chemoembolization (TACE) on-demand according to the clinical site's standards, with the goal of controlling all known liver lesions. Either conventional TACE (cTACE) or drug-eluting bead transarterial chemoembolization (DEB-TACE) may be used (as long as it is consistently applied for all patients at a given clinical site)."
3367131|NCT04774913|Experimental|Invest CTO PCI|A pre-planned two staged procedure in high-risk CTO PCI
3251759|NCT01398436|No Intervention|Catheter tip in superior vena cava|In this group a central venous catheter will be inserted for 15 cm in accordance with standard practice. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
3251760|NCT01398449|Experimental|B|After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI)
3251761|NCT01398449|Active Comparator|A|After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only
3251762|NCT01398462|Experimental|CWP232291|
3251763|NCT01398488|Active Comparator|Conventional Patient education|Conventional Patient education by health care professionals.
3251764|NCT01398488|Experimental|Patient education via Tablet computer|Patient education after lung transplantation via Tablet computers. An electronic patient questionnaire via tablet computer will be collected in addition.
3251765|NCT01398501|Experimental|Post-SCT Sorafenib|Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.
3251766|NCT01398527|No Intervention|LTC Osteoporosis Toolkit Only|Homes will receive the LTC osteoporosis toolkit only and will be required to attend an online webinar to outline the toolkit contents.
3251767|NCT01398527|Active Comparator|Educ sessions & LTC Osteoporosis toolkit|LTC homes will receive the LTC osteoporosis toolkit, on line webinar. Three educational sessions lead by an osteoporosis expert will also take place, 1 on-site visit and 2 webinars.
3251768|NCT01398540|Experimental|elderly|subjects are at least 60 years old (with no upper age limit), receiving 2 immunisations with IXIARO
3251769|NCT01398540|Experimental|young|subjects 18 to 40 years old, receiving 2 immunisations with IXIARO
3251770|NCT01398553|Experimental|Armeo Spring|
3251771|NCT01398553|Active Comparator|conventional physiotherapy|
3251772|NCT01398579|Active Comparator|Group A|Group A: WLE followed by AFI followed by NBI followed by pCLE.
3251773|NCT01398579|Active Comparator|Group B|Group B: WLE followed by NBI followed by AFI followed by pCLE.
3367139|NCT04762069|Experimental|Berubicin|"Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base as a 2 hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days)~Each treatment cycle is 21 days. Subjects will be allowed to continue on treatment at the discretion of the Investigator if there is no evidence of disease progression and the subject is not experiencing unacceptable toxicity as well as if both the subject and Investigator agree that further therapy is in the subject's best interest."
3367140|NCT04762069|Active Comparator|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules|Lomustine (CCNU, CeeNU®, or Gleostine®) capsules will be administered at the institutionally-approved dose and regimen or per the full prescribing information/summary of product characteristics.
3367141|NCT04761887|Experimental|Cool Block|Ropivacaine administered at approximately 4C, via a TAP block.
3367142|NCT04761887|Active Comparator|Room Temp Block|Ropivacaine administered at approximately 20-25C, via a TAP block.
3367149|NCT04759131|Experimental|Prophylaxis|Participants will receive weekly dose of BIVV001 for 52 weeks.
3367150|NCT04758234|Experimental|LY3549492 (Part A)|LY3549492 administered orally as single ascending doses.
3367151|NCT04758234|Experimental|LY3549492 (Part B)|LY3549492 administered orally as multiple ascending doses.
3367152|NCT04758234|Placebo Comparator|Placebo|Placebo administered orally.
3367154|NCT04753879|Experimental|Nab-paclitaxel, Gemcitabine , Cisplatin, Irinotecan, Capecitabine|Maintenance of Pembrolizumab and Olaparib
3251774|NCT01398592|Experimental|Vildagliptin|Experimental
3251775|NCT01398592|Active Comparator|Sitagliptin|Active comparator (drug)
3251776|NCT01398605|Experimental|moderate exercise training|
3251777|NCT01398605|Experimental|intensive exercise training|
3251778|NCT01398605|No Intervention|Control|
3251779|NCT01398618|Experimental|4M-RMP|adult household contacts with latent tuberculosis infection receiving 4-month rifampicin preventive therapy
3251780|NCT01398618|Active Comparator|9M-INH|adult household contact with latent tuberculosis infection receiving 9-month isoniazid preventive therapy
3251781|NCT01398631||Study Group|All included patients presented with chest pain at the emergency room within the inclusion period.
3251782|NCT01398644|Active Comparator|Phlebotomy -intervention phlebotomy|Patients are treated with phlebotomy if ferritin level >50 ug/l
3251783|NCT01398644|Experimental|Erythrocytapheresis|Patients are treated with erythrocytapheresis if serum ferritin level >50ug/l
3251784|NCT01398657|Experimental|Adjuvant Androgen-Deprivation Therapy|Cryotherapy with Short-term Adjuvant Androgen-Deprivation Therapy
3251785|NCT01398657|No Intervention|No adjuvant therapy|Cryotherapy without any adjuvant therapy
3251786|NCT01398670|Experimental|Lispro arm|Lispro and Lispro Mix 75/25 /Lispro Mix 50/50
3251787|NCT01398670|Active Comparator|Humalog® arm|Humalog® and Humalog® Mix75/25 / Humalog® Mix50/50
3251788|NCT01398696|Active Comparator|Patient Information Leaflets|Patient Information Leaflets (PIL) is given to the patient during consultation
3251789|NCT01398696|Placebo Comparator|usual consultation without PIL|no particular intervention during consultation for the patient.
3251790|NCT01398709|Active Comparator|Slow rewarming strategy|Slow rewarming strategy (0.24 degrees C/min)
3251791|NCT01398709|Active Comparator|Fast rewarming strategy|Fast rewarming strategy (0.5 degrees C/min)
3251792|NCT01398722|Active Comparator|Intensive insulin therapy|Intensive insulin therapy(Blood glucose target: 110-150 mg/dL)
3251793|NCT01398722|Active Comparator|Conventional insulin therapy|Conventional insulin therapy(Blood glucose target: 150-180 mg/dl)
3367157|NCT04751825|Experimental|I-EAET|Internet administrated Emotional and Awareness and Expression Therapy (I-EAET). 10 weeks. Self-help treatment with therapist contact via text messages at least once a week.
3367158|NCT04751825|No Intervention|WL|Wait-list.
3251794|NCT01398748|Active Comparator|Intranasal GSH 100mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
3367159|NCT04751487|Experimental|Itepekimab Q2W in former smokers|Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
3367160|NCT04751487|Experimental|Itepekimab Q4W in former smokers|SC administration of Itepekimab every 4 weeks (Q4W) for 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP
3367161|NCT04751487|Placebo Comparator|Placebo in former smokers|SC administration of matching placebo Q2W for 52 weeks
3367162|NCT04751487|Experimental|Itepekimab Q2W in current smokers|SC administration of Itepekimab every 2 weeks (Q2W) for 52 weeks
3367163|NCT04751487|Placebo Comparator|Placebo in current smokers|SC administration of matching placebo Q2W for 52 weeks
3367164|NCT04751045|Active Comparator|Percutaneous Liver biopsy|"Technique: The preprocedure time out protocol will be completed prior to initiation of the procedure. The patient will be positioned supine and right hepatic lobe was localized with ultrasound. Conscious sedation with Versed and fentanyl will be initiated and the patient's vital signs were monitored by an independent trained observer during the procedure.~After placing a mark on the skin overlying the right upper quadrant, the skin was then prepped and draped in the usual sterile fashion. Maximum sterile barrier technique used at the procedure. Under direct sonographic guidance, a 15 gauge percutaneous liver biopsy needle will be used with a 2 cm throw was advanced into the right hepatic lobe. The biopsy samples will be obtained and submitted to pathology."
3367165|NCT04751045|Active Comparator|Endoscopic ultrasound guided liver biopsy|Procedure details: patients will be screened preoperatively to assess cardiovascular health prior to undergoing procedure as this is standard of care. Patients will follow all standard preoperative instructions prior to anesthesia. Upon undergoing general anesthesia, a videoendoscope will be introduced into the esophagus under direct vision. Once endoscope is in position near the liver, a 19-gauge sharkcore needle will be used to puncture the left lobe with a 3 accentuation and another pass from right lobe with 4 accentuation. Doppler study will be used to interrogate for any significant doppler signals in needle path. Post procedure, patients will be provided instructions to avoid NSAIDs for 4 days and perform lightweight activity for 4 days. Patients will be observed for bleeding and significant abdominal pain postoperatively
3367166|NCT04750759|Active Comparator|Niclosamide + Camostat|Patients will receive the combination of niclosamide chewing tablets (2000 mg, once daily) and camostat tablets (600 mg, 4-times daily) over a period of 7 days.
3367167|NCT04750759|Placebo Comparator|Placebo|Patients will receive placebo orally over a period of 7 days.
3251795|NCT01398748|Active Comparator|Intranasal glutathione 200mg/ml|Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
3251796|NCT01398748|Placebo Comparator|Saline intranasal delivery|Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
3251797|NCT01398748|No Intervention|Watchful waiting|No intervention, watchful waiting only (n=4)
3251798|NCT01398761|Experimental|Intervention|nurses, residents, PAs, and attendings from the two pilot services
3251799|NCT01398878|No Intervention|Traditional work schedule|Residents in the intensive care unit perform overnight shifts in excess of 24 hrs every fourth night
3251800|NCT01398878|Active Comparator|Intervention work schedule|Residents in the Intensive Care Unit perform shifts less than 16 hours in length and have at least 8 hours off between shifts
3367168|NCT04749693||Patient with HbA1c >= 8% despite the use of insulin pump and frequent glycemic control|only group included in the study
3251801|NCT01398891|Experimental|Positive Psychology Exercises|
3367169|NCT04743141|Experimental|Rimegepant / BHV3000|BHV3000 (rimegepant) 75 mg or 50 mg ODT
3367173|NCT04735406||Multiple Sclerosis (MS)|Data from the participants with diagnosed MS treated and untreated will be part of this study. Medical records of participants will be used to collect demographics and data pertaining to Multiple Sclerosis (MS) management.
3367174|NCT04732286|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3251802|NCT01398904||Body dysmorphic disorder (BDD) Participants|Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
3251803|NCT01398904||Healthy Controls|Males and females 18 years of age or older with ability to provide informed consent and understand study staff.
3251804|NCT01398917|Active Comparator|short-term stenting|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
3251805|NCT01398917|Active Comparator|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
3251806|NCT01398930|Active Comparator|Group I was treated with etoricoxib|
3251807|NCT01398930|Active Comparator|Group II was treated with acupuncture and etoricoxib|
3367175|NCT04732156|Other|Prospective multicenter cohort|"Constitution of a prospective multicenter cohort of 420 patients with suspected prostate cancer that will undergo prostate multiparametric MRI followed by systematic and targeted biopsy.~When available (i.e., at the end of the RHU PERFUSE program, November 2022), the final version of the CAD will be used retrospectively to assess the risk that the prostate/targeted lesions harbor ISUP ≥2 cancer.~In addition, a blood sample will be taken in all patients before the biopsy to assess the performance of the PHI index in predicting the presence of ISUP ≥2 cancer at systematic and targeted biopsy (ancillary study, secondary objective)."
3251808|NCT01398930|Sham Comparator|Group III was treated with sham acupuncture and etoricoxib.|
3251809|NCT01398969|Experimental|Fresh FMT|Participants in this arm will receive Fresh FMT via rectal administration. They will be followed for 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
3251810|NCT01398969|Experimental|Frozen-and-Thawed FMT|Participants in this arm will receive Frozen-and-Thawed FMT via rectal administration. They will be followed 13 weeks to assess the cure or recurrence of CDI. All other procedures between the two arms will be identical.
3251811|NCT01398995|Experimental|90 minutes|Basal insulin infusion reduced to 50% of normal 90 minutes prior to exercise
3367183|NCT04721977|Experimental|Tucatinib + Trastuzumab + Capecitabine|Participants will receive tucatinib plus trastuzumab plus capecitabine. Tucatinib 300 mg will be administered orally twice daily (BID). Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose thereafter, will be administered intravenously (IV) on Day 1 of each 21-day cycle. Capecitabine 1000 mg/m^2 will be administered orally BID on Days 1-14 of each 21-day cycle. Tucatinib, trastuzumab and capecitabine treatment will continue until unacceptable toxicity, disease progression, death, withdrawal of consent or study closure.
3367184|NCT04720716|Experimental|Sintilimab combined with IBI310|
3367185|NCT04720716|Active Comparator|Sorafenib|
3367186|NCT04715997|Experimental|GX-19: Dose A|Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29.
3367187|NCT04715997|Placebo Comparator|Placebo: Normal saline|Placebo will be intramusculary administered via EP on day 1 and day 29.
3367192|NCT04712097|Experimental|M + Len|Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
3367193|NCT04712097|Experimental|R + Len|Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 6, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
3367194|NCT04711850||Imlifidase treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with imlifidase.
3367195|NCT04711850||Plasma exchange (PE) treatment in feeder Study 16-HMedIdeS-12|No treatment is given in this long-term follow-up study. In the feeder study (16-HMedIdeS-12) the patients in this group were treated with PE.
3367196|NCT04710784|Experimental|I-TEST Intervention Package|Each study site will begin in the baseline, pre-implementation phase, and then be randomized to implement the I-TEST intervention package for a duration of three months, followed by the post-implementation phase.
3251812|NCT01398995|Experimental|60 minutes|Basal insulin infusion reduced to 50% of normal 60 minutes prior to exercise
3251813|NCT01398995|Experimental|30 minutes|Basal insulin infusion reduced to normal 30 minutes prior to exercise
3251814|NCT01398995|Experimental|Start|Basal insulin infusion reduced to 50% of normal at the start of exercise
3251815|NCT01399021|Other|Flat Davol drain|both arms will have flat davol drains placed at the end of the parotidectomy surgery
3251816|NCT01399034||MicroRNA study|Obese group (+ periodontitis group) Non-obese group (+ periodontitis group)
3251817|NCT01399034||DNA methylation study|Periodontitis group Healthy periodontium group
3251818|NCT01399073||Patients with Neglect|
3251819|NCT01399073||Patients with Hemianopsia|
3251820|NCT01399073||Healthy age-matched controls|
3251821|NCT01399086||Fulvestrant|
3251822|NCT01399112|Experimental|Electronic Decision Support System|The Electronic Decision Support System (EDSS) is a 5-module computer program aimed to assess, motivate, educate, solicit preferences, and provide feedback and referrals for people with severe mental illness. The program provides: a) a personalized assessment of the individual's smoking, b) information to improve knowledge of smoking risks and treatment benefits, c) interactive exercises to personalize the impact of smoking, improve attitudes about quitting, and increase self-efficacy for seeking smoking cessation treatment, and d) a video patient vignette to develop social norms for smoking cessation treatment and increase self-efficacy. Usability testing among people with severe mental illness established that the system was comprehensible, easy to use, and took 30-90 minutes to complete.
3259447|NCT01470898|Experimental|anesthesia monitoring|Bispectral Index Monitoring (BIS) has been proven to be effective in preventing awareness. Optimizing anesthesia level using BIS monitoring, neither to light nor to deep will probably help to shorten recovery time and reduce drug consumption. A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.
3367199|NCT04707976|Experimental|Navina Smart|An electronic medical device to perform transanal irrigation. Treatment period 8 weeks.
3367200|NCT04707976|Active Comparator|Standard Bowel Care|Supportive bowel care without using irrigation.
3367201|NCT04706793|Experimental|Etrasimod 2 mg|
3367202|NCT04706793|Placebo Comparator|Placebo|
3367203|NCT04705051|Experimental|Venglustat|Patients will receive venglustat once daily for 24 months
3367204|NCT04703413|Experimental|LoFric® OrigoTM or LoFric® SenseTM|Hydrophilic male (LoFric Origo) and female (LoFric Sense) urinary catheters for single use. Target subject population are subjects suffering from bladder voiding dysfunction and are experienced in intermittent catheterization (IC).
3367205|NCT04701996||cohort|sero-surveillance will start in a cohort of 800 adults (18-50y). In case of an established outbreak, this sample will be extended to 400 children (0-17y) and 400 elderly (50+y).
3367206|NCT04698187|Experimental|CMP-001 and Nivolumab|All enrolled subjects will receive CMP-001 IT and nivolumab IV according to the treatment schedule until a reason for treatment discontinuation is reached.
3367214|NCT04684524|Experimental|Dupilumab|Dupilumab administered every 2 or 4 weeks based on weights
3367215|NCT04684524|Placebo Comparator|Matching placebo|Placebo administered every 2 or 4 weeks based on weights
3367218|NCT04678882|Experimental|Dupilumab|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
3367219|NCT04678882|Placebo Comparator|Placebo|Double dose on day1 and followed by single dose every 2 weeks.Or single dose every 4 weeks
3367223|NCT04674267|Other|Pre-Implementation Phase|"To evaluate the perceived needs of Older Adults A diagnosed with gastrointestinal malignancies, their identified caregivers, staff, and faculty to characterize the implementation setting at DF/BWCC for a geriatric consultation.~To refine the proposed REACH program implementation plan based on qualitative feedback provided by OA patients, their identified caregivers, staff, and faculty."
3367224|NCT04674033||Consumer|Participants who self-report regular consumption of non-nutritive sweeteners (>/=5 servings/week) based on a pre-screening dietary survey.
3367225|NCT04674033||Non-Consumer|Participants who self-report no consumption of non-nutritive sweeteners (0 servings/week) based on a pre-screening dietary survey.
3367226|NCT04673357|Experimental|Open- Label Ustekinumab Intravenous (IV): Induction Period|All participants will receive a single IV administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
3367227|NCT04673357|Experimental|Ustekinumab Subcutaneous (SC) Every 8 Weeks (q8w): Maintenance Period|Participants will receive SC administration of ustekinumab q8w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at maintenance weeks (Weeks M)-0, M-8, M-16, M-24, M 32, and M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
3367228|NCT04673357|Experimental|Ustekinumab SC Every 12 Weeks (q12w): Maintenance Period|Participants will receive SC administration of ustekinumab q12w based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
3367229|NCT04672226|Experimental|PDE MAX|PDE MAX will be prescribed by the study dietitian based on the patient's individual requirement.
3367230|NCT04671576|Active Comparator|Control Formula|A standard, milk-based, infant formula.
3367231|NCT04671576|Experimental|Investigational Formula|An organic milk-based infant formula.
3251823|NCT01399112|Active Comparator|thetruth.com website|"Participants who are assigned to use the web-based thetruth.com website will be asked to navigate through the website as they wish. The home page of thetruth.com site has links to access video games, fact sheets, and videos that highlight negative aspects of cigarettes or tobacco companies. Thetruth.com website is not structured and participants can utilize whatever aspects of the website they wish and in any order they wish to view them.~Individuals will use the computer with a research staff member present who can provide assistance if needed. The sections of the two programs website that are used and the time spend on each portion of the program will be recorded. Participants who use TheTruth.com will be given a referral for assistance in quitting smoking if requested."
3251824|NCT01399138|Experimental|Blueberry Powder|A blueberry smoothie will be consumed at the breakfast and dinner meals.
3251825|NCT01399138|Placebo Comparator|Placebo|A placebo smoothie will be consumed at the breakfast and dinner meals.
3251826|NCT01399151|Experimental|Vitamin D - Treatment 1|400 IU/day Vitamin D
3251827|NCT01399151|Experimental|Vitamin D- Treatment 2|2,000 IU/day Vitamin D
3251828|NCT01399151|Experimental|Vitamin D- Treatment 3|5,000 IU/day Vitamin D
3251829|NCT01399164|Experimental|Fortified Bread|A single serving of 14C-B12 fortified bread
3367248|NCT04659863|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
3367249|NCT04659863|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
3251830|NCT01399203||percutaneous coronary intervention|The investigators reviewed all consecutive patients who were undergoing percutaneous coronary intervention
3251831|NCT01399216|Experimental|Fucoidan supplement|
3251832|NCT01399216|Placebo Comparator|Placebo|
3259448|NCT01470898|Experimental|no bispectral index monitoring|At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
3251833|NCT01399242|Active Comparator|Certican, prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplantation to convert a immunosuppression to certican,prednisone and myfortic. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
3251834|NCT01399242|No Intervention|Tacrolimus,Prednisona, EC-MPS|Twenty patients will be selected at 16 weeks of renal transplant to continue use EC-MPS,Tacrolimus and Prednisone. The allocation will be done randomly to provide similar epidemiological characteristics with respect to gender, age, renal function and co morbidities in the two groups. The informed consent will obtained after an interview involving the researcher and patient when the protocol will be explained.A protocol renal biopsy will be performed at the end of the study, 12 months after transplantation
3251835|NCT01399255|Experimental|Listro™ Arm|Insulin Lispro (Listro™); 100 U/mL, DispoPen 3.0 mL.
3367256|NCT04656600|Experimental|Cerezyme® / Imiglucerase|Cerezyme® (imiglucerase for injection) is administered by intravenous infusion, 60 U/kg once every 2 weeks.
3367257|NCT04655092|Experimental|P1101 (Ropeginterferon alfa-2b)|Conventional treatment based on phlebotomies, lowdose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated prolineinterferon alpha-2b (P1101, Ropeginterferon alfa-2b) once every 2 weeks.
3367258|NCT04652726|Experimental|Inclisiran|Year 1 - inclisiran sodium 300 mg subcutaneous injection (given at Days 1, 90, and 270) Day 360 only - placebo subcutaneous injection Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 450 and 630)
3367259|NCT04652726|Placebo Comparator|Placebo|Year 1 - placebo subcutaneous injection (given at Days 1, 90 and 270) Year 2 - inclisiran sodium 300 mg subcutaneous injection (given at Days 360, 450, and 630)
3251836|NCT01399255|Active Comparator|Humalog® Arm|Insulin Lispro (Humalog®; 100 U/mL), Humalog® Kwik Pen™ 3.0 mL.
3251837|NCT01399281||Biologics alone or methotrexate alone|This group mainly refer to children with polyarticular course JIA treated with methotrexate ± biologics,
3367264|NCT04649242|Active Comparator|BHV3000 (active drug)|BHV3000 (rimegepant) 75 mg or 50 mg ODT
3367265|NCT04649242|Placebo Comparator|Placebo|Matching 75 mg or 50 mg ODT placebo
3367266|NCT04647227|Other|Hemophilia A and B Cases|SEVENFACT® has been approved for the treatment of bleeding events in individuals with hemophilia A or B with inhibitors. This study is intended to further investigate the safety and tolerability of SEVENFACT in participants with hemophilia A or B with inhibitors in the presence or absence of prophylactic therapies. Dosing will be at the discretion of the attending physician, and each participant will be supplied with the equivalent of nine 75 µg/kg doses, which aligns with the recommended dosing schedule as provided in SEVENFACT's United States Prescribing Information (USPI). In the event of a bleeding episode (BE), the participant will either self-administer the correct dose under the guidance of the treating investigator or the dose will be administered at a treatment facility.
3251838|NCT01399281||Biologics and MTX|JIA treated with a combination of biologic and MTX (including any other add on therapy e.g. cyclosporine, leflunomide etc). This group mainly refer to children with polyarticular course JIA treated with MTX ± biologics
3367274|NCT04644575|Experimental|Arm A: Previously treated in BIVV001 study|This arm includes all participants who have completed the previous phase 3 studies on BIVV001, as well as participants who have completed Arm B or Arm C of this study rolling over in Arm A, and participants who will have completed any future BIVV001 study who will be proposed to continue BIVV001 treatment. Participants in this arm will continue receiving BIVV001 prophylaxis treatment once-weekly (QW) for a total of 100 exposure days (EDs) cumulative from the parent study and this study. Participants will have the opportunity to continue in this study for up to 4 years, unless BIVV001 is commercially available in their applicable participating country.
3367275|NCT04644575|Experimental|Arm B: Newly initiated (China Only) in BIVV001|This arm includes Chinese participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) for 52 weeks. After 52 weeks of treatment in this arm B, participants will be able to roll into arm A.
3367276|NCT04644575|Experimental|Arm C: Newly initiated in BIVV001 with planned major surgery|This arm includes participants of any age who will be newly initiated on BIVV001 prophylaxis treatment once-weekly (QW) and will undergo planned major surgery after at least 6 initial EDs with BIVV001, and within 26 weeks from Day 1. After 52 weeks of treatment in arm C, participants will be able to roll into arm A.
3251839|NCT01399281||NSAIDs and/or steroid injections alone|This group refers to children with mostly oligoarticular persistent course who are usually NOT treated with second line agents and have a more benign course.
3367281|NCT04639050|Experimental|Cohort 1: Dose Level 1 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 1 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
3367282|NCT04639050|Placebo Comparator|Cohort 1: Placebo|Participants will receive matching placebo to dose level 1 Q4W for 28 weeks followed by a 28-week safety follow-up period.
3367283|NCT04639050|Experimental|Cohort 2: Dose Level 2 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 2 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
3251840|NCT01399307|Other|Elective Liposuction|
3251841|NCT01399320|Experimental|cyanoacrylate dressing,excesion|we excise the sinus tip then apply cyanoacrylate dressing and watch for healing
3251842|NCT01399333|Active Comparator|Group 1|full liquid diet utilizing meal replacements with PDCAAS of 1.0
3367284|NCT04639050|Placebo Comparator|Cohort 2: Placebo|Participants will receive matching placebo to dose level 2 Q4W for 28 weeks followed by a 28-week safety follow-up period.
3367285|NCT04639050|Experimental|Cohort 3: Dose Level 3 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 3 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
3367286|NCT04639050|Placebo Comparator|Cohort 3: Placebo|Participants will receive matching placebo to dose level 3 Q4W for 28 weeks followed by a 28-week safety follow-up period.
3367287|NCT04639050|Experimental|Cohort : Dose Level 4 of RO7126209|Participants will receive multiple doses of RO7126209 at dose level 4 once every 4 weeks (Q4W) for 28 weeks followed by a 28-week safety follow-up period.
3367288|NCT04639050|Placebo Comparator|Cohort 4: Placebo|Participants will receive matching placebo to dose level 4 Q4W for 28 weeks followed by a 28-week safety follow-up period.
3367291|NCT04634123|Experimental|Primary anterior teeth pulpotomy by White Portland Cement|
3367292|NCT04634123|Other|Primary anterior teeth pulpotomy by White MTA|
3367294|NCT04630028|Experimental|Induction Period (I): Ustekinumab|All participants will receive a single intravenous (IV) administration of ustekinumab at induction Week 0 (I-0) based on body surface area (BSA) (milligram per meter square [mg/m^2]) or weight-tiered induction dose (milligram per kilogram [mg/kg]).
3367295|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 8 Week (q8w)|Participants will receive subcutaneous (SC) administration of ustekinumab every 8 weeks (q8w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-8, M-16, M-24, M-32, M-40 and matching placebo at Weeks M-12 and M-36 to maintain the blind.
3251843|NCT01399333|Active Comparator|Group 2|full liquid diet utilizing protein supplements with PDCAAS of 0.5-0.99
3251844|NCT01399333|Active Comparator|Group 3|full liquid diet utilizing protein supplement with a PDCAAS less than 0.5
3251845|NCT01399346|Experimental|1 bolus of insulin aspart 18 IU|Subcutaneous administration of insulin aspart as one bolus of 18 IU at one injection site.
3367296|NCT04630028|Experimental|Maintenance (M) Period: Ustekinumab once every 12 Week (q12w)|Participants will receive SC administration of ustekinumab every 12 weeks (q12w) based on BSA (mg/m^2) or weight-tiered induction dose (mg/kg) at Weeks M-0, M-12, M-24, M-36 and matching placebo at Weeks M-8, M-16, M-32, and M-40 to maintain the blind.
3367297|NCT04628936|Experimental|KZR-616 45 mg + standard therapy (open-label)|All patients will receive a SC injection of 30 mg KZR-616 at Visit 1 (Day 1), followed by weekly SC injections of 45 mg KZR-616 up to a maximum of 96 weeks. Study drug administration will end for all patients in Study KZR-616-003E when the last patient enrolled has completed 48 weeks of dosing.
3251846|NCT01399346|Experimental|9 bolus of insulin aspart a 2 IU|Subcutaneous administration of insulin aspart as 9 separately and simultaneously applied bolus of 2 IU at 9 separate injection sites
3251847|NCT01399359||Women who decide not to take a SERM|Women participate in the counseling session, questionnaire 1, and questionnaire 2, and the online questionnaire.
3251848|NCT01399359||Women who decide to take a SERM|Women participate in the counseling session, questionnaire 1 and questionnaire 2.
3367306|NCT04622839|Experimental|Group 1|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
3367307|NCT04622839|Experimental|Group 2|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
3367308|NCT04622839|Experimental|Group 3|Participants will not be aware of the relation to the group they are randomized into in comparison to the other study groups; for example, if they were assigned a higher or lower frequency of ice usage (with Intervention 1 being frequency of ice usage), etc.
3367309|NCT04622228|Experimental|LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab|Participants will receive the following treatment regimens: LDRT concurrent cisplatin/carboplatin + etoposide + atezolizumab. Induction treatment will be administered on a 21-day cycle for four cycles. Concurrent radiation therapy will be conducted from Day 1 - Day 5 in the first cycle. Following the induction phase, participants will continue maintenance therapy with atezolizumab. Participants will be treated until loss of clinical benefit, or unaccepted toxicity, or withdrawal of consent, or death (whichever occurs first).
3367310|NCT04619602|Experimental|GSNO therapy|Intervention will be 30 minutes of inhaled GSNO agent in enrollment blocks of three subjects/dose (0.5 mL/kg of 0.25 mM, 0.5 mM, or 1 mM) to infants.
3367311|NCT04619524|Experimental|A: Patients undergo cycle with the transfer of fresh embryos|In study group A the cervical mucus will be collected from patients undergoing the in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI)/embryo transfer (ET) cycle with the transfer of fresh embryos.
3367312|NCT04619524|Experimental|B: Patients undergo cycle with the transfer of frozen embryos|In study group B cervical mucus will be sampled from patients undergoing treatment cycles with the transfer of cryopreserved embryos.
3367313|NCT04619420|Experimental|JNJ-63733657|Participants will receive single dose of JNJ-63733657 low dose or high dose administered by intravenous (IV) infusion every 4 weeks.
3367314|NCT04619420|Placebo Comparator|Placebo|Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks.
3251853|NCT01399450|Experimental|paliperidone add on|paliperidone add on
3367315|NCT04617964||IUGR|sample of 40 pregnant women affected by intrauterine growth restriction (IUGR) Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
3367316|NCT04617964||NORMAL|Ssample of 40 healthy pregnant women Two referees will perform four successive measurements of the diameter of the right portal vein (RPV) during the same ultrasound examination at the third trimester. Each operator will qualify the appearance of the right portal vein as normal or collapsed using an evaluation grid, and will independently performe a series of two measurements using the same method.
3367317|NCT04616677|Active Comparator|Parts 1 and 2: Cohort 1 (JNJ-42847922)|Healthy participants with normal renal function [estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 90 milliliter (mL)/minute (min)] will receive single oral dose of JNJ-42847922 on Day 1.
3367318|NCT04616677|Experimental|Part 1: Cohort 2 (JNJ-42847922)|Participants with severe renal impairment (eGFR 15 to 29 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
3367319|NCT04616677|Experimental|Part 2 (Optional): Cohort 3 (JNJ-42847922)|Participants with moderate renal impairment (eGFR 30 to 59 mL/min) will receive single oral dose of JNJ-42847922 on Day 1.
3367322|NCT04614909|Experimental|Arm A Newly diagnosed glioblastoma treated with pamiparib|Participants undergoing resection for a presumed newly diagnosed glioblastoma (nGBM) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
3367323|NCT04614909|Experimental|Arm B Recurrent glioblastoma treated with pamiparib|Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
3367324|NCT04614909|Experimental|Arm C Recurrent glioblastoma treated with olaparib|Arm C will be an exploratory arm in recurrent glioblastoma patients (rGBM) treated with Olaparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive olaparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
3367325|NCT04613648||Group A|Painful and stiff hemiplegic side shoulders of stroke patients
3251854|NCT01399463|Experimental|DEB + BMS|Paclitaxel drug-eluting balloon (DEB) dilatation and bare metal stenting
3251855|NCT01399463|Active Comparator|Stenting with commonly used Drug Eluting Stents (DES)|
3251856|NCT01399476|Experimental|Endoscopic Myotomy|
3367326|NCT04613648||Group B|Asymptomatic non-hemiplegic side shoulders of stroke patients
3367327|NCT04613648||Group C|Non-dominant side shoulders of healthy volunteers
3367328|NCT04612725|Experimental|Benralizumab Arm 1|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
3367329|NCT04612725|Experimental|Benralizumab Arm 2|Benralizumab Dose A regimen A until Week 12, Dose B regimen A until Week 24,and Dose B regimen A during the extension period until Week 52 (n=30)
3367330|NCT04612725|Experimental|Benralizumab Arm 3|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen B during the extension period until Week 52 (n=30)
3367331|NCT04612725|Experimental|Benralizumab Arm 4|Benralizumab Dose B regimen A until Week 12, Dose B regimen A until Week 24, and Dose B regimen A during the extension period until Week 52 (n=30)
3367332|NCT04612725|Experimental|Placebo and Benralizumab|Placebo regimen A until Week 24, benralizumab Dose B regiment A until Week 36, and Dose B regimen B until Week 52 (n=40).
3367333|NCT04609423|Experimental|Cod liver oil|supplementation for 6 months
3367334|NCT04609423|Placebo Comparator|Corn oil (placebo)|supplementation for 6 months
3251857|NCT01399489|Experimental|Exercise training|Individuals randomized to this arm get 48 sessions of personal training in a state of the art fitness facility
3376175|NCT02311621|Experimental|A: 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3251858|NCT01399489|No Intervention|Control|Individuals in the control arm are expected to continue to live normally, following their doctor's advice but not engage in any formal exercise training.
3251859|NCT01399502|Active Comparator|Self-help advice|Each email will contain a self-help strategy for coping with depressive symptoms. The email will contain information about why the strategy will be effective, tips for implementing the strategy and overcoming barriers, and how to set a goal to implement the strategy. Strategies are based on previous research published by the trial co-ordinators.
3251860|NCT01399502|Placebo Comparator|Depression information|Each email will contain different information about depression, such as symptoms, risk factors, prevalence.
3251861|NCT01399515|Active Comparator|Valproic acid|
3251862|NCT01399515|No Intervention|Control|
3251863|NCT01399528||Beaumont Hospital, Dublin, Ireland|
3251864|NCT01399528||St. James' Hospital, Dublin, Ireland|
3251865|NCT01399528||Hôpital Erasme, Brussels, Belgium|
3251866|NCT01399528||Duke Medical Centre, North Carolina, USA|
3251867|NCT01399528||The Institute of Neurology/University College London, UK|
3251868|NCT01399541||Under and over 65 years|
3251869|NCT01399554|No Intervention|Assessment Only|
3251870|NCT01399554|Experimental|Weekly Exercise Counseling Intervention|
3251871|NCT01399567|Experimental|Algorithm|The NH pain management algorithm is a series of decision-making tools that begins with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain. The algorithm is coupled with intense diffusion strategies (e.g., education, consultation, boosters) to increase adoption of these evidence-based practices
3251872|NCT01399567|Active Comparator|Control|Control sites received staff education for pain assessment and management comprised of four one-hour classes
3367337|NCT04607096|Active Comparator|Prediabetic subjects - cluster 3|Presence of a cluster 3 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
3367338|NCT04607096|Active Comparator|Prediabetic subjects - cluster 5|Presence of a cluster 5 phenotype will be examined according to the parameters described by Wagner et al.(Nat. Med. 2020).
3367339|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-deficient diabetes (SIDD)|Presence of a SIDD phenotype will be examined according to the parameters de-scribed Ahlqvist et al. (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
3367340|NCT04607096|Active Comparator|Patients with type 2 diabetes - subphenotype: Severe insulin-resistant diabetes (SIRD)|Presence of a SIRD phenotype will be examined according to the parameters de-scribed Ahlqvist et al (Lancet Diabetes Endocrinol. 2018 May;6(5):361-369).
3367342|NCT04605783|Experimental|Florastor®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
3367343|NCT04605783|Experimental|Travelan®|Product will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
3367344|NCT04605783|Placebo Comparator|Placebo|Placebo will be started 3 days prior to arrival in overseas destination and maintained for a duration of 10 days during travel or deployment.
3367345|NCT04604158|Experimental|Elly Mobile Phone Application|
3251873|NCT01399580|Placebo Comparator|Group A - Placebo QD|
3367346|NCT04602975|Experimental|Adults cohort 1 vaccinees|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 intramuscular (IM) injections with the 10μg OS adjuvanted dose (or matching placebo), at a ratio of 3:1.
3367347|NCT04602975|Placebo Comparator|Adults cohort 1 placebo recipients|Eligible subjects (adults - 18 to 50 yr-old) will be randomized to receive 3 IM injections with the adjuvanted matching placebo.
3367348|NCT04602975|Experimental|Children cohort 2 vaccinees|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the 10 μg OS dose with Alhydrogel (or matching placebo) at a ratio of 3:1.
3367349|NCT04602975|Placebo Comparator|Children cohort 2 placebo recipients|Eligible subjects (Children 2 to 5 yr-old) will be randomized to receive 3 IM injections of the matching placebo with Alhydrogel.
3367350|NCT04602975|Experimental|Infants cohort 3A vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
3367351|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
3367352|NCT04602975|Experimental|Infants cohort 3A vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 2 μg dose (or of matching placebo), at a ratio of 4:1.
3367353|NCT04602975|Placebo Comparator|Infants cohort 3A placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
3367354|NCT04602975|Experimental|Infants cohort 3B vaccinees (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
3367355|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (-)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the not adjuvanted matching placebo.
3367356|NCT04602975|Experimental|Infants cohort 3B vaccinees (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted 10 μg dose (or of matching placebo), at a ratio of 4:1.
3367357|NCT04602975|Placebo Comparator|Infants cohort 3B placebo recipients (+)|Eligible subjects (9 mo-old +/- 1mo infants) will be randomized to receive 3 IM injections of the adjuvanted matching placebo.
3251874|NCT01399580|Active Comparator|Group B - Low dose Atrasentan QD|
3251875|NCT01399580|Active Comparator|Group C - High dose Atrasentan QD|
3251876|NCT01399606|Experimental|BF2.649|
3251877|NCT01399632|Experimental|High Fat and Low Carbohydrate Diet|
3251878|NCT01399632|Experimental|Low Fat and High Carbohydrate Diet|
3259449|NCT01470911|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
3367358|NCT04599855|Experimental|Esketamine 56 Milligram (mg)|Participants will receive nasal spray treatment with esketamine 56 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 Montgomery-Asberg Depression Rating Scale [MADRS] assessment).
3367359|NCT04599855|Experimental|Esketamine 84 mg|Participants will receive nasal spray treatment with esketamine 84 mg twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
3251879|NCT01399645|Experimental|Liraglutide-Metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day until the end of the study.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
3251880|NCT01399645|Experimental|Insulin-Metformin|"Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU. The patients will be taught to increase their insulin dose by 1 unit each day until achieving an FPG ≤ 7.0 mmol/L.~All subjects will be given metformin with a starting dose of 500 mg in one tablet twice daily given before or during meals for the duration of the study."
3367360|NCT04599855|Experimental|Placebo|Participants will receive nasal spray treatment with placebo twice a week for 4 weeks. Participants may participate in an open-label treatment/observation phase, following completion of the double-blind treatment phase assessments (which includes the Day 28 MADRS assessment).
3251881|NCT01399658|Experimental|Image-Guided Brachytherapy|Image-guided brachytherapy
3251882|NCT01399684|Experimental|MEGF0444A + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A + mFOLFOX-6 (oxaliplatin, folinic acid, and 5-fluorouracil) regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles (Cycle = 14 days) and 5-fluorouracil, folinic acid, bevacizumab and MEGF0444A will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
3251883|NCT01399684|Placebo Comparator|Placebo + mFOLFOX-6 + Bevacizumab|Participants will receive MEGF0444A matching placebo + mFOLFOX-6 regimen + bevacizumab. Participants will receive oxaliplatin for up to 8 cycles and 5-fluorouracil, folinic acid, bevacizumab and placebo will be administered until disease progression or unacceptable toxicity for a maximum of up to 52 cycles.
3251884|NCT01399749|Experimental|Autologous ASC implantation|Treatment with autologous ASC
3251885|NCT01399749|Active Comparator|Autologous Chondrocytes implantation|Treatment with autologous chondrocytes
3251886|NCT01399762||mechanical recanalization|Patients with acute stroke being treated with endovascular devices for mechanical recanalization (no restriction to specific endovascular devices)
3251887|NCT01399775|Experimental|immediate implantation|Immediately after tooth extraction, dental implant is inserted.
3251888|NCT01399775|Other|Delayed implantation|Four months after extraction, Dental implant is inserted.
3251889|NCT01399801|Experimental|hemodynamicaly guided LV lead placement|optimized left ventricular lead placement
3251890|NCT01399801|Active Comparator|Standard lead placement|Standard LV lead placement with no measurements to guide LV lead placement
3251891|NCT01399814|Active Comparator|standard fluid regimen group|perioperative fluid treatment
3251892|NCT01399814|Experimental|restricted fluid regimen group|perioperative fluid treatment
3251893|NCT01399840|Experimental|Arm 1: BMN 673|Arm 1 will enroll patients with either AML or MDS
3251894|NCT01399840|Experimental|Arm 2: BMN 673|Arm 2 will enroll patients with either CLL or MCL
3251895|NCT01399853|Experimental|160U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 children aged 12-36 months old on day0,28
3251896|NCT01399853|Experimental|320U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 children aged 12-36 months old on day0,28
3251897|NCT01399853|Experimental|640U /0.5ml in children (from 12 to 36 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 children aged 12-36 months old on day0,28
3367365|NCT04597372|Experimental|Tamsulosin|"10 capsules will be distributed to subjects to be taken daily. Each capsule contains 0.4mg of Tamsulosin. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
3367366|NCT04597372|Placebo Comparator|Placebo|"10 capsules will be distributed to subjects to be taken daily. Subjects will take the capsule once daily until the end of the 10 day course or until the resolution of acute postoperative urinary retention.~Both study drug and placebo will appear identical and will be prepared by the pharmacy."
3367367|NCT04592731|Experimental|Gel containing Acetylated Natural Nucleotides|
3367368|NCT04592731|Placebo Comparator|Vehicle Gel|
3367369|NCT04591626|Experimental|Dulaglutide|Dulaglutide administered subcutaneously (SC) in combination with insulin glargine given SC.
3367370|NCT04591626|Placebo Comparator|Placebo|Placebo administered SC in combination with insulin glargine given SC.
3367377|NCT04585191|Experimental|Pre-Visit Conversation Aid|"Patients in the intervention arm will receive a newly developed, 1-page conversation aid/communication tool entitled Talking to Your Doctor about Diabetes: Are My Current Medicines Still Right for Me? prior to a scheduled appointment with their PCP. This document will provide brief education about changing risks and benefits of diabetes treatment as patients age, elicit values and preferences regarding treatment, and help direct next conversation steps."
3367378|NCT04585191|Active Comparator|General Health Education Handout|"Patients in the attention control arm will receive an existing 1-page health education handout entitled Embracing Life as You Age which provides some general advice geared towards older patients such as remaining physically active, limiting sun exposure, and eating well."
3367379|NCT04584684|Placebo Comparator|Saline|Subject participants will rinse mouth one time for 60 seconds with 10 mL of Isotonic Saline.
3251898|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in children (12-36months)|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 children aged 12-36 months old on day0,28
3367380|NCT04584684|Active Comparator|27% Ethanol plus essential oils|Subject participants will rinse mouth one time for 60 seconds with 10 mL 27% ethanol plus essential oils.
3367381|NCT04584684|Active Comparator|0.075% Cetylpyridinium Chloride|Subject participants will rinse mouth one time for 60 seconds with 10 mL 0.075% Cetylpyridinium Chloride.
3367382|NCT04584684|Active Comparator|1.5% w/v Hydrogen Peroxide|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 1.5% w/v hydrogen peroxide rinse.
3367383|NCT04584684|Active Comparator|0.5% w/v Povidone-iodide|Subject participants will rinse mouth one time for 60 seconds with 10 mL .5% w/v povidone-iodide.
3367384|NCT04584684|Active Comparator|0.12% Chlorhexidine Gluconate|Subject participants will rinse mouth one time for 60 seconds with 10 mL of 0.12% Chlorhexidine Gluconate.
3251899|NCT01399853|Experimental|160U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml in 120 infants aged 6-11 months old on day0,28
3251900|NCT01399853|Experimental|320U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 120 infants aged 6-11 months old on day0,28
3251901|NCT01399853|Experimental|640U /0.5ml in infants (from 6 to 11 months old)|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
3251902|NCT01399853|Experimental|(without adjuvant) 640U /0.5ml in infants (from 6 to 11 months|inactivated vaccine(vero cell) against EV71 of (without adjuvant) 640U /0.5ml in 120 infants aged 6-11 months old on day0,28
3251903|NCT01399853|Placebo Comparator|0/0.5ml placebo in children (from 12 to 36 months old)|0/0.5ml placebo in 120 children aged 12-36 months old on day0,28
3251904|NCT01399853|Placebo Comparator|0/0.5ml placebo in infants (from 6 to 11 months old)|0/0.5ml placebo in 120 infants aged 6-11 months old on day0,28
3251905|NCT01399879||Healthy Volunteers|
3251906|NCT01399918|Experimental|everolimus and bevacizumab|This is a single-institution, single-arm phase II trial of everolimus in combination with bevacizumab in patients with advanced non-clear cell RCC, who have not received prior VEGF-.or mTOR-targeted therapy. A separate cohort of patients with non-clear cell RCC with papillary features will be enrolled in order to gather information regarding the efficacy given the rarity of these entities.
3251907|NCT01399931||Early-stage Hodgkin Lymphoma Patients|Early-stage Hodgkin Lymphoma (HL) patients presenting bulky nodal lesions treated with ABVD and consolidation radiotherapy
3251908|NCT01399957||pwMS prescribed dalfampridine-ER|Anyone prescribed D-ER per usual clinical care was recruited into this observational study. All those willing to participate were consented and observed pre-drug and for a 14week period with two follow-up visits scheduled at 12 and 18months.
3251909|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Conventional in Office Care
3251910|NCT01399970|Experimental|Mobile Teleconsultation Arm (MTA)|Mobile Teledermatology Care
3251911|NCT01399983||pulmonary hypertension|patients with pulmonary hypertension and with exercise-induced pulmonary hypertension take part
3251912|NCT01399996|Placebo Comparator|Yogurt smoothie without probiotic.|
3367389|NCT04575896|Experimental|Deceased donor HCV RNA PCR+|Participants who receive a kidney from HCV RNA PCR + deceased donor will receive glecaprevir/pibrentasvir 300 mg/120 mg once daily by mouth for 2 weeks
3367390|NCT04574154|Experimental|FIB|ultrasound guided Fascia Iliaca Block
3367391|NCT04574154|Experimental|ESPB|ultrasound guided Erector Spinae Plane Block
3367393|NCT04572243|Experimental|Lorcaserin (Core Study and Open-label Extension Phase)|Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
3367394|NCT04572243|Placebo Comparator|Placebo (Core Study) + Lorcaserin (Open-label Extension Phase)|Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
3367399|NCT04563741|Experimental|MOVE!+UP (intervention)|usual care enhanced with MOVE!+UP (intervention)
3367400|NCT04563741|Active Comparator|MOVE! (control condition)|usual care enhanced with MOVE! (control condition)
3251913|NCT01399996|Experimental|Probiotic added post fermentation.|
3251914|NCT01399996|Experimental|Probiotic added pre-fermentation.|
3251915|NCT01399996|Experimental|A capsule containing the probiotic.|
3251916|NCT01400009|Placebo Comparator|Placebo|Subjects in this group will receive a placebo tablet (Lactose 100 mg) for the duration of the study
3251917|NCT01400009|Active Comparator|Vitamin D|Subjects in this arm will receive a dose of 50,000 IU of vitamin D3, followed by weekly doses of 10,000 IU of vitamin D3
3251918|NCT01400022|Active Comparator|Cortisone|
3367401|NCT04562766|Experimental|Rilzabrutinib|Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
3367402|NCT04562766|Placebo Comparator|Placebo|Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
3251919|NCT01400022|Experimental|UVA1 phototherapy|
3251920|NCT01400035||test group, control group|"Test group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg, intravenous infusion of Cavinton 30mg once a day.~Control group: Patients will be given cytidine diphosphate choline 0.4-0.5g, aspirin 75-100mg or Clopidogrel 75mg once a day."
3251921|NCT01400048|Active Comparator|Aloe vera effervescent tablet (AVH200)|
3251922|NCT01400048|Placebo Comparator|Placebo|
3251923|NCT01400061||normal|body mass index: 19-24
3251924|NCT01400061||overweight|body mass index: 25-29
3251925|NCT01400061||obesity|body mass index: 30-40
3251926|NCT01400061||modbid obes|body mass index: over 40
3251927|NCT01400074|Active Comparator|Nilotinib|400 mg twice daily
3251928|NCT01400074|Active Comparator|Imatinib|400 mg twice daily
3251929|NCT01400087|Active Comparator|Cap-attached Colonoscopy|
3251930|NCT01400087|Placebo Comparator|Regular colonoscopy|
3251931|NCT01400100|Experimental|Octreotide|Study patients receive after randomization a single shot of 5 mL 500 µg Octreotide in the gastroduodenal artery at the time of its transection.
3251932|NCT01400100|Placebo Comparator|Control|Control patients receive after randomization a single shot of 5 mL 0,9% NaCL solution in the gastroduodenal artery at the time of its transection.
3251933|NCT01400152|Active Comparator|Passive warming with additional active warming|
3251934|NCT01400152|No Intervention|Passive warming|
3251935|NCT01400165|Active Comparator|Desyrel/Teva-Trazodone|Both drugs will be given at the dose of 150 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication.
3251936|NCT01400165|Active Comparator|Visken/Teva-Pindolol|Both drugs will be given at the dose of 10 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
3251937|NCT01400165|Active Comparator|Seroquel/Teva-Quetiapine|Both drugs will be given at the dose of 100 mg. A washout period (corresponding to 10 half-life of the active compound) will be respected after receiving each medication
3251938|NCT01400191|Active Comparator|Homozygote wildtype OCT1|
3251939|NCT01400191|Active Comparator|Heterozygote OCT1|
3251940|NCT01400191|Active Comparator|Homozygote OCT1 variant|
3251941|NCT01400204||MDMA|poly drug users that used MDMA at New Years Eve
3251942|NCT01400204||Other Drugs|poly drug users that used drugs at New Years Eve, but not MDMA
3251943|NCT01400204||Alcohol|poly drug users that used no drugs at New Years Eve, but did consume alcohol
3251944|NCT01400217||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3251945|NCT01400217||IPDI SP HFA-BDP|Patients initiating inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3251946|NCT01400217||IPDA SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3251947|NCT01400217||IPDA EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extra fine particle HFA-BDP MDI at the index date
3367403|NCT04558866|Experimental|ExBAT Arm|Testosterone Cypionate 400 mg IM on Day 1 and Darolutamide 1,200mg/day (two 300 tablets every 12 hours) p.o. for 28 days, from day 29 to day 56 followed by a washout period of 7 days (63-day cycles), until loss of benefit (disease progression and/or limiting toxicity).
3367406|NCT04556370|Placebo Comparator|Control group|Normal saline infusion simultaneous with subarachnoid block
3367407|NCT04556370|Experimental|0.025 μg/kg/min group|A maintenance dose of norepinephrine (0.025 μg/kg/min) infusion simultaneous with subarachnoid block
3367408|NCT04556370|Experimental|0.050 μg/kg/min group|A maintenance dose of norepinephrine (0.050 μg/kg/min) infusion simultaneous with subarachnoid block
3367409|NCT04556370|Experimental|0.075 μg/kg/min group|A maintenance dose of norepinephrine (0.075 μg/kg/min) infusion simultaneous with subarachnoid block
3367410|NCT04555044|Experimental|Clinolipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
3367411|NCT04555044|Active Comparator|Intralipid|Dosing based on AAP, ASPEN, ESPGHAN/ESPEN/ESPR/CSPEN guidelines. Study treatment will be administered intravenously in the hospital setting from 7 up to 90 days using either a syringe pump or an infusion pump as appropriate for the daily volume of infusate. The flow rate will be prescribed by the Investigator to provide the daily dosage over 20 to 24 hours.
3367412|NCT04553640|Experimental|Group A/Intervention Curriculum|Virtual patient (VP) cases and feedback available through solving VP cases and participants' self-report on the diagnosis of dizzy patients in the emergency department.
3367413|NCT04553640|Active Comparator|Group B/Control curriculum|Online articles on dizziness AND regular emergency department clinical rotations
3251948|NCT01400217||IPDS SP HFA-BDP|Patients increased inhaled corticosteroid therapy as standard particle HFA-BDP MDI at the index date
3251949|NCT01400217||IPDS EF HFA-BDP|Patients increased inhaled corticosteroid therapy as extrafine particle HFA-BDP MDI at the index date
3251950|NCT01400230||CCTA-IVUS-FFR|Patients suspected ischemic heart disease by the symptom and CCTA and undergone IVUS and FFR in the Cath Lab with CAG enrolled consecutively.
3251951|NCT01400269|Experimental|Pacific Autism Center for Education (PACE)|Behavioral: Pacific Autism Center for Education (PACE) developmentally based parent delivered intervention
3251952|NCT01400282|Other|Sequence 1|Conventional stimulation (2 weeks)- High frequeny stimulation (2 weeks)- Conventional stimulation (2 weeks)and sham stimulation (2 weeks)
3251953|NCT01400282|Other|Sequence 2|Conventional stimulation (2 weeks)- sham stimulation (2weeks) - Conventional stimulation (2 weeks) - high frequeny stimulation (2 weeks)
3251954|NCT01400295||coronary angiography|The investigators reviewed all consecutive patients who were undergoing coronary angiography
3367414|NCT04550065|Experimental|Intervention arm|Digital game
3367417|NCT04543500|Experimental|Active Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left dorsolateral prefrontal cortex. Participants in this arm will receive active feedback while attempting to modulate their neural activity during an emotional cognitive control task.
3367418|NCT04543500|Active Comparator|Sham Left Dorsolateral Prefrontal Cortex rtfMRI-nf|Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) will target left postcentral gyrus. Participants in this arm will receive sham feedback while attempting to modulate their neural activity during an emotional cognitive control task.
3367419|NCT04542057|Experimental|Arm 1|Ensifentrine Nebulized Suspension; 3 mg BID
3251955|NCT01400308|Active Comparator|Chlorhexidine + Mupirocin|"Will be treated with the protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07, as shown listed in Table 4. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)."
3251956|NCT01400308|Experimental|Prontoderm|Will be treated with the protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
3251957|NCT01400321||Distal region|Patients with loss of tooth in the premolar and molar region of the atrophied mandible
3251958|NCT01400321||aesthetic zone|Patients with loss of tooth within the aesthetic zone (canine to canine)
3251959|NCT01400334||Ischemic Cardiomyopathy|Subjects with ischemic cardiomyopathy [pre-enrollment left ventricular ejection fraction ≤0.35, with coronary artery disease documented by cardiac catheterization, a history of definite myocardial infarction, or reversible ischemia on nuclear imaging] who are considered eligible to receive an implantable cardiac defibrillator for the primary prevention of sudden cardiac death.
3251960|NCT01400360|Active Comparator|invasive|After proof of perfusion relevant CVS in interventional therapy should be performed as best possible combination from TBA and intraarterial vasodilators additional to the conventional treatment.
3251961|NCT01400360|No Intervention|conventional|After proof of perfusion relevant CVS only conventional treatment should be performed (no intraarterial therapy).
3251962|NCT01400373|No Intervention|Control|Patients in the control group standard advanced cardiac life support care. Patients that achieve return of spontaneous circulation will be treated with hypothermia according to current guidelines upon arrival at the intensive care unit.
3367420|NCT04542057|Placebo Comparator|Arm 2|Placebo Nebulized BID
3367423|NCT04533594|Experimental|NOVELA|Hospice family caregivers will work with the interventionist to use a web-enabled device (computer, smartphone or tablet) to access and view the video (3-6 mins) over the course of 4 hospice telehealth visits.
3367424|NCT04533529|Experimental|Seltorexant|Participants will receive seltorexant tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase. Eligible participants who will enter the open label (OL) treatment phase will receive seltorexant tablet daily from OL baseline until the end of phase/ early withdrawal (EW) visit (Up to 1 Year).
3367425|NCT04533529|Placebo Comparator|Placebo|Participants will receive matching placebo tablet orally once daily, from Day 1 to Day 42 in double blind (DB) treatment phase.
3367426|NCT04532749|Experimental|Seltorexant|Participants will receive Seltorexant orally once daily from Day 1 to Day 42 (until the end of Week 6).
3367427|NCT04532749|Placebo Comparator|Placebo|Participants will receive matching placebo tablets orally once daily from Day 1 to Day 42 (until the end of Week 6).
3367428|NCT04527198|Experimental|group 1|Major patients, admitted in intensive care for a SARS-CoV-2 infection and requiring mechanical ventilation and deep sedation (with or without neuromuscular blockade)
3367429|NCT04527107|Experimental|THR-149 dose level 1|
3367430|NCT04527107|Experimental|THR-149 dose level 2|
3367431|NCT04527107|Experimental|THR-149 dose level 3|
3367432|NCT04527107|Active Comparator|aflibercept|
3367433|NCT04527107|Experimental|THR-149 selected dose level|
3367434|NCT04526821|Experimental|Bovine Lactoferrin|Bovine Lactoferrin plus standard measures of personal protection.
3251963|NCT01400373|Experimental|Intervention|Intra-arrest trans-nasal cooling with RhinoChill will be initiated during advanced cardiac life support. In patients achieving return of spontaneous circulation, trans-nasal cooling will continue until systemic cooling is started at the intensive care unit.
3251964|NCT01400386|Experimental|Soluble coffee 1|
3367435|NCT04526821|Placebo Comparator|Maltodextrin|Maltodextrin plus standard measures of personal protection.
3367442|NCT04524871|Active Comparator|Stage 1: Atezolizumab + Bevacizumab|Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367443|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tiragolumab|Participants will receive atezolizumab plus bevacizumab plus tiragolumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367444|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + Tocilizumab|Participants will receive atezolizumab plus bevacizumab plus tocilizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367445|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + SAR439459|Participants will receive atezolizumab plus bevacizumab plus SAR439459 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367446|NCT04524871|Experimental|Stage 1: Atezolizumab + Bevacizumab + TPST-1120|Participants will receive atezolizumab plus bevacizumab plus TPST-1120 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367447|NCT04524871|Experimental|Stage 1: RO7247669 + Bevacizumab|Participants will receive RO7247669 plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3367448|NCT04524013||School aged children|
3367449|NCT04524013||Pregnant women|
3251965|NCT01400386|Experimental|Soluble coffee 2|
3251966|NCT01400386|Experimental|Soluble coffee 3|
3251967|NCT01400386|Experimental|Soluble coffee 4|
3251968|NCT01400438|Experimental|patients group with Herceptin|Patients beginning Herceptin in adjuvant after chemotherapy
3251969|NCT01400438|Active Comparator|Control group|patient not beginning Herceptin after chemotherapy : control group
3251970|NCT01400490|Placebo Comparator|Olive Oil 6 grams/day|
3251971|NCT01400490|Active Comparator|DHA 1800 mg/day|
3251972|NCT01400490|Active Comparator|EPA 1800 mg/day|
3251973|NCT01400490|Active Comparator|Fish Oil with EPA 1800 mg/day and DHA 1200 mg/day|
3251974|NCT01400542||OSAS +|Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
3251975|NCT01400542||OSAS -|Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
3251976|NCT01400555|Experimental|001|Cohort 1 Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
3251977|NCT01400555|Experimental|002|Cohort 2 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
3367450|NCT04516512|Experimental|Investigated arm|Participants included in the study who met inclusion criteria
3367451|NCT04516447|Experimental|Combination with carboplatin|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles (± 3 days), and (2) carboplatin 5 mg/mL*min intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle (± 3 days)
3367452|NCT04516447|Experimental|Combination with PLD|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles (± 3 days), and (2) PLD 50 mg/m^2 intravenously over 60 minutes every 4 weeks, on Day 1 of each 28-day cycle
3251978|NCT01400555|Experimental|003|Cohort 3 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
3251979|NCT01400555|Experimental|004|Cohort 4 Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
3367453|NCT04516447|Experimental|Combination with paclitaxel|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 28-day treatment cycles, and (2) paclitaxel 80 mg/m^2 administered intravenously over 60 minutes (± 10 minutes) on Days 1, 8, and 15 of each 28-day cycle
3367454|NCT04516447|Experimental|Combination with gemcitabine|Participants will take: (1) ZN-c3 orally and continuously once daily (QD) in 21-day treatment cycles, and (2) gemcitabine 1000 mg/m^2 intravenously over 15 minutes or longer every 3 weeks, on Day 1 of each 21-day cycle
3367455|NCT04514926||Healthy Controls|Participants with no history of asthma or other lung diseases.
3367456|NCT04514926||Asthmatics newly prescribed therapeutic proteins|Participants with asthma, have been newly prescribed therapeutic proteins and have yet to start on those therapeutics at the time of enrollment.
3367457|NCT04514926||Asthmatics already being treated with therapeutic proteins|Participants with asthma who have already started on therapeutic proteins.
3367460|NCT04513912|Experimental|Seltorexant|Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
3367461|NCT04513912|Active Comparator|Quetiapine Extended-Release (XR)|Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.
3251980|NCT01400568|Experimental|LPS challenge and fluticasone propionate|In case LPS induced airway inflammation is reproducible, the effect of a single high dose of inhaled fluticasone propionate will be assessed after a 4-week wash-out period.
3251981|NCT01400581|Experimental|Collaborative Care [CC] Intervention|The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
3251982|NCT01400581|No Intervention|Usual Care|Observational
3367462|NCT04508153|Other|Leva PDHS arm|"Upon randomization, subjects randomized to the leva® arm will receive the leva® PDHS, and instructions for how to download the smartphone app to facilitate use of the device. They will be instructed to use leva® based on the in-app training provided.~Within the app, subjects will be instructed to use the leva® device to perform PFMT according to the training program provided through the smartphone app associated with the device. This entails 2 ½ minute training sessions, three times daily, 7 days per week for a total of 8 weeks."
3251983|NCT01400594|Experimental|HTU-520 Patch|Subjects will receive HTU-520 patch in a 1:1 ratio for 48 weeks applied to all toenails.
3251984|NCT01400594|Placebo Comparator|Placebo Patch|Subjects will receive placebo patch in a 1:1 ratio for 48 weeks applied to all toenails.
3251985|NCT01400607|Active Comparator|Neocartilage Implant|Neocartilage Implant surgically implanted and affixed to subchondral bone using commercial fibrin during mini-open knee arthrotomy.
3251986|NCT01400607|Other|Microfracture|Standard of care cartilage repair technique.
3251987|NCT01400620|Experimental|Active oral rinse|Oral rinse containing botanical extracts
3251988|NCT01400620|Placebo Comparator|Placebo rinse|
3251989|NCT01400633||001|decitabine injection decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
3251990|NCT01400646|Experimental|Rivaroxaban + Warfarin Concomitant Therapy Phase|Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for >= 2 to <= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.
3251991|NCT01400646|Experimental|Warfarin Monotherapy Phase|Warfarin monotherapy 10 mg/day for >=2 to <=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.
3251992|NCT01400659|Active Comparator|CARB Counting|For CARB counting, insulin dose will be calculated according to the carbohydrate content of the test meal (1 carb unit = 10 g carbohydrate). The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient.
3259450|NCT01470911|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
3259451|NCT01470937|Experimental|Acarbose|acarbose 100 mg once daily
3367463|NCT04508153|Other|Kegel arm|Subjects randomized to the Kegel arm will be provided links to view instructions on how to perform PFMT (written instructions per the handout adapted from Voices for PFD, the patient advocacy arm of the American Urogynecologic Society), as well as an audio/visual didactic instructing them to perform Pelvic Floor Muscle Exercises (PFME) three times daily, seven days per week throughout the 8-week study period.
3367464|NCT04501679|Experimental|Nemolizumab|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W). Participants weighing greater than or equal to (>=) 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.
3251993|NCT01400659|Active Comparator|CFP counting|For CFP counting, insulin dose will be calculated according the carbohydrate content (1 carb unit = 10 g carbohydrate) as well as fat/protein content (1 FPU = 100 kcal from fat and protein) of the meal. The insulin-to-carbohydrate ratio will be applied according to the current individual therapy of the patient. The insulin-to-FPU ratio is the same as the insulin to carb ratio.
3251994|NCT01400672|Experimental|DIPG Patients Receiving Vaccine|Patients with diffuse intrinsic pontine glioma (DIPG) receiving radiation therapy, Tumor Lysate Vaccine (dose of 4 x 10^6 cells divided into 2 doses then every 4 weeks for up to 1 year) and Imiquimod (5% Aldara cream at a total dose of 12.5 mg) topically at each site prior to and 24 hours after vaccination.
3367465|NCT04501679|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing >= 90 kg will receive two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.
3367466|NCT04501666|Experimental|Nemolizumab 30 milligram (mg)|Participants weighing less than (<) 90 kilogram (kg) will receive two subcutaneous (SC) injections of 30 milligrams (mg) nemolizumab (60 mg loading dose) at baseline then one SC injection once for every 4 weeks (Q4W) and participants >= 90 kg will receive two SC injections of 60 mg nemolizumab at baseline (no loading dose) and two SC injections Q4W up to 24 weeks.
3251995|NCT01400711|Active Comparator|ERAS patients|Patients planned to undergoing major intrabdominal surgery, following the ERAS perioperative care.
3367467|NCT04501666|Placebo Comparator|Placebo|Participants weighing < 90 kg will receive matching placebo of two SC injections at baseline, then one SC injection Q4W and participants weighing >= 90 kg will receive matching placebo of two SC injections at baseline, then two SC injections Q4W up to 24 weeks.
3367472|NCT04492241|Experimental|Study Arm|Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
3367473|NCT04492241|Placebo Comparator|Control Arm|Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID
3367474|NCT04491877|Experimental|Cohort 1 (RSV vaccine formulation 1)|1 administration of RSV vaccine formulation 1 on Day 0
3367475|NCT04491877|Placebo Comparator|Cohort 1 (Placebo)|1 administration of placebo on Day 0
3367476|NCT04491877|Experimental|Cohort 2 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
3367477|NCT04491877|Placebo Comparator|Cohort 2 (Placebo)|2 administrations of placebo on Day 0 and Day 56
3367478|NCT04491877|Experimental|Cohort 3 (RSV vaccine formulation 2)|1 administration of RSV vaccine formulation 2 on Day 0
3367479|NCT04491877|Placebo Comparator|Cohort 3 (Placebo)|1 administration of placebo on Day 0
3367480|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 1)|2 administrations of RSV vaccine formulation 1 on Day 0 and Day 56
3367481|NCT04491877|Experimental|Cohort 4 (RSV vaccine formulation 2)|2 administrations of RSV vaccine formulation 2 on Day 0 and Day 56
3367482|NCT04491877|Placebo Comparator|Cohort 4 (Placebo)|2 administrations of placebo on Day 0 and Day 56
3367483|NCT04478084|Experimental|Group 1: pediatric participants; VRVg-2|VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
3367484|NCT04478084|Active Comparator|Group 2: pediatric participants; Verorab|Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28
3367485|NCT04478084|Experimental|Group 3: adult participants; VRVG-2 + ERIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
3367486|NCT04478084|Active Comparator|Group 4: adult participants; Verorab + ERIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3 and 2 at Day 7~+ ERIG at D0"
3251996|NCT01400711|Active Comparator|Control patients|Patients planned to undergo major intrabdominal surgery, following the conventional perioperative care.
3251997|NCT01400724|Experimental|Inofolic NRT|
3251998|NCT01400737|Experimental|ibuprofen|The patients in the control group were given 3 doses of an orange starch suspension as placebo that looked like ibuprofen.
3251999|NCT01400750|Active Comparator|Ciproxin-inhaled Colistin|oral ciprofloxacin (30mg/kg/day) plus inhaled colistimethate sodium (Colistineb® 2x2 mill U daily) for 3 months
3252000|NCT01400750|Active Comparator|Tobramycine for inhalation (TIS)|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
3252001|NCT01400776|Experimental|Vaginal Gel Three Times Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 3X/week for 10 weeks
3252002|NCT01400776|Placebo Comparator|Vehicle Twice Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 2X/week for 10 weeks
3252003|NCT01400776|Experimental|Vaginal Gel Twice Weekly|Estradiol gel applied vaginally daily for 2 weeks, followed by dosing 2X/week for 10 weeks
3252004|NCT01400776|Placebo Comparator|Vehicle Three Times Weekly|Vehicle Vaginal Gel applied daily for 2 weeks, followed by dosing 3X/week for 10 weeks
3252005|NCT01400789|Experimental|ListroMix 50/50®|Insulin Lispro/ insulin Lispro protamine ( ListroMix 50/50®; 100 U/mL), DispoPen 3.0 mL.
3252006|NCT01400789|Active Comparator|Humalog Mix50/50®|Insulin Lispro/ insulin Lispro protamine (Humalog Mix50/50® ; 100 U/mL), Humalog Mix 50/50® Kwik PenTM 3.0 mL.
3252007|NCT01400802|Experimental|Listro Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Listro Mix75/25®; 100 U/mL), DispoPen 3.0 mL.
3367487|NCT04478084|Experimental|Group 5: adult participants; VRVG-2 + HRIG|"VRVg-2 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
3367488|NCT04478084|Active Comparator|Group 6: adult participants; Verorab + HRIG|"Verorab 8 injections: 2 at Day 0, 2 at Day 3, 2 at Day 7, and 2 at Day 28~+ HRIG at D0"
3367489|NCT04476446|Experimental|Intranasal Esketamine|Induction Phase: Participants will self-administer esketamine intranasally 56 milligram (mg) on Day 1 followed by 56 mg or 84 mg (as a flexible dose regimen) twice per week for 4 weeks. Participants greater than or equal to (>=) 65 years old will start at a dose of 28 mg on Day 1. Maintenance Phase: Participants will self-administer esketamine 56 mg or 84 mg intranasally once per week from Week 5 to Week 9. Subsequently from Week 9, based on the investigator's clinical judgment, participants will self-administer esketamine 56 mg or 84 mg intranasally once or twice a week.
3367490|NCT04471428|Experimental|Atezolizumab + Cabozantinib|Participants will receive atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on days 1-21 of each cycle.
3367491|NCT04471428|Active Comparator|Docetaxel|Participants will receive docetaxel on Day 1 of each 21-day cycle.
3367492|NCT04466293|No Intervention|Standard of care study arm|"Providers will receive training on benefits, indications, and contra-indications for TPT. Providers will use the standard approach of the default being to not prescribe. Only if providers specifically write for TPT will it be dispensed by a pharmacy or the provider."
3367493|NCT04466293|Experimental|Choice Architecture study arm|"Clinic staff will be responsible for strategy delivery for all patient interactions. Research staff will provide training and guidance for the choice architecture arm. Research staff will also work with the clinics to develop appropriate clinical stationary, ink stamps, stickers, or EMR modifications for prescribing, and reminder systems (e.g. written by pharmacy in clinic file, post-it on clinic file, post-it on lab results). The goal of this approach is for TPT prescribing to occur routinely and as part of ART prescribing. This is in contrast to considering prescribing only at the end of a long algorithm that includes TB and other assessments. With this approach, a patient will automatically be prescribed TPT unless the clinician specifically decides patients are not candidates due to active TB treatment or other clinical reasons."
3367494|NCT04463108||Participants with MDD and Active Suicidal Ideation with Intent|Participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent as defined/confirmed by Investigator will be enrolled and treated in accordance with routine clinical practice. The primary data source for this study will be the medical records of each participant.
3252008|NCT01400802|Active Comparator|Humalog Mix75/25®|Insulin Lispro/ insulin Lispro protamine (Humalog® Mix75/25TM; 100 U/mL), Humalog Mix 75/25® Kwik PenTM 3.0 mL.
3367495|NCT04458051|Experimental|SAR442168|Dose 1 of oral SAR442168 daily
3367496|NCT04458051|Placebo Comparator|Placebo|Placebo to match the SAR442168 daily
3367497|NCT04451187|Experimental|Treatment Sequence CADB|Participants will receive placebo once daily (OD) at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment C) in Period 1 followed by Dose 1 of seltorexant tablets and placebo OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment A) in Period 2 followed by Dose 2 of seltorexant tablets OD at bedtime for 8 consecutive days from Day 1 to Day 8 (Treatment D) in Period 3 followed by zopiclone on Day 1 and Day 8 and placebo from Day 2 to Day 7 OD at bedtime (Treatment B) in Period 4. There will be a washout period of 5 to 21 days between each period.
3367498|NCT04451187|Experimental|Treatment Sequence ABCD|Participants will receive Treatment A in Period 1 followed by Treatment B in Period 2 followed by Treatment C in Period 3 followed by Treatment D in Period 4. There will be a washout period of 5 to 21 days between each period.
3367499|NCT04451187|Experimental|Treatment Sequence BDAC|Participants will receive Treatment B in Period 1 followed by Treatment D in Period 2 followed by Treatment A in Period 3 followed by Treatment C in Period 4. There will be a washout period of 5 to 21 days between each period.
3367500|NCT04451187|Experimental|Treatment Sequence DCBA|Participants will receive Treatment D in Period 1 followed by Treatment C in Period 2 followed by Treatment B in Period 3 followed by Treatment A in Period 4. There will be a washout period of 5 to 21 days between each period.
3367501|NCT04445389|Experimental|GX-19: Dose A|Dose A of GX-19 will be intramusculary administered via EP on day 1 and day 29.
3367502|NCT04445389|Experimental|GX-19: Dose B|Dose B of GX-19 will be intramusculary administered via EP on day 1 and day 29.
3367503|NCT04445389|Placebo Comparator|GX-19: Dose C|Dose C of GX-19 will be intramusculary administered via PharmaJet® Needle Free Delivery on day 1 and day 29.
3367504|NCT04445389|Placebo Comparator|Placebo: Dose A, B, or C|Placebo will be intramusculary administered on day 1 and day 29 via EP or PharmaJet® Needle Free Delivery
3252009|NCT01400828|Experimental|Bilastine|Intervention: Drug: Bilastine
3252010|NCT01400828|Active Comparator|Desloratadine|Intervention: Drug: Desloratadine
3252011|NCT01400828|Placebo Comparator|Placebo|Intervention: Drug: Placebo
3252012|NCT01400854||Effentora®|Single group prospective treatment cohort
3252013|NCT01400867|Experimental|Ceftaroline fosamil|
3252014|NCT01400867|Active Comparator|Comparators|Vancomycin +/- Aztreonam Cefazolin +/- Aztreonam
3252015|NCT01400945|Experimental|S-Pantoprazole|Experimental drug: AGSPT201 Tab. (contain S-Patoprazole) Active comparator: Pantoloc Tab. (contain pantoprazole)
3367507|NCT04435626|Experimental|Arm 1_BAY94-8862|Adult patients receive BAY94-8862
3367508|NCT04435626|Placebo Comparator|Arm 2_Placebo|Adult patients receive placebo
3252016|NCT01401036|Active Comparator|Nobori|subjects receiving Biolimus A9 eluting stent implantation
3252017|NCT01401036|Sham Comparator|Uncoated stents|subjects receiving uncoated stent implantation
3252018|NCT01401075|Active Comparator|doxifluridine|oral chemotherapy with the 5-FU prodrug doxifluridine
3252019|NCT01401075|Experimental|doxifluridine + mistletoe extract|oral chemotherapy with the 5-FU prodrug doxifluridine + mistletoe extract as subcutaneous injection
3252020|NCT01401088|Experimental|Artificial drainage implant|Aurolab Artificial Drainage Implant (AADI) on intraocular pressure reduction will be implanted in patients with refractory glaucoma.
3252021|NCT01401114||Group 1|Drug (incl. Placebo)
3252022|NCT01401127||Type 1 Diabetes|Participants with type 1 Diabetes running their insulin pump at 70% of usual basal rate
3367514|NCT04434092|Experimental|Arm A (Crovalimab)|Adult Participants will receive an initial intravenous (IV) loading dose on Week 1 Day 1, followed by 4 weekly crovalimab subcutaneous (SC) doses on Week 1 Day 2, then on Weeks 2, 3 and 4. Maintenance dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter, for a total of at least 24 weeks of study treatment.
3367515|NCT04434092|Active Comparator|Arm B (Eculizumab)|Adult Participants will receive initial IV weekly doses for 4 weeks which will be followed by Q2W (every 2 weeks) IV administrations starting on Week 5.
3367516|NCT04434092|Experimental|Arm C (Crovalimab) (Exploratory)|Paediatric participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
3252023|NCT01401127||Participants without diabetes|Participants without diabetes or evidence of impaired glucose regulation
3252024|NCT01401140|Active Comparator|St Thomas|
3252025|NCT01401140|Experimental|Custodiol|
3367521|NCT04432584|Experimental|Arm A (Crovalimab)|Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
3367522|NCT04432584|Active Comparator|Arm B (Eculizumab)|Participants will receive an approved maintenance dose of eculizumab starting on Day 1 and Q2W (every 2 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of study eculizumab treatment, participants will have the option to switch to crovalimab or to discontinue from the study after completion of 10 weeks of safety follow-up.
3367523|NCT04432584|Experimental|Arm C (Crovalimab) (Exploratory)|Participants will receive a loading series of Crovalimab comprised of an IV dose on Week 1 Day 1, followed by weekly crovalimab SC doses for 4 weeks on Week 1 (Day 2) then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will be administered Q4W thereafter. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.
3252026|NCT01401179|Active Comparator|cefazolin|
3367524|NCT04431414||Group 1|Persons that are positive for SARS-CoV-2 and are asymptomatic
3252027|NCT01401179|Active Comparator|cefazolin plus erythromycin|cefazolin, erythromycin
3252028|NCT01401179|Active Comparator|cefazolin plus clarithromycin|
3252029|NCT01401192|Experimental|TS positive cohort & Gem/Cis Tx arm|Among TS expression positive patients, some will be randomized to Gem/cis therapy
3252030|NCT01401192|Active Comparator|TS+ cohort & Pem/Cis arm|Among patients with TS+, randomised to Pem/cis chemotherapy
3367525|NCT04431414||Group 2|Persons that are positive for SARS-CoV-2 with recent onset of mild symptoms (not hospitalized)
3367526|NCT04431414||Group 3|Persons that are positive for SARS-CoV-2 and are symptomatic hospitalized patients
3252031|NCT01401192|Active Comparator|TS negative cohort & Pem/Cis Tx arm|Among patients with TS-, some will be randomised to Pem/cis Tx arm
3252032|NCT01401192|Experimental|TS negative cohort & Gem/Cis Tx arm|Among patients with TS-, some will be randomised to Gem/Cis Tx arm
3252033|NCT01401205||shoulder arthroscopic surgery group|the patients who undergo the elective shoulder arthroscopic surgery of rotator cuff repair
3252034|NCT01401218||thoracic aortic surgery group|patients who underwent thoracic aortic surgery
3252035|NCT01401231|Experimental|Behavioral Activation|Behavioral activation psychotherapy
3252036|NCT01401231|Placebo Comparator|Usual Care|Continued care as usual
3252037|NCT01401244|Experimental|Norditropin®|
3252038|NCT01401244|Active Comparator|Genotropin®|
3252039|NCT01401270|No Intervention|Treatment Group A|Standard Care
3252040|NCT01401270|Experimental|Treatment Group B|100% probability of winning a prize with each draw and has 3 prize categories
3252041|NCT01401270|Experimental|Treatment Group C|31% probability of winning and has 3 prize categories
3252042|NCT01401270|Experimental|Treatment Group D|100% probability of winning and has 7 prize categories
3252043|NCT01401270|Experimental|Treatment Group E|31% probability of winning and has 7 prize categories
3367529|NCT04410523|Experimental|CSJ117 0.5 mg|0.5 mg
3367530|NCT04410523|Experimental|CSJ117 1 mg|1 mg
3367531|NCT04410523|Experimental|CSJ117 2 mg|2 mg
3367532|NCT04410523|Experimental|CSJ117 4 mg|4 mg
3367533|NCT04410523|Experimental|CSJ117 8 mg|8 mg
3367534|NCT04410523|Placebo Comparator|Placebo|0 mg
3252044|NCT01401270|Experimental|Treatment Group F|usual prize contingency management with a 50% probability of winning from 3 prize categories
3252045|NCT01401296|Active Comparator|Wait-list group|Subjects receive access to deprexis after eight weeks
3252046|NCT01401296|Experimental|Deprexis|Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.
3367543|NCT04401020|Experimental|Dose escalation|SAR442257 will be given intravenously with lead-in doses (LID) in the first-week, followed by twice weekly until week 4 (Cycle 1) and twice weekly for each subsequent cycle(s).
3252047|NCT01401335|Other|Trauma counseling|
3252048|NCT01401374||Vitiligo Patients|patients with vitiligo vulgaris
3252049|NCT01401374||Controls|Individuals without vitiligo vulgaris
3367552|NCT04394624|Experimental|Ramucirumab + SAR408701|Ramucirumab will be administered intravenously prior to intravenously adminstration of SAR408701 every two 2 weeks.
3367558|NCT04382820||Families of rare chronically ill children|Clinical study participants for the diagnostic study are patients who have sought treatment at the University Medical Center Hamburg-Eppendorf due to a rare pediatric surgical disease. Every family receives a comprehensive psychosocial diagnostic in the form of standardized instruments.
3367559|NCT04382820||Families in the comparative control group|Participants in the healthy control sample are matched to the clinical sample in terms of age and gender. Included are families of children aged 0-21 years, who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints; such as hernia surgery or testicular relocation.
3252050|NCT01401387|Active Comparator|Standard treatment|Treatment with pancreatic enzymes after clinical sings and symptoms of steatorrhea and 10% decrease of weight at time of randomisation.
3252051|NCT01401387|Active Comparator|Preventive treatment|Patients will be prescribed with pancreatic enzymes immediately after diagnosis with pancreatic cancer, regardless of the presence of steatorrhea
3367563|NCT04374253|Experimental|Group 1|Participants, who completed the double-blind part and did not enter the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the Week 104 visit of Study WN29922 or WN39658. This will be considered the OLE baseline visit (OLE Day 1).
3367564|NCT04374253|Experimental|Group 2|Participants, who completed the double-blind part and the OLE part of Study WN29922 or WN39658, will be enrolled and receive open-label gantenerumab approximately 2 weeks after the OLE Week 34 visit or the final dose visit in the Study WN29922 or WN39658 OLE.
3252052|NCT01401400||(Peg) interferon|Patients who are treated for at least 12 weeks with (peg-)interferon for chronic hepatitis B
3252053|NCT01401413|Placebo Comparator|1|placebo control nightly
3367569|NCT04367480|Experimental|Group I (TENS)|Patients wear an active wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
3367570|NCT04367480|Placebo Comparator|Group II (placebo TENS)|Patients wear a placebo wireless TENS device 5 hours daily for up to 6 weeks in the absence of unacceptable toxicity.
3252054|NCT01401413|Active Comparator|2|8 mg ramelteon nightly
3252055|NCT01401426|Active Comparator|Single incision laparoscopic vertical sleeve gastrectomy|Active Comparator Patients in this group will undergo laparoscopic vertical sleeve gastrectomy through a single periumbilical incision.
3367571|NCT04365257|Experimental|Prazosin|"Prazosin 1mg given to observe if medication is tolerated or if signs or symptoms of hypotension develop (e.g. dizziness, lightheadedness).~If the patient remains asymptomatic and BP >110/60 mmHg, prazosin is continued at 1mg every 8 hours (q8h).~Day 3: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 2mg q8h.~Day 6: If the patient remains asymptomatic and BP >110/60 mmHg, increase dose to 5mg q8h.~If the BP is <100/60 mmHg at any time, the next dose should be held, and patient continues with the highest previously tolerated dose 8 hours later.~If the patient did not tolerate dose escalation to 5mg q8h, one attempt is made to increase dose to 3mg q8h. If this is not tolerated, the patient continues with the highest previously tolerated dose 8 hours later.~If BP monitoring is not available, repeated occurrences of postural dizziness should trigger drug dose reduction or BP monitoring."
3252056|NCT01401426|Active Comparator|Five port laparoscopic vertical sleeve gastrectomy|Patients in this group will undergo conventional laparoscopic vertical sleeve gastrectomy using 5 small incisions.
3252057|NCT01401491|Active Comparator|clozapine + fluvoxamine|
3252058|NCT01401491|Placebo Comparator|clozapine + placebo|
3252059|NCT01401504|Experimental|ASP3026|
3367572|NCT04365257|Active Comparator|Standard of care|Subjects randomized to this arm will receive standard of care.
3367573|NCT04365088|Experimental|Deflazacort|Deflazacort is a glucocorticoid used as an anti-inflammatory drug. We used deflazacort 30 mg tablet. Patient took a pill once preoperatively (1 hour ago) in third molar surgery.
3367574|NCT04365088|Placebo Comparator|Sugar pill|Placebo is an inert substance or treatment which is designed to have no therapeutic value. Patients took sugar pill for plasebo once one hour before operation.
3252060|NCT01401556|Experimental|Case Manager Intervention|Osteoporosis case-managers will identify older fracture patients in Emergency Departments and Fracture Clinics; arrange bone mineral density (BMD) tests; meet with patients to counsel them and go over their results; and then offer and prescribe bisphosphonate treatment to those with low BMD.
3367575|NCT04356794|Experimental|Medical electroacupuncture(EA)|EA were treated for 4 weeks, 3 times per week.
3252061|NCT01401556|Active Comparator|Multifaceted quality improvement intervention|Active-comparator control consisting of telephone-based education for patients and treatment guidelines with reminders for family physicians
3252062|NCT01401569|Active Comparator|Control|All subjects (intervention and control groups) participate in a smoking cessation program composed of a pharmacological treatment (including nicotine replacement therapy or varenicline) and counseling.
3252063|NCT01401569|Experimental|physical activity program|Experimental group subjects were required to attend 2 supervised exercise sessions and 2 counseling sessions during Week 1 and Week 2. Supervised exercise and counseling sessions are realized successively. For Week 3 to 8, participants were required to attend 1 supervised exercise session and 1 counseling session plus 1 home exercise session.
3252064|NCT01401608||Treatment|Ablation of VT/PVCs using a magnetic RF ablation catheter
3252065|NCT01401621|Experimental|Scratch-Off Test Name Condition|The name of the test the recipient needs is hidden behind a scratchoff on the reminder
3259452|NCT01470937|Placebo Comparator|Placebo|Matched placebo was administered for acarbose 100 mg once daily
3367576|NCT04356794|Sham Comparator|Sham electroacupuncture|"Sham acupuncture was performed without stimulation and manipulation to avoid eliciting De Qi sensations.It were treated for 4 weeks, 3 times per week."
3252066|NCT01401621|Experimental|Scratch-Off Call to Action Condition|The recipient will be prompted to scratch-off the paper in order to find out how to follow the recommendation that the test be received.
3252067|NCT01401621|Experimental|Control Condition|A control condition with no scratch-off element.
3367577|NCT04349579|Experimental|Rifamycine|Rifamycine is a broad spectrum semi-synthetic antibiotic that acts on gram-positive and gram-negative microorganisms. As a local application, it has areas of use in dentistry such as washing fistula mouths, maxillary sinus and abscess wounds and treating osteomyelitis.
3367578|NCT04349579|Active Comparator|Saline|Saline, also known as saline solution, is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds. It is also used to dilute other drugs to be injected and to wash the operation site in dental surgery operations. It is most commonly used as a sterile 9 g of salt per litre (0.9%) solution, known as normal saline.
3252068|NCT01401634|Other|Intravenous Fluids|Intravenous fluids for patients with hyperglycemia is part of the standard protocol in our department
3252069|NCT01401634|Experimental|Oral Fluids|
3252070|NCT01401660||Group A|Subjects who do not currently have low back pain.
3367583|NCT04338321|Experimental|Esketamine Arm|Participants will receive treatment with esketamine nasal spray (28 milligram [mg] [initial dose for elderly participants 65 to 74 years of age and adults of Japanese ancestry; may be used throughout the study in these populations; may be uptitrated in 28 mg increments], 56 mg [initial dose for adult participants aged 18 to 64 years and may be used for all age groups throughout the study], or 84 mg [maximum dose esketamine nasal spray may be uptitrated to]) twice-weekly with a flexible dose regimen from Day 1 until Week 4, once weekly from Week 5 to Week 8 and once-weekly or once every 2 weeks from Week 9 to Week 32 in combination with continuing serotonin-norepinephrine reuptake inhibitor/selective serotonin reuptake inhibitor (SSRI/SNRI).
3367584|NCT04338321|Active Comparator|Comparator Arm|Participants will continue to take their current SSRI/SNRI augmented with quetiapine extended release (XR) as per the Summary of Product Characteristics (SmPC) (or local equivalent, if applicable). In adult participants aged 18 to 64 years, the initial dose is 50 mg/day on Days 1-2, 150 mg/day on Days 3-4 [lowest effective dose]; a further dose increase to 300 mg/day on Day 5 and onward will be based on individual participant evaluation. In elderly participants aged 65 to 74 years, the initial dose is 50 mg/day on Days 1-3, 100 mg/day on Days 4-7, and 150 mg/day on Day 8; a further dose increase to 300 mg/day will be based on individual participant evaluation no earlier than Day 22.
3252071|NCT01401660||Group B|Subjects who have low back pain at the time of the study, and who are currently being treated or have been previously treated for their low back pain and do not wish to receive further treatment for their pain.
3252072|NCT01401660||Group C|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
3252073|NCT01401712|Experimental|Paravertebral catheter (ON-Q® Pain Relief System)|
3252074|NCT01401712|Active Comparator|Thoracic epidural catheter|
3367590|NCT04313361||Smokers or Recent Smoking Quitters who Have lung Surgery|The enrolled eligible participants, that is smokers or recent smoking quitters, will be assessed for the current smoking status and smoking cessation attempts during the perioperative period, to describe postoperative complications (PCs) including postoperative pulmonary complications (PPCs) following a lung surgery, and to describe the smoking cessation methods and services participants received from their health care professionals (HCPs) and participant's satisfaction among participants with lung cancer, chronic obstructive pulmonary disorder (COPD), a pulmonary lesion (example nodule, ground glass opacity) or other pulmonary conditions who are admitted to the thoracic surgical unit of the participating hospitals in China.
3252075|NCT01401725|Experimental|Hamilton General Hospital|
3252076|NCT01401725|Active Comparator|Juravinski Hospital|
3252077|NCT01401725|Other|St. Joseph's Hospital|
3252078|NCT01401751|Other|Single Arm|non-randomized, uncontrolled, feasibility study
3252079|NCT01401764|Other|Platform II, PASS, ARG 100|
3252080|NCT01401777||Control, No PercuNav|Patient having procedure without PercuNav Guidance information
3252081|NCT01401777||PercuNav aided procedure|Biopsy procedure aided with use of PercuNav
3252082|NCT01401790|Experimental|Telehomecare|3 month use of a new telehomecare program
3252083|NCT01401790|Active Comparator|Control|3 month regular education program and follow up at the Diabetes Clinic
3252084|NCT01401803|Other|Dysport|Dysport injections into the glabella and orbicularis oculi muscles with dose based on muscle mass.
3252085|NCT01401816|Experimental|Intervention Group|Subjects in this group will receive a prescription for emergency contraception and then text-messages (on Day 1, 3 and 5 after enrollment) to their personal cell phone with a reminder to fill their prescription.
3367591|NCT04312789|Experimental|Treatment (avatrombopag)|Patients receive avatrombopag PO QD for up to 1 year in the absence of disease progression or unacceptable toxicity. Avatrombopag will be titrated weekly until platelet count of greater than or equal to 60,000/uL is achieved and persists for 7 consecutive days, and the patient remains free from platelet transfusion.
3367595|NCT04304599|Experimental|LoFric Elle|New hydrophilic female urinary catheter for single use. Ready-to-Use.
3252086|NCT01401816|No Intervention|Control Group|Subjects in this group will receive a only a prescription for emergency contraception and no reminder text messages.
3252087|NCT01401829|Experimental|75 weekly minutes walking|12-week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week
3252088|NCT01401829|Experimental|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week
3252089|NCT01401829|Active Comparator|Stretching and Flexibility exercise|Stretching/Flexibility exercise
3252090|NCT01401855||In Vivo Probe Prediction|
3252091|NCT01401855||Cytology Results|
3252092|NCT01401868|Experimental|single arm|dose escalation
3252093|NCT01401881||Post STEMI|The study population will consist of adult patients with acute STEMI and primary PCI with clear identification of symptoms onset, willing to participate in the research protocol and not having any of the exclusion criteria. Patient screening will take place after the primary PCI in the cardiac catheterization laboratory or in the coronary care unit. Participation will be offered to all those who meet eligibility criteria.
3252094|NCT01401920||patients undergoing open heart surgery|small infant or children patients undergoing open heart surgery
3252095|NCT01401933|Experimental|Linifanib|
3367602|NCT04288154|Experimental|EMS Group - Experimental|EMS device will be turned on during exercise for this group.
3367603|NCT04288154|Placebo Comparator|EMS Group - Control|EMS device will be turned off during exercise for this group.
3252096|NCT01401946|Active Comparator|soy isoflavones|
3252097|NCT01401946|Placebo Comparator|Placebo|
3252098|NCT01401985|Experimental|Cohort 1|5 mg TD-1211 once daily for 4 days followed by 10 mg for 14 days
3252099|NCT01401985|Experimental|Cohort 2|5 mg TD-1211 once daily for 4 days followed by 15 mg for 14 days
3367613|NCT04247282|Experimental|A/arm A|M7824 (Days 1, 15)
3367614|NCT04247282|Experimental|B/arm B|M7824 + TriAd vaccine (ETBX-011, ETBX-051 and ETBX-061) (DayS 1)
3367615|NCT04247282|Experimental|C/arm C|M7824 + TriAd vaccine (Day 1) + N-803 (Day 1)
3367616|NCT04240314|Experimental|Cohort 1 (Minimal Efficacious Dose)|The Minimal Effective Dose (MED) will be delivered.
3367617|NCT04234529|Active Comparator|AMATEA|3x 450mg capsules of AMATEA which contains 270mg of caffeine total
3252100|NCT01401985|Experimental|Cohort 3|5 mg TD-1211 once daily for 2 days followed by 10 mg for 14 days
3252101|NCT01401985|Experimental|Cohort 4|5 mg TD-1211 once daily for 2 days followed by 15 mg for 14 days
3367618|NCT04234529|Active Comparator|Caffeine|3x 450mg capsules each containing 360mg of microcellulose and 90mg of caffeine (270mg caffeine total)
3252102|NCT01401985|Experimental|Cohort 5|2 mg TD-1211 once daily for 14 days
3252103|NCT01401985|Experimental|Cohort 6|2.5 mg TD-1211 every 6 hours for 14 days
3367619|NCT04234529|Placebo Comparator|Placebo|3x 450mg capsules of microcellulose
3367620|NCT04233879|Experimental|Group 1: DOR/ISL|Treatment-naïve participants with HIV-1 receive DOR/ISL and placebo to BIC/FTC/TAF once daily (QD) for 96 weeks.
3367621|NCT04233879|Active Comparator|Group 2: BIC/FTC/TAF|Treatment-naïve participants with HIV-1 receive BIC/FTC/TAF and placebo to DOR/ISL QD for 96 weeks.
3367622|NCT04233554|Experimental|Intervention Arm - Implementing Patient Priorities Care|Practice staff and providers will be trained on how to identify patient health priorities. Staff and clinicians will implement Patient Priorities Care, document priorities in EHRs, and align patient priorities with health care decisions.
3367623|NCT04233554|No Intervention|Control Arm|Control arm practices will receive no intervention and patients will receive usual care.
3252104|NCT01402024|Experimental|Aprepitant|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on aprepitant arm will receive the study drug (aprepitant)along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
3252105|NCT01402024|Placebo Comparator|Control|It is an double blind randomized placebo controlled trial with age group of 5-18 years and weight between 15-65 kg, who will receive highly emetogenic chemotherapy. Patient who will meet the inclusion criteria will be randomly enrolled in either of the two arm-aprepitant arm and control arm. The patient on the control arm will receive the placebo along with standard anti-emetic therapy (as per the dosages mentioned in the protocol).
3367631|NCT04232228||Participants with Crohn's Disease (CD)|Adult participants with moderate to severe CD who agree to be part of the study and who fit the inclusion/exclusion criteria and use Care4Today inflammatory bowel disease (C4T IBD) alongside standard of care (SOC) at participating centers will be observed. Data available per clinical practice and via the C4T IBD application will be collected within this study. Participants will also be asked to complete questionnaires that are sent directly to the patients, which are not completed as part of clinical practice or via the application. Relevant data will be collected by prospectively following participants from the index date for 12 months, and also by retrospectively collecting data for the 6-month period prior to the index date from participant's medical records. Index is the activation date of C4T IBD application in participant's smartphone.
3367632|NCT04224740|Experimental|Pembrolizumab plus standard of care chemotherapy|"-Pembrolizumab combined with standard of care therapy~Standard of care therapy: ciplastin 70mg/m² IV D1(or carboplatin AUC 5) plus 5-Fluouracil 1000mg/m²/day IV( continuous infusion on Days 1-4) Q3W for 6 cycles"
3367633|NCT04217954|Experimental|OXA, 5-FU and Bev plus Toripalimab|the patients enrolled in this arm would receive hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil and bevacizumab plus intravenous Toripalimab
3367634|NCT04211337|Experimental|Selpercatinib|Selpercatinib given orally.
3367635|NCT04211337|Active Comparator|Cabozantinib or Vandetanib|Cabozantinib or vandetanib given orally.
3367636|NCT04204616|Experimental|Nemolizumab|Participants weighing less than (<) 90kilogram (kg) will receive 30 milligram (mg) nemolizumab every 4 weeks (Q4W) and participants weighing greater than or equal to (>=) 90 kg will receive 60 mg nemolizumab (two 30-mg injections) Q4W.
3367637|NCT04197713|Experimental|Treatment (olaparib, adavosertib)|Patients receive olaparib PO BID on days 1-5 and 15-19 of each cycle and adavosertib PO QD on days 8-12 and 22-26 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3367638|NCT04196959|Experimental|Single Arm|All patients will receive TYR sphere, a Food for Special Medical Purposes, as part of thier restricted diet for 28 consecutive days.
3367639|NCT04195776|Experimental|Three TFV Medicated Douche Sequences|Once enrolled, participants will complete a baseline sampling session and then three sequences of study product administration, along with sRAI and administration of autologous seminal fluid. Sequence A will be 1 TFV douche followed by sRAI; Sequence B will be one dose of TFV douche followed sRAI then a tap water douche; Sequence C will be 1 tap water douche followed sRAI then by a single dose of TFV douche. There will be a washout period of at least 14 days between sequences. Participants will have sequences administered in clinic or a research unit, followed by imaging and various specimen collections over 8 hours.
3367646|NCT04192110|Experimental|Diuretic initiation or augmentation|Participants will either initiate or increase the dose of a loop or thiazide-type diuretic
3367647|NCT04182100|Experimental|P1101|Conventional treatment based on phlebotomies, low-dose aspirin (acetylsalicylic acid, 75-150 mg/day) plus the subcutaneous administration of pegylated proline-interferon alpha-2b (P1101, ropeginterferon alfa-2b) once every 2 weeks.
3367648|NCT04179019|Experimental|Amlodipine|Amlodipine (dose 10 mg, once daily)
3367650|NCT04174222|Active Comparator|Moderate block|5-10mg rocuronium is administered to maintain train-of-four count 1-2. At the end of surgery, sugammadex 2mg/kg is administered IV for reversal of neuromuscular block.
3367651|NCT04174222|Experimental|Deep block|5-10mg rocuronium is administered to maintain train-of-four count 0, and post tetanic count 1-2 (deep block). At the end of surgery, sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
3252106|NCT01402037|Other|NDP 12-39 y|In newly diagnosed patients a hyperglycemic clamp tests will be performed within 4 weeks after diagnosis and 6, 12, 18 and 24 months later in 40 patients. The clamp will not be carried out in participants who became Cpeptide negative (defined as AUC C-peptide ≤ 0.03 nmol/L x min.) at a previous visit. HbA1c will be determined at the day of the clamp and glycemic variability during 5 days starting immediately after the clamp procedure. Insulin requirements and severe hypoglycemia (defined as an episode in which a patient required the assistance of another person and which was associated with a blood level of < 50 mg/dL or prompt recovery following intravenous glucose, glucagon or oral carbohydrate) will be recorded
3367658|NCT04166097|Experimental|Heart Smart Interventional Program|"Subjects participate in this 6-week intervention which include a weekly didactic session, with each week devoted to a different theme (food, exercise, etc). The intervention will follow the program outlined in the book Heart Smart for Women: Six S. T. E. P. S. in Six Weeks to Heart-Healthy Living."
3367659|NCT04164641|Experimental|Noraxon myoRESEARCH™ Software|All participants will be assigned to this group to receive study intervention.
3367660|NCT04163328|Experimental|HydroEye®|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
3367661|NCT04163328|Placebo Comparator|Placebo|Subjects will take a total of four capsules daily, with meals (two capsules taken orally, twice a day).
3367662|NCT04159519|Experimental|Treatment reduction arm|All participants will receive Fasenra® 30 mg Q8W + SMART or Symbicort® reliever only (starting with medium-dose Symbicort® 200/6 μg ×2 inhalations BID maintenance + Symbicort® 200/6 μg reliever PRN; tapering to Symbicort® 200/6 μg reliever only, as per tapering scheme and depending on degree of asthma control). The reduction period in this arm will last 32 weeks.
3367663|NCT04159519|Experimental|Reference arm|All participants will receive Fasenra® 30 mg Q8W + high-dose Symbicort® maintenance ×2 inhalations BID + Ventolin® (salbutamol 100 μg) reliever PRN therapy. Eligible participants randomised to the reference arm will continue on high-dose Symbicort® maintenance treatment and Ventolin® reliever treatment for 32 weeks.
3367664|NCT04157361||Asthma|Children/adults with moderate or IgE mediated asthma with inhaled and/or food allergies before and during inhaled corticosteroid, leukotriene modifiers or long-acting beta agonists treatment.
3367665|NCT04157361||Cystic fibrosis|Children/adults with cystic fibrosis before and after antibiotics treatment and during clinical deterioration.
3367666|NCT04157361||Healthy control|Healthy control children/adults without chronic or autoimmune disease
3367667|NCT04157101|Experimental|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
3367668|NCT04157101|Placebo Comparator|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
3367669|NCT04145427|Experimental|Low Carbohydrate Diet|This arm will be randomized to low carbohydrate diet
3367670|NCT04145427|Active Comparator|Standard Dietary Advice Control Group|This arm will be randomized to control diet
3367673|NCT04141592||Healthy Control|non-obese individuals without fatty liver disease
3367674|NCT04141592||Non-alcoholic fatty liver disease without NASH|
3367675|NCT04141592||Non-alcoholic steatohepatitis|
3252107|NCT01402037|Other|NDP 5-12 y|Ten childhood-onset patients (under age 12) will be tested for 5 days with CGM (without clamp) and their glycemic variability compared with that of 10 patients aged 12-17 years at diagnosis.
3367676|NCT04141592||Obese without non-alcoholic fatty liver disease|
3367677|NCT04137510|Experimental|Orsiro|
3367678|NCT04137510|Active Comparator|Resolute Onyx|
3367679|NCT04135417|Experimental|HAV|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. HAV for this study will be manufactured using the commercial manufacturing system.It will be implanted in the forearm or upper arm using standard vascular surgical techniques. All subjects will be required to start taking daily aspirin (75 or 325 mg) on Day 1 after surgical implantation of HAV unless they are already taking another antiplatelet agent. If low molecular weight heparin (LMWH) is administered post-operatively, aspirin or other antiplatelet agents should be initiated after stopping LMWH. Subjects who are known to be aspirin-sensitive should take another antiplatelet agent at the discretion of the Principal Investigator.
3367680|NCT04129619|Experimental|ORP-101 50 mg|ORP-101 (50 mg) once daily
3367681|NCT04129619|Experimental|ORP-101 100 mg|ORP-101 (100 mg), once daily
3367682|NCT04129619|Placebo Comparator|Placebo|Matching placebo, once daily
3367684|NCT04127578|Experimental|Low dose|
3367685|NCT04127578|Experimental|High dose|
3367686|NCT04126317|Experimental|intravitreal aflibercept injection (IAI)|"Treatment-naïve patients with neovascular wet age-related macular degeneration (nAMD) randomized in a 1:1 ratio"
3367687|NCT04126317|Experimental|High-dose aflibercept (HD)|Treatment-naïve patients with nAMD randomized in a 1:1 ratio
3367688|NCT04112524||Patients from routine treatment|all 30 patients from Routine Treatment, only observational
3252108|NCT01402037|Other|FDR 12-39 y|In first degree relatives of type 1 diabetes patients a hyperglycemic clamp tests will be performed at inclusion and 6, 12, 18 and 24 months later in 40 high-risk first-degree relatives (see previous definition) with a non-diabetic OGTT performed 1 to 2 weeks before the clamp procedure. An OGTT result suggestive of diabetes will be confirmed and the relative will be offered participation in the patient arm of the study. HbA1c will be determined at the day of the OGTT and glycemic variability during the 5 days preceding the OGTT procedure.
3252109|NCT01402037|Other|FDR 5-12 y|"Ten high-risk first-degree relatives (see criteria) aged 5 to 12 years will also be tested for CGM and their results correlated with beta-cell function derived from a mini-clamp procedure (first 10 min. C-peptide release in hyperglycemic clamp) and results (CGM and first clamp phase) from relatives aged 12-17 years."
3252110|NCT01402076|Experimental|Steady State PK Group|
3367689|NCT04109950|Experimental|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg flexibly dosed once daily
3252111|NCT01402076|Experimental|No steady state PK|
3252112|NCT01402154||All study patients|All patients included according to stated inclusion and exclusion criteria.
3252113|NCT01402167|Experimental|Kyphoplasty|Patients randomized to this arm will be treated via balloon kyphoplasty.
3252114|NCT01402167|Active Comparator|Vertebroplasty|Patients randomized to this arm will be treated via vertebroplasty.
3367692|NCT04105062|Experimental|Phase I: LS301 Dose Level 1 (0.05 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
3367693|NCT04105062|Experimental|Phase I: LS301 Dose Level 2 (0.075 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
3367694|NCT04105062|Experimental|Phase I: LS301 Dose Level 3 (0.1 mg/kg)|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
3367695|NCT04105062|Experimental|Phase II: LS301 Dose determined in Phase I|"The patient will undergo intravenous injection of LS301 4-24 hours prior to surgery.~The operating surgeon will conduct surgery as usual without using a device to visualize LS301 fluorescence. To prevent bias in data acquisition, a second surgeon will wear the CVG at the completion of the surgery to examine the excised tissue at the surgical margins and the surgical resection bed.~The operating surgeon will remain blinded to the fluorescence images throughout the operation. The examining surgeon will wear the CVG and image all six anatomical aspects (superior, inferior, anterior, posterior, medial and lateral) of the surgical specimen as well as the surgical cavity for LS301 fluorescence."
3252115|NCT01402180|Experimental|A|Patients randomized in Arm A will receive chemoradiation and weekly Nimotuzumab for 6 weeks concurrent with radiation
3252116|NCT01402180|Active Comparator|B|Patients randomized in Arm B will receive chemoradiation only
3252117|NCT01402193|Active Comparator|Study Arm|"Investigational treatment: Arimidex commenced before and continued during radiotherapy.~Interventions:~Drug: Pre-radiotherapy commencement of Arimidex Radiation: Radiotherapy"
3252118|NCT01402193|Active Comparator|Control Arm|"Standard Treatment: Arimidex delayed until 2 weeks after radiotherapy~Interventions:~Radiation: Radiotherapy Drug: Post radiotherapy commencement of Arimidex"
3252119|NCT01402206|Other|Structured patient visits|Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
3252120|NCT01402206|Other|Treatment as usual|The control group receives treatment as usual by general practitioner (no intervention).
3252121|NCT01402219|Active Comparator|Iopamiro-370|
3252122|NCT01402219|Active Comparator|Visipaque 320|
3252123|NCT01402232||coronary angiography|We recruit all consecutive patients who were undergoing coronary angiography or percutaneous coronary intervention.
3252124|NCT01402245|No Intervention|Pneumonia group|Patients with Pnc pneumonia
3252125|NCT01402245|Active Comparator|PPV Group|Volunteers immunized with Pnc polysaccharide vaccine
3252126|NCT01402245|Active Comparator|PCV Group|Volunteers immunized with Pnc conjugate vaccine
3252127|NCT01402258|Experimental|Tailored Internet-delivered CBT|Behavioral: Tailored Internet-delivered CBT
3252128|NCT01402271|Experimental|pazopanib in combination with paclitaxel and carboplatin|Phase I: Dose-escalation study of pazopanib in combination with paclitaxel and carboplatin given weekly in a group of patients with platinum-refractory or -resistant ovarian, fallopian tube or peritoneal carcinoma Phase II: Paclitaxel 30 mg/m² and Carboplatin 2.0 AUC weekly for 18 courses PLUS Pazopanib 400 mg daily
3252129|NCT01402271|Active Comparator|Paclitaxel and carboplatin only|Carboplatin AUC 2.7 and paclitaxel 60mg/m² weekly for 18 courses.
3252130|NCT01402297|Experimental|COPD patients|Thirteen nonsmoking patients, suffering from GOLD II and GOLD III stage participated in the study (mean age 57 years (range 42-79), 9 men, 4 women). COPD was diagnosed based on GOLD 2009 criteria. All the participants were diagnosed at Department of Clinical Physiology, Medical university of Lodz.
3367701|NCT04088370||Alcoholic Hepatitis|No intervention-blood draw only
3367702|NCT04088370||Healthy Controls|No intervention- blood draw only
3367703|NCT04088370||Healthy Heavy Drinkers|No intervention- blood draw only
3367704|NCT04088318|Experimental|OQL011 Dose I|OQL011, Dose I, ointment, to be applied topically, three times a day, for up to six weeks
3367705|NCT04088318|Experimental|OQL011 Dose II|OQL011, Dose II, ointment, to be applied topically, three times a day, for up to six weeks
3367706|NCT04088318|Experimental|OQL011 Dose III|OQL011, Dose III, ointment, to be applied topically, three times a day, for up to six weeks
3252131|NCT01402310||Women attending antenatal clinic|Women attending antenatal clinic were consecutively enrolled at between 39+6 and 40+1 weeks of gestation.
3252132|NCT01402323|Other|early or late tooth extraction|
3367707|NCT04088318|Other|Vehicle Ointment|Vehicle ointment, to be applied topically, three times a day, for up to six weeks
3367713|NCT04084717|Experimental|ROS1 Rearrangement|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented ROS1 rearrangement will be assigned to this arm.
3367714|NCT04084717|Experimental|MET-activating Mutation (exon 14)|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-activating mutation (exon 14) will be assigned to this arm.
3367715|NCT04084717|Experimental|MET-amplification|Patients with stage IV or incurable non-squamous non-small cell lung cancer with a documented MET-amplification will be assigned to this arm.
3367717|NCT04072575|Experimental|Paliperidone Palmitate 6 month(PP6M)|"Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level (moderate or higher) that the participant received during previous study. Participants in the moderate dose level will receive PP6M Dose 1 and higher dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months."
3367718|NCT04062552|Experimental|Group I (ENABLE palliative care program, phone calls, VLC)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites participate in a VLC consisting of group-based learning sessions, coaching, and applied quality improvement data collection, analysis and feedback opportunities monthly for 15 months.
3367719|NCT04062552|Experimental|Group II (ENABLE palliative care program, phone calls, TA)|Patients undergo a palliative care assessment, participate in 6 ENABLE phone-based sessions with a nurse coach over 20-40 minutes, and monthly follow-up calls for 6 months. Caregivers participate in 3 ENABLE sessions with a nurse coach and monthly follow-up calls for 6 months. The practice sites undergo practice-based consultation calls with an ENABLE/TA expert monthly for 15 months.
3367720|NCT04056182|Experimental|Lofexidine|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
3367724|NCT04049851|Experimental|Moxidectin|
3367725|NCT04049851|Active Comparator|Ivermectin|
3367726|NCT04043026||WP1: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease
3367727|NCT04043026||WP1: AF + no CKD|Anticoagulated participants with atrial fibrillation and no chronic kidney disease
3367728|NCT04043026||WP1: no AF + CKD|Anticoagulated participants with chronic kidney disease and no atrial fibrillation
3252133|NCT01402336|Experimental|GnRH antagonist, SD #1 starting group|Start GnRH antagonist from stimulation day 1 during ovulation induction cycles
3252134|NCT01402336|Experimental|GnRH antagonist, SD #6 starting group|Start GnRH antagonist from stimulation day 6 during ovulation induction cycles
3367729|NCT04043026||WP1: no AF + no CKD|Anticoagulated participants without atrial fibrillation or chronic kidney disease
3367730|NCT04043026||WP2: AF + CKD|Anticoagulated participants with atrial fibrillation and chronic kidney disease, and are commencing statin therapy
3367731|NCT04035174|Experimental|LTS-2 DEC patch|This is a transdermal device with diethylcarbamazine (DEC) applied directly on the skin. The reading will be done 24 hours after.
3252135|NCT01402336|Active Comparator|Conventional GnRH agonist long group|Conventional GnRH agonist long protocol
3252136|NCT01402362||Ethiopians participating in previous study, year 2000|
3252137|NCT01402388|Experimental|Lifestyle intervention group.|
3252138|NCT01402401|Experimental|AUY922 + Trastuzumab|
3367732|NCT04035174|Active Comparator|Skin snip|A skin snip will be performed using a 2 mm Holth corneoscleral's punch. Once done, the microfilariae of Onchocerca volvulus will be counted with a microscope.
3367733|NCT04025554|Experimental|1/Active treatment|Patients with MS will be assigned to the same intervention
3252139|NCT01402414|Active Comparator|NB-UVB|NB-UVB irradiations adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session.
3367734|NCT04014205|Experimental|Part 1 Dose Escalation|Patients with r/r B-cell malignancies including Grades 1-3a FL, MZL, MCL, and CLL/SLL
3252140|NCT01402414|Active Comparator|Bath-PUVA|Phototherapy with UVA irradiation following bathing in psoralen water
3252141|NCT01402414|Active Comparator|NB-UVB plus salt water baths|Balneophototherapy with NB-UVB and 3% Dead Sea salt water baths
3252142|NCT01402440|Experimental|AEB071|
3252143|NCT01402453|No Intervention|Control Subjects|Receive educational materials and a home BP monitor.
3252144|NCT01402453|Experimental|Intervention Subjects|Receive educational materials and a home BP monitor, as well as monetary incentives tied to amount of improvement in BP from baseline and a personalized intervention to internalize motivation for BP control. Monthly monetary incentives will cease after 6 months.
3252145|NCT01402466|Active Comparator|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
3252146|NCT01402466|Experimental|Project Bridge|Participants randomized to this arm will be given the Project Bridge intervention
3252147|NCT01402479|Active Comparator|ramipril|open label single arm trial
3367735|NCT04014205|Experimental|Part 2 Dose Expansion|"Arm 1: Patients with r/r MCL~Arm 2: Patients with other types of B-cell malignancies, including:~CLL/SLL with/without prior treatment~r/r FL~r/r MZL"
3252148|NCT01402505||Transvaginal NOTES sleeve gastrectomy|Transvaginal NOTES sleeve gastrectomy
3252149|NCT01402518||Per-oral endoscopic myotomy|
3252150|NCT01402557|Active Comparator|Telephone Support Only|These participants receive telephone support only during the weight maintenance phase.
3252151|NCT01402557|Experimental|Telehealth|These participants receive telehealth support (with Internet-enabled digital video recorders) during the weight maintenance phase. These participants also receive telephone support monthly.
3252152|NCT01402583||PEG IFN/Ribavirin|Subjects with Hepatitis C undergoing PEG IFN/Ribavirin treatment
3252153|NCT01402596|Active Comparator|Chloral hydrate|Children undergoing CT scanning will receive in this arm 50 mg per kg of rectal chloral hydrate.
3252154|NCT01402596|Active Comparator|Midazolam|Children undergoing CT scanning will receive in this arm 0,4 mg/kg of nasal midazolam.
3367738|NCT03998566|Experimental|TraceIT Tissue Spacer|
3367740|NCT03991728||Alloplastic total TMJ replacement|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.
3367741|NCT03989349|Placebo Comparator|Placebo|Placebo administered via subcutaneous injection
3367742|NCT03989349|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
3367743|NCT03985943|Placebo Comparator|Placebo|Placebo
3252155|NCT01402609|Placebo Comparator|Control group, usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
3252156|NCT01402609|Experimental|electronic discharge communication tool|Patients allocated to the experimental arm will receive a copy of the discharge summary that is generated by the electronic discharge communication tool. The same copy is shared with their healthcare providers using an electronic, web-based, communication platform that allows communication between acute-care and community -care physicians. The electronic discharge communication tool allows physicians to start generating the discharge summary from time of admission to hospital.
3252157|NCT01402622|Active Comparator|Control group|balanced anaesthesia with antiemetic prophylaxis
3252158|NCT01402622|Active Comparator|TIVA group|TIVA without antiemetic prophylaxis
3252159|NCT01402622|Active Comparator|TIVA-P group|TIVA with antiemetic prophylaxis
3252160|NCT01402635|Experimental|POCT lab|The patient group whose laboratory test perform by POCT chemistry analyzer.
3252161|NCT01402635|Active Comparator|central laboratory group(CLT)|The patients group whose laboratory test perform by central laboratory.
3252162|NCT01402648|Placebo Comparator|Dietary supplement|900 mg Maltodextrins
3252163|NCT01402648|Active Comparator|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside) + 750 mg non starch, insoluble and indigestible fiber (6% in lignin).
3252164|NCT01402661||Rheumatoid Arthritis|Pts presenting to enrolling sites across the US are invited to enroll if eligible.
3252165|NCT01402674|Active Comparator|LPT|Subjects treated with phentermine for 2 years or more.
3252166|NCT01402674|No Intervention|APT|Patients treated with phentermine for 7 to 14 days.
3252167|NCT01402687||Mucositis Positive|Participants who developed severe mucositis
3252168|NCT01402687||Mucositis Negative|Participants who did not develop severe mucositis
3252169|NCT01402713|Experimental|GC1107-T5.0|Dosage: 0.5ml
3252170|NCT01402713|Experimental|GC1107-T7.5|Dosage: 0.5ml
3252171|NCT01402713|Active Comparator|TD_PUR INJ /SK Td vaccine|The name: step 1(phase 2)-SK Td vaccine step 2(phase 3)-TD_PUR INJ Dosage: 0.5ml
3252172|NCT01402726|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with heart failure.
3367744|NCT03985943|Experimental|Nemolizumab|Nemolizumab Active
3367745|NCT03984994|Experimental|Aerobic exercise training followed by resistance training|Participants in this arm will undergo 3 months of aerobic exercise training, followed by 3 months of strength training
3367746|NCT03984994|Active Comparator|Resistance training followed by aerobic exercise training|Participants in this arm will undergo 3 months of strength training, followed by 3 months of aerobic exercise training
3367747|NCT03983850|No Intervention|Donor Arm|Collection of bone marrow and/or PBSC (Up to 40 donors)
3367748|NCT03983850|Experimental|Phase 1 duration de-escalation of MMF|MMF at de-escalating duration (days +5 to +18 only, no MMF))
3367749|NCT03983850|Experimental|Phase I Dose De-escalation|PTCy at de-escalating doses (25 mg/kg/day on days +3 and +4, and PTCy 25 mg/kg on day +4) to assess for safety and determine Phase II dose (up to 12 evaluable patients)
3367750|NCT03983850|Experimental|Phase I Pilot for Comparative Data|Standard PTCy 50 mg/kg/day on days +3 and +4, in a small pilot (up to 5 evaluable patients) for comparative data
3367751|NCT03983850|Experimental|Phase II Efficacy|PTCy at shortest duration, safe dose (from Phase I) to assess efficacy at providing adequate protection from grade 3-4 acute GVHD (up to 14 additional patients)
3367752|NCT03983850|Experimental|Phase II efficacy of reduced duration MMF|MMF at duration identified from de-escalation evaluation.
3367753|NCT03982901|Experimental|women with chest pain|women with chest pain and coronary artery stenosis less than 50%
3367754|NCT03982901|Sham Comparator|healthy women|women without chest pain and coronary artery stenosis less than 50%
3367755|NCT03981744|Experimental|Group 1: Ustekinumab + Placebo|Participants will receive body weight-range based IV dosing of approximately 6 milligram per kilogram (mg/kg) of ustekinumab at Week 0 followed by ustekinumab 90 milligram (mg) subcutaneously (SC) at Week 8 and every 8 Weeks (q8w) administrations through Week 72. At Week 24, participants will receive IV dosing of placebo.
3367756|NCT03981744|Placebo Comparator|Group 2: Placebo + Ustekinumab|Participants will receive IV dosing of placebo at Week 0 followed by placebo SC administrations at Weeks 8,16 and 24. At Week 24, participants will receive body weight-range based IV dosing of approximately 6 mg/kg of ustekinumab, followed by ustekinumab 90 mg SC q8w administrations Week 32 through Week 72.
3252173|NCT01402726|No Intervention|Absolute medicine therapy|Maintenance of anti-heart failure medications only
3252174|NCT01402739|Experimental|PoC algorithm guided transfusions|experimental arm
3252175|NCT01402739|Active Comparator|standard of care transfusions|control arm
3252176|NCT01402752|Experimental|All patients|All patients included in this study according to stated inclusion and exclusion criteria.
3367762|NCT03974945||Participants with Transtibial Amputation|The investigators will recruit participants with unilateral transtibial amputations who are at or above a K3 Medicare functional classification level (MFCL), and 18-60 years old. A K3 MFCL means that a person has the ability or potential for ambulation with variable cadence. A person at K3 MFCL is a typical community ambulator who has the ability to traverse most environmental barriers and may have vocational, therapeutic or exercise activity that demands prosthetic use beyond simple locomotion.
3252177|NCT01402765|Active Comparator|Group 1 (Summit first)|In Group 1 pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
3252178|NCT01402765|Active Comparator|Group 2 (Nimbus 3 first)|In Group 2 pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
3252179|NCT01402778||Cather fixation by tunneling and suture|
3252180|NCT01402778||Catheter fixation by adhesive tape|
3252181|NCT01402791||The study population|All patients included according to state inclusion and exclusion criteria.
3252182|NCT01402804||Stable CAD, ASA, NSAID|
3252183|NCT01402804||Stable CAD, ASA|
3252184|NCT01402830||001|Visual analogue scales (EVAs) This scale measures the pain intensity.
3252185|NCT01402843|Experimental|pitavastatin + valsartan|
3252186|NCT01402843|Placebo Comparator|pitavastatin + placebo|
3252187|NCT01402843|Placebo Comparator|valsartan + placebo|
3252188|NCT01402843|Placebo Comparator|placebo|
3252189|NCT01402856||Southern Lehigh HS, PA School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
3252190|NCT01402856||Bethlehem HS, PA Area School District|Freedom & Liberty HS's in Bethlehem, PA will serve as the study's control group.
3252191|NCT01402856||Phillipsburg HS, NJ Area School District|This school will not receive the education, yet, will be surveyed, quizzed and observed at the same time.
3367767|NCT03969901|Experimental|IMI/REL|Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
3367768|NCT03969901|Active Comparator|Active Control|Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.
3367769|NCT03961568|Experimental|Core Study Placebo|Subjects who did not receive Cenobamate in the Core Study will receive Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks.
3252192|NCT01402882|Experimental|Tranexamic acid|
3252193|NCT01402882|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
3252194|NCT01402895|Active Comparator|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
3367770|NCT03961568|Experimental|Core Study Active|Subjects who received cenobamate in the Core study will continue to receive the same daily dose (150 mg or 200mg).
3367771|NCT03960138|Experimental|Intermittent Theta-burst stimulation (iTBS)|Cross-over design - participants will receive both experimental treatments.
3367772|NCT03960138|Experimental|Continuous Theta-burst stimulation (cTBS)|Cross-over design - participants will receive both experimental treatments.
3252195|NCT01402895|Active Comparator|Exercise|The physiotherapist will teach the participant how to tighten the transversus abdominus muscle. The participant will be asked to do a series of these exercises.
3252196|NCT01402921|Experimental|Elastic Medical Compressive Therapy|"V0322BC verum medical compressive therapy is a progressive compressive sock with:~ankle pressure: 10 mmHg~calf pressure : 23 mmHg"
3252197|NCT01402921|Placebo Comparator|Placebo|"V0322BC placebo medical compressive therapy is a progressive compressive sock with:~ankle pressure: <5 mmHg~calf pressure : <7 mmHg"
3252198|NCT01402934|Experimental|fluid infusion|
3252199|NCT01402960|Experimental|Active Anodal HD-tDCS|Subject will receive one 20-minute session of active anodal HD-tDCS.
3252200|NCT01402960|Experimental|Active Cathodal HD-tDCS|Subject will receive one 20-minute session of active cathodal HD-tDCS.
3252201|NCT01402960|Sham Comparator|Sham HD-tDCS|Subject will receive one sham session of HD-tDCS
3252202|NCT01402973|Experimental|High-AGE Diet|The high-AGE diet will be approximately four times higher in AGEs than the low-AGE diet.
3252203|NCT01402973|Experimental|Low-AGE Diet|The low-AGE diet will be approximately four times lower in AGEs than the high-AGE diet.
3252204|NCT01403025||Liraglutide|
3252205|NCT01403038|Experimental|Elagolix Dose Regimen 1|Elagolix Dose regimen 1 for 84 days
3252206|NCT01403038|Experimental|Elagolix Dose Regimen 2|Elagolix Dose Regimen 2 for 84 days
3367773|NCT03959358|Experimental|Lenalidomide|"Participants will only receive lenalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of lenalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with lenalidomide at."
3252207|NCT01403038|Experimental|Elagolix Dose Regimen 3|Elagolix Dose Regimen 3 for 84 days
3252208|NCT01403038|Experimental|Elagolix Dose Regimen 4|"Elagolix Dose Regimen 4 for 84 days~Additional Dose Regimens may be added and will be administered for 84 days."
3252209|NCT01403038|Experimental|Elagolix Dose Regimen 5|Elagolix Dose Regimen 5 for 84 days
3252210|NCT01403038|Experimental|Elagolix Dose Regimen 6|Elagolix Dose Regimen 6 for 84 days
3252211|NCT01403038|Experimental|Elagolix Dose Regimen 7|Elagolix Dose Regimen 7 for 84 days
3252212|NCT01403077|Experimental|Scaffold Treatment|
3367774|NCT03959358|Experimental|Pomalidomide|"Participants will only receive pomalidomide if they had previously received this drug as a part of their treatment for multiple myeloma or amyloidosis and had experienced an allergic reaction to the drug.~Participants will first be given a low dose of pomalidomide with increasing doses over 10-12 steps over 3.5 to 5 hours. Participants will be monitored for side effects or reactions prior to each dose step and any reactions will be managed before giving the increased dose at the next step.~The final dose will be determined by the study doctor and is expected to be the dose that participants will restart treatment with pomalidomide at."
3367775|NCT03958240|Other|Patient with local and/or metastatic solid malignant tumor|Patient receiving an anticancer treatment in the context of their standard care.
3252213|NCT01403103|Experimental|Treatment (chemoprevention)|Patients receive cholecalciferol orally (PO) 7 days prior to scheduled surgery or endorectal ultrasound. Patients with sigmoid colon cancer or clinical stage I rectal cancer would proceed with surgical resection without preceding chemoradiation and will have a portion of normal colorectal mucosa and tumor tissue obtained for research purposes.
3252214|NCT01403129||Keratoconus-Suspect|A person who has or is suspected of having keratoconus. Will have either or both Artemis-2 exam and OCT exam.
3367776|NCT03954106|Experimental|Defibrotide|"Part 1 (lead-in phase) will evaluate a 2.5 mg/kg/dose regimen before escalating to a 6.25 mg/kg/dose regimen.~After the Safety Assessment Committee establishes the recommended phase 2 dose based on dose-limiting toxicities during Part 1, Part 2 will enroll subjects at the recommended phase 2 dose."
3367782|NCT03948893|Experimental|MORE|
3367783|NCT03948893|Active Comparator|CBT|
3367784|NCT03948867|Experimental|Elevated Initial Screening TCD|Those who have an elevated initial screening TCD (either conditional or abnormal TAMV) and will be a treatment cohort that receives open-label hydroxyurea therapy as per the dosing and administration schedule.
3367785|NCT03948867|Experimental|Normal Initial Screening TCD|Those who are found to have a normal TCD at enrolment are a part of the observation/control cohort and will undergo repeat TCD every 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the study participant will be reassigned to the elevated initial screening TCD arm and can begin study treatment (hydroxyurea), but will not be included in the primary endpoint analysis.
3367786|NCT03942120||Participants with Crohn's Disease|Participants that are diagnosed with Crohn's disease will be observed in this study who are being treated with ustekinumab under real world clinical practice. Only data available per clinical practice will be collected within this study.
3367787|NCT03937583|No Intervention|Limited screening|Complete clinical history, along with routine physical, analytical examination (creatinine, sodium, potassium, red series, white series, liver and calcium profile) and chest x-ray.
3367788|NCT03937583|Experimental|Extended screening|Limited screening plus positron emission tomography / computed tomography with 18 FDG (18FDG PET-CT).
3367789|NCT03930498|Experimental|PD-1 antibody plus chemoradiotherapy|
3367794|NCT03924635|Active Comparator|SYMBICORT as maintenance and reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 twice a day (BID) for maintenance and as needed (PRN) for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance and PRN for relief.
3367795|NCT03924635|Active Comparator|SYMBICORT as maintenance, salbutamol as reliever treatment|Patients on ICS (low dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 100/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief and patients on ICS (medium dose)/LABA prior to study entry (per GINA 2018 guidelines) will receive SYMBICORT (budesonide/formoterol 200/6 μg) × 2 BID for maintenance + salbutamol (100 μg) PRN for relief.
3367796|NCT03924310|Experimental|Arm amputees|This single arm conducts all experiments. In three out of four experiments both interventions (with feedback & without feedback) are used, the fourth experiment does not allow the intervention without feedback.
3367804|NCT03921424|Experimental|V114|Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
3367805|NCT03921424|Active Comparator|Prevnar 13™|Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)
3367815|NCT03911089|Other|Open label|UCD Anamix Infant
3367818|NCT03904043|Experimental|Radiation + FOLFOX|"Pelvic radiotherapy 5GY x 5 fractions once daily~Radiation to extra-mesorectal node 7 Gy x 5 fractions once daily~FOLFOX should begin 2-4 weeks after completion of radiotherapy and will consist of FOLFOX x 8 cycles (16 weeks).~Oxaliplatin day 1 every 14 days~Leucovorin day 1 every 14 days~5-FU bolus day 1 every 14 days~5-FU infusion day 1 every 14 days over 46 hours~Alternatively CAPOX (capecitabine and oxaliplatin) may be given for 5 cycles over 15 weeks.~An optional simultaneous integrated boost of 30 Gy in 5 fractions to the primary tumor is permitted"
3252215|NCT01403129||Keratoconus-Related|A person who is genetically related to someone with keratoconus. Will have either or both Artemis-2 exam and OCT exam.
3252216|NCT01403129||Age-Matched Normal|"A person who is approximately the same age as subjects who have been enrolled in the study.~Will have either or both Artemis-2 exam and OCT exam."
3252217|NCT01403155|Experimental|All subjects|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine) at Day o and Month 3.
3252218|NCT01403168|Experimental|osteopathy + conventional analgesic treatments|
3252219|NCT01403168|Placebo Comparator|conventional analgesic treatments|
3367820|NCT03898934|Experimental|Vitamin D group|These patients will receive 6000IU daily for 8 weeks then 2000IU maintenance till pregnancy or end of study
3252220|NCT01403181||Chronic hepatitis C|"10 naïve genotype 1 chronic hepatitis C patients treated with PEG plus RBV (control arm)~20 naïve genotype 1 chronic hepatitis C patients treated with a response guided therapy consisting of Boceprevir in combination with PEG plus RBV (experimental arm)"
3367821|NCT03898934|Placebo Comparator|Placebo group|These group will receive placebo for the same periods of study group
3252221|NCT01403207||knee osteoarthritis|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
3252222|NCT01403220|Active Comparator|Group 1 (hemodiafiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
3367828|NCT03893617|Active Comparator|Propranolol group|This group will receive a single oral dose (80mg) of propranolol in a blinded capsule during their acute stress study visit.
3252223|NCT01403220|Active Comparator|Group 2 (hemofiltration first)|This group of patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
3252224|NCT01403233|Experimental|cogniVida™ 50 mg/day|
3252225|NCT01403233|Experimental|cogniVida™ 100 mg/day|
3252226|NCT01403233|Active Comparator|Rebaudioside-A 303.7 mg/day|
3367829|NCT03893617|Placebo Comparator|Placebo group|This group will receive a single blinded capsule containing no active medication during their acute stress study visit.
3367832|NCT03869437|Experimental|Cefiderocol|Participants will receive Cefiderocol 2 g administered intravenously over 3 hours, every 8 hours for up to 14 days
3367833|NCT03869437|Active Comparator|Best Available Therapy (BAT)|BAT will be chosen by the investigator and intravenously administered per country-specific guidelines
3367834|NCT03866187|Experimental|Group A1_Step A|Subjects aged 18-65 years receive one dose of each of the study vaccines, Chimpanzee adenovirus HBV vaccine (ChAd155-hIi-HBV) low dose formulation at Day 1, Modified Vaccinia Ankara HBV vaccine (MVA-HBV) low dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169.
3367835|NCT03866187|Active Comparator|Group A2_Step A|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 low dose formulation, one dose each at Days 1, 57, 113 and 169.
3367836|NCT03866187|Placebo Comparator|Group A3_Step A|Subjects aged 18-65 years receive four doses of placebo, one dose each at Days 1, 57, 113 and 169.
3367837|NCT03866187|Experimental|Group B1_Step B|Subjects aged 18-65 years receive one dose of each of the study vaccines, ChAd155-hIi-HBV high dose formulation at Day 1, MVA-HBV high dose formulation at Day 57 and two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at Day 169.
3367838|NCT03866187|Active Comparator|Group B2_Step B|Subjects aged 18-65 years receive four doses of the study vaccine HBc-HBs/AS01B-4 high dose formulation, one dose each at Days 1, 57, 113 and 169.
3367839|NCT03866187|Active Comparator|Group B3_Step B|Subjects aged 18-65 years receive two doses of placebo, one each at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation at Day 169.
3367840|NCT03866187|Experimental|Group C1_Step C|Subjects aged 18-65 years receive one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 1 and the 3 following doses of MVA-HBV high dose formulation co-administered with HBc-HBc-HBs/AS01B-4 high dose formulation at Day 57, 113 and Day 169.
3252227|NCT01403259|Experimental|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks for 6 cycles
3252228|NCT01403272|Experimental|DermaTherapy® Linen group|The DermaTherapy® Linen group uses bed sheets and underpads made with DermaTherapy® fabric.
3252229|NCT01403298|Active Comparator|Adolescent Only Health Promotion|An individual adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
3252230|NCT01403298|Experimental|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
3252231|NCT01403311|Experimental|ALA|5-Aminolevuline Acid (ALA)
3252232|NCT01403324|Other|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
3252233|NCT01403337|Placebo Comparator|Control|Blood pressure cuff inflated in the right or left arm to 40-50 mmHg
3252234|NCT01403337|Active Comparator|Preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
3252235|NCT01403350|No Intervention|Current Practice|Study Phase I: No RDT or other parasite based diagnosis; Study Phase II: RDT used under the standard programme of training and support
3252236|NCT01403350|Active Comparator|Intervention Arm|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
3252237|NCT01403363|Experimental|fentanyl patch|
3252238|NCT01403389|Experimental|Eculizumab|
3252239|NCT01403389|Placebo Comparator|0.9% Sodium Chloride|
3367841|NCT03866187|Active Comparator|Group C2_Step C|Subjects aged 18-65 years receive two doses of placebo at Days 1 and 57, one dose of ChAd155-hIi-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 113 and one dose of MVA-HBV high dose formulation co-administered with HBc-HBs/AS01B-4 high dose formulation at Day 169.
3367842|NCT03860844|Experimental|Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia|This arm includes participants from 3 cohorts: AML, T-ALL and B-ALL.; AML: Weekly dosing of isatuximab with induction chemotherapy. The therapy may be repeated one more cycle; ALL: (Includes T-ALL and B-ALL) Weekly dosing of isatuximab with induction chemotherapy, then biweekly dosing of isatuximab with consolidation chemotherapy.
3367845|NCT03831932|Experimental|Treatment (telaglenastat HCl, osimertinib)|Patients receive telaglenastat hydrochloride PO BID and osimertinib PO QD (starting cycle 1 day 16 of phase I). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3367846|NCT03828903|Experimental|pleural effusion patients|medical thoracoscopy will e performed to patients with pleural effusion and pleural biopsy by forceps ad cryoprobe will be obtained
3367847|NCT03826992|Experimental|Venetoclax and Vyxeos combination|"Venetoclax will be given orally on Days 1-21 per the assigned dose level. A single course consisting of 3 doses of Vyxeos and 21 doses of venetoclax will be administered to participants in this study. Vyxeos will be administered by central venous catheter over 90 minutes on Day 1, 3, and 5.~Venetoclax is given daily by mouth per assigned dose level."
3367848|NCT03817554|Experimental|Treatment group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive pramipexole.
3252240|NCT01403402||Congenital Muscle Disease|The congenital muscle diseases include congenital muscular dystrophy, congenital myopathy, congenital myasthenic syndrome and bridge into the limb girdle/late onset spectrum. For data collection and analysis, subtype specific reports will be generated. True incidence of the congenital muscle diseases is unknown.
3252241|NCT01403415|Experimental|Treatment (temsirolimus, combination chemotherapy)|Patients receive dexamethasone PO or IV on days 1-5 and 15-19; mitoxantrone hydrochloride IV over 30 minutes on days 1-2; temsirolimus IV over 30 minutes on days 1 and 8; vincristine sulfate IV on days 1, 8, 15, and 22; and pegaspargase IV over 1 hour on days 3 and 17. Some patients may also receive methotrexate IT up to 72 hours prior to or on day 1 and on day 8.
3367849|NCT03817554|Placebo Comparator|Control group|Peritoneal dialysis patients diagnosed with restless legs syndrome will receive placebo.
3367852|NCT03799393|Active Comparator|Control Group|"The control group will receive a brief tablet-based questionnaire followed by standard, paper discharge instructions on car safety. Children ≥13 years old and above will answer questions themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
3252242|NCT01403428|Experimental|NPPV plus standard of care|Noninvasive positive pressure ventilation (NPPV) plus standard of care in the management of children admitted to the hospital with status asthmaticus
3367853|NCT03799393|Experimental|Experimental/CIAS Group|"The Experimental/CIAS Group will receive a brief tablet-based questionnaire followed by the intervention - CIAS, an interactive tablet computer program that gives educational information customized to the patient's age and size. Children ≥13 years old will answer questions and interact with the program themselves. They will complete a questionnaire on the usefulness of their discharge education.~One week after discharge, participants will receive an automatic text message and/or email message with a link to a web-based survey that will assess: knowledge of appropriate car restraints and whether the parent/patient engaged in any behavioral changes regarding child car restraint."
3367854|NCT03798041|Experimental|Debridement group|The subjects in this group will be debrided within 24 hours after surgery.
3367855|NCT03798041|No Intervention|Control group|The subjects in this group will experience wound dressing change regularly 24 hours after surgery.
3367856|NCT03796819|Experimental|lymphadenectomy|This group of patients would undergo routine hepatoduodenal lymphadenectomy combined with ICC resection
3367857|NCT03796819|No Intervention|No lymphadenectomy|This group of patients would not undergo hepatoduodenal lymphadenectomy when preoperative imaging and intraoperative exploration found no lymph node enlargement.
3367858|NCT03793907|Active Comparator|Cohort 2 (walking program)|Patients receive a Fitbit to track their physical activity, and complete an unsupervised walking program daily at home, increasing physical activity stepwise weekly, for 6 months.
3367859|NCT03793907|Experimental|Cohort 1 (strength training)|Patients receive a Fitbit to track their physical activity, and complete an in-person personalized and supervised full-body strength training program over 1 hour BID up to 52 sessions for 6 months.
3252243|NCT01403428|No Intervention|Standard of care|standard of care treatment in the management of children admitted to the hospital with status asthmaticus
3252244|NCT01403454|No Intervention|usual care|
3252245|NCT01403454|Active Comparator|Health Communication Application|
3252246|NCT01403467|Experimental|NIPPV|
3252247|NCT01403493|Active Comparator|Multidisciplinary patient education|A multidisciplinary (nurse, gastroenterologist, dietician, physiotherapist, psychologist) group education with six sessions for patients with IBS.
3252248|NCT01403493|Active Comparator|Nurse based patient education|A nurse based patient education with three sessions for patients with IBS.
3252249|NCT01403506|Active Comparator|N-Acetyl Cysteine|N-Acetyl Cysteine: receive N-Acetyl Cysteine in addition to standard treatment
3252250|NCT01403506|No Intervention|standard treatment|This group is without N-Acetyl Cysteine : just receives standard treatment
3252251|NCT01403519||Alzheimer's disease patients|Patients blood and CSF samples
3252252|NCT01403519||Control group|Blood and CSF samples
3252253|NCT01403519||FTD patients|Blood ad CSF samples
3252254|NCT01403532|Active Comparator|Traditional|
3252255|NCT01403532|Experimental|Sequential|
3252256|NCT01403532|Experimental|Sequential Plus|
3252257|NCT01403545|Experimental|Liposomal Curcumin|Single dose, dose escalation
3252258|NCT01403545|Placebo Comparator|5% Glucose|
3252259|NCT01403558|Experimental|Cognitive behavioral therapy|Ten weekly individual cognitive behavioral therapy sessions before bariatric surgery
3252260|NCT01403558|No Intervention|Control group|Usual preoperative care consisting of up to three voluntary sessions with nutritionist and physiotherapist before bariatric surgery
3252261|NCT01403571|Experimental|Salba supplement|30g/1000kal
3252262|NCT01403571|Placebo Comparator|Oat-bran based Control Supplement|36g/1000kcal
3252263|NCT01403597|Experimental|Treatment|The defined areas for treatment are the entire face or at least two facial sub areas (e.g., peri-orbital and peri oral) with the combination of two devices where a total of 5 treatments every 4 weeks will be administered
3252264|NCT01403623|Active Comparator|Resuscitation with plastic bag|Plastic bag will be used during and after resuscitation to assist with temperature regulation.
3252265|NCT01403623|Sham Comparator|Standard resuscitation- no plastic bag|Infant will be resuscitated per standard of care without being placed in a plastic bag for temperature regulation.
3252266|NCT01403636|Experimental|mantle cell|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
3252267|NCT01403636|Experimental|follicular lymphoma|50 mg twice daily: no eating for 2 hours prior and 1 hour after dose
3252268|NCT01403636|Experimental|CLL/SLL|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
3252269|NCT01403636|Experimental|Diffuse large B cell lymphoma|50 mg twice daily:no eating for 2 hours prior and 1 hour after dose
3252270|NCT01403649|Experimental|Increasing flu vaccination|Collect from billing records in the 10 intervention practice sites to test for an increase in the rate of receipt of ≥1 influenza vaccine during the post-intervention year compared to the pre-intervention year among children 6 months to 18 years during the season. The interventions include: 1. Develop practice-based intervention strategies (like use of reminder-recall of children due for influenza,2. Develop Private/public collaboration to increase flu vaccination between the intervention practices, their county public health department and visiting nursing associations, and 3. Implement both practice-based and private-public collaborative strategies in the intervention practices while monitoring only in the control practices
3252271|NCT01403649|Other|Usual care|Patients in control practices will continue to receive usual care with no change in practice regarding influenza immunization delivery.
3252272|NCT01403662|Experimental|Minocycline|
3252273|NCT01403675|Experimental|Ovarian autotransplantation|
3252274|NCT01403688||Random Fine Needle Aspiration (RPFNA)|RPFNA
3252275|NCT01403701|Experimental|Physical therapy|Standardized pelvic floor physical therapy
3252276|NCT01403701|No Intervention|routine care|Standard postoperative visits
3252277|NCT01403714|No Intervention|Medical Management|Patients may be randomized to medical management alone
3252278|NCT01403714|Active Comparator|Renal Artery Stenting|Those patients with recent heart failure exacerbations that cannot be attributed to poor left ventricular function and have a hemodynamically significant renal artery stenosis may be randomized to renal artery stenting
3252279|NCT01403727||Unassisted Biopsy - CONTROL GROUP|Routine biopsy needle placement and Physician blinded to needle location
3252280|NCT01403727||Assisted Biopsy - STUDY GROUP|The physician will be shown the PercuNav screen and will correct the desired approach path.
3367865|NCT03789591|Active Comparator|Standard Arm|Participants randomized to the standard arm will receive a starting dose of hydroxyurea of 20 mg/kg/day.
3367866|NCT03789591|Experimental|Alternative Arm|Participants randomized to the alternative arm will receive a pharmacokinetic guided starting dose of hydroxyurea based on PK labs drawn at a baseline visit to target an area under the curve (AUC) of 115 mg*h/L in an attempt to approximate maximum tolerated dose (MTD). This dose will not exceed the maximum tolerated dose of 35 mg/kg/day.
3367867|NCT03788746||Patients diagnosed with advanced urothelial carcinoma|Patients with a confirmed diagnosis of advanced urothelial carcinoma, prior to or during first line therapy, who have available tumor tissue samples collected as part of standard of care
3367868|NCT03787095|Experimental|Cohort 1: Cemiplimab|"Participants received 0.3 mg/kg of cemiplimab, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
3367869|NCT03787095|Placebo Comparator|Cohort 1: Placebo|"Participants received placebo, administered at Day 0 and Week 6 for a total of two infusions.~Participants continued their current non-study provided ART regimen."
3367870|NCT03786783|Experimental|Treatment(chemotherapy, dinutuximab, sargramostim, ASCT, EBRT)|See Detailed Description
3252281|NCT01403740||Acquired haemophilia patients|
3252282|NCT01403753||Non-clinical sample of children|
3252283|NCT01403766||Pediatric post-kidney transplant|Patients having standard of care surviellance biopsies.
3367871|NCT03782376|Experimental|Group 1: Ustekinumab (IV re-induction)|Participants who experience a secondary loss of response (LoR) to 90 mg ustekinumab maintenance treatment, administered subcutaneously every 8 weeks (q8w) will receive a weight-tiered based ustekinumab IV re-induction dose of approximately 6 mg/kg and matching placebo subcutaneously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
3367872|NCT03782376|Active Comparator|Group 2: Ustekinumab (Continuous q8w SC maintenance)|Participants who experience a secondary LoR to 90 mg ustekinumab maintenance treatment, administered subcutaneously q8w will receive ustekinumab 90 mg subcutaneously and matching placebo intravenously at Week 0. At Weeks 8 and 16, all participants will receive SC maintenance injections of 90 mg ustekinumab. Participants will resume their standard-of-care therapy at Week 24 at the discretion of the treating physician.
3367873|NCT03782259|Placebo Comparator|Placebo|10mg tabs placebo matching dapagliflozin.
3367874|NCT03782259|Active Comparator|Active|10mg tabs of dapagliflozin
3252284|NCT01403779|Active Comparator|1-Hypofractionated IMRT|hypofractionated IMRT for right sided breast cancer
3252285|NCT01403779|Active Comparator|2-Normofractioated IMRT|normofractionated IMRT for left sided breast cancer
3367881|NCT03778294|Experimental|Treatment (18F-DOPA, PET/MRI, PET/CT, temozolomide)|Patients receive 18F-DOPA IV and undergo PET/MRI or PET/CT imaging scan. Patients then receive proton beam radiotherapy over 5 or 10 consecutive days excluding weekend and standard of care temozolomide on days 1-7 or 1-14. Beginning cycles 2, patients receive standard of care temozolomide on days 1-5. Cycles with temozolomide repeat every 28 days for up to 7 cycles in the in the absence of disease progression or unacceptable toxicity.
3367882|NCT03777826|Other|Open label (1 arm)|Open label use of study product (post-marketing): PKU Synergy
3367883|NCT03771391|Experimental|4 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 4 weeks.
3252286|NCT01403792|Experimental|Up to 7mg P2G12|
3252287|NCT01403792|Experimental|Up to 14mg P2G12|
3252288|NCT01403792|Experimental|Up to 28mg P2G12|
3252289|NCT01403792|Placebo Comparator|Placebo (saline solution)|
3367884|NCT03771391|Experimental|8 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 8 weeks.
3367885|NCT03771391|Experimental|12 Weeks|All patients randomised to this arm will start on an amino acid based protein substitute and they will all swtich over to incorprating PKU Sphere after 12 weeks.
3367889|NCT03761069|Experimental|PTC299|PTC299 will be administered orally once daily (QD) for each 28-day cycle.
3252290|NCT01403818|Experimental|Part 1|"Subjects will receive ASP1941 alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
3252291|NCT01403818|Experimental|Part 2|"Subjects will receive Mitiglinide calcium hydrate alone and ASP1941 + Mitiglinide calcium hydrate in different orders."
3367890|NCT03757455|Experimental|Enchanced recovery after surgery protocol|ERAS-protocol as described in low risk patients after pancreaticoduodenectomy or total pancreatectomy
3367891|NCT03757455|No Intervention|Standard protocol|Standard recovery protocol after pancreaticoduodenectomy or total pancreatectomy
3252292|NCT01403831|Experimental|Text messages|Patients randomized to this arm will receive daily text messages to their mobile phones consisting of educational materials, motivational materials, trivia questions, and challenges to engage in healthy lifestyle choices
3252293|NCT01403831|No Intervention|Control|
3367895|NCT03736538|Experimental|Nitrous Oxide|"Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive inhaled nitrous oxide."
3367896|NCT03736538|Placebo Comparator|Placebo Gas|"Placebo gas given at 50% nitrogen [inert]/50% oxygen.~Participants will undergo a maximum of four one hour inhalation sessions as inpatients and 2 booster sessions as outpatients during which they will receive placebo gas."
3252294|NCT01403844|Other|Skin Carotenoids|Skin carotenoids will be measured under conditions of depletion or repletion
3252295|NCT01403857|Experimental|Whole Grain|Whole grain products as defined by the American Association of Cereal Chemists (AACC) given in a market basket that contains eight commonly used grain products over six weeks.
3252296|NCT01403857|Placebo Comparator|Refined Grains|Time control compared to experimental intervention.
3252297|NCT01403870||Low Back Pain Subjects|Subjects who have low back pain at the time of the study, and wish to receive physical therapy to reduce their low back pain.
3252298|NCT01403883|Active Comparator|Standard care|standard care of patient with psychological and enterostomal therapy clinic if necessary
3252299|NCT01403883|Experimental|Optimal care|Optimal care of patient with systematic and repeated psychological and enterostomal therapy follow up
3252300|NCT01403896|Active Comparator|Plerixafor Group|
3252301|NCT01403896|Experimental|Plerixafor + G-CSF group|
3367904|NCT03729518|Experimental|Arm 1|All patients will have the volume treated and radiation dose delivered to the regional lymphatics decreased according to the characteristics of the primary site and involved lymph nodes. The high risk neck will receive 50 Gy instead of 60 Gy, and the treated volume of the contralateral low risk neck will be reduced and receive only 45 Gy.
3367905|NCT03721328|Experimental|Experimental|Joint irrigation with vancomycin and tobramycin
3367906|NCT03717896|Experimental|Thiamine|200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days
3367907|NCT03717896|Placebo Comparator|Placebo|100mL 0.9% saline twice daily for two days
3367908|NCT03699020|Experimental|Acceptance and Commitment Therapy (ACT)|The intervention will consists of eight weekly two hour group ACT sessions led by trained lay personnel and followed by homework. ACT is a behavioral therapy.
3367909|NCT03699020|Experimental|Education Control|Consists of eight weekly two hour group chronic pain education sessions led by trained lay personnel and followed by homework.
3367912|NCT03697980||HVAD|
3367913|NCT03697421||Local Evaluation|The SHR program intends to serves couples who are over 18 years of age, are in a romantic relationship, and have at least one child (biological or adopted) under the age of 18 residing in the home or are expecting.
3367914|NCT03681210||Patients implanted with HVAD System|Patients intended to be implanted with a HVAD for use as destination therapy are eligible for enrollment into the DT PAS and must be consented for the study prior to the HVAD implant.
3367915|NCT03678753|Experimental|Cenobamate|Cenobamate 12.5 mg tablet once a day for two weeks, 25 mg tablet once a day for two weeks, 50 mg tablet once a day for two weeks, 100 mg tablets once a day for two weeks, 150 mg tablets once a day for two weeks and 200 mg tablets once a day for twelve weeks
3367916|NCT03678753|Placebo Comparator|Placebo|Matching placebo
3367917|NCT03664232|Experimental|JNJ-42165279|Participants will self-administer 25 milligram (mg) JNJ-42165279 tablets orally twice daily for 12 weeks.
3367918|NCT03664232|Placebo Comparator|Placebo|Participants will self-administer matching placebo tablets orally twice daily for 12 weeks.
3367919|NCT03651206|Experimental|Arm A - Niraparib|Niraparib, 200 mg or 300 mg, daily dose
3367920|NCT03651206|Experimental|Arm B - Niraparib + TSR-042 (Dostarlimab)|"Niraparib, 200 mg or 300 mg, daily dose~TSR042, intravenous infusion on Day 1 of every 21-day cycle at 500 mg for the 4 first cycles, followed by 1,000 mg on Day 1 of every 42-day cycle thereafter"
3367921|NCT03651206|Active Comparator|Arm C - Chemotherapy drugs|"Chemotherapies (Standard of care)~For Ovarian Cancer Patients Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Pegylated Liposomal Doxorubicin, 40 mg/m², Intravenous, every 28 days Topotecan, 4mg/m², Intravenous, Day 1, 8, 15 every 28 days~For Endometrial Cancer Patients Doxorubicin, 60 mg/m², Intravenous, every 21 days Paclitaxel, 80 mg/m², Intravenous, Day 1, 8, 15 every 28 days Gemcitabine, 800 mg/m², Intravenous, Day 1, 8 every 21 days"
3367922|NCT03651050|Experimental|intervention FBOs receive the P-MHDT|
3367923|NCT03651050|Experimental|control FBOs receive no P-MHDT|
3367924|NCT03630601|Experimental|Diagnostic (photoacoustic imaging)|Participants undergo PAI on different parts of the body over 20 minutes for up to 5 imaging sessions for 6 months.
3367925|NCT03629951||Participants with Schizophrenia|Participants will not receive any intervention as a part of this study. Participants with a diagnosis of schizophrenia or schizoaffective disorder receiving oral antipsychotics (OAP) for example, risperidone (1 to 6 milligram [mg] once daily [OD] to twice a day [BID]), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to thrice a day [TID]) etc, per their treating physician/clinician instruction will be observed. The primary data source for this study will be the clinical assessments by the treating physician of each participant conducted as a part of routine clinical practice.
3367926|NCT03607552||Phase 1: Pilot Study Phase|Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
3367927|NCT03607552||Phase 2: Development Phase|Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
3367928|NCT03607552||Phase 3: Reader Performance Phase|Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
3252302|NCT01403909|Experimental|With compression|The patients randomized to this group will have intermittent pneumatic venous compression of the lower limbs during surgery.
3252303|NCT01403909|Active Comparator|Without compression|The patients randomized to this group will not have intermittent pneumatic venous compression of the lower limbs during surgery. (Standard care)
3367929|NCT03606499||Inflammatory Bowel Disease (IBD) Participants with EIMs and/or IMIDs|IBD (Crohn's Disease [CD] or Ulcerative Colitis [UC]) participants with suspected extra-intestinal manifestations (EIMs) and/or one or more immune-mediated inflammatory diseases (IMIDs) will be enrolled into the study to assess effectiveness of ustekinumab on EIMs and/or IMIDs associated with IBD (both CD and UC). Participants will receive ustekinumab at study entry (Week 0) as treatment for IBD according to standard clinical practice and will be followed up to 24 weeks (+/- 3 weeks). Only data available per clinical practice will be collected within this study.
3252304|NCT01403922|Experimental|1|TC-5214
3367930|NCT03603275||Patient/caregiver of Kovaltry or Jivi|Patients who are switching factor replacement products to Kovaltry or Jivi and patients who have switched factor replacement products to Kovaltry or Jivi previously
3252305|NCT01403922|Experimental|2|TC-5214 with placebo
3252306|NCT01403922|Experimental|3|TC-5214 with placebo
3367931|NCT03603275||Physician Group|Physicians participating in the study are associated with US hemophilia treatment centers that are affiliated with the ATHN hemophilia treatment center network
3367932|NCT03598777|Experimental|Dysport - Dose Escalation stage 1|Intramuscular injection of Dysport on day 1 of each cycle.
3367933|NCT03598777|Placebo Comparator|Placebo - Dose Escalation stage 1 and Dose Expansion stage 2|Intramuscular injection on day 1 of cycle 1.
3367934|NCT03598777|Active Comparator|Dysport - Dose Expansion stage 2|Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.
3367935|NCT03597126|Active Comparator|robot-assisted ISR|Patients with low rectal cancer undergo intersphincteric resection assisted by Robotic
3367936|NCT03597126|Active Comparator|laparoscopic ISR|Patients with low rectal cancer undergo laparosocopic intersphincteric resection
3252307|NCT01403922|Experimental|4|TC-5214
3252308|NCT01403948|Experimental|Patients with relapsed or refractory NHL|Adult patients with relapsed or refractory non-Hodgkin lymphoma of B cell origin after at least two prior treatments
3252309|NCT01403961||HbA1c > 7|Diabetic patients with HbA1c > 7
3252310|NCT01403961||HbA1c ≤ 7|Diabetic patients with HbA1c ≤ 7
3252311|NCT01403974|Experimental|Monotherapy|BI 836845 dose escalation, infusion, once every week, monotherapy
3252312|NCT01404000|Active Comparator|Iodinated Active Charcoal|Iodinated activated charcoal 3 gram daily in the morning for 56 days +- 2 days (=8 weeks)
3252313|NCT01404000|Placebo Comparator|non-iodinated activated charcoal|3g non-iodinated activated charcoal is given daily for 8 weeks
3252314|NCT01404013|Active Comparator|Montelukast|Monotherapy with Montelukast 10mg, take orally ,every night,for 8 weeks
3252315|NCT01404013|Active Comparator|ICS/LABA and Montelukast|Combination therapy with inhaled corticosteroid/β2 agonist 160/4.5ug,twice a day and Montelukast 10mg，take orally,every night for 8 weeks
3367937|NCT03596645|Experimental|Group 1: Golimumab|Participants will receive subcutaneous (SC) golimumab through Week 50. Doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
3367938|NCT03596645|Experimental|Group 2: Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
3367939|NCT03593252|Experimental|Combination bowel prep|"Patients will received mechanical bowel preparation (age appropriate dose, starting 2 days before surgery) and prophylactic oral antibiotics (3 doses, 1 day before surgery).~Clear fluids (or breast milk if applicable) will be given starting day before surgery.~The standard care will also be delivered (NPO for anesthesia and intravenous antibiotics on induction) Patients/parents will be provided with stool diary to document the adequacy of preparation. This will include frequency and character of stool according to Bristol grade. The treating surgeon will rate the adequacy of the preparation intra-operatively."
3367940|NCT03593252|Active Comparator|Oral antibiotics|The patients will receive prophylactic oral antibiotics (3 doses, 1 day before surgery)as well as standard care (NPO for anesthesia and intravenous antibiotics on induction).
3367941|NCT03593252|Placebo Comparator|No prep|Patients will receive no pre-operative bowel prep. The will receive the standard care only.
3367942|NCT03582488|Experimental|Dementia with Lewy Bodies|18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology
3367943|NCT03574792|Active Comparator|Arm I (gabapentin, methadone, oxycodone)|Participants receive gabapentin PO daily or TID. Participants may also receive methadone PO TID and oxycodone PO every 8 hours as needed. Treatment continues for up to 12 months in the absence of disease progression or unacceptable toxicity.
3367944|NCT03574792|Experimental|Arm II (gabapentin, methadone, oxycodone, venlafaxine)|Participants receive gabapentin, methadone, and oxycodone as in Arm I and venlafaxine PO BID or venlafaxine hydrochloride extended release daily for up to 12 months in the absence of disease progression or unacceptable toxicity.
3367945|NCT03559270|Experimental|Baricitinib|Baricitinib administered orally.
3252316|NCT01404013|Active Comparator|ICS/LABA|Monotherapy with corticosteroid/β2 agonist 160/4.5ug,inhaled, twice a day, for 8 weeks
3252317|NCT01404026|Active Comparator|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
3252318|NCT01404026|Sham Comparator|Sham tDCS|Subjects will undergo sham tDCS stimulation, where the current is only active for 30 seconds.
3252319|NCT01404052|Experimental|Active tDCS + transcranial ultrasound|Subjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
3367948|NCT03550573|Experimental|hypertrophic cardiomyopathy without sudden death history|
3367949|NCT03550573|Experimental|hypertrophic cardiomyopathy with sudden death history|
3252320|NCT01404052|Sham Comparator|Sham tDCS + transcranial ultrasound|Subjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
3252321|NCT01404065|Experimental|Active tDCS + visual illusion|Subjects will receive active tDCS while watching a visual illusion movie (legs walking on a treadmill). Stimulation will last for 20 minutes.
3252322|NCT01404065|Sham Comparator|Sham tDCS + visual illusion|Subjects will receive sham tDCS stimulation (30 seconds ramp up/ramp down) while watching a visual illusion movie (legs walking on a treadmill)
3367956|NCT03503318|Placebo Comparator|Placebo|Participants will receive an SC injection of placebo matching to TV-46000 at baseline and every 4 weeks (q4w) thereafter. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
3252323|NCT01404065|Other|Healthy Subjects|Healthy subjects will receive both interventions (active and sham) in a randomized and counterbalanced order. Each stimulation session will be at least 1 week apart to prevent carry-over effects
3367957|NCT03503318|Experimental|TV-46000 q1m|Participants will receive an SC injection of TV-46000 at baseline and q4w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 milligrams (mg)/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
3367958|NCT03503318|Experimental|TV-46000 q2m|Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
3252324|NCT01404091|Experimental|Cohort 1: 40 milligram (mg) LY2940094|"40 mg LY2940094 was administered orally, one time only (it was originally expected that 100 mg LY2940094 would be administered).~If the receptor occupancy (RO) for a given dose is lower than 50%, (time to maximum concentration [tmax] or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3252325|NCT01404091|Experimental|Cohort 2: 10 mg LY2940094|"The dose levels for subjects in Cohort 2 will be defined based on the results of the receptor occupancy (RO) data of previous cohort and the ongoing review of safety data. This dose was determined to be 10 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3252326|NCT01404091|Experimental|Cohort 3: 4 mg LY2940094|"The dose levels for subjects in Cohort 3 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 4 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3252327|NCT01404091|Experimental|Cohort 4: 20 mg LY2940094|"The dose levels for subjects in Cohort 4 will be defined based on the results of the receptor occupancy (RO) data of previous cohort(s) and the ongoing review of safety data. This dose was determined to be 20 mg, and was administered orally, one time only.~If the RO for a given dose is lower than 50%, (tmax or an optimal time window) then a higher dose will be administered to the next cohort whereas if the RO for a given dose is higher than 50%, then a lower dose will be administered to the next cohorts."
3252328|NCT01404104|Experimental|Temsirolimus (pre-surgery)|
3252329|NCT01404117|Experimental|Laquinimod 0.6|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 0.6 mg
3367964|NCT03471676||Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
3367965|NCT03450707|Experimental|Thiamine|Patients randomized to the thiamine arm will receive thiamine 500mg in 100mL of normal saline intravenously every 12 hours for 5 doses. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
3367966|NCT03450707|Placebo Comparator|Placebo|Patients randomized to placebo will receive 100mL normal saline intravenously every 12 hours for 5 doses. All other aspects of the protocol will be the same as in the experimental arm. Patients will be connected to a noninvasive monitor for measurement of global oxygen consumption (VO2) for at least 48 hours or until extubated, whichever comes first. Blood will be drawn at 0,6,12,24,72 and 168 hours for measurement of lactate, thiamine level, pyruvate dehydrogenase, NSE, S100 and other markers of organ injury. CPC-E score will be assessed prior to hospital discharge and at 30 and 90 days to evaluate differences in neurologic and functional impairment.
3367967|NCT03444870|Experimental|Gantenerumab|Gantenerumab will be administered as SC injections with gradual uptitration.
3367968|NCT03444870|Placebo Comparator|Placebo|Placebo will be administered as SC injections with gradual uptitration.
3367969|NCT03442192|Other|PrEP Care Anywhere Services|The PrEP Care Anywhere intervention adapts peer PrEP case management for virtual delivery and provides clinical services through a tele-health program, delivered by the same clinic providers. After an initial face-to-face intake clinical evaluation within the clinic, will then receive the remaining PrEP clinical evaluations via telemedicine using the HIPPA compliant polycom platform. Case management interventions will be conducted virtually via the PrEPme application, telephone consultation, text, or email.
3367970|NCT03440450|Experimental|Cohort 1: Treatment at 1.2 mg/m2|FF-10832 Gemcitabine Liposome Injection, 1.2 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
3367971|NCT03440450|Experimental|Cohort 2: Treatment at 2.4 mg/m2|FF-10832 Gemcitabine Liposome Injection, 2.4 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
3367972|NCT03440450|Experimental|Cohort 3: Treatment at 4.8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 4.8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
3367973|NCT03440450|Experimental|Cohort 4: Treatment at 8 mg/m2|FF-10832 Gemcitabine Liposome Injection, 8 mg/m2 administered intravenously (IV) on Days 1 and 15 of each 28-day cycle
3367974|NCT03435510|Other|Live Donor Champion|The Live Donor Champion program is the sole educational intervention for this trial. LDC consists of 6 monthly sessions of approx. 1 hour each. Each LDC session is led by a transplant physician or clinical coordinator. LDC sessions incorporate formal didactics, active-participant learning, personal stories, moderated group discussions, role-playing, and other skill-building exercises. LDC sessions are as follows: 1) education about ESRD, KT, and LDKT 2) communication skills building 3) Exploring social networks 4) sharing successful donor and recipient stories 5) encouraging candidate self-efficacy 6) Program Recap.
3252330|NCT01404117|Experimental|Laquinimod 1.2|GA 20 mg/1mL or an IFN-B preparation + oral daily administration of laquinimod 1.2 mg
3252331|NCT01404117|Experimental|GA or IFN + Placebo|GA 20 mg/1mL or an IFN-B preparation + oral daily placebo
3252332|NCT01404130|Experimental|Isotretinoin therapy|0.5-1mg /kg titrated by clinical need and tolerance of each patient according to normal clinical practice
3252333|NCT01404143|Active Comparator|Subscapularis Tenotomy|"This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.~After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity."
3252334|NCT01404143|Experimental|Subscapularis Peel|This treatment group will use a technique that involves elevation of the tendon off the bone in order to gain access to the shoulder.The subscapularis will be elevated from the lesser tuberosity.
3252335|NCT01404156|Active Comparator|Neoadjuvant Chemotherapy|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous intravenous infusionIV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2 PO BID (ECX)"
3367977|NCT03430934|Experimental|NAVI mapping with Indocyanine green|Participants will undergo their scheduled Mohs surgery with the addition of the NAVI mapping with ICG dye
3367978|NCT03424005|Active Comparator|Atezolizumab + Nab-Paclitaxel|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab + nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3367979|NCT03424005|Experimental|Atezolizumab + Nab-Paclitaxel + Tocilizumab|1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3367980|NCT03424005|Experimental|Atezolizumab + Sacituzumab Govitecan|1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3367981|NCT03424005|Active Comparator|Capecitabine|"2L CIT-naive participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
3367982|NCT03424005|Experimental|Atezolizumab + Ipatasertib|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab + ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
3367983|NCT03424005|Experimental|Atezolizumab + SGN-LIV1A|"2L CIT-naive participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
3367984|NCT03424005|Experimental|Atezolizumab + Selicrelumab + Bevacizumab|"2L-CIT-naive participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.~Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.~Enrollment is closed."
3367985|NCT03424005|Experimental|Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)|2L CIT-naive participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naive participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemotherapy (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3367986|NCT03409328|Experimental|HIV and substance use prevention|Participants in the intervention condition will receive an HIV and substance use prevention program for self-identified bisexual adolescent men. The intervention content will be developed through formative research during the initial phase of the study.
3252336|NCT01404156|Experimental|Neoadjuvant Chemoradiation|"1) -carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment."
3367987|NCT03409328|No Intervention|Waitlist|The control condition will be a waitlist.
3367988|NCT03406078|Experimental|Tezepelumab|Tezepelumab subcutaneous injection
3367989|NCT03406078|Placebo Comparator|Placebo|Placebo subcutaneous injection
3367990|NCT03397589|Experimental|CHW Arm|The intervention is community health worker (CHW) services. CHWs trained in oral health will be assigned to half of the sites. Participants in these sites will be offered four in-person visits and follow-up phone calls over 12-months. These visits can occur at the location of the family's preference (recruitment site, home, or mutually-agreed upon other location). A core curriculum of oral health topics will be covered during visits, with an emphasis on developing and sustaining healthy oral health management routines for the entire family.
3367991|NCT03397589|No Intervention|Wait-list Control Arm|This arm will receive usual care. After completion of the final data collection at one year, participants and sites allotted to this arm will be offered CHW services.
3367992|NCT03391479|Experimental|Avelumab and Best Supportive Care|"Avelumab will be given intravenously (by vein) at a dose of 10 mg/kg, once every 2 weeks~Best supportive care will be provided as required."
3367993|NCT03387553|Active Comparator|Lead In Phase - Arm A|Arm A: One Dendritic Cell Vaccine (DC1) per week x 3 weeks.
3367994|NCT03387553|Active Comparator|Lead In Phase - Arm B|Arm B: Two DC1 vaccinations per week (given 3 days apart i.e., Mon and Thurs or Tues and Friday) x 3 weeks.
3367995|NCT03387553|Experimental|Expansion Phase|DC1 vaccinations according to optimal vaccination schedule. Participants will receive a booster intranodal study vaccine at week 25 prior to receiving surgery. Participants will then undergo definitive curative surgery following completion of the neoadjuvant therapy, additional adjuvant locoregional/systemic therapy (as deemed appropriate by their treating physicians).
3367996|NCT03382574|Experimental|Arm I (denosumab, risk-reducing salpingo-oophorectomy)|Beginning within 3 days of menstrual cycle, patients receive denosumab SC every 4 weeks for 1-2 doses and undergo risk-reducing salpingo-oophorectomy 14-28 days after last dose.
3367997|NCT03382574|Active Comparator|Arm II (risk-reducing salpingo-oophorectomy)|Patients receive no treatment for 2-8 weeks and then undergo risk-reducing salpingo-oophorectomy.
3367998|NCT03382561|Experimental|Arm A (nivolumab, CE)|Patients receive nivolumab IV over 30 minutes on day 1, carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients continue to receive nivolumab IV over 30 minutes every 2 weeks for up to 2 years.
3367999|NCT03382561|Active Comparator|Arm B (CE)|Patients receive carboplatin IV over 30-60 minutes on day 1 or cisplatin IV over 60-120 minutes on day 1, and etoposide IV over 60-120 minutes on days 1-3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
3368002|NCT03373045||Cohort of US adults with severe asthma|To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
3368003|NCT03368066|Experimental|Hospitalized cirrhosis patients|Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency
3368004|NCT03365622|Active Comparator|IV acetaminophen and placebo pills|
3368005|NCT03365622|Placebo Comparator|placebo IV (normal saline) + oral acetaminophen|
3368006|NCT03361436|Experimental|Treatment (eribulin mesylate, IMRT, surgery)|Patients receive eribulin mesylate IV over 2-5 minutes on days 1 and 8 and undergo intensity-modulated radiation therapy QD 5 days a week beginning on day 8 of cycle 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may undergo surgery within 3-10 weeks after radiation therapy.
3368007|NCT03356483|Experimental|Psilocybin|Psilocybin (0.25mg/kg)
3368008|NCT03356483|Placebo Comparator|Niacin|Niacin (250mg)
3368009|NCT03345342|Experimental|PP1M: Transition Phase|Participants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
3368010|NCT03345342|Experimental|PP1M/PP3M: Maintenance Phase|All the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
3368011|NCT03345342|Experimental|PP6M or Placebo: Double-Blind Phase|Participants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
3252337|NCT01404169|Experimental|1|
3368012|NCT03345342|Experimental|PP3M: Double-Blind Phase|Participants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
3368013|NCT03344848|Experimental|Single Arm|Implanted with the Orion Visual Cortical Prosthesis System
3368014|NCT03337724|Experimental|Ipatasertib + Paclitaxel|
3368015|NCT03337724|Experimental|Placebo + Paclitaxel|
3368016|NCT03333655|Other|Checkpoint Inhibitor Therapy|Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.
3368017|NCT03318406||BTVA treated patients|Patients with heterogeneous upper lobe emphysema undergoing Bronchoscopic Thermal Vapor Ablation treatment
3252338|NCT01404169|Placebo Comparator|2|
3368022|NCT03289650|Active Comparator|Standard of care tacrolimus twice-daily|
3368023|NCT03289650|Active Comparator|Extended-release tacrolimus once-daily|
3368024|NCT03289273||uHCC patients treated with regorafenib|Patients with a confirmed diagnosis of uHCC and for whom a decision to treat with regorafenib has been made (by the treating physician)
3368025|NCT03285763|Experimental|Atezolizumab|Participants with Stage IIIb or State IV NSCLC who have progressed after standard systemic chemotherapy will receive atezolizumab until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
3252339|NCT01404182|Experimental|Influenza vaccination|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
3252340|NCT01404195|Experimental|Ensure Plus Advance, Supplement|Participating patients will be dispensed two bottles daily, one at breakfast and one in the evening, seven days a week.
3368027|NCT03281369|Active Comparator|1L-Control: mFOLFOX6 (Gastric Cancer)|Participants in the 1L Gastric Cancer Control arm will receive modified FOLFOX6 (mFOLFOX6) treatment consisting of 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin. Participants who progressed on treatment may have the option of receiving Atezolizumab + Cobimetinib treatment, provided they meet the eligibility criteria. No longer enrolling participants as of June 2018.
3252341|NCT01404195|No Intervention|Control|without supplementation
3368028|NCT03281369|Experimental|1L-A: mFOLFOX6 + Atezo + Cobi (Gastric Cancer)|Participants in the 1L-A Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab plus cobimetinib. No longer enrolling participants as of June 2018.
3368029|NCT03281369|Experimental|1L-A2: Atezo+mFOLFOX6 followed by Atezo+Cobi (Gastric Cancer)|Participants in the 1L-A2 Gastric Cancer arm will receive mFOLFOX6 treatment consisting of 5-FU, leucovorin and oxaliplatin in combination with atezolizumab during cycles 1 and 2 followed by atezolizumab plus cobimetinib during cycles 3 and beyond. No longer enrolling participants as of June 2018.
3368030|NCT03281369|Active Comparator|2L-Control: Ramucirumab + Paclitaxel (Gastric Cancer)|Participants in the 2L Gastric Cancer Control arm received ramucirumab plus paclitaxel. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
3368031|NCT03281369|Experimental|2L-1: Atezo + Cobi (Gastric Cancer)|Participants in the 2L-1 Gastric Cancer arm received atezolizumab in combination with cobimetinib. Enrollment completed as of October 2019.
3368032|NCT03281369|Experimental|2L-2: Atezo + PEGPH20 (Gastric Cancer)|Participants in the 2L-2 Gastric Cancer arm received atezolizumab in combination with PEGylated recombinant human hyaluronidase (PEGPH20). Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
3368033|NCT03281369|Experimental|2L-3: Atezo + BL-8040 (Gastric Cancer)|Participants in the 2L-3 Gastric Cancer arm received atezolizumab in combination with BL-8040. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
3252342|NCT01404247|Experimental|OCT imaging in neonates|OCT imaging of all neonates, 38-42 weeks, enrolled in this study
3252343|NCT01404273|Experimental|Meditation/Relaxation Response Training|
3252344|NCT01404286|Experimental|physical exercise|Experimental group: physical exercise Control group: no physical exercise
3368034|NCT03281369|Experimental|2L-4: Atezo + Linagliptin (Gastric Cancer)|Participants in the 2L-4 Gastric Cancer arm received atezolizumab in combination with linagliptin. Participants who progressed on treatment had the option of receiving Atezolizumab + Cobimetinib treatment, provided they met the eligibility criteria. Enrollment completed as of October 2019.
3252345|NCT01404286|No Intervention|Control group|
3252346|NCT01404299|Experimental|Supplementary Group|
3252347|NCT01404299|No Intervention|Control Group|
3252348|NCT01404312|Experimental|RPT plus INH Regimen (Arm A)|Participants received RPT (dosage based on their weight), 300 mg of INH, and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 4. During Weeks 5 to 36, participants did not receive any study medications.
3252349|NCT01404312|Active Comparator|INH Regimen (Arm B)|Participants received 300 mg of INH and 25 mg or 50 mg of pyridoxine (vitamin B6) each day during Weeks 1 to 36.
3252350|NCT01404338|Active Comparator|Active Arm|1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
3252351|NCT01404338|Placebo Comparator|Vehicle Arm|Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
3252352|NCT01404351|Experimental|PEAK PlasmaBlade|
3252353|NCT01404351|Active Comparator|Standard of Care|The Standard of Care arm will consist of the scalpel for the skin incision and traditional electrosurgery for subcutaneous dissection.
3252354|NCT01404364|Active Comparator|Intravitreal Triamcinolone|Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
3252355|NCT01404364|Active Comparator|Retrobulbar Chlorpromazine|Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
3252356|NCT01404377|Active Comparator|ropivacaine|treated group (ropivacaine infiltration)
3252357|NCT01404377|Placebo Comparator|placebo|placebo group : infiltration with saline solution
3252358|NCT01404390|Experimental|Arm 1|
3252359|NCT01404390|Experimental|Arm 2|
3252360|NCT01404403|Other|Stroke patients|
3252361|NCT01404442|Active Comparator|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
3252362|NCT01404442|Active Comparator|midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
3252363|NCT01404442|Placebo Comparator|placebo|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
3368035|NCT03281369|Experimental|1L-1:Atezo+Tiragolumab+Cisplatin+5FU(Esophageal Cancer Cohort)|Participants in the 1L-1 Esophageal Cancer arm will receive atezolizumab in combination with tiragolumab and chemotherapy.
3368036|NCT03281369|Experimental|1L-2: Atezo+Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-2 Esophageal Cancer arm will receive atezolizumab in combination with chemotherapy.
3368037|NCT03281369|Active Comparator|1L-Control: Cisplatin+5-FU (Esophageal Cancer Cohort)|Participants in the 1L-Control Eophageal Cancer arm will receive chemotherapy.
3368038|NCT03281369|Experimental|1L-3: Atezo+Tiragolumab (Esophageal Cancer Cohort)|Participants in the 1L-3 Esophageal Cancer arm will receive atezolizumab + tiragolumab treatment. Participants from the cisplatin + 5-FU esophageal cancer cohort arm may be permitted to enroll in this arm if they progress after receiving chemotherapy.
3368039|NCT03280563|Active Comparator|Stage 1: Fulvestrant|Participants will receive fulvestrant until unacceptable toxicity or disease progression according to RECIST v1.1.
3368040|NCT03280563|Experimental|Stage 1: Atezolizumab + Entinostat|Participants will receive doublet combination treatment with atezolizumab plus entinostat until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3368041|NCT03280563|Experimental|Stage 1: Atezolizumab + Fulvestrant|Participants will receive doublet combination treatment with atezolizumab plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3368042|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib|Participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
3368043|NCT03280563|Experimental|Stage 1: Atezolizumab + Ipatasertib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus ipatasertib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator. Prior to enrollment into this arm, the first 6 participants in the study will complete a safety run-in with atezolizumab plus ipatasertib.
3368044|NCT03280563|Experimental|Stage 2: Atezolizumab + Bevacizumab + Endocrine Therapy|Those who progress or experience unacceptable toxicity during treatment in Stage 1 may be eligible to enter Stage 2. Participants will receive triplet combination therapy with atezolizumab plus bevacizumab plus one of three endocrine therapies (fulvestrant, exemestane, or tamoxifen) selected by the physician. Treatment in Stage 2 will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3368045|NCT03280563|Experimental|Stage 1: Mandatory On-Treatment Biopsy|For experimental combination arms that demonstrate clinical activity during the preliminary phase, the Sponsor may open enrollment into a separate mandatory on-treatment biopsy cohort for that combination.
3252364|NCT01404455|Other|Normal pulse pressure|pulse pressure <60mmHg
3252365|NCT01404455|Other|Wide pulse pressure|pulse pressure ≥60mmHg
3252366|NCT01404468|Active Comparator|pulsed|
3252367|NCT01404468|Sham Comparator|control|
3368046|NCT03280563|Experimental|Stage 1: Atezolizumab + Abemaciclib + Fulvestrant|Participants will receive triplet combination treatment with atezolizumab plus abemaciclib plus fulvestrant until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3368047|NCT03276052|Experimental|Aclidinium Bromide 400 μg|One inhalation from the 400 μg Aclidinium Bromide inhaler.
3368048|NCT03275857|Other|Cisplatin|
3368049|NCT03265145|Experimental|Stiolto Respimat|
3368050|NCT03265145|Active Comparator|ICS plus LABA plus LAMA (triple therapy)|ICS (Inhaled Corticosteroid) plus LABA (Long-Acting Beta Agonist) plus (Long-Acting Muscarinic Antagonist)
3252368|NCT01404468|Active Comparator|continuous|
3252369|NCT01404481||Single use group|New catheter for each Clean Intermittent Self Catheterisation (CISC), then discard.
3368054|NCT03219437|Active Comparator|Methotrexate|Participants to receive double-blind methotrexate.
3368055|NCT03219437|Experimental|Risankizumab|Participants to receive double-blind risankizumab.
3252370|NCT01404481||Re use of catheters group|"Use same catheter for 1week- Cleaning with sunlight liquid soap, air dry or dry with lint free towel, store in a snap lock bag.~Discard catheter and snap lock bag at end of each week."
3252371|NCT01404507|Active Comparator|Intracoronary abciximab|Intracoronary injection of bolus abciximab
3252372|NCT01404507|Active Comparator|Aspiration thrombectomy|Aspiration thrombectomy
3252373|NCT01404507|Active Comparator|Both use|Both use of intracoronary injection of bolus abciximab and aspiration thrombectomy
3252374|NCT01404520|Experimental|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme
3252375|NCT01404520|No Intervention|Control Group|Control group receives usual care
3252376|NCT01404533|Experimental|Iron supplement without food|
3368056|NCT03218995|Experimental|Eteplirsen|Eteplirsen will be administered once every 7 days by intravenous (IV) infusion starting on Day 1 for up to 96 weeks. The starting dose will be 2 milligrams/kilogram (mg/kg) eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg for 10 weeks, and then participants will continue to receive eteplirsen at 30 mg/kg for the duration of the study.
3368057|NCT03218488||Participants 6-18 years of Age With Moderate to Severe Plaque Psoriasis|All Participants diagnosed with moderate to severe plaque psoriasis who will either start therapy with ustekinumab within 2 months after the first assessment in the study or have started therapy with ustekinumab in the 12-week period before the first assessment in the study as per routine clinical practice, will be monitored for the long-term safety of ustekinumab and long-term effects of ustekinumab on growth and development. The primary data source for the study will be the medical records of participants and standardized questionnaires (completed by the physician and by the participant/parent).
3252377|NCT01404533|Experimental|Iron supplement with food|
3368061|NCT03211546||Femoral shaft fracture|Patients (children up to 16 years old) diagnosis of isolated closed femur shaft fracture (3.2-D) and open distal physis. Treatment strategies will follow standard of care (routine) procedures, either conservative (non-surgical) treatment or surgical treatment.
3252378|NCT01404533|Experimental|Iron fortificant with food|
3252379|NCT01404546|Experimental|Cost Free Pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
3368063|NCT03202537|Experimental|dexlansoprazole|dexlansoprazole 90mg per day (60mg am, 30mg pm dosing) for 4 weeks
3368066|NCT03199040|Experimental|Neoantigen DNA vaccine + Durvalumab|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days~For patients who are randomized to the neoantigen DNA vaccine plus durvalumab arm, the neoantigen-specific T cell response will be assessed prior to Day 85. If a neoantigen-specific T cell response is present, durvalumab will be started on Day 85, and will be administered Q4W at a dose of 1500 mg over the course of 60 minutes. If a neoantigen-specific T cell response is not present, these patients will be replaced but may continue to receive the neoantigen DNA vaccine on study. They will not be transferred to the vaccine-only arm."
3368067|NCT03199040|Experimental|Neoantigen DNA vaccine|"The first neoantigen DNA vaccine injection will take place following the completion of standard of care therapy. The day of the first vaccine injection will be referred to as Day 1~The schedule of vaccination is Day 1, Day 29 ± 7, Day 57 ± 7, Day 85 ± 7, Day 113 ± 7, and Day 141 ± 7 with at least 21 days between injection days"
3368068|NCT03198052|Experimental|CAR-T cell therapy group|Patients will receive 3 or more cycles of the CAR-T cells treatment via systemic or regional injection, from 1x10e6/kg-10x10e6/kg weight.
3252380|NCT01404546|Active Comparator|Usual Care Group|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
3252381|NCT01404585|Placebo Comparator|Arm 1: Placebo|
3252382|NCT01404585|Experimental|Arm 2: BMS-817399 (200 mg)|
3252383|NCT01404585|Experimental|Arm 3: BMS-817399 (400 mg)|
3252384|NCT01404598|Experimental|naproxcinod 750 mg bid|
3252385|NCT01404598|Experimental|naproxcinod 3000 mg od|
3252386|NCT01404598|Active Comparator|naproxen 500 mg bid|
3252387|NCT01404637|Experimental|Tamsulosin 0.4mg|
3252388|NCT01404637|Active Comparator|tamsulosin 0.2mg|
3252389|NCT01404663|Experimental|stem cell recipients|The 4-12 years old patients with cerebral palsy who undergone bone marrow derived CD133 transplantation
3252390|NCT01404676|Experimental|Vildagliptin + Metformin|Adding Vildagliptin to metformin users
3252391|NCT01404676|Active Comparator|Glimepiride + Metformin|Adding Glimepiride to metformin users
3252392|NCT01404689|Experimental|Midazolam-Meperidine-Dexmedetomidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and dexmedetomidine 1μg/Kg•hr infusion (30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
3252393|NCT01404689|Sham Comparator|Midazolam-Meperidine|midazolam 0.06mg/kg IV bolus, meperidine 50mg IV bolus and placebo(saline) infusion(30% reduction of midazolam dose and 25mg of meperidine for patients 65 years of age or older)
3252394|NCT01404702|Experimental|Zoledronic Acid and Interleukin-2|
3252395|NCT01404715|Experimental|Metformin and Imatinib Co-Adminisdered|Subjects will be dosed with Metformin (1850 mg) in conjunction with imatinib (600mg).
3252396|NCT01404715|Experimental|Metformin Alone|Subjects will be dosed with Metformin alone (1850mg)
3252397|NCT01404728||Pelvic Malignancies|Women with Vaginal Stenosis
3252398|NCT01404741|Active Comparator|5-azacytidine treatment until progress|5-azacytidine until progress
3252399|NCT01404741|Experimental|allogeneic stem cell transplantation|after 4 cycles 5-azacytidine and if donor available: allogeneic stem cell transplantation after reduced intensity conditioning
3368069|NCT03197935|Experimental|Atezolizumab and Chemotherapy|Participants received atezolizumab (840 milligrams [mg]) via intravenous (IV) infusion every 2 weeks in combination with nab-paclitaxel (125 milligrams per square meter [mg/m^2]) via IV infusion every week for 12 weeks, followed by atezolizumab (840 mg) every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants continued to receive unblinded atezolizumab post-surgery at a fixed dose of 1200 mg by IV infusion every 3 weeks for 11 doses, for a total of approximately 12 months of atezolizumab therapy.
3368070|NCT03197935|Placebo Comparator|Placebo and Chemotherapy|Participants received placebo matched to atezolizumab via IV infusion every 2 weeks in combination with nab-paclitaxel (125 mg/m^2) via IV infusion every week for 12 weeks, followed by placebo matched to atezolizumab every 2 weeks in combination with doxorubicin (60 mg/m^2) and cyclophosphamide (600 mg/m^2) every 2 weeks via IV infusions with filgrastim/pegfilgrastim support for 4 doses. Participants will be unblinded post-surgery and will continue to be followed.
3252400|NCT01404754|Placebo Comparator|Lactose (Inactive Placebo)|Participant receives inactive placebo during day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
3252401|NCT01404754|Active Comparator|3,4-methylenedioxymethamphetamine|Participant receives 125 mg MDMA possibly followed by 62.5 mg MDMA during a day-long experimental session. Mood, interpersonal closeness, psychological symptoms are measured before, during and after the session, and vital signs (blood pressure, heart rate, body temperature) are measured during the session.
3368071|NCT03190915|Experimental|Treatment (trametinib)|Patients receive trametinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3368072|NCT03185819|Placebo Comparator|Oral Midazolam + Intranasal Placebo|Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
3368073|NCT03185819|Experimental|Oral Placebo + Esketamine 84 mg|Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
3368074|NCT03185819|Experimental|Oral Placebo + Esketamine 56 mg|Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
3368075|NCT03185819|Experimental|Oral Placebo + Esketamine 28 mg|Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
3368076|NCT03185663|Placebo Comparator|a pillow between the legs|
3368077|NCT03185663|Experimental|traction-stuck|
3368078|NCT03165734|Experimental|Pacritinib 200 mg BID|To receive pacritinib 200 mg twice daily (BID) orally, at the same time of day, with or without food
3368079|NCT03165734|Active Comparator|Physician's Choice (P/C) therapy|The Physician's Choice (P/C) therapy (limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib). The proposed P/C regimen for a patient must be selected prior to randomization.
3368080|NCT03164226|Other|Patient consulting for chest Pain in ED|Any patient ≥ 25 years consulting for chest pain in the emergency department from 8:00 am to 8:00 pm (for the unavailability of the endopat device during the guard).
3368082|NCT03150511|Experimental|Tesamorelin treatment|
3368083|NCT03150511|Placebo Comparator|Placebo|
3368084|NCT03150095|Experimental|Health coaching|Patients will work with a health coach to improve self-management skills
3368085|NCT03150095|No Intervention|Control|Patients will receive usual pre-transplant education to improve self-management skills
3368086|NCT03141346|Active Comparator|Control|A control health education program to promote general health and safety
3368087|NCT03141346|Experimental|Sugar Reduction Program Only|A health education program that focuses on sugar reduction
3368088|NCT03141346|Experimental|Sugar Reduction Program & Water Delivery|A health education program that focuses on sugar reduction and provides home bottled water delivery
3368091|NCT03114345|Other|Single arm|Measurement of interface pressure and Measurement of micro-vascularization related parameters
3252402|NCT01404767|Active Comparator|Metoprolol oral dose or Placebo infusion|
3368096|NCT03089918|Experimental|Part A (Healthy Adult Male Participants)|Participants will receive intravenous (IV) injection with 370 megabecquerel (MBq) 11C-JNJ-63779586 on Day 1 of Part A.
3252403|NCT01404767|Experimental|Esmolol infusion or Placebo oral dose|
3252404|NCT01404780|Experimental|The GlideScope (GVL)|
3252405|NCT01404780|Active Comparator|Macintosh direct laryngoscope (MDL)|
3252406|NCT01404793||Liver transplant recipient|
3252407|NCT01404806|Experimental|GSK1349572|
3252408|NCT01404819|Experimental|Experimental arm|Patients in this arm undergo anesthesia with Xenon.
3252409|NCT01404819|Active Comparator|Standard arm|Patients in this arm undergo standard anesthesia
3368097|NCT03089918|Experimental|Part B (Mild AD and Healthy age- and Gender-Matched Controls)|Participants will receive single IV injection of 11C-JNJ-63779586 on Day 1 of Part B followed by saline flush. During Part B, the dose may be reduced based on whole body dosimetric findings and image quality seen in Part A.
3252410|NCT01404845|Active Comparator|B: patients with wet AMD in one eye.|group B: patients with wet AMD in one eye. In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin.
3252411|NCT01404845|Active Comparator|A :patients without retinal pathology|"group A :patients without retinal pathology who underwent cataract surgery 1 month previously.~In each group, A and B, half the patients will be randomized in a subgroup to Nutrof Total, and the other half in a subgroup to a food supplement not containing Lutein and Zeaxanthin."
3368098|NCT03068819|Experimental|CIML NK cell after T cell DLT (Pilot Pediatric/Young Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, cytarabine, & G-CSF (FLAG) (or decitabine as an acceptable alternative) to be started 2-4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, & Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI & NK cell isolation on Day -1.~A 2nd cycle of therapy may be administered if the patient shows evidence of AML > 30 days after the administration of the 1st course of protocol therapy, & if they continue to meet the eligibility criteria. Salvage chemotherapy may be omitted before a second infusion of DLI & CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, & ML NK cells administered. This optional second cycle will be considered a re-treatment, with date of 2nd NK cell infusion considered a 2nd Day 0."
3368099|NCT03068819|Experimental|CIML NK cell after T cell DLT (Phase 2 Adult Cohort)|"The recipient will receive standard of care salvage chemotherapy consisting of fludarabine, cytarabine, & G-CSF (FLAG) (or decitabine as an acceptable alternative) to be started 2-4 weeks prior to the CIML NK cell infusion, with Day -1 the day of T cell DLI, & Day 0 denoting the CIML NK cell infusion day. The donor will undergo non-mobilized large volume (20L) leukapheresis on Day -2 or -1, anticipating processing for T cell DLI & NK cell isolation on Day -1.~A 2nd cycle of therapy may be administered if the patient shows evidence of AML > 30 days after the administration of the 1st course of protocol therapy, & if they continue to meet the eligibility criteria. Salvage chemotherapy may be omitted before a second infusion of DLI & CIML NK cells. In the setting of GVHD following the first cycle of therapy, the T cell DLI may be omitted, & ML NK cells administered. This optional second cycle will be considered a re-treatment, with date of 2nd NK cell infusion considered a 2nd Day 0."
3252412|NCT01404858||Patients undergoing IVF|
3252413|NCT01404871|Active Comparator|Randomization to ECIT or CMI|Randomized trial of clomipramine or escitalopram
3368102|NCT03048227|Experimental|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
3368103|NCT03048227|No Intervention|Control|Patients will manage their diabetes as usual as recommended by their care team.
3368104|NCT03042819|Experimental|Selinexor plus Doxorubicin|"Selinexor will be given by mouth (orally) once a week:~Dose Level -1 = 40 mg Dose Level 1 (Starting Dose) = 60 mg Dose Level 2 = 80 mg~Doxorubicin will be given by vein (intravenously) at a dose of 75 mg/m2 once every 3 weeks."
3368105|NCT03037385|Experimental|Phase 1 Dose Escalation|Multiple doses of pralsetinib (BLU-667) for oral administration.
3252414|NCT01404871|Active Comparator|Open label Duloxetine|Open label trial of duloxetine
3252415|NCT01404884|Experimental|SUPRACOR|Treatment arm consisting of patients with history of myopia or myopic astigmatism who are also diagnosed with presbyopia.
3368106|NCT03037385|Experimental|Phase 2 Dose Expansion|Oral dose of pralsetinib (BLU-667) as determined during Dose Escalation.
3368107|NCT03030222|Active Comparator|Empagliflozin|Empagliflozin 10 mg tab, once daily, for 12 weeks
3368108|NCT03030222|Placebo Comparator|Placebo|Empagliflozin matching placebo oral tablet, once daily for 12 weeks
3368109|NCT03029598|Experimental|Treatment (pembrolizumab, carboplatin)|Patients receive pembrolizumab IV over 30 minutes on day 1 and carboplatin IV over 30 minutes on days 8 and 15. Cycles repeat every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity.
3252416|NCT01404897|Experimental|Dietary Intervention: Control Diet|
3252417|NCT01404897|Experimental|Dietary Intervention: DASH-based diet|
3252418|NCT01404897|Experimental|Dietary Intervention: Modified DASH diet|
3252419|NCT01404910|Experimental|Apheresis|Apheresis using Liposorber LA-15 System
3252420|NCT01404962|Other|Group 1|
3252421|NCT01404975|Experimental|Paravertebral Block|Patients randomized to receive PVB will have a continuous thoracic paravertebral block using local anesthetic after trans-apical aortic valve replacement. The patient will be placed in lateral decubitus position and under aseptic conditions the skin entry points will be 2.5-3cm from the spinal processes of the vertebra at a level of the proposed surgical incision. A 17G Touhy needle will be inserted perpendicular to the skin until the transverse process is contacted. After negative aspiration test an initial bolus of 8ml of plain ropivacaine 0.5% will be administered. This will be followed by a continuous infusion of 0.2% ropivacaine at 10 mL/hr. For break through pain additional doses of ropivacaine will be administered as required.
3252422|NCT01404975|Active Comparator|Standard intravenous opioid analgesia|"Patient Controlled Analgesia (PCA) :~PCA: the patients who are randomized to PCA group will receive standard of care for this modality."
3252423|NCT01405014|Experimental|Relationship enhancement group|One group, all involved in the intervention
3368113|NCT02988817|Experimental|Enapotamab vedotin (HuMax-AXL-ADC)|All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)
3368114|NCT02968108|Experimental|Group1: Ustekinumab Dose Regimen 1|Subjects will receive a single intravenous (IV) induction dose of 3 milligram per kilogram (mg/kg) for subjects less than < 40 kilogram (kg) or 130 milligram (mg) for subjects greater than or equal to >= 40 kg at Week 0 followed by subcutaneous (SC) maintenance dose of 2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at week 8.
3368115|NCT02968108|Experimental|Group2: Ustekinumab Dose Regimen 2|Subjects will receive a single Intravenous (IV) dose of 9 mg/kg for subjects <40 kg or 390 mg for subjects >= 40 kg at Week 0 followed by SC maintenance dose of 2 mg/kg for subjects <40 kg or 90 mg for subjects >= 40 kg at week 8.
3368118|NCT02948647|No Intervention|Control Group|Will receive standard of care, which is general dietary advice
3368119|NCT02948647|Experimental|Intervention Group|Will receive standard of care as well as sugar-reduction education
3368120|NCT02942368|Experimental|tDCS|Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
3368121|NCT02914912||GALS symptomatic patients group|Patents With symptoms of chronic mesenteric ischemia shall be investigated with GALS.
3368122|NCT02892708|Active Comparator|Surgery|Surgical resection followed by radiation therapy
3368123|NCT02892708|Experimental|radiotherapy alone|radiotherapy after a brain biopsy
3368124|NCT02892604|Experimental|insulin delivery driven by inControl|"Closed-loop insulin delivery using inControl AP system is assessed for two weeks, 24/7.~Connection of continuous glucose monitoring (CGM) system and insulin pump to inControl AP platform, all wireless and wearable, in free-life conditions Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data."
3368125|NCT02880241|Experimental|Cohort 1A - P. vivax malaria|A single oral dose of up to 120mg MMV390048
3368126|NCT02880241|Experimental|Cohort 1B - P. falciparum malaria|A single oral dose of up to 120mg MMV390048
3368127|NCT02880241|Experimental|Cohort 2A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
3368128|NCT02880241|Experimental|Cohort 2B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
3368129|NCT02880241|Experimental|Cohort 3A - P. vivax malaria|A single oral dose (to be determined) of MMV390048
3368130|NCT02880241|Experimental|Cohort 3B - P. falciparum malaria|A single oral dose (to be determined) of MMV390048
3368131|NCT02877134|Experimental|Part I : Placebo|Participants will receive placebo Subcutaneously (SC) at Weeks 0, 2, 4, 6, 8, and 10. From Week 12 Placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in Crohn's Disease Activity Index (CDAI) or CDAI <150) will continue to receive placebo SC injections every 2 weeks from Week 12 through Week 22. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 400 mg SC at Week 12 and then JNJ-64304500 200 mg every two weeks from Week 14 through Week 22.
3368132|NCT02877134|Experimental|Part I : JNJ-64304500|Participants will receive JNJ-64304500 400 milligram (mg) SC at Week 0 then 200 mg SC every two weeks through Week 22.
3252424|NCT01405040||EV1000 Observational Group|Patient must have an indwelling femoral arterial catheter and central venous catheter considered necessary for routine clinical monitoring; Patient, or legal guardian, will give consent prior to study enrollment and data capture; Patient must be at least 18 years old; Patient height and weight are available prior to study.
3252425|NCT01405066|Experimental|Dose Reports and Educational Seminar|
3252426|NCT01405079|Experimental|Gefitinib|Gefitinib 250 mg/day oral daily
3252427|NCT01405079|Active Comparator|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
3252428|NCT01405092|Placebo Comparator|Standard volume management|patients on this arm will receive usual care volume management during continuous renal replacement therapy
3252429|NCT01405092|Active Comparator|continuous volume management|use of Critline, Hemametrics USA, in conjunction with continuous renal replacment therapy to determine volume removal
3252430|NCT01405105||Patients with Flares of IBD|Active flare of Crohn's or UC
3252431|NCT01405105||Control Group|Patients with quiescent Crohn's disease or UC
3252432|NCT01405118|Experimental|Metformin/CP-690,550|
3252433|NCT01405131|Experimental|methylprednisolone suspension|
3368133|NCT02877134|Experimental|Part II : Placebo|"Placebo SC at Weeks 0, 2, 4, and 8. From Week 12, placebo-treated participants who are in clinical response at Week 12 (>=100-point reduction from baseline in CDAI or CDAI <150) will continue to receive placebo at Weeks 12, 14, 16, and 20. Placebo -treated participants who are not in clinical response at Week 12 will receive JNJ-64304500 150 mg SC at Week 12 and then JNJ-64304500 75 mg at Weeks 14, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive placebo up to 52 weeks (for a total of up to 72 weeks of placebo in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ- 64304500. Participants receiving placebo during the LTE will stop receiving placebo."
3368134|NCT02877134|Experimental|Part II : JNJ-64304500 High Dose|"JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 high dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
3252434|NCT01405131|Active Comparator|methylprednisolone tablets|
3252435|NCT01405144|Active Comparator|5% 5-fluoruracil cream|30 patients will use 5% 5-fluoruracil cream, twice a day, during 3 weeks, in one randomized forearm
3368135|NCT02877134|Experimental|Part II : JNJ-64304500 Middle Dose|"JNJ-64304500 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 middle dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
3368136|NCT02877134|Experimental|Part II : JNJ-64304500 Low Dose|"JNJ-64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, and 20. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive JNJ-64304500 low dose up to 52 weeks (for a total of up to 72 weeks of JNJ-64304500 in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving JNJ-64304500 during the LTE will stop receiving study drug and will have a final safety follow-up visit 16 weeks after the last dose of study drug."
3368137|NCT02877134|Experimental|Part II : Ustekinumab|"Participants will receive tiered doses of Ustekinumab 260 mg (weight <=55 kg), Ustekinumab 390 mg (weight >55 kg and <=85 kg), Ustekinumab 520 mg (weight >85 kg) intravenously at Week 0 followed by 90 mg subcutaneously at Weeks 8 and 16. Participants who complete Part II 24 weeks assessment and may benefit from continued treatment in the opinion of the investigator are eligible to enter the Part II LTE in which they will continue to receive Ustekinumab up to 52 weeks (for a total of up to 72 weeks of Ustekinumab in Part II).~The study has been unblinded due to lack of sufficient efficacy of JNJ-64304500. Participants receiving Ustekinumab during the LTE will stop receiving study drug and will have a final safety follow-up visit after the last dose of study drug. However, participants receiving Ustekinumab in countries where Ustekinumab is not commercially available or approved for adult Crohn's disease were continued to receive Ustekinumab in the LTE."
3368139|NCT02832687|Active Comparator|normal saline|Patients will receive 100 milliliters of normal saline with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses in 24 hours. Blinded medication will be prepared by research pharmacist.
3252436|NCT01405144|Active Comparator|5% 5-fluoruracil peeling|The same 30 patients will be submitted to 4 applications of 5% 5-fluoruracil superficial peeling in the other forearm
3252437|NCT01405157|Experimental|methylprednisolone suspension|
3252438|NCT01405157|Active Comparator|methylprednisolone tablets|
3252439|NCT01405170|Experimental|methylprednisolone suspension|
3252440|NCT01405170|Active Comparator|methylprednisolone tablets|
3252441|NCT01405183||Renal Cell Carcinoma patients|Newly diagnosed (within 6 months) renal cell carcinoma patients in who a biopsy or surgery will be performed
3252442|NCT01405183||Colorectal cancer patients|Newly diagnosed (6 months) colon cancer patients
3252443|NCT01405209||Atrial Fibrillation|Patients who develop atrial fibrillation
3252444|NCT01405209||Non Atrial FIbrillation|Patients without atrial fibrillation
3252445|NCT01405222||Acute COPD exacerbation|Patients admitted in to hospital with an acute exacerbation of COPD
3252446|NCT01405235|Active Comparator|Arm B: Cisplatin/Topotecane|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
3252447|NCT01405235|Experimental|Arm A: Paclitaxel/Topotecan|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
3252448|NCT01405248|Experimental|Butylphthalide|Single center of the placebo control a double-blind randomized control study to evaluate Butylphthalide prevention stents restenosis effect
3252449|NCT01405248|Placebo Comparator|control|Placebo
3252450|NCT01405261|Experimental|NNC 0113-0987 (gastro)|
3252451|NCT01405261|Experimental|NNC 0113-987 (coated)|
3252452|NCT01405261|Experimental|NNC 0113-987 (i.v)|
3252453|NCT01405274|Experimental|Physiotherapy intervention|
3368140|NCT02832687|Experimental|acetaminophen|Patients 50kg or more will receive either 1000mg IV acetaminophen with the first dose given preoperatively in the holding area followed by re-dosing every four hours from that point up to a maximum of 4 doses or 4000mg in 24 hours. Patients <50 kg will receive 12.5mg/kg to a maximum of 75 mg /per kg/per day as per the label dose with repeat dosing Q4 hours. Blinded medication will be prepared by research pharmacist in 100mL of normal saline
3252454|NCT01405274|No Intervention|standard care|
3252455|NCT01405287|Experimental|Combo Stent|PTCA with Combo Stent
3368143|NCT02830477||BAY81-8973|Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis
3368144|NCT02819440|Active Comparator|Tadalafil|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the Tadalafil arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of Tadalafil (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the active comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
3252456|NCT01405287|Active Comparator|Everolimus Eluting Stent (EES)|PTCA with DES (Everolimus Eluting Stent: Xience V or Promus)
3252457|NCT01405300|Experimental|Peanut|
3252458|NCT01405300|Placebo Comparator|Control|
3368145|NCT02819440|Placebo Comparator|Placebo|Subjects will be randomized to one of two arms. 100 obese adult subjects will be randomized to the placebo arm following the screening visit. Beginning at their baseline visit, they will receive an oral daily dose of a placebo pill (20mg) that they will take for 12 weeks (through their completion of the study). After randomization has occurred, the placebo comparator subjects will undergo the following visit protocol: baseline visit (two half-days), an interim visit (6 weeks post-baseline), and a 12-week visit (two half-days).
3368146|NCT02789345|Experimental|Ramucirumab + Osimertinib|"Dose Finding: Ramucirumab given intravenously (IV) on day 1 every 2 weeks (Q2W) and osimertinib given orally daily during each 14 day cycle.~Expansion: Ramucirumab given IV on day 1 Q2W and osimertinib given orally daily during each 14 day cycle."
3252459|NCT01405326|Experimental|Adalimumab|Adalimumab treatment for 6 months
3252460|NCT01405326|Placebo Comparator|Pacebo|Corresponding placebo for active treatment group
3368147|NCT02789345|Experimental|Necitumumab + Osimertinib|"Dose Finding: Necitumumab given IV on days 1 and 8 every 3 weeks (Q3W) and osimertinib given orally daily during each 21 day cycle.~Expansion: Necitumumab given IV on days 1 and 8 Q3W and osimertinib given orally daily during each 21 day cycle."
3252461|NCT01405339|Experimental|Budesonide via MAD|The current standard of care at St. Paul's Sinus Centre is to administer budesonide via the Mucosal Atomization Device (MAD). Its believed that MAD is a better device than the standard nasal lavage (Budesonide diluted in saline and delivered via Nasal Irrigation Bottle)because its fine mist and higher concentration enhances absorption and improves bioavailability.
3252462|NCT01405339|Active Comparator|Budesonide via Sinus Rinse Bottle|Budesonide via Sinus Rinse Bottle is the most commonly used delivery method.
3252463|NCT01405352|Active Comparator|Non obese/ vitamin A|Non obese individuals with body mass index 18.5-24.9 kg/m2 who receive 25000 IU/day vitamin A for 4 months .
3252464|NCT01405352|Placebo Comparator|obese/ placebo|obese individuals with body mass index greator than 30 kg/m2 who receive 1 cap placebo per day for 4 months .
3252465|NCT01405352|Active Comparator|Obese/ vitamin A|obese individuals with body mass index greater than 30 kg/m2 who receive 25000 IU/day vitamin A for 4 months
3252466|NCT01405365|Experimental|Metronidazole|
3252467|NCT01405365|Placebo Comparator|Placebo|
3252468|NCT01405378|Experimental|Robot Therapy and Real Transcranial Direct Current Stimulation|This group will involve carrying out robot therapy and real transcranial Direct Current Stimulation (tDCS).
3252469|NCT01405378|Placebo Comparator|Robot Therapy and sham tDCS|Participants will be randomised to group 2 whereby they will carry out the same robot therapy programme however, receiving sham stimulation.
3252470|NCT01405391|Experimental|A|Patients will receive PM01183 on Days 1 and 8 q3wk (three weeks = one treatment cycle) as an i.v. infusion, starting at 3.0 mg/day, flat dose (FD), over a minimum total volume of 100 ml dilution (on 5% glucose or 0.9% sodium chloride) via a central catheter or over a minimum total volume of 250 ml via a peripheral line, over one hour (at a fixed rate) and through a pump device.
3252471|NCT01405404|No Intervention|No intervention control|Parents complete surveys only
3252472|NCT01405404|Experimental|parent training but no discount|parent enrolled in the parent training intervention but do not receive childcare discounts for attending
3252473|NCT01405404|Experimental|Parent training with discount|parents receive parent training and a childcare discount for attending
3252474|NCT01405417|Experimental|Peroral endoscopic myotomy|"Patients with achalasia who are designed to either have balloon dilatation or botulinum toxine injection, or to have surgical intervention (Heller myotomy) for therapy.~Peroral endoscopic myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips."
3252475|NCT01405430|Experimental|Bevacizumab + blood samples|
3252476|NCT01405443||Basic training|Theory lecture esophagogastroduodenoscopy (EGD). One hour simulator training for EGD. 30 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. One hour simulator training for Colonoscopy. 30 minutes supervised training. Supervised endoscopy. Group will be followed up for 2 weeks training time.
3368148|NCT02782104|Experimental|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585), ESKETINTRD3003 (NCT02493868), ESKETINTRD3004 (NCT02497287), or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
3368150|NCT02737215|Active Comparator|CPAP group|patients will receive CPAP therapy for the first 7 days after extubation from CABG
3368151|NCT02737215|No Intervention|Control Group|Patients will receive usal care
3368152|NCT02732275|Experimental|DS-3201b|
3368153|NCT02728726|Experimental|Treatment group|study drug (sugammadex) administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and patient is extubated.
3368154|NCT02728726|Placebo Comparator|Control group|placebo administered intravenously after routine reversal of anesthesia is performed and patient is extubated.
3368155|NCT02703220|Experimental|Hyperoxia|Determine the effect of sustained hyperoxia overnight vs room air overnight on ventilatory control during sleep, including the apneic threshold, carbon-dioxide reserve and chemosensitivity measured via pressure support ventilation (PSV) during (non-rapid eye movement sleep) NREM sleep.
3368156|NCT02703220|Experimental|Acetazolamide (ACZ)|Determine the effect of acetazolamide on cerebrovascular responsiveness to CO2 during wake and sleep. Participants will receive oral ACZ therapy for 7 days prior to the experimental night, on the night of the study and the subsequent night when polysomnography (PSG) will be performed.
3368157|NCT02703220|Experimental|Finasteride|Determine the effect of oral finasteride therapy vs placebo for 1 month on SDB and the AT and chemosensitivity during NREM sleep.
3368158|NCT02697123||antepartum and postpartum|This prospective, observational cohort study was designed to assess the incidence of VTE in patients hospitalized for Cesarean Section, Vaginal delivery or any antepartum indication.
3368159|NCT02678351|Experimental|Diagnostic (68Ga-PSMA PET/MRI)|Patients receive 68Ga-PSMA IV. Patients then undergo PET/MRI after 45 minutes of administration of radiopharmaceutical injection.
3368160|NCT02650986|Experimental|Cohort I (cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
3368161|NCT02650986|Experimental|Cohort II (decitabine, cyclophosphamide, TCR/dnTGFbetaRII)|Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.
3368162|NCT02644941|Experimental|Human Acellular Vessel (HAV)|The HAV is a tissue-engineered vascular conduit (6mm diameter) for hemodialysis access in patients with end-stage renal disease. It will be surgically implanted in the forearm or upper arm on Study Day 0.
3252477|NCT01405443||Intermediate training|Theory lecture EGD. Three hours simulator training for EGD. 60 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Three hours simulator training for Colonoscopy. 60 minutes supervised training. Supervised endoscopy. Group will be followed up for 4 weeks training time.
3252478|NCT01405443||Extended training|Theory lecture EGD. Five hours simulator training for EGD. 90 minutes supervised training. Supervised endoscopy. Theory lecture Colonoscopy. Five hours simulator training for Colonoscopy. 90 minutes supervised training. Supervised endoscopy. Group will be followed up for 6 weeks training time.
3368163|NCT02644941|Active Comparator|ePTFE|The comparator (one of two commercially available 6mm ePTFE grafts) will be surgically implanted in the forearm or upper arm on Study Day 0.
3368164|NCT02634307|Experimental|ALKS 8700|Oral capsules taken twice daily.
3368165|NCT02627274|Experimental|Part A: RO6874281 Monotherapy|Dose Escalation: RO6874281 will be administered as an intravenous (IV) infusion. The starting dose regimen of RO6874281 as a single agent will be 5 milligrams (mg) once weekly (QW). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
3252479|NCT01405482|Active Comparator|Botulinum Toxin Type A injection|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of BTX-A into the scalene muscles and pectoralis minor muscle under EMG guidance.
3252480|NCT01405482|Placebo Comparator|Normal Saline|Double-blind, randomized, placebo-controlled trial evaluating changes in pain, paresthesias, and function in subjects with TOS before, at six weeks, and four months following injection of placebo into the scalene muscles under EMG guidance.
3252481|NCT01405495||PTSD group|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3368166|NCT02627274|Experimental|Part B: RO6874281 in Combination with Trastuzumab|Dose Escalation: RO6874281 will be administered as an IV infusion. RO6874281 will be administered QW for the first 4 administrations, then Q2W. The standard dose for trastuzumab will be a loading dose of 6 milligrams per kilogram (mg/kg) followed by a maintenance dose of 4 mg/kg from Cycle 2 in a Q2W regimen. Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with trastuzumab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with trastuzumab for a maximum of 24 months.
3368167|NCT02627274|Experimental|Part C: RO6874281 in Combination with Cetuximab|"RO6874281 will be administered as an IV infusion. The starting dose regimen of RO6874281 in combination with cetuximab will be 5 mg QW for the first 4 administrations, then Q2W. Cetuximab will be administered Q2W at 500 milligrams per square meter (mg/m^2). Different regimens may be explored based on the emerging safety, PK, and PD data of RO6874281 and may be tested in parallel. Participants will be treated with RO6874281 in combination with cetuximab until disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 in combination with cetuximab for a maximum of 24 months.~Extension Phase: The MTD for RO6874281 was determined to be 10mg and therefore patients in the extension will be treated with 10mg RO6874281. Cetuximab and R06874281 will be administered weekly during induction phase (cycle 1 and cycle 2). Both IMPs will be administered Q2W starting in cycle 3."
3368168|NCT02576431|Experimental|Arm 1_NSCLC|Patients with solid non-small cell lung cancer (NSCLC) harboring NTRK fusions (arm closed)
3368169|NCT02576431|Experimental|Arm 2_Thyroid|Patients with solid thyroid tumors harboring NTRK fusions (arm closed)
3368170|NCT02576431|Experimental|Arm 3_Sarcoma|Patients with soft-tissue sarcoma harboring NTRK fusions (arm closed)
3368171|NCT02576431|Experimental|Arm 4_Colorectal|Patients with solid colorectal tumors harboring NTRK fusions
3368172|NCT02576431|Experimental|Arm 5_Salivary|Patients with solid salivary tumors harboring NTRK fusions (arm closed)
3252482|NCT01405495||Exposed without PTSD|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3252483|NCT01405495||Healthy Controls|Intervention 'MRI-based techniques (sMRI, fMRI, DTI, ASL)'
3368173|NCT02576431|Experimental|Arm 6_Biliary|Patients with solid biliary tumors harboring NTRK fusions (arm closed)
3368174|NCT02576431|Experimental|Arm 7_Primary CNS|Patients with solid tumors in the primary central nervous system (CNS) harboring NTRK fusions (arm closed)
3368175|NCT02576431|Experimental|Arm 8_Other tumors|Patients with e.g. kidney cancer, squamous cell cancer of head or neck or ovarian solid tumors harboring NTRK fusions
3368176|NCT02576431|Experimental|Arm 9_Solid tumors without confirmed NTRK fusion|Patients eligible for arms 1 to 8, but with documented NTRK fusion from a laboratory where CLIA or equivalent certification cannot be confirmed by the sponsor at the time of consent (arm closed)
3368177|NCT02576431|Experimental|Arm 10- Perspective cohort|Patients with melanoma, non secretory breast and colorectal cancer harboring NTRK fusions.
3368178|NCT02568449|Experimental|Treatment (nintedanib)|Patients receive nintedanib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3252484|NCT01405521|Experimental|M01ZH09 vaccine|
3252485|NCT01405521|Placebo Comparator|Vaccine placebo|
3252486|NCT01405521|Other|Ty21a vaccine|Positive control
3252487|NCT01405534||Central venous catheter|All patients who require the placement of a central venous catheter
3252488|NCT01405573|Active Comparator|A: Best Supportive Care|best supportive care
3252489|NCT01405573|Experimental|B: Sorafenib 400 mg, twice a day + Best Supportive Care|sorafenib + best supportive care
3252490|NCT01405586|Active Comparator|gemcitabine|
3252491|NCT01405586|Experimental|gemcitabine + cisplatin|
3252492|NCT01405599|Experimental|Control|Healthy subjects
3252493|NCT01405599|Experimental|Severe hepatic impairment|CTP class C
3252494|NCT01405599|Experimental|Moderate hepatic impairment|CTP class B
3252495|NCT01405599|Experimental|Mild hepatic impairment|CTP class A
3252496|NCT01405612|Experimental|Midazolam|Those subjects to receive Treatment A will receive a single dose of midazolam on Day 1 and will be discharged from the study unit on Day 2, at least 30 hours after midazolam dosing.
3252497|NCT01405612|Experimental|Ulimorelin|Those subjects to receive Treatment B will receive once daily ulimorelin on Days 1 to 5. Midazolam will be administered on Day 5 with the last dose of ulimorelin and subjects will be discharged from the study unit on Day 6, at least 30 hours after midazolam dosing.
3252498|NCT01405625|Active Comparator|AAAAI Action Plan|Asthma Action Plan from the American Academy of Allergy, Asthma, and Immunology
3368182|NCT02548351|Experimental|10 mg Obeticholic Acid|10 mg Obeticholic Acid daily for the remainder of the study
3368183|NCT02548351|Experimental|25 mg Obeticholic Acid|25 mg Obeticholic Acid daily for the remainder of the study
3368184|NCT02548351|Placebo Comparator|Placebo|One tablet daily for the remainder of the study
3368185|NCT02546622||Arm A Prospective|"Patients who are switching to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~These patients will be followed prospectively for up to 1 year."
3368186|NCT02546622||Arm B Retrospective|"Patients who have recently switched to a new Factor VIII and Factor IX Replacement Product for Hemophilia A and B which was FDA approved after January 1, 2013.~Patients must have switched products within the past 50 weeks at the time of enrollment.~These patients will be assessed retrospectively and/or followed prospectively for up to 1 year."
3252499|NCT01405625|Experimental|Asthma pictogram written action plan|Cartoon/pictogram-based written action plan sheet
3252500|NCT01405638|Experimental|Motivational Interviewing|The use of a one-on-one motivational interviewing counseling intervention, 4 visits over 5 months, focusing on changes to behavior related to blood pressure control.
3252501|NCT01405638|Experimental|Patient Navigation|The use of a patient navigation intervention to guide participants through the process of getting screened for colorectal cancer.
3252502|NCT01405638|Experimental|PLUS|This group receives both the motivational interviewing intervention and the patient navigation intervention.
3368187|NCT02542696|Experimental|APL-130277|APL-130277 sublingual thin film (10 mg, 15 mg, 20 mg, 25 mg, 30 mg and 35 mg)
3368188|NCT02499900|Experimental|Copaxone® 40 mg/mL|Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
3368189|NCT02499900|Active Comparator|Copaxone® 20 mg/mL|Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
3368190|NCT02489708|Experimental|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
3368191|NCT02481986|Experimental|Community health worker|Participants in this arm will be offered 10 home visits in a 12-month period from community health workers (CHWs). Visits will cover a core asthma curriculum and provide social support.
3368192|NCT02481986|Active Comparator|Certified asthma educator|Participants in this arm will be offered 2 education sessions with a certified asthma educator in the clinic at start of the study and again at 6-months. These sessions will be followed by a telephone call from the certified asthma educator several weeks after the sessions.
3252503|NCT01405651|Experimental|E|ONO-6950
3252504|NCT01405651|Placebo Comparator|P|Placebo
3252505|NCT01405664|No Intervention|Non-Weight Bearing x 6 weeks|
3252506|NCT01405664|Experimental|Immediate Weight-Bearing as Tolerated|
3252507|NCT01405677|Experimental|Epaxal 0.25 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3252508|NCT01405677|Active Comparator|Epaxal 0.5 mL|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3252509|NCT01405677|Active Comparator|Havrix Junior|Single intramuscular dose (M. deltoideus) given on Day 1 and at Month 6
3252510|NCT01405703||percuataneous plate fixation|an approach with three small longitudinal incisions
3252511|NCT01405703||open plate fixation|large transverse incision
3252512|NCT01405716|Active Comparator|Behavioral-Mindfulness|Mindfulness Meditation
3252513|NCT01405716|Placebo Comparator|Behavioral-Health|Health Education Class
3252514|NCT01405755|Experimental|National Vaccine Program Plus Radio|Appropriate complementary feeding messages delivered using: (a) nurses during the 1st National Vaccination Week (NVW); and (b) radio.
3252515|NCT01405755|No Intervention|Comparison (no intervention)|No complementary feeding messages delivered.
3252516|NCT01405807|Experimental|Alemtuzumab - high dose (60mg)|Alemtuzumab 30mg will be administered on Day 1 and Day 2 at 0 and 6 months
3252517|NCT01405807|Experimental|Alemtuzumab - low dose (30mg)|Alemtuzumab 15mg will be administered on Day 1 and Day 2 at 0 and 6 months
3252518|NCT01405833|Experimental|BG00010 (Neublastin)|Participants may be randomized to escalating doses of BG00010
3252519|NCT01405833|Placebo Comparator|Placebo|Participants may be randomised to a matching placebo
3252520|NCT01405846|Other|Gefitinib|Single arm study
3252521|NCT01405859||TS controls|10
3252522|NCT01405859||Non TS Controls|11
3368231|NCT02422550||participants undergoing radiation therapy & normal volunteers|
3368232|NCT02394548|Experimental|Contralateral Esophagus Sparing Technique (CEST)|IMRT with CEST and concurrent chemotherapy (any standard-of-care regimen)
3368233|NCT02349815||Group 1|Women prescribed JAYDESS in Sweden
3252523|NCT01405859||TS remission|0
3252524|NCT01405885|Experimental|Arm A - 0.9mg of INO-3605|
3252525|NCT01405885|Experimental|Arm B - 0.9mg of INO-3609|
3368234|NCT02329951||Epidural steroid injections|Patients will receive a single interlaminar epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 1.5 ml of saline or a transforaminal epidural steroid injection with 60 mg depomethylprednisolone, 1.5 ml of 0.25% bupivacaine and 0.5 ml of saline.
3368235|NCT02329951||Facet interventions|Patients will receive diagnostic medial branch (facet joint nerve) blocks with 0.5 ml of 0.5% bupivacaine. If they experience a positive block (> 50% pain relief lasting more than 3 hours), they will then receive radiofrequency denervation.
3368236|NCT02329951||Sacroiliac joint injections|Patients will receive a single SI joint injection on the affected side(s) with 40 mg depomethylprednisolone and 2 ml of 0.5% bupivacaine.
3252526|NCT01405885|Experimental|Arm C- 0.9mg of INO-3401|
3368237|NCT02303821|Experimental|Phase 1b: Dose Escalation 1|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising an R3 backbone of dexamethasone, mitoxantrone, PEG asparaginase, and vincristine.~Subjects will have a 1 week carfilzomib single agent Lead in Window prior to the Induction Cycle.~Subjects will receive a 4 week cycle of induction chemotherapy and have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
3368238|NCT02303821|Experimental|Phase 1b: Dose Escalation 2|"Subjects will receive carfilzomib in combination with induction chemotherapy, comprising a VXLD backbone of vincristine, dexamethasone, PEG asparaginase, and daunorubicin.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy and then have the option to receive a 4 week cycle of consolidation chemotherapy (Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if stable disease or better response is achieved at the end of the Induction Cycle."
3368239|NCT02303821|Experimental|Phase 2: Aged ≥ 12 months at screening|"All subjects aged ≥ 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a 4 week cycle of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 4 week cycle of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine) if subjects showed no disease progression at the end of the Induction Cycle."
3252527|NCT01405885|Experimental|Arm D- 0.3mg of INO-3609|
3252528|NCT01405885|Experimental|Arm E - 0.45mg each INO-3605 , INO-3609|
3252529|NCT01405885|Experimental|Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609|
3252530|NCT01405885|Experimental|Arm G - 0.9mg of INO-3609|
3252531|NCT01405885|Experimental|Arm H - 0.9mg of INO-3609|
3252532|NCT01405885|Active Comparator|Arm I - Seasonal influenza vaccine|
3252533|NCT01405885|Experimental|Arm J - 1.8mg of INO-3609|
3252534|NCT01405963|Experimental|Active Arm|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
3252535|NCT01405963|Placebo Comparator|Placebo Arm|Placebo comparator administered as a multiple IV doses in subjects with mild atopic asthma
3252536|NCT01405976|Active Comparator|1|NIV for severe OSA group
3252537|NCT01405976|Active Comparator|2|CPAP for severe OSA group
3252538|NCT01405976|Active Comparator|3|Life stile modification for severe OSA group
3252539|NCT01405976|Active Comparator|4|NIV for non-severe OSA group
3252540|NCT01405976|Active Comparator|5|Life stile modification for non-severe OSA group
3252541|NCT01405989|Experimental|Treatment arm A|darexaban, wash-out, ketoconazole + darexaban
3252542|NCT01405989|Experimental|Treatment arm B|ketoconazole + darexaban, wash-out, darexaban
3252543|NCT01406002|Experimental|Treatment arm 1|darexaban, wash-out, rifampicin + darexaban
3368240|NCT02303821|Experimental|Phase 2: Aged < 12 months at screening|"All subjects aged < 12 months at screening.~Subjects will receive the recommended phase 2 dose (RP2D) of carfilzomib determined in Phase 1b.~Subjects will receive a modified 5 week cycle (based on Interfant-06) of carfilzomib and induction chemotherapy comprising of a VXLD backbone of vincristine, dexamethasone, PEG asparaginase and daunorubicin. Subjects will then have the option to receive a 5 week cycle (modified based on Interfant-06) of carfilzomib in combination with consolidation chemotherapy Children's Oncology Group (COG) modified Berlin Frankfurt Münster (BFM) chemotherapy backbone (6 mercaptopurine, cyclophosphamide, cytarabine, PEG asparaginase, vincristine), if subjects showed no disease progression at the end of the Induction Cycle."
3368241|NCT02286154|Experimental|Hydroxyurea|"All enrolled participants will receive hydroxyurea, but upon enrollment, participants will be identified as part of the New Cohort or Old Cohort New Cohort participants include those who are not receiving hydroxyurea therapy upon study entry. Old Cohort participants include those who are already receiving hydroxyurea therapy upon study entry. New Cohort participants will have starting dose predicted using PK/PD data and Old Cohort participants will continue dosing per clinical guidelines."
3368242|NCT02269917|Experimental|Experimental Treatment Regimen|Participants will receive a single fixed dose combination (FDC) tablet containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg (D/C/F/TAF tablet), orally once daily, up to Week 48. After Week 48, all participants will continue to receive the D/C/F/TAF tablet in a 48 week extension phase (up to Week 96).
3252544|NCT01406028|No Intervention|Standard of Care|Standard of care includes discharge instructions from one of our IVF nurses regarding medications and timing of follow-up, at which point patients are told what day they need to return for their pregnancy test. Patients have access to phone numbers for their IVF nurses and physicians, as well as information about how to contact the social workers if additional support is needed. They also are provided the emergency phone numbers for after-hour calls to the fellow on call. However, during the time between the embryo transfer and the pregnancy test, the current standard of care is that contact between the patient and our team is patient-initiated.
3252545|NCT01406028|Active Comparator|Intervention phone calls|The intervention consisted of two phone calls from an IVF social worker during the time between embryo transfer and pregnancy test. The first phone call occurred between days 2-4 after transfer and the second phone call occurred between days 5 and 9 after embryo transfer. Standard language for introductions to phone calls and for voice mails was established prior to the start of the study.
3368243|NCT02269917|Active Comparator|Current Treatment Regimen|Participants will receive a boosted protease inhibitor (bPI) (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) up to Week 52. After Week 52, all participants will receive the D/C/F/TAF tablet in a 44 week extension phase (up to Week 96).
3368244|NCT02229344||Newly Diagnosed Moderate to Severe Ulcerative Colitis|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
3368245|NCT02225366|Experimental|Intra-Tumoral Injection of LL37|LL37 administered intratumorally in cutaneous or subcutaneous tumors at least 1 cm in diameter. Patients will receive weekly intratumoral injections of LL37 for up to 8 weeks. The injections will be given every 7 days (+/- 48 hours). Starting dose 250 µg/tumor.
3252546|NCT01406041||Diseases|1. Pituitary adenomas; 2. Craniopharyngioma; 3. Sellar germinoma; 4. Sellar tuberalis meningioma; 5. Hypophystis; 6. Sellar glioma; 7. Rathke's cleft cyst; 8. Hypothalamic hamartoma
3252547|NCT01406054|Experimental|neuromuscular training|subjects in this arm will be exposed to a neuromuscular warm-up before practices and games
3252548|NCT01406054|No Intervention|control|
3252549|NCT01406067|Experimental|Social Skills Training|
3252550|NCT01406067|Active Comparator|Play group|
3252551|NCT01406080|Active Comparator|Adapalene|Differin® gel 0.3% (adapalene Gel 0,3%)
3252552|NCT01406080|Active Comparator|Tretinoin|Tretinoin 0,05% emollient cream
3252553|NCT01406093||Candidemia patients|Patients with diagnosis of candidemia
3252554|NCT01406106|Experimental|Liquid yoghurt with plant stanol esters|"Dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g).~It also contains: proteins 1.8 g, carbohydrates 9.8 g, fat 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg."
3252555|NCT01406106|Placebo Comparator|Yoghurt without plant stanol esters|Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg.
3252556|NCT01406119|Experimental|ABT-806 Arm|
3252557|NCT01406132|Experimental|ASP015K|
3252558|NCT01406145|Experimental|ASP0777 low dose|ASP0777 low dose for 6 weeks
3252559|NCT01406145|Experimental|ASP0777 low dose, then high dose|ASP0777 low dose for 1 week and ASP0777 high dose for 5 weeks
3252560|NCT01406145|Experimental|ASP0777 high dose|ASP0777 high dose for 6 weeks
3368257|NCT02185560||BAY43-9006|NEXAVAR treatment group
3368260|NCT02162472||Adalimumab|Subjects will receive adalimumab as standard of care for psoriasis
3368261|NCT02162472||Methotrexate|Subjects will receive methotrexate as standard of care for psoriasis
3368262|NCT02143388|Experimental|Concurrent chemoradiation + adjuvant chemotherapy|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
3368263|NCT02143388|Active Comparator|Concurrent chemoradiation|IMRT combine with cisplatin concurrent chemotherapy
3368264|NCT02114372||CogState Brief Battery|Enrolled participants will be randomized in a balanced manner to CogState brief battery in both the Main Study and the SubStudy. CogState consists of four tasks that respectively measure the functions of attention, processing speed, visual learning, and working memory. The CogState Brief Battery is an approximately 15 minute computerized battery with demonstrated reliability, validity, and short term stability, that was developed expressly for maximal sensitivity to detect change. CogState can be administered via the internet or on a stand-alone computer and is available in over 50 languages.
3368265|NCT02114372||Clinical Drug Research Assessment System (CDR-AS)|Enrolled participants will be randomized in a balanced manner to CDR-AS in both the Main Study and the SubStudy. CDR-AS is fully automated system that targets the core aspects of cognitive function crucial for everyday behavior which are vulnerable to numerous insults including aging, fatigue, disease, pathology, trauma, diet, and pharmaceuticals. CDR-AS is an approximately 20-minute computerized battery designed to reliably measure changes in cognitive function in clinical trial situations.
3368266|NCT02114372||Delis Kaplan Executive Function System (DKEFS)|Enrolled participants will be randomized in a balanced manner to DKEFS in the Main Study and at one site of the SubStudy. The DKEFS is a paper and pencil measure of verbal and nonverbal executive functions that has been normed and validated for children and adults from 8-89 years of age. The measure consists of nine subtests. For the purposes of this study, the Trail Making Test (TMT) and Verbal Fluency subtests will be used.
3368267|NCT02114372||COGNITO|Enrolled participants will be randomized in a balanced manner to COGNITO at the other site of the SubStudy. COGNITO is an approximately 45 to 60 minute computerized neuropsychometric examination based on well-known cognitive tests designed for both cognition research and clinical assessment. COGNITO assesses reaction time, primary and working memory, visuospatial and verbal secondary memory, implicit learning, language skills, functional and semantic categorization of visual data, focused and divided attention, and crystallized intelligence. Responses are made via a tactile screen which permits the recording of response latency (deducting reaction time provides an estimation of information processing time).
3368268|NCT02091960|Experimental|Enzalutamide + Trastuzumab|Participants received 160 mg enzalutamide orally once daily and 6 mg/kg trastuzumab administered by intravenous infusion or subcutaneous injection every 21 days. Participants continued on treatment until disease progression, unacceptable toxicity or any other discontinuation criteria were met.
3252561|NCT01406145|Placebo Comparator|Placebo|Placebo for 6 weeks
3252562|NCT01406158|Experimental|Treatment A|
3252563|NCT01406158|Experimental|Treatment B|
3252564|NCT01406158|Experimental|Treatment T|
3252565|NCT01406171|Experimental|Isavuconazole and Midazolam|Isavuconazole three times per day (TID) for 2 days followed by once a day (QD) for 9 days. Midazolam single doses on days 1 and 12
3252566|NCT01406184|Experimental|Durham Connects Eligible Group|From July 1, 2009 - December 31, 2010, all even-birth-date residential births in Durham County, North Carolina were randomly assigned to receive the Durham Connects nurse home visiting program.
3252567|NCT01406184|No Intervention|Control Group|From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
3252568|NCT01406197|Experimental|Vaginal progesterone|vaginal 150 mg micronized progesterone cream delivered via a vaginal applicator; dosed daily (Prochieve, Columbia Laboratories)
3368269|NCT02035280||Elderly suffering of spine deformity|Spinal deformity patients over the age of 60 years undergoing elective surgery and requiring fusion of at least 5 levels.
3368270|NCT02021773|Experimental|LBR-101 High Dose|Subcutaneous High Dose LBR-101 Administered Monthly x 3
3368271|NCT02021773|Experimental|LBR-101 Low Dose|Subcutaneous Low Dose LBR-101 Administered Monthly x 3
3368272|NCT02021773|Placebo Comparator|Placebo|Subcutaneous Placebo Administered Monthly x 3
3368273|NCT02000219|Experimental|Oxabact OC5 capsule|"This is an open-label study so all patients will receive the active drug product, Oxalobacter formigenes, OC5. This will be administered as an enteric-coated capsules twice daily for 6 weeks of treatment.~In Germany, the protocol has been amended such that patients can receive OC5 for a further 3 year of continued treatment after the initial part of the study."
3368274|NCT01991184|Experimental|Dose-escalation|
3368275|NCT01957748|No Intervention|Standard of Care (SoC)|Subjects randomized to the Standard of Care Arm will receive their HIV clinic's current standard of care retention services.
3368276|NCT01957748|Active Comparator|SoC + ALERT Intervention|Subjects randomized into the ALERT Enhanced Retention Intervention Arm will receive SoC at the HIV clinic where subjects are seen. In addition to SoC, the Intervention arm will receive aggressive engagement efforts by the ALERT specialist to ensure visit continuity and retention into care. The ALERT specialist will also administer an education intervention consisting of 5 retention modules designed to improve HIV knowledge and self-efficacy, and will also monitor health care visits and intervene via methods to track, find, and re-engage patients during the study.
3252569|NCT01406197|Experimental|Topical progesterone|topical 150 mg micronized progesterone gel applied to abdomen via a novel applicator; dosed daily
3252570|NCT01406197|Experimental|Intramuscular progesterone|injected IM (upper arm or thigh via syringe) 50mg/day micronized progesterone (Watson Pharmaceuticals)
3252571|NCT01406210||Prospective Group|Those patients that will be consented and data collected prospectively
3252572|NCT01406210||Retrospective Group|Those charts that will be utilized to collect retrospective data, waiver of consent will be granted by the IRBs.
3252573|NCT01406236|Other|Transradial PCI|
3252574|NCT01406236|Other|Transfemoral PCI|
3252575|NCT01406249|Active Comparator|S-1,Cisplatin|
3252576|NCT01406249|Experimental|Capecitabine, Cisplatin|
3252577|NCT01406262|Active Comparator|Albiglutide + moxifloxacin placebo|Once weekly subcutaneous injection of albiglutide for 6 weeks plus oral tablet of moxifloxacin matching placebo on Days -1 and 40
3252578|NCT01406262|Active Comparator|Albiglutide matching placebo + moxifloxacin|Once weekly subcutaneous injection of albiglutide matching placebo for 6 weeks, given with oral 400mg moxifloxacin tablet on Day -1 and moxifloxacin matching placebo on Day 40, or weekly albiglutide matching placebo for 6 weeks plus oral moxifloxacin matching placebo on Day -1 then oral 400mg moxifloxacin on Day 40
3252579|NCT01406275||Pediatrics patients prescribed amoxicillin and clavulanate|Pediatrics patients prescribed amoxicillin and clavulanate for treatment of diseases other than otitis media during study period
3252580|NCT01406288||HUS epidemy in Bordeaux, E. coli of the O104H4 serotype|
3252581|NCT01406301||Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI|Patients with a discharge diagnosis of ACS (UA/NSTEMI or STEMI)
3252582|NCT01406314|Experimental|Intervention|Intravenous infusion for approximately 48 hours followed by subcutaneous injection
3252583|NCT01406327||Subjects prescribed ambrisentan|Subjects with pulmonary arterial hypertension (PAH) prescribed ambrisentan during study period
3252584|NCT01406340|Experimental|Normal subjects and subjects with Stage 3/4 renal function|Subjects will receive 5mg GSK1278863 for 14 days.
3252585|NCT01406340|Experimental|Subjects with Stage 5 renal function|Subjects will receive 5mg GSK1278863 for 15 days.
3368286|NCT01794403|Experimental|Extended Hypofractionation Radiotherapy (EHRT) Group|Participants in this group will receive the EHRT intervention over a period of 6 weeks.
3368287|NCT01794403|Experimental|Accelerated Hypofractionation Radiotherapy (AHRT) Group|Participants in this group will receive the AHRT intervention over a period of 2 weeks.
3368288|NCT01793662|Active Comparator|Open aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
3368289|NCT01793662|Experimental|Laparoscopic aortobifemoral bypass|Patients with aortoiliac occlusive disease (only, TASC Type D lesions) shall be randomized to either laparoscopic aortobifemoral bypass or open aortobifemoral bypass operation.
3368292|NCT01530997|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive 54 to 60 Gy of Intensity Modulated Radiotherapy (IMRT) with concurrent weekly intravenous cisplatin (30 mg/m2). Diagnostic imaging (CT and/or MRI) will be obtained 4 to 8 weeks after completion of CRT to assess response. All patients will have surgical resection of any clinically apparent residual primary tumor or biopsy of the primary site if there is no evidence of residual tumor and will undergo a limited neck dissection to encompass at least those nodal level(s) that were positive pre-treatment, 4 to 14 weeks after CRT.
3368293|NCT01521039||Allogeneic SCT recipients|Patients who are receiving allogeneic stem cell transplantation at the Ohio State University are eligible and will be consented for the study.
3368294|NCT01508078||Asthmatics|Otherwise healthy asthmatic subjects
3252586|NCT01406353|Active Comparator|Early Percutaneous Mitral Intervention|early elective percutaneous mitral commissurotomy within 3 months of enrollment
3252587|NCT01406353|No Intervention|Conventional Treatment|All patients in the conventional treatment group regularly visit their attending physicians at 3 monthly interval for maintenance of anticoagulation therapy or every year for annual re-evaluation. Patients who become symptomatic during follow-up are referred for percutaneous mitral commissurotomy or mitral valve surgery.
3252588|NCT01406366||Group 1|Group 1: 16 programs / 148 residents
3368295|NCT01508078||Healthy controls|Healthy individuals without evidence of pulmonary disease.
3368296|NCT01464892|Experimental|Imagery Rescripting|
3368297|NCT01464892|Active Comparator|STAIR plus Imagery Rescripting|
3368298|NCT01464892|No Intervention|Wait-list control|Participants from this arm are randomized to the two active conditions after 8 weeks of waiting.
3252589|NCT01406366||Group 2|Group 2: 16 programs / 142 residents
3252590|NCT01406379|Experimental|Prophylactic clip|Prophylactic clip
3368299|NCT01411345|Other|Phase 3 - Arm I: Standard Salvage Radiation Treatment (SSRT)|"Phase 3 total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.~this arm is closed"
3368300|NCT01411345|Experimental|Phase 3 - Arm II: Mapped Tumor Salvage RT (MTSRT)|"Phase 3 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).~this arm was continues as single arm phase 2"
3368301|NCT01411345|Experimental|Phase 2: Mapped Tumor Salvage RT (MTSRT)|Phase 2 Patients will receive the same treatment to the CTV of 68 Gy in 34 fractions and the Gross Tumor Volume (GTV) defined by functional imaging will receive 2.25 Gy per day for a total of 76.5 Gy (biological equivalent to 80 Gy in 2.0 Gy fractions assuming an α/β ratio of 3).
3252591|NCT01406379|Active Comparator|Detachable snare|Detachable snare
3368302|NCT01331616|Experimental|Bevacizumab (Avastin)|
3252592|NCT01406392|Active Comparator|Sublingual Misoprostol 12,5mcg|Sublingual misoprostol or placebo tablete will be administered for each six hours until the maximum dose of 100mcg or eight tablets.
3368305|NCT01109004|Active Comparator|Tandem auto transplant|Initial autologous transplant followed by a second autologous transplant and lenalidomide maintenance
3368306|NCT01109004|Active Comparator|RVD consolidation|Initial autologous transplant followed by lenalidomide, bortezomib and dexamethasone (RVD) consolidation and lenalidomide maintenance
3368307|NCT01109004|Active Comparator|Lenalidomide maintenance|Initial autologous transplant followed by lenalidomide maintenance
3368308|NCT01067521|Experimental|GA 40 mg / GA 40 mg|Also referred to as the 'Early Start' treatment arm, participants were administered glatiramer acetate (GA) 40 mg/mL by subcutaneous injection three times a week for 12 months during the Double-Blind Period, and then continued that treatment as open-label therapy until the drug was commercially available or development stopped.
3368309|NCT01067521|Placebo Comparator|Placebo / GA 40 mg|Also referred to as the 'Delayed Start' treatment arm, participants were administered placebo subcutaneous injections three times a week for 12 months during the Double-Blind Period, and then switched to GA 40 mg/mL subcutaneous injections three times a week as open-label therapy until the drug was commercially available or development stopped.
3368310|NCT01047319|Experimental|Experimental: Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
3368311|NCT00988052|Experimental|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
3368314|NCT00861705|Active Comparator|Arm I (paclitaxel, doxorubicin, cyclophosphamide)|Patients receive paclitaxel IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19.
3252593|NCT01406392|Active Comparator|Vaginal Misoprostol 25 mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets. Each pacient will receve at the same time a sublingual placebo tablet and vaginal misoprostol or sublingual misoprostol and vaginal placebo tablet. It will depend of the randomization.
3252594|NCT01406405||PEEK cages|Patients will have fusion surgery performed using polyetheretherketone (PEEK) cages
3368315|NCT00861705|Experimental|Arm II (paclitaxel, ddAC, bevacizumab)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive bevacizumab IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17.
3368316|NCT00861705|Experimental|Arm III (paclitaxel, ddAC, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10.
3368317|NCT00861705|Experimental|Arm IV (paclitaxel, ddAC, bevacizumab, carboplatin)|Patients receive paclitaxel and ddAC as in Arm I, bevacizumab as in Arm II, and carboplatin as in Arm III.
3368318|NCT00606346||Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
3368319|NCT00606346||No Biologics|Treatments will be prescribed according to investigator judgement.
3368320|NCT00603616|Placebo Comparator|1|Placebo pills
3252595|NCT01406405||Allograft spacers|Patients will have fusion surgery performed using allograft spacers
3252596|NCT01406418|Experimental|Cohort 1: CR6261|2 mg/kg CR6261
3368321|NCT00603616|Active Comparator|2|Rifaximin
3368322|NCT00594750||Asthma|People who have been diagnosed with Asthma
3368323|NCT00593905||Group 1|"GROUP 1~Patients have to be currently enrolled or previously enrolled in STRIDE FPH01, FPH01-XC FPH02, FPH02x, FPH03, FPH04 or FPH06.~WHO Group 1 Pulmonary arterial Hypertension: Idiopathic, Familial, Associated with (APAH) Collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, Drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) Associated with significant venous or capillary involvement, Pulmonary veno-occlusive disease, Pulmonary-capillary hemangiomatosis."
3252597|NCT01406418|Placebo Comparator|Cohort 1: Placebo|5% dextrose in water
3252598|NCT01406418|Experimental|Cohort 2: CR6261|5 mg/kg CR6261
3368324|NCT00593905||Group 2|"Group 2~Patients currently receiving bosentan or ambrisentan OR who have previously received bosentan or ambrisentan for greater than 4 (four) months.~WHO Group 1 Pulmonary Arterial Hypertension: Idiopathic, Familial, Associated with (APAH), collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, drugs and toxins (e.g., anorexigens, rapeseed oil, L-tryptophan, methamphetamine, and cocaine), other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, or splenectomy), associated with significant venous or capillary involvement, pulmonary veno-occlusive disease, or pulmonary capillary hemangiomatosis."
3368325|NCT00548912|Other|1 group - no arms|no arm just error message
3368326|NCT00508547||Guselkumab|Participants will receive guselkumab as prescribed by the physician according to standard of care for psoriasis.
3368327|NCT00508547||Infliximab|Participants will receive infliximab as prescribed by the physician according to standard of care for psoriasis.
3368328|NCT00508547||Ustekinumab|Participants will receive ustekinumab as prescribed by the physician according to standard of care for psoriasis.
3368329|NCT00508547||Biological Therapies|Participants will receive biological therapies other than infliximab, ustekinumab, guselkumab, and IL-17 inhibitors as prescribed by physician for psoriasis. Participants will not receive any intervention as a part of this study.
3368330|NCT00508547||Conventional Systemic Agents|Participants will receive conventional systemic agents as prescribed by the physician for psoriasis. Participants will not receive any intervention as a part of this study.
3368331|NCT00508547||IL-17 Inhibitor|Participants will receive an IL-17 inhibitor as prescribed by the physician according to standard of care for psoriasis.
3368332|NCT00501826|Experimental|Treatment (nelarabine and combination chemotherapy)|See Detailed Description
3368335|NCT00196742||Patients with Fabry disease|No experimental intervention is given. A patient with Fabry Disease will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.
3368336|NCT00196742||Pregnant women with confirmed diagnosis of Fabry|No experimental intervention is given. Pregnant women with confirmed diagnosis of Fabry that are participating in the Fabry Registry and consented to participate in the Fabry Sub-registry, regardless of whether she is receiving disease-specific therapy (such as ERT with agalsidase beta) and irrespective of the commercial product with which she may be treated.
3252599|NCT01406418|Placebo Comparator|Cohort 2: Placebo|5% dextrose in water
3252600|NCT01406418|Experimental|Cohort 3: CR6261|15 mg/kg CR6261
3252601|NCT01406418|Placebo Comparator|Cohort 3: Placebo|5% dextrose in water
3252602|NCT01406418|Experimental|Cohort 4: CR6261|30 mg/kg CR6261
3252603|NCT01406418|Placebo Comparator|Cohort 4: Placebo|5% dextrose in water
3252604|NCT01406418|Experimental|Cohort 5: CR6261|50 mg/kg CR6261
3252605|NCT01406418|Placebo Comparator|Cohort 5: Placebo|5% dextrose in water
3252606|NCT01406418|Experimental|Cohort 6: CR6261|30 mg/kg CR6261
3252607|NCT01406418|Placebo Comparator|Cohort 6 Placebo|5% dextrose in water
3368341|NCT05154175||Ottobock helmet|Infants treated with an Ottobock helmet
3368342|NCT05154162|Experimental|Experimental|Pelvic PSMA PET ± transperineal targeted prostate biopsy
3368343|NCT05154162|Other|Control|No pelvic PSMA PET + transperineal template prostate biopsy
3368344|NCT05154136|Experimental|Etrumadenant then Etrumadenant + Itraconazole|"Participants will receive the Treatment A (etrumadenant) followed by Treatment B (etrumadenant + itraconazole).~A washout period of 5 days will be maintained between the two treatments."
3368345|NCT05154123|Experimental|AT-527 + rosuvastatin (simultaneous) n=14|
3368346|NCT05154123|Experimental|AT-527 + rosuvastatin (staggered) n=14|
3368347|NCT05154110|Experimental|strength training group|the group will receive strength training
3368348|NCT05154110|Experimental|whole body vibration stretching group|the group will receive stretching on whole-body vibration
3368349|NCT05154084||Audit only|This group of sites will participate in the audit. No performance feedback will be provided during the period under study. Feedback will be provided at the end of the study period.
3368350|NCT05154084||Audit with feedback|This group of sites will participate in the audit, and receive a feedback intervention about their practice based on retrospective data about surgery performed before the start of the study period.
3368351|NCT05154071||ECMO VV dedicated unit|Patient having benefited from an ECMO within the structured care unit
3368352|NCT05154071||ECMO VV without dedicated unit|Patient having benefited from an ECMO without the structured care unit
3368353|NCT05154058|Active Comparator|Control: electrocautery|Primary patients with Osteoarthritis (OA) undergoing Total Knee arthroplasty (TKA) will be randomly assigned into either the control or investigational group. The control arm of the study will undergo medial sub periosteal release with electrocautery.
3368354|NCT05154058|Active Comparator|Investigational: sharp dissection.|Primary patients with OA undergoing TKA will be randomly assigned into either the control or investigational group. The investigational arm will undergo medial sub periosteal release using sharp dissection.
3368355|NCT05154045|Experimental|Experimental Formula|One 330 ml serving of study product
3368356|NCT05154045|Active Comparator|Test Meal|40 g Instant oatmeal
3368357|NCT05154032|Experimental|Traditional Float-REST Therapy|Participants will utilize sensory deprivation tanks.
3368358|NCT05154019|Experimental|Intervention|Line Managers from organisations in the intervention arm will complete a self-led online training course consisting of 5 modules, over a period of 5-6 weeks
3368359|NCT05154019|No Intervention|Waitlist Control|Line Managers from organisations in the intervention arm will receive no training. They will be given access to the online intervention at the end of a 3-month period.
3252608|NCT01406431|Active Comparator|Pitavastatin + Valsartan|Intervention: Drug: Pitavastatin, Valsartan
3252609|NCT01406431|Experimental|Livalo fixed combination drug|Intervention: Drug: Livalo® fixed combination drug
3368360|NCT05154006|Active Comparator|Active Control (Information only)|Women in the active control group receive instruction on safe carrying behaviors (reduce carried weight & use safe lifting techniques) and information about benefits when performing the behavior and reducing strain on the pelvic floor.
3368361|NCT05154006|Experimental|Individual promotion of self-efficacy|"The group Individual promotion of self-efficacy receives the same instructions and information on safe carrying behavior as the control group.~Additionally, this group will receive behavior change techniques (Michie et al., 2013) to increase self-efficacy (psychological activities to increase self-confidence / belief in own capability to reduce risks of carrying loads with own behavior)."
3368362|NCT05154006|Experimental|Promotion of self-efficacy + social support|"The group Promotion of self-efficacy + social support receives the same instructions for safe carrying behavior as the control group. The intervention will also include the same behavior change techniques to promote self-efficacy.~Additionally, a social partner from the same or neighboring household will be involved in the intervention activities. The partner will participate in the intervention activities and will be instructed to provide emotional, practical and informational social support."
3368363|NCT05153993|Experimental|Stretch fascia plantaris|
3368364|NCT05153993|No Intervention|Control group|
3368365|NCT05153980|Experimental|Blood Flow Restriction|Incorporation of Blood Flow Restriction within the warm-up routine.
3368366|NCT05153980|Active Comparator|Control Group|Warm-up routine without any special intervention (no Blood Flow Restriction).
3368367|NCT05153967||Pediatric Myeloablative allo-HSCT|Participants ages 4 to 17 years old with SCD who underwent or are scheduled to undergo myeloablative allo-HSCT.
3368368|NCT05153967||Pediatric Standard Disease-Modifying Therapy|Participants ages 4 to 17 years old with SCD who receive standard therapy.
3368369|NCT05153967||Adult Non-Myeloablative allo-HSCT|Participants ages 18 to 65 years old with SCD who underwent or are scheduled to undergo non-myeloablative allo-HSCT.
3368370|NCT05153967||Adult Standard Disease-Modifying Therapy|Participants ages 18 to 65 years old with SCD who receive standard therapy.
3368371|NCT05153954||Colorectal cancer patients|Patients who can be treated with either PME or TME and receive a primary anastomosis during surgery.
3252610|NCT01406470|Experimental|IVIG-SN™|Immune Globulin Intravenous (Human) 5% Liquid
3252611|NCT01406483|Other|CABG|
3368372|NCT05153941||Main Study (tier 1)|Observational Study -The main study (tier 1) comprises 3,510 subjects matched by age and gender at a group level and aged over 50 years with a study partner available to actively contribute to the study will be recruited from memory clinics and/or ongoing observational studies in 3 sites across Greece
3368373|NCT05153941||Tier 2|Observational Study- Sub-study at the baseline visit (Tier 2) Amyloid PET : groups (1), (2), (3), (4) as described below FDG PET : groups (1), (2), (3), (4) as described below More than 400 subjects comprised of (1) >100 of cognitively unimpaired with (A-, T-, (N)-) group, (2) >100 of cognitively unimpaired with (A+, T+, (N)- or A+, T+, (N)+) groups, (3) >100 of mild cognitive impairment with (A+, T+, (N)- or A+, T+, (N)+) groups and (4) >100 of mild cognitive impairment with (A-, T-, (N)-) group will take Amyloid PET and FDG PET as sub-study.
3252612|NCT01406496|Experimental|Timing of insulin administration|
3252613|NCT01406509|Experimental|children aged 2-5 years (1 dose)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 2-5 years, on day 0
3368374|NCT05153928||fibroid cases|Norethisterone acetate for 5 months
3368375|NCT05153928||adenomyosis|Norethisterone acetate for 5 months
3368376|NCT05153915|Experimental|Tacrolimus granules (Modigraf)|"The first dose of Modigraf should be administered in the morning within 24 hours after reperfusion. Participants will be treated with a Modigraf-based immunosuppressive regimen.~The initial daily dose of Modigraf is given in two divided doses (recommended interval 12 hours) postoperatively. Subsequent oral Modigraf doses will be adjusted by the investigator based on clinical evidence of efficacy, occurrence of AEs, and tacrolimus whole blood trough level."
3368379|NCT05153876||Participants|Participants filling in the questionnaires
3252614|NCT01406509|Experimental|children aged 6-23months (2 doses)|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccines of 0.5ml/dose for a person in 20 children aged 6-23 months old, on day 0, 28
3368382|NCT05153837|Experimental|oral water|Experimental group: oral administration of 500 ml of water.
3368383|NCT05153837|Active Comparator|intravenous|Active comparator: Administration of 500 mL of saline (NaCl 0.9%) administered by the venous route
3368384|NCT05153824||Healthy volunteers|Healthy volunteers
3368385|NCT05153811|Experimental|Non-Contingent Condition|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
3368386|NCT05153811|Experimental|mHealth and CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings. Participants will also interact with a mobile health application to facilitate drinking reduction.
3252615|NCT01406522|Placebo Comparator|Oral placebo|Inactive treatment
3252616|NCT01406522|Experimental|Oral tacrine|Oral tacrine
3252617|NCT01406548|Experimental|BPS804 dosing frequency 1|
3252618|NCT01406548|Placebo Comparator|placebo dosing frequency 1|
3252619|NCT01406548|Experimental|BPS804 dosing frequency 2|
3252620|NCT01406548|Placebo Comparator|placebo dosing frequency 2|
3252621|NCT01406548|Experimental|BPS804 dosing frequency 3|
3252622|NCT01406548|Placebo Comparator|Placebo dosing frequency 3|
3252623|NCT01406561|Experimental|OMS103HP-S|OMS103HP-S injected into vehicle irrigation solution for administration during meniscectomy surgery
3368387|NCT05153811|Experimental|CM|Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
3368388|NCT05153798||PerioMonitor Testing|117 Subject to be tested for Oral Inflammatory Load (OIL) with PerioMonitor. Same subjects to be tested for Oral Inflammation with the BOP method.
3368389|NCT05153785|Experimental|Lidocaine arm|The experimental arm will receive a bolus of 1,5mg/kg Lidocaine before induction of anesthesia, immediately followed by an infusion of 1,5mg/kg/h until 1 hour post surgery.
3368390|NCT05153785|Placebo Comparator|Placebo arm|The placebo arm will receive the same amount of normal Saline.
3368391|NCT05153772|Experimental|Pb212-DOTAMTATE|investigational radiotherapeutic drug targeting somatostatin receptor-positive neuroendocrine tumors
3368392|NCT05153759|Active Comparator|High protein|High protein diet (1.8g/kg body weight)
3368393|NCT05153759|Placebo Comparator|RDA protein|Protein content based on the recommended daily allowance (RDA- 0.8g/kg body weight)
3368394|NCT05153746|Experimental|3D colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in 3D colonoscopy arm:~Colonoscopist will switch the image to 3D imaging form and wearing special glasses to enhance the 3D imaging. The 3D mode will be maintained during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
3368395|NCT05153746|Active Comparator|Conventional colonoscopy|"Colonoscopy insertion under regular method. After reaching cecum, the subjects will be randomized into 3D or conventional colonoscopy.~Subjects in conventional colonoscopy arm:~Colonoscopist will use regular colonoscopy imaging form during the whole colonoscopy withdrawal. When encountering suspicious neoplasm, the colonoscopist can use any image-enhancing technique (such as NBI or indigo carmine dye) to assist the diagnosis and use standard resection procedure (such as polypectomy) to complete lesion resection if necessary. The procedure time, withdrawal time, adenoma detection rate will be recorded during the colonoscopy. The pathology specimen will be sent for histology examination and any adverse event after colonoscopy (such as bleeding or perforation) will be recorded after routine surveillance."
3368396|NCT05153733|Experimental|RIFRAM implant|RIFRAM implant
3252624|NCT01406561|Placebo Comparator|Vehicle Irrigation Solution|Vehicle Irrigation Solution
3252625|NCT01406587|Experimental|PP4001 50 mg|
3252626|NCT01406587|Experimental|PP4001 100 mg|
3252627|NCT01406587|Experimental|PP4001 200 mg|
3252628|NCT01406587|Placebo Comparator|Placebo|
3252629|NCT01406600|Active Comparator|rhCG 250mcg|For final oocyte maturation triggering in ART, rhCG 250mcg will be administrated.
3252630|NCT01406600|Experimental|rhCG 500mcg|For final oocyte maturation triggering in ART, rhCG 500mcg will be administrated.
3252631|NCT01406613||Particpants of previous TRIO study|All participants to this study are being observed as a follow up to a previous study which involved 4 arms. All participants to this follow up study will be subject to identical study procedures.
3252632|NCT01406626|Experimental|Peer Navigation Intervention Arm|"Subjects will receive the following peer navigation services:~1) 10 Navigator meetings: Navigators will meet with participants in person to teach linkage/retention skills and knowledge~2a) 2 Navigator accompaniment sessions: the peer navigator will accompany participants to HIV care appointment. Before and after the appointment, participants and navigators will review linkage and retention skills/knowledge and things that make it hard or easy for him/her to get regular HIV care~2b) Optional peer navigator accompaniment sessions: If the participant requests, the peer navigator will provide accompaniment to supportive HIV care appointments (one per month max)~3) 14 peer navigator care calls: During these calls, navigators and participants will talk about any problems that could make it difficult to get regular HIV care."
3368397|NCT05153720|Experimental|Ultrasound guided erector spinae plane block|Unilateral erector spinae plane block will be performed under ultrasound guidance
3368398|NCT05153720|Active Comparator|Ultrasound guided caudal block|Caudal block will be formed under ultrasound guidance
3368399|NCT05153707|Experimental|Clinical Pharmacist-led discharge education program|Clinical pharmacist-led services
3368400|NCT05153707|No Intervention|Control group|Usual care
3368401|NCT05153681||Peloid Therapy|Peloidotherapy is a special balneotherapy method made with natural mud. In both domestic and international scientific studies on peloid treatment, it has been shown that pain in patients decreases, physical functions improve, quality of life increases, and the amount of painkillers use decreases.
3368402|NCT05153681||Kinesio Tape|Kinesio tapes, which have been used in the conservative treatment of plantar fasciitis in recent years, are elastic tapes similar to the structural properties and flexibility of human skin, without limiting joint movements.
3368403|NCT05153681||Home exercise|In addition to the cold application, gastrocnemius and plantar fascia stretching and strengthening exercises were applied to patients with plantar fasciitis.
3368404|NCT05153668|Experimental|Adjuvant Everolimus After Surgical Dilation|Individuals will take low dose everolimus for 6 weeks after dilation.
3368408|NCT05153629|No Intervention|Standard care|Participants will follow standard care until the ureteral stent is removed
3368409|NCT05153629|Experimental|TENS device|Participants will use the TENS device until the ureteral stent is removed
3368410|NCT05153616|Experimental|Diagnostic Polysomnography|
3368411|NCT05153603||Olaparib mono-maintenance therapy group|Olaparib monotherapy in clinical practice and will be conducted in patients with tBRCAwt newly diagnosed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy following the standard of care from Aug 2018 up to Dec 2020 (the time range could be extended in order to recruit enough eligible subjects as required) at tertiary-referral university hospitals and main cancer centers in China.
3252633|NCT01406626|No Intervention|Usual Care|Participants assigned to the control arm will receive the transitional case management (TCM) services that are currently offered at the jail
3252634|NCT01406639|Experimental|Ranibizumab|Patients treated with topical ranibizumab.
3368414|NCT05153577|Active Comparator|Group A: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $5 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
3368415|NCT05153577|Active Comparator|Group B: Free produce box|Participants receive free weekly produce boxes for the first 4 weeks of the study and are then randomized to pay $10 per box (with continued free weekly delivery) for the remaining 4 weeks of the study.
3368416|NCT05153564|Experimental|One-sequence cross-over arm|
3368417|NCT05153551|Experimental|PEARS assessment|
3368420|NCT05153499|Active Comparator|CP101|
3368421|NCT05153499|Placebo Comparator|Placebo|
3368422|NCT05153486|Experimental|Group A|Circumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + driver ablation
3368423|NCT05153486|Active Comparator|Group B|Circumferential pulmonary vein isolation + linear ablation + vein of Marshall ethanol infusion
3252635|NCT01406665||increased diabetes risk|the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes
3368424|NCT05153486|Active Comparator|Group C|Surgical ablation
3368425|NCT05153460||Single Arm Study (Cohort)|"All participants will be on standard telemetry monitoring for Heart Rate and Respiration Rate using the gold standard (Electrocardiography and Capnography respectively).~In addition, two contactless monitoring devices will be placed on the patient bed to measure data simulataneously. These devices include EarlySense (USFDA approved ballistocardiography device) and Dozee VS (Investigational Device)."
3259453|NCT01470950|Experimental|MotionMaker Training|Device description: MotionMaker™ is a stationary robotic system for the active mobilization of the lower limbs. With its proprietary 'Closed-Loop' technology, it is a novel and exciting development that offers a truly interactive patient training system Training 3 times a week with MotionMaker device together with conventional treatment
3252636|NCT01406678|Active Comparator|RIPC|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 and 10 Minutes after aortic unclamping during reperfusion of the myocardium.
3252637|NCT01406678|Placebo Comparator|Control|Control group: Coronary artery bypass surgery without remote ischemic preconditioning protocol
3252638|NCT01406691|Experimental|Light|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
3368426|NCT05153447|Experimental|M-Tech|M-Tech involves the use of a mobile app delivery platform to several interventions. The components of M-Tech include: 1) Hybrid in-person and telehealth visits with oncology providers; 2) Disease-specific education videos; 3) Activity level monitoring via a wearable device with promotion of physical activity; 4) Symptom monitoring with provision of self-management strategies, and 5) Medication management.
3368427|NCT05153447|Active Comparator|Usual Care|Participants randomized to the usual care arm will receive standard of care.
3368429|NCT05153421|Experimental|Interventional - Angioplasty|Angioplasty and angiography procedures with experimental medical device
3368430|NCT05153408|Experimental|Part 1A: BLU-701 as monotherapy|Phase 1 dose escalation of BLU-701 as monotherapy at various dose levels
3368431|NCT05153408|Experimental|Part 1B: BLU-701 with osimertinib|BLU-701 in combination with osimertinib 40 mg or 80 mg tablets for oral administration
3368432|NCT05153408|Experimental|Part 1C: BLU-701 with platinum-based chemotherapy|"BLU-701 in combination with platinum-based chemotherapy (carboplatin and pemetrexed):~Carboplatin - IV infusion dosed to target AUC of 5-6 mg/mL min q3w~Pemetrexed - IV infusion dosed to 500 mg/m2 q3w"
3368433|NCT05153408|Experimental|Part 2A: BLU-701 as monotherapy|Phase 2 expansion group for BLU-701 as monotherapy at a dose determined during Part 1A in patients harboring the EGFR C797X resistance mutation
3368434|NCT05153395|Experimental|Insulin|Human insulin (160 IU) will be administered as a bolus using an intra-nasal device.
3368435|NCT05153382|Experimental|Youth with bipolar disorder|60 youth aged 13 to 23 with bipolar disorder (type I, type II, not otherwise specified/nos) will be enrolled in the dialectical behavioral therapy intervention.
3368436|NCT05153369|Experimental|Level 1|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with no lifetime suicidal behaviors and ideations will be enrolled in Level 1. Participants with a score of < 73 on the DERS AND a score of ≤ 8 on the CALS (youth report) will be enrolled in Level 1.
3252639|NCT01406691|Placebo Comparator|Fake light|during three hours immediately prior to desired waketime, subjects will receive no light (light flash device will be disabled)
3252640|NCT01406704|No Intervention|Control|
3368437|NCT05153369|Experimental|Level 2|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with < 3 lifetime non-suicidal self-injurious (NSSI) behaviors with one behavior occurring in the past 3 months or ≥ 3 lifetime NSSI behaviors with none in the past 3 months AND no lifetime suicide attempts (actual, interrupted and/or aborted) AND a score of ≥ 16 and < 24 on the SIQ AND lifetime suicidal ideations will be enrolled in Level 2. Participants with a score of ≥ 73 and < 105 on the DERS OR a score of > 8 and < 20 on the CALS (youth report) will be enrolled in Level 2.
3368438|NCT05153369|Experimental|Level 3|At enrollment, participants will be categorized according to suicidality, emotion dysregulation, risk behaviors, and participant preference. Participants with at least 1 lifetime suicide attempt (actual, interrupted, and/or aborted) OR ≥ 3 lifetime NSSI behaviors, with one behavior occurring in the past 3 months OR a score of ≥ 24 on the SIQ will be enrolled in Level 3. Participants with a score of ≥ 105 on the DERS OR a score of ≥ 20 on the CALS (youth report) will be enrolled in Level 3. Participants who meet youth threshold for at least 2 impulsive behavior categories on question #4 from the SIDP-IV or 1 category is identified as severe will be enrolled in Level 3.
3368439|NCT05153356||Parkinson Disease patients|To examine the relationship between in-home continuous measures of tremor, bradykinesia, mobility, and dyskinesia acquired over a 7-day period, from 2 mobile health technologies (Personal Kinetigraph, Kinesia 360) with one-time in-clinic measures of motor functional ability pertaining to the same 7-day period as assessed by Part 2 of the MDS-UPDRS, Part 4 of the MDS-UPDRS, Neuro-QOL, and PDQ-39. This will be examined in n=20 patients (10 patients assigned to each technology with a crossover at 3 months for a total of 20 patients over 6 months, 6 timepoints with data collected every 2 weeks). Patients will then be following for an observational period of an additional 6 months.
3368440|NCT05153343|Experimental|flonoltinib 25mg|1 case，The starting dose，Take the medicine once on D1 ，D 5 through 21.
3368441|NCT05153343|Experimental|flonoltinib 50mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
3368442|NCT05153343|Experimental|flonoltinib 100mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
3368443|NCT05153343|Experimental|flonoltinib 150mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
3368444|NCT05153343|Experimental|flonoltinib 225mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
3252641|NCT01406704|Experimental|Rosiglitazone|Rosiglitazone (8 mg/day)
3252642|NCT01406704|Experimental|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
3252643|NCT01406704|Experimental|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and alpha-lipoic acid (1800 mg/day)
3368445|NCT05153343|Experimental|flonoltinib 325mg|6 case，Increasing dose，Take the medicine once on D1 ，D 5 through 21.
3368446|NCT05153330|Experimental|Dose Escalation Phase|All study participants will receive BMF-219. Arm A: Subjects who are not receiving CYP3A4 inhibitors. Arm B: Subjects who are receiving CYP3A4 inhibitor
3368447|NCT05153330|Experimental|Dose Expansion|Subjects with relapsed/refractory acute leukemia will receive the Optimal Biologic Dose (OBD) or Recommended Phase 2 Dose (RP2D) of BMF-219 as determined from the Dose Escalation Phase of the study to further assess safety and tolerability of BMF-219 and to identify initial efficacy signals.
3368448|NCT05153317|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
3368449|NCT05153304|Experimental|anti-PD1, anti-CTLA4, and personalized vaccine|
3368452|NCT05153278||Control group|Patients that received standard treatment (packed red blood cells) for iron deficiency anemia
3368453|NCT05153278||Experimental group|Patients that received intravenous iron instead of standard treatment (packed red blood cells) for iron deficiency anemia
3368456|NCT05153252|Experimental|Morning Exercise (AM)|Participants in this group will be prescribed morning aerobic exercise.
3368457|NCT05153252|Experimental|Evening Exercise (PM)|Participants in this group will be prescribed evening aerobic exercise.
3368458|NCT05153239|Experimental|Lurbinectedin|Patients will consecutively receive lurbinectedin on Day 1 q3wk (every three weeks = one treatment cycle)
3368459|NCT05153239|Experimental|Lurbinectedin plus Irinotecan|"Patients will consecutively receive the following q3wk (every three weeks = one treatment cycle):~Irinotecan (Day 1 and Day 8)~Lurbinectedin (Day 1)"
3368460|NCT05153239|Active Comparator|Control arm|"Best Investigator's choice prior to randomization between:~Irinotecan on Day 1 q3wk~Topotecan on Days 1-5 q3wk"
3368461|NCT05153226|Experimental|Cyclophosphamide|Cyclophosphamide 50 mg/kg (AIBW) i.v. d+3, d+4 post transplant
3368462|NCT05153226|Active Comparator|ATG|ATG Grafalon 10 mg/kg i.v. d-3, d-2, d-1 pre-transplant
3252644|NCT01406730|Experimental|exercise|16 weeks of running exercise
3252645|NCT01406730|No Intervention|control|
3368463|NCT05153213|Experimental|Finger Lengths|Vernier caliper was used to determine the length of Index Finger to record Vertical Dimensions of Occlusion
3368464|NCT05153213|Active Comparator|Conventional method|Willis gauge was used to determine the Length from Base of the nose to Base of the chin to record Vertical Dimensions of Occlusion
3368465|NCT05153200|Experimental|Upadacitinib(Rinvoq)|Upadacitinib(Rinvoq) 15 mg po daily
3368466|NCT05153200|Active Comparator|Adalimumab(Idacio)|
3368467|NCT05153187||Patients with HR+/HER2- advanced breast cancer|
3368468|NCT05153174|Experimental|2 tablets of Sulforaphane|Participants will be given 2 extra strength tablets per day
3368469|NCT05153174|Experimental|4 tablets of Sulforaphane|Participants will be given 4 extra strength tablets per day
3368470|NCT05153174|Experimental|6 tablets of Sulforaphane|Participants will be given 6 extra strength tablets per day
3368471|NCT05153161|Experimental|Persons with ADRD living in a residential care facility|Each consented participant will receive the current Memesto device and will be provided formal and informal training instructions. After consent and screening, a two-week training period with a Memesto device will be followed by ten weeks of data collection. An experienced research assistant will administer the baseline NPI in order to collect the agitation ratings by the family caregiver, and the professional caregiver will be collected by a trained research assistant and captured in an electronic case report form designed using REDCap.14,15 Then, participants will undergo evaluation of the NPI agitation domain at 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 10 weeks. Adverse events related to the device will be collected from the family and professional caregivers. Human centered system designers will work with the operations team to enhance participant engagement and maintain high quality data collection.
3368472|NCT05153148|Experimental|NDI-034858 study drug - Dose 1|NDI-034858 study drug will be orally administered QD for 12 weeks
3252646|NCT01406743||EOS™ Acquisition|
3252647|NCT01406769|Experimental|Diagnostic (bioimpedance to measure lymphedema)|Patients undergo preoperative and postoperative lower-extremity lymphedema assessment comprising serial circumferential measurements, bioimpedance spectroscopy measurements, and clinical evaluation using the Stemmer sign. Patients undergo radical vulvectomy or radical local excision as prescribed by GOG-0244, and unilateral or bilateral inguinal or inguinal-femoral lymphadenectomy.
3368473|NCT05153148|Experimental|NDI-034858 study drug - Dose 2|NDI-034858 study drug will be orally administered QD for 12 weeks
3368474|NCT05153148|Experimental|NDI-034858 study drug - Dose 3|NDI-034858 study drug will be orally administered QD for 12 weeks
3368475|NCT05153148|Placebo Comparator|Placebo|Placebo will be orally administered QD for 12 weeks
3252648|NCT01406808|Other|standard of care plus genetic information|
3252649|NCT01406808|No Intervention|usual standard of care without genetic information|
3252650|NCT01406821|Sham Comparator|Dry needling|Blood will be drawn, and tendon will be penetrated with dry needle. Nothing will be injected into the tendon.
3252651|NCT01406821|Experimental|Platelet-rich plasma (PRP)|Blood will be drawn, and platelet-rich plasma will be injected into the tendon.
3252652|NCT01406847|Experimental|Spinal Manipulation|High-velocity manual technique applied to the pelvis with the participant in supine
3252653|NCT01406847|Sham Comparator|Static Touch|Practitioner hands are placed on the lumbar spine with the participant in prone.
3252654|NCT01406847|Active Comparator|Spinal Mobilization|Oscillation of the third lumbar level performed with the participant in prone
3252655|NCT01406886|Experimental|Energy density|Low or high energy density meal
3252656|NCT01406899|No Intervention|Treatment as Usual|Standard treatment as usual (TAU) in the VA Connecticut Healthcare System substance abuse clinic consisting of individual and group therapy sessions and regular urine monitoring.
3252657|NCT01406899|Experimental|Computer-based treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
3368479|NCT05153122|Experimental|Investigational SenseGuard Device|Patients undergo SG monitoring at least twice daily before and after receiving treatment.
3368480|NCT05153109||Community sample|Participants will be recruited from families in Bochum who take part in experiments and studies at the department of delevopmental psychology at the Ruhr-University. The department of developmental psychology organizes a panel every year inviting all parents of newborn babies in Bochum to register if they want to participate in research.
3368481|NCT05153109||Clinical sample|Participants will be recruited from families in Bochum and Munich who seek treatment in the outpatient treatment centers at both sites. Both study sites offer special counselling for parents who experience difficulties with a child from zero to five years of age.
3368483|NCT05153083||patient undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)|Subjects undergoing open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA) using cryoablation of intercostal nerves
3368484|NCT05153070|Experimental|Ciclosporin/ILT-101|Ciclosporin during 2 months (for all patients) followed by ILT-101 during 10 months
3368485|NCT05153070|Placebo Comparator|Ciclosporin/placebo|Ciclosporin during 2 months (for all patients) followed by placebo during 10 months
3368486|NCT05153057||Birdshot chorioretinopathy|Patients with a diagnosis of birdshot chorioretinopathy, with confirmed HLA-A29 positivity.
3368487|NCT05153044|Other|sickle cell children group|sickle cell children group
3252658|NCT01406912|Active Comparator|Recreational Activity Arm|recreational activity includes playing cards, ominoes, jenga or a ball game.
3252659|NCT01406912|Experimental|Wii Gaming System Arm|Use of Wii gaming technology (e.g. commercially available games)
3252660|NCT01406925|Placebo Comparator|Control|Placebo control
3368488|NCT05153044|Other|sickle cell adult group|sickle cell adult group
3368489|NCT05153044|Other|control children group|control children group
3368490|NCT05153044|No Intervention|Vaccinated patients|Vaccinated patients
3368491|NCT05153031||lithiasic acute cholecystitis|Acute cholecystitis with the presence of one or more calculi (gallstones) in the gallbladder.
3368492|NCT05153031||alithiasic acute cholecystitis|Acute cholecystitis without the presence of one or more calculi (gallstones) in the gallbladder.
3368493|NCT05153031||elective cholecystectomy|Elective surgery is surgery that is scheduled in advance because it does not involve a medical emergency.
3368494|NCT05153031||emergency cholecystectomy|Emergence surgery
3368495|NCT05153031||management with percutaneous cholecystostomy alone|Patients that didnt recieve cholecystectomy during de whole study
3368496|NCT05153031||managemente with surgery|Patients that recieve cholecystectomy during de whole study
3368497|NCT05153018|Other|A representative random sample of the population|1,200 non-febrile individuals aged older than 6 years old
3252661|NCT01406925|Experimental|Low dose NRL001|0.5% NRL001 cream
3252662|NCT01406925|Experimental|Intermediate dose NRL001|0.75% NRL001 cream
3368501|NCT05152992|Experimental|Video and stimulation-based induction of emotion|Participants viewed visual stimuli while undergoing stimulation of brain regions involved in emotion during their inpatient hospitalization at the University of California, San Francisco (UCSF).
3368502|NCT05152979|Experimental|Telepractice treatment (TP-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy through an online platform."
3368503|NCT05152979|Active Comparator|In-clinic treatment (IC-T)|"Participants will receive 30 hours of training, 2-3 times a week in ten weeks using Verb Network Strengthening Treatment (VNeST).~Treatment will be done with a speech-language pathologist providing the therapy in person at a clinic."
3368504|NCT05152966|Experimental|FARAPULSE™ Endocardial Cardiac Ablation|Ablation using FARAPULSE™ Cardiac Ablation System Plus
3368505|NCT05152953||Persons with HIV|Persons with HIV who are currently taking antiretroviral therapy who reside in the study's target geographical areas.
3252663|NCT01406925|Experimental|High dose NRL001|1.0% NRL001 cream
3252664|NCT01406951||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3252665|NCT01406951||sepsis|SIRS + infection
3259454|NCT01470963|Experimental|Referral template|Implementation of the referral templates at the GP office
3259455|NCT01470963|No Intervention|Control|Normal referral pattern
3259456|NCT01470976|Active Comparator|Goal-directed Therapy (GDT) Protocol|
3259457|NCT01470976|Active Comparator|Standard Protocol|
3368506|NCT05152953||Pharmacy staff members|Pharmacists, pharmacy technicians, pharmacy managers, or clerks employed at a community pharmacy who would potentially be involved in program development, scheduling, financial aspects, planning or administration of long-acting injectable antiretroviral therapy in the pharmacy.
3368507|NCT05152953||Clinic staff members|Physicians, clinic managers, nurses, medical assistants, social work staff or case managers, therapists, and other clinic personnel who are involved or would potentially be involved in any aspect of long-acting antiretrovirals in the clinic facility including financial aspects, planning, scheduling patients, educating patients, ordering medication, or administering medications.
3368508|NCT05152940|Active Comparator|Ertugliflozin then Placebo|Treatment with Ertugliflozin for one month, washout period for one month, and then with Placebo for one month
3368509|NCT05152940|Active Comparator|Placebo|Treatment with matching placebo for one month, washout period for one month, and then Ertugliflozin for one month
3252666|NCT01406951||VAP|(1) after 48-72h endotracheal intubation, X-ray film displays new or progressive infiltrating focus; (2)The patient is in two of the following conditions: a. fever (temperature >38 ℃ or higher than basal temperature; b. peripheral WBC count≥10×10∧9/L，or <4×10∧9/L; c. appearance or increase of purulent respiratory tract secretion. Besides the diagnostic norms above, it is suggested that lower respiratory tract secretions be collected under the bronchoscope and half-quantitative etiological culture be carried out through the medium of BALF samples (diagnostic threshold value:104cfu/mL ).
3252667|NCT01406964|Experimental|Arm A|Arm A performs a CAT test to study tubal factor causes
3252668|NCT01406964|Experimental|Arm B|In Arm B a histerosalpingography is performed.
3252669|NCT01406977|Experimental|BPS804 dose escalation|
3368510|NCT05152927|Experimental|Parathyroid Eye (PTeye)|For patients assigned to the study arm, the surgeon will use the PTeye as an intraoperative tool to identify if a suspect tissue is a parathyroid or not, during the parathyroid surgery.
3368511|NCT05152927|No Intervention|Usual Standard of Care|The surgeon will proceed with the parathyroid surgery as usual, while relying solely on her/his surgical experience in identifying the parathyroid glands during the operations.
3368512|NCT05152914|Experimental|Intervention|
3368513|NCT05152901|Active Comparator|EpiPen ®.|Dosage Form- Intra muscularly (IM), Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via IM on day, Visit 2.
3368514|NCT05152901|Experimental|Epinephrine (0.3mg)|Dosage Form- Inhaled, Dosage- 0.3mg, Dosage Frequency and Duration- Single dose of 0.3mg epinephrine via inhalation on day 2 of Visit 2.
3368515|NCT05152901|Experimental|Epinephrine (1.3mg)|Dosage Form- Inhaled, Dosage- 1.3mg, Dosage Frequency and Duration- Single dose of 1.3mg epinephrine via inhalation on Visit 3.
3368516|NCT05152901|Experimental|Epinephrine (4mg)|Dosage Form- Inhaled, Dosage-4mg, Dosage Frequency and Duration- Single dose of 4mg epinephrine via inhalation on Visit 4.
3368517|NCT05152888|Experimental|Evolocumab|Informed consent will be obtained from study participants willing to participate in EMPOWER. Study participants will then undergo the baseline rest/stress cardiac PET scan along with CCTA. The final PET scan and CCTA will occur at 12 months after the intervention.
3368518|NCT05152849|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
3368519|NCT05152849|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
3368521|NCT05152823|Experimental|Single Intrathecal Delivery|
3368522|NCT05152810|Experimental|Active Transcranial Magnetic Stimulation|
3368523|NCT05152810|Placebo Comparator|Transcranial magnetic resonance imaging placebo|
3252670|NCT01407003|Experimental|LIK066 in healthy subjects|
3252671|NCT01407003|Placebo Comparator|Matching placebo in healthy subjects|
3368524|NCT05152797|Experimental|TILs infusion|Enrolled patients will be infused with their autologous TILs followed by IL-2 administration after post- NMA lymphodepletion
3368525|NCT05152784|Experimental|Octaray catheter|VT ablation guided by activation mapping using the Octaray catheter and integrated cardiac MRI data.
3368526|NCT05152784|Active Comparator|Standard of care|Identified retrospectively from registry data: propensity matched-controls undergoing VT ablation guided by substrate-modification alone.
3368527|NCT05152771|Other|Ketogenic Diet|This will be a prospective cohort study. All families with children who have been newly diagnosed with confirmed SSPE (based on Dyken's Criteria) will be approached to start the low glycemic index diet (liberalized kind of KD). A thorough dietary history will be taken from the parents/caregivers, and they will be counseled by a trained dietitian on the diet, all pros and cons, and the format. After the verbal agreement, formal consent will be taken from the parent/ caregiver for initiation of the diet.
3368528|NCT05152758|No Intervention|Usual Care|Patients will receive the usual care.
3368529|NCT05152758|Experimental|Physical Activity Prescription (PARx)|Patients will be prescribed technology-based physical activity programming.
3252672|NCT01407003|Experimental|LIK066 in patients with type 2 diabetes mellitus|
3252673|NCT01407003|Placebo Comparator|Matching placebo in patients with type 2 diabetes mellitus|
3252674|NCT01407016|Experimental|1.0|
3252675|NCT01407042||mb-UKA|Patients with unicondylar osteoarthritis of the knee
3252676|NCT01407055|No Intervention|Standard Medical Care|Patients receive standard treatment protocol for Coronary Artery Bypass Graft Surgery
3252677|NCT01407055|Active Comparator|Attention Control Group|In addition to standard medical care patients receive a comparable amount of therapist´s attention (common and unspecific factors = supportive therapy) to the intervention group, without targeting patients' expectations.
3252678|NCT01407055|Experimental|Expectation Manipulation Intervention|In addition to standard medical care patients' expectations prior to surgery are targeted in a brief psycho-educational intervention.
3368530|NCT05152745|Placebo Comparator|Placebo (OGTT)|The control group participants ingested glucose solution alone (OGTT) prepared with 75 g of anhydrous oral glucose as prescribed by the ADA, dissolved in 200 ml of water.
3368531|NCT05152745|Experimental|Intervention (OGTT plus Ginger extract)|The intervention group ingested glucose solution followed by 100 ml of ginger aqueous extract (0.2g ginger, each dose).
3368532|NCT05152732|Experimental|VGB-R04|Single intravenous (i.v.) infusion of VGB-R04 Intervention: Gene Therapy / Gene Transfer
3368533|NCT05152719|Experimental|Sprint Interval Training (SIT) Protocol|"Participants in the SIT group will start with a 5 minute warm-up jogging at around 70-80% of their heart rate max. The SIT protocol consists of 30 second intervals of all out shuttle runs, seperated by 2 minutes of low pace walking active rest. This will be repeated between 4 times during the first 2 weeks, 5 times during the second 2 weeks, and 6 times during the third 2 weeks. Participants will be instructed to sprint the greatest possible distance in 30 seconds, starting by running to the 5m marker and back, then to the 10m marker and back, then to the 15m marker etc. The SIT session will finish with 2 minutes walking at a pace 50% of their heart rate max."
3368534|NCT05152719|Active Comparator|Time Restricted Eating (TRE) Protocol|Participants will be asked to limit their food intake to the hours between 12pm to 8pm, and fast outside of these hours. During the fast, participants may consume zero calorie beverages with no caffeine or artificial sweetener. Participants are instructed to maintain their diet, with no restrictions on the type or amount of food consumed in the feeding window.
3252679|NCT01407081|Experimental|Training|telerehabilitation cognitive strategy training
3368535|NCT05152719|Active Comparator|Combined Sprint Interval Training (SIT) and Time Restricted Eating (TRE) Protocol|Participants will be asked to abide by the same eating regimen as the Time Restricted Eating Protocol Arm. Additionally, participants in this arm will perform the SIT protocol, in the fasted state. The SIT protocol will be identical to that listed in the Sprint Interval Training Protocol Arm.
3368540|NCT05152693|Experimental|Low Variety Small Portion Without Beverage|Test meal with food components mixed together (low variety) with a small portion of food served without water
3252680|NCT01407120|Experimental|Mother Program|11 session program focused on parenting skills
3368541|NCT05152693|Experimental|High Variety Small Portion Without Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food served without water
3368542|NCT05152693|Experimental|Low Variety Small Portion With Beverage|Test meal with food components mixed together (low variety) with a small portion of food and water
3368543|NCT05152693|Experimental|High Variety Small Portion With Beverage|Test meal with food components separated on the plate (high variety) with a small portion of food and water
3368544|NCT05152693|Experimental|Low Variety Large Portion With Beverage|Test meal with food components mixed together (low variety) with a large portion of food and water
3368545|NCT05152693|Experimental|High Variety Large Portion With Beverage|Test meal with food components separated on the plate (high variety) with a large portion of food and water
3368546|NCT05152680|Experimental|[14C]-NV-5138|[14C]-NV-5138 oral solution
3368547|NCT05152667||Arm 1|Women with adenomyosis pretreated with levonorgestrel-releasing intrauterine device (LNG-IUS) and proceeding with the ICSI
3252681|NCT01407120|Experimental|Mother Plus Child Program|11 session Mother Program focused on parenting skills plus 11 session Child program focused on child coping skills
3252682|NCT01407120|No Intervention|Literature Control|Families received books on children's post-divorce adjustment
3252683|NCT01407133|Experimental|Active rTMS|"48 subjects will receive active temporal rTMS, applied with the following combined parameters:~intensity: 100% of resting motor threshold~stimulation frequency: low-frequency continuous stimulation (0.5 or 1 Hz) or high-frequency stimulation trains (4 or 12 Hz)~number of stimulations per session: 300, 900 or 1800 per session~number of sessions per week: spaced out / low density protocol (1 per week) or dense / high density protocol (5 per week)~total number of sessions for the whole intervention: short protocol (5 sessions) or long protocol (20 sessions)."
3252684|NCT01407133|Sham Comparator|Sham rTMS|16 subjects will receive sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session (300 or 900)
3368548|NCT05152667||Arm 2|"Women with adenomyosis pretreated with oral progestin Dienogest and proceeding with the ICSI"
3368549|NCT05152654|No Intervention|Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will be fixed to the hernia area by the non-absorbable tacker.This method is the method used routinely in the treatment of laparoscopic hernia today.
3368550|NCT05152654|Experimental|Non-Fixation|Total extra peritoneal repair will be performed in this arm for the patients due to unilateral inguinal hernia. The 15x12 cm mesh will be marked with titanium clips from its 4 corners and placed in the hernia area. The mesh will not be detected in any way.
3368551|NCT05152641|Experimental|BGE-117 4mg|BGE-117 4mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
3252685|NCT01407159||Thoracic Stentgraft plus E-XL|male and female patients with complicated type B aortic dissection involving the infra-diaphragmatic aorta treated with any thoracic stentgraft extended by the E-XL aortic stent
3252686|NCT01407159||Control group|"historical control group fulfilling the following criteria:~Age +/- 3 years~Sex matched~Same follow-up period"
3368552|NCT05152641|Experimental|BGE-117 8mg|BGE-117 8mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
3368553|NCT05152641|Experimental|BGE-117 16mg|BGE-117 16mg, Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
3368554|NCT05152641|Placebo Comparator|Placebo|Matching Placebo Capsules, Oral-administered Once Per Day up to 12 weeks Ferrous sulfate 325mg, Tablets, Oral-administered 3 Times Per Week up to 12 weeks
3368555|NCT05152628|Experimental|Tacrolimus granules (Modigraf)|Participants will receive the first dose of Modigraf in the morning within 24 hours after reperfusion. Total initial dose will be received in two divided doses post operatively. Subsequent oral Modigraf doses will be adjusted by the investigator and will be received in two doses (recommended interval 12 hours)
3252687|NCT01407172||Symptomatic PAD|Patient with symptomatic PAD as defined by the presence of typical or atypical claudication symptoms or critical limb ischemia in conjunction with ABI <0.9.
3252688|NCT01407172||Patients without PAD|Patients without PAD as defined by ABI>0.9 and <1.3.
3252689|NCT01407172||Asymptomatic PAD|Patients with asymptomatic PAD as defined by ABI<0.9 but no symptoms.
3252690|NCT01407185|Experimental|Resistive Training|Subjects will be working at 30-60% of 1 RM. The therapist selects theraband that will produce muscle fatigue ~ 15 reps. Subjects should report that the exercise was somewhat light to somewhat hard 11 to 14 on RPE scale. Increase or decrease resistance until the desired RPE is obtained. Continues until momentary fatigue is evidenced. Fatigue is defined as the inability to move through the full ROM in a slow controlled fashion. Record the exercise performed, amount of resistance, and # of good quality reps performed before fatigue was reached. A single set will be done for each muscle group.
3252691|NCT01407198|Experimental|Nilotinib/XRT|Nilotinib is administered 400mg PO BID for 2 weeks and then administered concurrently with daily radiation therapy until completion of radiation therapy. Participants can then undergo surgery if clinically possible. After either surgery or definitive radiation, participants have the option to continue on nilotinib therapy.
3368556|NCT05152615|Experimental|New Onset Rheumatoid Arthritis (NORA) Patient|NORA patients receiving methotraxate as first line therapy (standard of care) will take additional oral SCFA supplementation for the purposes of the study.
3368557|NCT05152602||Unilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent unilateral ESP block for postoperative analgesia.
3368558|NCT05152602||Bilateral ESP block group|The group who underwent laparoscopic cholecystectomy and underwent bilateral ESP block for postoperative analgesia.
3368559|NCT05152602||Control group|The group that underwent laparoscopic cholecystectomy and underwent 1mg/kg tramadol and 50mg dexketoprofen for postoperative pain.
3368560|NCT05152589||gestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of gestational diabetes in the peritanotogy clinic
3368561|NCT05152589||pregestational diabetic mother|Hearing tests of the babies of pregnant women who are being followed up with the diagnosis of pregestational diabetes in the peritanotogy clinic
3368562|NCT05152589||non diabetic mother|Hearing tests of babies whose mothers do not have gestational or pregestational diabetes
3368567|NCT05152563|Experimental|SC 150 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.
3368568|NCT05152563|Experimental|SC 300 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 300 mg of lirentelimab (AK002) administered subcutaneously.
3368569|NCT05152563|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.
3368570|NCT05152563|Other|Placebo|Placebo
3368572|NCT05152524|Experimental|Treatment|Mechanical thrombectomy with Tigertriever 13 EVT + MM (without thrombolysis).
3368573|NCT05152524|No Intervention|Control|Medical Management alone (without thrombolysis).
3252692|NCT01407211|Active Comparator|with Multiple Sclerosis/ vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A
3368574|NCT05152511||All male children who had penile ischaemia after circumcision were included in the study|It is a cohort prospective study. All male children who had penile ischaemia after circumcision were included in the study between April 2017 and October 2020.
3368579|NCT05147337|Experimental|Cohort 1: E2511 10 mg or Placebo|Non-Japanese adult (greater than or equal to [>=] 18 years and less than [<] 55 years old) participants will receive 10 milligram (mg) E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368580|NCT05147337|Experimental|Cohort 2: E2511 20 mg or Placebo|Non-Japanese adult participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368581|NCT05147337|Experimental|Cohort 3: E2511 40 mg or Placebo|Non-Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368582|NCT05147337|Experimental|Cohort 4: E2511 80 mg or Placebo|Non-Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3252693|NCT01407211|Placebo Comparator|with Multiple Sclerosis/ placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
3252694|NCT01407224|Experimental|Only training|Training on Early Breastfeeding Practices to front line health workers
3368583|NCT05147337|Experimental|Cohort 5: E2511 20 mg or Placebo|Japanese adult (>=20 years and <55 years old) participants will receive 20 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368584|NCT05147337|Experimental|Cohort 6: E2511 40 mg or Placebo|Japanese adult participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368585|NCT05147337|Experimental|Cohort 7: E2511 80 mg or Placebo|Japanese adult participants will receive 80 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368586|NCT05147337|Experimental|Cohort 8: E2511 40 mg or Placebo|Non-Japanese older (>=55 years and less than or equal to [<=] 85 years old) participants will receive 40 mg E2511 or E2511 matched placebo, tablets, orally, once daily from Day 1 to Day 14.
3368587|NCT05144737|Other|Immediate Intervention Group|Participants in the immediate intervention group will immediately begin 6 months of the adapted DPP lifestyle intervention with a Lifestyle Coach and remote monitoring of blood pressure and body composition. This will be followed by a 6-month observation period where the intervention (Lifestyle Coach) will be withdrawn. In this period, participants will be evaluated for the maintenance of lifestyle changes.
3368588|NCT05144737|Other|Delayed Intervention Group|Participants in the delayed intervention group will receive remote monitoring of blood pressure and body composition for the 1st 6 months (without the Lifestyle Coach) and then will receive the adapted DPP lifestyle intervention with a Lifestyle Coach after 6 months.
3252695|NCT01407224|Active Comparator|Training and supervision|Training as well as supervision by field supervisor for six months intervention
3252696|NCT01407224|No Intervention|Control|No intervention such as training or supervision
3368590|NCT05137236|Experimental|mRNA-1283 Dose Level 1|Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.
3368591|NCT05137236|Experimental|mRNA-1283 Dose Level 2|Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.
3368592|NCT05137236|Experimental|mRNA-1283 Dose Level 3|Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.
3252697|NCT01407237||HIV-infected Individuals|
3368593|NCT05137236|Experimental|mRNA-1283.211 Dose Level 1|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.
3368594|NCT05137236|Experimental|mRNA-1283.211 Dose Level 2|Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.
3368595|NCT05137236|Active Comparator|mRNA-1273|Participants will receive single IM injection of mRNA-1273 on Day 1.
3368596|NCT05136716|Active Comparator|Control|Children in this group received traditional physical therapy
3368597|NCT05136716|Experimental|Study|Children in this group received the same traditional physical therapy plus hyperbaric oxygen therapy
3368598|NCT05135728|Experimental|Unstuck and On Target-Preschool|"UOT-P is based on the foundational principles of UOT for improving EF as well as evidence-based teaching methods (e.g., positive behavior supports, visual aids). Through this program, children, teachers and parents develop a shared self-regulatory vocabulary that enables children to improve EF at home and school through adult modeling and gradual scaffolding. The self-regulatory vocabulary (e.g., Flexible, Make a New Plan, Unstuck) becomes a contagious common language. We hypothesize this is the mechanism of change by which children will show improved EF skills, leading to increased academic readiness, improved social competence and reduced externalizing behaviors."
3368599|NCT05135325|Experimental|No-blood-type message|This group will receive a message that does not mention the patient's blood type, or that the patient's blood type is in short supply.
3252698|NCT01407237||non-HIV-infected Individuals|
3252699|NCT01407263|Experimental|Lymph node template|In patients randomized to standard, only the nodal packet under the external iliac vein and above the obturator nerve will be dissected. For patients randomized to the modified template, the external iliac, hypogastric and obturator fossa nodal groups will be removed.
3252700|NCT01407263|Experimental|Transverse versus vertical closure of the port site incision (Closed as of 9/30/2021)|
3252701|NCT01407263|Experimental|One vs. three days of antibiotic prophylaxis|
3252702|NCT01407289|Experimental|Insulin titration protocol|Patients in care at the Division of Endocrinology will be treated by enhanced version of published best paper based practice insulin titration protocol to control glycaemia in hospitalised patients with type 2 diabetes.
3368600|NCT05135325|Experimental|Blood-type message|This group will receive a message that mentions the patient's blood type and that states their blood type is in short supply.
3252703|NCT01407289|No Intervention|Standard care|Patients in care of the Division of Cardiology will be treated using antihyperglycaemic therapy according to standard care.
3252704|NCT01407302||LMA group|patients undergoing general anesthesia with LMA insertion
3252705|NCT01407302||E-tube group|patients undergoing general anesthesia with e-tube
3252706|NCT01407315|Experimental|GlucoMenDay - Multiple sampling (A)|
3252707|NCT01407315|Experimental|GlucoMenDay - Meal/Insulin test (B)|
3252708|NCT01407341|Experimental|Supportive care (ChronOS)|Patients undergo placement of beta-tricalcium phosphate bone graft strips posterolaterally during surgery.
3252709|NCT01407393|Experimental|Glucosanol|Glucosanol
3252710|NCT01407393|Placebo Comparator|Placebo|Placebo
3252711|NCT01407406|Experimental|Chinese Subjects - low dose BIIB023 IV|
3252712|NCT01407406|Experimental|Chinese Subjects - high dose BIIB023 IV|
3252713|NCT01407406|Experimental|Japanese Subjects - low dose BIIB023 IV|
3252714|NCT01407406|Experimental|Japanese Subjects - high dose BIIB023 IV|
3252715|NCT01407406|Experimental|Causasian Subjects - low dose BIIB023 IV|
3252716|NCT01407406|Experimental|Caucasian Subjects - high dose BIIB023 IV|
3252717|NCT01407419|Experimental|Treat to Target Intervention Strategy|Subjects at sites randomized to this arm will be expected to return to the clinic for Monthly Assessments until low disease activity (LDA) defined as CDAI of 10 or less has been achieved. Providers are prompted to accelerate therapy (Treatment Acceleration) at each visit that CDAI is >10 (unless not felt to be medically appropriate or refused by the subject.) Accelerations are expected at least every 3 months, until/unless LDA has been achieved.
3252718|NCT01407419|No Intervention|Control Group Treated with Usual Care|Subjects in this arm will be expected to complete study visits with their rheumatologist/study doctor at Baseline, Month 3, Month 6, Month 9 and Month 12. Data collection will occur at each of those visits. Subjects and Providers will continue managing disease per usual practices and do not receive protocol prompts relative to visit frequency or acceleration of therapy, regardless of disease activity level (by CDAI)
3368601|NCT05135325|No Intervention|Shortage control|This group will not receive a message.
3368602|NCT05135325|No Intervention|No-shortage control|This group will not receive a message.
3252719|NCT01407432|Experimental|Folic acid|tablets of 5 mg of folic acid
3252720|NCT01407432|Placebo Comparator|Placebo|Tablets of placebo of folic acid
3252721|NCT01407445|Placebo Comparator|Placebo|1 tablet of placebo/ oral/ 3 times a day for three months
3252722|NCT01407445|Active Comparator|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for three months
3368603|NCT05135156|Experimental|Intervention|Access to an investigator-designed web-based educational resource with information about lung transplant for two weeks.
3368604|NCT05135156|Active Comparator|Control|Access to a publicly available web-based educational resource with information about transplant for two weeks.
3368605|NCT05133271|Experimental|Scheduled cesarean section|Patient with scheduled cesarean section under spinal anesthesia.
3368606|NCT05132985|Experimental|Icotinib+chemotherapy|"Neoadjuvant chemotherapy (pemetrexed + carboplatin/cisplatin ) will start within 1-3 days from enrollment at 21-day (+/-3 days) intervals (Q3W) prior to surgery. Before surgery a tumor assessment will be done to exclude evidence of progression. Patients with radiographically stable disease or partial response may be considered for operation.~Icotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of Icotinib is 125mg 1tt(Take 1 tablet 3 times a day) orally.~Surgery: Surgery must be done within the 3rd to 4th week (+7 days) from day 21 cycle 2 of neoadjuvant treatment.~Adjuvant treatment: Patients receive additional 2 cycles of platinum-based doublet chemotherapy(Researcher decide) on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity"
3368607|NCT05132569|Experimental|SAR442168|Tolebrutinib oral daily dose from baseline until Week 130
3368608|NCT05132569|Placebo Comparator|Placebo|Matching placebo oral daily dose only for DB period
3252723|NCT01407458|Active Comparator|Experimental Group|Children doing additional exercises with upper limbs in physical education class
3252724|NCT01407458|Active Comparator|Control Group|Children doing normal physical education exercises
3368611|NCT05128487|Experimental|NDI-101150 (Monotherapy)|Patients in escalation and expansion, will receive NDI-101150 capsules orally once daily continuously in 4-week cycles (28 days).
3368612|NCT05128487|Experimental|NDI-101150-Pembrolizumab (Combination therapy)|Patients in escalation and expansion phase, will receive NDI-101150 capsules orally once daily continuously in 3-week cycles (21 days), along with pembrolizumab via intravenous (IV) infusion at a dose of 200 mg every 3 weeks.
3368613|NCT05124548||Post-COVID condition|
3252725|NCT01407471|Experimental|Clobetasol + Spironolactone|0.05% clobetasol and 5% spironolactone
3252726|NCT01407471|Active Comparator|Clobetasol + Placebo|0.05% clobetasol + inert excipient
3368614|NCT05124548||Healthy controls|
3368615|NCT05124171|Experimental|Comirnaty® (Pfizer-BioNTech)|Length of use : 1 day
3368616|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK|Length of use : 1 day
3368617|NCT05124171|Experimental|CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK|Length of use : 1 day
3368618|NCT05123183|Active Comparator|Acupressure group|Acupressure will be applied to ST36 and CV17 points.
3368619|NCT05123183|Active Comparator|Back Massage|Back massage will be applied.
3368620|NCT05123183|Active Comparator|Control Group|No application will be made to the mothers in this group, and the amount of milk will be measured by weighing the baby before and after breastfeeding.
3368621|NCT05121402|Experimental|Low dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
3252727|NCT01407471|Active Comparator|Placebo + Spironolactone|Inert excipient + 5% spironolactone
3252728|NCT01407471|Placebo Comparator|Placebo + placebo|Inert excipient
3252729|NCT01407484|Experimental|Treatment|Cortancyl (prednisone) 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
3252730|NCT01407484|Placebo Comparator|Placebo|Placebo
3252731|NCT01407497|Active Comparator|IA|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 108 pfu i.m. MVA boosting at weeks 24 and 36
3252732|NCT01407497|Placebo Comparator|IB|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 saline solution i.m at weeks 24 and 36
3252733|NCT01407497|Active Comparator|IIA|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12;108 pfu i.m. MVA boosting at weeks 24 and 36
3252734|NCT01407497|Placebo Comparator|IIB|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
3252735|NCT01407510|Experimental|Arm 1|
3252736|NCT01407549|Experimental|Intervention group|The intervention group will participate in the Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention.
3368622|NCT05121402|Experimental|Middle dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
3368623|NCT05121402|Experimental|High dose TLL018,BID|Drug: TLL018 all subjects will receive TLL018 for 8 weeks
3368624|NCT05121402|Placebo Comparator|Placebo|Placebo twice daily for 8 weeks.
3368626|NCT05120986||IND/GLY/MF with sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate with sensor
3368627|NCT05120986||IND/GLY/MF without sensor|Patients prescribed with indacaterol acetate, glycopyrronium bromide and mometasone furoate without sensor
3368628|NCT05119855|Experimental|Concomitant Group|Participants will receive the first dose of 9vHPV vaccine and first dose of mRNA-1273 vaccine on Day 1; participants will then receive the second dose of mRNA-1273 vaccine at Month 1 and the second dose of 9vHPV vaccine at Month 6.
3368629|NCT05119855|Experimental|Non-concomitant Group|Participants will receive the first and second doses of mRNA-1273 vaccine on Day 1 and at Month 1, respectively; participants will then receive the first and second doses of 9vHPV vaccine at Months 2 and 8, respectively.
3368630|NCT05118893||Ablation-based rhythm-control|Ablation-based rhythm-control consisted of pulmonary vein isolation in paroxysmal atrial fibrillation, and additional ablation for persistent atrial fibrillation
3368631|NCT05118893||Rate-control|Rate-control included AV-nodal blocking agents and AV node ablation with permanent pacing
3368632|NCT05118399|Active Comparator|To receive supraclavicular BPB using standard ropivacaine only.|20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.
3368633|NCT05118399|Experimental|To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.|10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.
3368634|NCT05117086|Experimental|Dietary Intervention Arm|Subjects will receive the active intervention of nutrition education and medical nutrition therapy counseling for dietary and behavioral lifestyle changes. The focus will be on DASH diet implementation and adherence for management of heart failure. The subjects will have 4 study visits with a Registered Dietitian over 6 months (visits at 1, 2, 3, and 6 months). Outcome measures will be assessed at baseline, 3 and 6 months.
3368635|NCT05116553|Active Comparator|SDT (MI)|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews.
3252737|NCT01407549|No Intervention|Control group|Participants in the control group will be assigned to a waiting list group. Participants will be told that they will be eligible for the intervention three months after the completion of a preliminary documentation of their symptoms and additional measures. Participants will complete the same battery of measures according to the same time table as participants in the intervention group.
3252738|NCT01407562|Experimental|Pazopanib with paclitaxel and carboplatin|
3368636|NCT05116553|Experimental|SDT (MI) + CA|This group will receive standard 2 SDT (Self Determination Theory) psychological interviews; moreover they will use an APP with a CA (Conversational Agent), an Artificial Intelligence.
3368637|NCT05115019|Experimental|Group A (RUTI)|Participants will receive one dose of RUTI® vaccine at the baseline visit, which will be administered subcutaneously in the deltoid region at a dose of 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli (FCMtb) in an injection volume of 0.3 m
3368638|NCT05115019|Placebo Comparator|Group B (Placebo)|Participants will receive one dose of sterile physiological serum at the baseline visit, which will be administered subcutaneously in the deltoid region.
3368639|NCT05112848|Experimental|Group 1 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
3368640|NCT05112848|Experimental|Group 2 PLWH|Three doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0, Day 21, and Day 70.
3368641|NCT05112848|Experimental|Group 3 PLWH|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
3368642|NCT05112848|Experimental|Group 4 HIV-Negative Participants|"2 doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 21.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 70."
3368643|NCT05112848|Experimental|Group 5 HIV-Negative Participants|"Two doses of 5μg monovalent prototype vaccine+50µg Matrix-M adjuvant, given on Day 0 and Day 70.~Alternating IM (deltoid) injection of placebo (0.5mL) given on Day 21."
3368644|NCT05111821|Experimental|Deferiprone|Patients receiving Deferiprone during 6 months. Oral deferiprone for 6 months at a dose of 30 mg/kg/d
3368645|NCT05111821|Active Comparator|Treatment As usual|Patients followed during 6 months according to standard care
3368646|NCT05108623|Experimental|Part 1: Monotherapy with agenT-797|Single prespecified dose of agenT-797 administered by intravenous infusion
3368647|NCT05108623|Experimental|Part 2: agenT-797 in Combination with approved immune checkpoint inhibitors (ICIs)|Single prespecified dose of agenT-797 administered by intravenous infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care
3368648|NCT05107011|Experimental|Evaluation of LBL-015 Phase I/II study in patients with advanced malignancies|Drug: LBL-015 for Injection The test drugLBL-003will be preset with 5 escalation dose levels: dose A , dose B, dose C ,dose D and dose E, administered twice a week.
3252739|NCT01407588|Experimental|Magnetic navigation|
3252740|NCT01407588|Experimental|Manual navigation|
3252741|NCT01407601|Experimental|45 µg MK-7|45 µg MK-7 daily over 6 weeks
3368653|NCT05103241|Experimental|[14C]GP681|Subject will receive single dose of orally [14C] GP681 .
3368654|NCT05099276|Experimental|Oral TXA|1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
3368655|NCT05099276|Placebo Comparator|Oral placebo|Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.
3368656|NCT05096468|Experimental|S-ketamine and pregabalin|
3368657|NCT05096468|Placebo Comparator|Normal saline and placebo capsule|
3368658|NCT05095922|Experimental|Heart-Protecting Musk Pill group|Heart-Protecting Musk Pill (pill, 45mg, three times a day, 3 months)+Valsartan Capsules(capsule, 80mg, once a day, 3 months）+Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
3368659|NCT05095922|Placebo Comparator|Control group|Valsartan Capsules(capsule, 80mg, once a day, 3 months), Calcium Dobesilate Capsules (capsule, 500mg, three times a day, 3 months)
3252742|NCT01407601|Experimental|135 µg MK-7|135 µg MK-7 daily over 6 weeks
3368663|NCT05092698|Active Comparator|Vit_D_suppl|Patients will receive 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil orally or via feeding tube followed by 60,000 IU of cholecalciferol dissolved in 45 ml herbal oil weekly until discharge or death.
3368664|NCT05092698|Placebo Comparator|Vit_D_placebo|Patients will receive 45 ml of herbal oil orally or via feeding tube followed by 45 ml of herbal oil weekly until discharge or death.
3252743|NCT01407601|Experimental|360 µg MK-7|360 µg MK-7 daily over 6 weeks
3252744|NCT01407614|Active Comparator|external lumbar drainage|Within 96 hours of initial subarachnoid hemorrhage, patients were randomized for external lumbar drainage (ELD)of cerebrospinal fluid during a maximum of 7 days or standard treatment of subarachnoid hemorrhage without ELD
3368665|NCT05092126|Active Comparator|6MST VO2|Completion of 6MST exercise protocol
3252745|NCT01407614|No Intervention|No intervention|In this arm the patients received standard treatment following protocol for patients with subarachnoid hemorrhage
3252746|NCT01407627|Experimental|Fructose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest fructose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest dextrose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
3368666|NCT05092126|Active Comparator|DASI VO2|Completion of DASI fitness activity questionnaire
3368667|NCT05091723|Experimental|Administration Scenario A|Single dose of TD-0903 at Dose A on Day 1, Period 1 delivered by nasal inhalation via nebulizer device with a high-flow nasal cannula delivering supplemental oxygen
3368668|NCT05091723|Experimental|Administration Scenario B|Single dose of TD-0903 at Dose A on Day 1, Period 2 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via low-flow nasal cannula
3368669|NCT05091723|Experimental|Administration Scenario C|Single dose of TD-0903 at Dose A on Day 1, Period 3 delivered by oral inhalation via nebulizer device with supplemental oxygen delivery via high-flow nasal cannula
3368670|NCT05091723|Experimental|Administration Scenario D|Single dose of TD-0903 at Dose B on Day 1, Period 4 delivered by a route to-be-determined based on data from Scenarios A, B and C.
3368671|NCT05090033||Part I study cohort|Retrospective data analysis of up to 3500 de-identified participants contributing onboarding and adherence data via the MSGo Kesimpta Patient App.
3368672|NCT05090033||Part II study cohort|Up to 100 participants responding to PROs via the MSGo Patient App
3368673|NCT05086796|Active Comparator|Substance Use Treatment and Recovery Team (START)|The intervention is administered to participants in this arm. Participants in this arm will work with the Substance Use Treatment and Recovery Team (START), a collaborative care team for inpatients with opioid use disorder.
3368674|NCT05086796|No Intervention|Usual Care|Usual care for people with opioid use disorder.
3368675|NCT05084638|Experimental|Ofatumumab|Ofatumumab will be provided in an autoinjector for subcutaneous administration. Dosing regimen for this study is an initial dose of 20mg at Baseline/Week 0, followed by Week 1, 2 and every month thereafter, beginning at Week 4 (Month 1) until Month 18. There will be an optional extension of dosing through month 30.
3368676|NCT05084638|No Intervention|Healthy Control|Healthy Control arm will be age- and sex-matched subjects (to the ofatumumab treated arm) and will not receive a study treatment.
3368677|NCT05083481|Experimental|ASP1570 Monotherapy Dose Escalation|Participants will receive daily dose of ASP1570 in a 21-day cycle.
3252747|NCT01407627|Active Comparator|Dextrose First|"Study Day 1 - measurement of renal hemodynamics and blood pressure~Subjects will ingest dextrose 200g daily x 14d~Study Day 2 - measurement of renal hemodynamics~Minimum 1 week washout period~Subjects will ingest fructose 200g daily x 14d~Study Day 3 - measurement of renal hemodynamics and blood pressure"
3252748|NCT01407640|Experimental|1|Allergy tests
3368678|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Metastatic Melanoma|Participants who have metastatic melanoma will receive recommended Phase 2 dose (RP2D) of ASP1570 in a 21-day cycle.
3368679|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Non-Small Cell Lung Carcinoma (NSCLC)|Participants who have NSCLC will receive RP2D of ASP1570 daily in a 21-day cycle.
3368680|NCT05083481|Experimental|ASP1570 Monotherapy Dose Expansion - Response Triggered Tumor|Participants who have response triggered tumor type will receive RP2D of ASP1570 daily or a dose level with confirmed response observed that has been cleared and deemed tolerable by the Dose Escalation Committee, in a 21-day cycle.
3252749|NCT01407653|Experimental|virtual reality|
3252750|NCT01407653|Other|usual care|
3252751|NCT01407666|Experimental|Bilateral paravertebral blocks|Bilateral continuous paravertebral blocks for open liver resection
3252752|NCT01407666|No Intervention|epidural block|received thoracic epidural block for open liver resection
3252753|NCT01407679|Experimental|Alitretinoin|
3368681|NCT05079633|Active Comparator|Moderna COVID-19 vaccine (mRNA 1273)|110 participants will be randomly assigned to Moderna COVID 19
3368682|NCT05079633|Experimental|Medigen COVID-19 vaccine (MVC COV1901)|110 participants will be randomly assigned to Medigen COVID 19 vaccine
3252754|NCT01407705||Control Group|"No diagnosis of cervical degenerative or traumatic disease~30 to 80 years of age~Ability of volunteers to tolerate 1 hr examination"
3252755|NCT01407705||Disease (Non-healthy) Group|"Cervical Spinal Cord:~Clinical and Radiographic evidence of cervical spondylotic myelopathy~18 to 80 years of age~Safe and stable clinical scenario to undergo imaging~Awake, alert patient able to cooperate with physical examination~Give written informed consent prior to any testing under this protocol~Degenerative Disease Group:~Have signs or symptoms consistent with spinal cord injury.~Be diagnosed with cervical spondylosis (degenerative disease).~Traumatic Group:~• A spinal cord injury associated with a traumatic event."
3368683|NCT05079230|Experimental|Magrolimab + Venetoclax + Azacitidine|"Participants will receive~magrolimab: 1 mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
3368684|NCT05079230|Placebo Comparator|Magrolimab Placebo + Venetoclax + Azacitidine|"Participants will receive~magrolimab placebo: Days 1, 4, 8, 11, and 15, then every week for 5 doses and every 2 weeks thereafter~venetoclax: 100 mg on Cycle 1 Day 1, 200 mg on Cycle 1 Day 2, 400 mg on Cycle 1 Day 3 and daily thereafter~azacitidine: 75 mg/m^2 on Days 1-7 or Days 1-5 and 8-9 of each cycle~Each cycle is 28 days."
3368689|NCT05078164|No Intervention|Treatment as Usual|Youth who will not receive BTG services and will receive treatment as usual (TAU) in the hospital.
3368690|NCT05078164|Experimental|Bridging the Gap (BTG)|Youth randomized to Bridging the Gap (BTG) services will receive a hospital-based violence prevention program with 3-months of community case management and a firearm counseling program.
3368691|NCT05077722|Experimental|AI Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy (PCIT) will wear a Garmin smartwatch that will provided targeted messages during tantrums picked up by the Garmin devices that will instruct them on how to deescalate their child.
3368692|NCT05077722|Sham Comparator|Sham Biometric - Parent Child Interaction Therapy|Subjects enrolled in Parent Child Interaction Therapy will wear Garmin smartwatch and will receive only random messages throughout the day with various relaxation strategies such as reminders to practice deep breathing with their child.
3368695|NCT05071079|Experimental|Challenge with whole dose blood-stage inoculum (neat)|Whole dose: one whole vial, containing approximately 0.5 mL of red blood cells, will be reconstituted in 0.9% saline, to a total volume of 5 mL
3368696|NCT05071079|Experimental|Challenge with 1:5 dilution blood-stage inoculum|1:5 dilution: one fifth of a vial (containing approximately 0.1 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
3368697|NCT05071079|Experimental|Challenge with 1:10 dilution blood-stage inoculum|1:10 dilution: one tenth of a vial (containing approximately 0.05 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
3368698|NCT05071079|Experimental|Challenge with 1:20 dilution blood-stage inoculum|1:20 dilution: one twenties of a vial (containing approximately 0.025 mL of red blood cells) will be reconstituted in 0.9% saline, to a total volume of 5 mL.
3368699|NCT05070988||Rare diseases|Children and adult patients with rare diseases and followed at the Necker Enfant Malades Hospital, Paris
3368700|NCT05069259|Other|Patients with active Ulcerative Colitis|
3368701|NCT05067491|Experimental|Intervention|The experimental group will go through an exposure therapy session using an augmented reality headset device. The participant will work with the therapist, who will control the augmented reality paradigm and cater the exposure to the needs of the participant. The duration of the exposure will be as long as is needed to reduce anxiety regarding the feared object until self-reported subjective distress is low and stable.
3368702|NCT05067491|No Intervention|Non-intervention|The control group will not go through an exposure therapy session using an augmented reality headset device. This will be a no-intervention control group that can have some form of exposure therapy following the conclusion of the treatment/research period.
3252756|NCT01407744||Correlative studies|Archived tumor tissue samples are analyzed by laboratory biomarker analysis for cellular density, mitotic count, tumor cell invasion, hTERT expression, telomere dysfunction, 1q gain, 9p deletion, and genetic mutations by IHC, Affymetrix MIP arrays, and FISH. Results are then correlated with patient-outcome variables and known risk factors, namely gender, age at diagnosis, tumor location infratentorial vs. supratentorial), tumor grade (differentiated vs anaplastic), and extent of surgery as well as pathologic variables.
3252757|NCT01407783|Experimental|Problem Solving Tools|The home visitation nurse will teach and utilize the problem solving tools to help low-income depressed mothers. It is a brief treatment with the a non-pathologizing intervention being done in 4-8 sessions.
3252758|NCT01407783|No Intervention|Enhanced Referral|
3252759|NCT01407796|Experimental|Endotoxin and [18F](+/-)NOS|All volunteers in this study will receive endotoxin in a single segment of the lung to induce mild, self-limited inflammation. They will also be imaged before and after endotoxin instillation with the novel PET tracer F-18 (+/-) NOS
3252760|NCT01407809|Experimental|Intervention|
3368705|NCT05063552|Experimental|Phase II, Arm A (Cetuximab, Docetaxel, Cisplatin, Carboplatin)|Patients receive cetuximab intravenously (IV) over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3368706|NCT05063552|Experimental|Phase II, Arm B(Docetaxel, Cisplatin/Carboplatin, Bevacizumab)|Patients receive bevacizumab IV over 30-90 on day 1, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3368707|NCT05063552|Experimental|Phase II, Arm C (Bevacizumab, Atezolizumab)|Patients receive bevacizumab IV over 30-90 on day 1 and atezolizumab over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3368708|NCT05063552|Experimental|Phase III, Arm A (Cetuximab, Docetaxel, Cisplatin/Carboplatin)|Patients receive cetuximab IV over 30-60 minutes on days 1, 8, and 15, docetaxel IV over 1 hour on day 1, and cisplatin IV or carboplatin IV on day 1. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive cetuximab IV over 30-60 minutes on day 1. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity.
3368709|NCT05063552|Experimental|Phase III,Arm B(Chemotherapy, Bevacizumab, Atezolizumab)|Patients receive treatment as in Arm B or C above based on results of the Phase II trial.
3368712|NCT05059353|Experimental|Patients with MCI|
3368713|NCT05059353|Experimental|Cognitively Normal Subjects|
3368714|NCT05059353|No Intervention|Caregivers of Patients with MCI|
3368715|NCT05059015|Active Comparator|CERVICAL HPV|Routine screening procedure based on HPV tests with cervical sampling by a health personnel
3368716|NCT05059015|Experimental|SELF SAMPLING HPV ARM 2|Screening based on HPV self-testing and colposcopic evaluation
3252761|NCT01407822|Experimental|Erlotinib arm|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
3252762|NCT01407822|Active Comparator|Chemo arm|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
3368717|NCT05059015|Experimental|SELF SAMPLING HPV ARM 3|Arm 3: screening based only on HPV self-testing
3368718|NCT05056441||Cohort 1: Vedolizumab|Biologic-naïve participants diagnosed with CD, who have initiated vedolizumab treatment will be observed from the data of diagnosis of CD until the date of index when vedolizumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when vedolizumab treatment was initiated.
3368719|NCT05056441||Cohort 2: Ustekinumab|Biologic-naïve participants diagnosed with CD, who have initiated ustekinumab treatment will be observed from the data of diagnosis of CD until the date of index when ustekinumab treatment was initiated during the eligibility period until the earliest of chart abstraction initiation, death or last contact with the site. Index date is defined as the date when ustekinumab treatment was initiated.
3252763|NCT01407835|Experimental|1|"Dactylis glomerata allergen extract at 4 different concentrations~Positive control~Negative control"
3252764|NCT01407848|Experimental|Furosemide|1 mg/kg/Ed
3252765|NCT01407848|Active Comparator|Saline 0,9%|1ml/kg/Ed
3252766|NCT01407861|Active Comparator|Relaxation training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
3252767|NCT01407861|Active Comparator|Aerobic endurance training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
3252768|NCT01407874|Experimental|Placebo|Placebo + Allopurinol 200mg
3368720|NCT05056246|Experimental|Group 1: Japanese participants - AMG 133 low dose|Japanese participants will receive the low dose of AMG 133 administered via subcutaneous injection.
3368721|NCT05056246|Experimental|Group 2: Japanese participants - AMG 133 medium dose|Japanese participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
3252769|NCT01407874|Experimental|Ulodesine (BCX4208) 5mg|BCX4208 5mg + Allopurinol 200 mg
3368722|NCT05056246|Experimental|Group 3: Japanese participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
3368723|NCT05056246|Experimental|Group 4: Caucasian participants - AMG 133 medium dose|Caucasian participants will receive the medium dose of AMG 133 administered via subcutaneous injection.
3368724|NCT05056246|Experimental|Group 5: Caucasian participants - AMG 133 high dose|Japanese participants will receive the high dose of AMG 133 administered via subcutaneous injection.
3368725|NCT05054348|Experimental|IO-108 Monotherapy|increasing dose levels of IO-108
3252770|NCT01407874|Experimental|Ulodesine (BCX4208) 10mg|BCX4208 10mg + Allopurinol 200mg
3252771|NCT01407887|Active Comparator|artesunate, amodiaquine methylene blue|two arms, open randomized controlled study in children with uncomplicated falciparum malaria in Burkina Faso. Intervention: artesunate (AS) - amodiaquine (AQ) - methylene blue (MB) control: artesunate (AS) - amodiaquine (AQ)
3252772|NCT01407887|No Intervention|artesunate amodiaquine|The control group will receive once daily a fixed dose AS-AQ over three days.
3252773|NCT01407900|Placebo Comparator|5% Dextrose in Water|Infusion of D5W
3252774|NCT01407900|Active Comparator|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
3252775|NCT01407939||Children, Adults|3- to 15-year old children and their parent (adults
3368726|NCT05054348|Experimental|IO-108 + pembrolizumab combination therapy|increasing dose levels of IO-108 in combination with a fixed dose of pembrolizumab
3368727|NCT05052996|Experimental|ISL+LEN|"Participants will receive the following for at least 48 weeks:~ISL 40 mg and LEN 600 mg on Days 1 and 2 (loading dose)~ISL 20 mg and LEN 300 mg on Day 8 and every week thereafter"
3368728|NCT05052996|Experimental|B/F/TAF|"Participants will receive the following for at least 48 weeks:~bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg once daily~After 48 weeks, participants will switch from B/F/TAF to ISL+LEN~ISL 40 mg and LEN 600 mg (loading dose over 2 days)~ISL 20 mg and LEN 300 mg 7 days after the first loading dose and every week thereafter~Participants who do not switch from B/F/TAF to ISL+LEN at Week 48 will be discontinued from the study."
3252776|NCT01407965|Experimental|Ertapenem|"Free tissue kinetics of ertapenem in fatty tissue and intraperitoneal fluid in mg/L~Free and bound plasma concentration of ertapenem or meropenem in mg/L"
3368734|NCT05050747||Arm 1|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of HCG on the day of trigger
3368735|NCT05050747||Arm 2|Women with unexplained infertility undergoing ovulation induction following endometrial injury by pipelle on day 8-9 of the same cycle of ovulation induction
3368736|NCT05050747||Arm 3|Women with unexplained infertility undergoing ovulation induction following intrauterine adminstration of placebo on the day of trigger
3368737|NCT05049733|Experimental|Arm 1|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 1 mg/kg and then switch to other doses after washout periods.
3252777|NCT01407965|Experimental|Meropenem|Free tissue kinetics of meropenem in fatty tissue and intraperitoneal fluid in mg/L up to 24 hours after administration. Free and bound plasma concentration of meropenem in mg/L.
3252778|NCT01407978|Active Comparator|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
3368738|NCT05049733|Experimental|Arm 2|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 2 mg/kg and then switch to other doses after washout periods.
3368739|NCT05049733|Experimental|Arm 3|Participants will start with ingestion of soft gel tablets high in CBD and CBD-A, but low in THC and THC-A. The total amount of cannabinoids ingested will be 4 mg/kg and then switch to other doses after washout periods.
3368740|NCT05049733|Placebo Comparator|Arm 4|Participants will begin with ingestion of placebo soft gel tablets that do not contain cannabinoids and then switch to other doses after washout periods.
3368741|NCT05048485||LEOPARD Cohort 1|"Control group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are not receiving nutritional supplementation.~TB LION group: The study will enroll 50 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are enrolled in the TB-LION study and who are receiving nutritional supplementation."
3368742|NCT05048485||LEOPARD Cohort 2|The study will enroll 300 newly diagnosed smear-positive (>/=1+ AFB) pulmonary TB patients whose household contacts are not enrolled in the TB-LION study.
3368743|NCT05047705|Experimental|Distress Tolerance Skills Training|Distress tolerance skills training is a multicomponent intervention drawn from third-wave cognitive-behavioral therapy (CBT) protocols.
3368744|NCT05047523|Experimental|ALXN1840|ALXN1840 will be administered at one of two starting doses, with incremental dose increases permitted.
3368745|NCT05047523|Active Comparator|Standard of Care|Participants will receive their current therapy or initiate Standard of Care therapy.
3252779|NCT01407978|Active Comparator|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
3252780|NCT01407978|Experimental|Vaccination with Fluval P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
3252781|NCT01407991|Experimental|Length or graph method|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
3252782|NCT01407991|Active Comparator|NEM method for NG/OG tube placement|Standard method- measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length. Nose to ear to mid-xiphoid-umbilicus (NEM).
3259458|NCT01471002|Experimental|Renal cancer without nephrectomy|patients with renal cancer that cannot be offered a partial nephrectomy
3252783|NCT01408004|Experimental|Alternating regimen|In the experimental arm (Arm A) alternating treatment will consist of 8 weeks of Pazopanib 800 mg qd alternated by 8 weeks of Everolimus 10 mg qd until first progression(PD per RECIST 1.1)followed thereafter by Pazopanib (when PD after 8 weeks of Everolimus)or Everolimus (when PD after 8 weeks of Pazopanib) monotherapy until second progression.
3368752|NCT05042908|Experimental|A phase I clinical study evaluating LBL-003 in the treatment of subjects with advanced solid tumors|Drug: LBL-003Injection The test drugLBL-003will be preset with 6 escalation dose levels: dose A, dose B, dose C, dose D and dose E, dose F , administered twice a week.
3368753|NCT05042609|Experimental|TRS01|
3368754|NCT05042609|Active Comparator|Active comparator|
3368755|NCT05042362|Experimental|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.
3252784|NCT01408004|Active Comparator|Sequential treatment|The comparative arm (Arm B) will be the standard regimen of Pazopanib (800 mg qd continuously) until progression, followed thereafter by Everolimus (10 mg qd continuously) until progression.
3252785|NCT01408056|Experimental|Timolol 0.5% Gel Forming Solution (GFS)|Half of enrolled subjects will receive topical Timolol
3252786|NCT01408056|Active Comparator|Mupirocin 2% ointment|Half of enrolled subjects will receive Mupirocin
3368756|NCT05042362|Placebo Comparator|Placebo + elinzanetant|Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.
3252787|NCT01408069|Experimental|MIGRANE|1 to 2 tablets ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg
3252788|NCT01408069|Active Comparator|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
3252789|NCT01408095|Experimental|LY2608204|80 to 400 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. The starting dose level depends on the participant's HbA1c level measured at Screening. Administered orally, daily for 12 weeks
3252790|NCT01408095|Active Comparator|Glimepiride|1 to 6 mg, Doses will be titrated to reach glycemic targets during the first 4 weeks. Administered orally, daily for 12 weeks
3368771|NCT05031416|Experimental|Consumers who smoke at outpatient community mental health clinic|Consumers with serious mental illness who attend outpatient community mental health clinic will participate in a smoking cessation with the LTQ application and nicotine replacement therapy
3368772|NCT05028699|Experimental|Snack|32 g of a common bean baked snack per day for 28 days.
3368773|NCT05028699|No Intervention|Control|
3252791|NCT01408108|Active Comparator|Lightweight mesh repair|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh
3252792|NCT01408108|Active Comparator|Primary crural repair|Laparoscopic primary posterior crural repair
3252793|NCT01408121||African-American on clopidogrel|
3252794|NCT01408121||African-American on prasugrel|
3252795|NCT01408121||Caucasian on clopidogrel|
3252796|NCT01408121||Caucasian on prasugrel|
3252797|NCT01408160|Experimental|Treatment (Combotox, cytarabine)|Patients receive high-dose cytarabine IV over 2-3 hours every 12 hours on days 1-3 and deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins IV over 4 hours on days 8, 10, and 12. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3252798|NCT01408173|Experimental|NPC-11|"Loading Dose (Day 1): Caffeine citrate 20 mg/kg body weight will be administered intravenously using a syringe infusion pump over 30 minutes.~Maintenance Dose (Day 2～Day 10): After an interval 24 hours, caffeine citrate 5 mg/kg body weight will be administered intravenously (over 10 minutes) or orally if the patients will be able to receive oral administration once a day. The maintenance dose can be increased to a maximum 10 mg/kg caffeine citrate once a day if apnea persists."
3252799|NCT01408186|Active Comparator|Rabeprazole|Tablet 20mg daily for 12 months
3252800|NCT01408186|Active Comparator|Famotidine|Tablet 40mg daily for 12 months
3368795|NCT05016024|Other|Colilen IBS + Placebo|First Period: Colilen IBS Second Period: Placebo
3368796|NCT05016024|Other|Placebo + Colilen IBS|First Period: Placebo Second Period: Colilen IBS
3368797|NCT05014867||Arm 1|Poor responders women undergoing frozen sequential embryo transfer on Day 3 and Day 5
3368798|NCT05014867||Arm 2|Poor responders women undergoing sequential fresh embryo transfer on Day 3 and Day 5
3368799|NCT05014867||Arm 3|Poor responders women undergoing sequential embryo transfer on Day 3 and Day 5 after performing PGS
3368800|NCT05014867||Arm 4|Poor responders women undergoing conventional frozen embryo transfer on Day 5
3252801|NCT01408199|Experimental|Lenalidomide Group|
3252802|NCT01408212|Experimental|Acupuncture therapy|
3252803|NCT01408238|Experimental|1|"Secale cereale allergen extract at 4 different concentrations~Positive control~Negative control"
3252804|NCT01408264|Active Comparator|0.035 guidewire|conventional 0.035 guidewire
3252805|NCT01408264|Active Comparator|Olympus Visiglide 0.025 guidewire|Olympus Visiglide 0.025
3252806|NCT01408290|Experimental|FAB-6011|- One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 2A/ and 32 subjects aged over 60 years /Group 2E/).
3252807|NCT01408290|Experimental|FAB-9011|- One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 3A/ and 32 subjects aged over 60 years/Group 3E/).
3252808|NCT01408290|Experimental|FLUVALAB|- One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 4A/ and 32 subjects aged over 60 years/Group 4E/).
3368802|NCT05010304|Experimental|Pediatric Patients with a history of penicillin allergy|
3252809|NCT01408290|Experimental|FAB-3511|- One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens (32 subjects aged 18-60 years /Group 1A/ and 32 subjects aged over 60 years /Group 1E/).
3252810|NCT01408316|Experimental|Part 1 (Crystalline vs. Amorphous)|Volunteers in part 1 of the study will initially receive either crystalline PX-866 tablets or amorphous PX-866 capsules, then after seven days, the same volunteers will respectively cross-over to receive the alternate amorphous PX-866 capsules or crystalline PX-866 tablets.
3252811|NCT01408316|Experimental|Part 2 (Crystalline Food Effect)|Volunteers in part 2 of the study will receive two single dose treatments of PX-866 crystalline tablets initially administered in either fed or fasted state, then after at least seven days, the same volunteers will respectively cross-over to receive PX-866 tablets in the alternate fed or fasted state.
3252812|NCT01408342|Other|Rituximab, Alemtuzumab|
3252813|NCT01408355|Experimental|50 microgram PF-06273588 intravenous|Subjects will receive a single intravenous microdose of PF-06273588 in period one
3252814|NCT01408355|Experimental|50 microgram PF-06273588 oral|Subjects will receive a single oral microdose of PF-06273588 in period two
3252815|NCT01408368|Active Comparator|Bilateral subtotal thyroidectomy|
3252816|NCT01408368|Experimental|Total thyroidectomy|
3252817|NCT01408381|No Intervention|Control|No cell therapy
3252818|NCT01408381|Experimental|Low dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 108
3252819|NCT01408381|Experimental|Intermediate dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 5 x 108
3252820|NCT01408381|Experimental|High dose|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells: 1 x 109
3368804|NCT05008107|Experimental|Virtual Reality|Virtual reality (VR) will be provided to families of patients undergoing ambulatory pediatric surgery. VR will provide personalized education to patients and their families about the entire continuum of the child's surgical experience. This will range from the hospital registration, the peri-operative experience, including the separation of the child from the parent in the pre-operative area and the anesthetic induction process, and the post-operative hospital ward.
3368805|NCT05008107|No Intervention|Control|Families will receive standard pre-operative instructions.
3368808|NCT05007756|Experimental|Ultraviolet B (UVB) Challenge|Participants will receive UVB (various doses) for minimal erythema dose (MED) assessment at baseline following which there will be washout period. Participants will then receive a single dose of UVB challenge dermally through Lumera Phototherapy System on Day 1, twice (2*) the MED at the challenge site with no UVB exposure at the contralateral control site.
3368809|NCT05003895|Experimental|1/ Arm 1|Escalating doses of CAR-T cells
3368810|NCT05003895|Experimental|2/ Arm 2|MTD of CAR-T cells
3368813|NCT05002543||MANTRA Aortic Sub-study|"Subjects diagnosed with aortic valve disease who are considered suitable to undergo aortic valve replacement with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Tissue Valve:~Perceval® PLUS SUTURELESS AORTIC HEART VALVE~Perceval® S SUTURELESS AORTIC HEART VALVE~Mechanical Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~Bicarbon Fitline Aortic (LFA)~Bicarbon Slimline Aortic (LSA)~Bicarbon Overline Aortic (LOV)~Carbomedics Prosthetic Heart Valve Models:~Standard Aortic Valve~Reduced Aortic Valve~Supra-Annular Aortic Valve (Top Hat)~Orbis™ Aortic Valve~Ascending Aorta Prostheses~CARBOMEDICS-CARBO-SEAL™~CARBOMEDICS CARBO-SEAL™ VALSALVA"
3368814|NCT05002543||MANTRA Mitral/Tricuspid Sub-study|"Subjects diagnosed with mitral and/or tricuspid valve disease who are considered suitable to undergo mitral valve repair/replacement and/or tricuspid valve repair with a CORCYM device can be included in this study.~The following devices can be entered in the study:~Annuloplasty Rings:~SOVERING™ ANNULOPLASTY DEVICE models~annuloplasty ring, mitral model~annuloplasty band, mitral and tricuspid models~Carbomedics Annuloplasty Ring models:~CARBOMEDICS ANNULOFLO®~CARBOMEDICS ANNULOFLEX®~Memo Annuloplasty Ring o MEMO 3D™ SEMIRIGID ANNULOPLASTY RING~Mitral Valves:~Bicarbon™ Bileaflet Heart Valve Prostheses Models:~o Bicarbon Fitline Mitral (LFM)~Carbomedics Prosthetic Heart Valve Models:~Standard Mitral Valve~Orbis™ Mitral Valve~OptiForm® Mitral Valve"
3368815|NCT05002543||MANTRA Memo 4D Sub-study|Subjects diagnosed with mitral valve disease who are considered suitable to undergo mitral valve repair with a CORCYM Memo 4D annuloplasty ring can be included in this study.
3368816|NCT05002452||Locally Advanced HCC Patients|Patients which are diagnosed with locally advanced hepatocellular carcinoma (HCC) will receive standard HAIC treatment.
3368817|NCT05001698|Experimental|Anifrolumab|All eligible participants will receive anifrolumab via intravenous (IV) infusion pump.
3368818|NCT04999020|Experimental|Ravulizumab|Participants will receive ravulizumab in both Parts A and B.
3368819|NCT04999020|Placebo Comparator|Placebo|Participants will receive placebo in both Parts A and B.
3368822|NCT04992637|Experimental|ClockWork|Participants who are randomized to treatment will receive the ClockWork intervention
3368823|NCT04992637|Active Comparator|Usual Care|Participants will receive usual care during the postpartum period.
3368831|NCT04987645|Other|Water-Assisted Colonoscopy|If this intervention is chosen randomly, the trainee will use water only technique for insertion.
3368832|NCT04987645|Other|Water and Air Insufflation|If this intervention is chosen randomly, the trainee will use water and air insufflation technique for insertion.
3252821|NCT01408394|Active Comparator|100 mg immediate release form|This is the formulation currently in use
3252822|NCT01408394|Experimental|90 mg controlled release|This is the low dose of the controlled release form
3252823|NCT01408394|Experimental|180 mg controlled release form|This is the medium controlled release dose
3252824|NCT01408407|Active Comparator|Arm A: standard of care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatment
3252825|NCT01408407|Experimental|Arm B: standard of care plus Alkagin paste|Patients will apply Alkagin Paste to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. They will also perform standard of care skin treatment.
3252826|NCT01408420|No Intervention|Standard blood pressure|Extracorporeal circulation during the surgery are conducted using standard blood pressure
3252827|NCT01408420|Active Comparator|MAP > 60 mmHg|A blood pressure of MAP > 60 mmHg is used during extracorporeal circulation. The higher MAP is maintained by using continuous intravenous administration of norepinephrine titrated to the appropriate dose for each patient.
3368833|NCT04986904|Experimental|SHUTi (Sleep Healthy Using the Internet)|Participants will be assigned to the SHUTi (Sleep Healthy Using the Internet) online intervention. They will spend 1-2 hours each week for 6-9 weeks completing daily sleep diaries as well as interactive core content covering topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the intervention, they will receive automated, tailored instructions for how to improve their sleep.
3368834|NCT04985812|Experimental|JNJ-67484703|Participants will receive multiple doses of JNJ-67484703.
3368835|NCT04985812|Placebo Comparator|Placebo|Participants will receive multiple doses of placebo.
3368837|NCT04979416|No Intervention|Control|No video message
3368838|NCT04979416|Experimental|Video message 1|
3252828|NCT01408433|Other|Single Embryo Transfer|Patients will have a single, chromosomally normal embryo transferred.
3252829|NCT01408433|Other|Double Embryo Transfer|Patients will have two (2) untested embryos transferred.
3252830|NCT01408446|Active Comparator|Menthol|Interventions Drug: Menthol Arms: Group 1
3252831|NCT01408446|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
3252832|NCT01408472|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye.
3252833|NCT01408498|No Intervention|Placebo Control|Control group who will not receive exogenous testosterone administration. Will act as a comparison group to the testosterone group.
3368839|NCT04979416|Experimental|Video message 2|
3368840|NCT04979416|Experimental|Video message 3|
3368841|NCT04978818|Active Comparator|Vaxelis|165 infants will be randomized to the Vaxelis group, which is licensed for primary vaccination at 2, 4 and 6 months of age.
3368842|NCT04978818|Active Comparator|PedvaxHIB arm|165 infants will be randomized to the PedvaxHIB group, which is licensed for primary vaccination at 2 and 4 months of age.
3252834|NCT01408498|Experimental|Testosterone administration group|Experimental group that will receive a single 10 g dose of 1% testosterone topical gel.
3252835|NCT01408511|Experimental|Arm 1|
3252836|NCT01408524|Active Comparator|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
3252837|NCT01408524|Active Comparator|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
3252838|NCT01408550|Active Comparator|NPB-01|Active Comparator: 1 Intravenous immunoglobulin
3252839|NCT01408550|Placebo Comparator|Placebo|Placebo Comparator: 2 Physiological saline
3368848|NCT04972019|Experimental|Telerehabilitation experimental group|Experimental training will occur in the home. The experimental training will last 8 weeks, each week having up to 4 sessions of therapeutic game play (based on tolerance). Each session will start with vitals being measured and logged. Data will be uploaded on a secure cloud server to which clinicians will have access.
3368849|NCT04972019|Sham Comparator|Telerehabilitation control group|Participants will perform web-based game play while wearing sham equipment. Duration and frequency of sessions will equal that of the experimental group training.
3252840|NCT01408589|Placebo Comparator|Sugar Pill|
3252841|NCT01408589|Experimental|Atomoxetine 40 mg|
3252842|NCT01408589|Experimental|Atomoxetine 60 mg|
3252843|NCT01408589|Experimental|Atomoxetine 80 mg|
3252844|NCT01408602|Experimental|MRC375 75 mg|MRC375 (enteric coated Tetracycline) 75 mg 3 times a day
3252845|NCT01408602|Experimental|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks.
3252846|NCT01408602|Placebo Comparator|Placebo|Placebo
3252847|NCT01408615||All Enrolled Participants|Women undergoing COS in combination with a GnRH antagonist for the development of multiple follicles in an ART program.
3252848|NCT01408654|Experimental|Peer Companionship|Behavioral intervention: Receipt of peer companionship provided by trained, supervised volunteer companions.
3252849|NCT01408654|No Intervention|Care-as-Usual|Care-as-Usual in Primary Care
3252850|NCT01408667|Placebo Comparator|Placebo|
3252851|NCT01408667|Active Comparator|TRC150094|
3252852|NCT01408680|Active Comparator|Coenzyme Q10 600 mg|
3368858|NCT04964557|Experimental|AZD8233|AZD8233 for subcutaneous use
3368859|NCT04964557|Placebo Comparator|Placebo|Placebo solution for subcutaneous injection
3252853|NCT01408680|Active Comparator|Coenzyme Q10 1200 mg|
3252854|NCT01408680|Placebo Comparator|Placebo|
3368863|NCT04961996|Experimental|Arm A: Giredestrant|
3368864|NCT04961996|Active Comparator|Arm B: Endocrine Therapy of Physician's Choice|
3368871|NCT04954196|Experimental|Amlodipine arm|Single dose per os Amlodipine 5mg administration per day
3368872|NCT04954196|Placebo Comparator|Placebo arm|Single dose per os placebo (microcrystalline cellulose) administration per day
3368873|NCT04952545|Experimental|Cohort 1: ALXN2050 (Dose 1)|Participants will receive ALXN2050 (Dose 1) as follows under fasting conditions: 120-milligrams (mg) single dose, 3-day washout, then 120-mg twice daily (BID) dosing.
3368874|NCT04952545|Experimental|Cohort 1: Placebo (Dose 1)|Participants will receive placebo (Dose 1) as follows under fasting conditions: 120-mg placebo single dose, 3-day washout, then 120-mg placebo BID dosing.
3368875|NCT04952545|Experimental|Cohort 2: ALXN2050 (Dose 2)|Participants will receive ALXN2050 (Dose 2) as follows under fasting conditions: 180-mg single dose, 3-day washout, then 180-mg BID dosing.
3252855|NCT01408693|Active Comparator|Anterior minimal invasive approach, AMIS|AMIS in 95 randomized patients.
3252856|NCT01408693|Active Comparator|Trans-gluteal approach, CLAS|CLAS in 95 randomized patients.
3368876|NCT04952545|Experimental|Cohort 2: Placebo (Dose 2)|Participants will receive placebo (Dose 2) as follows under fasting conditions: 180-mg placebo single dose, 3-day washout, then 180-mg placebo BID dosing.
3368877|NCT04951154|Other|Participants with Suspected Lung Cancer|Eligible participants with suspected lung cancer will be enrolled and undergo diagnostic and research bronchoscopic biopsies and research blood sample collection for biomarker analysis. Those participants who proceed to surgical resection will have additional research samples taken from the resected tumor and additional research blood samples drawn for biomarker analyses at the resection visit and at the post-operative follow up visit. Participants will then be followed clinically for two years for evidence of recurrence or until participants with confirmed lung cancer recurrence, whichever occurs earlier.
3252857|NCT01408745|Experimental|Sternumfix|sternotomy closure with Sternumfix
3252858|NCT01408745|Active Comparator|Steel wire|sternotomy closure with steel wire
3252859|NCT01408758|Other|VCRT|This group will have 2 visits with a study physician in addition to using the VCRT.
3252860|NCT01408758|Other|no VCRT|This group will have 2 visits with study physician only, no VCRT.
3252861|NCT01408797|Experimental|Donor specific transfusion|Subjects with uremia will undergo donor specific transfusion before transplantation
3252862|NCT01408797|Experimental|Clonal deletion|
3252863|NCT01408797|Experimental|Drugs Added When Needed|
3252864|NCT01408810|Experimental|Infliximab|Infliximab 5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter. The treatment should follow infliximab's Summary of Product Characteristics.
3252865|NCT01408823||Idiopathic Scoliosis|
3252866|NCT01408823||Non-idiopathic Scoliosis|
3252867|NCT01408836|Experimental|1|Plasma exchange x 7 over 14 days
3252868|NCT01408836|Active Comparator|2|Methyl prednisolone 1g x 3
3252869|NCT01408849|Experimental|Maytenus|Tea of Martens ilicifolia leaves
3252870|NCT01408849|Active Comparator|Omeprazole|Omeprazole as active comparator
3252871|NCT01408875|Experimental|Rehabilitation and EMS Group|Patient Heart Failure who follows physical training and sessions of electrical quadricipital myostimulation.
3252872|NCT01408875|No Intervention|Rehabilitation Group only|Patient Heart Failure who follows physical training
3252873|NCT01408953|Experimental|bevacizumab for all patients|This is a single arm trial. All patients receive treatment with bevacizumab.
3252874|NCT01408966|Experimental|DarkChocolate|11 patients were randomized to receiving dark chocolate 0.55 g/kg of body weight (Lindt Excellence 85% Cocoa, Lindt & Sprüngli España) together with the test meal
3368879|NCT04949438|Experimental|Cohort 1: Participants with severe renal impairment|Participants with severe renal impairment will receive a single oral dose of AZD4831 on Day 1.
3368880|NCT04949438|Experimental|Cohort 2 :Healthy participants|Healthy participants will receive a single oral dose of AZD4831 on Day 1.
3252875|NCT01408966|Placebo Comparator|White chocolate supplementation|11 patients received 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight.
3252876|NCT01408979|Experimental|12 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 12 hours after delivery
3252877|NCT01408979|Active Comparator|24 hours of magnesium sulfate|Patients in this group will have magnesium sulfate administered for 24 hours after delivery
3252878|NCT01409005|Experimental|Gemcitabine plus UFTE|Gemcitabine plus UFTE chemotherapy (Single arm)
3368881|NCT04947631|Experimental|DKF-313|Dutasteride 0.5mg + Tadalafil 5mg
3368882|NCT04947631|Active Comparator|Dutasteride|Dutasteride 0.5mg
3368883|NCT04947631|Active Comparator|Tadalafil|Tadalafil 5mg
3368884|NCT04944316|Active Comparator|Low-fat, vegan diet|For a 12-week period, participants will be asked to follow a low-fat, vegan diet which consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. In choosing grain products and starchy vegetables (e.g., bread, potatoes), participants will be encouraged to select those retaining their natural fiber and having a glycemic index <70, using tables standardized to a value of 100 for glucose.
3368885|NCT04944316|Active Comparator|Portion-controlled diet|For a 12-week period, participants will be asked to follow a portion-controlled diet that is compliant with American Diabetes Association (ADA) guidelines. This diet will include individualized diet plans that reduce daily energy intake by 500-1,000 kcal for overweight (body mass index > 25 kg/m2) participants and keep carbohydrate intake reasonably stable over time. It will derive 15-20% from protein, <7% saturated fat, 60-70% carbohydrate and monounsaturated fats and ≤200 mg/day of cholesterol/day.
3252879|NCT01409018|Experimental|Itraconazole|
3252880|NCT01409044|Experimental|Music|Research participant listened to music
3368886|NCT04939870||PREDIALYSIS GROUP|(n = 48) - patients in the pre-dialysis period (stage G3b-G4 CKD) with moderate or severe decrease in eGFR (eGFR 44-29 ml / min / 1.73 m2),
3368887|NCT04939870||END-STAGE RENAL DISEASE GROUP|patients with ESRD (n=78) - (eGFR <15 ml/min /1.73 m2) undergoing renal replacement therapy. Depending on the method of renal replacement therapy used, two subgroups are distinguished: PD subgroup (n=35) including patients treated by peritoneal dialysis. In this subgroup, initially, due to the treatment technique, two groups were separated, a group (n=15) treated with the automatic peritoneal dialysis (APD) technique, and a group of patients (n = 20) using the technique of continuous cycling peritoneal dialysis (CCPD), HD subgroup (n = 43) including patients treated with repeated hemodialysis. Hemodialysis procedures were performed in each patient three times a week, via an arteriovenous fistula from own or artificial vessels. The duration of hemodialysis was at least 10 hours/week using standard bicarbonate dialysis fluids and polysulfone low-flux dialyzers. The blood flow during hemodialysis was 200-350 ml/min, with an average dialysis fluid flow of 500 ml/min.
3368888|NCT04939870||CARDIOLOGY GROUP|• CARD group (n = 37) - patients with at least one history of cardiovascular events, admitted to hospital for elective angiography, without any signs of impaired kidney function. The studies in this group were to show the changes that occur as a result of diseases of the cardiovascular system and the functioning of the kidneys.
3368889|NCT04939870||HEALTHY VOLUNTEERS|Healthy volunteers, (n = 32) - it was composed of healthy people, with no evidence of impairment in renal function and cardiovascular function in the history and at the time of enrollment in the study.
3368898|NCT04931095|Placebo Comparator|Placebo cannabis + placebo alcohol|Participants administer oral cannabis containing 0mg THC in combination with a placebo alcohol drink.
3368899|NCT04931095|Experimental|low dose cannabis with placebo alcohol|Participants administer oral cannabis containing 10mg THC in combination with a placebo alcohol drink.
3368900|NCT04931095|Experimental|high dose cannabis with placebo alcohol|Participants administer oral cannabis containing 25mg THC in combination with a placebo alcohol drink.
3252881|NCT01409057||No heart lung machine|Coronary-artery-disease
3252882|NCT01409057||Heart lung machine|Coronary artery disease
3252883|NCT01409070||Azacitidine|200 MDS patients taking Azacitidine will be assessed
3252884|NCT01409070||Decitabine|100 MDS patients taking Decitabine will be assessed
3368901|NCT04931095|Experimental|low dose cannabis with low dose alcohol|Participants administer oral cannabis containing 10mg THC in combination with an alcohol drink (0.05 percent BAC).
3368902|NCT04931095|Experimental|high dose cannabis with low dose alcohol|Participants administer oral cannabis containing 25mg THC in combination with an alcohol drink (0.05 percent BAC).
3252885|NCT01409083|Experimental|intravenous bicarbonate|Diluted sodium bicarbonate will be injected to s new IV catheter expecting a rise in end-tidal CO2
3252886|NCT01409083|Placebo Comparator|control|equal volume of normal saline will be randomely injected
3368903|NCT04931095|Experimental|Placebo cannabis + low dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.05 percent BAC).
3368904|NCT04931095|Experimental|Placebo cannabis + high dose alcohol|Participants administer oral cannabis containing 0mg THC in combination with an alcohol drink (0.08 percent BAC).
3368911|NCT04925752|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2"
3252887|NCT01409109||Patient volunteers|This group is comprised of persons with Schizophrenia and Schizoaffective.
3252888|NCT01409109||Healthy volunteers|This group is comprised of individuals who have no current or past psychiatric diagnosis.
3368912|NCT04925752|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN placebo every 26 weeks~Oral F/TDF 200/300 mg once daily~PTM Oral LEN on Days 1 and 2"
3368913|NCT04925752|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and OLE Week 52 and will also receive oral LEN 600 mg on OLE Days 1 and 2."
3368914|NCT04925752|Experimental|PK Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Coverage Phase.~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last injection of LEN."
3368915|NCT04925700|Experimental|Probiotic Lozenge|
3368916|NCT04925700|Placebo Comparator|Placebo Lozenge|
3252889|NCT01409122|Experimental|Part A Multiple Dose|Ascending multiple dose administration (every 8 hours, [Q8H]) of AIR001 or placebo for 16 consecutive doses
3252890|NCT01409122|Experimental|Part B Single Dose with Sildenafil|Single escalating doses of AIR001 or placebo (Q8H, Day 4-6) administered in combination with steady-state sildenafil administration (Q8H, Days 1-6)
3368925|NCT04921800|Experimental|Wearable Sensor Applied|For these participants, the wearable ADAM sensor will be placed in the sternal notch to record anatomical data during the post-surgical period for up to 14 days
3252891|NCT01409122|Experimental|Part C, administration of AIR001 to patients with PAH|Four doses of AIR001 will be administered via nebulization to patients with PAH.
3252892|NCT01409122|Experimental|Part D, device crossover study|PK, safety and tolerability of single doses of AIR001 administered in a randomized order with three different nebulizers.
3252893|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 1|
3252894|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 2|
3252895|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 3|
3252896|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 4|
3368926|NCT04916938|Experimental|Interactive Guidance Therapy|Mother child psychotherapy based on video-feedback interaction after a free play session. The therapy usually enhances parent sensibility to the child.
3368927|NCT04916938|Active Comparator|Treatment as usual|Mother child psychotherapeutic sessions without video feed back.
3252897|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 5|
3252898|NCT01409135|Experimental|AGS-22M6E-11-1 Dose Level 6|
3252899|NCT01409135|Experimental|ASG-22CE Expansion Cohort 1|Breast Cancer
3252900|NCT01409135|Experimental|ASG-22CE Expansion Cohort 2|Bladder Cancer
3368930|NCT04916067|Experimental|Intervention|Patients undergoing mesh implantation during ileostomy closure to reinforce the abdominal wall
3252901|NCT01409135|Experimental|ASG-22CE Expansion Cohort 3|Lung plus other solid tumor cancers
3252902|NCT01409148|Other|I-124 Mu 11-1F4 sterile injection|Single arm study
3368933|NCT04905316|Experimental|Canakinumab with Chemoradiation and Durvalumab|Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first.
3368936|NCT04904354|Experimental|Paroxysmal atrial fibrillation|Subjects schedule for a de novo ablation of paroxysmal atrial fibrillation
3368937|NCT04904354|Experimental|Persistent atrial fibrillation|Subjects schedule for a de novo ablation of persistent atrial fibrillation
3368940|NCT04900103|Experimental|Tech-volunteer|"A complex intervention with two phases is proposed.~First phase: volunteers new technologies training (tech-volunteering). Volunteers will be trained in the use of NT and their interconnectivity as tools to support their volunteer work. This training will be integrated into the PC volunteer training programme.~Second phase: using the NT with patients and relatives."
3368941|NCT04900103|No Intervention|Usual volunteer|the control group will receive standard volunteer service.
3368942|NCT04898790|No Intervention|Feedback for Preliminary Adaptation|Participants in Aim 1 will participate in qualitative interviews to obtain feedback on the CHAMPS-II intervention and survivorship education active control condition materials. Interviews will be with 1)adult participants 60+ years who have recently undergone HCT, 2)participants' care-partner, and 3)HCT team members.
3368943|NCT04898790|Experimental|Adapted CHAMPS-II intervention|All participants in Aim 2, and those randomized to the physical activity intervention in Aim 3 will participate in the CHAMPS-II physical activity program adapted to the HCT setting. Testing for outcome measures will be completed, and feedback on the intervention will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
3368944|NCT04898790|Active Comparator|Survivorship Education Active Control Condition|Participants in Aim 3 who are randomized to the Survivorship Education active control condition will receive the survivorship education program. Testing for outcome measures will be completed, and feedback on the survivorship education program will be obtained via qualitative interviews from 1)adult participants 60+ years receiving HCT, 2)participants' care-partner, and 3)HCT team members.
3368945|NCT04897022|Experimental|Participants with malignant pleural mesothelioma (MPM)|Participants will be diagnosed with malignant pleural mesothelioma and be deemed unresectable per thoracic surgeon assessment
3252903|NCT01409161|Experimental|Treatment (tretinoin, arsenic trioxide, gemtuzumab ozogamicin)|"INDUCTION: Patients receive tretinoin PO BID, arsenic trioxide IV over 1-2 hours daily, and gemtuzumab ozogamicin IV over 2 hours once at weeks 1-4.~CONSOLIDATION: Patients achieving CR receive arsenic trioxide IV 5 days per week during weeks 1-4, 9-12, 17-20, and 25-28 and tretinoin PO BID for 2 weeks on and 2 weeks off. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3368950|NCT04894890||secukinumab|Patients administered secukinumab by prescription
3252904|NCT01409174|Experimental|Ipilimumab + Chemotherapy|Ipilimumab starting 1 mg/kg by vein (IV) Day 1 each cycle; Temozolomide 200 mg/m^2 orally Days 2-5 of Induction; Cisplatin 25 mg/m^2 IV for Days 2-4 of Induction; Interferon alfa-2b 5 million U/m2 subcutaneously on Days 1-5 of each cycle Induction + Consolidation; and Interleukin-2 9 million IU/m^2 IV as a continuous infusion on Days 2-5 of Induction + Consolidation.
3252905|NCT01409187|Experimental|Ipilimumab + Interferon + Interleukin-2|Ipilimumab starting dose 2 mg/kg intravenous (IV) day 1 only; IFN alfa-2b at 5 million U/m2 subcutaneously daily for 5 days starting day 1; IL-2 at 9 million IU/m^2 daily IV continuous infusion for 4 days on days 2-5.
3252906|NCT01409200|Experimental|Arm I (antiandrogen therapy, axitinib, surgery)|Patients receive antiandrogen therapy per standard care and axitinib PO BID for 4 months. Patients then undergo radical prostatectomy and pelvic lymph node dissection.
3368959|NCT04889105|Other|Performance evaluation|Preliminary performance evaluation to refine the Smart MOVE! intervention.
3368960|NCT04889105|Active Comparator|Smart MOVE!|Participants will be enrolled in the multi-component Smart MOVE! intervention for 12 weeks.
3368961|NCT04889105|Placebo Comparator|Usual care|Participants will receive general walking advice for 12 weeks.
3368969|NCT04887506|Experimental|TAVT-45|TAVT-45 administered twice daily as a 1 x sachet containing TAVT-45 (250 mg abiraterone acetate) + Prednisone (5mg once or twice daily, depending on prostate cancer population). TAVT-45 administered approximately every 12 hours without respect to food. Patients treated for 84 days.
3368970|NCT04887506|Active Comparator|Reference abiraterone acetate (Zytiga®) - R-AA|Zytiga (reference abiraterone acetate formulation, hereafter referred to as R-AA) administered once daily as (2 x 500mg Zytiga tablets) + Prednisone (5mg once or twice daily, depending on prostate cancer population). R-AA administered once daily either ≥ 1 hour before or ≥ 2 hours after a meal. Patients treated for 84 days.
3368974|NCT04884893|Experimental|Intermittent nitrous oxide|10 minutes of 50% nitrous oxide + 10 min 100% oxygen + 10 min 50% nitrous oxide + 10 min 100% oxygen
3368975|NCT04884893|Experimental|Continuous nitrous oxide|20 min 50% nitrous oxide + 20 min 100% oxygen
3252907|NCT01409200|Active Comparator|Arm II (antiandrogen therapy, surgery)|Patients receive antiandrogen therapy per standard care for 4 months and then undergo radical prostatectomy and pelvic lymph node dissection.
3252908|NCT01409226|Experimental|MRI|
3252909|NCT01409252||Hemorrhagic stroke patients|
3252910|NCT01409265||No treatment|
3368976|NCT04883762|Experimental|Fecal Microbiota Transplantation (FMT)|Study subjects will undergo standard bowel preparation and diagnostic colonoscopy with routine biopsies for pathologic assessment. FMT will be performed at the proximal extent of the colon reached, according to the same protocol used in prior randomized studies. FMT will use healthy donor stool provided by OpenBiome, a nonprofit 501(c)(3) organization that provides clinicians and hospitals with screened, filtered and frozen stool to be used for FMT. Routine clinical and research biopsies will be collected during the FMT colonoscopy procedure.
3368977|NCT04883242|Experimental|Treatment (isatuximab, carfilzomib, pomalidomide, steroid)|"INDUCTION: Patients receive isatuximab IV on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of subsequent cycles carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1,8, 15, and 22. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive isatuximab IV days 1 and 15, carfilzomib IV over 30 minutes on days 1 and 15, pomalidomide PO QD on days 1-21, and dexamethasone PO or IV on days 1, 8, 15, and 22. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3368978|NCT04881149|Experimental|TempSure Device|The TempSure will be used on the flanks during this study.
3368979|NCT04880460|Active Comparator|Experimental|45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
3368980|NCT04880460|Placebo Comparator|Control|45 MDD patients were included in this arm who were received SSRIs and placebo tablets
3368981|NCT04878432|Experimental|MBG453 (sabatolimab) + HMA|MBG453 + HMA (azacitidine, decitabine, or INQOVI (oral decitabine))
3368984|NCT04877379|Experimental|Part 1|Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.
3252911|NCT01409278|Experimental|Ropivacaine infiltration and infusion.|Ropivicaine infiltration followed by continuous ropivicaine infusion for 48 hours.
3252912|NCT01409278|Experimental|Ropivacaine and Saline|Ropivicaine infiltration followed by normal saline infusion.
3368985|NCT04877379|Experimental|Part 2A|Multiple dose administration of VNRX-7145 q8h for 10 days
3368986|NCT04877379|Placebo Comparator|Part 2B|Multiple dose administration of placebo q8h for 10 days
3368987|NCT04877379|Experimental|Part 3A|Multiple dose administration of low dose VNRX-7145 + VNRX-5024
3368988|NCT04877379|Experimental|Part 3B|Multiple dose administration of high dose VNRX-7145 + VNRX-5024
3368989|NCT04877379|Placebo Comparator|Part 3C|Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)
3368990|NCT04875975|Experimental|Rozanolixizumab|Participants will be randomized to receive a predefined dose of rozanolixizumab.
3368991|NCT04875975|Placebo Comparator|Placebo|Participants will be randomized to receive a predefined dose of placebo.
3368992|NCT04875533|Experimental|20vPnC/Saline|20vPnC and saline
3368993|NCT04875533|Active Comparator|13vPnC/PPSV23|13vPnC and PPSV23
3368994|NCT04875195|Experimental|Arm 1|Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.
3252913|NCT01409278|Placebo Comparator|Saline infiltration and infusion.|Normal saline infiltration followed by saline infusion.
3369002|NCT04864080|Active Comparator|Healthy Comparison Group|Behavioral tasks and surveys online.
3369003|NCT04864080|Experimental|Pain/Depression patients from clinic|MRI, TMS and EEG, and behavioral tasks and surveys online.
3369004|NCT04863352||Study group|Men who have been treated for localized or locally advanced prostate cancer with curative intent
3369005|NCT04863352||Matched population based controls|Existing population based data from men who participated in the Trøndelag Health Survey 2017-2019
3369006|NCT04862676|Experimental|Experimental Arm:single|Repeated treatments with hyperbaric oxygen on Days 0, +1 and +2 of high-dose therapy melphalan and autologous transplants.
3369009|NCT04855487|Experimental|Intervention group|Adolescents/young adults with cancer will participate in a 5-week online expressive storytelling intervention. They will independently create digital stories about themselves while their target audiences are their primary nurses. They will then participate in weekly online meetings with nursing research staff, during which they introduce their stories and discuss their reflections. In the final session, they will create a one-page or five-slide story to share with their primary nurses, if they want.
3369010|NCT04853290|Experimental|Intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
3369011|NCT04853290|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse from a clinical inpatient unit.
3369012|NCT04852679|Other|lanreotide Autogel 120 mg|Subjects will be treated with lanreotide Autogel® 120mg, every 28 days (+/- 3 days).
3369017|NCT04848285|Active Comparator|Standard care group|Standard of care (SC) mobility protocol performed by the Stroke Unit nursing and physiotherapy staff. The SC consists of one or two sessions per days of out-of-bed sitting and standing, adapted to patient´s tolerability, and one session of physiotherapy per day. Mobilization will be schedule to start from 24 hours from symptoms onset according to the local Stroke Unit protocol.
3369018|NCT04848285|Experimental|Intensive mobilization group|The Intensive mobilization intervention will include the standard care plus at least two additional sessions each day of at least 20 minutes each session focused on task specific sitting, standing and walking activities. The intervention will be schedule to start at 24 hours from symptoms onset and will last 14 days or until the patient is discharged.
3369019|NCT04848090|Other|Neonate WGS Testing|Neonate subjects who are eligible and whose parents consent to study will undergo blood sampling which will be sent for whole genome sequencing and bioinformatics analysis, filtering first a targeted panel of 1722 genes most likely to cause genetic disorders in the first year of life, and then with a whole exome filter if no obvious diagnosis is determined using the 1722 gene panel filter.
3369021|NCT04839809|Experimental|CC-92480-02 (Formulation A) with Placebo|CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.
3252914|NCT01409317|Experimental|Deep Transcranial Magnetic Stimulation|
3252915|NCT01409317|Active Comparator|Repetitive Transcranial Magnetic Stimulation|
3252916|NCT01409330|Experimental|hypocaloric diet containing increased fibers and coffee|In the intervention group the patients are allowed to eat only white meat and fish. They also need to increase their daily fiber intake to 50grams and drink 5 cups of coffee a day.
3252917|NCT01409330|Active Comparator|hypocaloric diet containing red meat|control group (n=20): diet according to the ADA/EASD guidelines (50% carbohydrates, 20% proteins, 30% fat). In the control group the patients should eat 150 grams of red meat a day and are not allowed to consume alcohol, coffee and whole grains.
3252918|NCT01409343|Experimental|TrasGEX|A total of 37 patients with advanced HER2-positive carcinomas and progressive disease.
3252919|NCT01409356|Experimental|Diet+Exercise|Program of weight loss through diet+exercise (=intervention)
3252920|NCT01409369|Experimental|1|
3252921|NCT01409369|Active Comparator|2|
3369022|NCT04839809|Experimental|CC-92480 (Formulation B)- fasted condition|A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.
3369023|NCT04839809|Experimental|CC-92480-02 (Formulation A) - fasted condition|A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.
3369024|NCT04839809|Experimental|CC-92480 (Formulation B) - Low-fat meal|A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).
3369025|NCT04839809|Experimental|CC-92480-02 (Formulation A) - high-fat meal|A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).
3252922|NCT01409395|Experimental|Metformin|Subjects will be dosed with Metformin alone (850 mg)
3369026|NCT04838457|Experimental|ACME-TM|Participants will obtain 4 sessions of telehealth cognitive behavioral therapy (CBT) focused on reducing alcohol misuse. Participants will receive a 5th telehealth coaching call to develop a plan for ensuing treatment regarding their elevated cardiovascular risk factors. Participants will then receive daily texts for one month aimed at helping them decrease these cardiovascular risk factors.
3369027|NCT04837833|Experimental|research ultrasound (rUS1)|Participants will undergo research ultrasound (rUS1) within three days of their routine contrast enhanced CT scan (CECT). A subset of participants will undergo a second research US (rUS2) at 3-4 weeks after rUS1 and at least one month prior to the next planned clinical CECT.
3369028|NCT04837508|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
3369029|NCT04836221|Experimental|Intervention|Will receive mHealth support for comorbidity and support from a Community Health Worker by phone
3252923|NCT01409395|Experimental|Metformin and Nizatidine|Subjects will be dosed with metformin in conjunction with nizatidine
3252924|NCT01409408|Active Comparator|Aliskiren|
3252925|NCT01409408|Active Comparator|Amlodipine|
3252926|NCT01409421|Experimental|motivational interviewing|3 phone and 3 in person counseling support sessions with glaucoma educator
3252927|NCT01409421|Active Comparator|reminder calls|behavioral: three phone calls to remind patients to take their eye drops
3252928|NCT01409421|No Intervention|standard care|standard care for glaucoma
3252929|NCT01409447|Experimental|Biphasic osteochondral composite|feasibility study for the new medical device & technique
3252930|NCT01409460|Experimental|True Obturator Nerve Block|
3252931|NCT01409460|Sham Comparator|Sham Block|
3252932|NCT01409473|Experimental|Prostate SBRT|Prostate SBRT with concurrent boost to intraprostatic lesion (IPL) will be delivered in 5 fractions using intensity-modulated radiotherapy planning techniques.
3252933|NCT01409499|Experimental|A, surgery|The patients in this group will receive palliative resection of HCC, then take sorafenib as remain therapy.
3252934|NCT01409499|Experimental|B, TACE|Patients in group B will receive transcatheter hepatic arterial chemoembolization, then take sorafenib as remain therapy.
3369038|NCT04832334||Stroke Participants|Stroke patients with hemiplegia or chronic hemiparesis
3369039|NCT04832334||Healthy Participants|The healthy control group was matched with stroke participants in terms of age, gender, dominant side and education level.
3252935|NCT01409499|Experimental|C, sorafenib|Patients in group C will receive monotherapy of sorafenib.
3369040|NCT04830839|Experimental|Recovery after Stress Toolkit (ReSeT)|"ReSeT is comprised of interactive web-based psychoeducational modules that are developmentally tailored for school age children (8-17 years) for use with synchronous e-health therapy sessions with a trained therapist.~Participants in the ReSeT treatment will complete 8 modules and therapy sessions. Parents will also have access to 4 modules During the study, children/youth will be asked to complete all eight sessions of the online treatment together with the therapist over an 8 -12 week time period (to allow for scheduling/cancellations). For younger children, parents will participate in the beginning and end of each session. Sessions will last approximately 30-60 minutes and will occur approximately every week for an anticipated 4-8 hour time commitment. Parents of older children will be permitted to review the content independently and participate in feedback sessions."
3369041|NCT04830787||hypertrophic cardiomyopathy|patients with hypertrophic cardiomyopathy
3369042|NCT04830787||control without hypertrophic cardiomyopathy|controls without hypertrophic cardiomyopathy
3369045|NCT04826029|Other|Standard arm|
3369046|NCT04826029|Experimental|Interventional arm|
3252936|NCT01409512||Women with OAB|Patients that will be diagnosed as having OAB syndrome by an urogynecologist based on their clinical symptoms (urinary urgency, with or without urinary urgency incontinence, urinary frequency or nocturia).
3369053|NCT04816604|Experimental|GB002 (seralutinib)|GB002 (seralutinib) inhaled orally twice per day (BID) over 72 weeks
3369056|NCT04814446|Experimental|Gardasil 9®|Nonavalent HPV vaccine
3369057|NCT04814446|Placebo Comparator|Placebo|NaCl 0.9 % solution for injection
3369058|NCT04809207|Experimental|CF Wellness Program|Participants will receive CF Wellness Program sessions.
3369059|NCT04809025||the pathology of endoscopic biopsy|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on endoscopic biopsies
3369060|NCT04809025||the pathology of surgical resection specimen|The histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status of gastric cancer testing on surgical resection specimens
3369062|NCT04808115|Experimental|KDS-1001|KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
3369063|NCT04806503|Experimental|UNR844 Low|UNR844 Low ophthalmic solution; one drop twice-a-day for three months
3252937|NCT01409525||cardiac surgery patients|
3252938|NCT01409538|Placebo Comparator|Placebo|Asymptomatic control participants receive Natural History and Placebo instructions in a within-subject design. There are no patients, or active agents in this study. It is not a Clinical Trial.
3252939|NCT01409538|Active Comparator|Control condition|"The control condition represents a no-intervention, repeated baseline control, since the active intervention in this study is placebo."
3252940|NCT01409551|Active Comparator|VATS hyperthermic pleural chemoperfusion|The patients undergo a VATS drainage of pleural effusion with adhesiolysis and complete mobilization of the lung, following by a 1 hour hyperthermic (40oC)chemoperfusion by means of a pump machine.
3369064|NCT04806503|Experimental|UNR844 Medium 1|UNR844 Medium 1 ophthalmic solution; one drop twice-a-day for three months
3369065|NCT04806503|Experimental|UNR844 Medium 2|UNR844 Medium 2 ophthalmic solution; one drop twice-a-day for three months
3369066|NCT04806503|Experimental|UNR844 High|UNR844 High ophthalmic solution; one drop twice-a-day for three months
3369067|NCT04806503|Placebo Comparator|Placebo Ophthalmic Solution|placebo ophthalmic solution; one drop twice-a-day for three months
3252941|NCT01409551|Active Comparator|Bedside talc slurry pleurodesis|The patients undergo tube thoracostomy under local anesthesia. When the lung is fully expanded, talc slurry bed-side pleurodesis is performed.
3252942|NCT01409577||FFR|Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible > 9months clinical follow-up
3369068|NCT04805385|Experimental|PS128|Subjects will consume the PS128 capsules every day, 2 capsules at a time, for 12 weeks.
3252943|NCT01409590|Other|Exercise and Diet program|All patients recruited in the study, participated in an homogeneous exercise program and diet.
3252944|NCT01409603|Experimental|Treatment arm A|darexaban, wash-out, naproxen, wash-out, combination therapy
3369069|NCT04805385|Placebo Comparator|Placebo|Subjects will consume the placebo capsules every day, 2 capsules at a time, for 12 weeks.
3369070|NCT04805385|No Intervention|Healthy Control|
3369071|NCT04804228|Experimental|Electrical dry needling|The experimental group consisting of 40 subjects will perform electrostimulation on the active myofascial trigger points of the following muscles: quadratus lumbar, multifidus and iliocostalis, following the PGM maps described by Travell and Simons. The electrostimulation of the PGM will be carried out using needle electrodes, the generated current will be produced by a TENS device with a frequency of 2 Hz and a pulse width of 250 μs, the application will be approximately 30 min. The therapeutic intervention will be 1 session per week for a total of 6 weeks.
3369072|NCT04804228|Active Comparator|Ischemic compression, analytical stretching and postural habits educational dossier|The control group consisting of 40 subjects will undergo an ischemic compression technique in active PGM with a time between 20 seconds and 1 minute until pain inhibition is achieved, and finally, analytical stretching will be carried out on the quadratus lumbar, multifid and iliocostal, 1 weekly session for 6 weeks providing a training dossier of postural education in their activities of daily life.
3369073|NCT04804163|Experimental|Upper urinary tract disease group|Patients with upper urinary diseases (renal cell carcinoma, nonfunctioning kidney and adrenal tumor) will be treated by telesurgery.
3369074|NCT04803409|Experimental|Ultrasound Group|Daily ultrasound application to the spleen of approximately 18 minutes for up to 7 days, in addition to standard clinical care.
3369075|NCT04803409|No Intervention|Control Group|Control Group
3369081|NCT04795531|Experimental|Once weekly insulin icodec + once daily placebo|Participants will get once daily and once weekly injections
3369082|NCT04795531|Experimental|Once weekly placebo and once daily insulin degludec|Participants will get once daily and once weekly injections
3252945|NCT01409603|Experimental|Treatment arm B|darexaban, wash-out, combination therapy, wash-out, naproxen
3252946|NCT01409603|Experimental|Treatment arm C|naproxen, wash-out, darexaban, wash-out, combination therapy
3252947|NCT01409603|Experimental|Treatment arm D|naproxen, wash-out, combination therapy, wash-out, darexaban
3252948|NCT01409603|Experimental|Treatment arm E|combination therapy, wash-out, naproxen, wash-out, darexaban
3252949|NCT01409603|Experimental|Treatment arm F|combination therapy, wash-out, darexaban, wash-out, naproxen
3252950|NCT01409616|Experimental|Treatment arm A|ASA, wash-out (w.o.), ASA + darexaban
3252951|NCT01409616|Experimental|Treatment arm B|ASA + darexaban, w.o., ASA
3252952|NCT01409616|Experimental|Treatment arm C|ASA, w.o., darexaban (double dose) + ASA
3252953|NCT01409616|Experimental|Treatment arm D|darexaban (double dose) + ASA, w.o., ASA
3252954|NCT01409616|Experimental|Treatment arm E|ASA + clopidogrel, w.o., ASA + clopidogrel + darexaban
3252955|NCT01409616|Experimental|Treatment arm F|ASA + clopidogrel + darexaban, w.o., ASA + clopidogrel
3252956|NCT01409616|Experimental|Treatment arm G|ASA + clopidogrel, w.o., darexaban (double dose) + ASA + clopidogrel
3252957|NCT01409616|Experimental|Treatment arm H|darexaban (double dose) + ASA + clopidogrel, w.o., ASA + clopidogrel
3252958|NCT01409629||Activity choices|Observe individuals' activity choices after playing a computer game.
3252959|NCT01409642|Active Comparator|Individual Child CBT|12 sessions of individual child-focused cognitive behavior therapy with a parent component
3252960|NCT01409642|Experimental|Positive Family Interaction Therapy|12 sessions of standard individual child CBT plus six sessions of positive family interaction therapy (PFIT)
3252961|NCT01409655|Experimental|cognitive-behavioral therapy intervention|Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
3252962|NCT01409668|Experimental|L. Amylovorus|
3252963|NCT01409668|Experimental|L. Fermentum|
3252964|NCT01409681||Observational Group|NSCLC subject undergoing bronchoscopy
3252965|NCT01409694|Active Comparator|Intervention|All participants start the treatment with memantine on the first day of the study and immediately start vitamin D supplementation.
3252966|NCT01409694|Placebo Comparator|Placebo|Participants in this arm start the treatment with memantine in the same way as the 'Intervention' group. They also immediately start Vitamin D placebo administered at the same pace.
3369085|NCT04786717|Experimental|core muscle training|Training the endurance of the core muscle.
3252967|NCT01409720|Experimental|A|patients in arm A carry out daily physical training consisting of three different isometric exercises under the guidance and supervision of a physiotherapist. Training starts day one (first radiotherapy session), 10 daily units of 30 min each are scheduled during radiotherapy. Patients are expected to continue training until 12 weeks post completion of radiotherapy at home.
3369086|NCT04786717|Experimental|movement control training|Based from the initial test, the subjects will receive lumbar movement control exercise. They will perform each lumbar movement control exercise in different position.
3252968|NCT01409720|No Intervention|B|Patients in arm B (control group) receive 10 daily sessions of 15 min manual therapy (i.e. massage, etc) starting from day one of radiotherapy.
3252969|NCT01409733|Experimental|Stage IV melanoma patients|
3369087|NCT04786717|Experimental|combined imagery and movement control training|The intervention of this group is mostly same as the movement control training group. The different part is that the first 3 times of the movement will be practiced through image training, and the subjects will practice the real movement in the rest of 7 times.
3369088|NCT04785144|Experimental|Arm 1A|50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
3369089|NCT04785144|Experimental|Arm 1B|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1 in participants who received two vaccinations of mRNA-1273 in DMID Protocol 20-0003 (NCT04283461). N=30.
3369090|NCT04785144|Experimental|Arm 2A|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
3369091|NCT04785144|Experimental|Arm 2B|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 57 in COVID-19 naïve participants. N=15
3369092|NCT04785144|Experimental|Arm 2C|100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
3369093|NCT04785144|Experimental|Arm 2D|50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
3369094|NCT04785144|Experimental|Arm 2E|100 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 100 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
3369095|NCT04785144|Experimental|Arm 2F|50 mcg mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Day 1, and 50 mcg mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid on Day 29 in COVID-19 naïve participants. N=20
3252970|NCT01409746||twins|twin pairs
3252971|NCT01409759|Experimental|Perforator based interposion flap|In our concept the flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
3252972|NCT01409759|Other|Full thickness graft|
3369096|NCT04785144|Experimental|Arm 2G|50 mcg of mRNA-1273 and 50 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
3369097|NCT04785144|Experimental|Arm 2H|25 mcg of mRNA-1273 and 25 mcg of mRNA-1273.351 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in COVID-19 naïve participants. N=20
3252973|NCT01409772||Intestinal Rehab|
3252974|NCT01409785||LMA Supreme|
3252975|NCT01409785||LMA unique|
3252976|NCT01409824|No Intervention|without CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will not be implemented
3252977|NCT01409824|Experimental|with CDSS|This arm includes 6 health facilities in each partner country, where the clinical decision support system will be implemented, parallel to the performance based incentive package
3252978|NCT01409850|Active Comparator|Aqualizer|
3252979|NCT01409850|Active Comparator|Soft splint|elastic splint made of copolyester foil
3252980|NCT01409850|No Intervention|Counselling|
3252981|NCT01409863|No Intervention|laser and standard diamond fraise dermabrasion|laser and standard diamond fraise dermabrasion
3252982|NCT01409876|Experimental|Brachytherapy|
3252983|NCT01409889|Active Comparator|Diabetes Prevetion Program|Individuals in this group will receive the Diabetes Prevention Program
3252984|NCT01409889|Active Comparator|Healthy Living Program|Individuals in this group will receive the Healthy Living Program
3252985|NCT01409954||Spinal decompression|Spinal decompression with an instrumented posterolateral fusion
3252986|NCT01409980||Triphalangeal Thumb|A search will be performed using CPT code 26587 (reconstruction of a supernumerary digit) at both Primary Children's Hospital and Shriners to identify all patients who Dr. Wang and Hutchinson operated on with a delta phalanx.
3252987|NCT01410019|Experimental|1|Gene transfer
3252988|NCT01410032|Active Comparator|Plate fixation|Reconstruction plate
3252989|NCT01410032|Active Comparator|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
3252990|NCT01410045|Experimental|Surgery|Ovariectomy
3252991|NCT01410071||sphincter of oddi dysfunction|endoscopic therapy vs conservative care
3252992|NCT01410123|Other|Treatment as Usual (TAU)|
3252993|NCT01410123|Other|Integrated Stepped Care (ISC)|
3252994|NCT01410136|Other|Chondrofix|Subjects with one or two confirmed knee articular cartilage lesion(s) each less than 8cm2, of the femoral condyle or trochlear groove
3369098|NCT04778267|Active Comparator|TPVB (thoracic paravertebral block)|TPVB will be performed in the sitting position A high frequency linear ultrasound probe will be applied in the parasagittal plane approximately 2-3 cm lateral to the midline till identification of the 3rd thoracic vertebra (T3) in the same side of surgery. Then the transducer will be moved progressively more medially until transverse processes are identified.The image acquired will have the transverse process located superiorly and an image of lower rib located inferiorly on the screen.The needle tip is to be observed to enter through the superior costotransverse ligament and loss of resistance sensation will be experienced. After confirming the anterior displacement of pleura with 2-3 mL of local anesthetic (LA), 30 ml of 0.25% bupivacaine and 4 mg dexamethasone will be administered for the block.
3252995|NCT01410149|Active Comparator|PAV|Proportional Assist Ventilation (PAV+ on PB840 ventilator)
3369099|NCT04778267|Experimental|ES-PI (erector spinae-pectointercostal block)|"ESPB In the second group (ES-PI) Using a high frequency linear ultrasound probe, it will be located in a longitudinal orientation at the level of T3 spinous process and then will be placed 3 cm laterally from the midline to the side involved in the surgery. .a 22-gauge block needle will be inserted in-plane at an angle of 30-40°. 20 mL of 0.25% bupivacaine hydrochloride and 3 mg dexamethasone will be injected in the plane deeper to the erector spinae muscle.~PIPB While the patient is in the supine position, a high frequency linear probe will be placed parallel to the long axis of the sternum at a distance 2-3 cm from the attachment of the second rib and sternum to identify the Pectoralis major muscle, external intercostal muscles and the second rib in the superficial plane. by separation of fascial layers of between the external intercostal and the pectoralis muscles, a total of 10 ml of 0.25% bupivacaine and 1 mg dexamethasone will be injected."
3369101|NCT04770090|Experimental|Early stage cervical cancer|Patients with cervical cancer eligible for surgery, stage IA1 to IB2
3252996|NCT01410149|Active Comparator|PSV|Pressure Support Ventilation (PSV on PB840 ventilator)
3369102|NCT04760847|Experimental|Intermittent Fasting|Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.
3369103|NCT04760847|Active Comparator|Control|These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.
3369104|NCT04760717|Experimental|Spironolactone|Participants randomized to the Spironolactone arm will be receiving Spironolactone in addition to their normal routine blood pressure treatment.
3369105|NCT04760717|No Intervention|Standard Care|Participants randomized to the Standard care arm will be receiving their normal routine blood pressure treatment.
3369106|NCT04758819|No Intervention|Control group|Embryo selection according to Day 5/6 usual morphological criteria (Istanbul consensus)
3369107|NCT04758819|Experimental|Comprehensive chromosomal Testing of Trophectoderm biopsies of Blastocysts: CTTEB group|Trophectoderm cells will be analyzed by NGS. Culture media will also be stored for further non-invasive chromosomal testing. Embryo selection will be done according to international guidelines (www.pgdis.org; Newsletter May 27, 2019).
3369108|NCT04758650|Experimental|Cancer, lymphoma, carotid plaque, patients suspected for hemophagocytic lymphohistiocytosis|"Cohort 1: Patients diagnosed with pathology-proven squamous cell carcinomas of the head and neck in need of a non-surgical therapy.~Cohort 2: Patients diagnosed with any malignancy with a solid component in need of immune checkpoint inhibitor-type immunotherapy.~Cohort 3: Patients diagnosed with carotid plaque, planned for standard-of-care carotid endarterectomy.~Cohort 4: Patients with a biopsy-proven Hodgkin (HL) or non-Hodgkin lymphoma (NHL) eligible for systemic treatment, radiotherapy or a combination of both.~Cohort 5: Patients suspected for hemophagocytic lymphohistiocytosis (HLH), planned for (SOC) bone marrow biopsy"
3369110|NCT04751435||Breast,Ovarian, Prostate & Pancreatic Cancer|"There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview.~This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2."
3369113|NCT04739982|Experimental|Treatment|The GuessWhat app is a charades style game and app that engages parent and child in fluid social interaction where the parent must guess what the child is acting out based on the prompt shown on the phone screen. Participants will use their own personal phone to download the study app. Parent and child will be encouraged to play using the emojis and emotion game mode at least 3 individual game sessions per week. Parents are asked to play GuessWhat with their child 3-4 times per week for 4 weeks.
3252997|NCT01410149|Active Comparator|ACV|Assist Control/ Pressure limited Ventilation (on PB840 ventilator)
3252998|NCT01410162|Active Comparator|Advagraf|
3252999|NCT01410162|Active Comparator|Prograf|
3253000|NCT01410175|Experimental|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layer.
3253001|NCT01410175|No Intervention|Electric scalpel|Use of electric scalpel to incise the skin and subcutaneous layer.
3253002|NCT01410188|Experimental|OPA-6566 low dose|Treatment with OPA-6566 low dose
3253003|NCT01410188|Experimental|OPA-6566 medium dose|Treatment with OPA-6566 medium dose
3253004|NCT01410188|Experimental|OPA-6566 high dose|Treatment with OPA-6566 high dose
3253005|NCT01410188|Active Comparator|Latanoprost|Treatment with Latanoprost
3253006|NCT01410188|Placebo Comparator|Placebo|Placebo
3253007|NCT01410188|Experimental|OPA-6566 additional dose|Treatment with OPA-6566 additional dose
3253008|NCT01410201|Experimental|PPV + MP + DEX|Patients will undergo pars plana vitrectomy, membrane peel, and concomitant Ozurdex implant (0.7 mg dose).
3253009|NCT01410201|Active Comparator|PPV + MP|Patients will undergo pars plana vitrectomy with membrane peel, without Ozurdex implant.
3253010|NCT01410214|Experimental|Erlotinib arm|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
3369114|NCT04739982|No Intervention|Treatment as Usual|Participants in control group will continue their treatment as usual.
3369115|NCT04739813|Experimental|Arm 1: Dose Escalation|Venetoclax (PO) 600mg on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at escalating doses (2 dose levels) on day 2 of each 21-day cycle (maximum 6 cycles) to determine MTD of polatuzumab
3369116|NCT04739813|Experimental|Arm 2: Dose Expansion|Venetoclax (PO) 600mg on days 2-14, ibrutinib (PO) 560mg on days 1-14, prednisone (PO) 100mg on days 1-7, obinutuzumab 1000mg (IV) on days 1 and 2, lenalidomide (PO) 15mg on days 1-14, and polatuzumab (IV) at the MTD of each 21-day cycle (maximum 6 cycles)
3253011|NCT01410214|Active Comparator|Chemo arm|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
3253012|NCT01410253|Experimental|Group 1|
3253013|NCT01410253|Experimental|Group 2|
3253014|NCT01410253|Experimental|Group 3|
3369121|NCT04732182|Experimental|Standard of care medication for early Alzheimer's disease and BrightGo device cognitive training|Participants randomized to the experimental group will have standard of care and 8 weeks of experimental computer-based therapy on the device. Then they will cross over in the control arm. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
3369122|NCT04732182|Other|Standard of care medication for early Alzheimer's disease|Wait list controls will have standard of care only, before they cross over into the experimental group for BrightGo therapy. Total participation 4 months during which they will be on Aricept 10 mg daily or Exelon 9.5 mg patch.
3369123|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A + Dapagliflozin|Participants will receive once daily oral dose A of zibotentan and 10 mg dapagliflozin for 12 weeks.
3369124|NCT04724837|Experimental|Part A and Part B: Zibotentan Dose A|Participants will receive once daily oral dose A of zibotentan alone for 12 weeks.
3369125|NCT04724837|Experimental|Part A and Part B: Dapagliflozin|Participants will receive once daily oral dose of dapagliflozin 10 mg alone for 12 weeks.
3369126|NCT04724837|Placebo Comparator|Part A and Part B: Placebo|Participants will receive once daily oral dose of placebo matched to zibotentan or dapagliflozin for 12 weeks.
3369127|NCT04724837|Experimental|Part B Only: Zibotentan Dose B + Dapagliflozin|Participants will receive once daily oral dose B of zibotentan and 10 mg dapagliflozin for 12 weeks.
3369128|NCT04724837|Experimental|Part B Only: Zibotentan Dose C + Dapagliflozin|Participants will receive once daily oral dose C of zibotentan and 10 mg dapagliflozin for 12 weeks.
3369132|NCT04717453||Adult Patients with OTC Deficiency|Eligible subjects will be asked to participate in 5 clinic visits, each lasting up to 3 days. Each visit will assess rate of ureagenesis during the 4 hours following ingestion of [1-13C]sodium acetate. Sodium acetate is used as a tracer to measure the rate of ureagenesis. Patient interview, reported outcomes and cognitive assessments will take place over the 3 days.
3253015|NCT01410253|Placebo Comparator|Group 4|
3253016|NCT01410266|No Intervention|Standard of care|Standard of care includes a routine clinic visit two weeks after misoprostol administration. At the clinic visit, the woman undergoes a bimanual examination. In the event the woman fails to return for the follow-up visit, clinic procedure is followed for contacting her to determine abortion status and the need for further intervention, if any.
3259459|NCT01471067|Experimental|Fludarabine/Clofarabine/Busulfan/Rituximab/TBI|Myeloablative Regimen: Rituxan 375 mg/m^2 (B cell malignancy) by vein (IV) on Day -10; Busulfan AUC 4,000 IV either as an outpatient prior to admission or as an inpatient on Day -9; Clofarabine 30 mg/m^2 IV Day -7 to Day -4; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; Fludarabine 10 mg/m^2 IV on Days -7 to -4; Total Body Irradiation (TBI) 2 Gy on Day -3; with Cord Blood infusions on Day 0.
3369134|NCT04715451|No Intervention|Conventional Swaddle|The management of the non-intervention group is with a cotton swaddle that is standard of care. It represents a conventional standard management method using a swaddle made of cotton.
3369135|NCT04715451|Experimental|Novel Swaddle|The Novel Swaddle is made of fabric consisting of 85% nylon and 15% polyurethane. This fabric provides heat retention, is hygroscopic and stretches in both longitudinal and transverse directions, thus more accurately replicating the intrauterine environment. The novel material is sewed into a bag shape.
3369140|NCT04709822|Experimental|Trauma exposed women|"No Intervention: Baseline phase ('A'):~Measurements collected in a daily diary four times a day (morning, afternoon, evening and night) over one week (number of intrusive memories of trauma). Individual baseline phases will be used as control periods for the primary outcome.~Experimental: Intervention phase ('B'):~Measurements collected in a daily diary four times a day during the fifth week after the second intervention session for the primary outcome (number of intrusive memories of trauma)."
3369141|NCT04707248|Experimental|Dose Escalation|Participants with ovarian cancer (OVC) or renal cell carcinoma (RCC) will receive an intravenous infusion of DS-6000a (starting dose 1.6 mg/kg).
3369142|NCT04707248|Experimental|Dose Expansion: Cohort B-1|Participants with RCC will receive an intravenous infusion of DS-6000a at the RDE.
3369143|NCT04707248|Experimental|Dose Expansion: Cohort B-2|Participants with OVC will receive an intravenous infusion of DS-6000a at the RDE.
3369146|NCT04703075|Experimental|Rifapentine 600 mg and Isoniazid 300 mg|Participants will receive Rifapentine 600 mg daily and isoniazid (INH) 300 mg daily for 4 weeks.
3369147|NCT04703075|Active Comparator|Rifapentine 900 mg and Isoniazid 900 mg|Participants will receive Rifapentine 900 mg and isoniazid 900 mg weekly for 12 weeks.
3253017|NCT01410266|Active Comparator|Alternative follow-up|At a clinic visit, before mifepristone administration, the woman completes a semi-quantitative pregnancy test. After mifepristone administration, she is provided with another pregnancy test and a checklist to be self-administered two weeks after she takes misoprostol. On an assigned date, the woman is contacted by phone by the clinic staff and asked to report on the results of both tests. The provider then confirms whether, based on the woman's responses, she should return for a follow-up visit.
3253018|NCT01410292|Experimental|meal D|low fiber and low GI
3369148|NCT04702256|Experimental|Obinutuzumab arm|Obinutuzumab administration plus oral mycophenolate mofetil (MMF)
3369149|NCT04702256|Active Comparator|Corticosteroids arm|Oral corticosteroids plus MMF
3369150|NCT04700202||Retrospective Cohort|Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.
3369151|NCT04696354|Other|Interrogation Arm|patients will first be evaluated with MPV (limited to 3 views). The prescribed course of treatment based on the MPV results will be documented and patients will then be evaluated using IVUS. A treatment plan based on IVUS results will be compared with the MPV guided treatment plan and any differences will be documented. Any patients determined to still require venous stenting based on IVUS results will be stented accordingly using IVUS to guide stent placement.
3253019|NCT01410292|Experimental|meal C|low Fiber and High GI
3253020|NCT01410292|Experimental|meal B|high Fiber and low GI
3369152|NCT04696354|Other|Deferred Interrogation Arm|"Deferred Interrogation Guidelines for this study are as follows:~Mandate:~• Continued compression therapy/stockings as prescribed.~Allow:~Periodic leg elevation.~Sclerotherapy under ulcer bed.~Recommend mechanical debridement as needed.~Wound biopsy if evidence of infection.~Systemic antibiotics if patient is diagnosed with an infection, avoid prophylactic prescription.~Pain management medication (Pentoxifylline/Trental) allowed but not recommended~Topical antimicrobial as needed.~Prohibit:~Negative pressure systems.~Artificial and/or autologous skin grafting within first 3 months after randomization and within the first 3 months for subjects that crossover from deferred interrogation to the interrogation arm."
3253021|NCT01410292|Experimental|meal A|high fiber and high GI meal
3253022|NCT01410305||HIV+|HIV Positive children or young people between the ages of 8 and 25
3253023|NCT01410305||HIV Negative|HIV Negative matched controls by age and race
3253024|NCT01410331|Experimental|Cohort 1|Subjects will be randomized to receive either 4 mg of JVS-100 or placebo over 8 injections.
3253025|NCT01410331|Experimental|Cohort 2|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 8 injections.
3253026|NCT01410331|Experimental|Cohort 3|Subjects will be randomized to receive either 8 mg of JVS-100 or placebo over 16 injections.
3253027|NCT01410331|Experimental|Cohort 4|Subjects will be randomized to receive either 16 mg of JVS-100 or placebo over 16 injections.
3253028|NCT01410370|Experimental|treatment|Radiotherapy plus Endostar
3253029|NCT01410370|Active Comparator|control|Radiotherapy
3253030|NCT01410383|Placebo Comparator|Placebo|
3253031|NCT01410383|Experimental|Eprotirome I|
3253032|NCT01410383|Experimental|Eprotirome II|
3253033|NCT01410422||COPD|COPD
3369157|NCT04688814|Active Comparator|Morphine Group|Patients will receive GA and analgesia will be based on opioids mainly intravenous morphine. Intravenous morphine in a dose of 0.05 mg/kg will be given as a rescue analgesic when the VAS ≥4 postoperatively for 24 hours
3369158|NCT04688814|Experimental|SEQ group|Patients will receive ultrasound guided SEQ block preoperatively before the induction of general anaesthesia. Twenty five ml of 0.25 % bupivacaine will be given in the QL plane and 25 ml of the same concentration will be given in the erector spine plane
3369159|NCT04688775|Experimental|Sequence 1: Eptinezumab Then Placebo|Eptinezumab in the Placebo-controlled Period, followed by administration of placebo in the Active Treatment Period
3253034|NCT01410422||Bronchiectasis|Bronchiectasis
3253035|NCT01410435|Experimental|Treatment|
3369160|NCT04688775|Experimental|Sequence 2: Placebo Then Eptinezumab|Placebo in the Placebo-controlled Period, followed by administration of eptinezumab in the Active Treatment Period
3369163|NCT04684862|Experimental|Hepatic Artery Infusion (HAI) Therapy|Eligible patients will be implanted with a device that combines components of two commercially available drug delivery pumps to administer regional chemotherapy (FUDR) to the liver. Specifically, a Medtronic pump is being used with an Intera tapered catheter, instead of the Medtronic catheter.
3369164|NCT04683848|Experimental|MT-3921|Intravenous (IV)
3369165|NCT04683848|Placebo Comparator|Placebo|Intravenous (IV)
3253036|NCT01410461||Patients with painful bladder syndrome|Patients with diagnosis of PBS Will be offered to take part in the following study.
3253037|NCT01410487||Obese group|
3253038|NCT01410513|Experimental|SAR245409 + rituximab|Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
3253039|NCT01410513|Experimental|SAR245409 + rituximab + bendamustine (iNHL, MCL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
3253040|NCT01410513|Experimental|SAR245409 + rituximab+ bendamustine (CLL)|Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
3253041|NCT01410526||VAC group|Patients with intra-abdominal sepsis treated with Vacuum Assisted Closure (VAC) system plus the dynamic sutures
3253042|NCT01410526||Control group|Patients suffering major abdominal surgery
3369174|NCT04659044|Experimental|Treatment (rituximab, polatuzumab vedotin, venetoclax)|"INDUCTION: Patients receive rituximab IV on day 1 of cycle 1 and rituximab and hyaluronidase human SC over 5 minutes on day 1 of cycles 2-6. Patients also receive polatuzumab vedotin IV over 30-90 minutes on day 1 and venetoclax PO daily on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive venetoclax PO daily and rituximab and hyaluronidase human SC over 5 minutes every 60 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
3369175|NCT04658940|Experimental|Non-randomized|All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
3253043|NCT01410539|Experimental|Stent Thrombosis|Consecutive patients with stent thrombosis with stent strut assessment by OCT
3253044|NCT01410539|Active Comparator|Controls|Control subjects without stent thrombosis from the RHR OCT database
3369180|NCT04649840||COVID-19 moderate|moderate COVID-19 associated pneumonia
3369181|NCT04649840||COVID-19 severe|severe COVID-19 associated pneumonia
3369182|NCT04646005|Experimental|Cemiplimab+ISA101b|
3253045|NCT01410578||systemic inflammatory response syndrome|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3253046|NCT01410578||sepsis|SIRS + infection
3253047|NCT01410578||bacteremia|(1) The blood culture tested positive at least for the same pathogen;(2) The patient had at least one of the following symptoms: fever, shivering, or low blood pressure and showed signs of at least one of the following conditions: the blood culture tested positive at least twice for common skin flora from different sites; the blood culture tested positive only once for the skin flora listed above, the intravascular catheter culture tested positive for the same pathogen and the correct antibiotic treatment had been initiated for the patient; or a positive serology test consistent with other clinical laboratory test results and unrelated to infections at different sites.
3253048|NCT01410591|Active Comparator|10-mm covered stent group|Patients treated with 10-mm covered stent.
3253049|NCT01410591|Active Comparator|8-mm covered stent group|Patients treated with 8-mm covered stent.
3253050|NCT01410617|Active Comparator|dialysis|the patients who undergo 3 sessions prophylactic hemodialysis
3253051|NCT01410617|No Intervention|control group|the patients who do not undergo hemodialysis
3253052|NCT01410630||FLT-PET/CT and FDG-PET/CT scan|Patients will have FLT-PET/CT and FDG-PET/CT scans performed 18-24 days after the second cycle of R-CHOP.
3253053|NCT01410643|Active Comparator|Reduced Carbohydrate|42% carbohydrate macronutrient modification
3253054|NCT01410643|Active Comparator|STandard Carbohydrate|60% carbohydrate macronutrient modification
3253055|NCT01410656|No Intervention|Standard PA Recommendation|Received the standard physical activity recommendation.
3369199|NCT04638634|Experimental|CSL760 (low dose)|Administered as an intravenous infusion
3253056|NCT01410656|Experimental|Telephone Implementation Intention|Behavioural Telephone Assisted Implementation Intention Intervention
3253057|NCT01410656|Experimental|Self-completed implementation intention|Self-administered implementation intention intervention.
3369200|NCT04638634|Experimental|CSL760 (high dose)|Administered as an intravenous infusion
3369201|NCT04635800|Experimental|Cohort 1|Cohort 1; open-label, non-randomized, single administration
3369202|NCT04635800|Experimental|Cohort 2|Cohort 2; open-label, non-randomized, single administration
3369203|NCT04635800|Experimental|Cohort 3|Cohort 3, open-label; non-randomized, single administration
3369204|NCT04635800|Experimental|Cohort 4|Cohort 4, open-label, non-randomized, single administration
3369206|NCT04630353|Experimental|HB-201 Intratumorally on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
3369207|NCT04630353|Experimental|HB-201 Intravenously on Day 1|Patients with resectable stage I-III, HPV 16+ genotype squamous cell cancer of the oropharynx.
3369208|NCT04630353|Experimental|HB-201 Intratumorally 7 to 14 days before chemoradiation|Patients with cervical cancer who have locally advanced squamous cell carcinoma with HPV 16+ genotype.
3253058|NCT01410669|Experimental|Motivational Interviewing (MI)|
3253059|NCT01410682|Experimental|0.12% Chlorhexidine Digluconate|Oral care included use of an oral gel containing chlorhexidine digluconate 0.12% as an active ingredient (chlorhexidine digluconate 0.12%; methylcellulose gel 2.12%, 25 g; gooseberry syrup, 4 drops; menthol solution 50%,3 drops; and distilled water, to 30 g).The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular,lingual, occlusal, and incisal). After each quadrant was cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto- anterior movements.
3259460|NCT01471067|Experimental|Fludarabine + Melphalan|Reduced Intensity: Fludarabine 40 mg/m^2 IV on Days -5 to -2; Melphalan 140 mg/m^2 IV on Day -2; ATG 1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3; with Cord Blood infusions on Day 0.
3259461|NCT01471080|Experimental|RFA group|using RFA to treat cavernous hemangiomas
3259462|NCT01471080|Active Comparator|hepatectomy group|using laparoscopic hepatectomy to treat cavernous hemangiomas of the liver
3253060|NCT01410682|Placebo Comparator|tothbrushing|This group received the same oral care that experimental group with the use of a similarly formulated gel without the antiseptic agent.The gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
3369209|NCT04630301||Measurement of pleural pressure|a. Patients admitted to the Johns Hopkins Hospital with spontaneous, iatrogenic, or tension pneumothorax referred to the Division of Interventional Pulmonology for thoracostomy will be recruited. Using standard sterile technique, a 14fr catheter will be inserted into the pleural space. An electronic manometer (Compass, Medline Industries, Inc.) will be connected in-line to the introducer needle and Ppl will be recorded for 3-5 respiratory cycles. After measurement, the manometer will be removed and the catheter will remain in place per routine standards of practice.
3253061|NCT01410695|Experimental|masitinib 3 mg|masitinib 3 mg/kg/day, tablets, orally, twice a day
3253062|NCT01410695|Experimental|masitinib 6.0 mg|masitinib 6.0 mg/kg/day, tablets, orally, twice a day
3253063|NCT01410695|Active Comparator|methotrexate|methotrexate at the dose of 15 or 20 mg per week
3253064|NCT01410721|Experimental|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
3253065|NCT01410721|Active Comparator|Cognitive Rehabilitation Control Arm|Baseline training and follow-up at two months and four months.
3253066|NCT01410734|Experimental|ICG|Patient will received IV injection of ICG intra-operatively. Surgeon will view bile ducts under fluorescence imaging mode to see if ICG helps to identify biliary ducts.
3253067|NCT01410747||tacrolimus group|Oral
3253068|NCT01410786|Active Comparator|Conventional Oxford instrumentation|Patients who receive an Oxford Partial Knee with Conventional instrumentation.
3253069|NCT01410786|Experimental|Signature Guides Oxford|Patients who receive an Oxford Partial Knee with Signature Custom Guides
3253070|NCT01410825|Experimental|Gene transfer|Open label single arm study
3253071|NCT01410838|Placebo Comparator|Broth- NaCl|Sodium chloride containing broth matched for sodium content to the MSG broth
3253072|NCT01410838|Active Comparator|Broth- MSG|MSG containing broth with the same sodium content as the placebo comparator.
3253073|NCT01410851|Experimental|Pasta, tomato sauce & added chickpeas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3253074|NCT01410851|Experimental|Pasta, tomato sauce and added lentils|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3253075|NCT01410851|Experimental|Pasta, tomato sauce and added navy beans|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3253076|NCT01410851|Experimental|Pasta, tomato sauce with yellow peas|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3253077|NCT01410851|Experimental|Pasta and tomato sauce|The pulse treatments and control (pasta with tomato sauce) were made the day before the session and the recipe was calculated to provide 1500 kcal at each session. All meals had the same energy density (~77kcal/100g). Calories derived from pulses were consistent among all pulse treatments (44%). The pulse treatments and control all contained macaroni pasta and homemade tomato sauce.
3253078|NCT01410864||DuraSeal Arm|Prospective enrollment of subjects who have received DuraSeal Exact Spinal Sealant System for treatment of an intentional or incidental dural tear during spine surgery.
3369223|NCT04624854|Placebo Comparator|Aspirin monotherapy|Patients will receive aspirin monotherapy without co-administration of clopidogrel for 12 months after randomization.
3369224|NCT04624854|Experimental|Clopidogrel and Aspirin dual-antiplatelet therapy|Patients will receive co-administration of clopidogrel and aspirin for 12 months after randomization.
3369225|NCT04624230|Experimental|tofacitinib|Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
3253079|NCT01410864||Control Arm|Subjects who have undergone a spinal procedure where techniques other than DuraSeal were administered for the treatment of either an intentional or incidental opening of the dura may be enrolled either prospectively or retrospectively (via medical record screening)
3253080|NCT01410877||Inhaler naive healthy volunteers|
3253081|NCT01410903|Experimental|TheraSorb Ig|
3259463|NCT01471106|Experimental|Group 1: Dasatinib 40 mg|Dasatinib 40 mg by mouth once a day for 3 months (+/- 7 days), At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3369231|NCT04618211|Other|Low dose/placebo|Single low dose of PHA-022121 or placebo
3369232|NCT04618211|Other|Medium dose/placebo|Single medium dose of PHA-022121 or placebo
3369233|NCT04618211|Other|High dose/placebo|Single high dose of PHA-022121 or placebo
3369234|NCT04616846|No Intervention|Control cohort|
3369235|NCT04616846|Experimental|Infected cohort|
3369239|NCT04608578|Experimental|Intervention group|The intervention group gain access to the game after filling in the baseline online questionnaire. The participants are asked to play at least two characters in the game. They have two weeks to play the game.
3369240|NCT04608578|No Intervention|Control group|Waitlist control group
3253082|NCT01410942|Placebo Comparator|Placebo + Sham Exercise|Placebo capsules by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
3259464|NCT01471106|No Intervention|Group 3: No Dasatinib|No treatment control group. At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3369253|NCT04590235|Experimental|Selumetinib|All eligible subjects will first receive a single oral dose of selumetinib 25 mg/m^2. Then, selumetinib 25 mg/m^2 oral twice daily will be administered continuously until disease progression or unacceptable drug-related toxicity, whichever occurs first.
3369254|NCT04589247||Patients with cancer treated with definitive-intent radiotherapy|Histologically confirmed loco-regional to advanced primary cancer, including but not limited to lung cancer, esophageal, or gastro-intestinal cancers at risk of developing radiotherapy-related toxicity.
3369255|NCT04588870|Experimental|Preoperative Cochlear Implant|The intervention will be the use of a surgical simulation system preoperatively by the surgeon to develop the surgical plan to optimize electrode array placement with respect to scalar location and modiolar distance.
3369256|NCT04587453|Experimental|Tralokinumab+TCS|Week 0 to Week 16: Tralokinumab will be given as subcutaneous injections. Participants will receive tralokinumab loading dose on Day 0 followed by multiple tralokinumab injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
3369257|NCT04587453|Placebo Comparator|Placebo+TCS|Week 0 to Week 16: Placebo will be given as subcutaneous injections. Participants will receive placebo loading dose on Day 0 followed by multiple placebo injections. The last administration will occur at Week 14. Topical corticosteroids (TCS) will be administered as needed.
3369258|NCT04586244|Experimental|Treatment Group A|epacadostat will be administered in combination with retifanlimab.
3369259|NCT04586244|Experimental|Treatment Group B|retifanlimab will be administered as monotherapy.
3369260|NCT04586244|Experimental|Treatment Group C|epacadostat will be administered as monotherapy.
3369261|NCT04581499|Experimental|DynamiCare Motivation Support Program|Intervention Group members will receive 32 weeks of remote Contingency Management (CM; financial motivational incentives), Recovery Coaching, substance testing, appointment reminding/tracking, and in-app Cognitive Behavioral Therapy (CBT). After 32 weeks, coaching, testing, appointment tracking and CBT will continue until an overall 12 months in the project is completed.
3369262|NCT04581499|Other|Untreated or Routine Care Control Group|Control participants will receive substance tests at the same frequency as Intervention participants, and the same incentive amounts for tests as treatment participants. Controls' payments, however, will not be contingent on positive/negative results, but rather only on valid, on-time submission. Controls will not receive coaching, CBT or rewards for appointments.
3253083|NCT01410942|Experimental|Methylphenidate + Sham Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Participants in sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
3253084|NCT01410942|Placebo Comparator|Exercise + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Placebo capsules by mouth twice daily.
3253085|NCT01410942|Placebo Comparator|Cognitive Therapy + Placebo|Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily.
3253086|NCT01410942|Experimental|Methylphenidate + Exercise|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
3369263|NCT04580654|Experimental|CSL312 (Cohort 1a, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
3369264|NCT04580654|Experimental|CSL312 (Cohort 1b, low dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
3369265|NCT04580654|Experimental|CSL312 (Cohort 2, high dose)|Factor XIIa antagonist monoclonal antibody administered subcutaneously
3369266|NCT04580654|Experimental|CSL312 (Cohort 3, low dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
3369267|NCT04580654|Experimental|CSL312 (Cohort 4, high dose)|Factor XIIa antagonist monoclonal antibody administered intravenously
3369268|NCT04580121|Experimental|RO7283420 Part A|Participants from Group I will receive escalating doses of RO7283420, once every 3 weeks (Q3W) starting on Cycle 1, Day 1 (C1D1) for up to 6 cycles with a starting dose of 0.15mg.
3369269|NCT04580121|Experimental|RO7283420 Part B|Multiple-participant cohorts of >= 3 participants will be enrolled for dose escalation for Group I and Group II independently. Participants will be administered a starting dose of 0.15 mg or highest dose administered in Part A of RO7283420 once Q3W starting on C1D1 up to Cycle 6 to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). If needed, a step-up dosing regimen with more frequent administrations of RO7283420 during cycle 1 will be evaluated.
3253087|NCT01410942|Experimental|Methylphenidate + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
3369270|NCT04580121|Experimental|RO7283420 Part C|Participants will receive the respective RP2D for Group I and Group II.
3369271|NCT04580043|Experimental|cTBS + Habit Override Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Habit Override Training.
3369272|NCT04580043|Active Comparator|Sham TBS + Habit Override Training|Sham Transcranial Magnetic Stimulation, paired with Habit Override Training.
3369273|NCT04580043|Active Comparator|cTBS + Sham Training|Transcranial Magnetic Stimulation delivered in a continuous Theta Burst Stimulation (cTBS) pattern, paired with Sham Training.
3369274|NCT04580043|Sham Comparator|Sham TBS + Sham Training|Sham Transcranial Magnetic Stimulation, paired with Sham Training.
3369275|NCT04578509||Salicov|Ambulatory adults or children requiring screening for SARS-CoV-2 by nasopharyngeal swab
3369276|NCT04578509||SalicovII (ancillary study)|Ancillar study : Children and teachers / staff from middle and high schools in Ile de France Saliva samples is collected as part of care. Only a self-rated questionnaire is collected.
3369277|NCT04574336|Experimental|Surgical Treatment|Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method
3369278|NCT04574336|Active Comparator|Non-surgical treatment|Treatment of humeral shaft fracture with sling and/or functional brace
3369279|NCT04571645|Experimental|Dociparstat sodium (DSTAT)|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Dociparstat 4 mg/kg IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Dociparstat 0.25 mg/kg/hr via continuous IV infusion 24 hours daily for 5 or 7 days.
3369280|NCT04571645|Placebo Comparator|Placebo|Treatment with standard intensive induction, reinduction, or consolidation chemotherapy and Placebo IV bolus on Day 1, administered 30 minutes after completion of the first dose of idarubicin or daunorubicin, followed by Placebo via continuous IV infusion 24 hours daily for 5 or 7 days.
3259465|NCT01471106|Experimental|Group 2: Dasatinib 80 mg|Dasatinib 80 mg by mouth once a day for 3 months (+/- 7 days). At the end of the 3 months (+/- 7 days) participants undergo a repeat FNA and blood collection for the same marker analyses.
3369281|NCT04570839|Experimental|Dose Escalation Cohorts.|Up to 5 sequential dose escalation cohorts of COM701 in combination with fixed doses of BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks until a maximum tolerated dose or recommended dose for expansion is identified.
3369282|NCT04570839|Experimental|Cohort 1 Expansion Cohort A (ovarian cancer)|Single arm: subjects with platinum resistant/refractory epithelial ovarian cancer, primary peritoneal or fallopian tube cancer will be randomized to receive study treatment with COM701 in combination with BMS-986207 and nivolumab. The study drugs will be administered IV every 4 weeks.
3369283|NCT04570839|Experimental|Cohort 2 Expansion Cohort (endometrial cancer).|Single arm: subjects with MSS-endometrial cancer will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
3369284|NCT04570839|Experimental|Cohort 3 Expansion Cohort (basket cohort - high PVRL2 tumors).|Single arm: subjects with tumor types with high expression of PVRL2 will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks.
3369285|NCT04570839|Experimental|Cohort 4 Expansion Cohort (Head and Neck cancer).|"Two arms: subjects with head and neck cancer. Equal number of subjects in each of the 2 arms. One arm will enroll subjects who have not previously received treatment with an immune checkpoint inhibitor, the other arm will enroll subjects who have received prior treatment with an immune checkpoint inhibitor.~All subjects will receive study treatment with COM701 in combination with BMS-986207 and nivolumab. All study drugs will be administered IV every 4 weeks."
3253088|NCT01410942|Placebo Comparator|Exercise + Cognitive Therapy + Placebo|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill. Placebo capsules by mouth twice daily
3369288|NCT04565977||Retrospective Cohort|All patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
3253089|NCT01410942|Experimental|Methylphenidate + Exercise + Cognitive Therapy|Methylphenidate starting dose 5 mg by mouth twice daily. Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist. Cognitive Therapy - 8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
3253090|NCT01410955|Experimental|Probiotics|Patients receiving probiotics.
3253091|NCT01410955|Placebo Comparator|Placebo|Patients receiving placebo
3253092|NCT01410968|Experimental|Vaccination|vaccination with investigational Poly-ICLC & peptide-pulsed dendritic cells
3369289|NCT04564547|Experimental|Group 1: ISL 20 mg + MK-8507 100 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD) [Part 1].
3369290|NCT04564547|Experimental|Group 2: ISL 20 mg + MK-8507 200 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 200 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
3369291|NCT04564547|Experimental|Group 3: ISL 20 mg + MK-8507 400 mg|Participants receive ISL 20 mg (Parts 1-3) + MK-8507 400 mg QW and placebo to BIC/FTC/TAF QD (Part 1).
3369292|NCT04564547|Active Comparator|Group 4: BIC/FTC/TAF|Participants receive placebo to ISL + placebo to MK-8507 QW (Part 1) and BIC/FTC/TAF 50 mg/200 mg/25 mg QD (Parts 1 and 2).
3369293|NCT04562428|Experimental|XSLJZ|Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
3369294|NCT04562428|Placebo Comparator|XSLJZ Placebo|10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
3369295|NCT04561193||Retrospective Cohort|Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between February 1, 2020 and April 30, 2020 with positive COVID-19 PCR test.
3369296|NCT04561180|Placebo Comparator|Arm 1: SOC + DEX + EG-009A placebo|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A placebo for 3 additional weeks.
3369297|NCT04561180|Experimental|Arm 2: SOC + DEX + Low Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A Low dose for 3 additional weeks.
3253093|NCT01410981||Multiple Myeloma subjects with bone marrow aspirate/biopsy|All patients seen at MUSC with a diagnosis of multiple myeloma or possible multiple myeloma who undergo bone marrow aspirate and biopsy will be approached for participation in this study.
3253094|NCT01411007||Smokers|Nicotine addicted smokers, smoking an average of at least 10 cigarettes per day.
3369298|NCT04561180|Experimental|Arm 3: SOC + DEX + High Dose EG-009A|In addition to the standard of care (SOC), patients will receive dexamethasone (DEX) for 10 days and EG-009A High dose for 3 additional weeks.
3369301|NCT04560088|Experimental|Mindfulness|Mindfulness using an individual mobile health mindfulness-based intervention training. These sessions are intended to act as a general introduction to mindfulness meditation and incorporate techniques such as breath awareness and body scanning.
3369302|NCT04560088|Active Comparator|Breathing|Breathing control intervention will use an individual breathing app. The intervention is designed to be structurally equivalent to the mindfulness-based study intervention on key common factors of psychosocial interventions: (a) the number of sessions, (b) the length of sessions, and (c) delivery format.
3369303|NCT04556383|Experimental|GB004 Dose A|GB004 dose A for oral administration for 36 weeks
3253095|NCT01411007||Non-Smokers|
3253096|NCT01411020|Experimental|Grupo 1|Doses of induction: propofol 4 mcg/ml and fentanyl 3 mcg/kg
3253097|NCT01411020|Experimental|Grupo 2|Dose of induction: propofol 4.5 mcg/ml and fentanyl 3 mcg/kg
3253098|NCT01411020|Experimental|Grupo 3|Doses of propofol: propofol 5 mcg/ml and fentanyl 3 mcg/kg
3253099|NCT01411020|Experimental|Grupo 4|Doses of induction: propofol 5.5 mcg/ml and fentanyl 3 mcg/kg
3253100|NCT01411020|Experimental|Grupo 5|Doses of induction: propofol 6 mcg/ml and fentanyl 3 mcg/kg
3253101|NCT01411020|Experimental|Grupo 6|Doses of induction: propofol 4 mcg/ml and fentanyl 5 mcg/kg
3253102|NCT01411020|Experimental|Grupo 7|Doses of induction: propofol 4.5 mcg/ml and fentanyl 5 mcg/kg
3253103|NCT01411020|Experimental|Grupo 8|Doses of induction: propofol 5 mcg/ml and fentanyl 5 mcg/kg
3253104|NCT01411020|Experimental|Grupo 9|Doses of induction: propofol 5.5 mcg/ml and fentanyl 5 mcg/kg
3253105|NCT01411020|Experimental|Grupo 10|Doses of induction: propofol 6 mcg/ml and fentanyl 5 mcg/kg
3253106|NCT01411033||Newly diagnosed diabetes mellitus type 1|
3253107|NCT01411046||RA treated with prednisolone|Patients with RA treated with prednisolone, minimum 5 mg/day for minimum 6 months. Patients are grouped according to haplotype of 4 SNPs of the glucocorticoid recepror gene. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not. Adrenal function is evaluated with a Synacthen test.
3253108|NCT01411059|Experimental|yoga|32 weeks of yoga training
3253109|NCT01411072|Experimental|Gemcitabine|
3253110|NCT01411072|Experimental|5-fluorouracil|
3253111|NCT01411098|Experimental|Treatment (radiation therapy and chemotherapy)|Patients undergo 3D-CRT or IMRT 5 days a week for 8 weeks. Patients also receive cisplatin IV over 60 minutes on days 1, 8, 28, and 36 and etoposide IV over 60 minutes on days 1-5, and 28-32.
3253112|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 30mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 30 mg/day for 7 days in treatment period 2A.
3253113|NCT01411111|Active Comparator|Rosuvastatin foll by GSK2190915 100mg + rosuvastatin|Subjects will be orally administered rosuvastatin 10 mg/day for 7 days in treatment period 1. The subjects will then receive rosuvastatin 10 mg/day in combination with GSK2190915 100 mg/day for 7 days in treatment period 2B.
3253114|NCT01411124|Experimental|Gabapentin Enacarbil|600 mg of Gabapentin Enacarbil
3369304|NCT04556383|Experimental|GB004 Dose B|GB004 dose B for oral administration for 36 weeks
3369305|NCT04556383|Placebo Comparator|Placebo|Placebo for oral administration for 36 weeks
3253115|NCT01411124|Active Comparator|diphenhydramine|50 mg
3253116|NCT01411124|Placebo Comparator|placebo|placebo to match
3253117|NCT01411150|Experimental|Creatine|
3369306|NCT04556383|Experimental|Open-Label GB004 Dose A|GB004 dose A for oral administration for 24 weeks
3253118|NCT01411163|Experimental|Creatine|
3253119|NCT01411176|Active Comparator|Menthol|20 ml NPO-11
3253120|NCT01411176|Placebo Comparator|Placebo|20 ml NPO-11(Placebo)
3253121|NCT01411189|Other|Menthol|20 mL NPO-11
3369307|NCT04546425|Experimental|20-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
3369308|NCT04546425|Active Comparator|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
3253122|NCT01411202|Experimental|Doxycycline|Pleurx insertion with injection of 500mg of doxycycline in 50cc of normal saline.
3253123|NCT01411202|Placebo Comparator|Normal Saline|Pleurx insertion with placebo injection of 50cc of normal saline
3369309|NCT04546009|Experimental|Giredestrant + Letrozole-matched Placebo + Palbociclib|
3369310|NCT04546009|Active Comparator|Letrozole + Giredestrant-matched Placebo + Palbociclib|
3369311|NCT04544917|Experimental|SmartManage Group|Participants in this group will receive ten 90-minute weekly therapist delivered SmartManage group sessions via video conference. Participants will have access to the SmartManage web platform, which will also guide the live intervention sessions.
3369312|NCT04544917|Active Comparator|Educational Control Group|Participants in this group will view ten weekly control content video recorded sessions.
3369313|NCT04544904|No Intervention|Usual Care|Patients will receive the usual care.
3369314|NCT04544904|Experimental|PAARx|Patients will be prescribed technology-based physical activity programming.
3369315|NCT04544904|Experimental|PAARx and JM|Patients will be prescribed technology-based physical activity programming and be referred to a web-based resource for evidence-based joint management.
3369316|NCT04544501|Experimental|Culturally-Targeted Video|
3369317|NCT04544501|Active Comparator|FORCE Fact Sheet|
3369318|NCT04540770|Placebo Comparator|Part A 1 (1 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
3369319|NCT04540770|Placebo Comparator|Part A 2 (3 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
3369320|NCT04540770|Placebo Comparator|Part A 3 (5 mg/kg HuL001)|6 healthy subjects will be enrolled and randomized to receive 1 dose of HuL001 (n = 4) or 1 dose of placebo (n = 2).
3369321|NCT04540770|Experimental|Part B 1 (Selected Dose)|"At the end of Part A, the SRC will review the accumulated unblinded data of safety, tolerability, PK (any available data), and immunogenicity (any available data) to select a dose to initiate Part B in MS subjects. Part B will be conducted in multiple-dose, uncontrolled, and open-label manner to explore the safety, tolerability, PK, and immunogenicity in MS subjects. Only one cohort will be enrolled to receive 3 repeated doses of the selected HuL001 dose, which will be administered bi-weekly.~A total of 6 MS subjects will be enrolled in this multiple-dose cohort."
3369322|NCT04539470|Experimental|Cohort A: Efmarodocokin Alfa Dosage Level 1|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
3369323|NCT04539470|Experimental|Cohort B: Efmarodocokin Alfa Dosage Level 2|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
3369324|NCT04539470|Experimental|Cohort C: Efmarodocokin Alfa Dosage Level 3|Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
3369327|NCT04532645||Patients with BRCA mutated ovarian cancer|BRCA mutated advanced (FIGO stage III-IV) ovarian cancer patients who received first dose maintenance olaparib in 1L setting
3369328|NCT04527003|Placebo Comparator|Group A - Placebo|Norethindrone acetate (5mg daily) + Placebo
3369329|NCT04527003|Active Comparator|Group B - Low Dose CBD|Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
3253124|NCT01411254|Experimental|1|
3253125|NCT01411254|Experimental|2|
3253126|NCT01411254|Sham Comparator|3|
3253127|NCT01411280|Placebo Comparator|Laboratory trial|Compare methylphenidate to placebo in an acute laboratory trial
3253128|NCT01411280|Experimental|Home/School trial|Low dose and moderate dose methylphenidate are compared to placebo in a home and school trial
3253129|NCT01411293|Experimental|Low-Fat Dairy|Participants will ingest 2 cups of low-fat milk on 1 occasion prior to measure postprandial changes in vascular function
3253130|NCT01411293|Active Comparator|Rice Milk|Participants will ingest 2 cups of rice milk on 1 ocassion prior to measuring postprandial vascular function
3253131|NCT01411306||Med/Surg ICU Inpatients, Intubated ≥ 48 hours|
3253135|NCT01411358|Experimental|AdimFlu-S 2011-2012|
3369330|NCT04527003|Active Comparator|Group C - High Dose CBD|Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
3253136|NCT01411371|Experimental|Catheter Ablation|Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.
3253137|NCT01411371|Active Comparator|Medical treatment alone|Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
3253138|NCT01411397|Active Comparator|mesh repair|MESH HERNIA REPAIR WHEN REqUIRE INTESTINAL RESECTION
3253139|NCT01411397|Active Comparator|mesh repair without intestinal resection|mesh repair of strangulated hernia without resection
3369337|NCT04524273|Experimental|Inebilizumab, (AChR-Ab+) MG|"Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183."
3369338|NCT04524273|Placebo Comparator|Placebo, (AChR-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183."
3369339|NCT04524273|Experimental|Inebilizumab, (MuSK-Ab+) MG|"Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.~During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183"
3369340|NCT04524273|Placebo Comparator|Placebo, (MuSK-Ab+) MG|"Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.~During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183"
3369356|NCT04516369|Experimental|Voretigene neparvovec|1.5 E11 vg (0.3 mL subretinal injection in each eye, 6-18 days apart)
3369359|NCT04512495|Other|Patients with sarcoma|
3369360|NCT04512378|Experimental|IU Group Treatment|Clinical intervention arm
3369361|NCT04508725|Experimental|Doppler Ultrasound|Patients receiving standard of care anti-angiogenesis inhibitor plus immune checkpoint inhibitor will have power doppler imaging at baseline, 3 weeks and 6 weeks.
3369362|NCT04506866|Other|Overactive Bladder Cohort|Subjects with overactive bladder will be treated with InterStim Micro Therapy and followed-up regarding their overactive bladder symptoms.
3369363|NCT04506866|Other|Fecal Incontinence Cohort|Subjects with fecal incontinence will be treated with InterStim Micro Therapy and followed-up regarding their fecal incontinence symptoms.
3253140|NCT01411410|Experimental|Copanlisib (BAY80-6946)|The treatment of consists of repetitive cycles, each over 4 weeks. It continues until disease progression or limiting toxicity. If paclitaxel is discontinued for toxicity, BAY80-6946 may continue at the discretion of the investigator if a clinical benefit (response or stable disease for 6 months) is noted.
3369364|NCT04506866|Other|Non-Obstructive Urinary Retention Cohort|Subjects with non-obstructive urinary retention will be treated with InterStim Micro Therapy and followed-up regarding their non-obstructive urinary retention symptoms.
3369365|NCT04504773|Experimental|Virtual Reality Exposure Therapy|Participants will receive a single session of exposure therapy to address specific phobia that includes the use of virtual reality exposures.
3253141|NCT01411423||Group 1|
3253142|NCT01411436||Group 1|
3253143|NCT01411449||Group 1|
3253144|NCT01411462||VIBE-DEB|
3369367|NCT04491292||Observational (questionnaire)|Participants complete 2 online questionnaires over 10 minutes each at baseline and at 3 months after the pandemic ends.
3369368|NCT04486833|Experimental|Phase 1|"Up to 3 sequential dose escalation cohorts will be treated with GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet.~The first group will receive GPX-001 IV infusion at 0.06 mg/kg, the next group 0.09 mg/kg and the third will receive 0.12 mg/kg. Additional GPX-001 dose levels may be evaluated until RP2D is identified."
3369369|NCT04486833|Experimental|Phase 2 Combination|Patients will receive the RP2D of GPX-001 intravenously on Day 1 in addition to osimertinib 80 mg fixed dose oral daily tablet starting on Day 10. The 21-day treatment cycle will continue until second progression event (PFS2) or unacceptable toxicity.
3369370|NCT04486833|Active Comparator|Phase 2 Active Comparator|Patients will continue on monotherapy osimertinib 80 mg fixed dose oral daily tablet until second progression event (PFS2).
3253145|NCT01411475||Bifurcation restenosis|Patients with either a main vessel or a side branch restenosis following succesful percutaneous coronary intervention
3253146|NCT01411514|Experimental|Prednisone|
3253147|NCT01411514|Placebo Comparator|Placebo|
3253148|NCT01411540|Experimental|Whole grain diet|Subjects will eat a whole grain based diet for eight weeks. Pre-and post-diet intervention testing will determine effects on body composition. Whole grain-based are will be compared to the refined grain based diet.
3253149|NCT01411540|Active Comparator|Refined grain diet|Subjects will eat a refined grain diet for 8 weeks matched with the whole grain arm for calorie and macro nutrient intake. Pre-and post-diet testing will determine effects on body composition.
3253150|NCT01411553|No Intervention|Reusable ECG leadwires-ICU|Current ECG leadwires will be used
3253151|NCT01411553|Active Comparator|Disposable ECG leadwires-ICU|Disposable ECG-LW
3253152|NCT01411566|Experimental|Treatment|
3253153|NCT01411566|Active Comparator|Control|
3253154|NCT01411579||Clinical Benefit|The patients responding to the chemotherapy, i.e. who show at least a non progressive disease
3253155|NCT01411579||Non responder|The patients non responding to the chemotherapy, i.e. who show a progressive disease
3253156|NCT01411605|Experimental|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
3253157|NCT01411618|Experimental|free alcohol essential oil moutwash|
3253158|NCT01411618|Active Comparator|alcohol containing essential oil mouthwash|
3253159|NCT01411631|Active Comparator|Grape juice|Participants will drink 100% concord grape juice daily for 12 weeks
3253160|NCT01411631|Placebo Comparator|Placebo drink|Participants will drink the placebo for 12 weeks. The placebo will be equicaloric and matched on appearance, taste, volume and macronutrient composition to the grape juice drink.
3253161|NCT01411657|Experimental|NT-501 CNTF Implant|Patients will receive single NT-501 CNTF implant in one eye
3253162|NCT01411670|Experimental|Human protein C concentrate|
3253163|NCT01411670|Active Comparator|activated protein C|Continuous infusion of Activated Protein C
3253164|NCT01411670|Placebo Comparator|Placebo|Standard treatment
3253165|NCT01411683|Experimental|4 mini dental implants|Retention of an overdenture by means of 4 mini implants.
3253166|NCT01411683|Experimental|2 mini dental implants|Retention of an overdenture by means of 2 mini implants.
3253167|NCT01411683|Active Comparator|2 conventional dental implants|Retention of an overdenture by means of 2 conventional implants associated to ball attachments.
3253168|NCT01411709|Active Comparator|Vitano|
3253169|NCT01411709|No Intervention|Control|No tablets - control group
3253170|NCT01411722|Other|EADIWEANING|Patients mechanically ventilated for more than 48 hours during the weaning process.
3369378|NCT04477733|Experimental|Butorphanol group|
3369379|NCT04477733|Placebo Comparator|control group|
3253171|NCT01411735|Active Comparator|Enalapril|2.5mg titrated up to 10mg- twice daily
3253172|NCT01411735|Placebo Comparator|placebo|2.5 mg titrate up to 10mg twice daily placebo comparator
3253173|NCT01411748|Experimental|S. boulardii|The patients in this group will be given 5 million unit/day S. boulardii until discharge.
3253174|NCT01411748|Active Comparator|nystatin|
3369381|NCT04471792|Experimental|Creatine monohydrate|Creatine Monohydrate will be given at a 5 day loading period (10g/day) followed by a maintenance phase (5 g/day). The objectives of the current trial are to investigate if creatine supplementation plus muscle stretching improves 6-minute walking distance and muscle oxygenation in patients with peripheral artery disease.
3369382|NCT04471792|Placebo Comparator|Cellulose|These participants will consume a fiber supplement in place of creatine monohydrate at a matched dose with muscle stretching.
3253175|NCT01411761|Experimental|Saccharomyces boulardii|study group
3253176|NCT01411761|Placebo Comparator|placebo|serum physiologic
3369385|NCT04457323|Experimental|Test|S-Metoprolol XR 25 mg Film Coated Tablets (first four weeks) S-Metoprolol XR 50 mg Film Coated Tablets (second four weeks)
3369386|NCT04457323|Active Comparator|REFERENCE|Beloc® (Metoprolol) Zok 50 mg Controlled Release Film Tablets (first four weeks) Beloc® (Metoprolol) Zok 100 mg Controlled Release Film Tablets (second four weeks)
3253177|NCT01411787|No Intervention|Control Group|Patient will continue normal activities. Ki-67 will be measured in the initial core biopsy and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to initiation of neoadjuvant chemotherapy, and then again after the last chemotherapy dose. Body mass index, percent body fat, and improving fitness levels will also be measured.
3369389|NCT04448431|Experimental|Vortioxetine|8 weeks treatment
3369390|NCT04448431|Active Comparator|Desvenlafaxine|8 weeks treatment
3253178|NCT01411787|Experimental|Exercise|"Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.~Ki-67 will be measured in the initial core biopsy specimen and then again in the final pathologic specimen which is removed for definitive surgical intervention. Insulin resistance levels will be measured by obtaining insulin-like growth factor binding protein one and C-peptide levels just prior to inititation of neoadjuvant chemotherapy and then again after the last chemotherapy dose in both arms. Body mass index, percent body fat, and improving fitness levels will also be measured."
3369391|NCT04446429|Active Comparator|Usual Care|Usual care as determined by the PI
3369392|NCT04446429|Experimental|Proxalutamide + Usual Care|Proxalutamide + Usual care as determined by the PI
3253179|NCT01411800|Experimental|Treatment A|500 mg LX1033, capsules administered two times per day orally
3253180|NCT01411800|Experimental|Treatment B|500 mg LX1033, tablets administered two times per day orally
3253181|NCT01411813||Alprazolam|Patients receiving Alprazolam.
3253182|NCT01411826|Active Comparator|Information|
3253183|NCT01411826|Experimental|Information + Narratives + Support group|
3253184|NCT01411865|Experimental|Intervention|
3253185|NCT01411865|Other|Control|
3253186|NCT01411878|Experimental|Reducing the Risk|Students will be randomly assigned to participate in Reducing the Risk training
3369395|NCT04442061|Active Comparator|Active transcranial magnetic stimulation|excitatory TMS will be applied to the right posterior STS
3369396|NCT04442061|Sham Comparator|Sham transcranial magnetic stimulation|The sham TMS follows the same procedure of the active TMS without stimulating cortical tissue
3369402|NCT04437667|Experimental|Intervention Arm|Adolescents participants enrolled in the intervention arm will receive the intervention, Tumaini, loaded on a low-cost Android smartphone, during the long November-December school holidays for the first three years of the study.
3253187|NCT01411878|Experimental|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov).
3369403|NCT04437667|Active Comparator|Control Arm|Adolescent participants enrolled in the control arm will receive a commercially available age- and language-appropriate educational game or knowledge quiz loaded on a study-provided low-cost Android smartphone.
3369404|NCT04432467|Experimental|mesenchymal stem cells|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment and mesenchymal stem cells
3369405|NCT04432467|Active Comparator|control|Patients with impending caesarean section or with chronic inflammation in the mucosa of the uterus and fallopian tubes receiving standard treatment
3369406|NCT04428931||PD patients|Patients with Asymmetric Parkinson's disease
3369407|NCT04428385|No Intervention|Arm 1 (control)|RDTs available at study-recommended price, providers trained on mobile reporting app
3253188|NCT01411904|Experimental|MagProbe (TM)|"Patients whose bone marrow aspirates are exposed to the MagProbe and CD34 nanoparticles.~Leukemia patients~MagProbe (TM)~Diagnosed or suspected leukemia~Non-leukemia patients~MagProbe (TM)~Requiring bone marrow biopsy"
3253189|NCT01411930|Experimental|Olanzapine -> Aripiprazole|Crossover design. Order of agents is randomized. For this arm, the order will be IM olanzapine (1st clamp study) and IM aripiprazole (2nd clamp study).
3369408|NCT04428385|Experimental|Arm 2 (provider-directed intervention)|Providers receive a small payment for each RDT that they perform, RDTs available at study-recommended price
3369409|NCT04428385|Experimental|Arm 3 (client-directed intervention)|ACT subsidy to client conditional on positive RDT, RDTs available at study-recommended price
3369410|NCT04428385|Experimental|Arm 4 (consumer-directed and provider-directed in|providers receive a small payment for each RDT that they perform and consumers with a positive test are eligible for a subsidy on a quality-assured ACT, RDTs are available at study recommended price
3369411|NCT04428164||Hospitalized patients|Any patient admitted to the study units (MDMC: 10ST; MCMC: A6; MMMC: A3; MRMC: 3Medical ) that do not have any of the exclusion criteria
3369412|NCT04421365|Active Comparator|Active neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using active EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected to be effective for symptom improvement.
3369413|NCT04421365|Sham Comparator|Sham neurofeedback BCI|Patients are presented with symptomatic speech and asymptomatic whisper and, using sham EEG-based neurofeedback, are trained to correct their speech by matching their brain patterns to those of whisper. This training is expected not to be effective for symptom improvement.
3369414|NCT04416958||CIED for cardiac resynchronisation|Patients implanted with an CIED for cardiac resynchronisation aiming to avoid pacing induced ventricular dyssynchrony, e.g. His bundle pacing, LBB-area pacing, CRT. These different implanted types of devices may be further analysed as subgroups.
3253190|NCT01411930|Experimental|Aripiprazole -> Olanzapine|Crossover design. Order of agents is randomized. For this arm, the order will be IM aripiprazole (1st clamp study) and IM olanzapine (2nd clamp study).
3253191|NCT01411956|Experimental|Treatment Group|"This group viewed the intervention video, a 24-minute episode of the sitcom White Coats, deliberately scripted with the five health behavior theory constructs we are testing."
3253192|NCT01411956|Placebo Comparator|Control Group|The control group viewed a 25-minute video on an unrelated subject (depression).
3253193|NCT01411969||External nasal dilator, decongestion|
3369417|NCT04406103|Experimental|Sleepwell|Mailed information package includes 2 Sleepwell booklets (How to get your sleep back and How to stop sleeping pills)
3369418|NCT04406103|Active Comparator|Empower|Mailed information package includes 2 Empower booklets (You may be at risk AND How to get a good night's sleep without sleeping pills)
3369419|NCT04406103|No Intervention|TAU|Treatment-as-usual group: no mailed intervention package.
3369420|NCT04404101|Active Comparator|1). EUS-FNA plus MFB|A 19-G needle plus micro-forceps will be used for FNA plus MFB.
3369421|NCT04404101|Active Comparator|2). EUS-FNA Alone|A 19-G needle will be used for FNA alone.
3253194|NCT01412008|No Intervention|botox diffusion|Each subject was given 3 injections in lateral gastrocnemius muscle:2 botox, 1 saline, each injection was 2.5mL. MRI of the lower leg was taken prior to injections and 2 months post for a comparison of diffusion properties.
3253195|NCT01412034|Experimental|CER-001|Open label single arm study of CER-001
3253196|NCT01412073|Active Comparator|oxytocin bolus|"5 IU bolus iv over 3 minutes after delivery of the baby Operative blood loss will be estimated in theatre based on the volume in the suction bottle and the weight of swabs used. We will record blood loss up until the time the woman will be discharged from the theatre recovery ward.~Hemoglobin level and haematocrit value will be done as follow:-~After admission of each case in the pre-operative period.~Immediately post- operative.~24 hours post- operative."
3253197|NCT01412073|Active Comparator|oxytocin bolus & oxytocin infusion|5 IU oxytoxin bolus over 3 minutes and 30 IU oxytocin infusion in 500 ml 0.9% saline over 4 hours after delivery of the baby
3369424|NCT04394546|Experimental|Device Group|Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
3369425|NCT04394546|Active Comparator|Control Group|Randomized to non-vitamin K oral anticoagulant (NOAC)
3253198|NCT01412073|Active Comparator|misoprostol intrauterine|misoprostol 800 micrograms intrauterine, placed manually on the bottom of the uterine cavity after delivery of the placenta and cleaning of the cavity
3253199|NCT01412099|Experimental|Feedback report plus peer counseling|
3369433|NCT04389281|Experimental|X-PACT Treatment|Single arm consisting of a six-week treatment period with X-PACT (phosphor device and methoxsalen sterile solution and subsequently exposing the tumor to X-ray energy) administered as an intra-tumoral injection. Intra-tumoral injections will be given on D1, D3 and D5 of Week 1, on D1 of Week 2, and a booster on D1 of Week 6. After the week 8 tumor assessment subjects demonstrating stable disease, partial response or unconfirmed progression assessed by iRecist, will be eligible to receive two additional booster treatments 4-6 weeks apart.
3253200|NCT01412099|Experimental|Feedback report|
3253201|NCT01412125||Patient|Voluntary Huntington patients symptomatic or asymptomatic, with a number of nucleotide expansion(CAG) ≥36 and who know their genetic status
3253202|NCT01412125||Healthy subject|Voluntary controls with no family history of huntington's disease
3253203|NCT01412138||ARM 1|ENDOMETRIAL SAMPLE
3253204|NCT01412177|Experimental|OTO-104|
3253205|NCT01412177|Placebo Comparator|Placebo|
3253206|NCT01412190|Other|Untreated|
3369450|NCT04372017|Experimental|Cohort A: Healthcare worker (hydroxychloroquine)|
3369451|NCT04372017|Placebo Comparator|Cohort A: Healthcare worker (placebo)|
3369452|NCT04372017|Experimental|Cohort B: High-Risk participant (hydroxychloroqine)|
3369453|NCT04372017|Placebo Comparator|Cohort B: High-Risk participant (placebo)|
3369454|NCT04370873|Experimental|Part 1: MK-5475|Participants receive MK-5475 360 μg once daily (QD) via inhalation from Days 1-7
3369455|NCT04370873|Placebo Comparator|Part 1: Placebo|Participants receive placebo QD via inhalation from Days 1-7
3369456|NCT04370873|Experimental|Part 2: MK-5475|Participants receive MK-5475 32 µg, 100 µg, 195 µg or 380 μg QD via inhalation from Days 1-28
3369457|NCT04370873|Placebo Comparator|Part 2: Placebo|Participants receive placebo QD via inhalation from Days 1-28
3369460|NCT04359420|Experimental|BC-Predict|"Women will be sent an invitation letter one to two days after their breast screening invitation letter, directing prospective participants to the online risk assessment platform. Once participants have consented to the study online, they will be directed to the BC-Predict risk assessment questionnaire. Assessment of the online questionnaire during the pilot phase estimated that most women would be able to complete this within 30 minutes.~Women who complete the questionnaire will receive 10-year breast cancer risk estimates once they have screened negative for breast cancer, based on the Tyrer-Cuzick model, incorporating mammographic density, and for some women, SNPs (single nucleotide polymorphisms). Women who are identified as being at high (>8%) or moderate (5% and <8%) 10-year risk will be offered a consultation to discuss prevention options including prescription of chemoprevention drugs and/ or more frequent mammography as part of the NHS Breast Screening Programme."
3369461|NCT04359420|Active Comparator|NHS-Breast Screening Programme|Usual care in the NHS Breast Screening Programme, which involves mammography every 3 years for the majority of women
3369462|NCT04357951|Experimental|Behavior Therapy + DCS|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the d-cycloserine pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
3369463|NCT04357951|Active Comparator|Behavior Therapy + Placebo|Youth with TD will receive four, 2-hour long sessions of evidence-based behavior therapy delivered in an intensive format. Participants will arrive an hour early for each session to take the placebo pill prior to starting each session of behavior therapy. Participants, therapists, and outcome assessors will be masked to pill condition.
3369468|NCT04341909||Trainee Group|Patients who undergo ERCPs with trainee involvement
3369469|NCT04341909||control group|Patients who undergo ERCPs without any trainee involvement
3369470|NCT04341259|Experimental|Ipatasertib as a Single Agent|Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD). This study has three study periods: a screening period (up to 14 days in length), followed by a treatment period of up to approximately 2 years (Cycle 1 will be 35 days in length, all subsequent cycles will be 28 days in length) and a 28-day follow-up period after the treatment discontinuation or study completion.
3369472|NCT04339049|Experimental|lidocaine spray|four puffs (10 mg/puff) of lidocaine spray before tenaculum placement plus vaginal placebo 3 hours before IUD insertion
3369473|NCT04339049|Active Comparator|vaginal misoprostol|vaginal misoprostol 200 mcg given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
3369474|NCT04339049|Placebo Comparator|placebo|vaginal placebo given 3 hours before IUD insertion plus four puffs of saline spray before tenaculum placement
3253207|NCT01412190|Active Comparator|Restylane Vital Light|Restylane Vital Light administered at 3 treatment sessions 4 weeks apart
3253208|NCT01412203|No Intervention|Usual Practice|School continues with regular programming
3253209|NCT01412203|Experimental|Action Schools! BC|School adopts the AS!BC model
3253210|NCT01412216|Experimental|Fish Oil (Omega-3 Fatty Acids)|High-dose, short-duration dietary omega-3 fatty acids supplementation
3253211|NCT01412216|Placebo Comparator|Placebo|Placebo control
3253212|NCT01412242|Experimental|Extensive search for isolated calf DVT|As this is a prospective cohort study, for definition there is only 1 arm
3369478|NCT04330703||Cases|Children and adolescents referred for their first visit to the outpatient clinic at the Child and Adolescent Psychiatry Department (BUGL) (n=15) will be invited to participate.
3253213|NCT01412294|Experimental|Capecitabine, Cisplatin|
3369479|NCT04330703||Contol|Age and sex-matched child from the same postal area (n=15).
3369480|NCT04330703||Syblings|Same parent siblings close in age to the study subjects (cases only) (+3y) (n=x)
3253214|NCT01412307|Experimental|lenalidomide plus bendamustine|
3369483|NCT04316611|Experimental|Potassium chloride|Potassium chloride
3369487|NCT04312971|Placebo Comparator|Placebo|Infusion of normal Saline 0.9%will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
3369488|NCT04312971|Active Comparator|Norepinephrine|Infusion of norepinephrine (40 µg/ml) will be started following arterial cannulation before initiation of cardiopulmonary bypass and continued until aortic declamping time.
3369489|NCT04310566|Experimental|Test/Control|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
3369490|NCT04310566|Experimental|Control/Test|Eligible subjects that are habitual soft contact lenses will be randomized into one of the two possible lens wear sequences: Test/Control or Control/Test
3369491|NCT04309292|Experimental|Treatment Arm|protein supplementation plus prebiotic supplementation
3369492|NCT04309292|Placebo Comparator|Placebo Arm|Protein supplementation plus placebo
3369493|NCT04303078|Experimental|Children with Cerebral Palsy (Cases)|Children meeting inclusion/exclusion criteria with a diagnosis of cerebral palsy.
3369494|NCT04303078|Other|Typically Developing Children (Controls)|Children meeting inclusion/exclusion criteria without a diagnosis of cerebral palsy or other condition.
3253215|NCT01412320|Experimental|Flavanol rich cocoa|
3253216|NCT01412320|Experimental|Flavanol poor|
3253217|NCT01412346|Active Comparator|Plant-based food and fish with salt restr.|The subjects consume plant based foods (fruits, berries, vegetables, whole grain) and fish in addition to a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
3253218|NCT01412346|Placebo Comparator|Diet with salt restriction|The subjects follow a salt-restricted diet. Intake of salt is normal to high for 8 weeks and low for 8 weeks (subjects receive salt and placebo capsules in a crossover design).
3253219|NCT01412385|Experimental|Epoch 1 (intravenous pre-study treatment) + Epoch 2|Study Epoch 1 (13 weeks): treatment with KIOVIG (once every 3 or 4 weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
3253220|NCT01412385|Experimental|Epoch 1 (subcutaneous pre-study treatment) + Epoch 2|Study Epoch 1 (12 weeks): treatment with SUBCUVIA (once every week or once every two weeks, dose as during pre-study period) + Study Epoch 2 (same for all subjects, 51 weeks): treatment with IGSC, 20% (every week, dose to be calculated on the basis of weekly equivalents)
3253221|NCT01412398||Group 1|Drug (incl. Placebo)
3369495|NCT04299100|No Intervention|Control Group|Participants randomized to the Control Group will receive usual care from their pain physician.
3369496|NCT04299100|Experimental|Sleep Health Program - Suspected No/mild sleep apnea|Participants randomized to the Sleep Health Program with no/mild sleep apnea.
3369497|NCT04299100|Experimental|Sleep Health Program - Suspected Moderate/severe sleep apnea|Participants randomized to the Sleep Health Program with suspected moderate/severe sleep apnea.
3369500|NCT04289935|Experimental|single arm|"Unicentric histologically confirmed invasive luminal B, HER2- enriched, triple negative breast cancer + Clipping + Neoadjuvant chemotherapy~rCR / near-rCR in MRI~Registration~US-guided VAB~Breast conserving surgery / mastectomy~Pathology examination 1. Preoperative VAB, 2. Surgical specimen"
3253222|NCT01412411|Active Comparator|Nutrition Education plus Multiple Micronutrient Fortification|In this group along with the nutritional education, multiple micronutrient fortification was given in the form of Sprinkles
3369502|NCT04286958|Experimental|Camrelizumab|All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.
3369503|NCT04286113|Active Comparator|Control group|Participants will receive non-personalized information (one-size-fits-all) diet, sleep and physical activity recommendations via messaging delivered by app.
3253223|NCT01412411|Active Comparator|OIS plus Nutritional Eductaion|In this group, along with the nutritional education, Oral Iron Supplementation was given.
3369504|NCT04286113|Experimental|Intervention Group|Participants will receive personalized messages about achieving healthy diet, physical activity and sleep as well as summary of their performance for the week and month. They will also receive personalized content about research volunteerism and altruistic activities.
3369506|NCT04282278|Experimental|Group A|
3369507|NCT04282278|Experimental|Group B|
3369508|NCT04282278|Experimental|Group C|
3369509|NCT04281186||Cross-sectional cohort|Up to 720 type 2 diabetic patients (>5 years duration), older than 65 years of age are expected to be recruited in orfer to asure the sample of 168 patients with MCI and 63 normocognitive fulfilling criteria for the prospective study.
3369510|NCT04281186||Prospective study-MCI|Target 168 Patients from the cross-sectional cohort diagnosed with mild cognitive impairment during the cross-sectional evaluation
3369511|NCT04281186||Prospective study normocognitive|63 Patients from the cross-sectional cohort without mild cognitive impairment evaluated during the cross-sectional evaluation
3369514|NCT04276415|Experimental|Dose Escalation: DS-6157a|Participants with advanced gastrointestinal stromal tumor (GIST) who will receive an intravenous infusion of DS-6157a (escalating doses starting at 1.6 mg/kg).
3369515|NCT04276415|Experimental|Dose Expansion: Cohort 1 (3rd line or later) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on or are intolerant to imatinib (IM) and at least one post-IM treatment will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
3369516|NCT04276415|Experimental|Dose Expansion: Cohort 2 (2nd line) treated at RDE|Participants with advanced gastrointestinal stromal tumor (GIST) who have progressed on imatinib (IM) and had not received a post-IM treatment (2nd line) will receive DS-6157a at the recommended dose for expansion (RDE) based on the Dose Escalation phase.
3253224|NCT01412411|Active Comparator|Nutrition Education Group|This is group was followed for the growth of the child and was given Nutritional Education to children's mothers.
3253225|NCT01412437|Experimental|Diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
3369522|NCT04264819|Experimental|RTH258/Brolucizumab|This is a single arm study in which all patients will be treated with brolucizumab 6mg; 3 loading injections (at Screening/Baseline, week 4 and week 8) followed by treat-to-control phase with adjustable treatment frequency based on disease activity from every 4 to up to 16 weeks; last treatment at week 44/46 based on the treatment regimen.
3369523|NCT04261153|Other|cognitive stimulation|3 cognitive stimulation sessions in total from the HAPPYNeuron® software, approximately 20 minutes each and spread over several days
3369524|NCT04260191|Experimental|Dose-exploration|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 910 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
3369525|NCT04260191|Experimental|Dose-expansion|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
3369527|NCT04247425|Experimental|Supportive Care (resistance training, exercise counseling)|Patients complete a series of progressive resistance training exercises at home twice weekly over 1 hour and receive instructional guidance from an exercise physiologist via videoconferencing once per week during one of these sessions for up to 12 weeks.
3369528|NCT04243629|Experimental|Rapid Insulin-Plus-Pramlintide|Rapid insulin and pramlintide infusion in two insulin pumps
3369529|NCT04243629|Placebo Comparator|Rapid Insulin-Plus-Placebo|Rapid insulin and placebo (saline) infusion in two insulin pumps
3253226|NCT01412437|Experimental|sapropterin dihydrochloride|Intervention: 24 participants will be randomized to receive the drug 10 mg/kg per day. Responders and non responders will remain on drug for four months
3253227|NCT01412450|Experimental|nitinol stent|Protégé EverFlex stent
3253228|NCT01412463|Experimental|Protégé EverFlex+|Stenting with Protégé EverFlex+
3253229|NCT01412476||case group|Subjects with metabolic syndrome
3253230|NCT01412476||control group|Healthy individuals
3253231|NCT01412489|Experimental|1|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
3253232|NCT01412502||Brain death with organ donation|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes brain death with multiple organ donation +/- tissues."
3253233|NCT01412502||Limitation/cessation of active treatment|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death includes limitation/cessation of active treatment without brain death."
3253234|NCT01412502||Sudden death|"Participants in this group are the nearest relatives (or person-of-trust) of a patient who has passed away within 3 days of admission to an intensive care unit. The cause of death was sudden death of a previously healthy patient (no physical or mental limitations; MacCabe score = 0) within 3 days of admission to ICU without LATA nor brain death."
3253235|NCT01412515|Experimental|Everolimus|everolimus 10 mg per day
3253236|NCT01412528|Other|Eight different allergens will be standardized in this study|
3253237|NCT01412567|Active Comparator|Vaccine+HBIG|
3253238|NCT01412567|Placebo Comparator|Vaccine+Placebo|
3259466|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
3253239|NCT01412580||observational followup|This was an observational follow-up to a larger study in which treatment group was given 20 mg of vitamin B1, 20 mg of vitamin B2, 25 mg of vitamin B6, 100 mg of niacin, 50 μg of vitamin B12, 500 mg of vitamin C, 30 mg of vitamin E, and 0.8 mg of folic acid
3253240|NCT01412593|Experimental|Stem cell transplant|
3253241|NCT01412593|No Intervention|Control|
3253242|NCT01412606|Experimental|Scrathcing|scratching of endometrium on day 21-26 of a spontaneous menstrual cycle
3369533|NCT04241835|Experimental|Open label Tazemetostat|Single and BID doses of oral tazemetostat 800 mg
3369534|NCT04232566||Weight loss surgery|Gastric bypass surgery will be followed by weight loss as standard of care. Liver fibrosis by elastography will be determined before surgery.
3369535|NCT04230421|Experimental|Monsenso with feedback|Daily smartphone-based monitoring and treatment using the Monsenso system with a clinical feedback loop feedback.
3253243|NCT01412606|Placebo Comparator|Control|Uterine sounding on day 21-26 of a spontaneous menstrual cycle
3253244|NCT01412632|Experimental|General vs deep sedation|General anesthesia: remifentanil and propofol Deep sedation: remifentanil, propofol and citanest
3369536|NCT04230421|Active Comparator|Monsenso without feedback|Daily smartphone-based monitoring and treatment using the Monsenso system WITHOUT a clinical feedback loop feedback.
3369537|NCT04230421|Active Comparator|Control|CAG Bipolar treatment alone and daily mood monitoring using only the mood monitoring part of the Monsenso system.
3253245|NCT01412645|Placebo Comparator|Placebo|
3253246|NCT01412645|Experimental|High-dose Resveratrol|
3253247|NCT01412645|Experimental|Low-dose Resveratrol|
3369540|NCT04221230|Experimental|BTRX-335140|BTRX-335140
3369541|NCT04221230|Placebo Comparator|Placebo|Placebo
3369542|NCT04216238||Cardiovascular surgical patients|Patients who received cardiovascular surgery and was released from the hospital due to meeting and exceeding a certain walking distance.
3369543|NCT04214119||Control|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and does not have a diagnosis of Barrett's esophagus or esophageal/gastric malignancy.
3369544|NCT04214119||Barrett's esophagus|Patients age 18 or greater who have undergone esophagogastroduodenoscopy and diagnosed with Barrett's esophagus via pathology.
3369545|NCT04214119||Esophageal carcinoma|Patients age 18 or greater who have diagnosis of primary esophageal carcinoma.
3369546|NCT04214119||Gastric cancer|Patients age 18 or greater who have diagnosis of primary esophageal cancer.
3369547|NCT04210596|Active Comparator|Control group|Connective tissue graft harvested from the palate
3369548|NCT04210596|Experimental|Collagen matrix|Pig-derived collagen matrix (Fibro-Gide, Geistlich Biomaterials, Wolhusen, Switserland)
3253248|NCT01412658|Experimental|Milk Peptides|
3253249|NCT01412658|Placebo Comparator|Placebo|Participants ingested 6ml - 21ml (based on participants' weight) of clear, sugar-less liquid placebo mixed with 1/2 cup milk twice daily (once immediately after breakfast and once immediately after dinner). The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a glycerol-based placebo matched for color, texture, and taste to the active supplement.
3253250|NCT01412671||Group 1|
3253251|NCT01412697|Experimental|Fruit and Vegetable Intake Behavioral Intervention|measure fruit and vegetable intake in rural youth based on specific behavioral intervention.
3253252|NCT01412697|No Intervention|Control Group|control group received the standard health information
3253253|NCT01412723|Active Comparator|Ferrous sulphate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin, which will be supplied with ferrous sulfate-fortified milk
3253254|NCT01412723|Experimental|Iron Amino acid chelate|Preschool children with depleted levels of iron enrolled in FAN Foundation of Medellin , which will be supplied with iron amino acid chelate-fortified milk
3253255|NCT01412736|Experimental|2mg|sterile lyophilized formulation, 2mg
3253256|NCT01412736|Experimental|20mg|sterile lyophilized formulation, 20mg
3369558|NCT04194528|Experimental|Oxycodone/acetaminophen (5/325 mg) DMP|The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
3369559|NCT04188067|Experimental|PPA patients|All study participants will carry a diagnosis of Primary Progressive Aphasia (PPA), either the logopenic, the non-fluent variant or the semantic variant. All participants will receive the same study interventions in a within-subject crossover design.
3369560|NCT04185415|Experimental|bepranemab|Subjects will be randomized to receive bepranemab.
3369561|NCT04185415|Placebo Comparator|Placebo|Subjects will be randomized to receive Placebo.
3369562|NCT04182607||hand-assisted kidney transplant|Kidney donors and recipients who underwent a hand-assisted kidney transplant
3253257|NCT01412736|Experimental|100mg|sterile lyophilized formulation, 100mg
3369563|NCT04182607||robotic kidney transplant|Kidney donors and recipients who underwent a robotic kidney transplant
3253258|NCT01412736|Placebo Comparator|Placebo|two SC administration on day 1
3253259|NCT01412749||eHNS Participant Registry|Participants diagnosed with head and neck cancer who are candidates for definitive surgical resection of the primary tumor and who are candidates for eHNS.
3369564|NCT04180228||Systemic lupus erythematosus|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire with systemic lupus erythematosus.
3369565|NCT04180228||Idiopathic juvenile arthritis|Investigators include in this group all young girls between 11 to 19 years old who accepted to respond to the questionnaire, with idiopathic juvenile arthritis.
3369566|NCT04179162|Experimental|Bacillus Calmette-Guérin (BCG) and Gemcitabine|Eligible patients will receive combination intravesical chemoimmunotherapy. Treatment is sequential, with twice-weekly intravesical gemcitabine given at weeks 1, 4, 7, and 10, for a total of 8 doses, administered in a standard fashion. In phase I, the dose of gemcitabine will depend on the dose level being assessed for the determination of the MTD. phase II, 1 dose level will be given (the MTD from phase I). Fixed doses of once-weekly intravesical BCG therapy (TICE strain, 50 mg) will be given at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6 (+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days), for a total of 6 doses, also administered in a standard fashion. All intravesical therapy will be administered in the chemotherapy suite on an outpatient basis, in accordance with standard clinical practice. Intravesical therapies will be retained in the bladder for up to 2 h (BCG) or 1 h (gemcitabine), or as tolerated.
3369567|NCT04176172|Active Comparator|Varenicline & Standard Cessation Counseling|varenicline plus standard behavioral smoking cessation treatment
3369568|NCT04176172|Active Comparator|NMR-Tailored Medication & Standard Cessation Counseling|varenicline or nicotine patch plus standard behavioral smoking cessation treatment
3369569|NCT04176172|Experimental|Varenicline & Standard Cessation Counseling + MAPS|varenicline plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
3253260|NCT01412762||patient interviews|We aim to interview 15 patients with confirmed thyroid malignancy both pre- and postoperatively, for a total of 30 interviews. For the expansion of this study, we will accrue 25 patients with biopsy-proven thyroid cancer undergoing thyroidectomy to be educated with the CITSAV application prior to surgery.
3253261|NCT01412775|Experimental|Psychological stress and exhaustion|Twenty four male and female nurses from the cardiac intensive-care unit (CCU) of Meir Hospital, who consent to take part in the offered intervention program, will participate in the study. The participants will be randomly assigned to an experiment group of 12 participants and a control group of 12 participants.
3253262|NCT01412788|Experimental|peri-areolar incision|Peri-areolar incision was used to carry out lumpectomy
3253263|NCT01412788|Active Comparator|traditional incision|traditional incision above tumor was used to carry out lumpectomy
3369570|NCT04176172|Experimental|NMR-Tailored Medication & Standard Cessation Counseling + MAPS|varenicline or nicotine patch plus standard behavioral smoking cessation treatment with Managed Problem Solving adherence intervention
3253264|NCT01412814|Experimental|Experimental|These patients will carry out the specified intervention of the study with the AposTherapy Biomechanical System in addition to the typical physical therapy regiment prescribed to them by their physician.
3253265|NCT01412814|Active Comparator|Control|The patients within this group will also carry out the typical physical therapy program for total knee replacement as prescribed by their physician. The patients will carry out a similar therapy program to the experimental group, but without the study intervention device (placebo walking shoe).
3253266|NCT01412827|Other|Comparison of radioisotope dosing|
3253267|NCT01412840|Experimental|Standard care and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
3253268|NCT01412840|Placebo Comparator|Standard care and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
3369576|NCT04170998|Experimental|Evogliptin 5mg group|Evogliptin 5mg/d + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
3369577|NCT04170998|Placebo Comparator|Evogliptin Placebo group|Evogliptin Placebo + Dapagliflozin 10mg/d + Metformin ≥ 1000mg/d
3369580|NCT04147650|Experimental|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
3369581|NCT04147650|Experimental|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
3369582|NCT04147650|Experimental|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
3253269|NCT01412840|No Intervention|Standard care|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac.
3253270|NCT01412853|Experimental|MR-spectroscopy|
3253271|NCT01412892|Experimental|Everolimus|RAD001: Everolimus
3253272|NCT01412931||1) Pregnant women with a single intrauterine pregnancy|50 women with uncomplicated pregnancies and no history of preterm birth.
3253273|NCT01412931||2) Pregnant women with a single intrauterine pregnancy|50 multiparous women with history of spontaneous preterm labor or preterm premature rupture of membranes (PPROM).
3253274|NCT01412931||3) Pregnant women with a single intrauterine pregnancy|20 women evaluated on the labor and delivery unit because they are deemed to be at high risk for preterm birth.
3253275|NCT01412970|Other|study group|comparison of ability to predict volume responsiveness and precision of measurement of stroke volume variation assessed by electrical impedance tomography in comparison to clinically established invasive hemodynamic monitoring devices, i.e. arterial pulse contour analysis during volume loading procedures
3253276|NCT01412996|Active Comparator|single ACCESS cholecystectomy|single ACCESS laparoscopic cholecystectomy
3369583|NCT04147650|Placebo Comparator|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
3369585|NCT04144751||Subjects Enrolled in 2019-01 BLUE-C|Subjects will be men and women, 40 years of age or older, who enroll in Exact Sciences Protocol 2019-01 BLUE-C. Subjects will provide a blood sample at time of enrollment.
3369586|NCT04144738||Individuals eligible for CRC Screening|Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy.
3369587|NCT04136730|No Intervention|Control|Usual Care
3369588|NCT04136730|Active Comparator|Home-based|Home-based resistance exercise training
3369593|NCT04120766|Experimental|Treatment|Nicorandil 20mg qd
3253277|NCT01412996|Active Comparator|traditional|conventional laparoscopic cholecystectomy
3253278|NCT01413009||ICU patients|
3369594|NCT04120766|Placebo Comparator|Placebo|Matched placebo qd
3369595|NCT04120610||Healthy|Healthy cohort is an age-matched population (over 40 years old) without history of PAD or suspected PAD. Healthy cohort will receive FlowMet-R measurement, Ankle Brachial Index (ABI), and Toe Brachial Index (TBI) measurements.
3369596|NCT04120610||PAD|PAD cohort is all-comers to the vascular lab that are scheduled to undergo assessment for Peripheral Artery Disease (PAD) or have a planned endovascular or surgical intervention to address PAD. PAD cohort patients will receive FlowMet-R measurement in addition to their routine standard of care.
3369597|NCT04120493|Experimental|Cohort 1|Low dose rAAV5-miHTT (6x10^12 gc/subject).
3369598|NCT04120493|Experimental|Cohort 2|High dose rAAV5-miHTT (6x10^13 gc/subject).
3369599|NCT04120493|Sham Comparator|Cohorts 1 and 2|Imitation (sham) surgery
3369600|NCT04117958|Experimental|Dose-exploration phase|The dose-exploration phase of the study will estimate the MTD (Maximum Tolerated Dose) of AMG 199 using a Bayesian logistic regression model (BLRM). A RP2D (Recommended Phase 2 Dose) may be identified based on emerging safety, efficacy, and PD (Pharmacodynamics) data prior to reaching an MTD. Alternative dosing schedule(s) may be explored based on emerging PK (Pharmacokinetics) and safety data.
3369601|NCT04117958|Experimental|Dose-expansion phase|The dose-expansion phase will be conducted to confirm safety, PK, and PD at the MTD or RP2D and to obtain further safety and efficacy data and enable correlative biomarker analysis.
3369602|NCT04114877|Experimental|attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. Attentional retraining (AR) is the most commonly used CBM intervention in the study of addiction-related attentional bias.
3369603|NCT04114877|Active Comparator|visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues.
3369604|NCT04110054|Experimental|S-600918 50 mg|Participants will receive 50 mg S-600918 orally once a day for 28 days.
3369605|NCT04110054|Experimental|S-600918 150 mg|Participants will receive 150 mg S-600918 orally once a day for 28 days.
3369606|NCT04110054|Experimental|S-600918 300 mg|Participants will receive 300 mg S-600918 orally once a day for 28 days.
3253279|NCT01413022|Active Comparator|Group A (FOLFIRINOX chemotherapy)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~Treatment is repeated every 14 days for 6 cycles."
3253280|NCT01413022|Experimental|Group B (FOLFIRINOX and PF-04136309)|"Patients receive FOLFIRINOX chemotherapy comprising of:~oxaliplatin 85 mg/m2 IV on Day 1~irinotecan 180 mg/m2 IV on Day 1~leucovorin 400 mg/m2 IV on Day 1~5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1~PF-04136309 500 mg PO BID on days 1-14~Treatment is repeated every 14 days for 6 cycles."
3369607|NCT04110054|Placebo Comparator|Placebo|Participants will receive placebo to S-600918 orally once a day for 28 days.
3369608|NCT04106193|Experimental|Toolkit + Implementation as Usual|Participating clinics assigned to this arm will receive a guiding toolkit and implementation as usual regarding IPV screening practices.
3369609|NCT04106193|Experimental|Toolkit + Blended Facilitation|Participating clinics assigned to this arm will receive a guiding toolkit and blended facilitation to support IPV screening practices.
3369610|NCT04093986||Retrospective Chart Review|Medical record chart review of women seen previously for clinical care prior to June 20, 2019 at participating institutions with SCD and hydroxyurea exposure during gestation or lactation will be identified by healthcare providers.
3253281|NCT01413035|Experimental|MSC and the oral hypoglycemic drugs|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former oral hypoglycemic drugs, such as Dimethylbiguanide, Glurenorm and Acarbose, et al. and regulates the dosage for 1 year.
3253282|NCT01413035|Experimental|MSC and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former insulins and regulates the dosage for 1 year.
3253283|NCT01413035|Experimental|MSC and the combination of drugs and insulins|1.0E+6 MSC/kg, IV drop and repeat to apply in Day 90 if the effect of MSC is better. At the same time, patient continues to apply the former combination of the oral hypoglycemic drugs and insulins and regulates the dosage for 1 year.
3369611|NCT04093986||Participant Survey and Retrospective Chart Review|Participants providing their medical records without the assistance of a health care provider will be asked to complete a questionnaire through REDCap and will have the option to upload their deidentified medical records if they are available.
3369612|NCT04091750|Experimental|Single Arm|"Induction phase:~Nivolumab 3mg/kg IV plus Ipilimumab 1mg/kg IV every 3 weeks x 4 cycles (12 week period)~Cabozantinib 40mg PO daily for 12 weeks~Maintenance phase:~Nivolumab 480mg IV every 4 weeks for up to 92 weeks~Cabozantinib 40mg PO daily for up to 92 weeks~Maintenance therapy will continue for up to 92 weeks to complete 2 years total of treatment if tolerating therapy well and disease is controlled."
3369613|NCT04090749|Experimental|Open Label Group|In this arm, 5 participants will be enrolled in the intervention without blinding or randomization. The intervention and study delivery will be improved based on findings from this arm.
3369614|NCT04090749|Other|Waitlist Control|The waitlist control group (n=20) will be provided written materials with community resources for caregivers during the first 16 weeks, then the intervention will begin.
3369615|NCT04090749|Experimental|Immediate Intervention|The immediate intervention group (n=20) will receive the intervention during weeks 0-16. There will be assessment at week 32 to examine maintenance on primary and secondary outcomes.
3253284|NCT01413048|Experimental|AGSCT101|
3253285|NCT01413048|Active Comparator|Carvedilol|
3253286|NCT01413061|Active Comparator|AlloStem Live Cellular Allograft|AlloStem is the combination of the Mesenchymal Stem Cells (MSC) derived from adipose with demineralized bone.
3369618|NCT04082442|Experimental|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in ACS patients.
3369619|NCT04082442|Placebo Comparator|Placebo|Placebo administered subcutaneously using an autoinjector/pen in ACS patients .
3253287|NCT01413061|Active Comparator|Control: Autologous Bone Marrow Aspirate|Autologous bone graft is recovered from the patient's own tibia or iliac crest, for transplantation in the subtalar joint.
3369620|NCT04075292|Experimental|Acalabrutinib|Acalabrutinib will be orally administered until disease progression or unacceptable toxicity
3369621|NCT04075292|Active Comparator|Rituximab and Chlorambucil|Chlorambucil orally administered and Rituximab via IV infusion for 6 cycles
3369622|NCT04073225|Experimental|MindPod Dolphin Arm|Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke.
3253288|NCT01413074|Active Comparator|ESRD patients receiving HD treatment|no investigational drug involved. Only oberseve therapy treatment
3253289|NCT01413074|Experimental|ESRD patients receiving PD treatment|no investigational drug involved. Only oberseve therapy treatment
3253290|NCT01413100|Experimental|Treatment (HDIT autologous PBSCT)|"STEM CELL MOBILIZATION AND PREPARATION: Patients receive filgrastim SC on mobilization days 1-4 followed by apheresis until a target dose of CD34+ cells >= 2.5 x 10^6/kg are collected. Patients difficult to mobilize with filgrastim alone receive cyclophosphamide IV or *plerixafor SC on mobilization days 1-2 and filgrastim SC on mobilization days 5-7.~HDIT CONDITIONING: Patients receive high-dose cyclophosphamide IV over 1-2 hours on days -5 to -2 and anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5.~TRANSPLANTATION: Patients undergo autologous PBSCT on day 0.~MAINTENANCE THERAPY: Beginning 2-3 months after transplant, patients receive mycophenolate mofetil PO BID for 2 years."
3253291|NCT01413113|Experimental|Treatment (enzyme inhibitor and radioactive drug therapy)|Patients receive iodine I 131 IM QD 5 days a week in weeks 5-6. Patients also receive pazopanib hydrochloride PO QD beginning in week 1 and continuing for 8 weeks post-radioactive iodine therapy.
3369623|NCT04073225|Active Comparator|Hand Bike Arm|Pedal Exerciser, a single-component upper-arm aerobic play. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
3369624|NCT04070573|Active Comparator|81mg ASA|Patients in Arm 1, will be instructed to take one tablet of 81mg aspirin per day.
3253292|NCT01413126|Experimental|Peanut butter|42.5 g of Peanuts butter were added to a 75g available carbohydrate-matched breakfast meal
3253293|NCT01413126|Experimental|Whole peanut|42.5 g of whole peanuts were added to a 75g available carbohydrate-matched breakfast meal
3253294|NCT01413126|No Intervention|No peanuts (control)|
3369625|NCT04070573|Active Comparator|162mg ASA|Patients in Arm 2, will be instructed to take two tablets simultaneously orally once per day.
3369626|NCT04070443|Experimental|Induction phase with Ponatinib followed by Imatinib|"Ponatinib (Iclusig®) : Tyrosine Kinase Inhibitor (BCR-ABL); oral (tablets) : 30mg/day during 6 months (induction phase); Takeda & Incyte Biosciences.~Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months (then, depending of MR4.5)"
3369627|NCT04068194|Active Comparator|Arm A (hypofractionated RT, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3369628|NCT04068194|Experimental|Arm B (hypofractionated RT, peposertib, avelumab)|Patients undergo 8 fractions of hypofractionated RT QD on days -17 to -7. Patients also receive peposertib PO BID on days 1-28, and avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3369629|NCT04058067|Experimental|Brolucizumab 6 mg|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
3369630|NCT04058067|Active Comparator|Aflibercept 2 mg|5 x every 4 weeks loading then every 8 weeks maintenance
3369635|NCT04051242|Experimental|XenMatrix AB Surgical Graft|This study proposes to use XenMatrix™ AB Surgical Graft which has 510(k) approval [#K162193] intended for implantation to reinforce soft tissue where weakness exists and for surgical repair of damaged or ruptured soft tissue. This trial proposes to test the applicability and utility of XenMatrix™ AB Surgical Graft in the restoration of function in the setting of volumetric muscle loss after trauma
3369636|NCT04046406|Experimental|Pelvic pain syndromes|Patients with pelvic pain syndromes who will undergo MR neurography-guided cryoanalgesia
3369637|NCT04042337|Experimental|PRT Telehealth|Participating parents will receive 12 weekly 60-minute parent training sessions via secure videoconference to learn Pivotal Response Treatment
3369638|NCT04042337|No Intervention|Waitlist|Participants will continue stable community-based treatments
3253295|NCT01413139|Other|4F portfolio products from Biotronik|The devices under investigation are the 4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18 and Cruiser-18.
3253296|NCT01413152|Experimental|0|
3253297|NCT01413217||Egg Breakfast|This group will be given a breakfast consisting of eggs. A breakfast consisting of eggs induces greater satiety and reduces Lunch Time intake.
3369645|NCT04010344|Experimental|Enhanced Usual Care Group|All participants in the enhanced usual care arm must own a cell phone with at least short message service (SMS) and voicemail. To control for attention exposure, they will receive SMS messages daily dealing with healthy lifestyle behaviors (smoking, diet, physical activity) but not with medication adherence or hypertension-specific issues. Every three days (comparable to intervention group monitoring) they will receive an automated SMS directing them to a different 2-3 min video/YouTube™ clips on healthy lifestyles. Patients in this arm of the study will also receive usual care as determined by their providers. Usual care is described in the next section.
3369646|NCT04010344|Active Comparator|Usual Care|Patients in this arm of the study will receive usual care as determined by their providers. Usual care in the region typically involves at least one visit every 2-3 months for review of adherence to treatment, blood pressure control, and prescriptions for medication refills. Similar to the intervention group, participants will have a total of three follow-up visits which will be separate from their regular appointments during which study outcomes will be assessed.
3369647|NCT04009395||Pregnant women|One-on-one in-depth interviewing
3369648|NCT04009395||Midwives|One-on-one in-depth interviewing or focus group discussions
3369651|NCT04003116|Experimental|Supplementary oxygen|Supplementary oxygen added to conventional anticoagulant treatment.
3369652|NCT04003116|No Intervention|Standard medical therapy|Standard management.
3253298|NCT01413217||Cereal Breakfast|This breakfast will consist of a breakfast that will include cereal. A breakfast cereal or white bread increases lunchtime energy intake.
3369653|NCT04002167|Experimental|Neurofeedback|The Neurofeedback group will receive 12 sessions of computerized cognitive intervention combined with neurofeedback in the lab.
3369654|NCT04002167|Active Comparator|Cognitive Training|The Cognitive Training group will receive 12 sessions of computerized cognitive intervention in the lab.
3369655|NCT04002167|No Intervention|Waitlist|Both Neurofeedback and Cognitive Training groups will be assigned to waitlist before starting the corresponding intervention.
3369656|NCT03999229|Active Comparator|Blood transfusion with SNO agent|"Autologous blood transfusion packed red blood cells (RBCs) while inhaling S-nitrosylating agent (SNO)~A single intra venous blood transfusion of one unit of packed Red Blood Cells (RBCs) will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of SNO agent, 20-40 parts per million will occur during the transfusion."
3369657|NCT03999229|Placebo Comparator|Normal Saline with SNO agent|"Normal Saline Transfusion while inhaling S-nitrosylating agent (SNO)~A single intra venous infusion of one unit of normal saline, will be given over the standard transfusion flow rate of 5 ml/min under the direction of a physician or a licensed medical professional.~Inhalation of the SNO agent at 20-40 parts per million, will occur during the transfusion."
3369658|NCT03995667|Experimental|Prevention (TTFields therapy, questionnaire)|Patients undergo TTFields therapy over 18-24 hours daily. Cycles repeat every 4 weeks for 12 months in the absence of disease progression or unacceptable toxicity.
3369659|NCT03990077|Experimental|dose escalation of HL-085 plus Docetaxel|"HL-085 will be administered as BID with specified dose. And Docetaxel will be taken as the instruction in the label ( 75mg/m2，IV).~f no Dose-limiting toxicity (DLT) occurs in the first three subjects in Cycle 1, the dose will be escalated to the next dose level; If a DLT occurs in one of the first three subjects, three additional subjects will be enrolled for the same dose cohort, and undergo the same procedures. Dose -escalation is performed based on the scheduled dose groups until DLT occurs in two or more subjects in a dose group which consists of 3 or 6 subjects."
3369660|NCT03985072|Experimental|Andes-1537|There will be 5 different cohorts each representing a different type of solid cancer (gallbladder and biliary tract cancer, cervical cancer, gastric cancer, pancreatic cancer, and colorectal cancer). All patients will receive a dose of 400 mg of Andes-1537 five days per week for continuous cycles of 4 weeks that will be repeated until the patients presents drug toxicity requiring treatment discontinuation or disease progression without any noted clinical benefit as assessed by the investigator.
3369661|NCT03978897|Experimental|Blood flow restriction with physical/occupational therapy|physical/occupational therapy including use of blood flow restriction tourniquet over 6 visits (within a twelve week period).
3369662|NCT03978897|Active Comparator|Evidence based physical/occupational therapy|evidence based physical/occupational therapy program over 6 visits (within a twelve week period) without use of blood flow restriction tourniquet
3369663|NCT03972280|Experimental|Dose Level 1 (HS)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
3369664|NCT03972280|Experimental|Dose Level 1 (PPP)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
3369665|NCT03972280|Experimental|Dose Level 1 (Total)|Dose 1 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
3369666|NCT03972280|Experimental|Dose Level 2 (HS)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS
3369667|NCT03972280|Experimental|Dose Level 2 (PPP)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with PPP
3369668|NCT03972280|Experimental|Dose Level 2 (Total)|Dose 2 of recombinant anti-G-CSF receptor monoclonal antibody administered intravenously to subjects with HS or PPP
3253299|NCT01413243|Experimental|Drug: Trichuris suis ova|Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months
3253300|NCT01413243|Placebo Comparator|Placebo|Drug: Placebo, fluid every 2 weeks
3253301|NCT01413269|Experimental|hypofractionation radiotherapy|irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
3253302|NCT01413269|Active Comparator|conventional fractionation radiotherapy|irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.
3253303|NCT01413282|Active Comparator|Cardiac CT|Triage based on cardiac CT results.
3369669|NCT03968107||Women with a pregnancy of at least 31 weeks|All pregnant women with a pregnancy of at least 31 weeks and having to perform a fetal MRI to identify a cerebral, pulmonary or renal fetal malformation, or due to a diagnostic doubt on ultrasound on an abnormality of these structures, will be proposed inclusion in the study.
3369670|NCT03963583|Experimental|HEROIC Intervention Group|This group will receive the HEROIC intervention.
3369671|NCT03963583|Experimental|Waitlist Control Group|The waitlisted group will receive usual care for caregivers for the first 16 weeks, which is normally limited to inclusion in some clinical assessment and teaching during patient visits. Waitlisted participants will receive monthly study postcards to encourage retention. After 16 weeks, they will begin the intervention.
3369672|NCT03958331|Active Comparator|Control Group|Automated reminders and individualized adherence feedback reports
3369673|NCT03958331|Experimental|Treatment Group|Automated reminders and individualized adherence feedback reports with social norms comparisons
3369674|NCT03954613|Experimental|Group A|Donepezil/Memantin Combination
3369675|NCT03954613|Experimental|Group B|Donepezil/Memantin Combination + Cognitive Exercises (BEYNEX Software)
3369676|NCT03954613|Active Comparator|Group C|Donepezil Mono
3369677|NCT03954613|Active Comparator|Group D|Donepezil Mono + Cognitive Exercises (BEYNEX Software)
3369678|NCT03954613|Active Comparator|Group E|Memantine Mono
3253304|NCT01413282|No Intervention|Standard Care|Standard diagnostic management according to the European guidelines.
3253305|NCT01413295|Experimental|Dendritic Cells Vaccine|Dendritic Cells Vaccine after 2 lines of chemotherapy
3369679|NCT03954613|Active Comparator|Group F|Memantine Mono + Cognitive Exercises (BEYNEX Software)
3369680|NCT03939169|Other|Skin-to-skin support|The newborn is dressed in one layer of clothing with a hat, he is placed in the ventral position directly on the mother's chest, covered with a warm blanket and held in place with a band during the insertion of the naso-gastric feeding tube.
3369681|NCT03939169|Other|Holding|The newborn is held in his mother's arms during insertion of the naso-gastric feeding tube.
3369682|NCT03939169|Other|Four hands care|Carried out by two professionals: one health-care professional supports the child and helps stabilize the newborn whilst the other professional inserts the naso-gastric feeding tube.
3369683|NCT03939169|Other|Containing support with equipment|Carried out by one healthcare Professional, who places the newborn in such a manner that he will be held in the optimum position (using a soft sheet) during the insertion of the naso-gastric feeding tube.
3369684|NCT03934372|Experimental|Ponatinib|Phase 1: Ponatinib administered according to age-based cohort doses and formulations to determine the maximum tolerated dose and recommended Phase 2 dose. Phase 2: Ponatinib administered at the recommended Phase 2 dose.
3369685|NCT03931941|Experimental|Active|RBX2660 is an enema of a microbiota suspension
3369686|NCT03930953|Experimental|Part A: Dose Escalation|
3369687|NCT03930953|Experimental|Part B: Dose Expansion|
3253306|NCT01413295|Other|Supportive treatment|Supportive treatment after 2 lines of chemotherapy
3253307|NCT01413321||SHABI|Subacute hemiparetic ABI subjects group
3369703|NCT03916419|Experimental|Safety lead-in: Chemoradiation + Durvalumab|"The first 6 patients enrolled on study will comprise the Safety Lead-In cohort and will be closely monitored for toxicity related specifically to the experimental chemoradiation portion of the study treatment. After these 6 patients have been enrolled, accrual will temporarily be suspended for a minimum of 6 months after completion of chemoradiation to allow for the evaluation of adverse events.~Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months."
3369704|NCT03916419|Experimental|Phase II: Chemoradiation + Durvalumab|-Patients will receive concurrent chemoradiation over the course of 3 weeks (15 fractions of radiation with online adaptive treatment planning at fractions 6, 9, and 12 and weekly carboplatin + paclitaxel). Four to 6 weeks after the end of chemoradiation, durvalumab immunotherapy will administered every two weeks for up to 12 months.
3369712|NCT03914326|Experimental|Oral semaglutide|One tablet daily for 3.5 to 5 years
3369713|NCT03914326|Placebo Comparator|Placebo|One tablet daily for 3.5 to 5 years
3369716|NCT03907540|Experimental|Part 1, Treatment A--Belumosudil 200 mg Tablet|Belumosudil 200 mg tablet
3369717|NCT03907540|Experimental|Part 1, Treatment B--[14C]-KD025 IV Microdose|[14C]-KD025 at a dose of 100 μg in a 5 mL solution containing NMT 37 kBq (1000 nCi) [14C] over 15 min IV
3253308|NCT01413321||CHABI|Chronic hemiparetic ABI subjects group
3369718|NCT03907540|Experimental|Part 2, Treatment C--[14C]-KD025 Capsule|[14C]-KD025 200 mg capsule containing NMT 9.8 MBq (215 μCi)
3369721|NCT03903094||Subjects With Overactive Bladder Treatment|Subjects who have dispensing records for treatment of overactive bladder will be included
3369722|NCT03903094||Subjects Without Overactive Bladder Treatment|Subjects who do not have dispensing records for treatment of overactive bladder will be included
3369725|NCT03896789|No Intervention|Baseline|All sites will collect usual care data from 9 months to 21 months.
3369726|NCT03896789|Experimental|PEGASUS Program (Intervention)|This arm (half of the sites) will receive the PEGASUS program (intervention) from 21 months to 57 months.
3253309|NCT01413347|Active Comparator|pillow|confirmation of double-lumen tube position with a head on a pillow
3369727|NCT03896789|No Intervention|Usual Care (Control)|This arm (half of the sites) will maintain usual care. They will receive the opportunity for the PEGASUS program training (intervention) at the end of study data collection (57 months) period.
3369734|NCT03894306||medication lock box + brief counseling|
3369735|NCT03894306||medication lock bag + brief counseling|
3369736|NCT03894306||brief counseling alone|
3369737|NCT03894215|Experimental|AGEN2034 + Placebo|AGEN2034 administered with placebo monotherapy: approximately 100 patients.
3369738|NCT03894215|Experimental|AGEN2034 + AGEN1884|AGEN2034 administered in combination with AGEN1884 (combination therapy): approximately 100 patients.
3253310|NCT01413347|Experimental|neutral|confirmation of double-lumen tube position in neutral position of a head
3253311|NCT01413386|Experimental|Paclitaxel Eluting Covered Metal Stent|
3253312|NCT01413386|Active Comparator|Covered Metal Stent|
3253315|NCT01413412|Experimental|Hernia repair using full-thickness skin graft|25 patients
3369739|NCT03885024|Active Comparator|Retention Video|"Participants the peer-driven retention arm will receive video-based and in-person training from Retention Specialists on how to encourage study retention. Participants will watch a 7 minute video that standardizes retention messages. A brief face-to-face conversation with the Retention Specialist follows the video viewing to answer questions and reinforce video messages. At the end of the training, participants receive information about their recruit(s) who consented to release their information to their recruiters. Peers remind their enrolled study buddy to attend their scheduled follow up assessments. Participants meet with a study Retention Specialist by phone or in person, at 3 and 9 months after enrollment to answer questions about peer retention strategies and remind participants of their peers' contact information and follow-up schedules."
3253316|NCT01413412|Experimental|Hernia repair using Mesh|25 patients
3253317|NCT01413477|Active Comparator|Calcipotriol ointment|
3253318|NCT01413477|Active Comparator|Betamethasone dipropionate ointment|
3369740|NCT03885024|No Intervention|Standard Retention Strategy|Control arm: At NROI enrollment, all participants provide detailed information to assist with retention and/or contact for future research, and contact information for up to three people who should know how to reach the participant if contact information changes. Participants randomized to receive the standard retention strategy are contacted at the mid-point of each follow-up interval (i.e., at 3-month post enrollment and 9-months post-enrollment) to update locator information and remind them about their follow-up appointment date. Study associates contact the participant using their contact information and, if not successful, will try to reach one of their contacts in the locator form.
3369741|NCT03883724|Experimental|Brief behavioral treatment for insomnia|This group will undergo behavioral intervention proven to improve sleep among older adults: brief behavioral treatment for insomnia
3253319|NCT01413477|Active Comparator|Calcipotriol and betamethasone ointment|
3253320|NCT01413477|Placebo Comparator|Vaseline Petroleum Jelly|
3369742|NCT03883724|Other|Information-only control|This group is called information-only control. They will be provided sleep-related information. They will also view a video content of which overlap substantially with BBTI but without individualized behavioral instructions.
3369743|NCT03876301||Observational Cohort|Adult males with clinically severe hemophilia A, who are negative for neutralizing antibody (NAb) to AAV-Spark200
3369744|NCT03875547||Patients with haemophilia B|Both patients who have not previously been exposed to Refixia® and patients previously exposed to Refixia® in one of the clinical trials can be included.
3369749|NCT03848143|Experimental|BOTOX|"Onabotulinum toxin A is distributed in 50 unit (50U) vacuum-dried powder bottles by Allergan (BOTOX (R)) for reconstitution only with sterile, preservative-free 0.9% Sodium Chloride Injection prior to injection.~1 mL of diluent will be drawn up to obtain a resulting dose of 10 U per 0.2 mL and injected into the vial. The BOTOX(R) will then be gently mixed with the saline by rotating the vial. The date and time of reconstitution will be recorded on the package on the label. BOTOX should be administered within 24 hours after reconstitution and stored in a refrigerator (2-8 °C).~Each patient will receive 50 U of onabotulinum toxin A."
3369750|NCT03842696|Experimental|Vorinostat|
3369751|NCT03836053|Experimental|AMG 420|Single Arm Design
3253321|NCT01413529|Experimental|HEART to HAART|HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
3253322|NCT01413529|Active Comparator|Adherence counseling|Adherence counseling with the addition of a smart phone control
3253323|NCT01413555|Experimental|Blood Culture QI Program|
3253324|NCT01413568|Experimental|Donor (Phase I and Phase II)|"On Day 1 (and possibly Day 2) POL6326 IV Infusion with increasing dose levels in Phase I or with random dose assignment (from the 2 selected from Phase I) in phase II~Leukapheresis collection on Day 1 (and possibly Day 2)"
3253325|NCT01413568|Experimental|Recipient|Day 0 - PBSC transplant with stem cells mobilized with IV POL6326
3253326|NCT01413581|Experimental|rhBSSL|rhBSSL (recombinant human bile-salt-stimulated lipase)
3369754|NCT03827759||septic arthritis (group A)|Patients with acute juvenile arthritis with suspicion of bacterial infection,confirmed on a bacteriological plan, either by culture of the articular liquid or by blood culture, or by molecular biology in the articular liquid;
3369755|NCT03827759||inflammatory arthritis (group B)|Patients with idiopathic juvenile arthritis
3369756|NCT03827759||control (group C)|Healthy children who are matched by the age and at the sex in the groups A and B, to analyze elements studied in the blood.
3253327|NCT01413581|Placebo Comparator|Placebo|Placebo
3253328|NCT01413594|Experimental|HABIT|Hand-Arm Bimanual Intensive Therapy (HABIT)
3369757|NCT03821558|Active Comparator|Interval training group|Patients to be randomized to the 'interval training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo interval exercise series composed of high-intensity intervals (80-90% of peak exercise performance) and low-intensity intervals (60-70% of peak exercise performance).
3369758|NCT03821558|Active Comparator|Continuous training group|Patients to be randomized to the 'continuous training group' will have exercise training sessions 3 times per week for a period of 12 weeks. During training, they will undergo moderate continuous exercise training at 75% of peak exercise performance.
3253329|NCT01413594|No Intervention|Ongoing usual and customary rehabilitation care|Subjects are tested over 6 months while receiving their ongoing usual and customary care schedule of physical and occupational therapy or following constraint-induced movement therapy received as usual and customary care independent of the study, and then are crossed-over to receive HABIT.
3253330|NCT01413607|Experimental|Quill knotless tissue-closure device|During partial nephrectomy participants in this group will receive the Quill Knotless Tissue-Closure device (Angiotech Pharmaceuticals) to close the central defect in their kidney.
3253331|NCT01413607|Active Comparator|2-0 absorbable vicryl suture|Participants in this group will be receiving traditional 2-0 vicryl sutures (Ethicon) during partial nephrectomy.
3369759|NCT03820947|Experimental|VenaSeal™ Closure System|CEAP 2-5 subjects will be randomized to VenaSeal™ Closure System vs. ETA or Surgical Stripping
3369760|NCT03820947|Active Comparator|Endothermal Ablation (ETA)|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or ETA
3369761|NCT03820947|Active Comparator|Surgical Stripping|CEAP 2-5 subjects will be randomized to either VenaSeal™ Closure System or surgical stripping (outside of the United States only)
3369762|NCT03820947|Other|VenaSeal™ Closure System VLU Study|CEAP 6 active leg ulcer subjects will not be randomized to a comparator, all subjects will be treated with VenaSeal™ Closure System
3369766|NCT03816163|Experimental|zolbetuximab +nab-paclitaxel + gemcitabine|Participants will be treated with zolbetuximab in combination with nab-paclitaxel and gemcitabine for the phase 1 portion of the study to establish the recommended dose of zolbetuximab for the phase 2 portion. In the phase 2 portion, the participants will be treated with zolbetuximab at dose determined by the phase 1 portion of the study in combination with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
3369767|NCT03816163|Active Comparator|nab-paclitaxel + gemcitabine|Participants will be treated with nab-paclitaxel and gemcitabine. Participants will be treated on continuous cycles until they no longer derive clinical benefit in the judgment of the treating physician, have unacceptable toxicity, undergo hematopoietic stem cell transplantation (HSCT), or meet one of the discontinuation criteria; whichever occurs first.
3369768|NCT03811873|Other|Intervention|Single-Arm trial
3369771|NCT03810729|Active Comparator|Modified Allen's Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on the participant's hand. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
3369772|NCT03810729|Active Comparator|Smartphone assessment|The smartphone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's index finger and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
3369773|NCT03810313|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
3369774|NCT03810313|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
3253332|NCT01413620|Experimental|Vitamin E Treated|
3253333|NCT01413620|No Intervention|Untreated|
3253334|NCT01413633|Experimental|cholecystectomy|single incision laparoscopic cholecystectomy
3253335|NCT01413646|Experimental|Walnut Supplementation|Eight weeks with walnut supplementation to an ad lib diet
3253336|NCT01413646|Placebo Comparator|2|Eight weeks ad lib diet without walnut supplementation
3253337|NCT01413659|Experimental|Symbiotic|Symbiotic is a combination of prebiotics and probiotics that is designed to have synergistic or additive effects benefiting the host
3253338|NCT01413672||person with ostomy|Community dwelling subject with either colostomy or ileostomy and at least 3 months post-surgery.
3253339|NCT01413685|No Intervention|Tacrolimus|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
3253340|NCT01413698||Patient with chronic cough|
3369775|NCT03809390|Experimental|Vaginal seeding group|Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
3369776|NCT03809390|No Intervention|Control group|Managed based on the standard practice in the study site
3369777|NCT03806608|Experimental|Crestal|Implants were placed with the implant-abutment interface(IAI) at the level of the the alveolar ridge
3369778|NCT03806608|Experimental|Subcrestal|Implants were placed with the implant-abutment interface(IAI) 1 mm below the level of the alveolar ridge
3369779|NCT03802630|Experimental|Brolucizumab 6 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
3369780|NCT03802630|Active Comparator|Aflibercept 2 mg|1 intravitreal injection every 4 weeks for a total of 6 injections, followed by 48 weeks of individual flexible treatment (IFT)
3253341|NCT01413711|Experimental|Vigabatrin|
3253342|NCT01413724||Surgical patients|PAtients who had surgery the previous day and are still hospitalized
3253343|NCT01413763|Active Comparator|Imiquimod cream|
3253344|NCT01413763|Placebo Comparator|Placebo cream|
3369781|NCT03796858|Experimental|Group 1: Guselkumab|Participants will receive guselkumab 100 milligram (mg) Subcutaneous (SC) injection at Weeks 0, 4, 12, 20, 28, 36, and 44 and placebo SC at Week 24 to maintain the blind. At Week 16, Participants who meet the early escape criteria will receive placebo at Week 16 and guselkumab at Week 20, then guselkumab every 8 weeks (q8w).
3369782|NCT03796858|Experimental|Group 2: Placebo followed by Guselkumab|Participants will receive placebo SC injection at Weeks 0, 4, 12, and 20, and will crossover to receive guselkumab 100 mg SC injection at Weeks 24, 28, 36, and 44. At Week 16, Participants who meet the early escape criteria will receive guselkumab at Weeks 16 and 20, then guselkumab q8w.
3253345|NCT01413776|Experimental|Dietary supplement|Pregnant women in 37 villages.
3253346|NCT01413776|No Intervention|Control group|Pregnant women in 38 villages
3253347|NCT01413789|Experimental|Patients and healthy volunteers|Patients with healed full thickness burns and healthy volunteers will be included in the study
3253348|NCT01413802|Experimental|Thyroid surgery.|Patients who undergo thyroid surgery during which intra operative continuous nerve monitoring will be used.
3253349|NCT01413815|Active Comparator|L-arginine|L-Arginine
3253350|NCT01413815|Placebo Comparator|corn starch|Placebo: Corn Starch
3253351|NCT01413828|Experimental|concurrent|trastuzumab was administered concurrently with any anthracycline-containing adjuvant regimen
3253352|NCT01413828|Active Comparator|sequential|trastuzumab was administered sequentially to any anthracycline-containing adjuvant regimen
3253353|NCT01413841|Active Comparator|Nasal oxygen|3 liter per minute
3253354|NCT01413841|Placebo Comparator|Nasal Air|3 l regular nasal air
3253355|NCT01413854|Active Comparator|diclofenac|
3253356|NCT01413854|Placebo Comparator|sugar pill|
3253357|NCT01413867|Experimental|EEA group|Group of patients with III degree hemorrhoids treated by EEA stapler
3253358|NCT01413867|Active Comparator|PPH group|group of patients with III degree hemorrhoids treated by PPH stapler
3253359|NCT01413893|Experimental|linifanib|
3253360|NCT01413906|Experimental|Arm 1: BMS-833923 (XL139)|
3253361|NCT01413932|Experimental|HT-2157|
3253362|NCT01413932|Placebo Comparator|Placebo|
3369788|NCT03792841|Experimental|Part 1 Dose-exploration: acapatamab treatment|Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.
3369789|NCT03792841|Experimental|Part 1 Dose-expansion: acapatamab treatment|Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.
3369790|NCT03792841|Experimental|Part 2: acapatamab + Pembrolizumab|Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
3369791|NCT03792841|Experimental|Part 3: acapatamab + Etanercept Prophylaxis|Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.
3369792|NCT03792841|Experimental|Part 4: acapatamab 24 Hour Monitoring|Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.
3369793|NCT03792841|Experimental|Part 5: acapatamab Outpatient Cohort|Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.
3369794|NCT03792841|Experimental|Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction|Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.
3369795|NCT03790956|Experimental|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
3369799|NCT03775486|Experimental|Durvalumab/Olaparib Combination Therapy|"Durvalumab/Olaparib Combination Therapy:~Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/Olaparib (maintenance phase)"
3369800|NCT03775486|Experimental|Durvalumab Monotherapy|Durvalumab Monotherapy: Durvalumab/SoC chemotherapy (initial therapy phase) followed by Durvalumab/placebo (maintenance phase)
3253363|NCT01413945||Normal volunteers|Normal volunteers without Irritable bowel syndrome who are undergoing screening colonoscopy.
3253364|NCT01413945||Irritable bowel syndrome|Patients with Irritable bowel syndrome are undergoing colonoscopy as standard of care.
3253365|NCT01413984|Experimental|cognitive behavioral group treatment|Helping Women Recover/Beyond Trauma integrated substance abuse and trauma treatment group. (Dr. Covington)
3253366|NCT01413984|No Intervention|comparison group|a comparison group of incarcerated women will receive the pre and post assessments with no interventions.
3253367|NCT01413997||Chronic Low Back Pain|
3253368|NCT01413997||No Low Back Pain|
3253369|NCT01414023|Experimental|CCT|Cognitive Control Training - Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
3369807|NCT03761277|Other|Intrathecal Therapy|Enrolled subjects who successfully wean from all systemic opioids and have a successful intrathecal trial, proceed to the intervention phase. This includes implantation with a SynchroMed™ II infusion system in the intrathecal space for targeted drug delivery of preservative-free morphine sulfate (PFMS).
3253370|NCT01414023|Placebo Comparator|PVT|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
3253371|NCT01414049|Experimental|On-pump CABG|
3369811|NCT03729258|Experimental|Cefpodoxime 200 (b.i.d)|
3369812|NCT03729258|Active Comparator|Cefpodoxime 400 (q.d)|
3369813|NCT03727438|Experimental|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
3369814|NCT03727438|Active Comparator|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
3369817|NCT03716349|Experimental|System A|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system w/Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan), informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment, clinical assessment
3369818|NCT03716349|Active Comparator|System B|ScotchBond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M) will randomly be applied to the other tooth informed consent signed, release of medical information signed, oral exam, health Questionnaire completed and/or updated, xray obtained if needed, pulp vitality testing, Tooth shade determination, photos of teeth, local and/or topical anesthetic applied as necessary, rubber dam isolation, tooth surface cleaned, cavity preparation performed as usual for caries removal, Enamel margins beveled, infinite invisible margins created, adhesive systems applied, dental composite placed, shade selection using Easy Shade 5. Light curing, restoration will be contoured and polished. teeth assessment and clinical assessment at periodic timepoints.
3369819|NCT03715335|No Intervention|Baseline|Current STI screening rates.
3369820|NCT03715335|Active Comparator|Targeted STI Screening|"Data from the Sexual Health Screen (SHS) will be integrated into the Electronic Health Record (EHR) and will provide Clinical Decision Support (CDS) for GC/CT testing based on SHS-calculated STI risk. Patients will be classified as at high risk for STIs, at risk or low risk if they deny any history of sexual activity. When patients classify as at high risk, clinicians will receive CDS that STI testing is highly recommended; when they care for patients who classify as at risk, they will receive CDS that STI testing is recommended; when caring for patients who classify as at low risk, they will receive CDS that STI testing is not necessary at this time. If the clinician chooses to follow the recommendation for screening based on patient's risk assessment, and the patient consents to testing on the tablet device, urine GC/CT testing will be performed."
3369821|NCT03715335|Active Comparator|Universally Offered STI Screening|During the universally offered screening intervention, STI screening will be offered to all eligible adolescents, regardless of risk. All eligible patients will also complete the SHS, will be informed of the CDC GC/CT testing recommendations and then be given the option to decline STI testing using the tablet device. During this phase, the SHS results will not be available to the clinician. STI testing recommendations will be based only on the patient's decision to undergo GC/CT testing. Like the process followed in the targeted screening phase, if the clinician follows the CDS that informs the clinician that the patient agreed to GC/CT screening and consequently orders testing, urine GC/CT testing will be performed.
3253372|NCT01414049|Experimental|Off-pump CABG|
3253373|NCT01414062|Active Comparator|Arm A|Participants receiving written dietary recommendations for breast cancer survivors (control arm)
3253374|NCT01414062|Experimental|Arm B|Participants attending Cocinar Para Su Salud Program held over a 12-week period
3253375|NCT01414088|Placebo Comparator|glucose|glucose 5 %
3253376|NCT01414088|Active Comparator|isotonic saline|isotonic saline 0.9 mg/ml
3253377|NCT01414088|Active Comparator|hypertonic saline|hypertonic saline 2.9 mg/ml
3253378|NCT01414101|Experimental|Group A|Dose 1 ISIS CRP Rx versus Placebo
3253379|NCT01414101|Experimental|Group B|Dose 2 ISIS CRP Rx versus Placebo
3253380|NCT01414101|Experimental|Group C|Dose 3 ISIS CRP Rx versus Placebo
3253381|NCT01414140||Group 1|
3253382|NCT01414218|Experimental|Humor as Way of Life Seminar|See description of study in previous section for further details.
3369827|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 20mg|Apremilast 20mg Twice Daily (BID)
3369828|NCT03701763|Experimental|Administration of Apremilast (CC-10004) - 30mg|Apremilast 30mg Twice Daily (BID)
3369829|NCT03701763|Placebo Comparator|Administration of Placebo|Placebo tablet Twice Daily (BID)
3369830|NCT03701724|Experimental|Systematic maintenance rTMS (arm A)|Active rTMS treatment followed, for responders, by systematic maintenance rTMS Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
3253383|NCT01414231|Active Comparator|Cytarabine low dose|This is the golden standard of AML treatment
3253384|NCT01414231|Active Comparator|Cytarabine intermediate dose|This is the OSHO internal arm
3253385|NCT01414283|Experimental|Arm 1|
3253386|NCT01414296|Experimental|Arm 1|
3253387|NCT01414309||Observational patients|Heart Failure patients with moderate to severe central sleep apnea
3253388|NCT01414322||Group 1: Patients ages 0 - 3|
3253389|NCT01414322||Group 2: Patients ages 3 - 7|
3253390|NCT01414322||Group 3: Patients ages 7 - 15|
3369831|NCT03701724|Experimental|rTMS course in case of relapse (arm B)|Active rTMS treatment followed, for responders, by additional rTMS courses, in case of relapse Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
3369832|NCT03701724|Sham Comparator|Sham rTMS (arm C)|sham rTMS followed, for responders, by either systematic sham mTMS (50%) or additional sham rTMS course in case of relapse(50%) Depression usual medical treatment (psychosocial approach and/or pharmacotherapy and/or, ECT…)
3369835|NCT03690843||DCD Group|Children diagnosed with DCD or at-risk DCD at two or three years of age
3369836|NCT03690843||Control Group|Typically developing children
3369839|NCT03663764|Experimental|Expeiment|"HRT using the IMRT technique was administered. For patients with limited pulmonary or pleural metastases (≤3 lesions), stereotactic body radiation therapy (SBRT) could be used.~All patients received weekly docetaxel(25mg/㎡) and nedaplatin or cisplatin (25mg/㎡), each of 1 day's duration, concurrently with hypofractionated radiotherapy .~Meanwhile they received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy."
3369840|NCT03662308|Other|Heated Vest Safety & Comfort (able-bodied subjects)|Able-bodied controls will be fitted with an appropriately sized heated vest, while wearing only a standard cotton T-shirt and shorts, and will remain seated in a wheelchair. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for 2 hours with the heated vest on full power. Outcome Variables for Visit 1: Skin thermocouple temperatures, subjective ratings of thermal sensation.
3253391|NCT01414335|Placebo Comparator|placebo|
3253392|NCT01414335|Active Comparator|amino acid composition|
3253393|NCT01414348|Active Comparator|Conventional rehabilitation|In-home work on problems in daily living.
3253394|NCT01414348|Experimental|Novel rehabilitation approach|
3253395|NCT01414361||intermediate lesion|intermediate lesions evaluated by both IVUS and FFR
3253396|NCT01414374|Active Comparator|Iron|
3253397|NCT01414374|Experimental|Herbal|
3253398|NCT01414387|Active Comparator|Carotid filter|For this intervention group, patients will receive FDA-approved filter devices for cerebral embolic protection during carotid artery stenting intervention.
3253399|NCT01414387|Active Comparator|Carotid reversal of flow|For this intervention group, patients will receive reversal of flow with the FDA-approved Gore Neuroprotection System for cerebral protection during carotid artery stenting.
3259467|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drops of placebo.
3259468|NCT01471119|Experimental|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
3259469|NCT01471119|Experimental|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
3259470|NCT01471132|Experimental|HIPEC|
3369841|NCT03662308|Experimental|Heated Vest Efficacy (persons with tetraplegia)|Subjects with tetraplegia, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized heated vest. Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the self-regulating heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
3369842|NCT03662308|Active Comparator|Non-Heated Vest control condition (persons with tetraplegia)|The same subjects with tetraplegia from the experimental arm, while seated and wearing only a standard cotton T-shirt and shorts, will be fitted with an appropriately sized, similarly insulated, but non-heated vest (control condition). Subjects will be transferred to a pre-cooled (18 degrees C) thermal chamber and data will be collected for up to 2 hours with the non-heated vest. Primary Dependent variables: core body temperature (Tcore), cognitive performance, and thermal comfort.
3253400|NCT01414439||Congestive Heart Failure Patients|40 patients diagnosed with heart failure at levels III and IV, according to the classification of the NYHA will participate in the research. The researchers will randomly allocate the patients to the treatment group or the control group. The subjects in the treatment group will participate in Existential Group Therapy, while the subjects in the control group will not participate in the treatment until after the completion of the study. Psychological data will be collected in the form of a self-reported questionnaire completed by all participants prior to the beginning of the research and again upon completion of the final group session.
3253401|NCT01414452||STEMI patients|Patients with ST elevation myocardial infarction,lasting <12 hour, who were succesfully treated with primary PCI
3253402|NCT01414465|No Intervention|low caloric diet|10 health obese women (BMI 30 to 40 kg/m2)
3369843|NCT03651505||Prior Burosumab Clinical Trial Participants|Patients who participated in burosumab clinical trials and continue to receive burosumab via prescription from their physician.
3369844|NCT03651505||Not from Prior Burosumab Clinical Trial|Patients may take other treatments for XLH and may start burosumab treatment at any time as prescribed by a physician.
3369845|NCT03650374|Active Comparator|Group 1|standard of care postoperative rehabilitation.
3369846|NCT03650374|Experimental|Group 2|experimental strength training
3369847|NCT03643146|Experimental|Wedge 1- Step 1|
3369848|NCT03643146|Experimental|Wedge 1-Step 2|
3369849|NCT03643146|Experimental|Wedge 1-Step 3|
3369850|NCT03643146|Experimental|Wedge 1-Step 4|
3369851|NCT03643146|Experimental|Wedge 1-Step 5|
3369852|NCT03643146|Experimental|Wedge 2- Step 1|
3369853|NCT03643146|Experimental|Wedge 2-Step 2|
3369854|NCT03643146|Experimental|Wedge 2-Step 3|
3369855|NCT03643146|Experimental|Wedge 2-Step 4|
3369856|NCT03643146|Experimental|Wedge 2-Step 5|
3369857|NCT03643146|Experimental|Wedge 3-Step 1|
3253403|NCT01414465|Experimental|Orlistat|10 obese women treated with Orlistat 120mg 3 times per day
3369858|NCT03643146|Experimental|Wedge 3- Step 2|
3369859|NCT03643146|Experimental|Wedge 3- Step 3|
3369860|NCT03643146|Experimental|Wedge 3- Step 4|
3369861|NCT03643146|Experimental|Wedge 3- Step 5|
3253404|NCT01414465|Sham Comparator|lifestyle counseling|Women with BMI < 30 kg/m2, no taking drug in study
3253405|NCT01414478|Active Comparator|High Protein Shake|Protein shake that contain 30 grams of protein in 11 fluid ounces.
3253406|NCT01414478|No Intervention|Ice Chips|Patients allowed consumption of ice chips only during labor.
3253407|NCT01414504|Active Comparator|Neonatal PCV + PPV 9 months|Group 1: Children receiving 7VPCV at 0-1-2 months of age and PPV at 9 months of age
3369862|NCT03643146|Experimental|Wedge 4-Step 1|
3369863|NCT03643146|Experimental|Wedge 4- Step 2|
3369864|NCT03643146|Experimental|Wedge 4-Step 3|
3369865|NCT03643146|Experimental|Wedge 4-Step 4|
3253408|NCT01414504|Active Comparator|Infant PCV + PPV at 9 months|Group 2: Children receiving 7VPCV at 1-2-3 months of age and PPV at 9 months of age
3253409|NCT01414504|Active Comparator|No PCV + PPV at 9 months|Group 3: Children who only received PPV at 9 months of age
3369866|NCT03643146|Experimental|Wedge 4-Step 5|
3369869|NCT03634488|Experimental|Nutritional Supplement and Hydroxyurea|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement and hydroxyurea (20mg/kg/day)
3253410|NCT01414504|Active Comparator|Control|Group 4: Children who have not received any previous pneumococcal vaccine
3253411|NCT01414517|Active Comparator|FOS|Prebiotic (FructoOligoSaccharide-FOS.
3253412|NCT01414517|Placebo Comparator|Placebo|Maltodextrin (non-prebiotic carbohydrate).
3253413|NCT01414530|Experimental|oral contraceptive|
3253414|NCT01414530|Active Comparator|NSAID|
3369870|NCT03634488|Placebo Comparator|Nutritional Supplement alone|50 children (5-12 years old) with SCA and severe malnutrition will be randomly allocated to receive nutritional supplement alone
3369871|NCT03634488|Placebo Comparator|non-SCD AND severe malnutrition|To decrease the likelihood of sharing limited food resources, we will enroll 100 malnourished non-SCD siblings.
3253415|NCT01414543|Other|providing information sheet|providing participants with information regarding the purpose of the research
3253416|NCT01414543|Other|Seeking consent|
3369876|NCT03581721|No Intervention|The control group|"Control group according to usual practices: no active warming (no fluid warming). The fluid warmer device will be set up but not activated. The control group will receive IV fluid coload at room temperature through the fluid warmer set to off. The device is hidden"
3369877|NCT03581721|Experimental|The warming group|"IV fluid warming with the enFlow® or Fluido®Compact IV fluid warmer : Women will receive IV fluid coload warmed to 40°C through the enFlow® or Fluido®Compact device. The box will be also hidden. The fluid warmer will be turned off at the end of surgery, just before transfer to the PACU."
3369878|NCT03573960|Experimental|Lenvatinib 24 mg|Participants will receive 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily with or without food in 28-day cycles until disease progression or until unacceptable toxicity occurs.
3369879|NCT03572374|Experimental|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
3369880|NCT03572374|Active Comparator|Information Booklet (control)|Participants will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
3369881|NCT03562728|Active Comparator|ECMO- Bridge to Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
3369882|NCT03562728|Other|ECMO- Bridge to Transplant Control Group|"Interventions: standard of care~Patients are not going to receive any additional intervention."
3369883|NCT03562728|Active Comparator|Transplant|Interventions: MRP+MNES(neuromuscular electric stimulation).Patients in the treatment arm will receive additional physical therapy(arm and leg exercises, using light weight machines, hand weights, or rubber bands, exercise machines such as portable arm or seated bikes) as well as therapy with an electric stimulator device. This device uses weak electric impulses to involuntarily exercise the muscles(one-two sessions a day).Four muscle groups(quadriceps and dorsiflexors bilaterally) will be stimulated using surface electrodes .In addition, patients in the experimental group will receive nutrition supplementation with essential amino acids 3 times a day in their feeding to prevent muscle breakdown and promote positive nitrogen balance.
3253417|NCT01414543|Other|Interview Participant|
3253418|NCT01414543|Other|Debrief|The Participants will be debriefed after the interview.
3253419|NCT01414556|Experimental|hyperglycemia|
3369884|NCT03562728|Other|Transplant Control Group|"Interventions: standard of care.~Patients are not going to receive any additional intervention."
3253420|NCT01414556|Experimental|fasting glycemia|
3369888|NCT03532282|Active Comparator|ONLINE ONLY|Online cognitive behavioral therapy for insomnia
3369889|NCT03532282|Experimental|STEPPED CARE|Cognitive behavioral therapy for insomnia online or therapist-led or sequentially both
3369890|NCT03527238|Active Comparator|Standard of Care|Standard of Care Tacrolimus Drug Dosing
3253421|NCT01414556|Experimental|hypoglycemia|
3253422|NCT01414569|Active Comparator|8 mg dexamethasone|
3253423|NCT01414569|Placebo Comparator|Placebo, saline|
3253424|NCT01414569|Experimental|40 mg dexamethasone|
3253425|NCT01414582|Experimental|Anodal tDCS and Motor Training|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
3369891|NCT03527238|Experimental|Phenotypic Precision Medicine (PPM)|PPM-based Computation Assisted Drug Dosing
3369892|NCT03523663||Control|healthy children without ADHD or other mental health issues
3369893|NCT03523663||ADHD|children diagnosed with ADHD
3369894|NCT03516838|Experimental|ACTIVA™ BioACTIVE|Restoring cavity using ACTIVA filling material
3369895|NCT03516838|Active Comparator|Compomer|Restoring cavity using compomer filling material
3369896|NCT03514368|Other|Patients treated with immune checkpoint blockade|
3369897|NCT03511664|Experimental|177Lu-PSMA-617 plus best supportive/best standard of care (BS/BSOC)|Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used
3369898|NCT03511664|Other|Best supportive/best standard of care (BS/BSOC) alone|Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator
3253426|NCT01414582|Sham Comparator|Sham tDCS and Motor Training|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
3253427|NCT01414595||Group 1|CALGB 140202 outlines the standard procedures for sample procurement. Samples to be used for this project have already been obtained and are currently banked at the CALGB Pathology Coordinating Office (PCO) and the Lung Cancer Tissue Bank at Brigham and Women's Hospital.
3253428|NCT01414608|Experimental|Arm I (cisplatin, radiation therapy, brachytherapy)|Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.
3253429|NCT01414608|Experimental|Arm II (cisplatin, radiation therapy, brachytherapy, chemo)|Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3253430|NCT01414621||CABG patients|atrial tissue samples from CABG patients
3369899|NCT03490864|Experimental|Meal timing + Melatonin|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a 1mg melatonin supplementation given daily during the intervention.
3369900|NCT03490864|Experimental|Meal timing + Placebo|This arm will consist of imposing a minimum overnight fasting period of 12 hours and a maximum of 16 hours (with exception of water and other non-caloric beverages), beginning 3 hours before their habitual bed time. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention.
3369901|NCT03490864|Experimental|Melatonin|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will include a 1mg melatonin supplementation given daily during the intervention.
3369902|NCT03490864|Placebo Comparator|Placebo|This arm will continue to eat at their habitual meal times, and maintain their average habitual caloric and macronutrient intake. No extended overnight fasting will be imposed. This arm will also include a melatonin placebo (lactose) supplementation given daily during the intervention
3369910|NCT03481660|Experimental|Brolucizumab 6 mg|Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule
3369911|NCT03481660|Active Comparator|Aflibercept 2 mg|Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks
3369912|NCT03478007|No Intervention|Usual Treatment|Usual standard of care (exercises)
3369913|NCT03478007|Experimental|Intervention Technology Only|Exercises with technology alone
3369914|NCT03478007|Experimental|Intervention Technology Plus Coaching|Exercises with technology plus coaching
3253431|NCT01414647|Experimental|SRC|Strawberry, raspberry and cloudberry intervention for 8 weeks
3253432|NCT01414647|Experimental|BB|Bilberry intervention for 8 weeks
3253433|NCT01414647|Experimental|C|Control diet with restricted berry consumption
3253434|NCT01414660||islet|type 1 diabetic patients undergoing islet transplantation
3253435|NCT01414660||liver|non diabetic patients undergoing a liver transplantation
3369917|NCT03471728||Irritable Bowel Syndrome|Patients with Irritable Bowel Syndrome with Constipation (IBS-C) who have used linaclotide for the first time
3369918|NCT03471728||Chronic Constipation|Patients with Chronic Constipation (CC) (excluding constipation due to organic diseases) who have used linaclotide for the first time
3369919|NCT03461861|Experimental|AGB101 220 mg, then Placebo|AGB101 220 mg/day capsule, once daily dosing for 2 weeks. After a 4 week washout, to be followed by Placebo, given as a capsule, once daily dosing for 2 weeks.
3369920|NCT03461861|Experimental|Placebo, then AGB101 220 mg|Placebo, given as a capsule, once daily for 2 weeks. After a 4 week washout, to be followed by AGB101 220 mg/day capsule, once daily dosing for 2 weeks.
3369921|NCT03455764|Experimental|MCS110+ Trametinib + Dabrafenib|"For Phase 1 MCS110 will be administered intravenously every 3 weeks.~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
3369922|NCT03455764|Experimental|MCS110 + Trametinib + Dabrafenib Phase 2|"MCS110 will be administered intravenously every 3 weeks.~The Dosage will be determine by the DLT of Phase 1~Dabrafenib is given orally every 12 hours.~Trametinib is given orally daily"
3369923|NCT03398200|Experimental|Hyperbaric Oxygen Therapy|Subjects on the experimental arm will receive 90 minutes of hyperbaric oxygen therapy approximately six hours prior to hematopoietic stem cell infusion.
3253436|NCT01414660||kidney|non diabetic patients undergoing a kidney transplantation
3253437|NCT01414673|Other|spontaneous LH|
3253438|NCT01414673|Experimental|HCG|
3369924|NCT03398200|Active Comparator|No Hyperbaric Oxygen Therapy|Subjects on the reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell infusion.
3369925|NCT03382639|Experimental|Double-blind: Luvadaxistat 50 mg|Luvadaxistat 50 milligram (mg), tablets, orally, once daily up to 14 weeks.
3369926|NCT03382639|Experimental|Double-blind: Luvadaxistat 125 mg|Luvadaxistat 125 mg, tablets, orally, once daily up to 14 weeks.
3369927|NCT03382639|Experimental|Double-blind: Luvadaxistat 500 mg|Luvadaxistat 500 mg, tablets, orally, once daily up to 14 weeks.
3369928|NCT03382639|Placebo Comparator|Double-blind: Placebo|Luvadaxistat placebo-matching tablets, orally, once daily up to 14 weeks.
3369929|NCT03380507|Experimental|Triple therapy group|"Experimental group will receive usual care according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017) PLUS triple therapy.~Triple therapy regimen:~Intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge, whichever is earlier), hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge, whichever is earlier, followed by a taper over 3 days) as well as intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge, whichever is earlier)."
3369930|NCT03380507|No Intervention|Control group|Control group will receive usual care only according to Hamad Medical Corporation Adult Sepsis Care Pathway (CPW 10311, May 2017).
3369931|NCT03376659|Experimental|Phase I - Safety|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks (colorectal cancer patients only)"
3369932|NCT03376659|Experimental|Phase II - Colorectal Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly~Bevacizumab - q2weeks"
3369933|NCT03376659|Experimental|Phase II - Pancreatic Cancer Arm|"MVA-BN-CV301 (prime) - Day 1 and Day 29.~FPV-CV301 (boost) - Day 1 of Weeks 9, 13, 17, 21, 25, 37, and q24 weeks starting week 53.~Durvalumab - q2 weeks~Capecitabine - twice a day, Monday - Friday Weekly"
3369936|NCT03374657|Experimental|CPK Dose 1 (lowest dose)|CPK850, one subretinal injection to the study eye
3369937|NCT03374657|Experimental|CPK Dose 2 (next lowest dose)|CPK850, one subretinal injection to the study eye
3369938|NCT03374657|Experimental|CPK Dose 3 (third lowest dose)|CPK850, one subretinal injection to the study eye
3369939|NCT03374657|Experimental|CPK Dose 4 (next to highest dose)|CPK850, one subretinal injection to the study eye
3369940|NCT03374657|Experimental|CPK Dose 5 (highest dose)|CPK850, one subretinal injection to the study eye
3369941|NCT03374371||S. epidermidis Infection (CASE)|Patients with confirmed infection at S. epidermidis
3369942|NCT03374371||S. epidermidis Contamination (CONTROL)|Patients with confirmed contamination at S. epidermidis
3253439|NCT01414686|Experimental|Immediate Treatment Group|
3253440|NCT01414686|No Intervention|Delayed Treatment Group|
3253441|NCT01414699|Active Comparator|One-Course, Variety|Participants will receive a snack in one course with a variety of fruit.
3253442|NCT01414699|Active Comparator|Two-Course, Variety|Participants will receive a snack in two courses with a variety of fruit.
3259471|NCT01471145|Experimental|Depot Naltrexone|
3369946|NCT03367364|Active Comparator|Patient education bundle (PEB)|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
3369947|NCT03367364|Placebo Comparator|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
3369952|NCT03363503|Experimental|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
3369953|NCT03363503|Active Comparator|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
3253443|NCT01414699|Active Comparator|One-course, Non-Variety|Participants will receive a snack in one course with no variety of fruit.
3253444|NCT01414699|Active Comparator|Two-Course, Non-Variety|Participants will receive a snack in two courses with no variety of fruit.
3253445|NCT01414712||prostate cancer patients|
3253446|NCT01414725|Experimental|Core Stability Training|
3369954|NCT03362177|Experimental|Romiplostim|The study in a 2:1 randomization ratio(108 subjects to romiplostim). Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
3369955|NCT03362177|Placebo Comparator|Placebo|The study in a 2:1 randomization ratio (54 subjects to placebo) Amgen investigational product (romiplostim or placebo) will be administered in the clinic by a qualified healthcare provider as a subcutaneous injection.
3369956|NCT03359785|Experimental|Luvadaxistat 500 mg + Luvadaxistat 50 mg|Luvadaxistat 500 milligrams (mg) or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by Luvadaxistat 50 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
3369957|NCT03359785|Experimental|Luvadaxistat 50 mg + Luvadaxistat 500 mg|Luvadaxistat 50 mg or matching Placebo tablets, orally, once daily for 8 days in period 1, followed by 14-21 day washout period, followed by Luvadaxistat 500 mg or matching Placebo tablets, orally, once daily for up to 8 days in period 2.
3369958|NCT03359421||Aeromedical transport|Patients transported to trauma center by helicopter
3369959|NCT03359421||Ground transport|Patients transported to trauma center by ground ambulance
3369960|NCT03347292|Experimental|Dose escalation|The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
3369961|NCT03347292|Experimental|Dose expansion|Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
3369962|NCT03344757|Experimental|C-CBSM|Participants randomized to this arm will receive 10 weekly group-based C-CBSM intervention.
3369963|NCT03344757|Active Comparator|CBSM|Participants randomized to this arm will receive 10 weekly group-based standard CBSM intervention.
3369964|NCT03342378||Oropharynx Cancer Patients|Patients with OPSCC will be treated with comprehensive head and neck RT to 70 Gy in 33 fractions with concurrent weekly cisplatin at 40 mg/m2 and at the University of Wisconsin.
3369965|NCT03327324|Other|Resident of the Skilled Nursing Facility|
3369966|NCT03321630|Other|Lenvatinib & Pembrolizumab|
3253447|NCT01414725|Placebo Comparator|Relaxation|
3253448|NCT01414725|Active Comparator|Standard Physiotherapy Exercises|
3253449|NCT01414751|Active Comparator|Absolute risk reduction information|Patients belonging to this arm receive effectiveness information by means of absolute risk reduction when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
3253450|NCT01414751|Active Comparator|Prolongation of life information|Patients belonging to this arm receive effectiveness information by means of prolongation of life/life extension when talking with their general practitioner concerning their cholesterol level and possible gain if starting therapy.
3259472|NCT01471158|Active Comparator|Azarga/Cosopt|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Azarga will be instilled one drop in each eye on Day One, after which Cosopt will be administered one drop in each eye on Day Two.
3369970|NCT03298269|Experimental|Mindfulness-Oriented Recovery Enhancement|
3369971|NCT03298269|Active Comparator|Supportive Counseling|
3369972|NCT03297307|Experimental|Mother-Child with Intervention|Children will attend presurgical visits with their mother
3369973|NCT03297307|No Intervention|Mother-Child Non-Intervention|Children will not attend presurgical visits with their mother
3369975|NCT03267277|Experimental|Treatment|Patient will be assessed for 10 weeks off treatment and then will receive 10 weeks of treatment. They will return at weeks 24 and 62 for safety and sustainability of efficacy assessments.
3369976|NCT03259763|Active Comparator|EUS-guided gastroenterostomy (EUS-GE)|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
3369977|NCT03259763|Active Comparator|Enteral Stenting (ES)|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
3369980|NCT03257033|Experimental|IA Therapy|IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.
3253451|NCT01414764|Active Comparator|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The red blood cells will be discarded, and the supernatant containing ACP (with additional CaCl to activate the ACP and local anaesthetic) is injected into the tendon bone junction and adjacent area under ultrasound guidance. No adverse consequences are anticipated by using the Arthrex ACP injection.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively~Other Names:~Platelet rich plasma (PRP)"
3253452|NCT01414764|Placebo Comparator|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
3253453|NCT01414777|Experimental|ondansetron|ondansetron 8 mg IV will be administered prior to placement of the spinal anesthesia
3253454|NCT01414777|Placebo Comparator|Placebo|Ondansetron 8 mg IV or Placebo will be administered prior to placement of the spinal anesthestic
3253455|NCT01414790|Experimental|ADM group|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
3253456|NCT01414790|No Intervention|control group|41 patients (control group) had a total parotidectomy alone
3369981|NCT03257033|Active Comparator|IV Therapy|IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.
3369982|NCT03250377|Experimental|Brivaracetam|Subjects randomized to this arm will receive open-label Brivaracetam
3369983|NCT03246230|No Intervention|NO VACCINES AT BIRTH|These will be newborns who will not receive any vaccines at birth and will have delayed immunization with catch-up (i.e., HBV, BCG and polio vaccine) by Day of Life 7.
3369984|NCT03246230|Other|HBV VACCINE AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) at birth (Day of Life (DOL)-0) with catch up immunization (i.e., BCG and polio vaccine) at DOL-1, -3, or -7.
3369985|NCT03246230|Other|BCG VACCINE AT BIRTH|Participants in this arm will receive licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life(DOL)-0) with catch up immunization (i.e., HBV and polio vaccine) at DOL-1, -3 or- 7.
3253457|NCT01414803|Experimental|rosuvastatin/fenofibrate combination|rosuvastatin 10 mg/fenofibrate 160 mg per day
3253458|NCT01414803|Active Comparator|rosuvastatin monotherapy|rosuvastatin 10 mg per day
3369986|NCT03246230|Other|(HBV + BCG) VACCINES AT BIRTH|Participants in this arm will receive licensed hepatitis B vaccine (HBV) and licensed Bacillus Calmette-Guérin (BCG) vaccine at birth (Day of Life (DOL- 0) with catch up immunization (i.e., polio vaccine) at DOL-1, -3, or -7.
3369987|NCT03242642|Experimental|Primary Cohort- TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
3369988|NCT03242642|Experimental|Mitral Annular Calcification -TMVR|Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
3369989|NCT03235739|Experimental|Treatment Arm|Naloxegol 25 mg given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
3369990|NCT03235739|Placebo Comparator|Placebo Arm|Matching placebo given once in the morning every day until Post-operative Day 3 or day of discharge whichever occurs first
3369991|NCT03223805|Other|Control Arm|Usual Care
3369992|NCT03223805|Experimental|Intervention Arm|Respiratory Distress Symptom Intervention plus Usual Care
3369993|NCT03207867|Experimental|NIR178 + PDR001|Part 1: all patients will receive NIR178 continuously in combination with PDR001 400mg every 4 weeks. The part 1 will enroll 9 different tumor types.
3369994|NCT03207867|Experimental|NIR178 BID Intermittent + PDR001|Three different dosing schedules of NIR178 will be explored.
3369995|NCT03207867|Experimental|Part 3|Initiation of part 3 will depend on results from parts 1 and 2 and will use a film-coated tablet of NIR178.
3253459|NCT01414816||Group 1|
3253460|NCT01414842|Active Comparator|Standard|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
3253461|NCT01414842|Experimental|Automated profiled|Automate sodium profiling in endogenous hemodiafiltration
3253462|NCT01414881|Experimental|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
3369996|NCT03207867|Experimental|Japanese safety run-in part|Two different dosing schedules of NIR178 will be explored.
3253463|NCT01414881|Placebo Comparator|Placebo|Placebo administered subcutaneously (SC) once weekly
3253464|NCT01414894|Active Comparator|Normal Fluids & Normal Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure).
3253465|NCT01414894|Active Comparator|Increased Fluids & Normal Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a normal range (Conventional Blood Pressure)
3253466|NCT01414894|Active Comparator|Normal Fluids & Higher Blood Pressure|Patients are treated with conventional fluid replacement (Normovolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
3253467|NCT01414894|Active Comparator|Increased Fluids & Higher Blood Pressure|Patients are treated with fluids to achieve higher volume expansion (Hypervolemia) and maintenance of blood pressure in a higher range (Augmented Blood Pressure).
3253468|NCT01414907|Active Comparator|Health Promotion activities|
3253469|NCT01414907|No Intervention|No Intervention|
3253470|NCT01414920|Placebo Comparator|Placebo QD|
3253471|NCT01414920|Experimental|TAK-875 25 mg QD|
3253472|NCT01414920|Experimental|TAK-875 50 mg QD|
3253473|NCT01414920|Experimental|Sitagliptin 100 mg QD|
3369997|NCT03207282||Participants with Diagnosis of Depression|Study population consists of participants with a clinical diagnosis of depression, being treated in a psychiatry reference site (example, clinic, ambulatory, hospital, day-hospital) in 4 Latin American countries. Participants with Major Depressive Disorder (MDD) enrolled in Phase 1, will be assessed to estimate the prevalence of Treatment Resistant Depression (TRD) and participants with this diagnosis will be included in Phase 2. Participants with TRD will be followed-up for 1 year.
3253474|NCT01414920|Experimental|TAK-875 25 mg QD + Sitagliptin 100 mg QD|
3253475|NCT01414920|Experimental|TAK-875 50 mg QD + Sitagliptin 100 mg QD|
3369998|NCT03194165||antiretroviral dosage|titration of Dolutegravir, Raltegravir, Rilpivirine, Nevirapine, Atazanavir, Darunavir, Ritonavir
3370005|NCT03179475|Other|Oxycodone Naloxone Combination|Open-Label
3253476|NCT01414946|Experimental|Glucose and amino acids|Perioperative nutrition with glucose and amino acids
3253477|NCT01414946|Active Comparator|Amino acids only|Perioperative nutrition with amino acids only
3253478|NCT01414972|Active Comparator|patients with atherosclerosis/ vitamin A|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive 25000 IU/day vitamin A
3253479|NCT01414972|Placebo Comparator|patients with atherosclerosis/ placebo|patients with angiographically confirmed CAD (defined as luminal stenosis ≥50% in at least one major coronary artery branch)who receive placebo
3253480|NCT01414972|Active Comparator|people without athrosclerosis/ vitamin a|people in whom significant (e.g. stenosis ≥ 50%) CAD is ruled out by coronary angiography, who receive 2500 Iu/day vitamin A
3253481|NCT01414985|Experimental|Group A|Group A consists of 2 subjects who received 9x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 900,000,000,000 molecules of the study drug. The drug will be administered only once in the study.
3370019|NCT03177746|Experimental|Dapoxetine/Tadalafil 30/20 mg film coated tablet|
3253482|NCT01414985|Experimental|Group B|Group B will consist of 6 subjects who will receive 2.85x10^11 molecules of AAVrh.10CUCLN2, the gene transfer vector carrying the CLN2 gene. This is equal to 285,000,000,000 molecules of the drug. The drug will be administered only once in the study.
3370020|NCT03177525|Experimental|Social SUCCESS|
3370021|NCT03177525|Other|Wait List|
3253483|NCT01414998|Active Comparator|Stress Ball|This is the active comparator for study 1
3253484|NCT01414998|Experimental|De-nicotinised Cigarette|This will be the experimental arm for study 2
3253485|NCT01414998|Experimental|Nicotine-free Electronic Cigarette (1)|This will be the experimental arm for study 1
3253486|NCT01414998|Active Comparator|Nicotine-free Electronic Cigarette (2)|This will be the active comparator for study 2
3253487|NCT01415011|Experimental|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
3253488|NCT01415037||Annular Array Ultrasound|Subject with possible or with known posterior vitreous detachment. Subjects with diabetic retinopathy will receive annular array ultrasound exam.
3253489|NCT01415050|Active Comparator|Alendronate|
3253490|NCT01415050|Active Comparator|Raloxifane|
3370022|NCT03136497|Experimental|ABT-199 Plus Ibrutinib and Rituximab|Cycle length will be 28 days. Venetoclax will be administered orally QD (Once Daily), continuously for 24 cycles. Ibrutinib will be administered orally QD, continuously for 24 cycles. Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1), Commercially available rituximab IV will be used.
3370023|NCT03132129||Type 2 diabetics|Participants will be aged (≥18 and ≤75 years) with T2D and no prior history of cardiovascular disease.
3370024|NCT03132129||Healthy controls|Cases will be compared with age-, gender- and ethnicity-matched healthy controls.
3370025|NCT03116685|Experimental|Oxabact OC5 capsules|Oxabact OC5 - Oxalobacter formigenes HC-1
3253491|NCT01415063|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3253492|NCT01415063|Experimental|TACE-RFA|TACE first, then RFA within 2 weeks
3253493|NCT01415076|Placebo Comparator|Insertion without CO2 insufflation|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
3253494|NCT01415076|Experimental|Insertion with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
3253495|NCT01415102|Experimental|Cohort 1|Subjects will be assigned to receive either PF-05212372 or placebo in each period
3253496|NCT01415102|Experimental|Cohort 2|Subjects will be assigned to receive either PF-05212372 or placebo in each period
3253497|NCT01415115||Type 1 Diabetes|Must have been diagnosed with type 1 diabetes. Subject group will be measured on SCOUT and compared to Type 2 diabetes cohort.
3253498|NCT01415115||Type 2 Diabetes|Must have been diagnosed with Type 2 diabetes. This group will be compared to the Type 1 cohort.
3253499|NCT01415128|Active Comparator|Omeprazole|Omeprazole with single dose of avanafil (200 mg)
3370026|NCT03116685|Placebo Comparator|Placebo capsules|Placebo
3370027|NCT03099304|Experimental|Ruxolitinib cream 1.5% twice daily (BID)|Ruxolitinib cream 1.5% BID for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
3370028|NCT03099304|Experimental|Ruxolitinib cream 1.5% once daily (QD)|Ruxolitinib cream 1.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
3370029|NCT03099304|Experimental|Ruxolitinib cream 0.5% QD|Ruxolitinib cream 0.5% QD in the morning (vehicle cream in the evening) for 52 weeks, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
3253500|NCT01415128|Active Comparator|Rosiglitazone|Rosiglitazone with single dose of avanafil (200 mg)
3253501|NCT01415128|Active Comparator|Desipramine|Desipramine with single dose of avanafil (200 mg)
3253502|NCT01415141|Active Comparator|PR|"Treatment with Peginterferon and Ribavirin for up to 48 weeks~Those who achieve eRVR will receive 24 weeks of treatment"
3370030|NCT03099304|Experimental|Ruxolitinib cream 0.15% QD|Ruxolitinib cream 0.15% QD in the morning (vehicle cream in the evening) for 52 weeks (opportunity for re-randomization to a higher dose at Week 24 if < 25% improvement in F-VASI score), followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
3370031|NCT03099304|Placebo Comparator|Vehicle BID|Vehicle cream BID for 24 weeks, followed by re-randomization to ruxolitinib cream 1.5% BID, 1.5% QD, or 0.5% QD for Weeks 24 to 52, followed by ruxolitinib cream 1.5% BID in a 104-week open-label extension.
3370036|NCT03095781|Experimental|Treatment (pembrolizumab, XL888)|Patients receive pembrolizumab IV over 30 minutes on day 1 and XL888 PO on days 1, 4, 8, 11, 15, and 18. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3370037|NCT03083665|Placebo Comparator|Placebo|"12 weeks Treatment Period: Subjects will receive Placebo~4 weeks Down-Titration Period: Subjects will receive Placebo"
3370038|NCT03083665|Experimental|BRV 50 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 50 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 50 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 25 mg/day for 1 week followed by Placebo for 3 weeks, followed by a Study Drug-Free Period"
3370039|NCT03083665|Experimental|BRV 200 mg/day|"12 weeks Treatment Period: Subjects will receive BRV 200 mg/day~- Subjects entering into the Long term follow up (LTFU) study or managed access program (MAP): 2 weeks Transition Period: Subjects will receive BRV 150 mg/day followed by LTFU or MAP: Subjects will receive BRV 100 mg/day~- Subjects not entering into the LTFU study or MAP: 4 weeks Down-Titration Period: Subjects will receive BRV 150 mg/day for 1 week followed by BRV 100 mg/day for 1 week, followed by BRV 50 mg/day for 1 week, followed by BRV 25 mg/day for 1 week followed by a Study Drug-Free Period"
3370040|NCT03067961|Experimental|Wild type S. Typhi Quailes strain|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
3370041|NCT03067961|Experimental|Quailes typhoid toxin knock-out|Administered by the oral route with sodium bicarbonate at a dose of 1-5x10 4 CFU.
3370042|NCT03058107|Experimental|Nutrition Therapy (NT) group|Nutrition Therapy is intensive dietary counseling based on practical measurements of energy expenditure, rather than calculating it using theoretic formulas or no method at all.
3253503|NCT01415141|Active Comparator|TPR|"Treatment with Telaprevir, Peginterferon and Ribavirin. Patients will receive all 3 drugs for 12 weeks then switch to Peginterferon and Ribavirin for 36 weeks~Those who achieve eRVR will receive 12 weeks of treatment with all 3 drugs and then 12 weeks of treatment with the 2 drugs."
3370043|NCT03058107|Active Comparator|Control Therapy (CT) group|Control Therapy is standard dietary counseling bij state-wide recognized onco-dietitians. Energy expenditure is never measured in this standard protocol.
3253504|NCT01415154|Experimental|Scheduled Treatment Arm|3 Week TMS taper, clinical assessments and one NeuroStar TMS session every 4th week of block and TMS reintroduction as needed for clinical deterioration.
3253505|NCT01415154|Experimental|Monthly Observational Follow up Arm|3 Week TMS Taper, clinical assessments and office follow up every 4th week of block and NeuroStar TMS reintroduction as needed for clinical deterioration.
3370049|NCT03034863|Experimental|SAFER|SAFER (Safe Actions for Families to Encourage Recovery): A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving supporting partners to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and supporting partners with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or partner concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase partner support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
3253506|NCT01415180||Children: previously healthy|Previously healthy children, without chronic disease prior to the sepsis episode, expected to comprise about 50-60% of the total study population.
3253507|NCT01415180||Children: chronic, complex conditions|Children with chronic, complex conditions prior to the sepsis episode, expected to comprise about 40-50% of the study population.
3253508|NCT01415193|Experimental|Selective Tibial Nerve Block|
3253509|NCT01415193|Active Comparator|Control: Sciatic Nerve Block|
3253510|NCT01415206|Experimental|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
3370050|NCT03034863|Active Comparator|I-SPI|The comparison condition will be an assessment-only enhanced treatment-as-usual called the Individual Safety Planning Intervention (I-SPI), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran's primary mental health provider.
3370054|NCT03022097|Experimental|Experimental 1|Aclidinium bromide 400μg/Formoterol fumarate 12 μg
3370055|NCT03022097|Experimental|Experimental 2|Aclidinium bromide 400 μg
3370056|NCT03022097|Active Comparator|Comparator|Formoterol fumarate 12 μg
3370057|NCT03022097|Placebo Comparator|Placebo|Placebo
3370058|NCT03018860|Experimental|"Moderate management"|Women are encouraged by physicians to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration.
3370059|NCT03018860|Active Comparator|"Intensive management"|Usual obstetrical care in France
3370060|NCT03000439|Experimental|Tofacitinib 5 mg BID|oral, twice daily, tablet or solution.
3253511|NCT01415206|Other|Usual Care|Participants in the usual care condition will complete the core assessments and the Staging Health Risk Assessment (S-HRA) online at baseline, 3, 6, 12, and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
3370061|NCT03000439|Placebo Comparator|Placebo|
3370068|NCT02994121||People with Multiple Sclerosis or Related Disorders|Individuals must be 7 years or older, diagnosed with multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease
3370069|NCT02994121||People without Multiple Sclerosis or Related Disorders|Control participants must be 7 years or older, have no known personal history of multiple sclerosis or related disorders, no other chronic disease, and can be a family member, unrelated household control, or control from the general population.
3370070|NCT02990663|Experimental|Bedtime BP Meds|Use of blood pressure lowering medication at bedtime
3370071|NCT02990663|Active Comparator|Morning BP Meds|Use of blood pressure lowering medication in the morning
3370072|NCT02990572||Amish and Mennonite|"Agree to allow access to past, current, and future medical records~Provide a detailed family health history~Provide contact information that may be used for future approach regarding research studies"
3370075|NCT02983396|Experimental|no transmural ischemia (NTI) and transmural ischemia (TI)|"Case cross-over from no transmural ischemia (NTI) to transmural ischemia at 60 s coronary occlusion during elective coronary angioplasty (TI)~Comparison of diagnostic accuracy of standard 12-lead ECG versus Mini RELF device for detection of transmural ischemia."
3253512|NCT01415219|Active Comparator|active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
3253513|NCT01415219|No Intervention|conventional care|community based physiotherapy
3253514|NCT01415245|Experimental|Treatment|Device applied to saphenous vein graft
3253515|NCT01415245|No Intervention|Control|Saphenous vein graft without device support
3253516|NCT01415271|Experimental|Internet Intervention|
3253517|NCT01415284|Experimental|Hydroxyethylstarch 130/0.4|
3253518|NCT01415297|Experimental|NKP-1339|"NKP-1339 will be administered in single patient cohorts until ≥ Grade 2 toxicity encountered, at which time cohorts converted to a standard 3 + 3 dose escalation scheme.~When MTD is reached, an expanded cohort of up to 25 patients will be enrolled at the MTD."
3253519|NCT01415310||Geriatric psychiatry|Elderly patients with psychiatric disorders in geriatric psychiatry units
3253520|NCT01415323||Acutely admitted psychiatric in-patients|
3253521|NCT01415336|Active Comparator|AC|doxorubicin 60 mg/m², iv, day 1 Cyclophosphamide 600 mg/m², iv, day 1 every 3 weeks for 4 cycles
3253522|NCT01415336|Experimental|AX|doxorubicin 60 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 4 cycles
3253523|NCT01415362|Active Comparator|Active tDCS|The subject will receive sessions of active tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
3370078|NCT02962817|Experimental|Educational intervention through a web platform|"This group will have access to our web platform where they will find information related to nonspecific chronic low back pain. This information will be presented through dynamic explanatory 3D videos made by the author.~The aim of this intervention is to change and modify wrong beliefs and attitudes about chronic low back pain of physicians and nurses working in primary care settings, using a web-based educational tool with the additional result of increasing knowledge on pain neurophysiology and reducing fear-avoidance beliefs."
3370079|NCT02962817|Active Comparator|Clinical practice guidelines on low back pain|Control group: They will have access to a video where medical staff and primary care nurses explain the content of the clinical practice guideline for addressing back pain.
3253524|NCT01415362|Sham Comparator|Sham tDCS|The subject will receive sessions of sham tDCS remotely triggered by the EEG monitoring system each time seizure activity is detected during the 24-hour period.
3253525|NCT01415375|Experimental|Prostate Cancer Screening Education|Men in the experimental intervention group received an educational pamphlet on prostate cancer testing as well as tailored telephone education in which the interventionist provided information, answered questions, and conducted a values clarification exercise with the participant.
3370080|NCT02961504|Experimental|HLCM051 (MultiStem)|single dose of 1.2 billion HLCM051 cells
3370081|NCT02961504|Placebo Comparator|Placebo|a single dose of placebo
3370082|NCT02927262|Experimental|ASP2215|Subjects will be treated with ASP2215 once daily (continuously for up to 2 years).
3370083|NCT02927262|Placebo Comparator|Placebo|Subjects will be treated with matching placebo tablets once daily (continuously for up to 2 years).
3370086|NCT02910700|Experimental|Arm A (NDT, CLOSED)|Patients receive nivolumab IV over 30 minutes on day 1, dabrafenib PO BID on days 1-28, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
3370087|NCT02910700|Experimental|Arm B (NT, closed to accrual)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, and trametinib PO QD on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
3370088|NCT02910700|Experimental|Arm C (NEB)|Patients receive nivolumab IV over 30 minutes on day 1 and 15, encorafenib PO QD on days 1-28, and binimetinib PO BID on days 1-28. Cycles repeats every 28 days for up to 3 years in the absence of disease progression or unacceptable toxicity.
3370089|NCT02899754|Experimental|Intervention Group|Participants in this arm will use the lung cancer screening decision aid (LCSDecTool)
3253526|NCT01415375|Other|Fruit and Vegetable Intake Education|Men in the attention control group received an educational pamphlet on daily recommended servings of fruits and vegetables as well as tailored telephone education in which the interventionist provided information, answered participant's questions, and discussed any barriers to eating fruits and vegetables.
3370090|NCT02899754|Active Comparator|Control Group|Content that provides general information on disease prevention and health promotion unrelated to lung cancer. The information will be delivered on the same modality and take a similar amount of time to administer.
3370091|NCT02898207|Experimental|Treatment (olaparib and onalespib)|Patients receive olaparib PO BID on days 1-7 (cycle 0). Beginning in cycle 1, patients receive olaparib PO BID on days 1-28 and onalespib IV over 1 hour on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3370092|NCT02875548|Experimental|Open-label Tazemetostat|Subjects will continue to receive the same tazemetostat dose and schedule as specified in their antecedent tazemetostat protocol. For subjects on combination therapy, the other therapeutic(s) must have been completed in the antecedent study or be provided by a source other than Epizyme if combination treatment is continued in this clinical rollover study.
3253527|NCT01415414||Group 1|
3253528|NCT01415466|Experimental|R|multiple dose of Rosuvastatin 20mg
3253529|NCT01415466|Experimental|O|multiple dose of CS-866 40mg
3370093|NCT02863068|Placebo Comparator|control|patients will receive placebo and standard of care
3370094|NCT02863068|Experimental|topical sodium nitrite|patients will receive 2% topical sodium nitrite cream and standard of care
3370095|NCT02861573|Experimental|Pembrolizumab+Olaparib|Participants with adenocarcinoma (AC) mCRPC in Cohort A will receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week dosing cycle (Q3W) and olaparib 400 mg capsules or 300 mg tablets by mouth (PO) twice a day (BID) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with olaparib will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
3253530|NCT01415466|Experimental|R+O|multiple dose of the combination of Rosuvastatin 20mg and CS-866 40mg
3259473|NCT01471158|Active Comparator|Cosopt/Azarga|Following administration of the baseline dose (each intervention instilled in one eye in a contralateral fashion to establish baseline ocular comfort for each medication), Cosopt will be administered one drop in each eye on Day One, after which Azarga will be administered one drop in each eye on Day Two.
3370096|NCT02861573|Experimental|Pembrolizumab+Docetaxel+Prednisone|Participants with AC mCRPC in Cohort B will receive pembrolizumab 200 mg IV on Day 1 Q3W, docetaxel 75 mg/m^2 IV on Day 1 Q3W, and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Participants will only be permitted to receive a maximum of 10 cycles of docetaxel and prednisone. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
3370097|NCT02861573|Experimental|Pembrolizumab+Enzalutamide|Participants with AC mCRPC in Cohort C will receive pembrolizumab 200 mg IV on Day 1 Q3W and enzalutamide 160 mg PO every day (QD) continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue until progression or a maximum of 35 treatment cycles (up to 2 years). Treatment with enzalutamide will continue until progression. Participants who must discontinue 1 of the 2 drugs in the combination due to adverse events may continue the study with the other combination drug.
3370098|NCT02861573|Experimental|Pembrolizumab+Abiraterone+Prednisone|Participants with AC mCRPC in Cohort D will receive pembrolizumab 200 mg IV on Day 1 Q3W, abiraterone acetate 1000 mg PO QD and prednisone 5 mg tablet PO BID continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
3370099|NCT02861573|Experimental|Pembrolizumab+Lenvatinib: AC|Participants with AC mCRPC in Cohort E will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
3370100|NCT02861573|Experimental|Pembrolizumab+Lenvatinib:t-NE|Participants with neuroendocrine (t-NE) mCRPC in Cohort F will receive pembrolizumab 200 mg IV on Day 1 Q3W, and lenvatinib 20 mg PO QD continuously from Day 1 of Cycle 1. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
3370101|NCT02861573|Experimental|Pembrolizumab/Vibostolimab coformulation|Participants with AC mCRPC in Cohort G will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
3370102|NCT02861573|Experimental|Pembrolizumab/Vibostolimab coformulation:t-NE|Participants with t-NE mCRPC in Cohort H will receive a coformulation fixed dose combination of 200 mg pembrolizumab and 200 mg vibostolimab (MK-7684) Q3W IV from Day 1 of Cycle 1. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression.
3370103|NCT02861573|Experimental|Pembrolizumab+Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 1 will receive pembrolizumab 200 mg IV on Day 1 Q3W + carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment with pembrolizumab will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 or 2 of the 3 drugs due to adverse events in the combination may continue the study with the other combination drug/drugs.
3370104|NCT02861573|Experimental|Carboplatin+Etoposide|Participants with neuroendocrine mCRPC in Cohort I Arm 2 will receive carboplatin titrated to an area under the plasma drug concentration-time curve [AUC] 5 IV on Day 1 Q3W + etoposide 100 mg/m^2 IV on Days 1, 2, and 3 Q3W. Treatment will continue for a maximum of 35 cycles (up to 2 years) or until progression. Treatment with carboplatin+etoposide will continue for a maximum of 4 cycles (up to 2.8 months). Participants who must discontinue 1 of the 2 drugs due to adverse events in the combination may continue the study with the other combination drug.
3370105|NCT02846350|Active Comparator|Experimental condition|The proposed intervention training utilizes a structured, sustainable MI training and supervision program designed to improve retention, adherence and persistence in challenging patients.
3370106|NCT02846350|No Intervention|Standard of Care (SOC)|Physicians providing SOC will attend 3 time-matched video presentations over 2 years on research on optimizing entry into and retention in care and adherence, from materials available at the International Association for Providers of AIDS Care
3370107|NCT02835261|No Intervention|Habitual Sleep (HS)|During the HS phase, participants will be asked to follow a fixed bedtime routine based on their screening sleep schedule.
3370108|NCT02835261|Experimental|Sleep Restriction (SR)|During the SR phase, participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 h in total sleep time. A delay in bedtimes was chosen rather than advancing wakeup time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
3253531|NCT01415479|Experimental|Quantitative|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)"
3370113|NCT02819050|Experimental|Sprinting|Take off NCPAP twice daily for 3hours (day 1), Take off NCPAP twice daily for 6hours (day 2), Take off NCPAP twice daily for 9hours (day 3), Placed back on NCPAP for 24hours (day 4), Switch to nasal cannula at a flow rate of 1.5-2 L/min (day 5)
3370114|NCT02819050|Active Comparator|Non-Sprinting|"If the infant was on NCPAP 6, Infant was weaned down to CPAP 5 for 96 hours. If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC.~If the infant was on NCPAP 5, the infant was continued on CPAP 5 for 96 hours If they met stability criteria, then infant was switched to room air (no flow) or no more than 2L NC."
3370115|NCT02781623||MRI|An MRI will be conducted pre-operatively, 3 months post-operatively, and 1 year post-operatively.
3253532|NCT01415479|Experimental|Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
3253533|NCT01415479|Experimental|Quantitative + Default|"Subjects view:~Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.~Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)~Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT)."
3253534|NCT01415479|Active Comparator|Control|Subjects view a computer-based presentation regarding colorectal cancer (CRC) and available screening tests for CRC, primarily a video produced by the American Cancer Society.
3253535|NCT01415492|No Intervention|Usual Care|At recruitment this group only received five pamphlets from the study. Four of these pamphlets were from the American Cancer Society, and one from Quitworks (a smoking cessation program).
3253536|NCT01415492|Active Comparator|HD2|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
3253537|NCT01415492|Active Comparator|HD2+|The intervention study information was delivered via print materials or access to a HD2 Web Site. Patients chose modality. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention.
3253538|NCT01415505|Other|1|Nebivolol and Valsartan free tablet combination
3370116|NCT02777372|Experimental|Sertraline|To determine the impact of short term luteal phase treatment with Sertraline 50mg tablets (PMD group only) on arousal regulation across the menstrual cycle.
3253539|NCT01415544||Type 2 Diabetes|Those previously diagnosed with type 2 diabetes
3253540|NCT01415544||Type 1 Diabetes|Those previously diagnosed with type 1 diabetes
3253541|NCT01415544||Gestational Diabetes|Those that are currently diagnosed with gestational diabetes
3253542|NCT01415544||Healthy Human Volunteers|Those that have not been diagnosed with any type of diabetes
3253543|NCT01415557|Placebo Comparator|Non-Fortified Control Product|Non-fortified control beverage
3253544|NCT01415557|Active Comparator|Micronutrient Fortified Test Product|Micronutrient fortified test beverage
3253545|NCT01415570||Chronic Hemodialysis Patients|Adult hemodialysis patients
3370118|NCT02744092|Experimental|Randomized Arm 1|Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
3370119|NCT02744092|Active Comparator|Randomized Arm 2|Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.
3370120|NCT02744092|Experimental|Preference Cohort|"If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).~Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).~Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin."
3253546|NCT01415570||Chronic hemodialysis patients|Adult hemodialysis patients
3253547|NCT01415596|Placebo Comparator|Placebo|
3253548|NCT01415596|Active Comparator|Salbutamol|
3253549|NCT01415622|Experimental|PlasmaDerm|Treatment of small to medium-sized Ulcera crurum with the PlasmaDerm VU-2010 device in addition to standard care.
3253550|NCT01415622|Other|standard care|standard care of Ulcera crurum
3370121|NCT02720432|Experimental|CIMT|"A soft splint or restraint will be posed to best functioning hand of the infant only during the therapy session. Parents will be educated to perform the therapy, which consists of stimulation of reaching and grasping with the hemiplegic arm.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform CIMTfor 30 minutes, 6 days a week."
3370122|NCT02720432|Experimental|HABIT|"No restraint will be implemented and instead of promoting unilateral grasping, bimanual grasping will be stimulated. Toys will be precisely selected to stimulate progressed bimanual grasping. The approach of the therapist and parents remain equal.~The whole intervention period lasts 18 weeks, separated into 3 blocks of 4 weeks intervention and 2 blocks of 3 weeks of rest. During the intervention weeks parents will perform HABIT for 30 minutes, 6 days a week."
3370123|NCT02720432|Sham Comparator|Baby-massage|3 sessions of baby-massage will be given by a qualified instructor
3370124|NCT02718300|Experimental|Part 1: Ruxolitinib + Parsaclisib|Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
3370125|NCT02718300|Experimental|Part 2: Ruxolitinib + Parsaclisib|Part 2 will compare 2 doses of parsaclisib .
3370126|NCT02718300|Experimental|Part 3: Ruxolitinib + Parsaclisib|Part 3 will compare 2 different long term dosing strategies.
3370127|NCT02718300|Experimental|Part 4: Ruxolitinib + Parsaclisib|Part 4 will compare 2 different daily dosing strategies.
3253551|NCT01415635|Experimental|Nutritional intervention|"The study will compare standard nutritional care (control group) with tailored nutritional care (the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)(intervention group)."
3253552|NCT01415648|Experimental|open NIRS|continuous per operative cerebral oximetry monitoring (using INVOS™ cerebral oximeter) associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
3253553|NCT01415648|Sham Comparator|Blinded NIRS|Continuously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre
3370128|NCT02709655|Experimental|Vortioxetine 10 mg/day|
3370129|NCT02709655|Experimental|Vortioxetine 20 mg/day|
3370130|NCT02709655|Active Comparator|Fluoxetine 20 mg/day,|A decision has been taken to stop recruitment into this treatment arm.
3253554|NCT01415661|Experimental|obese patient|
3253555|NCT01415661|Experimental|non obese patient|
3253556|NCT01415674|Experimental|Arm A: Afatinib 40mg per os daily|Patients randomized to the arm A will take a single oral dose of Afatinib from Day 1, for 14 to 28 days, depending on the date of surgery. The number of dosing days will be chosen so that patients are off treatment for a maximum of 7 days before surgery.
3253557|NCT01415674|No Intervention|Arm B : No pre operative treatment|
3370131|NCT02709655|Placebo Comparator|Placebo|
3370133|NCT02694068||Discovery for Aim One|2173 subjects will be involved in the discovery cohort.
3253558|NCT01415687|Active Comparator|PEG Arm|Patients randomized to this arm of the trial will be following preparation instructions using Polyethylene Glycol-Based Lavage in a split dose format
3370134|NCT02694068||Replication for Aim One|1673 subjects will comprise the replication cohort.
3370135|NCT02694068||Discovery for Aim Two|824 subjects will be involved in the discovery cohort.
3370136|NCT02694068||Replication for Aim Two|538 subjects will comprise the replication cohort.
3370137|NCT02682901|Active Comparator|Cycloset (Bromocriptine-QR)|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus bromocriptine-QR. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (0.8 mg bromocriptine-QR) per day on a weekly basis until a maximal tolerated dose of at least two tablets (1.6 mg/day bromocriptine-QR) and no more than four tablets (3.2 mg/per day b-QR) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (1.6 to 3.2 mg bromocriptine-QR per day) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
3253559|NCT01415687|Active Comparator|Pico-Salax + Bisacodyl Arm|Patients randomized to this arm will follow preparation instructions using Pico-Salax preparation plus Biscacodyl in a split dose format
3253560|NCT01415700|Experimental|Stimulator|
3370138|NCT02682901|Placebo Comparator|Placebo|Subjects will be randomized in a 1:1 ratio to receive UDT (usual diabetes therapy) plus placebo. Following randomization subjects will be titrated to the maximum tolerated dose of the study drug over a four-week period. During these first 4 weeks, the daily dose of the study drug will be titrated up by one tablet (1 matching placebo tablet) per day on a weekly basis until a maximal tolerated dose of at least two tablets (2 placebo tablets) and no more than four tablets (4 placebo tablets) is achieved. Subjects will be maintained at their maximum tolerated dose of between two to four tablets per day (2 to 4 placebo tablets) for the duration of the study. Subjects will be seen at 4 weeks after randomization, at 12 weeks after randomization, and then at study end (week 24 or early termination).
3253561|NCT01415700|Active Comparator|Orthosis|
3259474|NCT01471184|Experimental|Ectoin® Eye Drops/Nasal Spray|Eye Drops/Nasal Spray
3259475|NCT01471184|Placebo Comparator|Placebo Eye Drops/Nasal Spray|
3259476|NCT01471210|Experimental|Part 1 : Urelumab (BMS-663513) Dose escalation|Urelumab (BMS-663513) solution administered intravenously on specified days
3259477|NCT01471210|Experimental|Part 2 : Urelumab (BMS-663513) Cohort Expansion|Urelumab (BMS-663513) solution administered intravenously on specified days
3253562|NCT01415713|Experimental|Statin dose titration|"SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians."
3253563|NCT01415726|Experimental|Cord blood stem cell|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations. Stem Cell Educator will be used for isolation and purification of cord blood stem cells for the treatment.
3253564|NCT01415726|Experimental|Stem Cell Educator|used for the isolation and purification of cord blood stem cells.
3370143|NCT02658474|Experimental|ACT-group|Group based Acceptance and Commitment Therapy. The patients will attend to three sessions which last for three days. Between the sessions the patients will train at home on ACT related topics. The whole intervention will last for three months.
3370144|NCT02658474|No Intervention|Primary care|Treatment in a primary care setting.
3253565|NCT01415739||Novel Molecular NSCLC Classification (H & E staining, IHC)|Previously collected tissue samples are analyzed via H&E staining and IHC.
3370145|NCT02652247|Experimental|ventilated trauma patients with pneumonia|ventilated trauma patients with pneumonia
3370146|NCT02652247|Experimental|ventilated trauma patients without pneumonia|ventilated trauma patients without pneumonia
3370147|NCT02652247|Experimental|ventilated surgical ICU patients with pneumonia|ventilated surgical ICU patients with pneumonia
3370148|NCT02652247|Experimental|ventilated surgical ICU patients without pneumonia|ventilated surgical ICU patients without pneumonia
3370149|NCT02643667|Experimental|Phase I: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
3370150|NCT02643667|Experimental|Phase II: Ibrutinib|"Ibrutinib: will be given by mouth daily~Blood samples for PSA and for immune assays will be collected at baseline, before RP, and after RP~Radical prostatectomy will be performed at least 7 days but not more than 12 days following the last scheduled dose of ibrutinib"
3370157|NCT02638987|Experimental|Dry needling|After the second computer task, a single dry needling session will be performed with the subject lying on the non painful side. After palpation of a taut band and detection of MTrP 2 in the upper trapezius muscle, a trained physiotherapist will penetrate the needle into the MTrP and will move the needle up and down in multiple directions. When local twitch responses are elicited, this will be repeated until the local twitch responses are extinct.
3370158|NCT02638987|No Intervention|Rest|After the first computer task, participants will rest in sidelying position for 10 minutes.
3370160|NCT02611180||Arm 1: Acute skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
3370161|NCT02611180||Arm 2: Chronic skin GVHD|"When clinically indicated, patients will undergo a skin biopsy to confirm a suspected diagnosis of acute or chronic GVHD, or to assess the status of their previously diagnosed acute or chronic GVHD. After the necessary samples are obtained for optimal medical care of the patient, two 6 mm punch biopsies (or four 4 mm punch biopsies) will be performed for research purposes, one (or two) of the affected area and one (or two) of a non-affected area (normal skin).~Patients who have clinical resolution of their acute or chronic GVHD will undergo one additional 6 mm punch biopsy (or two additional 4 mm punch biopsies) of the previously affected area. This additional biopsy should occur within 10 cm of the previous affected area sample.~With each skin biopsy, peripheral blood will be obtained by venipuncture or cannulation of an indwelling venous access device."
3370162|NCT02608268|Experimental|Dose escalation MBG453 alone|
3370163|NCT02608268|Experimental|Dose escalation MBG453 in combination with PDR001|
3370164|NCT02608268|Experimental|Dose Ranging group|
3370165|NCT02608268|Experimental|Dose Expansion of MBG453 alone|
3370166|NCT02608268|Experimental|Dose Expansion of MBG453 in combination with PDR001|
3370167|NCT02608268|Experimental|Safety run in for MBG453 in combination with decitabine|
3253574|NCT01415778|Experimental|Active 1|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3370168|NCT02601950|Experimental|Open-label Tazemetostat|All Cohorts [Cohort 1 - MRT, RTK, ATRT, or tumors with rhabdoid features, including small cell carcinoma of the ovary hypercalcemic type [SCCOHT], also known as malignant rhaboid tumor of the ovary [MRTO] Cohort 2 - Relapsed/refractory synovial sarcoma (SS18-SSX rea), Cohort 3 - Other INI1-negative tumors or any solid tumor with an EZH2 GOF mutation, Cohort 4 - Renal medullary carcinoma, Cohort 5 - Epithelioid sarcoma, Cohort 6 - Epithelioid sarcoma undergoing mandatory tumor biopsy and Cohort 7 - Poorly differentiated chordoma (or other chordoma with Sponsor approval)] will receive 800 mg oral Tazemetostat BID x 28 days
3253575|NCT01415778|Experimental|Active 2|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3370170|NCT02567825|Active Comparator|Surgical Management|Tympanostomy Tube Placement Topical antimicrobial treatment of acute otitis media episodes with ofloxacin drops
3370171|NCT02567825|Other|Non-Surgical Management|Antimicrobial treatment of acute otitis media episodes with amoxicillin-clavulanate and/or ceftriaxone
3253576|NCT01415778|Experimental|Active 3|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3253577|NCT01415778|Experimental|Active 4|12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet
3253578|NCT01415791|Experimental|Active 1|8 subjects will receive ICI176,334-1
3253579|NCT01415804|Active Comparator|stentgraft|Stentgraft
3253580|NCT01415804|No Intervention|Medical management|Antihypertensive medication
3253581|NCT01415817|No Intervention|Baseline Data collection|
3253582|NCT01415817|Experimental|Randomization and Training Arm|
3253583|NCT01415830|Experimental|Anti-scorpion venom serum Birmex|Patients 0 to 15 years with scorpion sting, will receive serum antiscorpion elaborated by Birmex
3253584|NCT01415830|Active Comparator|Anti-scorpion venom serum Alacramyn|Patients 0 to 15 years with scorpion sting, will receive other commercial serum antiscorpion (Alacramyn)
3253585|NCT01415856|Placebo Comparator|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
3253586|NCT01415856|Active Comparator|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
3253587|NCT01415869||Cross Sectional|Patients with implanted non-pulsatile ventricular assist devices of any type and at any time after implantation
3253588|NCT01415869||Prospective|Patients with usual VAD indications will be invited to participate, when, in the opinion of their treating physician a VAD will be highly likely within one month.
3253589|NCT01415882|Experimental|Arm A (ixazomib citrate and dexamethasone, closed to accrual)|Patients receive ixazomib citrate PO on days 1, 8, and 15. Patients with lack of minor response by the end of the second cycle or lack of partial response by the end of the fourth cycle also receive dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3253590|NCT01415882|Experimental|Arm B (ixazomib citrate and dexamethasone)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3253591|NCT01415882|Experimental|Arm C (higher-dose ixazomib citrate and dexamethasone)|Patients receive higher doses of ixazomib citrate PO on days 1, 8, and 15 and dexamethasone PO on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3253592|NCT01415882|Experimental|Arm D (ixazomib citrate, dexamethasone, and cyclophosphamide)|Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO (cycles 1-18 only) and dexamethasone PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3370177|NCT02562235|Experimental|Riociguat|Participants with age ≥6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time.
3370178|NCT02555657|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) every 3 weeks (Q3W) for up to 35 administrations (up to ~2 years). Qualified participants who receive first course of pembrolizumab but continue to experience disease progression may, at investigator's discretion, initiate a second course of pembrolizumab at 200 mg IV Q3W for up to 17 administrations (up to ~1 year).
3370179|NCT02555657|Active Comparator|Chemotherapy|Participants receive capecitabine, eribulin, gemcitabine, or vinorelbine as TPC in accordance with local regulations and guidelines.
3253593|NCT01415882|Experimental|Arm E (ixazomib citrate, cyclophosphamide, daratumumab)|Patients receive ixazomib citrate PO on days 1, 8, and 15, cyclophosphamide PO (cycles 1-12 only) on days 1, 8, 15, 22, and daratumumab IV on days 1, 8, 15, 22 (cycles 1-2), days 1 and 15 (cycles 3-6), and day 1 in all subsequent cycles. Patients also receive dexamethasone IV or PO on days 1, 8, 15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3370185|NCT02541188||breast cancer in young women is in the Maghreb|breast cancer in young women (< 40years old) is in the Maghreb
3370186|NCT02541188||Breast cancer in young women in the western countries|Breast cancer in young women (< 40years old) in the western countries
3370196|NCT02520427|Experimental|Group 1: Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)|
3370197|NCT02520427|Experimental|Group 2: Minimal Residual Disease Positive (MRD+) AML|
3370198|NCT02520427|Experimental|Group 3: Myelodysplastic syndrome (MDS)|
3370199|NCT02520427|Experimental|Group 4: R/R AML with alternative pretreatment|
3370200|NCT02520427|Experimental|Group 5: R/R AML with alternative dose schedule|
3370202|NCT02482493|Active Comparator|All-polyethylene Tibial component|Sigma PFC All polyethylene Tibial component will be implanted
3370203|NCT02482493|Active Comparator|Metal Backed Tibial component|Sigma PFC metal-backed tibial component will be implanted
3370204|NCT02457156|Experimental|Blumgart Anastomosis|"Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a Blumgart method of pancreatico-jejunostomy.~Octreotide will be administered."
3253594|NCT01415895|Experimental|ATNC05 - a study drug capsule|Naltrexone and Clonidine Combination (ATNC05)
3253595|NCT01415895|Placebo Comparator|placebo|
3370205|NCT02457156|Active Comparator|Cattell-Warren Anastomosis|"Re-construction of the pancreatic remnant following pancreato-duodenectomy using a Cattell-Warren method of pancreatico-jejunostomy.~Octreotide will be administered."
3370206|NCT02451553|Experimental|Treatment (afatinib dimaleate, capecitabine)|Patients receive afatinib dimaleate PO QD on days 1-21 and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3370207|NCT02445248|Experimental|CTL019|Single arm
3253596|NCT01415973|Experimental|3 ounces of cooked, 85% lean ground beef|Subjects would consume 3 ounces of cooked, 85% lean ground beef at one setting on one day.
3253597|NCT01415973|Experimental|20 grams of Beef protein isolate|Subjects would consume 20 grams of beef protein isolate dissolved into 200mL water at one setting on one day.
3253598|NCT01415999||patient|adult survivors of childhood malignancies
3370208|NCT02445222|Other|Previously treated CAR-T patients|Patients who previously were exposed to lentiviral-based CART cell therapy
3370209|NCT02423057|Experimental|1|TdCyd will be administered orally once a day for 5 days of each week for 2 weeks, with one week off, in 21-day cycles
3253599|NCT01415999||control|healthy age-matched individuals
3253600|NCT01416012|Experimental|Group Kinect|Use of the available Kinect games on the Xbox to train balance and gait
3253601|NCT01416012|Active Comparator|Physical Therapy Standard|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
3253602|NCT01416012|Experimental|Group Nintendo|Use of video games available Balance and Gait training in Individualized training sessions.
3370214|NCT02421536|Experimental|Vibrent Smartphone Application|"We propose to pilot the application of the mobile application VibrentTM (research procedure) during a course of head and neck radiotherapy for eligible study subjects. Study subjects will be prospective consented and enrolled and will have baseline out of clinic assessment with the Vibrent smartphone application (research procedure)."
3370217|NCT02410356|Experimental|TV-1106|TV-1106 to be injected once weekly.
3370218|NCT02410356|Active Comparator|dGH|dGH to be given as daily injections.
3370221|NCT02402439|Experimental|Islet Transplant|Islet transplantation into the gastrointestinal submucosa
3253603|NCT01416012|Experimental|Group Xbox Kinect (MK)|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
3253604|NCT01416038|Experimental|Vaccine|Cohort A: 0.5 mL of DPX-Survivac (injection)
3253605|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide|Cohort B: 0.1 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
3253606|NCT01416038|Experimental|Vaccine + low dose cyclophosphamide.|Cohort C: 0.5 mL DPX-Survivac (injection) with low dose cyclophosphamide (oral)
3253607|NCT01416051|Active Comparator|Test|Subjects consumed a vegetable oil emulsion in yogurt at a food intake test and were asked to consume the product twice daily for 12 weeks.
3253608|NCT01416051|Placebo Comparator|Control Group|Subjects were given a placebo of milk fat in yogurt at food intake tests and asked to consume the placebo twice daily for 12 weeks.
3370222|NCT02381886|Experimental|IDH305|
3370223|NCT02362438|Experimental|10X|Highest dose in the escalation scheme
3253609|NCT01416064|Other|Molindone|Extension study, all subjects will be given Molindone at different (established) dosage levels based on the patient's weight, response and investigator discretion.
3370224|NCT02362438|Experimental|1X|Lowest dose in the escalation scheme
3370225|NCT02362438|Experimental|3.3X|2nd dose increase in escalation scheme
3370226|NCT02362438|Experimental|5X|3rd dose increase in escalation scheme
3253610|NCT01416077|No Intervention|standard treatment|Fluid and inotropic drugs are given based on conventional parameters such as blood pressure and heart rate as judged by the individual anesthesiologists judgement.
3370227|NCT02361944|Experimental|Normoxia|Oxygen administration to maintain a hemoglobin oxygen saturation of 95-97% or arterial PaO2 80-110 mmHg during surgery.
3370228|NCT02361944|Active Comparator|Hyperoxia|Fraction of inspired oxygen 1.0 during mechanical ventilation and 0.8 during cardiopulmonary bypass during surgery.
3370229|NCT02352753|Experimental|Denosumab|Single Arm Study
3370230|NCT02328014|Experimental|Dose Escalation and Expansion|"The acalabrutinib dose will be fixed and the ACP-319 dose will be escalated in each of three cohorts, and each cohort will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals.~Expansion groups of up to 12 subjects for Germinal center B-cell (GCB) DLBCL and Non-GCB DLBCL to take a fixed dose of acalabrutinib and ACP-319. Each disease group will take both study drugs by mouth, twice per day (BID) at approximately 12 hour intervals."
3370233|NCT02272348|Experimental|Education to functional insulin therapy immediately|Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
3370234|NCT02272348|Other|No education to functional insulin therapy immediately|After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.
3370235|NCT02233868|Experimental|Phase I|PET scan with [11C]PBR28 followed by PET scan with FDG and MRI.
3370236|NCT02233868|Experimental|Phase II|After 3 weeks of abstinence or non-abstinence, PET scan with [11C]PBR28 followed by PET scan with FDG and MRI are repeated.
3370250|NCT02190721|Experimental|tbo-filgrastim|Patients will receive subcutaneous doses of tbo-filgrastim 5 μg/kg body weight daily; each daily dose, to be administered at the investigative site
3370258|NCT02129543||Arm A: Treatment for Malignancy/Failure Group|Participants in this group will be those who are undergoing treatment for hematologic malignancy or bone marrow failure state.
3370259|NCT02129543||Arm B: Standard-of-Care SCT Group|Participants in this group will be cancer participants being treated with standard of care stem cell therapy
3370260|NCT02129543||Arm C: Adoptive T Cell Therapy Group|Participants in this group will be participants being treated with adoptive T cell therapy.
3370261|NCT02129543||Arm D: Control Group|Participants without cancer for studies of immunophenotype and immunologic function.
3370262|NCT02109744|Experimental|Decitabine followed by rapamycin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Rapamycin 6mg (loading dose) will be administered on day 6; thereafter 2 mg/day on days 11-22 in cycle 1 and on days 6-22 in subsequent cycles. (Arm A: for patients with non-morphologic M4/M5 subtypes).
3370263|NCT02109744|Experimental|Decitabine followed by ribavirin|Decitabine 20 mg/M2/day will be given as an IV infusion daily for 10 consecutive days starting on day 1 of cycle 1; in subsequent cycles, decitabine will be given for five days (days 1-5). Ribavirin will be dosed from day 11-day 28 beginning with dose level 1 (1000mg orally twice daily). Number of patients with Dose Limiting Toxicities (DLT) at a given dose level is 0 of out of 3: enter 3 patients at the next dose level (dose Level 2- 1200mg orally twice daily; and then dose Level 3-1400 mg orally twice daily).(Arm B: For patients with morphologic M4/M5 subtypes).
3370264|NCT02092155||Indwelling tunneled pleural catheter|
3370265|NCT02056054||Subjects with d-AIH|Pediatric transplant patients with de novo autoimmune hepatitis (d-AIH) will be enrolled at an outside center.
3370266|NCT02056054||Subjects with Acute Rejection|Pediatric transplant patients with acute rejection will be enrolled at an outside center.
3370267|NCT02056054||Subjects with Chronic Rejection|Pediatric transplant patients with chronic rejection will be enrolled at an outside center.
3370268|NCT02056054||Control Subjects|Healthy pediatric patients will be enrolled at the coordinating center (Yale).
3370269|NCT02056054||Subjects with Auto-immune Hepatitis|Adult non-transplant patients with auto-immune hepatitis will be enrolled at the coordinating center (Yale).
3370270|NCT02056054||Subjects with Chronic Hepatitis C Virus|Adult non-transplant patients with chronic hepatitis C will be enrolled at the coordinating center (Yale).
3370271|NCT02056054||Adult Subjects with d-AIH|Adult transplanted patients with de novo autoimmune hepatitis will be enrolled at the coordinating center (Yale).
3253611|NCT01416077|Active Comparator|goal-directed fluid treatment|Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
3370277|NCT02035085|Experimental|CS-1000|Breast cancer patients with RIF will undergo liposuction, the autologous SVF cell fraction will be isolated and labeled with CS-1000 in the operating room without entering cell culture, which will then be returned to the patient at the site of breast grafting.
3370280|NCT01998815||Obese patients|Laparoscopic Roux-en-Y gastric bypass
3253612|NCT01416103|Experimental|Intervention group|Intervention group
3253613|NCT01416103|Placebo Comparator|Intervention control|Control group
3253614|NCT01416116|Experimental|Tramadol|Tramadol prior to QUTENZA
3253615|NCT01416116|Experimental|Lidocaine|Lidocaine prior to QUTENZA
3370281|NCT01979003|Experimental|Fluorescein Injection|All research participants will receive fluorescein injection through existing intravenous line during the operative procedure. This will consist of one ampule (5 cc) injected intravenously 5- 10 minutes prior to ligation of the uterine arteries.
3370282|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 1|This portion comprises dose escalation and dose expansion to establish the recommended Phase 2 dose (RP2D) when tazemetostat is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of tazemetostat as well as the drug-drug interaction (DDI) potential of tazemetostat are evaluated. CLOSED TO ENROLLMENT
3253616|NCT01416168|No Intervention|Control Arm|Usual post-surgical care
3253617|NCT01416168|Experimental|Intervention arm|In addition to usual post-surgical care, the patients will receive a 4 week geriatric nurse practitioner-centered intervention, based on the McCorkle model.
3370283|NCT01897571|Experimental|Tazemetostat (formerly known as EPZ-6438 and E7438): Phase 2|This portion is restricted to subjects with DLBCL or FL for the determination of efficacy and safety of tazemetostat monotherapy and tazemetostat in combination with prednisolone as defined by histology, cell of origin and EZH2 mutation status.
3370286|NCT01851369|Experimental|1|combination treatment with oral TRC102 and oral TMZ for days 1-5 of 28-day cycles
3253618|NCT01416207|Experimental|Avonex|4 weekly injections of Avonex (IM)
3253619|NCT01416220|Experimental|Lithium|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l).
3253620|NCT01416220|Active Comparator|Paroxetine|Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or Paroxetine.Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7.At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines.
3370288|NCT01812694|Active Comparator|Enhanced Standard Care|Standard prenatal care plus education
3370289|NCT01812694|Experimental|Intensive lifestyle intervention|Intervention to limit excess gestational weight gain
3253621|NCT01416233|Experimental|autologous fat grafting|There is one arm of this study. People with anophthalmic sockets and orbital atrophy are given a single session of autologous fat grafting by a closed cannula technique and are observed to measure, by MRI, the amount of fat retained at one year
3253622|NCT01416246|Experimental|Fractionated Stem Cell Infusions|A single arm, open-label, single institution pilot trial is planned. Patients with chemosensitive MM and at least 7 x 10^6 CD34+ stem cells/kg (+/- 0.5 x 10^6 CD34+ stem cells/kg)available for use will be enrolled following initial induction or salvage therapy.
3370290|NCT01811576|Active Comparator|recombinant human growth hormone|Daily subcutaneous dose
3370291|NCT01811576|Experimental|TV-1106|Titration dose levels of TV-1106
3253623|NCT01416259||APF530 Exposure, Granisetron and Moxifloxacin, Placebo|Arm 1:APF530 Exposure Arm 2:Granisetron IV Arm 3:Moxifloxacin Arm 4:Placebo
3253624|NCT01416285||control group|control group receiving regular education from a nurse
3370300|NCT01740557|Experimental|Treatment (genetically modified T-cells, high-dose aldesleukin|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and CXCR2-transduced autologous TIL and NGFR-transduced autologous TIL IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
3253625|NCT01416285||Case management group|This is the study group. Extensive education and case management program will be performed in this group.
3253626|NCT01416311||Subjects prescribed REVOLADE|Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period
3253627|NCT01416324|Experimental|GSK2330672|experimental study drug
3253628|NCT01416324|Placebo Comparator|Placebo|placebo
3253629|NCT01416337|Experimental|Treatments A & B|Single 2 mg GSK1120212 oral tablet, fasted Single IV dose of 5 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK1120212 Both doses are given together.
3370314|NCT01625611|Experimental|Naltrexone|
3370316|NCT01600755|Experimental|Autologous Muscle-Derived Cells|Cell Treatment
3370317|NCT01581580|Other|treatment arm|patients with Parkinson's Disease, dysonia, and essential tremor
3253630|NCT01416350|Active Comparator|Part A - randomized, open-label parallel group|Part A is a randomized, open-label parallel group study evaluating PK/PD of a single azithromycin dose of 250 or 1000 mg. Data from Part A will be used to assess the dose resulting in induction/inhibition of various ex vivo biomarkers relative to a 250 mg dose of azithromycin (the clinical dose used in treatment of neutrophil-induced inflammatory conditions). This information will guide the range of doses to be studied in a FTIH study of a new chemical entity.
3253631|NCT01416350|Active Comparator|Part B - repeat dose group|Part B is a repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions. This information will provide insight into whether the biomarker effects change over time on repeat dosing and any potential differences observed between single and repeat doses.
3253632|NCT01416363|Experimental|Treatment Arm ACB: Part 1|Subjects will receive treatment sequence ACB; A : Firategrast immediate release tablet 1200 milligram (mg) once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3370343|NCT01511614|Active Comparator|active tDCS|(1) anodal left-dlPFC + cathodal right-vmPFC stimulation, with anode over the left dlPFC and cathode over the right-vmPFC; (2) cathodal left-dlPFC + anodal right-vmPFC stimulation, in which polarity is reversed between the two electrodes
3370344|NCT01511614|Sham Comparator|sham tDCS|To simulate the experience of tDCS stimulation, current is ramped on and turned off at the beginning and end of the tDCS session. An additional sham option is to have the current ramp up and down only at the beginning of the sham session, and not at the end. This second sham is supported in the literature as an effective blinding technique, which subjects cannot distinguish from active stimulation. One of these sham options will be used for data that will be analyzed together, to be determined based on equipment capabilities and preliminary analysis of blinding efficacy in our cross over design. We will assess the efficacy of sham condition by providing participants and the investigator with a questionnaire on the MRI/tDCS session, wherein they will report whether they thought the tDCS session was active or sham. The MRI operator (or other non protocol personnel) will control active/sham conditions.
3253633|NCT01416363|Experimental|Treatment Arm BAC: Part 1|Subjects will receive treatment sequence BAC; B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
3370355|NCT01468883|Active Comparator|M|Modified radical mastectomy
3370356|NCT01468883|Experimental|X|Excisional biopsy plus radiation
3253634|NCT01416363|Experimental|Treatment Arm CBA: Part 1|Subjects will receive treatment sequence CBA; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, B : Firategrast 3 hour release tablet 1200 mg once only orally, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3253635|NCT01416363|Experimental|Treatment Arm BCA: Part 1|Subjects will receive treatment sequence BCA; B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3370375|NCT01362803|Experimental|Arm 1|Phase 1: AZD6244 PO BID x 28 DAYS
3370376|NCT01362803|Experimental|Arm 2|Phase 2: AZD6244 PO BID x 28 DAYS
3370377|NCT01351545||Unlicensed CBU|The cohort includes recipients of any age receiving unlicensed cryopreserved cord blood units (CBUs) for designated indications.
3370378|NCT01345578|Experimental|Hepatocyte Transplantation|See Below
3370382|NCT01306045|Active Comparator|A/ Erlotinib|Erlotinib
3370383|NCT01306045|Active Comparator|B/ AZD6244|AZD6244
3253636|NCT01416363|Experimental|Treatment Arm CAB: Part 1|Subjects will receive treatment sequence CAB; C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route, A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally. There will be a washout period of 5 days between doses.
3370384|NCT01306045|Active Comparator|C/ MK-2206|MK-2206
3370385|NCT01306045|Active Comparator|D/ Lapatinib|Lapatinib
3253637|NCT01416363|Experimental|Treatment Arm ABC: Part 1|Subjects will receive treatment sequence ABC; A : Firategrast immediate release tablet 1200 mg once only orally, B : Firategrast 3 hour release tablet 1200 mg once only orally, C : Firategrast simulated gastro-retentive solution 1200 mg once only by naso-gastric route. There will be a washout period of 5 days between doses.
3253638|NCT01416363|Experimental|Treatment Arm D: Part 2|Subject will receive D: Firategrast immediate release tablet 600 mg twice daily for 7 days
3253639|NCT01416363|Experimental|Treatment Arm E: Part 2|Subject will receive E: Firategrast 3 hour release tablet 1200 mg twice daily for 7 days
3370386|NCT01306045|Active Comparator|E/Sunitinib|Sunitinib
3370387|NCT01306045|Other|F/ NOS|NOS (not otherwise specified)
3370388|NCT01306019|Experimental|1|Gene Therapy
3370391|NCT01273129|Experimental|1|Patients 8 years of age or older with drug resistant epilepsy or tumor related epilepsy
3253640|NCT01416363|Experimental|Treatment Arm F: Part 2|Subject will receive F: Firategrast simulated gastro-retentive solution 1200 mg twice daily for 7 days
3253641|NCT01416376|Active Comparator|50mg SRT2379|Single oral administration of 50mg SRT2379
3253642|NCT01416376|Active Comparator|250mg SRT2379|Single oral administration of 250mg SRT2379
3253643|NCT01416376|Active Comparator|1000mg SRT2379|Single oral administration of 1000mg SRT2379
3253644|NCT01416376|Placebo Comparator|Placebo|Single oral administration of placebo
3370410|NCT01138020|Experimental|Arm 1|Cognitive intervention
3370411|NCT01138020|Active Comparator|Arm 2|Educational intervention
3253645|NCT01416402|Other|Arhalofenate with febuxostat and colchicine|
3253646|NCT01416415|Experimental|Educational intervention|The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
3253647|NCT01416415|Placebo Comparator|Attention placebo|The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.
3253648|NCT01416454||Elective Cesarean delivery, age <35 yrs|Women undergoing elective cesarean delivery with a spinal anesthetic who are less than 35 y of age (at the time of delivery).
3253649|NCT01416454||Elective Cesarean delivery, age =>35 yrs|Women undergoing elective Cesarean delivery with a spinal anesthetic who are => 35 yrs of age (at the time of delivery).
3253650|NCT01416480|Experimental|Theobromine|Theobromine capsule 300mg
3253651|NCT01416480|Active Comparator|levodropropizine|levodropropizine syrup
3253652|NCT01416493|Experimental|bIAP treatment|
3253653|NCT01416506||Group 1|
3253654|NCT01416519|Experimental|Group 1|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
3253655|NCT01416519|Experimental|Group 2|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
3253656|NCT01416545|Active Comparator|Lifestyle counseling|Children received the same educational material for their parents and, additionaly, were exposed to a weekly educational program directed for cardiovascular prevention.
3253657|NCT01416545|Placebo Comparator|Control group|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
3253658|NCT01416597||Cross-Protection Studies|
3253659|NCT01416623|Experimental|Henatinib|Henatinib either at 12.5,25,37.5,50,62.5,75,87.5 or 100 mg, p.o. once daily
3253660|NCT01416662|Other|gemcitabine|gemcitabine
3253661|NCT01416688||Observation and Questionnaires|Patients will be given questionnaires for the assessment of therapy complications, psychosocial assessment and care, and quality-of-life assessment.
3253662|NCT01416701|Active Comparator|Vitamin D (D3, cholecalciferol)|
3253663|NCT01416701|Placebo Comparator|Placebo (cellulose)|
3253664|NCT01416714||Gastric Cancer|
3253665|NCT01416714||Gastrointestinal Stromal Tumors (GIST)|
3253666|NCT01416714||Esophageal Cancer|
3253667|NCT01416714||Pancreas Cancer|
3253668|NCT01416714||Hepatocellular Cancer|
3253669|NCT01416714||Biliary Cancer|
3253670|NCT01416714||Neuroendocrine Cancer|
3253671|NCT01416714||Peritoneal Mesothelioma|
3253672|NCT01416714||Anal Cancer|
3253673|NCT01416714||Colorectal Cancer|
3253674|NCT01416727|Experimental|OSkER|"Observed SKills in the Emergency Room - workplace-based supervision."
3253675|NCT01416727|Experimental|EPIC|"Emergency Psychiatry Immersion Course - simulation-based training."
3253676|NCT01416740|Experimental|Indirect MRA|After patient has signed consent and had blood tests to ensure normal kidney function (BUN and Creatinine) as well as serum and urine pregnancy tests for females to ensure there is no pregnancy, the patient will have an Indirect MRA. The participant will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into participant's arm. The gadopentetate dimeglumine will be injected into the IV and the patient will be asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
3253677|NCT01416753|Active Comparator|UCR|regulation of ultrafiltration and conductivity
3253678|NCT01416753|Active Comparator|UTR|regulation of ultrafiltration and temperature
3253679|NCT01416753|No Intervention|conventional dialysis|dry weight reduction without BVM
3370422|NCT01021033||Chronic stroke patients|Chronic stroke patients
3370438|NCT00908687|Experimental|Group 1: 30 µg HA, no LT patch|A/H5N1 Vaccine 30 µg HA i.m. on Day 0
3370439|NCT00908687|Experimental|Group 2: 30 µg HA + 50 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
3253680|NCT01416766|No Intervention|Control|Control participants will receive usual care during their year of enrollment. At enrollment, prior to randomization, they will be informed that, if randomized to control status, they will be offered a free BP monitor and the opportunity to receive the study intervention after completing the exit interview in 1 year.
3253681|NCT01416766|Experimental|Intervention|Self-monitoring-nurse-primary care provider feedback loop After randomization, intervention participants will receive the intervention (free home BP monitor, assistance setting up to upload BP readings from home/work or clinic computer; feedback loop with nurse-driven protocols to manage uncontrolled hypertension and maintain control once attained).
3370440|NCT00908687|Experimental|Group 3: 30 µg HA + 100 µg LT patch|A/H5N1 Vaccine 30 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
3370441|NCT00908687|Experimental|Group 4: 45 µg HA, no LT patch|A/H5N1 Vaccine 45 µg HA i.m. on Day 0
3370442|NCT00908687|Experimental|Group 5: 45 µg HA + 50 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 50 µg of LT on Day 0
3370443|NCT00908687|Experimental|Group 6: 45 µg HA + 100 µg LT patch|A/H5N1 Vaccine 45 µg HA i.m. + LT adjuvant patch containing 100 µg of LT on Day 0
3253682|NCT01416779|Experimental|Writing Group|This group will receive the writing intervention.
3253683|NCT01416779|No Intervention|No Intervention|Non Writing Group
3253684|NCT01416792|Experimental|Multiple-pass hemofiltration|
3253685|NCT01416818|Experimental|group 1|
3253686|NCT01416818|Active Comparator|group 2|
3253687|NCT01416818|Placebo Comparator|group 3|
3253688|NCT01416831|Active Comparator|High-dose IL-2|Patients receive standard high-dose IL-2 therapy, with an opportunity to crossover to the experimental arm if there is disease progression noted after two cycles of high-dose IL-2.
3253689|NCT01416831|Experimental|Radiation therapy and high-dose IL-2|Patients 1-20 who are assigned to receive radiation therapy will receive a single dose of radiation before IL-2; patients 21-44 assigned to receive radiation will receive two doses of radiation before receiving high-dose IL-2.
3253690|NCT01416857|No Intervention|MOD|Group evaluated using the currently available ED measure of disability (MOD)
3253691|NCT01416857|Experimental|RDDT|Group will be evaluated using ED Rasch Disability Diagnostic Tool (RDDT)
3253692|NCT01416870|Experimental|Active 1|34 subjects will receive ICI176,334-1without water
3370452|NCT00739401|Experimental|1|Test subjects requiring endovascular treatment of abdominal aortic or aorto-iliac aneurysms including a proximal cuff extension.
3370455|NCT00715611|Experimental|1|This is a multicenter phase II toxicity study of pleurectomy/decortication (P/D) followed by adjuvant chemotherapy and Intensity Modulated Radiation Therapy (IMRT) to the pleura in patients with malignant pleural mesothelioma. Alternatively, chemotherapy may be administered in the neoadjuvant setting prior to P/D, followed by IMRT. Patients deemed resectable at the time of enrollment will undergo P/D with the goal of a macroscopic complete resection (MCR). Those with disease progression or severe toxicity will stop chemotherapy and undergo a PET scan.
3370456|NCT00669188|Experimental|Information Type 1|genetic risk information
3370457|NCT00669188|Sham Comparator|Information Type 2|information absent
3253693|NCT01416870|Experimental|Active 2|34 subjects will receive ICI176,334-1 with water
3253694|NCT01416870|Experimental|Active 3|34 subjects will receive Casodex 80 mg tablet
3370458|NCT00663611|Experimental|Study I and IB|Each involve six subjects &amp; are designed to test the hypothesis that pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will yield a reasonable pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than that in Study I. Study I and IB will be done first before proceeding to Study II
3370459|NCT00663611|Experimental|Study II|Is a randomized, double-blinded, placebo-controlled 12 week study involving 26 subjects divided into 2 groups: Group A and Group B. Group A will involve 13 subjects receiving pulsatile GH or placebo infusion for 4 weeks with 8 week washout after intervention. Group B will involve 13 subjects receiving conventional once a day subcutaneous infusion of GH or placebo for 4 weeks with 8 week washout after intervention.
3370463|NCT00651742|Experimental|S-1 30 mg/m^2|Participants received 30 milligrams per meter square (mg/m^2) of S-1 orally twice daily (BID) for 2 weeks (i.e., Day 1 to 14), followed by 1 week recovery period (i.e., Day 15 to 21; one cycle equaled 21 days), treatment was repeated every 3 weeks until death, progression of disease, occurrence of intolerable side effects, withdrawal of consent, or removal by Investigator, whichever comes first.
3370468|NCT00404560||healthy blood relatives|relatives not ill with a known or suspected infection susceptibility syndrome
3370469|NCT00404560||Patients|patients who either have, or are suspected of having, an infection or infection susceptibility in order to further characterize such conditions
3253695|NCT01416883|Experimental|Active 1|8 subjects will receive ICI176,334-1
3253696|NCT01416896|Experimental|"New venous needle, the BME needle"|"Hemodialysis using the new venous needle, the BME needle."
3370474|NCT00368082|Experimental|TGFbeta resistant LMP-specific CTLs|"CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection."
3253697|NCT01416896|Active Comparator|"Standard venous needle, the standard needle"|"One hemodialysis using the standard venous needle, the standard needle (device)."
3253698|NCT01416909|Active Comparator|Dose Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on the dose of the opioid pain medication they are receiving.
3253699|NCT01416909|Active Comparator|Assessment Intervention - Opioid|Laxative Treatment: Participants Receiving Opioids for the Treatment of Pain. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be determined based on their severity of constipation.
3370485|NCT00308516|Experimental|Cohort A - Preoperative|"Each patient enrolled in the preoperative cohort received 5-fluorouracil (5-FU) 225 mg/m2 as a continuous infusion (IVCI) on days 1-42 through a portable infusion pump and central venous catheter. Bevacizumab 5 mg/kg was administered intravenously (IV) on days 1 and 15. Additionally these patients received radiation therapy to 50.4 Gy (1.8 Gy/day or 28 fractions) Monday through Friday during weeks 1-6.~At least 8 weeks after surgery, patients in cohort A began 4 months of chemotherapy and bevacizumab. This adjuvant treatment consisted of 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
3253700|NCT01416909|Other|Control Group - Opioid|Standard of Care: Participants Receiving Opioids for the Treatment of Pain will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
3370486|NCT00308516|Experimental|Cohort B - Combined Modality|"All patients enrolled in cohort B received 5-fluorouracil (5-FU) 225 mg/m2 IVCI on days 1-42. Bevacizumab was administered at 5 mg/kg IV on day 1 every 2 weeks. These patients also received radiation to 50.4 Gy (1.8 Gy/day or 28 fractions)Monday through Friday during weeks 1-6.~Six weeks after the completion of adjuvant 5-FU/radiation, patients began treatment with 5-FU 400 mg/m2 IV bolus over 2-4 minutes followed by 2400 mg/m2 IVCI over 46 hours, leucovorin 350 mg as a 2-hour infusion, oxaliplatin 85 mg/m2 IV (modified FOLFOX6) and bevacizumab 5 mg/kg IV all on days 1 and 15 of each cycle."
3253701|NCT01416909|Active Comparator|Assessment Intervention - Vinca Alkaloid|Laxative Treatment: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Participants will be taken off any laxative preparation they may already be on and will be put on laxative treatment based on the Constipation Treatment Protocol. The dose of laxative will be based on their level of constipation.
3370516|NCT00076830||Enrolled Cohort|All patients enrolled, as this is a evaluation/diagnostic study
3253702|NCT01416909|Other|Control Group - Vinca Alkaloid|Standard of Care: Participants Receiving a Specific Type of Chemotherapy (vinca alkaloids). Vinca alkaloids include medication such as Vincristine, Vinblastine, or Vinorelbine. Patients will receive standard of care while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
3253703|NCT01416922||LSIL|Women 21 years of age or older with an LSIL diagnosis
3253704|NCT01416935|Active Comparator|No Amiodarone|Patient will be randomized not to receive to Amiodarone post Cox-Maze procedure unless indicated.
3253705|NCT01416935|No Intervention|Amiodarone|Patients randomized to receive Amiodarone post Cox-Maze procedure which is our current standard of care.
3253706|NCT01416948|Placebo Comparator|Sugar Pill|
3253707|NCT01416948|Active Comparator|Galantamine|
3370556|NCT00005780|Experimental|1|EPOCH-R followed by idiotype vaccine and GM-CSF
3253708|NCT01416948|Experimental|Methylphenidate|
3253709|NCT01416974|Experimental|consolidative therapy with autologous T cells genetically|A phase I trial of consolidation therapy with autologous T cells genetically targeted to the B cell specific antigen CD19 for patients with chronic lymphocytic leukemia following upfront chemotherapy with pentostatin, cyclophosphamide and rituximab.
3253710|NCT01417013|Active Comparator|Systane Ultra|Systane Ultra Lubricant Eye Drops
3253711|NCT01417013|Active Comparator|Optive|Optive Lubricant eye drops
3253712|NCT01417052|Experimental|50 mg LX3305 QD|
3253713|NCT01417052|Experimental|100 mg LX3305 QD|
3253714|NCT01417052|Experimental|150 mg LX3305 QD|
3253715|NCT01417052|Experimental|200 mg LX3305 QD|
3253716|NCT01417052|Experimental|250 mg LX3305 QD|
3253717|NCT01417052|Experimental|300 mg LX3305 QD|
3253718|NCT01417052|Experimental|400 mg LX3305 QD|
3253719|NCT01417052|Experimental|250 mg LX3305 BID|
3253720|NCT01417052|Experimental|500 mg LX3305 QD|
3253721|NCT01417052|Placebo Comparator|Placebo|
3253722|NCT01417065|Experimental|Temsirolimus|Starting dose 0.02 mg intravenous administered once.
3253723|NCT01417091|Experimental|Treatment group|
3253724|NCT01417091|No Intervention|Untreated reference group|
3253725|NCT01417117||Spontaneous Intracerebral Hemorrhage|Patients with primary intracerebral hemorrhage within 24 hours of admission diagnosed by non-contrast head computed tomography (CT)
3253726|NCT01417130||Naproxen sodium (220 mg b.i.d)|Original assignment in the ADAPT trial
3253727|NCT01417130||Celecoxib (200 mg b.i.d.)|Original assignment in the ADAPT trial
3253728|NCT01417130||Placebo|Original assignment in the ADAPT trial
3253729|NCT01417143|Experimental|TKI258 (Dovitinib)|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
3253730|NCT01417169|Experimental|Micafungin|
3253731|NCT01417182|Experimental|Melanoma|
3253732|NCT01417208||SNaP® Wound Care System|
3253733|NCT01417221|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with essential hypertension.
3253734|NCT01417221|No Intervention|Absolute medicine therapy|Maintenance of anti-hypertensive medications only
3253735|NCT01417247|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with metabolic syndrome.
3253736|NCT01417247|No Intervention|Absolute medicine therapy|Maintenance of anti-metabolic syndrome medications only
3376176|NCT02311621|Experimental|B: 3rd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3376177|NCT02311621|Experimental|C: Long Spacer 2nd Generation CE7R CAR T Cells|"Autologous CD4 and CD8 cells are lentivirally transduced to generate patient-derived CD171 specific CAR T cells also expressing an EGFRt.~Patients will receive lymphodepletion chemotherapy prior to T cell infusion. CD171 specific CAR T cells will be administered approximately 2-3 days after lymphodepletion chemotherapy.~Cells will be administered approximately 1:1 CD4 and CD8 cells with planned dose level evaluations of total T cell dose of 1x10^6 cells/kg, 5x10^6 cells/kg, 1x10^7 cells/kg, 5x10^7 cells/kg, and 1x10^8 cells/kg will be evaluated."
3376178|NCT02288247|Experimental|Enzalutamide|Participants received an OL treatment with enzalutamide 160 milligrams (mg) capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received enzalutamide 160 mg capsules, orally once daily in combination with docetaxel 75 milligrams per square meter (mg/m^2) in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, DB period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cycle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
3253737|NCT01417260||Nocebo|Told breastfeeding may worsen pain
3253738|NCT01417260||No treatment|Told nothing
3253739|NCT01417260||Placebo|Told will improve pain
3253740|NCT01417273|Active Comparator|vitamin A, multiple sclerosis,|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 25000 IU/day vitamin A for 6 months and 10000 IU/day for next 6 months
3253741|NCT01417273|Placebo Comparator|placebo/Multiple Sclerosis|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type who receive 1 cap of placebo/day
3370611|NCT04331366|Experimental|Treatment with GO2 PEEP MOUTHPIECE|Participants receiving treatment with the GO2 PEEP MOUTHPIECE
3370618|NCT02325960|Active Comparator|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter
3370619|NCT02325960|Active Comparator|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
3370620|NCT05155696|Experimental|Kefir probiotic drink|Daily kefir for 6 weeks.
3370621|NCT05155696|Placebo Comparator|placebo comparator|Daily non-fermented dairy based equivalent drink for 6 weeks.
3370622|NCT05155683|Active Comparator|Photobiomodulation|PBM with infrared LED application + sham ultrasound + muscle electrostimulation
3370623|NCT05155683|Active Comparator|low frequency ultrasound|LED sham PBM + LOFU + muscle electrostimulation
3370624|NCT05155683|Active Comparator|Combined treatment (PBM + LOFU)|Combined treatment (PBM + LOFU) + muscle electrostimulation
3370625|NCT05155683|Sham Comparator|Sham Treatment|Sham combined treatment + muscle electrostimulation
3370626|NCT05155670|Experimental|Robotic therapy|All participants will receive a program of robot-assisted rehabilitation exercises., including passive, active-assisive and active MCP Range-of-Motion Exercises, and active bidigital pinching movements in the transparent mode.
3370627|NCT05155657|Experimental|Low dose umbilical cord mesenchymal stem cells (UCMSCs)|
3370628|NCT05155657|Experimental|Medium dose UCMSCs|
3370629|NCT05155657|Experimental|High dose UCMSCs|
3370630|NCT05155631|Experimental|Cognitive Behavioral Treatment Arm|"Subjects in the Cognitive Behavioral Treatment Arm will undergo 8-10 weeks of remote cognitive behavioral therapy. Subjects will complete modules on their phones and will be monitored by study coordinators for support and treatment completion."
3370631|NCT05155631|No Intervention|Usual Care Arm|"Subjects in the Usual Care Arm will undergo 8-10 weeks of continued lifestyle. Subjects will be asked to report any new medications or lifestyle changes to study coordinators throughout the 8-10 weeks."
3370632|NCT05155618|Experimental|Intervention group (IG)|Participants randomized to the IG will be offered an individualized counseling during cancer treatments that includes both a dietary and physical activity suggestions to control side effects, to cope with feelings of anxiety or depression and to improve quality of life.
3370633|NCT05155618|No Intervention|Control group (CG)|Participants included in the CG will receive at baseline general advice and materials available for patients undergoing RT. According to the crossover design, the CG will cross to the intervention as proposed for the IG, after the initial 6-month period.
3370634|NCT05155605|Experimental|Participants 50 years of age or older|The study will aim to enroll a diverse participant population generally representative of the US population with respect to race, ethnicity, and sex. The target age categories of 60-69 years and 70-79 years will be enriched to increase the number of cancer events that are observed during the study.
3370635|NCT05155592|Experimental|Patients with inactive uveitis|Patients with non-infectious uveitis whose inflammation reached remission for at least six months after treatment with Adalimumab
3370636|NCT05155579|Experimental|Groups 1a, 2a and 3a|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a two vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1a is 20 children aged 5-11 months, group 2a is 20 children aged 12-23 months, and group 3a is 20 children aged 24-36 months.
3370637|NCT05155579|Experimental|Group 1b, 2b and 3b|60 children, aged 5-36 months, who will receive 4 doses of 5µg R21/50µg Matrix-M as a single vial formulation. The first three doses will be given one month apart, followed by a booster vaccination 12 months after the third dose. The age range of 5-36 months has been split into three groups to ensure an even age spread across age groups. Group 1b is 20 children aged 5-11 months, group 2b is 20 children aged 12-23 months, and group 3b is 20 children aged 24-36 months.
3370638|NCT05155579|Experimental|Group 4a|150 participants, aged 6-7 months at the time of randomisation (to ensure third vaccination is given at approximately 9 months), who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart. At the time of the third dose they will receive their measles-rubella and yellow fever vaccinations at the same time as R21/Matrix-M.
3370639|NCT05155579|Active Comparator|Group 4b|150 participants, aged 6-7 months at the time of randomisation, who will receive a measles-rubella and yellow fever vaccination 2 months after randomisation.
3253742|NCT01417286|Experimental|Radiation Therapy|Patients undergo hypofractionated accelerated radiation therapy over 11 weekdays (for 15 elapsed days) within 21-63 days after last surgery or last course of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
3370640|NCT05155579|Experimental|Group 4c|Group 4c is 50 participants, aged 6-7 months at the time of randomisation, who will receive 3 doses of 5µg R21/50µg Matrix-M one month apart.
3370641|NCT05155579|Experimental|Group 5a|30 children who will receive 3 doses of 5µg R21/50µg Matrix-M, pentavalent and OPV vaccines at 6, 10 and 14 weeks of age.
3370642|NCT05155579|Active Comparator|Group 5b|30 children who will receive 3 doses of pentavalent and OPV vaccines at 6, 10 and 14 weeks of age.
3370643|NCT05155579|Experimental|Group 6a|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 6 months after the first dose.
3370644|NCT05155579|Experimental|Group 6b|30 children, aged 5-36 months, who will receive 3 doses of 5µg R21/50µg Matrix-M. The first two doses one month apart and the third dose 12 months after the first dose.
3370645|NCT05155566||Breast Cancer Patients|HR + /HER2- Advanced/Metastatic Breast Cancer patients in Latin America
3370648|NCT05155527|Experimental|Favipiravir plus Ivermectin|Ivermectin 600 mcg/kg once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
3370649|NCT05155527|Placebo Comparator|Favipiravir plus Placebo|Matching placebo once daily for 5 days in combination with Favipiravir for 5-10 days (1,800 mg twice a day in day 1 then 800 mg twice a day for the other days. For BW > 90 kg: 2,400 mg twice a day in day 1 then 1,000 mg twice a day for the other days).
3370650|NCT05155514||Group H|"Hypertension group (Group H):~Patients with a previous diagnosis of hypertension~Patients receiving antihypertensive therapy~Systolic blood pressure (SBP) ≥140mmHg and/or diastolic blood pressure (DBP) ≥90mmHg"
3370651|NCT05155514||Group N|Normotensive group (Group N): Other non-hypertensive patients
3370652|NCT05155501|Active Comparator|Robot-assisted radical prostatectomy (RP)|The conventional robotic-assisted radical prostatectomy is the gold standard approach to prostate cancer surgery.
3370653|NCT05155501|Experimental|Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP)|A novel, posterior approach to radical prostatectomy that preserves the dorsal vascular complex, nerves and fascial support structures that overlie the anterior prostate. These structures are disrupted and removed during conventional radical prostatectomy.
3370654|NCT05155488||Participants With MPS II|Retrospective data of participants diagnosed with MPS II will be collected from the database (DATASUS) from January 1st, 2008 to September 30th, 2020 in this observational study.
3370655|NCT05155475||Patient with jaundice|
3370656|NCT05155462||Patient treated for defined symptomatic chronic lower extremity ischemia|
3253743|NCT01417299|Active Comparator|RPh201 group|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
3253744|NCT01417299|Placebo Comparator|placebo group|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
3370659|NCT05155436|Experimental|Participants|Fixed-Dose Combination pill of Telmisartan 40 mg and Amlodipine 5 mg, once daily for 3 months
3370660|NCT05155423||group 1|patient using mask for immobilization
3370661|NCT05155423||group 2|patients using Elekta BodyFix
3370662|NCT05155410|Experimental|Experimental|"Participants will consume 15 g of an active oral exogenous ketone monoester supplement 15 minutes prior to each meal of the day for a 14-day period.~Pre-intervention (baseline) and post-intervention measurements will be obtained before and immediately after the 14-day period.~All meals will be provided throughout the supplementation period Participants will wear a continuous glucose monitor for 10 consecutive days during the supplementation period."
3370663|NCT05155410|Placebo Comparator|Placebo|Participants will consume a flavor-matched placebo drink and undergo the same procedures described in the Experimental Arm
3370666|NCT05155371|Experimental|Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen|Obtained Optimal Positive End-expiratory Pressure obtained with Titration of Fraction of Inspiratory Oxygen and sustained the PEEP intraoperatively
3253745|NCT01417312|Active Comparator|Green tea extract|
3253746|NCT01417312|Placebo Comparator|Placebo|
3370667|NCT05155371|Experimental|Optimal Positive End-expiratory Pressure obtained with electrical impedance tomography|Obtained Optimal Positive End-expiratory Pressure obtained with EIT and sustained the PEEP intraoperatively
3370668|NCT05155358||Control group|Healthy volunteers
3370669|NCT05155358||Patients within the acute phase of disease|Patients within 24 hours after onset
3370670|NCT05155358||Recovery stage of disease|Organ dysfunction was corrected, The patient had no obvious discomfort.
3370671|NCT05155345|Experimental|Non-fractionated/Dose-finding|Participants will receive a single dose of mosunetuzumab.
3370672|NCT05155345|Experimental|Fractionated/Dose-escalation|Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
3370679|NCT05155319|Active Comparator|Cohort 1, 1A|Low Dose/Placebo
3370680|NCT05155319|Active Comparator|Cohort 1, 1B|Low Dose/Low Dose
3370681|NCT05155319|Placebo Comparator|Cohort 1, 1C|Placebo/Placebo
3370682|NCT05155319|Active Comparator|Cohort 2, 2A|High Dose/Placebo
3253747|NCT01417338||Pulmonary hypertension group|Patients who were firstly diagnosed as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
3253748|NCT01417351|Placebo Comparator|400 IU Vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
3253749|NCT01417351|Experimental|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
3253750|NCT01417364|Active Comparator|Testosterone weekly injections continuously|Testosterone enanthate 100 mg Intramuscular (IM) weekly injections throughout the study
3253751|NCT01417364|Experimental|Cyclic testosterone administration|Testosterone injections 100 mg. IM weekly for one month alternating with placebo injections weekly for one month throughout the study
3253752|NCT01417364|Placebo Comparator|Placebo injections|Placebo injections weekly throughout the study.
3370683|NCT05155319|Active Comparator|Cohort 2, 2B|High Dose/High Dose
3253753|NCT01417390|Experimental|Concurrent chemoradiotherapy|Patients receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy
3253754|NCT01417390|Experimental|Inductive and concurrent|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
3253755|NCT01417403|Experimental|Treatment (radiosensitization therapy)|Beginning 3 days before the initiation of radiotherapy, patients receive hydroxychloroquine PO QD or BID. Treatment continues until completion of radiotherapy.
3370684|NCT05155319|Placebo Comparator|Cohort 2, 2C|Placebo/Placebo
3253756|NCT01417416||with combat training stress|
3253757|NCT01417416||without combat training stress|
3253758|NCT01417429|Active Comparator|Galantamine|galantamine will be given with intravenous nicotine
3253759|NCT01417429|Experimental|Nicotine|Subject will be given IV Nicotine
3253760|NCT01417442|Experimental|BRAF V600E POSITIVITY|This mutation will be analysed using the tumor tissues of the patients operated for thyroid diseases and diagnosed with papillary thyroid carcinoma. And mutation positive patients will be investigated for the aggressive characteristics of the tumor.
3370691|NCT05155280|Experimental|Anorexia Nervosa patients|"30 patients with anorexia nervosa = 15 with moderate to high anxiety (STAI YB anxiety (STAI YB > 51) and 15 with low anxiety (STAI YB<51).~A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2."
3370692|NCT05155280|Placebo Comparator|Controls|15 healthy volunteers (control group) and a low level of anxiety trait (< 51) A TOBII eye tracker will be realised at Day 1. PET and MRI scans will be acquired at Day 2.
3370693|NCT05155267||Chronic Kidney disease participants (CKD)|CKD submitted to hemodialysis
3370694|NCT05155267||Controls|Healthy participants
3370697|NCT05155241|Experimental|Intervention|Participants will watch an online health promotion video tailored to their current stage of change related to SIV uptake once every two weeks for four times (at week 0, 2, 4, and 6)
3370698|NCT05155241|Active Comparator|Control|Participants will watch a same online video providing general advices related to SIV at week 0, 2, 4, and 6
3370699|NCT05155228|Experimental|Attachment Regulation and Competency|Weekly individual psychotherapy for 24 weeks using the Attachment Regulation and Competency intervention.
3370700|NCT05155228|Active Comparator|Treatment as usual|Weekly individual psychotherapy for 24 weeks.
3370701|NCT05155215|Experimental|IM19 CAR-T cells|
3370702|NCT05155202||Nicardipine|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Nicardipine.
3370703|NCT05155202||Urapidil|Major patients hospitalized in intensive care unit, with systolic hypertension, requiring administration of intravenous Urapidil.
3370704|NCT05155189|Experimental|C-CAR031|Autologous C-CAR031 administered by intravenous (IV) infusion
3370705|NCT05155176||Individuals with Alcohol Use Disorder|Participants who meet the criteria for Alcohol Use Disorder will complete six weeks of smartphone monitoring. During this monitoring period, they will also complete two three-consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
3370706|NCT05155176||Social drinkers|Participants who have a past year history of alcohol use and do not meet the criteria for Alcohol Use Disorder will complete two weeks of smartphone monitoring. During this monitoring period, they will also complete three consecutive days of intensive monitoring including more frequent smartphone surveys, saliva samples, heart rate monitoring, and an alcohol use monitor.
3370707|NCT05155163|No Intervention|Treatment as Usual|Treatment as usual for opioid use disorder
3370708|NCT05155163|Experimental|SC-POWR|Treatment as usual for opioid use disorder with the addition of CBT with possible stepped care to exercise and stress reduction
3370709|NCT05155150|Experimental|Intervention group|Providing patient-reported outcome: patients receive personalized information on expected quality of life one year after ICU during ICU admission (during a family meeting)
3370710|NCT05155150|No Intervention|Control group|Family meetings take place as usual.
3370711|NCT05155137|Experimental|Riskometer + Polypill|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
3370712|NCT05155137|Placebo Comparator|Riskometer + Placebo|the unit (cluster) will use the stroke riskometer and the patients will be randomized to use placebo polypill
3253761|NCT01417468|Experimental|CLSI - Known|Participants will be assigned to a specific learning group via the Canfield Learning Style Inventory (CLSI).
3253762|NCT01417468|Active Comparator|CLSI - Unknown|Participants will be assigned to a traditional learning group (Control).
3253763|NCT01417494|Experimental|Chemotherapy associated with bevacizumab|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2) associated with bevacizumab
3253764|NCT01417494|Active Comparator|Chemotherapy|Chemotherapy (FOLFIRI, FOLFOX, LV5FU2)
3253765|NCT01417507||Supportive care (neurocognitive assessment and MRI)|"Patients undergo neurocognitive assessment using the CogState Test battery (the DET, the IDN, the OCLT, and the GMLT) at baseline* and at 12, 24, 36, 42, 48, 54, and 60 months. Patients also complete the EORTC QOL-30, the BCM20, and the EQ-5D questionnaires at baseline*, at 12, 24, 36, 48, and 60 months afterwards, and before undergoing any further treatment. Patients are instructed to complete a seizure and medication diary during study.~Patients undergo MRI scans at baseline*, at 12, 24, 36, 48, and 60 months, and at the time of radiological, clinical, or neurological failure."
3253766|NCT01417520||ECD|ECD patients of any gender and ethnicity age 2-80 years are eligible to enroll in this protocol
3253767|NCT01417546|Experimental|1|NHS-IL12 escalating doses on a 4 week schedule (Completed).
3253768|NCT01417546|Experimental|2|NHS-IL12 escalating doses on a 2 week schedule
3253769|NCT01417546|Experimental|3|NHS-IL12 expansion group on a 4 week schedule (Completed).
3370713|NCT05155137|Experimental|No Riskometer + Polypill|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the active polypill (valsartan 80 + amlodipine 5 + rosuvastatin 10)
3370714|NCT05155137|No Intervention|No Riskometer + Placebo (Usual Care)|the unit (cluster) will not use the stroke riskometer and the patients will be randomized to use the placebo polypill = usual care
3253770|NCT01417572|Experimental|lidocaine|
3253771|NCT01417598|Experimental|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
3370715|NCT05155124|Experimental|Cetuximab and trifluridin tipiracil|Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
3370717|NCT05155098||secukinumab|Patients receiving secukinumab in real world practice
3370721|NCT05155072|Experimental|Sequence A|
3370722|NCT05155072|Experimental|Sequence B|
3370723|NCT05155072|Experimental|Sequence C|
3370724|NCT05155072|Experimental|Sequence D|
3370725|NCT05155072|Experimental|Sequence E|
3370726|NCT05155072|Experimental|Sequence F|
3253772|NCT01417598|Experimental|Gait and balance trainig + nordic walking|(only for Osteoporosis group)
3253773|NCT01417598|No Intervention|Control group|
3253774|NCT01417611|Experimental|i-scan-CE/SE|Study Group using i-scan SE and CE mode: i-scan-CE/SE group was explored whole colon from the cecum to the rectum with i-scan-CE 2+ and SE 2+ mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
3253775|NCT01417611|Experimental|i-scan-CE/SE/TE-c|Study Group using i-scan SE & CE mode as well as TE-c mode: i-scan-CE/SE/TE-c group was explored whole colon from the cecum to the rectum with i-scan CE2+, SE2+, TE-c mode. They had a chance to switch from i-scan to WL to perform polyp removal using cold biopsy or polypectomy
3253776|NCT01417624|Placebo Comparator|Control Group - Standard|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation. Patients will be randomised to one of two groups (1:1 randomisation)~Conventional LV lead placement - the LV lead will be placed according to standard techniques without knowledge of the patient's CMR findings"
3370731|NCT05155020|Experimental|AK120 regimen 1|
3370732|NCT05155020|Experimental|AK120 regimen 2|
3253777|NCT01417624|Active Comparator|Active CMR guided Arm|"This will be a randomised controlled unblinded prospective study recruiting patients in sinus rhythm with LBBB (QRS width ≥ 120ms) and a LV ejection fraction of below 35% who meet the current guidelines for CRT implantation.Patients will be randomised to one of two groups (1:1 randomisation):~CMR guided LV lead placement - an expert panel will decide pre-operatively the optimal branch of the coronary sinus for LV lead placement based on the presence of myocardial scar tissue and coronary sinus anatomy. The operator will informed as to the optimal vein to target for delivery of the LV lead. Should this be technically unfeasible (e.g. due to pacing considerations or stability of LV lead position), then the most suitable vein will be used at the time of implantation."
3370733|NCT05155020|Experimental|AK120 regimen 3|
3370734|NCT05155020|Placebo Comparator|Placebo|
3253778|NCT01417637|Active Comparator|low level laser|"In this group, the 890 nm diode laser (Ga As) Mustang 2000+, Russia) with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles.~Laser therapy for both the treatment and placebo groups will be applied on all painful muscles three times a week for four weeks."
3253779|NCT01417637|Placebo Comparator|Placebo|In Group 2 (placebo) the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
3370742|NCT05154981|Experimental|Partners in School with Education Communication Skills (ECS) Training|Parents and teachers in the experimental condition will receive Partners in School with communication training.
3370743|NCT05154981|Active Comparator|Partners in School without Education Communication Skills (ECS) Training|Parents and teachers in the control condition will receive Partners in School without communication training.
3253780|NCT01417650|Active Comparator|laser|In this group, the 890 nm diode laser (Mustang 2000+,Russia) will be used with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
3253781|NCT01417650|Placebo Comparator|placebo|In this group the low power laser will be applied with minimal dose that is very lower than the threshold necessary for therapeutic effects.
3253782|NCT01417663|Placebo Comparator|Alagebrium|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
3253783|NCT01417663|Other|Exercise training|"In this study there will be four different groups:~One Alagebrium 100 mg twice daily and exercise training 3x/week Two Placebo twice daily and exercise training 3x/week Three Alagebrium 100 mg twice daily and no exercise training Four Placebo twice daily and no exercise training"
3253784|NCT01417676|Experimental|Radiation|
3253785|NCT01417689|Active Comparator|Open-eyes|Patients in this arm are encourage to attempt eye drop instillation using the most commonly used technique that involves looking up, pulling inferior lid down and putting the drop in the inferior cul de sac.
3253786|NCT01417689|Experimental|Closed-eyes|Patients in this group are encouraged to attempt eye drop instillation with both eyes closed near the medial canthal region. After feeling contact with the drop on the skin the drop is expected to enter the eye when opening the eye and resuming blinking.
3253787|NCT01417702||Crohn´s disease - active|Patients in the active phase of the disease
3253788|NCT01417702||Crohn´s disease - quiescent|Patients in the quiescent phase of the disease
3370744|NCT05154968|Experimental|Sequence 1 (ABCD)|Participants will receive 1 millilitre (ml) subcutaneous (SC) injection of treatment A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at the potential of hydrogen (pH) 5.7) followed by treatments B (higher pain Room Temperature [RT] solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), C (lower pain refrigerated solution contains mannitol), and D (lower pain RT solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
3370745|NCT05154968|Experimental|Sequence 2 (BDAC)|Participants will receive 1 ml SC injection of treatment B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) followed by treatments D (lower pain RT solution contains mannitol), A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), and C (lower pain refrigerated solution contains mannitol) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
3370746|NCT05154968|Experimental|Sequence 3 (CADB)|Participants will receive 1 ml SC injection of treatment C (lower pain refrigerated solution contains mannitol) followed by treatments A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), D (lower pain RT solution contains mannitol), and B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7) in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
3370747|NCT05154968|Experimental|Sequence 4 (DCBA)|Participants will receive 1 ml SC injection of treatment D (lower pain RT solution contains mannitol) followed by treatments C (lower pain refrigerated solution contains mannitol), B (higher pain RT solution is a formulation matrix solution of an acidic solution containing citrate buffer and sodium chloride at pH 5.7), and A (higher pain refrigerated solution is a formulation matrix solution of an acidic solution citrate buffer and sodium chloride at pH 5.7), in the right upper quadrant, left upper quadrant, right lower quadrant, and left lower quadrant respectively using a prefilled autoinjector device.
3370748|NCT05154955|Experimental|10XB-101 Solution for Injection, 2.0%|Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
3253789|NCT01417702||Ulcerative colitis - active|Patients in the active phase of the disease
3253790|NCT01417702||Ucerative colitis - quiescent|Patients in the quiescent phase of the disease
3253791|NCT01417715||Crohn´s disease - active|Patients with Crohn´s disease in the active phase.
3253792|NCT01417715||Crohn´s disease - quiescent|Patients with Crohn´s disease in the quiescent phase.
3253793|NCT01417715||Ulcerative colitis - active|Patients with ulcerative colitis in the active stage.
3253794|NCT01417715||Ucerative colitis - quiescent|Patients with ulcerative colitis in the quiescent stage.
3370749|NCT05154955|Experimental|10XB-101 Solution for Injection, 3.0%|Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
3370750|NCT05154955|Experimental|10XB-101 Solution for Injection, 4.5%|Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
3370751|NCT05154955|Placebo Comparator|10XB-101 Vehicle Solution for Injection|Participants receive 10XB-101 Vehicle Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
3370752|NCT05154942|Experimental|DOXO+electroacupuncture|EA is given every day for the first three days before DOXO pumping, and EA is given when DOXO is pumped for 30 minutes each time
3370753|NCT05154942|No Intervention|Non-electroacupuncture|Compared to the experimental group without EA treatment
3253795|NCT01417754|Other|Toremifene|
3253796|NCT01417767|Experimental|CHG regimen|one course of CHG regimen (low-dose cytarabine, homoharringtonine and G-CSF priming)
3253797|NCT01417767|Active Comparator|Decitabine|one course of Decitabine (5-aza-deoxycytidine,Dacogen)
3253798|NCT01417793|Experimental|Smoking Cessation Program|
3253799|NCT01417819|Other|SMS reminder|SMS reminders four days and one day before their appointments
3253800|NCT01417832|Experimental|Treatment with Infiltrant/Adhesive|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
3253801|NCT01417832|Placebo Comparator|Placebo, placebo treatment|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with a placebo treatment: At baseline one caries lesion was cleaned with a microbrush for 30 seconds and the procedure was repeated after two minutes.
3253802|NCT01417845|Experimental|High Intensity Exercise|High intensity resistance and aerobic training
3253803|NCT01417845|Active Comparator|Moderate Intensity Exercise|Moderate intensity resistance and aerobic training
3253804|NCT01417858|Active Comparator|brimonidine 0.2%|
3253805|NCT01417858|Active Comparator|brimonidine 0.1%|
3253806|NCT01417871||case goup|Lifestyle counseling, ABC program
3253807|NCT01417871||control group|usual care
3253808|NCT01417884||ischemic heart disease|stable coronary artery disease, acute coronary syndromes
3253809|NCT01417884||non-ischemic heart disease|inflammatory heart disease, heart failure (non-ischemic), valvular heart disease
3370758|NCT05154903|Active Comparator|Citicoline|the Citicoline group will receive citicoline in continuous Iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks
3370759|NCT05154903|No Intervention|control|the control group will not receive citicoline
3370760|NCT05154890|Experimental|ACN00177 Cohort 1|Planned for 4 subjects ≥18 years of age dosing at Dose A weekly for a total of 4 doses
3370761|NCT05154890|Experimental|ACN00177 Cohort 2|Planned for 4 subjects ≥12 years of age dosing at Dose B weekly for a total of 4 doses
3370762|NCT05154890|Experimental|ACN00177 Cohort 3|Planned for 4 subjects ≥12 years of age dosing at Dose C weekly for a total of 4 doses
3253810|NCT01417897|Experimental|Insulin Glulisine: bolus injections before each main meal|Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.
3370763|NCT05154890|Experimental|ACN00177 Cohort 4|Planned for 4 subjects ≥12 years of age dosing at Dose D weekly for a total of 4 doses
3370764|NCT05154890|Experimental|ACN00177 Cohort 5|Optional cohort for 4 subjects ≥12 years of age dosing at Dose E weekly for a total of 4 doses
3370765|NCT05154877|Active Comparator|DMI5R|The subject will undergo two PET/CT scans, one on the DMI5R scanner and one on the OMNI scanner
3370766|NCT05154877|Active Comparator|DIQ5R|The subject will undergo two PET/CT scans, one on the DIQ5R scanner and one on the OMNI scanner
3370768|NCT05154838||Patients with Pilonidal Abcess|All adult (18+) patients presenting at surgical assessment unit requiring treatment for pilonidal abscess. Wounds will be drained, cleaned and packed as per usual clinical practice. Extra standard wound swabs will be collected for additional microbiological analyses. Control wound dressings will be placed on adjacent, unaffected area of skin for 24 hours.
3370769|NCT05154825||Spine Surgery Participants|Spine surgical candidates that will be receiving posterior only surgery for spinal deformity
3370770|NCT05154812|Experimental|Yang Yin Fu Zheng Jie Du therapy|
3370771|NCT05154812|Placebo Comparator|Routine medical care|
3253811|NCT01417897|Active Comparator|Insulin Aspart: bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.
3253812|NCT01417897|Active Comparator|Regular human insulin:bolus injections before each main meal|Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.
3253813|NCT01417910||Peripheral vascular disease|Subjects who have peripheral vascular disease
3253814|NCT01417923|Experimental|vitamin D|We enrolled 80 patients of the age 18-80 years suffering from chronic musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6 months. The 40 patients will receive daily doses of 4000 units of vitamin D for 6 weeks
3253815|NCT01417949|Active Comparator|Immediate arm|Immediate arm: ART should be initiated as soon as possible but no later than 3 days after initiation of OI treatment.
3253816|NCT01417949|Active Comparator|Deferred arm|Deferred arm: ART should be initiated after the completion of OI treatment which is achieved at the earliest at day 21 for PCP and at day 28 for TE. ART should be initiated no later than 6 weeks after initiation of OI treatment.
3253817|NCT01417962||Fetuses|Still birth and Termination of pregnancies
3370776|NCT05154786|Experimental|Early Mobilization and endurance training|Early Mobilization and endurance training for prolonged mechanical ventilator
3370777|NCT05154786|Active Comparator|Usual care|Weaning protocols, bed exercise, and early mobilization.
3370778|NCT05154773|Experimental|KidneyTIME|KidneyTIME is a self-directed digital intervention. It contains 26 animated videos, each 1-3 minutes in length, designed to address knowledge gaps and concerns about kidney transplantation and living donation that were identified in literature reviews, formative research, and video development studies as critical for optimal prospective kidney recipient and donor participation in LDKT. We chose 6 videos from the entire series to be delivered sequentially for a total duration of 13 minutes. After completing the proscribed videos and an immediate-post exposure survey, everyone then received a link to access all 26 videos centralized on a website where the videos were activated for sharing through various modalities, including text, email, Facebook, and Twitter. The website could be accessed using this link from any electronic device throughout the study. Prompts to use the intervention were sent once a week for 3 weeks and then monthly for 12 months.
3370779|NCT05154773|No Intervention|Usual Care|Routine educational materials from non-study sources through usual Transplant Center protocols including booklets, nurse communications, and the usual care video, a nurse-narrated power-point presentation outlining recipient and donor evaluation, surgery, and recovery processes and outcomes.
3370780|NCT05154760|Active Comparator|one on one video conference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of one on one interviews with video conference method once a week.
3253818|NCT01417962||Children|Includes Newborns, Infants and Children
3253819|NCT01417975|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants waking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise is defined as 40-68% of heart rate reserve (HRR). Heart rate (HR) will be monitored using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
3253820|NCT01417975|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively in a chair for 10 minutes. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) with regards to distraction effects and researcher contact.
3253821|NCT01417988|Experimental|Empiric TB treatment|Empiric initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
3370781|NCT05154760|Active Comparator|group videoconference|Pelvic floor muscle training, diaphragmatic breathing exercise, core strengthening exercise will continue for 8 weeks. Participants will be asked to practice the exercises at least 4 days in a week, and the program will be continued in the form of group interviews with video conference method once a week.
3370782|NCT05154747|Active Comparator|Continuous Therapy (CT) Control Group|The control group is a continuous daily oral combination ART consisting of dolutegravir (DTG), with a tenofovir (TFV) and lamivudine(3TC)/emtricitabine(FTC) backbone
3253822|NCT01417988|Active Comparator|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
3253823|NCT01418014||Infected Cohort|Perinatally HIV-infected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment, engaged in care with ART treatment history available.
3370783|NCT05154747|Experimental|Long Acting (LA) Injectable Group|The intervention group is a long-acting injectable, cabotegravir (CAB) LA and rilpivirine (RPV) LA given every 8-weeks after an optional 4-week oral lead-in period with oral cabotegravir and rilpivirine, and two loading doses separated by 4 weeks.
3370784|NCT05154734|Experimental|Belimumab|Belimumab will be intravenously administered with a dose of 10mg/kg on Days 0,14 and28, then every 28 days until week 48, with a final evaluation at week 52.
3370785|NCT05154721|Experimental|EXPE Group|The experimental group (EXPE Group) will receive the Mila-Learn game.
3370786|NCT05154721|Placebo Comparator|CONT Group|The control group (CONT Group) will receive the Mila-Placebo game.
3370787|NCT05154708||Patient Group - Phase 1|15 to 30 patients are expected in Phase 1 for the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
3370788|NCT05154708||Health Professionals Group - Phase 1|15 to 30 healthcare professionals are expected to participate in Phase 1 regarding the identification of needs and expectations in relation to a systematic electronic assessment of symptoms by the patients themselves
3370789|NCT05154708||Patient Group - Phase 2|50 à 60 patients were expected to test a systematic electronic assessment
3370790|NCT05154695|Active Comparator|A.therapeutic ultrasound group|Group A receives 1 MHz therapeutic ultrasound for 5 min at a frequency of 2-3 times per week at the painful upper trapezius muscle.
3253824|NCT01418014||Uninfected Cohort|HIV-uninfected adolescents from 7 years of age (7th birthday) up to but not including the 16th birthday at enrollment born to HIV-infected mothers.
3253825|NCT01418027|Experimental|Intensive exercise|The subjects receive an intensive exercise for 6 months and a subsequent conventional exercise for another 6 months.
3370791|NCT05154695|Active Comparator|B.prolotherapy group|Group B receives hypertonic prolotherapy at perimysium of upper trapezius muscle. The injectant is 5ml 5% dextrose solution.
3370792|NCT05154682|Active Comparator|Oxycodone Group (Control Group)|Patients will receive oxycodone as needed after surgery
3370793|NCT05154682|Active Comparator|Oxycodone+ Naproxen/Acetaminophen (Study Group)|each patient will receive oxycodone plus acetaminophen and naproxen for 2 weeks after surgery
3253826|NCT01418027|No Intervention|Lifestyle counseling|Subjects receive a general lifestyle counseling for 12 months
3253827|NCT01418027|Experimental|Regular exercise|Subjects receive conventional exercise for 12 months
3253828|NCT01418040||High risk prostate cancer|Histologically confirmed patients with high risk prostate cancer seen at Calvary Mater Newcastle.
3253829|NCT01418053|Experimental|Hot Cataplasm with Caraway Oil|
3253830|NCT01418053|Active Comparator|Hot Cataplasm with Olive oil|
3253831|NCT01418053|Active Comparator|Cold cataplasm with Olive oil|
3253832|NCT01418066|Placebo Comparator|Placebo|Tea decoction made of Graminis Flores abd Maidis stigmata.
3253833|NCT01418066|Experimental|Ayurvedic herbs|Tea decoction made of Murraya koenigii leaves, Punica granatum and Curcuma
3253834|NCT01418079|Experimental|PMS-3000|Human volunteers undergo oxygen desaturation in order to determine the accuracy of the device over a clinical range of oxygen saturations 70 - 100%.
3253835|NCT01418092|Placebo Comparator|Placebo|Capsules for oral administration
3253836|NCT01418092|Experimental|ALKS 37|Capsules for oral administration
3253837|NCT01418105|Active Comparator|Videofluroscopic swallow study (VFSS)|To investigate the swallowing ability of patients with neurologic problems
3253838|NCT01418105|Active Comparator|cervical spine isometric excercises|isometric exercises in patients with cervical spine scoliosis
3253839|NCT01418105|Active Comparator|Fiberoptic endoscopic esophageal study (FEES)|To investigate the anatomic structures during swallowing of patients with neurologic problems
3253840|NCT01418118|Experimental|Pressors|Epinephrine, Norepinephrine, Dobutamine, Dopexamine
3253841|NCT01418131|Active Comparator|Rectal tacrolimus|Active medications - Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml 3mls will be applied rectally twice a day
3253842|NCT01418131|Placebo Comparator|Rectal Placebo|Placebo 3ml applied rectally twice a day. Identical to Interventional agent expect for the lack of tacrolimus
3370796|NCT05154656||patients with early stage of liver fibrosis|
3253843|NCT01418144|Experimental|Transversus abdominis plane (TAP) block|Transversus abdominis plane (TAP) block with ropivacaine
3370797|NCT05154656||subjects with no liver fibrosis|
3370798|NCT05154643||patients with liver fibrosis|
3370799|NCT05154643||healthy controls|
3253844|NCT01418144|Placebo Comparator|Block with saline|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
3370800|NCT05154630|Experimental|TQB2858 injection|Participants will receive 3 mg/60 mg/600 mg/1200 mg/1800 mg single dose of TQB2858 injection on Day 1, iv (injection of vein), once every three weeks.
3370801|NCT05154617|Other|Standard surgical monitoring, along with the Flo Trac® system monitoring.|
3370802|NCT05154604|Experimental|Treatment group: SHR-A1921|
3370803|NCT05154591|Experimental|Bilateral Treatment|Intra-arterial injection of SVF cells into the kidneys.
3370804|NCT05154578|Experimental|Group 1: 4 week dose interval; 2 doses|Participants will receive one injection of placebo at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
3370805|NCT05154578|Experimental|Group 2: early intervention; 4 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of GBS-NN/NN2 at 26 (±1) weeks GA and one injection of placebo at 30 (±1) weeks GA
3370806|NCT05154578|Experimental|Group 3: early intervention; 8 week dose interval; 2 doses|Participants will receive one injection of GBS-NN/NN2 at 22 (±1) weeks GA, one injection of placebo at 26 (±1) weeks GA and one injection of GBS- NN/NN2 at 30 (±1) weeks GA
3370807|NCT05154578|Experimental|Group 4: single dose|Participants will receive one injection of placebo at 26 (±1) weeks GA
3253845|NCT01418157|Active Comparator|Acetazolamide|
3253846|NCT01418157|Placebo Comparator|Placebo|
3370808|NCT05154578|Placebo Comparator|Group 5: placebo|Participants will receive one injection of placebo at 26 (±1) weeks GA
3370811|NCT05154552|Experimental|group A/ routine physical therapy and PNF|"In group A, PNF based gait training (15 minutes) and conventional physical therapy (45 minutes) will be performed.~PNF exercises involved PNF pelvic patterns (pelvic interior elevation and posterior depression), PNF lower extremity D1 Flexion and PNF lower extremity D1 extension (Unilateral during 1st to 3rd week and bilateral from 4th week onwards). Exercises will progress from rhythmic initiation and then progress to slow reversal and agonistic reversal up to 6th week of therapy and continues until 12th week. Each exercise will be repeated for 10 to 20 times.~Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson's disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
3370812|NCT05154552|Active Comparator|group B/ routine physical therapy|"Conventional physical therapy (45 minute session) will be performed in group B.Conventional physiotherapy will be administered according to the European Physiotherapy guidelines for Parkinson disease.~Other exercises include:~Range of motion exercises~Stretching exercises~Upper and lower limb strengthening exercises"
3370813|NCT05154539|Experimental|Test Group 1 (TG1)|"TG1 participants are testing the new digital assessment routine in a private setting.~Audiology assistants in private hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The private hearing clinics also conduct hearing aid treatment for TG1 participants with simple hearing loss.~TG21 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
3370814|NCT05154539|Experimental|Test Group 2 (TG2)|"TG2 participants are testing the new digital assessment routine in a public setting.~Audiology assistants in public hearing clinics located in the Region of Northern Jutland in Denmark are performing the standardized examination packages. The public hearing clinics also conduct hearing aid treatment for TG2 participants with simple hearing loss.~TG2 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
3370815|NCT05154539|Active Comparator|Control Group 3 (CG3)|"CG3 participants will be assessed conventionally by a private practicing ENT specialist in the Region of Northern Jutland in Denmark at physical consultation in accordance with current Danish practice. CG3 participants with simple hearing loss can choose whether hearing aid treatment should be conducted in either a private or a public hearing clinic.~CG3 participants with complicated hearing loss or ear-related diseases are referred to the Department of Audiology at Aalborg University Hospital for further examination prior to treatment initiation."
3370819|NCT05154513||Cohort 1|Children living with perinatally-acquired HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the United States National Institutes of Health.
3259478|NCT01471210|Experimental|Part 3:Urelumab (BMS-663513) Tumor-specific Cohort Expansions|Enrollment of subjects of three specific tumor types [(colorectal cancer (CRC), head and neck squamous cell carcinoma (SCCHN), and B-Cell non-Hodgkin's lymphoma (B-NHL)] who will be treated at the Maximum Tolerated Dose (MTD) (or highest dose tested)
3259479|NCT01471210|Experimental|Part 4:Urelumab (BMS-663513) Cohort Expansion in B-NHL|Arm A and Arm B: Urelumab (BMS-663513) liquid administered intravenously on specified days exploring q3w and q6w dosing regimen
3370820|NCT05154500|Experimental|Biofortified Potato with iron or zinc ('A')|Women volunteers will consume biofortified ('A') for one day in zinc study, and 10 days in iron study Zinc study and a local non-fortified Peruanita potato variety ('B') in a randomized order (either A-B or B-A). The potatoes have significantly different (p<0.001) content of iron or zinc, but no significant differences in vitamin C or phenolics (p>0.05). Based on this study design, every woman is her own control.
3370821|NCT05154500|Placebo Comparator|Non Biofortified potato with iron or zinc ('B')|Women volunteers will consume no biofortified ('B') for one day in zinc study, and 10 days in iron study
3370822|NCT05154487|Experimental|Apelisib and Fulvestrant|alpelisib 300mg orally daily of each 28-day cycle fulvestrant 500mg IM on Day 1 and Day 15 of Cycle 1, then 500mg IM on Day 1 of each 28-day cycle.
3370823|NCT05154474||Standard|Standard follow-up MNA, IPAQ, SARC-F and SarQOL questionnaire
3370824|NCT05154461|Experimental|GLP-1 in relation to the 2 major BHB release sites|The magnitude of plasma GLP-1 following an OGTT (75g glucose per os) when beta-hydroxybutyrate (BHB) is released either at an upper gastrointestinal site (alginate encapsulation), or at distal gastrointestinal site (pea-protein encapsulation). BHB is given per-os in a single dose of 18g, plus 2 g encapsulation material; totally 20 g.
3253847|NCT01418170|Experimental|Two rcSMT group|A rcSMT will be performed to the C5-C6 segment. A thrust maneuver will then be given to the C5-C6 segment. A rotational inferior drop thrust maneuver will be performed. Immediately after the first rcSMT the subject will turn over on the chiropractic table to lie in the prone position for a post-rcSMT PPT measurement with the same algometer performed by the research assistant. These will be taken at 5-minute intervals. A second rcSMT will be performed at 30 minutes after the first rcSMT. The invention protocol will be repeated. The subject will turn over to the prone position for repeat PPT measurements at 5-minute intervals post-rcSMT for 30 mins. Once the subject has left the treatment area the clinician will mark on the treatment card whether the rcSMT was performed with or without cavitation for quality control purposes.
3370825|NCT05154448|Experimental|Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound|Non-Invasive Thermal Ablation of the Medial Branch Nerves using the Neurolyser XR High Intensity Focused Ultrasound device
3370826|NCT05154435|Active Comparator|Grup HYT|The group (GRUP HYT) to be treated with targeted fluid therapy will be monitored with a Mostcaretm (Vygon, VytechHealth, Padova, Italy) pulse contour hemodynamic monitor after arterial cannulation. Cardiacindex (CI), stroke volume variance (SVV), pulse pressure variance (PPV), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), oxygen delivery (Do2), arterial elastance (Ea) measurements and mean arterial pressure Every 5 minutes to be followed, fluid therapy will be planned in accordance with our algorithm.
3370827|NCT05154435|No Intervention|Grup KON|Fluid deficit due to fasting time will be calculated in accordance with the 4-2-1 rule for patients in Group KON. half of the calculated fluid volume in the first hour; the remaining half will be given at the 2nd and 3rd Hours. (4ml/kg/hr for the first 10 kilograms, 2ml/kg/hr for the second 10 kg, 1ml/kg/hr for each subsequent kilogram). Maintenance fluid will be considered as a medium-sized surgical trauma and will be given at 4 ml/kg/hr. Hemorrhages will be replaced with 3 times the blood loss with balanced crystalloid or 1 times HES.
3370828|NCT05154422||Normal body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with normal body fat determined by air displacement plethysmograph.
3370829|NCT05154422||Excess body fat cohort|Determining the general amount of lipolysis, circulating insulin and growth hormone, and muscle quality of a group of recreational female endurance athletes with excess body fat determined by air displacement plethysmograph.
3370830|NCT05154396|Experimental|Neratinib escalation 2 weeks（group A）|Neratinib: 120mg/ day for days 1-7, 160mg/ day for days 8-14, and then 240mg/ day to complete 1-year treatment, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
3370831|NCT05154396|Experimental|Neratinib escalation 4 weeks（group B）|Neratinib: 160mg/ day for days 1-14, 200mg/ day for days 15-28, and then 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer, or unacceptable adverse reactions within 1 year.
3370832|NCT05154396|Placebo Comparator|Neratinib standard dose control （group C）|"Neratinib: 240mg/ day for 1 year, or to tumor recurrence and metastasis, new breast cancer or unacceptable adverse reactions within 1 year.~Loperamide prophylaxis: 4mg three times daily on days 1-14 and 4mg twice daily on days 15-56, followed by as needed, not exceeding 16mg/ day."
3370833|NCT05154383|Experimental|High-Dose Quadrivalent Influenza Vaccine|One injection of the high-dose Efluelda vaccine will be given to the patient
3370834|NCT05154383|Active Comparator|Standard-Dose Quadrivalent Influenza Vaccine|One injection of the standard-dose Influvactetra vaccine will be given to the patient
3370835|NCT05154370||MS/CIS|Diagnosis of MS and CIS based on the 2017 McDonald MS diagnostic criteria.
3259480|NCT01471223||Patients receiving Belatacept in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving Belatacept at the time of transplantation
3370836|NCT05154370||ADEM|Diagnosis of ADEM based on the 2012 IPMSSG diagnostic criteria for ADEM
3370837|NCT05154370||MOGAD|Diagnosis of MOGAD based on the 2020 Chinese Expert Consensus.
3370838|NCT05154370||NMOSD|diagnosis of NMOSD according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.
3259481|NCT01471223||Patients receiving CNI in CTS|Patients receiving a 1st kidney-only transplant at a center participating in the CTS and receiving CNI at the time of transplantation
3259482|NCT01471236|Experimental|Agili-c bi-phasic implant|mini-arthrotomy
3259483|NCT01471262||Elderly|Patients more or equal to 70 years old
3259484|NCT01471262||Young|Patients less than 70 years old
3370839|NCT05154357|Experimental|Group 1|Half an hour before the first feeding hour, the infant's heart rate and oxygen saturation will be recorded. Then, he/she will be placed in the elastic sac, positioned and will be allowed to take a rest until the feeding hour for 30 minutes. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When the feeding time begins, the chronometer will be started and it will be stopped when feeding is completed. At the second feeding time, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding time, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
3370840|NCT05154357|Experimental|Group 2|Half an hour before the first feeding time of the infant, his/her heart rate and oxygen saturation will be recorded. Then, he/she will be positioned without performing any different application and will be allowed to take a rest until the feeding time. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped. At the second feeding hour, the infant's heart rate and oxygen saturation will be recorded half an hour before the feeding hour. Then, he/she will be placed in the elastic sac, positioned, and allowed to take a rest until the feeding hour. His/her physiological parameters will be recorded ten minutes before the feeding hour, during feeding and ten minutes after feeding. When feeding begins, the chronometer will be started and when it is over, the chronometer will be stopped.
3253848|NCT01418170|Sham Comparator|One scSMT + One rcSMT Group|A scSMT will be performed with the contact hand of the clinician resting lightly on the paraspinal area of the neck of the subject. The subject's head will be rotated to 45 degrees and supported by the clinician's forearm, lying on headpiece. A inferior drop thrust will be applied to the drop piece. After the first scSMT maneuver the subject will turn over on the chiropractic table to lie in the prone position for a post-scSMT PPT measurement. PPT measurements will be taken at 5-minute intervals for 30 minutes. A rcSMT will be performed 30 minutes after the first scSMT. The subject will turn over to the prone position for repeat PPT measurements in 5-minute intervals for 30 minutes post-rcSMT. Once the subject has left the treatment area the clinician will mark on the treatment card weather the scSMT was performed adequately without cavitation and whether a cavitation occurred with the rcSMT.
3253849|NCT01418183|Experimental|5ml 5% levobupivacaine|5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
3370841|NCT05154331||Women of reproductive age|Women 15-49 years of age
3370842|NCT05154318|Experimental|Pericapsular Nerve Group Block|30ml 0.3% Ropivacaine will be injected between psoas muscle and iliopubic eminence.
3253850|NCT01418183|Placebo Comparator|5ml normal saline|5ml for maxillary and mandibular branches of trigeminal nerve (total 10ml on controlled side)
3253851|NCT01418183|Experimental|2.5ml 5% levobupivacaine|2.5ml 5% levobupivacaine to both maxillary and mandibular branches of trigeminal nerve on experimental side. (total 10ml)
3253852|NCT01418222|Experimental|A|
3253853|NCT01418222|Active Comparator|B|
3370843|NCT05154318|Active Comparator|Fascia iliaca compartment block|30ml 0.3% Ropivacaine will be injected into fascia iliaca compartment.
3370844|NCT05154305|Experimental|Children 6 months post acute treatment|children and adolescents between 6 months and 8 years post acute cancer treatment
3370845|NCT05154292|Experimental|eHealth Emotion Regulation Skills|The intervention aims to develop competencies for emotional regulation through exposure and acceptance strategies for coping with circumstances that produce stress or emotional discomfort. The application has a series of mini-games that the user will overcome throughout a narrative, with different challenges and rewards
3370846|NCT05154292|No Intervention|Waiting List|He or she will not be exposed to the intervention but will remain on the waiting list and will complete the pre and post-measures.
3253854|NCT01418235|Experimental|Group 1: MVA-C + gp140/MF59|
3253855|NCT01418235|Experimental|Group 2: MVA-C + gp140/MF59|
3253856|NCT01418235|Experimental|Group 3: DNA-C2 + MVA-C|
3253857|NCT01418235|Experimental|Group 4: DNA-C2 + MVA-C + gp140/MF59|
3253858|NCT01418261|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization and maintained baseline anti-hypertensive medications
3253859|NCT01418261|Sham Comparator|Control group|Subjects go through renal angiogram and Subjects maintained baseline anti-hypertensive medications
3370847|NCT05154279|Active Comparator|intramyometrial Terlipressin|intramyometrial injection of Terlipressin in women undergoing laparoscopic myomectomy procedure
3370848|NCT05154279|Active Comparator|intramyometrial carbitocin|intramyometrial injection of Carbetocin in women undergoing laparoscopic myomectomy procedure
3370849|NCT05154279|Placebo Comparator|intramyometrial saline|intramyometrial injection of saline in women undergoing laparoscopic myomectomy procedure
3253860|NCT01418274|Experimental|Single arm|
3253861|NCT01418287||Hospitalized|Subjects who are hospitalized due to influenza-like illness
3253862|NCT01418287||Non-hospitalized|Subjects who are not hospitalized
3253863|NCT01418300|Active Comparator|sequential therapy|first five day amoxicillin+PPI later five day PPI+clarithromycin+metronidazole
3253864|NCT01418300|Active Comparator|conventional triple thearpy|PPI+amoxicillin+clarithromycin
3253865|NCT01418313||DCE-MRI|Magnetic resonance imaging (MRI) with and without FDA approved contrast agents: MRI is a non invasive imaging technique used to visualize the internal structure of the body in detail. The MRI machine is an oversized magnet that is always on. It will be used in this study to provide anatomical and functional (MRI with contrast) information about atherosclerotic plaques.
3259485|NCT01471275|Experimental|Jiangtangtiaozhi decoction|
3259486|NCT01471275|Active Comparator|metformin|
3259487|NCT01471288|Active Comparator|Group3|Normal controls
3259488|NCT01471288|Placebo Comparator|Group4|Normal controls
3259489|NCT01471288|Active Comparator|Group 1|Hypothyroid patients taking levothyroxin.
3259490|NCT01471288|Placebo Comparator|Group2|Hypothyroid patients taking levothyroxin
3370850|NCT05154266|Experimental|Mindfulness Programme|Participants randomized to the mindfulness programme were invited to complete a twelve-week programme called 'Taking it Further'.
3370851|NCT05154266|No Intervention|Waitlist Control|Participants randomized to the waitlist control were asked to carry on as usual and were offered the Taking it Further course at a later time. No data was collected when the waitlist control group took part in the TiF programme.
3370852|NCT05154253|Experimental|Device resisted gait training (treatment)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
3370853|NCT05154253|Experimental|Standard gait training (control)|We will conduct a randomized controlled trial (treatment vs. control) to compare functional outcomes following bilateral targeted ankle resistance training (2 visits/week for 12 weeks) vs. dose-matched standard functional gait training.
3370854|NCT05154253|Experimental|Comparison to Standard PT (within subjects control)|We will use a within-subject repeated measures design to compare both gait training groups to matched standard physical therapy.
3370855|NCT05154253|Experimental|Device assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
3370856|NCT05154253|Experimental|Passive brace assisted ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
3370857|NCT05154253|Experimental|No ankle aid ambulation|We will compare task capacity and performance with adaptive ankle assistance vs. standard ankle foot orthoses and vs. shod (no ankle aid).
3370858|NCT05154240|Active Comparator|INS018_055|oral doses of INS018_055_single dose; oral doses of INS018_055_multiple ascending dose over 10days.
3370859|NCT05154240|Placebo Comparator|Placebo|No active ingredient. Frequency similar to the 2 arms above.
3370860|NCT05154214||Adenotonsillectomy|Excision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques.
3370861|NCT05154214||Drug-induced sleep endoscopy directed surgery (DISE)|DISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE.
3370862|NCT05154201|Experimental|Dose escalation of ORIN1001 as a single agent|"Single-agent dose escalation in Chinese patients with advanced solid tumors. Nine dose groups: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 650 mg, 900 mg, 1200 mg, and 1500 mg orally in 21-day cycles.~A total of 27-54 evaluable patients are expected to be enrolled. However, the dose in the escalation phase is not limited to these dose groups, and the number of enrolled patients is not limited to 27-54."
3253866|NCT01418313||PET/CT and PET/MR|Positron emission tomography (PET)/ computer tomography (CT): PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. Nowadays PET imaging is most useful in combination with anatomical imaging, such as CT scanners, thereby PET scanners are now available with integrated high-end multi-detector row CT scanners. Because the two scans can be performed in immediate sequence during the same session and with the patient not changing position between the two scans, areas of abnormality on PET images can be directly correlated with anatomy on the CT images.
3253867|NCT01418313||PET/MR|Positron emission tomography (PET)/MRI: PET is a nuclear medicine imaging technique, which produces images of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on a biologically active molecule. To avoid the additional radiation deriving from the CT scan during PET/CT imaging, nowadays PET imaging can be paired with MR anatomical images.
3253868|NCT01418326||Sevoflurane|Sevoflurane exposure for radical cancer surgery
3253869|NCT01418326||Propofol|Propofol exposure for cancer surgery
3253870|NCT01418391|Experimental|morphine consumption|
3253871|NCT01418404|Experimental|Noxious TS in study A|Noxious TS in study A
3253872|NCT01418404|Active Comparator|Innocuous TS|Innocuous TS in study A
3253873|NCT01418404|Experimental|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
3253874|NCT01418404|Active Comparator|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
3253875|NCT01418404|Experimental|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
3253876|NCT01418404|Active Comparator|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
3253877|NCT01418430|Experimental|CHOP-daclizumab|
3253878|NCT01418456|Experimental|Active Antibiotic Group|Patients in the antibiotic group will remain on antibiotics until their foot ulcer heals or up to 20 weeks
3253879|NCT01418456|No Intervention|Non antibiotic group|
3253880|NCT01418469|Experimental|Caseinate protein intake|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3253881|NCT01418469|Experimental|Whey protein isolate intake|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3253882|NCT01418469|Experimental|Soy protein intake|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3253883|NCT01418469|Experimental|soy+BCAA protein intake|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
3253884|NCT01418495||Ancillary-Correlative (pharmacokinetics of ch14.18)|Patients undergo blood sample collection at baseline and during and after course 1, 3, or 5 of treatment for pharmacokinetic analysis. Some patients undergo blood sample collection at baseline and during and after two treatment courses (1 and 3, 1 and 5, or 3 and 5).
3253885|NCT01418508|No Intervention|low protein diet|Behavioral: low protein diet 0.6g of proteins per kilo of body weight per day
3259491|NCT01471314||Spontaneous migraine|
3370863|NCT05154201|Experimental|Dose escalation of ORIN1001 in combination with Standard of Care|ORIN1001 will be administered daily as a tablet in combination with standard of care. This arm of the study will be carried out in 8 different cancer indications, including advanced triple-negative breast cancer received ≥ 3 lines of treatment, postmenopausal ER+/HER2-advanced breast cancer received the 1 line of treatment, advanced hepatocellular carcinoma received 1/2 line of treatment, chemotherapy-naive castrate-resistant prostatic cancer, advanced pancreatic cancer received 1/2 line of treatment, platinum-resistant/refractory advanced ovarian cancer received ≥ 2 lines of treatment, non-small cell lung cancer received ≥ 2 lines of treatment, and esophageal cancer received ≥ 2 lines of treatment.
3253886|NCT01418508|Experimental|low protein diet plusα-keto acid|0.6g of proteins per kilo of body weight per day
3253887|NCT01418508|Experimental|very low protein diet plus α-keto acid|0.3g of proteins per kilo of body weight per day
3253888|NCT01418521|Active Comparator|Ringer-albumin|Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
3253889|NCT01418521|Experimental|Tetraspan|patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
3370864|NCT05154201|Experimental|Dose expansion of ORIN1001 as a single agent or in combination with Standard of Care|"After the recommended phase 2 dose of single-agent ORIN1001 is determined, a single-agent efficacy expansion study for advanced esophageal cancer, as well as a single-agent efficacy expansion study for advanced solid tumors with failure of standard treatments or no effective standard treatment.~After the recommended phase 2 dose of the combination treatment is determined, the efficacy expansion study of the combination treatment will be conducted in the corresponding 8 different indications."
3370865|NCT05153005||Talaromycosis|Participants: AIDS patients complicated with Talaromycosis. Intervention(s): To use the specific antigen of taloromyces marneffei which is mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and qPCR, dd-PCR and mass spectrometry identification in the diagnosis and efficacy evaluation of AIDS patients complicated with Talaromycosis.
3370866|NCT05153005||Pneumocystis pneumonia|Participants: AIDS patients complicated with Pneumocystis pneumonia Intervention(s)：To use (1,3)- β- D-glucan (G antigen) , qPCR, dd-PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies.
3370867|NCT05153005||Cryptococcus|Participants: AIDS patients complicated with Cryptococcus Intervention(s)：To use (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen(CrAg) serological detection, qPCR, DD PCR and mass spectrometry identification, to explore the methods of screening and early diagnosis strategies of disease.
3253890|NCT01418560|Experimental|renal sympathetic modification|Renal artery ablation to modify sympathetic activity in patients with chronic renal failure.
3253891|NCT01418560|No Intervention|Absolute medicine therapy|Maintenance of anti-renal failure medications only
3370875|NCT05144477|Experimental|FAID Fear Intervention|Partners of CA patients assigned to intervention will receive the ICU diary.
3370876|NCT05144477|No Intervention|Control condition - Usual Care|Partners of CA patients assigned to usual care will not receive the ICU diary.
3370879|NCT05140993|Experimental|extended support|providing extended emotional and orientation support
3370880|NCT05140993|No Intervention|common practice|The hospital routine clinical standard- not providing extended emotional and orientation support
3370881|NCT05137704||Participant With ADHD|The record available for ADHD participants in primary care-based electronic medical records in the CPRD database linked to secondary care based episodic claims data available in HES database will be assessed.
3370882|NCT05137327|Experimental|Classroom Behavior Support (CBS) Condition|"Consultants follow the problem-solving process used in the comparison condition and attempt to address barriers to integrity using the knowledge, skills, beliefs, or stress components in the CBS manual. Consultants conduct a Values Interview, so teacher values can be used in the individual goal setting and decision making process. Consultants are trained to (a) incorporate the teacher's values into the problem-solving process, (b) elicit change talk from teachers using techniques borrowed from Motivational Interviewing, and (c) engage in Socratic questioning and cognitive restructuring for beliefs that may be barriers to integrity (e.g., should statements). Enhanced performance feedback involves highlighting connections between teacher integrity and child outcomes and using this as a catalyst for a knowledge, skills, beliefs, or stress component. Consultants use change rulers to elicit motivation to achieve the stated goals."
3253892|NCT01418573|Experimental|Palaeolithic-type meal 1|
3253893|NCT01418573|Experimental|Palaeolithic-type meal 2|
3253894|NCT01418573|Placebo Comparator|The reference meal|
3253895|NCT01418638||30 Patients with MDD.|30 Patients aged 18-65, who were diagnosed with MDD according to the DSM-IV criteria.
3253896|NCT01418651|Experimental|Milnacipran|Drug
3253897|NCT01418664|Active Comparator|Study group|Each woman in above group will recieve in addition to routine ferrous sulphate and calcium lactate, 4000IU of vitamin D
3253898|NCT01418664|No Intervention|control group|Women in this group will recieve ferrous sulphate and calcium lactate
3253899|NCT01418677|Active Comparator|Cohort 1|
3253900|NCT01418677|Active Comparator|Cohort 2|
3253901|NCT01418677|Active Comparator|Cohort 3|
3253902|NCT01418690||Non-invasive near infra-red device (NIRS)|
3370883|NCT05137327|Active Comparator|Standard Problem Solving Comparison Condition|Consultation in the comparison condition follows a 5-step problem solving approach and provide brief performance feedback procedures that mirror (in duration, content, and process) best practice procedures (Gilbertson et al., 2007; Noell et al., 1997). The guiding principles for this condition are that the performance feedback portion of the session should be limited to 5 to 10 minutes and unless the teacher initiates discussion of other content, the problem solving should remain student-focused, rather than teacher-focused. Discussion on teacher values and beliefs, and attempts to facilitate change talk, are contra-indicated. If the teacher initiates discussion of knowledge, beliefs, or skills, the consultant may answer questions, but may not use strategies associated with Motivational Interview or Cognitive-Behavioral Therapy (CBT) or strategies in CBS condition. We have separate scripts and checklists for each condition.
3370884|NCT05137067|Other|Chemotherapeutic agent A (Docetaxel)|The patients with breast cancer will receive chemotherapeutic agent A
3370885|NCT05137067|Placebo Comparator|Chemotherapeutic agent A (Docetaxel) plus placebo|The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.
3370886|NCT05137067|Active Comparator|Chemotherapeutic agent A (Docetaxel) plus RaproCell|The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.
3370887|NCT05137067|Other|Chemotherapeutic agent B (Cisplatin)|The patients with lung cancer will receive Chemotherapeutic agent B
3370888|NCT05137067|Placebo Comparator|Chemotherapeutic agent B (Cisplatin) plus placebo|The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.
3370889|NCT05137067|Active Comparator|Chemotherapeutic agent B (Cisplatin) plus RaproCell|The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.
3259492|NCT01471327|Experimental|SB-240563, 10mg|IV, single dose at Day 1
3370890|NCT05137067|Other|Chemotherapeutic agent C (Docetaxel)|The patients with prostate cancer will receive Chemotherapeutic agent C
3370891|NCT05137067|Placebo Comparator|Chemotherapeutic agent C (Docetaxel) plus placebo|The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.
3370892|NCT05137067|Active Comparator|Chemotherapeutic agent C plus (Docetaxel) RaproCell|The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.
3370893|NCT05136443|Experimental|Preventative Treatment|Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.
3370894|NCT05135026|No Intervention|Control Group (CG)|Usual care
3370895|NCT05135026|Experimental|Intervention Group (IG)|In the intervention hospitals, we will perform USG additional 2 times during the 3rd visit of 24-26 weeks and 5th visit of 34 weeks (2 USG and even more USG if needed + additional 4 ANC + Health education; pictorial flip chart showing danger sign during pregnancy and potential risks for unnecessary caesarean delivery to increase awareness for safe delivery) for all the enolled pregnant mothers.
3370896|NCT05134584|Experimental|linaclotide|Patients in linaclotide group were given with oral, once daily 290 μg linaclotide for consecutively 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
3370897|NCT05134584|Active Comparator|lactulose|Patients in Lactulose group were given with oral, once daily 20 mL Lactulose for 4 weeks, along with once daily 20 mg omeprazole, three times daily 50 mg Itopride, for the first ten days of the treatment.
3370898|NCT05134415|Experimental|Product Use Sequence 1|Period 1 - RELX ENDS tobacco flavor 1 Period 2 - RELX ENDS tobacco flavor 2
3370899|NCT05134415|Experimental|Product Use Sequence 2|Period 1 - RELX ENDS tobacco flavor 2 Period 2 - RELX ENDS tobacco flavor 1
3370900|NCT05134415|Experimental|Product Use Sequence 3|Period 1 - RELX ENDS menthol flavor 1 Period 2 - RELX ENDS menthol flavor 2
3370901|NCT05134415|Experimental|Product Use Sequence 4|Period 1 - RELX ENDS menthol flavor 2 Period 2 - RELX ENDS menthol flavor 1
3370902|NCT05133726|Experimental|Text Message cluster|This arm will receive only daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together)
3370903|NCT05133726|Experimental|Text message with or without peer support|All individuals in this cluster will receive daily text message support for six months plus weekly text message over 6 weeks (six information text messages all together) with some selected members also receiving peer support for six months
3370904|NCT05133726|No Intervention|Control group|This group will only receive usual care plus weekly text message over 6 weeks (six information text messages all together) with provides information about community services
3370910|NCT05131425|Experimental|Cognitive Behavioral Intervention|The experimental condition is a CBT intervention which focuses on developing 1) emotion regulation skills, 2) somatic management skills individually tailored for sensory and regulatory needs; 3) cognitive strategies such as individualized helpful thoughts and mantras (I can do it); and 4) graded exposure (e.g., facing fears).
3370911|NCT05131425|Other|Treatment as Usual|The TAU condition will serve as the control condition and participants' medication use and outside therapies will be tracked monthly. Following completion of the 16-week wait period, the TAU group will be invited to enroll in FYF:ASD/ID.
3370912|NCT05129475|Experimental|Treatment A|Single oral dose of ritonavir at -12 hours prior to PF-07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fasted conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
3370913|NCT05129475|Experimental|Treatment B|Single oral dose of ritonavir at -12 hours prior to PF 07321332/ritonavir dosing, followed by single oral dose of PF-07321332/ritonavir under fed conditions. Ritonavir will continue to be dosed at 12 hours PF-07321332 dosing.
3370914|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic coils|Device: Splenic artery embolization with vascular embolic coils
3370915|NCT05128955|Active Comparator|Active Comparator: Splenic artery embolization with vascular embolic plugs|Active Comparator: Splenic artery embolization with vascular embolic plugs
3253903|NCT01418716|Experimental|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
3253904|NCT01418716|Active Comparator|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
3253905|NCT01418729|Active Comparator|Sorafenib plus Pravastatin|The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
3370918|NCT05127057|Experimental|PRIME Parkinson Care|PRIME Parkinson Care is a multi-component model of care comprising individual components: a) Case management b) Empowerment of patients and care givers c) Empowerment of healthcare professionals d) IT infrastructure.
3370919|NCT05127057|Placebo Comparator|Usual care|
3370920|NCT05124106|Experimental|Diagnostic ability of Raman spectrometry|Endoscopic Raman spectrometry during endoscopic bladder cancer surgery
3370923|NCT05119686|Experimental|Group 1|AR882 Dose 1 x 12 weeks
3370924|NCT05119686|Experimental|Group 2|AR882 Dose 1 x 2 weeks, then Dose 2 x 10 weeks
3370925|NCT05119686|Placebo Comparator|Group 3|AR882 matching placebo x 12 weeks
3253906|NCT01418729|Placebo Comparator|Sorafenib plus Placebo|The treatment received will be sorafenib 400 mg/12 h + placebo/24 h.
3253907|NCT01418742|Active Comparator|Doxycycline 100 mg BID oral use|
3370937|NCT05115838|Experimental|Islatravir 47 mg|Participants receive an ISL 47 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
3370938|NCT05115838|Experimental|Islatravir 52 mg|Participants receive an ISL 52 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
3370939|NCT05115838|Experimental|Islatravir 57 mg|Participants receive an ISL 57 mg implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
3370940|NCT05115838|Placebo Comparator|Placebo|Participants receive a placebo implant for approximately 52 weeks. A subset of participants will receive a second implant for 12 weeks after removal of the first implant.
3370941|NCT05109234|Experimental|Brivaracetam arm|Subjects in this arm will receive various brivaracetam doses as oral solution or film-coated tablet twice per day.
3370942|NCT05107674|Experimental|Phase 1a Dose Escalation|Multiple dose levels of NX-1607 to be evaluated; determination of MTD/Phase 1b recommended dose
3253908|NCT01418742|Placebo Comparator|Placebo 100 mg BID oral use|
3370943|NCT05107674|Experimental|Phase 1b Dose Expansion in platinum-resistant EOC|Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma
3370944|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced gastric/GEJ cancer|Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma
3259493|NCT01471327|Experimental|Placebo|Saline IV, single dose at Day 1
3259494|NCT01471327|Experimental|SB-240563, 75mg|IV, single dose at Day 1
3370945|NCT05107674|Experimental|Phase 1b Dose Expansion in HNSCC|Patients with recurrent, locally advanced, or metastatic HNSCC
3370946|NCT05107674|Experimental|Phase 1b Dose Expansion in unresectable or metastatic melanoma|Patients with Stage IVa, IVb, or IVc Melanoma
3370947|NCT05107674|Experimental|Phase 1b Dose Expansion in advanced NSCLC|Patients with Stage IV adenocarcinoma NSCLC
3259495|NCT01471327|Experimental|SB-240563, 250mg|IV, single dose at Day 1
3370948|NCT05107674|Experimental|Phase 1b Dose Expansion in mCRPC|Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA progression
3370949|NCT05107674|Experimental|Phase 1b Dose Expansion in mixed solid tumor cohort|Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or MSS CRC
3370950|NCT05107674|Experimental|Phase 1b Dose Expansion in DLBCL-RT|Patients with DLBCL-RT previously treated with at least 1 line of standard, systemic chemotherapy, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options
3370953|NCT05104307||Cardiac Performance System (NSR)|Subjects will wear Cardiac Performance System (CPS) non-invasive device during their standard echocardiogram
3370955|NCT05094934|Active Comparator|Normal renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
3370956|NCT05094934|Experimental|Mildly decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
3253909|NCT01418755|Experimental|platelet rich plasma injection|Fifty consecutive and strictly selected patients, affected by Grade II or III chondromalacia, underwent one year treatment (9 injections) with autologous PRP in a liquid form with 2,0 to 2,5-fold platelets concentration. Outcome measures included the Lysholm, Tegner, IKDC, and Cincinnati scores. Magnetic resonance imaging was used to evaluate cartilage thickness and degree of degeneration.
3253910|NCT01418768|Experimental|Rehabilitation|
3370957|NCT05094934|Experimental|Moderately decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
3370958|NCT05094934|Experimental|Severely decreased renal function|All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days
3253911|NCT01418781||Gout|Patients with ICD-9 for gout
3253912|NCT01418781||No Gout|Patients withOUT ICD-9 for gout
3370962|NCT05089435|Other|14-day EZYPRO and 24-hr Holter|Patients wear simultaneously 14- day continuous ECG moniter (EZYPRO) and 24-hr Holter monitor.
3253913|NCT01418781||Tophaceous gout|Patients with ICD-9 for tophaceous gout
3253914|NCT01418781||non-tophaceous gout|those with ICD-9 for gout other than the codes specific for tophaceous gout
3253915|NCT01418794|Active Comparator|Low dose rapamycin group|Concentration of rapamycin was 1.5%
3253916|NCT01418794|Experimental|High dose rapamycin group|Concentration of rapamycin is 2.5%
3370965|NCT05086419|Experimental|Exercise group|The exercise group will in addition to treatment as usual, receive sub-symptom threshold aerobic exercise for approx. 30 minutes 3-5x / week for 12 weeks. Sub-symptom threshold aerobic exercise is based on the individual patient's symptom threshold and will be between 80-90% of the maximum heart rate achieved during testing/BCTT. To ensure proper exercise dosage and progression, participants will be retested every 3 weeks. An experienced doctor and / or physiotherapist will carry out the testing and guide the participants in the content and dosage (duration, intensity, and frequency) of the sub-symptom threshold aerobic exercise/intervention.
3370966|NCT05086419|No Intervention|Treatment as usual group|"The treatment as usual group will receive assessment and treatment provided by a multidisciplinary outpatient rehabilitation team. Patients will undergo a medical examination and assessment of physical, cognitive and mental health and functioning, followed by individually adapted rehabilitation. The interdisciplinary team consists of a specialist in physical medicine and rehabilitation, neuropsychologist, occupational therapist, physiotherapist, and social worker. The main focus is on stabilizing the level of function in everyday life and gradual return to work and education.~Participants receive general advice on physical activity based on recommendations from the Norwegian Directorate of Health, but not specific guidance in sub-symptom threshold aerobic exercise and help with exercise dosage (frequency, duration and intensity)."
3370967|NCT05084053|Experimental|Cohort 1: TAK-771 for CIDP Participants|TAK-771 includes Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20). Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
3370968|NCT05084053|Experimental|Cohort 2: TAK-771 for MMN Participants|TAK-771 includes IGI 10% and rHuPH20. Participants will receive subcutaneous infusion of rHuPH20 solution at a dose of 80 U/g IgG first, followed by SC infusion of 10% IGI within 10 minutes of completion of the infusion of rHuPH20 solution, every 2, 3, or 4 weeks.
3253917|NCT01418807|Experimental|TRANSVAGINAL EXTRACTION|
3253918|NCT01418807|Active Comparator|TRANSUMBILICAL EXTRACTION|
3253919|NCT01418820|Experimental|Verum stimulation|repetitive transorbital alternating current stimulation (rtACS)
3259496|NCT01471327|Experimental|SB-240563, 750mg|IV, single dose at Day 1
3370973|NCT05075876|Experimental|Group 1 (SP-01-K)|Application of SP-01 manufactured by Site K (SP-01-K) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site A (SP-01-A) for 6 days
3370974|NCT05075876|Active Comparator|Group 2 (SP-01-A)|Application of SP-01 manufactured by Site A (SP-01-A) for 6 days followed by washout period for 21 days followed by application of SP-01 manufactured by Site K (SP-01-K) for 6 days
3370975|NCT05074030|Active Comparator|PNF|Participants in the PNF condition will receive normative feedback only on their alcohol use.
3370976|NCT05074030|Experimental|PFIcope+EMI|The 6-week PFIcope+EMI includes: 1) an in-person personalized feedback session to present feedback on problems with drinking to cope, discuss the individual's use of alcohol to cope, and generate coping skills messages to be used in the EMI intervention; 2) EMA to monitor affect, intention to drink, coping skills usage, alcohol use, drinking to cope post-discharge; 3) tailored text messages (EMI) based on EMA (individualized coping skills messages when NA and intention to drink are reported).
3370981|NCT05068921|Experimental|TQB2858|TQB2858 injection: once every 3 weeks, 1800mg each time, intravenous infusion. Until the disease progression or unbearable adverse events occur.
3370982|NCT05067868|Experimental|Replagal|Participants with fabry disease will receive Replagal 0.2 milligram per kilogram (mg/kg) intravenous infusion on Day 1 and every 2 weeks up to Week 51.
3370983|NCT05064943||Total Knee Replacement|Patients who have undergone total knee replacement
3370986|NCT05063565|Active Comparator|TheraSphere alone|Treatment with TheraSphere
3370987|NCT05063565|Experimental|TheraSphere followed by Durvalumab and Tremelimumab|TheraSphere followed by Tremelimumab plus Durvalumab administered once, then repeated administration of Durvalumab monthly up 18 months post randomization
3253920|NCT01418820|Sham Comparator|Placebo stimulation|compared to verum stimulation the same electrode montage set-up is used during placebo stimulation, except that placebo patients receive a minimal stimulation
3370989|NCT05060601|Experimental|Gracey micro-curettes|Subgingival mechanical debridement will be performed using an ultrasonic scaler with specific thin tips and Gracey micro-curette.
3370990|NCT05060601|Active Comparator|Standard Gracey curettes|Subgingival mechanical debridement will be performed using a conventional ultrasonic scaler and standard Gracey curettes.
3370991|NCT05059301|Experimental|RSVPreF3_Grp1 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and are followed up until the study end (Month 6).
3253921|NCT01418846||adult hematology patients|
3370992|NCT05059301|Experimental|RSVPreF3_Grp2 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and are followed up until the study end (Month 6).
3370993|NCT05059301|Experimental|RSVPreF3_Grp3 Group|Participants receive 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and are followed up until the study end (Month 6).
3370994|NCT05058092|Experimental|Intervention|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at the randomization day (D0)"
3253922|NCT01418846||pediatric patients age 5-18years|
3370995|NCT05058092|Other|Control|"The Remedee Solution consists of:~a wristband designed to deliver millimeter wave~a mobile application that allows the patient to follow his treatment sessions~a personalized support to improve patient adherence to the technology and to increase compliance and effectiveness of the treatment~The use of the Remedee Solution start at three months (M3) after randomization day"
3370998|NCT05052710|Experimental|Treatment Arm|Subjects will receive midazolam on Day 1 and AZD4831 once daily from Days 2 to 10, and AZD4831 plus midazolam on Day 11.
3371001|NCT05051293||male cirrhotic with hypotension|Patients with cirrhosis have decreased spontaneous vascular resistance leading to hypotension.
3371002|NCT05051293||male cirrhotic without hypotension|The concentration of estrogen in cirrhotic patients is thought to increase by fourfold compared to individuals without cirrhosis.
3371008|NCT05047770|Active Comparator|HZ/suSeq Group|Participants randomized to HZ/suSeq Group receive one mRNA-1273 booster dose administered at Day 1, followed by the first dose of HZ/su vaccine administered at Week 2 and the second dose of HZ/su vaccine administered at Week 10.
3371009|NCT05047770|Experimental|HZ/suCoAd Group|Participants randomized to HZ/suCoAd Group receive one mRNA-1273 booster dose co-administered with the first dose of HZ/su vaccine at Day 1, followed by the second dose of HZ/su vaccine administered at Week 8.
3371010|NCT05047770|Active Comparator|FluD-QIVSeq Group|Participants randomized to FluD-QIVSeq Group receive one mRNA-1273 booster dose at Day 1, followed by one dose of Flu D-QIV vaccine at Week 2.
3371011|NCT05047770|Experimental|FluD-QIVCoAd Group|Participants randomized to FluD-QIVCoAd Group receive one mRNA-1273 booster dose co-administered with one dose of Flu D-QIV vaccine at Day 1.
3253923|NCT01418846||adult pneumology patients|
3371014|NCT05043038||General Anesthesia Night Float|The residents will be followed over a three week period - one week prior to night float (baseline), the week of night float, and one week after night float (recovery).
3371017|NCT05039307|Experimental|Intervention group (Educational and motivational strategy)|The intervention group will be provided with a multi-component intervention entailing the following components distributed over the 24-months study: 4 individualized education sessions at the household, 4 group activities (2 group education sessions and 2 physical activity sessions) at the healthcare center, and 4 focus groups at the healthcare center as well. The motivational components of goal setting and the use of a pedometer will be incorporated in the individualized education sessions. Moreover, community activities will be incorporated in the second year of the study after exploring whether the activities are feasible and acceptable by the community. The topics covered by the intervention are healthy diet, physical activity, weight control strategies and knowledge and awareness of T2DM and GDM. Additionally, at baseline participants will be provided with a healthy lifestyle brochure with general recommendations.
3371018|NCT05039307|No Intervention|Comparison group (Basic educational strategy)|The comparison group will be limited to receive the healthy lifestyle brochure with general recommendations at baseline only.
3371022|NCT05030584|Active Comparator|Elinzanetant (BAY3427080)|Participants will receive 120 mg elinzanetant orally once daily.
3253924|NCT01418859||radiation therapy only|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive radiation therapy only. radiation therapy regimen: 3D-CRT pelvic radiation, 95%CTV DT 45Gy/25f. Radiation field include tumor bed and regional lymph nodes area. Upper border: branching of abdominal aorta. The radiation fields go down along the iliac vessels (including regions of 7mm out of the iliac vessels) and include the tumor bed region. Lower border: the inferior margin of obturator foramen.
3253925|NCT01418859||concurrent chemoradiotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy. radiation therapy regimen is the same with radiation therapy only group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy.
3371023|NCT05030584|Placebo Comparator|Placebo|Participants will receive matching placebo orally once daily.
3371024|NCT05030428|Experimental|Inclisiran sodium|Subcutaneous injection
3371025|NCT05030428|Placebo Comparator|Placebo|Subcutaneous injection
3259497|NCT01471366|Active Comparator|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products
3371026|NCT05028608|Experimental|Period 1|Fixed treatment sequence starting with 2 single oral doses of midazolam and a single dose of elinzanetant.
3371027|NCT05028608|Experimental|Period 2|Up titration of carbamazepine over 4 days (dose 1, 2, 3) continued by fixed dose 3 of carbamazepine prior to administration of midazolam / elinzanetant, followed by carbamazepine administration.
3253926|NCT01418859||concurrent and additional chemotherapy|Including criteria: cervical cancer patients after surgery with big tumor, deep invasion or tumor thrombi in the vascular system, but without lymph invasion, positive surgery margin or parametrium invasion. Patients in this group receive concurrent chemotherapy and radiation therapy, and additional chemotherapy after concurrent treatment. radiation therapy regimen is the same with radiation therapy group. Chemotherapy regimen: Topotecan (1.5mg /m2 d1,2, 1mg d3) and Cisplatin (25mg /m2 d1-3). Chemotherapy will be carry out in the 2nd and 6th week of radiation therapy. Additional chemotherapy regimen is the same with concurrent chemotherapy, and will be carry out in the 4th and 8th week after radiation therapy.
3253927|NCT01418872|Active Comparator|Healthy Breakfast|"The activity will be performed at the school dining hall, scheduling 1 hour for breakfast,within the school hours, with maximum 50 children per turn It involves placing a table mat, a cup, a plate and two slices of bread per child, plus 1-liter bottle of milk for each four children and 1-liter bottle of oil for each twelve. The dining hall will be all set up before the students come in.~Participatory lesson : Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, The role of dairy products at breakfast,The role of fruits at breakfast, Importance of exercise for cardiovascular health, The role of unhealthy habits: sedentary lifestyle.~The students will be invited to take the table mat and the cup, in which is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity.~A pamphlet of the NAOS strategy will also be delivered."
3259498|NCT01471366|Active Comparator|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
3371040|NCT05021081|Experimental|TEST/CONTROL|For Phase 2, eligible subjects that are enrolled will be randomized to the Test/Control contralateral sequence.
3371041|NCT05021081|Experimental|CONTROL/TEST|For Phase 2, eligible subjects that are enrolled will be randomized to the Control/Test contralateral sequence.
3371042|NCT05019872|Active Comparator|Penne hard|20 g penne cooked for 7 minutes
3371043|NCT05019872|Active Comparator|Penne soft|20 g penne cooked for 20 minutes
3371044|NCT05019872|Active Comparator|Carrot hard|50 g diced carrot cooked for 2 minutes
3371045|NCT05019872|Active Comparator|Carrot soft|50 g diced carrot cooked for 20 minutes
3371046|NCT05019872|Active Comparator|Penne hard + sauce|20 g penne cooked for 7 minutes + 10 g tomato sauce
3371047|NCT05019872|Active Comparator|Penne soft + sauce|20 g penne cooked for 20 minutes + 10 g tomato sauce
3371048|NCT05019872|Active Comparator|Carrot hard + sauce|50 g diced carrot cooked for 2 minutes + 10 g tomato sauce
3371049|NCT05019872|Active Comparator|Carrot soft + sauce|50 g diced carrot cooked for 20 minutes + 10 g tomato sauce
3371050|NCT05019872|Active Comparator|Penne hard + carrot hard + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
3259499|NCT01471366|Active Comparator|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
3259500|NCT01471366|Active Comparator|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
3371051|NCT05019872|Active Comparator|Penne hard + carrot soft + sauce|20 g penne cooked for 7 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
3371052|NCT05019872|Active Comparator|Penne soft + carrot hard + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 2 minutes + 20 g tomato sauce
3371053|NCT05019872|Active Comparator|Penne soft + carrot soft + sauce|20 g penne cooked for 20 minutes + 50 g diced carrot cooked for 20 minutes + 20 g tomato sauce
3371054|NCT05017662|Other|Data collection|
3371055|NCT05017584|Experimental|Hyperbaric bupivacaine 10.5mg|
3371056|NCT05017584|Experimental|Hyperbaric bupivacaine 12mg|
3371057|NCT05017584|Experimental|Hyperbaric bupivacaine 13.5mg|
3371058|NCT05017584|Experimental|Hyperbaric bupivacaine 15mg|
3371059|NCT05017090|Sham Comparator|Group N|The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
3371060|NCT05017090|Experimental|Group M-TAPA|After tracheal intubation, a high-frequency linear probe will be placed in the sagittal direction at the 10th costal margin, and transversus abdominis, internal oblique, and external oblique muscles will be identified. A block needle will be inserted with in-plane technique and 25 ml 0.25 bupivacaine will be applied to the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
3371061|NCT05016687|Experimental|Experimental Part I Cohort 1-5: CUR-N399|Healthy subjects 18-55 years will receive single ascending doses of CUR-N399. Planned doses for respective Cohorts: Cohort 1: 2.5 mg, Cohort 2: 7.5 mg, Cohort 3: 17.5 mg, Cohort 4: 35 mg, Cohort 5: 50 mg.
3371062|NCT05016687|Placebo Comparator|Experimental Part I Cohort 1-5: Placebo|Healthy subjects will receive Placebo to match treatment of CUR-N399.
3371063|NCT05016687|Experimental|Experimental Part IIa Cohort 1-3: CUR-N399|Healthy subjects 18-55 years will receive multiple ascending doses of CUR-N399 during a 7-day period. Planned doses for respective Cohorts: Cohort 1: 10 mg/day, Cohort 2: 25 mg/day, Cohort 3: 50 mg/day.
3371064|NCT05016687|Placebo Comparator|Experimental Part IIa Cohort 1-3: Placebo|Healthy subjects 18-55 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
3371065|NCT05016687|Experimental|Experimental Part IIb: CUR-N399|Healthy subjects >/= 65 years will receive multiple ascending doses of CUR-N399 during a 7-day period. The dose to be administered will determined based on safety results in Part IIa.
3371066|NCT05016687|Placebo Comparator|Experimental Part IIb: Placebo|Healthy subjects >/= 65 years will receive Placebo to match CUR-N399 treatment during a 7-day period.
3371067|NCT05015439|Experimental|Cannabidiol|Participants will receive cannabidiol, starting at 100 mg twice daily, and increased to 200 mg twice daily by week 3. This arm will last six weeks.
3371068|NCT05015439|Placebo Comparator|Placebo|Participants will receive six weeks of placebo.
3253928|NCT01418872|Experimental|Didactic concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
3371080|NCT05006352|Experimental|DNL343 (High Dose)|
3371081|NCT05006352|Experimental|DNL343 (Low Dose)|
3371082|NCT05006352|Placebo Comparator|Placebo|
3371083|NCT05005897|Experimental|Screening - treatment|From 6 weeks of age, infants will be screened for elevated plasma total homocysteine concentrations. Those who have a concentration above the defined cut-off will be treated with cobalamin (vitamin B12).
3371084|NCT05005897|No Intervention|Control|The control-group sample will be stored and analyzed when the child is 12 months old. Those with elevated tHcy will contribute to the control group.
3371085|NCT05005026|Active Comparator|Virtual reality (VR) game 1|Participants will be asked to play a virtual reality game twice a day for 10 days.
3371086|NCT05005026|Active Comparator|Virtual reality (VR) game 2|Participants will be asked to play a virtual reality game twice a day for 10 days.
3371087|NCT05004272|Active Comparator|Massage|
3371088|NCT05004272|Active Comparator|Gymnastics|
3371089|NCT05004272|Placebo Comparator|Lecture|
3371090|NCT04989803|Experimental|KITE-363|"Phase 1a (Dose Escalation): Participants with r/r large B-cell lymphoma will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-363 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-363.~Phase 1b (Dose Expansion): After completion of dose escalation, additional participants with r/r B-cell lymphoma across different disease indications will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose of KITE-363 at 1 or more dose-level deemed to be tolerable."
3371095|NCT04984317|Experimental|Botox Injection|One-time injection of 100U BOTOX (onabotulinumtoxin A) into the fundus of the bladder under direct visualization via cystoscopy.
3253929|NCT01418885||SIVD,VaD|vascular disease in patients with SIVD
3371097|NCT04981587|Experimental|Intervention group|This is the group that receives strength exercise in addition to usual treatment
3371098|NCT04981587|Other|Control group|This is the group that only receives usual treatment
3253930|NCT01418885||SIVD,VCIND|vascular cognitive impairment no dementia in patients with SIVD
3253931|NCT01418885||normal controls|normal elderly controls
3371100|NCT04980391|Experimental|RSV_MAT Group|Maternal participants randomized to the RSV_MAT Group receive a single dose of the RSV MAT vaccine administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
3371101|NCT04980391|Placebo Comparator|Control Group|Maternal participants randomized to the Control Group receive a single dose of placebo administered intramuscularly between 24 and 36 weeks of gestation (Day 1) and are followed up until 180 days post-delivery.
3253932|NCT01418898|Experimental|Nutrient Fortified Beverage|
3253933|NCT01418898|Placebo Comparator|Control|
3253934|NCT01418911||diabetes type 2|type 2 diabetes patients 40-70 years of age hebrew speaking members of maccabi healthcare services
3253935|NCT01418950|Active Comparator|Control group|The control group will receive standard verbal counseling regarding outcome of premature infants
3253936|NCT01418950|Experimental|Study Group|Study Group will receive gestational age specific written information prior to receiving standard verbal counseling about outcome of premature infants.
3253937|NCT01418963|Experimental|Active|
3253938|NCT01418963|Placebo Comparator|Placebo|
3253939|NCT01418976|Experimental|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
3253940|NCT01418989|Experimental|1|
3253941|NCT01418989|Experimental|2|
3253942|NCT01419002|Experimental|Neoadjuvant RTx|
3253943|NCT01419002|Active Comparator|Surgery|
3253944|NCT01419041|Other|Arm A|CLCR: Creatinine clearance
3253945|NCT01419041|Other|Arm B|CLCR: Creatinine clearance
3253946|NCT01419067|Other|Craniopharyngioma Patients|"Craniopharyngioma patients will have limited surgery and a 5mm clinical target volume margin in combination with proton therapy. Proton therapy will be indicated for patients with diagnosed craniopharyngioma who are not treated with radical surgery (gross-total resection). Patients who have had radical surgery or limited surgery prior to enrollment on this study and have no evidence of tumor will be observed for 5 years.~Participants receive ^1^8F-fluorodeoxyglucose and ^1^1C-methionine will be given to aid in tumor visualization."
3253947|NCT01419093|No Intervention|5A Communication|Behavioral: 5 A intervention for physical activity
3371106|NCT04976634|Experimental|Pembrolizumab + Belzutifan + Lenvatinib|Participants will receive pembrolizumab 400 mg PLUS belzutifan 120 mg PLUS lenvatinib 20 mg (For HCC: 8 mg [body weight <60kg] or 12 mg [body weight ≥ 60 kg]). Pembrolizumab will be administered via intravenous (IV) infusion once every 6 weeks (Q6W) for a maximum of 18 doses (approximately 2 years). Belzutifan and lenvatinib will be administered orally once daily (QD) until progressive disease or discontinuation.
3371107|NCT04975256|Experimental|Dose escalation|Dose escalation of MRTX849 and BI 1701963 to determine maximum tolerated dose in combination
3371108|NCT04975256|Experimental|Dose expansion|Expansion cohorts in NSCLC and CRC patients to ensure sufficient safety experience, pharmacokinetic information, and early evidence of clinical activity of MRTX849 in combination with BI 1701963
3371109|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD1222|Previously vaccinated with AZD1222, dosing on day 1
3371110|NCT04973449|Other|ChAdOx1-S booster: one dose of AZD2816|Previously vaccinated with AZD1222, dosing on day 1
3371111|NCT04973449|Other|mRNA booster: one dose of AZD1222|Previously vaccinated with an mRNA vaccine, dosing on day 1
3371112|NCT04973449|Other|mRNA booster: one dose of AZD2816|Previously vaccinated with an mRNA vaccine, dosing on day 1
3371113|NCT04973449|Other|2 doses of AZD1222, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
3371114|NCT04973449|Other|2 doses of AZD2816, 4 weeks apart|Previously unvaccinated. First dose day 1, second dose day 29
3371115|NCT04973449|Other|2 doses of AZD2816, 12 weeks apart|Previously unvaccinated. First dose day 1, second dose day 85
3253948|NCT01419106|No Intervention|Control|This arm of the study will NOT receive point of care ultrasound. They will receive all other standard care implemented during their visit to the ED (currently, ultrasound is NOT standard of care). The same blood tests will be done in both groups, as this will offer a means of comparing physiological changes between the two arms.
3253949|NCT01419106|Experimental|Ultrasound|This group WILL receive point of care ultrasound. The protocol they will receive is the ACES protocol (described above).
3371116|NCT04973449|Other|one dose of AZD1222 + one dose AZD2816, 4 weeks apart|Previously unvaccinated. Dose of AZD1222 on day 1, dose of AZD2816 on day 29
3371117|NCT04971642|Experimental|Ultrasound scanning|"The subjects recruited are existing patients of the Orthodontic Clinic - Oral Health Clinic-Dentistry, University of Alberta. An intraoral ultrasound scanning will be done on the buccal side of the upper and lower incisor/canine/premolar/molar teeth for a total of sixteen (16) teeth (four(4) teeth in each of the four quadrants) of these subjects.~The ultrasound scans will be done separately by a research assistant not involved in patient care. The whole procedure for ultrasound scanning and data storage will take about 25-30 min including 3-5 min preparation time and 22-25 min of data acquisition and storage time."
3253950|NCT01419119|Experimental|Group 1|Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
3371122|NCT04966013|Active Comparator|RD-X19 Device, Dose A|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
3371123|NCT04966013|Active Comparator|RD-X19 Device, Dose B|RD-X19. Investigational device that uses safe electromagnetic energy to target the oropharynx.
3371124|NCT04966013|Sham Comparator|Sham Device|Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro.
3371128|NCT04960215|Active Comparator|Coenzyme Q10|
3371129|NCT04960215|Placebo Comparator|Placebo|
3253951|NCT01419119|Experimental|Group 2a|Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
3253952|NCT01419119|Experimental|Group 2b|Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
3253953|NCT01419119|Experimental|Group 3|Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L
3371130|NCT04959981|Experimental|Dose Escalation (Part 1): ERAS-007 plus osimertinib|ERAS-007 will be orally administered in combination with osimertinib to study participants with EGFRm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
3253954|NCT01419132|Placebo Comparator|High doses furosemide|administration of furosemide alone
3253955|NCT01419132|Experimental|HSS plus furosemide|administration of hypertonic saline solution plus high doses of furosemide bid
3371131|NCT04959981|Experimental|Dose Escalation (Part 2): ERAS-007 plus sotorasib|ERAS-007 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
3371132|NCT04959981|Experimental|Dose Escalation (Part 3): ERAS-601 plus sotorasib|ERAS-601 will be orally administered in combination with sotorasib to study participants with KRAS G12Cm NSCLC in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.
3253956|NCT01419145|Experimental|Multimodal intervention|
3253957|NCT01419145|Active Comparator|Standard Care|
3371133|NCT04959981|Experimental|Dose Expansion (Part 4): ERAS-007 plus osimertinib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 1) in combination with osimertinib to study participants with EGFRm NSCLC.
3253958|NCT01419210|Experimental|Complementary and Alternative Medicine (CAM) therapies|This pilot program attends to the need for appropriate patient-centered interventions that integrate CAM with traditional care to maximize both quantity and QOL for women with ovarian cancer.
3253959|NCT01419223||Consent to participate (Group 1)|Active military and veterans who consent to participate in an INTRuST PTSD or TBI research trial.
3253960|NCT01419223||Decline to participate (Group 2)|Active military and veterans who decline to participate in an INTRuST PTSD or TBI research trial.
3371134|NCT04959981|Experimental|Dose Expansion (Part 5): ERAS-007 plus sotorasib|ERAS-007 will be orally administered at the recommended dose (as determined from Part 2) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
3371135|NCT04959981|Experimental|Dose Expansion (Part 6): ERAS-601 plus sotorasib|ERAS-601 will be orally administered at the recommended dose (as determined from Part 3) in combination with sotorasib to study participants with KRAS G12Cm NSCLC.
3371139|NCT04957498|Active Comparator|FBT|Family Based Treatment (FBT) includes up to 15 session (50-60 minutes) with a trained therapist.
3371140|NCT04957498|Experimental|FBT-GSH|Family Based Treatment Guided Self-Help (FBT-GSH) includes an online website with educational videos, readings, discussion groups, and journals. Parents assigned to this arm will have up to 12 coaching sessions (20-30 minutes) with a trained therapist.
3371142|NCT04950075|Experimental|INBRX-109|IV every three weeks
3253961|NCT01419262|Experimental|2000 IU per day vitamin D|
3253962|NCT01419262|Active Comparator|400 IU per day vitamin D|
3371143|NCT04950075|Placebo Comparator|Placebo|IV every three weeks
3371144|NCT04941768||Avelumab + Axitinib|There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.
3371145|NCT04940234|Experimental|Black Expert|Survey respondents are exposed to a Black person wearing expert attire.
3253963|NCT01419288|Active Comparator|No Body weight support|
3371146|NCT04940234|Experimental|Black Layperson|Survey respondents are exposed to a Black person wearing layperson's attire.
3371147|NCT04940234|Experimental|White Expert|Survey respondents are exposed to a white person wearing expert attire.
3371148|NCT04940234|Experimental|White Layperson|Survey respondents are exposed to a white person wearing layperson's attire.
3253964|NCT01419288|Experimental|Body weight support|
3253965|NCT01419327||Group 1|Drug (incl. Placebo)
3253966|NCT01419353|Experimental|Follicular Estrogen, Antagonist, IVF|Follicular Estrogen in Antagonist IVF protocol
3253967|NCT01419353|Active Comparator|long IVF protocol|long IVF protocol
3253968|NCT01419379||1|
3253969|NCT01419392|Experimental|Sildenafil citrate|
3253970|NCT01419392|Placebo Comparator|placebo|
3253971|NCT01419405|Experimental|Pregabalin/placebo|
3253972|NCT01419405|Active Comparator|placebo/remifentanil|
3253973|NCT01419405|Placebo Comparator|placebo/placebo|
3253974|NCT01419405|Experimental|Pregabalin/Remifentanil|
3371158|NCT04934800||Cladribine|
3253975|NCT01419418||Peripheral Arterial Disease (PAD)|This is a longitudinal observational study. There were no interventions administered.
3253976|NCT01419431||Colon cancer patients|Laparoscopic resection
3253977|NCT01419444|Active Comparator|Traditional, Onsite Treatment|Onsite treatment using airflow exercises. Patients will receive face-to-face treatment with the research speech pathologist two times per week.
3253978|NCT01419444|Experimental|Telemedicine Treatment|Participants will receive treatment via telemedicine at select AHEC sites around the state of Arkansas. Treatments will occur twice per week with the research speech pathologist.
3253979|NCT01419457|Experimental|Group 1|Normal hepatic function
3253980|NCT01419457|Experimental|Group 2|Mild hepatic impairment
3371159|NCT04934670|Experimental|T-Guard|Participants will be administered four doses of T-Guard intravenously for a 4-hour period every other day
3371160|NCT04934670|Active Comparator|Ruxolitinib|Participants will take ruxolitinib twice daily for continuous daily dosing
3371164|NCT04930263|Experimental|Aerobic exercise|"Behavioral: walking exercise~The intervention was 24 weeks walking intervention program with moderate-intensity, 5 sessions a week for 30 minutes per section~individualized education~telephone and social media counselling~booklet guidance"
3371165|NCT04930263|Active Comparator|control group|Given routine care and life health manual for the participants.
3253981|NCT01419457|Experimental|Group 3|Moderate hepatic impairment
3253982|NCT01419457|Experimental|Group 4|Severe hepatic impairment
3371173|NCT04925180||Physicians|Physicians who have recently prescribed (e.g., within previous 12 months) CPA monotherapy will be invited to complete a brief web-based questionnaire regarding their knowledge of the revised summary of product characteristics (SmPC) and the direct healthcare professional communication (DHPC).
3371174|NCT04924660|Experimental|TXA127|An investigational peptide agonist of Mas receptors.
3371175|NCT04924660|Experimental|TRV027|An investigational peptide biased agonist of the AT1 receptor.
3371176|NCT04924660|Placebo Comparator|Placebo|"NaCl 0.9% infused to match the duration of the agent for TXA127, TRV027, and APN01.~Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included."
3253983|NCT01419470|Experimental|YHD1044 I|
3253984|NCT01419470|Experimental|YHD1044 III|
3253985|NCT01419470|Experimental|YHD1044 V|
3253986|NCT01419483|Experimental|Ketogenic diet|Diet designed to maintain elevated ketone levels during therapy
3253992|NCT01419587|Experimental|Ketogenic diet|Diet formulated to maintain elevated ketones during therapy
3253993|NCT01419600|Experimental|Group 1 - 4, single ascending dose AZD 8683|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
3253994|NCT01419600|Placebo Comparator|Group 1-4 single ascending dose Placebo|Subjects will participate in 1 of 4 groups. In each group, 6 subjects will receive AZD8683 and 2 subjects will receive placebo.
3253995|NCT01419613|Experimental|Motivational Interviewing|
3253996|NCT01419613|Active Comparator|Physical Activity Counseling|
3253997|NCT01419652|Active Comparator|continue hypglycemic meds|
3253998|NCT01419652|No Intervention|control - hold drug|
3253999|NCT01419678|Experimental|'collection of blood samples for PK testing'|collection of PK samples around a dosing of Posaconazole
3254000|NCT01419691|Experimental|Phase 2 Dose|Auranofin 6 mg orally in the morning / 6 mg orally in the evening
3254001|NCT01419704|Experimental|Hemoglobinopathies diagnosed patients|Recipients diagnosed with Hemoglobinopathies are treated with an enriched hematopoetic stem cell infusion from living donor bone marrow
3254002|NCT01419730|Active Comparator|Vitamin D3 50,000 IU|Vitamin D3 50,000 IU: Patients will be assigned to receive a daily multivitamin, calcium supplement and 50,000 IU/week of vitamin D for a period of 24 weeks.
3254003|NCT01419730|Active Comparator|Vitamin D3 50,000 IU and Physical Activity|Vitamin D3 50,000 IU and Physical Activity: Patients will be assigned to receive a daily multivitamin, calcium supplement, 50,000 IU/week of vitamin D, and a progressive walking and resistance band exercise prescription for a period of 24 weeks.
3371177|NCT04924660|Experimental|Fostamatinib|An investigational oral spleen tyrosine kinase inhibitor.
3371178|NCT04924660|Experimental|APN01|An investigational, recombinant, human, soluble angiotensin-converting enzyme 2 (rhsACE2).
3254004|NCT01419730|No Intervention|Control|Patients will be assigned to receive a daily multivitamin, calcium supplement, vitamin D placebo, and standard care monitoring.
3254005|NCT01419743||patients with Vit D level of < 20ng/mL: Group 1|randomized to receive 400 IU of vitamin D per day
3371183|NCT04924023|Experimental|Kaleidoscope Group|Children in this group were told what a kaleidoscope is and how to use it before their central venous catheter dressing. The children were then asked if they would like to look into the kaleidoscope. The children looked into the kaleidoscope and slowly turned it. The researcher asked the children about the colours and shapes seen inside the kaleidoscope. This distraction procedure began immediately before the central venous catheter dressing and continued until it was finished. The kaleidoscope was disinfected before each use. A kaleidoscope was provided for all children in this group by the same researcher. Parents accompanied their children during the catheter dressing.
3254006|NCT01419743||patients with Vit D levels <20ng/mL: Group 2|Randomized to receive 2000IU of Vitamin D per day
3254007|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 3|Randomized to receiving placebo
3254008|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 4|Randomized to receive 400IU of vitamin D per day
3254009|NCT01419743||patients with vit D levels between 20-30 ng/mL: Group 5|Randomized to receive 2000IU of vitamin D per day
3371184|NCT04924023|No Intervention|Control Group|No intervention was performed to reduce pain and anxiety for children in the control group. Parents accompanied their children during the procedure.
3254010|NCT01419743||patients with vit D levels > 30ng/mL: Group 6|No treatment
3254011|NCT01419756||Single Arm|Imaging comparison study. No intervention.
3254012|NCT01419782|Experimental|Whole-body vibration|whole body vibration will be applied the right lower limb.
3254013|NCT01419808|Active Comparator|Vascularized Bone Graft|Patients randomized to a vascularized bone graft will undergo a 1, 2-ICRSA vascularized bone graft based upon the 1,2 supra-retinacular vessels as described by Zaidemberg . (9. Zaidemberg C, Siebert JW, Angrigiani C. A new vascularized bone graft for scaphoid nonunion. J Hand Surg. 1991; 16A: 474-478.)
3254014|NCT01419808|Active Comparator|Non-Vascularized Bone Graft|Patients randomized to the non-vascularized group will undergo trapezoidal bone grafting from the iliac crest as described by Fernandez . (10. Fernandez DL. A technique for anterior wedge-shaped grafts for scaphoid nonunions with carpal instability. J Hand Surg [Am]. 1984 Sep;9(5):733-7.)
3254015|NCT01419821|Active Comparator|Vit D supplementation|Group 2-Infants with 25(OH)D below 15ng/ml receiving continued vitamin D supplementation of 800IU (4gtt/d) for one year.
3254016|NCT01419821|Placebo Comparator|Placebo group|Group 3- Infants with 25(OH)D below 15ng/ml those receiving the placebo.
3254017|NCT01419821|No Intervention|Normal group|Group 1- infants with 25(OH)D above 15ng/ml (normal levels) will receive no intervention.
3254018|NCT01419834|Experimental|Humanized 3F8 Monoclonal Antibody (Hu3F8)|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8.
3371191|NCT04916977||FD patients|
3371194|NCT04911972||Functional muscle transfer group|Patients who have undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
3371195|NCT04911972||Non-functional muscle transfer group|Patients who have not undergone functional muscle transfer to restore function after tumour surgery or injury, in which the tumour surgery or injury has resulted in functional loss.
3371199|NCT04906421|Experimental|TVB-2640 50 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
3371200|NCT04906421|Experimental|TVB-2640 75 mg|Subjects will receive TVB-2640 PO QD for 52 weeks, with the first dose administered on Day 1.
3371201|NCT04906421|Placebo Comparator|Placebo|Subjects will receive matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
3254019|NCT01419847|Active Comparator|topical Penlac nail lacquer|3-1 randomization of active to placebo
3254020|NCT01419847|Placebo Comparator|Placebo|
3371202|NCT04905264||Adults admitted in participating Rehabilitation Units for Severe Acquired Brain Injuries|Adults admitted in study's participants Rehabilitation Units for Severe Acquired Brain Injuries from the 1st of July 2021 to the 31st of December 2023. Patients entered into these units more than 14 weeks after the acute event are excluded
3371203|NCT04902677||School|
3371206|NCT04896476|Experimental|EchoMark|All subjects will undergo a physician exam prior an arteriovenous fistula creation per the institution's standard of care. After the fistula creation is completed, but prior to closure, the EchoMark will be implanted under the outflow vein.
3254021|NCT01419860|Experimental|Pixel intensity|Pixel intensity of fluorescence signal describing pixel microcirculation of colon
3254022|NCT01419886||Dysphagia|
3371213|NCT04891549|Active Comparator|Tension band fixation|Surgical fixation of the patella fracture utilizing the AO principles using K-wires, screws, cerclage and sutures by surgeons choice.
3371214|NCT04891549|Experimental|Plate fixation|Surgical fixation of the patella fracture utilizing the AO principles and a locking plate with the number of screws by surgeons choice. Additional fixation by surgeons choice.
3254023|NCT01419899|Experimental|Brief Intervention|This arm of the study will receive an assessments survey followed by a brief intervention concerning the relationship between the participants use of drugs and/or sexual risk and rik for HIV and hepatitis C infections. Following the intervention the participants will be offered free rapid testing for HIV and hepatitis C.
3254024|NCT01419899|No Intervention|Standard Care|This arm of the study will receive an assessments survey. Following the assessment the participants will be offered free rapid testing for HIV and hepatitis C.
3254025|NCT01419912|Experimental|soy milk|
3254026|NCT01419912|Experimental|cow's milk|
3254027|NCT01419925|Experimental|Group A|Two Multimeric-001 administrations followed by TIV
3254028|NCT01419925|Experimental|Group B|One administration of Multimeric-001 followed by TIV
3254029|NCT01419925|Experimental|Group C|One administration of adjuvanted M-001 followed by TIV
3254030|NCT01419925|Active Comparator|Group D|One administration of placebo followed by TIV
3254031|NCT01419938|Active Comparator|Light therapy for two weeks|
3254032|NCT01419938|Active Comparator|Light therapy and CBT|Two weeks of light therapy and after that 4 weeks of Cognitive behaviour therapy (CBT)
3254033|NCT01419951|Active Comparator|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
3254034|NCT01419951|Active Comparator|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
3254035|NCT01419951|Experimental|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
3371230|NCT04881032|Experimental|AGuIX + chemoradiotherapy (radiotherapy + temozolomide)|addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II
3371231|NCT04881032|Sham Comparator|chemoradiotherapy (radiotherapy + temozolomide)|standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II
3371235|NCT04876365||All Participants|All participants diagnosed with severe hemophilia A previous received prophylaxis regimen for Standard Half-life/Extended Half-life Factor VIII (SHL/EHL-FVIII) products will be compared to after the participants switched to regular prophylaxis with Adynovate with at least 6 months follow up.
3371236|NCT04876274|Experimental|Intervention group|Patients in the intervention group received Taipei Medical University (TMU) line-oriented video education and care in addition to usual care
3371237|NCT04876274|No Intervention|Control group|Patients in the control group received usual care
3254036|NCT01419964|Experimental|Group 01|ACH24
3254037|NCT01419964|Placebo Comparator|Group 02|Placebo
3371240|NCT04865588|Active Comparator|rotational atherectomy + cutting balloon|angioplasty with rotational atherectomy followed by cutting balloon
3371241|NCT04865588|Active Comparator|rotational atherectomy + plain old balloon|angioplasty with rotational atherectomy followed by plain old balloon
3371242|NCT04864678||Young people who are experiencing or at risk of homelessness|Young people aged 15-24 years who have accessed a homeless youth service, refuge, or flexible learning center in Melbourne, Australia.
3371243|NCT04861311|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
3371244|NCT04861311|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
3254038|NCT01419990|Experimental|GLPG0634 capsules|
3254039|NCT01419990|Placebo Comparator|Placebo capsules|
3371246|NCT04856813|Experimental|active|this is the group that does a treatment with active movement, a program of pain education and a program of home exercise.
3371247|NCT04856813|Active Comparator|non active|this is the group that does a treatment without active movement, a program of pain education and a program of home exercise.
3371248|NCT04853264|Experimental|Experimental: intervention group|Ultrasound-guided peripheral venipuncture performed by a registered nurse with expertise in vascular access.
3371249|NCT04853264|Active Comparator|Control group|Conventional peripheral venipuncture performed by a registered nurse.
3254040|NCT01420003|Experimental|Allergen Challenge|
3254041|NCT01420042|Placebo Comparator|Placebo (lemon flavoured cordial)|NNZ-2566 reconstituted in Lemon flavoured cordial and Water for Injection. 6/8 subjects in each cohort (3 cohorts in total) to receive NNZ-2566 experimental treatment.
3254042|NCT01420042|Experimental|NNZ-2566|
3254043|NCT01420055|Experimental|fingolimod|
3254044|NCT01420094|Experimental|Arm 1|
3371254|NCT04851717|Experimental|All Patients|All paediatric patients undergoing diagnostic and/or therapeutic procedures
3371255|NCT04849650|Experimental|Renal Impairment Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
3371256|NCT04849650|Experimental|Healthy Subjects|10mg dose of IV Amisulpride, followed 24 hours by a 10mg oral dose of Amisulpride
3371263|NCT04827381|No Intervention|Usual care|Patients visiting their clinician will receive the normal, written after-visit-summary (available on paper or via the patient portal).
3371264|NCT04827381|Experimental|Annotated Audio|In addition to usual care, patients will be given access to an annotated audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit which will be annotated with key information discussed (e.g., medications). The recording will also contain hyperlinks related to annotations, that will direct participants to the online health information resource at Medline Plus. Access to their HealthPAL can also be shared with a caregiver.
3371265|NCT04827381|Experimental|Audio|In addition to usual care, patients will also be given access to an audio-based PHL, HealthPal to listen to outside of the clinic. HealthPAL will allow participants to replay the audio recording of their clinic visit (no annotations or hyperlinks). Access to their HealthPAL can also be shared with a caregiver.
3254045|NCT01420094|Active Comparator|Arm 2|
3254046|NCT01420094|Placebo Comparator|Arm 3|
3254047|NCT01420133|Experimental|Normal regimen|without special regimen for corticosteroid therapy
3254048|NCT01420133|Active Comparator|Standard arm|with diet low in salt and sugar
3371273|NCT04802577||Primary Sjögren's syndrome|The patient's diagnosed with Primary Sjögren's according to 2016 ACR/EULAR classification criteria
3371274|NCT04802577||Healthy Controls|Healthy hospital workers without any chronic disease
3371280|NCT04798768|Experimental|Patients implanted with S-ICD and leadless cardiac pacemaker|Patients implanted with an S-ICD and leadless cardiac pacemaker that complete intended testing based on the study protocol
3371281|NCT04797611|Other|Investigational Treatment 1|Investigational treatment mode (stimulation pattern) 1
3371282|NCT04797611|Other|Investigational Treatment 2|Investigational treatment mode (stimulation pattern) 2
3254049|NCT01420159|Experimental|Methoxyflurane|
3254050|NCT01420159|Placebo Comparator|Normal Saline|
3254051|NCT01420172||Post hematopoietic stem cell transplantation|Patients who were seen post hematopoietic stem cell transplantation between 01Jan2000 and 30Jun2011
3371283|NCT04797559|Experimental|SZaMN Treatment Group|Patients randomized into the SZaMN-treatment group will receive a bilateral single injection SZaMN block under general anesthesia in the operating room. The injection will occur through the pterygomaxillary fissure into the pterygomaxillary fossa. Patients will receive 5 ml of local anesthestic per side.
3254052|NCT01420198|Experimental|Lifestyle intervention|Lifestyle intervention: 500 participants from Iraq with obesity and/or prediabetes (impaired fasting glucose) and we expect to recruit 308 participants. Half of them will be randomized to lifestyle intervention i.e. group counseling and physical activity during a period of 1 year. An equal amount of controls will have treatment as usual. Every third month blood tests and a physical exam will be conducted in the intervention group.
3371284|NCT04797559|No Intervention|Control Group|Patients in this group will receive the standard of care for T&A procedures within the pediatric population.
3371285|NCT04796285|Experimental|Lab Clasp|A finger based device to assay interstitial fluid lactate
3371286|NCT04793412|Experimental|AHL/SSD|Children with asymmetric hearing loss or single-sided deafness
3371287|NCT04783376|Active Comparator|Arm 1 (usual treatment)|intervention A
3371288|NCT04783376|Active Comparator|Arm 2(splitted bolus dose, fast-acting insulin only)|intervention B
3371289|NCT04783376|Active Comparator|Arm 3 (splitted bolus dose, fast acting insulin before the meal and regular insulin after the meal)|intervention C
3371290|NCT04780763|Active Comparator|Arm 1, Test: Fermented milk product containing probiotics L. rhamnosus CNCM I-3690|
3371291|NCT04780763|Placebo Comparator|Arm 2, Control: Milk-based non-fermented dairy product|
3371294|NCT04777331|Experimental|Prasinezumab|Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W).
3371295|NCT04777331|Placebo Comparator|Placebo|Participants will receive placebo as an IV infusion Q4W.
3371296|NCT04775953|Experimental|Arm 1 (Dalbavancin)|Dalbavancin 1500 mg will be administrated intravenously (IV) over 30 (-/+10) minutes on Day 1 and 1500 mg IV over 30 (-/+10) minutes on Day 8, renally dose-adjusted to 1125 mg for subjects with Creatinine Clearance (CrCl) <30 and not on dialysis. N=100
3371297|NCT04775953|Active Comparator|Arm 2 (Standard of Care)|For Methicillin-sensitive Staphylococcus aureus (MSSA): nafcillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks) OR oxacillin (2 g will be administrated intravenously (IV) every 4 hours for 4-6 weeks OR cefazolin (2 g will be administrated intravenously (IV) every 8 hours for 4-6 weeks) For Methicillin-resistant Staphylococcus aureus (MRSA): vancomycin (dose per local standard of care × 4-6 weeks) OR daptomycin (6-10 mg/kg will be administrated intravenously (IV) daily for 4-6 weeks). N=100
3371298|NCT04775368|Experimental|Diagnosis orientation group|For this study, there is only one arm. Each patient complete diagnosis questionnaires.
3371299|NCT04774718|Experimental|ALK-Fusion Positive|Part 1 is a dose-confirmation phase to confirm the recommended phase 2 dose (RP2D). In Parts 2 and 3, participants will receive alectinib at the RP2D on Days 1-28 of each 28-day cycle
3254053|NCT01420198|No Intervention|Controls|Controls have treatment as usual. Every third month blood tests and a physical exam will be conducted in the control group.
3254054|NCT01420211|Experimental|Primovist|
3371302|NCT04765137|Experimental|Atorvastatin 40 mg|Participants receive 40 mg atorvastatin orally daily in the evening.
3371303|NCT04764188||Cohort 1|Participants starting alectinib treatment before (Arm A) or after (Arm B) study enrollment as first-line treatment will be followed up for up to 4 years.
3371304|NCT04764188||Cohort 2|Participants receiving alectinib as second-line treatment after study enrollment will be followed up for up to 2 years.
3254055|NCT01420224||Healthy volunteers|
3254056|NCT01420224||Chuvash polycythaemia|
3254057|NCT01420237|Other|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
3254058|NCT01420250|Experimental|Cabazitaxel with Intensity Modulated Radiation Therapy (IMRT)|Weekly Cabazitaxel with concurrent IMRT
3254059|NCT01420263|Active Comparator|Re-feeding gastric residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
3259501|NCT01471392|Experimental|Identigene STD Test Kit Arm|Single-Arm trial where the group will complete the Identigene STD Test Kit at home and these results will be compared with the results from testing in the clinic with the Gen-Probe APTIMA kit. The subject will only be informed of the results from the approved test (Gen-Probe APTIMA) that is done in the clinic.
3259502|NCT01471418|Experimental|Disease population|
3371312|NCT04749173|Experimental|Cohort 1 (96 mg)|- Ventrogluteal area: 48 mg/0.2 mL x 2 sites
3371313|NCT04749173|Experimental|Cohort 2 (432 mg)|"Deltoid area: 72 mg/0.3 mL x 2 sites~Ventrogluteal area: 144 mg/0.6 mL x 2 sites"
3371314|NCT04749173|Experimental|Cohort A (144 mg)|- Deltoid area: 72 mg/0.3 mL x 2 sites
3371315|NCT04749173|Experimental|Cohort B (144 mg)|- Ventrogluteal area: 72 mg/0.3 mL x 2 sites
3254060|NCT01420263|Active Comparator|Fresh feeding breastmilk/formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breast milk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
3254061|NCT01420302|Experimental|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
3371316|NCT04745897|Experimental|eTB Catalogue of Recommendation (eTB)|New eTB catalogue of recommendations website (eTB).
3371317|NCT04745897|Active Comparator|World Health Organization Tuberculosis Website (WHO TB)|Current method of accessing tuberculosis (TB) recommendations using World Health Organization (WHO) website (WHO TB).
3371318|NCT04740918|Active Comparator|Arm A: Trastuzumab Emtansine and Placebo|Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor.
3371319|NCT04740918|Experimental|Arm B: Trastuzumab Emtansine and Atezolizumab|Atezolizumab 1200 mg IV infusion followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor.
3254062|NCT01420302|Active Comparator|Nurse-directed|Nurse-directed blood glucose control (80-110 mg/dL)
3371327|NCT04723758|Experimental|GI Genius-assisted colonoscopy (GGC)|In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
3371328|NCT04723758|Active Comparator|Standard Colonoscopy (SC)|In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
3254063|NCT01420328|Placebo Comparator|Placebo Arm|Obese subjects with near normal cholesterol
3254064|NCT01420328|Active Comparator|Vytorin Arm|Obese subjects with near normal cholesterol
3254065|NCT01420341|Active Comparator|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
3254066|NCT01420341|Experimental|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
3254067|NCT01420367|Experimental|Single dose of antibiotics|This group will receive one dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) in the pre-operative period and two post-operative IV 'doses' of normal saline 8 and 16 hours after the pre-operative dose, which will act as a placebo and facilitate blinding.
3254068|NCT01420367|Active Comparator|Three doses of antibiotics|This group will receive one pre-operative dose of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) and two post-operative doses of IV metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g) 8 and 16 hours after the pre-operative dose.
3254069|NCT01420393|Active Comparator|Rhythm Control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal Heart Failure therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug.
3254070|NCT01420393|Active Comparator|Rate Control|Patients in the rate control group will receive optimal Heart Failure therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
3254071|NCT01420406|Placebo Comparator|0 mg retinol|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
3254072|NCT01420406|Experimental|12 mg BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule.
3371336|NCT04721821||Patients with Rheumatoid Arthritis (RA)|
3371337|NCT04721457|Placebo Comparator|Distilled Water|15-second rinsing with 15 mL of Distilled Water
3371338|NCT04721457|Active Comparator|Povidone Iodine (PVP-I)|15-second rinsing with 15 mL of 1% PVP-I
3371339|NCT04721457|Active Comparator|Hydrogen Peroxide (H2O2)|15-second rinsing with 15 mL of 1.5 % Hydrogen Peroxide
3254073|NCT01420406|Experimental|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
3254074|NCT01420406|Experimental|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
3371340|NCT04721457|Active Comparator|Cetylpyridinium Chloride (CPC)|15-second rinsing with 15 mL of 0.075%CPC
3371341|NCT04721457|Active Comparator|Sodium Hypochlorite|15-second rinsing with 15 mL of 0.1% Sodium Hypochlorite
3254075|NCT01420419|Experimental|Lanolin|Pea sized amount of lanolin to be applied to nipple and areola after every breast feed (approximately every 2-3 hours), until pain is completely resolved for a maximum of 7 days
3254076|NCT01420419|Other|Standard postpartum nursing care|Women in standard care control group may receive any other nursing intervention to manage their nipple pain, including (but not limited to): recommending application of expressed breast milk, analgesics (such as acetaminophen or ibuprofen), breast shells, air drying, changing position / latch, cold or warm compresses
3371344|NCT04704505|Experimental|Bipolar Androgen Therapy in addition to RADium-223 (RAD)|Participants will receive Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD).
3371345|NCT04704219|Experimental|Pembrolizumab + Lenvatinib|Pembrolizumab 400 mg, every 6 weeks (Q6W) intravenous (IV) up to 18 infusions or up to progressive disease or discontinuation PLUS Lenvatinib 20 mg, daily (QD), oral, until progressive disease or discontinuation.
3371346|NCT04701437|Experimental|Peer-enhanced intervention|Those randomized to the peer-enhanced intervention group will be contacted by a peer mentor within 72 hours of enrollment to discuss the early release period, readiness for HCV treatment, and identify ancillary needs. Individuals randomized to this arm will be provided a study cell phone.
3371347|NCT04701437|Placebo Comparator|Standard of care|If randomized to the standard of care intervention, the participant will only receive passive referral to HCV-care.
3371354|NCT04690699|Experimental|Arm 1: Lerapolturev and Anti-PD-1/L1 Therapy|Subjects will be treated with a combination of lerapolturev and an FDA-approved anti-PD-1/L1 therapy, the choice of which will be determined based on the solid tumor cancer of interest and specified in the associated tumor specific appendix.
3371357|NCT04678206|Experimental|BLU-5937 Dose A|BLU-5937 oral dose A twice a day.
3371358|NCT04678206|Experimental|BLU-5937 Dose B|BLU-5937 oral dose B twice a day.
3371359|NCT04678206|Experimental|BLU-5937 Dose C|BLU-5937 oral dose C twice a day.
3371360|NCT04678206|Placebo Comparator|Placebo|Matching Placebo for BLU-5937 oral dose twice a day.
3371361|NCT04678206|Experimental|BLU-5937 Dose A (Population with baseline cough < 25 coughs/hour)|BLU-5937 oral dose A twice a day.
3371362|NCT04678206|Placebo Comparator|Placebo (Population with baseline cough < 25 coughs/hour)|Matching Placebo for BLU-5937 oral dose twice a day.
3371363|NCT04677595|Experimental|Cohort 1|Treatment Naive participants
3371364|NCT04677595|Experimental|Cohort 2|Participants received one or two prior lines of treatment
3254077|NCT01420432|Experimental|Human umbilical cord-derived MSCs and DMARDs|Human umbilical cord-derived MSCs at a dose of 1.0E+6 MSC/kg, repeated after three months and DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
3254078|NCT01420432|No Intervention|DMARDs|DMARDs such as sulfasalazine,methotrexate,thalidomide po for 12 months
3371365|NCT04670159|Experimental|Online Education Group|
3371366|NCT04670159|Experimental|Brochure Group|
3371367|NCT04669925||Users of Lombardy Emergency System 2018-2020|Adults (affected or not affected by Covid-19) who asked for assistance to the Lombardy region's emergency system during the pandemic period and the previous two years
3371368|NCT04656236|Experimental|Intervention|3 hours of continuously intravenous infusion of 3-hydroxybutyrate.
3371369|NCT04656236|Placebo Comparator|Control|3 hours of continuously intravenous infusion of saline (NaCl).
3371370|NCT04655586|Experimental|rNAPc2 Higher Dose|loading dose of 7.5 μg/kg SC on Day 1 followed by 5 μg/kg SC on Days 3 and 5
3371371|NCT04655586|Experimental|rNAPc2 Lower Dose|loading dose of 5 ug/kg SC on Day 1 followed by 3 ug/kg SC on Days 3 and 5
3371372|NCT04655586|Active Comparator|Heparin|heparin at either prophylactic or therapeutic doses per Standard of Care at Institution
3371373|NCT04653038|Experimental|Unresectable, recurrent or metastatic melanoma|Cohort1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy
3371374|NCT04653038|Experimental|Untreated mucosal or acral lentiginous melanoma|Cohort2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma
3371375|NCT04652479|Experimental|Treatment Group 1|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days
3371376|NCT04652479|Experimental|Treatment Group 2|Patients will receive one of the two dosing regimens of avexitide for 14 days followed by the other dosing regimen of avextide for 14 days (in the opposite sequence from Treatment Group 1)
3254079|NCT01420445|Experimental|YHD001 dose level 1|YHD001 dose level 1
3254080|NCT01420445|Experimental|YHD001 dose level 2|YHD001 dose level 2
3254081|NCT01420445|Active Comparator|Pelargonium sidoides extract|Pelargonium sidoides extract (Syrup)
3371380|NCT04644315|Experimental|ALK-positive Solid Tumors|Participants with locally advanced or metastatic ALK-positive tumors will receive alectinib twice daily (BID) until disease progression, unacceptable toxicity, death, or withdrawal from the study for any reason.
3371381|NCT04643769|Experimental|25 mg ORIN1001 (Active)|25 mg ORIN1001
3371382|NCT04643769|Experimental|50 mg ORIN1001 (active)|50 mg ORIN1001
3371383|NCT04643769|Experimental|100 mg ORIN1001 (active)|100 mg ORIN1001
3371384|NCT04643769|Placebo Comparator|Placebo - 25 mg|Placebo comparator for ORIN1001 at 25 mg
3371385|NCT04643769|Placebo Comparator|Placebo - 50 mg|Placebo comparator for ORIN1001 at 50 mg
3371386|NCT04643769|Placebo Comparator|Placebo - 100 mg|Placebo comparator for ORIN1001 at 100 mg
3371387|NCT04641156|Experimental|Low level LASER Therapy|Subjects in this group received low-level laser therapy
3371388|NCT04641156|Experimental|Exercise group|Subjects in this group received additional planned exercise therapy program
3254082|NCT01420445|Placebo Comparator|Placebo|Placebo for YHD001 & active comparator(syrup)
3254083|NCT01420471|Active Comparator|Saline-impregnated spacer|Saline-impregnated spacers are actively being used as the standard of care. It does not contain any active ingredients.
3254084|NCT01420471|Experimental|Triamcinolone-impregnated spacer|This study arm receives the experimental treatment, a Triamcinolone-impregnated spacer.
3254085|NCT01420484||different blood pressure intervals|
3254086|NCT01420497|Active Comparator|methylprednisolone,infiltration|
3254087|NCT01420497|Active Comparator|epidural injection|
3254088|NCT01420510|Experimental|Adelmidrol|Efficacy of Adelmidrol vaginal gel in preventing vaginitis in oncologic patients
3254089|NCT01420510|Placebo Comparator|Placebo|Efficacy of Placebo in preventing vaginitis in oncologic patients
3254090|NCT01420523|Experimental|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
3254091|NCT01420562||Posaconazole oral suspension|"One group of patients will receive posaconazole oral suspension as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
3371391|NCT04639531|Experimental|Orientation and Mobility Training with VR-IOMSs|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from Virtual Reality-base Intelligent O&M Specialists (VR-IOMSs). VR-IOMSs are intelligent, computer-controlled automatic O&M skill training programs in virtual streets.
3371392|NCT04639531|Active Comparator|Orientation and Mobility Training with COMS|Low vision subjects with Orientation and Mobility (O&M) difficulties learning O&M skills from human Certified O&M Specialists (COMS) in real streets
3371393|NCT04639531|Placebo Comparator|No Orientation and Mobility Training|Low vision subjects with Orientation and Mobility (O&M) difficulties watching low vision education videos and discuss low vision issues not related to O&M with COMSs.
3254092|NCT01420562||Posaconazole oral tablet|"Once the oral tablet is available for adminstration to patients, a second group of patients will receive these tablets as prophylactic agent.~Blood sampling: At day of transplantation, day 7 and 14, 9 blood samples will be collected to calculate AUC. Moreover, citrulline will be determined to objectively evaluate the severity of mucositis."
3254093|NCT01420575|Experimental|Visual Decision Making Aid|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower overweight patients with schizophrenia/schizoaffective disorder and help them efficiently arrive at a treatment decision that can be successfully implemented.
3371396|NCT04632953||Previously Treated with Triheptanoin|Patients who have been previously treated with triheptanoin in clinical studies: UX007-CL201 (NCT01886378), UX007-CL202 (NCT02214160), Investigator Sponsored Trials (ISTs), or UX007-EAP (NCT03773770).
3254094|NCT01420575|Active Comparator|Usual Care|Usual care reflects the standard of care in psychiatry. Psychiatrists will recommend treatment for overweight patients with schizophrenia on olanzapine who have failed to lose weight despite life style and dietary modifications. They may recommend switching to a comparable antipsychotic with a lower incidence of weight gain.
3371397|NCT04632953||Currently Treated with Triheptanoin|New patients enrolling into the DMP currently being treated with triheptanoin (excluding those in the previously treated with triheptanoin cohort).
3371398|NCT04632953||Triheptanoin Naïve|New patients enrolling into the DMP with no exposure to triheptanoin.
3371399|NCT04632953||Triheptanoin Naïve Transitioned toTriheptanoin|Patients already enrolled into the triheptanoin naïve cohort but transition to triheptanoin during the DMP after enrollment.
3371400|NCT04632940|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
3371401|NCT04632940|Placebo Comparator|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
3254095|NCT01420588||gastric cancer|
3254096|NCT01420588||gastritis|
3371406|NCT04630067|Experimental|AZD3427: Cohort 1a|Participants will receive single SC dose A of AZD3427 on Day 1.
3371407|NCT04630067|Experimental|AZD3427: Cohort 2a|Participants will receive single SC dose B of AZD3427 on Day 1.
3371408|NCT04630067|Experimental|AZD3427: Cohort 3a|Participants will receive single SC dose C of AZD3427 on Day 1.
3371409|NCT04630067|Experimental|AZD3427: Cohort 4a|Participants will receive single SC dose D of AZD3427 on Day 1.
3371410|NCT04630067|Experimental|AZD3427: Cohort 5a|Participants will receive single IV dose E of AZD3427 on Day 1.
3371411|NCT04630067|Experimental|AZD3427: Cohort 6a|Participants of Japanese descent will receive single SC dose anticipated equal to the highest dose of AZD3427 in the global cohorts on Day 1.
3371412|NCT04630067|Experimental|AZD3427: Cohort 7a|Participants will receive single SC dose F of AZD3427 on Day 1
3371413|NCT04630067|Placebo Comparator|Part A: Placebo|Participants will receive single SC or IV dose of placebo matched to AZD3427 on Day 1.
3371414|NCT04630067|Experimental|AZD3427: Cohort 1b|Participants with HFrEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
3371415|NCT04630067|Experimental|AZD3427: Cohort 2b|Participants with HFpEF will receive SC dose A of AZD3427 on Days 1, 8, 15, 22, and 29.
3371416|NCT04630067|Experimental|AZD3427: Cohort 3b|Participants with HFrEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
3371417|NCT04630067|Experimental|AZD3427: Cohort 4b|Participants with HFpEF will receive SC dose B of AZD3427 on Days 1, 8, 15, 22, and 29.
3371418|NCT04630067|Experimental|AZD3427: Cohort 5b|Participants with HFrEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
3371419|NCT04630067|Experimental|AZD3427: Cohort 6b|Participants with HFpEF will receive SC dose C of AZD3427 on Days 1, 8, 15, 22, and 29.
3371420|NCT04630067|Placebo Comparator|Part B: Placebo|Participants with HFrEF or HFpEF will receive SC dose of placebo matched to AZD3427 on Days 1, 8, 15, 22, and 29.
3371421|NCT04627922|Experimental|N-acetyl cysteine (NAC) & cognitive behavioral therapy|N-acetyl cysteine (NAC) & cognitive behavioral therapy experimental arm consists of 30 regular cigarette smokers with current TUD and CUD, who will be randomized to receive N-acetyl cysteine 3600 mg per day over 8 weeks to experimental arm. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
3254097|NCT01420588||gastric ulcer|
3371422|NCT04627922|Placebo Comparator|Placebo Comparator: Placebo & cognitive behavioral therapy|Placebo comparator & cognitive behavioral therapy arm consists of 30 regular cigarette smokers with current TUD and CUD, who will be randomized to receive placebo over 8 weeks. Participants will also receive weekly cognitive behavioral therapy for substance use disorders targeting TUD and CUD.
3254098|NCT01420588||normal|
3254099|NCT01420614|Experimental|Radial|group of patients undergoing primary angioplasty by transradial approach
3254100|NCT01420614|Active Comparator|Femoral|group of patients undergoing primary angioplasty by transfemoral approach
3371431|NCT04610775|Other|Small Cuff (0, +1, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Small
3371432|NCT04610775|Other|Small Cuff (0, +2, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Small
3371433|NCT04610775|Other|Small Cuff ( +1, 0, +2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Small
3371434|NCT04610775|Other|Small Cuff ( +1, +2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Small
3371435|NCT04610775|Other|Small Cuff ( +2, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Small
3371436|NCT04610775|Other|Small Cuff ( +2, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Small
3371437|NCT04610775|Other|Regular Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Small, Large, Regular
3371438|NCT04610775|Other|Regular Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Small, Regular
3254101|NCT01420640|Active Comparator|Tai Chi|
3254102|NCT01420640|Active Comparator|Aerobic Exercise Training|
3254103|NCT01420666|Active Comparator|Maxigesic 325|Maxigesic 325 (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day, orally, with food
3254104|NCT01420666|Active Comparator|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
3254105|NCT01420666|Active Comparator|Ibuprofen|ibuprofen 97.5mg, three tablets four times a day, orally, with food
3254106|NCT01420666|Placebo Comparator|Placebo|Placebo tablets
3254107|NCT01420692|Active Comparator|Gliclazide MR|
3254108|NCT01420692|Active Comparator|Insulin Detemir|Early initiation of insulin detemir in contrast to Gliclazide MR treatment
3254109|NCT01420705||Low birth-weight cohort|Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area
3254110|NCT01420718|Active Comparator|Mineral Trioxide Aggregate|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
3371439|NCT04610775|Other|Regular Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Regular, Large, Regular
3371440|NCT04610775|Other|Regular Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Small, Large, Regular, Regular
3371441|NCT04610775|Other|Regular Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Small, Regular, Regular
3371442|NCT04610775|Other|Regular Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Small, Regular
3371443|NCT04610775|Other|Large Cuff (-1, 0, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Large
3371444|NCT04610775|Other|Large Cuff (-1, +1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Large
3371445|NCT04610775|Other|Large Cuff (0, +1, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Large
3371446|NCT04610775|Other|Large Cuff (0, -1, +1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Large
3371447|NCT04610775|Other|Large Cuff (+1, 0, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Large
3371448|NCT04610775|Other|Large Cuff (+1, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Large
3254111|NCT01420718|Experimental|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
3254112|NCT01420744|Experimental|BT086 infusion|
3371449|NCT04610775|Other|Extra Large Cuff (0, -2, -1, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Regular, Large, Extra Large
3371450|NCT04610775|Other|Extra Large Cuff (0, -1, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Extra Large, Large, Regular, Extra Large
3371451|NCT04610775|Other|Extra Large Cuff (-1, 0, -2, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Extra Large, Regular, Extra Large
3371452|NCT04610775|Other|Extra Large Cuff (-1, -2, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Large, Regular, Extra Large, Extra Large
3371453|NCT04610775|Other|Extra Large Cuff (-2, -1, 0, 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Large, Extra Large, Extra Large
3371454|NCT04610775|Other|Extra Large Cuff (-2, 0, -1 0)|The order of blood pressure cuffs used for participants randomized to this arm will be: Regular, Extra Large, Large, Extra Large
3371456|NCT04606316|Experimental|Nivolumab and Ipilimumab Before and After Surgery|"One dose of nivolumab plus ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 9 weeks and then nivolumab alone every 4 weeks."
3371457|NCT04606316|Experimental|Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab After Surgery|"One dose of nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab alone every 4 weeks."
3371458|NCT04606316|Experimental|Placebo-Nivolumab and Placebo-Ipilimumab Before Surgery, Nivolumab and Ipilimumab After Surgery|"One dose of placebo-nivolumab plus placebo-ipilimumab will be administered 14(±5) days before surgery.~After surgery, participants receive nivolumab in combination with ipilimumab every 3 weeks for 12 weeks and then nivolumab alone every 4 weeks."
3371459|NCT04604860|Experimental|EL-FIT|Patients using the EL-FIT app
3254113|NCT01420744|Placebo Comparator|1% Human Albumin infusion|
3371460|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort A)|Patients with UC and FGFR3 mutation or FGFR1-4 fusion/rearrangement.
3371461|NCT04601857|Experimental|Futibatinib and Pembrolizumab (Cohort B)|All other patients than in Cohort A with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors).
3254114|NCT01420757|Active Comparator|open|open incisional hernia repair
3254115|NCT01420757|Active Comparator|laparoscopic|laparoscopic incisional hernia repair
3254116|NCT01420770|Experimental|SAR02503 300 mg qd|daily X 28 days
3254117|NCT01420770|Experimental|SAR302503 400 mg qd|daily X 28 days
3254118|NCT01420770|Experimental|SAR302503 500 mg qd|daily X 28 days
3254119|NCT01420783|Experimental|SAR302503 100 mg|once daily X 28 days
3254120|NCT01420783|Experimental|SAR302503 200 mg|once daily X 28 days
3254121|NCT01420783|Experimental|SAR302503 400 mg|once daily X 28 days
3254122|NCT01420783|Experimental|SAR302503 600 mg|once daily X 28 days
3254123|NCT01420796|Experimental|Swallowing and breathing exercises|This group will perform both swallowing and breathing exercises for five weeks.
3254124|NCT01420796|Experimental|Swallowing exercises|This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will perform sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
3254125|NCT01420796|Experimental|Breathing exercises|Expiratory Muscle Training will be performed with Threshold® (Respironics HealthScan, Inc, Cedar Grove, Nova Iorque, EUA).
3371467|NCT04587934|Experimental|iRes Warmer with ResusView|iRes Warmer with ResusView program with experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
3371468|NCT04587934|Active Comparator|iRes Warmer without ResusView|An external non-experimental electrocardiogram monitor will be used for heart rate monitoring in the first 10 minutes of life during routine care and and/or neonatal resuscitation.
3254126|NCT01420822||Subjects prescribed ALLERMIST|Subjects with allergic rhinitis prescribed ALLERMIST during study period
3254127|NCT01420835|Active Comparator|Without Protocol Group|"The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.~Five points will be chosen to treat stress according to the symptoms and Chinese diagnosis."
3254128|NCT01420835|Active Comparator|Auriculotherapy with protocol|Auriculotherapy with stress protocol points. Five points are indicated for stress (Liver yang1, Liver yang2, Shenmen, Brainstem and Kidney).
3254129|NCT01420835|No Intervention|Control Group|Control Group won't receive any treatment and will be evaluated at the same time and the same way of interventions group
3254130|NCT01420861|Experimental|1000 mg GTx-758|subjects will receive daily doses of 1000 mg GTx-758
3254131|NCT01420874|Experimental|FOLFOX6 & EGFRBi armed ATC Infusions|"FOLFOX6: IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.~EGFRBi armed ATC Infusions: Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion"
3371469|NCT04587427||Radium-223|Subjects who received the treatment of radium-223 during the before or after label change study periods.
3371470|NCT04586920|Experimental|LY3509754 - Part A|Escalating doses of LY3509754 administered orally
3371471|NCT04586920|Placebo Comparator|Placebo - Part A|Placebo administered orally
3371472|NCT04586920|Experimental|LY3509754 plus Itraconazole - Part B|LY3509754 and Itraconazole administered orally
3371473|NCT04586920|Placebo Comparator|Placebo plus Itraconazole - Part B|Placebo and Itraconazole administered orally
3371474|NCT04586920|Experimental|LY3509754 plus Midazolam - Part C|Multiple doses of LY3509754 administered orally. Some participants will also receive midazolam orally.
3371475|NCT04586920|Placebo Comparator|Placebo plus Midazolam - Part C|Multiple doses of placebo administered orally. Some participants will also receive midazolam orally.
3254132|NCT01420887|Experimental|Continuous Passive Motion|Subjects randomized to CPM therapy.
3254133|NCT01420887|Active Comparator|Physical Therapy|Subjects randomized to physical therapy.
3371476|NCT04586920|Experimental|LY3509754 (Japanese) - Part D|Multiple doses of LY3509754 administered orally to Japanese participants
3371477|NCT04586920|Placebo Comparator|Placebo (Japanese) - Part D|Placebo administered orally to Japanese participants
3254134|NCT01420900|Active Comparator|ABG II / Trident|
3254135|NCT01420900|Active Comparator|CLS / Trilogy|
3254136|NCT01420913|Active Comparator|Lyrica capsule(Pregabalin 150mg)|
3254137|NCT01420913|Experimental|YHD1119 A(Pregabalin SR 300mg)|
3371485|NCT04572854|Experimental|Group 1|Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.
3371486|NCT04572854|Other|Group 2|No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.
3371488|NCT04569084|Experimental|MT-1186|
3371489|NCT04569084|Experimental|MT-1186 and Placebo|
3371491|NCT04564573||antidepressant treatment group|participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
3371492|NCT04564573||non-antidepressant treatment group|participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
3371493|NCT04563026|Experimental|DUR-928 (30 mg)|
3371494|NCT04563026|Experimental|DUR-928 (90 mg)|
3371495|NCT04563026|Placebo Comparator|(Placebo) Sterile Water for Injection|
3371496|NCT04553913|Experimental|cooling device placed|A basic medical grade cooling pad will be secured to the non operative leg. Intermittent coolness will be assessed and subject will inform recovery room staff when sensation returns.
3371497|NCT04543825|Experimental|CPET|Patients with cirrhosis who have been wait listed for liver transplant or are undergoing liver transplant evaluation and will undergo cardiopulmonary exercise testing (CPET).
3371498|NCT04538573|Experimental|Virtual Reality Distraction|Use of virtual reality (VR) during during burn treatment, dressing changes and hydrotherapy.
3371499|NCT04538573|Active Comparator|Standard Treatment|Standard treatment during burn treatment, dressing changes and hydrotherapy.
3254138|NCT01420913|Experimental|YHD1119 B(Pregabalin SR 300mg)|
3254139|NCT01420913|Experimental|YHD1119 C(Pregabalin SR 300mg)|
3254140|NCT01420978|Experimental|High volume CSF diversion|The EVD will be set to an initial level of 5 mmHg. The drain will remain in place at a level of ≤ 5 mmHg until at least day 10 after SAH before a weaning trial is attempted.
3254141|NCT01420978|Active Comparator|Conventional CSF diversion|The EVD will be set to a level of 15 mmHg for as long as needed for the treatment of hydrocephalus, and subsequently weaned at the discretion of the treating physician. Lowering the level of the EVD can be considered by the treating physician if sustained intracranial hypertension occurs
3371502|NCT04534842|Experimental|SYNB1618|Dose ramp of SYNB1618
3371503|NCT04534842|Experimental|SYNB1934|Dose ramp of SYNB1934
3371504|NCT04534114|Placebo Comparator|Pooled Placebo|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
3371505|NCT04534114|Experimental|40 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
3371506|NCT04534114|Experimental|80 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
3371507|NCT04534114|Experimental|120 mg BAY2976217|Participants will be allocated at randomization to 1 of 3 dose cohorts 40 mg, 80 mg and 120 mg and within each cohort to receive subcutaneous treatment with either BAY2976217 or matching placebo.
3371510|NCT04529096|Experimental|LY3016859|LY3016859 administered intravenously (IV).
3371511|NCT04529096|Placebo Comparator|Placebo|Placebo administered IV.
3371518|NCT04524598|Experimental|Limbix Spark|A 5 week CBT-based intervention
3371519|NCT04524598|Active Comparator|Psychoeducation|5 weeks of psychoeducation about depression. Upon completion, participants will be automatically enrolled into the Limbix Spark CBT-based intervention
3371520|NCT04523220|Experimental|BAY1213790 low dose|Participants will receive Osocimab (BAY1213790) 105 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 52.5 mg until the end of the extension treatment period.
3371521|NCT04523220|Placebo Comparator|Placebo low dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
3254142|NCT01421004|Experimental|500 mg FMI capsule + 250 mg FMI tablet|BE phase sequence 1= 3 weeks on FMI capsule then 1 week on FMI tablet
3254143|NCT01421004|Experimental|500 mg TKI258 FMI capsule +250 mg FMI tablet|BE phase sequence 2= 3 weeks on FMI tablet then 1 week on FMI capsule
3371522|NCT04523220|Experimental|BAY1213790 high dose|Participants will receive Osocimab (BAY1213790) 210 mg single loading dose as subcutaneous abdominal injection, followed by monthly maintenance doses of 105 mg until the end of the extension treatment period.
3371523|NCT04523220|Experimental|Placebo high dose|Placebo will be administered subcutaneously in the same manner as Osocimab.
3254144|NCT01421030|Other|quality of life, clinical outcomes and costs|Quality of life, clinical outcomes and costs after two different treatment options in patients and closest relatives
3254145|NCT01421043|Experimental|triazolam liquid oral drops|
3254146|NCT01421043|Active Comparator|triazolam tablets|
3254147|NCT01421056|Experimental|CHF 5074 1x|oral tablet, multidose
3371541|NCT04514484|Experimental|Treatment (cabozantinib s-malate, nivolumab)|Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year or 1 year after a partial response is achieved, or 6 months after a complete response is achieved in the absence of disease progression or unacceptable toxicity.
3371542|NCT04511364|Experimental|AGN1 treated patients|Patients have been treated with the AGN1 LOEP kit in AgNovos study PST-EU-101.1. An X-ray and DXA scan are performed at 24 and 60 months post AGN1 LOEP treatment.
3371543|NCT04508621|Experimental|TNX-102 SL Tablet, 2.8 mg|1 x TNX-102 SL 2.8 mg Tablet taken sublingually each day at bedtime for 2 weeks then 2 x TNX-102 SL 2.8 mg (5.6 mg) Tablet taken sublingually each day at bedtime for 12 weeks.
3371544|NCT04508621|Placebo Comparator|Placebo SL Tablet|1 x Placebo Tablet taken sublingually each day at bedtime for 2 weeks then 2 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
3371545|NCT04505384|Experimental|Left bundle branch pacing|Left bundle branch pacing
3254148|NCT01421056|Experimental|CHF 5074 2x|oral tablet, multidose
3254149|NCT01421056|Experimental|CHF 5074 3x|oral tablet, multidose
3371546|NCT04505384|Active Comparator|Biventricular pacing|Biventricular pacing
3254150|NCT01421069|Experimental|1|
3254151|NCT01421082|Experimental|LVRC Treatment|
3254152|NCT01421095|Experimental|Basal Testing|
3254153|NCT01421108|Experimental|Loss-framed messages|
3254154|NCT01421108|Experimental|gain-framed messages|"Adolescents will randomly assign to three groups: gain-framed message , loss-framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images (6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
3254155|NCT01421121|Experimental|100U EV71 vaccine with adjuvant|120 infants received 2 doses of 100U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3254156|NCT01421121|Experimental|200 U EV71 vaccine with adjuvant|120 infants received 2 doses of 200U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3254157|NCT01421121|Experimental|400U EV71 vaccine with adjuvant|120 infants received 2 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant 28 days apart
3254158|NCT01421121|Experimental|200U EV71 vaccine without adjuvant|60 infants received 2 doses of 200U EV71 vaccine without adjuvant 28 days apart
3254159|NCT01421121|Placebo Comparator|Placebo|120 infants received 2 doses of placebo 28 days apart.
3254160|NCT01421173|Experimental|Vorinostat + GemBuMel|Vorinostat 200 mg by mouth on Days -8 to -2. Gemcitabine loading dose of 75 mg/m2 followed by continuous infusion. Remaining dose is 10 mg/m2/min on Day -8 and -3. Busulfan pharmacokinetics (PK) will be performed with the first dose of 105 mg/m2 by vein on Day -8. The doses of days -6 and -5 will be subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting were not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5. Melphalan 60 mg/m2 by vein on Days -2 and -3. Stem cells by vein over about 30-60 minutes on Day 0. Rituximab 375 mg/m2 on days +1 and +8 for cluster of differentiation antigen 20 (CD20+) tumors. G-CSF 5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented. Palifermin 60 mcg/kg by vein daily for 6 doses starting on Day 0. Dexamethasone 8 mg by vein twice a day from day -8 AM to day -2 PM.
3371547|NCT04501796|Experimental|NT-I7|NT-I7 will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
3254161|NCT01421199|Other|Myringotomy|On arm
3254162|NCT01421238|Experimental|Resuscitation Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive resuscitation, unless their parents object. If you decline resuscitation please check the box below:~Please check if you decline resuscitation []"
3371548|NCT04501796|Placebo Comparator|Placebo|Placebo will be administered once by IM injection within 24 hours of baseline (day 0). The treatment course pursued in all enrolled participants will be a single dose. Dosing will be staggered with at least 72 hours between each study participant.
3371550|NCT04489823|Experimental|Paravalvular Leak Closure|Includes all eligible subjects who undergo an AVP III implant attempt for treatment of significant paravalvular leakage with an echocardiographic severity grade of moderate or higher. This is a single arm study.
3371551|NCT04482309|Experimental|Arm 1|Cohort 1: Biliary tract cancer
3371552|NCT04482309|Experimental|Arm 2|Cohort 2: Bladder cancer
3371553|NCT04482309|Experimental|Arm 3|Cohort 3: Cervical cancer
3371554|NCT04482309|Experimental|Arm 4|Cohort 4: Endometrial cancer
3371555|NCT04482309|Experimental|Arm 5|Cohort 5: Ovarian cancer
3371556|NCT04482309|Experimental|Arm 6|Cohort 6: Pancreatic cancer
3371557|NCT04482309|Experimental|Arm 7|Cohort 7: Rare tumors
3371558|NCT04480840|Placebo Comparator|Placebo|
3371559|NCT04480840|Experimental|PLN-74809 Dose Level 1|Dose: 40 mg;
3371560|NCT04480840|Experimental|PLN-74809 Dose Level 2|Dose: 80 mg; PLN-74809 Dose Level 2 following PLN-74809 Dose Level 1
3371561|NCT04480840|Experimental|PLN-74809 Dose Level 3|Dose: 160 mg; PLN-74809 Dose Level 3 following PLN-74809 Dose Level 2
3371562|NCT04472286||Pediatric Cancer Survivors|Children and adolescents who have completed treatment of for acute lymphoblastic leukemia (ALL) and lymphoma.
3371563|NCT04461821||obstructive bronchitis/bronchiolitis|
3371564|NCT04461821||pneumonia|
3371565|NCT04461821||asthma|
3371566|NCT04461821||neurological diseases|
3371567|NCT04461821||type 1 diabetes (T1D)|
3371568|NCT04461821||pharmacotherapy with bronchodilators|
3371569|NCT04461821||pharmacotherapy with antibiotics|
3371570|NCT04461821||pharmacotherapy with antiviral medication|
3371571|NCT04461821||pharmacotherapy with antifungal medication|
3371572|NCT04461821||pharmacotherapy with antiepileptic medication|
3371573|NCT04461821||pharmacotherapy with immuno suppressants and immune-modulati|
3371574|NCT04461821||pharmacotherapy with anesthesia (including sedating, analges|
3371575|NCT04461639||Damoctocog alfa pegol|Participants with hemophilia A received damoctocog alfa pegol as prophylaxis treatment prescribed by the physician as part of normal clinical practice.
3371576|NCT04458259|Experimental|Monotherapy Dose Escalation: Part 1|Monotherapy dose escalation of PF-07265807 in participants with select tumor types.
3371577|NCT04458259|Experimental|Doublet Dose Escalation: Part 2|Doublet combination dose escalation of PF-07265807 with sasanlimab in participants with select tumor types. PF-07265807 will dose escalate. Sasanlimab dose will stay constant.
3371578|NCT04458259|Experimental|Triplet Dose Escalation: Part 3|Triplet combination dose escalation of PF-07265807 with sasanlimab plus axitinib in participants with RCC. PF-07265807 will dose escalate. Sasanlimab dose will stay constant. Axitinib dose will follow label.
3371579|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 1|PF-07265807 monotherapy in participants with METex14 mutant NSCLC.
3371580|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 2|PF-07265807 with sasanlimab in participants with MSS CRC
3371581|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 3|PF-07265807 with sasanlimab in participants with PD-L1+ gastric cancer/GEJ
3371582|NCT04458259|Experimental|Expansion Phase: Part 4, Cohort 4|PF-07265807 with sasanlimab plus axitinib in participants with RCC
3371583|NCT04454905|Experimental|Camrelizumab combination with Apatinib|Camrelizumab 200mg, every 3 weeks, intravenous infused. Apatinib 250mg, once a day, orally. Until progression or unacceptable toxicity events develop.
3371589|NCT04441996|Experimental|Therapeutic plasma exchange (TPE)|Participants with COVID-19-associated hyperviscosity randomized to receive therapeutic plasma exchange (TPE).
3371590|NCT04441996|Active Comparator|Standard of care|Participants with COVID-19-associated hyperviscosity randomized to receive standard of care treatment.
3254163|NCT01421238|Experimental|Comfort Care Default Arm|"After receiving a description of an impending delivery of a 23 week gestational infant, participants in this arm were presented with the following information:~The doctor goes on to say that at this hospital infants born at 23 weeks will receive comfort care, unless their parents object. If you decline comfort care please check the box below:~Please check if you decline comfort care []"
3254164|NCT01421251||Matched cohorts - population based|Two cohorts: vaccinated individuals are matched to unvaccinated individuals on the basis of age, sex, and postal code of residence.
3254165|NCT01421264|Experimental|Gabapentin|
3371591|NCT04439175|Experimental|Treatment (taselisib)|Patients receive taselisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3371592|NCT04432532||Neuroendocrine Tumor|
3371593|NCT04432532||Adrenal Tumor|
3371594|NCT04429100||liver fibrosis stage F0|
3371595|NCT04429100||early-stage liver fibrosis (F1-2)|
3371596|NCT04429100||late-stage liver fibrosis (F3-4)|
3371597|NCT04418167|Experimental|Part A: JSI-1187 Monotherapy Dose Escalation|Locally advanced or metastatic solid tumors with confirmed with MAPK pathway mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
3371598|NCT04418167|Experimental|Part B: JSI-1187 Plus Dabrafenib Combination Dose Escalation|Locally advanced or metastatic solid tumors with confirmed BRAF V600 mutation, refractory to or relapsed on prior therapy and received all available therapy known to confer clinical benefit
3254166|NCT01421290|Active Comparator|Conservative treatment|
3371599|NCT04418167|Experimental|Part C: JSI-1187 Plus Dabrafenib Expansion|"Cohort 1: BRAF V600-mutated metastatic melanoma after two prior therapies for metastatic disease, including anti-PD1 therapy, with or without ipilimumab, and BRAF/MEK inhibitor treatment.~Cohort 2: BRAF V600-mutated metastatic melanoma after adjuvant therapy for Stage 3 disease followed by one prior therapy for metastatic disease, including anti-PD-1 therapy, with or without ipilimumab, or BRAF/MEK inhibitor treatment.~Cohort 3: Either BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC), or BRAF V600-muated metastatic solid tumor, after 1 or 2 prior therapies."
3371602|NCT04408638|Experimental|Glofit-GemOx|Participants will receive up to 8 cycles of glofitamab (Glofit) in combination with gemcitabine and oxaliplatin (GemOx), followed by up to 4 cycles of glofitamab monotherapy. A single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. Treatment is administered in 21-day cycles.
3371603|NCT04408638|Experimental|R-GemOx|Participants will receive rituxumab (R) in combination with gemcitabine and oxaliplatin (GemOx) for up to 8 cycles. Treatment is administered in 21-day cycles.
3254167|NCT01421290|Active Comparator|Surgery|
3254168|NCT01421368|Experimental|DMPA and tenofovir 1% gel|
3254169|NCT01421368|Experimental|Oral contraceptive and tenofovir 1% gel|
3254170|NCT01421394||single group study|
3371606|NCT04396691||Instructors group|Group of flight instructors at the reactor school.
3371607|NCT04396691||Students group|Group of students at the reactor school.
3371608|NCT04390971|Experimental|ET-01|BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.
3254171|NCT01421407|Active Comparator|High Intensity Focused Ultrasound|
3254172|NCT01421407|No Intervention|Control group|
3254173|NCT01421420||Alzheimer's Disease|
3254174|NCT01421420||Mild Cognitive Impairment|
3254175|NCT01421420||Other forms of Dementia, not AD|
3254176|NCT01421420||Normal Elderly Individuals|
3254177|NCT01421433|Active Comparator|Tandrilax|Reference product Intervention: Drug: Tandrilax (caffeine+carisoprodol+sodium diclofenac+paracetamol)
3254178|NCT01421433|Experimental|Dolamin Flex|Test product Intervention: Drug: Dolamin Flex (Lysine clonixinate and cyclobenzaprine)
3254179|NCT01421485|Experimental|Integrated treatment Program|
3254180|NCT01421485|Active Comparator|Treatment as Usual|
3254181|NCT01421524|Experimental|CC-122 MM-2|A new MM cohort (MM-2) will be enrolled in order to evaluate tolerability, safety and preliminary efficacy of the CC-122 formulated capsule given on an intermittent schedule (5/7 days per week) in 2 parallel dose escalation cohorts (MM-2a and MM-2b, respectively) (DEX) in Pomalidomide naïve subjects
3254182|NCT01421524|Experimental|CC-122- DLBCL-2|A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week [5/7 days] and/or 21 continuous days out of 28 days per cycle [21/28 days]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
3254183|NCT01421524|Experimental|CC-122- GBM-2|A new GBM cohort (GBM-2) in order to evaluate doses of CC-122 above the 3 mg QD MTD determined in all comers in Part A. CC-122 dose will increase in 1 mg increments starting with 4 mg daily on a continuous schedule using the 3+3 design described in Part A in order to establish an MTD specific for GBM subjects. Following dose escalation, the cohort will be expanded at or below the new MTD in up to 20 total subjects.
3254184|NCT01421524|Experimental|Primary Central Nervous System Lymphoma (PCNSL)|During dose expansion of selected intermittent schedules, an additional cohort of up to 10 subjects with PCNSL will also be explored at the same dose and schedule as DLBCL to confirm some safety and preliminary efficacy signal
3254185|NCT01421550|Active Comparator|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
3254186|NCT01421550|Active Comparator|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
3254187|NCT01421563|Active Comparator|Anplag|
3254188|NCT01421563|Experimental|DP-R202|
3254189|NCT01421576|Active Comparator|High fat meal|
3371610|NCT04387552|Experimental|Prenatal SS/Postnatal BF|Prenatal Safe Sleep/Postnatal Breastfeeding Mobile Health Messages
3371611|NCT04387552|Experimental|Prenatal BF/Postnatal SS|Prenatal Breastfeeding/Postnatal Safe Sleep Mobile Health Messages
3371612|NCT04387552|Experimental|Prenatal SS/Postnatal SS|Prenatal Safe Sleep/Postnatal Safe Sleep Mobile Health Messages
3371613|NCT04387552|Experimental|Prenatal BF/Postnatal BF|Prenatal Breastfeeding/Postnatal Breastfeeding Mobile Health Messages
3371614|NCT04387461|Experimental|Single Arm|"CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Day 1 to Week 6. If the patient shows persistent high-grade disease at Week 12, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 12 (e.g., complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 24, patients will receive weekly x 3 treatments every 3 months through Week 48 then every 24 weeks thereafter.~Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 3 weeks for up to 2 years."
3371615|NCT04379791||case cohort|Patients with a surgical site infection or a wound complication after surgical treatment of an ankle fracture. The time horizon for wound complication was set to maximally 4 weeks after surgery.
3371616|NCT04379791||control cohort|Patients without a surgical site infection or a wound complication (normal wound-healing and suture or staple removal) after surgical treatment of an ankle fracture.
3371617|NCT04372121|Experimental|Linzagolix 75 mg|
3371618|NCT04372121|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
3371621|NCT04366973||Participants with Hepatitis C Virus With or Without Treatment|"This study includes 3 populations for analysis:~Target Population (TP): Defined as all participants enrolled in the study regardless of whether treated for HCV or not.~Core Population (CP): Defined as all participants of the TP who have been prescribed glecaprevir/pibrentasvir (G/P) and started treatment.~Safety Population (SP): Defined as all participants who received at least one dose of G/P."
3371622|NCT04366856|Experimental|1: Prone positioning|the interventional group will be suggested to spend at least 6 hours a day in prone position
3371623|NCT04366856|Other|2: No instruction regarding positioning|the control group will get no instruction regarding positioning
3371624|NCT04366531|No Intervention|Monitoring/Treatment as usual|Veterans will not receive any study related interventions.
3254190|NCT01421576|Experimental|DP-R202|under fed condition
3254191|NCT01421615|Placebo Comparator|lotion|lotion:the patients in control group receive washing medicine and are followed up to the 4rd～7th days of postpartum.
3254192|NCT01421615|Experimental|lactobacilli capsule|
3371625|NCT04366531|Active Comparator|Reentry Program|Veterans will receive the START-VET reentry program
3254193|NCT01421615|Experimental|lactobacilli capsules|
3254194|NCT01421628|Experimental|exercise|
3254195|NCT01421680|Active Comparator|Ensure powder|Oral Nutritional Supplements with carbohydrate, lipid, protein, vitamin and minerals
3254196|NCT01421680|No Intervention|Standard care|Standard care without oral nutritional supplements
3254197|NCT01421693|Active Comparator|Gatifloxacin|Gatifloxacin 10mg/kg/day for 7 days
3371632|NCT04340362|Experimental|VX-147|Subjects will receive VX-147 orally at Dose 1 for 2 weeks and at Dose 2 for 11 weeks.
3371634|NCT04340063|Active Comparator|Treadmill group|Participants randomized to the Treadmill group will complete high intensity gait training on a treadmill.
3371635|NCT04340063|Experimental|Movement Amplification group|The locomotor training protocol described for the Treadmill group will be used for the Movement Amplification group with one exception. The Movement Amplification group will perform all gait training within the movement amplification environment.
3371637|NCT04331717|Experimental|Diet and exercise with BAE|After enrollment in the clinical trial, all men will be enrolled in diet and exercise counseling through the weight management program for a total of 4 weeks. If participants lose >5 pounds of total body weight from weight management alone in the first 4 weeks, these participants will be excluded from study and will not undergo BAE but will be encouraged to continue with weight management. Those still enrolled will undergo BAE. Within 7 days of BAE, men will be given ADT (lupron subcutaneous injection).
3371638|NCT04326075|Experimental|Early CPAP treatment|Early treatment with CPAP in addition to current clinical practice
3371639|NCT04326075|No Intervention|Control|Current clinical practice, which currently does not involve the use of CPAP.
3371640|NCT04321252|Experimental|Cohort A1: 10.5 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
3371641|NCT04321252|Experimental|Cohort A2: 30 mg/placebo|Single iv bolus dose of KAE609 or placebo administered at the clinical site by the study personnel.
3371642|NCT04321252|Experimental|Cohort A3: 75 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
3371643|NCT04321252|Experimental|Cohort A4: 120 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
3371644|NCT04321252|Experimental|Cohort A5: 210 mg/placebo|Single iv infusion dose of KAE609 or placebo administered at the clinical site by the study personnel.
3254198|NCT01421693|Active Comparator|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days"
3254199|NCT01421706|Active Comparator|sibutramine-clopidogrel|sibutramine-clopidogrel
3254200|NCT01421706|Active Comparator|sibutramine-clarithromycin|sibutramine-clarithromycin
3254201|NCT01421732||Suspected dengue fever|Children aged 1-15 presenting at participating hospitals with symptoms of dengue fever
3371645|NCT04321252|Experimental|Cohort B1: 60 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv bolus doses of KAE609 or placebo administered at the clinical site by the study personnel.
3371646|NCT04321252|Experimental|Cohort B2: 120 mg/placebo, every 24 hours (q24h) × 5 days|Multiple iv infusion doses of KAE609 or placebo administered at the clinical site by the study personnel.
3371647|NCT04320732||Individuals with COVID-19 infection|"Confirmed by routine laboratory diagnosis. All types of COVID-19 disease from asymptomatic carriers to hospitalized patients can be included.~Only subjects >18 years old will be included in the study."
3371648|NCT04320732||Individuals tested for COVID-19 infection with negative test|Confirmed by routine laboratory diagnosis
3371649|NCT04320732||Healthy individuals|Recruitet from the general population
3371650|NCT04320732||Risk groups for COVID-19 exposure|Including, but not limited to healthcare workers.
3254202|NCT01421745|Experimental|Cultural Competence Module|The module will include lecture, case studies, and discussion of cultural competence.
3254203|NCT01421758|Experimental|online social network|
3371651|NCT04320732||Patients admitted to hospital|Without COVID-19 infection.
3371656|NCT04312932|Experimental|Long chain polyunsaturated fatty acid (LCPUFA) Oil Supplement|25 mg/kg, 50 mg/kg, or 75 mg/kg of gamma-linoleic acid (GLA) + eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) as Omega 3-6 oil to be administered twice per day by mouth for 90 days
3371657|NCT04312932|Placebo Comparator|Canola Oil|Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
3371658|NCT04311086|Experimental|Renal Denervation|Renal angiography and Renal Denervation (Symplicity Spyral™ multi-electrode renal denervation system)
3371659|NCT04310449|Experimental|Connective tissue graft and customized healing abutment|Immediate implant placement with CTG and customized healing abutment.
3371660|NCT04310449|Experimental|Bone graft and customized healing abutment|Immediate implant placement with bone graft till the crest of the bone and customized healing abutment
3371661|NCT04310449|Experimental|Bone graft and ovate pontic|bone grafts in the socket and ovate Pontic
3254204|NCT01421758|Active Comparator|web education control|
3254205|NCT01421771|Active Comparator|Treatment to an intensive BP goal|Treatment to a pre-dialysis standardized dialysis unit systolic blood pressure of 110-140 mm Hg
3371662|NCT04310449|Active Comparator|Bone graft in dual zone and customized healing abutment|immediate implant placement with bone grafts in the dual zone and customized healing abutment
3371663|NCT04309409|Experimental|Nivolumab (Arm A)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Nivolumab will be applied at a flat dose of 480 mg given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year. Afterwards these patients will receive intense clinical follow up according German Follow up guidelines."
3371664|NCT04309409|No Intervention|Observation, High Risk (Arm B)|"Patients with a risk score of > 0.0 corresponding to high risk of relapse (randomized):~Control group (observation only). These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines."
3254206|NCT01421771|Placebo Comparator|Treatment to standard BP goal|Treatment to a pre-dialysis Standardized dialysis unit systolic BP of 155-165 mm Hg
3254207|NCT01421784|Other|Cine-MRI|Rapid Cine-MRI
3254208|NCT01421797|Experimental|Dexamethasone, Cortrosyn|Dexamethasone given 1 mg PO Cortrosyn given single IV bolus 0f 0.25 mg
3254209|NCT01421810|Experimental|dexamethasone, rhCG (Ovidrel)|rhCG (Ovidrel) administered 25 mcg IV; dexamethasone administered 1 mg PO
3371665|NCT04309409|No Intervention|Observation, Low Risk (Arm C)|"Patients with a risk score of ≤ 0.0 corresponding to low risk of relapse who are not eligible for randomization:~These patients will receive intense clinical follow up but no further specific therapy according German Follow up guidelines. Documentation of clinical outcome of these patients."
3371666|NCT04302025|Experimental|ALK Cohort|Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib.
3371667|NCT04302025|Experimental|ROS 1 Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
3371668|NCT04302025|Experimental|NTRK Cohort|Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib.
3371669|NCT04302025|Experimental|BRAF Cohort|Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib.
3371670|NCT04302025|Experimental|RET Cohort|Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per standard of care. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the Adjuvant Treatment Phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib.
3371671|NCT04299048|Experimental|PF-06946860|subcutaneous injection
3371673|NCT04285684|Other|Ketamine, lactation|Lactating women--4 subjects, 2 dosage format: ketamine 0;5mg/kg and 1.0mg/kg IM at least 5 days apart.
3371674|NCT04276779|Experimental|Alcohol and Negative Mood|
3371675|NCT04276779|Placebo Comparator|Placebo and Negative Mood|
3254210|NCT01421823|Experimental|alpha agonist ointment|
3254211|NCT01421823|Placebo Comparator|Placebo|
3371676|NCT04276779|Active Comparator|Alcohol and Positive Mood|
3371677|NCT04276779|Placebo Comparator|Placebo and Positive Mood|
3254212|NCT01421836|Active Comparator|ERCP guided stent insertion|
3371683|NCT04251806||Prenatal Repair|This group received prenatal myelomeningocele repair.
3371684|NCT04251806||Postnatal Repair|This group received postnatal myelomeningocele repair.
3371685|NCT04251663||HS subjects|Subjects with active HS disease, among which at least 5 will be treatment-naïve
3371686|NCT04251663||Healthy Controls|Healthy subjects
3371687|NCT04250259|Placebo Comparator|Placebo|Alcoholic Cirrhosis on placebo
3371688|NCT04250259|Experimental|1,200 mg SAMe|SAMe supplement (SAMe 400 mg tablet), 2 tablets in the morning before breakfast and one tablet in the evening before dinner (a total dose of 1,200 mg daily) for 24 months
3371689|NCT04250259|No Intervention|Non-drinking Controls|Non-drinking healthy controls
3371690|NCT04248829|Experimental|Lazertinib + Gefitinib-matching placebo|Lazertinib (240 mg or 160 mg orally, once daily) plus Gefitinib-matching placebo (250 mg orally, once daily) in accordance with the randomization schedule
3371691|NCT04248829|Active Comparator|Gefitinib + Lazertinib-matching placebo|Gefitinib (250 mg orally, once daily) plus Lazertinib-matching placebo (240 mg or 160 mg orally, once daily) in accordance with the randomization schedule
3254213|NCT01421836|Active Comparator|EUS guided stent insertion|
3254214|NCT01421849|Experimental|Elderly with an unstable mandibular denture.|
3254215|NCT01421901|Experimental|Ertapenem|
3254216|NCT01421901|Active Comparator|appendectomy|Appendectomy is compared to Ertapenem
3371692|NCT04248283|Experimental|Adjustable Continence Therapy for Women|Implantation of the Adjustable Continence Therapy for the treatment of female SUI.
3371693|NCT04234659||Individuals Receiving Mechanical Circulatory Device Support|Individuals receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
3371694|NCT04234659||Individuals Without Mechanical Circulatory Device Support|Individuals not receiving mechanical circulatory support device (specifically the IMPELLA® device) for treatment of their index peripartum cardiomyopathy complicated by cardiogenic shock event.
3371695|NCT04232761||CRPC patients|Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases who are treated with radium-223 dichloride in routine clinical practice in Taiwan
3371697|NCT04198766|Experimental|Part 1 INBRX-106 Escalation|INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.
3254217|NCT01421914|Other|Bupivacaine 0,5%|Single arm study
3254218|NCT01421927|Experimental|lenalidomide|
3254219|NCT01421940|Placebo Comparator|Control|Individuals who take placebo after total mesorectal excision
3371698|NCT04198766|Experimental|Part 2 INBRX-106 Expansion|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.
3371699|NCT04198766|Experimental|Part 3 INBRX-106 Escalation in Combination with Pembrolizumab|INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.
3254220|NCT01421940|Experimental|Udenafil|Individuals who take udenafil after total mesorectal excision
3254221|NCT01421953|Experimental|Patients|
3254222|NCT01421966|Experimental|CureXcell®|
3371700|NCT04198766|Experimental|Part 4 INBRX-106 Expansion in Combination with Pembrolizumab|Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.
3371703|NCT04191499|Experimental|Inavolisib + Palbociclib + Fulvestrant|Participants will receive inavolisib, palbociclib, and fulvestrant.
3371704|NCT04191499|Placebo Comparator|Placebo + Palbociclib + Fulvestrant|Participants will receive placebo, palbociclib, and fulvestrant.
3371705|NCT04190212|Experimental|High-intensity interval training|Participants will complete 12 supervised high-intensity interval exercise sessions (3 times weekly for 4 weeks).
3371706|NCT04190212|No Intervention|Standard care|Participants will not participate in on-site supervised exercise sessions.
3371707|NCT04176445|Other|Bedside Sitting followed by Orthostatic Board|Bedside sitting posture protocol followed by orthostatic board posture protocol.
3371708|NCT04176445|Other|Orthostatic Board followed by Bedside Sitting|Orthostatic board posture protocol followed by bedside sitting posture protocol.
3371709|NCT04144023|Experimental|Treatment (multi-epitope HER2 peptide vaccine H2NVAC, GM-CSF)|Prior to standard of care surgery, patients receive GM-CSF admixed with multi-epitope HER2 peptide vaccine H2NVAC intradermally on day 1. Treatments repeat every 14 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
3371710|NCT04140500|Experimental|Part A: Single-Agent Dose Escalation|Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
3371711|NCT04140500|Experimental|Part B: Tumor Specific Expansion Cohorts|Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.
3371712|NCT04133233|Experimental|active treatment|"IL-2 (ILT-101) Sub-cutaneous~1 million UI/j"
3371713|NCT04133233|Placebo Comparator|placebo|placebo Sub-cutaneous The Placebo used is a sterile powder that will be produced by the CMO (AMATSI, France).
3371714|NCT04126213|Experimental|RSV MAT 60 Group-Mother|Maternal subjects randomized to RSV MAT 60 Group received a single dose of RSV MAT (60 µg) vaccine at Day 1, and were followed up until the study end.
3371715|NCT04126213|Experimental|RSV MAT 120 Group-Mother|Maternal subjects randomized to RSV MAT 120 group received a single dose of RSV MAT (120 µg) vaccine at Day 1, and were followed up until the study end.
3371716|NCT04126213|Placebo Comparator|Control Group-Mother|Maternal subjects randomized to the Control Group received a single dose of Placebo at Day 1, and were followed up until the study end.
3371717|NCT04126213|No Intervention|RSV MAT 60 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 60 Group-Mother) who received a single dose of RSV MAT (60 µg) vaccine during pregnancy.
3371718|NCT04126213|No Intervention|RSV MAT 120 Group-Infant|This group consisted of infants born to mothers (from RSV MAT 120 Group-Mother) who received a single dose of RSV MAT (120 µg) vaccine during pregnancy.
3371719|NCT04126213|No Intervention|Control Group-Infant|This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
3371720|NCT04116099||Conservative care alone|Conservative care alone which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
3254223|NCT01421966|Sham Comparator|Sham injection|
3254224|NCT01421979|Experimental|exposure under sleep deprivation|Examination of the effects of EDs in combination with alcohol consumption and sleep deprivation.
3254225|NCT01421979|Experimental|Exercise after consumption|Examination of the effects of EDs in combination with alcohol consumption and exercise.
3254226|NCT01421992|Placebo Comparator|Arm 1: Methylphenidate versus baseline|
3254227|NCT01421992|Placebo Comparator|Arm 2: Placebo versus baseline|One table placebo per day during 3 week
3371721|NCT04116099||Flexitouch Plus and conservative care|Flexitouch Plus and conservative care which includes Flexitouch Plus treatment as well as conservative care measures which may include graduated compression, manual lymphatic drainage (MLD) performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
3371722|NCT04111211||Individuals at high risk of developing Alzheimer's dementia|
3371725|NCT04107129||Known Endometriosis|Known Endometriosis undergoing IVF with PGTA
3371726|NCT04107129||Unexplained Infertility|Unexplained Infertility undergoing IVF with PGTA
3371727|NCT04107129||Low Risk Controls|Low Risk Controls undergoing IVF with PGTA
3371728|NCT04103788|Active Comparator|95% Curcuminoid Powder|Curcumin powder standardized to >95% curcuminoids, single dose, used to determine standard absorptivity of unformulated powder.
3371729|NCT04103788|Experimental|CurQ+|Highly absorbed curcumin coconut oil emulsion, single dose, used to produce serum samples for analytical comparison of sample preparation methodologies.
3254228|NCT01422005|Experimental|Experimental group|Simultaneous Bimanual training: Patients who have had either an acute/subacute and a Chronic stroke will get training on the devices.
3254229|NCT01422005|Active Comparator|Control Group|Conventional Occupational Therapy: Patients who have had either an acute/subacute and Chronic Stroke with hemiperisis will get conventional therapy.
3371734|NCT04091451|Experimental|HZ/su Group|Subjects randomized to the HZ/su group will receive 2 doses of HZ/su vaccine at visit day 1 and visit month 2 and will be followed up until the study end.
3371735|NCT04091451|Placebo Comparator|Placebo Group|Subjects randomized to Placebo group will receive placebo at visit day 1 and visit month 2 and will be followed up until the study end.
3371736|NCT04090957|Experimental|Estetrol 15 mg - Efficacy Part|Estetrol (E4) 15 mg will be administered orally once daily for 52 consecutive weeks.
3371737|NCT04090957|Experimental|Estetrol 20 mg - Efficacy Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
3254230|NCT01422018|Experimental|one arm for Anastin injection|intravitreal Avastin injection
3254231|NCT01422031||Regular Family Doctor (RFD)|People had a regular primary care doctor who is a family doctor
3254232|NCT01422031||Regular not Family doctor (RnFD)|People had a regular primary care doctor who is not a family doctor
3371738|NCT04090957|Placebo Comparator|Placebo - Efficacy Part|Placebo will be administered orally once daily for 52 consecutive weeks.
3371739|NCT04090957|Experimental|Estetrol 20 mg - Safety Part|Estetrol (E4) 20 mg will be administered orally once daily for 52 consecutive weeks.
3371745|NCT04079218|Experimental|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
3371746|NCT04079218|No Intervention|No treatment|No intervention
3254233|NCT01422031||Not regular doctor (NRD)|People had no regular primary care doctor
3254234|NCT01422096|Experimental|leuprolide|leuprolide 11.25 mg IM with adrenal suppression/stimulation testing with dexamethasone/Cortrosyn and ovarian stimulation testing with r-hCG before and 3 weeks after injection
3254235|NCT01422109|Experimental|Group A|
3254236|NCT01422109|Active Comparator|Group B|
3254237|NCT01422122|Experimental|Vitamin D|Oral vitamin D3 in syrup form
3254238|NCT01422122|Placebo Comparator|placebo|Placebo syrup identical in colour and taste to that of intervention
3254239|NCT01422148|Other|Amiodarone|oral amiodarone
3254240|NCT01422148|Experimental|minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
3254241|NCT01422174||ICD implantation|Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
3254242|NCT01422174||Non ICD implantation|Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
3254243|NCT01422252|Experimental|Persons equipped|Precocious fall detection device
3254244|NCT01422252|No Intervention|Persons non-equipped|No fall detection device
3254245|NCT01422265||Cohort|
3254246|NCT01422291|Active Comparator|morphine|
3254247|NCT01422291|Experimental|Paracetamole, dexketoprofen|Paracetamole, dexketoprofen
3254248|NCT01422317|Experimental|n-3 fatty acids|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each capsule containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters, in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
3371747|NCT04078152|Experimental|Treatment|Durvalumab Monotherapy
3371748|NCT04078152|No Intervention|Off Treatment|Follow up Only
3371749|NCT04077723|Experimental|Part I|Combination Dose-Escalation: Mixed r/r NHL participants will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by intravenous (IV) infusion in combination with obinutuzumab in a three-weekly schedule (Q3W).
3371750|NCT04077723|Experimental|Part II|Combination Dose-Escalation: Mixed r/r participants and participants with mixed r/r mantle cell lymphoma (MCL) and Richters transformation will receive a fixed dose of obinutuzumab seven days prior to first administration of RO7227166. RO7227166 will be administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
3371751|NCT04077723|Experimental|Part III|Dose-Expansion Stage: Participants with r/r follicular lymphoma (FL), r/r diffuse large B-cell lymphoma (DLBCL), and r/r MCL will receive RO7227166 administered by IV infusion in combination with glofitamab in a three-weekly schedule (Q3W).
3371757|NCT04052581||POEM-TIF|All participants will undergo the POEM-TIF in the same session.
3254249|NCT01422317|Active Comparator|Corn Oil|Two gelatine capsules twice a day, each containing 1 gram of corn oil. Alpha-Tocopherol (4 mg) was added to each capsule.
3254250|NCT01422330|Experimental|Etravirine|
3254251|NCT01422343||1|
3254252|NCT01422395|Experimental|freezing|
3254253|NCT01422395|No Intervention|No freezing|
3254254|NCT01422421|Active Comparator|intensive control|systolic blood pressure less than 120mmHg and LDL cholesterol within 70- 85mg/dl
3254255|NCT01422421|Active Comparator|standard control|systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
3254256|NCT01422447|Experimental|community intervention|Feedback on assessment results: distribute relevant brochures and hold regular lectures on depression, anxiety and alcohol-abuse.
3254257|NCT01422447|Active Comparator|regular intervention control|the subjects in the control group live in the used model
3254258|NCT01422460|Experimental|Platelet Rich Plasma|intra articular injection 2ml of platelet-derived preparation rich in growth factors
3254259|NCT01422473|Experimental|EnSeal Device|EnSeal Trio Tissue Sealing Device
3254260|NCT01422486|Experimental|ezatiostat hydrochloride (Telintra®)|Patients received ezatiostat at a starting dose of 2000 mg total daily dose in divided doses (1000 mg PO b.i.d.) for three weeks (21 days) on therapy followed by a one-week (7 days) off therapy rest period in four-week (28 days) treatment cycles.
3254261|NCT01422512|Experimental|cell culture derived TIV|single dose of cell culture derived seasonal trivalent influenza vaccine (TIV)
3254262|NCT01422525||Trabeculectomy RNFL thickness OCT|
3254263|NCT01422551|Experimental|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
3254264|NCT01422551|Active Comparator|Psycho-educational Control|a single day group-based psycho-educational seminar
3254265|NCT01422564|Active Comparator|Metal on Metal|Metal on Metal articulation system
3254266|NCT01422564|Active Comparator|HCLPC|THA using Highly Cross Linked Polyethylene cup System
3254267|NCT01422577|Active Comparator|Bright Narrow Band Imaging|Bright Narrow Band Imaging
3254268|NCT01422577|Active Comparator|White Light Endoscopy|White Light Endoscopy
3254269|NCT01422590|Active Comparator|Sitagliptin|
3254270|NCT01422590|Active Comparator|Mitiglinide|
3254271|NCT01422590|Experimental|Sitagliptin + Mitiglinide|
3254272|NCT01422603|Experimental|Clofarabine and Full intensity SCT|Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned allogeneic stem cell transplant (SCT).
3254273|NCT01422603|Experimental|Clofarabine and Reduced intensity SCT|Cohort 2: Patients not suitable for a full intensity TBI-based transplant due to age or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and Campath 1H.
3254274|NCT01422616|Experimental|Low-dose rtPA (Recruitment completed in August 2015)|low-dose 0.6 mg/kg (maximum of 60 mg) i.v. rtPA
3254275|NCT01422616|Active Comparator|Standard-dose rtPA (Recruitment completed in August 2015)|standard-dose 0.9 mg/kg (maximum of 90 mg) i.v. rtPA
3254276|NCT01422616|Experimental|Early intensive BP lowering|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents (e.g. Labetalol Hydrochloride, Metoprolol tartrate, Hydralazine Hydrochloride, Glycerol Trinitrate, Phentolamine mesylate, Nicardipine, Urapidil, Esmolol, Clonidine, Enalaprilat, Nitroprusside) will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA."
3371767|NCT04026009|Experimental|CDIFF Ag 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
3371768|NCT04026009|Placebo Comparator|Placebo 18 - 45 Years Group|Healthy male and female subjects, aged between and including 18 and 45 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
3254277|NCT01422616|Active Comparator|Control / guideline-based BP management|"The trial is an assessment of BP lowering management strategies, using routinely available drugs.~Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the American Heart Association (AHA). For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved."
3254278|NCT01422629|Experimental|High Intensity Focused Ultrasound (HIFU)|
3371769|NCT04026009|Experimental|CDIFF Ag 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF antigen (Ag) vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
3371770|NCT04026009|Experimental|CDIFF Ag + AS01B 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive CDIFF Ag + AS01B adjuvant vaccine administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule. A third dose of CDIFF Ag + AS01B adjuvant vaccine is to be administered to a subcohort of subjects aged 50-70 years, approximately 15 months after the administration of the second dose.
3371771|NCT04026009|Placebo Comparator|Placebo 50 - 70 Years Group|Healthy male and female subjects, aged between and including 50 and 70 years old, who receive Placebo administered intramuscularly in the deltoid, according to a 0, 1-month vaccination schedule.
3371772|NCT04013555|Experimental|N-acetylcysteine & Tryptophan|N-acetylcysteine 140 mg/kg up to a maximum of 15 g. Thirty minutes after N-acetylcysteine administration participants will receive Tryptophan, 6 grams.
3371773|NCT04013555|Placebo Comparator|Placebo & Tryptophan|Placebo 140 mg/kg up to a maximum of 15 g. Thirty minutes after placebo administration participants will receive Tryptophan, 6 grams.
3254279|NCT01422642|Experimental|legacy posterior stabilized high-flexion|NexGen LPS-Flex total knee system
3254280|NCT01422642|Experimental|legacy posterior stabilized standard|standard NexGen LPS prosthesis
3371774|NCT03994172|Experimental|teriparatide (TPTD) + the calcimimetic cinacalcet|Combination arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a 30-mg tablet of cinacalcet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
3254281|NCT01422668|Active Comparator|GI of Khalas dates|The Glycemic indices of the Khalas dates were measured for healthy and diabetic subjects.
3254282|NCT01422668|Experimental|GI of the Khalas dates with Coffee|measuring the effect of 100 ml of coffee consumption on the GI of the Khalas dates among healthy and diabetic subjects.
3254283|NCT01422681|Experimental|DECOPD|patients with severe COPD exacerbation on NIV treated with the minimally invasive extracorporeal carbon dioxide removal device (Decap Smart)
3371775|NCT03994172|Placebo Comparator|teriparatide (TPTD) + placebo|Monotherapy arm: Men randomized to this arm will take daily subcutaneous injections of teriparatide [PTH (1-34)] (20 mcg per day) and at the same time swallow a placebo tablet. Men in both arms of the study will take a total of approximately 1000 mg elemental Ca through their diets and study provided Ca supplements (Ca citrate) and approximately 1000 IU vitamin D3. Men will be followed and assessed throughout the entire study using the clinical (vital signs, adverse events), laboratory (blood and urine tests) and densitometric procedures (DXA BMD and TBS) outlined in the study protocol.
3371776|NCT03993054|Active Comparator|Standard CBSM|Participants will receive standard web-based cognitive behavioral stress management (CBSM) over 4 weeks.
3371777|NCT03993054|Experimental|Culturally-tailored CBSM|Participants will receive web-based CBSM that is culturally-tailored for Latino men specifically over 4 weeks.
3371780|NCT03989206|Experimental|Nemolizumab|Nemolizumab administered via subcutaneous injection
3371781|NCT03986944|Experimental|Linzagolix 75 mg|
3371782|NCT03986944|Experimental|Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)|
3371783|NCT03986944|Placebo Comparator|Placebo|
3254287|NCT01422707|Experimental|hydrocortisone|4 weeks hydrocortisone with pre- and post-intervention Dexamethasone and Cosyntropin to perform standardized adrenal stimulation testing
3254288|NCT01422733|Experimental|hydrocortisone, dexamethasone, Cosyntropin (ACTH), rhCG|12 weeks hydrocortisone, dexamethasone, and Cosyntropin (ACTH) to perform standardized adrenal stimulation testing; dexamethasone, and rhCG to perform standardized ovarian stimulation testing
3254289|NCT01422746|Experimental|metformin|12 weeks metformin, with pre- and post- dexamethasone and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
3254290|NCT01422759|Experimental|spironolactone|12 weeks spironolactone with pre- and post-intervention dexamethasone, and ACTH to perform standardized adrenal stimulation testing; dexamethasone and rhCG to perform standardized ovarian stimulation testing
3371785|NCT03941730|Experimental|Treatment (estradiol)|Patients receive estradiol PO TID for days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3371786|NCT03939767||wAMD patients|Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.
3371787|NCT03937973|Experimental|Social rejection by in-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone of their own race/ethnicity (e.g., African American rejected by another African American).
3371788|NCT03937973|Experimental|Social rejection by out-group|One hour prior to bed, participants will be exposed to a social rejection paradigm that includes a computerized ball-tossing game (Cyberball) and a speech task. Participants are made to believe that they are being rejected by someone not of their own race/ethnicity (e.g., Caucasian American rejected by another African American).
3371792|NCT03924947|Experimental|Arm A|Participants will receive Pancrelipase delayed release (DR) Capsules manufactured by modernized process uniform coated pellets (MP) in treatment period 1, followed by currently marketed Pancrelipase DR Capsules in treatment period 2.
3371793|NCT03924947|Experimental|Arm B|Participants will receive currently marketed Pancrelipase DR Capsules in treatment period 1, followed by Pancrelipase DR Capsules manufactured by MP in treatment period 2.
3254291|NCT01422772|Experimental|Cohort I|0.5mg/1mL of VM202RY was intramuscularly injected into 4 sites
3254292|NCT01422772|Experimental|Cohort II|1mg/2mL of VM202RY was intramuscularly injected into 8 sites
3371794|NCT03924947|Experimental|Arm C|Participants will receive Pancrelipase DR Capsules manufactured at a Alternate Active Pharmaceutical Ingredient Site (AAPIS) in treatment period 1, followed by currently marketed Pancrelipase DR Capsules in treatment period 2.
3371795|NCT03924947|Experimental|Arm D|Participants will receive currently marketed Pancrelipase DR Capsules in treatment period 1, followed by Pancrelipase DR Capsules manufactured at an AAPIS in treatment period 2.
3371796|NCT03924661||Single Arm|Surgical treatment of a diseased, damaged, or malfunctioning aortic valve using SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve surgical replacement device
3371799|NCT03919435|Experimental|On Drug|
3254293|NCT01422772|Experimental|Cohort III|2mg/4mL of VM202RY was intramuscularly injected into 8 sites
3254294|NCT01422785|Active Comparator|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|
3254295|NCT01422785|Active Comparator|clindamycin / tretinoin gel plus benzoyl peroxide|
3254296|NCT01422811|Experimental|Intervention|
3254297|NCT01422811|Other|Control|No Intervention
3254298|NCT01422863|Experimental|Lifestyle Intervention|
3254299|NCT01422902|Experimental|Plasticity-based Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 130 hours
3254300|NCT01422902|Active Comparator|Non-plasticity-based Training|Commercially available computerized training, up to 130 hours
3254301|NCT01422928|No Intervention|Standard treatment|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
3371800|NCT03916458||Subjects with reported metastatic renal cell carcinoma|The subjects have been treatment with sunitinib and they reached complete remission
3254302|NCT01422928|Experimental|Acupuncture|"Patients receiving standard radiation therapy for gastrointestinal or urogenital cancers with concurrent acupuncture once a week for 4 weeks.~All subjects will be asked to give 20 mL of blood and complete the Edmonton Symptom Assessment Form (ESAS) on 3 occasions:~before radiation~at 1st follow up 4-10 weeks after radiation completion~at second follow up 6 months after 1st follow up"
3254303|NCT01422941|Experimental|CAVU Attune Device|
3254304|NCT01422954|Active Comparator|Chloroquine immunisation|This group will receive chloroquine prophylaxis, and three times infected mosquito-bites.
3254305|NCT01422954|Experimental|Mefloquine immunisation|This group will receive mefloquine prophylaxis and infected mosquito-bites.
3254306|NCT01422954|Placebo Comparator|Mefloquine control|This group will receive mefloquine prophylaxis, and uninfected mosquito-bites.
3254307|NCT01422967|Active Comparator|Osteoarthritis group|
3254308|NCT01422967|Active Comparator|without osteoarthritis|
3254309|NCT01422980|Active Comparator|1 = Test product|Arm 1 - intervention 1 (test product)
3254310|NCT01422980|Placebo Comparator|2 = Control product|Arm 2 - intervention 2 (control product)
3254311|NCT01422993|Experimental|Excercise and Questionnaire|12 week exercise program followed by questionnaire.
3254312|NCT01423006|Experimental|Focal Prostate Radio-Frequency Ablation|Treatment is performed under a spinal or general anesthetic and will include the one to three regions of the prostate containing cancer based on the mapping biopsy.
3371814|NCT03887936|Experimental|Testosterone arm|Testosterone gel 1.62%
3371815|NCT03887936|Placebo Comparator|Placebo arm|Matching placebo will be prepared by the Michael DeBakey VA Medical Center Pharmacy.
3254313|NCT01423019|Active Comparator|Advantra Z|Proprietary ingredient for: stimulating thermogenesis, reducing weight, increasing lean muscle mass to total body mass, improving athletic performance, and suppressing appetite
3254314|NCT01423019|Active Comparator|Advantra Z + Naringin + Hesperiden|
3254315|NCT01423019|Placebo Comparator|Sugar pill|Capsule contains inert ingredient.
3254316|NCT01423032|Experimental|Bendamustine|
3254317|NCT01423032|Active Comparator|Fludarabine|
3254318|NCT01423058|Experimental|Momelotinib|
3254319|NCT01423071||COPD with PH|COPD patients with confirmed diagnosis of PH.
3254320|NCT01423071||COPD without PH|COPD patients without confirmed diagnosis of PH
3254321|NCT01423071||PAH without COPD|PAH patients who do not suffer from COPD
3254322|NCT01423110|Experimental|BYM338|
3254323|NCT01423110|Placebo Comparator|Placebo|
3259503|NCT01471431|Experimental|Spontaneous breathing trial|The spontaneous breathing trial will determine the extubation readiness of the subject.
3371816|NCT03884439||Infliximab [infliximab biosimilar 3]|Patients with Crohn's Disease or Ulcerative Colitis treated by Infliximab BS
3371817|NCT03878134|Active Comparator|Patients|750 male or female, 18 and older patients
3371818|NCT03866785|Other|STEP 1: Patient with prostate cancer|First, patients with prostate cancer will be included during step 1. They will have an interview.
3371819|NCT03866785|Other|STEP 2: Patient with prostate cancer and a physical activity|"Secondly, patient with prostate cancer and a physical activity will be included during step 2. They are called peer.~They will have a questionnaire Adult Physical Activity Questionnaire (APAQ), an activity actigraph and a peer training. The peer will help patients to realize the Physical Activity Program during step 3."
3371820|NCT03866785|Other|STEP 3: Physical Activity Program|"Finally, patients with prostate cancer (different from step 1) and who agrees to participate at the Physical Activity Program will be included during step 3.~They will have an activity actigraph and a questionnaire Adult Physical Activity Questionnaire (APAQ) at inclusion and 3 months later.~They will receive the Physical Activity Program."
3371821|NCT03859167||Participants with AV block with pacemaker|Participants will have a stress test, and results will be collected and recorded.
3371822|NCT03849326|Experimental|"Non-fatigued patients"|
3371823|NCT03849326|Experimental|"Fatigued patients"|
3371824|NCT03842969|Experimental|RO7234292 (RG6042) Q8W|Participants who received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q8W. Participants who previously received open-label of RO7234292 Q8W in a preceding study or are currently receiving RO7234292 Q8W in this study will receive RO7234292 Q8W. Participants who previously received placebo, or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q8W. Participants who previously received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q8W will receive open-label RO7234929 Q8W. Participants who received blinded placebo Q8W may receive RO7234292 Q8W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q8W.
3371825|NCT03842969|Experimental|RO7234292 (RG6042) Q16W|Participants who previously received open-label RO7234292 Q4W in a preceding study or who received RO7234292 Q4W in this study may be randomly allocated to receive RO7234292 Q16W. Participants who previously received placebo in a preceding study or did not previously receive treatment with RO7234292 or received short-term treatment with a treatment-free follow-up period may be randomly allocated to receive RO7234292 Q16W. Participants who previously received blinded placebo Q8W will receive RO7234292 Q8W. Participants who previously received blinded RO7234292 Q16W will receive open-label RO7234292 Q16W. Participants who received blinded RO7234292 Q4W or blinded placebo Q4W may be randomly allocated to receive open-label of RO7234292 Q16W. Participants who previously received open-label RO7234292 Q16W will receive open-label RO7234292 Q16W.
3371826|NCT03842137|Active Comparator|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
3371827|NCT03842137|Sham Comparator|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
3371828|NCT03841760|Experimental|PSMA PET/CT|One (1) PSMA PET/CT scan with with either PSMA-11 or DCFPyL
3371829|NCT03831711|Experimental|Diagnostic (68-Ga RM2, PET/MRI)|Patients receive 68-Ga RM2 IV and after 45 minutes undergo PET/MRI over 30-60 minutes.
3371832|NCT03829683|Active Comparator|Vitamin C infusion (ascorbic acid)|Vitamin C 200mg/kg/24hours administered in four doses per day (given every 6 hours)
3371833|NCT03829683|Placebo Comparator|Placebo|Dextrose 5% in water 50 milliliters (mL) administered intravenously every 6 hours
3371834|NCT03829462|Experimental|Irinotecan + regorafenib (REGIRI)|irinotecan (180 mg/m2) at day1 of each cycle + regorafenib (160 mg/day) from day 2 to day 8
3371835|NCT03829462|Active Comparator|regorafenib|Regorafenib (160 mg/day) for 3 weeks followed by 1 week off
3371836|NCT03809624|Experimental|Single Agent Escalation|INBRX-105 will be escalated in patients with locally advanced or metastatic solid tumors.
3371837|NCT03809624|Experimental|Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
3371838|NCT03809624|Experimental|Expansion Cohort Melanoma|Patients will be treated with single-agent INBRX-105 at either the MTD or RP2D.
3371839|NCT03809624|Experimental|Expansion Cohort PD-L1 Positive Basket|Patients with gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
3371840|NCT03809624|Experimental|Expansion Cohort Head and Neck Squamous Cell Carcinoma|Patients with head and neck squamous cell carcinoma will be treated with single-agent INBRX-105 at either the MTD or RP2D.
3371841|NCT03809624|Experimental|INBRX-105 Escalation in Combination with Pembrolizumab|INBRX-105 will be escalated in combination with Pembrolizumab in pateitns with locally advanced or metastatic solid tumors.
3371842|NCT03809624|Experimental|Combination Expansion Cohort Non-small Cell Lung Cancer|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
3371843|NCT03809624|Experimental|Combination Expansion Cohort Melanoma|Patients will be treated with INBRX-105 in combination with Pembrolizumab.
3254324|NCT01423123|Experimental|Neratinib|Paclitaxel (80 mg/m2 IV on days 1, 8, and 15 every 28 days) and trastuzumab (4 mg/kg/ loading dose, then 2 mg/kg) IV weekly beginning on day 1 of paclitaxel, neratinib orally daily beginning on day 1 of paclitaxel until disease progression.
3254325|NCT01423136||Routine postop care + Holter Monitoring|With sham remote ECG ST Monitoring
3254326|NCT01423136||Routine postop care + Holter + remote ECG monitoring|
3254327|NCT01423149|Experimental|36 mg/m2 Combretastin A-4 Phosphate|
3371844|NCT03809624|Experimental|Combination Expansion Cohort Cohort PD-L1 Positive Basket|Patients with head and neck squamous cell carcinoma, gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-105 in combination with Pembrolizumab.
3371845|NCT03809624|Experimental|Combination Expansion Cohort Treatment Naive Non-small Cell Lung Cancer|Treatment naive patients (PD-L1 IHC between 1 and 49%) will be treated with INBRX-105 in combination with Pembrolizumab.
3371846|NCT03805932|Experimental|1|Moxetumomab Pasudotox-tdfk + Rituximab
3371847|NCT03802110|Experimental|Single Arm|Defibrillation threshold (DFT) testing Arm
3371848|NCT03783975|Experimental|Simplified Cascade Screening|Free, mail-in, saliva-based screening for the KCNQ1 Thr224Met variant.
3371849|NCT03774641||Taking Lamotrigine|Lamotrigine (Lamictal), dosage will be based on a reference concentration of blood-serum levels
3254328|NCT01423149|Experimental|45 mg/m2 Combretastatin A-4 Phosphate|
3254329|NCT01423149|Experimental|27 mg/m2 Combretastatin A-4 Phosphate|
3254330|NCT01423175|Experimental|ClAraC|
3254331|NCT01423175|Active Comparator|FLAMSA|
3254332|NCT01423188|Experimental|RVX000222, 200 mg daily|
3254333|NCT01423188|Placebo Comparator|Placebo|
3371852|NCT03746704|Experimental|89Zr˗DFO˗REGN3504|Part A: Cohorts 1-3 Part B
3371853|NCT03735589|Experimental|Treatment (nCTLs, alpha-DC1 vaccine)|Patients receive the alpha-type-1 polarized dendritic cell vaccine ID 2 weeks before day 0, on day 0, and on day 28. Patients also receive aDC1 IP over 3-10 seconds on day 0. In the absence of unacceptable side effects, patients may receive the alpha-type-1 polarized dendritic cell vaccine every 1-3 months at the discretion of the physician.
3371860|NCT03710720|Experimental|TF-CBT plus TIPS app|
3371861|NCT03710720|Active Comparator|TF-CBT|
3371862|NCT03700606|Active Comparator|Nasal CPAP - Period 1|"Eligible infants stable on high flow nasal cannula (nCPAP) therapy of 5-7 cm H20 achieved with a ventilator, an underwater bubble system, or a variable-flow device will be enrolled. A data acquisition cart will be placed at the subject's bedside to collect hemodynamic and respiratory parameters measured including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices. A neonatal chest belt, sized to the infant's chest circumference (nipple level) using warmed ultrasound gel applied to the belt beforehand, will collect regional lung volume measurements using electrical impedance tomography (EIT). Subject video recording will capture apnea events and the interventions used to resolve them such as positive pressure ventilation, repositioning, or stimulation. Data will be collected for 15 minutes on nCPAP."
3371863|NCT03700606|Active Comparator|High Flow Nasal Cannula (HFNC) - Period 2 & 3|Respiratory support will be crossed over to a HFNC Optiflow Jr 2 (Fisher & Paykel Healthcare, Auckland, New Zealand) at a flow rate of 8 LPM. The size of the nasal cannula will be determined according to the manufacturer's instructions in order to maintain a leak at the nares. Identical data collection will occur for two 15 minute periods on HFNC, at the beginning and end of the six hour Study period.
3371864|NCT03700606|Active Comparator|Nasal CPAP - Period 4|After 6 hours of HFNC of 8 LPM, or sooner if the infant meets failure criteria, the infant will then be crossed back to the nCPAP device and at the settings previously utilized in Study Period 1. The infant will remain on the nCPAP device with identical data collection for 15 minutes. The total duration of the study and data collection will be 8 hours. The infant's body position will be similar for each lung volume measurement during the study periods.
3371865|NCT03697577||ER+/HER2- metastatic breast cancer|Subjects have metastatic ER+/HER2- breast cancer, and their doctor is offering treatment with CDK 4/6 inhibitors as standard of care treatment.We hypothesize that cyclin-dependent kinase (CDK) 4/6 inhibitors decrease fat mass among women with ER+/HER2- metastatic breast cancer without significant effect in the skeletal mass. Body composition will be obtained from CT scans (CT or PETCT) as part of their standard of care, and body fat mass will be obtained from DEXA scan(as part of proposed study)
3371866|NCT03695380|Experimental|Arm A: Cobimetinib - Niraparib|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1, Cohort 1.
3254334|NCT01423214|Experimental|Robotic LAR|Individuals who underwent robot-assisted surgery for primary rectal cancer
3254335|NCT01423214|Active Comparator|Lap LAR|Individuals who underwent laparoscopic surgery for primary rectal cancer
3254336|NCT01423227|Experimental|Home-based pulmonary rehabilitation|Home visit plus 8 weeks of once-weekly telephone calls
3254337|NCT01423227|Active Comparator|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
3254338|NCT01423240|Experimental|Lurasidone 20 mg|
3254339|NCT01423240|Experimental|Lurasidone 60 mg|
3254340|NCT01423240|Placebo Comparator|Placebo|
3254341|NCT01423266|Experimental|High Protein Group|12-week supervised weight loss program consisting of a HP diet defined as 30% of energy from protein, 40% from carbohydrates and 30% from fat
3254342|NCT01423266|Active Comparator|Standard Protein Group|12-week supervised weight loss program consisting of a SP diet defined as 15% of energy from protein, 55% from carbohydrates and 30% from fat
3371867|NCT03695380|Experimental|Arm B: Cobimetinib - Niraparib - Atezolizumab|Stage 2 - Patients will receive cobimetinib PO QD on Days 1-21 (21/7 schedule) in combination with niraparib QD on Days 1-28 at the established doses for the triplet regimen in Stage 1,Cohort 2 plus atezolizumab by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle.
3371868|NCT03695380|Experimental|Cohort 1 - Cobimetinib - Niraparib|"Stage 1 - Patients in Cohort 1 will be treated with cobimetinib plus niraparib.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle."
3371869|NCT03695380|Experimental|Cohort 2 - Cobimetinib - Niraparib - Atezolizumab|"Stage 1 - Patients in Cohort 2 will be treated with cobimetinib plus niraparib and atezolizumab.~Cobimetinib: Patients will receive a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle.~Niraparib: Patients will receive a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle.~Atezolizumab: Patients will also receive atezolizumab administered as an IV infusion at a fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle."
3371870|NCT03690596|Experimental|NRT + QuitBuddy|This smartphone app will identify high-risk situations through real-time EMA data collected before and during a quit attempt. One week of pre-quit smoking behaviors will be integrated with passively sensed GPS data to create hotspot maps. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
3371871|NCT03690596|Experimental|NRT + QuitBuddy-Recall|This smartphone app will identify high-risk situations through retrospective recall of locations where the patient typically smoked. Hotspot maps will provide interactive visualizations of relapse risk. GPS triggered NRT/behavioral prompts will occur when participants come within 50m from the centroid of a hotspot.
3371872|NCT03690596|Active Comparator|NRT Control (treatment as usual)|Standard Care Control is intended to approximate the real-world experience where smokers obtain over-the-counter NRT and, after brief instructions at the outset (~1 lozenge per hour, during cravings, and <20 per day), determine usage for themselves.
3371873|NCT03672188|Experimental|Part A: SAD VIR-2218 50 mg|Healthy subjects received a single dose of VIR-2218 of 50 mg administered SC
3371874|NCT03672188|Experimental|Part A: SAD VIR-2218 100 mg|Healthy subjects received a single dose of VIR-2218 of 100 mg administered SC
3371875|NCT03672188|Experimental|Part A: SAD VIR-2218 200 mg|Healthy subjects received a single dose of VIR-2218 of 200 mg administered SC
3371876|NCT03672188|Experimental|Part A: SAD VIR-2218 400 mg|Healthy subjects received a single dose of VIR-2218 of 400 mg administered SC
3371877|NCT03672188|Experimental|Part A: SAD VIR-2218 600 mg|Healthy subjects received a single dose of VIR-2218 of 600 mg administered SC
3254343|NCT01423292|Active Comparator|an odd numbered patients|TAP block with local anesthetics
3254344|NCT01423292|Placebo Comparator|an even numbered patients|TAP block without local anesthetics
3371878|NCT03672188|Experimental|Part A: SAD VIR-2218 900 mg|Healthy subjects received a single dose of VIR-2218 of 900 mg administered SC
3371879|NCT03672188|Placebo Comparator|Part A: SAD Placebo|Healthy subjects received a single dose of placebo administered SC
3371880|NCT03672188|Experimental|Part B: MAD VIR-2218 20 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 20 mg VIR-2218 administered 4 weeks apart.
3371881|NCT03672188|Experimental|Part B: MAD VIR-2218 50 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
3371882|NCT03672188|Experimental|Part B: MAD VIR-2218 100 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 100 mg VIR-2218 administered 4 weeks apart.
3371883|NCT03672188|Experimental|Part B: MAD VIR-2218 200 mg|Chronic HBV, HBeAg negative, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
3371884|NCT03672188|Experimental|Part C: MAD VIR-2218 50 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 50 mg VIR-2218 administered 4 weeks apart.
3371885|NCT03672188|Experimental|Part C: MAD VIR-2218 200 mg|Chronic HBV, HBeAg positive, subjects received 2 SC doses of 200 mg VIR-2218 administered 4 weeks apart.
3254345|NCT01423305|Experimental|Treatment A|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
3254346|NCT01423305|Experimental|Treatment B|Budesonide/formoterol capsule (Orion Pharma) for oral administration.
3371886|NCT03672188|Placebo Comparator|Part B: MAD Placebo|Chronic HBV, HBeAg negative, subjects received 2 SC doses of placebo administered 4 weeks apart.
3371887|NCT03672188|Placebo Comparator|Part C: MAD Placebo|Chronic HBV, HBeAg positive, subjects received 2 SC doses of placebo administered 4 weeks apart.
3371888|NCT03669718|Experimental|Active ISA101b and cemiplimab.|ISA101b 3 times plus cemiplimab every 3 weeks for up to 24 months
3371889|NCT03669718|Placebo Comparator|Placebo and cemiplimab|Placebo 3 times plus cemiplimab every 3 weeks for up to 24 months
3371890|NCT03669640|Experimental|Part A: Monotherapy|Participants will receive RO6889450 or a dose-matched placebo. NOTE: Part A has completed enrollment.
3371891|NCT03669640|Experimental|Part B: Add-On Therapy|Participants will receive a low or high dose of RO6889450 or a dose-matched placebo in addition to their usual anti-psychotic treatment(s).
3371892|NCT03665363|Experimental|SCOPE|Participants allocated to SCOPE, will receive an internet-based psychoeducation intervention, eight weeks of ASD-theme modules with coaching.
3371893|NCT03665363|Active Comparator|Self-study|Participants allocated to self-study will receive eight weekly emails containing informative and relevant websites about ASD. The emails are accessed on the same platform as the experimental condition (SCOPE), no active contact with the coaches is available.
3371894|NCT03665363|No Intervention|Wait-list controls/Treatment as usual|Participants allocated to wait-list will receive prompts to answer outcome measures but otherwise no other contact with the study coordinators or coaches. Participants may receive treatment as usual.
3254347|NCT01423318|Experimental|A|
3254348|NCT01423318|Placebo Comparator|B|
3254349|NCT01423357|Experimental|Condom distribution and peer education|Youth peer educators distribute condoms and conduct condom demonstration in venues where people meet new sexual partners, i.e. bars, night clubs, sherbeens, guest houses
3254350|NCT01423357|No Intervention|Business as usual|
3254351|NCT01423370|Experimental|Group A|
3254352|NCT01423370|Experimental|Group B|
3371897|NCT03643965|Experimental|Nefecon|Nefecon 16 mg once daily by mouth for 9 months.
3371898|NCT03643965|Placebo Comparator|Placebo oral capsule|Placebo oral capsule once daily by mouth for 9 months.
3371899|NCT03637959|Experimental|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Subjects that are scheduled to undergo a clinical indicated Magnetic Resonance Elastography (MRE) will also have mechanical vibrations ultrasound shear wave imaging to measure liver stiffness
3371900|NCT03631940|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
3371901|NCT03631940|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
3371902|NCT03621956|Active Comparator|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
3254353|NCT01423370|Experimental|Group C|
3371903|NCT03621956|Active Comparator|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
3371904|NCT03621670|Experimental|MenB+PCV Group|Approximately 1800 subjects enrolled in this group will receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other RIV (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6 and 12 months of age
3371905|NCT03621670|Placebo Comparator|Placebo+PCV Group|Approximately 900 subjects enrolled in this group will receive PCV13 concomitantly with placebo and other RIV at 2, 4, 6 and 12 months of age.
3371906|NCT03617783|Active Comparator|Prebiotin|
3371907|NCT03617783|Placebo Comparator|Placebo|
3254354|NCT01423370|Active Comparator|Group D|
3254355|NCT01423370|Placebo Comparator|Group E|
3371908|NCT03616574|Experimental|Dose Escalation - CA102N Monotherapy|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 of a 28-day cycle
3371909|NCT03616574|Experimental|Dose Escalation - CA102N plus LONSURF|0.36, 0.54, and 0.72 mg/kg of nimesulide equivalents of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
3371910|NCT03616574|Experimental|Dose Expansion - CA102N plus LONSURF|The preliminary RP2D of CA102N on Days 1 and 15 in combination with 35 mg/m2/dose of LONSURF orally twice daily on Days 1 through 5 and Days 8 through 12 of each 28-day cycle
3371911|NCT03606967|Experimental|Arm I (neoantigen vaccine, durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 4, patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 for 2 cycles at the discretion of the treating physician.~PART B: Patients receive personalized synthetic long peptide vaccine and poly-ICLC SC on days 1, 4, 8, 15, 22, 50, and 78 in the absence of disease progression or unacceptable toxicity. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3254356|NCT01423383||Random Populations|The aim of this study is to determine the prevalence and incidence of keloid in large populations.
3254357|NCT01423396|Other|standard care|Follow up with city doctor with recommendation HAS French guidelines
3254358|NCT01423396|Experimental|optimal care of VRF|Monitoring according to the strict recommendations of the HAS French guidelines
3254359|NCT01423409|Active Comparator|pictorial VAS|VAS with colours and 6 expressive faces
3254360|NCT01423409|Sham Comparator|usual VAS|VAS
3254361|NCT01423422||Frequency exposed patients|Patients exposed to the magnetic field with the specific frequency
3254362|NCT01423435|Experimental|Japanese|
3254363|NCT01423435|Experimental|Chinese|
3254364|NCT01423435|Experimental|South Korean|
3254365|NCT01423448|Experimental|Bulletin board|Participants will be given access to the online bulletin board (intervention) for a 6 month period
3254366|NCT01423448|No Intervention|Control|After 6 months participants allocated to the control group will receive access to the intervention
3254367|NCT01423474|Experimental|Short treatment time (11 days)|
3254368|NCT01423474|Experimental|Long treatment time (29 days)|
3254369|NCT01423487|Experimental|efficacy and safety|To investigate the efficacy and safety of Metformin in preventing patients with Risperidone from weight gain and amenorrhea.
3254370|NCT01423487|Placebo Comparator|placebo comparator|To investigate whether plcebo also could preventing patients with Risperidone from weight gain and amenorrhea.
3254371|NCT01423500|Other|MSD - Matched Sibling Donor|patients with a MSD receive a conditioning of TBI (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
3254372|NCT01423500|Other|MD - Matched Donor|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
3254373|NCT01423500|Other|MMD - Mismatched Donor|Patients with a MMD receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
3371912|NCT03606967|Active Comparator|Arm II (durvalumab, nab-paclitaxel)|"PART A: Patients receive gemcitabine hydrochloride IV over 30 minutes and carboplatin IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients with progression of disease within the first 18 weeks may switch and receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15 of each remaining cycle.~PART B: Patients receive tremelimumab IV over 60 minutes on day 1 of cycles 1-4, durvalumab IV over 60 minutes on day 1 and nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3371913|NCT03602495|Experimental|Donafenib|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
3371914|NCT03602495|Placebo Comparator|Placebo|Participants randomly assigned in a 2:1 ratio to receive blinded study drug (Donafenib or matching placebo) until documentation of disease progression (confirmed by IRC), development of unacceptable toxicity, or withdrawal of consent.
3371918|NCT03595566|Experimental|ridinilazole|
3371919|NCT03595566|Active Comparator|vancomycin|
3254374|NCT01423513|Experimental|Fibular Taping|With the ankle in a neutral position, two strips of nonrigid hypoallergenic tape will be applied beginning at the distal aspect of the fibula, wrapping around the posterior aspect of the leg, and finishing superior and medial to the starting point. Next,a strip of rigid zinc oxide tape will be applied to the distal aspect of the fibula with tension.
3254375|NCT01423513|Sham Comparator|Sham Taping|Sham taping will be applied in the same manner as the fibular taping, but tension will not applied to the zinc oxide tape
3254376|NCT01423526|Placebo Comparator|Placebo|"Drug: Placebo tablets, oral administration, single administrations~Arms: Placebo"
3254377|NCT01423526|Experimental|DWP10292|"Drug: DWP10292 tablets, oral administration, single administrations~Arms: DWP10292"
3254378|NCT01423539|Active Comparator|A|
3254379|NCT01423539|Experimental|B|
3371920|NCT03595553|Experimental|ridinilazole|
3371921|NCT03595553|Active Comparator|vancomycin|
3371922|NCT03584334|Other|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
3371923|NCT03584295|Active Comparator|Conventional care|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
3254380|NCT01423552||Post-heart transplant|All patients undergoing heart transplantation at the Queen Elizabeth Hosptial Birmingham in the last 12 months or in the next year.
3254381|NCT01423565|Experimental|Deep Brain Stimulation|
3371924|NCT03584295|Experimental|Extracorporeal carbon dioxide removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R (Extracorporeal carbon dioxide removal) to facilitate early extubation. ECCO2R is used in a standard configuration with either double lumen cannula (22-24Fr) or two small single vessel cannulas (15-19 Fr), allowing a blood flow rate between 1-1.75 L/min.
3254382|NCT01423578|Active Comparator|Hatha Yoga (HY)|Exercise and Smoking Cessation Counseling
3254383|NCT01423578|Experimental|Cardiovascular Exercise (CE)|Exercise and Smoking Cessation Counseling
3254384|NCT01423578|Other|Smoking Cessation Counseling Only|Control Group - Smoking Cessation Counseling
3254385|NCT01423591|Experimental|infliximab|
3254386|NCT01423591|Placebo Comparator|inactive powder|
3254387|NCT01423630|Experimental|Probiotics and fruit fibre|Probiotics and fruit fibre
3254388|NCT01423643||Main cohort|Adults infected with both HIV and Hepatitis C
3254389|NCT01423643||Control Group|Adults at risk for liver disease, but not infected with both HIV and Hepatitis C
3254390|NCT01423656|Experimental|LEO 29102|
3254391|NCT01423656|Placebo Comparator|LEO 29102 vehicle|
3254392|NCT01423669||Community dwelling adult population|
3254393|NCT01423695|Experimental|paclitaxel/trastuzumab|Single experimental arm in a phase II trial
3254394|NCT01423708|No Intervention|Control|Standard immunosuppression protocol with Tacrolimus, maintaining trough levels between 6 and 12 ng/ml in the first month, in association with steroids (20 mg/day with subsequent weaning within 3 months after transplantation).
3254395|NCT01423708|Experimental|Everolimus|Administration of Everolimus in association with Tacrolimus and steroids.
3254396|NCT01423721|Experimental|Bromihexine hydrochloride granules|16 mg granules
3254397|NCT01423721|Experimental|Bromihexine hydrochloride syrup|16 mg syrup
3254398|NCT01423734||MRI|Patients will be consented for a second MRI without additional intravenous contrast, referred to from now on as 'research MRI', to be performed later on the same day as their clinical liver MR examination, on one of two 3.0 Tesla MR 750 GE scanners at the Breast and Imaging Center. The research MRI will consist only of the localizer and diffusion weighted imaging (DWI) sequences, with acquisition parameters identical to our clinical MRI. The reproducibility of DWI is best assessed in separate MR imaging sessions, although the examinations can be performed the same day.
3254399|NCT01423747|Other|MSD - matched sibling donor|patients with a MSD receive a conditioning of total body irradiation (TBI) (12 Gy, 6 fractions) and VP16 60mg/kg for one day (-3)
3254400|NCT01423747|Other|MD - matched donor|patients with a HLA (Human Leukocyte Antigen) matched unrelated Donor (9/10 oder 10/10) receive total body irradiation (TBI) (12Gy in 6 fractions), VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
3371925|NCT03573336|Experimental|Vilaprisan (BAY1002670) 2 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 2 mg
3371926|NCT03573336|Experimental|Vilaprisan (BAY1002670) 4 mg|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1 Vilaprisan: 4 mg
3371927|NCT03573336|Placebo Comparator|Placebo group|Premenopausal women 18 years and older with endometriosis with randomized ratio = 1:1:1
3254401|NCT01423747|Other|MMD - mismatched Donor|Patients with a mismatched donor receive stem cells either from cord blood, a haploidentical donor (parent) or from a non-related donor with a match less or equal 8/10
3254402|NCT01423786|Other|Please help|"Dr. Kumar left Nationwide Children's Hospital in 2014 and efforts to get ahold of her to complete her ct.gov entries have been unsuccessful as we are not able to get ahold of her.~In July 2014, she wrote in her Continuing Review application to the NCH IRB: 34 patients have been recruited and data has mostly been collected. Follow up calls have been made and no adverse events occurred during the study period.~No other information is available."
3254403|NCT01423799|Experimental|Nutritional product|Nutritional intervention containing immuno-nutrients
3371929|NCT03533283|Experimental|Atezolizumab|Participants will receive Glofitamab in combination with Atezolizumab up to the maximum tolerated dose (MTD).
3371930|NCT03533283|Experimental|Polatuzumab Vedotin|Participants will receive Glofitamab in combination with polatuzumab vedotin up to the MTD.
3371931|NCT03533283|Experimental|Imaging Sub-study|"Participants will undergo positive-emission tomography/computed tomography (PET/CT) at screening, followed by an Imaging Cycle, to replace Cycle 1 of the main study. Eligible participants will have the option roll-over to the atezolizumab arm of the main study from Cycle 2 onwards."
3371932|NCT03530397|Experimental|Arm A: MEDI5752|MEDI5752
3371933|NCT03530397|Experimental|Arm B: MEDI5752 and chemotherapy|MEDI5752, pemetrexed and carboplatin.
3371934|NCT03530397|Active Comparator|Arm C: Pembrolizumab and chemotherapy|pembrolizumab, pemetrexed, and carboplatin
3371935|NCT03516292||OAB-POP group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
3371936|NCT03516292||POP only group|As an Observational Case-Control Study, the participants will divided in two groups depending whether they suffer from overactive bladder symptoms or not. All participants will have POP.
3371937|NCT03508934|Active Comparator|Intervention group (Continuous Glucose Monitroring and POC)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS) and Point of Care (POC) finger-stick blood glucose levels with application of hypoglycemia prevention protocol (activated based the GTS lower glucose alarms)
3371938|NCT03508934|Placebo Comparator|Control group (Point of Care-POC)|Hospitalized patients with DM2 will be monitored with POC blood glucose levels and application of hypoglycemia prevention protocol (activated based the POC values)
3371939|NCT03507452|Experimental|Dose escalation cohort a|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 mg."
3371940|NCT03507452|Experimental|Dose escalation cohort b|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with a total antibody dose within the range of 10 - 50 mg."
3371941|NCT03507452|Experimental|Dose Expansion Cohort 1|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 1 (to be determined after completion of the dose escalation)"
3371942|NCT03507452|Experimental|Dose Expansion Cohort 2|"Subjects with advanced recurrent epithelioid mesothelioma or serous ovarian cancer, who have exhausted available therapeutic options~Dose / Regimen 2 (to be determined after completion of the dose escalation)"
3371943|NCT03507452|Experimental|Dose expansion Cohort 3 (optional)|"Subjects with histologically or cytologically confirmed unresectable, metastatic or locally advanced pancreatic ductal adenocarcinoma~Dose / Regimen to be determined"
3254404|NCT01423799|Active Comparator|Control Group|Isocaloric and isonitrogenous control without immuno nutrients.
3254405|NCT01423825|Experimental|Sub C gp140/MF59C.1 Vaccine|Participants will receive Sub C gp140 vaccine (100 mcg) admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid at baseline and Month 3.
3254406|NCT01423825|Placebo Comparator|Sodium chloride for injection|Participants will receive placebo injection administered as 0.5 mL IM in either deltoid at baseline and Month 3.
3254407|NCT01423838|Active Comparator|Solifenacin|Anticholinergic molecule used in the treatment of overactive bladder.
3254408|NCT01423838|Active Comparator|Oxybutynin|Anticholinergic molecule used in the treatment of overactive bladder.
3254409|NCT01423851|Experimental|Intervention: Drug: NS-018|In Phase 1 part, subjects were treated with oral NS-018 at a dose of 75 - 400 mg once daily or 100 - 400 mg twice daily. In Phase 2 part, subjects were treated with oral NS-018 at a dose of 300 mg once daily.
3254410|NCT01423864|Sham Comparator|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
3254411|NCT01423864|Experimental|Drug: intrapleural steroid instillation|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome unresponsive to conventional extracorporeal membrane oxygenation
3254412|NCT01423890|Other|Early Stage Breast Cancer|Women and men with node negative, ER positive breast cancer who are receiving (or will receive) endocrine therapy, and who are candidates for chemotherapy.
3254413|NCT01423903|Experimental|OPDC-51602|Subjects with advanced solid tumors will be treated with OPDC-51602 once daily by mouth
3254414|NCT01423929|Experimental|10 L O2/min|Oxygen breathing via Oxymask TM
3254415|NCT01423929|Sham Comparator|Room air|Room air breathing via Oxymask TM
3371944|NCT03507452|Experimental|Dose escalation cohort c|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 150 mg mg."
3254416|NCT01423955|Placebo Comparator|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
3254417|NCT01423955|Experimental|Erythropoietin|• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.
3254418|NCT01423968|Experimental|Lipopolysaccharide infusion|Lipopolysaccharide infusion; dosage 4ng/kg body weight
3371945|NCT03507452|Experimental|Dose escalation cohort d|"Subjects with either advanced recurrent epithelioid mesothelioma or serous ovarian cancer who have exhausted available therapeutic options.~The dose of Thorium-227 will start at 1.5 MBq and increase in steps of 1.0 or 1.5 MBq, with antibody doses of 10 - 400 mg."
3371946|NCT03485924|Active Comparator|EUS-FNA with ROSE|EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
3371947|NCT03485924|Active Comparator|EUS-FNB without ROSE|EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.
3371950|NCT03456076|Experimental|Alectinib|
3371951|NCT03456076|Active Comparator|Platinum-Based Chemotherapy|
3371952|NCT03455439||Rivaroxaban|Adult patients diagnosed with Atrial Fibrilation and Heart Failure who started treatment with rivaroxaban at least 4 months prior to inclusion
3254419|NCT01423968|Placebo Comparator|saline|0.9% saline infusion
3254420|NCT01423981||Patients with keloid disorder.|All participants have a clinical diagnosis of keloid.
3254421|NCT01423994|Active Comparator|implantable loop recorder|
3371953|NCT03430089|Experimental|Group 1: 6 to 35 months|Shz QIV 0.25 mL, 2 doses
3371954|NCT03430089|Experimental|Group 2: 3 to 8 years|Shz QIV 0.5 mL, 2 doses
3371955|NCT03430089|Experimental|Group 3: 9 to 17 years|Shz QIV 0.5 mL, single dose
3371956|NCT03430089|Experimental|Group 4: 18 to 60 years|Shz QIV 0.5 mL, single dose
3371957|NCT03430089|Experimental|Group 5: 61 years and older|Shz QIV 0.5 mL, single dose
3371958|NCT03419689|Experimental|Sample Collection|"The following samples may be collected during the study:~Tumour tissue samples~Blood samples~Ascites samples~Other fluids requiring drainage"
3371961|NCT03401918|Experimental|Comparing the microbiome and ERA in RPL and infertility|"In this arm we will assess the uterine environment at the time of implantation in recurrent pregnancy loss patients and unexplained infertility patients and compare the environment in these patient populations to healthy parous controls.~We will test the uterine endometrial gene expression using the ERA test and the uterine micro biome."
3371962|NCT03401918|Experimental|The impact of progesterone and antibiotics/probiotics|In this arm, recurrent pregnancy loss and unexplained infertility patients who have abnormal results (an abnormal microbiome or an abnormal ERA) will have the option to undergo treatment followed by retesting of the uterine environment. For an abnormal ERA suggesting a pre-receptive result, luteal phase vaginal progesterone supplementation will be offered prior to re-testing of the ERA. For an abnormal microbiome a combination of oral antibiotics and vaginal probiotics will be offered prior to re-testing the uterine microbiome.
3371963|NCT03401762|Experimental|Chronic stroke MCI Electromyogram (EMG) pairs|Decoupling 2 muscles at a time with MCI
3371964|NCT03401762|Experimental|Chronic stroke MCI EMG triplets|Decoupling 3 muscles at a time with MCI
3254422|NCT01423994|Active Comparator|pacemaker|
3254423|NCT01424007|Experimental|Lower fat diet|Participants in this group will be individually counseled and receive print materials on a higher-carbohydrate, lower-fat diet.
3254424|NCT01424007|Experimental|Lower carbohydrate diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, higher-monounsaturated fat diet.
3254425|NCT01424007|Experimental|Walnut-rich diet|Participants in this group will be individually counseled and receive print materials on a lower-carbohydrate, walnut-rich higher-fat diet.
3254426|NCT01424020|Experimental|questionnaire|Patients suspected of peripheral artery disease and, as such, referred for a vascular investigations and submitted the WELCH questionnaire
3254427|NCT01424046|Experimental|basal insulin approach|Participants will be treated primarily with a daily basal insulin injection ( glargine) with later introduction of prandial coverage with a shortacting insulin.
3254428|NCT01424046|Active Comparator|standard therapy|Participants will continue current mixed insulin management and education
3254429|NCT01424059||fear of labor|Parous women with fear of labor
3254430|NCT01424085||Those receiving antibiotics|Patients who received one prophylactic dose of antibiotics.
3254431|NCT01424085||Placebo|Patients who did not receive one prophylactic dose of antibiotics (received placebo).
3254432|NCT01424098|Experimental|Balance Training|The treatment group will complete a specific balance training program in addition to conventional pulmonary rehabilitation.
3371965|NCT03401762|Experimental|Chronic stroke MCI while reaching|Decoupling muscles with MCI while reaching to targets
3371966|NCT03401762|Sham Comparator|Chronic stroke Sham MCI|Sham control group
3371967|NCT03401762|Experimental|Acute stroke MCI|Decoupling muscles with MCI in acute stroke subjects
3371968|NCT03401762|Sham Comparator|Acute stroke Sham MCI|Acute stroke subjects sham comparator
3371969|NCT03370614||IBS Group|Participants will complete initial baseline and follow up IBS evaluations and questionnaires. Pre and Post FDG-PET-MR scans will be conducted to evaluate changes at baseline and approximately 2 months after dietary and nutritional counseling.
3371970|NCT03370614||Healthy Control Group|Participants will complete initial baseline evaluations and questionnaires. Participants will also receive a FDG-PET-MR scan.
3371971|NCT03336541|Experimental|Ketamine group|Low-dose ketamine (0.5 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
3371972|NCT03336541|Placebo Comparator|Placebo group|Placebo (100 ml normal saline) is intravenously infused in 40 minutes after childbirth during cesarean delivery.
3371975|NCT03272828|Active Comparator|Parallel sided implant Group|A Parallel sided titanium dental implant will be placed in the edentulous mandible.
3371976|NCT03272828|Active Comparator|Tapered shaped implant Group|A tapered shaped titanium dental implant will be placed in the edentulous mandible.
3371977|NCT03259373|Experimental|Intervention|Educational mailing to (1) AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment at time of randomization and (2) their providers, where an individual provider may be identified
3371978|NCT03259373|Experimental|Control|Educational mailing to providers of AF patients with guideline-based indications for oral anticoagulation (CHA₂DS₂-VASc score of 2 or greater) who appear to not have received OAC treatment in the time following randomization. These patients will have received 'usual care' for the time between randomization and delayed educational mailing.
3371979|NCT03241732|Active Comparator|Dietary (AID) Cohort|Anti-inflammatory Diet: This arm will focus on adjusting dietary practices to eat foods that have lower amounts of inflammatory foods that might help reduce overall inflammation in the brain and body. This arm will introduce patients to an integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
3371980|NCT03241732|Active Comparator|Intravenous/Oral NAC Cohort|N-acetyl Cysteine: This arm provide patients with a natural supplement, n-acetyl cysteine (NAC) which is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine, that supports antioxidants to reduce oxidative damage in the body. NAC is a common over-the-counter supplement. It is used as an injectable pharmaceutical to protect the liver in cases of acetaminophen overdose. Laboratory studies have suggested that NAC might have a beneficial effect in neurodegenerative disorders such as TBI. Patients in this arm will receive IV NAC once a week plus oral NAC supplement 500 mg twice per day for approximately 3 months until the follow up evaluation.
3371981|NCT03241732|No Intervention|Control Cohort|Control Group: Standard of Care Treatment for at least 3 months. After the first 3 month, participants in this arm may crossover to the NAC study arm.
3371982|NCT03239990|Experimental|Incredible Years, Parent support|Incredible Years, Parent group supported by home visiting includes the Incredible Years Parent Training Program, Preschool Basic version, with 18-20 group meetings. Four home visits are added to the program to support parents in practicing new skills and to provide individual practical consultation.
3371983|NCT03239990|No Intervention|Treatment as usual|The control group will receive treatment as usual
3371984|NCT03234738|Active Comparator|Cohort A|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3371985|NCT03234738|Active Comparator|Cohort B|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3371986|NCT03234738|Active Comparator|Cohort C|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3371987|NCT03234738|Active Comparator|Cohort D|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.5 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3371988|NCT03234738|Active Comparator|Cohort E|Multiple IV doses of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg once daily for 7 days, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3371989|NCT03233594||Chiropractic Group|Participants receiving a chiropractic care technique Neuro Emotive Technique (NET) will complete initial pain evaluations and questionnaires for chronic pain symptoms. After approximately 8 weeks participants will receive follow evaluation for pain. Pre and Post PET-MRI scan will be conducted to evaluate changes.
3254433|NCT01424098|No Intervention|Usual care|The control group will undergo the usual pulmonary rehabilitation program offered at our centre with no additional balance training classes.
3254434|NCT01424111||Treatment|Those receiving an open-label, 10-20 mg/day, flexible-dose of escitalopram. The treatment period is 8 weeks long.
3254435|NCT01424111||Healthy Control|Those not receiving treatment.
3254436|NCT01424124|Experimental|YHD001 dose level 1|
3254437|NCT01424124|Experimental|YHD001 dose level 2|
3254438|NCT01424124|Active Comparator|Singulair|
3254439|NCT01424124|Placebo Comparator|Placebo|
3254440|NCT01424137|Other|Easyhaler type A|
3254441|NCT01424137|Other|Easyhaler type B|
3254442|NCT01424137|Other|Diskus inhaler|
3259504|NCT01471431|No Intervention|Usual care|Subjects will be extubated using usual care, without the use of the spontaneous breathing trial.
3254443|NCT01424150|Experimental|Liberal|At the commencement of surgery a bolus of Hartmann's balanced salt crystalloid 10 ml/kg followed by 8 ml/kg/h will be administered until the end of surgery. A maintenance infusion will then continue at 1.5 ml/kg/h, for at least 24 hours, but this can be reduced postoperatively if there is evidence of fluid overload and no hypotension, and increased if there is evidence of hypovolaemia or hypotension. Alternative fluid types (crystalloid, dextrose, colloid) and electrolyte supplements will be allowed postoperatively in order to account for local preferences and patient biochemistry, for which we will collect data.
3371990|NCT03233594||Healthy Control Group|Participants will receive initial evaluations and questionnaires followed by a PET-MRI scan.
3371991|NCT03230916|Experimental|IMI/REL FDC|Imipenem/Cilastatin/Relebactam (IMI/REL) administered as a single fixed 2:1 ratio of imipenem/cilastatin to relebactam, with a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
3371992|NCT03226847|Experimental|Pulmonary Vein Isolation|ablation
3371993|NCT03208907|Active Comparator|CQ coadministered with PQ|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine was administered for 14 days (0.50mg/kg/day)
3371994|NCT03208907|Experimental|DHA-PQP coadministered with PQ|Dihydroartemisinin/Piperaquine was administered according to the weight and Primaquine (0.50mg/kg/day)
3371995|NCT03208907|Experimental|CQ and PQ starting on Day 42|Chloroquine was administered for 3 days according to the brazilian protocol and Primaquine started on Day 42 for 14 days (0.50mg/kg/day)
3371996|NCT03208907|Experimental|DHA-PQP and PQ starting on Day 42|Dihydroartemisinin/Piperaquine was administered for 3 days according to the weight and Primaquine started on Day 42 for 14 days (0.50mg/kg/day)
3371997|NCT03202667|Active Comparator|Empagliflozin|Treatment with empagliflozin 25mg tablets once daily for 28 days
3371998|NCT03202667|Placebo Comparator|Placebo|Treatment with Placebo tablets once daily for 28 days
3371999|NCT03195894|Experimental|Conventional treatment and TripleA|Conventional treatment and TripleA medical device consisting of alcoholometer, a Bluetooth mobile app on cell phone and information stored on computer for caregiver
3372000|NCT03195894|No Intervention|Conventional treatment|Conventional treatment
3372004|NCT03190954|Placebo Comparator|[11C]NNC-112|[11C]NNC-112 PET scan obtained without any drug intervention to measure dopamine D1 receptors. Blind N/A
3372005|NCT03190954|Active Comparator|[11C]raclopride plus drug|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
3372006|NCT03190954|Placebo Comparator|[11C]raclopride plus placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan to measure baseline dopamine D2 receptors. MRI scan to follow end of PET scan. Subject blind as to drug administration.
3254444|NCT01424150|Experimental|Restrictive|Will provide less than 2.0 L water and 120 mmol sodium per day. Induction of anaesthesia will limit IV bolus fluid to ≤5 ml/kg; no other IV fluids will be used at the commencement of surgery (unless indicated by goal-directed device [see below]). Hartmann's balanced salt crystalloid 5 ml/kg/h will be administered until the end of surgery, and bolus colloid/blood used intraoperatively to replace blood loss (ml for ml); then an infusion at 1 ml/kg/h until expedited cessation of IV fluid therapy within 24 hours. The rate of postoperative fluid replacement can be reduced if there is evidence of fluid overload and no hypotension, and can be increased if there is hypotension AND evidence of hypovolaemia.
3254445|NCT01424163|Experimental|Treatment 1 (Part A)|Dexpramipexole single dose (reduced dose)
3372007|NCT03188965|Experimental|Dose escalation of BAY1895344 in Part A|Single-agent dose-escalation part. Part A has the objective to define the MTD and / or RP2D.
3372008|NCT03188965|Experimental|J-arm of Part A|Single-agent dose-escalation part in Japanese patients. J-arm has the objective to confirm the MTD (or RP2D) dose is safe and tolerable in Japanese patients.
3372009|NCT03188965|Experimental|Dose expansion of BAY1895344 in Part B|Single-agent expansion part. Once the MTD has been defined, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study. Once the MTD dose has been confirmed is safe and tolerable in Japanese patients, safety, PK profile, PD of target engagement, and preliminary efficacy will be further evaluated in Part B of the study.
3372010|NCT03188965|Experimental|Part A.1: Single-agent dose escalation part|Part A.1 - single-agent dose escalation part with alternative dosing schedule Patients with histologically confirmed solid tumors or NHL known to be positive for ATM loss and/or ATM deleterious mutations will be included.
3372011|NCT03176277|Experimental|ONO-7475 (Part A)|Successive dose escalation cohorts to determine MTD/OBD
3372012|NCT03176277|Experimental|ONO-7475 + venetoclax (Part D)|Successive dose escalation of ONO-7475 cohorts + venetoclax
3372014|NCT03169972||Previously treated patients (PTPs)|PTPs: patients who had 4 or more days to other Factor VIII (FVIII) products
3372015|NCT03169972||Previously untreated patients (PUPs)|PUPs: patients who had 3 or less previous exposure days to other products
3372016|NCT03145142|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infant at a speed of 20cm over 2 seconds.
3372017|NCT03145142|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for at least 60 seconds.
3372018|NCT03104699|Experimental|Monotherapy|Dose of 3 mg/kg IV every 2 weeks for up to 24 months.
3372020|NCT03085433|Experimental|Microfluidic sperm sorting|Couples undergoing in vitro fertilization randomized to microfluidic sperm sorting will have raw semen sorted by the microfluidics chip prior to fertilization with IVF/ICSI.
3372021|NCT03085433|Active Comparator|Conventional sperm preparation|Couples undergoing in vitro fertilization randomized to conventional methods for sperm processing will undergo separation of semen by density gradient centrifugation prior to IVF/ICSI.
3372022|NCT03067675||Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device
3372023|NCT03061201|Experimental|Sequential dose escalation|SB-525 (PF-07055480) is administered as a single infusion
3372024|NCT03055286|Experimental|CWP232291 in combination with cytarabine (ara-C)|
3372025|NCT03049462|Experimental|Cohort 1|Females taking 100 mg of mirabegron
3372026|NCT03049462|Active Comparator|Cohort 2A|Males taking 200mg mirabegron
3372027|NCT03049462|Placebo Comparator|Cohort 2B|Males taking placebo drug
3372028|NCT03049462|Active Comparator|Cohort 3A|Females taking 100 mg of mirabegron
3372029|NCT03049462|Placebo Comparator|Cohort 3B|Females taking placebo drug
3372030|NCT03039790|Experimental|NoV Vaccine|Participants who previously received NoV vaccine adjuvanted with aluminum as aluminum hydroxide or with monophosphoryl lipid A (MPL), injection, intramuscularly as planned in studies NOR-107, NOR-210 and NOR-204 will be assessed over 5 years post-primary vaccination. Vaccine formulations according to the parent trials: NOR-107, 210 and 204.
3372031|NCT03032705|Experimental|SonicFill™ 2|Composite: SonicFill™ 2; Bonding Agent: Optibond XRT
3372032|NCT03032705|Active Comparator|Filtek™ Supreme|Composite: Filtek™ Supreme Ultra Universal Restorative; Bonding Agent: Scotchbond™ Universal Adhesive
3254446|NCT01424163|Experimental|Treatment 2 (Part A)|Dexpramipexole single dose (Standard dose)
3254447|NCT01424163|Experimental|Treatment 3 (Part A)|Dexpramipexole multiple dosing
3254448|NCT01424163|Experimental|Treatment for Part B|Dexpramipexole multiple dosing
3254449|NCT01424176|Experimental|Dexpramipexole (dose 1)|Subjects with mild or moderate renal impairment.
3372033|NCT03027427||Patients|Patients with confirmation of, or suspicion of, a heritable gastric malignancy disorder
3372034|NCT03024034|Active Comparator|Cohort A|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 25 mg single dose (n = 6) or matching placebo (n = 2)
3372035|NCT03024034|Active Comparator|Cohort B|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg single dose (n = 6) or matching placebo (n = 2)
3372036|NCT03024034|Active Comparator|Cohort C|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 100 mg single dose (n = 6) or matching placebo (n = 2)
3372037|NCT03024034|Active Comparator|Cohort D|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 150 mg single dose (n = 6) or matching placebo (n = 2)
3372038|NCT03024034|Active Comparator|Cohort E|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 200 mg single dose (n = 6) or matching placebo (n = 2)
3372039|NCT03024034|Active Comparator|Cohort F|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 300 mg single dose (n = 6) or matching placebo (n = 2)
3372040|NCT03024034|Active Comparator|Cohort G|Oral dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 50 mg TP 271, cross-over to 50 mg TP 271/250 mg EDTA (n = 3); 50 mg TP 271/250 mg EDTA, cross-over to 50 mg TP 271 (n = 3); matching placebo, cross over to 250 mg EDTA (n= 1); or 250 mg EDTA, cross over to matching placebo (n = 1)
3372041|NCT03021993|Experimental|Nivolumab|Nivolumab (OPDIVO) will be administered every two weeks for up to four doses prior to surgery at 3mg/kg
3254450|NCT01424176|Experimental|Dexpramipexole (dose 2)|Subjects with severe renal impairment and end stage renal disease (ESRD).
3372045|NCT02999893|Experimental|APR-246|"The trial regimen consists of the investigational agent APR-246, along with standard chemotherapy, Cisplatin and 5-FU. A maximum of 8 cycles of treatment will be given.~APR-246 and 5-FU must both commence on Day 1 and given on days 1 to 4 via intravenous infusion over 6 hours, whilst 5-FU must be given as a continuous infusion over 96 hours.~On Days 2-4, APR-246 must be given first via intravenous infusion over 6 hours, then commence cisplatin via intravenous infusion over one hour.~This is a dose-escalation study to determine the maximum tolerated dose (MTD) of the combination therapy. The 3 dose levels are described as follows:~Dose Level 1:~APR-246 Dose: 75mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level 2:~APR-246 Dose: 100mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI~Dose Level -1:~APR-246 Dose: 50mg/kg LBM Cisplatin Dose: 25mg/m2 5-FU Dose: 750mg/m2/ day CI"
3254451|NCT01424202|Experimental|Group B|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications plus daily sessions of mechanical in-exsufflation (MI-E).
3254452|NCT01424202|No Intervention|Group A|Patients received (post-extubation) standard medical treatment (SMT), including NIV in case of specific indications.
3254453|NCT01424241|Experimental|Sandostatin LAR|This is a 9 month, open label dose escalation study of Sandostatin LAR therapy.
3254454|NCT01424254|Experimental|Video-Capsule Endoscopy|VCE will be performed in the early morning following 200 mg of simethicone and 250 - 500 mg of erythromycin (as per physician's prescription), ingestion also in the absence of contra-indications
3254455|NCT01424254|Experimental|Push Enterosopy|
3254456|NCT01424267||1|
3254457|NCT01424280|Experimental|Active drug|
3254458|NCT01424280|Placebo Comparator|Placebo|
3254459|NCT01424319|Experimental|ABT-627, Low dose|
3254460|NCT01424319|Experimental|ABT-627, High dose|
3254461|NCT01424319|Placebo Comparator|ABT-627, Placebo|
3254462|NCT01424332|Experimental|Treatment arm 1|darexaban, wash-out, ASA, wash-out, darexaban plus ASA
3254463|NCT01424332|Experimental|Treatment arm 2|darexaban, wash-out, darexaban plus ASA, wash-out, ASA
3254464|NCT01424332|Experimental|Treatment arm 3|ASA, wash-out, darexaban, wash-out, darexaban plus ASA
3254465|NCT01424332|Experimental|Treatment arm 4|ASA, wash-out, darexaban plus ASA, wash-out, darexaban
3254466|NCT01424332|Experimental|Treatment arm 5|darexaban plus ASA, wash-out, darexaban, wash-out, ASA
3254467|NCT01424332|Experimental|Treatment arm 6|darexaban plus ASA, wash-out, ASA, wash-out, darexaban
3372046|NCT02962167|Experimental|Locally Recurrent Medulloblastoma/ATRT|Patients must have local recurrent disease (defined as negative spine MRI and negative cytology within 21 days prior to study registration) and undergo resection of local recurrence as part of their standard of care. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, directly into the tumor bed during standard of care resection.
3372047|NCT02962167|Experimental|Disseminated Recurrent MB/ATRT|Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
3372048|NCT02962167|Experimental|Disseminated Recurrent Medulloblastoma|Patients must have disseminated recurrent medulloblastoma (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
3372049|NCT02958007|Experimental|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
3372050|NCT02958007|Active Comparator|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
3372051|NCT02953652|Experimental|HBI-8000|Four 10 mg tablets or less twice weekly orally approximately 30 minutes after any regular meal. The treatment will be continuous, with 3-4 days between dosing. Treatment will continue until disease progression in the absence of unacceptable toxicity.
3372052|NCT02915432|Experimental|3 mg/kg anti-PD-1 mAb JS001 Q2W|Subjects will be eligible for this study after they fulfill the inclusion criteria and exclusion criteria. Subjects diagnosed as the gastric adenocarcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma will receive treatment at the dose of 3 mg/kg.
3372053|NCT02915432|Experimental|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
3254468|NCT01424345|Active Comparator|control group|Dosages of immunosuppressants will be given according to the results of conventional post-transplant lab
3372054|NCT02915432|Experimental|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death
3372057|NCT02907372|Other|cognitive tests|
3254469|NCT01424345|Experimental|ImmuKnow Study group|The dosages of immunosuppressants will be adjusted according to the results of ImmuKnow and conventional post-transplant lab
3254470|NCT01424358|Experimental|Web-based Educational|
3254471|NCT01424371||Adjuvanted Vaccine Group|
3254472|NCT01424371||Unadjuvanted Vaccine Group|
3254473|NCT01424371||Unvaccinated Elderly|
3254474|NCT01424384|Active Comparator|Citalopram|Marketed comparitor
3254475|NCT01424384|Experimental|Investigational Medicinal Product|GSK424887
3254476|NCT01424384|Placebo Comparator|Placebo To Match Treatment|Placebo control
3254477|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 1|Eligible subjects will receive intravenous infusion of GSK1223249 with a starting dose of 0.02 milligrams per kilograms, followed by 0.2, 2, 10 and 30 milligrams per kilograms, administered by a programmable syringe pump.
3254478|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 1|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3254479|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 2|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 0.2 milligrams per kilograms administered by a programmable syringe pump.
3372065|NCT02803437||Xofigo / Cohort 1|Patients suffered from CRPC with bone metastases are enrolled after the physician's decision of Xofigo treatment under the routine clinical practice.
3372068|NCT02782702|Experimental|Botulism Toxin treatment|Injection of 50 UI Botulism toxin for the treated zone
3372069|NCT02763319|Experimental|Tafasitamab and bendamustine|Tafasitamab and bendamustine
3372070|NCT02763319|Active Comparator|Rituximab and bendamustine|Rituximab and bendamustine
3372071|NCT02759835|Experimental|Arm 1|osimertinib followed by LAT followed by osimertinib
3372072|NCT02759835|Experimental|Arm 2|LAT followed by osimertinib
3372073|NCT02724085|Active Comparator|Cohort A|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.15 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372074|NCT02724085|Active Comparator|Cohort B|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 0.45 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372075|NCT02724085|Active Comparator|Cohort C|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 1.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372076|NCT02724085|Active Comparator|Cohort D|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 2.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372077|NCT02724085|Active Comparator|Cohort E|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 3.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372078|NCT02724085|Active Comparator|Cohort F|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 4.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372079|NCT02724085|Active Comparator|Cohort G|IV dose of TP-271, a novel, broad-spectrum tetracycline-class antibiotic, 5.0 mg/kg single dose, 60 minute infusion or Placebo - sterile 0.45% saline for 60 minute IV infusion
3372080|NCT02700308|Active Comparator|Conventional vertebroplasty|Conventional vertebroplasty (device's trade at the discretion of the investigator)
3372081|NCT02700308|Experimental|Kyphoplasty|Vertebroplasty with balloon placement and inflation prior to cement injection (device's trade at the discretion of the investigator)
3372082|NCT02673567|Experimental|TEV-48125 - 1|Dose Regimen 1
3372083|NCT02673567|Experimental|TEV-48125 - 2|Dose Regimen 2
3372084|NCT02673567|Experimental|TEV-48125 - 3|Dose Regimen 3
3372085|NCT02673567|Placebo Comparator|Placebo|Matching Placebo
3372086|NCT02628626|Placebo Comparator|Placebo|Patients in this arm will receive placebo for 4 weeks.
3372087|NCT02628626|Active Comparator|Colesevelam and Clonidine|Patients in this arm will receive a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) for 4 weeks.
3372088|NCT02582957|Experimental|Sigh breaths|Sigh breaths consisting of a Tidal volume (VT) that produces a plateau pressure (Pplat) of 35 cmH2O (or 40 cmH2O in patients with BMIs > 35 or in patients with moderate or severe abdominal distension from ascites, blood and/or ileum, or prone patients). The sigh breaths will be delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
3372089|NCT02582957|No Intervention|Usual Care|Usual care, meaning that the treating physician will be free to treat the patient in any way he or she sees fit, including utilizing invasive mechanical ventilation as they wish.
3372090|NCT02579954|No Intervention|control group|
3372091|NCT02579954|Experimental|intervention|Rehabilitation
3254480|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 2|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3372092|NCT02573259|Experimental|Arm 1 PF-06801591|0.5 mg/kg IV every 21 days (Part 1)
3372093|NCT02573259|Experimental|Arm 2 PF-06801591|1.0 mg/kg IV every 21 days (Part 1)
3372094|NCT02573259|Experimental|Arm 3 PF-06801591|3.0 mg/kg IV every 21 days (Part 1)
3372095|NCT02573259|Experimental|Arm 4 PF-06801591|10 mg/kg IV every 21 days (Part 1)
3372096|NCT02573259|Experimental|Arm 5 PF-06801591|300 mg SC every 28 days (Part 1 and 2)
3372097|NCT02553460|Experimental|Treatment|"Participants who meet eligibility requirements will receive remission induction, consolidation treatment, reinduction, reintensification and maintenance therapy.~Interventions: ITMHA, dexamethasone, mitoxantrone, pegaspargase or asparaginase Erwinia chrysanthemi, bortezomib, vorinostat, cyclophosphamide, mercaptopurine, methotrexate, leucovorin calcium, cytarabine, etoposide, and vincristine."
3372098|NCT02536183|Experimental|Part A|LTLD will be administered intravenously in combination with MR-HIFU ablation on day 1 of every 21 day cycle. There will be two potential dose escalation of LTLD with highest dose not to exceed the adult recommended MTD. Patients may receive up to a total of 6 cycles.
3372099|NCT02536183|Experimental|Part B|LTLD at dose determined from Part A will be administered intravenously on day 1 of every 21 day cycle. MR-HIFU induced MHT will follow immediately post LTLD infusion for one hour to target area with target temperatures of 40-45°C. Patients may receive up to a total of 6 cycles
3372100|NCT02523313|Active Comparator|Nivolumab + Placebo|Nivolumab (3 mg/kg) i.v. every 2 weeks + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10
3372101|NCT02523313|Experimental|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) i.v. every 3 weeks for 4 doses. Both study drugs are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12: Nivolumab as maintenance and at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
3372102|NCT02523313|Placebo Comparator|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab i.v. every 3 weeks for 4 doses. Both placebos are administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab as maintenance and applied as IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
3372103|NCT02466217||1: AID groups|Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes (CAPS)/TNF-receptor Associated Periodic Syndrome (TRAPS), Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative colitis, Type 1 Diabetes
3372104|NCT02466217||2: Control groups|knee arthritis, hip arthritis, muscular dystrophy, healthy subject
3254481|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 3|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 2 milligrams per kilograms administered by a programmable syringe pump.
3254482|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 3|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3372105|NCT02464969|Experimental|Apixaban|Subjects between birth to <18 years will be dosed on a body weight tiered regimen. Subjects ≥35kg will receive 10mg twice daily(BID) for 7 days followed by 5mg BID thereafter;<35kg to 25kg will receive 8mg BID for 7 days followed by 4mg BID thereafter;<25 to 18kg will receive 6mg BID for 7 days and then 3mg BID thereafter;<18 to 12kg will receive 4mg BID for 7 days and then 2mg BID thereafter;<12 to 9kg will receive 3mg BID for 7 days and then 1.5mg BID thereafter;< 9kg to 6kg will receive 2 mg BID for 7 days and 1mg BID thereafter;<6kg to 5kg will receive 1mg BID for 7 days and 0.5mg BID thereafter;<5kg to 4kg will receive 0.6mg twice daily for 7 days and 0.3mg BID thereafter;PK cohort neonates ≥ 2.6kg will receive 0.1mg BID. Dose will be adjusted as determined by PK measurements (ie, to 0.2mg BID, 0.1mg daily or dose will stay the same).For the post PK cohort Neonates ˂4kg to 2.6kg, if confirmed by PK sub analysis,subjects will receive 0.2mg BID for 7 days and 0.1mg BID thereafter.
3372106|NCT02464969|Active Comparator|Standard of Care|Subjects will receive a dose and dosing regimen of anticoagulation treatment based on usual and customary care per local practices.
3372107|NCT02445651|Other|Oral and IV N acetyl Cysteine Cohort|Administration of Intravenous (IV) and Oral N-acetyl Cysteine (NAC) Intervention: IV NAC infusion: Dose: 50mg in 200ml of D5W, frequency: over one hour 1 x per week for 90 days ± 30 days AND Oral N-acetyl Cysteine - one 600 mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
3372108|NCT02445651|No Intervention|Control Cohort|Standard of Care Treatment
3254483|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 4|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 10 milligrams per kilograms administered by a programmable syringe pump.
3372112|NCT02318329|Experimental|Part 1A: FPA144 Dose Escalation Solid Tumors|Dose escalation of FPA144 (0.3 mg/kg to 15 mg/kg)
3372113|NCT02318329|Experimental|Part 1B: FPA144 Dose Escalation Gastric Cancer|Dose escalation of FPA144 (3-10 mg/kg) in patients with gastric cancer
3372114|NCT02318329|Experimental|Part 2: FPA144 Dose Expansion Gastric or Other Solid Tumors|Evaluation of objective responses in patients with tumors with various levels of FGFR2b overexpression
3372115|NCT02274987|Experimental|Treatment|The treatment plan for each patient is individualized and different depending on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
3254484|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 4|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3254485|NCT01424423|Experimental|Subjects receiving GSK1223249 in cohort 5|Eligible subjects will receive intravenous infusion of GSK1223249 with a dose of 30 milligrams per kilograms administered by a programmable syringe pump.
3254486|NCT01424423|Placebo Comparator|Subjects receiving placebo in cohort 5|Eligible subjects will receive intravenous infusion of placebo, administered by a programmable syringe pump.
3254487|NCT01424436|Experimental|GSK933776 1mg/kg|single dose
3254488|NCT01424436|Experimental|GSK933776 0.1 or 3mg/kg|single dose
3254489|NCT01424436|Experimental|GSK933776 3 or 6mg/kg|single dose
3254490|NCT01424449|Experimental|no treatment|Aripiprazole is a D2/D3 antagonist registered in the UK for use in the treatment of schizophrenia. It allows the highest clinically acceptable blockade of central D2/D3 receptors and will allow us to examine the amount of displaceable binding in the brain - a proposed reference tissue for [11C]PHNO.
3254491|NCT01424462|Experimental|Firategrast XRA|Low extended release tablet
3254492|NCT01424462|Experimental|Firategrast XRB|Medium extended releast tablet
3254493|NCT01424462|Experimental|Firategrast XRC|High extended release tablet
3254494|NCT01424462|Experimental|Firategrast IR|Immediate Release reference tablet
3254495|NCT01424475|Other|PKD Patients|PKD Patients with LRRK2 mutation
3254496|NCT01424475|Other|Healthy Controls|Healthy Controls with no LRRK2 mutation
3254497|NCT01424488|Experimental|sugammadex group|4 mg/kg of sugammadex for reversal of pipecuronium-induced neuromuscular blockade
3254498|NCT01424488|Placebo Comparator|placebo group|3 ml of saline (placebo) for reversal of pipecuronium-induced neuromuscular blockade
3254499|NCT01424527||Chronic Obstructive Pulmonary Disease|Males and females 40 years of age or older with a diagnosis of COPD
3254500|NCT01424540|Experimental|Treatment A|GSK2336805 150mg
3254501|NCT01424540|Placebo Comparator|Treatment B|GSK2336805 Placebo
3254502|NCT01424553|Other|Cohort|All patients
3254503|NCT01424579|Experimental|Actual Diacutaneous Fibrolysis|The group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of actual Diacutaneous Fibrolysis.
3254504|NCT01424579|Placebo Comparator|Placebo Diacutaneous Fybrolisis|This group received tree weeks of a daily protocolized treatment and additionally six sessions (two a week) of placebo Diacutaneous Fibrolysis.
3254505|NCT01424579|Other|No Diacutaneous Fibrolysis|This group received only tree weeks of a daily protocolized treatment.
3254506|NCT01424592||Study Group|Hospitalized inpatients referred by a general medicine service for evaluation of obstructive sleep apnea.
3254507|NCT01424605|Experimental|DLT intubation|
3254508|NCT01424618|Active Comparator|GnRh agonist|This arm will use a GnRH agonist to suppress pituitary-ovarian function
3254509|NCT01424618|Experimental|GnRH antagonist|A GnRH antagonist will be used to suppress pituitary-ovarian function
3372127|NCT02180243|Experimental|Yoga/Acupuncture|Eligible participants may be randomized to participate in iRest Yoga Nidra/ auricular acupuncture group classes.
3372128|NCT02180243|Active Comparator|Gulf War Health Education|Eligible participants may be randomized to participate in Gulf War Health Education group classes.
3254510|NCT01424631|Active Comparator|single incision laparoscopic appendectomy|
3254511|NCT01424631|Placebo Comparator|conventional laparoscopic appendectomy|
3372129|NCT02178332|Experimental|Yhteispeli, whole school programme|Yhteispeli-programme aims to support children's socio-emotional skills and well being at schools. Schools receive the Yhteispeli manual and teachers receive 3 and head masters 2 lecture days about use of Yhteispeli methods including group discussions and exercises. In addition every school is visited 4 times to support the use of Yhteispeli methods. (Lectures for the head masters March 2013 - November 2013, teachers August 2013 - January 2014)
3372130|NCT02178332|Active Comparator|Two theoretical lectures|Teachers receive two theoretical lectures on development of children's socio-emotional skills (3 hours in November 2013 and 3 hours in March 2014 ).
3254512|NCT01424657|Experimental|ERCP|ERCP is an endoscopic examination that allows opacification of the biliary tree by direct injection into the common bile duct through its distal opening in the duodenum at the ampulla of Vater
3254513|NCT01424657|Experimental|MRCP|The magnetic resonance cholangiopancreatography (MRCP)allows direct visualization of the biliary tree and pancreatic duct, similar to contrast cholangiography, but without the need for administration of contrast medium
3254514|NCT01424683||Endoscopic Vein Harvest (EVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
3254515|NCT01424683||Open Vein Harvest (OVH)|A short saphenous vein segment is commonly used as a conduit for coronary artery bypass grafting (CABG), and clinicians must decide whether to obtain it by performing a traditional open vein harvest (OVH) or by performing an endoscopic vein harvest (EVH).
3254516|NCT01424696||Cystic Fibrosis in 1st 3 months of life|Early Diagnosis: Children diagnosed with CF in first 3 months of life
3254517|NCT01424709|Experimental|Arm 1|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
3254518|NCT01424709|Active Comparator|Arm 2|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
3372133|NCT02097420|Other|Single device arm|Mitral valve replacement
3372134|NCT02088632|Active Comparator|Incobotulinumtoxina|Xeomin 25-100 units injected to chosen area one time.
3372135|NCT02088632|Placebo Comparator|Placebo Comparator|Placebo Comparator is 1-2 ml normal saline solution injected to chosen area one time.
3372136|NCT02022631|Experimental|Alternative SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
3372137|NCT02022631|Active Comparator|Current SoF|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
3372138|NCT01962337|Experimental|1-FPA008/Placebo Randomize DoseLevels1-4|Single infusion at 4 different dose levels
3372139|NCT01962337|Experimental|2-FPA008/Placebo Randomize DoseLevels1-2|Dual Infusions at 2 different dose levels
3372140|NCT01962337|Experimental|3-FPA008 Open-Label DoseLevels 1-3|Dual infusions at 1 dose level AND Dual/Triple infusions at 2 different dose levels
3372141|NCT01861106|Active Comparator|Arm A|10/10 HLA Matched Related Donor or Unrelated Donor or 9/10 HLA with DQ mismatch Transplant
3254519|NCT01424735|Experimental|Mw.|Administration of immunomodulator Mw.
3372142|NCT01861106|Active Comparator|Arm B|9/10 or 8/10 HLA Match Related Donor or Unrelated Donor or Haploidentical Donor Transplant
3372143|NCT01861106|Active Comparator|Arm C (combined with Arm B per Amendment N)|Haploidentical Related Donor Transplant
3372144|NCT01861106|Active Comparator|Arm D (Deleted this arm per amendment I)|Umbilical Cord Blood Transplant
3372145|NCT01861106|No Intervention|Arm E (Deleted this arm per amendment O)|Donor
3372146|NCT01842386|Experimental|Rituximab|Adults (=18 years of age) with anticytokine autoantibodyassociated diseases who are refractory to conventional treatment and who test negative for the human immunodeficiency virus (HIV)
3254520|NCT01424748|Placebo Comparator|Placebo|Placebo juice
3254521|NCT01424748|Experimental|30 mL Tahitian Noni Juice|30 mL Tahitian Noni Juice per day dose
3372147|NCT01837745|Active Comparator|Ablation group|"Administration of 1.1 GBq of I131 is given after the second intramuscular injections of rhTSH (0.9 mg). A whole body scan (WBS) is performed 2 to 5 days after the administration or I131 with determination of the neck uptake.~Follow-up consists in:~10 (+/- 2 months) after randomization: neck ultrasound + a serum Tg measurement after rhTSH stimulation~2 years (+/- 2 months) after randomization: serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
3254522|NCT01424748|Experimental|300 mL Tahitian Noni Juice|300 mL Tahitian Noni Juice per day
3254523|NCT01424748|Experimental|750 mL Tahitian Noni Juice|750 mL Tahitian Noni Juice per day
3254524|NCT01424761|Experimental|Placebo|Placebo:starch
3254525|NCT01424761|Experimental|Coenzyme Q10|
3254526|NCT01424787||OsvaRen treatment|Dialysis patients on OsvaRen treatment
3254527|NCT01424800|Experimental|change in blood pressure and blood flow|34 patients will form the experimental group, in which changes of blood pressure and blood flow will be induced and monitored.
3254528|NCT01424839|Other|Germinoma metastatic|"• Metastatic or incompletely staged germinomas (± teratoma) Do not receive chemotherapy in this protocol~Radiotherapy~Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracranial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)"
3254529|NCT01424839|Other|germinoma non-metastatic|"Chemotherapy:~• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide Note: Bifocal germinoma (pineal+suprasellar) are treated as non-metastatic germinoma, if staging shows no additional dissemination~Radiotherapy~Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
3254530|NCT01424839|Other|Non-germinoma non-metastatic standard risk|"Chemotherapy:~• Standard risk non-germinomatous malignant GCT Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions"
3254531|NCT01424839|Other|Non-Germinoma metastatic standard risk|Chemotherapy Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment ) Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
3254532|NCT01424839|Other|Non-germinoma non-metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
3254533|NCT01424839|Other|Non-Germinoma metastatic high risk|Chemotherapy Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support Radiotherapy After Chemotherapy: 30 Gy (20 fractions) to craniospinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)
3254534|NCT01424839|No Intervention|Teratoma|collection of information on surgery, applied treatment and outcome
3372148|NCT01837745|Experimental|Follow up group|Patients randomized in the follow up group neither received 131I nor rhTSH. Patients will undergo the same followup procedures as patients randomized to the ablation group, except that at 10 months after randomization, Tg will be measured under LT4 treatment and not after rhTSH stimulation.
3372149|NCT01799538|Experimental|1|Nebullizer
3372150|NCT01799538|Active Comparator|2|Inhaler
3254535|NCT01424852|Active Comparator|Probiotics in milk formula|B. lactis BB-12 and L. rhamnosus GG delivered in milk formula during the first year of infancy
3254536|NCT01424852|Placebo Comparator|Control milk formula|The children received milk formula with no probiotics
3372155|NCT01685008|Experimental|MOR00208 (formerly Xmab5574)|intravenous Infusion of MOR00208, Fc-Optimized Anti-CD19 Antibody
3372160|NCT01602666|Experimental|Treatment (combination chemotherapy, radiation therapy)|See Detailed Description
3372168|NCT01494662|Active Comparator|Cohort 1|"Patients With Progressive Brain Metastases~Intervention: HKI-272 (Neratinib)340 mg orally, once daily."
3254537|NCT01424891|Placebo Comparator|Placebo|Treatment with placebo over 8 weeks
3254538|NCT01424891|Active Comparator|Simvastatin 80 mg|treatment with 80 mg of simvastatin over 8 weeks
3254539|NCT01424891|Active Comparator|Sim10/Eze10|treatment with 10 mg of simvastatin in combination with 10 mg ezetimibe over 8 weeks
3254540|NCT01424904|Experimental|DGB-01|All subjects will receive DGB-01 during the study. Approximately one-half of the subjects during the first period and the other half during the second period.
3254541|NCT01424917||Heart Transplant|Heart Transplant subjects
3254542|NCT01424956||Asymptomatic Women who have Dense Breast Tissue|Women who have no signs or symptoms of breast cancer who have > 50% parenchymal density on mammography.
3254543|NCT01424969||PRFM Group|Patients were selected prospectively for the study based on a 3-part algorithm used to identify rotator cuff tears at risk for retear. A total algorithm score of 3 or greater was required for enrollment in the study.
3254544|NCT01424969||Control Group|The control group were recruited retrospectively. Patients who have undergone arthroscopic repair of rotator cuff tears with similar size characteristics without PRFM augmentation will be encouraged to participate by letter initially, and then by telephone invitation. The same inclusion and exclusion criteria applied. MRI, pain, and functional scores will be collected in the same manner as the PRFM group at one time point at least one year post operatively.
3254545|NCT01424982|Experimental|Treatment (combination chemotherapy, ponatinib hydrochloride)|See Detailed Description.
3254546|NCT01425008|Experimental|MLN2480|
3254547|NCT01425021||Total hip/knee joint revisions|All University of Utah orthopedic patients who have had total or partial joint arthroplasties at the time of revision surgery.
3254548|NCT01425034|Active Comparator|Cast group|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
3254549|NCT01425034|Active Comparator|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
3254550|NCT01425047||Females ingesting mangosteen juice|
3372169|NCT01494662|Active Comparator|Cohort 2|"Patients Who Are Candidates For Craniotomy.~Intervention: HKI-272 (Neratinib) 240 mg orally, once daily.~Surgical resection (biopsy).~Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib."
3372170|NCT01494662|Active Comparator|Cohort 3a/3b|"Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.~Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest."
3372171|NCT01494662|Active Comparator|Cohort 4a/4b/4c|"Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.~Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks."
3372172|NCT01489813|Placebo Comparator|Sugar pill|Patients will be given placebo pills for 10 weeks.
3372173|NCT01489813|Experimental|Genistein supplement|30 mg of genistein supplement by mouth three times daily (PO TID) for 10 weeks.
3254551|NCT01425047||Males ingesting mangosteen juice|
3254552|NCT01425060|Experimental|Contraceptive management program|
3372177|NCT01419561|No Intervention|1|Evaluation for Alternative Causes of KICS Symptoms
3254553|NCT01425060|Active Comparator|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
3254554|NCT01425073|Experimental|Stop TMP/SMZ|Arm 1 will have patients discontinue trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis; patients will follow up every 3 months with study staff.
3372178|NCT01419561|No Intervention|2|Natural History/Observation Arm
3372179|NCT01419561|Experimental|3|High dose zidovudine + valganciclovir
3372180|NCT01419561|Experimental|4|Rituximab with or without liposomal doxorubicin
3372181|NCT01419561|Other|5|Standard and alternative rational therapies
3372182|NCT01375959|Experimental|Resveratrol|resveratrol 500 mg capsules, 3 each day for 6 weeks
3372183|NCT01375959|Placebo Comparator|Placebo|matching placebo capsule containing lactose, 3 each day for 6 weeks
3372184|NCT01327105|Experimental|TVU|
3254555|NCT01425073|No Intervention|Standard of care TMP/SMZ prophylaxis|Arm 2 will continue standard of care treatment with trimethoprim-sulfamethoxazole (TMP/SMZ) prophylaxis.
3254556|NCT01425086||Incubator temperature support|Infant will be cared for in the current ongoing policy-driven temperature support provided by the incubator and handling as per bedside nursing interventions. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 weeks).
3254557|NCT01425086||Embrace blanket warming|Infant will be placed and wrapped in the embrace blanket and cared for and monitored for temperature support and monitored by bedside nursing interventions, as needed. Infant will be followed clinically until discharge from Lucile Packard Hospital (average 4 week
3254558|NCT01425099|Experimental|Part 1|In Part 1, approximately 12 healthy subjects will receive DTG 50mg q24h for 5 days in Period 1. Subjects will then be administered DTG 50mg q24h in combination with prednisone 60mg for 5 days followed by a 5 day taper (60 mg Days 1-5, 50 mg Day 6, 40 mg Day 7, 30 mg Day 8, 20 mg Day 9 and 10 mg Day 10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
3254559|NCT01425099|Experimental|Part 2|If DTG Cτ is reduced by more than 50% in Part 1, Part 2 will be carried out where a second cohort of subjects will receive DTG 50mg q24h DTG for 5 days in Period 1 followed by DTG 50mg q24h in combination with prednisone 20mg for 5 days followed by a 5 day taper (20 mg Days 1-5, 10 mg Days 6 and 7, 5 mg Days 8-10 - total duration of 10 days) in Period 2. There will be a screening visit 30 days before the first dose and a follow-up visit 7-14 days after the last dose of drug.
3254560|NCT01425112|Experimental|Topical/Subconjunctival|Depending upon the mode of administration
3254561|NCT01425125|Experimental|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
3254562|NCT01425138||Psoriasis|Published data on moderate-to-severe plaque psoriasis.
3254563|NCT01425151|Active Comparator|i-Gel|
3254564|NCT01425151|Experimental|ProSeal|
3254565|NCT01425164|Active Comparator|Carvedilol|
3254566|NCT01425164|Experimental|Ivabradine|
3254567|NCT01425177|Experimental|Normal saline irrigation|
3254568|NCT01425216|Experimental|Sorafenib arm|All patients will be treated with sorafenib.
3254569|NCT01425242|Experimental|Aliskiren|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with aliskiren, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with aliskiren monotherapy
3254570|NCT01425242|Active Comparator|Amlodipine|Half of all subjects with mild to moderate hypertension and a small abdominal aortic aneurysm are treated with amlodipine, combined with hydrochlorothiazide if hypertension cannot be treated sufficiently with amlodipine monotherapy
3372194|NCT01244438|Experimental|FP-1039|FP-1039
3372200|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2)|Participants with Alzheimer's disease received Placebo by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
3254571|NCT01425255||Parents of children with Type 1 diabetes|before and several weeks after initiating using RT-CGM of their children.
3254572|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3254573|NCT01425320|Experimental|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3372201|NCT01224106|Experimental|Gantenerumab 105 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 105 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
3372202|NCT01224106|Experimental|Gantenerumab 225 mg (Parts 1 and 2)|Participants with Alzheimer's disease received Gantenerumab 225 mg by SC injection every 4 weeks (Q4W) for 104 weeks or approximately 2 years during Part 1 of the study. Participants who completed the Week 104 visit were given an option to continue the treatment received during Part 1, for 2 additional years in Part 2.
3372203|NCT01224106|Placebo Comparator|Placebo (Parts 1 and 2) switched to Gantenerumab Up to 1200mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Placebo by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
3372204|NCT01224106|Experimental|Gantenerumab Up to 1200 mg (Part 3 Open-Label Extension [OLE])|Participants with Alzheimer's disease who had received Gantenerumab by SC injection in Part 1 or Part 2, now received Gantenerumab at doses up to 1200 mg by SC injection every 4 weeks (Q4W) for up to 5 additional years.
3254574|NCT01425320|Active Comparator|dapsone 5% gel (ACZONE®)|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
3254575|NCT01425320|Active Comparator|adapalene 0.3% gel (Differin®)|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
3254576|NCT01425333|Active Comparator|Cystectomy|Patients undergoing cystectomy for ovarian endometrioma
3372214|NCT00999609|Experimental|AAV2-hRPE65v2,voretigene neparvovec-rzyl|voretigene neparvovec rzyl, 1.5 E11 vector genomes, per eye, administered by subretinal injection in a volume of 0.3mL, 6-18 days apart
3372215|NCT00999609|No Intervention|Control|No intervention
3254577|NCT01425333|Active Comparator|Ablation|Patients undergoing ablation for ovarian endometrioma
3254578|NCT01425346||Normal Healthy|Normal, healthy males and females between the ages of 21 and 70 with healthy eyes as determined by a standard ophthalmic examination.
3254579|NCT01425385||Autoregulation monitoring|Patients will be grouped into Meld Score
3254580|NCT01425398|Experimental|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
3254581|NCT01425398|Placebo Comparator|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5
3254582|NCT01425411|Experimental|Valsartan treatment|
3254583|NCT01425424|Experimental|Fasting glucose (blood sugar)|This group is associated with a diagnosis of prediabetes
3254584|NCT01425424|Experimental|Resting Blood pressure|This group is associated with a diagnosis of prehypertension.
3372218|NCT00781612|Experimental|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine either as a single agent or in combination with other anti-cancer therapy (atezolizumab, paclitaxel, trastuzumab and docetaxel). Participants will receive the same dose and schedule on Cycle 1, Day 1 at which it was given at the end of the parent study. Study drug will be administered in 21-day cycles or weekly, depending on the schedule used in the parent study. Participants will receive study treatment until disease progression or unacceptable toxicity.
3372219|NCT00687505|Experimental|1|Single ascending doses
3372220|NCT00687115|Other|Overfeeding|an inpatient overfeeding arm in which obesity resistant individuals are prescribed a 150% increase in a weight maintenance calorie diet for 6 weeks which (by random assignment) is either low in protein (6%) content. Overfeeding or Overfeeding Low Pro or with normal (20%) protein content
3372221|NCT00687115|Other|Weight Loss|a weight loss arm in which obese individuals are placed on a 50% decrease from a weight maintenance calorie diet for 6 weeks which (by random assignment) is either a standard 50% decrease in energy intake with all macronutrients held at the same percentage (20% protein, 50% carbohydrate, 30% fat) or a 50% decrease in energy intake with the same absolute protein content (in grams) as the weight maintaining diet while on our clinical research unit then followed as outpatients monthly for 10 months
3372222|NCT00647387|Experimental|1|Implantation with the device
3372223|NCT00567567|Active Comparator|Consolidation Arm A: single myeloablative consolidation|Patients receive melphalan IV over 15-30 minutes on days -7 to -5, etoposide IV over 24 hours and carboplatin IV over 24 hours on days -7 to -4, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Patients undergo autologous PBSCT on day 0.
3254585|NCT01425424|Experimental|Fasting Glucose & Resting Blood Pressure|coexisting prediabetes and prehypertension
3254586|NCT01425437||Patients with keloid|All patients will have a clinical diagnosis of keloid and will consent to participate in this study.
3254587|NCT01425450|Experimental|HF1020|
3254588|NCT01425450|Placebo Comparator|Placebo|
3254589|NCT01425476|Placebo Comparator|Placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
3254590|NCT01425476|Active Comparator|Placebo & cholecalciferol 2,000 IU|
3254591|NCT01425476|Experimental|celecoxib 400 mg & cholecalciferol 2,000 IU|
3372224|NCT00567567|Experimental|Consolidation Arm B: tandem myeloablative consolidation|Patients receive thiotepa IV over 2 hours on days -7 to -5, cyclophosphamide IV over 1 hour on days -5 to -2, and G-CSF SC or IV beginning on day 0 and continuing until blood counts recover. Following clinical recovery from initial myeloablative therapy, patients also receive melphalan, etoposide, and carboplatin as in Arm A. Patients undergo autologous PBSCT on day 0.
3372225|NCT00497926|Experimental|Living Kidney Allograft|Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor
3372226|NCT00380653|Experimental|sapacitabine low dose|sapacitabine administered every 12 hours for 7 days followed by 14 days of rest or every 12 hours for 3 consecutive days per week for 2 weeks followed by 7 days of rest in patients with advanced leukemias or myelodysplastic syndromes The starting dose is (A) 75 mg twice daily x 7 days followed by 14 days of rest; Evaluated doses: 75mg, 100mg, 125mg, 175mg, 225mg, 275mg, 325mg and 375mg
3372227|NCT00380653|Experimental|sapacitabine high dose|"The starting dose is 375 mg twice daily x 3 consecutive days per week for 2 weeks followed by 7days of rest.~Evaluated doses: 375mg, 425mg and 475mg"
3372228|NCT00354835|Active Comparator|VAC|Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
3372229|NCT00354835|Experimental|VAC Alternating with VI|Patients receive VAC chemotherapy alternating with VI chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 17, 19, 20, 22-26, 28, 31-34, 37, 38, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 13, 22, 28, 34, and 40; cyclophosphamide IV over 1 hour on day 1 of weeks 1,10, 13, 22, 28, 34, and 40; and irinotecan hydrochloride IV over 1 hour on days 1-5 of weeks 4, 7, 16, 19, 25, 31, and 37. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.
3254592|NCT01425489||Observation|Patients with Krabbe Disease
3254593|NCT01425502|Other|All practices|The design is a stepped-wedge cluster randomised trial. All participating practices therefore receive the intervention at a start time which is randomised.
3254594|NCT01425541|Experimental|estrogen, progesterone|Estrace, 0.5-1 mg once a day Micronized progesterone powder (Spectrum Chemical Manufacturing Corporation, Irving, CA), Three times a day at 0700, 1500, and 2300 hr
3254595|NCT01425554|No Intervention|Diagnostic study|
3254596|NCT01425580|Experimental|liraglutide|The present trial is a two centre, open, assessor-blinded and active-controlled, parallel-group trial, in combination with metformin. The trial will compare the treatment with liraglutide 1.8 mg (s.c) QD + metformin up to 1 g BID, with that of glimepiride 4 mg QD (comparator) + metformin up to 1 g BID, on LV function in subjects with type 2 diabetes.
3254597|NCT01425580|Active Comparator|glimepiride|4 mg p.o. (QD)
3254598|NCT01425606||blood test|to measure levels of sodium, albumin and acid - base status in venous blood
3254599|NCT01425619|Placebo Comparator|Placebo cream, Skin test, Anxiety, Pain|After placing a placebo cream on both arms, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
3254600|NCT01425619|Active Comparator|Anesthetic cream, pain and anxiety, skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
3254601|NCT01425619|Active Comparator|Medical clown, placebo cream, skin test|After placing a placebo cream on both arms and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on one of the arms will be evaluated
3254602|NCT01425619|Active Comparator|Medical clown, Anesthetic cream, Skin test|After placing a placebo cream on one arm and anesthetic cream on the second arm and after receiving care and treatment from a medical clown, pain and anxiety resulting from performing allergy skin test on the second arm will be evaluated
3254603|NCT01425645|Active Comparator|Lifestyle and behavioural change support|Interventional arm will be offered a 12 month lifestyle program translating DM prevention issues to the family milieu
3254604|NCT01425645|No Intervention|control|Control arm will receive standard diabetes prevention care as outlined in the current Canadian diabetes association Clinical Practice Guidelines.
3254605|NCT01425658|Active Comparator|clonidine|The clonidine group (groupC) received bupivacaine 10mg combined with 75 microgram clonidine preservative free intrathecally
3254606|NCT01425658|Active Comparator|Fentanyl|The fentanyl group (groupF) received bupivacaine 10mg combined with 25 microgram clonidine preservative free intrathecally
3254607|NCT01425658|Placebo Comparator|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
3254608|NCT01425684||schizophrenia|smokers and nonsmokers
3254609|NCT01425684||control|smokers and nonsmokers
3254610|NCT01425697|Active Comparator|2% Chlorhexidine Gluconate cloths|2% Chlorhexidine Gluconate wipes will be used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery
3254611|NCT01425697|Other|Standard of Care Preoperative Preparation|Subject will receive standard of care preoperative preparation for the clinical site.
3254612|NCT01425710||Pheochromocytoma Group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy performed for pheochromocytoma
3372275|NCT00001177||healthy volunteers|healthy females
3372276|NCT00001177||patients|females with menstrually-related mood or behavioral difficulties
3254613|NCT01425710||Control group|Intraoperative esophageal doppler sonography during laparoscopic adrenalectomy for non-pheochromocytoma adrenal tumor
3376179|NCT02288247|Placebo Comparator|Placebo|Participants received an OL treatment with enzalutamide 160 mg capsules, orally once daily from day 1 in period 1 until randomization to period 2, confirmation of ineligibility for period 2, intolerable toxicity, withdrawal, or death. Participants with confirmed disease progression on enzalutamide in period 1 and who continued to meet all eligibility criteria received placebo matched to enzalutamide, orally once daily in combination with docetaxel 75 mg/m^2 in a one-hour infusion every 3 weeks and prednisolone 5 mg orally twice daily, in period 2. Docetaxel and prednisolone were administered up to 10 cycles (3 weeks/cyle) or more as assessed by the investigator. Enzalutamide was administered until disease progression, intolerable toxicity, withdrawal or death. Participants could continue the extension period, until investigator or participant decided to stop or disease progression, intolerable toxicity, withdrawal or death.
3376180|NCT02259725|Experimental|Treatment (regorafenib)|Patients receive regorafenib PO QD on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3376181|NCT02251821|Experimental|Treatment (ruxolitinib, transplant)|Patients receive a ruxolitinib and undergo myeloablative or reduced-intensity conditioning followed by transplant and GVHD prophylaxis; see detailed description.
3254614|NCT01425736|Placebo Comparator|Chemotherapy|"Chemotherapy~:Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)"
3376185|NCT02204462|Experimental|Newly diagnosed breast cancer|Patients with newly-diagnosed invasive and/or intraductal breast cancer detected by core needle or vacuum-assisted biopsy (i.e. index cancer). Patients will undergo FBnTP PET imaging for detection of malignant breast cancer.
3376186|NCT02204072|Experimental|BI 836845 & Enzalutamide|
3376187|NCT02204072|Active Comparator|Enzalutamide|
3376188|NCT02203305|Experimental|Cochlear Implant|Cochlear implantation of the affected ear
3376189|NCT02203305|Other|Control Group|A control group without the study intervention (cochlear implantation) will complete the test battery.
3376190|NCT02203305|Experimental|Cochlear Implant: Asymmetric hearing loss|Cochlear implantation of the poorer hearing ear
3376191|NCT02192502|Experimental|HES 130/0.4 (Voluven)|6% HES 130/0.4 during surgery
3376192|NCT02192502|Active Comparator|human albumin 5%|human albumin 5% during surgery
3376193|NCT02125136|Experimental|Gem/nab-Pac|2 further cycles Gem/nab-Pac (duration of each cycle 28 days)
3376194|NCT02125136|Experimental|FOLFIFINOX|4 cycles combination therapy with 5-fluorouracil/folinic acid, irinotecan, oxaliplatin (FOLFIFINOX) - duration of each cycle 14 days
3376195|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin (21-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
3376196|NCT02099058|Experimental|Monotherapy Telisotuzumab vedotin(28-day dosing cycles)|Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
3376197|NCT02099058|Experimental|Arm A (Telisotuzumab vedotin plus Erlotinib)|Telisotuzumab vedotin to be evaluated with Erlotinib.
3376198|NCT02099058|Experimental|Arm D (Telisotuzumab vedotin plus Nivolumab)|Telisotuzumab vedotin to be evaluated with Nivolumab.
3376199|NCT02099058|Experimental|Arm E (Telisotuzumab vedotin plus Osimertinib)|Telisotuzumab vedotin to be evaluated with Osimertinib.
3376200|NCT02065284|Active Comparator|Walking-Rhythmic Auditory Stimulation|Walking daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
3376201|NCT02065284|Active Comparator|Walking- only|Walking daily with no Rhythmic Auditory Stimulation (RAS) based music for 4 weeks
3376202|NCT02065284|Active Comparator|Rhythmic Auditory Stimulation (RAS)only|Listening to based music only daily for 4 weeks
3254615|NCT01425736|Experimental|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment: Docetaxel(75mg/m²,1 time/21d, 6times，);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times),Nimotuzumab treatment:(200mg/w,18weeks )."
3254616|NCT01425762|Experimental|Choice Group|
3254617|NCT01425762|Active Comparator|No Choice Group|
3372278|NCT05157282|Active Comparator|Active TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, active transcutaneous electrical spinal stimulation (TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
3372279|NCT05157282|Sham Comparator|Sham TESS Group 1|Subjects with SCI and without SCI (controls) will participate in two testing sessions, separated by 2-3 days, using a crossover design. In each session, sham transcutaneous electrical spinal stimulation (sham-TESS) will be applied over the cervical spinal cord. Functional and physiological measures will be acquired before and after each session.
3372280|NCT05157282|Active Comparator|Active TESS + Training|Develop methodologies to promote recovery of reaching and grasping movements. To accomplish this goal, the investigators will combine TESS applied in a closed-loop manner with massed practice upper-limb training. Participants will be assigned to one of three groups in a randomized order for a controlled design: [1) Closed-loop TESS applied during grasping + training, 2) Closed-loop TESS applied during reaching + training, and 3) Closed-loop TESS applied during grasping & reaching + training.] TESS for 20-min will be followed by 60 min of massed practice exercise training (total=20 sessions).
3372281|NCT05157269|Active Comparator|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
3372282|NCT05157269|Placebo Comparator|Placebo|Placebo tablets
3372283|NCT05157243|Experimental|Nitazoxanide|Nitazoxanide 300 mg extended release tablets
3372284|NCT05157243|Placebo Comparator|Placebo|Placebo tablets
3372285|NCT05157230|Experimental|exercise|volunteers in this group do shoulder/arm exercises after vaccine injection and fill in the pain diary
3372286|NCT05157230|No Intervention|no-exercise|volunteers in this arm only completed the pain diary without any intervention
3372287|NCT05157217||Group 1|COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization
3254618|NCT01425775|Active Comparator|Vitamin D|
3254619|NCT01425775|Placebo Comparator|Placebo|
3372288|NCT05157217||Group 2|COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU
3372289|NCT05157204||adult 20 patients with moderate to severe covid-19|adult 20 covid-19 patients with moderate to severe covid-19. for measurment of interleukin-6 from exhaled condensate during first 10 days of postive PCR
3372290|NCT05157204||20 healthy controls adult non pregnant humans f|20 healthy adults above 18 years non pregnant for measurment of interleukin-6 from exhaled condensate
3372291|NCT05157204||adult 20 patients with moderate to severe postcovid-19|adult 20 post covid-19 patients with moderate to severe covid-19 for measurment of interleukin-6 from exhaled condensate
3254620|NCT01425788|Active Comparator|Osiris Phleum pratense - Group A|"Group A up-dosing schedule from 1IR (index of Reactivity) /day to 240 IR/day in 11 days and thereafter 300 IR/day in 19 days.~Day 1-6: 1,2,4,6,8,10 IR/day Day 7-11: 30, 60, 120, 180, 240 IR/day Day 12-30: 300 IR/day"
3254621|NCT01425788|Active Comparator|Osiris Phleum pratense - Group B|"Group B Up-dosing schedule:~Day 1-5: 50 IR/day Day 6-10: 150 IR/day Day 11-30: 300 IR/day"
3372292|NCT05157191||mRNA COVID-19 vaccine|Children and adolescents (ages ≥ 5 to < 16) who receive mRNA COVID-19 vaccine per standard of care
3372293|NCT05157178|Experimental|4 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 4 week interval between the two doses.
3254622|NCT01425788|Active Comparator|Osiris Phleum pratense - Group C|"Group C up-dosing schedule:~Day 1-10: 50 IR/day Day 11-20: 150 IR/day Day 21-30: 300 IR/day"
3254623|NCT01425840|Experimental|Liposomal lidocaine, topical anesthesia|Efficacy of Liposomal lidocaine in topical anesthesia.
3254624|NCT01425866|Experimental|2 years self management education|Long-term program including initial self-management education program (1 to 7 sessions, based on individual assessment), and follow-up group sessions maintained for 2 years (4-monthly assessment, empowerment, and contextual action planning; facultative additional specific thematic sessions being delivered if needed).
3254625|NCT01425866|Active Comparator|Initial self-management education|Initial self-management group education: 1 to 7 sessions (< 3 months), based on individual assessment.
3254626|NCT01425905|Experimental|Depression Prevention|
3254627|NCT01425905|Active Comparator|Health Education|
3372294|NCT05157178|Experimental|8 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 8 week interval between the two doses.
3372295|NCT05157178|Active Comparator|12 week interval|Administration of two doses of the Covid-19 (recombinante) vaccine, with a 12 week interval between the two doses.
3372296|NCT05157139|No Intervention|Control|Patients receiving only standard care
3372297|NCT05157139|Active Comparator|Intervention (low dose)|Two capsules twice daily for 3 days then one capsule twice daily for 2 days
3372298|NCT05157139|Active Comparator|Intervention (high dose)|two capsules three times daily for 3 days, followed by one capsule three times daily for 4 days
3372299|NCT05157126|Experimental|Gentamicin|The intervention consists of 80mg of liquid gentamicin diluted in 5 mL normal saline (16mg/mL). The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
3372300|NCT05157126|Placebo Comparator|Saline|The control consists of 5 mL normal saline injected immediately after wound closure at the open fracture site. The solution is injected by inserting a 22-gauge needle down to bone through an anteromedial approach at the level of the fracture site such that the injected solution fills the wound cavity. A total of 5mL of study solution will be administered.
3372301|NCT05157113|Active Comparator|Dropless Regimen|"Intraoperative subconjunctival injection of triamcinolone acetonide (20mg) delivered 4-5 mm posterior to the limbus at the end of surgery~Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~No postoperative drops."
3372302|NCT05157113|Active Comparator|Standard Regimen|"Intraoperative intracameral injection of cefuroxime delivered at the end of surgery.~Neomycin/Polymyxin B ophthalmic solution: one drop to the operative eye four times daily for 1 week, then stop.~Ketorolac 0.5% ophthalmic solution: one drop to the operative eye four times daily for 1 month or until the bottle runs out.~Prednisolone acetate 1% ophthalmic solution: one drop to the operative eye four times daily for 1 month, then stop."
3372303|NCT05157100|Experimental|Ingrezza|Participants will receive Ingrezza orally once daily for 12 weeks.
3372306|NCT05157074|Experimental|Parkinson's Disease (PD) Group|Participants with PD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
3372307|NCT05157074|Experimental|Huntington's Disease (HD) Group|Participants with HD and their caregivers receive group drum classes twice a week for 12 weeks (24 lessons).
3372308|NCT05157061|Experimental|GOS arm|A single daily dose of a food supplement containing GOS for 8 weeks
3372309|NCT05157061|Placebo Comparator|Placebo arm|A single daily dose of maltodextrin, matching in taste, smell, appearance, and solubility, but without active ingredients (i.e. GOS), for 8 weeks
3372310|NCT05157048|Experimental|Marketing condition A|Participants will be randomized to a marketing condition.
3372311|NCT05157048|Experimental|Marketing condition B|Participants will be randomized to a marketing condition.
3254628|NCT01425918|Experimental|Social Enhancement Intervention|"For 5 months children will come in 4 days a week for 2-2.5 hours a session to participate in a classroom in an attempt to increase social communication and understanding.~Parent education sessions once a week for 2 hours each session over the 5-month period."
3254629|NCT01425918|Active Comparator|Parent Education|o Parent education sessions once a week for 2 hours each session over the 5-month period.
3254630|NCT01425931||Extracorporeal circulation|all patients were measured by microcirculation device O2C
3372312|NCT05157035|Experimental|Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention Group|The intervention is 6 weeks in duration. Participants will be asked to listen daily to at least one audio-guided mindfulness meditation embedded in the app. They will also be asked to watch a weekly video lesson on mindfulness and acceptance and will be asked to write a reflection about the video. They will also receive weekly emotional and technical support during the duration of the intervention.
3372313|NCT05157035|No Intervention|Wait-List Control Group|The control group is a wait-list control group. Participants in the control group will be offered to use the app after 10 weeks of being in the study. The control group participants once they opted to use the app after 10 weeks will only have access to the app for 6 weeks.
3372314|NCT05157022|Active Comparator|Focus extracorporeal shock wave therapy|
3372315|NCT05157022|Active Comparator|Radial extracorporeal shock wave therapy|
3372316|NCT05157022|Sham Comparator|Sham extracorporeal shock wave therapy|
3372317|NCT05157009|Other|Immediate implant placement without reconstruction|Immediate implant placement after tooth extraction
3372318|NCT05157009|Other|Immediate implant placement with reconstruction|Immediate implant placement and simultaneous bone reconstruction after tooth extraction
3372319|NCT05156996||Treatment Group|
3372320|NCT05156996||Control Group|
3254631|NCT01425957|Other|MCI Patient with Lumbar puncture|PartB: Patients affected by amnestic Mild Cognitive Impairment (aMCI).
3254632|NCT01425970|Experimental|25 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 1
3254633|NCT01425970|Experimental|50 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 2
3254634|NCT01425970|Experimental|100 mg INX-08189 + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 3
3254635|NCT01425970|Placebo Comparator|Placebo + Pegylated interferon alfa-2a + Ribavirin|PART A Arm 4
3254636|NCT01425970|Experimental|100 mg INX-08189 + Ribavirin|PART B Arm 1
3372321|NCT05156983|Experimental|PROTHROMPLEX TOTAL 25 IU/kg|Participants will receive PROTHROMPLEX TOTAL 25 international unit per kilogram (IU/kg) single intravenous infusion on Day 1 (prior to surgery) as an initial dose and an additional dose of 25 international unit per kilogram (IU/kg). PROTHROMPLEX TOTAL can be administered during the surgery if deemed necessary by the surgeon. The total dose of PROTHROMPLEX TOTAL administered to the participant should not exceed 50 IU/kg or 5,000 IU, whichever is smaller.
3372322|NCT05156983|Active Comparator|4F-PCC|Participants will receive 4F-PCC (excluding prothromplex total and activated 4F-PCC) as SOC on Day 1 (prior to surgery). The dose and infusion speed of the SOC 4F-PCC will be based on local institutional protocols. An additional dose of SOC 4F-PCC not exceeding label specified limits can be given during the surgery if required.
3372323|NCT05156970|Experimental|Camrelizumab + Chemotherapy|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus cisplatin 75 mg/m^2 IV or carboplatin at a target area under the curve of 5 (AUC 5) IV, per Investigator's choice, on Day 1 of each 3-week cycle (6 cycle maximum); plus docetaxel 75 mg/m^2 IV on Day 1 of each 3-week cycle (6 cycle maximum).
3372324|NCT05156970|Experimental|Camrelizumab +Apatinib mesylate|Participants receive Camrelizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle for up to 24 months;plus Apatinib 250mg qd for up to 24 months.
3254637|NCT01425970|Experimental|200 mg INX-08189 + Ribavirin|PART B Arm 2
3254638|NCT01425970|Experimental|Daclatasvir + INX-08189 100 mg|PART B Arm 3
3372325|NCT05156957|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including three exercises for daily self-guided therapy.
3372326|NCT05156957|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
3372327|NCT05156944|Experimental|intervention group|The study intervention is a brief physiotherapeutic assessment, a brief information on the expected course of the condition, and a brief instruction on self-management, including two exercises for daily self-guided therapy.
3372328|NCT05156944|No Intervention|control group|The control group will receive written information on the expected course of the condition, written instructions on self-management and written instructions on exercises for daily self-guided therapy.
3372329|NCT05156918|Experimental|Exercise Group|Exercise group participants will perform supervised high intensity exercise three times per week at the LLU department of physical therapy laboratory utilizing treadmills, stationary bicycles, and rowing machines.
3372330|NCT05156918|Active Comparator|Control Group|Control group participants will make no modifications to regular diet or exercise habits for 30 days.
3372331|NCT05156905|Experimental|Cirmtuzumab + Docetaxel|Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.
3254639|NCT01425970|Experimental|Daclatasvir + INX-08189 200 mg|PART B Arm 4
3254640|NCT01425970|Experimental|Daclatasvir + INX-08189 50 mg + Ribavirin|PART B Arm 5
3372332|NCT05156892|Experimental|Dose-escalation/ expansion|SUBA-itraconazole (oral 150mg twice daily) and escalating dose of Tamoxifen (oral once daily) then expansion cohort
3372333|NCT05156879|Experimental|Aspirin|Aspirin Enteric-coated Tablets，75mg/day，24 weeks
3372334|NCT05156879|Active Comparator|Drospirenone ethinyl estradiol|Drospirenone ethinyl estradiol，one tablet/day for 21 consecutive days, 28 days as a cycle of use，24 weeks
3372335|NCT05156866|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-ADC
3254641|NCT01425983|Active Comparator|amino acid composition (asn01)|Dietary supplement: specific amino acid composition with micronutrients
3254642|NCT01425983|Placebo Comparator|Sugar powder|Placebo contains no amino acids and no micronutrients and is identical in appearance and solution properties.
3372336|NCT05156866|Experimental|Expansion as Monotherapy - Part 2|TORL-2-307-ADC
3372337|NCT05156853|Experimental|Insect-based menu|Replacement of meat proteins with insect-based alternatives at main meals 3 times weekly.
3372338|NCT05156853|Active Comparator|Plant-based menu|Replacement of meat proteins with plant-based alternatives at main meals 3 times weekly.
3372339|NCT05156840||Telehealth|Patients/Caregivers who received a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
3372340|NCT05156840||Usual Care|Patients/Caregivers who did not receive a telehealth follow-up visit from a pediatric hospitalist following hospital discharge.
3372341|NCT05156827|Experimental|TB006|Participants will receive an intravenous (IV) infusion of TB006 1000 milligrams (mg) once weekly for 5 weeks.
3372342|NCT05156827|Placebo Comparator|Placebo|Participants will receive an IV infusion of normal saline once weekly for 5 weeks.
3372343|NCT05156814|Experimental|Fixed-dose Combination (FDC) estradiol / dydrogesterone|Femoston® 1 (1 mg estradiol / 10 mg dydrogesterone), Femoston® 2 (2 mg estradiol / 10 mg dydrogesterone)
3372344|NCT05156814|Active Comparator|Combination therapy with estradiol and dydrogesterone|Duphaston®, 10 mg and Divigel, 0.1%
3372345|NCT05156814|Active Comparator|non-hormonal therapy|Cimicifuga racemosa rhizomatum extract (Klimadynon®)
3372346|NCT05156801|Experimental|ArchSinus stent|Post-FESS implantation of the study device (ArchSinus) into ethmoid sinus cavity
3254643|NCT01425996|Experimental|Lipotecan® (TLC388)|"Dosage form: 40mg TLC388 base/vial lyophilized cake Dose: Chemotherapy, i.v. q.w. x 6 doses (dose-escalation)~* The dosage regimen would be escalated gradually until MTD had been found out."
3254644|NCT01426022|Placebo Comparator|Alcohol|"3 glasses of sparkling white wine (30g alcohol) with dinner~3 glasses of alcohol free sparkling white wine (<2g alcohol) with dinner"
3254645|NCT01426022|Experimental|Ambiance|"Pleasant ambiance~Unpleasant ambiance"
3372347|NCT05156801|Active Comparator|Propel stent|Post-FESS implantation of the comparator device (Propel) into ethmoid sinus cavity.
3372348|NCT05156801|Active Comparator|NasoPore packing|Post-FESS implantation of the comparator device (NasoPore) into ethmoid sinus cavity.
3372349|NCT05156788|Experimental|PD-1 antibody +Lenvatinib+Gemox|Tilelizumab 200mg, d1 Q3W Lenvatinib 8mg, po, qd, Gemox chemotherapy Gemcitabine 1000mg/m2, d1, 8, Q3W, + oxaliplatin 85mg/m2 d1, Q3W
3372350|NCT05156775|No Intervention|Intravenous analgesia group|35 Patients will receive intravenous morphine (mg) analgesia only.
3372351|NCT05156775|Experimental|Serratus Plane Block (SPB) group|35 Patients will receive ipsilateral serratus plane block using 30 ml bupivacaine 0.25% at the level of the 5th rib.
3254646|NCT01426035|Experimental|GROUP 1|
3254647|NCT01426035|Active Comparator|GROUP 2|
3372352|NCT05156775|Experimental|Rhomboid intercostal nerve block (RIB) group|35 Patients will receive ipsilateral rhomboid intercostal nerve block using 30 ml bupivacaine 0.25%.
3372353|NCT05156762|Experimental|Bariatric surgery group|Participants randomized to the bariatric surgery arm will undergo either a laparoscopic sleeve gastrectomy or a laparoscopic gastric bypass to achieve a BMI ≤ 40 kg/m2.
3254648|NCT01426048||Patients operated on with the TVT|
3254649|NCT01426061|Experimental|Reflexology plus conventional treatment|
3254650|NCT01426061|Experimental|Homeopathy plus conventional treatment|
3254651|NCT01426061|No Intervention|Conventional treatment|
3254652|NCT01426087|Experimental|endoscopic and somatostatin treatment|
3254653|NCT01426087|Other|endoscopic therapy|
3254654|NCT01426100|Experimental|CKD-828 40/2.5mg|
3254655|NCT01426100|Experimental|CKD-828 40/5mg|
3254656|NCT01426100|Active Comparator|Telmisartan 80mg|
3254657|NCT01426126|Experimental|Genexol PM|Genexol PM intravenous infusion every 3 weeks
3254658|NCT01426139|Experimental|Biotronik Orsiro DES|
3254659|NCT01426152||Low level progesterone group (1)|Progesterone < 1.50 ng/mL on day of ovulation induction
3254660|NCT01426152||Medium level progesterone group (2)|Progesterone 1.51-1.99 ng/mL on the day of ovulation induction
3254661|NCT01426152||High level progesterone group (3)|Progesterone > 1.99 ng/mL on the day of ovulation induction
3254662|NCT01426165|Experimental|Magnesium 8 grams over 4 hours|
3254663|NCT01426165|Experimental|Magnesium 8 grams over 8 hours|
3254664|NCT01426243|Active Comparator|Voluntary HIV positive subjects|40 HIV positive adults under HAART for at least one year (and stable on treatment for at least 3 months prior to enrolment), > 350 CD4/mm3 (with half of them a nadir < 200 CD4/mm3) and a viral load < 50 copies/mL for at least 6 months. Patients were HCV negative or non-replicative and treated for at least 2 years with normal ALT and negative HBs antigen.
3372354|NCT05156762|Experimental|Medical weight loss group|Participants randomized to the medical weight loss study arm will attempt to lose weight through diet, exercise, and potentially pharmacotherapy an effort to lower their BMI to ≤ 40 kg/m2.
3372355|NCT05156749|Experimental|short-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with fiberglass long-arm casts. The investigators were able to demonstrate that in distal metaphyseal forearm fracture, treatment with a short-arm cast is not inferior to a long-arm cast.~Patients are going to receive a short-arm cast for fracture treatment."
3372356|NCT05156749|Active Comparator|long-arm fiberglass cast|"salter harris fractures of the distal radius/forearm in children are usually treated with a fiberglass long-arm cast.~Patients are going to receive a long-arm cast for fracture treatment."
3372357|NCT05156736||Young Pakistanis|Young pakistani population with no history of cardiovascular disease and stroke
3372358|NCT05156723|Experimental|Group 1: Subunit recombinant vaccine for the prevention of coronavirus infection|5 volunteers have been vaccinated with a single dose (Stage I)
3372359|NCT05156723|Experimental|Group 2: Subunit recombinant vaccine for the prevention of coronavirus infection|15 volunteers have been vaccinated with a single dose (Stage I)
3372360|NCT05156723|Experimental|Group 3: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers will be vaccinated with the coronavirus vaccine intramuscularly twice (Stage II)
3372361|NCT05156723|Experimental|Group 4: Subunit recombinant vaccine for the prevention of coronavirus infection|45 volunteers have been vaccinated with a single dose of the coronavirus vaccine intramuscularly and then treated with a single dose of placebo (Stage II)
3372362|NCT05156723|Placebo Comparator|Group 5: Placebo|45 volunteers have been vaccinated with placebo intramuscularly twice (Stage II)
3372367|NCT05156697|Placebo Comparator|Placebo + Exercise|Placebo pills + 60 min of aerobic exercise
3372368|NCT05156697|Experimental|Dihydrocapsiate + Exercise|12 mg of dihydrocapsiate pills + 60 min of aerobic exercise
3254665|NCT01426243|Other|HIV negative subjects|Voluntary HIV negative subjects matched according to age (18-40 years and 40-55 years) and with HIV positive subjects, vaccinated at J0 and followed over one year
3254666|NCT01426256|Experimental|Cholecalciferol (Vitamin D3)|Patients will be given 250,000 IU cholecalciferol in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take 50,000 IU oral cholecalciferol every other week for 9 months.
3372373|NCT05156671|Experimental|Adrecizumab (HAM 8101)|Adrecizumab (HAM 8101) on top of standard of care. Adrecizumab (HAM8101) is a humanized IgG1 monoclonal antibody (mAb). 4 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion.
3372374|NCT05156671|Placebo Comparator|Placebo/ control substance (NaCl 0.9%)|100 mL saline as single dose infusion
3372375|NCT05156658|Active Comparator|Group A: With HIV receiving Monthly CARLA: ENG subcutaneous implant|Participants with HIV-1 receiving monthly cabotegravir-long acting and rilpivirine-long acting (CARLA) (not provided by the study) will receive ENG implant immediately after enrollment.
3372376|NCT05156658|Active Comparator|Group B: Without HIV: ENG subcutaneous implant|Participants without HIV-1 will receive ENG implant immediately after enrollment.
3372377|NCT05156645|Experimental|SCTA01 and SCTA01C+SOC|
3372378|NCT05156645|Placebo Comparator|Placebo+SOC|
3372379|NCT05156632|Experimental|Medium-dose group|4800 participants including 3400 participants aged 18-59 years ,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of medium-dose COVID-19 Vaccine 5-8 months after their second dose.
3254667|NCT01426256|No Intervention|Placebo|Patients will be given placebo pills in one bolus oral dose while they are in the hospital. Three months after the initial bolus dose, patients will take a placebo pill every other week for 9 months.
3254668|NCT01426282|No Intervention|control|
3372380|NCT05156632|Experimental|High-dose group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of high-dose COVID-19 Vaccine 5-8 months after their second dose.
3372381|NCT05156632|Placebo Comparator|Placebo group|4800 participants including 3400 participants aged 18-59 years,1200 participants aged 60 years and above who have received 2 doses of CoronaVac® (medium-dose COVID-19 Vaccine) in an interval between 21-56 days will receive a booster dose of placebo 5-8 months after their second dose.
3254669|NCT01426282|Experimental|nurse education|
3254670|NCT01426295|Experimental|Caphosol|
3254671|NCT01426295|Active Comparator|Référence|•Bicarbonate de sodium à 1.4% Biosedra Versylène® or PAROEX® :
3254672|NCT01426308||Method Comparison Group|The method comparison group will consist of de-identified, leftover DNA samples from patients referred for post-natal cytogenetic testing.
3372385|NCT05156606|Experimental|treatment|After the baseline imaging with FES- and FDHT-PET is completed, tamoxifen 20mg 1dd1 (standard dosage) plus testosterone (Androgel®) will be started. The first 3 patients will receive 25mg testosterone once daily (half the standard starting dosage for male hypogonadism). If this is well tolerated after 3 weeks, the dosage will be increased to 50mg once daily. Out of precaution, the safety profile of the 50mg dosage in the first 3 patients will be evaluated after all 3 patients have received 50mg testosterone for 2 cycli (8 weeks), prior to proceeding to the next 3 patients. Patients will be treated with tamoxifen and testosterone until disease progression or unacceptable toxicity.
3372386|NCT05156580||Obese hypertensive group|Patients who were diagnosed with obesity (body mass index (BMI)≥28kg/m2) and hypertension (systolic blood pressure (SBP)/diastolic blood pressure (DBP) ≥ 140/90 mmHg).
3254673|NCT01426308||Clinical Specificity Group|The clinical specificity group will consist of de-identified, leftover DNA samples from non-phenotypic patients, or patients not referred for post-natal cytogenetic testing.
3372387|NCT05156580||Overweight hypertensive group|Overweight patients (24 kg/m2≤BMI≤28 kg/m2) diagnosed with hypertension (SBP/DBP≥140/90 mmHg).
3372388|NCT05156580||Lean hypertensive group|Lean patients (BMI ≤ 24 kg/m2) diagnosed with hypertension (SBP/DBP ≥ 140/90 mmHg).
3372389|NCT05156567||routine physicians|
3372390|NCT05156567||DLS|
3372391|NCT05156554|Experimental|PEG-rhG-CSF|Patients in PEG-rhG-CSF group received PEG-rhG-CSF day+1 after transplantation.
3372392|NCT05156554|Active Comparator|rhG-CSF|Patients in rhG-CSF group received rhG-CSF day+1 after transplantation.
3372393|NCT05156541|Experimental|Interferon|After a cryodestruction session, therapy with Ingaron 100,000 IU once a day every other day. The course of treatment consisted of 5 injections.
3372394|NCT05156541|No Intervention|Control|Cryodestruction session only.
3372395|NCT05156528|Experimental|Experimental group|S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine, 0.5ml/dose, 2 doses with an interval of 30 days.
3372396|NCT05156528|Placebo Comparator|Placebo group|Aluminium phosphate adjuvant, 0.5ml/dose, 2 doses with an interval of 30 days.
3372397|NCT05156515|Experimental|Imaging cohort|All enrolled participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-THP-APN09 PET/CT scans.
3254674|NCT01426321|Active Comparator|Imaging guided LV lead positioning|
3254675|NCT01426321|No Intervention|Standard LV lead positioning|The LV lead position is decided at the discretion of the treating physician. Cardiac CT images are available for viewing, but no echocardiography data regarding segmental myocardial strain are available.
3254676|NCT01426334|Experimental|Treatment (dasatinib and cyclosporine)|Patients receive dasatinib PO QD on days 1-28 and cyclosporine PO BID on days 8-28. Treatment repeats every 28 days for 4 months in the absence of disease progression or unacceptable toxicity.
3372398|NCT05156502|Experimental|Fractionated Laser|
3372399|NCT05156502|Active Comparator|Fractionated.Laser|
3372400|NCT05156489|Experimental|Fractionated Laser|
3372401|NCT05156476|Active Comparator|Genicular nerve block-iPACK group|
3372402|NCT05156476|Active Comparator|Femoral triangle block-iPACK group|
3372403|NCT05156476|Active Comparator|Local Infiltration Analgesia (LIA)|
3372404|NCT05156463|No Intervention|Control|Participants will receive standard follow-up survivorship care, an accelerometer to measure physical activity and NCCN (National Comprehensive Cancer Network) patient materials.
3372405|NCT05156463|Experimental|Treatment|Participants will receive same materials as standard of care group. In addition participants will use PAI Activity tool, Garmin activity tracker and exercise logs, and also receive periodic exercise coaching.
3372406|NCT05156450|Experimental|Dose Extension|"At the recommended phase II dose of TQB3616 combined with abiraterone acetate (1000 mg, q.d.) plus prednisone (5 mg, b.i.d.), 20-40 patients are planned to be enrolled to evaluate the efficacy and safety of the combination therapy.~Metastatic and genomic tests based on tissue biopsy samples (primary or metastatic) and blood samples will be performed before treatment and after disease progression."
3372407|NCT05156437|Experimental|Group I (Experimental)|Two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of oral therapy with outpatient follow-up.
3372408|NCT05156437|Active Comparator|Group II (Control Group)|Conventional two (2) weeks of postoperative inpatient IV antibiotic therapy followed by four (4) weeks of IV antibiotic therapy (inpatient or facility supervised if indwelling catheter utilized).
3254677|NCT01426399|Experimental|LC15-0444|LC15-0444 50mg qd
3372409|NCT05156424|Experimental|Aerobic Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising aerobic exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration within each session.
3372410|NCT05156424|Experimental|Resistance Emphasised Exercise Intervention|The intervention will comprise of 24 weeks of twice weekly supervised exercise sessions, emphasising resistance exercise. To reflect a real-world setting, each group will experience both aerobic and resistance exercise, but there will be a 75%:25% predominant: subsidiary mode emphasis based on exercise duration of exercise within each session.
3372411|NCT05156411|Experimental|Eccentric Training|This Group will train on the KREHA for 20 Trainings
3372414|NCT05156385|Experimental|Hypertensive women|
3372415|NCT05156372|Experimental|Exercise Intervention|Participants will engage in 2-3 supervised high intensity aerobic and resistance exercise sessions per week.
3372416|NCT05156372|No Intervention|Control|Participants will continue daily routine as usual and given an informational flyer on physical activity and cancer.
3372417|NCT05156346|Experimental|LEAVES + usual care|The intervention consists of LEAVES online programme + usual care. LEAVES consists of 10 modules of readings and exercises.
3254678|NCT01426399|Experimental|Metformin|Metformin 1000mg bid
3254679|NCT01426399|Experimental|LC15-0444+Metformin|LC15-0444 50mg qd +Metformin 1000mg bid
3254680|NCT01426451|Experimental|Theatre intervention|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
3254681|NCT01426451|Experimental|Group tutoring intervention|In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes weekly). Individualized student objectives on reading fluency and math will be implemented (one in math and one in reading per student).
3254682|NCT01426451|No Intervention|No intervention|Classes not participating neither in drama workshops nor in group tutoring activities will fill out a questionnaire as a basis for comparison.
3254683|NCT01426477||Veritas Collagen Matrix|Observational study of subjects who undergo open ventral hernia repair using Veritas Collagen Matrix in an underlay technique.
3254684|NCT01426490|Other|Vitamin C|Vitamin C as control group.
3372418|NCT05156346|No Intervention|usual care|The control arm consists of the usual care which entails continuation of existing medication, with or without adjustments, continuation of the person's usual medical, psychological and/or nursing appointments whenever previously scheduled or deemed necessary. GRAI will also be given to participants at baseline (t0) and those meeting the criteria will be referred to specialized grief appointments.
3372419|NCT05156333|Placebo Comparator|Placebo|Daily oral administration of 1 capusle of placebo, composed of: hydroxypropylmethylcellulose; Anti-caking agent: Magnesium salts of fatty acids, Dioxide of silicon; Dye: E171.
3372420|NCT05156333|Active Comparator|Probiotic|Daily oral administration of 1 capsule of mixture of probiotics and milk glycoproteins with prebiotic action); Cornstarch; Anti-caking agents: Vegetable magnesium stearate, Silicon dioxide; Capsule orally administered: Hydroxypropylmethylcellulose (coloring: E171).
3254685|NCT01426490|Experimental|Vitamin B6|
3254686|NCT01426490|Experimental|Folic acid|
3372426|NCT05156294|Experimental|Test|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Consecutively, 4 to 6 mm height healing abutments and the allogenic membrane (NovoMatrix®, BioHorizon) folded in two on top of the implant (secured with the healing abutment), will be placed. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
3372427|NCT05156294|Other|Control|Mucoperiosteal flaps will be raised and the conventional drilling sequence for implants will be implemented (Camlog Conelog Screw-Line Promote Plus implants). Implants will be placed 1 mm below the bone crest. The diameter of the implant will be in the range of 3.8 and 4.3 mm. Finally, flaps will be sutured with 6/0 polypropylene monofilament. Patients will be instructed to rinse with 15 ml of 0.12% chlorhexidine (Perio-Aid tratamiento, Dentaid SL, Barcelona, Spain) 60 seconds twice per day until suture removal, that will take place 14 days later. Anti-inflammatory drugs will also be prescribed (Ibuprofen 600 mg every 8 hours upon patient´s needs).
3254687|NCT01426490|Experimental|Vitamin B6 plus folic acid|
3372432|NCT05156268|Experimental|Pembrolizumab with Olaparib|Eligible patients will receive olaparib in combination with pembrolizumab. Olaparib will be administered orally at 300 mg every 12 hours. Pembrolizumab will be administered intravenously (IV) at 200mg every 3 weeks.
3372433|NCT05156242|Experimental|Active-tDCS priming MCE|The subjects in active-tDCS priming with MCE group will receive the tDCS using 5X7 cm electrodes in which anodal electrode will be placed on M1 representing the back muscles (1 cm anterior and 4 cm lateral to the vertex), while cathodal electrode will be placed on contralateral supraorbital area. The intensity will be set at 2 mA with 10-second fade in/out. The subject will be stimulated by tDCS for 20 minutes. After that, the subjects will receive 20-minute MCE.
3254688|NCT01426542|Experimental|Topiramate|
3254689|NCT01426542|Active Comparator|Control|These infants will undergo surgery, but will not receive topiramate
3254690|NCT01426568|Active Comparator|Course of Multi-Convergent Thearpy|
3254691|NCT01426568|No Intervention|Waiting List for Multi-Convergent Therapy|
3254692|NCT01426607|Experimental|AMO|Adjustable mandibular repositioning appliance
3254693|NCT01426607|Placebo Comparator|placebo|placebo device in upper jaw
3254694|NCT01426620|Experimental|Blueberry powder|This is a two-part open-label clinical trial of blueberry powder administered to patients with stage IV NSCLC in combination with docetaxel as a second line treatment. Patients will initially be enrolled in part 1 of the study, which is the feasibility/toxicity evaluation section of the study. Once the part I enrollment is completed, the patients will be enrolled in part 2 of the study.
3254695|NCT01426633|Experimental|Gemcitabine + Trabectedin|
3254696|NCT01426646|Experimental|S-1 treatment|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
3372434|NCT05156242|Sham Comparator|Sham-tDCCS priming MCE|The subjects in sham-tDCS priming with MCE group will receive a 20-minute sham tDCS by setting the intensity at zero mA. After that, the subjects will receive 20-minute MCE.
3254697|NCT01426646|Experimental|S-1 plus cisplatin treatment|"S-1 plus cisplatin every 3 weeks, A total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
3254698|NCT01426659|Active Comparator|"Protocol say and do"|reeducation implicit 5 minutes every day at home and 30 minutes of speech therapy every week
3254699|NCT01426659|Active Comparator|"no stimulation say and do"|
3254700|NCT01426672|Experimental|Monovision Correctoin|Monovision correction
3254701|NCT01426698|Active Comparator|Immediate cord clamping|Infants in this arm will have had immediate cord clamping at birth which is routine care at the hospital
3372435|NCT05156242|Active Comparator|NMES priming MCE|The subjects in NMES priming with MCE group will receive the NMES using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral LM. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total NMES time is 20 minutes. After that, the subjects will receive 20-minute MCE.
3372436|NCT05156242|Active Comparator|Conventional physical therapy|The subjects in conventional physical therapy group will receive physical therapy modality (e.g., ultrasound, TENS, etc.) and general exercises.
3254702|NCT01426698|Experimental|Delayed Cord Clamping|Intervention: Following the delivery of the infant, the obstetrician holds the infant approximately 10-15 inches below the mother's introitus at vaginal delivery or 10 to 15 inches below the level of the placenta at Cesarean section. The research nurse records the time when the infant's buttocks are delivered from the vagina or the uterus and counts out the time elapsed in ten second intervals to the obstetrician while he/she is doing the suctioning and drying maneuvers. At 30 to 45 seconds, the obstetrician milks the umbilical cord once, clamps, and cuts it. If the baby appears jeopardized in any way, the obstetrician can alter the protocol for the safety of the infant.
3372437|NCT05156229|Experimental|CDK-003|
3372438|NCT05156216|Experimental|Experimental video|Knee OA educational video based on an empowerment discourse delivered online and embedded within the survey.
3372439|NCT05156216|Active Comparator|Control video|Knee OA educational video based on a disease and impairment discourse delivered online and embedded within the survey.
3372440|NCT05156203|Experimental|T-1301 Capsules|T-1301 Capsules will be administered orally QD or BID in a 28-day cycle (21 days on treatment followed by 7 days off treatment) in sequential cohorts.
3372441|NCT05156190|Experimental|bright classrooms with skylight or renovated artificial light|Students will study in bright classrooms with either skylight or renovated artificial light with light level of over 1000 lux on school time for three years and vision will be screened annually.
3372442|NCT05156190|No Intervention|conventional classrooms|Students will study in conventional classrooms with normal light level for three years and vision will be screened annual.
3372443|NCT05156164|Experimental|Kinesio-taping Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each) plus a bi-weekly treatment focused on the joint complex of the shoulder plus Kinesio-taping (KT) treatment.~The Kinesio-taping treatment consists in 4 applications of KT on the affected shoulder to be held for 5 days a week, followed by 2 days of rest to safeguard skin integrity before a further application.~5 KT strips with graded tensions will be placed on the following muscles:~supraspinatus with a tension of 70%.~infraspinatus with a tension of 70%. 3,4,5) deltoid (3 strips, 50% of tension) A sixth application with a tension of 90% originates at the level of the anterior face of the humeral head and it ends to the lower corner of the scapula."
3372444|NCT05156164|Sham Comparator|Control Group|"Conventional rehabilitative treatment (consisting in two treatments per day of 40 minutes each), plus a bi-weekly treatment focused on the joint complex of the shoulder, plus shame KT treatment.~- The CG will undergo a KT application on the deltoid but without support function with the same frequency and duration as the experimental group (shame-application)."
3254703|NCT01426750|Experimental|IOS, TFR|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren 1.0 or Jr (Nestlé-Clinical Nutrition).
3254704|NCT01426776|Other|heart valve replacement|a normal surgery that rheumatic valvular heart disease patients received.
3254705|NCT01426802|Experimental|Vildagliptin 50 bid|
3254706|NCT01426815|Placebo Comparator|Placebo|
3372445|NCT05156151|Other|Stromal lenticule implantation for management of herpetic stromal keratitis|"The thickness of the herpetic stromal scar in the cornea is calculated in microns in OCT. Based on that extraction is performed using SMILE, a new lenticular stromal pocket is placed in the same volume. AS-OCT evaluated the corneal topography, glass-corrected best visual acuity (BSCVA) measurements and electron microscopy. Postoperative complications were monitored during the follow-up period.~During the three year follow-up period, no signs of recurrence or infections were detected in this patient."
3254707|NCT01426815|Experimental|Golimumab 50mg (Simponi ®)|
3254708|NCT01426880|Experimental|Carboplatin + background treatment|Carboplatin AUC 2 min/mL weekly, infusion will be used as Add-on to the background therapy (same as comparator arm)
3254709|NCT01426880|Active Comparator|background treatment only|background treatment with NLPD (Myocet), Paclitaxel, Herceptin (Trastuzumab fpr Her2 pos), Tyverb (Lapatinib for Her2 pos), Avastin (Bevacizumab for triple negative) agents are used according to marketed formulation via normal procedures at each site and applied according to recommendations of the manufacturers.
3254710|NCT01426893||1|The inhaler device usage in patients with asthma or COPD
3254711|NCT01426906|Experimental|Study A|
3254712|NCT01426906|Experimental|Study B|
3254713|NCT01426919||Suspected traumatic brain injury with head CT|
3372446|NCT05156138||study group|patients with pseudoexfoliation fulfilling the inclusion criteria
3372447|NCT05156138||control group|patients without pseudoexfoliation fulfilling the inclusion criteria
3254714|NCT01426971|Experimental|Ibuprofen+caffeine|2 capsules
3254715|NCT01426971|Active Comparator|Ibuprofen|2 capsules
3254716|NCT01426984|Experimental|BPD adults|adults with Borderline Personality Disorder (BPD)
3254717|NCT01426997||High inflammation group (CRP>3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level >3 mg/L
3254718|NCT01426997||Medium inflammation group (CRP=1-3 mg/L)|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level = 1-3 mg/L
3372451|NCT05156112|Experimental|PAP Treatment on SARRTP Unit|Veterans will receive Positive Airway Pressure device while on the 28-day SARRTP Unit.
3372452|NCT05156112|No Intervention|Waitlist Control|Veterans will not receive PAP device until after 3-month Follow Up.
3372453|NCT05156099||ScanNav Anatomy PNB unaided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance without the device.
3372454|NCT05156099||ScanNav Anatomy PNB-aided|The participants will be asked to perform clinically relevant tasks on multiple healthy volunteers while under observation by a subject matter expert (expert observer) who will assess participant performance with the device.
3254719|NCT01426997||Low inflammation group (CRP<1 mg/L).|Forty-five participants each with a diagnosis of major depressive disorder and a CRP level <1 mg/L
3372457|NCT05156060|Experimental|Gabapentin plus Ketamine|Gabapentin and Ketamine will be taken 3 times per day.
3372464|NCT05156021|Experimental|pre-vitrectomy anti-VEGF injection group|Intravitreal injection of anti-VEGF drugs 3-5 days before surgery, followed by PPV combined with PRP and pressure-reducing valve implantation
3254720|NCT01427010|Experimental|Reirradiation of recurrent and 2nd primary head/neck cancer.|
3254721|NCT01427036|Experimental|MISS surgery group|hip screw MISS® (Minimally Invasive Screw System) : minimally invasive approach
3254722|NCT01427036|Active Comparator|PHS surgery group|PHS® hip screw design for standard approach
3372465|NCT05156021|Experimental|post-vitrectomy anti-VEGF injection group|At the same time as the PPV combined with PRP and pressure reducing valve implantation was completed, intravitreal injection of anti-VEGF drugs was performed
3254723|NCT01427049||renal denervation|Adults with a systolic BP ≥160 mmHg (≥150 mmHg for type 2 diabetics) with a stable drug regimen including 3 or more antihypertensive medications, including a diuretic, or inability to follow a stable drug regimen due to unacceptable side-effects of antihypertensive medication.
3254724|NCT01427062|Experimental|anticipatory and compensatory postural control training|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
3254725|NCT01427062|Active Comparator|strength-focused training|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
3254726|NCT01427075|Experimental|lateral pharyngoplasty|lateral pharyngoplasty
3254727|NCT01427088|Experimental|repetitive TMS|repetitive TMS is a quantified stimulation method of specifie area of brain, for which CR Technology, TAMAS for repetitive TMS was used.
3254728|NCT01427114|Experimental|R-CVP|6 cycles of R-CVP followed by 2 cycles of rituximab
3254729|NCT01427127|Experimental|ramosetron|Patients received intravenous ramosetron 0.3 mg at the end of surgery and 24hr after surgery.
3254730|NCT01427127|Placebo Comparator|Normal saline|Patients received intravenous normal saline at end of surgery and 24hr after surgery.
3254731|NCT01427140|Active Comparator|Saturated fatty acid group|Addition of saturated fatty acids to the diet inte the form of pastries
3254732|NCT01427140|Active Comparator|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
3254733|NCT01427153|Active Comparator|Corticosteroid|Corticosteroid injection
3254734|NCT01427153|Active Comparator|Orthopaedic Manual Physical Therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
3254735|NCT01427166|Experimental|Ultrasound imaging|Cords that are present in the participant's axilla and/or arm will be imaged with an ultrasound
3372466|NCT05156008|No Intervention|Group A|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by standard palpation of vein under strict aseptic measures. Application of tourniquet on upper arm, palpation of vein, disinfection of skin and insertion of cannula. After two unsuccessful punctures, UGVA operator will step in and perform insertion of cannula with ultrasound.~Medical staff will note:~number of attempts~time to obtain vascular access~type of cannula~DIVA score"
3372467|NCT05156008|Other|Group B|"Patient on the operating room, before primary hip or knee arthroplasty, will have his or her cannula inserted by ultrasound guided vascular access under strict aseptic measures. With or without tourniquet applied on upper arm operator will prescan vasculature of arm to choose applicable vein. After disinfection of skin optimal vein is on plain part of arm and cannula must not end in flection (elbow, wrist) of arm.~Medical staff will note:~number of attempts, if 2 attempts fail, another operator will perform insertion~time to obtain vascular access~diameter of vein~type of cannula~DIVA score"
3372468|NCT05155995|Experimental|Sequence 1|"Period 1: Fasted state + RLD2007 +RLD2008 + RLD2102~Period 2: Fasted state + HCP2001"
3372469|NCT05155995|Experimental|Sequence 2|"Period 1: Fasted state + HCP2001~Period 2: Fasted state + RLD2007 +RLD2008 + RLD2102"
3372470|NCT05155995|Experimental|Sequence 3|"Period 1: High fat diet + RLD2007 +RLD2008 + RLD2102~Period 2: High fat diet + HCP2001"
3372471|NCT05155995|Experimental|Sequence 4|"Period 1: High fat diet + HCP2001~Period 2: High fat diet + RLD2007 +RLD2008 + RLD2102"
3372472|NCT05155982|Experimental|Group A (18-54 yrs)|COVAC-1 25 ug
3372473|NCT05155982|Placebo Comparator|Group B (18-54 yrs)|Placebo Control
3372474|NCT05155982|Experimental|Group C (18-54 yrs)|COVAC-1 50 ug
3372475|NCT05155982|Placebo Comparator|Group D (18-54 yrs)|Placebo Control
3372476|NCT05155982|Experimental|Group E (55+ yrs)|COVAC-1 25 ug
3372477|NCT05155982|Placebo Comparator|Group F (55+ yrs)|Placebo Control
3372478|NCT05155982|Experimental|Group G (55+ yrs)|COVAC-1 50 ug
3254736|NCT01427192|Experimental|acetazolamide|1 week therapy, cross-over design
3254737|NCT01427192|Placebo Comparator|Placebo tablet|One week, cross-over design
3372479|NCT05155982|Placebo Comparator|Group H (55+ yrs)|Placebo Control
3372480|NCT05155969|Experimental|Eskatamine group|Low-dose esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction
3372481|NCT05155969|Placebo Comparator|Placebo group|Placebo (40 ml normal saline) is intravenously infused in 40 minutes before anesthesia induction.
3372482|NCT05155943|Experimental|KALPA X|The KALPA™ and KALPA X™ systems will be used during the performance of the LAAC procedure that is performed using customary and conventional tools and imaging technologies as currently performed in the participating center.
3372483|NCT05155930|Experimental|IFS|Internal Family Systems (IFS)
3254738|NCT01427192|Experimental|supplemental oxygen during nights|One week, cross-over design
3254739|NCT01427192|Experimental|Non-invasive ventilation|One week, cross-over design
3254740|NCT01427192|Sham Comparator|room air|room air applied via sham-oxygen-concentrator
3372484|NCT05155917|Experimental|basal insulin and insulin pump|Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.
3372485|NCT05155917|No Intervention|insulin pump|Patients in the control group did not receive placebo injections.
3254741|NCT01427205|Experimental|Group A: Cetuximab + OSI-906|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + OSI-906 150 mg orally twice a day. 21-Day Cycle.
3254742|NCT01427205|Experimental|Group B: Cetuximab + Placebo|Cetuximab loading dose of 400 mg/m2 by vein (IV) then 250 mg/m2 weekly + Placebo orally twice a day. 21-Day Cycle.
3372486|NCT05155891|Experimental|Embosphere Microspheres group|Participants in this group who are undergoing standard of care (SOC) prostate artery embolization (PAE) for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive Embosphere Microspheres during scheduled SOC PAE surgery.
3372487|NCT05155891|Active Comparator|HoLEP Group|Participants in this group who are undergoing SOC PAE for treatment of their symptomatic benign prostatic hyperplasia (BPH) will receive SOC Holmium laser enucleation of prostate (HoLEP).
3372488|NCT05155865|Experimental|Resynchronization with conduction system pacing|Implantation of permanent pacemaker with conduction system pacing (preferably left bundle branch) with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
3372489|NCT05155865|Active Comparator|Cardiac resynchronization therapy with biventricular stimulation|Implantation of cardiac resynchronization therapy with biventricular stimulation with or without defibrillator lead placement. Optimal guidelines-based heart failure treatment and antiarrhythmic drugs.
3372490|NCT05155852||Post-delivery preeclampsia patients|Women admitted to the high-risk unit(s) with elevated blood pressure and neurological symptoms, such as headache, after delivery.
3372491|NCT05155839|Experimental|MRG001|All patients in Phase Ia (dose escalation) and Phase Ib (dose expansion) will be administrated MRG001 on Day 1 of every 3 weeks (21-day cycle).
3372492|NCT05155826|No Intervention|standard care (control group)|Patient benefit the standard care during the placement of Cook's balloon (standard care).
3372493|NCT05155826|Experimental|standard care and virtual reality (experimental group)|Patient benefit the standard care during placement of Cook's balloon (standard care) with the use of a virtual reality.
3372494|NCT05155800||TBI patients with intracranial bleeding|
3372495|NCT05155800||TBI patients without intracranial bleeding|
3372496|NCT05155800||Control Subjects with normal brain health|
3372497|NCT05155787|Experimental|Group with neurofeedback training|The neurofeedback training system records the brain waves from the subject and converts the original brain wave signal into frequency energy through spectrum analysis. The system will help the subject to find self relax method for producing more alpha waves. Each person will arrange training three times a week for four weeks.
3372498|NCT05155787|Sham Comparator|Group with shame neurofeedback training|In the shame group, the system is not feedback to the actual wave. Each person will arrange training three times a week for four weeks.
3372499|NCT05155774|Active Comparator|Control group, controlled every 6th week|"This group was controlled every 6th week, in accordance with what is deemed to be golden standard for treatment with a Twin Block orthodontic appliance."
3372500|NCT05155774|Experimental|Test group, controlled every 4th week|This group was controlled every 4th week, testing if a more frequent control interval would increase compliance with a Twin block orthodontic appliance.
3372501|NCT05155761|Experimental|Osteoporotic patients|
3372502|NCT05155748|Experimental|Intervention|"Nursing staff, physicians and pharmacists will be invited to a continuous education - knowledge exchange session to inform them on the study rationale and the means of medication optimization.~Pharmacists will be asked to perform medication reviews, guided by the information and tools provided, for the participating residents.~Pharmacists' recommendations will be discussed during meetings with physician and nurses."
3372503|NCT05155748|No Intervention|Control|Care as usual.
3254743|NCT01427218|Experimental|Medication Therapy Management (MTM)|Medication Therapy Management visits with a pharmacotherapist will occur at a minimum of 6-9 weeks, 20-24 weeks, and 28-32 weeks. Additional interim face to face and telephonic visits may be scheduled based on patient's progress with meeting treatment goals and need for follow-up physical assessment and laboratory analysis.
3254744|NCT01427218|Placebo Comparator|Usual Care|Visits with a pharmacotherapist to create an accurate list of medications for those patients randomized to placebo (who receive usual care by their cardiologist and primary care provider).
3254745|NCT01427231|Active Comparator|Drink with 50 g glucose|The glucose drink contains 50 g of glucose soluted in 250 ml of water and lemon juice.
3254746|NCT01427231|Active Comparator|Drink with 100 gram of sacharose|The sacharose drink contains 100 g of sacharose soluted in 250 ml of water and lemon juice.
3254747|NCT01427231|Placebo Comparator|Placebo with sweeteners|The placebo contains a mixture of artificial sweeteners in order to have the same sweetness and appearance of the test drinks (the glucose drink and the sacharose drink).
3254748|NCT01427244|Experimental|Trastuzumab|Open Label
3254749|NCT01427257|Active Comparator|PB1023 Formulation A|
3254750|NCT01427257|Active Comparator|PB1023 Formulation B|
3254751|NCT01427257|Active Comparator|PB1023 Formulation B (2-8C)|
3372504|NCT05155735||Replantation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was replanted.
3372505|NCT05155735||Revision Amputation|This group will include subjects who suffered a single digit non-thumb amputation, and whose finger was not replanted.
3372506|NCT05155722|Experimental|Single group|First Phase: dose escalation study. It was divided into three dose groups: 100mg, 300mg and 600mg. The safety, tolerance and pharmacokinetics of BAT1308 injection were explored according to the 3+3 dose increasing mode. It is expected that 12-18 cases will be included in the group. Second Phase: dose expansion study. After the completion of dose increment, 300mg tolerated doses were selected for extended research on advanced non-small cell lung cancer, advanced hepatocellular carcinoma and cervical cancer (80-130 cases), so as to provide recommended doses for subsequent clinical trials.
3372509|NCT05155085|Experimental|SC 150 mg of lirentelimab (AK002)|Subjects in this arm will receive 4 monthly doses of 150 mg of lirentelimab (AK002) administered subcutaneously.
3372510|NCT05155085|Experimental|SC 450 mg of lirentelimab (AK002)|Subjects in this arm will receive 4 monthly doses of 450 mg of lirentelimab (AK002) administered subcutaneously.
3372511|NCT05155085|Other|Placebo|Placebo
3372516|NCT05151497|Experimental|Experimental group: Halliwick + Método Watsu|"The experimental group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 45 minutes of Halliwick, 15 minutes of Watsu and finally 15 minutes of immersion in hot water. .~In the application of the Halliwick Concept, it will be carried out in a pool at a temperature of 30ºC, and through the Ten Points Program.~To carry out Watsu, the pool water must be at a temperature of 35ºC. The Watsu Basic Maneuver will be performed, consisting of a sequence of various positions where the subject must be as relaxed as possible, placed in a supine position, floating with eyes closed, and supported by the physiotherapist who is standing, with a wide base of support."
3254752|NCT01427270|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
3254753|NCT01427270|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
3254754|NCT01427270|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
3254755|NCT01427283|Experimental|OXN|Oxycodone/Naloxone controlled-release tablets (OXN)
3254756|NCT01427283|Active Comparator|OXY|Oxycodone HCl controlled-release tablets (OXY)
3254757|NCT01427283|Placebo Comparator|Placebo|Placebo tablets to match OXN or OXY
3254758|NCT01427322|Experimental|lapatinib + radiation therapy|lapatinib given orally 2-4 hours prior to first fraction of radiation
3254759|NCT01427322|Active Comparator|No therapy prior to radiation|Radiation therapy alone
3254760|NCT01427335|Placebo Comparator|saline|0.9% saline intravenous infusion
3254761|NCT01427335|Experimental|calcium|Calcium intravenous infusion
3254762|NCT01427348|Experimental|with assistant|head extension by an assistant during direct laryngoscopy
3254763|NCT01427348|Active Comparator|without assistant|without the help of an assistant during direct laryngoscopy
3254764|NCT01427387|Experimental|Part-1 ASP group|ASP0456 receiving group
3254765|NCT01427387|Placebo Comparator|Part-1 Placebo group|Placebo treatment
3372517|NCT05151497|Active Comparator|Control group:Halliwick|The control group is made up of 7 subjects, the duration of the session being 75 minutes, divided into 60 minutes of Halliwick and 15 minutes of immersion in hot water. Treatment using the Halliwick Concept is carried out in a pool where the water temperature is 30ºC, following the Ten Points Program.
3372518|NCT05150496|Experimental|Two doses CoronaVac® + one dose medium-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using medium-dose CoronaVac®3-8 months after their second dose
3372519|NCT05150496|Experimental|Two doses CoronaVac® + one dose high-dose CoronaVac®|200 participants who were vaccinated with CoronaVac® will be given one dose booster immunization using high-dose CoronaVac® 3-8 months after their second dose
3372520|NCT05150496|Experimental|Two doses Comirnaty + one dose medium-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using medium-dose CoronaVac® 6-8 months after their second dose
3372521|NCT05150496|Experimental|Two doses Comirnaty + one dose high-dose CoronaVac®|120 participants were vaccinated with Comirnaty will be given one dose booster immunization using one dose high-dose CoronaVac® 6-8 months after their second dose
3254766|NCT01427387|Experimental|Part-2 group|cross-over study group to evaluate food effect on ASP0456 plasma concentration
3372526|NCT05148013|Experimental|Pilates exercise group|Pilates exercise group will receive a total of 20 sessions of 30 minute Pilates exercises 5 days a week which will be performed under the supervision of a physiotherapist.
3372527|NCT05148013|Experimental|PNF exercise group|A total of 20 sessions of PNF exercises for 30 minutes, 5 days a week, will be performed individually with a physiotherapist.
3372528|NCT05143905|Experimental|Cohort 1: AZD7503 dose 1|Randomised healthy participants will receive a single dose 1 of AZD7503.
3372529|NCT05143905|Experimental|Cohort 2: AZD7503 dose 2|Randomised healthy participants will receive a single dose 2 of AZD7503.
3372530|NCT05143905|Experimental|Cohort 3: AZD7503 dose 3|Randomised healthy participants will receive a single dose 3 of AZD7503.
3372531|NCT05143905|Experimental|Cohort 4: AZD7503 dose 4|Randomised healthy participants will receive a single dose 4 of AZD7503.
3372532|NCT05143905|Experimental|Cohort 5 : AZD7503 dose X|Randomised healthy participants will receive a single dose X of AZD7503.
3372533|NCT05143905|Experimental|Cohort 6: AZD7503 dose Y|Randomised healthy participants will receive a single dose Y of AZD7503.
3372534|NCT05143905|Placebo Comparator|Pooled Placebo for AZD7503 (Cohorts 1 to 6)|Randomised healthy participants will receive placebo.
3372535|NCT05143905|Experimental|Japanese Cohort 1: AZD7503 dose 3|Randomised healthy Japanese participants will receive a single dose 3 of AZD7503.
3254767|NCT01427400|Experimental|Expander Placement, Botulinum Toxin-A|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
3254768|NCT01427400|Placebo Comparator|Tissue expander Placement WITH Saline|During surgery, administered only once, 5 cc in 5 different locations on chest muscle.
3372536|NCT05143905|Experimental|Japanese Cohort 2: AZD7503 dose 4|Randomised healthy Japanese participants will receive a single dose 4 of AZD7503.
3372537|NCT05143905|Placebo Comparator|Placebo (Japanese Cohorts)|Randomised healthy Japanese participants will receive placebo.
3372538|NCT05143905|Experimental|Chinese Cohort: AZD7503 dose 4|Randomised healthy Chinese participants will receive a single dose 4 of AZD7503.
3372539|NCT05143905|Placebo Comparator|Placebo (Chinese Cohort)|Randomised healthy Chinese participants will receive placebo.
3372540|NCT05139342|Active Comparator|PD patients|patients diagnosed with PD will be allocated to this arm
3372541|NCT05139342|Active Comparator|MSA patients|patients diagnosed with MSAwill be allocated to this arm
3254769|NCT01427413||Hyper1|Only patients who achieved hyperstimulation pathology after external administration of gonadotrophin during IVF treatment
3372542|NCT05139342|Active Comparator|4RT patients|patients diagnosed with 4RT will be allocated to this arm
3372543|NCT05138666|Experimental|biological sample|respiratory and blood sample
3372544|NCT05137418|Experimental|3-5 years old age group|500 participants aged 3-5 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
3254770|NCT01427426|Experimental|All Greens|Subjects will consume the All Greens product daily. Product is prepared by mixing with either water, juice or in a smoothie.
3372545|NCT05137418|Experimental|6-11 years old age group|500 participants aged 6-11 years will receive two doses of COVID-19 vaccine,inactivated on day 0 and day 28.
3372546|NCT05136963|Experimental|volunteers|"48 volunteers will be included according to the following demographic characteristics (corresponding to the demographic profile of kidney donors according to the national data of the Biomedicine Agency):~aged between 20 and 35 years old: 4 women, 3 men~aged between 35 and 50 years old: 7 women, 5 men~aged between 50 and 65: 11 women, 8 men~> 65 years old: 6 women, 4 men"
3372547|NCT05133206|Experimental|Non-Fasting|Oral fluids and food up to the time of the procedure.
3372548|NCT05133206|No Intervention|Fasting|Clear fluids up to the time of the procedure and no food for at least 2 hours before the procedure - current practice.
3372549|NCT05132439|Experimental|Metformin ER 1000mg|daily by mouth
3372550|NCT05132439|Placebo Comparator|Matching placebo|daily by mouth
3254771|NCT01427426|Sham Comparator|Control formulation|Subjects will consume a product of similar consistency and comparable taste that does not have the same healthy ingredients as the All Greens.
3254772|NCT01427439||Major Depressive Disorder|
3254773|NCT01427452||Living Kidney Donor, Transplant Recipient, Healthy Control|Living kidney donors and their transplant recipient will be enrolled. Also, a smaller cohort of healthy controls (potential donors who were medically suitable but not used) will be enrolled.
3254774|NCT01427465|Experimental|Consult|Consult
3254775|NCT01427465|Experimental|Newsletter|Newsletter
3372553|NCT05132127|Experimental|sutimlimab|Participants in Japan with CAD who have completed CARDINAL or CADENZA studies will receive sutimlimab (BIVV009). The dosing schedule consists of an initial dose (Day 0), followed by a dose one week later (Day 7), which is followed by a maintenance dose every other week beginning on Day 21.
3372554|NCT05131464|Experimental|CM310|
3372555|NCT05131269|Experimental|Prolotherapy|"A solution of 7.5 ml of 15% dextrose with 2 ml of 40% lidocaine and 10.5 water is given to these shoulder segments as follows.~Supraspinatus muscle 2-4 ml~Infraspinatus muscle 2-4 ml~Teres minor muscle 2-3 ml,~Subscapularis muscle 2-3 ml.~Intraarticular glenohumeral joint 5 ml~Bursa sub acromial 1-2 ml,~Long head tendon biceps 1-2 ml~Acromioclavicular joint 1 ml"
3372556|NCT05131269|Placebo Comparator|Normal Saline 0.9%|"A solution of 20 ml normal saline 0.9% is given to these shoulder segments as follows.~Supraspinatus muscle 2-4 ml~Infraspinatus muscle 2-4 ml~Teres minor muscle 2-3 ml,~Subscapularis muscle 2-3 ml.~Intraarticular glenohumeral joint 5 ml~Bursa sub acromial 1-2 ml,~Long head tendon biceps 1-2 ml~Acromioclavicular joint 1 ml"
3372557|NCT05129943|Active Comparator|active distraction group|local anesthesia with video game using VR device
3372558|NCT05129943|Active Comparator|passive distraction group|local anesthesia with cartoon video using VR device
3372559|NCT05129228|Experimental|OCT-guided saphenous vein graft coronary artery bypass graft surgery|Optical Coherence Tomography (OCT) provides high quality intravascular images by using infrared light. OCT will assess the harvested saphenous vein conduit in Coronary Bypass Graft Surgery (CABG). Abnormalities found in the harvested conduits via OCT, at the discretion of the surgeon, will not be utilized for CABG.
3372560|NCT05129228|No Intervention|Visual inspection-guided saphenous vein graft coronary artery graft surgery|Harvested saphenous vein conduits will be assessed visually and will undergo a blinded OCT.
3372561|NCT05128227|Active Comparator|Pharm-SAVES|This an approximately 30-minute self-guided online module that covers basic information about suicide prevention gatekeeper skills training that is relevant to community pharmacists.
3372562|NCT05128227|Experimental|Interactive video case|An approximately 30-minute self-guided online suicide prevention gatekeeper skills training module, plus two approximately 5-minute interactive video cases in which participants are asked to respond to patients who exhibit suicidal warning signs.
3372563|NCT05123859||age groups|"A total of 30 participants in the 25- to 34-year age group~A total of 45 participants in the 35- to 44-year age group~A total of 50 participants in the 45- to 54-year age group~A total of 50 participants in the 55- to 64-year age group~A total of 45 participants in the 65- to 74-year age group~A total of 30 participants in the 75- to 85-year age group"
3254776|NCT01427465|Experimental|Parent Letter|Parent Letter
3254777|NCT01427465|Active Comparator|Control|Control
3372564|NCT05117034|Experimental|Morphine|Intraoperative intravenous administration of 0.08 mg/kg morphine at dura closure.
3372565|NCT05117034|Placebo Comparator|Placebo|Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
3372566|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 2 according to 0,28-day immunization schedule.
3372567|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 2 according to 0,28-day immunization schedule.
3372568|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 2 according to 0,28-day immunization schedule.
3372569|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 3 according to 0,28-day immunization schedule.
3372570|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 2 of the workshop 3 according to 0,28-day immunization schedule.
3372571|NCT05112913|Experimental|Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 3 of the workshop 3 according to 0,28-day immunization schedule.
3254778|NCT01427478|Experimental|AFATINIB|Radiotherapy combined with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
3254779|NCT01427478|Placebo Comparator|PLACEBO|Radiotherapy associated with a chemotherapy by Cisplatin IV at the dose of 100mg/m2 every 3 weeks, followed by a maintenance therapy with placebo of BIBW 2992 for 1 year at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
3254780|NCT01427491|Active Comparator|Aquacel® Ag|
3254781|NCT01427491|Active Comparator|Mepilex® Border Ag|
3254782|NCT01427543|Experimental|MILE group sessions|Participants will attend 6 - 2 hour long, interactive, culturally congruent, group sessions that address knowledge, beliefs, attitudes, and skills related to reducing HIV risk behaviors.
3254783|NCT01427543|No Intervention|Control|These subjects will be provided with access to post-incarcerations services that will be provided by the Center for Health Justice.
3372572|NCT05112913|Active Comparator|Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1|360 Participants aged 3-17 years(including 52 children aged 3-5 years,154 children aged 6-11 years and 154 adolescents aged 12-17 years) will receive Inactivated SARS-CoV-2 vaccine Lot 1 of the workshop 1 according to 0,28-day immunization schedule.
3372573|NCT05112874||Prospective Cross-Reactive Cohort|"Ages 18-89, Exhibiting symptoms compatible with a viral upper respiratory tract infection at the time of screening.~Lab test confirming~Negative for SARS-CoV-2 (by Polymerase Chain Reaction (PCR) or Antibody detection test)~Respiratory Panel positive for the common seasonal coronaviruses: NL63, 229E, OC43, and HKU1"
3372574|NCT05112549|Experimental|intrathecal Nivolumab|"This is a prospective, interventional, open label, multicenter phase I trial in leptomeningeal disease in subjects with solid tumor that have a registered indication for intravenous treatment with PD1 antibody. Subject will undergo 6 cycles each 14 days in duration and a safety visit 7 days after the 3th dosage and 7 days after the 6th dosage. The Follow-up phase will start four weeks after the last dose and will continue monthly (up to 4 Follow-up visits in total).The study consists of two parts:~Part I dose - escalation phase (3 + 3 design) with 4 cohorts and each subject will receive an intrathecal nivolumab treatment with a fixed predefined dose (20 mg, 30 mg, 40 mg or 50 mg). On each dose level, exposure of subjects to intrathecal nivolumab will follow a staggered approach. Part II dose expansion phase: subjects will receive an intrathecal PD1 treatment with a fixe dose, depending on the results from Part I."
3372577|NCT05104567|Experimental|Cohort A (Sub-study 01): 2-3L ESCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3372578|NCT05104567|Experimental|Cohort B1 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS ≥1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3372579|NCT05104567|Experimental|Cohort B2 (Sub-study 02): 1-3L GC/GEJ PD1/PD-L1 naïve non-MSI-H CPS < 1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3372580|NCT05104567|Experimental|Cohort B3 (Sub-study 02): 2-4L GC/GEJ Post PD1/PD-L1 non-MSI-H|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3372581|NCT05104567|Experimental|Cohort C (Sub-study 03): 2-3L HCC Post PD-1/PD-L1|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3372582|NCT05104567|Experimental|Cohort D1 (Sub-study 04): 3-6L CRC non-MSI-H any RAS|SAR444245 and pembrolizumab are administered every 3 weeks on Day 1 of each cycle (21 days per cycle) for up to 35 cycles.
3254784|NCT01427556||Breakfast Eaters|Women who self-report eating breakfast regularly.
3254785|NCT01427556||Non-Breakfast Eaters|Women who self-report skipping breakfast regularly.
3372583|NCT05104567|Experimental|Cohort D2 (Sub-study 04): 3-6L CRC non-MSI-H RAS wild type|SAR444245 is administered every 3 weeks on Day 1 of each cycle (21 days per cycle) and cetuximab is administered on Day 1, Day 8 and Day 15 of each cycle until progressive disease.
3372584|NCT05101096|Experimental|Sacituzumab Govitecan-hziy (SG) 6 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive sacituzumab govitecan-hziy (SG) 6 mg/kg by intravenous (IV) injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3372585|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3254786|NCT01427569|Experimental|IZN-6D4 Gel|patients in this arm will be treated by twice a week bandaging the wound with active IZN-6D4 Gel
3254787|NCT01427569|Placebo Comparator|Placebo Hydrogel|patients in this arm will be treated by twice a week bandaging the wound with a hydrogel used for wound care, but without the active IZN-6D4
3254788|NCT01427621|Experimental|RIPCcom group|
3254789|NCT01427621|No Intervention|Control group|
3254790|NCT01427634|Active Comparator|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
3254791|NCT01427634|Other|Control|Usual Care
3254792|NCT01427647|Active Comparator|Control group|Control group: open surgery under general anesthesia
3254793|NCT01427647|Active Comparator|Epidural group|Epidural group: Open surgery under thoracic epidural anesthesia
3254794|NCT01427647|Active Comparator|Laparoscopic group|Laparoscopic group: Laparoscopic surgery under general anesthesia
3254795|NCT01427660|Active Comparator|Traditional CERSG Arm|CHWs will provide and review with patients language-appropriate versions of the AHRQ consumer guides. CHWs will highlight key points on each page, review information on each medication and elicit and address questions. They will use the autonomy enhancing, motivational-interviewing based skills. As with the first arm, CHWs will schedule follow-up clinic appointments for participants who note a specific treatment change they would consider and will call participants two times after the session at three and six weeks to address additional questions and to follow up on any goals the participant set.
3254796|NCT01427660|Experimental|Web-Based Materials Arm|Participants randomized to this arm will be scheduled within 3 weeks of enrollment to have a one-hour face-to-face session with a CHW who will deliver the ipad platform personally tailored diabetes medication decision aid. Participants will receive a printed tailored preference summary at the completion of this visit. If participants note a specific treatment change they would like to discuss with their providers, the CHW will facilitate scheduling a clinic visit within the next month. Finally, CHWs will call participants two times after the session at 3 and 6 weeks to assess if the participant has additional questions and to follow up on any treatment or other goals the participant set during their session.
3254797|NCT01427673|Active Comparator|CPAP Procedure control group|Overlap patients randomly assigned to the CPAP titrated per AASM guidelines.
3372586|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, Advanced Solid Tumors|(Phase 1 Cohort A: dose escalation) Japanese participants with advanced solid tumors will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3372587|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 6 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 6 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3372588|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 8 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 8 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3372589|NCT05101096|Experimental|Sacituzumab Govitecan-hziy 10 mg, UGT1A1 Polymorphism|(Phase 1 Cohort B: dose escalation) Japanese participants with UGT1A1 polymorphism will receive SG 10 mg/kg by IV injection on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3254798|NCT01427673|Experimental|Bipap procedure group|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
3254799|NCT01427686|Active Comparator|Dobutamine|Start Dobutamine. If no success switch to Dopamine.
3254800|NCT01427686|Active Comparator|Dopamine|Start Dopamine. If no success switch to Dobutamine.
3372590|NCT05101096|Experimental|Sacituzumab Govitecan-hziy, Triple-negative Breast Cancer (TNBC)|(Phase 2: dose expansion) Japanese participants with TNBC will receive SG at the recommended Phase 2 dose (RP2D) on Day 1 and Day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
3372591|NCT05098860|Active Comparator|Home Exercise Program|"The home exercise program includes a general educational training program. The program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises.~Patients will be asked to do home exercises for 30-45 minutes once a day, 5 days a week for 8 weeks."
3372592|NCT05098860|Active Comparator|Manual Therapy Combined with Home Exercise Program|"Manual Therapy includes soft tissue and joint mobilizations of the cervical vertebrae, scapula and thoracic vertebrae. MT will be applied to the patients 2 days a week for 8 weeks.~The home exercise program includes active stretching, strengthening, and stabilization exercises of neck muscles, head and neck posture exercises as well as relaxation and diaphragmatic breathing exercises."
3372593|NCT05098860|Active Comparator|Tele-rehabilitation Assisted Program|Tele-rehabilitation assisted program will be given in the on-line environment. During 8 weeks, regularly planned exercises will be done via online applications for 30-45 minutes 2 days a week, accompanied by a physiotherapist. These patients will apply active cervical and thoracic region mobilizations called self-mobilization. Patients will be taught active mobilization applications with the help of a towel for the cervical region, with the assistance of a foam-roller for active mobilization of the thoracic region.
3372599|NCT05087992|Experimental|Phase 1a: BI 905711 + FOLFIRI + Bevacizumab|Phase 1a: Dose escalation in colorectal adenocarcinoma (CRC)
3372600|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI|Phase 1b: Dose Expansion: Single arm cohort in 2nd line Pancreatic Ductal Adenocarcinoma (PDAC)
3372601|NCT05087992|Experimental|Phase 1b: BI 905711 + FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm A.
3372602|NCT05087992|Experimental|Phase 1b: FOLFIRI + Bevacizumab|Phase 1b: Dose Expansion: Randomized cohort in 2nd line colorectal adenocarcinoma (CRC); Arm B.
3372603|NCT05085704||Adolescents and adults with Glut1 deficiency|"Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.~Ages 16 to 65~Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included."
3372604|NCT05085704||Normal healthy adolescents and adults|"Adolescents or adults in good general health.~Ages 16 to 65.~Persons with dental fillings, dental crowns, and short (max. 4 cm) dental retainer wires can be included."
3372608|NCT05076422|Experimental|BI 3006337 treatment group|BI 3006337
3372609|NCT05076422|Placebo Comparator|Placebo group|Placebo
3372610|NCT05076279|Experimental|Single port or reduced ports|Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection
3372611|NCT05075681|Experimental|Ruxolitinib combined with Chidamide|All recipients in this arm received the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. The conditioning regimen for allogeneic hematopoietic stem cell transplantation consist of ruxolitinib (35 mg bid [p.o.], days -15 to -10, diminishing to day -1), chidamide (30 mg/day, twice per week from days -15 to -2), cytarabine (4g/m2/day, days -10 to -9), busulfan (0.8mg/kg, Q6h, days -8 to -6), cyclophosphamide (1.8 g/m2/day, days -5 to -4), carmustine(BCNU) (250mg/m2/day, day -3)
3254801|NCT01427699|Experimental|T2-18C3 therapeutic antibody|9 subjects will receive the T2-18C3 therapeutic antibody.
3254802|NCT01427712||LipaCreon|those with an exposure
3254803|NCT01427725||LipaCreon|those with an exposure
3372612|NCT05075317|Active Comparator|Standard cardiac rehabilitation|The 16-week program consists of physician-directed risk factor management, an individualized aerobic and resistance exercise prescription, and virtual education on disease management and lifestyle behaviors (including exercise safety, stress management, and heart-healthy nutrition), and an assessment with a registered dietitian and individualized recommendations for a heart-healthy diet. Additionally, selected patients with identified issues such as depression, anxiety, trouble sleeping, anger and social and emotional issues will receive one-on-one counselling with a psychologist or social worker.
3372613|NCT05075317|Experimental|Standard cardiac rehabilitation + TRE|Participants in this group will receive the same standard assessment and individualized recommendations as the comparator group, but will also be counseled to restrict their eating to between 11 am and 7 pm during the program starting the evening of the consultation. They will also be advised to perform their home-based exercise sessions during the fasting period in the morning.
3372616|NCT05070364|Experimental|Peginterferon Lambda for 48 weeks|Peginterferon Lambda 180 mcg once weekly for 48 weeks with 24 weeks follow-up
3372617|NCT05070364|No Intervention|No treatment for 12 weeks|No treatment for 12 weeks followed by Peginterferon Lambda 180 mcg once weekly for 48 weeks and 24 weeks follow-up
3254804|NCT01427777||HPV Vaccine|People that receive HPV vaccine in V501-030
3372628|NCT05067816|Active Comparator|Distance Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a distance scale-up format where each site implementation team will receive technical assistance individually. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
3372629|NCT05067816|Experimental|Quality Improvement Collaborative Scale-Up Format|10 sites with up to 150 program participants will be randomly assigned to a quality improvement collaborative scale-up format where implementation teams will work collaboratively during training and implementation. All implementation training will occur using a virtual web-based format. Implementation teams will receive 8 hours of web-conferences, 2 hours of online training, and 4 hours of technical assistance.
3254805|NCT01427816|Experimental|KCT-0809 ophthalmic solution, low dose|
3254806|NCT01427816|Experimental|KCT-0809 ophthalmic solution, high dose|
3254807|NCT01427816|Placebo Comparator|Placebo|
3254808|NCT01427829|Experimental|Intervention (CaPRA)|
3254809|NCT01427829|No Intervention|Control (usual care)|
3254810|NCT01427842|Experimental|DEVINE vancomycin regimen|This is the intervention arm and will be the pharmacokinetically derived vancomycin dosing regimen.
3254811|NCT01427855|Experimental|High Saturated Fat Red Meat Diet|
3254812|NCT01427855|Experimental|High Saturated Fat White Meat Diet|
3254813|NCT01427855|Experimental|High Saturated Fat Non-Meat Diet|
3254814|NCT01427855|Experimental|Low Saturated Fat Red Meat Diet|
3254815|NCT01427855|Experimental|Low Saturated Fat White Meat Diet|
3254816|NCT01427855|Experimental|Low Saturated Fat Non-Meat Diet|
3254817|NCT01427868|Experimental|LB80380 maleat salt|
3254818|NCT01427868|Active Comparator|LB80380 free base|
3254819|NCT01427894|Experimental|Maternal Singing|Maternal singing during Kangaroo Care of stable preterm infants
3254820|NCT01427894|No Intervention|Kangaroo Care|Kangaroo Care without singing
3254821|NCT01427946|Experimental|Retaspimycin HCl (IPI-504) and Everolimus|Retaspimycin HCl (IPI-504) and everolimus will be administered on a 21-day cycle. All patients will remain on study until progression of disease or intolerability to study treatments occurs.
3372632|NCT05064397|Experimental|Eptinezumab|Participants will receive 4 intravenous (IV) infusions with eptinezumab at Baseline (Day 0) and at the end of Weeks 12, 24, and 36.
3254822|NCT01427985|Experimental|Relaxation followed by analgosedation|Give Atropin, then Mivacurium, immediately followed by Fentanyl
3254823|NCT01427985|Active Comparator|Analgosedation followed by Relaxation|Give atropin, then Fentanyl, then Mivacurium
3254824|NCT01427998|Active Comparator|olive leaf extract|Olive leaf polyphenol concentrate (OLPC) extraction OLPC was prepared from olive leaves as follows (Zaslave et al, 2005) : The leaves were randomly picked from the Barnea cultivar in the Jezreel Valley region of Israel and immediately freeze-dried on dry ice. After the leaves were thoroughly rinsed with sterile distilled water to remove dust, insecticides, and contaminating material, the leaves were ground and successively Soxhlet extracted with hexane for 3 h and 80% aqueous ethanol for 6 h. The alcoholic extract was concentrated under reduced pressure at 25 °C, and reconstituted with 30% ethanol in water.
3372634|NCT05061316|Experimental|Nutrition intervention group|Participants will receive Nestlé Impact Advanced Recovery Immunonutrition two times daily for 5 days leading up to the date of surgery. Nestlé Impact Advanced Recovery will be administered either orally or through a feeding tube.
3372635|NCT05057689|Experimental|Intranasal Dexmedetomidine (4 mcg/kg)|Dexmedetomidine 100 mcg/mL (concentration of 200 mcg/2 mL) will be atomized for intranasal administration at a dose of 4 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 200 mcg.
3372636|NCT05057689|Experimental|Intranasal Fentanyl (2 mcg/kg)|Fentanyl 50 mcg/mL (concentration of 100 mcg/2 mL) will be atomized for intranasal administration at a dose of 2 mcg/kg (0.04 mL/kg) according to a weight-based dosing chart. The maximum dose will be 100 mcg.
3372637|NCT05057689|Experimental|Intranasal Midazolam (5 mg/kg)|Midazolam 5 mg/mL (concentration of 10 mg/2 mL) will be atomized for intranasal administration at a dose of 0.3 mg/kg (0.06 mL/kg) according to a weight-based dosing chart. The maximum dose will be 10 mg
3372638|NCT05057013|Experimental|Part A Arm 1 Dose Escalation (single agent)|Groups of patients will receive increasing doses of HMBD-001 as a single agent to find a safe dose that best targets cancer cells. Approximately 26 patients with tumours known to express HER3 will be entered into this arm.
3372639|NCT05057013|Experimental|Part B Arm 1 Dose Expansion (single agent)|An expansion cohort of up to 25 patients with a confirmed HER3 positive or confirmed NRG1 fusion rearrangement RAS wild type colorectal cancer, castration resistant prostate cancer, triple negative breast cancer or squamous cell head and neck cancer will receive the HMBD-001 single agent RP2D as determined in Part A Arm 1.
3254825|NCT01427998|Placebo Comparator|placebo|matched placebo
3254826|NCT01428011||No treatment|African American/Black and Caucasian/White patients with hypertension
3254827|NCT01428037|Experimental|Misoprostol Vagianl Tablet|Misoprostol Vaginal Tablet 25 mcg.
3372645|NCT05050279|Placebo Comparator|Placebo|Delgocitinib placebo capsule
3372646|NCT05050279|Experimental|Active dose 1|Delgocitinib capsule (Dose 1)
3372647|NCT05050279|Experimental|Active dose 2|Delgocitinib capsule (Dose 2)
3372648|NCT05050279|Experimental|Active dose 3|Delgocitinib capsule (Dose 3)
3254828|NCT01428037|Placebo Comparator|Placebo|Tablet without active ingredient
3254829|NCT01428050|Experimental|3% saline|Patients will received 3% saline in conjunction with lactated ringers solution intra and post operatively for a net reduction in total fluid administration
3254830|NCT01428050|Active Comparator|Lactated Ringers|15cc/kg/hr of lactated ringers solution intraoperatively
3372649|NCT05050279|Experimental|Active dose 4|Delgocitinib capsule (Dose 4)
3254831|NCT01428089|Experimental|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml)
3254832|NCT01428089|Placebo Comparator|placebo|placebo at 1100, 1500, and 1900 h.
3254833|NCT01428102||RapidTEG|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent RapidTEG.
3254834|NCT01428102||Kaolin|Samples tested with TEG which are both citrated and non-citrated and are activated using the reagent Kaolin.
3254835|NCT01428141|Experimental|E7050|
3254836|NCT01428154|Experimental|Darbepoetin alfa|
3254837|NCT01428167||Thyroidectomy|All patients undergoing thyroidectomy for a variety of indications.
3254838|NCT01428180||Indomethacin|Infants treated with Indomethacin
3254839|NCT01428180||Ibuprofen|Infants treated with Ibuprofen
3254840|NCT01428180||Ligation|Infants undergoing surgical ligation
3254841|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway for dying at nursing homes
3254842|NCT01428206|No Intervention|control|Usual care is performed for the control group
3254843|NCT01428232|Experimental|BFHI steps 1-9|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems
3372658|NCT05036395|Experimental|The neonates evaluated by the routine assessment protocol and AI-assisted cEEG Diagnostic tool|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol and AI assisted cEEG diagnostic tool in real time during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
3372659|NCT05036395|Active Comparator|The neonates evaluated by the routine assessment protocol|"This group will be monitored by cEEG with standard operating procedure. The cEEG recording will be evaluated by neonatologists with the routine assessment protocol during cEEG monitoring. Both real-time cEEG and amplitude-integrated EEG traces are displayed at the bedside for clinical review.~This group will follow the standard clinical protocols of the recruiting hospitals for ASM administration after the neonatologists' review."
3372660|NCT05035784|Active Comparator|Fecal supernatant|Fecal supernatant is used for treatment of childhood Constipation
3372661|NCT05035784|Placebo Comparator|non-Fecal supernatant|Placebo is used for treatment of childhood Constipation
3372662|NCT05035641|Experimental|AND017 Dose A|AND017 will be administrated orally at dose A
3372663|NCT05035641|Experimental|AND017 Dose B|AND017 will be administrated orally at dose B
3372664|NCT05035641|Experimental|AND017 Dose C|AND017 will be administrated orally at dose C
3372665|NCT05035641|Placebo Comparator|Placebo|Placebo will be administrated orally
3372668|NCT05032196|Experimental|WVE-003 (Dose A) or placebo|
3254844|NCT01428232|Experimental|BFHI steps 1-9 +well-child clinic|Hospital retrained in BFHI steps 1-9 Mothers can call hospital to obtain BF support/Mothers given phone # of maternity nurse whom she can call or go see if she has BF problems Provision of BF support during 1) clinic visit to obtain birth certificate or home visit if mother does not come into clinic and 2) well-child clinics Flyers to mother with culturally appropriate messages designed to address some of the most important local barrier to EBF
3254845|NCT01428232|No Intervention|usual care|
3254846|NCT01428271||Herniorrhapy with caudal block|Children aged 0-72 months who are scheduled to undergo elective inguinal herniorrhapy under general anesthesia with caudal block
3254847|NCT01428284|Experimental|001|Canagliflozin/Probenecid
3254848|NCT01428297|Experimental|Cohort A and B, BPR277 and Placebo (vehicle)|
3372669|NCT05032196|Experimental|WVE-003 (Dose B) or placebo|
3372670|NCT05032196|Experimental|WVE-003 (Dose C) or placebo|
3254849|NCT01428297|Experimental|Part 2 BPR277|
3254850|NCT01428297|Placebo Comparator|Part 2 Placebo (vehicle)|
3254851|NCT01428297|Experimental|Part 3 BPR277 and Placebo (vehicle)|
3254852|NCT01428310|Active Comparator|Anatabloc(TM)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
3254853|NCT01428310|Active Comparator|CigRx(R)|dissolvable bit containing dietary ingredients, binders, fillers, and flavors
3254854|NCT01428349|Experimental|Attention to Context|
3254855|NCT01428349|Experimental|Affective Cognitive Control|
3254856|NCT01428362|Experimental|Placebo/VI-1121|Subjects received placebo during first treatment period and active treatment with VI-1121 during the second treatment period.
3254857|NCT01428362|Experimental|VI-1121/Placebo|Subjects received active treatment with VI-1121 during the first treatment period and placebo during the second treatment period.
3372671|NCT05032196|Experimental|WVE-003 (Dose D) or placebo|
3372673|NCT05030766|Experimental|MT plus NRT Group|Participants who receive the Mindfulness Training (MT) intervention for 4 weeks in addition to 6 weeks of Nicotine Replacement Therapy (NRT).These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
3372674|NCT05030766|Experimental|CM plus NRT Group|Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
3372675|NCT05030766|Experimental|MT plus NRT with additional CM Group|Participants who received the MT intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional CM intervention for another 4 weeks.
3372676|NCT05030766|Experimental|CM plus NRT with additional MT Group|Participants who received the CM intervention for 4 weeks with 6 weeks of NRT and are non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive an additional MT intervention for another 4 weeks.
3254858|NCT01428375|Active Comparator|(1) Active (Paracetamol) arm: n=60|(Paracetamol)
3254859|NCT01428375|Placebo Comparator|(2) Placbo (Sterile water) arm: n=60|Sterile water
3254860|NCT01428388|Active Comparator|Bevacizumab|
3254861|NCT01428388|Active Comparator|Ranibizumab|
3254862|NCT01428401|Experimental|Arm A|
3372687|NCT05027009|Experimental|Group I (low dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 3 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
3372688|NCT05027009|Experimental|Group II (middle dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 4 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
3254863|NCT01428401|Placebo Comparator|Arm B|
3254864|NCT01428414|Active Comparator|Trastuzumab+ Carboplatin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Carboplatin,Paclitaxel
3254865|NCT01428414|Active Comparator|Trastuzumab+Epirubicin+Paclitaxel|Neoadjuvant treatment regimen:Trastuzumab,Epirubicin,Paclitaxel
3372689|NCT05027009|Experimental|Group III (high dose simulated sunlight)|Patients undergo total body exam. The minimum dose of simulated sunlight required to cause mild sunburn is determined. One of the patient's moles is exposed to 6 times that minimum dose of simulated sunlight. One day later, that mole, and an untreated mole, are removed by punch biopsy.
3372692|NCT05021237|Experimental|Safety Lead In|Six patients with will be enrolled as first dose of 8.5Gy. If 0 or 1 patient experiences dose-limiting toxicity (DLT) out of six patients, then study will move on to expansion phase. If two or more patients experience DLT out of six patients, 6 additional patients will be recruited to lower dose level of 8Gy
3372693|NCT05020665|Experimental|Intensive Chemotherapy + Entospletinib (ENTO)|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with entospletinib (ENTO).
3372694|NCT05020665|Placebo Comparator|Intensive Chemotherapy + Placebo|Participants will receive intensive chemotherapy (cytarabine and anthracycline [daunorubicin or idarubicin]) in combination with the matching placebo.
3254866|NCT01428427|Experimental|Cohort|Dose escalation to maximum tolerated dose of GSK1120212 and Gemcitabine.
3372695|NCT05020236|Experimental|Part 1 Safety Lead-In Dose Escalation: Elranatamab + Daratumumab|
3372696|NCT05020236|Experimental|Part 2 Randomized Arm A: Elranatamab|
3372697|NCT05020236|Experimental|Part 2 Randomized Arm B: Elranatamab + Daratumumab|
3254867|NCT01428440|Other|no treatment|
3254868|NCT01428466|Experimental|GSK2585823|external preparation
3254869|NCT01428466|Active Comparator|Benzoic peroxide 3%|external preparation
3372698|NCT05020236|Active Comparator|Part 2 Randomized Arm C: Daratumumab + Pomalidomide + Dexamethasone|
3372720|NCT05005793|Experimental|Sodium bicarbonate|Oral sodium bicarbonate at a dose of 0.5 mEq/kg-lean body weight/day
3372721|NCT05005793|Placebo Comparator|Placebo|Oral placebo at a dose of 0.5 mEq/kg-lean body weight/day
3372722|NCT05004259|Experimental|Arm 1|Six weekly doses of subcutaneous daratumumab 1,800mg and hyaluronidase 30,000U.
3372723|NCT04999644|Experimental|Reduced Nicotine, Full Expectancy|Receive reduced nicotine cigarette expecting full
3372724|NCT04999644|Experimental|Full Nicotine, Full Expectancy|Receive full nicotine cigarette expecting full
3372725|NCT04999644|Experimental|Full Nicotine, Reduced Expectancy|Receive full nicotine cigarette expecting reduced
3372726|NCT04999644|Experimental|Reduced Nicotine, Reduced Expectancy|Receive reduced nicotine cigarette expecting reduced
3372727|NCT04999254|Experimental|Osteopathic treatment / Usual care|osteopathic treatment will be applied in this intervention group.
3372728|NCT04999254|Active Comparator|Usual care|Classic medical treatment
3372729|NCT04998747|Experimental|AMG 701: dose exploration|Cohorts of 3 to 6 participants each will be administered AMG 701 at different doses to determine the RP2D based on occurence of dose-limiting toxicities (DLTs) and on emerging safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy data.
3372730|NCT04998747|Experimental|AMG 701: dose expansion|Participants will be administered AMG 701 at the RP2D determined from dose exploration stage to further assess the safety, PK, PD, and efficacy of the selected dose.
3372731|NCT04996719|Experimental|Rapamycin|find safe doses for patients who have heart failure with preserved ejection fraction
3372732|NCT04995315||PK Deficiency Diagnosed Participants|Participants will receive online user access to the CBB. Participants will complete 2 CBB assessments on Study Day 0 and Study Day 90.
3372733|NCT04994691|Placebo Comparator|No message|No message sent
3372734|NCT04994691|Active Comparator|Standard message|2 MyChart reminders that child is overdue for well child check visit
3372735|NCT04994691|Active Comparator|Tailored message|2 MyChart reminders that child is overdue for well child check visit with date of last WCC and age
3254870|NCT01428466|Active Comparator|Benzoic peroxide 5%|external preparation
3254871|NCT01428466|Placebo Comparator|Vehicle|external preparation
3254872|NCT01428479|Experimental|Treatment Arm A|In Arm A subjects will receive 100 mg of GR121167 in Period 1 and 300 mg of GR121167 in Period 2. In Period 3 subject will receive single doses of placebo on Day 1 and multiple doses of placebo from Day 3 to Day 8
3254873|NCT01428479|Experimental|Treatment Arm B|In Arm B subjects will receive 100 mg of GR121167 in Period 1 and placebo in Period 2. In Period 3 subject will receive 600 mg of GR121167 as single dose on Day 1 and multiple doses of GR121167 from Day 3 to Day8
3372736|NCT04992624|Placebo Comparator|Placebo|
3372737|NCT04992624|Experimental|Cannabidiol (CBD)|Up to 150 mg/day.
3372738|NCT04992624|Experimental|Tetrahydrocannabinol (THC)|Up to 10 mg/day.
3372739|NCT04992624|Experimental|CBD plus THC|Up to 150 mg/day CBD plus up to 10 mg/day THC.
3372740|NCT04991779||The neonates with suspected seizures or high risk of seizures|The neonates with suspected seizures or high risk of seizures are monitored by continuous electroencephalogram (cEEG) at least 12 hours since admission. The cEEG will be interpreted by AI-assisted cEEG diagnostic tool at the end of cEEG monitoring. At the same time, the same cEEG will be manually reported according the reference standard.
3372741|NCT04989543|Other|healthy population|"Interventions: vaginal swabs:~Nugent scores,~cytobacteriological examination (in particular to determine the Clue Cells)~evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~healthy population~pathological population with bacterial vaginosis"
3372742|NCT04989543|Other|pathological population|"Interventions: vaginal swabs:~Nugent scores,~cytobacteriological examination (in particular to determine the Clue Cells)~evaluation of the vaginal microbiota.~On receipt of the Nugent score results, the doctor will confirm whether or not the patient is included in one of the two arms under study:~healthy population~pathological population with bacterial vaginosis"
3372743|NCT04986202|Experimental|Part A 2.5 mg|AZD4831 2.5 mg
3372744|NCT04986202|Experimental|Part A 5 mg|AZD4831 5 mg
3372745|NCT04986202|Placebo Comparator|Part A Placebo|Placebo
3372746|NCT04986202|Experimental|Part B Dose based on Part A|AZD4831 Dose based on Part A
3372747|NCT04986202|Placebo Comparator|Part B Placebo|Placebo
3372748|NCT04985838|Experimental|Online HEADS: UP|A group-based Mindfulness Based Stress Reduction (MBSR) course adapted for people affected by stroke and delivered using a video communication platform e.g. Zoom. An informal introductory session in the first week is followed by 8 weekly sessions (2.5 hours, incorporating 30-minute comfort breaks). A 6-hour silent retreat is offered in week 7. An optional follow-up session is offered six-eight weeks after completion of the 9-week course.
3372749|NCT04985838|No Intervention|Control|No intervention provided.
3372751|NCT04978493|Experimental|BI 706321 + ustekinumab|
3372752|NCT04978493|Placebo Comparator|Placebo + ustekinumab|
3372757|NCT04972981|Experimental|Part 1: Dose Escalation|In Part 1 (dose escalation) participants with selected advanced solid tumors will receive escalating doses of ADCT-901 as monotherapy.
3372758|NCT04972981|Experimental|Part 2: Dose Expansion|"In Part 2 (dose expansion), participants will receive ADCT-901 monotherapy at the dose identified in Part 1 (dose escalation).~Participants will be split into two groups:~Group 1: An indication for which ADCT-901 showed in Part 1 to have preliminary activity.~Group 2: A group of participants with Part 1 indications, except for the one selected in Group 1 of Part 2. No more than 30% of participants with the same indication are allowed in this basket group."
3372767|NCT04969887|Experimental|Ipilimumab and Nivolumab|All Subjects will be treated with: Nivolumab at 3 mg/kg and ipilimumab at 1 mg/kg concurrently every 3 weeks for 4 doses followed by nivolumab only at 480mg every 4 weeks until progression (up to 2 years)
3254874|NCT01428479|Experimental|Treatment Arm C|In Arm C subjects will receive placebo in Period 1, 300 mg of GR121167 in Period 2. In period 3 subject will receive 600 mg of GR121167 single dose on Day 1 and multiple doses from Day 3 to Day 8
3254875|NCT01428492|Experimental|Part 1-Dose Escalation|GSK2110183 is administered in combination with bortezomib and dexamethasone until MTD is met.
3254876|NCT01428492|Experimental|Part 2- Pharmacokinetic/Pharmacodynamics Cohort|Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
3372768|NCT04968548||Cases Series|Subjects with confirmed lung cancer diagnosis
3372769|NCT04968548||Screening Series|Subjects undergoing LDCT for lung cancer screening
3372770|NCT04964934|Experimental|AZD9833 + palbociclib or abemaciclib|The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + anastrozole placebo ( PO, once daily) or letrozole placebo ( PO, once daily)
3372771|NCT04964934|Active Comparator|Anastrozole or letrozole + palbociclib or abemaciclib|The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125,100 or 75 mg for 21 consecutive days followed by 7 days off treatment) or abemaciclib (PO, twice daily, 150,100 or 50 mg) + AZD9833 placebo (PO, once daily)
3372772|NCT04964323||PK Deficiency Diagnosed|Participants previously diagnosed with PK deficiency in Study AG348-C-008 (NCT03481738), will receive routine clinical care.
3254877|NCT01428492|Experimental|Part 2- Safety/Clinical Activity Cohort|"Enrolment into the safety/clinical activity cohort in Part 2 will begin prior to enrollment in the PK/PD cohort. Subjects with relapsed multiple myeloma who are either bortezomib sensitive or naive after failing one line of prior systemic therapy will be enrolled in the Safety/Clinical Activity cohort. Bortezomib sensitive is defined as having a response (PR or better) to the last bortezomib-containing therapy lasting at least 60 days beyond the end of therapy. A minimum of 15 subjects and a total of 40 subjects will be enrolled. This expansion cohort will further characterize the safety and clinical activity profile of GSK2110183 to inform the future development of this combination regimen."
3372776|NCT04962737|Experimental|Non-invasive Neuromodulation|Non-invasive Neuromodulation Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
3372780|NCT04958668|Active Comparator|Volatile procedere|Intensive care treatment with demand-adapted sedation with volatile anaesthetics
3372781|NCT04958668|No Intervention|Conventional procedere|Conventional Intensive care treatment with demand-adapted sedation with intravenous sedatives
3372782|NCT04958252|Experimental|Single dose part: BI 1569912 low dose|
3372783|NCT04958252|Experimental|Single dose part: BI 1569912 lower medium dose|
3372784|NCT04958252|Experimental|Single dose part: BI 1569912 higher medium dose|
3372785|NCT04958252|Experimental|Single dose part: BI 1569912 high dose|
3372786|NCT04958252|Experimental|Multiple dose part: BI 1569912|Additional dose group for multiple dose part may be added based on experience gained during the single dose part
3372787|NCT04958252|Placebo Comparator|Placebo|
3254878|NCT01428505|Other|no treatment|
3254879|NCT01428518||Patients with bipolar disorder|Patients with bipolar disorder prescribed lamotrigine tablets for the first time
3372788|NCT04957823||Diseased|type II diabetic patients with documented coronary artery disease.
3254880|NCT01428531||Patients prescribed fondaparinux|
3254881|NCT01428544||Patients with VTE treated with fondaparinux|Patients with VTE treated with fondaparinux
3372789|NCT04957823||Control|type II diabetic patients without coronary artery disease.
3254882|NCT01428557||Heart Failure patients|Patients admitted with clinical diagnosis of decompensate heart failure, > 18 years old.
3254883|NCT01428570|Experimental|Pentax-AWS|Patients in this group will be intubated using Pentax-AWS
3372791|NCT04952324||Pregnant women with GDM|Pregnant women with GDM
3372792|NCT04952324||Pregnant women without GDM|Pregnant women without GDM
3372793|NCT04951583|Experimental|Immune checkpoint inhibitor (ICI) therapy in combination with fecal microbial transplantation (FMT).|"Metastatic or advanced NSCLC: Single-agent Pembrolizumab (2 mg/kg or 200 mg every 3 weeks) in combination with investigational FMT capsules as follows: Full FMT at least 7 days prior to first cycle of Pembrolizumab.~Metastatic melanoma and uveal melanoma: Combination therapy of Ipilimumab plus Nivolumab (Ipilimumab 3 mg/kg every 3 weeks and Nivolumab 1 mg/kg every 3 weeks x 4 doses, followed by Nivolumab 3 mg/kg or 240mg every 2 weeks or 6 mg/kg or 480mg every 4 weeks) in combination with investigational FMT capsules as follows: full FMT at least 7 days prior to first treatment with Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the second cycle with combination Ipilimumab plus Nivolumab, followed by supportive FMT within 7 days of the third cycle of Ipilimumab plus Nivolumab."
3372795|NCT04946994|Experimental|High intensity interval training|
3372796|NCT04946994|Active Comparator|Continuous moderate intensity exercise|
3254884|NCT01428570|Active Comparator|laryngoscopy|Patients in this group will be intubated using Macintosh laryngoscope.
3254885|NCT01428596|Experimental|Arm I|Lower dose HIVAX vaccine
3254886|NCT01428596|Placebo Comparator|Arm II|lower dose, placebo control
3254887|NCT01428596|Experimental|Arm III|Higher dose HIVAX vaccine
3254888|NCT01428622|Placebo Comparator|Placebo + BI 54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
3254889|NCT01428622|Experimental|Olodaterol low dose + BI54903|"patient to receive 2 puffs of respimat A and 2 puffs of respimat B"
3254890|NCT01428622|Active Comparator|Olodaterol medium dose + BI54903|patient to receive 2 puffs of each device
3254891|NCT01428622|Experimental|Olodaterol high dose + BI54903|patient to receive 2 puffs of each device
3254892|NCT01428622|Experimental|Olodaterol l dose + BI54903|patient to receive 2 puffs of each device
3254893|NCT01428622|Experimental|Olodaterol m dose + BI54903|patient to receive 2 puffs of each device
3254894|NCT01428622|Experimental|Olodaterol h dose + BI54903|patient to receive 2 puffs of each device
3254895|NCT01428635|Experimental|Supportive care (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD in the absence of disease progression or unacceptable toxicity.
3254896|NCT01428648|Active Comparator|intervention|group of patients receiving ballroom dancing classes
3254897|NCT01428648|No Intervention|control|group of patients who will not receive dancing classes.
3254898|NCT01428674|Experimental|10 minutes reading|
3254899|NCT01428674|Experimental|20 minutes touch|
3254900|NCT01428674|Experimental|20 minutes reading|
3254901|NCT01428674|Experimental|10 minutes touch|
3254902|NCT01428687|Active Comparator|Increase Sleep Gradually|Subjects in this condition are taught to increase their sleep by 30 minutes per night during week 1 of the intervention; 60 minutes during week 2; and 90 minutes during week 3. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3254903|NCT01428687|Active Comparator|Increase Sleep Immediately|Subjects in this condition are taught to increase their sleep by 90 minutes per night starting in week 1. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3254904|NCT01428687|Active Comparator|No Intervention: Control Group|This group is told to make no changes in their sleep habits. Following the sleep intervention, these participants receive a standard behavioral with loss intervention.
3254905|NCT01428700||Non-Immune/Non-Viral (NINV)|Patients enrolled in ITN030ST transplanted for liver failure resulting from non-viral, non-immune causes
3254906|NCT01428700||Hepatitis C Virus (HCV) positive|Patients enrolled in ITN030ST transplanted for liver failure resulting from HCV genotype 1 infection
3254907|NCT01428726|Placebo Comparator|Placebo|
3254908|NCT01428726|Experimental|NT-KO-003 low dose|
3372803|NCT04945460|Placebo Comparator|Placebo|Delivered subcutaneously (SC) every 3 weeks (Q3W) for 24 weeks.
3372804|NCT04945460|Experimental|Sotatercept 0.3 mg/kg|Sotatercept SC at a dose level of 0.3 mg/kg Q3W for 24 weeks.
3372805|NCT04945460|Experimental|Sotatercept 0.3 mg/kg, escalating to 0.7 mg.kg|Sotatercept SC at a starting dose level of 0.3 mg/kg for 3 dosing visits (Q3W), then escalating to 0.7 mg/kg SC on the fourth dosing visit and Q3W for the remainder of the 24-week Treatment Period.
3372806|NCT04943523|Placebo Comparator|Placebo|vegetable oil 4g/day
3372807|NCT04943523|Active Comparator|Krill Oil|Krill Oil 4g/day
3254909|NCT01428726|Experimental|NT-KO-003 high dose|
3254910|NCT01428752||Family history|30- to 49-year-old asymptomatic subjects with a first relative history of colorectal cancer
3372809|NCT04939181|Experimental|Non-invasive Neuromodulation|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
3372810|NCT04939181|Placebo Comparator|Placebo Non-invasive Neuromodulation|Placebo microcurrents Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7 level.
3254911|NCT01428791|Active Comparator|Generations older adult member program|Rush Generations is a membership program for older adults, providing chronic disease prevention and management through educational programming, civic engagement, and individual and family consultations with social work staff.
3254912|NCT01428791|Experimental|BRIGHTEN Heart Virtual Team|BRIGHTEN Heart provides older adults with an interdisciplinary team evaluation of physical and mental health and on-going support for mental health and health behavior change for a minimum of six months. The five core components of the BRIGHTEN intervention consist of: 1) Assessment; 2) Virtual team case review; 3) Patient centered action planning; 4) Plan implementation, and; 5) When indicated, short-term evidence-based geriatric specialty psychotherapy.
3372816|NCT04937829|Experimental|BI 1569912 treatment group|
3372817|NCT04937829|Placebo Comparator|Placebo group|
3372818|NCT04936542|Other|Sequence 1|Participants will receive one cycle of aboBoNT-A followed by one cycle of onaBoNT-A in the selected overactive upper limb muscles
3372819|NCT04936542|Other|Sequence 2|Participants will receive one cycle of onaBoNT-A followed by one cycle of aboBoNT-A in the selected overactive upper limb muscles
3372823|NCT04931862|Experimental|WVE-004 (Dose A) or placebo|
3372824|NCT04931862|Experimental|WVE-004 (Dose B) or placebo|
3372825|NCT04931862|Experimental|WVE-004 (Dose C) or placebo|
3372826|NCT04931862|Experimental|WVE-004 (Dose D) or placebo|
3372827|NCT04931017|Experimental|Cohort A (metformin ER)|Participants receive metformin ER PO QD for 26 weeks in the absence of unacceptable toxicity.
3372828|NCT04931017|Active Comparator|Cohort B (metformin ER with waiting period))|Participants receive no intervention for 26 weeks, then cross-over to Cohort A.
3254913|NCT01428804|Active Comparator|active tDCS|a group named G1 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and 10 sessions of tDCS anode active at 2 sessions per day (1 morning and 1 afternoon) for 5 days with an electric current 2 mA
3372833|NCT04925765|Experimental|Virtual Reality Session|All participants in this study will complete a 1 hour virtual reality session.
3254914|NCT01428804|Sham Comparator|sham tDCS|a group named G2 and treated by medication with escitalopram (Seroplex®) stabilized for at least 1 month and sham tDCS.
3254915|NCT01428817|Active Comparator|Carbetocin 20mcg|
3254916|NCT01428817|Active Comparator|Carbetocin 40mcg|
3254917|NCT01428817|Active Comparator|Carbetocin 60mcg|
3254918|NCT01428817|Active Comparator|Carbetocin 80mcg|
3372840|NCT04922632|Experimental|Transcendental Medication (TM)|Transcendental Meditation (TM): a mind-body program that allows the participant to experience progressively quieter, less excited states of mental activity, with growing experience of restful alertness in mind and body.
3372841|NCT04922632|Experimental|Experience Resolution Methodology (ERM)|Experience Resolution Methodology (ERM): is a specific, protocolized coaching method that aims to maximize an individual's performance, professional development and well-being by recognizing and resolving subjective stress associated with specific situations, circumstances, events or experiences.
3372842|NCT04922632|Experimental|TM+ERM|Transcendental Meditation (TM) and Experience Resolution Methodology (ERM): an integrative method using both TM and ERM coaching with ERM with the aim of achieving an overall restful, alertness in mind and body and maximizing performance, professional development and well-being.
3372843|NCT04922632|Active Comparator|Treatment As Usual (TAU)|Treatment As Usual (TAU): is the existing Duke Health & Well-being services, such as the availability of acupuncture, integrative health coaching, integrative nutrition and weight management, personal exercise training, massage therapy, yoga therapy, mindfulness-based stress reduction (MBSR), experiencing mindfulness, group fitness classes, gentle yoga, or chair yoga, as well as additional resources such as Personal Assistance Services (PAS).
3372844|NCT04921384|Experimental|Eptinezumab 300 mg|"Double-Blind Treatment Phase (at baseline): 300 mg eptinezumab by intravenous (IV) infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
3254919|NCT01428817|Active Comparator|Carbetocin 100mcg|
3254920|NCT01428830|Experimental|7-day catheterization|
3254921|NCT01428830|Active Comparator|14-day catheterization|
3254922|NCT01428843|Active Comparator|Ferrisat|Infusion of Ferrisat (50mg/ml) at inclusion under usual practices
3254923|NCT01428843|Placebo Comparator|Placebo|Infusion of placebo at inclusion visit
3254924|NCT01428869||statin+ASA+dutasteride|
3254925|NCT01428869||statin+ASA|
3254926|NCT01428869||dutasteride+statin|
3372845|NCT04921384|Experimental|Eptinezumab 100 mg|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
3372846|NCT04921384|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion.~For patients outside Japan, at week 12: 100 or 300 eptinezumab by IV infusion."
3372847|NCT04921332|Experimental|Bright Light Therapy (BLT)|The intervention will consist of daily BLT sessions lasting 30 minutes at approximately 10AM (since many CF patients do not awaken until this time) starting on the day of admission through discharge for a goal of seven consecutive days. The intervention will use a 10,000-lux light box placed approximately 16-24 inches from the patient's face.
3372848|NCT04919499|Experimental|Part A: BI 765128 low dose|
3372849|NCT04919499|Experimental|Part A: BI 765128 medium dose|
3372850|NCT04919499|Experimental|Part A: BI 765128 high dose|
3372851|NCT04919499|Experimental|Part B: BI 765128|Highest safe dose from Part A
3372852|NCT04919499|Sham Comparator|Part B: Sham comparator|
3372853|NCT04917809|Experimental|Participants with FGFR3-mutant or -fusion noninvasive bladder tumors|25 participants with FGFR3-mutant or -fusion noninvasive bladder tumors will be accrued.
3372854|NCT04915950|Experimental|Temanogrel (Stage A Dose 1)|
3372855|NCT04915950|Experimental|Temanogrel (Stage A Dose 2)|
3372856|NCT04915950|Placebo Comparator|Placebo (Stage A)|
3372857|NCT04915950|Experimental|Temanogrel (Stage B Dose 1)|
3372858|NCT04915950|Experimental|Temanogrel (Stage B Dose 2)|
3372859|NCT04915950|Placebo Comparator|Placebo (Stage B)|
3372860|NCT04915729|Experimental|tenecteplase|Treatment Group
3372861|NCT04915729|Active Comparator|alteplase|Active control group
3254927|NCT01428869||dutasteride+ASA|
3372862|NCT04915599|Experimental|Intervention group|Patients are assigned to using the Cooral® MCD after radiotherapy for 60 min. along with general oral care (GOC). The MCD will be placed into the subjects' mouth and remain intraorally for 60 minutes. After each fraction, i.e. session of RT, the subjects insert the MCD inside their mouth and can start the Cooral ® thermostat system themselves when they feel comfortable. The stopwatch will be started by the patient as soon as thermostat is running. The patient is asked to write down the starting and the stopping time of the 60-minute procedure. Thereafter the subject will receive a questionnaire to record the tolerance for the device. Patients will be also informed about standard of care (SOC) that should be regularly performed.
3254928|NCT01428895|Active Comparator|Surgery Alone|
3254929|NCT01428895|Active Comparator|Surgery + Radiation Therapy|
3254930|NCT01428908|Experimental|children group A|600 children aged 2-5 years old, will be vaccinated on day0
3254931|NCT01428908|Experimental|infants group A|600 infants aged 6-23 months old, will be vaccinated on day0, 28
3254932|NCT01428908|Active Comparator|children group B|600 children aged 2-5 years old, will be vaccinated on day0
3254933|NCT01428908|Active Comparator|infants group B|600 infants aged 6-23 months old, will be vaccinated on day0, 28
3254934|NCT01428921|Experimental|Extended Education|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
3254935|NCT01428921|No Intervention|Standard education|- Each subject will receive advice from Sleep Lab staff on the need for CPAP treatment, and the care of CPAP device and mask.
3372863|NCT04915300|Active Comparator|Apabetalone|100mg BID, 24-week (168±3 days) Treatment Period.
3372864|NCT04915300|Placebo Comparator|Placebo|24-week (168±3 days) period.
3372867|NCT04914741|Experimental|Glofitamab plus R-CHOP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by R-CHOP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
3372868|NCT04914741|Experimental|Glofitamab plus polatuzumab vedotin-RCHP|Participants will receive treatment in 21 day cycles consisting of R-CHOP in cycle 1, followed by polatuzumab vedotin-RCHP plus glofitamab for cycles 2-6, and two cycles of glofitamab monotherapy consolidation. Patients may also receive high-dose methotrexate CNS prophylaxis at investigator discretion.
3372869|NCT04911751|Experimental|Low dose group|39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.
3372870|NCT04911751|Experimental|High dose group|39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.
3372871|NCT04911218|Experimental|GlideSheath Slender 5Fr arterial sheath|Placement of GlideSheath Slender 5Fr arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
3372872|NCT04911218|Active Comparator|Conventional 5Fr arterial sheath|Placement of Conventional 5Fr arterial sheath arterial sheath for diagnostic angiography through the distal radial artery (anatomical snuffbox).
3372873|NCT04910061|Experimental|NMN-C|Healthy individuals receiving NMN-C
3372874|NCT04904744|Placebo Comparator|No message|No message sent
3372875|NCT04904744|Active Comparator|Low tailored message|2 text or phone reminders that child is overdue for well child check visit
3372876|NCT04904744|Active Comparator|Low tailored message plus COVID-19 vaccine message|2 text or phone reminders that child is overdue for well child check visit AND COVID-19 vaccine is available
3254936|NCT01428934||Intermediate risk population|Population aged between 35 to 74 years who have an intermediate cardiovascular risk, defined as coronary risk between 5% -15% at 10 years according to the Framingham adapted risk equation or vascular mortality risk between 3-5% at 10 years according to the SCORE equation [27].
3254937|NCT01428947||Coronary angiography|Patents scheduled for elective coronary angiography
3254938|NCT01428960|Experimental|Palm Mid Fraction|
3254939|NCT01428960|Experimental|Shea Butter|
3254940|NCT01428960|Experimental|High Oleic Sunflower Oil|
3254941|NCT01428973|Active Comparator|Arm 1|GVHD prophylaxis: Mycophenolate mofetil (MMF) orally from the evening of day 0 through day 28 (sibling recipients) or day 42 (alternative donor recipients) at the dose of 15 mg/kg t.i.d. Tacrolimus (Tac)given orally at the dose of 0.06 mg/kg bid starting on day -3. The dose adapted according to through whole blood values following standard procedures (between 10 and 15 ng/ml the first 28 days and between 5-10 ng/ml thereafter). Full doses given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
3372881|NCT04903353|Active Comparator|Treatment with Risperidone|Patients prescribed Risperidone
3372882|NCT04903353|Active Comparator|Treatment with Aripiprazole|Patients prescribed Aripiprazole
3372883|NCT04902443|Experimental|1/Dose De-Escalation|Treatment with pomalidomide at de-escalating doses if necessary and nivolumab at a fixed dose
3372884|NCT04902443|Experimental|2/Dose Expansion|Nivolumab + pomalidomide (at optimal dose determined in dose escalation portion of the study) for up to 30 participants
3372885|NCT04901702|Active Comparator|(Arm A) ONI plus TAL|The phase I/II study will evaluate a treatment regimen; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL)
3372886|NCT04901702|Active Comparator|(Arm B) ONI plus TMZ|The phase I/II study will evaluate a treatment regimen; Onivyde (ONI) plus temozolomide (TMZ)
3372887|NCT04899661||Molidustat|Participants diagnosed with renal anemia treated with Molidustat at the discretion of investigators
3372888|NCT04899024|Experimental|PARTI and CM (Contingency Management)|The PARTI intervention will be delivered in five individual sessions during a 12-week contingency management protocol for PrEP adherence
3372889|NCT04899024|Active Comparator|Attention-Control and CM (Contingency Management)|The attention-control condition will consist of five individual sessions where participants complete self-report measures and neutral writing exercises during a 12-week contingency management protocol for PrEP adherence
3372890|NCT04897607|Active Comparator|Treatment Plan Option 1 (Standard Care)|Standard smoking cessation counseling will be offered + participant choice of nicotine patches or varenicline. Participants are also free to decline either medication.
3372891|NCT04897607|Experimental|Treatment Plan Option 2 (Precision Pharmacotherapy)|Standard smoking cessation counseling will be offered + a recommendation to take either the nicotine patch or varenicline based on the results of the NMR test. Regardless of the recommendation, it would still remain the participant's choice to be prescribed either nicotine patches or varenicline. Participants are also free to decline either medication.
3372892|NCT04896541|Experimental|AZD7442|Single dose (IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
3372893|NCT04896541|Experimental|placebo|Single dose (× 2 separate IM injections or IV administration) of AZD7442 or saline placebo on Day 1.
3372898|NCT04892147|Experimental|Experimental group|Randomly selected to participate first in MOBA group
3372899|NCT04892147|Other|Wait-list-control group|Randomly selected for study assessments parallel with experimental group. Participates in MOBA after completion of the experimental group
3372909|NCT04886804|Experimental|Phase Ia - Dose escalation part|Consecutive cohorts of patients treated with escalating doses of BI 1810631 monotherapy.
3372910|NCT04886804|Experimental|Phase Ib - Dose expansion part|
3372913|NCT04884152|Active Comparator|Home Exercise Group|"The home Exercise program includes an educational training program about parafunctional activities of patients having bruxism with myofascial temporomandibular disorders. The program includes stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
3254942|NCT01428973|Experimental|Arm 2|GVHD prophylaxis: Tacrolimus, orally (0.06 mg/kg) bid starting on day -3. The dose adapted between 5-10 ng/ml. Full doses until day 60 (sibling recipients) or day 100 (alternative donor recipients). Doses tapered to be definitely discontinued by day 100 (sibling donors) or 180 (alternative donor recipients) in the absence of GVHD. Sirolimus 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD
3254943|NCT01428986||Maraviroc|Those whose take maraviroc as a part of their HIV treatment
3372914|NCT04884152|Experimental|Telerehabilitation Group|"The program includes the same stretching and strengthening of masticatory and neck muscles and posture exercises as well as diaphragmatic breathing exercises using telerehabilitation once a week by video call, and reminder messages will be sent to the patients 3 times a week.~Relaxation: Relaxation exercises with diaphragmatic breathing Posture Exercise: Rest position of tongue and TMJ, head and neck posture correction exercises Stretching Exercises: Stretching exercises for chewing muscles, cervical muscles, and pectoral muscles Strengthening: The neck will consist of strengthening exercises for deep flexor muscles, suprahyoid and infrahyoid muscles, and scapular retractors."
3372915|NCT04883749|Experimental|Acalabrutinib|Acalabrutinib will be administered up to 24 cycles (= approx. 24 months total) until progression of disease (PD) or intolerable toxicity
3372918|NCT04880967||Standard Group|"Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected.~Participants of this cohort will not use the ICU Feel Better App."
3372919|NCT04880967||Experimental Group|Cohort of n=20 intensive care unit patients from the ages of 18 years will be collected. Participants of this cohort will have the opportunity to use the ICU Feel Better App every day from the second day after admission to the ICU until the day of discharge from ICU.
3372922|NCT04877691|Experimental|Anifrolumab|Solution for injection in aPFS
3372923|NCT04877691|Placebo Comparator|Placebo|Solution for injection in aPFS
3376206|NCT01966731|Experimental|Hydroxyurea|After patient enrollment, a two-month pre-hydroxyurea evaluation phase will be used to perform baseline evaluations including nutritional and infectious assessments, and to provide supplements or treatments as deemed necessary. After the pre-hydroxyurea evaluation and supplementation phase, hydroxyurea dosing will be administered as a single daily dose, using capsules provided as a monthly supply in 200mg, 300mg, 400mg, or 500mg sizes.
3376207|NCT01952288|Experimental|simvastatin|simvastatin 40 mg/day
3376208|NCT01952288|Placebo Comparator|placebo|placebo
3376209|NCT01905046|Experimental|Arm I: metformin hydrochloride|Patients receive metformin hydrochloride PO QD or BID for 24 months. Patients will continue metformin 850 mg PO BID for months 13-24. Patients will undergo RPFNA at 24 months. Follow up visits will be performed at 36 and 48 months after the start of treatment.
3376210|NCT01905046|Placebo Comparator|Arm II: placebo|Patients receive placebo PO QD or BID for 12 months. Patients may crossover to Arm I for months 13-24.
3254944|NCT01428986||No maraviroc|Those who do not take maraviroc
3254945|NCT01428999|Experimental|probiotics|1 pack bid use for 3 weeks
3254946|NCT01428999|Placebo Comparator|Placebo|placebo 1pack bid for 3 weeks
3372924|NCT04875052|Active Comparator|Standard ACL Rehabilitation|Patients will complete a 20-week supervised, progressive rehabilitation protocol directed by physical therapists at 1 of 3 participating clinics. While the specific rehabilitation exercises and techniques used for a given patient may vary depending on clinician preference/experience and patient responsiveness and progress, the general rehabilitation protocol will be standardized and follow current best practices emphasizing restoration of early weight bearing, range of motion, quadriceps function, balance, and neuromuscular control consistent with the Multicenter Orthopaedics Outcomes Network (MOON) rehabilitation protocol.
3372925|NCT04875052|Experimental|Whole Body Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to whole body vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
3372926|NCT04875052|Experimental|Local Muscle Vibration|Patients will perform standard rehabilitation for the first month post-ACLR. At 1 month they will continue with standard rehabilitation, but will also be exposed to local muscle vibration at the beginning of each session prior to rehabilitation exercises in an effort to enhance their efficacy.
3372927|NCT04873700||All Participants|Participants diagnosed with moderate to severe UC or CD will be observed on Day 1 for cross-sectional evaluation of disease activity, treatment patterns, burden of disease and quality of life along with retrospective data collection for previous 3 years prior to Day 1 to assess the IBD treatments and use of other healthcare resources related with the management of UC and CD.
3372928|NCT04873037|Active Comparator|Emsella Chair Active Treatment|Active subjects will be asked to sit on the center of the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the reminder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
3372929|NCT04873037|Placebo Comparator|Emsella Chair Sham Treatment|Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (less than 10% power).
3372930|NCT04868682|Experimental|Behavioral Education Intervention I|Manual-based education program provided in individual sessions
3254947|NCT01429012|Experimental|Mesenchymal Stem Cells|"2 ml with 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion space of the bone fracture.~MSC will be injected even if the number of available cells is lower than 40 X 10E6.~The injection of MSC in the nonunion space will be performed percutaneously using a 3-mm trephine needle under fluoroscopic control and loco-regional or general anesthesia, as deemed appropriate by the anesthetist."
3254948|NCT01429012|Placebo Comparator|Culture medium without MSC.|Culture medium used to resuspend the Mesenchymal Stem Cells.
3372931|NCT04868682|Active Comparator|Behavioral Education Intervention II|Manual-based education program provided in individual sessions
3372934|NCT04866472|Other|Video Laryngoscope and GlideRite Ridgid Stylet|
3372935|NCT04866472|Experimental|Video Laryngoscope and TCI Articulating Introducer|
3372936|NCT04865731|Experimental|Dermaprazole|30 HNC patients who will be using Dermaprazole twice daily for 7 weeks
3372937|NCT04865731|Active Comparator|Aquaphor|15 HNC patients using Aquaphor, the current clinical standard of care
3254949|NCT01429025|Experimental|rituximab, bendamustine and lenalidomide|Patients receive rituximab IV on day 1, bendamustine IV on days 1-2, and lenalidomide PO on days 1-10. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3254950|NCT01429038|Experimental|MSC Liver Transplantation|Patients undergoing a first liver transplantation. Beside receiving standard liver tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2
3254951|NCT01429038|Experimental|MSC Kidney Transplantation|Patients undergoing a first kidney transplantation. Beside receiving standard kidney tranplantation care (antibacterial and viral prophylactic treatments as well as a standard immunosuppressive regime i.e. tacrolimus, mycophenolate mofetil and steroids associated with ant-IL-2 antibodies), patients will be infused with 1,5-3,0 10E6 MSC/kg on postoperative day 3+/-2.
3254952|NCT01429090|Experimental|Test|Pharmacokinetics and -dynamics after single dose administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
3254953|NCT01429090|Active Comparator|Reference|Pharmacokinetics and -dynamics after single dose administration 100 ml methantheline solution (100 mg methantheline bromide)
3254954|NCT01429103||Early Perimenopause|Early perimenopause is defined as the presence of irregular periods (cycle length differs by 7 days from usual).
3254955|NCT01429103||Late Perimenopause|Late perimenopause is defined as at least 2 skipped periods over the past 12 months (cycle double usual length) and one period of amenorrhea (over 60 days without a period), with at least one menstrual cycle over the past 12 months.
3254956|NCT01429116|Experimental|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
3254957|NCT01429129|Experimental|Nicotine Replacement Therapy|
3254958|NCT01429129|No Intervention|Control|
3254959|NCT01429142|Experimental|AIMS intervention|see http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-13-274
3254960|NCT01429142|Active Comparator|Treatment as usual|see http://www.tandfonline.com/doi/abs/10.1080/08870446.2014.1001392
3254961|NCT01429155||Liver transplant recipeints|Patients suffering from chronic hepatitis C that required a living donor liver transplant.
3254962|NCT01429155||Liver Donors|Patients who donated part of their liver to a patient suffering from chronic hepatitis C
3254963|NCT01429168|Experimental|Part 1: All Enrolled Participants|All participants will receive open-label etoricoxib 60 mg orally daily during Part 1.
3254964|NCT01429168|Experimental|Part 2: Etoricoxib|
3254965|NCT01429168|Placebo Comparator|Part 2: Placebo|
3372938|NCT04864639|Experimental|Transition of Care|Experimental: 32 participants will be discharged to a culturally relevant newly developed discharge/transition of care model.
3372939|NCT04862741|Experimental|NX-13 250mg IR|Oral
3372940|NCT04862741|Experimental|NX-13 500mg IR|Oral
3372941|NCT04862741|Experimental|NX-13 500mg MR|Oral
3254966|NCT01429181|Experimental|Non Racemic Methadone|Non-Racemic Methadone Hydrochloride 5 mg Capsules containing a non-racemic mixture of methadone isomers.
3254967|NCT01429181|Placebo Comparator|Placebo|Matching placebo capsules
3372942|NCT04862741|Placebo Comparator|Placebo|Oral
3372943|NCT04862338|Experimental|Nicotinamide mononucleotide (NMN-C)|Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total
3372946|NCT04857372|Experimental|Group 1|Malignant pleural mesothelioma
3372947|NCT04857372|Experimental|Group 2|NF2 truncating mutations or deletions
3372948|NCT04857372|Experimental|Group 3|Solid tumors with functional YAP/TAZ fusions
3254968|NCT01429194|Experimental|ACE procedure|ACE procedure for the treatment of obesity
3254969|NCT01429246|Active Comparator|Normal Salt|100% Sodium Chloride
3372953|NCT04848779||Cohort 1|
3372959|NCT04846127||CanGaroo Envelope|Participants who receive a CanGaroo envelope during their CIED implant.
3372960|NCT04846127||No Envelope|Participants who do not receive an envelope of any kind during their CIED implant.
3372967|NCT04843423|Experimental|Cariprazine treatment|
3372969|NCT04839510|Experimental|MRG002|MRG002 will be administrated by an IV infusion of 2.6 mg/kg on Day 1 of every 3 weeks (21-day cycle).
3254970|NCT01429246|Experimental|Salt Substitute|65% Sodium Chloride, 25% Potassium Chloride, 10% Magnesium Sulphate)
3372970|NCT04838613|Experimental|PET/CT imaging with [18F]CTT1057 followed by [68Ga]Ga-PSMA-11 or vice versa|"All eligible participants will be assigned to one of the following two PET/CT scan sequences at random in a 1:1 ratio:~Sequence 1: [18F]CTT1057 on Day 1 (investigational imaging agent of interest) followed by [68Ga]Ga-PSMA-11 at least 14 days apart (as part of CTS if required, and for secondary endpoint)~Sequence 2: [68Ga]Ga-PSMA-11 (as part of CTS if required, and for secondary endpoint) on Day 1 followed by [18F]CTT1057 (investigational imaging agent of interest) at least 14 days apart"
3254971|NCT01429311||ADEH+|Subjects classified as Atopic Dermatitis (AD) and history of previous Eczema Herpeticum (EH) as defined by the ADRN Standard Diagnostic Criteria
3254972|NCT01429311||ADEH-|Subjects classified as AD without a history of EH as defined by the ADRN Standard Diagnostic Criteria
3254973|NCT01429311||Non-atopic Controls|"Subjects classified as Non-Atopic controls as defined by the ADRN Standard Diagnostic Criteria"
3254974|NCT01429324||Cardiac disease|Aortic arch surgery
3254975|NCT01429337|Experimental|Normal hepatic function - group 1|Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
3259507|NCT01471470|Experimental|neoadjuvant|
3372976|NCT04832685|Experimental|UP and DOWN-Modulation|All participants will receive UP- and DOWN-modulation of the posterior cingulate cortex (PCC).
3372977|NCT04830072|Experimental|AR group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support with AR pictures
3372978|NCT04830072|Active Comparator|Control group|Brief AWARD advice + active referral + leaflet + 3 months chat-based support
3372979|NCT04822298|Experimental|Part 1: Dose Exploration|The dose exploration part of the study will estimate the MTD and/or the RP2D.
3372980|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 1 Non-squamous NSCLC|Participants with non-squamous non-small cell lung cancer (NSCLC) will be administered the RP2D identified from the dose exploration part of the study.
3372981|NCT04822298|Experimental|Part 2: Dose Expansion - Cohort 2 Squamous NSCLC|Participants with squamous NSCLC will be administered the RP2D identified from the dose exploration part of the study.
3372986|NCT04816916|Experimental|AXA1665 53.8 g per day|AXA1665 administered orally TID
3372987|NCT04816916|Placebo Comparator|Matching placebo|Placebo administered orally TID
3372990|NCT04815109||critical ill COVID-19|Critically ill COVID-19 patients with need for ventilation and appropriate sedation
3372995|NCT04810260|Active Comparator|HIV +|Patients will have the application and use it to increase their awareness about their medical condition.
3372996|NCT04810260|Active Comparator|HIV -|Patients will have the application and use it to increase their awareness about their medical condition.
3254976|NCT01429337|Experimental|Mild hepatic impairment - group 2|Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
3254977|NCT01429337|Experimental|Moderate hepatic impairment - group 3|Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.
3373000|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-623|Participants with Relapsed/Refractory (R/R) B-cell malignancies will receive escalating doses of ABBV-623.
3373001|NCT04804254|Experimental|Monotherapy in Dose Escalation: ABBV-992|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-992.
3373002|NCT04804254|Experimental|Combination in Dose Escalation|Participants with R/R B-cell malignancies will receive escalating doses of ABBV-623 and ABBV-992.
3373003|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-623|Participants with R/R B-cell malignancies will receive ABBV-623 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
3373004|NCT04804254|Experimental|Monotherapy in Dose Expansion: ABBV-992|Participants with R/R B-cell malignancies will receive ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
3373005|NCT04804254|Experimental|Combination in Dose Expansion|Participants with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) will receive ABBV-623 and ABBV-992 at recommended Phase 2 dose (RP2D) determined in dose escalation phase.
3254978|NCT01429337|Experimental|Severe hepatic impairment - group 4|Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
3254979|NCT01429337|Experimental|Normal hepatic function - group 5|Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.
3373008|NCT04802759|Active Comparator|Cohort 1: Giredestrant Monotherapy|
3373009|NCT04802759|Experimental|Cohort 1: Giredestrant + Abemaciclib|
3373010|NCT04802759|Experimental|Cohort 1: Giredestrant + Ipatasertib|
3373011|NCT04802759|Experimental|Cohort 1: Giredestrant + Inavolisib|
3373012|NCT04802759|Experimental|Cohort 1: Giredestrant + Ribociclib|
3373013|NCT04802759|Experimental|Cohort 1: Giredestrant + Everolimus|
3373014|NCT04802759|Experimental|Cohort 1: Giredestrant + Samuraciclib|
3373015|NCT04802759|Active Comparator|Cohort 2: Giredestrant + PH FDC SC|
3373016|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Abemaciclib|
3373017|NCT04802759|Experimental|Cohort 2: Giredestrant + PH FDC SC + Palbociclib|
3373018|NCT04801693|Experimental|BI 1819479|single rising doses (SRD) part
3373019|NCT04801693|Placebo Comparator|Placebo|Single rising doses (SRD) part
3373020|NCT04801693|Experimental|BI 1819479 fed - fasted arm|Food effect part
3373021|NCT04801693|Experimental|BI 1819479 fasted - fed arm|Food effect part
3373025|NCT04798586|Experimental|Elranatamab (PF-06863135)|BCMA-CD3 bispecific antibody
3373026|NCT04798469|Experimental|Testosterone|Weekly injections of testosterone 125 mg.
3373027|NCT04798469|Placebo Comparator|Placebo|Weekly injections of placebo.
3373028|NCT04797195|Experimental|CKD-PD app user group|Patients on peritoneal dialysis using the CKD-PD app and home monitoring equipment to measure and record blood pressure, body weight, and dialysis fluid removed
3254980|NCT01429363|Experimental|Targeted disc decompression|
3373029|NCT04797195|No Intervention|Usual care group|Patients on peritoneal dialysis using handwritten notebook to record record blood pressure, body weight, and dialysis fluid removed; measurements obtained through usual method
3373030|NCT04796935|Experimental|Experimental Group 1: Tactile Imaging (VerTouch)|VerTouch used to identify and mark, or begin placement of a needle, at an insertion site.
3373031|NCT04796935|Active Comparator|Group 2: Control (palpation)|Palpation used to identify and mark an insertion site.
3373035|NCT04778618|Experimental|Individual dose of Thymoglobulin|Individual dose of Thymoglobulin (r-ATG) : Individual dose of ATG was Intravenous infused every day from day -5 to day -2 (total ATG dose was calculated based on pharmacokinetic index, within a range of 7 mg/kg to10mg/kg)
3373036|NCT04776473|Experimental|Open (i.e. surgical) treatment|"This includes reduction and internal fixation of the fracture (ORIF) performed using the preferred surgical approach and bone implants of the including centre that could be associated with one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient MMF~arch bars / screws / splint use for passive mobilization of the mandible"
3373037|NCT04776473|Other|Closed (i.e. conservative) treatment|"To date, there is no consensus on which procedures should be used in case of conservative treatment, which may vary between centres and, for a same centre, between patients. This includes one or several items among the following:~physical therapy based on exercises done by the patient himself~physical therapy performed by a specialized/non-specialized physical therapist~arch bars / screws / splint use for transient maxillo-mandibular fixation (MMF) (15 days max)~arch bars / screws / splint use for passive mobilization of the mandible"
3373038|NCT04776031|Experimental|Laser Treatment|Laser treatment using the R:GEN Laser System on Day 1 and at Week 24
3254981|NCT01429402|Experimental|study group I|For primary lip surgery, immediately after primary lip repair will received botulinum toxin injection (1-2U/kg, at 25U/mL) into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site
3254982|NCT01429402|Experimental|Study Group II|For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room.
3254983|NCT01429402|Placebo Comparator|Control Group I|Similar amount as group I (in C.C.) of normal saline will be injected after primary lip surgery at 3 months of age.
3254984|NCT01429402|Placebo Comparator|Control II|Similar amount (in C.C.) as Study Group II of normal saline will be injected after revision lip surgery (secondary cleft lip repair).
3373039|NCT04774250|Experimental|Zonisamide|For subjects randomized to zonisamide, the package will contain one zonisamide capsule (100 mg PO).
3373040|NCT04774250|Placebo Comparator|Placebo|For the subjects randomized to placebo, the package will contain one placebo capsule that looks, smells, and taste the same as zonisamide capsule.
3373041|NCT04774094|Experimental|CAZ-AVI|
3373043|NCT04770779|Experimental|Mitapivat|"Double-Blind Period: Participants will receive mitapivat 100 milligrams (mg) orally, twice daily (BID) for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
3373044|NCT04770779|Placebo Comparator|Placebo|"Double-Blind Period: Participants will receive placebo matching mitapivat orally, BID for 48 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
3373045|NCT04770753|Experimental|Mitapivat|"Double-blind Period: Participants will receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to continue to receive mitapivat for up to an additional 5 years after the Double-blind Period."
3373046|NCT04770753|Placebo Comparator|Placebo|"Double-blind Period: Participants will receive placebo matching mitapivat, orally, BID for 24 weeks.~Open-label Extension Period: Participants who do not discontinue study drug may choose to receive mitapivat for up to an additional 5 years after the Double-blind Period."
3373049|NCT04768569|Active Comparator|Zonisamide Pre-op + Placebo Post-op|For subjects randomized to zonisamide pre-op, the pre-op package will contain one zonisamide capsule (100 mg PO) and the post-op package will contain one placebo capsule that looks, smells, and tastes the same as zonisamide capsules.
3373050|NCT04768569|Placebo Comparator|Placebo Pre-op + Placebo Post-op|For the subjects randomized to placebo, both pre- and post-op packages will contain placebo capsules that looks, smells, and taste the same as zonisamide capsules.
3373051|NCT04768569|Active Comparator|Placebo Pre-op + Zonisamide Post-op|For subjects randomized to zonisamide post-op, the pre-op package will contain one placebo capsule and the post-op package will contain one zonisamide capsule (100 mg PO).
3373052|NCT04766866|No Intervention|Non-intervention or non-reveal group|Non-intervention or non-reveal (result unknown) group: routine follow-up and spontaneous delivery
3254985|NCT01429415|Experimental|Experimental Group|Magnesium Sulfate Sandoz/PPC 600mg and Salbutamol (GlaxoSmithKline/Pharmascience) 5mg by inhalation via Aeroneb Go nebulizer (Philips) with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
3254986|NCT01429415|Placebo Comparator|Control Group|Sodium Chloride USP PPC/Omega (5.5%) placebo and salbutamol GlaxoSmithKline/Pharmascience 5 mg by inhalation via Aeroneb Go nebulizer Philips with Idehaler Pocket chamber DTF q 20 minutes, 3 treatments.
3254987|NCT01429428|Placebo Comparator|Stockings side one|This side of the compression stockings is just the fabric (placebo).
3254988|NCT01429428|Active Comparator|Stocking side two|This side of compression stocking emits far-IR radiation.
3373053|NCT04766866|Experimental|Intervention group or reveal group|A ratio cutoff of >p90th will be used to define low and elevated risk of developing a placental complications of pregnancy and therefore induction of labour will be offered from 37th weeks of gestation
3254989|NCT01429467|Other|Continuous Glucose Monitoring (CGM)|10 participants from phase 1 will undergo 6 weeks of CGM with telemedicine support at weeks 1,3 + 5. After this period HIF, Erythropoietin, VEGf and cortisol will again be measured and compared with the subjects glucose variability.
3254990|NCT01429480|Active Comparator|TAP Block|
3254991|NCT01429480|Active Comparator|II/IH Block|
3254992|NCT01429480|Active Comparator|Control Group|
3254993|NCT01429493|Active Comparator|Conventional radiotherapy|
3254994|NCT01429493|Experimental|Biological image-guided radiotherapy with conventional dose.|
3254995|NCT01429493|Experimental|Biological image-guided SBRT with dose-escalation.|
3254996|NCT01429506|Active Comparator|Sleeve gastrectomy|Will undergo laparoscopic sleeve gastrectomy
3254997|NCT01429506|Active Comparator|Intensive medical management|Will receive VLCD, exenatide, metformin, insulin detemir
3254998|NCT01429519|Experimental|Treatment|
3254999|NCT01429545|Active Comparator|Group 1 - Atosiban|Patients on single agent atosiban alone
3255000|NCT01429545|Experimental|Group 2|Patients on combination of atosiban and nifedipine
3255001|NCT01429571||Systemic and local antibiotics|
3255002|NCT01429571||Local antibiotics|
3255003|NCT01429571||No antibiotics|
3255004|NCT01429597||Observation|All Patients with a diagnosis of Fabry disease with N215S
3255005|NCT01429610|Experimental|Rituximab+mVPDL|Patients who were CD20(+), newly-diagnosed adult ALL and treated with rituximab + mVPDL treatment plan
3255006|NCT01429636|Experimental|Applied Relaxation (AR)|
3255007|NCT01429636|Experimental|Modified Relaxation (MR)|
3255008|NCT01429649|Experimental|ablation|Cryoablation or Radiofrequency ablation for the pGGO
3255009|NCT01429649|No Intervention|Follow up CT scann|The patients will receive follow up with CT scan every 6-9 months.
3255010|NCT01429662|Sham Comparator|Lifestyle Education (LE)|Lifestyle Education (LE) Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
3255011|NCT01429662|Experimental|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
3255012|NCT01429675|Active Comparator|Bonviva|
3255013|NCT01429675|Experimental|DP-R206|
3255014|NCT01429688|Experimental|DP-R202|Multiple oral administration for 3 days
3255015|NCT01429688|Active Comparator|Anplag|Multiple oral administration for 3days
3255016|NCT01429701|Experimental|Test association cream|polymyxin B sulphate + prednisolone + benzocaine + clioquinol
3255017|NCT01429701|Active Comparator|Comparative association cream|betamethasone + gentamicin + tolnaftato + clioquinol
3255018|NCT01429714|Experimental|Intervention: individually tailored ECS|Individually tailored duration of elastic compression therapy, based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months.
3255019|NCT01429714|Active Comparator|Control: ECS 24 months|Elastic compression therapy with a standard duration of 24 months
3255020|NCT01429727||SCAD Registry|Individuals who have experienced at least one episode of spontaneous coronary artery dissection.
3255021|NCT01429740|Experimental|PF-05180999|
3255022|NCT01429740|Placebo Comparator|Placebo|
3255023|NCT01429753|Active Comparator|Standard LV lead placement|
3255024|NCT01429753|Experimental|Advanced Imaging Guided LV Lead Placement|
3255025|NCT01429779|Experimental|Movicol|Administration of 1 sachet of Movicol® daily during one week preoperatively (experimental care) and 2 sachets of Movicol® daily postoperatively (standard care).
3255026|NCT01429779|No Intervention|Control|Control group; standard postoperative care (administration of 2 sachets of Movicol® postoperatively daily)
3255027|NCT01429818|Experimental|Glimepiride/metformin|
3255028|NCT01429818|Active Comparator|Metformin|
3255029|NCT01429831|Experimental|Aripiprazole|
3255030|NCT01429844|Active Comparator|Tacrolimus|Tacrolimus in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
3255031|NCT01429844|Active Comparator|Cyclosporine|Cyclopsorine in combination with mycophenolate mofetil and steroids for denovo immunosuppression after lung transplantation
3255032|NCT01429870|Active Comparator|Steroid active treatment|Triamcinolone acetonide 0.1% in unguentum leniens topically
3255033|NCT01429870|Placebo Comparator|Vehicle|unguentum leniens topically
3255034|NCT01429896|Experimental|Arm 1|Exercise followed by sleep restriction followed by control challenge
3255035|NCT01429896|Experimental|Arm 2|Sleep restriction followed by exercise followed by control challenge
3255036|NCT01429896|Experimental|Arm 3|control followed by sleep restriction followed by exercise
3255037|NCT01429896|Experimental|Arm 4|control followed by exercise followed by sleep restriction
3255038|NCT01429896|Experimental|Arm 5|Sleep Restriction followed by control followed by exercise
3255039|NCT01429896|Experimental|Arm 6|Exercise followed by control followed by sleep restriction
3255040|NCT01429935|Active Comparator|Ginger powder|
3255041|NCT01429935|Active Comparator|Ibuprofen|capsules of Ibuprofen 400 mg
3255042|NCT01429935|Placebo Comparator|placebo|capsules contain starch
3373070|NCT04757363|Experimental|Nivolumab Combined With FOLFOX and Regorafenib|Each treatment cycle consists of 28 days. Patients will initially receive induction therapy with regorafenib (80 mg on days 1-21 of the 28-day cycle) and nivolumab (240 mg on days 1 and 15 of the 28-day cycle). Starting on cycle 2, day 1, patients will also receive FOLFOX chemotherapy with oxaliplatin (85 mg/m2 IV), leucovorin (400 mg/m2 IV), 5-FU (400 mg/m2 IV bolus), and 5-FU (2400 mg/m2/day continuous IV infusion over 48 h). If the patient is not a good candidate for induction regorafenib and nivolumab (i.e. symptomatic from a large burden of disease), 5-FU and oxaliplatin can be added during cycle 1 at the treating physician's discretion. 39 Patients will continue with this regimen until disease progression, unacceptable toxicity, or development of serious intercurrent illness. Treatment will be performed on the scheduled day (±7-day treatment window).
3373072|NCT04752371|Experimental|Cohort 1: AEVI-007 7 mg/kg|6 participants will be administered AEVI-007 at a dose of 7 mg/kg (500 mg maximum) at Baseline, Week 4 and Week 8. Based on safety results in first 6 participants, additional participants may be enrolled in this cohort.
3373073|NCT04752371|Experimental|Cohort 2: AEVI-007 Dose escalation/reduction|Based on safety results in Cohort 1, 6 participants will be administered AEVI-007 at a dose of 14 mg/kg (1000 mg maximum) at Baseline, Week 4 and Week 8, or may receive a lower dose (4 mg/kg, maximum 300 mg). Dose in participants receiving 14 mg/kg may be reduced based on safety results.
3255043|NCT01429948||Case group|Healthy subjects with silent cerebral infarction
3255044|NCT01429948||Control group 1|Patients with acute cryptogenic embolic stroke
3255045|NCT01429948||Control group 2|Patients with acute stroke with conventional stroke mechanisms
3255046|NCT01429961|Experimental|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1-14
3255047|NCT01429974||volunteers|
3255048|NCT01430013|Experimental|Endostar|CHOPT chemotherapy plus Endostar
3373085|NCT04750070|Experimental|Dopamine arm|Children in the dopamine arm (Treatment plan A) will receive dopamine, 8 microgram/kg/min (increasing the dose after 15 minutes to 12 microgram/kg/min to a maximum of 15 microgram/kg/min)
3373086|NCT04750070|Experimental|Adrenaline arm|Children in the adrenaline arm (Treatment plan B) will receive adrenaline, 0.1 microgram/kg/min (increasing the dose after 15 minutes to 0.2 microgram/kg.min to a maximum of 0.3 microgram/kg.min)
3373087|NCT04750070|Active Comparator|Blood transfusion arm|Children in the blood transfusion arm (Treatment plan C) will receive a transfusion of whole human blood in a dose of 10 mL/kg over 2-3 hours. While the blood transfusion is being arranged, IV fluid would be given @ of 3 ml per kg per hour
3373088|NCT04744155|Experimental|Multi-Level Intervention|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral.Those randomized to MLI will be offered immediate, ED-based contraception (i.e., oral pill, transdermal patch, vaginal ring, injection, subdermal implant) in addition to receive a warm referral (provider helping to schedule follow-up appointment) to follow-up on selected method (or to initiate in clinic, if preferred)
3373089|NCT04744155|Active Comparator|Enhanced Standard of Care|All adolescents receive the Motivational Interviewing (MI) enhanced counseling and clinic referral. eSOC participants may obtain contraception only at the referral.
3373090|NCT04742556|Experimental|BI 3011441|
3255049|NCT01430039||Crohn's, ulcerative colitis|Patients with diagnosed with Crohn's disease or ulcerative colitis who agreed to participate in the study and singed informed consent and answered a Crohn's disease activity index questioner for Crohn's disease or the ulcerative colitis activity index questioner for ulcerative colitis.
3373101|NCT04736121|Experimental|Open-label Single Arm|Open-label single arm study evaluating treatment with hepatic arterial injection of SIR-Spheres.
3373102|NCT04736004||Athletes with COVID-19|
3373103|NCT04736004||Athletes without COVID-19 (control)|
3373104|NCT04735835|Experimental|Dietary Intervention|Dietary intervention using standardized test meals after which the postprandial metabolic response is measured.
3373105|NCT04714996|Experimental|ES-481|
3255050|NCT01430039||No disease|Healthy subjects with no known inflammatory disease. For basal serum levels of syndecan 1
3373106|NCT04714996|Placebo Comparator|Placebo|
3373107|NCT04714996|Other|Open-Label Extension Study|
3373110|NCT04708262|Experimental|Cognitive Analytic Therapy for Containing Self-Harm in Young People|Brief one-to-one psychological therapy using Cognitive Analytic Therapy principles, designed for young people who self-harm
3373111|NCT04699461|Experimental|Loncastuximab Tesirine|Participants will be administered loncastuximab tesirine as an intravenous (IV) infusion on Day 1 of each cycle, where 1 cycle is 3 weeks. Loncastuximab tesirine will be administered at a dose of 150 μg/kg for 2 cycles, then at a dose of 75 μg/kg for subsequent cycles.
3373112|NCT04699461|Active Comparator|Idelalisib|Participants will be administered 150 mg idelalisib, orally, twice a day throughout each cycle, where 1 cycle is 4 weeks.
3255051|NCT01430052|Other|Gemcitabine , S-1|Gemcitabine 1000mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks
3255052|NCT01430052|Experimental|Gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/m2 on Day 1 and 8, every 3 weeks. S-1 60-100mg/day on Day 1 to 14, every 3 weeks with radiotherapy 50.4Gy in 28 fractions
3373122|NCT04683250|Experimental|TAS0953/HM06 Phase 1|Dose escalation and dose expansion until recommended Phase 2 dose determined
3373123|NCT04683250|Experimental|TAS0953/HM06 Phase 2|Treatment phase at recommended Phase 2 dose in three different populations
3255053|NCT01430065|Experimental|Tacrolimus and ASP015K|
3255054|NCT01430078|Experimental|Regimen A|ASP015K oral tablet
3373124|NCT04682639|Experimental|Etrasimod Dose 1|
3373125|NCT04682639|Experimental|Etrasimod Dose 2|
3373126|NCT04682639|Placebo Comparator|Placebo|Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.
3373127|NCT04681729|Experimental|Dupilumab|Dose regimens, on top of regular or as needed non-sedating H1-antihistamine
3373128|NCT04681729|Placebo Comparator|Matched Placebo|Placebo,on top of regular/as needed non-sedating H1-antihistamine
3255055|NCT01430078|Experimental|Regimen B|ASP015K solution delivered to distal small bowel via oral capsule
3255056|NCT01430078|Experimental|Regimen C|ASP015K solution delivered to ascending colon via oral capsule
3373133|NCT04679402|Experimental|Respiratory Muscle Training Breathing Low Dose Carbon Monoxide|Carbon monoxide 200 ppm in air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe the experimental gas through a mouthpiece with nose-clip in place.
3373134|NCT04679402|Sham Comparator|Respiratory Muscle Training Breathing Air|Air breathing during daily 30 minute inspiratory loading training sessions. Subjects will breathe air through a mouthpiece with nose-clip in place.
3373135|NCT04676646|Experimental|Open-label run-in phase|"Cohort 1 (4 weeks duration): Patients who are hyperkalemic at study entry will begin SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily).~Cohort 2 (up to 6 weeks duration): Patients who develop hyperkalemia during the uptitration of spironolactone will receive SZC 10 g TID for up to 48 hours followed by SZC 10 g once daily to achieve and maintain normokalemia. The SZC dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
3373136|NCT04676646|Experimental|Randomized withdrawal phase (8 months)|"SZC arm and Placebo arm: Patients will continue on the SZC dose they were receiving at the end of the run-in phase.~The SZC / Placebo dose will be adjusted as needed to maintain normokalemia (dose range = 5 g every other day, to 5-15 g once daily)."
3373137|NCT04675034|Experimental|Cohort 1|Dose A: MEDI7352 Q2W
3255057|NCT01430078|Experimental|Regimen D|ASP015K solution delivered to distal transverse colon via oral capsule
3255058|NCT01430117|Experimental|1|"Poa pratensis allergen extract at 4 different concentrations.~Positive control.~Negative control."
3255059|NCT01430143|Experimental|600 kcal/day|Exercise combusting 600 kcal/day, 7 days/week for 12 weeks.
3255060|NCT01430143|Experimental|300 kcal/day|Exercise combusting 300 kcal/day, 7 days/week for 12 weeks.
3255061|NCT01430143|No Intervention|Sedentary|Continued sedentary living.
3255062|NCT01430156|Active Comparator|Heme arginate (Normosang)|This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
3373138|NCT04675034|Experimental|Cohort 2|Dose B: MEDI7352 Q2W
3373139|NCT04675034|Experimental|Cohort 3|Dose C: MEDI7352 Q2W
3373140|NCT04675034|Experimental|Cohort 4|Dose D: MEDI7352 Q2W
3373141|NCT04675034|Placebo Comparator|Cohort 5:|Placebo to match MEDI7352 Q2W
3255063|NCT01430156|Placebo Comparator|0.9% saline|The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.
3255064|NCT01430195|Experimental|Afamelanotide + NB-UVB: Experimental|Subject in this arm will receive both afamelanotide implants (one implant administered every 28 days, 4 implants in total) and NB-UVB light (administered thrice weekly, 72 treatments in total).
3373142|NCT04673721|Active Comparator|Fortified eggs + Intermittent fasting|Consume at least 12 fortified eggs per week with 16-hour fast and then an 8-hour nutritional window.
3373143|NCT04673721|Active Comparator|Non-egg supplemented diet + Intermittent fasting|Maintain consumption of 2 or less eggs per week with 16-hour fast and then an 8-hour nutritional window.
3373144|NCT04673721|Active Comparator|Fortified eggs + Usual care diet|Consume at least 12 fortified eggs per week with consistency with current diet.
3373145|NCT04673721|Placebo Comparator|Non-egg supplemented diet + Usual care diet|Maintain consumption of 2 or less eggs per week with consistency with current diet.
3255065|NCT01430195|Active Comparator|NB-UVB alone: Active Comparator|Subjects in this arm will receive NB-UVB light only (administered thrice weekly, 72 treatments in total).
3373149|NCT04671082|Experimental|Tolperisone 50 mg|Tolperisone 50 mg
3373150|NCT04671082|Experimental|Tolpersione 100 mg|Tolperisone 100 mg
3373151|NCT04671082|Experimental|Tolperisone 200 mg|Tolperisone 200 mg
3373152|NCT04671082|Placebo Comparator|Placebo|Placebo
3373153|NCT04670965||E-PRF/rhBMP-2 (similar ratios)|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
3373154|NCT04670965||E-PRF/ACS/rhBMP-2|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
3373155|NCT04670965||rhBMP-2/E-PRF|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
3373156|NCT04670965||E-PRF only|Subjects will be used to procure the venous blood samples to make the enhanced platelet rich fibrin (E-PRF). Subjects have an established treatment plan that utilizes autologous PRF as an adjunctive biologic therapy during periodontal treatment.
3255066|NCT01430208|Active Comparator|mini-resectoscope|
3255067|NCT01430208|Active Comparator|tradiorional resectoscope|
3373157|NCT04666740|Experimental|Cohort A: Core HRD|Patients with either pathogenic germline or somatic alterations of 3 core homologous recombination-genes (HR-genes) - (BRCA1/2, or PALB2) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort A.
3373158|NCT04666740|Experimental|Cohort B: Non core HRD|Patients with either pathogenic somatic or germline non-core 14 HR-gene alterations (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, RAD50, RAD51, RAD51C, RTEL1) who have stable or responding disease on first-line or second-line platinum therapy in two consecutive imaging assessments over at least 4 months are eligible for inclusion in Cohort B.
3255068|NCT01430208|Active Comparator|bettocchi resectoscope|
3255069|NCT01430221|Experimental|MB-PHP Group|Mindfulness-based Personalized Health Planning (MB-PHP)with health coaching. MB-PHP includes weekly small group meetings for 22-weeks and 10 bi-weekly telephonic health coaching.
3255070|NCT01430221|Active Comparator|SAGE Group|Structure & Guided Education (SAGE) includes small group-education sessions once per week for 22 weeks. Subjects also participate in 10 bi-weekly telephone calls with education partners who use supportive listening techniques..
3255071|NCT01430234|Other|Panzytrat fixed dose vs. self-dosing|In Phase I (week 1-4) patients will use the fixed amount of lipase as was prescribed by their treating physician. Phase II (week 5-9) patients will start the self-dosage regimen with pancreatic enzymes (without exceeding the maximum amount of 16 capsules per day). They are properly educated by the researcher and dietician how to adjust the amount of pancreatic enzymes to the fat intake in their diet.
3255072|NCT01430247|Other|Amblyopia screening|
3255073|NCT01430260|Experimental|ciclesonide nasal spray|ciclesonide nasal spray, alone
3255074|NCT01430260|Active Comparator|Levocetirizine|Levocetirizine, alone
3255075|NCT01430260|Active Comparator|Ciclesonide nasal spray & Levocetirizine|Ciclesonide nasal spray & Levocetirizine in combination
3255076|NCT01430273||Planned hip or knee arthroplasty|Patients with planned hip or knee arthroplasty
3255077|NCT01430273||urgent hip or knee arthroplasty|Patients with hip or knee arthroplasty in emergency.
3255078|NCT01430286|Experimental|Psycho-educational program|This group is trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
3255079|NCT01430286|Active Comparator|Standard treatment|This group will receive treatment as usual : consultation in memory clinic every 6 months during the AD patient's consultation.
3255080|NCT01430312|Experimental|Verum|Topical application of verum (azelaic acid pre-foam formulation) on the skin
3255081|NCT01430312|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
3373159|NCT04666740|Experimental|Cohort C: Platinum sensitive|Patients without any of the above HR-gene alterations included in Cohort A and B who have platinum-sensitivity, which is defined as a partial response (PR) or complete response (CR) for the best overall response (BOR) during at least 4 months on platinumbased therapy. Variants of unknown significance of candidate HR-genes from Cohort A or B will be eligible for Cohort C if they meet the partial response to platinum criterion.
3255082|NCT01430312|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
3255083|NCT01430312|Active Comparator|Positive control|Topical application of 0.5% Sodium Lauryl sulfate (positive control) on the skin
3255084|NCT01430338||BAT|brown adipose tissue detected, undetected
3373160|NCT04653350|Experimental|HIT-MMEX Group|In this group Supervised High intensity Progressive Resistance Training, High intensity weightbearing/Impact exercises and High challenging Balance Training will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
3373161|NCT04653350|Active Comparator|Control Group|In this Group Supervised general fitness exercises including general body stretches, treadmill walking, mild to moderate intensity progressive resistance training & balance exercises will be given. 2 times/week for 40-50minutes session progressively over the duration of 8 months.
3373162|NCT04653142|Experimental|BI 765063 (Part A) and BI 765063 + BI 754091 (Part B)|
3373163|NCT04652570|Experimental|VB119 dose escalation|Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.
3373164|NCT04650581|Experimental|Ipatasertib + Fulvestrant|
3373165|NCT04650581|Placebo Comparator|Placebo|
3373166|NCT04648306||Impella cohort|Single arm study of patients who underwent non-emergent percutaneous coronary intervention with prophylactic Impella support
3373167|NCT04647708|Experimental|Part A (Cohort 1): M5049 Dose A|
3373168|NCT04647708|Experimental|Part A (Cohort 2): M5049 Dose B|
3373169|NCT04647708|Experimental|Part A (Cohort 3): M5049 Dose C|
3255085|NCT01430351|Experimental|Arm 1 (temozolomide)|Patients receive temozolomide PO QD on days 1-5.
3255086|NCT01430351|Experimental|Arm 2 (temozolomide, memantine hydrochloride)|Patients receive temozolomide PO as in Arm 1 and memantine hydrochloride PO BID.
3373170|NCT04647708|Experimental|Part A (Cohort 4): M5049 Dose D|
3373171|NCT04647708|Placebo Comparator|Part A: Placebo|
3373172|NCT04647708|Experimental|Part B (Cohort 5): M5049 Dose E|
3255087|NCT01430351|Experimental|Arm 3 (temozolomide, mefloquine)|Patients receive temozolomide PO as in Arm 1 and 30 mg mefloquine PO QD on days 1-3 of week 1 and then days 2, 4, and 6 every other week.
3373173|NCT04647708|Placebo Comparator|Part B: Placebo|
3373174|NCT04645602|Experimental|Lenvatinib + Pembrolizumab|"Participants will take:~Lenvatinib - At a pre-determined dose, 1x daily during each 3 week study cycle up to 35 cycles/2 years~Pembrolizumab - At a pre-determined dose, 1x on Day 1 of each 3 week study cycle up to 35 cycles/2 years~Participants will be given a drug diary and asked to document information in the drug diary about the study treatment.~Participants will be asked to check their blood pressure 3x every week and document in a supplied diary.~Participants will be followed up to one (1) year after study treatment."
3373175|NCT04645173||CanGaroo Envelope|Participants who received a CanGaroo envelope during CIED implantation
3373176|NCT04645173||Tyrx Envelope|Participants who received a Tyrx envelope during CIED implantation
3255088|NCT01430351|Experimental|Arm 4 (temozolomide, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1 and metformin hydrochloride PO BID.
3255089|NCT01430351|Experimental|Arm 5 (temozolomide, memantine hydrochloride, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and mefloquine PO QD as in Arm 3.
3373177|NCT04645173||No Envelope|Participants who did not receive an envelope during CIED implantation
3255090|NCT01430351|Experimental|Arm 6 (temozolomide, memantine hydrochloride, metformin)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, and metformin hydrochloride PO BID as in Arm 4.
3255091|NCT01430351|Experimental|Arm 7 (temozolomide, mefloquine, metformin hydrochloride)|Patients receive temozolomide PO as in Arm 1, mefloquine PO QD as in Arm 3, and metformin hydrochloride PO BID as in Arm 4.
3255092|NCT01430351|Experimental|Arm 8 (TMZ, memantine hydrochloride, metformin, mefloquine)|Patients receive temozolomide PO and memantine hydrochloride PO BID as in Arm 2, metformin hydrochloride PO BID as in Arm 4, and mefloquine PO QD as in Arm 3.
3255093|NCT01430364|Active Comparator|BIOSS implantation|
3255094|NCT01430377|Experimental|SB predilatation|
3259508|NCT01471483||patient will receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
3373183|NCT04637932|Active Comparator|Use of endotracheal tube During Percutaneous Dilatation Tracheostomy|Group 1 was determined as endotracheal tube
3373184|NCT04637932|Active Comparator|Use of Pro-seal LMA and Bronchoscopy During Percutaneous Dilatation Tracheostomy|group 2 as pro-seal laryngeal mask group.
3373185|NCT04634825|Experimental|Retifanlimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus retifanlimab 375 mg every 3 weeks for up to 35 cycles
3373186|NCT04634825|Experimental|Tebotelimab Cohort|Enoblituzumab 15 mg/kg every 3 weeks plus tebotelimab 600 mg every 3 weeks for up to 35 cycles
3373188|NCT04627142|Experimental|Expansion dose 1|Part C: Combination therapy expansion part
3373189|NCT04627142|Experimental|Expansion dose 2|Part C: Combination therapy expansion part
3373192|NCT04621890|Experimental|LOAN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary deductions from a virtual bank of $210 for missed doses of insulin at mealtimes. According to the methodology for calculating BOLUS(1) breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will deduct $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus missed (maximum -$1.50/day). Youth can also lose an additional amount of up to $5.00/week for weeks during which they don't achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will deduct the virtual account up to $2.00 per week for failing to share their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum deduction of $24.00). Maximum total deductions is $210.
3373193|NCT04621890|Experimental|COIN2DOSE|From one-week post-randomization to the 12-week study visit, youth randomized to this treatment arm will receive personalized feedback via monetary incentives for dosing insulin at mealtimes. Mealtimes will be defined based on hour of the day and the presence of a carbohydrate entry associated with the insulin bolus. Breakfast will be 0600-1000, lunch will be 1100-1500, and dinner will be 1600-2000. Thus, we will reimburse youth up to $0.50 per mealtime with at least one meal-associated (carbohydrate-associated) insulin bolus completed (maximum $1.50/day). We will offer the opportunity for youth to earn a bonus reimbursement of up to $5.00/week for weeks during which they achieve at least 5 days of 3 mealtime insulin boluses. Finally, we will pay youth up to $2.00 per week for sharing their insulin use data at least two times per week with the study team during the three-month treatment phase (maximum $24.00). Therefore, maximum total incentive available is $210.
3373194|NCT04621890|No Intervention|Control|This group will engage have usual diabetes care without intervention. They will fill out all questionnaires, attend clinic visits and provide A1C samples at the same times as the participants in the other groups.
3373198|NCT04618406|Experimental|PICO VAC|PICO14 device from Smith and Nephew. It is a Single-Use Negative Pressure Wound Therapy Device that provides an effective negative pressure of -80 mmHg for 14 days. It is an easily applied all-in-one system that ensures uniform application each time it is applied. The dressing consists of 4 distinct layers that reduce the risk of skin trauma, applies equal negative pressure to the skin and manages fluid transport away from the wound through a combination of absorption and evaporation through an airlock layer. The device is approved for the treatment of open wounds, closed surgical incisions and skin grafts. Both PICO-VAC and soft dressing are applied immediately postoperatively and removed after 12 days.
3373199|NCT04618406|Active Comparator|Standard care|Standard care (sterile surgical silicone foam dressing and soft dressing)
3373200|NCT04618198|No Intervention|Diagnosis dependent / conventional dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then WHO recommended weight-based anti-TB therapy x 28 days"
3373201|NCT04618198|Experimental|Immediate anti-TB therapy/conventional dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric WHO recommended weight-based dose anti-TB therapy x 28 days
3373202|NCT04618198|Experimental|Diagnosis dependent/sepsis specific dose anti-TB therapy|"Standard care per admitting team including ceftriaxone x 7 days~If subsequent TB test positive, then sepsis specific dose anti-TB therapy x 28 days"
3373203|NCT04618198|Experimental|Immediate anti-TB therapy/sepsis specific dose anti-TB therapy|Standard care per admitting team including ceftriaxone x 7 days plus immediate empiric sepsis specific dose anti-TB therapy x 28 days
3373204|NCT04615182|Experimental|OCS Preservation|
3373205|NCT04614441||Idiopathic Pulmonary Fibrosis (IPF)|
3373206|NCT04614441||Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|
3373207|NCT04614441||Systemic Sclerosis-associated-Interstitial Lung Disease (SSc-ILD)|
3255095|NCT01430390|Experimental|Biological/Genetically Modified T cells|Utilizing our initial trial experience, it was amended to include three (3) expansion cohorts. Cohort 1: patients with CD19+ relapse/refractory (R/R) B cell malignancies occurring after allogeneic/autologous HSCT or solid organ transplant (SOT) infusion occurring following conditioning chemotherapy. Cohort 2:patients with CD10+ high risk B cell malignancies eligible for autologous HSCT followed by 19-28z CRA EBV-CTLs (auto-HSCT preparative regimen serves as conditioning chemotherapy. Cohort 3: patients with CD19+ high risk B cell malignancies eligible for allogeneic HSCT followed by consolidative 19-28z CAR EBV-CTLs (allo-HSCT preparative regimen serves as conditioning chemotherapy) Each expansion cohort has a target accrual of 6 patients treated with fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose.
3373215|NCT04603495|Experimental|CPI-0610 + ruxolitinib|CPI-0610 monohydrate tablets + ruxolitinib phosphate tablets
3373216|NCT04603495|Active Comparator|Placebo + ruxolitinib|Matching placebo tablets + ruxolitinib phosphate tablets
3373217|NCT04602221|Experimental|Lamotrigine treatment (T1)|
3373218|NCT04602221|Experimental|BI 409306 treatment (T2)|
3373219|NCT04602221|Placebo Comparator|Placebo treatment (R)|
3373220|NCT04602221|Experimental|BI 425809 treatment (T3)|
3373221|NCT04600323|Placebo Comparator|Placebo|Placebo medication will be used at a dose of 0.5 mEq/kg-lean body weight/day
3373222|NCT04600323|Experimental|Sodium bicarbonate|Sodium bicarbonate will be used at a dose of 0.5 mEq/kg-lean body weight/day.
3255096|NCT01430416|Experimental|AEB071|
3255097|NCT01430429|Experimental|NI-0801|
3373228|NCT04593342|Active Comparator|Standard + B-Cure Pro|Subjects from the Standard + B-Cure Pro group will receive standard care and in addition will self-treat at home with the B-Cure device
3373229|NCT04593342|Sham Comparator|Standard + Sham|Subjects from the Standard + Sham group will receive standard care and in addition will self-treat at home with the sham B-Cure device
3373231|NCT04589221||Degree of food processing and food texture|"Processed vs unprocessed foods based on NOVA classification~Soft and hard foods manipulated by cooking method"
3373232|NCT04583150||Obese women with planned surgery (BS group)|Obese women with planned BS procedure in standard care
3373233|NCT04583150||Obese women with no planned surgery (control group)|Obese women matched for age and BMI who did not undergo surgery
3255098|NCT01430481|Active Comparator|Standard Rosehip Powder (A)|6 capsules of standardized hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3255099|NCT01430481|Experimental|New rosehip formulation (B)|6 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3255100|NCT01430481|Experimental|New rosehip formulation in half dose (C)|3 capsules of modified hip powder of Rosa canina made from the seeds and husks of the fruits from a subtype of R. canina hip powder (i.e., rosehip)
3255101|NCT01430494||No treatment|
3373237|NCT04577807|Experimental|Arm 1: Lerapolturev Only|Lerapolturev (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions given every 3 or 4 weeks
3373238|NCT04577807|Experimental|Arm 2: Lerapolturev and anti-PD-1|Lerapolturev (up to 6x10^8 TCID50) administered via direct injection to amenable melanoma lesions and anti-PD-1 therapy given every 3 or 4 weeks as per the anti-PD-1 approved package insert
3255102|NCT01430507|Experimental|Medium Dose|Medium Dose Revamilast
3255103|NCT01430507|Experimental|High Dose|High Dose Revamilast
3373239|NCT04575740|Experimental|Positive Airway Pressure Device|All participants will receive PAP therapy
3373240|NCT04574895|Other|VTE risk prediction scores|Patients in the intervention arm will have their VTE risk prediction scores presented to the study team daily on weekdays via an automated report, which will list patients in descending order of risk severity for review by the VTE research team each weekday. Starting with the highest risk patients, the VTE research team will review each patient and clinical situation, and then the VTE research team will directly discuss risks/benefits of prophylactic anticoagulation with the admitting team. Patients with a risk score <1% will not be reviewed, and the investigators anticipate most of the intervention arm patients will fall into this category (based on our previous data, the investigators anticipate >90% of all patients will score <1%). The VTE risk report will be re-calculated based on updated EHR data every day at midnight.
3373241|NCT04574895|No Intervention|Standard of care|Patients randomized to the control arm will continue to receive current standard of care anticoagulation practice, which is at the discretion of the admitting team. In general, nearly no pediatric patients are offered prophylactic anticoagulation unless a previous VTE has been identified. This currently is at the discretion of the provider and no risk scoring is used. VTE risk prediction scores will be calculated and stored for analysis, these will not be visible to the study team in real time.
3373242|NCT04570657|Experimental|MEDI3506 Dose 1|Approximately 76 participants will be randomized to this arm to receive the higher dose of MEDI3506
3373243|NCT04570657|Experimental|MEDI3506 Dose 2|Approximately 76 participants will be randomized to this arm to receive the lower dose of MEDI3506
3373244|NCT04570657|Placebo Comparator|Placebo|Approximately 76 participants will be randomized to this arm. Participants in this group will receive the placebo.
3255104|NCT01430507|Placebo Comparator|Placebo|Matching Placebo in Triple Dummy Format
3255105|NCT01430507|Experimental|Low dose|Low dose Revamilast
3255106|NCT01430520|Active Comparator|Escitalopram|
3255107|NCT01430520|Placebo Comparator|Placebo|
3255108|NCT01430533|Experimental|Verum|Topical application of verum (azelaic acid pre foam formulation) on the skin
3255109|NCT01430533|Placebo Comparator|Vehicle|Topical application of vehicle formulation (same as verum but without active drug substance) on the skin
3255110|NCT01430533|Placebo Comparator|Negative control|Topical application of distilled water (negative control) on the skin
3255111|NCT01430572|Experimental|Pazopanib + Everolimus|Pazopanib 200 mg and Everolimus 5.0 mg oral dosing every other day (except for lead in 5 days of Cycle 1 where both drugs administered daily).
3255112|NCT01430598|Active Comparator|A|Subacromial decompression before repair of a complete rotator cuff tear.
3255113|NCT01430598|Active Comparator|B|Subacromial decompression after repair of a complete rotator cuff repair.
3255114|NCT01430650|Experimental|Oral strogen|
3255115|NCT01430650|Experimental|Transdermal strogen|
3255116|NCT01430663||Hematological patients with proven or probable aspergillosis|
3255117|NCT01430663||Hematological patients with possible aspergillosis|
3255118|NCT01430676||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3255119|NCT01430689|Experimental|Inactivated Influenza Vaccine Trivalent Types A and B|Women will be vaccinated with Influenza vaccine: Inactivated Influenza Vaccine Trivalent Types A and B
3255120|NCT01430689|Active Comparator|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate|Women will be vaccinated with IM injection of Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine
3255121|NCT01430702|Experimental|Computerized medication delivery unit|Those hospitalized patients that meet all inclusion and exclusion criteria will be provided with a computerized medication delivery unit for use in their homes for the 30-day period following discharge.
3255122|NCT01430715|Experimental|Outside play|
3255123|NCT01430715|Experimental|Active video game|
3255124|NCT01430728||Very low birthweight infants|
3255125|NCT01430767||Depression|Ten subjects with diagnosis of major depressive disorder from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for depression.
3255126|NCT01430767||ADHD|Ten subjects with a diagnosis of attention-deficit hyperactivity disorder (ADHD) from the Wake Forest University Student Health Clinic, being treated with FDA-approved standard-of-care medication for their ADHD.
3255127|NCT01430780||control group|placebo
3255128|NCT01430780||nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
3373246|NCT04568486|Other|Rural-dwelling older adults (seed) and Key players (alter|Rural-dwelling older adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. This group will be paired with their key players (identified during interviews) to receive the diabetes education. The pair complete the intervention as a dyad.
3255129|NCT01430793|Active Comparator|Vitamin D 600,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
3255130|NCT01430793|Active Comparator|Vitamin D 600,000 orally|Vitamin D3 600,000 units will be given orally
3373253|NCT04560725|Experimental|[68Ga] P137|Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo [68Ga]P137 PET/CT scans.
3373254|NCT04559581||Patients newly initiating Nintedanib|
3373255|NCT04553692|Experimental|IGM-8444 Single Agent Escalation|IGM-8444 will be administered intravenously as a single agent.
3373256|NCT04553692|Experimental|IGM-8444 Single Agent Alternate Dosing Escalation|IGM-8444 will be administered intravenously as a single agent on an alternate dosing schedule.
3373257|NCT04553692|Experimental|IGM-8444 + FOLFIRI Escalation|IGM-8444 will be administered intravenously in combination with FOLFIRI.
3373258|NCT04553692|Experimental|IGM-8444 Single Agent Expansion|IGM-8444 will be administered intravenously as a single agent in disease specific cohorts.
3255131|NCT01430793|Active Comparator|Vitamin D 200,000 IM|Vitamin D3 600,000 units will be given by intramuscular injection
3255132|NCT01430793|Active Comparator|Vitamin D 200,000 orally|Vitamin D 200,000 units will be given orally
3255133|NCT01430806|Other|Dronedrone Arm|
3255134|NCT01430832||Normal Development|The infant's development level will be assessed using a phone interview with parents
3373259|NCT04553692|Experimental|IGM-8444 + FOLFIRI Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI.
3373260|NCT04553692|Experimental|IGM-8444 + FOLFIRI + Bevacizumab (and approved biosimilars) Expansion|IGM-8444 will be administered intravenously in combination with FOLFIRI and bevacizumab (and approved biosimilars).
3373261|NCT04553692|Experimental|IGM-8444 + Birinapant Escalation|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
3255135|NCT01430832||Abnormal Development|The infant's level of development will be assessed using a phone interview with parents
3373262|NCT04553692|Experimental|IGM-8444 + Birinapant Expansion|IGM-8444 will be administered intravenously in combination with Birinapant which will also be administered intravenously.
3373263|NCT04553692|Experimental|IGM-8444 + Venetoclax Escalation|IGM-8444 will be administered intravenously in combination with Venetoclax.
3255136|NCT01430858|Other|Strain Gauge|We wish to determine the relationship between tibial bone strain (recorded from implanted tibial strain gauges) and measured displacements of the limb and pelvis (using video motion analysis) during vibration exercise and a range of habitual locomotor activities. Only healthy volunteers will be recruited to this one arm.
3373264|NCT04553692|Experimental|IGM-8444 + Venetoclax Expansion|IGM-8444 will be administered intravenously in combination with Venetoclax.
3373265|NCT04553575||CoViD-19 patients cohort|Patients are followed for 2 years after diagnosis. The only one intervention is blood samples withdrawn for serologies
3373266|NCT04552288|Experimental|Participants with eosinophil-related cutaneous events|Study participants will have grade 2/3 eosinophil-related cutaneous adverse events
3373267|NCT04550780||The study population|The study population will comport all beneficiaries in the national French SNDS database who were prescribed mepolizumab and for whom health resource use data is available for the 12 months preceding and following a first filled prescription for mepolizumab.
3373268|NCT04549051|Experimental|Tenex plus local anesthetic|Use of the TENEX device for sectioning of the CHL
3373269|NCT04549051|Other|Local Anesthetic|Only Local anesthetic will be injected into the CHL. This arm will have the option to cross over into Tenex arm at 1 month
3255137|NCT01430871||Carcinoid syndrome|Patients: Men and women age 18 years or older with carcinoid syndrome attending the Sheffield neuro-endocrine tumour clinic
3255138|NCT01430871||Healthy Volunteers|Control group: Healthy men and women individually matched to the patients by gender, age, height and BMI
3255139|NCT01430884||Aspirate Blood|
3255140|NCT01430910|Experimental|1|CAZ104 (2000mg Ceftazidime/500mg Avibactam)
3255141|NCT01430910|Active Comparator|2|500mg Avibactam
3255142|NCT01430910|Active Comparator|3|2000mg Ceftazidime
3255143|NCT01430923|Experimental|Refrigeration free Latanoprost|Latanoprost refrigeration free formulation as per randomization schedule.
3255144|NCT01430923|Active Comparator|latanoprost 2-8˚ C|latanoprost stored at 2-8˚ C
3255145|NCT01430949|Experimental|Over-the-Wire Mesh Ablation System|
3255146|NCT01430962||General Anesthesia|Patients will receive Total Intravenous Anesthesia (TIVA) with a combination of Propofol, Ketamine and neuromuscular blockade by anesthesia. Either an LMA or an ETT will be used to secure airway.
3373272|NCT04542148|Experimental|Sliding Scale Insulin|Addition of supplemental sliding scale insulin to home insulin regimen for maximum of 5 days after antenatal corticosteroids
3373273|NCT04542148|Experimental|Up-Titration of Home Insulin|Increase in home insulin regimen based on standardized algorithm for maximum of 5 days after antenatal corticosteroids
3373274|NCT04542148|Experimental|Continuous Insulin Infusion|Discontinuation of home insulin regimen and receipt of continuous insulin infusion for maximum of 5 days after antenatal corticosteroids
3373275|NCT04537377|Experimental|VTX-801|
3373278|NCT04533373|Experimental|Neurotized Patients|Neurotization will be performed at the time of reconstruction.
3255147|NCT01430962||Moderate Sedation|Patients will receive moderate sedation given by the physician performing EBUS with a combination of Versed and Fentanyl per hospital protocol.
3255148|NCT01430988||Head Injured Group|Subjects who are suspected of a traumatically induced structural brain injury and/or clinical manifestations of functional brain injury, as a result of insult to the head from an external force, e.g., the head being struck by an object, the head striking an object, the head being exposed to forces generated from a blast or explosion, and/or the brain undergoing an acceleration/deceleration movement without direct external trauma to the head will be recruited from patients who enter the Emergency Department at hospitals that are participating as clinical sites for this study
3255149|NCT01430988||Normal Control Group|A normal control group will be recruited for comparison and will consist of Emergency Department patients who have sustained an injury but do not exhibit any trauma above the clavicle and no history of Road Traffic Accident requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope.
3255150|NCT01430988||Head Injured Control Group|A 'head injured' control group will be recruited and will consist of Emergency Department patients who are suspected or who have sustained a head injury but do not report or manifest symptoms, e.g. facial lacerations and/or whiplash.
3373279|NCT04533373|No Intervention|Non-Neurotized Patients|No Neurotization will be performed at the time of reconstruction.
3373280|NCT04532528||Patients receiving standard of care (SOC)|(without advanced educational Intervention)
3373281|NCT04532528||Patients receiving SOC with advanced educational intervention|
3373282|NCT04531241|Experimental|Test/Control|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Test/Control.
3373283|NCT04531241|Experimental|Control/Test|Eligible subjects that are habitual wearers of daily disposable contact lenses in both eyes will be randomly assigned to sequence, Control/Test.
3373284|NCT04530552|Experimental|Treatment (apalutamide)|The first 40 patients taking part in this trial receive apalutamide PO QD TIW (on Monday, Wednesday, and Friday) for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Based on PSA levels of the first 40 patients, the next group of 40 patients receive apalutamide either QW or QD for 4-8 weeks prior to before prostate surgery in the absence of disease progression or unacceptable toxicity. Patients may receive apalutamide for up to 4 to 12 weeks before prostate surgery (in the event surgery is delayed).
3373285|NCT04530539|Experimental|Experimental- Melatonin|Patients will receive melatonin
3373286|NCT04530539|Experimental|Experimental- Vit C|Patients will receive vitamin C
3373287|NCT04530539|Placebo Comparator|Control|Patients will receive placebo
3255151|NCT01431001|Experimental|Coil Configuration A|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
3255152|NCT01431001|Experimental|Coil Configuration B|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
3255153|NCT01431027||Diastolic Function|Patients scheduled for cardiac catheterization.
3255154|NCT01431040|Active Comparator|Group A|Group A will have no bowel preparation and be permitted a regular diet the day prior to surgery until midnight.
3255155|NCT01431040|Active Comparator|Group B|Participants in this group will consume a clear liquid diet and perform 2 Fleets enemas in the late afternoon the day before surgery and nothing after midnight.
3255156|NCT01431053|Experimental|Exemestane + Aspirin|
3255157|NCT01431053|Active Comparator|Exemestane|
3373294|NCT04521686|Experimental|LY3410738|Phase 1 dose escalation - Multiple doses of LY3410738 Phase 1 dose expansion - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
3373313|NCT04518306|Experimental|Triple ¼ (GMRx2)|Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg
3373314|NCT04518306|Active Comparator|Triple ½ (GMRx2)|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
3373315|NCT04518306|Placebo Comparator|Placebo|Placebo
3373316|NCT04518293|Experimental|Triple - TAI|Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg
3373317|NCT04518293|Active Comparator|Dual - TA|Telmisartan 20 mg/amlodipine 2.5 mg . At week 6 visit, forced up-titration to telmisartan 40 mg/amlodipine 5 mg
3373318|NCT04518293|Active Comparator|Dual - TI|Telmisartan 20 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to telmisartan 40 mg/indapamide 2.5 mg
3373319|NCT04518293|Active Comparator|Dual - AI|Amlodipine 2.5 mg/indapamide 1.25 mg. At week 6 visit, forced up-titration to amlodipine 5 mg/indapamide 2.5 mg
3373320|NCT04512547|Experimental|Obese Asthmatics|Obese patients that come to Duke that have been diagnosed with Asthma will be approached.
3373321|NCT04512547|Active Comparator|Obese Non-Asthmatics|The obese non-asthmatics will be collected from an IRB pre-approved Healthy Volunteer Data Repository.
3373322|NCT04506138|Experimental|Camrelizumab plus Chemotherapy|
3373323|NCT04504630|Active Comparator|Active HD-tDCS|Participants will receive 10 sessions of active stimulation (1 mA anodal HD-tDCS targeting dorsal anterior cingulate region for 20 minutes) across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
3373324|NCT04504630|Sham Comparator|Sham HD-tDCS|Participants will receive 10 sessions of sham stimulation across 2 weeks, with episodic memory tasks completed at baseline, immediate follow-up after session 10, and a 3-month follow-up.
3373325|NCT04503707||Follitropin Delta|Treatment according to routine clinical practice.
3373326|NCT04502758|Active Comparator|Sequential bilateral accelerated theta burst stimulation|Three sessions of Sequential bilateral accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
3373327|NCT04502758|Sham Comparator|Sham seqential billateral accelerated theta burst stimulation|Three sessions of Sequential bilateral sham accelerated theta burst stimulation (aTBS) are administered daily for 10 days (5 days per week).
3373328|NCT04498130|Experimental|12-Week Home Exercise Group|The 12-week theory-based physical activity intervention will involve mailing participants an exercise manual with health and exercise information (i.e. information about exercising safely, modules related to the social cognitive theory, weekly goal setting worksheets, exercise-tracking logs, etc.), a resistance band, and a standard Omron pedometer. Participants will receive a weekly 30-minute Zoom--based group meetings to discuss different strategies to begin and maintain a consistent exercise routine and access to a social media page to facilitate social support and interaction among the group participants. Participants will be able to join the group if they would like, but it will not be required. Participants will be encouraged to connect with each other to promote social support and social modeling. Lastly participants will receive a weekly exercise video to follow along with on their own time and tailored weekly step goals.
3373329|NCT04498130|Active Comparator|Educational Comparison Group|The education group participants will receive the same exercise manual, fitness items, exercise videos, and same weekly tailored step goal as the 12-week intervention group. This group will not have weekly zoom discussions, or be a part of the same social media page as the 12-week intervention group. Instead, the education group will be contacted by research staff once a week via telephone to discuss their manuals and activity for the week, and to ensure they have been safely engaging in exercise. A separate social media page will be created for this group, where pre-existing materials related to physical activity recommendations, benefits, other resources, and more will be shared.
3373331|NCT04496674|Experimental|Treatment with bispecific Ab CC-1|administration of bispecific PSAMxCD3 Ab CC-1.
3373333|NCT04492904||COVID-19 Positive (Case)|Participants who were present for COVID-19 screening and their test results will later indicate positive of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days.
3255158|NCT01431066|Placebo Comparator|Control|Sham device that resembles the Actipatch PRFE device, including the light that illuminates when active, but the transmitting function has been disabled.
3255159|NCT01431066|Experimental|Actipatch|Use of the Actipatch PRFE device that is integrated into a viscoelastic heel pad for the treatment of plantar fasciopathy
3255160|NCT01431092|Experimental|Melatonin|
3255161|NCT01431092|Placebo Comparator|Placebo|
3255162|NCT01431118|Active Comparator|sports intervention male|male athletes of the german national dragon boat team
3373334|NCT04492904||COVID-19 Negative/Other respiratory diseases (Control)|Participants who were present for COVID-19 screening and their test results will later indicate negative of infection. Participants will complete a one-time assessment of the various online questionnaires (Singapore Smell and Test Questionnaire, Sino-nasal Outcome Test-22, and Global Consortium for Chemosensory Research Questionnaire - Optional) in the hospital/clinic. Taste and smell acuity, as well as experienced symptoms, changes in appetite and food-related quality of life will be assessed using the Home-use Tests and Follow-up questionnaire over a period of 28 days
3373335|NCT04490395|Experimental|Engage PA|
3373336|NCT04490395|Other|Treatment as usual plus fitness tracker|
3373337|NCT04486573|Other|CMRI|"Clinical data will be collected regarding cardiac risk factors, cancer type, and cancer treatment.~CMRI will be performed:~Within 2 weeks before the first fraction of radiation therapy (RT)~Within 1 week of the final fraction of RT (before or after)~Any patient with a pre-RT and post-RT MRI scan will be considered evaluable.~Pre- and post-RT CMRI parameters will be compared.~3D reconstructed CMR images will be co-registered with RT treatment plans to assess for spatial associations."
3255163|NCT01431118|Active Comparator|sports intervention women|women athletes of the german national dragon boat team
3255164|NCT01431157|Active Comparator|Nasal oxygen|Nocturnal nasal oxygen
3255165|NCT01431157|Placebo Comparator|No nasal oxygen|
3373338|NCT04484441||Fetal surgical intervention group|Pregnant adult women carrying a fetus with a diagnosed congenital anomaly and scheduled to undergo fetal surgical intervention at Mayo Clinic.
3373339|NCT04484441||Control group - normal pregnancy|Pregnant adult women with normal ultrasound findings. These women will be matched with the subjects enrolled in the intervention cohort for parity, maternal age, ethnicity, fetal sex and gestational age at time of surgical intervention.
3373340|NCT04479241|Experimental|Lerapolturev|
3373341|NCT04478773|Experimental|Experimental|Patient will receive MRI
3373342|NCT04478279|Experimental|Dose Escalation|This cohort only patients diagnosed with locally advanced or metastatic melanoma, carcinoma or sarcoma of any tumor type who are refractory or intolerant to all available therapies. ST101 will be administered intravenously (IV), initially once per week.
3373343|NCT04478279|Experimental|Dose Expansion HR+ Breast|This cohort must have progressed after 1-2 hormone based therapies. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
3373344|NCT04478279|Experimental|Dose Expansion Melanoma|This cohort must have Melanoma that has progressed after/or on treatment with an immune checkpoint inhibitor (CPI) and have received 1-2 prior lines of therapy for their advanced/metastatic disease. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
3373345|NCT04478279|Experimental|Dose Expansion GBM|Primary (de novo) GBM that has recurred or progressed (per modified RANO criteria) after 1 standard treatment regimen. Standard therapy is defined as maximal surgical resection, radiotherapy, and concomitant temozolomide with radiotherapy or adjuvant chemotherapy with temozolomide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
3373346|NCT04478279|Experimental|Dose Expansion CRPC|CRPC that has progressed after previous treatment with taxanes, abiraterone and enzalutamide/apalutamide. The starting dose of ST101 for Expansion will be derived from the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) and the best dosing schedule determined during Dose Escalation.
3373347|NCT04473651|Experimental|Part A: Single dose of Lu AG06479 or Placebo|
3373348|NCT04473651|Experimental|Part B: Repeated dose of Lu AG06479 and Food interaction|"Sequence B1: Fed - Fasting - Fasting~Sequence B2: Fasting- Fed - Fasting~Sequence B3: Fasting- Fasting - Fed"
3373349|NCT04472676|Experimental|LY3473329 (Part A)|LY3473329 administered orally.
3373350|NCT04472676|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
3373351|NCT04472676|Experimental|LY3473329 (Part B)|LY3473329 administered orally.
3373352|NCT04472676|Experimental|Placebo (Part B)|Placebo administered orally.
3373353|NCT04472598|Experimental|Navitoclax + Ruxolitinib|Participants will receive Navitoclax in combination with Ruxolitinib
3373354|NCT04472598|Active Comparator|Placebo for Navitoclax + Ruxolitinib|Participants will receive placebo for Navitoclax and Ruxolitinib
3373357|NCT04471064|Experimental|XY0206-12.5mg|Drug:XY0206;Dosage form:Tablet;Dosage：12.5mg; multiple dose phase
3373358|NCT04471064|Experimental|XY0206-25mg|Drug:XY0206;Dosage form:Tablet;Dosage：25mg; multiple dose phase
3373359|NCT04471064|Experimental|XY0206-50mg|Drug:XY0206;Dosage form:Tablet;Dosage：50mg; multiple dose phase
3373360|NCT04471064|Experimental|XY0206-100mg|Drug:XY0206;Dosage form:Tablet;Dosage：100mg; multiple dose phase
3373361|NCT04471064|Experimental|XY0206-150mg|Drug:XY0206;Dosage form:Tablet;Dosage：150mg; multiple dose phase
3373362|NCT04471064|Experimental|XY0206-200mg|Drug:XY0206;Dosage form:Tablet;Dosage：200mg; multiple dose phase
3255166|NCT01431183|Active Comparator|mailed reminder notice|Seasonal influenza vaccination reminder sent by postal mail
3255167|NCT01431183|No Intervention|No reminder notice|No seasonal influenza vaccination reminder sent by postal mail
3255168|NCT01431196|Experimental|DENDRITIC CELL VACCINATION|Px will receive standard neoadjuvant chemotherapy plus active vaccination. we will compare results with an historic cohort of patients treated with the same chemotherapy without the vaccines
3255169|NCT01431222|Active Comparator|percutaneous treatment|
3255170|NCT01431222|No Intervention|optimal medical treatment|
3373363|NCT04471064|Experimental|XY0206-250mg|Drug:XY0206;Dosage form:Tablet;Dosage：250mg; multiple dose phase
3373364|NCT04465708|Other|Homework, Organization, and Planning Skills (HOPS)|"The Homework, Organization, and Planning Skills (HOPS) intervention is delivered through a series of 16 frequent but brief sessions between the school professional and student. For the purposes of this study, the school professional will be called a school partner. Each session is approximately 20 minutes. The three main skill areas covered as part of the program are: (1) school materials organization, (2) homework management and (3) time management and planning. A reward system is utilized in effort to change behavior patterns by making rewards available when a student engages in productive organizing and planning behaviors. The intervention also includes two parent meetings and one teacher meeting."
3373365|NCT04465708|No Intervention|Treatment-As-Usual Waitlist (WL-TAU)|The Treatment-As-Usual Waitlist (WL-TAU) will be enacted for study participants attending the enrolled schools assigned to this arm. After providing post data (and in some cases, follow-up data as well), participants will then receive the HOPS intervention.
3373366|NCT04464798|Experimental|Cohort A- Monotherapy in R/R lymphoma subjects|Subjects with Relapsed or Refractory (R/R) lymphoma who have been allocated to Cohort A will receive CC-220 monotherapy (MonoT). Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.
3373367|NCT04464798|Experimental|Cohort B- CC-220 and rituximab in R/R B-Cell NHL subjects|"Subjects with R/R B-cell Non Hodgkin Lymphoma (NHL) who have been allocated to Cohort B will receive CC-220 in combination with rituximab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle up to PD or maximum 24 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
3373368|NCT04464798|Experimental|Cohort C - CC-220 and obinutuzumab in R/R FL or MZL subjects|"Subjects with R/R FL (Grade 1 to 3a) or MZL who have been allocated to Cohort C will receive CC-220 in combination with obinutuzumab.~Oral CC-220 at dose specified by cohort dose level from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15, and on D1 of every 28-day cycle from C2 to C6."
3373369|NCT04464798|Experimental|Cohort D - Monotherapy in other lymphomas subtype subjects|"Subjects with other lymphoma subtype who have been allocated to Cohort D will receive CC-220 monotherapy (MonoT).~- Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles."
3373370|NCT04464798|Experimental|Cohort E - CC-220 and rituximab in B-cell lymphoma subjects|"Subjects with aggressive B-cell lymphoma who have been allocated to Cohort E will receive CC-220 in combination with rituximab~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 24 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2."
3373371|NCT04464798|Experimental|Cohort F - CC-220 and rituximab in FL and MZL subjects|"Subjects with follicular lymphoma (FL) (1 to 3a) and marginal zone lymphoma (MZL) who have been allocated to Cohort F Part 2 will receive CC-220 in combination with rituximab.~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Rituximab will be administered at 375 mg/m2 IV at C1D1 and then on D8, D15, and D22 of C1 and then every 28-day cycle at D1 from C2 to C5, either by SC infusion at a dose of 1400 mg or by IV infusion at a dose of 375 mg/m2"
3255171|NCT01431235|No Intervention|standard addiction treatment|10 sessions of standard addiction treatment. No ADHD treatment.
3255172|NCT01431235|Experimental|addiction treatment and ADHD treatment|10 sessions cognitive behavioral therapy on addiction treatment combined with 5 sessions on ADHD treatment.
3373372|NCT04464798|Experimental|Cohort G -CC-220 and obinutuzumab in FL and MZL subjects|"Subjects with FL (1 to 3a) and MZL who have been allocated to Cohort G will receive CC-220 in combination with obinutuzumab.~Oral CC-220 at RP2D from Day 1 to 21 of each 28-day cycle, up to PD or a maximum of 12 cycles.~Obinutuzumab will be administered at 1000 mg at C1D1, D8, and D15 and on D1 of every 28-day cycle from C2 to C6."
3373373|NCT04462952|Experimental|Adavosertib (AZD1775) monotherapy|Dose escalation of adavosertib monotherapy for patients with advanced solid tumours
3255173|NCT01431248||Azithromycin|Azithromycin 1gm PO once
3255174|NCT01431248||Erythromycin 250mg|Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
3255175|NCT01431261|Active Comparator|Pain Management + Training|Education in pain management strategies and treatment sessions including instructions in neck exercises and aerobic training
3255176|NCT01431261|Active Comparator|Pain Management|Education in pain management strategies
3255177|NCT01431352|Experimental|Letrozole+ Chinese herbal medicine granules|
3255178|NCT01431352|Placebo Comparator|Letrozole+ Chinese herbal medicine granules placebo|
3373374|NCT04462952|Experimental|Adavosertib (AZD1775) in combination with gemcitabine|Dose escalation of adavosertib in combination with gemcitabine for patients with advanced solid tumours
3373375|NCT04461236|Experimental|Isoleucine|Type 2 Diabetics randomized to isoleucine group
3373376|NCT04461236|Placebo Comparator|Placebo|Type 2 Diabetics randomized to placebo group
3373377|NCT04461236|No Intervention|Healthy|gender-, age-, BMI-matched controls for baseline measurements only. No supplementation provided.
3373378|NCT04460014|Experimental|Simple cognitive task intervention|"Session 1: A memory cue followed by playing the computer game Tetris (e.g. on own smartphone) with mental rotation instructions.~Options to engage in self-administered/guided booster sessions per intrusive memory."
3255179|NCT01431365|Experimental|Moderate Exercise Group|The moderate exercise condition will involve participants walking briskly (equivalent to moderate intensity) on a treadmill for 10 minutes. Moderate intensity exercise will be defined as 40-68% of the resting heart rate reserve. Heart rate (HR) will be monitored in participants using a Polar RS100 Heart Rate monitor to serve as a guide for participants to attain the appropriate intensity.
3255180|NCT01431365|Active Comparator|Passive Sitting Group|The passive sitting condition will involve participants sitting passively for 10 minutes on a chair. Heart rate (HR) will be monitored in participants of the passive sitting group to help maintain group equivalency (with the moderate exercise condition) in regards to distraction effects and researcher contact.
3373379|NCT04460014|Placebo Comparator|Attention placebo|Session 1: Digital activity for same amount of time (e.g. listening to podcast on own smartphone).
3255181|NCT01431378||CNS|CNS: Known or suspected pathology in the posterior fossa
3255182|NCT01431378||Thorax|Thorax: Patients referred for staging of a known or suspected lung cancer
3255183|NCT01431378||Abdomen 1|Abdomen: Patients with acute flank pain and suspected urolithiasis
3373380|NCT04458831||Cohort 1|Patients with multiple myeloma (MM) and are considered as RRMM according to the International Myeloma Working Group (IMWG) criteria
3373381|NCT04457596|Active Comparator|Arm I (trastuzumab emtansine, placebo)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and placebo PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
3373382|NCT04457596|Experimental|Arm II (trastuzumab emtansine, tucatinib)|Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.
3373383|NCT04456686|Experimental|LY3016859|LY3016859 given intravenously (IV).
3373384|NCT04456686|Placebo Comparator|Placebo|Placebo given IV.
3373385|NCT04456153|Experimental|standard of care therapy with atovaquone|The first treatment group will receive continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days.
3373386|NCT04456153|Placebo Comparator|standard of care therapy with matching placebo|The second treatment group will receive continued standard of care therapy together with matching placebo.
3373387|NCT04455464|Experimental|Midodrine|Midodrine will be given 10 mg for one time only. HVPG will be done at baseline and after 3 hours
3255184|NCT01431378||Abdomen 2|Abdomen: Patients with a known or suspected focal liver lesion
3255185|NCT01431404|Active Comparator|Enbrel, prefilled syringe|
3255186|NCT01431404|Experimental|HD203, prefilled syringe|
3255187|NCT01431417||Healthy volunteers|Healthy volunteers, less than 35 years old and presenting with no shoulder condition
3373388|NCT04447027|Experimental|1- Experimental Treatment: Dose Escalation|Lenalidomide by oral intake at escalating doses of 5, 10, 15, or 20 mg/day on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle, to determine MTD
3373389|NCT04447027|Experimental|2 - Experimental Treatment: Dose Expansion|Lenalidomide by oral intake at MTD on days -7 to 10 of each 21-day cycle (max 6 cycles) with CC-486 (5-azacitidine) at 300mg/day by oral intake on days 1-10, romidepsin at 12mg/m2 by IV infusion on Day 1 and 10 and dexamethasone at 40mg by oral intake on days 1 and 10 of each cycle
3373392|NCT04442503|Experimental|SAGE-217|Participants will receive SAGE-217 capsules, once daily for 14 days.
3255188|NCT01431417||Patients with rotator cuff condition|Patients with rotator cuff condition, conservative treatment indicated
3255189|NCT01431417||Patients with shoulder instability|Patients with shoulder instability, conservative treatment indicated
3255190|NCT01431417||Patients with proximal humerus fracture|Patients with diaphyseal humerus fracture or subcapital humerus fracture treated surgically or conservatively, at 6 weeks post stabilization. (Surgical and conservative treatment will be considered as the same population from the functional point of view as functional outcome is similar) (Handoll et al. 2003).
3255191|NCT01431417||Patients with frozen shoulder|Patients with frozen shoulder, conservative treatment indicated
3373393|NCT04442503|Placebo Comparator|Placebo|Participants will receive SAGE-217 matched-placebo capsules, once daily for 14 days.
3255192|NCT01431430|Experimental|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
3255193|NCT01431430|Active Comparator|Cholecalciferol 12 000 UI (Control)|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
3255194|NCT01431443|Experimental|Dark chocolate|
3255195|NCT01431443|Placebo Comparator|Placebo chocolate|Placebo intervention
3255196|NCT01431456|Active Comparator|Dabigatran|Dabigatran
3255197|NCT01431456|Active Comparator|Rivaroxaban|Rivaroxaban
3255198|NCT01431456|Active Comparator|Nadroparin|Nadroparin
3255199|NCT01431469|Placebo Comparator|Cow's Milk|Powdered Whole Cow's Milk
3255200|NCT01431469|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
3255201|NCT01431495|Active Comparator|plavix|patient treated by the princeps
3255202|NCT01431495|Active Comparator|Pidogrel|patient treated by Pidogrel
3255203|NCT01431547|Experimental|Part 1: Dalotuzumab|
3255204|NCT01431547|Experimental|Parts 2 and 3: Dalotuzumab + ridaforolimus|
3255205|NCT01431560|Active Comparator|metallic implant|fixation of the ankle fracture with metallic implants
3255206|NCT01431560|Active Comparator|biodegradable implant|fixation of the ankle fracture with Freedom plate and screws
3255207|NCT01431586|Experimental|Single dose JDTic 1 mg, 3 mg, or 10 mg|
3255208|NCT01431599|Experimental|short-course|
3255209|NCT01431612|Active Comparator|Esmolol|50 µg/kg/min of the ß-1-receptor-blocker esmolol (Qilu Pharmaceutical Co, Shandong, China) wss infused intravenously over 3 hours
3255210|NCT01431612|Active Comparator|Phenylephrine|Intravenous infusion of 0.01 µg/kg/min of phenylephrine (alpha1-adrenergic agonist) over 3 hours.
3255211|NCT01431612|Placebo Comparator|Lactated Ringer´s solution|10 ml/h lactated Ringer's solution without active drug was infused intravenously over 3 hours.
3373403|NCT04430517|Experimental|Mild Cognitive Impairment and Alzheimer's Dementia|Participants will take 4 pills every day, each containing 250 mg NR (NIAGEN® by Chromadex; www.chromadex.com), via the oral route, for 12 weeks.
3373404|NCT04424290|Experimental|BI 764524|Single rising dose part followed by a multiple dosing part.
3373405|NCT04423757|Experimental|BI 1358894|
3373406|NCT04423757|Placebo Comparator|Placebo|
3373407|NCT04418453||Integration of telemedicine in primary care settings for MOUD|Primary care providers may refer OUD patients to receive telemedicine for MOUD
3259509|NCT01471483||patients will not receive a phone call from nurse|The proposed study will be a prospective longitudinal feasibility study of 50 older adults with a recent diagnosis of stage II, III or IV ovarian cancer who will receive standard first line chemotherapy and surgery over approximately a six-month period. Half of the 50 patients receive a weekly telephone call from geriatric nurse practitioner (NP); the remaining 25 patients would receive standard oncology care alone (randomization).
3373408|NCT04417036|Experimental|Part A - Active Drug Dose 1|Participants will receive Active Drug Dose 1 for a maximum of 14 days in study phase Part A
3373409|NCT04417036|Experimental|Part A - Active Drug Dose 2|Participants will receive Active Drug Dose 2 for a maximum of 14 days in study phase Part A
3373410|NCT04417036|Placebo Comparator|Part A - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part A
3373411|NCT04417036|Experimental|Part B - Active Drug Dose|Participants will receive Active Drug 1 or 2 for a maximum of 14 days in study phase Part B
3373412|NCT04417036|Placebo Comparator|Part B - Placebo|Participants will receive Placebo for a maximum of 14 days in study phase Part B
3373413|NCT04410133|Experimental|Patients|Single intravenous administration of 18F fluciclovine for PET Scan
3373416|NCT04408417|Experimental|Harnessing Sequence A|Participants will harness their child into the 2 different child safety seats in the following order: control, prototype, prototype, control.
3373417|NCT04408417|Experimental|Harnessing Sequence B|Participants will harness their child into the 2 different child safety seats in the following order: prototype, control, control, prototype.
3373418|NCT04408417|Experimental|Harnessing Sequence C|Participants will harness their child into the 2 different child safety seats in the following order: control, control, prototype, prototype.
3373419|NCT04408417|Experimental|Harnessing Sequence D|Participants will harness their child into the 2 different child safety seats in the following order: prototype, prototype, control, control.
3373420|NCT04406987||decompression|patients treated with decompression for lumbar spinal stenosis
3373421|NCT04406987||fusion|patients treated with decompression with fusion for lumbar spinal stenosis
3373422|NCT04404283|Experimental|Experimental Arm|Brentuximab vedotin + lenalidomide + rituximab
3373423|NCT04404283|Active Comparator|Control Arm|Placebo + lenalidomide + rituximab
3373424|NCT04403971|Experimental|0.12% chlorhexidine|Participants will be randomized to Chlorhexidine solution group, applied twice a day by care givers.
3373425|NCT04403971|Sham Comparator|Listerine|Participants will be randomized to Listerine solution group, applied twice a day by care givers.
3373426|NCT04403971|Placebo Comparator|Normal saline|Participants will be randomized to Normal saline group, applied twice a day by care givers.
3373429|NCT04399538|Placebo Comparator|Placebo|Participants will receive medication for 6 weeks
3373430|NCT04399538|Experimental|DGAT2i (25 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
3373431|NCT04399538|Experimental|DGAT2i (100 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
3373432|NCT04399538|Experimental|DGAT2i (300 mg QD) + ACCi (20 mg QD)|Participants will receive medication for 6 weeks
3373433|NCT04399538|Experimental|DGAT2i (300 mg BID) + ACCi (10 mg BID)|Participants will receive medication for 6 weeks
3373434|NCT04397367|Experimental|Ruxolitinib10 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 10 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
3373435|NCT04397367|Experimental|Ruxolitinib5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5 mg twice a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
3373436|NCT04397367|Experimental|Ruxolitinib5 mg once a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 5mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
3373437|NCT04397367|Experimental|Ruxolitinib 2.5 mg twice a day combined with Corticosteroids|Newly diagnosed acute GVHD patients started therapy with methylprednisolone of 1 mg/kg/day after diagnosis. Ruxolitinib was administered at a median of 2 days after the use of methylprednisolone. Participants began oral administration of ruxolitinib at 2.5 mg once a day. Ruxolitinib was subsequently tapered due to the resolution of acute GVHD after three months of therapy. A dose-tapering schedule that would discontinue ruxolitinib in three months was recommended.
3373440|NCT04394169|Experimental|Intervention arm|The intervention is a program that includes early patient care, therapeutic education, and psychological intervention. It will be performed through three medical visits and a psychological intervention that requires seven face-to-face sessions.
3373441|NCT04394169|No Intervention|Standard care arm|Standard medical practice: patient follow-up is carried out by their referring physicians (primary care physicians or specialists) who are outside the study.
3255212|NCT01431625|Active Comparator|COPD with emphysema-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The identification threshold of normal lung density and LAA is set at -960 HU. The cut-off level between high or low LAA% is the mean + 2SD of LAA% of the asymptomatic non-COPD smokers.
3255213|NCT01431625|Active Comparator|COPD with airway-predominant|The degree of involvement of the lung parenchyma and the airway are assessed by computed tomography. The HRCT is performed using 2-mm collimation, scan time 1.0 s, 120 kVp, and 200 mA. Images at three different levels (a cranial section is obtained 1 cm above the superior margin of the aortic arch, a middle section is taken at 1 cm below the carina, and a caudal section is taken approximately 3 cm above the top of the diaphragm) are selected and LAA% is then automatically calculated. The helical scan is performed using 120 kVp, 50 mA, 3-mm collimation, and pith 1.0. The dimensions of the right apical segmental bronchus are measured and WA% is calculated. The cut-off level between high or low WA% is the mean + 2SD of WA% of the asymptomatic non-COPD smokers.
3373442|NCT04391894|Experimental|ECF843 0.45 mg/mL TID or vehicle (Part 1)|ECF843 0.45 mg/mL TID or vehicle (Part 1)
3373443|NCT04391894|Experimental|ECF843 0.15 mg/mL TID or vehicle (Part 1)|ECF843 0.15 mg/mL TID or vehicle (Part 1)
3373444|NCT04391894|Placebo Comparator|ECF843 vehicle TID (Part 1)|ECF843 vehicle TID (Part 1)
3373445|NCT04391894|Experimental|ECF843 0.15 mg/mL BID or vehicle (Part 1)|ECF843 0.15 mg/mL BID or vehicle (Part 1)
3373446|NCT04391894|Placebo Comparator|ECF843 vehicle BID (Part 1)|ECF843 vehicle BID (Part 1)
3373447|NCT04391894|Experimental|ECF843 -Part 2 (concentration/frequency TBD from Part 1)|ECF843 -Part 2 (concentration/frequency TBD from Part 1)
3373448|NCT04391894|Placebo Comparator|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)|ECF843-Part 2 vehicle(concentration/frequency TBD from Part 1)
3373449|NCT04390399|Active Comparator|Cohort A Control Treatment Arm|SBRT + gemcitabine + nab-paclitaxel
3373450|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 1|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin HCl + N-803
3255214|NCT01431651|Experimental|probiotic, lifestyle counseling|
3255215|NCT01431690|Experimental|Warfarin and Epanova|
3255216|NCT01431690|Active Comparator|Lovaza|
3255217|NCT01431729||mucositis|
3373451|NCT04390399|Experimental|Cohort A Experimental Treatment Arm 2|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
3255218|NCT01431742|Experimental|BEMA Buprenorphine|buprenorphine buccal soluble film
3255219|NCT01431781|Experimental|stilamin+common daily treatment|
3255220|NCT01431781|Active Comparator|common daily treatment|
3255221|NCT01431807|Experimental|SYR-472 group|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3255222|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 1|
3255223|NCT01431820|Experimental|Luliconazole Solution, 10% Regimen 2|
3255224|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 1|
3255225|NCT01431820|Placebo Comparator|Vehicle Solution Regimen 2|
3255226|NCT01431833|Experimental|Moderate hepatic|
3255227|NCT01431833|Experimental|Severe Hepatic|
3255228|NCT01431833|Experimental|Matched control|
3373452|NCT04390399|Active Comparator|Cohort B Control Treatment Arm|Irinotecan liposome + 5-FU/leucovorin
3373453|NCT04390399|Experimental|Cohort B Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel+ aldoxorubicin HCl + N-803 + PD-L1 t-haNK
3373454|NCT04390399|Experimental|Cohort C Experimental Treatment Arm|SBRT + cyclophosphamide + gemcitabine + nab-paclitaxel + aldoxorubicin + N-803 + PD-L1 t-haNK
3373455|NCT04388241|Experimental|Behavioral Intervention|Children and adolescents with SCD between the ages of 8 and 17 years old (n=20) will be recruited to complete a four-week behavioral intervention designed to reduce pain-related impairment in SCD.
3373457|NCT04387448|Experimental|GFB-887 multiple ascending dose (MAD) active|GFB-887 active once-daily dosing
3373458|NCT04387448|Placebo Comparator|GFB-887 MAD placebo|GFB-887 placebo once-daily dosing
3255229|NCT01431859|Placebo Comparator|Subcutaneous injection of placebo|
3255230|NCT01431859|Active Comparator|Birch pollen immunotherapy|
3373459|NCT04383210|Experimental|Cohort 1|"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
3373460|NCT04383210|Experimental|Cohort 2|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
3373461|NCT04383210|Experimental|Cohort 3|"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.~Seribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively."
3255231|NCT01431872||Post menopausal breast cancer patients|
3255232|NCT01431885|Active Comparator|PLAT|Diagnosis of preterm labor will be made by the March of Dimes Preterm Labor Assessment Toolkit Algorithm B, incorporating transvaginal ultrasound measurement of cervical length, and vaginal fetal fibronectin
3373462|NCT04380051|Experimental|Arm 1 : skin-to-skin contact associated with a sensory-tonic s|skin-to-skin contact left free for parents associated with a sensory-tonic stimulation five times a week during 15 minutes at each time
3373463|NCT04380051|Active Comparator|Arm 2 : skin-to-skin contact only|skin-to-skin contact left free for parents
3373464|NCT04379518|Experimental|Arm I (rintatolimod, recombinant interferon alfa-2b)|Patients receive rintatolimod IV over 2.5-3 hours and recombinant interferon alfa-2b IV over 20 minutes on day 1 and on day 3 (or 4) in the absence of disease progression or unacceptable toxicity.
3373465|NCT04379518|Active Comparator|Arm II/IV (standard of care)|Patients receive standard of care.
3373466|NCT04379518|Experimental|Arm III (rintatolimod)|Patients receive rintatolimod IV over 2.5-3 hours once.
3373467|NCT04371666|Experimental|Arm A|pamrevlumab 35 mg/kg IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
3373468|NCT04371666|Experimental|Arm B|matching placebo IV Q2 weeks + systemic deflazacort or equivalent potency of corticosteroids administered orally
3373471|NCT04368559|Experimental|Group 1: Rezafungin for Injection|Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 13 weeks. Subjects will receive oral placebo for standard antimicrobial regimen (SAR) azole prophylaxis and oral placebo for SAR anti-PCP prophylaxis in accordance with the respective SAR dosing regimens for each. For subjects who are switched to a SAR IV regimen, oral placebo for SAR azole prophylaxis will be changed to IV placebo.
3373472|NCT04368559|Active Comparator|Group 2: Oral Antifungal|Subjects in SAR treatment group will receive 400 mg oral fluconazole once daily for 13 weeks. Fluconazole may be switched, due to acute clinically significant GVHD, to 300 mg oral posaconazole twice daily on the first day of the medication switch and 300 mg once daily, thereafter. However, subjects who are switched to posaconazole cannot be switched back to fluconazole. Azole-based antifungal therapy (fluconazole or posaconazole) can be switched from daily oral therapy to daily IV therapy at the discretion of the Investigator. In addition, subjects in the SAR group will receive anti-PCP prophylaxis with oral TMP/SMX (80 mg TMP/400 mg SMX) once daily.
3373473|NCT04351243|Experimental|Gimsilumab|Gimsilumab 400 mg on Day 1 Gimsilumab 200 mg on Day 8
3373474|NCT04351243|Placebo Comparator|Placebo|Normal saline on Day 1 Normal saline on Day 8
3373475|NCT04351061|Experimental|Acetazolamide Arm|Participants in this arm will receive the Acetazolamide intervention for 7 consecutive days post standard of care endoscopic skull base surgery.
3373476|NCT04348604|Experimental|Customized Adherence Enhancement for AYA|This arm will receive the experimental intervention, Customized Adherence Enhancement for Adolescents and Young Adults (CAE-AYA).
3255233|NCT01431885|Placebo Comparator|Cervical Change|Diagnosis of preterm labor will be made by cervical change by digital examination
3255234|NCT01431898|Experimental|Multiple-dose, dose-escalation study of GS-9669|Multiple-dose, dose-escalation study of GS-9669, a nonnucleotide NS5B inhibitor of hepatitis C virus (HCV), in subjects with chronic HCV infection. Dosing is planned in up to 7 unique dosing cohorts. Each cohort will be comprised of 10 genotype 1a (Cohorts 1, 2, 3, 4, and 5) or genotype 1b (Cohort 6 and 7), with eight subjects randomized to receive active drug and two subjects randomized to receive placebo per cohort.
3255235|NCT01431911||Patients diagnosed with COPD|Patients diagnosed with COPD using ICD codes with a COPD-related exacerbation and receiving maintenance therapy
3373477|NCT04348604|Active Comparator|Enhanced Treatment as Usual (ETAU)|This arm will receive the control intervention, Enhanced Treatment as Usual (ETAU).
3255236|NCT01431924||Adolescent and adult patients with asthma|Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination
3255237|NCT01431937|Active Comparator|GSK2018682|Active Drug
3255238|NCT01431937|Placebo Comparator|Placebo Control|Placebo
3373478|NCT04345952|Experimental|Calm Meditation|Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (~2 hours) and while at home between treatment cycles ad libitum. Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed). This data will be provided to us through data coordinator of the app.
3255239|NCT01432028|Active Comparator|Non-oral hormone therapy|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
3373479|NCT04345952|No Intervention|Usual Care|The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles. They will receive their treatment as intended without any additional intervention.
3373480|NCT04343573|Experimental|Proton CSI Followed by Standard of Care (NSCLC & Breast)|Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
3373481|NCT04343573|Experimental|Standard of Care|Involved field photon RT including WBRT and/or focal spine RT (30Gy in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
3373482|NCT04343573|Other|Proton CSI Followed by Standard of Care (Other Solid Tumors)|(Exploratory arm) Patients with solid tumor malignancies other than NSCLC or breast cancer will be enrolled to the exploratory proton CSI arm (Arm C) and will not undergo randomization. Proton CSI (30Gy [RBE] in 10 fractions) followed by standard of care systemic treatments for leptomeningeal metastases per physician choice.
3373484|NCT04338204||Patients prescribed tofacitinib|Patients with a confirmed diagnosis of ulcerative colitis with confirmed active disease (biomarker or endoscopy) initiating tofacitinib as per the Swedish summary of product characteristics (SmPC).
3255240|NCT01432028|Active Comparator|oral homone therapy|estradiol 1mg and drospirenone 2 mg/day
3255241|NCT01432067|Other|Adaptated physical activity|Physical activity advices adaptated to physical status of patients
3373485|NCT04334174|Experimental|Single Arm|Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
3373489|NCT04325659|Active Comparator|Lofexidine/Sham Bridge Device|Lofexidine (Lucemyra) encapsulated
3373490|NCT04325659|Placebo Comparator|Sham Bridge Device /Placebo Study Drug|Inactive Bridge Device and placebo study drug
3373491|NCT04325659|Experimental|Active Bridge Device/ Placebo Study Drug|Active Bridge Device and placebo study drug
3373492|NCT04325217||Patients newly initiating Ofev®/Nintedanib Capsules|
3373493|NCT04321174|Experimental|Lopinavir/ritonavir|This arm will receive oral lopinavir/ritonavir 400/100 mg (or equivalent weight-based dosing) twice daily for 14 days.
3373494|NCT04321174|No Intervention|Control|This arm will receive no intervention.
3373496|NCT04318145|Experimental|Part A: PL-3994 Dose Ascension|Dose ascension: up to 15 subjects with HFpEF. N = 3 per dose level, up to 5 dose levels.
3373497|NCT04318145|Experimental|Part B: PL-3994 Single Dose|Up to 40 subjects with HFpEF (20 Females, 20 Males) will receive a single dose of PL-3994.
3373501|NCT04312256|Experimental|Dominant Hand and great toe|Subject scheduled to undergo an elective surgical procedure will have TetraGraph device lead placement on the dominant hand and great toe.
3255242|NCT01432067|Other|Standard physical activity|Daily physical activities based on a standard guide
3255243|NCT01432080|No Intervention|Standard of Care|Standard of Care includes fluids, antipyretics, ribavirin for RSV infection, and oseltamivir for influenza infection, and intravenous immune globulin for patients with low IgG levels.
3255244|NCT01432080|Experimental|SAMS|Subjects randomized to the SAMS arm will receive a four-drug combination (Steroids, Azithromycin, Montelukast, and Symbicort).
3255245|NCT01432093|Active Comparator|Intensive glycemic management|Multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
3373506|NCT04300140|Experimental|Phase 1b: Batiraxcept + cabozantinib|Two dose levels of batiraxcept administered Q2W (once every two weeks) in combination with QD (once a day) cabozantinib will be evaluated.
3373507|NCT04300140|Experimental|Phase 2 Part A: batiraxcept + cabozantinib|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib will be evaluated.
3373508|NCT04300140|Experimental|Phase 2 Part B: batiraxcept + cabozantinib + nivolumab|One dose level of batiraxcept administered Q2W in combination with QD cabozantinib and nivolumab.
3255246|NCT01432093|Active Comparator|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
3255247|NCT01432106|Active Comparator|Aliskiren/Valsartan (Valturna)|Valturna contains two prescription medicines in one tablet that work together to lower blood pressure. It contains aliskerin (Tekturna), a direct rennin inhibitor (DRI), and valsartan (Diovan), an angiotensin II receptor blocker (ARB). Aliskerin reduces the effect of rennin, and the harmful process that narrows blood vessels. It also helps blood vessels relax and widen so blood pressure is lower. Valsartan can help lower blood pressure by blocking a potent chemical, angiotensin II, which leads to blood vessel constriction and narrowing.
3373509|NCT04300140|Experimental|Phase 2 Part C: batiraxcept alone|One dose level of batiraxcept administered Q2W will be evaluated.
3373511|NCT04278781|Experimental|Chondrosarcoma|Participants will have locally advanced/metastatic or recurrent operable chondrosarcoma
3373514|NCT04277546|Experimental|Brazikumab Maintenance Dose|Administer at 4-week intervals through Week 52 Participants who receive IV induction dosing will be administered brazikumab SC at 4-week intervals starting Week 12 through Week 52
3373515|NCT04277546|Experimental|Brazikumab Induction Dose|Administer at Week 0, Week 4, and Week 8
3373516|NCT04274218|Experimental|Walking perturbation - Free|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with both arms free and individuals with amputation will walk with their prosthesis.
3373517|NCT04274218|Experimental|Walking perturbation - Limited|Healthy controls without limb loss and individuals with upper limb loss between the wrist and elbow will receive a treadmill belt disturbance while walking. Able-bodied individuals will walk with one arm bound to their side with straps and individuals with amputation will walk without their prosthesis.
3255248|NCT01432106|Active Comparator|Ramipril|Ramipril (Altace) is an angiotensin-converting enzyme inhibitor (ACEI). It is a chemical compound that helps create a protein named angiotensin II. Angiotensin II can raise blood pressure by causing your blood vessels to narrow. Altace helps lower blood pressure by decreasing the amount of ACE the body makes. Ramipril has been proven by the investigators to stabilize decline in kidney function in African American patients with evidence of damage.
3373521|NCT04254107|Experimental|Monotherapy (Parts A and B)|
3373522|NCT04254107|Experimental|Combination Therapy (Part C)|
3373523|NCT04252625|Active Comparator|Arm 1: Q-Urol|"Patients will be randomized in a 1:1 ratio to receive Q-Urol, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
3373524|NCT04252625|Placebo Comparator|Arm 2: Placebo|"Patients will be randomized in a 1:1 ratio to receive Placebo, two capsules, twice daily for 6 weeks after brachytherapy placement.~Questionnaires will be administered pre- and post-treatment to assess the change in prostatitis symptoms and quality of life measures. The mean values between groups will be compared."
3373525|NCT04252040|Experimental|Active tDCS with guided imagery|Subjects will receive 2 miliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
3373526|NCT04250662|Experimental|Active tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes concurrently while listening to a guided imagery CD specifically designed for women with chronic pelvic pain.
3373527|NCT04250662|Experimental|Active tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for 20 minutes while remaining seated, no guided imagery will be provided.
3373528|NCT04250662|Sham Comparator|Sham tDCS with guided imagery|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject listens to a guided imagery CD specifically designed for women with chronic pelvic pain.
3255249|NCT01432119|Experimental|Arm 1 SIR-Spheres + Cetuximab|"Arm 1: SIR-Spheres with yttrium-90 attached and cetuximab. SIR-Spheres Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
3373529|NCT04250662|Sham Comparator|Sham tDCS alone (no guided imagery)|Subjects will receive 2 milliamps of electrical stimulation to the brain (transcranial direct stimulation-tDCS) for only 30 seconds and then the device will turn off. The device will remain in place, however, for 25 minutes the subject will remain seated, no guided imagery will be provided.
3373530|NCT04247347|Experimental|Self-Management|
3373531|NCT04247347|Active Comparator|Usual Care|
3255250|NCT01432119|Experimental|Arm 2 SIR-Spheres + Cetuximab + Erlotinib.|"Arm 2: SIR-Spheres with yttrium-90 attached, cetuximab, and erlotinib. Physicians will assign patients to Arm 1 or Arm 2 based on their discretion. SIR-Spheres on Day 1 of Cycle 1; Cetuximab start 200 mg/m2 by vein (IV) Weeks 2-4 of Cycle 1, then weekly Cycles 2+. 28-day Cycles. Erlotinib start 100 mg by mouth daily starting with Cycle 2. 28-day Cycles. Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
3255251|NCT01432132||Head & Neck Patients|Patients undergoing surgical treatment for head and neck cancer.
3255252|NCT01432132||Clinicians|Clinical staff who care for head and neck surgical participants during active treatment.
3373536|NCT04236856|Other|Robotic Endovascular Procedure|Subjects with a clinical indication for endovascular coil and/or stent assisted coiling embolization of cerebral aneurysms will be treated using the CorPath GRX System.
3373539|NCT04235413|Experimental|Real-Time Incentives Group|Each participant will be randomized using a blocking procedure (SNAP participant or not). The intervention will last 6 months and consist of receiving real-time financial incentives at the point of purchase for eligible fruits and vegetables purchases.
3373540|NCT04235413|No Intervention|Control Group|No intervention administered. Each participant will be randomized using a blocking procedure (SNAP participant or not).
3373541|NCT04231162|Experimental|probiotic powder, Bifidobacterium lactis|
3373542|NCT04231162|Placebo Comparator|Placebo|
3373543|NCT04223934|Experimental|optima4BP|"Treating physicians receive periodic (every 5-8 weeks) medication treatment recommendations intended to optimize the current patient treatment.~The recommendations are generated based on periodic remote data collected from the patient and from the Electronic Health Record. The analysis of the data allows assessment of the patient's response to current treatment and need for a treatment optimization. If a treatment optimization is needed, one is generated and sent to the treating physician for consideration."
3373544|NCT04223934|No Intervention|Standard of Care (SOC)|The treating physician follows usual care practices.
3373545|NCT04216329|Experimental|1/Experimental therapy|Selinexor with temozolomide and radiation
3255253|NCT01432158|Experimental|PCV-13 group|1 dose of Prevenar-13
3255254|NCT01432158|Experimental|PPV-23 group|1 dose of Pneumovax-II
3255255|NCT01432184|Active Comparator|Intervention|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
3255256|NCT01432184|No Intervention|Control|the cerebral oxymetry screen will be blinded and changes in NIRS values will be unknown to the anesthesiologist. The management of the case will proceed as per normal local practice. The screen will remain blinded in the ICU and the intensivist will not see the values.
3255257|NCT01432197|Experimental|Occupational therapy intervention|"Intervention group: Standard treatment and care added with an ADL intervention program: 1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.~Control group: Standard treatment and care. No occupational therapy intervention."
3255258|NCT01432197|No Intervention|Standard treatment and care|Control group: Standard treatment and care. No occupational therapy intervention.
3255259|NCT01432210|Other|Tomato Meal|A tomato meal will be fed with and without avocado.
3255260|NCT01432210|Other|Carrot Meal|A carrot meal will be fed with and without avocado.
3255261|NCT01432223|Experimental|Nab-paclitaxel|Nab-paclitaxel q3w 260mg/m2
3255262|NCT01432249||Enbrel|The patients who are prescribed Enbrel for pediatric psoriasis
3255263|NCT01432314|Experimental|Treatment group|Child A Hepatocellular carcinoma patients with unilobar portal vein invasion.
3255264|NCT01432340||Vaccinated group|Children between 6months- 10years of age who have received the influenza vaccine
3373556|NCT04213261|Experimental|FCX-007 COL7A1 Genetically-Corrected Autologous Fibroblasts|Intra-subject randomized (paired wounds in each subject receive experimental treatment, FCX-007, or remain untreated). Up to three target wound pairs will be identified for each subject. Following pairing, target wounds will be randomly assigned as the treatment wound (FCX-007 is administered) or control wound. Subjects will receive intradermal injections of FCX-007 in each specified treatment wound in two or more treatment sessions. The first treatment session occurs at Day 1 and the second at Week 12/Month 3. Additional treatment sessions may occur at Week 24/Month 6 and Week 36/Month 9 when unclosed treatment wounds may be re-treated, and unclosed control wounds may be treated.
3373557|NCT04210024|Other|Rural-Dwelling Community Members/Residents|Rural-dwelling adults will be interviewed to map their social network structure, determine the types of social support provided by members of their social network, and identify key players within these networks. A subset of participants (~4) will be identified as Community Health Workers and will receive training with the Diabetes Empowerment Education Program (DEEP).
3255265|NCT01432340||Unvaccinated group|Eligible children between 6months and 10years who didn't receive the influenza vaccine
3255266|NCT01432353|Experimental|Single Arm|
3373560|NCT04206787||Patients with non-small cell lung cancer (NSCLC)|
3255267|NCT01432392||1|
3255268|NCT01432418|Experimental|wheelchair training|
3255269|NCT01432418|No Intervention|Control|Standard of care only
3255270|NCT01432431|Experimental|Supportive care (spiritual care)|See Detailed Description.
3255271|NCT01432470|Experimental|Oxytocin, Intravaginal administration|
3255272|NCT01432470|Placebo Comparator|Placebo, Intravaginal administration|
3255273|NCT01432496|Experimental|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity with the Aeroneb Pro system
3255274|NCT01432496|Placebo Comparator|Saline 15 ml|Nebulization of Saline 15 ml in the peritoneal cavity with the Aeroneb Pro system
3255275|NCT01432522|Experimental|epinephrine IN, epinephrine IM, saline IN|"Intranasal saline~Intramuscular epinephrine~Intranasal epinephrine"
3255276|NCT01432613|Other|MRI-oriented muscle biopsy|Muscle sample will be done following the usual care.
3255277|NCT01432639|Experimental|Experimental group|Patients undergoing the exercise-based cardiac rehabilitation program (intervention)
3255278|NCT01432639|No Intervention|Control group|Usual medical care
3255279|NCT01432652||vascular surgery|Patients undergoing vascular surgery
3255280|NCT01432665|Experimental|Placebo|30 subjects administered a placebo
3255281|NCT01432665|Experimental|sildenafil + testosterone combination drug 1|30 subjects are given combination drug 1 (sildenafil 25mg and testosterone 0.25mg)
3255282|NCT01432665|Experimental|Sildenafil and testosterone combination drug 2|Sildenafil 50mg and testosterone 0.25mg
3373561|NCT04206761|Experimental|Treatment - QVM149|Participants will complete a two week treatment with QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate) 150/50/160 μg delivered as powder in hard capsules via Breezhaler, a breath-activated device which will deliver a specific dose of medication via inhalation.
3373562|NCT04206761|Active Comparator|Control|Participants will continue their clinically prescribed treatment with a high dose dual therapy of Inhaled Corticosteroid (ICS)/Long-Acting Beta2-Agonist (LABA) in any approved drug formulation and delivery device for the treatment period of two weeks. (Participants will continue receiving high dose ICS/LABA therapy at the same dose and in the same formulation as at baseline).
3373563|NCT04203836|Experimental|Fed|Single oral dose given after a full breakfast
3255283|NCT01432665|Experimental|Sildenafil and testosterone combination drug 3|30 subjects are given sildenafil 25mg and testosterone 0.50mg
3255284|NCT01432665|Experimental|Sildenafil and Testosterone Combination drug 4|30 subjects are given sildenafil 50mg and testosterone 0.50mg
3373564|NCT04203836|Experimental|Fasting|Single oral dose given in fasting state
3373565|NCT04194814|Other|crisaborole and topical Corticosteroid|"crisaborole (2%) ointment on the other forearm, twice daily application for 4 weeks (randomised site allocation)~betamethasone valerate (0.1%) cream on one forearm, twice daily application for 4 weeks (randomised site allocation)"
3373566|NCT04189614|Experimental|Cofetuzumab Pelidotin|Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
3255285|NCT01432665|Experimental|Sildenafil 50mg|30 subjects are given sildenafil 50mg
3255286|NCT01432665|Experimental|Testosterone 0.50mg|30 subjects are given testosterone 0.5mg
3255287|NCT01432678||asthma patients|controlled asthma partly controlled asthma uncontrolled asthma
3373573|NCT04185220|Experimental|1- Experimental Treatment: Dose Escalation|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at escalating doses of 2 and 4 mcg/kg/day on days 1-5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle to determine MTD.
3255288|NCT01432691|Other|Surgery|RSA study on hemi
3373574|NCT04185220|Experimental|2- Experimental Treatment: Dose Expansion|Interleukin-15 (IL-15) by continuous intravenous (CIV) infusion at the maximum tolerated dose (MTD) on days 1- 5 of each 28-day cycle (max 6 cycles) with mogamulizumab by intravenous (IV) infusion at a dose of 1 mg/kgdays 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent cycle.
3373577|NCT04180436|Experimental|morbidly obese patients with BMI ≥ 40|Morbidly obese patients with BMI ≥ 40
3373578|NCT04180436|Experimental|Patients operated by gastric bypass|Patients operated by gastric bypass for over a year and with stable weight
3373579|NCT04180436|Experimental|Patients operated by sleeve gastrectomy|Patients operated by sleeve gastrectomy for over a year and with stable weight
3373580|NCT04180436|Experimental|Control group: non-operated subjects|Control group: non-operated subjects but with an age and a BMI corresponding to those of the patients of the 2 operated groups.
3373581|NCT04173273|Experimental|Etrasimod Dose A|
3373582|NCT04173273|Experimental|Etrasimod Dose B|
3373583|NCT04173273|Placebo Comparator|Placebo|
3373584|NCT04164121|Experimental|FLZ-150mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
3373585|NCT04164121|Placebo Comparator|FLZ-150mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 150mg each time from day 8 to day 17.
3373586|NCT04164121|Experimental|FLZ-600mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
3373587|NCT04164121|Placebo Comparator|FLZ-600mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 600mg each time from day 8 to day 17.
3373588|NCT04164121|Experimental|FLZ-900mg experimental|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
3373589|NCT04164121|Placebo Comparator|FLZ-900mg placebo|Oral administration was conducted on an empty stomach, and the drug or placebo was administered once a day on day 1 and 900mg each time from day 8 to day 17.
3373591|NCT04162275|Experimental|pre-trial, fasting administration|2 cases were given 150mg Finamine tablets（pre-trial，fasting administration）
3255289|NCT01432704|Placebo Comparator|placebo capsules|Identically appearing placebo capsules not containing colecalciferol
3255290|NCT01432704|Active Comparator|colecalciferol capsules|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
3373592|NCT04162275|Experimental|pre-trial,after high fat meal|2 cases were given 150mg Finamine tablets (pre- trial，after high fat meal)
3255291|NCT01432717|Experimental|ACE-536|Subjects assigned to 1 of 5 possible dosing groups.
3373593|NCT04162275|Placebo Comparator|formal trial-150mg|4 cases were given 150mg Finamine tablets 2 cases were given placebo
3255292|NCT01432717|Placebo Comparator|Placebo|
3373594|NCT04162275|Placebo Comparator|formal trial-300mg|6 cases were given 300mg Finamine tablets 2 cases were given placebo
3373595|NCT04162275|Placebo Comparator|formal trial-600mg|6 cases were given 600mg Finamine tablets 2 cases were given placebo
3373596|NCT04162275|Placebo Comparator|formal trial-1200mg|6 cases were given 1200mg Finamine tablets 2 cases were given placebo
3373597|NCT04157400|Experimental|Epidural Spinal Cord Stimulation|Subjects with chronic pain that have been scheduled to receive spinal cord simulators for standard of care treatment.
3255293|NCT01432743|Experimental|Cartomerge|Use of Cartomerge to guide ablation
3255294|NCT01432743|Active Comparator|NavX Fusion|Use of NavX fusion to guide ablation
3373599|NCT04147234|Experimental|Arm A: BI 1387446|superficial lesions
3373600|NCT04147234|Experimental|Arm B: BI 1387446 in combination with ezabenlimab (BI 754091)|superficial lesions
3373601|NCT04147234|Experimental|Arm C: BI 1387446 in combination with ezabenlimab (BI 754091)|deep lesions
3373604|NCT04145622|Experimental|Dose escalation|All participants enrolled in the dose escalation part
3373605|NCT04145622|Experimental|Dose expansion|All participants enrolled in the dose expansion part
3373607|NCT04143204||very preterm infants cohort|A prospective cohort of very preterm or very low birth weight infants from birth to corrected age 18 months.
3373608|NCT04138823|Experimental|Part A: BI 891065 followed by Part B: BI 891065 + BI 754091|
3373610|NCT04137120||Patients_Ocular disease|Adult patients treated for wet age-related macular degeneration (wAMD), or diabetic macular edema (DME), or macular edema secondary to central retinal vein occlusion (CRVO), or macular edema secondary to branch retinal vein occlusion (BRVO) or myopic choroidal neovascularization (mCNV) in routine clinical practice in Mexico (overall cohort)
3373611|NCT04133623|Experimental|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
3373612|NCT04133623|Active Comparator|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
3373613|NCT04132141|Other|VR intervention|each subject will be own control. subjects breaks will be randomly assigned to VR or WT until they complete 3 for each type or a total of 6
3373614|NCT04129931|Experimental|Medium Chain Triglycerides (MCT)|Participants in this arm will receive Medium Chain Triglycerides (MCT) powder packets (10 g each) at each treatment visit at any point in the study. Participants will mix 1-2 packets of MCT supplement powder into liquids or semi-solid food and ingest 3 times a day during the 16-week treatment period. Participants will be randomized to the treatment sequence and will receive either the active MCT or the matching placebo first or vice versa.
3373615|NCT04129931|Experimental|Clazakizumab|Participants randomized to this arm will receive a 12.5 mg dose of Clazakizumab via a subcutaneous injection at every study visit, every 4 weeks, during the 16-week treatment period at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Clazakizumab or the matching placebo first or vice versa.
3373616|NCT04129931|Experimental|Broncho-Vaxom|Participants randomized to this arm will receive 7 mg of Broncho-Vaxom once a day on an empty stomach for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Broncho-Vaxom or the matching placebo first or vice versa.
3255295|NCT01432769|Active Comparator|individualized diet|patients will receive a diet individualized to their calorie and protein requirements besides to dietary supplementation with a polymeric formula
3255296|NCT01432769|No Intervention|standardized diet|"patients in the standardized diet will receive the dietary management established by the hospital"
3255297|NCT01432782|Placebo Comparator|Placebo|Placebo arm: per-endoscopic injection of saline
3255298|NCT01432782|Active Comparator|Botulinum toxin|Botulinum toxin (Botox) 100 u in 4 ml, injected per-endoscopically
3255299|NCT01432795|Experimental|Test series of 6 types of gliding aids|"Each study subjects tests a series of gliding aids or stocking butlers:~4 gliding aids~2 stocking butlers, one with and without handle~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed stockings with closed tip, compression class 1 (18-21 mmHg)"
3255300|NCT01432821|Experimental|Apomorphine|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~-sequence A: 1 mg/kg and then 5 mg/kg of apomorphine"
3255301|NCT01432821|Placebo Comparator|Saline|"After randomization healthy volunteers or patients with idiopathic generalized epilepsy receive:~sequence B: 2 injections of saline"
3255302|NCT01432834|Other|LASIK group (LG group)|Volunteers of this group received LASIK treatment.
3373617|NCT04129931|Experimental|Imatinib|At any point in the study, participants randomized to this arm will take two 100 mg Imatinib tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Participants will then take four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Participants will be randomized to the treatment sequence and will receive either the active Imatinib or the matching placebo first or vice versa.
3373618|NCT04129931|Experimental|Cavosonstat|Participants randomized to this arm will take one 50 mg Cavosonstat capsule orally twice a day for the 16-week treatment period duration at any point in the study. Participants will be randomized to the treatment sequence and will receive either the active Cavosonstat or the matching placebo first or vice versa.
3373619|NCT04129528|Active Comparator|CFZ533|Randomized in a 2:1 ratio: 2 Active / 1 Placebo
3255303|NCT01432834|Other|PRK group (PG group)|Volunteers of this group received PRK treatment
3373620|NCT04129528|Placebo Comparator|Placebo|Similar in appearance to active study drug
3373621|NCT04126733|Experimental|Regorafenib + Nivolumab|
3373622|NCT04122976||Men with nmCRPC|Men with nmCRPC for whom a decision to treat with darolutamide has been made before enrollment, and who have signed informed consent, will be eligible for the study.
3373623|NCT04120545|Experimental|Microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
3373624|NCT04120545|Placebo Comparator|Placebo microcurrents|Intervention with microcurrents: application of 6 electrodes per extremity and an adhesive electrode at C7, L3 or S1 level depending on the session number.
3373625|NCT04119713||Study Population|Adult patients with a diagnosis of cancer receiving checkpoint inhibitor therapy at the University of Pennsylvania's Abramson Cancer Center (ACC).
3373626|NCT04118036|Experimental|Surgery Arm|"In the surgical arm participants who require reoperation and have evidence of CDKN2A/B or C loss and intact RB from a prior tumor sample will receive~Pembrolizumab-prior to surgery, at predetermined dose and time point~Abemaciclib: every 12 hours from the day of pembrolizumab infusion to the morning of surgery~Post surgery Participants with receive~Abemaciclib, twice daily oral at specified dose for 21 day cycle~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
3373627|NCT04118036|Experimental|Non Surgery Arm|"The treatment arm will be comprised of participants not requiring surgery.~- Participants will receive treatment with~Abemaciclib, twice daily oral at specified dose for 21 day cycle~Pembrolizumab intravenous once in 21 day cycle (3 weeks)"
3255306|NCT01432860|Active Comparator|In-person Counseling and Education|In the in-person training the Research Assistant demonstrates the use of a mm ruler, a lighted magnifying lens, a set of body maps and a scorecard, 4 pens, ABCDE rule on the skin exam card and discusses the ABCDE rule by pointing to the color examples on the skin exam card. 165 pairs (330 subjects) are randomized to this arm.
3255307|NCT01432860|Active Comparator|Workbook|The workbook, which includes all of the information delivered in the in-person intervention, is 39 pages in length, and has 76 color figures. Each element of the in-person training represents a chapter in the workbook. The introduction explores the partners' understanding of melanoma and their personal risk of developing another melanoma, and attitudes about the benefit of early detection assisted by a partner. The early detection segment uses a skin diagram to illustrate the difference between thin and thick melanoma and presents the treatment based on the depth of the melanoma. 165 pairs (330 subjects) are randomized to this arm.
3255308|NCT01432860|No Intervention|Control|Education and counseling as usually delivered in clinical practice. 100 pairs (200 subjects) are randomized to this arm.
3373628|NCT04111458|Experimental|BI 1701963 monotherapy|
3373629|NCT04111458|Experimental|BI 1701963 + Trametinib|
3373630|NCT04106986|Experimental|PEMF and PRE|The PEMF and PRE group received 24 sessions (3 sessions/week for 8 weeks) of combined treatment group (pulsed electromagnetic field with PRE training)
3373631|NCT04106986|Experimental|PRE|The PRE group received 24 sessions (3 sessions/week for 8 weeks) of only progressive resistance exercise
3373632|NCT04106570|Experimental|YOMH|Young obese metabolically healthy Description: Aged from 20 to 40 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l.
3373633|NCT04106570|Experimental|YOMD|"Young obese with metabolic disorders~Description: Aged from 20 to 40 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
3259510|NCT01471496|Experimental|prophylactic injection therapy group|In addition to medical therapy which included 2x 30 mg Pantoprazole and intravenous fluids this group of the patients recieved injection therapy.
3373634|NCT04106570|Experimental|MAOMH|"Middle-Age obese metabolically healthy~Description: Aged from 40 to 50 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
3373635|NCT04106570|Experimental|MAOMD|Middle-Age obese with metabolic disorders Description: Aged from 40 to 50 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l.
3373636|NCT04106570|Experimental|EOMH|"Elderly obese metabolically healthy~Description: Aged from 50 to 70 years old and with a glycemia < 1g/l and a triglyceridemia < 1,5g/l."
3373637|NCT04106570|Experimental|EOMD|"Elderly obese with metabolic disorders~Description: Aged from 50 to 70 years old and with a glycemia > 1g/l and a triglyceridemia > 1,5g/l."
3373638|NCT04102098|Experimental|Arm A (atezolizumab plus bevacizumab)|Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity.
3373639|NCT04102098|No Intervention|Arm B (active surveillance)|Active surveillance of participants.
3373640|NCT04099251|Experimental|Nivolumab|
3373641|NCT04099251|Placebo Comparator|Placebo|
3373642|NCT04098276|Experimental|Online weWomen Intervention|For first stage randomization, women in the intervention group receive the online safety planning intervention informed by culturally specific danger assessment (DA) tool.
3373643|NCT04098276|No Intervention|Online usual care or no treatment control|Women in the control group receive the non-DA informed usual safety planning resources modeled on national and state domestic violence online resources, but not provided with immediate and visual feedback to their level of danger or a tailored safety planning.
3255309|NCT01432860|Active Comparator|Tablet Computer-Based Education|Education will be given by an interactive tablet app. Each pair will view video recordings of certain parts of the in-person presentation as well as select slides from the in-person PowerPoint presentation. Parts of the workbook will be incorporated as well. 70 pairs (140 subjects) are randomized into this arm.
3255310|NCT01432873|Experimental|Experimental|Oral selenium therapy arm
3373644|NCT04098276|Experimental|WeWomen Plus Text messaging only|For second stage randomization, the text messaging intervention will follow-up with non-responder group of immigrant women (those who did not improve in intervention or control arms above) on their enactment of tailored (tailored to the DA Score and priorities) safety plan provided in the online weWomen intervention or non-tailored (standard list of resources) safety recommendations provided in the usual care control arm
3373645|NCT04098276|Experimental|WeWomen Plus Text messaging and phone|Second stage randomization will involve both text (described above) and phone calls for non-responder group of women in intervention or control arm. The phone calls will draw from motivational interviewing adapted for abused women, solution focused therapy and a strengths perspective to discuss women's safety concerns and other needs, and strategies to strengthen social support networks
3373646|NCT04094688|Experimental|Arm I (bevacizumab, chemotherapy, high-dose vitamin D3)|Patients receive bevacizumab IV over 30-90 minutes on day 1 and oxaliplatin IV over 2 hours on day 1, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV on days 1-3 or irinotecan hydrochloride IV on day 1, leucovorin calcium IV over 90 minutes on day 1, and fluorouracil IV on days 1-3. Patients also receive high-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
3255311|NCT01432873|Placebo Comparator|Placebo|Oral placebo
3255312|NCT01432912|No Intervention|Patients|
3255313|NCT01432925|Other|evaluation surgical intervention at week 8|
3255314|NCT01432925|Other|evaluation surgical intervention at week 14|
3373647|NCT04094688|Active Comparator|Arm II (bevacizumab, chemotherapy, standard-dose vitamin D3)|Patients receive bevacizumab and chemotherapy as in Arm I. Patients also receive standard-dose cholecalciferol PO QD on days 1-14. Cycles repeat every 14 days for 5 years in the absence of disease progression or unacceptable toxicity.
3373648|NCT04093752|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly.
3373649|NCT04093752|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once weekly.
3373650|NCT04093752|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once weekly.
3255315|NCT01432964||1|Adult patients (>18 years) presenting a unilateral orbital blow-out or blow-in fracture of ≥ 2.0cm2, causing an actual or expected functional or aesthetical deficit.
3373651|NCT04093752|Active Comparator|Insulin Glargine|Insulin glargine administered SC once daily.
3373659|NCT04086082|Experimental|Markerless Image Guidance Arm|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
3255316|NCT01432977|Active Comparator|comparateur|paracetamol / droperidol
3255317|NCT01432977|Experimental|Eperimental|paracetamol / ondansetron
3255318|NCT01432990|Experimental|robotic gait training|conventional physical therapy plus robot gait training program for SCI patients.
3255319|NCT01432990|No Intervention|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
3255320|NCT01433003|Active Comparator|Standard-dose plasma exchange|50-75 ml/kg/day
3255321|NCT01433003|Experimental|High-dose Plasma Exchange|125 ml/kg/day up to 10 L/day
3255322|NCT01433029||Conventional Rater (CR)|CR Group receives conventional training from PI about how to rate coronary artery bypass (CAB) videos.
3255323|NCT01433029||Video Rater (VR)|VR Group receives conventional training from PI about how to rate CAB videos, along with a video rater training manual.
3255324|NCT01433029||CAB Recording|CAB recording of performance cardiothoracic surgeon or surgical trainee in 1st, 2nd, or 3rd year of training.
3255325|NCT01433068|Experimental|NBTXR3|
3373666|NCT04067310|Experimental|Group Experimental|Participants who will use the spray skin protector
3373667|NCT04067310|Active Comparator|Group control|Participants who will use moisturizer containing in its composition calendula officinalis
3373668|NCT04066959|Experimental|Question Prompt List (QPL)|A QPL is a simple, inexpensive communication tool that is comprised of list of questions related to the physical and psychosocial aspects of an illness and treatment components about which patients may want to ask their diabetes care team during a routine diabetes clinic visit.
3373669|NCT04066959|Experimental|Motivation Enhancement System (MES)|MES is a brief, 2-session computer-delivered intervention to enhance intrinsic motivation for behavior change. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. Session 1 begins with psychoeducation describing optimal diabetes self-management, then youth motivation for diabetes self-management is assessed and followed by exercises designed to increase or reinforce his/her current motivational state (e.g., decisional balance) and build self-efficacy, (e.g., building on strengths and past success). Session 1 concludes with goal setting to promote autonomous diabetes self-management. Session 2 begins with an assessment of progress toward the behavioral goal and proceeds to build motivation and self-efficacy with exercises consistent with the youth's current motivational state. Session 2 concludes with goal setting to promote autonomous diabetes self-management.
3373670|NCT04066959|Experimental|Text Message Reminders (TXT)|Participants will receive 30 days of one-way text messages targeting one of three key daily diabetes care behaviors: monitoring blood glucose, insulin administration, or carbohydrate counting. Participants will set a reminder schedule, i.e., frequency and timing of text message reminders.
3373671|NCT04066959|Experimental|QPL & MES|Participants will receive the QPL and MES interventions as described above.
3373672|NCT04066959|Experimental|QPL & TXT|Participants will receive the QPL and TXT interventions as described above.
3373673|NCT04066959|Experimental|MES & TXT|Participants will receive the MES and TXT interventions as described above.
3373674|NCT04066959|Experimental|MES, QPL & TXT|Participants will receive the MES, QPL, and TXT interventions as described above.
3373675|NCT04066959|No Intervention|Standard Medical Care|Participants will receive standard medical care at one of two participating clinical sites. Clinical practices at these sites are consistent with the standards of T1D care recommended by the American Diabetes Association and will include diabetes clinic visits every 3-4 months for routine diabetes medical care provided by an endocrinologist and/or nurse practitioner.
3373676|NCT04066244|Other|Cohort 1|Dose 1 of BLZ945
3373677|NCT04066244|Other|Cohort 2|Dose 2 of BLZ945
3373678|NCT04066244|Other|Cohort 3|Dose 3 of BLZ945
3373679|NCT04066244|Other|Cohort 4|Dose 4 of BLZ945
3373680|NCT04066244|Other|Cohort 5|Dose 5 of BLZ945
3373681|NCT04060134||HADM|Patients who had human acellular dermal matrix used in their breast reconstruction procedure.
3373682|NCT04055428|Experimental|Sacubitril/Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
3373683|NCT04055428|Active Comparator|Valsartan|We will enroll 100 adult Black individuals. Each participant will take the assigned dose of medication twice daily for 12 weeks. We evaluate insulin sensitivity and energy expenditure at baseline and after 12 weeks of intervention.
3373684|NCT04054947|Experimental|Suicide Prevention Program|
3373685|NCT04054947|No Intervention|Usual Care|
3255326|NCT01433094|Experimental|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving
3373690|NCT04044456|Experimental|GMT plus attention|GMT consists of 2-hour, 10 weekly sessions using an interactive Power Point presentations. Attention training consists of 2-hour computerized attention training using Attention Process Training III and Brain HQ.
3373691|NCT04044456|Placebo Comparator|BHW plus movies|Brain Health Workshop consists of 2-hour, 10 weekly sessions using Power Point presentations and national geographic movies (2-hour, 10 weekly sessions).
3255327|NCT01433094|Active Comparator|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
3255328|NCT01433120|Experimental|Probiotic L. casei F19|
3255329|NCT01433120|Experimental|Flax seed fibres|
3255330|NCT01433120|Placebo Comparator|Placebo|
3255331|NCT01433133|Experimental|1|• Genotype 3 chronic HCV with detectable serum HCV RNA
3255332|NCT01433185|Experimental|Text message (SMS)|Text messages sent to women before and after delivery
3255333|NCT01433185|No Intervention|Usual care (current standard of care)|Current standard of care for women enrolled in PMTCT programs
3373698|NCT04040348|Experimental|hMSC Treatment group|Participants in the hMSC treatment group will receive a total of 4 doses of the hMSC intervention. Each dose will be administered once about every 13 weeks within a year period.
3255334|NCT01433198|Active Comparator|Aquatic exercise group|
3255335|NCT01433198|No Intervention|Control group|
3373701|NCT04032704|Experimental|Ladiratuzumab Vedotin|SGN-LIV1A monotherapy
3373702|NCT04031456|Experimental|Participants receiving PRP treatment|Women presenting with POI, 25-39 years of age, treated with autologous PRP intra ovarian infusion
3373703|NCT04031456|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP) treatment|Women presenting with POI, 25-39 years of age, treated with autologous PFP intra ovarian infusion
3255336|NCT01433211||No treatment|
3373707|NCT04023487|Experimental|Lifestyle Intervention|Resilient, Empowered, Active Living-Telehealth (REAL-T)
3373708|NCT04023487|No Intervention|Usual Care|Participants will continue to have access to routine diabetes care from the provider of their choosing; they will not receive any study-related intervention.
3373709|NCT04009512|Experimental|Primary Study Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
3373710|NCT04009512|Experimental|Expanded Use Arm|The Valiant Thoracoabdominal Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcate and the Visceral Manifold. These devices work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments. The expanded use arm provides broaden inclusion criteria to include select patients excluded from the primary study arm.
3373711|NCT03998293|Other|proinsulin clearance|all participants will be studied once where somatostatin will be used to block endogenous insulin secretion
3373712|NCT03995966|Active Comparator|Subtype 2 Automatically Maintained SIB|
3373713|NCT03995966|Active Comparator|Subtype 3 Automatically Maintained SIB|
3373715|NCT03978806|Active Comparator|peer navigator|The first PN visit will take place within 1-2 weeks of consent. Each of the 5 subsequent PN visits will take place every 1-2 weeks. We expect patients to complete the intervention within 2-3 months of consent. The function of the initial visit is to establish trust and ensure a more personal approach with participants. The community-based PN intervention is grounded in core Latino values (e.g. trust, personalized relationships). The core elements of the PN intervention include patient motivational interviewing as well as patient activation, empowerment (e.g. help with scheduling of healthcare appointments and re-scheduling of missed HD sessions), education (e.g. education of ESKD and need for renal replacement therapy), and social challenges (e.g. access to resources for transportation, benefits, immigration issues). The duration, individuals present during the visit, and content discussed will be documented in the visit form.
3373716|NCT03978806|Placebo Comparator|Control Arm (standard of care)|Standard of care
3255337|NCT01433276|Experimental|Totilac|
3255338|NCT01433276|Active Comparator|Ringer's lactate|
3255339|NCT01433289|Experimental|Polyphenon E 1600 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Four capsules twice a day.
3255340|NCT01433289|Experimental|Polyphenon E 2400 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Six capsules twice a day.
3255341|NCT01433289|Experimental|Polyphenon E 3200 mg/day|Drug: Polyphenon E Polyphenon E capsules containing 200 mg of epigallocatechin-gallate. Eight capsules twice a day.
3373719|NCT03972150|Experimental|Part I: BI 836880 alone|Part I followed by Part II
3373720|NCT03972150|Experimental|Part II: BI 836880 and BI 754091|
3255342|NCT01433302||Punch Biopsy|
3255343|NCT01433315|Experimental|sleep restriction|restricted sleep during the experimental period
3255344|NCT01433315|No Intervention|normal sleep|normal sleep during the experimental period
3255345|NCT01433328|Experimental|Lidocaine|
3255346|NCT01433328|Placebo Comparator|Placebo|Remodulin only
3255347|NCT01433341||Young athletes|
3255348|NCT01433367||CerPass® Total Disc Replacement|
3255349|NCT01433380|Experimental|600 mg PF-05175157|Subjects will receive one dose of PF-05175157. The sequence of receiving 600 mg PF-05175157 or placebo will be randomized.
3373721|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091|All neoplasms
3373722|NCT03964233|Experimental|Dose Expansion - Cohort 1-Arm A -BI 907828+BI 754091|NSCLC
3373723|NCT03964233|Experimental|Dose Expansion - Cohort 1 - Arm B - BI 907828|NSCLC
3373724|NCT03964233|Experimental|Dose Expansion - Cohort 2 - BI 907828 + BI 754091|Melanoma
3373725|NCT03964233|Experimental|Dose Expansion - Cohort 3 - BI 907828 + BI 754091|Liposarcoma
3373726|NCT03964233|Experimental|Dose Expansion - Cohort 4 - BI 907828 + BI 754091|Hepatocellular carcinoma
3373727|NCT03964233|Experimental|Dose Escalation - BI 907828 + BI 754091 + BI 754111|All neoplasms
3373728|NCT03962998|Active Comparator|Lactulose/Rhamnose|1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution
3373729|NCT03962998|Experimental|MB-102|4 μmol of MB-102/kg body weight administered orally as a solution
3373730|NCT03960892|Experimental|E-CAU with Group Problem Management Plus (PM+)|"190 participants will be randomly assigned to E-CAU with Group PM+. The PM+ is developed by the World Health Organization (WHO) especially for the communities who are exposed to adversity. PM+ (Dawson et al., 2015) belongs to a set of programs which are low-intensity, shorter, less expensive and trans-diagnostic (i.e., not condition-specific, but targeted at a broader set of symptoms of common mental disorders) programs to reduce common mental health symptoms (including depression, anxiety and stress symptoms) and improve psychosocial functioning.~The participants in the experimental arm will receive Group PM+ by trained, non-specialist peer-refugees in addition to E-CAU."
3373731|NCT03960892|No Intervention|Enhanced care as usual (E-CAU) only|190 participants will be randomly assigned to E-CAU group. CAU ranges from the free health services government provides to Refugee and Asylum Seekers Assistance and Solidarity Association's (RASASA) mental health services which are provided by the Psychological Support Unit (MHPSS Support Unit) which includes counselling as well. The enhanced care arm (CAU, with the addition of a leaflet which will include information on the services that they can get from RASASA and other public services. ), is to be used as a benchmark for measuring the effectiveness of STRENGTHS's intervention, which is Problem Management Plus (PM+).
3255350|NCT01433380|Placebo Comparator|Placebo|Subjects will receive one dose of placebo. The sequence of receiving placebo or 600 mg PF-05175157 will be randomized.
3255351|NCT01433393|Experimental|TAK-875 25 mg|
3255352|NCT01433393|Experimental|TAK-875 50 mg|
3255353|NCT01433393|Placebo Comparator|Placebo|
3255354|NCT01433406|Experimental|TAK-875 25 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3373735|NCT03951194|Experimental|Participants receiving PRP treatment|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
3373736|NCT03951194|Placebo Comparator|Participants receiving Platelet Free Plasma (PFP)|Perimenopausal women, 40-50 years of age, treated with autologous PRP intra ovarian infusion.
3373737|NCT03950414|Experimental|Tier 1|3 participants enrolled at dose level 5x10^3 cells/kg of CMV viral specific T-cells
3373738|NCT03947255|Experimental|Brentuximab vedotin|
3373742|NCT03937661|Experimental|Group of participants receiving PRP treatment|Women presenting with POR, treated with autologous PRP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period.
3373743|NCT03937661|Placebo Comparator|Control Group: participants receiving Platelet Free Plasma|Women presenting with POR, treated with autologous PFP intra ovarian infusion and undergoing a subsequent fresh ET-ICSI cycle on the third month of the follow-up period
3373744|NCT03932968||Symptomatic pain|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry during 24 hours will be performed.
3373745|NCT03932968||Control|patients after a sleeve gastrectomy without symptomatic pain
3373746|NCT03931187|Experimental|Women intervention arm|Intervention will be applied to the women within the couple.
3373747|NCT03931187|Experimental|Couple intervention arm|Intervention will be applied to the couple, both men and women.
3373748|NCT03931187|No Intervention|Control arm|The couple will receive the normal nursing care.
3373750|NCT03925246|Experimental|Nivolumab|Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 weeks for 8 doses (4 months), followed by a 60 minutes intravenous infusion at dose of 480 mg every 4 weeks for 8 doses (8 months) or until progression, death , unacceptable toxicity or end of the research.
3255355|NCT01433406|Experimental|TAK-875 50 mg|(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
3255356|NCT01433419|Experimental|TAK-875 25 mg|
3255357|NCT01433419|Experimental|TAK-875 50 mg|
3255358|NCT01433432|Active Comparator|Purinethol|Subjects who previously received 12 weeks of Purinethol (at 1-1.5 mg/kg)in the original study will now receive 80 mg DR-6MP (2 x 40 mg tablets) once dailyh, in the evening, for an additional 12 weeks
3259511|NCT01471496|No Intervention|control group|This group of the patients recieved medical therapy only.
3373753|NCT03916978|Experimental|Participants receiving PRP treatment|Menopausal women minimum 45 years of age, receiving ovarian PRP treatment.
3373754|NCT03916978|Placebo Comparator|Control Group: Participants receiving Platelet Free Plasma|Women in menopause, 45-55 years old, treated with autologous PFP intra ovarian infusion.
3373755|NCT03915951|Experimental|Treatment Period|"Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.~Patients will receive the following per 28-day (± 3 days) cycle:~Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)~Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)"
3255359|NCT01433432|Experimental|Test Drug|Subjects who previously received test drug (80 mg DR-6MP) for 12 weeks in the original study, will continue to receive 80 mg DR-6MP (2 x 40 mg tablets) once daily, in the evening, for an additional 12 weeks
3255360|NCT01433445|Experimental|Cohort 1|Subjects will be treated with ruxolitinib 5 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3255361|NCT01433445|Experimental|Cohort 2|Subjects will be treated with ruxolitinib 10 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3255362|NCT01433445|Experimental|Cohort 3|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 10 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3255363|NCT01433445|Experimental|Cohort 4|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 15 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3373758|NCT03914105|Active Comparator|Without music|Test without music
3373759|NCT03914105|Experimental|With music|
3373768|NCT03891888|No Intervention|Control|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
3373769|NCT03891888|Experimental|Intervention|Patients in this group will receive a bone graft in addition to the undergoing standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing)
3255364|NCT01433445|Experimental|Cohort 5|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 20 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3255365|NCT01433445|Experimental|Cohort 6/6+|Subjects will be treated with ruxolitinib 15 mg twice daily (BID) and panobinostat 25 mg three times per week (TIW) every other week (QOW) on a 28 day cycle
3255366|NCT01433458|Experimental|RLX030: Group 1 mild hepatic impairment|Patients with mild hepatic impairment will receive a single IV 24 hour infusion of RLX030
3255367|NCT01433458|Experimental|RLX030: Group 2 moderate hepatic impairment|Patients with moderate hepatic impairment will receive a single IV 24 hour infusion of RLX030
3255368|NCT01433458|Experimental|RLX030: Group 3 severe hepatic impairment|Patients with severe hepatic impairment will receive a single IV 24 hour infusion of RLX030
3255369|NCT01433458|Active Comparator|RLX030: Group 4 - healthy volunteers|Participants will receive a single IV 24 hour infusion of RLX030. This group will consist of 3 sub-groups to match patients of groups 1, 2and 3.
3255370|NCT01433484|Active Comparator|Maintenance of Weight Loss--Control|The control arm will receive bi-monthly telephone contacts during the one-year maintenance phase.
3255371|NCT01433484|Experimental|Maintenance of Weight Loss--Experimental|The experimental arm will receive monthly telephone contacts for one year during the maintenance phase.
3259512|NCT01471509|Placebo Comparator|Control|240 ml water
3255372|NCT01433497|Experimental|Experimental Arm A|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily.
3373770|NCT03890536||Biliary atresia|Biliary atresia is an obstructive cholangiopathy of infancy. It is the most common cause of neonatal cholestasis and the most frequent indication for liver transplantation in children. Patients with biliary atresia have conjugated hyperbilirubinemia (serum direct bilirubin > 1mg/dL) AND are scheduled for/undergo exploratory laparotomy for diagnosis and Kasai portoenterostomy for surgical treatment of BA.
3373771|NCT03890536||Non-BA=disease controls|All infants with other cholestatic syndromes (except biliary atresia) will be eligible for study enrollment in disease controls/non-biliary atresia. This involves the diagnosis of liver diseases caused by syndromes of intrahepatic cholestasis with or without hyperbilirubinemia.
3373772|NCT03890536||Normal|All healthy infants with no acute or chronic liver related illness.
3373778|NCT03878251|Other|X fragile syndrome patients|
3255373|NCT01433497|Experimental|Experimental Arm B|Participants receive masitinib (4.5 mg/kg/day), given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment.
3255374|NCT01433497|Placebo Comparator|Placebo Comparator A|Participants receive placebo given orally twice daily.
3373779|NCT03878251|Other|Angelman syndrome patients|
3373780|NCT03878251|Other|Rett syndrome patients|
3373781|NCT03878251|Other|Patients with other genetic rare syndromes with intellectual d|
3373783|NCT03864614|Experimental|SAGE-217|
3255375|NCT01433497|Placebo Comparator|Placebo Comparator B|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment.
3255376|NCT01433510|Experimental|Grazax Tablets 75000 SQT|Timothy Extract
3255377|NCT01433523|Placebo Comparator|Placebo|
3255378|NCT01433523|Experimental|ALK HDM AIT 6 DU|
3255379|NCT01433523|Experimental|ALK HDM AIT 12 DU|
3255380|NCT01433536||cranial trauma and fracture|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3255381|NCT01433536||cranial trauma|Individuals presenting a cranial trauma that are classified at equal to or less than 8 on the Glasgow scale
3255382|NCT01433536||spinal trauma with fracture|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C, combined with a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3255383|NCT01433536||spinal trauma|Individuals presenting a spinal fracture that are classified with an ASIA score of A, B, or C
3373785|NCT03859973|Experimental|BI 425809|Active drug treatment arm
3373786|NCT03859973|Experimental|Placebo|Placebo drug arm
3373787|NCT03851107|Experimental|Community-based activity program|Engagement in 6-week community-based activity program
3373788|NCT03844347|Experimental|C-Bien|
3373789|NCT03844347|No Intervention|Control|
3373790|NCT03842930|Other|Platinum-fibered Microcoils (FPC)|Embolization using platinum fibred Coils (Cook Incorporated, Bloomington, IN, USA)
3373791|NCT03842930|Other|MVP® Vascular Plug|Embolization using MVP®-Plug (Medtronic Inc., Minneapolis, MI, USA).
3255384|NCT01433536||high velocity fracture, inferior limb|Individuals that present a fracture to the femur, tibia, or pelvis resulting from a high-velocity impact
3255385|NCT01433536||Control|Healthy individuals
3255386|NCT01433562|Experimental|DLBS1425|
3255387|NCT01433562|Placebo Comparator|Placebo|
3255388|NCT01433575|Experimental|A|
3255389|NCT01433575|Experimental|B|
3255390|NCT01433588|Active Comparator|Calmer|This therapeutic platform, called the Calmer interacts with the infant to help reduce stress to help promote better outcomes. It is being tested to see if it mimics Kangaroo care, maternal skin to skin, to help promote better health outcomes. Infants would be placed on it prior, during and after bloodwork to see if it elicits a favorable response.
3255391|NCT01433588|Placebo Comparator|Standard Care|Standard of care during bloodwork is receiving a soother and facilitated tucking.
3255392|NCT01433601|No Intervention|Self Supervised Treatment (SST)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. The patient is self responsible to take the drugs and no additional adherence support is provided.
3255393|NCT01433601|Experimental|Enhanced Treatment Support (ETS)|Treatment according to the National Treatment Guidelines in Vietnam including treatment counseling before initiation of ART and clinical follow up every 3 months. In addition adherence support is provided according to the description under intervention.
3255394|NCT01433614|Active Comparator|Epirubicin + paclitaxel (Taxol)|Epirubicin 75mg/m2 i.v., paclitaxel 175 mg/m2 i.v. on day 1 every 21 days.
3255395|NCT01433614|Active Comparator|Paclitaxel + epirubicin + capecitabine|Paclitaxel 155 mg/m2 i.v., epirubicin 75 mg/m2 i.v day 1, capecitabine 1650 mg/m2 p.o. on days 1-14 every 21 days.
3255396|NCT01433627|Experimental|trans-radial and short-term Bivalirudin|Patients will be randomized to receive a trans-radial intervention and concomitant bivalirudin infusion. bivalirudin will be stopped at the end of PCI.
3259513|NCT01471509|Active Comparator|glucose|50 g glucose
3259514|NCT01471509|Active Comparator|Amino acid|1 mmol amino acid/kg lean body mass
3259515|NCT01471509|Active Comparator|amino acid plus glucose|50 g glucose plus 1 mmol amino acid/kg lean body mass
3373792|NCT03840993|Experimental|MT-2990|MT-2990, IV, over 16 weeks
3373793|NCT03840993|Placebo Comparator|Placebo|Placebo, IV, over 16 weeks
3373794|NCT03836261|Experimental|Acalabrutinib, Venetoclax|Acalabrutinib in combination with Venetoclax
3373795|NCT03836261|Experimental|Acalabrutinib, Venetoclax, Obinutuzumab|Acalabrutinib in combination with Venetoclax with or without Obinutuzumab
3373796|NCT03836261|Active Comparator|Chemoimmunotherapy|"Chemoimmunotherapy~FCR: Fludarabine, Cyclophosphamide and Rituximab"
3373797|NCT03831048|Experimental|DCD Heart Possible|
3373798|NCT03831048|Active Comparator|Standard of Care Heart Only|
3255397|NCT01433627|Experimental|trans-radial and long-term bivalirudin|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
3255398|NCT01433627|Experimental|trans-radial and standard of care pharmacology|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~unfractionated heparin (UFH) which may be followed by the addition of a glycoprotein IIb/IIIa inhibitor"
3255399|NCT01433627|Experimental|trans-femoral and short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
3373806|NCT03816839|Experimental|SAR439859|administered orally once daily or twice daily as monotherapy in fasted or fed state
3373807|NCT03816345|Experimental|Treatment (nivolumab)|Patients receive nivolumab IV over 30 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
3255400|NCT01433627|Experimental|Trans-femoral and long-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
3255401|NCT01433627|Active Comparator|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
3255402|NCT01433640||Contrast-enhanced Mammography|Subjects will undergo 2D imaging with iodine contrast.
3373810|NCT03815175|Experimental|XIENCE|XIENCE + 1 month DAPT
3373811|NCT03813459||Subsyndromal delirium positive|Presence of Subsyndromal delirium in Intensive Care patients
3373812|NCT03813459||Delirium positive|Presence of Delirium in Intensive Care patients
3373813|NCT03813459||No delirium|Non subsyndromal delirium or delirium in Intensive Care patients
3255403|NCT01433640||Contrast-enhanced Breast Tomosynthesis|Subjects will undergo 3D imaging with iodine contrast.
3255404|NCT01433640||Contrast-enhanced MRI|Each subject imaged with iodine contrast will also be imaged with contrast-enhanced MRI using gadolinium.
3255405|NCT01433653|Experimental|CG-CBT|
3255406|NCT01433653|No Intervention|wait list control|
3255407|NCT01433666|Experimental|roflumilast 100ug|
3255408|NCT01433666|Experimental|roflumilast 300ug|
3255409|NCT01433666|Experimental|roflumilast1000ug|
3255410|NCT01433666|Placebo Comparator|placebo|
3255411|NCT01433679|Experimental|Website intervention|Participants randomly assigned to the Website Intervention arm receive access to the motivational rewards website. The website displays the individual's physical activity data and allocates reward points based on the amount and intensity of physical activity. The website also allows reward points to be redeemed for various rewards such as gift cards to retail outlets, donations to charities, small tangible goods, and customization of participants' cartoon-like avatars on the website.
3255412|NCT01433679|No Intervention|Control|Participants in the control group will not have access to the motivational website. No other product or intervention will be introduced to the control group.
3373819|NCT03808389|Experimental|Treatment group: Donor FMT|Fecal microbiota transplantation using fecal matter from a healthy donor selected through strict inclusion criteria assessing the presence of any infectious diseases.
3373820|NCT03808389|Sham Comparator|Control group: Autologous FMT|Fecal microbiota transplantation using the patient's own fecal matter.
3373821|NCT03808337|Active Comparator|Standare of Care|Patients with newly diagnosed metastatic non-small cell lung cancer or triple negative breast cancer may be enrolled on protocol prior to receiving any systemic therapy. If these patients are randomized to the standard of care arm (Arm 1), they will initiate appropriate therapy as determined by their oncologist. Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist.
3373822|NCT03808337|Experimental|Stereotactic Body Radiotherapy (SBRT) + Standard of Care|Patients enrolled on Arm 2 of the study will undergo Stereotactic Body Radiotherapy/SBRT to all known metastases seen on imaging studies performed prior to enrollment. Radiotherapy will be given concurrently to all metastatic sites. Minimum BED for ablative SBRT is more than or equal to 48 Gy10. Patients can undergo systemic therapy concurrently with SBRT at the discretion of treating radiation oncologist and medical oncologist. After completion of SBRT to all sites of known metastatic disease, patients will continue standard of care therapy per the treating oncologist.
3373823|NCT03806257|No Intervention|Control|Subjects in the control arm will receive standard of care, which consists of mobilization to a bedside chair at least once, and ambulate one-half ICU circumference on postoperative day one. On postoperative days two through five, the subject will be mobilized to the bedside chair at least once, and ambulated at least once with target of one full ICU circumference. These subjects will receive gait training and safe ambulation education, and wear a FitBit Charge 2 watch for five days after surgery.
3373824|NCT03806257|Experimental|Enhanced Physical Therapy Protocol|Subjects in the experimental arm will recieve a FitBit Charge 2 watch, and will be mobilized to the bedside chair on postoperative day zero. On postoperative day two subjects will be mobilized to the bedside chair twice, ambulate one-half of the ICU circumference, and receive gait and safe ambulation training. On postoperative days two through five, subjects will mobilize to the bedside chair three times, and will be encouraged to ambulate three times, each time with a target of one full ICU circumference.
3373825|NCT03802825|Active Comparator|Patient Navigation|Participants randomized to the patient navigation only arm will be referred to a KPNW patient navigator using a standard electronic health record-based referral process. Once the participant has completed the Your Current Life Situation (YCLS) assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 month period by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention. Participant will also receive monthly mailing of American Diabetes Association educational materials.
3255413|NCT01433692|Experimental|intervention group|
3255414|NCT01433692|Other|control group|
3255415|NCT01433705|Other|Rb-82 and N-13 ammonia Pet scans|Rest and vasodilator stress Rb-82 images and N-13 ammonia images will be taken according to standard clinical imaging protocol. Each of these two imaging studies require the injection of Rb-82 and N-13 ammonia by intravenous administration (IV) in the patient's arm.
3255416|NCT01433705|Other|F-18 FDG Imaging and Rb-82|Volunteers not excluded by abnormal rest/stress imaging with Rb-82, will begin F-18 FDG protocol.
3255417|NCT01433705|Other|F-18 FDG Imaging and N-13 ammonia|Volunteers not excluded by abnormal rest/stress imaging with N-13 ammonia, will begin F-18 FDG protocol.
3255418|NCT01433718|Experimental|ACL prevention training|
3255419|NCT01433744|Experimental|Chronic periodontal disease|C-reactive protein levels assesments and periodontal treatment
3255420|NCT01433744|No Intervention|Periodontally healthy|
3255421|NCT01433757|Active Comparator|Ampicillin|Patients who are randomly selected to receive the active drug will receive Ampicillin (2mg daily for adults and 1 mg daily for children).
3255422|NCT01433757|Placebo Comparator|Placebo|Patients who are randomly selected to receive the placebo will be given a sugar pill that resembles the active drug.
3255423|NCT01433770|Experimental|Alefacept action on memory T cells|
3255424|NCT01433796||Antiretroviral therapy, tuberculosis|Patients eligible for starting ART in health centres in Ethiopia
3255425|NCT01433835|Placebo Comparator|Placebo|
3255426|NCT01433835|Experimental|MBX-400|
3255427|NCT01433848||Child A liver cirrhosis|
3373826|NCT03802825|Experimental|Patient Navigation+Diabetes Self-Management Training|"In addition to receiving patient navigation as described above, participants in this arm will also be referred to Project Access NOW by study staff using REDCap. As part of the partnership with KPNW, Project Access NOW will be provided with participants' contact information via REDCap to facilitate the referral to a certified CHW within a community-based organization. Project Access NOW will connect participants to a community-based organization based on their preference, previous experience with an agency, geography, and capacity.~The CHW will follow-up with the participant to conduct a home visit and follow-up on community-based referrals already placed by the KPNW patient navigator and assess for additional needs. The timing of the diabetes self-management training will be based on the needs of the participant."
3373827|NCT03800355||Male breast cancer|The study target population is all cases of male breast cancer (MBC), diagnosed with invasive breast cancer between the years 2000 and 2017, and treated in the Medical Oncology Departments of participating sites.
3373828|NCT03799523|Experimental|Subjects undergoing breast radiotherapy|At the time of CT simulation study participants will receive temporary skin markings to be covered in clear medical grade tape. Light-based surface imaging will be used to determine alignment between the patient and the radiation machine. Radiation treatment will proceed as standard of care.
3373829|NCT03798301|Experimental|Treatment Arm|Suspension of CMV-specific T-cells in 10 mL of 0.9% NaCl with 2% HSA. Single dose max. 25,000 T cells/kg body weight (BW) of the recipient delivered via IV bolus injection.
3373837|NCT03785912|Experimental|Internet-based self-help|The self-help program consists of eight text- and video-based modules. All participants in this group receive immediate access to the self-help program. The program's self-management approach does not provide for regular support from a specialist. However, participants can contact the study team if they need or want additional help.
3255428|NCT01433848||Child B liver cirrhosis|
3373838|NCT03785912|No Intervention|Waiting control group|Access to internet-based intervention after 12 weeks.
3373839|NCT03781778|Experimental|Group I (resistant starch foods)|Patients eat a diet consisting of resistant starch foods daily for 8 weeks.
3373840|NCT03781778|Active Comparator|Group II (foods with regular corn starch)|Patients eat a diet consisting of regular corn starch foods daily for 8 weeks.
3373841|NCT03777215|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of angiotensin-(1-7). The doses are: 2, 4, and 8 ng/kg/min. Each dose will be maintained for 10 minutes, with the highest dose maintained for an additional 90 minutes. The total infusion period is 120 minutes.
3373842|NCT03777215|Placebo Comparator|Placebo|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7). The total infusion period is 120 minutes.
3373843|NCT03776799|Other|Stent-avoiding approach|using clinically proven drug coated balloons
3255429|NCT01433848||Child C liver cirrhosis|
3255430|NCT01433861|Active Comparator|LAPG|LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group
3255431|NCT01433861|Active Comparator|LATG|LATG : laparoscopy-assisted total gastrectomy group
3255432|NCT01433874|Experimental|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
3255433|NCT01433874|Experimental|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc we will leave the fluid in the abdominal cavity.
3255434|NCT01433874|Experimental|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH20. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
3255435|NCT01433874|Placebo Comparator|Control group|Co2 was removed by passive exsufflation through the port site
3373844|NCT03776799|Other|Stent-based approach|using drug eluting nitinol stents. Interwoven nitinol stents in heavily calcified lesions at the operator's discretion.
3373847|NCT03768570|No Intervention|Surveillance|
3373848|NCT03768570|Active Comparator|Durvalumab|
3255436|NCT01433887|Experimental|Genotype 6|Genotype 6 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
3255437|NCT01433887|Experimental|Genotype 1|Genotype 1 chronic hepatitis C patients will be treated with Peginterferon alfa-2a plus ribavirin for 48 weeks
3255438|NCT01433887|Experimental|Genotype 2/3|Genotype 2/3 chronic hepatitis C patients will be treated with Peginterferon alfa-2a/2b plus ribavirin for 24 weeks
3373851|NCT03752970|Experimental|Spesolimab|
3373852|NCT03752970|Placebo Comparator|Placebo|
3255439|NCT01433900|Active Comparator|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
3373853|NCT03743402|Experimental|Pain self-management|"This intervention will have 4 components:~telephone-delivered evidence-based pain self-management training,~web-based video of successfully tapered patients with motivational interviewing debriefing,~a voluntary, self-paced opioid taper~opioid and non-opioid prescribing guidance for the patient's primary care provider."
3373854|NCT03743402|Active Comparator|usual care|Patients randomized to usual care will continue to receive care as usual from their Kaiser primary care provider.
3373855|NCT03742505|Experimental|Vitamin D|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Vitamin D Group and will receive a single dose of cholecalciferol at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
3373856|NCT03742505|Placebo Comparator|Placebo|"Approximately half of the subjects randomized into VITdALIZE-KIDS will be randomized into the Placebo Group and will receive a single dose of placebo at enrolment.~Participants may also receive standard vitamin D dosing at the discretion of the care team (e.g. 400-1000 IU/day)."
3373857|NCT03740490|Experimental|Smart-T + NRT|Smart-T provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free nicotine replacement therapy (NRT).
3373858|NCT03740490|Active Comparator|NCI QuitGuide + NRT|The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free nicotine replacement therapy (NRT).
3255440|NCT01433900|Active Comparator|Latanoprost|1 drop of latanoprost to eligible eye(s) once daily (at 9 pm)
3373870|NCT03710824||Subjects with Idiopathic Pulmonary Fibrosis|
3373871|NCT03710564|Experimental|Masked Arm 1|Brolucizumab 6 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
3373872|NCT03710564|Active Comparator|Masked Arm 2|Aflibercept 2 mg dosed every 4 weeks from Baseline (Week 0) through Week 100
3255441|NCT01433952|Placebo Comparator|0 mg Thiamine|
3255442|NCT01433952|Experimental|100 mg Thiamine|
3373873|NCT03706885|Placebo Comparator|Placebo|Treatment with placebo - 1 pill per day for 20 weeks
3373874|NCT03706885|Active Comparator|Sustiva 50mg|Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
3373875|NCT03706885|Active Comparator|Sustiva 200mg|Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
3373878|NCT03695978||Nuwiq|All patients receiving Nuwiq (recombinant FVIII)
3373879|NCT03695978||Octanate|All patients receiving Octanate (plasma derived FVIII)
3373880|NCT03695978||Wilate|All patients receiving Wilate (plasma derived FVIII/von Willebrand factor [VWF])
3255443|NCT01433952|Experimental|500 mg Thiamine|
3255444|NCT01433952|Experimental|1500 mg Thiamine|
3255445|NCT01433965|Experimental|Phase I Dose Escalation|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
3255446|NCT01434004|Experimental|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
3255447|NCT01434004|No Intervention|Control group|Usual care (watchful waiting).
3255448|NCT01434017|Active Comparator|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
3373881|NCT03691207|Experimental|SINGLE-ARM|AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
3373882|NCT03687320|Experimental|Standard and B-Cure Pro|Subjects from the Standard and B-Cure Pro group will receive standard care and in addition will self-treat at home daily with the B-Cure device.
3373883|NCT03687320|Sham Comparator|Standard and Sham|Subjects from the Standard and sham group will receive standard care and in addition will self-treat at home daily with the sham B-Cure device.
3373884|NCT03673800|Experimental|Cognitive Training|Online Cognitive training on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
3373885|NCT03673800|Sham Comparator|Online sensorial program|Online sensorial program on the Scientific Brain Training® (SBT®) platform with optional guidance by phone
3373886|NCT03668639|Other|Akynzeo plus dexamethasone|Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
3255449|NCT01434017|Active Comparator|Dexamethasone and Droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
3255450|NCT01434017|Active Comparator|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
3255451|NCT01434043||Myocardial ischemia patients|
3255452|NCT01434056||Liver transplantation waiting list|Patients waiting for liver transplantation with chronic end staged liver disease
3255453|NCT01434069|Experimental|Combination Therapy: FOLFIRI and SOM 230|"Treatment will be administered on an outpatient basis. FOLFIRI is administered by IV infusion every 2 weeks. The dose should be based on the patient's actual baseline body weight; the dose will be recalculated if there is a weight change of > 10% from baseline.~SOM 230 will be administered as an intramuscular dose determined by the dosing schema, every 28 days."
3255454|NCT01434095|Active Comparator|half-dose PDT(photodynamic therapy)|The study include single arm; treated group, and no control group was included.
3255455|NCT01434108|Experimental|Ornithine-phenylacetate|Administration of OP (OCR-002) during 5 days in addition to standard treatment of gastrointestinal bleeding.
3255456|NCT01434108|Placebo Comparator|Saline iv|Administration of control infusion (saline infusion) during 5 days in addition to standard treatment of gastrointestinal bleeding.
3255457|NCT01434134|Experimental|Metoprolol|Tablet, target dose 100 mg once daily
3255458|NCT01434134|Placebo Comparator|Placebo for Metoprolol|Tablet, target dose 100 mg once daily
3255459|NCT01434134|Experimental|Candesartan|Tablet, target dose 32 mg once daily
3255460|NCT01434134|Placebo Comparator|Placebo for Candesartan|Tablet, target dose 32 mg once daily
3259516|NCT01471535|Experimental|peginterferon alpha 2a|the inactive chronic HBsAg carriers were treated with peginterferon alpha 2a for 72 weeks and followed for 24 weeks.
3259517|NCT01471548|Experimental|TKI258|dose escalation
3259518|NCT01471587||Patients with COPD|
3255461|NCT01434147|Experimental|induction chemotherapy + radiochemotherapy|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine induction chemotherapy: starts within 28 days after bioptical diagnosis. All patients are administered with capecitabine (Xeloda®) 1000 mg/m2 bid during 14 days (d1-d14), oxaliplatin 130 mg/m2 and bevacizumab (Avastin®) 7.5 mg/kg body weight on day 1; repetition days 22 and 43 (3 cycles) Combined radiochemotherapy: starts at the earliest one week after concluded third cycle of induction chemotherapy. Radiotherapy takes place on 5 x 5 days (dose: 1.8 Gy; cumulative dose: 45 Gy). For chemotherapy patients are administered with capecitabine (Xeloda®) 825mg/m² bid, on each radiation day during the first 4 weeks of radiochemotherapy.
3255462|NCT01434160|Experimental|Arm 1|
3373898|NCT03643705|Experimental|Nurse Intervention|This multi-component intervention will consist of four evidence-based components delivered at 4 in-person visits (0, 4, 8, and 12 months) and by telephone contact: (1) nurse-led care coordination, (2) nurse-managed medication protocols and adherence support (3) home blood pressure monitoring, and (4) electronic medical records support tools.
3373899|NCT03643705|Active Comparator|Education Control|Participants in the education control arm will receive general prevention education delivered at 4 in-person visits (0, 4, 8, and 12 months), which will consist of evidence-based material on diet, exercise, smoking, sexually transmitted infections, and cancer prevention.
3373900|NCT03639025||Standard Donor Lungs Primary Analysis Population|The first 289 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
3373901|NCT03639025||Initially Unacceptable Donor Lung Primary Analysis Pop.|The first 266 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.
3373902|NCT03639025||All Other Enrolled Patients|All OCS Lung transplanted patients that do not meet any of the above analysis populations.
3373903|NCT03638128|Experimental|Denosumab 3-Month Dosing Regimen|
3373904|NCT03638128|Active Comparator|Alternative Treatment|Alternative osteoporosis medication/s at the discretion of the investigator, including the commercially available denosumab on a 6-month dosing regimen.
3373905|NCT03638128|Active Comparator|No Intervention|Subjects who discontinue any osteoporosis medication when joining Study 20170534 for off-treatment observation.
3373906|NCT03633279|Experimental|Branched Chain Amino Acid|Branched Chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg). one packet at 6pm and two at 9pm.
3373907|NCT03633279|Placebo Comparator|Placebo|Equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
3373908|NCT03618693|Experimental|spinal analgesia SSS|"Patients will receive a spinal analgesia (group SSS) with a single shot of bupivacaine 0.5% combined with fentanyl intrathecally during induction of anaesthesia. The technique used is referred to daily practice.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
3373909|NCT03618693|Experimental|TAP block|"Patients will receive a TAP block with a single shot of ropivacaine 0.375% combined with clonidine bilaterally. The technique used is referred to daily practice. The blocks will be performed under ultrasound guidance.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours intravenously and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets (per oral administration).~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
3255463|NCT01434173||Group 1|
3255464|NCT01434173||Group 2|
3255465|NCT01434199|Experimental|UPD guided group|Both the colonoscopist and assistant will be viewing the imager screen during the whole procedure.
3373910|NCT03618693|Active Comparator|Standard|"Standard care for prostatectomy in the investigators institution consists in the concomitant systemic administration of lidocaine to standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.~All patients included in the study will receive the same postoperative multimodal analgesia starting at the end of surgery with the following regimen: 30 mg ketorolac 3* per day for 48 hours and 1 gr 4* per day metamizol intravenously or per oral, depending of the return of bowel function as baseline analgesia during length of hospitalization.~Additional rescue analgesia will be provided and consisted in boluses of 25 mcg fentanyl intravenously (first 24 hours) and thereafter 5-10 mg oxycodone tablets.~Postoperative rehabilitation according to the investigators enhanced recovery program including early mobilization and drinking (clear drinks)."
3373911|NCT03616821|Experimental|Brazikumab Dose 1|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through week 50
3373912|NCT03616821|Experimental|Brazikumab Dose 2|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50
3255466|NCT01434199|No Intervention|non-UPD guided group|Conventional colonoscopy would be done without image guidance.
3255467|NCT01434212||Interferon and ribavirin|All the patients followed the standard treatment protocol.
3255468|NCT01434225|Experimental|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
3255469|NCT01434238|Experimental|Intervention participant|
3373913|NCT03616821|Placebo Comparator|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous every 4 weeks beginning on day 71 through Week 50.
3373916|NCT03612713|Active Comparator|Oxycodone Medication First|one hour before fMRI scan participants will be given a single dose 15mg immediate release oxycodone
3373917|NCT03612713|Placebo Comparator|Placebo First|one hour before fMRI scan participants will be given a single dose placebo.
3373918|NCT03609216|Experimental|Arm I (gemcitabine, cisplatin, bladder sparing)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage < cT1 undergo bladder sparing.
3373919|NCT03609216|Experimental|Arm II (gemcitabine, cisplatin, cystectomy, chemoradiotherapy)|Participants receive gemcitabine hydrochloride IV over 30 minutes on day 1, cisplatin IV on days 1 and 2, and pegfilgrastim SC on day 3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unaccepted toxicity. Participants with DDR gene alteration and disease stage >= cT1 or participants without DDR gene alteration undergo radical cystectomy or chemoradiotherapy.
3373924|NCT03604289|Experimental|Angiotensin-(1-7)|Participants receive intravenous angiotensin-(1-7) at one study visit for 100 minutes total. Angiotensin-(1-7) will be given in escalating doses of 2ng/kg/min, 4ng/kg/min, and 8ng/kg/min. Each of these doses will be infused for 10 minutes. Following the dose escalation, angiotensin-(1-7) will be given at 8ng/kg/min for an additional 70 minutes. Infusion rates will be calculated for each patient based on body mass.
3373925|NCT03604289|Placebo Comparator|Saline|Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.
3255470|NCT01434251|Active Comparator|Standard care|Infants will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU): anti-hypotensive therapy will be started when the mean blood pressure (in mmHg) is below the gestational age in weeks.
3255471|NCT01434251|Other|Delayed intervention|Anti hypotensive therapy will be started when the mean blood pressure (in mmHg) is < (gestational age in weeks - 5 mmHg) or when there is clinical or biochemical evidence of impaired tissue perfusion.
3255472|NCT01434264|Experimental|Self-selected energy healing|Self-selected healing in the self-selection arm
3255473|NCT01434264|No Intervention|self-selected control|Self-selected control in the self-selection arm
3255474|NCT01434264|Experimental|randomized to energy healing|Randomized to healing in the randomization arm
3255475|NCT01434264|No Intervention|Randomized control|Randomized to control in the randomization arm
3255476|NCT01434277|Experimental|Healthy Subjects|Healthy Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
3255477|NCT01434277|Experimental|Dry-Eye Subjects|Dry-Eye Subjects instill 1-2 drops of the experimental eye drops into each eye four times per day for two weeks.
3255478|NCT01434303|Experimental|Treatment (entinostat, lapatinib ditosylate and trastuzumab)|Patients receive entinostat PO on days 1 and 15 and lapatinib tosylate PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients in the Phase I Trastuzumab Cohort also receive maintenance dose of trastuzumab IV over 30-90 minutes every 3 weeks.
3373926|NCT03600714|Experimental|Treatment|Treatment with Lonafarnib, Ritonavir, and Peginterferon lambda
3373927|NCT03599622|Experimental|BMS-986165 Dose 1|
3255480|NCT01434355||Correlative studies|Patients and parents or siblings undergo saliva sample collection. DNA extracted from saliva samples and from patients' archived tumor tissue samples is genotyped and analyzed by methylation arrays, including methylation-specific PCR (pyrosequencing) assays. Genetic variation between pediatric germ cell tumors and parent or sibling is also analyzed. Patients' and family members' health history, demographics, and environmental exposures are collected by questionnaires or telephone interviews. Medical history, such as chronic conditions, prescribed medications and congenital abnormalities, including cryptorchidism, is also collected. Birth characteristics of the child, including birth weight and gestational age, are also captured.
3373928|NCT03599622|Experimental|BMS-986165 Dose 2|
3373929|NCT03599622|Placebo Comparator|Placebo|
3373932|NCT03598244|Experimental|Treatment (volitinib)|Patients receive volitinib PO QD. Treatment repeats every 28 days for up to 39 cycles in the absence of disease progression or unacceptable toxicity.
3373933|NCT03594110|Experimental|Empagliflozin|
3373934|NCT03594110|Placebo Comparator|Placebo|
3373935|NCT03587116|Other|Standard of Care FIX replacement therapy|
3373936|NCT03587116|Other|Standard of Care FVIII replacement therapy|
3373937|NCT03570385|Experimental|Patient with Optic Neuritis|
3255486|NCT01434381|Experimental|Pfs25-EPA/Alhydrogel|Dose-escalation of Pfs25-EPA/Alhydrogel. Participants will receive 1 of 3 doses of Pfs25-EPA/Alhydrogel- 8 micro g, 16 micro g, or 47 micro g.
3259519|NCT01471600|No Intervention|No intervention|Group overnight fasting
3373938|NCT03568422|Experimental|CFI-402257 + Paclitaxel|Oral CFI-402257 on intermittent schedule:* days 1, 2, 8, 9, 15 & 16 q4w Plus Paclitaxel 80 mg/m2 IV days 1, 8 & 15 every 28 days
3373939|NCT03556319|Placebo Comparator|Placebo|Placebo
3373940|NCT03556319|Experimental|2-HOBA Low Dose|2-Hydroxybenzylamine acetate: 500mg dose
3373941|NCT03556319|Experimental|2-HOBA High Dose|2-Hydroxybenzylamine acetate: 750mg dose
3373942|NCT03554655|Experimental|Intervention: Momentum app|Intervention Group will receive treatment as usual together with the Momentum app.
3373943|NCT03554655|No Intervention|Control|Control Group will receive treatment as usual without the Momentum app.
3373944|NCT03550391|Experimental|Hippocampal-avoidant (HA-WBRT) plus Memantine|WBRT 30Gy in 10 fractions + memantine
3373945|NCT03550391|Experimental|Stereotactic Radiosurgery (SRS)|SRS 18-20 or 22Gy in single fraction
3373946|NCT03548116|Sham Comparator|Group 1|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
3373947|NCT03548116|Experimental|Group 2|Individuals will receive half-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
3373948|NCT03548116|Experimental|Group 3|Individuals will receive full-powered non-imaging mode ultrasound delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
3373949|NCT03548116|Sham Comparator|Group 4|Individuals will receive sham non-imaging mode ultrasound (control group) delivered to the lower, middle, and upper spleen based on the spleen's size.
3373950|NCT03548116|Experimental|Group 5|Individuals will receive half-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
3373951|NCT03548116|Experimental|Group 6|Individuals will receive full-powered non-imaging mode ultrasound delivered to the lower, middle, and upper spleen based on the spleen's size.
3373952|NCT03548116|Sham Comparator|Group 7|Individuals will receive sham non-imaging mode ultrasound with a disconnected probe (control group) delivered to just the spleen's hilum (area of spleen that allows passage of blood vessels, lymphatic vessels, and nerves).
3373953|NCT03530124|Other|Vaccinated|In the study arm, infants will receive PCV13, DTaP, HBV, IPV, and Hib vaccines within 12 hours of randomization. Infants will be monitored from randomization to 48 hours post-vaccination for the occurrence of apnea, bradycardia and desaturation.
3373954|NCT03530124|No Intervention|Unvaccinated|In the study arm, infants will not receive PCV13, DTaP, HBV, IPV, and Hib vaccines during the study. Infants will be monitored from randomization to 48 hours post-randomization for the occurrence of apnea, bradycardia and desaturation.
3373955|NCT03526549|Experimental|EN3835 Active|EN3835 up to 1.68 mg (Collagenase Clostridium Histolyticum)
3255487|NCT01434394|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitus-based chemotherapy before surgery: Erbitus, Docetaxel, Cisplatin.
3255488|NCT01434394|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
3373956|NCT03526250|Experimental|Treatment (palbociclib)|Patients receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3373957|NCT03525418|Experimental|Cohort A - Phase 1 (Open Label)|10 consecutive HLHS patients will be enrolled and treated with Longeveron Mesenchymal Stem Cells (LMSCs). A single administration of LMSCs will be performed via intramyocardial injections during the Stage II (BDCPA) surgery. Dosing is based on body weight. Each LMSC-treated patient will be given 2.5 x 105 LMSCs per kg of body weight. The entire dose of the cells will be roughly 600 microliters.
3373958|NCT03525418|Experimental|Cohort B - Phase 2 Treatment Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
3373959|NCT03525418|No Intervention|Cohort C - Phase 2 Control Group|Double-blinded, in which 20 HLHS patients will be randomized to either receive treatment with Longeveron Mesenchymal Stem Cells (LMSCs) (Cohort B, 10 patients) performed via intramyocardial injections during the Stage II (BDCPA) surgery, or will receive no cells and no injection (Cohort C, 10 patients) during the Stage II (BDCPA) surgery. The second stage is to obtain preliminary safety and efficacy data the will enable and guide a subsequent larger Phase 2 trial.
3373960|NCT03518203|Experimental|Eculizumab|All patients will receive eculizumab based on their weight for 24 weeks.
3373962|NCT03506451|Other|Single arm non-therapeutic interventional study|All subjects who enroll on study will be asked to complete questionnaires at baseline before treatment starts; the questionnaires are repeated at one month, three and six months after radiation therapy has been completed. the demographics questionnaire is completed at baseline only; the FACT-HN is completed at all four time points.
3373963|NCT03499899|Experimental|LAG525 + spartalizumab|"Patients in this arm were given LAG525 plus spartalizumab and approximately 20 patients were randomized to this arm.~The sponsor and the study steering committee decided to prematurely stop enrollment of subjects to Arm 1 after data review showed an increased treatment discontinuation rate due to progressive disease in Arm 1 as compared to Arms 2 and 3 (both containing Carboplatin)."
3373964|NCT03499899|Experimental|LAG525+spartalizumab+carboplatin|Patients in this arm will be given LAG525 plus spartalizumab plus carboplatin and approximately 32 patients will be randomized to this arm.
3373965|NCT03499899|Experimental|LAG525 + carboplatin|Patients in this arm will be given LAG525 plus carboplatin and approximately 32 patients will be randomized to this arm.
3255489|NCT01434407|Experimental|Low AGE meal|Test meal prepared by boiling/steaming the food
3255490|NCT01434407|Experimental|High AGE meal|Test meal prepared by frying/grilling the food
3373969|NCT03496883|Active Comparator|Recombinant Activated Factor VII (rFVIIa)|rFVIIa given as IV injection over 2 minutes within 120 minutes of stroke onset
3373970|NCT03496883|Placebo Comparator|Placebo|Matching placebo given as IV injection over 2 minutes within 120 minutes of stroke onset
3373971|NCT03488693|Active Comparator|No Regional Radiotherapy|A. Whole Breast Irradiation (WBI) following BCS or; B. No Radiotherapy (RT) following mastectomy
3255491|NCT01434420|Experimental|Triple negative breast cancer|Triple negative breast cancer
3373972|NCT03488693|Active Comparator|Regional Radiotherapy|A. WBI plus RT to the regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following BCS or; B. RT to the chestwall and regional nodes (supraclavicular, non-dissected axillary, and internal mammary) following mastectomy
3255492|NCT01434459|Experimental|Gemcitabine with TheraSphere|
3255493|NCT01434485||Nexium|
3255494|NCT01434498|Active Comparator|Arm 1|GS-5885, GS-9451, tegobuvir (GS-9190), and Copegus® for 24 weeks
3373973|NCT03485209|Experimental|Tisotumab Vedotin - Q3W Schedule|Tisotumab Vedotin every 3 weeks
3373974|NCT03485209|Experimental|Tisotumab Vedotin - 3Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of 28-day cycle
3373975|NCT03485209|Experimental|Tisotumab Vedotin - 3Q4W/2Q4W Schedule|Tisotumab Vedotin on Days 1, 8, and 15 of a 28-day cycle and Tisotumab Vedotin on Days 1 and 15 of every 28-day cycle
3373978|NCT03479307|Experimental|Bilastine Ophthalmic Solution 0.6%|"Bilastine Ophthalmic Solution 0.6%~1 drop in each eye at 2 separate times during an 8 day period."
3255495|NCT01434498|Active Comparator|Arm 2|GS-5885, GS-9451, tegobuvir (GS-9190), and a placebo matching ribavirin for 24 weeks
3255496|NCT01434498|Active Comparator|Arm 3|GS-5885, GS-9451, a placebo matching tegobuvir, and Copegus® for 24 weeks
3255497|NCT01434524|No Intervention|Control|normal dietary
3255498|NCT01434524|No Intervention|LIVACT|The present study used LIVACT for preoperative supplementation, commencing two weeks prior to surgery, and continuing for at least 6 months postoperatively with careful monitoring of compliance.
3255499|NCT01434537||SCAN|Venepuncture performed with support of the AccuVein 300 vein scanner.
3255500|NCT01434537||NO_SCAN|Venepuncture without support of the vein scanner.
3373979|NCT03479307|Active Comparator|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|"Ketotifen Ophthalmic Solution 0.025% (Zaditen)~1 drop in each eye at 2 separate times during an 8 day period."
3255501|NCT01434550|Active Comparator|TBRI Subgroup: TBRI and SBRT|"Six patients will be asked to be part of a subgroup called TBRI (Tissue, Blood, Research Imaging). In this subgroup, we want to study if there is early death of tumor cells from the treatment by looking at the tumor using PET/CT scans and biopsies, and by testing the participant's body's white blood cells taken by a procedure called leukapheresis.~Participants do not have to take part in the TBRI subgroup to get treatment on this study with SBRT.~SBRT:~30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
3255502|NCT01434550|Active Comparator|SBRT Alone|"30 Gy in 5 fractions to pancreatic tumor~50 Gy in 5 daily consecutive fractions unresectable portion and avoiding bowel, stomach, and duodenum"
3255503|NCT01434563||HIV positive|Subjects must have documented HIV, be english speaking, with life expectancy greater than 6 months, and must have adequate information available in their medical record to apply HAND predictive algorithm (HIV-associated neurological disease)
3255504|NCT01434563||HIV negative|Must have documented negative HIV test within 12 months of study entry, have no traumatic brain injury or history of chronic neurological illness/psychiatric conditions (such as bipolar or depression),be english speaking and have no history of drug or alcohol abuse.
3373980|NCT03479307|Placebo Comparator|Vehicle of Bilastine Ophthalmic Solution|"Vehicle of Bilastine Ophthalmic Solution~1 drop in each eye at 2 separate times during an 8 day period."
3373981|NCT03474640|Experimental|Toripalimab 80 mg repeat dose every 14 days|3-6 subjects (Part A)
3373982|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 14 days|3-6 subjects (Part A)
3373983|NCT03474640|Experimental|Toripalimab 480 mg repeat dose every 14 days|3-6 subjects (Part A)
3373984|NCT03474640|Experimental|Toripalimab 240 mg repeat dose every 21 days|240 subjects (Part B)
3373985|NCT03473873||SHIELD|Patients with anterior cruciate ligament injury
3255505|NCT01434576|Experimental|HGS1025 2 mg/kg|
3255506|NCT01434576|Experimental|HGS1025 10 mg/kg|
3255507|NCT01434576|Placebo Comparator|Placebo|
3255508|NCT01434589|No Intervention|Wait list control|
3255509|NCT01434589|Experimental|STICA Intervention|
3373986|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part A|"Part A: Part A is conducted in patients who are cisplatin-ineligible and have had no prior systemic treatment for locally advanced or metastatic disease.~Patients will receive rogaratinib plus atezolizumab combination treatment."
3373987|NCT03473756|Placebo Comparator|Placebo + Atezolizumab|Part B:Patients will receive placebo in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
3373988|NCT03473756|Experimental|Rogaratinib + Atezolizumab in Part B|Part B:Patients will receive rogaratinib in combination with atezolizumab until disease progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
3373989|NCT03470441|Experimental|FDY-5301 Low Dose|Anticipated n=20
3373990|NCT03470441|Experimental|FDY-5301 Intermediate Dose|Anticipated n=20
3373991|NCT03470441|Experimental|FDY-5301 High Dose|Anticipated n=20
3373992|NCT03470441|Placebo Comparator|Placebo|Anticipated n=20
3373993|NCT03468868|Active Comparator|Facility-based rehabilitation|Participants will conduct the exercise program for people with MS in a facility, for example a gym, or rehabilitation center. They will receive coaching on site at the facility.
3373994|NCT03468868|Active Comparator|Telerehabilitation|Participants will conduct the exercise program for people with MS at home and receive coaching via phone or Skype sessions.
3255510|NCT01434602|Experimental|1/Phase I (closed)|daily everolimus (days 1- 28) in combination with sorafenib as per the Phase I dosing table
3255511|NCT01434602|Experimental|2/Phase II|combination of sorafenib and everolimus. Sorafenib will be taken daily for 7 days on, then 7 days off. Everolimus will be taken daily.
3373995|NCT03452397|Active Comparator|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)|0.2 % hemigalactarate (0.11% free base) 0.2 % OC-02 Low Dose (1.1 mg/mL)
3373996|NCT03452397|Active Comparator|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)|1.0 % hemigalactarate (0.11% free base) 1.0 % OC-02 Mid Dose (5.5 mg/mL)
3373997|NCT03452397|Active Comparator|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)|2.0 % hemigalactarate (0.11% free base) 2.0 % OC-02 High Dose (11.1 mg/mL)
3373998|NCT03452397|Placebo Comparator|Placebo (vehicle) nasal spray|Placebo (vehicle) nasal spray
3373999|NCT03449381|Experimental|Dose Escalation|
3374000|NCT03449381|Experimental|Dose Expansion|
3374001|NCT03448939|Experimental|S5G4T-1|Participants will topically apply S5G4T-1 cream, once daily to face for 12 weeks.
3374002|NCT03448939|Placebo Comparator|S5G4T-2 Vehicle Cream|Participants will topically apply S5G4T-2 vehicle cream, once daily to face for 12 weeks.
3374003|NCT03433898|Experimental|Part 1|
3374004|NCT03433898|Experimental|Part 2|
3374005|NCT03433898|Experimental|Part 3|
3255512|NCT01434615|Experimental|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
3374006|NCT03433261|No Intervention|Normal Diet|The participant will eat their usual diet for at least 72 hrs prior to the experiment, document their diet during that time and be tested for ketone level immediately prior to the experiment.
3374007|NCT03433261|Experimental|Ketogenic Diet|The participant will follow a ketogenic diet for 72 hrs prior to the experiment and consume a ketone supplement 60 minutes prior to the experiment. They will document their diet and be tested for ketone level immediately prior to the experiment.
3374008|NCT03432741|Experimental|Treatment (FDG-PET, direct tumor microinjection)|Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.
3374009|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA </= 1.5m^2|"Phase I Part B BSA </= 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
3374010|NCT03429803|Experimental|DAY101 (formerly TAK-580, MLN2480) BSA > 1.5m^2|"Phase I Part B BSA > 1.5m^2~Patients (< 25 years) with radiographically recurrent or radiographically progressive non-hematologic malignancies (Central Nervous System (CNS) or solid tumors) associated with activation of the RAS/RAF/MEK/ERK pathway will be eligible with the exception of patients with NF1~Study treatment cycle lasts 28 days, oral, once a week"
3374011|NCT03429543|Experimental|Linagliptin|Linagliptin arm. Oral route. Linagliptin tablets administered once daily for 52 weeks
3374012|NCT03429543|Experimental|Empagliflozin|Empagliflozin arm. Oral route. Start with a low dose of empagliflozin administered once daily and randomly up titrate to the high dose of empagliflozin administered once daily if HbA1c ≥ 7% at week 12
3374013|NCT03429543|Placebo Comparator|Placebo|Placebo arm. Oral route. Placebo tablets administered once daily up to 26 weeks and then linagliptin or low dose of empagliflozin or high dose of empagliflozin administered once daily up to 52 weeks
3374014|NCT03423459||CT Cohort|"Compare the rate of ≥mild PVL in patients with none/mild versus moderate/severe LVOT calcification.~Comparison of the rate of PPM implantation in patients with none/mild versus moderate/severe LVOT calcification.~Determine how the Evolut PRO conforms to LVOT calcification.~Compare the impact of LVOT calcification on the implantation depth of the Evolut PRO.~Analyze the interaction and geometry of the Evolut PRO in patients with moderate/severe LVOT calcification.~Assess for leaflet thickening, subclinical leaflet thrombosis and/or restricted leaflet motion 30-60 days after TAVR."
3374015|NCT03423459||Non-CT Cohort|"Compare the rate of ≥mild PVL with the Evolut PRO with a propensity score matched cohort of historical control subjects who underwent TAVR with the Evolut R and/or CoreValve within the MedStar Health System.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict ≥mild PVL.~Determine which features of LVOT calcification (volume, location relative to aortic annulus and sinuses, prominence into the LVOT lumen) predict PPM implantation."
3374016|NCT03418857|Experimental|Experimental|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains 3.16 × 109 colony forming units (CFU) bifidobacterium animalis subsp. lactis BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
3374017|NCT03418857|Placebo Comparator|Control|Participants will consume one yogurt smoothie daily for the duration of the intervention that contains no BB-12. Participants will be asked to refrain from consumption of other yogurt or probiotic-containing foods.
3374018|NCT03410615|Active Comparator|Radiation/Cisplatin|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Cisplatin IV 100 mg/m2 days 1, 22, 43 concurrently with RT"
3374019|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab|"All patients will receive standard fractionation radiation therapy (RT) scheme: 70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)~Concurrent Phase: Durvalumab IV 1500 mg, days -7 and 22 (the second dose is given concurrently with RT).~Adjuvant Phase (to start 4 weeks after completion of concurrent phase): Durvalumab IV 1500 mg q4 weekly for 6 doses."
3374020|NCT03410615|Experimental|Radiation/Durvalumab + Adjuvant Durvalumab/Tremelimumab|ARM CLOSED TO ACCRUAL WITH AMENDMENT #1
3374021|NCT03410108|Experimental|Brigatinib 90 mg + Brigatinib 180 mg|Brigatinib 90 milligram (mg), tablets, orally, once daily (QD) for first 7 days followed by brigatinib, 180 mg, tablets, orally, QD in Cycle 1 of 28 days followed by brigatinib 180 mg, tablets, orally, QD in Cycle 2 and onward cycles of 28 days until investigator-assessed progressive disease (PD) or intolerable toxicity, withdrawal of consent, or discontinuation for any other reason, whichever comes first up to Cycle 34 of 28-day cycle, until data cut-off date 29 September 2020.
3374022|NCT03407729||Post-hypoxic former preterm|Born in the years 2005-2009 with birth gestational age between 23-28 weeks and birth weight appropriate for gestational age (AGA). Part of a research cohort with available oxygen saturation level data recorded continuously from the first day of life to 8 weeks postnatal age (n=20).Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
3374023|NCT03407729||Healthy term-born children|Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging, Electroencephalography, and Cognitive Performance Testing.
3374024|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
3374025|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 2|Participants randomized to receive risankizumab dose 2 administered by intravenous (IV) infusion.
3374026|NCT03398148|Experimental|Substudy 1, Induction 1: Double-blind Risankizumab Dose 3|Participants randomized to receive risankizumab dose 3 administered by intravenous (IV) infusion.
3255513|NCT01434615|Experimental|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
3255514|NCT01434628|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3255515|NCT01434706|Other|Nucleic Acid Amplification Testing|Nucleic Acid Amplification Testing
3255516|NCT01434719||S.suis cases|This group consists of human cases with S.suis infection (confirmed or probable) admitted to National Hospital for Tropical Diseases in 2010.
3255517|NCT01434719||Sepsis controls|This group consists of hospital controls diagnosed with sepsis (not caused by S.suis) admitted to National Hospital for Tropical Diseases in 2010.
3255518|NCT01434732|Experimental|Umbilical Cord Milking|Umbilical Cord Milking involved milking the umbilical cord at birth.
3255519|NCT01434732|Active Comparator|Immediate Cord Clamping|Umbilical cord is clamped soon after birth without any milking of the cord.
3255520|NCT01434758||Children|Children age 0-15 years presenting to NHP thought to have TB infection
3374027|NCT03398148|Placebo Comparator|Substudy 1, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
3374028|NCT03398148|Experimental|Substudy 1, Induction 1: Open-label Risankizumab Dose 1|Participants receive risankizumab dose 1 administered by intravenous (IV) infusion.
3255521|NCT01434784||Surgery alone|Patients undergoing any kind surgery for lung cancer, no additional surgery, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
3255522|NCT01434784||Surgery in combination with any other tx|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer module within 3 months after surgery
3255523|NCT01434784||Surgery (late effects)|Patients undergoing any kind surgery for lung cancer, additional therapy is permitted, quality of life assessment with the provisional updated lung cancer moduleat least 3 months after surgery and 3 months after any other active treatment
3374029|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
3374030|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
3374031|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
3374032|NCT03398148|Experimental|Substudy 1, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
3374033|NCT03398148|Experimental|Substudy 2, Induction 1: Double-blind Risankizumab Dose 1|Participants randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion.
3374034|NCT03398148|Placebo Comparator|Substudy 2, Induction 1: Double-blind Placebo|Participants randomized to receive placebo for risankizumab administered by intravenous (IV) infusion.
3374035|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(a)|Participants who received placebo with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
3255524|NCT01434784||Chemotherapy alone|Patient undergoing any kind of chemotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
3374036|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 1(b)|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Induction 2.
3374037|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 2|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Induction 2.
3374038|NCT03398148|Experimental|Substudy 2, Induction 2: Double-blind Risankizumab Dose 3|Participants who received risankizumab with inadequate response in Induction 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Induction 2.
3374039|NCT03393741||Taxane (nab-paclitaxel or paclitaxel)|"Up to 10 participants will be enrolled on the Taxane arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
3374040|NCT03393741||Eribulin|"Up to 5 participants will be enrolled on the Eribulin arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
3374041|NCT03393741||Vinorelbine|"Up to 5 participants will be enrolled on the Vinorelbine arm. TThe dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
3376211|NCT01858740|Experimental|Treatment (CD45RA+ T cell depleted PBSCT)|"CONDITIONING REGIMEN: Patients undergo TBI BID on days -10 to -7, receive thiotepa IV over 4 hours on days -6 and -5 and fludarabine phosphate IV over 30 minutes on days -6 to -2.~TRANSPLANT: Patients undergo CD34+ enriched, CD45RA+ T cell-depleted allogeneic PBSCT on day 0.~POST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive tacrolimus IV continuously or PO every 12 hours beginning on day -1 and continuing through day 50 with taper. Patients also receive methotrexate IV on days 1, 3, 6, and 11."
3255525|NCT01434784||Radiotherapy alone|Patient undergoing radiotherapy for lung cancer, no additional therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3374042|NCT03393741||Ixabepilone|"Up to 5 participants will be enrolled on the Ixabepilone arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
3374043|NCT03393741||Control Arm|"Up to 10 participants will be enrolled on the control arm. The dose and schedule of administration is determined by the treating physician. The first dose will be coordinated in conjunction with research staff who will schedule a research biopsy to be completed on Day 2 of the first planned chemotherapy treatment cycle (C1D2). Participants are not eligible for replacement as long as they are able to have the C1D2 biopsy completed.~Two tubes of blood of up to 15ml each drawn prior to chemotherapy and again just before or after research biopsy on C1D2. A 15ml sample of blood drawn at the time subject comes off study or at the time of disease progression.~Tumor core biopsy is obtained as close as possible to 20 hours following initiation of the first planned treatment infusions. Between 2 and 4 cores will be obtained for research biopsy."
3374044|NCT03390335|Experimental|Altitude Dive Altitude profile|Subjects are exposed to Pressure profiles (Altitude followed by a Dive with a return to Altitude) and Breathing Gases during dive exposures.
3374045|NCT03379389|Experimental|Methenamine + Methylthioninium|Dosage: Methenamine (120mg) + Methylthioninium (20mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
3374046|NCT03379389|Active Comparator|Methenamine+Methylthioninium+Acriflavine+Atropa belladona|Dosage: Methenamine (250mg) + Methylthioninium (20mg) + Acriflavine hydrochloride (15mg) + Atropa belladonna L. (15mg) Dosage form: coated tablets Frequency: 2 coated tablets twice daily Duration: 6 days
3374047|NCT03377803|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
3374048|NCT03377803|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
3374049|NCT03377790|Active Comparator|VP-102|VP-102 is contained within a single-use applicator. The VP-102 applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450 μL of VP-102 (0.7% [w/v] cantharidin) solution.
3374050|NCT03377790|Placebo Comparator|Placebo|Placebo is contained within a single-use applicator. The placebo applicator consists of a plastic tube containing a sealed glass ampule and an applicator tip. One ampule contains 450μl of placebo solution with the same color and consistency as VP-102.
3374053|NCT03367169|Active Comparator|minimally invasive method|The patients are treated with minimally invasive method
3374054|NCT03367169|Active Comparator|open reduction method|The patients are treated with open reduction method
3374055|NCT03335267|Experimental|CPX-351 (Cytarabine:Daunorubicin) Injection|"Dosing for first induction: CPX-351~• CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5~Dosing for second induction:~• CPX-351 at 100 u/m2 will be administered on days 1 and 3~Dosing for consolidation:~• CPX-351 at 65 u/m2 will be administered on days 1 and 3"
3255526|NCT01434784||Sequential radiochemotherapy|Patient undergoing sequential radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3255527|NCT01434784||Concurrent radiochemotherapy|Patient undergoing concurrent radiochemotherapy for lung cancer, no surgery, no targeted therapy, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3374056|NCT03329092|Experimental|Aztreonam-Avibactam ± Metronidazole|All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
3374057|NCT03329092|Active Comparator|Meropenem ± Colistin|All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
3374058|NCT03315260||Bone metastatic CRPC patients|Japanese patients who are designated to undertake Ra-223/Xofigo therapy based on physician judgement
3374060|NCT03310957|Experimental|LV plus pembrolizumab|LV + pembrolizumab
3374063|NCT03301896|Experimental|LHC165 single agent|LHC165 intratumoral injection given alone
3255528|NCT01434784||Targeted therapy alone|Patient undergoing targeted therapy for lung cancer, no surgery, no radiochemotherapy , quality of life assessment with the provisional updated lung cancer module during or up to 4 weeks after completion of therapy
3255529|NCT01434784||Targeted therapy in combination|Patient undergoing targeted therapy for lung cancer, additional therapies permitted, quality of life assessment with the provisional updated lung cancer module during or up to 3 months after completion of therapy
3255530|NCT01434797||Confirmed CVCP infection before removal|Patients with permanent central venous catheter infection confirmed by conventional method
3255531|NCT01434797||Presumed CPVP infection before removal|Patients with probable permanent central venous catheter infection (standard methods for infection detection not conclusive)
3255532|NCT01434797||Uninfected CVCP before removal|Patients with planned permanent central venous catheter removal (no infection)
3255533|NCT01434836|Active Comparator|active tDCS and working memory training|
3255534|NCT01434836|Placebo Comparator|sham tDCS and working memory training|
3255535|NCT01434849|Experimental|Timolol|Application of 1-2 drops of Timolol maleate 0.5% ophthalmic aqueous solution to hemangioma twice daily.
3255536|NCT01434849|Placebo Comparator|Placebo|Application of 1-2 drops of placebo gel twice daily to hemangioma.
3374064|NCT03301896|Experimental|LHC165 in combination with PDR001|LHC165 intratumoral injection given with PDR001 infusion
3374065|NCT03283371|Experimental|Natalizumab 300 mg|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab 300 mg intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will continue to receive natalizumab 300 mg IV infusion every 4 weeks for up to an additional 24 weeks in open label phase.
3374066|NCT03283371|Placebo Comparator|Placebo|Participants will undergo a prospective baseline period of 6 weeks (Weeks -6 to 0) followed by placebo controlled phase to receive natalizumab matching placebo intravenous (IV) infusion every 4 weeks from Week 0 to Week 24. Participants will then receive natalizumab 300 mg IV infusion every 4 weeks for 24 weeks in open label phase.
3374067|NCT03278184|Sham Comparator|tDCS sham motor cortex|25 participants will have sham stimulation for 20 minutes using transcranial direct current stimulation device.
3374068|NCT03278184|Active Comparator|Active motor cortex stimulation|25 participants will have active stimulation targeting the left motor cortex for 20 minutes using transcranial direct current stimulation device.
3374069|NCT03278184|Active Comparator|active prefrontal cortex stimulation|25 participants will have active stimulation targeting the left dorsolateral prefrontal cortex for 20 minutes using transcranial direct current stimulation device.
3374070|NCT03269994|Active Comparator|Cefoxitin|
3374071|NCT03269994|Experimental|Piperacillin-tazobactam|
3374072|NCT03259074|Experimental|Secukinumab 150 mg s.c.|Secukinumab 150 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
3374073|NCT03259074|Experimental|Secukinumab 300 mg s.c.|Secukinumab 300 mg will be administered at Baseline, Weeks 1, 2, 3 and 4, followed by dosing every 4 weeks until Week 100
3374074|NCT03259074|Experimental|GP2017 (adalimumab biosimilar) 40mg s.c.|GP2017 (adalimumab biosimilar) 40 mg will be administered at Baseline followed by dosing every 2 weeks until Week 102
3374075|NCT03258905|Experimental|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
3255537|NCT01434862|Experimental|Closed loop with pramlintide|Pramlintide will be provided to study subjects who will subsequently be admitted for inpatient testing with the closed loop system. The term closed loop refers to insulin adjustment automatically regulated by computer input to the insulin pump based on monitoring (often a combination of patient blood glucose (BG) testing and/or continuous glucose monitoring (CGM)).
3374076|NCT03258905|Active Comparator|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
3374077|NCT03247023||Integra Cadence Total Ankle System|
3374078|NCT03240068|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of five ascending doses of angiotensin-(1-7). The doses are: 1, 2, 4, 8, and 12 ng/kg/min. Each dose will be maintained for 10 minutes, for a total infusion period of 50 minutes.
3255538|NCT01434862|Experimental|Closed loop without pramlintide|This visit is necessary to assess how well the closed loop system works without the pramlintide (how well it protects from hypoglycemia and hyperglycemia). It will be the exact protocol as for the closed loop with pramlintide but without the medication.
3255539|NCT01434862|Experimental|Open loop with pramlintide|The term open loop refers to insulin infusions regulated in their delivery based on patient self-monitoring and adjustment. The study subject will be in charge of their insulin treatment while also receiving pramlintide.
3374079|NCT03240068|Placebo Comparator|Saline|Subjects will receive intravenous infusion of saline that is matched in volume to the angiotensin-(1-7) arm. Saline infusion will be maintained for a total infusion period of 50 minutes.
3374080|NCT03221517|Experimental|Cohort 1|Shift workers receive a standardized meal with a glucose challenge test
3374081|NCT03221517|Experimental|Cohort 2|Matched healthy controls receive a standardized meal with a glucose challenge test
3374082|NCT03216603|Experimental|Health literacy intervention group|Health literacy intervention group will receive self-management help using a motivating interviewing technique delivered by nurses trained on motivating interviewing technique and COPD.
3374083|NCT03216603|No Intervention|Usual care group|Usual care group will receive usual follow up
3374084|NCT03215342|Experimental|pGMT|Pediatric Goal Management Training
3374085|NCT03215342|Experimental|pBHW|Pediatric Brain Health Workshop
3376212|NCT01856478|Experimental|afatinib|oral intake, once daily
3255540|NCT01434888|Active Comparator|Tafluprost 0.0015%|
3255541|NCT01434888|Active Comparator|Timolol 0.5%|
3255542|NCT01434888|Experimental|Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%|
3255543|NCT01434901|Experimental|Normal Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels less than 140mg/dl two hours after ingestion of 75-g of glucose.
3255544|NCT01434901|Experimental|Impaired Glucose Tolerance|Healthy individuals exhibiting plasma glucose levels between 140 and 199 mg/dl two hours after ingestion of 75-g of glucose.
3259520|NCT01471600|Active Comparator|Group drink|Glucose drink (200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia)
3374089|NCT03181893|Placebo Comparator|Placebo ARM|
3374090|NCT03181893|Experimental|PF-06823859 ARM high|
3374091|NCT03181893|Experimental|PF-06823859 ARM low|
3374092|NCT03173924|Experimental|1/Experimental intervention|18F-DCFPyL is administered to cohorts
3374093|NCT03161912||DME/naïve|patients with pre-treatment in diabetic macular edema (DME)
3255545|NCT01434901|Experimental|Type 2 Diabetes Mellitus|Healthy individuals exhibiting plasma glucose levels greater than 150 mg/dL under fasting conditions OR greater than 199 mg/dl two hours after ingestion of 75-g of glucose.
3255546|NCT01434914|Active Comparator|verum|
3255547|NCT01434914|Placebo Comparator|Placebo|
3374094|NCT03161912||DME/pre-treatment|patients without pre-treatment in DME
3374095|NCT03161912||RVO/pre-treatment|Macular edema secondary to RVO with prior treatment
3255548|NCT01434927||Colonoscopy outpatients|All patients referred to our Unit to undergo colonoscopy for any indication
3374096|NCT03161912||RVO/naïve|Macular edema secondary to RVO without prior treatment
3374097|NCT03153319|Experimental|Adalimumab|20 mg subQ every other week (weight 15to <30 kg) 40 mg subQ every other week (weight ≥30 kg). Non-responders will be escalated to weekly dosing.
3255549|NCT01434940|Experimental|Alzheimer|Patients suffering of Alzheimer disease
3255550|NCT01434940|Experimental|Depression|Patients suffering from depression
3255551|NCT01434940|Experimental|Healthy|Healthy volunteers
3374098|NCT03153319|Placebo Comparator|Placebo|Saline placebo comparator
3374099|NCT03153319|Experimental|Open-label adalimumab|Open-label extension of adalimumab dose
3374100|NCT03126747||BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain or dysmenorrhea
3374101|NCT03110809|Placebo Comparator|BAT Positive Placebo|Participants will be confirmed positive for BAT activity, but on Placebo
3374102|NCT03110809|Placebo Comparator|BAT Negative Placebo|Participants will be confirmed negative for BAT activity, but on Placebo
3374103|NCT03110809|Experimental|BAT Positive Capsinoid|Participants will be confirmed positive for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
3374104|NCT03110809|Experimental|BAT Negative Capsinoid|Participants will be confirmed negative for BAT activity, but taking Capsinoids. Capsinoids are a derivative of sweet peppers that may activate and recruit BAT.
3374105|NCT03098576||Matched|Matched targeted drug treatment
3374106|NCT03098576||Control|Unmatched standard of care
3374107|NCT03089203|Experimental|Cohort 1|CART T cells 1-3x10^7 Day 0
3374108|NCT03089203|Experimental|Cohort 2|Cart T cells 1-3x10^8 Day 0
3374109|NCT03089203|Experimental|Cohort -3|Cyclophosphamide 300 mg/m^2/day and fludarabine 30 mg/m^2/day Day -3 CART T cells 1-3x10^7 Day 0
3255552|NCT01434953|Experimental|Labeled|
3255553|NCT01434953|Active Comparator|Unlabeled|
3255554|NCT01434966|Experimental|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
3259521|NCT01471613|Experimental|Group C - Cord blood cell|Conventional treatment, cord blood cell transplant and placebo
3259522|NCT01471613|Placebo Comparator|Group A - Control|Conventional treatment and placebo
3374110|NCT03088202|Experimental|Intervention arm|Educational program Standardized care pathways Early palliative care
3374111|NCT03088202|No Intervention|Control arm|Usual care
3374112|NCT03084718|Experimental|Treatment A|CHF 718 pMDI 100 μg Total Daily Dose (TDD), Dose 1; CHF 718 pMDI 50 μg/actuation: 1 inhalation twice daily (BID);
3259523|NCT01471613|Experimental|Group B - Lithium Carbonate|Conventional treatment and lithium carbonate
3259524|NCT01471613|Experimental|Group D - Combination Therapy|Conventional treatment, cell transplant and 6-weeks course of lithium carbonate
3259525|NCT01471652|Active Comparator|Nutraceuticals|Subjects will receive a combination of 4 nutraceuticals (CoEnzyme Q10, acetyl-L-carnitine, alpha-lipoic acid, docosahexaenoic acid (DHA)) and a multivitamin.
3259526|NCT01471652|Placebo Comparator|Placebo|
3259527|NCT01471665|Experimental|GSK2190915 100mg|This is a crossover study so patients will receive 100mg of GSK2190915 once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the placebo arm of the study.
3259528|NCT01471665|Placebo Comparator|Placebo|This is a crossover study so patients will receive placebo once daily for up to 16 days followed by a wash out period of at least 14 days before they cross over onto the GSK2190915 100mg arm of the study.
3259529|NCT01471678|Experimental|Fixed dose combination product|Fixed Dose Combination capsule containing dutasteride 0.5mg and tamsulosin 0.2 mg
3259530|NCT01471678|Experimental|Dutasteride (0.5mg)|Commercial formulation of dutasteride
3259531|NCT01471678|Experimental|Harnal-D Tablets and Harnal capsules|Commercial formulations of Harnal-D Tablets and Harnal Capsules both comprising 0.2mg tamsulosin HCl
3259532|NCT01471704|Experimental|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
3259533|NCT01471704|Active Comparator|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
3374113|NCT03084718|Experimental|Treatment B|CHF 718 pMDI 400 μg Total Daily Dose (TDD) 400 μg, Dose 2; CHF 718 pMDI 100 μg/actuation: 2 inhalations BID;
3374114|NCT03084718|Experimental|Treatment C|CHF 718 pMDI Total Daily Dose (TDD) 800 μg, Dose 3; CHF 718 pMDI 100 μg/actuation: 4 inhalations BID;
3374115|NCT03084718|Placebo Comparator|Treatment D|Placebo Control, Placebo; CHF 718 pMDI matched Placebo: 4 inhalations BID;
3376213|NCT01856478|Active Comparator|methotrexate|intravenous bolus injection, once weekly
3374116|NCT03084718|Active Comparator|Treatment E|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA), Total Daily Dose (TDD) 320 µg; QVAR® 80 μg/actuation: 2 inhalations BID;
3255555|NCT01434966|Experimental|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
3255556|NCT01434966|Experimental|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
3255557|NCT01434979||Controls|Active Duty,DoD Beneficiary, or civilian men and women between the ages of 18 and 45 years, with a waist circumference ≤ 39.4 inches (100 cm) will be asked to participate.
3255558|NCT01434979||Exertional Heat Illness / Stroke|Active duty men and women between the ages of 18 and 45 years will be asked to participate. They must have a clinically documented heat stroke within the last year; they will not be tested any sooner than six weeks following the heat stroke. Heat stroke for the purpose of this study is defined as: a syndrome of hyperthermia, physical collapse or debilitation, and encephalopathy as evidenced by delirium, stupor, or coma, occurring during or immediately following exertion or significant heat exposure.
3255559|NCT01434992||H. pylori gastritis|
3374120|NCT03069417|Experimental|Intervention: INSPireD|"This 5-8 session group intervention, Integrating Nuanced Support for Perinatal adherence and Depression, aimed to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women. Intervention content was based on two established cognitive-behavioral interventions: problem-solving therapy and Cognitive Behavioral Therapy for Adherence and Depression."
3374121|NCT03069417|Other|Treatment-as-usual + abbreviated intervention|This group received treatment-as usual, plus the option of completing an abbreviated version of the intervention (one session of problem-solving related to adherence and mental health) at the conclusion of study.
3374122|NCT03063164|Active Comparator|Intralase IFS|Intralase IFS vs. Visumax
3374123|NCT03063164|Active Comparator|Visumax|Visumax vs. Intralase iFS
3374124|NCT03059511|Active Comparator|intravenous|single iv application of nalbuphine 0.05mg/kg
3374125|NCT03059511|Active Comparator|intranasal|single intranasal application of nalbuphine 0.1mg/kg in infants.
3374126|NCT03036657|Experimental|Manual Acupuncture|"Device:~Sterile single-use MAC acupuncture needles - 0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea~Used for Intervention:~Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
3374127|NCT03036657|Experimental|Low-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~Low-frequency Continuous Electroacupuncture (2Hz) to PC3, PC5 or HT3, HT4 for 20 min"
3374128|NCT03036657|Experimental|High-Frequency Electroacupuncture|"Device:~Electrostimulator 6c.Pro, Pantheon Research, Venice, CA~Used for Intervention:~High-frequency Continuous Electroacupuncture (100 Hz) to PC3, PC5 or HT3, HT4 for 20 min"
3374129|NCT03035552|Experimental|Treatment prior to surgery|Infants randomized to receive the pacifier activated music player and mother's voice treatment prior to surgery for 5 sessions, and mother's voice playing freely post surgery.
3374130|NCT03035552|Experimental|Treatment post surgery|Infants randomized to receive the mother's voice playing freely prior to surgery,and pacifier activated music player and mother's voice treatment post surgery for 5 sessions.
3374131|NCT03033303|Experimental|Hu3F8/GM-CSF Plus Isotretinoin|In this phase II single arm trial, patients with HR-NB in first CR or VGPR undergo consolidation by using hu3F8/GM-CSF x5 cycles and isotretinoin x6 cycles. Isotretinoin starts after cycle 2 of hu3F8/GM-CSF.
3374132|NCT03017885||Group A|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.
3374133|NCT03017885||Group B|Patients who started treatment with nintedanib & docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .
3374134|NCT03017885||Group C|Patients who have been newly prescribed nintedanib & docetaxel at the time of participation in the active surveillance.
3374135|NCT03014037|Other|Unilateral Procurement of Bone Marrow|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to unilateral procurement of bone marrow.
3374136|NCT03014037|Experimental|Bilateral Bone Marrow Procurement|Participants currently scheduled to undergo a bone marrow aspirate concentration (BMAC) procedure will be randomized to bilateral procurement of bone marrow.
3374137|NCT03007095|Experimental|preterm children|
3374138|NCT03007095|Active Comparator|term children|
3374139|NCT03003546|Experimental|Treatment (AR160)|Patients receive nab-paclitaxel/rituximab-coated nanoparticle AR160 IV over 30-60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3374140|NCT03002272||TAVR|This observational study will enroll subjects that underwent TAVR more than 3 years ago.
3374141|NCT03002272||SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
3374142|NCT03000829|Experimental|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest response team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
3374143|NCT03000829|Placebo Comparator|Control|"Simulated observation by ICU physician by displaying a silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site participants will be told that an intensive care physician is observing the mock code."
3374154|NCT02972840|Experimental|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
3374155|NCT02972840|Placebo Comparator|Placebo in combination with bendamustine and rituximab|Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.
3374156|NCT02965703|Experimental|Arm I (aspirin)|Patients receive aspirin PO daily for 12 weeks in the absence of unacceptable toxicity.
3255560|NCT01435005|Active Comparator|High Volume|Participate in one year of high volume (300 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
3255561|NCT01435005|Active Comparator|Moderate Volume|Participate in one year of moderate volume (150 minutes per week) aerobic exercise with free provision of a personal trainer, membership to an exercise facility, body composition assessment.
3255562|NCT01435044|Experimental|SOF+RBV 12 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 12 weeks.
3255563|NCT01435044|Experimental|SOF+RBV 24 Weeks|Participants were randomized to receive sofosbuvir plus RBV plus placebo to match GS-0938 for 24 weeks.
3374157|NCT02965703|Experimental|Arm II (aspirin, placebo)|Patients receive aspirin PO daily at weeks 1-3 and 7-9 and placebo PO daily at weeks 4-6 and 10-12 in the absence of unacceptable toxicity.
3374158|NCT02965703|Placebo Comparator|Arm III (placebo)|Patients receive placebo PO daily for 12 weeks in the absence of unacceptable toxicity.
3374159|NCT02960087|Active Comparator|Arm 1 LDR|Low Dose Rate (LDR) brachytherapy with I-125 to a total dose of 144 Gy
3374160|NCT02960087|Active Comparator|Arm 3 HDR|High Dose Rate brachytherapy: 27 Gy in 2 fractions
3374161|NCT02952365|Other|Eyes undergoing LASIK enhancement|Eyes undergoing LASIK enhancement will have tissue sealant applied to the eye to prevent epithelial ingrowth
3374162|NCT02944578|Experimental|Curcumin Arm|Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 12 weeks.
3374163|NCT02944578|Placebo Comparator|Placebo Arm|Participants in this arm will use 2000 mg of a placebo once a week for 12 weeks.
3255564|NCT01435044|Experimental|GS-0938 Alone|Participants were randomized to receive GS-0938 plus placebo to match sofosbuvir for up to 24 weeks.
3255565|NCT01435044|Experimental|GS-0938+SOF|Participants were randomized to receive GS-0938 plus sofosbuvir for up to 24 weeks.
3374164|NCT02938624|Experimental|cohort1|Pembrolizumab 200 mg I.V single dose
3374165|NCT02938624|Experimental|Cohort II|Pembrolizumab 200 mg I.V Twice interval 21 days
3374166|NCT02938624|Experimental|Cohort III|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
3374167|NCT02938624|Experimental|COHORT -1|Pembrolizumab 100 mg I.V single dose
3374168|NCT02936323|Experimental|Phase 1: Dose Escalation|"Cohort 1 will consist of two (2) participants who will receive PEN-221 at the starting dose of 1.0 mg. The first participant will be followed for at least 7 days for safety and dose limiting toxicity (DLT). If PEN-221 is tolerated, the second participant will be enrolled into the cohort. The two (2) participants will be followed for safety and DLTs for at least a 4-week observation period. The Safety Review Committee (SRC) will determine the initiation of cohort 2.~Cohort 2 and each subsequent dose escalation cohort will consist of 3 to 6 participants who will be treated at each dose level of PEN-221 as determined by the SRC and will be followed for safety and DLTs for at least a 3-week observation period. Each dose escalation level and cohort initiation will be determined by the SRC.~Dose escalation will continue until the Maximum Tolerated Dose (MTD) of PEN-221 is determined and the Recommended Phase 2a Dose (RP2D) is established by the SRC."
3374169|NCT02936323|Experimental|Phase 2a: Dose Expansion (GI mid-gut NET)|Gastrointestinal mid-gut NET Cohort
3374170|NCT02936323|Experimental|Phase 2a: Dose Expansion (PNET)|Pancreatic NET Cohort
3374171|NCT02936323|Experimental|Phase 2a: Dose Expansion (SCLC)|Small Cell Lung Cancer Cohort
3374172|NCT02922751||All Subjects|All subjects will be recruited from the Children parent studies: LOGIC (NCT00571272), BASIC (NCT00345553) and PROBE (NCT00061828) and will undergo Liver Stiffness Measurement (LSM). Subjects in these studies have one or more of the following conditions: biliary atresia (BA), Alpha1 Anti-trypsin Deficiency (A1AT) or Alagille Syndrome (ALGS).
3374173|NCT02918435|No Intervention|Usual Care-Control|Participants in the usual care group will receive standard pediatric care.
3374174|NCT02918435|Experimental|On-site WE CARE implementation arm|"WE CARE will be implemented in the study site using a facilitated on-site strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via an on-site team which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room."
3374175|NCT02918435|Experimental|Self-directed web-based WE CARE implementation arm|WE CARE will be implemented in the study site using a web-based implementation strategy. 1. Participants will receive the WE CARE survey at health supervision visits; this survey will be used to identify unmet material needs. 2. Providers will be trained on WE CARE via web-based tools (e.g., web-based seminar) which will teach them how to review the survey and provide referrals (community resource information sheets) from a Family Resource Book located in each exam room
3374176|NCT02913664|Experimental|Aerobic Exercise (Ex)|Aerobic exercise training; blood and cholesterol management will be standard-care by participant's regular doctor.
3255566|NCT01435044|Experimental|GS-0938+SOF+RBV|Participants were randomized to receive GS-0938 plus sofosbuvir plus RBV for up to 24 weeks.
3255567|NCT01435044|Experimental|Placebo|Deferred start group: Participants were randomized to receive placebo to match GS-0938 plus placebo to match sofosbuvir for 24 Weeks.
3374177|NCT02913664|Experimental|Intensive Reduction of Vascular Risk Factors (IRVR)|Lowering SBP < 130 mmHg, administration of atorvastatin 80 mg daily, and stretching exercise.
3374178|NCT02913664|Experimental|IRVR+Ex|A combination of IRVR and aerobic exercise training.
3374179|NCT02913664|Placebo Comparator|Usual Care|Blood and cholesterol management will be standard-care by participant's regular doctor, and stretching exercise.
3374182|NCT02891564|Placebo Comparator|Control Arm (R 33)|a mobile 3D video game to be used as placebo.
3374183|NCT02891564|Experimental|Intervention Arm (R 33)|a mobile 3D video game (Band Together) that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
3374184|NCT02888353|Experimental|Device: MRI no pre-screen|"Clinically Indicated MRI will be done in patients with cardiac devices (pacemakers and defibrillators).~Patients will not be pre-screened prior to hospital visit."
3374185|NCT02866838|Experimental|Tranexamic acid|Intravenous tranexamic acid: 1g loading dose given as 100 mls infusion over 10 minutes, followed by another 1g in 250 mls infused over 8 hours.
3374186|NCT02866838|Placebo Comparator|Placebo|Saline 0.9% given in identical dosage as experimental
3255568|NCT01435044|Experimental|Retreatment Group - SOF+RBV 24 Weeks|After discontinuing a regimen containing GS-0938, participants received sofosbuvir plus RBV for up to 24 weeks.
3255569|NCT01435057|Active Comparator|endurance training|"Endurance training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min tread mill, rawing device or bicycle training.~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
3374187|NCT02864914||Empagliflozin|Patients initiating Empagliflozin treatment within the study period
3374188|NCT02864914||DPP-4 inhibitors|Patients initiating DPP-4 inhibitor treatment within the study period
3374191|NCT02824679|Active Comparator|20mg hyoscine butylbromide|They received (20mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
3374192|NCT02824679|Active Comparator|40 mg hyoscine butylbromide|They received (40mg) hyoscine butylbromide (one ml HBB+ one ml saline) intravenously
3374193|NCT02824679|Placebo Comparator|Saline|They received two ml of normal saline intravenously as a placebo
3374194|NCT02819882||Luminal A-like subtype|Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (< 14%).
3374195|NCT02819882||Luminal B-like (HER2 negative) subtype:|Patients that express ER and are either PgR- or low (< 20%) and/or Ki67 'high' (≥ 14%).
3374196|NCT02819882||Luminal B-like (HER2 positive) subtype:|Patients that express ER and HER2 irrespective of PgR or Ki67 status.
3374197|NCT02819882||HER2-enriched subtype|Patients that express HER2 and don't express ER or PgR.
3374198|NCT02819882||Triple Negative (TN) subtype|Patients who are negative for the expression of ER, PgR and HER2.
3374201|NCT02754141|Experimental|Arm A-Monotherapy|BMS-986179, dose as specified
3374202|NCT02754141|Experimental|Arm B- Combination Therapy|BMS-986179 + nivolumab, dose as specified
3374203|NCT02754141|Experimental|Arm C-Combination Therapy|BMS-986179 + rHuPH20, dose as specified
3374204|NCT02701543|Active Comparator|Ranger Drug Eluting Balloon|Intervention with Over the Wire (OTW) Percutaneous transluminal angioplasty (PTA )balloon catheter with a semi-compliant balloon coated with a formulation of 2μg/mm2 paclitaxel and acetyl tri-n-butyl citrate (ATBC) as carrier substance
3255570|NCT01435057|Active Comparator|strength training|"Strength training:~Supervised, twice a week, each training session consists of a 20 min warm up and cool down period and a minimum of 40min circle training~During the study period of 24 months, we will perform an open randomized, prospective training intervention study comparing the effects of two to three times a week either strength or endurance training on reduction of visceral fat area as determined by MRI scans at the level of L4-L5."
3374205|NCT02701543|Active Comparator|In Pact Drug Eluting Balloon|Intervention with Over the Wire (OTW) peripheral balloon catheter. The balloon surface is coated with a formulation of 3μg/mm2 paclitaxel and urea as carrier substance.
3374206|NCT02692872||1|We plan to perform genetic screening of up to 2,000 individuals of African ancestry, an ethnic group with a high prevalence of alpha thalassemia.
3374207|NCT02688959|Experimental|Tai Chi|Participants in this arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize experiential learning with 2 weeks of introductory sessions on gait, posture, and tai chi principles followed by instruction in the 24-form Yang style sequence. Students will be given a video to aid learning outside of class, and maintenance of practice post-intervention.
3374208|NCT02688959|Active Comparator|Exercise|Participants in the exercise arm will attend 50-minute classes 2 times per week for 8 weeks. The course will emphasize cardio-aerobic fitness training. Students will be given a video to aid practice outside of class, and maintenance of practice post-intervention.
3374209|NCT02688959|No Intervention|Control|Participants in the control arm will not attend a class and not be given a video.
3374210|NCT02686203|Experimental|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment."
3255571|NCT01435070||Distal radius fracture|Patients aged 18 years and older with a fracture of the distal radius, within 3 cm of the radiocarpal joint
3255572|NCT01435083|Experimental|nocturnal polyuria patient with desmopressin MELT|
3255573|NCT01435096|Experimental|BN80927|
3255574|NCT01435109|No Intervention|Usual Care|
3374211|NCT02684461|Active Comparator|Arm A: Sequential Consolidation|Completion of four cycles of Sequential Consolidation of Pembrolizumab 200mg every 21 days and then four cycles Nab-paclitaxel 100 mg/mg2 on day 1 and day 8 every 21 days
3374212|NCT02684461|Active Comparator|Arm B: Sequential Consolidation|Completion of 4 cycles of Sequential Consolidation of Nab-paclitexel 100 mg/m2 on day 1 and day 8 every 21 days and then Pembrolizumab 200 mg every 21
3374213|NCT02684461|Active Comparator|Arm C: Concurrent Consolidation|Concurrent Consolidation of Nab paclitaxel 100 mg/m2 on day 1 and day 8 plus Pembrolizumab 200 m5 on day 1 every 21 days for four cycles
3374214|NCT02670525|Experimental|Relapsed/Refractory leukemia|"Cohort 1: Relapsed/refractory leukemia~Acute lymphoblastic leukemia, first or greater relapse~Acute myeloid leukemia, first or greater relapse~Leukemia refractory to induction chemotherapy~Other recurrent leukemia~Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy~After the screening procedures confirms patient eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
3374215|NCT02670525|Experimental|New diagnosis|"Cohort 2: New diagnosis~Acute myeloid leukemia, new diagnosis (excluding acute promyelocytic leukemia (APL))~New diagnosis infant MLL-rearranged ALL or low hypodiploid (<40 chromosomes) ALL~Rare leukemia- e.g., JMML, leukemia of ambiguous lineage~Secondary leukemia~Myelodysplastic syndrome (MDS) not eligible for stem cell transplant~After the screening procedures confirms eligibility:~Leukemia Profiling will be performed~Identifying an actionable genomic alteration and making a matched targeted therapy treatment recommendation."
3255575|NCT01435109|Experimental|Patient Behavioral Intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
3255576|NCT01435109|Experimental|Provider Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
3374220|NCT02632344|Experimental|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Treatment will be administered on Day 1 of each cycle after all procedures/assessments have been completed
3374221|NCT02631837|Experimental|vNOTES hysterectomy|vaginal Natural Orifice Transluminal Endoscopic Surgery
3374222|NCT02631837|Active Comparator|LSC hysterectomy|Laparoscopic hysterectomy
3255577|NCT01435109|Experimental|Patient and Provider Interventions|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
3255578|NCT01435135|Experimental|Group I|ALVAC-HIV + AIDSVAX B/E or ALVAC-HIV placebo + AIDSVAX B/E placebo at Weeks 0 and 24
3255579|NCT01435135|Experimental|Group II|AIDSVAX B/E or AIDSVAX B/E placebo at Weeks 0 and 24
3374223|NCT02612662|Experimental|Cohort 1|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3374224|NCT02612662|Experimental|Cohort 2|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3374225|NCT02612662|Experimental|Cohort 3|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3374226|NCT02612662|Experimental|Cohort 4|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3255580|NCT01435135|Experimental|Group III|ALVAC-HIV or ALVAC-HIV placebo at Weeks 0 and 24
3255581|NCT01435148|Experimental|Stimulation of SGC then VACNAC targets|Stimulation of the subgenual cingulate cortex (SGC) target will take place first, followed by stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) if no clinical response after a minimum of 4 months.
3374227|NCT02612662|Experimental|Cohort 5|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3374228|NCT02612662|Experimental|Cohort 6|Subjects will be fasted for at least 10 hours before dosing and until 4 hours after dosing of a single dose of AZD4076 tetracosasodium or placebo (high doses may be fractionated)
3255582|NCT01435148|Experimental|Stimulation of VACNAC then SGC targets.|Stimulation of the ventral anterior capsule nucleus accumbens target (VACNAC) will take place first, followed by stimulation of the subgenual cingulate cortex target (SGC) if no clinical response after a minimum of 4 months.
3255583|NCT01435161|Active Comparator|Nifedipine|Patients in arm 1 receive Nifedipine;
3374229|NCT02607722||Nintedanib|Patients with IPF
3374230|NCT02600130|Experimental|Cohort 1|Cohort 1 (10 subjects) Target dose 20 million Longeveron Mesenchymal Stem Cells (LMSCs) via peripheral intravenous infusion.
3374231|NCT02600130|Experimental|Cohort 2|Cohort 2 (10 subjects) Target dose 100 million Longeveron Mesenchymal Stem Cells (LMSCs)via peripheral intravenous infusion.
3374232|NCT02600130|Placebo Comparator|Cohort 3|Cohort 3 (5 subjects) Placebo (Plasmalyte A and 1% human serum albumin (HSA)) via peripheral intravenous infusion.
3255584|NCT01435161|Active Comparator|Telmisartan|Arm 2 receive telmisartan
3374233|NCT02598219|Experimental|Pre-operative SN mapping with radionucleide|"1 Pre-operative Sentinel Node (SN) mapping with Nanocis or Nanocoll or Rotop-nanoHSA~2- Intra-operative SN mapping with patent V blue dye, or Intra-operative SN mapping with indocyanin green for patients with known hypersensitivity, allergy to patent V blue dye~3- Full bilateral laparoscopic lymphadenectomy and Hysterectomy: If bilateral SN are detected, all positive SN are removed, then the surgeon proceeds to a total hysterectomy.~If unilateral SN are detected, surgeon will complete intervention with pelvic LN dissection on the opposite side, in accordance with risk group definition (ex: omentectomy for high-risk non endometrioid carcinomas).~If non SN are detected, surgeon will proceed to a total hysterectomy, a bilateral salpingo-oophorectomy, a complete and bilateral pelvic LND with more enlarged dissection regardless the pathology"
3374234|NCT02598219|Other|B : Current initial staging protocols|Current initial staging protocols
3374235|NCT02553876||Observational|All patients referred with pain in the hand and/or upper limb will be evaluated. Patients will first be assessed for suitability for neurostimulation implantation and then included in the study. Patients wiil fill in questionnaires (pain scores, Quality of Life and satisfaction) at baseline and post-operatively at regular intervals (as per standard of care in the Netherlands.)
3374236|NCT02530658||Participants|"St. Jude patients with a diagnosed solid or liquid tumor (benign or malignant) and their biological parents or legally authorized representative.~Interventions: Study Introduction Visit, Informed Consent Visit, Informed Consent Follow-Up Visit, Return of Results Conversation, two Return of Results Follow-Up Visits, Tissue Sample (when available), Blood Sample or Skin Biopsy."
3374237|NCT02525562|Other|Scorpio NRG Total Knee System|Patients eligible for Scorpio NRG Total Knee System with X3 insert
3374238|NCT02525562|Other|Triathlon Total Knee System|Patients eligible for Triathlon Total Knee System with X3 insert
3374239|NCT02525562|Other|Triathlon Partial Knee Resurfacing|Patients eligible for Triathlon PKR System with X3 insert
3374240|NCT02497248||- Patients with paroxysmal AF.|Patients with AF episodes that terminates spontaneously or with intervention in less than seven days with clinical indication of pulmonary vein ablation.
3255585|NCT01435187||Infant Pulmonary Function Testing (iPFT)|A standardized method of performing infant PFTs using the raised volume rapid thoracoabdominal compression (RVRTC) technique will be used. This test will be performed on infants at one year (corrected age). The target sample size of 180 studies will represent the largest number of RVRTC PFTs in the preterm population and will enhance study of the relationship between lung function at 1 year of age and clinical and biologic factors associated with respiratory disease. Although the primary PFT measures will be derived from RVRTC, V'maxFRC, respiratory system compliance (Crs) and resistance (Rrs) will also be measured because these can be easily obtained. Crs and Rrs will be obtained using the single breath occlusion method.
3255586|NCT01435200|Experimental|Intravenous iron|Iron sucrose 200 mg intravenous infusion in 15 minutes
3374241|NCT02497248||- Patients with persistent AF.|Patients with AF episodes that fails to self-terminate within seven days or require pharmacologic or electrical cardioversion to restore sinus rhythm with clinical indication of pulmonary vein ablation..
3374242|NCT02497248||- Patients with mitral stenosis.|- Patients with mitral stenosis and clinical indication for AF ablation undergoing percutaneous balloon mitral valvuloplasty (PBMV) with clinical indication of pulmonary vein ablation..
3255587|NCT01435200|Placebo Comparator|Oral iron|Ferrous fumarate 200 mg oral three times a day
3255588|NCT01435213|Experimental|Atipamezole|
3255589|NCT01435213|Experimental|Atomoxetine|
3255590|NCT01435213|Experimental|Ketamine|
3255591|NCT01435213|Experimental|Insulin-induced hypoglycemia|
3255592|NCT01435213|Experimental|Cold pressor test|
3374243|NCT02473341|Experimental|Bovine colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
3374244|NCT02473341|Placebo Comparator|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
3255593|NCT01435213|Experimental|Placebo|
3255594|NCT01435226|Active Comparator|Arm 1|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV BID
3255595|NCT01435226|Active Comparator|Arm 2|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir 30 mg BID + RBV placebo BID
3255596|NCT01435226|Active Comparator|Arm 3|GS-5885 90 mg QD + GS-9451 200 mg QD + tegobuvir placebo BID + RBV BID
3255597|NCT01435239|Experimental|resting volume group|
3255598|NCT01435239|Active Comparator|maximum volume group|
3255599|NCT01435252|Experimental|Arm A|Patients will be treated with chemoradiation in combination with concurrent cetuximab. Two weeks after end of chemoradiation the consolidation phase will start and patients will receive biweekly consolidation cetuximab, maximally 6 infusions over 12 weeks.
3255600|NCT01435252|Experimental|Arm B|Patients will be treated with chemoradiation in combination with concurrent cetuximab.
3255601|NCT01435278|Active Comparator|Glucosanol|2 tablets 3 times a day
3255602|NCT01435291|Experimental|Advagraf|
3255603|NCT01435291|Active Comparator|Prograf|
3255604|NCT01435317|Experimental|standard|Standard treatment with the ANM T30 CR®-System
3255605|NCT01435330|Experimental|BVS857|
3255606|NCT01435330|Placebo Comparator|Placebo|
3255607|NCT01435369|Active Comparator|CT-011 at dose level 1 (1.5 mg/kg).|
3255608|NCT01435369|Active Comparator|CT-011 at dose level 2 (6 mg/kg).|
3255609|NCT01435395|Experimental|Therapy|Therapy with temozolomide, bevacizumab and bortezomib
3255610|NCT01435408|Active Comparator|Conventional treatment.|Conventional primary PCI in STEMI.
3255611|NCT01435408|Experimental|IPost|Ischemic postconditioning in STEMI.
3255612|NCT01435408|Experimental|Deferred primary PCI.|Deferred strategy in STEMI.
3255613|NCT01435434|Experimental|sepax, ignite, fracture healing|the mesenchymal cells will be separated by sepax separation system and demineralized bone matrix will be done using IGNITE INJECTABLE REPAIR GRAFT
3255614|NCT01435447|Experimental|FLu-Bu-Cy|Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
3255615|NCT01435473||Children undergoing heart surgery|The study will follow children undergoing cardiac surgery at The Hospital for Sick Children from pre-consultation, throughout surgery, recovery and post-operative follow-up
3255616|NCT01435486|Active Comparator|caffeine Citrate|
3255617|NCT01435486|Placebo Comparator|Normal saline|
3374285|NCT02445131|Experimental|Bendamustine + GA101 + CAL-101|Bendamustine: 70 mg/m2 i.v. GA101: 1000 mg CAL-101: 150 mg p.o.
3374286|NCT02437318|Experimental|fulvestrant + alpelisib|Alpelisib (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
3374287|NCT02437318|Placebo Comparator|fulvestrant + placebo|Placebo (300 mg; oral; once daily) in combination with fulvestrant (500 mg; intramuscular injection on Day 1 and Day 15 of Cycle 1, and then Day 1 of each subsequent 28-day cycle)
3374288|NCT02436707|Active Comparator|R-GDP|"Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
3374289|NCT02436707|Experimental|Ibrutinib plus R-GDP (ACCRUAL COMPLETE)|"Ibrutinib 560 mg PO -- D1 - D21~Rituximab 375 mg/m2 IV 1.5 - 6 hours D1 (prior to cisplatin)~Gemcitabine 1000 mg/m2 IV 30 min D1, D8~Dexamethasone 40 mg daily PO -- D1 - D4~Cisplatin 75 mg/m2 IV 1 hour D1"
3374290|NCT02436707|Experimental|R-DICEP|"Rituximab 375 mg/m2 IV 1.5-6hrs Day 1 and Day 5 prior to Cisplatin~Mesna 1.75 g/m2 IV 24 hour Cycle 1, Day 2, Day 3 and Day 4~Cyclophosphamide, 1.75 g/m2 IV 2 hours, Day 2, Day 3 and Day 4~Etoposide 350 mg/m2 IV 2 hours, Day 2, Day 3 and Day 4~Cisplatin 35 mg/m2 IV, 2 hours, Day 2, Day 3 and Day 4~G-CSF 300 mcg (<60kg); 480 mcg (60-90kg); 600 mcg (>90kg); SC, Daily, starting Day 15 until apheresis completed."
3374291|NCT02436707|Experimental|Selinexor + R-GDP|"Selinexor - 40mg PO, D1, D3, D8~Rituximab - 375 mg/m2 IV, 1.5 - 6 hours D1 (prior to cisplatin);~Gemcitabine - 1000 mg/m2, IV 30 min D1, D8;~Dexamethasone - 40 mg daily PO D1 - D4;~Cisplatin - 75 mg/m2 IV, 1 hour D1;"
3374292|NCT02429791|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
3374293|NCT02429791|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
3374294|NCT02422797|Active Comparator|Participants receiving CAR|Participants will receive CAR from Day 1 to Week 52 (Early Switch Phase), and eligible participants will switch to DTG 50 milligrams (mg) + RPV 25 mg once daily from Week 52 to 148 (Late Switch Phase).
3374295|NCT02422797|Experimental|Participants receiving DTG 50 mg + RPV 25 mg|Participants will receive DTG 50 mg + RPV 25 mg once daily from Day 1 through Week 148 (Early and Late Switch Phase).
3374296|NCT02422615|Experimental|Ribociclib + fulvestrant|Ribociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
3374297|NCT02422615|Placebo Comparator|Ribociclib placebo + fulvestrant|Ribociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle) in combination with fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
3374298|NCT02379416|Experimental|treatment|The starting dose of nilotinib will be administered at 300 mg orally BID from cycle 1 day 2 and paclitaxel will be administered IV at 60 mg/m2 at dose level 1 on Days 1, 8, and 15 in 28-day cycles. For cycle 2 on, nilotinib will be administered from day 1. Dose escalation will follow a 3+3 design, with dose limiting toxicities defined during cycle 1.
3374299|NCT02376699|Experimental|IV Monotherapy in Solid Tumors|SEA-CD40 administered IV
3374300|NCT02376699|Experimental|IV Monotherapy in Lymphomas|SEA-CD40 administered IV
3255618|NCT01435499|Experimental|Cohort A|Cohort A will receive four doses of vaccine, each containing 5E7 melanoma GVAX cells.
3374301|NCT02376699|Experimental|Combination Therapy in Solid Tumors|SEA-CD40 (administered IV) + pembrolizumab
3255619|NCT01435499|Experimental|Cohort B|Cohort B will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells.
3255620|NCT01435499|Experimental|Cohort C|Cohort C will receive four doses of vaccine, each containing 2E8 melanoma GVAX cells. One day prior to each vaccination, patients in cohort C will receive a single, low dose of intravenous cyclophosphamide.
3374302|NCT02376699|Experimental|SC Monotherapy in Solid Tumors|SEA-CD40 administered SC
3255621|NCT01435525||Nexium|
3255622|NCT01435538|Experimental|Care pathway teams.|In this experimental arm, the interprofessional teams will develop and implement a care pathways.
3255623|NCT01435538|No Intervention|Usual care teams.|In the no intervention arm, the interprofessional teams will deliver usual care without implementing the intervention.
3255624|NCT01435564|Active Comparator|pedometer|
3255625|NCT01435564|Experimental|Mobile phone physical activity intervention|
3255626|NCT01435629||Norditropin®|
3255627|NCT01435642||A|
3255628|NCT01435668|Other|Control|A simple written advice.
3255629|NCT01435668|Experimental|Brief Motivational Intervention (BMI)|Brief Motivational Intervention (BMI)
3255630|NCT01435681||DYT-1 Postive|This group includes those participants who enroll having a genetically confirmed primary generalized dystonia diagnosis.
3255631|NCT01435681||Control|This group includes healthy subjects between the ages of 18 and 80.
3255632|NCT01435694|Experimental|Robot-assisted gait training|Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. Training sessions will last for an hour with 30 minutes of real walking time, because subject set-up in the device take approximately 30 minutes.
3259534|NCT01471704|Active Comparator|INX-08189 50 mg & verapamil HCLER 240 mg|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
3259535|NCT01471717|Experimental|C 1:INX-08189 50 mg qd X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg every day (QD) on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
3259536|NCT01471717|Active Comparator|C1: INX-08189 / Victrelis 800 mg TID X 3 days|Cohort 1:INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg three times a day (TID) for 3 additional days
3374303|NCT02376699|Experimental|SC Monotherapy in Lymphomas|SEA-CD40 administered SC
3374304|NCT02376699|Experimental|Combination Therapy in Pancreatic Cancer|SEA-CD40 (administered IV) + pembrolizumab + gemcitabine + nab-paclitaxel
3374305|NCT02375204|Other|Arm A: TIP|"Patients will receive treatment for 4 cycles administered every 21 days.~Cycles 1-4 (1 cycle = 21 days)~paclitaxel 250 mg/m^2 IV over 24 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 1500 mg/m^2 IV daily on Days 2-5 with mesna protection as defined in the protocol~cisplatin 25 mg/m^2 IV daily on Days 2-5~pegylated G-CSF 6 mg subcutaneous on Day 6 or 7 or G-CSF as defined in the protocol on Days 6-18~Patients may commence with each Arm A cycle provided they meet the criteria as defined in the protocol."
3374306|NCT02375204|Other|Arm B: TI-CE|"Patients will receive treatment for a total of 5 cycles.~Cycles 1-2 (1 cycle = 14 days)~paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 including premedication as defined in the protocol (eg, dexamethasone, diphenhydramine and H2 blocker)~ifosfamide 2000 mg/m^2 IV daily on Days 1-3 with mesna protection as defined in the protocol~G-CSF 10 µg/kg subcutaneously on Days 3-15 (cycle 1) and Days 3-14 (cycle 2) or pegylated G-CSF 6 mg subcutaneous on Day 4 or 6 (cycle 1) and Day 4 or 5 (cycle 2)~leukapheresis every 14 days, if there is an inadequate number of CD34+ cells/kg collected in cycle 1~Cycles 3-5 (1 cycle = 21 days)~carboplatin daily on Days 1-3~etoposide 400 mg/m^2 daily on Days 1-3~stem cell reinfusion on day 5~pegylated G-CSF 6 mg subcutaneously or G-CSF at approximately 5 µg/kg daily on Days 5-15~Patients may commence with each Arm B cycle provided they meet the criteria as defined in the protocol."
3255633|NCT01435694|Active Comparator|Conventional Therapy|Training sessions will focus on locomotor function improvements. Subjects will receive 45 minutes of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that they will be trained on walking abilities (like walking at different speeds, rapid changes directions) for 30 minutes with or without assistive aids.
3255634|NCT01435707|Experimental|Caudal 40 group|subjects who undergo caudal epidural block with triamcinolone 40 mg
3255635|NCT01435707|Experimental|STE 20 group|subjects who undergo selective transforaminal block with triamcinolone 20 mg
3255636|NCT01435707|Experimental|Caudal 20 mg|subjects who undergo caudal epidural block with triamcinolone 20 mg
3255637|NCT01435707|Experimental|STE 40 group|subjects who undergo selective transforaminal block with triamcinolone 40 mg
3374309|NCT02296918|Experimental|Double combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
3374310|NCT02296918|Experimental|Double combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles.
3374311|NCT02296918|Experimental|Triplet combo with acalabutinib in RR|For Relapse Refractory subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with rituximab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
3374312|NCT02296918|Experimental|Triplet combo with acalabutinib in TN|For previously untreated subjects, acalabrutinib starting at Cycle 1 as monotherapy then combine with obinutuzumab starting at Cycle 2 for 6 cycles. Venetoclax, starting at Cycle 3 taken up to 12 cycles
3374313|NCT02287493||Meropenem|Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.
3374314|NCT02287493||Ceftazidim|Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.
3374315|NCT02259517|Experimental|Guanfacine|Participants will be administered extended-release guanfacine, which is in tablet form, and will be instructed to take the medication once daily for 6 weeks. The daily dose will range between 1 and 4 mg.
3374316|NCT02259517|Experimental|Lisdexamfetamine|Participants will be administered lisdexamfetamine, which is in tablet form, and will be instructed to take the medication daily for 6 weeks. The daily dose will range between 30 and 70mg.
3374317|NCT02254863|Experimental|Intrathecal administration of DUOC-01|Administration of DUOC-01, given intrathecally, between day 26 and 28 post unrelated cord blood transplant
3374318|NCT02211794||1 cohort|subject requires primary total knee arthroplasty with the Journey II BCS Total Knee System, including patella resurfacing due to degenerative joint disease (primary osteoarthritis, post-traumatic arthritis, avascular necrosis, rheumatoid arthritis)
3374319|NCT02209545|Experimental|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
3374320|NCT02209545|Placebo Comparator|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
3374321|NCT02156232|Active Comparator|TIPS, SPSS Emboliaztion|The covered stents wil be used for TIPS The SPSS will be embolized during the procedure of TIPS
3374322|NCT02156232|Active Comparator|TIPS alone|The covered stents will be used for TIPS No embolization of SPSS will be performed during TIPS
3374323|NCT02145741|Experimental|Xentuzumab|Patients to receive low, middle, and high doses of Xentuzumab intravenously (IV)
3255638|NCT01435720|Experimental|Cohort 1|0.0125 mg/kg
3255639|NCT01435720|Experimental|Cohort 2|0.05 mg/kg
3255640|NCT01435720|Experimental|Cohort 3|0.2 mg/kg
3255641|NCT01435720|Experimental|Cohort 4|0.375 mg/kg
3374324|NCT02132611|Experimental|Diamondback 360® Coronary OAS Micro Crown|Diamondback 360® Coronary Orbital Atherectomy System Micro Crown
3374325|NCT02119988|Experimental|TIPS combined with variceal embolization|"The covered stents will be used for TIPS~The gastroesophageal collaterals will be embolized during the procedure of TIPS"
3374326|NCT02119988|Active Comparator|TIPS alone|"The covered stents will be used for TIPS~No embolization of any collateral will be performed during TIPS"
3374327|NCT02119689||Diabetic Patients|Mild, Moderate and Severe Retinopathy
3374328|NCT02119689||Healthy Controls|Age and sex matched Healthy Controls
3374329|NCT02117791||Group 1|Riociguat treatment group
3374330|NCT02001142|Experimental|Exercise|
3374331|NCT02001142|No Intervention|Sedentary Control|
3374332|NCT02000869||wait-listed kidney transplant candidates|
3374333|NCT01969643|Experimental|LV Dose Escalation|
3374334|NCT01969643|Experimental|LV + Trastuzumab|
3255642|NCT01435733||Parents of children with ASD|Parents with one or more children diagnosed with Autism Spectrum Disorder
3255643|NCT01435746|Experimental|Liberal Transfusion|Patients in the liberal transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 10 g/dl. The aim should be to reach a hemoglobin concentration between 10 and 12 g/dl.
3374335|NCT01969643|Experimental|LV Monotherapy|LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
3374336|NCT01910402|Experimental|DTG/ABC/3TC FDC|As per the randomization schedule subjects will be administered with DTG/ABC/3TC (50mg/600mg/300mg) FDC tablet OD up to Week 48 and if continued if applicable in the Continuation Phase. DTG/ABC/3TC FDC may be administered with or without food
3374337|NCT01910402|Active Comparator|ATV +RTV +TDF/FTC FDC|As per the randomization schedule subjects will be administered with ATV (300mg capsule) +RTV (100mg tablet) + TDF/FTC (300mg/200mg tablet) FDC OD up to Week 48. ATV+RTV+ TDF/FTC FDC must be taken with food
3374338|NCT01901094|Other|Arm 1: ALND + nodal radiation therapy|"Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment.~Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks."
3374339|NCT01901094|Other|Arm 2: Axillary radiation and nodal radiation therapy|Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
3255644|NCT01435746|Active Comparator|Conservative Transfusion|Patients in the conservative transfusion group will receive red blood cell transfusions when their hemoglobin concentration drops below 8 g/dl. The aim should be to reach a hemoglobin concentration between 8 and 10 g/dl.
3255645|NCT01435811|Experimental|Norovirus challenge pool (GII.4, CIN-1)|
3376214|NCT01852968||Patients with type 1 diabetes|"Hippocampal neurochemistry and metabolism will examined in Patients with type 1 diabetes using magnetic resonance spectroscopy.~Patients with type 1 diabetes will also undergo neurocognitive testing to assess hippocampal function"
3255646|NCT01435811|Placebo Comparator|Sterile water|
3255647|NCT01435837|Experimental|Caffeine and hydration.|"200 mg of caffeine (over the counter caffeine tablet)~1 liter of water"
3255648|NCT01435837|Placebo Comparator|No caffeine, no hydration.|
3255649|NCT01435850|Sham Comparator|HIP STEM SL PLUS|study group
3255650|NCT01435850|Active Comparator|HIP STEM SL PLUS MIA|control group
3255651|NCT01435863|Experimental|SP-02L|
3255652|NCT01435876|Active Comparator|Surgical arm|UNIOCULAR/BINOCULAR RECESSION/RESECTION PROCEDURES
3255653|NCT01435876|Active Comparator|Exercises|ORTHOPTICS/MINUS LENS THERAPY
3255654|NCT01435876|Active Comparator|Postoperative Exercises|POST SURGICAL ORTHOPTICS/MINUS LENS
3255655|NCT01435876|Active Comparator|Surgical|
3255656|NCT01435902|Active Comparator|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 4 weeks
3255657|NCT01435902|Active Comparator|Fluticasone Propionate|Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder once daily for 4 weeks
3255658|NCT01435915|Experimental|Subjects receiving ropinirole|Eligible subjects will receive single and multiple oral dose of ropinirole prolonged release tablet in sequence over 14 days without dosing on washout period from Day 2 to Day 7.
3255659|NCT01435941||Respondents who report episodic migraines (EM)|Survey respondents whose headaches meet the diagnostic criteria for migraine and report that they experienced between 1 and 14 headache days in the month prior to the survey administration
3255660|NCT01435954||Patients with Benign Prostatic Hyperplasia (BPH)|Insured male patients age 50 or older with BPH but no evidence of acute urinary retention (AUR) or prostate surgery at the index date
3255661|NCT01435967||Cohort A|Children aged <=5 years in Belgium, with opportunity to receive Rotarix, requiring hospitalisation during which rotavirus detection test was performed and with available results.
3255662|NCT01435980|No Intervention|basal treatment|basal treatment
3255663|NCT01435980|Experimental|Gastric Bypass|basal treatment and Gastric Bypass
3255664|NCT01435980|Experimental|Exenatide|basal treatment and Exenatide
3374345|NCT01853826|Experimental|afatinib|Patients will receive afatinib once daily
3374346|NCT01811862|Experimental|Acupuncture|Acupuncture treatment once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
3374347|NCT01811862|Sham Comparator|Sham acupuncture|Sham acupuncture once daily inpatient for 5 consecutive days starting at on the day after chemotherapy plus usual pre- and post-transplantation care.
3374352|NCT01796197|Experimental|Treatment Arm|"Run in: Trastuzumab IV 4 mg/kg, Pertuzumab IV 840 mg (Day 1 Week 1)~Pre-Op:~Trastuzumab IV 2 mg/kg weekly, Paclitaxel 80 mg/m2 IV weekly (beginning on Day 8 Week 2) x 16 doses.~Starting Day 21 (week 4) continue trastuzumab and paclitaxel as above, add Pertuzumab 420 mg IV x 3 weeks. After completing 16 doses of Paclitaxel, Trastuzumab (6 mg/kg IV) and Pertuzumab 420 mg IV may be continued x 3 weeks until surgery Modified Radical Mastectomy~Post-Op:~Option 1: Adriamycin 60 mg/m2 IV and Cyclophosphamide 600 mg/m2 IV x 2-3 weeks x 4 cycles. Followed by Trastuzumab 8 mg/kg and Pertuzumab 840 IV load; followed by Trastuzumab 6 mg/kg every and Pertuzumab 420 mg IV every 3 weeks to complete 12 months of HER2-directed therapy Option 2: Continue Trastuzumab 6 mg/kg and Pertuzumab 420 mg x 3 weeks to complete 12 months of HER2-directed therapy Post-mastectomy radiation to the chest wall / regional lymph nodes and endocrine therapy by standard of care."
3374353|NCT01790035|Experimental|LGG|LGG (containing 10^10 viable bacteria) taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
3374354|NCT01790035|Experimental|Placebo|Placebo taken by mouth twice daily beginning at baseline (but starting at least 3 days prior to the start of radiation) and continue during RT and for the 2 weeks following RT.
3374355|NCT01790035|No Intervention|No intervention|Patients who prefer not to receive LGG will not be randomized and will receive standard of care RT. These patients will serve as a non-intervention comparator cohort to the first 20 patients and will have specimens collected but will not receive the placebo.
3255665|NCT01435993|Experimental|Active|GSK1223249 slow (60 minutes) intravenous infusion
3255666|NCT01435993|Placebo Comparator|Placebo|Saline slow (60 minutes) intravenous infusion
3255667|NCT01436019||anti-TNF treatment|Children or young adolescents with juvenile idiopathic arthritis receiving either infliximab, adalimumab or etanercept.
3255668|NCT01436032|Experimental|N1539 15 mg|
3255669|NCT01436032|Experimental|N1539 30 mg|
3255670|NCT01436032|Active Comparator|Ketorolac|IV
3255671|NCT01436032|Placebo Comparator|Placebo|IV
3255672|NCT01436032|Experimental|N1539 7.5mg|
3255673|NCT01436058|Experimental|stem cell recipient|patients with ankle joint osteoarthritis
3259537|NCT01471717|Active Comparator|C2: Victrelis 800 mg TID x 3 days|Cohort 2: Subjects will begin administration of Victrelis 800 mg three times a day (TID) on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days
3259538|NCT01471717|Active Comparator|C 2:Victrelis 800 mg TID with INX-08189 50 mg QD|Cohort 2: Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days
3259539|NCT01471717|Placebo Comparator|C1: Placebo with Victrelis 800 mg|Cohort 1: Placebo QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days
3259540|NCT01471717|Placebo Comparator|C 2: Victrelis 800 mg with Placebo|Cohort 2: Victrelis 800 mg TID will be administered concurrently with Placebo QD for 5 additional days
3259541|NCT01471730|Placebo Comparator|Saline solution|
3259542|NCT01471730|Active Comparator|Fibrinogen|
3259543|NCT01471730|Active Comparator|Prothrombin complex|
3259544|NCT01471743|Experimental|Impact Advance Recovery (R)|3 supplements per day for 5 days pre-operatively
3259545|NCT01471743|Active Comparator|Standard Supplement|3 supplement per day for 5 days pre-operatively
3259546|NCT01471756|Experimental|iSnare with Gonak solution|
3259547|NCT01471756|Experimental|Snaremaster braided snare with Gonak solution|
3259548|NCT01471756|Experimental|iSnare with saline solution|
3259549|NCT01471756|Experimental|Snaremaster braided snare with saline solution|
3259550|NCT01471769|Experimental|pain management video|Experimental
3259551|NCT01471769|Placebo Comparator|falls prevention video|placebo
3374356|NCT01763320|Experimental|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
3255674|NCT01436097|Active Comparator|Usual Care arm|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
3255675|NCT01436097|Experimental|Information provision intervention|Participants in the Information provision group will receive the same care as those in the Usual Care arm. In addition, the Information provision group participants will receive weekly reminders about the benefits of eating five servings of fruits and vegetables a day and their Way to Health portal will provide graphical depictions of their produce purchase proportions through information from their Price Plus card. This data will be available to them throughout the entire intervention.
3255676|NCT01436097|Experimental|Information provision + flat incentive|Participants assigned to the Information provision + flat group will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the Information provision arm.
3374357|NCT01763320|Active Comparator|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
3374358|NCT01598116||Hemangioma|Identify biomarkers in children with hemangiomas.
3374359|NCT01598116||Without Hemangioma|Age-matched controlled group without hemangioma.
3374360|NCT01585805|Experimental|Arm A (veliparib, gemcitabine hydrochloride, cisplatin)|Patients receive veliparib PO BID on days 1-12 or 1-21. Patients also receive gemcitabine hydrochloride IV over 30 minutes and cisplatin IV over 30 minutes on days 3 and 10. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3374361|NCT01585805|Active Comparator|Arm B (gemcitabine hydrochloride, cisplatin)|Patients receive gemcitabine hydrochloride IV and cisplatin IV as patients in arm A. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3255677|NCT01436097|Experimental|Information provision + tiered incentive|In addition to receiving all features of the Information provision treatment the participants assigned to the Information provision + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption. In this arm, the more participants spend on produce the more money they can earn back.
3255678|NCT01436123|Experimental|Stenting + Micro-infusion|Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.
3255679|NCT01436123|Active Comparator|Stenting|Put in everolimus-eluting stent
3374362|NCT01585805|Experimental|Arm C (veliparib)|Patients receive veliparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3259552|NCT01471795||Study Population|150 subjects with end-stage heart failure who have been scheduled to undergo device implantation with a VAD, either as a bridge to cardiac transplantation or for destination therapy.
3259553|NCT01471808|Active Comparator|CSII|continuous subcutaneous insulin infusion
3374365|NCT01147822|Experimental|Pazopanib|800 mg administered once daily orally continuous dosing
3259554|NCT01471808|Active Comparator|Metformin & Pioglitazone|CSII combined with metformin and pioglitazone
3259555|NCT01471808|Active Comparator|Sitagliptin|CSII combined with sitagliptin 100mg/d
3259556|NCT01471821|Experimental|simplification|Lopinavir/ritonavir (400/100 BID) plus lamivudine (300 QD)
3259557|NCT01471821|Active Comparator|Continue with current treatment|
3259558|NCT01471847|Experimental|BEZ235 + Trastuzumab (Phase l /Phase ll)|"Phase l: Eligible patients will receive increasing doses of oral BEZ235 administered on a continuous twice daily (BID) schedule + weekly trastuzumab at a fixed dose of 2 mg/kg. Treatment will be organized into cycles of 28 days.~Phase ll: Eligible patients will receive weekly trastuzumab (2 mg/kg) + oral BEZ235 on a continuous twice daily (BID schedule) at the MTD or RP2D.~Treatment will be organized into cycles of 21 days."
3259559|NCT01471847|Active Comparator|Lapatinib + Capecitabine (Phase II)|Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
3259560|NCT01471860|Experimental|Device and Medical Management|"Medical Management, to be determined by the participant's physician, described as:~Optimal pharmacological therapy: Prescribed to a beta blocker, a diuretic, and an ACE (Angiotensin-converting-enzyme) inhibitor or ARB (Angiotensin Receptor Blocker) unless contraindicated or not tolerated. These drugs must be used in a manner consistent with their labeling.~Stable pharmacological therapy: No more than a 50% increase or a 50% decrease of the dosage of any one medication, and post titration of all heart failure medications.~Participants should remain on their prescribed heart failure medications and same dosing schedule for the duration of the study unless investigators determine medically necessary changes are needed. Additionally, every effort should be made to maintain adequate rate control for subjects with atrial fibrillation throughout the duration of the study."
3259561|NCT01471873||Keratoconus Group (KG)|Keratoconus group (KG) included patients with progressive keratoconus.
3259562|NCT01471873||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
3259563|NCT01471886|Active Comparator|Naproxen|Every 8 hours for 4 days.
3259564|NCT01471886|Experimental|Ketorolac Tromethamine|Every 8 hours for 4 days
3259565|NCT01471899|Active Comparator|Naproxen|2 tablets every 8 hours for 4 days.
3259566|NCT01471899|Experimental|Ketorolac Tromethamine|10 drops every 8 hours for 4 days
3259567|NCT01471925|Experimental|Esomeprazole (40mg) + Sodium Bicarbonate (721mg)|
3374366|NCT01147822|Active Comparator|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
3374367|NCT01090154|Experimental|Cimzia|Treatment with open label Cimzia (certolizumab pegol)
3374370|NCT00695279||Participants|Venipuncture
3374371|NCT00645645||holoprosencephaly (HPE)|individuals with overt or subtle clinical findings consistent with the HPE spectrum are eligible to participate
3374372|NCT00580203||1|Patients with head and neck cancers
3374373|NCT00521846||1|As part of their routine care, patient's will receive Biomet modular radial head replacement. This study is an observational, prospective study that monitors the patient's pain, functional ability, and patient-reported outcomes.
3374374|NCT00481546|Experimental|Experimental|All clinical trial subjects received the same vector.
3374376|NCT00328653|Experimental|NOVA22007 0.05%|four times daily
3374377|NCT00328653|Experimental|NOVA22007 0.1%|four times daily
3374378|NCT00328653|Sham Comparator|Vehicle|administered four times daily
3376215|NCT01852968||healthy controls|"Hippocampal neurochemistry and metabolism will be examined in healthy controls using magnetic resonance spectroscopy.~Healthy controls will also undergo neurocognitive testing to assess hippocampal function"
3376216|NCT01850082|Other|Endoscopic Vein Harvest (EVH)|An endoscopic vein harvest allows a portion of vein from the inside of the leg to be removed through small incisions. This reduces the length of the incision by several inches. An endoscope, or video camera, is used to view the vein and remove the needed length.
3376217|NCT01850082|Other|Open Vein Harvest (OVH)|"Open vein harvesting is the traditional method for vein harvesting. It is performed under direct vision using a single long incision or, more commonly, multiple-smaller incisions (referred to as bridging technique) along the course of the vein."
3376218|NCT01846663|Experimental|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months of treatment
3376219|NCT01846663|Placebo Comparator|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
3376220|NCT01844518|Experimental|Short and Long Terms: Orencia|"Short Term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 4 months~Long term: Orencia 50 mg/mL, 87.5 mg/mL, 125 mg/mL pre-filled syringes subcutaneously (0.4 mL/0.7 mL/1.0 mL) weekly for 20 months"
3376221|NCT01844362|Experimental|Uterine transplantation|Patients undergo transplantation of the uterus from live donor.
3376222|NCT01795586|Experimental|Dose Escalation|Every patient will receive eribulin and carboplatin. Each cycle is 21 days (or 3 weeks). Eribulin and carboplatin will be given intravenously on days 1 and 8 of each cycle.
3376223|NCT01795573|Other|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg cells given prior to allogeneic stem cell transplant
3259568|NCT01471925|Active Comparator|Nexium®|
3259569|NCT01471938||Caucasians|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3259570|NCT01471938||Afro Americans|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3259571|NCT01471938||East and Southeast Asian|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3259572|NCT01471938||Hispanics|31 healthy adults in an age range of 18 to 65 years with a BMI of 18.5 to 35 kg/m2 are planned to be recruited.
3259573|NCT01471951|Experimental|single embryo transfer|
3259574|NCT01471964|Experimental|MLN8237 and Erlotinib|"Phase I Erlotinib 100 mg PO daily* + MLN8237 30 mg PO BID (days 1 - 7), escalating to Erlotinib 150mg PO daily + MLN8237 starting at 30mg PO BID days 1-7, escalating to 40mg BID (days 1 - 7) , then 50mg BID (days 1 - 7).~Phase II Erlotinib 150mg PO daily + MLN8237 at MTD from phase I."
3259575|NCT01471977|Experimental|education, counselling, default tracer|
3259576|NCT01471990|Active Comparator|PACAP38|
3259577|NCT01471990|Active Comparator|VIP|
3259578|NCT01472003|Experimental|ABT-806 Arm|Subjects with advanced solid tumors
3259579|NCT01472003|Experimental|ABT-806i Arm|Subjects with advanced solid tumors
3259580|NCT01472016|Experimental|Cohort A|ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.
3259581|NCT01472016|Experimental|Cohort B|ABT-700 plus docetaxel.
3259582|NCT01472016|Experimental|Cohort C|ABT-700 plus FOLFIRI/cetuximab
3259583|NCT01472016|Experimental|Cohort D|ABT-700 plus erlotinib
3259584|NCT01472029|Experimental|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|
3259585|NCT01472042||Sports induced concussion|Exposure to sports induced concussion
3259586|NCT01472042||Routine Athletic Exertion|Exposure to routine athletic exertion (non-concussion control)
3259587|NCT01472042||Other Non-Penetrating Trauma to the Head|Exposure to other non-penetrating trauma to the head that is witnessed or self-reported
3259588|NCT01472055|Experimental|Fludarabine|Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients
3259589|NCT01472068|Experimental|Inko RS device|30 minutes of treatment with the Inko RS device, five days each week, for 12 weeks.
3259590|NCT01472094||Patients|All patients 65 years old with Stage I to III breast cancer who are beginning adjuvant or neo-adjuvant chemotherapy.
3259591|NCT01472120||P and C|"P: NAFLD patients~C: Healthy controls"
3259592|NCT01472133||Young Healthy Volunteers|Healthy volunteers under the age of 40
3374384|NCT05159154||Septic Shock Patients|Patients admitted with diagnosis of septic shock
3374385|NCT05159141|No Intervention|control|Infant sleep monitoring (Actigraphy and sleep dairy) and parental surveys
3376224|NCT01717586|Active Comparator|Pravastatin Group|Pregnant women at high-risk for preeclampsia who are taking pravastatin during their pregnancy.
3255680|NCT01436136|Active Comparator|Intervention group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
3255681|NCT01436136|Active Comparator|Usual care (control) group|Within the context of an open, cohort study, GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
3255682|NCT01436188|Other|001 (Healthy Elderly Cohort 1)|standard frequent CSF sampling procedure for 36 hours
3255683|NCT01436188|Other|002 (Healthy Elderly Cohort 2)|an alternative frequency of CSF sampling procedure for 36 hours
3259593|NCT01472133||Older healthy volunteers|Healthy volunteers over the age of 70
3259594|NCT01472133||Patients with atrial fibrillation|Patients with permanent AF
3259595|NCT01472133||Patients with a pacemaker|Patients who have an implanted pacemaker that is continually pacing
3259596|NCT01472133||Patients with restricted chest movement|Patients whose chest expansion is less than 2.5cm
3259597|NCT01472146|Experimental|Zometa neoadjuvant HER2 breast cancer|"Zo-Nantax arm - Neoadjuvant chemotherapy with association of zoledronic acid and standard treatment with anthracycline followed taxane plus trastuzumab in locally advanced breast cancer HER2 positive HR positive/negative.~Drug:Cyclophosphamide Drug:Adriamycin Drug:Docetaxel Drug:Trastuzumab Drug:Zolendronic acid"
3259598|NCT01472159|No Intervention|CGM-Usual Care|Routine CGM education
3259599|NCT01472159|Experimental|CGM-Teamwork|"Routine CGM education~CGM Family Teamwork Intervention"
3259600|NCT01472172|Experimental|Cryobiopsy|Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
3259601|NCT01472198|Experimental|Simtuzumab (open-label)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3259602|NCT01472198|Experimental|Simtuzumab 200 mg (randomized)|Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3259603|NCT01472198|Experimental|Simtuzumab 700 mg (randomized)|Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
3259604|NCT01472198|Placebo Comparator|Placebo (randomized)|Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
3259605|NCT01472211|Experimental|intervention filter|children consuming purified and zinc enriched water delivered by a household-based water filter
3259606|NCT01472211|Placebo Comparator|placebo filter|children consuming purified water delivered by a household-based water filter
3259607|NCT01472211|Active Comparator|disinfection tablets|children will consume water treated with government promoted disinfection tablets (aquatabs)
3259608|NCT01472237|Active Comparator|Nutritional intervention|It will last 6 months. Will be conducted by a physician nutrition specialist assisted by a technician in diet and nutrition. The first visit will take place during admission. The patient receives dietary advice and a customized diet designed to optimize energy intake and macro/micro-nutrients needs.
3259609|NCT01472237|Placebo Comparator|Care as usual|The patients are referred to their cardiologyst and primary care physicians
3259610|NCT01472250||chemotherapy|Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
3259611|NCT01472263|Experimental|Pentoxifylline|
3259612|NCT01472263|Placebo Comparator|Placebo|
3259613|NCT01472276|No Intervention|Control|
3259614|NCT01472276|Active Comparator|Web-based program|
3259615|NCT01472302|Experimental|ASV|Adaptive Support Ventilation
3259616|NCT01472302|Active Comparator|PCV|Pressure Controlled Ventilation
3259617|NCT01472315|Active Comparator|medroxyprogesterone acetate|
3259618|NCT01472315|Placebo Comparator|Placebo|Placebo pills taken in the same way as the active comparator
3259619|NCT01472328|Experimental|Hyperbaric oxygen therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
3259620|NCT01472328|Sham Comparator|Hyperbaric room air|Effect of 2 hrs hyperbaric room air herapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
3259621|NCT01472354|No Intervention|Standard of care referral to specialist|Subjects are referred for education, counseling and evaluation for HCV treatment to a specialty health care provider
3259622|NCT01472354|Experimental|LEAP-C Group Intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with HCV treatment to decrease decisional conflict, increase HCV knowledge, improve communication
3259623|NCT01472393|Experimental|Creatine supplementation|
3259624|NCT01472393|Placebo Comparator|Placebo|
3259625|NCT01472406|Experimental|Closed-loop session|The study consists of an evaluation of the Sansum Closed-loop Artificial Pancreas Device, insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, and a Safety Health Monitoring System. during a 24-hour closed-loop in a clinic environment (Sansum Diabetes Research Institute, Santa Barbara, CA).
3259626|NCT01472458|Active Comparator|Active Intervention|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
3374386|NCT05159141|Experimental|Infant behavioral sleep intervention|Interventionists collaborate with the family to design a tailored sleep intervention strategy, which involves appropriate sleep schedule and bedtime routine, putting the child to bed while still sleepy rather than when already asleep, and waiting 1 to 2 minutes before attending to the child during nocturnal awakenings. Parents are educated to implement the behavioral protocol at bedtime and subsequent night wakings.
3374387|NCT05159128|Experimental|Part 1: Single Ascending Dose (SAD) Cohorts|Healthy Japanese participants will receive JNJ-75105186 or matching placebo orally in Cohorts 1-3.
3374388|NCT05159128|Experimental|Part 2: Single Dose (SD) Cohort|Healthy Chinese participants will receive JNJ-75105186 or matching placebo orally in Cohort 4.
3255684|NCT01436188|Other|003 (Healthy Elderly Cohort 3)|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
3255685|NCT01436188|Other|004 (Elderly Volunteers with MCI or AD)|standard CSF sampling procedure for 36 hours
3374389|NCT05159115|Active Comparator|Low-FODMAP diet|Patients with IBS on a 4-week low-FODMAP diet.
3374390|NCT05159115|Experimental|Starch- and Sucrose Reduced Diet|Patients with IBS on a s 4-week Starch- and Sucrose Reduced Diet (SSRD).
3374391|NCT05159102|Experimental|Workshop group|Participants in the workshop group will be offered four one-day workshops (3-hours each) covering topics of 1) Sensory Integration, 2) Communication, 3) Physical activity, and 4) Sports (during intervention)-[Parents and Children-Workshop Group]. These workshops will be offered in person. In addition to the workshops, this group and the home-based group will receive information (activity booklets via the Fit Families App) and physical education (physical activity)-related equipment.
3374392|NCT05159102|Experimental|Home-based group|Participants in the home-based group will not participate in the four half-day workshops (face to face), but they will receive the same information remotely (workshop content) and will have access to the activity booklets (via the App) and physical activity equipment as the workshop group (during intervention)-[Parents and Children-Home Group].
3374393|NCT05159102|Other|wait-listed home-based group|Wait-list home-based group will serve as the control group (during intervention)-[Parents and Children-Control Group]. This group will be instructed to continue their typical routines and activities for the duration of the intervention. They will be asked to attend the pre and posttest, as well as a follow up three weeks after the completion of the 12-week period. Immediately following the follow-up test, participants in the wait-list home-based group will be offered the home-based program (e.g., receiving the same intervention protocol and materials (physical education equipment and lesson plans/workbook) following all procedures as described for that group previously.
3374394|NCT05159089|Active Comparator|Nordic Walking Group|Each group will be received 26 sessions of nordic walking. In each session, the intensity will be controlled and expected to be between 3 to 5 in the Borg scale adaptation. Patients will receive a schedule with all three-month sessions.
3374395|NCT05159089|Experimental|Physical activity base on SEM (Socioecological models)|The intervention group based on SEM will apply nordic walking in the same way as the Nordic Walking group. However, in this group, instructors will apply a SEM (instructors will not be the same as in the Nordic Walking group): in each session, the instructors in charge of the Nordic Walking will be also in charge to prescribe the PA.
3374396|NCT05159089|No Intervention|Congrol group|Control group outcomes assessment will be the same as the intervention group. However, they will receive common health care professional advice. A common health care professional advice used to recommend patients to walk more and do more PA or physical exercise at the gym. Visits with doctors and nurses will be the same as the intervention group. The difference will be that at intervention group nurses will refer participants to the instructor's physiotherapist to promote PA throughout nordic walking and use the SEM to apply it.
3374397|NCT05159076|Experimental|Behavioral Intervention|Participants will undergo an eight-week behavioral intervention protocol (once a week) aimed at increasing the level of physical activity, consisting of a brief educational program: brief education for asthma and benefits of physical activity and behavioral intervention based on Social Cognitive Theory and the Theory of Stages of Behavior Change.
3255686|NCT01436188|Other|005 (Healthy Eldely Cohort 5)|an alternative lower frequency of CSF sampling in comparison to Cohort 1
3255687|NCT01436214|Experimental|APC-100|
3255688|NCT01436227|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 4 weeks for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients benefitting from treatment may continue pazopanib hydrochloride in the absence of disease progression.
3255689|NCT01436240||Spanish-speaking Latino participants|The investigators will conduct up to two rounds of PRO-CTCAE (patient-reported outcome- Common Terminology Criteria for Adverse Events) version questionnaire administration followed by cognitive interviews in Spanish-speaking Latino patients who are receiving cancer treatment or who have completed treatment for cancer within the past six months at one of the participating sites.
3255690|NCT01436292|Experimental|Albumin|Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level
3255691|NCT01436318||Respiratory Function|Children will undergo one session of pulmonary function and strength testing
3255692|NCT01436331|Active Comparator|Treatment As Usual (TAU)|
3255693|NCT01436331|Experimental|TAU+CBT for pts+Family Intervention+CM|
3255694|NCT01436344||1|"Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the cases group."
3255695|NCT01436344||2|Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
3255696|NCT01436409|Other|only vaginal touch|
3255697|NCT01436409|Experimental|vaginal touch +echography|
3255698|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive the TetraVax-DV Vaccine - Admixture TV003 at Day 0 and Day 180.
3255699|NCT01436422|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive the TetraVax-DV Vaccine - Admixture TV005 at Day 0 and Day 180.
3255700|NCT01436422|Placebo Comparator|Placebo|Participants will receive the placebo at Day 0 and Day 180.
3255701|NCT01436448|Experimental|Probiotics Lactobacillus Rhamnosus|dose of 1010 Colony forming Units (CFU) once daily till delivery will be given orally
3255702|NCT01436448|No Intervention|Placebo|Microcrystalline cellulose/d each, up till deliver
3255703|NCT01436474|Experimental|Varenicline|We will be comparing Varenicline to placebo in a single-blinded placebo controlled, randomized study
3255704|NCT01436474|Placebo Comparator|Placebo|We will be using a placebo in a randomized, controlled, single-blinded trial to look at varenicline for the indication of facilitating opioid tapering in opioid-dependent patients with chronic pain.
3255705|NCT01436487|Experimental|Cohort 1|Low dose MultiStem or Placebo
3255706|NCT01436487|Experimental|Cohort 2|High dose MultiStem or Placebo
3255707|NCT01436487|Experimental|Cohort 3|Highest, safe MultiStem dose (from Cohorts 1 and 2) or Placebo
3374398|NCT05159063||Right heart catheterization|
3374399|NCT05159050|Experimental|Intraperitoneal paclitaxel-loaded tumor penetrating microparticles (TPM)|Paclitaxel-loaded tumor penetrating microparticles (TPM), dose escalation starting at 50 mg/m^2 instilled in the peritoneal cavity at study start and again 6-8 weeks after the first TPM treatment.
3374400|NCT05159037|Experimental|Active GC-MRT Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will have been trained with prior to a stressful speech task.
3374401|NCT05159037|Placebo Comparator|Control Booster|Following four sessions of Gaze-Contingent Music Reward Therapy training participants' attention away from threats and towards neutral stimuli, participants will listen to a musical track they will not have been trained with but ranked as highly liked prior to a stressful speech task.
3374402|NCT05159024||Patients with leak after colorectal anastomosis|Patients who developed anastomotic leak, clinical or radiologic, after colorectal resection and anastomosis
3374403|NCT05159011|No Intervention|Usual Care|Virtual Genetic Counseling
3374404|NCT05159011|Other|Chatbot|computer program that that uses machine learning to provide tailored counseling to patients
3374405|NCT05158998|Other|propofol group|For patients in the propofol group, anaesthesia will be maintained with propofol infusion(target controlled infusion), of which the target concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Propofol infusion will be stopped at the end of surgery.
3255708|NCT01436513|Experimental|A|Premarin reference tablet as a single oral dose under fasted conditions
3255709|NCT01436513|Experimental|B|Premarin new tablet as a single oral dose under fasted conditions
3255710|NCT01436513|Experimental|C|Premarin reference tablet as a single oral dose under fed conditions
3255711|NCT01436513|Experimental|D|Premarin new tablet as a single oral dose under fed conditions
3374406|NCT05158998|Other|sevoflurane group|For patients in the sevoflurane group, anaesthesia will be maintained with sevoflurane inhalation, of which the concentration will be adjusted to maintain the BIS value between 40 and 60. Analgesia will be maintained with remifentanil(0.1-0.5ug/(kg.min)), muscle relaxation will be maintained with atracurium(10ug/(kg.min)). Sevoflurane inhalation will be stopped at the end of surgery.
3374407|NCT05158985|Experimental|group A|diclofenac sodium phonophoresis using continuous ultrasound with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
3374408|NCT05158985|Experimental|group B|diclofenac sodium phonophoresis using pulsed US with 1:1 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 4 minutes
3374409|NCT05158985|Experimental|group C|diclofenac sodium phonophoresis using pulsed US with 1:4 duty cycle with a frequency of 1MHz, an intensity of 1.5W/Cm2 for 10 minutes
3255712|NCT01436539|Experimental|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
3255713|NCT01436539|Active Comparator|Adefovire Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
3255714|NCT01436565|Experimental|dose escalation and expansion|SAR245408 taken every day in the morning: no eating 2 hours prior and 1 hour after dose; SAR256212 will be given weekly by IV infusion over 1 hour, right after the SAR245408 oral dose
3374410|NCT05158985|Experimental|group D|exercises only in form of (strengthening, stretching and occupational exercises).
3374411|NCT05158972||Dymista®|Dymista® (Azelastine hydrochloride and Fluticasone propionate) nasal spray as prescribed within routine clinical practice
3374412|NCT05158946|Experimental|Intervention Group|Participants in the intervention group received Future Oriented Group Training in addition to their treatment as usual.
3374413|NCT05158946|No Intervention|Control Group|Participants in the control group received their treatment as usual.
3374414|NCT05158933|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3374415|NCT05158920|Experimental|Intervention Group|Participants in the intervention group received Mindfulness-Based Cognitive Therapy in addition to their treatment as usual.
3374416|NCT05158920|No Intervention|Control Group|Participants in the control group received their treatment as usual.
3374417|NCT05158894||Ubrelvy-Exposed Women With Migraine|Pregnant women with migraine who took at least 1 dose of Ubrelvy, the exposure of interest, at any time during pregnancy as part of routine care.
3255715|NCT01436578||All Participants|All participants treated with posaconazole oral suspension during the pre-specified surveillance period.
3255716|NCT01436604|Other|LV dysfunction group|Cardiac MRI
3255717|NCT01436604|Other|Control group|Cardiac MRI
3255718|NCT01436630||Stroke|"To accomplish the study it was assessed a group of 12 post-stroke patients who were admitted in the Rehabilitation Clinic inside the University. As inclusion criteria it was established to be able to walk alone without supervision and with no aids.~All the patients signed an informed consent before performing the tests. To characterize the sample it were used the Fugl-Meyer scale, Orpington test, Mini Exam of the Mental State and some other data regarding the age, gender, type of the lesion and side of the lesion."
3255721|NCT01436669|Experimental|Home Monitoring|All participants will receive a home telemonitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home.
3255722|NCT01436695||Epicall group|patients will be connected to Epicall sensor
3255723|NCT01436721|No Intervention|Surgicel® absorbable Haemostat|
3374418|NCT05158894||Unexposed Women With Migraine|Pregnant women with migraine (treated and untreated) who have never taken Ubrelvy (i.e., before or during the enrolled pregnancy) or who have discontinued Ubrelvy at least 3 months prior to the first day of last menstrual period (LMP).
3255724|NCT01436734|Experimental|GIP|
3255725|NCT01436747|Active Comparator|Paricalcitol|
3255726|NCT01436747|Placebo Comparator|Matching placebo|
3374419|NCT05158881||Neonates delivered by normal vaginal delivery|
3255727|NCT01436773||Recent Acute Coronary Event|Patients admitted to the hospital for recent STEMI or NSTEMI.
3255728|NCT01436773||Stable Coronary Artery Disease|Patients with known Coronary Artery Disease without recent acute coronary event.
3255729|NCT01436773||No Coronary Artery Disease|Patients with no evidence of coronary artery disease, assessed by coronary angiography.
3255730|NCT01436786|Experimental|Guided Imagery Intervention|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
3374420|NCT05158881||Neonates delivered by elective cesarean section.|
3255731|NCT01436786|No Intervention|Control group|continues usual plan of care
3255732|NCT01436812|Placebo Comparator|zero end-expiratory pressure|not applying PEEP during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
3255733|NCT01436812|Active Comparator|positive end expiratory pressure|applying PEEP 10cmH2O during operation just applying TV=IBW*6-8ml IBW = (male; 50+0.91[(Ht-cm)-152.4], female; 45.5 +0.91[(Ht-cm)-152.4], RR 8-12/min,
3255734|NCT01436825||Group 1|
3255735|NCT01436838||Group 1|
3255736|NCT01436851|Experimental|Storage mite and placebo nasal challenge|Provocation in the nose with an allergen extract of a storage mite (A. Siro or L. Destructor) and with placebo allergen extract (physiologic salt water)
3255737|NCT01436864|Experimental|0.5 mg KH902|Patients will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, and then patients will receive 2 sham injections monthly, respectively, at the end of month 3 (visit 5), and following these injections you will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 5, month 8 and month 11)
3374421|NCT05158868||Post covid infected group|normal pregnant women infected by covid during 3rd trimester
3374422|NCT05158868||Control group|normal pregnant women
3374424|NCT05158842|Other|Bubble CPAP Oxygen Therapy|Feasibility of Device
3374425|NCT05158816||COVID-19 patients|COVID-19 patients admitted to the ICU
3374426|NCT05158803||covid 19 in acute phase|
3374427|NCT05158803||covid 19 follow up|
3374428|NCT05158777|Experimental|Experimental Group with the immunization course of 0,28 days or 0,56 days|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of experimental vaccine with the immunization course of 0,28 days or 0,56 days.
3374429|NCT05158777|Active Comparator|Control Group|1240 subjects (including 620 children aged 13-17 years and 620 adults aged 18 years and older) will receive two doses of control vaccine with the immunization course of 0,28 days or 0,56 days.
3374430|NCT05158764|Experimental|URGO BD001|Treatment with URGO DB001 during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12)
3374431|NCT05158764|Active Comparator|Kit Biflex|Treatment with Kit Biflex during 12-week treament period (5 medical visits are planned: D0, W2, W4, W8, W12
3374432|NCT05158725|Active Comparator|Standard Colonoscopy|Subjects will undergo colonoscopy using a standard colonoscope
3255738|NCT01436864|Sham Comparator|Sham-injection|Patients will receive sham injection once per month for three times, and then you will receive intravitreal injection of KH902 0.5mg/eye once per month for three times in the study eye, after three months' treatment they will receive intravitreal injection of KH902 once every three months, till month 12 (respectively at month 8 and month 11.
3255739|NCT01436877|Experimental|device|Insertion of Temporary Implantable Nitinol Device (TIND)
3255740|NCT01436890|Experimental|Low dose|Low dose revamilast
3374433|NCT05158725|Active Comparator|Discovery aided colonoscopy|Subjects will undergo colonoscopy using a a standard colonoscope and the Discovery aided colonoscopy
3255741|NCT01436890|Experimental|Medium dose|Medium dose Revamilast
3255742|NCT01436890|Experimental|High dose|High dose Revamilast
3374434|NCT05158725|Experimental|Discovery and G-EYE aided colonoscopy|Subjects will undergo colonoscopy using the G-EYE Endoscope and the Discovery aided colonoscopy
3374435|NCT05158699|Active Comparator|topical bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week.
3374436|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide|one subconjunctival injection of 10 mg triamcinolone acetonide during cataract surgery (TA, Triesence/Vistrec) in the inferotemporal quadrant, 6mm from the limbus.
3374437|NCT05158699|Active Comparator|intracameral ketorolac|intracameral injection of ketorolac tromethamine solution during cataract surgery (Omidria). A 4ml vial of Omidria (ketorolac concentration 2.88mg/ml) is added to 500ml of the irrigation solution used during cataract surgery, resulting in a ketorolac concentration of 0.023mg/ml. At the end of the surgery, the anterior chamber will be filled with the ketorolac solution.
3255743|NCT01436890|Placebo Comparator|Placebo|Matching placebo in triple dummy format
3255744|NCT01436916|Active Comparator|oral cholecalciferol + lifestyle counselling|will receive Oral cholecalciferol
3255745|NCT01436916|Placebo Comparator|Placebo + lifestyle counselling|will receive placebo
3255746|NCT01436929|Experimental|Silymarin|Silymarin: prophylactic administration of silymarin with anti-TB drugs Placebo: prophylactic administration of placebo with anti-TB drugs
3255747|NCT01436929|Placebo Comparator|Placebo|administration of placebo with anti-TB drugs
3374438|NCT05158699|Active Comparator|subconjunctival triamcinolone acetonide & intracameral ketorolac|one subconjunctival injection of 10 mg triamcinolone acetonide & intracameral injection of ketorolac tromethamine solution (Omidria; 0.023mg/mL) during cataract surgery.
3374439|NCT05158686||Paclitaxel-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with paclitaxel coated balloon immediately proximal to the CTO during the index procedure
3374440|NCT05158686||Non-coated balloon angioplasty|Patients with previous failed recanalization of a CTO treated with non-coated balloon immediately proximal to the CTO during the index procedure
3374441|NCT05158673|Placebo Comparator|Group A (Placebo)|The administration of two capsules of 500 mg orally of placebo (excipient q.s. starch capsule) 1 every 12 hours, for 12 weeks.
3374442|NCT05158673|Active Comparator|Group B (Flavonoid)|Two capsules of 500 mg of the flavonoid supplement (whose total flavonoid content is 15 mg/capsule) orally every 12 hours for 12 weeks.
3255748|NCT01436942|Experimental|Exercise group|
3374443|NCT05158660|Experimental|patients assessed by transcranial duplex sonography|
3374444|NCT05158647|Placebo Comparator|control group|10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade
3374445|NCT05158647|Active Comparator|MgSo4 group|10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used.
3374446|NCT05158634||Cerebral Palsy|"Inclusion Criterias: Being diagnosed with Cerebral Palsy. Volunteer. Be between the ages of 6-18. Being at level 1 and level 2 according to Gross Motor Function Classification System (GMFCS) (Level 1 and 2).~To have the cognitive skills to understand and apply the evaluation parameters.~Exclusion Criterias: Cognitive impairment of participants diagnosed with Cerebral Palsy. Participants diagnosed with Cerebral Palsy have vision or hearing problems. Participants diagnosed with Cerebral Palsy must have a history of trauma such as botox or muscle relaxation operation and/or fracture at least 6 months before participating in the study."
3374447|NCT05158621||Advanced/Metastatic Colorectal Cancer|Eligible patients include those with newly-diagnosed or recurrent advanced/metastatic CRC who are initiating fluoropyrimidine and oxaliplatin (FOLFOX or CAPEOX) in combination with bevacizumab. Patients will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE, to warrant manufacturing of a patient-specific vaccine. Patients with sufficient neoantigens will have vaccine manufactured while receiving FOLFOX or CAPEOX/bevacizumab.
3374448|NCT05158621||Localized Colon Cancer|Eligible patients include those with high-risk Stage II or Stage III colon cancer who have MRD based on the presence of ctDNA following surgical resection. Patients with MRD will then be assessed to determine if sufficient neoantigens are identified using Gritstone's proprietary prediction algorithm, EDGE, to warrant manufacturing of a patient-specific vaccine.
3374449|NCT05158608|Active Comparator|Cyclophosphamide on day +3,+4 at dose 50 mg/kg/day|Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 50 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
3255749|NCT01436942|No Intervention|Control group|
3255750|NCT01436955|Experimental|A|
3255751|NCT01436955|Placebo Comparator|B|
3255752|NCT01436968|Experimental|ProstAtak®|Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT
3255753|NCT01436968|Placebo Comparator|Control|Placebo + valacyclovir + radiation therapy +/- ADT
3255754|NCT01436981||CABG with papaverine|Patients with CABG procedure
3255755|NCT01436994|Active Comparator|Block and Replace|Carbimazole is commenced in a dose of 0.75 mg/kg/day. The intention is to completely prevent endogenous thyroxine production. Thyroxine is then added in a replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.
3374450|NCT05158608|Experimental|Cyclophosphamide on day +3,+4 at dose 25 mg/kg/day|Post-transplantation Cyclophosphamide will be aplly for GVHD prophylaxis on day +3,+4 at dose 25 mg/kg/day in combination with cyclosporine A at 3 mg/kg/day from day +5 and mycophenolate mofetil at dose 30-45mg/kg/day from day +5.
3374451|NCT05158595|Experimental|low intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
3255756|NCT01436994|Active Comparator|Dose Titration|"Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining the euthyroid state. The principal measure of control during the first 6 months will be thyroid hormone levels rather than TSH.~Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.~Drug: Carbimazole 5mg and 20 mg tablets. Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry Drug: propylthiouracil 50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry."
3255757|NCT01437020|Experimental|Dose escalating-IV infusion of SCH708980 and Ambisome|
3255758|NCT01437046|Experimental|Doxazosin|Doxazosin 16mg/day
3255759|NCT01437046|Placebo Comparator|Placebo|Placeno
3255760|NCT01437059|Active Comparator|ALN-PCS02|
3255761|NCT01437059|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3255762|NCT01437072||Total study population|
3255763|NCT01437137|Active Comparator|LMA group|
3255764|NCT01437137|Experimental|I-gel group|
3255765|NCT01437150|Experimental|Simple posterior wall fracture|Simple posterior wall fracture means the fracture was only occurred in the posterior wall of acetabular.
3255766|NCT01437150|Experimental|Complex posterior wall fracture|Complex posterior wall fracture means the fracture was not only occurred in the posterior wall of acetabular, but also occurred in other part of acetabular.
3255767|NCT01437163|Sham Comparator|Red Incandescent light source|
3255768|NCT01437163|Active Comparator|TopHat 655|
3255769|NCT01437176|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
3255770|NCT01437176|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
3374452|NCT05158595|Experimental|moderate intensity group|Will receive wobble board based Exergame balance training, game intensity will be low for this group (Size of goal will be kept large)
3374453|NCT05158595|Experimental|high intensity group|Will receive wobble board-based Exergame balance training, game intensity will be high for this group (Size of goal will be kept small).
3374454|NCT05158595|Active Comparator|control group|Will receive Exer-game balance training with Wii Fit balance games
3374455|NCT05158582|Experimental|SPECIFIC MODIFIED EXERCISE PROGRAM GROUP|The modified exercise group will perform 12 exercises.
3374456|NCT05158582|Active Comparator|CONVENTIONAL EXERCISES PROGRAM GROUP|The conventional exercises program will perform conventional exercises.
3374457|NCT05158569|Experimental|Slow breathing exercise group|Slow breathing 5-6 breaths/minute, 3 sets of 5 minutes 2 times/day for 4 weeks.
3374458|NCT05158569|Experimental|Diaphragmatic breathing exercise group|Diaphragmatic breathing, 3 sets of 5 minutes 2 times/day for 4 weeks.
3374459|NCT05158556|Experimental|myofascial release technique|Myofascial Release Technique will be applied with forearm/ ulnar border of palm. deep pressure will be applied and glided medially towards the thoraco-lumbar region.ins
3374460|NCT05158556|Experimental|Instrument Assisted Soft Tissue Mobilization|instrument assisted soft tissue mobilization is done via M2T Blade. it is a multifunctional instrument consisting of many planes and is very effective in treating pain and spasm. Its efficacy is proven over soft tissues that it releases fascial tightness.
3374461|NCT05158543|Active Comparator|Control Group|the control group will receive conventional intervention for upper and lower limb motor function & balance.
3255771|NCT01437202||high risk group|Identified by the predictive model using 2 genotypes and disease stage
3374462|NCT05158543|Experimental|moderate intensity group|this group will get task-oriented training with moderate intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
3374463|NCT05158543|Experimental|high intensity group|this group will get task-oriented training with high intensity using Functional activities specific training-table (FAST-Table) with 100 functional tasks.
3374464|NCT05158530|Experimental|Interventional Group|Aerobic training, 40%-60% intensity 3 days/ week for 4 weeks
3255772|NCT01437202||intermediate risk group|Identified by the predictive model using 2 genotypes and disease stage
3374465|NCT05158530|Placebo Comparator|Control group|Pulmonary rehab protocols, 3 sessions per week and 3-5 repetitions in a session for 4 weeks.
3374466|NCT05158504|Experimental|Motivation|Motivational notifications were sent to the nurses in the motivational group (n=30) via SMS messages to their mobile phones at 07.00, 12.00 and 16.00 for 21 days. Like a good morning message that allows you to start the day with a beautiful energy (Example: Thank you for the hard and selfless work you do every day. We love and appreciate angels like you and you. Good morning). Motivational notifications sent to the participants were prepared each day to be different from the previous day. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
3374467|NCT05158504|No Intervention|Control|Motivational notifications were not sent to the nurses in the control group (n=30) and they continued their routine work in the emergency room. only pretest and posttest were applied. Data were obtained with the Individual Introduction Form, Job Satisfaction, Compassion Fatigue and Communication Skills Scale.
3374468|NCT05158491|Active Comparator|180 mg/mm2|Subjects will be dosed at 180 mg/mm2 level.
3374469|NCT05158491|Active Comparator|220 mg/mm2|Subjects will be dosed at 220 mg/mm2 level.
3255773|NCT01437202||Low risk group|Identified by the predictive model using 2 genotypes and disease stage
3255774|NCT01437215|Experimental|Fenestrated Endografting|
3255775|NCT01437228|Other|povidone iodine|30-second vaginal scrub with povidone- iodine solution.
3374470|NCT05158491|Active Comparator|260 mg/mm2|Subjects will be dosed at 260 mg/mm2 level.
3374471|NCT05158491|Active Comparator|300 mg/mm2|Subjects will be dosed at 300 mg/mm2 level.
3374472|NCT05158478|Experimental|Subject glucometer measurement|
3374473|NCT05158465|Experimental|Motivational Interviewing and Assessments|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo. Three one-on-one, half hour educational and skill-building MI sessions will address: proper oral hygiene technique, bacteria and dental caries process, and nutrition. Intervention group adolescents will also receive three calls over one month reinforcing their hygiene behavior goals.
3374474|NCT05158465|No Intervention|Assessments Only|Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo.
3374475|NCT05158452||Observational (focus group)|Participants attend a focus group over 90-120 minutes providing feedback on GCPP intervention.
3374476|NCT05158439|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3374477|NCT05158426||propofol susceptibility group|patients undergoing gastrointestinal endoscopy
3374480|NCT05158400|Experimental|Cases|
3255776|NCT01437228|Placebo Comparator|CONTROL|
3255777|NCT01437241||etravirine|Antiretroviral regimens based on etravirine plus 2 active nucleos(t)ide reverse-transcriptase inhibitors (NRTIs)
3255778|NCT01437254|Experimental|Arm Number 1 CPERT|1 CPERT scan, blood and vital sign collection
3255779|NCT01437254|Active Comparator|Arm Number 2 GPERT|1 GPERT Scan
3255780|NCT01437280|Experimental|CGTG-102|CGTG-102 is an oncolytic adenovirus
3255781|NCT01437293|Experimental|Experimental|L-dopa / carbidopa / entacapone (LCE)
3255782|NCT01437306|Experimental|Lofexidine following overnight fast|A single dose of lofexidine (400 mcg or 2 x 200 mcg tablets) will be given to subjects following a minimum 10 hour overnight fast.
3255783|NCT01437306|Experimental|Lofexidine Following a High Fat Meal|A single dose of lofexidine 400 mcg (or 2 x 200 mcg tablets) will be administered to subjects following a standard high-fat meal.
3255784|NCT01437332||Diabetes|
3255785|NCT01437332||Nerve injury|
3255786|NCT01437332||Other|
3374481|NCT05158387|Experimental|MEDI3506 Dose 1|Dosing subcutaneously MEDI3506 Dose 1 and placebo
3374482|NCT05158387|Experimental|MEDI3506 Dose 2|Dosing subcutaneously MEDI3506 Dose 2
3374483|NCT05158387|Placebo Comparator|Placebo|Dosing subcutaneously with equivalent volume to MEDI3506
3374484|NCT05158374|No Intervention|Control|No medication, 6 weeks
3374485|NCT05158374|Active Comparator|Aspirin 24 Hours|24 Hours Aspirin
3374486|NCT05158374|Active Comparator|Aspirin 7 Days|7 Days Aspirin
3374487|NCT05158374|Active Comparator|Aspirin 28 Days|28 Days Aspirin
3374488|NCT05158374|Active Comparator|Aspirin 6 Weeks|6 Weeks Aspirin
3374489|NCT05158374|Active Comparator|Metformin 24 Hours|24 Hours Metformin
3374490|NCT05158374|Active Comparator|Metformin 7 Days|7 Days Metformin
3374491|NCT05158374|Active Comparator|Metformin 28 Days|28 Days Metformin
3374492|NCT05158374|Active Comparator|Metformin 6 Weeks|6 Weeks Metformin
3374493|NCT05158374|Active Comparator|Aspirin & Metformin 24 Hours|24 Hours Aspirin & Metformin
3374494|NCT05158374|Active Comparator|Aspirin & Metformin 7 Days|7 Days Aspirin & Metformin
3374495|NCT05158374|Active Comparator|Aspirin & Metformin 28 Days|28 Days Aspirin & Metformin
3374496|NCT05158374|Active Comparator|Aspirin & Metformin 6 Weeks|6 Weeks Aspirin & Metformin
3374499|NCT05158348|Active Comparator|Group A|receive intra-operative local infiltration of saline in tonsillar bed and post-operative nebulised dexametomidine and lidocaine.
3374500|NCT05158348|Active Comparator|Group B|receive intra-operative local infiltration of saline and post-operative will receive nebulised lidocaine
3374501|NCT05158348|Active Comparator|Group C|receive intra-operative local infiltration of lidocaine and post-operative nebulised saline.
3374502|NCT05158335|Experimental|MBX 2109 (Part A)|Single ascending SC doses
3374503|NCT05158335|Experimental|MBX 2109 (Part B)|Repeated ascending SC doses
3374504|NCT05158335|Placebo Comparator|Placebo|
3374505|NCT05158309|Experimental|Capsaicin|Capsaicin condition: in this condition participants received pain using a (5x10 cm) 8% topical capsaicin patch on the volar part of the dominant right forearm.
3255787|NCT01437358||intensive care unit|
3255788|NCT01437371|Other|optimized|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
3255789|NCT01437371|Other|usual care|
3255790|NCT01437384|Experimental|E5501 plus minus verapamil; plus minus cyclosporine|
3374506|NCT05158309|Placebo Comparator|Placebo|Placebo condition: participants received no pain.
3255791|NCT01437410||EUS-FNA|
3255792|NCT01437436||obesity|otitis media patient with obesity
3255793|NCT01437436||non obesity|otitis media patient with non obesity
3255794|NCT01437475|Experimental|Sci-B-Vac|The study involves only one, open label arm. Rate of immunization will be compared to results obtained using the ENGERIX B vaccine among HIV positive persons in formerly published, historical cohorts.
3255795|NCT01437514|Experimental|lower risk group with pSRT|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients accept the preoperative short-course radiotherapy before the surgery
3255796|NCT01437514|No Intervention|lower risk group with operation only|the patients that was divided into the lower risk group that the mesorectum involvement less than 5mm, and no lymph node larger than 8mm,according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
3374510|NCT05158283|Experimental|Intervention: Chocolate balloon|Chocolate balloon group
3255797|NCT01437514|Experimental|higher risk group with pSRT|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.these patients have the preoperative short-course radiotherapy before the surgery.
3374511|NCT05158283|Experimental|Intervention: plain balloon|plain balloon group
3374512|NCT05158270|Active Comparator|Ultrasound Guided Erector Spinae Plane Block|Patient will be placed in lateral decubitus position. By palpation of spinous processes starting from C7 downward, T7 spinous process will be located. Under complete aseptic precautions, linear probe of US machine will be placed in a transverse orientation at this level to identify tip of T7 transverse process (TP). By probe rotation into a longitudinal orientation, a parasagittal view will visualize skin and subcutaneous tissue, trapezius, and erector spinae (ES) muscle layers superficial to TPs. After local anesthetic (LA) infiltration, a 20 gauge spinal needle will be inserted in-plane and directed cranio-caudally until it contacts T7 TP. Target site for injection will be fascial plane deep to ES muscle. 1 mL saline will be injected to confirm correct needle-tip position by visualization of lifting of ES muscle off TP without distending the muscle and spreading cranio-caudally. 20 - 30 mL of 0.25% bupivacaine will be injected. Procedure will be performed bilaterally.
3376225|NCT01717586|Placebo Comparator|Control Group|Pregnant women who are at high-risk for developing preeclampsia who are taking a placebo during their pregnancy.
3376226|NCT01675479|Experimental|wavefront-guided LASIK|
3376227|NCT01599520|Experimental|Spanish-Language Self-Administered Training + Usual Care|Participants randomized to this arm will receive Spanish-Language Self-Administered Training + Usual Care.
3255798|NCT01437514|No Intervention|higher risk group with operation directly|the patients that was divided into the higher risk group that the mesorectum involvement more than 5mm, or with lymph node larger than 8mm according to the preoperative CT, MRI and Endosonography,and these patients have a operation directly without preoperative radiotherapy.
3255799|NCT01437527|Experimental|Interventional arm|Body image therapy with Anamorphic Micro software
3374513|NCT05158270|Active Comparator|Ultrasound Guided Anterior Quadratus Lumborum Block|"Patient will be placed in lateral decubitus position. Under complete aseptic precautions, curved US probe will be placed in midaxillary line immediately above the iliac crest to identify anterior abdominal wall muscles. Probe will be then moved dorsally until visualization of transversus abdominis muscle becoming aponeurotic, then visualization of shamrock sign with psoas major muscle anteriorly, erector spinae muscle posteriorly and quadratus lumborum (QL) muscle adherent to the apex of L4 transverse process. After LA infiltration, a 20 gauge spinal needle will be inserted in-plane from posterior to anterior, and needle tip will be advanced through QL muscle, penetrating the ventral proper fascia of QL muscle. Target site for injection will be fascial plane between QL and psoas major muscles. 1 mL saline will be injected to confirm correct needle-tip position, followed by injection of 20 - 30 mL of 0.25% bupivacaine. Procedure will be performed bilaterally."
3255800|NCT01437527|Active Comparator|control arm|Body image therapy as usual
3255801|NCT01437553|Other|IVUS|Patients undergoing catheterization due to acute coronary syndrome will have IVUS done with grayscale and iMAP analysis performed.
3255802|NCT01437566|Placebo Comparator|GDC-0941 Matching Placebo + Fulvestrant (Arm E)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 matching placebo QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3255803|NCT01437566|Experimental|GDC-0941-260 mg + Fulvestrant (Arm D)|Participants with PIK3CA mutation will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 260 mg QD orally starting on Day 1 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3255804|NCT01437566|Experimental|GDC-0941-340 mg + Fulvestrant (Arm A)|Participants will receive fulvestrant 500 milligrams (mg) as 2 intramuscular (IM) injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0941 340 mg once daily (QD) orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3374514|NCT05158270|Other|Intravenous Multimodal Analgesia|Postoperative pain in the post-anesthesia care unit (PACU) and on the ward will be treated with a combination of IV multimodal analgesia in the form of Acetaminophen (15 mg/kg 4/day) and Ketorolac (0.5 mg/kg 3/day) using a fixed scheme. In addition, Morphine, as 3 mg IV bolus at each dose, will be given when VAS equals or above 3. VAS will be assessed 5 - 10 min. after each opioid dose to assess the need for additional opioid doses.
3374515|NCT05158257|Active Comparator|Intervention: balloon and Stents|plain balloon and Stents group
3374516|NCT05158257|Experimental|Intervention: debulking and drug coated balloon|debulking and drug coated balloon group
3374517|NCT05158244|Experimental|PF-07081532|multiple dosing, once-daily for 42 days
3374518|NCT05158244|Placebo Comparator|Placebo|multiple dosing, once-daily for 42 days
3374519|NCT05158218|Active Comparator|Cerebral Palsy Youth/Young Adults Physical Therapy|Baseline and 8 week assessments; 8 week gait therapy
3374520|NCT05158218|Experimental|Cerebral Palsy Youth/Young Adults Robotic Exoskeleton|Baseline and 8 week assessments; 8 week gait therapy using robotic exoskeleton
3374521|NCT05158205|Experimental|Yoga postures or slow, deep breathing|
3374522|NCT05158205|Sham Comparator|Control|
3374523|NCT05158192|Experimental|Diosmin/Hesperidin (90/10) Test Product|Participants received one tablet of the test formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
3374524|NCT05158192|Active Comparator|Diosmin/Hesperidin (90/10) Reference Product|Participants received one tablet of the marketed reference formulation containing Diosmin/Hesperidin (90/10) 500 mg. The tablets was taken with water and in a fasting condition.
3374525|NCT05158179|Experimental|Spasmodic Dysphonia Patients|
3374526|NCT05158166|Experimental|Administration of Daxi|Injectible daxibotulinumtoxinA (DAXI, Revance Therapeutics Inc., Newark, CA) is an investigational botulinum toxin type A which has been shown in large clinical trials to provide safe, effective treatment for glabellar lines and cervical dystonia and may offer longer-lasting results when compared with onabotulinumtoxinA. Dosage will be same number of units as prior Botox A dose.
3374527|NCT05158153|Experimental|ORKID Bundled Intervention|
3374528|NCT05158140|Experimental|V110 + concomitant mRNA-1273|Single dose vaccination of V110 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V110 on Day 30
3374529|NCT05158140|Experimental|V110 + non-concomitant mRNA-1273|Single dose vaccination of placebo for V110 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V110 on Day 30
3374530|NCT05158140|Experimental|V114 + concomitant mRNA-1273|Single dose vaccination of V114 concomitantly with a single dose vaccination of mRNA-1273 on Day 1, followed by a single dose vaccination of placebo for V114 on Day 30
3374531|NCT05158140|Experimental|V114 + non-concomitant mRNA-1273|Single dose vaccination of placebo for V114 on Day 1 concomitantly with a single dose vaccination of mRNA-1273, followed by a single dose vaccination of V114 on Day 30
3374532|NCT05158127|Experimental|Treatment Group (AlloRx)|intravenous infusion and intralesional injection of 100 million cells
3374533|NCT05158114|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3374534|NCT05158101|Experimental|Treatment Group (AlloRx)|Single intravenous infusion of 100 million cells
3374535|NCT05158088|Active Comparator|Borescope group|Using an Endotracheal tube mounted over Borescope with the aid of conventional laryngoscope for intubation
3374536|NCT05158088|Active Comparator|Videolaryngoscope group|Using videolaryngoscope for intubation
3255805|NCT01437566|Placebo Comparator|GDC-0948 or GDC-0980 Matching Placebo + Fulvestrant (Arm C)|Participants will be randomized in 1:1 ratio to receive GDC-0948 matching placebo or GDC-0980 matching placebo with fulvestrant. Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0948 or GDC-0980 matching placebo QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3255806|NCT01437566|Experimental|GDC-0980-30 mg + Fulvestrant (Arm B)|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle and GDC-0980 30 mg QD orally starting on Day 15 of Cycle 1, each cycle of 28 days. Study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3374537|NCT05158075|Experimental|Neurocognitive training|The experimental group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group neurocognitive intervention sessions, that will last about 60-90 minutes each. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
3374538|NCT05158075|Sham Comparator|Sham cognitive training|The active control group will: i) receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise); ii) receive an individualized diet and physical exercise planning for 6 weeks; iii) participate in 4 weekly group sessions of sham intervention that mimic the neurocognitive sessions of the experimental group. Two neurocognitive sessions are intended to train impulsivity, and the other two neurocognitive sessions will focus on reflexive training. Participants will practice the content of each session daily at home.
3374539|NCT05158075|Other|Control|Participants in the control group will receive three pre-treatment group sessions (Motivational Interviewing, nutrition and physical exercise) and will receive an individualized diet and physical exercise planning for 6 weeks.
3374540|NCT05158062|Experimental|pembrolizumab and bevacizumab with PBC followed by pembrolizumab, bevacizumab and olaparib|Participants will continue treatment period up to 6 cycles and enter maintenance period after treatment period. Study treatment will be continued until progressive disease (PD) based on RECIST 1.1, death, unacceptable toxicity, or participant withdrawal from the study.
3374541|NCT05158036|Active Comparator|Classic massage group|Classical massage will be applied to the lumbal and abdominal region 5 days a week, from the estimated date of ovulation until the next menstrual bleeding begins. The application will take approximately 15 minutes. During the massage, the physiotherapist will apply stroking and kneading movements by using baby oil. During the treatment of the lumbal region, the patient will be in the prone position; during the treatment of the abdominal region, the patient will be in the supine position.
3374542|NCT05158036|Active Comparator|Connective tissue massage group|Connective tissue massage will be applied to the lumbosacral, lower thoracic, abdominal and anterior pelvic regions 5 days a week, from the estimated date of ovulation until the onset of the next menstrual bleeding. The application will take approximately 15 minutes. During the massage, the physiotherapist will bring the tip of the middle finger of the hand into contact with the patient's skin and apply traction to the skin. During the treatment of the lumbar region, the patient will be in the sitting position, during the treatment of the abdominal and anterior pelvic region, the patient will be in the supine position.
3374543|NCT05158023|Placebo Comparator|Arm 1|Placebo q2w - placebo injections at Baseline and Week 1, then every 2 weeks (q2w) to Week 14.
3374544|NCT05158023|Experimental|Arm 2|ASLAN004 300 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 300mg (q2w) to Week 14.
3374545|NCT05158023|Experimental|Arm 3|ASLAN004 400 mg q2w - loading doses at Baseline and Week 1, followed by regular doses of 400mg (q2w) to Week 14.
3374546|NCT05158023|Experimental|Arm 4|ASLAN004 400 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 400 mg or alternating placebo (q2W) to Week 14.
3374547|NCT05158023|Experimental|Arm 5|ASLAN004 600 mg q4w - loading doses at Baseline, Week 1 and Week 2, followed by regular doses of 600 mg or alternating placebo (q2W) to Week 14.
3374548|NCT05158010|Other|HELIX's follow-up|
3374549|NCT05157997|Experimental|Casirivimab and Imdevimab Antibody Cocktail|Patients receiving a Covid-19 positive liver, kidney, or heart transplant.
3374550|NCT05157984||Retrospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System
3374551|NCT05157984||Prospective cohort|Any patient of the physicians listed in this study who has undergone the ZPOEM procedure to treat ZD at Methodist Health System and has agreed to be follow-up post-procedure.
3374552|NCT05157971|Experimental|Treatment (venetoclax, C10403 regimen)|See Detailed Description
3374553|NCT05157958|Experimental|ALLO-ASC-SHEET|"Allogeneic mesenchymal stem cells~Dressing for Dystrophic Epidermolysis Bullosa wound"
3374554|NCT05157958|Active Comparator|Conventional Therapy|"Hydrogel Sheet~Matching control"
3374555|NCT05157945|Experimental|ALTO-300|ALTO-300 tablet PO; daily dosing 8 weeks
3374556|NCT05157932|Experimental|Talk Test|Virtual Cardiac Rehab + Exercise prescription based on the Talk test.
3374557|NCT05157932|Experimental|Cardiopulmonary Exercise Test|Virtual Cardiac Rehab + Exercise prescription based on the CPET results.
3374558|NCT05157919|No Intervention|Control|Usual care continues. The caregiver will not get to use the app. The caregiver will be asked daily measures and the patient will be asked about thirst and anxiety daily when the patient is awake enough to answer these questions. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU.
3374559|NCT05157919|Experimental|Intervention with App|The caregiver gets access to use the app. Each day, investigators will ask the patient to rate their thirst and anxiety and the caregiver to answer daily measures through the application. The caregiver will be asked questions at 3 different times: Day 1, 24-48 hours after enrollment, and 2-4 weeks after the patient is discharged from the ICU. The caregiver will be taught how to use the app. The caregiver will be given the supplies that the caregiver needs to perform the symptom management intervention. Investigators will ask the caregiver to use the app at least once a day, but the caregiver can use it as much as desired while the patient is in the ICU.
3374560|NCT05157906|Experimental|Experimental Group|Subjects will have access to the Grow Happy program materials, including the Grow Happy Book, 99+ Ways to Grow Happy Tips and Engagement Videos, which are provided digitally during the trial duration of 12 weeks.
3255807|NCT01437579|Active Comparator|Botulinum toxin|Bladder intratrigonal injection of botulinum toxin (100 units) in 10 injection sites during cystoscopy under general anesthesia
3255808|NCT01437579|Sham Comparator|cystoscopy with hydrodistension|cystoscopy with hydrodistension under general anesthesia
3255809|NCT01437592|Experimental|IDeg|
3255810|NCT01437618||BRAF mutant mCRC|
3374561|NCT05157906|Active Comparator|Control Group|No additional education materials will be proactively provided during trial duration. Subjects will only be provided with the Indonesian standard of care only.
3255811|NCT01437631|Experimental|endoclip|The group of patients who undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
3255812|NCT01437631|No Intervention|no endoclip|The group of patients who do not undergo prophylactic clip application after colonoscopic polypectomy of a large pedunculated polyp(>1cm).
3374562|NCT05157893|Experimental|VR analgesic therapy|Patients receive a single VR therapy lasting 15 min.
3374563|NCT05157880|Experimental|Experimental Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily skills.
3374564|NCT05157880|Active Comparator|Control Patient-Caregiver Dyads|There will be 6 sessions with 2 general sessions delivered in person at bedside in the NICU (or virtual depending on COVID and discharge status) and 4 tailored specific sessions (chosen from by the dyads from 6 available modules) to be delivered via live video using Zoom. Content will be primarily educational.
3374565|NCT05157867|Experimental|Amylase trypsin inhibitors (ATIs), then placebo|Test day 1: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline. After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of placebo (physiological saline).
3374566|NCT05157867|Experimental|Placebo, then Amylase trypsin inhibitors|Test day 1: intraduodenal administration of placebo (physiological saline). After a wash-out period of 4-6 weeks, test day 2: intraduodenal administration of amylase trypsin inhibitors (ATIs) isolated from Triticum aestivum (bread wheat), dissolved in physiological saline.
3374567|NCT05157854||SH residents|Participants in the AiMH intervention
3374568|NCT05157854||SH staff|Staff in the SH, acting as AiMH supporters
3374569|NCT05157841|Experimental|Part A: EXPAREL 266 mg arm|subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline
3374570|NCT05157841|Experimental|Part A: EXPAREL 133 mg arm|subjects randomized to this treatment arm will receive 10 mL (133 mg) EXPAREL mixed with 20 mL saline
3374571|NCT05157841|Active Comparator|Part A: Bupivacaine HCl arm|Subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
3374572|NCT05157841|Experimental|Part B: EXPAREL 133 mg arm OR EXPAREL 266 mg arm|Subjects randomized to this treatment arm will receive 20 mL (266 mg) EXPAREL mixed with 10 mL saline OR 10 mL (133 mg) EXPAREL mixed with 20 mL saline. Dose will be determined following interim analysis of Part A.
3374573|NCT05157841|Active Comparator|Part B: Bupivacaine HCl arm|subjects randomized to this treatment arm will receive 20 mL (50 mg) 0.25% bupivacaine HCl mixed with 10 mL saline
3374574|NCT05157815|Experimental|Soluble Corn Fibre|12g compound per Sachet (providing 10g fibre) consumed twice per day
3374575|NCT05157815|Placebo Comparator|Maltodextrin|Calorie matched control of 2 g compound per sachet (0 g fibre), composed of: Maltodextrin, consumed twice per day
3374576|NCT05157802|Experimental|Physical Activity Coaching|Participants will receive up to 5 individualized coaching sessions delivered via telehealth to facilitate and optimize exercise uptake. The therapist will facilitate discussion on specific and measurable goals, and will provide options for tracking their progress, such as written or web-based exercise logs or an activity monitor. The recommended exercises will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. Balance and strengthening exercises will also be recommended as appropriate.
3374577|NCT05157789|Experimental|Sms group|Relatives of patients who were sent SMS
3374578|NCT05157789|No Intervention|Control Group|Relatives of patients who were no intervation
3374579|NCT05157776|Active Comparator|Control group|Neoadjuvant therapy of Sintilimab and chemotherapy in 2 cycles before surgery and optional adjuvant therapy of Sintilimab and chemotherapy in 2 cycles after surgery
3374580|NCT05157776|Experimental|Experimental group|Neoadjuvant therapy of Sintilimab and chemotherapy in 4 cycles before surgery
3374581|NCT05157763|Experimental|EscharEx 5%|The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
3374582|NCT05157750||IBD patients with endoscopic remission|No intervention will be administered. All patients with endoscopic remission will be monitored for the future development of major clinical events. Diagnostic performances of endoscopic remission for predicting major clinical events will be calculated.
3374583|NCT05157750||IBD patients with histologic remission|No intervention will be administered. All patients with histologic remission will be monitored for the future development of major clinical events. Diagnostic performances of histologic remission for predicting major clinical events will be calculated.
3374584|NCT05157750||IBD patients with barrier healing|No intervention will be administered. All patients with barrier healing will be monitored for the future development of major clinical events. Diagnostic performances of barrier healing for predicting major clinical events will be calculated.
3374585|NCT05157737||BFNS group|(1) Epileptic seizure in neonatal period; (2) Epileptic seizure duration is short, which under spontaneous control in 4~6 months; (3) The patient was in normal state of feeding, physical examination and psychomotor development; (4) There were no signs of hypsarrhythmia or burst suppression in EEG.
3374586|NCT05157737||DEE group|(1) Epileptic seizures occur within a week after birth and recur frequently; (2) Epilepsy is refractory; (3) Feeding difficulties, accompanied by moderate to severe mental retardation and psychomotor retardation; (4) The EEG showed hypsarrhythmia or burst suppression.
3374589|NCT05157711|Experimental|Anusol ointment|Anusol ointment (Zinc oxide [10.75g], Bismuth subgallate [2.25 g], Balsam peru [1.875 g], Bismuth oxide [0.875 g] in each 100g of ointment).
3374590|NCT05157711|Active Comparator|Benchmark|RELIEF® rectal ointment (phenylephrine hydrochloride 2.5mg/g), marketed
3374591|NCT05157711|Placebo Comparator|Placebo|Anusol ointment after the removal of the active ingredients
3374592|NCT05157698|Experimental|BWL + NB medication|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and NB medication. The naltrexone and bupropion will be taken daily in pill form.
3374593|NCT05157698|Experimental|BWL + Placebo|Participants randomly assigned to this arm will receive 6 months of Behavioral Weight Loss (BWL) counseling and placebo. Placebo will be inactive and taken daily in pill form.
3374594|NCT05157698|Experimental|NB medication|Participants randomly assigned to this arm will receive 6 months of NB medication taken daily in pill form.
3255813|NCT01437644|Active Comparator|Botulinum Toxin TypeA|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. A total of 2 ml of isotonic saline will be used to dissolve the contents of the trial vial of Botox. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo arm of the study."
3255814|NCT01437644|Placebo Comparator|Saline|The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Injections of normal saline will be administered in those children randomised to the placebo arm of the study. The volume of normal saline injected will be equal to the volume of normal saline that would have been used if the child had been randomised to botulinum toxin. The injector will be blinded, as the solution is drawn up by unblinded nurses.
3255815|NCT01437657|Placebo Comparator|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
3255816|NCT01437657|Experimental|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
3374595|NCT05157698|Placebo Comparator|Placebo|Participants randomly assigned to this arm will receive 6 months of placebo. Placebo will be inactive and taken daily in pill form.
3255817|NCT01437657|Experimental|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
3255818|NCT01437670||dry mouth patients with solifenacin|dry mouth patients with solifenacin 5mg, 10mg
3255819|NCT01437683||traumatic brain injury patients|a large group of traumatic brain injury patients
3374596|NCT05157685|Experimental|Azithromycin oral tablet|Azithromycin 250 mg once daily morning or evening (with or without meals)
3374597|NCT05157685|Placebo Comparator|Placebo|Placebo once daily morning or evening (with or without meals)
3374598|NCT05157672|Experimental|Cinnamon|Arm 1 will consist of administration of a single dose of cinnamon (2 g) with water by mouth to 6 subjects (3 biological men, 3 biological women). Blood will be drawn from 0-48 hours. Urine will be collected from 0-24 hours. The subjects may or may not elect to participate in Arms 2-5. If they do, a washout of at least 7 days will occur between Arm 1 administration of cinnamon and the Arm 2 administration of nicotine.
3374599|NCT05157672|Experimental|Nicotine|Arm 2 will consist of administration of a single dose of nicotine gum (2 mg) to 16 subjects (8 biological men, 8 biological women). If these subjects participated in Arm 1, they will have completed a washout of 7 days since administration of cinnamon before starting Arm 2. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 3.
3374600|NCT05157672|Experimental|Letrozole|Arm 3 will consist of administration of a single oral dose of letrozole (2.5 mg) to the same 16 subjects. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration. Participants will undergo a washout of at least 14 days before beginning Arm 4.
3255820|NCT01437696|Experimental|Vitamin D fortified food 500 IU|One portion of a specific food item will be provided each day. 500 IU Vitamin D added.
3255821|NCT01437696|Experimental|Vitamin D fortified food 1000 IU|One portion of a specific food item will be provided each day. 1000 IU Vitamin D added.
3255822|NCT01437696|Placebo Comparator|Placebo|One portion of a specific food item will be provided each day. No vitamin D added.
3255823|NCT01437709|Experimental|patients receiving Immunotherapy (This arm is closed)|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The study design will allow for an estimation of the single agent response of ofatumumab in patients at low biologic risk for immediate disease progression.
3255824|NCT01437709|Experimental|patients receiving Chemoimmunotherapy|The proposed study is a Simon 2 stage optimal study design investigating the activity of ofatumumab alone or in conjunction with Bendamustine for patients with MCL who are either not candidates for ASCT or aged 65 or older. The combined regimen will assess the response rates of the combined chemo- immunotherapy program in patients with need for cytoreductive therapy, or high risk for disease progression. Patients with a leukemic phase only presentation of mantle cell lymphoma generally have clinically low-risk disease, regardless of mantle cell IPI calculations. Upon reciew with the principal investigator, these patients may be stratified to the immunotherapy only arm if clinically appropriate.
3374601|NCT05157672|Experimental|Cinnamon and Nicotine|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and nicotine gum (2 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-12 hours relative to nicotine administration. Participants will undergo a washout of at least 4 days before beginning Arm 5.
3374602|NCT05157672|Experimental|Cinnamon and Letrozole|The same 16 subjects will self-administer the cinnamon product (2 g) three times daily for five consecutive days. On the sixth day, subjects will be administered cinnamon (2 g) and letrozole (2.5 mg). Cinnamon will be administered two additional times. Blood and urine will be collected from 0-240 hours and 0-24 hours, respectively, relative to letrozole administration.
3255825|NCT01437722|Experimental|1% SPL7013 Gel|
3255826|NCT01437722|Experimental|3% SPL7013 Gel|
3374603|NCT05157659|Experimental|[18F]F-AraG PET procedures|Within one week prior to resection two [18F]F-AraG PET-scans will be performed.
3374604|NCT05157646|Experimental|Exercise trackers|Fitbit physical activity trackers
3374605|NCT05157633||Controls|Children without eating difficulties
3374606|NCT05157633||Patients|Children with eating difficulties
3374607|NCT05157620|Experimental|Yoga-based Exercise (YE)|The Yoga-based Exercise (YE) intervention is a series of yoga-based poses that consists of sitting, standing, kneeling, and lying postures as well as breathing exercises. The duration of the intervention will be 12 months. Participants will engage in yoga-based exercise sessions lasting 60 minutes twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in yoga-based exercises once a week. The remainder of the study (6 months), participants will engage in yoga-based exercises once a month.
3374608|NCT05157620|Active Comparator|Wellness Lifestyle Program (WLP)|The Wellness Lifestyle Program (WLP) is a comprehensive lifestyle program that consists of 30 minutes of educational information covering various topics, such as nutrition, healthy living, stress reduction, and more will be followed by 30 minutes of low-intensity exercise such as walking. The duration of the intervention will be 12 months. Participants will engage in the 60 minute WLP session twice a week for the first 12 weeks (3 months) of the project. The following 12 weeks, participants will engage in WLP sessions once a week. The remainder of the study (6 months), participants will engage in WLP sessions once a month.
3374609|NCT05157607|Experimental|Family Connections Protocol for Relatives of Patients with SBD.|"The intervention lasts three months and includes 12 sessions with a weekly two-hour group format. The FC program is divided into six modules:~Module 1: Up-to-date information and research on suicide (Epidemiology, frequency, Risk factors, protective factors).~Module 2: Psychoeducation on the development of suicide, explanatory theories, available treatments, comorbidity.~Module 3: Emotional regulation skills, skills of acceptance, validation, approach, awareness, and to decrease emotional reactivity.~Module 4: Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~Module 5: Communication skills and effective self-expression. Module 6: Problem management and making safe plans for crisis management."
3374610|NCT05157607|Active Comparator|Treatment as Usual Optimized Protocol (TAU-O).|"Family members in this condition will continue to receive their treatment as usual in their care center of reference. In addition, we will optimize the treatment based on the recommendations of the international guidelines for the treatment of suicide. There will be one three-hour session in group format with the following component:~Module 1: Updated information and research on suicide (Epidemiology, frequency, Risk factors, protective factors). Psychoeducation on the development of Suicide, Explanatory theories. Available treatments, and comorbidity."
3374611|NCT05157594||All patients|A fasting blood sample will be taken on the day of the beginning and the day of the end of the radiotherapy and during the adjuvant chemotherapy (every 3 cycles). A follow-up will be performed for 9 months, with a blood sample taken every three months on the day of the follow-up MRI.
3374612|NCT05157581||Sezary Syndrome|15 subjects with Sezary Syndrome will comprise the single arm of this study
3255827|NCT01437722|Placebo Comparator|placebo gel|
3255828|NCT01437735|Experimental|QAW039 po dose 1|
3255829|NCT01437735|Experimental|QAW039 po dose 2|
3255830|NCT01437735|Experimental|QAW039 po dose 3|
3255831|NCT01437735|Experimental|QAW039 po dose 4|
3255832|NCT01437735|Experimental|QAW039 po dose 5|
3255833|NCT01437735|Experimental|QAW039 po dose 6|
3255834|NCT01437735|Experimental|QAW039 po dose 7|
3255835|NCT01437735|Experimental|QAW039 po dose 8|
3255836|NCT01437735|Experimental|QAW039 po dose 9|
3255837|NCT01437735|Experimental|QAW039 po dose 10|
3255838|NCT01437735|Experimental|QAW039 po dose 11|
3255839|NCT01437735|Experimental|QAW039 po dose 12|
3255840|NCT01437735|Experimental|QAW039 po dose 13|
3255841|NCT01437735|Active Comparator|Montelukast po 10 mg|Comparator leukotriene receptor antagonist (LRTA)
3255842|NCT01437735|Placebo Comparator|Placebo|
3255843|NCT01437748|Experimental|Indacaterol maleate|Indacaterol 300 mcg via Breezehaler Inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
3255844|NCT01437748|Active Comparator|Tiotropium bromide|Tiotropium 18 mcg, via HandiHaler inhaler will be administered by a third independent investigator not involved in the performing of any of the tests decribed, following a randomization list
3255845|NCT01437761||2008 Sorbent system|Hemodialysis with the 2008 Sorbent system
3255846|NCT01437774|Active Comparator|Concentric Thrombectomy Catheter|Control Arm
3255847|NCT01437774|Experimental|Reverse ReStore mechanical thrombectomy|Reverse ReStore Device mechanical thrombectomy Each arm will use either ReStore or Merci as the primary thrombectomy device
3374613|NCT05157568|Active Comparator|Control (C)|Participants will receive a exercise prescription and a home exercise plan. It will specify how many days per week they should exercise and will indicate how hard they should be working using their heart rate and rating of perceived exertion (RPE) as a guide. They will attend 8 onsite rehabilitation classes at the University of Ottawa Heart Institute (1 class per week for 8 weeks). These classes will be led by a specially trained instructor who will teach and encourage self-monitoring of heart rate and RPE. The class will include a warm-up, 30 minutes of aerobic exercise and a 15 min cool-down, including strength exercises and stretches. Following each class there will be a short mini-education session highlighting a variety of topics on how to manage risk factors. Patients will have access to onsite classes for nutrition and stress management. Participants will receive access to 8 additional educational videos that highlight topics such as exercise safety, goal setting and nutrition.
3374614|NCT05157568|Active Comparator|Exercise Streaming (ES)|"Participants will complete 1 live virtual class per week for 8-weeks. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the instructor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rates and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. They will be encouraged to access them on demand throughout the week. In addition participants will have access to the same 8 pre-recorded educational videos that the control group will receive. Topics include; exercise safety, goal setting, nutrition, stress management, medication information, risk factor awareness and transition planning."
3255848|NCT01437787|Placebo Comparator|Placebo comparator|once daily X 28 days, orally, empty stomach, approximately same time each day
3255849|NCT01437787|Experimental|SAR302503 400 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
3255850|NCT01437787|Experimental|SAR302503 500 mg|once daily X 28 days, orally, empty stomach, approximately same time each day
3255851|NCT01437800|Experimental|Glimepiride / Extended release Metformin|Pharmaceutical Form: Tablets Dosage: (4/850 mg). Administration way: Oral On fasting conditions
3255852|NCT01437813|Experimental|Group A: Glimepiride / Extended Release Metformin|Pharmaceutical Form: Tablets Dosage: 4 mg / 850 mg Administration way: Oral
3255853|NCT01437826|Experimental|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
3255854|NCT01437826|Placebo Comparator|Sugar pill|placebo had an identical appearance as intervention
3255855|NCT01437839|Experimental|1|Period I: fasting state, Period II: fed state
3255856|NCT01437839|Experimental|2|Period I: fed state, Period II: fasting state
3255857|NCT01437865|Experimental|Gadofosveset enhanced MRI Axilla|
3255858|NCT01437904|Experimental|Outpatient|Outpatient recovery following Percutaneous nephrolithotomy
3255859|NCT01437904|Sham Comparator|In hospital|Inpatient recovery following Percutaneous nephrolithotomy
3255860|NCT01437917|Experimental|Bread with 20% amylose content|Bread with 20% amylose content
3255861|NCT01437917|Experimental|Bread with 10% amylose content|Bread with 10% amylose content
3255862|NCT01437917|Experimental|carbohydrates|50g of carbohydrates ingested with 400 ml of water
3255863|NCT01437930|Placebo Comparator|placebo|products (sausage, bread rolls, milk beverage, wafers) enriched with 20g sunflower oil/d
3255864|NCT01437982|Experimental|Loteprednol Etabonate|Ophthalmic Gel 0.5%
3255865|NCT01437982|Experimental|Prednisolone Acetate 1% Oph Susp|Ophthalmic suspension 0.5%
3255866|NCT01438021|Experimental|Treatment (intraventricular chemotherapy)|Patients receive intraventricular methotrexate continuously on days 1-14. Treatment continues in the absence of disease progression or unacceptable toxicity.
3255867|NCT01438034|Experimental|kisspeptin|intravenous administration of kisspeptin 112-121 0.24 nmol/kg and GnRH 75 ng/kg
3255868|NCT01438073|Experimental|kisspeptin, GnRH|24-hour continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg), and single bolus of GnRH (gonadotropin-releasing hormone) (2.5-250 ng/kg)
3255869|NCT01438086|Active Comparator|mecasermin low dose|
3255870|NCT01438086|Active Comparator|mecasermin high dose|
3255871|NCT01438086|Placebo Comparator|saline placebo|
3255872|NCT01438099||normal subjects|parturients admitted to the labor ward who request epidural analgesia with BMI < 30
3255873|NCT01438099||obese subjects|parturients admitted to the labor ward who request epidural analgesia with BMI > 30
3255874|NCT01438112|Experimental|CG0070 oncolytic virus|Interventions: CG0070 oncolytic virus intravesical instillations weekly X6 with each instillation lasting 45 minutes after prior transduction agent of DDM intravesically for 15 minutes
3255875|NCT01438112|Active Comparator|Chemotherapy or Interferon|"Quadruple Choice as interventions~Mitomycin C~Interferon~Valrubicin~Gemcitabine"
3255876|NCT01438125|Active Comparator|MF-4181|Scar halves randomized to treatment with device, opposite side treated per standard of care
3255877|NCT01438125|Active Comparator|Standard surgical wound closure|
3255878|NCT01438138||Correlative studies|Archived bone marrow mononuclear cells are analyzed by single cell network proteomic profiling assay, the My Profile™ AML Risk of Relapse Assay. Molecular markers analyzed include Flt3-ITD, NPM1, and MRA. Results are then correlated with each patient's clinical data including patient's age, race/ethnic background, gender, treatment received, and outcomes.
3255879|NCT01438164||oncologic patients|initial staging
3255880|NCT01438190|Experimental|Experimental|Metformin plus step-down protocol
3255881|NCT01438190|Active Comparator|Control|Placebo and step-up protocol
3374615|NCT05157568|Active Comparator|Exercise Streaming + Equipment (ES+E)|"Participants will receive an indoor bicycle and an exercise band (delivered and set up in their home). Participants will complete 1 live class per week for 8 weeks. Their exercise prescription will be based on a stress test. Classes will be led by a specially trained instructor and will include a warm-up, 30 minutes of aerobic exercise, 10 minutes of strength exercises, and a cooldown and stretching segment. During each live class, the exercise supervisor will play the corresponding video and supervise the participants through the Zoom for Healthcare platform. Heart rate and RPE data will be collected from each participant. Participants will have access to other pre-recorded exercise videos that they can stream on demand at any time. Participants will be encouraged to access them throughout the week. Participants will have access to the same 8 pre-recorded educational videos that the control and exercise streaming groups will receive."
3374616|NCT05157555||"with laryngectomy group"|"with laryngectomy group: patients with laryngectomy for any type of cancer"
3374617|NCT05157542|Experimental|Arm|"Durvalumab 1500mg, IV, Q3W, 2 cycles Albumin paclitaxel 260 mg/m2 +~Carboplatin AUC5, IV, Q3W, 2 cycles Chemoradiotherapy(CRT):~Cohort 1: 2 Gy in 5 Fraction~Cohort 2: 2 Gy in 10 Fraction~Cohort 3: 2 Gy in 15 Fraction"
3374618|NCT05157529|Experimental|Aquablation|The participant will undergo aquablation procedure for Benign Prostate Hypeplasia (BPH) treatment using the AQUABEAM Robotic System and Ultrasound Accessories
3374619|NCT05157516|Active Comparator|group ESPB|Erector Spinae Plane Block
3374620|NCT05157516|Active Comparator|In group CEA|Caudal epidural block
3374621|NCT05157490|Experimental|Mindfulness training|Completion of guided meditations in the preoperative time period, at least 3 sessions per week, leading up to surgery
3374622|NCT05157490|No Intervention|Control|
3374623|NCT05157477|Experimental|VR-Group|The participants who are randomized into 'CBT-based VR exposure program' (CBT+VR group) will receive the individual intervention weekly with a total of 8 sessions. The therapists, PI (Chien YL) and a clinical psychologist who is familiar with ASD psychopathology and CBT approach, will provide the CBT-based VR exposure intervention for each individual every week based on the above protocol. The participants complete the homework (i.e., relaxation and real-life exposure) between the sessions, and record 'anxiety level' before, during, and after the real-life exposure. The outcome measures will be scheduled at the end of intervention (8th week) within one week of program closure.
3374624|NCT05157477|Experimental|CBT-GROUP|The 'CBT alone' intervention applies the same protocol excluding VR exposure, which is replaced by traditional role play with the therapist.
3374625|NCT05157477|No Intervention|Control group|The participants who are randomized into control group will be regularly followed in a naturalistic outpatient clinic setting (every 2-4 week). During the clinic, sensory and socioemotional problems will be discussed face-to-face for 10 to 20 minutes, some self-help books will be recommended.
3374626|NCT05157464|Experimental|Losartan Group|
3255882|NCT01438203|Experimental|Thrust manipulation|Clinicians will use thrust manipulation at a targeted level to provide the treatment on selected individuals
3374627|NCT05157464|No Intervention|Control Group|No additional steps in management are required for the control arm of the study.
3374628|NCT05157451|Experimental|Arm I (SBRT)|Patients undergo SBRT every other day for a total of 5 days over 2 weeks.
3374629|NCT05157451|Experimental|Arm II (Y-90 radioembolization)|Patients receive Y-90 radioembolization via injection on day 1.
3374630|NCT05157438|Experimental|Group I (virtual reality group)|The virtual reality device is a 3D head-mounted display which provides a wide field of view and a high-resolution visual display, the system consists of head mounted glasses, a compatible smartphone and headphones. This technology creates a computer stimulated virtual environment.
3374631|NCT05157438|Active Comparator|Group II (screen program group).|the screens shows such as cartoons, animation movies or recorded video games are used for distraction during dental treatments. They could be seen on tablets, iPads or LCD screen.
3374632|NCT05157425|Experimental|Experimental|Probiotic multi-strain formulation comprising L. plantarum CECT30292, CECT7484, CECT7585 and P. acidilactici and maltodextrin (E1400, qs) as excipient in hydroxymethylpropyl-cellulose (HPMC) capsules. Probiotic strains have Qualified Presumption of Safety (QPS) status by European Food Safety Authority
3374633|NCT05157425|Placebo Comparator|Placebo|Maltodextrin (E1400, qs) in HPMC capsules
3374634|NCT05157412|Experimental|Steroids + Doxycycline|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) along with Doxycycline (200 mg as a loading dose on the 1st day, followed by 100 mg once daily as a maintenance dose) for 3 weeks.
3374635|NCT05157412|Active Comparator|Steroids Only|Systemic Prednisolone in decreasing doses (40 mg/d on days 1-7, 20 mg/d on days 8-14, and 10 mg/d on days 15-21) for 3 weeks.
3374636|NCT05157399|Experimental|OtoBand Efficacy on Vertigo and Dizziness|During the single site visit, participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand will be set to 92dB or 98dB bone conduction level (Re: 1 Dyne). The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
3255883|NCT01438203|Active Comparator|Non-thrust manipulation|Clinicians will apply non-thrust manipulation (targeted) as performed in a clinical manner for treatment for included individuals
3255884|NCT01438216||VUmc IC|Due to multicentre, 2 groups of patient in 1 cohort
3255885|NCT01438216||UMCN IC|Due to multicentre, 2 groups of patient in 1 cohort
3255886|NCT01438242|Experimental|Assay Guided Treatment - Genecept Asay|Subjects donate DNA sample for genetic testing and treatment decisions take genetic results into account. Genetic analysis is performed using the Genecept Assay, a genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
3374637|NCT05157399|Placebo Comparator|Placebo Device Efficacy on Vertigo and Dizziness|Participants will wear the Otoband, on the flat part of the right mastoid bone, about an inch behind the pinna and level with the ear canal. OtoBand set to a bone conduction level 10dB lower than the level used in the experimental condition. Once fitted with the Otoband, participants will undergo the vestibular battery test. The investigator will record the outcome measurements.
3374638|NCT05157399|No Intervention|No Device|Participants will wear the OtoBand, but turned off, to collect baseline data. This will be randomized. The participants will be fitted with the Otoband and will undergo the vestibular battery test. The investigator will record the outcome measurements.
3374639|NCT05157386||Participants in Braining, years 2017-2020|"Braining was primarily open for patients with a main or secondary diagnosis within affective disorder or anxiety syndromes, sleep disturbance or stress.~Participants in Braining (n≈600), who have participated in three or more training sessions 2017-2020 (n≈250), and who agree to contribute to this study, will be included."
3374640|NCT05157373||Group 1|Patients with any type of endometrial cancer
3374641|NCT05157373||Group 2|Patients with hyperplastic endometrial lesion (all type of endometrial hyperplasia and endometrial polyps). In this group will be included the breast cancer survivors under tamoxifen.
3374642|NCT05157373||Control group|A random sample of women without any endometrial pathology.
3374643|NCT05157360|Experimental|Treatment Arm|"Patients will be enrolled within 24 hours of diagnosis of sepsis related to a necrotizing soft-tissue infections (NSTI). HAT will be initiated within 4 hours of enrollment (thus treatment with HAT can occur no later than 28 hours from diagnosis).~Per Dr. Marik's original study, HAT consists of:~1.5 g vitamin C every 6 hours for 4 days or until ICU discharge~50 mg hydrocortisone every 6 hours for 7 days or until ICU discharge (followed by a taper over 3 days)~200 mg thiamine every 12 hours for 4 days or until ICU discharge In our study, due to the prolonged ICU course typical of most patients with NSTIs, it is not felt feasible to continue indefinitely until ICU discharge. Thus, treatment will be continued for 4 to 7 days plus a 3 day taper (respectively) as above, with no plan for a longer duration of treatment."
3374644|NCT05157360|Placebo Comparator|Control Arm|The control arm will receive the same standard ICU care for NSTI but will not receive HAT. They will receive a placebo consisting of normal saline, indistinguishable to the treatment team (blinded) but known to the pharmacy team (unblinded to treatment and placebo groups). This is so that if the treatment team elects to give stress dose steroids, they can be administered without breaking protocol (i.e. if the patient is getting HAT, it includes steroids, so if the treating team wanted to start hydrocortisone - because they didn't know if the patient was on HAT or placebo and felt steroids were indicated - the pharmacist could ensure the patient was on steroids one way or another without unblinding the providers).
3374645|NCT05157347|Experimental|Robot-assisted Training Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks. The robot-assisted training group is given 30 min conventional gait training and another 30 min (excluding robot attachment and detachment time) gait training using an exoskeletal wearable robot, while the control group is given 1 hr conventional gait training for the same time as the robot-assisted training group. In all participants in each group, no other robot-assisted rehabilitation such as Lokomat, Erigo, or Morning Walk could be performed.
3374646|NCT05157347|Other|Control Group|- After the baseline test, the training is performed with 20 sessions in total (60 min / session); five sessions a week for four weeks.
3374647|NCT05157334|Experimental|Deep breathing|"Sub-project 1: To compare the effect of one session of DB and one session of non-invasive auricular tVNS on vagal nerve tone measured by HRV in healthy participants and in patients with RA and SLE.~Sub-project 2: A dose-response study in healthy participants comparing the effect of 5, 15 and 30 minutes of DB on HRV.~Sub-project 3: To investigate the effect of the optimal dose found in sub-project 2 in patients with RA and SLE measured by HRV, and to investigate its reproducibility by doing it twice."
3255887|NCT01438242|Experimental|Clinician's utilizing Assay Guided Treatment in Psychiatry|Prescribing clinicians responsible for the treatment of patients age 18 and older with a primary diagnosis of Major Depressive Disorder or Generalized Anxiety disorder, and for whom the Genecept Assay has been utilized to perform genetic testing.
3255888|NCT01438255||Alvesco|
3255889|NCT01438268||Reconstructive breast cancer patients|Patients having unilateral, bilateral immediate or delayed TRAM flaps who are discharged 18 hours postoperatively
3374648|NCT05157321|Active Comparator|Study Group|The patients in this group will receive active repetitive transcranial magnetic stimulation sessions for 4 weeks.
3374649|NCT05157321|Sham Comparator|control group|The patients in this group will receive sham repetitive transcranial magnetic stimulation sessions for 4 weeks.
3255890|NCT01438281|Experimental|SYL1001|
3255891|NCT01438320|Experimental|Quercetin|Quercetin is a bioflavonoid.
3255892|NCT01438333|Experimental|Lactobacillus brevis|
3255893|NCT01438333|Placebo Comparator|Placebo|5 tablets a day for 6 weeks
3255894|NCT01438346|Active Comparator|Substance Abuse Education (SED)|The Substance Abuse Education (SED) group will serve as the control intervention in which participants will receive instruction on a variety of topics included in the substance abuse treatment program curriculum. These will include, but are not limited to, information about anger management, smoking cessation, women's issues, and stress management, and approaches to help reduce cravings. Each week the TAU group will meet and a House of Hope (HOH) clinical staff member will discuss the above and related issues and how these may help individuals deal with their substance abuse and related psychological issues.
3255895|NCT01438346|Experimental|Mind-body Bridging (MBB)|Participants in the experimental Mind-Body Bridging (MBB) group, in addition to their usual treatment for substance abuse, will additionally receive instruction on the basics of MBB, and will learn MBB techniques to help deal with their cravings and comorbid psychological conditions. A workbook will be incorporated into the curriculum to provide MBB participants with daily exercises and activities to help facilitate adherence to the MBB program.
3255896|NCT01438359|Experimental|PA21 and Furosemide with food|
3255897|NCT01438359|Experimental|No PA21; Furosemide with food|
3255898|NCT01438359|Experimental|PA21 with food and Furosemide 2hrs later|
3255899|NCT01438372|Experimental|Intravenous iron sucrose arm|
3374650|NCT05157295|Experimental|Experimental Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 4 different detrusor muscle sites along the posterior bladder wall and dome.
3374651|NCT05157295|Active Comparator|Control Group|100 U of onabotulinumtoxinA toxin diluted in 10 mL of saline cystoscopically injected into approximately 20 different detrusor muscle sites along the posterior bladder wall and dome.
3374652|NCT05156086||Kidney transplant recipients with booster|Patients who received kidney-only transplant or multi-organ transplant including kidney and fully vaccinated with standard dose(s) of messenger RNA (mRNA) or vector vaccine
3255900|NCT01438372|Active Comparator|Oral ferrous sulfate|
3255901|NCT01438385||Interventional Endoscopy|Any group that went Interventional Endoscopy procedures.
3255902|NCT01438398|Other|Submucosal Endoscopic Mucosal Flap Technique|Submucosal Endoscopic Mucosal Flap Technique
3255903|NCT01438437|Active Comparator|Percutaneous acetic acid|
3374653|NCT05155306|Experimental|Tfasted|T: Test Treatment fasted: under fasted conditions
3374654|NCT05155306|Experimental|Tfed|T: Test Treatment fed: under fed conditions
3374655|NCT05155306|Experimental|Rfasted|R: Reference Treatment fasted: under fasted conditions
3374656|NCT05155306|Experimental|Rfed|R: Reference Treatment fed: under fed conditions
3374657|NCT05155111|Experimental|Telemedicine arm|Neonates will have telemedicine consultation to evaluate symptoms of neonatal encephalopathy
3255904|NCT01438437|Active Comparator|Radiofrequency ablation|
3255905|NCT01438450|No Intervention|Supportive|Supportive therapy
3255906|NCT01438450|Active Comparator|Oral|Oral thalidomide and capecitabine
3255907|NCT01438463|Placebo Comparator|placebo|
3255908|NCT01438463|Experimental|PURETHAL Mites, 6,667 AU/ml|
3255909|NCT01438463|Experimental|PURETHAL Mites, 20,000 AU/ml|
3255910|NCT01438463|Experimental|PURETHAL Mites, 50,000 AU/ml|
3255911|NCT01438463|Experimental|PURETHAL Mites, 100,000 AU/ml|
3255912|NCT01438502||HyperHAES|
3255913|NCT01438515|Experimental|Systemic decolonization|7-day course of 4% chlorhexidine gluconate daily washes and 2% mupirocin ointment to the anterior nares twice daily in addition to oral rifampin (600mg daily), and doxycycline (100mg twice daily)
3255914|NCT01438515|Active Comparator|Standard decolonization|7-day course of 2% mupirocin ointment to the anterior nares twice daily and 4% chlorhexidine gluconate washes once per day.
3255915|NCT01438554|Experimental|Pazopanib and GSK1120212|Treatment will be administered on an outpatient basis. Both drugs are taken orally. Each cycle lasts 28 days. The doses of each drug will depend on when patient enters study.
3255916|NCT01438567|Experimental|OXN PR tablets|
3255917|NCT01438567|Active Comparator|OxyPR tablets|
3255918|NCT01438580|Experimental|standard intensity warfarin group|Eligible 80 patients(83.14±4.05,33.0%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 2.1-3.0
3255919|NCT01438580|Experimental|low intensity warfarin group|Eligible 81 patients(84.0±4.71,33.5%)with chronic NVAF were randomly assigned to this group and the target international normalised ratio(INR) was 1.5-2.0
3374669|NCT05142540||blood and saliva sampling|blood and saliva samples will be taken
3374670|NCT05140174|Experimental|RHIS Informed Psychotherapy|Therapists will be trained in Radical Healing and Internalized Stigma (RHIS) and meet with their clients as part of their usual care for 15 tele-psychotherapy sessions
3374671|NCT05140031|Active Comparator|Usual care|Participants will initially undergo 2 weeks of usual care.
3374672|NCT05140031|Experimental|PNE4Adults|Participants will undergo 2 sessions (1-2 weeks) where they will be introduced to the PNE4Adult board.
3374673|NCT05139745|Experimental|Histological evaluation of BTL-899 device´s effect on fat tissue|This group will be treated with 100% of the treatment parameter settings
3374674|NCT05139745|Sham Comparator|Sham treatment|This group will be treated with 5% of the treatment parameter settings
3374675|NCT05139654||Shoulder pain climbers group|Subjects with shoulder pain will be included to perform scaption and pull-up, and assess shoulder kinematics and muscle activation at the same time.
3374676|NCT05139654||Healthy climbers group|Healthy subjects will be included to compare the differences in shoulder kinematics and muscle activation between healthy subjects and subjects with shoulder pain. Subjects in this group will received the same assessments as the shoulder pain climbers group.
3374677|NCT05138315|Experimental|Study Group|Alleye App and M-chart examinations will be performed pre- and postsurgically.
3374678|NCT05137899|Experimental|Neoadjuvant Atezolizumab/Bevacizumab|• Arm 1: neoadjuvant atezolizumab 1200 mg IV q3weeks x 4 cycles, and bevacizumab 15 mg/kg IV q3weeks x 4 cycles
3255920|NCT01438580|Active Comparator|aspirin group|Eligible 81 patients(83.4±5.13,33.5%)with chronic NVAF were randomly assigned to this group and 100mg aspirin was administrated every day
3255921|NCT01438593|Experimental|HUCB, Medicine, Rehabilitation|Stroke patients are received intracerebral implantation of human cord blood stem cells (CD34+), Antiplatelet Medication, and Rehabilitation.
3255922|NCT01438606|Experimental|1 x 10^4 PFU VSV-Indiana HIV gag vaccine (Group 1)|Participants will receive 1 x 10^4 PFU of the study vaccine by intramuscular (IM) injection in each deltoid at baseline and Week 8. (1 x 10^4 PFU is the nominal dose; the actual dose is 4.6 x 10^3 PFU given as 2.3 x 10^3 PFU in each deltoid)
3255923|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 1)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3255924|NCT01438606|Experimental|1 x 10^5 PFU VSV-Indiana HIV gag vaccine (Group 2)|Participants will receive 1 x 10^5 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^5 PFU is the nominal dose; the actual dose is 4.6 x 10^4 PFU given as 2.3 x 10^4 PFU in each deltoid)
3255925|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 2)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3255926|NCT01438606|Experimental|1 x 10^6 PFU VSV-Indiana HIV gag vaccine (Group 3)|Participants will receive 1 x 10^6 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^6 PFU is the nominal dose; the actual dose is 4.8 x 10^5 PFU given as 2.4 x 10^5 PFU in each deltoid)
3255927|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 3)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3255928|NCT01438606|Experimental|1 x 10^7 PFU VSV-Indiana HIV gag vaccine (Group 4)|Participants will receive 1 x 10^7 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^7 PFU is the nominal dose; the actual dose is 4.2 x 10^6 PFU given as 2.1 x 10^6 PFU in each deltoid)
3255929|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 4)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3255930|NCT01438606|Experimental|1 x 10^8 PFU VSV-Indiana HIV gag vaccine (Group 5)|Participants will receive 1 x 10^8 PFU of the study vaccine by IM injection in each deltoid at baseline and Week 8. (1 x 10^8 PFU is the nominal dose; the actual dose is 3.4 x 10^7 PFU given as 1.7 x 10^7 PFU in each deltoid)
3374679|NCT05137899|Experimental|Neoadjuvant SBRT|• Arm 2: neoadjuvant stereotactic body radiation therapy (SBRT), target volume 30 40 Gy, in 6-8 Gy per day over five days, delivered every other day
3374680|NCT05137769|Experimental|Body Scan|Participants will listen to a 20-minute, audio-guided mindfulness-based body scan exercise.
3374681|NCT05136391|Experimental|XTR003|Administration and investigation of myocardial fatty acid radiotracer
3374682|NCT05129605||Cohort 1|Documented germline known pathogenic or likely pathogenic mutation in a prostate cancer related risk gene
3374683|NCT05129605||Cohort 2|Family history suggestive of high genetic risk for prostate cancer with clinical genetic testing negative for known pathogenic or likely pathogenic mutations in prostate cancer-related risk genes
3374684|NCT05129124|Experimental|T01: +6.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374685|NCT05129124|Experimental|T02: +6.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374686|NCT05129124|Experimental|T03: -3.00-2.75 x180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374687|NCT05129124|Experimental|T04: -3.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374688|NCT05129124|Experimental|T05: -9.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374689|NCT05129124|Experimental|T06: -9.00 -2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374690|NCT05129124|Experimental|T07: -12.00 -2.75 x 180|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374691|NCT05129124|Experimental|T08: -12.00-2.75 x 090|kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
3374692|NCT05129124|Active Comparator|C01: +6.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
3374693|NCT05129124|Active Comparator|C02: +6.00-2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
3374694|NCT05129124|Active Comparator|C03: -3.00-2.75 x180|Commercially available Ultra for Astigmatism Contact Lenses
3374695|NCT05129124|Active Comparator|C04: -3.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
3374696|NCT05129124|Active Comparator|C05: -9.00 -2.75 x 180|Commercially available Ultra for Astigmatism Contact Lenses
3374697|NCT05129124|Active Comparator|C06: -9.00 -2.75 x 090|Commercially available Ultra for Astigmatism Contact Lenses
3374698|NCT05126862|Experimental|MindTrails pilot|This intervention involves completion of five, 20-minute MindTrails online training sessions over five weeks.
3255931|NCT01438606|Placebo Comparator|Placebo injection (normal saline) (Group 5)|Participants will receive placebo by IM injection in each deltoid at baseline and Week 8.
3255932|NCT01438619||representitives of Goyang city|"Representative population of Goyang city who were randomly selected by digit dialing (RDD) method~Volunteers who are reside in Goyang city"
3374699|NCT05125484|Experimental|Experimental Intervention group 1|"Patient was in lying position. Therapist placed thumb on the effected side muscke. Then hooked thumb on lateral edge of muscle to apply pressure against the muscle. Took a pause. Thumb flattened in a medial direction and pluck was created in muscle.~Set of 15-20 bowen moves on upper , middle and lower fibres each with 2 mins gap between each set.~Total treatment time: 20 mins"
3255933|NCT01438632|Experimental|jet injector|Jet injectors deliver insulin at a high velocity (typically >100m/s) across the skin in the subcutaneous tissue, without the use of a needle
3255934|NCT01438632|Active Comparator|conventional insulin pen|
3255935|NCT01438645|Experimental|ScopeGuide-assisted colonoscopy|These patients will undergo colonoscopy with the assistance of the Olympus ScopeGuide system.
3255936|NCT01438645|No Intervention|Conventional colonoscopy|These patients will undergo colonoscopy identical to that in the intervention arm, except with endoscopes lacking the ScopeGuide system.
3255937|NCT01438658||All|A cohort of all the patients.
3255938|NCT01438671|Experimental|All participants|Nintendo Wii Fit Balance training followed by traditional balance training
3255939|NCT01438684|Active Comparator|RPh201 group|7 patients will receive the treatment
3255940|NCT01438684|Placebo Comparator|non RPh201 group|3 patients will receive placebo
3255941|NCT01438697|Experimental|Internet Intervention|Assigned to Sleep Healthy Using the Internet (SHUTi)
3255942|NCT01438697|Active Comparator|Patient Education Website|Assigned to Patient Insomnia Educational Website
3255943|NCT01438723|Experimental|metformin|
3374700|NCT05125484|Experimental|Experimental interventional group II|"Patient was in lying position. MFR applied via ulnar border of both palms while patient being in contralateral side flexion.~20 mins"
3374701|NCT05123417|Experimental|Intervention Group|Intervention group students will be educated with educational materials (lecture presentation, video) will be uploaded through the system in accordance with the flipped learning model, and students will be asked to come prepared to the planned lesson. No classical presentations will be made to the students, but the education will be carried out in the form of question and answer discussion, in line with the Flipped Learning model. After the lesson, the questions of the students who have questions will be answered.
3374702|NCT05123417|No Intervention|Control Group|The training, consisting of control group students will be trained with Powerpoint presentation, which will last 20-30 on average, will be given in accordance with the traditional education model. After the lesson, the questions of the students who have questions will be answered.
3374703|NCT05121857||ACLR group|Individuals who are 7 months post primary ACLR
3374704|NCT05121857||healthy control group|Healthy uninjured individuals who are actively playing sport and have not sustained any knee injuries, ankle injuries or concussions.
3255944|NCT01438723|Placebo Comparator|placebo|
3374705|NCT05121831|Experimental|Single Ascending Dose Cohort S1|Subjects will receive a single dose of either dose level 1 of DGX-001 or placebo
3374706|NCT05121831|Experimental|Single Ascending Dose Cohort S2|Subjects will receive a single dose of either dose level 2 of DGX-001 or placebo
3255945|NCT01438736|Experimental|Desogestrel, Etonogestrel|Arm 1: 75 microgr desogestrel POP (cerazette) daily for 3 months followed by etonogestrel implant (Nexplanon, 68 mg etonogestrel) for following 6 months
3255946|NCT01438736|Experimental|Etonogestrel|Arm 2: Women staring straight with Nexplanon implant for 6 months
3374707|NCT05121831|Experimental|Single Ascending Dose Cohort S3|Subjects will receive a single dose of either dose level 3 of DGX-001 or placebo
3374708|NCT05121831|Experimental|Single Ascending Dose Cohort S4|Subjects will receive a single dose of either dose level 4 of DGX-001 or placebo
3374709|NCT05121831|Experimental|Multiple Ascending Doses Cohort M1|Subjects will receive multiple doses of either dose level 1 of DGX-001 or placebo
3374710|NCT05121831|Experimental|Multiple Ascending Doses Cohort M2|Subjects will receive multiple doses of either dose level 2 of DGX-001 or placebo
3374711|NCT05121831|Experimental|Multiple Ascending Doses Cohort M3|Subjects will receive multiple doses of either dose level 3 of DGX-001 or placebo
3374712|NCT05121831|Experimental|Stress Exposure Resilience Panel Cohort 1|Subjects will receive any of the MAD dose panel or placebo
3374713|NCT05121831|Experimental|Stress Exposure Resilience Panel Cohort 2|Subjects will receive any of the MAD dose panel or placebo
3374714|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 1|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
3374715|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 2|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
3374716|NCT05117060|Experimental|LEO 152020 tablet - Dose regimen 3|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
3374717|NCT05117060|Placebo Comparator|LEO 152020 placebo tablet|Participants will be asked to take tablets from Week 0 to Week 16 (end of treatment).
3374718|NCT05115071|Experimental|Experimental|
3374719|NCT05115071|No Intervention|No intervention|
3255947|NCT01438749|Active Comparator|A|
3255948|NCT01438749|Placebo Comparator|B|
3255949|NCT01438749|Experimental|C|
3255950|NCT01438762|Active Comparator|Information and patient education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
3374720|NCT05112666||Cancer patients with VTE|Adults diagnosed with active (primary or metastatic) cancer experiencing a hospitalization or emergency department admission or a primary care visit with an incident venous thromboembolism (VTE), being administered rivaroxaban or other direct-acting oral anticoagulants (DOACs) or a low molecular weight heparin (LMWH) will be included.
3374721|NCT05111041|Experimental|Smokeless Tobacco Reduction Group|Participants in this group will receive a mobile gradual smokeless tobacco reduction intervention
3374722|NCT05111041|Active Comparator|Control|Participants in this group will receive tobacco cessation materials
3374723|NCT05110027|Experimental|Period 1: Enpatoran + [14C]enpatoran microtracer|
3374724|NCT05110027|Experimental|Period 2: Enpatoran + [14C]enpatoran microdose|
3374729|NCT05100056||HL Participants: BV Salvage Pre-ASCT|Participants diagnosed with HL who undergone or undergoing pre-ASCT BV salvage and continue with post-ASCT treatment will be observed prospectively over 24-month period after treatment cessation.
3374730|NCT05100056||HL Participants: BV Consolidation Treatment Post-ASCT|Participants diagnosed with HL who undergone or undergoing post-ASCT BV consolidation treatment will be observed prospectively over 24-month period after treatment cessation.
3255951|NCT01438762|Active Comparator|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas."
3255952|NCT01438762|No Intervention|Observational cohort|Those who do not wish to participate in the randomization procedure will be followed through an observational cohort. The observational cohort will be followed at the same time-points and they will be asked which treatment they have received.
3255953|NCT01438775|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
3255954|NCT01438788|Experimental|All patients on a low protein diet|
3255955|NCT01438801|Experimental|NutropinAq|
3255956|NCT01438827|Active Comparator|Avanz Phleum pratense 15,000 SQ+|
3255957|NCT01438827|Active Comparator|Avanz Phleum pratense 4,000 SQ+|
3255958|NCT01438827|Placebo Comparator|Injection with no active grass component|
3374736|NCT05089513|Experimental|Robotic surgery|Robotic surgery in both live donor and recipient
3374737|NCT05084924|Experimental|Delta-beta tACS|The study is investigating the use of transcranial alternating current stimulation (tACS). The stimulation is delivered at 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA zero to-peak amplitude at the return electrode. For the experimental arm, the tACS will be delivered using the cross-frequency stimulation waveform delta-beta (3-20Hz).
3374738|NCT05084924|Active Comparator|Theta-gamma tACS|This arm serves as an active control where tACS will be delivered using the cross-frequency stimulation waveform theta-gamma (5-50Hz).
3255959|NCT01438853|Experimental|TNX-832|Anti-tissue factor antibody
3255960|NCT01438853|Placebo Comparator|Drug Placebo|Placebo control
3255961|NCT01438866|Experimental|Preventing occlusal caries|Comparing preventing effect of fissure sealants vs. fluoride varnish
3374739|NCT05084924|Sham Comparator|Active-sham tACS|For active sham stimulation, either delta-beta or theta-gamma stimulation is delivered for 10 seconds and then returns to baseline. This is intended to mimic the skin sensations (e.g., itching, burning, tingling) that are experienced at the onset of stimulation, assisting with blinding the participant's assignment.
3374740|NCT05084625|Experimental|Arm A- access to digitized support, an app|Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.
3374741|NCT05084625|No Intervention|Arm B-standard follow-up|Patients in Arm B-will continue with standard follow-up from baseline and onwards
3374742|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Monotherapy)|HMBD-002 administered as a 60-minute IV infusion as a monotherapy. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.
3374743|NCT05082610|Experimental|Part 1 - Dose Escalation Phase (Combination Therapy)|"HMBD-002 administered as a 60-minute IV infusion at escalating doses in combination with pembrolizumab. HMBD-002 will be administered on Days 1, 8, and 15 of a 21-day cycle.~Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg on Day 1 of every 21-day cycle."
3374744|NCT05082610|Experimental|Part 2 - Dose Expansion (Monotherapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion as a monotherapy in patients with TNBC or NSCLC.
3374745|NCT05082610|Experimental|Part 2 - Dose Expansion (Combination Therapy)|HMBD-002 administered at the MTD/RP2D as a 60-minute IV infusion in combination with pembrolizumab at the standard labeled dose in patients with TNBC or NSCLC.
3374746|NCT05080946|Experimental|Participants Randomized to Aspirin|Participants randomized to this arm will receive 325mg daily dose aspirin
3374747|NCT05080946|Placebo Comparator|Participants Randomized to Placebo|Participants randomized to this arm will receive a daily dose of a placebo (inactive substance)
3374748|NCT05079282|Experimental|ONO-4685 monotherapy|Patients with relapsed or refractory T cell Lymphoma who meet eligibility criteria will be enrolled to receive ONO-4685 monotherapy
3255962|NCT01438879||pleocytosis group|40 patients with clinical signs of CNS infection and having CSF pleocytosis.
3255963|NCT01438879||non-pleocytosis group|20 patients not having CNS infection clinically and not having CSF pleocytosis.
3255964|NCT01438892||tDMARDs Group|traditional DMARDs
3255965|NCT01438892||Biologics group|Biologics used in RA
3255966|NCT01438905|No Intervention|Control|Parameters will be identical to the lower intensity (Small amplitude oscillation mobilization; Grade IV) talocrural mobilization. No force, other than light hand contact will be applied by the therapist.
3255967|NCT01438905|Experimental|Lower intensity mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
3374749|NCT05079126|Experimental|2.5 mg/kg Trans Sodium Crocetinate|Subjects will receive a single IV bolus dose of 2.5 mg/kg TSC.
3374750|NCT05079126|Placebo Comparator|Placebo|Subjects will receive a single IV bolus dose of 7 mL Normal Saline.
3255968|NCT01438905|Experimental|Higher intensity mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
3255969|NCT01438918|Active Comparator|200 mg|High dose active comparator
3255970|NCT01438918|Active Comparator|50 mg|Low dose active comparator
3374754|NCT05076838|Experimental|Valtoco In Pediatric Subjects with Epilepsy|5 mg, 10 mg, or 15 mg dose of intranasal VALTOCO will be administered based on the subject's body weight.
3374755|NCT05076253|Active Comparator|Ivermectin|Ivermectin 12 mg per day for 5 plus standard care
3374756|NCT05076253|Placebo Comparator|Placebo|Placebo plus standard care
3374757|NCT05075746||enVista Toric 0.9D intra ocular lens|
3374758|NCT05075746||enVista non-Toric (spherical) intra ocular lens|
3374759|NCT05075577|Experimental|Phase 1 Cohort 1|600 mg EPI-7386 in combination of Enzalutamide120 mg
3374760|NCT05075577|Experimental|Phase 1 Cohort 2|800 mg EPI-7386 in combination of Enzalutamide120 mg
3374761|NCT05075577|Experimental|Phase 1 Cohort 3|1000 mg EPI-7386 in combination of Enzalutamide120 mg
3374762|NCT05075577|Experimental|Phase 1 Cohort 4|RP2D mg EPI-7386 in combination of Enzalutamide160 mg
3374763|NCT05075577|Experimental|Phase 1 Dose Expansion|RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
3374764|NCT05075577|Experimental|Phase 2 Enzalutamide + EPI-7386 (Randomized 2:1)|RP2D mg EPI-7386 in combination of Enzalutamide RP2D mg
3255971|NCT01438918|Placebo Comparator|Placebo|Placebo comparator to be used for control purposes
3255972|NCT01438931|Placebo Comparator|Placebo group|Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo
3255973|NCT01438931|Active Comparator|DA-9501 0.5 mcg/kg group|Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
3255974|NCT01438931|Active Comparator|DA-9501 1.0 mcg/kg group|Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr
3374765|NCT05075577|Active Comparator|Phase 2 Enzalutamide single agent|Enzalutamide 160 mg
3374766|NCT05074719||Cohort A|Cohort A comprises individuals that enroll within two weeks of diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a baseline mid-turbinate nasal swab for SARS-CoV-2 testing and complete questionnaires at baseline and on Days 7 and 14. Through these questionnaires, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). Enrolled Cohort A index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
3374767|NCT05074719||Cohort B|Cohort B comprises individuals that enroll more than two weeks after diagnosis of SARS-CoV-2 infection. These individuals will be asked to provide a mid-turbinate nasal swab for SARS-CoV-2 testing and to complete a questionnaire reporting retrospectively on their COVID-19 illness and household environment. Through this questionnaire, index individuals will report on the clinical course of their illness and share information about their household environment, including potential exposures there-in and any COVID-19 transmission mitigation strategies implemented (whether intentional or as part of standard home routines). These individuals will also complete a questionnaire reporting on the persistence and/or delayed onset of symptoms and complications that they associate with their COVID-19 illness. Enrolled Cohort B index individuals will also be invited to participate in the SARS-CoV-2 Antibody Sub-study and provide a dried blood spot specimen (at baseline) for antibody testing.
3374768|NCT05074641|Experimental|Direct myofascial release treatment|Myofascial Release will be applied with Forearm and/or ulnar border of the palm. Deep Pressure will be applied and glided medially towards the base of the neck and/ or towards the upper scapular region
3374769|NCT05074641|Active Comparator|Bowen therapy|Thumb of the therapist will be placed on the top of the targeted muscle. The skin will be carried away gently from the spine without disturbing the muscle. The thumb was then hooked into the lateral aspect of the muscle to form a pressure on the muscle. Then the thumb will be flattened in the medial direction, when this happened the muscle would plop or respond in some way.
3255975|NCT01438944|Other|Nicabate 21mg transdermal NRT|21mg Transdermal NRT applied for 24hrs over a 14day period.
3255976|NCT01438970|Other|ALFApump system implantation|Implantation of ALFApump system
3255977|NCT01438983||breastfeeding infants|
3255978|NCT01438983||bottle feeding infants|
3255979|NCT01439022|Experimental|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist.
3255980|NCT01439022|Active Comparator|Hand writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
3255981|NCT01439048||Term infants|Infants born at greater than 37 weeks gestation
3255982|NCT01439048||Preterm Infants|Infants born at less than 37 weeks gestation
3255983|NCT01439100|Active Comparator|OXN PR|Oxycodone/Naloxone Prolonged Release tablets
3255984|NCT01439100|Placebo Comparator|Dummy tablet|Placebo
3255985|NCT01439113|No Intervention|Standard of care|In this arm, patients who have difficult IV access will undergo the standard of care. The options include a) repeated attempts by a primary nurse, b) new attempts by a second nurse, c) central line placement by a physician, d) intraosseous line placement by a physician, e) physician use of ultrasound for peripheral IV placement
3255986|NCT01439113|Experimental|Ultrasound-guided IV|In this arm, the emergency nurse will apply the ultrasound machine to locate and cannulate a patient's peripheral veins
3255987|NCT01439152|Experimental|BAY94-9343 (Dose-Escalation)|BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days. (ENROLLMENT CLOSED).
3255988|NCT01439152|Experimental|BAY94-9343 (Expansion)|"After Maximum tolerated dose (MTD) had been defined, expansion cohorts were conducted at the MTD dose. Overall up to 32 subjects were planned to be enrolled in the expansion cohort:~Ovarian Carcinoma, 20 subjects~Mesothelioma, 6-12 subjects (ENROLLMENT CLOSED)."
3255989|NCT01439152|Experimental|BAY94-9343 (1.8 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
3255990|NCT01439152|Experimental|BAY94-9343 (2.2 mg/kg)|This part of study was randomized and open-label. BAY94-9343 in two parallel dose cohorts of twenty (20) patients with recurrent platinum-resistant or platinum partially-sensitive ovarian cancer and up to four (4) patients with advanced malignant epithelioid peritoneal mesothelioma and eight (8) patients with advanced pleural mesothelioma.
3255991|NCT01439178|Experimental|Intravitreal Avastin Day 2|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
3255992|NCT01439178|Active Comparator|Intravitreal Avastin Day 7|randomized to either treatment with preoperative IVB 2 days before PPV (Group A) or 7 days before PPV (Group B).
3255993|NCT01439191|Experimental|combination agent group|
3255994|NCT01439191|Experimental|single agent group|In this arm, patients would be treated with Cipterbin® for 12 or 24 weeks
3255995|NCT01439230|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
3255996|NCT01439230|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
3255997|NCT01439243|Experimental|Investigational Test Product|Donepezil 10 mg Tablets
3255998|NCT01439243|Active Comparator|Reference Listed Drug|Aricept® 10 mg Tablets
3259627|NCT01472458|No Intervention|Control Hospitals|This stepped-wedge cluster randomized evaluation will randomly allocate 18 hospitals into 4 groups to receive our active intervention at different sequential time points according to the randomly assigned stepped-wedge schedule. Hospitals will function as control hospitals until it is their turn to receive the active intervention, according to the stepped wedge schedule. Each wedge consists of 4-5 hospitals and will last 5 months.
3259628|NCT01472471||acute asthmatic children|Children hospitalized with a diagnosis of acute asthma exacerbation
3259629|NCT01472471||stable asthmatic children|Children with a history of asthma currently asymptomatic
3259630|NCT01472484|Experimental|lpa with high polyphenol|
3259631|NCT01472484|Experimental|lpa with low polyphenol|
3259632|NCT01472484|Experimental|control bean with low polyphenol|
3259633|NCT01472484|Experimental|control bean with high polyphenol|
3259634|NCT01472497|Experimental|glymepiride|
3259635|NCT01472510|Active Comparator|Arm 1:The PRN Group|You will receive 6 monthly intravitreal injections of 0.5% Ranibizumab administered about every 28 days. It is possible you may receive additional injections into the study eye for the next six months if certain criteria is met.
3259636|NCT01472510|Active Comparator|arm 2:The Monthly Group:|You will receive 12 monthly intravitreal injections of 0.5% Ranibizumab administered every 28 days.
3259637|NCT01472523||Controls|
3259638|NCT01472523||Aneuploidy|T13, 18, 21 and other chromosomal abnormalities yet to be determined
3259639|NCT01472536|Experimental|3-day sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms
3259640|NCT01472536|No Intervention|Control|No intervention
3259641|NCT01472575||Pre- rotavirus vaccination introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2005-30Apr2007 (pre vaccine introduction)
3259642|NCT01472575||post rotavirus vaccine introduction|Children aged 0-less than 6 years of age admitted to hospital in South Australia with ICD10-AM separation codes consistent with rotaviral infection or gastroenteritis of any cause during the period 01May2009-30Apr2011 (post vaccine introduction)
3259643|NCT01472588|Experimental|Community Health Coach|DPP behavioral lifestyle intervention delivered by Community Health Coach (CHWs)
3259644|NCT01472588|Experimental|Public Health Coach|DPP behavioral lifestyle intervention delivered by health professionals (PHCs)
3259645|NCT01472588|Other|Self Help|Booklet, Aim for a Healthy Weight (DHHS, NIH-NHLBI) provided.
3259646|NCT01472601||FOLFOX_6|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, first 6 cycles, then Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, 6 cycles
3259647|NCT01472601||FOLFOX_12|Oxaliplatin : 85 mg/m2/day D1 Leucovorin : 200 mg/m2/day D1 5-FU : 400 mg/m2/day D1 5-FU : 2,400 mg/m2/day D1 over 46 hrs Every 2 weeks, total of 12 cycles
3259648|NCT01472614|Experimental|DLBS3233|
3259649|NCT01472627||Bortezomib treatment|Subjects receiving standard of care regimen including Bortezomib
3259650|NCT01472640|Active Comparator|Liraglutid|Liraglutid
3259651|NCT01472640|Placebo Comparator|Placebo|Placebo
3259652|NCT01472666|Experimental|Fat rich in MC-SFA|63 gram milk fat with high content of MC-SFA (C6-C12=8.5 g) incorporated in rolls, muffin and as butter.
3259653|NCT01472666|Experimental|Fat low on MC-SFA|63 gram milkfat with low content of MC-SFA (C6-C12=6.9 g) incorporated in rolls, muffin and as butter
3255999|NCT01439256|Experimental|Computer Controlled Telephone Counseling|This arm intervenes with subjects and their treating physicians. The intervention is periodic medical adherence promotion counseling for subjects regarding their prescribed HTN medications through a computer-controlled telephone counseling program that has data on subject's recent BP values and their prescribed HTN medications. The subjects' treating physicians receive at regularly scheduled office visits information about subject's recent BP and medication adherence for each prescribed medication and also get physician information and management recommendations
3256000|NCT01439256|No Intervention|Usual Care|In this arm, patients with hypertension that is not adequately controlled receive usual care from their physicians. Usual care is defined as receiving regular care from the physician and no additional care or intervention from the study.
3256001|NCT01439269|No Intervention|Phase 1: Standard Care|Mothers are given infant care instruction as part of standard care
3256002|NCT01439269|Experimental|Phase 1: Facilitated infant care|Family Nurture Intervention (FNI)
3256003|NCT01439269|Experimental|Phase 2: Effectiveness|All participants who agree to participate will receive Family Nurture Intervention.
3256004|NCT01439295||Preterm less than 33 weeks|This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
3256005|NCT01439308|Placebo Comparator|Arm 1|3 incremental capsaicin doses
3256006|NCT01439308|Active Comparator|Arm 2|3 incremental capsaicin doses
3256007|NCT01439321||Patient with Chronic Immune Thrombocytopenic Purpura|Patients with chronic ITP who switch from their previous treatment of corticosteroids, rituximab, or eltrombopag or romiplostim to eltrombopag or romiplostim and have been on the new treatment for at least four weeks
3256008|NCT01439334|Experimental|Online Program Brief|Online Program Brief
3256009|NCT01439334|Experimental|Online Program Extended Length|Online Program Extended Length
3256010|NCT01439334|Active Comparator|Control|Control
3256011|NCT01439386|Active Comparator|AF ablation with or without AFL ablation|Pulmonary vein antral isolation (PVAI)with or without cavo-tricuspid isthmus (CTI) ablation
3256012|NCT01439386|Active Comparator|AFL ablation only|Cavo-tricuspid isthmus ablation only
3256013|NCT01439399|Active Comparator|Lidocaine|Intravenous lidocaine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
3256014|NCT01439399|Active Comparator|Ketamine|Intravenous ketamine administered preoperatively (anesthesia induction) and postoperatively during 48 hours
3259654|NCT01472666|Experimental|Casein protein|60 gram casein protein (Miprodan 30) ingested twice daily with 600 ml water.
3259655|NCT01472666|Experimental|Whey protein|60 gram whey protein (Lacprodan DI-9224) ingested twice daily with 600 ml water.
3259656|NCT01472705||everolimus-eluting stents (EES)|Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.
3259657|NCT01472705||biolimus-eluting stents (BES)|Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.
3259658|NCT01472731|Experimental|GC1008 imaging and treatment|"Part 1: Feasibility of 89Zr-GC1008 PET imaging in patients with suspicion of a malignant glioma to assess if GC1008 penetrates into the brain tumor and to quantify its uptake.~Part 2: 89Zr-GC1008 PET imaging in patients with relapsed malignant glioma and phase II extension study with therapeutic GC1008 in these patients"
3259659|NCT01472744|Experimental|Dance|Participants will be instructed in various forms of dances such as ballroom, swing, waltz, folk, and English country.
3259660|NCT01472744|Active Comparator|Strengthening, Stability, Stretching|Participants will be instructed in various forms of strength, stretching (flexibility) and stability (balance)exercises.
3259661|NCT01472744|Experimental|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate.
3259662|NCT01472744|Experimental|Walking + Nutritional Supplement|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. These participants will also be provided with a daily nutritionally balanced liquid, milk-based formula.
3259663|NCT01472783|Experimental|Veliparib|
3259664|NCT01472796|Active Comparator|Tekturna (Aliskirin) with vit. D supplementation|Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.
3259665|NCT01472796|Placebo Comparator|Tekturna (Aliskiren) with placebo|Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)
3259666|NCT01472809|Placebo Comparator|Placebo|Placebo tablets
3259667|NCT01472809|Experimental|ZYGK1|"ZYGK1 tablets; 0.125, 0.25, 0.5, 1, 2, ... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
3259668|NCT01472848|Experimental|Cohort 1|
3259669|NCT01472848|Experimental|Cohort 2|
3259670|NCT01472848|Experimental|Cohort 3|
3259671|NCT01472848|Experimental|Cohort 4|
3259672|NCT01472848|Experimental|Cohort 5|
3259673|NCT01472848|Active Comparator|Cohort 6|
3259674|NCT01472861|Placebo Comparator|No AECC|Routine procedures without AECC
3259675|NCT01472861|Experimental|AECC|Endometrial biopsy and Autologous endometrial coculture
3259676|NCT01472887|Experimental|SAR3419|All patients will receive SAR3419 until evidence of disease progression, unacceptable toxicity, or other reasons for therapy discontinuation
3259677|NCT01472900|Experimental|Er:YAG laser|
3259678|NCT01472900|Active Comparator|BP gel|
3259679|NCT01472913|Active Comparator|Fibrin Sealent|
3259680|NCT01472913|Placebo Comparator|Saline water|
3259681|NCT01472926|Experimental|Tenecteplase 0.25 mg/kg|Intravenous tenecteplase 0.25 mg/kg (single bolus, maximum 25 mg)
3259682|NCT01472926|Active Comparator|Alteplase 0.9 mg/kg|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
3256015|NCT01439399|Active Comparator|Ketamine-Lidocaine|Intravenous association of ketamine and lidocaine administered preoperatively (at anesthesia induction) and postoperatively during 48 hours.
3256016|NCT01439399|Placebo Comparator|Saline 0,9%|Control group
3256017|NCT01439412|Experimental|Acupuncture and standard treatment|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
3256018|NCT01439412|Other|Standard treatment in general practice|Adults (20-55 years) who contact their general practitioners office because of acute nonspecific low back pain (0-14 days).
3256019|NCT01439425|Experimental|weight loss|balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
3256020|NCT01439438|Active Comparator|Test formulation|Test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 1, followed by 28 days washout period during which no medication was administered; followed by reference product: Topamax® 100 mg coated tablets in Period 2
3256021|NCT01439438|Active Comparator|Reference formulation|Topamax® 100 mg coated tablets marketed by Janssen-Cilag farmacêutica Ltda. in Period 1, followed by 28 days washout period during which no medication was administered; followed by test product: Topiramate 100 mg coated tablets produced by Dr. Reddy's Laboratories Ltd. in Period 2
3256022|NCT01439451|Experimental|experimental|perturbation training during walking
3256023|NCT01439451|Active Comparator|controls|treadmill walking
3256024|NCT01439464|Active Comparator|Control device|
3256025|NCT01439464|Experimental|Investigational device|
3256026|NCT01439490|Experimental|FES-PET|Patients undergo FES-PET prior to obtaining histology
3259683|NCT01472978|Active Comparator|Immediate antibiotic treatment|Patients will be treated with an antibiotic as soon as the aspirate obtained at the colonoscopy is found to be positive for C. diff.
3259684|NCT01472978|Sham Comparator|Delayed treatment with an antibiotic|Treatment will be started after a delay after the aspirate obtained at the colonoscopy is found to be C. diff positive.
3259685|NCT01472991|Experimental|TC-5619-238 (25mg)|TC-5619-238 25 mg will be provided as hard gelatin capsules
3259686|NCT01472991|Placebo Comparator|Placebo|Placebo will be provided as hard gelatin capsules similar to TC-5619-238
3259687|NCT01472991|Experimental|TC-5619-238 (5 mg)|TC-5619-238 5 mg will be provided as hard gelatin capsules.
3259688|NCT01473004|Experimental|Sirspheres, response evaluation|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
3259689|NCT01473017|Experimental|CBT-based guided self-help|Providing a guided self-help booklet to patients with anxiety/depression meeting criteria, with two telephone calls by a clinician to provide support with this.
3259690|NCT01473017|No Intervention|No CBT intervention|Control group in comparison to CBT guided self-help group
3259691|NCT01473030||Dutasteride|No PCa at Year 2 or Year 4
3259692|NCT01473030||Placebo|No PCa at Year 2 or Year 4
3259693|NCT01473056|Experimental|Dose 1 JTK-853|
3259694|NCT01473056|Experimental|Dose 2 JTK-853|
3259695|NCT01473056|Experimental|Dose 3 JTK-853|
3259696|NCT01473056|Experimental|Dose 4 JTK-853|
3259697|NCT01473056|Placebo Comparator|Placebo|
3259698|NCT01473069|Experimental|Dose 1 JTK-853, 400 mg ketoconazole|
3259699|NCT01473069|Experimental|Dose 2 JTK-853|
3259700|NCT01473069|Experimental|Dose 3 JTK-853|
3259701|NCT01473069|Experimental|Dose 4 JTK-853|
3259702|NCT01473069|Placebo Comparator|Placebo|
3259703|NCT01473082|Active Comparator|PFNA|Proximal Femoral Nail Antirotation (PFNA Synthes)
3259704|NCT01473082|Active Comparator|PFNA Augmentation|Proximal Femoral Nail Antirotation PFNA Augmentation (Synthes) with Traumacem V+ Synthes
3259705|NCT01473108|Experimental|Finerenone (20 mg solution)|3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3259706|NCT01473108|Experimental|Finerenone (10 mg solution)|3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3259707|NCT01473108|Experimental|Finerenone (5 mg solution)|3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3259708|NCT01473108|Experimental|Finerenone (20 mg as tablets)|3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3259709|NCT01473108|Experimental|Finerenone (2.5 mg solution)|3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.
3259710|NCT01473121||Group 1|
3259711|NCT01473147|Active Comparator|GLP-1|
3259712|NCT01473147|Placebo Comparator|Normal saline|
3259713|NCT01473173|Experimental|CJ-12420 50mg|"Single dose~8 volunteers will be administered CJ-12420 50mg or placebo comparators.(CJ-12420:placebo=6:2)"
3259714|NCT01473173|Experimental|CJ-12420 100mg|"Single dose~8 volunteers will be administered CJ-12420 100mg or placebo comparators.(CJ-12420:placebo=6:2)"
3259715|NCT01473173|Experimental|CJ-12420 200mg|"Single dose~8 volunteers will be administered CJ-12420 200mg or placebo comparators.(CJ-12420:placebo=6:2)"
3259716|NCT01473173|Experimental|CJ-12420 400mg|"Single dose~8 volunteers will be administered CJ-12420 400mg or placebo comparators.(CJ-12420:placebo=6:2)"
3259717|NCT01473173|Experimental|CJ-12420 100mg (repeated dose)|"Repeat doses~100mg is the anticipated dose~8 volunteers will be administered CJ-12420 100mg or placebo comparator.(CJ-12420:placebo=6:2)"
3259718|NCT01473173|Experimental|CJ-12420 200mg (repeated dose)|"Repeat doses~200mg is the anticipated dose~8 volunteers will be administered CJ-12420 200mg or placebo comparator.(CJ-12420:placebo=6:2)"
3259719|NCT01473173|Active Comparator|Esomeprazole 40mg|8 volunteers will be administered Esomeprazole 40mg
3259720|NCT01473199|Experimental|BioPoly RS Implant|BioPoly RS Implant
3374774|NCT05071872||Rotarex®S|Treatment performed with Rotarex®S
3374775|NCT05071872||Aspirex®S|Treatment performed with Aspirex®S
3374776|NCT05071183|Experimental|TPX-0005 + Trametinib|"TPX-0005 + Trametinib Dose Escalation and Dose Expansion~Dose escalation: KRAS G12D mutant advanced solid tumors. Dose expansion: KRAS G12D locally advanced or metastatic NSCLC"
3374777|NCT05067972|Experimental|Monotherapy dose escalation (Part 1)|Participants will receive PF-07260437
3374778|NCT05067972|Experimental|Dose Expansion (Part 2A) - Tumor specific Arm A|Participants will receive PF-07260437
3374779|NCT05067972|Experimental|Dose Expansion (Part 2B) - Tumor specific Arm B|Participants will receive PF-07260437
3256027|NCT01439503|No Intervention|Control|Men receiving the control condition will be comprised of standard of care counseling from the clinic plus a variety of free condoms and water-based lubricants. They will also provide a specimen for STD testing, and receive text message questions for 12 weeks. The text messaging system will be used to collect self-reported dependent variables from men on a weekly basis. Texting will also serve as a constant method of contact between the PD and the enrolled men to remind them of follow-up assessments. In addition, the participants will complete the ACASI questionnaire to assess their sexual behavior, as well as demonstrate their condom application ability.
3256028|NCT01439503|Experimental|Treatment|Men receiving the treatment condition will receive text messages each week after their enrollment date and this will continue for 12 weeks to collect self-reported dependent variables. Text messaging will also be used to confirm and remind men about the day of each follow-up assessment. Each participant will also provide a specimen for STD testing, as well complete the ACASI questionnaire to assess sexual behavior and demonstrate their condom application ability. These participants will also be provided with a variety of free condoms and water-based lubricants. In addition, men in the treatment condition will also be enrolled in an education program.
3256029|NCT01439516|Experimental|Information|Participants randomized to this arm of the study will received the PREPARED educational book and video.
3374780|NCT05067972|Experimental|Dose Expansion (Part 2C) - Tumor specific Arm C|Participants will receive PF07260437
3374781|NCT05067855|Experimental|Pilates exercise program group|The pilates exercise program group will perform five exercises
3256030|NCT01439516|Experimental|Information and Financial Assistance|Participants randomized to this arm of the study will receive the PREPARED educational book and video plus financial assistance for family members to cover costs associated with an evaluation for becoming a live kidney donor.
3374787|NCT05060081|Experimental|Pilates exercise program group|Pilates exercise program group will perform five exercises.
3374788|NCT05060081|Active Comparator|Traditional plank exercise program group|Traditional plank exercise program group will perform five exercises.
3374789|NCT05059522|Experimental|Arm 1|Avelumab monotherapy as specified by sub-study protocol B9991001C
3374790|NCT05059522|Experimental|Arm 2|Avelumab in combination with CMP 001, Utomilumab or PF04518600 as specified by sub-study protocol B9991004C
3374791|NCT05059522|Experimental|Arm 3|Avelumab in combination with Loratanib as specified by sub-study protocol B9991005C
3374792|NCT05059522|Experimental|Arm 4|Avelumab monotherapy as specified by sub-study protocol B9991009C
3374793|NCT05059522|Experimental|Arm 5|Avelumab monotherapy or in combination with Pemetrexed as specified by sub-study protocol B9991023C
3374794|NCT05059522|Experimental|Arm 6|Avelumab in combination with Talazoparib as specified by sub-study B9991025C.
3374795|NCT05059522|Experimental|Arm 7|Avelumab in combination with Axitinib as specified by sub-study B9991027C.
3374796|NCT05059522|Experimental|Arm 8|Avelumab in combination with Talazoparib as specified by sub-study B9991032C.
3374797|NCT05054088||Cohort 1|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with symptoms compatible with SARS-CoV-2 infection.
3374798|NCT05054088||Cohort 2|Subjects who have tested positive for SARS-CoV-2 by EUA RT-PCR testing with or without symptoms compatible with SARS-CoV-2 infection.
3374799|NCT05052697|Experimental|mIRV A strain, 3.75 micrograms (ug) dose|
3374800|NCT05052697|Experimental|mIRV A strain, 7.5ug dose|
3374801|NCT05052697|Experimental|mIRV A strain, 15ug dose|
3374802|NCT05052697|Experimental|mIRV A strain, 30ug dose|
3374803|NCT05052697|Experimental|mIRV B strain, 3.75ug dose|
3374804|NCT05052697|Experimental|mIRV B strain, 7.5ug dose|
3374805|NCT05052697|Experimental|mIRV B strain, 15ug dose|
3374806|NCT05052697|Experimental|mIRV B strain, 30ug dose|
3374807|NCT05052697|Experimental|bIRV 15ug + 15ug dose|
3374808|NCT05052697|Experimental|bIRV 7.5ug + 7.5ug dose|
3374809|NCT05052697|Experimental|bIRV 7.5ug + 15ug dose|
3374810|NCT05052697|Experimental|bIRV 3.75ug + 15ug dose|
3374811|NCT05052697|Active Comparator|QIV|
3374812|NCT05052697|Experimental|qIRV|
3374815|NCT05051904||Warfarin users|
3374816|NCT05051904||Dabigatran users|
3374817|NCT05051904||Rivaroxaban users|
3256031|NCT01439516|No Intervention|Usual Care|Participants randomized to this arm of the study will receive usual care from their physician.
3256032|NCT01439529|Active Comparator|Nominal|CRT device is programmed with the nominal values.
3256033|NCT01439529|Experimental|Narrow QRS|CRT device is programmed by QRS optimization
3256034|NCT01439542|Experimental|Radiotherapy|
3256035|NCT01439607|Experimental|Bone marrow and blood sampling|
3256036|NCT01439646||Non neutropenic, ICU, empiric ,antifungals|
3256037|NCT01439659|Other|Nutritional Counseling|For 6 months control group receives dietary counseling.
3256038|NCT01439659|Experimental|Daily Supplements|2 capsules (Juice Plus+) twice a day (morning and evening) plus Juice Plus+ Complete drink each evening for 6 months.
3256039|NCT01439685||Biliary Stent plus Photodynamic therapy|Biliary Stent plus Photodynamic therapy
3256040|NCT01439685||Biliary Stent group|Biliary Stent group
3256041|NCT01439698||RFA for Pancreatico-biliary disorders|Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.
3256042|NCT01439737||asthma|
3256043|NCT01439750|Experimental|Phase I|The phase I portion of the study is a standard dose-escalation schemed designed to determine the maximum tolerated dose (MTD) of cladribine in the combination of bortezomib, cladribine, and rituximab therapy. The MTD is defined as the dose level in which ≤1 out of 6 patients have dose-limiting toxicity (DLT). Rituximab 375 mg/m2 on day 5,12, 19, 26 for 1st cycle, then day 5 of cladribine for next 5 cycles and then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days 1-5 for 6 cycles. Bortezomib 1.6 mg/m2 sub Q days 12,19,26 for 3 cycle, then every 2 weeks maintenance dose until toxicity or progression.
3256044|NCT01439750|Experimental|Phase II|The phase II portion of the study is a two-arm, single-stage design with no interim analysis. One arm will accrue newly diagnosed patients, and one arm will accrue relapsed patients. In each arm, the progression-free survival rate at 2 years will be used as the primary endpoint for determining whether the treatment is sufficiently active in each arm. No comparisons will be made between the arms. Rituximab 375 mg/m2 on day 5,12,19,26 for 1st cycles, then day 5 montly for next 5 cycles, then every 2 months maintenance dose. Cladribine 3-5 mg/m2 days for 6 cycles (dose determined from phase I). Bortezomib 1.6 mg/m2 weekly on day 12,19,26 for 3 cycles then every 2 weeks as maintenance dose until toxicity or progression.
3256045|NCT01439776|No Intervention|Peginterferon alfa 2a+Ribavirin|standard of care for HCV : peginterferon alfa 2a and ribavirin
3256046|NCT01439776|Experimental|Vit D+Peginterferon alfa 2a+Ribavirin|VitD+Peginterferon alfa 2a+Ribavirin
3256047|NCT01439789|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
3256048|NCT01439789|Placebo Comparator|Plaebo|Excipient placebo in addition to basic therapy of chronic heart failure
3256049|NCT01439828|Experimental|Experimental : N-acetylcystein|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
3256050|NCT01439828|Placebo Comparator|Placebo Comparator|N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to the previous visit. The doses start at 200 mg x 4/24h to 800 mg x 4/24h
3256051|NCT01439841|Experimental|Probiotics|A multi-strain Probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk (Biola®, TINE SA, Oslo), 250 mL/day for 8 weeks.
3256052|NCT01439841|Placebo Comparator|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk (TINE SA) as active placebo.
3256053|NCT01439841|No Intervention|Control|No intervention
3259721|NCT01473225|Experimental|Calorie label|
3259722|NCT01473225|Active Comparator|No calorie label|
3259723|NCT01473238|Active Comparator|Desktop PC|Conventional institutional Desktop Personal Computers will be used to collect data of patients via a password protected encrypted interface.
3259724|NCT01473238|Experimental|Mobile|Novel Mobile Clinical Trial Management System on iPads will be used to collect data of patients via a password protected encrypted interface.
3259725|NCT01473251|Active Comparator|Avastin for Diabetic Macular Edema|1.25 mg avastin monthly for 4 months
3259726|NCT01473251|Active Comparator|Avastin for Exudative Macular Degeneration|1.25 mg Avastin monthly for 4 months
3259727|NCT01473251|Active Comparator|Lucentis for Exudative Macular Degeneration|0.5 mg Lucentis monthly for 4 months
3259728|NCT01473264|Placebo Comparator|Control|
3259729|NCT01473264|Experimental|High dose rhCC10|5 mg/kg study drug (rhCC10)
3259730|NCT01473264|Experimental|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
3259731|NCT01473277|Active Comparator|BT-A (Dysport 500U)|
3259732|NCT01473277|Active Comparator|Triamcinolone acetonide|
3259733|NCT01473290|Experimental|Arm I|Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®) orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
3259734|NCT01473290|Placebo Comparator|Arm II|Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
3259735|NCT01473303|Experimental|Arm I|Patients receive oxaliplatin IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV over 48 hours beginning on day 2 (mFOLFIRINOX) and ganitumab IV over 30-60 minutes on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
3259736|NCT01473303|Experimental|Arm II|Patients receive mFOLFIRINOX as in arm I and placebo IV over 30-60 minutes on day 1.
3259737|NCT01473316|Experimental|A|
3259738|NCT01473329|Experimental|Structured Diabetes education|The intervention group received a structured DSME course. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
3259739|NCT01473342|Other|Control & Intervention Phases|The control phase will run for 8 weeks, including survey completion and accelerometer wear during Week 1 and Week 8. The intervention phase will run for the 9 weeks following the control phase; where participants are assigned a smartphone to interact with the Mila Blooms gaming app and integrated social network & receive weekly supportive coaching phone calls from study staff for 8 weeks (Week 9 - Week 16) followed by accelerometer wear & survey completion during the 9th and final week (Week 17).
3256054|NCT01439893|Active Comparator|rhNRG-1|Recombinant human neuregulin-1 administration in addition to basic therapy of chronic heart failure
3256055|NCT01439893|Placebo Comparator|Placebo|Excipient placebo in addition to basic therapy of chronic heart failure
3256056|NCT01439906||Adult degenerative scoliosis|Patients aged 40-75 years affected by lumbar or thoraco-lumbar degenerative kyphoscoliosis presenting chronic low back pain from six months at least and/or neurological deficits who underwent a surgical correction of the deformity
3256057|NCT01439919|Experimental|SSR411298 200 mg|SSR411298 200 mg, one tablet once daily for 4 weeks
3256058|NCT01439919|Placebo Comparator|Placebo|Placebo (for SSR411298), one tablet once daily for 4 weeks
3256059|NCT01439932|Experimental|ankle mobilization for pain release|"stretching exercise for the plantar fascia and triceps surae muscles three times a day throughout the study period.~During each visit the exercise performance will be checked by the therapist. In addition, participants from both groups will get ultra sound therapy in frequency of 1 MHz, power of 1.5 watts per centimeter-squared, pulses of 50% for 5 minutes.~The study group will receive the same treatment and a number of manual techniques that include antero-posterior (AP) mobilization for talocrural joint in two variations (weight baring and non-weight baring) to improve the range of dorsi flexion, subtalar joint mobilization to improve range of eversion and mid-tarsal mobilization to improve pronation / supination of the forefoot. Each technique will be carried out for 1 to 1.5 minutes for a total of 5 minutes of manual treatment.~All patients will receive information and guidance to practice at home."
3256060|NCT01439958|Experimental|L-CsA|Twice daily inhalation of L-CsA
3256061|NCT01439984|Experimental|PED-1|PED-1 (Clomipramine 15 mg)
3256062|NCT01439984|Placebo Comparator|placebo|
3256063|NCT01439997|Experimental|Desmopressin Melt Therapy in Nocturnal Polyuria Patients|
3256064|NCT01440010||IORT with 50 kV x-rays, 20 Gy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
3256065|NCT01440023|Experimental|CBIT + Response Inhibition Training|CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
3259740|NCT01473433|Other|Control|Patients in which the non-revascularizable area will be left untouched and the revascularizable area will be treated normally.
3259741|NCT01473433|Experimental|adiFLAP|Patients in which the non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure.
3259742|NCT01473446|No Intervention|Control|Standard monitoring. Initial optimization of fluid status is performed by pulse, BP and anaesthesiologist assessment with Ringer acetate. Followed by an infusion of 10ml/kg/t Ringer acetate. Urinary output and blood pressure is used as a surrogate parameter: the infusion rate is increased by a fall in blood pressure or urine output <0.5ml/kg/t. Bleeding replaced with HES 1:1, otherwise see table for fluid therapy page 9. Vasoactive agents (noradrenaline / phenylephrine) is given if the anesthesiologist considers this necessary. Postoperative give 1000ml Glucose 5%. HES or Ringer when low blood pressure, eventually noradrenaline as vasoactive agent.
3259743|NCT01473446|Experimental|Goal directed fluid therapy|
3259744|NCT01473459|Active Comparator|IVM Treatment|
3259745|NCT01473459|Active Comparator|Antagonist Protocol|
3259746|NCT01473472|Active Comparator|Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
3259747|NCT01473472|Placebo Comparator|Placebo of Truvada|associated with an overall offer of prevention (counselling, STD screening, condoms, HAV and HBV vaccinations, treatment post-exposure to the HIV infection)
3259748|NCT01473485|Experimental|ExAblate Transcranial Device|
3259749|NCT01473498|Experimental|Test group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients (A maximum dose of 1.2 mcg / kg / min is not exceeded). Key details, e.g., for drugs include dosage form, dosage, frequency and duration."
3259750|NCT01473498|Active Comparator|Control group|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
3259751|NCT01473511|Experimental|Strongest Families Program + Usual care|50% randomized to receive Strongest Families intervention immediately as well as the usual care services available via the referring agency for the 22 month study period.
3259752|NCT01473511|No Intervention|Usual care|50% randomized will not receive Strongest Families Intervention during the 22 month study phase, but will receive the usual care services available via the referring agency. At the end of the 22 month study period study participants will be offered the Strongest Families Intervention services.
3259753|NCT01473537|Active Comparator|calcium lactate solution 75 mM|
3259754|NCT01473537|Active Comparator|calcium lactate solution 150 mM|
3259755|NCT01473537|Placebo Comparator|placebo|
3259756|NCT01473550|Experimental|Early Intervention|At Phase 1 (first 3 months of project), the 200 participants in Group 1 will be provided with a Personal Health Record (PHR) through TELUS Health Space, as well as they will be introduced to smart phone technology to ready them for deployment of the prompts and reminders. Two months later, they will be provided with a smart phone.
3259757|NCT01473550|Experimental|Later Intervention|A delayed implementation plan will be used (but will have no effect on the standard of care for the remaining 200 participants), so the remaining 200 participants in Group 2 will initially act as a control group, but at Phase 2 (six months later - approximately June 2012) the remaining 200 participants will be introduced to the technology in the same order (PHR -> Smart Phone). Group 2 will have the benefit of any enhancements made during Phase 1 of the project.
3256066|NCT01440023|Placebo Comparator|Experimental: CBIT + Placebo Computer Training|In this condition, participants receive the same package of CBIT treatment, which consists of awareness training, competing response training, and social support training (Woods, Twohig, Roloff, & Flessner, 2003). Additionally, the standard CBIT treatment is combined with computer-based placebo cognitive training that is irrelevant to the target cognitive ability (i.e., response inhibition). During the first 4 weeks of the CBIT treatment, participants will receive 8 sessions of placebo cognitive training.
3256067|NCT01440036||Carotid endarterectomy|Patients that have the common indication for the treatment of carotid artery stenosis by surgery - CEA (carotid endarterectomy), symptomatic and asymptomatic patients.
3256068|NCT01440062|Experimental|Verum (high dose)|verum arm receiving high dose Vitamin D oil
3256069|NCT01440062|Experimental|Verum (low dose)|low dose arm receiving neutral oil and low dose of Vitamin D
3256070|NCT01440075|Other|Patients KD|Adults with a history of KD disease in childhood
3256071|NCT01440075|Other|Case Control|Control group, healthy volunteers matched for age and sex with the KD group
3256072|NCT01440088|Experimental|TH-302 in Combination with Doxorubicin|
3256073|NCT01440088|Active Comparator|Doxorubicin|
3256074|NCT01440114|Active Comparator|fentanyl group|First arm: intervention group. Patient in this group received fentanyl 1 mcg/kg (concentration 10mcg/ml) intravenous route 15 minutes before the end of surgery.
3256075|NCT01440114|Placebo Comparator|controlled group|patient in this group received NSS 0.1 ml/kg 15 minutes before the end of surgery
3259758|NCT01473576|Experimental|Nitrate|Sodium nitrate ingestion prior to ingesting intrinsically labeled protein
3259759|NCT01473576|Placebo Comparator|Sodium chloride|Sodium chloride placebo group
3259760|NCT01473615|Experimental|Treatment As Usual + Mindfulness Based Cognitive Therapy|Subjects randomized into the intervention group will receive, a manualized 8-week MBCT group skills program with sessions that each last 2 hours, in addition to their treatment as usual (TAU).
3259761|NCT01473615|No Intervention|Treatment As Usual|Patients randomized into the TAU group will continue to receive their care as usual and be put on a waitlist. They will be offered the MBCT treatment after the completion of the study.
3259762|NCT01473628|Experimental|Radiation Therapy and Rituximab (Arm I)|Patients undergo radiation therapy five days a week for 2.5 weeks (12 treatments) and receive rituximab IV over 4-6 hours weekly with the start of radiation for 4 weeks and then every 2 months for up to 4 additional doses in the absence of disease progression or unacceptable toxicity.
3259763|NCT01473628|Experimental|Radiation Therapy and Observation (Arm II)|Patients undergo radiation therapy five days a week for 2.5 weeks and then undergo observation.
3259764|NCT01473641||New users of Nexplanon|
3259765|NCT01473654|Experimental|ADAPT tool|prediabetes counseling using ADAPT tool
3259766|NCT01473654|No Intervention|Control|
3259767|NCT01473667|Active Comparator|Superficial Cervical Plexus Block|
3259768|NCT01473667|Active Comparator|Local Infiltration|
3259769|NCT01473680||Patients who will receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3259770|NCT01473680||Patients who will not receive chemo|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3259771|NCT01473680||Healthy Controls|This study is an assessment of individuals' cognitive functioning through administration of NP and psychological instruments and EEG. These assessments do not require manipulation of a participant's environment to elicit change in behavior or treatment outcome. NP and psychological instruments.
3259772|NCT01473693||surgery-only group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without, induction systemic chemotherapy treatment.
3259773|NCT01473693||induction chemotherapy group|This will be a prospective study to investigate chemotherapy related structural brain changes in individuals undergoing anatomic lung resection for non-small cell carcinoma with and without induction systemic chemotherapy treatment.
3259774|NCT01473706||Consumers|Adults aged ≥ 65 years; Employed part-time, unemployed, retired, full-time or a homemaker; English speaking
3259775|NCT01473706||Caregivers of Consumers|Family, relative, friend, professional caregiver of an individual age ≥ 65 years; Lives with individual aged ≥ 65 years OR Visits individual aged ≥ 65 years five or more days a week; Makes decisions or has strong influence on the individual aged ≥ 65 years' diet and medical needs; English speaking
3259776|NCT01473719|Active Comparator|motivational intervention|7-session individual motivationally-based intervention
3259777|NCT01473719|Placebo Comparator|health education|7-session individual session focusing on health education
3259778|NCT01473771|Experimental|Caring Letter Condition (CL)|"In the Caring Letters (CL) group, participants will be emailed letters for two years on a planned schedule. The emailed letters are simple expressions of care and include standard contact information for available health care services."
3259779|NCT01473771|No Intervention|Usual Care (UC)|The participants in the Usual Care (UC) group will not receive the emails.
3259780|NCT01473784|Experimental|Transoral robotic surgery (TORS)|Patients will undergo TORS for oral and laryngopharyngeal benign and malignant lesions using the Da Vinci Robotic Surgical System. After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
3259781|NCT01473797|Experimental|cladribine|
3259782|NCT01473810|Experimental|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3259783|NCT01473810|Experimental|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3256076|NCT01440127|Experimental|Metformin|Subjects in this arm are randomized to receive metformin during the period of time between planning the surgery or biopsy and the actual procedure. After approximately 1 week of taking metformin, we will re-check the blood glucose. We will draw blood for cancer stem cells (about 2 teaspoons) and ask about symptoms. Subjects will stop taking metformin 2 days before the procedure.
3256077|NCT01440127|No Intervention|Observation|No metformin will be given prior to the scheduled surgery or biopsy.
3256078|NCT01440140|Experimental|Closed loop (algorithm)|
3256079|NCT01440140|Placebo Comparator|Open loop|
3256080|NCT01440153|Experimental|Active Intervention|
3256081|NCT01440153|Active Comparator|passive intervention|
3256082|NCT01440166|Experimental|Cohort 1 / Dose level 1|Single dose orally: CAT-1004 Dose level 1 or placebo
3256083|NCT01440166|Experimental|Cohort 2 / Dose level 2|Single dose orally: CAT-1004 Dose level 2 or placebo
3256084|NCT01440166|Experimental|Cohort 3 /Dose level 3|Single dose orally: CAT-1004 Dose level 3 or placebo
3256085|NCT01440166|Experimental|Cohort 4/ Dose level 4|Single dose orally: CAT-1004 Dose level 4 or placebo
3256086|NCT01440166|Experimental|Cohort 5/ Dose level 5|Single dose orally: CAT-1004 Dose level 5 or placebo
3256087|NCT01440166|Experimental|Cohort 2/ Dose level 2 ( FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo
3256088|NCT01440166|Experimental|Cohort 3/ Dose level 3 (FE)|Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo
3256089|NCT01440166|Experimental|Cohort 6 / Dose level 6 (FE)|Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.
3256090|NCT01440166|Experimental|Cohort 7 / Dose level 7 (FE)|Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.
3256091|NCT01440179|Experimental|SAR3419|Administered for one to two induction cycles, followed by maintenance cycles up to 6 cycles.
3256092|NCT01440192|Experimental|Cohort A: 1 Unit PDA001 (cenplacel-L)|
3256093|NCT01440192|Experimental|Cohort B: 1 Unit PDA001 (cenplacel-L)|1 unit PDA001(cenplacel-L)
3259784|NCT01473810|Experimental|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity
3259785|NCT01473810|Placebo Comparator|Zero dose|Adjuvant only, i.e. 300 µl Endocine divided into two administrations, one for each nose cavity
3259786|NCT01473823|Placebo Comparator|Placebo oil|Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
3259787|NCT01473823|Active Comparator|Omega-3 LCPUFA|"The omega-3 LCPUFA supplementation comprises of 5 ml daily of Möller's Tran flavored with lemon. This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA."
3259788|NCT01473888|Other|T89|
3259789|NCT01473901|Experimental|BKM120 + Temozolomide (Concomitant Phase)|Cranial radiation: Days 1 - 5 every 7 days for 42 days60 Gy in 30 fractions; Temozolomide: 75 mg/m2 Daily, orally; BKM120: 0, or 40, or 60, or 80 mg/d Daily, orally or Days 1-5 every 7 days, orally
3259790|NCT01473901|Experimental|BKM120 + temozolomide with/without radiotherapy|"Adjuvant phase cycle 1:~Temozolomide 150 mg/m2 - Days 1 - 5 every 28 days Daily; BKM120 60, or 80, or 100 mg/d;~Adjuvant phase cycle 2+:~Temozolomide 200* mg/m2 - Day 1 ~ 5 every 28 days Daily BKM120 0, or 40, or 60, or 80 or 100 mg/d"
3259791|NCT01473914|Experimental|Low dose|"Standard renal vitamin plus low dose zinc and selenium plus vitamin E~1 capsule p.o, daily"
3259792|NCT01473914|Experimental|Medium dose|"Standard renal vitamin plus medium doses of zinc and selenium plus vitamin E~1 capsule p.o, daily"
3259793|NCT01473914|Active Comparator|Standard treatment|"Standard renal vitamin~1 capsule p.o, daily"
3259794|NCT01473927||1|Crohn's Disease patients
3259795|NCT01473927||2|Ulcerative colitis patients
3259796|NCT01473966|No Intervention|standard of care|patients receive standard care
3259797|NCT01473966|Experimental|Coffee orally|patients will receive standard of care plus coffee orally
3259798|NCT01473966|Experimental|coffee rectally|patients receive standard of care plus coffee rectally
3259799|NCT01473979|Active Comparator|Arm A) Secondary closure with the vacuum-assisted system (VAC|"after the diagnosis of the poststernotomy wound infection is established the clinical procedure is obtained as follows: firstly the empiric antibiotic therapy with vancomycin is induced. The lab samples including bacteriology test are obtained. Surgical debridement is made until occurrence of tissue bleeding. Finally VAC sponge is implanted wit the negative suction pressure of 75 mmHg.~The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 48/72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done."
3259800|NCT01473979|Active Comparator|Arm B) Surgical procedure by delayed primary closure|In the first step, after the diagnosis of the infection was done, and the empiric antibiotic therapy is induced with vancomycin in the first surgical intervention the sternal wires will be removed, the mediastinum is explored and extensive surgical debridement is performed until occurrence of tissue bleeding.The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed.
3259801|NCT01474031||20 DAA subjects|20 DAA subjects: THA with a Deltamotion articulating surface utilizing the Direct Anterior Approach
3259802|NCT01474031||Control group|healthy volunteers
3259803|NCT01474044|Placebo Comparator|Placebo|
3259804|NCT01474044|Active Comparator|Gastropyloric Complex Capsules|
3259805|NCT01474057|Experimental|DESTRESS-PC|A brief, nurse-assisted, Internet-based online self-management tool for PTSD (DESTRESS-PC), based on empirically valid cognitive-behavioral therapy (CBT) strategies and designed for implementation in a primary care setting. DESTRESS-PC stands for DElivery of Self-TRaining and Education for Stressful Situations for Primary Care.
3259806|NCT01474057|Active Comparator|OUC|Optimized Usual Care (OUC) for PTSD--usual PTSD treatment offered within the primary care setting, optimized by training PC providers in PTSD identification and treatment and providing basic care management including phone check-ins to monitor symptoms and feedback to providers.
3259807|NCT01474083|Experimental|GK1-399, low dose|
3259808|NCT01474083|Experimental|GK1-399, high dose, once per day|
3256094|NCT01440205|Experimental|Easy list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly easy, and thus most participants will answer yes to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how healthy their habits are, it will seem natural to them to engage in yet another healthy habit and receive a flu shot."
3256095|NCT01440205|Experimental|Challenging list of healthy habits|"In this condition, participants will be prompted to think about a list of healthy behaviors and check off (privately - they will never send this flyer back or show it to anyone) whether yes they conform to the healthy habit or no they do not. The list of healthy behaviors is a list that most people will find fairly difficult, and thus most participants will answer no to each habit. The final question will be a prompt to get a flu shot. The hope is that when people realize how unhealthy their habits are, it will seem wise to engage in one healthy habit that is easy (to make up for other bad behaviors) and receive a flu shot."
3256096|NCT01440205|Experimental|Control|A control condition with no list of healthy behaviors.
3256097|NCT01440218||Patients with idiopathic diseases|Study population is limited to individuals with a rare severe illness, and/or their family members.
3256098|NCT01440231|Placebo Comparator|Arm 1|
3256099|NCT01440231|Experimental|Arm 2|
3256100|NCT01440231|Experimental|Arm 3|
3256101|NCT01440231|Experimental|Arm 4|
3256102|NCT01440231|Experimental|Arm 5|
3256103|NCT01440244|Other|Single group assignment|Cervical mediastinoscopy
3256104|NCT01440257|Placebo Comparator|Placebo (Group A)|
3256105|NCT01440257|Experimental|Active study medication (Group B)|CCX140-B
3256106|NCT01440270|Experimental|Neo-adjuvant Erbitux-based chemotherapy|Neo-adjuvant Erbitux-based chemotherapy before surgery: Erbitux, Docetaxel, Cisplatin.
3256107|NCT01440309|Experimental|allogenic mesenchymal stem cells (MSCs)|Patients who have primary biliary cirrhosis.
3256108|NCT01440309|Active Comparator|ursodeoxycholic acid (UDCA)|Patients who have primary biliary cirrhosis.
3256109|NCT01440348|Experimental|Achilles allograft|
3256110|NCT01440361|Experimental|Belimumab|Reconstituted solution for intravenous infusion
3256111|NCT01440361|Placebo Comparator|Normal saline|Solution for intravenous infusion
3256112|NCT01440400|No Intervention|Conventional spinal anesthesia|
3256113|NCT01440400|Experimental|Ultrasound guided spinal anesthesia|
3256114|NCT01440426|Active Comparator|Autologous connective tissue graft|Soft tissue harvested from patient palate
3256115|NCT01440426|Experimental|Collagen Matrix Construct|Mucograft collagen matrix manufactured by Geistlich AG, Switzerland
3256116|NCT01440439|Active Comparator|Insulin detemir|Metabolism during and after submaximal exercise during treatment with insulin detemir
3256117|NCT01440439|Active Comparator|Insulin glargine|Metabolism during and after submaximal exercise during treatment with insulin glargine
3256118|NCT01440478|Experimental|LY2140023 + ammonium chloride|1 g of ammonium chloride administered orally every 3 hours for 33 hours (totaling 12 doses) in combination with a single 80 mg dose of LY2140023 administered orally 17 hours after first dose of ammonium chloride (acidified urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3259809|NCT01474083|Experimental|GK1-399, high dose, twice per day|
3259810|NCT01474083|Placebo Comparator|Placebo|
3259811|NCT01474096|Experimental|implementation strategy|determining whether the use of implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding CPG in primary care is more effective than the usual practice of mere circulation.
3259812|NCT01474096|No Intervention|Conventional intervention|
3259813|NCT01474135|Experimental|0.25% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
3259814|NCT01474135|Experimental|0.5% AR-12286/ 0.004% travoprost|Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
3259815|NCT01474135|Active Comparator|0.004%Travoprost|Travatan(R) Z(travoprost ophthalmic solution)
3259816|NCT01474148|Experimental|Neuroprosthesis|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures.
3259817|NCT01474161|Placebo Comparator|Matching placebo|
3259818|NCT01474161|Active Comparator|GFT505 20mg - old formulation|Study Part I : dose level = 120mg
3259819|NCT01474161|Experimental|GFT505 60mg - new formulation|Study Part I : dose level = 120mg ; Study Part II : dose level = 180mg, 240mg and 300mg ; Study Part III : dose level = 120mg, 180mg and 240mg ; Study Part IV : dose level = 120mg or 180mg.
3259820|NCT01474174||Supportive care (vaccine therapy)|Patients receive trivalent influenza vaccine IM on day 0.
3259821|NCT01474187|Experimental|Irinotecan|irinotecan dose initial from 50mg/m2/week, increased by 15mg/mg/week
3259822|NCT01474226|Experimental|Lysine Amino Acid|
3259823|NCT01474252|Experimental|RSI technique|"Intubation with RSI technique. RSI technique includes the administration of inductive and neuromuscular blocking agents to facilitate an intubation.~In this study, we have no restriction of medication use. Physicians can chose any of medication as an individual judgement."
3259824|NCT01474252|No Intervention|Non-RSI|Intubation without RSI technique. No any medication use during intubation period.
3259825|NCT01474265|Placebo Comparator|varenicline placebo|
3259826|NCT01474265|Active Comparator|varenicline|
3259827|NCT01474265|Active Comparator|Nicorette TX|
3259828|NCT01474265|Active Comparator|Nicorette TX optional|
3259829|NCT01474265|No Intervention|control group smokers|
3259830|NCT01474278|Experimental|1|
3259831|NCT01474278|Placebo Comparator|2|
3259832|NCT01474304|Active Comparator|Acetaminophen|Craniotomy patients will receive a 1000 mg dose of intravenous (IV) acetaminophen before incision and a second 1000 mg dose of IV acetaminophen 6 hours later.
3374821|NCT05046392|Experimental|mHealth Facilitated Adherence Coaching|
3374822|NCT05046392|Active Comparator|Control|
3374823|NCT05045157|Experimental|percutaneous A1 pulley release with corticosteroid injection|
3374824|NCT05045157|Active Comparator|corticosteroid injection alone|
3374825|NCT05045079|Other|Severe tricuspid regurgitation due to atrial fibrillation|Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.
3374830|NCT05040373||Patisiran|Pregnant women exposed to commercial patisiran-LNP (ONPATTRO) during the 12 weeks prior to their last menstrual period (LMP) or at any time during pregnancy.
3374831|NCT05039073|Experimental|Treatment (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response or partial response at any time after 4 cycles may discontinue study therapy to proceed to autologous or allogeneic stem cell transplant.
3374835|NCT05030974|Active Comparator|stratum A1 - 3rd dose of mRNA-1273|Patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
3374836|NCT05030974|Active Comparator|stratum A2 - 3rd dose of mRNA-1273 with discontinuation of MMF/MPA|patients treated with triple immunosuppressive therapy consisting of a calcineurin inhibitor, MMF/MPA, and steroids, receiving a 3rd dose of mRNA-1273 (100 μg, i.m), with temporary discontinuation of MMF/MPA during one week before and one week after the 3rd dose
3256119|NCT01440478|Experimental|LY2140023 + sodium bicarbonate|4 g of sodium bicarbonate administered orally every 4 hours for 32 hours (totaling 9 doses) in combination with a single 80 mg dose of LY2140023 administered orally 18 hours after first dose of sodium bicarbonate (alkalized urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3256120|NCT01440478|Experimental|LY2140023|A single 80 mg dose of LY2140023 administered orally (normal urine). All participants will receive the three treatments in a randomized order. There will be a minimum of a 5 day wash out period between treatment periods.
3256121|NCT01440491|Other|physiotherapy orientated|"G1 patients were orientated by the physiotherapist during the performance of physiotherapy exercises, using the booklet~G2 received the booklet to self perform the physiotherapy exercises"
3374837|NCT05030974|Active Comparator|stratum B1 - 3rd dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m)
3374838|NCT05030974|Active Comparator|statum B2 - 3rd double dose of mRNA-1273|patients treated with any combination of immunosuppressive drugs, receiving a 3rd dose of mRNA-1273 (100 μg, i.m) in both upper arms
3374839|NCT05030974|Active Comparator|stratum B3 - Ad26.COV2.S vaccine|patients treated with any combination of immunosuppressive drugs, receiving a 3rd COVID vaccination with Ad26.COV2.S vaccine (Janssen, 5x1010 viral particles i.m.)
3374840|NCT05028829|Experimental|Group A: Atorvastatin 20 mg|Atorvastatin 20mg will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
3374841|NCT05028829|Placebo Comparator|Group B: Placebo to Match (PTM)|PTM will be administered daily via oral route for 48 consecutive weeks on an outpatient basis.
3374849|NCT05026528|Experimental|Digital DSME/S|Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.
3374850|NCT05026528|No Intervention|Standard care|Control group continuing with regular standardized care.
3374853|NCT05023681|Experimental|r-SAK treatment group|intravenous injection of single bolus 5 mg r-SAK in 3min
3374854|NCT05023681|Placebo Comparator|saline control group|intravenous injection of 10ml saline in 3min,r-SAK and saline are the same in appearance
3374855|NCT05022563||Parenteral anticoagulant only|LMWH, UFH
3374856|NCT05022563||Warfarin-based|Warfarin only + parenteral anticoagulant bridged warfarin
3374857|NCT05022563||Parenteral anticoagulant / NOAC|NOAC: apixaban, rivaroxban, dabigatran, edoxaban
3374858|NCT05022563||NOAC only|NOAC: apixaban, rivaroxban, dabigatran, edoxaban
3374861|NCT05020327|Experimental|Low Risk Patients|This is the group of patients who will undergo the graded oral amoxicillin challenge testing. Total dose of the amoxicillin will be 45 mg/kg (maximum of 1000 mg). 10 % of this dose will be given first followed by 90 % of the dose 30 minutes after. Each dose will be given only once.
3374862|NCT05020327|Other|No Risk Patients|Patients in the group will be de-labeled in the electronic medical record for No Risk for allergic reaction to amoxicillin based on screening questionnaire.
3256122|NCT01440530|Experimental|Educational Intervention|
3256123|NCT01440530|Active Comparator|Control Group (usual care)|
3256124|NCT01440582|Experimental|Panobinostat + Bortezomib + Lenalidomide + Dexamethasone|"Induction Starting Doses: Lenalidomide 25 mg orally daily on days 1-14; Bortezomib 1.3 mg/m^2 intravenous (IV) daily on days 1, 4, 8 and 11; Dexamethasone 20 mg orally daily on days 1, 2, 4, 5, 8, 9, 11, 12 and Panobinostat orally 10 mg on days 1, 3, 5, 8, 10 and 12. Induction therapy consists of 21 day cycle in Part A and 28 day cycle in Part B.~Symptom Questionnaire completed on day 1 of each cycle."
3256125|NCT01440608|Experimental|Zinc therapy|High-dose zinc, equivalent 20 mg elemental zinc, to be given once per day for 14 days
3256126|NCT01440608|Experimental|Albendazole|Albendazole to be given once on the day of enrollment. Placebo will then be given for 13 days following.
3374863|NCT05020327|Other|High Risk|Patients in this group are deemed high risk for allergic reaction to penicillin based on screening questionnaire and will remain labeled with allergy in the electronic medical record. They will be referred as outpatient to allergy-immunology for further evaluation.
3256127|NCT01440608|Placebo Comparator|Placebo|Placebo will be given for 14 days
3256128|NCT01440621|Active Comparator|Arm M|Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.
3256129|NCT01440621|Placebo Comparator|Arm P|Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.
3256130|NCT01440660||Leaking Phenotype|Retinal thickness (RT) increase (increase in RT above normal range as measured by OCT, considering the macular thickness normative data) in the central subfield, the inner ring and/or the outer ring.
3256131|NCT01440660||Ischemic Phenotype|Neovascular disease activity as shown by microaneurysms (MA) turnover (MA formation rate >= 2, i.e. number of new MA per year) computed from CFP using the RetmarkerDR software.
3256132|NCT01440673|Active Comparator|aprepitant 125mg|NK1 receptor antagonist
3256133|NCT01440673|Active Comparator|Aprepitant 80 mg|
3256134|NCT01440686|Experimental|HL-032 30mg|A single dose 30mg administered orally
3256135|NCT01440686|Experimental|HL-032 60mg|A single dose 60mg administered orally
3256136|NCT01440686|Experimental|HL-032 120mg|A single dose 120mg administered orally
3256137|NCT01440699|Experimental|Treatment|For ALLO-ASC 1xE7 cells/ml,3 patients are to be enrolled. If there is no safety issue, 3 more patients will be enrolled to be treated with ALLO-ASC 3xE7 cells/ml.
3374884|NCT05004584|Experimental|Wheat home-based|
3374885|NCT05004584|Experimental|Rye home-based|
3374886|NCT05004584|Experimental|Rye clinic-based|
3374887|NCT05004584|Experimental|Wheat clinic-based|
3374888|NCT05004584|Experimental|Wheat/Rye clinic-based with blood sampling|
3256138|NCT01440712|Experimental|Gastrografin|Patients located in this group will be treated with the administration of 100 ml of gastrografin by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
3256139|NCT01440712|Placebo Comparator|physiological serum|Patients included in this group will be treated with 100 ml of physiological serum 0,9% by the nasogastric tube, only once, after the diagnosis of postoperative ileus.
3256140|NCT01440725|Experimental|PRP|Administration of 4-8cc of autologous Platelet-rich plasma (PRP)into the muscle wound after the evacuation of the haematoma.
3374910|NCT04998617|Experimental|Toothpaste Containing Curcumin|After screening, participants will be randomly assigned to receive toothpaste that contains 0.5% curcumin.
3374911|NCT04998617|Placebo Comparator|Toothpaste Without Curcumin|After screening, participants will be randomly assigned to receive toothpaste that does not contain curcumin.
3374912|NCT04994509|Experimental|Blinded Phase: LEN + Placebo-to-match (PTM) F/TAF|"Participants will receive the following for at least 52 weeks:~Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Alafenamide (F/TAF) once daily~Oral LEN 600 mg on Days 1 and 2"
3374913|NCT04994509|Experimental|Blinded Phase: LEN + PTM F/TDF|"Participants will receive the following for at least 52 weeks:~SC LEN 927 mg every 26 weeks~Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily~Oral LEN 600 mg on Days 1 and 2"
3256141|NCT01440725|Active Comparator|Evacuation of haematoma|Evacuation of the hematoma, and simulation of the administration of PRP
3256142|NCT01440738|Experimental|health workshops|Health promotion group intervention
3374914|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TAF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TAF 200/25 mg once daily~Oral PTM LEN on Days 1 and 2"
3374915|NCT04994509|Experimental|Blinded Phase: Placebo LEN + F/TDF|"Participants will receive the following for at least 52 weeks:~SC placebo LEN every 26 weeks~Oral F/TDF 200/300 mg once daily~Oral PTM LEN on Days 1 and 2"
3374916|NCT04994509|Experimental|LEN Open-Label Extension (OLE) Phase|"After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.~Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.~Participants randomized to F/TAF or F/TDF will receive SC LEN 927 mg on OLE Day 1 and OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2."
3374917|NCT04994509|Experimental|Pharmacokinetic (PK) Tail Coverage Phase|"At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.~Additionally, participants that either prematurely discontinue the study drug during the blinded phase or choose not to continue in the LEN OLE phase (if randomized to LEN in the blinded phase) or who discontinue the study drug in the LEN OLE phase are also eligible to transition to the PK Tail Coverage phase.~Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last LEN injection."
3256143|NCT01440738|No Intervention|comparison group|usual care
3256144|NCT01440751|Experimental|ologen Collagen Matrix|When performing glaucoma surgery, a trabeculectomy, use ologen Collagen Matrix instead of MMC before closing the conjunctiva
3374918|NCT04993976|Experimental|Prehabilitation group|Strength training along with warm-up and cool down for 8 weeks
3374919|NCT04993976|Active Comparator|Control group|Supervised Standard care plan for 8 weeks
3256145|NCT01440751|Active Comparator|Mitomycin-C (MMC)|When performing glaucoma surgery, a trabeculectomy, use MMC as antifibrotic agent before closing the conjunctiva
3256146|NCT01440777|Active Comparator|Go! to Sleep|Participants access and utilize the 6-week online program that provides a set of various psycho-educational materials and behavioral techniques to treat insomnia.
3374927|NCT04988152|Experimental|Part 1 Sotrovimab intravenous infusion, single dose|
3256147|NCT01440777|No Intervention|Control Group|No intervention provided. These participants will receive the Go! to Sleep program after the research trial has been completed (10 weeks after registration).
3256148|NCT01440790|Placebo Comparator|Glucose bolus alone|50g glucose dissolved in water and consumed within 5 minutes.
3256149|NCT01440790|Experimental|Glucose sipping alone|50g glucose dissolved in water and consumed gradually over 3 hours.
3256150|NCT01440790|Active Comparator|Glucose bolus plus 1g vitamin C|50g glucose dissolved in water and consumed in 5 minutes with 1g vitamin C
3256151|NCT01440790|Experimental|Glucose sipping plus 1g vitamin C|50g glucose dissolved in water and consumed gradually of 3 hours. In addition 1g vitamin C will be taken with the first mouthful of glucose solution.
3256152|NCT01440829|Experimental|LOLA group|Intervention: LOLA (30g per day) for a week.
3256153|NCT01440829|No Intervention|Control group|Patients will not be treated with LOLA.
3256154|NCT01440842|Experimental|Closed-loop (Model Predictive Control Algorithm)|
3256155|NCT01440842|Active Comparator|Open loop (Standard treatment)|
3256156|NCT01440855|Active Comparator|CIS Fact Sheet (CIS: Cancer Information Service)|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
3256157|NCT01440855|Experimental|Facing Forward booklet|NCI's Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
3256158|NCT01440868|Experimental|SLI group|In this group the preterm infants will receive sustained lung inflation (SLI) with mask in the delivery room
3256159|NCT01440868|No Intervention|Control|Preterm infants will be assisted in the delivery room without sustained lung inflation.
3256160|NCT01440894||Body Analysis|
3256161|NCT01440907|Experimental|Intervention Group|Those age 65 or older who are discharged from Maimonides Medical Center to home during the study period and enrolled in the Care Coordination Program
3256162|NCT01440907|No Intervention|Control Group|Those age 65 or older who are discharged from Maimonides Medical Center to home
3256163|NCT01440933|Active Comparator|Magnesiumsulphate|
3256164|NCT01440933|Placebo Comparator|Physiologic saline|
3256165|NCT01440985|Experimental|Nicotine Gum|After being randomized to the gum or tablet, dosage will be based on baseline level of nicotine dependence. Highly dependent smokers will receive nicotine 4 mg gum, while low nicotine-dependent smokers will receive nicotine 2 mg gum to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
3259833|NCT01474304|No Intervention|No acetaminophen|Patients will receive standard of care with no intraoperative doses of acetaminophen.
3259834|NCT01474330|Experimental|0.5-mg Pomalidomide or placebo (Cohort A)|A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions
3259835|NCT01474330|Experimental|1-mg Pomalidomide or placebo (Cohort B)|This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
3259836|NCT01474330|Experimental|2-mg Pomalidomide or placebo (Cohort C)|This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.
3259837|NCT01474343|Experimental|SAF-301|
3259838|NCT01474356|No Intervention|BT (brachytherapy)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy only was performed.
3259839|NCT01474356|Experimental|BTHT (brachytherapy and hyperthermia)|Cervical cancer patients after the treatment with external beam radiotherapy combined with chemotherapy. In this group of patients, interstitial brachytherapy with interstitial hyperthermia was performed.
3259840|NCT01474369|Experimental|TAK-438 10 mg QD|
3259841|NCT01474369|Experimental|TAK-438 20 mg QD|
3259842|NCT01474369|Placebo Comparator|Placebo QD|
3259843|NCT01474382|Experimental|OraVerse|OraVerse in doses of either 1/4, 1/2 or 1 cartridge (1.8mL)
3259844|NCT01474382|Sham Comparator|Sham injection|Dentist simulates injection with dental syringe
3259845|NCT01474395|Experimental|D-serine 60 mg/kg|double blind dose of d-serine
3259846|NCT01474395|Placebo Comparator|Placebo D-serine|
3259847|NCT01474408|Experimental|interval training|4 x 4 minutes exercise at 90 - 95 % of peak heart rate separated with 3 minutes at 70 % of peaks heart rate
3259848|NCT01474408|Active Comparator|moderate exercise|moderate continuous exercise at 70 % of peak heart rate on venous function.
3259849|NCT01474408|Other|control|routine measurements, no exercise
3259850|NCT01474421|Experimental|AQW051 High Dose|AQW051 high dose daily given orally for 28 days.
3259851|NCT01474421|Experimental|AQW051 Low Dose|AQW051 low dose daily given orally for 28 days.
3259852|NCT01474421|Placebo Comparator|Placebo|Placebo daily given orally for 28 days.
3259853|NCT01474447|Experimental|Grinberg Method|
3259854|NCT01474460|Placebo Comparator|Control group|The control group only receiving warfarin therapy (individualized therapy, hence no specific form, dosage, frequency and duration is applicable here - i.e. 5mg daily everyday for 6 months may be applicable to one patient but not all researched patients).
3259855|NCT01474460|Experimental|Phytonadione|Patients receiving 200mcg of phytonadione.
3259856|NCT01474473|Experimental|CACIPLIQ20 and Cast Boot|This arm receives treatment by CACIPLIQ20 application every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
3259857|NCT01474473|Placebo Comparator|Placebo and Cast Boot|This arm receives a placebo (saline solution) every 3 to 4 days and the wounded leg is held with a nonremovable, windowed, fiberglass Cast Boot.
3259858|NCT01474499|Experimental|Docusate sodium and sorbitol rectal solution|
3259859|NCT01474499|Active Comparator|Glycerine|
3259860|NCT01474525|Experimental|Telemonitoring|
3259861|NCT01474525|Active Comparator|Usual Care|
3256166|NCT01440985|Active Comparator|Nicotine Microtab|After being randomized to the gum or tablet, subjects will receive instructions according to their baseline level of nicotine dependence. Highly dependent smokers will be instructed to use a 4 mg dosage of the Microtab (2 x 2 mg tablets), while low nicotine-dependent smokers will be instructed to use a 2 mg dosage of the Microtab to help them quit. Subjects will be advised to use the treatment frequently, according to the product labeling, in order to minimize or avoid symptoms of tobacco withdrawal. Study medication will be used for 12 weeks.
3374928|NCT04988152|Placebo Comparator|Part 1 Volume-matched placebo, intravenous infusion|
3374929|NCT04988152|Experimental|Part 2 Sotrovimab intramuscular injection, single dose|
3374930|NCT04988152|Placebo Comparator|Part 2 Volume-matched placebo, intramuscular injection|
3374931|NCT04983888|Experimental|Primary Focal Segmental Glomerulosclerosis (FSGS)|Subjects with immunosuppression-dependent or immunosuppression/treatment-resistant primary FSGS or contraindication/patient refusal to take high dose corticosteroids, will receive obinutuzumab 1 gram on day 1 and 1 gram on day 15, given intravenously and then an identical course at 6 months.
3256167|NCT01440998|Experimental|Treatment (dasatinib, paclitaxel, carboplatin)|Patients receive induction therapy comprising dasatinib PO QD for 14 days. *Beginning 7 days later, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1, and dasatinib PO QD on days 1-21. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3374932|NCT04983498|Experimental|Prospective Experimental Group|For the experimental group, we will recruit 200 participants who will receive the Enhanced Recovery Pathway, which will be ordered as a standing order set by the attending provider and managed by their peri-procedural nurses. The modified ERP for this study includes the following interventions: nursing managed order sets with ERP instructions to receive goal-directed fluid management within anesthesia approved parameters utilizing the NMH Colorectal ERAS protocol for IV fluid administration, PONV prophylaxis for participants with an apfel score of 2 or greater (ondansetron 4 mg IV), an additional dose of ondansetron 4mg IV will be available in recovery if the patient has nausea/vomiting despite prophylaxis, early mobilization up to chair (within 5-30 minutes of admission to the recovery room) based on nursing parameters, and early PO intake within 15-30 minutes of admission to the recovery room post-procedure based on nursing parameters.
3374933|NCT04983498|No Intervention|Retrospective Control Group|The retrospective group will consist of 200 randomly selected medical records of patients who had colonoscopy procedures for a 6 month period prior to study implementation (between 10/1/2019 to 4/1/2020). The retrospective control group will have received the current standard of care including: IV fluids for management of intra-procedural hypotension as indicated/ordered by the physician, PO intake at 30-45 minutes, up to a chair at 60 minutes, and all procedure related complications will have been treated (e.g. PONV) per physician order as is the current standard of practice in the GI Lab recovery area.
3256168|NCT01441011|Experimental|Group (GRP) phone counseling|The group phone counseling includes 26 bi-weekly phone sessions from 6 to 18 months and focuses on group problem-solving. Women continue in the same group as in weight loss intervention phase.
3256169|NCT01441011|Active Comparator|Mail-based Comparison Condition|Participants in this group will receive a newsletter by mail every other week for 12 months starting after the initial 6 month weight loss period. The newsletters will provide problem-solving tips and will review nutrition and physical activity information.
3256170|NCT01441024|Experimental|1|DAS181
3256171|NCT01441024|Placebo Comparator|2|Placebo
3256173|NCT01441128|Experimental|Arm 1|The starting doses will be 200 mg by mouth, twice a day of PF 02341066 in tablet form and 30 mg by mouth once a day of PF 0029804 in tablet form. Thedose of each drug in the combination will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
3256174|NCT01441128|Experimental|Arm 2|45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
3256175|NCT01441141||Arm 1|Subjects with SCD
3256176|NCT01441141||Arm 2|Subjects without SCD
3256177|NCT01441154||Group 1|Adults with clinical indication for withdrawal from thyroid hormone replacement therapy in preparation for nuclear medicine imaging or therapeutic procedures with radioactive iodine
3256178|NCT01441193|Experimental|HIV-1 Tat/delta-V2 Env combined vaccine|Tat 7.5 microg and delta-V2 Env 100 microg associated proteins administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at weeks 24 and 36
3256179|NCT01441193|Active Comparator|HIV-1 delta-V2 Env vaccine|delta-V2 Env 100 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
3256180|NCT01441193|Active Comparator|HIV-1 Tat vaccine 7.5 microg|Tat 7.5 microg administered i.d. (priming) at week 0, 4 and 8 or i.m. (boosting) at week 24 and 36
3256181|NCT01441193|Active Comparator|HIV-1 Tat vaccine 30 microg|Tat 30 microg administered i.d. at week 0, 4 and 8
3256182|NCT01441206|Other|rifampin|Cohort 1 will include infants who will be receiving up to 4 doses rifampin per study protocol.
3256183|NCT01441206|No Intervention|rifampin per standard of care|Cohort 2: Receiving rifampin per standard of care
3256184|NCT01441219|Experimental|Colon 2|using Colon 2 capsule in detecting bleeding events in small bowel
3256185|NCT01441232|Experimental|Treatment A|
3256186|NCT01441232|Experimental|Treatment C|
3256187|NCT01441232|Active Comparator|Treatment B|
3256188|NCT01441258|Experimental|Dialectical Behavior Therapy Skills (DBT-S) Groups|Patients in the Dialectical Behavior Therapy Skills (DBT-S) group will receive the newly adapted 18-week group-skills training protocol, one-and-a-half hours in length, with weekly homework assignments to facilitate skill generalization.
3256189|NCT01441258|Placebo Comparator|Wait List-Treatment as Usual|Participants assigned to the wait-list condition will be given the opportunity to participate in a DBT skills group after their 18-week wait period has ended.
3256190|NCT01441271|Active Comparator|total abdominal colectomy|the standard of care for fulminant clostridium difficile colitis is a total abdominal colectomy
3256191|NCT01441271|Experimental|Ileal diversion and lavage|The tested intervention in this trial will be: intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution, that will clear Clostridium difficile infection resulting in eradication of FCDC while preserving the colon.
3256192|NCT01441284|Active Comparator|Process 1|10 weeks of pramipexole treatment 2 weeks wash-out period (cross-over) 10 weeks placebo treatment
3256193|NCT01441284|Placebo Comparator|Process 2|10 weeks of placebo treatment 2 weeks wash-out period (cross-over) 10 weeks pramipexole treatment
3256194|NCT01441297|Experimental|study arm|BIBF 1120 study arm
3256195|NCT01441310|Experimental|Laparoscopic sentinel node navigation surgery|Laparoscopic sentinel node navigation surgery
3256196|NCT01441323|No Intervention|Control (C)|
3256197|NCT01441323|Experimental|Nutrition (N)|
3256198|NCT01441323|Experimental|Strength Training & Nutrition (ST)|
3256199|NCT01441336|Experimental|Laparoscopic gastrectomy|"Laparoscopic gastrectomy procedure:~D2 lymphadenectomy & total omentectomy in case of tumor with serosa exposure under laparoscopic exploration"
3374935|NCT04982393||Patients with PH1|Patients with a diagnosis of PH1 will be eligible for the study and will be managed and treated per routine clinical practice.
3374936|NCT04981795||Adults (> or = 18 years of age)|Adults (> or = 18 years of age) diagnosed with relapsed or refractory DLBCL and initiating second- or third-line therapy meeting inclusion criteria.
3374937|NCT04978506|Experimental|BI 1569912 MRD: treatment group 1|Multiple rising dose (MRD) part
3374938|NCT04978506|Experimental|BI 1569912 POSO treatment group|Posology part (optional)
3256200|NCT01441349|Active Comparator|Control arm|IP chemotherapy arm
3256201|NCT01441349|Experimental|Treatment arm|IP chemotherapy plus simvastatin arm
3256202|NCT01441362|Active Comparator|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
3256203|NCT01441362|Experimental|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
3374939|NCT04978506|Placebo Comparator|Placebo|
3374940|NCT04978506|Experimental|BI 1569912 MRD: treatment group 2|Multiple rising dose (MRD) part
3374941|NCT04978506|Experimental|BI 1569912 MRD: treatment group 3|Multiple rising dose (MRD) part
3374942|NCT04978506|Experimental|BI 1569912 MRD: treatment group 4|Multiple rising dose (MRD) part
3256204|NCT01441375||Sickle cell patients non-transfused|
3256205|NCT01441375||Sickle cell patients transfused with no ICT|
3374953|NCT04969471|Experimental|Thrombectomy Arm|enVast stent deployed at occlusion site as first measure to obtain reperfusion and withdraw the clot
3374954|NCT04969471|Experimental|Conventional Treatment Arm|Treatment strategies may include balloon angioplasty, manual aspiration thrombectomy and/or coronary stenting.
3256206|NCT01441375||Sickle cell patients transfused with ICT|
3256207|NCT01441388|Experimental|Dose Escalation|Histological or cytological diagnosis of advanced/metastatic solid tumor that is resistant to standard therapy or for which no standard therapy is available.
3256208|NCT01441388|Experimental|Expansion Population 1|Patients with histologically confirmed metastatic renal cell cancer with no prior systemic therapy directed at the malignant tumor.
3256209|NCT01441388|Experimental|Expansion Population 2|Patients with histologically confirmed metastatic renal cell cancer whose prior systemic therapy directed at the malignant tumor was single agent VEGF inhibitor and who now have acquired resistance to this treatment.
3256210|NCT01441388|Experimental|Expansion Population 3|Patients with histologically confirmed glioblastoma whose disease has failed on previous therapy, and which must have included treatment with external beam radiation and temozolomide chemotherapy, and who now have radiographically recurrent or progressive disease.
3256211|NCT01441388|Experimental|Expansion Population 4|Patients with histologically confirmed advanced-stage (unresectable or metastatic) hepatocellular carcinoma who have not received previous systemic therapy directed at the malignant tumor will be eligible to receive crizotinib plus sorafenib, should this combination be tested.
3256212|NCT01441427|Experimental|G-CSF|
3256213|NCT01441427|Experimental|EPO|
3256214|NCT01441427|Experimental|G-CSF and EPO|
3256215|NCT01441427|Placebo Comparator|Placebo|
3256216|NCT01441453|Other|Preoperative FibroScan|
3256217|NCT01441518|Experimental|Home care|
3256218|NCT01441518|Active Comparator|Hospital care|
3256219|NCT01441531|Experimental|Gabapentin|Gabapentin 600 mg po given 1 hour before surgery
3256220|NCT01441531|Placebo Comparator|Placebo sugar pill|
3256221|NCT01441544|Experimental|VAREITY|
3374955|NCT04963439|Experimental|Treatment Sequence AB|Participants will receive single oral dose of macitentan formulated as final market image (FMI) in fasted conditions (test) (Treatment A) in treatment period 1 followed by a single oral dose of macitentan as the clinical service formulation (CSF) in fasted conditions (reference) (Treatment B) in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
3374956|NCT04963439|Experimental|Treatment Sequence BA|Participants will receive Treatment B in treatment period 1 followed by Treatment A in treatment period 2 on Day 1. Study intervention intake in subsequent intervention periods in an individual participant will be separated by a washout period of at least 10 days.
3374965|NCT04957758|Active Comparator|OC-01 (varenicline) nasal spray, 1.2 mg/mL|OC-01 (varenicline) nasal spray, 1.2 mg/mL
3374966|NCT04957758|Placebo Comparator|Placebo (vehicle control) nasal spray|Placebo (vehicle control) nasal spray
3256222|NCT01441544|Experimental|NON-VARIETY|
3256223|NCT01441583|Active Comparator|RYTHMIQ Off at Pre-discharge, On at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ Off at Pre-Discharge will have RYTHMIQ programmed Off until their 1-month follow up, when they will be crossed over to RYTHMIQ On until their 3-month follow up.
3374967|NCT04955990|Experimental|Participants with PAH|Participants with pulmonary arterial hypertension (PAH) who newly initiate any PAH therapy(ies) at the index date (date when a participant starts the first new PAH therapy after baseline assessments) in a real-world clinical setting, either as first-line therapy, as replacement therapies, or or concomitant with other PAH therapies. The primary data source for this study will be the medical records of each participant.
3374968|NCT04955730|Experimental|NPWT - Negative Pressure Wound Therapy|Participants will receive Negative Pressure Wound Therapy (NPWT) after surgery and wear the NPWT until postop day 3. NPWT dressing will be removed and a new NPWT will be replaced until Postop day 7, where NPWT dressing will be removed.
3374969|NCT04955730|No Intervention|Standard of Care Wound Therapy|Participants will receive standard of care wound therapy after surgery. Postop day 3, dressings will be removed and new sterile dressings will be applied if needed.
3374972|NCT04949828||Participants on CREON|
3374975|NCT04948606||Diroximel Fumarate (DRF)|Participants with a confirmed diagnosis of MS who are newly prescribed DRF in routine clinical practice and who satisfy the approved therapeutic indication for DRF will be enrolled.
3374976|NCT04943614|Experimental|BIODEX training group|These individuals will receive conventional along with postural stability training with biodex balance system which stimulates specific movement patterns or strategies by placing markers on a specific location on-screen grid subject attempted to touch targets nine times using an onscreen cursor manoeuvred by the subject leg on the device platform
3374977|NCT04943614|Active Comparator|Conventional therapy group|These individuals will perform balance exercises including proprioception exercises, balance board exercises, walking on different surfaces, Wobble board exercise and parallel bars for ambulatory training, range of motion exercises, foot care as a home program (advices).
3374978|NCT04943601|Experimental|Action observation training group|The experimental group will receive a training program with Action observation by watching videos of complex tasks while imitating them. All the movements will be performed bilaterally so that regardless of the affected side the patient had the correct perspective to perform the exercise.
3374979|NCT04943601|Active Comparator|Conventional therapy group|The control group will receive conventional rehabilitation, with exercises of bimanual activities that will target their shoulder, elbow, wrist and finger joints similar to the experimental group but without Action observation
3374980|NCT04943367|Active Comparator|GROUP TEAS|Patients will receive TEAS bilaterally at two acupoints: Hegu (L14) and Neiguan (PC6).
3374981|NCT04943367|Placebo Comparator|Control Sham Group|Patients in the sham group will be undergoing electrode attachment on the target acupoints without electronic stimulation.
3374982|NCT04939090|Experimental|Arm I (olanzapine)|Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
3374983|NCT04939090|Active Comparator|Arm II (megestrol acetate)|Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
3256224|NCT01441583|Active Comparator|RYTHMIQ On at Pre-Discharge, Off at 1-Month|For the RYTHMIQ endpoint only, subjects implanted with a pacemaker will be randomized. Those randomized to RYTHMIQ On at Pre-Discharge will have RYTHMIQ programmed On until their 1-month follow up, when they will be crossed over to RYTHMIQ Off until their 3-month follow up.
3256225|NCT01441609||the value of anti-HBs =0 mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs be zero.
3256226|NCT01441609||the value of anti-HBs≤5mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≤5mIU/ml.
3256227|NCT01441609||5mIU≤anti-HBs≤10mIU/ml|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of 5mIU≤anti-HBs≤10mIU
3256228|NCT01441609||anti-HBs≥1000mIU|Recent serological testing result show HBsAg, HBeAg, anti-HBe, anti-HBc, HBV DNA and Pre-S1 should be negative. had vaccinated hepatitis B vaccine and the value of anti-HBs≥1000mIU.
3374992|NCT04932785|Active Comparator|Regular Diet|Patient randomized to regular diet will begin with a regular diet.
3374993|NCT04932785|Active Comparator|Clear Liquid Diet|Patient randomized to clear liquid diet will begin with a clear liquid diet.
3374996|NCT04927572|Experimental|FMX114|
3374997|NCT04927572|Placebo Comparator|Vehicle|
3256229|NCT01441622|Experimental|AL539|Device AL539
3256230|NCT01441648||experimental group|(1) age 20-35 years old (2) myopia less than -6.00D and astigmatism less than -1.50D (3) previous soft contact lens wear discontinued for at least 2 weeks. Exclusion criteria includes: (1) subjects with previous Rigid Gas Permeable (RGP) wear (2) any ocular inflammation or infection, dry eye syndrome, glaucoma, ocular trauma or surgery, and topical medication instillation (3) diabetic mellitus (4) pregnancy (5) any corneal disorders or dystrophies.
3256231|NCT01441661||Sunitinib Renal Cell Carcinoma|Patients diagnosed with Renal Cell Carcinoma (RCC) and treated with Sunitinib from 2008 to present will be eligible. This will include current active patients as well as patients who have expired and have medical records available.
3256232|NCT01441674|Experimental|Animal Assisted Therapy Visit 1|Standard OT Therapy with Animal Assisted Therapy at Visit 1 and Not at Visit 2
3256233|NCT01441674|Experimental|Animal Assisted Therapy at Visit 2|Standard OT Therapy with Animal Assisted Therapy at Visit 2 and not Visit 1
3256234|NCT01441687|Experimental|Arm I (PMU)|Patients receive digital rectal palpation and then void a spontaneous urine sample for PMU analysis. Patients then undergo a prostate biopsy.
3256235|NCT01441687|Experimental|Arm II (EPS)|Patients receive DRE with prostatic massage for 30-60 seconds and are then milked at the urethra to provide a collection of EPS. Patients then undergo a prostate biopsy.
3256236|NCT01441700|Active Comparator|Prone position|
3256237|NCT01441700|Active Comparator|Supine position|
3256238|NCT01441713||Pharmaceutical group|Patients in pharmaceutical castration treatment for advanced prostate cancer
3256239|NCT01441713||Surgical group|Patients having undergone surgical castration treatment for advanced prostate cancer
3256240|NCT01441726||Training of staff|
3256241|NCT01441726||No training of staff|
3256242|NCT01441739||NEC suspected - Final diagnosis NEC|
3256243|NCT01441739||NEC suspected - Final diagnosis no NEC|
3256244|NCT01441739||Controls|
3256245|NCT01441752|Experimental|Chemotherapy + TCM group|"The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.~Prescriptions formulated into granules origin from Professor Liu Jiaxiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe . Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number."
3256246|NCT01441752|Placebo Comparator|Chemotherapy + placebo group|The chemotherapy for NSCLC patients is a combination of Vinorelbine, 25mg/m2, d1, 8 and DDP, 75mg/m2, d1 (NP) giving three-weekly for four cycles.we compromise the raw materials for the placebo including 10% of Chinese medicine, food color and artificial flavors. The placebo and therapeutic packages were stored in different cabinets, and only the dispensing technician knew the contents of the packages.
3256247|NCT01441778|Active Comparator|NSS irrigation salt|
3256248|NCT01441778|Experimental|BHS nasal irrigaiton salt|
3256249|NCT01441791|Experimental|Lung protective strategy ventilation|Lung protective strategy ventilation: PEEP at 12 cmH2O, Recruitment maneuvers (after intubation, after any disconnection from the mechanical ventilator, directly before detubation)
3375009|NCT04920058|Experimental|Wellness Program combined with Continuous Glucose Monitoring (CGM)|Continuous Glucose Monitoring (CGM) sensor combined with Levels CGM software that provides real-time visualization, analysis and feedback will be added to a Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
3375010|NCT04920058|Active Comparator|Wellness Program|Wellness Program incorporating a low carbohydrate diet (<50 g carbohydrate). Subjects in the group will be manually randomized and listed in a sealed envelope by someone who is not part of the study team
3375011|NCT04919811|Experimental|Taletrectinib|Single-arm trial whereby all consented, enrolled, eligible patients receive taletrectinib
3256250|NCT01441791|No Intervention|Conventional Strategy|"PEEP at maximum 2 cmH2O, if possible 0 cmH2O~No recruitment maneuvers Patients are randomized and intra-operatively ventilated with conventional strategy (PEEP at maximum 2 cmH2O without recruitment maneuvers)."
3256251|NCT01441804|Experimental|24-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 20 weeks
3375016|NCT04909515|Experimental|naxitamab + GM-CSF + isotretinoin|8 cycles. Cycles 1+2 naxitamab + GM-CSF, cycles 3-5 naxitamab + GM-CSF + isotretinoin, cycles 6-8 isotretinoin
3256252|NCT01441804|Active Comparator|48-Week treatment group|Genotype 1 chronic hepatitis C patients with IL28B CC Polymorphism and rapid virological response(undetectable HCV RNA at weeks 4) in this group will be treated with Peginterferon alfa-2a plus ribavirin for an additional 44 weeks
3256253|NCT01441817|Other|Surgery|
3375017|NCT04905810|Experimental|Treatment (azacitidine, decitabine, venetoclax)|Patients receive azacitidine IV over 10-40 minutes or SC on days 1-7 (for patients with prior decitabine use), or decitabine IV on days 1-5 (for patients with prior azacitidine), and venetoclax PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3256254|NCT01441830|Sham Comparator|sham rESWT|
3375019|NCT04903496||Group A: Diabetic patients with CVD, CKD or at risk|The group A includes all Patients with diagnosis of diabetes, and with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
3375020|NCT04903496||Group B: Diabetic patients without CVD, CKD or at risk|The group B includes all patients with diagnosis of diabetes, but not with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk.
3375021|NCT04903496||Group C: Non-diabetic patients with CVD, CKD or at risk|The group C includes all patients with diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, but not with diagnosis of diabetes.
3375022|NCT04903496||Group D: Non-diabetic patients without CVD, CKD or at risk|The group D includes all patients without diagnosis of cardiovascular disease, heart failure, chronic kidney disease or at high cardiovascular risk, and without diagnosis of diabetes.
3375023|NCT04901507|Experimental|The Voutia System|The Voutia System oral irrigation device
3375024|NCT04900922||Healthy tennis players|Participants in this group need to perform three times of shoulder elevation and five times of tennis serving before and after a fatigue protocol. The fatigue the participants will receive will be conducted with a dynamometer. Surface electromyography on infraspinatus, pectoralis major, anterior deltoid ,and latissimus dorsi will be used to detect muscle activity related to fatigue.
3256255|NCT01441830|Active Comparator|rESWT|
3256256|NCT01441856|Active Comparator|Open or Laparocopic Left|Open or Laparoscopic left hemihepatectomy
3256257|NCT01441856|Active Comparator|Open or Laparoscopic Right|Open or Laparoscopic right hemihepatectomy
3256258|NCT01441856|Active Comparator|Prospective registry|Prospective registry of patients that cannot be randomized (both open and laparoscopic left + right hemihepatectomy)
3256259|NCT01441869|Experimental|A|5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet
3256260|NCT01441869|Experimental|B|5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet
3256261|NCT01441869|Experimental|C|5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet
3256262|NCT01441869|Experimental|D|5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet
3256263|NCT01441908|No Intervention|Control Group|Control Group
3256264|NCT01441908|Active Comparator|Statin|Receiving Statin
3256265|NCT01441921|Active Comparator|Control diet|Low-fat normocaloric diet (30% fat, 55% carbohydrates, 15% proteins)
3256266|NCT01441921|Experimental|Pistachio diet|Diet supplemented with 2 ounces of pistachio (35% fat, 50% carbohydrates adn 15% protein)
3375042|NCT04883905||Patients with AHP|Patients with a diagnosis of AHP will be eligible for the study and will be managed and treated per routine clinical practice.
3375043|NCT04882449|Experimental|Bodyport Scale|All subjects will be given the Bodyport scale to use
3375044|NCT04880434|Experimental|Brexucabtagene autoleucel (KTE-X19)|Participants with relapsed/refractory mantle cell lymphoma will receive conditioning chemotherapy consisting of fludarabine 30 mg/m^2/day and cyclophosphamide 500 mg/m^2/day intravenous (IV) infusion for 3 days followed by a single infusion of brexucabtagene autoleucel (KTE-X19) at a targeted dose of 2 x 10^6 anti-CD19 chimeric antigen receptor (CAR) T cells/kg, with a maximum flat dose of 2 x 10^8 anti-CD19 CAR T cells for participants ≥ 100 kg on Day 0 in Cohort 3.
3375047|NCT04876391|Experimental|Participants from parent trial (1368-0052) who were on placebo or active medication|
3375048|NCT04871893|Other|Treatment with the blood-gas exchanger multiECCO2R for CO2 removal|Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.
3375049|NCT04870112|Experimental|Patients with NSCLC|Patients with Non-Small Cell Lung Cancer
3375050|NCT04870112|Experimental|Patients with SCLC|Patients with Small Cell Lung Cancer
3256267|NCT01441934|Active Comparator|Sildenafil citrate|20 mg t.i.d.
3375053|NCT04865939|Active Comparator|gemcitabine|intravesical instillation of gemcitabine (1 g in 50 mL saline) with dwell time of 1 - 3 hours
3375054|NCT04865939|Experimental|sterile water irrigation|intravesical continuous bladder irrigation with sterile water for 1 - 3 hours and a total instilled volume of approximately 4 - 16 liters
3375055|NCT04865770|Experimental|Semaglutide 1.0 mg OW|Once-weekly (OW) Semaglutide administered subcutaneously (s.c., under the skin).
3375056|NCT04865770|Placebo Comparator|Placebo (Semaglutide) 1.0 mg OW|Once-weekly (OW) placebo (Semaglutide) administered subcutaneously (s.c., under the skin).
3375058|NCT04865393|Experimental|SPR206|SPR206 100mg single-dose IV infused over 1 hour
3256268|NCT01441934|Placebo Comparator|Sugar pill|
3256269|NCT01441947|Experimental|Cabozantinib plus fulvestrant|Combination therapy with cabozantinib 60 mg daily plus fulvestrant 500 mg monthly Intramuscularly (IM)
3256270|NCT01441999|Active Comparator|Less rigid rods|Titanium rods that have a soft, plastic end
3256271|NCT01441999|Active Comparator|Rigid Rods|Titanium rods
3256272|NCT01442012|Active Comparator|Group A|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Pericardium 6, Heart 7 and Stomach 25
3256273|NCT01442012|Sham Comparator|Group B|Patients receive cutaneous stimulation and self-stimulation of acupuncture points Gall Bladder 34, Kidney 6 and Liver 3
3375059|NCT04861038|Experimental|aerSleep II|Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
3375060|NCT04860830|Experimental|BI 425809 treatment group|
3375061|NCT04860830|Placebo Comparator|Placebo group|
3256274|NCT01442025|Placebo Comparator|Cohort 1 =Control Group|the dose of IFX will be increased by 5 mg/kg (maximally 1 time) based on symptom relapse (usual clinical practice) Dose will be kept stable ofr the rest of the trial Dose decreases will not be allowed.
3375068|NCT04852198|Active Comparator|OAGB|149 patients receiving one anastomosis gastric bypass (OAGB) with a Biliopancreatic-limb of 150cm
3375069|NCT04852198|Active Comparator|RYGB|149 patients receiving Roux-en-Y gastric bypass (RYGB) with a Biliopancreatic-limb of 150cm
3375070|NCT04847739|Experimental|Standard of Care Treatment + AVB-114|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and the AVB-114 study treatment is inserted.
3256275|NCT01442025|Active Comparator|Cohort 2|Dose of IFX will be increased by 2.5 mg/kg (maximally 2 times) if the following criteria are met A dose increase is maintained for the following infusions
3256276|NCT01442025|Active Comparator|Cohort 3|Dose of IFX will be increased by 5 mg/kg (maximally 1 time) if the following criteria are met A dose increase is maintained for the following infusions
3375071|NCT04847739|Active Comparator|Standard of Care Treatment|Subjects receive the standard of care treatment (seton placement) prior to Day 0, when it is removed and then replaced.
3375073|NCT04841473|Active Comparator|Standard Concussion Education|Participants will receive standard concussion education materials (online training) focused on concussion prevention in youth sport.
3375074|NCT04841473|Experimental|TRAIN Concussion Education|After receiving the standard concussion education materials (online training), participants will receive an additional module, the TRAIN concussion education module.
3375078|NCT04831892|Experimental|Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal|Topical lotion containing isosorbide diesters and colloidal oatmeal to be applied to the entire body once daily.
3375079|NCT04831892|Active Comparator|Moisturizer containing colloidal oatmeal|Topical moisturizer with colloidal oatmeal to be applied to the entire body once daily
3256277|NCT01442051|Experimental|Acute Normovolemic Hemodilution|A pilot study will be performed. Intraoperative data including vital signs, procedures performed, and transfusions of allogenic blood will be collected prospectively. Postoperative outcomes, including transfusions of allogenic blood, perioperative complications, and 30-day mortality will be collected prospectively. These outcomes will be compared to historical controls to assess for the safety and efficacy of ANH in ovarian cancer cytoreductive surgery.
3256278|NCT01442077|Active Comparator|arm 1|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments.
3256279|NCT01442077|Active Comparator|arm 2|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
3375080|NCT04825379|Experimental|bioactive composite|Cention N, Ivoclar Vivadent, Schaan, Liechtenstein (CN)
3375081|NCT04825379|Experimental|posterior resin composite|G-ænial Posterior (GC, Tokyo, Japan) (GP)
3375082|NCT04823858||Examination Group|There will only be one arm of subjects in this study. The arm will include subjects who plan to undergo a single-level TLIF stabilized with pedicle screws and meet all of the eligibility criteria.
3375087|NCT04814186|Experimental|Chinese participants treated with Tafamidis|treatment group with tafamidis
3375093|NCT04806971||Periodontitis|Patients with grade B / C, stage III periodontitis were classified based on the new classification criteria.Clinical attachment loss ≥5 mm, probing depth (PD) ≥6 mm, ≥20 teeth and radiographic bone loss extending to the root middle third. Grade was assessed considering the radiographic bone loss in the most affected tooth in the dentition as a function of age (Grade B=0.25-1.0, Grade C= >1.0).
3375094|NCT04806971||Healthy|The periodontally healthy subjects without any clinical sign of inflammation,not showing a history of periodontitis; PD ≤3 mm; <10% of sites with BOP; an absence of detectable bone loss and/or attachment ; without extensive caries or restorations and presence of at least 28 permanent teeth. In addition, all the control subjects showed the absence of any local or systemic pathology.
3375095|NCT04805879|Active Comparator|FMT capsules|"Each dose of FMT capsules consists of 20 capsules. The 20 over encapsulated capsules are derived from 100 grams of stool and each containing 0.67 ml of pelleted intestinal microbes.~PArticipants will recieve a loading dose of 60 capsules over 3 consecutive days followed by a booster dose of 20 caspules 1 month after and a second similar booster dose a month after that"
3375096|NCT04805879|Placebo Comparator|Placebo oral Capsules|Placebo casules are inactive capsules that look and weigh the same as the Active FMT caspules. Participants will follow the same schedule as the Active arm.
3375097|NCT04803201|Experimental|Arm A (duvelisib, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive duvelisib PO BID on days 1-21. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3375098|NCT04803201|Experimental|Arm B (CC-486, CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Patients also receive CC-486 PO QD on days -6 to 0 of cycle -1 and days 8-21 of cycles 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3375099|NCT04803201|Active Comparator|Arm C (CHO[E]P)|Patients receive cyclophosphamide IV on day 1, doxorubicin IV on day 1, vincristine IV on day 1, etoposide IV on day 1 or days 1-3 or PO QD on days 2-3 for patients =< 60 years old, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3375100|NCT04799353|Experimental|Group 1: Placebo SC + Placebo IV|Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.
3375101|NCT04799353|Experimental|Group 2: Budigalimab (SC) + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
3375102|NCT04799353|Experimental|Group 3: Budigalimab SC + Placebo IV|Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.
3375103|NCT04799353|Experimental|Group 4: Placebo SC + Budigalimab IV|Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.
3256280|NCT01442077|Active Comparator|arm 3|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
3375107|NCT04797767|Experimental|Treatment (CLAG-M, venetoclax)|Patients will receive induction with granulocyte colony-stimulating factor on days 0-5 (if peripheral white blood cell count is less than 20,000/uL), cladribine on days 1-5, cytarabine on 1-5, and mitoxantrone on days 1-3. Patients also receive venetoclax orally (PO) on days 1-14. Treatment repeats every 28-35 days for up to 2 induction cycles including mitoxantrone, and up to 4 consolidation cycles without mitoxantrone in the absence of disease progression or unacceptable toxicity.
3256281|NCT01442077|Active Comparator|arm 4|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
3256282|NCT01442090|Active Comparator|Everolimus|Participants will receive everolimus (10 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3375111|NCT04789408|Experimental|KITE-222|"Dose Escalation: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single target starting dose of KITE-222 chimeric antigen receptor (CAR) transduced autologous T cells. Based on dose limiting toxicities (DLTs) observed in the first cohort, additional participants will be enrolled and administered escalating dose of KITE-222 to determine the maximum tolerated dose (MTD) of KITE-222.~Dose Expansion: Participants will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine followed by a single dose (at the MTD determined) of KITE-222."
3375116|NCT04787874|No Intervention|Control|The control arm will receive no additional prehabilitation material prior to material. Rather, they will receive standard preoperative care in which they will be given standard advice on nutrition and fitness. REDcap surveys will be administered.
3375117|NCT04787874|Experimental|Prehab Intervention Arm|The intervention arm will receive access to the prehab program (abdominal workout videos) and surveys via RedCAP.The program will start no less than 14 days before the date of surgery.
3375118|NCT04786184|Experimental|CALM Breathing|
3375119|NCT04786184|Active Comparator|Wait-List Control|
3375120|NCT04785352|No Intervention|Standard well-baby care|Children in this arm (control group), as well as children in the two intervention groups, will receive standard care as outlined in the Essential Package of Health Services by Haiti's Ministry of Public Health and Population (MSPP). This includes a World Health Organization (WHO) immunization schedule of vaccines, high dose vitamin A supplements, and growth monitoring and promotion.
3375121|NCT04785352|Experimental|Nutrition Intervention|Children in this arm will receive one egg per day for six months.
3375122|NCT04785352|Experimental|Grandi Byen|This arm comprises a multicomponent intervention on responsive parenting, nutrition, hygiene, and one egg per day for six months for children.
3375123|NCT04783246|Experimental|Group A- Intervention/Non-Intervention|Participants in this arm will initially be randomized to the intervention period and will receive the interventions for 11 weeks followed by no interventions for 11 weeks.
3375124|NCT04783246|Active Comparator|Group B- Non-Intervention/Intervention|Participants in this arm will initially be randomized to the non-intervention period for 11 weeks followed by the intervention period for 11 weeks.
3375125|NCT04777175||KRAS mutation|patients carry with KRAS mutation
3375126|NCT04777175||ALK fusion|patients carry with ALK fusion
3375127|NCT04777175||ERBB2 mutation|patients carry with ERBB2 mutation
3375128|NCT04777175||MET skipping/amplication|patients carry with MET skipping/amplication
3375129|NCT04777175||RET fusion|patients carry with RET fusion
3375130|NCT04777175||BRAF mutation|patients carry with BRAF mutation
3256283|NCT01442090|Experimental|GDC-0980|Participants will receive GDC-0980 (40 mg) orally daily until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
3256284|NCT01442116|Experimental|Hypertensives|
3375132|NCT04770428|Experimental|Cohort 1: Japanese MEDI7352|Randomized Japanese participants will receive single doses of MEDI7352 subcutaneously.
3375133|NCT04770428|Placebo Comparator|Cohort 1: Japanese Placebo|Randomized Japanese participants will receive matching placebo subcutaneously.
3256285|NCT01442142|Experimental|Appetitie Awareness|"Parents and kids assigned to this group with learn about appetite awareness and to appropriately respond to their hunger meter."
3256286|NCT01442142|Experimental|Cue Reactivity and Sensitivity Training|Parents and kids in this group learn about how external cues can lead to overeating and how to better respond to these cues.
3256287|NCT01442142|Experimental|Combined CAAT/CRST|In this 14 week intervention combining Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST), parents and kids learn about both internal hunger cues and external cues that can cause one to overeat. Skills to learn the internal hunger cues and better responses to external cues are taught.
3256288|NCT01442142|No Intervention|Control|Between baseline and the post-intervention data collection point, no intervention is given. Participants are given a take home binder of intervention materials at that second data collection point; they have the option of reviewing the material prior to the final follow-up data collection point.
3375134|NCT04770428|Experimental|Cohort 2: Caucasian MEDI7352|Randomized Caucasian participants will receive single doses of MEDI7352 subcutaneously.
3375135|NCT04770428|Placebo Comparator|Cohort 2: Caucasian Placebo|Randomized Caucasian participants will receive matching placebo subcutaneously.
3256289|NCT01442168|Experimental|Sevuparin/DF02|Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
3256290|NCT01442168|Active Comparator|Control|Anti-malarial regimen (Malanil®) alone
3256291|NCT01442194||Fingolimod|non-interventional
3256292|NCT01442194||parallel cohort|non-interventional
3256293|NCT01442207|Active Comparator|Placement of Cervical Cerclage|Cervical Cerclage is to be placed in an inpatient hospital setting within 24 to 72 hours of being assigned to this treatment group
3375136|NCT04765202|Experimental|All participants|"Each participant will receive both treatments.~On each participant, similar wounds will be identified as treatment sites.~Treatment sites will be randomized to receive either AG Tx (control) or SOMA Tx (experimental)."
3259862|NCT01474564||Pts with Pancreatic Adenocarcinoma|This is an observational study to assess the feasibility of 1) isolating and enriching circulating tumorigenic cells from the peripheral blood of eligible pancreatic cancer patients and 2) successful gene expression profiling of these circulating tumorigenic cells.
3259863|NCT01474577||pts who have had Rb-82 PET myocardial perfusion imaging|Eligible patients will have had Rb-82 PET myocardial perfusion imaging at MSKCC, 2008 - 2011. Patients will complete one questionnaire over the phone.
3259864|NCT01474603||1|overweight or obese diabetic
3259865|NCT01474616|Other|Sit-to-Stand Activity|
3259866|NCT01474629|Active Comparator|probiotic-based dietary supplement|
3259867|NCT01474629|Placebo Comparator|placebo|
3259868|NCT01474642|Active Comparator|Capecitabine/Cisplatin(XP)|Capecitabine AND Cisplatin
3259869|NCT01474642|Active Comparator|Capecitabine/Paditaxel(XG)|Capecitabine + Paditaxel(genexol)
3259870|NCT01474668|Experimental|A|Experimental
3259871|NCT01474707|Experimental|Group one|Group1 will view the knowledge-based video only
3259872|NCT01474707|Experimental|Group two|Group two will view the motivational video only
3259873|NCT01474707|Experimental|Group three|Group three will view both knowledge-based and motivational videos
3259874|NCT01474707|Experimental|Group four|Group four will view the printed educational pamphlet and will not view either video
3259875|NCT01474720|Experimental|SLE patients|Subjects with mild SLE over age 50 years will receive open-label Zostavax vaccine.
3259876|NCT01474720|Active Comparator|Healthy subjects|Healthy subjects aged 50 years and older without any history of autoimmune disease will receive zostavax vaccine. Immune responses to varicella zoster virus and adverse events will be compared to those seen in SLE patients
3259877|NCT01474733|Experimental|educational intervention|participants undergo a series of educational interventions over 3 years
3259878|NCT01474759|Experimental|Portion size instruction|Advice on diet, physical activity, and behavior change. Instruction in food portion size.
3259879|NCT01474759|Experimental|Pre-portioned foods|Advice on diet, physical activity, and behavior change. Provision of pre-portioned foods.
3259880|NCT01474759|Active Comparator|Comparison|Advice on diet, physical activity, and behavior change. Advice on healthy eating for weight loss.
3259881|NCT01474785|Experimental|RYGB|Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.
3259882|NCT01474785|Experimental|VSG|Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.
3259883|NCT01474785|Experimental|Low Calorie Diet|Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.
3259884|NCT01474798|Experimental|RA-18C3|
3259885|NCT01474837|Experimental|Exercise with motivational interviewing|Young people with depression exposed to exercise with motivational interviewing
3259886|NCT01474837|No Intervention|Treatment as usual|Young people with depression receiving treatment as usual
3259887|NCT01474850|Active Comparator|open lung|The lung recruitment maneuver (RM) immediately after intubation using pressure controlled ventilation, increase in peak inspiratory pressure up to 30 cm H2O during tidal ventilation, respiratory rate 4/min and positive end expiratory pressure (PEEP) 15 cm H20. PEEP 7 cm H2O until extubation. Inspiratory oxygen concentration (FiO2) 40% during recovery from anesthesia.
3259888|NCT01474850|No Intervention|control|No recruitment maneuver is performed. PEEP 0 cm H2O. Inspiratory oxygen concentration (FiO2) 100 % during recovery from anesthesia.
3259889|NCT01474902|Experimental|Treatment group|"The initial enoxaparin dose will be: 1.75 mg/kg/dose SC q12h for patients ≤ 2 months old or~1 mg/kg/dose SC q12h for patients > 2 months old~Adjust the dose of enoxaparin according to the following monogram. Depending on the Enoxaparin Anti-factor Xa level achieved, successive actions are indicated, including whether to hold the next scheduled dose, whether any dose change is indicated and when the next anti-factor Xa level should be drawn."
3259890|NCT01474902|No Intervention|No-treatment|
3259891|NCT01474928|Experimental|Group 2: community video group|In each community intervention group two subject viewed the patient role played community video
3259892|NCT01474928|Experimental|Group three: both videos group|In each community intervention group three subject viewed two videos (the patient role played community and physician-led knowledge videos)
3259893|NCT01474928|Active Comparator|Group four: pamphlet group|In each community intervention group four subject read an educational pamphlet only - act as active comparator group
3259894|NCT01474928|Experimental|Group one: knowledge video group|In each community intervention group one subject viewed the physician-led knowledge video
3259895|NCT01474941|Experimental|5 mg QD PF-04620110 or Placebo|
3259896|NCT01474941|Experimental|5 mg BID PF-04620110 or Placebo|
3259897|NCT01474941|Experimental|Optional Arm, PF-04620110 or Placebo|
3259898|NCT01474967|Experimental|Lower metformin dose group|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
3259899|NCT01474967|Active Comparator|Higher metformin dose group|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
3259900|NCT01475006|Experimental|Part I Dose Exploration|Pre-specified nominal doses are proposed in the dose exploration. Intermediate doses may also be used if required based on the CRM design.
3259901|NCT01475006|Experimental|Part II Dose Expansion|Dose selected from Part 1 dose exploration
3259902|NCT01475019|Experimental|PCOS obese Orlistat|Obese PCOS women treated with Orlistat, diet and physical exercise
3259903|NCT01475019|Experimental|Obese Orlistat|Obese women (non PCOS) treated with Orlistat, diet and physical exercise
3259904|NCT01475019|Experimental|PCOS obese diet|Obese PCOS women treated with diet and physical exercise
3259905|NCT01475019|Experimental|PCOS obese Sibutramine|Obese PCOS women treated with Sibutramine, diet and physical exercise
3259906|NCT01475032|Experimental|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
3259907|NCT01475032|Active Comparator|BDP|BDP for 12 weeks
3259908|NCT01475032|Active Comparator|BDP+FF|free combo BDP+FF for 12 weeks
3256294|NCT01442207|Placebo Comparator|Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, Premature rupture of the membranes (PROM) > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
3256295|NCT01442233|Experimental|plasma exchange|6 plasma exchanges during 2 weeks after randomization
3256296|NCT01442233|Sham Comparator|sham exchange|6 sham plasma exchanges during 2 weeks after randomization
3256297|NCT01442246|Experimental|Adjuvant treatment|Leuproreline acetate
3256298|NCT01442246|No Intervention|Surveillance|Surveillance
3256299|NCT01442259|Experimental|All study subjects|
3256300|NCT01442272|No Intervention|Habitual medication withuot additional|
3256301|NCT01442272|Active Comparator|Habitual medication plus Hidroferol®|
3256302|NCT01442272|Active Comparator|Habitual medication plus Zemplar®|
3259909|NCT01475045||Turbuhaler inhaler use|
3259910|NCT01475045||Discus inhaler use|
3259911|NCT01475045||Elpenhaler inhaler use|
3259912|NCT01475058|Experimental|Treatment (T cell therapy)|Patients undergo one IV infusion of donor-derived CD8+ central memory-derived CMV/CD19 or EBV/CD19 bi-specific T cells, at least 30 days after HCT.
3259913|NCT01475084|Experimental|Cryobiopsy, forceps biopsy|"Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation.~Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps."
3259915|NCT01475123|Active Comparator|Nicorandil|Nicorandil was administered orally (15mg/day).
3259916|NCT01475123|No Intervention|Non-nicorandil|Nicorandil was not administered.
3259917|NCT01475149||aPL positive - group 1|aPL positive with APS, receiving HCQ
3259918|NCT01475149||aPL positive - group 2|aPL positive with APS and SLE, receiving HCQ
3259919|NCT01475149||aPL positive - group 3|aPL positive without APS but with SLE, receiving HCQ
3259920|NCT01475149||aPL positive - group 4|aPL positive without APS or SLE, receiving HCQ
3259921|NCT01475149||aPL negative - group 1|aPL negative with SLE, receiving HCQ
3259922|NCT01475149||aPL negative - group 2|aPL negative with SLE, not receiving HCQ
3259923|NCT01475188|Placebo Comparator|placebo|20 patients with intermittent allergic rhinitis sensitized to grass pollen allergens
3259924|NCT01475188|Active Comparator|Specific subcutaneous immunotherapy|21 symptomatic patients with intermittent allergic rhinitis sensitized to grass pollen allergens
3259925|NCT01475201|Experimental|Step Count Prescription Arm|The active trial arm intervention consists of usual care plus step count prescription delivered by the treating doctor, over a one-year period.
3259926|NCT01475201|Active Comparator|Usual care arm|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week). Consistent with clinical practice guidelines, our collaborating doctors have indicated that the usual care of the target population requires clinic visits at roughly three-month intervals to ensure vascular risk factor monitoring and management.
3259927|NCT01475227|Experimental|Arm A- early Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 2 to day 15
3259928|NCT01475227|Experimental|Arm B- late Solvazinc group|Zinc sulphate 125mg (1 Solvazinc tablet) once daily orally after dissolution in water, day 15 to day 28
3259929|NCT01475240||Group 1: Controls|HIV-infected patients on stable > 6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with normal bilirubin
3259930|NCT01475240||Group 2: Cases|HIV-infected patients on stable >6 months on TDF/FTC or ABC/3TC plus PI/r based ARV regimen with HBR (>2.5 X upper limit)
3259931|NCT01475266|Experimental|EO9 (Apaziquone)|
3259932|NCT01475266|Placebo Comparator|Placebo|
3259933|NCT01475292|Experimental|RV568 treatment group low dose|
3259934|NCT01475292|Experimental|RV568 treatment group high dose|
3259935|NCT01475292|Placebo Comparator|Placebo treatment group|
3259936|NCT01475318|Experimental|misoprostol + mifepristone + letrozole|
3259937|NCT01475344|Active Comparator|Human Fibrinogen Concentrate|"Fibrinogen Concentrate will be administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
3259938|NCT01475344|Placebo Comparator|Placebo|"Placebo administrated over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
3259939|NCT01475357|Other|Arm 1: NPO pre-operative|1) Current care - NPO (nothing by mouth) postnatal intestinal function of neonates with complex CHD who receive enteral trophic breastmilk (10cc/kg/day) feeds (intervention) vs NPO (nothing by mouth) in the pre-operative period.
3256303|NCT01442285|Experimental|personalized, motivational messages|A Healthcare Provider Report will be reviewed by oncologist. If mental health functioning scores are elevated or high range,treatment plan is constructed. Subjects receive personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
3256304|NCT01442285|No Intervention|Control Group|Control subjects will receive a resource packet upon initial diagnosis consisting of brochures and printed material describing local resources and support groups as part of their routine care. At 12 months, subjects will receive the full assessment with reports and referrals.
3375137|NCT04761627|Active Comparator|Continued-use Group (Ustekinumab)|Participants will receive subcutaneous injection of ustekinumab up to Week 52.
3375138|NCT04761627|Experimental|Switching Group (Ustekinumab - ABP 654)|Participants will initially receive injection of ustekinumab up to Week 16. Thereafter, starting from Week 28, participants will switch between ABP 654 and ustekinumab every 12 weeks up to Week 52.
3375139|NCT04761614|Experimental|Treatment (riluzole, mFOLFOX6, bevacizumab)|Patients receive riluzole PO BID on days 1-14. Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
3256305|NCT01442298|Active Comparator|conventional treatment|the Standard method;tourniquet pressure based on systolic blood pressure, plus a safety margin.
3256306|NCT01442298|Experimental|limb occlusion pressure(LOP)|cuff pressure is based on limb occlusion pressure measurement
3256307|NCT01442311|Experimental|enhanced DOT (PEG/RBV-DOT)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
3256308|NCT01442311|Active Comparator|standard DOT (PEG-DOT)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
3256309|NCT01442324|Experimental|IRE|Patients will be subjected to irreversible electroporation (IRE) as the sole treatment of nodules not considered treatable by resection or thermal ablation.
3375146|NCT04758117||Participants Receiving Upadacitinib|Participants receiving Upadacitinib for psoriatic arthritis (PsA).
3375148|NCT04753697|Experimental|Administration of CC-93538|CC-93538 360 mg Subcutaneously (SC) once weekly for 24 weeks followed by CC-93538 360 mg SC once weekly for 24 weeks
3375149|NCT04753697|Experimental|Administration of CC-93538 and Placebo|"CC-93538 360 mg SC once weekly for 24 weeks followed by CC-93538 360 mg SC once every other week for 24 weeks.~During the Maintenance Phase, matching placebo will be administered once every other week on alternate weeks to maintain the blind."
3256310|NCT01442337|Experimental|ASP8597 low dose|
3256311|NCT01442337|Experimental|ASP8597 high dose|
3256312|NCT01442337|Experimental|ASP8597 highest dose|
3256313|NCT01442337|Placebo Comparator|Placebo|Placebo comparator used in Part 2 only
3256314|NCT01442363|Experimental|BLI-1300 (low dose)|Low dose BLI-1300
3256315|NCT01442363|Experimental|BLI-1300 (high dose)|High dose BLI-1300
3256316|NCT01442363|Placebo Comparator|placebo|placebo (vehicle)
3256317|NCT01442402||2 APOL1 genotypes|African American transplant recipients with homozygous APOL1 gene variants
3256318|NCT01442402||0 or 1 APOL1 genotypes|African American transplant recipients without homozygous APOL1 gene variants
3256319|NCT01442415|Other|Lifestyle Modification|Weekly 2 hour study sessions for 10 weeks; each session includes one hour of physical activity and one hour of dietary counseling
3256320|NCT01442428|Experimental|Steroid+Statin|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
3375150|NCT04753697|Placebo Comparator|Administration of Placebo|Matching placebo SC once weekly for 24 weeks followed by matching placebo SC once weekly for 24 weeks
3375151|NCT04748588|No Intervention|Standard of care|
3375152|NCT04748588|Experimental|Anti SARS-CoV-2 monoclonal antibody|Single IV administration of an anti-SARS-CoV-2 Monoclonal antibody
3375153|NCT04744636|Other|Healthy volunteers aged of 18-30 years|
3375154|NCT04744636|Other|Healthy volunteers aged of 50-59 years|
3375155|NCT04744636|Other|Healthy volunteers aged of 60-70 years|
3375156|NCT04744636|Other|Type 2 diabetic patients aged of 50-70 years|
3375157|NCT04743765|Experimental|Accelerated medical clearance and surgery|Accelerated medical clearance and targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
3256321|NCT01442428|Active Comparator|NSAID+Statin|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration)"
3256322|NCT01442428|Active Comparator|Steroid+Placebo|"Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
3256323|NCT01442428|Active Comparator|NSAID+Placebo|"Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week;~Placebo"
3375158|NCT04743765|No Intervention|Standard surgical care|Hip fracture repair and surgical care according to treating institution guidelines.
3375159|NCT04743635|Experimental|Investigational Device Treatment|Cellulite can be treated across thighs and buttocks
3375160|NCT04741126|Experimental|Intervention Protocol|Hospital-based manually assisted cough technique for 4 weeks.
3375163|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Adults|Healthy adults with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of parents of participating children and other healthy volunteers.
3375164|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Adults|Adults with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic parents that are in the hospital with their children and symptomatic adults that are admitted to the infectious disease ward.
3375165|NCT04739020|Active Comparator|PCR SARS-CoV-2 Negative Children|Children with recent negative SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of children admitted to the Children's Hospital or presenting for planned diagnostic testing or follow up.
3375166|NCT04739020|Active Comparator|PCR SARS-CoV-2 Positive Children|Children with recent positive SARS-CoV-2 PCR test (nasopharyngeal swab). Will consist of asymptomatic children that are admitted to the Children's Hospital for reasons other than COVID-19 and symptomatic children.
3375167|NCT04731519|Active Comparator|General Health Education Active Control Group|The control condition will receive General Health Education a structured manualized group health education intervention previously developed by VISN 2 MIRECC investigators as a control condition for group psychotherapy RCTs. It has 12 1.5-hour weekly group sessions focusing on health and wellness topics such as Sleep, Physical Activity, Impact of Stress, Relaxation Techniques, Substance Use, Nutrition, Managing Daily Activities, Medication Benefits and Side Effects. GHE was chosen for the AC because it aligns in many respects with CI-CT (e.g., group format, length of sessions, similar expectations) while diverging in specific topics and skills targeted allowing for control of common factors like attention without causing confounding due to overlap in concepts
3375168|NCT04731519|Experimental|CI-CT Group|The experimental group will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
3375169|NCT04731519|Other|CI-CT Treatment Development Group|The 3 treatment development groups will receive CI-CT (Continuous Identity Cognitive Therapy). CI-CT is planned to be a weekly, 90-minute, 12-session group treatment and to be run by two clinicians using the final version manual and workbook. CI-CT was developed as a manualized treatment integrating components of CBT and Acceptance and Commitment Therapy (ACT) with self-continuity and future-self related interventions to help Veterans develop a better present-to-the-future life story as a framework for increasing hopefulness, a sense of life meaning, empowerment, and an ability to attain future self-goals. The CI-CT includes eight components: 1) constructing a CI narrative, 2) mindfulness training, 3) life values identification, 4) developing a self-growth perspective, 5) identifying possible future selves - timelines, 6) connecting with the desired future self, 7) CI as context for current problems, and 8) moving toward the future self.
3256324|NCT01442441||chronic pancreatitis|
3256325|NCT01442454||Chronic Pancreatitis|
3256326|NCT01442467||Mild to Severe MAC|
3256327|NCT01442467||No to mild MAC|
3256328|NCT01442480|Experimental|Fish oil|
3256329|NCT01442480|Experimental|Olive oil|
3256330|NCT01442506||Barrett|
3375179|NCT04719247|Experimental|Turmeric|Turmeric extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
3375180|NCT04719247|Experimental|Thymus Vulgaris|Thymus Vulgaris extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
3375181|NCT04719247|Experimental|Nigella Sativa|Nigella Sativa extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
3375182|NCT04719247|Experimental|Aloe Vera|Aloe Vera extract will be used as a dental pulp dressing material after pulpotomy and compared with Formocresol
3375183|NCT04719247|Active Comparator|Formocresol|Formocresol will be used as a dental pulp dressing material after pulpotomy to be compared with other materials.
3256331|NCT01442519|Active Comparator|Intravesical BCG alone|
3256332|NCT01442519|Experimental|Intravesical sequential BCG and EMDA MMC|
3256333|NCT01442532|Experimental|1|
3256334|NCT01442532|Experimental|2|
3256335|NCT01442532|Experimental|3|
3256336|NCT01442532|Placebo Comparator|4|
3375186|NCT04714398|Experimental|Opt-In Recruitment|All recruitment messaging will be framed for patients as they must opt-in to participate in the remote monitoring program.
3375187|NCT04714398|Experimental|Opt-Out|All recruitment messaging will be framed as though participation is the default, and patients must opt-out of participating in the remote monitoring program.
3375188|NCT04714398|No Intervention|Usual Care|Patients in the usual care arm will not be contacted by study staff, they will not receive a blood pressure cuff, and they will not be asked to participate in any component of the blood pressure monitoring program.
3375189|NCT04713592|Experimental|Risankizumab|Participants will receive risankizumab for 52 weeks
3375190|NCT04713592|Placebo Comparator|Placebo|Participants will receive placebo for 16 weeks followed by risankizumab for 36 weeks.
3256337|NCT01442532|Experimental|5|
3256338|NCT01442545|Experimental|001|
3256339|NCT01442558|Active Comparator|SCL|Supraclavicular ultrasound-guided brachial plexus block
3256340|NCT01442558|Active Comparator|ICL|Infraclavicular ultrasound-guided brachial plexus block
3256341|NCT01442558|Active Comparator|AX|Axillary ultrasound-guided brachial plexus block
3375191|NCT04710212||Induction Chemotherapy for Acute Leukemia|Receiving induction chemotherapy for acute leukemia, and receiving fluoroquinolone (FQ) prophylaxis.
3256342|NCT01442571|Experimental|Hyaluronic Acid Injection, pain, function|
3256343|NCT01442571|Placebo Comparator|Saline Injection|
3256344|NCT01442584|Experimental|fertility restoration by transplantation|fertility restoration by transplantation of ovarian cortex slivers that were cryopreserved prior to chemotherapy
3256345|NCT01442597|Active Comparator|Individual clinician-provided CBT|Individual treatment provided by a trained Cognitive Behavioral Therapy (CBT)clinician who will cover the same skills provided by the CBT4CBT computer program.
3256346|NCT01442597|Experimental|CBT4CBT|A computerized program that teaches skills for stopping drug use and increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc.
3256347|NCT01442597|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on substance abuse.
3256348|NCT01442610|Experimental|Rasagiline|Effect of Rasagiline on sleep parameters in PD Patients
3256349|NCT01442610|Placebo Comparator|Placebo|Effect of placebo on sleep parameters in PD Patients
3256350|NCT01442623|Active Comparator|Conventional Vestibular Rehabilitation|Six week program of conventional vestibular rehabilitation.
3256351|NCT01442623|Experimental|Nintendo Wii Vestibular Rehabilitation|Six week program of vestibular rehabilitation using the Nintendo Wii Fit Plus.
3375192|NCT04710212||Hematopoietic stem cell transplantation (HCT)|Undergoing hematopoietic stem cell transplantation (HCT), and receiving fluoroquinolone (FQ) prophylaxis.
3375193|NCT04703738|Active Comparator|Control|Soft tissue flap + Connective Tissue Graft
3375194|NCT04703738|Experimental|Test|Soft tissue flap + Geistlich Fibro-Gide®
3375195|NCT04694248|Experimental|Anticoagulant plus antiplatelet therapy|For anticoagulant, it is rivaroxaban 20mg once a day for 6 months. For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
3375196|NCT04693351|Experimental|Troriluzole|Troriluzole- 2 100mg capsules once daily for the first two weeks. Troriluzole- 2 140mg capsules once daily from week two through week ten.
3375197|NCT04693351|Placebo Comparator|Placebo|Placebo- 2 100mg capsules once daily for the first two weeks. Placebo- 2 140mg capsules once daily from week two through week ten.
3375199|NCT04691557|Experimental|Intervention Group|The intervention group receives the YoungAsthma developing for the smartphone or tablet additionally usual nursing care.
3375200|NCT04691557|Active Comparator|Control Group|The control group receives the usual nursing care.
3375206|NCT04684238|Active Comparator|Drug: Midazolam|Midazolam for sedation in the ICU
3375207|NCT04684238|Experimental|Drug: Isoflurane|Volatile for sedation in the ICU
3375208|NCT04682197|Active Comparator|Cereset Research|For this single arm, open label, exploratory trial this will be the intervention arm using 4 CR sessions.
3375209|NCT04682197|Other|Continued Current Care|Participants will continue their current care.
3375210|NCT04677374|Placebo Comparator|Standard of care|Participants in this arm will be offered Standard of Care (SOC) referral process for voluntary medical male circumcision (VMMC) services
3375211|NCT04677374|Experimental|Block 1 (intensified health education)|Participants in this arm will be offered intensified health education
3375212|NCT04677374|Experimental|Block 2 (intensified health education and SMS/telephonic tracing)|Participants in this arm will be offered intensified health education and SMS/telephonic tracing
3375213|NCT04677374|Experimental|Block 3 (intensified health education, SMS/telephonic tracing and transport reimbursement)|Participants in this arm will be offered intensified health education, SMS/telephonic tracing and transport reimbursement
3375214|NCT04667377|Experimental|Very low dose group|
3375215|NCT04667377|Placebo Comparator|Placebo group|
3375216|NCT04667377|Experimental|Low dose group|
3375217|NCT04667377|Experimental|Medium dose group|
3375218|NCT04667377|Experimental|High dose group|
3375219|NCT04665115|Experimental|Cohort I (ibrutinib)|Patients may continue to receive ibrutinib PO daily or stop ibrutinib per provider's discretion.
3375220|NCT04665115|Experimental|Cohort II Arm 2A (ibrutinib)|Patients continue to receive ibrutinib PO daily in the absence of disease progression or unacceptable toxicity.
3375221|NCT04665115|Experimental|Cohort II Arm 2B (temporary interruption)|Patients undergo temporary interruption of ibrutinib for up to 28 days unless they are discharged home and are thought to be medically fit by the primary caregiver to resume therapy according to their primary treating oncologist.
3375222|NCT04659408|Experimental|Bactosan - oat bran|This group will receive Bactosan first, followed by oat bran.
3375223|NCT04659408|Experimental|Oat bran - Bactosan|This group will receive oat bran first, followed by Bactosan.
3256352|NCT01442636|Experimental|Xience Prime stent|Patients with critical limb ischemia due to below the knee arterial lesion between 30 and 100mm in length, treated with the XIENCE PRIME™ Everolimus Eluting Coronary Stent System.
3256353|NCT01442649|Experimental|Arm A : bevacizumab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Bevacizumab 5 mg/kg IV every 2 weeks."
3375224|NCT04656795|Experimental|Subjects with severe renal impairment|
3375225|NCT04656795|Experimental|Subjects with normal renal function|
3375226|NCT04656795|Experimental|Subjects with moderate renal impairment|
3375227|NCT04656795|Experimental|Subjects with mild renal impairment|
3375228|NCT04650152||Fenofibrate|Adult patients with triglycerides > 2,3 mmol/l who are on statins and who are primary prescribed fenofibrate (or fenofibrate treatment break is at least 6 months) in accordance with ordinary physician practice in Russia.
3375229|NCT04646200|Experimental|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
3375230|NCT04646200|Active Comparator|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
3256354|NCT01442649|Experimental|Arm B : cetuximab + fluoropyrimidine-based chemotherapy|"Every 2 weeks :~- mFOLFOX6 : Oxaliplatin 85 mg/m2 over 120 mn IV on D1, Folinic Acide 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~OR~- FOLFIRI : Irinotecan 180 mg/m2 en 90 mn IV on day D1, Folinic acid 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1, 5-fluoro-uracil 400 mg/m² in bolus IV on D1 and 5-fluoro-uracil 2400 mg/m² in infusion IV over 46 h.~AND~Cetuximab : 500 mg/m² IV every 2 weeks"
3256355|NCT01442662|Experimental|pazopanib, gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
3256356|NCT01442701||No triclosan / Triclosan|Participants are randomized to receive household and personal cleaning products from one of 2 arms: products that either do not contain triclosan or that may contain triclosan. Participants select products from an arm-specific list of commercially available items.
3375234|NCT04644172|Experimental|Immediate Treatment|The treatment will have 3 components. The first component, Speed of Processing Training, is a computer game. Participants identify targets on the screen as rapidly as possible. The second component is training following shaping principles on simulated instrumental activities of daily living (IADL), such as making a telephone call or generating a shopping list, in the treatment setting. Shaping involves progressively increasingly the complexity of a task in incremental steps as a participant gains mastery. Frequent, positive feedback is another important aspect of shaping. The third component is a set of psychological techniques that will help participants apply the improvements from the game to carrying out tasks that rely on thinking in their daily
3375235|NCT04644172|Other|Delayed Treatment|Participants in this arm will receive testing on the same schedule as the Immediate Treatment up to six-month followup. Delayed Treatment participants will not receive any treatment from the study during this period but will permitted to receive any healthcare that is available on a clinical basis. After six-month followup, participants in this arm will be crossed over to receive the experimental treatment.
3375236|NCT04642534||Postpartum women who had gestational diabetes mellitus|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
3375237|NCT04642534||Postpartum women after an uneventful pregnancy|Inclusion at 4-8 weeks postpartum Follow-up for 6 months
3256357|NCT01442727|Placebo Comparator|Placebo|Patients who receive control (placebo)
3256358|NCT01442727|Active Comparator|Selenium|Patients who receive treatment (selenium)
3256359|NCT01442740|Experimental|15-degree Reverse Trendelenburg Position|Patients will be placed on the operating table in a position where the lower extremities are leveled lower than the head and neck. The angle of incline will be set at 15 degrees from the horizontal.
3256360|NCT01442740|No Intervention|0-degree Supine Position|Patients will be placed on the operating table in the standard, 0-degree supine position.
3256361|NCT01442753|Active Comparator|Intervention Group|Families will be randomized to either receive the intervention (family-skills training) immediately. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
3256362|NCT01442753|Active Comparator|Control Group|Control group will receive the intervention (family-skills training) in approximately ten months. The intervention will be delivered over eight weeks. Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
3375243|NCT04637594|Active Comparator|Arm A (immune checkpoint inhibitor)|"CONTINUATION OF ICI TREATMENT:~Patients receive either pembrolizumab intravenously (IV) over 30 minutes on day 1, nivolumab IV over 30 minutes on days 1 and 15, atezolizumab IV over 30-60 minutes on day 1, durvalumab IV over 60 minutes on days 1 and 15, or avelumab IV over 60 minutes on days 1 and 15. Cycles repeat every 21 or 42 days for pembrolizumab, every 21 days for atezolizumab, and 28 days for nivolumab, durvalumab, and avelumab in the absence of disease progression or unacceptable toxicity."
3375244|NCT04637594|Experimental|Arm B (immune checkpoint inhibitor)|"DISCONTINUATION OF ICI TREATMENT:~Patients receiving ICI treatment will discontinue ICI treatment within 1 cycle length after randomization. Cycle length is determined by the ICI regimen the patient is receiving at randomization. At disease progression patients may restart the same ICI treatment they were receiving upon randomization at physician discretion."
3375245|NCT04634162|Experimental|Cangrelor|Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion
3375246|NCT04634162|Placebo Comparator|Placebo|Ticagrelor loading dose followed after 1 hour by placebo infusion
3256363|NCT01442766|Experimental|Donepezil|
3256364|NCT01442766|Placebo Comparator|Placebo|
3375247|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Exploration|The dose-exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with enzalutamide.
3256365|NCT01442792|Active Comparator|Arm 1|
3256366|NCT01442792|Experimental|Arm 2|
3256367|NCT01442792|Experimental|Arm 3|
3256368|NCT01442792|Experimental|Arm 4|
3256369|NCT01442805|Experimental|RV|Cognitive Behavioral Therapy with Virtual Reality Exposures
3256370|NCT01442805|Experimental|IMAGO|Cognitive Behavioral Therapy with Exposure Therapy through Imagination
3256371|NCT01442818|Experimental|Scheduled IV post op|Patient's will receive scheduled nurse administered IV pain medications post operatively.
3256372|NCT01442818|Experimental|PCA post op|Patients will receive PCA for pain control post operatively.
3256373|NCT01442831|Experimental|Human ADME|
3256374|NCT01442857|Experimental|Block technique|"Active Comparator: Arm 1: catheter injection 40 ml of LA through the catheter~Active Comparator: Arm 2: catheter and transarterial injection 20 + 10 ml transarterial block and 10 ml through the catheter"
3256375|NCT01442870|Experimental|Metformin|Metformin
3256376|NCT01442870|No Intervention|No metformin|No metformin during primary endpoint assessment period (at least 3 weeks). Patients will subsequently be initiated on metformin.
3256377|NCT01442883||treatment resistant hypertensives with CKD 3-5|
3259940|NCT01475357|Active Comparator|Arm 2: Fresh Breast Milk pre-operative|2) Intervention - Trophic mother's own fresh (non-frozen) breastmilk gavage feeds via nasogastric tube every 3 hours at 10 cc/kg/day
3259941|NCT01475383|Active Comparator|PF-03654746|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
3259942|NCT01475383|Placebo Comparator|Placebo|Subjects are randomized to either active drug or placebo in Period 1; in Period 2 the sequence is reversed.
3259943|NCT01475396|Experimental|Aerobic Exercise|
3259944|NCT01475396|Experimental|Anaerobic Exercise|
3259945|NCT01475396|No Intervention|Unchanged condition|
3259946|NCT01475409|Experimental|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, tuberculin skin test (TST) and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset.
3259947|NCT01475422|Experimental|Conversation Maps Diabetes Education|
3259948|NCT01475422|Active Comparator|Usual Care|
3259949|NCT01475435|Active Comparator|chronic periodontitis|Saliva and GCF samples will be evaluated before and after treatment from patients treated of chronic periodontitis.
3259950|NCT01475435|Placebo Comparator|periodontally healthy individuals|Saliva and GCF samples will be evaluated from periodontally healthy individuals at baseline.
3259951|NCT01475435|Active Comparator|chronic periodontitis with diabetes type 2|Saliva and GCF samples will be evaluated before and after treatment from patients with diabetes type 2 treated of chronic periodontitis
3259952|NCT01475435|Placebo Comparator|periodontally healthy individuals with diabetes type 2|Saliva and GCF samples will be evaluated from periodontally healthy individuals with diabetes type 2 at baseline
3259953|NCT01475448|Experimental|Sedentary older adults - running|Sedentary older adults (60 years old or more) recruited from local community
3259954|NCT01475448|Active Comparator|Sedentary older adults - walking|Sedentary older adults (60 years old or more) recruited from local community
3259955|NCT01475526|Experimental|Intervention|El Valor de Nuestra Salud Store Intervention
3259956|NCT01475526|No Intervention|Control|No intervention. Business as usual
3259957|NCT01475539|Experimental|Group A (Sequential 1): IPV-OPV-OPV|Participants will receive 1 dose of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 2 doses of a commercially available Oral Poliovirus Vaccine (OPV)
3259958|NCT01475539|Experimental|Group B (Sequential 2): IPV-IPV-OPV|Participants will receive 2 doses of Sanofi Pasteur's injectable Inactivated Poliovirus Vaccine (IPV) followed by 1 dose of a commercially available Oral Poliovirus Vaccine (OPV)
3259959|NCT01475539|Experimental|Group C (Reference): OPV-OPV-OPV|Participants will receive 3 doses of a commercially available Oral Poliovirus Vaccine (OPV)
3259960|NCT01475552|Experimental|abciximab|
3259961|NCT01475552|Active Comparator|control|
3259962|NCT01475565||African-American women|Observational study--no intervention
3259963|NCT01475565||Caucasian women|Observational study--no intervention
3259964|NCT01475578|Experimental|STA-1|"STA-1 capsule (Cistanche tubulosa), 2 capsules/time, 3 times/day, orally~Dummy Ergoloid Mesylates tablet (Placebo), 2 tablets/time, 3 times/day, orally"
3259965|NCT01475578|Active Comparator|Ergoloid Mesylates|"Ergoloid Mesylates tablet, 2 tablets/time, 3 times/day, orally before meal~Dummy STA-1 capsule (Placebo), 2 capsules/time, 3 times/day, orally"
3259966|NCT01475591|No Intervention|Multimodal rehabilitation|The arm intervention is just multimodal rehabilitation.
3259967|NCT01475604|Active Comparator|Targeted pulsed electromagnetic field|
3259968|NCT01475604|Sham Comparator|Sham|
3259969|NCT01475617|Experimental|Novel Multivitamin/Mineral Supplement|These subjects will be given a novel multivitamin/mineral supplement post RYGB bariatric surgery for 6 months duration.
3259970|NCT01475617|Active Comparator|Standard of care supplement|These subjects will be given the standard recommended regimen at Johns Hopkins Bayview Medical Center post RYGB bariatric surgery for 6 months duration.
3259971|NCT01475630|Other|control|information, avoiding parafunctions
3259972|NCT01475630|Experimental|physical therapy|mobilisation, exercises ,..
3259973|NCT01475656||Levetiracetam as first line|Babies who receive levetiracetam as a first line drug for seizures
3259974|NCT01475656||Phenobarbital as first line|Babies who receive phenobarbital as a first line drug for seizures and levetiracetam as a second line drug
3259975|NCT01475669|Experimental|Fibrinogen Concentrate (Human)|
3259976|NCT01475669|Placebo Comparator|Placebo|
3259977|NCT01475682||1|"167 subjects recruited from our previous OSA and metabolic syndrome (OSAMS) cohort from October 2002 to June 2007 will be invited to be reassessed at this time point."
3259978|NCT01475695|Experimental|Single cohort|14C GSK2251052
3259979|NCT01475708||no symptoms|patients with erythema migrans and no additional newly onset symptoms treated with doxycycline
3259980|NCT01475708||mild symptoms|patients with erythema migrans and mild unspecific newly onset symptoms treated with doxycycline
3256378|NCT01442896||Primary Open Angle Glaucoma|"• Group A (diagnosis of primary open-angle glaucoma or pseudo-exfoliative glaucoma) - subjects with documented disease progression in the past and high IOP (IOP above target), disc hemorrhage, family history of glaucoma-related vision loss or thin central cornea (<510um),~Progression is confirmed with repeatable abnormal standard automated perimetry (SAP) or progressive glaucomatous optic neuropathy~For patients that have had previous glaucoma surgery, they can be included if they have had documented glaucomatous progression post-surgery~Best corrected visual acuity of 20/40 or better at enrollment"
3256379|NCT01442896||Healthy Individuals|"• Group B (healthy controls)- healthy subjects without any ophthalmic disease and an IOP < 22mmHg~o Normal appearing optic disc and no evidence of optic disc damage"
3375248|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with enzalutamide.
3375249|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Exploration|The dose exploration part of the study will estimate the MTD/recommended phase 2 dose (RP2D) of Acapatamab in combination with abiraterone.
3256380|NCT01442909|Active Comparator|D followed by P|Docetaxel 60 mg/m2 intravenous infusion (IV) day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles), followed by pemetrexed 500 mg/m2 IV day 1 every 3 weeks for 4-6 cycles (stable disease up to 4 cycles, partial or complete response up to 6 cycles).
3256381|NCT01442909|Active Comparator|P followed by D|"Pemetrexed treatment followed by docetael (in reverse sequence of Arm D followed by P"
3256382|NCT01442922||Human Meniscus Allograft (HMA)|Patients with degenerative disk disease at L3-L4, L4-L5, or L5-S1 scheduled to undergo surgery for (HMA) implantation to replace the nucleus pulposus.
3256383|NCT01442935|Active Comparator|Arm A1 : Folfiri + targeted therapy|"Every 2 weeks :~irinotecan 180 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3256384|NCT01442935|Active Comparator|Arm A2 : Folfox 4 + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3256385|NCT01442935|Experimental|Arm B : Folfirinox + targeted therapy|"Every 2 weeks :~oxaliplatin 85 mg/m² D1~irinotecan 150 mg/m² D1~Folinic acid 400 mg/m² D1~5FU 400 mg/m² bolus~5FU 2400 mg/m² infusion over 46 h, D1. From D7 to D12, prophylactic G-CSF such as Granocyte® will be administered.~And targeted therapy in function of Kras:~For mutated Kras = bevacizumab: 5 mg/kg IV on D1 of each cycle of chemotherapy, every 14 days~For non-mutated Kras = cetuximab : 500 mg/m² IV, on D1 of each cycle of chemotherapy, every 14 days."
3256386|NCT01442948||Acute coronary syndrome|
3256387|NCT01442948||Stable Angina|
3375250|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with abiraterone.
3375251|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Exploration|The dose-exploration part of the study will estimate the MTD/RP2D of Acapatamab in combination with AMG 404.
3375252|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Expansion|Following dose exploration, dose expansion will be conducted to confirm the safety and tolerability of the selected dose and to further evaluate the efficacy of Acapatamab in combination with AMG 404.
3375253|NCT04631601|Active Comparator|AMG 404 Monotherapy|AMG 404 monotherapy is being conducted to evaluate the preliminary anti-tumor activity of PD-1 inhibition in the mCRPC population.
3375254|NCT04631601|Experimental|Acapatamab and Enzalutamide: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with enzalutamide for subjects in Asia.
3375255|NCT04631601|Experimental|Acapatamab and Abiraterone: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with abiraterone for subjects in Asia.
3375256|NCT04631601|Experimental|Acapatamab and AMG 404: Dose Expansion Asia Cohort|Following dose exploration, dose expansion will be conducted in the Asia cohort at the combination MTD/RP2D determined in dose exploration to confirm the safety, tolerability and PK of Acapatamab in combination with AMG 404 for subjects in Asia.
3256388|NCT01442961|Active Comparator|laparoscopy|Intervention: Procedure: laparoscopy
3256389|NCT01442961|Active Comparator|vaginal|Intervention: Procedure: vaginal
3256390|NCT01442974|Experimental|Gemcitabine plus nab-paclitaxel|This is a single arm study.
3256391|NCT01442987|Experimental|Irbesartan/Atorvastatin A|
3256392|NCT01442987|Active Comparator|Irbesartan|
3256393|NCT01442987|Active Comparator|Atorvastatin A|
3256394|NCT01442987|Placebo Comparator|Placebo|
3256395|NCT01442987|Experimental|Irbesartan/Atorvastatin B|
3256396|NCT01442987|Active Comparator|Atorvastatin B|
3256397|NCT01443013||Cohort of Renal Transplant recipients|
3256398|NCT01443039|Experimental|phenotypical approach|phenotypical approach
3256399|NCT01443052||post-stroke patients|Stroke patients who had only one cerebrovascular accident, at least one year before inclusion and Able to walk without using assisting devices or ambulatory aids
3256400|NCT01443052||healthy subjects|Aged 65 to 80 years
3256401|NCT01443052||fallers|Reported 2 or more falls within 6 months prior to the beginning of the study and Able to walk without using assisting devices or ambulatory aids
3256402|NCT01443065|Active Comparator|Arm A : simplified Folfox 4|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn (2h) IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 followed by :~5-fluoro-uracil : 400 mg/m² in IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV infusion over 46 h"
3256403|NCT01443065|Experimental|Arm B : simplified FOLFOX 4 + panitumumab|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic acid : 400 mg/m² (racemic form) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y to oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m², IV bolus on D1, followed by :~5-fluoro-uracil : 2400 mg/m², IV infusion IV over 46 h~Panitumumab : 6 mg/kg de 60 à 90 mn ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the 1st infusion of panitumumab is well tolerated, the next infusions can be administered over 30 ± 10 mn."
3259981|NCT01475708||severe symptoms-lumbar puncture|"patients with erythema migrans and newly onset intense neurologic symptoms with lumbar puncture performed, treated with doxycycline"
3259982|NCT01475747||Observational - SPRINT trial subjects|Subjects in the Systolic Pressure Intervention Trial (SPRINT) observed to examine factors that affect atherosclerosis in chronic kidney disease
3259983|NCT01475760|Active Comparator|K2CG chewing gum (20 mg chitosan)|
3259984|NCT01475760|Active Comparator|K2CG chewing gum (60 mg chitosan)|
3259985|NCT01475760|No Intervention|Standard of Care|
3259986|NCT01475773||Adults (starting from age 17)|adults seeking orthodontic treatment at the university of Leuven
3259987|NCT01475786|Active Comparator|Low Dose 16mg VM202 and Placebo|intramuscular injections in each calf for a total of 16mg VM202: Day 0 - 32 injections / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf) and 16 injections of normal saline 0.5mL / calf Day 14 - 32 injections / calf and 16 injections of normal saline 0.5mL / calf 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
3259988|NCT01475786|Active Comparator|High Dose 32mg VM202|Day 0 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) Day 14 - 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf) For a total of 32mg VM202
3259989|NCT01475786|Placebo Comparator|Control - Placebo (normal saline)|32 injections / calf of 0.5 mL normal saline at Day 0 and Day 14
3259990|NCT01475799|Experimental|Percutaneous Aortic Valve 18F System|Evaluation of the Direct Flow Medical Percutaneous Aortic Valve 18F System for the Treatment of Patients with Severe Aortic Stenosis.
3259991|NCT01475812||COPD hyperinflation|
3259992|NCT01475864||Incomplete biliary stone extraction.|
3259993|NCT01475877||Nepafenac|
3259994|NCT01475890|Active Comparator|7000IU/day|29 subjects will be randomized to receive 7000IU/day of vitamin D3.
3259995|NCT01475890|Placebo Comparator|Placebo|29 subjects will be randomized to receive placebo.
3259996|NCT01475903||sleeve gastrectomy|
3259997|NCT01475929|Active Comparator|Probiotic low|Lower dose of probiotic supplement
3259998|NCT01475929|Placebo Comparator|Placebo|
3259999|NCT01475929|Active Comparator|Probiotic high|Higher dose of probiotic supplement
3260000|NCT01475942|Active Comparator|Probiotic|Lactobacillus
3260001|NCT01475942|Placebo Comparator|Placebo|Sucrose
3260002|NCT01475968|Active Comparator|Ultrafine Air Pollution Particulate Matter|<2.5 microns concentrated from outside ambient air
3260003|NCT01475968|Sham Comparator|Filtered Air|Filtered Air
3260004|NCT01475981|Experimental|Dose 1 JTK-853 (fasted condition)|
3260005|NCT01475981|Experimental|Dose 2 JTK-853 (fasted condition)|
3260006|NCT01475981|Experimental|Dose 3 JTK-853 (fasted condition)|
3260007|NCT01475981|Experimental|Dose 2 JTK-853 (fed condition)|
3260008|NCT01475981|Experimental|Dose 3 JTK-853 (fed condition)|
3260009|NCT01475981|Experimental|Dose 4 JTK-853 (fed condition)|
3260010|NCT01475981|Experimental|Dose 5 JTK-853 (fed condition)|
3260011|NCT01475981|Experimental|Dose 6 JTK-853 (fed condition)|
3260012|NCT01475981|Experimental|Dose 7 JTK-853 (fed condition)|
3260013|NCT01475981|Experimental|Dose 5 JTK-853 (high-fat fed condition)|
3260014|NCT01475981|Placebo Comparator|Placebo|
3260015|NCT01475994|Experimental|Challenge with grass pollen|
3260016|NCT01475994|Placebo Comparator|Challenge with clean air|
3260017|NCT01476007|Experimental|oral Cobalamin (vitamin B12)|oral Cobalamin (vitamin B12)
3260018|NCT01476007|Experimental|intramuscular Cobalamin (vitamin B12)|intramuscular Cobalamin (vitamin B12)
3260019|NCT01476020||no clopidogrel 6 months after DES|Patients with a single treatment antiplatelet therapy (aspirin) 6 months after drug-eluting stent implantation (Xience V Abbott company), including a 12-, 24- and 36-month follow-up analysis.
3260020|NCT01476020||2 antiplatelet therapy 2 years after DES|patients with dual antiplatelet therapy with clopidogrel and aspirin 24 months after drug-eluting stent implantation, including a 12-, 24- and 36-month follow-up analysis.
3260021|NCT01476033|Active Comparator|fruit, berry and vegetable concentrate|20 ladies receive an encapsulated, powdered fruit, berry and vegetable concentrate for 8 weeks
3260022|NCT01476033|Placebo Comparator|20 women with placebo|placebo for 8 weeks
3260023|NCT01476046|Experimental|GSK1995057|Single intravenous dose
3260024|NCT01476046|Placebo Comparator|Placebo|Single intravenous dose
3260025|NCT01476059|Other|telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
3260026|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
3260027|NCT01476072|No Intervention|no treatment|MRI scans only
3260028|NCT01476085|No Intervention|no treatment|no treatment
3260029|NCT01476098|Placebo Comparator|Arm 1|incremental doses capsaicin
3260030|NCT01476098|Active Comparator|Arm 2|incremenrtal doses casaicin
3260031|NCT01476111||Group 1|Patients with primary invasive breast cancer
3260032|NCT01476124|Experimental|Regimen A|Morphine placebo + GEn 600 mg
3260033|NCT01476124|Experimental|Regimen B|Morphine Extended release (60 mg) + GEn placebo
3260034|NCT01476124|Experimental|Regimen C|Morphine Extended release (60mg) + GEn 600 mg
3260035|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 1|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
3375257|NCT04631601|Experimental|Acapatamab Monotherapy|Acapatamab monotherapy is being conducted to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and efficacy of Acapatamab in subjects with mCRPC.
3375259|NCT04630977|Experimental|Multi-Ingredient Pre-workout Supplement|"This group of participants will intake a multi-ingredient supplement around ~15 minutes before every workout.~The nutritional information of the supplement is: ~90 Kcal. for 25g of powder: carbohydrates -isomaltulose, fructose, maltodextrin- 15 g, essential amino-acids -Beta-alanine: 2.5g, L-arginine AKG: 2.5g, L-Leucine: 800mg, Taurine: 500mg, L-citrulline: 500mg- 6.8 g, Creatine monohydrate: 2.0g, Guarana Extract: 800mg, total caffeine: 160mg, and Magnesium: 112.5mg.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
3375260|NCT04630977|Active Comparator|Isocaloric Placebo|"This group of participants will intake an isocaloric (only carbohydrates: Maltodextrin) supplement comparator, around ~15 minutes before every workout.~The nutritional information of the supplement is: ~90 Kcal. for 23g of powder.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
3375261|NCT04630977|Sham Comparator|Control|"These participants will drink a non-caloric admixture with the same taste, texture and flavour.~They will also follow a previously designed progressive resistance training (3 times a week, around 1 hour a day, consisting of different exercises).~Also, they will receive a specific guideline with simple tips to improve their nutritional patterns.~The training sessions and the nutritional guideline will be the same for the three groups."
3375262|NCT04623216|Experimental|Sabatolimab 400mg|Safety cohort 1: Participants in this arm will receive sabatolimab 400mg intravenously every 4 weeks.
3256404|NCT01443065|Experimental|Arm C : simplified FOLFOX 4 + AMG 102|"Every 2 weeks :~Oxaliplatin : 85 mg/m2 over 120 mn IV on D1~Folinic Acid : 400 mg/m² (racemic) (or 200 mg/m² with L-folinic acid) over 2 h IV on D1 (in Y/concomitant with oxaliplatin) followed by :~5-fluoro-uracil : 400 mg/m² IV bolus on D1 followed by :~5-fluoro-uracil : 2400 mg/m² in IV perfusion over 46 h~AMG 102 : 10 mg/kg over 60 ± 15 mn IV every 14 days, just before chemotherapy administration (oxaliplatin and folinic acid), on Day 1 of each cycle. If the first infusion is well tolerated (without severe infusion-related reactions), the following infusions can be administered over 30 ± 10 mn."
3256405|NCT01443091|Experimental|Colostrum|
3375263|NCT04623216|Experimental|Sabatolimab 800mg|Safety cohort 2: Participants in this arm will receive sabatolimab 800mg intravenously every 4 weeks.
3375264|NCT04623216|Experimental|Sabatolimab + Azacitidine|Expansion cohort 3: Participants in this arm will receive sabatolimab at the recommended dose for expansion in combination with azacitidine.
3375265|NCT04623216|Experimental|Sabatolimab|Expansion cohort 4: Participants in this arm will receive sabatolimab at the recommended dose for expansion.
3375266|NCT04623216|Experimental|Sabatolimab (adolescent cohort)|Adolescent safety cohort (cohort 5): ≥12 to < 18 year old adolescent participants in this arm will receive sabatolimab at the recommended dose for expansion.
3375268|NCT04615624|Experimental|Furosemide|When patient meets inclusion criteria and is randomized to treatment drug, she receives 40mg /4 milliliters (mL) IV furosemide in addition to usual antihypertensive.
3375269|NCT04615624|Placebo Comparator|Placebo|When patient meets inclusion criteria and is randomized to placebo, she receives one dose of 4mL normal saline in addition to usual antihypertensive.
3256406|NCT01443091|Placebo Comparator|Sterile water|
3256407|NCT01443104|Active Comparator|Orsiro Stent|Sirolimus-eluting Stent with a Biodegradable Polymer
3256408|NCT01443104|Active Comparator|Xience Prime Stent|Everolimus-eluting Stent with a Durable Polymer
3375270|NCT04613882|Experimental|Soft Toric Custom Made contact lenses|Subjects will be randomized to wear Soft Toric custom made contact lenses for 30 minutes in one eye with other eye patched.
3375271|NCT04613882|Active Comparator|Soft Spherical Contact Lenses|Subjects will be randomized to wear soft spherical contact lens for 30 minutes in one eye with other eye patched
3375272|NCT04613882|Active Comparator|Spectacle Correction|Subjects will be randomized to wear spectacle Correction for 30 minutes in one eye with other eye patched.
3375274|NCT04608955|Experimental|Arm A: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 150mg orally once daily for 2 weeks.
3375275|NCT04608955|Experimental|Arm B: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 300mg orally once daily for 2 weeks.
3375276|NCT04608955|Experimental|Arm C: WX-081|Participants with newly-treated drug sensitivity tuberculosis receive WX-081 450mg orally once daily for 2 weeks.
3375277|NCT04608955|Active Comparator|Arm D: Standard treatment|Participants with newly-treated drug sensitivity tuberculosis receive standard treatment for two weeks.
3256409|NCT01443117|Experimental|Step 1: PPV-23 Vaccine (Arm 1a)|Participants will receive one intramuscular (IM) injection of 0.5 mL of the PPV-23 vaccine at baseline.
3375278|NCT04608955|Experimental|Arm E: WX-081+MBT|Participants with drug-resistant tuberculosis receive WX-081 400mg orally once daily for 2 weeks, and then MBT+ WX-081 150mg orally once daily for 6 weeks.
3375279|NCT04608955|Active Comparator|Arm F: Bedaquiline+MBT|Participants with drug-resistant tuberculosis receive Bedaquiline 400mg orally once daily for 2 weeks, and then MBT+ Bedaquiline 200mg orally 3 times per week for 6 weeks.
3256410|NCT01443117|Experimental|Step 1: PCV-13 Vaccine (Arm 1b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine at baseline.
3256411|NCT01443117|Placebo Comparator|Step 1: Placebo Vaccine (Arm 1c)|Participants will receive one IM injection of 0.5 mL of the placebo vaccine at baseline.
3256412|NCT01443117|Experimental|Step 2: PPV-23 Vaccine (Arm 2a)|Participants will receive one IM injection of 0.5 mL of the PPV-23 vaccine 6 months after delivery.
3256413|NCT01443117|Experimental|Step 2: PCV-13 Vaccine (Arm 2b)|Participants will receive one IM injection of 0.5 mL of the PCV-13 vaccine 6 months after delivery.
3256414|NCT01443143|Experimental|Commercial diet|Commercially available diet program (i.e., Nutrisystem D) that includes pre-packaged low-glycemic index portion-controlled entrees and snacks that are supplemented with grocery items in accordance with a structured meal plan.
3256415|NCT01443143|No Intervention|Usual Diet|Participants' usual consumption of food and beverages.
3256416|NCT01443156||Caregivers|Employees at a local medical facility, including (but not limited to): nurses, laboratory technicians, non-clinical hospital staff
3256417|NCT01443169|Experimental|Sequence 1|
3256418|NCT01443169|Experimental|Sequence 2|
3256419|NCT01443169|Experimental|Sequence 3|
3256420|NCT01443169|Experimental|Sequence 4|
3256421|NCT01443182|Experimental|STAIR + MPE|A two-phased treatment with Skills Training in Affective and Interpersonal Regulation (STAIR) in Phase 1 en modified prolonged exposure (MPE) in Phase 2
3256422|NCT01443182|Active Comparator|STAIR + EMDR|a two-phase treatment Phase 1: Skills Training in Affective and Interpersonal Regulation (STAIR) Phase 2: Eye Movement Desensitization and Reprocessing (EMDR)
3256423|NCT01443195|Experimental|Iron suplementation|Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal
3256424|NCT01443208|Experimental|50 mg|
3256425|NCT01443208|Experimental|100 mg|
3256426|NCT01443208|Experimental|200 mg|
3256427|NCT01443221|Active Comparator|Free combination|Free combination of Mitiglinide 10mg and Metformin 500mg
3256428|NCT01443221|Experimental|Fixed-dose combination|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
3256429|NCT01443234|Experimental|OxIGen program|Internet based intervention taking place over 4 weeks
3256430|NCT01443234|Placebo Comparator|OxIGen: control version|A control version of the internet-based OxIGen intervention
3256431|NCT01443247|Experimental|platelet support + anti-d|
3256432|NCT01443247|No Intervention|platelet support|
3256433|NCT01443273||Infants with thrombotic events|All infants (premature and term) diagnosed at the Neonatal Intensive Care Unit with thrombotic events
3260036|NCT01476137|Experimental|Part 2A and 2B: GSK1120212 + GSK2110183 Dose Combination 2|One of two dose combination levels (GSK1120212+GSK2110183) based on data from Part 1 of the trial
3260037|NCT01476137|Experimental|Part 1: Cohort 1|GSK1120212 1.5mg + GSK2110183 50mg
3260038|NCT01476137|Experimental|Part 1: Cohort 2|GSK1120212 1.5mg + GSK2110183 100mg
3260039|NCT01476137|Experimental|Part 1: Cohort 3a|GSK1120212 2mg + GSK2110183 100mg
3260040|NCT01476137|Experimental|Part 1: Cohort 3b|GSK1120212 1.5mg + GSK2110183 125mg
3260041|NCT01476137|Experimental|Part 1: Cohort 4a|GSK1120212 2mg + GSK2110183 125mg
3260042|NCT01476137|Experimental|Part 2A: GSK1120212 2mg|Maximum tolerated dose of GSK1120212 as determined in prior single-agent trials
3260043|NCT01476137|Experimental|Part 2A; GSK2110183 125mg|GSK2110183 125mg
3260044|NCT01476137|Experimental|Part 2A: GSK2110183 MTD|Maximum tolerated dose (MTD) as determined in ongoing single agent trial PKB115340
3260045|NCT01476150||Dongcheng|
3260046|NCT01476150||Haidian|
3260047|NCT01476150||Xicheng|
3260048|NCT01476150||Chaoyang|
3260049|NCT01476150||Chongwen|
3260050|NCT01476150||Tongzhou|
3260051|NCT01476150||Fengtai|
3260052|NCT01476150||Xuanwu|
3260053|NCT01476176|Experimental|Experimental paracetamol formulation|experimental formulation
3260054|NCT01476176|Active Comparator|paracetamol marketed formulation|Paracetamol marketed formulation
3260055|NCT01476189|Experimental|Experimental paracetamol formulation|test formulation
3260056|NCT01476189|Active Comparator|Marketed paracetamol|Marketed paracetamol
3260057|NCT01476189|Active Comparator|Higher dose marketed paracetamol|higher dose marketed paracetamol
3260058|NCT01476215|Experimental|Fast dissolution suspension|
3260059|NCT01476215|Experimental|Medium dissolution suspension|
3260060|NCT01476215|Experimental|Slow dissolution suspension|
3260061|NCT01476215|Active Comparator|Marketed suspension|
3260062|NCT01476228|Experimental|study group|EEG recording
3260063|NCT01476241||EarNoseThroatGroup|a cohort of patients that had undergone PEG tube placement from October 2008 until October 2010 at the Department of Otorhinolaryngology - Head and Neck Surgery
3260064|NCT01476241||SurgeryGroup|a historic cohort group of patients with the PEG tube placed in the Department of Surgery from September 2005 until September 2009
3260065|NCT01476254||Cholecystectomy|Women scheduled for laparoscopic cholecystectomy
3260066|NCT01476254||Hysterectomy|Women scheduled for laparoscopic hysterectomy
3260067|NCT01476280|Sham Comparator|Palonosetron|
3260068|NCT01476280|Sham Comparator|Ramosetron|
3260069|NCT01476306|Placebo Comparator|In-patient care|
3260070|NCT01476306|Experimental|Telemedicine care|
3260071|NCT01476319|No Intervention|control|
3260072|NCT01476319|Experimental|video|
3260073|NCT01476332|Experimental|Group 1: Cis-UCA 0.5% eye drops|
3260074|NCT01476332|Experimental|Group 2: Cis-UCA 2.5% eye drops|
3260075|NCT01476332|Placebo Comparator|Group 3: Placebo for cis-UCA, eye drops|
3260076|NCT01476358|Active Comparator|Vitamin A|Capsule containing oil vehicle with Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
3260077|NCT01476358|Placebo Comparator|Placebo|Capsule containing oil vehicle withOUT Vitamin A (retinyl palmitate). Capsules are prepared by the manufacturer (Strides Arcolab Limited, India) and assigned blinded codes by World Health Organization officials.
3256434|NCT01443312||Thalassemia Intermedia Patients|Patients with Beta Thalassemia Intermedia treated at the Pediatric Hematology Unit. The characterization of Thalassemia Intermedia was based on age at diagnosis (Older than 2 ys) and / or clinical characteristics that are milder than Thalassemia Major in patients homozygous for beta globin genes.
3256435|NCT01443325|Experimental|lidocaine patch|
3256436|NCT01443338|Active Comparator|Triptergium Wilfordii|a kind of traditional chinese medicine
3256437|NCT01443338|Active Comparator|Acitretin|
3256438|NCT01443351||ITP patients|Patients with refractory ITP eligible for treatment with TPO-ra
3256439|NCT01443416|Experimental|13-valent pneumococcal conjugate vaccine|12 month booster dose of Prevenar
3256440|NCT01443416|Experimental|10-valent pneumococcal conjugate vaccine|12 month booster dose of Synflorix
3256441|NCT01443429|Experimental|subjects with normal renal function|
3256442|NCT01443429|Experimental|patients with mild renal impairment|
3256443|NCT01443429|Experimental|patients with moderate renal impairment|
3256444|NCT01443429|Experimental|patients with severe renal impairment|
3256445|NCT01443455|Experimental|VideoDance|
3256446|NCT01443455|Active Comparator|Brisk Walking|
3256447|NCT01443455|Other|Delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
3256448|NCT01443481|Experimental|TKI258 normal hepatic function|TKI258 Capsule, @ 500 mg p.o. o.d. 5 days on/2 days off
3256449|NCT01443481|Experimental|TKI258 mild hepatic impairment|TKI258 capsule @ 500 or 400 mg p.o. o.d. 5 days on/2 days off
3256450|NCT01443481|Experimental|TKI258 moderate hepatic impairment|TKI258 capsule @ starting dose at 400 mg p.o. o.d. 5 days on/2 days off
3256451|NCT01443481|Experimental|TKI258 severe hepatic impairment|TKI258 capsule Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
3256452|NCT01443507|Experimental|high intensity long interval|A group training four by four minutes interval at 90-95% of maximal heart rate dispersed by three minutes active pauses at 70% of maximal heart rate.
3256453|NCT01443507|Experimental|long duration at moderate training|a continuous training group exercising at 70% of maximal heart rate for 90 minutes.
3256454|NCT01443520|Placebo Comparator|Placebo|
3256455|NCT01443520|Active Comparator|Duloxetine|
3256456|NCT01443520|Active Comparator|Venlafaxine|
3256457|NCT01443533|Experimental|LARC script|Received routine postpartum counseling and LARC script.
3256458|NCT01443533|No Intervention|No LARC script|Received only routine postpartum counseling
3256459|NCT01443559|Experimental|Xenogenic cornea|
3256460|NCT01443559|Active Comparator|human cornea|
3256461|NCT01443572|Experimental|desflurane group|
3256462|NCT01443572|Active Comparator|sevoflurane group|
3256463|NCT01443611||Infants with first episode of Febrile Convlusions|
3256464|NCT01443624|Experimental|critical care patients venofer|Critically ill patients are injected with Venofer (ferric hydroxide sucrose) 100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
3256465|NCT01443637||Coronary CT Angiography (CCTA)|Patients included in the CONFIRM Registry are those that have previously undergone clinically-indicated CCTA as part of their standard of care.
3256466|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 1)|A single subcutaneous injection of Formulation A
3256467|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation B x 1)|A single subcutaneous injection of Formulation B
3256468|NCT01443650|Experimental|alirocumab SAR236553 (REGN727) (Formulation A x 2)|2 single subcutaneous injections of Formulation A
3256469|NCT01443663|Experimental|Group 1 (Previously Received H5N1 VN 04 ca Vaccine)|Participants will have previously received two doses of 10^7.5 tissue culture infectious dose (TCID)50 of H5N1 A/VN/1203/04 x A/AA/6/60 ca LAIV (H5N1 VN 04 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3260078|NCT01476371|Experimental|Mindfulness-based group treatment|8 group mindfulness sessions (1 per week), complemented by home mindfulness exercises
3260079|NCT01476371|No Intervention|Treatment as usual|Treatment as usual (including individual CBT and medication)
3260080|NCT01476384|Experimental|Glucose drink|75 gram glucose, dissolved in 250 ml water
3260081|NCT01476384|Placebo Comparator|Placebo|250 ml water
3260082|NCT01476397|Active Comparator|control infant formula|partially hydrolyzed whey infant formula
3260083|NCT01476397|Experimental|test infant formula|partially hydrolyzed whey infant formula with probiotic
3260084|NCT01476410|Experimental|Treatment (antibody-drug conjugate and combination chemo)|"LEAD-IN: Patients receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.~AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.~CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3260085|NCT01476423||A|
3260086|NCT01476436|Experimental|LCHF diet|Advice of a diet low in carbohydrate
3260087|NCT01476436|Active Comparator|Usual diet|Subjects shall continue to eat their usual daily diet with no low carbohydrate intervention
3260088|NCT01476462||ALL diagnosed 1980-2007|Cases of childhood acute lymphoblastic leukemia (ALL) diagnosed between 1980 and 2007 and included in the clinical trials of the participating ALL study groups
3260089|NCT01476488|No Intervention|Advagraf|single group, conversion of prograf to advagraf
3260090|NCT01476501|Experimental|2,000 IU/day vitamin D|2,000 IU/day vitamin D for 6 months (n=60).
3260091|NCT01476501|Experimental|40,000 IU/month vitamin D|40,000 IU/month for 6 months (n=60).
3256470|NCT01443663|Experimental|Group 2 (Previously Received H5N1 HK 03 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H5N1 A/HK/213/03 x A/AA/6/60 ca LAIV (H5N1 HK 03 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3256471|NCT01443663|Experimental|Group 3 (Previously Received H7N3 ca Vaccine)|Participants will have previously received two doses of 10^7.5 TCID50 of H7N3 A/ck/BC/CN-6/04 x A/AA/6/60 ca LAIV (H7N3 ca). In this study, they will receive one dose of the H5N1 vaccine at baseline.
3375280|NCT04606160|Experimental|Single Session Problem-Solving Intervention|Participants will receive a single session problem-solving intervention during visit 2 of the 4 visit research study. During visit 3, participants will receive a review of the intervention from visit 2. During visits 1, 3, and 4, participants will complete measures.
3375281|NCT04606160|No Intervention|Control - Non Single Session Problem-Solving Intervention|These participants will complete measures at visits 1,2,3, and 4. They will also receive a visit during visit 2 of the 4 visit study, where they will only complete measures.
3375282|NCT04600336|Experimental|Arm A (low-dose oxybutynin)|Patients receive low-dose oxybutynin chloride (2.5 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
3375283|NCT04600336|Experimental|Arm B (high-dose oxybutynin chloride)|Patients receive high-dose oxybutynin chloride (5.0 mL twice daily) PO BID on days 8-49 (6 weeks) in the absence of unacceptable toxicity.
3375284|NCT04600336|Placebo Comparator|Arm C (low-dose placebo)|Patients receive a low-dose placebo (2.5 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm A per physician discretion.
3375285|NCT04600336|Placebo Comparator|Arm D (high-dose placebo)|Patients receive a high-dose placebo (5.0 mL twice daily) PO BID on days 8-49 (6 weeks). After 6 weeks, patients may cross over to Arm C per physician discretion.
3256472|NCT01443663|Experimental|Group 4 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive one dose of the H5N1 vaccine at baseline.
3375290|NCT04596150|Experimental|ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative|CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer
3375291|NCT04596150|Experimental|ARM B - CX-2009 Monotherapy, TNBC|CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)
3375292|NCT04596150|Experimental|ARM C - CX-2009 Combination therapy, TNBC|CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC
3256473|NCT01443663|Experimental|Group 5 (Have Not Previously Received LAIV)|Participants will have not previously received an LAIV of any kind. In this study, they will receive two doses of the H5N1 vaccine at baseline and Day 28.
3256474|NCT01443676|Active Comparator|Radiotherapy|Radiotherapy
3256475|NCT01443676|Experimental|Radiotherapy plus Bevacizumab|Radiotherapy plus Bevacizumab
3256476|NCT01443689|Experimental|Group1 :Conventional plus hUCMSCs treatment|Participants will be given conventional therapy plus human cord mesenchymal stem cells transplantation with a 6 months follow-up.
3256477|NCT01443689|Experimental|Group 2: Conventional plus hCBMNCs and hUCMSCs therapy|Participants will be given conventional therapy plus combination of hCBMNCs together with hUCMSCs transplantation with a 6 months follow-up.
3256478|NCT01443689|Active Comparator|Group 3:Conventional therapy|Participants will be given conventional therapy only with a 6 months follow-up.
3256479|NCT01443702|Placebo Comparator|Placebo|
3256480|NCT01443702|Active Comparator|Lapis judaicus|
3256481|NCT01443715|Experimental|Stepped Care IPT-A - Interpersonal Psychotherapy|IPT-A focuses on communication and problem-solving skills.
3256482|NCT01443715|Active Comparator|Treatment as Usual|Treatment as Usual is the standard treatment received in the community
3256483|NCT01443728|Experimental|Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
3256484|NCT01443728|Active Comparator|Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
3256485|NCT01443741|Active Comparator|FIT Therapy|Patient with functional insulin therapy
3256486|NCT01443741|Active Comparator|Traditional way|Patient with traditional way
3375295|NCT04585815|Experimental|Sub-Study A|Sasanlimab will be administered subcutaneously. Encorafenib & binimetinib will be administered orally. Treatments will be administered until progressive disease, unacceptable AE, participant withdraws, or study is terminated.
3375296|NCT04585815|Experimental|Sub-Study B|Sasanlimab will be administered subcutaneously. Axitinib will be administered orally. SEA-TGT will be administered intravenously. Treatments will be administered until progressive disease, unacceptable AE, patient withdraws, or study is terminated.
3375297|NCT04579783|Active Comparator|Ultrasound intracarpal corticosteroid injection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~1st injection (0 week): 40mg triamcinolone acetonide (40mg/mL ) with 4mL normal saline, 2nd injection (6 week): 5 mL normal saline"
3375298|NCT04579783|Active Comparator|Ultrasound guided intracarpal dextrose hydro-dissection|"Twice ultrasound-guided hydro-dissection of median nerve at carpal tunnel level.~Group B: 1st injection (0 week): 5 mL 5% dextrose, 2nd injection (6 week): 5 mL 5% dextrose"
3375305|NCT04565717|Experimental|Part A: ALN-HSD|Participants will be administered a single dose of ALN-HSD.
3375306|NCT04565717|Placebo Comparator|Part A: Placebo|Participants will be administered a single dose of ALN-HSD-matching placebo.
3375307|NCT04565717|Experimental|Part B: ALN-HSD|Participants will be administered multiple doses of ALN-HSD.
3375308|NCT04565717|Placebo Comparator|Part B: Placebo|Participants will be administered multiple doses of ALN-HSD-matching placebo.
3375309|NCT04562194|Other|Intervention|NeVa Stent Retriever
3375310|NCT04561518||Patients with ATTR amyloidosis|Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
3375311|NCT04561518||Pre-symptomatic Carriers|Pre-symptomatic carriers with a known disease-causing TTR mutation will be eligible for the study and will follow routine clinical care.
3256487|NCT01443754||Hybrid group|Patients with multi-vessel coronary artery disease (CAD) amenable to hybrid revascularization (LIMA-LAD surgical revascularization followed by PCI)
3256488|NCT01443767||Partial liver resection|Adult patients scheduled for elective partial liver resection
3256489|NCT01443780|Experimental|sellenium + Q10|Active dietary supplement that is compared against a placebo arm
3256490|NCT01443780|Placebo Comparator|Sugar pills|Placebo arm that is compared against active intervention with a dietary supplement with selenium + Q10
3375314|NCT04559347|Experimental|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine|Single Shot Liposomal Bupivacaine (EXPAREL®)/Bupivacaine for erector spinae block as local anesthetic
3375315|NCT04559347|Active Comparator|Continuous catheter infusion ropivacaine|Ropivacaine (0.5% bolus followed by 0.2% infusion) using a continuous catheter for erector spinae plane block as local anesthetic
3375316|NCT04558918|Experimental|LNP023 monotherapy|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
3375317|NCT04558918|Active Comparator|anti-C5 antibody treatment|Participants will be randomized to one of the two treatment arms in a 8:5 ratio to either LNP023 monotherapy at a dose of 200 mg orally b.i.d. (approximately 56 participants), or i.v. anti-C5 antibody treatment (approximately 35 participants continuing with the same regimen during the randomized treatment period as they were on prior to randomization), respectively.
3375318|NCT04558619|Other|Kōmmour Prenatal|
3375319|NCT04558593||active surveillance|220 participants will be included in the active surveillance group. Active surveillance is close monitoring (every 6 months the first 3 years following diagnosis and annually the following years), done per standard of care Close monitoring include: abdominal imaging (ultrasound, CT or MRI), chest X-ray or CT scan and blood tests
3375320|NCT04558593||surgery|110 participants will be included in the surgery group. Surgery is done per standard of care. The type of surgery is at the discretion of the treating physician and may include: partial resection, total resection, thermoablation.
3375321|NCT04557956|Active Comparator|ARM I (tazemetostat) phase II|Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At the time of progression, patients may crossover to Arm II after completion of radiation therapy.
3256491|NCT01443806|Experimental|Oseltamivir, genetic testing|
3256492|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|
3256493|NCT01443819|Other|Physical Therapy|
3256494|NCT01443819|Other|Cohort observational|
3256495|NCT01443832||iron absorption|
3375322|NCT04557956|Experimental|ARM II (tazemetostat, dabrafenib, trametinib) phase I/phase II|Patients receive tazemetostat orally PO BID, dabrafenib PO BID, and trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3375323|NCT04557618|Experimental|Auricular VNS Stimulation|Participants receive twice daily auricular vagal nerve stimulation
3256496|NCT01443871|Experimental|Aromatherapy|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the odor for 10 minutes as during inhalation. The last part, the odor was dispersed and assessed EEG activity for 10 minutes as after inhalation.
3256497|NCT01443871|Placebo Comparator|Pure water|Experimental procedures were conducted in the morning. Subjects individually entered the closed room where the temperature was kept at 25-26 oC and humidity 50-60%. The subjects were blinded using mask and were seated comfortably with eyes closed during experimental period. The EEG was recorded using silver electrodes. EEG activity was monitored 4 areas (F7, F8, T3 and T4) and ground electrodes. The experiments were divided into 3 parts. The first part, no-odor were recorded EEG activity for 10 minutes as a baseline. The second part, subject was exposure to the water for 10 minutes as during inhalation. The last part, the water was dispersed and assessed EEG activity for 10 minutes as after inhalation.
3256498|NCT01443884|Experimental|Group 1|After a 1 week baseline, volunteers will consume two packets of grape powder stirred into water for three weeks. Each packet will contain the equivalent of approximately 2 servings of fresh grapes (46 grams of powder). Following a two week washout period, volunteers will cross-over to a placebo powder.
3256499|NCT01443884|Experimental|Group 2|After a 1 week baseline, volunteers will consume two packets of placebo powder stirred into water for three weeks. Following a two week washout period, volunteers will cross-over to grape powder for three weeks.
3256500|NCT01443897|Placebo Comparator|Group 1|Untreated mushrooms plus placebo capsule.
3375324|NCT04557618|Sham Comparator|Sham Auricular VNS Stimulation|Participants will have an auricular vagal nerve stimulator applied twice daily, without the stimulation applied
3375325|NCT04555915||Intervention group|Intervention Group of the SafeboosC Phase III Trial
3375326|NCT04555915||Control group|Control Group of the SafeboosC Phase III Trial
3375327|NCT04554966|Experimental|Part A: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Day 1.
3375328|NCT04554966|Experimental|Part A: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Day 1.
3375329|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose A|Participants will receive intravenous (IV) ABBV-382 dose A on Days 1, 29 and 57.
3256501|NCT01443897|Experimental|Group 2|UVB-treated mushrooms (400 IU vitamin D2 per serving) plus placebo capsule.
3256502|NCT01443897|Experimental|Group 3|UVB-treated mushrooms (1,000 IU vitamin D2 per serving) plus placebo capsule.
3375330|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose A|Participants will receive intravenous (IV) placebo for ABBV-382 dose A on Days 1, 29 and 57.
3375331|NCT04554966|Experimental|Part B: Intravenous Cohort: ABBV-382 Dose B|Participants will receive intravenous (IV) ABBV-382 dose B on Days 1, 29 and 57.
3375332|NCT04554966|Experimental|Part B: Subcutaneous Cohort: ABBV-382|Participants will receive subcutaneous (SC) ABBV-382 dose C on Days 1, 29 and 57.
3375333|NCT04554966|Placebo Comparator|Part B: Intravenous Cohort: Placebo for ABBV-382 Dose B|Participants will receive intravenous (IV) placebo for ABBV-382 dose B on Days 1, 29 and 57.
3375334|NCT04551066|Experimental|Group A : parsaclisib + ruxolitinib|Participants will receive parsaclisib and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
3375335|NCT04551066|Placebo Comparator|Group B : placebo + ruxolitinib|Participants will receive placebo and ruxolitinib starting from Day 1 for the duration of study, ruxolitinib dose will be determined by baseline platelet count.
3375336|NCT04551053|Experimental|Group A : ruxolitinib +parsaclisib|Participants will receive parsaclisib starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
3375337|NCT04551053|Placebo Comparator|Group B : ruxolitinib + placebo|Participants will receive placebo starting from Day 1 for the duration of study, while continuing to receive the stable dose of ruxolitinib they were taking for the 8 weeks prior to Day 1.
3375338|NCT04543617|Experimental|Arm A: Tiragolumab + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab.
3375339|NCT04543617|Experimental|Arm B: Tiragolumab Placebo + Atezolizumab|Participants will receive atezolizumab followed by tiragolumab matching placebo.
3375340|NCT04543617|Placebo Comparator|Arm C: Tiragolumab Placebo + Atezolizumab Placebo|Participants will receive matching placebos to tiragolumab and atezolizumab.
3256503|NCT01443897|Experimental|Group 4|Untreated mushrooms plus 1,000 IU Vitamin D2 in capsule
3256504|NCT01443962|Experimental|Zero positive end expiratory pressure|Number: 30, apply no PEEP during the pneumoperitoneum during the laparoscopic cholecystectomy PEEP was not applied whole investigation period
3256505|NCT01443962|Active Comparator|positive end expiratory pressure|applying PEEP 10 cmH2O during pneumoperitoneum continuously
3256506|NCT01443975||All patients|Measurement with x-pander in acetabulum prior to inserting the artificial hip socket.
3256507|NCT01443988|Active Comparator|iStent|Implantation of two iStent devices
3256508|NCT01443988|Active Comparator|Drug|Travoprost drops
3256509|NCT01444001|Experimental|Pneumococcal Vaccine Dose 1 (Low dose)|Participants will receive 2 injections of Dose 1 investigational Pneumococcal vaccine (Low dose) on Day 0 and Day 30, respectively.
3256510|NCT01444001|Experimental|Pneumococcal Vaccine Dose 2 (Middle dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (Middle dose) on Day 0 and Day 30, respectively.
3256511|NCT01444001|Experimental|Pneumococcal Vaccine Dose 3 (High dose)|Participants will receive 2 injections of the investigational Pneumococcal vaccine (High dose) on Day 0 and Day 30, respectively.
3375341|NCT04543409|Experimental|Benralizumab|Benralizumab active solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
3375342|NCT04543409|Placebo Comparator|Placebo|Placebo solution will be administered SC to patients by healthcare professionals in this clinical study using an accessorized prefilled syringe (APFS)
3375343|NCT04541992||Airborne Group|Participants in this group will be tested for balance and agility within a 20 minute time frame.
3375344|NCT04538144||Younger participants|Individuals aged 18-39 years
3375345|NCT04538144||Older participants|Individuals aged 65 years or older
3375346|NCT04536688|Experimental|RGLS4326 1 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 1 mg/kg of RGLS4326 every other week for 4 doses
3375347|NCT04536688|Experimental|RGLS4326 0.3 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.3 mg/kg of RGLS4326 every other week for 4 doses
3375348|NCT04536688|Experimental|RGLS4326 0.1 or 0.5 mg/kg Q2W|Eligible participants will receive subcutaneous injection of 0.1 or 0.5 mg/kg of RGLS4326 every other week for 4 doses
3375351|NCT04533737|Experimental|Arm 1 (brodalumab + dummy 1)|"Participants receive:~Brodalumab 210 mg (1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks.~Dummy 1 (placebo 1.0 ml) at Weeks 0, 4, and then every 8 weeks."
3375352|NCT04533737|Active Comparator|Arm 2 (guselkumab + dummy 2)|"Participants receive:~Guselkumab 100 mg (1.0 ml) at Weeks 0, 4, and then every 8 weeks.~Dummy 2 (placebo 1.5 ml) at Weeks 0, 1, 2, and then every 2 weeks."
3375353|NCT04531462|Experimental|Empagliflozin|
3375354|NCT04531462|Placebo Comparator|Placebo|
3375355|NCT04528199|Experimental|[18F]FLOR (FC303)|[18F]FLOR (FC303) PET/CT imaging.
3375356|NCT04527185|Experimental|Endotoxin|Endotoxin (0.4ng/kg i.v.) will be administered one time during the laboratory session.
3375357|NCT04527185|Placebo Comparator|Placebo|Administered one time during the laboratory session.
3375364|NCT04524611|Experimental|Risankizumab Dose A Followed by Dose B|Participants will receive intravenous risankizumab dose A at Week 0, 4 ,8 followed by subcutaneous (SC) risankizumab dose B every 8 weeks through Week 48. Participants who complete the Week 48 visit will continue SC risankizumab for up to an additional 220 weeks.
3375365|NCT04524611|Active Comparator|Ustekinumab|Participants will receive weight-based intravenous ustekinumab at Week 0 followed by subcutaneous ustekinumab every 8 weeks through Week 48.
3375366|NCT04524195|Experimental|[18F]F-AraG|A one-time nominal injection dose of 5 millicurie (mCi) +/- will be administered at each PET/CT imaging time point.
3375367|NCT04523857|Experimental|A (Abema)|Abemaciclib (150 mg BID)
3375368|NCT04523857|Experimental|B (Abema + HCQ)|"Abemaciclib (100 mg or 150 mg BID*) + Hydroxychloroquine (600 mg BID)~*Abemaciclib dose will be determined by safety cohort"
3375369|NCT04521231|Experimental|Blinatumomab: Dose escalation|Cohorts of at least 3 participants each will be treated with escalating doses of blinatumomab to determine the maximum tolerated dose (MTD). The MTD will be defined as the dose for which the estimate of the toxicity rate from an isotonic regression (Yan et al, 2017) is closest to the target toxicity rate. Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy will be assessed.
3375370|NCT04521231|Experimental|Blinatumomab: Dose expansion|Participants will be administered the recommend phase 2 dose (RP2D) determined from dose escalation stage to further assess safety, pharmacokinetics (PK), pharmacodynamic (PD), and efficacy.
3375371|NCT04519216|Active Comparator|Traditional education|Participants in the control group will complete an online unfolding case scenario. Then these same participants will participate in a videoconferencing case based lecture with the academic pediatric fellow
3375372|NCT04519216|Experimental|Telesimulation|Participants in the intervention group will complete an online unfolding case scenario. Then these participants will complete a telesimulation case with a standardized patient via video conferencing.
3375373|NCT04514510|Experimental|ISO|Subjects with sickle cell disease; Isoquercetin 1000mg once daily 28 days.
3375374|NCT04514510|Placebo Comparator|Placebo|Subjects with sickle cell disease; placebo once daily fr 28 days.
3256512|NCT01444014|Experimental|YF476|
3256513|NCT01444040|Active Comparator|iStent inject|Implantation of two iStent inject devices
3256514|NCT01444040|Active Comparator|Drug|Travoprost drops
3256515|NCT01444053||Wearers of contact lenses without UV Protection|Subjects who have worn a soft contact lens without UV protection for the past five years or more.
3375377|NCT04506892||Adept Meditators|Subjects will undergo scanning during awake, sleep deprived, and meditative states of consciousness.
3256516|NCT01444053||Wearers of contact lenses with UV Protection|Subjects who have worn a soft contact lens with UV protection for the last 5 years or more.
3256517|NCT01444066|Placebo Comparator|dilation to 27 French|
3256518|NCT01444066|Experimental|Dilation of the esophagus to 54 French|Esophagus will be dilated with a Savory dilator
3256519|NCT01444079||Liver transplant recipients|Recipients who will undergo liver transplantation during study period
3256520|NCT01444105|Active Comparator|iStent|implantation of two iStent devices
3256521|NCT01444105|Active Comparator|SLT|Laser treatment
3256522|NCT01444118|Experimental|EGF Vaccine|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
3256523|NCT01444118|No Intervention|Best Supportive Care|Patients in this arm will receive best supportive care
3375378|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - NHL|Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Mantle Cell Lymphoma (MCL), large cell lymphoma (LCL), and peripheral T-cell lymphoma (PTCL). Subjects must have relapsed or be refractory to at least 2 prior lines of therapy and have either failed or were not eligible for any available therapies expected to provide clinical benefit.
3375379|NCT04500587|Experimental|Znd5 Single Agent Dose Escalation - AML|Subjects with relapsed and/or primary refractory AML as defined by WHO 2016 revised criteria, who have either relapsed or are refractory to previously available therapy.
3375381|NCT04478344|Experimental|Ultrasound guided hydrodissection to superior cluneal nerve|Ultrasound guided perineural injection with 5% dextrose 4 c.c. + 1% xylocaine 1 c.c. to superior cluneal nerve of affected side.
3256524|NCT01444131|Placebo Comparator|Varenicline and Placebo Patch|Varenicline and Nicotine Patch (placebo)
3256525|NCT01444131|Active Comparator|Varenicline and Nicotine Patch|Varenicline and Nicotine Patch 15mg
3256526|NCT01444144||Ankle Fracture|Patients aged 55 years at time of surgery undergoing treatment for ankle fractures.
3375382|NCT04476251|Experimental|Arm 1/E7 T-Cell Receptor (TCR) T Cell Therapy|E7 TCR T Cell Therapy
3375383|NCT04474054|Experimental|FARAPULSE Ablation System Plus|Ablation using the FARAPULSE Ablation System Plus
3256527|NCT01444157|Experimental|Palliative homecare nursing group|In addition to the standard homecare nursing the families will receive six home visits from a research nurse with at least 1 year specialised palliative care experience. During the first 2 hour visit a family assessment is obtained containing identification of family roles, resources and coping strategies. The first home visit takes place no later than one week after randomization. The visits continues every third week up to 16 weeks, each visit with a duration of 1,5 hours. At every visit the EORTC-QLQ-C30 patient administered questionnaire is used to identify the nature, frequency and intensity of the patients physical and psychosocial problems.
3256528|NCT01444157|No Intervention|Standard homecare nursing group|Patients continue to receive the standard homecare nursing. They can contact municipality services for visitation to homecare nursing if they feel that additional homecare is needed or if they do not yet receive this service and feel they need homecare nursing.
3375384|NCT04471844|Experimental|Optune® + RT + TMZ for 6 weeks|Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
3375385|NCT04471844|Active Comparator|RT +TMZ for 6 weeks|RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression or 24 months.
3375386|NCT04469023|Experimental|TS-142 2.5 mg|Period in which participants received multiple-dose of 2.5 mg TS-142 prior to bedtime
3375387|NCT04469023|Experimental|TS-142 5 mg|Period in which participants received multiple-dose of 5 mg TS-142 prior to bedtime
3375388|NCT04469023|Experimental|TS-142 10 mg|Period in which participants received multiple-dose of 10 mg TS-142 prior to bedtime
3375389|NCT04469023|Experimental|Placebo|Period in which participants received single placebo prior to bedtime
3375390|NCT04458181|Experimental|Treatment Group|Participants in this group will complete the intervention, Positive Peer Journaling (PPJ), while also continuing to attend intensive outpatient treatment for addiction.
3375391|NCT04458181|No Intervention|Control Group|There will be no intervention for those randomized to the control group. However, they will complete assessment instruments throughout the study period while also continuing to attend intensive outpatient treatment for addiction.
3375392|NCT04455750|Experimental|Arm I (enzalutamide, rucaparib)|Patients receive enzalutamide PO QD and rucaparib PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3375393|NCT04455750|Active Comparator|Arm II (enzalutamide, placebo)|Patients receive enzalutamide PO QD and placebo PO BID. Patients who did not undergo bilateral orchiectomy also receive ADT consisting of leuprolide acetate IM, goserelin acetate SC every 12 weeks or degarelix SC. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3256529|NCT01444170|Placebo Comparator|Sugar pill|"Placebo sugar pill was used as a sham control"
3256530|NCT01444170|Experimental|dicreatinol sulfate|
3256531|NCT01444183|Active Comparator|Progressive muscle relaxation|Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM
3256532|NCT01444183|Sham Comparator|Sham exercise|Subjects practice a sham exercise consisting of focused attention activities
3256533|NCT01444196|Other|Desloratadine dose|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
3256534|NCT01444196|Other|Dose of Desloratadine|"Study group: 5 mg Desloratadine during the whole study~Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4."
3256535|NCT01444222||Pulmonary Hypertension|
3256536|NCT01444222||pulmonic valve stenosis|
3256537|NCT01444222||pulmonic valve homograft|
3375398|NCT04446468|Experimental|PEACE|The PEACE intervention will be delivered by a trained mental health staff member, such as a study psychologist, mental health nurse, social worker, or psychiatrist. The intervention consists of three synergistic components that work to support the patient after inpatient psychiatric discharge: 1) Brief educational component, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study psychologist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed; and 3) Mobile app, which aims to improve the patient's social connectedness and provide additional educational materials on suicide. Patients in this arm will also continue to receive standard post-discharge psychiatric care.
3375399|NCT04446468|Experimental|Control|Those randomized to the control arm will receive standard psychiatric hospital discharge care alone. Current VA standard discharge care includes five core elements. First, patients and their outpatient providers are required to be involved in discharge planning. Second, patients should be offered evidence-based treatments to address their mental health symptoms. Third, the inpatient team should work with the patient to complete a safety plan prior to discharge. Fourth, the inpatient team should arrange two follow-up care visits within 30 days of discharge. Fifth, the inpatient team in conjunction with the SPC assess whether patients are appropriate to be placed on the High Risk for Suicide List. Patients who are placed on the High Risk for Suicide List receive enhanced oversight as outlined in VA policy.
3375400|NCT04439110|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3375401|NCT04435600|Experimental|Part 1: Risankizumab Dose A|Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.
3375402|NCT04435600|Experimental|Part 2: Ustekinumab Dose A/B/C then Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Ustekinumab Dose A, Dose B, or Dose C based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Risankizumab Dose A or B based on body weight for 24 weeks."
3256538|NCT01444222||pulmonic valve insufficiency|
3256539|NCT01444222||atrial septum defect|
3256540|NCT01444222||Ebstein's anomaly|
3256541|NCT01444222||transvalvular right ventricular lead|
3256542|NCT01444222||control|
3256543|NCT01444235|Active Comparator|Custodiol|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
3256544|NCT01444235|Experimental|Custodiol-N|After cross clamping of the aorta on cardiopulmonary bypass, the Custodiol-N solution, at a temperature of 4 - 6°C, will be infused antegrade into the root of the aorta.
3256545|NCT01444248|Experimental|Amaryl MEX|
3256546|NCT01444248|Active Comparator|Amaryl M|
3256547|NCT01444261|Active Comparator|Intervention|Fer-in-Sol drops and iron-fortified cereal
3375403|NCT04435600|Experimental|Part 2: Risankizumab Dose A/B|"Participants age 12 to less than 18 will receive:~Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).~Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare.~Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4)."
3375404|NCT04435600|Experimental|Part 3: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
3375405|NCT04435600|Experimental|Part 4: Risankizumab Dose A/B|Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.
3375406|NCT04430140||1|"CT Scan~Number of research exams: 1 Effective Dose (mSv) for 1 exam: 0.6 Total Effective Dose (mSv)*: 0.6"
3256548|NCT01444261|Other|Control|No intervention
3256549|NCT01444274||Obalon Gastric Balloon|One or two balloons administered to each patient
3256550|NCT01444313|Other|nelfilcon A OD / narafilcon A OS|Soft contact lens without UV protection worn on the right eye (OD) and soft contact lens with UV protection worn on the left eye (OS).
3256551|NCT01444313|Other|narafilcon A OD / nelfilcon A OS|Soft contact lens with UV protection worn on the right eye (OD) and soft contact lens without UV protection worn on the left eye (OS).
3256552|NCT01444326|Experimental|Dairy diet|
3256553|NCT01444326|Placebo Comparator|Control diet|
3256554|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 1|Participants will receive an injection of pneumococcal vaccine (Formulation 1, 1 middle dose) on Day 0 and Day 30, respectively.
3256555|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 2|Participants will receive an injection of Pneumococcal vaccine (Formulation 2, 2 low doses) on Day 0 and Day 30, respectively.
3256556|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 3|Participants will receive an injection of pneumococcal vaccine (Formulation 3, 2 middle doses) on Day 0 and Day 30, respectively.
3256557|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 4|Participants will receive an injection of pneumococcal vaccine (Formulation 4, 2 middle doses) on Day 0 and Day 30, respectively.
3256558|NCT01444339|Experimental|Pneumococcal Vaccine Formulation 5|Participants will receive an injection of pneumococcal vaccine (Formulation 5, 2 high doses) on Day 0 and Day 30, respectively.
3256559|NCT01444339|Placebo Comparator|Pooled placebo Group|Participants will receive an injection of a placebo on Day 0 and Day 30, respectively.
3256560|NCT01444352|Experimental|Vaccine Formulation 1 (Low dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).
3256561|NCT01444352|Experimental|Vaccine Formulation 2 (Middle dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).
3256562|NCT01444352|Experimental|Vaccine Formulation 3 (High dose)|Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).
3256563|NCT01444352|Placebo Comparator|Placebo Pooled|Participants who receive 2 injections of tris buffered saline
3256564|NCT01444365|Experimental|ABT-652 NSAID|ABT-652 capsules -2 ABT-652 capsules twice daily (add-on) NSAID - as prescribed
3375407|NCT04415372||Cognitive Impairment|Adults diagnosed with MS that have evidence of cognitive decline.
3375408|NCT04415372||No Cognitive Impairment|Adults diagnosed with MS that have no evidence of cognitive decline.
3375409|NCT04415372||Healthy Controls|Healthy adult volunteers will form a control group matched for age, gender, education, handedness
3375412|NCT04408794|Experimental|Vazegepant (BHV-3500)|10 mg intranasal (IN) up to 8 times per month, up to 1 year
3375420|NCT04380753|Experimental|Treatment Arm|Subjects will be enrolled and will receive AMG 510 PO QD.
3375421|NCT04379570|Experimental|Arm I (TMR)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive daily text message reminders to take their ET medication and monthly text messages about how they are doing with taking their ET medication. These text messages continue for 9 months.
3375422|NCT04379570|Experimental|Arm II (MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive a total of 5 motivational interviewing counseling sessions via telephone over 30-90 minutes for up to 9 months. These sessions are designed to support patients while they take their ET medication, develop health goals, and stay on track in achieving those goals.
3375423|NCT04379570|Experimental|Arm III (TMR + MI)|Patients receive online educational information about ET at the start of their ET medication. Patients also receive text messages as in Arm I and motivational interviewing counseling sessions as in Arm II.
3375424|NCT04379570|Active Comparator|Arm IV (enhanced usual care)|Patients attend usual care clinic visits every 3-6 months and receive online educational information about ET at the start of their ET medication. Patients also receive optional online information about living a healthy life after breast cancer.
3375425|NCT04377672|Experimental|Anti- SARS-CoV-2 Plasma|Human Convalescent Plasma
3375426|NCT04376268|Active Comparator|Chlorhexidine gluconate|Chlorhexidine is one of the most commonly used medications after tooth extraction. It exhibits a wide spectrum of antiseptic, bactericidal and bacteriostatic effects.
3375427|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3256565|NCT01444365|Placebo Comparator|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID - as prescribed
3256566|NCT01444404|Experimental|Dose Expansion|The dose expansion will consist of up to 20 subjects and the dose level of AMG 820 will be dependent upon emerging safety and PK data from the dose escalation part of the study.
3256567|NCT01444404|Experimental|Dose Escalation|The dose escalation part of the study is aimed at evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 820.
3375428|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (0.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3256568|NCT01444443|Experimental|Closed-loop glucose control|Blood glucose controlled by control algorithm.
3256569|NCT01444443|Active Comparator|Open-loop glucose control|Blood glucose controlled by patient
3256570|NCT01444469|Experimental|Azithromycin (Zithromax)|500 mg of azithromycin (2×250mg capsules)
3256571|NCT01444469|Placebo Comparator|Placebo|Placebo
3256572|NCT01444482|Experimental|Matrix M adjuvanted influenza vaccine|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M
3256573|NCT01444482|Active Comparator|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
3256574|NCT01444495|Active Comparator|Short time interval|Patients operated on 7-10 days after completing preoperative radiotherapy 5x5Gy.
3256575|NCT01444495|Experimental|Long time interval|Patients operated on 4-5 weeks after completing preoperative radiotherapy 5x5Gy.
3256576|NCT01444508|Active Comparator|crystalloid|
3256577|NCT01444508|Placebo Comparator|colloid|
3256578|NCT01444521|Experimental|single-arm Irinotecan-Cisplatin|
3256579|NCT01444534|Experimental|use of the diabetes application|
3256580|NCT01444534|Active Comparator|Control arm without app (usual care)|
3256581|NCT01444547|Experimental|single-arm Paclitaxel-Cisplatin|
3256582|NCT01444560||Cutaneous Melanoma|
3256583|NCT01444560||Cutaneous Melanoma Metastases|
3256584|NCT01444560||Benign Melanocytic Nevi|
3375429|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3375430|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (1.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3256585|NCT01444573|Active Comparator|Group 2 (Lenient control <120bpm)|
3256586|NCT01444573|Active Comparator|Group 1 (Strict control <80 bpm)|
3256587|NCT01444586||Group 1|
3375431|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3375432|NCT04376268|Active Comparator|Chlorhexidine mouthwash with boric acid (2.5%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3375433|NCT04376268|Active Comparator|Boric acid mouthwash (2%)|Due to its antibacterial properties, boric acid is effective on gram (+) and gram (-) microorganisms such as candida albicans, streptococcus mutans, staphylococcus aureus, enterococcus faecalis, enterococcus faesium, escherichia coli, klebsiella pneumonia and pseudomonas aeruginosa. With these features, it is used in periodontology, endodontics and restorative therapy as a antiseptic.
3256588|NCT01444599||low FFR group (<0.8)|the patient with FFR values less than 0.8
3375434|NCT04375631|Experimental|Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)|"Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC > 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.~GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD."
3375435|NCT04375332|Experimental|HARPOON™ Beating Heart Mitral Valve Repair System|Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
3256589|NCT01444599||high FFR group (>0.8)|the patient with FFR values greater than 0.8
3256590|NCT01444612||Cancer-related surgery patient records|Healthcare claims records from patients aged 18 years or older with at least one primary inpatient discharge diagnosis of cancer and a cancer-related surgery during the hospitalization
3256591|NCT01444625|Experimental|Dark chocolate|Flavanol-rich chocolate
3256592|NCT01444625|Placebo Comparator|Placebo chocolate|Flavanol-free chocolate
3375438|NCT04362748|Experimental|Dose Escalation Phase|Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.
3375439|NCT04362748|Experimental|Dose Expansion Phase: Group 1|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
3375440|NCT04362748|Experimental|Dose Expansion Phase: Group 2|Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.
3375441|NCT04362254|Experimental|Spesolimab arm|
3375442|NCT04361955|Other|PD with DBS on|intervention is EEG while at rest and performing tasks, on anti PD medications and off anti PD medications
3375443|NCT04361955|Other|PD with DBS off|intervention is EMG while at rest and performing tasks, on anti PD medications and off anti PD medications
3375444|NCT04361955|Other|ET with DBS on|intervention is EEG while performing tasks and at rest
3375445|NCT04361955|Other|ET with DBS off|intervention is EEG while performing tasks and at rest
3256593|NCT01444638|Experimental|Ultrasound|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
3256594|NCT01444638|No Intervention|Control|Control group. (Standard practice) Trainees will NOT receive pre-procedure U/S guided examination.
3375448|NCT04345913|Active Comparator|Group I (eribulin)|Patients receive eribulin IV over 2-5 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3375449|NCT04345913|Experimental|Group II (eribulin, copanlisib)|Patients receive copanlisib IV over 60 minutes and eribulin IV over 2-5 minutes on days 1 and 8 or days 1 and 15. Cycles repeat every 21 or 28 days in the absence of disease progression or unacceptable toxicity.
3256595|NCT01444664|Experimental|Aneurysm|
3256596|NCT01444677|Experimental|MB12066 300mg|single dose
3256597|NCT01444677|Active Comparator|MB12066 400mg|single dose
3256598|NCT01444677|Active Comparator|MB12066 100mg|multiple dose
3256599|NCT01444677|Active Comparator|MB12066 200mg|multiple dose
3256600|NCT01444677|Placebo Comparator|Placebo|Placebo 300mg(single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
3256601|NCT01444690|Experimental|Active|Dimiracetam 400 mg capsules
3375450|NCT04345861|Active Comparator|monotherapy hydroxychloroquine|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) + placebo from Day 1 to Day 5
3375451|NCT04345861|Experimental|combination hydroxychloroquine + azithromycin|Hydroxychloroquine 800mg (Day 1), 600mg (from Day 2 to Day 10) and azithromycin 500mg (Day 1 ), 250 mg (from day 2 to Day 5)
3375453|NCT04336202|Other|External beam radiotherapy + Endorectal brachytherapy|In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.
3375454|NCT04333524||Group A|Staging
3375455|NCT04333524||Group B|Criteria for response assessment
3375456|NCT04332926|Active Comparator|Own Brand Cigarette|
3375457|NCT04332926|Experimental|ECIG 30 Watts, 0 mg/ml nicotine|
3375458|NCT04332926|Experimental|ECIG 30 Watts, 8 mg/ml nicotine|
3375459|NCT04332926|Experimental|ECIG 30 Watts, 15 mg/ml nicotine|
3375460|NCT04332926|Experimental|ECIG 30 Watts, 30 mg/ml nicotine|
3375461|NCT04321031|Placebo Comparator|Placebo|participants will receive medication for 48 weeks
3375462|NCT04321031|Experimental|PF-06865571 25 milligrams (mg) twice daily (BID)|participants will receive medication for 48 weeks
3375463|NCT04321031|Experimental|PF-06865571 75 mg BID|participants will receive medication for 48 weeks
3375464|NCT04321031|Experimental|PF-06865571 150 mg BID|participants will receive medication for 48 weeks
3375465|NCT04321031|Experimental|PF-06865571 300 mg BID|participants will receive medication for 48 weeks
3375466|NCT04321031|Experimental|PF-06865571 (150 mg BID) + PF-05221304 (5 mg BID)|participants will receive medication for 48 weeks
3375467|NCT04321031|Experimental|PF-06865771 (300 mg BID) + PF-05221304 (10 mg BID)|participants will receive medication for 48 weeks
3256602|NCT01444690|Placebo Comparator|Pseudo-placebo|Dimiracetam 25 mg capsules
3256603|NCT01444703|Placebo Comparator|sugar solution|Gargle 5 minutes before induction of general anesthesia with sugar solution.
3256604|NCT01444703|Active Comparator|licorice|Gargle 5 minutes before induction of general anesthesia with licorice solution.
3256605|NCT01444729||xiapex|Subject treated with Xiapex
3375470|NCT04318080|Experimental|Cohort 1|Participants with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after autologous hematopoietic stem cell transplantation (HSCT)
3375471|NCT04318080|Experimental|Cohort 2|Participants with relapsed or refractory cHL who have received at least 1 prior systemic regimen and are not candidates for autologous or allogeneic HSCT
3256606|NCT01444729||Surgery|Fasciotomy or fasciectomy
3256607|NCT01444755||1-Neoadjuvant Chemotherapy|This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
3256608|NCT01444755||2 Surgery|Surgery will be performed in patients of this arm.
3375475|NCT04310358|Experimental|PLM group 1|Participants will do a pretest (Test 1), the 4 short PLMs, an immediate post-test (Test 2) and a remote post-test (Test 1).
3375476|NCT04310358|Experimental|PLM group 2|Participants will do a pretest (Test 2), the 4 short PLMs, an immediate post-test (Test 1) and a remote post-test (Test 2).
3256609|NCT01444807|Experimental|Sorafenib|Active Arm
3256610|NCT01444807|No Intervention|Best Supportive Care|Comparator
3375477|NCT04309188|Experimental|Stroboscopic Training Group|Treatment group, which will receive stroboscopic training during hitting and fielding drills. The glasses look like sunglasses but have liquid crystal technology that causes a flicker from clear to opaque. The glasses flickering will be controlled on the side of the glasses by the researcher. When the athlete can complete a skill proficiently by catching or hitting during training the level of flickering will be increased to challenge the visual system more.
3375478|NCT04309188|Active Comparator|Standard softball drills|Control group, which will perform normal hitting and fielding drills without stroboscopic training
3375479|NCT04308785|Experimental|Arm A: Atezolizumab + Tiragolumab|Participants will receive atezolizumab + tiragolumab intravenously on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and tiragolumab treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
3256611|NCT01444820|Experimental|Hypofractionation|One phase technique (IMRT or 3D-CRT): radiotherapy to the prostate + pelvic lymphnodes
3256612|NCT01444820|Other|Conventional|two-phase technique (IMRT or 3D-CRT): 1) whole pelvis including the prostate and regional lymph nodes; 2) boost to the prostate
3256613|NCT01444846|Active Comparator|SPI-1005 Low dose|200mg SPI-1005, capsule, bid, po, x4d
3256614|NCT01444846|Active Comparator|SPI-1005 Middle Dose|400mg SPI-1005, capsule, bid, po, x4d
3256615|NCT01444846|Active Comparator|SPI-1005 High Dose|600mg SPI-1005, capsule, bid, po, x4d
3256616|NCT01444846|Placebo Comparator|Placebo|0mg SPI-1005, capsule, bid, po, x4d
3256617|NCT01444859|Placebo Comparator|Placebo capsule|40 subjects allocated to daily placebo capsule for 10 weeks
3256618|NCT01444859|Experimental|Trenev Trio®/Healthy Trinity®|80 subjects allocated to Trenev Trio®/Healthy Trinity® for 10 weeks
3256619|NCT01444872|Experimental|TRV120027|TRV120027 administered as an IV infusion
3256620|NCT01444872|Placebo Comparator|Normal Saline|Normal Saline administered as an IV infusion
3375480|NCT04308785|Experimental|Arm B: Atezolizumab + Placebo|Participants will receive atezolizumab + placebo on the first day of each cycle. One cycle of therapy will be defined as 21 days. Atezolizumab and placebo treatment will continue up to 17 doses unless investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
3375481|NCT04306146|Experimental|CAD-9303|Capsules of CAD-9303 will be administered as a single or multiple dose(s). The initial dose will be 3 mg up to 1000 mg total daily dose.
3375482|NCT04306146|Placebo Comparator|Placebo|Matching placebo will be provided in capsules and administered as a single or multiple dose(s).
3375483|NCT04305067|Experimental|Supervised aerobic and resistance exercise|16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
3375484|NCT04304781|Experimental|Dimer Application with SFE imaging|Subjects having a standard-of-care ERCP will have the dimer sprayed on an area of interest in the bile duct and images taken with the SFE.
3256621|NCT01444885|Experimental|Cilostazol|To investigate the efficacy and safety of Pletaal(Cilostazol) in comparison with placebo for 4 weeks in vasospastic angina patients who have an insufficient response to Amlodipine (Calcium channel blocker).
3256622|NCT01444976|Active Comparator|topical pharyngeal anesthesia|There were 26 patients who had the procedure under topical pharyngeal anesthesia.
3256623|NCT01444976|Active Comparator|midazolam|There were 25 patients who received midazolam.
3256624|NCT01444976|No Intervention|hypnosis|There were 27 patients receiving hypnosis.
3256625|NCT01444989|Experimental|Patients without actinic keratosis|Patients with out the diagnosis of actinic keratosis will receive the experimental questionnaire.
3375487|NCT04278404||Children and young adults who are prescribed drugs of interest|Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.
3375488|NCT04266379|Experimental|Closed-Loop Control (CLC)|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
3375489|NCT04266379|Active Comparator|Sensor Augmented Pump (SAP)|Closed-loop subcutaneous insulin infusion and continuous glucose monitoring manage by patient
3375492|NCT04261413|Experimental|RS-0139|There will be only RS-0139 arm in the study.
3256626|NCT01444989|Experimental|Patients with Actinic Keratosis|Patients with the diagnosis of actinic keratosis will receive the experimental questionnaire.
3256627|NCT01445002|Experimental|BM32 low dose|3 subcutaneous injections of 10 micrograms in a time span of 8 weeks
3256628|NCT01445002|Experimental|BM32 medium dose|3 subcutaneous injections of 20 micrograms in a time span of 8 weeks
3256629|NCT01445002|Experimental|BM32 high dose|3 subcutaneous injections of BM32 over a time span of 8 weeks
3256630|NCT01445002|Placebo Comparator|Placebo|3 subcutaneous injections over a time span of 8 weeks
3375497|NCT04240093|Experimental|Experimental|Experimental: Behavioral Activation (8 sessions) + Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
3375498|NCT04240093|Active Comparator|Standard of Care|Substance Abuse and Health Navigation Counseling (2 sessions) + Meds
3375499|NCT04237792|Experimental|dexmedetomidine low dose group|low dose of dexmedetomidine to be given
3375500|NCT04237792|Experimental|dexmedetomidine middle dose group|middle dose of dexmedetomidine to be given
3256631|NCT01445015|Experimental|Stress management program|
3256632|NCT01445015|Active Comparator|peer viewed movies|
3256633|NCT01445041|Experimental|Single infusion of UCB|(autologous red blood cell and volume reduced cord blood cells)
3256634|NCT01445041|Experimental|Three infusions of UCB|(autologous red blood cell and volume reduced cord blood cells)
3256635|NCT01445054|Experimental|1-Arm 1|Subjects with primary or metastatic cancer other than melanoma, basal cell carcinoma, sarcoma, or lymphoma.
3256636|NCT01445067|Active Comparator|Arm 1: BMS-927711 (300 mg)|
3256637|NCT01445067|Active Comparator|Arm 2: BMS-927711 (600 mg)|
3256638|NCT01445158||1|bone marrow or stem cell donors ages 10 to 15
3256639|NCT01445158||2|bone marrow or stem cell donors ages 16 to 26
3256640|NCT01445197|Experimental|Biostate|
3256641|NCT01445210|Active Comparator|0,2% Ropivacaine|"Patients randomized to the experimental group receive a continuous infusion of 0,2 % Ropivacaine by elastomeric infusion pump at 5 ml/h in the saphenous catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
3375501|NCT04237792|Experimental|dexmedetomidine high dose group|high dose of dexmedetomidine to be given
3375502|NCT04234477|Experimental|Beta-blocker strategy|MICU patients assigned to Team Blue will receive an intravenous (IV) beta-blocker strategy to manage AF with RVR
3375503|NCT04234477|Experimental|Calcium channel blocker strategy|MICU patients assigned to Team Red will receive an intravenous (IV) calcium channel blocker strategy to manage AF with RVR
3375504|NCT04234477|Active Comparator|Physician preference strategy|MICU patients assigned to Team Green will receive a physician preference strategy with usual/standard of care interventions to manage AF with RVR
3375505|NCT04232449|Active Comparator|Intervention group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of 40 mg (2 tablets of 20 mg) of prednisone (intervention group) are provided by General Physicians (GPs) to participants. PREDNISON Galepharm Tabl. 20 mg are manufactured according to Good Manufacturing Practice (GMP)-guidelines.~The prednisone medication is manufactured by Galepharm AG, 8700 Küsnacht (ZH) and packaged and labelled by the Hospital Pharmacy of the University Hospital Basel. The PREDNISON tablets' active substance is Prednisonum; the tablets also contain Excipiens pro compresso. Swissmedic authorization 50821"
3375506|NCT04232449|Placebo Comparator|Control group|"Identically looking, numbered and marked medication glass jars with 5 daily doses of placebo (control group) are provided by General Physicians (GPs) to participants.~The content of the placebo tablets is as follows: Lactose monohydrate 140 mg, microcrystalline cellulose 68 mg, Croscarmellose sodium 5 mg, Magnesium stearate 2mg. The placebo tablets were manufactured by Apotheke Hotz, Zürichstrasse 176, CH- 8700 Küsnacht."
3375508|NCT04225871|Experimental|0.3 mg/kg zilucoplan (RA101495)|
3375509|NCT04224987|Active Comparator|Azithro 1-11|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-11 months old and oral placebo to children 12-59 months old
3375510|NCT04224987|Active Comparator|Azithro 1-59|Biannual weight- or height-based dose of oral azithromycin suspension to children 1-59 months old
3375511|NCT04224987|Placebo Comparator|Placebo|Biannual weight- or height-based dose of oral placebo to children 1-59 months old
3375512|NCT04224155|Experimental|enVista MX60EFH trifocal intraocular lens (IOL)|
3375513|NCT04224155|Active Comparator|enVista MX60E monofocal intraocular lens (IOL)|
3375514|NCT04217967|Active Comparator|Lenalidomide group|lenalidomide 25mg qod d1~21 days, rest 7 days
3375515|NCT04217967|Active Comparator|Ixazomib group|ixazomib 4mg orally, once a week, 3 times a month
3375516|NCT04217967|Experimental|Combination group|ixazomib 4mg orally, once a week, 3 times a month lenalidomide 25mg qod d1~21 days, rest 7 days use in combination
3375517|NCT04214756||Patients treated pre-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
3375518|NCT04214756||Patients treated post-MAPP|The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance
3375521|NCT04211766|Active Comparator|Group I (supplemental fiber and fat followed by placebo)|Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.
3375522|NCT04211766|Active Comparator|Group II (placebo followed by supplemental fiber and fat)|Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.
3375523|NCT04211181|Experimental|The multifaceted QI interventions|Hospitals randomized into experimental group will implement follow interventions including：the distribution of the guideline and pathway, a computer alert(computer-based clinical decision support system and computerized reminders),audit and feedback.
3256642|NCT01445210|Placebo Comparator|Control|"Patients randomized to the control group receive a continuous infusion of isoton saline by elastomeric infusion pump at 5 ml/h in their catheter after major ankle surgery. Infusion for 48 postoperative hours.~All patients receive a preoperative single shot of Ropivacaine around saphenous and sciatic nerve and a postoperative continuous sciatic nerve block."
3256643|NCT01445223|Active Comparator|lopinavir/ritonavir|400/100 mg BID + 2 NRTIs BID
3256644|NCT01445223|Active Comparator|atazanavir/ritonavir|300mg+100mg QD+ 2 NRTI QD
3256645|NCT01445223|Active Comparator|efavirenz|600mg QD + 2NRTI QD
3256646|NCT01445236|Experimental|Weaning patients|
3256647|NCT01445249|Active Comparator|Landmark guided ankle block|This group will receive a landmark guided ankle block.
3375524|NCT04211181|Active Comparator|Routine VTE prophylaxis in local clinical practice|Patients in the routine VTE prophylaxis(control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices.
3256648|NCT01445249|Active Comparator|This group will be given a PNS guided ankle block|Peripheral nerve stimulation will be used in this group to guide local anaesthetic infiltration. The technique is termed medial forefoot block.
3256649|NCT01445262||Subjects prescribed levocetirizine tablets|Subjects prescribed levocetirizine tablets for treatment of allergic rhinitis, urticaria, eczema, dermatitis, skin irritation, prurigo or pruritus cutaneous
3256650|NCT01445275||Ancillary-Correlative (Health Services Research)|Outcome data, such as incidence and stage at diagnosis of ovarian, fallopian tube, and peritoneal cancers; number and timing of screening and serum tests performed; number and timing of pelvic ultrasounds performed; surgical procedures performed; cancer-specific and overall survival (if available); and the incidence, type, and grade of significant adverse events, are collected from the Gynecologic Oncology Group (GOG)-0199 records and analyzed. Cost of each medical intervention is also estimated.
3256652|NCT01445366|Experimental|Patients with end-stage renal disease|
3256653|NCT01445379|Experimental|1|Ipilumumab (DSE) given on day 1 of 21 day cycle for 4 cycles, from cycle 5+ ipilumumab will be given ~every 12wks
3256654|NCT01445392|Experimental|1|Multi-cycle cohort
3256655|NCT01445392|Experimental|2|Single cycle cohort
3375527|NCT04204408|Experimental|Single dose (part 1) Mim8|Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
3375528|NCT04204408|Placebo Comparator|Single dose (part 1) placebo|Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
3375529|NCT04204408|Experimental|Multiple dose (part 2)|Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
3375530|NCT04201418||Patisiran Prospective Cohort|Patients who are naive to patisiran at study enrollment with the intention to initiate commercial patisiran therapy.
3256656|NCT01445418|Experimental|Arm 1|Standard dose escalation
3256657|NCT01445418|Experimental|Arm 2|Expanded cohort
3256658|NCT01445431|Experimental|Virgin Coconut Oil|
3256659|NCT01445431|Active Comparator|Mineral Oil|
3256660|NCT01445444|Experimental|HRT group|This group receives habit reversal training immediately.
3256661|NCT01445444|Active Comparator|TAU group|This group receives treatment as usual for 8 weeks.
3256664|NCT01445561|Experimental|1|100,000 international units/m2 SQ daily for 5 days
3256665|NCT01445561|Experimental|2|200,000 international units/m2 SQ daily for 5 days
3375531|NCT04201418||Patisiran Mixed Cohort|Patients who are currently on commercial patisiran therapy for less than 12 months at study enrollment.
3375532|NCT04201418||Patisiran Retrospective Cohort|Patients who have been on commercial patisiran therapy for at least 12 months prior to study enrollment, regardless of current treatment status at enrollment.
3375533|NCT04196283|Experimental|Arm 1: ABBV-368 + Tilsotolimod|Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.
3375534|NCT04196283|Experimental|Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel|Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.
3375535|NCT04196283|Experimental|Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181|Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.
3256666|NCT01445587|Experimental|GSK2110183|The oral dose of GSK2110183 the subjects received will be dependent on when the subject is enrolled to the study. GSK2110183 will be provided in 25mg and 50mg capsules containing the hydrochloride salt form of the API, microcrystalline cellulose, magnesium stearate, and microcrystalline cellulose (optional). They are filled into hard gelatin capsules. The 25mg tablets are opaque, swedish orange, size 2 capsules with no external markings, filled with a white powder. The 50mg tablets are opaque, white, size 1 capsules with no external markings, filled with a white powder.
3256667|NCT01445587|Other|Bortezomib|Bortezomib salvage therapy will be administered as a 3 to 5 second intravenous (IV) push at 1.3 mg/m2 on Days 1, 8, and 15 in each 21-day cycle until one of the Treatment Discontinuation Criteria is met.
3256668|NCT01445600||ALTARGO(retapamulin)|The subjects with bacterial skin and skin structure infections (SSSI)
3256669|NCT01445639|Experimental|Dexmedetomidine group|
3256670|NCT01445639|Placebo Comparator|Placebo group|
3375537|NCT04184973|Experimental|CG-100|Patients receive CG-100 during rectal cancer surgery
3375538|NCT04184973|Active Comparator|SOC|Patients receive a protective stoma during rectal cancer surgery
3375539|NCT04181788|Experimental|Arm A1 (Phase 1b)|
3375540|NCT04181788|Experimental|Arm B1 (Phase 1b)|
3375541|NCT04181788|Experimental|Arm A2 (Phase 2)|
3375542|NCT04181788|Experimental|Arm B2 (Phase 2)|
3256671|NCT01445691|Experimental|5-ALA (Gliolan)|Fluorescent substance to help visualize and remove as much tumor as possible without harming healthy tissue.
3375543|NCT04177511|Experimental|Transcutaneous auricular vagus nerve stimulation|"A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus.~Standard treatment will be continued by the patients of this arm."
3375544|NCT04177511|No Intervention|Standard treatment|Patients of this arm will continue their standard treatment.
3375545|NCT04174443|Experimental|Pulsed radiofrequency + Continuous radiofrequency|
3375546|NCT04174443|Active Comparator|Pulsed radiofrequency|
3375548|NCT04165772|Experimental|Cohort 1|Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy.
3256672|NCT01445704|Experimental|Probiotics|Patients treated with a probiotic (in capsule form) once daily for 12 weeks
3256673|NCT01445704|Placebo Comparator|Placebo|Patients treated with a placebo (in capsule form) identical to that of the probiotic capsule once daily for 12 weeks
3256674|NCT01445743|Experimental|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention women will receive a blinded dose of Tdap vaccine (ADACEL)
3375549|NCT04165772|Other|Cohort 2|The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory
3375550|NCT04165317|Experimental|PF-06801591 + BCG induction and maintenance|PF-06801591 in combination with Bacillus Calmette Guerin(induction+maintenance).
3375551|NCT04165317|Experimental|PF-06801591 + BCG induction only|PF-06801591 in combination with Bacillus Calmette Guerin (induction only).
3256675|NCT01445743|Placebo Comparator|Placebo Comparator: Physiologic Saline solution|Administration of Tdap vaccine or placebo as a single 0.5 mL of Saline (0.9% NaCl) solution
3256676|NCT01445756|Active Comparator|Topical Lidocaine|Topical Lidocaine
3375552|NCT04165317|Active Comparator|BCG induction and maintenance|Bacillus Calmette Guerin (induction and maintenance).
3375553|NCT04165317|Experimental|BCG Unresponsive CIS|PF-06801591
3375554|NCT04165317|Experimental|BCG Unresponsive NMIBC|PF-06801591
3375555|NCT04164225|Experimental|Qigong|Qigong exercises, focused on a mind-body connection
3375556|NCT04164225|Active Comparator|P.Volve|P.Volve exercises, focused on just physical movement
3375557|NCT04162015|Experimental|nivolumab with pemetrexed and cisplatin or carboplatin|Eligible patients will receive two cycles of neoadjuvant therapy with nivolumab 360 mg, pemetrexed 500 mg/m2, and cisplatin 75 mg/m2 or carboplatin AUC=5. Subsequently, they will undergo pleurectomy/decortication.
3375558|NCT04156698|Experimental|Camrelizumab (PD-1 inhibitor) group|"Induction chemotherapy combined with immunotherapy (TPF + Camrelizumab), q3w, 3 cycles in total:~Docetaxel (domestic) 75 mg/m2 i.v. d1, Cisplatin 25 mg/m2 i.v. d1-3, Capecitabine 800 mg/m2 po bid d1-d14, Camrelizumab 200mg i.v. d1;~Radical radiotherapy followed by concurrent immunotherapy:~Radiotherapy: Using intensity-modulated radiation therapy (IMRT). Primary site: GTV dose 66 (2.2Gy / fraction)-70 Gy (2Gy / fraction)；CTV 1.6-1.9 Gy / fraction. Cervical lymph nodes: Radiotherapy plan is the same as the radiotherapy plan of original site; Concurrent immunotherapy : Camrelizumab 200mg i.v. d1, d22;~Maintenance period:~After completing concurrent chemoradiotherapy combined with immunotherapy, Camrelizumab 200 mg q3w will be given up to 12 months (calculated from the time of the first dose of PD-1 immunotherapy)."
3375559|NCT04152200|Experimental|Lumasiran|All participants will receive open-label lumasiran.
3375560|NCT04152018|Experimental|Dose Escalation|Single Agent Dose Escalation
3375561|NCT04152018|Experimental|Dose Finding Anti-PD-1 Combination 1|Part 1B PF-06940434 plus anti-PD-1
3375562|NCT04152018|Experimental|Dose Expansion Arm A|PF-06940434 with anti-PD-1 in SCCHN
3375563|NCT04152018|Experimental|Dose Expansion Arm B|PF-06940434 with anti-PD-1 in RCC
3375564|NCT04150029|Experimental|MBG453+Venetoclax +Azacitidine|Patients will receive MBG453 in combination with Venetoclax and Azacitidine
3375565|NCT04143243|Active Comparator|ACT on Life|"Acceptance and Commitment Therapy plus Education, Resources and Support ('ACT on Life').~The ACT+ERS intervention will include: 1) Acceptance and Mindfulness Training (2-3 hours); 2) Committed Action Training (2-3 hours) involving helping Veterans clarify what matters most to them and what they want to stand for in life, how they want to behave, and what sorts of strengths and qualities they want to develop; and; 3) Education, Resources, and Support (1 hour)."
3256677|NCT01445756|Placebo Comparator|Placebo|Placebo
3256678|NCT01445782|Experimental|1|AZD2115
3375566|NCT04143243|Placebo Comparator|Education, Resources, and Support|Information provided in the ERS workshop was compiled from existing VHA and community resources. Veterans will be educated about 1) symptoms of depression, anxiety and PTSD and how these conditions do and do not impact daily life and functional ability; 2) common difficulties and challenges with reintegration into civilian life; 3) mild TBI, differences between civilian and Veteran TBIs, shared/crossover symptoms (for example, memory and concentration difficulties, sleep disturbance, irritability can be symptoms of depression, PTSD, and mild TBI); 4) chronic pain; how it is often often misinterpreted as on-going damage, leading to fear of physical activities and resulting in increased sedentary behavior and declines in physical functioning; and 5) treatment options and resources. Basic resource counseling will include guidance on the evidence-based treatments available at VHA. Problem solving, relaxation, and deep breathing techniques will be covered
3375567|NCT04142814|Experimental|T-PEP|"Each T-PEP session includes 10 inspiratory/expiratory cycles, repeated 3 times and interspersed by a pause of about 3 minutes.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (as detected by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for the outcome stabilization, as confirmed also by arterial-blood gas test (ABG), spirometry, chest X-ray and chest ultrasound.~T-PEP sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks after the attainment of a stabilized effective pulmonary ventilation."
3375568|NCT04142814|Active Comparator|IPV|"Each IPV session includes 3 treatment cycles, interspersed with a pause, consisting of a first high-frequency steps, lasting about 5 minutes, immediately followed by a second low-frequency step lasting approximately one minute.~Each session will be immediately followed by bronchoaspiration and/or Mechanical Insufflation-Exsufflation (MI-E).~Sessions will take place at least twice a day for a number of days until the attainment of an effective pulmonary ventilation (by thoracic auscultation), then continued for a further 3 days (at least 2 times a day) for outcome stabilization, as confirmed by ABG test, spirometry, chest X-ray and chest ultrasound.~IPV sessions will take place at least 1 hour after meals or nutrition via nasogastric tube.~Tracheal cannula will be kept constantly cuffed during the sessions. Ipratropium Bromide treatment will be on place from study entry until at least 4 weeks, after the attainment of a stabilized effective pulmonary ventilation."
3375569|NCT04142177|Active Comparator|Internet-based pain self-management program|Internet-based treatment (Step 1 Treatment)
3256679|NCT01445782|Placebo Comparator|2|Placebo to AZD2115
3256680|NCT01445795|Experimental|200 mg INX-08189 Fasted|Cohort 1: 200 mg INX-08189 QD fasted for seven days
3256681|NCT01445795|Placebo Comparator|Placebo QD Fasted|Cohort 1: Placebo QD fasted for seven days
3375570|NCT04142177|Active Comparator|Enhanced Physical Therapy|Intervention that combines the internet-based pain self-management program with tailored exercise and physical activity guided by a physical therapist (Step 1 treatment)
3375571|NCT04142177|Placebo Comparator|Continued Care and Active Monitoring (CCAM)|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management (Step 1 Treatment)
3375572|NCT04142177|Active Comparator|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive face-to-face treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months (Step 2 Treatment).
3375573|NCT04142177|Active Comparator|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT (Step 2 Treatment).
3375574|NCT04142177|Active Comparator|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace (Step 2 Treatment).
3375575|NCT04137900|Experimental|TAB004 0.3 mg/kg repeat dose every 21 days up to 2 years|
3375576|NCT04137900|Experimental|TAB004 1 mg/kg repeat dose every 21days up to 2 years|
3256682|NCT01445795|Experimental|100 mg INX-08189 with Ribavirin|Cohort 2: 100 mg INX-08189 100 mg dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID, the AM dose will be taken 4 hours after INX-08189 so it may be taken with food)
3375577|NCT04137900|Experimental|TAB004 3 mg/kg repeat dose every 21 days up to 2 years|
3375578|NCT04137900|Experimental|TAB004 10 mg/kg repeat dose every 21 days up to 2 years|
3375579|NCT04137900|Experimental|TAB004 200mg repeat dose every 21 days up to 2 years|
3375580|NCT04137900|Experimental|TAB004 20mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
3256683|NCT01445795|Active Comparator|Placebo QD dosed with ribavirin|Cohort 2: Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
3256684|NCT01445795|Experimental|100 mg INX-08189 with a low-fat meal|Cohort 3: 100 mg INX-08189 with a low-fat meal QD x7 days
3375581|NCT04137900|Experimental|TAB004 70mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
3375582|NCT04137900|Experimental|TAB004 200mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
3375583|NCT04137900|Experimental|TAB004 500mg and Torpalimab 240mg repeat dose every 21 days up to 2 years|
3375584|NCT04137107|Experimental|Phase II, Arm I (duloxetine hydrochloride, placebo)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD and placebo (1 placebo capsule) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
3256685|NCT01445795|Placebo Comparator|Placebo with low-fat meal|Cohort 3: Placebo administered with a low-fat meal QD for 7 days
3256686|NCT01445795|Experimental|100 mg INX-08189 Fasted|Cohort 4: 100 mg INX-08189 BID fasted x7 days
3256687|NCT01445795|Placebo Comparator|Placebo BID Fasted|Cohort 4: Placebo BID fasted x7 days
3256688|NCT01445808|Experimental|Psychodynamic Motivation and Training Program (PMT)|
3256689|NCT01445808|Active Comparator|Advice in Exercise Training|One session of advice in exercise training based on the results of spiroergometry
3256690|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor and cardiologist
3256691|NCT01445834||Incontinent women|
3256692|NCT01445860|Experimental|Treatment|
3256693|NCT01445899|Experimental|PF-04523655 (Stratum II)|Stratum II, 6 monthly injections of PF-04523655 only
3256694|NCT01445899|Experimental|PF-04523655 and ranibizumab|Stratum II, 6 monthly injections of PF-0423655 and ranibizumab administered in combination
3256695|NCT01445899|Active Comparator|ranibizumab|Stratum II, 6 monthly IVT injections of ranibizumab only
3256696|NCT01445899|Experimental|PF-04523655 (Stratum I)|Stratum I
3256697|NCT01445925|Active Comparator|Pulmonary vein isolation|Patients will undergo pulmonary venous isolation plus pharmacological substrate modification
3256698|NCT01445925|Experimental|Pulmonary vein isolation + Linear Lesions|Patients will undergo pulmonary venous isolation plus both pharmacological and interventional substrate modification
3256699|NCT01445938|Experimental|Step 1 (SAR97276A od)|1 group of paediatric patients will receive 0.5 mg/kg SAR97276A administration once daily (od) for 3 days
3256700|NCT01445938|Experimental|Step 1 (SAR97276A bid)|1 group of paediatric patients will receive 0.25 mg/kg SAR97276A administration twice daily (bid) for 3 days
3256701|NCT01445938|Active Comparator|Step 1 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
3375585|NCT04137107|Experimental|Phase II, Arm II (duloxetine hydrochloride)|Patients in Phase II receive duloxetine hydrochloride 30 mg (1 duloxetine capsule) orally (PO) once daily (QD) during week 1, duloxetine hydrochloride 60 mg (2 duloxetine capsules) PO QD during weeks 2-16, followed by duloxetine hydrochloride 30 mg (1 duloxetine capsule) PO QD during week 17 in the absence of unacceptable toxicity.
3375586|NCT04137107|Placebo Comparator|Phase II, Arm III (placebo)|Patients in Phase II receive placebo (1 placebo capsule) orally (PO) once daily (QD) during week 1, placebo (2 placebo capsules) PO QD weeks 2-16, followed by placebo (1 placebo capsule) PO QD during week 17 in the absence of unacceptable toxicity.
3375587|NCT04137107|Experimental|Phase III, Arm I (duloxetine hydrochloride)|Patients in Phase III receive most promising dose of duloxetine hydrochloride from Phase II PO QD in the absence of unacceptable toxicity.
3375588|NCT04137107|Placebo Comparator|Phase III, Arm II (placebo)|Patients in Phase III receive placebo PO QD in the absence of unacceptable toxicity.
3375589|NCT04131166|Other|Metabolically healthy lean|Metabolically normal lean - Lean individuals that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content.
3375590|NCT04131166|Experimental|Metabolically healthy obese - Mediterranean diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the Mediterranean diet group.
3375591|NCT04131166|Experimental|Metabolically healthy obese - Low-carbohydrate ketogenic diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-carbohydrate ketogenic diet group.
3375592|NCT04131166|Experimental|Metabolically normal obese - Low-fat diet|Metabolically normal obese - Persons with obesity that have good glucose (sugar) control, normal plasma triglyceride (fat) levels and a low liver fat content randomized to the low-fat diet group.
3375593|NCT04131166|Experimental|Metabolically unhealthy obese - Mediterranean diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the Mediterranean diet group.
3375594|NCT04131166|Experimental|Metabolically unhealthy obese - Low-carbohydrate ketogenic diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-carbohydrate, ketogenic diet group.
3375595|NCT04131166|Experimental|Metabolically unhealthy obese - Low-fat diet|Metabolically abnormal obese - Persons with obesity with glucose levels higher than recommended and a moderate to high amount of fat in the liver randomized to the low-fat diet group.
3375597|NCT04127695|Experimental|ABBV-0805 Dose 1 or Placebo|Participants will receive ABBV-0805 Dose 1 or Placebo.
3375598|NCT04127695|Experimental|ABBV-0805 Dose 2 or Placebo|Participants will receive ABBV-0805 Dose 2 or Placebo.
3375599|NCT04127695|Experimental|ABBV-0805 Dose 3 or Placebo|Participants will receive ABBV-0805 Dose 3 or Placebo.
3375600|NCT04127695|Experimental|ABBV-0805 Dose 4 or Placebo|Participants will receive ABBV-0805 Dose 4 or Placebo. Note: This dosing group may be added after a review of data from dosing groups 1-3.
3375601|NCT04121325||Gastroparesis patients with abdominal pain|Patients with gastroparesis who have had an Enterra device in place for at least two months who continue to have moderate to severe abdominal pain.
3375602|NCT04114981|Active Comparator|Arm I (SSRS)|Patients undergo SSRS over 1 session.
3256702|NCT01445938|Experimental|Step 2 (SAR97276A)|1 or 2 groups of paediatric patients will receive SAR97276A once daily (od) or twice a day (bid) administration for 3 days (the choice of the od or bid regimen will be based on the results obtained in step 1)
3256703|NCT01445938|Active Comparator|Step 2 (ACTs)|1 group of paediatric patients will receive arthemeter + lumefantrine (ACTs) bid for 3 days
3256704|NCT01445938|Experimental|Step 3 (SAR97276A)|1 group of paediatric patients (2 to 11 years old) will receive: SAR97276A od or bid administration for 3 days (depending on results of step 1)
3375603|NCT04114981|Experimental|Arm II (FSRS)|Patients undergo FSRS over 3 or 5 daily sessions.
3375604|NCT04109586|Experimental|Personalized nutrition therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
3375605|NCT04109586|No Intervention|Standard treatment|Standard treatment includes dietitian-led group session on nutrition after SCI and patient visits / consultations on request from doctor.
3375606|NCT04106349||1st line|
3256705|NCT01445964|Experimental|1|SLCO2B1 wild type allele
3375607|NCT04106349||2nd line|
3375608|NCT04106349||later lines|
3375609|NCT04102579|Experimental|Valbenazine|Capsule, administered orally once daily for 12 weeks.
3375610|NCT04102579|Placebo Comparator|Placebo|Capsule, administered orally once daily for 12 weeks.
3375611|NCT04102111|Experimental|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily for 12 weeks.
3375612|NCT04102111|Placebo Comparator|Placebo|Participants will receive oral tablets of matching placebo twice daily for 12 weeks.
3375613|NCT04097717|Experimental|Decision Aid Arm|Participants will use the web-based decision aid plus usual medical care.
3375614|NCT04097717|Other|Usual Care Arm|Participants will receive usual medical care.
3375615|NCT04093323|Experimental|Treatment (IFNA2, rintatolimod, celecoxib, alphaDC1 vaccine)|Patients receive recombinant interferon alpha-2 IV over 30 minutes, rintatolimod IV over 2.5 hours, and celecoxib PO BID on days 1-3. Beginning cycle 2, patients also receive alpha-type-1 polarized dendritic cells ID on day 1. Treatment repeats every 3 weeks up to 4 cycles in the absence of disease progression or unacceptable toxicity. At 12 weeks, patients with progressive disease may switch to ipilimumab with or without a PD-1/PD-L1 inhibitor and patients with a complete response CR, PR, or stable disease SD may switch to a PD-1/PD-L1 inhibitor or best alternative care.
3375616|NCT04091022|Active Comparator|Diclofenac + DFMO|Participants in this arm will apply topical diclofenac to bilateral forearms once per day and topical DFMO to bilateral forearms once per day.
3375617|NCT04091022|Placebo Comparator|Placebo + Placebo|Participants in this arm will apply placebo for topical diclofenac to bilateral forearms once per day and placebo for topical DFMO to bilateral forearms once per day.
3375618|NCT04087395|Experimental|RHA®4 with new anesthetic agent|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
3375619|NCT04087395|Experimental|RHA®4-Lidocaine|"Split-face injection of RHA®4 with new anesthetic agent in the nasolabial fold of one side of the face and RHA®4-Lidocaine in the nasolabial fold of opposite side of the face.~Up to 3 mL injected per side."
3256706|NCT01445964|Experimental|2|SLCO2B1 variant allele
3256707|NCT01446016|Active Comparator|Taxane|Taxane
3256708|NCT01446016|Active Comparator|Taxane-Like|Taxane-Like (Paclitaxel, Docetaxel, Abraxane, Ixabepilone)
3256709|NCT01446029|No Intervention|Usual Care|
3256710|NCT01446029|Active Comparator|Intervention Device|
3256711|NCT01446055|Experimental|ResQ process group|Autologous BM-MNC is enriched with ResQ process(an automatic cell separator). Then the cell product is transplanted into the ischemia limbs of a patient.
3256712|NCT01446055|Active Comparator|Ficoll-based conventional method|A conventional method based on Ficoll cell separation is used to process bone marrow.
3256713|NCT01446068|Experimental|Lean Subjects|
3256714|NCT01446068|Experimental|Obese subjects|
3256715|NCT01446081|Experimental|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
3256716|NCT01446081|No Intervention|Control|Participants assigned to this arm will receive usual care.
3256717|NCT01446094|Other|single-arm|Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
3256718|NCT01446107|Experimental|fissure sealant|single placement of resin fissure sealant on tooth surface
3375626|NCT04081220|Experimental|IMG-7289|
3375627|NCT04059484|Experimental|Amcenestrant|Daily amcenestrant dose administered orally under fed or fast condition
3375628|NCT04059484|Active Comparator|Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator|"Control treatment of the choice of the physician depending on each participant's medical condition and in accordance with the approved label may include 1 of the following treatments used as monotherapy.~Fulvestrant~Aromatase inhibitors (anastrozole, letrozole, exemestane)~Selective estrogen receptor modulator (Tamoxifen)"
3375629|NCT04057573|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
3375630|NCT04057573|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
3375631|NCT04057469|Experimental|Tulobuterol patch|
3375632|NCT04057469|Placebo Comparator|Placebo|
3256719|NCT01446107|Experimental|fluoride varnish|application of a 5% sodium fluoride varnish every 6 months
3256720|NCT01446107|Experimental|SDF solution|application of a 38% silver diamine fluoride solution onto tooth surface every year
3256721|NCT01446107|Placebo Comparator|control|application of water onto tooth surface every year
3256722|NCT01446120|Experimental|Insulin loaded Orally Dissolved Films (insulin-ODF)|
3256723|NCT01446120|Active Comparator|Human Insulin Specific RIA Kit <5uCi|
3256724|NCT01446146|Experimental|IDM intervention|Will receive a 40 minute intervention session with a clinician, learning about PTSD treatment options and choosing a preferred treatment.
3256725|NCT01446146|Placebo Comparator|Treatment as usual plus placebo session|Will work with provider to select a treatment plan and will receive a 40 minute session without IDM intervention.
3256726|NCT01446172||cognitive, schema focused, guided mastery, exposure|
3256727|NCT01446185|Other|a HR+, N- or pN1(mi), Her2- breast cancer adjuvant population|
3256728|NCT01446198||AHPV positive and negative subjects|
3256729|NCT01446211|Experimental|Test group - gusperimus|Both severity subgroups (severe and non-severe) will be treated with gusperimus + glucocorticoids.
3256730|NCT01446211|Active Comparator|Control group|"The severe subgroup will receive a course (13 - 22 weeks) of cyclophosphamide followed by methotrexate + glucocorticoids. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids.~The non-severe subgroup will receive methotrexate + glucocorticoids(or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
3256731|NCT01446224||Subjects who experience cardiac ischemia|Subjects who experience cardiac ischemia including myocardial infarction, unstable angina, transient ischemic attack, and cerebrovascular accident
3375636|NCT04052425|Experimental|Ruxolitinib cream|Ruxolitinib cream 1.5% twice daily (BID) for 24 weeks followed by ruxolitinib cream 1.5% BID for an additional 28-week treatment extension period.
3375637|NCT04052425|Placebo Comparator|Vehicle|Vehicle cream for 24 weeks followed by crossover to ruxolitinib cream 1.5% BID in a 28-week treatment extension period.
3375638|NCT04052126|Experimental|Individualized physical activity program|
3375639|NCT04046614|Experimental|nintedanib nivolumab|nintedanib-nivolumab combination therapy
3375640|NCT04046003|Experimental|Tai Chi intervention|24-form Yang style Tai Chi
3375641|NCT04034082|Experimental|IHT group|Intermittent hypoxia therapy on top of the conventional phase 2 in-hospital rehabilitation program
3375642|NCT04034082|Active Comparator|Conventional group|Conventional phase 2 in-hospital rehabilitation program
3375643|NCT04026620|Other|Pamphlet-only|Pamphlet-only women will be provided with two (2) informational pamphlet(s) (both in Afrikaans).
3375644|NCT04026620|Other|MET Group|MET women will be provided with a one (1) hour and 30 minute session of Motivational Enhancement Therapy (MET) and informational pamphlet(s) (both in Afrikaans).
3375645|NCT04026412|Experimental|Arm A: nivolumab + CCRT + ipilimumab|Concurrent chemoradiotherapy (CCRT)
3375646|NCT04026412|Experimental|Arm B: nivolumab + CCRT|Concurrent chemoradiotherapy (CCRT)
3375647|NCT04026412|Experimental|Arm C: CCRT + durvalumab|Concurrent chemoradiotherapy (CCRT)
3375648|NCT04023552|Experimental|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
3375649|NCT04023552|Placebo Comparator|Placebo|Monthly subcutaneous injections.
3375650|NCT04018820|Experimental|Training program|
3375651|NCT04009174|Experimental|Imaging Panel|Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.
3375652|NCT04006457|Experimental|Treatment sequence 1|"Participants who did not previously receive study intervention in either study B7931005 or B7981015 will receive 200 milligrams (mg) PF-06651600, given as four 50 mg tablets once daily (QD) for 1 month, followed by 50 mg PF-06651600 given QD for 35 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or one of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 9 visit and prior to or on the Month 32 visit of the main B7981032 study."
3375653|NCT04006457|Experimental|Treatment sequence 2|"Participants who previously received study intervention in either study B7931005 or B7981015 will receive 50 mg PF-06651600 given QD for 36 months.~Patients participating in the vaccine sub-study will receive the 2 vaccines or 1 of the 2 vaccines at the vaccine sub-study Day 1, which will occur at a scheduled study visit on or after the Month 6 visit and prior to or on the Month 32 visit of the main B7981032 study."
3375654|NCT04002310|Experimental|BI 754132|Single Rising Dose (SRD) part followed by a Multiple Dosing (MD) part
3375655|NCT04001881||Hypotension group|spinal anesthesia in Hypotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
3375656|NCT04001881||Normotension group|spinal anesthesia IN Normotensive patients with low LV-EF Transthoracic echocardiography of IVC before spinal anaesthesia
3375657|NCT03997383|Experimental|Patisiran|Participants will be administered multiple doses of patisiran in the double-blind and open-label extension period.
3375658|NCT03997383|Placebo Comparator|Placebo|Participants will be administered multiple doses of placebo in the double-blind period. In the open-label extension period, participants will be administered multiple doses of patisiran.
3375659|NCT03994796|Experimental|Arm I (CDK gene mutation)|Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3375660|NCT03994796|Experimental|Arm II (PI3K gene mutation)|Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3375661|NCT03994796|Experimental|Arm III (NTRK/ROS1 gene mutation)|Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3375662|NCT03984513|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
3375663|NCT03984513|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
3375664|NCT03984487|Experimental|STRW|Participants will receive the daily living skills intervention, Surviving and Thriving in the Real World (STRW).
3375665|NCT03984487|Active Comparator|PEERS|Participants will receive a social skills intervention, Program for the Education and Enrichment of Relational Skills (PEERS).
3256732|NCT01446224||Subjects who do not experience cardiac ischemia|Subjects who do not experience cardiac ischemia
3256733|NCT01446224||Subjects who experience Torsades de Pointes|Subjects who experience Torsades de Pointes
3375666|NCT03982511|Experimental|PCIT-Health|Participants assigned to the PCIT-Health arm will receive the intervention.
3375667|NCT03982511|No Intervention|Wait list control|Participants in the wait list control will receive an invitation to participate in the intervention 10 months after baseline data collection.
3375668|NCT03978741|Experimental|Test Device|Yōni.Fit Test Device
3375669|NCT03978741|Active Comparator|Comparator Device|Yōni.Fit Comparator Device
3375670|NCT03948919|Active Comparator|FMT Treatment|Fecal microbiota - 1.0-3.0 x 10^11 CFU / day (2 capsules per day for 8 weeks).
3256734|NCT01446224||Subjects who do not experience Torsades de Pointes|Subjects who do not experience Torsades de Pointes
3256735|NCT01446263|Active Comparator|Radial access|
3256736|NCT01446263|Active Comparator|Femoral access|
3256737|NCT01446276|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for six month
3256738|NCT01446276|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for six month
3256739|NCT01446276|No Intervention|Control group|Men without non-alcoholic fatty liver disease
3375671|NCT03948919|Placebo Comparator|Placebo|The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product. Two capsules taken daily for 8 weeks.
3375672|NCT03947177|Placebo Comparator|Control|GMIT
3375673|NCT03947177|Experimental|Intervention|Modified GMIT + Parenting support groups
3375674|NCT03944941|Active Comparator|Arm I (Avelumab)|Patients receive avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with avelumab failure will crossover to Arm II.
3375675|NCT03944941|Experimental|Arm II (Avelumab, cetuximab)|Patients receive cetuximab IV over 1-2 hours on days 1, 8,15, and 22 and avelumab IV over 60 minutes on days 1 and 15. Treatment repeats every 28 days for up to 12 cycles for cetuximab and 24 cycles for avelumab in the absence of disease progression or unacceptable toxicity.
3375676|NCT03941834|Active Comparator|BHV3000|
3375677|NCT03941834|Placebo Comparator|Placebo|
3375678|NCT03940196|Experimental|NovoTTF-100L(O)|Patients receive TTFields using the NovoTTF-100L(O) System together with weekly Paclitaxel
3375679|NCT03940196|Active Comparator|Best Standard of Care|Patients receive best standard of care with weekly Paclitaxel
3375680|NCT03938792|Experimental|PF-06741086|Participants will be assigned to treatment with PF-06741086 after a 6 month Observation Phase on their current hemophilia regimen.
3375681|NCT03935425|Experimental|FitMi Plus|"Participants will perform targeted movement exercises by interacting with the FitMi Plus Functional modules at least 50% of the time they spend exercising.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
3375682|NCT03935425|Active Comparator|FitMi Basic|"Participants will perform targeted movement exercises by interacting with the FitMi Basic pucks, as described and monitored on a computer.~Participants will be asked to exercise at least 3 hours per week for 3 consecutive weeks."
3375683|NCT03934307|Experimental|Part A: SAD: ALN-AGT01|Participants will be administered a single dose of ALN-AGT01.
3375684|NCT03934307|Placebo Comparator|Part A: SAD: ALN-AGT01-Matching Placebo|Participants will be administered a single dose of ALN-AGT01-matching placebo.
3375685|NCT03934307|Experimental|Part B: SD: ALN-AGT01|Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
3375686|NCT03934307|Placebo Comparator|Part B: SD: ALN-AGT01-Matching Placebo|Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
3375687|NCT03934307|Experimental|Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo|Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
3375688|NCT03934307|Active Comparator|Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan|Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
3375689|NCT03934307|Experimental|Part E: Open Label: ALN-AGT01 + Irbesartan|Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.
3256740|NCT01446302|Active Comparator|Double meal on a HD day|A standardized meal is served 1 h after start of HD and 1 h after end of HD
3256741|NCT01446302|No Intervention|Single meal on a HD day|A standardized meal is served 1 h after start of HD. After the meal participants fast for 9 h (6 h after end of HD).
3256742|NCT01446302|No Intervention|Single meal on a non-HD day|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
3256743|NCT01446302|No Intervention|Single meal (healthy controls)|A standardized meal is served 1 h after study start. After the meal participants fast for 9 h.
3375691|NCT03927794|Experimental|Self-Assembling Peptide P11-4|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed at baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive the intervention by the self-Assembling Peptide P11-4 at Day 0 and will be followed up at 3 months, 6 months and 1 year."
3375692|NCT03927794|Active Comparator|5% Fluoride Varnish|"Twenty two teeth affected with white spot lesions of ICDAS II score 1-2 will be assessed as baseline using ICDAS II Scoring and Light Induced Fluorescence by Soprolife System.~Then they will receive Topical Fluoride Varnish at Day 0 and will be followed up at 3 months, 6 months and 1 year."
3375693|NCT03927027|Active Comparator|Group I (ALND)|Patients receive isosulfan blue SC and undergo ALND.
3256744|NCT01446315|Experimental|Asthma APGAR|Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
3256745|NCT01446315|Placebo Comparator|Usual care|Usual asthma care as provided by the sites.
3375694|NCT03927027|Experimental|Group II (ARM, ALND)|Patients undergo ARM. Patients then receive isosulfan blue and undergo ALND as in Group I.
3375695|NCT03927001|Other|Intervention|NeVa Stent Retrievers
3375696|NCT03926988|Other|Intervention|NeVa Stent Retriever
3375697|NCT03926819|Active Comparator|Single Ascending Dose|
3375698|NCT03926819|Active Comparator|Multiple Ascending Dose|
3256746|NCT01446328|Active Comparator|Amisulpride|
3256747|NCT01446328|Active Comparator|Aripiprazole|
3256748|NCT01446328|Active Comparator|Olanzapine|
3256749|NCT01446341|Active Comparator|Immobilization|50 patients will be randomly assigned to have their lateral ankle sprain immobilized in a below knee cast
3256750|NCT01446341|Active Comparator|Functional Rehabilitation|50 patients will be randomly assigned to a functional rehabilitation program for their lateral ankle sprain
3256751|NCT01446354||Cardiac surgery with HCA|Patients undergoing cardiac surgery with the help of hypothermic cardiac arrest for pathologies of the proximal aorta
3256752|NCT01446380||Pseudoxanthoma elasticum|
3256753|NCT01446406|Active Comparator|MONARCA|MONARCA self-monitoring application on a cell phone to monitor affective symptoms every day.
3256754|NCT01446406|Placebo Comparator|NON-MONARCA|This is the same mobile phone as the MONARCA mobile phone. Yet the MONARCA application has not been installed. The mobile phone can only be used as a normal mobile phone for communication purposes.
3375699|NCT03924765|Experimental|Individuals post-stroke using a powered hip exoskeleton|This study will be conducted on a sample population of stroke subjects (single arm). Each subject will test with each condition of the exoskeleton (repeated measures).
3375702|NCT03916185|Experimental|RSV ΔNS2/Δ1313/I1314L Vaccine|Participants will receive a single dose of the RSV ΔNS2/Δ1313/I1314L vaccine at study entry (Day 0).
3375703|NCT03916185|Experimental|RSV 6120/ΔNS2/1030s Vaccine|Participants will receive a single dose of the RSV 6120/ΔNS2/1030s vaccine at study entry (Day 0).
3256755|NCT01446445|Active Comparator|1.A (Prophylaxis-SPC)|Prophylaxis for CMV infection and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
3256756|NCT01446445|Experimental|1.B (Prophylaxis- PK model)|Prophylaxis for CMV infection and Ganciclovir/Valganciclovir doses according to pharmacokinetic model.
3375704|NCT03916185|Experimental|RSV 276 Vaccine|Participants will receive a single dose of the RSV 276 vaccine at study entry (Day 0).
3375705|NCT03916185|Placebo Comparator|Placebo|Participants will receive a single dose of placebo at study entry (Day 0).
3256757|NCT01446445|Active Comparator|2.A (Treatment-SPC)|Treatment for CMV infection/disease and Ganciclovir/ Valganciclovir doses according to summaries of product characteristics (SPC).
3256758|NCT01446445|Experimental|2.B (Treatment-PK model)|Treatment for CMV infection/disease and Ganciclovir/Valganciclovir doses according to pharmacokinetic model
3256759|NCT01446458|Experimental|5-Fluorouracil, Oxaliplatin, Irinotecan|5-Fluorouracil, Oxaliplatin, Irinotecan are administered as a modified FOLFIRINOX regimen every 15 days. Subjects receive bi-weekly cycles of therapy on the 1st week, the 3rd week, the 5th week and finally the 7th week for a total of 4 cycles. Assessments include history and physical, laboratory tests on a weekly basis throughout the treatment period prior to and including week 8 assessment for stereotactic body radiotherapy (SBRT).
3375706|NCT03915860|Experimental|Trifarotene|Participants applied Trifarotene 50 μg/g topically once daily in the evening for 24 weeks.
3375709|NCT03910075|Experimental|I-ACQUIRE High Dose|High Dose I-ACQUIRE (6hrs/day, 5 days/wk X 4 wks)
3375710|NCT03910075|Experimental|I-ACQUIRE Moderate Dose|Moderate Dose I-ACQUIRE (3 hrs/day, 5 day/wk X 4 wks)
3375711|NCT03910075|Active Comparator|Usual & Customary Treatment|Usual & Customary Treatment
3375714|NCT03905694|Experimental|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
3375715|NCT03902093|Experimental|Hearing Aid|Actual Patients in the clinic will be evaluated by their Audiologist, if they are candidates to use the Lyric Hearing aid they will be asked if they want to participate in the study which will include imaging of the ear canal with a device similar to the regular ear device used in the clinic to check if there are any changes to the morphology of the ear canal.
3375716|NCT03897699|Experimental|active tDCS + Mindful Breathing Training|20 minutes of active or sham stimulation will be applied at 2.0 mA in parallel with mindful breathing training
3375717|NCT03897699|Sham Comparator|sham tDCS + Mindful Breathing Training|The sham condition will apply stimulation only for the first and last 30 seconds of the 20-minute session
3256760|NCT01446471||Cardiac Arrest|Patients in Cardiac Arrest will be enrolled
3256761|NCT01446484|Experimental|T reg therapy|Kidney transplantation, followed by immunotherapy given along with autologous CD4+CD25+CD127lowFoxP3+ T regulatory cells infusions
3256762|NCT01446484|Active Comparator|Immunosuppression|Patients will undergo immunosuppressive therapy followed by living related kidney transplantation
3256763|NCT01446497|Active Comparator|Timolol|non selective beta blocker, aqueous humor suppressant ophthalmic solution
3256764|NCT01446497|Active Comparator|Combigan (Timolol/Brimonidine) combination drug|Brimonidine: alpha-2 agonist
3256765|NCT01446510||Hospitalized Medical Patients|All hospitalized medical adult patients
3256766|NCT01446523|Placebo Comparator|Lactulose|Group L receives lactulose Group NL receives placebo
3256767|NCT01446523|Placebo Comparator|Placebo|Group NL receives placebo
3256768|NCT01446536|No Intervention|Control group|This arm which was control group, was randomly selected among patients with acute decompensated heart failure in whom the checklist was not used. This group was managed as per the standard guidelines.
3256769|NCT01446536|Active Comparator|Checklist (intervention) cohort|checklist was used in this group arbitrarily by their treating physician
3256770|NCT01446549|Experimental|Deep Brain Stimulation|
3256771|NCT01446549|Experimental|Locomotor Exercise|
3256772|NCT01446562|Experimental|Y90 Ibritumomab Tiuxetan|Addition of Y90 Ibritumomab Tiuxetan RIT to CHOP-R treatment for follicular lymphoma-patients also receive maintenance Rituximab every 3 months for 2 years after the Y90 Ibritumomab Tiuxetan
3256773|NCT01446588|Experimental|Yoga|Yoga group
3256774|NCT01446601|Experimental|Treatment|The Treatment Arm is implanted with the HGNS System and therapy is turned on at 1 month post-implant.
3256775|NCT01446601|Other|Control|The Control Arm is implanted with the HGNS System and therapy is turned on at 7 months post-implant.
3256776|NCT01446614|Experimental|MSC|Intravenous autologous bone marrow derived mesenchymal stem cells infusion to patients with Parkinson's disease.
3256777|NCT01446627||metal staples|
3256778|NCT01446627||Insorb vicryl staples|
3256779|NCT01446640|Experimental|MSC|Intravenous combined with intrathecal administration of autologous bone marrow derived mesenchymal stem cells to patients with spinal cord injury.
3256780|NCT01446653|Experimental|EARLY|Motivational Interviewing plus feedback counseling with information via video and brochures
3256781|NCT01446653|Active Comparator|Video Information|Providing FASD information via documentary video clips
3256782|NCT01446653|Active Comparator|Informational Brochure|Participants will receive informational brochures on contraception, women and drinking, and cutting down your drinking.
3256783|NCT01446679||atrovastatin group|Who receive atrovastatin
3256784|NCT01446692||Patients with suboptimal response|
3256785|NCT01446692||Patients with symptomatic remission|
3256786|NCT01446718||Gardasil Vaccine|"This is an extension of follow up for participants who received 3 doses of Gardasil vaccine in the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Vaccine in HIV-Infected Pre-Adolescent Girls and Boys in Kenya study."
3256787|NCT01446731|Experimental|Arm A|DC vaccine (mRNA transfected dendritic cell) + Docetaxel
3256788|NCT01446731|Active Comparator|Arm B|Docetaxel alone
3256789|NCT01446744|Active Comparator|Standard arm|Standard of care, palliative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
3256790|NCT01446744|Experimental|Stereotactic arm|Stereotactic ablative radiotherapy, and chemotherapy at the discretion of the treating medical oncologist
3260092|NCT01476514|Experimental|1|"In the setting of comparing patients with a genetic mutation and healthy volunteers blinding of the PI would demand a substantial increase in co-workers (i.e. recruitment, selection of age-and sex matched volunteers), reason why no blinding was chosen.~Affected patients will be compared to age and sex matched volunteers, recruited after completion of testing 23 hyperekplexia patients."
3260093|NCT01476527|Experimental|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
3260094|NCT01476540|Experimental|Deep Brain Stimulation|Deep Brain Stimulation
3260095|NCT01476553|Experimental|Intervention arm|Extensive Intraperitoneal Lavage (EIPL)
3260096|NCT01476566|Experimental|Educational intervention|A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented.
3260097|NCT01476566|No Intervention|Control group|
3260098|NCT01476579|Other|Non-invasive CT coronary angiography|This study is evaluating diagnostic accuracy of non-invasive CT coronary angiography with invasive coronary angiography.
3260099|NCT01476592|Experimental|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
3260100|NCT01476605|Active Comparator|PrT-DMS|1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
3260101|NCT01476605|Experimental|PrT-D|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
3260102|NCT01476605|No Intervention|Waitlist|
3260103|NCT01476605|Active Comparator|Platelet rich plasma|
3260104|NCT01476618||Denver VA OIF/OEF and mental health providers|Denver VA OIF/OEF and mental health providers
3260105|NCT01476631|Experimental|Arm A: 30 minutes walking|First Step program with 30 minutes of walking and 10,000 steps per day for 3 months.
3260106|NCT01476631|Experimental|Arm B: 60 minutes walking|First Step program with 60 minutes of walking and 13,000 steps per day for 3 months.
3260107|NCT01476657|Experimental|IPI-145|IPI-145 is administered orally as a capsule formulation. The IPI-145 drug product is supplied as 1 mg, 5 mg, 25 mg, and 100 mg formulated capsules. IPI-145 will be administered orally daily during each 28-day cycle. Patients will be evaluated for DLTs in the dose escalation portion of the study during Cycle 1 (28 days), after which treatment may continue for additional cycles.
3260108|NCT01476670||Posterior fossa tumor|Patients with posterior fossa tumor scheduled for elective surgery will be enrolled in the study.
3260109|NCT01476683|Experimental|FCT|A single 2 x100 mg dose of an experimental Racecadotril Film-coated tablet (FCT) administered orally with 240 ml of water, with a 7- day washout between visits.
3260110|NCT01476683|Experimental|RPB|A single 2 x100 mg dose of an experimental Racecadotril Powder Blend administered orally with 240 ml of water, with a 7- day washout between visits.
3256791|NCT01446757|Experimental|The intervention group|The intervention group will receive Comprehensive Geriatric Assessment and follow up as a complement to the same standard health care services as the control group. The Comprehensive Geriatric Assessment and follow up will be provides through an outpatient facility that tailors care from a holistic perspective and, based on each patient's individual needs in line with the policy program that Sweden's pensioners' organizations have presented in 2010 together with the Swedish Association of Geriatric Medicine. The team includes, among other things. a. geriatricians, nurses, physiotherapists, assistance officer, dietician, pharmacist and co-operation with the dental hygienist.
3256792|NCT01446757|Placebo Comparator|Control group|The control group will receive care in the same way as usual meaning access to primary care, hospital in- and outpatient care and care received by the municipality. The only difference between the two groups are that the control group will not have access to the geriatric care team.
3375724|NCT03893955|Experimental|Dose Expansion Arm 5: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with NSCLC will receive ABBV-927 (at the RP2D established in Arm B) + ABBV-368 + ABBV-181 by IV.
3375725|NCT03893955|Experimental|Dose Expansion Arm 4: ABBV-927+ Nab-paclitaxel + ABBV-368 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Nab-paclitaxel + ABBV-368 by IV.
3375726|NCT03893955|Experimental|Dose Expansion Arm 3: ABBV-927 + Carboplatin TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin by IV.
3375727|NCT03893955|Experimental|Dose Expansion Arm 2: ABBV-927 + Carboplatin + ABBV-181 TNBC|Participants with TNBC will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-181 by IV.
3375728|NCT03893955|Experimental|Dose Expansion Arm 1: ABBV-927 + Carboplatin + ABBV-368 TNBC|Participants with Triple Negative Breast Cancer (TNBC) will receive ABBV-927 (at the RP2D established in Arm A) + Carboplatin + ABBV-368 by IV.
3256793|NCT01446783|Active Comparator|mecasermin + Ehlers-Danlos|
3256794|NCT01446783|Placebo Comparator|Saline + Ehlers-Danlos|
3256795|NCT01446783|Active Comparator|Mecasamin + healthy control|
3375729|NCT03893955|Experimental|Dose Escalation Arm B: ABBV-927 + ABBV-368 + ABBV-181 NSCLC|Participants with non-small-cell-lung-cancer (NSCLC) will receive ABBV-927 IV at various dose levels + ABBV-368 + ABBV-181. This will determine the recommended phase two dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181.
3375730|NCT03893955|Experimental|Dose Escalation Arm A: ABBV-927 + ABBV-368 Solid Tumors|Participants with Solid Tumors will receive various doses of ABBV-927 by intravenous (IV) infusion plus ABBV-368. This will determine the recommended phase two dose (RP2D) of ABBV-927.
3375731|NCT03872778|Experimental|Phase I Cohort I|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 50 mCi (1.85 GBq) cycle 1, 60% Estimated Cumulative Dose (ECD) for cycles 2-4, q6w"
3375732|NCT03872778|Experimental|Phase I Cohort II|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 60% ECD for 3 cycles (q6w)"
3375733|NCT03872778|Experimental|Phase I Cohort III|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 80% ECD for 3 cycles (q6w)"
3375734|NCT03872778|Experimental|Phase I Cohort IV|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 3 cycles (q6w)"
3375735|NCT03872778|Experimental|Phase I Cohort V|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 3 cycles (q6w)"
3375736|NCT03872778|Experimental|Phase I Cohort VI|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 100% ECD for 2 cycles (q6w)"
3256796|NCT01446783|Placebo Comparator|Saline + healthy control|
3256797|NCT01446822|Experimental|Bipolar transurethral resection|
3256798|NCT01446822|Active Comparator|Monopolar transurethral resection|
3256799|NCT01446835|Experimental|nelfilcon A|Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
3256800|NCT01446835|Active Comparator|etafilcon A|Etafilcon A printed contact lens randomly assigned to one eye, with nelfilcon A printed contact lens assigned to the fellow eye for contralateral wear.
3256801|NCT01446848|Experimental|iron supplement|open-label iron supplement intervention group
3256802|NCT01446861||Cystic fibrosis patients|Consecutive cystic fibrosis patients attending regular Controls at the CF clinic in Bergen
3256803|NCT01446861||Healthy controls|Age and gender matchet healthy Controls recruited by Board notice and advertising.
3256804|NCT01446887|No Intervention|non-prophylactic anticoagulation|without prophylactic anticoagulation
3256805|NCT01446887|Experimental|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
3256806|NCT01446900|Experimental|Rituximab cladribine|
3256807|NCT01446926|Experimental|Group 1: Adults High Dose (Formulation 1)|Adults who will receive a single injection of high dose investigational Pneumococcal vaccine
3256808|NCT01446926|Placebo Comparator|Group 2: Adults Placebo|Adult participants who will receive an injection of placebo
3256809|NCT01446926|Experimental|Group 3: Toddlers High Dose (Formulation 1)|Toddlers who will receive a single injection of high dose Pneumococcal vaccine
3256810|NCT01446926|Placebo Comparator|Group 4: Toddlers Placebo|Toddlers who will receive a single injection of placebo
3256811|NCT01446926|Experimental|Group 5: Infants Low Dose (Formulation 2)|Infants who will receive 3 injections of low dose low dose Pneumococcal vaccine
3256812|NCT01446926|Placebo Comparator|Group 6: Infants Placebo|Infants who will receive 3 injections of placebo
3256813|NCT01446926|Experimental|Group 7: Infants Middle Dose (Formulation 3)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
3256814|NCT01446926|Experimental|Group 8: Infants Middle Dose (Formulation 4)|Infants who will receive 3 injections of middle dose Pneumococcal vaccine
3256815|NCT01446926|Placebo Comparator|Group 9: Infants Placebo|Infants who will receive 3 injections of placebo
3256816|NCT01446926|Experimental|Group 10: Infants High Dose (Formulation 1)|Infants who will receive 3 injections of high dose Pneumococcal vaccine
3256817|NCT01446926|Placebo Comparator|Group 11: Infants Placebo|Infants who will receive 3 injections of placebo
3375737|NCT03872778|Experimental|Phase I Cohort VII|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: 120% ECD for 2 cycles (q6w)"
3375738|NCT03872778|Experimental|Phase IIa|"[68 Ga]-NeoB: 50 micrograms/dose at screening~[177Lu]-NeoB: dose TBD based on Cohorts I-VI, 3 cycles q6w"
3256818|NCT01446939||Parkinson's disease|Patients with primary Parkinson's disease
3256819|NCT01446939||Essential tremor|Patients with essential tremor
3256820|NCT01446939||Healthy volunteers|Healthy volunteers
3375741|NCT03869970|Active Comparator|Rest|Discharge instructions focused on 24 - 48 hours of rest then symptom guided activity, Fitbit monitored.
3375742|NCT03869970|Active Comparator|mHealth|"Use of the resilience application on a smart phone to assess daily symptoms over 14 days and follow a self directed, symptom guided return to physical activity. Also Fitbit monitored."
3375743|NCT03869970|Active Comparator|Activity|Low intensity activity regardless of symptoms using their Fitbit to measure said activity with goals (eg. 10,000 steps/ day.
3375744|NCT03869970|Active Comparator|Both Activity and mHealth|"This group will receive both interventions and utilize the SuperBetter app. Interventions will be integrated by having research assistants support the subject to set and physical activity goals and milestones to the subject's pre-programmed general resilience goals in the SuperBetter© app (e.g. take a 30 min walk, march in place for 5 minutes, increase my step count by 2000 today, achieve 10,000 steps today)."
3375745|NCT03869190|Active Comparator|Atezolizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375746|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375747|NCT03869190|Experimental|Atezolizumab + Niraparib for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Niraparib (Nira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375748|NCT03869190|Experimental|Atezolizumab + Hu5F9-G4 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Hu5F9-G4 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375749|NCT03869190|Experimental|Atezolizumab + Tiragolumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3256821|NCT01446952|Experimental|Dose Escalation|Vitamin E δ-Tocotrienol will be administered orally as a single agent once. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules.
3256822|NCT01446978|Active Comparator|initial single dose of hep A vaccine|The participants will receive a single dose of hepatitis A vaccine at 0+1+6 months
3375750|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375751|NCT03869190|Experimental|Atezolizumab + Tocilizumab for mUC Cohort (Stage 1)|Participants will receive atezolizumab and Tocilizumab (TCZ) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375752|NCT03869190|Experimental|Atezolizumab + RO7122290 for mUC Cohort (Stage 1)|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3256823|NCT01446978|Active Comparator|initial double dose|Participants will receive one dose of hepatitis A vaccine in each M. deltoids and an additional dose at 6 months later
3256824|NCT01446991|Experimental|Favorable prostate cancer with pubic arch interference|Men in this arm have chosen brachytherapy for management of localized prostate cancer and do not require androgen ablation for oncologic reasons but have an enlarged prostate causing pubic arch interference and thus require prostate size reduction prior to brachytherapy. They will have 2-3 months of Degarelix with measurement of prostate volume at 8 and 12 weeks.
3256825|NCT01446991|Experimental|Intermediate risk prostate cancer, 6 months Degarelix|Men in this arm have higher risk prostate cancer (upper tier intermediate risk by National Comprehensive Cancer Network [NCCN] guidelines) and require 6 months of androgen ablation in conjunction with brachytherapy. Prostate size must be > 40 cc at baseline so that prostate size reduction measurements are appropriate. Prostate measurements by transrectal ultrasound with be taken at 12 weeks and 20 weeks.
3256826|NCT01447043||Group 1|
3256827|NCT01447056|Experimental|LMP Specific T cells|LMP specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line and the IV flushed with saline. The volume of infusion will depend upon the concentration of the cells when frozen, the dose level, and the size of the patient.
3375753|NCT03869190|Experimental|RO7121661 for mUC Cohort (Stage 1)|Participants will receive RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375754|NCT03869190|Experimental|Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Enfortumab Vedotin (EV) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375755|NCT03869190|Experimental|Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2)|Participants will receive atezolizumab and Sacituzumab Govitecan (SG) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375756|NCT03869190|Active Comparator|Atezolizumab for MIBC Cohort 1 PD-L1+|Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375757|NCT03869190|Experimental|Atezolizumab + Tiragolumab for MIBC Cohort 1 PD-L1+|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375758|NCT03869190|Experimental|Atezolizumab + RO7122290 for MIBC Cohort PD-L1+|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375759|NCT03869190|Active Comparator|Atezolizumab for MIBC Cohort 2 PD-L1-|Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375760|NCT03869190|Experimental|Atezolizumab + Tiragolumab for MIBC Cohort 2 PD-L1-|Participants will receive atezolizumab and Tiragolumab (Tira) until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3256828|NCT01447069|Active Comparator|Salbutamol|The patients in the study groups will receive the selective β2 agonist, Salbutamol, in addition to their ongoing optimal heart failure therapy.
3256829|NCT01447069|No Intervention|control|The patients in the control group will continue with their regular optimal medical therapy without any intervention.
3375761|NCT03869190|Experimental|Atezolizumab + RO7122290 for MIBC Cohort 2 PD-L1-|Participants will receive atezolizumab and RO7122290 until unacceptable toxicity or loss of clinical benefit, as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3375763|NCT03861234|Experimental|BI 836880|Single Rising Dose part followed by a Multiple Rising Dose part
3375764|NCT03857620|Active Comparator|Arm I (usual care)|Healthcare providers/institutions perform usual care.
3375765|NCT03857620|Experimental|Arm II (OPTI-Surg training and materials)|Healthcare providers/institutions receive OPTI-Surg training and informational materials.
3375766|NCT03857620|Experimental|Arm III (OPTI-Surg training and materials, coach)|Healthcare providers/institutions receive OPTI-Surg training and informational materials and meet with a coach.
3375767|NCT03855449|Other|Task Analysis Intervention Group|DECIDE problem-solving curriculum will be delivered in a group setting.
3256830|NCT01447082||Quetiapine XR group|
3256831|NCT01447082||Non-quetiapine comparison group|
3256832|NCT01447095|Active Comparator|Low dose prostacyclin|
3256833|NCT01447095|Active Comparator|High dose prostacyclin|
3256834|NCT01447095|Placebo Comparator|Placebo|
3256835|NCT01447108|Experimental|TN patients|Patients suffering from Trigeminal neuralgia
3256836|NCT01447134||Surgical|Group (a) [Those to undergo surgical excision or biopsy] patients will receive RGD-K5 scan within two weeks of conventional image evaluations. The image result will be confirmed with histopathological results.
3256837|NCT01447134||Chemotherapy concurrent Radiation|Group (b) patients [Those with N2c-3M0 disease to receive chemotherapy followed by concurrent chemoradiotherapy] will receive RGD-K5 scan prior to beginning of the therapy, after induction chemotherapy, within two weeks after concurrent chemoradiotherapy and two months after completion of concurrent chemoradiotherpy; all within two weeks of conventional image evaluations.
3256838|NCT01447134||RGD-K5 scan|Group (c) patients [Those with M1 disease to receive biotherapy or chemotherapy] will receive RGD-K5 scan prior to the beginning of the first line systemic therapy, two weeks after beginning of the first line systemic therapy, within two weeks of first response evaluation for the first line systemic therapy, and within two weeks after end of the first line systemic therapy; each RGD-K5 scan would be performed within two weeks of conventional image studies. The systemic therapy might be biotherapy or chemotherapy.
3256839|NCT01447147|Placebo Comparator|Placebo (Group A)|
3256840|NCT01447147|Experimental|CCX140-B (Group B)|
3256841|NCT01447147|Experimental|CCX140-B (Group C)|
3375774|NCT03852901|Experimental|Single Arm|Single group
3375775|NCT03845517|Placebo Comparator|Placebo|Placebo
3375776|NCT03845517|Experimental|PF-06700841 15 mg|PF-06700841 15 mg
3375777|NCT03845517|Experimental|PF-06700841 30 mg|PF-06700841 30 mg
3375778|NCT03845517|Experimental|PF-06700841 45 mg|PF-06700841 45 mg
3375779|NCT03836079|Experimental|ADHF Patients|Treatment with preCARDIA System
3375780|NCT03817606|Experimental|Tritanium Posterior Lumbar Cage|Surgical placement of the Tritanium Posterior Lumbar Cage
3256842|NCT01447160|Experimental|facet joint infiltration|The experimental group will be submitted to intra-articular infiltration of six facet joints (L3/L4;L4/L5;L5/S1 bilaterally) with triamcinolone hexacetonide
3256843|NCT01447160|Active Comparator|intramuscular injection|The control group which were submitted to triamcinolone acetonide intramuscular injection of six lumbar paravertebral points
3256844|NCT01447173|Experimental|2000 IU vitamin D Daily|
3256845|NCT01447173|Placebo Comparator|400 IU Vitamin D pill|
3375781|NCT03817606|Active Comparator|AVS PEEK UniLIF|Surgical placement of the AVS PEEK UniLIF Posterior Lumbar Cage
3256846|NCT01447186||Patient Decision Aid for Spanish Speaking Men|Spanish-Language Slide Set
3256847|NCT01447199||Gene Mutation|Group with increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset.
3256848|NCT01447199||No Cancer History|Group with little/no personal or family history of cancer.
3256849|NCT01447199||Spouses|Spouses of those who may have an increased risk for developing colorectal and/or other cancers as the result of an inherited gene mutation, family history of cancer, or an early age of cancer onset, or little/no personal or family history of cancer.
3256850|NCT01447212|Experimental|Hydromorphone|Phase I: Injectable Hydromorphone is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; or 2) switch to oral hydromorphone, for another six months.
3256851|NCT01447212|Active Comparator|Diacetylmorphine|Phase I: Injectable Diacetylmorphine is received for 6 months of the study. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable Diacetylmorphine; or 2) switch to oral Diacetylmorphine, for another six months.
3256852|NCT01447251|Experimental|A: Newly Diagnosed/CPAP/NO DM/PreDx DRS|patients who have newly-diagnosed obstructive sleep apnea (OSA) requiring continuous positive airway pressure (CPAP) therapy without diabetes and are given the result of the diabetes risk score
3256853|NCT01447251|Experimental|B: Newly Diagnosed/CPAP/NO DM/NO PreDx DRS|patients who have newly-diagnosed OSA requiring CPAP therapy without diabetes and are not given the result of the diabetes risk score
3256854|NCT01447251|Active Comparator|C: Controls|age, sex, and BMI-matched controls without OSA or diabetes
3256855|NCT01447251|Active Comparator|D: Controls on CPAP|age, sex, BMI, and OSA severity matched patients on CPAP therapy for OSA
3256856|NCT01447264|Placebo Comparator|Land exercises|The patients of this group will perform the same exercises from water exercises
3256857|NCT01447264|Active Comparator|Water exercises|The patients of this group will perform the same exercises from land exercises
3256858|NCT01447264|No Intervention|Control group|No intervention will be recommended
3256859|NCT01447277|Experimental|Femoral and Sciatic Block|Administration of preoperative femoral and sciatic nerve blocks
3256860|NCT01447277|Other|Femoral Block Only|Administration of a femoral nerve block prior to surgery
3256861|NCT01447290||Women being evaluated for preeclampsia|
3256862|NCT01447303||Outcomes following viscosupplemantation|Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.
3256863|NCT01447316||Bariatric surgery|Patients undergoing bariatric surgery for weight loss.
3256864|NCT01447329|Experimental|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
3256865|NCT01447329|Placebo Comparator|standard|placebo
3256866|NCT01447355|Experimental|Prevention (cholecalciferol)|Participants receive cholecalciferol PO twice weekly for up to 8-9 weeks.
3256867|NCT01447368|Experimental|Cinacalcet treatment|Oral Cinacalcet treatment arm, 25mg daily to be administered and gradually step up as required to control iPTH between 2 - 9 times lab reference range, Maximum dose to be given is 100mg daily
3256868|NCT01447368|Active Comparator|Surgical total parathyroidectomy|Surgical total parathyroidectomy with forearm autografting will be performed for patients randomized to this arm.
3256869|NCT01447381||mycophenolate mofetil|Moderate to severe atopic dermatitis being treated with systemic mycophenolate mofetil
3256870|NCT01447381||cyclosporine|Moderate to severe atopic dermatitis being treated with systemic cyclosporine
3256871|NCT01447381||azathioprine|Moderate to severe atopic dermatitis being treated with systemic azathioprine
3256872|NCT01447381||methotrexate|Moderate to severe atopic dermatitis being treated with systemic methotrexate
3256873|NCT01447394|Experimental|Arm 1: Pegylated Interferon Lambda + Ribavirin|
3256874|NCT01447394|Active Comparator|Arm 2: Pegylated Interferon Alfa-2a + Ribavirin|
3256875|NCT01447459|Experimental|Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 months (t2), and 3 months (t3) after enrollment.~This group will also receive reinforced asthma education via telephone at 2 weeks, 1 month, and 3 months after enrollment."
3256876|NCT01447459|No Intervention|No Reinforced Education|"The caregivers of the subjects enrolled in this group will be administered two survey instruments at enrollment (t0), and again via telephone at 2 weeks (t1), 1 month (t2), and 3 months (t3) after enrollment.~This group will not receive reinforcing of the asthma education at 2 weeks, 1 month, and 3 months after enrollment."
3256877|NCT01447472|Experimental|MDMA|One single dose of MDMA (1.5 mg/kg; range 75-100 mg)
3256878|NCT01447485|Experimental|Valsartan 20 mg or 40 mg|
3256879|NCT01447498|No Intervention|Control group|
3256880|NCT01447498|Active Comparator|Screening and risk assessment|
3375784|NCT03810144||Vectra Guided|For patients in the guided care arm, treating physicians will receive the Vectra MBDA Test score prior to the patient visit and will have a set of guidance for decision-making based on these scores. Treating physicians will be strongly encouraged to follow the guidance but will not be required to do so. For test results to be available at the time of each visit in the MBDA guided treatment arm, blood testing will be performed 7-10 days before the visit.
3375785|NCT03810144||Usual Care|For patients in the UC arm, treating physicians will not have access to MBDA scores until the end of the study.
3256881|NCT01447537|Active Comparator|Exercise, relaxation|Active comparator: Exercise + relaxation Patients will perform exercise + relaxation for 3 months
3256882|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
3256883|NCT01447550||Bosentan|Bosentan
3256884|NCT01447563|Experimental|Clopidogrel tablets 75mg|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
3256885|NCT01447563|Experimental|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
3256886|NCT01447589|Experimental|Nelfinavir plus radical radiotherapy|Nelfinavir given in combination with radical RT
3256887|NCT01447602|Experimental|Interpersonal psychotherapy (IPT-A)|Interpersonal psychotherapy for depressed adolescents which focuses on identifying problematic relationships connected to onset or maintenance of depression and suicidal behavior. The treatment teaches skills such as communication and problem-solving to the adolescent and parents.
3256888|NCT01447615|Experimental|Bridges|
3256889|NCT01447615|Experimental|Bridges PLUS|
3256890|NCT01447615|Other|Usual Care|
3256891|NCT01447628|Active Comparator|Ferinject or CosmoFer|"IV iron formulation used in Europe - Ferinject - given over 15 minutes~IV iron formulation used in China - CosmoFer - over a period of 4 to 6 hours"
3256892|NCT01447628|Placebo Comparator|Saline|Placebo comparator
3256893|NCT01447641||Cluster headache|Cluster headache sufferers (both chronic and episodic)
3256894|NCT01447654|Active Comparator|Losartan|
3256895|NCT01447654|Placebo Comparator|Placebo|
3256896|NCT01447667|Experimental|Magnetic resonance elastography|Magnetic resonance elastography before radiofrequency ablation therapy will be performed.
3256897|NCT01447680||Blood samples, low risk population|
3256898|NCT01447680||Blood samples, high risk population|
3256899|NCT01447680||Blood samples, known HIV positive|
3256900|NCT01447732|Experimental|Part 1|Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804
3256901|NCT01447732|Experimental|Part 2|Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804
3256902|NCT01447745||Observational, longitudinal study|Adult men and women representative of the population of asymptomatic adult men and women aged from 35-65 years living in the Québec City metropolitan area
3256903|NCT01447758|Experimental|LEO 29102 2,5 mg/g cream|
3256904|NCT01447758|Placebo Comparator|LEO 29102 Cream Vehicle|
3256905|NCT01447771|Experimental|Lifestyle counseling|Decision control preference intervention
3256906|NCT01447784|Placebo Comparator|Placebo|
3256907|NCT01447784|Experimental|ToleroMune HDM Dose 1|
3256908|NCT01447784|Experimental|ToleroMune HDM Dose 2|
3256909|NCT01447784|Experimental|ToleroMune HDM Dose 3|
3256910|NCT01447797|Experimental|HCP0912|Irbesartan/Atorvastatin combination tablet
3256911|NCT01447797|Active Comparator|Irbesartan and Atorvastatin|coadministration of irbesartan and atorvastatin
3256912|NCT01447810|Experimental|Treatment|
3256913|NCT01447836||Sepsis|Sepsis patients who are admitted to SICU of our clinical center.
3256914|NCT01447836||Control|Postoperative patients who underwent abdominal surgery and then was directly transferred to SICU of our clinical center.
3256915|NCT01447862|Active Comparator|Vernakalant|Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
3256916|NCT01447862|Active Comparator|Ibutilide|Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
3256917|NCT01447901||previously treated LPLD Cohort|Subjects in Cohort 1 (previously treated LPLD Cohort) must have received AMT-011 during Studies CT-AMT-011-01 or -02
3256918|NCT01447901||untreated LPLD control Cohort|Subjects in Cohort 2 (untreated LPLD control Cohort)) may have completed study PREPARATION-02 or known patients with genetically confirmed LPLD
3256919|NCT01447901||normal healthy control Cohort|Volunteers in Cohort 3 (normal healthy control Cohort) must not have LPLD
3256920|NCT01447940|Placebo Comparator|Conventional Care|Patients will have conventional care with 2 standard visits (inclusion and 12 months) + HbA1c measure at 6 months. Patients won't use Meos ePortal
3256921|NCT01447940|Experimental|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
3256922|NCT01447953|Experimental|Activity targeted pain rehabilitation|A new activity and life-role targeting pain rehabilitation program (ALAR) has been developed to reduce psychosocial barriers to rehabilitation progress, promote re-integration into life-role activities and facilitate return-to-work.
3256923|NCT01447953|Active Comparator|Treatment as usual|Usual treatment consisting of multimodal rehabilitation provided by multi-professional teams in primary health care in the County of Dalarna, Sweden.
3375786|NCT03801902|Experimental|Arm I (durvalumab, ACRT)|Patients receive durvalumab IV over 60 minutes on day 1 starting 2 weeks prior to radiation therapy. Treatment repeats every 4 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ACRT 1 fraction per day, 5 days per week for 15 fractions.
3375787|NCT03801902|Active Comparator|Arm II (durvalumab, standard RT)|Patients receive durvalumab as in Arm I. Patients also undergo conventionally fractionated radiation therapy 1 fraction per day, 5 days per week for 30 fractions.
3256924|NCT01447966|No Intervention|Treatment as Usual|Participants randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice.
3256925|NCT01447966|Experimental|Immediate CBT|Therapists will work with families for 12 twice weekly sessions, each lasting up to 60 minutes implementing a developmentally appropriate modulated cognitive behavioral therapy approach. A manualized CBT protocol will be followed.
3256926|NCT01447979|Experimental|All patients|this is the only arm of the study, and concerns all patients.
3256927|NCT01447992|Experimental|Portable artificial pancreas system with Control-To-Range|
3256928|NCT01448005||wearable defibrillator use|subjects will use a wearable defibrillator
3256929|NCT01448018|Active Comparator|ranibizumab|patients in this arm receive 3 monthly injection of ranibizumab
3256930|NCT01448018|Active Comparator|Hemodilution|hemodilution using erythrocytapheresis is performed as early as possible after inclusion, in order to lessen hematocrit level (target hematocrit of 35%)
3256931|NCT01448018|Active Comparator|ranibizumab and hemodilution|patients receive both treatments
3256932|NCT01448031|Experimental|1|Capsule ASA 81mg/esomeprazole 20mg
3256933|NCT01448031|Active Comparator|2|ASA (Acetylsalicylzuur Apotex cardio 80 mg) Tablet 80 mg
3256934|NCT01448070|Experimental|NN729 manufacturing process|
3256935|NCT01448070|Active Comparator|Current manufacturing process|
3256936|NCT01448083||Neuroendocrine tumor patients|
3256937|NCT01448096|Experimental|primary breast DLBCL|isolated breast involvement with or without nodal disease
3256938|NCT01448109|Active Comparator|Hydrocortisone|
3256939|NCT01448109|Placebo Comparator|Sterile air filled vial|
3256940|NCT01448122|Active Comparator|Avene Compact Honey SPF 50|Study product will be scraped from compact case and weighed. Product will be applied to half the area to be exposed with visible light at a concentration of 2 mg/mL.
3256941|NCT01448122|No Intervention|No intervention|Half of the area to be exposed to visible light will have no study product applied.
3256942|NCT01448135|Experimental|Vital AF|
3256943|NCT01448135|Active Comparator|Osmolite 1.2|
3256944|NCT01448148|Experimental|Cognitive intervention|Use of Memo protocol for 8 weeks
3256945|NCT01448148|Experimental|Psychosocial intervention|"Use of Programme d'intervention psychosociale axé sur le bien-être psychologique for 8 weeks"
3256946|NCT01448148|No Intervention|no contact control group|waiting list
3256947|NCT01448161||Pediatric and Adult ICU patients|Pediatric and Adult ICU patients
3256948|NCT01448174|Active Comparator|atorvastatin|"The prospective, randomized, double-blind, placebo-controlled study:~will be preceded by one month non-pharmacological treatment of hyperlipidemia (prerandomization phase)~130 hyperlipidemic hemodialysis (HD) patients will be randomly assigned to receive blinded study drug: 65 patients will be allocated to start with atorvastatin and 65 patients - with placebo.~Atorvastatin will be administered and monitored according to the K/DOQI guidelines (2003).~The prospective, observational study:~- 35 hyperlipidemic patients will be followed for 30 weeks on the prescribed non-pharmacological treatment of hyperlipidemia"
3256949|NCT01448174|No Intervention|Lifestyle counseling|"Protocol of the prospective study in obese persons:~after taking the anthropometric measurements and collecting a blood sample, the start of weight lowering therapy with a prescribed diet and planned physical activity~follow-up for 30 weeks (measurement of body weight every week)."
3256950|NCT01448174|No Intervention|The controls (healthy volunteers)|
3256951|NCT01448200|Experimental|Part I: single dose escalation in healthy volunteers|"There will be three sequential single dose cohorts:~Cohort A: PPI-668 dose D1 or placebo~Cohort B: PPI-668 dose D2 or placebo~Cohort C: PPI-668 dose D3 or placebo"
3256952|NCT01448200|Experimental|Part I: multiple dose administration to healthy volunteers|"Upon completion of the single dose escalation phase, an additional cohort will receive repeat doses:~Cohort D: highest well-tolerated dose from Cohorts A-C or placebo once daily for five days"
3256953|NCT01448200|Experimental|Part II: multiple dose escalation in HCV subjects|"Upon completion of Part I, there will be 3, and potentially 4, sequential cohorts of HCV patients:~Cohort E (genotype-1): PPI-668 dose E1 or placebo~Cohort F (genotype-1): PPI-668 dose E2 or placebo~Cohort G (genotype-1): PPI-668 dose E3 or placebo~Cohort H (genotype-1): if necessary for dose-response assessment; dose to be determined~Cohort I (genotype-2 or -3): PPI-668 dose E4 or placebo"
3375788|NCT03800784|Experimental|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
3256954|NCT01448226||proven or probable aspergillosis|
3256955|NCT01448226||possible aspergillosis|
3256956|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
3256957|NCT01448239|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
3256958|NCT01448252|Active Comparator|TCV|multiple T cell vaccinations against nine myelin peptides at days 1, 30, 90, 180
3256959|NCT01448252|Sham Comparator|Placebo|saline injections subcutaneously at the same 4 time points with active treatment
3256960|NCT01448265|Experimental|Paroxysmal atrial fibrillation.|
3256961|NCT01448278|Experimental|All-inside technique|
3256962|NCT01448278|Active Comparator|Classical technique|
3256963|NCT01448291|Experimental|Nuvaring|This is a single-group study in which data points after use of the etonogestrel/ethinyl estradiol vaginal ring will be compared to baseline.
3256964|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose A|A single subcutaneous injection of Dose A
3256965|NCT01448304|Experimental|alirocumab SAR236553 (REGN727) - Dose B|A single subcutaneous injection of Dose B
3256966|NCT01448317|Experimental|Cohort 1|Alirocumab dose 1 versus placebo
3256967|NCT01448317|Experimental|Cohort 2|Alirocumab dose 2 versus placebo
3256968|NCT01448317|Experimental|Cohort 3|Alirocumab dose 3 versus placebo
3256969|NCT01448317|Experimental|Cohort 4|Alirocumab dose 4 versus placebo
3256970|NCT01448330|Experimental|HCP0911|clopidogrel/aspirin combination tablet
3256971|NCT01448330|Active Comparator|clopidorel and aspirin|coadministration of clopidogrel and aspirin
3256972|NCT01448343|Experimental|FMS|Patients who received blood transfusion using FMS
3256973|NCT01448369|Active Comparator|EyeGiene|EyeGiene (Eyedetec Medical Inc., US) is a self-contained, convenient warm compress system for the eyes. The system is composed of a reusable eye mask and one time use warmers that are inserted into the eye mask. The warming units are activated by squeezing just prior use and deliver 40°C heat for up to 5 minutes within 30-60 seconds.
3256974|NCT01448369|Active Comparator|Blephasteam|Blephasteam (Spectrum Théa, France) is an eyelid warming device that can be conveniently used at home. The goggles provide standardised heat of about 38 degrees to liquefy lipids and also humidify the chambers with mineral water to ensure optimal moisture levels.
3256975|NCT01448369|Placebo Comparator|Control- Hot Compress|The participants in this group will be using warm compresses with a hot towel.
3256976|NCT01448382|Experimental|Healthy volunteers|healthy volunteers
3256977|NCT01448382|Experimental|GI bleeding subjcets|Symptomatic patients referred to undergo standard Gastroscopy (EGD) as part of their standard medical care
3256978|NCT01448395|Experimental|1|
3256979|NCT01448408||Forme Fruste Keratoconus group (FFKG)|FFK eyes had to present a) no apparent signs of KC in clinical examination b) stage 0 in the Amsler-Krumeich scale, and c) demonstrate a KISA index value between 60-100%
3256980|NCT01448408||Normal Group (CG)|Eligibility for participation in the CG was confirmed by consecutive topographies, while all CG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography and KISA index value less than 60%, as well.
3256981|NCT01448434|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs
3256982|NCT01448434|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
3256983|NCT01448460||Fertility Patients|IVF patients with extra eggs or other subjects who desire egg vitrification for fertility preservation
3256984|NCT01448473|Experimental|4 views radiograph serie|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
3256985|NCT01448473|Active Comparator|2-view radiography serie|The 2-film series will include the following views: anterior-posterior and one lateral.
3256986|NCT01448499|Experimental|Clozapine|Clozapine monotherapy
3256987|NCT01448499|Experimental|Amisulpride|Amisulpride monotherapy
3256988|NCT01448499|Experimental|Augmentation|Augmentation of clozapine with amisulpride
3256989|NCT01448512|Other|Usual Care|Participation in 4 time matched sessions on health education topics
3256990|NCT01448512|Experimental|PartnerPlus intervention|Four group counseling sessions focused on prevention of mother to child transmission (PMTCT) sexual risk reduction & adherence.
3256991|NCT01448538||Group 1|
3256992|NCT01448551|Experimental|Text Messaging|
3256993|NCT01448551|No Intervention|Control|Participation in the MPOWER program without receiving tailored text messages
3256994|NCT01448564|Active Comparator|Laser therapy|Recently has been using the LED, known by its acronym in English LED (Light Emitting Diode), devices that are light-emitting non-coherent and monochromatic, having a longer wavelength (± 10 - 30 nm) compared to lasers. The difference between the fundamental radiation emitted by a laser and an LED is the coherence of the beam.
3256995|NCT01448564|Placebo Comparator|Placebo Laser therapy|
3256996|NCT01448577||Dose 3 x 1011 gc/kg|Subjects received AMT-011 at dose 3 x 1011 gc/kg
3256997|NCT01448577||Dose 1 x 1012 gc/kg|Subjects received AMT-011 at dose 1 x 1012 gc/kg
3256998|NCT01448590||Epidural Resite|After ADP, those patients who receive an epidural resite.
3256999|NCT01448590||Spinal catheter|After ADP, those who receive the epidural catheter into the spinal space
3257000|NCT01448603||Placebo|Subjects previously randomised to placebo in TR002
3257001|NCT01448603||ToleroMune Ragweed Regimen 1|Subjects previously randomised to receive ToleroMune Ragweed regimen 1 in study TR002
3257002|NCT01448603||ToleroMune Ragweed Regimen 2|Subject previously randomised to receive ToleroMune Ragweed regimen 2 in study TR002
3257003|NCT01448603||ToleroMune Ragweed regimen 3|Subject previously randomised to receive ToleroMune Ragweed regimen 3 in study TR002
3257004|NCT01448603||ToleroMune Ragweed regimen 4|Subjects previously randomised to receive ToleroMune Ragweed regimen 4 in study TR002
3257005|NCT01448629|Experimental|River|
3257006|NCT01448629|Active Comparator|Standard Care|Standard Care can have several manufacture and brand names. Standard Care is defined af the participants currently used stoma care product.
3257007|NCT01448642|Active Comparator|Atorvastatin|
3375789|NCT03799354|Experimental|Treatment Group|Maximal strenght training (MST) plus endurance training (ET)
3375790|NCT03799354|Active Comparator|Control group|Endurance training (ET)
3257008|NCT01448642|Placebo Comparator|Placebo|
3257009|NCT01448655||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3257010|NCT01448655||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3257011|NCT01448668||Test group with Iscador® Qu|The test group will receive the mistletoe extract Iscador® Qu as supportive treatment in addition to post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3257012|NCT01448668||Control group|The parallel control group will receive no mistletoe but only post-operative conventional oncological therapy (radio-, chemo-, targeted therapy).
3257013|NCT01448681||SICU patients with ICP|Surgical intensive care unit patients with elevated intracranial pressure
3257014|NCT01448694||Blood donors|Healthy volunteers who are donating a pint of whole blood
3257015|NCT01448720|Experimental|Paliperidone palmitate|
3257016|NCT01448733|Experimental|Acanya Plus Atralin|A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.
3257017|NCT01448746|Experimental|intermittent pneumatic compression|another arm include intermittent pneumatic compression plus low molecular weight heparin
3257018|NCT01448772|Active Comparator|Marinol|
3257019|NCT01448772|Experimental|oral solution|
3257020|NCT01448785|Active Comparator|abiliti Group|Subjects will receive implanted abiliti System. The device will be activated to deliver therapy at implant. Gastric stimulation performance testing, therapy adjustment and dietary/exercise counseling will be conducted at each visit.
3257021|NCT01448785|Active Comparator|Gastric Band Group|Subjects will receive an implanted laparoscopic adjustable gastric band. The subjects will have their band adjusted following the standard of care. Dietary/exercise counseling will be conducted at each visit.
3257022|NCT01448798|Experimental|gelatine-thrombin matrix|Nerves-paring during robotic-assisted laparoscopic prostatectomy is conducted without mono- or bipolar electrocautery and clipping by using a hemostatic gelatine-thrombin matrix.
3257023|NCT01448798|Sham Comparator|Control|Nerve-sparing during robotic-assisted radical prostatectomy is conducted with the use of mono- and bipolar electrocautery and surgical clipping.
3257024|NCT01448811|Experimental|AEP monitoring|
3257025|NCT01448811|Active Comparator|RSS monitoring|
3257026|NCT01448837|Active Comparator|Bimatoprost/Timolol drops|The patients will be treated with bimatoprost/timolol fixed combination therapy
3257027|NCT01448837|Active Comparator|Latanoprost drops|The patients will be crossed over to therapy with latanoprost
3257028|NCT01448863||CONTROL|Fertile women (egg-donors)
3257029|NCT01448863||WITH PCO|Obese women with Polycystic Ovarian Syndrome
3257030|NCT01448863||NO PCO|Obese women without Polycystic Ovarian Syndrome
3257031|NCT01448876||chlamydia care as usual|
3257032|NCT01448889|Active Comparator|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
3257033|NCT01448889|Placebo Comparator|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
3257034|NCT01448902|Experimental|OC000459|
3257035|NCT01448902|Placebo Comparator|Placebo|
3257036|NCT01448915||Persons with HIV and HCV coinfection|Persons with HIV and HCV coinfection who receive medical care for HIV infection at Johns Hopkins Hospital
3257037|NCT01448928||Group 1|
3257038|NCT01448941|Active Comparator|Primary arthrodesis TMT 1|Arthrodesis TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
3257039|NCT01448941|Experimental|Temporary extraarticular plate fixation|Temporary extraarticular plate fixation of TMT 1 when instability is present. Primary arthrodesis TMT 2 and 3 when instability present
3257040|NCT01448954|Experimental|ADC3680B oral|
3257041|NCT01448954|Placebo Comparator|Placebo oral|
3257042|NCT01448980|Active Comparator|Physical therapy|The control group will receive physical therapy 2 time per week for 6 weeks
3257043|NCT01448980|Experimental|Thai Traditional Massage|The experimental group will receive Thai traditional massage program 2 times per week for 6 weeks.
3257044|NCT01448993|Placebo Comparator|Placebo|Taking placebo 3 times per week for four weeks
3257045|NCT01448993|Active Comparator|AZI|
3257046|NCT01449019|Active Comparator|intravenous infusion|
3257047|NCT01449019|Experimental|intraduodenal perfusion|
3257048|NCT01449032|Active Comparator|MSC|Adipose derived stem cells
3257049|NCT01449032|Placebo Comparator|Saline|
3257050|NCT01449045|Placebo Comparator|Community Case Management|Provision of access to prompt diagnosis and treatment for malaria by community volunteers in the village (PECADOM)
3257051|NCT01449045|Experimental|Community Case Management plus IPTc|Monthly Intermittent Preventive Treatment with sulfadoxine pyrimethamine plus amodiaquine, in addition to community case management
3257052|NCT01449058|Experimental|BYL719 + MEK162|BYL719 plus MEK162. Dose escalation with a starting dose for the first cohort of 200mg QD BYL719 and 30mg BID MEK162
3257053|NCT01449071|Placebo Comparator|Placebo Group|
3257054|NCT01449071|Experimental|Epratuzumab 600 mg Group|
3257055|NCT01449071|Experimental|Epratuzumab 100 mg Group|
3257056|NCT01449071|Experimental|Epratuzumab 400 mg Group|
3257057|NCT01449071|Experimental|Epratuzumab 1200 mg Group|
3257058|NCT01449084|Active Comparator|early removal of pancreatic duct stent|immediate removal of the pancreatic duct stent at the end of the ERCP procedure
3257059|NCT01449084|No Intervention|leaving the stent in place|the pancreatic duct stent is left in place
3257060|NCT01449097|Experimental|Adductor-Canal-Blockade|
3375791|NCT03797313||Patient's expectations met at Hospital discharge|ARF survivors whose expectations for recovery at hospital discharge are fully met 6 months later.
3375792|NCT03797313||Patient's with unmet expectations at Hospital Discharge|ARF survivors whose expectations for recovery at hospital discharge are not fully met 6 months later.
3375793|NCT03795233|Experimental|Fecal microbiota transplantation|Fecal microbiota transplant G3 capsules will be administered after standard of care with oral vancomycin therapy in participants with primary Clostridium difficile infection.
3375794|NCT03795233|Active Comparator|Oral vancomycin alone (Control)|Oral vancomycin therapy will be administered as per standard of care in participants with primary clostridium difficile infection.
3375795|NCT03793543|Experimental|18F-DCFPyL Injection|9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
3257061|NCT01449097|Active Comparator|The femoral nerve block|
3257062|NCT01449097|Placebo Comparator|Placebo|
3257063|NCT01449110|Placebo Comparator|Placebo in PP|Placebo arm in primary cardiovascular prevention (PP)
3257064|NCT01449110|Placebo Comparator|Placebo in SP|Placebo arm in secondary cardiovascular prevention (SP)
3257065|NCT01449110|Active Comparator|Grape extract in PP|Grape extract obtained without resveratrol in primary cardiovascular prevention
3257066|NCT01449110|Active Comparator|Grape extract in SP|Grape extract without resveratrol in secondary cardiovascular prevention
3257067|NCT01449110|Experimental|Resveratrol-enriched grape extract in PP|Resveratrol-enriched grape extract (Stilvid) in primary cardiovascular prevention
3257068|NCT01449110|Experimental|Resveratrol-enriched grape extract in SP|Resveratrol-enriched grape extract (Stilvid) in secondary cardiovascular prevention
3257069|NCT01449123|Experimental|Inhaler|Subjects prescribed fixed dose combinations perform Mannitol Challenge Test and Reversibility Test once
3257070|NCT01449136|Experimental|antibacterial cement|
3257071|NCT01449149|Experimental|Proton group|Proton radiation total dose 72.00 to 79.2 Gy(RBE) in 40-44 fractions
3257072|NCT01449162|Experimental|Masitinib as add-on to oral corticosteroids|Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
3257073|NCT01449162|Placebo Comparator|Placebo as add-on to oral corticosteroids|Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids
3257074|NCT01449188|Active Comparator|ondansetron, 8 mg IV over 15 minutes|the lower ondansetron IV dose will be used in one of the four treatment periods
3257075|NCT01449188|Active Comparator|ondansetron, 32 mg IV over 15 minutes|the higher ondansetron IV dose will be used in one of the four treatment periods
3257076|NCT01449188|Placebo Comparator|placebo for ondansetron, IV over 15 minutes|placebo for ondansetron IV dose will be used in one of the four treatment periods
3257077|NCT01449188|Active Comparator|moxifloxacin, 400mg tablet (oral)|moxifloxacin is known to produce mild QT prolongation and will be used in one of the four treatment periods
3257078|NCT01449201|Experimental|PF-00299804|
3257079|NCT01449214|Experimental|Ultrasound|Use of ultrasound to identify interlaminar spaces for needle insertion. Intervention/Procedure: ultrasound-guided technique.
3257080|NCT01449214|Active Comparator|Landmarking|Use of manual palpation to identify anatomic landmarks for needle insertion. Procedure/Intervention: landmark-guided technique.
3257081|NCT01449253|Active Comparator|Monotherapy|Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months
3257082|NCT01449253|Active Comparator|Sequential Therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started be added after 3 months. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. Bosentan and sildenafil will be in combination in the last 3 months. No fixed dose combination will be used.
3257083|NCT01449253|Active Comparator|Combination therapy|Bosentan will be started at 62.5mg BD for 4 weeks and then increased to 125mg BD. Sildenafil will be started at 20mg OD and then increased to 20mg TDS if there is no fall in BP. Total duration is of 6 months. No fixed dose combination will be used.
3257084|NCT01449292|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System and Optimal Medical Therapy
3257085|NCT01449292|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
3257086|NCT01449318|No Intervention|Patients undergoing hysterectomy|
3257087|NCT01449344|Experimental|R-HAD + Bortezomib|
3257088|NCT01449344|Active Comparator|R-HAD|
3257089|NCT01449357|Experimental|zalutumumab|
3257090|NCT01449383|Active Comparator|low meat high fibre (lmhf)|consumption of less than 30g red meat per day and at least 40g dietary fibre per day
3257091|NCT01449383|Active Comparator|high meat low fibre (hmlf)|consumption of 200g red meat and not more than 20g dietary fibre per day
3257092|NCT01449396|Sham Comparator|SHAM ACUPUNCTURE|Sham intervention: acupuncture needle without puncture nor stimulation
3257093|NCT01449396|Experimental|REAL ACUPUNCTURE|Experimental: acupuncture in selected points of the protocol designed
3257094|NCT01449396|Other|Control|Bed Rest
3257095|NCT01449409|No Intervention|Usual care|
3257096|NCT01449409|Experimental|Real-time asthma care outreach|
3257097|NCT01449422|Experimental|URGO 310 3082|
3257098|NCT01449422|Active Comparator|Aquacel|
3257099|NCT01449448|Experimental|NSAID|Test Group: This group was given subacromial injections of Ketorolac.
3257100|NCT01449448|Active Comparator|Steroid|This group was given a subacromial injection triamcinolone.
3257101|NCT01449474|Experimental|Group 1|Patient matched instruments
3257102|NCT01449474|Experimental|Group 2|Jig based instruments
3257103|NCT01449487|Active Comparator|PPC-5650|
3257104|NCT01449487|Placebo Comparator|Placebo|
3257105|NCT01449500|Placebo Comparator|Placebo|Placebo
3257106|NCT01449500|Active Comparator|L. reuteri|"L. reuteri will be delivered at a dose of 1x108 CFU of each strain of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day.~Intervention: Dietary Supplement: L. reuteri DSM 17938 and ATCC PTA 6475"
3257107|NCT01449552|Experimental|Group A|No clamp and placebo
3257108|NCT01449552|Experimental|Group B|Tranexamic acid
3257109|NCT01449552|Experimental|Group C|Drain clamping
3257110|NCT01449552|Experimental|Group D|Drain clamping and tranexamic acid
3257111|NCT01449565|Active Comparator|Naltrexone|
3257112|NCT01449565|Placebo Comparator|Placebo|
3257113|NCT01449578|Experimental|Part A, Treatment 1|Dexpramipexole single dose (SAD Dose 1)
3257114|NCT01449578|Placebo Comparator|Part A, Treatment 1 placebo|Dexpramipexole single dose placebo (SAD Dose 1)
3257115|NCT01449578|Experimental|Part A, Treatment 2|Dexpramipexole single dose (SAD Dose 2)
3257116|NCT01449578|Placebo Comparator|Part A, Treatment 2 placebo|Dexpramipexole single dose placebo (SAD Dose 2)
3257117|NCT01449578|Experimental|Part A, Treatment 3|Dexpramipexole single dose (SAD Dose 3)
3257118|NCT01449578|Placebo Comparator|Part A, Treatment 3 placebo|Dexpramipexole single dose placebo (SAD Dose 3)
3257119|NCT01449578|Experimental|Part B, Treatment 1|Dexpramipexole multiple dose (MAD Dose 1)
3257120|NCT01449578|Placebo Comparator|Part B, Treatment 1 placebo|Dexpramipexole multiple dose placebo (MAD Dose 1)
3257121|NCT01449578|Experimental|Part B, Treatment 2|Dexpramipexole multiple dose (MAD Dose 2)
3257122|NCT01449578|Placebo Comparator|Part B, Treatment 2 placebo|Dexpramipexole multiple dose placebo (MAD Dose 2)
3257123|NCT01449591|Experimental|BFH772|
3257124|NCT01449591|Placebo Comparator|Vehicle|
3257125|NCT01449591|Active Comparator|Metronidazole|
3257126|NCT01449604|Active Comparator|stereotactic radiosurgery|Radio surgery single fraction 12 Gy
3257127|NCT01449604|Active Comparator|stereotactic radiotherapy|Stereotactic radiotherapy hypo fraction 18 Gy in 3 fraction
3257128|NCT01449617||Aspirin plus clopidogrel|Patients undergoing stenting for critical carotid stenosis, either symptomatic (previous events of cerebral ischemia) or asymptomatic, undergoing CAS.
3257129|NCT01449643|Active Comparator|IMT Group|Threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cm H20). When patients inhale through Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
3257130|NCT01449643|Sham Comparator|Sham Group|Non-training protocol
3257131|NCT01449656||LMA proseal|
3257132|NCT01449656||LMA Supreme|
3257133|NCT01449695|Experimental|Lifestyle counseling|Group consultation and individual nurse consultation
3257134|NCT01449695|Experimental|e health|An individual web based entry
3257135|NCT01449695|No Intervention|usual care|Usual care
3257136|NCT01449760|No Intervention|No treatment|
3257137|NCT01449760|Active Comparator|Physical Therapy|
3257138|NCT01449760|Experimental|Wii Balance group|
3257139|NCT01449773|Experimental|n-3 PUFAs|
3257140|NCT01449773|Placebo Comparator|Corn and soybean oil pill|
3257141|NCT01449786|Experimental|treatment with rMal d 1|these apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major apple allergen, Mal d 1 during 4 months
3257142|NCT01449786|Active Comparator|treatment with rBet v 1|These apple and birch pollen allergic patients are treated with daily sublingual application of 25µg recombinant Major birch pollen allergen,Bet v 1 during 4 months
3257143|NCT01449786|Placebo Comparator|treatment with placebo drops|These apple and birch pollen allergic patients are treated daily with placebo applied sublingually during 4 months
3257144|NCT01449799|Experimental|Sequence 1|In period 1, subjects will be administered GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers in period 2. In period 3 and period 4, the subjects will receive fluticasone propionate and GSK961081 respectively.
3257145|NCT01449799|Experimental|Sequence 2|In period 1, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by administration of GSK961081 in period 2. In period 3 and period 4, the subjects will receive GSK961081/fluticasone propionate blend via Diskus inhaler followed by the administration of fluticasone propionate respectively.
3257146|NCT01449799|Experimental|Sequence 3|In period 1, subjects will be administered GSK961081 followed by administration of fluticasone propionate in period 2. In period 3, subjects will be administered GSK961081 and fluticasone propionate concurrently via separate Diskus inhalers followed by GSK961081/fluticasone propionate blend via Diskus inhaler in period 4.
3257147|NCT01449799|Experimental|Sequence 4|In period 1, subjects will be administered fluticasone propionate followed by the administration of GSK961081/fluticasone propionate blend via Diskus inhaler in period 2. The subjects will receive GSK961081 in period 3 and concurrent administration of GSK961081 and fluticasone propionate in period 4.
3257148|NCT01449825||Prescriber compliance group|Adult (18+ years) new users of pazopanib with an indication of RCC evaluated for prescriber compliance
3257149|NCT01449825||Incidence of liver chemistry test (LCT) elevation group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib in monotherapy who have a baseline LCT evaluated for LCT elevations
3257150|NCT01449825||Incidence of drug induced liver injury (DILI) cases group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of LCT elevations consistent with Hy's Law to evaluate for drug-induced liver injury
3257151|NCT01449825||Incidence of cases of ALF group|Adult (18+ years) new users of pazopanib, sunitinib, bevacizumab, and sorafenib with RCC (as defined by ICD-9 codes) longitudinally followed up in order to capture occurrences of ICD-9 codes indicative of possible ALF to evaluate for drug-induced liver injury
3257152|NCT01449838|Placebo Comparator|Saline|Subjects were administered single dose or twice daily for 2.5 days repeat dose of placebo by the intravenous route.
3257153|NCT01449838|Experimental|Colistimethate sodium|2.5 milligrams (mg)/kilogram (kg) of CMS-NA (as colistin activity or 75,000 International Unit/kg) was administered as single dose or twice daily for 2.5 days repeat dose by the intravenous route.
3257154|NCT01449877|Active Comparator|Trimethoprim-Sulfamethoxazole|1 tablet every other day, morning.
3257155|NCT01449877|Placebo Comparator|Starch tablet|1 starch tablet every other day, morning.
3257156|NCT01449890|Experimental|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises they have learned during the initial treatment phase in order to cope with depression, e.g. integrating positive activities in their all day life or monitoring the interdependence of cognition, emotion and behaviour.
3257157|NCT01449890|No Intervention|Treatment as usual|After having terminated inpatient CBT patients receive treatment as usual within routine care.
3257158|NCT01449903||Rebilda DC|
3257159|NCT01449903||Clearfil Core DC / Plus|
3257160|NCT01449903||Multicore Flow|
3257161|NCT01449916|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
3257162|NCT01449916|Active Comparator|Usual care|Early blood cultures and antibiotics. Monitoring by study nurses as in experimental arm. Other interventions are according to admitting (non-study) doctors' orders.
3257163|NCT01449942|Experimental|DZ1|DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
3257164|NCT01449942|Placebo Comparator|Saline|Placebo group receives saline injection in combination with radiation therapy.
3257165|NCT01449968||home visit of UMG|home visit with evaluation and management of the situation (control over in-home telephone)
3257166|NCT01449968||telephone management|geriatric mobile unit provides a telephone advice only to the general practitioner with guidance and recommendations (call control)
3257167|NCT01449981|Experimental|Integrated Twelve-Step Facilitation|
3257168|NCT01449981|Experimental|Cognitive Behavioral Therapy|
3257169|NCT01449994|Placebo Comparator|Placebo-Activator|Treatment with Placebo Activator IV
3257170|NCT01449994|Active Comparator|Activator|Treatment with Activator IV adjusting instrument
3257171|NCT01450020|Experimental|Arm I (PN and ACS material)|Participants receive 4 PN sessions tailored to their needs followed by a 6 month booster session and ACS materials.
3257172|NCT01450020|Active Comparator|Arm II (ACS material)|Participants receive ACS materials only.
3257173|NCT01450033|No Intervention|Control group|Standard of care
3257174|NCT01450033|Experimental|Mentoring group|Subjects in this group will participate in the following intervention activities: medical record review; questionnaires including the Hollingshead Socioeconomic Status Survey, modified Medication Adherence Module, Peds QL Transplant Module, Medical Outcomes Study Social Support Scale, and self-efficacy scale; in-person meetings with mentor; e-communication with mentor (i.e. texts, Facebook, phone calls, etc); and collection of pharmacy refill data and clinical data.
3257175|NCT01450046|Experimental|Phase I Dose Escalation|Each investigator will be provided with adequate supplies of Vitamin E δ -Tocotrienol, which will be supplied as 100-mg, 200-mg, and 400-mg capsules. Vitamin E δ-Tocotrienol will be administered orally once. The dose administered to each subject will be fixed and based on cohort assignment. Doses will be administered at the clinical site during each protocol-defined visit.
3257176|NCT01450059||Spontaneous delivery|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via spontaneous delivery.
3257177|NCT01450059||Cesarean section|Approximately 15 HiV exposed Newborns with low HiV transmission risk, born via cesarean section.
3257178|NCT01450072|Sham Comparator|Control arm|Venography and sham angioplasty
3257179|NCT01450072|Active Comparator|Active arm|therapeutic balloon angioplasty
3257180|NCT01450085|Active Comparator|GeneXpert|Point of care GeneXpert
3257181|NCT01450085|Active Comparator|LED Microscopy|Point of care LED Microscopy
3257182|NCT01450111|Experimental|Lacosamide 50 mg group|Lacosamide 50 mg tablet, once a day per os (po)
3257183|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 50 mg|Placebo matched with lacosamide 50 mg tablet, po
3257184|NCT01450111|Experimental|Lacosamide 100 mg group|Lacosamide 100 mg tablet, po
3257185|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 100 mg|Placebo matched with lacosamide 100 mg tablet, po
3257186|NCT01450111|Experimental|Lacosamide 200 mg group|Lacosamide 200 mg tablet, po
3257187|NCT01450111|Placebo Comparator|Placebo group matched with lacosamide 200 mg|Placebo matched with lacosamide 200 mg tablet, po
3257188|NCT01450124|Experimental|Boswellic acids (BOSWELAN)|Baseline to treatment single arm - 4 months baseline and 8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg of BOSWELAN.
3257189|NCT01450150|Experimental|Active tDCS|
3257190|NCT01450150|Sham Comparator|Sham tDCS|
3257191|NCT01450163|Active Comparator|Pregabalin|
3257192|NCT01450163|Placebo Comparator|Placebo|
3257193|NCT01450176|Active Comparator|Pataday once daily|15 subjects will administer Pataday once daily for 2 weeks. Then these subjects will administer Bepreve twice daily for 2 weeks.
3257194|NCT01450176|Active Comparator|Bepreve twice daily|Bepreve twice daily for 2 weeks, then subjects will use Pataday once daily for 2 weeks
3257195|NCT01450202|Placebo Comparator|Air insufflation, colonoscopy, esophagogastroduodenoscopy|
3257196|NCT01450202|Active Comparator|CO2 insufflation, colonoscopy, esophagogastroduodenoscopy|
3257197|NCT01450215|Experimental|Revlimid|
3257198|NCT01450215|No Intervention|Revlimid and dexamethasone|
3257199|NCT01450228|Placebo Comparator|Placebo KI1001|
3257200|NCT01450228|Experimental|KI1001|
3257201|NCT01450241|Experimental|Early antibiotic discontinuation|Antibiotic treatment stopped after 72h, regardless of fever.The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
3257202|NCT01450241|Other|Usual practice|Antibiotic treatment continued according to accepted guidelines and current clinical practice. The antibiotics used will be piperacillin tazobactam for high-risk patients and amoxycillin-clavulanate + ciprlofloxacin for low-risk patients (defined by MASCC scoring system). Alternatives in case of penicillin allergy will be ceftazidine and levofloxacin, respectively.
3257203|NCT01450254|Experimental|Experimental|These patients will carry out a therapy program with the study intervention device.
3257204|NCT01450254|Active Comparator|Control|The patients in this group will not carry out a therapy program with the study intervention device.
3257205|NCT01450267|Placebo Comparator|Physiological solution|
3257206|NCT01450267|Experimental|Reduced Inhaled Glutathione|
3257207|NCT01450280|Experimental|Group 1A|AdCh63 CS 5x10^9 vp
3257208|NCT01450280|Experimental|Group 1B|ChAd63 CS 5x10^9 vp Day 0; MVA CS 2x10^8 pfu Day 56
3257209|NCT01450280|Experimental|Group 2A|AdCh63 CS 5 x 10^10 vp
3257210|NCT01450280|Experimental|Group 2B|ChAd63 CS 5x10^10 vp Day 0; MVA CS 2x10^8 pfu Day 56
3257211|NCT01450293|Experimental|Group A|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
3257212|NCT01450293|Experimental|Group B|5 to 12 months old infants; AdCh63 ME-TRAP, MVA ME-TRAP
3257213|NCT01450293|No Intervention|Group C|5 to 12 months old infants; no vaccination
3257214|NCT01450293|Experimental|Group D|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
3257215|NCT01450293|Experimental|Group E|10 week old babies; AdCh63 ME-TRAP, MVA ME-TRAP
3257216|NCT01450293|No Intervention|Group F|10 week old babies; no vaccination
3257217|NCT01450332|Experimental|study|
3257218|NCT01450345|Experimental|Pregabalin Group|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
3257219|NCT01450358|Active Comparator|Pathogen detection by Multiplex PCR|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. Multiplex PCR will be immediately undertaken and its results will be reported to prompt medical researcher (6-12 hours).The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR.
3257220|NCT01450358|No Intervention|Pathogen detection by blood culture|Blood samples for cultures and Multiplex PCR will be collected before start the antibiotic therapy in patients with sepsis. The results of multiplex PCR will be not informed to the medical researcher, being focused care as a result of blood culture (at least after 72 hours).
3257221|NCT01450371||Interferential|The individuals are treated acutely with interferential electrical stimulation (IES) during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
3257222|NCT01450371||Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
3257223|NCT01450384|Experimental|Treatment (enzyme inhibitor therapy, antiangiogenesis)|Patients receive pemetrexed disodium IV on day 1 every 2 weeks and sorafenib tosylate PO BID for 4 weeks on days 1-5. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3257224|NCT01450410|Active Comparator|Nicotinic Acid|
3257225|NCT01450410|Placebo Comparator|Placebo|
3257226|NCT01450423|Experimental|Physical activity|
3257227|NCT01450423|No Intervention|Control|
3257228|NCT01450436||preterm infants (<35 weeks gestation)|
3257229|NCT01450449|Experimental|Arm 1 - Short Course Radiotherapy|Short Course
3257230|NCT01450449|Active Comparator|Arm 2 - Standard Course Radiotherapy|Standard Course
3257231|NCT01450462|Experimental|Vitamin D (cholecalciferol)|
3257232|NCT01450462|Placebo Comparator|Placebo|
3257233|NCT01450475|Experimental|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
3257234|NCT01450475|No Intervention|control|A blood cuff was around leg without inflation or deflation.
3257235|NCT01450488|Experimental|masitinib 3 mg/kg/day|
3257236|NCT01450488|Experimental|masitinib 6 mg/kg/day|
3257237|NCT01450501||Patients with vascular chronic Q-fever|All patients with chronic Q-fever and an aneurysm or vascular reconstruction
3257238|NCT01450514|Placebo Comparator|Placebo|Sugar pill
3257239|NCT01450514|Experimental|Pipamperone|15 mg once daily
3257240|NCT01450527||Patient fulfilling the criteria of ARDS|
3257241|NCT01450566|Experimental|Lidocaine|Use of lidocaine
3257242|NCT01450566|Placebo Comparator|No lidocaine|No lidocaine/standard of care
3257243|NCT01450579|Placebo Comparator|Placebo|Saline
3257244|NCT01450579|Experimental|Dose -1|ASP7373
3257245|NCT01450579|Experimental|Dose -2|ASP7373
3257246|NCT01450579|Experimental|Dose -3|ASP7373
3257247|NCT01450592||Group 1|
3257248|NCT01450592||Group 2|
3257249|NCT01450605||Patients ≥ 13 years of age with HIV-1|Patients ≥ 13 years of age with HIV-1 who are on Reyataz® treatment at the time of enrollment and have never been participated in this study previously or who are initiating Reyataz® treatment for the first time in the real-life conditions in its registered indication(s) as required by KFDA
3257250|NCT01450618||Atazanavir|HIV patients on antiretroviral therapy using Atazanavir
3257251|NCT01450618||Darunavir|HIV patients on antiretroviral therapy using Darunavir
3257252|NCT01450618||Fosamprenavir|HIV patients on antiretroviral therapy using Fosamprenavir
3257253|NCT01450618||Lopinavir|HIV patients on antiretroviral therapy using Lopinavir
3257254|NCT01450644|Other|Fast track|If patients are randomised to fast-track, their information will be passed to the H2H nurse to organise a case conference within one week of discharge.
3257255|NCT01450644|Other|Waiting list|If patients are in the control arm, they will continue to receive Standard Best Practice (SBP) and their data will be held by the researcher until after the second interview (4 weeks). After this time, they will be contacted by the H2H nurse to receive the intervention and will be interviewed and followed up as for the fast track group.
3257256|NCT01450657||Chronic Kidney Failure 3/4|
3257257|NCT01450670||Dialysis patients|
3257258|NCT01450709||Dialysis patients|
3257259|NCT01450722|Active Comparator|drug eluting stent|Paclitaxel eluting stent for long superficial femoral artery obstruction
3257260|NCT01450722|Active Comparator|bypass operation|femoropopliteal artery bypass operation by using synthetic PTFE graft
3257261|NCT01450748|Experimental|Sodium alginate|oral suspension, 50 mg/ml
3257262|NCT01450748|Placebo Comparator|Placebo|oral suspension without active ingredient
3257263|NCT01450774|Experimental|CHF 1535 50/6µg|
3257264|NCT01450774|Active Comparator|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|
3257265|NCT01450839|Experimental|E2020 5 mg tablet and tape|
3257266|NCT01450839|Placebo Comparator|2|
3257267|NCT01450852|Experimental|Strength Training|The strength training group completed 12 weeks of progressive, periodized resistance training 3d/wk.
3257268|NCT01450852|No Intervention|Active Control Group|The active control group was instructed to maintain normal activity and eating habits. They participated in all pre and post intervention measures.
3257269|NCT01450865|Experimental|Placebo first|Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
3257270|NCT01450865|Experimental|Flupirtine first|Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
3257271|NCT01450878|Experimental|Graft with EPO|intravenous 1000 000UI beta-epoietin one hour before organe retrieval.
3257272|NCT01450878|No Intervention|graft without EPO|no injection befoe organ retrieval
3257273|NCT01450891||total patient group|all new consecutive patients of the participating memory clinics who are suspected of having a primary neurodegenerative disease, meaning that all patients with subjective as well as objective memory complaints are included
3257274|NCT01450904|Experimental|Group A|The length of Quadriceps incision was less than 2 cm.
3257275|NCT01450904|Experimental|Group B|The length of Quadriceps incision was 2 to 4 cm.
3257276|NCT01450904|Experimental|Group C|The length of Quadriceps incision was more than 4 cm.
3257277|NCT01450917||Group A|Brachial plexus injured patients with phrenic nerve dysfunction
3257278|NCT01450917||Group B|Brachial plexus injured patients without phrenic nerve dysfunction
3257279|NCT01450917||Group C|Non brachial plexus injured patients
3257280|NCT01450930|Active Comparator|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
3257281|NCT01450930|Active Comparator|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
3257282|NCT01450956|Experimental|Sevoflurane|Patients will receive 2% sevoflurane via oxygenator during CPB
3257283|NCT01450956|No Intervention|Control|Patients will receive only oxygen and air through oxygenator
3257284|NCT01450969||Interventional Radiologists|All operators are Interventional Radiologists and co-investigators. Prior to start of the study, all operators are asked to provide written informed consent to participate in the study.
3257285|NCT01450982|Experimental|001|JNJ-38518168 / MTX Day 1: MTX: Route=oral use single dose of participant's weekly MTX dose Days 2-15: MTX: Route=oral use single dose of participant's weekly MTX dose and of JNJ-38518168 Type=exact unit=mg number=100 form=capsule route=oral use administered daily.
3257286|NCT01450995|Active Comparator|Treximet|
3257287|NCT01450995|Active Comparator|Imitrex and Aleve|
3257288|NCT01451034|Active Comparator|WHYX cancer group|WHYX cancer diagnosed by pathologic report
3257289|NCT01451034|Placebo Comparator|non-WHYX cancer group|all cancer except WHYX cancer diagnosed by pathologic report
3257290|NCT01451086|Experimental|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
3257291|NCT01451086|Active Comparator|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
3257292|NCT01451112|Experimental|Treated|
3257293|NCT01451125|Experimental|Treated|
3257294|NCT01451138|Experimental|Treated|
3257295|NCT01451151|Experimental|Treated|
3257296|NCT01451177|Experimental|Treated|
3257297|NCT01451190|Experimental|Treated|
3257298|NCT01451216||ABI 50-70 y|patients suffering from acquired brain injury aged 50-70 years old
3257299|NCT01451216||ABI 25-50y|Patients suffering from acquired brain injury aged 25-50 years oled
3257300|NCT01451242||brain injury|
3257301|NCT01451268|Experimental|Panobinostat Arm A|
3257302|NCT01451268|Experimental|Panobinostat Arm B|
3257303|NCT01451294|Active Comparator|Ephedrine|
3257304|NCT01451294|Active Comparator|Phenylephrine|
3257305|NCT01451307||Gastrointestinal malformations|Children who underwent standardized neonatal pediatric surgery due to gastrointestinal malformations
3257306|NCT01451307||No gastrointestinal malformations|Control group of healthy children matched concerning gestational age, weight class and gender
3257307|NCT01451320|Active Comparator|rapid streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
3257308|NCT01451320|Active Comparator|high dose tpa|5-hour infusion of 90 mg t-PA(Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
3257309|NCT01451320|Active Comparator|slow streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
3257310|NCT01451320|Active Comparator|half-dose slow infusion tpa|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
3257311|NCT01451320|Active Comparator|low dose slow infusion tpa|6-hour infusion of 25 mg t-PA(Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
3257312|NCT01451333|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3257313|NCT01451333|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3257314|NCT01451346|Placebo Comparator|Placebo|Placebo sachets contained 5 grams of Maltodextrin only.
3257315|NCT01451346|Experimental|B Infantis 35624|Each 5gram freeze-dried powder contained ≥1*1010 Colony forming units (CFU) of B. infantis 35624/sachet.
3257316|NCT01451359|Experimental|endobronchial valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
3257317|NCT01451450|Experimental|QGE031 A|
3257318|NCT01451450|Experimental|QGE031 B|
3257319|NCT01451450|Experimental|QGE031 C|
3257320|NCT01451450|Experimental|QGE031 D|
3257321|NCT01451450|Placebo Comparator|Placebo A|
3257322|NCT01451450|Placebo Comparator|Placebo B|
3257323|NCT01451450|Placebo Comparator|Placebo C|
3257324|NCT01451450|Placebo Comparator|Placebo D|
3257325|NCT01451476||Healthy females aged >=18|Healthy female volunteers of skin type I or II
3257326|NCT01451489|Active Comparator|Cyclophosphamide|CTX
3257327|NCT01451489|Experimental|FK506|0.05-0.1mg/kg/d;adjust the dose according the serum concentration(aim 5-10ng/ml),maximum dose 6mg/day;divided in twice, interval 12 hours.
3257328|NCT01451502|Experimental|Unlicensed Umbilical Cord Blood Infusion|"All patients will be registered in OnCore under this protocol as well as the specific treatment protocol.~Pre-infusion treatment using intravenous hydration, acetaminophen and diphenhydramine hydrochloride~Unlicensed Umbilical Cord Blood Infusion according to institutional guidelines.~Infusion of minimally manipulated unlicensed UCB units:~vital signs Monitoring during and after UCB infusion:~Management of infusion reactions~Post-transplant care and follow-up: will be done according to the disease specific treatment protocol and institutional guidelines."
3257329|NCT01451515|Experimental|Treatment|"Patients will undergo treatment as described in the intervention section. Interventions include:~Remission induction: prednisone, vincristine, daunorubicin, PEG-asparaginase (or Erwinia asparaginase), IT-MHA (Methotrexate, hydrocortisone, and cytarabine), cyclophosphamide, cytarabine, thioguanine~Consolidation: PEG-asparaginase, High-dose methotrexate (HD-MTX), mercaptopurine~Postremission continuation: Dexamethasone, doxorubicin, vincristine, mercaptopurine, PEG-asparaginase, cyclophosphamide, cytarabine, methotrexate~Reintensification: dexamethasone, cytarabine, etoposide, PEG-asparaginase, clofarabine, cyclophosphamide~All patients receive IT-MHA on days 1 and 15. Some patients also receive additional IT-MHA on days 8 and 22."
3257330|NCT01451528|Experimental|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation
3257331|NCT01451593|Experimental|phenytoin|active arm of trial 1:1 allocation active versus placebo
3257332|NCT01451593|Placebo Comparator|placebo|1:1 allocation active versus placebo
3257333|NCT01451619|Experimental|Laropiprant|
3257334|NCT01451619|Placebo Comparator|Placebo|
3257335|NCT01451658|No Intervention|EVL or GVS treatment|"Endoscopic treatment alone is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.~endoscopic variceal ligation (EVL) or Gastric Variceal Sclerotherapy (GVS)"
3257336|NCT01451658|Experimental|Endoscopic treatment combined propranolol|Endoscopic treatment alone versus combined propranolol is used for 2nd prevention of gastroesophageal variceal bleeding in patients with HCC.
3257337|NCT01451697|Experimental|Experimental: Cognitive Remediation|The remediation intervention will consist of a sequence of computerized cognitive exercises designed to improve a variety of aspects of attention, through repeated drill-and-practice (Bell, Bryson, Greig, Corcoran, & Wexler, 2001; Bracy, 1995; Kurtz et al., 2007). Exercises will be started and continued at the highest level of difficulty, in order to best establish improvement over time. Components of the planned intervention produce performance gains on practiced tasks (e.g., Wexler et al., 1997) and generalization of improvement to other tasks (Kurtz et al., 2007). All training on computer exercises will be conducted with coaching from staff trained in these procedures.
3257338|NCT01451697|Placebo Comparator|Control (Placebo)|The placebo control condition will consist of structured relaxation training, which will involve viewing and participating with meditation and stress-reduction DVDs, and listening to and following a CD of Progressive Muscle Relaxation. Participants will benefit from learning stress reduction techniques in this condition, but will not exercise any of the cognitive domains of interest targeted in the treatment group.
3257339|NCT01451710|Experimental|Prednisone or Prednisolone|
3257340|NCT01451736|Experimental|paliperidone palmitate (Invega Sustenna)|Participants will be provided paliperidone palmitate (Invega Sustenna), administered in injectible long-acting form, plus group skills training and case management
3257341|NCT01451736|Active Comparator|oral risperidone|Participants will be provided oral risperidone, plus group skills training and case management
3257342|NCT01451788|No Intervention|Conventional group|conventional blood saving methods (use of bone wax for cancellous bony bleeding; bipolar diathermy and epidural space packing for epidural venous bleeding)
3257343|NCT01451788|Experimental|Floseal|Gelatin matrix with human derived thrombin (Floseal) used in adolescents undergoing posterior spinal deformity surgery for adolescent idiopathic scoliosis (AIS)
3257344|NCT01451801|Other|HBsAg|
3257345|NCT01451840|Active Comparator|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of intravenous remifentanil before emergence of a desflurane-based anesthesia
3257346|NCT01451840|Experimental|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
3257347|NCT01451853|Active Comparator|SPI-1005 Low Dose|200 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3257348|NCT01451853|Active Comparator|SPI-1005 Middle Dose|400 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3257349|NCT01451853|Active Comparator|SPI-1005 High Dose|600 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3257350|NCT01451853|Placebo Comparator|Placebo|0 mg SPI-1005, capsule, po, bid, x3d surrounding each cycle of chemotherapy
3257351|NCT01451866|Active Comparator|classic leg-press training|Classic resistance training on the dynamic leg press. 6 x 8 repetitions at 60% 1 RM
3257352|NCT01451866|Experimental|Complex leg-press training|Complex leg-press training with visual feed-back on a dynamic leg-press.
3257353|NCT01451879||Age 0 months to 65 years|Confirmed diagnosis of Pompe Disease, and clinically prescribed immune modulation regimen with agents such as rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone Miglustat, N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their primary/specialist caregiver.
3257354|NCT01451892|Experimental|Dance therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
3257355|NCT01451892|Active Comparator|Education|overweight individuals participating in a patient education ambulatory program for obese people
3257356|NCT01451905|Active Comparator|Psoriasis|
3257357|NCT01451905|Placebo Comparator|Placebo|
3257358|NCT01451918|Active Comparator|Resveratrol|
3257359|NCT01451918|Placebo Comparator|Placebo|
3257360|NCT01451944|Experimental|asthma education and case management|asthma education and case management
3257361|NCT01451957|Experimental|Exercise|90 min exercise on Day 1
3257362|NCT01451957|Experimental|Sedentary Control|Subjects remain sedentary on Day 1 and will either consume a hyper-caloric or a caloric balanced diet
3257363|NCT01451970|Other|High Monounsaturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
3257364|NCT01451970|Other|High Saturated Fat Diet|Subjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
3257365|NCT01452009|Experimental|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|
3257366|NCT01452009|Active Comparator|TRAVATAN®|TRAVATAN® administered one drop once daily
3257367|NCT01452022|Experimental|Inductigraft|open label non randomised to assess performance of synthetic bone graft using the product, Inductigraft, in posterolateral lumbar fusion
3257368|NCT01452035|Experimental|Exercise|
3257369|NCT01452035|No Intervention|Sedentary Control|
3257370|NCT01452048||Obese Sedentary Adults, but otherwise healthy|
3257371|NCT01452061||ASD|Participants with autism spectrum disorder.
3257372|NCT01452061||ADHD/DD|Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.
3257373|NCT01452061||Siblings|Siblings without a developmental or psychiatric disorder.
3257374|NCT01452061||Control|Unrelated individuals without a developmental or psychiatric disorder.
3257375|NCT01452074|Other|Exercise Training with Weight Loss|"During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week~After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight"
3257376|NCT01452087|Other|Exercise Session|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
3257377|NCT01452100|Experimental|prednisone|• Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
3257378|NCT01452100|Placebo Comparator|placebo|Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
3257379|NCT01452113|Other|neuropathy|patients with autonomic neuropathy
3257380|NCT01452113|Other|control|patients without autonomic neuropathy (ewing score <= 0.5)
3257381|NCT01452139|Experimental|At-Risk Genetics Arm: Prasugrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with prasugrel 10mg daily for 1 month.
3257382|NCT01452139|Active Comparator|At-Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients carrying at least 1 at-risk genetic variant with clopidogrel 150mg daily for 1 week followed by 75mg daily.
3257383|NCT01452139|Active Comparator|Low Risk Genetics Arm: Clopidogrel|Treatment of STEMI patients with no at-risk genetic variants with clopidogrel 75mg daily.
3257384|NCT01452204|Experimental|Pulsed Electromagnetical Field|
3257385|NCT01452204|Placebo Comparator|Placebo|
3257386|NCT01452217|Experimental|Secretin|
3257387|NCT01452230|Experimental|Supervised physical activity|
3257388|NCT01452230|No Intervention|Usual care|
3257389|NCT01452243|Experimental|Calcium and vitamin D|The pharmacological intervention will be the daily administration of chewable tablets containing vitamin D and calcium.
3257390|NCT01452256|Experimental|Desflurane|Desflurane for pharmacological conditioning
3257391|NCT01452256|Experimental|Propofol|
3257392|NCT01452282||Ankle Brachial Index|
3257393|NCT01452295|Experimental|AOCH patients|Patients with acute on chronic hepatitis
3257394|NCT01452295|Experimental|AAH patients|Patients with acute alcoholic hepatitis
3257395|NCT01452308|Experimental|Cohort 1|Participants will receive simtuzumab at a dose of 10 mg/kg by intravenous (IV) infusion every other week for a total of 3 infusions.
3257396|NCT01452308|Experimental|Cohort 2|Participants will receive simtuzumab IV every other week for a total of 3 infusions. The dose will depend on the safety and tolerability of simtuzumab seen in Cohort 1 but will not exceed 20 mg/kg.
3257397|NCT01452321|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
3257398|NCT01452321|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of active rTMS delivered to the left dorsolateral prefrontal cortex.
3257399|NCT01452334|Experimental|Arm 1: BMS-936559|
3257400|NCT01452360||Collection of CKD patient group|
3257401|NCT01452360||Collection of CKD high-risk group|
3257402|NCT01452360||Collection of healthy control group|
3257403|NCT01452373|Placebo Comparator|Control (placebo)|
3257404|NCT01452373|Experimental|DHEA + Acolbifene|
3257405|NCT01452386||Experimental Group|
3257406|NCT01452386||Control Group|
3257407|NCT01452399|Experimental|Shave Margins|
3257408|NCT01452399|Active Comparator|No shave margins|
3257409|NCT01452438||MenACYW-CRM vaccinated children|All children between the age of 2 to 10 years old who have received of MenACYW-CRM vaccine during the study period.
3257410|NCT01452451|Placebo Comparator|Placebo|Placebo
3257411|NCT01452451|Active Comparator|HM11260C|HM11260C
3257412|NCT01452464||MenACYW-CRM vaccinated adolescents|All adolescent recipients of MenACYW-CRM vaccines during the study period. Among these, adolescents who have additionally experienced an event of interest within the 1-year observation period following vaccination will be included in the self-controlled case series.
3257413|NCT01452477|Active Comparator|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
3257414|NCT01452477|Placebo Comparator|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
3257415|NCT01452490|Experimental|Diode Laser Treatment|
3257416|NCT01452503|Active Comparator|PATH Women's Condom|PATH Women's Condom
3257417|NCT01452503|Active Comparator|FC2 female condom|Female Health Company's FC2 female condom
3257418|NCT01452503|Active Comparator|Reddy 6 female condom (V-Amour)|Reddy 6 female condom (Commercially known as the V-Amour female condom)
3257419|NCT01452516|Other|nanOss Bioactive Bone void filler|Lumbar fusion using interbody cages with autograft in conjunction with instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
3257420|NCT01452542|Experimental|Sequence 1|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: TRTR, with a 7-day washout between dosing in each period.
3257421|NCT01452542|Experimental|Sequence 2|Participants will receive a single oral dose of the following two study treatments under fasting conditions, in accordance with a randomly allocated treatment sequence: three 50-mg Phase 3 capsules of eliglustat (Reference Treatment [R]) or one 150-mg common blend capsule of eliglustat (Test Treatment [T]) according to the following treatment sequence: RTRT, with a 7-day washout between dosing in each period.
3257422|NCT01452555|Active Comparator|In Person Counseling|Participants will receive an in person HIV and HIV testing counseling session
3257423|NCT01452555|Experimental|Video Presentation|Participants will watch an HIV and HIV testing video
3257424|NCT01452568|Experimental|Aspirin|Aspirin 150mg daily, starting day 1 after surgery, for three months.
3257425|NCT01452568|Active Comparator|Warfarin|Warfarin daily dosage to International normalized ratio(INR) value between 2,0 to 3,0.
3257426|NCT01452581|Active Comparator|RBC transfusion|"Administration of up to 2 RBC units on the first postoperative day.~(1 unit at a time followed by evaluation of the primary outcome measure)"
3257427|NCT01452581|Placebo Comparator|Restrictive: Colloid infusion|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
3257428|NCT01452594||Diphenylcyclopropenone|topical gel administration to skin
3257429|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x1|Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose
3257430|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x2|2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose
3257431|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x4|4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose
3257432|NCT01452607|Experimental|SPI-1005 Capsule 200mg Ebselen x8|8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose
3257433|NCT01452607|Placebo Comparator|SPI-1000 Capsule 0 mg Ebselen Placebo|Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose
3257434|NCT01452620||EVAR cohort|All consecutive patients undergoing endovascular AAA repair (EVAR) in our community setting were followed for outcomes.
3257435|NCT01452633|Placebo Comparator|Preincision Placebo|This group of patients will receive saline injection at study port site before incision
3257436|NCT01452633|Active Comparator|Preincision Marcaine|This group will receive marcaine injection at the study port site prior to incision
3257437|NCT01452633|Placebo Comparator|Postincision Placebo|This group of patients will receive preincisional marcaine and then saline injection at study port site prior to closure
3257438|NCT01452633|Active Comparator|Postincision marcaine|This group will receive preincisional marcaine and then marcaine injection at study port site prior to closure
3257439|NCT01452646|Experimental|MRD-directed therapy|
3257440|NCT01452659|Experimental|TAK-385 10 mg QD|
3257441|NCT01452659|Experimental|TAK-385 20 mg QD|
3257442|NCT01452659|Experimental|TAK-385 40 mg QD|
3257443|NCT01452659|Placebo Comparator|Placebo|
3257444|NCT01452672|Active Comparator|RT to chest wall and S/C|Irradiation of the chest-wall and supraclavicular fossa
3257445|NCT01452672|Experimental|RT to chest wall|Irradiation of the chest-wall alone
3257446|NCT01452685|Placebo Comparator|Placebo|
3257447|NCT01452685|Experimental|TAK-385 10 mg QD|
3257448|NCT01452685|Experimental|TAK-385 20 mg QD|
3257449|NCT01452685|Experimental|TAK-385 40 mg QD|
3257450|NCT01452685|Other|Leuplin|
3257451|NCT01452698|Experimental|TAK-438 20 mg QD|
3257452|NCT01452698|Active Comparator|AG-1749 30 mg QD|
3257453|NCT01452711|Experimental|TAK-438 20 mg QD|
3257454|NCT01452711|Active Comparator|Lansoprazole 30 mg QD|
3257455|NCT01452724|Experimental|TAK-438 20 mg QD|
3257456|NCT01452724|Active Comparator|Lansoprazole 30 mg QD|
3257457|NCT01452737|Experimental|2L Golytely/15mg bisacodyl|Subjects will be asked to take 2L Golytely + 15mg bisacodyl for bowel prep the day before colonoscopy.
3257458|NCT01452737|Active Comparator|Standard bowel prep|Subject will receive standard bowel prep (4L Golytely) prior to colonoscopy.
3257459|NCT01452750|Experimental|TAK-438 10 mg QD|
3257460|NCT01452750|Experimental|TAK-438 20 mg QD|
3257461|NCT01452750|Active Comparator|Lansoprazole 15 mg QD|
3257462|NCT01452763|Experimental|TAK-438 10 mg QD|
3257463|NCT01452763|Experimental|TAK-438 20 mg QD|
3257464|NCT01452763|Active Comparator|Lansoprazole 15 mg QD|
3257465|NCT01452776|Experimental|TAK-438 10 mg QD|
3257466|NCT01452776|Experimental|TAK-438 20 mg QD|
3257467|NCT01452802||HM II (HeartMate II LVAD)|Subjects who elect to, and receive HM II LVAD therapy at baseline
3257468|NCT01452802||OMM (Optimal Medical Management)|Subjects who elect to remain on optimal medical management
3257469|NCT01452815|Placebo Comparator|1|Drug: placebo
3257470|NCT01452815|Experimental|2|10mg TZP-102
3257471|NCT01452815|Experimental|3|20mg TZP-102
3257472|NCT01452828|Experimental|Renal Impairment Nondialyzed|
3257473|NCT01452828|Experimental|Renal Impairment Dialyzed|
3257474|NCT01452828|Experimental|Matched Control|
3257475|NCT01452841|Experimental|Grapefruit Consumption|
3257476|NCT01452841|Active Comparator|Control|
3257477|NCT01452867|Active Comparator|Bag-Mask-Ventilation|Bag-Valve Mask-Ventilation in 50 patients in general anesthesia
3257478|NCT01452867|Active Comparator|Laryngeal Mask Ventilation|Laryngeal Mask Ventilation in 50 patients in general anesthesia
3257479|NCT01452867|Active Comparator|Laryngeal Tube Ventilation|Laryngeal Tube Ventilation in 50 patients in general anesthesia
3257480|NCT01452893||Type I diabetes|Adult patients with diabetes mellitus type I but normal adrenal function
3257481|NCT01452893||Addison's disease|Adult patients with Addison's disease
3257482|NCT01452893||Type I diabetes and Addison's disease|Patients suffering from both, diabetes mellitus type I and Addison's disease
3257483|NCT01452893||healthy controls|healthy controls with normal adrenal function and normal glucose regulation
3257484|NCT01452906|Experimental|PA21 and Omeprazole with food|
3257485|NCT01452906|Experimental|No PA21; Omeprazole with food|
3257486|NCT01452906|Experimental|PA21 with food, Omeprazole 2 hrs later|
3257487|NCT01452932|Experimental|Physiotherapy|Group of participants who recive physiotherapy treatment using Kabat technique for the upper limbs resistance training during 12 weeks
3257488|NCT01452932|Other|Yoga|Group of participants who recive Yoga sessions during 12 weeks
3257489|NCT01452958|Experimental|TNF-α|Beromun, Boehringer-Ingelheim, Germany
3257490|NCT01452958|Experimental|Endotoxin|
3257491|NCT01452984||Single Retrospective Interviews|Each retrospective interview will be conducted by the Principal Investigator and/or Project Manager to collect denmographic information and experiential narratives from the patient, using open-ended questions and structured probes based on individual responses. Retrospective interviews will be recorded and scheduled at the patients' convenience either in the clinic, at the home, or at a place that is convenient to them.
3257492|NCT01452984||Prospective Observations|Prospective Observations of clinic visits will be combined with informal interview to document conversations with their treating physicians about concerns emerging from appearance, function, and other factors that may impinge on clinical decision making and experience including quality of life. The Project Manager will be present for the clinical visit during which the Mohs surgery takes place and record field observations as well as informal interview notes in a notebook.
3257493|NCT01452997|Active Comparator|Ibuprofen Gel|Ibuprofen 5% gel
3257494|NCT01452997|Placebo Comparator|Ibuprofen placebo|K-Y jelly
3257495|NCT01452997|Active Comparator|Eumovate|0.05% w/w clobetasone butyrate
3257496|NCT01452997|Placebo Comparator|Cream Placebo|Aqueous Cream B.P.
3257497|NCT01453010|Experimental|8 individual case reviews|SaeboFlex Self-directed training
3257498|NCT01453062||Patients with a diagnosis of CLL|Patients with a diagnosis of CLL
3257499|NCT01453088|Active Comparator|Treatment A|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
3257500|NCT01453088|Experimental|Treatment Arm B|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
3257501|NCT01453101|Other|Fludarabine, Melphalan, Bortezomib|
3257502|NCT01453114|Experimental|Psychotherapy|Cognitive Behavioral Therapy
3257503|NCT01453127|Experimental|Alzheimer's Disease|Alzheimer's Disease
3257504|NCT01453127|Experimental|Dementia with Lewy Bodies|Dementia with Lewy Bodies
3257505|NCT01453127|Experimental|Frontotemporal Dementia|Frontotemporal Dementia
3257506|NCT01453127|Experimental|Parkinson's Disease|Parkinson's Disease
3257507|NCT01453127|Experimental|Corticobasal Degeneration|Corticobasal Degeneration
3257508|NCT01453127|Experimental|Essential Tremor|Essential Tremor
3257509|NCT01453127|Experimental|Mild Cognitive Impairment|Mild Cognitive Impairment
3257510|NCT01453127|Experimental|REM sleep behavior disorder|REM sleep behavior disorder
3257511|NCT01453140|Experimental|Cyclophosphamide and Sirolimus|Patients will be treated in sequential cohorts of 5. In cohort A, the first 5 enrolled patients will be receive cyclophosphamide and sirolimus only
3257512|NCT01453140|Experimental|Low dose IL-2 with Cytoxan + Sirolimus|
3257513|NCT01453140|Experimental|Low dose IL-2, Vidaza, Cytoxan & Sirolimus|
3257514|NCT01453179|Experimental|Aldara 5% Cream|
3257515|NCT01453179|Active Comparator|Solaraze 3% Gel|
3257516|NCT01453192|Experimental|Raltegravir|Raltegravir associated to an antiretroviral regimen without ritonavir boosted antiprotease
3257517|NCT01453218|No Intervention|Basiliximab|Historical comparable cohort treated with Basiliximab 20mg iv administered at 0 and 4th day post-transplant
3257518|NCT01453218|Active Comparator|ATeGe-Fresenius|
3257519|NCT01453231|No Intervention|Control|No surgery
3257520|NCT01453231|Experimental|thighplasty|
3257521|NCT01453244||SVR group|A patients who achieved SVR (sustained virologic response)
3257522|NCT01453244||non-SVR group|A patients who not achieved SVR (sustained virologic response)
3257523|NCT01453257|Experimental|Chemotherapy treatment|Tailored chemotherapy by Therapeutic Targets
3257524|NCT01453270|Experimental|NICOM and PLR|A systematic approach to resuscitation started in the ED and using a step-wise approach to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues will be applied to the intervention group using the Non-Invasive Cardiac Output Monitor (NICOM) and passive leg-raising (PLR) maneuver.
3257525|NCT01453270|Active Comparator|Usual care|
3257526|NCT01453309|Active Comparator|Cell Saver|Patients will have the use of a cell-saver during surgery
3257527|NCT01453309|Placebo Comparator|No Cell saver|Patient will not have cell saver available during surgery.
3257528|NCT01453400|Experimental|Arm 1|
3257529|NCT01453400|Active Comparator|Arm 2|
3257530|NCT01453400|Placebo Comparator|Arm 3|
3257531|NCT01453426|Experimental|Chinese Subjects - Dose 1 BG00012|
3257532|NCT01453426|Experimental|Chinese Subjects - Dose 2 BG00012|
3257533|NCT01453426|Experimental|Japanese Subjects - Dose 1 BG00012|
3257534|NCT01453426|Experimental|Japanese Subjects - Dose 2 BG00012|
3257535|NCT01453426|Experimental|Caucasian Subjects - Dose 1 BG00012|
3257536|NCT01453426|Experimental|Caucasian Subjects - Dose 2 BG00012|
3257537|NCT01453452|Experimental|Exercise and Lifestyle counseling|Patients will receive behavioral dietary intervention & counseling intervention by phone, exercise intervention at Curves(R) facility, and take a quality-of-life assessment online.
3257538|NCT01453465||Ancillary-Correlative (gene expression profile, miRNA profile)|Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.
3257539|NCT01453478|Experimental|GSK1325756 Immediate Release 50 mg|Administered to volunteers in the fasted and fed states
3257540|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 1 50 mg|Administered to volunteers in the fasted and/or fed states
3257541|NCT01453478|Experimental|GSK1325756 Bioenhanced Formulation 2 50 mg|Administered to volunteers in the fasted and/or fed states
3257542|NCT01453491|Experimental|50mg SRT2104|Single oral administration of 50mg SRT2104 study drug will be supplied as 25 mg and 250 mg capsules and will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
3257543|NCT01453491|Experimental|500mg SRT2104|Single oral administration of 500mg SRT2104 will be taken orally once daily for 56 days. SRT2104 is to be taken at approximately the same time every morning, in the fasted state. Water is permitted ad libitum. Subjects are allowed to consume liquids but should refrain from eating solid food for approximately 1 hour after dosing.
3257544|NCT01453504|Active Comparator|Ever-DHAP|Combination of Everolimus and DHAP
3257545|NCT01453504|Placebo Comparator|Placebo-DHAP|
3257546|NCT01453530|Active Comparator|Sugammadex|A single dose of sugammadex 2 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed
3257547|NCT01453530|Active Comparator|Neostigmine/glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv. Dose calculation will be based on the patient's actual body weight. No dose adjustments are allowed.
3257548|NCT01453530|Placebo Comparator|No reversal agent|No treatment
3257549|NCT01453543|Experimental|Deep transverse friction massage|Massage technique will be used.
3257550|NCT01453556|Experimental|Intracorpopreal anastomosis|Intracorporeal mechanical anastomosis
3257551|NCT01453556|Active Comparator|Extracorporeal anastomosis|Extracorporeal mechanical anastomosis
3257552|NCT01453582|Experimental|Propolis|Total Flavonoids of Propolis dropping pill
3257553|NCT01453582|Placebo Comparator|Placebo|Simulant of total Flavonoids of Propolis dropping pill
3257554|NCT01453608|Experimental|Ferinject (ferric carboxymaltose)|
3257555|NCT01453608|Placebo Comparator|Placebo (saline)|
3257556|NCT01453621|Experimental|Clinical decision support (post-intervention phase)|Clinicians will receive computerized clinical decision support regarding the risk of clinically important traumatic brain injury (TBI) based on the prediction rules
3257557|NCT01453621|No Intervention|Standard care (pre-intervention phase)|Prior to implementation of the computerized clinical decision support, we will collect data to determine the baseline rate of CT use for children with minor blunt head trauma at very low risk of clinically-important traumatic brain injuries.
3257558|NCT01453634|Experimental|Lunacalcipol 180|180 µg (n=4)Lunacalcipol Injection
3257559|NCT01453634|Experimental|Lunacalcipol 270|270 µg (n=8)Lunacalcipol Injection
3257560|NCT01453647|Experimental|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
3257561|NCT01453647|No Intervention|control|Participants in the control group will be instructed to maintain their FM treatment regimens as reported at baseline.
3257562|NCT01453660||Cisplatin-Based Chemotherapy Group|GCT patients who are planned to start cisplatin-based chemotherapy will be identified within the genitourinary oncology service clinics and offered inclusion in the trial.
3257563|NCT01453660||Surgery-Only Group|GCT patients who have been treated with surgery and who do not require chemotherapy or radiation will be used as a comparison group to confirm that there is not a significant change in endothelial function among GCT patients treated with surgery alone.
3257564|NCT01453686|Experimental|Hydrocortisone 1%|
3257565|NCT01453686|Experimental|Clobetasol Propionate 0.05%|
3257566|NCT01453712|No Intervention|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
3257567|NCT01453712|Experimental|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
3257568|NCT01453738|Experimental|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2-4ml Plasmalyte A followed by 2 ml of Hyaluronan
3257569|NCT01453738|Placebo Comparator|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte
3257570|NCT01453751|Experimental|Intravenous Injection of AD-SVF|Intravenous administration of AD-SVF.
3257571|NCT01453764|Experimental|Adipose SVF IV Infusion|IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
3257572|NCT01453790|Experimental|Parent-Specific Depression Education-Motivation|Mothers receive depression education (verbal and written) with messages targeted to parent status which are drawn from previous research. They also receive motivational messages at 2 days via telephone.
3257573|NCT01453790|Active Comparator|General Depression Education|Mothers receive general depression education (verbal and written) which are drawn from previous research. They also receive attention control telephone calls at 2 days.
3257574|NCT01453803|Experimental|Intravenous Injection and Intanasal infusion of AD-SVF|AD-SVF
3257575|NCT01453842|Experimental|Diet oil|
3257576|NCT01453842|Active Comparator|Olive oil|
3257577|NCT01453842|Placebo Comparator|Carrot|
3257578|NCT01453868|Active Comparator|Active non impact aerobics|This group will be performing a 12 week non impact aerobics program twice a week.
3257579|NCT01453868|Active Comparator|Control group: Passive lecture series|The control group will also be measured for balance and then attend a 12 week lecture series with no exercise. They will then also be remeasured post lectures series
3257580|NCT01453881|Experimental|Spacer|Beclomethasone/Formoterol 100/6mcg/puff pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
3257581|NCT01453881|Active Comparator|Comparator|Beclomethasone/Formoterol pMDI 100/6mcg/puff pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
3257582|NCT01453907|Experimental|ETI-204|ETI-204, Anthim
3257583|NCT01453907|Sham Comparator|placebo|
3257584|NCT01453920|Active Comparator|Treat-and-extend|Ranibizumab injection every 3 months, with follow-up assessments at each visit (every 3 months)
3257585|NCT01453920|Experimental|Treat-and-observe'|No injection, follow-up assessments every month
3257586|NCT01453933|Active Comparator|Raltegravir|At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).
3257587|NCT01453933|No Intervention|Lopinavir/ritonavir|Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)
3257588|NCT01453959|Other|Diet cycles|The patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days). After 4 weeks without any intervention, the patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days.
3257589|NCT01453959|Other|Fludrocortisone|The patient will received fludrocortisone in a dose of 0.4 mg/day for 7 days. After 4 weeks without any intervention, the patient will be analysed for salt sensitivity by two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days).
3257590|NCT01453972|Experimental|Long distanse moderate training|40 minutes moderate treadmill running
3257591|NCT01453972|Experimental|Long interval training|4x4min interval treadmill running
3257592|NCT01453972|Experimental|Short interval training|10x1min interval treadmill running
3257593|NCT01453985|Experimental|Full-Thickness-Gastroplication|
3257594|NCT01454011|Active Comparator|Testosterone 250mg injection,|
3257595|NCT01454011|Active Comparator|Testosterone transdermal application|
3257596|NCT01454024||Total study population|
3257597|NCT01454037||Prostate cryoablation|Subjects receiving cryotherapy for prostate cancer
3257598|NCT01454037||Radical prostatectomy|Subjects receiving radical prostatectomy
3257599|NCT01454037||Radiation|Subjects receiving radiation for prostate cancer
3257600|NCT01454089|Experimental|OGX-427 600 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (600 mg)
3257601|NCT01454089|Experimental|OGX-427 1000 mg|Standard chemotherapy (gemcitabine and cisplatin) in combination with OGX-427 (1000 mg)
3257602|NCT01454089|Active Comparator|Placebo|Standard chemotherapy (gemcitabine and cisplatin) in combination with placebo
3257603|NCT01454115|Experimental|Panel 1: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257604|NCT01454115|Experimental|Panel 2: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257605|NCT01454115|Experimental|Panel 3: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257606|NCT01454115|Experimental|Panel 4: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257607|NCT01454115|Experimental|Panel 5: BMS-708163 or Placebo|"Healthy male subjects (age: 18 to 45 years).~In Period 2: Subjects will receive BMS-708163 or placebo as a capsule formulation.~In Period 3: Subjects will receive BMS-708163 or placebo as a capsule formulation within 5 minutes of consuming a standard high-fat breakfast on Day 1"
3257608|NCT01454115|Experimental|Panel 6: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257609|NCT01454115|Experimental|Panel 7: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257610|NCT01454115|Experimental|Panel 8: BMS-708163 or Placebo|Healthy male subjects (age: 18 to 45 years)
3257611|NCT01454115|Experimental|Panel 9: BMS-708163 or Placebo|Healthy, elderly male subjects (age: 60 years and greater)
3257612|NCT01454115|Experimental|Panel 10: BMS-708163 or Placebo|Healthy, elderly female subjects (age: 60 years and greater)
3257613|NCT01454115|Experimental|Panel 11: BMS-708163 or Placebo|Healthy male subjects (age: between 46 to 59 years)
3257614|NCT01454115|Experimental|Panel 12: BMS-708163 or Placebo|Healthy male and/or female subjects or subjects with MCI (age: between 60-74 years)
3257615|NCT01454115|Experimental|Panel 13: BMS-708163 or Placebo|Healthy male and/or female subjects or with AD or MCI (age: 75 years or greater)
3257616|NCT01454115|Experimental|Panel 15: BMS-708163 or Placebo|Healthy young male subjects
3257617|NCT01454128|Active Comparator|Non-EPB|with exercise
3257618|NCT01454128|Experimental|EPB with exercise|with exercise
3257619|NCT01454141|Experimental|Peripheral Vision Task|During this task participants viewed a circular array of 15 discs and were asked to move their attention, but not their eyes, clockwise around the array while auditory tones were presented. Following the presentation of a distinct target tone, the discs changed color and participants reported the color of the disc by pressing a designated button on the keyboard. This task was developed to be a non-active control condition, targeting visual and occipital areas of the brain, and therefore allows us to discriminate between the effects of completing a computer-based task from interventions that specifically target the PFC.
3257620|NCT01454141|Experimental|Cognitive Control Training|Cognitive Control Training (CCT) A modified version of the Paced Auditory Serial Addition Task (PASAT) and the Attention Control Intervention were used to train participants' attentional control in accordance with procedures used by Siegle and colleagues.
3257621|NCT01454154|Experimental|Glyburide|Glyburide delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
3257622|NCT01454154|Placebo Comparator|Placebo|Matching placebo delivered by injection as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
3257623|NCT01454180|Active Comparator|Arm A|Control treatment arm will be treated with any of the schemes used in the study according to the discretion of the physician responsible
3257624|NCT01454180|Experimental|Arm B|treatment guided by the therapeutic targets
3257625|NCT01454206|No Intervention|Treatment as Usual|
3257626|NCT01454206|Experimental|iSBIRT|Participants will receive the internet-facilitated screening, brief intervention and referral to treatment (iSBIRT intervention)
3257627|NCT01454232|Other|gastric surgery|obese patients addressed for gastric surgery
3257628|NCT01454232|Active Comparator|lean healthy subjects evaluated once|lean healthy subjects evaluated once
3257629|NCT01454245|Experimental|001|"JNJ-39439335 Part 1:Type=1 unit=mg number=25 form=capsule route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods.,JNJ-39439335 Part 2:Type=2 unit=mg number=12.5 form=capsule route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods."
3257630|NCT01454271|Experimental|Total Hip Arthroplasty CERAFIT® grafted|
3257631|NCT01454297||Newly diagnosed Multiple Myeloma|This is a prospective observational study in patients with symptomatic multiple myeloma who have not yet initiated therapy for their disease.
3257632|NCT01454310|Experimental|Acellular skin substitute|
3257633|NCT01454310|Active Comparator|Autologous skin graft|
3257634|NCT01454323|Experimental|Intervention|Dose of bone marrow mononuclear cells: 5-7 x 108 total cells
3257635|NCT01454336|Experimental|Cirrhotic Patients|3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy
3257636|NCT01454349|Experimental|PRX302|
3257637|NCT01454349|Placebo Comparator|Inactive substance|
3257638|NCT01454375|No Intervention|Control Arm|No change in current practice
3257639|NCT01454375|Experimental|Referral fo QuitNow Services|Behavioural - referral to QuitNow Services, smoking cessation counseling telephone line supported by the Ministry of Healthy Living and Sport
3257640|NCT01454388|Active Comparator|PEG plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
3257641|NCT01454388|No Intervention|PEG without breakfast|
3257642|NCT01454388|Active Comparator|picosalax plus breakfast|patients are allowed to have a low residue breakfast the day prior to colonoscopy
3257643|NCT01454388|No Intervention|picosalax without breakfast|
3257644|NCT01454427||healthy volunteers|
3257645|NCT01454440|Experimental|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure).
3257646|NCT01454440|Placebo Comparator|Placebo|
3257647|NCT01454453|Experimental|Patients - dose titration|Amisulpride 50-200mg, 4-12 weeks, with brain imaging
3257648|NCT01454479|Experimental|Lapatinib (Tykerb) Plus Ixabepilone|
3257649|NCT01454492||Allergy rhinitis|Allergy rhinitis patients group
3257650|NCT01454492||Non- Allergy rhinitis|Non- Allergy rhinitis patients group
3257651|NCT01454518|Experimental|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
3257652|NCT01454518|Placebo Comparator|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
3257653|NCT01454544|Experimental|ALK house dust mite tablet 6 DU|
3257654|NCT01454544|Experimental|ALK house dust mite tablet 12 DU|
3257655|NCT01454544|Placebo Comparator|Placebo|
3257656|NCT01454557|Experimental|Acquired Brain Injury|auditory stimuli for ABI group
3257657|NCT01454557|Experimental|Controls|Auditory stimuli for control group
3257658|NCT01454609|Placebo Comparator|Saline|0.9% normal saline
3257659|NCT01454609|Experimental|Bupivacaine|0.25% bupivacaine
3257660|NCT01454609|Experimental|Bupivacaine with clonidine|0.25% bupivacaine with 1 microgram/kg of clonidine
3257661|NCT01454622|Experimental|Treatment Sequence AB|
3257662|NCT01454622|Experimental|Treatment Sequence BA|
3257663|NCT01454635|Other|Sertraline, Treatment response|dosage, frequency and duration
3257664|NCT01454648||Physician-staffed|Patients treated by physician-staffed emergency medical service (EMS) unit
3257665|NCT01454648||Paramedic-staffed|Patients treated by paramedic-staffed emergency medical service (EMS) unit
3257666|NCT01454661|Active Comparator|placebo mother - LGG infant|Placebo is administered to the lactating mother whilst the infant receives the probiotic LGG.
3257667|NCT01454661|Placebo Comparator|placebo mother - placebo infant|Placebo is administered to both the lactating mother and her infant.
3257668|NCT01454661|Active Comparator|LGG mother - placebo infant|The probiotic LGG is administered to the lactating mother whilst the infant receives placebo.
3257669|NCT01454661|Active Comparator|LGG+Bb-12 mother - Placebo infant|A combination of the probiotics LGG and Bb-12 is administered to the lactating mother, the infant receives placebo.
3257670|NCT01454661|Active Comparator|Pacebo mother - LGG+Bb-12 infant|Placebo is administered to the lactating mother, the infant receives a combination of the probiotics LGG and Bb-12
3257671|NCT01454700|Experimental|CSII plus CGM|Patients who has never been treated with insulin pump are randomized to 12 months with insulin pump therapy plus continuous glucose monitoring.
3257672|NCT01454700|Active Comparator|Multiple daily insulin injections|randomized to 12 months standard/usual insulin regimen (multiple daily injections). (stays on insulin pen).
3257673|NCT01454713||Veritas|Breast reconstruction with Veritas
3257674|NCT01454752|Active Comparator|Intermittent parasite clearance|Children sleeping under a long-lasting insecticidal net (LLIN) receive an additional intermittent preventive treatment for clearance of asymptomatic malaria infection given once a year at the end of the malaria transmission season
3257675|NCT01454752|Placebo Comparator|Control|Children sleeping under a long-lasting insecticidal net (LLIN) receive placebo
3257676|NCT01454765||Sperm sample from healthy volunteers|
3257677|NCT01454804|Experimental|Arm A: Pazopanib + Lapatinib|Oral Pazopanib 200 mg every other day starting on day 1 and oral Lapatinib 500 mg daily starting day 1, both for 28 days.
3257678|NCT01454804|Experimental|Arm B: Pazopanib + Trastuzumab|Oral Pazopanib 200 mg daily for 28 day cycle and Trastuzumab (Herceptin®) 4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1, with a maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
3257679|NCT01454817|Other|Patients with ICDs|
3257680|NCT01454817|Other|Caregivers of Patients with ICDs|
3257681|NCT01454856||Surgical cancer patients|No modification of the treatment
3257682|NCT01454856||Non-surgical cancer patients|No modification of the treatment
3257683|NCT01454856||Surgical non-cancer patients|No modification of the treatment
3257684|NCT01454856||Non-surgical non-cancer patients|No modification of the treatment
3257685|NCT01454869|Active Comparator|Standard care|nac + salotamul
3257686|NCT01454869|Experimental|heparin group|heparin group
3257687|NCT01454882||Behavioral effects of clothing and temperature|In this first study, we will determine how variations in clothing and ambient temperature influence the accuracy of EE determined from measurements of total heat production. 65 individuals will be studied. This will be a randomized cross-over trial with two within subject factors: 1) ambient temperature and 2) amount of clothing. There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
3257688|NCT01454882||Behavioral effects of age, sex, and adiposity|THe aim of this study is to Determine how age, sex, and adiposity influence the accuracy of EE determined from measurements of total heat production . This will be a randomized study with two within subject conditions(high and low physical activity levels). A heterogenous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age range (≥ 18 yrs).
3257689|NCT01454882||Effects of free living energy expenditure|The primary aim of this study is to compare the accuracy of measuring free-living energy expenditure in humans measured using portable direct calorimetry. This will be a comparison study; TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied. We will study subjects across a wide range of weight (up to 300 lbs) and age (>18 yrs).
3257690|NCT01454895|Experimental|Interactive Web-based Info (IWI) & HPDs|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
3260111|NCT01476683|Active Comparator|TFT|A single 2 x 100 mg dose of a marketed Tiorfast® capsule administered orally with 240 ml of water, with a 7-day washout between visits.
3260112|NCT01476683|Active Comparator|TFR|A single 175 mg dose of a marketed Tiorfanor® 175 mg FCT administered orally with 240 ml of water, with a 7-day washout between visits.
3375798|NCT03786380|Experimental|Relamorelin 10 μg|Relamorelin 10 micrograms (μg) injected subcutaneously twice daily for up to approximately 22 months.
3375799|NCT03785964|Experimental|Nirogacestat|Nirogacestat 150 mg by mouth, twice daily
3375800|NCT03785964|Placebo Comparator|Placebo|Placebo 150 mg by mouth, twice daily
3375801|NCT03783091|Experimental|Hydroxocobalamin|Single IV infusion administered over a 10-15 minute period
3375802|NCT03783091|Placebo Comparator|Saline Placebo|Single IV saline administered over a 10-15 minute period.
3375803|NCT03778957|Experimental|Arm A|Transarterial Chemoembolization (TACE) in combination with Durvalumab
3375804|NCT03778957|Experimental|Arm B|Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab
3375805|NCT03778957|Placebo Comparator|Arm C|Transarterial Chemoembolization (TACE) in combination with Placebos
3257691|NCT01454895|Experimental|Interactive Web-based Information (IWI)|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
3375808|NCT03774888|Experimental|connective tissue graft|Connective tissue grafting (CTG) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
3375809|NCT03774888|Experimental|Acellular Dermal Matrix|Acellular Dermal matrix (ADM) will be placed at the time of lateral ridge augmentation.Following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
3375810|NCT03774888|Active Comparator|No soft tissue graft|Control group where no soft tissue graft is added to the lateral ridge augmentation.Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
3375811|NCT03772899|Experimental|Study Intervention|Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.
3375812|NCT03770286|Active Comparator|Fluoride Varnish alone|5% sodium fluoride varnish will be applied to all teeth the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
3375813|NCT03770286|Experimental|SDF with Super Floss|SDF will be applied to target interproximal lesions with the use of Super Floss for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
3375814|NCT03770286|Experimental|SDF without Super Floss|SDF will be applied to around the (buccal, lingual, and occlusal) embrasures of the target interproximal lesions with the use of a microbrush for 1 minute. 5% sodium fluoride varnish will then be applied to all teeth. Both will occur the day of acceptance into the study and then at 3 months, 6 months, and 12 months.
3375815|NCT03769376|Active Comparator|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
3375816|NCT03769376|Active Comparator|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction. Half of participants will be randomly assigned to this treatment group (1:1).
3375817|NCT03766009|Active Comparator|Arm I (surgical consultation)|Prior to institutional crossover, participants receive care as per usual care.
3375818|NCT03766009|Experimental|Arm II (web-based breast cancer surgery decision aid)|Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..
3257692|NCT01454895|Experimental|Static Web information (SWI) & HPDs|Subjects will receive static Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing, as well as a mailed sample of various types of hearing protection devices.
3257693|NCT01454895|Active Comparator|Static Web information only|Subjects will receive interactive Web-based information regarding farm noise exposures, risks to hearing, and strategies for protecting hearing.
3375821|NCT03759379|Experimental|Vutrisiran (ALN-TTRSC02)|Participants will receive vutrisiran during the Treatment and Treatment Extension Periods.
3375822|NCT03759379|Active Comparator|Patisiran|Participants will receive patisiran during the Treatment Period and will switch to vutrisiran during the Treatment Extension Period.
3375823|NCT03749447|Experimental|Bardoxolone methyl|"The maximum dosage is determined by proteinuria status from the last on-treatment visit in the prior qualifying study or a screening visit, if necessary. Initial daily dose of bardoxolone methyl will dose-escalate at Week 2, Week 4, and Week 6.~Patients under the age of 18 will start dosing with bardoxolone methyl capsules every other day during Week 1 and daily at Week 2.~Patients will receive doses of bardoxolone methyl capsules in an escalating scheme from 5 mg up to no more than 30 mg."
3375824|NCT03744494|Experimental|Bilateral simple orchidectomy (BSO)|The patients would have the testis, epididymis and distal cord structures excised
3375825|NCT03744494|Experimental|Subcapsular orchidectomy (BSCO)|The tunica albuginea was incised longitudinally and the testicular parenchyma scraped off it. The hilar region was secured with a haemostat and the parenchyma excised off it. A haemostatic suture was applied at the hilum. A running interlocking water-tight capsular suture was inserted
3375826|NCT03744494|Experimental|Epididymal-sparing orchidectomy (BESO)|The epididymal sinus was developed. The epididymal vessels were sequentially clamped and divided, removing the testicle from the epididymis. The caput was looped to meet the head and the adjoining surfaces of the body sutured together (epididymoplasty) Vasectomy done to reduce future risk of epididymitis
3375831|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose A|Participants of age group 12 to <18 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
3375832|NCT03725007|Experimental|Participants of age group 12 to <18 years receiving dose B|Participants of age group 12 to <18 years administered with upadacitinib dose B (weight dependent) as described in the protocol.
3375833|NCT03725007|Experimental|Participants of age group 6 to <12 years receiving dose A|Participants of age group 6 to <12 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
3375834|NCT03725007|Experimental|Participants of age group 2 to <6 years receiving dose A|Participants of age group 2 to <6 years administered with upadacitinib dose A (weight dependent) as described in the protocol.
3257694|NCT01454895|Experimental|Hearing protection Devices only|Subjects will receive a mailed sample of various types of hearing protection devices.
3257695|NCT01454895|Other|Interactive Web-based information only|used for cases enrolling after achievement of study enrollment goal
3257696|NCT01454908|Other|Partial Knee Arthroplasty|Oxford Mobile Bearing Unicompartmental Knee Arthroplasties
3257697|NCT01454921|Experimental|Intervention I|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
3257698|NCT01454921|Experimental|Intervention II|"Intervention group participants will be enrolled for the duration of one intervention program, which will last approximately 6 months. Each intervention program will consist of two individual and six group intervention sessions with each session lasting approximately 2-3 hours.~Intervention participants will also complete two ACASI assessments (baseline and post-intervention) lasting approximately 1.5-2 hours each."
3257699|NCT01454960|Experimental|SA, AJ, PC|"Participants are given all 3 interventions:~Suggested Alternatives, Accountable Justification, and Peer Comparison."
3257700|NCT01454960|Experimental|SA, AJ|Participants receive the Suggested Alternatives and Accountable Justification interventions, but not the Peer Comparison intervention.
3257701|NCT01454960|Experimental|SA, PC|Participants receive the Suggested Alternatives and Peer Comparison interventions, but not the Accountable Justification intervention.
3257702|NCT01454960|Experimental|AJ, PC|Participants receive the Accountable Justification and Peer Comparison interventions, but not the Suggested Alternatives intervention.
3257703|NCT01454960|Experimental|Peer Comparison|Participants receive the Peer Comparison intervention, but do not receive the Suggested Alternatives or Accountable Justification interventions.
3257704|NCT01454960|Experimental|Suggested Alternatives|Participants receive the Suggested Alternatives intervention, but not the Accountable Justification or Peer Comparison interventions.
3257705|NCT01454960|Experimental|Accountable Justification|Participants receive the Accountable Justification intervention, but do not receive the Suggested Alternatives or Peer Comparison interventions.
3257706|NCT01454960|No Intervention|Control|Participants do not receive any of the 3 interventions.
3257707|NCT01454973||Healthy obese individuals|
3257708|NCT01454986|Active Comparator|Cohort 1|0.06 mg/kg ALXN1007
3257709|NCT01454986|Active Comparator|Cohort 2|0.1 mg/kg ALXN1007
3257710|NCT01454986|Active Comparator|Cohort 3|0.3 mg/kg ALXN1007
3257711|NCT01454986|Active Comparator|Cohort 4|1.0 mg/kg ALXN1007
3257712|NCT01454986|Active Comparator|Cohort 5|3.0 mg/kg ALXN1007
3257713|NCT01454986|Active Comparator|Cohort 6|6.0 mg/kg ALXN1007
3257714|NCT01454986|Active Comparator|Cohort 7|10.0 mg/kg ALXN1007
3257715|NCT01454999|Experimental|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
3257716|NCT01454999|Experimental|CTI + text|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change. Tailored feedback messages based on stage of change will also be sent by cell phone.
3257717|NCT01455025|Experimental|Plerixafor granulocyte-colony stimulating factor|4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.
3257718|NCT01455038||Control group|Healthy controls had no history of psychiatric disorder and had no psychiatric symptom when interviewed by a board-certified psychiatrist.
3257719|NCT01455038||Bipolar group|individual patient as being in subsyndromal depressive phase when the patient had a Montgomery-Åsberg depression rating scale score of 10 or less and Clinical Global Impression severity of 3 or less for last one month.
3257720|NCT01455051|Experimental|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
3257721|NCT01455077||Obese patients|BMI > 35
3257722|NCT01455090|Experimental|Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
3257723|NCT01455090|Experimental|Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)|"BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3257724|NCT01455090|Experimental|Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 60 mg tablet by mouth once daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
3257725|NCT01455090|Experimental|Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)|"* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 60 mg tablet by mouth once daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3257726|NCT01455090|Experimental|Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3257727|NCT01455090|Experimental|Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3257728|NCT01455090|Experimental|Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3257729|NCT01455090|Experimental|Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 4 treatment-naive subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3257730|NCT01455090|Experimental|Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 75 mg table by mouth twice daily for 12 Weeks"
3257731|NCT01455090|Experimental|Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks~BMS 791325 150 mg table by mouth twice daily for 12 Weeks"
3257732|NCT01455090|Experimental|Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 75 mg table by mouth twice daily for 24 Weeks"
3257733|NCT01455090|Experimental|Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)|"* Genotype 1 treatment-null/non-responder subjects~BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks~BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks~BMS 791325 150 mg table by mouth twice daily for 24 Weeks"
3260113|NCT01476735|Active Comparator|split-dose polyethylene glycol solution|first dose (1,5 l) of polyethylene glycol solution taken at 6-7.00 in the evening before colonoscopy, second dose (1,5 l) taken at 5.30-6.00 in the morning of a day of colonoscopy; additional bisacodyl taken at 12.00 at the day before colonoscopy
3260114|NCT01476735|Active Comparator|Individual preparation for colonoscopy|
3260115|NCT01476761|Active Comparator|MicroCutter Stapling Device|Patients undergoing surgical treatment with the MicroCutter Stapling Device
3260116|NCT01476774|Active Comparator|Buprenorphine Transdermal System|
3260117|NCT01476774|Active Comparator|Tramadol CR|
3260118|NCT01476787|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles.~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
3260119|NCT01476787|Active Comparator|Control|• ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
3260120|NCT01476800|Experimental|YM178 OCAS alone|
3260121|NCT01476800|Active Comparator|Ketoconazole alone|
3260122|NCT01476800|Experimental|YM178 OCAS and ketoconazole|
3260123|NCT01476813|Experimental|Glyco 25|BDP/FF (400/24 daily)+ Glyco 25µg daily
3260124|NCT01476813|Experimental|Glyco 50|BDP/FF (400/24 daily)+ Glyco 50 µg daily
3260125|NCT01476813|Experimental|Glyco 100|BDP/FF (400/24 daily)+ Glyco 100µg daily
3260126|NCT01476813|Active Comparator|BDP/FF 400/24|BDP/FF 400/24
3260127|NCT01476839|Experimental|Treatment (radiolabeled monoclonal antibody, chemotherapy)|"DOSIMETRY STUDY: Patients receive basiliximab IV and indium In 111 basiliximab IV on day -21. Patients undergo indium In 111 imaging scans daily. Patients with appropriate biodistribution continue on to treatment.~TREATMENT: Patients receive basiliximab IV and yttrium Y 90 basiliximab IV on day -14. Patients also receive BEAM chemotherapy comprising carmustine IV over 2 hours on days -7 and -6, etoposide IV BID over 4 hours and cytarabine IV over 2 hours BID on days -5 to -2, and melphalan IV on day -1. Patients undergo autologous hematopoietic progenitor cell infusion on day 0."
3260128|NCT01476865||Healthy|normal, healthy people
3260129|NCT01476865||RA|rheumatoid arthritis patients
3260130|NCT01476878|Experimental|Open Arm|Each study patient will receive high dose, single treatment radiation using a plastic mask instead of a head frame that pins into a patient's skull.
3260131|NCT01476891|Active Comparator|Wait-List|Wait-list Control Group. The control group will receive the next available online MBSR program.
3260132|NCT01476891|Active Comparator|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
3260133|NCT01476904|Experimental|Arm T|Arm T is the experimental treatment arm consisting of 2 x 125 mcg/inhalations of epinephrine inhalation, QID, with 4-6 hr intervals
3260134|NCT01476904|Placebo Comparator|Arm P|Arm P is a placebo comparator consisting of 2× 0 mcg of placebo inhalations, QID, with 4-6 hr intervals
3260135|NCT01476904|Active Comparator|Arm A|Arm A is an active comparator, Primatene Mist, consisting of 2× 220 mcg/inhalation, QID, with 4-6 hr intervals
3260136|NCT01476917|Experimental|Treatment|Subjects that completed the ATLAST Study
3260137|NCT01476930|Experimental|cupping serkangabin|migraine cases treated by cupping and serkangabin syrup
3260138|NCT01476930|Active Comparator|conventional|migraine cases treated by conventional drug treatment protocols
3260139|NCT01476943||Patient treated with Belatacept at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with Belatacept at the time of transplantation
3260140|NCT01476943||Patient treated with CNI at the time of transplantation|Patients undergoing solid organ transplantation, whose transplant center participates in CTS and who are treated with a Calcineurin inhibitor (CNI) based regimen at the time of transplantation
3260141|NCT01476956||Rheumatoid Arthritis|
3260142|NCT01476969|Experimental|Manual Tourniquet|
3260143|NCT01476982||Emergency Department Patients|Patients presenting to the Emergency Department complaining of chest pain.
3260144|NCT01476995||Controls|Men and women ages 18-85 lacking any medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
3260145|NCT01476995||Five Diagnosis Group|Men and women ages 18-85 with at least one active medical diagnosis (as defined in the protocol) of one or more of the following systems/organs: cardiovascular system; gastrointestinal system; kidneys; liver; lungs.
3260146|NCT01477008|Experimental|BiCRI|BiPhasic Cartilage Repair Implant
3260147|NCT01477008|Active Comparator|Marrow Stimulation|Microfracture or Subchondral Drilling
3260148|NCT01477021|Experimental|Treatment (NY-ESO-1 specific CD8+ T cells)|Patients receive cyclophosphamide IV on days -3 and -2. Patients receive NY-ESO-1-specific T cells IV on day 0.
3260149|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 6 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 6 months.
3260150|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 6 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 6 months.
3260151|NCT01477034|Experimental|2,000 IU/day vitamin D3 x 3 months|Subjects will take a 2,000 IU daily vitamin D3 supplement for 3 months.
3260152|NCT01477034|Experimental|4,000 IU/day vitamin D3 x 3 months|Subjects will take a 4,000 IU daily vitamin D3 supplement for 3 months.
3260153|NCT01477047||Patients receiving primary hip or knee arthoplasty|
3260154|NCT01477060|Other|ARM A - Lapatinib|hormonal therapy + lapatinib (1250mg/die) until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3260155|NCT01477060|Other|ARM B - Metformin|Hormonal therapy + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3260156|NCT01477060|Other|ARM C - Lapatinib + Metformin|Hormonal therapy + lapatinib + metformin until disease progression or extraordinary medical circumstances occur or intolerable toxicities occur or the patient withdraws consent.
3260157|NCT01477073|Experimental|FSH-GEX 75 IU|follitropin epsilon 75 IU QD
3260158|NCT01477073|Experimental|FSH-GEX 150 IU|follitropin epsilon 150 IU QD
3257734|NCT01455090|Experimental|Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV|"* Genotype 1 treatment-naive subjects~BMS-650032 200 mg tablets orally twice daily 12 weeks~BMS-790052 30 mg tablets orally twice daily 12 weeks~BMS-791325 75 mg tablets orally twice daily 12 weeks~Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM]"
3257735|NCT01455103|Experimental|Arm 1: BMS-936559 (1mg/kg)|
3257736|NCT01455103|Experimental|Arm 2: BMS-936559 (3mg/kg)|
3257737|NCT01455103|Experimental|Arm 3: BMS-936559 (10mg/kg)|
3257738|NCT01455116|Experimental|Mild induced hypothermia|Induced hypothermia to 32-34 degrees Celsius (90 - 93 degrees Fahrenheit)
3257739|NCT01455116|No Intervention|Fever Respect|Standard of care septic shock therapy according to Surviving Sepsis Campaign guidelines
3257740|NCT01455129|Active Comparator|tiotropium group|18 mcg tiotropium, once daily, inhaled by HandiHaler
3257741|NCT01455129|Placebo Comparator|placebo group|matching placebo, once daily, inhaled by HandiHaler
3257742|NCT01455142|Experimental|Formulation 1|
3257743|NCT01455142|Experimental|Formulation 2|
3257744|NCT01455155|Experimental|Creative therapy|Conventional physical therapy program (5 times/week) plus creative therapy (Art and Music) 2 times/week for 4 weeks
3257745|NCT01455155|Active Comparator|Control|Conventional physical therapy (5 times/week) for 4 weeks
3257746|NCT01455168||No treatment|Capsular tension ring is not used in the group.
3257747|NCT01455168||CTR simply implanted|Capsular tension ring is simply implanted in the group.
3257748|NCT01455168||CTR with the eyelets closed|Capsular tension ring is implanted and closed by tying both eyelets in the group.
3257749|NCT01455207|Other|alcoholic patients|
3257750|NCT01455207|Other|korsakoff patients|
3257751|NCT01455207|Other|healthy controls|
3257752|NCT01455233|Active Comparator|besivance|ocular antibiotic
3257753|NCT01455233|Active Comparator|vigamox|ocular antibiotic
3257754|NCT01455246|Experimental|Daptomycin + Meropenem|30 patients with cirrhosis and nosocomial SBP
3257755|NCT01455246|Active Comparator|Ceftazidime|30 patients with cirrhosis and nosocomial SBP
3257756|NCT01455259|Experimental|AdCD40L|Treatments once a week with 2.5x10e11 VP AdCD40L, maximum 4 treatments (total dose 1x10e12 VP). If no effect in less than 2 out of 6 melanoma patients, the following 9 melanoma patients and 6 patients with other solid tumors will receive preconditioning therapy 1-2 days prior to first and last treatment with 300mg/m2 cyclophosphamid. The next 9 melanoma patients will receive one local radiotherapy.
3257757|NCT01455272|Experimental|high-risk leukemia|
3257758|NCT01455298|Other|Transient elastography and fibrotest|
3257759|NCT01455311||Cystic Pancreatic Tumor Specimens|Specimen collection via EUS Guided Fine Needle Aspiration EchoBrush Sampling
3257760|NCT01455324||Lower Limb Amputees|Those with lower limb amputations
3257761|NCT01455337|Active Comparator|prednisolone|
3257762|NCT01455337|Experimental|pentoxifylline|
3257763|NCT01455350|Active Comparator|Lidocaine|10 week treatment of daily application of topical lidocaine
3257764|NCT01455350|Experimental|Multimodal physiotherapy|10 weeks of weekly multimodal physiotherapy treatments
3257765|NCT01455376|No Intervention|Hyperosmolar sodium chloride|Patients in this group received intravenous infusion of hyperosmolar Sodium Chloride 3% at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
3257766|NCT01455376|Experimental|Hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
3257767|NCT01455389|Experimental|DOTAP + Erlotinib|DOTAP:Chol-TUSC2 0.045 mg/kg by vein over 25-35 minutes on day 1 of each 21 day cycle; and Erlotinib 100 mg by mouth daily for each 21 day cycle.
3257768|NCT01455441|Active Comparator|Training and liraglutide|Treatment with both training and liraglutide for 16 weeks
3257769|NCT01455441|Placebo Comparator|Training and placebo|Treatment wiht both training and placebo for 16 weeks
3257770|NCT01455454||coronary artery disease|patients undergoing coronary artery bypass grafting using cardiopulmonary bypass
3257771|NCT01455467|Active Comparator|One iStent|Implantation of one iStent in conjunction with cataract surgery
3257772|NCT01455467|Active Comparator|Two iStent|Implantation of two iStent devices in conjunction with cataract surgery
3257773|NCT01455480|Experimental|RPh201|
3257774|NCT01455493|Experimental|A|
3257775|NCT01455506|Experimental|Decitabine with fludarabine and busulfan|decitabine with fludarabine and busulfan in the setting of allogeneic stem cell transplantation
3257776|NCT01455532|Experimental|Iniparib, single agent|Iniparib will be initially administered intravenously once weekly (days 1, 8, and 15) for 3 weeks, in a 21-day cycle. Then, iniparib will be administered twice weekly (days 1, 4, 8, 11, 15, and 18) in a 21-day cycle. Cycle1 (day 1 thru day 21) will be defined as the dose limiting toxicities (DLT) observation period. Starting dose is 15 mg/kg once weekly.
3257777|NCT01455532|Experimental|Iniparib/Gemcitibine/Carboplatin|Gemcitabine/carboplatin (GC) : Gemcitabine will be administered at 1,000 mg/m² as a 30min IV infusion and carboplatin area under the curve (AUC) 2 as a 60min IV infusion. Patients will receive gemcitabine/carboplatin infusions once weekly (days 1 and 8). Iniparib will be administered for two weeks, followed by a 1week of rest in a 21-day cycle (weekly schedule: days 1 and 8; twice weekly schedule: days: 1, 4, 8 and 11).
3257778|NCT01455532|Experimental|Iniparib/Paclitaxel|Paclitaxel (P): Paclitaxel will be administered at the dose of 80 mg/m2 as a 60-minute intravenous infusion administered on days 1, 8, and 15 followed by a 1week of rest. Iniparib will be administered for three weeks, followed by 1week of rest in a 28-day cycle (weekly schedule: days 1, 8 and 15; twice weekly schedule: days 1, 4, 8, 11, 15 and 18).
3257779|NCT01455532|Experimental|Iniparib/Pegylated liposomal doxorubicin/Carboplatin|Pegylated liposomal doxorubicin (Doxil)/Carboplatin (PLD) : Doxil will be administered at 30 mg/m² as a 30min IV infusion and carboplatin AUC 4 as a 60min IV infusion on day 1 every four weeks. Iniparib will be administered for two weeks in a 28-day cycle (weekly schedule: days 1, and 8; twice weekly schedule: days 1, 4, 8, and 11).
3257780|NCT01455558|Experimental|Cilostazol|
3257781|NCT01455571|Experimental|HM781-36B|Dose : 0.5mg, 1mg, 2mg, 4mg, 8mg, 12mg, 16mg, 20mg,...
3257782|NCT01455584|Experimental|HM781-36B|HM781-36B
3257783|NCT01455597|Experimental|Estradiol Vaginal Gel|WC3011 Estradiol Vaginal Gel, administered 3X weekly for 40 weeks
3257784|NCT01455623||Health Care Provider|A person working within the field of CMT.
3257785|NCT01455623||Patient with CMT|Any person of any age self-identifying as having CMT and belonging to the Inherited Neuropathies Consortium Contact Registry hosted by the Rare Disease Clinical Research Network.
3257786|NCT01455636|Experimental|Hand hygiene with Hand Sanitizer (HS)|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
3257787|NCT01455636|Experimental|Hand hygiene with no Hand Sanitizer|"To obtain 480 low birth weight infants the entire area of Kaliganj and Norsinghdi will be divided into 48 clusters based on the list of pregnant women identified through a household survey.~24 clusters will be randomized to receive Hand Sanitizer plus nutrition and hygiene education and the remaining 24 will receive only nutrition and hygiene education."
3257788|NCT01455636|Experimental|Micronutrient Powder|"From 6 months of age, children in randomized clusters will be assigned to receive one sachet of Improved Micronutrient Powder, I-MNP per day for six months with or without hand sanitizer.~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
3257789|NCT01455636|Placebo Comparator|Control|"From 6 months of age, children in randomized clusters will be assigned to receive no hand sanitizer or no micronutrient powder~Throughout the entire intervention period, mothers/caregivers of the children in all groups will receive simple, standardized, and age and culturally appropriate nutrition and health education that aims to improve feeding and health-seeking behavior and caring practices."
3257790|NCT01455649|Experimental|Everolimus|
3257791|NCT01455649|Active Comparator|calcineurin inhibitor|
3257792|NCT01455662||all patients after cardiac arrest|
3257793|NCT01455675|Experimental|IgY, gargling solution|Avian polyclonal anti-pseudomonas antibodies (IgY), 70 ml gargling solution contains 50 mg IgY with an activity against PA, once daily
3257794|NCT01455675|Placebo Comparator|Placebo, gargling solution|70 ml gargling solution without antibodies, once daily
3257795|NCT01455688|Experimental|Early antiviral therapy|
3257796|NCT01455688|Active Comparator|Conventional therapy|
3257797|NCT01455701|Experimental|Tocilizumab|Participants will receive tocilizumab intravenous (IV) infusion at a dose of 12 milligrams per kilogram (mg/kg) every two weeks (Q2W) during main evaluation period of 12 weeks (a total of 6 infusions including one at baseline visit). Participants will have the option to be treated in an optional extension period after completion of main evaluation period. In optional extension period, participants will receive tocilizumab 12 mg/kg IV infusion Q2W from Week 12 until the participant reaches 2 years of age or has been treated for one year from baseline, whichever is longer.
3257798|NCT01455714||A, B, C|Group A- 40 patients without symptoms of heart failure Group B- 40 patients with exertional dyspnoea Group C - 40 patients with overt heart failure
3257799|NCT01455727|Experimental|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
3257800|NCT01455727|Active Comparator|Usual care|Patients received usual care directed by their physician.
3257801|NCT01455740|Experimental|Provider Visit Incentive (PVI)|"Participants were told that they would receive $30 after attending each scheduled provider visit (a CCT).~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 21 individuals to the PVI arm."
3257802|NCT01455740|Experimental|Incentive Choice (IC)|"Participants were given a choice between the CCT described in the PVI arm and a commitment contract, which made the $30 payment conditional on the patient attending the provider visit AND meeting an ART adherence threshold.~A block randomization scheme, stratified on whether or not the majority of the participant's three previous viral load measurements were suppressed, assigned 19 individuals to the IC arm."
3257803|NCT01455740|No Intervention|Passive Control (PC)|The study also included 70 individuals in a PC arm, who did not receive financial incentives. Individuals in the PC arm were not enrolled in the randomized trial but met basic study eligibility criteria during the same time period.
3257804|NCT01455753||Employees|A total of 1,801 employees of a health benefits administrator that held a free workplace influenza vaccination clinic.
3257805|NCT01455779|Other|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
3257806|NCT01455792|Experimental|MRI and soft image fusion biopsy|Preoperative MRI and soft image ultrasound guided biopsy.
3257807|NCT01455792|Active Comparator|Gold standard biopsy|Gold standard TRUS biopsy
3257808|NCT01455805|Active Comparator|Minuteman Fusion Implant|Minuteman™ interspinous interlaminar fusion Implant (interspinous interlaminar fusion device) which gained CE Mark approval in May 2011
3257809|NCT01455805|Other|Surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis.
3257810|NCT01455831|Experimental|Extended peri-operative thromboprophylaxis|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
3257811|NCT01455831|Active Comparator|Standard thromboprophylaxis|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
3257812|NCT01455844|Experimental|CaPre 1.0g|
3257813|NCT01455844|Experimental|CaPre 2.0g|
3257814|NCT01455844|Placebo Comparator|Placebo|
3257815|NCT01455857|Experimental|ITCA 650 40 mcg/day|
3257816|NCT01455857|Experimental|ITCA 650 60 mcg/day|
3257817|NCT01455857|Placebo Comparator|ITCA placebo|
3257818|NCT01455870|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3257819|NCT01455870|Active Comparator|sitagliptin|sitagliptin 100 mg/day
3257820|NCT01455883|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3257821|NCT01455883|Active Comparator|glimepiride|glimepiride up-titrated to 8 mg/day over first 13 weeks
3257822|NCT01455896|Experimental|ITCA 650 60 mcg/day|ITCA 650 is exenatide in DUROS
3257823|NCT01455896|Other|ITCA placebo|
3257824|NCT01455909|Experimental|ITCA 650 60 mcg/day|
3257825|NCT01455909|Active Comparator|sitagliptin|sitagliptin 100 mg/day
3257826|NCT01455922|Experimental|ITCA 650 60 mcg/day|
3257827|NCT01455922|Active Comparator|glimepiride|
3257828|NCT01455935|Active Comparator|Medical Therapy|"Current standard of care per the latest stroke guidelines~Permissive Hypertension up to 220~Antipletelets therapy:~ASA 81 mg PO daily or~Plavix 75 mg PO daily or~Aggrenox 225mg PO twice daily~Anti-inflammatory therapy:~Lipitor 80 mg PO daily or~Crestor 20 mg PO daily"
3257829|NCT01455935|Experimental|Intravenous Thrombolysis|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
3257830|NCT01455935|Experimental|Intra-Arterial Therapy|"-Choice of therapy per experienced Endovascular surgeon and includes:~Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
3257831|NCT01455948|Active Comparator|Balloon Sinuplasty™ System|
3257832|NCT01455948|Active Comparator|Functional Endoscopic Sinus Surgery|
3257833|NCT01455974|Experimental|Dialysate sodium set at 136 mmol/L|
3257834|NCT01456013|Active Comparator|Standard Therapy|Standard of care for patients at risk of CIN
3257835|NCT01456013|Experimental|RenalGuard Therapy|Induced Diuresis with Matched Replacement
3257836|NCT01456026|Experimental|Glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
3257837|NCT01456026|Active Comparator|Non-glycated beta-lactoglobulins|In this randomized, double blind,cross-over study, half of the subjects will receive on one day a beverage with a high AGE content and will be switched after a wash-out of min. 7 days to receive a low-AGE beverage (comparator). The other half will receive the beverages in inverse sequence.
3257838|NCT01456065|Other|Vaccine weekly administration|
3257839|NCT01456065|Other|Vaccine biweekly administration|
3257840|NCT01456078|Experimental|177Lu-DOTA-TATE|
3257841|NCT01456091|Experimental|AIM 4 Teen Moms|
3257842|NCT01456091|No Intervention|Control|
3257843|NCT01456104|Experimental|vaccine|This is a single-arm phase I trial in patients with AJCC stage IIB, IIC, III, and IV (MIa) melanoma in which autologous human Langerhans-type dendritic cells (CD34+hematopoietic progenitor cell (HPC)-derived Langerhans cells, or LCs) will be electroporated with mRNA encoding full-length murine tyrosinase-related peptide 2 (TRP2). LCs will also be loaded with control antigens (HLA-A*0201-restricted flu matrix peptide).
3257844|NCT01456117|Experimental|Pioglitazone (Dose 1) QD|
3257845|NCT01456117|Experimental|Pioglitazone (Dose 2) QD|
3257846|NCT01456117|Experimental|Pioglitazone (Dose 3) QD|
3257847|NCT01456117|Placebo Comparator|Placebo QD|
3257848|NCT01456156|Experimental|hepatectomy plus radiotherapy|
3257849|NCT01456182|Other|Dose arm 1|
3257850|NCT01456182|Other|Dose arm 2|
3257851|NCT01456182|Other|Dose arm 3|
3257852|NCT01456182|Other|Dose arm 4|
3257853|NCT01456182|Other|Dose arm 5|
3257854|NCT01456234|Active Comparator|Patients with Oseltamivir Prescription|Patients arriving at the pharmacy with a prescription for Oseltamivir
3257855|NCT01456234|Experimental|Patients with signs, symptoms of flu|Patients arriving at the pharmacy with signs, symptoms of flu that the pharmacist diagnoses as having flu and being suitable for pharmacist prescribing of Oseltamivir according to an algorithm.
3257856|NCT01456247|Experimental|TAK-438 10 mg QD|
3257857|NCT01456247|Experimental|TAK-438 20 mg QD|
3257858|NCT01456247|Active Comparator|AG-1749 15 mg QD|
3257859|NCT01456260|Experimental|TAK-438 10 mg QD|
3257860|NCT01456260|Experimental|TAK-438 20 mg QD|
3257861|NCT01456260|Active Comparator|Lansoprazole 15 mg QD|
3257862|NCT01456273|Placebo Comparator|A2- Medical consultation + placebo|Traditional medical interview + placebo
3257863|NCT01456273|Active Comparator|B1 - Therapeutic Encounter / Omeprazol|
3257864|NCT01456273|Placebo Comparator|B2 - Therapeutic Encounter / Placebo|
3257865|NCT01456273|Active Comparator|A1- Medical consultation + omeprazole|Traditional medical interview + omeprazole
3257866|NCT01456286|Experimental|Sapropterin|5 mg/kg daily first week; 10 mg/kg daily second week of treatment
3257867|NCT01456286|Placebo Comparator|placebo|
3257868|NCT01456312|Sham Comparator|HBsAg quantification>20,000 IU/ml|stop peginterferon alfa 2a if patients reach HBsAg quantification>20,000 Iu/ml at 12w
3257869|NCT01456312|Sham Comparator|HBsAg<=1500IU/ml|extend peginterferon alfa 2a until 48weeks
3257870|NCT01456312|Sham Comparator|HBsAg >1500 <=20,000 IU/ML|add Entecavir for 12w with peginterferon alfa 2a then, extend peginterferon alfa 2a until 48w
3257871|NCT01456325|Experimental|Onartuzumab+Erlotinib|Participants will receive onartuzumab 15 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally once daily (QD) from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
3257872|NCT01456325|Placebo Comparator|Placebo+Erlotinib|Participants will receive onartuzumab matching placebo on Day 1 of every cycle of 3 weeks along with erlotinib 150 mg tablet orally QD from Day 1, Cycle 1 until there is evidence of disease progression, death, or unacceptable toxicity, whichever occurred first.
3257873|NCT01456338|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based, manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
3260159|NCT01477073|Experimental|FSH-GEX 150 IU QAD|follitropin epsilon 150 IU QAD
3260160|NCT01477073|Active Comparator|recombinant FSH|Gonal-f 150 IU QD
3260161|NCT01477073|Active Comparator|urinary FSH|Bravelle 150 IU QD
3260162|NCT01477073|Placebo Comparator|Placebo|Placebo QD
3260163|NCT01477086||Hip fracture|We included patients with traumatic hip fracture, with surgery and who are admitted for rehabilitation
3260164|NCT01477099|Experimental|Toothbrushing with a manual brush|Toothbrushing with a manual brush
3260165|NCT01477099|No Intervention|No toothbrushing|no toothbrushing
3260166|NCT01477112|Experimental|Supplemented Diabetics (DB)|Diabetics supplemented with betacarotene for 45 days
3260167|NCT01477112|Experimental|Unsupplemented Diabetics (DS)|Diabetics without betacarotene supplementation
3260168|NCT01477112|Active Comparator|Supplemented Controls (CB)|Controls supplemented with betacarotene for 45 days
3260169|NCT01477112|Active Comparator|Unsupplemented Controls (CS)|Controls without betacarotene supplementation
3260170|NCT01477125|Experimental|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
3260171|NCT01477125|Placebo Comparator|Control version of Flex|30-40 minutes of training with a control version of Flex, 5 days a week for 5 weeks.
3260172|NCT01477138||DDD(R)|SSS. PM programmed to DDD(R) mode with ventricular pacing on the right ventricular septum.
3260173|NCT01477138||AAI(R)<=>DDD(R)|SSS, PM-mode programmed for minimizing right ventricular pacing on the right interventricular septum
3260174|NCT01477151|Active Comparator|sevoflurane|These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
3260175|NCT01477151|Experimental|isoflurane|These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
3260176|NCT01477164|Experimental|Aerobic Exercise Training|Participants will perform 12-weeks of high intensity aerobic training.
3260177|NCT01477164|Active Comparator|Combined|The combined group will have 12-weeks of no exercise followed by 12-weeks of combined aerobic and resistance exercise training. Assessments will be made at three time points: baseline, after 12-weeks of no training, and after 12-weeks of combined training.
3260178|NCT01477164|Experimental|Resistance Exercise Training|Participants will perform 12-weeks of resistance exercise training.
3260179|NCT01477190|Experimental|Spinal group|Isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
3260180|NCT01477190|Active Comparator|PCA group|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
3260181|NCT01477203|Active Comparator|Escitalopram|50 Major Depressive Disorder Patients and 50 Anxiety Disorder Patients will receive Escitalopram as medication
3260182|NCT01477203|No Intervention|Remitted Patients|
3260183|NCT01477203|No Intervention|Healthy Controls|
3260184|NCT01477216|Experimental|Measuring method|To compare glycemic responses and GI values from capillary and venous blood and to compare glucose solution with white bread as the reference food and to study the effect of the number of reference tests on GI values.
3260185|NCT01477216|Experimental|Mixed meals|To examine the glycaemic and insulinaemic responses of a mashed potato-based meal when a high fat food (rapeseed oil) or a high protein food (chicken breast) or fat, protein and salad together were added to the meal. Furthermore, we studied how the predicted and measured GI values of the mixed meal differed from each other.
3260186|NCT01477216|Experimental|Coffee|To examine the effects of two different coffee portions with glucose and caffeine-containing soft drinks on postprandial glucose and insulin responses. Further objectives were to study how coffee and different accompaniments affect glucose and insulin responses.
3260187|NCT01477216|Experimental|Snacks|To measure GI and II values for Finnish snack foods
3260188|NCT01477216|Experimental|Berries|To study the effects of berries on glycemic and insulinemic responses
3260189|NCT01477216|Experimental|GIs of low-carbs|To measure glycemic and insulinemic responses to low-carbohydrates foods
3260190|NCT01477216|Experimental|Glucose metabolism and BMI|To examine the effects of overweight and glucose tolerance on the glucose, insulin and lipid responses to an HGI meal and an LGI meal. Furthermore, the second aim was to study the effect of BMI and glucose tolerance on the GI measured.
3260191|NCT01477216|Experimental|Insulin measurement|To compare how methodological choices affect measured insulin values
3260192|NCT01477216|Experimental|Alcohol|To investigate the effect of alcohol on postprandial glucose and insulin responses, and to determine glycemic and insulinemic indices values for beer and non-alcoholic beer.
3260193|NCT01477229||Abdominoperineal resection|Patients with low rectal cancers
3260194|NCT01477229||Anterior resection|Patients where it is possible to perform an anterior resection
3260195|NCT01477229||Preoperative chemo-radiation treatment|Patients with locally advanced rectal cancer
3260196|NCT01477229||Palliative treatment|Patients with systemic disease
3257874|NCT01456338|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
3257875|NCT01456351|Experimental|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
3257876|NCT01456351|Active Comparator|Fludarabine plus Rituximab|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
3257877|NCT01456364|Active Comparator|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
3257878|NCT01456364|Active Comparator|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
3257879|NCT01456377|Active Comparator|corticosteroids, analgesics oral pill|Oral Corticosteroids and oral analgesics
3257880|NCT01456377|Placebo Comparator|placebo|oral placebo and oral analgesics
3257881|NCT01456390|Other|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
3257882|NCT01456403||Carotid endarterectomy patients|Patients scheduled for clinically indicated carotid endarterectomy
3257883|NCT01456416||Glatiramer Acetate|GA administered SQ daily in MS patients who met all Inclusion-Exclusion Criteria and were approved by their Health Care Plans for GA treatment.
3257884|NCT01456429|Experimental|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
3257885|NCT01456468|Experimental|UDCA + ATRA|This is a single-arm study. All subjects will take UDCA and ATRA.
3257886|NCT01456481|Active Comparator|midodrine hydrochloride pills|
3257887|NCT01456481|Placebo Comparator|oral placebo or sugar pill|
3257888|NCT01456507|Experimental|A|1×40 mg ALO-02 capsule administered with 240 mL of water under fasting conditions.
3257889|NCT01456507|Experimental|B|1×40 mg ALO-02 capsule administered with 240 mL of water under fed conditions (standard high fat breakfast).
3257890|NCT01456507|Experimental|C|1×40 mg ALO-02 with the ALO-02 pellets sprinkled approximately on one table spoon of applesauce, and administered with 240 mL of water under fasting conditions.
3257891|NCT01456520|Experimental|A: single dose Vycavert (Test)|
3257892|NCT01456520|Active Comparator|B: single dose Norco (Reference)|
3257893|NCT01456533||hospitalized patients|hospitalized patients with hyponatremia
3257894|NCT01456546|Active Comparator|Period A: proguanil|Proguanil pharmacokinetics
3257895|NCT01456546|Active Comparator|Period B: clopidogrel|Clopidogrel pharmacokinetics
3257896|NCT01456572|Active Comparator|satiation_obese weight|Obese subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
3257897|NCT01456572|Active Comparator|gastric emptying_obese weight|Obese subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
3257898|NCT01456572|Placebo Comparator|gastric emptying_normal weight|Normal weight subjects will receive a standardized meal, consisting of two scrambled eggs (cooked with 10 g butter), placed on two slices of whole wheat bread and 200 mL of milk (in total: 468 kcal). The test meal will be labeled with 100 mg of 13C-octanoic acid for determination of gastric emptying.
3257899|NCT01456572|Placebo Comparator|satiation_normal weight|Normal weight subjects will receive a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate, 1 kcal/mL). Nutrient intake will be stopped when subjects had reached maximal or unbearable satiation; the time needed to reach the maximal level of satiation (tmax) and the quantity of volume drunk will be recorded and calorie intake calculated.
3257900|NCT01456572|Active Comparator|hormone profiles_obese weight|Obese subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
3257901|NCT01456572|Placebo Comparator|hormone profiles_normal weight|Normal weight subjects will receive 500 mL of a complex nutrient drink (Ensure Plus; 17 % protein, 30 % fat and 53 % carbohydrate). At regular time intervals fasting and post-prandial blood samples will be collected.
3257902|NCT01456598|Experimental|Laparoscopic gastrectomy|Laparoscopic subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
3257903|NCT01456598|Active Comparator|Open gastrectomy|Open subtotal gastrectomy and D2 lymph node dissection are performed for locally advanced gastric cancer.
3257904|NCT01456611|Experimental|Diclofenac Sodium Gel|Diclofenac sodium Topical Gel 1%
3257905|NCT01456611|Active Comparator|Voltaren (R) Gel|Voltaren (R) Gel 1%
3257906|NCT01456611|Placebo Comparator|Placebo|Placebo Topical Gel
3257907|NCT01456624|Active Comparator|Megace / Fasting condition|800mg
3257908|NCT01456624|Experimental|DW-ES(B) / Fasting condition|625mg
3257909|NCT01456624|Active Comparator|Megace / Fed condition|800mg
3257910|NCT01456624|Experimental|DW-ES(B) / Fed condition|625mg
3257911|NCT01456637|Experimental|CBT for insomnia with feedback|In this arm participants received internet based self-help CBT for insomnia with e-mail feedback form a therapist.
3257912|NCT01456637|Experimental|CBT for insomnia without feedback|In this arm participants receive internet based self-help CBT for insomnia without feedback from a therapist.
3260197|NCT01477242|Experimental|Ondansetron|Ondansetron use group
3260198|NCT01477242|Placebo Comparator|Placebo|Placebo group
3257913|NCT01456650|Experimental|Glyburide|Patients in which the fasting glucose persisted above the treatment goal (fasting glucose <126 mg/dl) after a 4 week diet period will receive glyburide. The dose of the medication will be adjusted based on the results of fasting glucose values. At each visit patients will return the leftover tablets; counts of the tablets will be the method for measuring the adherence to treatment. The medical study participants who decided to doses of glibenclamide will not know the allele of ABCA1 gene under study.
3257914|NCT01456663|Experimental|AFQ056|
3257915|NCT01456676|Experimental|Nilotinib + LDE225|The planned dose of nilotinib 400 mg b.i.d (twice a day) was selected for the combination as this is the dose approved for the treatment of the patient population that will be included in the present study. The starting dose for LDE225 chosen for the current study is 400 mg once daily(q.d.). The maximum dose of LDE225 that will be tested in combination with nilotinib is 800 mg once dail.y
3257916|NCT01456689|Experimental|LGH447|Eligible patients will be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
3257917|NCT01456689|Experimental|LGH447 and midazolam|Eligible patients will receive midazolam on two separate days, the first dose will be administered prior to the start of LGH447 and the second will be co-administered with LGH447. After that, the patients will continue to be treated with oral LGH447 until disease progression or occurrence of unacceptable toxicity.
3257918|NCT01456702|No Intervention|control arm|volume therapy via standard operating procedure
3257919|NCT01456702|Experimental|intervention arm|goal-directed volume therapy due to svv in dependence of preoperative risk stratefication
3257920|NCT01456715|Active Comparator|Gardasil, Immunogenicity, Booster dose.|
3257921|NCT01456715|Experimental|Cervarix, Immunogenicity, Booster dose.|
3257922|NCT01456728|Experimental|Progastria|One chewable tablet of the study product is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day together with omeprazole 2x20mg. The study product and omeprazole will be taken daily for 28 consecutive days.
3257923|NCT01456728|Placebo Comparator|Placebo|The placebo will have identical appearance and taste with the study product only lacking the bacteria. All subjects from this group will receive 2 x 20 mg omeprazole per day and Placebo 1 chewable tablet per day for 28 days.
3257924|NCT01456741|Experimental|1-EBNA with ROSE|
3257925|NCT01456741|Experimental|1-EBNA without ROSE|
3257926|NCT01456754|Experimental|High feeding frequency (14x)|
3257927|NCT01456754|Experimental|low feeding frequency (3x)|
3257928|NCT01456767|Active Comparator|Lactobacillus plantarum WCFS1|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum WCFS1).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3257929|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104448|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104448).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3257930|NCT01456767|Active Comparator|Lactobacillus plantarum CIP104450|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of Lactobacillus plantarum CIP104450).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3257931|NCT01456767|Placebo Comparator|Placebo|"Al study subjects will in randomized sequence participate in this arm (7-days supplementation period of a placebo).~Each arm represents a 7-days supplementation period (with probiotics or placebo). The 7-days supplementation period will be followed by a month washout time after which the next supplementation period with another probiotic (or placebo) will start. The sequence is randomized and double blind. The different measurements will be performed at baseline and after each supplementation period."
3257932|NCT01456793|Experimental|Teen Options to Prevent Pregnancy|
3257933|NCT01456793|No Intervention|Usual care services|
3257934|NCT01456806|No Intervention|Patients and provider non educated|In this arm neither the patients nor the providers have attended the groupal education courses
3257935|NCT01456806|Active Comparator|Provider educated|Provider attend the interactive group education, while patients do not.
3257936|NCT01456806|Active Comparator|Patients Educated|Patients attend the interactive group education, while providers do not.
3257937|NCT01456806|Active Comparator|Providers/Patients Educated|Provider and Patients both attend the interactive group education.
3257938|NCT01456819|Experimental|Mononuclear and mesenchymal stem cells|Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells
3257939|NCT01456819|Active Comparator|Mononuclear cells only|Autologous bone marrow-derived mononuclear cells
3257940|NCT01456832||Renal Transplant Patients with Post-operative Hypoatremia|All renal transplant recipients at the Mayo Clinic of Florida from 1/1/2010 through 8/19/2011 who received a kidney from either a living or cadaveric donor.
3257941|NCT01456845||2|"Cases - those patients who develop DIH while on regular treatment with anti-TB drugs.~Controls - patients who do not develop DIH while on regular treatment with anti-TB drugs."
3257942|NCT01456858|Placebo Comparator|Child UPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Untreated plastic sheeting (interior wall and ceiling lining)
3257943|NCT01456858|Experimental|Child ITPS Largo Camp|Children 4months-36months enrolled who resided in Largo refugee camp under Insecticide treated plastic sheeting (interior wall and ceiling lining)
3257944|NCT01456858|Placebo Comparator|Child UPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Untreated plastic sheeting (ceiling and interior roof lining)
3257945|NCT01456858|Experimental|Child ITPS Tobanda Camp|Children 4months-36months enrolled who resided in Tobanda refugee camp under Insecticide treated plastic sheeting (ceiling and interior roof lining)
3257946|NCT01456871||Healthy adult females|Females, aged 20 to 30 with no history of upper extremity injury or disorder in the non-dominant arm, no history of neurologic or bleeding disorder, and no evidence of Linburg-Comstock syndrome.
3257947|NCT01456884|Experimental|Live - Vibroacoustic|Treatment order A: live guitar and vocal music therapy on day one, vibroacoustic music therapy on day two.
3257948|NCT01456884|Experimental|Vibroacoustic - Live|Treatment order B: vibroacoustic music therapy live guitar on day one, and vocal music therapy on day two.
3257949|NCT01456910|Experimental|Working group|G1 intervention group of 20 participants aged 14-36 years old and mild to severe intellectual disability of both gender.
3257950|NCT01456910|Active Comparator|Daily Living|G2 control group continue usual routine
3257951|NCT01456923|Active Comparator|Control (chemotherapy and surgery)|Patients treated with chemotherapy + surgery
3257952|NCT01456923|Active Comparator|Study|Patients treated only with chemotherapy
3257953|NCT01456975|Experimental|Valsalva|Reimplantation procedure using Valsalva prosthesis
3257954|NCT01457001|Experimental|25-OH-D vitamin|
3257955|NCT01457001|No Intervention|control|
3257956|NCT01457027|Experimental|All subjects|
3257957|NCT01457040|Experimental|Complete Remission (CR)|CR Cohort: high-risk ALL in CR and standard-risk ALL in the status of ≥CR2
3257958|NCT01457040|Experimental|Non-Remission (NR)|NR Cohort: ALL in non-remission
3257959|NCT01457066|Experimental|Intervention|This group will receive the peer navigator intervention.
3257960|NCT01457066|No Intervention|Control|This group will receive usual care.
3257961|NCT01457092|Experimental|FC Nitinol SEMS|FC Nitinol SEMS
3257962|NCT01457105|Experimental|ComVi biliary stent|
3257963|NCT01457144|Experimental|RiBVD|Rituximab Bendamustine Velcade® Dexamethasone 6 cycles every 28 days
3257964|NCT01457170|Experimental|Apelin/Saline|Apelin infusion then crossover to Saline infusion
3257965|NCT01457170|Experimental|Saline/Apelin|Saline infusion then crossover to Apelin infusion
3257966|NCT01457183|Experimental|Lavage group|Healthy subjects with intact skin will be lavaged within the device in 3 locations on their bodies.
3257967|NCT01457222|Active Comparator|Mindfulness|Mindfulness intervention 10 minutes daily
3257968|NCT01457222|Active Comparator|Music relaxation|Music intervention 10 minutes daily
3257969|NCT01457222|No Intervention|Business as usual|No intervention - control group.
3257970|NCT01457235|Active Comparator|Active Group|This group receives cognitive remediation in groups (each group consisting of 6-8 subjects)
3257971|NCT01457235|No Intervention|Waiting List|Patients randomized to the waiting list group continues standard treatment and will be offered a course of cognitive remediation upon completion of participation provided that they still meet the inclusion criteria.
3257972|NCT01457248|Experimental|endotracheal tube with taper-shaped cuff|
3257973|NCT01457248|Active Comparator|Endotracheal tube with cylindrical-shaped cuff|
3257974|NCT01457261|Experimental|Partical size 1|Monodisperse particle delivered with radiolabel
3257975|NCT01457261|Experimental|Particle size 2|Monodisperse particle delivered with radiolabel
3257976|NCT01457261|Experimental|Nebulised salbutamol|Polydisperse particle via a nebuliser
3257977|NCT01457261|Experimental|Salbutamol MDI|Unlabelled salbutamol via a metered dose inhaler
3257978|NCT01457274|Experimental|"light sedation"|"In this study the depth of sedation will be guided by the Bispectral Index monitor (BIS monitor). A BIS value of 70-80 will be targeted in the light sedation arm."
3257979|NCT01457274|Active Comparator|"deep sedation"|"In this study the deep sedation arm will have a BIS value of less than 60 targeted."
3257980|NCT01457300||District Rehabilitation Centre (Model 1)|Patients admitted to Primary Health Care Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited continuously at Entrance to the Rehabilitation Centre.
3257981|NCT01457300||Standard PHC Rehabilitation (Model 2)|Patients admitted to Standard Primary Health Care (PHC) Rehabilitation, either Post-Acute from the Same District General Hospital or Directly from their Homes. They were recruited Continuously at Entrance to the Short Term Rehabilitation Beds in Nursing Homes or at the Beginning of Rehabilitation in their Own Homes.
3257982|NCT01457313||BTKA|patients undergoing bilateral staged total knee arthroplasty
3257983|NCT01457326||Immersion Therapy- Study|1. Patients who participate in the immersion therapy post-operative protocol and begin progressive weight bearing at 4 weeks (study)
3257984|NCT01457326||Control Group|2. Patients who undergo the traditional 10-week non-weight bearing post-operative care protocol (control)
3257985|NCT01457365||subjects|it is a cross-sectional research and there is only one group.
3257986|NCT01457378||Healthy volunteers|100 healthy volunteers
3257987|NCT01457378||IBS Subjects|100 IBS Subjects
3257988|NCT01457391|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a non-exposure based manual-guided individual therapy. CBT for PTSD consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Breathing retraining: A behavioral anxiety reduction skill; and 3) Cognitive restructuring: A cognitive approach and functional analysis of the link among emotions, cognitions and situations.
3257989|NCT01457391|Active Comparator|Individual Addiction Counseling|Individual Addiction Counseling (IAC) was adapted from the Individual Drug Counseling (IDC) manual used in the NIDA Cocaine Collaborative Study. IAC is a manual-guided treatment that focuses on substance use and history of use, consequences of use and denial, developing strategies for relapse prevention, and facilitation of connection with peer recovery support groups, specifically twelve step groups. The current adaptation of IAC modified the IDC manual by broadening the focus to include drugs other than cocaine, as well as alcohol.
3260199|NCT01477255||Cancer patient|Patient participants will include children and adolescents between the ages of 8-17 years who have been recently diagnosed with cancer. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
3257990|NCT01457391|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical intensive outpatient (IOP) treatment that the patient would receive ordinarily at the identified addiction treatment program. Each TAU service operates using the American Society of Addiction Medicine criteria for Level II Intensive Outpatient services: 9-12 hours per week; group and individual sessions focused on motivation to address substance use, education about the consequences of substance use on major life areas, education about the disease concept and brain changes associated with addiction, exposure to information about social and family relationships and recovery, and relapse prevention skills.
3257991|NCT01457404|Experimental|Integrated Cognitive Behavioral Therapy|Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
3257992|NCT01457404|Active Comparator|Treatment-as-usual|Treatment-as-usual (TAU) is the typical outpatient treatment that patients would receive ordinarily at the PVAMC Substance Abuse Treatment Program (SATP) or PTSD Clinic.
3257993|NCT01457443||Observation|Patients with Pompe disease
3257994|NCT01457456||Observation|Patients with Morquio disease
3257995|NCT01457469|Active Comparator|Arm I (usual care plus) (closed to accrual as of 3/6/2012)|"Patients receive a personalized letter from their physician with advice to quit smoking and a copy of the National Cancer Institute's Cleaning the Air smoking cessation booklet."
3257996|NCT01457469|Experimental|Arm II (enhanced quitline)|Patients receive a personalized letter and a smoking cessation booklet. Patients also receive an 8-week supply of nicotine replacement patches and undergo a counseling session over 30-45 minutes with a trained nurse or midlevel provider that focuses on the benefits of quitting smoking for cancer patients and addresses cancer-specific concerns about smoking cessation. Patients also undergo a quitline-based smoking cessation intervention comprising 5 individual 25- to 30-minute telephone counseling sessions and unlimited inbound phone-based access to Quit Coaches over 8-11 weeks, mailed written materials, and an interactive online program.
3257997|NCT01457482|Experimental|Art therapy group|Treatment in this arm consists of five Art Therapy sessions and therapeutic conversations.
3257998|NCT01457482|Active Comparator|Therapeutic conversation group|Treatment by therapeutic conversations only
3257999|NCT01457495|Experimental|DTPa 1 Group|
3258000|NCT01457495|Active Comparator|DTPa 2 Group|
3258001|NCT01457508|Experimental|Group A|Subjects will receive one single injection of DTPa-HBV-IPV vaccine mixed with Hib vaccine.
3258002|NCT01457508|Active Comparator|Group B|Subjects will receive two separate injections of DTPa-HBV-IPV and Hib vaccine.
3258003|NCT01457534||liver transplantation|
3258004|NCT01457547|Experimental|DTPa 1 Group|
3258005|NCT01457547|Active Comparator|DTPa 2 Group|
3258006|NCT01457560|Experimental|Group A|
3258007|NCT01457586|Active Comparator|Transfusion|Patient who received blood transfusion in the perioperative period
3258008|NCT01457586|No Intervention|No Transfusion|Patients who did not receive blood transfusion in the perioperative period
3258009|NCT01457599||Marking Liver|
3258010|NCT01457612|Placebo Comparator|Placebo1|Placebo Beverage 1 without fiber
3258011|NCT01457612|Active Comparator|Strawberry|Strawberry Beverage 20g/BID
3258012|NCT01457612|Placebo Comparator|Placebo2|Placebo Beverage 2 with Fiber
3258013|NCT01457625||liver fat contents|
3258014|NCT01457638|Sham Comparator|No inferior turbinate surgery|During rhinoseptoplasty there is no intervention on inferior turbinates
3258015|NCT01457638|Experimental|Inferior Turbinate surgery|During rhinoseptoplasty, inferior turbinate submucosal cauterization is performed.
3258016|NCT01457651|Active Comparator|Recruitment 40x40|The group where recruitment is performed by increase in airway pressure up to 40 cm H2O for 40 seconds
3258017|NCT01457651|Active Comparator|Recruitment PEAK40|Increase in peak airway pressure up to 40 cm H2O during tidal ventilation
3258018|NCT01457651|Active Comparator|Recruitment 15x300|Recruitment by increase in airway PEEP up to 15 cm H2O for 300 sec
3258019|NCT01457651|Active Comparator|No recruitment|No recruitment is performed: standard respiratory support.
3258020|NCT01457664|Placebo Comparator|Placebo|
3258021|NCT01457664|Experimental|RO4995819|
3258022|NCT01457677|Placebo Comparator|Placebo|
3258023|NCT01457677|Experimental|RO4995819 15 mg|
3258024|NCT01457677|Experimental|RO4995819 30 mg|
3258025|NCT01457677|Experimental|RO4995819 5 mg|
3258026|NCT01457690|Experimental|Tocofersolan: Vitamin E water-soluble|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
3258027|NCT01457690|Active Comparator|Tocopherol alpha: Vitamin E conventional fat-soluble form|2 months off the conventional treatment before the study. Administration of a daily dose of vitamin E for 4 months
3258028|NCT01457690|Active Comparator|volunteers|
3258029|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler A|
3258030|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler B|
3258031|NCT01457716|Experimental|Budesonide/Formoterol Easyhaler C|
3258032|NCT01457716|Active Comparator|Budesonide/Formoterol Turbohaler Forte|
3258033|NCT01457729|No Intervention|No Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes per day, no more intervention is done.
3258034|NCT01457729|Other|Motivation|Patients are asked to complete a telemonitored Ergometer training for 4 Weeks, at least 30 minutes every day. If training time declines to less than 20 minutes per day for one week, a motivation phone call will take place once a week.
3258035|NCT01457742|Active Comparator|Pulsed Radio Frequency (PRF)|
3258036|NCT01457742|Sham Comparator|Sham|Use of Sham device for 15 minutes simulated treatment twice per day
3258037|NCT01457781|Active Comparator|0.025 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
3258038|NCT01457781|Active Comparator|0.075 mg inhaled nitric oxide|Inhaled nitric oxide (iNO) 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (6.0 mg/L [4880 ppm] NO mini-cylinder; change q 24 hours)
3258039|NCT01457781|Placebo Comparator|placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks* (99.999% Nitrogen [N2] mini-cylinder; change q 24 hours)
3258040|NCT01457794|Other|NewNordicDiet first|Intervention with NND for 3 mo then no intervention for 3 mo
3258041|NCT01457794|Other|NewNordicDiet last|No intervention for 3 mo and then intervention with NND for 3 mo
3258042|NCT01457807|Experimental|1|AZD3241 300mg extended release formulation 1
3258043|NCT01457807|Experimental|2|AZD3241 300mg extended release formulation 2
3258044|NCT01457807|Placebo Comparator|3|Placebo
3258045|NCT01457820|Experimental|Allopurinol High dose|
3258046|NCT01457820|Experimental|Allopurinol Low dose|
3258047|NCT01457820|Placebo Comparator|Placebo|
3258048|NCT01457833|Active Comparator|Endobronchial valves (EBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of endobronchial valves
3258049|NCT01457833|Active Comparator|Intrabronchial valves (IBV)|Complete occlusion of one emphysematous destroyed lobe by implantation of intrabronchial valves
3258050|NCT01457859|Active Comparator|Conventional sutures|
3258051|NCT01457859|Experimental|Antiseptic sutures|
3258052|NCT01457872|Experimental|Strength-based case management|Case management plus referral (vs referral-only)
3258053|NCT01457872|Active Comparator|Referral only|Referral only (no case management intervention)
3258054|NCT01457898|Experimental|VPAP II®|VPAP II® Group
3258055|NCT01457911|Experimental|AMARYL M (Glimepiride and Metformin hydrochloride combination)|AMARYL M at a dosage regimen from 1 tablet to 6 tablets, once during a meal or twice during a meal
3258056|NCT01457911|Active Comparator|AMARYL (Glimepiride)|AMARYL at a dosage regimen from 1 mg to 6 mg, once during a meal or twice during a meal
3258057|NCT01457937|Active Comparator|PEG IFN/Ribavirin|Standard of care for HCV-positive CAH
3258058|NCT01457937|Experimental|PEG IFN/Ribavirin/Boceprevir|Combination to be tested for possible higher efficacy
3258059|NCT01457963||pulmonary embolism, deep venous thrombosis|
3258060|NCT01457976||Members of the US public, non-probability sample|
3258061|NCT01457976||Members of the German public, non-probability sample|
3258062|NCT01457976||Members of the US public, probability sample|
3258063|NCT01457989||retigabine/ezogabine|retigabine/ezogabine; dose range up to 1200 mg/day
3258064|NCT01458002|No Intervention|Control|Assessment only
3258065|NCT01458002|Other|Tailored Internet Communications|TTM expert system only
3258066|NCT01458002|Experimental|Tailored Internet Communication with Relational Agent|TTM expert system plus relational agent
3258067|NCT01458015|Active Comparator|oxycodone|
3258068|NCT01458015|Active Comparator|tapentadol|
3258069|NCT01458028|Experimental|Arm 1|
3258070|NCT01458028|Placebo Comparator|Arm 2|
3258071|NCT01458041||Group 1|
3258072|NCT01458054|Experimental|Treatment A|GSK2336805 60mg x 1 dose (fasted) [Reference Treatment]
3258073|NCT01458054|Experimental|Treatment B|Omeprazole 40 mg q24h x 4 days (fed)
3258074|NCT01458054|Experimental|Treatment C|GSK2336805 60 mg x 1 dose and Omeprazole 40 mg on Day 1 (fasted) [Test Treatment]
3258075|NCT01458054|Experimental|Treatment D|GSK2336805 30mg x 1 dose (fasted) [Reference Treatment]
3258076|NCT01458054|Experimental|Treatment E|Ritonavir 100mg q12h x 4 days (fed)
3258077|NCT01458054|Experimental|Treatment F|GSK2336805 30 mg x 1 dose (fasted) and ritonavir 100mg q12h on Day 1 (fasted) [Test Treatment]
3258078|NCT01458054|Experimental|Treatment G|Ritonavir 100mg q12h x 1 day
3258079|NCT01458067|Experimental|Part 1|GSK2636771 single dose and then daily dosing after approximately 1 week
3258080|NCT01458067|Experimental|Part 2|GSK2636771 single dose and then daily dosing starting on Day 4
3258081|NCT01458067|Experimental|Part 3|GSK2636771 daily dosing
3258082|NCT01458080||Patients w/secondary thrombocytopenia related to hepatitis C|Patients w/secondary thrombocytopenia related to hepatitis C
3258083|NCT01458093||Colonoscopy patients|Consecutive colonoscopy outpatients referred to one of 29 endoscopy units in Italy
3258084|NCT01458145|Experimental|Home visits|
3258085|NCT01458145|No Intervention|routine primary care at community health center|
3258086|NCT01458158||Diabetic nephropathy|Diabetic nephropathy in patients with type 2 diabetes
3258087|NCT01458158||chronic glomerulonephritis|chronic glomerulonephritis in patients without diabetes mellitus
3258088|NCT01458158||controls|participants without diabetic nephropathy and chronic glomerulonephritis
3258089|NCT01458184|Experimental|PhoneCare system|This arm is evaluating whether utilizing the PhoneCare system aids participants with their complex health care needs.
3258090|NCT01458184|No Intervention|Control Group: without PhoneCare System|Subjects in this arm will receive the usual care. Usual care is defined as receiving regular care from their physicians and no additional care or intervention from the study.
3258091|NCT01458197|Experimental|Tarafenacin 0.2 mg|Group 1
3258092|NCT01458197|Experimental|Tarafenacin 0.4 mg|Group 2
3258093|NCT01458197|Placebo Comparator|Placebo|Group 3
3258094|NCT01458223|Active Comparator|Control|24 hours post-operative antibiotics
3258095|NCT01458223|Experimental|experimental|72 hours of post-operative antibiotics
3258096|NCT01458236|Experimental|BPS-314d-MR|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration.
3258097|NCT01458236|Experimental|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group.
3258098|NCT01458301|Placebo Comparator|Placebo|
3258099|NCT01458301|Experimental|TAK-385 10 mg QD|
3258100|NCT01458301|Experimental|TAK-385 20 mg QD|
3258101|NCT01458301|Experimental|TAK-385 40 mg QD|
3258102|NCT01458301|Other|Leuplin|
3258103|NCT01458314|Active Comparator|Rehabilitation without NIV|A usual rehabilitative training will be performed in patients using nocturnal NIV, without adoption of daily NIV
3258104|NCT01458314|Experimental|Daily NIV during rehabilitation|Daily NIV will be adopted during the rehabilitation program in patients already using nocturnal NIV
3258105|NCT01458340|Experimental|TD-9855 Dose 1|
3258106|NCT01458340|Experimental|Placebo|
3258107|NCT01458340|Experimental|TD-9855 Dose 2|
3258108|NCT01458353|Experimental|Handsewn ileocolonic anastomosis|Swabs obtained from patients undergoing handsewn ileocolonic anastomosis
3258109|NCT01458353|Experimental|Stapled ileocolonic anastomosis|Swabs obtained for culture in those patients undergoing stapled ileocolonic anastomosis
3258110|NCT01458405|Placebo Comparator|Placebo|
3258111|NCT01458405|Active Comparator|CAP-1002 Allogeneic Cardiosphere-Derived Cells|
3258112|NCT01458431|Experimental|Levobupivacaine|Continuous levobupivacaine subfascial infusion
3258113|NCT01458431|Placebo Comparator|NaCl|Continuous NaCl subfascial infusion
3258114|NCT01458444|Active Comparator|BIPAP|Non invasive ventilation (VNI) by BIPAP® vision
3258115|NCT01458444|Experimental|OPTIFLOW|OPTIFLOW system
3258116|NCT01458457|Active Comparator|Usual care|
3258117|NCT01458457|Active Comparator|Usual Care + Complementary Medicine|
3258118|NCT01458470|Active Comparator|Memantine|NMDA Receptor Antagonist
3258119|NCT01458470|Placebo Comparator|Sugar pill|
3258120|NCT01458483|Experimental|Baroreceptor Stimulation|
3258121|NCT01458496|Experimental|Health Coaching|
3258122|NCT01458496|No Intervention|Usual Care -Control|Patients assigned to the control (usual care) group will be advised to seek standard lifestyle counselling from their primary care physician.
3258123|NCT01458509||IVRS ( interactive voice response system) EASP|Telephone Group with Nurse Intervention
3258124|NCT01458509||Web EASP|Web Group with Nurse Intervention
3258125|NCT01458509||IVRS ( interactive voice response system) No EASP|Telephone Group without nurse intervention
3258126|NCT01458509||Web No EASP|Web Group without nurse intervention
3258127|NCT01458600|Active Comparator|diclofenac|12 months treatment with diclofenac 50 mg 1x2 in addition to regular treatment for thyrotoxicosis.
3258128|NCT01458600|Other|without diclofenac|12 months treatment without diclofenac in addition to regular treatment for thyrotoxicosis.
3258129|NCT01458613||Observation|Patients with Maroteaux-Lamy disease
3258130|NCT01458626|Active Comparator|Add-on therapy|mirtazapine 30mg QD and paroxetine 20mg QD
3258131|NCT01458626|Active Comparator|mirtazapine monotherapy|mirtazapine 30mg QD
3258132|NCT01458626|Active Comparator|paroxetine monotherapy|paroxetine 20mg QD
3258133|NCT01458652|Experimental|Lifestyle counseling|"Drug:Kremezin~Other Names:AST-120~Kremezin is an oral adsorbent, 9g/day in treatment arm"
3258134|NCT01458665|Experimental|PRP group|
3258135|NCT01458665|Placebo Comparator|Conventional group|
3258136|NCT01458678|Active Comparator|Oesophageal Doppler (OD)|Goal directed volume therapy is most often guided by stroke volume measurements by OD.
3258137|NCT01458678|Active Comparator|Pleth Variability Index (PVI)|The Pleth variability index (PVI) is an automated function in pulse oximetry that continuously calculates the dynamic variation between the pulse oximetry pulse variation and its baseline for every breathing circuit. Dynamic indicators are advantageous in predicting a responder to a volume bolus, thus facilitating goal directed volume therapy.
3258138|NCT01458691|Active Comparator|Steroid group|Triamcinolone injection group
3258139|NCT01458691|Experimental|PRP group|Allogeneic PRP injection group
3258140|NCT01458704||fresh frozen tumor tissue|patients providing fresh frozen tumor tissue
3258141|NCT01458717|Experimental|Neoadjuvant|Neoadjuvant - operation - maintenance chemotherapy
3258142|NCT01458717|Active Comparator|Upfront surgery|Operation - adjuvant chemoradiation - maintenance chemotherapy
3258143|NCT01458743|Experimental|Ceftaroline q12h|Ceftaroline 600mg q12h
3258144|NCT01458743|Experimental|Ceftaroline q8h|ceftaroline 600mg q8h
3258145|NCT01458756||liver transplant patients|Population of adult patients awaiting liver transplant, status on the waiting list in the transplant center of University Hospital of Lille.
3258146|NCT01458769|Active Comparator|Part A1|"Part A1 will evaluate two single ascending doses of the single agent C-10276 (an ATV isotopolog), and a dose of Reyataz.~C-10276 200 mg -> C-10276 400 mg -> Reyataz 400 mg~C-10276 200 mg -> Reyataz 400 mg -> C-10276 400 mg"
3258147|NCT01458769|Active Comparator|Part A2|"Part A2 will evaluate the single agent C-10276, co-administration of CTP-518 and C-10276, and a dose of Reyataz.~C-10276 300 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)-> C-10276 400 mg~C-10276 300 mg -> C-10276 400 mg -> Co-dose Ratio 1 CTP-518 (100 mg) with C-10276 (300 mg)"
3258148|NCT01458769|Active Comparator|Part B Group 1|"Group B1 will evaluate single doses of an ATV isotopolog, C-10297.~C-10297 200 mg"
3258149|NCT01458769|Active Comparator|Part B Group 2|"Group B2 will evaluate single doses of an ATV isotopolog, C-10299.~C-10299 200 mg"
3258150|NCT01458769|Active Comparator|Part B Group 3|"Group B3 will evaluate two single ascending doses of isotopologs C-10297 and 400 mg dose of Reyataz in a 3-way crossover design.~C-10297 400 mg -> Reyataz 400 mg -> C-10297 600 mg"
3258151|NCT01458769|Active Comparator|Part B Group 4|"Group B4 will evaluate two single ascending doses of isotopolog C-10299 and a 400 mg dose of Reyataz in a 3-way crossover design.~C-10299 400 mg -> Reyataz 400 mg -> C-10299 600 mg"
3258152|NCT01458769|Active Comparator|Part B Group 5|"Group B5 will evaluate a single dose of C-10276 and a 400 and 600 mg dose of Reyataz in a 3-way crossover design.~C-10276 600 mg -> Reyataz 400 mg -> Reyataz 600 mg"
3258153|NCT01458782|Active Comparator|ACI-C|Autologous chondrocyte implantation using collagen membrane (ChondroGide) Please see reference 1 and 2 for details regarding ACI. In this study we are using the collagen membrane instead of periosteum- the other details are exactly the same as in our previous RCT.
3258154|NCT01458782|Active Comparator|AMIC|"Autologous matrix induced chondrogenesis. Microfracture of the defect and covering using the collagen membrane (ChondroGide).~Please see reference 3 for details regarding AMIC"
3258155|NCT01458808|Experimental|Group A|Composed by 21 patients treated with reduction of 2 grams of sodium reduction in their habitual diet.
3258156|NCT01458808|Experimental|Group B|Composed by 20 patients treated by reduction of dialysate concentration from 138 to 135 mEq/L
3258157|NCT01458808|No Intervention|Group C|Composed by 18 patients followed without changes in dialysate sodium concentration or diet sodium amount.
3258158|NCT01458821|Experimental|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
3258159|NCT01458821|No Intervention|No treatment|Subject will make no changes in their usual daily routine. No intervention. Will repeat all study procedures at end of 8 weeks.
3258160|NCT01458834|Experimental|Active attention training condition|
3258161|NCT01458834|Placebo Comparator|Control condition|
3258162|NCT01458847|Experimental|Cohort I: 2% cis-UCA solution (50 ml)|
3258163|NCT01458847|Experimental|Cohort II: 4% cis-UCA solution (50 ml)|
3258164|NCT01458847|Experimental|Cohort III: 6% cis-UCA solution (50 ml)|
3258165|NCT01458860||GROUP A|patients had a CT
3258166|NCT01458860||GROUP B|patients with severe carotid artery stenosis
3258167|NCT01458873|Experimental|sodium bicarbonate 4.2%|"sodium bicarbonate 4.2% 50 ml"
3258168|NCT01458873|Experimental|sodium bicarbonate 2.1%|"sodium bicarbonate 2.1% 1 50 ml"
3258169|NCT01458873|Placebo Comparator|normal saline|"50 ml normal saline"
3258170|NCT01458886|Experimental|BI 54903 LD b.i.d.|Patients receive 2 puffs b.i.d. via Respimat inhaler
3258171|NCT01458886|Experimental|BI 54903 MD q.d.|Patients receive 2 puffs q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
3258172|NCT01458886|Placebo Comparator|Placebo|Patients receive 2 puffs b.i.d. via Respimat inhaler
3258173|NCT01458899|Experimental|A - first fed then fasted treatment|TC-5214
3258174|NCT01458899|Experimental|B - first fasted then fed treatment|TC-5214
3258175|NCT01458912|Experimental|BI 54903 HD q.d.|Patients receive 2 puffs BI 54903 HD q.d. via Respimat inhaler (p.m.) combined with 2 puffs placebo (a.m.)
3258176|NCT01458912|Placebo Comparator|Placebo|Patients receive 2 puffs Placebo b.i.d. via Respimat inhaler
3258177|NCT01458912|Experimental|BI 54903 MD b.i.d.|Patients receive 2 puffs BI 54903 MD b.i.d.via Respimat inhaler
3258178|NCT01458925|Other|P1 capsule and screening Cscopy|"Male and female patients older than 40 and younger than 75 years old who volunteer for the experiment and qualify with the inclusion / Exclusion criteria.~The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study"
3258179|NCT01458938||Healthy volunteers|
3258180|NCT01458938||surgery for spinal radiculopathy|
3258181|NCT01458938||surgery for axial spine pain|
3258182|NCT01458938||myelography for spinal pain|
3258183|NCT01458964|Active Comparator|Quetiapine|Quetiapine will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
3258184|NCT01458964|Placebo Comparator|Sugar pill|Sugar pill will be administered orally, QHS at a dosage of 100 mg for 1 week increasing to a target dosage of 200 mg for 11 weeks.
3258185|NCT01458977|Experimental|TDF/FTC (3 months) + Placebo (6 months)|TDF/FTC (3 months) + Placebo (6 months)
3258186|NCT01458977|Placebo Comparator|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)|Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)
3258187|NCT01459003|Experimental|experimental|
3258188|NCT01459003|No Intervention|control|
3258189|NCT01459029|Active Comparator|D-serine|D-serine up to 6000 mg/day subject to tolerability
3258190|NCT01459029|Placebo Comparator|Control|Treatment with inert capsules (placebo)
3258191|NCT01459042||primary aldosteronism|
3258192|NCT01459042||essential hypertension|
3258193|NCT01459081|Experimental|Zanamivir|
3258194|NCT01459081|Placebo Comparator|Placebo|
3258195|NCT01459094|Experimental|Treatment Sequence AB|
3258196|NCT01459094|Experimental|Treatment Sequence BA|
3258197|NCT01459107|Experimental|Treatment (Transplantation)|Hand/arm transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
3258198|NCT01459120|Experimental|Door-to-Door|Health care workers propose the integrated service package including VCT at the peoples' homes.
3258199|NCT01459120|Active Comparator|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (pitso)."
3258200|NCT01459120|No Intervention|control|Within each cluster (catchment area of a health center), five villages are randomly chosen as comparators on cluster level. These villages get no particular intervention (VCT-campaign). However, routine services continue to be provided. These villages serve as a control for the third primary outcome that assesses the overall numbers newly enrolled into chronic HIV/AIDS care at facility-level.
3258201|NCT01459133|Experimental|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
3258202|NCT01459146|Experimental|AL plus ABZ; Arm 1|Artemether-Lumefantrine combination 20mg/120mg 12 hourly for 3 days oral, plus albendazole 400mg stat oral
3258203|NCT01459146|Active Comparator|AL plus PZQ plus ABZ; Arm 2|artemether-lumefantrine combination 120mg/20mg 12 hourly for 3 days; plus praziquantel 40mg/kg stat; plus albendazole 400mg stat oral
3258204|NCT01459146|Active Comparator|ABZ plus PZQ; Arm 3|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
3258205|NCT01459172|Experimental|Limonene intervention|
3258206|NCT01459185|Experimental|S-1|Single arm of the patients who received complete resection of pathological stage IB, II, or IIIA Non-small cell lung cancer
3258207|NCT01459198|Experimental|Adults: Vaccine (Group 1)|Adult participants will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3258208|NCT01459198|Experimental|Seropositive Children: Vaccine (Group 2)|Seropositive children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3258209|NCT01459198|Placebo Comparator|Seropositive Children: Placebo Vaccine (Group 2)|Seropositive children will receive one dose of the placebo vaccine intranasally.
3258210|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 3)|Seronegative infants and children will receive one dose of the 10^5 RSV MEDI ΔM2-2 vaccine intranasally.
3258211|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 3)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
3258212|NCT01459198|Experimental|Seronegative Infants and Children: Vaccine (Group 4)|Seronegative infants and children will receive one dose of the 10^6 RSV MEDI ΔM2-2 vaccine intranasally.
3258213|NCT01459198|Placebo Comparator|Seronegative Infants and Children: Placebo Vaccine (Group 4)|Seronegative infants and children will receive one dose of the placebo vaccine intranasally.
3258214|NCT01459211|Other|Lenalidomide & Dexamethasone|Lenalidomide, 5mg daily, increased to 10mg after 1st cycle. Dexamethasone, 20mg days 1-4 each cycle
3258215|NCT01459250|Experimental|AGO178C|
3258216|NCT01459263||GSV insufficiency|Patients with insufficiency of the greater saphenous vein (GSV) will be included.
3258217|NCT01459276|Experimental|FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
3258218|NCT01459276|Active Comparator|FLUVALAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μg HA of seasonal A/H1N1, A/H3N2 and B influenza antigens
3258219|NCT01459289|Active Comparator|leaflet|
3258220|NCT01459289|Active Comparator|counseling|
3258221|NCT01459302||Familial and Sporadic ALS|Individuals with ALS and families with a history of two or more people in the family who have had ALS or other forms of motor neuron disease.
3258222|NCT01459315|Experimental|GSK1349572|
3258223|NCT01459328|Active Comparator|Arm A: Conventional Long Course Chemo-Radiation|Conventional long course chemo-radiation
3258224|NCT01459328|Experimental|Arm B: Short Course Radiation Followed by Chemotherapy|Experimental short course radiation followed by chemotherapy.
3258225|NCT01459354||post, bimanual laryngoscopy, POGO score|one control, one study group
3258226|NCT01459367|Experimental|TAK-438 10 mg QD|
3258227|NCT01459367|Experimental|TAK-438 20 mg QD|
3258228|NCT01459367|Active Comparator|Lansoprazole 15 mg QD|
3258229|NCT01459380|Experimental|Regimen I (intermittent veliparib)|Patients receive veliparib PO BID on days 1-7, and pegylated liposomal doxorubicin hydrochloride IV over 1 hour and carboplatin IV over 30 minutes on day 1.
3258230|NCT01459380|Experimental|Regimen II (continuous veliparib)|Patients receive veliparib PO BID on days 1-28, and pegylated liposomal doxorubicin hydrochloride and carboplatin as in Regimen I.
3258231|NCT01459393|Experimental|5-ALA Photodynamic Therapy|Topical application of a 2mm of thickness layer of 20% 5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion, over the actinic keratosis lesion and over a 0,5 cm margin around it. After a 4 hours interval under light protection with plastic film and aluminum foil, the light protection and the emulsion is removed. Then the lesion is lightened with a red (630 nm) incoherent LED lamp AKTILITE CL 128 (PhotoCure ASA, Oslo, Norway) with a total light dose of 37J/cm2.After that dressings are done and kept for 24H, and removed at patient home.
3258232|NCT01459393|Active Comparator|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
3258233|NCT01459406|Experimental|Glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g glucose
3258234|NCT01459406|Experimental|Fructose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose
3258235|NCT01459406|Experimental|Fructan drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructan
3258236|NCT01459406|Experimental|Fructose and glucose drink|Serial MRI of the gastrointestinal tract upon 500 ml water drink containing 40g fructose and 40 g glucose
3258237|NCT01459419|Experimental|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up to 9 subjects will be treated at each dosage level
3258238|NCT01459419|Placebo Comparator|Sodium chloride|Up to 9 subjects will receive placebo. Subjects will receive the drug in a similar manner as as the treatment group
3258239|NCT01459432||Follow-on blood sample from previous study|
3258240|NCT01459445|Other|Metformin+Drospirenone / EE 30µg|
3258241|NCT01459458|Experimental|Clinics trained in brief intervention|Female clients ages 16-29 seeking care in 11 reproductive health clinics in Western Pennsylvania where clinic providers are trained to implement the brief partner violence/reproductive coercion intervention.
3258242|NCT01459458|No Intervention|Control sites providing standard of care|Female clients ages 16-29 seeking care in 14 reproductive health clinics in Western Pennsylvania where clinic providers are providing standard domestic violence screening per usual standard of care.
3258243|NCT01459471|Experimental|bleeding, leak, operative time|
3258244|NCT01459484|Experimental|Mifamurtide arm|Chemotherapy for patients who over express ABCB1/P-glycoprotein (methotrexate, cisplatinum, doxorubicine, ifosfamide + mifamurtide)
3258245|NCT01459484|Other|3 drugs arm|High grade osteosarcoma treatment for patients who do not over express ABCB1/P-glycoprotein
3258246|NCT01459497|Active Comparator|Radiation Therapy|Arm A:Image-Guided Radiation Therapy (IGRT), 60 Gy in 15 fractions in 3 weeks
3258247|NCT01459497|Active Comparator|Conventional Radiation|Arm B: Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
3258248|NCT01459510|Experimental|multi media intervention|Play Nicely Program
3258249|NCT01459510|No Intervention|Routine primary care|Routine primary care
3258250|NCT01459523|Active Comparator|Imaging technique|In one substudy, subjects will be randomly assigned to either short axis or long axis target ultrasound imaging for perineural catheter insertion. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
3258251|NCT01459523|Active Comparator|Catheter location|In another substudy, subjects will be randomly assigned to receive their perineural catheters either proximally or distally along the same target nerve or plexus.
3258252|NCT01459536||Rotator Cuff Tear-surgical|
3258253|NCT01459536||Health Older Adult Control|
3258254|NCT01459536||Rotator cuff tear - non surgical|
3258255|NCT01459549|No Intervention|Control Group|Just clear the stone without choledochojejunostomy
3258256|NCT01459549|Experimental|Experimental Group|Clear the stone combined with Roux-en-y choledochojejunostomy
3258257|NCT01459562|Experimental|NI-0501|
3258258|NCT01459562|Placebo Comparator|Placebo|
3258259|NCT01459627|Active Comparator|6 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.
3258260|NCT01459627|Active Comparator|12 months DAPT|Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study
3258261|NCT01459640|Active Comparator|Hyaluronic acid|
3258262|NCT01459640|Experimental|Bone marrow mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells
3258263|NCT01459666|Experimental|Dysport (abobotulinumtoxinA)|Each patient will be able to receive up to 120 units of Dysport/placebo at the initial visit to treat the entire forehead area (the frontalis, procerus, and corrugator muscles) to insure cosmetic symmetry. Injections will be placed a minimum of 1.5cm above the orbital rim at the mid papillary line to minimize the risk of lid ptosis. The actual amount to be injected will be at the discretion of the Mohs surgeon based on his or her opinion of what amount is needed for sufficient wound paralysis and cosmetic symmetry.
3258264|NCT01459666|Placebo Comparator|Placebo|
3258265|NCT01459679|Active Comparator|VibeX Treatment Group A|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 8 minutes
3258266|NCT01459679|Active Comparator|VibeX Treatment Group B|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 4 minutes
3258267|NCT01459679|Active Comparator|VibeX Treatment Group C|Corneal collagen cross-linking using riboflavin ophthalmic solution and ultraviolet-A (UVA) light for 2 minutes and 40 seconds
3258268|NCT01459692|No Intervention|Control group - No Music Exposure|Subjects that were assigned to the control group of the study were not exposed to music.
3258269|NCT01459692|Experimental|Music Exposure|The treatment subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
3258270|NCT01459731||Age 18-29|
3258271|NCT01459731||Age 30-39|
3258272|NCT01459731||Age 40-49|
3258273|NCT01459731||Age 50-59|
3258274|NCT01459731||Age 60-69|
3258275|NCT01459731||Age 70+|
3258276|NCT01459744|Experimental|Communication training for cardiologists|The intervention consists of an educational workshop for heart failure physicians, a reminder system, and a system providing aggregated feedback on their conversations with patients about ICD deactivation.
3258277|NCT01459744|Placebo Comparator|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
3258278|NCT01459757||Data generated from the past sunitinib A6181036 GIST study|
3258279|NCT01459770|Active Comparator|control|"usual care for hospital discharge:~CKD group~ESRD group"
3258280|NCT01459770|Active Comparator|intervention|"pharmacist administered medication information transfer intervention~CKD group~ESRD group"
3258281|NCT01459809|Experimental|ARM 1: glimepiride alone|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if Fasting Plasma Glucose (FPG) at baseline < 180 mg/dL (10 mmol/L) taken once in the morning before breakfast. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg, and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3258282|NCT01459809|Experimental|ARM 2: metformin alone|24-week treatment period: After randomization, starting dose will be of 500 mg of metformin twice a day during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 2000 mg, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3258283|NCT01459809|Experimental|ARM3: Glimepiride/metformin free combination|24-week treatment period: After randomization, starting dose will be of 2 mg /day or 1 mg/day of glimepiride if FPG at baseline < 180 mg/dL (10 mmol/L) taken once in the morning and 500 mg of metformin twice a day taken during or after meals. The treatment's dose will be increased every 2 weeks up to the maximum tolerated dose of 4 mg of glimepiride and 2000 mg of metformin, and adjusted throughout the 24-week treatment period according to fasting SMPG values in the objective to obtain values ≤.
3258284|NCT01459822||Survival Group|
3258285|NCT01459822||Death Group|
3258286|NCT01459835|Experimental|media diet|advice tips and tools to reduce exposure to violent programming
3258287|NCT01459835|Active Comparator|Nutrition intervention|diet advice
3258288|NCT01459848|Active Comparator|block play|30 minutes of block play with parent
3258289|NCT01459848|Experimental|baby dvd|watch baby dvd with parent
3258290|NCT01459861|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
3258291|NCT01459861|Active Comparator|Femoral with Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa.
3258292|NCT01459874||Cardiac Implantable Device recipients|
3258293|NCT01459887|Experimental|combination group|
3258294|NCT01459887|Experimental|sequential group|
3258295|NCT01459900|Active Comparator|Renal artery ablation|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
3258296|NCT01459900|Sham Comparator|Sham|By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
3258297|NCT01459926|Experimental|Dose 1|
3258298|NCT01459926|Experimental|Dose 2|
3258299|NCT01459926|Experimental|Dose 3|
3258300|NCT01459926|Experimental|Placebo|
3258301|NCT01459939|Placebo Comparator|Placebo|Daily treatment with placebo
3258302|NCT01459939|Active Comparator|Rose-hip powder|Daily treatment with Rose-hip powder
3258303|NCT01459952|Experimental|Rose hip Liquid|20 ml Rose hip Liquid BID
3258304|NCT01459952|Placebo Comparator|Placebo|20 ml placebo liquid BID
3258305|NCT01459965|Active Comparator|10 French Stent|10 French biliary plastic stent
3258306|NCT01459965|Active Comparator|11.5 French stent|11.5 French biliary plastic stent
3258307|NCT01459978||Early CUSUM result group|"Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity.~Phase 2: results of the CUmulative SUM (CUSUM) will be provided for a period of 12 months (Early CUSUM result group), Phase 3: maternity will continue to receive the results of the CUmulative SUM (CUSUM) for a period of 12 months,"
3258308|NCT01459978||CUSUM result Delayed group|Phase 1: 3 months testing and observation period. During this phase, rates of each quality indicator selected will be collected to adjust the acceptable and unacceptable rate set by practitioners of each maternity Phase 2: the results of CUmulative SUM (CUSUM) will not be shared. Phase 3: group receive CUmulative SUM (CUSUM) result (CUSUM result Delayed group) during the same period 12 months
3258309|NCT01459991|Experimental|Mediterranean|Participants in this arm will follow a Mediterranean style diet, rich in olive oil and fruits and vegetables, and also consume 1 ounce of walnuts daily.
3258310|NCT01459991|Active Comparator|MyPyramid|
3258311|NCT01460004|No Intervention|patella knee strap|infra patella knee strap- cotton, applied in straight leg
3258312|NCT01460017|Active Comparator|DS arm|Deep sclerectomy surgery will be conduct in this arm
3258313|NCT01460017|Active Comparator|Trab arm|combined Trabeculectomy and Trabeculotomy surgery will be conducted in this arm
3258314|NCT01460030|Experimental|KRN1493|
3258315|NCT01460043|Placebo Comparator|placebo|
3258316|NCT01460043|Experimental|Homeopathy|Individualized symptom based therapy
3258317|NCT01460056||Peritoneal dialysis|
3258318|NCT01460069|Active Comparator|Victoza treatment|
3258319|NCT01460069|Placebo Comparator|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
3258320|NCT01460082||Exacerbation|The study sample will consist of patients admitted to the hospital because of an acute exacerbation of COPD
3258321|NCT01460095|Experimental|HbA1c measurement and education|3-monthly Hba1c determination with immediate feedback and targeted education delivered to all participants
3258322|NCT01460108|Experimental|AeriSeal System Treatment|Candidates for the trial include patients with advanced non-bullous upper lobe predominant emphysema who have a DLco between 20 and 60% predicted and target sites in at least 1 upper lobe. Eligible and consented patients will undergo evaluation with the Chartis System, and only patients found to have significant collateral ventilation will be enrolled.
3258323|NCT01460121|Experimental|SpotOn's corrective elements|
3258324|NCT01460121|Placebo Comparator|Placebo corrective elements|
3258325|NCT01460134|Experimental|Hematologic Malignancies (Dose Escalation)|B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
3258326|NCT01460134|Experimental|Solid tumors (Dose Escalation; COMPLETED)|
3258327|NCT01460134|Experimental|Solid Tumors (Expansion Phase; COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
3258328|NCT01460134|Experimental|Hematologic Malignancies (COMPLETED)|Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
3258329|NCT01460147|Other|DXA scan + MRI|
3258330|NCT01460173|Other|Normal subjects|
3258331|NCT01460173|Other|OSA Patients|
3258332|NCT01460186|Experimental|Blood samples|
3258333|NCT01460199|Placebo Comparator|Placebo|Matching Placebo
3258334|NCT01460199|Experimental|CTP-499|
3258335|NCT01460212|Experimental|Cognitive-Behavior Therapy group|treatment with Cognitive-Behavior Therapy
3258336|NCT01460212|Active Comparator|SSRI antidepressants|treatment by SSRI antidepressant
3258337|NCT01460238||No treatment|No intervention. Each patient will have blood drawn at a standard of care venipuncture.
3258338|NCT01460251|Experimental|Drug:Diapep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
3258339|NCT01460264||exposed|current daily smokers 100 cigarettes or more during lifetime
3258340|NCT01460264||unexposed|current non-smokers
3258341|NCT01460277|Experimental|Hydrokinesiotherapy|A 6-week water-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
3258342|NCT01460277|Active Comparator|Conventional exercise intervention|A 6-week land-based exercise program that focused on balance and weight bearing exercises (3 days a week for 1 hour a session)
3258343|NCT01460316||Conotruncal cardiac defects patients|
3258344|NCT01460316||Mothers of patients|
3258345|NCT01460329||USCOM Cardiac index|
3258346|NCT01460355|Active Comparator|Botulinum toxin plus surgery|Intraoperative injection of 5U (0.1 ml) of Botulinum Toxin will be given to the recessed muscle during surgery
3258347|NCT01460355|Placebo Comparator|Saline solution plus surgery|Saline solution (0,1 ml)will be given to the recessed muscle during surgery procedure
3258348|NCT01460394||Healthy adolescents and young adults|
3258349|NCT01460420|Experimental|Bortezomib + Lenalidomide|After conditioning treatment and graft versus host disease prophylaxis with Bz 1.3 mg/m2 on days +1, +4 and +7 plus sirolimus/rapamycin at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL, a maintenance therapy with Bz 1.3 mg/m2 on days 1, 8 and 15 in cycles of 56 days up to 6 cycles post-transplant and on day +180 Len will be started at a dose of 5 mg and will be maintained until relapse.
3258350|NCT01460459|Experimental|high frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day weekly in group A.
3258351|NCT01460459|Experimental|middle frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) one day per two weeks in group B.
3258352|NCT01460459|Experimental|low frequency of SMBG|Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime) Group C: one day monthly
3258353|NCT01460472|Experimental|Racotumomab plus Best Support Treatment|Patients will receive Racotumomab and Best Support Treatment, which includes any further onco-specific therapy for progressive disease.
3258354|NCT01460472|Active Comparator|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC including onco-specific therapies when disease progresses.
3258355|NCT01460498|Experimental|Dose Escalation Group (AZA)|Azacitidine (AZA) starting dose 50 mg/m2 a day for 3 days subcutaneous or intravenous of 28 day cycle. TKI at dose received during last 6 months.
3258356|NCT01460498|Experimental|Expansion Group (AZA MTD)|Dose Escalation Group plus additional 36 participants for Azacitidine 75 mg/m2 (or Phase I MTD) either subcutaneous or intravenous every day for 3 days of 28 day cycle. TKI at dose received during last 6 months.
3258357|NCT01460511|Placebo Comparator|P - Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
3258358|NCT01460511|Experimental|T - E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
3258359|NCT01460537|Experimental|Treatment A: Gemcitabine-Copanlisib|The treatment consists of repetitive cycles, each over 28 days. Treatment continues until disease progression or dose limiting toxicity. If gemcitabine is discontinued for toxicity, Copanlisib may be continued at the discretion of the Investigator if a clinical benefit (response or stable disease for 3 months) is noted. - Hour 0 to 0.5: Gemcitabine (1000 mg/m2 as 30-minute IV infusion) on Days 1, 8 and 15 every 28 days - Hour 1.5 to 2.5: BAY80-6946 (starting dose = 0.6 mg/kg as 60-minute IV infusion, starting 1 hour post completion of gemcitabine infusion) on Days 1, 8 and 15 every 28 days
3258360|NCT01460537|Experimental|Treatment B: Cisplatin-Gemcitabine-Copanlisib|Treatment consists of repetitive 21 day cycles for a maximum of 8 cycles. Treatment continues until disease progression, DLT or completion of 8 cycles. After 8 cycles, gemcitabine and Copanlisib, without cisplatin, may continue at the discretion of the Investigator until disease progression or DLT if a clinical benefit is noted (response or stable disease for 3 months). Treatment is administered on Days 1 and 8 every 21 days as follows: - Hour 0 to 1: Cisplatin IV infusion over 60 min (One liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 mmol of magnesium sulfate) - Hour 1 to 1.5: IV infusion of 500 ml of 0.9% NaCl over 30 min - Hour 1.5 to 2: Gemcitabine (1000 mg/m2 as 30 min IV infusion) - Hour 3 to 4: Copanlisib IV infusion at the MTD determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one Copanlisib Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
3258361|NCT01460550|Experimental|gastrointestinal reconstruction|
3258362|NCT01460563|Experimental|Mg_orfil|patients preloaded with sodium valproate receives MgSO4 during the craniotomy.
3258363|NCT01460563|Placebo Comparator|control_orfil|patients preloaded with sodium valproate receives 0.9% saline as placebo.
3258364|NCT01460563|Placebo Comparator|control_no orfil|patients not preloaded with sodium valproate receives 0.9% saline as placebo.
3258365|NCT01460589|Experimental|early commencement|Individuals who initiate the adjuvant chemotherapy from 10 to 14 days after surgery
3258366|NCT01460589|Active Comparator|conventional commencement|Individuals who initiate the adjuvant chemotherapy after 14 days after surgery
3258367|NCT01460602|Experimental|Part 1: establish MTD|Part 1 consists of dosing to determine maximum tolerated dose (MTD) and dose limiting toxicity (DLT).
3258368|NCT01460602|Experimental|Part 2: The MTD from Part 1|During the Phase 2 part of the study, approximately 24 additional subjects will be enrolled in order to obtain a total of 30 response-evaluable subjects treated at the maximum tolerated dose.
3258369|NCT01460641||CT perfusion|
3258370|NCT01460654|Placebo Comparator|Testosterone and Placebo Alendronate|
3258371|NCT01460654|Placebo Comparator|Alendronate and Placebo Testosterone|
3258372|NCT01460654|Experimental|Testosterone and Alendronate|
3258373|NCT01460667|Active Comparator|IV acetaminophen|
3258374|NCT01460667|Placebo Comparator|IV 0.9% normal saline|
3258375|NCT01460680||Fibromyalgia patients|Patients diagnosed as suffering from Fibromyalgia according to the ACR 1990 criteria
3258376|NCT01460680||SLE patients|Patients diagnosed as suffering from Systemic Lupus Erythematosus by the ACR criteria
3258377|NCT01460680||Healthy controls|Healthy controls
3258378|NCT01460693|Active Comparator|Arm A - Imatinib|Imatinib 400mg daily
3258379|NCT01460693|Experimental|Arm B - Dasatinib|Dasatinib 100mg daily
3258380|NCT01460706|Experimental|68Ga-DOTATOC|
3258381|NCT01460758|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
3258382|NCT01460758|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
3258383|NCT01460758|Sham Comparator|Placebo Stimulation|Sham Stimulation (Conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz,2000 Stimuli each session, 110% motor threshold
3258384|NCT01460771|Experimental|Treatment|Active Transcranial Direct Current Stimulation (TDCS) at 1mA or highest tolerated current
3258385|NCT01460771|Sham Comparator|sham|inactive Transcranial Direct current stimulation (TDCS) at 0mA
3258386|NCT01460784||N=60|Cross-sectional study of obese young adults who underwent PET/CT after cold exposure to identify active brown fat. No intervention. Enrolled 44 participants.
3258387|NCT01460784||N=600|Cross-sectional study of patients undergoing clinical PET/CT to identify active brown fat. No intervention. Enrolled 405 participants.
3258388|NCT01460784||N=220|Longitudinal observational study of obese adolescents to determine changes in adiposity and adipokines during puberty. No intervention. Enrolled 125 participants.
3258389|NCT01460797|Other|High Glycemic Index|Hypocaloric diet with predominating high glycemic index foods
3258390|NCT01460797|Other|Low Glycemic Index|Hypocaloric diet with predominant low glycemic index foods
3258391|NCT01460797|Other|Low Glycemic Index plus Metformin|Hypocaloric diet with predominant low glycemic index foods plus Metformin (1g/d)
3258392|NCT01460810|Experimental|1000CsK Silicon Oil Tamponade|In 20 patients, a standard three-port vitrectomy will be performed. Following a standard air-fluid exchange, the eye will be filled with Silikon-1000 silicone oil in standard fashion. At a subsequent surgery, a standard two-port pars plana vitrectomy will be performed to remove the silicone oil and replace it with saline. The removed silicone oil will be tested onsite for traces of radiation.
3258393|NCT01460823|Experimental|Use of image guided surgery|
3258394|NCT01460836||Tobramycin Solution|
3258395|NCT01460836||Aztreonam lysine|
3258397|NCT01460888|Experimental|OLA-0 (de-escalation dose)|25mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3258398|NCT01460888|Experimental|OLA-1|50mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3258399|NCT01460888|Experimental|OLA-2|100mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3258400|NCT01460888|Experimental|OLA-3|200mg olaparib twice daily + radiotherapy (50Gy in 25 fractions)
3258401|NCT01460888|Active Comparator|RT alone|
3258402|NCT01460953|Experimental|training intervention|Students participating in didactic training
3258403|NCT01460966|Active Comparator|Filtrap™+ Thrombus aspiration catheter|
3258404|NCT01460966|Active Comparator|Thrombus aspiration catheter|
3258405|NCT01460979|Experimental|Temsirolimus|
3258406|NCT01460992||Pacemaker therapy|Patients with an EVIA/ ENTOVIS pacemaker device. See inclusion and exclusion criteria.
3258407|NCT01461018|Experimental|IgPro20|
3258408|NCT01461070||Breast Cancer Cases|Breast Cancer Cases
3258409|NCT01461070||Controls|Controls
3258410|NCT01461083|Experimental|Assess [18F]MPPF and PET imaging|To assess [18F]MPPF and PET imaging
3258411|NCT01461109|Experimental|Assess [18F] CFPyPB and PET imaging|To assess [18F]CFPyPB and PET imaging
3258412|NCT01461148|Experimental|FSP peptides|Vaccination with three FSP peptides
3258413|NCT01461161|Experimental|20 mg bardoxolone methyl|
3258414|NCT01461161|Experimental|60 mg bardoxolone methyl|
3258415|NCT01461161|Experimental|80 mg bardoxolone methyl|
3258416|NCT01461174|Experimental|Modafinil|200 mg tablet, single dose
3258417|NCT01461174|Experimental|Donepezil|5 mg tablet one per day, 15 days
3258418|NCT01461174|Experimental|Memantine|10 mg tablet one per day, 15 days
3258419|NCT01461187|Experimental|exercise in pregnancy|37 pregnant women who performed supervised aerobic physical exercises twice a week
3258420|NCT01461187|No Intervention|Control group|29 pregnant women who had not performed any kind of physical activity during pregnancy
3258421|NCT01461200||Non allergics|
3258422|NCT01461200||allergics|
3258423|NCT01461213|Experimental|Dose 1|Dose 1 = single subretinal injection of vector suspension containing approximately 10e10 rAAV2.REP1 genome particles. Six patients have now received Dose 1.
3258424|NCT01461213|Experimental|Dose 2|Dose 2 = single subretinal injection of vector suspension containing approximately 10e11 rAAV2.REP1 genome particles. Three patients thus far have received Dose 2.
3258425|NCT01461226|Experimental|Exercise training|
3258426|NCT01461226|Other|Usual Care|
3258427|NCT01461239|Active Comparator|cast post and core|
3258428|NCT01461239|Experimental|fiber post - self-adhesive cement|
3258429|NCT01461239|Experimental|fiber post - conventional cement|
3258430|NCT01461252|Other|Cryoablation combined with radiation|All subjects will have cryoablation combined with radiation on one or two painful metastatic bone tumors.
3258431|NCT01461265|Other|Cryoablation|All subjects will have cryoablation on one or two painful metastatic bone tumors.
3258432|NCT01461278|Experimental|Cataract surgery plus iStent supra|
3258433|NCT01461278|Active Comparator|Cataract surgery|
3258434|NCT01461291|Experimental|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
3258435|NCT01461291|Active Comparator|Cataract surgery|Cataract surgery alone
3258436|NCT01461317|Experimental|Etrolizumab|Etrolizumab 100 milligrams (mg) subcutaneous (SC) administration every 4 weeks during the treatment period of up to 240 weeks.
3258437|NCT01461330|Experimental|DASH diet|DASH DIET + EXERCISE
3258438|NCT01461330|Active Comparator|ADA DIET|DIET ACCORDING AMERICAN DIABETES ASSOCIATION DIETARY RECOMMENDATIONS FOR DIABETES
3258439|NCT01461343|Experimental|pulmonary hypertension|Patients with Group I pulmonary arterial hypertension and exercise-induced pulmonary hypertension to undergo CT imaging, functional PET imaging
3258440|NCT01461343|Active Comparator|healthy controls|healthy adults to serve as controls and to undergo the same study procedures: CT imaging, functional PET imaging
3258441|NCT01461356|Experimental|Minimally Invasive Surgical approach|Minimally invasive surgical approach for total knee replacement.
3258442|NCT01461356|Active Comparator|Medial Parapatellar surgical approach|Standard medial parapateller surgical approach for total knee replacement.
3258443|NCT01461382|Experimental|Phase I|Entered Study May 2008.
3258444|NCT01461382|Experimental|Phase II|Phase II entered 6 months after Phase I. Phase II was a no intervention control for 6 months, then followed an identical intervention protocol to Phase I.
3258445|NCT01461408|Experimental|Beauty Salon #1b|Females ages 18-26
3258446|NCT01461408|Experimental|Beauty Salon #1a|Mothers of 9-18 year old females
3258447|NCT01461408|Experimental|Beauty Salon #2b|Females ages 18-26
3258448|NCT01461408|Experimental|Beauty Salon #3a|Mothers of 9-18 year old females
3258449|NCT01461408|Experimental|Beauty Salon #3b|Females ages 18-26
3258450|NCT01461408|Experimental|Beauty Salon #4a|Mothers of 9-18 year old females
3258451|NCT01461408|Experimental|Beauty Salon #4b|Females ages 18-26
3258452|NCT01461408|Experimental|Beauty Salon #2a|Mothers of 9-18 year old females
3258453|NCT01461408|Experimental|Beauty Salon #5a|Mothers of 9-18 year old females
3258454|NCT01461408|Experimental|Beauty Salon #5b|Females ages 9-26
3258455|NCT01461408|Experimental|Beauty Salon #6a|Mothers of 9-18 year old females
3258456|NCT01461408|Experimental|Beauty Salon #6b|Females ages 18-26
3258457|NCT01461408|Experimental|Beauty Salon #7a|Mothers of 9-18 year old females
3258458|NCT01461408|Experimental|Beauty Salon #7b|Females ages 18-26
3258459|NCT01461408|Experimental|Beauty Salon #8a|Mothers of 9-18 year old females
3258460|NCT01461408|Experimental|Beauty Salon #8b|Females ages 9-18
3258461|NCT01461421|Active Comparator|Standard Behavioral Treatment|Nutrition education, behavioral weight loss techniques, and standard cognitive strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
3258462|NCT01461421|Experimental|Acceptance Based Behavioral Intervention|Nutrition education, behavioral weight loss techniques, and acceptance based strategies for dealing with stress and emotions. Six months weekly, 3 months bi-weekly, 3 months monthly.
3258463|NCT01461434|Experimental|loop recorder|patients will be implanted with a subcutaneous loop recorder and have regular follow-ups
3258464|NCT01461434|No Intervention|regular follow-up|patients will receive regular follow-ups with standard ECG
3258465|NCT01461447|Experimental|MVA|Volunteers who were primed with 3 HIVIS DNA and further boosted with 2 MVA vaccine will receive a third MVA there shall not be an comparator for this study.
3258466|NCT01461460|Active Comparator|Moxifloxacin 400 mg|
3258467|NCT01461460|Experimental|TR-701 FA 1200 mg|
3258468|NCT01461460|Experimental|TR-701 FA 200 mg plus Placebo|
3258469|NCT01461460|Placebo Comparator|Placebo|
3258470|NCT01461486|Active Comparator|Continuous Positive Airway Pressure|Intervention group
3258471|NCT01461486|Active Comparator|Oral Appliance (BRD)|Intervention group
3258472|NCT01461486|No Intervention|Hygiene sleep care|Control group
3258473|NCT01461512|Placebo Comparator|Placebo|
3258474|NCT01461512|Experimental|Heme arginate treatment|
3258475|NCT01461525|Experimental|Sphincter preservation surgery|Temporary ileostomy with anal sphincter preservation
3258476|NCT01461525|Experimental|Abdominoperineal Resection|Permanent colostomy with total anal sphincter sacrifice
3258477|NCT01461564|Experimental|Carbon dioxide|Patients insufflated with carbon dioxide during screening colonoscopy
3258478|NCT01461564|Active Comparator|Air|Patients insufflated with air during screening colonoscopy
3258479|NCT01461577|Experimental|insulin glargine|Insulin glargine will be administered once a day, in the morning, at initial dose of 4 units/day. Titration of insulin dose will be performed referred with the median fasting plasma glucose value for the last 3 consecutive days according to the titration algorithm
3258480|NCT01461590|Active Comparator|20ml/kg of whole blood transfusion|Standard care recommended by WHO
3258481|NCT01461590|Experimental|30ml/kg of whole blood|Higher volume than currently recommended
3258482|NCT01461603|Active Comparator|Amino acids|Amino acids compared to saline
3258483|NCT01461603|Active Comparator|3hydroxybutyrat (3OHB)|Ketone body, 3OHB compared to saline
3258484|NCT01461616|Experimental|NPH insulin injection|NPH insulin will be injected in random order in one of three seperated visit days.
3258485|NCT01461616|Experimental|detemir insulin injection|insulin detemir will be injected in random order in one of three seperated visit days.
3258486|NCT01461616|Experimental|glargine insulin injection|insulin glargine will be injected in random order in one of three seperated visit days.
3258487|NCT01461629||heart failure|left systolic heart failure (EF </= 40%)
3258488|NCT01461642|Experimental|Asthma - ICT support.|
3258489|NCT01461642|No Intervention|Asthma, comparator - no ICT support|
3258490|NCT01461681|Experimental|Symptom Management Service for heart failure|Subjects randomized to the SMS-HF group will receive a comprehensive PC consultation by the interdisciplinary PC team at each site consisting of a nurse practitioner, physician, social worker and chaplain with 6 months of follow up. All members of the PC team are experienced PC clinicians. The SMS-HF intervention is based on National Quality Forum preferred practices and the National Consensus Project guidelines for quality PC. The SMS-HF will include assessment and management of symptoms, particularly focused on depression, pain and dyspnea, and a discussion of goals of care.
3258491|NCT01461681|No Intervention|Usual cardiology care|The usual cardiology care group will receive usual care provided by the HF clinic. We will assess symptoms and QoL at enrollment and symptoms, QoL, satisfaction, advance care planning documentation, and resource utilization at follow up 6 months later.
3258492|NCT01461694|Active Comparator|IPL|Half face treated with IPL
3258493|NCT01461694|Active Comparator|Alexandrite Laser|Half face treated with Alexandrite Laser
3258494|NCT01461720|Other|Standard medical care|This is the control arm, which is given the best evidence-based standard treatment for the management of acute stroke
3258495|NCT01461720|Experimental|BM-MSCs|Autologous bone marrow-derived mesenchymal stem cells(BM-MSCs)
3258496|NCT01461746|Experimental|Chemotherpay and radiation therapy|Docetaxel plus cisplatin followed by radiation therapy
3258497|NCT01461759|Experimental|Chemotherapy|Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
3258498|NCT01461772|Experimental|CCRT weekly carboplatin|Concurrent chemoradiation therapy with weekly carboplatin
3258499|NCT01461772|Active Comparator|CCRT weekly cisplatin|Concurrent chemoradiation therapy with weekly cisplatin
3258500|NCT01461785|Experimental|GROUP A: PRP +|Group A (16 subjects) will receive lipofilling enriched with 3 ml of autologous PRP ( Platelet rich plasma) with lipofilling
3258501|NCT01461785|Placebo Comparator|GROUP B: PRP -|Group B ( 16 subjects) will receive lipofilling without addition PRP. 27 ml blood will be drawn from the patient, but will be discarded, and not turned into PRP.
3258502|NCT01461798|Experimental|Benecol|In 2009, the dairy Cooperative Colanta Launches Benecol ® yogurt, a product with optimal daily dose of plant stanol, each portion of 100 g containing 3.4 g of Benecol ®, corresponding to 2 g of plant stanol esters . Skim yogurt with Benecol ® is a product made from pasteurized skim milk, sweetened with sucralose homogenized and fermented by the action of specific lactic culture to obtain the optimal characteristics of texture and acidity. With the addition of fruit pulp and supplemented with plant stanol esters (Benecol ®) to help reduce the risk of cardiovascular disease (31). According to Weiss et al, drinkable yogurt with Benecol ® reduces total cholesterol by 5.8% and 9.8% in LDL cholesterol (32).
3258503|NCT01461798|Placebo Comparator|yogurt|Yogurt without plant stanols
3258504|NCT01461837|Experimental|Haplo Stem Cell Transplantation|CD34 selected T-cell depleted allogeneic SCT
3258505|NCT01461850|Active Comparator|Primary debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted to an attempt of primary debulking surgery in order to obtain RT < 1 cm, followed by adjuvant chemotherapy.
3258506|NCT01461850|Experimental|Interval debulking surgery|All patients with suspicion of advanced ovarian carcinoma (FIGO stage IIIC) will undergo to a diagnostic laparoscopy in order to obtain a laparoscopic score (PIV) based on seven parameters: omental cake, peritoneal and diaphragmatic extensive carcinosis, mesenteric retraction, bowel and stomach infiltration, spleen and/or liver superficial metastasis, as previously published (Fagotti et al, American Journal of Obstetrics and Gynecology, 2008) Patients with PIV ≥ 8 and ≤ 12 randomized in this group will be submitted only to diagnostic laparoscopy followed by neoadjuvant chemotherapy and subsequent Interval Debulking Surgery, followed by further cycles of chemotherapy.
3258507|NCT01461876||HIV-infected cohort|
3258508|NCT01461876||HIV-uninfected control group|
3258509|NCT01461889|Experimental|High INR|Transfuse plasma to High INR target. Plasma will be transfused to reach a target INR=2.5 for 48 hours while patient is actively bleeding.
3258510|NCT01461889|Active Comparator|Low INR|Transfuse plasma to Low INR target. Plasma will be transfused to reach a target INR=1.8 for 48 hours while patient is actively bleeding.
3258511|NCT01461902||Pediatric Traumatic Brain Injury|Children from 5 days to 15 years of age who have been admitted to the hospital with a traumatic brain injury.
3258512|NCT01461915|Experimental|Run-in|10 Subjects to be enrolled in the study to receive : gemcitabine + nab-paclitaxel + ODSH
3258513|NCT01461915|Experimental|Arm A|25 patients to be enrolled to receive gemcitabine + nab-paclitaxel + ODSH
3258514|NCT01461915|Active Comparator|Arm B|25 patients will be enrolled in the study to receive gemcitabine + nab-paclitaxel
3258515|NCT01461941|Experimental|Drug: 0.2% E6005 ointment|
3258516|NCT01461941|Placebo Comparator|Drug: 0.0% E6005 ointment (vehicle)|
3258517|NCT01461954|Experimental|FST-100|
3258518|NCT01461954|Placebo Comparator|FST-100 Vehicle|
3258519|NCT01461967|Experimental|Part 1a|
3258520|NCT01461967|Placebo Comparator|Part 1b|
3258521|NCT01461967|Experimental|Part 2|
3258522|NCT01462006|Experimental|Sirolimus|
3258523|NCT01462006|Placebo Comparator|Placebo|
3258524|NCT01462019|No Intervention|Control|
3258525|NCT01462019|Experimental|Photobiomodulation|
3258526|NCT01462032|Experimental|Cognitive enhancing games|Children will be introduced to specific games believed to enhance cognitive functioning. Parent will be encouraged to play these games with their children.
3258527|NCT01462032|Active Comparator|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
3258528|NCT01462058|Active Comparator|Vitamin D3|one tablet of vitamin D3 (70µg) per day for 12 weeks.
3258529|NCT01462058|Placebo Comparator|placebo|one tablet of sugar pill per day for 12 weeks.
3258530|NCT01462071||Chronic kidney disease|
3258531|NCT01462097|Experimental|Aerobic exercise|12 months of treadmill walking and strength training exercise. Exercise is gradually progressed in walking speed and time on the treadmill based on the individual's tolerance, abilities, and safety. For months 1-6 exercise will take place 3 times per week at the research center. For months 6-12 exercise will take place 2 times per week at the center and 1 time per week at home.
3258532|NCT01462097|Active Comparator|Health Education|12 months of Health education sessions which will cover topics important to older adults (safe travel, age-appropriate preventative screenings, resources for reliable health information, and topics relevant to chronic kidney disease). For months 1-6 classes will take place 1 time per week. For months 6-12 classes will take place 1 time per month.
3258533|NCT01462123||small polyps patients|Patients with one small polyps at colonoscopy
3258534|NCT01462136|Experimental|ACHN-490 Injection|
3258535|NCT01462149|Experimental|Chemotherapy|Neoadjuvant chemotherapy with docetaxel plus carboplatin
3258536|NCT01462175|Experimental|Schedule A: RO5503781 QW|Participants will receive multiple ascending doses of RO5503781 orally once weekly (QW) x 3 followed by 13 days of rest in a 28 days cycle.
3258537|NCT01462175|Experimental|Schedule B: RO5503781 QD|Participants will receive multiple ascending doses of RO5503781 orally QD x 5 followed by 13 days of rest in a 28 days cycle.
3258538|NCT01462188|Active Comparator|Immediate stenting|Patients being randomized to the immediate stenting arm will be managed according to the guidelines. Irrespective of TIMI flow at presentation, investigators will be requested to thrombus aspirate immediately after successful wiring of the culprit vessel followed by direct stenting. In cases where insertion of thrombus removal catheter and/or direct stenting is not successful, balloon angioplasty will be allowed.
3260200|NCT01477255||Control|For each pediatric patient enrolled, a child without a history of a serious medical illness will be recruited from the larger community who is matched on variables of age, race/ethnicity, gender, and socioeconomic status. They will use an iPad as a diary to track their daily experiences. They will use an iPad as a diary to track their daily experiences.
3258539|NCT01462188|Experimental|Delayed stenting|"Patients being randomized to the delayed/staged stenting arm will be managed with the aim to obtain stable TIMI 3 flow with no considerations given at the percentage of residual stenosis at the culprit lesion.~In patients presenting with TIMI 3 flow, investigators will be left free to wire the vessel and proceed to thrombus aspiration to decrease thrombus burden in the culprit lesion or to leave the vessel untreated at the time of index PCI. Patients presenting with suboptimal TIMI flow (i.e. less than 3), investigators are required to wire the vessel and thrombus aspirate. If stable (persisting for at least 5 minutes) TIMI 3 flow is obtained, investigators are requested to stop the procedure. The goal is to achieve s table TIMI 3 flow with no considerations given to the percentage of residual stenosis. Stenting in this arm will be allowed only on a bail-out strategy."
3258540|NCT01462201|Experimental|Group 1 - Non Invasive Ultrasound|Group 1 3 visits - Measurement of abdominal circumferences 3 visits - Treatment with Ultrashape Contour I VER 3.1 4 visits - Follow up visits The intervention is non invasive ultrasound.
3258541|NCT01462201|Experimental|Group 2 - Non Invasive Ultrasound|Group 2 3 visits - Treatment with Contour I VER 3.1 system 3 visits - Measurements of abdominal circumference 4 visits - Follow Up visits The intervention is non invasive ultrasound.
3258542|NCT01462240||1 - LPS Flex Pororus Femoral Components|Patients suffering from severe knee pain and disability.
3258543|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-1|A group of 20 subjects (10 male and 10 females) will take IMO dose-1 (12g/dose) powder; three times a day dissolved in a glass of water
3258544|NCT01462331|Other|VitaSugar/VitaFiber-IMO dose-2|A group of 20 subjects (10 male and 10 females) will take IMO dose-2 (18g/dose) powder; three times a day dissolved in a glass of water
3258545|NCT01462331|Placebo Comparator|Placebo|A group of 20 subjects (10 male and 10 females) will take Placebo (12g/dose) powder; three times a day dissolved in a glass of water
3258546|NCT01462396|Experimental|Single Arm|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
3258547|NCT01462409|Experimental|heated humidification|
3258548|NCT01462409|Experimental|No Humidification|
3258549|NCT01462409|Experimental|Controlled heated Humidification with heated tube|
3258550|NCT01462422|Other|Primary prevention|
3258551|NCT01462422|Other|Secondary Prevention|
3258552|NCT01462448||Phantom Limb Pain|Subjects will have lower or upper extremity amputation(s) that have resulted in the presence of phantom limb pain.
3258553|NCT01462448||No Phantom Limb Pain|Subjects in the group will have a lower or upper extremity amputation(s) without the presence of phantom limb sensation.
3258554|NCT01462474|Experimental|Drug: Famitinib|
3258555|NCT01462487||Pregnancy outcomes analysis group|Pregnant women evaluated for the following pregnancy outcomes: elective termination, spontaneous abortion (defined as spontaneous fetal loss at < 20 weeks' gestation), fetal death (defined as death of a fetus at > 20 weeks' gestation), premature birth (defined as a birth occurring at < 37 weeks' gestation), and live birth at term
3258556|NCT01462487||Congenital anomalies analysis group|Infants evaluated for congenital anomalies
3258557|NCT01462487||Treatment-emergent diagnoses analysis group|Pregnant women evaluated for treatment-emergent diagnoses
3258558|NCT01462500|Experimental|Miltefosine|Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days
3258559|NCT01462513|Experimental|L-BLP25|L-BLP25 treatment
3258560|NCT01462513|Placebo Comparator|Placebo|Placebo
3258561|NCT01462526||Control|Participants who do not have glaucoma in either eye
3258562|NCT01462526||Glaucoma|Participants who have glaucoma in one or both eyes
3258563|NCT01462539||OSAS group|
3258564|NCT01462539||Non-OSAS group|
3258565|NCT01462552||Metastatic breast cancer pre-label group|Patients with metastatic breast cancer who initiated lapatanib between January 1, 2007 and December 31, 2007. Follow-up time for this group will continue until June 30, 2008 to allow these patients to have at least six months of follow-up time prior to the label change.
3258566|NCT01462552||Metastatic breast cancer post-label group|Patients with metastatic breast cancer who initiated lapatanib between July 9, 2008 and December 31, 2009. Follow-up time for this group will continue until June 30, 2010 to allow these patients to have at least six month of follow-up.
3258567|NCT01462591|Experimental|L-citrulline|L-citrulline (100mg/kg of body weight per day for 2 weeks)
3258568|NCT01462591|Placebo Comparator|Maltodextrin|6g/day of placebo (maltodextrin)
3258569|NCT01462604||HER2 overexpressing metastatic or advanced breast cancer pts|
3258570|NCT01462617|Experimental|Pi3K|Experimental
3258571|NCT01462617|Placebo Comparator|Placebo|Placebo Comparator
3258572|NCT01462630|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive pazopanib hydrochloride PO QD. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3258573|NCT01462643|Experimental|variant1|topical ointment, once daily application
3258574|NCT01462643|Experimental|variant 2|topical ointment, once daily application
3258575|NCT01462643|Experimental|variant 3|topical ointment, once daily application
3258576|NCT01462643|Experimental|variant4|topical ointment, once daily application
3258577|NCT01462643|Experimental|variant 5|topical ointment, once daily application
3258578|NCT01462643|Placebo Comparator|variant 6|topical ointment, once daily application
3258579|NCT01462643|Active Comparator|control positive|topical ointment,once daily application
3258580|NCT01462656||Patients with urinary retention|Patients with urinary retention
3258581|NCT01462669|Other|Treatment Period 1|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3258582|NCT01462669|Other|Treatment Period 2|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3258583|NCT01462669|Other|Treatment Period 3|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3258584|NCT01462669|Other|Treatment Period 4|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
3258585|NCT01462708|Experimental|Assess [18F]MK-9470 and PET imaging|To Assess [18F]MK-9470 and PET imaging
3258586|NCT01462721|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery (Cx) or the Right Coronary Artery (RCA) will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3258587|NCT01462734||human vitreous, human blood serum, PCR|Vitreous and bloodserum samples from macula hole patients without previous ocular or systemic disease
3258588|NCT01462747|Experimental|KULIST|Medical Device, Activated carbon
3258589|NCT01462760|Other|First assessment: inclinometer|First assessment: inclinometer Second assessment: actigraph and inclinometer
3258590|NCT01462760|Other|first: Inclinometer and actigraph|first: Inclinometer and actigraph second: inclinometer
3258591|NCT01462786|Experimental|ATX-101 in abdomen area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
3258592|NCT01462786|Experimental|ATX-101 in submental area|Crossover study in which subjects will receive 2 mg/cm2 ATX-101 in one dosing session in either the submental area or the abdomen crossing over to the alternate area for the second dosing session
3258593|NCT01462799|Experimental|PBL- patient education|Patients will be randomised to PBL in patient education (experiment group)
3258594|NCT01462799|Experimental|Mailed patient information|Patients will be randomised to controlgroup receiving mailed patient information during the year
3258595|NCT01462825|Experimental|tomato ketchup meal|
3258596|NCT01462825|Placebo Comparator|Placebo meal|
3258597|NCT01462838|Experimental|Immunization|P16_37-63 peptide plus Montanide ISA-51 VG
3258598|NCT01462851|Experimental|Dose Escalation|Ascending doses in healthy volunteers
3258599|NCT01462851|Experimental|Part 2: CSF PKPD|Pharmacokinetic and pharmacodynamic cerebrospinal fluid assessment
3258600|NCT01462864|Active Comparator|Intervention|Lifestyle education intervention
3258601|NCT01462864|No Intervention|Control|The control group will receive an information leaflet which is generally distributed in our speciality clinic to patients with diagnosis of PCOS. The leaflet includes general information on PCOS, treatment options and advice on increasing physical activity.
3258602|NCT01462890|Other|Control Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 16 cycles.
3258603|NCT01462890|Experimental|Research Arm|Patients receive bevacizumab iv followed by paclitaxel iv and carboplatin iv on day 1. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then continue to receive bevacizumab iv alone every 3 weeks for 38 cycles.
3258604|NCT01462903|Experimental|Drug, T cell immunoterhapy|
3258605|NCT01462916||honey, no honey|
3258606|NCT01462968|Active Comparator|Activated clotting time (ACT) group|heparinization measured as activated clotting time during surgery
3258607|NCT01462968|Experimental|Hepcon group|heparinization measured as heparin concentration in the blood during surgery
3258608|NCT01462994|No Intervention|Single arm|
3258609|NCT01463020|Experimental|Smartphone delivered BA|
3258610|NCT01463020|Active Comparator|Smartphone delivered mindfulness|
3258611|NCT01463046|Experimental|Panobinostat|
3258612|NCT01463059|Placebo Comparator|Placebo every 2 weeks|Injections administered at week 0, 2, 4, 6, 8 and 10
3258613|NCT01463059|Experimental|Olokizumab 60 mg every 2 weeks|Olokizumab 60 mg injections administered at week 0, 2, 4, 6, 8 and 10
3258614|NCT01463059|Experimental|Olokizumab 60 mg every 4 weeks|Olokizumab 60 mg injection administered at week 0, 4, and 8 and Placebo injection administered at week 2, 6, and 10
3258615|NCT01463059|Experimental|Olokizumab 120 mg every 2 weeks|Olokizumab 120 mg injections administered at week 0, 2, 4, 6, 8 and 10
3258616|NCT01463059|Experimental|Olokizumab 120 mg every 4 weeks|Olokizumab 120 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
3258617|NCT01463059|Experimental|Olokizumab 240 mg very 4 weeks|Olokizumab 240 mg injections administered at week 0, 4 and 8 and Placebo injections at week 2, 6 and 10
3258618|NCT01463072|Experimental|Treatment (nab-paclitaxel)|Patients receive nab-paclitaxel IV over 30 minutes on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3258619|NCT01463085|Placebo Comparator|Control foods|3 servings per day of control foods
3258620|NCT01463085|Experimental|Low-fat dairy|3 servings per day of low-fat dairy products
3258621|NCT01463124|Experimental|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
3258622|NCT01463124|Active Comparator|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
3258623|NCT01463137|Sham Comparator|Control training with words|Computerized, internet-based control training program. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency.
3258624|NCT01463137|Sham Comparator|Control training with words + pictures|Computerized, internet-based control training program. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
3258625|NCT01463137|Active Comparator|Positive bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
3258626|NCT01463137|Active Comparator|Positive bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
3258627|NCT01463137|Active Comparator|Negative bias training with words|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
3258628|NCT01463137|Active Comparator|Negative bias training with words + pictures|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
3258629|NCT01463150|Active Comparator|Clopidogrel|Clopidogrel 150mg per day for 15 days
3258630|NCT01463150|Experimental|Prasugrel|Prasugrel 5mg for 15 days
3258631|NCT01463163|Active Comparator|Prasugrel|Prasugrel 60mg LD followed by 10mg MD starting post 24 hours
3258632|NCT01463163|Experimental|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting post 12±6 hours
3258633|NCT01463176|No Intervention|Standard Care|Children in the Standard Care Control group will receive standard care and will be videotaped by the music therapist but will not receive music therapy during their immunization
3258634|NCT01463176|Experimental|Music Therapy|Children in this group will receive live music therapy during their immunization.
3258635|NCT01463189|Experimental|painACTION: Arthritis|
3258636|NCT01463189|No Intervention|treatment as usual|
3258637|NCT01463215|Experimental|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
3258638|NCT01463228|Experimental|Treatment Sequence AB|
3258639|NCT01463228|Experimental|Treatment Sequence BA|
3258640|NCT01463241|Other|BASIC treatment|As an open trial, all participants in this study will receive the BASIC treatment.
3258641|NCT01463254||Surveillance|- a surveillance cohort of 300 women who will report back to the clinic during 12 months after enrolment only if they have complications, medical problems, pregnancy, or want to remove the implant
3258642|NCT01463254||Prospective|a prospective cohort consisting of 300 women who will be followed-up 3 and 12 months after enrollment
3258643|NCT01463280|Experimental|tumescent lidocaine infiltration|Assess Platelet function with respect to dosage of tumescent lidocaine There is only one arm.
3258644|NCT01463319|Experimental|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
3258645|NCT01463319|Experimental|air insufflation|air insufflation during insertion phase of colonoscopy
3258646|NCT01463332|Placebo Comparator|Group NS|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
3258647|NCT01463332|Active Comparator|Group D25|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
3258648|NCT01463332|Active Comparator|Group D50|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
3258649|NCT01463345|Experimental|Conservative Transfusion Arm|Subjects in the conservative transfusion arm will receive transfusion only when their hemoglobin levels reach 7.5 g/dl.
3258650|NCT01463345|Active Comparator|Liberal Transfusion Arm|Subjects in the liberal transfusion arm will receive transfusion only when their hemoglobin levels reach 9.0 g/dl.
3258651|NCT01463371|No Intervention|Control|without azithromycin
3258652|NCT01463371|Active Comparator|azithromycin|treatment with azithromycin during three months
3258653|NCT01463397|Experimental|SAR292833 dose level 1|Dose level 1 twice daily immediately after breakfast/dinner
3258654|NCT01463397|Experimental|SAR292833 dose level 2|Dose level 2 twice daily immediately after breakfast/dinner
3258655|NCT01463397|Placebo Comparator|Placebo|Placebo (for SAR292833) twice daily immediately after breakfast/dinner
3258656|NCT01463423|Experimental|Limited primary NSCLCs|Participants with limited primary NSCLCs (T1aN0M0, T1bN0M0, T2aN0M0, T2bN0M0, or T3N0M0) non-small cell lung cancer;
3258657|NCT01463423|Experimental|History of NSCLC|Participants with a history of NSCLC who have new limited primary NSCLC lesion(s)
3258658|NCT01463423|Experimental|Advanced lung cancer|Participants with more advanced lung cancer or lung metastases from a variety of different cancers.
3258659|NCT01463436|Experimental|soy isoflavone 100 mg|the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
3258660|NCT01463436|Placebo Comparator|calcium carbonate 500 mg|The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
3258661|NCT01463449||Obese|Obese subjects half with type 2-diabetes. Before and after gastric bypass. Expected reduction in weight 25 %. We expect a reduction in low grade inflammation in adipose tissue after weight loss.
3258662|NCT01463462||Electronic Catheter Stethoscope|
3258663|NCT01463475|Other|Bone Marrow Aspirate|A qualified enrolled donor will have an aspirate bone marrow draw.
3258664|NCT01463488|Experimental|SAR113945 - Dose 1|
3258665|NCT01463488|Experimental|SAR113945 - Dose 2|
3258666|NCT01463488|Experimental|SAR113945 - Dose 3|
3258667|NCT01463488|Placebo Comparator|Placebo|
3258668|NCT01463501|Experimental|Neoadjuvant Treatment|Preoperative chemotherapy/radiotherapy
3258669|NCT01463501|Experimental|Adjuvant Treatment|Postoperative chemotherapy/radiotherapy
3258670|NCT01463514|Experimental|AIR|"Randomization sequences according to modified catheter protocol.~1. AIR 2. Target Oxygen(88-90%) 3. 100% Oxygen 4. Nitric Oxygen"
3258671|NCT01463514|Experimental|NO|"Randomization sequences according to modified catheter protocol.~1.Nitric Oxygen 2. AIR 3. Target Oxygen(88-90%) 4. 100% Oxygen"
3258672|NCT01463514|Experimental|Oxygen|"Randomization sequences according to modified catheter protocol.~1. 100% Oxygen 2. NO 3. AIR 4. Target Oxygen (88-90%)"
3258673|NCT01463514|Experimental|Target Oxygen|"Randomization sequences according to modified catheter protocol.~1. Target Oxygen (88-90%) 2. 100% Oxygen 3. NO 4. AIR"
3258674|NCT01463540|Active Comparator|Push/pull endoscopic gastrostomy|
3258675|NCT01463540|Experimental|Gastrostomy after gastropexy|
3258676|NCT01463553|No Intervention|wedge resection|
3258677|NCT01463553|Experimental|Wedge resection and pleurodosis|
3258678|NCT01463566||1 - Gender Natural Knee|Patients suffering from severe knee pain and disability.
3258679|NCT01463579|Experimental|Exercise programme|
3258680|NCT01463579|Other|Standard Care|
3258681|NCT01463592|Experimental|Group II a|TRIPPLE THERAPY
3258682|NCT01463592|Active Comparator|Group II b|DUAL THERAPY
3258683|NCT01463592|Experimental|Group I|ORAL RENESSANS
3258684|NCT01463605|Other|radiotherapy|It is just a single group assignment
3258685|NCT01463644|Active Comparator|mepolizumab|
3258686|NCT01463644|Placebo Comparator|placebo|
3258687|NCT01463657|Experimental|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
3258688|NCT01463657|Active Comparator|Juvéderm® Ultra Plus|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
3258689|NCT01463670|Experimental|lenalidomide|The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.
3258690|NCT01463709|Experimental|nanopulse|Administer nano pulse to lesion for varying time intervals.
3258691|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|
3258692|NCT01463748|Experimental|Placebo|starch
3258693|NCT01463748|Experimental|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
3258694|NCT01463761||high-level athletes|High-level athlete, enrolled in a Ministry-recognized Pôle
3258695|NCT01463774|Experimental|Treatment Sequence AB|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
3258696|NCT01463774|Experimental|Treatment Sequence BA|The study consists of 2 treatment periods (A and B). Each treatment period wiill be separated by a washout period of 10-15 days.
3258697|NCT01463787|Experimental|inguinal group|
3258698|NCT01463787|Active Comparator|sub-inguinal group|
3258699|NCT01463800|Active Comparator|Structured Exercise training|12 weeks ambulatory low level exercise training
3258700|NCT01463800|No Intervention|Control group|No structured exercise training
3258701|NCT01463813|Placebo Comparator|Placebo|Placebo, no Vitamin D3
3258702|NCT01463813|Experimental|Vitamin D3 80|Vitamin D3 80 micrograms (3200 IU) per day
3258703|NCT01463813|Experimental|Vitamin D3 40|Vitamin D3 40 micrograms (1600 IU) per day
3258704|NCT01463826||Children with bruxism|14 children with bruxism
3258705|NCT01463826||children without bruxism|19 children without bruxism
3258706|NCT01463839||Children 3 to 6|Fifty children (3 to 6 years of age) from a private school in the city of Sao Paulo
3258707|NCT01463852|Experimental|Vincrisitne 2mg|Single Arm study: Vincristine 2mg administered IV by infusion over 5 minutes.
3258708|NCT01463865|Placebo Comparator|Placebo|Sodium chloride
3258709|NCT01463865|Active Comparator|ropivacaine|Naropin
3258710|NCT01463891||Eribulin Mesylate|
3258711|NCT01463904||Morbid obese, diabetics|Patients with morbid obesity or severe metabolic disease
3258712|NCT01463917|Active Comparator|Hypertonic|Use of Hypertonic solution during left marginal branch CABG surgery.
3258713|NCT01463917|Placebo Comparator|Isotonic|Use of Isotonic solution during left marginal branch CABG surgery.
3258714|NCT01463930|Experimental|Audiovisual videodisc and medical verbal information|
3258715|NCT01463930|Active Comparator|Medical verbal information|
3258716|NCT01463943|Experimental|Saccharomyces boulardii capsules (200 mg).|
3258717|NCT01463943|Active Comparator|Floratil®|
3258718|NCT01463943|Experimental|Saccharomyces boulardii powder (200 mg).|
3258719|NCT01463956|Experimental|Boceprevir, Pegylated interferon and Ribavirin|"Lead-in phase (4 week): Pegylated interferon + Ribavirin~Triple therapy regimen for 44 weeks :Boceprevir + Pegylated interferon + Ribavirin~Pegylated interferon + Ribavirin therapy until transplantation (less or equal to 24 weeks)"
3258720|NCT01463969||PCOS patients|
3258721|NCT01463969||Control group|
3258722|NCT01463995||severe neurological diseases|Patients with severe neurological diseases treated on the neurological intensive care unit
3258723|NCT01464008||chronic hepatitis C|
3258724|NCT01464034|Experimental|Carfilzomib, Pomalidomide, Dexamethasone|All eligible subjects will receive the study intervention of Carfilzomib, Pomalidomide, and Dexamethasone.
3258725|NCT01464047||Patients with CML or Ph+ ALL|
3258726|NCT01464060|Active Comparator|"Hybrid therapy"|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
3258727|NCT01464060|Experimental|"Concomitant therapy"|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
3258728|NCT01464073|Active Comparator|arm 3 : Good Medical Practices|physical exercise at home monitored by telephone (achieving a minimum of 30 minutes per day)
3258729|NCT01464073|Active Comparator|arm 2 : 60% VO2peak|physical exercise at the intensity of 60% of VO2 peak. 4 times a week. duration will be adjusted for arm 1 and arm 2 have the same total energy expenditure by session.
3258730|NCT01464073|Experimental|arm 1 : LIPOXmax|physical exercise at the LIPOXmax intensity during 60 minutes. 4 times a week
3258731|NCT01464086|No Intervention|Standard arm|standard follow-up
3258732|NCT01464086|Experimental|Intensive follow-up|Standard follow-up plus whole body MRI at inclusion, one and two years
3258733|NCT01464099|Active Comparator|Insulin aspart 100U/mL|
3258734|NCT01464099|Experimental|Insulin aspart 200U/mL|
3258735|NCT01464112|Experimental|001|
3258736|NCT01464125|Experimental|Fos-Azi|Open label single arm concurrent administration of fosmidomycin and azithromycin.
3258737|NCT01464138|Experimental|Fosmidomycin-Clindamycin|Single arm study. Co-administration of Fosmidomycin and Clindamycin.
3258738|NCT01464151||Patients with inflammatory bowel disease|patients with a diagnosis of ulcerative colitis, Crohn's colitis or indeterminate colitis between 18 and 70 years of age. Patients should have an indication for surveillance according to the current guidelines, which means a disease duration of at least 8 years and involvement of at least 30% of the colon.
3258743|NCT01464203|Experimental|CT coronary angiography|Patients in this arm will undergo CT coronary angiography to assess the patency of coronary arteries and their clinical management will be decided by the results of CT coronary angiography.
3258744|NCT01464203|Active Comparator|Control Arm|"Patients in this arm will receive the standard of care (SoC). They will undergo either coronary angiography, myocardial perfusion scan or stress echocardiography as decided by the physician in charge, depending on the local availability of individual investigations and the patient's clinical scenario."
3258745|NCT01464242|Experimental|Glucantime® + pentoxifylline|Glucantime® 20mg/kg/day intramuscular injection (IM) daily for 20 days + pentoxifylline 400mg orally 3 times a day for 20 days.
3258746|NCT01464242|Placebo Comparator|Glucantime® + placebo|Glucantime® 20mg/kg/day IM each day for 20 days + placebo 400mg orally 3 times a day for 20 days.
3258747|NCT01464268|Active Comparator|Riboflavin drops every minute|Administration of riboflavin every 2 minutes for the duration of UV exposure.
3258748|NCT01464268|Active Comparator|Riboflavin drops every 2 minutes|Administration of riboflavin every 1 minute for the duration of UV exposure.
3258749|NCT01464281|Experimental|48-week standard treatment|48-week standard treatment by Peginterferon alfa 2a 180µg/week
3258750|NCT01464281|Active Comparator|96-week prolonged treatment|96-week prolonged treatment by Peginterferon alfa 2a 180µg/week
3258751|NCT01464294||nano-composite|crowns and onlays
3258752|NCT01464294||ceramic|crowns & onlays
3258753|NCT01464320|Experimental|ABT-614|
3258754|NCT01464320|Placebo Comparator|Placebo Comparator|
3258755|NCT01464372|Experimental|Investigational Device|Treatment using electrical field stimulation of peripheral nerves
3258756|NCT01464372|Sham Comparator|Sham Device|Control group using sham device to mimic sound and sensation of investigational device
3258757|NCT01464385|Experimental|Nutritional Beverage #2|Nutritional Beverage with an amino acid Oral 237 ml
3258758|NCT01464385|Experimental|Nutritional Beverage #3|Nutritional Beverage with an amino acid Oral 237 ml
3258759|NCT01464385|Placebo Comparator|Nutritional Beverage #1|Nutritional Beverage Oral 237 ml
3258760|NCT01464398|Active Comparator|Stress reduction|Mindfulness-based stress reduction
3258761|NCT01464398|Active Comparator|Stress reduction with Health education|General stress management and health education
3258762|NCT01464437|Active Comparator|AMG 151 - Arm 1|AMG 151 - Arm 1
3258763|NCT01464437|Active Comparator|AMG 151 - Arm 2|AMG 151 - Arm 2
3258764|NCT01464437|Active Comparator|AMG 151 - Arm 3|AMG 151 - Arm 3
3258765|NCT01464437|Active Comparator|AMG 151 - Arm 4|AMG 151 - Arm 4
3258766|NCT01464437|Active Comparator|AMG 151 - Arm 5|AMG 151 - Arm 5
3258767|NCT01464437|Active Comparator|AMG 151 - Arm 6|AMG 151 - Arm 6
3258768|NCT01464437|Placebo Comparator|Placebo Arm|AMG 151 Placebo Arm
3258769|NCT01464450|Active Comparator|Sequence 1: Treatment A - B - C|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
3258770|NCT01464450|Active Comparator|Sequence 2: Treatment A - C - B|Participants will receive a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment A,) followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
3258771|NCT01464450|Active Comparator|Sequence 3: Treatment B - C - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment C) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
3258772|NCT01464450|Active Comparator|Sequence 4: Treatment B - A - C|Participants will receive a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment B,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by 20 mL of water via NG tube (to prime and pre-wet the lumen), followed by a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment C.)
3258773|NCT01464450|Active Comparator|Sequence 5: Treatment C - A - B|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment A) and followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment B.)
3258774|NCT01464450|Active Comparator|Sequence 6: Treatment C - B - A|Participants will receive a single 20 mg-dose of rivaroxaban crushed and suspended in 50 mL of water given via NG tube, followed by 2 mortar rinses of 65 mL each of water and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 1 (Treatment C,) followed by and followed by a single 20 mg-dose of rivaroxaban crushed and mixed in 70 ml of applesauce, followed by 2 mortar rinses of 65 mL each of water (to ensure delivery of the entire dose) and a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 2 (Treatment B) and followed by a single 20 mg-dose of rivaroxaban as a whole tablet swallowed intact with 70 mL of applesauce and 130 mL of water followed by a liquid meal (100 mL of Osmolite® 1.5 Cal at 0, 0.5, 1, 1.5 and 2 hours after receiving the study drug) in Period 3 (Treatment A.)
3258775|NCT01464463|Experimental|CBT-active|Patients with Major Depression (N = 50) get a common CBT treatment in combination with physical exercise.
3258776|NCT01464463|Active Comparator|CBT-euthymic|"Patients with Major Depression (N = 50) get the same common CBT treatment as the CBT-active-group, but instead of physical exercise they receive an enjoyment training, which is based on exercises from the Kleine Schule des Genießens (Koppenhöfer, 2004)"
3258777|NCT01464463|Active Comparator|CBASP|Patients with Major Depression (N=50) get a cognitive therapy according to the Cognitive Behavioral Analysis System of Psychotherapy (CBASP).
3258778|NCT01464463|No Intervention|Waiting List|Patients randomized to the waiting list receive psychological treatment after waiting for 4 month.
3258779|NCT01464476|Experimental|Azimilide|Azimilide 75 mg film coated tablets
3258780|NCT01464476|Placebo Comparator|Placebo|
3258781|NCT01464489|Experimental|Control group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.And receive normal saline for control group
3258782|NCT01464489|Active Comparator|Atropine group|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1. And receive atropine (atropine sulfate) 10 μg.kg-1 for atropine group.
3258783|NCT01464502|Active Comparator|Standard CRT Implant|
3258784|NCT01464502|Active Comparator|Pressure-wire guided CRT Implant|
3258785|NCT01464515|Active Comparator|Real TMS|this group will receive high frequency deep TMS treatment of 10HZ
3258786|NCT01464515|Sham Comparator|SHAM TMS|this group will receive SHAM treatment of deep TMS
3258787|NCT01464528|Active Comparator|Hyaluronan|Use of hyaluronic acid gel
3258788|NCT01464528|No Intervention|control|
3258789|NCT01464541|Experimental|orbital fractures size|patients who undergo surgical repair of orbital fracture with measuring the fracture size intraoperatively and had available orbital Ct scan preoperatively.
3258790|NCT01464554|Active Comparator|Usual Care|Teens will receive six sessions of an alcohol and drug education group
3258791|NCT01464554|Experimental|Project Free Talk|Teens will receive six sessions of and evidenced based motivational interviewing alcohol and drug program
3258792|NCT01464567|Active Comparator|"T Tube Spontaneous Breathing Trial"|"Spontaneous Breathing Trial wuth T Tube for 30 minutes."
3258793|NCT01464567|Experimental|Pressure Support Ventilation|Spontaneous Breathing Trial wuth Ventilation on Pressure-Support mode set at 10cmH2O for 30 minutes
3258794|NCT01464593|Experimental|Thermodox|Thermodox 50 mg/m2 intravenous infusion over 30 minutes starting 15 minutes before thermal ablation.
3258795|NCT01464606|Experimental|Type I PPB therapy|PPB Type I therapy: All patients will be treated with surgery. Chemotherapy after surgery is per the treating physician(s) discretion. If chemotherapy is used the Registry will suggest that it be combination chemotherapy with Vincristine, Dactinomycin, Cyclophosphamide (VAC).
3258796|NCT01464606|Experimental|Types II and III PPB therapy|"Combination chemotherapy with Ifosfamide, Vincristine, Dactinomycin and Doxorubicin (IVADo). Second look and possible 3rd look surgery may be required. Radiation therapy is recommended only for residual disease after maximum surgery."
3258797|NCT01464632||Primary|Post Market Study
3258798|NCT01464645||Primary|Post Market Study
3258799|NCT01464658|Other|panniculectomy|surgical intervention
3258800|NCT01464671|Active Comparator|Bivalirudin|Anticoagulation during percutaneous coronary intervention
3258801|NCT01464671|Active Comparator|Unfractionated Heparin|Anticoagulation during percutaneous coronary intervention
3258802|NCT01464736|Experimental|Physical Training Group|This group performed aerobic physical training in treadmill.
3258803|NCT01464736|Experimental|NIV Trained|"This group performed aerobic physical training associated with ventilation in the bilevel modality (BiPAP®), using a nasal mask as an interface.~On evaluation day, the levels of inspiratory positive airway pressure (IPAP) (between 10 and 15cmH2O) and expiratory positive airway pressure (EPAP) (between 4 and 6cmH2O) were defined, varying according to the comfort level of each patient."
3258804|NCT01464749|Experimental|Task-oriented circuit class training|"Functional Circuit include 6 different work-stations in which patients exercise for 5 minutes in each one : 3 minutes exercises and 2 minutes rest. Total training takes about 30 minutes (2 laps/session over 60 minutes).~Walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary.~It is a progressive circuit and subjects, while exercising, receives feedback (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One task oriented session may include up to 3 patients and lasts 120 minutes. At the end of the 2 weeks an exercises brochure will be given to patients so that they can independently train for 3 month. Independent home training takes about 90 minutes."
3258805|NCT01464749|Active Comparator|Usual Care|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement (usual care). At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) or do physical rehabilitation in rehabilitative gyms not directly addressed to gait, mobility or balance training such as stretching exercises, active and passive mobilization and Bobath neurorehabilitation or similar.
3258806|NCT01464801|Experimental|Resveratrol|Subjects are given resveratrol 500 mg 3 times daily for 6 months.
3258807|NCT01464801|Placebo Comparator|Placebo|Subjects are given Placebo tablets 3 times daily for 6 months.
3258808|NCT01464814|Experimental|Probiotic|Lactobacillus casei in fish oil capsule
3258809|NCT01464814|Placebo Comparator|Placebo|Fish oil capsule
3258810|NCT01464853|Experimental|Specialized Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
3258811|NCT01464853|Active Comparator|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
3258812|NCT01464866|Active Comparator|Hospital Feed|Standard hospital food
3258813|NCT01464866|Experimental|Hospital Feed plus nutritional supplement|Standard hospital food plus nutritional supplement
3258817|NCT01464905|Experimental|NU100|
3258818|NCT01464905|Placebo Comparator|Placebo|
3258819|NCT01464905|Active Comparator|recombinant human interferon beta- 1b|
3258820|NCT01464918|Experimental|ESD using the MASTER device|Endoscopic submucosal dissection of gastric/colon cancer using the device, MASTER
3258821|NCT01464944|Experimental|Arm 2|
3258822|NCT01464944|Active Comparator|Arm 3|
3258823|NCT01464944|Active Comparator|Arm 4|
3258824|NCT01464944|Placebo Comparator|Arm 5|
3258825|NCT01464944|Experimental|Arm 1|
3258826|NCT01464957|Experimental|Newsletter intervention|Semi-tailored newsletter intervention for parents and children
3258827|NCT01464957|No Intervention|Usual care|No newsletter intervention
3258828|NCT01464970|Active Comparator|SIE Vessels Both Clamped|
3258829|NCT01464970|Active Comparator|SIE Vessels both Unclamped|
3258830|NCT01464970|Active Comparator|SIE Artery Unclamped; Vein Clamped|
3258831|NCT01464970|Active Comparator|SIE Artery Clamped, SIE Vein Unclamped|Superficial Inferior Epigastric Artery Clamped; Vein Unclamped
3258832|NCT01464983|Active Comparator|Arm 1|
3258833|NCT01464983|Experimental|Arm 2|
3258834|NCT01464983|Active Comparator|Arm 3|
3258835|NCT01464983|Active Comparator|Arm 4|
3258836|NCT01464983|Placebo Comparator|Arm 5|
3258837|NCT01465009|Experimental|Arm 1|
3258838|NCT01465009|Active Comparator|Arm 2|
3258839|NCT01465009|Placebo Comparator|Arm 3|
3258840|NCT01465035|Experimental|TIV and MVA-NP+M1|"Co-administration group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of 1.5 x108pfu MVA-NP+M1"
3258841|NCT01465035|Placebo Comparator|Saline placebo and seasonal influenza vaccine TIV|"Control group~1 dose of seasonal influenza vaccine (TIV) and 1 dose of a saline placebo"
3258842|NCT01465061||Online support user|
3258843|NCT01465074|Active Comparator|Nicotine gum (4 mg)|Nicotine gum will be given once on one of the two test days in a randomized, double-blinded fashion. Gum will be chewed for 30 min before the plasticity induction occurs.
3258844|NCT01465074|Placebo Comparator|Regular Mint Gum|Regular, taste-, texture- and color matched with the Nicotine Gum will be ingested once on one of the two testing days, 30 min before plasticity induction.
3258845|NCT01465087|Experimental|Diagnosis|Diagnosis, breath and confounding factor
3258846|NCT01465100|Experimental|Hepatocyte Transplantation|See Below.
3258847|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
3258848|NCT01465113|Experimental|high grade dysplasia|Barrett's esophagus with high grade dysplasia
3258849|NCT01465113|Experimental|Indefinite, LGD or no dysplasia arm:Vitamin D/Metformin Subarm|Barrett's esophagus patients who have no dysplasia or low grade dysplasia
3258850|NCT01465139|Experimental|CDX-301|CDX-301 (rhuFlt3L), administered to healthy patients.
3258851|NCT01465152|Experimental|Met|
3258852|NCT01465152|Active Comparator|Rep|
3258853|NCT01465152|Active Comparator|Met+Rep|
3258854|NCT01465165||Depressed, unmedicated|Participants with MDD who are not treated with any antidepressant medication
3258855|NCT01465165||Depressed, on antidepressant|Participants with MDD, currently depressed but on a stable dose of an SSRI antidepressant
3258856|NCT01465165||Healthy control|Healthy participant with no MDD or other psychiatric condition, matched by age and gender to MDD participants
3258857|NCT01465204|No Intervention|Control|
3258858|NCT01465204|Experimental|Handwashing Intervention|scaling up handwashing with soap
3258859|NCT01465204|Experimental|Sanitation Intervention|total sanitation and sanitation marketing
3258860|NCT01465204|Experimental|Combined|combined scaling up handwashing with soap and total sanitation and sanitation marketing interventions
3258861|NCT01465217|Experimental|text message medication reminders|
3258862|NCT01465217|No Intervention|control|
3258863|NCT01465243|Experimental|Icotinib|This is a single arm study.
3258864|NCT01465256|No Intervention|Aspirin holding group|Aspirin holding group (group 1): the patients enrolled into group 1 can stop taking aspirin during colon polypectomy. The patients are usually taking aspirin for primary prevention of vascular disease and have no risk of thromboembolism despite of they stop taking aspirin temporary
3258865|NCT01465256|Experimental|Aspirin continuing group|Aspirin continuing group (group 2): the patients enrolled into group 2 should take aspirin during colon polypectomy because these patients are usually take thienopyridines and aspirin, and if they would stop taking aspirin during colon polypectomy, they have a thromboembolism risk.
3258866|NCT01465269|Experimental|GIST Intervention|
3258867|NCT01465269|Active Comparator|Alternative Intervention|
3258868|NCT01465282|Experimental|0.05% (w/w) CT327 ointment|0.05% (w/w) CT327 ointment applied BID for up to 8 weeks.
3258869|NCT01465282|Experimental|0.1% (w/w) CT327 ointment|0.1% (w/w) CT327 ointment applied BID for up to 8 weeks.
3258870|NCT01465282|Experimental|0.5% (w/w) CT327 ointment|0.5% (w/w) CT327 ointment applied BID for up to 8 weeks.
3258871|NCT01465282|Placebo Comparator|Placebo ointment|Placebo ointment
3258872|NCT01465295|Experimental|HemiBridge|Patients meeting eligibility criteria will be treated with the HemiBridge System.
3258873|NCT01465308|Experimental|receiving Honey|The patients will receive honey mouthwash rinses
3258874|NCT01465308|Active Comparator|Saline mouthwash|The patients in this group will receive saline rinses
3258875|NCT01465360||Study patients|Patients newly referred to a Reference Memory Center with a complaint of memory impairment for AD diagnostic workup.
3258876|NCT01465373|Active Comparator|Progesterone in Oil|"Donor egg recipients will begin progesterone 50 mg IM injection starting the day after donor egg fertilization, and continue daily until pregnancy results can be determined.~If pregnant, donor egg recipient will continue progesterone 50 mg IM injections daily until approximately 9 weeks of pregnancy."
3258877|NCT01465373|Active Comparator|Endometrin|"Donor egg recipients will begin Endometrin 100 mg per vagina three times daily starting the day after donor egg fertilization and continue until pregnancy result can be determined.~If pregnant, donor egg recipients will continue Endometrin 100 mg TID until approximately 9 weeks of pregnancy."
3258878|NCT01465399|Experimental|PRGF-Endoret|
3258879|NCT01465399|Active Comparator|Conventional treatment|
3258880|NCT01465425||E3/E4 Case Group|The Case Group will target consenting 141 participants from the cases with indeterminate but potentially significant findings (E3/E4s) other than pulmonary nodules.
3258881|NCT01465425||Pulmonary Nodules Case Group|The Pulmonary Nodules Case Group will comprise 119 cases with E3/E4 ECFs characterized as pulmonary nodules.
3260201|NCT01477268|Other|zoloft|Both arms of the study will include zoloft. However, the treatment response to zoloft will be compared in two different subgroups.
3258882|NCT01465425||E1 Control Group|The E1 Control Group will be drawn from the 866 E1 ECF cases from ACRIN 6664 to create a cohort of 260 E1 ECF cases. The Control Group for comparison with the Case Group and the Pulmonary Nodules Case Group will be selected at the Biostatistics and Data Management Center (BDMC). The BDMC will match E1 141 controls to the 141 case-group participants with indeterminate but potentially significant findings (E3/E4s). The BDMC will also match 119 E1 controls to the 119 E3/E4 pulmonary nodules cases. Controls will be matched by site, age caliper (5 years), and sex where possible.
3258883|NCT01465438|Experimental|Adalimumab|Responders at week 24 continue treatment with adalimumab. Non-responders at week 24 stops treatment with adalimumab.
3258884|NCT01465451|Active Comparator|ARM A- surgery alone|all cases will receive standard surgical procedures of curative resection for colorectal cancer, without intra-operative chemotherapy.
3258885|NCT01465451|Experimental|ARM B surgery plus chemotherapy|all cases will receive standard surgical procedures described as arm A. In addition, all cases will receive 5-FU chemotherapy during operation.
3258886|NCT01465477|Experimental|Fibromyalgia arm|Patients fulfilling ACR 1990 Criteria for classification of Fibromyalgia, receiving the vaccination.
3258887|NCT01465477|Experimental|Heathy controls|Healthy controls receiving Influenza vaccination
3258888|NCT01465490|Experimental|Monitoring and Feedback Intervention|
3258889|NCT01465490|No Intervention|Treatment as usual|
3258890|NCT01465503|Placebo Comparator|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparin (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
3258891|NCT01465503|Active Comparator|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
3258892|NCT01465516||Hispanic, HCV genotype 1|Historical group will be a continuous group of Hispanic patients with genotype 1 who were naive to treatment and completed or initiated 48 weeks of pegylated interferon and ribavirin. Patients, who discontinued the treatment due to side effects, adherence issues, or treatment failure, will be included and analyzed based on intention to treat analysis. All patients will be stratified according to their SVR, relapse and no response rate. RVR, EVR, and ETR will be also collated and compared to the study group.
3258893|NCT01465529|Experimental|Active|
3258894|NCT01465529|Placebo Comparator|Placebo|
3258895|NCT01465542||Oral NAC|Patients receiving oral NAC treatment after an acute acetaminophen ingestion.
3258896|NCT01465542||IV NAC|Patients receiving IV NAC after an acute Acetaminophen ingestion.
3258897|NCT01465555|Experimental|Clinical Alert|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
3258898|NCT01465555|No Intervention|Treatment As Usual|Counselors in this condition will work with the original RecoveryTrack which has not been altered to provide automated Clinical Alerts for High Risk patients. Supervisors will receive no automated help in identifying these clients in the counselors' caseloads. The Clinical Alert feature will not be discussed in the training these counselors receive. Rather, the counselors will receive an attention-control training, a one-day training on assessment and treatment planning, with monthly tips and reminders for six months.
3258899|NCT01465568|Active Comparator|Denosumab|denosumab
3258900|NCT01465568|Active Comparator|bisphosphonates|continuation of bisphosphonates
3258901|NCT01465581||Neurogenic incontinence|The target population of this study is children with primary or secondary daytime urinary incontinence, who have failed to improve adequately despite compliance with at least 6 months of standard medical therapy. These children will have abnormal urodynamics, a normal bladder ultrasound and an MR imaging showing that the conus of the spinal cord is at a normal position and that there is no other significant dysraphic lesion present.
3258902|NCT01465594|Active Comparator|transurethral catheter after EERPE/ RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
3258903|NCT01465594|Active Comparator|suprapubic catheter after EERPE /RALP|Recording of QoL measured by visual analogue ( pain )scale,EORTC QlQ -C 30 and QLQ - PR 25 questionnaires, incontinence rate, complication rate regarding insufficiency and strictures of vesicourethral anastomoses and urinary tract infection; demand of re-catheterization due to urinary retention and demand of antispasmodics
3258904|NCT01465607|Experimental|Theory-based counseling (Mujer Segura)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
3258905|NCT01465607|Active Comparator|CENSIDA counseling program (didactic)|Will consist of 40 FSWs at each of 12 clinics, randomized into this condition from a pool of 80 eligible participants.
3258906|NCT01465620|Experimental|Coaching|active hygienic-dietetic coaching
3258907|NCT01465620|Active Comparator|control|reference hygienic-dietetic recommendations
3258908|NCT01465633|Active Comparator|with iodine|
3258909|NCT01465633|Experimental|without iodine|
3258910|NCT01465646|Active Comparator|with idodine|
3258911|NCT01465646|Experimental|without iodine|
3258912|NCT01465672||neurosurgical patients|Patients undergoing transphenoidal pituitary adenoma resection and patients with transcranial surgery of tumors close to the pituitary gland and hypothalamus.
3258913|NCT01465685|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject.
3258914|NCT01465698|Experimental|Exercise|
3258915|NCT01465698|Experimental|Counseling|
3258916|NCT01465698|Experimental|Exercise and counseling|
3258917|NCT01465698|Other|Control group|Participants in the control group only participate in study measurements.
3258918|NCT01465711||Control|Admission to the Intensive Care Unit (ICU) after abdominal surgery without suspicion / evidence of peritonitis.
3258919|NCT01465711||Peritonitis|Admission to the Intensive Care Unit (ICU) after abdominal surgery with suspicion / evidence of peritonitis
3258920|NCT01465724|Experimental|Renal denervation|
3258921|NCT01465737||Patients with uterine cancer|All patients diagnosed with uterine cancer in Taiwan between 1979-2008
3258922|NCT01465750||Ovarian Cancer|
3258923|NCT01465776|Experimental|Treatment (chemoprevention)|
3258924|NCT01465815|Experimental|Treatment (adjuvant enzyme inhibitor and radiation therapy)|"Optional non-therapeutic (biomarker) portion: Patients are randomized to 1 of 3 treatment arms.~Arm A: Patients receive erlotinib hydrochloride PO QD and linsitinib PO BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3258925|NCT01465815|Experimental|Erlotinib and Placebo (Sugar Pill)|"Arm B: Patients receive erlotinib hydrochloride PO QD and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3258926|NCT01465815|Experimental|OSI-906 and Placebo (Sugar Pill)|"Arm C: Patients receive linsitinib PO BID and placebo PO QD or BID on days 1-7 or 1-14.~Treatment continues until 1 day before planned surgical resection (for up to 28 days if surgery is delayed).~Therapeutic portion: This is a phase I dose-escalation study of linsitinib followed by a phase II study.~Patients undergo standard QD conventional radiotherapy at the discretion of the treating physician. Patients receive concurrent linsitinib PO BID and erlotinib hydrochloride PO QD during the entire course of radiation in the absence of disease progression or unacceptable toxicity."
3258927|NCT01465828|Active Comparator|high clopidogrel dose|Patients will be randomized to this arm to receive before high clopidogrel dose and after crossover they will receive standard dose of prasugrel
3258928|NCT01465828|No Intervention|prasugrel standard dose|Patients will be randomized to this arm to receive before standard dose of prasugrel and after crossover they will receive high clopidogrel dose.
3258929|NCT01465854||LCINS|Never smokers with newly diagnosed lung cancer
3258930|NCT01465867|Experimental|Selenium|
3258931|NCT01465867|Placebo Comparator|Sugar Pill Placebo|
3258932|NCT01465867|Experimental|Selenium + L-Thyroxine (LT4)|
3258933|NCT01465867|Experimental|Sugar Pill Placebo + L-Thyroxine (LT4)|
3258934|NCT01465880|No Intervention|Part B. Healthy Caucasian adult non-smokers|Non-smokers
3258935|NCT01465880|Experimental|Part A.Healthy Caucasian adult smokers|No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
3258936|NCT01465893|Active Comparator|vitamin D|vitamin d 50000/w
3258937|NCT01465893|Sham Comparator|control|follow up
3258938|NCT01465906|Experimental|tulobuterol combined with tiotropium bromide|
3258939|NCT01465906|Active Comparator|Tiotropium bromide|
3258940|NCT01465919|Experimental|mirtazapine|mirtazapine
3258941|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be given by a specialized psychiatrist.
3258942|NCT01465932|Active Comparator|No proprioception|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, in addition to cryotherapy reduction of pain.
3258943|NCT01465932|Experimental|Proprioceptive exercises|Nursing professionals to diagnose disorders of the rotator cuff previously randomly allocated in this group did stretching exercises of the muscles of the cervical spine and chest, strengthening the muscles of the rotator cuff and stabilizers of the scapula, proprioception exercises to improve motor control, besides cryotherapy for reduction of pain.
3258944|NCT01465945|Other|Rectal Defect Sutured|The subject will have his/her defect sutured after the rectal tumors have been removed.
3258945|NCT01465945|Other|Rectal Defect Unsutured|The defect will be left open and let naturally close after the rectal tumor has been removed by TEM.
3258946|NCT01465971||not acclimatized|no stay in an altitude above 2500 m within the last 3 Months
3258947|NCT01465971||acclimatized|stay above 2500 m with the last 14 days
3258948|NCT01465984|Experimental|IV Paracetamol|
3258949|NCT01465984|Active Comparator|IV Morphine Sulfate|
3258950|NCT01466010||osteoid osteoma|patients with osteoid osteoma at any location
3258951|NCT01466036|Experimental|Metastatic or Unresectable PNET|35 patients with pancreatic neuroendocrine tumors receiving cabozantinib
3258952|NCT01466036|Experimental|Metastatic or Unresectable Carcinoid|35 patients with advanced or metastatic carcinoid tumor receiving cabozantinib
3258953|NCT01466088|Experimental|AZD3480|
3258954|NCT01466088|Active Comparator|Donepezil|Donepezil will be administered at 5 mg daily for 4 weeks and escalated to 10 mg daily for the remainder of the study.
3258955|NCT01466101|Active Comparator|Pregabalin administration|Administration of pregabalin
3258956|NCT01466101|Placebo Comparator|Placebo|Administration of placebo
3258957|NCT01466114|Experimental|Group A: Estriol|Standard MS Treatment + Estriol
3258958|NCT01466114|Placebo Comparator|Group B: Placebo|Standard MS Treatment + Placebo
3260202|NCT01477281|Experimental|Venafon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
3260420|NCT01479088|Experimental|cinacalcet tab or extemporaneous solution po added to SoC|"Subjects who meet all inclusion/exclusion criteria at baseline will be given cinacalcet 30mg film-coated tablet, for oral use added to phosphate binders and vitamin D analogue.~For subjects receiving a cinacalcet dose <30mg, commercially available cinacalcet 30mg tab will be ground and diluted with a 5% dextrose solution. Then, an aliquot of this solution corresponding to the individually prescribed dose will be administered as indicated.~Initial dosing of cinacalcet will be 0.5-0.75mg/kg or 30 mg po once daily (OD) each evening with food.~During the cinacalcet dose-titration 6-month period for efficacy assessment, the dose will be increased on monthly basis by 0.5 mg/kg or by 30mg OD to achieve the target iPTH value <180 pg/mL, as tolerated by the subject, up to maximum of 180mg OD in absence of signs of hypocalcemia, according to the current summary of product characteristics."
3260421|NCT01479101||MammaPrint, BluePrint, neo-adj CT or HT|All patients receive the MammaPrint and BluePrint gene expression profile. Treatment at the discretion of the physician while adhering to NCCN guidelines.
3260422|NCT01479114|No Intervention|control group|
3260423|NCT01479114|Experimental|G-CSF group|
3260424|NCT01479114|No Intervention|Non-GCSF group|
3260425|NCT01479153|Active Comparator|Subclavian catheterization|
3260426|NCT01479153|Active Comparator|Internal Jugular catheterization|
3260427|NCT01479153|Active Comparator|Femoral Catheterization|
3260428|NCT01479166||affected patients with small airway disease (SAD)|20 patients suffering from mild cystic fibrosis and involvement of small airways
3260429|NCT01479166||affected patients without small airway disease (SAD)|20 patients suffering from mild cystic fibrosis without SAD
3260430|NCT01479166||non-affected patients|20 matched controls not suffering from cystic fibrosis
3260431|NCT01479179|Experimental|AMG 479 + Trastuzumab|AMG 479 18 mg/kg or 12 mg/kg intravenously (IV) 30 minutes after trastuzumab. Trastuzumab loading dose (Week 1) 8 mg/kg IV over 90 minutes; maintenance dose 6 mg/kg IV over 30 minutes every 3 weeks.
3260432|NCT01479192|Experimental|Fenretinide|100mg: 2cps/day for 5 years followed by
3260433|NCT01479192|Placebo Comparator|Placebo|matched placebo 2 cps/day for 5 years
3260434|NCT01479205||mite allergic patients without SIT|patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy
3260435|NCT01479205||mite allergic patients with SIT|patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy
3260436|NCT01479218|Other|PDA Occluder|single arm
3260437|NCT01479231|Experimental|dexlansoprazole|
3260438|NCT01479244|Experimental|NeuVax™|NeuVax™ in WFI solution with Leukine®
3260439|NCT01479244|Active Comparator|Leukine®|Leukine® with WFI
3260440|NCT01479257||Bilingual Latinos|Bilingual Houston area Latinos surveyed for 7 continuous days with objective and subjective assessments using accelerometer and smart phone.
3260441|NCT01479283|Active Comparator|Short-Arm Antibiotic Regimen|"Intervention: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
3260442|NCT01479283|Experimental|Long-Arm Antibiotic Regimen|"Intervention: 5-Days Prophylactic Cefazolin* Antibiotic Regimen~*or another cephalosporin with equivalent gram-positive coverage in centers where cefazolin is not routinely used or not approved for use"
3260443|NCT01479296|Experimental|Group 1: rAd5 Plus Placebo|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection in their right arm (1×10^10 PU), and placebo vaccine injections in their left arm, right thigh, and left thigh.
3260444|NCT01479296|Experimental|Group 2: Separated Vaccine Components|Participants will receive the rAd5 gag-pol vaccine injection in their right arm (0.5×10^10 PU), the rAd5 env A vaccine injection in their left arm (0.17×10^10 PU), the rAd5 env B vaccine injection in their right thigh (0.17×10^10 PU), and the rAd5 env C vaccine injection in their left thigh (0.17×10^10 PU).
3260445|NCT01479296|Experimental|Group 3: Divided Dose rAd5|Participants will receive the VRC rAd5 gag-pol/env A/B/C vaccine injection divided into fourths, with one fourth of the total dose given in each of 4 sites: right arm, left arm, right thigh, and left thigh (each at 0.25×10^10 PU).
3260446|NCT01479387||Group 1|
3260447|NCT01479400||infants who were exposed to antipsychotics as fetus|
3260448|NCT01479400||infants who were not exposed to antipsychotics as fetus|
3260449|NCT01479413||Schizophrenia|
3260450|NCT01479452|Other|Bariatric surgery|Bariatric surgery
3260451|NCT01479452|Other|Controls|Usual care
3260452|NCT01479491||Case Group|Children aged < 12 months presenting with IS and covered by the Japan Medical Data Centre Company Limited (JMDC), Tokyo referred to as the JMDC Medical Data Bank (JMDC-MDB).
3260453|NCT01479504|Experimental|1A(nedaplatin and IMRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and Intensity-modulated Radiation Therapy(IMRT)
3260454|NCT01479504|Active Comparator|1B(cisplatin and IMRT)|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and Intensity-modulated Radiation Therapy(IMRT)
3260455|NCT01479504|Experimental|2A(nedaplatin and CRT)|neoadjuvant chemotherapy using nedaplatin plus docetaxel followed by concurrent chemotherapy using nedaplatin and conventional fractionation radiotherapy(CRT)
3260456|NCT01479504|Active Comparator|2B((cisplatin and CRT))|neoadjuvant chemotherapy using cisplatin plus docetaxel followed by concurrent chemotherapy using cisplatin and conventional fractionation radiotherapy(CRT)
3260457|NCT01479556|Placebo Comparator|Placebo|Study subjects wil be randomized to the Placebo arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
3260458|NCT01479556|Active Comparator|Pregabalin|Study subjects wil be randomized to the Pregabalin arm following a stratification procedure based on AIS scale (A-E), neurological level of injury (cervical or thoracic), and presence of at-level neuropathic pain before or after 3 months from the time of spinal cord injury.
3260459|NCT01479608|Experimental|A: Transplantation or resection (randomized)|Liver transplantation or liver resection by 1:1 randomization (open label)
3260460|NCT01479608|Experimental|B: Liver transplantation|For non-resectable patients metachronous disease.
3260461|NCT01479608|Experimental|C:Liver transplantation|For non-resectable patients synchronous disease.
3260462|NCT01479608|Experimental|D:Liver transplantation|For non-resectable patients synchronous disease.
3260463|NCT01479634|Active Comparator|Arm A|Treatment for HIV in participants with CD4+ cell counts 250-350 cells/uL
3260464|NCT01479634|Active Comparator|Arm B|Treatment for HIV in participants with CD4+ cell counts >350 cells/uL
3260465|NCT01479647|Experimental|PH-797804 1 mg Fasted|Subjects will receive a single 1 mg dose in the fasted state
3260466|NCT01479647|Experimental|PH-797804 1 mg Fed|Subjects will receive a single 1 mg dose following a high-fat meal
3260467|NCT01479647|Experimental|PH-797804 10 mg Fasted|Subjects will receive a single 10 mg dose in the fasted state
3260468|NCT01479647|Experimental|PH-797804 10 mg Fed|Subjects will receive a single 10 mg dose following a high-fat meal
3260469|NCT01479647|Experimental|PH-797804 24 mg Fed|Subjects will receive a single 24 mg dose following a high-fat meal
3260470|NCT01479660|Placebo Comparator|Control|
3260471|NCT01479660|Experimental|Probiotic|
3260472|NCT01479673|No Intervention|Control group|"Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the liberal  regimen, i.e. according to local practice."
3260473|NCT01479673|Experimental|Indirect Calorimetry|Study group: Indirect Calorimetry (IC) Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry measurement of Resting Energy Expenditure (REE).
3260474|NCT01479686|Active Comparator|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
3260475|NCT01479686|Experimental|intraoperative MRI|iMRI guided resection in adults with glioma
3260476|NCT01479699|Placebo Comparator|Placebo capsule|Four placebo capsules containing safflower oil only
3260477|NCT01479699|Active Comparator|Olive leaf extract capsule|Four olive leaf capsules. Each containing 4mg oleuropein plus safflower oil.
3260478|NCT01479712|Active Comparator|Irrigation|This is the arm that will receive irrigation.
3260479|NCT01479712|No Intervention|No Irrigation|This is the arm that will not receive irrigation.
3260480|NCT01479738|Experimental|Capitate bone grafting|18 patients with PIP joint defects were included in the study. There were 13 male and 5 female patients with a mean age of 31 years (range, 18-47 years). The injury occurred in the right hand in 11 patients and on the left hand in 7. The injured PIP joints were in the index finger (n=7), long finger (n=9), and ring finger (n=2).
3260481|NCT01479751|Experimental|ketamine|Patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
3260482|NCT01479751|Experimental|priming|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
3260483|NCT01479751|No Intervention|Roc 0.9|Patients receive Roc 0.9 mg/kg as an induction dose.
3260484|NCT01479751|No Intervention|Control|Patients receive Roc 0.6 mg/kg without any pretreatments of Mg, ketamine, or priming.
3260485|NCT01479751|Experimental|Mg|Patients receive magnesium sulfate (MgSO4) 50 mg/kg over 10 min before Roc injection.
3260486|NCT01479790|No Intervention|Visante AS-OCT and Cirrus AS-OCT|The tear meniscus is the thin concave strip of the tear film near the eyelid margins. During the acquisition the participants place their chins on a chin rest and look at a fixation light/target. This whole procedure should not take more than 5 minutes. The patients are allowed to blink freely except for during the acquisition time of less than 5 seconds. The procedure will be repeated for the upper and lower tear meniscus of both eyes.
3260487|NCT01479790|Experimental|Thermography measurement|"In total, four pairs of thermographic sequences on the ocluar surface temperature from volunteers will be taken.~A thermographic sequence will be captured from each eye.~After 20 minutes, a second pair of thermographic sequences will be captured.~An eye mask with a temperature of not more than 40 deg C (will be worn by the volunteer for 5 minutes and a third pair of thermographic sequences will be captured immediately after mask removal.~A fourth pair of thermographic sequences will be captured 1 hour after mask removal."
3260488|NCT01479803|Active Comparator|EchoTip HD ProCore 22 Gauge|first passage in the pancreatic tumor with the EchoTip HD ProCore 22 Gauge then with the EchoTip 22 Gauge
3260489|NCT01479803|Active Comparator|Echo Tip 22 Gauge|First passage through the tumor with the EchoTip 22 Gauge then with Echotip HD ProCore 22 Gauge
3260490|NCT01479829|Active Comparator|ESC + CBX|Escitalopram 10 mg twice day plus Celecoxib 200 mg twice daily.
3260491|NCT01479829|Placebo Comparator|ESC + PBO.|Escitalopram 10 mg twice day plus placebo administered twice daily.
3260492|NCT01479842|Experimental|Treatment (enzyme inhibitor, chemo, monoclonal antibody)|Patients receive BTK inhibitor PCI-32765 PO QD on days 1-28. Patients also receive rituximab IV on day 1 and bendamustine hydrochloride IV over 30 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may continue receiving BTK inhibitor PCI-32765 PO in the absence of disease progression or unacceptable toxicity.
3260493|NCT01479855||Patients|Patients referred to a memory clinic due to memory problems and their healthy spouse
3260494|NCT01479881|Experimental|001|a single 100-mg dose of cyclosporine, and after a wash out period of at least 10 days, TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7.
3260495|NCT01479881|Experimental|002|TMC435 150 mg once daily (q.d.) for 10 days on Days 1 to 10, coadministered with a single 100-mg dose of cyclosporine on Day 7 and after a wash out period of at least 10 days, a single 100-mg dose of cyclosporine.
3260496|NCT01479881|Experimental|003|a single 2-mg dose of tacrolimus on Day 1. After a wash out period of at least 10 days, participants will receive TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7.
3260497|NCT01479881|Experimental|004|TMC435 150 mg q.d. for 12 days on Days 1 to 12, coadministered with a single 2-mg dose of tacrolimus on Day 7. After a wash out period of at least 10 days, participants receive a single 2-mg dose of tacrolimus.
3260498|NCT01479894||Sample Collection|This is an exploratory study utilizing archived tumor specimens and demographic and pathologic characteristics derived from the patient's medical charts. As such, all eligible patients must have a stored tumor specimen which can be accessed for analysis.
3260499|NCT01479907|Active Comparator|Synbiotics|"A specific multistrain/multifi ber synbiotic composition of prebiotics and probiotics (Synbiotic Forte™, IONIA Pharmaceuticals, Athens, Greece) was administered at the active comparator arm of the study. It contained 10 [11] of each of four lactic acid bacteria (LAB): Pediococcus pentosaceus 5-33:3, Leuconostoc mesenteroides 32-77:1, Lactobacillus paracasei ssp. paracasei 19, and Lactobacillus plantarum 2362, and 2.5 g of each of the four fermentable fibers (prebiotics): b-glucan, inulin, pectin and resistant starch. The synbiotics were delivered in sachets and then mixed with water (12 g in 250 mLof water once daily). Th e treatment started on the day patients tolerated per os liquid intake (2nd-4th POD). The intervention period lasted 15 days."
3260500|NCT01479907|Placebo Comparator|Placebo|The patients belonging to the placebo comparator arm received only the 4 fi bers and no LAB (12 gin 250 mLof water once daily for 15 days). All the subjects were interviewed by a dedicated research fellow (KP) and reactions to the product, and any adverse events occurring in the 15-day period were recorded.
3260501|NCT01479920|Active Comparator|DCEAS|"Dense cranial electroacupuncture stimulation (DCEAS)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3260502|NCT01479920|Sham Comparator|n-CEA|"Non-invasive cranial electroacupuncture (n-CEA)~For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day."
3260503|NCT01479933|Experimental|Vitamin D 40|Vitamin D3 40 micrograms (1600 IU) per day
3260504|NCT01479933|Experimental|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
3260505|NCT01479933|Placebo Comparator|Placebo|
3260506|NCT01479946|Experimental|Early Electrochemotherapy|Electrochemotherapy is given as early as possible after the discovery of skin metastases
3260507|NCT01479946|No Intervention|Delayed or no Electrochemotherapy|patients are to be treated for their breast cancer according to clinical routine with electrochemotherapy as an option only after 6 months from randomization
3260508|NCT01479959|Active Comparator|No PEEP level|protocol conducted while no PEEP is applied
3260509|NCT01479959|Active Comparator|effective PEEP level (PEEPeff)|PEEP level allowing the entire expiratory volume to go through the upper airways during quiet breathing
3260510|NCT01479959|Active Comparator|intermediate PEEP level (PEEP50)|50% of PEEPeff
3260511|NCT01479972|Experimental|VPM1002|
3260512|NCT01479972|Active Comparator|BCG|
3260513|NCT01479998|Active Comparator|Standard care and nicotine replacement therapy|standard care is 4 counseling sessions and nicotine replacement therapy
3260514|NCT01479998|Experimental|standard care plus NRT plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
3260515|NCT01480011|Experimental|lactobacillus lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
3260516|NCT01480037||Elderly|Individuals between 60 and 70 years-old
3260517|NCT01480037||Long-lived|Individuals above 85 years-old
3260518|NCT01480037||Young|Individuals between 20 and 30 years-old
3260519|NCT01480050|Experimental|Dose Finding and Dose Expansion|"DOSE FINDING 4 Levels~For all Levels:~Cycle 1 Mibefradil QID dosing, Days 1-8 (to accommodate PKs) (*2 doses on Days 1 and 8) Temozolomide daily at 150-200 mg/m2, Days 9-13;~Cycles 2+ Mibefradil QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12~DOSE EXPANSION 28-day cycles FLT PET scans, Baseline x2, Day 7 Mibefradil MTD determined at Dose Finding QID, Days 1-7 Temozolomide daily at 150-200 mg/m2, Days 8-12"
3260520|NCT01480063||Fampyra|Fampyra administered as prescribed in routine clinical practice.
3260521|NCT01480102|Placebo Comparator|Group B- No Block|Participants randodmized to this arm will have a local anesthetic injection and pressure applied to the paravertebral space. A paravertebral injection will not be conducted.
3260522|NCT01480102|Active Comparator|Group A- Paravertebral block|Participants randodmized to this arm will have a local anesthetic (Bupivicaine 0.5% without epinephrine) injection and will be given a paravetebral block into the T10 paravertebral space..
3260523|NCT01480141|Experimental|Single Arm Study|Single arm trial where all patients will be treated with afatinib until the day of surgery and for a minimum of two weeks. Patients will receive treatment with afatinib 40mg orally daily.
3260524|NCT01480154|Experimental|Treatment (Akt inhibitor MK2206, hydroxychloroquine)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15. Beginning on cycle 2, patients also receive hydroxychloroquine PO BID on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3260525|NCT01480167|Active Comparator|RF-TVA with STABILIT Vertebral Augmentation System|All RadioFrequency-Targeted Vertebral Augmentation (RF-TVA) arm participants will be treated with the StabiliT Vertebral Augmentation System. This system is a commercially available device in the United States designed to perform percutaneous vertebral augmentation (also known as kyphoplasty).
3260526|NCT01480167|Active Comparator|Non Operative Management|All non-operative management (NOM) arm participants will receive non-operative standard of care management, which can include: analgesics, bed rest, back braces, physiotherapy, rehabilitation programs, and walking aids according to standard practices of participating institutions.
3260527|NCT01480180|Experimental|Prophylaxis|
3260528|NCT01480180|Experimental|On-demand|
3260529|NCT01480193|Active Comparator|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
3260530|NCT01480193|Experimental|Integrative Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
3260531|NCT01480245|Experimental|Continuous Dosing|GSK2402968 6mg/kg/week
3260532|NCT01480245|Experimental|Intermittent Dosing|GSK2402968 6mg/kg/week
3260533|NCT01480245|No Intervention|Natural History Observation|The objective of this arm will be to explore DMD disease progression in a naturalistic setting once discontinuing active treatment
3260534|NCT01480271|Experimental|Part 1 Cohort 1 GSK2445053|2ng GSK2245053
3260535|NCT01480271|Placebo Comparator|Part 1 Cohort 1 Placebo|Placebo
3260536|NCT01480271|Experimental|Part 1 Cohort 2 GSK2445053|20ng GSK2445053
3260537|NCT01480271|Placebo Comparator|Part 1 Cohort 2 Placebo|Placebo
3260538|NCT01480271|Experimental|Part 1 Cohort 3 GSK2245053|100ng GSK2445053
3260539|NCT01480271|Placebo Comparator|Part 1 Cohort 3 Placebo|Placebo
3260540|NCT01480271|Experimental|Part 1 Cohort 4 GSK2445053|200ng GSK2445053
3260541|NCT01480271|Placebo Comparator|Part 1 Cohort 4 Placebo|Placebo
3260542|NCT01480271|Experimental|Part 1 Cohort 5 GSK245053|400ng GSK2445053
3260543|NCT01480271|Placebo Comparator|Part 1 Cohort 5 Placebo|Placebo
3260544|NCT01480271|Experimental|Part 1 Cohort 6 GSK2445053|1000ng GSK2245053
3260545|NCT01480271|Placebo Comparator|Part 1 Cohort 6 Placebo|Placebo
3260546|NCT01480271|Experimental|Part 1 Cohort 7 GSK2445053|2000ng GSK2445053
3260547|NCT01480271|Placebo Comparator|Part 1 Cohort 7 Placebo|Placebo
3260548|NCT01480271|Experimental|Part 1 Cohort 8 GSK2445053|4000ng GSK2445053
3260549|NCT01480271|Placebo Comparator|Part 1 Cohort 8 Placebo|Placebo
3260550|NCT01480310|Experimental|A|
3260551|NCT01480310|Experimental|B|
3260552|NCT01480323|Experimental|Ipilimumab|Ipilimumab i.v. + Interleukin-2 intratumoral
3260553|NCT01480336|Placebo Comparator|Amiodarone with Placebo|
3260554|NCT01480336|Active Comparator|Amiodarone with Ranolazine|
3260555|NCT01480362|Experimental|Negative Pressure Wound Therapy|The therapy involves the controlled application of sub-atmospheric pressure to the local wound environment,using a sealed wound dressing connected to a vacuum pump.
3260556|NCT01480362|Active Comparator|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
3260557|NCT01480375|Experimental|Navigo™ and Smartbx™ system.|all biopsy cores were handled using the Smartbx™ system. part of the procedures were performed with both Navigo™ and Smartbx™ system.
3260558|NCT01480375|No Intervention|standard method|all biopsy cores were handled using standard method - shaking the biopsy needle into formalin vial. no navigation system.
3260559|NCT01480388|Placebo Comparator|Placebo|
3260560|NCT01480388|Experimental|JNJ-39758979 (10 mg/d)|
3260561|NCT01480388|Experimental|JNJ-39758979 (30 mg/d)|
3260562|NCT01480388|Experimental|JNJ-39758979 (100 mg/d)|
3260563|NCT01480388|Experimental|JNJ-39758979 (300 mg/d)|
3260564|NCT01480401|Experimental|low-sodium diet|(1500 mg daily)
3260565|NCT01480401|No Intervention|moderate-sodium diet|sodium (100 mmol or 2300 mg daily; Usual Care)
3260566|NCT01480414|Experimental|4times injection|the patients with ischemic lower limb ulcer who underwent 4times stem cell injection.
3260567|NCT01480414|Experimental|one injection|Patients with peripheral artery disease underwent cell transplantation just one time.
3260568|NCT01480440||Trabecular Metal Reverse Shoulder System|Patients requiring primary or revision reverse total shoulder arthroplasty who receive the Trabecular Metal Reverse Shoulder System
3260569|NCT01480453||Trabecular Metal Humeral Stem|Patients requiring primary, total or hemi shoulder arthroplasty who receive the Trabecular Metal Humeral Stem.
3260570|NCT01480466|Experimental|Obesity tools in electronic health record|This arm will consist of a new set of tools within the electronic health record to help primary care clinicians address overweight and obesity with their patients.
3260571|NCT01480466|No Intervention|Standard care|This arm is standard care for overweight/obesity.
3260572|NCT01480479|Experimental|Rindopepimut/GM-CSF plus Temozolomide|
3260573|NCT01480479|Active Comparator|KLH plus Temozolomide|
3260574|NCT01480492|No Intervention|therapy|
3260575|NCT01480505||High myopic eye|Persons with high Myopia suffered from Rhegmatogenous Retinal detachment
3260576|NCT01480544|No Intervention|Mothers at endline|Data collected on new mothers (up to three weeks after childbirth) in 180 clusters with 100 mothers in each cluster at endline.
3260577|NCT01480544|Experimental|Treatment 1|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for clinical improvements in quality of maternity care in the providers' patient populations and the catchment areas served by the providers.
3260578|NCT01480544|Experimental|Treatment 2|Data collected on new mothers (up to three weeks after childbirth) and on providers with incentives for improvement in maternal and infant health outcomes in the providers' patient populations and in the catchment areas served by the providers.
3260579|NCT01480544|No Intervention|Control|Data collected on new mothers (up to three weeks after childbirth) and providers with no incentives
3260580|NCT01480557|Active Comparator|Liquefaction group|Subjects that were operated for cataract using liquefaction technology
3260581|NCT01480557|Active Comparator|Torsional ip group|Subjects that were operated for cataract using torsional ip technology
3260582|NCT01480583|Experimental|GRN1005|GRN1005 alone in HER2- MBC patients with brain mets. 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
3260583|NCT01480583|Experimental|GRN1005 with trastuzumab|GRN1005 in combination with trastuzumab in MBC patients with brain mets 18F-FLT may also be administered to this arm (if patient enrolled at NCI)
3260584|NCT01480609|Active Comparator|Dose-Dialysis|Subjects will be dosed with study drug followed by a scheduled dialysis session
3260585|NCT01480609|Active Comparator|Dialysis-Dose|Subjects will be dosed following the completion of their scheduled dialysis session
3260586|NCT01480622|Experimental|TDF tablets|Tenofovir disoproxil fumarate tablets
3260587|NCT01480635||Incomplete Colonoscopy|
3260588|NCT01480648|Experimental|BI144807|Subjects receive a single oral dose of BI144807solution
3260589|NCT01480648|Placebo Comparator|Placebo|Subjects receive a single oral dose of placebo solution
3260590|NCT01480661|Active Comparator|Roflumilast|
3260591|NCT01480661|Placebo Comparator|Placebo|
3260592|NCT01480687|Experimental|Omega-3 fatty acid|
3260593|NCT01480687|Active Comparator|Ciprofibrate|
3260594|NCT01480700|Experimental|rich-eggs|subjects consume 2 eggs rich in lutein/zeaxanthin and DHA per day during 4 months
3260595|NCT01480700|Active Comparator|standard eggs|subjects consume 2 standard eggs per day
3260596|NCT01480713|Experimental|Monotherapy with IPs+ Raltegravir 400 mg|Lopinavir/r 400/100 mg every 12 hours + Raltegravir 400 mg every 12 hours or Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
3260597|NCT01480726||Open vein harvest|Conventional open vein harvest from the lower leg
3260598|NCT01480726||Endoscopic vein harvest|Endoscopic vein harvest from the calf
3260599|NCT01480739|Experimental|1|AZD5069 100 mg capsules (50 mg BD) for 7 days
3260600|NCT01480739|Experimental|2|Placebo twice daily for 7 days
3260601|NCT01480752|Active Comparator|Lornoxicam|
3260602|NCT01480752|Placebo Comparator|normal saline|
3260603|NCT01480752|Placebo Comparator|no injection|
3260604|NCT01480765|Placebo Comparator|Control: Placebo + Placebo|Placebo capsules and Placebo infusion
3260605|NCT01480765|Active Comparator|Pregabalin and Placebo infusion|Pregabalin capsules and Placebo infusion
3260606|NCT01480765|Active Comparator|Pregabalin + Ketamine infusion|Pregabalin capsules + Ketamine infusion
3260607|NCT01480778|Experimental|LNG+EE2|pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
3260608|NCT01480778|Active Comparator|Nordette|pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
3260609|NCT01480791|Active Comparator|Hydrochlorothiazide|Treatment of patients with hydrochlorothiazide and effect on small arteries
3260610|NCT01480791|Experimental|Aliskiren|Treatment of patients with aliskiren and effect on small arteries
3260611|NCT01480791|No Intervention|Normotensive non diabetic subjects|A comparator non intervention normotensive non diabetic group of healthy subjects will be used for baseline comparison of primary and secondary endpoints
3260612|NCT01480804|Experimental|Geriatric diabetes team intervention group|The subjects in this group underwent evaluation for barriers to self care by a diabetes educators well versed with age specific barriers. After consideration of patients clinical, functional, and psychosocial background a geriatric diabetes team devised strategy to help patients cope respective barriers. A care manager then implemented the coping strategies by educating patients and caregivers. She also made home visits to assess any safety issues not know to clinic based geriatric team. She helped the patients and caregivers with all aspects of care coordination. Patients in this group received phone contact from care managers as many times as needed over the six month intervention period.
3260613|NCT01480804|No Intervention|Attention Control Group|The subjects in the group received similar, in person, contact as the intervention group. An educator, separate from the one involved in the intervention team, called patents in this group for a total of eleven time within the first six months. The phone calls were forces toward general discussion without any diabetes related advice.
3260614|NCT01480817|Active Comparator|Sorafenib|Sorafenib 400mg po bid
3260615|NCT01480817|Experimental|TACE for HCC with portal vein invasion|Antineoplastic agents are directly injected into the hepatic artery, allowing high intratumoral concentrations of drugs and thereby reducing systemic side effects. The mixture of chemotherapeutic agents and iodized oil is almost completely retained in neoplastic nodules and can remain in HCC tissue for a long time. Subsequent mechanical embolization of the artery feeding the neoplasm causes ischemic damage to the tumor and prolongs the duration of the effects of chemotherapeutic agents.
3260616|NCT01480830|No Intervention|Standard colonoscopy|
3260617|NCT01480830|Experimental|Magnetic endoscopic imaging colonoscopy|
3260618|NCT01480856|Active Comparator|Cobedding|Newborn twins are settled in a single bed : this is cobedding
3260619|NCT01480856|Placebo Comparator|Single -bedding|Newborn twins are settled in two beds : this is single-bedding
3260620|NCT01480869|Active Comparator|Conventional vitamin D and calcium supplementation|Conventional vitamin D and calcium supplementation with 2 daily OROCAL VITAMINE D3® (500 mg calcium/200 IU cholecalciferol) tablets.
3260621|NCT01480869|Experimental|vitamin D supplementation tailored to vitamin D deficiency|"Conventional calcium supplementation with 2 daily OROCAL 500® (500 mg calcium) tablets to suck + vitamin D3 supplementation (UVÉDOSE®, cholecalciferol, 100 000 IU drinkable solution, 2 ml vial) whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25OHD level < 30 ng/mL"
3260622|NCT01480882|Active Comparator|Conventional Chest PhysioTherapy|Conventional Chest Physiotherapy (CCPT) is delivered by professional physiotherapist for 15 minutes.
3260623|NCT01480882|Experimental|Mechanical percussion|"Mechanical percussion will be delivered by a device called LEGA for 15 minutes"
3260624|NCT01480895|No Intervention|Post GDM follow-up group.|
3260625|NCT01480895|Experimental|lifestyle intervention group.|The women in this group had participated in lifestyle intervention by diet instructions and physical exercise program.
3260626|NCT01480908|Experimental|VSD, +Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and have a postoperative right bundle branch block, about 20 patients
3260627|NCT01480908|Experimental|VSD, -Right bundle branch block|Patients undergone surgical closure of ventricular septal defect and does not have a postoperative right bundle branch block, about 20 patients
3260628|NCT01480908|Experimental|Control|Healthy control subjects, about 20 patients
3260629|NCT01480921|Experimental|home based exercise training|
3260630|NCT01480921|Active Comparator|supervised exercise training|
3260631|NCT01480934||Group:A-cases-Patients with a history of Diabetes Mellitus|(N=75 eyes). The inclusion criteria for group A: Diabetes mellitus was defined as glycosylated haemoglobin (Hb A1c ) levels of 6% or more , use of diabetic medication (oral hypoglycemic agents, insulin injection or diet restriction), or a physician's diagnosis of diabetes.
3260632|NCT01480934||Group - B:controls|Patients with uncomplicated age-related cataract who were otherwise healthy constituted the controls(Group:)B (n=75 eyes).
3260633|NCT01480947|Experimental|Bio-Three|add-on treatment of the probiotics (Bio-three)
3260634|NCT01480947|No Intervention|control treatment|control treatment (intravenous fluid, oral rice and half strength milk formula)
3260635|NCT01480960|Active Comparator|Whole body vibration training|Whole body vibration training in addition to pulmonary rehabilitation
3260636|NCT01480960|No Intervention|No whole body vibration training|Pulmonary rehabilitation without whole body vibration training
3260637|NCT01480973|Experimental|MRI post lung SBRT|Feasibility of MRI to differentiate between benign and malignant changes seen after lung SBRT.
3260638|NCT01480986|Experimental|Treatment arm|This is a single arm trial. The patient will enter phase one and will continue to phase two once the disease progresses in phase one or the phase one has been completed.
3260639|NCT01480999||Laparotomy (open surgery)|
3260640|NCT01480999||Laparoscopic surgery|
3260641|NCT01480999||Robotic assisted surgery|
3260642|NCT01481012||Group I: Cardiopulmonary Bypass + Heart Transplantation|CPB for orthotopic heart transplantation (excluding any patients with VADs)
3260643|NCT01481012||Group II: Cardiopulmonary Bypass + Pulsatile LVAD|CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
3260644|NCT01481012||Group III: Cardiopulmonary Bypass + Continuous Flow LVAD|CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
3260645|NCT01481012||Group IV: Cardiopulmonary Bypass + CABG Surgery|CPB for CABG surgery
3260646|NCT01481025|Experimental|Cimicifuga+Hiperico|80 + 450 mg / tablet
3260647|NCT01481025|Active Comparator|Cimicifuga Herbarium|80 mg / caps
3260648|NCT01481025|Active Comparator|Aplause®|20 mg / tablet
3260649|NCT01481038||Group dialysis patients|Patient on hemodialysis with central venous catheter
3260650|NCT01481038||Group hematology patients|Patients with hemato-oncologic underlying disease (plus/minus hematopoietic stem cell transplantation HSCT) and central venous catheter
3260651|NCT01481064|Active Comparator|Multifaceted approach|After baseline measurement a multifaceted approach will start for 1 year, including audit and feedback, an educational outreach visit, and patient-mediated interventions.
3260652|NCT01481064|No Intervention|Usual care|After baseline measurement no intervention will occur in these hospitals.
3260653|NCT01481077|Experimental|Treatment A|
3260654|NCT01481077|Experimental|Treatment B|
3260655|NCT01481077|Experimental|Treatment C|
3260656|NCT01481090|Active Comparator|Electro-Acupuncture|Group will receive 4 acupuncture treatments over 14 days during hormone treatment
3260657|NCT01481090|No Intervention|Control|Group will not receive acupuncture.
3260658|NCT01481103|Active Comparator|Acupuncture group|Participants will keep a headache diary for 4weeks and then attend eight weekly acupuncture sessions. Acupuncture will be done by a licensed acupuncturist and will last approximately 25 minutes. Following the acupuncture sessions, participants will keep a headache diary for an additional 4 weeks
3260659|NCT01481103|No Intervention|Control group|participants will be asked to maintain a daily diary of headache occurrences and OTC medication use for 16 weeks.
3260660|NCT01481142|Experimental|Adacolumn|
3260661|NCT01481168|Active Comparator|"Pacemaker on"|DDD+/-R pacing
3260662|NCT01481168|Placebo Comparator|"Pacemaker off"|ODO pacing
3260663|NCT01481168|Experimental|Implantable Loop Recorder|Implantable loop recorder in adenosine test negative patients
3260664|NCT01481181|Experimental|zinc enriched water|zinc enriched purified water at 2-6mg/l per day
3260665|NCT01481181|No Intervention|purified water only|non zinc enriched, purified drinking water
3260666|NCT01481181|No Intervention|control group|group of households receiving hygiene practice recommendations and water guard (water purifying solution)
3260667|NCT01481194|Experimental|ACVDL|ACVDL is a combination of doxorubicin, cyclophosphamide, bortezomib, dexamethasone, and lenalidomide
3260668|NCT01481207||neonates with perinatal asphyxia|neonates with suspected perinatal asphyxia (HIE)
3260669|NCT01481220|Experimental|Azacitidine + Eltrombopag|
3260670|NCT01481233|Experimental|Single arm|Colchicine 0.5 mg BID x 21 days
3260671|NCT01481246||Normal Aging/Cognitive Decline|Health adults as well as adults with MCI and early stage AD are being recruited in the study
3260672|NCT01481259|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every 21 days
3260673|NCT01481259|Active Comparator|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days
3260675|NCT01481285||healthy adults|The study will cover 992 healthy adults. 496 men and 496 women in an age range of 18 to 65 years are planned to be recruited.
3260676|NCT01481298||LVNC|12 patients with left ventricular non-compaction cardiomyopathy
3260677|NCT01481298||HCM|10 patients with hypertrophic cardiomyopathy
3260678|NCT01481298||DCM|11 patients with dilatative cardiomyopathy
3260679|NCT01481298||controls|24 healthy controls
3260680|NCT01481311||Patients before dialysis treatment|
3260681|NCT01481311||Patients after dialysis treatment|
3260682|NCT01481337||Polypectomy or mucosal endoscopic resection under aspirin|
3260683|NCT01481350|Experimental|Sildenafil|All patient will be treat with a intravenous administration of the drug from the beginning of the intervention, for a maximum of 72 hours.
3260684|NCT01481363|Active Comparator|Treatment as usual|Half of participants recruited will be randomly assigned to the control group to receive treatment as usual. This is will be based on a single one hour consultation which will include communication advice and information.
3260685|NCT01481363|Experimental|The Talking Sense treatment|Half of carer participants recruited will be randomly assigned to receive the Talking Sense treatment. This will be conducted one to one and individualised over 3 sessions and no more than 4.5 hours during no more than 8 weeks.
3260686|NCT01481389|Active Comparator|Theobromine drink|
3260687|NCT01481389|Active Comparator|Cocoa drink|
3260688|NCT01481389|Placebo Comparator|Placebo drink|
3260689|NCT01481389|Active Comparator|Cocoa and theobromine drink|
3260690|NCT01481402|Placebo Comparator|Placebo-liothyronine|3 months of placebo followed by 3 months of Liothyronine treatment.
3260691|NCT01481402|Other|Liothyronine-Placebo|3 months of Liothyronine treatment followed by 3 months of Placebo treatment.
3260692|NCT01481428|Active Comparator|Attention Control|
3260693|NCT01481428|Experimental|Computer-facilitated HIV intervention|
3260694|NCT01481441|Other|SonoVue|Ultrasound Contrast Agent
3260695|NCT01481454|Experimental|Group 1: QIV Lot 1|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
3260696|NCT01481454|Experimental|Group 2: QIV Lot 2|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
3260697|NCT01481454|Experimental|Group 3: QIV Lot 3|Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
3260698|NCT01481454|Active Comparator|Group 4: TIV|Participants will receive the Trivalent Influenza Vaccine (TIV).
3260699|NCT01481467|Experimental|Intervention|Influenza vaccination implementation strategy applied.
3260700|NCT01481467|No Intervention|Control|Usual care.
3260701|NCT01481480|Experimental|Latissimus dorsi tendon transfer|A Latissimus dorsi tendon transfer is performed
3260702|NCT01481480|Active Comparator|Arthroscopic repair|An arthroscopic repair is performed
3260703|NCT01481493|Experimental|Active Treatment|BT061 monoclonal antibody (subcutaneous)
3260704|NCT01481493|Placebo Comparator|Placebo|subcutaneous injection of placebo
3260705|NCT01481506|Experimental|Telemonitoring|
3260706|NCT01481506|No Intervention|Usual care|
3260707|NCT01481519|Active Comparator|dexamethasone 0.1%/povidone-iodine 0.4%|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
3260708|NCT01481519|Placebo Comparator|artificial tears|Patients were instructed to put one drop into each symptomatic eye four times daily for 7 days.
3260709|NCT01481532|Experimental|Cohort 3|The third cohort will include up to 18 patients with Crotoxin doses of 0.12 to 1.16 mg per m2 in which the dose escalation speed will be faster. Drug is administered over 48 hour intervals using ambulatory infusion pumps; treating on an outpatient basis. Subjects will receive increasing doses over the course of 35 treatment days (15 dose levels).
3260710|NCT01481571|Experimental|Vitrification media and device|Vitrification medium oocyte, warming medium oocyte and Rapid-i
3260711|NCT01481584|Experimental|Canola protein|Canola protein (Brassica juncea; incorporated in a drink)
3260712|NCT01481584|Active Comparator|Reference protein|Reference Protein (soy protein isolate; incorporated in a drink)
3260713|NCT01481584|No Intervention|Wash out|Wash out (four weeks without any intervention between interventional periods)
3260714|NCT01481584|No Intervention|Run-in|Run-in period (three days before intervention, defined diet)
3260715|NCT01481597|Experimental|deuteporfin 1mg/kg|
3260716|NCT01481597|Active Comparator|deuteporfin 2.5mg/kg|
3260717|NCT01481597|Active Comparator|deuteporfin 5mg/kg|
3260718|NCT01481597|Active Comparator|deuteporfin 7.5mg/kg|
3260719|NCT01481597|Placebo Comparator|placebo|
3260720|NCT01481610|Experimental|Lumiracoxib group|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day) for a period of maximum 10 days, but no shorter than 7 days.
3260721|NCT01481610|Active Comparator|Diclofenac group|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
3260722|NCT01481623|Other|Gene identification and phenotyping|Identification of patients (probands), questionnaire and informed consent of patients and their families, biological sampling, DNA and RNA extraction, genetic study for gene identification, re-contact of family members and relatives (with consent) for metabolic study of mutation carriers, and complementary studies of homozygous patients in some cases
3260723|NCT01481636||No treatment, OSA (AHI >15)|Patients with OSA recruited prior to receiving NHS treatment.
3260724|NCT01481649||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing hematopoietic stem cell transplantation (HSCT)
3260725|NCT01481662||retrospective|cases retrospectively reported the last 20 years
3260726|NCT01481662||Prospective|"Diffusion tensor magnetic resonance imaging of the brain:~new cases prospectively reported"
3260727|NCT01481675||BPDLL group|Patients subjected to the Biliopancreatic Diversion Long Limbs surgical operation will undergo an oral glucose tolerance preoperatively and 12 months after the operation
3260728|NCT01481675||LSG group|Patients subjected to laparoscopic sleeve gastrectomy will undergo an oral glucose tolerance test preoperatively and 12 months postoperatively
3260729|NCT01481688|No Intervention|Control|Routine haemodialysis sessions as per usual
3260730|NCT01481688|Experimental|Intradialytic exercise|One hour of exercise completed during haemodialysis.
3260731|NCT01481688|Active Comparator|Extra time|30 minutes extra dialysis time.
3260732|NCT01481701|Experimental|intravenous chemotherapy|treatment of ovarian carcinoma in relapse
3260733|NCT01481714|Active Comparator|Sodium Picosulphate preparation the day before|"Preparation the day before of the procedure using sodium picosulphate:~A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
3260734|NCT01481714|Experimental|Split-dose sodium picosulphate preparation|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
3260735|NCT01481727|Placebo Comparator|cpap sham|non invasive mechanical ventilation type cpap sham manoeuver
3260736|NCT01481727|Active Comparator|high-intensity NIMV|Non-invasive mechanical ventilation, biPAP modality, with high-intensity IPAP (>18cmH2O)
3260737|NCT01481753|Active Comparator|Braun arm|patients received Braun enteroenterostomy
3260738|NCT01481753|Active Comparator|Non Braun Arm|Patients do not receive a Braun enteroenterostomy
3260739|NCT01481766|Experimental|Iron plus dietary counseling (Non-anemic iron deficiency)|
3260740|NCT01481766|Placebo Comparator|Placebo plus dietary counseling (Non-anemic iron deficiency)|
3260741|NCT01481766|No Intervention|Iron sufficient|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
3260742|NCT01481766|Active Comparator|Iron deficiency anemia|From the screening cohort of it is anticipated that 25 children will have iron deficiency anemia and an equal number of randomly selected children with iron sufficiency (n=25) will be sampled. These children will be compared to the children with non-anemic iron deficiency.
3260743|NCT01481805||Hepatocellular carcinoma patients treated with sorafenib|
3260744|NCT01481818|Experimental|radioprotector|
3260745|NCT01481831|Active Comparator|H PALO day 1|Highly Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
3260746|NCT01481831|Experimental|H PALO day 1,3,5|Highly Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
3260747|NCT01481831|Active Comparator|M PALO day 1|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*1 dose on day 1
3260748|NCT01481831|Experimental|M PALO day 1,3,5|Moderately Emetogenic Arm, Palonosetron 0.25mg IV*3 doses on days 1,3 and 5
3260749|NCT01481844|Experimental|sequential treatment|1.drugs experimental-Sequential -PPI( Lansoprazole 30mg x2/day) + amoxicillin 1gx2/day for 5days, followed by 5 days of PPI(Lansoprazole 30mg x2/day) + ( Clarithromycin500mg x2/day and Tinidazole 500mg x2/day )
3260750|NCT01481844|Active Comparator|quadruple therapy|Quadruple drug regimen (i.e.-14 days of PPI (Lansoprazole 30mg x2/day) + Bismuth Subsalicylate 525mg X4/day + Metronidazole 500mg x3/day + Tetracycline 500mg x4/day )-is standard of care as second line treatment in eradication of H pylori
3260751|NCT01481857|Experimental|Thoracolumbar proprioception|
3260752|NCT01481857|Experimental|Segmental Stabilization|
3260753|NCT01481870|Active Comparator|Sorafenib-sunitinib|Sorafenib is first line treatment followed by sunitinib.
3260754|NCT01481870|Active Comparator|Sunitinib-sorafenib|Sunitinib is first line treatment followed by sorafenib.
3260755|NCT01481883|Experimental|Raloxifene Hydrochloride 120mg oral per day|120mg raloxifene plus antipsychotic drug
3260756|NCT01481883|Placebo Comparator|Placebo tablet - one per day|Lactose pill plus antipsychotic medication
3260757|NCT01481909|Placebo Comparator|Sugar Pill|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
3260758|NCT01481909|Active Comparator|Rupafin|All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
3260759|NCT01481922|Active Comparator|Whitacre 22 gauge|lumbar puncture performed with a Whitacre 22 gauge (BD)
3260760|NCT01481922|Experimental|Whitacre 24 gauge|lumbar puncture performed with a Whitacre 24 gauge (BD)
3260761|NCT01481948|Experimental|story plus behaviorial procedures|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will also engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
3260762|NCT01481948|Active Comparator|story only|The girls randomized to this arm of the study will view an interactive story about 6 8-10 year old African American girls who seek to find clues to solve a mystery about the town in which they live. The episodes will contain information about healthy nutrition and physical activity, as well as basic information about physical activity and kitchen safety tips, developmentally appropriate recipes, and portion sizes. Girls randomized to this arm of the study will not engage in key behavior change procedures, such as goal setting, problem solving, and self monitoring.
3260763|NCT01481948|No Intervention|Wait list control|This group will participate in data collection only; after the 3rd data collection point, they will be given access to the intervention
3260764|NCT01481961|Experimental|rTMS arm|
3260765|NCT01481974|Experimental|Treprostinil|This is a single center, open-label, dose-escalation Phase I/II study of Treprostinil.
3260766|NCT01481987|Experimental|Epiretinal Membrane|The investigators prospectively included 49 eyes of 49 patients with idiopathic ERM for which surgical treatment had been planned.
3260767|NCT01481987|No Intervention|Control|Subjects with normal visual acuity and OCT profile
3260768|NCT01482000|Experimental|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
3260769|NCT01482000|Active Comparator|Control|The control group will get the usual care with some additional tests for the study.
3260770|NCT01482013|Experimental|HPP854|Oral HPP854 once a day for 28 days.
3260771|NCT01482013|Placebo Comparator|Placebo|Oral, placebo once a day for 28 days.
3376228|NCT01599520|Active Comparator|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
3376229|NCT01568723||Radiofrequency ablation|participants with barrett's esophagus with high grade dysplasia who undergo radiofrequency ablation (RFA)
3376233|NCT01398839|Sham Comparator|Sham Control|
3376234|NCT01398839|Experimental|CXL Treatment|
3376235|NCT01374360||Receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are receiving Soliris or Ultomiris
3376236|NCT01374360||Not receiving Soliris or Ultomiris|PNH patients of any age, including minors, that are not receiving Soliris or Ultomiris
3376237|NCT01349959|Experimental|Treatment (entinostat and azacitidine)|Patients receive azacitidine SC on days 1-5 and 8-10, and entinostat PO on days 3 and 10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease may continue azacitidine and entinostat in combination with hormonal therapy, at treating physician discretion, or undergo event monitoring.
3376238|NCT01331018|Experimental|Treatment (hematopoietic stem progenitor cells)|"STEM CELL MOBILIZATION FOR CELL COLLECTION: Patients receive filgrastim SC BID for up to 6 days (on days 1-6 of mobilization). Patients receive plerixafor SC QD on days 4-6 of mobilization. PBSC count will be checked daily starting on day 4 of mobilization. Patients who have a PBSC count of >= 5 CD34+ cells/mcL will undergo up to 2 apheresis collections on consecutive days.~BONE MARROW HARVEST FOR CELL COLLECTION: Patients with inadequate PBSC counts undergo bone marrow harvest for collection of stem/progenitor cells.~REINFUSION: Patients receive methylprednisolone IV or prednisone PO on days -1 to 7 followed by a rapid taper over approximately 1 week and undergo reinfusion of genetically modified hematopoietic stem/progenitor cells on day 0."
3260772|NCT01482026|Experimental|Treated patients|Patients for whom ADHD treatment is introduced at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
3260773|NCT01482026|Experimental|Non treated patients|Patients for whom no ADHD treatment is required at enrolment. Evolution of the ADHD Rating Scale-IV inattention subscore
3260774|NCT01482039|No Intervention|Standard Ultrasound|Current standard of care - one abdominal view of the cervix to rule out placenta previa
3260775|NCT01482039|Experimental|Sequential Screen|Start with 3 abdominal views of the cervix with measurement. If 3 adequate views cannot be obtained, or if measurement is less than 3cm, then will perform transvaginal scan for measurement.
3376239|NCT01327781|Experimental|Treatment (Z-endoxifen hydrochloride)|Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3376240|NCT01281176|Experimental|Arm I (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive high-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3 of all subsequent courses.
3260776|NCT01482039|Experimental|Screening Transvaginal Ultrasound|Obtain 3 adequate cervical length measurements using transvaginal ultrasound
3260777|NCT01482052|Experimental|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate vaccine
3260778|NCT01482052|Active Comparator|US Licensed Vaccine|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
3376241|NCT01281176|Experimental|Arm II (high- and low-dose vorinostat and carboplatin)|Patients receive high-dose vorinostat and low-dose vorinostat as in Arm I. After 5 days, patients receive lower-dose vorinostat PO QD on days 1-3 and carboplatin IV over 30 minutes on day 3.
3376242|NCT01281176|Experimental|Arm III (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat PO QD on days 1-3 and high-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive vorinostat and carboplatin as in Arm I.
3376243|NCT01281176|Experimental|Arm IV (low- and high-dose vorinostat and carboplatin)|Patients receive low-dose vorinostat and high-dose vorinostat as in Arm III. After 5 days, patients receive vorinostat and carboplatin as in Arm II.
3376244|NCT01281176|Experimental|Arm V (low- and mid-dose vorinostat and paclitaxel)|Patients receive low-dose vorinostat PO QD on days 1-3 and mid-dose vorinostat PO QD on days 8-10 (course 0). After 5 days, patients receive mid-dose vorinostat PO QD on days 1-3 and paclitaxel IV over 3 hours on day 3.
3376245|NCT01281176|Experimental|Arm VI (mid- and low-dose vorinostat and paclitaxel)|Patients receive mid-dose vorinostat PO QD on days 1-3 and low-dose vorinostat PO QD on days 8-10. After 5 days, patients receive vorinostat and paclitaxel as in Arm V.
3260779|NCT01482078||Receive MgSO4 infusion|Parturients who present to the hospital at less than 34 weeks gestational age with potential pre-term labor, pre-term rupture of membranes or intrauterine growth restriction
3260780|NCT01482078||Do not receive MgSO4 infusion|"We will approach a control group of subjects: i.e. parturients undergoing cesarean section (elective or emergency) with neuraxial anesthesia.~We will seek to ensure that the control group is similar to the study group with respect to the following parameters:~Number of singleton or multiple pregnancy~Parity of parturients~Anesthetic technique (spinal or epidural)~Time of cesarean section (08:00-19:59 or 20:00 to 07:59) Once informed consent is obtained these subjects will be treated identically to the study group in terms of anesthetic management and data collection."
3260781|NCT01482104|Experimental|MAL-PDT re-treatment|1 treatment of MAL-PDT with re-treatment of non-complete responders
3260782|NCT01482104|Active Comparator|usual MAL-PDT|2 MAL-PDT treatments 1 week apart
3260783|NCT01482117|Active Comparator|Clopidogrel|single oral administration of 300mg of clopidogrel
3260784|NCT01482117|Active Comparator|Cilostarole|single oral administration of 100mg of cilostazole
3260785|NCT01482117|Active Comparator|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
3260786|NCT01482130|Experimental|Training group|All participants in the training group will pursue a 12 weeks of strength training.
3260787|NCT01482130|Other|Controls|The control group will be encouraged to follow a training program according to recommended exercise guidelines
3260788|NCT01482143|Experimental|All Study subjects|
3260789|NCT01482156|Experimental|RAD001 + BEZ235|Patients will receive first dose of RAD001 at 2.5mg/5mg/10 mg weekly or 2.5mg/5mg daily in combination of BEZ235 at 50 mg/100 mg/200 mg/300 mg/400 mg twice a day. In the initial cohort of the dose finding phase, patients will receive a single 2.5 mg dose of RAD001 on Cycle 1 Day 1 and the combination therapy of RAD001 2.5 mg/week and BEZ235 200 mg bid starting on Cycle 1 Day 8. Dose escalation phase: patients will start RAD001 and BEZ235 on Cycle 1 Day 1 with both study drugs being administered at the center. Dose expansion phase: the first 15 patients enrolled at selected sites will take RAD001 as monotherapy from Day 1 to Day 7 (for PK sampling). The combination therapy of RAD001 and BEZ235 will start on Day 8. All remaining patients will receive the combination therapy of RAD001 and BEZ235 starting on Cycle 1 Day 1.
3260790|NCT01482234|Experimental|pedometers only|Participants randomized to this arm will receive pedometers only. They will participate in baseline and 3 months data collection.
3260791|NCT01482234|Experimental|pedometers + prompts|Participants randomized to this arm will receive pedometers plus a weekly prompt to set a step goal. They will participate in baseline and 3 months data collection.
3260792|NCT01482234|Experimental|pedometer + prompt + messages|Participants randomized to this arm will receive pedometers, weekly prompts, and 6 motivational text messages a week. They will participate in baseline and 3 months data collection.
3260793|NCT01482234|No Intervention|Control|Participants randomized to this group will participate in data collection only; they will not receive an intervention.
3260794|NCT01482247|Active Comparator|L-arginine|
3260795|NCT01482247|Placebo Comparator|Placebo Supplement|
3260796|NCT01482260||Primary Cutaneous Malignant Melanoma|
3260797|NCT01482260||Cutaneous Malignant Melanoma Metastases|
3260798|NCT01482260||Benign Melanocytic Nevi|
3260799|NCT01482273|Active Comparator|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
3260800|NCT01482273|Active Comparator|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
3260801|NCT01482286|Experimental|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
3260802|NCT01482286|Experimental|Dietary Restriction|Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
3260803|NCT01482286|Experimental|Exercise|Subjects randomized to the exercise training group will complete a structured program of aerobic training 3 to 4 times per week and resistance exercises 2 times per week.
3260804|NCT01482286|No Intervention|Control|Subjects randomized to the no treatment control group will be asked to continue, as normal their usual dietary and exercise regimen. Subjects will be asked to not begin diet or exercise regimens through the 24-week study or to begin medical treatment for PCOS.
3260805|NCT01482299|Experimental|RAD001 (everolimus)|
3260806|NCT01482338|Experimental|DSG|The low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
3260807|NCT01482338|Active Comparator|DRSP|The other low-dose oral contraceptive pill which consists of 20 microgram ethinyl estradiol and 3 mg drospirenone were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
3260808|NCT01482364|Experimental|HOTMAN-driven therapeutic approach arm|"Hotman-driven therapeutic approach arm(group IHM) will receive treatment according to the results of the HOTMAN® System."
3260809|NCT01482364|Placebo Comparator|Control arm|Control arm will receive usual antihypertensive care according to the 2007 ESH Guidelines.
3260810|NCT01482377|Experimental|Part A: RO5479599 Dose Escalation|Participants will receive a dose of 100 milligrams (mg) RO5479599 followed by dose escalation from Day 1 of Cycle 1. RO5479599 dose will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%) until MTD.
3260811|NCT01482377|Experimental|Part B: RO5479599 Dose Escalation + Cetuximab|Participants will receive RO5479599 in combination with cetuximab. Escalation of RO5479599 in combination with cetuximab will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of cetuximab and lower doses of RO5479599.
3260812|NCT01482377|Experimental|Part C: RO5479599 Dose Escalation + Erlotinib|Participants will receive RO5479599 in combination with erlotinib. Escalation of RO5479599 in combination with erlotinib will start in a standard 3+3 design until MTD/OBD is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of erlotinib and lower doses of RO5479599.
3260813|NCT01482377|Experimental|Imaging (IMG) Substudy|RO5479599 will be administered with zirconium- 89-labeled RO5479599.
3260814|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (24 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV (total treatment duration of 24 weeks).
3260815|NCT01482390|Experimental|TVR (12 Weeks), MCB (24 Weeks), PEG-IFN/RBV (48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with MCB and PEG-IFN/RBV and then 12 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3260816|NCT01482390|Experimental|TVR, MCB, Placebo MCB( each for 12Weeks),PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with MCB, TVR, and PEG-IFN/RBV, followed by 12 weeks of therapy with placebo matching to MCB and PEG-IFN/RBV, and then 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3260817|NCT01482390|Active Comparator|TVR(12 Weeks), Placebo MCB (24 Weeks), PEG-IFN/RBV(48 Weeks)|Twelve weeks of therapy with placebo matching to MCB, TVR, PEG-IFN/RBV, will be followed by 12 weeks of therapy with placebo matching to MCB along with PEG-IFN/RBV , following 24 weeks of therapy with PEG-IFN/RBV (total treatment duration of 48 weeks).
3260818|NCT01482403|Experimental|Treatment Arm A|24 weeks of therapy with mericitabine 1000 mg twice a day (BID), boceprevir 800 mg three times daily (TID), Pegasys 180 microgram/week, and Copegus 1000/1200 mg/day (total treatment duration of 24 weeks), followed by a 24-week treatment-free follow-up period.
3260819|NCT01482403|Experimental|Treatment Arm B|24 weeks of therapy with mericitabine + boceprevir + Pegasys/Copegus followed by 24 weeks of therapy with boceprevir + Pegasys/Copegus (triple) (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
3260820|NCT01482403|Active Comparator|Treatment Arm C (Control)|4 weeks of therapy with mericitabine placebo, boceprevir placebo + Pegasys/Copegus, then 20 weeks of therapy with mericitabine placebo + boceprevir + Pegasys/Copegus, then 24 weeks of therapy with boceprevir + Pegasys/Copegus (total treatment duration of 48 weeks), followed by a 24-week treatment-free follow-up period.
3260821|NCT01482416|Experimental|Estrogen use|climacteric women will use conjugated equine estrogens
3260822|NCT01482416|Placebo Comparator|use of Placebo|climacteric women will use placebo
3260823|NCT01482442|Active Comparator|sorafenib group|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
3260824|NCT01482442|Active Comparator|radioembolization group|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
3260825|NCT01482455|Placebo Comparator|Clamp/Glycerol|"Glycerol infusion (glycerol in 0.9% saline provided by the pharmacy of the Vienna General Hospital, will be applied at a rate of 0.7 mg.kg-1.min-1) in order to match the lipid-induced rise in serum glycerol concentrations in the same experimental setting. 0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
3260826|NCT01482455|Active Comparator|OGTT/Lipid|On study-day 1, four hours after start of a triglyceride/heparin infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
3260827|NCT01482455|Placebo Comparator|OGTT/Glycerol|On study-day 2, four hours after start of a glycerol infusion an oral glucose tolerance test (OGTT, 75g glucose dissolved in 300ml flavoured water) will be performed (240-420 min).
3260828|NCT01482455|Active Comparator|Clamp/Lipid|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1. After two hours, a hyperinsulinemic-euglycemic clamp (Actrapid, Novo Nordisk, Bagsvaerd, Denmark; 40 mU.m-2 body surface area min-1) test will be commenced (120-240 min)."
3260829|NCT01482468|Active Comparator|continuous infusion|continuous infusion of palonosetron added to prophylactic single injection of palonosetron
3260830|NCT01482468|Placebo Comparator|singel injection|continuous infusion of normal saline added to prophylactic single injection of palonosetron
3260831|NCT01482494||Pompe suspected patients|"Patients who go to an Internal Medicine clinic for examination of a limb-girdle myopathy.~Patients with asymptomatic hyper-CK-emia. Patients with a prior diagnosis of polymyositis. Patients with a myopathy of uncertain origin and respiratory insufficiency. Patients with polymyositis unresponsive to steroid therapy"
3260832|NCT01482520||Renal cell carcinoma|
3260833|NCT01482520||Hepatocellular carcinoma patients|
3260834|NCT01482533||Revision Total Hip Arthroplasty|
3260835|NCT01482533||Revision Total Knee Arthroplasty|
3260836|NCT01482546||Water Colonoscopy Method|As first described by Dr. Felix W. Leung, the maneuvers can be summarized as warm water infusion in lieu of air insufflation combined with suction removal of all residual colonic air and residual feces by water exchange. The air pump will be turned off before insertion of the colonoscope into the rectum to avoid accidental insufflation of air. Warm water (at 36-37ºC) maintained using a water bath and heat saver envelop will be infused intermittently. The minimum amount of water needed to distend the colon and open the lumen will be used during scope insertion. Cecal intubation will be suggested by appropriate movement of the endoscopic image on the monitor screen when the right lower quadrant is palpated or the appendiceal orifice visualized under water. The cecum will then be distended by air to confirm visualization of the ileocecal valve and appendiceal orifice. No specific limit will be set for the volume of water to be used.
3260837|NCT01482546||Air Colonoscopy Method|The minimal amount of air will be used during insertion to open the lumen. Minimal amounts of water (10 to 50 mL) at room temperature will be used for washing of residual feces. If insertion is hindered by scope looping, attempts at loop reduction will be made. If advancement does not occur within 3 to 5 minutes, an assistant will provide abdominal compression, followed by changing the patient's position to facilitate passage of the colonoscope. Cecal intubation will be suggested by identification of the appendiceal orifice and ileocecal valve or intubation of the terminal ileum.
3260838|NCT01482559|Placebo Comparator|dextrose 5%|IV Infusion
3260839|NCT01482559|Experimental|Dopamine Hydrochloride|IV Infusion
3260840|NCT01482572||Gene profiling Success|
3260841|NCT01482585||early stage lung adenocarcinoma|
3260842|NCT01482611|Experimental|Panel 1: Caucasian|10, 75 and 300 mg JNJ-47910382 or placebo
3260843|NCT01482611|Experimental|Panel 2: Caucasian|30, 150, 600 mg JNJ-47910382 or placebo
3260844|NCT01482611|Experimental|Panel 3: Japanese|Session VIII and X: Doses of JNJ-47910382 or placebo to be determined
3260845|NCT01482611|Experimental|Panel 4: Japanese|Session IX: Dose of JNJ-47910382 or placebo to be determined
3260846|NCT01482624|Active Comparator|VISCOSEAL® SYRINGE|
3260847|NCT01482624|Other|Standard arthroscopic meniscal surgery|
3260848|NCT01482637||CAS|There are no separate groups. All subjects are being asked to complete the CAS measure.
3260849|NCT01482650|Experimental|Baska mask|
3260850|NCT01482650|Active Comparator|single use laryngeal mask airway (LMA)|
3260851|NCT01482663|No Intervention|Chronic hand eczema patients|Written information sheets and a 14-minutes DVD about hand eczema handed out by the dermatologist
3260852|NCT01482663|Experimental|Behavioral: Healthy Skin Clinic|1-2 counselling sessions with a nurse, tailored according to individual risks and resources and user access to a website comprising a self-monitoring log, a patients' forum and the possibility of communication with the intervention team of nurses
3260853|NCT01482676||1|controls (normal bladder function)
3260854|NCT01482676||2|acontractile bladder
3260855|NCT01482676||3|overactive bladder
3260856|NCT01482676||4|bladder pain syndrome
3260857|NCT01482689|Experimental|Fish oil capsule|
3260858|NCT01482689|Experimental|Multivitamin tablet|
3260859|NCT01482702|Experimental|weight loss intervention|Behavioral weight loss intervention
3260860|NCT01482702|Experimental|Weight Loss plus Resistance Training|Behavioral weight loss intervention with the addition of resistance training
3260861|NCT01482702|Active Comparator|Comparator|Group of women who did not receive chemotherapy
3260862|NCT01482741||Pts undergoing chemotherapy for Stage IV colorectal carcinoma|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260863|NCT01482741||Parents of pediatric patients stage 1-3 neuroblastoma|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260864|NCT01482741||Women who have undergone tx for early stage breast cancer|within the preceding 6 months. Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260865|NCT01482741||Men undergoing surveillance imaging after tx for testicular ca|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260866|NCT01482741||Men & women enrolled in the MSKCC lung ca screening program|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260867|NCT01482741||Men and women enrolled in the thoracic survivorship|Six focus groups of 7-9 participants each will be conducted for approximately 90 minutes according to the established methodology of Krueger and Casey. Focus group sessions are semi-structured group interviews in which previously chosen, open-ended questions about topics of interest are posed to participants by a trained moderator.
3260868|NCT01482754|Experimental|Rituximab Infusion at 90-minutes|
3260869|NCT01482780|Experimental|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion), a special coronary sinus catheter will be introduced after induction of anaesthesia until going on bypass.
3260870|NCT01482780|No Intervention|Control|normal procedure of preparing Bypass grafts. Equivalent time before going on Bypass is determined as control period
3260871|NCT01482793|Active Comparator|AVAMAX|Avamax vertebroplasty kits provided by Care Fusion
3260872|NCT01482793|No Intervention|Simulated injection procedure|Patient will be unaware as to whether the control procedure or vertebroplasty had been performed since full sterile preparation, sedation and simulated injection procedure will be used.
3260873|NCT01482806|Experimental|Computerized CBT + Internet Support Group|Guided patient access to Beating the Blues plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants (CCBT+ISG; N=300).
3260874|NCT01482806|Experimental|Computerized CBT Alone|Guided patient access to Beating the Blues, a proven-effective, on-line 8-session CCBT program approved for use in the United Kingdom (CCBT-alone; N=300).
3260875|NCT01482806|No Intervention|Usual Care|"Primary care physicians' usual care for mood and anxiety disorders (UC; N=100)."
3260876|NCT01482832|Experimental|Experimental|Behavioral: Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
3260877|NCT01482832|Active Comparator|Control|Behavioral: Standard care Participants assigned to receive standard care will focus on prenatal education including issues associated with pregnancy and postpartum. Both groups will attend 5 weekly sessions and have a brief booster session postpartum.
3260878|NCT01482845|Experimental|Group 1|
3260879|NCT01482845|Experimental|Group 2|
3260880|NCT01482858|Experimental|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
3260881|NCT01482858|Placebo Comparator|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
3260882|NCT01482871|Experimental|Arm 1.5 mg ALG-1001|Group Using 1.5 mg per 100 ul of ALG-1001
3260883|NCT01482871|Experimental|Arm 2.5 mg ALG-1001|Group Using 2.5 mg per 100 ul of ALG-1001
3260884|NCT01482871|Experimental|Arm 5.0 mg ALG-1001|Group Using 5.0 mg per 100 ul of ALG-1001
3260885|NCT01482871|Experimental|Arm 7.5 mg ALG-1001|Group Using 7.5 mg per 100 ul of ALG-1001
3260886|NCT01482897|Experimental|corticoïd|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
3260887|NCT01482897|Placebo Comparator|physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
3260888|NCT01482897|Sham Comparator|feigning of peridural infiltration|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
3260889|NCT01482897|No Intervention|no intervention|natural evolution of discal sciatica
3260890|NCT01482923||Treatment As Usual (TAU)|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
3260891|NCT01482923||Aspiration, Inspiration Respiration, or AIR|This study is a pilot intervention trial examining the feasibility of a motivational smoking cessation intervention using respiratory biomarker feedback in low income PLWHA. The plan is to recruit a pilot sample of 50 eligible and consented participants, randomized at a 1:1 ratio into either the Treatment As Usual (TAU) condition or the experimental (Aspiration, Inspiration Respiration, or AIR) intervention condition.
3260892|NCT01482936|Experimental|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg
3260893|NCT01482949|Experimental|AGS-003 in combination with sunitinib|Subjects will undergo Induction (AGS-003 every 3 weeks until 5 doses are administered) followed by Booster (AGS-003 at 3 month intervals). Subjects that will begin sunitinib therapy will be on this arm.
3260894|NCT01482975|Experimental|Smoking and Alcohol Prevention|TTM expert system
3260895|NCT01482975|Active Comparator|Diet and Exercise|TTM expert system
3260896|NCT01482988||Critical care patients antipated to stay more than 72 hours|
3260897|NCT01483001|Experimental|Sensitivity Assay|Patients treated with a treatment chosen by sensitivity assay in vitro
3260898|NCT01483014|Experimental|imatinib|
3260899|NCT01483027|Experimental|Treatment group|Standard of care second-line chemotherapy plus TheraSphere
3260900|NCT01483027|No Intervention|Control group|Standard of care second-line chemotherapy with no added therapy
3260901|NCT01483053|Active Comparator|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
3260902|NCT01483053|Active Comparator|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
3260903|NCT01483066|Experimental|ShapeMatch Instrumentation|
3260904|NCT01483066|Active Comparator|Usual Instrumentation|
3260905|NCT01483079||Former preterm infants|A cohort of infants less than or equal to 1250 grams birth weight that received donor human milk products in the NICU will be recruited and followed. Some infants recruited will be from a previously studied population of very low birth weight infants receiving donor human milk products in the NICU at Texas Children's Hospital.
3260906|NCT01483092|Experimental|inulin|
3260907|NCT01483092|Placebo Comparator|maltodextrin|
3260908|NCT01483105|Experimental|DVD self-hypnosis|This group will receive standard care, and parents/children in this group will receive in the mail a set of questionnaires and the DVD self-hypnosis training program. Parents will be asked to review these materials and practice the training at home with their children for one week leading up to the procedure Parents will also be asked to try to use these techniques with their child during his or her upcoming VCUG procedure.
3260909|NCT01483105|No Intervention|Standard care|Children in this arm will receive standard care and parents/children will be mailed a set of questionnaires to complete before and after your child's upcoming VCUG.
3260910|NCT01483131|Experimental|Low intensity resistance training|
3260911|NCT01483131|Experimental|High intensity resistance training|
3260912|NCT01483131|Experimental|Low intensity resistance training with vascular occlusion|
3260913|NCT01483157|Experimental|low intensity with vascular occlusion|
3260914|NCT01483157|Experimental|high intensity resistance training|
3260915|NCT01483157|No Intervention|no exercise training|
3260916|NCT01483170|Experimental|Fexinidazole|
3260917|NCT01483170|Placebo Comparator|Placebo fexinidazole|
3260918|NCT01483196|Experimental|Diagnostic (TCD)|Patients undergo TCD examination including bilateral evaluation of standard intracranial arterial segments including the M1 and M2 segments of the MCA, the ACA and PCA, via the transtemporal acoustic windows, the ICA siphon via transorbital approach, and the vertebral and basilar arteries (proximal, mid, and distal) via the suboccipital approach. Patients also undergo MRI. All tests occur between 21 days after completion of surgery and up to 30 days prior to adjuvant chemotherapy and between 20-60 days after completion of adjuvant chemotherapy.
3260919|NCT01483222|Experimental|QUIKDRAW Pro|Wearing an inelastic lumbar support for 6 months
3260920|NCT01483222|Experimental|MUELLER 4581|Wearing an elastic lumbar support for 6 months
3260921|NCT01483222|No Intervention|Blank Control|Receiving no intervention
3260922|NCT01483235|Experimental|Reduced cardiac rehabilitation (rCRP)|The rCRP is the intervention group, compared to the standard cardiac rehabilitation program group (sCRP). The rCRP will have the core elements of the sCRP, that is, in-hospital exercise sessions, dietary counseling, educational sessions, follow-up with the cardiologist, dietician and exercise specialist. The only difference will be the number of in-hospital exercise sessions (10 sessions for the rCRP v/s 32 sessions for the sCRP). Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
3260923|NCT01483235|Active Comparator|Standard cardiac rehabilitation (sCRP)|The standard cardiac rehabilitation (sCRP) follows the standard cardiac rehabilitation program model of a four-month period. Patients receive an initial intake evaluation by a cardiologist, nurse, exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counseling, medical care, psychological screening and smoking cessation if needed.
3260924|NCT01483248|Experimental|Intervention|Conventional therapy plus MenSCs treatment
3260925|NCT01483248|Active Comparator|No intervention|"Conventional therapy plus placebo treatment:~Oral or intravenous administration"
3260926|NCT01483261|Experimental|Trauma-Focused Cognitive Behavioral Therapy|
3260927|NCT01483261|No Intervention|Waiting List Control|
3260928|NCT01483274|Experimental|Safety|Decitabine and donor lymphocyte infused dendritic cell (DC).
3260929|NCT01483274|Active Comparator|Vaccine|Decitabine and Dendritic cell (DC) pulsed with MAGE-A1, MAGE-A3, NY-ESO-1 Peptides
3260930|NCT01483287|Active Comparator|Enzyme|Capsules with alpha-galactosidase (enzyme) (400 GaIU x 3) are ingested at breakfast, lunch and dinner.
3260931|NCT01483287|Placebo Comparator|Placebo|3 capsules with a non-active substance are ingested at breakfast, lunch and dinner
3260932|NCT01483300|Experimental|lobaplatin|gemcitabine plus lobaplatin
3260933|NCT01483300|Active Comparator|cisplatin|gemcitabine plus cisplatin
3260934|NCT01483326||Cohort|
3260935|NCT01483339|Experimental|Metacognitive Therapy|
3260936|NCT01483339|Experimental|Exposure and Response Prevention|
3260937|NCT01483391|Active Comparator|Enhanced Care|Three sessions of family education and three sessions of individual support over 4 months.
3260938|NCT01483391|Experimental|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training.
3260939|NCT01483404||Patient with fracture of femural neck|All patient with fracture of the femural neck in the listed period of time
3260940|NCT01483417|Experimental|SILS|Laparoscopic hysterectomy including LAVH, LH(a), and TLH using SILS port
3260941|NCT01483417|Active Comparator|Conventional multi-port laparoscopic hysterectomy|3-4 ports laparoscopic hysterectomy including LAVH, LH(a), or TLH
3260942|NCT01483430|Placebo Comparator|Placebo|
3260943|NCT01483430|Experimental|Ginseol Kg1, high dose|
3260944|NCT01483430|Experimental|Ginseol Kg1, low dose|
3260945|NCT01483443|Experimental|Oophrectomy group|Patient undergone oophrectomy along with primary tumor
3260946|NCT01483443|No Intervention|without oophrectomy|Patient group without oophrectomy
3260947|NCT01483456|Other|Usual care|
3260948|NCT01483469|Active Comparator|Concept Proof|
3260949|NCT01483469|Experimental|Receptor Occupancy|
3260950|NCT01483482|Other|Conservative treatment|"The group allocated to conservative treatment is treated with a simple sling. The sling is removed when the patient is pain free.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
3260951|NCT01483482|Other|Surgical treatment|"Patients allocated to surgical treatment are operated with a superior locking plate.~The first 6 weeks max 1 kg of weight-bearing is allowed and the patient is instructed to restrict movement of the arm to the level of the shoulder."
3260952|NCT01483495||Diagnostic tool|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
3260953|NCT01483508|Active Comparator|Flavanol and procyanidins|
3260954|NCT01483508|Experimental|Flavanols only|
3260955|NCT01483508|Experimental|Procyanidins only|
3260956|NCT01483521|Experimental|Waitlist families|"Experimental arm consisted of randomized waitlist families who received home visitation where mothers were taught to play with their children in a developmentally appropriate manner and also engaged in a co-construction task.~Control arm families did not get any active intervention. Parents from both arm types completed pre and post questionnaires to measure child's externalizing behaviors and parenting stress.~Parents from experimental group were encouraged to keep a diary of their play record."
3260957|NCT01483534|Experimental|Targeted Lung Denervation|Targeted Lung Denervation
3260958|NCT01483547||Neurosurgical|
3260959|NCT01483547||Non-neurosurgical|
3260960|NCT01483573|Experimental|straight leg raise|stretch the muscle
3260961|NCT01483573|Experimental|neural mobilization|stretch the nerve
3260962|NCT01483586|Experimental|KLTc high dose|6 KLTc gelcaps taken four times a day
3260963|NCT01483586|Experimental|KLTc low dose|3 KLTc gelcaps taken four times a day
3260964|NCT01483612|Experimental|Lifestyle counseling|
3260965|NCT01483612|No Intervention|control|
3260966|NCT01483638|Experimental|Experimental|axitinib
3260967|NCT01483638|Placebo Comparator|control|placebo
3260970|NCT01483677|Experimental|Nintendo Wii|Subjects in this arm of the study play a game (Boomblox) on the Nintendo Wii for 30 minutes.
3260971|NCT01483677|Active Comparator|Playstation2|Subjects in this arm of the study play a game (Time Crisis 2) on the Playstation 2 for 30 minutes.
3260972|NCT01483703||Diagnostic tool|Laser Speckle Imaging of Critical Care Neonates
3260973|NCT01483716|No Intervention|Control|NIV alone
3260974|NCT01483716|Experimental|Intervention|Rehabilitation arm
3260975|NCT01483729|Active Comparator|Part 1 A|
3260976|NCT01483729|Experimental|Part 1 B|
3260977|NCT01483729|Experimental|Part 1 C|
3260978|NCT01483729|Active Comparator|Part 2 D|
3260979|NCT01483729|Experimental|Part 2 E|
3260980|NCT01483729|Experimental|Part 2 F|
3260981|NCT01483742|Experimental|Combination without RO5024048|Ritonavir-boosted danoprevir in combination with Pegasys (peginterferon alfa-2a) and ribavirin in treatment-naïve patients
3260982|NCT01483742|Experimental|Combination with RO5024048|RO5024048 added to the combination treatment (ritonavir-boosted danoprevir in combination with Pegasys [peginterferon alfa-2a] and ribavirin) in prior null responder patients
3260983|NCT01483755|Experimental|Postconditionned|36 postconditionned patients
3260984|NCT01483755|Sham Comparator|Conventional intervention|36 control patients with conventional primary percutaneaous intervention (PCI)
3260985|NCT01483768|Experimental|Arm A:|Sleeve gastrectomy for morbid obesity
3260986|NCT01483781|Experimental|Canagliflozin|
3260987|NCT01483781|Placebo Comparator|Placebo|
3260988|NCT01483794||Genital warts treated|Patients that have had treatment on their genital warts
3260989|NCT01483794||Genital warts on treatment|Patients currently being treated for genital warts
3260990|NCT01483833|Active Comparator|Iferanserin|Iferanserin administration intra-anally twice daily for 14 days
3260991|NCT01483833|Placebo Comparator|Placebo|Placebo administration intra-anally twice daily for 14 days
3260992|NCT01483846|Experimental|AV-101|"Subjects will be randomized into one of three dose cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.~--------------------------------------------------------------------------------"
3260993|NCT01483846|Placebo Comparator|microcrystalline cellulose|Subjects will be randomized into one of three cohorts (360, 1,080, and 1,440 mg) to receive a daily oral dose for 14 consecutive days. Each cohort will have 12 subjects on active drug and 4 subjects on placebo.
3260994|NCT01483859|Other|right hepatectomy with preoperative LSM|patients undergoing right hepatectomy with preoperative LSM between August 2007 and July 2011
3260995|NCT01483885|Experimental|TENS 4Hz|
3260996|NCT01483885|Experimental|Interferential Current 4Hz|
3260997|NCT01483885|Placebo Comparator|TENS|
3260998|NCT01483885|Placebo Comparator|Interferential Current|
3260999|NCT01483885|Experimental|Manual Acupuncture|
3261000|NCT01483885|Experimental|TENS 100 Hz|
3261001|NCT01483885|Experimental|Interferential Current 100Hz|
3261002|NCT01483898|Experimental|ixmyelocel-T|
3261003|NCT01483898|Placebo Comparator|Placebo|
3261004|NCT01483911|Experimental|ALX-0171|
3261005|NCT01483911|Placebo Comparator|Placebo|
3261006|NCT01483950||Patients with hypercholesterolaemia|
3261007|NCT01483976|Active Comparator|Oral medical nutritional supplement without AN777|orally over a three hour period
3261008|NCT01483976|Experimental|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
3261009|NCT01483989|Experimental|SYSTANE® Gel Drops Lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
3261010|NCT01484002||Crosslinked polyethylene liners|Polyethylene liners from joint replacements that were crosslinked and heat treated to eliminate free radicals.
3261011|NCT01484002||Conventional polyethylene liners|Polyethylene liners from joint replacements that manufactured from conventional UHMWPE and terminally sterilized by methods that did not involve gamma-irradiation.
3261012|NCT01484015|Experimental|Arm I (standard infusion)|Patients receive cefepime hydrochloride IV over 30 minutes.
3261013|NCT01484015|Experimental|Arm II (prolonged infusion)|Patients receive cefepime hydrochloride IV over 3 hours. Treatment repeats every 8 hours.
3261014|NCT01484067|Experimental|Patch|At onset of signs/symptoms, subjects will apply assigned patch, and return to study center within 24 hours. Patch will be worn continuously, being replaced as needed.
3261015|NCT01484067|No Intervention|No Patch|No treatment will be initiated at onset of signs and symptoms although subject is still required to return to study center with 24 hours of onset of signs/symptoms.
3261016|NCT01484080|Experimental|Arm I: BIBF1120+Paclitaxel|2 weeks run-in of BIBF 1120 alone followed by paclitaxel + BIBF 1120 combination
3261017|NCT01484080|Active Comparator|Arm II: Paclitaxel|Paclitaxel monotherapy treatment will start within 2 weeks after randomization.
3261018|NCT01484106|Experimental|Treatment group|"Patients will be randomized (1:1, stratified by site, in permutation blocks of 4) to the Treatment or Standard Care arms."
3261019|NCT01484106|Active Comparator|Control|Standard of Care
3261020|NCT01484119|Active Comparator|Investigational Drug|ACT-129968
3261021|NCT01484119|Placebo Comparator|Comparative Drug|matching placebo tablets and capsules
3261022|NCT01484119|Active Comparator|Reference Drug|Cetirizine
3261023|NCT01484145|Active Comparator|6 mA.min, 20 mins|
3261024|NCT01484145|Experimental|6 mA/min, 20 mins, clamping|
3261025|NCT01484145|Experimental|6 mA/min, 20 mins, debridement, clamping|
3261026|NCT01484145|Experimental|15 mA/min, 30 mins, clamping|
3261027|NCT01484145|Experimental|15 mA/min, 50 mins, debridement, clamping|
3261028|NCT01484158||Myocardial Infarction|Patients with myocardial infarction
3261029|NCT01484171|Active Comparator|idarubicin|The patients will receive induction chemotherapy containing standard dose of idarubicin in combination with cytarabine.
3261030|NCT01484171|Experimental|microtransplantation|The patients will receive induction chemotherapy containing high dose of idarubicin in combination with cytarabine and follow by infusioning granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells
3261031|NCT01484184|Active Comparator|buspirone or levodopa/carbidopa|Another 2-arm design will be tested composed of 16 subjects receiving drug A or drug B at MTD dose of the combined study drug as identified in the previous 2-arm groups.
3261032|NCT01484184|Placebo Comparator|Placebo|First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of SPINALON, the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively with increasing doses, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.
3261033|NCT01484210|Experimental|Elpenhaler Active - Diskus Placebo|Patients on treatment with both devices, Elpenhaler and Diskus, first active substance, second placebo.
3261034|NCT01484223|Experimental|Experimental Group|Intervention group: Structured nursing intervention
3261035|NCT01484223|No Intervention|No intervention|Control group: conventional intervention or non_support
3261036|NCT01484262||Liraglutide|
3261037|NCT01484262||Any insulin|
3261038|NCT01484327||Carvedilol, LVEF, Heart Failure|Patients with Heart Failure on carvedilol therapy measured for their LVEF value
3261039|NCT01484353|Experimental|Intervention group|This is the only arm in the study. They will be compared before and after
3261040|NCT01484366|Active Comparator|intramedullary nailing and plating|intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
3261041|NCT01484366|Active Comparator|plating|plating of both the radius and ulna in the treatment of both bone forearm fractures
3261042|NCT01484379|Experimental|unilateral neck exploration|unilateral neck exploration of elderly with primary hyperparathyroidism
3261043|NCT01484405|Other|anterolateral approach|surgical intervention THA anterolateral approach
3261044|NCT01484405|Other|posterior approach|surgical intervention THA posterior approach
3261045|NCT01484418|Experimental|A Exposure long|Exposure in vivo for fear avoidant chronic low back pain patients. This treatment means that the individual is exposed to movements and tasks that have been avoided due to fear of (re)injury. The treatment begins after three educational lessons including the rational and developing a fear hierarchy. Exposure phase includes 10 exposures sessions which are highly individualized. Behavioral experiments can be included to correct catastrophic misinterpretations. The main purpose of this intervention type is to reduce pain related disability via diminishing fear avoidance.
3261046|NCT01484418|Experimental|B Exposure short|See above exposure long. This treatment comprises 5 exposure sessions.
3261047|NCT01484418|Active Comparator|C Cognitive behavioural psychotherapy|Cognitive behavioural psychotherapy for fear avoidant chronic low back patients. The therapy is modularized in three main parts. The educational lesson is followed by the module graded activity which represents the behavioral part of the program. The second module comprises relaxation. And the last part contains cognitive interventions. Cognitive behavioural intervention techniques are employed to support the patient in the process of coping with chronic pain: i.e. reduction of disability and improving functional ability.
3261048|NCT01484444||gastrointestinal cancer|
3261049|NCT01484457|Experimental|Closed-loop control system|"The objective of this study is to automate glucose control in subjects with type 1 diabetes using a computer control algorithm in a controlled in-clinic research setting.~The controller will be evaluated under two conditions:~restoring euglycemia (80-140 mg/dL) when the controller is initiated during a period when the subject's glucose is above the euglycemic range;~restoring euglycemia (80-140 mg/dL) when the controller is challenged with a small unannounced meal (~25 g CHO)."
3261050|NCT01484470|No Intervention|Unmanipulated arm|Participants that do not meet criteria for StemEx®, will be registered into the unmanipulated UCB arm and receive the standard conditioning regimen.
3261051|NCT01484470|Experimental|Stemx Arm|StemEx is a stem/progenitor cell-based product of ex-vivo expanded allogeneic UCB, which is administered to the subject in combination with the non-manipulated portion of the same cord blood unit (CBU). The CBU must be cryopreserved in two portions of which the larger (or equal) CBU portion contains at least 1.5 x 107 total nucleated cells (TNC)/Kg. This portion remains unmanipulated and is transplanted on Day 0. StemEx is derived from the smaller (or equal) CBU portion, which is expanded ex vivo for 21 days starting pre-transplant in the presence of cytokines TPO, IL-6, Flt-3L and SCF at a concentration of 50ng/ml and 5μM tetraethylenepentamine (TEPA)
3261052|NCT01484483||Cohort|
3261053|NCT01484509||Intermittent claudication|
3261054|NCT01484522||Group A|Influenza A 2009 Monovalent vaccine
3261055|NCT01484522||Group B|Influenza A 2009 monovalent vaccine
3261056|NCT01484522||Group C|Influenza A 2009 monovalent vaccine
3261057|NCT01484535|Other|Ankle aspiration|ankle aspiration
3261058|NCT01484535|Placebo Comparator|placebo procedure|placebo procedure
3261059|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 2 ug GLA-SE|Low dose of adjuvant.
3261060|NCT01484548|Experimental|Vaccine: 20 ug LEISH-F3 + 5 ug GLA-SE|Higher dose of adjuvant.
3261061|NCT01484548|Active Comparator|20 ug LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
3261062|NCT01484574|Experimental|Low dose|Stempeucel - CLI will be administered at the lowest dose
3261063|NCT01484574|Experimental|Intermediate dose|Stempeucel - CLI will be administered at intermediate dose
3261064|NCT01484574|No Intervention|Control arm|Standard protocol of care alone
3261065|NCT01484587|Experimental|001|
3261066|NCT01484587|Placebo Comparator|002|
3261067|NCT01484600|Experimental|Group 1|
3261068|NCT01484600|Experimental|Group 2|
3261069|NCT01484613||Quadripolar lead|All participants receive a CRT-D system with quadripolar lead
3261070|NCT01484639|Active Comparator|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
3261071|NCT01484639|Active Comparator|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
3261072|NCT01484665|Experimental|Participants (Males, age 50-75 yrs)|Eligible men will be identified from the administrative database and electronic medical record at the University of Minnesota (EMR) at least 24 hours prior to the clinic visit. They will be asked to complete the PROCASE Decision-Aid.
3261073|NCT01484678||Age Matched Controls|"Age matched non-affected (non-DMD) boys * This arm is full~Age matched non-affected men, matched for men with Becker MD *Recruiting"
3261074|NCT01484678||Boys/Men with DMD|This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. *Recruiting
3261075|NCT01484678||Adults with Becker MD|This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. * Recruiting
3261076|NCT01484691|No Intervention|Healthy non-asthmatic controls|Healthy non-asthmatic controls who will be studied at one point in time and serve as a control group for the baseline bronchoscopy and evaluation of T-cell miRNA expression.
3261077|NCT01484691|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma (randomized to 8 weeks of treatment with inhaled corticosteroids). Asthmatics not on inhaled corticosteroids, randomized to inhaled budesonide, 1 puff (180mcg) twice a day for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline (before corticosteroids) and again after treatment with inhaled corticosteroids.
3261078|NCT01484691|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthma (randomized to 8 weeks of no inhaled corticosteroid treatment). Asthmatics not on inhaled corticosteroids, randomized to no change in treatment for 8-10 weeks. These subjects will undergo bronchoscopy and T-cell miRNA measurement at baseline and again after 8 weeks without treatment with inhaled corticosteroids.
3261079|NCT01484704||No treatment|
3261080|NCT01484704||MRI|
3261081|NCT01484717|Active Comparator|Standard Care|Telephone counseling plus nicotine patch
3261082|NCT01484717|Experimental|Contingency management for abstinence from cigarettes|Telephone counseling and nicotine patch plus contingency management
3261083|NCT01484730||Vascular Occulsion|Multi-Spectral & Laser Speckle Imaging
3261084|NCT01484743||Patients with parastomal hernia repair|Patients registered in the Danish Ventral Hernia database
3261085|NCT01484756|Placebo Comparator|calcium carbonate 500 mg|Control group received one daily tablet of calcium carbonate 500 mg for 6 months
3261086|NCT01484756|Experimental|daily multi micronutrient supplement|Experimental group received one daily multi micro-nutrient supplement tablet for 6 months
3261087|NCT01484782|Experimental|Interactive Voice Response (IVR) calls|Weekly automated telephone assessment and behavior change calls focused on blood pressure management. The experimental group will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
3261088|NCT01484782|No Intervention|Usual care|This group received results of blood pressure readings. PCP referrals. Educational materials about hypertension and self-management. At follow-up, patients received home blood pressure monitoring cuffs.
3261089|NCT01484795|Experimental|Continuous positive airway pressure|
3261090|NCT01484795|Experimental|BILEVEL|
3261091|NCT01484821|Active Comparator|Arm A|Volunteers (18 -30 years)
3261092|NCT01484821|Active Comparator|Arm B|Volunteers (70 years or older)
3261093|NCT01484821|Experimental|Arm C|70 years patient or older with curative cares for cancer
3261094|NCT01484847|Experimental|PF-00299804|Patients with locally advanced head and neck squamous cell carcinoma will be treated with a single dose (45mg) of PF-00299804 via G-Tube on an empty stomach
3261095|NCT01484860|Experimental|AUY922|AUY922 will be administered as a weekly infusion at a dose of 70 mg/m2 based on the recommended phase II dose from the phase I study or alternate dose based on the phase I study final results.The drug will be continued until disease progression or unacceptable toxicity. One cycle will be defined as 4 weeks of treatment.
3261096|NCT01484886|Experimental|Restrictive transfusion strategy|RBC will be transfused if the hemoglobin level falls below 7 for bi-ventricular repairs and under 9.0 for single ventricle palliations.
3261097|NCT01484886|Experimental|Liberal RBC transfusion strategy|RBCs will be transfused for Hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
3261098|NCT01484899||PAH|Patients with pulmonary arterial hypertension (PH). PH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg
3261099|NCT01484899||CTEPH|Patients with chronic thromboembolic pulmonary hypertension. CTEPH defined as mean pulmonary artery pressure >25mmHg with a pulmonary capillary occlusion pressure ≤ 15mmHg.
3261100|NCT01484899||Controll group|Data from 16322 (10336 females) participants of the Swiss health survey (SHS) 2007 will serve as control. The SHS was performed in 2007, a representative sample of 30000 Swiss citizens were asked to participate, 66% answered per telephone to detailed health question.
3261101|NCT01484925||With Barrett's Esophagus|Patients who have been diagnosed in the past with Barrett's Esophagus
3261102|NCT01484925||Without Barrett's Esophagus|Patients without Barrett's Esophagus will be asked to take part so that comparison can be made with patients' tissue for those with the condition and those without the condition.
3261103|NCT01484964|Experimental|Treatment A|ASP015K Formulation 1 with moderate-fat meal
3261104|NCT01484964|Experimental|Treatment B|ASP015K Formulation 2 under fasting conditions
3261105|NCT01484964|Experimental|Treatment C|ASP015K Formulation 2 with moderate-fat meal
3261106|NCT01484990|Experimental|1|
3261107|NCT01485016||ambulatory epilepsy subjects|
3261108|NCT01485029|Experimental|NP children|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
3261109|NCT01485042|Experimental|Dose Escalation|This is a Phase 1 dose escalation with an expanded cohort that will enroll at MTD.
3261110|NCT01485068|Experimental|Danubio|
3261111|NCT01485081|Experimental|Danubio|
3261112|NCT01485107|Experimental|Ultherapy™ treatment on the décolleté|All enrolled subjects will receive the study treatment.
3261113|NCT01485133||Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3261114|NCT01485133||Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered via a needle adaptor or the built-in scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
3261115|NCT01485146|Experimental|Cohort 1|8 Healthy Subjects in Phase I Unit
3261116|NCT01485146|Experimental|Cohort 2|8 Healthy Subjects in Phase I Unit
3261117|NCT01485146|Experimental|Cohort 3|8 Healthy Subjects in Phase I Unit
3261118|NCT01485159||All|All subjects enrolled in the study
3261119|NCT01485185|Experimental|Gabapentin lower dose alone|low dose
3261120|NCT01485185|Active Comparator|Gabapentin higher dose alone|higher dose
3261121|NCT01485185|Experimental|Gabapentin in combination with donepezil|Gabapentin lower dose and donepezil
3261122|NCT01485185|Placebo Comparator|Placebo|Placebo
3261123|NCT01485198|Active Comparator|Control|Patients treated with Acetaminophen
3261124|NCT01485198|Experimental|Experimental|Patients who underwent a BMASC extraction and joint infusion
3261125|NCT01485211|Experimental|crosslinking with hypoosmolar riboflavin|Riboflavin and UVA-induced corneal cross-linking increases the stability of keratoconic corneas. The current inclusion criteria require a minimum stromal thickness of 400 µm. Hypo-osmolar riboflavin solution increases the stromal thickness before CXL in cases with preoperatively thin corneas.
3261126|NCT01485224|Experimental|Thalidomide|"Single arm study:~Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
3261127|NCT01485237||Severe H1N1 pneumonia in adult patients|Severe adult H1N1 pneumonia patients undergoing antiviral and oxygen therapy, mechanical ventilation and support with pulmonary rescue therapies ( nitric oxide, ECMO, HFO)in Winnipeg
3261128|NCT01485237||Severe pneumonia in adults not H1N1|Patients admitted to the hospital and/or ICU with viral pneumonia, bacterial pneumonia, septic shock, ARDS in Winnipeg
3261129|NCT01485289||Investigational Stabilimax|
3261130|NCT01485289||Control, Posterolateral Fusion|
3261131|NCT01485302|Experimental|Cohort 1|Dose 1 IV infusion
3261132|NCT01485302|Experimental|Cohort 2|Dose 2 IV infusion
3261133|NCT01485302|Experimental|Cohort 3|Dose 3 IV infusion
3261134|NCT01485302|Experimental|Cohort 4|Dose 4 IV infusion
3261135|NCT01485302|Experimental|Cohort 5|Dose 1 SC injection
3261136|NCT01485302|Experimental|Cohort 6|Dose 2 SC injection
3261137|NCT01485315|Active Comparator|Liberal blood transfusion|Blood transfusion at haemoglobin 9.0 g/dl (5.6 mM) or less
3261138|NCT01485315|Active Comparator|Restrictive blood transfusion|Blood transfusion at haemoglobin 7.0 g/dl (4.3 mM) or less
3261139|NCT01485328|Active Comparator|AMARGOL|per oral solution 40 mL single dose
3261140|NCT01485328|Placebo Comparator|Vehicle without active principles|per oral solution 40 mL single dose
3261141|NCT01485341|Active Comparator|gluten|gluten is administered blindly versus placebo for 15 days at 10 g/day
3261142|NCT01485341|Placebo Comparator|rice starch|placebo (rice starch) will be administered blindly versus gluten for 15 days at 10 g/day
3261143|NCT01485367|Active Comparator|Adapalene gel 0.3%|All odd numbered subjects will receive treatment to the left arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
3261144|NCT01485367|Active Comparator|Adapalene gel 0.3 %|All even numbered subjects will receive treatment to the right arm. The untreated arm will serve as an intrapatient control and will be evaluated separately from the treated arm for signs of purpura.
3261145|NCT01485406|Experimental|Pn Group|Toddlers 12-23 months of age receiving GSK2830930A vaccine.
3261146|NCT01485406|Active Comparator|Control Group|Toddlers 12-23 months of age receiving Synflorix.
3261147|NCT01485432||P group|Group P: Fluid Management according to measurements with PiCCO®
3261148|NCT01485432||C group|Group C: Conventional fluid management
3261149|NCT01485445|Experimental|Fluticasone Furoate (single strip configuration)|400mcg, administered as 2 inhalations of 200mcg
3261150|NCT01485445|Experimental|Fluticasone Furoate (two strip configuration)|400mcg, administered as 2 inhalations of 200mcg. Second strip contains lactose and magnesium stearate
3261151|NCT01485445|Experimental|Fluticasone Furoate/Vilanterol|400/50mcg, administered as 2 inhalations of 200/25mcg
3261152|NCT01485458|Experimental|Early surgery|
3261153|NCT01485458|Active Comparator|Delayed surgery|
3261154|NCT01485471||Medical Tool|Diffuse optical spectroscopy imaging ear exam
3261155|NCT01485484||Sinus|Optic imaging use near-infrared trans-illumination methods
3261156|NCT01485497|Other|3D endoscopic Fourier Domain OCT|3D endoscopic Fourier Domain OCT
3261157|NCT01485510|Experimental|Glasgow Infant and Family Team (GIFT)|A service developed by Charles Zeanah and colleagues in New Orleans, that aims to improve the mental health of maltreated infants.
3261158|NCT01485510|Active Comparator|Family Assessment & Contact Service|A social-work based service that aims to assess maltreated children and make recommendations about their future care.
3261159|NCT01485523||Patients|A = Patients with allergic rhinitis sensitized to dust mites
3261160|NCT01485523||Control Subjects|B = control subjects with allergic rhinitis not sensitized to dust mites C = control subjects without allergic rhinitis
3261161|NCT01485549||MSA Patients|Patients suffering from Multiple system atrophy (MSA)
3261162|NCT01485549||Controls|Patients requiring spinal tap without being affected by a neurodegenerative disorder.
3261163|NCT01485562|Active Comparator|Misoprostol|women who experience a PPH will be randomized to receive 800 misoprostol (four tablets of 200 mcg administered sublingually)
3261164|NCT01485562|Placebo Comparator|placebo|women who experience a PPH will be randomized to receive 4 placebo tablets administered sublingually
3261165|NCT01485575||Filter use during vitrectomy|
3261166|NCT01485601|Experimental|MT10109|Clostridium botulinum toxin type A
3261167|NCT01485601|Active Comparator|Botox (registered trade mark)|Clostridium botulinum toxin type A
3261168|NCT01485653|Experimental|Mepivacaine, Ultrasound Axillary Block|Group 1) 20mL 1.5% mepivacaine Group 2) 30mL 1.5% mepivacaine
3261169|NCT01485679|Experimental|positrons emission tomography|
3261170|NCT01485692|Active Comparator|ziprasidone injection|ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation
3261171|NCT01485692|Active Comparator|haloperidol + midazolam, injection|Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation
3261172|NCT01485692|Active Comparator|haloperidol + promethazine, injection|haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation
3261173|NCT01485692|Active Comparator|olanzapine, injection|olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation
3261174|NCT01485718|Active Comparator|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day.
3261175|NCT01485718|Placebo Comparator|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
3261176|NCT01485731|Experimental|Nelfinavir + Cisplatin + Pelvic Radiation Therapy|Nelfinavir in combination with Cisplatin and Pelvic Radiation Therapy
3261177|NCT01485744|Experimental|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|
3261178|NCT01485757|Experimental|L-arginine|
3261179|NCT01485809|Experimental|Gefitinib|
3261180|NCT01485822||TRAVATAN|As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
3261181|NCT01485822||Treatment Naive|No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue
3261182|NCT01485835|Experimental|Ganetespib + Bortezomib + Dexamethasone|"Ganetespib: IV; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 100 mg/m²~Cohort 2: 100 mg/m²~Cohort 3: 120 mg/m²~Cohort 4: 144 mg/m²~Cohort 5: 173 mg/m²~Bortezomib: IV or subcutaneous; days 1, 4, 8, 11; every 3 weeks~Cohort 1: 1.0 mg/m²~Cohort 2, 3, 4, 5: 1.3 mg/m²~Dexamethasone: Oral prior to bortezomib~Cohort 1, 2, 3, 4, 5: 20 + 20 mg~Day of and following bortezomib"
3261183|NCT01485848|Active Comparator|Paclitaxel|A single 1 hour intravenous infusion every week for 6 cycles (each cycle is 4 weeks)
3261184|NCT01485848|Experimental|Paclitaxel + EP-100|Paclitaxel every week plus EP-100 twice weekly by 1 hour intravenous infusion for the first 3 weeks of each 4 week cycle for 6 cycles (each cycle is 4 weeks)
3261185|NCT01485861|Experimental|Phase Ib: Ipatasertib 400 mg + abiraterone|Participants will receive ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3261186|NCT01485861|Experimental|Phase Ib: Apitolisib 30 mg + abiraterone|Participants will receive apitolisib 30 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg twice daily (bid) continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3261187|NCT01485861|Experimental|Phase II: Ipatasertib 400 mg + abiraterone|Participants will receive Ipatasertib 400 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3261188|NCT01485861|Experimental|Phase II: Ipatasertib 200 mg + abiraterone|Participants will receive Ipatasertib 200 mg once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3261189|NCT01485861|Placebo Comparator|Phase II: Placebo + abiraterone|Participants will receive placebo (for Ipatasertib) once daily, abiraterone 1000 mg once daily, and prednisone/prednisolone 5 mg bid continuously in 28-day treatment cycles until disease progression or intolerable toxicity.
3261190|NCT01485861|Experimental|Safety Cohort: Ipataseritib 400 mg + Abiraterone + Prednisone|"Participants will receive Ipataseritib 400 mg once daily in the AM for Cycle 1 day 1-18. On Day 19, Ipataseritib 400 mg will be switched to PM dosing for the remainder of the Cycle 1.~Prednisone 5 mg starts in the PM of Cycle 1 day 8 and taken BID thereafter for the remainder of the study treatment Abiraterone 1000mg once a day starts on Cycle1 day 12 in the AM and should be taken at the same time as Ipataseritib. Starting from cycle 1 day 19, Ipataseritib and Abiraterone are dosed in PM at should be taken together at the same time each day until cycle 2 day 1. Starting from Cycle 2 Day 1, Participants may choose to take Ipatasertib and Abiraterone in either the AM or PM; however, they should be taken together at approximately the same time each day.~Participants will receive the study treatment until disease progression or intolerable toxicity."
3261191|NCT01485874|Experimental|Doxil + BIBF 1120|
3261192|NCT01485900|Experimental|Cohort 1|Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
3261193|NCT01485900|Experimental|Cohort 2|Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
3261194|NCT01485913|Experimental|Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
3261195|NCT01485913|No Intervention|No Lifestyle counseling|"The group subjected to educations will follow the whole process of peer education described in Part 1 of this Protocol.~The control group will perform these classic individual consultations but will not follow the whole process of peer education.~The classical management in diabetes consultations consists of:~A counselling session~A measure of blood glucose~A measurement of blood pressure~A measure of weight and size~A complete clinical examination~A prescription or a renewal of treatment (diabetes pills, insulin, IEC, statins etc ...)"
3261196|NCT01485926|Experimental|Docetaxel, Carboplatin and Trastuzumab|Arm A- 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
3261197|NCT01485926|Experimental|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|Arm B - 6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
3261198|NCT01485939|Placebo Comparator|placebo patch|
3261199|NCT01485939|Active Comparator|lidocaine patch|
3261200|NCT01485952|Experimental|SEN0014196 (Low Dose)|10 mg, once daily administration (immediate release capsule)
3261201|NCT01485952|Experimental|SEN0014196 (High dose)|100 mg, once daily administration (immediate release capsule)
3261202|NCT01485952|Placebo Comparator|Placebo|Once daily (immediate release capsule)
3261203|NCT01485965|Experimental|Fasted condition|Subjects in the Fasted group will take study drug after an overnight fast (since at least midnight). Additionally, on PK assessment days, no food will be allowed for at least 4 hours after study drug administration.
3261204|NCT01485965|Experimental|Fed condition|Subjects in the Fed group will take study drug within 30 minutes after starting breakfast; these subjects will otherwise maintain their normal eating schedule.
3261205|NCT01485978|Active Comparator|Ramipril blinded|oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years
3261206|NCT01485978|Placebo Comparator|placebo to ramipril|Oral placebo treatment to ramipril once daily for 3 years or until progress to next disease level. After progression to next disease level, patients will be unblinded, and ramipril treatment will be initiated.
3261207|NCT01485978|Other|open label ramipril|Open label treatment with ramipril as per protocol, if randomization is refused.
3261208|NCT01486004|Experimental|001|35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total) + 150 mg capsule once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle
3261209|NCT01486017|Experimental|Treatment A|ASP015K oral dose low strength
3261210|NCT01486017|Experimental|Treatment B|ASP015K oral dose medium strength
3261211|NCT01486017|Experimental|Treatment C|ASP015K oral dose high strength
3261212|NCT01486056||healthy patients, may have epilepsy|Subjects at least 12 years old and in general good health for Phase I, and at least 18 years old and in general good health for Phase II. It is desired, but not required, for subjects to have epilepsy and taking at least 1 antiepileptic medication.
3261213|NCT01486069||Dentofacial Deformity|Patients with dentofacial deformities candidate to orthognathic surgery
3261214|NCT01486082||Empirical OCA|This group will be treated with omeprazole, amoxicillin and clarithromycin without having a previous antibiogram.
3261215|NCT01486082||OCA after antibiogram|This group will be treated with omeprazole, clarithromycin and amoxicillin after an antibiotic susceptibility confirmation.
3261216|NCT01486095|Experimental|AXXESS + Biomatrix|After mandatory predilatation, a self-expanding, conically shaped nickel-titanium AXXESS biolimus A9-eluting stent is placed at the level of the carina. The device is available in 3.0 and 3.5 mm calibre and 11 and 14 mm length. Depending on the lesion anatomy, additional Biomatrix™ Drug Eluting Coronary Stent Systems are placed distally if necessary. The procedure is completed with kissing balloon postdilatation using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
3261217|NCT01486095|Active Comparator|Culotte technique: Xience V/Prime|The culotte technique consists of stenting one of both branches of the bifurcation lesion first, and after balloon dilatation of the stent meshes, stenting the uncovered branch through the first stent and leaving the main vessel covered with two overlapped stents. The procedure is terminated by kissing balloon dilatation of both branches using non-compliant balloons sized to the reference vessel diameter of the distal branches. Before this kissing balloon inflation, consecutive high pressure inflations should be performed in both branches.
3261218|NCT01486108|Experimental|Tonic|5 hz stimulation at an amplitude that the patient find bearable (+/- 1.5 mA)
3261219|NCT01486108|Experimental|Sham|no stimulation, patient receive a sham stimulation (actually the IPG is not running)
3261220|NCT01486108|Experimental|burst|500 hz burst at 5 hz stimulation
3261221|NCT01486121|Other|S.O.S.-V|
3261222|NCT01486121|No Intervention|Standard|
3261223|NCT01486134|Experimental|procedure|
3261224|NCT01486147|Experimental|Visual|Group provided with nutrition information using visual nutrient profiling tool
3261225|NCT01486147|Other|Table|Group provided nutrition information using table format
3261226|NCT01486160||nursing home residents|participants in this group are nursing home residents
3261227|NCT01486160||Nursing home employees|Participants in this group are health care workers, employees at the nursing home
3261228|NCT01486173||Premature infants with a GA < 32 Weeks|
3261229|NCT01486173||New born with a GA > 37Weeks|
3261230|NCT01486186|Experimental|traditional chinese medicine|The experimental group will receive three type of TCM, they are Baofei granule, Bufeijianpi granule and Bufeiyishen granule.
3261231|NCT01486186|Placebo Comparator|placebo|placebo chinese medicine in addition to best care according to clinical guidelines for COPD patients
3261232|NCT01486212||Healthy volunteers.|Male aged 18-40 years. Non-smokers. No known familiar disposition to vascular/heart diseases. No intake of prescription medicine.
3261233|NCT01486225|Other|Innothera's brand Stokings|Innothera's branded grip-top silicone band stokingc
3261234|NCT01486225|Other|Other than Innothera's brand|
3261235|NCT01486251|Experimental|experimental|"axitinib will be given BID orally. One cycle is defined as a 14-day period (7 days ON / 7 days OFF). The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
3261236|NCT01486277|Experimental|Quisinostat|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
3261237|NCT01486290|Experimental|Geriatric Diabetes Team Intervention|The subjects in this group underwent evaluation for barriers to self care by a diabetes educator well versed with age specific barriers. After consideration of patient clinical, function, and psychosocial background, a geriatric diabetes team devised strategy to help patients cope with respective barriers. An office based diabetes diabetes educator conveyed the strategy to patient and caregivers viz phone calls. the educator called study participants up wot eleven times over a sex month period.
3261238|NCT01486290|No Intervention|Atention Control Arm|The subjects in the group received similar, in person contact, as the intervention group. an educator, separate from the one involved in the intervention team, called patients in this group for a total of eleven times within the first six months. The Phone calls were focused toward general discussion without any diabetes related advice.
3261239|NCT01486303|Experimental|Facial Cosmetic Acupuncture|28 Patients with grade III to IV wrinkling on the face, according to the Glogau classification system, were treated with Facial Cosmetic Acupuncture.
3261240|NCT01486329|Experimental|VXM01|Investigational anti-angiogenic live cancer vaccine
3261241|NCT01486329|Placebo Comparator|Placebo|Placebo control
3261242|NCT01486342||Group 1|Mechanically ventilated patients without acute lung injury and lung injury prediction score < 4
3261243|NCT01486355|Experimental|Early measles vaccine|Receives an early measles vaccine in addition to the standard measles vaccine at 9 months of age
3261244|NCT01486355|No Intervention|No early measles vaccine|Receives only the standard measles vaccine at 9 months of age
3261245|NCT01486368|Experimental|PF-03446962|
3261246|NCT01486381|Experimental|BIAsp 30|
3261247|NCT01486394|Experimental|Focused sonography|Intervention group: After the primary evaluation by a physician in the emergency department, focused sonography of the patients heart, lungs and deep veins in the legs are performed. Hereafter the further examinations and treatment are done according to hospital guidelines.
3261248|NCT01486394|No Intervention|Usual treatment and diagnostic work-up|Control group: After the primary evaluation by a physician in the emergency department. Hereafter the further examinations and treatment are done according to hospital guidelines.
3261249|NCT01486407||Intravenous (IV) drug delivery|patients on whom intravenous vascular access has been established for the purpose of rapid sequence intubation drug delivery.
3261250|NCT01486407||Intraosseous (IO) drug delivery|Patients on whom intraosseous vascular access has been established for rapid sequence intubation drug delivery.
3261251|NCT01486420|Active Comparator|Open surgery|
3261252|NCT01486420|Active Comparator|Corticosteroid Injection|
3261253|NCT01486433|Experimental|Epanova and Simvastatin|
3261254|NCT01486433|Active Comparator|Simvastatin|
3261255|NCT01486459|Experimental|PCI with lithium|Prophylactic cranial irradiation Lithicarb® tablets 250mg/day for 6 weeks. Initial dosing will be 250mg given once daily, and increased by 250 - 500 mg increments depending on plasma levels.
3261256|NCT01486459|No Intervention|Standard|Prophylactic cranial irradiation alone.
3261257|NCT01486472||GC patients receiving adjuvant S-1 chemotherapy|
3261258|NCT01486485|Experimental|heparinized saline priming group|Experimental group : heparinized saline priming group
3261259|NCT01486485|Active Comparator|nafamostat infusion group after heparinized saline priming|active comparator : nafamostat infusion group after heparinized saline priming
3261260|NCT01486511||Liver resection patients|All patients that underwent elective liver resection for both malignant and benign diseases.
3261261|NCT01486524||DrotAA Treatment Group|Patients with severe sepsis at high risk of death (INDICATED patients) who received treatment with drotrecogin alfa (activated (DrotAA) as part of standard care in ICU. The standard dosing regimen for DrotAA is 96 hours of continuous infusion at a dose of 24 ug/kg/hour. DrotAA is also known as recombinant human activated protein C.
3261262|NCT01486524||Control Group (non-DrotAA treated)|Patients with severe sepsis at high risk of death (INDICATED patients) who did not receive DrotAA treatment as part of their standard care in an ICU. The Control group patients will be selected to match the DrotAA-treated patients based on numerous clinical covariates, including propensity score (for DrotAA treatment).
3261263|NCT01486537||theeth undergoing pulpotomy|
3261264|NCT01486537||teeth undergoing pulpectomy|
3261265|NCT01486550|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3261266|NCT01486550|Placebo Comparator|Sodium Chloride 9mg/ml|Patients undergoing laparoscopic nephrectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3261267|NCT01486563|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3261268|NCT01486563|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing radical prostatectomy will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride)
3261269|NCT01486576|Active Comparator|Voluven (Hydroxyethyl starch 130/0,4)|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
3261270|NCT01486576|Placebo Comparator|Sodium Chloride 9 mg/ml|Patients undergoing hip replacement surgery will receive either fluid therapy with active comparator (Voluven) or placebo (Sodium Chloride. Patients will receive minimum 7,5 ml/kg in the first hour of the surgery and 5 ml/kg in the subsequent hours.
3261271|NCT01486602|Experimental|Concurrent therapy + consolidation therapy|"Concurrent Therapy (1 cycle = 14 days, Cycles 1-3): Patients will receive paclitaxel 45 mg/m^2 by IV over 1 hour weekly followed by carboplatin AUC 2 by IV over 30-60 minutes for 4 weeks (there will be no chemotherapy during Cycle 3). Patients will receive radiotherapy concurrently for up to 5.5 weeks, depending on the cohorts the patient is registered defined per the protocol.~Consolidation Therapy (1 cycle = 21 days, Cycles 4-5): Four weeks following the end of radiotherapy patients will receive paclitaxel 200 mg/m^2 by IV over 3 hours followed by carboplatin AUC 6 by IV over 30-60 minutes on day 1 of each 21 day cycle for a total of 2 cycles (days 1 and 22)."
3261272|NCT01486628|Placebo Comparator|levodopa and carbidopa|
3261273|NCT01486628|Placebo Comparator|Placebo|Saline solution for subcutaneous administration
3261274|NCT01486641|Active Comparator|Anterolateral approach|"Patients with a displaced femoral neck fracture operated through the anterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
3261275|NCT01486641|No Intervention|Posterolateral approach|"Patients with a displaced femoral neck fracture operated through the posterolateral approach to the hip arthroplasty.~Lubinus total hip arthroplasty or varikopf hemiarthroplasty."
3261276|NCT01486654|Active Comparator|Anodal stimulation|
3261277|NCT01486654|Active Comparator|Cathodal stimulation|
3261278|NCT01486654|Placebo Comparator|Sham stimulation|
3261279|NCT01486667|Placebo Comparator|sugar pill|
3261280|NCT01486667|Active Comparator|Levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients. Serum levels of TSH and FT4 will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
3261281|NCT01486680|Active Comparator|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|
3261282|NCT01486680|Active Comparator|Laparoscopic Sleeve Gastrectomy|
3261283|NCT01486706|Experimental|Gabapentin|Two to three months of behavioral therapy prior to start of Gabapentin 100mg/capsule, initially 1 capsule once a day for 1 week then titrate dosage according to symptoms until maximum dose of 1500mg/day Placebo tablet of Solifenacin Succinate will titrate dose same as Solifenacin arm according to symptoms of patient
3261284|NCT01486706|Active Comparator|Solifenacin Succinate|Two to three months of behavioral therapy prior to Solifenacin Succinate 5mg/tablet initially 1 tablet once a day then titrate dosage according to symptoms upto maximum dose of 10mg/day Placebo form of Gabapentin will titrate dosage same as Gabapentin group according to symptoms of patient
3261285|NCT01486706|Placebo Comparator|Placebo|Two to three months of behavioral therapy prior to Placebo form of Gabapentin and Solifenacin and titrate accordingly same as the treatment arms
3261286|NCT01486732|Experimental|Umbilical Cord Blood & Rehabilitation|Allogeneic umbilical cord blood infusion and active rehabilitation
3261287|NCT01486732|Active Comparator|Placebo Umbilical Cord Blood & Rehabilitation|Placebo Umbilical Cord Blood infusion and active rehabilitation
3261288|NCT01486745||Normal colonoscopy|
3261289|NCT01486745||Colonic polyps|
3261290|NCT01486745||Colorectal cancer patients|
3261291|NCT01486745||Breast & Prostate Cancer patients|
3261292|NCT01486771|Experimental|IV Macugen Q6|Will receive 3 intravitreal pegaptanib injections at 6-week intervals, then 3 additional injections at 12-week intervals
3261293|NCT01486771|Experimental|IV Mac Q6 Arm|Will Selective Laser Photocoagulation after 3 intravitreal pegaptanib injections
3261294|NCT01486771|Experimental|Pan Retinal Photocoagulation|Will act as the control group, thus subjects in this group will receive standard PRP (modified ETDRS protocol)
3261295|NCT01486797|Experimental|NOX-A12|
3261296|NCT01486823|Experimental|Cohort A|
3261297|NCT01486823|Experimental|Cohort B|
3261298|NCT01486836||ICD therapy|
3261299|NCT01486849|Experimental|Dose Titration of CK-2017357 (Group 1)|Dose titration of active drug as add-on therapy to riluzole
3261300|NCT01486849|Placebo Comparator|Matching Placebo (Group 2)|Placebo as add-on therapy to riluzole
3261301|NCT01486862|Experimental|BIAsp 30|
3261302|NCT01486875||BIAsp 30|
3261303|NCT01486888|Experimental|Formulation A|
3261304|NCT01486888|Active Comparator|Formulation B|
3261305|NCT01486901|Experimental|Formulation A|
3261306|NCT01486901|Active Comparator|Formulation B|
3261307|NCT01486914|Experimental|NN2000|
3261308|NCT01486914|Active Comparator|IAsp|
3261309|NCT01486940|Experimental|Basal/bolus regimen 1|
3261310|NCT01486940|Active Comparator|Basal/bolus regimen 2|
3261311|NCT01486953|Active Comparator|sevoflurane|Anesthesia with sevoflurane
3261312|NCT01486953|Experimental|Desflurane|Anesthesia with desflurane
3261313|NCT01486979|Experimental|Low dose|
3261314|NCT01486979|Active Comparator|High dose|
3261315|NCT01486992|Experimental|Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
3261316|NCT01487005||elderly subjects|Healthy
3261317|NCT01487018|Experimental|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
3261318|NCT01487018|Active Comparator|Traditional Surgery|To compare with the experimental arm.
3261319|NCT01487031|Experimental|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room.
3261320|NCT01487031|Active Comparator|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
3261321|NCT01487057||Thyroid cancer, lipids, LT4 withdrawal|
3261322|NCT01487057||Thyroid cancer, Lipids, LT4 substitution|
3261323|NCT01487070|Experimental|Macugen (Pegaptanib Sodium)|Open-label, single-center trial. Subjects will recieve intravitreous injections of Macugen 7-14 days before Vitrectomy.
3261324|NCT01487083|Experimental|Pomaglumetad methionil|Pomaglumetad methionil will be administered orally. Participants entering the study will be flexibly dosed between 20 mg, 40 mg, and 80 mg twice daily.
3261325|NCT01487096|Placebo Comparator|Placebo|"Placebo (for teriflunomide),~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3261326|NCT01487096|Experimental|Teriflunomide 7 mg|"Teriflunomide 7 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3261327|NCT01487096|Experimental|Teriflunomide 14 mg|"Teriflunomide 14 mg:~two tablets once daily for 1 week then,~one tablet once daily for 35 weeks."
3261328|NCT01487109|Placebo Comparator|Placebo|matching placebo tablets
3261329|NCT01487109|Active Comparator|CTP-499|600 mg tablet
3261330|NCT01487122|Experimental|Continuous Microwave|
3261331|NCT01487122|Experimental|Pulsed Microwaves|
3261332|NCT01487122|Sham Comparator|sham microwaves|
3261333|NCT01487135|Experimental|EVP-6124|A single low dose of 8-mg EVP-6124 and A single high dose of 80-mg EVP-6124
3261334|NCT01487135|Placebo Comparator|Placebo|Cranberry juice (180 mL)
3261335|NCT01487135|Active Comparator|Moxifloxacin|A single dose of 400-mg Moxifloxacin
3261336|NCT01487174|Experimental|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
3261337|NCT01487174|Active Comparator|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
3261338|NCT01487187|Active Comparator|immediate umbilical cord clamping|The control group will receive immediate cord clamping at birth which is the standard of care in our institution
3261339|NCT01487187|Experimental|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord.
3261340|NCT01487213|No Intervention|Controls|Routine follow-up at the clinic 2-3 weeks after the treatment
3261341|NCT01487213|Other|Home self test|Intervention
3261342|NCT01487239|Experimental|A|[14C]-GDC-0980 administered as a 10-mg oral dose
3261343|NCT01487252|Active Comparator|Healthy Controls|
3261344|NCT01487252|Active Comparator|Delayed Sleep Phase Disorder|
3261345|NCT01487278|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
3261346|NCT01487278|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
3261347|NCT01487291||Psychotic patients|Inpatients and outpatients followed at Instituto de Psiquiatria da Universidade Federal do Rio de Janeiro, Brazil
3261348|NCT01487304||Low dose HRT|
3261349|NCT01487317|Experimental|Rivastigmine transdermal patch|
3261350|NCT01487317|Placebo Comparator|placebo|
3261351|NCT01487330|Experimental|Subjects receiving TAVI valve|
3261352|NCT01487343||breast or gastrointestinal cancer pts taking capecitabine|This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
3261353|NCT01487356||Patients undergoing colonoscopy|Data was collected on all adult patients undergoing outpatient colonoscopy at St. Paul's Hospital from May 2008 to June 2009. Exclusion criteria were prior colon resection and repeat colonoscopy for the purpose of endoscopic therapy for known lesions.
3261354|NCT01487369||Insulin Aspart|
3261355|NCT01487382||Insulin Aspart|
3261356|NCT01487395|Active Comparator|Donepezil|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
3261357|NCT01487395|Placebo Comparator|Placebo|The placebo will be presented as tablet comparable to ARICEPT
3261358|NCT01487408||Insulin Aspart|
3261359|NCT01487421||SIT|
3261360|NCT01487434|Experimental|Check & Connect|Check and Connect Structured Mentoring and Case Management
3261361|NCT01487447|Experimental|Intervention|
3261362|NCT01487447|Active Comparator|Control|
3261363|NCT01487460|Experimental|TAP311 in Healthy Volunteers|
3261364|NCT01487460|Placebo Comparator|Matching Placebo|Healthy Volunteers and Patients will be treated in Placebo group.
3261365|NCT01487460|Experimental|TAP311 and Simvastatin|
3261366|NCT01487460|Experimental|TAP311 in Patients|
3261367|NCT01487473|Active Comparator|Mindfulness-Based Stress Reduction|
3261368|NCT01487473|No Intervention|Waitlist Control|
3261369|NCT01487486||Normal patients|Women with infertility diagnosis of male factor only or women who are oocyte donors
3261370|NCT01487486||Polycystic Ovary Syndrome, High BMI|Women with Polycystic Ovary Syndrome with a BMI between 30-35
3261371|NCT01487486||Polycystic Ovary Syndrome, Low BMI|Women with Polycustic Ovary Syndrom with a BMI between 20 & 25
3261372|NCT01487512|Experimental|Sequence 1: Treatment A-D-B-C|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3261373|NCT01487512|Experimental|Sequence 2: Treatment B-A-C-D|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3261374|NCT01487512|Experimental|Sequence 3: Treatment C-B-D-A|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3261375|NCT01487512|Experimental|Sequence 4: Treatment D-C-A-B|The study consists of 4 single-dose treatment periods. Successive drug administrations will be separated by a washout period of at least 7 and no more than 14 days.
3261376|NCT01487538|Experimental|intervention group|
3261377|NCT01487538|Active Comparator|Standard Advice Group|
3261378|NCT01487551|Experimental|paquinimod|
3261379|NCT01487564|Experimental|Hydromorphone 16 mg|
3261380|NCT01487590|Active Comparator|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
3261381|NCT01487590|Placebo Comparator|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
3261382|NCT01487603||confirmed or suspected lung cancer|
3261383|NCT01487616||Women with previous preterm birth|Women with history of preterm birth (birth of a baby of less than 37 weeks gestational age, where labour was spontaneous) regardless of past pregnancy history.
3261384|NCT01487616||Women with previous miscarriage|Women with history of miscarriage (spontaneous pregnancy loss before 24 weeks of gestation), regardless of past pregnancy history.
3261385|NCT01487616||Women with previous term births|Women with previous term births (37 or more weeks of gestation)
3261386|NCT01487629|Experimental|Bevacizumab|Treatment of macular edema with intravitreal Bevacizumab
3261387|NCT01487629|Experimental|Ranibizumab|Treatment of macular edema with intravitreal Ranibizumab
3261388|NCT01487642|Experimental|Telephone counselling|
3261389|NCT01487642|Experimental|Proactive telephone counselling|
3261390|NCT01487642|Experimental|web-based smoking cessation programme|
3261391|NCT01487642|Active Comparator|Self-help material|
3261392|NCT01487655||healthy age matched controls|
3261393|NCT01487655||normal tension glaucoma patients|
3261394|NCT01487655||primary open angle glaucoma patients|
3261395|NCT01487681||Invasive cervical cancer|
3261396|NCT01487681||Cervical intraepithelial neoplasia 2/3|
3261397|NCT01487681||Cervical intraepithelial neoplasia 1|
3261398|NCT01487694|Experimental|Cimicifuga racemosa|patients receive cimicifuga racemosa rhizome and root extract 40 mg/day (equivalent to triterpene glycosides 12.3 mg)
3261399|NCT01487694|Placebo Comparator|Placebo|Placebo containing no active ingredient which match the drug in bottle, shape, color and smell
3261400|NCT01487707|Experimental|Voluntary Health Worker (VHW) Program|
3261401|NCT01487707|Experimental|VHW program plus Safe Birth Kit|
3261402|NCT01487707|Experimental|VHW program plus Folk Media Activities|
3261403|NCT01487720|Experimental|GEMOX|GEMOX treatment
3261404|NCT01487746||treatment|Stroke patients
3261405|NCT01487746||Controls|healthy controls
3261406|NCT01487759|Active Comparator|Prebiotic|
3261407|NCT01487759|Placebo Comparator|Placebo|
3261408|NCT01487772||Hip-fracture patients|Hip-fracture patients admitted to Orthopaedic Department of Danderyd Hospital
3261409|NCT01487785|Experimental|LDE225+gemcitabine|Increasing doses of LDE225 (from 400 mg) once a day + 1000 mg/m2 of gemcitabine on days 1, 8 and 15 of every 28 day cycle.
3261410|NCT01487798|Experimental|Treatment period 1|
3261411|NCT01487798|Active Comparator|Treatment period 2|
3261412|NCT01487811|Experimental|Formulation 1|
3261413|NCT01487811|Active Comparator|Formulation 2|
3261414|NCT01487824||Preterm-born Young Adults|
3261415|NCT01487824||Term-born Young Adults|
3261416|NCT01487837|Active Comparator|Fibrinogen if FibTEM < 8 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 8 mm
3261417|NCT01487837|Experimental|Fibrinogen if FibTEM < 13 mm|Administration of fibrinogen concentrate if ROTEM FibTEM revealed MCF < 13 mm
3261418|NCT01487876|Experimental|LAM+DNA vaccine|lamivudine (LAM) chemotherapy and DNA vaccine
3261419|NCT01487876|Placebo Comparator|LAM+Placebo|"Each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.~lamivudine (LAM) chemotherapy and Placebo"
3261420|NCT01487889|Experimental|Rapeseed oil|Study group receive commercial vegetable-potato-meat-meals containing rapeseed oil as part of complementary food
3261421|NCT01487889|Experimental|Fatty fish|Study group receive 2 times per week a vegetable-potato-meat-meals as part of complementary food.
3261422|NCT01487889|Active Comparator|Corn oil|Study group receive commercial vegetable-potato-meat-meals containing corn oil as part of complementary food
3261423|NCT01487902|Experimental|ADT arm|Concomitant androgen deprivation treatment
3261424|NCT01487902|Active Comparator|No ADT arm|No concomitant androgen deprivation treatment arm
3261425|NCT01487915|Active Comparator|GCb|Gemcitabine plus Carboplatin
3261426|NCT01487915|Experimental|GemOx|Gemcitabine plus Oxaliplatin
3261427|NCT01487928|Experimental|Human Milk Cream Group|For infants randomized to the human milk cream group, the human milk (either mother's own or donor) being provided to the infant will be tested each time a new container is used to prepare feedings. The test will be for the caloric content of the milk using a commercially available device provided for this purpose. If the caloric level falls below 20 kcal/oz for any test, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. The amount added will be calculated to the nearest mL rounding down for 0.1-0.4mL and up for 0.5-0.9 mL to avoid imprecision due to the measuring device used in the nutrition preparation area.
3261428|NCT01487928|No Intervention|Control Group|For infants randomized to the Control group, human milk and human milk derived fortifier will be provided according to the institutional standard of care and there will be no use of the milk analysis (mother's own or donor), which is typical for the vast majority of neonatal intensive care units.
3261429|NCT01487967|Experimental|Intervention|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
3261430|NCT01487967|No Intervention|Control|Parents will receive education on ADHD and its treatment, and otherwise receive standard care.
3261431|NCT01487980|Active Comparator|Early cord clamping|Within 30 seconds after birth.
3261432|NCT01487980|Experimental|Delayed cord clamping|Between 2 and 3 minutes after birth
3261433|NCT01487993|Active Comparator|Metformin|Metformin with lifestyle intervention during 18 months
3261434|NCT01487993|Placebo Comparator|Placebo|Placebo and lifestyle intervention during 18 months
3261435|NCT01488006||Bigliani/Flatow Shoulder System|Other than the Bigliani/Flatow device, there will be no difference in treatment between those patients undergoing arthroplasty with the Bigliani / Flatow prosthesis and those who previously received other prosthesis. APatients who decide to participate in the study will complete various forms prior to surgery (The Informed Consent, Contact Information Form, Demographics Module, and standard outcomes forms such as American Shoulder and Elbow Surgeon Score form, Constant's Score form, and the Simple Shoulder Test, EuroQOL and SF-36). The patient will also complete forms postoperatively at 3-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year intervals (American Shoulder and Elbow Surgeon Score form, Constant's Score form, Simple Shoulder Test, EuroQOL and SF-36).
3261436|NCT01488032||high-tension glaucoma|subjects with IOP>22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
3261437|NCT01488032||low-tension glaucoma|subjects with IOP<22 mmHg without eyedrops and signs of glaucomatous optic nerve damage
3261438|NCT01488045|Active Comparator|Fentanyl and Midazolam|Fentanyl and Midazolam sedation for colonoscopy discomfort
3261439|NCT01488045|Active Comparator|Propofol|Propofol sedation for colonoscopy discomfort
3261440|NCT01488058|Other|Group 2|Waitlist control
3261441|NCT01488058|Experimental|Group 1|CBM intervention (OxIGen) plus Internet based Cognitive Behavioural Therapy for depression
3261442|NCT01488084|Experimental|"Pedicled no-touch SVG harvesting"|Saphenous vein harvested with a pedicle of surrounding fat and distension with heparinized blood at arterial pressure. No manual distention.
3261443|NCT01488084|Active Comparator|Conventional open SVG harvesting|Saphenous vein is harvested with an open technique, stripped of adventitia, and manually distended with crystalloid solution.
3261444|NCT01488110|Experimental|Migraine medical device|Treatment with an active nasal probe
3261445|NCT01488110|Placebo Comparator|Inactive migraine medical device|Treatment with an inactive nasal probe.
3261446|NCT01488123|Experimental|Ayurvedic Intervention|
3261447|NCT01488136|Active Comparator|Diazoxide|Oral diazoxide 7 mg/kg
3261448|NCT01488136|Placebo Comparator|Placebo|Matched placebo
3261449|NCT01488149||Recipients of intrapartum epidural analgesia|
3261450|NCT01488149||Non-recipients of intrapartum epidural analgesia|
3261451|NCT01488162||Cohort|
3261452|NCT01488175|Active Comparator|with tourniquet|
3261453|NCT01488175|Placebo Comparator|without tourniquet|
3261454|NCT01488201|Experimental|KHK4827|
3261455|NCT01488201|Placebo Comparator|Placebo|
3261456|NCT01488214|Experimental|Scleroderma patient|Evaluation of Scleroderma patient
3261457|NCT01488214|Placebo Comparator|Healthy subjects|Evaluation of healthy subjects
3261458|NCT01488227|Experimental|Vitamin D|Vitamin D
3261459|NCT01488227|Placebo Comparator|Oil pill|Contains vegetable and soybean oil supplied by Nature Made by Pharmavite LLC located in Northridge, CA and is United States Pharmacopeia (USP) certified.
3261460|NCT01488240|Active Comparator|Proximal|part of scar proximal to heart
3261461|NCT01488240|Active Comparator|Distal|part of scar distal to heart
3261462|NCT01488253|Experimental|acute GVHD prevention by sirolimus based regimen|The investigators will evaluated the primary endpoint and secondary endpoints comparing with historical control, that is used tacrolimus/methotrexate as a GVHD prophylaxis after HLA-matched, related PBSCT.
3261463|NCT01488266|Experimental|aripiprazole augmentation|
3261464|NCT01488266|Active Comparator|different class of antidepressant|
3261465|NCT01488292|Experimental|RECAP social skills and reading program|
3261466|NCT01488292|No Intervention|Control group (services as usual)|Control Group (services as usual)
3261467|NCT01488305|No Intervention|Only government regular program|One arm is control arm, in this arm no additional program is added in government regular program
3261468|NCT01488305|Experimental|AAMA arm (HFP and IYCF BCC)|Second arm is AAMA project intervention which includes HFP activities, ENA and BCC activities
3261469|NCT01488305|Experimental|MNP added in AAMA|It is actually a intervention arm
3261470|NCT01488331||Cohort|
3261471|NCT01488344|Experimental|BIBF 1120|
3261472|NCT01488357||Early stage breast cancer patients receiving mastectomy|
3261473|NCT01488383|Experimental|Stevioside capsules 200mg|Capsules of 200mg Stevioside
3261474|NCT01488383|Active Comparator|Sodium Saccharin 250 capsules|Capsules of 250mg Saccharin
3261475|NCT01488396|Experimental|0.05%cyclosporin eye drop|
3261476|NCT01488422|Active Comparator|Group 1|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
3261477|NCT01488422|Active Comparator|Group 2|Both groups will receive stress reduction materials. We expect both groups to achieve similar amounts of stress reduction, but to use different brain regions to do so.
3261478|NCT01488435|Placebo Comparator|Cow's Milk|Powdered whole cow's milk
3261479|NCT01488435|Experimental|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
3261480|NCT01488461||patients ataxic|
3261481|NCT01488474||Diabetes Mellitus (DM)|Patients with diagnosed diabetes mellitus type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
3261482|NCT01488474||Control (C)|Patients with no history of diabetes mellitus Type 1 or 2 undergoing surgery of the lower limb and are receiving regional anesthesia with peripheral nerve stimulation
3261483|NCT01488500|Experimental|Filtered air exposure|3 hour exposure to filtered air with intermittent exercise
3261484|NCT01488500|Experimental|Wood smoke exposure|3 hour exposure to dilute wood smoke generated from incomplete combustion in a wood burning stove at approximately 300 mcg/m3
3261485|NCT01488500|Experimental|Wood pellet smoke emission|3 hour exposure to dilute wood smoke generated from wood pellets during incomplete combustion during intermittent exercise at approximately 300 mcg/m3
3376248|NCT01193842|Experimental|Arm A (VR-DA-EPOCH)|Patients receive vorinostat PO QD on days 1-5; rituximab IV on day 1; etoposide IV over 24 hours, doxorubicin hydrochloride IV over 24 hours, and vincristine sulfate IV over 24 hours on days 1-4; prednisone PO daily on days 1-5; and cyclophosphamide IV over 1 hour on day 5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3376249|NCT01193842|Experimental|ARM B (DA-R-EPOCH)|Patients receive rituximab, etoposide, doxorubicin hydrochloride, vincristine sulfate, prednisone, and cyclophosphamide as in Arm A. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3448425|NCT04064047|Active Comparator|External Anal application - 10 minutes exposure|Anal application of lidocaine cream 5% for 10 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
3448426|NCT04064047|Active Comparator|External Anal application - 20 minutes exposure|Anal application of lidocaine cream 5% for 20 minutes before probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
3448427|NCT04064047|Active Comparator|External Anal plus intrarectal - 5 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 5 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
3448428|NCT04064047|Active Comparator|External Anal plus intrarectal - 10 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 10 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
3448429|NCT04064047|Active Comparator|External Anal plus intrarectal - 20 minutes exposure|"Anal application plus intrarectal application of 5% lidocaine cream for 20 minutes before probe insertion.~After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side)."
3261486|NCT01488513|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sphingosine kinase-2 inhibitor ABC294640 PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3261487|NCT01488526|No Intervention|Control arm: HBIG & vaccine for infants|Provide standard of care to mothers and standard immunoprophylaxis to their infants
3261488|NCT01488526|Experimental|TDF treatment arm|tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum for mothers and standard immunoprophylaxis to their infants
3261489|NCT01488539|Experimental|STAIR/NT|Patients will receive STAIR/NT treatment
3261490|NCT01488539|Other|Treatment as Usual (TAU)|Patients will receive Treatment as Usual (TAU)
3261491|NCT01488552|Experimental|Gemcitabine & Abraxane Pancreatic Cancer|Gemcitabine+Nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin and Folfiri
3261492|NCT01488565|Experimental|Azacitidine and Eltrombopag|Vidaza (azacitidine) Revolade (eltrombopag)
3261493|NCT01488604|Experimental|PNS|2 sprays of experimental nasal spray per nostril 4 times per day for 7 days
3261494|NCT01488604|Sham Comparator|SNS|2 sprays of sham nasal spray per nostril 4 times per day for 7 days
3261495|NCT01488630|No Intervention|Treatment as Usual|Chart review only.
3261496|NCT01488630|Experimental|STaRS|Patients asked to participate in follow-up study to get information on whether they went to referral recommended by their provider through the STaRS system.
3261497|NCT01488643||OBESITY PATIENTS|PATIENTS WITH BMI >35
3261498|NCT01488643||CONTROL TEAM BMI <35|
3261499|NCT01488656|Placebo Comparator|Placebo dietary supplements|Visually identical inactive dietary supplement pack
3261500|NCT01488656|Experimental|Active dietary supplements|Combination of antioxidants, minerals, fish oil, proflavanol and vitamin D
3261501|NCT01488669|Experimental|Robotic neck dissection|Robotic neck dissection was performed via modified face lift or retroauricular approach using the robotic arms, while conventional neck dissection was conducted after transverse skin incision from the mastoid tip to the midline.
3261502|NCT01488669|Active Comparator|Conventional neck dissection|Neck dissection is performed after an external transverse skin incision.
3261503|NCT01488682|Experimental|Harmonic scalpel|Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
3261504|NCT01488682|Active Comparator|conventional hand tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels.
3261505|NCT01488695|Experimental|GlideScope Groove|Patient will be intubated using the GlideScope Groove device.
3261506|NCT01488695|Active Comparator|Control|Control Group: Macintosh Blade
3261507|NCT01488721||General Newborn Population-Prospective|Specimens prospectively collected in the course of routine newborn screening originating from hospitals, birthing centers, and/or clinics.
3261508|NCT01488721||Newborn Specimens-Confirmed Positive|Banked confirmed positive specimens that were originally collected as part of the newborn screening program, but when found to screen positive for a disease, were followed up clinically to definitively diagnose the subject with the disease (CF, CAH or CH). Follow up results were reported to the sites by the treating clinicians.
3261509|NCT01488734|Experimental|Mushroom with 600 IU vitamin D2|Mushroom with 600 IU of vitamin D2 daily and placebo tablet
3261510|NCT01488734|Experimental|Mushroom with 4000 IU Vitamin D2|Mushroom with 4000 IU of Vitamin D2 daily and placebo tablet
3261511|NCT01488734|Active Comparator|600 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 600 IU/day of Vitamin D3 and untreated mushroom
3261512|NCT01488734|Active Comparator|4000 IU Vitamin D3 and untreated mushroom|Commercially available tablets with 4000 IU/day of Vitamin D3 and untreated mushroom
3261513|NCT01488747|Experimental|Coromega Omega-3 Squeeze|5.03 g
3261514|NCT01488747|Experimental|Coromega Nectar|12.22 g
3261515|NCT01488747|Experimental|Barleans Swirl|17.45 g
3261516|NCT01488747|Active Comparator|Nordic Omega-3 Softgel|4 softgels
3261517|NCT01488760||Nineteen women with low back pain|
3261518|NCT01488760||Twenty pain-free women|
3261519|NCT01488773||ICS + salmeterol|"Patients treated with both inhaled glucocorticosteroid (ICS) and salmeterol (long-acting β2-agonist).~90 patients met the inclusion criteria for this group."
3261520|NCT01488773||ICS + montelukast|"Patients treated with both inhaled glucocorticosteroid (ICS) and montelukast (leukotriene receptor antagonist).~42 patients met the inclusion criteria for this group."
3261521|NCT01488786|Experimental|BrainPort Vision Device|Single Arm
3261522|NCT01488799|Active Comparator|MI-CBT|
3261523|NCT01488799|Active Comparator|CBT alone|
3261524|NCT01488812||Hip-fracture patients|All the hip-fracture patients admitted to the Orthopaedic Depart of Danderyd Hospital between 1st June 2007- 1st June 2008 who fulfilled the inclusion criteria of the study.
3261525|NCT01488825|No Intervention|Wait-list control group|The wait-list control group received no intervention, or instruction and they were observed with their usual care for 12-weeks intervention period. Upon completion of the study, this group received 12 weeks of yoga intervention.
3261526|NCT01488825|Experimental|Yoga Intervention Group|The yoga sessions developed specifically for study participant consisted of 12 weekly 60-minute designed to benefit in episodic tension type headache.
3261527|NCT01488838|Experimental|Arm 1:|Radiation: 60-66 Gy in 2 Gy daily fractions Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
3261528|NCT01488838|Active Comparator|Arm 2:|Radiation: 60-66 Gy in 2 Gy daily fractions
3261529|NCT01488864|Experimental|Applied Relaxation (AR)|
3261530|NCT01488864|No Intervention|Untreated Control Group (CG)|The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
3261531|NCT01488903||Premenopausal Women|600 health premenopausal Women
3261532|NCT01488903||Postmenopausal women|600 healthy postmenopausal women
3261533|NCT01488916||Vitamin D deficiency|patients with serum vitamin D levels of the lower tertile
3261534|NCT01488916||Vitamin D inadequacy|patients with serum vitamin D levels of the middle tertile
3261535|NCT01488916||Reference group|patients with serum vitamin D levels of the upper tertile
3261536|NCT01488929|Experimental|5 mg TC-5619|One tablet of 5 mg TC-5619 will be administered orally once a day.
3261537|NCT01488929|Experimental|50 mg TC-5619|One tablet of 50 mg TC-5619 will be administered orally once a day.
3261538|NCT01488929|Placebo Comparator|Placebo|One tablet of placebo will be administered orally once a day.
3261539|NCT01488942|Experimental|monetary reinforcer|Subjects randomized to this arm will receive an escalating reinforcer initially for attendance at each clinic visit (until month 6 after starting HAART) and subsequently (until month 12 after starting HAART) will receive an escalating variable reinforcer for each month in which a viral load at or below 100 copies/mL is maintained
3261540|NCT01488942|No Intervention|no reinforcer|All subjects will receive HAART and standard medical care, but subjects in the control arm will not receive monetary reinforcers.
3261541|NCT01488955|Experimental|Ibuprofen|Ibuprofen 400 mg oral once daily from day 0 for 3 days, placebo granulate oral day 0
3261542|NCT01488955|Experimental|Fosfomycin-Trometamol|Fosfomycin-Trometamol (Monuril) 3 g granulate oral at day 0, placebo to Ibuprofen once a day from day 0 for 3 days
3261543|NCT01488968|Active Comparator|Standard|Standard Radiation Treatment
3261544|NCT01488968|Experimental|Hypofractionated|Hypofractionated
3261545|NCT01489007||Vegetarian Children|"Self-described lacto-ovo vegetarians for the past 6 months (Subjects who include a small amount of fish or chicken in the diet (not more than 2 servings total/week of both combined) will be allowed to participate in this study as these are not major iron contributors to the diet. Subjects must not have eaten any red meat however for 6 months.) Control subjects will be non-vegetarians."
3261546|NCT01489033|Experimental|Group A active|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3261547|NCT01489033|Placebo Comparator|Group A placebo|"6 administrations and 5 weeks duration~Vial 2: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml and 0.5 ml at 1 week intervals."
3261548|NCT01489033|Experimental|Group B active|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3261549|NCT01489033|Placebo Comparator|Group B placebo|"8 administrations and 7 weeks duration~Vial 1: 0.2 ml at 1 week intervals~Vial 2: 0.1 ml, 0.2 ml, 0.4 ml at 1 week intervals~Vial 3: 0.1 ml, 0.2 ml, 0.4 ml and 0.5 ml at 1 week intervals"
3261550|NCT01489033|Experimental|Group C active|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3261551|NCT01489033|Placebo Comparator|Group C placebo|"8 administrations, 2 administrations in the same day. 1 week interval between 2 doses, during 3 weeks.~Week 1: vial 2 - 2 administrations of 0.1 ml with 30 minute interval~Week 2: vial 2 - 0.2 ml and 0.3 ml with 30 minute interval~Week 3: vial 3 - 2 dose of 0.1 ml with 30 minute interval~Week 4: vial 3 - 0.2 ml and 0.3 ml with 30 minute interval"
3261552|NCT01489046|Experimental|Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine|
3261553|NCT01489046|Experimental|Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine|
3261554|NCT01489046|Experimental|Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine|
3261555|NCT01489046|Experimental|Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine|
3261556|NCT01489059|Experimental|Part 1 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Dose Escalation
3261557|NCT01489059|Experimental|Part 1 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Dose Escalation
3261558|NCT01489059|Experimental|Part 2 - Arm 1: BMS-982470 (Daily x 5) + Ipilimumab|Cohort Expansion
3261559|NCT01489059|Experimental|Part 2 - Arm 2: BMS-982470 (Weekly) + Ipilimumab|Cohort Expansion
3261560|NCT01489059|Active Comparator|Part 2 - Arm 3: Ipilimumab monotherapy|Cohort Expansion
3261561|NCT01489072|Experimental|Remifentanil 0.25 mcg/kg|Administration of a bolus dose of remifentanil 0.25 mcg/kg before emergence of a desflurane-based anesthesia
3261562|NCT01489072|Active Comparator|Remifentanil 0.5 mcg/kg|Administration of a bolus dose of remifentanil 0.5 mcg/kg before emergence of a desflurane-based anesthesia
3261563|NCT01489098||Breast Fed reference group|3 and 5 year olds from the above group
3261564|NCT01489098||Infant formula - protein level 1|3 ad 5 year olds from the above group
3261565|NCT01489098||Infant formula - protein level 2|3 and 5 year olds from the above group
3261566|NCT01489124|Experimental|0.5 g of imipenem by 0.5-hr infusion|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
3261567|NCT01489124|Experimental|0.5 g of imipenem by 2-hr infusion|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
3261568|NCT01489124|Experimental|1 g of imipenem by 2-hr infusion|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
3261569|NCT01489137|Experimental|neurosurgery with fixation|
3261570|NCT01489163|Experimental|Lifestyle Counseling|
3261571|NCT01489163|No Intervention|Control|
3261572|NCT01489176|Experimental|Regadenoson; Optison|Use of Regadenoson as the chemical stress agent using Optison as a contrast agent during stress echocardiography.
3261573|NCT01489202|Active Comparator|platinum chromium EES|Patients undergoing PCI with stenting will have implantation of platinum chromium everolimus-eluting stents
3261574|NCT01489202|Active Comparator|cobalt chromium everolimus-eluting stent|Patients undergoing PCI with stenting will have implantation of cobalt chromium everolimus-eluting stents
3261575|NCT01489215|Experimental|"Clinical group-presence intervention"|"The Presence intervention is based on based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine."
3261576|NCT01489215|Experimental|"Clinical group-checking intervention"|"The Checking training is based on the principles of graduated extinction, which has been defined has been defined as effective and recommended therapy in the treatment of bedtime problems and night wakings by the Standard of Practice Committee of the American Academy of Sleep Medicine"
3261577|NCT01489215|No Intervention|Control Group|
3261578|NCT01489228|Experimental|High Dose E1224|High Dose (HD - 8weeks) Group
3261579|NCT01489228|Experimental|Low Dose E1224|Low Dose (LD - 8 weeks) Group
3261580|NCT01489228|Experimental|Short Dose E1224|Short Dose (SD - 4 weeks) Group
3261581|NCT01489228|Placebo Comparator|Placebo|Placebo (8 weeks) Group
3261582|NCT01489228|Active Comparator|Benznidazol|BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days
3261583|NCT01489241|No Intervention|Usual care|Patients in the control group receive usual care and visit the outpatient department at 4 and at 12 weeks after discharge when pulse rate, oxygen saturation and spirometry is performed. In the case of clinical deterioration during the study, the patients contact as usual their general practitioner. Usual care of COPD patients consists of regular visits to the specialist or primary care clinics every time a medication change is made or a medical examination is needed
3261584|NCT01489241|Experimental|Telemonitoring|
3261585|NCT01489267|No Intervention|Control group|Ten patients in the group only receive nerve functional evaluation and electrophysiology examination before and 1,3,6,12 months after recruit. They will not accept cell therapy.
3261586|NCT01489267|Experimental|Stem cell transplantation|10 patients in the group accept stem cell transplantation.
3261587|NCT01489293||atopic subjects|Patients with one atopic disease or more (atopic dermatitis,rhinitis, asthma, food allergy)
3261588|NCT01489293||non-atopic subjects|Control group without atopic diseases.
3261589|NCT01489306|Experimental|MDT-637|Active formulation
3261590|NCT01489306|Placebo Comparator|Placebo|Matched Placebo Comparator
3261591|NCT01489319|Experimental|Nl Wt PCOS - Nl Abdominal Adiposity|10 normal weight women with PCOS who have normal abdominal adiposity established by DEXA
3261592|NCT01489319|Experimental|Nl Wt PCOS - Increased Abdominal Adiposity|10 normal weight women with PCOS who have increased abdominal adiposity established by DEXA
3261593|NCT01489319|No Intervention|Obese PCOS|10 obese women with PCOS
3261594|NCT01489319|No Intervention|Nl Wt Controls - Nl Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have normal abdominal adiposity established by DEXA
3261595|NCT01489319|No Intervention|Nl Wt Controls - Increased Abdominal Adiposity|10 normal weight ovulatory women serving as controls who have increased abdominal adiposity established by DEXA
3261596|NCT01489319|No Intervention|Obese Controls|10 obese ovulatory women serving as controls
3261597|NCT01489345|Experimental|Arm 1: Experimental|
3261598|NCT01489345|Placebo Comparator|Arm 2: Placebo Comparator|
3261599|NCT01489371|Experimental|Treatment (EGEN-001, pegylated liposomal doxorubicin)|Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and EGEN-001 IP over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3261600|NCT01489384||3 months: Discontinue vs continue DMARDS|At 3 months those patients who achieved a change in DAS28 of 1.2 or greater will be randomized to discontinue versus continue DMARDs and will be followed for an additional 15 months
3261601|NCT01489384||6 months: discontinue vs continue DMARDs|(Protocol amendment 4.0)At 6 months, those patients still on Cimzia and DMARD therapy who were not randomized at month 3 AND achieve a change in DAS28> 1.2 will be randomized to discontinue versus continue DMARDs and will be followed for an additional 12 months.
3261602|NCT01489384||6 months: D/C vs Cont'd DMARDs if change in DAS28|(Protocol amendment 4.0)At 6 months, if the change in DAS28 is at least 0.6 and there is a decision to continue Cimzia, then the patients will be randomized to discontinue versus continue DMARDs with Cimzia and will be followed for an additional 12 months.
3261603|NCT01489384||3 or 6 months: stop CIMZIA and treat as per SOC|(Protocol amendment 4.0)If a change in DAS28 of <0.6 occurs at 6 months (at 3 months for protocol amendment 6.1)in patients not randomized at month 3 then the patient will stop Cimzia and treatment will be standard of care. However, patient will still be followed until the end of study.
3261604|NCT01489397|Experimental|Gastric intestinal metaplasia|
3261605|NCT01489397|Placebo Comparator|Normal|
3261606|NCT01489410|Active Comparator|Drug-Eluting Beads with Doxorubicin|Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
3261607|NCT01489410|Active Comparator|Lipiodol Ethanol Mixture (LEM)|Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
3261608|NCT01489436|Active Comparator|Single port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary; this device is placed percutaneously without the need for a trocar. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port, adequate hemostasis is ensured, the umbilical trocar removed, and the single operative site will be closed and sterile dressings applied (four Band-Aids).
3261609|NCT01489436|Active Comparator|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder. Trocar sites will be closed and sterile dressings applied (four Band-Aids).
3261610|NCT01489449|Placebo Comparator|Stent|Stent Implantation (DES or BMS), no further treatment
3261611|NCT01489449|Active Comparator|DCB|"DEBonly strategy: treatment with drug coated balloon, additional spot-stenting in case of severe dissection"
3261612|NCT01489462|Experimental|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
3261613|NCT01489462|Experimental|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
3261614|NCT01489462|Active Comparator|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
3261615|NCT01489488|Experimental|Arm 1|
3261616|NCT01489488|Experimental|Arm 2|
3261617|NCT01489488|Experimental|Arm 3|
3261618|NCT01489488|Experimental|Arm 4|
3261619|NCT01489488|Experimental|Arm 5|
3261620|NCT01489501|Experimental|only one arm available|Caomecs transplantation on eye cornea.
3261621|NCT01489514||Peanut allergic subjects|
3261622|NCT01489540|Active Comparator|new diagnostic strategy|Combination of laser Doppler imaging and clinical assessment of burn depth
3261623|NCT01489540|No Intervention|current diagnostic strategy|Clinical assessment of burn depth
3261624|NCT01489566|Active Comparator|Tyroserleutide for injection|the Tyroserleutide for injection at the dosage of 6mg/d
3261625|NCT01489566|Placebo Comparator|the placebo|
3261626|NCT01489592|Experimental|curcumin|oral administration of 6g of curcumin
3261627|NCT01489592|Placebo Comparator|placebo|oral administration of 12 sugar pill
3261628|NCT01489605|Experimental|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
3261629|NCT01489605|Active Comparator|Control: Standard GlideScope|Control: Patients will be intubated using standard practice, a standard GlideScope (Verathon)
3261630|NCT01489618|Active Comparator|PPS|Group 1: patients will a single administration of the PPS (one dose at W4). 25 patients will be randomised in this group.
3261631|NCT01489618|Experimental|PnCJ PPS|Group 2: patients will receive a first boost with the PnCj (one dose at W0) and then one administration of the PPS vaccines (one dose at W4). 47 patients will be randomised in this group.
3261632|NCT01489631|Active Comparator|epidural analgesia|The first group will be treated with epidural analgesia. Before surgery the epidural catheter will be placed according to local guidelines. After the operation epidural infiltration with bupivacaine and sufentanil will be commenced.
3261633|NCT01489631|Active Comparator|local infiltration|The second group will receive local infiltration with ropivacaine of the knee during surgery.
3261634|NCT01489631|Active Comparator|local infiltration and gabapentin|The third group will receive local infiltration with ropivacaine of the knee during surgery and will additionally be treated with gabapentin.
3261635|NCT01489644|Experimental|Treatment period 1|
3261636|NCT01489644|Experimental|Treatment period 2|
3261637|NCT01489644|Experimental|Treatment period 3|
3261638|NCT01489644|Active Comparator|Treatment period 4|
3261639|NCT01489683|Experimental|control|3 ml of normal saline was instilled to larynx and trachea
3261640|NCT01489683|Active Comparator|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea before endotracheal intubation
3261641|NCT01489696|Experimental|Treatment Arm 1|tamsulosin singles doses; mirabegron multiple dose
3261642|NCT01489696|Experimental|Treatment Arm 2|mirabegron single doses; tamsulosin multiple dose
3261643|NCT01489709||Vesicare group|Who receive vesicare
3448430|NCT04064047|Sham Comparator|Control group|No anal application of lidocaine cream prior to probe insertion. After probe insertion and prior to biopsy, a periprostatic nerve block was performed with 10 mL of 1% Lidocaine (5 mL on each side).
3448431|NCT04064164|Experimental|Treatment|The treatment NHs will received immediate feedback from the Speeko App after each recording sessions
3261644|NCT01489722|Experimental|AZD1208|Single ascending dose escalation of 3 - 6 patient cohorts until maximum tolerated dose (MTD) is established. Up to 12 patients may be included at any dose not determined to be intolerable. Safety expansion using MTD in up to 44 Acute myelogenous leukemia (AML) patients.
3261645|NCT01489735||1|
3448432|NCT04064164|No Intervention|Control|The Control NHs will not receive app feedback until all recording sessions are complete.
3448433|NCT04064034|Experimental|Subjects with pancreas cancer|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
3261646|NCT01489761|Active Comparator|zotarolimus-eluting stent|Resolute Integrity or Resolute Onyx stent
3261647|NCT01489761|Experimental|everolimus-eluting stent|Xience Prime or Xience Xpedition or Xience Alpine stent
3261648|NCT01489774|Placebo Comparator|Placebo|
3261649|NCT01489774|Experimental|CJ-12406|CJ-12406 Tablet, daily for 1 day or bid for 10 days
3261650|NCT01489787|Experimental|Phase I : HIFU|
3261651|NCT01489787|Experimental|Phase IIa : HIFU|
3261652|NCT01489787|Experimental|Phase IIb : HIFU|
3261653|NCT01489800|Experimental|Early Feeding|Introduction of clear liquid diet 24 hours after extubation with advancement to regular diet 24 hours thereafter if there is no significant nausea or vomiting.
3261654|NCT01489800|No Intervention|Control Feeding|Standard of care with introduction of clear liquid diet at time of return of bowel function as determined by flatus. Advancement to full diet 24 later if clear diet well tolerated.
3261657|NCT01489839||Periodontal diseased|Subjects with periodontal disease will be enrolled. Subjects with mild disease will have at least 4 teeth with at least 1 site with pocketing of 5 mm or more and concomitant attachment greater than or equal to 2 mm, and radiographic evidence of mesial or distal alveolar bone loss around at least 2 of the affected teeth. Subjects with severe disease will have at least 8 teeth with a site having >5mm pocketing and loss of 3 mm attachment with evidence of alveolar bone loss in 2 teeth.
3261658|NCT01489839||Periodontally healthy|Periodontally healthy subjects have no teeth with pocketing of 4 mm or greater and attachment loss, with the exception of the distal of the second molars where a pocket of 4 mm and concomitant attachment of up to 2 mm will be acceptable. Healthy subjects can have up to 3 sites with gingival recession and no radiographic evidence of alveolar bone loss.
3261659|NCT01489852|Active Comparator|Estrogen pre-treatment|
3261660|NCT01489852|No Intervention|Control|The control group did not receive any pre-treatment.
3261661|NCT01489865|Experimental|ABT-888 and mFOLFOX-6|ABT-888 orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
3261662|NCT01489878||β-lactams|amoxicillin-clavulanate or penicillins M
3261663|NCT01489878||macrolides|
3261664|NCT01489878||fluoroquinolones|
3261665|NCT01489878||synergistins|
3261666|NCT01489904|Experimental|Botulinum Toxin|Botulinum Toxin type-A
3261667|NCT01489904|No Intervention|Control Treatment|No intervention
3261668|NCT01489917|No Intervention|Compression without adjustment|TR band (Terumo medical) applied. The TR band is then deflated gradually till pulsatile bleeding is observed under the transparent plastic inflatable chamber and then 1-2 cc of air is placed back in the TR band chamber to stop bleeding. The band is left in place for 2 hours and not adjusted further unless patient complained of symptoms or bleeding occurred.
3261669|NCT01489917|Experimental|Patent hemostasis & heparin|TR-band is placed and positioned similarly to the other study arm. However, in theses cases, patency is evaluated at the time of application of the TR-band, and monitored every 15 minutes afterwards till the band is removed and hemostasis completed. After TR-band placement, if maintenance of radial artery patency is obtained, no heparin is administered and TR band is left in place for 1-hour. If radial artery patency is not maintained, a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the band is left in place for 2 hours.
3261670|NCT01489930|Experimental|Endurance Exercise|Participants will perform 8-weeks of moderate intensity endurance (cycling) exercise
3261671|NCT01489930|Experimental|Resistance Exercise|Participants will perform 8-weeks of whole-body resistance exercise training.
3261672|NCT01489930|Experimental|Control / Combined Training|Participants will perform 8-weeks of no exercise, followed by an additional 8-weeks of combined endurance plus resistance exercise training.
3261673|NCT01489943|Experimental|All subjects receiving treatment|During the treatment subjects will receive Midazolam 3 mg on Day 1, Pioglitazone 15 mg on Day 2, Omeprazole 40 mg on Day 3, Rosuvastatin 10 mg on Day 4, GSK1605786 500 mg twice daily (BID) from Day 5 to 10, GSK1605786 500 mg BID + Midazolam 3 mg on Day 11, GSK1605786 500 mg BID + Pioglitazone 15 mg on Day 12, GSK1605786 500 mg BID + Omeprazole 40 mg on Day 12, GSK1605786 500 mg BID + Rosuvastatin 10 mg on Day 14 as single sequence.
3261674|NCT01489982|Experimental|Light therapy|For patients who have sleep maintenance insomnia light therapy will be administered daily. If patients suffer only from sleep onset insomnia, this light therapy will be given upon awakening in the morning. Light boxes will be provided by Litebook company. In the active therapy group, the intensity of the light will be set at 10,000 lux with a head-to-light distance of 20cm. Patients will be instructed to let the light shine indirectly on their eyes (i.e. they do not look directly at the light). Patients can be reading, eating, watching TV, etc., during the time of light therapy.
3261675|NCT01489982|Experimental|CBT and sleep hygiene training|This will involve education about sleep in general, giving techniques related to sleep and relaxation, tips on stress management, etc.. This will take place at the Lady Davis Institute of the Jewish General Hospital. There will be 6 weekly sessions totalling 90 minutes - most of the time this will be in a group setting, with a maximum of 6 patients per group. Light therapy will also be part of this treatment strategy. There will be separate gropus for English and French-speaking patients
3261676|NCT01489982|Experimental|Insomnia medications|Pharmacologic treatment will be individualized depending on patient characteristics and initial response. It will consist of two potential treatments - Doxepin or Zopiclone. Both of these agents are currently used commonly in the general population and also in PD patients. The agents will be prescribed exactly as any other medical prescription (i.e. patients will fill their own prescriptions at their own pharmacy).The decision for which agent to use will be as follows: a)If patients suffer from sleep onset insomnia (with or without sleep maintenance insomnia), or if doxepin is contraindicated, Zopiclone will be prescribedb) or b)If patients suffer from sleep maintenance insomnia only (or if Zopiclone is contraindicated), Doxepin will be the first choice agent.
3261677|NCT01489982|Placebo Comparator|Placebo intervention of light therapy|The inactive/placebo intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles. This therefore functions as a placebo condition for the active light therapy protocol. Patients be informed that some forms of light therapy will be expected to be less active, but we will not disclose what type of condition is inactive.
3261678|NCT01489995|Experimental|Reference|Fasted
3261679|NCT01489995|Experimental|Glucose Drink|Fed
3261680|NCT01489995|Experimental|Before High Fat Meal|Fed
3261681|NCT01489995|Experimental|Before Light Meal|Fed
3261682|NCT01489995|Experimental|After Light Meal|Fed
3261683|NCT01490008|Experimental|Veregen|Veregen® (sinecatechins) Ointment, 15%, local application of 250 mg corresponding to 0.5 cm strand of ointment, 3 times daily (total dose of 750 mg/d)
3261684|NCT01490008|Active Comparator|Tea|"Lipton® Green Limone, a green tea beverage; oral intake of 500 mL green tea, 3 times daily (total dose on 1500 mL/d)"
3261685|NCT01490021|Experimental|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
3261686|NCT01490021|Placebo Comparator|rTMS/Placebo TBS|rTMS/Placebo TBS
3261687|NCT01490034|Experimental|Energy dense beverage|Metabolic effects of consuming energy dense beverages before and after regular consumption
3261688|NCT01490034|Experimental|Energy dense solid food form|Metabolic effects of consuming energy dense solid foods before and after regular exposure.
3261689|NCT01490034|Experimental|Eenergy dilute beverages|Metabolic effects of consumption of energy dilute beverages on a regular basis.
3261690|NCT01490034|Experimental|Energy dilute solid food form|Metabolic effects of consuming energy dilute sold foods before and after regular exposure.
3261691|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 40 mg/m²|Cohort 2: rhTNF-α 25 µg/m² + Caelyx 40 mg/m²
3261692|NCT01490047|Experimental|rhTNF-α 50 µg/m² + Caelyx 40 mg/m²|Cohort 3: rhTNF-α 50 µg/m² + Caelyx 40 mg/m²
3261693|NCT01490047|Experimental|rhTNF-α 100 µg/m² + Caelyx 40 mg/m²|Cohort 4: rhTNF-α 100 µg/m² + Caelyx 40 mg/m²
3261694|NCT01490047|Experimental|rhTNF-α 150 µg/m² + Caelyx 40 mg/m²|Cohort 5: rhTNF-α 150 µg/m² + Caelyx 40 mg/m²
3261695|NCT01490047|Experimental|rhTNF-α 200 µg/m² + Caelyx 40 mg/m²|Cohort 6: rhTNF-α 200 µg/m² + Caelyx 40 mg/m²
3261696|NCT01490047|Experimental|rhTNF-α 250 µg/m² + Caelyx 40 mg/m²|Cohort 7: rhTNF-α 250 µg/m² + Caelyx 40 mg/m²
3261697|NCT01490047|Experimental|rhTNF-α 25 µg/m² + Caelyx 30 mg/m²|Cohort 1 rhTNF-α 25 µg/m² + Caelyx 30 mg/m²
3261698|NCT01490099|Experimental|Treatment period 1|
3261699|NCT01490099|Active Comparator|Treatment period 2|
3261700|NCT01490112||IAsp|
3261701|NCT01490164||scoliosis|young adults requiring surgical correction
3261702|NCT01490177|Experimental|One|
3261703|NCT01490203||Group 1: HCC resection/RFA|Patients who will undergo resection of at least two hepatic segments for HCC or radiofrequency ablation (RFA) for HCC and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
3261704|NCT01490203||Group 2: Potential liver donor|Potential liver donors with normal hepatic function and and underwent gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI
3261705|NCT01490216|Other|lisdexamfetamine|open label
3261706|NCT01490229|Active Comparator|Ezetimibe|Patients assigned to ezetimibe will receive for 1 year ezetimibe (10 mg/day)
3261707|NCT01490229|Active Comparator|Nutraceuticals|Patients assigned to nutraceuticals will receive for 1 year 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg
3261708|NCT01490255|Active Comparator|Ranolazine|Patients will receive ranolazine (750 mg bid) for 15 days
3261709|NCT01490255|Active Comparator|Amlodipine|Patients will receive amlodipine (10 mg once daily) for 15 days
3261710|NCT01490268|Active Comparator|Sufentanil Group 1|Sufentanil Low Titration
3261711|NCT01490268|Active Comparator|Sufentanil Group 2|Sufentanil High Titration
3261712|NCT01490281|Experimental|water-based exercise intervention|
3261713|NCT01490281|Experimental|land-based exercise intervention|
3261714|NCT01490281|No Intervention|Control group|
3261715|NCT01490307|Experimental|FCU offered|
3261716|NCT01490307|No Intervention|No feedback or services offered|
3261717|NCT01490320|Placebo Comparator|Control|Parents in control group experienced a routine primary care visit.
3261718|NCT01490320|Experimental|Handout intervention|"Caregivers assigned to the hand-out group were instructed to read the AAP hand-out Pulling the Plug On TV Violence. This 2 page hand-out emphasizes the negative effect that television has on children's behavior and makes recommendations about limiting media. The RA did not supervise the reading of the handout."
3261719|NCT01490320|Experimental|Multimedia intervention|"Caregivers assigned to the multimedia group were instructed to watch Recommendation 3: Decrease Exposure to Violence from the Play Nicely program, a 5 minute video in English and Spanish that teaches caregivers about the negative impact of violent media and instructs parents about the importance of limiting media. The intervention was presented to the parents on a mobile laptop computer."
3261720|NCT01490333|Experimental|2500 IU Vitamin D3|
3261721|NCT01490333|Active Comparator|400 IU Vitamin D3|
3261722|NCT01490346||ART treated individuals|
3261723|NCT01490372||GDM offspring|Children born from gestational diabetes mellitus pregnancy
3261724|NCT01490372||No-GDM offspring|Children born from a normal pregnancy
3376250|NCT01168219|Experimental|Treatment (chemotherapy and transplant)|"REDUCED-INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 45 minutes on days -6 to -3, and anti-thymocyte globulin IV over 4-10 hours on days -6 to -5 (matched sibling donor [MSD]) or -6 to -4 (matched unrelated donor [MUD]).~TRANSPLANTATION: Patients undergo allogeneic hematopoietic stem cell transplantation on day 0 or on days 0-1.~GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus PO or IV on days -2 to 90 with taper on days 150-180. Patients also receive methotrexate IV on days 1, 3, 6 (MSD), and 11 (MUD).~CONSOLIDATION: Beginning on day 42, patients receive azacitidine SC or IV on days 1."
3261725|NCT01490385|Active Comparator|LED Phototherapy|LED phototherapy will be delivered transdermally via an extra-oral device and in a split mouth manner (half of the dental arch).
3376251|NCT01104220|No Intervention|Lean, metabolically normal|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
3376252|NCT01104220|No Intervention|Obese, metabolically normal|Subjects with body mass index ≥30.0 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
3376253|NCT01104220|No Intervention|Obese, metabolically abnormal|Subjects with body mass index ≥30.0 kg/m² and impaired fasting or oral glucose tolerance and increased liver fat.
3376254|NCT01104220|Experimental|Obese, scheduled for bariatric surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing bariatric surgery
3261726|NCT01490385|No Intervention|Control: conventional orthodontic tooth movement|
3261727|NCT01490398|Experimental|Rosuvastatin|Rosuvastatin 10mg qd for 12 months.
3261728|NCT01490411|Placebo Comparator|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV.
3261729|NCT01490411|Experimental|20 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3261730|NCT01490411|Experimental|80 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3261731|NCT01490411|Experimental|160 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3261732|NCT01490411|Experimental|320 µg rBet v1-FV Immunotherapy|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
3261733|NCT01490424||sepsis|SIRS plus inflammation
3261734|NCT01490424||Control|normal person under medical examination
3261735|NCT01490437|Experimental|PemCis|Pemetrexed plus Cisplatin
3261736|NCT01490476|Experimental|RAD001|Patient with Neurofibromatosis Type 2 and Vestibular Schwannoma treated with RAD001.
3261737|NCT01490489|Other|Pregnent women with blood sample|
3261738|NCT01490502|Active Comparator|Low-dose vitamin D3|
3261739|NCT01490502|Active Comparator|High-dose vitamin D3|
3261740|NCT01490515|Active Comparator|Morphology embryo evaluation|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
3261741|NCT01490515|Experimental|non-invasive metabolomic profiling|To compare non-invasive metabolomic profiling and the traditional method of morphology assessment for embryo selection in terms of implantation and pregnancy rates in a clinical IVF program.
3261742|NCT01490541||Gastric intestinal metaplasia patient|
3261743|NCT01490554|Experimental|autologous fibroblast grafts|autologous fibroblast grafts
3261744|NCT01490567|Placebo Comparator|placebo|Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
3261745|NCT01490567|Active Comparator|donepezil|Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
3261746|NCT01490593||Patients with Eye Injuries|The database is being established to record the number and types of eye injuries occurring in Canada. Thus there is only one cohort group, individuals who have sustained an eye injury.
3261747|NCT01490606|Experimental|knee OA project|12 sessions of PT, 6 INDIVIDUAL AND 6 GROUP TREATMENTS
3261748|NCT01490606|No Intervention|conventional PT|
3261749|NCT01490619|Experimental|Healthy Thinking in Teens|Group-based, manualized program, based on cognitive behavioral therapy techniques.
3261750|NCT01490619|Active Comparator|Advanced Diabetes Education|Group-based, manualized program designed to provide diabetes education, focused on adolescent-specific topics.
3261751|NCT01490645||one group (all patients)|
3261752|NCT01490658|Experimental|Treatment period 1|
3261753|NCT01490658|Experimental|Treatment period 2|
3261754|NCT01490658|Active Comparator|Treatment period 3|
3261755|NCT01490671|Experimental|Group 1a (tenofovir gel)|Group 1a will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive 1% tenofovir gel
3261756|NCT01490671|Placebo Comparator|Group 1b (placebo gel)|Group 1b will include women with a gestational age range of 36 0/7 to 37 6/7 weeks; they will receive placebo gel.
3261757|NCT01490671|Experimental|Group 2a (tenofovir gel)|Group 2a will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive 1% tenofovir gel.
3261758|NCT01490671|Placebo Comparator|Group 2b (placebo gel)|Group 2b will include women with a gestational age range of 28 0/7 to 32 6/7 weeks; they will receive placebo gel.
3261759|NCT01490671|Experimental|Group 3a (tenofovir gel)|Group 3a will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive 1% tenofovir gel.
3261760|NCT01490671|Placebo Comparator|Group 3b (placebo gel)|Group 3b will include women with a gestational age range of 20 0/7 to 24 6/7 weeks; they will receive placebo gel.
3261761|NCT01490671|Experimental|Group 4a (tenofovir gel)|Group 4a will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive 1% tenofovir gel.
3261762|NCT01490671|Placebo Comparator|Group 4b (placebo gel)|Group 4b will include women with a gestational age range of 12 0/7 to 16 6/7 weeks; they will receive placebo gel.
3261763|NCT01490736|Experimental|LTS/Vehicle|Within subject control study
3261764|NCT01490749|Experimental|XELOX/Radiation/Carboplatin/RAD001|Patients receive XELOX comprising oxaliplatin intravenously (IV) over 120 minutes on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then undergo radiotherapy (RT) 5 days a week for up to 6 weeks. Patients also receive carboplatin IV over 15 minutes to 24 hours once weekly for 5-6 weeks and RAD001 PO every other day (QOD) or once daily (QD) for 5-6 weeks during radiation therapy (RT). Patients with resectable disease undergo surgery.
3261765|NCT01490762|Active Comparator|Regular Human Insulin|Subcutaneous injection
3261766|NCT01490762|Experimental|TI and Regular Human Insulin|All subjects have 4 clamp procedures with 10, 30, 60,80 units of TI and 1 clamp with 15 IU Regular Human Insulin
3261767|NCT01490775|Experimental|eMedonline access|patients will be followed for 3 months with access to eMedonline
3261768|NCT01490775|Active Comparator|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
3261769|NCT01490827||Argus II Retinal Prosthesis|Patients implanted with an Argus II Retinal Prosthesis
3261770|NCT01490853||CML and interpheron alpha|Adult Ph+CML pts in CCgR after IFN alpha.
3261771|NCT01490879|Experimental|Nexagon® Low Dose|Twice weekly applications of Nexagon® low dose in addition to off-loading using a Removable Cast Walker
3261772|NCT01490879|Experimental|Nexagon® Medium Dose|Twice weekly applications of Nexagon® medium dose in addition to off-loading using a Removable Cast Walker
3261773|NCT01490879|Experimental|Nexagon® High Dose|Twice weekly applications of Nexagon® high dose in addition to off-loading using a Removable Cast Walker
3261774|NCT01490879|Placebo Comparator|Nexagon® vehicle|Twice weekly applications of Nexagon® vehicle in addition to off-loading using a Removable Cast Walker
3261775|NCT01490905|Active Comparator|Theramine active and ibuprofen placebo|2 capsules Theramine twice daily with one ibuprofen-like placebo once daily.
3261776|NCT01490905|Active Comparator|Theramine and Ibuprofen (Theraprofen)|Two capsules Theramine twice daily with Ibuprofen 400mg once daily.
3261777|NCT01490905|Active Comparator|Theramine placebo and Ibuprofen|Two Theramine-like placebo twice daily and one ibuprofen 400mg.
3261778|NCT01490944|Active Comparator|Iron and Folic Acid|
3261779|NCT01490944|Experimental|Iron, Folic acid and cyanocobalamin|
3261780|NCT01490983|Experimental|eMedonline access|patients will have access to eMedonline access for 3 months
3261781|NCT01490983|Other|no access to eMedonline|patients will be followed for 3 months with no access to eMedonline
3261782|NCT01490996|Active Comparator|Chemotherapy only|Patients receiving up to 12 cycles of therapy. Standard care pathway management.
3261783|NCT01490996|Experimental|Chemotherapy plus curcumin|Patients taking daily oral curcumin for up to 12 cycles of therapy. Standard care pathway management.
3261784|NCT01491048|Active Comparator|THA Physiotherapy|Physiotherapy care during the period of hospitalization after THA.
3261785|NCT01491048|Active Comparator|No physiotherapy after THA|No Physiotherapy care during the period of hospitalization after THA.
3261786|NCT01491061|Active Comparator|Ranolazine|Administration of two preprocedural doses of Ranolazine 12 hours apart (1,000 mg the night before PCI and 1,000 mg prior to PCI)
3261787|NCT01491061|Placebo Comparator|Placebo|Placebo
3261788|NCT01491074|Placebo Comparator|NaCl 0.9% 100 ml|
3261789|NCT01491074|Experimental|Tocilizumab 280 mg|Intravenous infusion, 280 mg Tocilizumab (14 ml) added to 86 ml of 0.9% NaCl
3261790|NCT01491087|Experimental|PENTAXIM® vaccine group|
3261791|NCT01491100||Group 1|
3261792|NCT01491126||examinees undergoing bidirectional endoscopy|Study population will include sequential examinees undergoing bidirectional endoscopy, age> 18 years
3261793|NCT01491139|Experimental|single arm|"All patients will receive induction chemotherapy (cisplatin and 5-FU), followed by cisplatin chemotherapy and radiotherapy in addition to oral olaparib.~Induction chemotherapy (21 day cycle)~Drug: cisplatin 80mg/m2 (day 1)~Drug: 5-FU (fluorouracil) 1000mg/m2/day (day 1-4 continuous infusion)~olaparib plus chemoradiotherapy (8 weeks)~Drug: olaparib~Drug: Cisplatin~Radiation"
3261794|NCT01491152|Experimental|WBV Training|
3261795|NCT01491152|No Intervention|Control|No WBV Training. Standard of Care.
3261796|NCT01491165|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
3261797|NCT01491191|Experimental|PEA|Administration of PEA from 8 days before surgical operation until 30 days after surgery.
3261798|NCT01491191|Active Comparator|Sugar pill|Administration of placebo from 8 days before surgical operation until 30 days after surgery.
3261799|NCT01491204|Experimental|paclitaxel +HM30181|
3261800|NCT01491230||25 autologous/25 allogeneic patients|
3261801|NCT01491243|Active Comparator|Intensive treatment group|Patients will receive high concentration sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h after PCI in case of abnormal NGAL findings
3261802|NCT01491243|Active Comparator|Standard treament group|Patients will receive i.v. 1 ml/kg/h saline infusion for 48 h after PCI in case of abnormal NGAL findings
3261803|NCT01491256|Active Comparator|High dose Atorvastatin|Arm of pre-procedural high dose atorvastatin loading
3261804|NCT01491256|Placebo Comparator|Control|No pre-procedural high dose atorvastatin loading
3261805|NCT01491269|Experimental|Internet delivered CBT|Internet delivered cognitive behavioral intervention, 8 weeks treatment.
3261806|NCT01491269|No Intervention|Control condition|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
3261807|NCT01491282||No treatment|
3261808|NCT01491295|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
3261809|NCT01491295|Experimental|Tenofovir|Switch from lamivudine/adefovir add on threatment to tenofovir monotherapy
3376255|NCT01104220|No Intervention|Obese, scheduled for gallbladder surgery|Subjects with a body mass index ≥35.0 kg/m² undergoing gallbladder surgery
3376256|NCT01104220|No Intervention|Lean, scheduled for inguinal hernia, hysterectomy or myomectomy surgery|Subjects with body mass index 18.5 - 24.9 kg/m² and normal fasting blood glucose and oral glucose tolerance and liver fat.
3376257|NCT01084629||Surveillance Barrett's esophagus|Patients scheduled for endoscopic surveillance of Barrett's esophagus
3376258|NCT01084629||Barrett's esophagus post ablation|Patients scheduled for surveillance endoscopy who have undergone ablative therapies (PDT, RF ablation) for their Barrett's esophagus
3376259|NCT01081262|Experimental|Arm I (carboplatin and paclitaxel)|Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3376260|NCT01081262|Experimental|Arm II (oxaliplatin and capecitabine)|Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
3448434|NCT04064034|Experimental|Subjects with non-cancerous disorders|Subjects will have blood collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
3261810|NCT01491308|Active Comparator|Restrictive|Hemoglobin concentrations will be maintained in the range of 7.5 to 9.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 7.5 g per deciliter.
3261811|NCT01491308|Active Comparator|Liberal|Hemoglobin concentrations will be maintained in the range of 10.0 to 12.0 g per deciliter, with a transfusion given when the hemoglobin concentration is below 10.0 g per deciliter.
3261812|NCT01491321|Experimental|Bee Venom Acupuncture & Loxoprofen|
3261813|NCT01491321|Placebo Comparator|Sham Bee Venom Acupuncture & Loxoprofen|
3261814|NCT01491334||Asymptomatic|Asymptomatic women presenting at various ages without prolapse condition.
3261815|NCT01491334||Symptomatic|Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
3261816|NCT01491347||alcohol dependent|
3261817|NCT01491360|Experimental|LaserACE(R) procedure performed|The LaserACE(R) procedure (partial depth scleral micro-excisions with an Er:YAG laser in a specified pattern) will be performed.
3261818|NCT01491373|Experimental|rhBMP-2/ACS|
3261819|NCT01491373|Active Comparator|Autograft|
3261820|NCT01491386|Experimental|rhBMP-2/ACS|
3261821|NCT01491386|Active Comparator|Autogenous Bone|
3261822|NCT01491399|Experimental|INFUSE™ Bone Graft/CORNERSTONE-SR™|
3261823|NCT01491399|Active Comparator|Autogenous bone/CORNERSTONE-SR™|
3261824|NCT01491412||Acute psychotic episode in schizophrenia|Subjects suffering from schizophrenia being discharged from the hospital following hospitalisation due to acute psychotic episode
3261825|NCT01491425|Experimental|rhBMP-2/ACS|
3261826|NCT01491425|Active Comparator|Autogenous Bone|The control group of patients from another study (Protocol ID: C-9702 Pivotal Study of rhBMP-2/ACS/LT-CAGE® Device for Anterior Lumbar Interbody Fusion in Patients With Symptomatic DDD).
3261827|NCT01491438|Experimental|PRGF and conventional treatment|PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)
3261828|NCT01491438|Active Comparator|Conventional treatment alone|Conventional treatment (cleaning, debridement of the wound and application of the corresponding dressing and using of antibiotics if necessary) twice a week (days 1 and 4).
3261829|NCT01491451|Experimental|rhBMP-2/ACS|
3261830|NCT01491451|Active Comparator|Autogenous bone|
3261831|NCT01491464|Experimental|rhBMP-2/ACS|
3261832|NCT01491464|Active Comparator|Autogenous bone|
3261833|NCT01491477|Experimental|INFUSE™ Bone Graft|
3261834|NCT01491477|Active Comparator|Autogenous bone|
3261835|NCT01491503|Experimental|Montelukast and levocetirizine|
3261836|NCT01491503|Active Comparator|Montelukast|
3261837|NCT01491503|Active Comparator|Levocetirizine|
3261838|NCT01491516|Experimental|Investigational|
3261839|NCT01491529|Experimental|AFQ056 150 mg|Patients randomized to the AFQ056 150 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 150 mg twice daily.
3261840|NCT01491529|Experimental|AFQ056 200 mg|"Patients randomized to the AFQ056 200 mg arm will receive AFQ056 oral tablets to be titrated until reaching the target dose of 200 mg twice daily.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
3261841|NCT01491529|Placebo Comparator|Placebo|Patients randomized to the Placebo arm will receive oral AFQ056 Placebo twice daily
3261842|NCT01491542|Experimental|rhBMP-2 / ACS|
3261843|NCT01491542|Active Comparator|Autogenous bone|
3261844|NCT01491555||DMD patients|35 boys ages 2 through 30 with DMD
3261845|NCT01491555||Control Group|35 healthy boys ages 2 through 30
3261846|NCT01491568|Experimental|Investigational|
3261847|NCT01491581|Experimental|micronutrient enriched bar|bar enriched with micronutrients
3261848|NCT01491581|Placebo Comparator|control arm|normal bar
3261849|NCT01491620|Experimental|532 nm KTP laser treatment|
3261850|NCT01491646||Pulmonary Hypertension|Previous diagnosis of PH by right heart catheterization
3261851|NCT01491646||Healthy Controls|Healthy controls without lung/heart conditions
3261852|NCT01491659|Active Comparator|Amoxicillin/clavulanate/Idoform Plus|
3261853|NCT01491659|Placebo Comparator|Amoxicillin/clavulanate/Placebo|
3261854|NCT01491685||Pregnant|
3261855|NCT01491685||Non- Pregnant|
3261856|NCT01491698|Experimental|pts undergoing Roux-en-Y pouch reconstruction (RYP)|This is a pilot randomized controlled trial comparing changes in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
3261857|NCT01491698|Active Comparator|pts undergoing conventional Roux-en-Y reconstruction (RYC)|This is a pilot randomized controlled trial comparing change in health-related quality of life (HRQOL) in patients undergoing Roux-en-Y pouch reconstruction (RYP) with patients undergoing conventional Roux-en-Y reconstruction (RYC) following total gastrectomy for adenocarcinoma.
3376261|NCT01081262|Experimental|Arm III (carboplatin, paclitaxel, bevacizumab)|Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
3376262|NCT01081262|Experimental|Arm IV (oxaliplatin, capecitabine, bevacizumab)|Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.
3261858|NCT01491711|Active Comparator|Fractionated 5-ALA HCl 20% gel PDT|Twice on day 1
3261859|NCT01491711|Active Comparator|Methylaminolevulinate PDT in 2 sessions|On day 1 and 8
3376263|NCT01062425|Experimental|Cediranib, TMZ, and RT|Cediranib (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + cediranib followed by cediranib monotherapy (4 weeks) followed by TMZ + cediranib for 12 cycle maximum.
3376264|NCT01062425|Active Comparator|Placebo, TMZ, and RT|Placebo (3 days) followed by radiation therapy (RT) + daily temozolomide (TMZ) + placebo followed by placebo monotherapy (4 weeks) followed by TMZ + placebo for 12 cycle maximum.
3376265|NCT01023737|Experimental|Hydroxychloroquine and Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily and HCQ will be administered starting on Day 2 of Cycle 1 and both will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
3376266|NCT01015833|Experimental|Arm I (doxorubicin hydrochloride, sorafenib tosylate)|Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
3376267|NCT01015833|Experimental|Arm II (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3376268|NCT00954915|Experimental|teplizumab|Anti CD-3 monoclonal antibody
3376271|NCT00919217||Relapsing-remitting multiple sclerosis|Females with relapsing-remitting multiple sclerosis
3376272|NCT00899405||Patients with lung cancer|Collection of archival tumor specimen at the beginning of the study and collection of blood samples at the beginning of the study and then at regular intervals
3261860|NCT01491724||pCLE images|
3261861|NCT01491750|Experimental|GUIDED IMAGERY|
3261862|NCT01491750|Placebo Comparator|AUDIO BOOK|
3261863|NCT01491789|Experimental|Virtual Sailing|you will be doing 60 minutes of Virtual Sailing training, 1 time a week for 12 weeks
3261864|NCT01491815|Active Comparator|Active conventional therapy (ACT)|Non-biological DMARD's: Methotrexate plus steroids or Methotrexate plus Sulphasalazine and Hydroxychloroquine and steroids
3261865|NCT01491815|Active Comparator|Biologic agent 1|Cimzia: Certolizumab-pegol plus Methotrexate and steroids
3261866|NCT01491815|Active Comparator|Biologic agent 2|Orencia: Abatacept plus Methotrexate and steroids
3261867|NCT01491815|Active Comparator|Biologic agent 3|RoActemra: Tocilizumab plus Methotrexate and steroids
3261868|NCT01491867|Experimental|Travoprost arm|All individuals receive travoprost 0.003% 1/day in both eyes after 6 weeks wash-out for 3 months
3261869|NCT01491880|Experimental|Child Anxiety Program by Telephone|The child anxiety program by telephone is an adaptation of Ron Rapee's Cool Kids Outreach Program (Lyneham and Rapee, 2006) for child anxiety, with appropriate adaptations made to meet the needs of rural Latino families (including a Spanish translation). This is a parent mediated program, where parents are taught how all the skills of cognitive behavior therapy (CBT) and how to apply these skills to these children's anxieties. Children are also expected to participate, however all direct contact that a therapist may have, is with the parent only.
3261870|NCT01491880|Experimental|Child Anxiety Program- Self Help|Families randomized to the Self-Help CBT condition will receive program materials along with instructions for completing weekly assignments. Specifically, they will receive the same materials as families in the telephone-based condition however in the self-help group, parents and children are expected to read the materials for that week and complete the workbook activities without planned therapist involvement. Instead they will be given the option to initiate a telephone call to the therapist, if they have questions or need extra support.
3261871|NCT01491906|Experimental|Text-Messaging|The group that receives the behavioral counseling and text messaging lifestyle intervention
3261872|NCT01491906|No Intervention|Usual Care|This group will receive usual care
3261873|NCT01491932|Experimental|AFQ056|Patients entering the study will be titrated to target dose of AFQ056 twice daily or the highest tolerated dose at weekly intervals.
3261874|NCT01491971|Experimental|Degarelix - Cohort 1|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3261875|NCT01491971|Experimental|Degarelix - Cohort 2|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3261876|NCT01491971|Experimental|Degarelix - Cohort 3|(gonadotrophin-releasing hormone (GnRH) receptor blocker)
3261877|NCT01491997|Active Comparator|Mind Body Medicine Course 1|The subject of each course is Mind/Body medicine. One course is learning about the mind and the body through experiences. The other is learning about the mind and the body through experiences. Both courses will follow the same format, meeting once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. . You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary ½ day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
3261878|NCT01491997|Active Comparator|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
3261879|NCT01492010|Experimental|25 g protein|25 g whey protein
3448435|NCT04064034|Experimental|Subjects with pancreas cyst|Subjects already undergoing biopsy of a pancreas cyst will have cyst fluid collected and tested for Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein with the lateral flow assay (LFA).
3261880|NCT01492010|Experimental|6.25 g protein supplemented with leucine|6.25 g protein supplemented with leucine
3261881|NCT01492010|Experimental|6.25 g whey protein with EAA|6.25 g protein supplemented with a mixture of essential amino acids devoid of leucine
3261882|NCT01492023||control|control group: no intervention
3261883|NCT01492023||neuropsychological rehabilitation|intervention group: neuropsychological rehabilitation (13 times 60 minutes, once per week, during 13 weeks) control group: no intervention
3261884|NCT01492036||Gene Transfer Therapy|Study participants receiving gene therapy product at MD Anderson Cancer Center
3261885|NCT01492049|Experimental|Patient Decision Aid (PtDA)|Participants view Patient decision aid (PtDA) video.
3261886|NCT01492049|Active Comparator|Control|Participants view a video on Essential Hypertension.
3261887|NCT01492062|Experimental|closed-loop control|Multiple Model Predictive Controller
3261888|NCT01492075|Active Comparator|Continuous infusion|Continuous infusion of LA intraabdominally
3261889|NCT01492075|Experimental|PCRA (Intermittent injection)|Patient controlled LA intraabdominally
3261890|NCT01492114|Experimental|Resveratrol first|"Subjects in the group resveratrol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
3261891|NCT01492114|Active Comparator|Placebo first|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
3261892|NCT01492127|No Intervention|Blood test|Blood test :carcinoma in cirrhotic patients
3261893|NCT01492153||NovoLet® device|
3261894|NCT01492166||Novolet®|
3261895|NCT01492179|Active Comparator|Intravenous Lidocaine|Intravenous lidocaine would be administered as an infusion for pain management both intra- and post-operatively.
3261896|NCT01492179|Active Comparator|Intra-abdominal Lidocaine|Lidocaine would be administered intermittently, once each hour intra-abdominally for postoperative pain management.
3261897|NCT01492179|Placebo Comparator|Normal saline|Normal saline would be administered intra-abdominally and intravenously in the same patient. Rescue analgesia in the form of morphine (PCA) would be used for pain management.
3261898|NCT01492192|Experimental|RCC Patients Antiangiogenic treatment|
3261899|NCT01492205||Human insulin|
3261900|NCT01492218||NovoLet®|
3261901|NCT01492231||Chart Review|Chart review of patients who had a procedure done at H. H. Chao Comprehensive Digestive Disease Center
3261902|NCT01492244||Patients with knee pain and a known diagnosis|
3261903|NCT01492257|No Intervention|SDM Control|The control arm will consist of usual care, patients will receive existing educational materials.
3261904|NCT01492257|Experimental|SDM Intervention|RCT intervention will include a package of decision and communication aids question-asking, and information recall. The intervention includes digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
3261905|NCT01492283||NAFLD|Non alcoholic fatty liver disease without type 2 diabetes
3261906|NCT01492283||NAFLD+T2D|Non alcoholic fatty liver disease with type 2 diabetes
3261907|NCT01492283||T2D|Type 2 diabetics without non alcoholic fatty liver disease
3261908|NCT01492283||cirrhosis|Patients with liver cirrhosis
3261909|NCT01492283||Kontrol groups|Healthy control subjects
3261910|NCT01492296|Active Comparator|conventional fasting|patients were evaluated after fasting for 8 hours
3261911|NCT01492296|Experimental|Short fasting|patients who were evaluated with endoscopy after fasting for two hours
3261912|NCT01492322||Sated and withdrawal group|To determine differences in TRODAT binding to the DAT between a smoker when sated and when in withdrawal
3261913|NCT01492335|Experimental|Cognitive Report|Primary care physicians in the Cognitive Report group receive the results of their patients cognitive testing together with clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations.
3261914|NCT01492335|Experimental|Treatment As Usual|Physicians in the Treatment As Usual Group do not receive the results of their patients cognitive assessment, they do not receive treatment recommendations, nor are they told of the patients diagnosis (Normal, Mild Cognitive Impairment, Dementia)
3261915|NCT01492348|Experimental|STEPS UP Intervention|STEPS UP is a centrally assisted stepped collaborative telecare management program within primary care. The STEPS UP intervention added to Optimized Usual Care (PCMH-BH; formerly RESPECT-Mil) in 4 ways: (1) care management enhancements; (2) stepped psychosocial treatment options (web, phone, in person); (3) electronic symptom registry for measurement-based treatment planning (symptoms are measured at regular intervals and care is intensified for patients with recurrent or persistent PTSD and/or depressive) and for telecare manager caseload and site performance monitoring; and (4) routine assisted review of patient, telecare manager, and site performance by a central psychiatrist and psychologist.
3261916|NCT01492348|Active Comparator|Optimized Usual Care (OUC)|Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system.
3261917|NCT01492361|Experimental|AMR101|
3261918|NCT01492361|Placebo Comparator|Placebo|
3261919|NCT01492374|Experimental|Arm 1: BMS-241027 (0.003 mg/kg)|
3261920|NCT01492374|Experimental|Arm 2: BMS-241027 (0.01 mg/kg)|
3261921|NCT01492374|Experimental|Arm 3: BMS-241027 (0.03 mg/kg)|
3261922|NCT01492374|Experimental|Arm 4: Placebo matching BMS-241027|
3261923|NCT01492387|No Intervention|Local standard of care|Patients randomized to this arm will be treated for the duration of therapy dictated by the primary care physician.
3261924|NCT01492387|Experimental|Individualized arm|Patients randomized to this arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
3261925|NCT01492413|Experimental|Online basic lifestyle counseling (OBLI)|Subjects receive one online informational class.
3261926|NCT01492413|Experimental|Online lifestyle counseling (OLC)|Subjects receive 12 weekly online classes with a focus on behavior modification for weight loss.
3261927|NCT01492413|Experimental|OBLI intervention plus a fortified diet beverage (BEV)|Subjects receive online basic lifestyle information (OBLI) plus a fortified diet beverage.
3261928|NCT01492413|Experimental|OLC plus fortified diet beverage (BEV)|Subjects receive OLC plus diet beverage (BEV).
3261929|NCT01492452|No Intervention|guidelines|22 parents in the intervention group were randomized and received standardized guidelines for nursing:The guidelines took around an hour and involved pre-operative care such as bathing with detergent solution, pre-anesthetic administration (as prescribed), preoperative fasting (as prescribed), clothing, hygiene care and nail oral. They were also provided information on the endotracheal tube, tubes, catheters, epicardial pacemaker wires and electrodes to be used in the perioperative period and which remain for some period after surgery, as well as possible complications.
3261930|NCT01492465|Active Comparator|AMG 876|
3261931|NCT01492465|Placebo Comparator|Placebo|
3261932|NCT01492491|No Intervention|standard HFR therapy|standard HFR hemodiafiltration therapy
3261933|NCT01492491|Active Comparator|SUPRA-HFR therapy|SUPRA-HFR hemodiafiltration therapy
3261934|NCT01492504||Subjects with chronic hepatitis C|Subjects who participated in a clinical trial in which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) was administered for the treatment of chronic hepatitis C
3261935|NCT01492517|Sham Comparator|Clean air exposure|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to clean air for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC.
3261936|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
3261937|NCT01492517|Other|Diesel exhaust exposure|Exposure to diesel exhaust will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed to diesel exhaust (up to 300 ug/m3). Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. The DE will be generated from a diesel generator used to power a load bank that is located outside the Human Studies Facility, and subsequently introduced into the exposure chamber after different dilutions with clean HEPA and charcoal filtered and humidified air to give a chamber concentration of up to 300 μg/m3.
3261938|NCT01492517|Other|18Ozone|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O). Exposure to 0.3ppm 18O will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus. Each subject will be exposed for 2 hours. Subjects will begin exercising on an exercise bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/m2/BSA followed by a 15 minute rest period. The exposure atmosphere will be at approximately 40 + 10% RH and approximately 22 + 2 oC. Ozone exposures will be conducted in a (6 ft x 6 ft x 8 ft) stainless steel chamber with a continuous supply of exposure medium. Ozone will be monitored continuously.
3261939|NCT01492530|Experimental|6-session, small group|Men of African American Legacy Empowering Self (MAALES) Intervention, a six-session, theoretically grounded, small-group intervention held over 3 weeks. Includes an additional 2 booster sessions at 6 and 18 weeks following Session 6.
3261940|NCT01492530|Active Comparator|HIV Education & Risk Reduction Session|20-30 minute standard, client-centered HIV education and risk-reduction session administered over the phone or in person. Similar to that received during pre-test counseling for HIV testing.
3261941|NCT01492543|Experimental|Aiyi®|Tegafur Gimeracil Oteracil Potassium Capsule
3261942|NCT01492556|Experimental|Etoposide|Etoposide Capsules
3261943|NCT01492569|Experimental|Arm I (TAPS at the P6 point)|Patients undergo TAPS at the true acupuncture point (P6) 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm II for the second course of chemotherapy.
3261944|NCT01492569|Sham Comparator|Arm II (TAPS at a non-P6 point)|Patients undergo TAPS at a sham non-acupuncture point 30 minutes prior to first chemotherapy infusion and then four times a day for 20 minutes every 2 hours at 8am, 10am, 12pm, and 2pm. Patients then crossover to Arm I for the second course of chemotherapy.
3261945|NCT01492608|Active Comparator|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
3261946|NCT01492608|Placebo Comparator|Natriumchlorid|Placebo and the active drug (Magnesium sulphate) will be administered identically (same loading and maintenance dose for the same period of time).
3261947|NCT01492647|Experimental|JNJ 10229570-AAA 1.2%|
3261948|NCT01492647|Experimental|JNJ 10229570-AAA 3.6%|
3261949|NCT01492660|Experimental|Echogenic needle and catheter|The echogenic needle will be positioned using ultrasonography and neurostimulation with an end point of plantar or dorsiflexion with 0.6mA of current strength. The catheter will be inserted using ultrasonography alone. 20 Ml of 2% mepivacaine will be inserted using the catheter. The distribution of drug will be evaluated using short axis and long axis views. Sensory motor block evaluation every 5 minutes for 30 minutes. Duration of block procedure, number of passes and success will be evaluated
3261950|NCT01492660|Active Comparator|Neurostimulation|The non echogenic needle will be positioned using ultrasonography and neurostimulation with plantar or dorsiflexion as the end point with 0.6mA current.The catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current.
3261951|NCT01492699|Experimental|PRX-03140|PRX-03140 for the treatment of PTSD
3261952|NCT01492712|Experimental|Low-high-low blood target concentration|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
3261953|NCT01492712|Experimental|High-low-high target blood concentration|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
3261954|NCT01492725|Experimental|Intra-arterial Clot Retrieval after iv tPA|
3261955|NCT01492725|Active Comparator|Standard care iv tPA|
3261956|NCT01492738|No Intervention|Control Group|Participants will be asked to make themselves comfortable lying on a massage table for 20 minutes.
3261957|NCT01492738|Active Comparator|Acupuncture group|Acupuncture group will receive one acupuncture treatment for twenty minutes.
3261958|NCT01492751||Spanish Multicentric Clinically Localized Prostate Cancer|A consecutive sample of clinically localized prostate cancer patients treated with radical prostatectomy, external beam radiotherapy and prostate brachytherapy in 10 Spanish hospitals.
3261959|NCT01492764||Active Group|This group will receive brief ablation at localized sources (Focal Impulse and Rotor Modulation, FIRM)
3261960|NCT01492764||Control Group|This group receives traditional ablation for this disorder
3261961|NCT01492790|Experimental|Cholecystectomy first|Patients enrolled in this arm will undergo emergency cholecystectomy first without any common bile duct imaging
3261962|NCT01492790|Active Comparator|Sequential common bile duct imaging/cholecystectomy|Patients enrolled in this arm will undergo common bile duct imaging and, if needed, ERCP first followed by emergency cholecystectomy
3261963|NCT01492803|Placebo Comparator|Placebo|Subjects randomized to the placebo arm.
3261964|NCT01492803|Experimental|Probiotics|The probiotics use in the study contains two strains of Lactobacillus plantarum. Each dose of the active study agent contains contains 1 g maltodextrin plus the probiotic bacteria Lp299v (5 x 109 cfu) and Lp299 (5 x 109 cfu).
3261965|NCT01492816|Experimental|Intervention Group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members.
3261966|NCT01492842||Youth with behaviorally-acquired HIV who enrolled in ATN 106|Behaviorally-acquired HIV-infected adolescents and young adults, ages 12-24, inclusive, who have enrolled in ATN 106.
3261967|NCT01492855|Experimental|Operative treatment|
3261968|NCT01492855|Experimental|Conservative treatment|
3261969|NCT01492881|Experimental|Vorinostat, Bortezomib, Doxil|"Induction therapy will consist of up to 8 cycles of vorinostat, bortezomib, and doxil. One cycle is defined as 21 days.~Maintenance therapy will consist of Vorinostat and bortezomib. One maintenance cycle is 28 days and repeated for up to 1 year."
3261970|NCT01492894|Active Comparator|50% decrease in calcineurin inhibitor|
3261971|NCT01492894|Active Comparator|Rapamune|
3261972|NCT01492907|Active Comparator|Healthy Control Participants|age/sex matched normal controls - the subject will swallow a capsule with a dietary relevant dose of MeIQx
3261973|NCT01492907|Active Comparator|Pancreatic Cancer Patients|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
3261974|NCT01492920|Experimental|Arm I (acetyl-L-carnitine hydrochloride)|Patients receive ALC PO BID on days 1-21 (during chemotherapy treatment).
3261975|NCT01492920|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID on days 1-21 (during chemotherapy treatment) (maximum of 8 courses).
3261976|NCT01492946||Elective surgical patients|Elective surgical patients in the Charité University Berlin Campus Charité Mitte
3261977|NCT01492959||Insulin human|
3261978|NCT01492972|Active Comparator|Radiation Alone|Proton Radiation Total Dose=70 Gy(RBE) OR High Dose Radiation with IMRT Alone=81 Gy OR Intraoperative LDR Brachytherapy and IMRT=45 Gy
3261979|NCT01492972|Experimental|Radiation + Androgen Suppression|Androgen Suppression Therapy x 6 months + Radiation
3261980|NCT01492985|Placebo Comparator|Vaccine placebos|Vaccine placebos corresponding to the dilutant of these vaccines
3261981|NCT01492985|Experimental|Vaccine arm|
3261982|NCT01492998|Experimental|Guggulsterone|One arm of 15 chronically HCV genotype one infected patients
3261983|NCT01493011|Experimental|chemotherapy & WBH|Standard chemotherapy protocol combined with whole body hyperthermia
3261984|NCT01493011|No Intervention|chemotherapy|standard chemotherapy protocol for advanced NSCLC
3261985|NCT01493037|Other|PICSO|PICSO treatment for 90 minutes
3261986|NCT01493050|Experimental|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
3261987|NCT01493050|Active Comparator|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
3261988|NCT01493076||Baby-S group|The baby-sphincterotome was in patients in whom biliary sphincterotomy was clinically indicated but in whom after standard techniques to gain biliary access had failed (study population).
3261989|NCT01493102|Active Comparator|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
3261990|NCT01493102|Active Comparator|Norepinephrine|Norepinephrine: Norepinephrine will be reduced first (0.1 microgram/kg/hour)
3261991|NCT01493115|Experimental|Sequence 1|Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2)
3261992|NCT01493115|Experimental|Sequence 2|Test1 (insulin glargine - new formulation dose 1) - Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine)
3261993|NCT01493115|Experimental|Sequence 3|Test2 (insulin glargine - new formulation dose 2) - Reference (insulin glargine) - Test1 (insulin glargine - new formulation dose 1)
3261994|NCT01493128||stable sinus rhythm|
3261995|NCT01493128||permanent atrial fibrillation|
3261996|NCT01493128||paroxysmal atrial fibrillation|
3261997|NCT01493141||MOMHR|Patients who have had metal-on metal hip resurfacing (MOMHR)
3261998|NCT01493141||THA|Patients who have had metal-on-polyethylene or ceramic total hip arthroplasty (THA)
3261999|NCT01493154|Experimental|Cohort 1 - DNA Vaccine (Dose 0.5 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 0.5 mg/dose) + Cyclophosphamide (200 mg/m2)
3262000|NCT01493154|Experimental|Cohort 2 - DNA Vaccine (Dose 1.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 1.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3262001|NCT01493154|Experimental|Cohort 3 - DNA Vaccine (Dose 2.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 2.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3262002|NCT01493154|Experimental|Cohort 4 - DNA Vaccine (Dose 4.0 mg/dose)|pNGVL-4a-CRT/E7 (detox) DNA Vaccine (Dose 4.0 mg/dose) + Cyclophosphamide (200 mg/m2)
3262003|NCT01493193|Active Comparator|Endurance training with constant work load|
3262004|NCT01493193|Experimental|Pyramid-Training|
3262005|NCT01493193|Experimental|High-intensity interval training|
3262006|NCT01493206|Experimental|intraoperative radiotherapy|
3262007|NCT01493219||Epilepsy|Blood and urine sample collection, pre and post op
3262008|NCT01493219||Glioma|Blood and urine sample collection, pre and post op
3262009|NCT01493232|Experimental|Denture, edentulous patient, treatment|Dentures with different type of occlusion
3262010|NCT01493232|Experimental|Denture, Edentulous patient, treatment|Dentures with different type of occlusion
3262011|NCT01493245|Experimental|JNS020QD|
3262012|NCT01493258|No Intervention|Control Group|The study participants randomized to the Group 2 will serve as a control. At the beginning of the study, they will receive a CERSG brochure printed from the AHRQ site. They will be asked to study it to the best of their ability throughout the day.
3262013|NCT01493258|Experimental|iCOPE Intervention group|iCOPE intervention group will receive a CERSG brochure via the iCOPE system.
3262014|NCT01493271|Placebo Comparator|Placebo|
3262015|NCT01493271|Experimental|RO5093151|
3262016|NCT01493297|Other|Retinyl palmitate|Labeled iron as FeSO4 (4 mg) added to a test meal with or without retinyl palmitate (1000 RE)
3262017|NCT01493297|Other|Beta-carotene|Labeled iron as FeSO4 (4 mg) added to a test meal with or without beta-carotene (1000 RE)
3262018|NCT01493310|Experimental|Arm A (hormone therapy, chemotherapy)|Patients will receive mifepristone and nab-paclitaxel in 28-day treatment cycles. Patients receive mifepristone once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Treatment cycles are repeated every 28 days in the absence of disease progression or unacceptable side effects.
3262019|NCT01493310|Active Comparator|Arm B (chemotherapy)|"Patients will receive nab-paclitaxel and placebo for a 28-day treatment cycle (Cycle 1).~Patients receive placebo once a day by mouth on days 0, 1, 7, 8, 14, and 15 and nab-paclitaxel by intravenous infusion (IV) on days 1, 8, and 15. Patients then cross-over to Arm A after completion of the first treatment cycle."
3262020|NCT01493323|Experimental|Control|
3262021|NCT01493323|Experimental|Depressive attempters|
3262022|NCT01493336|Experimental|Capecitabine RTD|
3262023|NCT01493336|Active Comparator|Xeloda|
3262024|NCT01493349||Controls|No diverticular disease or other gastrointestinal and liver diseases
3262025|NCT01493349||Uncomplicated diverticular disease|
3262026|NCT01493349||History of complicated diverticular disease|
3262027|NCT01493349||Current complicated diverticular disease|
3262028|NCT01493362||1|Participants with Bulimia Nervosa
3262029|NCT01493362||2|Participants who are healthy controls
3262030|NCT01493388||A|
3262031|NCT01493401|Experimental|Midurethral sling|Currently available midurethral procedures for stress urinary incontinence can be used.
3262032|NCT01493440|Other|Atosiban|
3262033|NCT01493453|Experimental|Single Arm - aCD19z cells, interleukin 2, Chemotherapy|
3262034|NCT01493466||Normal|normal person under physical examination
3262035|NCT01493466||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3262036|NCT01493466||spesis|sepsis is defined as SIRS plus confirmed infection.
3262037|NCT01493466||severe sepsis|"severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3262038|NCT01493466||death|sepsis patients within 48 hours before death
3262039|NCT01493479|Experimental|Fractionated Initial Zevalin|
3262040|NCT01493492||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3376273|NCT00887146|Experimental|Arm A (RT, procarbazine, lomustine, vincristine)|Patients undergo 3D-CRT or IMRT on days 1-5 for 5-7 weeks. Patients also receive procarbazine hydrochloride PO on days 8-21, lomustine PO on day 1 and vincristine sulfate IV on days 8 and 29 of courses 3-8. Treatment repeats every 6-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3262041|NCT01493492||sepsis|"Sepsis~sepsis: SIRS plus infection;~severe sepsis: sepsis associated with organ dysfunction, hypoperfusion, or hypotension;~septic shock: sepsis with arterial hypotension, despite adequate ﬂuid resuscitation."
3262042|NCT01493492||non-survivors with sepsis|sepsis patients who died within 28 days
3376274|NCT00887146|Experimental|Arm B (RT, temozolomide)|Patients undergo RT as in arm I and receive temozolomide PO QD on days 1-5 for 5-7 weeks. Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive adjuvant temozolomide PO QD days 1-5. Treatment with adjuvant temozolomide repeats every 4 weeks for 6-12 courses in the absence of disease progression and unacceptable toxicity.
3262043|NCT01493505|Placebo Comparator|Placebo|Placebo Paclitaxel Carboplatin
3262044|NCT01493505|Active Comparator|AMG 386|AMG 386 Paclitaxel Carboplatin
3448436|NCT04064086|Active Comparator|Comprehensive Pre-ESRD Patient Education (CPE)|These patients will receive CPE for a total of up to 3 session in an intent-to-teach format, either via Face-to-face or telemedicine delivery.
3262045|NCT01493518|Placebo Comparator|PLACEBO|
3262046|NCT01493518|Experimental|AMG 557|
3262047|NCT01493570|Experimental|BI 409306 low dose|Film-coated tablet
3262048|NCT01493570|Experimental|BI 409306 low dose II|Film-coated tablet
3262049|NCT01493570|Experimental|BI 409306 medium dose|Film-coated tablet
3262050|NCT01493570|Experimental|BI 409306 high dose|Film-coated tablet
3262051|NCT01493570|Experimental|Placebo|Film-coated tablet
3262052|NCT01493583||severely obese women|
3262053|NCT01493583||Women after Roux-en Y gastric bypass surgery|Women recruited for this group had undergone Roux-en Y gastric bypass surgery at least one year before. In this women measurement of brain activity and gastrointestinal and metabolic response took place between 13 and 106 month after surgery.
3262054|NCT01493583||lean women|
3262055|NCT01493609|No Intervention|Waitlist Control|
3262056|NCT01493609|Experimental|Click-East app|Participants will receive a copy of the game immediately following recruitment and assessment.
3262057|NCT01493622|Placebo Comparator|placebo|Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
3262058|NCT01493622|Active Comparator|minocycline|Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
3262059|NCT01493635|Active Comparator|Standard 3 Step approach.|Standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
3262060|NCT01493635|Experimental|2 Step approach.|2 Step approach of the WHO analgesic ladder (Step 1 - Step 3).
3262061|NCT01493648|Experimental|Vitamin D|
3262062|NCT01493648|Placebo Comparator|Placebo|
3262063|NCT01493661||Group 1|Men with Total Sleep Time ≤ 6h that will undergo 25 percent of chronic sleep restriction of their TST
3262064|NCT01493661||Group 2|Men with Total Sleep Time (range 7-8h)that will undergo 25 percent of chronic sleep restriction of their TST
3262065|NCT01493661||Group 3|Men with Total Sleep Time ≥ 9h that will undergo 25 percent of chronic sleep restriction of their TST
3262066|NCT01493674|No Intervention|placebo tablets|two identical tablets, but composed of crystalline cellulose, lactose and colouring
3262067|NCT01493674|Experimental|a suplemented group|two 5-mg tablets of folic acid
3262068|NCT01493700|Experimental|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
3262069|NCT01493700|Active Comparator|electrically heated circuit|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
3262070|NCT01493713|Experimental|Bevacizumab, XELOX|Bevacizumab in combination with XELOX
3262071|NCT01493726|Experimental|ALKS 9072, Low dose|
3262072|NCT01493726|Experimental|ALKS 9072, Med dose|
3262073|NCT01493726|Experimental|ALKS 9072, High dose|
3262074|NCT01493726|Placebo Comparator|Placebo|
3262075|NCT01493739||lymphadenopathy|
3262076|NCT01493752|Active Comparator|Nitrate-rich beetroot juice|Six weeks once daily dose of nitrate rich beetroot juice
3262077|NCT01493752|Placebo Comparator|Nitrate deplete beetroot juice|six weeks daily dose beetroot juice (nitrate deplete)
3262078|NCT01493765||Benchmarking|All resident study subjects will drill virtual temporal bones within the computer based system. The performance data will be used to validate the rating metrics and computer scoring process.
3262079|NCT01493817||Basic science (biomarker analysis)|Paraffin-embedded specimens are analyzed for macrophage markers. Results of each sample are then compared with patient's tumor stage, presence of vascular invasion, tumor progression, and survival.
3262080|NCT01493843|Experimental|Arm A: 340 mg pictilisib + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P).
3262081|NCT01493843|Placebo Comparator|Arm B: Placebo + CP|Participants with advanced (Stage IV) or recurrent squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm A during the first 4 cycles with carboplatin + paclitaxel or after chemotherapy has been completed (Cycle >/= 5).
3262082|NCT01493843|Experimental|Arm C: 340 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
3262083|NCT01493843|Placebo Comparator|Arm D: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 340 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm C during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
3262084|NCT01493843|Experimental|Arm E: 260 mg pictilisib + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P) plus bevacizumab (B).
3262085|NCT01493843|Placebo Comparator|Arm F: Placebo + CPB|Participants with advanced (Stage IV) or recurrent non-squamous NSCLC will be administered placebo corresponding to 260 mg pictilisib plus carboplatin (C) plus paclitaxel (P). Participants with investigator assessed radiographic progression of NSCLC per RECIST 1.1 will be allowed to cross over to Arm E during the first 4 cycles with carboplatin + paclitaxel + bevacizumab or after chemotherapy has been completed (Cycle >/= 5).
3262086|NCT01493856|Active Comparator|Rosuvastatin+Olmesartan|single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg
3262087|NCT01493856|Experimental|DWJ1276|Single dose of DWJ1276
3262088|NCT01493869|Experimental|Group 1|Subjects with normal hepatic function: healthy normal adult subjects
3262089|NCT01493869|Experimental|Group 2|Subjects with mild hepatic impairment: adult subjects with a Child-Pugh grade A (score 5-6).
3262090|NCT01493869|Experimental|Group 3|Moderate hepatic impairment: adult subjects with a Child-Pugh grade B (score 7-9).
3262091|NCT01493869|Experimental|Group 4|Severe hepatic impairment: adult subjects with a Child-Pugh grade C (score 10-15).
3262092|NCT01493882|Placebo Comparator|Placebo|
3262093|NCT01493882|Experimental|JNJ-39758979 30 mg/d|
3262094|NCT01493882|Experimental|JNJ-39758979 100 mg/d|
3262095|NCT01493882|Experimental|JNJ-39758979 300 mg/d|
3262096|NCT01493895|Active Comparator|control group,|The control group will be treated with a sham B-cure laser machine, emitting only green indicator light and no 808nm laser.
3262097|NCT01493895|Experimental|study, LLLT-808 B-cure laser machine|The study group will be treated with the LLLT-808 B-cure laser machine, emitting the 808nm laser beam together with a green indicator light.
3262098|NCT01493908|Active Comparator|High price|
3262099|NCT01493908|Active Comparator|Low price|
3262100|NCT01493908|Active Comparator|Low price participants aware paying part|
3262101|NCT01493908|Active Comparator|No price|
3262102|NCT01493908|Active Comparator|Free of charge|
3262103|NCT01493921|Experimental|SR-T100 gel|Patient group receiving medication SR-T100 gel with active ingredient under investigation, enrolled subjects randomly assigned to this group to accurately depict statistical significance of the measured outcome.
3262104|NCT01493921|Active Comparator|Vehicle gel|Patients given placebo with non-SR-T100 ingredients as they are being administered to patients, subjects are under random assignments from patient pool to depict statistically significant outcome measurement.
3262105|NCT01493934|Active Comparator|Healthy volunteers|First injection in human, on 6 healthy volunteers, sequentially : volunteer number1, then volunteers n°2 to n° 6, before infusion in type 2 diabetic patients.
3262106|NCT01493934|Experimental|type 2 diabetic patients|After completion of the study for the 6 healthy volunteers, infusion in 6 type 2 diabetic patients.
3262107|NCT01493973|Experimental|Epoetin alfa|Patients will be treated with Epoetin alfa 1200 IU/Kg s.c. every 12 weeks
3262108|NCT01493973|Placebo Comparator|Placebo|Placebo 1200 IU/Kg s.c. every 12 weeks
3262109|NCT01493999|Active Comparator|Prasugrel arm|A loading dose of 60 mg prasugrel in patients with HPR after 600 mg clopidogrel.
3262110|NCT01493999|Active Comparator|Clopidogrel reloading|A maximum of three adjusted loading doses of 600 mg clopidogrel until normal platelet reactivity is achieved in patients with HPR after the first 600 mg clopidogrel.
3262111|NCT01494012|Experimental|Treatment (SBRT)|Patients undergo SBRT 5 days a week for approximately 1 week in the absence of disease progression or unacceptable toxicity.
3262112|NCT01494025|Experimental|Diet and Exercise|
3262113|NCT01494064||Retrospective|Included patients have been no specific nursing practice.
3262114|NCT01494064||Prospective|Standardization of nursing supervision of included patients using a grid of appropriate surveillance for the prevention of complications in the ICU
3262115|NCT01494077||EUS-FNA of Pancreatic Cyst|Patients who have a pancreatic cyst requiring standard of care EUS-FNA that yields 2.25 ML (or greater) of fluid will be included in the study.
3262116|NCT01494090|Active Comparator|Rosuvastatin|
3262117|NCT01494090|Placebo Comparator|placebo|
3262118|NCT01494103|Experimental|iCaspase9-transduced T cells|"The 5 dose levels are:~1 x 10^4 T cells/kg~1 x 10^5 T cells/kg~5 x 10^5 T cells/kg~1 x 10^6 T cells/kg~5 x 10^6 T cells/kg~AP1903 will be administered if there is development of Grade 1 or greater GvHD."
3262119|NCT01494116|Experimental|10 mL syringe size|
3262120|NCT01494116|Experimental|20 mL syringe size|
3262121|NCT01494116|Experimental|30 mL syringe size|
3262122|NCT01494116|Experimental|60 mL syringe size|
3262123|NCT01494142||ADEH-Staph+|Atopic Dermatitis without a history of Eczema Herpeticum and with S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph+ participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
3262124|NCT01494142||ADEH-Staph-|Atopic Dermatitis without a history of Eczema Herpeticum and without S. aureus skin colonization. A minimum of 1100 participants will be enrolled; we will target 500 Non-Hispanic Caucasian, 300 Non-Hispanic African American, and 300 Mexican American Caucasian ADEH-Staph- participants. Although we will target these three groups, no racial/ethnic groups will be excluded.
3262125|NCT01494142||ADEH+|Atopic Dermatitis with previous or current Eczema Herpeticum.We will try to include a minimum of 150 Non-Hispanic Caucasian ADEH+ participants. ADEH+ participants of other racial/ethnic groups will not be excluded
3262126|NCT01494142||ADEV+|Atopic Dermatitis with previous or current Eczema Vaccinatum. ADEV+ sub-phenotype is very rare so all eligible participants will be enrolled.
3262127|NCT01494142||Non-atopic|Non-atopic healthy participants. A minimum of 250 non-atopic participants will be enrolled. Non-atopic participants will serve as a control group for the genetic, biomarker, Staph characterization, and microbiome studies.
3262128|NCT01494155|Experimental|Hydroxychloroquine|Hydroxychloroquine with chemoradiation
3262129|NCT01494194|Placebo Comparator|placebo for food challenge|
3262130|NCT01494194|Experimental|ASP Skin prick solution|
3262131|NCT01494194|Experimental|ASP sorbet|
3262132|NCT01494207|Experimental|Lifestyle intervention|Participants will receive the intervention (counseling) or usual care (control group)
3262133|NCT01494220||Living donor liver transplantation|Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010
3262134|NCT01494233|Experimental|Low dose|500 mg LX1033 two times daily
3262135|NCT01494233|Experimental|Mid dose|500 mg LX1033 three times daily
3262136|NCT01494233|Experimental|High dose|1000 mg LX1033 two times daily
3262137|NCT01494233|Placebo Comparator|Placebo|Matching placebo dosing
3262138|NCT01494246|Experimental|electronic mail|
3262139|NCT01494246|No Intervention|brief advise|
3262140|NCT01494259|Experimental|Bupivacaine (Treatment) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the bupivacaine. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of 0.5% bupivacaine, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
3262141|NCT01494259|Placebo Comparator|Saline (Placebo) Group|The Symbios GOPump is the Food and Drug Administration-approved delivery device used to infuse the saline. The pump is attached to catheters placed in the patient's breast reconstruction site. A 10cm long 16-guage needle is provided to aid insertion of the catheter into the patient. The entire catheter will pass through the bore of the introducer needle. A 60cc syringe is used to fill the Symbios GOPump through the fill port. After filling the 60cc syringe with up to 300cc of normal saline, the syringe is attached to the port and the medication injected into the infusion pump. The steady-flow pressure regulator maintains a constant 6 psi pressure in the outflow chamber ensuring a uniform flow of medication through each catheter inserted into the Symbios GOPump.
3262142|NCT01494272||Group CB (Caudal Before-study group)|This group will receive caudal ropivacaine and epinephrine after induction of general anesthesia prior to surgical incision
3262143|NCT01494272||Caudal After (CA)-control group|This group will receive caudal ropivacaine with epinephrine after completion of surgery but before emergence from anesthesia
3262144|NCT01494272||Local Infiltration After (LIA) control group|This group will receive local infiltration of ropivacaine around the surgery site at the conclusion of surgery but before emergence from anesthesia
3262145|NCT01494285|Experimental|ARK-E021 5% foam|
3262146|NCT01494285|Experimental|ARK-E021 10% foam|
3262147|NCT01494285|Placebo Comparator|Placebo foam|
3262148|NCT01494311|Active Comparator|Placebo patch and lidocaine injection|Fourty-five patients were randomly assigned to receive a placebo patch, looking identically to the Rapydan patch and subsequent subcutaneous injection of 0.5 ml of lidocaine 1%.
3262149|NCT01494311|Experimental|Lidocaine/tetracaine patch|Fourty-five patients were randomly assigned to receive a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution.
3262150|NCT01494324|Experimental|CT guided percutaneous ablation|The selected patients will undergo CT guided percutaneous ablation. The use of multi-tined electrode is encouraged, unless tumor location requires the use of an internally cooled needle electrode to eliminate injury to an adjacent vital structure or the operator prefers to use an internally cooled electrode for a specific reason.
3262151|NCT01494337|Active Comparator|HOLEP|HOLEP In the first arm, holmium laser enucleation of the prostate will be done
3262152|NCT01494337|Active Comparator|PVEP/XPS|PVEP/XPS green light photoselective Vapo-Enucleation of prostate using XPS 180W machine will be used in the second arm
3262153|NCT01494389||SIRS|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3262154|NCT01494389||sepsis|SIRS + infection
3262155|NCT01494389||Normal|not SIRS and have no infection
3262156|NCT01494402|Experimental|D961S|2 way crossover
3262157|NCT01494402|Experimental|esomeprazole + buffered acetylsalicylic acid|2 way crossover
3262158|NCT01494415|Experimental|chemoradiotherapy|This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
3262159|NCT01494428|Experimental|rhBMP-2/ACS|
3262160|NCT01494428|Active Comparator|Autogenous Bone|
3262161|NCT01494441|Experimental|rhBMP-2/BCP|
3262162|NCT01494441|Experimental|rhBMP-2/BCP/TSRH® Spinal System|
3262163|NCT01494441|Active Comparator|Autograft/TSRH® Spinal System|
3262164|NCT01494454|Experimental|rhBMP-2/BCP|
3262165|NCT01494454|Active Comparator|Autograft|
3262166|NCT01494480|Experimental|stem cell transplantation|After stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
3262167|NCT01494493|Experimental|rhBMP-2/ACS|
3262168|NCT01494493|Active Comparator|Autogenous Bone|
3262169|NCT01494519|Active Comparator|Treament Arm 1|Definitive fixation with an external ring fixator.
3262170|NCT01494519|Active Comparator|Treatment arm 2|Definitive fixation with a locked IM nail or plate
3262171|NCT01494558|Active Comparator|PE concurrent chemotherapy|Radiotherapy concurrently with PE chemotherapy
3262172|NCT01494558|Active Comparator|PC concurrent chemotherapy|Radiotherapy concurrently with PC chemotherapy
3262173|NCT01494571||90 pediatric, 7 to 14 year old subjects|
3262174|NCT01494571||30 pediatric, 5 to 6 year old subjects|
3262175|NCT01494571||30 pediatric, 3 to 4 year old subjects|
3262176|NCT01494571||30 pediatric, 1 to 2 year old subjects|
3262177|NCT01494571||30 pediatric, 6 to 12 month old subjects|
3262178|NCT01494571||30 pediatric, 4 to 6 month old subjects|
3262179|NCT01494571||30 pediatric, 2 to 4 month old subjects|
3262180|NCT01494597|Experimental|Isavuconazole and cyclosporine|Isavuconazole three times per day (TID) for two days followed by once a day (QD) for 6 days. Cyclosporine single doses on Days 1 and 15.
3262181|NCT01494623|Active Comparator|Active rTMS|Active treatment will be delivered at an intensity that is 90% of the RMT. Stimulation will be delivered at either 20 Hz or 10 Hz, depending on the patients' tolerance to the stimulation, with 50 stimulation trains of 30 stimuli each (i.e., 1500 stimuli) and an intertrain interval of 30 sec. 25 trains will be applied to to the left or right hemisphere followed by the other hemisphere.
3262182|NCT01494623|Sham Comparator|Sham rTMS|Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3262183|NCT01494636|Experimental|GSK2339345 (solution) (part A)|Part A
3262184|NCT01494636|Experimental|GSK2339345/ Placebo/ Lidocaine (nebulised) (part B)|Part B
3262189|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554|Participants will receive a single, low dose of 100 milligrams (mg) RO5509554 in 7-day PK run-in period (Cycle 0), followed by dose escalation from Day 1 of Cycle 1. RO5509554 will be escalated as monotherapy in approximately 6 cohorts with dose increments between cohorts of up to 100 percent (%). The doses will be escalated further until MTD/OBD as single agent is reached.
3262190|NCT01494688|Experimental|Part 1 - Dose Escalation: RO5509554 + Paclitaxel|RO5509554 will be administered in combination with a fixed dose of weekly (QW) paclitaxel (80 milligrams per square meter [mg/m^2]). The starting dose for RO5509554 in combination with paclitaxel will be 2 dose levels below to that of the highest dose of monotherapy RO5509554. Escalation of RO5509554 in combination with QW paclitaxel will start in a standard 3 + 3 design until MTD/OBD as combination dose is reached. If the initial combination is not tolerated, further cohorts will be dosed with the same dose of paclitaxel and lower dose of RO5509554. If insufficient safety, pharmacokinetic or pharmacodynamic data have been collected at the MTD/OBD, up to an additional 4 participants may be enrolled at that dose level.
3262191|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554|Participants will receive RO5509554 1000 mg Q2W, Q3W or initial biweekly followed by monthly maintenance.
3262192|NCT01494688|Experimental|Part 2 - Expansion Cohort: RO5509554 + Paclitaxel|Participants will receive RO5509554 1000 mg Q2W in combination with a fixed dose of QW paclitaxel (80 mg/m^2).
3262193|NCT01494701|Experimental|Cohort 1 (n=6)|
3262194|NCT01494701|Experimental|Cohort 2 (n=6)|
3262195|NCT01494701|Experimental|Cohort 3 (n=6)|
3262196|NCT01494701|Experimental|Cohort 4 (n=10)|
3262197|NCT01494714|Experimental|Closed-patch test|
3262198|NCT01494727|Experimental|CJ Amlodipine/Valsartan 10/160mg|
3262199|NCT01494727|Active Comparator|Novartis Exforge 10/160mg|
3262200|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 7.5 μg|split-virion, non-adjuvanted H1N1 vaccine of 7.5 μg.
3262201|NCT01494740|Experimental|split-virion, non-adjuvanted vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
3262202|NCT01494740|Placebo Comparator|split-virion, non-adjuvanted vaccine of seasonal influenza|split-virion, non-adjuvanted H1N1 vaccine of seasonal influenza.
3262203|NCT01494766|Other|Tyrosine|"Dietary Supplement: L-Tyrosine~Other Names:~NOW Brand L-Tyrosine 750 mg Tablets~-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study."
3262204|NCT01494779|Experimental|Somatropin Test|Somatropin of Blausiegel Indústria e Comércio Ltda.
3262205|NCT01494779|Active Comparator|Saizen|Somatropin of Merck Serono
3262206|NCT01494805|Experimental|Low Dose rAAV.sFlt-1|
3262207|NCT01494805|Experimental|High Dose rAAV.sFlt-1|
3262208|NCT01494805|Active Comparator|Control - ranibizumab only|
3262209|NCT01494831|Experimental|TF-CBT|
3262210|NCT01494831|No Intervention|Waiting List control|
3262211|NCT01494844|Other|Device interface comfort assessment|Single group rates one noninvasive respiratory monitoring interface and then another.
3262212|NCT01494857|Experimental|Adalimumab|Adalimumab 40 mg
3262213|NCT01494883|No Intervention|Treatment as usual|
3262214|NCT01494883|Experimental|Mindfulnes Based Stress Reduction|A weekly training of eight session lasting two and a half hours.
3262215|NCT01494909|Experimental|Ensure plus|Ensure sip feeds during 6 hours. After 2 hours pancreatic intake
3262216|NCT01494935|Experimental|Normal glycemic diet|COntrol diet with fat and glycemic index similar to typical American diet.
3262217|NCT01494935|Experimental|High-fat, high-glycemic diet|High-fat, high-glycemic diet
3262218|NCT01494948|Placebo Comparator|placebo|skin test negative
3262219|NCT01494948|Active Comparator|allergic|Skin test positive
3262220|NCT01494961|Experimental|Couple-oriented post-test HIV counseling|Women received couple-oriented post-test HIV counseling
3376275|NCT00812708|Experimental|Morcher iris diaphragm implantation|This is a non-randomized, non-comparative interventional surgical series. Patients will undergo Morcher iris diaphragm implantation in their affected eye(s). After surgery, patients will complete 5 postoperative examinations. At each examination, they will be evaluated for changes in light and glare sensitivity and visual acuity. They will also be monitored for adverse reactions.
3376276|NCT00792259||1|Patients with Retinal Disease
3376277|NCT00792259||2|Patients without Retinal Disease
3376278|NCT00792259||3|Normal Subjects
3262221|NCT01494961|No Intervention|Standard post-test HIV counseling|Women received post-test HIV counseling as per standard site protocol
3376279|NCT00741988|Experimental|Cohort A|ixabepilone 30 mg/m2 and carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
3262222|NCT01494974|Active Comparator|FP7 implant|
3376280|NCT00741988|Experimental|Cohort B|ixabepilone 30 mg/m2, carboplatin AUC = 6 intravenously (IV), and bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
3262223|NCT01494974|Active Comparator|FP8 implant|
3376281|NCT00586872||1|patients with barretts esophagus and/or early esophageal adenocarcinoma who have undergone endoscopic mucosal resection
3376282|NCT00568997||1|Single-group Open Label Registry of patients exposed to Elidel/Pimecrolimus
3262224|NCT01495013|Active Comparator|Glimepiride Atorvastatin fixed dose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin fixed dose combination (FDC) and either treatment can be titrated up based on fasting glucose or LDL levels. The following glimepiride/atorvastations FDCs will be available for use 1mg/10mg, 2mg/10mg, 3mg/10mg, 4mg/10mg, 1mg/20mg, 2mg/20mg, 3mg/20mg, 4mg/20mg.
3262225|NCT01495013|Active Comparator|Glimepiride +Atrovastatin loose combination|All subjects will start on 1mg glimepiride/10 mg atorvastatin loose combination (given as separate tablets) and either treatment can be titrated up based on fasting glucose or LDL levels. Glimepiride single dose tablets are available for 1mg, 2mg, 3mg and 4mg. Atorvastatin single dose tablets are available for 10mg and 20mg.
3262226|NCT01495026|Experimental|Fixed dose combination product|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg
3262227|NCT01495026|Experimental|Dutasteride|Commercial formulation of Dutasteride 0.5mg
3262228|NCT01495026|Experimental|Harnal-D Tablets|Commercial formulation of Harna--D Tablets comprising 0.2mg Tamsulosin Hydrochloride
3376283|NCT00563576|Experimental|Depo-Provera/Femring|Subjects will receive an estrogen vaginal ring (100 mcg) during the first 90 days of Depo-Provera use.
3376284|NCT00563576|Other|Depo-Provera Injection Alone|Subjects will receive Depo-Provera intramuscular injection.
3376285|NCT00515671|Experimental|Arm 1_IMR|Illness Management and Recovery was offered in small groups (less than 8), co-facilitated by either an experienced masters level clinician or a doctoral level psychologist and by a doctoral student in clinical psychology. Facilitators used the IMR curriculum, incorporating psychoeducation, cognitive-behavioral approaches, relapse prevention, social skills training, and coping skills training. Facilitators worked with groups to set personal recovery goals and address progress towards those goals throughout the intervention. Home assignments helped participants apply newly learned skills and/or make progress on goals. Groups were open to rolling admission across the study period
3376286|NCT00515671|Placebo Comparator|Arm 2_PS|Problem Solving was the active control condition (also offered in groups weekly for 9 months). Participants were encouraged to discuss current concerns and receive group support; we did not use structured problem solving tasks. These groups were led by the same facilitators described above, who helped establish group expectations (attendance, confidentiality), encouraged participation, and provided process-oriented observations; there was no formal curriculum, goal setting, or homework assignments.
3376287|NCT00455403|Experimental|Chloroquine Subjects|Participants will receive 80 mg of chloroquine on a daily basis.
3376288|NCT00455403|Placebo Comparator|Placebo Subjects|Participants will receive a placebo comparator tablet on a daily basis.
3376289|NCT00238420|Experimental|Group I (paclitaxel, trastuzumab, radiation therapy)|Patients receive paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, and 43 and trastuzumab IV over 90 minutes on day 1 and then over 30 minutes on days 8, 15, 22, 29, 36, and 43. Patients also undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50. Treatment continues in the absence of disease progression or unacceptable toxicity.
3262229|NCT01495039|Active Comparator|Nystatin|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.Patients were allocated to receive systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
3262230|NCT01495039|Placebo Comparator|Control|surgical patients admitted to our ICU older than 18 years of age and expected to require invasive mechanical ventilation for more than 48 h.
3376290|NCT00238420|Experimental|Group II (paclitaxel, radiation therapy)|Patients receive paclitaxel and undergo radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, 43-47, and 50.
3262231|NCT01495052|No Intervention|Usual care group|The usual care group was used as control group and didn't receive any intervention except standard health advice at the beginning and the end of the study.
3262232|NCT01495052|No Intervention|diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention.
3376291|NCT00085982|Experimental|Leptin Treatment|300 mg of study drug administered via SC injections.
3262233|NCT01495052|Experimental|50g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 50g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g ONOG.
3448437|NCT04064086|Active Comparator|Enhanced Usual Care|This group will receive usual care. This care will be enhanced by providing them with the freely available education material for the Kidney Disease Education
3448438|NCT04063943|Experimental|Sidus Stem-Free Total Shoulder|This arm will include all subjects who are implanted with the Sidus Stem-Free Total Shoulder Arthroplasty System
3448439|NCT04064099|Experimental|Rugby Players|Rugby player will be given custom-fitted mouthguards to be worn for 6-month
3448440|NCT04063891|Placebo Comparator|Placebo-Controlled|Placebo group will have placebo treatment by standing on the LMHFV platform for 20 minutes/day
3262234|NCT01495052|Experimental|100g-ONOG plus diet group|This group received systematic education about nutrition and diabetes combined with a structured dietary intervention. Participants in the 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 100g ONOG.
3262235|NCT01495065|Experimental|Part A|Japanese subjects in cohort 1 and 2 will receive treatments A, B and C. Caucasian subjects in cohort 3 will receive treatment B and C.
3262236|NCT01495065|Experimental|Part B|Subjects in cohort 4 and 5 will receive repeat doses of IV GSK2251052 for 10 days.
3262237|NCT01495078|Experimental|Telemonitoring|Patients with follow-up telemonitoring
3262238|NCT01495078|No Intervention|Non - telemonitoring|Patients with usual face follow-up
3262239|NCT01495104|Experimental|Single Arm|
3262240|NCT01495117|Active Comparator|Povidone Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
3262241|NCT01495117|Active Comparator|Chlorhexidine Gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
3262242|NCT01495130|Experimental|Diagnostic (TRUS)|Patients undergo TRUS during RALP.
3262243|NCT01495143|Active Comparator|Healthy group|Eight healthy volunteers (five males and three females) with a body mass index of 23.8 and without chronic metabolic disease or low back pain. They are all non-smokers and non-medicated.
3262244|NCT01495143|Experimental|Surgery group|"Two MD catheters is placed in the paraspinal muscle at the level of midpoint of incision bilaterally.~A reference catheter is placed in the deltoid muscle."
3262245|NCT01495156|Experimental|Lithium/Adjunctive SGA|
3262246|NCT01495156|Placebo Comparator|Placebo/Adjunctive SGA|
3262247|NCT01495169|Experimental|Iloperidone|Part A (dose-escalation and fixed dose): Eligible patients receive iloperidone 2mg/day (1 mg BID) on day 1, then escalated every day for up to 12days utilizing a forced titration regimen to achieve a maximum dose of 12, 16, 20 or 24 mg/day given BID. Part B (optional extension phase): Patients who successfully complete Part A of the study are eligible to continue treatment with iloperidone for an additional 26 weeks
3262248|NCT01495182|Experimental|Dietary Fiber - Dose 1|Dietary fiber will be added to study foods
3262249|NCT01495182|Experimental|Dietary Fiber - Dose 2|Dietary fiber will be added to study foods
3262250|NCT01495182|Active Comparator|Control|Study foods with no added fiber will be given
3262251|NCT01495195|Experimental|Donepezil, high-dose|Titration of donepezil to 22.5 mg daily
3262252|NCT01495195|Experimental|Selegiline & low-dose donepezil|Low-Dose Donepezil [titrated to 10 mg daily] and transdermal selegiline [6 mg daily]
3262253|NCT01495195|Experimental|Selegiline & high-dose donepezil|High-Dose Donepezil [titrated to 22.5 mg daily] and transdermal selegiline [6 mg daily]
3262254|NCT01495195|Placebo Comparator|Sugar pill|Inert pill for comparison
3262255|NCT01495208|Experimental|aflibercept|
3262256|NCT01495234|Experimental|Cohort 1|Each patient will receive 15mg of rhBMP-2 in rhBMP-2/BCP device and implant unilaterally during a posterolateral spinal fusion procedure. The contralateral side was fused using standard fusion techniques with autograft bone.
3262257|NCT01495234|Experimental|Cohort 2|Each patient will receive 20mg of rhBMP-2 in rhBMP-2/BCP device and implant bilaterally.
3262258|NCT01495247|Experimental|BEZ235 100 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 100 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days.
3262259|NCT01495247|Experimental|BEZ235 200 mg bid + paclitaxel 80 mg (phase lb)|Increasing doses of oral BEZ235 200 mg administered on a continuous twice daily (BID) schedule + weekly paclitaxel infusion at a fixed dose of 80 mg/m2. Treatment was organized into cycles of 28 days
3262260|NCT01495260|Experimental|N-acetylcysteine, lipoic acid and vitamin E|Two Dose titration design
3262261|NCT01495273|Experimental|Nerve stimulator|Experimental group; will undergo transtracheal injection with needle connected to nerve stimulator.
3262262|NCT01495273|Active Comparator|Standard needle/syringe|Control group; will undergo transtracheal injection with standard needle/syringe assembly.
3262263|NCT01495299||cataract patients with glaucoma|
3262264|NCT01495312|Experimental|SLT|
3262265|NCT01495325|Sham Comparator|Filtered Air Exposure|1 hour exposure to filtered air during intermittent exercise
3262266|NCT01495325|Active Comparator|Woodsmoke Exposure|1 hour exposure to dilute woodsmoke at a concentration of 1000µg/m3 during intermittent exercise
3262267|NCT01495338|Experimental|AC-170 0.17%|
3262268|NCT01495338|Experimental|AC-170 0.24% (Formulation 1)|
3262269|NCT01495338|Experimental|AC-170 0.24% (Formulation 2)|
3262270|NCT01495338|Placebo Comparator|Olopatadine hydrochloride 0.2%/Tears Naturale II|
3262271|NCT01495351|Experimental|ABT-888/Bortezomib|Patients will be on a treatment schedule including twice daily oral dosing for 14 days followed by 1 week rest in combination with standard dosing of Bortezomib and Dexamethasone in a 21 days cycle for a total of 14 cycles.
3262272|NCT01495364|Experimental|NBS10|active treatment - CD34+ cells
3262273|NCT01495364|Placebo Comparator|placebo|matching placebo
3262274|NCT01495377|Active Comparator|Remifentanil|
3262275|NCT01495377|Placebo Comparator|Placebo|
3262276|NCT01495377|Experimental|Technetium|
3262277|NCT01495377|Experimental|Dynamometer|
3262278|NCT01495403|Experimental|hydroxychloroquine|
3262279|NCT01495429|Experimental|PICC line (Peripherally)|placement of a picc line
3262280|NCT01495429|Active Comparator|CICVC (central insertion)|placement of a centrally inserted central venous catheter
3262281|NCT01495442|Active Comparator|modified Handihaler DPI|
3262282|NCT01495442|Placebo Comparator|standard Handihaler DPI|
3262283|NCT01495455||Knee osteoarthritis|
3262284|NCT01495455||No knee pain/osteoarthritis|
3262285|NCT01495494|Active Comparator|Marketed nasal strip|Marketed nasal strip
3262286|NCT01495494|Experimental|Prototype nasal dilator|Prototype nasal dilator
3262287|NCT01495507||Patellofemoral Instability|Patients with diagnosis of patellofemoral instability receiving MPFL-reconstruction as part of the clinical routine
3262288|NCT01495520|Active Comparator|Ranolazine|Patients will receive ranolazine 750 mg bid for 30 days
3262289|NCT01495520|Placebo Comparator|Placebo|Patients will receive placebo for 30 days
3262290|NCT01495533|Placebo Comparator|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
3262291|NCT01495533|Active Comparator|drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
3262292|NCT01495546|Experimental|Early loading|
3262293|NCT01495546|Active Comparator|late loading|
3262294|NCT01495624|Placebo Comparator|Ropivacaine with perineural dexamethasone|30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
3262295|NCT01495624|Active Comparator|Ropivacaine with systemic steroid|30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
3262296|NCT01495637|Experimental|GM-CSF|GM-CSF is given in one of four treatment regimens (three days at a dose of 30, 62, or 125 mcg/m2/day, or extended dosing at 125 mcg/m2 through post-trauma day 6) to critically injured children who demonstrate severe reduction in innate immune function on post-trauma day 1, 2, or 3.
3262297|NCT01495650|Experimental|Intervention arm|
3262298|NCT01495650|No Intervention|Control arm|Routine practice
3262299|NCT01495663|Other|Single Group|I-131-CLR1404
3262302|NCT01495715|Experimental|Idebenone|
3262303|NCT01495715|Placebo Comparator|Placebo|
3262304|NCT01495728|Experimental|Thrust Manipulation -Thoracic Spine|Mid and Upper Thoracic Spine
3262305|NCT01495728|Placebo Comparator|Sham Manipulation|Mid and Upper Thoracic Spine
3262306|NCT01495741||Asenapine|Participants prescribed asenapine
3262307|NCT01495741||Risperidone Comparator|Participants prescribed risperidone
3262308|NCT01495741||Olanzapine Comparator|Participants prescribed olanzapine
3262309|NCT01495754|Experimental|coffee3|
3262310|NCT01495754|Experimental|coffee6|
3262311|NCT01495754|Placebo Comparator|water|
3262312|NCT01495767||females, males|females: patients of female sex males: patients of male sex
3262313|NCT01495780|Experimental|Remote Health Monitoring|Subjects assigned to this arm will conduct daily at-home health monitoring using several electronic devices that will transmit data back to the study team. Everyday, subjects will measure pulse oximetry (SpO2) using a finger clip, answer questions about symptoms and medication use, answer a quality of life questionnaire, perform breathing tests, and record physical activity (using a physical activity monitor that will be mailed to the study team). Wearing the activity monitor is optional and will only occur during months 1, 6, and 12.
3262314|NCT01495806|Experimental|Glucomannan|5 g 2x 10 day
3262315|NCT01495806|Placebo Comparator|Placebo|
3262316|NCT01495832|Experimental|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
3262317|NCT01495832|Active Comparator|Control Group|The control group will consume comparator foods for 12 weeks.
3262318|NCT01495871|Active Comparator|Amino acids|Amino acid supplementation for 6 weeks
3262319|NCT01495871|Placebo Comparator|Placebo|Supplementation of placebo (inert components)for 6 weeks
3262320|NCT01495871|Active Comparator|Valine|Valine supplementation for 6 weeks
3262321|NCT01495884|Experimental|Lapatinib (Tyverb™) and (Myocet™)|
3262322|NCT01495897|Other|Healthy|Healthy volunteers
3262323|NCT01495897|Experimental|Dystonia|patients with Primary Dystonia
3262324|NCT01495897|Experimental|Parkinson|patients with Parkinson's disease
3262325|NCT01495897|Experimental|Essential tremor|patients with essential tremor with or without deep brain stimulation
3262326|NCT01495910|Experimental|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
3262327|NCT01495936|Active Comparator|Continuous Positive Airway Pressure|"After 20 minutes ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm Continuous Positive Airway Pressure (CPAP). CPAP will be applied for 20 minutes to the non-ventilated lung at a pressure of 5cmH20 using the disposable Mallinckrodt Bronchocath CPAP system."
3262328|NCT01495936|Active Comparator|RM + Positive End Expiratory Pressure|"After 20 minutes of ventilation on one lung (during anesthesia) the patient will be randomly assigned to the study arm RM + Positive End Expiratory pressure which is a Recruitment Maneuver (RM) followed by Positive End Expiratory Pressure (RM-PEEP) which will be applied to the ventilating lung at a pressure of 5cmH2O."
3262329|NCT01495949|Active Comparator|etomidate|
3262330|NCT01495949|Active Comparator|thiopentone|
3262331|NCT01495962|Active Comparator|Botulinum Toxin A injection|
3262332|NCT01495962|Placebo Comparator|Placebo (Normal Saline) injection|
3262333|NCT01496001|Experimental|Cohort|
3262334|NCT01496014||severe open fractures of the tibia bone|
3262335|NCT01496027||term newborns|
3262336|NCT01496027||Preterm Newborns (32-37 GA)|
3262337|NCT01496040|Experimental|rAAV2/4.hRPE65|"3 cohortes of 3 patients each.~All the patients enrolled in the study will receive a single subretinal injection in one eye. The eye, that will be injected, will be the eye with the poorest visual acuity."
3262338|NCT01496053|Active Comparator|AndoSan|AndoSan given to IBD patients
3262339|NCT01496053|Sham Comparator|Sugar extract|Sugar extract to IBD patients
3262340|NCT01496079||Inactivated influenza vaccine in pregnancy|Healthy pregnant women who elect to receive inactivated influenza vaccine in early pregnancy (< 20 weeks gestation) and their infants
3262341|NCT01496079||No inactivated influenza vaccine during pregnancy|Healthy pregnant women who decline inactivated influenza vaccine in pregnancy and their infants
3262342|NCT01496092|Experimental|Keto Acid supplemented with usual protein diet|
3262343|NCT01496092|No Intervention|usual protein diet|
3262344|NCT01496105|Active Comparator|lidocaine spray 10%|
3262345|NCT01496105|Placebo Comparator|Saline|
3262346|NCT01496118|Experimental|Carfilzomib and Panobinostat|
3262347|NCT01496144|Experimental|Manual therapy and active exercises|Spinal manipulation /mobilisation
3262348|NCT01496144|Placebo Comparator|Detuned ultrasound and active exercises|
3262349|NCT01496170|Experimental|Treatment A: MK-8931 12 mg|Participants receiving 12 mg MK-8931 for 7 days
3262350|NCT01496170|Experimental|Treatment B: MK-8931 40 mg|Participants receiving MK-8931 40 mg for 7 days
3262351|NCT01496170|Placebo Comparator|Treatment C: Placebo matching MK-8931 12 mg or 40 mg|Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days
3262352|NCT01496170|Experimental|Treatment D: MK-8931 60 mg|Participant receiving MK-8931 60 mg for 7 days
3262353|NCT01496170|Placebo Comparator|Treatment E: Placebo matching MK-8931 60 mg|Participants receiving placebo matching MK-8931 60 mg for 7 days
3262354|NCT01496196|Active Comparator|tranexamic acid-500 mg/5 ml 3-4 times a day|tranexamic acid arm: inhalations of tranexamic acid 500 mg/5 ml 3-4 times a day
3262355|NCT01496196|Placebo Comparator|tranexamic|placebo arm
3262356|NCT01496209|Sham Comparator|Placebo control|
3262357|NCT01496209|Experimental|Group: Cardiosphere Treatment|Biological: Allogeneic Human Cardiospheres (allogeneic CSps or alloCSps), a 3D micro-tissue heart-derived cell therapy product. Subjects will receive 150 million cell-equivalents of alloCSps via endomyocardial injection (10 million per site at 15 peri-infarct sites)
3262358|NCT01496235|Active Comparator|Dark chocolate|Presence of 70% cocoa solids
3262359|NCT01496235|Placebo Comparator|White chocolate|
3262360|NCT01496261|Active Comparator|Clopidogrel and Aspirin|
3262361|NCT01496261|Experimental|Coprigerl|
3262362|NCT01496300|Sham Comparator|Manual|Manual Implantation of THA
3262363|NCT01496300|Experimental|Navigated|Navigated Implantation of THA
3262364|NCT01496326|Experimental|Ibuprofen|
3262365|NCT01496326|Placebo Comparator|Placebo|
3262366|NCT01496339|Active Comparator|Traditional therapy control|
3262367|NCT01496339|Experimental|Stem cell infusion|
3262368|NCT01496378|Experimental|Problem-Solving Skills Training|In addition to standard medical care, parents in the problem-solving skills training group will receive 8 sessions (1 hour each) of individual problem-solving therapy over 8 weeks. Caregivers will be asked to complete the first training session and at least 3 subsequent sessions in person at their local treatment facility (Seattle Children's Hospital or Oregon Health and Science University). Remaining sessions will be completed via telephone.
3262369|NCT01496378|No Intervention|Standard Care|Parents and children in the Standard Care group will continue with the care that has been prescribed for their child's pain problem by their treating physician, which may include medications, physical therapy, and mental health intervention.
3262370|NCT01496391||Healthy Participants|eGFR ≥60 ml/min/1.73m^2, healthy prospective kidney donor
3262371|NCT01496391||Moderate Renal Function Impairment|eGFR 30-59 ml/minute/1.73m^2
3262372|NCT01496391||Severe Renal Function Impairment|eGFR <30 mL/minute/1.73m^2
3262373|NCT01496404|Experimental|Electrocautery|Epidermis and dermis incised with cutting setting of electrocautery.
3262374|NCT01496404|Active Comparator|Scalpel|Control, incision of epidermis and dermis with scalpel.
3262375|NCT01496417|Experimental|Belatacept therapy|20 Patients receiving belatacept based immunosuppressive protocol for 12 months post-transplantation.
3262376|NCT01496443|Experimental|TAK-875 & Glimepiride QD|TAK-875 50 mg, tablets, orally and glimepiride 2 mg, capsules, orally and glimepiride placebo matching capsules, orally, once daily on dosing days for up to 19 days.
3262377|NCT01496482||Patients without dry eye symptoms|Patients without dry eye symptoms as measured by standard questionnaire.
3262378|NCT01496482||Patients with dry eye symptoms|Patients with dry eye symptoms as measured by standard questionnaire.
3262379|NCT01496495|Experimental|ARRY-614|
3262380|NCT01496508|Experimental|HFOV|A SLE5000 infant ventilator was used as the high-frequency ventilator.HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg.Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min.
3262381|NCT01496508|Experimental|CV|A Servo-i-Maquet will be used as the conventional mechanical ventilator. CV settings were: exhaled tidal volumes set at 5-6 mL/kg, initial peak inspiratory pressure (PIP) of 15-25 cmH2O; positive expiratory end pressure (PEEP) set to 4-6 cmH2O; inspiratory times of 0.25-0.40s; rates set to <60/min. The weaning process was initiated when the following parameters were achieved: PIP <18 cmH2O, PEEP <4 cmH2O, and FIO2 <0.4. Extubation was considered when the patient's condition was stable for 12-24h, while adequate oxygenation could be maintained with an FIO2 <0.3 and respiratory rate <25/min. All infants extubated onto nasal continuous positive airway pressure (Infant Flow, Electro Medical Equipment) and then weaned to a nasal cannula, and then to room air.
3262382|NCT01496521|Experimental|Aspirin|
3262383|NCT01496521|Experimental|Tea Polyphenols|
3262384|NCT01496521|No Intervention|Control|
3262385|NCT01496534|Active Comparator|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
3262386|NCT01496534|Active Comparator|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts.
3262387|NCT01496547|Experimental|intensive chemo - RIC preparation|The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
3262388|NCT01496573||Basic science (biomarker analysis)|Archived tumor tissue samples are analyzed for CRKL expression.
3262391|NCT01496638|Experimental|"No side branch treatment group"|Implantation of coronary stent in bifurcation lesion
3262392|NCT01496638|Experimental|"Stenting of main vessel and side branch group"|Implantation of coronary stent in bifurcation lesion
3262393|NCT01496651|Active Comparator|Percutaneous coronary intervention|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
3262394|NCT01496651|Active Comparator|Coronary artery bypass graft operation|Coronary Artery Bypass Grafting Versus Drug Eluting Stent Percutaneous Coronary Angioplasty in the Treatment of Unprotected Left Main Stenosis
3262395|NCT01496664|Experimental|Result of combined CABG and PCI treatment|The registry is to assess results of combined operative and catheter based (hybrid procedure) treatment of patients with significant coronary artery disease using essential clinical and angiographic parameters.
3262396|NCT01496677|Experimental|Elderly subjects (65 or older)|
3262397|NCT01496677|Experimental|Younger adults (18-45 years old)|
3262398|NCT01496690|Active Comparator|pregabalin|The pregabalin dose is 75 mg daily the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response.
3262399|NCT01496690|Placebo Comparator|Pregabalin Placebo Capsules|
3262400|NCT01496703||renal transplantation with MMF from day 1|
3262401|NCT01496716||Hip Osteoarthritis|
3262402|NCT01496729|Active Comparator|Transversus abdominis plane (TAP) block with ropivacaine|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure
3262403|NCT01496729|Sham Comparator|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
3262404|NCT01496742|Experimental|Bevacizumab+MetMAb|
3262405|NCT01496742|Active Comparator|Bevacizumab+Placebo|
3262406|NCT01496742|Experimental|Pemetrexed+MetMAb|
3262407|NCT01496742|Active Comparator|Pemetrexed+Placebo|
3262408|NCT01496755|Placebo Comparator|Placebo|
3262409|NCT01496755|Experimental|RG7667|
3262410|NCT01496768|Experimental|Leucine|
3262411|NCT01496768|Placebo Comparator|Alanine|
3262412|NCT01496781|Experimental|EndoClot|This arm is designed to observe if the Endoclot treatment can achieve comparable hemostasis efficacy compared with hemoclip.
3262413|NCT01496781|Active Comparator|Hemoclip|This arm is used as a control treatment group to compare with Endoclot treatment.
3262414|NCT01496794||Endophthalmitis cultures|
3262415|NCT01496820|Experimental|GO2KA1|
3262416|NCT01496820|Placebo Comparator|Placebo|
3262417|NCT01496833|Experimental|Endovascular|Total endovascular arch reconstruction
3262418|NCT01496859|Experimental|Baska|
3262419|NCT01496911|Experimental|Levocetirizine (5 mg)|
3262420|NCT01496911|Active Comparator|Hydroxyzine (50 mg)|
3262421|NCT01496911|Placebo Comparator|Placebo|
3262422|NCT01496924|Other|speech therapy group|All dysphagic patients will be submitted to speech therapy
3262423|NCT01496937|Experimental|GLPG0974 oral solution|GLPG0974 oral solution
3262424|NCT01496937|Placebo Comparator|Placebo oral solution|Placebo oral solution
3262425|NCT01496950|Active Comparator|Active Comparator: Active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
3262426|NCT01496950|Placebo Comparator|Placebo|10Hz placebo rTMS delivered to the vertex
3262427|NCT01496963||group a)|Patients with pulmonary artery pressure (PAP) assessed (by echocardiogram) <36 mmHg or a tricuspid regurgitant jet velocity (TG) <3 m / sec and data on PAP and mean left ventricular ejection fraction (LVEF) > 50%
3262428|NCT01496963||group b)|"Patients with:~PAP estimated (by echocardiography)> 40 mmHg or TG> 3.2 m / sec and LVEF> 50% As indicated by the Guidelines, patients b) with increased PAP (TG> 3.2 m / sec or> 40 mm Hg) will be further studied using RHC and vasoreactivity testing. Angio CAT, 6MWT and BNP."
3262429|NCT01496963||group c)|patients with PAP estimated (by echocardiography) in the range of values > 3 m / sec (TG) and <3.2 m / sec or> 36 mm Hg and <40 mmHg and LVEF> 50%
3262430|NCT01496989|Experimental|Group 1: HIV-MAG followed by Ad35-GRIN/ENV|HIV-MAG (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo = 12/3)
3262431|NCT01496989|Experimental|Group 2: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo=12/3)
3262432|NCT01496989|Experimental|Group 3: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Months 0,1,2 followed by Ad35-GRIN/ENV (IM) at Month 6. (Vaccine:Placebo= 12/3)
3262433|NCT01496989|Experimental|Group 4: HIV-MAG+GENEVAX® IL-12 followed by Ad35-GRIN/ENV|HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 0 followed by Ad35-GRIN/ENV (IM) at Month 4. (Vaccine:Placebo=12/3)
3262434|NCT01496989|Experimental|Group 5: Ad35-GRIN/ENV followed by HIV-MAG+GENEVAX® IL-12|Ad35-GRIN/ENV (IM) at Month 0 followed by HIV-MAG + GENEVAX® IL-12 (IM/EP) at Month 4. (Vaccine:Placebo=12/3)
3262435|NCT01497002|Active Comparator|standard arm|standard treatment arm
3262436|NCT01497002|Experimental|OSHO - intensified consolidation|Intermediate dose AraC
3262437|NCT01497002|Experimental|OSHO - allografting as consolidation|allogeneic stem cell Transplantation versus no transplantation
3262438|NCT01497015|Experimental|memory training|memory training 10 1-hour sessions with interventionist to be delivered over 6-8 weeks
3262439|NCT01497015|Experimental|speed of processing training|Speed of processing training 10 1-hour sessions delivered over 6-8 weeks
3262440|NCT01497015|Experimental|waitlist control|Breast cancer survivors will be randomized to 1 of 3 groups: memory training, speed of process training or waitlist control
3262441|NCT01497028||Plicated Gastric Banding|
3262442|NCT01497028||Standard Gastric Banding|
3262443|NCT01497080||1|
3262444|NCT01497080||activity level|
3262445|NCT01497080||no treatment|
3376294|NCT05161117|Experimental|virtual reality education|The experimental group will receive both an online fall prevention education module and additional education using a virtual reality simulation app for mobile devices designed for specifically for hospital caregivers
3376295|NCT05161117|Active Comparator|online education only|The control group will receive an online fall prevention education module
3376296|NCT05161104||left ventricular systolic dysfunction(LVSD)|
3376297|NCT05161104||left ventricular diastolic dysfunction(LVDD)|
3262446|NCT01497093|Experimental|Pomalidomide/Bortezomib/Dexamethasone|1, 2, 3 or 4 mg of pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1 or 1.3 mg/m2 of bortezomib administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
3262447|NCT01497106|Experimental|Calorie restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks.
3262448|NCT01497106|Active Comparator|Control|Participants will continue their normal living for entire time of the study, totaling 16 weeks.
3262449|NCT01497119|Experimental|JNJ-39758979, 300 mg|
3262450|NCT01497119|Experimental|JNJ-39758979, 100 mg|
3262451|NCT01497119|Placebo Comparator|Placebo|
3262452|NCT01497132|Experimental|Vitamin D3|
3262453|NCT01497132|Placebo Comparator|Placebo|
3262454|NCT01497158|Active Comparator|Control Group|Participants who received only self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home.
3262455|NCT01497158|Active Comparator|Active Group|Participants who received self-help brochure regarding environmental tobacco smoking (ETS) exposure in the home and biomarker feedback from the urine of cohabitating adult non-smoker in the home.
3262456|NCT01497184|Experimental|DLI (Adults)|Arm 1: Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously (IV) between 6 weeks - 12 weeks following date of allogeneic hematopoietic stem-cell transplantation (HSCT) as a planned DLI.
3262457|NCT01497184|Experimental|DLI any time|Arm 2: DLI will be administered at any point after disease recurrence following HSCT.
3262458|NCT01497184|Experimental|DLI Pediatrics|Arm 3: DLI administered intravenously between 6 weeks and 12 weeks following date of HSCT as a planned DLI in pediatric patients, aged 1-17 years-old.
3262459|NCT01497184|Experimental|DLI - Haplo-Identical Family Donor|Arm 4: DLI administered as planned DLI or after recurrence in adult and pediatric patients undergoing transplant with a haplo-identical family donor.
3262460|NCT01497210|Experimental|EASH|
3262461|NCT01497223|Experimental|MGCD290 and Fluconazole|Oral Administration of MGCD290 and Fluconazole
3262462|NCT01497223|No Intervention|Fluconazole|This is an Active Comparator: Oral Administration of Fluconazole with Placebo
3262463|NCT01497236|Experimental|Experimental: Ready to Use Terapeutic Food (RUTF)|
3262464|NCT01497236|Experimental|Multi Micronutrient Powder (MNP)|
3262465|NCT01497236|No Intervention|no supplement|
3262466|NCT01497249|Placebo Comparator|Placebo|Placebo Beverage
3262467|NCT01497249|Active Comparator|A dietary fiber (FCHO)|15g/BID
3262468|NCT01497288|Experimental|Sequence 1 (A-B-C)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~B: single dose of 400 μg INFS (100 μL), administered 4 hours after the first treatment~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 24 hours after the first treatment (Day 2)"
3262469|NCT01497288|Experimental|Sequence 2 (A-C-B)|"A: single dose of 200 μg INFS (100 μL) (Instanyl®), administered on Day 1~C: two single doses of 400 μg INFS (100 μL) (10 min apart), administered 4 hours after the first treatment~B: single dose of 400 μg INFS (100 μL), administered 24 hours after the first treatment (Day 2)"
3262470|NCT01497301|No Intervention|Standard Individual Medical Appointment|
3262471|NCT01497301|Active Comparator|Group Visits|
3262472|NCT01497314|Other|Low Lactose Infant Formula|
3262473|NCT01497327|Experimental|PSI-352938 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
3262474|NCT01497327|Experimental|PSI-352938 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
3262475|NCT01497327|Experimental|PSI-352938 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
3262476|NCT01497327|Experimental|PSI-7977 Group A|Mild (Child-Pugh Class A; 5-6) hepatic impairment
3262477|NCT01497327|Experimental|PSI-7977 Group B|Moderate (Child-Pugh Class B; 7-9) hepatic impairment
3262478|NCT01497327|Experimental|PSI-7977 Group C|Severe (Child-Pugh Class C; 10-15) hepatic impairment
3262479|NCT01497340|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth with a plastic clamp placed at 1 cm from its cutaneous insertion.
3262480|NCT01497340|Experimental|position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weight measurement. The cord will be clamped at 2 minutes after birth .
3262481|NCT01497353|Active Comparator|Position at introitus level|The newborn will be held by the neonatologist at the level of the introitus, the cord will be clamped at 2 minutes after birth. New weigh will be obtained after that.
3262482|NCT01497353|Experimental|Position at Maternal Abdomen|The newborn will be placed on the abdomen and of the mother immediately after the first weigh measurement. The cord will be clamped at 2 minutes after birth .
3262483|NCT01497379|Experimental|intra-individual implant ON|intra-individual implant activation
3262484|NCT01497379|Placebo Comparator|intra-individual implant OFF|intra-individual implant deactivation
3262485|NCT01497392|Experimental|Treatment (dovitinib lactate, gemcitabine, and capecitabine)|Patients receive dovitinib lactate PO on days 1-5, 8-12, and 15-19, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and capecitabine PO twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3262486|NCT01497405|Active Comparator|Test, Treat, Retain(TTR) only|Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
3262487|NCT01497405|Experimental|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment. Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities. This intervention is an adaptation of the evidence-based Women's CoOp(PI: Dr. Wendee M. Wechsberg).
3262488|NCT01497431|Experimental|Arm I (Se-methyl-seleno L-cysteine)|Participants receive Se-methyl-seleno L-cysteine on days 1-84.
3262489|NCT01497431|Experimental|Arm II (selenomethionine)|Participants receive selenomethionine PO on days 1-84.
3262490|NCT01497431|Placebo Comparator|Arm III (placebo)|Participants receive placebo PO on days 1-84.
3262491|NCT01497444|Experimental|sorafenib and TH-302|Patients will be administered sorafenib tablets to take twice daily by mouth, every day of each cycle. Patients will also be given TH-302 intravenously (IV) on days 8, 15 and 22 of each cycle. A cycle is 28 days.
3262492|NCT01497457|Experimental|MR saline peritoneography|Patients that will undergo MR saline peritoneography
3262493|NCT01497470|Experimental|Paclitaxel/carboplatin with custirsen|Custirsen added to standard paclitaxel/carboplatin chemotherapy
3262494|NCT01497483|Active Comparator|Pravastatin alone|Subjects will be dosed with Pravastatin alone (40 mg)
3262495|NCT01497483|Experimental|Pravastatin and Cyclosporine|Subjects will be dosed with pravastatin and cyclosporine.
3262496|NCT01497509|Experimental|Patients electing to receive intrapartum epidural analgesia|
3262497|NCT01497509|No Intervention|Patients electing not to receive epidural analgesia|
3262498|NCT01497522|Experimental|Vildagliptin|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin 50 mg twice daily.
3262499|NCT01497522|Placebo Comparator|Placebo|In addition to their stable dose of metformin monotherapy, patients should take vildagliptin matching placebo.
3262500|NCT01497535|Experimental|Insulin detemir|
3262501|NCT01497535|Active Comparator|Insulin glargine|
3262502|NCT01497548|Experimental|Methylphenidate add on to Mirtazapine|Methylphenidate add on to the usual treatment (Mirtazapine)
3262503|NCT01497548|Placebo Comparator|Placebo add on to Mirtazapine|Non active compund add on to the usual treatment (Mirtazapine)
3262504|NCT01497561|Experimental|insulin detemir|
3262505|NCT01497561|Active Comparator|insulin NPH|
3262506|NCT01497574|Experimental|Insulin detemir|
3262507|NCT01497574|Active Comparator|Insulin glargine|
3262508|NCT01497587|Experimental|Insulin detemir|
3262509|NCT01497600|Experimental|insulin detemir|
3262510|NCT01497600|Active Comparator|insulin NPH|
3262511|NCT01497626|Experimental|Bortezomib plus lapatinib|Combination treatment with lapatinib and bortezomib
3262512|NCT01497639|Active Comparator|Process 1|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of interleaving stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to double-monopolar stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
3262513|NCT01497639|Active Comparator|Process 2|"Visit 1: Baseline evaluation (maximum 1 week before operation)~Visit 2: Testing of electrodes and subsequent initiation of double-monopolar stimulation mode (4th postoperative week).~Visit 3 Evaluation and cross-over to interleaving stimulation mode (16th postoperative week).~Visit 4 Final evaluation. (28th postoperative week)."
3262514|NCT01497652|Active Comparator|Treatment Group|Treatment group will receive Rasagiline (Azilect) 1mg daily
3262515|NCT01497652|Placebo Comparator|Placebo Group|will receive placebo daily
3262516|NCT01497678|Other|Extracellular Matrix|Implantation of Extracellular Matrix
3262517|NCT01497691|Other|Control|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol.
3262518|NCT01497691|Sham Comparator|Sham NIPPV|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. The pressure settings will be fixed at a positive end-expiratory pressure (PEEP) of 5-8 cm H2O.
3262519|NCT01497691|Active Comparator|BiPAP|This group will receive all standard of care therapies as per the pediatric ED Asthma Severity Protocol. All nebulized treatments will be given via the NIPPV/BiPAP machine. Settings will be adjusted based on the age and clinical presentation of the child.
3262520|NCT01497704|Experimental|YN968D1|Active therapy arm for safety evaluation
3262521|NCT01497717|Experimental|Adalimumab, Behcet with arthritis|
3262522|NCT01497730||CR FB|Subjects receiving a Cruciate Retaining Fixed Bearing implant configuration
3262523|NCT01497730||PS FB|Subjects Receiving a Posterior Stabilized Fixed Bearing implant configuration
3262524|NCT01497730||CR RP|Subjects receiving a Cruciate Retaining Rotating Platform implant configuration
3262525|NCT01497730||PS RP|Subjects receiving a Posterior Stabilized Rotating Platform implant configuration
3262526|NCT01497743|Placebo Comparator|placebo|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
3262527|NCT01497743|Active Comparator|Probiotic|Subjects will be randomized into either the probiotic or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
3262528|NCT01497769|Experimental|Group 1|Aerosol inhaled MVA85A and intradermal saline placebo
3262529|NCT01497769|Experimental|Group 2|Intradermal MVA85A and inhaled aerosol saline placebo
3262530|NCT01497782|Experimental|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
3262531|NCT01497782|No Intervention|No instructor feedback|Control group who did not receive instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
3262532|NCT01497821|Experimental|Dose exploration|Pre-specified nominal doses are proposed in the dose exploration at two dosing frequencies: every two weeks and every three weeks. Intermediate doses may also be used if required based on the Continuous Reassessment Method (CRM) design.
3262533|NCT01497821|Experimental|Dose expansion|Dose and dosing frequency selected from Part 1 dose exploration.
3262534|NCT01497834|Experimental|Daclatasvir + Asunaprevir|
3262535|NCT01497847||travelers to tropical destinations|
3262536|NCT01497873|Experimental|Belotecan|Camtobell Injection
3262537|NCT01497873|Active Comparator|Topotecan|Hycamtin Injection
3262538|NCT01497886|Active Comparator|Hip Hop Stroke educational program|Hip Hop Stroke is a school-based educational program that incorporates educational hip hop music and two cartoons to communicate stroke knowledge to children.
3262539|NCT01497886|Placebo Comparator|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
3262540|NCT01497912|Active Comparator|Atorvastatin|Atorvastatin 80mg once daily
3262541|NCT01497912|Placebo Comparator|Placebo|Matched placebo tablets
3262542|NCT01497925|Experimental|ADI-PEG 20|
3262543|NCT01497951|Experimental|Aminolaevulinic acid|
3262544|NCT01497951|Placebo Comparator|Placebo|
3262545|NCT01497964|Experimental|Cabazitaxel|Cabazitaxel, several dosages
3262546|NCT01497977|Experimental|soya phytoestrogens|
3262547|NCT01497977|Experimental|red clover phytoestrogens|
3262548|NCT01497977|No Intervention|No drugs|
3262549|NCT01497990|Experimental|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
3262550|NCT01498003|Placebo Comparator|Control group|normal saline was applied to those randomized to control group, with same use as tirofiban
3262551|NCT01498003|Experimental|Tirofiban group|after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion
3262552|NCT01498016|Experimental|Iv-Busulfan|iv busulfan 1.6mg/kg given q12h
3262553|NCT01498029|Active Comparator|Randomized to Microfracture|This group of patients who have been randomised to receive microfracture procedure will be the control group for this study
3262554|NCT01498029|Experimental|Randomized to CAIS|This group of patients who have been randomised to receive the CAIS procedure will be the experimental group for this study
3262555|NCT01498042||stroke, thrombolysis, over 80, outcome|To study the outcome of stroke patients over 80 years treated with thrombolysis.
3262556|NCT01498055||CIK therapy group|
3262557|NCT01498055||control group|
3262558|NCT01498081|Experimental|Single dose of AZD2115 25 µg|
3262559|NCT01498081|Experimental|Single dose of AZD2115 80 µg|
3262560|NCT01498081|Experimental|Single dose of AZD2115 240 µg|
3262561|NCT01498081|Placebo Comparator|Single doses of placebo|
3262562|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg|
3262563|NCT01498081|Active Comparator|Single dose of indacaterol 150 µg + tiotropium 18 µg|
3262564|NCT01498094|Active Comparator|Control|Standard low-flow oxygen therapy.
3262565|NCT01498094|Experimental|Intervention|High Flow Nasal Cannula Oxygen Therapy
3262566|NCT01498133|Experimental|skin-to-skin contact|Newborns in the study group had skin-to-skin contact with their mothers in the NICU, twice a day (morning and evening) for 60 minutes, for seven days (including weekends).
3262567|NCT01498133|No Intervention|control group|The control group (n = 49) received routine care without skin-to-skin contact.
3262568|NCT01498159|Experimental|Pharmacist + Health Promoter|Participants in this group will receive support from both a pharmacist and health promoter. Number of sessions will be determined by the study team member and patient.
3262569|NCT01498159|Active Comparator|Pharmacist|Participants will receive support from pharmacist.
3262570|NCT01498172|Experimental|NMIBC at intermediate risk of progression|
3262571|NCT01498172|Experimental|NMIBC at high risk of progression|
3262572|NCT01498172|Experimental|NMIBC at low risk of progression|
3262573|NCT01498198|Experimental|Expedited Surgery|Participants will have surgery within 3 months
3262574|NCT01498198|Experimental|Non Operative Management|Participants will undergo non operative care for as long as they are improving, and will return to the surgeon when no progression is reached.
3262575|NCT01498211|Experimental|Biopsy|
3262576|NCT01498224|Active Comparator|Suture|Suture application
3262577|NCT01498224|Experimental|ReSure Sealant|Sealant application
3262578|NCT01498237|Experimental|Photoacoustic endoscopy|This is a one-arm, feasibility study to determine how well the experimental procedure photoacoustic endoscopy will evaluate the human endometrial cavity in vivo.
3262579|NCT01498250||basal cell carcinoma|
3262580|NCT01498250||non-lesional skin|
3262589|NCT01498315||Women following hysterecomy|
3262590|NCT01498328|Experimental|Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.|About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
3262591|NCT01498328|Experimental|Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control|About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
3262592|NCT01498328|Experimental|Group 2 and 2C: Refractory to Bevacizumab|Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
3262593|NCT01498354|Experimental|2-D high definition TEO (transanal endoscopic operation)|
3262594|NCT01498354|Active Comparator|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM), 3-D vision system using a rectoscope, which allows access to rectal tumors located up to 20 cm from the anal verge
3262595|NCT01498367|No Intervention|Usual care|Participants in the control group receive usual care. Usual care consists of regular visits to the specialist when required. In the occasion of the visit, HbA1c and glucose measurements are performed and the current oral or insulin therapy is modified if necessary. Patients also receive basic education in the management of diabetes.
3262596|NCT01498367|Experimental|Telemonitoring of diabetes 2 patients|Patients will have one educational visit to set up the system and explain how it works. Patients will download their measurements from their tele-glucose meter to their mobile phone and the data will be transferred to the regional database. The care team (a nurse specially trained and the allocated physician) will regularly access the patient's home diary, and will provide the appropriate counselling and medication changes as frequently as necessary. In addition to blood glucose measurements, routine questions about symptoms and eventual difficulties related to diabetes as well as diabetic management will be routinely captured and reported.
3262597|NCT01498380|Experimental|Dexmedetomidine Rapid Bolus|All subjects will receive a rapid bolus of dexmedetomidine following induction of anesthesia with propofol and remifentanil and placement of laryngeal mask airway.
3262598|NCT01498393|Other|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
3262599|NCT01498406|Experimental|high dose vitamin D3|4,000 IU of vitamin D3 daily for 8 months
3262600|NCT01498406|Active Comparator|low dose vitamin D3|400 IU of vitamin D3
3262601|NCT01498432|Experimental|Heliox21|
3262602|NCT01498432|Active Comparator|Air O2|
3262603|NCT01498484|Experimental|EBV-specific T cells|Patients will each receive a course of three weekly infusions of EBV-specific T cells (EBV-CTLs). Each weekly dose will provide 2 x 10^6 T cells/kg recipient weight (+/- 3 days). After the third dose, patients will be observed for approximately 3 weeks.
3262604|NCT01498497||PR-021 Eosinophilic Esophagitis (EoE) Subjects|Subjects who received study drug and completed PR-021 study
3262605|NCT01498510|No Intervention|treatment-as-usual (TAU)|The standard medical treatment provided to chronic pain patients at the study site pain specialty practice
3262606|NCT01498510|Experimental|TAU plus web-based intervention|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that teaches chronic pain patients with aberrant behavior self-management skills to reduce pain severity and medication misuse and improve functioning
3262607|NCT01498523|Experimental|raw camel milk|
3262608|NCT01498523|Experimental|camel milk powder solution|
3262609|NCT01498523|Active Comparator|raw cow milk|
3262610|NCT01498523|Active Comparator|Glucose solution|
3262611|NCT01498562|Experimental|Gefitinib plus Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) and Nimotuzumab (200mg weekly)
3262612|NCT01498562|Active Comparator|Gefitinib alone|Mono-therapy group: Gefitinib(250mg daily)
3262613|NCT01498614|Experimental|Affect school|Affect school is an educational intervention which includes 8 group sessions followed by 10 individual meetings with therapist
3262614|NCT01498614|Active Comparator|Basal body awareness|Basal body awareness is an educational method with 9 group sessions followed by 6 individual meetings
3262615|NCT01498627||Case Group|Subjects in this group are incident cases (i.e. newly diagnosed subjects) reported as having occurred in the previous twelve months before the recruitment consultation.
3262616|NCT01498627||Control Group|Subjects selected from the pool of potential referents reported by physicians in general practice, who meet the same general inclusion and exclusion criteria as the cases.
3262617|NCT01498666|Experimental|L. reuteri protectis tablets|one tablet a day for 4 weeks
3262618|NCT01498666|Placebo Comparator|Placebo tablet|one tablet a day for 4 weeks
3262619|NCT01498705||Hemmorhagic Stroke|"Hospitalization for an admitting diagnosis of hemorrhagic stroke admitted to the neurosurgical intensive care unit~Age greater than 18 years~No evidence of ischemic cerebrovascular injury"
3262620|NCT01498718|Experimental|Group 1A (18-50 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
3262621|NCT01498718|Experimental|Group 2A (51-70 yrs): DNA vaccine + TIV|HA DNA Vaccine (VRC-FLUDNA061-00-VP) at Day 0 and licensed TIV at Week 36
3262622|NCT01498718|Placebo Comparator|Group 1B (18-50 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
3262623|NCT01498718|Placebo Comparator|Group 2B (51-70 yrs): TIV only|Phosphate buffered saline (PBS) on Day 0 + TIV at Week 36
3262624|NCT01498731|Experimental|Copeptin|"Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home without further interventions.~To secure the patients safety they will be transferred into our co-operating network of resident cardiologists using the software Praxis-connect i.e. these patients will be discharged with an electronically booked appointment to see a cardiologist preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.~Patients who test positive for Copeptin will be treated as by standard practise."
3262625|NCT01498731|No Intervention|Standard|Patients will be managed as by standard practice abiding current guidelines for the management of patients with suspected ACS.The copeptin result will not be available for the treating physician.
3262626|NCT01498757||Patients treated with Taxane/5-FU/platinum based chemo.|
3262627|NCT01498770||Asenapine|
3262628|NCT01498770||Aripiprazole|
3262629|NCT01498770||Quetiapine|
3262630|NCT01498770||Risperidone|
3262631|NCT01498770||Olanzapine|
3262632|NCT01498770||Ziprasidone|
3262633|NCT01498770||Iloperidone|
3262634|NCT01498770||Paliperidone|
3262635|NCT01498770||Lurasidone|
3262636|NCT01498770||Clozapine|
3262637|NCT01498770||Amisulpride|
3262638|NCT01498770||Sertindole|
3262639|NCT01498770||Zotepine|
3262640|NCT01498783|Experimental|Treatment|"Participants meeting the eligibility requirements.~Intervention: 5-fluorouracil"
3262641|NCT01498796|Experimental|Ketorolac|
3262642|NCT01498796|Placebo Comparator|Placebo|
3262643|NCT01498835|Experimental|Combined Sunitinib and irradiation|Patients with locally advanced or recurrent soft tissue sarcoma will receive Sunitinib and irradiation as neoadjuvant treatment. Restaging and tumor resection will be performed 6 weeks after completion of sunitinib and irradiation.
3262644|NCT01498848|Active Comparator|Soybean oil|Families were given soybean oil for cooking during 4 weeks
3262645|NCT01498848|Active Comparator|Sunflower oil|Families were given sunflower oil for cooking during 4 weeks
3262646|NCT01498861|Other|Run-In Period|Ortho-Cyclen for 21 days. Only for subjects who are not already taking Ortho-Cyclen prior to the study
3262647|NCT01498861|Experimental|Sequence AB|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take dolutegravir 50 mg twice a day from Days 1-10 and placebo twice a day from Day 12-21
3262648|NCT01498861|Experimental|Sequence BA|Subjects will take Ortho-Cyclen once a day from Day 1-21 of their menstrual cycle. In addition they will take placebo twice a day from Days 1-10 and dolutegravir 50 mg twice a day from Day 12-21
3262649|NCT01498874|Placebo Comparator|Placebo|
3262650|NCT01498874|Experimental|low dose gevokizumab|
3262651|NCT01498874|Experimental|high dose gevokizumab|
3262652|NCT01498900||Repaglinide|
3262653|NCT01498913||Repaglinide|
3262654|NCT01498926|Experimental|Glycerol|
3262655|NCT01498926|Active Comparator|Mannitol|
3262656|NCT01498939|Experimental|IDet 0.2 U/kg|
3262657|NCT01498939|Experimental|IDet 0.4 U/kg|
3262658|NCT01498939|Experimental|IDet 0.8 U/kg|
3262659|NCT01499004|Experimental|Treatment A|tofacitinib (CP-690,550) modified-release formulation A-Fed
3262660|NCT01499004|Experimental|Treatment B|tofacitinib (CP-690,550) modified-release formulation B1-Fed
3262661|NCT01499004|Experimental|Treatment C|tofacitinib (CP-690,550) modified-release formulation A-Fasted
3262662|NCT01499004|Experimental|Treatment D|tofacitinib (CP-690,550) modified-release formulation B1-Fasted
3262663|NCT01499004|Experimental|Treatment E|tofacitinib (CP-690,550) modified-release formulation B2-Fasted
3262664|NCT01499004|Experimental|Treatment F|tofacitinib (CP-690,550) immediate-release formulation-Fasted
3262665|NCT01499017|Experimental|Cohort A|Each subjects in Cohort A will receive 3 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-4.
3262666|NCT01499017|Experimental|Cohort B|Each subjects in Cohort B will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
3262667|NCT01499056|Experimental|hip osteoarthritis|The patients with hip joint osteoarthritis who underwent cell injection
3262668|NCT01499069|Experimental|Antimuscarinic agents|
3262669|NCT01499108|Experimental|Liraglutide|single-group study were participants recieve Liraglutide
3262670|NCT01499121|Other|Sunitinib|Starting dose/schedule of Sunitinib 50 mg/28 days on, 14 days off. The intent is to maximize dose intensity of Sunitinib and minimize time off therapy based on individual tolerability using dose modification criteria.
3262671|NCT01499186|No Intervention|Control group|There will be no participation in a training program. The control group will perform all measurements.
3262672|NCT01499186|Experimental|Intervention group|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators. These subjects will perform all measurements.
3262673|NCT01499212|Experimental|I:E ratio 1:1|
3262674|NCT01499225|Experimental|YH14642 A-I|
3262675|NCT01499225|Experimental|YH14642 A-II|
3262676|NCT01499225|Experimental|YH14642 A-III|
3262677|NCT01499225|Active Comparator|Active Comparator B|
3262678|NCT01499225|Active Comparator|Active Comparator C|
3262679|NCT01499225|Placebo Comparator|Placebo|
3262680|NCT01499238|Active Comparator|nasal SIMV|rate: 30-50/min, PIP: 16, PEEP: 4-6, fİO2: 40%
3262681|NCT01499238|Active Comparator|nasal CPAP|PEEP: 4-6 mmHg, Fio2: 40%
3262682|NCT01499251|Experimental|Macitentan|Macitentan in combination with dose-dense temozolomide
3262683|NCT01499264|Experimental|MySkin patch|Hydrogel e polyurethane film
3262684|NCT01499264|Active Comparator|Traditional Dressing|
3262685|NCT01499316|Experimental|High Flow oxygen|10 minute of 10/L min of inhaled oxygen with reservoir bag.
3376298|NCT05161104||right ventricular dysfunction(RVD)|
3262686|NCT01499316|Experimental|Room Air|
3262687|NCT01499329||Patient receiving stent therapy|
3262688|NCT01499342||Rutherford category 2 - 5|
3262689|NCT01499381||Routine prostate biopsy patients|
3262690|NCT01499394||Normal|"Donor samples reflective of a normal non-disease state"
3262691|NCT01499394||Disease state or condition|Donor samples reflective of a known disease state or condition
3262692|NCT01499407|Active Comparator|Standard abciximab bolus|
3262693|NCT01499407|Experimental|ClearWay-infused abciximab|
3262694|NCT01499407|Experimental|Thrombectomy plus ClearWay-infused abciximab|
3262695|NCT01499407|Active Comparator|Thrombectomy plus standard abciximab bolus|
3262696|NCT01499420|Experimental|CSL112|
3262697|NCT01499420|Placebo Comparator|Placebo|
3262698|NCT01499433|Experimental|caspofungin|
3262699|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Morning|
3262700|NCT01499446|Experimental|GW685698X (fluticasone furoate) 100mcg Evening|
3262701|NCT01499446|Experimental|GW685698X (fluticasone furoate) 250mcg Evening|
3262702|NCT01499446|Placebo Comparator|Placebo|
3262703|NCT01499459|Experimental|autologous mesenchymal stem cell transplantation|
3262704|NCT01499472|Active Comparator|shock wave therapy, shortened wound healing time|
3262705|NCT01499472|Other|normal wound care|standard of care intervention
3262706|NCT01499485|Experimental|Acetazolamide|
3262707|NCT01499485|Placebo Comparator|placebo|
3262708|NCT01499537|Active Comparator|Percutaneous Drainage|Percutaneous Transhepatic Biliary Drainage (PTBD)
3262709|NCT01499537|Experimental|EUS-guided drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
3262710|NCT01499550|Experimental|TNI application|In this study arm the patient is treated with humidified transnasal high flow (TNI) plus oxygen (result flow: 20 L/min).
3262711|NCT01499550|Active Comparator|Oxygen treatment|Long term oxygen treatment (LOT) is the routine treatment in patients suffering from COPD. In this study arm the patient is treated with his individual oxygen flow rate.
3262712|NCT01499563|Experimental|ITI-007 Low Dose|
3262713|NCT01499563|Experimental|ITI-007 High Dose|
3262714|NCT01499563|Placebo Comparator|Placebo|
3262715|NCT01499563|Active Comparator|Risperidone|
3262716|NCT01499589||RA in block room|Performing regional anesthesia in the block room
3262717|NCT01499589||RA inside OR|Performing regional anesthesia inside the main orthopedic operating room
3262718|NCT01499602|Experimental|LNG-IUS|Release rate of 20µg Levonorgestrel(Mirena, Bayer Schering Pharma Oy, Finland) per day with one year follow up.
3262719|NCT01499602|Active Comparator|Norethisterone Acetate|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
3262720|NCT01499615||children undergoing general anesthesia|The intervention was the application of 4 ekg electrodes so as to non-invasivly measure cardiac output
3262721|NCT01499628|No Intervention|Group 1-Control|No extra training will be given.
3262722|NCT01499628|Active Comparator|Group 2-Control plus supervised reading|The same amount of contact time as Groups 3 and 4 - three 45 minute sessions completed over three weeks.
3262723|NCT01499628|Experimental|Group 3-EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
3262724|NCT01499628|Experimental|Group 4-EVT at the TRL|Eccentric viewing training at the Trained Retinal Locus (TRL), using reading/target cards and microperimeter. Three 45 minute sessions completed over three weeks.
3262725|NCT01499641|Active Comparator|Epidural steroid|1.0 mL methylprednisolone acetate 40 mg/mL instilled at the decompressed nerve root
3262726|NCT01499641|Experimental|None epidural steroid|
3262727|NCT01499680||NV in XLIF|This group will have the XLIF procedure done using NV.
3262728|NCT01499693|Experimental|Magnesium Pantoprazole 20mg|
3262729|NCT01499693|Active Comparator|Magnesium Pantoprazole 40mg|
3262730|NCT01499706|No Intervention|Standard of Care Control|Participants will receive standard sexual risk reduction services available to them through medical and community-based organizations
3262731|NCT01499706|Experimental|1-session motivational interviewing|Participants will receive a single session of motivational interviewing delivered over the telephone
3262732|NCT01499706|Experimental|4-session motivational interviewing|Participants will receive four weekly sessions of motivational interviewing delivered over the telephone.
3262733|NCT01499719||Surgical checklist|Compliance for surgical checklist
3262734|NCT01499732||Early Rheumatoid Arthritis|Subjects currently experiencing active early rheumatoid arthritis (duration of symptoms < or = 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening. Must be drug naive (no prior treatment with traditional disease-modifying antirrheumatic drugs (DMARDs), or biologic response modifying agents)
3262735|NCT01499732||Healthy subjects without rheumatoid arthritis|Healthy subjects without rheumatoid arthritis
3262736|NCT01499732||Established Rheumatoid Arthritis|Subjects currently experiencing active established rheumatoid arthritis (duration fo symptoms > or = 2 years) according to the 2010 ACR/EULAR criteria at screening. Subjects with active established RA currently receiving methotrexate, must have received it for at least 12 weeks, and at a stable dose (> or = 15 mg/week) for at least 6 weeks prior to screening. They must be biologic naive, and must recieve at least 5mg oral folic acid weekly
3262737|NCT01499745|Active Comparator|Exercise Training at Pulmonary Rehabilitation Program|Exercise Training at Pulmonary Rehabilitation Program 2 weekly sessions of 60 min for 12 weeks
3262738|NCT01499745|Placebo Comparator|Standard Treatment for IPF|Continue for normal live with standard treatment
3262739|NCT01499758|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
3262740|NCT01499758|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
3262741|NCT01499771|Experimental|1|Atorvastatin Calcium Tablets of OHM Laboratories Inc.
3376299|NCT05161104||diffuse ventricular dysfunction|
3262742|NCT01499771|Active Comparator|2|LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
3262743|NCT01499784|Experimental|Pelvic Floor muscle Training|educational class for behavioral modification and group exercise class for pelvic floor muscle training
3262744|NCT01499797|No Intervention|regular medical care|Identified community dwelling frail elderly people receiving regular medical care in their primary care setting
3262745|NCT01499797|Experimental|The CareWell programme|Identified community dwelling frail elderly people receiving care in line with the CareWell programme
3262746|NCT01499823||Patients with high-grade glioma|Patients with high-grade glioma (glioblastoma multiforme or anaplastic astrocytoma), who receive concurrent chemoradiation (CCRT) with temozolomide
3262747|NCT01499836|Experimental|general anesthesia and PVB|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given. After intubation, paravertebral injections will be performed under ultrasound guidance.
3262748|NCT01499836|Experimental|sedation and PVB|After sedation with midazolam and fentanyl, the patients in sedation and PVB group will receive PVB. paravertebral injections will be performed under ultrasound guidance.Intraoperative sedation will be provided with propofol titrated to moderate sedation.
3262749|NCT01499836|Active Comparator|general anesthesia|general anesthetics consisting of propofol, cisatracurium and fentanyl for endotracheal intubation and deaflurane for maintenance will be given.
3262750|NCT01499875|Other|Phenoxymethylpenicillin|It is a descriptive trial to find out about the pharmacokinetics
3262751|NCT01499888|Experimental|Allogeneic Non-Myeloablative Stem Cell Transplantation|The transplant regimen will consist of alemtuzumab 1mg/kg divided over five days, 300 cGy TBI, followed by sirolimus dosed for a target serum trough level of 10- 15 ng/mL.
3262752|NCT01499901|Experimental|sequential|implantation bilateral sequential
3262753|NCT01499901|Experimental|simultaneous|implantation bilateral simultaneous
3262754|NCT01499914|Experimental|Influenza vaccination|Influenza vaccination in patients with cystic fibrosis
3262755|NCT01499927|Active Comparator|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
3262756|NCT01499927|No Intervention|no electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents without computerized decision support
3262757|NCT01499953|Experimental|Rivaroxaban|Rivaroxaban for 45 days oral dose: 10 mg OD
3262758|NCT01499953|Active Comparator|Fondaparinux|Fondaparinux for 45 days subcutaneous application: 2,5 mg OD
3262759|NCT01499966|Experimental|group POP|PLASTER OF PARIS
3262760|NCT01499966|Experimental|TG|TUBIGRIP
3262761|NCT01499979|No Intervention|Vascular inflow occlusion|Patients that will receive intermittent vascular inflow occlusion, the standard method for vascular occlusion at our institution, during liver resection.
3262762|NCT01499979|Experimental|Hypothermic perfusion|Patients will receive in situ hypothermic perfusion of the future remnant liver during liver resection.
3262763|NCT01499992|Experimental|aquatic physical therapy|aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focussing on the shoulder.
3262764|NCT01499992|No Intervention|standard care|
3262765|NCT01500005|Experimental|vitamin D|Baby D3 drops
3262766|NCT01500018|Experimental|Crossover Treatment Sequence 1|Period 1: Placebo, Period 2: Phentermine 45 mg, Period 3: Phentermine 90 mg, Period 4: Ketamine 100 mg, Period 5: TC-5214 2 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 16 mg
3262767|NCT01500018|Experimental|Crossover Treatment Sequence 2|Period 1: Phentermine 45 mg, Period 2: Ketamine 100 mg , Period 3: Placebo, Period 4: TC-5214 8 mg , Period 5: Phentermine 90 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 2 mg
3262768|NCT01500018|Experimental|Crossover Treatment Sequence 3|Period 1: Ketamine 100 mg, Period 2: TC-5214 8 mg, Period 3: Phentermine 45 mg, Period 4: TC-5214 16 mg, Period 5: Placebo, Period 6: TC-5214 2 mg, Period 7: Phentermine 90 mg
3262769|NCT01500018|Experimental|Crossover Treatment Sequence 4|Period 1: TC-5214 8 mg, Period 2: TC-5214 16 mg, Period 3: Ketamine 100 mg, Period 4: TC-5214 2 mg, Period 5: Phentermine 45 mg , Period 6: Phentermine 90 mg, Period 7: Placebo
3262770|NCT01500018|Experimental|Crossover Treatment Sequence 5|Period 1: TC-5214 16 mg, Period 2: TC-5214 2 mg, Period 3: TC-5214 8 mg, Period 4: Phentermine 90 mg, Period 5: Ketamine 100 mg, Period 6: Placebo , Period 7: Phentermine 45 mg
3262771|NCT01500018|Experimental|Crossover Treatment Sequence 6|Period 1: TC-5214 2 mg, Period 2: Phentermine 90 mg, Period 3: TC-5214 16 mg, Period 4: Placebo, Period 5: TC-5214 8 mg, Period 6:Phentermine 45 mg , Period 7: Ketamine 100 mg
3262772|NCT01500018|Experimental|Crossover Treatment Sequence 7|Period 1: Phentermine 90 mg, Period 2: Placebo, Period 3: TC-5214 2 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 16 mg, Period 6: Ketamine 100 mg, Period 7: TC-5214 8 mg
3262773|NCT01500018|Experimental|Crossover Treatment Sequence 8|Period 1: TC-5214 16 mg, Period 2: TC-5214 8 mg, Period 3: TC-5214 2 mg, Period 4: Ketamine 100 mg, Period 5: Phentermine 90 mg, Period 6: Phentermine 45 mg, Period 7: Placebo
3262774|NCT01500018|Experimental|Crossover Treatment Sequence 9|"Period 1: TC-5214 2 mg, Period 2: TC-5214 16 mg, Period 3: Phentermine 90 mg, Period 4: TC-5214 8 mg, Period 5: Placebo, Period 6: Ketamine 100 mg, Period 7:~Phentermine 45 mg"
3262775|NCT01500018|Experimental|Crossover Treatment Sequence 10|Period 1: Phentermine 90 mg, Period 2: TC-5214 2 mg, Period 3: Placebo, Period 4: TC-5214 16 mg Ketamine 100 mg, Period 5: Phentermine 45 mg, Period 6: TC-5214 8 mg, Period 7: TC-5214 2 mg
3262776|NCT01500018|Experimental|Crossover Treatment Sequence 11|Period 1: Placebo, Period 2: Phentermine 90 mg, Period 3:Phentermine 45 mg, Period 4: TC-5214 2 mg, Period 5: Ketamine 100 mg, Period 6: TC-5214 16 mg, Period 7: TC-5214 8 mg
3262777|NCT01500018|Experimental|Crossover Treatment Sequence 12|Period 1: Phentermine 45 mg, Period 2: Placebo, Period 3: Ketamine 100 mg, Period 4:Phentermine 90 mg, Period 5: TC-5214 8 mg, Period 6: TC-5214 2 mg, Period 7: TC-5214 16 mg
3262778|NCT01500018|Experimental|Crossover Treatment Sequence 13|Period 1: Ketamine 100 mg, Period 2: Phentermine 45 mg, Period 3: TC-5214 8 mg, Period 4: Placebo, Period 5: TC-5214 16 mg, Period 6: Phentermine 90 mg, Period 7: TC-5214 2 mg
3376300|NCT05161104||hyperdynamic state left ventricular function|
3376301|NCT05161104||Normal|
3262779|NCT01500018|Experimental|Crossover Treatment Sequence 14|Period 1: TC-5214 8 mg, Period 2: Ketamine 100 mg, Period 3: TC-5214 16 mg, Period 4: Phentermine 45 mg, Period 5: TC-5214 2 mg, Period 6: Placebo, Period 7: Phentermine 90 mg
3376302|NCT05161091|Experimental|Radio-induced oral mucositis / Medical Device|Patient with radio-induced oral mucositis at least grade 2 treated with experimental medical device
3262780|NCT01500044|Active Comparator|Conventional Rehabilitation Program|The conventional program consists in cervicothoracic mobilizations and stabilization exercises. This program is based on the intervention used in clinical practice, and on programs proposed in two RCTs evaluating individuals with neck and arm pain that do not include any specific mobilization or exercise leading to the opening of the intervertebral foramen. Four mobilisation techniques will be executed at each treatment session. However, the therapists will not be allowed to use techniques that specifically open the intervertebral foramen of the affected segment, two segments above and two segments below.
3262781|NCT01500044|Experimental|Program targeting the opening of foramen|"The same interventions as for the conventional rehabilitation program will be applied, except:~Of the four mobilisation techniques, there will be two mandatory techniques targeting the opening of the intervertebral foramen on the same side and at the same level as the radiculopathy: global contralateral rotation mobilisation and ipsilateral lateral shearing in a flexion position. The therapist, according to the biomechanical evaluation results, will choose the two other mobilisation techniques."
3262782|NCT01500070|Experimental|Drug-eluting stent|Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
3262783|NCT01500148|Experimental|Intevention-PMVr Procedure|
3262784|NCT01500161|Experimental|Single Arm|The following conditioning regimens will be used, depending on the underlying hematologic malignancies. Conditioning regimens with Busulfan/clofarabine and with fludarabine/melphalan will be used for all patients except those with Non-Hodgkin's lymphoma when the conditioning regimen of BCNU, Etoposide, ARA-C and Melphalan will be used.
3262785|NCT01500174|Experimental|active UVC device|Three times per week irradiation of wound base and periwound skin
3262786|NCT01500174|Placebo Comparator|Placebo UVC device|Three times per week irradiation of wound base and periwound skin
3262787|NCT01500265||Patient naive|Patient with hepatitis B virus naive untreated
3262788|NCT01500265||Patient with TDF|Patient with hepatits B treated with Tenofovir
3262789|NCT01500265||Patient with ETV|Patient with hepatitis B virus treated with Entecavir
3262790|NCT01500291||Anesthesiologist|
3262791|NCT01500291||Nurse anesthetist|
3262792|NCT01500304|Experimental|Minimally invasive surgery|Minimally invasive inguinal lymph node dissection is a 10-step technique to provide novel inguinal lymph node staging and treatment.
3262793|NCT01500330|Experimental|cupping massage|12 weeks home use of cupping massage (delivered by the partner or friend) twice a week for 20 minutes
3262794|NCT01500330|Active Comparator|control group|progressive muscle relaxation twice a week for 20 minutes
3262795|NCT01500343|Experimental|Saccharomyces boulardii|
3262796|NCT01500343|Placebo Comparator|Placebo|
3262797|NCT01500356|Experimental|Diet alone|Weight loss intervention that focuses only on reducing energy intake of the diet.
3262798|NCT01500356|Experimental|Diet plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
3262799|NCT01500356|Experimental|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
3262800|NCT01500369|Active Comparator|remote ischemic conditiong|"Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
3262801|NCT01500369|Placebo Comparator|Standard Care|Patients in the control group will have the sphygmomanometer cuff placed on their right upper arm, but the cuff will not be inflated. Similar to patients in the treatment group, patients in the control group will undergo the same 30 minute delay before induction of anesthesia and surgery
3262802|NCT01500395||Stent Graft and open surgery|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al.
3262803|NCT01500408|Other|Commercial INFB followed by Investigational INFB|Process A (currently-approved manufacturing process involving FBS) first, then Process B (new serum-free manufacturing process, without FBS)
3262804|NCT01500408|Other|Investigational INFB followed by Commercial INFB|Process B (new serum-free manufacturing process, without FBS) first, then Process A (currently-approved manufacturing process involving FBS)
3262805|NCT01500421|Experimental|TH - Endovacular alone|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with an endovascular groin catheter (Copenhagen only).
3262806|NCT01500421|Experimental|TH - Endovascular + nasopharyngeal induction|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with endovascular catheter along with nasopharyngeal induction (Copenhagen only).
3262807|NCT01500421|No Intervention|Standard Treatment|Patients are treated with standard care in the stroke ward.
3262808|NCT01500421|Experimental|TH - Surface Cooling|Patients randomized to this arm are cooled to a bodytemperature of 33 degrees with cold saline infusion followed by surface cooling with Arctic Sun Cooling system, Medivance, USA (Malmø only)
3262811|NCT01500473|Experimental|Females with CCHS > 16 years old on desogetrel|
3262812|NCT01500486||PenMate device|
3262813|NCT01500512||Observation (observe patients undergoing SLN dissection)|Patients receive standard therapy including sentinel lymph node dissection. Patients are then observed to collect information about treatment and outcomes every 2 months for 2 years.
3376303|NCT05161091|Placebo Comparator|Radio-induced oral mucositis / Placebo comparator|Patient with radio-induced oral mucositis at least grade 2 treated with placebo
3376304|NCT05161091|Experimental|Chemo-induced oral mucositis / Medical Device|Patient with chemo-induced oral mucositis at least grade 2 treated with experimental medical device
3262814|NCT01500538|Experimental|Eltrombopag and vorinostat combination therapy|Daily oral intake of 400mg vorinostat if necessary with combination therapy eltrombopag commencing at 50mg per day increasing to a maximum of 200mg per day
3262815|NCT01500564|Sham Comparator|Sham tDCS and motor training: sham comparator|"Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Intervention: placebo tDCS Other: Motor Training"
3262816|NCT01500564|Experimental|Anodal tDCS and motor training: experimental|"Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).~Interventions:~Device: anodal tDCS~Other: motor Training during physiotherapy"
3262817|NCT01500577|Experimental|Nimesulide|Nimesulide 100 mg (capsules), 100mg/die every day for 1 year. Oral administration
3262818|NCT01500577|Experimental|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
3262819|NCT01500577|Placebo Comparator|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
3262820|NCT01500590|Experimental|renin-angiotensin system blockers|Those eligible patients will be randomized into 2 groups. One group use renin-angiotensin systems (RAS) blockers to control their blood pressure, the other group will use other types of anti-hypertensive agents other than RAS blockers
3262821|NCT01500590|Active Comparator|non-renin angiotensin system blockers|"These includes norvasc adalat retard natrilix betaloc aldomet~amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg once daily to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg once daily to 500mg twice daily"
3262822|NCT01500603|Experimental|Experimental|Patients will receive AdvanceXP retrourethral male sling implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route
3262823|NCT01500603|Active Comparator|Active comparator|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
3262824|NCT01500616|Experimental|open label telaprevir|Depending on the patient's HAART regimen, 750 or 1125 mg telaprevir every 8 hours for 12 weeks in combination with pegylated interferon alfa and ribavirin for 48 weeks.
3262825|NCT01500642|Active Comparator|sublingual immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
3262826|NCT01500642|Active Comparator|vestibular immunotherapy|15 patients treated with vestibular immunotherapy (SLIT One, ALK Abello) administered at standard dose (200 STU / dose) from June to August 2001
3262827|NCT01500642|Active Comparator|sublingual doubled immunotherapy|15 patients treated with sublingual immunotherapy (SLIT One, ALK Abello) administered at doubled dose (400 STU / dose) from June to August 2001
3262828|NCT01500655|Experimental|Catheter|An ultrasound guided block of the LFCN is performed, followed by the placement of a catheter underneath the fascia iliaca.
3262829|NCT01500655|Experimental|Ultrasound guided LFCN block|An ultrasound guided regional nerve block --using ropivacaine 0.2%-- will be performed around the lateral femoral cutaneous nerve (LFCN).
3262830|NCT01500655|No Intervention|Control|This group gets the current standard of care--the donor site is infiltrated with 0.25% bupivacaine.
3262831|NCT01500668|Active Comparator|Treatment|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
3262832|NCT01500668|Placebo Comparator|Control|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
3262834|NCT01500707|Experimental|SCH 900800|Participants receiving a single dose of SCH 900800
3262835|NCT01500785|Active Comparator|levosimendan|
3262836|NCT01500785|Placebo Comparator|placebo|
3262837|NCT01500798|Placebo Comparator|Placebo|
3262838|NCT01500798|Experimental|Bardoxolone methyl|
3262839|NCT01500811|Experimental|chondrocyte|Patients with sever hip osteoarthritis who underwent intra articular cell injection.
3262840|NCT01500824|Experimental|Crizotinib|
3262841|NCT01500837|Active Comparator|RIFAMPIN|CLINDAMYCIN + RIFAMPIN
3262842|NCT01500837|Active Comparator|LEVOFLOXACIN|CLINDAMYCIN + LEVOFLOXACIN
3262843|NCT01500850|Active Comparator|NPH insulin + insulin glulisine|Patients will be randomized to be treated with NPH insulin + Insulin Glulisine for 24 weeks.
3262844|NCT01500850|Active Comparator|NPH insulin + human insulin|Patients will be randomized to be treated with NPH insulin + human insulin for 24 weeks.
3262845|NCT01500850|Experimental|Insulin glargine + insulin glulisine|Patients will be randomized to be treated with insulin glargine + insulin glulisine for 24 weeks.
3262846|NCT01500850|Experimental|Insulin Glargine + Human insulin|Patients will be randomized to be treated with insulin glargine + human insulin for 24 weeks.
3262847|NCT01500863|Active Comparator|hCG|
3262848|NCT01500863|Experimental|Triptorelin 0.2mg s.c.|
3262849|NCT01500863|Experimental|0.2mg triptorelin plus estradiol/progesterone|
3262850|NCT01500863|Experimental|0.2mg tripoterlin plus single bolus hCG 1500 IU|
3262851|NCT01500863|Experimental|0.2mg tripoterlin plus multiple boluses hCG 500 IU|
3262852|NCT01500863|Experimental|0.2mg tripoterlin plus multiple doses recLH|
3262853|NCT01500876|Experimental|Study Arm|Single Arm
3376305|NCT05161091|Placebo Comparator|Chemo-induced oral mucositis / placebo comparator|Patient with chemo-induced oral mucositis at least grade 2 treated with placebo
3262854|NCT01500889|Active Comparator|CLI sphincterotomy|Conventional Lateral internal sphincterotomy LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
3262855|NCT01500889|Active Comparator|GroupII: V-Y advancement flap|The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide. Figures 1, 2, 3 and 4 illustrate the procedure.
3262856|NCT01500889|Active Comparator|TLIS with VY anoplasty|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
3262857|NCT01500902|Other|vascular testing|We are assessing vascular testing in patients presenting with acute coronary syndrome to determine if this type of testing will help identify which patients are more likely at risk to have another heart attack.
3262858|NCT01500915|Experimental|ranibizumab|
3262859|NCT01500941|Active Comparator|probiotics|
3262860|NCT01500941|Placebo Comparator|maltodextrin|
3262861|NCT01500954||squamous cell carcinoma|
3262862|NCT01500954||non-lesional skin|
3262863|NCT01500967|Active Comparator|Traction|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
3262864|NCT01500967|Experimental|Manipulations|Shi-style manipulations is a cervical manipulation for cervical radiculopathy.This manipulation is a kind of traditional Chinese massage and it can dredge the meridians. Patients are treated every day for 30 minutes. Seven times as one course and totally there are two courses. 3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
3262865|NCT01500980|Experimental|Pilot Phase|Pilot phase will include 6 subjects and will investigate the timing of PQ dosing relative to parasite exposure.
3262866|NCT01500980|Experimental|Chloroquine, ITV, primaquine, malaria challenge|
3262867|NCT01500980|Active Comparator|Sporozoite negative vaccine|
3262868|NCT01500980|Active Comparator|Primaquine placebo|
3262869|NCT01500980|No Intervention|malaria challenge|
3262870|NCT01500993|Active Comparator|5-Fluorouracil (5-FU)|Drug - 5FU based chemoradiotherapy and chemotherapy
3262871|NCT01500993|Experimental|Capecitabine|Drug - Capecitabine-based radiochemotherapy and chemotherapy
3262872|NCT01501006||Patient Roles|Physician communication styles will be evaluated with different patient roles.
3262873|NCT01501019|No Intervention|Sjogren and Myositis Control (no control for takayasu's)|
3262874|NCT01501019|Experimental|Sjogren, Myositis and Takayasu's Trained|
3262875|NCT01501032|Experimental|Closed Loop Control- MD-Logic|The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
3262876|NCT01501045|Experimental|healthy subjects|healthy subjects
3262877|NCT01501045|Experimental|pain patients|Migraine and muscle headache patients
3262878|NCT01501058|Experimental|case group|
3262879|NCT01501058|Other|waitlist control group|For this group, same intervention with the Experimental group will be provided after waiting for 14 weeks.
3262880|NCT01501071|Experimental|esophageal calibration|Esophageal calibration tube was applied to this group of patients during laparoscopic Nissen fundoplication operation
3262881|NCT01501071|No Intervention|Control|Standard Laparoscopic Nissen fundoplication without esophageal calibration
3262882|NCT01501084|Active Comparator|Exenatide|Exenatide injection 10 mcg subcutaneous
3262883|NCT01501084|Placebo Comparator|Saline|.2cc SC injection of sterile normal saline
3262884|NCT01501097|No Intervention|Control group|
3262885|NCT01501097|Experimental|early HV-crrt|
3262886|NCT01501123|Experimental|Haloperidol|IM Haloperidol
3262887|NCT01501123|Active Comparator|IM Midazolam|
3262888|NCT01501136|Experimental|sequential trial,DDGP, radiotherapy|sequential DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment followed by radiotherapy
3262889|NCT01501136|Experimental|sequential trial,VIPD, radiotherapy|sequential VIPD（cisplatin，Etoposide,Ifosfamide,dexamethasone，Mesna） regiment followed by radiotherapy
3262890|NCT01501136|Experimental|sequential trial, radiotherapy,DDGP|sequential radiotherapy followed by DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
3262891|NCT01501136|Experimental|sequential trial,radiotherapy, VIPD|sequential radiotherapy followed by VIPD（cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna）regiment chemotherapy
3262892|NCT01501136|Experimental|Radiotherapy|Suitable type intensity-modulated radiation therapy (IMRT) 50GY
3262893|NCT01501149|Experimental|DDGP regiment|DDGP(gemcitabine,pegaspargase,cisplatin,dexamethasone) regiment
3262894|NCT01501149|Experimental|SMILE Regiment|Modified SMILE （methotrexate，hexadecadrol，Ifosfamide，L-AsparaginaseL，Etoposide，Mesna）Regiment
3262895|NCT01501175||patients with suspected SVT|patients with suspected SVT and inhabitants of the Saint Etienne region
3262896|NCT01501188|Experimental|Kinesio taping|Specific type of muscle and joint taping
3262897|NCT01501188|Placebo Comparator|Kinesio taping placebo|Kinesio taping placebo
3262898|NCT01501201|Experimental|Gastric By-Pass|group treated with Gastric By-Pass
3262899|NCT01501201|Active Comparator|optimized medical management|group receiving an optimized medical management
3262900|NCT01501214|Active Comparator|Atosiban|
3262901|NCT01501214|Placebo Comparator|Placebo|Normal saline
3262902|NCT01501227|Active Comparator|Taper Guard Endotracheal Tube|Patients in the test group will be intubated with the Taper Guard Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
3262903|NCT01501227|Sham Comparator|conventional endotracheal tube|Patients in the placebo comparator group will be intubated with the conventional Endotracheal Tube. The incidence of VAP, the length of ventilation, the length of intensive care stay, the length of hospital stay and the mortality rate will be monitored.
3376306|NCT05161078||All Patients Enrolled|Patients will be treated with CARPEDIEM per standard of care.
3262904|NCT01501240||liver cirrhosis, liver transplantation|Patients with known liver cirrhosis and planned to undergo liver transplantation within 1 month will be eligible population in the study
3262905|NCT01501253|Experimental|CKD-828 2.5/40mg|CKD-828 2.5/40mg
3262906|NCT01501253|Experimental|CKD-828 2.5/80mg|CKD-828 2.5/80mg
3262907|NCT01501253|Active Comparator|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg
3262908|NCT01501266||Faslodex|
3262909|NCT01501279|Experimental|pudendal nerve block|USG guided pudendal nerve block performed under general anesthesia
3262910|NCT01501279|No Intervention|no nerve block|Control group without nerve block
3262911|NCT01501292||Immature oocytes (GV, M-I)|
3262912|NCT01501292||Mature oocytes (M-II)|
3262913|NCT01501305|Placebo Comparator|Placebo|Mineral rehydration solution
3262914|NCT01501305|Active Comparator|Carob powder|Carob powder and probiotics
3262915|NCT01501318|Active Comparator|Personalized feedback plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.Treatment as usual with participants receiving a personalized feedback report about the risks associated with their current substance use behaviors and a brief (5-15 minute) motivational interviewing based education session provided by a trained health coach.
3262916|NCT01501318|Experimental|Personalized feedback report alone|Provision of the personalized feedback report alone.
3262917|NCT01501331||RRT diagnostic tool|Patients implanted with an Energen device or successor.
3262918|NCT01501357|Experimental|multilevel filaments toothbrush|Children will brush with anteroposterior toothbrushing and a modified toothbrush (multilevel filaments)
3262919|NCT01501357|Active Comparator|cross toothbrushing|Children will brush with cross toothbrushing.
3262920|NCT01501370|Experimental|ZLd|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive:~Cohort 1: ZLd association:~Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle.~Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
3262921|NCT01501370|Active Comparator|Ld|"Patients, who are receiving Lenalidomide maintenance treatment with or without prednisone, will be randomized to receive: Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days~• Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days."
3262922|NCT01501383|Active Comparator|VX-765 Dose 1 Part A|
3262923|NCT01501383|Active Comparator|VX-765 Dose 2 Part A|
3262924|NCT01501383|Active Comparator|VX-765 Dose 3 Part A|
3262925|NCT01501383|Active Comparator|VX-765 Dose 4 Part A|
3262926|NCT01501383|Placebo Comparator|Placebo Dose Part A|Placebo
3262927|NCT01501383|Active Comparator|VX-765 Dose Part B|
3262928|NCT01501396|Experimental|Arm A (megestrol alone)|Megestrol acetate 800 mg PO daily x 8 weeks
3262929|NCT01501396|Experimental|Arm B (megestrol plus mirtazapine)|"Megestrol acetate 800 mg PO daily x 8 weeks~Mirtazapine 15 mg PO at bedtime x 1 week followed by 30 mg PO at bedtime x 7 weeks"
3262930|NCT01501409|Experimental|Group I|
3262931|NCT01501409|Active Comparator|Group II|
3262932|NCT01501409|Active Comparator|Group III|
3262933|NCT01501422|Experimental|Estrogen|Use estrogen patch for 8 weeks
3262934|NCT01501422|Experimental|Placebo|Use placebo patch for 8 weeks
3262935|NCT01501435|Experimental|CJ-30039|Incrementally Modified Drugs of fenofibric acid
3262936|NCT01501435|Active Comparator|fenofibric acid|Greencross Lipidil Supra 160mg
3262937|NCT01501448|Active Comparator|OCP|
3262938|NCT01501448|Active Comparator|Oral estradiol valerate|
3262939|NCT01501474||CholangioFlex and Fluorescent in situ Hybridization(FISH)|
3262940|NCT01501487|Active Comparator|HER2 negative patients|"In order to provide some consistency in management and have a treatment policy in place only recommended therapy with several well accepted and presumed equivalent chemotherapy regimens will be used. The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients include:~TAC chemotherapy~TC chemotherapy~Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy"
3262941|NCT01501487|Active Comparator|Her2 positive patients|The proposed neo-adjuvant chemotherapy regimens for HER2 negative patients is TCH chemotherapy.
3262942|NCT01501500|Active Comparator|botulinum toxin type A. HV angle|intramuscular injection of BTA into target muscle
3262943|NCT01501500|Placebo Comparator|Normal saline, HV angle|intramuscular injection of normal saline into target muscle
3262944|NCT01501513|Experimental|BLI800 approved preparation regimen|BLI800 approved preparation regimen
3262945|NCT01501513|Experimental|BLI800 investigational preparation regimen|BLI800 investigational preparation regimen
3262946|NCT01501513|Active Comparator|PEG-3350 based bowel preparation|PEG-3350 based bowel preparation
3262947|NCT01501539|No Intervention|Standard postop gastrostomy tube care|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions and the gastrostomy tube will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. Standard postop gastrostomy tube care. Insertion site cleaned with soap and water. No dressing added.
3262948|NCT01501539|Experimental|Standard hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to the surgeons preference. The gastrostomy tube will have a thin layer of hydrocolloid dressing (HD) placed around the gastrostomy tube. The HD will be changed once every other day fo the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
3376309|NCT05161026|Other|Patients with AML|Patients with AML
3262949|NCT01501539|Experimental|Silver hydrocolloid dressing|At the completion of the operative procedure for gastrostomy tube placement, the surgical incisions will be covered with dermabond, steristrips, and/or tegaderm dressings, according to surgeon preference. The gastrostomy tube will have a thin layer of silver hydrocolloid dressing (HD) placed around the gastrostomy tube. The silver HD will be changed once every other day for the first 30 days after gastrostomy tube placement. After 30 days, care will revert to standard care.
3262950|NCT01501552|No Intervention|Treatment as usual|In the no-intervention treatment as usual group, a package, containing a summary card of the national guideline recommendation, will be delivered to each provider unit without demonstration. In Poland, the summary card will be adapted from the PHEPA guidelines (ref) for the purposes of this trial. The treatment as usual group will be requested to screen and offer person-to-person SBI at the PHCU.
3376311|NCT05161000|Experimental|Oral Nutritional Supplement (ONS) Group|Two servings per day in addition to dietary counseling
3376312|NCT05161000|Other|Control Group|dietary counseling
3376313|NCT05160987|Experimental|Remimazolam Group|The patients are administered with sedation of remimazolam and analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drug before enrollment, patient would be administered with a bolus of remimazolam with 0.1-0.3mg/kg intravenously in 1 minute for the first time. And maintenance dose is 0.25-0.1mg/kg/h, meanwhile the dose of remimazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
3376314|NCT05160987|Placebo Comparator|Midazolam Group|The patients are administered with sedation of midazolam analgesia of remifentanil on the basis of routine treatment. If the patient does not receive sedative drugs before enrollment, patients would be administered with a bolus of midazolam with 0.01-0.05mg/kg intravenously in 1 minute for the first time. And the maintenance dose is 0.02-0.1mg/kg/h, meanwhile the dose of midazolam should be titrated according to RASS scores. Nonbenzodiazepines could be administrated to the patients if sedation targets were not achieved, and the medication and dosage is recorded.
3376315|NCT05160961|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique beneath the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
3376316|NCT05160961|Active Comparator|Erector spinae plane block|After the linear ultrasound (US) probe will be placed 2-3 cm lateral to the T5 spinous process, 20 ml of 0.25% bupivacaine hydrochloride will be injected into the interfacial space below the erector spinae muscle, above the transverse process.
3376317|NCT05160935|Experimental|Coronary Angiography Training Manual|It is the form prepared by the researchers in line with the literature information and the opinion of the specialist physician was taken. It contains information about coronary artery disease, what to do before coronary angiography procedure and what kind of situations await individuals after the procedure.
3262951|NCT01501552|Experimental|Training & support (T&S)|The T&S only group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
3262952|NCT01501552|Experimental|Financial incentive|The financial incentive only group will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3376318|NCT05160922|Other|crizotinib|crizotinib oral treatment
3376319|NCT05160909||Beach Chair|Patient positioned in beach chair position during arthroscopic shoulder stabilization
3376320|NCT05160909||Lateral decubitus|Patient positioned in lateral decubitus position during arthroscopic shoulder stabilization
3376321|NCT05160896|Experimental|MSS or MSI-L/pMMR, RAS and BRAF are both wild type|"the primary lesion is located in the left colorectal:~SALIRI plus cetuximab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 cetuximab 500 mg/ m² , iv, day 1~the primary lesion is located in the right colorectal:~SALIRI plus bevacizumab~One cycle (cycle duration 14 days) consists of:~Raltitrexed 2 mg/m² iv, 15min. day 1 Irinotecan 180 mg/m² iv, 30 - 90 min. day 1 Bevacizumab 5 mg/kg, iv, day 1"
3376322|NCT05160857|Experimental|test group|
3376323|NCT05160844||Diseased|young Egyptian patients with premature myocardial infarction
3376324|NCT05160844||Control|healthy young Egyptians
3376325|NCT05160831|Experimental|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells injection is applied for knee OA patients.
3262953|NCT01501552|Experimental|E-SBI|The e-SBI (online screening and brief intervention)only group are expected to refer identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
3262954|NCT01501552|Experimental|T&S and financial incentive|The T&S and financial incentive group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. Also, they will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3376326|NCT05160818|Active Comparator|Arm A: HSFRT|Hypofractionated stereotactic radiotherapy to the resection cavity, dose prescription: 6-7 x 5 Gy
3376327|NCT05160818|Active Comparator|Arm B: SRS|Single fraction stereotactic radiotherapy to the resection cavity, dose prescription: 1 x 12-20 Gy
3376328|NCT05160805|Experimental|Treatment Group A|ONL1204 Ophthalmic solution (Dose A) administered by intravitreal injection
3376329|NCT05160805|Experimental|Treatment Group B|ONL1204 Ophthalmic solution (Dose B) administered by intravitreal injection
3376330|NCT05160805|Sham Comparator|Treatment Group C|Sham procedure without penetrating the eye
3262955|NCT01501552|Experimental|T&S and e-SBI|The T&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
3262956|NCT01501552|Experimental|Financial incentive and e-SBI|The financial incentive and e-SBI (online screening and brief intervention) group will be paid for screening and referral performance instead of actual delivery of e-SBI by themselves as in line with the e-SBI only group, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3262957|NCT01501552|Experimental|T&S, financial incentive and e-SBI|The T&S, financial incentive and e-SBI (online screening and brief intervention) group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Also, they are expected to offer screening at the PHCU and to refer screen positive patients to e-SBI programmes. Additionally, they will be paid for screening and referral performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
3262958|NCT01501565|No Intervention|Control|Standard analgesic therapy: iv Metamizol 2 g q8h
3262959|NCT01501565|Experimental|TAP|"Transverse abdominal plain (TAP) blockade with local anesthetic: Bupivacaine chlorhydrate 0.25% adjusted by weight and type of surgery. Maximum dose: 150 mg of bupivacaine.~Two approaches are done: 1)Posterior TAP: the needle insertion point is cephalad to the iliac crest, behind the midaxillary line. The needle is inserted under ultrasound guidance in plane. Local anesthetics is deposited between the internal oblique and transversus abdominis muscles, 2)Subcostal TAP: the needle is inserted ultrasound guided perpendicularly to abdominal wall, directed parallel to the costal margin but oblique to the sagittal plane. Local anesthestic is deposited between transversus abdominis and the rectus abdominis muscles."
3262960|NCT01501578||telomerase mutation|Patients with interstitial lung disease and telomerase mutation
3376331|NCT05160792|Experimental|Volunteers|Index leg - compression with GraduCheck Control leg - compression without Graducheck
3376332|NCT05160779|Active Comparator|Mild/asymptomatic cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed mild or asymptomatic conditions.
3376333|NCT05160779|Active Comparator|Serious cases|For the collection of cells from the oral cavity, a sterile swab will be used for the procedure, and will be opened by the collector in the presence of the participant. The biological material will be collected from the participant's cheek mucosa (rotating the swab 360º using light pressure (approximately 75N) on the mucosa tissue and then packed in a tube containing 3ml of sterile 0.9% saline solution) of the participant. confirmation of identification data in order to analyze and relate polymorphisms found in components of vasoactive peptide systems in DNA samples collected from patients diagnosed with SARS-CoV-2 (COVID-19) who developed severe pathology.
3376334|NCT05160766|Active Comparator|Comirnaty-Comirnaty|"Comirnaty (BioNTech/ Pfizer vaccine BNT162b2)~Participants are already fully vaccinated with 2x Comirnaty (BNT162b2) when entering the trial, only the 3rd dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial."
3376335|NCT05160766|Active Comparator|Spikevax-Spikevax|"Spikevax (Moderna vaccine mRNA-1273)~Participants are already fully vaccinated with 2x Spikevax (mRNA-1273) when entering the trial, only the 3rd dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial."
3376336|NCT05160766|Active Comparator|Vaxzevria-Vaxzevria|"Vaxzevria (Astra Zeneca vaccine ChAdOx-1-S)~Participants are already fully vaccinated with 2x Vaxzevria (ChAdOx-1-S) when entering the trial, only the 3rd dose will be administered in the study. Treatment will be given as a single shot of either Comirnaty (BTN162b2) or Spikevax (mRNA-1273) using the approved dose and mode of administration of each vaccine included in this trial."
3448441|NCT04063891|Experimental|Vibration Group|Vibration group is treated with LMHFV at 35Hz, 0.3g, for 20 minutes/day, 5 times/week
3448442|NCT04064073|Experimental|1|
3448443|NCT04064073|Experimental|2|
3448444|NCT04064073|Experimental|3|
3448445|NCT04064931||recurrent abortion|women of childbearing age who have spontaneous abortion within 20 weeks of pregnancy for 2 or more consecutive times.
3262961|NCT01501578||control|Patients with idiopathic pulmonary fibrosis and without telomerase mutation
3262962|NCT01501591|Other|Hydroxyzine|This group will receive a first generation H-1 receptor antagonist, hydroxyzine (25 mg) twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
3262963|NCT01501591|Other|Placebo|This group will receive a placebo twice on two days; on one day described by the investigator as hydroxyzine and on the other day described by the investigator as placebo, in a randomized balanced crossover design.
3262964|NCT01501591|Other|Hydroxyzine/placebo|This group will receive hydroxyzine and placebo in a randomized double-blind placebo-controled crossover design.
3262965|NCT01501617|Experimental|HSC- Hair Stimulating Complex|Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
3262966|NCT01501617|Placebo Comparator|Dulbecco's Modified Eagle Medium, DMEM|Dulbecco's Modified Eagle Medium (DMEM) will be administered the same way as described above into treatment zone of the test subject's scalp not treated with HSC.
3262967|NCT01501630||PET/CT and MRI|all patients will benefit from PET/CT and MRI
3262968|NCT01501643|Active Comparator|Spirometry|Spirometry
3262969|NCT01501643|Experimental|Non invasive positive pressure ventilation|Non invasive positive pressure ventilation
3262970|NCT01501669|No Intervention|Capecitabine alone arm|X arm
3262971|NCT01501669|Experimental|Irinotecan plus capecitabine arm|
3262972|NCT01501682||primary suture|operated with primary suture
3262973|NCT01501682||other mesh|operated with insertion of another mesh
3262974|NCT01501682||ventralex|operated with insertion of ventralex mesh
3262975|NCT01501695|Experimental|5LGr, granule and placebo tablet|"Drug:5LGr; Dosage form:Granule;Strength:5 gram/sack;Mimic Tablet:0 mg/tablet. Dosage: 5LGr Granule: 1 sack, t.i.d. for patients less than 12 yrs,whereas 1.5 sacks, t.i.d. for patients 13-18 yrs.~Mimic tablet:For patients 5-12 yrs: 0.5 tablet, b.i.d for first 2 weeks, then 1 tablet, bid for next 6 weeks; for patients 13-18 yrs: tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
3262976|NCT01501695|Active Comparator|tiapride tabletand mimic 5LGr granule|"Tiapride are 100 mg scored tablets. Mimic 5LGr granule are preparation that contain no active ingredient, and act as placebo.~Dosage: Tiaptride tablet: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Mimic 5LGr Granule:Strength:0 gram/sack.Dosage:1 sack for patients less than 12 yrs,while 1.5 sacks for patients 13-18 yrs.Frequency: T.i.d.~Duration: 8 weeks."
3262977|NCT01501695|Placebo Comparator|placebo, granule and tablet|"This arm includes mimic preparation of 5LGr granule and tiapride tablets , which doesn't contain active ingredients.~Dosage form: Mimic Granule:Strength:0 gram/sack Dosage:1 sack, t.i.d for patients less than 12 yrs,while 1.5 sacks, t.i.d for patients 13-18 yrs.~Mimic tablet:Strength:0 mg/tablet.For patients 5-12 yrs: 0.5 tablets b.i.d for first 2 weeks, then 1 tablet,b.i.d for next 6 weeks; for patients 13-18 yrs:1 tablet b.i.d for first 2 weeks, then 2 tablets b.i.d for next 6 weeks.~Duration: 8 weeks."
3262978|NCT01501708|Experimental|Caspofugin based combination therapy|"Caspofugin based combination therapy:~Patients will recieve caspofungin with voriconazole or amphotericin B"
3262979|NCT01501721|Experimental|Exercise|Home-based exercise program
3262980|NCT01501721|Experimental|Nutritional counseling|Nutrition counseling aiming to reduce suggar intake
3262981|NCT01501734|Experimental|all patients with symptomatic CHF|"Single arm prospective study~Study population will include all patients referred to our outpatient clinic for congestive heart failure for a two-year period, who will be screened for sleep apnea and found to have sleep disordering breathing (SDB).~200 patients will visit the outpatient clinic for congestive heart failure.~Approximately 30% will be eligible for this study."
3262982|NCT01501747|Active Comparator|overt drug|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving such medication.
3262983|NCT01501747|Placebo Comparator|Placebo (Covert drug)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
3262984|NCT01501760|Experimental|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at inclusion, 1 month, 2 month.
3262985|NCT01501760|Placebo Comparator|Placebo|Three subconjunctival injections of 0.5 ml of Nacl at inclusion, 1 month, 2 month.
3262986|NCT01501773|Experimental|Autologous bone marrow stem cell|
3262987|NCT01501773|No Intervention|Control|
3262988|NCT01501786|Sham Comparator|control|propofol and saline are administered
3262989|NCT01501786|Experimental|Ket10|ketamine is co-administered with propofol
3262990|NCT01501786|Experimental|Ket20|ketamine is co-administered with porpofol
3262991|NCT01501799|Experimental|Adapalene 0.1% and benzoyl peroxide 2.5% topical gel|
3262992|NCT01501799|Active Comparator|EPIDUO™ (adapalene 0.1% and benzoyl peroxide 2.5%) Gel|
3262993|NCT01501799|Placebo Comparator|Vehicle Gel|
3262994|NCT01501812||Schizophrenia|Subjects who are suffering from Schizophrenia or Schizoaffective disorder acording to the DSM-IV-R criteria
3262995|NCT01501812||Control|Healthy subjects without any mental ilness in axis I or II.
3262996|NCT01501812||Bipolar|Subjects who are suffering from bipolar I or 2 disorder acording to the DSM-IV-R criteria
3262997|NCT01501812||MDD|Subjects who are suffering from Major Depressive disorder acording to the DSM-IV-R criteria
3262998|NCT01501812||Anxiety|Subjects who are suffering from Panic disorder or from Generalized Anxiety disorder acording to the DSM-IV-R criteria
3262999|NCT01501812||PTSD|Subjects who are suffering from Post Traumatic Stress Disorder acording to the DSM-IV-R criteria
3263000|NCT01501825|Active Comparator|single channel|Single Channel with a coil placed over the left PFC (10 Hz).
3263001|NCT01501825|Experimental|four channels|"Four channels:~10 Hz over the left PFC.~1 Hz over the right PFC.~10 Hz over the left parietal cortex.~1 Hz over the right parietal cortex."
3448446|NCT04064931||normal pregnancy history|Women of childbearing age who had a normal pregnancy history and are not in pregnancy status now.
3448447|NCT04064931||general population|Women of childbearing age in general examination.
3263002|NCT01501864|Experimental|School Support Group|School Support Intervention
3263003|NCT01501864|No Intervention|Control|No school support
3263004|NCT01501877|Experimental|Distress Tolerance|Acceptance and Commitment Therapy based Distress Tolerance (DT) smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
3263005|NCT01501877|Active Comparator|Standard Smoking Cessation|Standard smoking cessation intervention delivered in 7 2-hour group, 1 50-minute individual, and 2 10-minute phone sessions and 8 weeks of transdermal nicotine patch.
3263006|NCT01501890|Active Comparator|Progesterone|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation
3263007|NCT01501890|Placebo Comparator|Placebo|Women attending the Gynecological Emergency Unit due to first trimester vaginal bleeding, with a viable singleton pregnancy at a gestational age of 6-13 completed weeks of gestation.
3263008|NCT01501903|Active Comparator|Standard|Biopsy using standard technique of FNA
3263009|NCT01501903|Other|Fanning|Biopsy using fanning technique
3263010|NCT01501916|Experimental|vitamin d|
3263011|NCT01501916|Placebo Comparator|Placebo|
3263012|NCT01501942|Experimental|Active|The active drug product is an oral solution of AIM-102 in phosphate buffered saline at a concentration of 35.0 mg/ml.
3263013|NCT01501942|Placebo Comparator|Inactive product|The matching placebo is an oral solution of phosphate buffered saline
3263014|NCT01501968|Active Comparator|Colistin|Colistimethate sodium 2.5-5mg/kg iv
3263015|NCT01501968|Experimental|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv and ascorbic acid 2 grams iv every 12 hours
3263016|NCT01501994|Experimental|Walking workstation, counseling, accelerometry feedback|2 week baseline: accelerometer with no feedback 12 experimental: Use of the walking workstation, counseling on increasing activity levels, feedback from the accelerometer 12 week crossover: Feedback from accelerometer, no counseling or walking workstation
3263017|NCT01501994|Other|Control then crossover|2 week baseline: accelerometer with no feedback 12 week control period: accelerometer with no feedback 12 week crossover period: accelerometer with feedback, counseling on increasing activity, and use of a walking workstation
3263018|NCT01502007|Experimental|Accelerometer feedback and lifestyle counseling|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling.
3263019|NCT01502007|Experimental|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The control group will continue to wear the fitbit for the next 24 weeks without any feedback or activity counseling. Following the 26th week of the study, the subjects in the control group will complete the same program given to the experimental group in weeks 2 through 26.
3263020|NCT01502020|Active Comparator|Zyclara™|
3263021|NCT01502020|Experimental|Generic Imiquimod Cream, 3.75%|
3263022|NCT01502020|Placebo Comparator|Vehicle Cream|
3263023|NCT01502046|Experimental|Sativex|
3263024|NCT01502046|Placebo Comparator|Placebo|
3263025|NCT01502059|Experimental|Pilates Group|This group keep their usual treatment and did a Pilates treatment twice a week (one hour each class) during 90 days.
3263026|NCT01502059|No Intervention|Control Groups|This group keep their usual treatment and can do the Pilates training after the end of the study.
3263027|NCT01502085|Experimental|Vorinostat, Lenalinomide, Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
3263028|NCT01502098|Active Comparator|Early passive motion|Pendulum exercises starting on the first postoperative day. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises were not permitted until four weeks after surgery.
3263029|NCT01502098|No Intervention|Immobilization|Immobilization with sling during a month. Pendulum exercises starting on the fourth postoperative week. The patients are instructed to commence passive range-of-motion exercises in the plane of the scapula with the assistance with the contralateral limb. Active motion exercises.
3263030|NCT01502111||Airway management|Patients receiving advanced airway management in physician manned helicopter emergency medical services over a 12-month period.
3263031|NCT01502124|Active Comparator|Lyophilized|
3263032|NCT01502124|Experimental|Liquid|
3263033|NCT01502137|Experimental|ESRD patients|
3263034|NCT01502137|Experimental|Healthy subjects|
3263035|NCT01502150||Pediatric Proton Therapy Patients|Data collection of MDACC patients under the age of 18 treated with proton radiotherapy. Proton dosimetry data collection, corresponding radiation dose distribution and imaging data in order to correlate normal tissue response with dose distribution.
3263036|NCT01502163|No Intervention|Control|"No prewarming~Intraoperative forced air warming (Thermoflect™/Mistral Air™) (after induction of anaesthesia, before surgery starting)~Passive insulation with Thermoflect™ material.~All fluids administrated intraoperative will be warmed."
3263037|NCT01502163|Active Comparator|Group passive prewarming|"Passive prewarming / insulation on nursery ward before transport to the OR (Thermoflect TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
3263038|NCT01502163|Active Comparator|Group Active prewarming|"Active prewarming on nursery ward before transport to the OR (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)~Intraoperative forced air warming (Thermoflect™ / Mistral Air ™) The forced air warming will be applied after induction of anaesthesia.~All fluids administrated intraoperative will be warmed."
3263039|NCT01502176||Atrial fibrillation patients|All patients discharged from hospital with a diagnose of atrial fibrillation
3263040|NCT01502189|Experimental|Representational approach|The Representational approach as described in the detailed description.
3263041|NCT01502202|Active Comparator|Study arm|Pemetrexed plus Cisplatin plus Gefitinib
3263042|NCT01502202|Placebo Comparator|Placebo arm|Pemetrexed plus Cisplatin plus Placebo
3263043|NCT01502215|Active Comparator|Liberal Transfusion Strategy|Liberal Group - transfusion when hemoglobin is lower than 9 g/dL. Intervention: Other: Red blood cell transfusion
3263044|NCT01502215|Active Comparator|Restrictive Transfusion Strategy|Restrictive Group - transfusion when hemoglobin is lower than 7 g/dL Intervention: Other: Red blood cell transfusion
3263045|NCT01502241|Active Comparator|Radiotherapy|6 weeks standard partial brain treatment.
3263046|NCT01502241|Experimental|Temozolomide|Temozolomide in a one week on/one week off schedule per Wick et al. 2004 and A. Wick et al. 2007
3263047|NCT01502254|Experimental|Copy of audio recording|Patients receive a copy of the audio recorded information about the clinical trial directly after the clinical visit. This makes it possible to repeat the information before a decision is made to participate in the clinical trial or not.
3263048|NCT01502254|No Intervention|No copy of audio recording|Patients in the control arm receive no copy of the audio recording.
3263049|NCT01502267|No Intervention|Group 1|This group will not receive IVIG and B cell depleting agents
3263050|NCT01502267|Experimental|Group 2|This group will receive IVIG and B cell depleting agents
3263051|NCT01502280|Experimental|5-ALA/Gliolan® /5-Aminolevulinic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 5-ALA/Gliolan®/5-Aminolevulinic acid mixed with sterile water (20mg/kg)
3263052|NCT01502280|Placebo Comparator|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
3263053|NCT01502319||All subjects|Group/Cohort label is not applicable to this umbrella protocol. The Consortium funds specific research teams who will determine the number of group(s)/cohort(s) relevant to their study.
3263054|NCT01502345|Experimental|PUUV DNA Vaccine|This group will receive Puumala Virus DNA Vaccine only
3263055|NCT01502345|Experimental|HTNV + PUUV|This group will receive a 1:1 mixture of HTNV and PUUV DNA Vaccines
3263056|NCT01502345|Experimental|HTNV DNA Vaccine|This group will receive Hantaan Virus DNA Vaccine only
3263057|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV)|low dose (no adjuvant)
3263058|NCT01502358|Experimental|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|low dose (with adjuvant)
3263059|NCT01502358|Experimental|Tetravalent dengue Vaccine (TVDV) with Vaxfectin® (high-dose)|high dose (with adjuvant)
3263060|NCT01502384||healthy relatives|healthy 1st degree relatives of PD patients
3263061|NCT01502397||HBsAg-negative, anti-HBc-positive|HBsAg-negative, anti-HBc-positive subjects undergoing rituximab-containing chemotherapy
3263062|NCT01502449|Experimental|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program over 8 weeks that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
3263063|NCT01502449|Active Comparator|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
3263064|NCT01502475||Veteran Attitudes toward CAM|
3263065|NCT01502527|Experimental|Treatment with Femarelle|An open labeled , twice daily treatment with Femarelle
3263066|NCT01502553|Experimental|Blood Pressure, Heart Rate, Monitor|"Device Comparison Test DUT: Transtek Blood Pressure Monitor, LS-802 Refrence Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Groups/Cohorts: Blood Pressure & Heart Rate Monitor"
3263067|NCT01502566|Experimental|Educational Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries. This intervention will be applied at the Brazilian National Vaccination Day
3263068|NCT01502566|No Intervention|Control group|This group will receive no intervention
3263069|NCT01502592|Experimental|Cryoablation alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3263070|NCT01502592|Experimental|Ipilimumab alone|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3263071|NCT01502592|Experimental|Ipilimumab & Cryoablation|This is a pilot study evaluating the safety and tolerability of pre-operative, single-dose ipilimumab and/or cryoablation in patients with early stage/resectable breast cancer.
3263072|NCT01502605|Experimental|5-ALA|This arm will receive the investigational agent, 5-ALA.
3263073|NCT01502618|Experimental|Focus Group|The focus group participants for this study will be Black Young Men who have Sex with Men (B-YMSM) ages 16-24 years (inclusive) who are diagnosed as HIV-positive and receive medical care at one of the two participating AMTUs or their community partners.
3263074|NCT01502670|Experimental|Lung Nodule|
3263075|NCT01502683|Experimental|Off-pump No Clamp|Off-pump coronary artery bypass patients randomized to no clamp for proximal anastomoses.
3448448|NCT04064892|Experimental|Exercise Intervention|Participants will receive a 12-week, individually-tailored, video conference-based physical activity intervention
3263076|NCT01502683|Experimental|Off-pump Partial Occluding Clamp|Off-pump coronary artery bypass patients randomized to partial occluding clamp for proximal anastomoses.
3263077|NCT01502683|Experimental|On-pump Single Cross Clamp|On-pump coronary artery bypass patients randomized to single cross clamp for cardioplegic arrest and proximal anastomoses.
3263078|NCT01502683|Experimental|On-pump Double Clamp|On-pump coronary artery bypass patients randomized to cross-clamp for cardioplegic arrest and partial-occluding clamp for proximal anastomoses. This strategy involves the application of two clamps.
3263079|NCT01502696|Experimental|PEG IFN alfa-2b|
3263080|NCT01502696|No Intervention|Observation|
3263081|NCT01502722|Experimental|Group 1 - Crossover|This group will drink water in the 1st study.
3263082|NCT01502722|Experimental|Group 2 - Crossover|This group will drink Pineapple Soda in the 1st study
3263083|NCT01502722|Experimental|Group 3 - Crossover|This group will drink Pineapple Diet Soda in the 3rd study
3263084|NCT01502735|Experimental|DENV-1 PIV (high dose)|
3263085|NCT01502735|Experimental|DENV-1 PIV (low dose)|
3263086|NCT01502748|Experimental|Endovascular Sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study
3263087|NCT01502774|Experimental|Cyclosporin|Injection of Cyclosporin A : one single intravenous bolus injection of 2.5 mg/Kg Echocardiography
3263088|NCT01502774|Placebo Comparator|Control|one single intravenous bolus injection of Placebo Echocardiography
3263089|NCT01502800|Experimental|Part 1 (ARQ 761)|"ARQ 761 (beta lapachone) will be given once a week. The same dose of ARQ761 each week for 4 weeks (1 cycle = 28 days). The total infusion time will be one (1) hour.~Beginning dose level will be 195 mg/m2 and will increase until the maximum tolerated dose is defined. Seven dose levels that may be administered:~1-195 mg/m2 2-390 mg/m2 3-450 mg/m2 4-550 mg/m2 5-660 mg/m2 6-800 mg/m2 7-1000 mg/m2"
3263090|NCT01502800|Experimental|Part 2 Arm A|"The same dose of ARQ761 will be given each week for 8 weeks. The total infusion time will be 2 or 3 hours.~Beginning dose level will be 390 mg/m2."
3263091|NCT01502800|Experimental|Part 2 Arm B|"ARQ 761 (beta lapachone) will be given bi-weekly for 8 weeks. The total infusion time may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
3263092|NCT01502800|Experimental|Part 2 Arm C|"ARQ 761 (beta lapachone) will be given 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
3263093|NCT01502826||Group A|less insulin-resistant
3263094|NCT01502826||Group B|severely insulin-resistant
3263095|NCT01502839||OEF/OIF Veterans|Operation Enduring Freedom (OEF)/Operation Iraqi Freedom (OIF) Veterans
3263096|NCT01502852||OEF/OIF Veterans with TBI|
3263097|NCT01502852||Family Members and Friends|Family Members and Friends of OEF/OIF Veterans with TBI
3263098|NCT01502852||Community Mental Health Center Providers|Community Mental Health Center providers working with OEF/OIF Veterans with TBI
3263099|NCT01502878|Active Comparator|Nut challenge|Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
3263100|NCT01502878|Placebo Comparator|Nut challenge: Placebo|See intervention
3263101|NCT01502878|Experimental|Nut oral desensitization|Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.
3263102|NCT01502891|Active Comparator|Decision aid|DEPRESSION CHOICE decision aid is provided to clinician to share with patient
3263103|NCT01502891|No Intervention|Normal care|
3263104|NCT01502904|Active Comparator|Cypher group|
3263105|NCT01502904|Experimental|Nobori group|
3263106|NCT01502904|Active Comparator|Pravastatin group|
3263107|NCT01502904|Active Comparator|Pitivastatin group|
3263108|NCT01502904|Active Comparator|Non-ARB group|
3263109|NCT01502904|Experimental|ARB group|
3263110|NCT01502917|Experimental|Radioactive iodine-labeled monoclonal antibody omburtamab|This is a therapeutic Phase I study intended to assess the safety of convection-enhanced delivery (CED) of radioimmunotherapy in the treatment of children with diffuse pontine glioma.
3263111|NCT01502930|Experimental|IRT|Imagery Rehearsal Therapy
3263112|NCT01502930|Active Comparator|CONT|Stress reduction and positive imagery
3263113|NCT01502930|No Intervention|REG|Registration only
3263114|NCT01502943|Experimental|Phlegm and blood stasis Syndrome G|
3263115|NCT01502943|Placebo Comparator|Phlegm and blood stasis control G|
3263116|NCT01502943|Experimental|Qi deficiency and blood stasis G|
3263117|NCT01502943|Placebo Comparator|Qi deficiency and blood stasis control G|
3263118|NCT01502969|Placebo Comparator|Placebo|Children receiving placebo (cell culture medium in absence of virus)
3263119|NCT01502969|Active Comparator|Rotavirus vaccine|Rotavin-M1, 10e6.3ffu/dose, 2 doses
3263120|NCT01502982|Experimental|Chemoimmunotherapy|
3263121|NCT01502995|Active Comparator|With laser light|Trial of walking tasks using laser light on walker.
3263122|NCT01502995|Active Comparator|Without laser light|Trial of walking task without laser light on walker.
3263123|NCT01503008|Experimental|Sustained Behavior Change system support|
3263124|NCT01503008|Active Comparator|Control|
3263125|NCT01503034||Study cohort|This cohort is made up of pregnant women with a breast cancer diagnosed between 2000 and 2014.
3263126|NCT01503034||Compared cohort|This cohort is made up of non-pregnant women with a breast cancer diagnosed between 2000 and 2009.
3263127|NCT01503047|Experimental|CLA group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
3263128|NCT01503047|Placebo Comparator|Placebo group|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo, P group.
3263129|NCT01503060|Placebo Comparator|Group 1|"Visit 1-4 (2,4,6,12 month vaccinations): Patients will receive standard care~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3263130|NCT01503060|Active Comparator|Group 2|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3263131|NCT01503060|Active Comparator|Group 3|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3263132|NCT01503060|Active Comparator|Group 4|"Visit 1-4 (2,4,6,12 month vaccinations): Parents will be taught about managing pain and their infant will be given sugar water and a topical anesthetic~Visit 5 (15 month vaccination): At the last visit all 4 groups will receive all three active interventions."
3263133|NCT01503073|Active Comparator|Real stimulation|real NIBS
3263134|NCT01503073|Sham Comparator|Sham stimulation|sham NIBS
3263135|NCT01503086|Experimental|Arm I (interactive training program)|Patients undergo a home-based, computerized, interactive training program comprising 3-5 sessions of 15-45 minutes every week for 5-9 weeks. The program contains twelve visually engaging and interesting exercises that target skills involving visual-spatial and verbal WM. The program is adaptive in a way that each difficulty task is automatically adjusted on a trial-by-trail basis to match a patient's current WM. Each patient has an interventional coach who has online access to patient's training sessions and outcomes (pass or fail). Coaches are able to modify the training sequence or make suggestions to patients and/or parents about how progress can be maximized. Coaches also have telephone meetings with patients and/or families once a week to ensure compliance, track progress, provide feedback, and answer questions that arise during training.
3263136|NCT01503086|Experimental|Arm II (non-adaptive training program)|Patients undergo a home-based, computerized, interactive, non-adaptive training program comprising 3-5 sessions of 15-45 minutes a week for 5-9 weeks. Each patient also has an interventional coach as in arm I. Patients in both arms complete a brief neuropsychological/behavioral assessment comprising the WIS-IV, the CMS, and the CVLT-C at baseline, after completion of study, and at 6 months after completion of study. Additionally, parents complete a parent-report questionnaire to gather information about patient's behaviors, thoughts, emotions, adaptive skills, and social and functional impairment. Parents and children also complete surveys about the program regarding technical feasibility, adherence, ease-of-use, and satisfaction.
3263137|NCT01503099||Active ITB|Patients with active intestinal tuberculosis (ITB)
3263138|NCT01503099||Controls India|Healthy subjects serving as controls
3263139|NCT01503099||CD India|Patients with active Crohn's Disease (CD) in India
3263140|NCT01503099||Active PTB|Patients with active pulmonary tuberculosis (PTB)
3263141|NCT01503099||CD Norway|Patients with active Crohn's Disease (CD) in Norway
3263142|NCT01503099||Controls Norway|Healthy subjects serving as controls in Norway
3263143|NCT01503112||Patients starting incretin treatments|Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
3263144|NCT01503138|Experimental|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
3263145|NCT01503138|No Intervention|Standard community health education program|The community health education programme consists of two group sessions with one on the topic of osteoporosis and one on dietary therapy based on the concepts of Chinese medicine.
3263146|NCT01503151|Placebo Comparator|Placebo|repeated trials of a dot-probe task and repeated trials of an interpretation task, both not intended to change threat-related biases patterns.
3263147|NCT01503151|Experimental|Attention Bias Modification (ABM)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3263148|NCT01503151|Experimental|Interpretation Bias Modification (IBM)|Interpretation training intended to facilitating a more benign interpretation bias
3263149|NCT01503151|Experimental|Attention and interpretation biases modification|Attention and interpretation training intended to direct cognitive biases away from threat stimulus.
3263150|NCT01503177|Experimental|Treatment (viral therapy)|Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
3263151|NCT01503203|Experimental|Wii Group|This group will do the same training of the Prime Group. However will do also Physical Virtual Training using Nintendo Wii and Wii Balance Board. The physical virtual training going to applied during thirty minutes.
3263152|NCT01503203|Active Comparator|Prime Group|This group will do strength exercises and core training.
3263153|NCT01503216|Experimental|cholecalciferol|Human volunteers receiving cholecalciferol (vitamin D3) for 8 weeks
3263154|NCT01503216|Experimental|Ergocalciferol|Ergocalciferol 2000 IU per day for 8 weeks
3263155|NCT01503216|Placebo Comparator|Placebo|Placebo for 8 weeks
3263156|NCT01503242|Experimental|Treatment (monoclonal antibody, chemo, TBI, transplant)|Patients receive 90Y-BC8 Ab IV on day -12 and fludarabine phosphate IV on days -4 to -2. Patients undergo TBI and allogeneic peripheral blood stem cell transplant on day 0. Patients also receive graft-vs-host disease prophylaxis comprising cyclosporine PO BID on days -3 to 56 with taper to day 180 or on days -3 to 100 with taper to 180; and mycophenolate mofetil IV or PO BID on days 0-27, or 0-40 with taper to 96.
3263157|NCT01503255|Experimental|cognitive behavioral group therapy|
3263158|NCT01503255|Active Comparator|health education group|
3263159|NCT01503268|Active Comparator|Percutaneous ablation|
3263160|NCT01503268|Active Comparator|Surgical ablation|
3263161|NCT01503268|Active Comparator|DCCV|Direct current cardioversion
3263162|NCT01503281|Experimental|Hospital-based exercise program|Exercise monitored at the hospital
3263163|NCT01503281|Experimental|Home-based exercise program|Participants perform exercise at home
3263164|NCT01503281|No Intervention|Control|Control Group participants maintained their usual levels of daily activity, with no additional exercise components.
3263165|NCT01503307||Prenatal/Postpartum CHD Diagnosis|parent of a baby (prenatal or postpartum)who was recently found to have a heart defect.
3263166|NCT01503320|Experimental|Enteral glutamine|
3263167|NCT01503320|Placebo Comparator|Placebo|
3263168|NCT01503346|Experimental|herbal medicine|"Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
3263169|NCT01503359|Experimental|Dietary Supplement: Sarcosine|Sarcosine Group
3263170|NCT01503359|Placebo Comparator|Placebo|Control Group
3263171|NCT01503372|Experimental|Arm A: FLO + Pazopanib|
3263172|NCT01503372|Active Comparator|Arm B: FLO|
3263173|NCT01503385|Experimental|Celecoxib|"Combination of and concurrent radiotherapy Cisplatin/etoposide with or without Celecoxib.~Intervention: Drug: Celecoxib"
3263174|NCT01503398|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
3263175|NCT01503398|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
3263176|NCT01503424|Experimental|Olanzapine Tablets, 5 mg|Olanzapine Tablets, 5 mg of Dr. Reddy's Laboratories Limited
3263177|NCT01503424|Active Comparator|Zyprexa|Zyprexa Tablets, 5 mg of Eli Lilly and company
3263178|NCT01503437|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
3263179|NCT01503437|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
3263180|NCT01503450|Experimental|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
3263181|NCT01503450|Active Comparator|Zyprexa Zydis 5 mg Tablets|Zyprexa Zydis 5 mg Tablets of Cardinal Health, UK
3263182|NCT01503463|No Intervention|Usual Care|Patients in the control group receive usual care delivered by their primary care physicians and cardiologists. Usual care consists of regular visits to the specialist or primary care clinics every time a medication change is required, or a medical examination is needed.
3263183|NCT01503463|Experimental|Home telemonitoring of patients with CHF|
3263184|NCT01503476|Experimental|Healthy volunteers|healthy volunteers
3263185|NCT01503476|Experimental|symptomatic patients|symptomatic patients with known or suspected gastro esophageal reflux disease
3263186|NCT01503502|Experimental|flumatinib 400mg qd|
3263187|NCT01503502|Experimental|flumatinib 600 mg qd|
3263188|NCT01503502|Active Comparator|imatinib|
3263189|NCT01503528|Active Comparator|Motor Sparing Nerve Block|Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
3263190|NCT01503528|Experimental|Peri-Articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by peri-articular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices. Spinal anesthetic with 15 mg of hyperbaric bupivacaine. Patients will be discharged home following removal of the anaesthetic catheter and fulfilling criteria for discharge.
3263191|NCT01503554|Experimental|Social Worker + Pharmacist Intervention|Intervention arm offering enhanced services from a social worker and a pharmacist post-discharge
3263192|NCT01503554|Experimental|Usual Care|Patients receiving usual care will have a medication reconciliation performed by a physician or nurse during their hospital stay. No further support or interventions are provided post discharge.
3263193|NCT01503567||Subjects 6 to 18 years old without inhibitors|
3263194|NCT01503567||Subjects 6 to 18 years old with inhibitors|
3263195|NCT01503567||Subjects above18 years old without inhibitors|
3263196|NCT01503567||Subjects above 18 years old with inhibitors|
3263197|NCT01503580|Experimental|antimuscarinic drug|
3263198|NCT01503593|No Intervention|Alveolar ridge dimensions|Control group - Only extraction teeth
3263199|NCT01503593|Experimental|Alverolar ridge dimension|Extraction of teeth and implant a bone substitute
3263200|NCT01503606|Active Comparator|one-week treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization for one week
3263201|NCT01503606|Active Comparator|until-delivery treatment group|Cefazolin 1.0gm IVs q 12 hours plus clarithromycin 500mg po bid after randomization until delivery
3263202|NCT01503619||Basic science (biomarker analysis)|DNA isolated from archived tumor tissue and blood samples are analyzed for genetic mutations and gene expression profiling using Illumina exome sequencing. Results are compared with transcriptome of tumors (or cell lines) with and without the specific mutation. Cell culture studies overexpressing or inhibiting the genes of interest are also performed in a mouse model to identified potential drivers of small cell lung cancer.
3263203|NCT01503632|Experimental|Arm I (intervention program and mercaptopurine)|See detailed description.
3263204|NCT01503632|Active Comparator|Arm II (standard of care and mercaptopurine)|Patients receive the usual standard of care and the mercaptopurine from the MEMS® medication bottle with TrackCap™ as patients in arm I. Patients and caregivers also view an interactive multimedia educational program on day 29.
3263205|NCT01503658|Experimental|Clopidogrel+Aspirin|Clopidogrel on Day 1, Aspirin on Day 2 - Day 14, Clopidogrel + Aspirin Day 15, Aspirin on Day 16 - Day 28, Clopidogrel + Aspirin Day 29
3263206|NCT01503671|Experimental|Atorvastatin|Atorvastatin 40 mg/day for high inflammation CAPD patient
3263207|NCT01503671|No Intervention|No intervention arm|Placebo arm without intervention
3263208|NCT01503684||Patients with sepsis|Patients who are admitted to ICU with the diagnosis of sepsis
3263209|NCT01503723||Patients with acute lung injury|Patients who are admitted to ICU with the diagnosis of acute hypoxemic respiratory failure
3263210|NCT01503736|Placebo Comparator|Placebo|
3263211|NCT01503736|Experimental|4g/day|Ferric Citrate for a total daily dose of 4g
3263212|NCT01503736|Experimental|6g/day|Ferric Citrate for a total daily dose of 6g
3263213|NCT01503762|Experimental|Mirror Therapy Group|Mirror Therapy Group
3263214|NCT01503762|Sham Comparator|Control Group|Control Group receive classical rehabilitation techniques including splinting, tendon gliding, ...
3263215|NCT01503775||TRUFILL® DCS Orbit Galaxy|
3263216|NCT01503788|Active Comparator|periprocedural sedation with midazolam|periprocedural sedation with IV midazolam 5-10 minutes before diagnostic lumbar puncture
3263217|NCT01503788|No Intervention|No intervention|Participants will undergo the diagnostic lumbar puncture as routinely practiced
3263218|NCT01503801|Experimental|inhaled nitric oxide|The preterm infants in the experimental group inhaled nitric oxide
3263219|NCT01503801|Active Comparator|oxygen|The preterm infants enrolled but subjected to routine respiratory support.
3263220|NCT01503814|No Intervention|Control (Usual Care)|Control
3263221|NCT01503814|Experimental|Intervention|"Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a2+2model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable"
3263222|NCT01503827|Experimental|WBRT|Patients will receive WBRT after local treatment. A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
3263223|NCT01503827|No Intervention|Observation|No Intervention
3263224|NCT01503840|Active Comparator|Sugammadex|
3263225|NCT01503840|Placebo Comparator|Sodium chloride solution|
3263226|NCT01503866|Experimental|20 mg bardoxolone methyl|
3263227|NCT01503892|Placebo Comparator|Placebo|The control group will receive placebo pill twice daily for twelve months.
3263228|NCT01503892|Active Comparator|Metanx|Metanx group will receive one pill twice daily for twelve months.
3263229|NCT01503905|Active Comparator|Docetaxel plus epirubicin|
3263230|NCT01503905|Active Comparator|docetaxel plus epirubicin plus cyclophosphamide|
3263231|NCT01503918|Experimental|Valaciclovir/Aciclovir|
3263232|NCT01503918|Experimental|Valganciclovir/Ganciclovir|
3263233|NCT01503918|No Intervention|control|
3263234|NCT01503931||Alcohol-dependent patients|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no other psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
3263235|NCT01503931||Healthy control subjects|"men and women, aged 18 to 75~legally effective, written informed consent for participation within the study~right handedness~no psychiatric disorder according to ICD 10~no psychotropic substances within the last 7 days"
3263236|NCT01503944|Other|Dementia with Lewy Bodies|
3263237|NCT01503944|Other|Parkinson's disease|
3263238|NCT01503944|Other|Healthy Elderly Volunteers|
3263239|NCT01503944|Other|Alzheimer's Disease|
3263240|NCT01503957|Placebo Comparator|Saline solution|Nasal spray
3263241|NCT01503957|Experimental|Nasya|Thixotropic nasal spray suspension
3263242|NCT01503970|Experimental|Chondrocyte implantation|
3263243|NCT01503983|Experimental|Trastuzumab+Oxaliplatine+capecitabine|Patient takes Trastuzumab (initial dose 8 mg/kg and a maintenance dose 6 mg/kg) anda oxaliplatin (dose 130mg/m2) during the first day os cycle and them Capecitabine (dose 2000 mg/m2)during 14 days in cycle of 21 days.
3263244|NCT01503996||glaucoma|hospitalized glaucoma patients
3263245|NCT01503996||controls|hospitalized patients without glaucoma
3263246|NCT01504009|Experimental|Muscle strength|
3263247|NCT01504022|No Intervention|Control group.|Control group.
3263248|NCT01504022|Experimental|Telecare, self monitoring, lifestyle counseling|Patients in the intervention group will measure their blood pressure with home blood pressure monitor which is linked to a secured website. Patients will measure as recommended in the European guidelines of hypertension. This includes 2 measurements in the morning and two times in the evening on 7 consecutive days every month. The measurements of the first day will be discarded. These measurements will be forwarded to the web-based system, which will be managed by the nurse practitioner and the research doctor. At least every month patients are contacted about the state of their condition. If needed, antihypertensive medication is added of adjusted by the nurse practitioner or research doctor under the supervision of one consultant physician. Tailored lifestyle advices are given every month.
3263249|NCT01504035|Experimental|Hemostatic putty plus Lidocaine (Orthostat-L)|
3263250|NCT01504035|Active Comparator|Hemostatic putty (Orthostat)|
3263251|NCT01504048|Experimental|Chromoendoscopy|
3263252|NCT01504061|Experimental|Mederma Ultra Gel|
3263253|NCT01504061|Active Comparator|Mederma N&I|
3263254|NCT01504074||Patients suffering on CME secondary to cataract surgery|
3263255|NCT01504087||patinet with deep venous thrombosis|patient with deep venous thrombosis by ultrasonography as case; patient with no deep venous thrombosis by ultrasonography as control
3263256|NCT01504087||patient without deep venous thrombosis|
3263257|NCT01504100||femoral internal rotation|
3263258|NCT01504100||no femoral internal rotation|
3263259|NCT01504113||Study 1 goup|Patients who are planned to receive targeted agents
3263260|NCT01504113||Study 2 case group|Patients who have received targeted therapy
3263261|NCT01504113||study 2 control group|Psoriasis patients without target therapy
3263262|NCT01504126|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID beginning 48-72 hours before treatment. Patients undergoing surgery resume propranolol hydrochloride post-operatively once oral drugs are tolerated and continue until completion of 6 cycles of chemotherapy. Patients undergoing neoadjuvant chemotherapy continue propranolol hydrochloride PO BID during 3 chemotherapy cycles pre-surgery and 3 cycles post-surgery. Treatment repeats every 3 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3263263|NCT01504139|Experimental|hCG in the late follicular phase + luteal phase|
3263264|NCT01504139|Experimental|hCG in the follicular phase + luteal phase|
3263265|NCT01504139|Experimental|LH in the luteal phase|
3263266|NCT01504139|Active Comparator|vaginal progesterone and estradiol in the luteal phase|
3263267|NCT01504152||patients who received HSCT at MSKCC between 2005-2010|A self-administered patient questionnaire will be used to collect data that will assess the prevalence of international travel after HSCT and travel related morbidity and exposure risks among HSCT recipients.
3263268|NCT01504165|Experimental|Group 1|Healthy volunteers: matched subjects with normal renal function
3263269|NCT01504165|Experimental|Group 2|Mild renal impaired subjects
3263270|NCT01504165|Experimental|Group 3|Moderate renal impaired subjects
3263271|NCT01504165|Experimental|Group 4a|First group of Severe renal impaired subjects
3263272|NCT01504165|Experimental|Group 4b|Second group of severe renal impaired subjects
3263273|NCT01504178|Experimental|duloxetine|The first group (12 patients) will receive, after 28 days of duloxetine treatment, one duloxetine dose, an injection of apomorphine and a placebo of L-Dopa.
3263274|NCT01504178|Placebo Comparator|positive control (L-Dopa)|The second group (12 patients) will receive, after 28 days of placebo treatment, one placebo dose of duloxetine, an injection of apomorphine and injection of placebo of L-Dopa.
3263275|NCT01504178|Placebo Comparator|negative control|The third group will receive, after 28 days of placebo treatment, one placebo of duloxetine, an injection of placebo of apomorphine and a dose of L-Dopa.
3263276|NCT01504191|Experimental|Internet-based CBT|Randomized patients with symptoms of anxiety and/or depression after MI will participate in an Internet-based CBT-program.
3263277|NCT01504191|No Intervention|Treatment as usual (TAU)|"Control: After randomization patients with symptoms of anxiety and/or depression after MI will participate in the treatment as usual (TAU).~Reference: A reference group without depressive or anxiety symptoms will participate in the treatment as usual (TAU)."
3263278|NCT01504230||health older adults|
3263279|NCT01504230||Osteoporosis participants|
3263280|NCT01504243||Control|normal person under medical examination
3263281|NCT01504243||sepsis|SIRS plus inflammation
3263282|NCT01504256|Experimental|catumaxomab|"this arm was stopped. the antibody previously used as a study drug is not available at this time. patients will be randomized only into the standard arm~[Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10) and 7 days after the last catumaxomab infusion FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1))"
3263283|NCT01504256|Active Comparator|standard therapy|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
3263284|NCT01504282|Active Comparator|MMC group|One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.
3263285|NCT01504282|Placebo Comparator|BSS group|One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.
3263286|NCT01504295|Experimental|Metadoxine|Metadoxine 500mg tablet t.i.d.for 12 weeks
3263287|NCT01504295|Placebo Comparator|Sugar pill|Placebo group
3263288|NCT01504308|Experimental|MR-HIFU treatment|Patients receiving MR-HIFU treatment
3263289|NCT01504308|Sham Comparator|Sham Treatment|Patients receiving sham treatment
3263290|NCT01504321|Active Comparator|Active|
3263291|NCT01504321|Placebo Comparator|Placebo|
3263292|NCT01504334|Experimental|Pirfenidone(200mg)|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
3263293|NCT01504334|Placebo Comparator|Placebo (without active ingredient)|
3263294|NCT01504347|Experimental|Primary vaccination in seronegative subjects|
3263295|NCT01504347|Experimental|Booster vaccination in seronegative subjects|
3263296|NCT01504347|Experimental|Primary + booster vacc. (seronegative + seropositive subjects)|
3263297|NCT01504360|Experimental|sarcoma group|patient suffering form radiation-induced sarcoma
3263298|NCT01504360|Active Comparator|free from sarcoma group|patient without sarcoma 5 years after radiation therapy
3263299|NCT01504373|Other|NAVA-PSV|Subject will receive 4 hours of NAVA followed by 4 hours of PSV.
3263300|NCT01504373|Other|PSV-NAVA|Subject will receive 4 hours of PSV followed by 4 hours of NAVA.
3263301|NCT01504386|Experimental|TAP block|TAP block with ropivacaine
3263302|NCT01504386|Placebo Comparator|Placebo TAP block|Sham block with saline
3263303|NCT01504399||Microscopic:|Microscopic (single nostril, direct endonasal with nasal speculum)transsphenoidal nasal surgery
3263304|NCT01504399||Endoscopic|Fully endoscopic: (bi-nostril, no nasal speculum) transsphenoidal pituitary surgery
3263305|NCT01504438|Other|Salto Talaris Total Ankle Replacement|
3263306|NCT01504438|Other|STAR Total Ankle Replacement|
3263307|NCT01504451|Active Comparator|Biosense Webster ablation|Biosense Webster irrigated multi-electrode phased radiofrequency AF ablation
3263308|NCT01504451|Active Comparator|Surgical ablation|Minimally invasive thoracoscopic surgical AF ablation
3263309|NCT01504451|Active Comparator|Medtronic ablation|Medtronic multi-electrode phased radiofrequency AF ablation
3263310|NCT01504464|Experimental|mesenchymal stem cell|Patients with knee joint osteoarthritis who underwent intra articular mesenchymal stem cell injection.
3263311|NCT01504464|Experimental|placebo|The patients who are in control group and underwent placebo injection.
3263312|NCT01504490|Experimental|CS-7017 and Bexarotene|Combination of CS-7017 and Bexarotene
3263313|NCT01504503|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
3263314|NCT01504503|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
3263315|NCT01504516|Experimental|Donepezil Hydrochloride10 mg Tablets|Donepezil Hydrochloride 10 mg Tablets of Dr. Reddy's Laboratories Limited
3263316|NCT01504516|Active Comparator|Aricept 10 mg Tablets|Aricept 10 mgTablets of Pfizer Inc
3263317|NCT01504529||Neupro Treatment|Data from patients with advanced PD who have been treated with Rotigotine (Neupro®) for at least the previous 6 months as prescribed by physicians according to usual clinical practice in Spain, will be retrospectively collected.
3263318|NCT01504542|Experimental|Low-dose HS-110|2,000,000 cells/0.5mls + erlotinib 150mg orally once daily
3263319|NCT01504542|Experimental|High dose HS110|10,000,000 HS110 cells/0.5ml + erlotinib 150mg orally once daily.
3263320|NCT01504542|Placebo Comparator|Placebo vaccine + erlotinib 150mg orally once daily|Placebo vaccine buffered saline solution + erlotinib 150mg orally once daily
3263321|NCT01504555||Patients under investigation for hypercortisolism|Patients undergoing routine evaluation for hypercortisolism at Haukeland University Hospital, Bergen, Norway, will be asked to participate.
3263322|NCT01504568|Other|Prophylactic Antibotics|Amoxicillin/clavulanic acid
3263323|NCT01504568|No Intervention|Non Treatment|Subjects will be followed without the use of antibiotics.
3263324|NCT01504581|Experimental|HM10660A|
3263325|NCT01504581|Active Comparator|Pegasys|
3263326|NCT01504581|Placebo Comparator|HM10660A Placebo|
3263327|NCT01504594|Experimental|Patients|Children which meet eligibility criteria and after being assessed, are stimulated with G-CSF, undergo bone marrow extraction and then have them applied directly to the coronary arteries through cardiac catheterization.
3263328|NCT01504607||Congenital cataract surgery with IOL implantation|Congenital cataract surgery was performed with or without anterior vitrectomy, followed by in the bag IOL implantation
3263329|NCT01504620|Other|Sugar infusion|Diagnostic assessment of blood glucose by means of different devices
3263330|NCT01504620|Experimental|insulin infusion|infusion of insulin to achieve low glucose levels
3263331|NCT01504633|Experimental|DHA+EPA Group|DHA/EPA capsule (100mg DHA + 20mg) and placebo syrup per day
3263332|NCT01504633|Experimental|Fe Group|Placebo capsule and Fe syrup (16mg elemental iron) per day
3263333|NCT01504633|Experimental|DHA/EPA+Fe Group|DHA/EPA capsule (100mg DHA + 20mg) and Fe syrup (16mg elemental iron) per day
3263334|NCT01504633|Experimental|Placebo Group|Placebo capsule and placebo syrup
3263335|NCT01504646|Placebo Comparator|Olive Oil Capsule|Ten subjects will take eight placebo olive oil capsules per day for three weeks.
3263336|NCT01504646|Experimental|Lyprinol|Ten subjects will take eight Lyprinol capsules per day for three weeks.
3263337|NCT01504659|Active Comparator|Bipolar-Ketalar|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of intranasal ketalar
3263338|NCT01504659|Placebo Comparator|Bipolar-Placebo|Children with a diagnosis of BP-I, BP-II or BP-NOS will receive 4 administrations of placebo
3263339|NCT01504685|Active Comparator|Unbanded laparoscopic gastric bypass|Laparoscopic Roux- en-Y gastric bypass without any band around de gastric reservoir
3263340|NCT01504685|Active Comparator|Banded laparoscopic gastric bypass|Placement of a premeasured band or ring around the gastric reservoir, adjacent to the gastroenterostomy.
3263341|NCT01504698|Experimental|Treatment with manipulation|
3263342|NCT01504698|Active Comparator|Treatment without manipulation|
3263343|NCT01504724|Experimental|IVB group|Patients were treated with IVB injections approximately within 1 week before the first PRP. Then patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
3263344|NCT01504724|No Intervention|only PRP group|Patients had PRP, which was done in three sessions at weeks 0, 1, and 2 according to ETDRS guidelines. The superior, inferior, and nasal and temporal areas were treated sequentially.
3263345|NCT01504737|Experimental|Supervised Exercise Training|12 weeks of 40 min aerobic bicycle ergometer exercise 3 times per week.
3263346|NCT01504737|Active Comparator|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
3263347|NCT01504750|Experimental|lighting room|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals.
3263348|NCT01504750|No Intervention|control room|Normal lighted patient room
3263349|NCT01504763|Experimental|Massage|Chair massage for 15 minutes once a week for 10 weeks.
3263350|NCT01504776|Experimental|Open Label Drug Therapy|Single arm
3263351|NCT01504789|Experimental|Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
3263352|NCT01504789|Experimental|Non-Cultural Related Material Group|Patients will be randomized to receive either culturally adapted AI materials or non-culturally adapted SI materials. Intervention materials will be mailed to patients every 2 weeks. Based on the results of the fitness tests, a specific exercise program will be presented. The research staff will call about every 2 weeks to check that materials were received and have been sent back whatever materials are due. The phone call should take no more than 15 minutes. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. The questionnaire packet will be mailed with a postage-paid return envelope. It should take about 10 minutes to complete the questionnaires.
3263353|NCT01504789|Active Comparator|Waitlist Group|Patients may choose to participate in the exercise program after 16-week assessment. After 4 months of exercise, all the follow-up tests repeated. Exercise recommendation then given, and all of the intervention materials.
3263354|NCT01504802||Growth hormone deficient|Children with short stature, a peak growth hormone response on stimulation testing of less than 7 ng/ml, and no other identifiable cause of short stature
3263355|NCT01504802||Idiopathic short stature|Children with short stature, a peak growth hormone response on stimulation testing of greater than or equal to 7 ng/ml, and no identifiable cause for the short stature
3263356|NCT01504815|Active Comparator|Cisplatinum + conventional RT|Cisplatinum 100mg/m2 on days 1, 22 and 43, with conventional RT 70 Gy in 7 weeks
3263357|NCT01504815|Experimental|Cisplatinum + adaptive high dose RT|Cisplatinum, 100 mg/m2 on days 1, 22 and 43 with adaptive high dose RT to 84 Gy max on 50% uptake GTV in 7 weeks
3263358|NCT01504828|Experimental|Ramipril|Those who are 40 years and older receive an ACE inhibitor to determine if this reduces age-related changes in left ventricular energetics and function
3263359|NCT01504893|Experimental|protective|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure streets ≤ 25 cm H2O, I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 4 mL / kg, peak airway pressure ≤ 35 cmH2O, respiratory rate <30, I:E = 1:2 / 1:3.~During OLV in case of desaturation (before increasing the FiO2) and / or within 1 hour you perform recruitment maneuvers followed by the setting of a PEEP of 5 cmH2O"
3263360|NCT01504893|No Intervention|conventional|"Two-lung ventilation (TLV): tidal volume = 8 mL / kg, peak pressure ≤ 25 cmH2O airway; I: E = 1:2; after lung re-expansion to the closure of the chest will set a PEEP of 5 cmH2O~OLV (OLV): 8 mL / kg, peak airway pressure ≤ 35 cmH2O; I: E = 1:2."
3263361|NCT01504906|Experimental|A|cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor
3263362|NCT01504906|Experimental|B|single dose cyclosporine 600 mg
3263363|NCT01504906|Experimental|C|single dose 180 mg ticagrelor
3263364|NCT01504919|Experimental|Health Education (HE)|HE of brief counseling and self-help materials addressing 3 risk behaviors, referrals to available resources, and a home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed.
3263365|NCT01504919|Experimental|Motivation and Problem Solving (MAPS)|HE counseling, self-help materials, and resource referrals, and home-based exercise kit; 6-week supply of nicotine patches for smoking cessation if needed. Plus 9 proactive, telephone counseling sessions over the 18 month period.
3263366|NCT01504932|Experimental|Arm I: BRB Lozenge|"Former oral cancer patients receive lozenges containing freeze-dried black raspberry (BRB) powder. They will take the lozenges four times each day (QID) by mouth (PO) for up to 6 months.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Black Raspberry (BRB) Lozenge Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
3263367|NCT01504932|Other|Arm II: Biomarker Control|"Former oral cancer patients will not receive lozenges containing freeze-dried black raspberry (BRB) powder.~Patients will be asked to complete a baseline survey documenting any family history of cancer, tobacco, alcohol, and mouthwash use, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) Survey, and a Brief Fatigue Inventory (BFI) Survey.~They will receive a trial-specific logbook to record their usages.~Intervention: Survey Administration Intervention: Laboratory Biomarker Analysis"
3263368|NCT01504945|Active Comparator|RBC transfusion|
3263369|NCT01504945|Placebo Comparator|Normal saline infusion|
3263370|NCT01504984|Experimental|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
3263371|NCT01504984|Active Comparator|Glivec film coated tab 4T(400mg)|100mg/tablet, po, 4 tablets once daily for period I&II D1(crossover)
3263372|NCT01505023|Active Comparator|Partial meal replacement|
3263373|NCT01505023|Experimental|Partial meal replacement with inulin|
3263374|NCT01505023|Active Comparator|Inulin|
3263375|NCT01505023|No Intervention|No intervention|
3263376|NCT01505036|Experimental|SMARTCARE service|U-Health service
3263377|NCT01505036|No Intervention|Usual care|Usual care
3263378|NCT01505049||Previously received all three doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received their third dose of vaccine three or more years ago. Recruitment of this group was completed in Sept 2012.
3263379|NCT01505049||Previously received two doses of HPV vaccine|This group will consist of 78 women ages 18 to 30 who have received two doses of the HPV vaccine. The second dose must have been received six or more months ago.
3263380|NCT01505049||Unvaccinated Cohort|This group will consist of 45 women who have not received their HPV vaccination. Women ages 18-26 are eligible for this cohort. Recruitment for this group was completed in January 2013.
3263381|NCT01505075|Experimental|Hypofractionated radiation|40 Gy in 5 fractions over 29 to prostate; 30 Gy in 5 fractions over 29 days to seminal vesicles
3263382|NCT01505088|Experimental|Iontophoretic Dexamethasone Phosphate Ophthalmic Solution|Dexamethasone phosphate (40 mg/mL) solution delivered by iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying placebo eyedrops (saline solution) for up to 28 days.
3263383|NCT01505088|Active Comparator|Prednisolone Acetate Ophthalmic Suspension (1%)|Placebo (100 mM sodium citrate buffer solution) iontophoresis treatment consisting of 4.0 mA-min at 1.5 mA on Day 0 and Day 7 with accompanying prednisolone acetate ophthalmic suspension (1%) (positive control) eyedrops for up to 28 days.
3263384|NCT01505101|Experimental|Mindfulness-Oriented Recovery Enhancement|
3263385|NCT01505101|Active Comparator|Conventional Support Group (SG)|
3263386|NCT01505127|Experimental|TAK-438 20 mg BID|"TAK-438 20 mg, tablets, orally, twice daily for 1 week~Lansoprazole placebo-matching capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
3263387|NCT01505127|Experimental|Lansoprazole 30 mg BID|"TAK-438 placebo-matching tablets, orally, twice daily for 1 week~Lansoprazole 30 mg, capsules, orally, twice daily for 1 week~Amoxicillin 750 mg, capsules, orally, twice daily for 1 week~Clarithromycin 200 or 400 mg, tablets, orally, twice daily for 1 week"
3263388|NCT01505140|No Intervention|Usual Western style diet|Participants will consume their usual Western style diet avoiding tree nuts
3263389|NCT01505140|Experimental|Whole walnuts|Participants will consume usual Western style diet adding 75 gm whole walnuts per day
3263390|NCT01505153|Experimental|pbi-shRNA STMN1 LP|pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection.
3263391|NCT01505218|Active Comparator|Propofol sedation by nurse anaesthetist|Nurse anaesthetists managed infusion of propofol 10 mg/ml at doses of 0.2 - 0.8 ml/kg during ERCP. The target of moderate sedation was achieved within 5 minutes from start of the sedation.
3263392|NCT01505218|Active Comparator|Patient-controlled propofol sedation|"Self-administration of propofol via patient-controlled sedation pump (CME...). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
3263393|NCT01505218|No Intervention|Midazolam sedation by the ERCP-team|Midazolam doses for sedation during ERCP. Initial dose of 2-3 mg and after ERCP start, 1-2 mg as additional doses. Maximum total dose 6-8 mg. ERCP performing doctor is responsible for dose ordination.
3263394|NCT01505231|Active Comparator|Norepinephrine group|Blinded norepinephrine
3263395|NCT01505231|Active Comparator|Vasopressin Group|Blinded vasopressin
3263396|NCT01505244|Experimental|Physical Activity|Before-school moderate to vigorous physical activity 3 days/week
3263397|NCT01505257|Experimental|END-DSD Intervention|
3263398|NCT01505257|No Intervention|Control|
3263399|NCT01505270||Autistic Children|
3263400|NCT01505283|Placebo Comparator|Group Saline|Epidural administration of saline
3263401|NCT01505283|Experimental|Group Sufentanil|Epidural administration of sufentanil
3263402|NCT01505283|Experimental|Group Lidocaine|Epidural administration of lidocaine
3263403|NCT01505296|Active Comparator|Antiarrhythmic drug|Class I or III antiarrhythmic drug
3263404|NCT01505296|Experimental|Catheter ablation|Pulmonary vein isolation
3263405|NCT01505309|Experimental|Stent Graft|TEVAR procedure using devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
3263406|NCT01505322||Thoracic surgery|Lung cancer patients
3263407|NCT01505335||Implant osteotomy measurements|Drilled implant locations
3263408|NCT01505348|Experimental|Fasting|Overnight fast
3263409|NCT01505348|No Intervention|Feeding|Normal breakfast
3263410|NCT01505361|Experimental|Probiotic|Pregnant women at 30 week of pregnancy(n=50) receiving Lactobacillus salivarius PS2(9 log per day, until birth)
3263411|NCT01505361|Placebo Comparator|Placebo|Pregnant women at 30 week of pregnancy(n=50) receiving the excipient (once a day, until birth)
3263412|NCT01505400||Advanced cancer|Advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas; as well as patients who are phase I trial candidates
3263413|NCT01505413|Experimental|Tarceva, Gemcitabine, Oxaliplatin|"Erlotinib 100 mg po qd daily AND~Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1~Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2 Every 2 weeks~Each two weeks is a cycle. If at end of 12 cycles response continues, will administer Gemcitabine and erlotinib until progression."
3263414|NCT01505426|Experimental|ASP1941 group|ASP1941 + metformin
3263415|NCT01505426|Placebo Comparator|placebo group|placebo + metformin
3263416|NCT01505439|Experimental|Solifenacin group|Once daily
3263417|NCT01505478||Patients admitted with infection|All consecutive ED patients during the study period that have been admitted and identified to have a suspected infection at ED disposition using a data collection tool
3263418|NCT01505517||individuals with low back pain|
3263419|NCT01505517||healthy controls|
3263420|NCT01505543||chronic obstructive pulmonary disease|
3263421|NCT01505543||healthy matched controls|
3263422|NCT01505556||Diaphragm paresis|
3263423|NCT01505556||Healthy controls|
3263424|NCT01505569|Other|Arm A: Patients with High Risk or Relapsed Solid Tumor|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, busulfan (1.1 mg/kg IV every 6 hours on days -8 through -6), melphalan (50 mg/mg^2 on days -5 and -4), thiotepa conditioning (250 mg/m^2 IV over 2 hours on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0) and, if appropriate, disease specific radiation therapy at day +60.
3376337|NCT05160753|Experimental|gastric function preserving surgery combined with resection of the anterior lymphatic drainage area.|"Steps of sentinel lymph node dissection Indocyanine green (ICG) tracing of anterior lymph nodes. ICG injection: A 4mL volume of double tracer is injected into the submucosa of the four quadrants of the primary tumor by intraoperative gastroscopic method. 0.5 mL was injected at each site, and 15 minutes after gastroscopic tracer injection, the green anterior lymph nodes were carefully dissected and removed from the surgical area and evaluated for lymph node metastasis by parallel intraoperative freezing.~Intraoperative and postoperative pathological examination Intraoperative histological examination of lymph nodes collected from the anterior lymph node pool was performed, If all collected anterior lymph nodes are negative, laparoscopic gastric function preserving surgery will be performed. After surgery, anterior lymph nodes that proved to be tumor-free on intraoperative frozen section examination were reevaluated."
3376338|NCT05160753|Active Comparator|Patients in the control group will undergo standard laparoscopic gastrectomy|Patients in the control group will undergo standard laparoscopic gastrectomy (laparoscopic distal gastrectomy with simultaneous D1+ lymph node dissection).
3376339|NCT05160740|Experimental|ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will be used in local hepatectomy of primary liver cancer in this group
3376340|NCT05160740|Placebo Comparator|No ICG molecular fluorescence imaging guided surgery|ICG molecular fluorescence imaging will not be used in local hepatectomy of primary liver cancer in this group
3376342|NCT05160714|Experimental|Adaptive SBRT Boost|Dose-escalated SBRT boost to an ADC-based high risk subvolume in HNC
3376343|NCT05160701|No Intervention|Usual Care|Usual Care: no intervention elements.
3376344|NCT05160701|Active Comparator|Existing Medherent|Group using the Medherent Device with no added intervention components.
3376345|NCT05160701|Experimental|New Medherent|Group using Medherent Device with added interventional components.
3376346|NCT05160688|Experimental|Contingency management|Contingency management (CM) is an incentive-based intervention providing patients with tangible rewards as reinforcement for positive behaviors like abstinence from drug use. Incentives are provided with each urine sample that is drug-free and are increased with each subsequent drug-free urine sample. Participants in the CM condition will receive increasing payments for abstinence: $30 on day 3, $45 on day 5, $60 on day 7, $75 on day 14, $90 on day 21, $105 on day 28, and $120 on day 42. Participants in both conditions also receive increasing payment for visit attendance: $10 on day 1, $15 on day 3, $20 on day 5, $25 on day 7, $30 on day 14, $35 on day 21, $45 on day 28, and $55 on day 42. At the end of the baseline visit, those in the CM condition will sign a behavioral contract with study staff that clearly outlines expectations as well as the payment schedule.
3376347|NCT05160688|No Intervention|No intervention|Participants in this condition will be monitored and will not receive any compensation for cannabis abstinence.
3376348|NCT05160675||Group 1|Group 1: 690 healthy infants and their mother followed from birth to 12 months
3376349|NCT05160675||Group 2|Group 2: 690 healthy infants and their mother followed from 6 months to 3 years of age
3376350|NCT05160662|No Intervention|Women with BMI>=35 (2019-2020)|Pregnant women with BMI>=35 delivered at the hospital 2019-2020
3376351|NCT05160662|Experimental|Women with BMI>=35 (2021-2023)|Pregnant women with BMI>=35 delivered at the hospital 2021-2023
3376352|NCT05160636||Study cohort positive for COVID 19|Cohort will be those that are COVID19 positive by RTPCR from a SOC nasopharyngeal swab.
3376353|NCT05160623|Experimental|Study eyes|Once-daily eyelid hygiene with povidone-iodine 1%
3376354|NCT05160623|Active Comparator|Control eyes|Once-daily eyelid hygiene with available lid wipes
3376355|NCT05160610|Experimental|Intervention group|receiving multilevel intervention, electronic monitoring and stroke registry participation
3376356|NCT05160610|No Intervention|Control group|receiving routine care , electronic monitoring and stroke registry participation
3376357|NCT05160597|Experimental|Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)|"SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.~IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS."
3376359|NCT05160571||Subjects with Ion Endoluminal sampling of pulmonary nodule|Subjects in which a pulmonary lesion biopsy was attempted or performed with the Ion Endoluminal System
3376360|NCT05160558|Experimental|BIIB132: Dose 1|Participants will receive BIIB132, Dose 1, intrathecally (IT), every 4 weeks (Q4W), up to Day 85.
3376361|NCT05160558|Experimental|BIIB132: Dose 2|Participants will receive BIIB132, Dose 2, IT, Q4W, up to Day 85.
3376362|NCT05160558|Experimental|BIIB132: Dose 3|Participants will receive BIIB132, Dose 3, IT, Q4W, up to Day 85.
3376363|NCT05160558|Experimental|BIIB132: Dose 4|Participants will receive BIIB132, Dose 4, IT, Q4W, up to Day 85.
3376364|NCT05160558|Experimental|BIIB132: Dose 5|Participants will receive BIIB132, Dose 5, IT, either Q4W or every 12 weeks (Q12W), up to Day 85 or every 8 weeks (Q8W) up to Day 57.
3263425|NCT01505569|Other|Arm B: Certain CNS Tumors|Treatment consists of a mobilization chemotherapy (ifosfamide 1.8 g/m^2/day intravenously [IV], etoposide 100 mg/mg^2 IV, mesna 1.8 g/m^2 divided in every 6 hours dosing, and granulocyte colony stimulating factor 10 mcg/kg subcutaneously or IV until absolute neutrophils > 1,000/mm^2) for 5 days in a 30-100 day pretransplant window, carboplatin (dose based on GFR and age 17 mg/kg/day IV or 510 mg/m^2/day IV) , thiotepa conditioning (10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2) followed by an autologous peripheral blood stem cell transplant (infusion on Day 0). This will be repeated up to 2 additional 30 day cycles.
3263426|NCT01505569|Other|Arm C: Germ Cell Tumors|"High-Dose Chemotherapy (3 cycles)~Carboplatin AUC=8 & Etoposide 400 mg/m^2 daily, days -4, -3, and -2 every 21 days~Autologous Stem Cell Infusion ≥ 3 x 106 CD34+ cells/kg Day 0 Cycles 1, 2 and 3~TI Chemotherapy & PBSC Collection.~Paclitaxel 200mg/m^2 IV over 3 hours on Day 1 every 14 days for 2 cycles~Ifosfamide 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles~Mesna 2000 mg/m^2 on Days 1-3 every 14 days for 2 cycles~G-CSF 10 μg/kg sub q daily on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first~Leukapheresis starting on approx. day 11 and continued daily until reaching the collection goal of ≥ 8 x 106 CD34+ cells/kg) or day 15, whichever occurs first"
3263427|NCT01505569|Other|Arm D: Certain CNS Tumors|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (3 cycles)~Day -8, -7, -6: Carboplatin as calculated from AUC of 7 approx.~Day -5, -4, -3: Thiotepa 10 mg/kg, Etoposide 8.3 mg/kg~Day 0: Autologous Hematopoietic Cell Reinfusion~Day +1: Begin G-CSF(filgrastim) 5 mcg/kg"
3263428|NCT01505569|Other|Arm E: Neuroblastoma|"Mobilization Chemotherapy and PBSC Collection (day -100 to day -30)~Pre-Transplant Conditioning Chemotherapy (day -7 to day -0)~Day -7: anti-seizure prophylaxis with lorazepam or levetiracetam~Day -6 - -3: Busulfan IV q24 hours x 4 doses~Day -1: Melphalan 140 mg/m2 IV~Day 0: Autologous Hematopoietic Cell Reinfusion"
3263429|NCT01505582|Experimental|Inspiratory muscle training|
3263430|NCT01505582|Sham Comparator|Sham inspiratory muscle training|
3263431|NCT01505595|Experimental|Proprioceptive training|
3263432|NCT01505595|Sham Comparator|Sham proprioceptive training|
3263433|NCT01505621||Young|Healthy adults 18-30 years old
3263434|NCT01505621||Elderly|Healthy adults greater than 65 years old
3263435|NCT01505660|No Intervention|Usual Care|Patients not randomized to the intervention will receive usual care which includes a patient reported outcomes assessment every 6 months as part of routine clinical procedures and patient-initiated interactions with case managers.
3263436|NCT01505660|Experimental|Care management|The intervention will include frequent healthcare delivery team notification of PROs including medication adherence and adherence barriers such as depression symptoms along with tailored intervention recommendations and targeted care management using a stepped care approach.
3263437|NCT01505686|Experimental|study group|All patients in this study have MRI scan prior to hernia repair surgery. If inflammatory changes are present, the scan is repeated 6 months after surgery. If not, the scan is performed only if the patient has pain problems at 6 months.
3263438|NCT01505738||bacterial cultures|Bacterial samples are collected preoperatively from urine, nose and possible lower limb ischaemic wounds, perioperatively from inguinal area and wound edges, and twice postoperatively. In addition, in case of a wound infection, bacterial samples are taken for diagnosis as usual.
3263439|NCT01505751||cervical cancer|
3263440|NCT01505777|Experimental|Probiotics(Medirac) 10/mosapride 10mg|
3263441|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 10mg|
3263442|NCT01505777|Experimental|Probiotics(Medirac) 15/mosapride 15mg|
3263443|NCT01505777|Experimental|Probiotics(Medirac) 30/mosapride 15mg|
3263444|NCT01505777|Placebo Comparator|Probiotics(Medirac) placebo/mosapride placebo|
3263445|NCT01505790|Experimental|CLOPIDOGREL GROUP|
3263446|NCT01505790|Active Comparator|PRASUGREL GROUP|
3263447|NCT01505803|Active Comparator|Zinc supplement|
3263448|NCT01505803|Active Comparator|Omega 3 supplement|
3263449|NCT01505803|Active Comparator|Zinc and omega 3 supplements|
3263450|NCT01505803|Placebo Comparator|Placebo supplement|
3263451|NCT01505816|No Intervention|Toric|Multifocal Toric IOL implantation
3263452|NCT01505829||Biological validation cohort 1|
3263453|NCT01505829||Response assessment cohort 2|
3263454|NCT01505842|Experimental|Colonoscopy with chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
3263455|NCT01505842|Active Comparator|Conventional colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
3263456|NCT01505855|Experimental|anti-TNF only|Crohn's disease, on an anti-TNF agent [infliximab or adalimumab] only
3263457|NCT01505855|Experimental|Combined immunosuppression|Crohn's disease, on combined immunosuppression (both anti-TNF agent and immunomodulator [azathioprine or 6-MP])
3263458|NCT01505855|Experimental|Immunomodulator only|Crohn's disease, on an immunomodulator only
3263459|NCT01505855|Experimental|Non-immunosuppression|Crohn's disease, not on immunosuppressive medications (5-ASA only: control arm)
3263460|NCT01505894|Experimental|BI 409306 low dose|Film-coated tablet
3263461|NCT01505894|Experimental|BI 409306 medium dose|Film-coated tablet
3263462|NCT01505894|Experimental|BI 409306 high dose|Film-coated tablet
3263463|NCT01505894|Experimental|BI 409306 high dose II|Film-coated tablet
3263464|NCT01505894|Placebo Comparator|Placebo|Film-coated tablet
3263465|NCT01505907|Experimental|CXB909 15mg|CXB909 15mg
3263466|NCT01505907|Experimental|CXB909 30mg|
3263467|NCT01505907|Experimental|CXB909 60mg|
3263468|NCT01505907|Experimental|CXB909 120mg|Dose
3263469|NCT01505907|Experimental|CXB909 250mg|
3263470|NCT01505920|Experimental|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
3263471|NCT01505920|Active Comparator|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally to the four quadrant of the cervix, 3 minutes before starting cervical excision
3263472|NCT01505946||LOW RESPONDERS|Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre >0.6 and < 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre >0.6 and < 5 BU/ml and no increase in the INH titer > 5 BU over treatment with FVIII)
3263473|NCT01505946||HIGH RESPONDERS|Patients who documented high response after FVIII exposure (FVIII inhibitors titre > 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI
3263474|NCT01505959|Experimental|Conventional|
3263475|NCT01505959|Active Comparator|Telemedicine|
3263476|NCT01505972|Experimental|Six and three time schedule|
3263477|NCT01505972|Experimental|Four and two time schedule|
3263478|NCT01505985|Experimental|Specialized Oral Nutritional Supplement|
3263479|NCT01505985|Placebo Comparator|Placebo|
3263480|NCT01505998|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
3263481|NCT01505998|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
3263482|NCT01506011|Experimental|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Dr. Reddy's Laboratories Ltd.
3263483|NCT01506011|Active Comparator|Lotrel|Lotrel® Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules of Novartis Pharmaceuticals
3263484|NCT01506024|Active Comparator|THA Direct lateral|Total hip arthroplasty (THA) carried out by direct lateral approach (DLA)
3263485|NCT01506024|Experimental|THA Posterior|Total hip arthroplasty (THA) carried out by posterior approach (DLA)
3263486|NCT01506024|Experimental|THA Anterior|Total hip arthroplasty (THA) carried out by anterior approach (DLA)
3263487|NCT01506037|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
3263488|NCT01506037|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
3263489|NCT01506050|Experimental|Desloratadine OD tablets 5 mg|Desloratadine OD tablets 5 mg of Dr. Reddy's Laboratories Limited
3263490|NCT01506050|Active Comparator|Clarinex|Clarinex 5 mg of Schering Corporation Inc USA
3263491|NCT01506063|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
3263492|NCT01506063|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
3263493|NCT01506076|Experimental|Levocetirizine DiHCl Tablets, 5 mg|Levocetirizine DiHCl Tablets, 5 mg of Dr. Reddy's Laboratories Ltd.
3263494|NCT01506076|Active Comparator|XYZAL|XYZAL Tablets 5 mg of UCB Farchim S.A.
3263495|NCT01506089|Experimental|36 degree group|36 degrees Celsius for the incubators is the experimental condition in this study.
3263496|NCT01506089|No Intervention|37 degree group|37 degrees Celsius is the standard incubator temperature for the culture of embryos.
3263497|NCT01506115|Experimental|HCC with bile duct invasion|Photodynamic therapy with biliary drainage in patients with bile duct invasion of unresectable HCC
3263498|NCT01506128||HPV|Premenopausal women with HSIL in Pap test or high-risk HPV
3263499|NCT01506141|Experimental|Idursulfase-IT|Idursulfase-IT will be administered once monthly and weekly IV infusions of Elaprase at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
3263500|NCT01506154|Placebo Comparator|Placebo|Therapy with placebo
3263501|NCT01506154|Experimental|MRX-7EAT|Therapy with experimental drug
3263502|NCT01506167||Bevacizumab and Capecitabine/Oxaliplatin|Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
3263503|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
3263504|NCT01506167||Bevacizumab and Capecitabine|Participants who receive bevacizumab in combination with capecitabine
3263505|NCT01506167||Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan|Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
3263506|NCT01506167||Bevacizumab and Capecitabine/Irinotecan|Participants who receive bevacizumab in combination with capecitabine/irinotecan
3263507|NCT01506167||Bevacizumab and Fluorouracil +/- Folinic Acid|Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
3263508|NCT01506167||Other|Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
3263509|NCT01506180||Patients admitted to Geriatric Department|The patients receive comprehensive geriatric assessment
3263510|NCT01506180||Patients admitted to general medical departments|This group do not receive comprehensive geriatric assessment
3263511|NCT01506206||Patients with Deep Brain Stimulators|Patients with deep brain stimulation for either major depressive disorder (MDD) or obsessive compulsive disorder (OCD).
3263512|NCT01506206||Patients with MDD or OCD|Patients with MDD or OCD who do not have a deep brain stimulator.
3263513|NCT01506219|Experimental|Geriatrician-performed CGC|Geriatrician-performed CGC in addition to the usual care at Community Rehabilitation Unit.
3263514|NCT01506219|No Intervention|Usual care|Usual services at Community Rehabilitation Unit.
3263515|NCT01506232||ADHD|Youth diagnosed with ADHD.
3263516|NCT01506232||ASD|Youth diagnosed with an Autism Spectrum Disorder (ASD).
3263517|NCT01506232||BPD|Youth diagnosed with Bipolar Disorder.
3263518|NCT01506232||Healthy Controls|Youth not diagnosed with any psychiatric/psychological disorder.
3263519|NCT01506245|No Intervention|Control|
3263520|NCT01506245|Experimental|Family-based behavioral therapy|Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
3263521|NCT01506258|No Intervention|Patients not infused with stem cells|Historic Controls
3263522|NCT01506258|Experimental|Patients infused with stem cells|
3263523|NCT01506284||Anesthetized patients ASA I-II|ASA classification I-II, scheduled for elective surgery requiring general anesthesia.
3263524|NCT01506310|No Intervention|Diet alone|
3263525|NCT01506310|Experimental|Behavioral therapy|
3263526|NCT01506310|Experimental|Exercise|
3263527|NCT01506310|Experimental|Behavioral therapy and exercise|
3263528|NCT01506336|Experimental|masitinib|masitinib 12 mg/kg/day
3263529|NCT01506336|Active Comparator|sunitinib|sunitinib 50 mg/day
3263530|NCT01506349|Experimental|Crossover Group 1|"Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3."
3263531|NCT01506349|Experimental|Crossover Group 2|"Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3."
3263532|NCT01506375|Experimental|gpASIT|grass pollen peptides alone
3376365|NCT05160558|Placebo Comparator|BIIB132-Matching Placebo: Doses 1 to 5|Participants will receive BIIB132-matching placebo of Doses 1 to 4, IT, Q4W, up to Day 85 and BIIB132-matching placebo of Dose 5, IT, either Q4W or Q12W, up to Day 85 or Q8W, up to Day 57.
3376366|NCT05160545|Experimental|GNC-035|Patients receive GNC-035 intravenous infusion (IV, QW) for 2 weeks (a 2-week cycle). Participants with no intolerable AEs could continue for another three cycles
3376367|NCT05160532|Placebo Comparator|Four injections of placebo|Subjects will receive four placebo intraarticular knee injections under ultrasound guidance. A placebo looks exactly like the study drug, but it contains no active ingredient.
3263533|NCT01506375|Experimental|gpASIT/adjuvant|grass pollen peptides + adjuvant
3263534|NCT01506388|Experimental|folye catheter plus vaginal IMN|intracervical foley catheter plus vaginal IMN
3376368|NCT05160532|Experimental|One injection of DPT and three injections of placebo|Subjects will receive one intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by three intraarticular knee injections of placebo under ultrasound guidance.
3376369|NCT05160532|Experimental|Two injections of DPT and two injections of placebo|Subjects will receive two intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT), followed by two intraarticular knee injections of placebo under ultrasound guidance.
3376370|NCT05160532|Experimental|Four injections of DPT|Subjects will receive four intraarticular knee injection under ultrasound guidance of dextrose prolotherapy (DPT).
3263535|NCT01506388|Active Comparator|Misoprostol vaginally|intravaginal misoprostol
3263536|NCT01506401|Active Comparator|Conventional Ventilation|Low tidal volumes, relatively high PEEP.
3263537|NCT01506401|Experimental|High Frequency Oscillation|Open-lung strategy for high frequency oscillation.
3376371|NCT05160519|Experimental|Experimental|43 participants will be irradiated with Class IV laser therapy over the left parasternal area to improve ejection fraction, cardio biomarkers.
3376372|NCT05160519|Sham Comparator|Sham Controlled|43 participants will subject to irradiation but the equipment will be kept off.
3376373|NCT05160506|Experimental|Hydrocortisone|Patients in this arm will be administered 100 mg of hydrocortisone in 50 milliliters of saline solution by nursing staff every 8 hours for 72 hours as per standard clinical procedures (9 administrations)
3376374|NCT05160506|Placebo Comparator|Placebo|Patients in this arm will be given matching placebo (50ml 0.9%NACL) by nursing staff every 8 hours for 72 hours (9 administrations)
3376375|NCT05160493|Experimental|S-ketamine and pregabalin|"Drug: S-ketamine and pregabalin~Drug: Pregabalin 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~Drug: S-ketamine infusion 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h"
3376376|NCT05160493|Placebo Comparator|Normal saline and placebo capsule|"Drug: Normal saline and placebo capsule~Drug: Placebo capsules :Two placebo capsules(2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days~Drug: Normal saline• 0.9% saline bolus after induction of anesthesia +intravenous infusion for 48 hours"
3376377|NCT05160480|Experimental|Total-body PET scan|All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.
3376378|NCT05160467||Deresuscitation cohort|"Patients with fluid overload (defined by a cumulative fluid balance > 5%), stable hemodynamic (defined by Norepinephrine equivalent < 0.5µg/kg/min and nor clinical nor biological sign of hypoperfusion) and continuous renal replacement therapy. All these patients benefit in our service from a protocol directed, perfusion based deresuscitation strategy with a 2mL/kg/h net ultra filtration to induce negative fluid balance and correct fluid overload. If hypoperfusion occurs, the net ultra filtration is stopped; if pulmonary oedema or right ventricular dysfunction occurs, the net ultra filtration is set to 3mL/kg/h.~We carried out at day 0, 1,3 and 5 bio electrical impedance analysis with an eight polar multifrequency bio impedance monitor (InBody S10), and monitor cumulative fluid balance with our prescription software and daily weight assessment."
3263538|NCT01506414|Experimental|combination treatment|
3263539|NCT01506427|Experimental|[F-18] HX4|
3263540|NCT01506440||Supportive Care (cognitive assessment)|Patients complete cognitive assessments, comprising HVLT-R, TMT-A, TMT-B, DSC, Animals, MoCA, and DST. Patients also complete the Beck Depression Inventory. Assessments are administered on day 1 of chemotherapy and at 6-8 weeks and 12-16 weeks after day 1 of chemotherapy.
3263541|NCT01506466|Other|additional examinations/measurements|
3263542|NCT01506492|No Intervention|Usual Care|Usual care includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed.
3263543|NCT01506492|Experimental|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
3263544|NCT01506505|Experimental|Polypill in the morning|Cardiovascular agents in a polypill used from 05.00-11.00 in the morning (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
3263545|NCT01506505|Experimental|Polypill in the evening|Cardiovascular agents in a polypill used from 18.00-00.00 in the evening (acetylsalicylic acid 75 mg, simvastatin 40 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg)
3263546|NCT01506505|Active Comparator|Individual agents of the polypill)|"Cardiovascular agents in as acetylsalicylic acid 75 mg, lisinopril 10 mg, hydrochlorothiazide 12,5 mg used 05.00-11.00 in the morning.~Simvastatin 40 mg used 18.00-00.00 in the evening."
3263547|NCT01506518||Duchenne muscular dystrophy and age 5-6 years|Boys diagnosed with Duchenne muscular dystrophy and age 5-6 years at enrollment.
3263548|NCT01506518||Duchenne muscular dystrophy and age 7-8 years|Boys diagnosed with Duchenne muscular dystrophy and age 7-8 years at enrollment.
3263549|NCT01506518||Duchenne muscular dystrophy and age 9-10 years|Boys diagnosed with Duchenne muscular dystrophy and age 9-10 years at enrollment.
3263550|NCT01506518||No known neuromuscular disorders and age 5-14 years|Volunteer boys ages 5-14 years with no known neuromuscular disorders to serve as controls.
3263551|NCT01506531|Active Comparator|primary closure of gastroschisis|Attempt primary skin closure of gastroschisis shortly after birth
3263552|NCT01506531|Active Comparator|silo for gastroschisis|Surgical placement of silo over gastroschisis shortly after birth
3263553|NCT01506544|Experimental|Arm 1 Pharmacokinetic study|This will be a single dose study where participants will receive 20mg/kg or the participant's usual dose as a liquid containing hydroxyurea 100mg/mL. For a subset of participants (n= at least 6), a multiple-dose, steady state (i.e. at least 4 consecutive days of dosing) study will be performed.
3263554|NCT01506544|Active Comparator|Arm 2: Relative bioavailability study|This will be a single dose study. Participants will receive each of the two following treatments of HU in a randomized, crossover fashion: Either approximately 20 mg/kg/day (rounded to the nearest 200mg and no greater than 30 mg/kg) or the participant's usual daily dose as: 1) a liquid containing 100 mg/mL of hydroxyurea, or 2) Droxia® 200 mg capsules administered orally.
3263555|NCT01506557|Experimental|choecalciferol|
3263556|NCT01506557|Placebo Comparator|placebo|
3263557|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV003|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV003 in their upper arm at Day 0 and Day 180.
3263558|NCT01506570|Experimental|TetraVax-DV Vaccine - Admixture TV005|Participants will receive one SC injection of the TetraVax-DV Vaccine - Admixture TV005 in their upper arm at Day 0 and Day 180.
3263559|NCT01506570|Placebo Comparator|Placebo|Participants will receive one SC injection of placebo in their upper arm at Day 0 and Day 180.
3263560|NCT01506583||General population|This group of participants is primarily an out-patient population.
3263561|NCT01506583||In-patient population|This group of participants is primarily an in-patient population.
3263562|NCT01506583||Pediatric Group|Participants in this group are children 18 years or younger.
3263563|NCT01506622|Active Comparator|Propofol group|intravenous administration of propofol 1 mg/kg at the end of anesthesia
3263564|NCT01506622|Active Comparator|Fentanyl group|intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia
3263565|NCT01506622|Active Comparator|Control group|intravenous administration of saline at the end of anesthesia
3263566|NCT01506635|Placebo Comparator|Control group|included patients who received artificial tear twice a day as control group.
3263567|NCT01506635|Experimental|Timolol group|included the patients with myopic regression who received timolol 0.5% eye drop twice a day
3263568|NCT01506661|Experimental|Rheumatoid Arthritis|10 subjects with mild rheumatoid arthritis aged 50 years and older will be enrolled and will receive a single dose of Zostavax vaccine.
3263569|NCT01506661|Active Comparator|Healthy Subjects|10 healthy subjects aged 50 years or older who have not been previously immunized, will receive a single injection of Zostavax.
3263571|NCT01506687|Experimental|Navigator intervention|
3263572|NCT01506687|Active Comparator|Usual Care Control|Usual care
3263573|NCT01506713|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
3263574|NCT01506713|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
3263575|NCT01506739|Active Comparator|1|
3263576|NCT01506739|Active Comparator|2|
3263577|NCT01506739|Active Comparator|3|
3263578|NCT01506752|Active Comparator|E2020 improved 10 mg without water|
3263579|NCT01506752|Active Comparator|E2020 current 10 mg without water|
3263580|NCT01506752|Active Comparator|E2020 improved 10 mg with water|
3263581|NCT01506752|Active Comparator|E2020 current 10 mg with water|
3263582|NCT01506765|Active Comparator|patients who receive NAC first|this group will receive 2g/day of NAC (2 caps of 0.5g twice day)for a duration of 8 weeks first, and after this 8 weeks their receive placebo for 8 weeks.
3263583|NCT01506765|Placebo Comparator|patients who receive placebo first|this patients will receive first placebo for a duration of 8 weeks, and after this 8 weeks their receive NAC for 8 weeks
3263584|NCT01506778|Active Comparator|Group 1(With Tenaculum)|This group consisted of the patients whose had been applied tenaculum at cervix during the endometrial sampling procedure
3263585|NCT01506778|No Intervention|Group 2 (Without Tenaculum)|This group consisted of the patients whose had been not applied tenaculum during the endometrial sampling procedure.
3263586|NCT01506791|Experimental|Desloratadine and pseudoephedrine ER tablets 5/240 mg|Desloratadine and pseudoephedrine ER tablets 5/240 mg of Dr. Reddy's Laboratories Limited
3263587|NCT01506791|Active Comparator|Clarinex D 24-hour|Clarinex D-24 of Schering Corporation Inc USA
3263588|NCT01506804|Experimental|Training of painful shoulder|Steroid injection X 2 and 10 weeks exercise program of painful shoulder
3263589|NCT01506804|Placebo Comparator|Contralateral training|Steroid injection X 2 and 10 weeks exercise program of asymptomatic shoulder
3263590|NCT01506817||Fibromyalgia|patients with fibromyalgia fulfilling the 1990-ACR research criteria and with pain in the hands as a prominent clinical feature
3263591|NCT01506817||Controls|healthy aged matched pain-free controls
3263592|NCT01506830|Active Comparator|Absolute isolation|Absolute isolation of the operatory field with rubber dam: Moisture control is provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
3263593|NCT01506830|Experimental|Relative isolation|Relative isolation of the operatory field with cotton rolls: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
3263594|NCT01506843|Active Comparator|mite allergen drop|Children with allergic rhinitis sensitized with dust mites will receive progressive doses of allergen drops comparing those receiving placebo.
3263595|NCT01506843|Active Comparator|mite plus bacterial extracts|Vaccine constituted with mite and bacterial extracts will be compared to placebo.
3263596|NCT01506843|Placebo Comparator|Placebo|Placebo will be constituted by the same solution used to make dilution of the allergen extracts.
3263597|NCT01506856|Active Comparator|Standard treatment: dd-TCiv therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IV infusion once every 3 weeks
3263598|NCT01506856|Experimental|Study treatment: dd-TCip therapy|Paclitaxel administered by IV infusion weekly plus concurrent carboplatin administered by IP injection once every 3 weeks
3263599|NCT01506869||Type 2 diabetes|
3263600|NCT01506869||Prediabetes|
3263601|NCT01506869||Normal glucose regulation|
3263602|NCT01506895|Experimental|darapladib|darapladib dosed at 160 mg once daily
3263603|NCT01506895|Placebo Comparator|placebo|Placebo to match once daily
3263604|NCT01506921|Active Comparator|Racemic ketamine|
3263605|NCT01506921|Active Comparator|S-ketamine|All subjects receive both study drugs in a cross- over design. Equipotent doses are used. 0,6 mg/kg racemic ketamine equals 0,3 mg/kg s-ketamine
3263606|NCT01506934|Experimental|linifanib|Single Doses
3263607|NCT01506973|Experimental|Gemcitabine/Abraxane/Hydroxychloroquine|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15 Hydroxychloroquine: 1200 mg/day PO daily (600mg BID) Daily from D1
3263608|NCT01506973|Experimental|Gemcitabine/Abraxane|Abraxane: 125mg/m2 IV infusion over 30 minutes on Days 1, 8, 15 Gemcitabine: 1000mg/m2 IV infusion over 30-100 minutes on Days 1, 8, 15
3263609|NCT01506986|Active Comparator|H. pylori eradication treatment|Active treatment will consist of seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
3263610|NCT01506986|Placebo Comparator|Placebo H. pylori eradication treatment|Placebos to seven days of lansoprazole 30mg twice daily, clarithromycin 500mg twice daily and metronidazole 400mg twice daily.
3263611|NCT01506999||Stable phase of ischemic heart disease|patients with history of angina pectoris, or myocardial infarction
3263612|NCT01506999||acute phase of ischemic heart disease|patients with unstable angina or acute myocardial infarction
3263613|NCT01506999||control group|subjects without ischemic heart disease (IHD)
3263614|NCT01507012|Experimental|Powdered berryfruit extract|Powdered berry extract containing 500mg of polyphenols
3263615|NCT01507012|Placebo Comparator|Placebo|
3263616|NCT01507012|Experimental|Berryfruit juice|Berryfruit juice containing 500mg polyphenols
3263617|NCT01507025||horizontal flap|patients were scheduled to undergo LASIK and with horizontal flaps(nasal- or temporal-hinge)
3263618|NCT01507025||vertical flap|patients were scheduled to undergo LASIK and with vertical flaps(superior- hinge)
3263619|NCT01507038|Experimental|Group A|
3263620|NCT01507038|Experimental|Group B|
3263621|NCT01507038|Experimental|Group C|
3263622|NCT01507038|Placebo Comparator|Group D|
3263623|NCT01507064|Active Comparator|Group A|Patients who undergo to LA without sorafenib pretreatment
3263624|NCT01507064|Experimental|Group B|Patients who are treated with sorafenib before LA
3263625|NCT01507077|Placebo Comparator|ZGN-440 sterile diluent|
3263626|NCT01507077|Experimental|ZGN-440|
3263627|NCT01507116||People with Diabetes|
3263628|NCT01507116||Family Members|
3263629|NCT01507116||Healthcare Professionals|
3263630|NCT01507142||cART-unresponsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, <200 CD4 Tcells/mm3 and Viral Load >5000 copies/ml
3263631|NCT01507142||cART-responsive AIDS|HIV-positive, AIDS diagnosis, cART for >18 months, >350 CD4 Tcells/mm3 and Viral Load<50 copies/ml
3263632|NCT01507142||Acute or early HIV infection|Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease
3263633|NCT01507142||HIV-negative Hepatitis B|Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load
3263634|NCT01507168|Placebo Comparator|Placebo|
3263635|NCT01507168|Experimental|GC33 (RO5137382)|
3263636|NCT01507194|Active Comparator|Ondansetron 4 mg|
3263637|NCT01507194|Experimental|Vestipitant 6 mg|
3263638|NCT01507194|Experimental|Vestipitant 12 mg|
3263639|NCT01507194|Experimental|Vestipitant 18 mg|
3263640|NCT01507194|Experimental|Vestipitant 24 mg|
3263641|NCT01507194|Experimental|Vestipitant 36 mg|
3263642|NCT01507259||100 g containing 70% or 34% cocoa|Healthy controls
3263643|NCT01507272|Experimental|NNC 90-1170 (liraglutide)|
3263644|NCT01507272|Placebo Comparator|Placebo|
3263645|NCT01507285|Experimental|NNC 90-1170|
3263646|NCT01507285|Placebo Comparator|Placebo|
3263647|NCT01507311|Experimental|NNC 90-1170|
3263648|NCT01507311|Placebo Comparator|Placebo|
3263649|NCT01507337|Experimental|Elderly|
3263650|NCT01507337|Experimental|Young|
3263651|NCT01507363|Active Comparator|"Gabapentin high"|Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
3263652|NCT01507363|Active Comparator|"Gabapentin intermediate"|Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
3263653|NCT01507363|Placebo Comparator|Placebo|Placebo tablets for 7 days, starting on the day of surgery
3263654|NCT01507376|Experimental|A: recombinant hCG(250 µg Ovitrell)|1- Group A consisted of 60 infertile women who received recombinant hCG(250 µg Ovitrelle)
3263655|NCT01507376|Experimental|B: recombinant hCG(500 µg Ovitrell)|2- Group B consisted of 60 infertile women who received recombinant hCG(500 µg Ovitrelle)
3263656|NCT01507376|Experimental|C: urinary hCG|3- Group C consisted of 60 infertile patients received 10,000 IU urinary hCG
3263657|NCT01507389|Experimental|Mild|
3263658|NCT01507389|Experimental|Moderate|
3263659|NCT01507389|Experimental|Severe|
3263660|NCT01507389|Experimental|Normal|
3263661|NCT01507402|Experimental|Cohort 1|Dose regimen 1 (Participants 18 to ≤ 65 yrs old)
3263662|NCT01507402|Experimental|Cohort 2|Dose regimen 2 (Participants 18 to ≤ 65 yrs old)
3263663|NCT01507402|Experimental|Cohort 3|Dose regimen 3 (Participants 18 to ≤ 65 yrs old)
3263664|NCT01507402|Experimental|Cohort 4|Dose regimen 4 (Participants 18 to ≤ 65 yrs old)
3263665|NCT01507402|Experimental|Cohort 5|Dose regimen 5 (Participants 18 to ≤ 65 yrs old)
3263666|NCT01507402|Experimental|Cohort 6|Dose regimen 6 (Participants 18 to ≤ 65 yrs old)
3263667|NCT01507402|Experimental|Cohort 7|Dose regimen 7 (Participants 18 to ≤ 65 yrs old)
3263668|NCT01507402|Experimental|Cohort 8|Dose regimen 3 (Participants > 65 to ≤ 85 yrs old)
3263669|NCT01507402|Experimental|Cohort 9|Dose regimen 9 (Participants 18 to ≤ 65 yrs old)
3263670|NCT01507415||Exacerbation|Patients with Chronic Obstructive Pulmonary Disease (COPD)
3263671|NCT01507428|Active Comparator|Arm I (standard chemoradiotherapy)|Patients undergo radiotherapy QD 5 days a week for 30 fractions. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once weekly for 6 weeks. Patients undergo FDG-PET/CT imaging between fractions 18 and 19.
3263672|NCT01507428|Experimental|Arm II (experimental chemoradiotherapy)|Patients undergo an individualized dose of image-guided radiotherapy QD 5 days a week for 30 fractions and undergo 18 F FDG-PET/CT between fractions 18 and 19. Based on the scan results, patients undergo individualized adaptive radiotherapy for the final 9 fractions. Patients also receive paclitaxel and carboplatin as in Arm I.
3263673|NCT01507454||Local treatment|
3263674|NCT01507467|Active Comparator|Accl. RT|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
3263675|NCT01507467|Experimental|Accl. RT + Nimorazole|Accelerated Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week + Nimorazole
3263676|NCT01507480|Experimental|Bevacizumab|This study is to be carried out sequentially (dose escalation) on 5 groups of 8 patients. Each group is made up of 6 verum and 2 placebos.
3263677|NCT01507506|Active Comparator|Conventional arm|3-dimensional conformal radiotherapy + Temozolomide
3263678|NCT01507506|Experimental|Experimental arm|simultaneous-integrated boost with intensity-modulated radiotherapy guided by magnetic resonance spectroscopic imaging + Temozolomide
3263679|NCT01507519|Experimental|BioMime™|BioMime™ DES
3263680|NCT01507532|Other|Ceftazidime|pharmacokinetic monitoring
3263681|NCT01507545|Active Comparator|MORAb-004|
3263682|NCT01507545|Placebo Comparator|Placebo|
3263683|NCT01507558|Experimental|Intervention|Perivascular administration of dexamethasone following endovascular superficial femoral and popliteal artery angioplasty or atherectomy.
3263684|NCT01507571|Experimental|Dignity Therapy|
3263685|NCT01507597|Other|Healthy Subjects|
3263686|NCT01507597|Other|T2DM|
3263687|NCT01507597|Other|T1DM|
3263688|NCT01507610|Experimental|Investigational|OPTINOSE SUMATRIPTAN, single dose of 20 mg intranasally (10 mg to each nostril).
3263689|NCT01507610|Active Comparator|IMITREX Nasal Spray|IMITREX® (sumatriptan) Nasal Spray, single dose of 20 mg intranasally (20 mg to one nostril).
3263690|NCT01507610|Active Comparator|IMITREX Oral Tablet|IMITREX® (sumatriptan) Oral Tablet, single dose of 100 mg, administered orally with 240 mL water.
3263691|NCT01507610|Active Comparator|IMITREX Subcutaneous Injection|IMITREX® (sumatriptan) Subcutaneous Injection, single dose of 6 mg injected subcutaneously in the abdomen.
3263692|NCT01507623|Experimental|With Capnograpy|Intervention group with the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
3263693|NCT01507623|No Intervention|No Capnography|Control group without the addition of capnography to standard monitoring (non-invasive blood pressure, pulse, pulse oximetry, clinical observation of respiration, electrocardiography (ECG) and respiratory frequency measured by the ECG)
3263694|NCT01507636|Active Comparator|Group 1|Occupational therapy using a special arm function training.
3263695|NCT01507636|Active Comparator|Group 2|Physical therapy using the Theraband for training of force.
3263696|NCT01507649|No Intervention|Control|
3263697|NCT01507649|Experimental|Telephone-based intervention|
3263698|NCT01507675||Military Veterans|Participants will be recruited from the Denver VA Medical Center (DVAMC), regardless of clinic.
3263699|NCT01507701|Experimental|Clonidine|
3263700|NCT01507714|No Intervention|control arm|vaginal wall repair surgery will be done to women in this arm, with no treatment for stress incontinence
3263701|NCT01507714|Active Comparator|TVT-O arm|the women in this arm will have a TVT-O procedure in addition to the vaginal wall repair
3263702|NCT01507727|Experimental|Drug: Tolvaptan|
3263703|NCT01507727|Placebo Comparator|Drug: Placebo|
3263704|NCT01507740||1|Control group n=20
3263705|NCT01507740||2|investigational group (cancer patients) n=40 patients treated with antiangiogenic agent
3263706|NCT01507753|Placebo Comparator|Placebo Supplement and No PEP|Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
3263707|NCT01507753|Experimental|Omega-3 and PEP|"Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3263708|NCT01507753|Experimental|Omega-3 and No PEP|Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
3263709|NCT01507753|Experimental|Placebo Supplement and PEP|"Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment."
3263710|NCT01507766|Experimental|Early enteral nutrition|The enteral nutrition was started within 48h after admission
3263711|NCT01507766|Active Comparator|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
3263712|NCT01507805|Experimental|EA preconditioning|electroacupuncture five days pre-operation
3263713|NCT01507805|Sham Comparator|Sham EA preconditioning|Patients treated with sham EA preconditioning Intervention
3263714|NCT01507818|Active Comparator|Ivivi Torino II|Active treatment with Non-thermal Pulsed Radio Frequency device
3263715|NCT01507818|Sham Comparator|Inactive Sham|Sham treatment
3263716|NCT01507844|Sham Comparator|ventilation|
3263717|NCT01507857|Experimental|400U /0.5ml in infants|inactivated vaccine(vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
3263718|NCT01507857|Placebo Comparator|0/0.5ml placebo in infants|0/0.5ml placebo in 5000 infants aged 6-35 months old on day0,28
3376379|NCT05160454|Active Comparator|patient|child with moyamoya
3376380|NCT05160454|Active Comparator|control|unaffected control
3376381|NCT05160441|Experimental|Platelet Rich Plasma Injection Group|Minimum 2cc Leukocyte Poor Platelet Rich Plasma
3376382|NCT05160441|Active Comparator|Corticosteroid Injection Group|5cc Normal Saline + 2cc 10 mg/ml Triamcinolone Acetonide (Kenalog)
3263719|NCT01507870|Active Comparator|prophylactic onlay mesh|
3263720|NCT01507870|No Intervention|continuous running suture|continuous running suture of the linea alba
3263721|NCT01507883||human oocytes/embryos|Sibling oocytes cultured in single or sequential media until day6
3263722|NCT01507922|Experimental|Fenoverine|Fenoverine 100mg three times a day will be administered for 8 weeks.
3263723|NCT01507922|Active Comparator|Trimebutine|Trimebutine maleate 150mg three times a day will be administered for 8 weeks.
3263724|NCT01507935|Active Comparator|Intervention Group I|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture I
3263725|NCT01507935|Active Comparator|Intervention Group II|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with added prebiotic oligosaccharides mixture II
3263726|NCT01507935|Placebo Comparator|Control Group|Healthy infants receiving regular non-hydrolysed cow's milk based infant formula with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
3263727|NCT01507935|No Intervention|Reference group|Exclusively breast-fed infants
3263728|NCT01507948|Experimental|Immediate Prolonged Exposure Treatment|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
3263729|NCT01507948|No Intervention|Wait list, immediately followed by Prolonged Exposure|Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks. After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
3263730|NCT01507974|No Intervention|control arm|The women in this arm will not receive preventive antibiotic treatment after delivery
3263731|NCT01507974|Active Comparator|preventive antibiotic treatment|The women in this arm will receive preventive antibiotic treatment after the delivery to 6 weeks
3263732|NCT01508000|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3263733|NCT01508000|Experimental|Arm B: modified FOLFOX6 + Bevacizumab and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m2 2-h infusion~Hour 0: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 2 (before 5-FU bolus): Bevacizumab 5 mg/kg IV over 90 minutes infusion*.~Hour 3.5: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3.5: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3263734|NCT01508000|Experimental|Arm C: modified FOLFOX6 + Panitumumab and Surgery|"Experimental: Arm B: modified FOLFOX6 + Bevacizumab and Surgery~6 cycles before and 6 cycles after surgery consisting in:~Hour - 1 (pre chemotherapy): Panitumumab 6 mg/kg IV over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg) +/- 15 min. infusion*.~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3263735|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
3263736|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
3263737|NCT01508026|Experimental|Nebivolol and Valsartan Fixed Dose Combination 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
3263738|NCT01508026|Experimental|Nebivolol Low Dose|Nebivolol Monotherapy 5 mg
3263739|NCT01508026|Experimental|Nebivolol High Dose|Nebivolol Monotherapy 20 mg
3263740|NCT01508026|Experimental|Valsartan Low Dose|Valsartan Monotherapy 80 mg
3263741|NCT01508026|Experimental|Valsartan High Dose|Valsartan Monotherapy 160 mg
3263742|NCT01508026|Placebo Comparator|Placebo|Dose Matched placebo
3263743|NCT01508039|Experimental|Treatment with chitin micro-particles|The study will involve 14-healthy subjects confirming to the inclusion criteria randomised to the treatments.
3263744|NCT01508065||controlled type one diabetes mellitus.|
3263747|NCT01508091|Experimental|Calorie restricted|25 % calorie restriction respect measured total energy expenditure, using a Mediterranean diet
3263748|NCT01508104|Experimental|BEZ235 and Everolimus|
3263749|NCT01508143|Experimental|400 microgram misoprostol|400 micrograms misoprostol each 6 hours for 8 dose
3263750|NCT01508143|Active Comparator|800 micrograms misoprostol|800 micrograms misoprostol each 12 hours for 4 dose
3263751|NCT01508156|Experimental|Group A: Healthy Participants|Healthy participants take IDX719 (5 mg - 100 mg) or matching placebo by mouth as either 1 single dose or as 7 daily doses.
3263752|NCT01508156|Experimental|Group B: HCV Participants|Treatment-naive participants infected with HCV genotype (GT) 1, GT2, or GT3 take IDX719 (1 mg - 100 mg) or matching placebo as either 1 single dose or as 7 daily doses.
3263753|NCT01508182|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
3263754|NCT01508182|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between Treatment Periods.
3263755|NCT01508195|Experimental|Treatment Sequence AB|Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 1 followed by Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
3263756|NCT01508195|Experimental|Treatment Sequence BA|Treatment B (canagliflozin/metformin IR FDC tablets) administered on Day 1 of Treatment Period 1 followed by Treatment A (canaglifozin + metformin IR tablets) administered on Day 1 of Treatment Period 2 with a washout period of 10-15 days between treatment periods.
3263757|NCT01508208|Other|Hypertensive disorder of pregnancy|Patients with an hypertensive disorder of pregnancy (28 weeks or more of gestation)will collect a random sample of urine for a spot test (protein/creatinine ratio) and urine for 24 hours. The level of proteinuria will be determined in this sample.
3263758|NCT01508221|Experimental|Trental + Vitamin E|Trental 400 mg TID and Vitamin E 400IU BID starting the first day after the last radiosurgery treatment
3263759|NCT01508247|Experimental|vaccine against EV71|Inactivated vaccine (Vero Cell) against EV71 of 320U /0.5ml in 5000 children aged 6-35 months on day0, 28
3263760|NCT01508247|Placebo Comparator|placebo|0/0.5ml placebo in 5000 children aged 6-35 months on day0, 28
3263761|NCT01508260|Experimental|Pilot Phase Aquapheresis|The first portion of this study is an open label pilot experience to evaluate the safety of aquapheresis in leukemia patients with severe fluid overload non-responsive to diuretics. A total of 10 patients will be treated.
3263762|NCT01508260|Experimental|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. About 6 teaspoons of blood will flow through the blood circuit, and the excess fluid will slowly be collected in the collection bag. The exact length of time of aquapheresis treatment is determined by how much fluid needs to be removed and how fast it can be removed. The average treatment is about 24 hours but can extend up to 7 days. About 6 liters or 13 pounds will be removed.
3263763|NCT01508260|Active Comparator|Diuretics|Furosemide by vein over about 15 minutes every 8 hours or by vein as a continuous (non-stop) infusion.
3263764|NCT01508273|Experimental|Exercise Intervention Program Group|At baseline study visit, participant shown how to complete the physical exercises performed while on study. Pedometer received to track physical activity. Resistance training bands given to use as part of the home-based exercise program. At the baseline study visit, directions received on how to use the study website. Access given to website that will allow tracking of exercise behavior and help set goals. Access given to an internet-based curriculum that will help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participant asked to visit website every week. Participant records activity and the number of steps taken every day on the website. Survey completed monthly about attitudes and beliefs about physical activity.
3263765|NCT01508273|Other|Sedentary Behavior and Dietary Intervention Group|Access given to internet-based curriculum to help teach about goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Participants read information about improving the quality of their diet and cutting back on sedentary behavior. Participants record on the website how much television watched and how many fruits and vegetables eaten every day. Survey completed monthly about attitudes and beliefs about sedentary behavior and dietary intake.
3263766|NCT01508273|Experimental|Chair-based Study Group|Patients participate in chair-based exercise study. Participants receive chair-based exercise DVD. Chair-based exercise program participation for a total of 8 weeks. Participants receive self-report assessments about quality of life and asked to participate in physical assessments of their balance and coordination.
3263767|NCT01508299|Experimental|raw food skin test|skin test with the suspected raw food
3263768|NCT01508312|Experimental|FDG-PET abnormal|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
3263769|NCT01508312|Experimental|FDG-PET normalization|Patients will receive 2 cycles of weekly brentuximab vedotin and then undergo evaluation with FDGPET/CT. Patients with normalization of FDG-PET/CT will proceed to ASCT. Patients with persistent abnormalities on FDG-PET/CT will receive 2 cycles of augmented ICE chemotherapy followed by repeat FDG-PET/CT prior to ASCT. Following augmented ICE, patients with negative FDG-PET/CT will proceed to ASCT. Those with persistent abnormalities on FDG-PET/CT will be treated according to their physician's recommendations.
3263770|NCT01508338|Placebo Comparator|Placebo|
3263771|NCT01508338|Experimental|HMB|
3263772|NCT01508338|Experimental|ATP and HMB|
3263773|NCT01508338|Experimental|ATP|
3263774|NCT01508351||Propofol Induction|All patients receiving propofol induction of anesthesia who are ASA 1-3
3263775|NCT01508364||Group 1|
3263776|NCT01508377|Experimental|Treatment of PTSD with cognitive restructuring|"In this arm the PTSD treatment can be divided into three phases.~First phase: self-confrontation (4 essays)~Second phase: cognitive restructuring (4 essays)~Third phase: parting (2 essays)"
3263777|NCT01508377|Experimental|Treatment of PTSD without cognitive restructuring|"In this arm the PTSD treatment can be divided into only two phases. Compared to the other arm the phase dealing with cognitive restructuring is excluded.~First phase: self-confrontation (4 essays)~Second phase: parting (2 essays)"
3263778|NCT01508390|Experimental|Boost|CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day
3263779|NCT01508403||Shuxuetong injection|a cohort using Shuxuetong injection
3263780|NCT01508416||Patients with Multiple Myeloma|Patients with newly diagnosed Multiple Myeloma required chemotherapy
3263781|NCT01508429|Active Comparator|misoprostol|800mcg misoprostol (four tablets of 200 mcg administered sublingually)
3263782|NCT01508429|Placebo Comparator|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
3263783|NCT01508468|Active Comparator|active comparator|"Non Immunosuppressive Symptomatic Treatment (NIST). No specific treatment Converting Enzyme Inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin."
3263784|NCT01508468|Experimental|experimental|NIST and Rituximab: 500 Mg and 100Mg in solution to be diluted for IV infusion (Mabthera®)
3263785|NCT01508481||Diabetes high risk group|
3263786|NCT01508494|Active Comparator|Galantamine|16mg galantamine progressively
3263787|NCT01508494|Placebo Comparator|placebo|placebo
3263788|NCT01508507||Cholera cases group|"Any diarrheal cases or suspected cholera cases from study area, whose stool specimen collected in study health center and examined in reference laboratory, reveals V. cholerae serotype O1/O139 is defined as cholera case"
3263789|NCT01508507||Control group|"A randomly selected age matched individual, who have been living in the study area and did not seek care for diarrheal illness in the study health center since vaccination is defined as control"
3263790|NCT01508533||Cohort 1|Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
3263791|NCT01508533||Cohort 2|Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
3263792|NCT01508546|Experimental|Arm 1: breast surgery with axillary lymphnodes removal|
3263793|NCT01508546|Experimental|Arm 2: breast surgery without axillary lymphnodes removal|
3263794|NCT01508559||HIV infected|HIV infected MSM 18-50 years old
3263795|NCT01508559||HIV uninfected|HIV uninfected MSM 18-50 years old
3263796|NCT01508572|Experimental|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
3263797|NCT01508585|Active Comparator|Pre-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) before bariatric surgery
3263798|NCT01508585|Active Comparator|Post-Op CBT|This group will receive CBT (Telephone Based Cognitive Behavioral Therapy) after bariatric surgery
3263799|NCT01508611|Active Comparator|30% silver diammine fluoride|The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied in erupting molars with a disposable microbrush for 3m. Then the surface will be washed for 30s.
3263800|NCT01508611|Active Comparator|cross-toothbrushing|Children will be oriented to proceed cross-toothbrushing in erupting molars
3263801|NCT01508624|No Intervention|Control|participants will receive standard usual care
3263802|NCT01508624|Experimental|Interaction|Participants will interact with nurses during their procedure
3263803|NCT01508624|Experimental|Music|Participants will listen to music using head phones during their procedure.
3263804|NCT01508624|Experimental|Touch - stress balls|Participants will be provided with stress balls to use during their procedure
3263805|NCT01508624|Experimental|DVD|Participants will watch a DVD during their procedure and will listen to the accompanying audio through head phones
3263806|NCT01508637|Experimental|Diesel Exhaust + Terazosin|
3263807|NCT01508637|Experimental|Diesel Exhaust + placebo|
3263808|NCT01508637|Sham Comparator|Filtered Air + terazosin|
3263809|NCT01508637|Sham Comparator|Filtered air + placebo|
3263810|NCT01508663|Experimental|PCI+OMT group|PCI (Everolimus Eluting Stent or Zotalolimus Eluting Stent) added to OMT after randomization and follow up for 12 months
3263811|NCT01508663|Active Comparator|OMT alone group|OMT alone after randomization and follow up for 12 months
3263812|NCT01508689|Other|Receive cereal bars first|This group will receive Kellogg's Nutri-Grain® cereal bars during the second three weeks of the study.
3263813|NCT01508689|Other|Receive cereal bars second|This group will receive Kellogg's Nutri-Grain® cereal bars during the last three weeks of the study.
3263814|NCT01508715|Active Comparator|Concentric exercise group|The participants in this group will perform the intervention exercises by actively completing the lifting portion of the resistive shoulder exercises. The physical therapist will then perform the lowering portion of the exercise for the participant.
3263815|NCT01508715|Experimental|Eccentric exercise group|The participants in this group will actively perform the lowering portion of the resistive shoulder exercises in the intervention. The physical therapist will perform the lifting portion of the exercise for the participant.
3263816|NCT01508728|Experimental|Active vibration|
3263817|NCT01508728|Placebo Comparator|Placebo Vibration|
3263818|NCT01508741|Active Comparator|5-Aminolevulinic Acid (5-ALA)|Active component 50 mg. capsules of 5-Aminolevulinic Acid (5-ALA)
3263819|NCT01508741|Placebo Comparator|Placebo capsule|Non-active component capsules
3263820|NCT01508754|Active Comparator|CPAP|Treatment with Continuous Positive Airway Pressure
3263821|NCT01508754|No Intervention|Control|Usual anti-hypertensive treatment without CPAP treatment
3263822|NCT01508767|Experimental|Study group 1|Early removal of urethral catheter 48 hours post-operatively.
3263823|NCT01508767|Other|Study group 2|Removal of urethral catheter once epidural analgesia has been withdrawn.
3263824|NCT01508780|Experimental|Pulmonary Arterial Hypertension, bosentan|Subjects include patients being diagnosed with pulmonary arterial hypertension and starting treatment with bosentan.
3263825|NCT01508793|No Intervention|Control|
3263826|NCT01508793|Experimental|Optimize Sleep|
3263827|NCT01508806|Experimental|Normal renal function|
3263828|NCT01508806|Experimental|Mild renal impairment|
3263829|NCT01508806|Experimental|Moderate renal impairment|
3263830|NCT01508806|Experimental|Severe renal impairment|
3263831|NCT01508806|Experimental|End-stage renal disease|
3263832|NCT01508819||1|Guidelines for ICU admission of elderly patients arriving in Emergency Departments with a life threatening conditions
3263833|NCT01508819||2|no intervention
3263834|NCT01508845|Active Comparator|High MUFA/PUFA, 1600 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 800 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3263835|NCT01508845|Active Comparator|High MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a high MUFA/PUFA ratio (20g/5g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3263836|NCT01508845|Active Comparator|Low MUFA/PUFA, 50,800 IU vitamin D3|Subjects will receive 3 meals (1 day) with a low MUFA/PUFA ratio (5g/20g), along with 50,000 IU of vitamin D3 and 800 IU of deuterated vitamin D3
3263837|NCT01508845|Active Comparator|Fat free meal, 50,800 IU vitamin D3|Subjects will receive 3 fat-free meals (1 day) and 50,000 IU vitamin D3 and 800 IU of deuterated vitamin D3
3263838|NCT01508858|Experimental|Treatment period 1|
3263839|NCT01508858|Placebo Comparator|Treatment period 2|
3263840|NCT01508871||Cardiomyopathy|
3263841|NCT01508884|Active Comparator|IM vaccine and placebo cream|A single dose of intramuscular influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
3263842|NCT01508884|Active Comparator|ID vaccine and placebo cream|A single dose of intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with aqueous cream
3263843|NCT01508884|Experimental|ID vaccine and imiquimod cream|A single dose intradermal influenza vaccine (15ug non-adjuvanted 2011/2012 TIV) with pre-treatment of the injected skin with imiquimod cream applied to the skin before vaccination
3263844|NCT01508897|Experimental|Phase 2 formulation|
3263845|NCT01508897|Experimental|Phase 3 formulation|
3263846|NCT01508923|Experimental|Treatment period 1|
3263847|NCT01508923|Placebo Comparator|Treatment period 2|
3263848|NCT01508949|Experimental|NNC 90-1170|
3263849|NCT01508949|Placebo Comparator|Placebo|
3263850|NCT01508962||Healthy individuals (controls)|
3263851|NCT01508962||Individuals affected with ALS (sporadic or familial)|
3263852|NCT01508975|Experimental|white rice|White rice
3263853|NCT01508975|Experimental|Brown rice|Brown Rice
3263854|NCT01508975|Experimental|Glucose|Glucose
3263855|NCT01508988|Experimental|Eye drops 0.3 µg/mL|
3263856|NCT01508988|Experimental|Eye drops 1 µg/mL|
3263857|NCT01508988|Experimental|Eye drops 3 µg/mL|
3263858|NCT01508988|Experimental|Eye drops 10 µg/mL|
3263859|NCT01508988|Experimental|Eye drops 20 µg/mL|
3263860|NCT01508988|Experimental|Eye drops 30 µg/mL|
3263861|NCT01508988|Experimental|Eye drops placebo|
3263862|NCT01509001|Active Comparator|metformin|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
3263863|NCT01509001|Active Comparator|glimepiride|Participants will randomized into Metformin (750 to 2500 mg/day) or Glimepiride (1 to 8 mg/day) therapy. After 4 months, the patients will crossed-over with no washout period to the alternative treatment for an additional 4-month period on similar dosage schedule
3263864|NCT01509014|Experimental|Pharmacy Intervention Arm|All patients receiving statins from pharmacies allocated to the pharmacist intervention arm of the study
3263865|NCT01509014|No Intervention|Usual Care|Pharmacies not allocated to the intervention arm will serve as the control. They received no training on the CPATCH intervention and provide usual care to patients at their pharmacy.
3263866|NCT01509027|Active Comparator|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
3263867|NCT01509027|Active Comparator|Education by unpersonalised DVD|Information on detrimental consequences of hyperphosphatemia is presented on DVD
3263868|NCT01509027|Placebo Comparator|Standard Care|standard care
3263869|NCT01509066|Experimental|Vegan diet|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask participants to keep foods low in fat and low in glycemic index.
3263870|NCT01509066|Active Comparator|Low-calorie|A low-calorie diet contains all food groups. However, participants will be provided with a calorie goal which should promote weight loss.
3263871|NCT01509092|No Intervention|obervation|patients in this arm received 6-months observation alone after injury
3263872|NCT01509092|Active Comparator|Surgical intervention|patients in this arm received vitrectomy surgery as soon as possible after injury
3263873|NCT01509131|Experimental|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L PEG-CS plus bisacodyl (10-20 mg according to patient bowel habit)
3263874|NCT01509131|Active Comparator|2L PEG-ASC|Patients will be asked to take PEG-ASC according to labeling instructions
3263875|NCT01509144|Active Comparator|nasal active low dose + IM active|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
3263876|NCT01509144|Active Comparator|nasal active mid dose + IM active|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
3263877|NCT01509144|Active Comparator|nasal active full dose + IM active|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
3263878|NCT01509144|Active Comparator|nasal placebo + IM active|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
3263879|NCT01509144|Placebo Comparator|nasal placebo + IM placebo|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
3263880|NCT01509157|Experimental|MDRS system|Participants will be using the MDRS system combined with their regular treatment with Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
3263881|NCT01509157|Active Comparator|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
3263882|NCT01509196|Experimental|HIP0901|Fenofibric acid
3263883|NCT01509196|Active Comparator|Lipidilsupra|Fenofibrate
3263884|NCT01509209|Placebo Comparator|Placebo|placebo
3263885|NCT01509209|Experimental|Cossac L|Pseudoephedrine 120mg + Levocetirizine 2.5mg
3263886|NCT01509222|Other|Personalized nurition counseling|Personalized nutrition counseling based on dietary intake and motivation to change.
3263887|NCT01509222|No Intervention|Control|No intervention, control group.
3263888|NCT01509235|Experimental|1. Exercise testing and self drainage session|
3263889|NCT01509235|Active Comparator|2. Chest physiotherapy (CP) session|
3263890|NCT01509261|Experimental|Ilaprazole|Ilaprazole 20mg
3263891|NCT01509261|Active Comparator|lansoprazole|lansoprazole 30mg
3263892|NCT01509274|Experimental|Plasma|
3263893|NCT01509274|Sham Comparator|Saline|
3263894|NCT01509274|Active Comparator|Physiotherapy + heel cap|
3263895|NCT01509287||Donnai-Barrow Syndrome (DBS)|Individuals affected with Donnai-Barrow Syndrome (DBS)
3263896|NCT01509287||Unaffected|Healthy family members of individuals affected with Donnai-Barrow Syndrome (DBS)
3263897|NCT01509300|Experimental|HAPLO|
3263898|NCT01509313|Experimental|Uterine polypectomy using morcellator|A new instrument using a mechanical cutting edge has come to market for uterine polypectomy. In patients having a general anaesthesia the mechanical cutting instrument has been shown to be easier to learn, more effective at completely removing polyps and quicker than current techniques. However, the instrument is slightly larger, which could potentially cause more discomfort and prolong the procedure in the outpatient setting.
3263899|NCT01509313|Active Comparator|Electical Resection|At present the most commonly used device for removing the uterine polyps in the outpatient setting is by electrical resection. This will provide comparison for the morcellator device being tested
3263900|NCT01509326|Active Comparator|Chiropractic|spinal manipulation, mobilization, massage, advice, exercises
3263901|NCT01509326|Experimental|Chiropractic PLUS pillow|spinal manipulation, mobilization, massage, advice, exercises, pillow
3263902|NCT01509339|Experimental|Vancomycin for Inhalation|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
3263903|NCT01509352|Active Comparator|with esophageal stitches|fundoplication with crural stitches
3263904|NCT01509352|Experimental|without esophageal stitches|fundoplication without crural stitches.
3263905|NCT01509365|No Intervention|sensible|Patients who show adequate response to loading dose of clopidogrel and receive standard 1x75 mg clopidogrel for at least 7 days.
3263906|NCT01509365|Active Comparator|simple dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x75 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
3263907|NCT01509365|Experimental|double dose|Patients who show suboptimal response to loading dose of clopidogrel and receive 1x150 mg clopidogrel for 1 month followed by standard 75 mg clopidogrel for 3 months to one year.
3263908|NCT01509391|Experimental|Keyhole-limpet hemocyanine|
3263909|NCT01509417|Experimental|Ad lib feeding|ad lib feedings following pyloromyotomy
3263910|NCT01509417|Active Comparator|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
3263911|NCT01509430|Experimental|Early training patient|12 weeks of Progressive Resistance Training followed by 12 weeks of a self chosen level of physical activity
3263912|NCT01509430|Experimental|Late training patients|12 weeks of a self chosen level of physical activity followed by 12 weeks of progressive resistance training
3263913|NCT01509443|Experimental|Interventional|Participants will receive standard asthmatic treatment and breathing/mild physical exercise
3263914|NCT01509443|No Intervention|Control Arm|The control arm will receive standard medical care for asthma
3263915|NCT01509456|Active Comparator|Potassium Bicarbonate|
3263916|NCT01509456|No Intervention|Control|
3263917|NCT01509469|Experimental|Low dose casein|Ileal infusion of low dose casein
3263918|NCT01509469|Experimental|High dose casein|Ileal infusion of high dose casein
3263919|NCT01509469|Experimental|Low dose sucrose|Ileal infusion of low dose sucrose
3263920|NCT01509469|Experimental|High dose sucrose|Ileal infusion of high dose sucrose
3263921|NCT01509469|Placebo Comparator|Placebo|Ileal infusion saline
3263922|NCT01509469|Active Comparator|Safflower oil|Ileal infusion safflower oil
3263923|NCT01509482|Experimental|insulin resistance|unexplained oligospermia and azoospermia. Blood samples will be taken for hormonal and blood lipids analysis.
3263924|NCT01509482|Active Comparator|Fertile males|Healthy Men with proven fertility. Blood samples will be taken for hormonal and blood lipids analysis
3263925|NCT01509508|Experimental|Immediate ARV treatment initiation|Initiation of ARV treatment regardless of participants's immunological and clinical staging
3263926|NCT01509508|Other|South African recommendation guided ARV initiation|HIV-infected individuals will be assessed clinically and immunologically and when eligible for treatment as per South African guidelines will be offered ART
3263927|NCT01509521|Active Comparator|Ephedrine|
3263928|NCT01509521|Active Comparator|Phenylephrine|
3263929|NCT01509560|Experimental|Everolimus|All patients will be given everolimus and the magnitude of the side effects will be measured
3263930|NCT01509573|Experimental|FSI-R (Intervention group)|The intervention group will participate in the mental health assessments and FSI-R, and will participate in post-intervention assessments and follow-up assessments.
3263931|NCT01509573|No Intervention|TAU (Treatment as Usual)|The TAU control group will not receive any intervention, but will participate in treatment as usual as provided by Partners In Health. They will complete assessments at all three time points.
3263932|NCT01509599|Experimental|Cryotherapy|"Cryotherapy is delivered via a cooling gel wrap applied to the affected lower leg using a dosing regimen, starting with daily cooling in month one to PRN in the last 3 months over the 9 month study."
3263933|NCT01509599|Sham Comparator|Usual care|"The sham wrap, filled with cotton, is applied to the affected lower leg using a dosing regimen, starting with daily application in month one to PRN in the last 3 months over the 9 month study."
3263934|NCT01509651|Experimental|Sugammadex|
3263935|NCT01509703|Experimental|High flow therapy|
3263936|NCT01509729|Placebo Comparator|Sham operation|
3263937|NCT01509729|Active Comparator|Knee arthroscopic surgery|
3263938|NCT01509742|Experimental|NNC 90-1170|
3263939|NCT01509742|Placebo Comparator|Placebo|
3263940|NCT01509755|Placebo Comparator|Placebo|
3263941|NCT01509755|Experimental|0.045 mg|
3263942|NCT01509755|Experimental|0.225 mg|
3263943|NCT01509755|Experimental|0.45 mg|
3263944|NCT01509755|Experimental|0.60 mg|
3263945|NCT01509755|Experimental|0.75 mg|
3263946|NCT01509755|Active Comparator|Glim|
3263947|NCT01509768||No treatment|This is a longitudinal, prospective, observational, natural history study of patients with MPS IIIB to identify endpoints that may be used for future ERT trials via standardized clinical, biochemical, neurocognitive, developmental, behavioral and imaging measures
3263948|NCT01509781|Active Comparator|Suction drain|Patients in Arm A undergo simplex mastectomy or modified radical mastectomy. One plastic Redon drain (16 Ch) is placed after simplex mastectomy and two plastic Redon drains (16 Ch each) following modified radical mastectomy.
3263949|NCT01509781|Experimental|Adaptive suture|Following mastectomy, wound cavity is closed with adaptive skin sutures. No suction drain is inserted.
3263950|NCT01509794|Active Comparator|Low Valence|Participants in the low valence condition will participate in photo-based simulations. They will see a photo of the patient and hear affectively flattened audio. The script and clinical information remain the same as the high valence condition.
3263951|NCT01509794|Experimental|High Valence|Participants in the high valence condition will participate in video-based simulations. They will see a rich multimedia presentation of the clinical encounter, with affectively enhanced audio. The script and clinical information remain the same as the low valence condition.
3263952|NCT01509833|Experimental|rFSH|Administration of recombinant FSH for ovarian stimulation.
3263953|NCT01509833|Experimental|hCG(100IU)|Administration of late follicular low dose hCG(100U) for ovarian stimulation.
3263954|NCT01509833|Experimental|hCG(200IU)|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
3263955|NCT01509859|Active Comparator|PFNA|"these patients will be treated with synthes PFNA device"
3263956|NCT01509859|Active Comparator|INTERTAN|"these patients will be treated with Smith&Nephew INTERTAN device"
3263957|NCT01509885||Complete Spinal Cord Injured Subjects|Patients with no motor scores in their legs and suffering a complete spinal cord injury.
3263958|NCT01509885||Incomplete Spinal Cord Injured Subjects|Patient with some motor preservation below the injury and suffering an incomplete spinal cord injury.
3263959|NCT01509898|Experimental|water-Jet|use of water jet for 1 month
3263960|NCT01509911|Experimental|TL-118 with standard of care Gemcitabine|
3263961|NCT01509911|Active Comparator|Gemcitabine with out TL-118|
3263962|NCT01509924|Experimental|Physical activity on Prescription (PaP)|Intervention group receives a PaP for 12 month.
3263963|NCT01509924|No Intervention|Control Group|The control group has the same monitoring as the experimental group but receives no PaP.
3263964|NCT01509924|No Intervention|Cognitiv function in patients with TIA|"Before discharged from hospital cognitive function is assessed. At the first visit the patients fill in a self assessment questionnaire for mental fatigue.~If impaired at the previous assessment cognitive function will be assessed at 3, 6 and 12 month."
3263965|NCT01509924|No Intervention|Controlgroup Cognitive function|In order to determine whether hospitalization in itself is associated with transient impaired cognition, a comparison group will be included. The comparison group will consist of patients with angina pectoris consecutively admitted to the Norrtälje Hospital. The patients with angina pectoris will be age and sex matched with the patients with TIA and assessed for cognitive function when their angina symptoms have subsided.
3263966|NCT01509937|Experimental|BCM Arm|BCM measured every 2 months
3263967|NCT01509937|Sham Comparator|Control arm|patients care according to standard of care
3263968|NCT01509963||patients candidates for the SN procedure|The study will focus on patients candidates for the SN procedure as recommended by Saint-Paul de VENCE initially in 2005 but modified in 2009.
3263969|NCT01509976|Other|Red|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
3263970|NCT01509976|Other|Blue|This arm will either start with personal care products that contain triclosan and then and cross over to personal care products that do not contain triclosan or vice-versa. Since the investigators are blinded, it is not clear which arm is which.
3263971|NCT01510002|Active Comparator|TT|Extracapsular total thyroidectomy
3263972|NCT01510002|Experimental|TT+CND|Extracapsular total thyroidectomy puls prophylactic central neck dissection
3263973|NCT01510015|Active Comparator|Anti-psychotic medication|Participants are treated with psychological treatment both group and individually as well as medications according to their mental condition.
3263974|NCT01510015|Active Comparator|Counseling|Participants will receive individual and group therapy
3263975|NCT01510041|Experimental|Inspiratory muscle training group|
3263976|NCT01510041|Experimental|Respiratory exercise group|
3263977|NCT01510054||steroid support|Endometrial biopsies from subjects of with or without luteal phase steroid support will be compared for miRNA expression
3263978|NCT01510080|Experimental|Computer-assisted live supervision|"Supervisees assigned to this group will receive 8 sessions of computer-assisted live supervision and 4 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. Computer-assisted live supervision is also known as bug-in-the-eye (BITE) supervision. The supervisor observes the therapy session with the help of a webcam and types messages on his computer. The instructions to the supervisee appear on a second monitor located in the therapy room where the supervisee can view it whenever he wants to."
3263979|NCT01510080|Experimental|Delayed video-based supervision|Supervisees assigned to this group will receive 12 sessions of delayed video-based supervision while treating 2 patients during 26 therapy sessions each. During delayed video-based supervision the supervisor and the supervisee spend 50 minutes reviewing selected parts of video recorded therapy sessions and discussing the case.
3263980|NCT01510093|Other|Insulin Aspart without glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply
3263981|NCT01510093|Other|Insulin Aspart with glucose supply|Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply
3263982|NCT01510119|Experimental|Intervention - Dose Level 1|RAD001 given 10mg/daily by mouth and 400mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
3263983|NCT01510119|Experimental|Intervention - Dose Level 2 Phase 2|RAD001 given 10mg/daily by mouth and 600mg hydroxychloroquine twice daily by mouth. Cycle 1 will include 1 week run-in of RAD001. Following this, both RAD001 and hydroxychloroquine given without interruption. Cycle 1 duration is 35 days; all subsequent cycles are 28 days. RAD001 and hydroxychloroquine continuously administered until progression of disease or unacceptable toxicity.
3263984|NCT01510132|Experimental|Travacom|Travoprost/timolol fixed combination self-administered at the rate of 1 drop per eye, one time a day, at approximately 8 a.m. each day for 8 weeks.
3263985|NCT01510171|Active Comparator|Prasugrel loading dose|
3263986|NCT01510171|Active Comparator|Ticagrelor Loading dose|
3263989|NCT01510223|Experimental|Dietary supplementation macademia oil|emia oil
3263990|NCT01510223|Experimental|Dietary supplementation olive oil|Olive oil
3263991|NCT01510223|Experimental|Dietary Supplementation fish oil|fish oil
3263992|NCT01510236|Experimental|Early self-help program|The early self-help program starts directly after randomization i.e. 4 weeks after diagnosis.
3263993|NCT01510236|Experimental|Later self-help program|The later self-help program starts sixty-two weeks after diagnosis.
3263994|NCT01510262|Experimental|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
3263995|NCT01510262|Active Comparator|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
3263996|NCT01510275|Experimental|Intervention|Combined use of RESPIVOL® and RESPILIFT® (with resistive load)
3263997|NCT01510275|Sham Comparator|Control|Combined use of RESPIVOL® and RESPILIFT® (without resistive load)
3263998|NCT01510288|Experimental|Ipilimumab and GVAX|
3263999|NCT01510301|Other|Self-report|
3264000|NCT01510340|No Intervention|Web sites|Patients assigned to this arm are given a list of Web sites where they can collect information related to their condition at their leisure.
3264001|NCT01510340|Experimental|VIH-TAVIE|Patients assigned to this arm must follow the four interactive computer sessions
3264002|NCT01510353|Experimental|Use of a radiation monitoring device|Use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
3264003|NCT01510353|No Intervention|No use of radiation monitoring device|No use of a radiation monitoring device that provides real-time auditory feedback on radiation exposure during cardiac catheterization
3264004|NCT01510366|Experimental|Cohort 1|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections.
3264005|NCT01510366|Experimental|Cohort 2:|Inactivated Poliomyelitis Vaccine (Salk strains) 3 x 0.5ml intramuscular injections.
3264006|NCT01510405||40 Participants|Participants undergoing or who have undergone thoracic surgery for presumed lung cancer with a wedge resection, lobectomy, bilobectomy, segmentectomy and/ or pneumonectomy thoracic surgical operation.
3264007|NCT01510418||Person with congenital bleeding disorder|Adult men with congenital hemophilia A or B
3264008|NCT01510418||Spouse/Significant Other|Spouse/significant other of person with congenital bleeding disorder participating in this study.
3264009|NCT01510483|Experimental|Obesity prevention|Orthodontist promotion of physical activity and healthy diet
3264010|NCT01510483|Active Comparator|Tobacco prevention|Orthodontist promotion of tobacco and second hand smoke avoidance
3264011|NCT01510496||Patients who had inguinal herniorraphy.|
3264012|NCT01510496||Patients who had hysterectomy.|
3264013|NCT01510496||Patients who had thoracotomy.|
3264014|NCT01510509|Experimental|Titanium bare metal stent|Titanium bare metal stent (Titan2®, Hexacath, Paris, France)
3264015|NCT01510509|Experimental|Everolimus Drug Eluting Stent|Xience-V®, Abbott Vascular, Santa Clara, California, USA
3264016|NCT01510522|Experimental|Glucophage sachets|Patients receive Glucophage sachets, the powder formulation for oral solution in sachets.
3264017|NCT01510522|Active Comparator|Glucophage tablets|Patients received Glucophage tablets.
3264018|NCT01510535|Experimental|Placebo and then LBSA0103|The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the target knee.
3264019|NCT01510535|Active Comparator|Hyruan Plus|The control group received once weekly for 3 weeks intraarticular injections of Hyruan Plus Inj. into the target knee.
3264020|NCT01510548|Active Comparator|Adalimumab 20 mg per week|Patient will get at double blind situation adalimumab 20 mg every week (six injections) injections
3264021|NCT01510548|Active Comparator|Adalimumab 40 mg per week|Patient will get at double blind situation adalimumab 40 mg per week injections
3264022|NCT01510548|Placebo Comparator|placebo arm|Patient will get at double blind situation placebo (= NaCl liquid solution, absolutely same color as the active drug) injections one per week during six weeks - same as the adalimumab arms
3264023|NCT01510561|Experimental|90Y-hPAM4|90Y-hPAM4 is administered weekly for 3 weeks
3264024|NCT01510561|Experimental|90Y-hPAM4 + gemcitabine|90Y-hPAM4 is administered weekly for 3 weeks, while gemcitabine is administered weekly for 4 weeks.
3264025|NCT01510574|Active Comparator|misoprostol|3 tablets of 200mcg misoprostol self-administered following home birth, taken orally immediately after delivery of baby
3264026|NCT01510574|Placebo Comparator|placebo|3 tablets of placebo resembling misoprostol self-administered following home birth, taken orally immediately after delivery of baby
3264027|NCT01510587|Experimental|4-Health Educational curriculum|Parents participate in 10 face-to-face educational sessions delivered by Extension Agents at individual county locations over a 8-month period (fall to spring).
3264028|NCT01510587|Active Comparator|Healthy Living Information|Participants receive 10 mailed packets of written information derived from USDA's MyPlate website on approximately the same schedule as meetings of the experimental group.
3264029|NCT01510613|Experimental|Pomalidomide and Dexamethasone|
3264030|NCT01510626|Experimental|One|
3264031|NCT01510639|Experimental|Cuff repair PRP|Cuff repair Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the cuff repair group
3264032|NCT01510639|No Intervention|Cuff repair Control|No intervention
3264033|NCT01510639|Experimental|NEER PRP|Neer Platelet Rich Plasma: The application of autologous thrombocyte concentrate in the NEER surgery group
3264034|NCT01510639|No Intervention|NEER Control|No intervention
3264035|NCT01510665|Experimental|Magnesium Supplement|Magnesium citrate dietary supplement (300 mg elemental Magnesium daily dose) given week 13 to week 28 (two pills daily)
3264036|NCT01510665|Placebo Comparator|Placebo|Identical appearing pill with inactive ingredients given week 13 to week 28 (two pills daily)
3264037|NCT01510665|Active Comparator|Diet|Nutritionist counseling session and advice on following a magnesium rich diet from week 13 to week 28
3264038|NCT01510678|Experimental|Decrease Condition|In the Decrease Snack Foods condition participants will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
3264039|NCT01510678|Experimental|Increase + Decrease Condition|Families will be encouraged to increase fruits and vegetables and decrease snack foods.
3264040|NCT01510678|Experimental|Increase Condition|A parent and child will be encouraged to increase fruits and vegetables. Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables.
3264041|NCT01510691||Epiretinal membrane|
3264042|NCT01510691||diabetic macular edema|
3264043|NCT01510691||vein occlusion|
3264044|NCT01510730|No Intervention|control group|no treatment for Helicobacter pylori infection
3264045|NCT01510730|Active Comparator|treatment group|treatment group receive eradication treatment for helicobacter pylori infection
3264046|NCT01510743|Active Comparator|Group SC|US guided subclavian vein catheterization
3264047|NCT01510743|Active Comparator|Group IJ|US-guided internal jugular vein catheterization
3264048|NCT01510782|Experimental|BI 655064 subcutaneous|Escalating single dose as solution for subcutaneous injection
3264049|NCT01510782|Placebo Comparator|Placebo to BI 655064 subcutaneous|Escalation single dose as solution for subcutaneous injection (Placebo)
3264050|NCT01510782|Experimental|BI 655064 intravenous|Escalating single dose as solution for intravenous infusion
3264051|NCT01510782|Placebo Comparator|Placebo to BI 655064 intravenous|Escalating single dose as solution for intravenous infusion (Placebo)
3264052|NCT01510795|No Intervention|retrospective control|
3264053|NCT01510795|Active Comparator|spironolactone|
3264054|NCT01510808||aggressive Periodontitis|Aggressive Periodontitis during maintenance
3264055|NCT01510808||aggressive periodontitis|aggressive periodontitis patients during maintenance
3264056|NCT01510821|Experimental|Maquet Vasoshield Arm|Pressure limiting syringe
3264057|NCT01510821|Active Comparator|Non-regulated Arm|standard non-regulated syringe
3264058|NCT01510847|Other|Oral Testosterone Therapy|90 day oral testosterone therapy
3264059|NCT01510860|Active Comparator|Ursodeoxycholic acid (UDCA)250 mg|UDCA 250 mg capsule
3264060|NCT01510860|Experimental|Ursodeoxycholic acid (UDCA)500 mg|UDCA 500 mg tablet
3264061|NCT01510873||Newly Diagnosed pITP|Patients within 3 months from diagnosis.
3264062|NCT01510873||Persistent pITP|Patients between 3 to 12 months from diagnosis; includes patients not reaching spontaneous remission or not maintaining complete response off therapy.
3264063|NCT01510873||Chronic pITP|Patients with ITP lasting for more than 12 months.
3264064|NCT01510886||1|
3264065|NCT01510899|Experimental|Healthy Subjects Arm|
3264066|NCT01510899|Experimental|Renal Impaired Subjects Arm|
3264067|NCT01510938|Placebo Comparator|Placebo|1 g of rice maltodextrin will be reconstituted in 25-50 ml of tepid water or juice and immediately fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
3264068|NCT01510938|Experimental|Probiotic|"powder of L. acidophilus DDS-1, B. lactis UABLA-12, 50 mg of fructooligosaccharide~1 g of probiotic will be reconstituted in 25-50 ml tepid water or juice and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer."
3264069|NCT01510951|Placebo Comparator|PLACEBO|
3264070|NCT01510951|Experimental|AMG 811|
3264071|NCT01510964|Experimental|prompt-sheet|"Patients and companions of intervention group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and the prompt sheet. An introduction explains the importance of asking questions during the consultations. The patient (companion) is invited to select among a written list of about 50 possible questions those, if any, s/he would like to ask today to the oncology."
3264072|NCT01510964|Other|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
3264073|NCT01510977|Active Comparator|PEG|2L of polyethylene glycol addition immediately after first colonoscopy failure
3264074|NCT01510977|Experimental|PEG + bisacodyl|One week after initial colonoscopy failure, conventional amount (5L) of polyethylene glycol together with bisacodyl administration
3264075|NCT01510990|Experimental|Gefitinib|"After a baseline 18F FDG-PET, patients are treated with gefitinib 250mg/d as 1st line treatment for 7 days. And follow up 18F-FDG PET image is acquired after 1 week's treatment of gefitinib (with window period +/- 2 days).~If % decrease of peak SUV of main lesion is 20% or more, gefitinib treatment is continued till progression, unacceptable toxicities or patient's refusal. But if % decrease of peak SUV of main lesion less than 20% or peak SUV increase, gefitinib treatment is stopped, and changed to Pemetrexed/Cisplatin chemotherapy."
3264076|NCT01511003|Experimental|Tacrolimus group|oral
3264077|NCT01511029|Experimental|Dexpramipexole|
3264078|NCT01511029|Placebo Comparator|Dexpramipexole (placebo)|
3264079|NCT01511029|Active Comparator|Moxifloxacin|
3264080|NCT01511094|Experimental|Eye Surgery|Goniocurettage was used to treat open angle glaucoma patients
3264081|NCT01511120|Active Comparator|Tetraspan|
3264082|NCT01511133||HRV Group|Subjects received two or three doses of HRV in previous studies.
3264083|NCT01511133||Placebo Group|Subjects received two or three doses of placebo in previous studies.
3264084|NCT01511146|Experimental|Mitomycin+Gemcitabine|Intrahepatic treatment, where all standard treatments have been used
3264085|NCT01511159|Experimental|NNC 90-1170, initial dose|
3264086|NCT01511159|Experimental|NNC 90-1170|
3264087|NCT01511159|Active Comparator|Insulin|
3264088|NCT01511159|Experimental|NNC 90-1170, final dose|
3264089|NCT01511172|Experimental|NNC 90-1170 + Met|
3264090|NCT01511172|Experimental|NNC 90-1170 + Met placebo|
3264091|NCT01511172|Placebo Comparator|Met + NNC 90-1170 placebo|
3264092|NCT01511172|Active Comparator|Met + Glim|
3264093|NCT01511185|Experimental|NNC 90-1170|
3264094|NCT01511185|Placebo Comparator|Placebo|
3264095|NCT01511185|No Intervention|Healthy|
3264096|NCT01511198|Experimental|0.045 mg|
3264097|NCT01511198|Experimental|0.225 mg|
3264098|NCT01511198|Experimental|0.45 mg|
3264099|NCT01511198|Experimental|0.60 mg|
3264100|NCT01511198|Experimental|0.75 mg|
3264101|NCT01511198|Active Comparator|Met|
3264102|NCT01511211|Experimental|Ropivacaine + Dexamethasone Combination|
3264103|NCT01511211|Active Comparator|Ropivacaine-Only Block|
3264104|NCT01511224||Colistin monotherapy|
3264105|NCT01511224||Colistin based combination therapy|Colistin-Tigecycline, Colistin-Carbapenem, Colistin-Rifampin, Colistin-HD Unasyn
3264106|NCT01511224||Non-colistin containing regime|
3264107|NCT01511224||Glycopeptide with colistin combination|
3264108|NCT01511224||Colistin with loading dose|
3264109|NCT01511237|Experimental|Perinatal intensification|"Perinatal antiretroviral intensification (study treatment):~Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks~The standard of care in Thailand is defined as:~Maternal: ZDV 300 mg, 3TC 150mg and LPV/r 400/100 twice a day starting as soon possible after 14 weeks of pregnancy + ZDV 300 mg every 3 hours during labor~Newborn: ZDV 4 mg/kg every 12 hours for 4 weeks (ZDV dosing adjusted for premature infants)."
3264110|NCT01511263|Active Comparator|Arm A|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B).
3264111|NCT01511263|Experimental|Arm B|The patients will be divided into 4 strata according to cardiac dysfunction and to the quality of hematologic response. After stratification the patients will be randomized (1:1) within each stratum to receive Standard Therapy alone (Arm A) or Standard Therapy plus Investigational Drug (Arm B)
3264112|NCT01511276|Experimental|Diet-induced weight loss|The diet-induced weight loss group will follow a calorie restricted diet. They are asked to keep their habitual sedentary lifestyle. The aim of this group is to loose 5-6 kg of body weight in 14 weeks time.
3264113|NCT01511276|Experimental|Mainly exercise induced weight loss|"Participants in the exercise- plus diet-induced weight loss group are enrolled in an exercise programme. Next to the exercise programme, they will follow a calorie restricted diet.~The aim of this group is to loose 5-6 kg of body weight in 14 weeks time."
3264114|NCT01511276|No Intervention|Control, stable weight|The control group is asked to follow a baseline isocaloric diet and to not change their habitual sedentary lifestyle.
3264115|NCT01511289|Active Comparator|Imatinib|Imatinib 400mg QD
3264116|NCT01511289|Experimental|Radotinib 600mg|Radotinib 300mg BID
3264117|NCT01511289|Experimental|Radotinib 800mg|Radotinib 400mg BID
3264118|NCT01511302|Experimental|RNS60-BD 0.25|RNS60 in combination with Budesonide 0.25mg/2ml concentration
3264119|NCT01511302|Experimental|RNS60-BD 0.5|RNS60 in combination with Budesonide 0.5mg/2ml concentration
3264120|NCT01511302|Placebo Comparator|NS-BD 0.5|Normal Saline control (NS) in combination with Budesonide 0.5mg/2ml concentration
3264121|NCT01511328|Experimental|HPV testing|Women randomised to this arm get primary HPV testing
3264122|NCT01511328|No Intervention|cytology|women included follow the standard procedure with primary cytology
3264123|NCT01511341|Experimental|Telenursing|
3264124|NCT01511341|No Intervention|Standard practice|Group receive the standard practice, without telephone nursing intervention.
3264125|NCT01511354||Standard clinical care|Standard nutritional therapy and treatment
3264126|NCT01511367|Active Comparator|Flutiform|
3264127|NCT01511367|Active Comparator|Seretide|
3264128|NCT01511367|Active Comparator|Flixotide|
3264129|NCT01511380|Experimental|Risk Reduction Therapy for Adolescents|Youth randomly assigned to RRTA will complete a family focused treatment program that will work with the youth and his or her caregiver to help reduce youth substance use and risky sexual behavior using principals of behavior modification and contingency management.
3264130|NCT01511380|Active Comparator|Usual services|For youth randomly assigned to usual treatment services, the youth will receive the treatment services recommended by the drug court.
3264131|NCT01511393||Questionnaire|None. Non-interventional study.
3264132|NCT01511406|Experimental|cognitive behavioral therapy|Cognitive behavioral therapy up to 26 sessions
3264133|NCT01511432|Experimental|Part A|Part A will be a 4-formulation, 4-sequence, 4-period crossover relative bioavailability study of 3 novel oral telaprevir formulations relative to the 375-mg Incivek tablet in the fed state.
3264134|NCT01511432|Experimental|Part B|Part B will be a 2-formulation, 6-sequence, 3-period cross-over relative bioavailability study of the novel oral telaprevir formulation selected from Part A in the fasted relative to the fed state and relative to the 375-mg Incivek tablet in the fasted state
3264135|NCT01511458||Case|Patient with a trisomy 21 pregnancy confirmed by genetic testing.
3264136|NCT01511458||Control|Patients without a trisomy 21 pregnancy confirmed by either genetic testing or a normal newborn phenotype.
3264137|NCT01511471|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
3264138|NCT01511484|Experimental|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
3264139|NCT01511484|Experimental|Generic-appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
3264140|NCT01511484|Experimental|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
3264141|NCT01511497|Experimental|PF-04427429|
3264142|NCT01511497|Placebo Comparator|Placebo|Normal saline
3264143|NCT01511510|Experimental|PF-04958242|
3264144|NCT01511510|Placebo Comparator|Placebo|
3264145|NCT01511523|Active Comparator|RGMA001|Proprietary blend of Vitamin E, Silymarin, and Carnitine.
3264146|NCT01511523|Placebo Comparator|Sugar Pill|No treatment.
3264147|NCT01511549|Experimental|Dose 1|SAR113945 low dose
3264148|NCT01511549|Experimental|Dose 2|SAR113945 medium dose
3264149|NCT01511549|Experimental|Dose 3|SAR113945 high dose
3264150|NCT01511549|Placebo Comparator|Placebo|Placebo
3264151|NCT01511562|Other|Arm I|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo stem cell transplant.
3264152|NCT01511562|Other|Arm II|Patients undergo induction therapy for five cycles as defined in the protocol. Patients undergo consolidation chemotherapy.
3264154|NCT01511627|Active Comparator|General Anesthesia|
3264155|NCT01511627|Experimental|General Anesthesia + Spinal Anesthesia|
3264156|NCT01511666|Experimental|Hyperinvasive arm|Hyperinvasive arm encompasses immediate institution of a mechanical chest compression device (LUCAS) and pre-hospital intraarrest cooling by Rhino-Chill device. Immediately after institution of these two devices the patients will be directly transferred to cardiac center cathlab under continuous CPR. The use of drugs and further defibrillations are on a discretion of the emergency physician. After admission to cathlab, overall status, ROSC presence and ECLS inclusion/exclusion criteria will be evaluated.
3264157|NCT01511666|Active Comparator|Standard arm|Patients in standard arm will be further managed as per recent ERC guidelines, ie. continued ACLS. The use of drugs and further defibrillations are on a discretion of the emergency physician. If ROSC is attained, patients will be transferred to the same hospital to one of intensive care units, coronary angiography/PCI will be performed only if indicated according to routine practice and mild therapeutic hypothermia will be instituted as soon as possible as per recent guidelines recommendation.
3264158|NCT01511679||Alcohol-naive adolescents|A general population longitudinal cohort of alcohol-naïve (or h/o minimal recent-onset drinking) adolescents in three specific age-groups: early (12-14 y/o), middle (15-17 y/o), and late (18-21 y/o).
3264159|NCT01511679||Treatment sample|A sample of adolescents who have a >1 year history of heavy drinking but have agreed to stop drinking as part of their treatment plan
3264160|NCT01511679||High risk sample|High-risk adolescents who have a family history of alcohol-use disorder and other risk factors (symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD), Conduct Disorder, or Mood Disorder)
3264161|NCT01511692|Experimental|Lira --> placebo|
3264162|NCT01511692|Placebo Comparator|Placebo --> glim|
3264163|NCT01511692|Active Comparator|Glim --> lira|
3264164|NCT01511705|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
3264165|NCT01511705|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
3264166|NCT01511718|Experimental|Ondansetron Hydrochloride Tablets 8 mg|Ondansetron Hydrochloride Tablets 8 mg of Dr. Reddy's Laboratories Limited
3264167|NCT01511718|Active Comparator|Zofran Tablets 8 mg|Zofran Tablets 8 mg of GlaxoSmithKline
3264168|NCT01511731|Experimental|Famotidine|Famotidine tablets 40 mg of Dr. Reddy's
3264169|NCT01511731|Active Comparator|Pepcid|Pepcid 40 mg Tablets of Merck & Co.,
3264170|NCT01511744|Experimental|Inactivated influenza split vaccine|Biological: Experimental: influenza split vaccine of 15 μg HA, one dose regime
3264171|NCT01511744|No Intervention|Blank control|
3264172|NCT01511757|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
3264173|NCT01511757|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
3264174|NCT01511770|Experimental|Fluconazole|Fluconazole Tablets 200 mg of Dr. Reddy's Laboratories limited.
3264175|NCT01511770|Active Comparator|Diflucan|Diflucan 200 mg fluconazole tablets of Pfizer
3264176|NCT01511783|Experimental|E2609|E2609 at ascending doses
3264177|NCT01511783|Placebo Comparator|Placebo|
3264178|NCT01511796|Experimental|upper limb rehabilitation for total of 6 months|upper limb rehabiliation
3264179|NCT01511822|Active Comparator|Drospirenone + Ethinyl estradiol|
3264180|NCT01511822|Experimental|Drospirenone + Ethinyl estradiol + Myo-inositol|
3264181|NCT01511822|Placebo Comparator|Placebo|
3264182|NCT01511835|Experimental|Myo-inositol powder|
3264183|NCT01511835|Experimental|Myo-inositol soft gel capsules|
3264184|NCT01511835|Placebo Comparator|Folic acid|
3264185|NCT01511848|Active Comparator|arm 1|30 Patients will be treated with combined DFP and deferasirox.
3264186|NCT01511848|Active Comparator|arm 2|Patients will be treated for 6 days with a combination of deferoxamine and DFP
3264187|NCT01511874|Experimental|ELIGRAD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
3264188|NCT01511887|Experimental|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
3264189|NCT01511887|No Intervention|No treatment|No treatment
3264190|NCT01511900|Experimental|Cohort 1: Dose level 1|Multiple dose orally: CAT-1004 Dose level 1 or placebo
3264191|NCT01511900|Experimental|Cohort 2: Dose level 2|Multiple dose orally: CAT-1004 Dose level 2 or placebo
3264192|NCT01511900|Experimental|Cohort 3: Dose level 3|Multiple dose orally: CAT-1004 Dose level 3 or placebo
3264193|NCT01511900|Experimental|Cohort 4: Dose level 4|Multiple dose orally: CAT-1004 Dose level 4 or placebo
3264194|NCT01511900|Experimental|Cohort 5: Dose level TBD|Multiple dose orally: CAT-1004 Dose level TBD or placebo
3264197|NCT01511926||1|Adult patients treated with Vimovo™ for diagnosed osteoarthritis (OA), rheumatoid arthritis (RA) or ankylosing spondylitis
3264198|NCT01511952|Active Comparator|Music intervention- SGA|Infants will be randomly assigned to receive one of three music interventions randomized for the AM or PM
3264199|NCT01511952|Active Comparator|Music Intervention- RDS|Infants will be randomly assigned to receive music-one of 3 randomized interventions in the AM or PM
3264200|NCT01511952|Active Comparator|Music Intervention- Sepsis|Infants randomly assigned to receive one of three interventions-randomized for the AM or PM
3264201|NCT01511965|Other|traitement A|Lesion 1= graft and lesion 2 = UltraViolet B
3264202|NCT01511965|Other|traitement B|Lesion 1 = UltraViolet B and lesion 2 = graft
3264203|NCT01511991|Experimental|sevoflurane|10 min exposure to sevoflurane 1.0, 2.0 and 3.0 inspiratory vol% at sevoflurane dosage titration
3264204|NCT01512004|Active Comparator|Propiverine Hydrochloride Extended-Release Capsule|30 mg/capsule; oral; once per day
3264205|NCT01512004|Placebo Comparator|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
3264206|NCT01512017|Active Comparator|Veloderm|
3264207|NCT01512017|Placebo Comparator|Vaseline|
3264208|NCT01512043|Experimental|1. Breathing control|Description ...
3264209|NCT01512043|Active Comparator|2. Listening to music|Listening to music without guiding on breathing on the same device as breathing control twice a day for four weeks. Using the device to measure breathing movements.
3264210|NCT01512043|Sham Comparator|3. Silence|Using the device to measure breathing movement twice a day for four weeks. No instruction on breathing control and no music.
3264211|NCT01512056|Experimental|the immunogenicity profiles of the AdimFlu-S|"Experimental group: to receive either only one dose of influenza vaccine at day 0 or one more booster vaccination 3 weeks later.~Negative control group: dialysis patients who refused to receive influenza vaccination."
3264212|NCT01512056|No Intervention|The safety outcome of the vaccine|Any adverse effect, including systemic or local site, will be recorded during the study period.
3264213|NCT01512069|Experimental|Web-based, Stage-matched Exercise and Diet Planning program|The experimental arm is a group that assigned to use web-based, stage-matched exercise and diet planning program.
3376383|NCT05160441|Experimental|Delayed Platelet Rich Plasma Injection Group upon Corticosteroid Injection Failure|If a participant does not have any benefit from the corticosteroid injection by the six-week follow-up time point, then that participant will be eligible for a platelet rich plasma injection.
3264214|NCT01512069|Active Comparator|Non-tailored booklet on exercise and diet|The control group is provided a booklet containing same information on exercise and diet as in the experimental group's web-based program, but the information on a booklet is not tailored to participants' stage of motivational readiness for exercise and diet based on the TTM.
3264215|NCT01512082|Experimental|Active pulsed electromagnetic field|
3264216|NCT01512082|Sham Comparator|Non-active pulsed electromagnetic field|
3264217|NCT01512095|Experimental|Norditropin®|
3264218|NCT01512095|Active Comparator|Nutropin AQ®|
3264219|NCT01512121||functional MRI testing|"fMRI scanning with SCS on and off at different settings."
3264220|NCT01512134|Experimental|DBS Surgery|All patients enrolled will undergo DBS implantation in the targeted region to assess the safety of the procedure and the efficacy through weight loss.
3264221|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|Our trial will examine the changes in latency and amplitude of SSEP and changes in amplitude and morphology of MEP while using different anesthetic combinations including isoflurane, proposal and dexmedetomidine. Monitoring teams will document any changes throughout the surgery and communicate with the team about those changes. The design of the study will be a prospective AB design.
3264222|NCT01512173|Experimental|propranolol gel|
3264223|NCT01512173|Placebo Comparator|Placebo|
3264224|NCT01512199|Experimental|U3-1287 with trastuzumab + paclitaxel (Phase 1b)|The Phase 1b portion is an open label, dose de escalation, single arm study designed to assess the safety and tolerability of up to 3 dose levels of U3- 1287 in combination with trastuzumab plus paclitaxel and will determine the recommended Phase 2 dose (RP2D) of U3 1287. The first cohort will receive U3- 1287 18 mg/kg intravenously (IV) in combination with trastuzumab plus paclitaxel once every 3 weeks (q3w).
3264225|NCT01512199|Experimental|U3-1287 with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
3264226|NCT01512199|Placebo Comparator|Placebo with trastuzumab+paclitaxel (Ph 2)|The Phase 2 portion is a randomized, 2 arm, placebo controlled, double blind study designed to evaluate the safety and the efficacy of U3-1287 at the recommended phase 2 dose in combination with trastuzumab plus paclitaxel (experimental arm) relative to the control arm (trastuzumab plus paclitaxel and placebo).
3264227|NCT01512212|No Intervention|single group|FNAB will be perform first with standart technique and after with new FNAB apparatus
3264228|NCT01512238||Pharmaceutical care|
3264229|NCT01512238||Control|
3264230|NCT01512277|Experimental|3 administrations of 100 µg of rSh28GST|Adult volunteers (n=8) receive 100μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0, D28, and D150.
3264231|NCT01512277|Experimental|2 administrations of 300 µg of rSh28GST|Adult volunteers (n=8) receive 300μg of rSh28GST together with aluminium hydroxide (Alum) as adjuvant at D0 and D28.
3264232|NCT01512277|Placebo Comparator|Placebo|Adult volunteers (n=8) receive aluminium hydroxide (Alum) alone at D0 and D28.
3264233|NCT01512290|Active Comparator|Theta burst treatment|patients randomized to this arm will receive 10 TBS treatments distributed over 5 days
3264234|NCT01512290|Placebo Comparator|sham treatment|
3264235|NCT01512303|Experimental|Sudarshan Kriya Yoga: SKY|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment. All are soothing and present-focused. Participants will be encouraged to learn all the breathing exercises, and to utilize the exercises the ones that seems most appropriate for their needs. 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3 hours/session).
3264236|NCT01512303|Experimental|Mindfulness-Based Stress Reduction: MBSR|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts, allowing the practitioner to calm his or her mind and come back to the present moment. The typical MBSR format will be adapted to match the SKY intervention. This intervention will include an 8-day intensive group class (2.5 hours/day) followed by 4 weekly sessions (3hrs/session).
3264237|NCT01512303|No Intervention|Wait-List Control: WLC|Participants will undergo no intervention. These participants will have the option of receiving one of the two interventions at the conclusion of the study.
3264238|NCT01512303|No Intervention|Non-PTSD control|Baseline measures only will be collected from a group of 50 combat-exposed veterans without PTSD to assess group differences on these measures prior to treatment.
3264239|NCT01512316|Active Comparator|d-Cycloserine Acquisition|d-Cycloserine will be given on day1, before acquisition
3264240|NCT01512316|Active Comparator|d-Cycloserine Extinction|d-Cycloserine will be administered on day2, before extinction
3264241|NCT01512316|Placebo Comparator|Placebo|A placebo pill will be administered on day1 and 2
3264242|NCT01512329|Experimental|pacing|The pacing self-management program (3 one-on-one sessions weekly for 3 consecutive weeks) focused on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), MS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
3264243|NCT01512329|Active Comparator|relaxation|Relaxation therapy (3 one-on-one sessions weekly for 3 consecutive weeks) comprised of education about the role of stress in MS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
3264244|NCT01512342|Experimental|Pacing|The pacing self-management program focussed on teaching the patient to estimate their current physical capabilities prior to commencing an activity. In order to appropriately pace activities (daily activities and exercise bouts), CFS patients were learned to estimate their current physical capabilities prior to commencing an activity, keeping in mind the regular fluctuating nature of their symptoms. The activity duration used within the program was less than that reported by the patient so to account for typical overestimations made by the patient. Each activity block was interspersed with breaks, with the length of this break equating to the duration of the activity.
3264245|NCT01512342|Active Comparator|relaxation therapy|Relaxation therapy comprised of education about the role of stress in CFS biology, and the opportunities stress management provides to handle this issue. Patients were then taught how to apply stress management techniques like Jacobson relaxation skills, Schultz relaxation skills, visualization, etc.
3264246|NCT01512355|Experimental|dexmedetomidine|
3264247|NCT01512355|Placebo Comparator|placebo|
3264248|NCT01512381|Experimental|CRT|
3264249|NCT01512381|Active Comparator|pacemaker|
3264250|NCT01512394|Active Comparator|Standard bowel prep|Standard bowel prep
3264251|NCT01512394|Experimental|No bowel prep|No bowel prep
3264252|NCT01512407|Experimental|Hepatectomy plus TACE|Transarterial chemoembolisation will be performed 4 to 6 weeks after hepatectomy
3264253|NCT01512407|No Intervention|Hepatectomy alone|
3264254|NCT01512420||Cohort|
3264255|NCT01512433|Active Comparator|True acupuncture|True acupuncture was a real acupuncture which had been used in conventional Chinese medicine practice
3264256|NCT01512433|Sham Comparator|Sham acupuncture|Sham acupuncture was a procedure which mimicked the real acupuncture procedure.
3264257|NCT01512459|Experimental|Venlafaxine MR Capsules 150|Venlafaxine MR Capsules 150 of Dr.Reddy's Laboratories Limited
3264258|NCT01512459|Active Comparator|Effexor XR 150 mg Capsules|Effexor XR 150 mg Capsules of Wyeth Laboratories Philadelphia, PA, USA
3264259|NCT01512472|Active Comparator|10 month degarelix therapy|
3264260|NCT01512472|Active Comparator|4 month degarelix therapy arm|
3264261|NCT01512485|Experimental|Clopidogrel|Clopidogrel tablets 75 mg of Dr. Reddy's Laboratories Limited
3264262|NCT01512485|Active Comparator|Plavix|Clopidogrel Tablet 75 mg
3264263|NCT01512498||Patients who underwent allogeneic HSCT|Patients who underwent allogeneic HSCT before the age of 18, who are 18 years or older at the time of the study and who are alive.
3264264|NCT01512511|Experimental|nitrous oxide|use nitrous oxide for pneumoperitoneum creation
3264265|NCT01512511|Placebo Comparator|carbon dioxide|use carbon dioxide for pneumoperitoneum creation
3264266|NCT01512524|Other|Patients With Traumatic Brain Injury|Study of the association between quality of life and MRI scans and endocrinology analysis (quantification of Growth Hormone) 18 months post-trauma.
3264267|NCT01512537|Active Comparator|UVB|UVB exposed group
3264268|NCT01512537|Active Comparator|Oral vitamin D tablet|Vitamin D supplementation
3264269|NCT01512550|Active Comparator|instrumented hip guide technique|A mechanical device used to measure and decide how the hip prosthesis (ABG II modular) should be implanted
3264270|NCT01512550|No Intervention|conventional measuring technique|Standard way of implanting the prosthesis (ABG II standard) without special measuring device or computer navigation technique
3264271|NCT01512550|Active Comparator|computer assisted navigation|A method to use computer navigation when positioning and sizing the hip prosthesis (ABG II modular).
3264272|NCT01512563|Experimental|Paclitaxel ElutingCovered Metal Stent|
3264273|NCT01512563|Active Comparator|Covered Metal Stent|
3264274|NCT01512576|Experimental|acupuncture|All patients were treated at the basic points bilaterally situated in the local region (neck), distal region (low back, arms and legs) and ear. In addition, acupuncture treatment was performed according to the rules of traditional Chinese medicine and was semi-standardized. This means that the therapist was allowed to choose from a list of the following acupuncture points: GV14, Huatuojiaji C1-C7, GB20, SI11, GB21, TE15, SI14, BL17, MT10, SI3, BL64, TE5, GB41, Zero point, Jerome point, C0. The combination of acupuncture points were chosen individually, according to the patients' self-reported symptoms. In order to obtain the required information, patients had to fill out a Margolis pain diagram, and the acupuncturist questioned the patient and performed a tongue- and pulse diagnosis.
3264275|NCT01512576|Active Comparator|relaxation|For the relaxation treatment the method of guided imagery is applied. Guided imagery is a system of visualization. During guided imagery relaxation, the patient's state of consciousness is similar to one which occurs in meditative status. Patients are instructed to listen to a CD with relaxation music (Arcade TV-CD Ad Vissesr's Brainsessions, track 3). Patients will sit in an identical position like during the acupuncture treatment (i.e. on a relaxation chair) and listened to the audio CD by headphone.
3264276|NCT01512589|Experimental|Proton Beam Therapy (PBT)|"Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy (or at RBE (Relative Biologic Equivalence for PBT)) to be delivered to the periphery of the planning target volume (PTV)."
3264277|NCT01512589|Active Comparator|Intensity Modulated Radiation Therapy (IMRT)|Radiation therapy 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments. 1.8 Gy to be delivered to the periphery of the planning target volume (PTV).
3264278|NCT01512602|Active Comparator|Dialectical Behavior Therapy DBT|16 weeks DBT-treatment
3264279|NCT01512602|Active Comparator|CAMS|Collaborative Assessment and Management of Suicidality, CAMS-informed supportive psychotherapy
3264280|NCT01512615|Experimental|Intervention group|Complex Cardiac Rehabilitation
3264281|NCT01512615|Experimental|Control group|Usual care
3264282|NCT01512628|Active Comparator|PENTA group|Pentaspan is administered as a colloid.
3264283|NCT01512628|Active Comparator|voluVEN group|Voluven is administered as a colloid.
3264284|NCT01512628|Active Comparator|voluLYTE group|Volulyte is administered as a colloid.
3264285|NCT01512641|Experimental|Children with Dissociative Disorders|Children will take first the primary stage. If one child is positive, he will pass the secondary stage.
3264286|NCT01512654|Other|algorithm DIAdvisor activated|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
3264287|NCT01512654|Other|algorithm of DIAdvisor disactivated|Glucosepredictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
3264288|NCT01512680|Experimental|Type 1 diabetes patient|Type 1 diabetes patient are included in this study to have an education to Functional Insulin Therapy (intervention)
3264289|NCT01512706|Experimental|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
3264290|NCT01512706|Experimental|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
3264291|NCT01512706|Experimental|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
3264292|NCT01512706|Experimental|1280Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
3264293|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
3264294|NCT01512706|Experimental|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
3264295|NCT01512706|Experimental|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
3264296|NCT01512706|Experimental|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
3264297|NCT01512706|Experimental|1280Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
3264298|NCT01512706|Placebo Comparator|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
3264299|NCT01512706|Experimental|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
3264300|NCT01512706|Experimental|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
3264301|NCT01512706|Experimental|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
3264302|NCT01512706|Experimental|1280Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 children aged 24 months-5 years months old on day 0, 28
3264303|NCT01512706|Placebo Comparator|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
3264304|NCT01512719|Experimental|POEM procedure|Patients with achalasia that undergo POEM
3264305|NCT01512732||healthy control group|Young (20-49) and Older (50-70) healthy group (n=60)
3264306|NCT01512732||Parkinson's disease patients|(n=30).
3264307|NCT01512732||Major depressive disorder patients|(n=30).
3264308|NCT01512784|Experimental|HIV-infected adolescents and young adults|female and male HIV-infected subjects aged from 13-27 years old
3264309|NCT01512784|Active Comparator|healthy adolescents and young adults|female and male healthy adolescents and young adults aged 13-27 years
3264310|NCT01512823|Experimental|Interactive educational intervention|Two education sessions (four-hours and two-hours respectively), emailed notes and reminders
3264311|NCT01512823|Experimental|Didactic educational intervention|Education alone
3264312|NCT01512836|Experimental|Case Management|The patients who are randomized to the intervention group will be assigned to case management. The case manager is expected to integrate care from a health maintenance and promotion perspective, where the overall goal is the promote and support the patients self care (see intervention description).
3264313|NCT01512836|No Intervention|Usual Care|Patients randomized to the usual care group will receive conventional health and social services. Patients in this group will not receive support from a case manager.
3264314|NCT01512862|Experimental|Calcitriol|
3264315|NCT01512862|No Intervention|Placebo|
3264316|NCT01512875||biopsy proven H. pylori|Patient must have lived in the districts of Lima, Peru listed in the protocol.
3264317|NCT01512888|Experimental|Treatment|Participants will undergo a bone marrow harvest in the operating room to obtain bone marrow cells. Cells will be isolated and purified utilizing the CliniMacs device. These cells will undergo vector transduction with the lentiviral vector that contains a normal copy of the γc gene gene (CL20-i4-EF1α-hγc-OPT) and then the transduced cells will be reinfused back into the patient. Participants will receive a conditioning regimen of busulfan 3 days prior and 2 days prior to infusion of vector-corrected cells.intervention: CL20-i4-EF1α-hγc-OPT
3264318|NCT01512901|Experimental|1|
3264319|NCT01512901|Experimental|2|
3264320|NCT01512901|Sham Comparator|3|
3264321|NCT01512914|Placebo Comparator|CONTROL group|
3264322|NCT01512914|Experimental|PREOPERATIVE nebulization|
3264323|NCT01512914|Experimental|POSTOPERATIVE nebulization|
3264324|NCT01512914|Active Comparator|INSTILLATION group|
3264325|NCT01512927||ESRD with regular hemodialysis|
3264326|NCT01512953|No Intervention|no PPI|Patients, stratified according to the genetic stratum, will be randomized not to take any PPI on top of clopidogrel
3264327|NCT01512953|Experimental|PPI|Patients stratified to the genetic stratum will be randomized to take PPI on top of clopidogrel
3376385|NCT05160402|Experimental|Cohort 1 (SAD)|In Cohort 1, subjects will be randomized to receive a single intranasal and intraoral administration of 1 mg of IGM 6268 or placebo
3376386|NCT05160402|Experimental|Cohort 2 (SAD)|In Cohort 2, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo
3264328|NCT01512966|Experimental|VTE 2Q4 first, then VTE 2Q8|VEGF Trap-Eye [BAY86-5321; EYLEA (aflibercept) Injection] 2 mg Q4 (VTE 2Q4) administered every 4 weeks from Week 0 to Week 16, followed by every 8 weeks until Week 48 (2Q8)
3264329|NCT01512992|Experimental|Home telehealth|
3264330|NCT01512992|No Intervention|Usual care|
3264331|NCT01513005|Experimental|Laparoscopic Sleeve Gastrectomy|
3264332|NCT01513018|Active Comparator|high (10 ml/kg) tidal volumes|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
3264333|NCT01513018|Active Comparator|low tidal volume (5 ml/kg)|Evaluate the influence of low (5 ml/kg) and high (10 ml/kg) tidal volumes on arterial oxygenation and Intrapulmonary shunt during one lung ventilation.
3264334|NCT01513031|Experimental|Phone follow-up|All study participants will be receiving education and monthly telephone follow-up.
3264335|NCT01513044|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
3264336|NCT01513044|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
3264337|NCT01513057|Experimental|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
3264338|NCT01513057|Active Comparator|Cellcept|Cellcept 250 mg capsules of Roche Laboratories Inc.
3264339|NCT01513070|Experimental|Quick-Acting Heart Reliever group|Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets
3264340|NCT01513070|Active Comparator|Isosorbide Dinitrate group|Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets
3264341|NCT01513083|Experimental|Mild hepatic dysfunction|
3264342|NCT01513083|Experimental|Moderate hepatic dysfunction|
3264343|NCT01513083|Experimental|Normal hepatic function|
3264344|NCT01513096|No Intervention|Split-dose PEG|Bowel preparation using split dose PEG without prokinetics
3264345|NCT01513096|Active Comparator|Split dose PEG with prokinetics|Bowel preparation using split-dose PEG with prokinetics
3264346|NCT01513109|Experimental|Treatment arm|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic combined with Treg depletion
3264347|NCT01513135|Experimental|Group A, Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin; administered intradermally 3 times at weeks 0, 4 & 8
3264348|NCT01513135|Placebo Comparator|group B, Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin, administered intradermally 3 times at weeks 0, 4 & 8
3264349|NCT01513161|Active Comparator|TRK-820 5μg|Taking TRK-820 5μg(two 2.5μg capsules) by oral route once daily for 14 days
3264350|NCT01513161|Active Comparator|TRK-820 2.5μg|Taking TRK-820 2.5μg(one 2.5μg capsule & one placebo capsule)by oral route once daily for 14 days
3264351|NCT01513161|Placebo Comparator|Placebo|Taking Placebo(two placebo capsule) by oral route once daily for 14 days
3264352|NCT01513174|Active Comparator|Gefitinib|Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.
3264353|NCT01513174|Experimental|Gefitinib in combination with olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.
3264354|NCT01513187|Experimental|Pazopanib + interferon|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
3264355|NCT01513200|Placebo Comparator|UFH + Placebo|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with saline (placebo) administered as infusion for the last 4 hours of UFH
3264356|NCT01513200|Experimental|UFH + Bendavia|UFH (60U/kg bolus followed by 12U/kg/hr for approx.11 hours) with Bendavia (0.25mg/kg/hr) administered as infusion for the last 4 hours of UFH
3264357|NCT01513226|Experimental|Dim light|Day and nighttime dim light conditions
3264358|NCT01513252|Experimental|1|Gröber and Buschke test
3264359|NCT01513265|Active Comparator|RASP|
3264360|NCT01513265|No Intervention|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care with registration of drug use at admission and discharge without interference of RASP or clinical pharmacist.
3264361|NCT01513278|Placebo Comparator|Control arm|All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201, the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
3264362|NCT01513278|Active Comparator|APN201|APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel)
3264363|NCT01513304|Experimental|Chiropractic manual therapy|
3264364|NCT01513343|Experimental|Parent and child classes|Parent and child groups focused on self-regulation of eating
3264365|NCT01513343|No Intervention|Treatment as usual|Treatment as usual
3264366|NCT01513356|Experimental|CBKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)during 28 days
3264367|NCT01513369|Experimental|ferric carboxymaltose|Dose: according to SmPC; Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
3264368|NCT01513369|Placebo Comparator|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
3264369|NCT01513382|Experimental|Methylene Blue|The effect of methylene blue dye in detection and total excision of pilonidal sinus will be studied histopathologically.
3264370|NCT01513395|No Intervention|Immediate|"Participants randomized to the Immediate or control arm (voiding within five minutes of cervical assessment), will undergo any indicated trans-abdominal ultrasound imaging and preparations for vaginal ultrasound (including readying the probe and preparing the exam table for lithotomy position) prior to using the restroom. The participant will be instructed to proceed to the restroom to empty her bladder completely. A synchronized clock will be placed in the restroom, and the patient will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. Vaginal ultrasound and cervical assessment will then be performed immediately upon return to the ultrasound room (within a maximum of 5 minutes from voiding time)."
3264371|NCT01513395|Experimental|Interval|"Participants randomized to the Interval or experimental arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time"
3264372|NCT01513408|Experimental|CD8/Foxp3|patient suffering from non-metastatic breast cancer
3264373|NCT01513421||Active vacuum pressure drainage|
3264374|NCT01513421||Free drainage|
3264375|NCT01513434|Active Comparator|transtibial technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via tibial tunnel.
3264376|NCT01513434|Active Comparator|Transportal technique|In anterior cruciate ligament reconstruction, femoral tunnel was made via anteromedial portal.
3264377|NCT01513486|Experimental|Immobilization with NMES|Immobilization with daily NMES
3264378|NCT01513486|Placebo Comparator|Immobilization without NMES|Immobilization without daily NMES
3264379|NCT01513499|Active Comparator|Oxytocin|Intranasal oxytocin
3264380|NCT01513499|Placebo Comparator|Placebo|Intranasal placebo
3264381|NCT01513525|Experimental|Abdomen|
3264382|NCT01513525|Experimental|Thigh|
3264383|NCT01513525|Experimental|Upper arm|
3264384|NCT01513564|Experimental|Conservative treatment program|"The control group were supervised isometric passive and active exercises by a physiotherapist. On the second day patients were allowed to sit in a chair being instructed to a low intensity exercise training program with regard to back pain and fear of activity. From the third or fourth day stair training, low intensity exercise, daily walks and instruction in home training were allowed.~The intervention group received the same training program but with a faster program plus a higher intensity exercise-training program."
3264385|NCT01513577|Experimental|Minimal invasive pedicular screw|
3264386|NCT01513577|Experimental|Standard open insertion|
3264387|NCT01513603|Experimental|CLAG-M|
3264388|NCT01513616|Experimental|Pulmonary rehabilitation|A supervised 8-wk outpatient pulmonary rehabilitation program consisting of multi-modality exercise training and COPD self-management education.
3264389|NCT01513616|Sham Comparator|Usual care control|An 8-wk control period consisting of usual medical care which included optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education.
3264390|NCT01513642|Other|Incentive spirometry|
3264391|NCT01513642|No Intervention|Breath Stacking|
3264392|NCT01513655|Experimental|LTNIV group|"LTNIV group is discharged with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.~Furthermore, the patients are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
3264393|NCT01513655|No Intervention|Control group|"Patients in the control group are discharged with usual care, i.e., the golden standard of COPD treatment as described in GOLD-guidelines.~Outpatient visits are given every three months."
3264394|NCT01513668|Experimental|Acetaminophen extended release Gel tabs|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3264395|NCT01513668|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA
3264396|NCT01513681|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
3264397|NCT01513681|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
3264398|NCT01513694|Experimental|MSC seeded onto a phosphate ceramic|Instrumented posterolateral fusion and autologous mesenchymal stem cells arranged in a phosphate ceramic.
3264399|NCT01513707||Hemodialysis group|Hemodialysis group
3264400|NCT01513707||peritoneal dialysis group|peritoneal dialysis group
3264401|NCT01513720|Experimental|Lamotrigine Tablets 200 mg|Lamotrigine Tablets 200 mg of Dr. Reddy's Laboratories Limited
3264402|NCT01513720|Active Comparator|Lamictal® 200 mg Tablets|Lamictal® 200 mg Tablets of GlaxoSmithKline Inc
3264403|NCT01513733|Experimental|Tasquinimod single dose|
3264404|NCT01513733|Experimental|tasquinimod 0.25 mg followed by 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
3264405|NCT01513733|Experimental|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
3264406|NCT01513772|Placebo Comparator|Control|
3264407|NCT01513772|Active Comparator|Dexmedetomidine|
3264408|NCT01513785|Active Comparator|group R20A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R20A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 20 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
3264409|NCT01513785|Active Comparator|group R10A|All the patients were sent to a penicillin skin test before treatment except they were given penicillin before. The group R10A will receive 14 days of Amoxicillin 1g t.i.d and Rabeprazole 10 mg b.i.d. PPI was taken 30 minutes before meals while antibiotic was taken 30 minutes after meals.
3264410|NCT01513798|Experimental|Exercise under observation|Modified paleolithic diet and exercise 3 sessions/week under observation
3264411|NCT01513798|Experimental|General advice on exercise|Modified paleolithic diet and general advice on exercise
3264412|NCT01513811|Active Comparator|group PEG|This group is set as a control group and received 2 packets of Polyethylene glycol electrolyte solutions on the morning of the examination day as us we usually done.
3264413|NCT01513811|Active Comparator|group PEG+Itp|Patients in group were assigned to itopride half hour before administration of lavage solution in the morning of examination day.
3264414|NCT01513811|Active Comparator|group PEG+4Itp|Patients in this group received itopride three times 24 hours before the examination day and another time 30 min before administration of lavage solution.
3264415|NCT01513824|Active Comparator|stress management, acupressure|bio feedback guided stress management by daily measurement of pressure pain sensitivity followed by acupressure´for 3 months
3264416|NCT01513824|No Intervention|bio feedback guided, stress management|control without treatment
3264417|NCT01513850|Experimental|Hepabulin IV|
3264418|NCT01513863|Experimental|Metronidazole Topical Gel 1%|
3264419|NCT01513863|Active Comparator|Metronidazole Topical Gel 1% (Metrogel )|
3264420|NCT01513863|Placebo Comparator|Placebo|
3264421|NCT01513915|Active Comparator|A parent only group CBT|"There was a Group cognitive behavioral intervention -based on parent training component of FRIENDS program- for parents of children with anxiety disorders who were allocated to intervention group."
3264422|NCT01513915|No Intervention|Waiting list group|Parents of children with anxiety disorders who met the inclusion criteria and gave written informed consent and were allocated to wait list group.
3264423|NCT01513941|Experimental|Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV)|All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.
3264424|NCT01513954||IVF population|Long Lupron IVF Population
3264425|NCT01513954||IUI patients|Patients undergoing IUI
3264426|NCT01513980|No Intervention|Control group|Treatment as usual
3264427|NCT01513980|Experimental|Self monitoring for patients with COPD|Procedure: self-monitoring for patients with severe COPD
3264428|NCT01513980|Experimental|Nurse monitoring for patients with COPD|Procedure: nurse-monitoring for patients with severe COPD
3264429|NCT01513993|No Intervention|Control group|Treatment as usual
3264430|NCT01513993|Experimental|Telemonitoring for patients with Congestive Heart Failure|
3264431|NCT01514006||Study Cohort|Patients, aged 65 or above, undergoing elective primary unilateral hip arthroplasty in a fast-track setting.
3264432|NCT01514019|Experimental|Acebutolol|Acebutolol 200 mg capsule (Acetanol®)
3264433|NCT01514019|Placebo Comparator|Placebo|
3264434|NCT01514032|Active Comparator|Extracorporal shockwave lithotripsy|
3264435|NCT01514032|Active Comparator|Retrograde intrarenal surgery|
3264436|NCT01514058|Active Comparator|EUS-FNA First|Patients will undergo EUS-FNA first, followed by ERCP with biliary stenting (using a plastic stent).
3264437|NCT01514058|Active Comparator|ERCP with stent placement first|Patients will undergo ERCP with stent placement first, followed by EUS-FNA.
3264438|NCT01514071|Experimental|Pop-up picture|
3264439|NCT01514084||PEM group|Patients whose lacerations have been repaired by PEM trained physicians.
3264440|NCT01514084||GP group|Patients whose lacerations have been repaired by general pediatricians.
3264441|NCT01514084||PNP group|Patients whose lacerations have been repaired by PNPs.
3264442|NCT01514084||RN group|Patients whose lacerations have been repaired by suture RNs.
3264443|NCT01514097||Fractures reduced|
3264444|NCT01514097||Fractures splinted|
3264445|NCT01514110|Experimental|RAD001|
3264446|NCT01514123|Experimental|Arm A - VGX-100 alone|Dose escalation of VGX-100 monotherapy
3264447|NCT01514123|Experimental|Arm B - VGX-100 plus bevacizumab|Dose escalation of VGX-100 in combination with escalating doses of bevacizumab
3264448|NCT01514175|Experimental|ibuprofen versus ketoralac|IV ibuprofen (800 mg intravenous ibuprofen administered intravenously over 10 minutes) will be administered as a single dose prior to surgery at the initiation of anesthesia. A corresponding volume of NS will be administered to the group randomized to ketorolac, at the same time to maintain the study blind.
3264449|NCT01514188|Active Comparator|Doxorubicin|
3264450|NCT01514188|Experimental|INNO-206|
3264451|NCT01514214|Active Comparator|Winged perimeter stent|Patients who receive the Viaduct stent during ERCP
3264452|NCT01514214|Active Comparator|polyethylene stent arm|Patient who receive the traditional polyethylene stent during ERCP
3264453|NCT01514227|Experimental|Short-term DAPT (6 months) group|6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
3264454|NCT01514227|Experimental|Long-term DAPT (18 months) group|18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent
3264455|NCT01514253|Experimental|glucose 25%|1 ml of glucose once
3264456|NCT01514253|Experimental|infant formula|Materna RTF stage 1
3264457|NCT01514253|Placebo Comparator|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
3264458|NCT01514266|Experimental|Curcumin+bioprine|The study involves active arm of Curcumin+Bioprine
3264459|NCT01514266|Placebo Comparator|Placebo|
3264460|NCT01514305||Type 1 Diabetes Mellitus (TIDM)Type 2 Diabetes Mellitus (T2DM)|Adults that have been diagnosed with insulin-requiring diabetes and are on multiple daily injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) insulin therapy;
3264461|NCT01514331|Active Comparator|PSV+VG|Neonates who require mechanical ventilation and randomised to pressure support + volume guarantee (PSV+VG) mode
3264462|NCT01514331|Active Comparator|SIMV+VG|Neonates who require mechanical ventilation and randomised to synchronised intermittant mandatory ventilation + volume guarantee (SIMV+VG) mode
3264463|NCT01514344|Experimental|intralesional rituximab|
3264464|NCT01514409|Experimental|5-Hydroxytryptophan|
3264465|NCT01514409|Placebo Comparator|Placebo|
3264466|NCT01514435|Experimental|ECT verum group|Patients with treatment refractory depression treated with ECT
3264467|NCT01514487|Experimental|pH 7.7|
3264468|NCT01514487|Experimental|pH 7.9|
3264469|NCT01514487|Experimental|pH 8.15|
3264470|NCT01514500|Experimental|Single dose (SD)|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
3264471|NCT01514500|Experimental|Multiple dose (MD)|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
3264472|NCT01514526|Experimental|Dovitinib|Dovitinib (TKI-258) f 500 mg / day (5 x 100mg) once daily. The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal.
3264473|NCT01514539|Other|Four weeks Postpartum Lactating|women between 18 and 45 who delivered their first child 4 weeks prior and who were currently lactating and planning to lactate for one year postpartum.
3264474|NCT01514539|Other|Control Never Pregnant|women between 18 and 45 who have never been pregnant
3264475|NCT01514552|Placebo Comparator|Placebo gummy|Each 6 gram placebo gummy contains 79% corn syrup (Karo, ACH Food Companies, Memphis, TN), 20% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL), 1% artificial strawberry flavors (Kool-Aid Kraft Foods, East Hanover, NJ).
3264476|NCT01514552|Active Comparator|Strawberry gummy|Each 6 gram strawberry gummy contains 45% freeze-dried fruit (California Strawberry Commission), 44% corn syrup (Karo, ACH Food Companies, Memphis, TN), 11% wheat starch (Confectioners G, Tate and Lyle PLC., Decatur, IL). With this formulation, daily fruit consumption is equivalent to 1 cup of whole strawberries. All ingredients (wheat starch, freeze-dried fruit, and high fructose corn syrup) will be purchased from a single lot. When a single lot is not available then the multiple manufacturing lots will be mixed into a single lot to be used for production of fruit gummies.
3264477|NCT01514578|Experimental|TRV130A|
3264478|NCT01514578|Placebo Comparator|Dextrose in Water|
3264479|NCT01514591||Non-elective Cesarean Delivery|We will only enroll patients undergoing non-elective CS with an 'epidural top-up' for surgical anesthesia. By definition, our study will only apply to laboring women with working labor epidurals (which were provided for labor analgesia).
3264480|NCT01514604||Little or no experience.|All participants will be asked to declare their degree of experience in the technique being studied. Those declaring themselves as 'New to in-plane ultrasound guided needling. Little or no experience in technique' belong to this cohort and will form the study group.
3264481|NCT01514604||Regular practitioner. Teaching|Participants declaring themselves as 'Regularly incorporate in-plane ultrasound guided needling in clinical practice. Teaching technique to others' fall within this cohort and form the 'control' group allowing application of a realistic acceptable failure rate to Cusum analysis of the study group.
3264482|NCT01514604||Some exposure. Infrequent clinical use.|Participants declaring themselves as belonging to this group will not form part of the analysis. They will be welcome to complete training and receive feedback on their performance according to the study protocol.
3264483|NCT01514643||tibial plateau or plafond fracture|Tibial plateau or plafond fracture based on radiographs and/or CT scan will have synovial fluid aspirated from both the injured and uninjured joints in either the operating room if a procedure is planned for within 24 hours or in the emergency department. While the patient is under anesthesia in the operating room, the investigators will obtain blood samples.
3264484|NCT01514656|Active Comparator|Video Self-Instruction (VSI) kit|Individuals will learn CPR using American Heart Association's Video Self-Instruction kit. Main data points being collected at various increments over 12 months are: 1) CPR quality at 6 to 12 months 2) Comfort Level using the skills they learned
3264485|NCT01514656|Experimental|Video-only|Individuals will learn CPR skills using a Video training method. Main data points being collected at various increments over 12 months are: 1) CPR Skills at 6 to 12 months 2) Comfort Level with using CPR
3264486|NCT01514656|Active Comparator|Recruitment with Volunteers|Volunteer subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3264487|NCT01514656|Active Comparator|Recruitment with Nurses|Nurse subjects will be identified by hospital stakeholders, and they will be given surveys to assess their confidence, attitudes and beliefs towards this program at 3-month integrals.
3264488|NCT01514656|Active Comparator|Prompting to practice skills|Individuals will be prompted every two months and encouraged to practice the skills that they learned. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
3264489|NCT01514656|Active Comparator|No prompting to practice skills|Individuals will not be prompted to practice skills. Main data points being collected at various increments over 12 months are: 1) Comfort Level with using CPR 2) CPR Skills at 6 to 12 months.
3264490|NCT01514669||No treatment|No Tx, this is observational
3264491|NCT01514695|Experimental|Fentanyl|Fentanyl arm
3264492|NCT01514695|Placebo Comparator|Placebo|Placebo of identical appearance
3264493|NCT01514708|Experimental|AdimFlu-S Influenza Vaccine, 0.5mL/dose, receive 1 dose|
3264494|NCT01514721|Experimental|DuoTrav|Travoprost/Timolol Maleate BAK-Free Fixed Combination, 1 drop self-administered in treated eye(s) once a day for 12 weeks
3264495|NCT01514747||ELBW infants|
3264496|NCT01514773||ICD placement|Those subjects who have an ICD.
3264497|NCT01514773||No ICD placement|Those subjects who have not had an ICD placed.
3264498|NCT01514799|Active Comparator|standard length bp limb, long alimentary limb|our normal way of doing a gastric bypass 60 cm BP limb
3264499|NCT01514799|Experimental|Long BP limb|200 cm BP limb
3264500|NCT01514812|Experimental|YM150-placebo sequence group|YM150+digoxin; Washout; Placebo+digoxin
3264501|NCT01514812|Experimental|placebo-YM150 sequence group|Placebo+digoxin; Washout; YM150+digoxin
3264502|NCT01514825|Experimental|YM150 low dose group|
3264503|NCT01514825|Experimental|YM150 middle dose group|
3264504|NCT01514825|Experimental|YM150 high dose group|
3264505|NCT01514825|Placebo Comparator|placebo group|
3264506|NCT01514838|Experimental|1941 group|Once daily over a 24-week treatment period
3264507|NCT01514838|Active Comparator|acarbose group|Once daily over a 24-week treatment period
3264508|NCT01514851|Experimental|Arm 1|750-2250mg/day, tid (three times a day), 8 weeks
3264509|NCT01514851|Active Comparator|Arm 2|1500-4500mg/day, tid, 8 weeks
3264510|NCT01514877|Experimental|Icotinib plus Whole Brain Radiotherapy|Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.
3264511|NCT01514890||Telaprevir|
3264512|NCT01514890||Boceprevir|
3264513|NCT01514903|Active Comparator|viagra,anti-erectile dysfunction agent|
3264514|NCT01514903|Experimental|HIP0908|
3264515|NCT01514929|Experimental|Supratherapeutic Dose|20mg/kg ACHN-490 Injection
3264516|NCT01514929|Experimental|Possible Therapeutic Dose|15mg/kg ACHN-490 Injection
3264517|NCT01514929|Active Comparator|Moxifloxacin|400mg moxifloxacin
3264518|NCT01514929|Placebo Comparator|Placebo|Placebo
3264519|NCT01514942|Other|Insulin resistant patients|
3264520|NCT01514942|Other|Non-insulin resistant patients|
3264521|NCT01514968|Experimental|DNV/r+cyclosporine|
3264522|NCT01514968|Active Comparator|cyclosporine|
3264523|NCT01514968|Active Comparator|danoprevir+ritonavir|
3264524|NCT01514981|Experimental|AMG 761|
3264525|NCT01514981|Placebo Comparator|Placebo|
3264526|NCT01514994|Experimental|AngioScore's Valvuloplasty Scoring Balloon|
3264527|NCT01515007|Experimental|Ciprofloxacin dispersion for inhalation|Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin
3264528|NCT01515007|Placebo Comparator|Placebo|Liquid formulation of empty liposomes
3264529|NCT01515020|Active Comparator|vancomycin monotherapy|vancomycin monotherapy: standard therapy
3264530|NCT01515020|Experimental|daptomycin monotherapy|daptomycin monotherapy: experimental therapy
3264531|NCT01515033|Experimental|Continuous exercise training|The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
3264532|NCT01515033|Experimental|interval exercise training|The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes
3264533|NCT01515059||Bariatric sugery patients|Obese patients who are awaiting either a gastric bypass or sleeve gastrectomy
3264534|NCT01515085||biopsy proven glioma, no prior treatment|
3264535|NCT01515098|Experimental|Blueberry Group|
3264536|NCT01515098|Placebo Comparator|Placebo Group|
3264537|NCT01515098|No Intervention|Reference Group|
3264538|NCT01515111||Internal Medicine Staff|All interns, residents and attendings training (or working) at an Internal Medicine department of a Guatemalan teaching hospital.
3264539|NCT01515124|No Intervention|Lymphedema Care Only|"All 4 groups receive lymphedema care as follows:~2 custom fitted compression garments (baseline and 6 months)~evaluations for flare-ups at request (and at each measurement time point)~lymphedema treatment by a certified lymphatic therapist upon detection of a flare-up, paid for by the study. No limit was placed on number of sessions."
3264540|NCT01515124|Experimental|Exercise only|The Exercise Intervention combines 60-90 minute twice-weekly supervised weight-lifting sessions with 180 minutes of weekly aerobic exercise. Women will be trained by certified fitness professionals in both the weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions. All exercise participants will be provided with 'Power Blocks' which are adjustable dumbbells with which they can increase resistance in 1-2 pound increments from 1-21 pounds. All weight training will be done in their homes except for the first 6 weekly session and monthly check-in sessions. Exercise only group members also received the Lymphedema care intervention described above.
3264541|NCT01515124|Experimental|Weight loss only|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem®, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day. Participants will be guided to stay at the same number of calories per day until reaching goal weight, followed by a gradual increase in caloric intake (of approximately 500 calories/d) to maintain their weight throughout the remainder of the intervention. The treatment groups will be led by registered dietitians and will receive ongoing supervision via telephone and email contact. Weight loss only group members also received the Lymphedema care intervention described above.
3264542|NCT01515124|Experimental|Exercise and Weight loss combined|Participants in this group will receive a combination of the supervised twice-weekly weight training sessions and the weight loss program. Combined group members also received the Lymphedema care intervention described above.
3264543|NCT01515137|Experimental|Arm A erlotinib plus sulindac|erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A),
3264544|NCT01515137|Experimental|Arm B erlotinib|erlotinib (150 mg PO QD) (Arm B)
3264545|NCT01515137|Experimental|Arm C|placebo (for Erlotinib) QD (Arm C).
3264546|NCT01515150||Out-patients in diverticulitis|All patient with acute uncomplicated diverticulitis how accept participation in the study will be enrolled in the study.
3264547|NCT01515163|Experimental|Exercise|3-month exercise training program
3264548|NCT01515163|No Intervention|Control|Control group
3264549|NCT01515163|Experimental|Healthy control|
3264550|NCT01515202|Experimental|Panel 1: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3264551|NCT01515202|Experimental|Panel 2: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3264552|NCT01515202|Experimental|Panel 3: BMS-823778 or Placebo matching BMS-823778|Healthy Subjects
3264553|NCT01515202|Experimental|Panel 4: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
3264554|NCT01515202|Experimental|Panel 5: BMS-823778 or Placebo matching BMS-823778|Subjects with T2DM
3264555|NCT01515215|Active Comparator|High-frequency Left rTMS|"Intensity: rTMS treatment intensity determined by using resting motor threshold (RMT). Treatment will be delivered at 120% of the RMT.~Site of Stimulation: left hemisphere of DLPFC.~Frequency: 10 Hz.~Duration: 42 Trains, 5 second duration, 25 second inter-train interval."
3264556|NCT01515215|Active Comparator|Bilateral rTMS|"Intensity: rTMS treatment intensity determined by the RMT. Treatment will be delivered at 120% of the RMT.~Sites of Stimulation: right and left hemispheres of the DLPFC.~Frequency: 1 Hz over the right DLPFC followed by 10 Hz over the left DLPFC.~Duration: right: 1 Train of 600 pulses; left: 30 Trains, 5 second duration, 25 second inter-train interval."
3264557|NCT01515215|Sham Comparator|Sham rTMS|Sham rTMS Treatment is applied as either Bilateral rTMS or HFL-rTMS (randomly assigned), but with the coil angled 90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
3264558|NCT01515228|Active Comparator|Xience Prime stent|everolimus eluting stent
3264559|NCT01515228|Experimental|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent
3264560|NCT01515241|Other|Open label single arm study of CER-001|Open label single arm study of CER-001
3264561|NCT01515254|No Intervention|No intervention- control group|Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken. The control group subjects will have the opportunity to receive the intervention at the end of the study
3264562|NCT01515254|Experimental|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
3264563|NCT01515280||Chronic cough|Patients taking part in supplementary study must be randomised to main study which includes a placebo arm and treatment arm
3264564|NCT01515293|Experimental|Single Incision Laparoscopic Appendectomy|
3264565|NCT01515293|Experimental|Conventional appendectomy|Conventional appendectomy
3264566|NCT01515358|Placebo Comparator|Placebo|Single dose of placebo administered orally in 1 out of 3 study periods separated by at least a 7-day wash-out period between each dose.
3264567|NCT01515358|Experimental|LY3000328|Single escalating dose of up to 300 mg/kg of LY3000328 administered orally in 2 out of 3 study periods separated by at least a 7 day wash-out period between each dose.
3264568|NCT01515371|Experimental|IncobotulinumtoxinA (Xeomin) 2.5 Units [U], 5U and 7.4U|"IncobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection."
3264569|NCT01515371|Placebo Comparator|Placebo Comparator|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.
3264570|NCT01515384|Experimental|Type 1 Diabetes|
3264571|NCT01515384|Experimental|Type 2 Diabetes|
3264572|NCT01515384|Experimental|Healthy Controls|
3264573|NCT01515397|Experimental|balanced gelatine solution|isotonic colloidal volume substitute
3264574|NCT01515397|Active Comparator|non-balanced gelatine solution|colloidal volume substitute
3264575|NCT01515436|Active Comparator|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
3264576|NCT01515436|Active Comparator|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
3264577|NCT01515462|Experimental|OTL-103 gene therapy|Eligible subjects will receive intravenous (IV) infusion of OTL-103 gene therapy. Subjects affected by WAS who don't have a suitable matched donor for allogenic hematopoietic stem cell transplantation will be included
3264578|NCT01515501|Other|Endoscopic mucosal resection|At time of rectal section biopsy all subjects will under go the additional intervention of an endoscopic muscosal resection.
3264579|NCT01515553|Experimental|Formulation 4|
3264580|NCT01515553|Experimental|Final formulation 4|
3264581|NCT01515579|Experimental|Formulation 3|
3264582|NCT01515579|Experimental|Formulation 4|
3264583|NCT01515592|Experimental|15 mcg/kg|
3264584|NCT01515592|Experimental|20 mcg/kg|
3264585|NCT01515592|Experimental|25 mcg/kg|
3264586|NCT01515631||Study|Patients with alagille syndrome
3264587|NCT01515644|Experimental|Intervention group I|Intervention group I: Powder based Infant formula with Inulin I
3264588|NCT01515644|Experimental|Intervention group II|Intervention group II: Powder based Infant formula with Inulin II
3264589|NCT01515644|Placebo Comparator|Intervention group III|Intervention group III: Powder based Infant formula without Inulin
3264590|NCT01515670||Fast-track THA/TKA|Any patient receiving THA/TKA in the participating wards
3264591|NCT01515683|Experimental|An anaesthetic nurse|
3264592|NCT01515683|Active Comparator|Theatre nurse + An anaesthetic nurse|Support from theatre nurse and an anaesthetic nurse
3264593|NCT01515683|Experimental|A nurse from ward + an anaesthesic nurse|Support from a nurse from the ward and an anaesthetic nurse
3264594|NCT01515683|Experimental|Optional relative + an anaesthetic nurse|Support from an optional relative and an anaesthetic nurse
3264595|NCT01515709||Chronic Obstructive Pulmonary Disease|Patients with a diagnosis of COPD
3264596|NCT01515722|Experimental|Health education intervention (HEI)|
3264597|NCT01515722|No Intervention|No intervention|
3264598|NCT01515735||pseudoexfoliation|The study group composted of the patients with pseudoexfoliation syndrome
3264599|NCT01515761|Active Comparator|Postero-lateral|Left ventricular lateral wall lead position
3264600|NCT01515761|Active Comparator|Antero-lateral|Left ventricular lateral wall lead position
3264601|NCT01515774|Active Comparator|Group 1|Give QD dose first then BID dosing
3264602|NCT01515774|Active Comparator|Group 2|Give BID dosing and then QD dosing
3264603|NCT01515787|Experimental|Group 1|"Patients will receive FOLFOX chemotherapy once every two weeks for 6 cycles total over a period of 12 weeks. After completing FOLFOX chemotherapy, the patient will have an MRI scan or endorectal ultrasound (ERUS) to examine the tumor. If the tumor has not decreased in size by at least 20%, the patient will receive 5FUCMT (radiation with chemotherapy). If the tumor has decreased in size by 20%, then the patient will proceed directly to surgery.~If all borders of the tumor are normal post surgery, then the patient receives six additional cycles of FOLFOX chemotherapy. If all borders of the tumor are not normal then the patient receives chemoradiation therapy for 5.5 weeks after surgery. After chemoradiation, additional cycles of FOLFOX or similar chemotherapy will be recommended for 4 cycles or 8 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization."
3264604|NCT01515787|Active Comparator|Group 2|Patients receive 5FUCMT including chemotherapy and radiation therapy for 5.5 weeks. Patients will be given either 5-fluorouracil or capecitabine and radiation therapy. After the chemoradiation therapy is completed, patients will proceed directly to surgery. Post-surgery, patients will receive FOLFOX chemotherapy once every two weeks for 8 cycles total over a period of 16 weeks. Patient observation with follow up evaluations and event monitoring will occur up to 8 years post randomization.
3264605|NCT01515800|Experimental|Text message reminder|Patients undergo a text message education checklist involving confirmation of cellular telephone capability to receive text messages, how to retrieve and read messages, including a confirmation evaluation, at baseline and at any time a patient obtains a new cellular telephone. Patients then receive a text message twice a week at 8 o'clock in the morning (for each time zone) for up to 3 years. Additionally, patients receive standard follow-up care.
3264606|NCT01515800|No Intervention|No text message reminder|Patients receive standard follow-up care.
3264607|NCT01515813|Experimental|Arm A: Pravastatin sodium alone for 24 weeks|One 40 mg tablet of Pravastatin sodium taken orally once daily for 24 weeks starting at week 0 and ending at week 24.
3264608|NCT01515813|Experimental|Arm B: EFV/FTC/TDF plus Pravastatin sodium at week 13|EFV/FTC/TDF once daily for 24 weeks starting at week 0 and ending at week 24 plus pravastatin sodium (80 mg)once daily for 12 weeks starting at week 13 ending at week 24.
3264609|NCT01515813|Experimental|Arm C: Pravastatin sodium + EFV/FTC/TDF for 24 weeks|Participants will be administered Pravastatin sodium once daily for 24 weeks starting at week 0 and ending at week 24 plus EFV/FTC/TDF once daily for 24 weeks starting week 0 and ending at week 24.
3264610|NCT01515826|Experimental|VIGADEXA Gel|VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
3264611|NCT01515826|Active Comparator|VIGADEXA Solution|VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
3264612|NCT01515839|Experimental|Supplement intervention|Dietary Supplement: Multivitamin, Omega 3 Supplement, Brain and Memory Formula
3264613|NCT01515852|Other|Stress level after general anesthesia|
3264614|NCT01515852|Other|Stress level after local anesthesia|
3264615|NCT01515878|Experimental|Dialysis with BVT|Dialysis using the BVT monitor biofeedback called Hemocontrol
3264616|NCT01515878|No Intervention|Conventional dialysis|Conventional dialysis without blood volume tracking or similar therapies
3264617|NCT01515904||Control|Approximately 50% of attendees choose not to book into the STOMP program, for reasons including difficulty attending the frequent appointments due to distance or inability to leave work early. This population will serve as the control group for the evaluation. Control participants will be recruited from the community through posters in the hospital
3264618|NCT01515904||STOMP|12-17 yrs. Patients in the program have severe complex obesity defined as children and youth who have a BMI >95th %ile for their age and gender in addition to one of the following: at least one significant obesity-related co-morbidity requiring specialty care (e.g. type 2 diabetes), other co-existing chronic illness impacted by obesity (e.g. CNS tumor, post-organ transplant), or a BMI ≥99th percentile for their age and gender
3264619|NCT01515917|Experimental|Citicoline and Omega-3|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of citicoline and omega-3 fatty acid, of which they will be instructed to take 1000 mg and 2000 mg daily, respectively. This will be done in a double-blind, randomized fashion.
3264620|NCT01515917|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
3264621|NCT01515930|Active Comparator|Active Caregiver and Active Child|Parent & Child Computer-Delivered Motivational Intervention will be delivered to participants. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered behavior change counseling intervention for children with diabetes to improve completion of daily diabetes care.
3264622|NCT01515930|Experimental|Active Caregiver and Child Education|Parent Computer-Delivered Motivational Intervention will be delivered to the parents only. A brief computer delivered behavior change counseling intervention for parents of children with diabetes to improve monitoring of diabetes care and a brief computer delivered informational session about diabetes related topics for their child with diabetes.
3264623|NCT01515930|Active Comparator|Education Caregiver/Education Child|Participants will receive computer-delivered information. A brief computer delivered information session about diabetes related topics for both the caregiver and the child with diabetes.
3376387|NCT05160402|Experimental|Cohort 3 (SAD)|In Cohort 3, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo
3264624|NCT01515969|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive erlotinib hydrochloride PO QD. Starting on day 15, patients also receive dovitinib lactate PO QD on days 1-5 of each week. Treatment continues in the absence of disease progression or unacceptable toxicity.
3264625|NCT01515982|Experimental|Aerobic exercise|The training exercise intensity is established at 60% of VO2máx. Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
3264626|NCT01515982|No Intervention|Control group|All participants were asked not to commence any new exercise regimen.
3264627|NCT01516021|Experimental|high fat yoghurt intake|500 ml of a high fat yoghurt
3264628|NCT01516021|Experimental|low fat yoghurt intake|
3264629|NCT01516047|Experimental|Cohort 1|Patients with severe hepatic impairment.
3264630|NCT01516047|Experimental|Cohort 2|Healthy individuals with normal hepatic function.
3264631|NCT01516060|Experimental|Reduced dose Efavirenz arm|Patient's on main study that was randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
3264632|NCT01516060|Active Comparator|Normal Efavirenz dose arm|Patient's on main study randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
3264633|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
3264634|NCT01516073|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
3264635|NCT01516073|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
3264636|NCT01516073|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
3264637|NCT01516073|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
3264638|NCT01516073|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution 2mL
3264639|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 1|FP BID (twice daily)
3264640|NCT01516086|Experimental|Fluticasone propionate (FP) - arm 2|FP BID
3264641|NCT01516086|Experimental|Fluticasone Propionate (FP) - arm 3|FP BID
3264642|NCT01516086|Experimental|FLuticasone Propionate (FP) - Arm 4|FP BID
3264643|NCT01516086|Experimental|Fluticasone Propionate (FP) - Arm 5|FP BID
3264644|NCT01516086|Placebo Comparator|Placebo - Arm 6|Placebo inhalation solution
3264645|NCT01516099|Experimental|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
3264646|NCT01516099|Experimental|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor. The investigators aim for a brief coaching period of 10 weeks with the objective that the people continue their active lifestyle afterwards.
3264647|NCT01516125||Screening only - no intervention|
3264648|NCT01516138|Active Comparator|GIK|glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).
3264649|NCT01516138|Placebo Comparator|Control|6.12 g/L sodium acetate, 5.85 g/L sodium chloride, 0.3 g/L potassium chloride and 0.33 g/L calcium chloride
3264650|NCT01516151|Active Comparator|Group A|0.5g total CaPre™ from baseline to week 4 and 1.0g total CaPre™ from week 4 to week 8
3264651|NCT01516151|Active Comparator|Group B|1.0g total CaPre™ from baseline to week 4 and 2.0g total CaPre™ from week 4 to week
3264652|NCT01516151|Active Comparator|Group C|2.0g total CaPre™ from baseline to week 4 and 4.0g total CaPre™ from week 4 to week 8
3264653|NCT01516151|Other|Group D|Standard of care
3264654|NCT01516151|Active Comparator|Group E|4.0g total CaPre™ from baseline to week 8
3264655|NCT01516164|Active Comparator|MacIntosh|
3264656|NCT01516164|Active Comparator|McGrath MAC direct|
3264657|NCT01516164|Active Comparator|McGrath MAC indirect|
3264658|NCT01516177||Renal Transplant Recipients|Subjects who received a kidney transplant within the past 1 to 5 years
3264659|NCT01516190|Active Comparator|Exercise Group|Supervised exercise sessions and independent exercise
3264660|NCT01516190|Active Comparator|Mind-Body Group|Surgical preparation program
3264661|NCT01516203|Experimental|Arm 1|AZD5847 500 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3264662|NCT01516203|Experimental|Arm 2|AZD5847 500 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3264663|NCT01516203|Experimental|Arm 3|AZD5847 1200 mg orally once daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3264664|NCT01516203|Experimental|Arm 4|AZD5847 800 mg orally twice daily given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3264665|NCT01516203|Active Comparator|Arm 5|Rifafour e-275 mg tablets given to 15 male and female subjects aged 18 to 65 years with newly diagnosed sputum smear positive pulmonary tuberculosis
3264666|NCT01516216|Active Comparator|Standard Dose Vitamin D|Standard Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
3264667|NCT01516216|Active Comparator|Higher Dose Vitamin D|Higher Dose Vitamin D with Bevacizumab and FOLFOX. FOLFOX contains: 5-FU (5-fluorouracil), Leucovorin and Oxaliplatin (Eloxatin).
3264668|NCT01516229||Somatropin|
3264669|NCT01516242||NovoPen® 4|
3264670|NCT01516255|Experimental|Double-blind / liraglutide|
3264671|NCT01516255|Placebo Comparator|Double-blind / placebo|
3264672|NCT01516255|Active Comparator|Open-label / moxifloxacin|
3264673|NCT01516255|Placebo Comparator|Open-label / placebo|
3264674|NCT01516281||mTBI|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI+ subjects are randomly selected for clinical assessment and DaTscan.
3264675|NCT01516281||mTBI-|Historical cohort of subjects seen in the emergency rooms of NorthShore University HealthSystem with ICD-9 diagnoses of disorders other than mild or moderate traumatic brain injury during the years 2006-2011 (7,122 subjects). 100 mTBI- subjects are randomly selected for clinical assessment and DaTscan.
3264676|NCT01516294|Experimental|Iray plus Lucentis|open label arm in which all subjects recieve a single 16 gy dose of radiation plus an injection of Lucentis.
3264677|NCT01516307|Experimental|OPT-822/OPT-821 (30 μg/100 μg) and Cyclophosphamide|Patients will be randomized 2:1 to receive OPT-822/OPT-821(30 μg/100 μg) plus Cyclophosphamide IV (300mg/m2).
3264678|NCT01516307|Placebo Comparator|Phosphate Buffer Saline (PBS) and Cyclophosphamide|Patients will receive Phosphate Buffer Saline (PBS) plus Cyclophosphamide IV (300mg/m2).
3264679|NCT01516320|Experimental|Gastric Bypass (GBP) Subjects|Subjects enrolled in the study who are receiving Roux-en-Y Gastric Bypass surgical technique for treatment of their obesity.
3264680|NCT01516320|Active Comparator|Laparoscopic adjustable gastric banding (LAGB) Subjects|Subjects enrolled in the study who are receiving laparoscopic adjustable gastric banding surgical technique for treatment of their obesity.
3264681|NCT01516320|Active Comparator|Vertical Sleeve Gastrectomy (VSG) Subjects|Subjects enrolled in the study who are receiving vertical sleeve gastrectomy surgical technique for treatment of their obesity.
3264682|NCT01516333|Experimental|Diet 1|High GI; High Carb; High GL
3264683|NCT01516333|Experimental|Diet 2|High GI, Low Carb, Med GL
3264684|NCT01516333|Experimental|Diet 3|Low GI, High Carb, Med GL
3264685|NCT01516333|Experimental|Diet 4|Low GI, Low Carb, Low GL
3264686|NCT01516346|Active Comparator|Isosorbide dinitrate|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain placebo capsules.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3264687|NCT01516346|Active Comparator|Isosorbide dinitrate + Hydralazine|"Research pharmacy-formulated capsules will be given to the subjects in two bottles. For this interventional arm, one of the bottles will contain the active ingredient Isosorbide Dinitrate and the other will contain the active ingredient Hydralazine.~Dosage of Isosorbide Dinitrate will be 20mg (if Stage 1) OR 40mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks.~Dosage of Hydralazine will be 37.5mg (if Stage 1) OR 75mg (if Stage 2). All the subjects will be uptitrated to Stage 2 dosing, if they tolerate Stage 1 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3264688|NCT01516346|Placebo Comparator|Placebo|"Research pharmacy-formulated capsules will be given to subjects in two bottles. For this interventional arm, both the bottles will contain placebo capsules.~Dosage will be same regardless of up-titration from Stage 1 dosing to Stage 2 dosing. Frequency is three times daily, to be taken at 8 AM, 2 PM and 8 PM. Duration is for 24 weeks."
3264689|NCT01516359||patients with cardiac surgery|
3264690|NCT01516372|Experimental|Treatment 1|Healthy Volunteers will receive Treatments ABDC
3264691|NCT01516372|Experimental|Treatment 2|Healthy Volunteers will receive Treatments BCAD
3264692|NCT01516372|Experimental|Treatment 3|Healthy Volunteers will receive Treatments CDBA
3264693|NCT01516372|Experimental|Treatment 4|Healthy Volunteers will receive Treatments DACB
3264694|NCT01516385||spinal cord injury|
3264695|NCT01516385||other neurological conditions|
3264696|NCT01516398||Preterm infants|No interventions were performed. Group consisted of preterm infants enrolled in the study.
3264697|NCT01516398||Term control infants|No interventions were performed. Group consisted of term infants enrolled in the study to serve as controls for the preterm infant group.
3264698|NCT01516411|Active Comparator|Cognitive app|Cognitive app promotes behavior change via goal setting, feedback, and problem solving
3264699|NCT01516411|Active Comparator|Social app|Social app promotes behavior change via social relationships and feedback
3264700|NCT01516411|Active Comparator|Affect app|Affect app promotes behavior change via game-like elements including the use of a bird avatar as a visual representation of one's activities and operant conditioning
3264701|NCT01516411|Active Comparator|Nutrition app|Nutrition app promotes behavior change bvia tracking of food consumption
3264702|NCT01516450|Active Comparator|GSK1550188 200mg for SC|Single SC dose of belimumab 200mg
3264703|NCT01516450|Active Comparator|GSK1550188 200mg for IV|Single IV dose of belimumab 200 mg
3264704|NCT01516463|Active Comparator|Collagenase Santyl|
3264705|NCT01516463|Sham Comparator|Bacitracin|
3264706|NCT01516476|Experimental|Liraglutide Arm|
3264707|NCT01516476|Placebo Comparator|Placebo Arm|
3264708|NCT01516476|Experimental|RO6807952 Arm 1|
3264709|NCT01516476|Experimental|RO6807952 Arm 2|
3264710|NCT01516489|No Intervention|Stage 1 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
3264711|NCT01516489|Experimental|$5 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
3264712|NCT01516489|Experimental|$10 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $10 at PVAMC.
3264713|NCT01516489|Experimental|$20 Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $20 at PVAMC.
3264714|NCT01516489|Experimental|$5 Voucher-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be mailed a voucher that can be exchanged for $5 at PVAMC.
3264715|NCT01516489|Experimental|$50 Lottery-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will have a 1 in 10 chance of being mailed a voucher that can be exchanged for $50 at PVAMC.
3264716|NCT01516489|Experimental|$500 Raffle-Based Incentive|In the FOBT kit, individuals will receive a card that states that if they complete and return their FOBT kit within 30 days, they will be entered into a raffle in which 1 randomly chosen patient (out of about 100 patients) will be mailed a check in the amount of $500.
3264717|NCT01516489|No Intervention|Stage 2 Control Group|In the FOBT kit, individuals will receive a card that asks them to complete and return their FOBT kit within 30 days.
3264718|NCT01516502|Active Comparator|laser to acupoint|
3264719|NCT01516502|Sham Comparator|sham laser to acupoint|
3264720|NCT01516502|Active Comparator|laser to trigger point|
3264721|NCT01516502|Sham Comparator|sham laser to trigger point|
3264722|NCT01516515|Placebo Comparator|placebo, gel|placebo comparator
3264723|NCT01516515|Active Comparator|SR-T100 with 2.3% of SM, gel|2.3% of SM in Solanum undatum plant extract
3264724|NCT01516528||All|All subjects enrolled in the study
3264725|NCT01516541|Experimental|Dalcetrapib|Dalcetrapib 600 mg orally daily on a background of contemporary, guidelines-based medical care.
3264726|NCT01516541|Placebo Comparator|Placebo|Placebo orally daily, on a background of contemporary, guidelines-based medical care.
3264727|NCT01516554|Experimental|Testosterone undecanoate|
3264728|NCT01516554|Placebo Comparator|Sugar pill|
3264729|NCT01516567|Experimental|DA-EPOCH-R|6 courses of Dose Adjusted-EPOCH-Rituximab
3264730|NCT01516580|Active Comparator|LMB chemo|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m²~in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
3264731|NCT01516580|Experimental|LMB chemo + Rituximab|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
3264732|NCT01516593|Experimental|intensive short term immuno-chemotherapy|Experimental treatment consists of an induction phase followed by a consolidation or intensified phase according to tumor response.
3264733|NCT01516606|Experimental|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
3264734|NCT01516619|Experimental|romiplostim|
3264735|NCT01516645|Experimental|KHK2898|
3264736|NCT01516658|Experimental|Hydrogel coil group|use Hydrogel Coil as much as be able to use
3264737|NCT01516658|Active Comparator|Bare platinum coil group|use only bare platinum coil
3264738|NCT01516697|Other|Control|The patients in Group A will serve as controls and will receive standard monitoring in addition to continuous measurement of SV and CO. The physicians will not know the CO and SV and will manage the patients in a standard fashion.
3264739|NCT01516697|Experimental|experimental|The patients in Group B will receive the same monitoring as those in Group A. But the physicians will know instantaneously the CO and SV in real time and will manage the patients accordingly.
3264740|NCT01516710|Active Comparator|Open liver resection|Patients will be operated with open liver resection
3264741|NCT01516710|Active Comparator|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
3264742|NCT01516723|Experimental|Hybrid sirolimus-eluting stents|ORSIRO, Biotronik Inc.
3264743|NCT01516723|Active Comparator|Everolimus-eluting stents|XIENCE PRIME, Abbott
3264744|NCT01516775|Experimental|1 hour fluid fasting|allowed to drink until 1 hour before scheduled anaesthesia induction
3264745|NCT01516775|Active Comparator|2 hours fluid fasting|allowed to drink until 2 hour before scheduled anaesthesia induction
3264746|NCT01516788|Experimental|Phototesting|
3264747|NCT01516801|Experimental|PSA flyer|
3264748|NCT01516801|No Intervention|Control|
3264749|NCT01516814|Experimental|Arm 1|
3264750|NCT01516814|Active Comparator|Arm 2|
3264751|NCT01516814|Active Comparator|Arm 3|
3264752|NCT01516827|Experimental|TF-CBT|"12 Sessions Trauma-focused Cognitive Behavioral Therapy including the child/adolescents and a non-abusive caregiver according to the treatment manual:~Cohen JA, Mannarino AP, and Deblinger E (2006) Treating Trauma and Traumatic Grief in Children and Adolenscents. Guilford, N.Y."
3264753|NCT01516827|No Intervention|Wait-list|Patients in the control condition will be assigned to a wait-list (duration 4 months). During waiting time, clinical services will be provided as needed (excluding TF-CBT).
3264754|NCT01516840|Experimental|Arm 1|
3264755|NCT01516840|Experimental|Arm 2|
3264756|NCT01516840|Active Comparator|Arm 3|
3264757|NCT01516840|Active Comparator|Arm 4|
3264758|NCT01516853||Patient Group|Subjects with known or suspected iron overload will undergo serum iron measurements and a non-contrast MRI scan.
3264759|NCT01516853||Control Group|Subjects with no known history of iron overload or liver disease will undergo a serum iron measurement and a non-contrast MRI scan.
3264760|NCT01516866||Cohort A: Microtubule directed chemotherapy treatment|Subjects receiving antimicrotubule chemotherapy-based treatment will have NaF PET/CT scans at baseline and again after 8 weeks of starting treatment. A subset of subjects will have a second NaF PET/CT scan at baseline 1-8 days after the first baseline scan.
3264761|NCT01516866||Cohort B: AR-directed therapy|Subjects receiving AR-directed therapy will undergo a baseline NaF PET/CT scan at baseline and again after having been on treatment for 6 weeks and again at 12 weeks. A subset of subjects will also undergo a second baseline NaF PET/CT scan 1-8 days after the first baseline scan.
3264762|NCT01516905||I124-NM404 brain metastases or GBM imaging|determining appropriate imaging timepoints. Image at 6 hour, 24 hour and 48 hour post injection of I-124NM404
3264763|NCT01516918|Experimental|Quadruple Regimen|All subjects will receive active study drugs (quadruple regimen: VX-222, telaprevir,Peg-IFN, and RBV) for a fixed treatment duration of 24 weeks.
3376388|NCT05160402|Experimental|Cohort 4 (MAD)|In Cohort 4, subjects will be randomized to receive a single intranasal and intraoral administration of 3.75 mg of IGM 6268 or placebo once a day for 5 days.
3376389|NCT05160402|Experimental|Cohort 5 (MAD)|In Cohort 5, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo once a day for 5 days.
3264764|NCT01516931|Experimental|active rTMS and venlafaxine|"rTMS：Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months.~venlafaxine：150-225mg/day"
3264765|NCT01516931|Placebo Comparator|sham rTMS and venlafaxine|Sham stimulation will be given at the same site and frequency, using a Magstim sham-coil system. During rTMS, participants will be instructed to keep their eyes open and relax.
3264766|NCT01516931|Placebo Comparator|venlafaxine alone|responders will be maintained on the same effective dose of venlafaxine for the entire duration of the RCT, unless they relapse and will have to exit the protocol and enter a naturalistic follow-up
3264767|NCT01516944|Active Comparator|postoperative chemotherapy,SOX|
3264768|NCT01516944|Experimental|Perioperative chemotherapy,SOX|
3264769|NCT01516944|Experimental|Perioperative chemotherapy,XELOX|
3264770|NCT01516983|Experimental|Icotinib+WBRT|"Standard whole brain radiotherapy plus icotinib, which is designed to administered at 5 dose according to 3+3 until disease progression or intolerable toxicity."
3264771|NCT01516996|Active Comparator|Neoadjuvant and CCRT|
3264772|NCT01516996|Experimental|Neoadjuvant and CCRT and Nimotuzumab|
3264773|NCT01517022|No Intervention|Control arm|Control arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along with routine DOTS treatment
3264774|NCT01517022|Active Comparator|Intervention arm|Cessation arm patients will receive pre designed pamphlets and structured conselling for smoking cessation by trained counsellors along and nicotine replacement therapy(NRT) and routine DOTS treatment
3264775|NCT01517035|Experimental|1|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
3264776|NCT01517087||1|neurologically normal, healthy adults, age 35 or older.
3264777|NCT01517139||Feasibility Cohort|100 pairs of children and their mothers recruited from 2 provinces.
3264778|NCT01517165|Experimental|Group 1|
3264779|NCT01517165|Placebo Comparator|Group 2|
3264780|NCT01517191||Influenza Positive Case|Influenza cases are hospitalized adults who have tested positive for influenza.
3264781|NCT01517191||Influenza Negative Control|Control Controls are hospitalized adults who have tested negative for influenza.
3264782|NCT01517204|Experimental|Direct laryngoscope|Direct laryngoscope was used to facilitate the intubation of left-sided double lumen endobronchial tube.
3264783|NCT01517204|Experimental|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate left-sided double lumen endobronchial tube intubation.
3264784|NCT01517217|Other|No girdle postoperative|patients undergoing major abdominal surgery will get NO individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
3264785|NCT01517217|Other|Girdle postoperative|patients undergoing major abdominal surgery will get an individualized girdle. Functional outcomes as pulmonary function and pain are measured daily. Participants will be followed for the duration of 5 days or the duration of hospital stay, if shorter than 5 days.
3264786|NCT01517230|Active Comparator|intervention|seven clusters where radio media campaign will be broadcast.
3264787|NCT01517230|No Intervention|control|Seven clusters where radio media campaign won't be broadcast.
3264788|NCT01517243|Experimental|Alternating Sunitinib and Temsirolimus|"A cycle is defined as:~Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest"
3264789|NCT01517256|Experimental|Early Intervention Group|
3264790|NCT01517256|Placebo Comparator|Delayed Intervention Group|Initially wait-listed and served as control group. But later participants underwent the experimental intervention.
3264791|NCT01517269|Experimental|Education with simulator|Parent randomized to this group will be taught diabetes management with vignette and simulator
3264792|NCT01517269|Active Comparator|Control arm: standard diabetes education|Parents will receive standard diabetes education with a diabetes educator
3264793|NCT01517308|Active Comparator|Control Arm 24 weeks|PEG-IFN α2a 180 μg/week+ ribavirin 800 mg/die for 24 weeks
3264794|NCT01517308|Experimental|Active arm (48 weeks)|PEG-IFN α2a 180 μg/week + ribavirin 800 mg/die per 48 weeks
3264795|NCT01517321|Experimental|E|
3264796|NCT01517321|Placebo Comparator|P|
3264797|NCT01517334|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
3264798|NCT01517334|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
3264799|NCT01517347|Experimental|Interleukin-2|Interleukin-2 post-transplantation to prevent relapse of standard risk leukemia
3264800|NCT01517347|No Intervention|controlled group|controlled standard risk leukemia received regular transplantation without IL-2 intervention
3264801|NCT01517360|Active Comparator|Placebo+Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to placebo. Each training session will last for about 90 minutes (1 hour training and 30 minutes between placebo administration and start of training).
3264802|NCT01517360|Experimental|Oxytocin+Social Cognitive Skill Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. The treatment groups will include individuals who are assigned to oxytocin. Each training session will last 90 minutes (1 hour training and 30 minutes between oxytocin administration and start of training).
3264803|NCT01517386||paravertebral anesthesia|patients scheduled for elective unilateral thoracic surgery under paravertebral block and general anesthesia
3264804|NCT01517399|Other|Test drug administration|All drugs except vitamin K will be administered as a single dose once by itself as a reference treatment and once with tivantinib
3264805|NCT01517425||Cases|Subjects previously enrolled in the Scripps Genebank Study
3264806|NCT01517425||Controls|Subjects previously enrolled in the Scripps Healthy Elderly Active Longevity (HEAL) Cohort
3264807|NCT01517451|Experimental|Radiation with Androgen Deprivation Therapy (ADT)|This will be a Phase I/II study evaluating the effectiveness and toxicity of a combined regimen of 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions) with androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT (stereotactic body radiation therapy). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens.
3264808|NCT01517464|Experimental|SGT-94|Dose escalation of experimental therapeutic SGT-94 to assess safety
3264809|NCT01517477|Experimental|First Arm: One iStent|Device: One iStent
3264810|NCT01517477|Experimental|Second Arm: Two iStents|Device: Two iStent devices
3264811|NCT01517477|Experimental|Third Arm: Three iStents|Device: Three iStent devices
3264812|NCT01517490||Type 1 Insulin Pump|Patients with type 1 diabetes starting insulin pump treatment
3264813|NCT01517490||Type 1 conventional therapy|Patients with type 1 diabetes continuing treatment with multiple daily insulin injections.
3264814|NCT01517490||Type 2 Bariatric surgery|Patients with type 2 diabetes who are enrolled in pre-operative weight loss protocol prior to bariatric surgery.
3264815|NCT01517490||Type 2 conventional|Severely obese patients with type 2 diabetes who are to continue with non-surgical treatments of diabetes and obesity and with no planned bariatric surgery.
3264816|NCT01517490||Type 1 insulin pumpe follow-up|Patients with type 1 diabetes previously followed in an observational study with electrophysiological and psychophysical measures of retinal function.
3264817|NCT01517490||Healthy|Healthy volunteers.
3264818|NCT01517503|Experimental|Cognitive Therapy (CT)|Cognitive Therapy (CT)
3264819|NCT01517503|Experimental|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT)
3264820|NCT01517516||Functional Pain Conditions and Inflammatory bowel disease|Cyclical Vomiting Syndrome, Irritable Bowel Syndrome, Inflammatory Bowel disease (Ulcerative colitis and Crohns)and Vulvodynia (vestibulodynia)
3264821|NCT01517516||Inflammatory Bowel Disease|Subjects diagnosed with Crohn's Disease or Ulcerative Colitis.
3264822|NCT01517542|Experimental|Nutritional counseling|It was composed by patients who received specific written orientation to follow the DASH diet recommendations. Calories were calculated with the goal of maintaining body weight and divided into 3 main meals and two to three snacks.
3264823|NCT01517542|No Intervention|Usual diet|It was composed by patients who were stimulated to follow the general orientations of the neurologist or keep their food intake habits
3264824|NCT01517555|Experimental|Liraglutide|
3264825|NCT01517555|Placebo Comparator|Placebo|
3264826|NCT01517568|Experimental|Liraglutide|
3264827|NCT01517581||Malignant Disease with no visualized BAT|Children 18 years or younger who 1) had PET/CT scans with evidence of malignant disease but no metabolically active brown adipose tissue (BAT) at diagnosis and 2) were disease free within 1 year of diagnosis.
3264828|NCT01517607||Mesalazine|
3264829|NCT01517620|Experimental|Total Glucosides Paeony, Capsules|
3264830|NCT01517620|No Intervention|no intervention|
3264831|NCT01517633|Experimental|A device for identifying between amniotic fluid and urine|
3264832|NCT01517646|No Intervention|Fat Reduction|
3264833|NCT01517685|Experimental|Flax Oil and then Fish Oil|All people in the study will use the flax seed oil and then the fish oil.
3264834|NCT01517698|Experimental|RO4917523 0.5 mg|
3264835|NCT01517698|Experimental|RO4917523 1.5 mg|
3264836|NCT01517698|Placebo Comparator|Placebo|
3264837|NCT01517711|Experimental|Tramadol ER|
3264838|NCT01517711|Placebo Comparator|Sugar pill|
3264839|NCT01517724|Experimental|Bortezomib consolidation|Bortezomib administered once a week 1.3mg/sq m; maximum of 8 cycles (each cycle is 4 weeks)
3264840|NCT01517776|Experimental|Cilengitide and metronomic temozolomide|Cilengitide 1800 mg/m² i.v. twice weekly and Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
3264841|NCT01517789|Experimental|Patients|
3264842|NCT01517802|Experimental|Abiraterone acetate|Patients will continue the same treatment regimen they were receiving during their participation in the previous abiraterone acetate clinical study.
3264843|NCT01517815|Experimental|No overweight patient|Patient with weight less than or equal to 120kg
3264844|NCT01517815|Experimental|Overweight patients|Patient with weight more than 120kg
3264845|NCT01517828|Experimental|Ketamine Arm|Phial of Ketamine (50mg/5ml) will be used and the dose administered will be 2 mg/kg.
3264846|NCT01517828|Active Comparator|Midazolam Arm|Phials of midazolam (5mg/5ml)will be used and the dose administered will be 0.2 ml/kg.
3264847|NCT01517841||Chronic kidney disease|Patients with chronic kidney disease (20% or less kidney function remaining. Patients with end stage renal disease who are currently receiving dialysis.
3264848|NCT01517854|Active Comparator|Revatio|
3264849|NCT01517854|Placebo Comparator|Placebo|
3264850|NCT01517880|Experimental|6,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
3376390|NCT05160402|Experimental|Cohort 6 (MAD)|In Cohort 6, subjects will be randomized to receive a single intranasal and intraoral administration of 7.5 mg of IGM 6268 or placebo twice a day for 5 days.
3376391|NCT05160389|Experimental|Fasted|Study drug will be administered with water, after an overnight fast.
3264851|NCT01517880|Placebo Comparator|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (48 weeks total study duration).
3264852|NCT01517880|Experimental|3,000 mg SA-ER|Subjects will receive this dose for the duration of the study (total study duration of 48 weeks).
3264853|NCT01517906|Experimental|Cognitive behavioral counseling|
3264854|NCT01517906|Active Comparator|Supportive therapy|
3264855|NCT01517919|Experimental|Intervention: Peer Led Self-Management|Intervention: Peer Led Self-Management (PLSM) involves the DSME program followed by 12 months of peer-led ongoing self-management support
3264856|NCT01517919|No Intervention|Diabetes Self-Management Education|Control: Diabetes Self-Management Education (DSME) involves 12 sessions of self-management training including diabetes education, one-on-one sessions, bi-weekly phone contacts, and preparation for a clinic visit.
3264857|NCT01517932|Experimental|Group-DEX|Patients in this arm received dexmedetomidine 0.2 microgram per kg i.v. during 10 minutes 1 hour before the end of surgery
3264858|NCT01517932|Placebo Comparator|Group-PLB|Patients in this arm received saline placebo 0.05 ml per kilogram i.v. during 10 minutes 1 hour before the end of surgery
3264859|NCT01517958||Respiratory Distress Group|Neonates 28 weeks GA or greater with respiratory distress
3264860|NCT01517958||Control Group|Neonates 28 weeks GA or greater without respiratory distress.
3264861|NCT01517971||Ancillary-correlative (whole-genome expression)|RNA extracted from archived tumor tissue samples are analyzed for whole-genome expression profiling by Gene Profiling Array cGMP U133 P2 and RT-PCR.
3264862|NCT01517997|Experimental|Drug Coated Balloon (DCB) Arm|Patients included in this arm will undergo PTA with the use of a paclitaxel coated balloon.
3264863|NCT01517997|Active Comparator|Drug Eluting Stents (DES) Arm|Patients in this arm will undergo primary infrapopliteal stenting of the target lesion using a drug-eluting stent.
3264864|NCT01518010|Experimental|GamePlay|
3264865|NCT01518023||Cancer gastrectomy|Patients previously submitted to partial/total gastrectomy for gastric cancer
3264866|NCT01518023||Colorectal cancer operation|Patients previously submitted to right colectomy or rectosignoidectomy for cancer
3264867|NCT01518023||Bariatric patients|Morbidly obese participants who underwent antiobesity Roux-en-Y gastric bypass
3264868|NCT01518036|Experimental|Low dose|
3264869|NCT01518036|Experimental|High dose|
3264870|NCT01518062|Experimental|Low dose|
3264871|NCT01518062|Experimental|Medium dose|
3264872|NCT01518062|Experimental|High dose|
3264873|NCT01518075|Experimental|Non invasive mechanical ventilation|Evaluation of breathing swallowing interaction under non invasive mechanical ventilation
3264874|NCT01518075|Active Comparator|Spontaneous Breathing|Evaluation of breathing swallowing interaction without non invasive mechanical ventilation
3264875|NCT01518088|Experimental|Low dose dietary fiber|
3264876|NCT01518088|Experimental|High dose dietary fiber|
3264877|NCT01518088|Placebo Comparator|No added fiber|
3264878|NCT01518101|Experimental|Vildagliptin/Metformin followed by Liraglutide+Metformin|In period I, Patients receiving vildagliptin will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for 12 weeks. In period II, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid for the first week (week 13 - week 14) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid.
3264879|NCT01518101|Experimental|Liraglutide + Metformin followed by Vildagliptin/Metformin|In period I, patients will receive 0.6mg liraglutide od (once daily) + 1000mg metformin bid (twice daily) for the first week (week 0 - week 1) and increase the dose after 7 days up to 1.2mg liraglutide od/1000mg metformin bid (week 2 -12). In period II, patients will receive a stable dose of 50mg vildagliptin bid (twice daily) + 1000mg metformin bid for next 12 weeks.
3264880|NCT01518114|Experimental|Exercise Training|"Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.~Exercise prescription will be based upon cardiopulmonary test done at baseline."
3264881|NCT01518114|Active Comparator|Best Medical Care|Advanced HCM patients who are eligible to participate in the study but cannot do so for technical reasons will be invited to participate in the project as a control group.These subjects will continue their regular follow up in the Cardiomyopathy Clinic and their usual voluntary physical activity at home.
3264882|NCT01518127|Experimental|stem cell group|intravitreal injection of autologous bone marrow stem cells
3264883|NCT01518140|Experimental|VapoTherm|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
3264884|NCT01518140|Experimental|BiPAP|"Participants receive air through bilevel positive airway pressure (BiPAP) for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
3264885|NCT01518140|Experimental|Non-Rebreather Mask|"Participants receive air through Non-Rebreather Mask for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through VapoTherm for up to 30 minutes, followed by 30 minutes using bilevel positive airway pressure (BiPAP)."
3264886|NCT01518166|Experimental|Trial period A|
3264887|NCT01518166|Experimental|Trial period B|
3264888|NCT01518179|Experimental|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
3264889|NCT01518179|Other|Control|Routine follow up and treatment
3264890|NCT01518205|Experimental|LDL-apheresis and TT|"The patient of the experimental Arm, in addition to Traditional Therapy (TT), will undergo a cycle of 10 LDL-apheresis session.~Apheretic treatment scheme: 10 apheretic session carried out as follow: first and second apheresis with a 3 days interval (i.e. 2 treatment in one week), then one session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
3264891|NCT01518205|No Intervention|Traditional Treatment|"All patients will receive the traditional treatment for the ulcer healing Standardized medication.~All lesions taken into consideration will be treated in a standardized way, with a different approach according to the presence of a possible infection.~The evolution of lesions might be documented by means of mapping the same by drawing their profiles on an Opsite film.~antibiotics therapy (according to antibiogram). Anti-platelet therapy. Statin therapy."
3264892|NCT01518218|Experimental|laying-on-of-hands|Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.
3264893|NCT01518218|No Intervention|control group|Patients of this arm did not receive any alternatives other than conventional treatment.
3264894|NCT01518231|Experimental|cell transplantation|The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.
3264895|NCT01518231|No Intervention|Convention therapy|The control group just receive drug therapy.
3264896|NCT01518283|Experimental|Cabazitaxel|Drug: Cabazitaxel 10 mg/m2
3264897|NCT01518296|Experimental|Patients referred to urodynamic test|Patients that are referred to urogynecology and the pelvic reconstruction unit undergoes a physical gynecological examination and a urodynamic test, During which the degree of pelvic organs prolapse is evaluated with full and empty bladder.
3264898|NCT01518335|Experimental|Platelet Rich Plasma|Patients receive Platelet rich plasma injection + standard of care therapy(bandaging or boot and crutches) + non-NSAID pain medicine
3264899|NCT01518335|Placebo Comparator|Placebo/Standard of Care|Patient receives Placebo Comparator: Placebo/Standard of Care [saline injection + standard of care (bandaging or boot and crutches)] + non-NSAID pain medicine
3264900|NCT01518348|Experimental|Patch Test|
3264901|NCT01518387|Experimental|Arm 1|750-2250mg/day, tid, 8 weeks
3264902|NCT01518400||Eligible Population|Cancer Survivors of all ages (Must be diagnosed with cancer at 21 years or younger)
3264903|NCT01518413|Experimental|Combination Therapy|Three to 6 patient will be enrolled at each dose level and dose escalations will proceed in the absence of dose-limiting toxicity attributed to therapy, first with dose escalation of sorafenib and then, if tolerated, escalation of irinotecan.
3264904|NCT01518426|Experimental|Extraction of P300 ERPs|Extract P300 ERPs with Emotiv EEG headset
3264905|NCT01518439|Experimental|neuromuscular patients|neuromuscular patients with cough inefficiency in a stable respiratory state upon inclusion
3264906|NCT01518452|Experimental|working memory training|Cogmed JM working memory training
3264907|NCT01518452|Experimental|delayed working memory training|Cogmed JM working memory training after 8 weeks waiting
3264908|NCT01518465|Experimental|Arm I (5000 IU dalteparin)|Patients receive a prophylactic dose of dalteparin SC on days 1-28; lenalidomide PO on days 1-21; and low-dose dexamethasone PO on days 1, 8, 15, and 22.
3264909|NCT01518465|Experimental|Arm II (200 IU/kg dalteparin)|Patients receive a therapeutic dose of dalteparin SC on days 1-21 and lenalidomide PO and low-dose dexamethasone PO as in Arm I.
3264910|NCT01518478|Other|20 Non-atopic|Non-atopic, healthy control.
3264911|NCT01518478|Other|20 ADEH- (mild to severe AD)|Atopic Dermatitis without previous or current Eczema Herpeticum.
3264912|NCT01518491|Experimental|NanoDOX Hydrogel plus VAC|NanoDOX™ Hydrogel in conjunction with serial wound debridement and irrigation on open traumatic orthopedic and soft tissue wounds in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
3264913|NCT01518491|Active Comparator|VAC Alone|Serial wound debridement and irrigation alone in patients receiving negative pressure wound therapy/vacuum assisted closure (NPWT/VAC) with reticulated open cell foam (ROCF) dressings.
3264914|NCT01518504|Experimental|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
3264915|NCT01518504|Sham Comparator|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
3264916|NCT01518517|Experimental|GRASPA|"Each patient randomized in GRASPA® group is to receive at least 2 and up to 10 administration of GRASPA® 150 IU/kg, in combination with standard chemotherapy (COOPRALL).~GRASPA® administration takes place as below:~for induction phase: at Day 4 and D18 (F1-F2 induction ) or at D6 if Vanda induction applies (according disease severity)~for consolidation phase: at Day 6 of R2 / R1 blocks, each time block of chemotherapy is given (up to 8 cycles)"
3264917|NCT01518517|Active Comparator|reference L-asparaginase|"For patient randomized in control group, reference L-asparaginase 10,000 IU/m² will be administered every 3 days intravenously, in combination with standard chemotherapy (COOPRALL).~•for induction phase:at Day 4 , D7, D10, D13 (F1 block ) then at Day 18, D21, D24, D27 (of F2 Blocks).~NB: administrations take place at D6, D9, D12 and D15 in case of F1-F2 Induction is replaced by VANDA (according disease severity)~•for consolidation phase: at D6, D9, D12 ofR2/R1 blocks, each time block of chemotherapy is given (up to 8 cycles)."
3264918|NCT01518543||ASTUS|Patient candidate for an arthrodesis in the following joints:Ankle,1st MTP, Metatarso - Cuneiform (1st), Navicular - Cuneiform, Talo-Navicular, Calcaneum - Cuboid, and whose surgeon has recommended the implantation of an ASTUS Staple from Newdeal-INTEGRA.
3264919|NCT01518556|Experimental|Idarubicin|Idarubicin dose intensification for remission induction in acute myeloid leukemia
3264920|NCT01518569|Placebo Comparator|placebo|normal saline, same amount, iv
3264921|NCT01518569|Active Comparator|ulinastatin|5000 unit/kg iv
3264922|NCT01518582||Radiculopathy Cervical|Radiculopathy, Cervical
3264923|NCT01518595|Placebo Comparator|placebo|Patients will receive placebo tablets twice daily for 3 months.
3264924|NCT01518595|Active Comparator|bosentan|pts. will receive bosentan for 3 months
3264925|NCT01518621|Active Comparator|Radiotherapy alone|Total brain irradiation, 3Gy x10
3264926|NCT01518621|Experimental|Radiation plus erlotinib|Total brain irradiation, 3Gy x10 plus erlotinib 150 mg q d from radiation day -1 through last day of irradiation
3264927|NCT01518634|Experimental|Imipramine treatment|
3264928|NCT01518634|Placebo Comparator|Placebo|
3264929|NCT01518647|Experimental|Group Therapy|ACT given as conventional group therapy in groups of 7-8 patients 3,5 hours each session, 9 sessions during 3 month
3264930|NCT01518647|Experimental|Workshop|ACT given as a one-day workshop with 15 patients with a following individual consultation
3264931|NCT01518647|Active Comparator|Standard treatment|Standard treatment is one single advisory consultation given 2 weeks after randomization
3264932|NCT01518660|Experimental|Training|
3264933|NCT01518660|No Intervention|Control|
3264934|NCT01518686|No Intervention|one arm|observational study, no cohort, single group of different ages
3264935|NCT01518712|Experimental|Treatment Sequence AB|
3264936|NCT01518712|Experimental|Treatment Sequence BA|
3264937|NCT01518725|Experimental|Vitamin D Supplementation|The vitamin D supplementation will consist of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day.
3264938|NCT01518725|Placebo Comparator|Gel-like Substance|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
3264939|NCT01518738|Experimental|breath attention training|
3264940|NCT01518738|Active Comparator|working memory attention training|
3264941|NCT01518738|No Intervention|no training|
3264942|NCT01518764|Experimental|Red Wine Polyphenols|Red Wine Polyphenols 600mg/day (capsules)
3264943|NCT01518764|Placebo Comparator|placebo|placebo (capsules)
3264944|NCT01518777|Other|Half-dose isotope for NuclearStressTest|"Intervention is Nuclear stress test of the heart. Single-arm of this study Half-dose of isotope for Nuclear stress test is group of study subjects who will do Research Nuclear stress test with half-dose of isotope that normally used for routine Nuclear stress test. Isotope is the tracer CZT (cadmium zinc telluride) that used for Nuclear stress test routinely to see the function of arteries of the heart. Patients with suspected Coronary Artery Disease who meet entry criteria undergo a research nuclear stress test using a decreased dose of isotope, using a new camera."
3264945|NCT01518790|Experimental|Polyethylene glycol 3350|
3264946|NCT01518803|Active Comparator|Mediterranean-style breakfast|
3264947|NCT01518803|Active Comparator|Western-style breakfast|
3264948|NCT01518816||preterm labor cases|Group A: 35 pregnant women diagnosed with preterm labor(Preterm labor pain at least 3 contraction every 20 minutes ,cervical dilatation < 2cm and effacement< 50%) which will deliver within one week maximum after hospitalization.
3264949|NCT01518816||control group|Group B: 35 pregnant women( controls )with uncomplicated pregnancies at a similar gestational ages followed routinely in the antenatal care unit.
3264950|NCT01518829||Patients with hepatocellular carcinoma|Patients with hepatocellular carcinoma who will undergo locoregional therapy
3264951|NCT01518829||patients with chronic liver disease|patients with chronic liver disease, as a control group
3264952|NCT01518842|Experimental|test group intravitreal stem cell|"Open-label study of Ischemic Retinopathy patients with best-corrected visual acuity (BCVA) worse than 20/200.~Intervention: Biological: intravitreal injection of autologous bone marrow stem cells"
3264953|NCT01518855|Experimental|Arm 1|Adalat CR 20-40mg od + Diovan 40-80mg od
3264954|NCT01518855|Active Comparator|Arm 2|Norvasc 2.5-5mg od + Diovan 40-80mg od
3264955|NCT01518881|Experimental|TKM-100201|
3264956|NCT01518881|Placebo Comparator|Placebo|
3264957|NCT01518894|Experimental|PF-04958242|
3264958|NCT01518894|Placebo Comparator|Placebo|
3264959|NCT01518907|Experimental|AA4500 0.0029 mg in 1 mL|
3264960|NCT01518907|Experimental|AA4500 0.0145 mg in 5 mL|
3264961|NCT01518907|Experimental|AA4500 0.0145 mg in 1 mL|
3264962|NCT01518907|Experimental|AA4500 0.0435 mg in 5 mL|
3264963|NCT01518907|Experimental|AA4500 0.0435 mg in 1 mL|
3264964|NCT01518907|Experimental|AA4500 0.116 mg in 5 mL|
3264965|NCT01518907|Experimental|AA4500 0.116 mg in 1 mL|
3264966|NCT01518907|Experimental|AA4500 0.232 mg in 5 mL|
3264967|NCT01518907|Experimental|AA4500 at 0.232 in 1 mL|
3264968|NCT01518907|Experimental|AA4500 0.464 mg in 5 mL|
3264969|NCT01518907|Experimental|AA4500 0.464 mg in 1 mL|
3264970|NCT01518920|Experimental|PF-04958242|
3264971|NCT01518920|Placebo Comparator|Placebo|
3264972|NCT01518933|Experimental|Silibilin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL) ,as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
3264973|NCT01518933|Placebo Comparator|Saline|Placebo (saline), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
3264974|NCT01518959|Placebo Comparator|Placebo|no treatment
3264975|NCT01518959|Active Comparator|Cholecalcipherol|Treatment with 180 000 IU cholecalcipherol monthly
3264976|NCT01518985|Placebo Comparator|Placebo|Intravenous infusion of saline (0.9%) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
3264977|NCT01518985|Experimental|Bendavia|Intravenous infusion of Bendavia (0.25mg/kg/hr) for 4 hours with smoking of one unfiltered cigarette at 30 minutes post-study-drug administration start
3264978|NCT01518998|Placebo Comparator|Placebo|Take one double-blind capsule filled with a placebo tablet in the every morning
3264979|NCT01518998|Active Comparator|Fimasartan 60mg|Take one double-blind capsule filled with of Fimasartan 60mg in the every morning
3264980|NCT01518998|Active Comparator|Fimasartan 30mg|Take one double-blind capsule filled with Fimasartan 30mg in the every morning
3376392|NCT05160389|Experimental|Low-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard low-fat breakfast will be given.
3376393|NCT05160389|Experimental|High-fat Meal|Study drug will be administered with water, after an overnight fast, after which time a standard high-fat breakfast will be given.
3264981|NCT01518998|Active Comparator|Amlodipine 5mg|Take one double-blind capsule filled with Amlodipine 5mg in the every morning
3376394|NCT05160376|Experimental|Guided Intervention Group|The participants in the guided intervention group will receive feedback calls (approximately 15 minutes) on participants' progress from a clinical psychology trainee or an undergraduate trained psychology student under the supervision of a clinical psychology professor, after each online self-help intervention session. The participants in the guided intervention group will also receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
3376395|NCT05160376|Experimental|Unguided Intervention Group|The participants in the unguided intervention group will not receive the aforementioned feedback calls. The participants in the unguided intervention group will only receive an email reminder and text message if the participants have not completed the required session of that week on the 5th, 6th, and 7th of the same week. Technical supports are available.
3376396|NCT05160376|No Intervention|Wait-list Control Group|The waitlist control group will not receive any online self-help intervention. Unguided intervention will be provided to the waitlist control group after both the Post-treatment Assessment Phrase are finished.
3376397|NCT05160363|Experimental|PYR and PQP Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg
3376398|NCT05160363|Placebo Comparator|PYR and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Pyronaridine tetraphosphate 540 mg (three tablets) if body weight 50kg - <65kg; OR, 720 mg (4 tablets) if body weight is ≥65 kg Matched placebo for piperaquine (3 or 4 tablets based on body weight)
3376399|NCT05160363|Placebo Comparator|PQP and Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Piperaquine tetraphosphate 960 mg (three tablets) if body weight 50kg - <75kg; OR, 1280 mg (4 tablets) if body weight ≥75kg Matched placebo for pyronaridine (3 or 4 tablets based on body weight)
3264982|NCT01518998|Active Comparator|Amlodipine 10mg|Take one double-blind capsule filled with Amlodipine 10mg in the every morning
3376400|NCT05160363|Sham Comparator|Placebo Combination|Single dose in the morning on Days 1, 2 and 3 of the study Matched placebo for pyronaridine (3 or 4 tablets dependent on body weight) and matched placebo piperaquine (3 or 4 tablets dependent on body weight)
3376401|NCT05160350|Active Comparator|Probiotic|Familact 2 plus (Zist takhmir pharmaceutical company, Iran), one capsule per day
3376402|NCT05160350|Placebo Comparator|Placebo|Similar capsule in shape and size (Zist takhmir pharmaceutical company, Iran), one capsule per day
3376403|NCT05160337|Other|Healthy Volunteers|Healthy Volunteers will be recruited into the study
3376404|NCT05160324|Active Comparator|A standard treatment|"Axillary dissection in women with sentinel lymph node metastases.~Removal of at least 10 lymph nodes is recommended."
3376405|NCT05160324|Experimental|B experimental treatment|Omission of Axillary dissection in women with sentinel lymph node metastases.
3264983|NCT01518998|Experimental|Fimasartan 60mg/ Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 5mg in the every morning
3264984|NCT01518998|Experimental|Fimasartan 60mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 60mg and Amlodipine 10mg in the every morning
3376406|NCT05160311|Other|Optimized Medical Treatment (OMT)|The patient considered non-viable by MRI and randomized to Optimized Medical Treatment (OMT) will be treated according to Optimized Medical Treatment guidelines for CAD
3376407|NCT05160311|Experimental|Angioplasty (PCI) and Optimized Medical Treatment (OMT)|The patient considered non-viable and randomized to Angioplasty will be treated with drug-eluting stent (PCI) and Optimized Medical Treatment (OMT)
3376408|NCT05160298|Experimental|Ropivacaine group|Performance of an echo-guided bilateral erector spinae block at the arrival in the intensive care unit with 20ml of Ropivacaine 2mg/ml in each side.
3376409|NCT05160298|Sham Comparator|Control group|Performance of a sham block at the arrival in the intensive care unit with no drugs administration
3376410|NCT05160285|Experimental|Neoadjuvant nivolumab treatment arm|Nivolumab 360mg intravenous adminstration every 3 weeks
3264985|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 5mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 5mg in the every morning
3376411|NCT05160272|Experimental|AP-325 Treatment|AP-325, film-coated tablet, 50mg once daily
3376412|NCT05160272|Placebo Comparator|Placebo Treatment|Placebo matching AP-325 film-coated tablet, once daily
3376413|NCT05160246|Experimental|taping group|Facilitation taping will be applied to the quadriceps femoris of patients with knee OA in the taping group.
3376414|NCT05160246|Placebo Comparator|placebo group|The patients with knee OA in the placebo group will be placed tape on the quadriceps femoris without any tension.
3376415|NCT05160233|Active Comparator|Standard Implementation|All primary care clinics will implement reSET and reSET-O using standard implementation approach.
3376416|NCT05160233|Experimental|Standard Implementation Plus Health Coaching|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O.
3376417|NCT05160233|Experimental|Standard Implementation Plus Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and a practice facilitator will provide the clinic with support for implementation.
3376418|NCT05160233|Experimental|Standard Implementation Plus Health Coaching and Practice Facilitation|The clinics in this arm will implement reSET and reSET-O with a standard implementation strategy and patients at the clinic will receive support from a health coach to help them engage with reSET and reSET-O. Additionally, a practice facilitator will provide the clinic with support for implementation.
3264986|NCT01518998|Experimental|Fimasartan 30mg/Amlodipine 10mg|Take one double-blind capsule filled with Fimasartan 30mg and Amlodipine 10mg in the every morning
3264987|NCT01519011|Experimental|1: A, B, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264988|NCT01519011|Experimental|2: B, C, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264989|NCT01519011|Experimental|3: C, A, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264990|NCT01519011|Experimental|4: B, A, C|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264991|NCT01519011|Experimental|5: A, C, B|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264992|NCT01519011|Experimental|6: C, B, A|"Dose A: Single oral administration with three 100-mg tablets under fasted condition Dose B: Single oral administration with two 150-mg tablets under fasted condition.~Dose C: Single oral administration with two 150-mg tablets under fed condition."
3264993|NCT01519011|Experimental|Extension|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
3264994|NCT01519024||Women with breast hypertrophy|Fourteen women with breast hypertrophy
3264995|NCT01519024||Women without breast hypertrophy.|Fourteen women without breast hypertrophy for de control group (CG).
3264996|NCT01519037|Active Comparator|calcimimetic agent (cinacalcet)|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or the placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
3264997|NCT01519037|Placebo Comparator|Placebo|3 days of a low-sodium diet (50 mmol of Na+ per day, equivalent to 3 grams of salt/day), followed by an investigation day at the hospital during which the subjects will be studied before and after exposure to the cinacalcet or placebo. The 2 periods will be separated by a therapeutic wash-out lasting 14-28 days. The total length of the study per participant will be 1, max. 2 months
3264998|NCT01519102|Active Comparator|CHO-independent partial insulin bolus with closed-loop|
3264999|NCT01519102|Active Comparator|CHO-dependent full insulin bolus combined with closed-loop|
3265000|NCT01519115|Active Comparator|Usual care|usual care of one physical therapy visit in hospital after ACF surgery
3265001|NCT01519115|Experimental|Early physical therapy intervention|early physical therapy program instructed and followed at home for 6 weeks
3265002|NCT01519128|Experimental|Treatment sequence AB|In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1. In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11.
3265003|NCT01519128|Experimental|Treatment sequence BA|In Treatment B, TMC278 at 25 mg, once daily will be administered for 16 days, with digoxin 0.5 mg (single oral dose) administered in the morning on Day 11. In Treatment A, digoxin 0.5 mg (single oral dose) will be administered on Day 1.
3265004|NCT01519154|Active Comparator|Propofol|Propofol 10 mg/h as maintenance infusion
3265005|NCT01519154|Experimental|Ketamine-Propofol|Additional Ketamine at induction, Propofol 5 mg/h as maintenance infusion
3265006|NCT01519180||Control group|Healthy volunteers
3265007|NCT01519180||Idiopathic gastroparesis|Idiopathic gastroparesis
3265008|NCT01519193|Experimental|Narrative Exposure Therapy|
3265009|NCT01519193|No Intervention|No treatment control|
3265010|NCT01519219||Hepatic Irradiation|
3265011|NCT01519232||Liver Irradiation|patients already scheduled to undergo liver irradiation
3265012|NCT01519258|Active Comparator|PSV|Patients will be ventilated with the a conventional mode of ventilation called Pressure Support Ventilation (PSV) for 15 minutes. Mechanical ventilator settings will be set to match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
3265013|NCT01519258|Experimental|NAVA|Patients will be ventilated with NAVA for 15 minutes. Nava level will be titrated prior to randomization, to deliver the same peak of airway pressure obtained with the active comparator, PSV. The resulting tidal volume should match the tidal volume applied by the ICU team, in accordance to current standard of care recommendations.
3265014|NCT01519297|Other|Single arm intervention|Irbesartan 150 mg orally for one dose
3265015|NCT01519310|Active Comparator|Group 1|Group 1 (Antibiotics/probioitic):
3265016|NCT01519310|Active Comparator|Group 2|Group 2 (Antibiotics/no-probiotic):
3265017|NCT01519310|Active Comparator|Group 3|Group 3 (no-Antibiotics/probiotic):
3265018|NCT01519336|Active Comparator|A danoprevir|
3265019|NCT01519336|Placebo Comparator|B darunavir|
3265020|NCT01519336|Experimental|C danoprevir/darunavir|
3265021|NCT01519349|Experimental|Cohort 1|Low Dose: 2E11 vg/kg of rAAV1.CMV.huFollistatin344 administered via intramuscular injection unilaterally to single quadriceps muscle (n=3, sIBM only)
3265022|NCT01519349|Experimental|Cohort 2|Mid Dose: 3E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
3265023|NCT01519349|Experimental|Cohort 3|Low Dose: 6E11 vg/kg per quadriceps of rAAV1.CMV.huFollistatin344 administered via intramuscular injection bilaterally to both quadriceps muscles (n=6; 3 sIBM and 3 BMD)
3265024|NCT01519375||1|Patients with Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis, 18 years or older
3265025|NCT01519388|Experimental|neuromuscular patients|Neuromuscular non invasively ventilated patients in stable at the time of the study
3265026|NCT01519401|Active Comparator|3 mg drospirenone and 20 µg ethinyl-estradiol|
3265027|NCT01519401|Active Comparator|3 mg drospirenone and 30 µg ethinyl-estradiol|
3265028|NCT01519440||blunt|Blunt expansion of the primary incision was derived by placing the index fingers of the operating surgeon into the incision and pulling the fingers apart laterally and cephalad.
3265029|NCT01519440||sharp|Sharp expansion of the primary incision was developed by cutting laterally and cephalad using bandage scissors
3265030|NCT01519479|Experimental|Palliative Care Consultation|Participant will get one palliative care consultation while in the hospital. The participants desire for subsequent palliative care visits will be determined and mutually agreed upon at the initial consultation.
3265031|NCT01519479|Active Comparator|Control|Usual care for HF patient which may include a palliative care consult if ordered by treating physician.
3265032|NCT01519492|Experimental|AFN-12520000|100 mg tablet
3265033|NCT01519505|Experimental|Lifestyle counseling|"Complete lifestyle counseling including~Individual intervention, OR~Group intervention"
3265034|NCT01519505|No Intervention|Usual health care|Usual health care, including self-administered information by leaflets
3265035|NCT01519531|Experimental|VIA-3196|
3265036|NCT01519531|Placebo Comparator|Placebo|Multiple, ascending dosing groups (cohorts) will be evaluated.
3265037|NCT01519544|Active Comparator|Temazepam|50 subjects are instructed to take 7.5mg temazepam by mouth prior to going to sleep for one night only.
3265038|NCT01519544|Active Comparator|Acetazolamide|50 subjects are instructed to take 125mg of acetazolamide by mouth prior to going to sleep one night only.
3265039|NCT01519557|Experimental|DAR-100A|DAR-0100A is a dopamine D1 full agonist, the active component of the racemic mixture DAR-0100
3265040|NCT01519557|Placebo Comparator|Placebo|Intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
3265041|NCT01519583|Experimental|Basic Pedometry Intervention|Basic pedometry intervention: Participants will have a goal of obtaining 10,000 steps/day (with no direction with regards to walking intensity/speed/cadence)
3265042|NCT01519583|Experimental|Enhanced Pedometry Intervention|Enhanced pedometry Intervention: Participants will have the goal of obtaining 10,000 steps/day and at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min);
3265043|NCT01519583|Placebo Comparator|Control Group|Control group: Will maintain their usual activity and return for follow-up measures
3265044|NCT01519596|Experimental|Arm I (physical activity)|Patients participate in an orientation session introducing the exercise program and protocol, reviewing fundamental principles, and demonstrating each activity. Patients also receive educational materials to facilitate orientation and adherence. Patients are offered 20-50 minute standard, intermediate, and/or low intensity physical activity sessions 5 days a week for 4 weeks. Patients also receive lifestyle-related counseling for 20-30 minutes once weekly.
3265045|NCT01519596|Active Comparator|Arm II (usual care)|Patients undergo usual care for 4 weeks.
3265046|NCT01519609|Active Comparator|Moviprep|Moviprep bowel preb
3265047|NCT01519609|Active Comparator|Phosphoral|Bowel prep
3265048|NCT01519622||Sick elderly in community|
3265049|NCT01519687|Experimental|Levotofisopam|All patients will receive a single dose of 50 mg on Day 1, 50 mg three times a day (TID) on Days 2 through 6, and a single dose of 50 mg on Day 7. Each dose of study drug will be administered by authorized site personnel throughout the 7-day inpatient treatment period.
3265050|NCT01519726|Experimental|Morbidly obese patients|
3265051|NCT01519739|Experimental|MediGuide Arm|
3265052|NCT01519752|Experimental|Oxiconazole Nitrate Cream 1%|
3265053|NCT01519752|Active Comparator|Oxiconazole Nitrate Cream 1% (Oxistat®)|
3265054|NCT01519752|Placebo Comparator|Placebo|
3265055|NCT01519804|Experimental|MetMAb+paclitaxel+platinum|
3265056|NCT01519804|Active Comparator|Placebo+paclitaxel+platinum|
3265057|NCT01519830|Experimental|Verum|Iron Carboxymaltose (Ferinject)
3265058|NCT01519830|Placebo Comparator|Placebo|0.9% NaCl solution
3265059|NCT01519843|Active Comparator|Real|Real tDCS
3265060|NCT01519843|Placebo Comparator|sham|Sham tDCS
3265061|NCT01519856||tablet|
3265062|NCT01519895|No Intervention|Existing care|routine existing care
3265063|NCT01519895|Experimental|Telephone intervention|in addition to provide telephone intervention support
3265064|NCT01519973|Other|Evaluation of technology in SPECT|Evaluation of the accuracy of SPECT with new technologies for attenuation correction (AC), scatter correction (SC) and resolution recovery (RR) for assessment of myocardial perfusion using Rb-82 PET as the gold standard.
3265065|NCT01519986|Experimental|Low fat Meal|50,000 UI vitamin D3 with low fat meal
3265066|NCT01519986|Experimental|Medium fat meal|50,000 UI vitamin D3 with medium fat meal
3265067|NCT01519986|Experimental|High fat meal|50,000 UI vitamin D3 with high fat meal
3265068|NCT01519999|Experimental|Shared Decision Making|
3265069|NCT01519999|No Intervention|Comparison (control)|
3265070|NCT01520012|Experimental|Sequence 1|
3265071|NCT01520012|Experimental|Sequence 2|
3265072|NCT01520012|Experimental|Sequence 3|
3265073|NCT01520012|Experimental|Sequence 4|
3265074|NCT01520012|Experimental|Sequence 5|
3265075|NCT01520025|Experimental|18F-FDG PET imaging|Positron Emission Tomography nuclear stress scan following either pharmacologic or treadmill stress test with radiopharmaceutical injection at peak stress or within 1 hour following peak stress.
3265076|NCT01520051|Experimental|Mepolizumab|
3265077|NCT01520051|Placebo Comparator|Saline|
3265078|NCT01520077|Other|Vytorin|"Subjects will receive Vytorin for 24 weeks. At 24 weeks if regrowth greater or equal than 20%, subjects will be randomized 1/1 to either stop or continue vytorin. Subjects will be follow for additional 24 weeks.~Subjects that at 24 weeks don't meet the 20% regrowth will be dropped out of the study."
3265079|NCT01520103|Experimental|Vinorelbin and Everolimus|
3265080|NCT01520103|Other|standard therapy|Vinorelbin
3265081|NCT01520116|Experimental|Stage 1 - Arm 1 - Dose 1|
3265082|NCT01520116|Experimental|Stage 1 - Arm 2 - Dose 2|
3265083|NCT01520116|Experimental|Stage 1 - Arm 3 - Dose 3|
3265084|NCT01520116|Experimental|Stage 1 - Arm 4 - Dose 4|
3265085|NCT01520116|Placebo Comparator|Stage 1 - Arm 5 - Vehicle|
3265086|NCT01520116|Experimental|Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1|
3265087|NCT01520116|Experimental|Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1|
3265088|NCT01520116|Active Comparator|Stage 2 - Arm 3 -Timoptic 0.5% BID|
3265089|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
3265090|NCT01520142|Experimental|Treatment|
3265091|NCT01520142|Placebo Comparator|Placebo|
3265092|NCT01520155||Systemic lupus erythematosus with renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus with renal affection
3265093|NCT01520155||Systemic lupus erythematosus without renal affection|30 patients will be investigated suffering from a known systemic lupus erythematosus without renal affection
3265094|NCT01520155||Non-autoimmune kidney disease|Patients with non-systemic, non-autoimmune kidney disease
3265095|NCT01520194||psychosocial burden|122 women attending reproductive health clinics were interwied using HPV Impact Profile (HIP) and a socio-economic characteristics questionnaire.
3265096|NCT01520194||economic burden|Medical records of 102 patients diagnosed with genital warts were reviewed in the six BEMFAM's participating reproductive health clinics
3265097|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
3265098|NCT01520220|Experimental|Part A: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days.
3265099|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen A|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
3265100|NCT01520220|Experimental|Part B: LY2784544 Dosing Regimen B|LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
3265101|NCT01520259||cases|Women from the cohort with gallbladder cancer
3265102|NCT01520259||cohort|Women from Chile screened for gallbladder cancer with and without gallstones
3265103|NCT01520259||controls|Women from the cohort with gallstones
3265104|NCT01520285|Active Comparator|Zanidip|tablets
3265105|NCT01520285|Placebo Comparator|Control Drug|Felodipine sustained-release tablet (5mg/tablet)
3265106|NCT01520298|Placebo Comparator|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
3265107|NCT01520298|Active Comparator|Acetaminophen treatment|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer.
3265108|NCT01520311|Other|SVG + eSVS Mesh vs Control SVG|Either the Circumflex Coronary Artery or the Right Coronary Artery will receive the mesh supported vein graft and the native saphenous vein as second and control graft.
3265109|NCT01520337||patients undergoing outpatient colonoscopy|
3265110|NCT01520350|Experimental|Mood stabilizer + Aripiprazole|
3265111|NCT01520350|Placebo Comparator|Mood stabilizer + placebo|
3265112|NCT01520376|Active Comparator|Counselling|People receiving a psychiatric evaluation after screening (HADS test > 12 points) and revised at 1 and 6 months
3265113|NCT01520376|No Intervention|Usual care|People after screening (HADS test > 12 points) and send to their primary care physician
3265114|NCT01520389|Experimental|MM-151 Dose Escalation|MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
3265115|NCT01520389|Experimental|MM-151 Expansion in KRAS wild type colorectal cancer|MM-151 given weekly
3265116|NCT01520389|Experimental|MM-151 + irinotecan|MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
3265117|NCT01520415|Active Comparator|bupivacaine|
3265118|NCT01520415|Placebo Comparator|saline|
3265119|NCT01520428|Active Comparator|Motivational Interviewing, CBT and E-mail support|
3265120|NCT01520428|Active Comparator|E-Mail-support|
3265121|NCT01520441|Experimental|BOTOX Injection|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
3265122|NCT01520467|Experimental|Anastrozole|stratification according to the rare disease. Oral administration of Anastrozole (1mg/day) for 18 months
3265123|NCT01520467|Placebo Comparator|Placebo|stratification according to the rare disease. Oral administration of 1 placebo tablet /day for 18 months
3265124|NCT01520480||Non-pathological fracture|Non pathological subtrochanteric femur fractures
3265125|NCT01520480||Pathological fracture|Pathological subtrochanteric fractures
3265126|NCT01520493|Experimental|Exercise|All patients are subject to this Arm.
3265127|NCT01520545|Experimental|Gablofen 3 mg/mL (baclofen Injection)|3 mg/mL Gablofen (baclofen Injection)
3265128|NCT01520571|Active Comparator|Non-Computer Assistance TKA|Non-Computer Assistance TKA
3265129|NCT01520571|Experimental|Computer Assistance TKA|Computer Assistance TKA
3265130|NCT01520584|Active Comparator|vitamale|
3265131|NCT01520584|Placebo Comparator|sham pill|
3265132|NCT01520597||Case|Patient with culture-proven listeriosis
3265133|NCT01520597||Control|Patient above the age of 18 years with medical background and clinical features compatible with one of the 3 forms of systemic listeriosis: febrile pregnant women (temp > 38°C), febrile patient with co-morbidity for septicaemic listeriosis, and any febrile symptom leading to empiric amoxicillin prescription.
3265134|NCT01520610||CTT|Patients with cardiopathy of tako TSUBO.
3265135|NCT01520610||SCA|Patients with acute coronary syndrome but without Tako-TSUBO cardiomyopathy.
3265136|NCT01520610||Surgical stress|patients with stressful event (emergency postoperative patients) but without Tako-TSUBO cardiomyopathy.
3265137|NCT01520623|Other|Allografted patients|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
3265138|NCT01520636|Placebo Comparator|group 1: standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day.
3265139|NCT01520636|Experimental|group 2: experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
3265140|NCT01520649|Experimental|NSI-189 Phosphate|There will be 3 ascending cohorts. The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
3265141|NCT01520649|Placebo Comparator|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
3265142|NCT01520662|Experimental|Wellness Portal Intervention|Wellness Portal Intervention: patients have access to the portal in the course of the study.
3265143|NCT01520662|No Intervention|Wellness Portal Control|Control patients don't have access to the Wellness Portal in the course of the study.
3265144|NCT01520675|Active Comparator|Surgery|Patients will be randomized to surgery
3265145|NCT01520675|Active Comparator|Endotherapy|Patients will be randomized to endoscopic therapy
3265146|NCT01520701|Active Comparator|Ialuset® application|Arm with application to the skin Ialuset ® cervical during radiotherapy
3265147|NCT01520701|Experimental|bandage skin Hydrosorb|Arm bandage skin hydrogel (Hydrotac®) on the skin cervical during radiotherapy
3265148|NCT01520740|Active Comparator|Collateral Ventilation Positive (CV+)|
3265149|NCT01520740|Active Comparator|Collateral Ventilation Negative (CV-)|
3265150|NCT01520753|Experimental|BIAsp 70|
3265151|NCT01520753|Experimental|BIAsp 70 + BIAsp 50|
3265152|NCT01520766|Experimental|glass fiber|
3265153|NCT01520766|Experimental|titanium|
3265154|NCT01520779||Patients with recurrence|Hepatocellular carcinoma patients with intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
3265155|NCT01520779||Patients with no recurrence|Hepatocellular carcinoma with no intra-hepatic or distant recurrence of hepatocellular carcinoma within 1 year after radiofrequency ablation
3265156|NCT01520792|Experimental|Paracetamol|
3265157|NCT01520805|Experimental|CPI-613|CPI-613 will be intravenously infused over 2 hours, given twice weekly for 3 weeks followed by a week of rest.
3265158|NCT01520818|Experimental|BIAsp 50 or 70|
3265159|NCT01520818|Active Comparator|BHI 30|
3265160|NCT01520831|Experimental|BIAsp 30|
3265161|NCT01520831|Experimental|BIAsp 50|
3265162|NCT01520831|Experimental|BIAsp 70|
3265163|NCT01520831|Active Comparator|Insulin aspart|
3265164|NCT01520844|Other|Cohort study|Blood sampling
3265165|NCT01520857|Active Comparator|Spinal anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. spinal anesthesia
3265166|NCT01520857|Active Comparator|General Anesthesia|Transabdominal Preperitoneal repair of inguinal hernia. general anesthesia
3265167|NCT01520883||DEcisional conflict|
3265168|NCT01520896|Experimental|Part 1 - A|Single dose NKTR-118 25 mg on Day 1 only
3265169|NCT01520896|Active Comparator|Part 1 - B|Ketoconazole 400 mg once daily on Days 4 to 8
3265170|NCT01520896|Active Comparator|Part 1- C|Ketoconazole 400 mg plus NKTR-118 25 mg on Day 7
3265171|NCT01520935||Cohort Group|
3265172|NCT01520948|Experimental|Exercise-based behavioral therapy|Pelvic floor muscle exercise-based behavioral therapy
3265173|NCT01520948|Placebo Comparator|Behavioral control|Mirrored Star Drawing
3265174|NCT01520961||Hueter Anterior Approach|
3265175|NCT01520961||posterolateral approach|
3265176|NCT01520974|Active Comparator|Probiotic tablet|
3265177|NCT01520974|Placebo Comparator|Placebo tablet|Comparison tablet without the probiotic bacteria
3265178|NCT01521000|No Intervention|Observation|Observation arm will continue to be followed with serial L-Dex and water volume displacement methods.
3265179|NCT01521000|Other|Intervention-garment sleeve|If the L-Dex is outside the normal range, or has increased 10 units from baseline, the patient will then be randomized to wear a compression sleeve (20 to 30 mm of Hg) daily for 4 weeks or observation (no sleeve). After 4 weeks, L-Dex measurements and water volume displacement will be reassessed in the treatment group.
3265180|NCT01521013|Active Comparator|Supported self-care|
3265181|NCT01521013|Active Comparator|Unsupported self-care|
3265183|NCT01521052|Experimental|elderly depressed patients|Twenty seven (27) patients aged 68 years or above, currently suffering from a major depressive episode, who did not respond to treatment with at least one antidepressant medications in the recommended dosage and duration, or could not tolerate at least two antidepressants.
3265184|NCT01521065|Experimental|16 Gy IRay|16 Gy IRay + PRN Lucentis®
3265185|NCT01521078|Experimental|Intervention|Provided access to the Check Your Drinking University version (CYDU).
3265186|NCT01521078|No Intervention|Control|No invention control group
3265187|NCT01521130|No Intervention|Healthy Control|Healthy Control
3265188|NCT01521130|No Intervention|BECTS, no medication|BECTS, no medication
3265189|NCT01521130|Experimental|Levetiracetam Higher dose|Levetiracetam Higher dose
3265190|NCT01521156|Active Comparator|1 = Control product|
3265191|NCT01521156|Experimental|2 = Tested product|
3265192|NCT01521169|Active Comparator|1 = Tested product dose 1|
3265193|NCT01521169|Active Comparator|2 = Tested product dose 2|
3265194|NCT01521169|Sham Comparator|3 = Control product|
3265195|NCT01521182|Active Comparator|1 = Tested product|
3265196|NCT01521182|Placebo Comparator|2 = Control product|
3265197|NCT01521195|Experimental|Patients on veno-arterial (VA) ECMO|
3265198|NCT01521208|Active Comparator|LUCAS, Continuous chest compressions|Mechanical continuous chest compressions performed by LUCAS device (also during defibrillation)
3265199|NCT01521208|Active Comparator|Manual chest compressions|Manual chest compression is performed, chest compressions halted during defibrillation
3265200|NCT01521221|Experimental|Patients|Patients with autonomic failure.
3265201|NCT01521221|Experimental|Healthy subjects|Control group
3265202|NCT01521234|Experimental|Feedback group|For participants assigned to the feedback group, physiotherapists will receive a summary of patients' walking activity for the previous week as a tool to guide goal planning. Physiotherapists will use the information as a 'homework checker' to determine if patients are complying with an assigned walking program. In the case of non-compliance, the physiotherapist will discuss a coping strategy for better integrating walking activity into the patients' day. In the event that the patient is meeting their specific sub-goals for walking activity, the physiotherapist will re-evaluate these sub-goals and suggest more challenging goals.
3265203|NCT01521234|No Intervention|No-feedback group|For participants assigned to the control group, physiotherapists will not receive accelerometer-based feedback of daily walking activity. However, physiotherapists will still discuss the achievement of walking goals with their patients. This is usual care around goal planning.
3265204|NCT01521247|No Intervention|Control group|Usual care.
3265205|NCT01521247|Other|Asthma Transition Program|Asthma Transition Program
3265206|NCT01521273|Experimental|high iron bean with native phytic acid concentration|
3265207|NCT01521273|Experimental|normal iron bean with native phytic acid concentration|
3265208|NCT01521273|Experimental|high iron bean partially dephytinized|
3265209|NCT01521273|Experimental|normal iron bean partially dephytinized|
3265210|NCT01521273|Experimental|high iron bean totally dephytinized|
3265211|NCT01521273|Experimental|normal iron bean totally dephytinized|
3265212|NCT01521286||Group A|Subjects presenting with HZ episode.
3265213|NCT01521312|Experimental|Saxagliptin|Saxagliptin 5 mg (tablet) at BREAKFEAST
3265214|NCT01521312|Placebo Comparator|placebo pill|at BREAKFEAST
3265215|NCT01521325|Experimental|Amatuximab infusion|Subjects will receive one infusion of radiolabeled amatuximab.
3265216|NCT01521351||carotid thermal heterogeneity|Patients that have carotid thermal heterogeneity detected by MR
3265217|NCT01521351||no carotid thermal heterogeneity|Patients that DONT have carotid thermal heterogeneity detected by MR
3265218|NCT01521351||carotid artery disease|Patients with detected carotid artery disease by ultrasound
3265219|NCT01521351||no carotid artery disease|Patients with no carotid artery disease detected by ultrasound
3265220|NCT01521377|Placebo Comparator|Placebo|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin.
3265221|NCT01521377|Active Comparator|Moxifloxacin Positive|Single inhalation from matching placebo dry powder inhaler once daily on days 1-10. Single dose oral tablet moxifloxacin (400mg) on day 10.
3265222|NCT01521377|Experimental|GSK573719 Supra-therapeutic dose|Single inhalation from GSK573719 (500 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral moxifloxacin.
3265223|NCT01521377|Experimental|GSK573719/Vilanterol Therapeutic dose|Single inhalation from GSK573719/Vilanterol (125/25 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
3265224|NCT01521377|Experimental|GSK573719/Vilanterol Supra-therapeutic dose|Single inhalation from GSK573719/Vilanterol (500/100 microgram) dry powder inhaler once daily on days 1-10. Single dose placebo oral tablet moxifloxacin on day 10.
3265225|NCT01521390|Other|Treatment Arm|Subjects receive one inhalation from each intervention
3265226|NCT01521403|Active Comparator|Metronidazole|Metronidazole 3x500 mg per day for 10 days
3265227|NCT01521403|Placebo Comparator|Placebo|Placebo 3x1 tablet per day for 10 days
3265228|NCT01521416||Cohort Group|
3265229|NCT01521429||MPS I|Mucopolysaccharidosis I (Hurler, Scheie, Hurler-Scheie)
3265230|NCT01521429||MPS II|Mucopolysaccharidosis II (Hunter)
3265231|NCT01521429||MPS VI|Mucopolysaccharidosis VI (Maroteaux-Lamy)
3265232|NCT01521442|Experimental|Arm 1|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3265233|NCT01521442|Other|Arm 2|12-week delay before beginning Mindful Yoga Therapy treatment which will consist of 12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3265234|NCT01521455|Experimental|HCP0910|Fluticasone /salmeterol 250/50 combination capsule
3265235|NCT01521455|Active Comparator|Seretide Diskus|Seretide 250 Diskus
3265236|NCT01521481|Experimental|Triple inguinal nerve block|Ropivacaine 5 mg/ml
3265237|NCT01521481|Active Comparator|Unilateral subarachnoid anesthesia|Bupivacaine 10 mg/ml
3265238|NCT01521520||Clinical Type 1 Diabetes|This group will be subdivided into individuals with recent onset clinical type 1 diabetes (within 6 months of diagnosis), latent autoimmune diabetes of the adult, and longer standing type 1 diabetes.
3265239|NCT01521520||High Risk Pre-Type 1 Diabetes|High risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).
3265240|NCT01521520||Low Risk Pre-Type 1 Diabetes|Low risk pre-type 1 diabetes is defined as first degree family relative with type 1 diabetes but no islet autoantibody markers (GAD, IAA, or IA-2).
3265241|NCT01521520||Normal Control|Normal control is based on history with no known history or family history of type 1 diabetes.
3265242|NCT01521533|Experimental|NOX-A12|
3265243|NCT01521572|Experimental|Salbutamol|Short-acting bronchodilator for use in humans released by the Ministry of Health, widely used worldwide for the treatment of chronic obstructive pulmonary disease.
3265244|NCT01521585|Experimental|SEN0014196 50 mg oral tablet|
3265245|NCT01521585|Experimental|SEN0014196 200 mg oral tablet|
3265246|NCT01521585|Placebo Comparator|Placebo tablet|
3265247|NCT01521598|Experimental|SKL11197|This arm is the experimental drug (SKL11197) arm. Patients will be randomized to this arm.
3265248|NCT01521598|Placebo Comparator|Placebo|This arm is the placebo comparator arm. Patients will be randomized to this arm.
3265249|NCT01521611|Experimental|Targeted radiotherapy|Patients receive therapy with an yttrium-90 labelled anti-CD66 following favourable dosimetry with the same antibody radiolabelled with indium-111.
3265250|NCT01521624|Active Comparator|Case|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
3265251|NCT01521624|No Intervention|Control|Subjects provided only advice for lifestyle modification with no drug intervention
3265252|NCT01521637|Experimental|NMES|The 'NMES' arm will be treated with NMES.
3265253|NCT01521637|Sham Comparator|No NMES|The 'No NMES' arm of the experiment will be sham-treated with NMES. The device will be installed, but not used.
3265254|NCT01521650|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
3265255|NCT01521650|No Intervention|Control|No intervention. What has been the standard procedure so far
3265256|NCT01521663|Experimental|IPX159|IPX159 90 mg daily at week 1 with titration to 180 mg daily at week 2 with possible titration to 270 mg daily at week 3.
3265257|NCT01521663|Placebo Comparator|Sugar Pill|IPX159 90 mg matching placebo daily at week 1 with titration to 180 mg matching placebo daily at week 2.
3265258|NCT01521676|Experimental|breast cancer|blood and tumor sample
3265259|NCT01521689|Experimental|Rituximab|Consolidation treatment with sub cutaneaous low doses of Rituximab
3265260|NCT01521702|Experimental|Neoadjuvant chemotherapy|After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).
3265261|NCT01521702|Active Comparator|surgery|surgery
3265262|NCT01521715|Experimental|Pazopanib|800 mg (2x400mg) pazopanib per day
3265263|NCT01521728|Active Comparator|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
3265264|NCT01521728|Active Comparator|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
3265265|NCT01521728|Active Comparator|Stretching/Range-of-Motion Exercise|"In ALS, stretching and range of motion are routinely recommended for the prevention of frozen shoulder syndrome and contractures resulting from weakness. The problem is compounded in ALS where upper motor neuron dysfunction may result in spasticity and incapacitating contractures with pain. Therefore, maintaining an aggressive program for stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
3265266|NCT01521741||Breast Cancer|
3265267|NCT01521754||Perspective|Prospective cohort: new patients who are initially implanted with a Medtronic neurostimulation system on or after a site's activation date. The classification is static and will not change in the case of a re-implant.
3265268|NCT01521754||Retrospective|Retrospective cohort: existing patients comprised the sub-group of patients who were implanted with a Medtronic neurostimulation system prior to a site's activation date. This cohort contains a part of retrospective data and a part of prospective data according to the enrolment date. The classification is static and will not change even when an existing patient will be subsequently re-implanted after the site's activation date.
3265269|NCT01521767|Experimental|A|4 mg tolterodine extended release capsules, administered with water and under fasting condition.
3265270|NCT01521767|Experimental|B|4 mg microspheres in powder blend release rate 2 (MPB-RR2), administered without water and under fasting condition.
3265271|NCT01521767|Experimental|C|4 mg microspheres in powder blend release rate 1 (MPB-RR1), administered without water and under fasting condition.
3265272|NCT01521767|Experimental|D|4 mg MPB-RR1, administered without water and under fed condition.
3265273|NCT01521767|Experimental|E|4 mg MPB-RR1, administered with water and under fasting condition.
3265274|NCT01521806|Experimental|Low dose|15 g of fiber per day will be added to snack foods
3265275|NCT01521806|Experimental|High dose|30 g of fiber per day will be added to snack foods
3265276|NCT01521806|Placebo Comparator|No fiber|Snack foods without fiber will be given
3265277|NCT01521819|Experimental|Iray plus Lucentis|open label arm in which all subjects receive a single 16 gy dose of radiation plus an injection of Lucentis.
3265278|NCT01521832|Experimental|Dose Group A|
3265279|NCT01521832|Experimental|Dose Group B|
3265280|NCT01521832|Experimental|Dose Group C|
3265281|NCT01521832|Experimental|Dose Group D|
3265282|NCT01521832|Experimental|Dose Group E|
3265283|NCT01521832|Experimental|Dose Group F|
3265284|NCT01521832|Experimental|Dose Group H|
3265285|NCT01521832|Experimental|Dose Group I|
3265286|NCT01521832|Experimental|Dose Group J|
3265287|NCT01521832|Experimental|Dose Group K|
3265288|NCT01521832|Experimental|Dose Group L|
3265289|NCT01521910|Experimental|Low protein diet|
3265290|NCT01521910|Active Comparator|Normal protein diet|
3265291|NCT01521936|Experimental|Arm I (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive lower-dose cholecalciferol PO beginning on day 8.
3265292|NCT01521936|Experimental|Arm II (25(OH)-D3 levels 20-31.9 ng/mL [insufficient levels])|Patients receive a loading dose of cholecalciferol PO on day 1. Patients then receive higher-dose cholecalciferol PO beginning on day 8.
3265293|NCT01521962|Experimental|SYR-322 (Alogliptin) QD|SYR-322 25 mg, orally.
3265294|NCT01521962|Placebo Comparator|Insulin|injection
3265295|NCT01521975|Experimental|HBeAg Negative Hepatitis|HBeAg Negative Hepatitis patients.
3265296|NCT01521988|Active Comparator|Atrial flutter ablation|RF atrial flutter ablation
3265297|NCT01521988|Experimental|Atrial flutter ablation and pulmonary vein isolation|RF Atrial flutter ablation and pulmonary vein isolation using cryoablation
3265298|NCT01522001|No Intervention|Hospital-based|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 to 3 individual consultations with nurse specialized in cardiac rehabilitation~Examination by cardiologist 8-12 weeks after discharge."
3265299|NCT01522001|Active Comparator|Shared care Model|"First visit at cardiac ambulatory approximately 14 days after discharge includes examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
3265300|NCT01522014|Active Comparator|Ceramic on Ceramic|Subjects received a ceramic on ceramic bearing total hip replacement.
3265301|NCT01522014|Active Comparator|Ceramic-on-Highly Crosslinked Polyethylene|
3265302|NCT01522027|Experimental|Nerve stimulator|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
3265303|NCT01522040|Active Comparator|Magnesium|Half the enrolled subjects will be randomized to receive active drug, a magnesium infusion.
3265304|NCT01522040|Placebo Comparator|Control|Half the subjects will be randomized to receive a drip that does not have active drug (magnesium sulfate).
3265305|NCT01522053|Experimental|Catheter-over-needle|Patients will receive a catheter placed by a catheter-over-needle method.
3265306|NCT01522053|Active Comparator|Catheter-through-needle|Patients will receive a catheter placed by the traditional catheter-though-needle method.
3265307|NCT01522066|Experimental|Perineural catheter|Local anesthetic will be delivered through an indwelling perineural catheter
3265308|NCT01522066|Active Comparator|Single-shot block|Local anesthetic will be delivered by the conventional, single-shot method.
3265309|NCT01522079|Experimental|Air stacking|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position.
3265310|NCT01522092|Experimental|escitalopram|escitalipram tablets 5mg, 10 mg and 20 mg, once a day for 12 months
3265311|NCT01522105|Experimental|1|i.v. daptomycin given 24 hours after first ceftriaxone dose at age appropriate dosage
3265312|NCT01522118|Experimental|HIFU|(high intensity focused ultrasound)
3265313|NCT01522144|Experimental|Asthma clinical decision support|decision support compared to no decision support in a cluster-randomized trial by practise
3265314|NCT01522157|Active Comparator|All test patients|All test patients are given low-fat, low-carbohydrate and mediterranean diet, in randomised order on different days.
3265315|NCT01522196|Active Comparator|Varespladib|48 hour continuous infusion delivered intravenously (IV)
3265316|NCT01522196|Placebo Comparator|Placebo|48 hour continuous infusion delivered intravenously (IV)
3265317|NCT01522222|No Intervention|Control|half of the study subjects will receive standard of care during their open heart surgery.
3265318|NCT01522222|Experimental|Treatment|half of the study subjects will receive the prescribed ventilatory support during open heart surgery.
3265319|NCT01522261|Active Comparator|Mechanical Bowel Prep|Patients randomized to complete a Mechanical Bowel Prep. (complete bowel cleansing) and fleet enemas prior to surgery.
3265320|NCT01522261|Active Comparator|No Mechanical Bowel Prep.|Patients randomized to complete two fleets enemas only prior to surgery.
3265321|NCT01522274|Active Comparator|Moderate intensity exercise|Brisk walk on treadmill for 56 minutes 3x per week.
3265322|NCT01522274|Active Comparator|Health education|Attend health education sessions 3x per week.
3265323|NCT01522287|Active Comparator|BT STEPS alone|"Subjects assigned to BT STEPS without coaching will receive computer assisted Cognitive Behavior Therapy. They will receive a welcome and orientation call from the project manager and up to three automated reminder e-mails if there is no activity in the BT Steps website for 5 days. E-mails will describe most recent step the participant used and what to expect in upcoming steps. The focus of reminder messages is on the patients progress through BT STEPS."
3265324|NCT01522287|Active Comparator|BT Steps with non-therapist coaching|Subjects randomized to BT STEPS with coaching will receive computer assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching, encouragement and support via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session. Coaches will be supervised by the CBT therapist, and may consult with the CBT clinician as needed.
3265325|NCT01522287|Active Comparator|BT STEPS with therapist coaching|Subjects randomized to BT STEPS with therapist coaching will receive computer-assisted Cognitive Behavior Therapy plus regularly scheduled weekly coaching and support from a CBT therapist via phone. Calls will focus on user's progress in BT STEPS, troubleshoot problems the participant is having with the program, and set progress goals for the next coaching session.
3265326|NCT01522313||Patients|Data of patients anesthetized in the years 2006 to 2012 (Hospital stay: January 2006 - June 2012) will be analysed in the study.
3265327|NCT01522326|Experimental|Metoclopramide|150 subjects with acute mountain sickness will be randomly assigned to take metoclopramide.
3265328|NCT01522326|Active Comparator|Ibuprofen|150 subjects with acute mountain sickness will be randomly assigned to take ibuprofen.
3265329|NCT01522352|Experimental|pericardial aortic valves|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
3265330|NCT01522365|Active Comparator|Abutment-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
3265331|NCT01522365|Active Comparator|Implant-supported XiVE CAD/CAM bridge|After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
3265332|NCT01522378|Experimental|Biv-ICD|Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
3265333|NCT01522430|Experimental|Renal angiography followed by renal sympathetic denervation|Catheter based therapy for renal denervation using the Simplicity (TM) catheter (Ardian/Medtronic)
3265334|NCT01522430|Sham Comparator|Renal angiography alone|Renal selective angiography using standardized method: Local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
3265335|NCT01522469|Experimental|Crenolanib Besylate|
3265336|NCT01522482|Experimental|High saturated fat meal|
3265337|NCT01522482|Experimental|Saturated fatty acid and fish oils meal|Equivalent to two portions of oily fish
3265338|NCT01522482|Active Comparator|High unsaturated fat meal|Provided a fatty acid profile representative of a typical UK diet
3265339|NCT01522495|Experimental|SPY Imaging|SPY Imaging Prior to Amputation or Debridements (50 participants)
3265340|NCT01522495|No Intervention|No SPY Imaging|Amputation or Debridements as Standard of Care (50 participants)
3265341|NCT01522495|Experimental|Validation Against Angiogram|"Patients who are scheduled to undergo an angiogram will also receive ICG angiography (SPY). This will occur at specific time points: 1.) before the angiogram/intervention is performed 2.) immediately after the angiogram/intervention is performed 3.) 5-7 days after angiogram/intervention 4.) 21-30 days after angiogram/intervention.~(30 participants)"
3265342|NCT01522495|Experimental|Establishing Normal Values|To establish baseline lower extremity perfusion in non-PVD patients. Patients requiring an angiogram for other vascular processes unrelated to the lower extremity will be recruited into this study. ICG angiography (SPY) of the lower extremity will be performed at the time of the angiogram. (30 Participants)
3265343|NCT01522508||propofol/remifentanil|patients receive standardized propofol and changing remifentanil concentrations
3265344|NCT01522508||sevoflurane/remifentanil|patients receive standardized sevoflurane and changing remifentanil concentrations
3265345|NCT01522521|Experimental|1.|
3265346|NCT01522521|Placebo Comparator|2.|
3265347|NCT01522534|Experimental|Blind block with mepivacaine|Blind block with mepivacaine and intravenous morphine
3265348|NCT01522534|Active Comparator|Morphine|Intravenous Morphine and placebo blind block
3265349|NCT01522547|Experimental|Cohort 1: 0.5 mg pomalidomide|0.5 mg pomalidomide orally daily for 84 days
3265350|NCT01522547|Experimental|Cohort 2: 1.0 mg pomalidomide|1.0 mg pomalidomide orally daily for 84 days
3265351|NCT01522547|Experimental|Cohort 3: 2.0 mg pomalidomide|2.0 mg pomalidomide orally daily for 84 days
3265352|NCT01522547|Experimental|Cohort 4: 3.0 mg pomalidomide|3.0 mg pomalidomide orally daily for 84 days
3265353|NCT01522547|Experimental|Cohort 5: 4.0 mg pomalidomide|4.0 mg pomalidomide orally daily for 84 days
3265354|NCT01522560|Placebo Comparator|Control Group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
3265355|NCT01522560|Active Comparator|Feedback group|Residents will be randomly assigned to a feedback group or to the control group. Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a MSF evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation. Only the group assigned to feedback is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the MSF.
3265356|NCT01522573||EUS guided ERCP procedure group|Subjects who will undergo Endoscopic Ultrasound (EUS) guided Endoscopic retrograde cholangiopancreatography (ERCP) procedures for their pancreatico-biliary conditions.
3265357|NCT01522586|Experimental|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
3265358|NCT01522586|Placebo Comparator|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
3265359|NCT01522599|Active Comparator|ARDS-Net strategy (Control)|
3265360|NCT01522599|Experimental|ECCO2-R with 4 mL/Kg Vt (Treatment)|
3265361|NCT01522612|Experimental|5-fluorouracil/leucovorin plus cetuximab|
3265362|NCT01522612|Active Comparator|5-fluorouracil/leucovorin alone|
3265363|NCT01522625|Experimental|TDF|tenofovir disoproxil fumarate (TDF) 300mg
3265364|NCT01522625|Placebo Comparator|Placebo|
3265365|NCT01522638||ADOA|This group includes subjects diagnosed with autosomal dominant optic atrophy
3265366|NCT01522638||Healthy subjects|
3265367|NCT01522664|Experimental|Single group|
3265368|NCT01522677|Experimental|PDT|Participants receive neoadjuvant 5-ALA and PDT.
3265369|NCT01522716|Experimental|Mesenchymal stromal cell treatment|
3265370|NCT01522729|Experimental|Fentanyl|
3265371|NCT01522729|Experimental|Placebo|
3265372|NCT01522742||Healthy control subjects|Healthy control subjects matched to psoriasis patients on traditional cardiovascular risk factors will be studied at baseline.
3265373|NCT01522742||Psoriasis patients starting etanercept|Patients with moderate to severe psoriasis with or without arthritis who are about to be started on etanercept (enbrel) by their treating clinicians will be studied at baseline and 3 months after etanercept therapy.
3265374|NCT01522768|Experimental|Afatinib and Paclitaxel|This is a multi-institution, open-label, non-randomized, Phase II evaluation of oral afatinib daily and intravenous paclitaxel (weekly, 3 weeks on, 1 week off) in patients with trastuzumab refractory HER2-positive metastatic or recurrent esophagogastric adenocarcinoma. An initial biopsy prior to the start of therapy is required for the correlative studies evaluating the biologic effects of afatinib. It will be obtained for all patients whose tumors are feasible to biopsy. At the site investigator's discretion, a second biopsy will also be obtained. At the discretion of the MSK Principal Investigator, select participants who show response on this study and then progress may be asked to have an optional third biopsy.
3265375|NCT01522794|Experimental|NOX-H94|Single dose of NOX-H94
3265376|NCT01522794|Placebo Comparator|Placebo|Single dose of placebo control
3265377|NCT01522807|Experimental|100 mg PF-05190457|Three fasted treatments and fed with the short-duration osmotic capsule
3265378|NCT01522807|Experimental|100 mg PF - 05190457|Three fasted treatments and fed with the long-duration osmotic capsule
3265379|NCT01522820|Experimental|Cohort 1a (vaccine therapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 protein vaccine intranodally on days 1, 29, 57, and 113.
3265380|NCT01522820|Experimental|Cohort 1b (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-14, 29-42, and 57-70.
3265381|NCT01522820|Experimental|Cohort 1c (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 vaccine as in Cohort 1a and sirolimus PO or PEG on days 15-28, 43-56, and 71-84.
3265382|NCT01522820|Experimental|Cohort 1d (vaccine therapy and immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in Cohort 1a and sirolimus PO or PEG on days 1-84.
3265383|NCT01522820|Experimental|Cohort 2 (vaccine therapy with or without immunotherapy)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 as in the Cohort (1a-1d) that is determined to be safe and produces optimal immunological effects and sirolimus PO on days 1-14 as in Cohort 1b dose.
3265384|NCT01522833||Cohort A|EGFR Wild Type patients
3265385|NCT01522833||Cohort B|EGFR mutation patients
3265386|NCT01522846||Heparin|
3265387|NCT01522859|No Intervention|standard care|A standardised home based programme of specialist respiratory assessment and monitoring provided by the local Community Respiratory Team (CRT) and General Practitioner (GP) for a period of six months.
3265388|NCT01522859|Experimental|Telehealth monitoring|Daily monitoring of patient's health status using a small telecommunications device.
3265389|NCT01522872|Experimental|Monotherapy TH-302 Dose Escalation|
3265390|NCT01522872|Experimental|TH-302 and Dexamethasone Dose Expansion|
3265391|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Bortezomib|
3265392|NCT01522872|Experimental|TH-302 Dose Escalation and Dexamethasone with Pomalidomide|
3265393|NCT01522885|Active Comparator|KatGuide|Chest tube insertion is performed by using the KatGuide
3265394|NCT01522885|Active Comparator|Conventional group|Chest tubes are inserted by using conventional method (forceps) for large bore chest tube insertion.
3265395|NCT01522898|Active Comparator|Medical Rate Control|Medical Rate Control aimed at ventricular rate target of 90 beats per minute. Specific medical therapy to be determined for each patient by individual clinician.
3265396|NCT01522898|Experimental|AV nodal ablation|AV node ablation performed by percutaneous catheter ablation, with endpoint of complete heart block.
3265397|NCT01522911|Other|atrial and brain natriuretic peptide|Impact on atrial an brain natriuretic peptide secretion after percutaneous left atrial appendage closure
3265398|NCT01522989|Experimental|PD-0332991, 5-FU and oxaliplatin|PD-0332991 with 5-FU and oxaliplatin
3265399|NCT01523002|Active Comparator|Arm A: Metoprolol DDI and Pyramax 90-day re-dosing|Subjects will take 1 day of metoprolol followed by a 7 day wash out period; then 2 days of Pyramax followed by 1 day of Pyramax + metoprolol and then a 87 day follow-up period. Subjects will then receive Pyramax once daily for three days followed by a 40 day follow-up period and a study completion evaluation.
3265400|NCT01523002|Active Comparator|Arm B: Pyramax 60-day re-dosing|Subjects will take Pyramax once daily for 3 days, followed by a 57 day follow-up period. Subjects will then take Pyramax once daily for 3 days followed by a 40 day follow-up period.
3265401|NCT01523015|Experimental|Combined therapy|The combined modality therapy will be consisted of preoperative chemoradiotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil, 45Gy) for type I i II cancer or preoperative chemotherapy (Docetaxel, Oxaliplatin, 5-Fluorouracil) for type III cancer and followed by surgery.
3265402|NCT01523015|Active Comparator|Surgery|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
3265403|NCT01523028|Experimental|Coffee, bread and honey|200 mL coffee + 2 bread rolls + honey
3265404|NCT01523028|Experimental|Coffee, bread and peanut butter|200 mL coffee + 1 bread roll + peanut butter
3265405|NCT01523028|Experimental|200 mL black coffee|
3265406|NCT01523041|Experimental|BIAsp 70 clinical trial formulation|
3265407|NCT01523041|Experimental|BIAsp 70 final formulation|
3265408|NCT01523041|Experimental|BIAsp 50 final formulation|
3265409|NCT01523054|Experimental|Metoprolol- Toprol XL|Metoprolol extended release (CR/XL) tablet 200 mg once daily
3265410|NCT01523054|Active Comparator|Metoprolol- Lopressor|Metoprolol immediate release (IR) tablet
3265411|NCT01523067|Active Comparator|Vasomera (PB1046)|
3265412|NCT01523067|Placebo Comparator|0.9% Sodium Chloride|
3265413|NCT01523080|Active Comparator|Tylenol® 650 mg|Tylenol® 650 mg of McNeil Consumer and Specialty Pharmaceuticals, Division of McNeil PPC, INC. Fort Washington, PA 19034 USA.
3265414|NCT01523080|Experimental|Acetaminophen extended release Gel tabs 650 mg|Acetaminophen extended release Gel tabs 650 mg of OHM Laboratories Inc. (A subsidiary of Ranbaxy Pharmaceuticals Inc., USA)
3265415|NCT01523093|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) orally disintegrating tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
3265416|NCT01523093|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron 8 mg Orally Disintegrating Tablets Manufactured By OHM Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals Inc, USA)
3265417|NCT01523106|Active Comparator|Carnitine|Patients will take 4grams of L-carnitine (2 grams twice daily) for 3 months
3265418|NCT01523106|Placebo Comparator|Placebo|Patients will take placebo for 3 months. Placebo is manufactured by the same company as the L-carnitine and will have a similar appearance.
3265419|NCT01523119|Active Comparator|Zofran ODT|Zofran ODT (Ondansetron) Orally Disintegrating Tablets 8mg Manufactured By Cardinal Health, Blagrove, Swindon, Wiltshire, UK SN58RU
3265420|NCT01523119|Experimental|Ondansetron Orally Disintegrating Tablets|Ondansetron Orally Disintegrating Tablets 8 mg Manufactured By Ohm Laboratories Inc (A subsidiary of Ranbaxy Pharmaceuticals, USA)
3265421|NCT01523132||Breast cancer patients|Female breast cancer patients without metastasis and locally advanced disease
3265422|NCT01523145|Experimental|Intervention|
3265423|NCT01523145|Experimental|Control gruop|
3265424|NCT01523158|Other|Immunotherapy|Open label study of changes to cellular responses following immunotherapy
3265425|NCT01523171|Experimental|SAR302503 400 mg|once daily in consecutive 28-day cycles, flexible dosing regimen (the starting dose is 400mg/day), orally, empty stomach, approximately same time each day
3265426|NCT01523184|Placebo Comparator|Placebo Capsule|Placebo Capsules
3265427|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 10 mg|
3265428|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 20 mg|
3265429|NCT01523184|Active Comparator|YKP10811 Drug Product Capsule, 30 mg|
3265430|NCT01523197|Other|ventilator|The comparison of the curative effect on OS between BiPAP and auto-trilevel ventilations
3265431|NCT01523210||upper limb spasticity|patients suffering from upper limb spasticity and are treated with botulinum toxin
3265432|NCT01523223|Experimental|Treatment (DLI)|Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.
3265433|NCT01523236|Experimental|Investigational Test Product|Mometasone furoate anhydrous 50 mcg/actuation Nasal Spray (Teva)
3265434|NCT01523236|Active Comparator|Reference Listed Drug|Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray (Schering)
3265435|NCT01523236|Placebo Comparator|Placebo|Saline Placebo Nasal Spray
3265436|NCT01523249||Scanned and palpated|Healthy, pregnant, term women delivering at BC Women's Hospital and expecting to have neuraxial anesthesia.
3265437|NCT01523262|Active Comparator|Preconditioning and normal treatment|
3265438|NCT01523262|Placebo Comparator|normal treatment|Standard treatment
3265439|NCT01523288||Prader-Willi patients|
3265440|NCT01523288||Control group|Control group for ultrasound scan
3265441|NCT01523314|Experimental|dexamethasone - Cyclodextrin|
3265442|NCT01523314|Active Comparator|Avastin/Laser|
3265443|NCT01523327||A|40 pregnant Women with hypertension who have uric acid level more than 6 mg per dL.
3265444|NCT01523327||B|40 pregnant women with hypertension who have uric acid level less than 6 mg per dl.
3265445|NCT01523340||Erlotinib treatment|
3265446|NCT01523353|Active Comparator|Exercise Intervention|4 week personalised exercise program on a static bicycle.
3265447|NCT01523353|No Intervention|Control Arm|Patients having standard preoperative preparation and advice.
3265448|NCT01523405||1|
3265449|NCT01523418||Group 1|
3265450|NCT01523431|Active Comparator|Standard FOLFIRI for wild/hetero UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3265451|NCT01523431|Experimental|Reduced Dose of CPT-11 for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 90 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3265452|NCT01523431|Active Comparator|Standard FOLFIRI for homo UGT1A1|Irinotecan Injection [Camptosar] (CPT-11) 180 mg/m2, day 1; Leucovorin (LV) 400mg/m2, day 1; 5-fluorouracil (5-FU) 400mg/m2, day 1, 5-fluorouracil (5-FU) 2400mg/m2, day 1; Repeat every two weeks.
3265453|NCT01523444|No Intervention|Treatment as Usual|
3265454|NCT01523444|Active Comparator|computer Screening & Brief Advice|All participants receiving care at the site assigned to the computer-facilitated screening and brief advice (cSBA) condition will receive the cSBA intervention as part of their care at that clinic.
3265455|NCT01523444|Experimental|computer Screening & Brief Advice Plus|All participants receiving care at the site assigned to the cSBA+ condition will receive the cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider as part of care at that clinic.
3265456|NCT01523470|Active Comparator|stepwise withdrawal of NIV|On the day of decision of withdrawal (day0), the duration of non-invasive ventilator (NIV) will be decreased to 16 hours. On the following day (day1), the duration of NIV will be further decreased to 12 hours. The duration will be further decreased to 8 hours at night on the following day (day 2), and it will be stopped on the day after (day 3). Vital signs and blood gases will be monitored for a total of 5 days after withdrawal is planned (day 0 to day 5).
3265457|NCT01523470|Experimental|immediate withdrawal of NIV|The patient will have immediate withdrawal of non-invasive ventilator (NIV). Vital signs and blood gases will be monitored for 2 more days after NIV is stopped (day 0-2).
3265458|NCT01523483|Experimental|Progesterone|Patients in this arm will receive two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
3265459|NCT01523483|Placebo Comparator|placebo|Patients will receive two placebo capsules placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
3376419|NCT05160220|Active Comparator|Psilocybe cubensis|0.5 g dried and powdered P. cubensis in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
3265460|NCT01523509|Experimental|Contrast|All subjects will be in one group who will have a control radiograph of teeth before applying the Sodium Iodide contrast agent topically between the teeth (the intervention) when another radiograph will be taken to test for the presence of contrast in a cavity.
3265461|NCT01523522|Active Comparator|myoblast injection|autologous myoblast
3265462|NCT01523522|Placebo Comparator|saline solution injection|saline solution injection in anal sphincter
3265463|NCT01523535|Placebo Comparator|normal sleep|Subjects have 8 hours of sleep opportunity per night
3265464|NCT01523535|Experimental|cycles of sleep restriction|subjects are exposed to bouts of reduced sleep duration. The sleep loss is the intervention (experimental challenge).
3265465|NCT01523548|Experimental|Carbon Monoxide|Inhaled Carbon Monoxide therapy administered over 16 weeks
3265466|NCT01523561|No Intervention|usual care|The participants in the no intervention group were informed that they should continue living as usual
3265467|NCT01523561|Experimental|dance intervention|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
3265468|NCT01523574|Placebo Comparator|Control Group|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
3265469|NCT01523574|Experimental|Vitamin e|Five days before chemotherapy:1 x daily Used until one week after third oxaliplatin infusion: 1 x daily
3265470|NCT01523600|Experimental|Whole body vibration training|
3265471|NCT01523600|Active Comparator|Wellness group|
3265472|NCT01523626|Other|Conventional imaging|The control group will be evaluated with X-rays, ultrasonography and selective CT scanning.
3265473|NCT01523626|Other|Immediate total body CT|The intervention group will receive a 'total body' CT scan from head to pelvis. Conventional radiography and FAST will be completely omitted.
3265474|NCT01523639|Active Comparator|Metformin|FOLFIRI + cetuximab + metformin every 2 weeks for 12 cycles
3265475|NCT01523639|Placebo Comparator|Placebo|FOLFIRI + cetuximab + placebo every 2 weeks for 12 cycles
3265476|NCT01523652||Nadroparin/control (phase 1)|patients affected by benign pelvic gynaecologic diseases were enrolled and treated with nadroparin for prophylactic anticoagulation; patients untreated with nadroparin were as control group.
3265477|NCT01523652||Nadroparin (phase 2)|patients were enrolled among women planning gynaecological pelvic surgery and treated for 4 weeks with nadroparin for prophylactic anticoagulation. All these patients underwent laparotomy;
3265478|NCT01523678|Experimental|Filgrastim|
3265479|NCT01523691|Experimental|repeated sleep restriction and recovery|
3265480|NCT01523691|Experimental|control sleep|
3265481|NCT01523730|Active Comparator|Repetitive Transcranial Magnetic Stimulation (rTMS)|
3265482|NCT01523730|Placebo Comparator|Sham rTMS|
3265483|NCT01523769|No Intervention|Control|Control group, the cord was not milked
3265484|NCT01523769|Experimental|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery
3265485|NCT01523795|Experimental|Motion-controlled video gaming|Participants played motion-controlled video games that involved at least throwing, hitting, or dancing motions using a Wii or Xbox 360 console for one hour
3265486|NCT01523795|Active Comparator|Traditional video gaming|Participants played traditional (handheld gamepad controller-based) video games using a Playstation 3 console for one hour
3265487|NCT01523795|Active Comparator|Television watching|Participants watched television via Netflix instant streaming for one hour
3265488|NCT01523847|Experimental|MBVD (Myocet+BVD)|"2 MBVD courses, after early restaging with PET scan (PET-2)~The subsequent treatment will be planned as follows:~-Stage I and IIA patients will go on with 1 more course of MBVD (total of 3 courses) followed by involved field radiotherapy (30 Gy-36 Gy).~-Advanced stage (IIB-IV) patients will go on with 4 more courses of MBVD (total of 6 courses). Radiotherapy limited to bulky or non complete responder areas (30 Gy) is optional."
3265489|NCT01523860|Experimental|1|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration.
3265490|NCT01523912|Experimental|gastric RFA|Ablation of gastric dysplastic mucosa
3265491|NCT01523925|Experimental|Combined dCIT with FET|Combined distributed constraint induced therapy with functional electrical therapy
3265492|NCT01523925|Experimental|Combined BAT with FET|Combined bilateral arm treatment with functional electrical therapy
3265493|NCT01523925|Active Comparator|Control intervention group|Control intervention
3265494|NCT01523925|Experimental|dCIT|distributed constraint induced therapy
3265495|NCT01523925|Experimental|BAT|bilateral arm treatment
3265496|NCT01523938|Experimental|Hypnotherapy|
3265497|NCT01523938|No Intervention|No Hypnotherapy|
3265498|NCT01523951||Healthy volunteers|
3376420|NCT05160220|Placebo Comparator|Inactive placebo|Same weight of inactive placebo in gel capsules, dosing on two separate days, separated by one week from the placebo, randomized order.
3265499|NCT01523990|Experimental|Panel I (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3265500|NCT01523990|Placebo Comparator|Panel I (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 50 mg (fasted) to 50 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3376421|NCT05160194|Other|GROW Intervention|Every participant received the GROW Intervention, chose not to participate in the GROW intervention, or dropped out before completing the GROW Intervention.
3376422|NCT05160181||Yogatherapy|Retrospective study on medical file of patients seen in consultation for chronic pain with prescription of Yogatherapy
3376428|NCT05160155|Active Comparator|Serratus Anterior Plane Block|Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
3376429|NCT05160155|Active Comparator|Intercostal Block|The USG probe will be placed at the level of the posterior axillary line and the broken ribs. After imaging the ribs, external intercostal muscle and internal intercostal muscle structures, 3 ml of 0.25% bupivacaine will be injected into the subcostal area. This 3 ml 0.25% bupivacaine injection will be administered for each broken rib. The block will then be terminated.
3376431|NCT05160129|Experimental|Circuit-selective DBS|People suffering from severe obsessive-compulsive disorder (OCD)
3376432|NCT05160090|Active Comparator|Test- BUPROPION HCl MR TABLETS 300mg|Single dose of Test- BUPROPION HCl MR TABLETS 300mg
3376433|NCT05160090|Active Comparator|Reference-Elontril 300 mg|Elontril 300 mg (Bupropion HCl MR tablets 300mg)
3376434|NCT05160077|Other|Fasting|All examinations are in a fasting state.
3376435|NCT05160077|Other|Standardised Breakfast|"Preprandial examination is in fasting state, all postprandial examinations will be conducted with standardized dietary.~30 minutes after the beginning of the preprandial examination participants receive an standardized breakfast. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal."
3265501|NCT01523990|Experimental|Panel II (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3265502|NCT01523990|Placebo Comparator|Panel II (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 100 mg (fasted) to 100 mg (fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3376436|NCT05160077|Other|Standardised Breakfast and ICG|"Preprandial examination are in a fasting state, all postprandial examinations will be conducted with standardized dietary including indocyanine green (ICG) dye.~30 minutes after the beginning of the preprandial examination participants receive an standardised breakfast containing ICG. 270 minutes after the beginning of the preprandial examination participants receive an standardised meal without ICG."
3376437|NCT05160064||Patients Treated with Loncastuximab Tesirine|Patients with B-cell lymphomas and other diagnoses who have been treated with loncastuximab tesirine will have their medical chart data entered into the registry.
3376438|NCT05160051|Experimental|68Ga-FAPI-46 PET Scan|A single-center prospective interventional single-arm clinical trial. All eligible subjects undergo FAPI-PET Scan
3376439|NCT05160038|Experimental|Bodily illusions|Participants in the experimental group see a bodily illusion applied to their embodied virtual avatar.
3376440|NCT05160038|No Intervention|No bodily illusions|Participants in the control group embody a virtual avatar, but without bodily illusions
3376441|NCT05160025|Other|Virtual Reality Bicycling|This is a single arm study in which all participants will execute the same three bicycling tasks over one session. Exercise intensity and enjoyment are measured while participants bicycle in a virtual reality environment (wearing virtual reality goggles) in three different conditions lasting approximately 8 minutes each.
3376442|NCT05160012|No Intervention|Control|This group will not receive peer comparison messages and will continue with usual care.
3376443|NCT05160012|Experimental|Intervention|This group will receive peer comparison messages.
3376444|NCT05159999|Experimental|Home Systolic Blood Pressure <140 mmHg|Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <140 mmHg.
3376445|NCT05159999|Active Comparator|Pre-Dialysis Systolic Blood Pressure <140 mmHg|Participants will have their blood pressure taken by an automated blood pressure device by dialysis unit staff using regular dialysis unit equipment according to usual clinical care. Pre-dialysis blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a pre-dialysis systolic blood pressure target of <140 mmHg.
3265503|NCT01523990|Experimental|Panel III (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3376446|NCT05159999|Other|Home Systolic Blood Pressure <130 mmHg|This will be an optional, exploratory 2 month study at the end of the primary 10-month trial. Participants will take their home blood pressure two times per week (one in the morning and one in the evening) on non-dialysis days, ideally mid-week. Home blood pressures will be reviewed every two weeks and dry weight and medications adjusted accordingly to reach a home systolic blood pressure target of <130 mmHg.
3376447|NCT05159986|Experimental|Group Diadynamic and Exercises|Group Diadynamic and Exercises received Diadynamic currents associated to Exercise three times a week for 8 weeks following initial assessment (n=30, 60 knees) Diadynamic currents was performed with the following parameters: application of the two-phase current and then the long-term one. Each current was applied for 4 minutes on the medial and lateral sides of the knee.
3376448|NCT05159986|Experimental|Group Exercises|Group Exercises received only exercises three times a week for 8 weeks following initial assessment (n=30, 60 knees).
3376449|NCT05159960|Experimental|180/low|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
3265504|NCT01523990|Placebo Comparator|Panel III (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 200 mg (fasted or fed) to 400 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3265505|NCT01523990|Experimental|Panel IV (TG-2349)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of TG-2349 with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3376450|NCT05159960|Experimental|180/high|SLT treatment in either half of the trabecular meshwork (180 degrees) consisting of 50+/-5 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
3376451|NCT05159960|Experimental|360/low|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted 0,1 mJ below the threshold of formation of micro bubbles.
3265506|NCT01523990|Placebo Comparator|Panel IV (placebo)|Sequential single oral dose taken by healthy East and Caucasian volunteers from 600 mg (fasted or fed) to 800 mg (fasted or fed) of placebo with 1 week follow-up after each dosage. A washout period of at least 10 days between the 1st and the 2nd dose is required.
3265507|NCT01523990|Experimental|Panel V (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
3265508|NCT01523990|Placebo Comparator|Panel V (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 100 mg taken by healthy East and Caucasian volunteers .
3265509|NCT01523990|Experimental|Panel VI (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
3376452|NCT05159960|Experimental|360/high|SLT treatment in the full circumference of the trabecular meshwork (360 degrees) consisting of 100+/-10 adjacent laser effects. The energy is adjusted to achieve the formation of micro bubbles at 50-75% of laser effects.
3376453|NCT05159947|Experimental|Test group (SPT-07A injection group)|
3376454|NCT05159947|Placebo Comparator|Control group (placebo group)|
3376455|NCT05159934|Active Comparator|Nicotine|Experimental Session 2 will determine if smokers can discriminate 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
3376456|NCT05159934|Placebo Comparator|saline|Saline will compared to different nicotine doses. Nicotine doses: 0.05, 0.025, and 0.0125 mg nicotine/pulse of nicotine from saline.
3265510|NCT01523990|Placebo Comparator|Panel VI (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 200 mg taken by healthy East and Caucasian volunteers .
3265511|NCT01523990|Experimental|Panel VII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
3265512|NCT01523990|Placebo Comparator|Panel VII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 400 mg taken by healthy East and Caucasian volunteers .
3265513|NCT01523990|Experimental|Panel VIII (TG-2349)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
3265514|NCT01523990|Placebo Comparator|Panel VIII (placebo)|Oral dose taken once daily for 5 consecutive days at dose level of 600 mg taken by healthy East and Caucasian volunteers .
3265515|NCT01523990|Experimental|Panel IX (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265516|NCT01523990|Placebo Comparator|Panel IX (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 200 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265517|NCT01523990|Experimental|Panel X (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265518|NCT01523990|Placebo Comparator|Panel X (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 400 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265519|NCT01523990|Experimental|Panel XI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265520|NCT01523990|Placebo Comparator|Panel XI (placebo)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 1 (including subtypes 1a or 1b or mixed 1a/1b) infected patients.
3265521|NCT01523990|Experimental|Panel XII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 2 infected, treatment-naive patients.
3265522|NCT01523990|Experimental|Panel XIII (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 3 infected, treatment-naive patients.
3265523|NCT01523990|Experimental|Panel XIV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 4 infected, treatment-naive patients.
3265524|NCT01523990|Experimental|Panel XV (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 5 infected, treatment-naive patients.
3265525|NCT01523990|Experimental|Panel XVI (TG-2349)|Oral dose taken once daily for 3 consecutive days at dose level of 600 mg (fed) taken by HCV genotype 6 infected, treatment-naive patients.
3265526|NCT01524003|Experimental|Cryotherapy after VIA triage|Women who test HPV positive will be randomized to the experimental arm or the standard of care arm. In the Experimental arm VIA will be done to determine acceptability for cryotherapy [R/O high-grade CIN too large for cryotherapy (usually 3-4 quadrant disease) or cancer]. All acceptable patients will have an ECC done and then immediate cryotherapy.
3265527|NCT01524003|Active Comparator|Colposcopy and biopsy|Standard of care. Women testing positive for HPV will be randomized to the experimental arm (immediate cryotherapy) or the Standard of care arm, for colposcopy, biopsy, and leep based on the pathology results.
3265528|NCT01524016|Experimental|68Ga-DOTATATE, PET/CT scan|We will perform 68Ga-DOTATATE PET/CT scanning on subjects
3265529|NCT01524029||Breast Cancer Screening Patients|Group 1 consists of Women referred to Breast Cancer Screening examinations at a participating Austrian Breast Imaging Site
3265530|NCT01524029||Diagnostic Patients|Patients referred to a participating Breast Imaging Center for a clinically or radiologically detected breast lesion
3265531|NCT01524042|Experimental|group 2|study group:double pants group
3265532|NCT01524055|Other|Air|Air as insufflation gas during single-balloon enteroscopy.
3265533|NCT01524055|Other|CO2|CO2 as insufflation gas during single-balloon enteroscopy.
3265534|NCT01524068|Experimental|Arm A - Standard Steroid Treatment|
3265535|NCT01524068|Experimental|Arm B - Experimental Treatment|
3265536|NCT01524081|Experimental|APPE - antibiotic prophylaxis|Patients indicated for emergent appendectomy with antibiotic prophylaxis
3265537|NCT01524081|Experimental|GERD - antibiotic prophylaxis|Patients indicated for emergent surgery due to gastroduodenal perforation with antibiotic prophylaxis.
3265538|NCT01524081|Experimental|ILEUS - antibiotic prophylaxis|Patients indicated for emergent due to small bowel obstruction with antibiotic prophylaxis
3265539|NCT01524081|Placebo Comparator|APPE - placebo|Patients indicated for emergent appendectomy without antibiotic prophylaxis. Placebo (saline) was administrated.
3265540|NCT01524081|Placebo Comparator|GERD - placebo|Patients indicated for emergent surgery due to gastroduodenal perforation without antibiotic prophylaxis. Placebo (saline) was administrated.
3265541|NCT01524081|Placebo Comparator|ILEUS - placebo|Patients indicated for emergent due to small bowel obstruction without antibiotic prophylaxis. Placebo (saline) was administrated.
3265542|NCT01524094|Experimental|Arm A: CRS plus postop intraperitoneal chemotherapy.|Cytoreductive surgery and postoperative intraperitoneal chemotherapy.
3265543|NCT01524094|Active Comparator|Arm B: Systemic chemotherapy alone|Systemic chemotherapy alone
3265544|NCT01524107||Urgent Caesarian Section|
3265545|NCT01524107||Elective Caesarian Section|
3265546|NCT01524120||Crohn's disease (CD)|Patients with CD and mucosal healing on endoscopy.
3265547|NCT01524120||Crohn's disease|Patients with CD and mucosal healing on endomicroscopy.
3265548|NCT01524120||Ulcerative colitis (UC)|Patients with UC and mucosal healing on endoscopy.
3265549|NCT01524120||Ulcerative colitis|Patients with UC and mucosal healing on endomicroscopy.
3265550|NCT01524146||Photodynamic therapy|Subjects who will receive photodynamic therapy for palliation of unresectable Cholangiocarcinoma.
3265551|NCT01524159|Placebo Comparator|placebo group|This group will receive placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
3265552|NCT01524159|Active Comparator|bromelain group|Bromelain Group This group will receive bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
3265553|NCT01524172|Active Comparator|Standard Mental Health Treatment|Trauma-informed evidence supported mental health treatment
3265554|NCT01524172|Experimental|Yoga Based Psychotherapy Group|Yoga Based Psychotherapy will be used as an adjunct mental health interventions
3265555|NCT01524185|Experimental|FamilyLive|Multi-therapist group intervention for families with a history of intergenerational neglect and trauma exposure
3265556|NCT01524185|Active Comparator|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
3265558|NCT01524237|Experimental|10 mg LY2140023 + ketamine|Single oral dose of 10 mg LY2140023 followed by intravenous (IV) ketamine during one of the crossover periods
3265559|NCT01524237|Experimental|20 mg LY2979165 + ketamine|Single oral dose of 20 mg LY2979165 followed by IV ketamine during one of the crossover periods
3453153|NCT04024488|Experimental|TI-CBT Intervention Arm|In the Randomized Trial, youth participants will be randomized in a 1:1 ratio with their caregivers to one of two study arms. One arm is the TI-CBT intervention arm consisting of: six 2-hour TI-CBT group sessions lead by Indigenous Youth Leaders (IYL) during weeks 1 - 6 and one 2-hour booster group session at 6-months. The caregivers (willing to participate with youth permission) for youth who are enrolled into the TI-CBT arm will be enrolled onto the same arm, and receive two 2-hour group sessions led by adult study staff during weeks 1-6 and one 2-hour booster group session at 6-months. The youth and caregiver sessions are held separately.
3265560|NCT01524237|Experimental|40 mg LY2140023 + ketamine|Single oral dose of 40 mg LY2140023 followed by IV ketamine during one of the crossover periods
3265561|NCT01524237|Experimental|60 mg LY2979165 + ketamine|Single oral dose of 60 mg LY2979165 followed by IV ketamine during one of the crossover periods
3265562|NCT01524237|Experimental|160 mg LY2140023 + ketamine|Single oral dose of 160 mg of LY2140023 followed by IV ketamine during one of the crossover periods
3265563|NCT01524237|Placebo Comparator|Placebo capsules + ketamine|Single oral dose of placebo capsules followed by IV ketamine during one of the crossover periods
3265564|NCT01524237|Placebo Comparator|Placebo tablets + ketamine|Single oral dose of placebo tablets followed by IV ketamine during one of the crossover periods
3265565|NCT01524250|Experimental|oral prednisone|1250mg oral prednisone daily for 3 days
3265566|NCT01524250|Active Comparator|IV methylprednisolone|1000mg IV methylprednisolone daily for 3 days
3265567|NCT01524315|Experimental|Supplementation|6 ml Vitamin-B1-ratiopharm in 100 ml normal saline, intravenous, preoperative
3265568|NCT01524315|Placebo Comparator|Placebo|100 ml normal saline, intravenous, preoperative
3265569|NCT01524341|Experimental|Cohort 1|10 subjects with Plasmodium vivax malaria will receive 30 mg KAE609 once a day for three days
3265570|NCT01524341|Experimental|Cohort 2|10 subjects with Plasmodium falciparum malaria will receive 30 mg KAE609 once a day for three days
3265571|NCT01524354|Active Comparator|Control|Patients received maintenance of anesthesia with continuous infusion of propofol according to recommendations of the manufacturer.
3265572|NCT01524354|Active Comparator|cerebral state index|Patients received continuous infusion of propofol with rate maintaining cerebral state index (CSI) between 40 and 60 points.
3265573|NCT01524367|Placebo Comparator|saline group|We administrate the saline single bolus (0.01ml/kg,intravenously) at time of oral cavity sealing.
3265574|NCT01524367|Experimental|dexmedetomidine group|We administrate the dexmedetomidine single bolus (1ug/kg, intravenously) at time of oral cavity sealing.
3265575|NCT01524380|Active Comparator|Ginkgo biloba extract, antioxidant|Active treatment with Ginkgo biloba extract
3265576|NCT01524380|Placebo Comparator|Placebo|Treatment with placebo
3265577|NCT01524393||IVF pregnancy|
3265578|NCT01524406|Experimental|HPP593|
3265579|NCT01524406|Placebo Comparator|Placebo|
3265580|NCT01524419||women after vaginal birth|
3265581|NCT01524432|Experimental|Drug loaded microcapsules socks|Study medication
3265582|NCT01524432|Placebo Comparator|No drug loaded microcapsules socks|Placebo medication
3265583|NCT01524445||bortezomib retreatment|bortezomib retreatment due to relapse Patients who received bortezomib-containing chemotherapy as first-line treatment for MM experienced partial response or better and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
3265584|NCT01524458|Experimental|POEM|To perform myotomy using endoscopy through a long submucosal tunnel
3265585|NCT01524471|Experimental|POEM|Endoscopic Myotomy
3265586|NCT01524484||Anesthesia staff Interviewees|Staff entering quality data into the electronic anesthesia record are interviewed regarding working conditions and record layout
3265587|NCT01524484||Anesthesia records|Anesthesia records (all types of procedures) are checked for correct reporting of defined events
3265588|NCT01524497|Active Comparator|Trazodone|
3265589|NCT01524497|Placebo Comparator|Placebo|
3265590|NCT01524510|Experimental|MRA|All OSAS patients will be asked to sleep two nights without MRA and, +/- 1 week later, two nights with MRA
3265591|NCT01524536|Other|1|All subjects will receive a single oral dose of prednison (1 mg/kg rounded to the neares 5 mg). The subjects will then begin GC therapy at 30 mg prednisone daily followed by a standardized taper.
3265597|NCT01524562||Rakai Community Cohort|HIV Patients
3265598|NCT01524562||Rakai HIV Care Program|HIV Patients
3265599|NCT01524575|No Intervention|ERCC1 high expression|Patients with ERCC1 high expression tumors will be treated at discretion of investigator
3265600|NCT01524575|Experimental|ERCC1 low expression|Patients with ERCC1 low expression will be treated with gemcitabine and oxaliplatin
3265601|NCT01524601|Experimental|Rosuvastatin|Rosuvastatin treatment for 4 weeks
3265602|NCT01524614|Experimental|Nasal mask with no PEEP|Nasal mask with PEEP 0, then add PEEP 5, and 10
3265603|NCT01524614|Experimental|Nasal mask with PEEP|Nasal mask with PEEP 5, then add PEEP 10
3265604|NCT01524614|Experimental|Face mask with no PEEP|Face mask with PEEP 0 then add PEEP 5, 10
3265605|NCT01524614|Experimental|Face mask with PEEP|Face mask with PEEP 5, then add PEEP 10
3265606|NCT01524640|Experimental|Killed oral cholera vaccine|"Killed Bivalent (O1 and O139) Whole cell oral cholera vaccine (Shanchol TM) Vaccine strain Reformulated version~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) of lipopolysaccharide (LPS) V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
3265607|NCT01524640|Placebo Comparator|Placebo|"Non biologic placebo~Ingredients Per 1.5 ml dose~Starch 60mg~Red color[1mg/ml] 10 µl~Yellow color [1mg/ml] 5 µl~Xanthum Gum (1% solution) 300 µl~Water for Injection Upto 1.5 ml~All the above ingredients are of pharmaceutical grade.~Non-biological placebo of above composition has been used in 2010 for Randomized, double-blind, placebo controlled trial to evaluate the safety and immunogenicity of orally administered, killed, bivalent whole-cell , cholera vaccine, Shanchol in Bangladeshi Adults and Children. This study involving 330 subjects was carried out at International Center for Diarrheal Disease Research Bangladesh (ICDDR,B) located in Dhaka, Bangladesh with Dr. Firdausi Qadri as Principal Investigator (NCT01042951). There were no safety concerns associated with this placebo in this study and the report of this study has been submitted to the National Regulators in Bangladesh and the World Health Organization."
3265608|NCT01524653|Experimental|Rosuvastatin First, Placebo Last|This arm will receive rosuvastatin during the first treatment period followed by placebo in the second treatment period after washout.
3265609|NCT01524653|Experimental|Placebo First, Rosuvastatin Last|This arm will receive placebo during the first treatment period followed by rosuvastatin in the second treatment period after washout.
3265610|NCT01524705|Experimental|Insulin Glargine, metformin, exenatide|Approximately 60 Type 2 DM participants will be instructed on an AHA/ADA meal plan. Insulin Glargine, metformin and exenatide will used as a combination strategy to control individual HBA1Cs between 6.7 and 7.3% throughout the trial.
3265611|NCT01524705|Active Comparator|glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
3265612|NCT01524718|Experimental|Imaging with two X-ray image intensifiers|There is no change in the procedure except for the imaging technique, while in the first group the X- ray image intensifier serves in the two planes, and being moved from one plane to the other, and in the second group the two devices are static in the same position, one in the AP plane and the other as the axial plane.
3265613|NCT01524718|No Intervention|Imaging with one X-ray image intensifier.|The X- ray image intensifier serves in the two planes, and being moved from one plane to the other
3265614|NCT01524731|Placebo Comparator|Placebo|Placebo group
3265615|NCT01524731|Active Comparator|4 mg dexamethasone|4 mg dexamethasone group
3265616|NCT01524731|Active Comparator|Dexamethasone 8 mg|Dexamethasone 8 mg group
3265617|NCT01524744|Active Comparator|Pimecrolimus ointment 0.1 %|This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
3265618|NCT01524744|Active Comparator|Adcortyle|Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
3265619|NCT01524757|Experimental|pantoprazol|
3265620|NCT01524757|Placebo Comparator|placebo|
3265621|NCT01524809|Experimental|Treatment period 1|
3265622|NCT01524809|Experimental|Treatment period 2|
3265627|NCT01524835||Live lung donors|Live lung donors who participated in donation from 1993 through 2006
3265628|NCT01524848|Other|Open label|Single arm pazopanib
3265629|NCT01524861|Placebo Comparator|Placebo|30 subjects receive placebo (placebo group)
3265630|NCT01524861|Experimental|alpha-lipoic acid|30 subjects receive alpha-lipoic acid, 400 mg/day per os bis in die (800 mg/day)(ALA group)
3265631|NCT01524861|Experimental|L-acetil-carnitine|30 subjects receive L-acetyl carnitine, 500 mg per os bis in die (1000 mg/day) (LAC group)
3265632|NCT01524874|Active Comparator|Powder D3 Capsule - 2,000 IU per Cap|Vital Nutrients
3265633|NCT01524874|Active Comparator|Chewable D3 Tablet - 2,000 IU per Tab|Integrative Therapeutics Inc.
3265634|NCT01524874|Active Comparator|Liquid D3 Drop - 2,000 IU per Drop|Biotics Research
3265635|NCT01524926|Experimental|Crizotinib in Anaplastic large cell lymphoma|
3265636|NCT01524926|Experimental|Crizotinib in Inflammatory myofibroblastic tumor|
3265637|NCT01524926|Experimental|Crizotinib in Papillary renal cell carcinoma type 1|
3265638|NCT01524926|Experimental|Crizotinib in Clear cell sarcoma|
3265639|NCT01524926|Experimental|Crizotinib in Alveolar soft part sarcoma|
3265640|NCT01524926|Experimental|Crizotinib in Alveolar rhabdomyosarcoma|
3265641|NCT01524939|Experimental|Investigational product|
3265642|NCT01524952|Experimental|Active|cTEMS
3265643|NCT01524965|Experimental|Immediate mobilisation|
3265644|NCT01524965|Active Comparator|Standard mobilisation|
3265645|NCT01525004|Active Comparator|Standard dose trivalent inactivated influenza vaccine|
3265646|NCT01525004|Experimental|High-Dose trivalent inactivated influenza vaccine|
3265647|NCT01525017|Experimental|Combig-DC Cancer Vaccine|Two vaccinations of Combig-DC (allogeneic dendritic cells) Cancer Vaccine given before nephrectomy.
3265648|NCT01525043|Active Comparator|Naproxen|
3265649|NCT01525043|Experimental|Synera single patch applied for 12 hrs/day|
3265650|NCT01525043|Experimental|Synera sinlgle patch applied for 4hrs twice daily|
3265651|NCT01525056|Other|imaging with ct, mri and pet scans|ct,mri and pet scans pre and post radiation
3265652|NCT01525069|Experimental|Arm A (HAI FUDR alone)|"14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3265653|NCT01525069|Experimental|Arm B (HAI FUDR + gemcitabine)|"Consists of Cohort B1, B2, and B3. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR and gemcitabine.~Gemcitabine IV will be given on Days 1, 8, and 15 of each 28 day cycle in Cohort B1~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle in Cohort B2 & B3~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3265654|NCT01525069|Experimental|Arm C (HAI FUDR + gemcitabine + oxaliplatin)|"Consists of Cohort C1, C2, C3, and C4. Enrollment to specific cohorts will depend on the number of DLTs in each cohort. Each cohort has a different dose of FUDR, gemcitabine, and oxaliplatin.~Gemcitabine IV will be given on Days 1 and 15 of each 28 day cycle.~Oxaliplatin IV will be given on Days 1 and 15 of each 28 days cycle.~14-42 days after surgery for insertion of the HAI pump, floxuridine (FUDR) and dexamethasone plus heparin in normal saline to a total volume of 30 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump.~The pump will be emptied and refilled with heparinized normal saline and dexamethasone on Day 15 of each cycle to be infused over the next 14 days."
3265655|NCT01525095||Candida Positive Patients|Symptomatic adult patients, confirmed via concordant diagnostic blood culture and species identification and subsequent second blood culture results and species identification that are Candida positive
3265656|NCT01525095||Candida Negative Patients|Hospitalized adult patients, confirmed via concordant diagnostic blood culture with subsequent species identification and subsequent second blood culture with subsequent species identification that are Candida negative
3265657|NCT01525108|Experimental|Home-based blood pressure monitoring|
3265658|NCT01525108|Active Comparator|Usual care|
3265659|NCT01525121|Experimental|Expiratory Rib Cage Compression|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
3265660|NCT01525121|No Intervention|Control|This a crossover study, so all subjects performed both, control and experimental interventions. The patients were kept in supine at 30 degree head-up position. Ventilatory mode was changed to volume-controlled, with a tidal volume of 8mL/kg, inspiratory flow of 60 Lpm and positive end expiratory pressure (PEEP) of 5 cmH2O. A first tracheal suctioning was done, and the mucus was discarded. Then, a series of two minutes of bilateral expiratory rib-cage compressions ensued. Aiming to minimize inter-therapist variability, the maneuver was applied by the same registered and trained physiotherapist. Control intervention followed the same sequence, but instead of the compressive maneuver they were kept on normal ventilation with the parameters described above.
3265661|NCT01525147|Experimental|YHB1411-2: Level 2|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3265662|NCT01525147|Experimental|YHB1411-2: Level 3|The ratio of Test Drug(YHB1411-2) to Placebo is 13 :2.
3265663|NCT01525147|Experimental|YHB1411-2: Level 4|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3265664|NCT01525147|Experimental|YHB1411-2: Level 5|The ratio of Test Drug(YHB1411-2) to Placebo is 4 :1.
3265665|NCT01525147|Experimental|YHB1411-2: Level 1|All investigational products are YHB1411-2(This level is pilot study).
3265666|NCT01525199||Case|
3265667|NCT01525199||Control|
3265668|NCT01525212|Experimental|Arm 1: BMS-929075 (≤ 25 mg) OR Placebo matching BMS-929075|
3265669|NCT01525212|Experimental|Arm 2: BMS-929075 (≤ 100 mg) OR Placebo matching BMS-929075|
3265670|NCT01525212|Experimental|Arm 3: BMS-929075 (≤ 400 mg) OR Placebo matching BMS-929075|
3265671|NCT01525212|Experimental|Arm 4: BMS-929075 (≤ 800 mg) OR Placebo matching BMS-929075|
3265672|NCT01525264|Experimental|Culturally Relavent Education|Education about improving diet using a DVD with Korean role models and native Korean language.
3265673|NCT01525264|Active Comparator|Healthy Wife Intervention|Intervention group of couples who received education about importance of a Healthy Diet. It was an attention control group
3265674|NCT01525277||left subclavian vein|CVC implanted in the left subclavian vein
3265675|NCT01525277||right subclavian vein|CVC implanted in the right subclavian vein
3265676|NCT01525290|Experimental|intravenous tissue plasminogen activator|Intervention drug: intravenous tissue plasminogen activator (tPA), alteplase
3265677|NCT01525290|Placebo Comparator|Placebo|Intervention drug: placebo
3265678|NCT01525303|Experimental|Exercise-Start (ES)|The ES group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches. In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 1. The exercise prescription will increase to 25 minutes in Week 2, and 30 minutes in Week 3. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
3265679|NCT01525303|Experimental|Exercise-Middle (EM)|The EM group will receive standard behavioral treatment in the Self-Management Training Program for Chronic Headaches.In addition to this material, participants in this group will receive an exercise prescription for 20 minutes of moderate-intensity aerobic activity at the beginning of Week 5. The exercise prescription will increase to 25 minutes in Week 6, and 30 minutes in Week 7. They are asked to maintain 30 minutes per day of exercise through Week 8. Participants choose the type of exercise, and have the option to break it up into 10-minute increments throughout the day.
3376457|NCT05159921|No Intervention|Standard Consent|Standard consent procedure: The rationale, risks, benefits, and alternatives for the intended procedure (diagnostic or screening OGD or colonoscopy) will be discussed in the outpatient clinic by a consultant general surgeon (DOK) or members of the surgical team. Patients will be given the opportunity to ask questions. All patients will receive a written information leaflet, which includes contact details for the endoscopy department should patients wish to ask further questions (supplemental data). Those undergoing colonoscopy will receive further instructions along with prescribed colonoscopy 'prep' medication by post. On the day of the procedure, patients are required to sign a standardised consent form.
3376458|NCT05159921|Experimental|Standard consent + access to an automated conversational agent (SurgInfoBot)|Patients in the SurgInfoBot arm will be consented as above, but will also be granted access to the SurgInfoBot, which they will be invited to use between their outpatient appointment and their endoscopy procedure date. Participants will be provided with an access link and Unique Study Identifier in order to pseudonymise participant data. Participants will be able to access the SurgInfoBot as many times as they wish, and can ask any questions they see fit.
3265682|NCT01525355||EUS prior to ERCP|
3265683|NCT01525368||cognitive intervention group|
3376459|NCT05159908|Placebo Comparator|Placebo schedule|Participant follows Placebo schedule (13 weeks)
3265684|NCT01525368||active control group|
3265685|NCT01525394|Experimental|Lenvatinib Capsules|
3376460|NCT05159908|Experimental|Dose schedule A|Participant follows Dose schedule A (13 weeks)
3376461|NCT05159908|Experimental|Dose schedule B|Participant follows Dose schedule B (13 weeks)
3265686|NCT01525394|Active Comparator|Moxifloxacin tablets|
3265687|NCT01525394|Placebo Comparator|Placebos|
3376462|NCT05159908|Experimental|Dose schedule C|Participant follows Dose schedule C (13 weeks)
3265688|NCT01525433|No Intervention|Control|
3265689|NCT01525433|Active Comparator|Low Intensity Information (DVD)|A low-intensity information program, consisting of a video approach educating women on the importance of cervical cancer screening;
3376463|NCT05159895|Experimental|[14C]-DZD9008|A Single dose of [14C]-DZD9008
3376464|NCT05159882|Experimental|THR-1442 20mg|Each subject will receive THR-1442 20 mg and Dapagliflozin placebo, once daily for the duration of the study.
3376465|NCT05159882|Active Comparator|Dapagliflozin10mg|Each subject will receive Dapagliflozin 10 mg and THR-1442 placebo, once daily for the duration of the study.
3265690|NCT01525433|Active Comparator|High Intensity Information (Promotora)|A higher intensity information program consisting of the video plus a 'promotora' or lay-community health educator led-intervention at the participant's home to encourage cervical cancer screening.
3376466|NCT05159869|Experimental|Experimental|After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia. Persons randomized to the User-Led Meaningful Activity intervention group will begin the treatment protocol right after randomization. The intervention will consist of 3-4 sessions lasting 60-90 minutes each in which participants receive feedback from the neuropsychological assessment, identify the basis/topic of the activity plan, receive dementia psychoeducation, and map out an activity gradation plan. A brief cognitive screening tool will be re-administered at six months and 12 months. The neuropsychological battery that was administered at baseline will be re-administered 12 months later. Follow-up will also involve solicitation of feedback from the person with dementia and his or her caregiver regarding participants' participation in the study.
3376467|NCT05159869|Active Comparator|Wait-List Control|"After participants are recruited, participants will undergo neuropsychological testing prior to randomization in order to establish baseline cognitive functioning and verify that the participants are indeed in the early stages of dementia (i.e., mild dementia). Those who meet criteria will be randomly assigned. Persons randomized to the wait-list control group will begin the treatment protocol after four months' time."
3376468|NCT05159856||cross-sectional study of 1 cohort (observational)|400 children/adolescents, aged 6-18 years, with type 1 diabetes for more than 12 months
3376469|NCT05159843|Experimental|Diabetes Self-Management education|"Participants randomized to this arm receive therapeutic education during four sessions of four consecutive days. An advanced practice nurse who specializes in diabetes will teach these sessions. The sessions will have small groups of five patients and it will last of one hour each day. The outline of the session is as follow (Figure 1):~First session: Insulin administration and blood glucose self-analysis Second session: Management of hypoglycemia and hyperglycemia Third session: Healthy diet adapted to the diabetic patient Four session: Physical exercise"
3376470|NCT05159843|Experimental|Usual care|Participants in control group receive usual services offered in University Hospital and other local health systems for patients with diabetes, which include regular visits with a diabetes provider (primary care or endocrine) and standard Spanish Diabetes Society information pamphlets. Consultation care is centralized in the pharmacological treatment regimen, dosage and guidelines.
3376471|NCT05159830|Experimental|Cannabidiol (CBD)|CBD Group from 20mg x 2/day up to 600mg/day
3265691|NCT01525446|Experimental|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
3265692|NCT01525459||Glioma patients|
3265693|NCT01525485||Electrical Stimulation|Participants will have a dedicated visit with a pelvic floor physical therapist during which instructions on usage and technique for the Minnova unit will be given. The electrical parameters selected will be: 10 Hertz frequency, 5-second on/10=second off cycle, and a pulse width of 0.4 milliseconds. The bipolar square will be delivered over a range that varies from 0 to 100 milliamps, depending on the maximum current intensity comfortably tolerated by the patient. The participant will perform each treatment session for 20 minutes twice daily for 8 weeks. Participants will be asked to keep a log recording the dates, times, and duration of each treatment session.
3265694|NCT01525485||Interstim device|Participants assigned to the sacral neuromodulation group will undergo InterStim device placement by one of the three Urogynecologists at OUHSC using a staged implant technique according to manufacturer's specifications.
3265695|NCT01525498||1 day catheter removal|Participants randomized to group 1 will have their catheter removed 1 day after surgery.
3376472|NCT05159830|Placebo Comparator|PLACEBO (PCB)|PCB Group from 20mg x 2/day up to 600mg/day
3265696|NCT01525498||2 day catheter removal|Participants randomized to group 2 will have their catheter removed 2 days after surgery.
3265697|NCT01525511|Experimental|Group A|Primaquine only followed by Dihydroartemisinin-piperaquine and followed by Primaquine together with Dihydroartemisinin-piperaquine.
3265698|NCT01525511|Active Comparator|Group B|Primaquine only followed by Primaquine together Dihydroartemisinin-piperaquine and followed by Dihydroartemisinin-piperaquine only.
3265699|NCT01525524|Sham Comparator|Sham Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the Transcranial Direct Current Stimulation. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 1 minute, after that the device will be automatically turned off for 29 minutes.
3265700|NCT01525524|Active Comparator|Active Stimulation|In active stimulation, the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex with the transcranial Direct Current Stimulation device. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp. The device will deliver a charge of 2mA for 30 minutes.
3265701|NCT01525537|Experimental|SPI guided arm|sufentanil was adjusted to SPI level
3265702|NCT01525537|Active Comparator|Standard practise|Sufentanil was given at standard practise
3265703|NCT01525576|No Intervention|Control group|No offer of booster program.
3265704|NCT01525576|Experimental|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
3265705|NCT01525654|Active Comparator|Partners|Patients who are matched with support partners and have a billing diagnosis of RA (714.0) or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS) or the Patient-Centered Outcomes Initiative (PACO)
3265706|NCT01525654|No Intervention|Controls|Controls will be BRASS patients who continue to receive regular care without being matched with a peer support partner.
3265707|NCT01525680|Active Comparator|Prolonged Exposure therapy with Hydrocortisone|
3265708|NCT01525680|Placebo Comparator|Prolonged Exposure therapy with placebo|
3265709|NCT01525693||Diagnosed within 6 months|No (test) intervention to be adminisitered
3265710|NCT01525706|Experimental|Ethanol and Paclitaxel Injection|All patients will receive at least one treatment with alcohol and paclitaxel.
3265711|NCT01525719|Experimental|RAD001|
3265712|NCT01525732|Other|POEM|Per Oral Endoscopic Myotomy
3265713|NCT01525758|Experimental|SI000413 400mg|tablet, SI000413 200mg bid
3265714|NCT01525758|Experimental|SI000413 600mg|tablet, SI000413 200mg tid
3265715|NCT01525758|Experimental|SI000413 800mg|SI000413 200mg, 2T bid
3265716|NCT01525758|Placebo Comparator|placebo|placebo 2T tid for 8 weeks
3265717|NCT01525771|No Intervention|No intervention|Single-center, open-label, prospective, single-arm, phase I-II study
3265718|NCT01525784||Rt-CGMS|Using Rt-CGMS, approved by ministry of health as part f clinical care
3265719|NCT01525784||Control|Not approved or suggested for RtCGMS. Other acceptabl means of therapy
3265720|NCT01525797||Control|
3265721|NCT01525797||Rejection|
3265722|NCT01525810||Subjects treated with Peginterferon Lambda-1a (BMS-914143)|Subjects who participated in a clinical trial in which Peginterferon Lambda-1a (BMS-914143) was administered for the treatment of chronic hepatitis C
3265723|NCT01525823|Experimental|BMS-754807 + Metformin|
3265724|NCT01525836|Experimental|combination treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with Rh-TPO at the indicated dose.
3265725|NCT01525836|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take Rituximab at the indicated dose.
3265726|NCT01525888|No Intervention|control|continue with treatment with angiotensin converting enzyme inhibitor or angiotensin blocker during all study period
3265727|NCT01525888|Experimental|drug stop|temporary stop of angiotensin converting enzyme inhibitor and angiotensin blocker treatment at least 72 hours before coronary angiography and renew of treatment 72 hours after angiography
3265728|NCT01525901|Experimental|Insulin-Like Growth Factor-1 (IGF-1)|Injection
3265729|NCT01525901|Placebo Comparator|Normal saline|Injection
3265730|NCT01525914||dutasteride, active surveillance|men with favorable risk prostate cancer on surveillance treated with dutasteride
3265731|NCT01525940|Other|Colon capsule and CT-colonography|PillCam Colon Capsule Endoscopy (Given® Diagnostic System) ingestion first and CT-colonography about 10-12 hours post-ingestion
3265732|NCT01525966|Experimental|Treatment (carboplatin and nab-paclitaxel)|Patients receive carboplatin IV over 30 minutes on day 1 and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes once weekly. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3265733|NCT01525979|Experimental|Task-Related UAT|Therapist conducted unilateral arm training Task-related unilateral arm training
3265734|NCT01525979|Experimental|Task-Related BAT|Therapist conducted bilateral arm Training Task-related bilateral arm training
3265735|NCT01525979|Experimental|Task-Related UAT coupling BAT|Therapist conducted task-related unilateral training for 45 minutes, followed by task-related bilateral arm training for another 45 minutes during each training session
3265736|NCT01525979|Experimental|Robot-assisted UAT|Robot-assisted unilateral arm training
3265737|NCT01525979|Experimental|Robot-assisted BAT|Robot-assisted bilateral arm training
3265738|NCT01525992|Experimental|Community Pharmacy-based Program|
3265739|NCT01525992|Active Comparator|Usual care|
3265740|NCT01526005||Active agent (nicotine patch)|
3265741|NCT01526005||Placebo patch|
3265742|NCT01526018||Novel bottle|
3265743|NCT01526031|Experimental|BV1|1:10,000 bee venom (BV) acupuncture plus physiotherapy
3265744|NCT01526031|Experimental|BV2|1:30,000 bee venom (BV) acupuncture plus physiotherapy
3265745|NCT01526031|Placebo Comparator|NS|Normal saline injection plus physiotherapy
3376473|NCT05159804||Carotid plaque length|Patients underwent coronary angiography and carotid ultrasonography simultaneously
3265746|NCT01526044|Experimental|Freestyle group|Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
3376474|NCT05159791|Experimental|Anomalous coronary blood flow|Subjects suspected to have AAOCA will be submitted to angiographic coronary CT imaging to confirm the diagnosis. If the diagnosis of AAOCA will be confirmed, subjects will undergo to invasive coronary blood flow evaluation (intervention).
3376475|NCT05159778|Experimental|Experimental|
3265747|NCT01526044|Active Comparator|AccuChek group|Glucose levels are being measured by the AccuChek. Patients also get a Freestyle Navigator, which will be blinded. The device will stay on the patient up to 5 days, or until discharge from the ICU.
3265748|NCT01526070||Patients with Exudative Age-Related Macular Degeneration|Patients with eAMD who received intravitreal thearpy
3265749|NCT01526083|Other|Single dose of Warfarin on day 3|Single dose of Warfarin on day 3 of a 7 day course of Lacosamide 200 mg BID
3265750|NCT01526083|Other|Single dose of Warfarin|
3265751|NCT01526096|Active Comparator|Standard ASCT (Grp 1)|Standard autologous stem cell transplantation (ASCT)
3265752|NCT01526096|Experimental|Depletion of T-cells after ASCT (Grp 2)|Standard ASCT followed by treatment with basiliximab to remove certain immune cells (called regulatory T-cells or Tregs) from the blood
3265753|NCT01526096|Experimental|Depletion of T-cells before ASCT(Grp 3)|Blood collected for an ASCT will be processed using a special cell sorting machine (CliniMACS device) to remove Treg cells before the stem cells are infused back into the body during stem cell transplant.
3265754|NCT01526109|Experimental|strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
3265755|NCT01526109|Placebo Comparator|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
3265756|NCT01526109|Experimental|whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
3265757|NCT01526122|Experimental|G0041(75/100mg)|
3265758|NCT01526122|Active Comparator|Clopidogrel & Aspirin|
3265761|NCT01526161|Experimental|Inhaled Fluticasone propionate and salmeterol|inhaled fluticasone propionate 100 micrograms and salmeterol 50 m
3265762|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and placebo|inhaled fluticasone propionate 100micrograms twice daily + placebo
3265763|NCT01526161|Active Comparator|Inhaled Fluticasone propionate and Montelukast|inhaled fluticasone propionate 100micrograms twice daily + Montelukast
3265764|NCT01526174|Experimental|First Arm|Determine safety of intratympanic injection
3265765|NCT01526174|Experimental|Second Arm|Efficacy evaluation of 4 intratympanic injections
3265766|NCT01526187||Sub-Saharan Africa|
3265767|NCT01526187||Asia|
3265768|NCT01526187||Latin America|
3265769|NCT01526200||CEIOUS|One hundred and twenty-seven consecutive patients -77 males and 50 females, mean age of patients was 61 years (median 65 years; range 29-85 years)- underwent liver resection using intraoperative ultrasound and contrast-enhanced intraoperative ultrasound.
3265770|NCT01526226|Experimental|HFNC|High flow nasal cannula
3265771|NCT01526226|Active Comparator|nCPAP|Nasal CPAP
3265772|NCT01526239|Experimental|Intervention group|Intervention consisted of a pamphlet about the benefit of CRC-S, given to patients prior to their PCP visit and a reminder note about CRC screening to be given to their physician during the encounter.
3265773|NCT01526239|No Intervention|Control group|Control group will not receive the pamphlet regarding colorectal cancers.
3265774|NCT01526265|Active Comparator|Usual Care|Participants will be offered free smoking cessation programs, and be provided web-based education regarding the health and economic benefits of smoking cessation. Participants will also have the opportunity to submit weekly reports on their smoking habits. They will be informed that they will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
3265775|NCT01526265|Experimental|Individual Rewards|Same as USUAL CARE arm, plus financial incentive as follows: if participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators.
3265776|NCT01526265|Experimental|Fixed Deposits|Same as USUAL CARE arm, plus financial incentive as follows: participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
3265777|NCT01526265|Experimental|Competitive Deposits (Pari-Mutuel)|"Same as USUAL CARE, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
3265778|NCT01526265|Experimental|Collaborative Rewards|"Same as USUAL CARE arm, plus financial incentive as follows: groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
3265779|NCT01526278|Other|Maxmarvil®|single-arm study
3376476|NCT05159765|Placebo Comparator|Control|Contact lens with refractive correction, single vision optic
3376477|NCT05159765|Experimental|Treatment|Contact lens with refractive correction, multifocal optic
3376478|NCT05159752|Experimental|Afamelanotide|
3265780|NCT01526317|Experimental|1|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
3265781|NCT01526317|Experimental|2|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
3265782|NCT01526317|Experimental|3|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
3265783|NCT01526317|Experimental|4|This arm is consist of 6 subject. Glucodown 750mg alone for 5 day during period 1. Crestor 10mg alone for 5 day during period 2. Crestor 10mg and Glucodown 750mg for 5 day during period 3.
3265784|NCT01526317|Experimental|5|This arm is consist of 6 subject. Crestor 10mg alone for 5 day during period 1. Crestor 10mg and Glucodown 750mg for 5 day during period 2. Glucodown 750mg alone for 5 day during period 3.
3265785|NCT01526317|Experimental|6|This arm is consist of 6 subject. Crestor 10mg and Glucodown 750mg for 5 day during period 1. Glucodown 750mg alone for 5 day during period 2. Crestor 10mg alone for 5 day during period 3.
3265786|NCT01526330|Experimental|Group A|
3265787|NCT01526330|Experimental|Group B|
3265788|NCT01526330|Experimental|Group C|
3265789|NCT01526330|Placebo Comparator|Group D|
3265790|NCT01526369|Active Comparator|Paclitaxel and Trastuzumab|Weekly paclitaxel (80mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8mg/kg loading dose on cycle 1 day 1 and 4mg/kg every 2 weeks) until disease progression, unacceptable toxicity or consent withdrawal.
3265791|NCT01526369|Experimental|Paclitaxel, Trastuzumab and Lapatinib|"Weekly paclitaxel (80 mg/m², for 3 weeks of a 4 week cycle) + trastuzumab (8 mg/kg loading dose on cycle 1 day 1 and 4 mg/kg every 2 weeks)~+ lapatinib (1,000 mg daily), until disease progression, unacceptable toxicity or consent withdrawal."
3265792|NCT01526382|Active Comparator|intervention arm|patients allocated to intervention arm receive PiCCO monitoring for hemodynamics and pulmonary conditions
3265793|NCT01526382|Placebo Comparator|control arm|Patients in this arm do not receive PiCCO monitoring device to guide fluid management, but central venous catheter can be inserted at the discretion of treating physician.
3265794|NCT01526395|No Intervention|Unmodified ECT|Data will be collected on patients receiving ECT in its unmodified form prior to the introduction of low dose propofol sedation.
3265795|NCT01526395|Active Comparator|Low Dose Propofol|Subjects will be given low dose propofol prior to ECT.
3265796|NCT01526421|Experimental|monetary reinforcer|
3265797|NCT01526421|No Intervention|no reinforcer|
3265798|NCT01526434||Certolizumab Pegol treatment|Patients with RA who begin therapy with Certolizumab Pegol (CZP) will be consecutively included in accordance with the selection criteria. The choice of medical treatment is made independently by the physician before evaluating the possible participation of the patient in the protocol.
3265799|NCT01526447|Experimental|Craniosacral Therapy (CST)|Each participant of the experimental group receives 8 Craniosacral Therapy units once a week of 45 minutes.
3265800|NCT01526447|Sham Comparator|Sham Craniosacral Therapy (SHAM)|Each participant of the sham group receives 8 sham therapy units once a week of 45 minutes.
3265801|NCT01526460|Active Comparator|Atorvastatin|Atorvastatin 80 mg
3265802|NCT01526460|Active Comparator|Rosuvastatin|Rosuvastatin 40 mg
3265803|NCT01526460|Placebo Comparator|No statin loading dose|No statin loading dose
3265804|NCT01526473|Experimental|AVX901|AVX901 at 4 x 108 IU intramuscularly, given every 2 weeks for a total of three doses.
3265805|NCT01526486|Experimental|Videoscopic (Minimally invasive)|Patients in this arm will have the procedure done through the three port minimally invasive approach.
3265806|NCT01526486|Active Comparator|Open (traditional approach)|Patients in this arm will have the traditional, open approach in conjunction with a sartorius muscle transposition.
3265807|NCT01526499|Experimental|TC|Docetaxel plus Cyclophosphamide
3265808|NCT01526499|Active Comparator|T|Docetaxel
3265809|NCT01526512|Experimental|metroCX|metroCX Cyclophosphamide 50mg PO d1-28; Capecitabine 1500mg PO d1-28; every 28days
3265810|NCT01526525|Placebo Comparator|TK|In TK group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point in both hands, the needles were not inserted in the skin but they were put atop the skin and were secured by adhesive tape. For 30min in the E/A stimulator ITO ES-160 the indicator light was on but no electrical current was applied. Thereafter the E/A device deactivated and after the awakening of the patients, it was connected in ST36 and LI4 points for 30min with the same technique. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36. The patients were told that they may or may not feel electrical current because of its very high frequency.
3265811|NCT01526525|Active Comparator|TKE|In TKE group when the closure of the abdominal walls started, a certified acupuncturist expert put needles, Ener-Qi 0.26Χ25mms, in LI4 point at 2cm depth in both hands and E/A was applied for 30min with the E/A stimulator ITO ES-160 in constant pulse program with 300μs duration and 100Hz frequency. After the needles were connected to the E/A stimulator, they were secured by adhesive tape. The response which certified the right needle placement was the adjacent muscular twitch. Thereafter the E/A device was deactivated and after the awakening of the patients, E/A was administered in ST36 and LI4 points for 30min with 4Hz frequency. The electrodes were connected to each other in every point, as the right with the left point of LI4 and the right with the left point of ST36.
3265812|NCT01526564|Active Comparator|ALC|ALC
3265813|NCT01526564|Placebo Comparator|Placebo|
3265814|NCT01526590|Experimental|Definity|Patients enrolled in the study will undergo contrast enhanced endoscopic ultrasound of the pancreas with Definity contrast after they have undergone their standard of care endoscopic ultrasound of the pancreas.
3265815|NCT01526603|Other|Patients Treated for Neuroblastoma|According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.
3265816|NCT01526616|Active Comparator|Metformin|850 mg/day twice a day
3265817|NCT01526616|Active Comparator|Metformin plus spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
3265818|NCT01526642|No Intervention|Long Term Oxygen Therapy|
3265819|NCT01526642|Active Comparator|Non Invasive Ventilation|
3265820|NCT01526655|Active Comparator|Abdominal total hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision
3265821|NCT01526655|Active Comparator|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
3265822|NCT01526668|Active Comparator|No contact after discharge|In Arm A: The patient do not have planned contacts with the study nurse or doctor after discharge. All patients are seen by the study nurse six weeks postoperatively.
3265823|NCT01526668|Active Comparator|Single telephone contact|In Arm B: The patient has one planned telephone contact with the study nurse the day after discharge. All patients are seen by the study nurse six weeks postoperatively.
3265824|NCT01526668|Active Comparator|Telephone contacts regularly|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively.
3265825|NCT01526668|Active Comparator|Telephone contact using CBT-inspired strategy|In Arm C: The patient has planned telephone contacts with the study nurse the day after discharge and then once weekly until the six weeks follow-up visit postoperatively. At these telephone contacts the study nurse uses a cognitive behavior therapy (CBT)-inspired strategy in counselling and support.
3265826|NCT01526681||RANGER: Avance Nerve Graft|Processed Human Nerve Graft
3265827|NCT01526681||Historical Control for Standard Treatment|Literature review for outcomes from standard treatments, i.e. Autogenous Nerve Graft.
3265828|NCT01526681||MATCH Arm: Contemporary Control|Addendum 1: Autogenous Nerve Graft and Nerve Tube Conduit
3265829|NCT01526681||Sensation-NOW Arm: Breast Neurotization|Addendum 2: Post-mastectomy autologous breast reconstruction with or without neurotization
3265830|NCT01526694|Experimental|treatment with BDT|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
3265831|NCT01526707|Experimental|inhaled steroid|inhaled steroid treatment for 7 days
3265832|NCT01526720||Group A: Diabetic|Newly diagnosed type 2 diabetic patients (i.e. diagnosis made no more than 6 months before recruitment)
3265833|NCT01526720||Group B: Relatives|Relatives of patients with potentially monogenic newly diagnosed type 2 diabetes
3265834|NCT01526746|Experimental|End Stage Renal Disease, dialysis|eGFR <15 ml/min/1.73m^2
3265835|NCT01526746|Experimental|Severe renal impairment|eGFR < 29 ml/min/1.73m^2
3265836|NCT01526746|Experimental|Healthy controls|eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status
3265837|NCT01526759|Experimental|pectin|10 gram high gelling-high viscous fiber, added to a drink
3265838|NCT01526759|Placebo Comparator|control|10g gelatin, added to a drink
3265839|NCT01526772||Patients who have undergone RYGB|Patients who have undergone RYGB and have been referred for an EGD
3265840|NCT01526798|Experimental|Therlite hemodialysis|
3265841|NCT01526798|Active Comparator|Control group hfHDF|Control group hfHDF
3265842|NCT01526811||AAA patients|Subjects presenting with a non-ruptured infra-renal abdominal aortic aneurysm (AAA) and requiring endovascular treatment with Endurant™ Stent Graft, and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional study
3265843|NCT01526824|No Intervention|Control arm, clopidogrel without Lovaza|These patients will be receiving standard of care therapy with either standard dose (75mg daily) or high dose (150mg daily) clopidogrel +/- aspirin based on physician discretion.
3265844|NCT01526824|Experimental|Clopidogrel plus Lovaza|This is the study arm of the trial, in which patients will be receiving either a standard dose (75mg daily) or high dose (150mg daily) clopidogrel with or without aspirin as well as therapy with daily Lovaza.
3265845|NCT01526837|Experimental|bevacizumab (Avastin)|Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects).
3265846|NCT01526850|Experimental|allogenic mesenchymal stem cells (MSCs)|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
3265847|NCT01526850|Active Comparator|Control group|patients who have developed an extensive chronic graft versus host disease (with skin and/or liver damage) after HSCs transplantation and do not respond to standard first-line regimen including cyclophosphamide and prednisolone.
3265848|NCT01526863|Placebo Comparator|Placebo|
3265849|NCT01526863|Active Comparator|HA egg|
3265850|NCT01526876|Experimental|Single Arm drug study|The effect of systemic blood pressure reduction using Clevidipine on intracranial pressure (ICP) and cerebral perfusion pressure (CCP)
3265851|NCT01526915|Experimental|Bone curettage + PRF|Bone curettage and PRF insertion
3265852|NCT01526915|Other|Bone curettage alone|Bone curettage without PRF insertion
3265853|NCT01526941|Experimental|Treatment period 1|
3265854|NCT01526941|Experimental|Treatment period 2|
3265855|NCT01526954|Experimental|TissuGlu Surgical Adhesive|Experimental Arm: standard of care plus TissuGlu Surgical Adhesive and no drains
3265856|NCT01526954|No Intervention|Control- Standard of Care|Control Arm: standard of care plus drains and no TissuGlu Surgical Adhesive
3265857|NCT01526967||New moldable user|Subjects presenting with peristomal lesions with a traditional barrier and for whom a ConvaTec Moldable Technology™ Skin Barrier is used as a replacement.
3265858|NCT01526967||New osomate|Subjects for whom a ConvaTec Moldable Technology™ Skin Barrier is used as the first long-term (within 7 days of ostomy surgery) system following surgery and have intact peristomal skin.
3265859|NCT01526980|Experimental|Treatment period 1|
3265860|NCT01526980|Active Comparator|Treatment period 2|
3265861|NCT01527019|Experimental|Cephalosporin oral suspension|130 research subjects on cephalosporin oral suspension (test) 400 mg once daily
3265862|NCT01527019|Experimental|Cephalosporin capsules|130 research subjects on cephalosporin capsules (test) 400 mg once daily
3265863|NCT01527019|Active Comparator|Norfloxacin|130 research subjects on norfloxacin (test) 400 mg twice daily
3265864|NCT01527058|Experimental|68Ga-BNOTA-PRGD2 PET/CT scanning|Determine if 68Ga-BNOTA-PRGD2 PET/CT is safe and effective method for imaging of lung cancer
3265865|NCT01527084|Other|Group A|undergo surgery between days 10 - 15 after PCD
3265866|NCT01527084|Other|Group B|"continued with PCD beyond 15 days and indications for surgery in them will be,~Persistent sepsis or symptoms~Worsening of clinical condition~Failure to thrive~Complications of SAP or PCD"
3265867|NCT01527097|Experimental|Atorvastatin|
3265868|NCT01527097|Placebo Comparator|Placebo|
3265869|NCT01527123|Experimental|GSK2585823|External Preparation
3265870|NCT01527136|Experimental|Treatment (entolimod)|Patients receive entolimod IM or SC on days 1, 4, 8, and 11. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
3265871|NCT01527175|Active Comparator|supraclavicular|supraclavicular: supraclavicular approach for subclavian venous catheterization
3265872|NCT01527175|Placebo Comparator|infraclavicular|infraclavicular: infraclavicular approach for subclavian venous catheterization
3265873|NCT01527188|Experimental|100IR|
3265874|NCT01527188|Experimental|300IR|
3265875|NCT01527188|Experimental|500IR|
3265876|NCT01527188|Placebo Comparator|Placebo|
3265877|NCT01527201|Experimental|Treatment Group|Worn out cartilage will be surgically treated.
3265878|NCT01527201|No Intervention|Control Group|Worn out cartilage will be observed, but will not be treated surgically.
3265879|NCT01527214|Experimental|CT scan and education|All general practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital.Randomized 1:1. In the intervention group, GPs continue to refer to the lung cancer fast track when indicated. In addition, they are allowed to refer directly to a rapid chest CT scan in cases where they find reasons to examine the patient for lung diseases without having sufficient suspicion of lung cancer to refer the patient to the lung cancer fast track. The GPs will be offered special training related to the diagnosis of lung cancer in general practice before the new referral option is introduced. This will be done by offering training sessions and written material.
3265880|NCT01527214|No Intervention|Control|Cluster eligibility: all practices referring to the Department of Pulmonary Medicine, Aarhus University Hospital. Randomized 1:1. Control arm continues with the usual referral pattern
3265881|NCT01527227||children of mentally ill|This research will include 130 children between the ages of 10-18 who live with at least one parent who struggles with serious mental illness in a comparison to 130 children of the same socio-demographic characteristics raised by parents from a non-clinical population
3265882|NCT01527240|Experimental|Ciclosporin A|Injection of 50 mg / ml IV infusion. 5 ml ampoules (250 mg of ciclosporin)
3265883|NCT01527240|Placebo Comparator|Placebo|Injectable Saline Solution.
3265884|NCT01527253|Experimental|Active Diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations containing important amounts of specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics)
3265885|NCT01527253|Experimental|Control diet|Subjects eat a diet designed according to the Nordic Dietary Recommendations but lacks the specific legume and cereal ingredients that provide substrates for the intestinal microflora (prebiotics).
3265886|NCT01527266|Experimental|carbohydrate mouth rinse fasted|sucrose mouth rinse in the fasted state
3265887|NCT01527266|Experimental|carbohydrate mouth rinse fed|sucrose mouth rinse fed state
3265888|NCT01527266|Placebo Comparator|Placebo mouth rinse fed|placebo (non-caloric sweetened drink) in the fed state
3265889|NCT01527266|Placebo Comparator|Placebo mouth rinse fasted|placebo (non-caloric sweetened drink) in the fasted condition
3265890|NCT01527279|Placebo Comparator|Placebo|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
3265891|NCT01527279|Experimental|Antazoline|Any patient fulfilling the inclusion criteria will be prepared to pharmacological cardioversion in a standard way comprising of standard baseline 12-lead ECG, continuous ECG monitoring, periodic noninvasive blood pressure monitoring (BP) and iv line. After drug administration the patient will be observed for 1.5 hour after the last dose with exit ECG and BP measure taken at the end of observation. Further treatment of the patient depends on clinical state and follows appropriate clinical guidelines.
3265892|NCT01527305|Experimental|Paliperidone palmitate|
3265893|NCT01527318|Experimental|Fibrate Treatment|Patients will be treated during 28 weeks with a fibrate to assess the effects of PPAR activation on the NLSDM disease.
3265894|NCT01527331|No Intervention|control group|usual care
3265895|NCT01527331|Experimental|Video decision aid arm|
3265896|NCT01527409|Experimental|Experimetal Arm|"Providing tailored health care program, which provides various information related to exercise, diet, and posttraumatic growth.~Tailored health partnership program consists of three strategic areas (exercise, diet, and posttraumatic growth). Those areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients who participate in the tailored health partnership program will be received tailored manual and workbook for tele-coaching that help them to lead their healthy life.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life."
3265897|NCT01527409|No Intervention|Control Arm|"Providing usual care. Also, patients will be provided a workshop for health education that is dealt with ten areas (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation).~Twelve month later, patients will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth."
3265898|NCT01527448|Experimental|Atypical antipsychotic treatment|Quetiapine XR is given to postpartum women diagnosed with bipolar disorder II. Starting dose is 50mg, maximum dose is 300mg/day.
3265899|NCT01527461||Lung Cancer Patients|diagnosed lung cancer patients .
3265900|NCT01527461||COPD Patients|COPD patients, not diagnosed with lung cancer.
3265901|NCT01527539|Experimental|BIAsp 30|
3265902|NCT01527552|Experimental|Formulation A|
3265903|NCT01527552|Experimental|Formulation B|
3265904|NCT01527565|Experimental|Formulation A|
3265905|NCT01527565|Experimental|Formulation B|
3265906|NCT01527604|Active Comparator|Avenanthramide-enriched oat muffin|
3265907|NCT01527604|Placebo Comparator|Refined flour muffin|
3265908|NCT01527617|Active Comparator|Cranberry beverage|
3265909|NCT01527617|Placebo Comparator|Non-cranberry beverage|
3265910|NCT01527630|Experimental|Formulation A|
3265911|NCT01527630|Experimental|Formulation B|
3265912|NCT01527643|Experimental|Formulation A|
3265913|NCT01527643|Experimental|Formulation B|
3265914|NCT01527656|Experimental|Formulation A|
3265915|NCT01527656|Experimental|Formulation B|
3265916|NCT01527669|Experimental|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
3265917|NCT01527669|Experimental|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
3265918|NCT01527695|Experimental|AZD3241|AZD3241 tablets 25 mg or 100 mg, titration first 5 days (50 mg bd on Day 1, 100 mg bd on Day 2, 200 mg bd on Day 3, 300 mg bd on Day 4, 400 mg bd on Day 5) Maintenance treatment from Day 6, 600 mg bd until Day 56±3 days
3265919|NCT01527695|Experimental|Placebo|AZD3241 placebo bid for 8 weeks
3265920|NCT01527708||Keratoconus Group (KCG)|Keratoconus group (KCG) included patients with progressive keratoconus.
3265921|NCT01527708||Collagen-Cross-linking group (CXLG)|Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.
3265922|NCT01527708||Normal Group (NG)|Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.
3265923|NCT01527721|Experimental|CxL group|Volunteers of this group received CxL treatment.
3265924|NCT01527721|Experimental|tCxL group|Volunteers of this group received CxL combined with t-PRK treatment
3265925|NCT01527734|Placebo Comparator|Placebo|
3265926|NCT01527734|Experimental|Tetrodotoxin, TTX|
3265927|NCT01527747|Placebo Comparator|Placebo|Placebo arm
3265928|NCT01527747|Experimental|Saxagliptin|Active drug arm
3265929|NCT01527773||COPD cohort|Cohort of patients with proven COPD
3265930|NCT01527786|Experimental|SNRI treatment|Participants are undergoing pharmacotherapy treatment with Desvenlafaxine (SNRI).
3265931|NCT01527799||Subjects with Sickle Cell Anemia|Subjects with Sickle Cell Anemia, 10-21 years of age
3265932|NCT01527799||Healthy controls|Healthy controls, 10 to 21 years of age
3265933|NCT01527812|Experimental|Above the femoral nerve|In Group I we will inject the local anaesthetic below the fascia iliaca and above the femoral nerve.
3265934|NCT01527812|Experimental|Below the femoral nerve|In Group II we will inject the local anaesthetic below the femoral nerve and above the fascia of the iliopsoas muscle.
3265935|NCT01527812|Experimental|Circumferential|In Group III a circumferential spread will be achieved with multiple injections.
3265936|NCT01527825|Active Comparator|Single dose|Trivalent Influenza Vaccine (seasonal)
3265937|NCT01527825|Experimental|Double dose TIV|Trivalent Influenza vaccine (seasonal) Two doses will be administered at enrolment
3265938|NCT01527825|Experimental|Two dose TIV|Trivalent Influenza vaccine (seasonal) Participants will receive two doses of TIV, one month apart
3265939|NCT01527838|Experimental|Single FT1050 treated UCB Unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
3265940|NCT01527864|Experimental|pegylated endostatin|
3265941|NCT01527864|Placebo Comparator|Control|
3265942|NCT01527877|Experimental|BKM120|
3265943|NCT01527903|Active Comparator|Propofol|
3265944|NCT01527903|Active Comparator|Midazolam|
3265945|NCT01527916|Placebo Comparator|sugar pill|
3265946|NCT01527916|Active Comparator|donepezil|
3265947|NCT01527916|Experimental|ABT-126 Low Dose|low dose
3265948|NCT01527916|Experimental|ABT-126 Middle Dose|middle dose
3265949|NCT01527916|Experimental|ABT-126 high dose|high dose
3265950|NCT01527929|Experimental|Cohort A|Normal renal function - Cabazitaxel administered once every 3 weeks
3265951|NCT01527929|Experimental|Cohort B|Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks
3376479|NCT05159739||Total Joint Arthroplasty (TJA)|Recruitment of families with an increased incidence of TJI with PJI.
3376480|NCT05159726|Experimental|Written Discharge Education + Video Education|These patients will view a 10-minute educational video on SMM warning signs, in addition to the written discharge instructions provided by nursing staff. At the completion of the video, they will complete a post-video questionnaire to assess their knowledge on the covered topics.
3376481|NCT05159726|No Intervention|Written Discharge Education|They will receive the written discharge instructions provided by nursing staff and complete the post-discharge instruction questionnaire.
3376482|NCT05159713|Other|Treatment as Usual (TAU)|Participants who are randomly assigned to the Treatment as Usual (TAU) group will receive standard care, which will consist of a tiered stepped care model of behavioral therapy offered by the embedded behavioral therapist at each practice as part of routine care, with the provision of augmentation of therapy (or addition of an antidepressant) at the discretion of the clinical team. Psychotropic medications at baseline and previous behavioral treatment will be recorded at baseline. Number of therapy sessions, delivery modality (face to face versus telemedicine), and addition of antidepressant or other psychotropic medication or dose change will be monitored and recorded over the study period.
3376483|NCT05159713|Experimental|dCBI + Treatment as Usual|Participants randomly assigned to the intervention group (dCBI+TAU) will receive standard care and also gain access to the dCBI. The dCBI, RxWell, is a trans-Cognitive Behavioral Therapy (CBT) mobile app product addressing depression and anxiety that was developed based on standard CBT techniques.
3376485|NCT05159687|Active Comparator|Atomoxetine|Atomoxetine 40 mg PO BID (morning and late afternoon) Dosing will start at 40 mg daily for 3 days1 week, followed by a forced titration to 40 mg BID, as per the FDA label for atomoxetine.
3376486|NCT05159687|Placebo Comparator|Placebo|Matching placebo will be identical in appearance to the active treatment pill. BID (morning and late afternoon)
3265952|NCT01527929|Experimental|Cohort C|Severe renal dysfunction - Cabazitaxel administered once every 3 weeks
3265953|NCT01527968|Active Comparator|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
3265954|NCT01527968|Active Comparator|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
3265955|NCT01527968|Placebo Comparator|Placebo|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
3376487|NCT05159674|Experimental|Dexmedetomidine+electroacupuncture compound anesthesia|EA was given every day three days before surgery, 30 minutes before induction of anesthesia + the whole course of surgery, and every 12 hours from the first day after surgery, each treatment was performed for 30 minutes until 48 hours after surgery. During the operation, only dexmedetomidine was used to make BIS<80.
3265956|NCT01527981|Experimental|CBT-AD|Participants received weekly one-hour CBT-AD sessions focusing on diabetes self-care and depression for approximately 10 sessions. Participants also had meetings with a registered dietitian and a nurse educator, focusing on nutritional management of diabetes and diabetes self-care education, respectively.
3265957|NCT01527994|Experimental|Aprepitant 125 mg|Day Number Dose Procedure Day 0 Aprepitant 125mg Admitting Medication Treatment Day 1 Aprepitant 125mg Saline-Saline Day 2 Aprepitant 125mg Morphine-Morphine Day 3 Aprepitant 125mg Saline-Morphine Day 4 Aprepitant 125mg Naloxone-Morphine and Discharge
3265958|NCT01527994|Placebo Comparator|Placebo|Day Number Dose Procedure Day 0 placebo Admitting Medication Treatment Day 1 placebo Saline-Saline Day 2 placebo Morphine-Morphine Day 3 placebo Saline-Morphine Day 4 placebo Naloxone-Morphine and Discharge
3376488|NCT05159674|No Intervention|Dexmedetomidine anesthesia|There was no EA treatment before, during or after operation. During the operation, only dexmedetomidine was used to make BIS<80.
3376489|NCT05159635|Experimental|Active Living programme and wearable technical aids|Active Living programme and wearable technical aids
3376490|NCT05159635|Active Comparator|Wearable technical aids|Wearable technical aids
3453154|NCT04024488|Active Comparator|Discussion Control Arm|Arm two is the discussion control arm consisting of: six 2 hour discussion group sessions lead by IYL during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The caregivers (willing to participate with youth permission) for youth randomized to the discussion control arm will have two 2-hour discussion group sessions led by adult study staff during weeks 1-6 and one 2-hour booster discussion group session at 6 months. The youth and caregiver sessions are held separately.
3265959|NCT01528007|Placebo Comparator|Placebo pill.|
3265960|NCT01528007|Active Comparator|50mg Naltrexone when needed|
3453155|NCT04024306||ULTRAFILTRATION|
3453156|NCT04024306||DIURETICS|
3265961|NCT01528020|Experimental|Dialectical Behavior Therapy|
3265962|NCT01528020|Active Comparator|Inidividual and Group Supportive Therapy|
3265963|NCT01528046|Experimental|Metformin in Combination with VIT|Participants will receive metformin in combination with vincristine, irinotecan and temozolomide (VIT).
3265964|NCT01528059|Active Comparator|Billroth II|After stomach resection, the remnant stomach is connected to the jejunum.
3265965|NCT01528059|Active Comparator|Roux en Y|After stomach resection, the remnant stomach is connected to the distal jejunum while duodenum and the proximal jejunum is reconnected to jejunum.
3265966|NCT01528098||PEG plus bisacodyl|Those who taken PEG 4L + bisacodyl 10mg
3265967|NCT01528098||PEG 4L|Those who taken PEG 4L alone
3265968|NCT01528111|Experimental|Low dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3265969|NCT01528111|Experimental|High dose LX7101|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3265970|NCT01528111|Placebo Comparator|LX7101 Vehicle|Days 1-3: once daily dose in study eye (eye with highest IOP); Days 4-7: once daily dose in study eye (eye with highest IOP) and fellow eye (other eye); Days 8-14: twice daily dose in study eye (eye with highest IOP) and fellow eye (other eye)
3265971|NCT01528137|Experimental|Treatment (immunomodulator)|Patients receive talactoferrin PO BID for 12 weeks. Courses repeat every 14 weeks in the absence of disease progression or unacceptable toxicity.
3265972|NCT01528163|Experimental|Cabazitaxel|Cabazitaxel (XRP6258) is a new taxoid, which promotes tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel
3265973|NCT01528163|Active Comparator|Methotrexate|"Methotrexate is the historical control and has been widely used in SCCHN for palliation.~This medication is an antimetabolite and antifolate drug. It acts by inhibiting the metabolism of folic acid."
3265974|NCT01528176|Other|(CKD) stages III-V and non -CKD patients|We recruited patients with wide range of eGFR
3265975|NCT01528189|Placebo Comparator|Standard glucose management|
3265976|NCT01528189|Active Comparator|Hyperinsulinemic normoglycemic clamp|
3265977|NCT01528202|No Intervention|Baseline placebo|measures taken before administration of placebo
3265978|NCT01528202|Placebo Comparator|Placebo|Placebo intervention given after 'baseline placebo' arm
3265979|NCT01528202|No Intervention|baseline cherry juice|measures taken before the cherry juice intervention
3265980|NCT01528202|Experimental|cherry juice|trial where cherry juice is taken following the 'baseline cherry juice' arm
3265981|NCT01528241|Experimental|ABP688|Elderly MDD patients and demography matched healthy volunteer
3265982|NCT01528267|Active Comparator|Autologous blood|Patients will have 50mls of autologous blood injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
3265983|NCT01528267|Sham Comparator|Saline|Patients will have 50mls of normal saline injected into each of 3 bronchopulmonary segments during bronchoscopy under conscious sedation.
3265984|NCT01528280|Experimental|Shiftwork|The comparison will consider nightworkers versus dayworkers.
3265985|NCT01528306|Experimental|HP802-247|
3265986|NCT01528306|Placebo Comparator|Placebo (Vehicle)|
3265987|NCT01528358||Early Sepsis Critically Ill Patients|Patients who are admitted to ICU with a diagnosis of early sepsis.
3265988|NCT01528358||Non-septic Critically ill patients|Patients who are critically ill and admitted to ICU without diagnosis of sepsis.
3265989|NCT01528371|Active Comparator|Midazolam|Intravenous administration of midazolam at dose of 0.02mg/kg
3265990|NCT01528371|Placebo Comparator|NSS|Intravenous administration of saline solution at dose of 0.004ml/kg as a placebo drug
3265991|NCT01528410|Experimental|ALFApump removal of ascites|Removal of ascites
3265992|NCT01528410|Active Comparator|Large volume paracentesis for removal of ascites|Removal of ascites
3265993|NCT01528423||Men 16 - 18yrs|
3265994|NCT01528423||Men 30 - 32 yrs|
3265995|NCT01528423||Men 70 yrs +|
3265996|NCT01528423||Women 16 - 18 yrs|
3265997|NCT01528423||Women 30 - 32 yrs|
3265998|NCT01528423||Women 70 yrs +|
3265999|NCT01528436|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
3266000|NCT01528436|Active Comparator|Placebo Umbilical Cord Blood and Rehabilitation|Placebo Umbilical Cord Blood infusion and Active Rehabilitation
3266001|NCT01528449|Experimental|retrospective|archived specimens from blood donors whose units have already been released and transfused into recipients will be tested. Attempts will be made to contact and obtain follow up specimens from both the donor and recipient of units initially testing positive for B.microti. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
3266002|NCT01528449|Experimental|prospective, real time|specimens from current blood donors will be tested and those testing positive for B.microti will not be released and the units will be disgarded, and the donors notified and deferred from future blood donation. the interventions are investigational diagnostic tests for B.microti (PCR and IFA).
3266003|NCT01528462||Expedited Treatment of Sleep Disorders|Please see below.
3266004|NCT01528475|Active Comparator|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs, initiation of an intravenous infusion of cold saline, and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
3266005|NCT01528475|No Intervention|Usual pre-hospital care|Patients in this arm will receive usual post-resuscitation care by paramedics. Usual post-resuscitation care does not include initiation of cooling in the pre-hospital setting.
3266006|NCT01528488|Experimental|EVOZAC|EVOZAC should be sprayed to the skin of the total face three times per day.
3266007|NCT01528488|Placebo Comparator|Physiological saline|Physiological saline should be sprayed to the total face three times per day.
3266008|NCT01528501|Experimental|I|
3266009|NCT01528514|Active Comparator|Curcuminoids|
3266010|NCT01528514|Placebo Comparator|Placebo|
3266011|NCT01528540|Placebo Comparator|Placebo|This group will contain a placebo for antioxidant cocktail and pregabalin
3266012|NCT01528540|Experimental|Antioxidant plus pregabalin|This group will contain antioxidant cocktail and pregabalin
3266013|NCT01528553|Active Comparator|Staples|Old implant type
3266014|NCT01528553|Active Comparator|8plate|New implant type
3266015|NCT01528566|Experimental|Tai Chi|
3266016|NCT01528566|Placebo Comparator|Attentation control|
3266017|NCT01528579|Active Comparator|Neck Specific exercises|Neck Specific exercises from a structured frame of exercises
3266018|NCT01528579|Active Comparator|Behavioral approach|Behavioral physiotherapeutic approach in combination with neck specific exercises from a structured well defined frame of exercises and how to treat the patient. 2 times a week for 3 months.
3266019|NCT01528579|Active Comparator|Prescribed physical activity|Prescribed physical activity from a physiotherapist without neck specific exercises
3266020|NCT01528618|Experimental|gemcitabine and cisplatin|gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
3376491|NCT05159622|Experimental|Intervention|Description of behavioral intervention Water Up! at Home: The intervention is theory-based and was designed to be sensitive to the context, perceptions and needs of this high risk population. It was collaboratively developed with key stakeholders in the predominantly Latino immigrant community. The curriculum consists of 12 infographics and lessons (bilingual Spanish/English) designed to increase knowledge of drinking water health benefits, safety/cleanliness, cost/convenience, prior experience. The 12-week intervention will be delivered in participants' home by the home visitor. Participants will receive a water filter for use in their home in addition to educational information about water and sugary beverages. Throughout the lessons, they will be asked to complete various activities such as taking pictures and engaging in discussions about their water drinking habits.
3376492|NCT05159622|No Intervention|Control|Participants will receive the standard educational curriculum from the home visiting program (and also a water filter as a token of appreciation).
3266021|NCT01528618|Active Comparator|5-Fluorouracil and cisplatin|5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
3266022|NCT01528631|Placebo Comparator|Control Product|200 ml water with 50g of sucrose
3376493|NCT05159609|Active Comparator|Stim First|Participants slept for one night while auditory sounds were played at specific points during slow wave sleep. At least one week later, an identical procedure occured with no acoustic sounds.
3376494|NCT05159609|Sham Comparator|Sham First|Participants slept for one night while no acoustic sounds were played. At least one week later, an identical procedure occured while acoustic sounds were played at specific points during slow wave sleep.
3376495|NCT05159596|Experimental|In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
3376496|NCT05159596|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by Spanish-speaking caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
3376497|NCT05159583|Experimental|In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
3376498|NCT05159583|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 advanced gateway with a dual-SIM cellular connection to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 2 Vayyar fall detection and sleep quality sensors] will be self-installed by rural caregivers (N=60) in their homes. Only monitoring of the water leak sensor and associated warnings will be activated remotely for those participants who have been randomly assigned to this arm."
3376499|NCT05159570|Experimental|Ketone ester|
3376500|NCT05159570|Placebo Comparator|Placebo|
3376501|NCT05159557|Experimental|In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights; (g) 1 Apple Watch to detect falls and activity outside the home] will be self-installed by caregivers (N=60) in their homes. Monitoring of sensors, provision of warnings, messaging, and social networking features will be activated remotely for those participants who have been randomly assigned to this arm. Participation will extend over a 6 month period with questionnaires (e.g., health and well-being) administered 3 times (at the time of installation and every 3 months thereafter)."
3266023|NCT01528631|Active Comparator|Product 1|200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
3266024|NCT01528644|Experimental|Iron in beads|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3266025|NCT01528644|Experimental|Iron in capsule|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3376502|NCT05159557|Sham Comparator|Limited In-Home Technology System|"The full system [(a) 1 gateway that connects with home internet to communicate/control the equipment; (b) 5 indoor motion sensors; (c) 3 door/cabinet entry sensors; (d) 1 water leak sensor; (e) 1 call for help button; (f) 2 motion-activated LED night lights], with the exception of the Apple Watch that those in the experimental condition receive will be self-installed by caregivers (N=60) in their homes. Only monitoring of the water leak and associated warnings will be activated remotely for those participants who have been randomly assigned to this limited (sham comparator) arm."
3376503|NCT05159544||Multi-omics model developing and training arm|Blood samples and individual health information from 50,000 participants in community, who got 3-year follow-up are selected.
3376504|NCT05159544||Multi-omics model validating arm|10,000 participants in routine annual physicals from hospitals will be selected, and they will be followed up for 2 years.
3376505|NCT05159544||Multi-omics model evaluating arm|Participants in Taizhou cohort will be selected.
3376506|NCT05159531|Experimental|Standard model of care|Delivery of PrEP care through the local standard of care.
3376507|NCT05159531|Active Comparator|mHealth model of care|Delivery of PrEP care through the Freddie® mobile Health (mHealth) platform.
3376508|NCT05159518|Experimental|PRT2527|PRT2527 will be administered by intravenous infusion
3376509|NCT05159505||"the before group"|40 teenagers after scoliosis surgery before interdisciplinary program implementation
3266026|NCT01528644|Experimental|Iron in beads in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3376510|NCT05159505||"the after group 1"|40 teenagers after scoliosis surgery after ERAS program implementation
3376511|NCT05159505||"the after group 2"|40 teenagers after scoliosis surgery after ERAS and educational program implementation
3376514|NCT05159466||Kidney transplant recipients|Up to 25 HIV-positive participants requiring kidney organ transplantation
3376515|NCT05159466||Kidney living donors|Up to 5 HIV-positive living donors will be enrolled.
3376517|NCT05159440|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-2-307-MAB
3376518|NCT05159440|Experimental|Expansion as Monotherapy - Part 2|TORL-2-307-MAB
3376519|NCT05159427|Experimental|G.I Intubation|Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet) administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water. A 'Stable isotope' means a heavier version of the drug that is not radioactive.
3376520|NCT05159427|Experimental|SmartPill®|Single dose of Glipizide (5 mg modified-release tablet), Rifaximin (200 mg tablet) and SmartPill® administered with 200 mL of 14% glucose solution in water + 1 mg of the stable isotope Glipizide (13C6-Glipizide) with 40 ml of 14% glucose solution in water.
3376522|NCT05159401|Experimental|"the first group: the method of vibroacoustic lung massage using the BARK VibroLUNG device"|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
3376523|NCT05159401|Experimental|the second group:the method of oscillating REР therapy using Acapella DH Green|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
3376524|NCT05159401|Experimental|the third group:the method of hardware stimulation of cough (Comfortable cough Plus)|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
3376525|NCT05159401|Experimental|the fourth group:classical manual chest massage with percussion|dynamics blood saturation by pulse oximeter,minute inspiratory lung volume befor/after research
3376526|NCT05159388|Experimental|PRS-344/S095012|PRS-344/S095012
3376527|NCT05159375|Experimental|Elio (supplement under investigation)|2.4g of Elio administered orally daily with the first meal of the day for a 17 day period
3376528|NCT05159375|Placebo Comparator|Placebo|2.4g of SMCC administered orally daily with the first meal of the day for a 17 day period
3453157|NCT04024319||Genicular Nerve Block|GNB will be performed on this group of patients undergoing TKR. The patient will be positioned in the supine position, with the extremity to operate slightly in external rotation. The anesthesiologist will be located ipsilateral to the knee to intervene; asepsis will be performed with 70% chlorhexidine, sterile gloves will be used and the ultrasound probe will be protected with a sterile cover. The ultrasound transducer will be placed in a long axis of the knee in the corresponding area to block according to anatomical repairs. 4 ml of 0,2% ropivacaine was administered in each GN.
3266027|NCT01528644|Experimental|Iron in capsule in presence of calcium|All experimental days will be exactly the same with the exception of the test meal administered to the volunteer. Volunteers will undergo a 10 hour overnight fast from 10:00pm, then they will be asked to attend the CRTU at approximately 8:00 am the following morning. A nurse will take and record the volunteer's blood pressure and if within the range an intravenous (i.v.) cannula will be inserted into a vein in one of the volunteer's arms. The cannula will remain in situ for six hours. After the first blood sample (t=0) will be taken, volunteers will consume one out of 4 test meals. After consumption further blood samples will be collected at: 20, 40, 60, 80, 100, 120, 150, 180, 240, 300 and 360 min. Blood samples will subsequently be analysed for serum iron concentrations.
3266028|NCT01528657|Experimental|Ventricular Pace Suppression (VpS)|The function Ventricular Pace Suppression (VpS) is activated
3266029|NCT01528657|Experimental|Intrinsic Rhythm Support (IRSplus)|The function Intrinsic Rhythm Support (IRSplus) is activated
3266030|NCT01528670||Skull Base|
3266031|NCT01528670||Lower GI|
3266032|NCT01528670||Prostate|
3266033|NCT01528670||Pelvic Region|
3266034|NCT01528670||Head-and-Neck|
3266035|NCT01528670||Upper GI|
3266036|NCT01528670||Brain|
3266037|NCT01528670||Other|
3266038|NCT01528683|Experimental|Carbon Ion Radiotherapy|
3266039|NCT01528722|Sham Comparator|Saline sham injection|Sham wash and injection with normal saline (09%)
3266040|NCT01528722|Active Comparator|Bupivacaine|Bupivacaine injection/wash treatment arm
3266041|NCT01528748||Chronically Depressed, Alcohol Dependent|Participants who have been formally diagnosed with a clinical diagnosis of Chronic Depression and Alcohol Dependence.
3266042|NCT01528761|Experimental|Prosocial Behavior Physical Activity|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
3266043|NCT01528761|Active Comparator|Healthy Aging (HA)|Behavioral: Healthy Aging (HA) The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
3266044|NCT01528774||Melanoma|Patients with histologically confirmed melanoma
3266045|NCT01528774||Prostate|Patients with histologically confirmed prostate cancer
3266046|NCT01528774||Solid tumors - other|Patients with histologically confirmed solid tumor cancers other than melanoma and prostate
3266047|NCT01528774||Benign Hematologic Conditions|Patients diagnosed with non-cancerous hematologic conditions
3266048|NCT01528774||Healthy Volunteers|Family members of patients undergoing treatment at Comprehensive Cancer Centers of Nevada, or other healthy volunteers
3266049|NCT01528800|Placebo Comparator|Placebo|Microcrystalline Methylcellulose
3266050|NCT01528800|Active Comparator|Vitamin K1|Vitamin K1
3266051|NCT01528813|Active Comparator|Er:YAG + amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
3266052|NCT01528813|Placebo Comparator|Amorolfine lacquer|30 ungual units affected by onychomycosis due to dermatophytes
3266053|NCT01528826|Experimental|NVBOX regimen|Vinorelbine plus oxaliplatin
3266054|NCT01528839|Placebo Comparator|Pill|
3266055|NCT01528839|Experimental|L-Thyroxine as addon|
3266056|NCT01528852|Experimental|CHX Cord application|Chlorhexidine cord application for 10 days
3266057|NCT01528852|Active Comparator|Control|Same liquid as intervention without the chlorhexidine used for cord cleaning for 10 days once daily
3266058|NCT01528852|No Intervention|Dry Cord care|Use current recommended keep cord dry
3266059|NCT01528865|Experimental|Study Drugs|The medications to be used in this study are Lamivudine (EPIVIR®) and Tenofovir disoproxil fumarate (VIREAD®), medications already used in people with certain other types of viruses [but not HERV-K(HML2)] in their body. Treatment will last 16 weeks. This is an experiment combining these two drugs and has been issue an Investigational New Drug (IND) Exemption by the FDA.
3266060|NCT01528904||Hyperthyroid pregnant women|hyperthyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination.
3266061|NCT01528904||Hypothyroid pregnant women|hypothyroidism diagnosed and treated by an endocrinologist, based on clinical and laboratory tests and ultrasound thyroid examination
3266062|NCT01528904||Healthy pregnant women|uncomplicated pregnancies in healthy women, older then 35 years, directed for cordocentesis due to age, because of missed karyotyping in previous period of pregnancy
3266063|NCT01528930|Experimental|Amikacin for inhalation|"Drug: Amikacin~Amikacin is provided for inhalation via nebulization.~500 mg of amikacin is administered once daily using the Pari-Boy N/Long Life Nebulizer.~Administration time is approximately 20 minutes.~Amikacin will be administered for 2 years."
3266064|NCT01528943|Experimental|Prostacyclin|Treatment with prostacyclin
3266065|NCT01528943|Placebo Comparator|Isotonic saline|Treatment with isotonic saline
3266066|NCT01528982|No Intervention|Control|Psychoeducation
3266067|NCT01528982|Active Comparator|Mindfulness|Mindfulness activity and psychoeducation
3266068|NCT01528982|Active Comparator|Cognition|Cognitive training and psychoeducation
3266069|NCT01528995|Active Comparator|sacral nerve modulation|Implantation of Interstim II-3058 impulse generator after positive PNE test. Randomized controlled trial.
3266070|NCT01528995|Active Comparator|anal bulking agents|anal injection with Permacol after positive PNE test. Randomized controlled trial.
3266071|NCT01528995|Active Comparator|Anal bulking agents|Anal injection with Permacol after negative PNE test. cohort study.
3266072|NCT01529008|Experimental|Core decompression/PREOB® implantation|
3266073|NCT01529008|Placebo Comparator|Core decompression/placebo implantation|
3266074|NCT01529021||humanoid robot distration|The robot NAO, academic edition (Aldebaran Robotics) was used in this study. Some of its features include an on-board fully programmable computer CPU: x86 AMD Geode with 500 MHz, 256 MB SDRAM and 1 GB flash memory, WiFi (802.11g) and Ethernet, two cameras with up to 30 frames per second, two hands with self adaptive gripping abilities, force sensitive sensors on its arms and feet to perceive contact with objects, Light Emission Diodes in its eyes and body, four microphones to identify the source of sounds, and two loud speakers for communication where tone and voice pitch can be modified in real-time. It runs on a native Linux Operating system platform and can be programmed using a proprietary SDK called NaoQi, or in C, C++, Ruby and Urbi, which makes it compatible with other robot simulators such as Microsoft Robotics Developer Studio.
3266075|NCT01529021||control|standard care procedures were used during the vaccination
3266076|NCT01529047|Experimental|In-person PFI|In-person personalized feedback intervention
3266077|NCT01529047|Experimental|Web-based PFI|Web-based personalized feedback intervention
3266078|NCT01529047|No Intervention|Assessment Only|Complete online survey assessments only.
3266079|NCT01529073|Experimental|Nitazoxanide|
3266080|NCT01529086||Group 1|"Subjects on Dutasteride that meet the following criteria:~. A rise in PSA from nadir at any time post-nadir~. PSA change from baselin >0.2 mg/ml at any time post-baseline~. Abnormal DRE at any time post-baseline~. Free-PSA <12% at any time post-baseline~. At least one of the above 4 criteria~Subjects on Dutasteride that do not meet the above criteria"
3266081|NCT01529086||Group 2|"Subjects on placebo treatment that meet the following criteria:~Change from baseline PSA between 0.0 and 0.35 (ie, 0.0 ≤ change from baseline PSA < 0.35) at any time post-baseline. Note that in REDUCE PSA was recorded to the nearest 0.1.~Abnormal DRE at any time post-baseline~Change from baseline PSA ≥ 0.35 at any time post-baseline~Change from baseline PSA ≥ 0.75 at any time post-baseline~PSA ≥ 2.5 at any time post-baseline~PSA ≥ 4.0 at any time post-baseline~Percent Free PSA < 12% at any time post-baseline~At least one of the above 7 criteria.~Subjects on placebo that do not meet the above criteria"
3266082|NCT01529099|Experimental|Sigma HP Partial Knee|Partial knee replacement
3266083|NCT01529125||Kwashiorkor|HIV-positive children aged 6-59 months with kwashiorkor receiving nutritional rehabilitation and who are started on HAART.
3266084|NCT01529125||Marasmus|HIV-positive children aged 6-59 months with marasmus receiving nutritional rehabilitation and who are started on HAART.
3266085|NCT01529125||Control|HIV-positive children aged 6-59 months who are not severely malnourished and who are started on HAART for a non-nutritional reason.
3266086|NCT01529138|Experimental|Temsirolimus|An ester of the macrocyclic immunosuppressive agent sirolimus.
3266087|NCT01529138|Experimental|Axitinib|An oral, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3.
3266088|NCT01529151|Active Comparator|OMT Group|Participants will receive Osteopathic Manipulative Treatment (OMT) with the objective of treating diagnosed somatic dysfunction and this will entail the use of specific indirect and direct techniques, including soft tissue, inhibitory, myofascial release, articulatory and high-velocity / low-amplitude (HVLA) techniques.
3266089|NCT01529151|Active Comparator|VRT Group|Participants will receive Vestibular Rehabilitation Therapy (VRT), which includes balance exercises in sitting and standing positions that include gaze stabilization, kinesthetic and proprioceptive retraining.
3266090|NCT01529151|Active Comparator|OMT - VRT Group|Participants will receive both Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT).
3266091|NCT01529151|No Intervention|Control Group|
3266092|NCT01529164|Experimental|treatment|
3266093|NCT01529177|Experimental|Metformin / clomid / hCG|"Metformin 1000 mg orally to be given daily for one week then twice daily for 2 weeks then 3 times daily for 6 months.~After 3 months from starting metformin the participant will receive 2 more medications in addition to metformin:~Clomid 50 mg orally per day and 5000 IU human chorionic gonadotrophin (hCG ) IM once per week for three months."
3266094|NCT01529177|Experimental|Clomid / hCG|Clomid 50 mg per day will be administered orally and human chorionic gonadotrophin ( choriomon ) 5000 IU will be administered IM once per week. Both medications will be given for 6 month.
3266095|NCT01529190|Active Comparator|pregabalin 300mg|Group 1 patients will receive a single dose of 300 mg pregabalin, 1 hour before the surgical incision; group 2 patients will receive a placebo dose. Pain intensity will be assessed with the numeric rating scale. The consumption of tramadol in 24 hours after surgery and the time for the first complementation dose will be registered. Blood samples will be collected by 6 hours and 24 hours after surgical incision, for IL-6 dosage, and maintained at -70 celsus degree
3266096|NCT01529190|Placebo Comparator|sugar pill|group 2 will receive a placebo dose, 1 hour before tue surgical icnision
3266097|NCT01529216|Experimental|Electrical signal ON|Subjects randomized to this group (Group A) will receive electrical stimulation delivered to the fundus for 24 months.
3266098|NCT01529216|Sham Comparator|Sham|"Subjects randomized to this group (Group B) will have their device in turned off mode for the first 12 months (48 weeks) after implant. Then the device will be turned ON and these subjects will receive therapy for the remaining 12 months of the study."
3266099|NCT01529229|Experimental|Desloratadine + Prednisolone|Desloratadine(0.5 mg/ml) Associated With Prednisolone (4 mg/ml) Oral Solution once a day - bottle 1 + placebo 2 times a day - bottles 2 and 3.
3266100|NCT01529229|Active Comparator|Dexchlorpheniramine + Betamethasone|Dexchlorpheniramine (0.4 mg/ml) + Betamethasone (0.05 mg/ml) three times a day - bottles 1, 2 and 3.
3266101|NCT01529242|Experimental|Desloratadine + Prednisolone|desloratadine 0,5 mg/ml + prednisolone 4 mg/ml - oral solution
3266102|NCT01529242|Active Comparator|Dexchlorpheniramine + Betamethasone|dexchlorpheniramine maleate 0,4 mg/ml + Betamethasone 0,05 mg/ml - oral solution
3266103|NCT01529255|Experimental|ROADMAP|
3266104|NCT01529255|Active Comparator|SOC (Standard of Care)|
3266105|NCT01529281|Experimental|BCAA|Branched chain amino acid
3266106|NCT01529281|Placebo Comparator|Asparmate|Placebo control containing no protein or carbohydrate
3266107|NCT01529294|Experimental|Iloperidone|Eligible subjects receive a single oral dose of 2 mg iloperidone as a tablet
3266108|NCT01529307|Experimental|TAS266|
3266109|NCT01529320|Experimental|Adventan® (metilprednisolona aceponato 0,1%)|
3266110|NCT01529359|Placebo Comparator|Placebo|Probiotics Excipients
3266111|NCT01529359|Experimental|Lactibiane Tolerance|Probiotics combination
3266112|NCT01529372|Experimental|Percutaneous renal denervation|
3266113|NCT01529398|Active Comparator|sensorimotor training (SMT)|
3266114|NCT01529398|Active Comparator|Resistance training (RT)|
3266115|NCT01529398|Sham Comparator|Control group (CG)|
3266116|NCT01529411|Experimental|Vinflunine|"Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min)~+ best suportive care, with regards clinical practice."
3266117|NCT01529411|Other|Best suportive care|Best suportive care
3266118|NCT01529424|Experimental|Group 1|Non-extensive PK/non post-prandial
3266119|NCT01529424|Experimental|Group 2a|Extensive PK
3266120|NCT01529424|Experimental|Group 2b|Post-prandial assessment
3266121|NCT01529424|Experimental|Group 3|Stable dose of fibrate
3266122|NCT01529424|Experimental|Group 4|Fredrickson Type 1 dyslipidemia
3266123|NCT01529437|Active Comparator|Sublingual immunotherapy|Subjects will take sublingual immunotherapy who have dust mite and timothy grass allergies
3266124|NCT01529437|Placebo Comparator|placebo arm|The placebo arm will be double blinded and is an important control in SLIT therapies
3266125|NCT01529463||Disease Management|
3266126|NCT01529476|Experimental|Nemonoxacin 500 mg|
3266127|NCT01529476|Active Comparator|Levofloxacin 500 mg|
3266128|NCT01529489|Active Comparator|Interval physical training Control group|
3266129|NCT01529489|Experimental|Resisted/Aerobic physical training group|
3266130|NCT01529489|Active Comparator|Aerobic/resisted physical training group|
3266131|NCT01529489|Experimental|Interval physical training group|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
3266132|NCT01529528|Placebo Comparator|Placebo of CWP-0403 100mg|Placebo of CWP-0403 100mg
3266133|NCT01529528|Experimental|CWP-0403 200mg|CWP-0403 200mg
3266134|NCT01529528|Experimental|CWP-0403 100mg|CWP-0403 100mg
3266135|NCT01529541|Active Comparator|Sitagliptin|Sitagliptin 100mg
3266136|NCT01529541|Experimental|CWP-0403|CWP-0403 100mg
3266137|NCT01529554|Active Comparator|Everolimus|Everolimus p.o. for 5 days (d0=7.5 mg, d1=7.5 mg, d2=7.5 mg, d3=5 mg, d4=5mg)
3266138|NCT01529554|Placebo Comparator|Placebo|Placebo comparator with identical composition of tablets except everolimus
3266139|NCT01529567|Active Comparator|CBT without exposure|
3266140|NCT01529567|Experimental|CBT with exposure|
3266141|NCT01529580|Experimental|1 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 1 week before your child begins active treatment with their interventionist.
3266142|NCT01529580|Experimental|2 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 2 weeks before your child begins active treatment with their interventionist.
3266143|NCT01529580|Experimental|3 Week Basline Prior to Intervention|If eligible, you will be randomly assigned- as if by flipping a coin- to one of three baseline durations, during which your child will engage in daily interactions with their interventionist to determine if skills targeted by this intervention are improving naturally as your child matures, without active treatment from the study's interventionist. In this case, the duration is 3 weeks before your child begins active treatment with their interventionist.
3266144|NCT01529619|Experimental|Rivastigmine 18 mg|During the 16-week titration period patients received daily rivastigmine 4.5mg patch for the first 4 weeks, rivastigmine 9mg patch for the next 4 weeks, rivastigmine 13.5mg patch for the next 4 weeks and then rivastigmine 18mg patch for the final 4 weeks. For patients who experienced intolerability, the dose was adjusted downward. Patients then entered the 8-week maintenance period during which time they continued to receive the dose of rivastigmine they were taking at the end of the titration period.
3266145|NCT01529658|No Intervention|No hypothermia|After clamping of the renal vessels, no ice slush will be used.
3266146|NCT01529658|Experimental|Hypothermia|saline ice slush around kidney for 10 minutes.
3266147|NCT01529671|Experimental|Cohort 1: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.
3266148|NCT01529671|Experimental|Cohort 2: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
3266149|NCT01529671|Experimental|Cohort 3: Experimental intervention: PF-05089771 or placebo|Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
3266150|NCT01529671|Experimental|Cohort 4: Experimental intervention: PF-05089771 or placebo|Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.
3266151|NCT01529671|Experimental|Cohort 5: Experimental intervention: PF-05089771 or placebo|Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.
3266152|NCT01529684|Experimental|OSI-906|"Two Parts:~Part A: 14C-labeled OSI-906~Part B: (Optional) OSI-906 (non-labeled)"
3266153|NCT01529697|Active Comparator|Active Feedback|In this arm patients will receive monthly review and education on inhaler technique and use based on a computer download of their last month of inhaler use
3266154|NCT01529697|Placebo Comparator|Control|In this arm patients will be reviewed monthly, however will not have information from INCA device to tailor inhaler education.
3266155|NCT01529710|Experimental|Mirazid|Mirazid is an antischistosomal drug available in the local Egyptian market since 2001 (Mirazid®). It originates from Myrrh a medicinal herb that has been used for thousands of years. Myrrh (Arabian or Somali Myrrh) is an oleo-gum resin, obtained from the stem of various species of Commiphora (Burseraceae) growing in northeast Africa and Arabia.
3266156|NCT01529710|Active Comparator|Praziquantel|Tablets
3266157|NCT01529736|Experimental|High torque insertion|High torque insertion
3266158|NCT01529736|Active Comparator|Low torque insertion|Low torque insertion
3266159|NCT01529762||Osseotite Certain Tapered|Dental implant Osseotite Certain Tapered design
3266160|NCT01529775|Experimental|Osseotite Certain Tapered Prevail|Osseotite Certain Tapered Prevail design with platform switching feature
3266161|NCT01529775|Active Comparator|Osseotite Certain Tapered|Osseotite Certain Tapered implant with non-platform switching design
3266162|NCT01529788|Active Comparator|Lateral orbital injection of Botox Cosmetic or Dysport|Lateral orbital injection of either Botox Cosmetic, 10 units or Dysport, 30 units as a single dose in a randomized (right or left sides) double blind fashion in 90 consecutive subjects
3266163|NCT01529801|Experimental|Roughness group A|Osseotite Certain Tapered Group A
3266164|NCT01529801|Experimental|Roughness Group B|Osseotite Certain Tapered Group B
3266165|NCT01529801|Experimental|Roughness Group C|Osseotite Certain Tapered Group C
3266166|NCT01529814|Experimental|New abutment connection implant|Implant with new abutment connection
3266167|NCT01529814|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3266168|NCT01529840|Experimental|Low dose 33 mcg/kg/day|
3266169|NCT01529840|Experimental|High dose 66 mcg/kg/day|
3266170|NCT01529853|Experimental|SAR156597 dose 1|SAR156597 dose 1, subcutaneous injection once every week
3266171|NCT01529853|Experimental|SAR156597 dose 2|SAR156597 dose 2, subcutaneous injection once every week
3266172|NCT01529853|Experimental|SAR156597 dose 3|SAR156597 dose 3, subcutaneous injection once every week
3266173|NCT01529853|Placebo Comparator|Placebo|Placebo (for SAR156597), subcutaneous injection once every week
3266174|NCT01529866|Experimental|New abutment connection implant|Implant with new abutment connection
3266175|NCT01529866|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3266176|NCT01529879|Experimental|New abutment connection implant|Implant with new abutment connection
3266177|NCT01529879|Active Comparator|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
3266178|NCT01529892|Experimental|methamphetamine EM|Extensive metabolizer will be give a single oral 5 mg of duterium labeled methamphetamine
3266179|NCT01529892|Experimental|methamphetamine PM|Poor Metabolizers will be give a single oral 5 mg of duterium labeled methamphetamine
3266180|NCT01529918|Experimental|web-intervention group|Participants will receive access to the CAN-RISK (Canadian Diabetes Risk Assessment) questionnaire either via personal patient electronic health record or an online version
3266181|NCT01529918|No Intervention|paper-based group|Participants allocated to paper-based will receive the CAN-RISK questionnaire for diabetes risk-assessment via paper-based
3266182|NCT01529931|Experimental|Maintenance|This arm receives Hair2Go treatments once a month for 6 months
3266183|NCT01529944|Experimental|Low dose 33 mcg/kg/day|
3266184|NCT01529944|Experimental|High dose 66 mcg/kg/day|
3266185|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 25 mg|Nemonoxacin Malate Sodium Chloride 25 mg
3266186|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 50 mg|Nemonoxacin Malate Sodium Chloride 50 mg
3266187|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 125 mg|Nemonoxacin Malate Sodium Chloride 125 mg
3266188|NCT01529957|Placebo Comparator|placebol|placebol
3266189|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 250 mg|Nemonoxacin Malate Sodium Chloride 250 mg
3266190|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 500 mg|Nemonoxacin Malate Sodium Chloride 500 mg
3266191|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 650 mg|Nemonoxacin Malate Sodium Chloride 650 mg
3266192|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 750 mg|Nemonoxacin Malate Sodium Chloride 750 mg
3266193|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1000 mg|Nemonoxacin Malate Sodium Chloride 1000 mg
3266194|NCT01529957|Active Comparator|Nemonoxacin Malate Sodium Chloride 1250 mg|Nemonoxacin Malate Sodium Chloride 1250 mg
3266195|NCT01529970||parkinson's disease, young onset|
3266196|NCT01529970||Normal|
3266199|NCT01530009|Active Comparator|Amoxicillin|A liquid preparation of amoxicillin will be administered during the study through a nasoduodenal catheter after random patient assignment.
3266200|NCT01530009|Placebo Comparator|Placebo|A liquid placebo will be administered via a nasoduodenal catheter to patients based on random assignment.
3266201|NCT01530022|Other|LCM 300 mg/CBZ-IR 600 mg|Crossover sequence of experimental treatment and active comparator
3266202|NCT01530022|Other|CBZ-IR 600 mg/LCM 300 mg|Crossover sequence of active comparator and experimental treatment
3266203|NCT01530035|Active Comparator|soccer training intervention|
3266204|NCT01530035|Other|strength training intervention|
3266205|NCT01530035|No Intervention|control group|elderly men with no change in daily activities
3266206|NCT01530035|No Intervention|active soccer control group|veteran soccer players with a 40 year history of continues soccer playing
3266207|NCT01530048|Experimental|U200|
3266208|NCT01530048|Active Comparator|U100|
3266209|NCT01530061|Experimental|Preschool Children age 4-6 years|Preschool children participate in eating either an egg breakfast or a bagel breakfast.
3266210|NCT01530061|Experimental|Teenagers 14-17 years of age|Teenagers participate in eating either an egg breakfast or a bagel breakfast.
3266211|NCT01530074|Experimental|Study Group|
3266212|NCT01530126|Active Comparator|B-TCP +buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed in sodium acetate buffer only.
3266213|NCT01530126|Experimental|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 0.3 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
3266214|NCT01530126|Experimental|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|Administration of synthetic beta-tricalcium phosphate (B-TCP) mixed with purified 1.0 mg/ml recombinant human platelet-derived growth factor (rhPDGF-BB) in sodium acetate buffer.
3266215|NCT01530139|Placebo Comparator|Level 0|Level 0: Control group - participants will receive non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
3266216|NCT01530139|Experimental|Level 1|Level or Group 1: participants will receive personalised dietary advice based on their dietary intake data alone.
3266217|NCT01530139|Experimental|Level 2|Level or Group 2: participants will receive personalised dietary advice taking their dietary intake and phenotypic data ( obesity-related phenotypes and clinical biomarkers) into account.
3266218|NCT01530139|Experimental|Level 3|Level or Group 3 : participants will receive personalised dietary advice taking their dietary intake, phenotypic (obesity-related markers) and genotypic data into account.
3266219|NCT01530165|Other|Standard|Pre diabetics randomized to control arm will receive standard life style advice which is given to all pre diabetics seeking medical advice.
3266220|NCT01530165|Experimental|life style intervention arm|This arm would be given aggressive life style intervention in comparison to standard (control) arm. The intervention would consist of nutritional and physical activity advice.
3266221|NCT01530191||Abdominal|- Participants undergoing surgeries with an abdominal approach will be given a Morphine PCA at a dose of 2mg every 10 minutes with a 12mg/hour lockout. They will also be given IV Toradol at 30mg every 6 hours as needed for a maximum of four doses.
3266222|NCT01530191||Vaginal|- Participants undergoing surgeries with a vaginal approach will be given hydrocodone/acetaminophen at a dose of 5/325 (1-2 tablets every four hours as needed), and provided with Ibuprofen 800mg every 8 hours as needed.
3266223|NCT01530204|Active Comparator|Physical Therapy|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
3266224|NCT01530204|Active Comparator|Cognitive Behavioral Therapy for Pain|8-12 session pain-focused Cognitive Behavioral Therapy
3266225|NCT01530204|Active Comparator|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
3266226|NCT01530230|Other|Oxytocin 5 units|
3266227|NCT01530230|Other|Oxytocin 10 units|
3266228|NCT01530269|Experimental|PET/CT imaging with C11-Sodium Acetate|
3266229|NCT01530282|Experimental|measurement of respiratory mechanics|Invasive method: two catheters will be inserted to measure reference respiratory mechanics Non_invasive method: airway pressure measured during a 150-200 ms occlusion at the beginning of inspiration.
3266230|NCT01530295|No Intervention|contol|control group
3266231|NCT01530295|Other|chemotherapy|neoadjuvant chemotherapy
3266232|NCT01530308|Active Comparator|Investigational medicinal product|Haloperidol 1 mg twice daily at 12am and 20pm
3266233|NCT01530308|Placebo Comparator|Placebo group|Placebo 1 mg twice daily at 12am and 20pm
3266234|NCT01530321|Experimental|High dose spinal manipulation|18 visits for spinal manipulation
3266235|NCT01530321|Experimental|Moderate dose spinal manipulation|12 visits for spinal manipulation and 6 visits for light massage
3266236|NCT01530321|Experimental|Low dose spinal manipulation|6 visits for spinal manipulation and 12 visits for light massage
3266237|NCT01530321|Other|High dose massage|18 visits for light massage
3266238|NCT01530347|Experimental|Easy Check versus reference glucometer and blood ketone meter|Collection of paired measurements of capillary blood glucose using reference method (approved glucometer)and blood beta Hydroxybutyrate (approved ketone meter) and data generated by the non invasive study device
3266239|NCT01530360|Experimental|cerebral oximetry + treatment guideline|Cerebral oximetry applied as soon as possible after birth and continued until 72 hours of life Clinical staff administer the routine medical management according to local practice as well as respond to out-of-range values with the help of the treatment guideline
3266240|NCT01530373|Experimental|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
3266241|NCT01530373|Active Comparator|clonidine|oral clonidine 0.1 mg daily for 3 weeks
3266242|NCT01530386|Experimental|Lacosamide|300 mg/day
3266243|NCT01530412|No Intervention|Control Group|Patients are randomized to the control group and are assessed pre rehabilitation and post rehabilitation after which they proceed to the intervention group.
3266244|NCT01530412|Experimental|Pulmonary Rehabilitation|Patients undergo an active seven week pulmonary rehabilitation programme. Assessments occur pre rehabilitation, post rehabilitation, at three months and at one year.
3266245|NCT01530425||Phase 1 assessments|Regency Wheelchairs and APDK 12-inch wide wheelchairs
3266246|NCT01530425||Phase 2 assessments|Hope Haven and APDK 14-16 inch wide wheelchairs
3266247|NCT01530425||Phase 3 assessments|Motivation and Whirlwind wheelchairs
3266248|NCT01530438|Other|ALS patients without cognitive disorders|Amyotrophic lateral sclerosis without cognitive disorders
3266249|NCT01530438|Other|ALS patients with cognitive disorders|Amyotrophic lateral sclerosis with cognitive disorders
3266250|NCT01530438|Other|ALS patients + frontal-temporal dementia|Amyotrophic lateral sclerosis plus frontal-temporal dementia
3266251|NCT01530451|Experimental|A: Drug/ Placebo|Initial phase on Desmopressin and then cross over to placebo on the second phase
3266252|NCT01530451|Experimental|B: Placebo/ Drug|Initial phase on Placebo and then cross over to Desmopressin on the second phase
3266253|NCT01530490|No Intervention|Hemoes|
3266254|NCT01530490|Experimental|Cabergoline|cabergoline
3266255|NCT01530503|Experimental|capecitabine|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food
3266256|NCT01530503|Experimental|capecitabine plus mitomycin|oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion Mitomycin 6 mg/m2 day 1
3266257|NCT01530516|Active Comparator|Full brackets plus Forsus springs|Standard of care - Class II springs used after le el and alignment.
3266258|NCT01530516|Experimental|Xbow plus full brackets|Alternative treatment - First use the Xbow appliance and then full brackets after Class II occlusion has been corrected.
3266259|NCT01530529|Experimental|PF-05180999 Immediate-Release|
3266260|NCT01530529|Experimental|PF-05180999 Modified-Release 1|
3266261|NCT01530529|Experimental|PF-05180999 Modified-Release 2|
3266262|NCT01530529|Experimental|PF-05180999 Modified-Release 1 With Food|
3266263|NCT01530542|Experimental|Treatment A|
3266264|NCT01530542|Experimental|Treatment B|
3266265|NCT01530542|Experimental|Treatment C|
3266266|NCT01530542|Experimental|Treatment D|
3266267|NCT01530542|Experimental|Treatment E|
3266268|NCT01530555|Experimental|Treatment arm|"Rabbit ATG, Thymoglobuline (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months, with later tailing according to individual patient response. Aim to maintain trough whole blood CSA levels between 150 and 250 ng/ml."
3266269|NCT01530568|Active Comparator|Smear|Routine microbiology based diagnostics for TB
3266270|NCT01530568|Experimental|GeneXpert|Arm that will receive the Xpert test
3266271|NCT01530581|Experimental|G-BM Transplant|
3266272|NCT01530581|Other|G-PB Transplant|G-PB Transplant
3266273|NCT01530594|Active Comparator|Lenalidomide|Lenalidomide/Low dose Dex (LLD)
3266274|NCT01530594|Experimental|Bortezomib/Lenalidomide|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
3266275|NCT01530607|Active Comparator|cyclophosphamide|Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
3266276|NCT01530607|Experimental|Goserelin (Zoladex)|Goserelin (Zoladex) plus Standard cyclophosphamide containing adjuvant or neoadjuvant chemotherapy
3266277|NCT01530620|Experimental|Propiverine hydrochloride ER|45 mg
3266278|NCT01530620|Active Comparator|Propiverine hydrochloride IR|15 mg
3266279|NCT01530646|Placebo Comparator|Control|Carbohydrate & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of maltodextrin (no protein) for 14 days. Weight loss.
3266280|NCT01530646|Experimental|Whey|Whey protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of WPI for 14 days. Weight loss.
3266281|NCT01530646|Experimental|Soy|Soy protein & 750 kcal dietary restriction while they receive a daily supplement (2 x 25 g) of SPC for 14 days. Weight loss.
3266282|NCT01530659|Experimental|NT-501|Encapsulated cell therapy that delivers ciliary neurotrophic factor to the retina
3266283|NCT01530659|Sham Comparator|Sham|Sham surgery
3266284|NCT01530672|Experimental|ANC clients|
3266285|NCT01530685|Experimental|Glycabiane, gelule|
3266286|NCT01530685|Placebo Comparator|Placebo|
3266287|NCT01530698|Experimental|single step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for single-step antigen loading and TLR activation (TriMix-DC)
3266288|NCT01530698|Active Comparator|two step DC treatment|vaccination with autologous dendritic cells treated with mRNA electroporation for antigen loading and separately for TLR activation
3266289|NCT01530711|Experimental|terlipressin|
3266290|NCT01530724|Experimental|low fat diet|Weight-loss diet strategy
3266291|NCT01530724|Experimental|low carb diet|Weight-loss diet strategy
3266292|NCT01530737|Placebo Comparator|Control Group|
3266293|NCT01530737|Experimental|Active Antithrombin Group|
3266294|NCT01530750||Post cardiac surgery|
3266295|NCT01530763|Experimental|Ceftaroline fosamil|
3266296|NCT01530763|Active Comparator|Ceftriaxone|
3266297|NCT01530776|Experimental|Healthy Lifestyle Group|Participants randomized to this condition will receive information and strategies to help them eat healthier and be more active during and after pregnancy. They will get this information about eating and activity through handouts, text messages, Facebook updates, and in-person visits and phone calls from a health coach.
3266298|NCT01530776|No Intervention|Usual Care|This condition is meant to represent standard clinical care provided to pregnant and postpartum mothers at Temple University.
3266299|NCT01530802|Experimental|Uterine artery clipped|Both uterine arteries are temporarily clipped by Yasargil clips during laparoscopic myomectomy.
3266300|NCT01530802|No Intervention|Control group|Conventional laparoscopic myomectomy is performed. (No intervention to temporarily occlude uterine arteries is made)
3266301|NCT01530815|Experimental|Bupivicaine Infusion|We will infuse bupivicaine between the abdominal wall and mesh to try and reduce postoperative pain
3266302|NCT01530828||Premature infants|Weight less than 1000 grams, age 1 - 16 days.
3266303|NCT01530841|Experimental|AVAPS|Arm assigned to AVAPS mode for nocturnal ventilation with the same setting than bilevel pressure support but with AVAPS mode activated
3376529|NCT05159362|Experimental|OARSCM|After successful completion of usability testing (Patients: n=11, Providers: n=4), a proof-of-concept field test was completed. OARSCM patients (n = 10) received TAU procedures during enrollment (SBIRT for opioid use disorder and a warm handoff to outpatient MOUD treatment). TAU outpatient MOUD treatment consists of urine toxicology (Utox) screening, group/individual therapy, and MOUD prescription. Treatment visits are typically weekly in weeks 1-4 and taper over time. Patients earned chances for prizes, for targeted behaviors, which escalated for each targeted behavior in a row, with reset criteria. For scheduling a MOUD treatment intake, patients will earn 2 chances for prizes. Chances for prizes will increase by 2 chances with each targeted behavior in a row up to a max of 10 draws/targeted behavior. There are 18 targeted behaviors during the 4-week field test (schedule intake, complete intake, 4 opioid-negative Utox/week plus bonuses for cocaine-negative Utox, and 4 therapy/week).
3376530|NCT05159349||Exposed group|
3376531|NCT05159349||Non-exposed group|
3376532|NCT05159336|Experimental|schizophrenia patients with auditory hallucinations|For schizophrenia patients with auditory hallucinations, tACS for implementation intervention
3376533|NCT05159323|Experimental|Diffusion Spectrum Imaging|All participants accept diffusion spectrum imaging, the quantitative parameters of the diffusion spectrum imaging are obtained. The quantitative parameters are compared in different subgroups based on the pathologic examination results.
3376534|NCT05159310|Other|Cast|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
3376535|NCT05159310|Other|Splint|Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast. A research assistant will facilitate the randomisation process so that the RC and the treating physician remain blinded to treatment allocation.
3376536|NCT05159284|Experimental|Intervention group|Softacort® Lephanet® Thealoz Duo® MGD Rx EyeBag®
3376537|NCT05159284|Other|Control group|Lephanet® Thealoz Duo® MGD Rx EyeBag®
3376538|NCT05159271|Experimental|Azeol spray nasal group|Azéol Spray Nasal is a nasal spray. The constituents responsible for achieving the intended action are: Bifidobacterium breve LA 708, extract of cypres Cupressus sempervirens L., extract of Leguminosae Glycyrrhiza glabra L., glycerin and mannitol.
3376539|NCT05159271|Placebo Comparator|Placebo group|The control product is a placebo with the same characteristics of appearance and packaging as Azéol Spray Nasal without the active ingredients
3376540|NCT05159245|Experimental|Alectinib|For patients with a molecular tumor profile that can potentially be targeted by alectinib.
3376541|NCT05159245|Experimental|Cobimetinib|For patients with a molecular tumor profile that can potentially be targeted by cobimetinib.
3266304|NCT01530841|Active Comparator|Bilevel pressure|Arm treated only with bilevel pressure support for nocturnal ventilation without activation of AVAPS mode
3266305|NCT01530854||Septic|
3266306|NCT01530854||Healthy|
3376542|NCT05159245|Experimental|Vismodegib|For patients with a molecular tumor profile that can potentially be targeted by vismodegib.
3376543|NCT05159245|Experimental|Trastuzumab+Pertuzumab|For patients with a molecular tumor profile that can potentially be targeted by trastuzumab+pertuzuma combination.
3376544|NCT05159245|Experimental|Entrectinib|For patients with a molecular tumor profile that can potentially be targeted by entrectinib.
3376545|NCT05159245|Experimental|Atezolizumab|For patients with a molecular tumor profile that can potentially be targeted by atezolizumab.
3376546|NCT05159245|Experimental|Vemurafenib|For patients with a molecular tumor profile that can potentially be targeted by vemurafenib.
3376547|NCT05159245|Experimental|Regorafenib|For patients with a molecular tumor profile that can potentially be targeted by regorafenib.
3376548|NCT05159232|Active Comparator|laparoscopic trans abdominal preperitoneal repair|length of hospital stay
3376549|NCT05159232|Active Comparator|open mesh repair of inguinal hernia|length of hospital stay
3376550|NCT05159219|Experimental|Oral Colchicine, 0.5mg once daily|Active colchicine tablet
3376551|NCT05159219|Placebo Comparator|Oral matching placebo, once daily|Matching placebo tablet
3376552|NCT05159206|Other|CT group|CT-scan preoperatively, postoperatively and at 3 months, 1 and 2 years. Peroperative navigation based on the CT scan.
3376553|NCT05159193|Experimental|PLD + C + HP followed by THP|pegylated liposomal doxorubicin (PLD) 30 mg/m^2, i.v., d1 + cyclophosphamide (C) 600 mg/m^2, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 followed by docetaxel (T) 90~100 mg/m^2, i.v., d1 + trastuzumab (H) 6 mg/kg, i.v., d1 + pertuzumab (P) 420 mg, i.v., d1 q3w, for 4 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
3266307|NCT01530893|Experimental|Intervention group A: flavanones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3266308|NCT01530893|Experimental|Intervention group B: isoflavones|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3376554|NCT05159193|Active Comparator|TCbHP|docetaxel (T) 75 mg/m^2, i.v., d1 + carboplatin (Cb) AUC 6, i.v., d1 + trastuzumab (H) 8 mg/kg loading dose, 6 mg/kg maintenance doses, i.v., d1 + pertuzumab (P) 840 mg loading dose, 420 mg maintenance doses, i.v., d1 q3w, for 6 cycles. After neoadjuvant therapy, patients are required to receive a total of 1 year of treatment with trastuzumab (6mg/kg) combined with pertuzumab (420mg), i.v., d1, q3w, regardless of surgery.
3376556|NCT05159167|Experimental|Intervention group|Participants in the intervention group received two months of Baduanjin exercise training provided by the specialist coach 3 days per week in Hubei Cancer Hospital, and they were also required to do Baduanjin exercise at home for the remaining 4 days each week for at least 20 min per day. All the participants are requested to monitor and record adverse effects during their exercise sessions.
3376557|NCT05159167|Placebo Comparator|Control group|Participants in the control group were requested to maintain their original daily physical activity for no less than 20 min per day over the following 6-month period and record their daily activity at home by themselves. These data were collected by a researcher during the participants' time in the study and at the 6-month follow-up at the hospital. After the 6-month follow-up, the participants were provided with 1-month professional Baduanjin exercise guidance by the trial's specialist coach for free if they wished.
3376558|NCT05157087||Commercial Population|Individuals with at least one omalizumab prescription in the Marketscan commercial claims during the identification period (07/07/2016 - 12/31/2018)
3376559|NCT05157087||Medicaid Population|Individuals with at least one omalizumab prescription in the Truven Medicaid claims during the identification period (07/07/2016 - 12/31/2018)
3376560|NCT05155332|Experimental|Part 1 (Monotherapy): Arm A|Arm A: Intratumoral (i.t.) administration
3266309|NCT01530893|Experimental|Intervention group C: Flavan-3-ols|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3266310|NCT01530893|Experimental|Intervention group D: Anthocyanins|All experimental days will be exactly the same. All volunteers will attend the clinical research and trial unit in a fasted state. Prior to test administration, baseline vascular function will be assessed and biological samples taken by a trained and qualified research nurse. Subsequently, assessments will be repeated at times corresponding to anticipated peak plasma concentration of the flavonoid of interest.
3266311|NCT01530906|Experimental|rTMS|"patients included in this arm will receive 10 sessions of transcranial magnetic stimulation (10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC).~Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol Intervention: Repetitive transcranial Magnetic Stimulation (rTMS)"
3376561|NCT05155332|Experimental|Part 1 (Monotherapy): Arm B|Arm B: Intravenous (i.v.) administration
3376562|NCT05155332|Experimental|Part 1 (Monotherapy): Arm C|Arm C: i.t.+i.v. administration
3376563|NCT05155332|Experimental|Part 2 (Combination therapy): Arm D|Arm D: Intratumoral (i.t.) administration
3376564|NCT05155332|Experimental|Part 2 (Combination therapy): Arm E|Arm E: Intravenous (i.v.) administration
3376565|NCT05155332|Experimental|Part 2 (Combination therapy): Arm F|Arm F: i.t.+i.v. administration
3376570|NCT05153265||Residents|We plan to distribute a survey to the Stanford anesthesiology residents to determine their assessment of the bleeding risk of nerve blocks. The survey will list the most common nerve blocks and ask the resident anesthesiologists at Stanford whether the block is low/intermediate/high risk based on a scoring system of location relative to critical structures, compressibility, and whether bleeding or hematoma would be readily apparent.
3376571|NCT05153265||Attending physicians|We plan to distribute a survey to the Stanford anesthesiology attending physicians to determine their assessment of the bleeding risk of several different nerve blocks. The survey will list the most common nerve blocks and ask Stanford anesthesiologists whether the block is low/intermediate/high risk based on their experience with nerve blocks.
3376572|NCT05152173|Experimental|EN3835 Group|Participant will receive a maximum dose of up to 1.8mg of EN3835 injection
3376573|NCT05152173|Placebo Comparator|Placebo Group|Participant will receive a maximum dose of up to 1.8mg of Placebo injection
3376574|NCT05150431|Experimental|Parecoxib|Parecoxib 40mg will be administered to this group 15 minutes before the end of the surgery.
3376575|NCT05150431|Placebo Comparator|Placebo|2ml normal saline will be administered to this group 15 minutes before the end of the surgery.
3376580|NCT05146687||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
3376581|NCT05146687||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
3376582|NCT05146687||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
3266312|NCT01530906|Placebo Comparator|rTMS SHAM|Transcranial magnetic stimulation SHAM Intervention: Repetitive transcranial Magnetic Stimulation SHAM Fifty percent of patients will be included in this arm. During the first and last session a food challenge task will be administered before and after rTMS. Salivary cortisol level will be assessed throughout the protocol
3266313|NCT01530919||Parathyroid surgery|Database of patients who have undergone minimally invasive radioguided parathyroidectomy
3266314|NCT01530958|Experimental|ATSM + Health Coach and CKD Registry|
3266315|NCT01530958|Active Comparator|CKD Registry|
3266316|NCT01530958|Active Comparator|ATSM + Health Coach|
3266317|NCT01530958|Placebo Comparator|Usual Care (no interventions)|
3266318|NCT01530971|No Intervention|room air|no supplemental oxygen in intraoperative period
3266319|NCT01530971|Experimental|Oxygen|Supplemental 3LPM oxygen via canula
3266320|NCT01530984|Experimental|Ipilimumab alone|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance).
3266321|NCT01530984|Experimental|Ipilimumab with GM-CSF|Ipilimumab 3 mg/kg (IV) will be given every 28 days for six cycles (induction) followed by administration once every three months for patients who are not progressing (maintenance). GM-CSF 250 mcg/m2 SQ will be administered on days 1-14 in Cycles 1-6 and then every 3 months for 14 days beginning on the day of ipilimumab administration during the maintenance therapy phase
3266322|NCT01531010|Active Comparator|Pressure-limited ventilation|
3266323|NCT01531010|Active Comparator|Volume-targeted ventilation|
3266324|NCT01531023||ESBL producing E. coli bacteria|Group of patients with identified ESBL producing E.coli in a urine sample taken in a primary care setting.
3266325|NCT01531023||Non-ESBL E.coli urinary tract infection|E.coli bacteria found in the setting of a urinary tract infection in a primary care setting where ESBL producing bacteria are not found.
3266326|NCT01531036|Experimental|shear wave imaging|Single arm study evaluating breast 3D elastography by means of shear wave propagation into breast tissue.
3266327|NCT01531049|Experimental|Varenicline|A varenicline treatment group (with motivational interview technique combined with varenicline and placebo transdermal patch). Intervention with Nicorette 15mg /16 h patch
3266328|NCT01531049|Experimental|Nicotine cutaneous patch 15mg|Intervention with Varenicline for 12 weeks. Nicotine cutaneous patch 15mg/16h
3266329|NCT01531049|Experimental|Nicotine cutaneous patch 10mg|Intervention with Placebo transdermal patch for 8 weeks. Nicotine cutaneous patch 10mg/16h
3266330|NCT01531049|Placebo Comparator|Placebo cutaneous patch|No active medication.One transdermal patch/16 h.Total duration was 8 weeks.
3266331|NCT01531062|Experimental|Nigella sativa|Nigella sativa extracts, 300 mg twice daily
3266332|NCT01531062|Placebo Comparator|Placebo|
3266333|NCT01531075|Experimental|ENGERIX-B|
3266334|NCT01531075|Experimental|Sci-B-Vac|
3266335|NCT01531088|No Intervention|Usual care|Recommendations made by consultant pharmacists as part of their federally-mandated medication regimen review process
3266336|NCT01531088|Experimental|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events
3266337|NCT01531101|Experimental|Individual PDT with TW|Individual Psychodynamic psychotherapy with transference work (TW).
3266338|NCT01531101|Active Comparator|Individual PDT without (TW)|Individual Psychodynamic psychotherapy without focus on transference work (TW).
3266339|NCT01531114|Active Comparator|Prasugrel loading dose|Patients will be randomized to this arm to receive loading dose of prasugrel
3266340|NCT01531114|No Intervention|ticagrelor loading dose|Patients will be randomized to this arm to receive loading dose of ticagrelor
3266341|NCT01531127||Combined Therapy|ADHD Medication and Learning Strategies Treatment
3266342|NCT01531127||ADHD Medication Treatment|Control group
3266343|NCT01531140|Active Comparator|Polyethylene glycol|Polyethylene glycol p.o.(Fortrans):60 ml/kg for 2 days
3266344|NCT01531140|Experimental|PEG + Bisacodyl|Polyethylene glycol p.o.(Fortrans): 30 ml/kg for 2 days + Bisacodyl p.o.: 10-15 mg/day
3266345|NCT01531140|Experimental|Sennosides|Sennosides: 1tbl/8kg/day for 2 days (1 tbl=8,6 mg sennosides B)
3266346|NCT01531166||Chronic hepatitis B|
3266347|NCT01531179|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
3266348|NCT01531179|Placebo Comparator|Control|Placebo for 3 months
3266349|NCT01531192|Experimental|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
3266350|NCT01531192|Active Comparator|Nystatin|50000 unit/3 times a day
3266351|NCT01531218|Active Comparator|azithromycin|azithromycin 500mg
3266352|NCT01531218|Placebo Comparator|placebo|placebo 500mg
3266353|NCT01531231||YOUNGER HEALTHY NO CORONARY ARTERY DISEASE (CAD)|- Whether an association between typical daily experiences and recovery time varies with age; this group will be compared to the older comparison group and to previous data collected from those subjects who participated in the Long QT Syndrome study (LQTS).
3266354|NCT01531231||OLDER HEALTHY SUBJECTS NO CORONARY ARTERY DISEASE (CAD)|- Determine whether daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD when comparing CAD patients with healthy patients
3266355|NCT01531231||HIGH RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether emotion assessed randomly throughout the day is associated with myocardial ischemia
3266356|NCT01531231||LOW RISK CORONARY ARTERY DISEASE (CAD)|- Determine whether typical daily emotion influences ischemia and repolarization differentially as a function of the severity of CAD and presence of CAD
3266357|NCT01531244|Experimental|Treatment (targeted gene therapy and ILI)|Patients receive melphalan and dactinomycin via ILI. Patients then receive CRAd 3/5-delta via ILI.
3266358|NCT01531257||Kidney Transplant Recipients|The intention of our biomarker panel is to be broadly applicable to all patients with a kidney transplant with the assumption that there are common underlying molecular mechanisms of AR and CAN/IFTA that can be detected hopefully at early stages of disease. We therefore want to validate and test our biomarker panel in a broad collection of patient types. We chose not to include patients with dual organ transplants so that we could isolate the molecular signal we are studying.
3266359|NCT01531283|Experimental|decaylated ghrelin|UAG (4.0 µg/kg/hr)
3266360|NCT01531283|Experimental|acyl ghrelin|AG (1.0 µg/kg/hr)
3266361|NCT01531283|Experimental|combined acyl and desacyl ghrelin|the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr)
3266362|NCT01531283|Placebo Comparator|saline|saline
3266363|NCT01531309|Experimental|Mild Hepatic Impaired Participants|Mild hepatic impaired participants will receive a single sublingual dose of AGO178, 1 milligram (mg) on Day 1.
3266364|NCT01531309|Experimental|Moderate Hepatic Impaired Participants|Moderate hepatic impaired participants will receive a single sublingual dose of AGO178, 1 mg on Day 1.
3266365|NCT01531309|Experimental|Healthy Participants Matched by Aged, Gender and Body Mass Index (BMI)|Healthy participants matched by aged, gender and BMI will receive a single sublingual dose of AGO178, 1 mg on Day 1.
3266366|NCT01531322|Experimental|Group 1|Adults aged 18 through 55 years (before the fifty sixth birthday)
3266367|NCT01531322|Experimental|Group 2|Children aged 3 through 5 years (before the sixth birthday)
3266368|NCT01531322|Experimental|Group 3|Infants aged approximately 2 months (42 to 98 days)
3266369|NCT01531348|Experimental|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
3266370|NCT01531361|Experimental|Arm I (vemurafenib and sorafenib tosylate)|Patients receive vemurafenib PO BID and sorafenib tosylate PO BID on days 1-28.
3266371|NCT01531361|Experimental|Arm II (vemurafenib and crizotinib)|Patients receive vemurafenib as in Arm I and crizotinib PO QD or BID on days 1-28.
3266372|NCT01531400|Experimental|music|Investigators played self-selected background music in the music group
3266373|NCT01531400|No Intervention|no music (control)|Investigators played no music in the music group
3266374|NCT01531413|Experimental|Oxygen Insufflation|At the end of the laparoscopic appendectomy we will desufflate the abdomen of CO2 then reinsufflate with oxygen to washout the CO2 leaving an oxygen rich environment
3266375|NCT01531426||NIRS continuous monitoring|
3266376|NCT01531452|Experimental|treatment|oxaliplatin+s1
3266377|NCT01531465|Other|HFNC to NCPAP|Infants who are currently on HFNC.
3266378|NCT01531465|Other|NCPAP to HFNC|Infants who are currently on NCPAP.
3266379|NCT01531478||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
3266380|NCT01531491|Experimental|Hypercapnia group|Respiratory rate will be 10/min and the rebreathing tube will be connected between the y-piece of corrugated tube and the tracheal tube to maintain the partial pressure of the end-tidal carbon dioxide at around 50 mmHg during emergence after propofol anesthesia.
3266381|NCT01531491|Experimental|Hypocapnia group|No rebreathing tube (Nothing) will be connected. Respiratory rate will be 10/min and the tidal volume will be modulated to maintain the partial pressure of the end-tidal carbon dioxide at around 30 mmHg during emergence after propofol anesthesia.
3266382|NCT01531504|Other|Hysterectomy|candidate for a conventional laparoscopic-assisted
3266383|NCT01531517|Experimental|Pedyphar|Ointment
3266384|NCT01531517|Active Comparator|Panthenol|Ointment
3266385|NCT01531530|Experimental|Vaccine-recipients|
3266386|NCT01531530|Placebo Comparator|Placebo|
3266387|NCT01531543|Experimental|VAC-laparostomy|Primary use of Vacuum Assisted Closure (VAC) laparostomy after surgical revision because of severe peritonitis
3266388|NCT01531543|No Intervention|Primary abdominal closure|The abdominal wall is primary closed after the surgical revision because of severe peritonitis
3266389|NCT01531569|Experimental|BeneFlax|BeneFlax given as a single oral dose to assess pharmacokinetics
3266390|NCT01531582|Experimental|Children with Angelman Syndrome|Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.
3266391|NCT01531595|Experimental|Chemotherapy plus bevazicumab|
3266392|NCT01531621||mCRC treatments|All used treatments for metastatic colorectal cancer
3266393|NCT01531634|Active Comparator|Dynamic Cognitive Intervention Group|Twelve Meetings of Dynamic Cognitive Intervention.
3266394|NCT01531634|No Intervention|No Additional Intervention|
3266395|NCT01531647|Active Comparator|Period 1 Control|
3266396|NCT01531647|Experimental|Period 2 danoprevir/ritonavir|
3266397|NCT01531660|Experimental|training|step up jogging program
3266398|NCT01531699|Experimental|ALT005 Ophthalmic Prep Solution|
3266399|NCT01531699|Placebo Comparator|saline control|
3266400|NCT01531699|Experimental|Comparator Product|Betadine ophthalmic prep solution
3266401|NCT01531712|Experimental|QT + QRT|"Chemotherapy (6 cycles x 14 days): Gemcitabine 1000 mg/m2 (day 1) + Oxaliplatin 100 mg/m2 (day 2) + Tarceva 100 mg/day.~Chemoradiotherapy (5,5 weeks): Gemcitabine 40 mg/m2 (2 days/week) + Tarceva 100 mg/day + Radiotherapy (1,8 Gy/day x 28 doses, total dose: 50,4 Gy)."
3266402|NCT01531751|Experimental|High Cut-off Hemodialysis|
3266403|NCT01531777|Experimental|Apatinib 500mg|500mg,p.o.,qd
3266404|NCT01531777|Experimental|Apatinib 750mg|750mg,p.o.,qd
3266405|NCT01531790|Experimental|Endostar plus pemetrexed/carboplatin|21 days as one cycle, for a total of 4-6 cycles
3266406|NCT01531816|Experimental|Single Arm: Study Intervention|Cycle ergometry and/or Interactive video-game
3266407|NCT01531829|Experimental|Low dose (50mg/2h) rt-PA plus LMWH|Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
3266408|NCT01531829|Active Comparator|LMWH|Low molecular weight heparin
3266409|NCT01531842|Experimental|Topical antibiotic|Patients will be randomized in a 1:1 fashion to receive a drop of topical antibiotic before and after the intravitreal injection in the +ABX arm (in addition to the typical prep with betadine).
3266410|NCT01531842|Other|No Antibiotic Arm|No topical antibiotics in the -ABX arm (only the typical prep with betadine)
3266411|NCT01531855|Other|Insulin dose|Reducing rapid-acting insulin dose (insulin aspart or lispro) after exercise.
3266412|NCT01531868|Other|Auditory qualitative|
3266413|NCT01531868|Other|Auditory absolute risk|
3376583|NCT05146687||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
3266414|NCT01531868|Other|Auditory relative risk|
3266415|NCT01531868|Other|Visual qualitative|
3266416|NCT01531868|Other|Visual relative risk|
3266417|NCT01531868|Other|Visual absolute risk|
3266418|NCT01531907||Obese|Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2
3266419|NCT01531907||Lean|Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2
3266420|NCT01531920|Other|alcohol + placebo|Part A alcohol + placebo
3266421|NCT01531920|Other|alcohol + perampanel|Part A : alcohol + perampanel
3266422|NCT01531920|Other|perampanel + alcohol|Part B: perampanel + alcohol
3266423|NCT01531920|Other|placebo + alcohol|Part B: placebo + alcohol
3266424|NCT01531933|Experimental|DLBS3233|
3266425|NCT01531933|Placebo Comparator|Placebo of DLBS3233|
3266426|NCT01531972|Experimental|SEP-228432 (Cohort 1)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days; followed by (steady state) at a dose of 200 mg orally once per day for 5 days.
3266427|NCT01531972|Experimental|SEP-228432 (Cohort 2)|Subjects will receive 40 mg of SEP-228432 (titration) orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
3266428|NCT01531972|Experimental|SEP-228432 (Cohort 3)|Subjects will receive 40 mg of SEP-228432 (titration) 40 mg of SEP 228432 orally once per day for 3 days followed by a dose (TBD) of SEP 228432 ≤ 300mg, orally once per day for 5 days.
3266429|NCT01532011|Experimental|Erlotinib + Pralatrexate|"Dose escalation group starting dose: Erlotinib 75 mg by mouth daily for a 28 day cycle. Starting dose of Pralatrexate 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
3266430|NCT01532024|Experimental|Healthy Volunteers|Delivery of intrapulmonary NAP Dose escalation from 5 mcgs to 80mcgs
3266431|NCT01532024|Experimental|Pulmonary Infiltrate in ICU|Delivery of NAP (80mcgs) to ventilated patients with pulmonary infiltrates
3266432|NCT01532024|Experimental|Patients with Bronchiectasis|Delivery of NAP (80mcgs) to patients with bronchiectasis
3266433|NCT01532037|Experimental|Guided Self Help|Participant receives usual care and 4, 45 minute sessions with a therapist to support them to complete the cognitive behavioural therapy based workbook for fatigue in Multiple Sclerosis.
3266434|NCT01532037|Experimental|Pure Self Help|Participant receives usual care and cognitive behavioural therapy based self help work book for fatigue in multiple sclerosis to complete alone
3266435|NCT01532037|Placebo Comparator|Treatment as Usual|Participants receive usual care from healthcare professionals
3266436|NCT01532050|Other|Mandibular Advancement Device (MAD)|Mandibular Advancement Device (MAD)
3266437|NCT01532063|Other|INTUBATION|Subjects intubed in Intensive Care Unit
3266438|NCT01532076|Experimental|cellularized composite graft augmentation|lipoaspiration by experienced plastic surgeon, isolation of SVF cells using a Cellution/CR800® cell isolation device and single use kits (Cytori Therapeutics Inc., San Diego) during open reduction and internal fixation, augmentation of bone with cell-seeded bone graft substitute;
3266439|NCT01532076|Active Comparator|Control acellular composite graft augmentation|open reduction internal fixation (ORIF) of the fracture, augmentation with acellular bone graft substitute.
3266440|NCT01532102|Experimental|AP611074 5% gel|Twice daily application of 100 mg dose of AP611074 5% gel for 41 days followed by a single morning application on Day 42
3266441|NCT01532102|Placebo Comparator|Placebo gel|Twice daily application of 100 mg dose of placebo gel for 41 days followed by a single morning application on Day 42
3266442|NCT01532115|Experimental|BIA 9-1067|
3266443|NCT01532115|Placebo Comparator|Placebo|
3266444|NCT01532115|Active Comparator|moxifloxacin|
3266445|NCT01532180|Experimental|THN Therapy|
3266446|NCT01532193|Experimental|Hipoxia|The low oxygen tension group
3266447|NCT01532193|No Intervention|Control group|Conventional culture conditions
3266448|NCT01532206|Experimental|Remote ischemic preconditioning|Remote ischemic preconditioning performed with Blood pressure cuff insufflation
3266449|NCT01532206|No Intervention|Standard of care|Standard of care
3266450|NCT01532219|Experimental|Internet-delivered Psychodynamic Treatment|Participants in the experimental condition will receive 8 text-modules delivered as guided self-help, via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail. The treatment is a short-term psychodynamic treatment psychodynamic treatment.
3266451|NCT01532219|Active Comparator|Internet-delivered structured support|Participants in the active control condition will receive a structured support treatment via the Internet. The intervention lasts for 10 weeks and includes weekly contacts with a therapist via a secure online environment similar to e-mail.
3266452|NCT01532232||placebo|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
3266453|NCT01532232||varenicline|This is a randomized, double-blind, placebo-controlled trial comparing the effectiveness and tolerability of varenicline with placebo for smoking cessation in 30 tobacco dependent breast cancer patients.
3266454|NCT01532245|Active Comparator|two-lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
3266455|NCT01532245|Active Comparator|one lung ventillation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
3266456|NCT01532245|Active Comparator|one lung ventilation (OLV) with PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2Opositive end-expiratory pressure (PEEP) were alternated
3266457|NCT01532258|No Intervention|Control Group|No intervention provided. These participants will receive access to the Go! Foods for You program after the research trial has been completed (12 weeks after registration).
3266458|NCT01532258|Active Comparator|GFFY-1 without weekly MA support|Utilization of the 8-week online nutrition program Go! Foods for You without weekly contact from staff at the medical provider's office.
3266459|NCT01532258|Active Comparator|GFFY-2 with weekly MA support|Utilization of the 8-week online nutrition program combined with weekly contact from the staff at the medical provider's office.
3266460|NCT01532271||Concussed|Patients with recent concussion
3266461|NCT01532271||Matched controls|Athletes with no recent concussion
3266462|NCT01532284|Experimental|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
3266463|NCT01532284|No Intervention|No Polar Body Biopsy|
3266464|NCT01532297|Active Comparator|HD treated with standard dialysate|
3266465|NCT01532297|Active Comparator|post-dilution oHDF with standard dialysate|
3266466|NCT01532297|Experimental|pre-dilution oHDF with citrate dialysate|
3266467|NCT01532297|Experimental|HD treated with citrate dialysate|
3266468|NCT01532297|Experimental|post-dilution oHDF with citrate dialysate|
3266469|NCT01532297|Active Comparator|pre-dilution oHDF with standard dialysate|
3266472|NCT01532323|Experimental|Oral disorder children|Oral disorder children aged 2 to 15 years
3266473|NCT01532323|Active Comparator|Control group|No oral disorder children aged 2 to 15 years
3266474|NCT01532336|Experimental|NVC-422 Solution, 0.3%|Dosed for 10 days
3266475|NCT01532336|Placebo Comparator|NVC-422 Vehicle Solution|Dosed for 10 days
3266476|NCT01532375|Experimental|Kochujang(32g)|
3266477|NCT01532375|Placebo Comparator|placebo(32g)|
3266478|NCT01532401|Experimental|chlorure de sodium|
3266479|NCT01532401|Placebo Comparator|Methylcellulose|
3266480|NCT01532466|Experimental|Rocuronium, fentanyl-induced cough, normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
3266481|NCT01532466|No Intervention|Normal saline|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
3266482|NCT01532479||Treatment Group|Subjects with ORN treated with Hyperbaric Oxygen Therapy
3266483|NCT01532479||Postive Control Group|Subjects treated with Hyperbaric Oxygen Therapy that have not had head or neck radiation therapy
3266484|NCT01532479||Negative Control Group|Subjects who have had head and neck radiation that have not had Hyperbaric Oxygen Therapy
3266485|NCT01532492||Rotator cuff repair group|Patients undergoing an arthroscopic rotator cuff repair
3266486|NCT01532492||DRC without rupture|Disorders of the rotator cuff without rupture
3266487|NCT01532492||Shoulder instability|Shoulder instability
3266488|NCT01532518|Experimental|Cohort 3|Nepadutant low dose for 7 days followed by Nepadutant high dose for additional 7 days
3266489|NCT01532518|Experimental|Cohort 2|Nepadutant medium dose for 7 days followed by Nepadutant high dose for additional 7 days
3266490|NCT01532518|Experimental|Cohort 1|Nepadutant low dose for 7 days followed by Nepadutant medium dose for additional 7 days
3266491|NCT01532531|Experimental|Collateral Meridian Therapy|"The CMT group patients received, according to the CMT protocol described previously, CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
3266492|NCT01532531|No Intervention|Control (CT) group|Patients in the CT group received electronic lead-patches applied on the treatment points, which was identical to what the CMT patients received, also for 6 minutes, though no electric stimulation was applied.
3266493|NCT01532544|Experimental|Integrilin and Ilomedin given as continous infusion|
3266494|NCT01532544|Placebo Comparator|Standard treatment daily doses of low molecular weight heparin|Standard treatment daily doses of low molecular weight heparin.
3266495|NCT01532583||Patients operated on with the TOT|
3266496|NCT01532596|Experimental|Mindfulness-Based Stress Reduction|A standardized 8-week mindfulness meditation training program
3266497|NCT01532596|No Intervention|Wait-List|
3266498|NCT01532609|Experimental|Intervention|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
3266499|NCT01532609|No Intervention|Standard care|No additional training or service is provided for standard care group service providers or clients.
3266500|NCT01532622|Active Comparator|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days.
3266501|NCT01532622|Placebo Comparator|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
3266502|NCT01532661||observational study|haemorrhagic trauma received rFVIIa
3266503|NCT01532674|Experimental|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy and scaling and root planing
3266504|NCT01532674|Active Comparator|scaling and root planing|Only scaling and root planing
3266505|NCT01532713|Experimental|non-block side|
3266506|NCT01532726||Eslicarbazepine Acetate (ESL)|ESL and concomitant medication should be managed by the neurologist according to the respective SPC.Summary of Product Characteristics
3266507|NCT01532739|Experimental|Cognitive training|
3266508|NCT01532739|No Intervention|No cognitive training|
3266509|NCT01532765|Active Comparator|Epiretinal Membrane Surgery without ILM peel|
3266510|NCT01532765|Active Comparator|Epiretinal Membrane Surgery with ILM peel (ICG assisted)|
3266511|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery without ILM peel|
3266512|NCT01532765|Active Comparator|Combined CE & IOL and ERM surgery with ILM peel (ICG assisted)|
3266513|NCT01532791||mtDNA mutation|m.3243 A>G carriers and their maternal relatives Other mutations in the mitochondrial genome may be included
3266514|NCT01532791||Control|controls (people not maternally related to mutation carriers) Preference is for married in relatives
3266515|NCT01532804|Experimental|Arm A|FOLFOX6 + bevacizumab (D1=D15, 12 cycles)
3266516|NCT01532804|Experimental|Arm B|Raltitrexed + Oxaliplatin + Bevacizumab (D1=D21, 8 cycles)
3266517|NCT01532843|Active Comparator|PegIFN alfa-2b + nucleos(t)ide analogue|Peginterferon alfa-2b 1.5 μg/kg per week s.c. for 48 weeks in addition to standard nucleos(t)ide analogue treatment
3266518|NCT01532843|No Intervention|Nucleos(t)ide analogue|Continuation of Nucleos(t)ide analogue mono-therapy
3266519|NCT01532856|Active Comparator|Group A induction therapy|Thalidomide + Cyclophosphamide + Dexamethasone
3266520|NCT01532856|Active Comparator|Group B induction therapy|thalidomide + dexamethasone
3266521|NCT01532856|Active Comparator|Group C induction therapy|thalidomide + melphalan + prednisone
3266522|NCT01532882|Experimental|Diosmin|
3266523|NCT01532882|Placebo Comparator|Placebo|
3266524|NCT01532895||Hydromorphone HCI OROS|
3266525|NCT01532947|Experimental|post restoration|
3266526|NCT01532947|No Intervention|no post restoration|no post placement
3266527|NCT01532960|Experimental|9 Peptides from Her-2/neu, CEA, & CTA, peptide-tet, poly-ICLC|9 class I MHC-restricted synthetic peptides (100 mcg each peptide) derived from breast cancer associated proteins, a class II MHC-restricted tetanus derived peptide (200 mcg), plus polyICLC (1 mg).
3266528|NCT01533012|Experimental|Pressure difference|Peak inspiratory pressures difference between two lungs
3266529|NCT01533012|No Intervention|FOB evaluation|FOB evaluation for the optimal position of tubes
3266530|NCT01533025|Active Comparator|bone-tendon Achilles allograft group|the group which underwent anterior cruciate ligament reconstruction using bone-tendon Achilles allograft
3266531|NCT01533025|Active Comparator|free tendon Achilles allogarft group|the group which underwent anterior cruciate ligament reconstruction using free tendon Achilles allograft
3266532|NCT01533051||Chronic hepatitis B|
3266533|NCT01533064||Psychiatric Outpatients|
3266534|NCT01533090|Active Comparator|polyethylene glycol (PEG)|
3266535|NCT01533090|Experimental|PEG low volume with bisacodyl|
3266536|NCT01533129|Active Comparator|Daily testosterone transdermal gel|
3266537|NCT01533129|Active Comparator|Injectable Testosterone esters|Testosteron 250mg injection per 3-4 weeks for 6 months
3266538|NCT01533142||surgical methods|Different methods are used among hospitals in Helse-Vest, and this allows us to compare different clinical and biological effects following bariatric surgery different methods) among a homogeneous population in the western part of Norway (Vestlandet
3266539|NCT01533142||Morbid obesity|
3266540|NCT01533155|Active Comparator|NKTR-118/ Quinidine|One 25-mg NKTR-118 tablet will be administered once with 3 Quinidine 200mg tablets in the morning of period 1 or period 2 (part 1)
3266541|NCT01533155|Placebo Comparator|NKTR-118/ Placebo|One 25-mg NKTR-118 tablet will be administered once with 3 Placebo tablets in the morning of period 1 or period 2 (part 1)
3266542|NCT01533155|Active Comparator|NKTR-118/ Quinidine/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 Quinidine 200mg tablets with Morphine inj 5mg/70kg once in the morning on period 3 or period 4 (Part 2)
3266543|NCT01533155|Placebo Comparator|NKTR-118/ Placebo/ Morphine|One 25-mg NKTR-118 tablet will be administered with 3 placebo tables with Morphine inj 5mg/70kg once in the morning of period 3 or period 4 (part 2)
3266544|NCT01533194|Experimental|Treatment (wild-type reovirus)|Patients receive wild-type reovirus IV over 60 minutes on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3266545|NCT01533220|Experimental|Test group|"Naphazoline Hydrocloride (1.0mg) + Pheniramine Maleate (0.2mg) + Panthenol(5.0mg).~02 drops in each nostril every 12 hours for 3 days"
3266546|NCT01533220|Active Comparator|Comparator group|"Naphazoline Hydrocloride (0.5mg)~02 drops in each nostril every 12 hours for 3 days"
3266547|NCT01533233|Experimental|nonintubated anesthesia|Thoracoscopic lobectomy using nonintubated anesthesia
3266548|NCT01533233|Active Comparator|intubated general anesthesia|Thoracoscopic lobectomy using intubated general anesthesia
3266549|NCT01533272|Experimental|Tenofovir, emtricitabine, Maraviroc|New postexposure prophylaxis (it is a combination drug)
3266550|NCT01533272|Active Comparator|Tenofovir, emtricitabine, lopinavir/r|Standard prophylaxis (it is a combination drug)
3266551|NCT01533285|Other|Group 1|Treatment AB: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment B (typhoid vaccination) administered [Period 2]
3266552|NCT01533285|Other|Group 2|Treatment BA: Treatment B (typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3266553|NCT01533285|Other|Group 3|Treatment AC: Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment C (TSST+Placebo vaccination) administered [Period 2]
3266554|NCT01533285|Other|Group 4|Treatment CA: Treatment C (TSST+Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3266555|NCT01533285|Other|Group 5|Treatment AD:Treatment A (Placebo vaccination) administered [Period 1], after the washout period (7-14 days) Treatment D (TSST+typhoid vaccination) administered [Period 2]
3266556|NCT01533285|Other|Group 6|Treatment DA:Treatment D (TSST+typhoid vaccination) administered [Period 1], after the washout period (7-14 days) Treatment A (Placebo vaccination) administered [Period 2]
3266557|NCT01533298|Experimental|CombiflexOmega peri|
3266558|NCT01533298|Active Comparator|SmofKabiven peripheral|
3266559|NCT01533324|Experimental|S-1 combined with LV|S-1 combined with LV
3266560|NCT01533350||group1|women with a ultrasonographic homogeneous echo endometrium in the late follicle phase
3266561|NCT01533350||group2|"women with a ultrasonographic  triple-line endometrium in the late follicle phase"
3266562|NCT01533363|Active Comparator|Stapled hemorrhoidopexy|surgical procedure to treat hemorrhoids
3266563|NCT01533363|Active Comparator|Milligan Morgan|surgical procedure to treat hemorrhoids
3266564|NCT01533376|Experimental|Timolol|Participants in this group will receive topical timolol
3266565|NCT01533376|Placebo Comparator|Placebo|Participants in this group will receive Preservative free artificial tear gel.
3266566|NCT01533389|Experimental|Silodosin|8mg QD
3266567|NCT01533389|Placebo Comparator|Placebo|8mg QD
3266568|NCT01533402|Placebo Comparator|Attention control|Weekly support from therapist without CBT-interventions
3266569|NCT01533402|Experimental|Internet CBT|Internet-delivered cognitive behavioural therapy with therapy support
3266570|NCT01533415|Active Comparator|Active CES treatment|Out of the total population of 150 participants,75 of them will be assigned to the active treatment group. Because this is a double-blind study it is unknown which members will belong to this group until completion of the study.
3266571|NCT01533415|Sham Comparator|Sham CES treatment|Of the 150 participants in this study, half of them will be assigned to the sham treatment group. Because this is a double-blind study, it is unknown which members will be assigned to this group until the completion of the study.
3266572|NCT01533441|Placebo Comparator|placebo low VKA|
3266573|NCT01533441|Placebo Comparator|Placebo high VKA|Microcrystalline cellulose
3266574|NCT01533441|Active Comparator|Vitamin K2 Low VKA|
3266575|NCT01533441|Active Comparator|Vitamin K2 high VKA|
3266576|NCT01533454|No Intervention|Control|Control participants will attend a 4-month structured weight-loss program and attend subsequent follow-ups at 4-month intervals upon completion of the program.
3266577|NCT01533454|Experimental|Incentives|Incentive arm participants will be offered an additional program (in addition to the COMM program) where they can earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
3266578|NCT01533467|Other|Perineal device used|Use of the perineal device during delivery
3266579|NCT01533467|No Intervention|No intervention|Controls, delivered as normal
3266580|NCT01533480|Active Comparator|Zirgan, Adenovirus conjunctivitis,|Zirgan
3266581|NCT01533480|Placebo Comparator|genteal gel|0.3% Hypromellose gel (genteal gel)
3266582|NCT01533519|Experimental|NPY/placebo|This arm gets NPY first then placebo (saline). The placebo is 0.9% USP-grade saline without NPY.
3266583|NCT01533519|Experimental|placebo/NPY|This arm gets placebo (saline) first then NPY.
3266584|NCT01533532|Experimental|KLH-2109, low dose|
3266585|NCT01533532|Experimental|KLH-2109, medium dose|
3266586|NCT01533532|Experimental|KLH-2109, high dose|
3266587|NCT01533532|Placebo Comparator|placebo|
3266588|NCT01533545|Active Comparator|Plain mepivacaine|
3266589|NCT01533545|Active Comparator|Mepivacaine with epinephrine|
3266590|NCT01533558||caspofungin|caspofungin dosing
3266591|NCT01533571|Active Comparator|Immediate implant + xenogenic graft|Treatment with immediate implant and GBR using xenogenic bone graft material
3266592|NCT01533571|Active Comparator|Immediate implant + allogenic graft|Treatment with immediate implant and GBR using allogenic bone graft material.
3266593|NCT01533623|Other|mandibular advancement device treatment|Patients diagnosed with sleep-disordered breathing that receive treatment with a titratable, duobloc mandibular advancement devices
3266594|NCT01533636||Healthy Control|This group will be comprised of healthy individuals without evidence of lung disease.
3266595|NCT01533636||Cystic Fibrosis|This group will be comprised of individuals who have been diagnosed with cystic fibrosis.
3266596|NCT01533649|Experimental|A/R intervention|The A/R intervention will accommodate 10 study subjects who will participate in an epilepsy-specific counseling intervention.
3266597|NCT01533649|Experimental|Relaxation|The relaxation group will accommodate 10 study subjects who will participate in a condition unspecific supportive relaxation intervention.
3266598|NCT01533649|No Intervention|Usual care|10 Potential study subjects who are not interested in participating in either intervention will be asked to provide data as a usual care control group.
3266599|NCT01533662|Experimental|phenylephrine|patients more than 60 years receiving 100micrograms of phenylephrine infusion (2 groups 60-75 years and more than 75 years)
3266600|NCT01533662|Placebo Comparator|placebo|patients more than 60 years receiving saline infusion (2 groups 60-75 years and more than 75)
3266601|NCT01533675|Experimental|Hydrogen peroxide|
3266602|NCT01533675|Active Comparator|Saline|
3266603|NCT01533714|Experimental|Olokizumab 120 mg|Olokizumab 120 mg : subcutaneous injections at q2w (every two weeks).
3266604|NCT01533727|Experimental|Group A|Autologous CIK Transfusion plus Chemotherapy
3266605|NCT01533727|Active Comparator|Group B|chemotherapy alone
3266606|NCT01533766|Experimental|CombiflexOmega|
3266607|NCT01533766|Active Comparator|SmofKabiven|
3266608|NCT01533792|Experimental|Supra/subgingival therapy|The experimental group received supra and subgingival scaling associated with oral hygiene orientation (OHO)
3266609|NCT01533792|Active Comparator|Control group|Control group received only supragingival scaling with OHO too.
3266610|NCT01533805|Experimental|Pilates with stabilization|This group will do pilates exercises with a focus on control of segmental stabilization of the lumbar spine neutral.
3266611|NCT01533805|Active Comparator|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine.
3266612|NCT01533818|Active Comparator|Amoxicillin|This is an active intervention
3266613|NCT01533818|Placebo Comparator|Sugar Syrup|
3266614|NCT01533844||Neonates|Neonates with CDAD
3266615|NCT01533857|Experimental|Black tea|black tea
3266616|NCT01533857|Placebo Comparator|placebo|
3266617|NCT01533870|Experimental|NKTR-118|Single dose NKTR-118 25 mg on Day 1 only
3266618|NCT01533870|Active Comparator|Rifampin|Rifampin 600 mg once daily on Days 4 to 12
3266619|NCT01533870|Active Comparator|Rifampin/ NKTR-118|Rifampin 600 mg plus NKTR-118 25 mg on Day 13
3266620|NCT01533896|No Intervention|Control|Parents and children in the control group received routine primary care during the well child visit.
3266621|NCT01533896|Experimental|Grow Nicely|Grow Nicely multimedia program.
3266622|NCT01533909||Cancer patients|As this is not an intervention study there is only one cohort. Patients that will be included and excluded are described in the eligibility section.
3266623|NCT01533961|Experimental|SCYX-7158|In each dose group (8 subjects) , 6 Healthy Volunteers receive SCYX-7158
3266624|NCT01533961|Placebo Comparator|Placebo of SCYX-7158|In each dose group (8 subjects) , 2 Healthy Volunteers receive placebo of SCYX-7158
3266625|NCT01533987|Experimental|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
3266626|NCT01533987|Placebo Comparator|Placebo|The placebo consists of microcrystalline cellulose,dicalcium phosphate, magnesium stearate, and FD & C yellow #6.
3266627|NCT01534000|Active Comparator|CT guided group|For Patients with chest pain randomised to this arm, clinical decision will be based on the results of a Cardiac computed tomographic angiography (CCTA)
3266628|NCT01534000|No Intervention|Control group|Patients with chest pain randomised to the control group will be evaluated using the standard functional-based strategy with either a treadmill stress-test or SPECT (single-photon emission computed tomography). A Cardiac CT will will be performed, but will be blinded for initial clinical evaluation.
3266629|NCT01534026|Active Comparator|Aspirin|Current dose of aspirin for 12 weeks
3266630|NCT01534026|Experimental|Withdrawal arm|Withdrawal of aspirin for 12 weeks
3266631|NCT01534039|Active Comparator|Sur-Fit Natura/FormaFlex|Subject will be on Surfit Moldable for 2 weeks then crossover to Formaflex
3266632|NCT01534039|Active Comparator|FormaFlex/Sur-Fit Natura|Subject will be on Formaflex for 2 weeks then crossover to Surfit Moldable
3266633|NCT01534065|Experimental|Barricaid|CE Marked Device
3266634|NCT01534091|Active Comparator|Pedometer with supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff will review the child weekly reports, guide the child, encourage him and supervise that the recommended PA level is achieved.
3266635|NCT01534091|Active Comparator|Pedometer without supervision|Participants will get pedometers to evaluate their daily PA. The sport center stuff won't give any recommendation or supervision for PA level.
3266636|NCT01534091|No Intervention|Control group|Overweight & obese children not participating in an intervention.
3266637|NCT01534104|Experimental|pts who have primary or secondary brain tumors|The study will prospectively enroll subjects who have primary or secondary brain tumors located near the motor pathway (corticospinal tract) or language pathway (arcuate fasciculus). This is a nonrandomized study in which each subject will receive the standard of care as per the treating neurosurgeon.
3266638|NCT01534117|Active Comparator|Platelets/DDAVP|Fall on ASA/Plavix that sustained head trauma requiring administration of platelets and/or DDAVP
3266639|NCT01534117|No Intervention|No Platelets|Those that sustain head trauma NOT requiring platelet transfusion. The investigators are evaluating platelet function in those not requiring platelet transfusion
3266640|NCT01534130|Experimental|acupuncture|
3266641|NCT01534130|Sham Comparator|sham acupuncture|
3266642|NCT01534169|Experimental|Isotonic Na chloride|The treatment strategy is the same with intervention, only the drug (dexamethasone) will be changed to isotonic Na chloride.
3266643|NCT01534221|Active Comparator|Study group two|Endeavor resolute drug eluting stent
3266644|NCT01534221|Active Comparator|Study group three|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3266645|NCT01534221|Active Comparator|Study group four|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3266646|NCT01534221|Active Comparator|Study group five|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3266647|NCT01534221|Active Comparator|Study group one|The precise selection of brand name depends on negotiations with suppliers and may change during the study period
3266648|NCT01534234|Experimental|SonR group|SonR CRT Optimization
3266649|NCT01534234|Active Comparator|ECHO group|Echocardiographic Optimization
3266650|NCT01534247|Experimental|CAZAVI|CAZ-AVI (2000 mg ceftazidime/500 mg avibactam)
3266651|NCT01534247|Active Comparator|Metronidazole|Metronidazole (500 mg)
3266652|NCT01534247|Active Comparator|CAZAVI+metronidazole|CAZ-AVI (2000mg ceftazidime/500 mg avibactam) + metronidazole (500 mg)
3266653|NCT01534286|Active Comparator|Theramine|Theramine 2 capsules three times per day in addition to post surgical analgesic medication.
3266654|NCT01534286|Placebo Comparator|Theramine-like Placebo|Theramine-like placebo 2 capsules three times per day in addition to post surgical analgesic medication.
3266655|NCT01534299||Renal Denervation Treatment|All patients treated with renal denervation procedure will be enrolled as part of this single arm registry
3266656|NCT01534312|Experimental|CGMP protein|Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose
3266657|NCT01534312|Active Comparator|Standard oral 5ASA maximal dose|Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)
3266658|NCT01534325|Experimental|Study arm|The Arm who uses the real study device Daily use of SD device
3266659|NCT01534325|Sham Comparator|Control Arm|Daily use of Sham comperator
3266660|NCT01534325|Experimental|Staudy2 arm|Uses the under study device in a different time frames Daily use of SD device in a different time frames than of Study Arm
3266661|NCT01534338|Experimental|Mindfulness Meditation|The MAPs program is based on experiential training in mindfulness meditation offered at the UCLA Mindful Awareness Research Center (MARC). A certified UCLA instructor will provide didactic training in mindfulness meditation in a group-based setting. Participants will be guided through in-class meditation practices and will be assigned daily meditation homework. Active program components include sitting and walking somatosensory-focused meditation, audio-guided body scan meditation, and loving kindness meditation. Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. In addition to the MAPs training, sleep hygiene material will also be presented to match the sleep hygiene material in the sleep education condition.
3266662|NCT01534338|Active Comparator|Sleep Education|The sleep education condition is founded on knowledge acquisition. In the sleep seminar condition, a trained health educator will provide didactic presentations on sleep, sleep hygiene, sleep problems, and potential solutions to sleep problems in a group-based setting. Active components of sleep education include increasing knowledge of sleep biology, identifying characteristics of healthy and unhealthy sleep, sleep problems, and self-monitoring of sleep behavior. Participants attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary. The health education condition is comparable to MAPs in terms of time, attention, group support, and participant expectancy of a benefit in sleep parameters.
3266663|NCT01534364|No Intervention|control|Ad libitum alimentation
3266664|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
3266665|NCT01534377|Experimental|Interpersonal Psychotherapy|Adolescents will receive Interpersonal Psychotherapy for the treatment and prevention of depression.
3266666|NCT01534377|Experimental|Enhanced Care|Adolescents will receive the Enhanced care model or care that they would typically receive in community setting to treat and prevent depression.
3266667|NCT01534390|Experimental|Use of in-line microfilters|
3266668|NCT01534390|No Intervention|Standard therapy without the use of in-line microfilters|
3266669|NCT01534403|Experimental|Epratuzumab 4x600 mg every 12 weeks Group|
3266670|NCT01534429||chronic post-herniorraphy pain|patients with severe chronic post-herniorraphy pain
3266671|NCT01534442|Active Comparator|Atropin|Atropin
3266672|NCT01534442|Placebo Comparator|Placebo|Saline
3266673|NCT01534455|Experimental|Lapatinib + 1,23 mg Eribulin|
3266674|NCT01534455|Experimental|Lapatinib + 1,76 mg Eribulin|
3266675|NCT01534468|Experimental|Group 1: Previous H7N7 ca LAIV recipients|Participants in Group 1 will have previously received an H7N7 ca LAIV. In this study, they will receive one intramuscular (IM) injection of the H7N7 vaccine at study entry.
3266676|NCT01534468|Experimental|Group 2: Previous H7N3 ca LAIV recipients|Participants in Group 2 will have previously received an H7N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3266677|NCT01534468|Experimental|Group 3: Previous H2N3 ca LAIV recipients|Participants in Group 3 will have previously received an H2N3 ca LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3266678|NCT01534468|Experimental|Group 4: Vaccine-naive participants|Participants in Group 4 will have not previously received a LAIV. In this study, they will receive one IM injection of the H7N7 vaccine at study entry.
3266679|NCT01534494|Experimental|psilocybin|
3266680|NCT01534507||Healthy Volunteer 1 (Group 1)|For study 1 : Up to 5 healthy volunteers for the initial pilot study and further 21 healthy volunteers for the main study 1
3266681|NCT01534507||Group 2 for study 2|Patients with diarrhoea due to irritable bowel syndrome
3266682|NCT01534507||Group 3 for study 2|Patients with constipation due to irritable bowel syndrome
3266683|NCT01534507||Group 4 for study 2|Patients with mixed bowel habit due to irritable bowel syndrome
3266684|NCT01534507||Group 5 for study 2: Healthy volunteer 2|Healthy participants to act as control
3266685|NCT01534546|Active Comparator|arm A postoperative Oxaliplatin/capecitabine（XELOX）|"postoperative Oxaliplatin/capecitabine（XELOX） patients in arm A will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant XELOX later.~capecitabine：1000 mg/m2 ，bid, d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
3266686|NCT01534546|Experimental|arm B: postoperative Oxaliplatin/S-1（SOX）|"postoperative Oxaliplatin/S-1（SOX） patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.~S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)"
3266687|NCT01534546|Experimental|Arm C：postoperative Oxaliplatin /S-1（SOX）|"Postoperative Oxaliplatin /S-1（SOX） patients in arm C will receive 3 cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and 5 cycles of adjuvant SOX followed by 3 cycles of S-1 monotherapy.~Dose of s-1 and oxaliplatin are same to arm B Dose of S-1 monotherapy is same to combination therapy (SOX 3 cycles before surgery, 5 cycles of SOX and 3 cycles of S-1 monotherapy, 6 months after surgery)"
3266688|NCT01534559|Experimental|Outpatient Medicine Management Clinic|Consented patients will attend two outpatient clinic appointments to receive help with any (potential) medicine-related problems
3266689|NCT01534559|No Intervention|Control|Patients will receive the normal care provided by the hospital
3266690|NCT01534572|Experimental|Probiotics_Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
3266691|NCT01534572|Experimental|Probiotics_Bifidobacterium|Intervention (2 weeks) of daily supplementation of a probiotic strain of Bifidobacterium.
3266693|NCT01534702|Experimental|Treatment|
3266694|NCT01534715|Experimental|IMGN529|Dose escalation study, dosing done every 3 weeks.
3266695|NCT01534741|Active Comparator|Dialyser|FX CorDiax 60 dialyzer
3266696|NCT01534741|Active Comparator|FXDialyser|FX 60 dialyzer
3266697|NCT01534754|Active Comparator|Mesalazine|Active mesalazine 800 mg, 2 tablets/day for 10 days/month plus Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
3266698|NCT01534754|Active Comparator|Lactobacillus casei|Active Lactobacillus casei, 1 sachet/day for 10 days/month plus mesalazine 800 mg placebo, 2 tablets/day for 10 days/month.
3266699|NCT01534754|Active Comparator|Mesalazine plus Lactobacillus casei|Active mesalazine 800 mg, 2 tablets/day plus active Lactobacillus casi, 1 sachet/day for 10 days/month.
3266700|NCT01534754|Placebo Comparator|Placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month.
3266701|NCT01534780|Experimental|fixation with Protack|
3266702|NCT01534780|Experimental|fixation with Securestrap|
3266703|NCT01534780|Experimental|fixation with Glubran|surgery
3266704|NCT01534793||HoLEP|Holmium Laser Enucleation of the Prostate
3376584|NCT05144152||Average risk CRC screening group|Subjects with average risk of CRC require elective colonoscopy for colorectal cancer screening or polyp surveillance, or investigation of symptoms
3376585|NCT05142345|Experimental|CONTINUUM Intervention Post-Hospital Discharge|Participants will receive CONTINUUM intervention visit with a nurse practitioner within three business days of hospital discharge and complete questionnaires about their cancer and care.
3376586|NCT05142345|Active Comparator|Usual Care Post-Hospital Discharge|Participants will receive standard oncology care following hospital discharge with follow-up appointments scheduled per primary team and participant preferences. Participants will complete questionnaires about their cancer and care.
3376587|NCT05142306|Experimental|COVID-HIG Intramuscular|COVID-HIG single dose administered IM
3376588|NCT05142306|Experimental|COVID-HIG Subcutaneous|COVID-HIG single dose administered SC
3376589|NCT05142306|Experimental|COVID-HIG Intravenous|COVID-HIG single dose administered IV
3266705|NCT01534806|Experimental|ketorolac|
3376590|NCT05142098|Active Comparator|Dexamethasone|Dexamethasone 4mg will be injected intramuscularly into the pterygomandibular space after achieving effective inferior dental block.
3376591|NCT05142098|Experimental|Etoricoxib|2 tablets 60mg each would be given orally one hour prior to the surgery.
3376592|NCT05141929|Experimental|intervention group|web based education and routine clinical procedure
3376593|NCT05141929|No Intervention|control group|only routine clinical procedure
3376594|NCT05141669||Fingolimod|Participants who initiated fingolimod to treat multiple sclerosis (MS)
3376595|NCT05141669||Non-fingolimod Disease Modifying Treatment (DMT)|All patients with ≥ 1 medical or pharmacy claim for a DMT other than fingolimod. Among patients included in the study that those with ≥ 1 pharmacy or medical claim for any MS DMT during pre-index would be excluded.
3376596|NCT05141604|Experimental|Field expansion view|Various configurations of field expansion views will be additionally displayed on HMD
3376597|NCT05141578|Experimental|Luci Intervention|Participants enrolled in this group will receive the Luci intervention for a 24-week period.
3376598|NCT05141578|No Intervention|Wait-list Control|Participants in the waiting-list control group will not receive any intervention during the study. They will be invited to participate to the program at the end of the trial.
3376599|NCT05141266|Experimental|Brief Intervention Medication Therapy Management (BI-MTM)|Brief Intervention Medication Therapy Management (BI-MTM) is the overarching model made up of 4 evidence-based components: Medication Therapy Management (MTM); Screening, Brief Intervention, and Referral to Treatment (SBIRT); naloxone dispensing, and Patient Navigation (PN). Each component is sequentially delivered within the model and addresses a critical aspect of opioid medication misuse and risk. The pharmacy-based portion of BI-MTM (MTM+SBIRT+naloxone) will be delivered by a PharmD level pharmacist, and PN will be delivered by a bachelor's level interventionist.
3376600|NCT05141266|Other|Standard of Care|Standard of Care is the treatment as usual condition, which follows federal and Utah state pharmacy requirements for pharmacists where in patients filling prescriptions receive information and opt-in counseling. Specifically, SMC in Utah requires pharmacists to: (1) offer counseling, (2) document counseling has been offered, (3) offer a counseling process for patients not present, and (4) discuss generic substitution.The duration of SMC in the current study is a single 5-10 minute session delivered by a University of Utah pharmacist other than the study pharmacist that possesses a similar level of education and professional licensing.
3376601|NCT05141240||Ribociclib|Participants who initiated CDK4/6i therapy
3376602|NCT05141240||Palbociclib|Participants who initiated CDK4/6i therapy
3376603|NCT05141240||Abemaciclib|Participants who initiated CDK4/6i therapy
3376605|NCT05139875|Experimental|Betamethasone (Diprospan)|Participant received single intra-articular Betamethasone Dipropionate / Betamethasone Sodium Phosphate 1 ml
3376606|NCT05139875|Active Comparator|Triamcinolone acetonide|Participant received single intra-articular Triamcinolone acetonide 40 mg
3376608|NCT05139576||Pediatric Subjects and adults|Subjects were categorized into two age groups: <18 years (pediatric) and ≥18 years (adult).
3266706|NCT01534806|Placebo Comparator|Placebo|Placebo IV push
3376609|NCT05139576||Pediatrics and adults|Subjects were categorized into two age groups: <18 years (pediatric) and ≥18 years (adult).
3376610|NCT05138731||Stable angina (SA)|Typical chronic exersive angina pectoris attacks, lasting several minutes to more than 10 minutes, 3-5 minutes in most cases, generally not more than 30 minutes. The pain disappeared after rest or taking nitrates, and the pain degree, frequency, duration, nature and inducing factors did not change in the last 1-3 months.
3376611|NCT05138731||Unstable angina (UA）|Including resting angina (attack at rest, the duration is usually >20 minutes), primary angina (usually the first symptoms within 1-2 months, very light physical activity can be induced, at least CCSIII level), worsening angina (angina gradually increases on the basis of relatively stable labor angina. More severe pain, longer or more frequent pain, at least grade I increase according to THE CCS classification, at least GRADE II CCSI). TNI was negative, routine electrocardiogram may have transient ST segment depression, T wave low flat or inverted.
3376612|NCT05138731||Acute non-ST-segment elevation myocardial infarction （NSTEMI）|Patients with elevated troponin accompanied by one or more of the following conditions: electrocardiogram showed new ST segment depression or T wave flatness or inversion; Persistent ischemic chest pain; Echocardiography showed abnormal segmental ventricular wall activity. Abnormal coronary angiography.
3266707|NCT01534819||Protocol B, abdominal arm, revision group|AAA subjects with previously implanted commercial endografts for the treatment of graft migration and/or Type Ia endoleak
3266708|NCT01534819||Protocol B, abdominal arm, primary group|AAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
3266709|NCT01534819||Protocol B, thoracic arm, revision group|TAA subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
3266710|NCT01534819||Protocol B, thoracic arm, primary group|TAA subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation
3266711|NCT01534819||Protocol B, advanced disease arm, revision group|Advanced disease subjects with previously implanted commercial endografts for the treatment of migration and/or Type Ia and/or Type Ib endoleak at the proximal or distal attachment site
3266712|NCT01534819||Protocol B, advanced disease arm, primary group|Advanced disease subjects at the time of initial endograft implantation either to prevent endograft migration and Type I endoleak, or to treat Type Ia and/or Ib endoleak at the proximal or distal attachment site evident at the time of implantation.
3266713|NCT01534819||Protocol C, abdominal arm, short neck, primary group|Planned use of Heli-FX™ in conjunction with the Endurant II/IIs endograft in AAA subjects with short proximal necks (≥ 4 mm and < 10 mm) in primary group.
3266714|NCT01534832|Experimental|Smoke clearance|Smoke clearance device active
3266715|NCT01534845|No Intervention|only Radiotherapy|fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy
3266716|NCT01534845|Active Comparator|CCRT with Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles).
3266717|NCT01534858|Experimental|Partial and full thickness burns with split thickness grafts|
3266718|NCT01534871|Experimental|Exercise|Subjects enrolled in the exercise arm will receive the study intervention.
3266719|NCT01534871|No Intervention|Control|Subjects in the control arm will receive standard of care (e.g. medication and medical supervision) for rheumatoid arthritis. These subjects will not participate in the exercise intervention.
3266720|NCT01534884|Active Comparator|MabThera|rituximab
3266721|NCT01534884|Active Comparator|CT-P10|rituximab
3266722|NCT01534923||Pts having colorectal cancer screening|The target sample of this study will be approximately 200 primary care physician-patient consultations who discuss CRC screening during the course of a clinical visit. Physician and patient participants will come from primary care practices associated with the New York City Research and Improvement Networking Group (NYC RING).
3266723|NCT01534936||Schizophrenic outpatients with affective symptoms.|
3266724|NCT01534949|Experimental|CT-P10|rituximab
3266725|NCT01535027|Active Comparator|Teriparatide|18 months of daily 20 ug sc. teriparatide monotherapy (TPTD)
3266726|NCT01535027|Active Comparator|Teriparatide and Raloxifene|9 months teriparatide 20 ug/day sc. monotherapy (TPTD) continued by combination therapy of raloxifene 60 mg/day orally(RAL)and TPTD for another 9 months
3266727|NCT01535027|Active Comparator|Teriparatide and Alendronate|9 months teriparatide monotherapy 20 ug/day sc.(TPTD) continued by combination therapy of alendronate 70 mg/week orally(ALN)and TPTD for another 9 months
3266728|NCT01535066|Experimental|Arm I|Patients receive acupuncture therapy twice weekly for 6 weeks and then once weekly for 6 weeks.
3266729|NCT01535066|Sham Comparator|Arm II|Patients receive sham acupuncture twice weekly for 6 weeks and then once weekly for 6 weeks.
3266730|NCT01535066|No Intervention|Arm III|Patients are assigned to a waiting list for 12 weeks with standard follow-up care.
3266731|NCT01535079|Placebo Comparator|Placebo|
3266732|NCT01535079|Experimental|V0498TA01A 15 mg|
3266733|NCT01535079|Experimental|V0498TA01A 25 mg|
3266734|NCT01535079|Experimental|V0498TA01A 35 mg|
3266735|NCT01535079|Other|Strefen|Positive control
3266736|NCT01535092|Experimental|silibinin|Silibinin 20mg/Kg/day (Legalon SIL) by intravenous infusion for 14-21 days before OLT and for 7 days after OLT
3266737|NCT01535092|Placebo Comparator|Placebo|Placebo (NaCl 0.9% - saline) administered daily by intravenous infusion for 14-21 days before OLT and 7 days after OLT
3266738|NCT01535105||Obese Adolescents|
3266741|NCT01535144|Experimental|degradable metallic device|
3266742|NCT01535144|Active Comparator|non-degradable metallic device|
3266743|NCT01535157|Experimental|Fenretinide/LXS + Ketoconozale|One course is defined as 7 days of Fenretinide/LXS + Ketoconazole followed by 14 days of rest. A course is repeated every 21 days if no evidence of disease progression for six courses.
3266744|NCT01535170|Experimental|bovine Lactoferrin|"Lactoferrin and placebo will be masked as drug A and B in the factory. Randomization will be stratified by center and patients will be randomized into A or B groups by a random-number table sequence after informed consents are obtained. No patients, research nurses, investigators, or other medical staffs in RCC will be aware of the assignment during the study period.~Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17]. Drug administration will begin within 24 hours after RCC admission and will last for 6 weeks or until discharge. Medication and nutritional support will be prescribed as the medical routine."
3266745|NCT01535170|Placebo Comparator|Placebo|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control.
3266746|NCT01535183|Experimental|Irinotecan|
3266747|NCT01535196|Experimental|25-OH-D3 vitamin|180 000 IU 25-OH-D3 vitamin oil per os, per month in the 0, 1, 2, 3, and 6 month at the visit. The patient take the drug under medical control
3266748|NCT01535196|Placebo Comparator|MCT oil|9 ml MCT oil as placebo in the 0,1,2,3,6 month at the visit, under medical contol
3266749|NCT01535209|Experimental|SBRT to resection cavity|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
3266750|NCT01535209|Active Comparator|WBRT|30Gy in 10 fractions over 12 days to whole brain
3266751|NCT01535248||All ERCP Patients|All patients that will be approached for this study will be undergoing ERCP as part of their medical care.
3266752|NCT01535274|Experimental|Desflurane|Patients will receive general anesthesia with desflurane. Both arms have rSO2 measured and undergo identical changes in ventilation strategy.
3266753|NCT01535274|Experimental|Propofol|Patients will receive total intravenous general anesthesia (TIVA) with propofol. Both have rSO2 measured and undergo identical changes in ventilation strategy.
3266754|NCT01535300||Elective pediatric surgery|
3266755|NCT01535313|Active Comparator|Manual (Hospital Systems TRAP Needle)|Bone marrow biopsy with a standard manual system
3266756|NCT01535313|Experimental|Powered|
3266757|NCT01535339||Phase I - Normative|Athletes who does not participate in contact sport with no recent concussion
3266758|NCT01535339||Phase IIa - Concussed|Athletes with recent concussion
3266759|NCT01535339||Phase IIa - Control|Athletes with no recent concussion
3266760|NCT01535339||Phase IIb - Athletes|Athletes with no recent concussion
3266761|NCT01535352|Experimental|Internet-facilitated CBT|Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
3266762|NCT01535352|Active Comparator|Coach-facilitated Treatment as Usual|Participants in the FUC condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
3266763|NCT01535404|Active Comparator|Right ventricular apex pacing|
3266764|NCT01535404|Experimental|Left ventricular apex pacing|
3266765|NCT01535417|Experimental|GCSB|
3266766|NCT01535417|Active Comparator|Celebrex|
3266767|NCT01535456|Experimental|F-FLT PET scan, 5-azacitidine treatment|F-FLT Pet scan followed by 5-azacitidine treatment followed by FLT-PET scan. Three additional cycles of 5-azacytidine and follow up FLT-PET scan.
3266768|NCT01535469|Experimental|CrAg Screening and Fluconazole|Cryptococcal Antigen (CrAg) Screening with preemptive antifungal treatment per World Health Organization (WHO) guidelines. Randomized Stepped Wedge design of phased implementation.
3266769|NCT01535482|Experimental|Cognitive Therapy|A cognitive therapy protocol specifically designed to target suicidal ideation in older adults.
3266770|NCT01535482|Active Comparator|Enhanced Usual Care|Enhanced usual care consists of the usual care that individuals receive for suicide prevention, plus assessment and referral services provided by project staff, and weekly phone calls provided by study therapists.
3266771|NCT01535495|Experimental|Complete laser|Patients who have had complete panretinal photocoagulation laser treatment and active retinal neovascularization
3266772|NCT01535495|Experimental|Laser naive|"Patients who have not had panretinal photocoagulation laser treatment and active retinal neovascularization without so called high-risk characteristics"
3266773|NCT01535508|Experimental|Liquid Vitamin D|
3266774|NCT01535521|Other|SPT in patients with MAD|
3266775|NCT01535547|Experimental|isavuconazole and tacrolimus|
3266776|NCT01535586|Active Comparator|CPAP|participants will be treated with continuous positive airway pressure (CPAP) for 12 weeks
3266777|NCT01535586|Active Comparator|MAD|Participants will be treated with a mandibular advancing device for 12 weeks
3266778|NCT01535612|Experimental|PaQ™ insulin infusion device|PaQ™ insulin infusion device which delivers rapid acting insulin.
3266779|NCT01535625|Other|Momo stent|Patients with PCI
3266780|NCT01535651|Experimental|TOP Program plus Text messaging|Boys and Girls Club members who participate in TOP over 9 months will receive regular text messages in addition to TOP
3266781|NCT01535651|No Intervention|TOP Program alone|Boys and Girls Club participants will participate in TOP for 9 months
3266782|NCT01535677|Experimental|1|5 mg dapagliflozin and 850 mg Glucophage in fasted state
3266783|NCT01535677|Experimental|2|dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted
3266784|NCT01535677|Experimental|3|5 mg dapagliflozin and 850 mg Glucophage in fed state
3266785|NCT01535677|Experimental|4|dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state
3266786|NCT01535690|Experimental|laser and methilene blue|After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler (Profi III Bios, Dabi Atlante, Ribeirão Preto, São Paulo, Brazil) for 1 hour. Specific tips were used (Perio sub, Dabi Atlante, Ribeirão Preto, São Paulo, Brazi). PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl (Photon Laser III - PL7336, DMC, São Carlos -São Paulo, Brazil) was applied (660 nm, 100 mW, 9 J, 90 seconds per site, 320 J/cm2).
3266787|NCT01535716|Experimental|ECOM group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
3266788|NCT01535716|Active Comparator|standard management group|50 Patients scheduled for elective coronary surgery with cardiopulmonary bypass
3266789|NCT01535742|Experimental|Ambu Aura-i size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
3266790|NCT01535742|Experimental|air-Q size 1.5|patients will receive either the Ambu Aura-i size 1.5 or air-Q ILA 1.5 based on manufacturer recommendations of body weight
3266791|NCT01535742|Experimental|Ambu Aura-i size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
3266792|NCT01535742|Experimental|air-Q size 2|patients will receive either the Ambu Aura-i size 2 or air-Q ILA 2 based on manufacturer recommendations of body weight
3266793|NCT01535755|Active Comparator|protocol group|This group patients are weaned as the protocol which the investigators described.
3266794|NCT01535755|Other|clinicians' order group|This group patients are weaned as the clinicians' order.
3266795|NCT01535768|Experimental|Intervention Group|Patients randomized to the intervention group will receive aqueous suppressant eyedrops in a stepwise fashion in order to maintain their intraocular pressure between 7-10mmHg.
3266796|NCT01535768|No Intervention|Control Group|"Patients randomized to the control group will receive standard of care treatment. They will not be aqueous suppressed within the first three postoperative months unless the bleb hyperencapsulates.~(If they experience the hyperencapsulation phase, they will continue to receive standard of care treatment, which would then be aqueous suppressant eye drops added in a stepwise fashion)"
3266797|NCT01535781|Placebo Comparator|Placebo|Patients are given saline instead of tranexamic acid in the placebo group
3266798|NCT01535781|Active Comparator|Tranexamic Acid|Tranexamic acid; 1 gram as a bolus prior to surgery. 3 grams of Tranexamic acid in 1 liter of saline as a 24 hour infusion.
3266799|NCT01535794||18-26 year old men who have sex with men|
3266800|NCT01535820|Experimental|Treatment sequence AB|
3266801|NCT01535820|Experimental|Treatment sequence BA|
3266802|NCT01535833|Other|Robotic sacral colpopexy|To assess subjects with stage 2 pelvic organ prolapse undergoing robotic sacral colpopex
3266803|NCT01535846|Experimental|Conscious food tasting intervention|Instead of focusing on dieting rules to restrict food intake, paying attention to sensory stimulation allow the recognition of internal cues of hunger and satiety which can be helpful to facilitate a more internalized regulation of food intake among restrained eaters. In the experimental group, the conscious food tasting intervention will be conducted by a registered dietitian into small groups of ten to twelve women during six weekly 2-hour workshops. Workshops will be taking place in a well-ventilated room to insure that there are no extraneous odours or noises that may hamper the activities involving senses.
3266804|NCT01535846|No Intervention|Control|
3266805|NCT01535859|Experimental|Cabergoline|
3266806|NCT01535859|Placebo Comparator|Placebo|
3266807|NCT01535872|Experimental|DHEA treatment|
3266808|NCT01535872|No Intervention|No treatment|
3266809|NCT01535885|Experimental|Multi-Virus CTLs|The treatment plan delivers a single dose of Multi-Virus CTL to all patients enrolled on study.
3266810|NCT01535898||Pts having an MRI|This is a technology assessment protocol. The study is designed to assess the utility of the technology using a limited number of participants.
3266811|NCT01535950|Experimental|LFG316|
3266812|NCT01535950|Sham Comparator|Sham|
3266814|NCT01535989|Experimental|intravenous|dose escalation
3266815|NCT01536002|Experimental|Pharmacokinetics|Propofol pharmacokinetics
3266816|NCT01536028|Active Comparator|BIAsp 30|
3266817|NCT01536028|Experimental|BIAsp 50|
3266818|NCT01536028|Experimental|BIAsp 70|
3266819|NCT01536028|Active Comparator|IAsp|
3266820|NCT01536041|Experimental|Experimental 200 mg dose|
3266821|NCT01536041|Experimental|Experimental 20 mg dose|
3266822|NCT01536041|Active Comparator|Active Comparator Montelukast|
3266823|NCT01536041|Placebo Comparator|Placebo Comparator|
3266824|NCT01536054|Experimental|Treatment (vaccine, sirolimus, GM-CSF)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and GM-CSF SC on days 1-4. Patients also receive sirolimus PO QD on days 1-14 OR 15-28 OR 1-28. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients then receive an additional course of ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine only followed by ALVAC(2)-NY-ESO-I (M)/TRICOM vaccine SC 8 weeks after completion of course 4.
3266825|NCT01536080||Reflux esophagitis (RE)|
3266826|NCT01536080||Non-erosive reflux disease (NERD)|
3266827|NCT01536080||Functional heartburn (FH)|
3266828|NCT01536106|Experimental|Treatment|Implantation of bone marrow derived mononuclear cells
3266829|NCT01536106|Placebo Comparator|Placebo Control|Infusion of autologous peripheral blood
3266830|NCT01536132|Active Comparator|Levosimendan|levosimendan at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
3266831|NCT01536132|Placebo Comparator|Placebo|placebo (same appereance than levosimendan in colour) at a dose of 0.2 micrograms/kg/min for 6 hours intravenous infusion
3266832|NCT01536158|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
3266833|NCT01536158|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
3266834|NCT01536210|Experimental|YY-162|"YY-162(Ginkgo Extract 30mg + Ginseng Extract 50mg)~1T/Three times a day(Tid) for 8 weeks, PO medication"
3266835|NCT01536210|Placebo Comparator|Placebo|Placebo 1T /Three times a day(Tid) for 8 weeks, PO medication
3266836|NCT01536223|Active Comparator|PF group|the group of participants who undergoing cisplatin and 5-fluorouracil(PF)neoadjuvant chemotherapy
3266837|NCT01536223|Experimental|TPF group|TPF(docetaxel , cisplatin and 5-fluorouracil)neoadjuvant chemotherapy
3266838|NCT01536236|Active Comparator|Subthreshold programming|During one of the first 2 weeks of the trial the subject will be randomized to a subthreshold stimulation arm. They will be blinded and receiving therapy, but will it will be delivered at a level (subthreshold) that they will not feel the stimulation.
3266839|NCT01536236|Placebo Comparator|Placebo or Stimulation off arm|During one of the first two weeks of the study, the patient will be randomized to a no stimulation arm. They will be blinded and will not be receiving therapy.
3266840|NCT01536236|Active Comparator|Optimal stimulation programming|During the third week of the trial period, all subjects will receive optimal stimulation.
3266841|NCT01536249|Experimental|Dexpramipexole single dose & 12 Doses Cimetidine|300 mg Dexpramipexole Oral Dose (to be taken in conjunction with multiple doses of Cimetidine at 400 mg per dose)
3266842|NCT01536249|Experimental|Dexpramipexole single Dose|300 mg Dexpramipexole Oral Dose
3376613|NCT05138731||Acute ST-segment elevation myocardial infarction （STEMI）|Troponin was elevated, and ECG showed ST segment arcuate back elevation, accompanied by one or more of the following conditions: persistent ischemic chest pain; Echocardiography showed segmental abnormal ventricular wall activity; Abnormal coronary angiography.
3376614|NCT05138731||normal coronary artery （NCA）|symptoms of chest pain and no stenosis in coronary arteries (such as myocardial bridging, reflux esophagitis, intercostals neuralgia, cervical spondylopathy, and unexplained chest pain)
3376615|NCT05138731||nonobstructive coronary atherosclerosis （NOCA）|stenosis < 50% in coronary arteries
3376616|NCT05138731||healthy volunteers|Healthy control subjects who had no significant systemic diseases (e.g. ischemic heart disease, hypertension,diabetes,cancer, pulmonary disease, or infectious diseases) were recruited from Physical Examination Center of Ningxia Medical University General Hospital
3266843|NCT01536275|No Intervention|Early parenteral nutrition|Parenteral nutrition supplements insufficient enteral nutrition from admission to ICU according to the current standard of care per center
3266844|NCT01536275|Experimental|Late parenteral nutrition|Parenteral nutrition will be withheld during the first 7 days of ICU stay
3266845|NCT01536288|Active Comparator|Rhodiola crenulata-placebo sequence|Rhodiola crenulata for the first treatment period and placebo for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
3266846|NCT01536288|Active Comparator|Placebo-Rhodiola crenulata sequence|Placebo for the first treatment period and Rhodiola crenulata for the second treatment period, with a washout period of 4 months. Overall study population were 120 subjects, who were randomised and allocated into 2 sequences.
3266847|NCT01536301|Active Comparator|Morphine|The patients in this arm will have post-operative analgesia including morphine (patient controlled analgesia).
3266848|NCT01536301|Experimental|Oxycodone|The patients in this arm will have post operative analgesia including oxycodone (patient controlled analgesia).
3376619|NCT05137782|Experimental|Arm 1|Patients and care partners receive specialty primary care and participate in pre- and post- functional MRI scans to measure the effects of the specialty palliative care intervention.
3376620|NCT05137275|Experimental|Anti-5T4 CAR-raNK Cells|
3376621|NCT05137080|Active Comparator|Treatment A|24mg dexamethasone i.v. perioperatively and 24mg dexamethasone i.v. on the first postoperative day
3376622|NCT05137080|Active Comparator|Treatment B|24mg dexamethasone i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
3266849|NCT01536327||Observation|Patients with Metachromatic Leukodystrophy disease or profound suspicion for Metachromatic Leukodystrophy disease
3376623|NCT05137080|Placebo Comparator|Treatment C|Placebo (isotonic saline) i.v. perioperatively and placebo (isotonic saline) i.v. on the first postoperative day
3266850|NCT01536353|Experimental|AGSAV301|
3266851|NCT01536353|Active Comparator|Exforge 10/160|
3376624|NCT05135169||Contrast administration|
3376625|NCT05132855|Experimental|Booster group 1 (BNT162b2 30ug)|The participants in this group will receive BNT162b2 30ug as the booster dose.
3376626|NCT05132855|Experimental|Booster group 2 (mRNA-1273 50ug)|The participants in this group will receive mRNA-1273 50ug as the booster dose.
3376627|NCT05132855|Experimental|Booster group 3 (mRNA-1273 100ug)|The participants in this group will receive mRNA-1273 100ug as the booster dose.
3376628|NCT05132855|Experimental|Booster group 4 (MCV COVID-19 vaccine 15ug)|The participants in this group will receive MCV COVID-19 vaccine 15ug as the booster dose.
3376629|NCT05132660|Experimental|Sinemet|25 mg carbidopa/100 mg levodopa
3376630|NCT05132660|Placebo Comparator|Placebo|Placebo pill of similar size/shape
3376631|NCT05132660|No Intervention|follow-up|Follow-up testing on participants previously prescribed levodopa
3266852|NCT01536431|Experimental|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
3266853|NCT01536431|Active Comparator|Pro insulin peptide & saline|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
3266854|NCT01536431|Placebo Comparator|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls)
3266855|NCT01536444|Experimental|Micrografting|
3266856|NCT01536470|Experimental|Noradrenaline|Continuous infusion of noradrenaline to maintain arterial blood pressure management in high-risk surgical patients
3266857|NCT01536470|Experimental|Ephedrine chorhydrate|Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline)using intravenous bolus of Ephedrine chorhydrate
3266858|NCT01536483|Experimental|Butyrate|"New born with a birth weight <1000g: Seven enemas of butyrate will be performed every 2 days from PND5~New born with a birth weight >1000g: Seven enemas of butyrate will be performed every day from PND5"
3266859|NCT01536483|No Intervention|Therapeutic Abstention|The protocol will pretend enema: instillation in the diaper the product under consideration, to make the two indistinguishable processes (time, odor, wicking diaper ...)
3266860|NCT01536509|Experimental|Telehealth Behavioral Treatment|
3266861|NCT01536509|Active Comparator|Education Only|
3266862|NCT01536522|Active Comparator|Nutritional Approach for Asthma|individuals will be provide a pre measured dose of medium chain triglyceride to consume along with their meals. They will be instructed to add the MCT to their meal 3 times per day
3266863|NCT01536522|Placebo Comparator|Standard American Diet|patients will consume their usual diet with a pre measured dose of canola oil in place of the medium chain triglyceride as a control group. They will be instructed to add the placebo dose to their meal 3 times a day
3266864|NCT01536522|Active Comparator|Alternate Day Diet|"patients will consume a regular Standard American Diet for 4 weeks and then provided a regulated dosed quantity of low caloric value shakes. they will consume this on alternating days"
3266865|NCT01536522|Active Comparator|Whole Lung Allergen Challenge|patients with or without asthma will be given controlled doses of specified allergens
3266866|NCT01536548|Experimental|Skin drawing|
3266867|NCT01536548|Active Comparator|No skin drawing|
3266868|NCT01536600||BIAsp 30 users|
3266869|NCT01536613||BIAsp 30 users|
3266870|NCT01536626||BIAsp 30 users|
3266871|NCT01536639||BIAsp 30 users|
3266872|NCT01536652||BIAsp 30 users|
3266873|NCT01536665|Experimental|Low|
3266874|NCT01536665|Experimental|Medium|
3266875|NCT01536665|Experimental|High|
3266876|NCT01536678|Active Comparator|Test formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2..
3266877|NCT01536678|Active Comparator|Reference formulation of levothyroxine|Single dose of 600 mcg of levothyroxine administered in dosing period 1 or 2.
3266878|NCT01536691|Experimental|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
3266879|NCT01536691|Active Comparator|ondansetron, aprepitant, dexamethasone|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
3266880|NCT01536717|Active Comparator|Bupivacaine hydrochloride 0.5%|Bupivacaine hydrochloride is related chemically and pharmacologically to the aminoacyl local anesthetics. Bupivacaine hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.
3266881|NCT01536717|Placebo Comparator|Sodium chloride 0,9%|
3266882|NCT01536730|Experimental|Homework Intervention Strategy|
3266883|NCT01536730|No Intervention|Control|
3266884|NCT01536743|Experimental|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
3266885|NCT01536756|Experimental|Exercise Intervention -- Physical Rehabilitation Program|
3266886|NCT01536756|Other|Wait List Control Group|
3266887|NCT01536769||Parkinson patients|Parkinson patients, symptom onset > 50 years of age, non-smoker, no relevant gastrointestinal or ENT diseases
3266888|NCT01536769||Control subjects|No parkinsonism, age and gender matched to PD subjects, non-smoker, no relevant gastrointestinal or ENT diseases
3266889|NCT01536782|Active Comparator|Bolus|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3266890|NCT01536782|Active Comparator|Gravity|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3266891|NCT01536782|Active Comparator|Pump|Upon tube feeding initiation determined by the HNC multidisciplinary team, the patients will be randomized into three different groups, each consisting of 20 patients each: Bolus (Group 1), Gravity (Group 2), and Pump (Group 3). The randomization process within these three groups will based on 1) age and 2) estimated caloric need. For example, if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either Bolus, Gravity or Pump group. Another example is that if we have two 45-year-old patients whose estimated needs are 2400kcals/day, then one patient will randomly be assigned to the Bolus group, and the other one will be randomly assigned to the Gravity group. The third patient that will fit that category will be assigned to the Pump group.
3266892|NCT01536808|Experimental|Type 2 Diabetes Mellitus|
3266893|NCT01536834|Experimental|Medical Device|The Investigational device is a liquid in a delivery system for the treatment of verrucas
3266894|NCT01536847|Placebo Comparator|Control Test Drink|Control drink
3266895|NCT01536847|Experimental|Experimental Test Drink 1|Control drink containing ingredient 1
3266896|NCT01536847|Experimental|Experimental Test Drink 2|Control drink containing ingredient 2
3266897|NCT01536964|Experimental|Morphine|the effect of morphine on prasugrel absorption will be tested
3266898|NCT01536964|Placebo Comparator|Saline|
3266899|NCT01536977|Experimental|Supportive care (BBT-I)|"Patients complete the BBT-I, comprising the following modules: 1) What to expect in terms of fatigue and insomnia as it occurs with cancer and cancer treatment; 2) A review of the Spielman Model of insomnia; 3) A discussion (based on the Spielman Model) regarding how insomnia and fatigue may co-occur and interact in the context of cancer and cancer treatment; 4) An introduction to the concept and practice of Stimulus Control Therapy; 5) An introduction to Sleep Scheduling Specifically modified for cancer patients; 6) Sleep Compression; and 7) Concomitant Medications and Substance Use."
3266900|NCT01536990||Stroke|Medically stable patients receiving inpatient or outpatient physical therapy care for lower extremity dysfunction secondary to stroke.
3266901|NCT01537003|Experimental|Promogran and Low EPA|Patients with low EPA will be treated with PROMOGRAN and standard of care for vlu compression
3266902|NCT01537003|Active Comparator|Low EPA and compression|Patients with Low EPA will only get standard of care for VLU which is compression.
3266903|NCT01537003|Active Comparator|High EPA and compression|Patients with high EPA will get standard of care for VLU which is compression.
3266904|NCT01537003|Experimental|Promogran High EPA|patients with HIGH EPA will then be treated with PROMOGRAN and standard of care for VLU compression
3266905|NCT01537016|Experimental|Promogran and High EPA|Wound with high EPA will be treated with promogran and covered with a secondary dressing that is standard of care
3266906|NCT01537016|Experimental|Promogran and Low EPA|Wounds with low EPA will be treated with Promogran and covered with a secondary which is standard of care
3266907|NCT01537016|Active Comparator|High EPA and standrad of care|Wounds with high EPA will get standard of care as in line with current practice as they is no other test currently available for EPA
3266908|NCT01537016|Active Comparator|Low EPA and standard of care|Low EPA wounds will be treated with the standard of care for diabetic foot ulcers.
3266909|NCT01537055|Experimental|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy
3266910|NCT01537055|Active Comparator|levofloxacin-based triple therapy|levofloxacin-based triple therapy for 10 days
3266911|NCT01537094|Active Comparator|Vitamin C low dose|vitamin C 250 mg oral once daily
3266912|NCT01537094|Active Comparator|Vitamin C high dose|vitamin C 1,000 mg oral once daily
3266913|NCT01537094|Placebo Comparator|Placebo|Placebo oral once daily
3266914|NCT01537107|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive sirolimus PO QD and vismodegib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3266915|NCT01537146|Active Comparator|Femoral Block|
3266916|NCT01537146|Active Comparator|Local Infiltration Anagesia|
3266917|NCT01537159||Acute Myelogenous Leukemia (AML)|Patients who have been diagnosed with AML
3266918|NCT01537172|Experimental|ONO-4053|E Experimental Intervention Drug: ONO-4053
3266919|NCT01537172|Placebo Comparator|Placebo|
3266920|NCT01537224|Other|neurostimulation|
3266921|NCT01537237||intra-procedure 3DATG|Patients who will undergo intra-procedure 3DATG rotational angiography to guide their ablation procedure
3266922|NCT01537237||pre-procedure CT|Patients who will undergo pre-procedure CT scan to guide their ablation procedure
3266923|NCT01537250|Active Comparator|Nemonoxacin 750 mg|Nemonoxacin 750 mg 2 tablets.
3266924|NCT01537250|Active Comparator|Nemonoxacin 500 mg|Nemonoxacin 500 mg 3 tablets
3266925|NCT01537250|Active Comparator|Levofloxacin 500 mg|Levofloxacin 500 mg
3266926|NCT01537263||Ultrasound Perfusion Imaging|Patient with subarachnoid hemorrhage.
3266927|NCT01537276|Experimental|real-time fluoroscopy|evaluating the tubal patency and pathology under fluoroscopy real-timely
3266928|NCT01537276|No Intervention|respective image|evaluating the tubal patency and pathology by Two supine and two oblique static images.
3266929|NCT01537289|Experimental|Pigtail catheter|
3266930|NCT01537289|Active Comparator|Traditional chest tube|28-French chest tube
3266931|NCT01537328|Experimental|Progressive Treatment|Progressive intervention will involve the early initiation of intensive rehabilitation using progressive exercise and faster progression to functional strengthening exercises.
3266932|NCT01537328|Active Comparator|Traditional treatment|Traditional intervention represents the synthesis of previously published total knee arthroplasty rehabilitation programs.
3266933|NCT01537341|Active Comparator|Traditional Treadmill|Participants will follow the same guidelines as the split belt component but will complete the intervention on a traditional, single belt/speed treadmill.
3266934|NCT01537341|Experimental|Split-belt|Participants will walk on a custom-built split-belt treadmill comprised of two separate belts, each with its own motor, that permitted the speed of each belt (i.e. each leg) to be controlled independently.
3266935|NCT01537354|Active Comparator|Survanta®|Survanta® (Beractant, Abbot Laboratories, Columbus, OH) Surfactant will be administered by respiratory therapist not involved in patient's care.
3266936|NCT01537354|Active Comparator|Curosurf®|Curosurf® (Cornerstone Therapeutics, Inc., Cary, NC Surfactant will be administered by respiratory therapist not involved in patient's care.
3266937|NCT01537380|Experimental|Cefazoline|
3266938|NCT01537445||Patients with pancreastransplantation|All patients undergoing pancreas transplantation.
3266939|NCT01537458||Isolated TI repair|Patients that underwent isolated tricuspid valve repair
3266940|NCT01537471|Other|Placebo|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. On one of three visits, a subject will receive placebo. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
3266941|NCT01537471|Experimental|Meclizine|A counterbalanced design will be used with each male subject receiving placebo and each of the anti-histamine low (12.5 mg) and high (25 mg) doses in a counterbalanced order to keep order of administration from being confounded with dose level. By the time they finish, they will have all received placebo, 12.5mg meclizine and 25mg meclizine. The subject, study coordinator, co-investigator and outcomes assessor will remain blinded to what they received until data analysis is completed.
3266942|NCT01537484|Experimental|Swedish Massage|Swedish massage for one hour, once per week, for eight weeks. At week 10, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), and 50% will be randomized to Usual Care.
3266943|NCT01537484|Active Comparator|Light Touch Bodywork|Light-touch bodywork for one hour, once per week, for eight weeks. At week 10, 50% of the patients will be randomized to a maintenance dose (one hour of light-touch massage every two weeks, and 50% will be randomized to Usual Care.
3266944|NCT01537484|Other|Usual Care|Those initially randomized to the usual care control will be rolled into the Swedish massage intervention (one hour of Swedish massage, once/week for eight weeks) at week 25. At week 34, 50% of patients will be randomized to a maintenance dose (one hour of Swedish massage every two weeks), while 50% will be randomized back to Usual Care.
3266945|NCT01537497|Experimental|100 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3266946|NCT01537497|Experimental|250 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3266947|NCT01537497|Experimental|600 mg PF-05175157|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3376632|NCT05130632|Experimental|The community working group|Female participants over the age of 15 randomized to the intervention group will participate in working group sessions over 12 weeks' time that addresses plastic waste and introduce strategies to reduce use, recycle, and repurpose plastic. Community members of participants in the intervention group will also be invited to participate in the working groups.
3376633|NCT05130632|No Intervention|Control Group.|No specific activities
3376634|NCT05130086|Experimental|Islatravir|60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
3266948|NCT01537497|Placebo Comparator|Placebo|The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.
3266949|NCT01537510|Active Comparator|Usual Care|
3266950|NCT01537510|Experimental|Clinician intervention only|This arm will entail the development and deployment of alerts and access to a SmartSet at the time of a well child visit with a child between the ages of 6-12 years with a BMI ≥ 95th percentile.
3266951|NCT01537510|Experimental|Clinician intervention plus Direct-to-parent communication|Parents of children enrolled in this intervention arm will receive mailings, text messages and a series of 4 calls with a health coach to encourage behavior change in addition to the intervention received by the clinicians.
3266952|NCT01537523|Experimental|community-care program|receive intervention for 12 weeks
3266953|NCT01537523|No Intervention|control|
3266954|NCT01537536|Experimental|EndoTAG-1|Weekly treatment with EndoTAG-1 (22 mg/m2) plus paclitaxel (70 mg/m2) for 12 weeks (ET+P) followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
3266955|NCT01537562|Active Comparator|Delayed IUC insertion|Patients randomised to delayed, routine, insertion had their IUC inserted at 3-4 weeks (day 21-35 after mifepristone treatment
3266956|NCT01537562|Active Comparator|Early IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment.
3266957|NCT01537575|Placebo Comparator|saline solution|
3266958|NCT01537575|Experimental|intravenous immunoglobulins|
3266959|NCT01537588|Active Comparator|Standard|ACL reconstruction with autograft harvest of STG from ACL-deficient leg
3266960|NCT01537588|Experimental|Autograft harvest of STG from ACL-deficient leg|Autograft harvest of STG from leg contralateral to ACL-deficient leg
3266961|NCT01537588|No Intervention|Normal matched|
3266962|NCT01537601|Other|Antibiotic prophylaxis alone|Children will be on antibioprophylaxis and will not have a circumcision.
3266963|NCT01537601|Experimental|Circumcision and antibiotic prophylaxis|Children will have a circumcision at the time of valve resection and will be on antibioprophylaxis
3266964|NCT01537614|Experimental|COLIMYCINE injectable|
3266965|NCT01537614|Experimental|COLIMYCINE inhalation|
3266966|NCT01537627|Active Comparator|Low-intensity training (LT)|
3266967|NCT01537627|Active Comparator|High-intensity training (HT)|
3266968|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 1|SAR231893 (REGN668) Drug Product 1 in a single subcutaneous injection
3266969|NCT01537640|Experimental|SAR231893 (REGN668) Drug Product (DP) 2|SAR231893 (REGN668) Drug Product 2 in a single subcutaneous injection
3266970|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 4|Dose Level 4
3266971|NCT01537653|Placebo Comparator|Placebo|Placebo
3266972|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 1|Dose Level 1
3266973|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 2|Dose Level 2
3266974|NCT01537653|Experimental|SAR231893 (REGN668), Dose Level 3|Dose Level 3
3266975|NCT01537679|Other|Meditation Intervention|
3266976|NCT01537679|Other|Relaxation Intervention|
3266977|NCT01537692|Experimental|BDP HFA Nasal Aerosol 80 mcg/d|single dose, intranasal aerosol
3266978|NCT01537692|Experimental|BDP HFA Nasal Aerosol 320 mcg/d|single dose, intranasal aerosol
3266979|NCT01537692|Active Comparator|BDP HFA Inhalation Aerosol 320 mcg/d|single dose, orally inhaled aerosol
3266980|NCT01537705|Experimental|Neuron012703|Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
3266981|NCT01537718|Experimental|REPLY 200 implanted patients|REPLY 200 implanted patients
3266982|NCT01537731||hysterectomy|Patient who previously underwent vaginal or laparoscopic hysterectomy
3266983|NCT01537744|Experimental|oral 5-azacitidine + romidepsin|oral 5-azacitidine in combination with romidepsin
3266984|NCT01537757|Experimental|Part 1, Panel A - Severe Renal Impairment Group|
3266985|NCT01537757|Experimental|Part 1, Panel B - Healthy Control Group to Match Panel A|
3266986|NCT01537757|Experimental|Part 2, Panel C - Moderate Renal Impairment Group|
3266987|NCT01537757|Experimental|Part 2, Panel D - Healthy Control Group to Match Panel C|
3266988|NCT01537757|Experimental|Part 2, Panel E - Mild Renal Impairment Group|
3266989|NCT01537757|Experimental|Part 2, Panel F - Healthy Control Group to Match Panel E|
3266990|NCT01537770|Active Comparator|Vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3266991|NCT01537770|Sham Comparator|lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
3266992|NCT01537796|Experimental|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
3266993|NCT01537796|Experimental|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
3376635|NCT05126992||AZD1222|at least one dose of AZD1222
3376636|NCT05126992||comparator|non vaccinated
3376637|NCT05125289|Experimental|experimental intervention group 1|Graston technique group
3376638|NCT05125289|Experimental|Experimental :interventional group II|Active release technique group
3376639|NCT05125289|Experimental|experimental group III|Proprioceptive Neuromuscular Facilitation stretching group
3376640|NCT05124834|Experimental|Subject glucometer measurement|Blood glucose measurement BGM for personal use
3376641|NCT05124639|Experimental|Group self-management support|Group self-management support program for anxiety disorders developped by Relief (https://myrelief.ca/).
3376642|NCT05124639|No Intervention|Treatment-as-usual|Treatment-as-usual and a delayed intervention (if desired by participants) after the 12-month follow up
3376643|NCT05124340|Experimental|Vaccine|1 dose of BCG vial vaccine injected in right deltoid armintradermally
3376644|NCT05124340|Active Comparator|Active Comparator|1 dose of BCG ampoule vaccine injected in right deltoid arm intradermally
3376645|NCT05122078|Experimental|ANI group|Investigator will attach the ANI monitor V2 (MDoloris Medical Systems, Lille, France) to the patient and monitor Analgesia Nociception Index (ANI) during anesthesia. Remifentanil infusion rate is adjusted according to ANI monitoring. The ANI is adjusted to be between 50 and 70.
3376646|NCT05122078|No Intervention|Control group|Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. We will not monitor ANI in this group.
3376647|NCT05120323|Experimental|vDOT Intervention Group|The VDot group will submit videos via app to Emocha to have their inhaler technique graded to assess their inhaler technique.
3376648|NCT05120323|No Intervention|Standard Asthma Care Group|Participants in the standard asthma care group will receive standard of care asthma education conducted by a respiratory therapist in the specialty clinics at Arkansas Children's Hospital at the baseline visit. Education will include standard of care instruction on the participant's prescribed asthma medications, how to use an asthma action plan, as well as training and demonstration of proper inhaler technique. They will not have any additional study activities until the 3-month visit. They will be instructed to take their medications as prescribed.
3376649|NCT05117931|Experimental|Amivantamab|Patients will receive amivantamab intravenously weekly for the first cycle, and biweekly subsequently at a dose of 1050mg (patients <80kg) or 1400mg (patients ≥80kg). The initial dose will be administered over 2 days in split doses in order to mitigate the risk of infusion reactions. Therapy will continue for up to 2 years or until progression of disease, initiation of alternative cancer therapy, unacceptable toxicity, or other reason to discontinue treatment occurs-whichever comes first.
3376650|NCT05117450|Active Comparator|HeprAN first|Each included patient will have hemodialysis sessions with HeprAN membrane and then HYDROLINK
3376651|NCT05117450|Active Comparator|HYDROLINK first|Each included patient will have hemodialysis sessions with HYDROLINK and then HeprAN membrane
3376652|NCT05116930|Experimental|Postpartum dural puncture headache following dural puncture from Tuohy needle|Subjects identified as experienced a post dural puncture headache after a confirmed dural puncture from a Tuohy needle will receive an IV administration of the study medications neostigmine and atropine
3376655|NCT05111431|Experimental|Dexmedetomidine Hydrochloride Nasal Spray|
3376656|NCT05111431|Placebo Comparator|Dexmedetomidine hydrochloride nasal spray blank preparation|
3376657|NCT05110937||Sepsis|Blood collection: Blood will be collected from patient at day 4, day 7, day 14-21 and at 3 and 6 months.
3376658|NCT05110937||Healthy Controls|"Blood Collection.~The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable."
3266994|NCT01537796|Experimental|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
3266995|NCT01537809|Active Comparator|D3 600 IU/ daily|Subjects randomized to 600 IU/day of vitamin D3 taken orally for six months.
3266996|NCT01537809|Active Comparator|D3 1000 IU/ daily|Subjects randomized to 1000 IU/day of vitamin D3 taken orally for six months.
3266997|NCT01537809|Active Comparator|D3: 2000 IU/daily|Subjects randomized to 2000 IU/day of vitamin D3 taken orally for six months.
3266998|NCT01537822|Experimental|hysteroscopic morcellator|Women, randomized into getting a treatment with the hysteroscopic morcellator.
3266999|NCT01537822|Active Comparator|Resectoscope|Women, randomized into getting a treatment with the resectoscope.
3267000|NCT01537848||post-operative collection|patients suffering from a post-operative abdominal collection
3267001|NCT01537861|Experimental|Arm 1|"Filgrastim 5 ug/kg from Day -3 to Day 10 of a single cycle.~Bortezomib will be given at the patient's current dose on Days 1, 4, 8, and 11 OR Carfilzomib will be given at the patient's current dose on Days 1, 2, 8, 9, 15, and 16 OR IMID will be given at the patient's current dose once daily on Days 1-21. Patients receiving an IMID (thalidomide, lenalidomide, or pomalidomide) as part of a bortezomib or carfilzomb regimen should continue the same scheduled as the current regimen.~Dexamethasone should be continued at the same dose and schedule as the patient's current regimen.~PO cyclophosphamide should be continued at the same dose and schedule as the patient's current regimen."
3267002|NCT01537874|Experimental|Motivational Interview Intervention|Motivational interviewing session (1 hour in home) plus 2 follow-up phone calls
3267003|NCT01537874|Other|Usual Best Practices|Standard care delivered using informational materials
3267004|NCT01537939|Other|Walking|Quasi-experimental design with one-group, post-test only
3267005|NCT01537978|Experimental|Video game play|Changes in upper limb; strength, active range of motion, electromyographic activity as well as heart rate response.
3267006|NCT01537991|Experimental|Group 1A|Group 1A is where less than or equal to 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
3267007|NCT01537991|Experimental|Group 1B|Group 1A is where more than 6.5cm length of oesophagus is lying with the Planning Target Volume. Dose will be between 58 and 65Gy determined by current trial cohort in Phase I.
3267008|NCT01537991|Experimental|Phase II|All patients will receive radiotherapy to a maximum dose of 65Gy in 20 fractions. The dose to the individual patient will be determined by their individual dose constraints for organs at risk.
3267009|NCT01538004||BpTRU readings in private office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an exam room. The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
3267010|NCT01538004||BpTRU readings in open office area|Consenting patients will be randomly allocated using a random number table to BpTRU in an open office area The first reading will be done with the research assistant present to ensure proper placement and recording and will then be left alone for the subsequent five measurements at one minute intervals. This will be immediately followed by a second set of readings in the alternate location. During both sets of readings the patient will be seated comfortably in a chair with arms and will be instructed not to talk or cross their legs. The same arm will be used for both sets of measurements with the blood pressure cuff at heart level. The average of the last five out of six blood pressure readings for each office location will be recorded. The decibel levels in each location will be recorded during BP readings using a Reed Sound Level Meter C-322. The patient's weight in kg, height in cm, gender and self reported history of hypertension will also be recorded.
3267011|NCT01538017|Active Comparator|Collagenase injection|Injection of collagenase obtained from Clostridium Histolyticum in contracture string
3267012|NCT01538017|Active Comparator|Percutaneous needle fasciotomy|PNF ad modum Lermusiaux and Debeyre
3267013|NCT01538030||Amniotic Fluid Volume > 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index above 5.1
3267014|NCT01538030||Amniotic Fluid Volume < 5|Pregnant patients with gestations between 24-34 weeks with premature rupture of membranes that, when the decision was made to interrupt the pregnancy, had amniotic fluid volume index of 5 or less.
3267015|NCT01538043|Active Comparator|local mud packs and thermal-mineral bath|50 patients with primary knee OA will be treated with daily local mud packs and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
3267016|NCT01538043|No Intervention|regular routine ambulatory care|50 patients, the control group, will continue regular routine ambulatory care
3267017|NCT01538056|Experimental|Fenestrated procedure|Fenestrated device with fenestrations for bilateral renal ateries and SMA. May include all three fenestrations or only one
3267018|NCT01538069|No Intervention|Control group|
3267019|NCT01538069|Experimental|Exercise group|
3267020|NCT01538069|Experimental|CPAP group|
3267021|NCT01538069|Experimental|Exercise and CPAP group|
3267022|NCT01538082||Patients without stress|Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
3267023|NCT01538082||Patients with stress|Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
3267024|NCT01538095|Experimental|Treatment (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
3267025|NCT01538108|Experimental|NMB's PTA Balloon catheter with paclitaxel|
3267026|NCT01538108|Active Comparator|Standard Angioplasty Balloon|
3267027|NCT01538121||Cases-Early Severe Preeclampsia|Patients with severe preeclampsia before 34 weeks of gestation
3267028|NCT01538121||Controls|Patients with normal pregnancies at term.
3267029|NCT01538134||Cases|Patients with ultrasonographic diagnosis of fetal growth restriction.
3267030|NCT01538134||Control|Patients with normal pregnancies at term.
3267031|NCT01538147||Cases|Patients with Severe preeclampsia
3267032|NCT01538147||Control|Patients with normal pregnancies at term
3267033|NCT01538173|Experimental|HES group|Application of twice a day 250ml HES 6% for three days postoperatively.
3267034|NCT01538173|Active Comparator|NaCl group|Application twice a day 500ml 9% NaCl for three days postoperatively.
3267035|NCT01538186||PCI without treating the side branch|
3267036|NCT01538186||PCI with treating the side branch|
3267037|NCT01538225|Experimental|first sativex, second placebo|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (Sativex), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (placebo)
3267038|NCT01538225|Experimental|first placebo, second sativex|2 weeks first titration period (as per approved SmPC), a 2-week first treatment period (placebo), a 2-week washout, a cross-over followed by another 2 weeks titration period (as per SmPC), followed by a second 2-week period treatment (Sativex)
3267039|NCT01538238|Experimental|pazopanib|pazopanib 800mg qd
3267040|NCT01538251|Experimental|Propionyl-L-carnitine|modified release tablets 500 mg
3267041|NCT01538251|Placebo Comparator|Placebo|Modified release tablet 500 mg
3267042|NCT01538277|Experimental|Contact Force arm|the real-time contact force will be known to the operator
3267043|NCT01538277|Active Comparator|Standard|Standard ablation arm
3267044|NCT01538303||measurement absolute flow and resistance|
3267045|NCT01538316|Active Comparator|Quercetin supplement|
3267046|NCT01538316|Active Comparator|Genistein supplement|
3267047|NCT01538316|Placebo Comparator|Placebo|
3267048|NCT01538329|Experimental|Amantadine|Patients with amantadine
3267049|NCT01538329|Placebo Comparator|Placebo|Patients with amantadine placebo
3267050|NCT01538342|Other|chronic plaque psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3267051|NCT01538342|Other|pustular psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3267052|NCT01538342|Other|erythrodermic psoriasis|3 biopsies: 2 lesional and 1 non-lesional
3267053|NCT01538342|Other|atopic dermatitis|2 biopsies: 1 lesional and 1 non-lesional
3267054|NCT01538342|Other|healthy patients|1 biopsy of healthy skin.
3267055|NCT01538355|Experimental|Prolonged fasting|Patients undergo an initial 7-day fasting episode.
3267056|NCT01538355|Experimental|Ketogenic low glycemic load treatment|Patients receive a ketogenic low glycemic load treatment from the outset of the study.
3267057|NCT01538355|Experimental|Control diet|Patients stay on their regular diet.
3267058|NCT01538381|Experimental|Afatinib|Afatinib given orally for 2 weeks after randomization till day -1 prior to surgery (day 0) at a dose of 40 mg/day
3267059|NCT01538381|Other|Observation|No treatment only observation
3267060|NCT01538394|Experimental|Varenicline & nicotine patches|"Combined therapy by using Varenicline plus nicotine patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus placebo transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
3267061|NCT01538394|Placebo Comparator|Varenicline & placebo patches|"Monotherapy by using Varenicline plus placebo patches.The intervention-phase will comprise two fasses:~Pre-NRT: Patients take 1 week VRN impregnation (0.5mg/day during the first 3 days + 0.5mg twice daily for the next for days)~Treatment: starting at day 8 and during the next 11 weeks patients continue taking VRN 1mg twice daily plus nicotine transdermal patches of 30cm2/24 hours per 8 weeks and then 20cm2/24 hours per 3 weeks."
3267062|NCT01538407|No Intervention|Control group|No intervention group
3267063|NCT01538407|Active Comparator|Strength training group|The knee extension strength training intervention period is 12 weeks with training sessions three times per week.
3267064|NCT01538420|Experimental|GLPG0492 oral solution|Multiple ascending doses once daily for 7 days (part 1) or 14 days (part 2), starting at 0.5 mg/day
3267065|NCT01538420|Placebo Comparator|Placebo|Placebo oral solution, once daily for 7 days (part 1) or 14 days (part 2).
3267066|NCT01538433||biopsy-proven IgA nephropathy|
3267067|NCT01538446|Experimental|1: Monitoring Arm|Monitoring Arm: dose adjustment of prasugrel with down-adjustment of the dose of prasugrel in high responders and up-adjustment of the dose of prasugrel in low responders
3267068|NCT01538446|Active Comparator|2: Conventional Arm|Conventional Arm: fixed dose of prasugrel 5 mg
3267069|NCT01538459|Active Comparator|Bupivacaine|50 randomized participants in group receive 20cc 0.25% bupivacaine injected perineurally for interscalene nerve block.
3267070|NCT01538459|Experimental|Dexamethasone and Bupivacaine|50 randomized participants in group will 8 mg(2cc of 4mg/cc solution) Dexamethasone added to 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection. Injected perineurally for interscalene nerve block pre-operatively.
3267071|NCT01538485|Experimental|Cholecalciferol|
3267072|NCT01538511|Experimental|BIAsp 70|
3267073|NCT01538511|Experimental|BIAsp 30|
3267074|NCT01538550|Experimental|Flexible sigmoidoscopy|70,000 men and women at age 50-74 years are randomised from the population registry to be invited to have a screening examination using flexible sigmoidoscopy once-only
3267075|NCT01538550|Experimental|iFOBT|70,000 men and women at age 50-74 years randomised from the population registry to be invited to have a screening examination biennially using an immunochemical test for fecal occult blood testing (iFOBT).
3267076|NCT01538576||Insulin aspart users|
3267077|NCT01538589||Insulin aspart users|
3267078|NCT01538602||PCOS patients|
3376659|NCT05110300|Active Comparator|Body weight support system control group|The Body weight support system (BWSS) active comparator control group will conduct 2 to 6, 30 minute sessions, over two-weeks. To be as pragmatic and clinically relevant as possible, treatment sessions will be incorporated directly to the participants' normal care. Furthermore, participants are allowed to complete 2 to 6 sessions as dictated by short or unexpected changes to the discharge planning timeline. During each session, participants will conduct balance exercises, including: marching, side-stepping, retro-ambulation, step-taps, and step-ups. Participants will also conduct various standard gait exercises, including: ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions.
3376660|NCT05110300|Experimental|Body weight support system with balance perturbations|The BWSS with balance perturbations (BWSS-P) experimental intervention group will also conduct 2 to 6, 30 minute sessions, over two-weeks. Participants in the BWSS-P group will conduct the same balance and gait exercises as the control group, including: marching, side-stepping, retro-ambulation, step-taps, step-ups, ambulation over the ground, going up and down stairs, and performing sit-to-stand transitions. However, each sessions will include eight, resistive or assistive, balance perturbations, two in each cardinal direction (lateral, anterior, and posterior).
3376661|NCT05110001|Placebo Comparator|Standard Therapy|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
3376662|NCT05110001|Experimental|Cross-Linking with rose Bengal (RB-PDT)|Patients in this arm will receive topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT
3267079|NCT01538602||Healthy volunteers|
3376666|NCT05103683|Experimental|Monotherapy Dose Dose Finding - Part 1|TORL-1-23
3376667|NCT05103683|Experimental|Expansion as Monotherapy - Part 2|TORL-1-23
3376668|NCT05103618|Active Comparator|Healthy Control Couple Pairs|All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.
3267080|NCT01538641|Experimental|1|
3267081|NCT01538654||'enteral protein tube feeding in obese|protein sparing modified fast with a defined enteral formula by tube
3267082|NCT01538667|Experimental|Arm 1|
3267083|NCT01538667|Experimental|Arm 2|
3267084|NCT01538667|Experimental|Arm 3|
3267085|NCT01538667|Experimental|Arm 4|
3267086|NCT01538693|Active Comparator|escitalopram oxalate|Exercise testing with escitalopram oxalate dose
3267087|NCT01538693|Active Comparator|cyproheptadine|exercise testing with cyproheptadine dose
3267088|NCT01538693|Placebo Comparator|placebo|exercise testing with placebo dose
3267089|NCT01538706|Experimental|Hospital-based home care|Patients were included if below the age of 18, had been diagnosed with any type of cancer at least one month prior to inclusion, on intravenous anticancer therapy with a curative intent, and the parent was fluent in speaking and reading Danish. Patients living within a radius of 50 kilometres from the hospital were assigned to the home care program. Moreover, patients were assigned to one of three groups according to the geographical distance from the hospital and timing of the inclusion period: (1) home care group if participating in the program, (2) historical standard care group for an eight-month period before the program started regardless of their residence distance from the hospital, and (3) concurrent standard care group if living more than 50 km from the university hospital.
3267090|NCT01538758|Active Comparator|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
3267091|NCT01538758|Active Comparator|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
3267092|NCT01538771|Placebo Comparator|Control group|Received same volume of saline
3267093|NCT01538771|Active Comparator|Darbepoetin group|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning & conventional treatment
3267094|NCT01538823||Group 1|Enrollment of surgical patients at Barnes Jewish Hospital (BJH) with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy.
3267095|NCT01538823||Group 2|Surgical patients at BJH with non urological cancers
3267096|NCT01538823||Group 3|Surgical patients at BJH with a presumptive diagnosis of RCC and planned nephrectomy or partial nephrectomy
3267097|NCT01538823||Group 4|Surgical patients at BJH with non urological cancers
3267098|NCT01538823||Group 5|Healthy volunteers with no history of cancer or renal disease
3267099|NCT01538823||Group 6|Patients at BJH/Washington University School of Medicine under post procedure surveillance for RCC recurrence and patients under treatment for metastatic disease.
3267100|NCT01538823||Group 7|Patients with a presumptive diagnosis of bladder cancer or prostate cancer
3267101|NCT01538836|No Intervention|Weight maintenance|Weight maintenance with normal protein intake
3267102|NCT01538836|Active Comparator|Weight loss with normal protein intake|
3267103|NCT01538836|Experimental|Weight loss with protein supplementation|
3267104|NCT01538849|Experimental|YH4808 A mg (Twice daily)|YH4808 A mg (Twice daily, Oral administration)
3267105|NCT01538849|Experimental|YH4808 B mg (Once daily)|YH4808 B mg (Once daily, Oral administration)
3267106|NCT01538849|Experimental|YH4808 B mg (Twice daily)|YH4808 B mg (Twice daily, Oral administration)
3267107|NCT01538849|Experimental|YH4808 C mg (Once daily)|YH4808 C mg (Once daily, Oral administration)
3267108|NCT01538849|Active Comparator|Esomeprazole 40mg (Once daily)|Esomeprazole 40mg (Once daily, Oral administration)
3267109|NCT01538875|Experimental|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes (Maximum number of doses: 3).
3267110|NCT01538875|Active Comparator|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
3267111|NCT01538888|Experimental|WHOLE BODY VIBRATION|SEARCH THE CARDIOPULMONARY EFFECTS IN WHOLE BODY VIBRATION IN HEALTH ELDERLY
3267112|NCT01538901|Experimental|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix 160mg/g cream) will be applied 1 mm thick on the treated area, which has a maximal diameter of 8 cm2, and will be covered with a semipermeable dressing (Suprasorb F, Lohmann & Rauscher, Vienna, Austria)for 3 hours. Afterwards the cream leftovers will be removed by 0.9% NaCl solution. Following the treated area will be irradiated with heat-free visible red light at a peak wavelength of 630 nm with a single dose of 37 J/cm2 (Actilite model: CL128, PhotoCure, Norway). This treatment will be repeated in two weeks.
3267113|NCT01538901|Active Comparator|imiquimod 5% cream|250 mg imiquimod 5% cream (Aldara 5% cream) will be applied over night, for a total of 3 nights in a week, for duration of 4 weeks.
3267114|NCT01538914|Experimental|PVB|Postoperative pain is controlled with local analgesics delivered via PVB.
3267115|NCT01538914|Active Comparator|PCA|Postoperatve pain is controlled with intravenous PCA.
3267116|NCT01538927|Experimental|Fibrin Sealant|One quadrant surgically elevated will be closed with fibrin sealant
3267117|NCT01538927|Placebo Comparator|Suture|The surgically elevated flap is closed with non resorbable sutures.
3267118|NCT01538940|Active Comparator|HIV+, CD4<200, ID vaccine|
3267119|NCT01538940|Active Comparator|HIV+, CD4<200, IM vaccine|
3267120|NCT01538940|Active Comparator|HIV+, CD4>=200, ID vaccine|
3267121|NCT01538940|Active Comparator|HIV+, CD4 >=200, IM vaccine|
3267122|NCT01538940|Other|HIV-, ID vaccine|
3267123|NCT01538940|Other|HIV-, IM vaccine|
3267124|NCT01538953|Experimental|Handwashing|participants received weekly, in-home handwashing promotion and soap as needed
3267125|NCT01538953|Experimental|handwashing and water treatment|
3267126|NCT01538953|Experimental|Water treatment with sodium hypochlorite|
3267127|NCT01538953|Experimental|Water treatment with flocculent-disinfectant|participants received a supply of flocculent-disinfectant product and instruction to use it to treat drinking water
3267128|NCT01538953|No Intervention|Control|
3267129|NCT01538966|Active Comparator|High dose SRL + weekly Pegvisomant|"High dose of SRL monthly~Octreotide LAR 30mg~Lanreotide 120mg~Weekly Pegviosmant (40-120mg/week)"
3267130|NCT01538966|Active Comparator|Low dose SRL + daily Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Daily Pegviosmant (15-60mg/day)"
3267131|NCT01538966|Active Comparator|Low dose SRL + weekly Pegvisomant|"Low dose of SRL monthly~Octreotide LAR 10mg~Lanreotide 60mg~Weekly Pegviosmant (40-120mg/week)"
3267132|NCT01538979|Experimental|BM32 low dose|7 subcutaneous injections of 20 micrograms over two grass pollen seasons
3267133|NCT01538979|Experimental|BM32 high dose|7 subcutaneous injections of 40 micrograms over two grass pollen seasons
3267134|NCT01538979|Placebo Comparator|Placebo|7 subcutaneous injections over a time span of two pollen seasons
3267135|NCT01538992|Experimental|renal denervation|in this group percutaneous renal denervation with Standard steerable Mariner Radiofreqency ablation Catheter (5F or 7F)
3267136|NCT01538992|No Intervention|medical thrapy|medical treatment
3267137|NCT01539018|Active Comparator|Sorafenib alone.|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
3267138|NCT01539018|Experimental|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily continuously and UFT 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
3267139|NCT01539031|Experimental|10 mg group|
3267140|NCT01539031|Active Comparator|23 mg group|
3267141|NCT01539044|Active Comparator|IB-neostigmine|subject will be given intermittent bolus of rocuronium during the surgery and reversal of neostigmine at the end of surgery at TOF 2
3267142|NCT01539044|Experimental|CI-Sugammadex|subject will be given continuous infusion of rocuronium and reversal of sugammadex at the end of surgery at PTC 1-2
3267143|NCT01539057|Experimental|Intravenous Fibrinogen|Fibrinogen will be administered until an expected plasmatic value of 2.9 g / L is achieved.
3267144|NCT01539057|Placebo Comparator|Saline Serum|the same dose in volume of saline dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of saline dilution
3267145|NCT01539096|Sham Comparator|Sham tDCS plus CIMT|Subjects in this group will be trained on Constraint induced movement therapy (CIMT) for the hand while concurrently receiving placebo noninvasive brain stimulation (tDCS). They will be receiving Sham tDCS: placebo noninvasive brain stimulation. They will be provided treatment for 3 days a week for 5 weeks for 1 hr each day at the Cleveland Clinic. They would be asked to use affected hand in daily activities for 5 hrs everyday at home while wearing a mitt on their unaffected hand.
3267146|NCT01539096|Experimental|tDCS plus CIMT|Patients with stroke affecting the hand will receive Constraint-induced movement therapy (CIMT) concurrent with tDCS: noninvasive brain stimulation. TDCS will be applied to areas of the brain responsible for movement of the affected hand. This combination of tDCS and CIMT will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
3267147|NCT01539109|Experimental|Rehab and tDCS|Patients in this group will receive Noninvasive brain stimulation: tDCS, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase.
3267148|NCT01539109|Sham Comparator|Rehab and sham tDCS|Patients in this group will receive Sham tDCS: placebo noninvasive brain stimulation, during rehabilitation exercises of the weak upper limbs for 2 hours per day, 5 times a week, for 2 weeks. tDCS is Transcranial Direct Current Stimulation. Prior to this 2-week intervention phase, all patients will be monitored over a 2-week control phase
3267149|NCT01539122|Active Comparator|TM Glenoid|Zimmer TM glenoid shoulder replacement component will be used for the glenoid component of the total shoulder replacement.
3267150|NCT01539122|Active Comparator|Cemented Glenoid|Cemented glenoid shoulder replacement component
3267151|NCT01539161|Experimental|Reveal XT plus SOC|Standard of care treatment plus the Reveal XT Implantable Cardiac Monitor. Treatment will follow the same schedule of the standard of care arm regarding exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. The addition will be device interrogation at every 6 month exam. Participation will last 36 months.
3267152|NCT01539161|Active Comparator|Standard of Care|Standard of care arm as described by exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months. Participation will last 36 months.
3267153|NCT01539174|Experimental|Treatment (monoclonal antibody, combination chemotherapy)|Patients receive rituximab IV on days 0, 1, 4, 8, and 15 of course 1; days 1, 8, and 15 of course 2; and day 1 of all subsequent courses. Patients also receive CHOP chemotherapy comprising cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3267154|NCT01539187|Experimental|VizAblate intervention|VizAblate System with subject serving as her own control
3267155|NCT01539200|Placebo Comparator|Control|
3267156|NCT01539200|Active Comparator|Oral Nutritional Supplement (ONS) and JDR|
3267157|NCT01539213|Experimental|AIN457|secukinumab (AIN457)
3267158|NCT01539226|Placebo Comparator|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
3267159|NCT01539226|Experimental|Dapivirine Vaginal Ring|Vaginal Ring containing 25mg of Dapivirine
3267160|NCT01539252|Active Comparator|Single dialyzer|Single dialyzer
3267161|NCT01539252|Experimental|Double dialyzer|Two dialyzers in parallel
3267162|NCT01539265|Experimental|silodosin, arm 1|
3267163|NCT01539265|Experimental|silodosin, arm 2|
3267164|NCT01539265|Placebo Comparator|placebo|
3267165|NCT01539278|Active Comparator|Observation, no surgery (control)|Patients have been diagnosed with mild OSA, no intervention is done; enrolled patients may be randomly or nonrandomly placed in this group
3267166|NCT01539278|Experimental|Surgery (adenotonsillectomy)|Patients who have been diagnosed with mild OSA. Patient may be randomly assigned or non-randomly choose to be in this group; all undergo adenotonsillectomy
3267167|NCT01539304|Experimental|CITUS Dry Syrup|Pranlukast dry syrup 10%
3267168|NCT01539304|Placebo Comparator|Placebo|Placebo
3267169|NCT01539343|Experimental|Antimicrobial Lock Solution|Participants receive the HEAL antimicrobial solution for 2 hours once daily for a minimum of 5 consecutive days. Participants also receive the lock therapy once weekly for two additional weeks. Principle ingredients include minocycline, calcium disodium ethylenediaminetetraacetate (CaEDTA) and ethanol.
3267170|NCT01539356||preterm infants|"preterm infants receiving blood transfusion~preterm infants with neonatal sepsis."
3267171|NCT01539369|Experimental|High fibre diet|
3267172|NCT01539369|Active Comparator|Healthy eating diet|
3267173|NCT01539382|Experimental|Cerebral oxygenation intervention|Cerebral oxygenation levels for people in this group will be monitored and maintained above 60%. If levels decrease to below 60%, a protocol is followed to guide possible interventions to increase cerebral oxygenation levels above 60%
3267174|NCT01539382|No Intervention|Cerebral oxygenation control|Cerebral oxygenation levels for people in this group will be masked and thus doctors and care staff will not use the cerebral oxygenation levels to make any interventions. If the cerebral oxygenation levels drop to below 40%, the cerebral oxygenation levels will be unmasked so that doctors can follow the protocol to increase levels to above 60%.
3267175|NCT01539395||Inactive Disease|Inactive disease; RRMS patients who have been treated with monthly infusions of Tysabri for 12 months and have had stable disease for the last 6 months or more and show stable or improving neurological deficits over 3 months on Tysabri.
3267176|NCT01539395||Active Disease|Active disease; RRMS patients in acute clinical relapse or with active MRI. Blood sample obtained within 30 days of event AND before steroid treatment (or) patients in early disease on or off first line agents with relapse in prior 3 months AND not treated with steroids for at least 2 months.
3267177|NCT01539395||Active Disease - Steroid Therapy|Patient with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin steroid therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
3267178|NCT01539408|Active Comparator|Misoprostol|400 mcg of sublingual misoprostol in one dose
3267179|NCT01539408|Active Comparator|Manual vacuum aspiration (MVA)|Standard surgical treatment (MVA)
3267180|NCT01539421|Experimental|Exercise Intervention|Use of Wii computer for enhanced exercise in COPD patients.
3267181|NCT01539434|Experimental|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
3267182|NCT01539434|Active Comparator|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
3267185|NCT01539460|Experimental|minimally invasive surgery|There is only one arm to this study. All patients will receive treatment with the minimally invasive surgery for their axillary bromidrosis
3267186|NCT01539473|Experimental|TR-701 FA with Tyramine|TR-701 FA 200 oral with Tyramine
3267187|NCT01539473|Placebo Comparator|Placebo-controlled with Tyramine|Placebo-controlled with Tyramine
3267188|NCT01539551||1|sepsis and septic shock patients
3267189|NCT01539564|Experimental|Treatment|Treatment (minocycline HCl microspheres, 1mg) administered at Baseline (following randomization) and Day 90 to qualifying implant sites, plus full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180.
3267190|NCT01539564|No Intervention|Control|Full-mouth mechanical debridement (deep cleaning) at Baseline and Day 180; no treatment
3267191|NCT01539577||OZURDEX®|OZURDEX® (dexamethasone 700 μg intravitreal implant) administered according to general clinical practice.
3267192|NCT01539603|Experimental|DEB-BMS|Drug eluting balloon + Bare metal stent
3267193|NCT01539603|Active Comparator|Drug eluting stent|conventional PCI with drug eluting stent drug eluting stent (Zotarolimus-eluting stent)
3267194|NCT01539616|Experimental|ZYH7 4mg|ZYH7 4mg
3267195|NCT01539616|Experimental|ZYH7 8mg|ZYH7 8mg
3267196|NCT01539616|Experimental|ZYH7 16mg|ZYH7 16mg
3267197|NCT01539616|Active Comparator|Fenofibrate 160mg|Fenofibrate 160mg
3267198|NCT01539629||Pulse Width|One group reflecting two different pulse widths.
3267199|NCT01539655|Experimental|vandetanib then vandetanib + omeprazole|Vandetanib alone in period 1 followed by vandetanib in combination with omeprazole in period 2
3267200|NCT01539655|Experimental|vandetanib + omeprazole then vandetanib|Vandetanib in combination with omeprazole in period 1 followed by vandetanib alone in period 2
3267201|NCT01539655|Experimental|vandetanib then vandetanib + ranitidine|Vandetanib alone in period 1 followed by vandetanib in combination with ranitidine in period 2
3267202|NCT01539655|Experimental|vandetanib + ranitidine then vandetanib|Vandetanib in combination with ranitidine in period 1 followed by vandetanib alone in period 2
3267203|NCT01539668||Pap sampling|Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
3267204|NCT01539681||Group 1|
3267205|NCT01539707|Experimental|AD-PED 5 mg|Male and female adolescents aged 12 to less than 18 years old who receive pediatric equivalent dose (PED) of 5 mg of solifenacin succinate.
3267206|NCT01539707|Experimental|CH-PED 5 mg|Male and female children aged 5 to less than 12 years old who receive PED of 5 mg of solifenacin succinate.
3267207|NCT01539720|Experimental|Levonorgestrel Intrauterine System|Participants randomized to the levonorgestrel IUS will undergo placement at the time of randomization. They will follow-up with a self-administered urine pregnancy test 5-6 weeks following.
3267208|NCT01539720|Active Comparator|Ulipristal acetate|Women in this arm will receive the oral Ulipristal acetate (Ella) regimen, which is currently the most effective method of oral emergency contraception.
3267209|NCT01539733|Experimental|Olanzapine|
3267210|NCT01539733|Active Comparator|Haloperidol|
3267211|NCT01539746|Experimental|TAVI without predilation|
3267212|NCT01539746|Active Comparator|Standard TAVI procedure|
3267213|NCT01539772||Becker|"BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.~."
3267214|NCT01539785|Active Comparator|Secondary cytoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction.
3267215|NCT01539785|Experimental|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique.
3267216|NCT01539798|Experimental|Oral Saline|Ingestion of 0.9% saline solution
3267217|NCT01539798|Active Comparator|Intravenous Saline|Intravenous infusion of 0.9% saline solution
3267218|NCT01539824|Experimental|IMM-101 plus SBRT|The treatment regimen with IMM-101 (Mycobacterium obuense) will be every 2 weeks for the first three doses with the last of these doses being on the same day as the radiotherapy by CyberKnife treatment on a liver lesion targeted by the Principal Investigator. Following a rest of 4 weeks, patients will again receive IMM-101 every 2 weeks for the next 3 doses followed by a further 4 weeks rest. Thereafter, IMM-101 will be given at 4 week intervals for up to 12 months or until patient withdrawal for any reason
3267219|NCT01539876|Other|Fine Needle aspiration will be done X5:|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
3267220|NCT01539889|Experimental|DFH-12 PulmoBind|DFH-12 PulmoBind - 3 doses of; 5mCi for 5 subjects, 10mCifor 5 subjects and 15mCi for 10 subject
3267221|NCT01539902|Experimental|Human Umbilical Cord derived MSCs|
3267222|NCT01539902|Placebo Comparator|Cyclophosphamide|
3267223|NCT01539915|Experimental|BCT194|
3267224|NCT01539928||lung cancer or high suspicion of lung cancer|After initial work-up (chest x-ray, CT of thorax and upper abdomen, spirometry) found to have surgically resectable lung cancer
3267225|NCT01539941|Experimental|Medication Integration Protocol|
3267226|NCT01539954||Youth 9-18 years of age|
3267227|NCT01539993||1|
3267228|NCT01540019|Experimental|Paullinea cupana|50mg of Paullinia cupana as capsule, twice daily
3267229|NCT01540032|No Intervention|Control|
3267230|NCT01540032|Experimental|Diet|
3267231|NCT01540058|Experimental|test-guided strategy|"Treatment considered as the standard at the time of patient inclusion based on the primary cancer suspected by the BioTheranostics Cancer Type ID test molecular analysis"
3267232|NCT01540058|Active Comparator|Empiric strategy|Gemcitabine/Cisplatin
3267233|NCT01540084|Active Comparator|conventional group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary.
3267234|NCT01540084|Experimental|cocktail group|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered. To maintain conscious level of patient at moderate or deep level, 1% propofol at the rate of 1 mg/kg/hr was administered. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
3267235|NCT01540110|Experimental|Docetaxel + cyclophosphamide|
3267236|NCT01540123|Placebo Comparator|Control|Sugar matched control containing no phytochemicals
3267237|NCT01540123|Experimental|Berry drink standardised to contain 500mg of polyphenols|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
3267238|NCT01540136|Experimental|Nedaplatin|Nedplatin combine with IMRT
3267239|NCT01540136|Active Comparator|Cisplatin|Cisplatin combine with IMRT
3267240|NCT01540149||ICD implant|
3267241|NCT01540175||Participants|Participants enrolled on the study will have blood samples obtained.
3267242|NCT01540188|No Intervention|Starndard care arm|Participants of the standard care arm are control groups of IDUs and family members. They do not attend intervention sessions.
3267243|NCT01540188|Experimental|Intervention arm|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
3267244|NCT01540201|Active Comparator|1:2 group|conventional I:E ratio group, inspiratory time : expiratory time = 1:1
3267245|NCT01540201|Experimental|1:1 group|inspiratory time : expiratory time = 1:1
3267246|NCT01540214||POP surgery|All women who present with POP at the outpatient clinic of our centre and who will undergo prolapse repair surgery will be asked informed consent for participation in this study
3267247|NCT01540227||Syphilis Patients|Individuals presenting for treatment of primary, secondary or early latent syphilis at the Ottawa Hospital Immunodeficiency Clinic, the Ottawa Sexual Health Clinic or its satellite GayZone, the Montreal Chest Institute Immunodeficiency Clinic, or the Toronto General Immunodeficiency Clinic will be invited by their attending health care worker to participate in this study. Only patients presenting for and requiring treatment of infectious syphilis will be asked to participate.
3267248|NCT01540240|Active Comparator|standard dosage zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
3267249|NCT01540240|Active Comparator|low dosage zidovudine|
3267250|NCT01540253|Experimental|Treatment (enzyme inhibitor and chemotherapy)|Patients receive PI3K inhibitor BKM120 PO QD and docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3267251|NCT01540279||Cohort one with abdominal wall closure with Monocryl|
3267252|NCT01540279||Cohort two with abdominal wall closure with Monocryl plus|
3267253|NCT01540292|Experimental|MSC|Patients with Crohn's disease (refractory or intolerant to conventional therapies) treated with 2 successive injections of 1.5-2.0 x 10E6 allogenic MSC/kg BW at baseline and 4 weeks later.
3267254|NCT01540305|Active Comparator|Transcranial Magnetic Stimulation|Actual transcranial magnetic stimulation of supplementary motor areas bilaterally.
3267255|NCT01540305|Sham Comparator|Sham Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation over the supplementary motor areas.
3267256|NCT01540318|Experimental|Abdominal Ultrasound|"Patients in the experimental arm will receive a Focused Assessment with Sonography for Trauma (FAST) which includes the use of abdominal ultrasound."
3267257|NCT01540318|No Intervention|No Abdominal Ultrasound|
3267258|NCT01540331|Experimental|PNT treatment|all subjects enrolled in the study, that underwent PNT treatment
3267259|NCT01540344|Experimental|Treatment Arm|"FOLFOX/FOLFIRI + cetuximab (6 cycles)~CRS and HIPEC~FOLFOX/FOLFIRI + cetuximab (6 cycles)"
3267260|NCT01540357|Active Comparator|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
3267261|NCT01540357|Active Comparator|Treatment after waiting time|Treatment was performed after completion of the active arm.
3267262|NCT01540383|Experimental|Intensive aphasia therapy group|Group starts intensive integrative aphasia therapy within 3 workdays (or as soon as possible) after baseline exam
3267263|NCT01540383|Other|Waiting list control group|Group starts intensive integrative aphasia therapy after a waiting period of at least three weeks
3267264|NCT01540396|Active Comparator|75 Gram OGTT|The 2011 ADA criteria will be used to diagnose gestational diabetes in this study arm.
3267265|NCT01540396|Active Comparator|100 gram OGTT|A 2 step approach to the diagnosis of gestational diabetes will be used in this arm. Patients who have a 50 gram, 1 hour glucose challenge test result greater than 135 mg/dL will be diagnosed with gestational diabetes if their 3 hour, 100 gram OGTT results exceed the diagnostic threshold recommended by Carpenter and Coustan.
3267266|NCT01540422||CABG w/saphenous vein grafts harvested using endoscopy|Those who have CABG surgery with saphenous vein grafts harvested using endoscopic techniques
3267267|NCT01540435|No Intervention|Postoperative Arm (Arm A)|"FOLFOX:~Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery."
3267268|NCT01540435|Experimental|Perioperative Arm (Arm B)|"Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.~FOLFOXIRI + bevacizumab:~bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)~Duration of treatment:~Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively."
3267269|NCT01540448|Active Comparator|No-3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography but the surgeon was able to view the 3D reconstruction only after surgery.
3267270|NCT01540448|Experimental|3DCT|All patients were subjected to a CT scan with 3D mesenteric angiography and the surgeon was able to view 3D reconstruction before and during laparoscopic colorectal resection.
3267271|NCT01540461|Experimental|Arm: Brivanib|
3267272|NCT01540500|Experimental|Steady State PK Group|
3267273|NCT01540526|Experimental|Safety cohort|6 evaluable patients with RECIST measurable solid malignancies will be enrolled to establish the safety and toxicity of axitinib at 7 mg PO BID days 1-14 in 21 day cycles.
3267274|NCT01540526|Experimental|Pharmacodynamic cohort|PD cohort A: Up to 6 patients with metastatic castrate-resistant prostate cancer (evidence of soft-tissue metastases amendable to FLT-PET/CT imaging), and PD cohort B: Up to 12 patients with other solid malignancies (evidence of radiographic metastases amendable to FLT-PET/CT imaging) will be enrolled with scans obtained at baseline, peak exposure, and peak withdrawal of axitinib, in cycle#1, with repeat imaging in select patients in PD cohorts A and B at a later cycle of therapy.
3267275|NCT01540539|Experimental|Dosing cohort 1|
3267276|NCT01540539|Experimental|Dosing cohort 2|
3267277|NCT01540539|Experimental|Dosing cohort 3|
3267278|NCT01540539|Experimental|Dosing cohort 4|
3267279|NCT01540539|Experimental|Dosing cohort 5|
3267280|NCT01540539|Experimental|Dosing cohort 6|
3267281|NCT01540539|Experimental|Dosing cohort 7|
3267282|NCT01540539|Experimental|Dosing cohort 8|
3267283|NCT01540552||Budesonide Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Budesonide.
3267284|NCT01540552||Placebo Arm|Retrospective Medical Chart Review of low dose CT scans for participants who received Placebo.
3267285|NCT01540578||Observational|Archived cell samples are analyzed for replication timing by flow cytometry, microarray, and single-cell fluorescence in situ hybridization (FISH) assays. Replication-timing results among cases and controls are also analyzed.
3267286|NCT01540591|Placebo Comparator|control|Saline 0.9% IV infusion between day 4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
3267287|NCT01540591|Experimental|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
3267288|NCT01540604|Experimental|CRD007 10 mg tablet|
3267289|NCT01540617||Persons with low back pain|
3267290|NCT01540617||Healthy persons|
3267291|NCT01540630|Experimental|CNV1014802|
3267292|NCT01540630|Placebo Comparator|Placebo|
3267293|NCT01540643||Abdominal aortic aneurysm|
3267294|NCT01540656|Active Comparator|Group 1|This group will receive immediate TMNS treatment beginning at baseline and ending at the 6 week point of the study.
3267295|NCT01540656|Active Comparator|Group 2|This group will receive delayed TMNS treatment beginning at the 6 week point of the study and ending at 12 weeks.
3267296|NCT01540669|Active Comparator|Polydextrose, low dose|Polydextrose, low dose
3267297|NCT01540669|Active Comparator|Polydextrose, medium dose|Polydextrose, medium dose
3267298|NCT01540669|Active Comparator|Polydextrose, high dose|Polydextrose, high dose
3267299|NCT01540669|Placebo Comparator|Placebo powder|Placebo powder
3267300|NCT01540708|Experimental|SERETIDE Rotacaps|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a capsule-based inhaler (Rotahaler). Devices with varying airflow resistance, low, intermediate and high, will be used.
3267301|NCT01540708|Active Comparator|SERETIDE Diskus|Fluticasone propionate/Salmeterol combination administered at 2 doses (250/50 mcg and 100/50 mcg) and delivered in a multi-dose dry powder inhaler
3267302|NCT01540721|Experimental|Experimental paracetamol formulation|Experimental formulation
3267303|NCT01540721|Active Comparator|Marketed paracetamol|Marketed formulation
3267304|NCT01540734|Active Comparator|Marketed paracetamol|marketed formulation
3267305|NCT01540734|Experimental|Experimental paracetamol formulation|Experimental formulation
3267306|NCT01540747|Experimental|Inofolic plus|178 patients
3267307|NCT01540747|Active Comparator|Inofolic|180 patients
3267308|NCT01540760|Experimental|MCAF5352A|
3267309|NCT01540760|Placebo Comparator|Placebo|
3267310|NCT01540786|Experimental|Part 1: OAB subjects|
3267311|NCT01540786|Experimental|Part 2: Healthy subjects|
3267312|NCT01540786|Experimental|Part 2: OAB subjects|
3267313|NCT01540799|Experimental|Treatment|
3267314|NCT01540799|Other|Other|Stimulation not able to be felt
3267315|NCT01540812||V + Dauno+ Pred+ Metot+ Cyta+ Hc + Ida + Flud|Vincristine in induction:5 mg/m2 i.v. days 1, 8, 15 and 22 in induction phase Daunorubicin in induction 45 mg/m2 i.v. days 1, 8, 15 and 22 Prednisone in induction: 60 mg/m2/ day, i.v. o p.o., days 1 to 14; 30 mg/m2/day, i.v. o p.o., days 15 to 21; 15 mg/m2/day i.v. o p.o., days 21 to 28 Metotrexato 12 mg days 1 and 22 (intrathecal) Cytarabine (ARA-C): 30 mg days 1 and 22 (intrathecal) Hydrocortisone: 20 mg days 1 and 22 (intrathecal) Idarubicin-induction 2 12 mg/m2, i.v., days 1, 3 and 5 Fludarabine in induction-2: Fludarabine 30 mg/m2, i.v., days, 1 to 5
3267316|NCT01540864|Experimental|HPP404 35 mg|
3267317|NCT01540864|Experimental|HPP404 50 mg|
3267318|NCT01540864|Placebo Comparator|Placebo|
3267319|NCT01540877|Experimental|Capsaicin application|application of 0.6%
3267320|NCT01540877|Experimental|Local anesthetics application|application of EMLA
3267321|NCT01540877|Experimental|Combined application of 1. capsaicin 2. local anesthetics|application of 1. capsaicin 0.6% and 2. EMLA
3267322|NCT01540877|Experimental|Combined application of 1. local anesthetics and 2. capsaicin|application of 1. EMLA and 2. capsaicin 0.6%
3267323|NCT01540890||withdrawal|patients who undergo an opioid withdrawal
3267324|NCT01540890||opioids|patients on opioid medication without withdrawal
3267325|NCT01540890||opioid-free|patients with chronic pain without opioid medication
3267326|NCT01540903|Experimental|Group 1 10,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 10,000 PfSPZ administered by 2 injections of 50µL each.
3267327|NCT01540903|Experimental|Group 2 25,000 PfSPZ|12 volunteers, ID PfSPZ Challenge total dose 25,000 PfSPZ administered in 4 injections of 10µL each.
3267328|NCT01540903|Placebo Comparator|Controls - saline|4 Volunteers, ID saline administered in 2 injections of 50µL each and 2 volunteers, ID saline administered in 4 injections of 10µL each.
3267329|NCT01540916|Experimental|Hyperventilation|Minute ventilation will be increased of about 30% of baseline value, through an increase in respiratory rate
3267330|NCT01540916|Experimental|Hypoventilation|Minute ventilation will be decreased of about 30% of baseline value, through a decrease in respiratory rate
3267331|NCT01540929||Study Group|DoD Smallpox Screening Form 600 (2 part format)
3267332|NCT01540942|Active Comparator|Nutrition treat|perioperative nutrition support until the patients get the normal nutrition or disease remission
3267333|NCT01540942|Active Comparator|bowel resection|bowel resection until the patients get the normal nutrition or disease remission after bowel resection
3267334|NCT01540955|Experimental|Group Intervention program|
3267335|NCT01540955|No Intervention|Wait-list control group|The wait-list-control group will also be able to participate in the group intervention, but not until after all the study visits have been completed.
3267336|NCT01540968|Experimental|Nutrition & physical exercise|
3267337|NCT01540968|No Intervention|Control|
3267338|NCT01540994|Experimental|SBRT|Stereotactic Body Radiation Therapy
3267339|NCT01541007|Active Comparator|Standard Cabazitaxel Schedule|Cabazitaxel 25 mg/m2 every three weeks
3267340|NCT01541007|Experimental|Weekly cabazitaxel schedule|cabazitaxel 10 mg/m2 given weekly for 5 consecutive weeks of a six week cycle
3267341|NCT01541020||Healthy individuals|
3267342|NCT01541020||Individuals with low back pain|
3267343|NCT01541033||Autism with FAH|Children diagnosed with autism with first degree relatives that have autoimmune disorders.
3267344|NCT01541033||Autism without FAH|Children diagnosed with autism without first degree relatives that have autoimmune disorders.
3267345|NCT01541033||Control|Typically developing children
3267346|NCT01541046|Experimental|Biogaia L. reuteri DSM 17938|Biogaia L. reuteri DSM 17938, probiotic infant drops (5 drops=10^8 cfu),5 drops, once per day for 21 days.
3267347|NCT01541046|Placebo Comparator|Probiotic Placebo|Placebo drops (sunflower oil, medium chain triglyceride oil, silicon chloride), 5 drops, once a day for 21 days.
3267348|NCT01541059|Placebo Comparator|Placebo|Patients in this arm will have standard anesthesia with the injection of placebo solution into the vestibular of each tooth to be extracted
3267349|NCT01541059|Experimental|Ropivacaine|Patients in this arm will have general anesthesia with injection of ropivacaine into the vestibular next to each tooth to be extracted.
3267350|NCT01541072|Experimental|Pegfilgrastim|
3267351|NCT01541072|Active Comparator|Filgrastim|
3267352|NCT01541085||Darunavir/Ritonavir (DRV/r)|
3267353|NCT01541085||Efavirenz (EFV)|
3267354|NCT01541098|Active Comparator|Licensed Plasma|
3267355|NCT01541098|Experimental|Lyophilized Plasma|
3267356|NCT01541111|Other|Magnesiun, pain relief, sugar pills|Magnesiun 75mg po each 12h pain relief Sugar pills po each 12h
3267357|NCT01541124|Experimental|Morphine, Pain intensity|For cancer pain treatment, World Health Organization recomends tritation of opioids associated with non steroidal antiinflamatory drugs. This study compares the analgesic effect with diferents dosages in 63 patients with cancer pain.
3267358|NCT01541137|Active Comparator|diclofenac + IV-PCA|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine boluses, from the 2nd postoperative morning the patients were given oral diclofenac 75 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
3267359|NCT01541137|Active Comparator|parecoxib/ valdecoxib + IV-PCA|oral valdecoxib 40 mg, a 44-hour iv-infusion parecoxib 80 mg/24h, intercostal nerve block with 20 ml of 0.5% bupivacaine, IV-PCA programmed with morphine, From the 2nd postoperative morning valdecoxib 40 mg x 2, IV-PCA-morphine was discontinued after removal of pleural drains, and the patients were given oral oxycodone
3267360|NCT01541137|Active Comparator|patient controlled epidural analgesia|At the induction of anesthesia the PCEA-patients were given IV paracetamol 1g and an epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses, IV paracetamol 1g x 4 for the first 24 hours and thereafter 1g x 3 orally, PCEA was discontinued and paracetamol was replaced with ibuprofen 600 mg x 3 and oral oxycodone
3267361|NCT01541150|Active Comparator|patient suffering pedophilia|This group is the active comparator because patients suffering pedophilia with neuropsychological questionnaires
3267362|NCT01541150|Placebo Comparator|control group|This group is the placebo comparator
3267363|NCT01541163||Acute Ischemic Stroke|Patients with acute ischemic stroke admitted within 12 hours after onset.
3267364|NCT01541176|Experimental|Absence of corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) without corticotherapy post-transplantation.
3267365|NCT01541176|Active Comparator|Corticotherapy post-transplantation|All patients included in this arm will receive the usual treatment strategy (including Advagraf, Cellcept ou Myfortic and Simulect) with corticotherapy post-transplantation : prednisone or prednisolone orally for at least one year post-transplantation.
3267366|NCT01541189|Experimental|valsartan|After 1-week screening period, all of the eligible patients receive valsartan 80mg/day for 2 weeks, then the dosage will be titrated to 160mg/day for further 8 weeks therapy for all of the subjects.
3267367|NCT01541202|Placebo Comparator|Placebo|placebo in addition to standard therapy
3267368|NCT01541202|Experimental|rhNRG-1|rhNRG-1 in addition to standard therapy
3267369|NCT01541228|Active Comparator|Group I|Patients with actinic keratosis (AK) on the left and right sides of face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
3267370|NCT01541228|Active Comparator|Group II|Patients with actinic keratosis (AK) on the left and right sides of the face/scalp region treated with photodynamic therapy using 20% 5-aminolevulinic acid.
3267371|NCT01541241||copper IUD used|"Group I: includes 50 cases using CIUD and complaining of menorrhagia or menometrorrhagia.~Group II: includes 50 cases using CIUD and not complaining of abnormal uterine bleeding."
3267372|NCT01541267|Active Comparator|C - A - B|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3267373|NCT01541267|Active Comparator|B - A - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3267374|NCT01541267|Active Comparator|A - B - C|(A) telmisartan 80 mg + aliskiren 300 mg - (B) telmisartan 80 mg + eplerenon 50 mg - (C) telmisartan 160 mg
3267375|NCT01541293|Experimental|Intrauterine Lidocaine|The experimental arm will receive 100mg lidocaine (5mL of 2% concentration) instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
3267376|NCT01541293|Placebo Comparator|Intrauterine Saline|Placebo arm will receive 5mL of normal saline instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
3267377|NCT01541306||achondroplasia or hypochondroplasia|Children or adults with achondroplasia or hypochondroplasia
3267378|NCT01541319||Randomized to <= 10day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored no more than 10 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
3267379|NCT01541319||Randomized to >= 21day RBCs & transfused|Subjects in the RECESS study who were randomized to receive red blood cell (RBC) units stored at least 21 days, and who received at least one RBC transfusion between randomization and 96 hours after the cardiac surgery ends
3267380|NCT01541319||Randomized but not transfused|Subjects randomized in the RECESS study who did not receive any red blood cell units between randomization and 96 hours after the end of surgery
3267381|NCT01541319||Healthy volunteers|
3267382|NCT01541332|Experimental|Pomalidomide + PLD + Dexamethasone|Pomalidomide + Pegylated Liposomal Doxorubicin + Dexamethasone in an open label, dose escalation study
3267383|NCT01541436|Active Comparator|Capsaicin, UV-B, RIPC|
3267384|NCT01541436|Sham Comparator|Capsaicin, UV-B|
3267385|NCT01541449||RA patients treated with plaquenil|
3267386|NCT01541449||Patients who do not use plaquenil|
3267387|NCT01541462|Active Comparator|Pressure support|Patients randomized to the pressure support arm will wean using pressure support ventilation. The level of pressure support will be decreased by 2 cm H2O every 6 hours. The maximum decrement in pressure support permitted in one day will be 6 cm H2O.
3267388|NCT01541462|Active Comparator|Spontaneous Breathing|Patients randomized to spontaneous breathing arm will be disconnected from the ventilator and allowed to breathe spontaneously through the tracheostomy. Duration of the trial will be increased sequentially as tolerated.
3267389|NCT01541475|Experimental|Escitalopram + Bupropion|
3267390|NCT01541475|Active Comparator|Escitalopram|
3267391|NCT01541488|Experimental|BI 1021958|Single rising dose (SRD) part
3267392|NCT01541488|Experimental|BI 1021958 (Food effect)|Food effect part (FE)
3267393|NCT01541488|Placebo Comparator|Placebo to BI 1021958|Matching placebo as drinking solution and tablets
3267394|NCT01541501||Pachymetry|All recruited volunteers in present study, that underwent pachymetry measurement with four different instruments
3267395|NCT01541527||severe, moderate and mild HA patients|one Arm: biological collection of 300 severe, moderate and mild HA patients
3267396|NCT01541540|Experimental|e-Counseling plus Usual Care|
3267397|NCT01541540|Active Comparator|e-Info Control plus Usual Care|
3267398|NCT01541566||Home blood pressure telemonitoring|Patients regularly monitoring their blood pressure at home with an electronic validated upper arm device, transmitting blood pressure values at monthly intervals to the doctors office through the Internet.
3267399|NCT01541566||Conventional blood pressure measurement|Blood pressure measured only in the doctor's office during quarterly visits, without regular home blood pressure monitoring.
3267400|NCT01541579|Experimental|Treatment Arm|Cx601 is a cell suspension in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given at a dose of 120 million cells (5 million cells / mL) for intralesional injection.
3267401|NCT01541579|Placebo Comparator|Placebo-control group|Placebo (saline solution) will be given also for intralesional injection at the same quantity (volume, 24 mL) and following the same schedule.
3267402|NCT01541592|Active Comparator|Saturated fat|Palm oil (rich in the saturated fat palmitate)
3267403|NCT01541592|Active Comparator|Monounsaturated fat|Olive oil (rich in the monounsaturated fat oleate)
3267404|NCT01541592|Active Comparator|Polyunsaturated fat|Safflower oil (rich in the polyunsaturated fat linoleate)
3267405|NCT01541605|Active Comparator|methylphenidate|
3267406|NCT01541605|Placebo Comparator|placebo|
3267407|NCT01541618||Tysabri Group|Patients with a diagnosis of relapsing remitting multiple sclerosis (RRMS) who is about to begin Natalizumab (Tysabri) therapy for a relapse in clinical symptoms (either diagnosed clinically or via gadolinium MRI).
3267408|NCT01541631|Experimental|HIV-1 co-infected with schistosoma mansoni|HIV-1 patients co-infected with Schistosoma mansoni
3267409|NCT01541631|No Intervention|HIV-1 positive individuals with negative S. mansoni|HIV-1 positive individuals with negative Schistosoma mansoni
3376669|NCT05103618|Active Comparator|Active Couple Pairs Parkinson's Group|"15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD.~The female subject will undergo the baseline scan. Both members of the couple will complete surveys. The active group will receive training materials in the practice of OM which they will be asked to practice for the next 2-3 months The active couple-pair will begin the OM practice initially (in between the baseline and follow up). FDOPA scans will be conducted with female members with PD the couple pair at approximately 2-3 months."
3376670|NCT05103618|Other|Waitlist Couple Pairs Parkinson's Group|15 Couple pairs (30 subjects) in which one female member has a diagnosis of PD. The female subject will undergo the baseline scan. Both members of the couple will complete surveys The waitlist period in which the female member with PD will continue to receive standard of care for those 2-3 months; who then receive follow up scan. After the follow up scan, the waitlist group may be trained in the practice of OM for the next two months (but there will not be an additional FDOPA scan). Couple-pairs in the waitlist group will be asked to complete surveys at baseline and follow up scan and again after completing the OM Meditation practice. Couple pairs will engage in OM Meditation together approximately 3-4 times a week after the baseline and follow up scans for 2-3 months but female subjects with PD will not receive and additional post OM Meditation FDOPA scan
3267410|NCT01541631|Experimental|Schistosoma mansoni positive but HIV-1 negative|Schistosoma mansoni positive individuals but HIV-1 negative to be compared with HIV-1 co-infected with Schistosoma mansoni individuals
3267411|NCT01541631|No Intervention|HIV-1 and Schistosoma mansoni negative|Individuals with no HIV-1 and S. mansoni infections
3267412|NCT01541657|No Intervention|Control Group|This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
3376671|NCT05098873||Group gifted teens|
3267413|NCT01541657|Experimental|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
3376672|NCT05098873||Group no gifted teens|
3376673|NCT05098509|Active Comparator|RAD011 high dose|
3376674|NCT05098509|Active Comparator|RAD011 medium dose|
3376675|NCT05098509|Active Comparator|RAD011 low dose|
3376676|NCT05098509|Placebo Comparator|Placebo|
3376677|NCT05097235||t0|acute low back pain, inclusion criteria.
3376678|NCT05096221|Experimental|SRP-9001 followed by Placebo|Participants will receive single intravenous (IV) infusion of SRP-9001 on Day 1. Then, participants will receive a single IV infusion of matching placebo at Year 2.
3376679|NCT05096221|Placebo Comparator|Placebo followed by SRP-9001|Participants will receive matching placebo IV infusion on Day 1. Then, participants will have the opportunity to receive a single IV infusion of SRP-9001 at Year 2.
3376680|NCT05096039||Treatment Group 1 (use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
3376681|NCT05096039||Treatment Group 2 (use of ACEI or ARB and no use of sacubitril/valsartan)|Beneficiaries with one or more prescription claim with an NDC for any ACEI/ARB and no prescription claims for sacubitril/valsartan during the 90-day episode window (for BPCA) and CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
3376682|NCT05096039||Treatment Group 3 (no use of ACEI, ARB, or sacubitril/valsartan)|Beneficiaries who did not qualify for Group 1 or Group 2 were assigned a value of '1'; patients that did not meet this criteria were assigned a value of '0'
3376683|NCT05096039||Cohort Group 1 (Overall cohort)|"The beneficiaries who met the inclusion criteria and were divided into the three treatment groups were considered Cohort Group 1 or the overall cohort."
3376684|NCT05096039||Cohort Group 2 (subgroup 1)|Patients with evidence of systolic HF defined as: having at least 2 medical claims (on different dates) with an ICD-9/-10 diagnosis code for systolic HF in any position during the lookback period and/or during the entire 90-day episode window (for BPCA) and CY2017 and/or CY2018 (for MSSP). Patients who met these criteria were assigned a value of '1'; patients that did not meet these criteria were assigned a value of '0'
3376685|NCT05096039||Cohort Group 3 (subgroup 2)|Patients with evidence of Heart Failure Reduced Ejection Fraction (HFrEF) identified based on a published algorithm
3376687|NCT05093569||Iteration|35 patients will be included in 4 iterations.
3376690|NCT05090696||One group only|Participants recruited from patients hospitalized in intensive care units and pulmonary unit of the University Hospital of Clermont-Ferrand, France.
3376691|NCT05088629|Other|One group|3-meter Walk Back Test, Proprioception, Trunk Control and Muscle Strength test
3376692|NCT05084651|Experimental|Group 1|Each participant will receive a single oral dose of ganaplacide and lumefantrine combination on Day 1 of Period 1. In Period 2, participants will receive itraconazole q.d. on Days 1 to 18 and a single dose of ganaplacide and lumefantrine combination on Day 5, approximately 2 hours after the itraconazole dose
3267414|NCT01541657|Experimental|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
3267415|NCT01541657|Experimental|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
3267416|NCT01541670|Experimental|Open-label Dose-Escalation Arm|Conducted in an ascending dose manner, subjects will be assigned to single- or multiple-dose administration of the investigational product
3267417|NCT01541683|Experimental|Halls|every patient will drink 4 Liters of PEG solution (FORTRANS®) split into 2 days with sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy with Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure with Halls®).
3267418|NCT01541683|Other|no Halls|Every patient will drink 4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
3267419|NCT01541696||Group B|subjects in this group will receive Micronutrient Supplements only.
3267420|NCT01541696||Group C|Subjects in this Group will receive Micronutrient Supplements plus Zinc.
3267421|NCT01541709|Experimental|Imatinib|
3267422|NCT01541761|Experimental|Family groups|Intervention group members will participate in family groups focused on early childhood obesity prevention in addition to standard care from pediatricians at the primary care clinic.
3267423|NCT01541761|No Intervention|Standard care|Mothers enrolled into the control group will continue to receive care from their pediatrician in the primary care clinic.
3267424|NCT01541774|Experimental|Phoenix Atherectomy System|
3267425|NCT01541800||Patients|All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age
3267426|NCT01541813||iron overloads except C282Y homozygosity|Patients with an iron overloads except C282Y homozygosity
3267427|NCT01541839|Experimental|Septal Stapler|This group will have closure of their nasal septal flaps via septal stapler.
3267428|NCT01541839|No Intervention|Control (Suture)|This arm will have closure of their nasal septal flaps as routinely performed with suture passed in a quilting fashion.
3267429|NCT01541852|Active Comparator|Losmapimod|7.5mg tablet twice daily
3267430|NCT01541852|Placebo Comparator|Placebo|One tablet twice daily
3267431|NCT01541904|Experimental|Arm A. PRO-118/Placebo 0.015%,0.020%|
3267432|NCT01541904|Experimental|Arm B. PRO-118/Placebo 0.015%,0.020%|
3267433|NCT01541904|Experimental|Arm C. PRO-118/Placebo 0.015%,0.020%|
3267434|NCT01541904|Experimental|Arm D. PRO-118/Placebo 0.015%,0.020%|
3267435|NCT01541904|Placebo Comparator|Arm E PRO-118/Placebo 0.015%,0.020%|
3267436|NCT01541943|Experimental|HL-040XC|Once daily, administered orally, 8 week
3267437|NCT01541943|Active Comparator|Atorvastatin|Once daily, administered orally, 8 week
3267438|NCT01541943|Active Comparator|Losartan|Once daily, administered orally, 8 week
3267439|NCT01541943|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
3267440|NCT01541956|Active Comparator|metformin up titration|metformin 500 mg bid will be up titrated (total daily dose up to 2000 mg)
3267441|NCT01541956|Experimental|vildagliptin add on to metformin|Vildagliptin 50 mg twice daily + Metformin 500mg twice daily
3267442|NCT01541982||virtual and classic autopsy|"Goldstandard: A group of patients in which virtual and classic autopsy is performed."
3267443|NCT01541982||virtual autopsy only|"Intervention: A group of patients in which for various reasons virtual autopsy only is performed."
3267444|NCT01541995||virtual and classic autopsy|Patients where contrast medium enhanced post mortem CT and classic autopsy will be performed.
3267445|NCT01541995||virtual autopsy only|Patients where only contrast medium enhanced post mortem CT will be performed.
3267446|NCT01542008|Experimental|Customized Adherence Enhancement (CAE)|This arm will receive the CAE intervention.
3267447|NCT01542008|Active Comparator|broad non-individualized education (EDU)|This arm will receive the EDU intervention.
3267448|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 4± 1|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy
3267449|NCT01542021|Experimental|Untreated patients degarelix injection occur at days and 7± 1.|Treatment will consist of a single 240 mg injection of degarelix 7±1 day before radical prostatectomy
3267450|NCT01542021|Experimental|treated patients with androgen deprivation|Patients already treated with androgen deprivation are assigned to Cohort 3 and maintained on current androgen deprivation therapy until they undergo or have already undergone RP at MSKCC. Will include patients who have already undergone hormonal therapy (of any duration between 1 and 6 months) prior to prostatectomy.
3267451|NCT01542021|Experimental|Untreated patients degarelix injection occur at days 14±1|Treatment will consist of a single 240 mg injection of degarelix 14±1 day before radical prostatectomy
3267452|NCT01542047|Experimental|Carboplatin AUC5 + escalating pazopanib|Carboplatin AUC5 IV Day 1 Pazopanib in escalating dosages, 200 mg to 800 mg starting on days 2 or 3 and ending on days 19 or 21
3267453|NCT01542060||BIAsp 30 users|
3267454|NCT01542073|Experimental|68Ga-BNOTA-PRGD2 cardiac PET/CT scanning|We will perform 68Ga-BNOTA-PRGD2 cardiac PET/CT scanning on myocardial infarction patients to determine its value.
3267455|NCT01542086|Active Comparator|Myocardial SPECT|
3267456|NCT01542086|Experimental|64-channel coronary CT angiography (CCTA)|
3376693|NCT05081557||Participants Receiving Upadacitinib|Participants receiving upadacitinib for atopic dermatitis.
3376698|NCT05078411|Other|Patients without a history of tooth loss due to periodontitis (NTLP)|
3376699|NCT05078411|Other|Patients with a history of tooth loss due to periodontitis (TLP)|
3376700|NCT05075772|Experimental|BI 765080 - Administration mode 1 (T)|Subcutaneous (SC) injection (Test, T)
3376701|NCT05075772|Experimental|BI 765080 - Administration mode 2 (R)|Intravenous (IV) infusion (Reference, R)
3376706|NCT05070650|Experimental|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution|Acetylcysteine/Paracetamol/Phenylephrine 200 mg/500 mg/10 mg granules for oral solution: one sachet three times per day
3376707|NCT05070650|Active Comparator|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution|Paracetamol/Phenylephrine 500 mg/10 mg granules for oral solution: one sachet three times per day
3376712|NCT05063227||Study group|As this is a single-group, observational study all patients will be monitored with all three nociception monitoring systems (the Surgical Pleth Index (SPI), the Pupillary Pain Index (PPI) and the Nociception Level (NOL)) and data on heart rate changes as a variable used in current clinical practice to choose the opioid dosage during general anesthesia will be obtained additionally.
3376714|NCT05061862||CIED Indicated Subjects|Subjects indicated to receive a cardiac implantable electronic devices (CIEDs)
3376715|NCT05061693|Experimental|INCB054707 Dose A|Participants will receive INCB054707 Dose A for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
3376716|NCT05061693|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
3376717|NCT05061693|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
3376718|NCT05061693|Placebo Comparator|Placebo followed by INCB054707 Dose B or C|Participants will receive placebo for 16 weeks (Period 1), followed by INCB054707 Dose B (responders) or by INCB054707 Dose C (partial or nonresponders) for 24 weeks (Period 2).
3376719|NCT05061563|Experimental|Period 1|A single dose of elinzanetant and an additional IV (microtracer dose) of [13C5]BAY 3427080 will be administered.
3376720|NCT05061563|Experimental|Period 2|Once daily oral dose of esomeprazole and a single oral dose of elinzanetant will be administered.
3376721|NCT05056233|Experimental|Systane Hydration|Systane Hydration lubricant eye drops dosed 4 times a day for 6 weeks (2 weeks prior to surgery and 4 weeks post surgery), with investigator defined post-operative standard of care
3376722|NCT05056233|No Intervention|No Treatment|Investigator defined post-operative standard of care
3376723|NCT05052333||Examining the psychosocial impacts of Covid-19 in Pakistan.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Urdu-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3376724|NCT05052333||Examining the psychosocial impacts of Covid-19 in Iraq.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Arabic-English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3376725|NCT05052333||Examining the psychosocial impacts of Covid-19 in Turkey.|This is exploratory research and data will be obtained on a set of measures (N=500) using a unilingual (Turkish) survey with longitudinal assessment after 3 weeks of initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3376726|NCT05052333||Examining the psychosocial impacts of Covid-19 in USA.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (English) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3376727|NCT05052333||Examining the psychosocial impacts of Covid-19 in Bangladesh.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Bangla) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3376728|NCT05052333||Examining the psychosocial impacts of Covid-19 in Malaysia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a bilingual (Malay-English) survey. Data will be obtained longitudinally after 12 months of initial assessment. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3267457|NCT01542099|Active Comparator|Single lumen tube|Single lumen tube intubation during remifentanil infusion
3267458|NCT01542099|Active Comparator|Double lumen tube|Double lumen tube intubation during remifentanil infusion
3267459|NCT01542112|Experimental|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
3267460|NCT01542112|Experimental|No treament|Usual routine in the department
3267461|NCT01542138|Active Comparator|Niacinamide|4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.
3267462|NCT01542138|Active Comparator|Desonide|Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation
3267463|NCT01542138|Placebo Comparator|Placebo|Humectant placebo cream
3267464|NCT01542151|Active Comparator|Morning|Women randomized to a labor induction in the morning between 0600 and 1000.
3267465|NCT01542151|Experimental|Evening|Women randomized to a labor induction begun in the evening between 1700-2100
3267466|NCT01542177||Pancreatic cancer|
3267467|NCT01542190|Active Comparator|ketorolac tromethamine|
3267468|NCT01542190|Placebo Comparator|Dextrano 70 / Hypromellose|
3267469|NCT01542203||Breast Cancer, Various BMIs|18 female breast cancer patients who are normal weight (body mass index [BMI] < 25 kg/m2, overweight or class I obese(BMI 25-34.9 kg/m2), or class II-III obese (BMI > 35 kg/m2).
3267470|NCT01542216|Placebo Comparator|Yoga and Stretching Group|Patients undergo yoga and stretching exercises
3267471|NCT01542216|Active Comparator|Nutrition and Exercise Group|Patients are provided with nutrition, cardiovascular exercise and strength exercise consultations
3267472|NCT01542242|Experimental|Liraglutide|Treatment of Diabetes Mellitus Type 2 with Liraglutide in the setting of Prader Willi Syndrome
3267473|NCT01542268|Active Comparator|pentoxifylline|
3267474|NCT01542268|Placebo Comparator|pentoxifylline placebo|
3267475|NCT01542281|Experimental|Nutritional supplementation and prehab|The first group (pre-hab) will receive both nutritional supplementation and a prehabilitation program.
3267476|NCT01542281|Active Comparator|Prehab exercise|
3267477|NCT01542294|Experimental|treatment|s1+oxaliplatin
3267478|NCT01542320|Experimental|Probiotic|Lactobacillus reuteri DSM 17938
3267479|NCT01542320|Placebo Comparator|Placebo|Solution without the active probiotic Lactobacillus reuteri
3267480|NCT01542346|Experimental|wound closure with subcutaneous adaption|
3267481|NCT01542359|Experimental|Yoga|"The integrated yoga program was designed to: 1) include the three primary elements of yoga as most commonly practiced in western cultures (physical postures, breath control and meditation); and 2) be appropriate for those without any prior yoga experience and with pre- and Stage I hypertension. The yoga program was designed by Eddie Stern, Founder and Director of Ashtanga Yoga New York (AYNY) in consultation with Drs. Hagins and Rundle, and are in large part congruent with the yoga program we studied previously (see Preliminary Studies). The yoga class includes: instruction on yogic principles regarding moral precepts (yamas and niyamas); active postures requiring mild-moderate physical exertion; conscious control of the breath in synchrony with active postures; and meditation. We expect approximately 10-15 minutes of the integrated yoga program to consist of isolated practice of meditation (occurring independently of the moving postures, typically in seated or lying positions)."
3267482|NCT01542359|Active Comparator|Conventional Exercise|Conventional exercise such as standing toe touch with arm swings, curl ups, push ups, leg lifts, etc. All done at a relatively slow rate which will be non-aerobic and at an average rate across the session of 3 METs
3267483|NCT01542385|Active Comparator|Immediate stenting|the stent selection (bare metal vs drug eluting) and implantation will be performed as recommended by current practice guidelines.
3267484|NCT01542385|Experimental|Delayed stenting|participants randomised to delayed stenting will be treated with GPIIb-IIIa inhibitors for 12-18 hours after reperfusion followed by anticoagulation for until the control angiogram, expected no sooner than 18-24 hours after the index reperfusion.
3267485|NCT01542411||recurrent pregnancy loss|
3267486|NCT01542411||thrombophilia, aspirin|
3267487|NCT01542411||heparin|
3267488|NCT01542424||BIAsp 30 users|
3267489|NCT01542424||IDet users|
3267490|NCT01542437|Experimental|BIBW 2992|Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
3267491|NCT01542450|Experimental|Treatment period 1|
3267492|NCT01542450|Active Comparator|Treatment period 2|
3267493|NCT01542463||IDet users|
3267494|NCT01542476||IDet users|
3267495|NCT01542489||IDet + IAsp users|
3267496|NCT01542489||IDet + HI users|
3267497|NCT01542515||Osteoarthritis of the carpometacarpal joint of the thumb|The group of patients enrolled in this study all have the diagnosis of carpometacarpal arthritis of the thumb. The patients did not respond favorably to non-operative management including oral anti-inflammatory medications, corticosteroid injections, and thumb splinting. Operative management was therefore recommended using the technique of meniscal allograft arthroplasty.
3267498|NCT01542554|Experimental|Low glycaemic index diet|
3267499|NCT01542554|Active Comparator|Usual diabetic diet|
3267500|NCT01542567|Active Comparator|diclofenac|suppositories to prevent BCG side effects
3267501|NCT01542567|Placebo Comparator|placebo suppositories|
3267502|NCT01542580||Vanguard SSK 360 with PS Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized (non-constrained) tibial bearing.
3267503|NCT01542580||Vanguard SSK 360 with PSC Bearing|Patients enrolled using a Vanguard SSK 360 Posterior-Stabilized Constrained tibial bearing.
3267504|NCT01542580||Vanguard DA 360|Patients enrolled using a Vanguard DA 360 component.
3267505|NCT01542580||Vanguard 360 TiNbN Femur with PS Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
3267506|NCT01542580||Vanguard 360 TiNbN Femur with PSC Bearing|The Vanguard 360 TiNbN is the same system and functions in the same manner as the non-coated device.
3267507|NCT01542593|Experimental|Ureteral catheterization|"During a planned procedure involving ureteroscopy or ureteral stenting, ureteral catheterization will be performed for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
3267508|NCT01542606|Experimental|color status|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
3267509|NCT01542619|Experimental|rVIIa-FP|
3267510|NCT01542619|Placebo Comparator|Placebo (0.9% normal saline)|
3267511|NCT01542658||uterine myoma|
3267512|NCT01542671|Experimental|Intervention|Lifestyle counseling at baseline, six, twelve months; Food and exercise log recording and feedback, motivational phone calls monthly for 12 months, 4 tailored mailings on lifestyle change, and weekly mailings on weight loss, exercise, and healthy eating for first 12 months. Maintenance mailings biweekly for six months and then monthly during the second year.
3267513|NCT01542671|Placebo Comparator|Control|Lifestyle counseling at baseline, six and twelve months similar to intervention group, and infrequent non-tailored pamphlets.
3267514|NCT01542697|Active Comparator|Magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline at the end of surgery before closure
3267515|NCT01542697|Placebo Comparator|normal saline|intraperitoneal nebulisation of 5 ml of normal saline after end of surgery before closure
3267516|NCT01542710|Experimental|Glaucoma fixed Combination Medications|
3267517|NCT01542723|Experimental|LMWH|750 patients with an arthroscopy or the knee will be randomized to receive treatment with a LMWH
3267518|NCT01542723|No Intervention|No intervention|750 patients with an arthroscopy of the knee will be randomized to receive no treatment.
3267519|NCT01542736|Experimental|Reduced radiation with concurrent chemotherapy|Reduced dose craniospinal radiation with concurrent carboplatin and vincristine administration
3267520|NCT01542762|Experimental|LMWH|750 patients with lower leg cast immobilization will be randomized tot receive treatment with a LMWH.
3267521|NCT01542762|No Intervention|No intervention|750 patients with lower leg cast immobilization will be randomized tot receive no treatment with LMWH.
3267522|NCT01542775|Placebo Comparator|Control|
3267523|NCT01542775|Active Comparator|Exercise|
3267524|NCT01542801|Active Comparator|Norfloxacin|norfloxacin 400 mg once daily administration
3267525|NCT01542801|Experimental|Ciprofloxacin|Ciprofloxacin 750 mg per week
3267526|NCT01542814||Fujifilm 3Dimensional Mammography|Group of subjects being given Fujifilm 3D Mammography Imaging
3267527|NCT01542814||2D FFDM|Group of Subjects receiving FujiFilm or other FDA Approved 2D Mammography Imaging
3267528|NCT01542827|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
3267529|NCT01542827|Experimental|Biofreeze|Biofreeze topical gel containing 3.5% menthol
3267530|NCT01542866|Experimental|Home Monitoring Test|Health management tool (HMT) for measuring vision impairment
3267531|NCT01542879|Experimental|WB-DW-MR scan|simultaneous WB-DW-MR scan and 18-F FDG PET scan
3267532|NCT01542892|Experimental|Supplement|
3267533|NCT01542892|Sham Comparator|Placebo|
3267534|NCT01542892|Experimental|Exercise|
3267535|NCT01542905|Experimental|Korean Red Ginseng|
3267536|NCT01542905|Placebo Comparator|Placebo|
3267537|NCT01542918|Experimental|Study intervention|Lenalidomide Plus Rituximab
3267538|NCT01542931|No Intervention|Surgery and radiotherapy|Surgery and post-operative radiotherapy.
3267539|NCT01542931|Experimental|TPF induction chemotherapy|Induction chemotherapy before surgery: docetaxel, cisplatin, and 5-fluorouracil.
3267540|NCT01542944|Experimental|TevaGastrim|treatment with TevaGastrim for allogeneic stem cell collection
3267541|NCT01542970|Placebo Comparator|Placebo|Placebo for both L. reuteri and omega-3 fatty acids.
3267542|NCT01542970|Experimental|L. reuteri and placebo|Active Lactobacillus reuteri and placebo for omega-3 fatty acids
3267543|NCT01542970|Experimental|Omega-3 fatty acids and placebo|Placebo for L. reuteri and active for omega-3 fatty acids
3267544|NCT01542970|Experimental|L. reuteri and omega-3 fatty acids|Active L. reuteri and active omega-3 fatty acids
3267545|NCT01542983|Active Comparator|Treatment-as-usual|Treatment as usual for fatigue and insomnia
3267546|NCT01542983|Active Comparator|Behavioral treatment|Brief behavioral treatment for insomnia and bright light Light and BBTI combined treatment for insomnia and fatigue
3267547|NCT01543009|No Intervention|Emla + no additional intervention|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) without warming
3267548|NCT01543009|Experimental|Emla + Local Warming|Children in this arm will receive standard preparation of the venipuncture site (local analgesia with Emla) plus warming with a heating pad at 40°C for 5 minutes
3267549|NCT01543022|Experimental|Symphony system|
3267550|NCT01543035|Experimental|Etravirine switch|Patients in need of lipid-lowering drug switched from boosted PI or EFV to Etravirine
3267551|NCT01543048||Women with CIN3 treated by conization|
3267552|NCT01543061|Active Comparator|New study eye drop|One month of contact lens wear with use of the Test study eye drops
3267553|NCT01543061|Placebo Comparator|No Eyedrop|One month of contact lens wear with no eye drop use
3267554|NCT01543061|Active Comparator|BLINK Contacts Lubricating eye drop|One month of contact lens wear with use of the Control study eye drops
3267555|NCT01543100|Experimental|monoclonal gamopathy|"Patients with monoclonal gammopathy either MGUS or myeloma at diagnosis or more than 3 months after a first myeloma treatment with chemotherapy and/or antiangiogenic drugs.~Patient's age ≥18 yo,~Patients having signed the specific consent of the study."
3267556|NCT01543113|Other|melanoma|melanoma
3267557|NCT01543126||pleural effusion|patients with pleural effusion
3267558|NCT01543139|Experimental|Valproate+Cytidine-+Creatine-|The subjects with bipolar depression, treated with cytidine- and creatine-containing drug and dietary supplement in addition to valproate
3267559|NCT01543139|Active Comparator|Valproate+Cytidine-|The subjects with bipolar depression, treated with cytidine-containing drug and dietary supplement in addition to valproate
3267560|NCT01543139|Active Comparator|Valproate|The subjects with bipolar depression, treated with valproate
3267561|NCT01543165|Experimental|Group 1|Sequential intravenous administration of ketorolac and nefopam
3267562|NCT01543165|Active Comparator|Group 2|Sequential intravenous administration of ketorolac and morphine
3267563|NCT01543165|Placebo Comparator|Group 3|Intravenous administration of ketorolac
3267564|NCT01543191|Experimental|PUR118|
3267565|NCT01543191|Placebo Comparator|Placebo|
3267566|NCT01543217|Active Comparator|Control|Ususal care.
3267567|NCT01543217|Active Comparator|Intervention|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
3267568|NCT01543230|Experimental|CoMplete™ Acetabular Hip System (CoM)|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
3267569|NCT01543243|Experimental|Group 1|"Group 1: immediate effects: T0, Stochastic resonance whole-body vibration A intervention, immediate T1 (one minute after Stochastic resonance whole-body vibration B intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration intervention, immediate T3 (one minute after Stochastic resonance whole-body vibration intervention)~long term effect: T4, Stochastic resonance whole-body vibration A intervention over four weeks, three time a week;T5, 16 days wash-out period; T6, Stochastic resonance whole-body vibration B intervention over four weeks, three times week, T7"
3267570|NCT01543243|Experimental|Group 2|"Group 2: immediate effect: T0, Stochastic resonance whole-body vibration B intervention, immediate T1 (one minute after intervention), 7 days wash-out period; T2, Stochastic resonance whole-body vibration A intervention, immediate T3 (one minute after intervention)~Long term effect: T4, Stochastic resonance whole-body vibration B intervention over four weeks, three time a week;T5, 16 days wash-out period;T6, Stochastic resonance whole-body vibration A intervention over four weeks, three times week, T7"
3267571|NCT01543256|Active Comparator|Metal stents|The WallFlex Biliary Fully Covered Stent System is being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
3267572|NCT01543256|Active Comparator|Plastic Stents|Plastic stents per Investigator preference are being evaluated for treatment of benign biliary strictures secondary to chronic pancreatitis.
3267573|NCT01543269|Active Comparator|ZYT1 tablets|ZYT1 tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
3267574|NCT01543269|Placebo Comparator|Placebo|Placebo tablets: Route of administration: Oral Dosage: 0.5mg, 1mg, 2 mg, 4mg, 8 mg, 16mg, 32mg and 64mg
3267575|NCT01543282|Active Comparator|EUS 22 gauge needle|EUS 22 g needle is the most common needle used in clinical practice. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
3267576|NCT01543282|Experimental|EUS 25 gauge needle|25 gauge needle is usually used less frequently but nowadays is increasingly used and is as well a valid option. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
3267577|NCT01543295||Known Positive Syphilis Infection|Individuals known to have a clinical diagnosis of Syphilis
3267578|NCT01543295||High Risk for Syphilis Infection|Individuals with previous and confirmed STD infection, MSM, persons with high risk sexual behavior or clinical examination with classic manifestations of syphilis.
3267579|NCT01543295||Pregnant Women (High Risk and Low Risk)|"1st or 3rd trimester from either High Risk (see description above) or Low Risk population.~Low Risk are individuals not known to belong to any of the defined high-risk groups - i.e. healthy patients presenting for routine physicals or other unrelated non-life threatening illnesses, or individuals from a general low risk population such as students, employees of academic or other institutions, etc…"
3267580|NCT01543308||coronary heart disease|
3267581|NCT01543308||healthy control group|
3267582|NCT01543321|Experimental|Tetrabenazine group|Tetrabenazine is a drug that is administered orally. This is 25 mg tablets, divisible into 2.
3267583|NCT01543321|Placebo Comparator|Plagebo group|Patients will receive a buccal tablet identical to the experimental product
3267584|NCT01543334||Patients|Patients with a vein or artery catheter and who are being administered antibiotics. The latter can be of the following: Amoxicillin-clavulanic acid, ampicillin, piperacillin-tazobactam, penicillin G, flucloxacillin, dicloxacillin, cloxacillin, cefazolin, ceftazidime, ceftriaxone, cefepime, meropenem, imipenem, doripenem, ertapenem; Vancomycin, teicoplanin. (see inclusion/exclusion criteria).
3267585|NCT01543347|Experimental|Temocillin|Treatment group
3267586|NCT01543360|Active Comparator|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein).
3267587|NCT01543360|Active Comparator|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein).
3267588|NCT01543373|Experimental|CRE8 arm|
3267589|NCT01543373|Active Comparator|Vision/Multilik8 arm|
3267590|NCT01543386|Other|curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
3267591|NCT01543399|Experimental|Tibolone use|climacteric women will use Tibolone for 30 days
3267592|NCT01543399|Placebo Comparator|Placebo use|climacteric women will use placebo for 30 days
3267593|NCT01543412|Experimental|FOLFIRI|Folfiri consist of Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1and 2, 5-FU 400 mg/m2 iv bolus on day 1and 2, 5-FU 600 mg/m2 iv by ci for 22 hours on day 1 and 2, repeated every 2 wks The use of antiemetic prophylaxis was decided locally.
3267594|NCT01543438|No Intervention|Control|current standard of care
3267595|NCT01543438|Experimental|Intervention Group|receives video prescription
3267596|NCT01543451|Experimental|Elsiglutide|
3267597|NCT01543451|Placebo Comparator|Placebo|
3267598|NCT01543464|Experimental|Vaccine+adjuvants+temozolomide treatment|Experimental arm
3267599|NCT01543477||Single group|
3267600|NCT01543516||Patients with Asthma|"Affected patients~-20 Patients suffering from asthma with an eNO over 30 bbp"
3267601|NCT01543516||Healthy Subjects|"Non-affected patients~-20 matched controls not suffering from asthma"
3267602|NCT01543529|Active Comparator|RO4917838 + non-alcoholic drink|
3267603|NCT01543529|Experimental|RO4917838 + alcohol|
3267604|NCT01543529|Placebo Comparator|RO4917838 placebo + alcohol|
3267605|NCT01543529|Placebo Comparator|RO4917838 placebo + non-alcoholic drink|
3267606|NCT01543542|Other|Radiation Therapy Treatment|Whole Brain XRT 30Gy/10 fractions with Simultaneous Infield Boost of Brain Lesions to 60Gy
3267607|NCT01543555|Experimental|Atorvastatin active|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
3267608|NCT01543555|Placebo Comparator|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
3267609|NCT01543620||Patients with cystic fibrosis treated with aminoglycosides|
3267610|NCT01543620||Patients with cystic fibrosis not treated with aminoglycosides|
3267611|NCT01543633|Experimental|Active Study Arm|Subjects recruited into this study will be required to undergo a base MRI scan of the brain. On a separate day propofol will be administered with concurrent EEG while subjects respond to stimuli.
3267612|NCT01543646||Liver Biopsy patients|All patients due to have a liver biopsy for the assessment of parenchymal liver disease.
3267613|NCT01543659|Experimental|89Zr-DFO-huJ591|Registered patients will undergo a baseline FDG PET scan up to 14 days before administration of a single dose of the 89Zr-DFO-huJ591 tracer, this scan is considered for research purposes. The exception to the 14-day timeframe is that patients who have already had an FDG PET scan up to 4 weeks prior to registration are not required to repeat the FDG PET scan on study.
3267614|NCT01543672|Experimental|SBRT group A|escalate MLD in medically inoperable patients with tumors larger than 5 cm in diameter (primary or solitary metastases)
3267615|NCT01543672|Experimental|SBRT group B|Escalate the MLD in patients with ≥ 2 lung metastases
3267616|NCT01543698|Experimental|dual combination|LGX818 QD and MEK162 BID
3267617|NCT01543698|Experimental|triple combination|LGX818 QD and MEK162 BID and LEE011 QD 3 weeks on, 1 week off.
3267618|NCT01543711||Breast cancer survivors|Women treated for breast cancer, without signs of recurrence or metastasis
3267619|NCT01543724|Experimental|Lithium|
3267620|NCT01543737|Active Comparator|Single injection hyaluronic acid|3ml hyaluronic acid (DUROLANE)
3267621|NCT01543737|Active Comparator|Three injection hyaluronic acid|2ml hyaluronic acid (HYALGAN)
3267622|NCT01543750|Experimental|Study Medication|4-aminopyridine 10mg twice daily for 8 weeks
3267623|NCT01543750|Experimental|Placebo|placebo twice daily for 8 weeks
3267624|NCT01543763|Experimental|Panobinostat with PC124871|
3267625|NCT01543789|Experimental|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity
3267626|NCT01543789|Active Comparator|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
3267627|NCT01543802|Experimental|Pazopanib|
3267628|NCT01543815|Experimental|WBT-WEB|Well-Being Therapy based on Web Mobile technology
3267629|NCT01543815|Active Comparator|CBT|Cognitive Behavior Therapy
3267630|NCT01543815|No Intervention|CM|Standardized Care Management
3267631|NCT01543841||Advanced Cancer|Patients with histologically confirmed metastatic or unresectable solid tumors will have one tube of whole blood (~6mL) collected at the time of venipuncture for routine sample collection. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
3267632|NCT01543841||Healthy Volunteers|Eligible volunteers will have one tube of whole blood (~6mL) collected. The sample will undergo in vitro stimulation of TEMs with ANG 1 and 3 in the presence or absence of pharmalogic inhibitors, and flow cytometry analysis.
3267633|NCT01543854|Experimental|RLX030|RLX030 as intravenous infusion for 20 hours
3267634|NCT01543854|Placebo Comparator|Placebo|Matching placebo as intravenous infusion for 20 hours.
3267635|NCT01543867||Users of somatropin|
3267636|NCT01543880||Users of somatropin|
3267637|NCT01543893|Experimental|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
3267638|NCT01543893|Active Comparator|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
3267639|NCT01543906|Experimental|QLT091001|oral QLT091001 administered once daily for 7 days
3267640|NCT01543919|Experimental|PH-787904 (arm1)|
3267641|NCT01543919|Experimental|PH-787904 (arm2)|
3267642|NCT01543919|Experimental|PH-787904 (arm3)|
3267643|NCT01543919|Experimental|PH-787904 (arm4)|
3267644|NCT01543919|Experimental|PH-787904 (arm5)|
3267645|NCT01543919|Experimental|Placebo|
3267646|NCT01543932|Experimental|Prasugrel standard dose|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
3267647|NCT01543932|Experimental|high clopidogrel dose|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 15 days and 30 days we will control the responsivness of the study drug.
3267648|NCT01543932|Experimental|Ticagrelor standard dose|Patient will be randomized to this intervention will receive in the first time ticagrelor and after 15 days and 30 days we will control the responsivness of the study drug.
3267649|NCT01543945|Experimental|Multimodal antiemetic management group|Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg
3267650|NCT01543945|Active Comparator|Control group|Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv
3267651|NCT01543971|Active Comparator|TXA127|(Group A) TXA127 at 300 mcg/kg once a day for 5 days
3267652|NCT01543971|Active Comparator|Neupogen|(Group B) Neupogen 10 mcg/kg once a day for 5 days
3267653|NCT01543971|Active Comparator|TXA127 and Neupogen|(Group C) both TXA127 (300mcg/kg) and Neupogen (10mcg/kg) together once a day for 5 days
3267654|NCT01543984|Experimental|Tailored Physical Activity|"Health guidance (1,5h) and Tailored Physical Activity (3*50 min/week in 10 weeks)"
3267655|NCT01543984|Other|Reference group|Health Counselling (1,5h)
3267656|NCT01543997|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP)to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
3267657|NCT01543997|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
3267658|NCT01544010|No Intervention|assessment only control group|Assessment at baseline, 12, and 24 months
3267659|NCT01544010|Active Comparator|Minimal Stage Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Stage Tailored Feedback Reports based on assessments at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3267660|NCT01544010|Active Comparator|Moderate TTM Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Moderate TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance and temptations at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3267661|NCT01544010|Active Comparator|Full TTM tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Full TTM-Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3267662|NCT01544010|Active Comparator|Enhanced TTM+Addiction Tailoring|This group will receive a Stage-Tailored Manual at baseline. It will also get Enhanced TTM+Addiction Tailored Feedback Reports, that is, integrated tailored feedback reports based on assessments of addiction levels (# cigarettes/day) stage of change, decisional balance (pros + cons), temptations and (ten) processes of change at Baseline, 6, and 12 months. Outcomes will be assessed at 24 months.
3267663|NCT01544036|Experimental|Contrast Enhanced Ultrasound|Renal blood flow before and after exposure to iodinated contrast agent (perflutren) also known as Definity will be measured using contrast enhanced ultrasound (CEUS).
3267664|NCT01544049||Fallopian tube removal|Women who have had one or both fallopian tube(s) removed as method of ovarian cancer prevention.
3267665|NCT01544075|Experimental|PNE+PI|The interventional group who will receive the experimental PNE+PI treatment.
3267666|NCT01544075|Active Comparator|NS|The control group who will receive the neck school treatment.
3267667|NCT01544101|Experimental|Vegan Diet|
3267668|NCT01544101|Placebo Comparator|Supplement|
3267669|NCT01544140|Experimental|midazolam then midazolam + vandetanib|Midazolam alone followed by midazolam in combination with vandetanib
3267670|NCT01544192|Active Comparator|retinal nerve fiber thickness|
3267671|NCT01544192|Active Comparator|Mean Deviation|
3267672|NCT01544192|Active Comparator|Pattern Standard Deviation|
3267673|NCT01544192|Active Comparator|ganglion cell count|
3267674|NCT01544192|Active Comparator|c/d ratios|
3267675|NCT01544205|Experimental|Emotion network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to positive affective pictures (as identified during a functional localiser scan).
3267676|NCT01544205|Active Comparator|Place processing network up-regulation|Participants use fMRI-based neurofeedback to train the upregulation of brain areas that respond to place and house pictures (as identified during a functional localiser scan).
3267677|NCT01544218||YCMC|Youth ages 9-18 with one of four chronic medical conditions - asthma, diabetes, rheumatic or gastroenterologic conditions
3267678|NCT01544231||Patients|Adult patients with suspected rhabdomyolysis admitted to the participating University Hospital emergency rooms (see inclusion/exclusion criteria).
3267679|NCT01544244|Experimental|GSC physcial therapy|Patients included in this arm of the study will follow the Global Shoulder Concept physical therapy sequence.
3267680|NCT01544244|Active Comparator|Standard|Patients in this arm of the study will follow the standard physical therapy sequence.
3267681|NCT01544257|Experimental|OMT|patients under standard medical care plus OMT.
3267682|NCT01544257|No Intervention|Control|patients under standard medical care plus only osteopathic evaluation
3267683|NCT01544270|Active Comparator|Study product containing milk proteins|Yoghurt-like milk-based product
3267684|NCT01544270|Active Comparator|Study product containing probiotics|Yoghurt-like milk-based product
3267685|NCT01544270|Placebo Comparator|Control product|Yoghurt-like milk-based product without supplemented nutrients
3267686|NCT01544283|Experimental|Patch|Patch will be applied directly to the lateral tip of the affected shoulder, at the site of maximal tenderness. Subjects will apply a single patch at home approximately every 12 hours (e.g., morning and evening patch applications) for 14 days. Subjects will remove each patch after 4 hours. Subjects will have the option of applying the Synera patch as needed for an additional 2 week period (weeks 2-4) if they feel their shoulder impingement pain is severe enough to warrant treatment. Patches will be applied every 12 hours for up to 4 hours as needed during this period.
3267687|NCT01544283|Active Comparator|Subacromial Injection|A single injection will be administered into the subacromial space utilizing triamcinolone acetonide at the baseline visit.
3267688|NCT01544296|Experimental|KHK6188, high dose|
3267689|NCT01544296|Experimental|KHK6188, low dose|
3267690|NCT01544296|Placebo Comparator|Placebo|
3267691|NCT01544374|Experimental|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
3267692|NCT01544374|No Intervention|Control- no intervention|Usual Care
3267693|NCT01544387|Other|Bed Rest|Subjects will have limited activity. Bed Rest
3267694|NCT01544387|Other|Activity|Activity
3267695|NCT01544413|Experimental|Laparoscopic sentinel lymph node biopsy|This is a single armed study. After endoscopic marking using Tc99m HSA and indocyanine green fluid, Laparoscopic sentinel lymph node biopsy was performed and evalute at backtable.
3267696|NCT01544426|Experimental|Office hysteroscopy and endometrial snip|Office hysteroscopy and endometrial snip
3267697|NCT01544426|Active Comparator|Office hyteroscopy|Office hysteroscopy
3267698|NCT01544439|Experimental|Oral stabilization appliance,counselling|The reversible occlusal therapy by stabilizing appliance used by patients in Study Group shall be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. Patients receive oral and written instructions about self-care (counseling), including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
3267699|NCT01544439|Placebo Comparator|Non-occluding splint, counselling|The non-occlusive splint (placebo) will also be made by the same dental technician. They differ by the plates did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. As not lead acrylic on the occlusal surfaces of teeth, adequate retention is given by an arch wire in orthodontic buccal surface of teeth. All patients will submitted a counseling approach / self-care. Patients receive oral and written instructions about self-care, including, in addition to instructions on their condition of TMD and an explanation of the possible factors that contribute to the etiology of the same.
3267700|NCT01544452|Other|Total preoperative MR evaluation|Total diagnostic evaluation with MRI of the liver, abdomen, colonography and rectum in one session combined with CT thorax
3267701|NCT01544452|Other|Standard diagnostic evaluation|Standard preoperative diagnostic evaluation for patients with rectal cancer, incl. CT thorax, abdomen and MRI of the rectum and colonoscopy
3267702|NCT01544465|Experimental|Structured physical activity|Rehabilitation evaluation followed by physical therapy for approximately 8 weeks
3267703|NCT01544465|Active Comparator|Sleep hygiene education|Sleep hygiene education consists of educational materials on insomnia published by the American Academy of Sleep Medicine.
3267704|NCT01544504|Experimental|Norepinephrine|Topical norepinephrine
3267705|NCT01544517|Experimental|5d-QCT|5-day eradication regimen consisting in the concomitant administration of esomeprazole 40mg bid + amoxicillin 1g bid + levofloxacin 500mg bid + tinidazole 500mg bid
3267706|NCT01544517|Active Comparator|10-day sequential regimen|5 days of esomeprazole 40mg bid + amoxicillin 40mg bid followed by 5 more days of esomeprazole 40mg bid + levofloxacin 500mg bid + tinidazole 500 mg bid
3267707|NCT01544530|Experimental|Hypothermia (32-33 degree C)|Following randomization, hypothermia will be induced by a combination of cold isotonic fluid and sustained until organ procurement by a central venous catheter
3267708|NCT01544530|No Intervention|Normothermia (36.5 - 37.5 degree C)|Normothermia will be maintained until organ procurement as per current standard of care
3267709|NCT01544543||COPD Exacerbation Cohort|Patients hospitalized for a COPD exacerbation
3267710|NCT01544556||Prineo|An open, prospective, controlled, randomized clinical Study
3267711|NCT01544556||Steristrips|An open, prospective, controlled, randomized clinical Study
3267712|NCT01544608||Subjects who are hospitalized due to acute psychotic episode.|All subjects who are hospitalized due to acute psychotic episode. The subjects should be managed according to normal clinical practice until discharge time.
3267713|NCT01544621||Successful quitters Sustained smokers|Successful quitters
3267714|NCT01544634|Experimental|Propranolol + Low dose Qvar|
3267715|NCT01544634|Active Comparator|Placebo + high dose Qvar|
3267716|NCT01544647|Active Comparator|Usual spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
3267717|NCT01544647|Active Comparator|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
3267718|NCT01544660||Scanning|no treatment
3267719|NCT01544660||scanning|no treatment
3267720|NCT01544673|Active Comparator|Arm A|
3267721|NCT01544673|Placebo Comparator|Arm B|
3267722|NCT01544686|Active Comparator|3M™ Tegaderm CHG IV|Patients receive the 3M Tegaderm CHG IV securement dressing after placement of a central venous catheter.
3267723|NCT01544686|Placebo Comparator|3M™ Tegaderm™ Advanced IV'|Patients receive the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
3267724|NCT01544699|Active Comparator|Real stimulation|real tDCS (well, that's the way it is I am not gonna change it)
3267725|NCT01544699|Sham Comparator|Sham|sham tDCS
3267726|NCT01544712|Active Comparator|Control|Core decompression
3267727|NCT01544712|Experimental|Bone marrow|core decompression plus autologous concentrated bone marrow
3267728|NCT01544725|Experimental|Ketamine-propofol|
3267729|NCT01544725|Active Comparator|Ketamine alone|
3267730|NCT01544738|Experimental|Aponeurotic stimulation group|The stimulation consisted of manipulating, with a hook (the diacutaneous fibrolysis method), the aponeurotic tissues enrobing the heads of the trunk and upper limb muscles.
3267731|NCT01544738|Active Comparator|Placebo stimulation group|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the Aponeurotic stimulation group.
3267732|NCT01544751|Active Comparator|Low dose Metformin|500 mg twice a day for one year
3267733|NCT01544751|Active Comparator|Metformin|1000 mg twice a day for one year
3267734|NCT01544751|Active Comparator|Atorvastatin|20 mg day
3267735|NCT01544764|No Intervention|Control|This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
3267736|NCT01544764|Experimental|AFIX In-Person Visit|"This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
3267737|NCT01544764|Experimental|AFIX Webinar Visit|"This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.~Intervention:~Other: Assessment , Feedback, Incentives, and eXchange Program"
3267738|NCT01544777|Experimental|Both Eyes|Model 751 IOL implanted in both eyes.
3267739|NCT01544777|Experimental|Single eye|Model 751 IOL in one eye
3267740|NCT01544777|Active Comparator|Control|Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
3267741|NCT01544790|Experimental|Robot-assisted esophagectomy|Robot-assisted thoraco-laparoscopic esophagectomy with gastric conduit formation.
3267742|NCT01544790|Active Comparator|Open transthoracic esophagectomy|traditional open transthoracic esophagectomy with gastric conduit formation.
3267743|NCT01544803|No Intervention|Control group|
3267744|NCT01544803|Experimental|Web based self-monitoring|
3267745|NCT01544803|Active Comparator|Web based self-help|
3267746|NCT01544816|Placebo Comparator|Control Food Product|Control food product
3267747|NCT01544816|Experimental|Experimental Food Product 1|Experimental food product 1
3267748|NCT01544816|Experimental|Experimental Food Product 2|Experimental food product 2
3267749|NCT01544829|Active Comparator|Active Comparator: Single serving of theobromine|
3267750|NCT01544829|Active Comparator|Multiple servings of theobromine|
3267751|NCT01544829|Placebo Comparator|Placebo capsules|
3267752|NCT01544842|Active Comparator|Tacrolimus|Tacrolimus ointment 0.1%, three times a day for 6-9 weeks.
3267753|NCT01544842|Active Comparator|Triamcinolone|Triamcinolone paste 0.1%, three times a day for 3-6 weeks.
3267754|NCT01544842|Placebo Comparator|Placebo|Orabase paste, three times a day for 3-6 weeks.
3267755|NCT01544855|Experimental|APOE4 carriers|The results obtained for APOE4 carriers will be compared to the one obtained from APOE4 non-carriers. Carriers are defined as being at least carrier of one APOE4 allele.
3267756|NCT01544868|Other|Energy expenditure measurement|Descriptive measurements
3267757|NCT01544881|Experimental|TI Inhalation Powder|Technosphere Insulin Inhalation Powder using the Gen2C inhaler
3267758|NCT01544881|Active Comparator|RAA|Rapid Acting Analog
3267759|NCT01544894|Active Comparator|raloxifene|60 mg/d for one year.
3267760|NCT01544894|Active Comparator|strontium ranelate|2 g/d for one year.
3267761|NCT01544907|Active Comparator|Conventional PTA only|"Treatment Arm 1- Conventional PTA only~The conventional balloon is used and the diameter of the balloon should be the same or oversized by 1mm the diameter of the reference vessel.~An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 2 minutes.~At the end of the first angioplasty, an AVFistulogram/AVGraftogram will be obtained to document results. If there is residual stenosis of >30%, a repeat angioplasty using the same balloon or another appropriately oversized balloon by 1mm will be used for an additional 2 minutes. A final angiogram will be obtained for documentation."
3267762|NCT01544907|Experimental|Drug Eluting Balloon (DEB)|"Treatment arm 2 - Conventional Balloon with DEB~A Conventional balloon is used to pre-dilate the target lesion. The DEB of a similar diameter to the conventional balloon used is then inflated across the stenosis. An inflation device with a pressure gauge is used to inflate up to manufacturers' stated burst pressure. The duration of balloon inflation will be 1 minute. A final angiogram will be obtained for documentation. The drug coated on the DEB is Paclitaxel."
3267763|NCT01544933||burst fractures in vertebrae with true ribs|between T1 and T10
3267764|NCT01544933||burst fractures in vertebrae with floating ribs|between T11 and T12
3267765|NCT01544946|Experimental|sucrose po|
3267766|NCT01544946|Placebo Comparator|placebo po|
3267767|NCT01544959|Active Comparator|fentanyl|
3267768|NCT01544959|Experimental|beta-blocker|Instead of narcotics (fentanyl), esmolol and lopressor are being used for hemodynamic control
3267769|NCT01544972|Active Comparator|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days
3267770|NCT01544972|Active Comparator|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
3267771|NCT01544985|Experimental|sucrose po|88% sucrose solution (Syrup B.P.)
3267772|NCT01544985|Placebo Comparator|placebo po|sterile water
3267773|NCT01545011|No Intervention|standard|conventional respiratory rehabilitation
3267774|NCT01545011|Experimental|IMT|Inspiratory muscle training and conventional respiratory rehabilitation
3267775|NCT01545024||DPP-IV inhibitor|
3267776|NCT01545037|Active Comparator|Probiotic capsules|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks.
3267777|NCT01545037|Placebo Comparator|Placebo capsules|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria. Dosage of 2 capsules per day , corresponding to 100 billions bacterias for a period of 12 weeks
3267778|NCT01545050|Experimental|Induction Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
3267779|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(600 IV/200 SC mg)|
3267780|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(300 IV/100 SC mg)|
3267781|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(150 IV/100 SC mg)|
3267782|NCT01545050|Experimental|Induction Cohort: BMS-945429 (Clazakizumab)(400 SC/200 SC mg)|
3267783|NCT01545050|Experimental|Maintenance Cohort: Placebo matching with BMS-945429 (Clazakizumab)|
3267784|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(100 SC mg)|
3267785|NCT01545050|Experimental|Maintenance Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
3267786|NCT01545050|Experimental|Open Label Cohort: BMS-945429 (Clazakizumab)(200 SC mg)|
3267787|NCT01545089|Experimental|Mattress protector days 1,2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
3267788|NCT01545089|Experimental|Mattress protector days 3,4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
3267789|NCT01545154||Prostate Cancer|
3267790|NCT01545167||African Americans with pancreatitis|pancreatitis
3267791|NCT01545167||African Americans without Pancreatitis controls|people without pancreatitis
3267792|NCT01545180||HTPcap in IC|HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.
3267793|NCT01545206||acute STEMI, Primpary PCI|
3267794|NCT01545219|Experimental|Prebiotic|
3267795|NCT01545219|Experimental|Probiotic|
3267796|NCT01545219|Experimental|Synbiotic|
3267797|NCT01545219|Placebo Comparator|Placebo|
3267798|NCT01545245||Treated|Palivizumab treated
3267799|NCT01545245||Untreated|Palivizumab untreated
3267800|NCT01545258|Experimental|Exercise|Exercise training supervised by trained physiotherapists lasting 60 minutes performed 3 times/week.
3267801|NCT01545258|No Intervention|Control|
3267802|NCT01545271|Experimental|72h cooling + 18h xenon inhalation|Babies in poor condition at birth and referred to our neonatal unit for standard therapy of cooling to 33.5 degree C body temperature will be randomised to receive xenon gas at 50% concentration for 18 hours
3267803|NCT01545271|Active Comparator|Standard 72 h whole body cooling therapy|Whole body cooling therapy to rectal temperature of 33.5 degree Centigrade (standard therapy)
3267804|NCT01545284|Experimental|Acitretin|Patients will receive acitretin once daily for a maximum of 24 weeks. Patients who reach a Physician Global Assessment (PGA) of clear or almost clear at week 12 will end the study. Patients who do not reach a PGA of clear or almost clear at week 12 will continue treatment up to week 24. The starting dose will be 10mg/day and, if well tolerated, it will be increased in the first 4 weeks to a maximum of 30 mg/day.
3267805|NCT01545297|Active Comparator|Propofol-Remifentanil|Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
3267806|NCT01545297|Experimental|Dexmedetomidine|Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
3267807|NCT01545310|Experimental|Group 1 (healthy), Group 2 (schizophrenia)|
3267808|NCT01545323|Experimental|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
3267809|NCT01545349|Experimental|LGG|Lactobacillus rhamnosus GG (LGG) containing 1x10^10 LGG per capsule will be given to subjects with verbal and written instructions at the baseline visit. Capsules are to be taken orally twice a day on an outpatient basis.
3267810|NCT01545349|Placebo Comparator|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis.
3267811|NCT01545362||Staged bilateral total knee arthroplasty|Patients that have bilateral total knee arthroplasty staged within one week
3267812|NCT01545401|Experimental|EMPOWER-PAR Intervention|"The intervention arm receives the EMPOWER-PAR intervention package consisting of:~Chronic Disease Management (CDM) Training Workshops for the staff in the respective clinics~The Global CV Risks Self-Management Booklet (patient self-management tool) to empower patients to self-manage their CV risk factors~Facilitation and support of the staff in these clinics so that they may implement the interventions"
3267813|NCT01545401|No Intervention|Control|"The control arm continues with usual care.~The EMPOWER-PAR intervention package will be made available after the trial ends."
3267814|NCT01545414|Experimental|ICBT|Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
3267815|NCT01545414|Active Comparator|ICONTROL|Internet-based treatment with a focus on relaxation training
3267816|NCT01545414|No Intervention|SMT|Standard Medical Treatment while being on the waitlist for randomization to any of the active treatments
3267817|NCT01545427|Experimental|Gleevec|Gleevec 200 mg bid for 6 months.
3267818|NCT01545427|Placebo Comparator|Placebo|Placebo coated to appear identical to Gleevec.
3267819|NCT01545440|Experimental|lebrikizumab - highest dose|
3267820|NCT01545440|Experimental|lebrikizumab - lowest dose|
3267821|NCT01545440|Experimental|lebrikizumab - middle dose|
3267822|NCT01545440|Placebo Comparator|placebo|
3267823|NCT01545453|Experimental|lebrikizumab - highest dose|
3267824|NCT01545453|Experimental|lebrikizumab - lowest dose|
3267825|NCT01545453|Experimental|lebrikizumab - middle dose|
3267826|NCT01545453|Placebo Comparator|placebo|
3267827|NCT01545466|Experimental|Mindfulness Based Stress Reduction|Participants will complete an 8 week course in Mindfulness Based Stress Reduction (MBSR), meeting once/week for 8 weeks and having a 4-6 hour retreat after the 6th class
3267828|NCT01545466|No Intervention|Wait-List Control Group|These participants will continue in usual care during the trial and will be offered the intervention of MBSR after the trial is over.
3267829|NCT01545479|Other|Captopril 25mg|To study the renal blood oxygenation, the subjects took captopril (25mg).
3267830|NCT01545492||Tight|"Children born to women in the CHIPS RCT randomized to Tight blood pressure control [target diastolic BP 85mmHg]"
3267831|NCT01545492||Less Tight|"Children born to women in the CHIPS RCT randomized to Less Tight [target diastolic BP 100mmHg]."
3267832|NCT01545505|Other|In remission phase of PTSD|Patients having suffered from PTSD in the past and in remission od PTSD and their parents
3267833|NCT01545505|Other|Activ PTSD|patients suffering from PTSD (Post-traumatic Stress Disorder) and their parents
3267834|NCT01545531||Iohexol GFR|
3267835|NCT01545557|Experimental|Hyaluronic acid|
3267836|NCT01545570|Active Comparator|GSK2376497|single dose escalation or multiple-dose titration
3267837|NCT01545570|Placebo Comparator|0.9% sodium chloride|placebo injection
3267838|NCT01545596|Experimental|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
3267839|NCT01545596|No Intervention|No Notification|No additional notification given to anesthesia team apart from the information on their monitors.
3267840|NCT01545609|Experimental|Text messaging|Text messaging
3267841|NCT01545609|No Intervention|No intervention|No intervention
3267842|NCT01545635|Active Comparator|Coagulation factor concentrates|
3267843|NCT01545635|Active Comparator|Fresh Frozen Plasma|
3267844|NCT01545661|Experimental|Sputum induction|Enrolled patients receive sputum induction (using ultrasonic nebulisation with hypertonic saline)
3267845|NCT01545661|Active Comparator|No sputum induction|Enrolled patients randomised to this study arm will receive an observed expectorated sputum collection attempt. Research nurses train study patients on the method of producing sputum spontaneously.
3267846|NCT01545674||Pregnant Women Blood Draw|Pregnant Women with elevated risk of trisomic pregnancy to donate a blood sample through one time blood draw
3267847|NCT01545687|Experimental|Arm I|Patients dissolve in mouth 1 lozenge of Lactobacillus bevis CD2 every 2-3 hours (total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and for 4 weeks after, including weekends.
3267848|NCT01545687|Placebo Comparator|Arm II|Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per day) daily during CRT and for 4 weeks after, including weekends.
3267849|NCT01545713||Renal Transplant Recipients|Patients undergoing living-donor kidney transplant at NMH who have a positive XM-One AbSorber® positive test result.
3267850|NCT01545726|Experimental|QAW039|Eligible patients will receive QAW039 po 450 mg daily dose.
3267851|NCT01545726|Placebo Comparator|Placebo|Placebo to QAW039 (oral capsules) will be administered to match QAW039 schedule.
3267852|NCT01545739||CRT pacemaker implantation|
3267853|NCT01545752|No Intervention|coventional group|Teaching just by book
3267854|NCT01545752|Experimental|non-interactive CD|Teaching book with non-interactive CD
3267855|NCT01545752|Experimental|interactive CD|Teaching book with interactive CD
3267856|NCT01545778||Tapentadol IR|
3267857|NCT01545778||Oxycodone IR|
3267858|NCT01545791||Insulin detemir users|
3267859|NCT01545804|Experimental|Lenalidomide|
3267860|NCT01545830|Active Comparator|Regular Dose|Intervention: 600 IUs of cholecalciferol taken by mouth daily.
3267861|NCT01545830|Experimental|High Dose D|Intervention: 6,000 IUs of cholecalciferol taken by mouth daily.
3267862|NCT01545856||New levodopa users|Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 but no previous levodopa prescriptions prior to study period
3267863|NCT01545869|Experimental|Fractional carbon dioxide laser|
3267864|NCT01545882|Experimental|Degarelix|Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
3267865|NCT01545908|Placebo Comparator|placebo enema|Participants in this arm undergo 6 retention enemas, week 1, week 2, week 3, week 4, week 5, week 6
3267866|NCT01545908|Active Comparator|Fecal transplant from an unrelated donor|Participants in this arm undergo 6 retention enemas,week 1, week 2, week 3, week 4, week 5, week 6,using stool specimen prepared from a healthy, screened donor.
3267867|NCT01545921|Experimental|Arm A|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month until death"
3267868|NCT01545921|Experimental|Arm B|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month until death"
3267869|NCT01545921|Experimental|Arm C|"Patients will complete QoL questionnaires in the following order :~MVQOLI, then QLQ-C15-PAL, then QUAL-E, evaluation every month and spontaneous QoL completion, until death"
3267870|NCT01545921|Experimental|Arm D|"Patients will complete QoL questionnaires in the following order :~QLQ-C15-PAL, then MVQOLI, then QUAL-E, evaluation every month and spontaneous QoL completion, until death."
3267871|NCT01545947|Experimental|CC-223/erlotinib concurrent|Cohorts will receive escalating continuous daily doses (15 mg and 30 mg) of CC-223 in capsules concurrently with at least two different daily dose levels of erlotinib tablets (100 mg and 150 mg) in 28-day cycles.
3267872|NCT01545947|Experimental|CC-223/oral azacitidine concurrent|Cohorts will receive escalating continuous daily doses of CC-223 (15 mg and 30 mg) with one or more dose levels of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Day 1 to 21 of each 28-day cycle.
3267873|NCT01545947|Experimental|CC-223/oral azacitidine sequential|Cohorts will receive escalating continuous daily dose levels of CC-223 (15 mg and 30 mg) administered on Days 8 through 28 sequentially with one or more dose levels of of oral azacitidine (200 mg or 300 mg, as two or three 100 mg tablets) administered on Days 1 to 7 of each 28-day cycle
3267874|NCT01545960||Healthy Volunteers|
3267875|NCT01545973||Healthy Volunteers|Human subjects without chronic medical conditions, defined as conditions requiring chronic medication use.
3267876|NCT01545986|Experimental|High Velocity Exercise|The high velocity exercise group performed the concentric contraction phase of resisted exercise in one second or less. This group performed sit to stand exercise, walking, curbs, and stairs as fast as was comfortable without an increased limp. Other exercises were performed at the participant preferred rate.
3267877|NCT01545986|Active Comparator|Low Velocity exercise|The low velocity exercise group performed the concentric contraction phase of resisted exercise in two seconds. This group performed sit to stand exercise, walking, curbs, stairs, and other exercises at the participant preferred rate.
3267878|NCT01545999|Active Comparator|PAS 25|In humans, paired associative stimulation (PAS-25) is a transcranial magnetic stimulation (TMS) protocol that has been shown to result in LTP-like plasticity (PAS-LTP) in the motor cortex (M1). PAS-LTP has been shown to be dependent on the NMDAR and to correlate significantly with performance on a motor learning task.
3267879|NCT01545999|Sham Comparator|PAS 100|To control for non-specific effects of PAS protocol, the investigators will use a modified PAS protocol (PAS-100) that does not result in any neurophysiologic effects. Patients with schizophrenia and healthy controls will be assessed first with the N-back task and then randomized
3267880|NCT01546012|Experimental|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
3267881|NCT01546012|Active Comparator|HYLO-COMOD®:|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
3267882|NCT01546025|Placebo Comparator|Relaxation training|
3267883|NCT01546025|Active Comparator|Brief Motivational Counseling|
3267884|NCT01546051|Experimental|BCI-838 Food Effect Dosing Arm 1|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3267885|NCT01546051|Experimental|BCI-838 Fasted Dosing (100 & 300 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3267886|NCT01546051|Experimental|BCI-1038, BCI-1206 & BCI-1283|Six subjects will be enrolled, all 6 will receive single doses of BCI-1038, BCI-1206 and BCI-1283.
3267887|NCT01546051|Experimental|BCI-838 Fasted Dosing (900 mg)|Eight subjects will be enrolled, 6 will receive BCI-838 and 2 will receive matching placebo.
3267888|NCT01546064|Active Comparator|Bile duct anastomosis with T-tube|
3267889|NCT01546064|Active Comparator|Bile duct anastomosis without T-tube|
3267890|NCT01546077|Active Comparator|Hydrolocalization technique group|Technique of placement of popliteal perineural catheter using the hydrolocalization technique with ultrasound
3267891|NCT01546077|Active Comparator|Stimulating Catheter technique group|A technique for placement of popliteal catheter with the aid of a neurostimulator
3267892|NCT01546090|Experimental|alprazolam|Alprazolam is a short-acting anxiolytic of the benzodiazepine class of psychoactive drugs
3267893|NCT01546090|Placebo Comparator|placebo|placebo capsules were filled with starch
3267894|NCT01546103|Active Comparator|Vitamin D3 supplementation of 1000 IU|
3267895|NCT01546103|Active Comparator|Vitamin D3 supplementation of 5000 IU|
3267896|NCT01546116|Experimental|Adefovir and lamivudine combination|
3267897|NCT01546129|Experimental|Dianatal Obstetric Gel|Standard of care according to the established Guidelines of the Department plus use of Dianatal applied with a vaginal applicator in stage I and stage II of labor
3267898|NCT01546129|No Intervention|Control|Standard of care according to the established Guidelines of the Department.
3267899|NCT01546181||Controls|subjects older than 10 years old, with no know ocular or general disease
3267900|NCT01546181||Age-related macular degeneration|
3267901|NCT01546181||inherited retinal dystrophies|
3267902|NCT01546181||retinal trauma|
3267903|NCT01546181||toxic retinopathies|
3267904|NCT01546181||arterial hypertensive patients|
3267905|NCT01546181||diabetic patients|
3267906|NCT01546181||inflammatory diseases|
3267907|NCT01546220|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3267908|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3267909|NCT01546233||multidisiplinary self care program|Patient with Lung cancer will be participated in group education with multidisiplinary self care program
3267910|NCT01546233||Conventional education|Lung cancer patient will be received standard education
3267911|NCT01546246|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3267912|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3267913|NCT01546259|No Intervention|Air colonoscopy|Colonoscopy will be performed without medications and with judicious air insufflation during colonoscope insertion.
3267914|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope.
3267915|NCT01546272|Experimental|Resorbable staples|Suture using Insorb Resorbable staples
3267916|NCT01546272|Active Comparator|Resorbable wires|Suture using Monocryl resorbable wire
3267917|NCT01546311||lower limb amputees|
3267918|NCT01546324||Pregnant women|Women pregnant following the use of Natera's PGS/PGD testing
3267919|NCT01546350|No Intervention|Control - regular ART treatment|patients will have up to two embryos replaced on day 5 based on morphological and developmental characteristics, and the other embryos reaching blastocyst stage will be vitrified. If patients in the control group do not have a pregnancy to term from that fresh cycle, they will be offered free PGD either for the frozen embryos of that cycle or for the next cycle (up to the center and patient). Data from that PGD is not part of the study.
3267920|NCT01546350|Experimental|Test - PGD|patients will have grade A,B or C blastocysts hatched on day 5, biopsied on day 5, analyzed by array CGH, and a single euploid embryo transferred on day 6. Any morulas developing to grade A,B or C blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
3267921|NCT01546363||Validation|
3267922|NCT01546363||Testing|
3267923|NCT01546376||HIV-cancer patients who recived RT|
3267924|NCT01546389|Experimental|Cohort 3, Group E|Cohort 3 (High Dose, Low Aliquot), Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose); 5 subjects
3267925|NCT01546389|Experimental|Cohort 1, Group A|Cohort 1 (Medium Dose, Medium Aliquot), Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose); 5 subjects.
3267926|NCT01546389|Experimental|Cohort 1, Group B|Cohort 1 (Medium Dose, Medium Aliquot), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose); 5 subjects
3267927|NCT01546389|Experimental|Cohort 3, Group F|Cohort 3 (High Dose, Low Aliquot), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose); 5 subjects
3267928|NCT01546389|Experimental|Cohort 2, Group D|Cohort 2 (Medium Dose, Low Aliquot), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose); 5 subjects
3267929|NCT01546389|Experimental|Cohort 2, Group C|Cohort 2 (Medium Dose, Low Aliquot), Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose); 5 subjects
3267930|NCT01546415|Experimental|Desferasirox|
3267931|NCT01546428|Experimental|INC280|
3267932|NCT01546441|Experimental|interprofessional assessment|patients receive an interprofessional assessment in a team environment
3267933|NCT01546441|Active Comparator|usual care|Usual care in family practice
3267934|NCT01546467|Experimental|Cognitive remediation|30 hour computer based cognitive remediation integrated in participants current rehabilitation program (school, work, day program)
3267935|NCT01546467|No Intervention|Wait list control group|Participant continues in treatment/rehabilitation program as usual until 9 month assessment when participant receives the same cognitive remediation program as the experimental group.
3267936|NCT01546480||Pain patients|Patients with unexplained chronic abdominal pain 12 months after elective cholecystectomy
3267937|NCT01546480||Operated painfree Patients|Painfree patients 12 months after elective cholecystectomy
3267938|NCT01546480||Nonoperated painfree patients|Painfree patients with no previous abdominal operation
3267939|NCT01546493|Experimental|Controls|Asymptomatic control subjects with no deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis.
3267940|NCT01546493|Experimental|Symptomatics|Subjects with bilateral cam deformity and unilateral symptoms. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
3267941|NCT01546493|Experimental|Asymptomatic|Asymptomatic subjects with cam deformity. All patients will undergo all 3 interventions: MRI, qCT, and motion analysis. Select patients will be asked to participate in a PET-MRI scan being conducted at The Royal Ottawa.
3267942|NCT01546506|Experimental|Midodrine|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
3267943|NCT01546506|No Intervention|No treatment|
3267944|NCT01546532|Experimental|RLX030|RLX030 as intravenous infusion for 24 hours.
3267945|NCT01546532|Placebo Comparator|Placebo|Placebo as intravenous infusion for 24 hours.
3267946|NCT01546545||Enrollment Group|Healthy participants between the age of 18 and 70 years with fasting blood sugar that is between normal and diabetes.
3267947|NCT01546558|Experimental|Metformin, Ranolazine|"Single cohort, 2-period study:~Period 1, metformin 1000 mg bid on Days 1-5~Period 2, metformin 1000 mg bid + ranolazine 500 mg bid on Days 6-10"
3267950|NCT01546597|Experimental|Metformin, Ranolazine|"Single cohort, 4-period study:~Period 1, metformin 500 mg bid on Days 1-5~Period 2, metformin 850 mg bid on Days 6-10~Period 3, metformin 500 mg bid + ranolazine 1000 mg bid on Days 11-15~Period 4, metformin 850 mg bid + ranolazine 1000 mg bid on Days 16-20"
3267951|NCT01546610|Experimental|intervention foot orthoses|Ethyl vinyl acetate (EVA) insole with medial arch support and bar retrocapital
3267952|NCT01546610|Placebo Comparator|placebo insole|Foot orthose with support retrocapital and support of medial arch insole intervention
3267953|NCT01546662|Experimental|E-RH-06 - Low Dose|1 Capsule twice daily
3267954|NCT01546662|Experimental|E-RH-06 - High Dose|2 capsules twice daily
3267955|NCT01546662|Placebo Comparator|Placebo ;|Placebo Comparator
3267956|NCT01546701|Experimental|Buprenorphine|Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
3267957|NCT01546701|Active Comparator|Morphine|Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
3267958|NCT01546714||AAWSW/AAWSWM|African American Women Who Have Sex with Women/African American Women Who Have Sex with Women and Men
3267959|NCT01546727|Experimental|Family Behavioral Treatment|This intervention will provide nutritional counseling for a health diet, parent training in effective child behavioral management strategies, and stimulus control of the home environment delivered via group based clinic visits and individual home visits on alternate weeks
3267960|NCT01546727|Active Comparator|Motivational Interviewing|This intervention will shared information with parents about their child's weight and use motivational interviewing to elicit changes parents would like to make to their child diet and activity patterns.
3267961|NCT01546727|No Intervention|Standard of Care|Participants in this arm will be followed over time and be assessed on the primary and secondary outcomes at the same time points as the two treatment arms
3267962|NCT01546740||Glaucoma patients|all the ,medical records of patients who were diagnosed with primary open angle glaucoma, closed angle , pseudoexfoliative and neovascular glaucoma.
3267963|NCT01546753|Experimental|Walnut Protein Powder|146 weeks for active treatment subjects
3267964|NCT01546753|Placebo Comparator|Oat Powder|184 weeks for placebo
3267965|NCT01546766||Subjects with diabetes|(Subjects that have been diagnosed with diabetes).
3267966|NCT01546766||Control volunteers|(Subjects with no history of ocular problems).
3267967|NCT01546766||Subjects with retinal conditions|(Subjects with a history of retinal disorders except diabetes).
3267968|NCT01546779|Experimental|lung function|
3267969|NCT01546792|No Intervention|Usual care control|Leaflet on exercise and diet
3267970|NCT01546792|Experimental|Lifestyle intervention|Exercise training (mixture of supervised and non-supervised) Dietary advice Behaviour change counselling (physical activity, diet)
3267971|NCT01546805|Placebo Comparator|Placebo|
3267972|NCT01546805|Experimental|Zinc Group|
3267973|NCT01546844|Experimental|Care4Life|Text message and online interactive component to help patients with self-management.
3267974|NCT01546844|No Intervention|Standard of Care|Patients enrolled in this arm will receive their normal standard of care from their physician for treatment of type II Diabetes Mellitus.
3267975|NCT01546870||pediatric heart transplant recipients|
3267976|NCT01546896|Experimental|buspirone+alprazolam|
3267977|NCT01546896|Active Comparator|alprazolam|
3267978|NCT01546896|No Intervention|healthy controls|
3267979|NCT01546909|Experimental|TETRAVAC-ACELLULAIRE|
3267980|NCT01546935|Experimental|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
3267983|NCT01546961|Experimental|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
3267984|NCT01546974|Experimental|HME filter|
3267985|NCT01546974|Experimental|Heated humidificator MR 730 Fisher & Paykel|
3267986|NCT01546987|Active Comparator|ADT + GnRH agonist + dose escalated radiation|Patients receive standard androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 24 months from initiation and oral (PO) antiandrogen (such as flutamide or bicalutamide) beginning 2 months prior and for the duration of radiation therapy (RT).
3267987|NCT01546987|Experimental|ADT + GnRH agonist + dose escalated radiation + TAK-700|Patients receive the same standard ADT with a GnRH agonist and oral antiandrogen. In addition, patients also receive steroid 17alpha-monooxygenase TAK-700 (TAK-700) PO twice daily (BID) for 2 years.
3267988|NCT01547013||COHORT 1|"Critical Controls: Twenty five (25) critically injured subjects with NO severe traumatic lower extremity traumatic injuries to provide control data for critically injured physiological status, a state which may induce systemic, vs. regional hypoperfusion. (Critical CONTROLS)"
3267989|NCT01547013||COHORT 2|"Ninety five (95) total (35 Cohort 2A; 35 Cohort 2B; 25 Cohort 2C) subjects with severe leg injuries presenting to a participating level 1 trauma center within 12 hours of their injury, to provide data on the acute post-injury phase. (STUDY COHORT)"
3267990|NCT01547013||COHORT 2A|"Subjects meeting COHORT 2 inclusion criteria, who have UNILATERAL severe leg injuries. Unilateral injuries include patients who meet the inclusion criteria for a severe lower extremity injury for ONE lower extremity, with no more than a simple soft tissue injury (eg, simple laceration) on the contralateral leg."
3267991|NCT01547013||COHORT 2B:|"Subjects meeting COHORT 2 inclusion criteria, who have BILATERAL lower extremity injuries, with at least one being a severe leg injury. Bilateral injury patients include patients with at least one lower extremity injury classified as severe based on Cohort 2 inclusion criteria, with a contralateral injury greater than a simple soft tissue injury, including femur, foot, and crush injuries. Note that it is not necessary for both lower extremity injuries to meet the inclusion criteria to be enrolled in this cohort."
3267992|NCT01547013||COHORT 2C|Subjects meeting COHORT 2 inclusion criteria, clinically diagnosed by the treating provider using that treating provider's standards of diagnosing ACS, and in addition to being diagnosed with ACS, the subject undergoes four-compartment leg fasciotomy. data collection to start BEFORE fasciotomy and continue AFTER fasciotomy.
3267993|NCT01547026|Active Comparator|Psycho-education|Patients receive a 10 min. psycho-education on positive health effects of sports
3267994|NCT01547039||Carotid endarterectomy (CEA)|Patients undergoing carotid endarterectomy
3267995|NCT01547052|Experimental|DBT for children|Dialectical Behavior Therapy adapted for children
3267996|NCT01547052|Active Comparator|Enhanced Supportive-Educational Therapy|Enhanced Treatment-As-Usual, including supportive-educational model, cognitive-behavioral skills and parent management training
3267997|NCT01547078|Active Comparator|Licensed Plasma|
3267998|NCT01547078|Experimental|Lyophilized Plasma|
3267999|NCT01547091|Experimental|UC-MSCs Treatment|Patients in UC-MSCs treatment will be infused umbilical cord-derived mesenchymal stem cells intravenously only.
3268000|NCT01547091|Active Comparator|DMARDS|Patients will be treated by Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs).
3268001|NCT01547091|Active Comparator|UC-MSC+DMARDS|Patients will be treated in combination with UC-MSC and DMARDS.
3268002|NCT01547104|Active Comparator|Glimepiride-ratiopharm|Glimepiride (1-4mg) as add on therapy
3268003|NCT01547104|Experimental|Trajenta|Linagliptin 5 mg as add on therapy
3268006|NCT01547143|Experimental|IST and/or alloHCT|Patients who are newly diagnosed as HLH by HLH-2004 criteria, excluding those with HLH owing to malignancy or rheumatic disorder.
3268007|NCT01547156|No Intervention|Control group|Control group received usual care
3268008|NCT01547156|Experimental|Telemonitoring group|Intervention patients were given a remote patient monitoring toolbox that included a mobile telephone, software application, and assessment devices for measuring and remote reporting of hypertension and diabetes -related health parameters at home. The monitored parameters were body weight, steps, blood pressure and blood glucose. Based on their self-monitored data, patients received feedback that was automatically generated, theory-based, health promotion rich information that aimed at strengthening their self-care practices.
3268009|NCT01547169|Placebo Comparator|Saline|
3268010|NCT01547169|Experimental|Low Dose Insulin Detemir (10IU bid)|
3268011|NCT01547169|Experimental|High Dose Insulin Detemir (20IU bid)|
3268012|NCT01547182|Active Comparator|Weight Loss|Caloric restriction
3268013|NCT01547182|Experimental|Weight Loss and Aerobic Training|Caloric restriction and walking
3268014|NCT01547182|Experimental|Weight Loss and Resistance Training|Caloric restriction and lifting weights
3268015|NCT01547195|Experimental|Group-swimming|
3268016|NCT01547195|Active Comparator|Control-walk|
3268017|NCT01547208|Experimental|Group A|Patients will be randomized to a VT ablation procedure immediately after an appropriate ICD shock
3268018|NCT01547208|Active Comparator|Group B|Patients will wait until an arrhythmic storm to undergo a VT ablation procedure
3268019|NCT01547221|Active Comparator|3% boric acid|control
3268020|NCT01547221|Experimental|1% clotrimazole ear drop|3% boric acid is set as control while 1% clotrimazole ear drop is set as intervention.
3268021|NCT01547260|Experimental|Lenalidomide|Phase I; Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
3268022|NCT01547260|Experimental|gemcitabine|Gemcitabine, 1000 mg/m2 in 0.9% sodium chloride will be administered iv over 30 minutes, at days 1, 8, 15 of each 28-day cycle in both phase I and II. Phase I:Lenalidomide capsules will be taken orally each day on days 1-21 of each 28-day cycle. 3 subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day. Phase II: Every other consecutive included subject in phase II part will be treated with either single lenalidomide (days 1-21 of 28) or single gemcitabine (days 1, 8, 15 of 28) during Cycle 1. The first included patient in phase II part will start with single lenalidomide. From treatment cycle number 2 and beyond, all subjects in the phase II part of the study will be treated with lenalidomide in combination with gemcitabine.
3268023|NCT01547273|Experimental|bone graft inside socket only|bone graft inside socket only
3268024|NCT01547273|Experimental|bone graft inside and outside socket|bone graft inside and outside socket
3268025|NCT01547273|Experimental|no bone graft|no bone graft
3268026|NCT01547312|Experimental|Main Pt. 2: 800 mg Grazoprevir + Peg-IFN/RBV|800 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
3268027|NCT01547312|Experimental|Main Pt. 2: 100 mg Grazoprevir + Peg-IFN/RBV|100 mg Grazoprevir combined with Peg-Interferon/Ribavirin treatment.
3268028|NCT01547312|Experimental|Main Pt.1: 800 mg Grazoprevir|800 mg Grazoprevir.
3268029|NCT01547312|Experimental|Procedural Pilot|Optimization of FNA procedure.
3268030|NCT01547325|Experimental|NanoDOX Hydrogel|
3268031|NCT01547325|Placebo Comparator|Placebo Hydrogel|
3268032|NCT01547338||Breast reconstruction patient|Unilateral breast reconstruction patients
3268033|NCT01547351||ARMS Questionnaire Group|Patients with confirmed multiple sclerosis relapse who are willing to participate in the ARMS questionnaire. These patients could not have been treated with any therapies other than oral or intravenous corticosteroids for their previous relapse.
3268034|NCT01547364|Placebo Comparator|Caudal Saline|
3268035|NCT01547364|Active Comparator|Caudal Dextrose|
3268036|NCT01547377|Experimental|zinc and selenium supplementation|Patients received 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation during 4 months
3268037|NCT01547377|Placebo Comparator|rosuvastatin + placebo|Patients received 10 mg rosuvastatin concomitantly placebo pills similar zinc and selenium supplementation
3268038|NCT01547416|Experimental|combined general/epidural anesthesia|epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. Epidural analgesia was maintained using the patient-controlled analgesia technique.
3268039|NCT01547416|Active Comparator|General anesthesia|Patients allocated to general anesthesia group did not receive epidural anesthesia.
3268040|NCT01547429|Experimental|Intraocular Lens Implantation for the Treatment for Aphakia|Implantation of an Artisan intraocular lens to correct aphakia in Adults. No other information is needed to describe this section
3268041|NCT01547442|Experimental|Artisan Aphakia Intraocular Lens|Implantation of an Artisan intraocular lens to correct aphakia in children
3268042|NCT01547455|Experimental|Atorvastatin|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
3268043|NCT01547455|Placebo Comparator|Control|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
3268044|NCT01547468|Active Comparator|Intravenous Opioids|
3268045|NCT01547468|Experimental|Femoral Nerve Catheterization|
3268046|NCT01547481||Parkinson's Disease Cohort|Individuals Diagnosed with Parkinson's Disease
3268047|NCT01547481||Essential Tremor cohort|Individuals Diagnosed with Essential Tremor
3376729|NCT05052333||Examining the psychosocial impacts of Covid-19 in Indonesia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off unilingual (Indonesian) survey. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3268048|NCT01547481||Rapid Eye Movement Disorder Cohort|Individuals Diagnosed with Rapid-Eye Movement Behavior Disorder (RBD). Eligible individuals will have been diagnosed with RBD based on a sleep study prior to entering the study. This study does not pay for or support a sleep study.
3268049|NCT01547481||Healthy Control group|Individuals are healthy, without a known neurologic disease.
3268050|NCT01547481||Progressive Supranuclear Palsy Cohort|Individuals diagnosed with Progressive Supranuclear Palsy (PSP).
3268051|NCT01547481||Parkinsonism - Undifferentiated|Individuals with any form of Parkinsonism, not meeting any of the above cohorts.
3268052|NCT01547494|Placebo Comparator|Dietary Supplement|
3268053|NCT01547494|Experimental|Vegan Diet|
3268054|NCT01547507|Active Comparator|KimVent Turbo-Cleaning Closed Suction System Kimberly clark|
3268055|NCT01547507|Active Comparator|Airway Medix Closed Suction System|
3268056|NCT01547520|Experimental|meperidine|25 mg of meperidine is injected intramuscularly before EGD
3268057|NCT01547520|Placebo Comparator|placebo|placebo was given intramuscularly before EGD
3268058|NCT01547533||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with benznidazole, and who are also lactating
3268059|NCT01547546|Experimental|Single Arm|
3268060|NCT01547559|No Intervention|part1:blank control|NO maintain drugs with Hp negative patients.
3268061|NCT01547559|Experimental|part1:teprenone 1|maintain treatment with Teprenone for Hp negative patients
3268062|NCT01547559|Experimental|part1:EAC-T|eradication of Hp with triple treatment
3268063|NCT01547559|Experimental|part1：EA-EMC-T|eradication of Hp with sequential therapy
3268064|NCT01547559|Active Comparator|part1：T-T|Teprenone as maintain drugs for Hp positive patients
3268065|NCT01547559|Experimental|part2:GGA group|Geranylgeranylacetone plus diclofenac sodium for patients with rheumatic diseases
3268066|NCT01547559|No Intervention|part2:control group|diclofenac sodium only for patients with rheumatic diseases
3268067|NCT01547572|Experimental|Study group|The study group will get a video and leaflet on enhanced recovery.
3268068|NCT01547572|No Intervention|Control group|The control group will receive a leaflet only.
3268069|NCT01547585|Placebo Comparator|Control|- Isocaloric control muffins
3268070|NCT01547585|Experimental|Low Dose Soy|- Isocaloric muffins containing low dose of soy
3268071|NCT01547585|Experimental|High Dose Soy|- Isocaloric muffins containing high dose soy
3268072|NCT01547611|Active Comparator|Customary treatment|Group A (physiotherapy as usual), customary treatment. The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
3268073|NCT01547611|Experimental|structured behavioural medicine program|Group B (extended physiotherapy treatment), customary treatment (please see above) plus a standardised and structured behavioural medicine program. The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
3268074|NCT01547624|Experimental|Neck Specific exercises|3 months of neck specific exercises for 30 patients.
3268075|NCT01547624|No Intervention|Waiting list|Thirty patients on the waiting list for 3 month before they have their intervention
3268076|NCT01547624|No Intervention|Healthy controls|Forty healthy controls. Comparisons between forty included WAD patients and 40 healthy controls matched for age and gender will be investigated at baseline.
3268077|NCT01547637|Experimental|Ultrasound Guided|Ultrasound guided obturator nerve block will be performed after induction of general anesthesia. The anterior and posterior divisions of the obturator nerve will be identified with ultrasound. A stimulating needle will be inserted under direct ultrasound visualization. The anterior division will be blocked first. When adductor twitches are present at less than or equal to 0.5 mA, 10 ml of 2% lidocaine will be injected. Next, the needle will be re-directed under direct ultrasound visualization towards the posterior branch of the obturator nerve. After twitches < 0.5 mA are achieved then 10 mL of 2% lidocaine will be injected when the needle tip is visualized in proximity of the posterior branch.
3268078|NCT01547637|Experimental|Anatomic landmark|Obturator nerve block will be performed after induction of general anesthesia. The adductor magnus tendon approach will be used. A 4 cm insulated stimulating needle will be used to verify location of the obturator nerve by contraction of the thigh adductor group. The needle will be advanced until nerve stimulation is still present at less than or equal to 0.5 mA. When the appropriate nerve stimulation is achieved 10 ml of 2% lidocaine will be injected in divided doses with frequent aspiration. Nerve conduction studies will be repeated once a minute for the first 10 minutes after block completion.
3268079|NCT01547650||SIADH, CSWS, CDI, PP, DIH, HF|CSWS (cerebral salt wasting syndrome), SIADH (syndrome of inappropriate ADH) , CDI (central diabetes insipidus), PP (primary polydipsia), DIH (drug-induced hyponatremia), HF (heart failure with hyponatremia)
3268080|NCT01547676|Experimental|Arm A (unclamped partial nephrectomy)|Patients undergo unclamped partial nephrectomy. Some patients may undergo unclamped partial nephrectomy with controlled hypotension.
3268081|NCT01547676|Active Comparator|Arm B (clamped partial nephrectomy)|Patients undergo clamped partial nephrectomy.
3268082|NCT01547689|Experimental|Human Umbilical Cord Derived MSC|
3268083|NCT01547702|Experimental|Treatment|This group will have access to the Teacher Help for ADHD intervention program during the randomized controlled trial.
3268084|NCT01547702|No Intervention|Waitlist Control|This group will not receive the intervention until all data collection is complete for their study cohort.
3268085|NCT01547741|Active Comparator|Arm 1: Anthracycline-based chemotherapy|"4 anthracycline-based chemotherapy regimens (Regimens A, B, C, or D).~Regimen A (TAC): 75 mg/m2 docetaxel (T) + 50 mg/m2 doxorubicin (A) + 500 mg/m2 cyclophosphamide (C) IV every 3 weeks for 6 cycles.~Regimen B (AC then WP): 60 mg/m2 doxorubicin (A) + 600 mg/m2 cyclophosphamide (C) every 3 weeks for 4 cycles followed by weekly paclitaxel (WP) 80 mg/m2 IV every week for 12 doses.~Regimen C (DD AC then WP): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by weekly paclitaxel 80 mg/m2 IV every week for 12 doses.~Regimen D (DD AC then DD P): 60 mg/m2 doxorubicin + 600 mg/m2 cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel (P) 175 mg/m2 IV every 2 weeks for 4 cycles."
3268086|NCT01547741|Active Comparator|Arm 2: docetaxel + cyclophosphamide|TC: 75 mg/m2 docetaxel and 600 mg/m2 cyclophosphamide IV every 3 weeks for 6 cycles
3268087|NCT01547884||1|Latent TB positive with helminth positive
3268088|NCT01547884||2|Latent TB positive with helminth negative
3268089|NCT01547897|Active Comparator|NOX-E36|
3268090|NCT01547897|Placebo Comparator|Placebo|
3268091|NCT01547910|Experimental|Fish oil|Children will receive fish oil capsules according to age as described in the protocol
3268092|NCT01547910|Placebo Comparator|Placebo|Sunflower oil in the same capsules (the same shape and colour) given in the same regime as 'fish oil' capsules
3268093|NCT01547923|Experimental|A : pre-therapeutic screening for DPD deficiency|Prior to treatment by fluoropyrimidines,a DPD deficiency is identified by a joint phenotypic-pharmacogenetic approach.
3268094|NCT01547923|Other|B : no pretherapeutic research of DPD deficiency|For patients included in this arm, a blood sample will be taken prior to treatment by fluoropyrimidines but not analysed. If grade 3 or 4 toxicity levels are encountered during treatment, DPD deficiency will be detected.
3268095|NCT01547949|Experimental|tart cherry juice|
3268096|NCT01547949|Placebo Comparator|cherry flavored fruit drink|
3268097|NCT01547962|Experimental|Split-mouth design: Treatment|
3268098|NCT01547962|Active Comparator|Split-mouth design: Control|
3268099|NCT01547988|Experimental|Balance Training Intervention|The Balance Training Intervention group received 24 training sessions over three months that included perturbation as well as dual-task exercises.
3268100|NCT01547988|No Intervention|Reference Group|
3268101|NCT01548001|Experimental|Iguratimod monotherapy|
3268102|NCT01548001|Experimental|Iguratimod and MTX combination|
3268103|NCT01548001|Active Comparator|MTX monotherapy|
3268104|NCT01548027|Experimental|No intervention|no injection of local anesthetic agents
3268105|NCT01548027|Experimental|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
3268106|NCT01548027|Experimental|TAP block group|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
3268107|NCT01548066|Experimental|Sodium valproate|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
3268108|NCT01548066|Placebo Comparator|Control|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
3268109|NCT01548079|No Intervention|Control|Untreated controls
3268110|NCT01548079|Active Comparator|Ursodeoxycholic acid|Oral ursodeoxycholic acid 20 mg/kg/day in three weeks
3268111|NCT01548092|Experimental|Autologous SVF|Intralesional application
3268112|NCT01548105||Prolapse and Smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and have been smoking more than one pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3268113|NCT01548105||Prolapse and non smoker|Patients in this arm have been determined to have more than stage 2 pelvic organ prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3268114|NCT01548105||No prolapse and smoker|Patients in this arm, have been determined not to have prolapse and smokes more than 1 pack per day Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3268115|NCT01548105||No prolapse and non smoker|Patients in this arm have been determined not to have prolapse and non smoker for more than 7 years Blood draw for the study participants will be done. These will include: Procollagen 1-N propeptide levels (PINP), Matrix metalloproteinase (MMP9) and Plasma Vitamin C levels
3268116|NCT01548118|Experimental|Adult Group 1, HPV vaccine 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
3268117|NCT01548118|Placebo Comparator|Adult Group 1, Placebo 0.5ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
3268118|NCT01548118|Experimental|Adult Group 2, HPV vaccine 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
3268119|NCT01548118|Placebo Comparator|Adult Group 2, Placebo 1.0ml|20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
3268120|NCT01548118|Experimental|Children Group 1, HPV vaccine 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.
3268121|NCT01548118|Placebo Comparator|Children Group 1, Placebo 0.5ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.
3268122|NCT01548118|Experimental|Children Group 2, HPV vaccine 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.
3268123|NCT01548118|Placebo Comparator|Children Group 2, Placebo 1.0ml|20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.
3268124|NCT01548131|Experimental|Psychoeducative group therapy|Psychoeducative group therapy
3268125|NCT01548131|No Intervention|Control|Women screened for fear of childbirth were taken cared by primary health care nurses and if needed referred to specialized care in hospital
3376730|NCT05052333||Examining the psychosocial impacts of Covid-19 in Somalia.|This is exploratory research and data will be obtained on a set of measures (N=500) using a one-off bilingual (Somalia-English) longitudinally. No predefined conditions apply to explain the nature of the study group other than inclusion and exclusion criteria.
3268126|NCT01548144|Experimental|Crizotinib + Pazopanib - Group A|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3268127|NCT01548144|Experimental|Crizotinib + Pemetrexed - Group B|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3268128|NCT01548144|Experimental|Pazopanib + Pemetrexed - Group C|"Starting dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Expansion group starting dose: MTD from Phase 1.~Starting dose for Pemetrexed: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion group starting dose: MTD from Phase 1."
3376737|NCT05047354||Disorders of cholesterol synthesis and metabolism|Disorders of cholesterol synthesis and metabolism
3376738|NCT05047354||Smith-Lemli-Opitz syndrome|Smith-Lemli-Opitz syndrome
3376739|NCT05044832|Experimental|Personalized Music|Those assigned to the music group will receive music in the preoperative holding area as well as in the post-operative care unit in addition to standard care.
3376740|NCT05044832|No Intervention|Standard of Care|Those assigned to the Standard of Care arm will only receive standard of care in the preoperative holding area as well as in the post-operative care unit
3376743|NCT05043324|Experimental|AIDS, HIV, HBV, HCV, co-infections.|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (1) for various therapeutic purposes.
3376744|NCT05043324|Experimental|"stable cancer, acquired or congenital immunodeficiency."|Experimental benefits in resistance to SARS-COV-2 were observed in all patients who had previously received certain components of the AntiCov-220 (2) for various therapeutic purposes.
3376745|NCT05042583|Experimental|experimental group|The experimental group was injected with 0.5% ropivacaine 6ml
3376746|NCT05042583|Placebo Comparator|Control group|control group was injected with 6ml normal saline.
3376747|NCT05041959|Other|Smoking Abstinence|Participants will abstain from smoking for 24 hours before one MRI scan. Smoking abstinence will be confirmed using exhaled carbon monoxide breath testing
3376748|NCT05041959|Other|Ad Lib Smoking|"Participants will continue smoking as usual (i.e. ad lib) before one MRI scan and smoke one additional cigarette immediately prior to scanning. Continued smoking will be confirmed using exhaled carbon monoxide breath testing."
3376751|NCT05040581|Experimental|Experimental Group - 1 Day CBT|"The intervention is a 6-hour long CBT-based workshop. Cognitive behavioural therapy is a structured psychotherapy based on the cognitive theory of depression that posits that negative thoughts about the self, others and the future can lead to and perpetuate depressed mood states. CBT equips participants with skills that enable them to identify and modify distortions in their thinking that lead to depressed mood and maladaptive behavioural responses.~The intervention will be delivered in in modules and contain content on PPD etiology (with a focus on modifiable risk factors), the development of cognitive skills including cognitive restructuring, behavioural skills such as problem solving, sleep strategies, behavioural activation, assertiveness, and self-care, and the final module will involve goal setting and action planning."
3376752|NCT05040581|Other|Control Group - 90-minute Information Session|Participants in the control group will be invited to participate in a 90-minute information session that will contain information about PPD.
3376753|NCT05039138|Experimental|Group I (control)|: it includes 17 patients who will receive traditional strength training program.
3376754|NCT05039138|Experimental|Group II (experimental):|it includes 17 patients who will receive upper extremity neuromuscular training exercises
3376755|NCT05036135|Experimental|Phase 2b low dose AV-101|
3376756|NCT05036135|Experimental|Phase 2b medium dose AV-101|
3376757|NCT05036135|Experimental|Phase 2b high dose AV-101|
3376758|NCT05036135|Placebo Comparator|Phase 2b Placebo|
3376759|NCT05036135|Experimental|Phase 3 dose AV-101 (Optimal dose selected in Phase 2b)|
3376760|NCT05036135|Placebo Comparator|Phase 3 Placebo|
3376765|NCT05034484|Experimental|ALPN-303 Regimen A|
3376766|NCT05034484|Placebo Comparator|Placebo Regimen A|
3376767|NCT05034484|Experimental|ALPN-303 Regimen B|
3376768|NCT05034484|Placebo Comparator|Placebo Regimen B|
3268129|NCT01548144|Experimental|Crizotinib + Pazopanib + Pemetrexed - Group D|"Starting dose for Crizotinib: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Dose Expansion Group: MTD from Phase 1.~Starting Dose for Pazopanib: 200 mg by mouth daily in a 21 day cycle.~Dose Expansion Group: MTD from Phase 1.~Starting dose for Pemetrexed: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Dose Expansion Group: MTD from Phase 1."
3268130|NCT01548157|Experimental|HCP1007|HCP1007
3268131|NCT01548157|Active Comparator|omarco and crestor|Rosuvastatin plus Omega-3
3268132|NCT01548170|Active Comparator|Sunitinib 50mg|Sunitinib 50 mg administered as a single dose.
3268133|NCT01548170|Experimental|Sunitinib 37.5mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3376782|NCT05025293|Experimental|ZOLearly|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 5mg zoledronate (Aclasta) will be administered intravenously.~The ZOLearly group will have no further infusions during the study period."
3376783|NCT05025293|Placebo Comparator|ZOLlate|"Within 3 days after hip fracture surgery: A single dose of 100 ml containing 100ml NaCl 9mg/ml (placebo) will be administered intravenously.~3 months after hip fracture surgery (at the out-patient clinic): A single dose of 100 ml containing 5mg zoledronate (Aclasta) will administered intravenously."
3376784|NCT05023655|Experimental|Tazemetostat|tazemetostat 800 mg po twice daily in continuous 28- day cycles
3376785|NCT05022472|Experimental|Intervention|We will use a 2-armed randomized controlled trial (RCT) where Latino and AA adults >18 years or older from six participating communities and surrounding community health centers (CHC) will be assigned to the 2 VIDA! intervention (n=3 CHC; N=500 participants) or to the control site (e.g., standard of care) (n=3 CHC; N=500 participants). The two major components of the 2VIDA! intervention are: COVID-19 Individual Awareness and Education, COVID-19 Community Outreach and Health Promotion, COVID-19 Individual Health Education and Linkages to Medical and Supportive Services, and pop-up vaccination stations in Latino and AA communities.
3376786|NCT05022472|No Intervention|Standard of care|The standard of care for vaccine delivery at the control sites. This includes individuals who make an appointment on their own or receive the vaccine at a health center and may receive information about the vaccine from their primary healthcare provider.
3376787|NCT05020912|Experimental|Photodynamic therapy (PDT)|"Each participant will serve as their own control, receiving PDT for one tumor, no PDT for the second tumor (untreated control).~Visit 1:~Informed consent~Blood draw~Lesion(s) Photographed~(ALA) applied for4 hours~PpIX measured in lesions (PpIX buildup monitored every 30 minutes over a 4 h period)~PDT with blue light~Visit 2 (scheduled for within one of the following time intervals: 1-3 days, 4-7 days, or 8-14 days post-PDT):~Blood draw~Lesion(s) Photographed~Mohs surgery~After procedure, excess frozen BCC tissue will be saved for analysis"
3376788|NCT05019170|Experimental|Best Practices + Incentives group|Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
3376789|NCT05019170|Active Comparator|Best Practices|Participants assigned to this condition will receive the best practices treatment alone.
3376790|NCT05013632||Exposed pregnant women|Pregnant women who received at least one dose of a medication indicated for the treatment of mild to severe COVID-19 at any time during pregnancy or within 90 days prior to the first day of the LMP
3376791|NCT05013632||Active comparator pregnant women|Pregnant women treated with another therapy for mild to severe COVID-19
3376792|NCT05013632||Unexposed pregnant women|Pregnant women hospitalized but not treated with a medication specifically indicated for the treatment of mild to severe COVID-19
3268134|NCT01548170|Experimental|Sunitinib 37.5 mg + Ketoconazol 400 mg|"The drugs will be administered as follows:~Sunitinib 37.5mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3376799|NCT05010759|Experimental|Ablation Arm|Subjects in this arm of the study will have focal ablation of the prostate cancer lesion with the NanoTherm technology. This ablation will be followed-up transperineal prostate biopsy at 4 months after treatment.
3268135|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 200mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 200 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3268136|NCT01548170|Experimental|Sunitinib 25mg + Ketoconazol 400mg|"The drugs will be administered as follows:~Sunitinib 25mg oral single dose.~Ketoconazole 400 mg orally, once daily for 6 days. (Combination with sunitinib will be performed on day 4)"
3268137|NCT01548183|Experimental|Lifestyle counseling|Weekly SMS assessing risky sexual encounters and providing feedback including concern, goal-setting and tools to reduce risk
3268138|NCT01548183|No Intervention|Usual care|Usual care includes ED provider counseling as per normal clinical care
3268139|NCT01548196|Other|standard percutaneous nephrostomy|Standard PCN
3268140|NCT01548196|Other|double-J ureteral stent,|double-J ureteral stent,
3268141|NCT01548196|Other|open-ended ureteral catheter|open-ended ureteral catheter
3268142|NCT01548196|No Intervention|no nephrostomy or ureteral stent/catheter.|no nephrostomy or ureteral stent/catheter.
3268143|NCT01548209|Experimental|Group D|A single dose dexmedetomidine 0.5 mcg/kg iv. 30 min before end of the surgery
3268144|NCT01548209|Placebo Comparator|Group P|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
3268145|NCT01548235||BIAsp 30 users|
3268146|NCT01548248||Levemir® users|
3268147|NCT01548261||Health people.|
3268148|NCT01548300||Enrolled participants|Subjects will be recruited from clinics affiliated with the Fuwai Hospital, PUMC. The participants will be nonsmokers with cardiometabolic disease, that are not taking anti-hypertensive, glucose-lowering, or lipid-lowering medications or drugs that alter baseline insulin sensitivity, blood pressure, or endothelial function, daily use of NSAIDS is not allowed.
3268149|NCT01548313||Pregnant women from Ljubljana region|Women at 3rd trimester of pregnancy living in the Ljubljana region.
3268150|NCT01548313||Pregnant women from Izola region|Women at 3rd trimester of pregnancy living in the Izola region.
3268151|NCT01548313||Pregnant women from Murska Sobota region|Women at 3rd trimester of pregnancy living in the Murska Sobota region.
3268152|NCT01548326|Active Comparator|Atorvastatin|will receive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
3268153|NCT01548326|Placebo Comparator|Placebo|will receive one Placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeast-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
3268154|NCT01548365|No Intervention|Control Group|routine care for the selection, placement and maintenance of venous access devices (VAD).
3268155|NCT01548365|Experimental|Infusion Therapy Nursing Expert|Patients in this group will receive the infusion therapy nursing expert (ITNE) service.
3268156|NCT01548378|Experimental|High Dose|Patients in this treatment group will receive 8mg NL003 respective in D0、14、28
3268157|NCT01548378|Experimental|Middle Dose|Patients in this treatment group will receive 6mg NL003 respective in D0、14、28
3268158|NCT01548378|Experimental|Low Dose|Patients in this treatment group will receive 4mg NL003 in D0、14、28
3268159|NCT01548378|Placebo Comparator|Placebo|Patients in this group will receive normal saline respective in D0、14、18
3268160|NCT01548391|Experimental|HX-1171 20 mg (20mg 1T)|
3268161|NCT01548391|Experimental|HX-1171 40 mg (20mg 2T)|
3268162|NCT01548391|Experimental|HX-1171 80 mg (20mg 4T)|
3268163|NCT01548391|Experimental|HX-1171 160 mg (20mg 8T)|
3268164|NCT01548391|Experimental|HX-1171 300 mg (200mg 1T, 20mg 5T)|
3268165|NCT01548391|Experimental|HX-1171 600 mg (200mg 3T)|
3268166|NCT01548391|Experimental|HX-1171 1200 mg (500mg 2T, 200mg 1T)|
3268167|NCT01548391|Experimental|HX-1171 1500 mg (500mg 3T)|
3268168|NCT01548391|Experimental|HX-1171 2000 mg (500mg 4T)|
3268169|NCT01548430|Experimental|TTP4000 1.0 mg/kg|Administered subcutaneously
3268170|NCT01548430|Experimental|TTP4000 3.0 mg/kg|Administered subcutaneously
3268171|NCT01548430|Placebo Comparator|Placebo|Administered subcutaneously
3268172|NCT01548443|Experimental|Medifoam H|"A group which treated with medifoam H on the wound."
3268173|NCT01548443|Active Comparator|Duoderm THIN|"A group which treated with  Duoderm THIN  on the wound"
3268174|NCT01548456||Intramedullary nailing|Subjects with a femur fracture who undergo operative fixation with an intramedullary nail
3268175|NCT01548456||Open Reduction Internal Fixation|Subjects with a femur fracture who undergo open reduction internal fixation with a dynamic compression plate
3268176|NCT01548469|Active Comparator|Perio Total Care toothpaste|A Group which use Perio Total Care toothpaste during participation.
3268177|NCT01548469|Experimental|Bio Mineral toothpaste|A Group which use Bio Mineral toothpaste during participation.
3268178|NCT01548482|Experimental|Treatment (trebananib, temsirolimus)|Patients receive trebananib IV over 60 minutes and temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3268179|NCT01548495||Responded to rHuEPO treatment|response to EPO was defined as a rise in untransfused hemoglobin concentration of at least 2 g/dl or a 50% decrease in transfusion requirements over the treatment period
3268180|NCT01548495||IR to rHuEPO treatment|No rise in hemoglobine consentration at normal and high dose rHuEPO treatment
3268181|NCT01548495||Responded to high level rHuEPO|Responded to more than 80,000UI of rHuEPO treatment
3268182|NCT01548495||No rHuEPO treatment|
3268183|NCT01548508|Experimental|Functionnal ElectroStimulation (FES)|
3268184|NCT01548508|Sham Comparator|SHAM|
3268185|NCT01548521|Experimental|Oxytocin|
3268186|NCT01548534|Placebo Comparator|DHA-free arm|Dietary supplementation with vegetable oil.
3268187|NCT01548534|Experimental|DHA arm|Dietary supplementation with fish oil.
3268188|NCT01548547|Experimental|LP mastery learning group|
3268189|NCT01548547|Active Comparator|IV mastery learning group|
3268190|NCT01548560|Experimental|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
3268191|NCT01548560|Placebo Comparator|Placebo Gel|Dosage form: vaginal gel Dosage: N/A Frequency: 7 daily doses
3268192|NCT01548560|Experimental|Dapvirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
3268193|NCT01548560|Placebo Comparator|Vaginal Film|Dosage form: vaginal film Dosage: N/A Frequency: 7 daily doses
3268194|NCT01548586|Active Comparator|Anodal tDCS|
3268195|NCT01548586|Active Comparator|Cathodal tDCS|
3268196|NCT01548586|Placebo Comparator|Placebo type tDCS|
3268197|NCT01548612|Experimental|Sodium nitroprusside|
3268198|NCT01548612|Placebo Comparator|Placebo|Glucose solution 5%
3268199|NCT01548625||Healthy middle-aged human volunteers|
3268200|NCT01548664|Experimental|Nintendo Wii FitTM|Fifteen minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
3268201|NCT01548664|Active Comparator|Lower extremity exercise|Fifteen minutes of lower extremity exercises that addressed balance, posture, weight shifting and strengthening were provided bilaterally, following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area
3268202|NCT01548677|No Intervention|observation|18 weeks
3268203|NCT01548677|Experimental|Herceptin (trastuzumab)|18 weeks
3268204|NCT01548703|Experimental|BCI-838 Dosing Arm 1|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3268205|NCT01548703|Experimental|BCI-838 Dosing Arm 2|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3268206|NCT01548703|Experimental|BCI-838 Dosing Arm 3|Ten subjects will be enrolled, 8 will receive BCI-838 and 2 will receive matching placebo.
3268207|NCT01548729|Experimental|Patient with cystic fibrosis|Patients with end-stage cystic fibrosis
3268208|NCT01548781|Experimental|Viscous Resistance & Abduction Loading|The intervention for the experimental group entails practicing reaching utilizing the robotic device, ACT3D, with the experimental element of horizontal viscosity in combination with abduction loading.
3268209|NCT01548781|Active Comparator|Abduction Loading|The intervention for the active comparison group entails practicing reaching utilizing the robotic device, ACT3D, with only abduction loading.
3268210|NCT01548794|Active Comparator|Bupivacaine(Group B)|spinal anesthesia
3268211|NCT01548794|Experimental|Bupivacaine+Lidocaine (Group BL)|spinal anesthesia
3268212|NCT01548794|Active Comparator|Local Infitration Anesthesia(Group LI)|local infiltration anesthesia
3268213|NCT01548820||Chronic HBV Egyptian patients|chronic HBV patients receiving Lamivudine therapy in hepatology clinic in the National Hepatology & Tropical Medicine Research Institute in Egypt.
3268214|NCT01548859|Active Comparator|Midazolam|Used for maintenance anaesthesia (0.2 mg/kg/saat continuous infusion)
3268215|NCT01548859|Active Comparator|Sevoflurane|Used for the maintenance for anaesthesia (% 0.5-8 end tidal concentration)
3268216|NCT01548872|Active Comparator|crystalloid cardioplegia solution|After aortic cross clamp 30ml/kg will be administered
3268217|NCT01548872|Active Comparator|HTK solution|After aortic cross clamp 50ml/kg will be administered
3268218|NCT01548911|Experimental|Treatment (monoclonal antibody therapy)|Patients receive gemtuzumab ozogamicin IV over 2 hours on days 1 and 15. Treatment continues for 28 days in the absence of disease progression or unacceptable toxicity.
3268219|NCT01548924|Experimental|Priming Phase|The study treatment begins with the period of seven days of priming Phase, which is administered in monoterapi dovitinib
3268220|NCT01548924|Experimental|Treatment Phase|The phase of treatment with two drugs (paclitaxel dovitinib more fixed dose of 80 mg/m2 per week) will begin after a washout period of seven days after the priming phase.
3268221|NCT01548937|Experimental|I-123 ADAM|I-123 ADAM Serotonin transporter imaging
3268222|NCT01548950|Other|Single-arm study|Preoperatively, sildenafil until development of pulmonary congestion (1-4 weeks). On treatment pulmonary congestion (dyspnea and need for increasing diuretics) occurs when there is a substantial decrease in pulmonary vascular resistance, which may be confirmed noninvasively by Doppler-echocardiography. At that moment, patient will be assigned to surgery. If pulmonary congestion is not observed, bosentan will be added on top of sildenafil, and the patient will be kept on treatment for 10-12 months. In this case, a new cardiac catheterization will be performed before surgery. In both cases (short-term and medium-term treatment) patients will be kept on treatment for six months following surgery, and then re-catheterized.
3268223|NCT01548963|Experimental|Perioperative glycemia control|Group of perioperative intensive glycemia control: blood glucose level will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) according to actual glycemia to keep it within normoglycemia limits (4.4 - 6.1 mmol/l) since patient's admission to operating room. Samplings will be taken in 1 to 4 hours intervals in accordance with glycemia stability and MPC algorithm suggestions.
3268224|NCT01548963|Active Comparator|Postoperative glycemia control|Group of standard glycemia control: blood glucose level will be maintained by continuous insulin infusion (see above) within normoglycemia limits (4.4 - 6.1 mmol/l) after patient's admission to ICU after cardiac surgery. During surgery hyperglycemia will not be interfered before it will reach level of 10 mmol/l.
3268225|NCT01548976||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
3268226|NCT01548989||The study population|Patients suffering from pelvic organ prolapse and/or urinary incontinence and/or fecal incontinence. See inclusion/exclusion criteria.
3268227|NCT01549028|Experimental|Mobile-based PR program.|Home based mobile PR program for 3 months.
3268228|NCT01549054|Experimental|10-mg dose of E5501 2G tablet|
3268229|NCT01549054|Experimental|10-mg dose of E5501 cyclodextrin oral solution|
3268230|NCT01549054|Experimental|10-mg dose of E5501-P21% powder|
3268231|NCT01549054|Experimental|10-mg dose of E5501 lipid-based oral|
3268232|NCT01549080||research|biological research on the effects of yisuishengxuegranule
3268233|NCT01549080||clinical research|clinical research on thalassemia
3268234|NCT01549093|Experimental|Endostar -Continued Pumping into+GC|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Carboplatin
3268235|NCT01549093|Active Comparator|Endostar -injecting into +GC|Endostar that is injecting into vein with Gemcitabine -Carboplatin
3268236|NCT01549093|Active Comparator|GC|Gemcitabine -Carboplatin
3268237|NCT01549106|Experimental|IPI-145|
3268238|NCT01549106|Placebo Comparator|Placebo|
3268239|NCT01549119|Experimental|Low dose VAC-3S|
3268240|NCT01549119|Experimental|Medium dose VAC-3S|
3268241|NCT01549119|Experimental|High dose VAC-3S|
3268242|NCT01549119|Placebo Comparator|Placebo|
3268243|NCT01549119|Experimental|Double-dose VAC-3S|
3268244|NCT01549145|Experimental|NIMBUS multifunctional stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
3268245|NCT01549158|Experimental|Torasemide PR 10 mg|
3268246|NCT01549158|Active Comparator|Furosemide-IR 40 mg|
3268247|NCT01549158|Active Comparator|Torasemide-IR 10 mg|
3268248|NCT01549171||Iloprost|This is the study group with 1 uM Iloprost.
3268249|NCT01549171||Control|This is the control group with vehicle (normal saline) only.
3268250|NCT01549197||ICU staff and relatives|
3268251|NCT01549249|No Intervention|vitrectomy|
3268252|NCT01549262|Active Comparator|Standard Incubator|
3268253|NCT01549262|Experimental|ESD Time-lapse Monitoring system|
3268254|NCT01549288|Experimental|modified Atkins diet|
3268255|NCT01549288|Other|control arm|the control arm continues the anti-epileptic drugs without any added dietetic input
3268256|NCT01549301|Experimental|Group D 10 i.v.|Two periods, crossover, single dose, i.v., 10 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3268257|NCT01549301|Experimental|Group C 5 i.v.|Two periods, crossover, single dose, i.v., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3268258|NCT01549301|Experimental|Group B 10 s.c.|Two periods, crossover, single dose, s.c., 10 mcg/kg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3268259|NCT01549301|Experimental|Group A 5 s.c.|Two periods, crossover, single dose, s.c., 5 mcg, Comparator (n=16) x Test (n=16) in the first period and Test (n=16) x Comparator (n=16) in the second period, in a crossover basis.
3268260|NCT01549327|Active Comparator|Routine Care|Participants who are randomized to the active comparator arm will receive routine care, which is the care routinely provided to the participant's patient population at the study centre.
3268261|NCT01549327|Experimental|Routine Care plus OIN|OIN (Oncology Interactive Navigator) is the intervention. Participants who are randomized to routine care plus OIN will receive routine care and have unlimited access to the website for the study duration.
3268262|NCT01549353|Experimental|chewing gum|
3268263|NCT01549366|Experimental|Aspen Spinous Process Fixation Device|Subjects randomized to the Aspen study arm will have the Aspen device implanted as supplemental posterior fixation only and according to the manufacturer's recommendations.
3268264|NCT01549366|Active Comparator|Pedicle Screws|Subjects randomized to the pedicle screw group will have polyaxial top loading pedicle screws implanted according to the standard procedures and practices at that institution. The procedure may be performed according to surgeon preference, including a traditional open, minimally invasive or percutaneous approach. Only pedicle screws cleared by FDA for this indication will be used in this study.
3268265|NCT01549379|Active Comparator|Surgical patients|This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
3268266|NCT01549379|Active Comparator|Chemoradiation Patients|This group will consist of 15 patients with locally advanced HNSCC with lymph nodes ≥3 cm in which chemoradiotherapy is the primary treatment as per standard of care. This group will be composed of patients with a primary malignancy originating in the nasopharynx, oropharynx, hypopharynx or larynx. Pre-treatment DCE-CT of neck will be obtained. The standard therapy, radiation and chemotherapy, will be administered and the patients will have standard follow up. A post-treatment DCE-CT of neck will be obtained 8-10 weeks after treatment along with standard CT neck.
3268267|NCT01549418|Active Comparator|Aspirin|Patients with at least one large polyps taking aspirin in dose 75 mg daily for 21 days (7 days before and 14 days after polypectomy)
3268268|NCT01549418|Placebo Comparator|Placebo|Patients with at least one large polyps taking placebo daily for 21 days (7 days before and 14 days after polypectomy)
3268269|NCT01549431|Experimental|Combo of Panobinostat and Carfilzomib|A cycle of therapy is 4 weeks (28 days in duration). Carfilzomib (with dexamethasone during cycle 1) will be administered intravenously infusion on days 1, 2 and 8, 9 and 15, 16 of every 28 day cycle. Panobinostat is administered orally three times per week.
3268270|NCT01549444||Group 1|Babies of mothers that have diabetes and/or hypertension and babies that are small for dates
3268271|NCT01549444||Group 2|Babies born to mothers without diabetes and/or hypertension and babies that are correct size for gestational age
3268272|NCT01549457|No Intervention|Non-intervention|Participants will only receive standard of care
3268273|NCT01549457|Experimental|Cell phone intervention arm|Upon consent, participants will be randomly assigned to receive either 1) standard of care (9 months of INH or 4 months of RIF) and weekly SMS text messages via mobile phone or 2) standard of care (9 months of INH or months of RIF) without weekly SMS text messages via mobile phone.
3268274|NCT01549470|Experimental|Study vaccine|Participants in this arm will receive a total of three doses of study vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection (dose strength 4 mg/mL) and will be administered by IM injection in the deltoid muscle.
3268275|NCT01549470|Placebo Comparator|Placebo vaccine|Participants in this arm will receive a total of three doses of a placebo vaccine: the first dose at Day 0, the second dose at Day 28 (plus or minus 7 days), and the third dose at Day 56 (plus or minus 7 days). Each dose will consist of a 1-mL injection and will be administered by IM injection in the deltoid muscle.
3268276|NCT01549483||Asthma|asthmatic subjects
3268277|NCT01549483||Asymptomatic AHR|Asymptomatic subjects with airway hyperresponsiveness
3268278|NCT01549483||Control|Healthy controls, without airway hyperresponsiveness
3268279|NCT01549496|Experimental|boceprevir|boceprevir 800 mg tid
3268280|NCT01549509|Experimental|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection of the study vaccine (VRC-HIVADV014-00-VP) in their upper arm at study entry.
3268281|NCT01549535|Active Comparator|Group A (study group)|Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope System™ extended view colonoscopy.
3268282|NCT01549535|Active Comparator|Group B (control group)|Group B (control group) will undergo a PeerScope System™ extended view colonoscopy followed immediately by a Standard view colonoscopy.
3268283|NCT01549561|No Intervention|Services As Usual|Foster care services as usual
3268284|NCT01549561|Experimental|Parent and Youth Training|16 Weeks of Parent Training in group context with 5 to 10 relative and non-relative foster caregivers; Youth training with skills coaches
3268285|NCT01549561|Experimental|Parent Training|16 weeks of parent training with 5 to 10 relative and non-relative foster caregivers
3268286|NCT01549574|Experimental|crizotinib/crizotinib+esomeprazole crossover|Each subject in this study will receive two treatments (A and B) separated by at least 14 days of washout period. Treatment A is a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule. Treatment B consists of 40 mg daily esomeprazole dose from Day 1 to Day 5 and a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5.
3268287|NCT01549600|Experimental|psyllium|5.1 g psyllium husk in at least 8 ounces of water
3268288|NCT01549600|Active Comparator|Microcrsytalline Cellulose|1.18 g Microcrystalline Cellulose in at least 8 ounces of water, taken twice a day
3268289|NCT01549626|Active Comparator|defatted flaxseed flour|30 grams per day of defatted flaxseed flour
3268290|NCT01549626|Active Comparator|golden flaxseed flour|30 grams per day of golden flaxseed flour
3268291|NCT01549626|Active Comparator|whole brown flaxseed flour|30 grams per day of whole brown flaxseed flour
3268292|NCT01549639||General Anaesthesia|Patients undergoing general anaesthesia using Marsh model target controlled infusion in effect site mode.
3268293|NCT01549678|Experimental|Intervention foot orthoses|Ethyl Vinil Acetate EVA insole shaped in the cast of the patient's foot.
3268294|NCT01549678|Placebo Comparator|Placebo insole|EVA flat insole.
3268295|NCT01549691|Experimental|zopiclone|zopiclone given before sleep, the day before surgery (placebo given at awakening the day of surgery)
3268296|NCT01549691|Experimental|alprazolam|given at awakening, the day of surgery (placebo given before sleep, the day before surgery)
3268297|NCT01549691|Placebo Comparator|placebo|Placebo given night before operation and the morning of operation
3268298|NCT01549704|Other|Arm RP|first blockade: ropivacaine 7,5mg/ml 30 ml second blockade: placebo: saline 30 ml
3268299|NCT01549704|Other|Arm PR|first blockade: placebo: saline 30 ml second blockade: ropivacaine 7,5mg/ml 30 ml
3268300|NCT01549717|Experimental|Elective cardiac surgery patients|Patients undergoing elective cardiac surgery
3268301|NCT01549730|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with cervix cancer
3268302|NCT01549743|Experimental|Celecoxib|
3268303|NCT01549743|Experimental|Rebamipide|
3268304|NCT01549743|Experimental|Celecoxib plus Rebamipide|
3268305|NCT01549756||Qualitative Research|Experiential/opinion based research
3268306|NCT01549769|Experimental|Bardoxolone Methyl 20 mg|
3268307|NCT01549782|Active Comparator|Fiber supplement|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
3268308|NCT01549782|Placebo Comparator|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
3268309|NCT01549808|Experimental|group 2|"Participants:~100 patients will be included in the observation phase of this project, and another 100 in the intervention phase, according to the following criteria: Patients hospitalized in Unit 4141, at Rigshospitalet or ICU at Slagelse, who have been intubated for more than 48 hours, age ≥18, and after positive confirmation from relatives that the patient before the hospitalization was able to read and understand instructions.~The research is divided in 3 phases:~An 8 month observation phase.Current practice relatede to mobilize is measured.~An 2 month implementation phase and third: an 8 month intervention phase. The effect is measured as the difference in the functional level between the observation phase and the intervention phase related to primary and secondary outcome.~The effect of the intervention is described by using following test:~walking distance,ADL function, capability to sit and stand"
3268310|NCT01549834|Experimental|ABT-126 Low Dose|low dose
3268311|NCT01549834|Experimental|ABT-126 High Dose|high dose
3268312|NCT01549834|Placebo Comparator|sugar pill|Placebo
3268313|NCT01549847|Experimental|L-carnitine and piracetam|
3268314|NCT01549847|Placebo Comparator|Placebo|
3268315|NCT01549899|Active Comparator|In-person CBT of Insomnia|CBTi consisted of 6 weekly 60-minute sessions and included identical informational material. The treatments contained the following efficacious and commonly used modules of cognitive behavioral treatments for insomnia: Stimulus Control, Sleep Restriction, Sleep Hygiene, Relaxation Training, Cognitive Restructuring.
3268316|NCT01549899|Active Comparator|Internet CBT of Insomnia|The I-CBTi protocol was developed by the National Center for Telehealth and Technology with the first author (DJT) serving as the subject matter expert, and administered on the afterdeployment.org website. The information and instructions for I-CBTi were identical to in-person CBTi; however, their mode of delivery in I-CBTi is considerably different due to the constraints of its automated, online format. The lessons were presented as audio recordings accompanied by visual graphics and animations and several lessons, had interactive components such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
3268317|NCT01549899|No Intervention|Minimal Contact|Those assigned to the MC control group will be asked to not work with another therapist or seek additional treatment for insomnia-related difficulties during the 6-week MC period. They will be called every other week to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MC participants will also be given contact information to use in case of worsening of symptoms or increasing distress. At the end of six weeks, they will complete the baseline assessments again, which will serve as the post-treatment assessment for the MC period. They will then be randomly assigned to either the CBTi or ICBTi groups.
3268318|NCT01549912||Rotator cuff tear|
3268319|NCT01549938|Active Comparator|Treatment|20,000 IU cholecalciferol capsule
3268320|NCT01549938|Placebo Comparator|Placebo|Microcellulose capsule
3268321|NCT01549990||Sevoflurane group|donors who went through donor nephrectomy under general anesthesia with sevoflurane
3268322|NCT01549990||desflurane group|donors who went through donor nephrectomy under general anesthesia with desflurane
3268323|NCT01550003|Experimental|Certolizumab Pegol|Active treatment with Certolizumab Pegol; dose adjustment is based on weight.
3268324|NCT01550016||Febrile Patients|Observation of patients with possible dengue fever in the early phase of disease
3268325|NCT01550029|Experimental|Counseling/Mood Management|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help you develop knowledge and skills that can help you quit. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
3268326|NCT01550029|Active Comparator|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways to establish a healthier lifestyle."
3268327|NCT01550042||Intensive observation cohort|Patients > 18 years of age diagnosed with a recent episode of cryptogenic stroke with long term rhythm observation using an implantable loop recorder for detecting atrial fibrillation.
3268328|NCT01550055|Experimental|CMAB009 plus Irinotecan|
3268329|NCT01550055|Active Comparator|Irinotecan-only and sequential-CMAB009|
3268330|NCT01550068|Experimental|Experimental Arm|Echocardiographic screening
3268331|NCT01550068|No Intervention|Control Arm|No echocardiographic screening
3268332|NCT01550081|Active Comparator|Rate of perceived exertion|Exercise intensity controlled by Borg
3268333|NCT01550081|Active Comparator|Heart rate monitor|Exercise intensity controlled by heart rate monitors
3268334|NCT01550107|Active Comparator|Allopurinol|Allopurinol 600mg tablets
3268335|NCT01550107|Placebo Comparator|Lactose tablets|Placebo Lactose tablets
3268336|NCT01550133|Experimental|Not Learned: Non-nutritive bev to Nutritive bev|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid and act as a control for the learned effects.
3268337|NCT01550133|Experimental|Not Learned: Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid and act as a control for the learned effects.
3268338|NCT01550133|Experimental|Not Learned: Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage and act as a control for the learned effects.
3268339|NCT01550133|Experimental|Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
3268340|NCT01550133|Experimental|Learned: Non-Nutritive beverage to Non-Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of non-nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive beverage to determine if cephalic phase response changes with learning.
3268341|NCT01550133|Experimental|Learned: Nutritive solid to Nutritive solid|15 participants will be randomly assigned to eat 250 grams of nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive solid to determine if cephalic phase response changes with learning.
3268342|NCT01550133|Experimental|Learned: Nutritive beverage to Nutritive beverage|15 participants will be randomly assigned to drink 400 grams of nutritive beverage consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a nutritive beverage to determine if cephalic phase response changes with learning.
3268343|NCT01550133|Experimental|Not Learned: Non-Nutritive solid to Non-Nutritive solid|15 participants will be randomly assigned to eat 250 grams of non-nutritive solid consecutively for 2 weeks. After this conditioning, the cephalic phase response of half of these participants will be tested against a non-nutritive solid to determine if cephalic phase response changes with learning.
3268344|NCT01550146|Experimental|Dexamethasone, 0.1 mg/kg|The patients in the Dexamethasone group get iv 0.1 mg/kg dexamethasone preoperative.
3268345|NCT01550146|Placebo Comparator|Placebo|In the Placebo group the patients get 0.1 ml/kg normal saline.
3268346|NCT01550172|Experimental|Sleep Behavioral Therapy A and NHMS|Participants in this arm receive behavioral therapy A for insomnia and the night home monitoring system.
3268347|NCT01550172|Active Comparator|Sleep Behavioral Therapy B and NHMS|Participants in this arm receive sleep behavioral therapy B and the night home monitoring system.
3268348|NCT01550185|Experimental|Treatment (eltrombopag olamine)|Patients receive eltrombopag olamine PO QD from day 1 up to day 62. Treatment continues for up to 9 weeks in the absence of disease progression or unacceptable toxicity.
3268349|NCT01550198||Newborns|"Critically ill newborns admitted to level III neonatal intensive care unit of a university hospital, who will be monitored using transpulmonary ultrasound dilution (advanced hemodynamic monitoring)"
3268350|NCT01550211||Students|Healthy students from Bar-Ilan University
3268351|NCT01550211||Schizophrenic patients' relatives|Healthy family members (parents or siblings) of the schizophrenic participants (chronic and naive)
3268352|NCT01550211||Naive schizophrenic patients|Naive patients with a diagnosis of schizophrenia, a history of only one psychotic episode and un-medicated
3268353|NCT01550211||Chronic schizophrenia patients|Chronic patients with a diagnosis of schizophrenia and a history of more than one psychotic episode
3268354|NCT01550237|Experimental|radiotherapy daily reduced|radiotherapy, with daily CT position verification and reduced safety margins
3268355|NCT01550237|Active Comparator|radiotherapy weekly standard|radiotherapy, with weekly orthogonal position verification and standard safety margins
3268356|NCT01550250|Experimental|Immediate Night-time Compression|Women randomized to the immediate night-time compression system group will be measured for a custom-made night-time compression system. Women in this group will be instructed to wear their night-time compression system garment for a minimum of 5 nights per week over the 12-week intervention period. A gradual increase in nights worn and wear-time of the garment will occur over the first two weeks. From weeks 3 to 12 of the study, the participants will be asked to wear the garment for 8 hours per night, for a minimum of five nights per week.
3268357|NCT01550250|Active Comparator|Delayed Group: Standard Care|Women randomized to the delayed night-time compression system group will receive standard care for lymphedema maintenance. Each participant will be instructed to wear their day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week. Following the twelve-week delay period, women in this arm of the trial will be fitted for their respective night-time compression system garment and will follow the protocol outlined in the experimental arm of the trial.
3268358|NCT01550276|Experimental|Suboccipital soft tissue inhibition|The SI treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
3268359|NCT01550276|Experimental|Occiput-atlas-axis global manipulation|The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex
3268360|NCT01550276|Experimental|The combination of both treatments|
3268361|NCT01550276|Placebo Comparator|control group|
3268362|NCT01550302|No Intervention|Controls|Subjects enrolled in this group will only have a line drawn on the side of their neck for superficial cervical plexus block, but we will not perform the injection. The subjects will not be aware whether they received an intra-operative block or not. In addition, neither the Post-Anesthesia Care Unit nurse nor the providers involved in the post-operative care will be aware of subjects group assignment.
3268363|NCT01550302|Active Comparator|Superficial Cervical Plexus Block|Subjects enrolled in this group will have a line drawn and will receive a superficial cervical plexus block at the end of the surgery just prior to emergence from anesthesia.
3268364|NCT01550315|Active Comparator|High Sodium - POTS & Controls|Subjects will receive a high sodium diet for 4-5 days prior to study day. Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation.
3268365|NCT01550315|Other|Low Sodium Diet (POTS & Controls)|"Participants will consume a very low sodium diet (10 mEq/day) for 4-5 days prior to study day.~Procedures include: blood work, urine collection, Pulsitile Arterial Tonometry (PAT), PAT analysis, Calf Blood Flow in Reactive Hyperemia (CBF-RH), & evaluation of forearm-mediated dilation."
3268366|NCT01550354|Active Comparator|Propofol group|Intravenous administration of propofol 2 mg/kg before intubation
3268367|NCT01550354|Active Comparator|Alfentanil group|Intravenous administration of alfentanil 14 μg/kg before intubation
3268368|NCT01550354|Active Comparator|Rocuronium group|Intravenous administration of rocuronium 0.3 mg/kg before intubation
3268369|NCT01550380|Experimental|All participants|
3268370|NCT01550406|Active Comparator|Tachocomb|Tachocomb will be applicated on the cut surface of distal pancreatectomy
3268371|NCT01550406|Active Comparator|PGA|PGA will be applicated on the cut surface of distal pancreatectomy
3268372|NCT01550406|No Intervention|Control|No mesh will be applicated on the cut surface of distal pancreatectomy
3268373|NCT01550419|Experimental|Atorvastatin(50 characters)|
3268374|NCT01550419|Placebo Comparator|Placebo(50 characters)|
3268375|NCT01550432|Experimental|High-Dose Glutathione|2,260 mg/day
3268376|NCT01550432|Experimental|Low-Dose Glutathione|1,130 mg/day
3268377|NCT01550432|Experimental|High-Dose N-Acetylcysteine|1,200 mg/day
3268378|NCT01550432|Experimental|Low-Dose N-Acetylcysteine|600 mg/day
3268379|NCT01550432|Placebo Comparator|Placebo|Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.
3268380|NCT01550445|No Intervention|steroid withdrawal|The clinical outcome after kidney transplantation, under the immunosuppression of steroid withdrawal starting at 3 months post-transplantation using tacrolimus, mycophenolate mofetil, and basilixumab should be analyzed.
3268381|NCT01550458|Experimental|Mibefradil|
3268382|NCT01550458|Placebo Comparator|Placebo|
3268383|NCT01550497|Experimental|Home Exercise Group|Perform home exercises of unsupervised spinal stabilization exercises for 8 weeks
3268384|NCT01550497|Experimental|Weeky Physical Therapy Group|weekly physical therapy of supervised spinal stabilization exercises for 8 weeks
3268385|NCT01550523|Experimental|18-mer oligodeoxynucleotide|
3268386|NCT01550536|Experimental|Training|Sedentary women who exercised <2 hours per week and who had never engaged in a regular exercise program were enrolled in an exercise training intervention, following baseline measurements. See intervention below.
3268387|NCT01550536|No Intervention|Active|Postmenopausal women who exercised >5 hours per week and had been doing so for at least the past 10 years. These women were asked to maintain their normal activity habits for the duration of the study.
3268388|NCT01550588|Placebo Comparator|Medication|Anticoagulation, Antiplatelet agent
3268389|NCT01550588|Active Comparator|Device closure|Amplatzer PFO occluder device
3268390|NCT01550601|Other|bariatric surgery 1|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with conservation of gastric antrum.
3268391|NCT01550601|Experimental|bariatric surgery 2|Longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery. In this arm, patients have a bariatric surgery with ablation of gastric antrum.
3268392|NCT01550614|Experimental|Arm A: Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer and standard of care angina medication
3268393|NCT01550614|No Intervention|Arm B|Standard of care angina medication
3268394|NCT01550627|Active Comparator|extra-fluid|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day).
3268395|NCT01550627|Placebo Comparator|non extra fluid (control group)|The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
3268396|NCT01550640|Experimental|remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
3268397|NCT01550640|No Intervention|standard|control standard group
3268398|NCT01550653|Experimental|Liraglutide|"See Intervention"
3268399|NCT01550653|Placebo Comparator|Placebo|"See Intervention"
3268400|NCT01550666|Experimental|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
3268401|NCT01550666|No Intervention|Treatment As Usual|Participants of this group will continue to receive medication follow up at the Center for Health Care Services. They will not be required to do anything additional except to complete assessment visits.
3268402|NCT01550679||Smokers or ex-smokers|Smokers or ex-smokers 40-65 years of age with a smoking history of at least 20 pack-years with no diagnosis of COPD or asthma
3268403|NCT01550718|Active Comparator|ESML-Exercise (Physical Activity Program)|ESML-Exercise consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic. Classes are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the class gets individual attention and that all exercises are done safely using proper form.
3268404|NCT01550718|Active Comparator|ESML-SOCIAL (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session. Seminars are carried out in small groups of five to six participant/care partner dyads (10-12 people total), to ensure everyone in the seminar gets individual attention and that everyone has a chance to bring up any concerns."
3268405|NCT01550718|No Intervention|No Intervention|This arm will receive no intervention during the active treatment period. After the 4 month assessment participants can choose to attend a support group.
3268406|NCT01550770|Experimental|proprofol|
3268407|NCT01550783|Experimental|Group I (home-based HPV screening)|Participants collect 2 vaginal specimens using polyester swabs that are then placed in a specimen tube. Specimens are then submitted to the Harborview Medical Center clinical pathology lab. Participants with a positive HPV test result will have a Pap test. Participants with an abnormal Pap test will undergo standard of care as in Group II.
3268408|NCT01550783|Experimental|Group II (clinic-based standard of care screening)|Participants undergo standard of care cervical cancer screening and follow-up. That is, participants undergo Pap testing. Participants with an abnormal Pap test undergo HPV testing, colposcopy, cervical biopsy and/or ECC. Participants with cervical biopsies showing precancerous changes are offered to undergo LEEP or are referred to appropriate care.
3268409|NCT01550796|Active Comparator|d-cycloserine|d-cycloserine 250 mg two days per week one hour prior to(cognitive training)
3268410|NCT01550796|Placebo Comparator|Placebo|Placebo pill two days per week 1 hour prior to cognitive training
3268411|NCT01550822|Active Comparator|HEALS|Intervention group which will receive group clinics addressing smoking cessation, healthy eating, physical activity, and the risk factors of stroke.
3268412|NCT01550822|No Intervention|Usual Care|This group will receive usual care for stroke survivors
3268413|NCT01550835|Experimental|Distal Embolic Protection Only|Carotid stenting with distal embolic protection only
3268414|NCT01550835|Active Comparator|Distal embolic protection and aspiration thrombectomy|Aspiration thrombectomy following stent deployment and prior to removal of distal embolic protection
3268415|NCT01550848|Experimental|Abraxane and Gemcitabine|Abraxane and Gemcitabine
3268416|NCT01550874|No Intervention|Control Group|Wear the pedometer provided by study everyday with weekly charging and syncing of data.
3268417|NCT01550874|Experimental|Experimental Group|Wear the pedometer provided by the study everyday and also participate in phone-based physical activity behavior-change counselling for 6 months and then check sustainability without further motivational support for another 6 months.
3268418|NCT01550887|No Intervention|Impulsivity evaluation|
3268419|NCT01550900|Experimental|Metformin ER|Participants receive two tablets of Metformin ER 500 mg once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy. Dose will be reached in a gradual escalation scheme to improve gastrointestinal tolerance. If participants experience side effects during dose escalation regimen, they will be reduced to one tablet of 500 mg daily, and may continue taking 500 mg daily for the duration of the study.
3268420|NCT01550900|Active Comparator|Placebo|Control group given matched Placebo once daily for no more than twelve to eighteen months allowing time for at least one follow up colonoscopy.
3268421|NCT01550913|Experimental|Sober Network IPT|Participants are assigned to Sober Network Interpersonal Psychotherapy (IPT)
3268422|NCT01550913|Other|Treatment as Usual|Participants are assigned to have Treatment as Usual
3268423|NCT01550926|Active Comparator|Arm 1|60 mg orlistat
3268424|NCT01550926|Active Comparator|Arm 2|120 mg orlistat (2 X 60 mg capsules)
3268425|NCT01550926|Experimental|Arm 3|orlistat experimental formulation
3268426|NCT01550939|No Intervention|Time Comparison between the Lenstar and IOLMaster|
3268427|NCT01550978|Experimental|Study Group|Patients intubated with AnapnoGuard EndoTracheal Tube and connected to the AnapnoGuard 100 Control System
3268428|NCT01550978|No Intervention|Control Group|Patients intubated with the Standard of Care EndoTracheal Tube and Connected to a Suction Regulator
3268429|NCT01551004|Experimental|Cohort A|8 subjects (6 active, 2 placebo) receive a single oral dose of 100 mg CRS3123 or placebo
3268430|NCT01551004|Experimental|Cohort B|8 subjects (6 active, 2 placebo) receive a single oral dose of 200 mg CRS3123 or placebo
3268431|NCT01551004|Experimental|Cohort C|8 subjects (6 active, 2 placebo) receive a single oral dose of 400 mg CRS3123 or placebo
3268432|NCT01551004|Experimental|Cohort D|8 subjects (6 active, 2 placebo) receive a single oral dose of 800 mg CRS3123 or placebo
3268433|NCT01551004|Experimental|Cohort E|8 subjects (6 active, 2 placebo) receive a single oral dose of 1200 mg CRS3123 or placebo
3268434|NCT01551017||c-treatment|test group
3268435|NCT01551017||standard cooling|comparison group
3268436|NCT01551043|Experimental|Arm 1|
3268437|NCT01551069|Active Comparator|HCQ|HCQ 200~400mg, once daily, oral administration
3268438|NCT01551069|Other|Placebo|HCQ-placebo, once daily, oral administration
3268439|NCT01551108|Active Comparator|Mobile phone intervention: minimal|Intervention: limited behavioral strategies
3268440|NCT01551108|Experimental|Mobile phone intervention: intensive|Intervention: advanced behavioral strategies
3268441|NCT01551121||intervention group|"Patient in the intervention group will have camera installed in their room. These cameras can either work in visible or infrared range. They are physically linked to a server that will store and analyze images in real-time. The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy"
3268442|NCT01551121||non-equipped group|"Patient in the non-equipped group will have usual care"
3268443|NCT01551134|Active Comparator|Open fundoplication|Fundoplication performed with open surgery
3268444|NCT01551134|Experimental|Lap fundoplication|Primary fundoplication performed by laparoscopic surgery
3268445|NCT01551147|Experimental|Experimental 200 mg dose|
3268446|NCT01551147|Active Comparator|Active Comparator|
3268447|NCT01551147|Placebo Comparator|Placebo Comparator|
3268448|NCT01551160|Experimental|Medical Emergency Team|A communication and team-working initiative
3268449|NCT01551225|Active Comparator|Escitalopram|17 or 18 Patients with IBS and panic disorder treated with Escitalopram.
3268450|NCT01551225|Placebo Comparator|Placebo tablets to Escitalopram|17 or 18 Patients with IBS and panic disorder treated with placebo.
3268451|NCT01551238|Experimental|Protein intake of 5 energy percent|
3268452|NCT01551238|Experimental|Protein intake of 30 energy percent|
3268453|NCT01551251||Advanced NSCLC with high TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with high TAM were included as one cohort group.
3268454|NCT01551251||Advanced NSCLC with low TAM|All patients with advanced non-small cell lung cancer who had been treated at the Linkou Branch of Chang Gung Memorial Hospital were included. Tumor specimens with low TAM were included as one cohort group.
3268455|NCT01551277|Placebo Comparator|Control Group|
3268456|NCT01551277|Experimental|BREATH STACKING|
3268457|NCT01551290|Placebo Comparator|Group I: Placebo|Participants in Group I receive placebo
3268458|NCT01551290|Experimental|Group II: Infliximab|Participants in Group II receive 5 mg/kg infliximab
3268459|NCT01551316|Experimental|MN-221|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
3268460|NCT01551316|Experimental|PLACEBO|If the participants qualify, they will be randomized into one of two arms for 4 days. The arms are either Placebo (no medication) or MN-221 intravenously infused.
3268461|NCT01551329|Experimental|Drug: Ketamine|
3268462|NCT01551342||Cystoscopic surveillance, TURT or Cystectomy|The following subjects will be enrolled: Subjects previously diagnosed with bladder cancer undergoing routine cystoscopic surveillance, TURT or Cystectomy.
3268463|NCT01551368|Experimental|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hCG will be given immediately and two IUIs will be performed 24 hours apart.
3268464|NCT01551368|Placebo Comparator|Placebo|Same as for nimodipine but an identical placebo will be self-administered.
3268465|NCT01551381|Experimental|EV-077|Oral administration
3268466|NCT01551381|Placebo Comparator|Placebo|Oral administration
3268467|NCT01551394|Experimental|Meropenem|"Infants will received the Meropenem 20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes.~Treatment duration is 11 ± 3 days."
3268468|NCT01551394|Active Comparator|Standard of care|"The two accepted therapeutic options are:~ampicillin + gentamicin (SOC regimen 1) and~cefotaxime + gentamicin (SOC regimen 2)."
3268469|NCT01551433||Pts scheduled for Ivor Lewis esophagectomy|During the operation, once the gastric conduit has been mobilized and positioned, and once the anastomotic site has been identified by the surgeon, the assigned RSA will provide the Wipox instrument to the fellow (the primary surgeon will be blinded to the result) who will then obtain one measurement from the anastomotic site.
3268470|NCT01551446|Experimental|Bardoxolone Methyl 20mg|
3268471|NCT01551459|Active Comparator|Arm 1: Dacarbazine|Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
3268472|NCT01551459|Experimental|Arm 2: Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity.
3268473|NCT01551472||3DKnee™ with e-plus Insert|Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty.
3268474|NCT01551485|Experimental|Zolpidem|
3268475|NCT01551485|Placebo Comparator|Placebo|
3268476|NCT01551498|Placebo Comparator|Placebo|subject takes one oral placebo lozenge, three times per day
3268477|NCT01551498|Active Comparator|Anatabloc Supplement|subject takes one oral Supplement lozenge, three time per day
3268478|NCT01551511|Experimental|delta-9-tetrahydrocannabinol (namisol)|
3268479|NCT01551511|Placebo Comparator|Placebo|
3268480|NCT01551524|Experimental|Intravenous Erwinia|
3268481|NCT01551537||Cohort Group|Healthy females aged 10 years and above will receive 1, 2 or 3 doses of Cervarix as per the Prescribing Information (PI) in Sri Lanka.
3268482|NCT01551576||photoacoustic imaging (PAI)|Men seen in the urology clinic for elevated PSA and/or abnormal digital rectal exam (DRE) will be offered PAI at the time of transrectal ultrasound guided biopsy, which is standard of care. In addition, patients with a biopsy proven prostate cancer may also be approached for this PAI scan
3268483|NCT01551589|Experimental|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):The clinical target volume of regional lymph node (CTVn) of IFI included the nodal region(s) in which the involved lymph node(s) was/were located.chemothrapy:docetaxel and cisplatin.
3268484|NCT01551589|Active Comparator|Elective Nodal Irradiation (ENI)|Elective Nodal Irradiation (ENI):The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17 were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.chemothrapy:docetaxel and cisplatin.
3268485|NCT01551602|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
3268486|NCT01551602|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
3268487|NCT01551602|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
3268488|NCT01551602|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
3268489|NCT01551602|Active Comparator|MN-10-T SD|Single administration of MN-10-T
3268490|NCT01551602|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
3268491|NCT01551602|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
3268492|NCT01551602|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
3268493|NCT01551602|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
3268494|NCT01551602|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
3268495|NCT01551602|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
3268496|NCT01551615|Experimental|Metformin then metformin + vandetanib|Metformin alone followed by metformin in combination with vandetanib
3268497|NCT01551628|Experimental|Recombinant Human Arginase 1 Peg5000|
3268498|NCT01551641|Experimental|VEGF decressed|patients will receive concurrent chemoradiotherapy only
3268499|NCT01551641|Experimental|thalidomide|patients will be given thalidomide concurrent chemoradiotherapy
3268500|NCT01551641|Experimental|without thalidomide|patients will receive concurrent chemoradiotherapy only
3268501|NCT01551654|Placebo Comparator|Placebo Acu-TENS|No Electrical output was coming out from the TENS unit
3268502|NCT01551654|Experimental|TENS over acupuncture points|A constant mode of electrical stimulation at 2 pulses per second and pulse width at 200µs for 45 minutes. Intensity was set to just initiate muscle contraction.
3268503|NCT01551667||Cases / bacteraemia|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients has bacteraemia.
3268504|NCT01551667||Controls|Patients consulting at the departments of Diabetology, Dermatology or Infectious Diseases of the participating hospitals and who have (1) inaugural or recurrent diabetic foot/ankle ulcers of Grade 2-4, or (2) who have an infected leg ulcer (arterial, venous, or mixed. This infection must involve S. aureus in a mono-or polymicrobial setting. This group of patients does not have bacteraemia.
3268505|NCT01551680|Experimental|Concurrent whole brain radiotherapy and iniparib|
3268506|NCT01551706|Active Comparator|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract (350 mg) per day
3268507|NCT01551706|Placebo Comparator|Exicipient pill|
3268508|NCT01551719|No Intervention|Standard Procedure (phase I)|Antibiotic prescription following in vitro sensitivity test according to each surgeon's will.
3268509|NCT01551719|Experimental|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection, according to each surgeon's will.
3268510|NCT01551732|Active Comparator|Anger Control Therapy|10 session manualized cognitive behavioral anger control therapy
3268511|NCT01551732|Experimental|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with an interactive biofeedback videogame.
3268512|NCT01551771|Experimental|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
3268513|NCT01551771|Placebo Comparator|GW824575 matched-placebo|Placebo
3268514|NCT01551784||1|
3268515|NCT01551797|Experimental|Test Sustained Release (SR) Paracetamol (2000 mg)|A single 2000 mg oral dose of SR paracetamol formulation (2 x 1000 mg) administered with 150 mL of water.
3268516|NCT01551797|Experimental|Test SR Paracetamol (1500 mg)|A single 1500 mg oral dose of SR paracetamol formulation (2 x 750 mg) administered with 150 mL of water.
3268517|NCT01551797|Active Comparator|Reference Paracetamol (2000 mg)|Two single 1000 mg doses of paracetamol (2 x 500 mg/dose) administered orally 6 hours apart, administered with 150 mL of water.
3268518|NCT01551810|Experimental|Influenza Virus Vaccine|Influenza Virus Vaccine（no Preservative ) 0.5ml intramuscular injections
3268519|NCT01551810|Experimental|Influenza Virus Vaccine(Preservative)|Influenza Virus Vaccine（add Preservative ) 0.5ml intramuscular injections
3268520|NCT01551823|Experimental|Team 1|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
3268521|NCT01551823|Experimental|Team 2|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
3268522|NCT01551836|Other|Paracetamol formulation 1|Higher dose level of marketed paracetamol (compared to the other dosage arm)
3268523|NCT01551836|Other|Paracetamol formulation 2|Lower paracetamol concentrations
3268524|NCT01551849||VA-ECMO patients|Patients placed on VA-ECMO support for primary cardiac dysfunction.
3268525|NCT01551875||subjects who are meeting the inclusion criteria|
3268526|NCT01551901|Experimental|Luna Interbody System|
3268527|NCT01551914|Experimental|ultrasonic scissors|
3268528|NCT01551914|Active Comparator|conventional techniques of haemostasis|clips, ligatures, and bipolar coagulation
3268529|NCT01551940|Experimental|Botox|Botox injection : 100 UI of botulinum toxin type A (Botox®) diluted in 2.2 ml of NaCl 0.9 %
3268530|NCT01551940|Placebo Comparator|Placebo|Placebo injection : NaCl 0.9 %
3268531|NCT01551953|Experimental|tai chi exercise|
3268532|NCT01551953|Experimental|mind-body breathing|
3268533|NCT01551953|Active Comparator|education|
3268534|NCT01551966|Experimental|video capsule endoscopy|
3268535|NCT01551992|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
3268536|NCT01551992|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
3268537|NCT01552005||Population of patients treated with Saxagliptin|
3268538|NCT01552018|Active Comparator|Saxagliptin|Saxagliptin 5 mg/day
3268539|NCT01552018|Placebo Comparator|Placebo|Placebo
3268540|NCT01552031||Observational group|
3268541|NCT01552044|Experimental|spironolactone|Spironolactone 25mg/day
3268542|NCT01552044|Placebo Comparator|Placebo|placebo tablets
3268543|NCT01552070|Experimental|With recruitment maneuver group|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds. Blood gases were sampled and blood samples taken for culture before, within 2 minutes, 5 minutes, and 30 minutes after intubation. Haemodynamic and respiratory parameters were continuously recorded throughout the study.
3268544|NCT01552070|Active Comparator|Without recuritment maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
3268545|NCT01552096|Placebo Comparator|Placebo|The placebo group (n=30) will receive a submucosal infiltration with 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
3268546|NCT01552096|Active Comparator|lidocaine|will receive a total of 2 mg.kg-1 of 2% lidocaine HCl (Xylocaine, Astra-Zeneca,) in 3 mL of normal saline (1.5 ml around each tonsil), 5 minutes before surgical incision.
3268547|NCT01552096|Experimental|Tramadol|(n=30) will receive a submucosal infiltration with 2 mg kg-1 tramadol in 3 mL of normal saline (1.5 ml around each tonsil), 3 minutes before surgical incision.
3268548|NCT01552122|Experimental|Odanacatib|
3268549|NCT01552122|Active Comparator|Alendronate|
3268550|NCT01552135||Healthy|Healthy men above 50 years old
3268551|NCT01552148|Active Comparator|Group TAP (US guided)|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
3268552|NCT01552148|Other|Group Control|
3268553|NCT01552161||Patients with negative coronarography.|Subjects who underwent coronary angiography and were classified as having no critical lesions in coronary arteries (a lesion of up to 50% of artery lumen is accepted as non-critical).
3268554|NCT01552161||Patients with positive coronarography|Subjects who underwent coronary angiography and were classified as having critical lesions in coronary arteries (over 50% narrowing of artery lumen).
3268555|NCT01552174||Outpatients attending general ophthalmologic consultation|"Outpatients of either sex, aged at least 18 years, seen in general ophthalmological consultation~Patients informed of the objectives of the survey and agreeing to participate.~Patient attending to the ophthalmological consultation for any reasons: regular check-up of chronic disease, acute symptoms, or for surgery preparation or follow up."
3268556|NCT01552187|Placebo Comparator|Placebo|Placebo
3268557|NCT01552187|Active Comparator|Colchicine|Colchicine
3268558|NCT01552200|Experimental|A-Standard Colonoscopy, G-Eye procedure|Standard Colonoscopy,G-Eye procedure
3268559|NCT01552200|Active Comparator|B- G-Eye procedure, Standard Colonoscopy|G-Eye procedure,Standard Colonoscopy
3268560|NCT01552226|Active Comparator|Continuous Preperitoneal Analgesia|Continuous Preperitoneal Analgesia for pain management
3268561|NCT01552226|Active Comparator|Continuous Epidural Analgesia|Continuous Epidural Analgesia for pain management
3268562|NCT01552239|Experimental|1 Arm|"Stratum A:~R0, primary wound closure~Stratum B:~R0, secondary wound closure~Stratum C:~R1, tertiary wound closure"
3268563|NCT01552252|Placebo Comparator|0% POs-Ca|
3268564|NCT01552252|Active Comparator|0.5% POs-Ca|
3268565|NCT01552252|Active Comparator|1% POs-Ca|
3268566|NCT01552252|Active Comparator|1.5% POs-Ca|
3268567|NCT01552252|Active Comparator|2% POs-Ca|
3268568|NCT01552265||single-group MCI patients|
3268569|NCT01552291|Active Comparator|Glutamin|
3268570|NCT01552291|Placebo Comparator|Placebo|
3268571|NCT01552304|Experimental|Oxygen treatment group|Besides routine care, patients in this group will receive postoperative oxygen therapy with nasal prolong at 3 liters/min during the first 3 nights after surgery.
3268572|NCT01552304|Other|Control group|Patients will be managed by the anesthesiologists and surgeons as per routine practice.
3268573|NCT01552317|Experimental|lifestyle counselling|A package of advice and interventions to help participants reduce their salt intake.
3268574|NCT01552317|No Intervention|Normal care|This group will receive the normal care that they would get anyway.
3268575|NCT01552330|Experimental|Group A|Primaquine only followed by Pyronaridine-Artesunate and followed by Primaquine together with Pyronaridine-Artesunate.
3268576|NCT01552330|Active Comparator|Group B|Primaquine only followed by Primaquine together Pyronaridine-Artesunate and followed by Pyronaridine-Artesunate only.
3268578|NCT01552382||cardiac surgical patients|patients undergoing a cardiac surgical procedure
3268579|NCT01552421|Active Comparator|TV NOTES cholecystectomy|Participants randomized to TV NOTES cholecystectomy
3268580|NCT01552421|No Intervention|Laparoscopic cholecystectomy|Participants randomized to laparoscopic cholecystectomy
3268581|NCT01552434|Experimental|Group I (temsirolimus, bevacizumab, cetuximab)|Patients receive temsirolimus IV over 30-60 minutes on days 1, 8, 15, and 22; bevacizumab IV over 30-90 minutes on days 1 and 15; and cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3268582|NCT01552434|Experimental|Group II (temsirolimus, bevacizumab, valproic acid)|Patients receive temsirolimus and bevacizumab as in Group I and valproic acid PO on days 1-7 and 15-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3268583|NCT01552434|Experimental|Group III (temsirolimus, bevacizumab)|Patients receive temsirolimus and bevacizumab as in Group I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3268584|NCT01552447|Other|1 application of EpiFix|1 x dehydrated human amnion/chorion membrane
3268585|NCT01552447|Other|2 applications of EpiFix|2 x dehydrated human amnion/chorion membrane
3268586|NCT01552447|Other|Standard of care|Compression bandaging
3268587|NCT01552473|Active Comparator|Brain Training Program 1|Training Program focusing on providing educational information of cognitive issues related to TBI
3268588|NCT01552473|Experimental|Brain Training Program 2|Program focuses on strategies to address cognitive issues following TBI
3268589|NCT01552486|Experimental|Chiropractic Spinal Manipulative Therapy|
3268590|NCT01552486|Other|Usual Care|
3268591|NCT01552499|Other|Control|
3268592|NCT01552499|Experimental|Treatment|
3268593|NCT01552512|No Intervention|MSPP Integrated Package|Participants in this arm only receive the standard care offered by the Ministry of Health (MSPP)called the Integrated Package. During the trial, they do not receive Nutributter.
3268594|NCT01552512|Experimental|Nutributter 3 Months, Integrated Package|Participants receive a one-month supply for the first 3 months of the 6-month trial in addition to the Integrated Package.
3268595|NCT01552512|Experimental|Nutributter 6 Months, Integrated Package|Participants receive a one-month supply for each month of the 6-month trial in addition to the Integrated Package.
3268596|NCT01552525||acute kidney injury|Patients with acute kidney injury according to the definition of AKIN (Acute Kidney Injury Network)
3268597|NCT01552538|Experimental|Cyberonics VNS System|Continued stimulation w/Cyberonics VNS
3268598|NCT01552551|Active Comparator|Healthy Steps|Healthy Steps program as currently implemented by the PA Department of Aging
3268599|NCT01552551|Experimental|Healthy Steps with Falls Case Management|Healthy Steps program augmented with research interventionist guidance on seeking physician care and home safety assessment
3268600|NCT01552551|Experimental|Healthy Steps in Motion|Healthy Steps program augmented with Healthy Steps in Motion, a 4-week, twice a week program of group exercise.
3268601|NCT01552564||STEMI patients|Consecutive patients presenting through the PPCI service
3268602|NCT01552577||TBI Group|Adults (civilian or military) with a history of one or more brain injuries / concussions.
3268603|NCT01552577||Control Group|Healthy adults (civilian or military) with no history of brain injury.
3268604|NCT01552590|Active Comparator|Tolvaptan, Tablet, QD, 2 weeks|
3268605|NCT01552590|Placebo Comparator|Placebo, Tablet, QD, 2 weeks|
3268606|NCT01552616|Experimental|Activation Treatment|
3268607|NCT01552616|No Intervention|Usual Care|This arm will not receive any study-motivated intervention. Subjects will receive usual care, but will participate in outcomes assessments.
3268608|NCT01552629|Experimental|Group 1 QGE031|QGE031 will be administered as a subcutaneous dose q2 weeks
3268609|NCT01552629|Placebo Comparator|Group 2 Placebo|A QGE031 matched placebo will be administered as a subcutaneous dose q2 weeks
3268610|NCT01552629|Experimental|Group 3 Cyclosporine A|Cyclosporine A will be administered (as per label) for atopic dermatitis.
3268611|NCT01552642|Active Comparator|Intervention Group|Intervention Group
3268612|NCT01552642|No Intervention|Control Group|Control Group
3268613|NCT01552655|Other|Dual-time PET/CT|
3268614|NCT01552668|Experimental|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
3268615|NCT01552668|Placebo Comparator|Placebo|
3268616|NCT01552707|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue for spinal fusion"
3268617|NCT01552707|Sham Comparator|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest.
3268618|NCT01552733|Experimental|Robotic Therapy|Robotic Therapy using 'Inmotion' device plus standard care. Participants randomised to robotic therapy will receive up to 12 sessions (approximately 1 hour each) performing tasks (including circle drawing, reaching targets and holding/moving against moderate resistance.
3268619|NCT01552733|Placebo Comparator|Standard Care|Rehabilitation therapy according to local guidelines.
3268620|NCT01552759|Experimental|Obese subjects with BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) and the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3268621|NCT01552759|Experimental|Obese without BED|"Subjects who meet the BMI requirement for obesity (>30 kg/m^2) but who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3268622|NCT01552759|Experimental|Normal-weight without BED|"Subjects with BMI 20-25 kg/m^2 who do not meet the DSM requirements for binge eating disorder based on responses to validated questionnaires.~Subjects will undergo the postprandial responses, cold pressor test and ad libitum test meal."
3268623|NCT01552785||Healthy adults|
3268624|NCT01552798|Experimental|Arm 1|
3268625|NCT01552798|Active Comparator|Arm 2|
3268626|NCT01552798|Placebo Comparator|Arm 3|
3268627|NCT01552811||Type 1 diabetes|
3268628|NCT01552811||healthy controls|
3268629|NCT01552824|Experimental|Vesico-amniotic shunt|In this arm, patients will be randomly selected to undergo vesico-amniotic shunting.
3268630|NCT01552824|Experimental|CYSTO|In this arm, all patients will be randomly selected for fetal cystoscopy.
3268631|NCT01552837|No Intervention|Healthy volunteers|MRI compatible, no present or past DSM-IV diagnosis
3268632|NCT01552837|Active Comparator|patients with Bipolar Disorder|MRI compatible, presence of DSM-IV diagnosis for Bipolar Disorder
3268633|NCT01552850|Experimental|Oxycodone Formulation A Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3268634|NCT01552850|Experimental|Oxycodone Formulation B Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3268635|NCT01552850|Experimental|Oxycodone Formulation C Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3268636|NCT01552850|Experimental|Oxycodone Formulation D Capsule|single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
3268637|NCT01552850|Experimental|Oxycodone Oral Solution|40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
3268638|NCT01552863|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268639|NCT01552863|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268640|NCT01552863|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268641|NCT01552863|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268642|NCT01552863|Experimental|Treatment E|Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268643|NCT01552863|Experimental|Treatment F|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3268644|NCT01552941|Experimental|Vagal Nerve Stimulation|
3268645|NCT01552993|Experimental|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and sucrose
3268646|NCT01552993|Placebo Comparator|placebo|pacifier and sucrose only
3268647|NCT01553006|Active Comparator|cefditoren pivoxil|cefditoren 10 mg/kg/day for 14 days
3268648|NCT01553006|Active Comparator|cefditoren pivoxil high dose|cefditoren 20 MKD were used to compare efficacy of treatment.
3268649|NCT01553019|Experimental|1- R(0) negative|50.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3268650|NCT01553019|Experimental|2- R(1) micro-positive|54.00 cobalt gray equivalent(CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3268651|NCT01553019|Experimental|3- R(2) gross positive|59.40 cobalt gray equivalent (CGE) Proton Radiation and concomitant chemotherapy with weekly gemcitabine
3268652|NCT01553032|Active Comparator|Erbitux®|
3268653|NCT01553032|Active Comparator|Fractionated Radiotherapy|
3268654|NCT01553045||atrial fibrillation, catheter ablation|Patients referred for ablation of atrial fibrillation
3268655|NCT01553071|Experimental|Investigational|Fenretinide (4-HPR) plus Intravenous Safingol
3268656|NCT01553097||women with stage I or II BC with adjuvant chemotherapy|"women with Stage I or II BC who~have undergone surgical treatment (biopsy, lumpectomy or mastectomy) and;~will be receiving adjuvant chemotherapy"
3268657|NCT01553097||women with Stage I or II BC without adjuvant therapy|"Women with stage I or II BC who~Have undergone surgical treatment (biopsy, lumpectomy or mastectomy) \~will not be receiving adjuvant chemotherapy"
3268658|NCT01553097||Healthy control|healthy education-age-matched women without cancer
3268659|NCT01553110||Cold Population|Male and female subjects 12 years of age and older with acute nasal discharge fewer then 7 days. Patients must be symptomatic at screening.
3268660|NCT01553110||Allergic Rhinitis|Male and female subjects of 12 years of age and older with a history suggesting nasal allergic symptoms for at least 1 year. Patients must be symptomatic at screening.
3268661|NCT01553123|Experimental|Ulipristal with iron|
3268662|NCT01553123|Placebo Comparator|Placebo|Placebo with iron
3268664|NCT01553227|Experimental|ventilator|The overall purpose of this study is to determine the effects of auto-Trilevel ventilation on patients with OSAHS and OHS by comparison with BiPAP ventilation. The following parameters are compared such as apnea hypopnea index, lowest SPO2, arousal index, sleep efficiency, PaCO2, daytime sleepiness and so on.
3268665|NCT01553266||MDET intervention|
3268666|NCT01553266||Control group|Patients who have not received the MDET intervention.
3268667|NCT01553305|Experimental|Supervised exercise programme|Six-weeks supervised high-intensity exercise programme with training sessions twice a week followed by 6-weeks unsupervised exercise programme.
3268668|NCT01553305|No Intervention|Unsupervised exercise programme|
3268669|NCT01553331|Active Comparator|conventional diathermy hook|Laparoscopic cholecystectomy made with diathermy hook starting from Calot´s triangle
3268670|NCT01553331|Active Comparator|ultrasonic dissection|Laparoscopic cholecystectomy made with ultrasonic dissection starting from gallbladder fundus
3268671|NCT01553370|Active Comparator|Alternate Intake-time|
3268672|NCT01553370|Experimental|Immediately post-exercise|
3268673|NCT01553383|Active Comparator|Dental device|"Provent nasal peep valve vs dental device"
3268674|NCT01553383|Active Comparator|CPAP|"continuous positive airway pressure CPAP vs nasap peep valve Provent"
3268675|NCT01553422|Active Comparator|before fluid Therapy|
3268676|NCT01553422|Active Comparator|after fluid Therapy|
3268677|NCT01553435|Placebo Comparator|Dextromethorphan, opioid analgisia, efficacy|
3268678|NCT01553435|Placebo Comparator|Placebo,opioid analgesia, efficacy|
3268679|NCT01553487|Experimental|Excercise|The forearm vibration training
3268680|NCT01553487|No Intervention|Control|Patients will be treated by routine fracture treatment methods (fixation and rest).
3268681|NCT01553500|Experimental|glucomannan|
3268682|NCT01553500|Placebo Comparator|placebo|
3268683|NCT01553513||Group 1 - STEMI|Patients with acute cardiovascular event and typical aberrations in the ECG(STEMI) and positive serum markers
3268684|NCT01553513||Group 2 - NSTEMI|Patients with acute coronary syndrome without typical aberrations in the ECG (NSTEMI) or without positive serum markers
3268685|NCT01553513||Group 3 - symptomatic CAD|Symptomatic patients with stable CAD, who are eligible for ICA
3268686|NCT01553513||Group 4 - STEMI|Patients eligible for ICA 6 months after STEMI and revascularization
3268687|NCT01553526||Orsiro DES|
3268688|NCT01553552||Infected by Schistosoma haematobium|
3268689|NCT01553552||Not infected by Schistosoma haematobium|
3268690|NCT01553565|Active Comparator|Conventional polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed with electrocautery. Submucosal injection of some solution before the removal are not performed.
3268691|NCT01553565|Experimental|Cold polypectomy|
3268692|NCT01553578|Experimental|Arm A (healing touch therapy)|Patients receive 30 minutes of healing touch therapy consisting of magnetic clearing, pain drains, hands in motion/hands still and mind clearing.
3268693|NCT01553578|Experimental|Arm B (guided imagery)|Patients listen to guided imagery audiotapes for 30 minutes.
3268694|NCT01553578|Active Comparator|Arm C (standard care)|Patients receive standard of care.
3268695|NCT01553604|Experimental|Postoperative day 6|Dressing is removed on the sixth postoperative day
3268696|NCT01553604|Experimental|Postoperative day 1|Dressing is removed on the first postoperative day
3268697|NCT01553617|Experimental|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
3268698|NCT01553617|Active Comparator|Human serum albumin|Human serum albumin (HSA 50g/L)
3268699|NCT01553630|Active Comparator|RIA bone graft|Surgery: open reduction and internal fixation (ORIF) of high energy metaphyseal fractures with Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
3268700|NCT01553630|Active Comparator|Surgery without bone graft|Surgery:open reduction and internal fixation (ORIF) of high energy metaphyseal fractures without Reamed Irrigator Aspirator (RIA) bone graft at the time of fixation.
3268701|NCT01553643|Experimental|Chinese Herb Huang-Chi-Wu-Wu-Tang|
3268702|NCT01553643|Placebo Comparator|Placebo|
3268703|NCT01553656|Experimental|Cabozantinib capsules and tablets|Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.
3268704|NCT01553669|Experimental|reminiscence therapy|Reminiscence therapy is a method of using the memory to protect mental health and improve the quality of life.
3268705|NCT01553669|No Intervention|Control group|The participants assigned to the waiting-list as the control group will be treated as before. After the intervention period, we will conduct reminiscence therapy on them if they ask for.
3268706|NCT01553682|No Intervention|Enhanced Standard-Of-Care|Participants will watch a video about how to prevent STIs and HIV, then do question and answer session. This group will be last 1 hour. It will be led by one African American health educator, and have about 4-8 other young women participants. Participants will be asked to rate the workshop anonymously.
3268707|NCT01553682|Active Comparator|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
3268708|NCT01553682|Experimental|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
3268709|NCT01553695|Active Comparator|general population|
3268710|NCT01553695|Experimental|ADHD Patient|
3268711|NCT01553721|Experimental|udenafil|"Phase IIa Experimental : Udenafil Dose 1, Dose 2~Phase IIb Experimental : Udenafil"
3268712|NCT01553721|Placebo Comparator|placebo|"Phase IIa Placebo Comparator : Placebo~Phase IIb Placebo Comparator : Placebo"
3268713|NCT01553760|Experimental|Tri-MICS|
3268714|NCT01553760|Active Comparator|Conventional Phaco|
3268715|NCT01553773|Experimental|Isoflavone|a gel with isoflavones (genistein 4%)
3268716|NCT01553773|Experimental|Estradiol|gel with 17-β estradiol 0.01%
3268717|NCT01553786|Experimental|lenalidomide|lenalidomide + CHOP
3268718|NCT01553799||US check tube|
3268719|NCT01553799||US check tube, Endobronchial|
3268720|NCT01553825||Pathologically diagnosed carcinoma|
3268721|NCT01553838|Experimental|Sequentially MRI guided and TRUS guided biopsy|Targeted MRI guided biopsy according to findings in a multiparametric MRI followed by transrectal guided biopsy
3268722|NCT01553877|Active Comparator|Pushti Packet|
3268723|NCT01553877|Experimental|Rice based Ready to Use Complementary Food Supplements|
3268724|NCT01553877|Active Comparator|Chick-pea based Ready to Use Complementary Food Supplements|
3268725|NCT01553890|Other|Patients diagnosed with scleroderma|patients diagnosed with scleroderma, clinical and lab support
3268726|NCT01553890|Other|No disease|Blood sample, venous blood, about 10 ml will be drawn from participants
3268727|NCT01553903|Experimental|Tamoxifen,|Current hormonotherapy treatment in hormone dependent breast cancer
3268728|NCT01553903|Experimental|Exemestane|Current hormonotherapy treatment in hormone dependent breast cancer
3268729|NCT01553903|Experimental|Anastrozole|Current hormonotherapy treatment in hormone dependent breast cancer
3268730|NCT01553903|Experimental|Letrozole|Current hormonotherapy treatment in hormone dependent breast cancer
3268731|NCT01553929|Experimental|Physical and cognitive activity group|
3268732|NCT01553929|Active Comparator|Physical activity group|
3268733|NCT01553929|Placebo Comparator|control group|
3268734|NCT01553942|Experimental|Afatinib|Afatinib
3268735|NCT01553968|Other|Endurance Trained Subjects|
3268736|NCT01553968|Other|Untrained Subjects|
3268737|NCT01553981|Active Comparator|Tadalafil|Tablet Tadalafil 20 mg every alternate day
3268738|NCT01553981|Placebo Comparator|Placebo|Tablet Placebo every alternate day
3268739|NCT01553994||HPV vaccinated, non-vaccinated|Individuals born between 1989 and 1996. HPV-vaccinated will be compared to non-vaccinated in regards to condyloma status post vaccination.
3268740|NCT01554007||Crohn's disease|Korean patients diagnosed with Crohn's disease
3268741|NCT01554020|Active Comparator|Multiherb product|Herbal product
3268742|NCT01554020|Placebo Comparator|Placebo|Maltodextrin control
3268743|NCT01554033||Huntington's disease patients|Huntington's disease patients and his(/her) family
3268744|NCT01554033||age-sex matched control|age-sex matched control about huntington patients
3268745|NCT01554046|Experimental|couples of first-degree family members|
3268746|NCT01554072|Placebo Comparator|Placebo|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. Patients will be instructed individually on each exercise, performing with supervisor that there be no doubt about execution, thereby minimizing any possible mistake in practice at home. For each day of the year ended data should be recorded in a daily monitoring. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
3268747|NCT01554072|Active Comparator|exercise|Patients will receive a booklet of exercises, besides containing an explanation of his illness and the importance of exercise in their quality of life, an exercise routine physical to be held three times a week for two consecutive months. For each day of the year ended data should be recorded in a daily monitoring. Is also scheduled a visit to the laboratory biweekly in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused. At the end of two months of the PR program semi-home patients will be subject to review so that all tests should be applied again.
3268748|NCT01554085|Experimental|ALS-002158|
3268749|NCT01554085|Placebo Comparator|Placebo|
3268750|NCT01554098|Active Comparator|Strategy : supine first|"This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.~Withdrawal in supine position followed by withdrawal with dynamic position change"
3268751|NCT01554098|Active Comparator|Strategy : dynamic first|This study will be performed as a cross over study, comparing withdrawal in the supine position versus withdrawal with dynamic position change.
3268752|NCT01554111|Active Comparator|Picosalax with rectal enema|This arm will receive one satchet of Picosalx and a rectal enema before the sigmoidoscopy for their bowel preparation regimen.
3268753|NCT01554111|Active Comparator|rectal enema|This group of patients will receive only a rectal enema for bowel preparation before their flexible sigmoidoscopy.
3268754|NCT01554111|Active Comparator|Pico-Salax|patient will take one sachet of pico-salax
3268755|NCT01554124|Experimental|Meropenem|"Infants will received Meropenem 40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
3268756|NCT01554137|Experimental|With isokinetic strength training|60 minutes isokinetic strength training on concentric mode
3268757|NCT01554137|Placebo Comparator|without isokinetic strength training|passive motion 60 minutes
3268758|NCT01554150|Experimental|Method of Levels Cognitive Therapy (MOL)|Participants in this arm will be able to receive therapy over a 3 month period. They will be able to schedule sessions with a therapist as and when they need them.
3268759|NCT01554150|No Intervention|Contact Service|The Contact Service arm is effectively a waiting list control. Participants assigned this arm will remain on the service's waiting list during the 3 months of the therapy phase. These participants will have access to a 'Contact Service' provided by the study therapist, where they are able to contact him if they want further information about the study or their treatment options.
3268760|NCT01554189|Experimental|Panel A (GT1 10 mg)|
3376803|NCT05006781|Experimental|tDCS+Dose A|Drug: DAOIB at dose A The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
3268761|NCT01554189|Experimental|Panel B (GT1 50 mg)|
3268762|NCT01554189|Experimental|Panel C (GT1 100 mg)|
3268763|NCT01554189|Experimental|Panel D (GT1 200 mg)|
3268764|NCT01554189|Experimental|Panel E (GT3 10 mg)|
3268765|NCT01554189|Experimental|Panel F (GT3 50 mg)|
3268766|NCT01554189|Experimental|Panel G (GT3 100 mg)|
3268767|NCT01554189|Experimental|Panel H (GT3 200 mg)|
3268768|NCT01554189|Experimental|Panel I (GT1a 10 mg)|
3268769|NCT01554189|Experimental|Panel J (GT1a 50 mg)|
3268770|NCT01554189|Placebo Comparator|Placebo Panel|
3268771|NCT01554202|Experimental|Young controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268772|NCT01554202|Experimental|Middle age controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268773|NCT01554202|Experimental|Elderly controls|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268774|NCT01554202|Experimental|Autosomal dominant forms of early-onset Alzheimer disease|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268775|NCT01554202|Experimental|Subjectif Cognitive Impariment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268776|NCT01554202|Experimental|Mild Cognitive Impairment patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268777|NCT01554202|Experimental|Alzheimer Disease patients|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268778|NCT01554202|Experimental|Non degenerative amnsesic syndrome|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268779|NCT01554202|Experimental|Frontotemporal lobe dementia|Assessment of memory, circulating tPA dosage, ApoE4, brain imaging examination MRI and PET examinations.
3268780|NCT01554215|Experimental|Mom Power Intervention Group|Participants that are randomly assigned to be in the intervention group will be invited to learn about parenting and self-care skills information at a community location, facilitated by two trained and experienced clinicians in a group setting. They will benefit from the en-vivo experience of being supported as a parent and will receive feedback and support about their challenges and strengths in parenting.
3268781|NCT01554215|Active Comparator|Mom Power Attentional Control Group|Participants randomly assigned to this group will receive parenting and self-care skills information through the mail weekly.
3268782|NCT01554228||Bariatric Surgery|
3268783|NCT01554254|Experimental|300mcg/kg/day for 28 days|
3268784|NCT01554267|Experimental|Mastectomy Skin Flap SPY Excision|Single arm study where areas of necrosis predicted by Laser-Assisted Indocyanine Green Dye Angiography (SPY system) will be excised intraoperatively during breast reconstruction surgery.
3268785|NCT01554280|Experimental|Oesophageal Stents|Patients enrolled will receive a fully coated, removable, self-expanding oesophageal stent.
3268786|NCT01554293|Experimental|PBL 1427 capsules|
3268787|NCT01554293|Placebo Comparator|Matching placebo|
3268788|NCT01554306||parkinson's disease, nocturnal hypokinesia, rotigotine|
3268789|NCT01554319|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
3268790|NCT01554319|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using a hand-held inhalation device.~Initial single dose on Day 1 (single-dose PK profile); after 48 h washout, twice-daily with a dosing interval of 12 h for 9 consecutive days (Days 3 to 11); last inhalation on Day 12."
3268791|NCT01554332|Active Comparator|Active stimulation|
3268792|NCT01554332|Sham Comparator|Sham stimulation|
3268793|NCT01554358|Other|Lifestyle counseling|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.
3268794|NCT01554358|No Intervention|Control|"the subjects in the control group had been educated regarding general principles of healthy lifestyle that benefits T2D and obesity prevention, and also informed about the current evidence showing that the lifestyle intervention is effective in women at high risk for T2D during the run-in period."
3268795|NCT01554384|Experimental|Xpert MTB/RIF|Patients in this arm will receive 1 sputum Xpert MTB/RIF test (point-of-treatment) and 1 sputum sample for MGIT liquid TB culture (regional lab)
3268796|NCT01554384|Active Comparator|Sputum smear microscopy|Patients in this study arm will receive 2 sputum samples for same-day smear microscopy and 1 of the sputum samples will have a MGIT Liquid culture (regional lab).
3268797|NCT01554397|Experimental|Phase II|All patients receive IMRT with concurrent cisplatin 40 mg/m2
3268798|NCT01554397|Active Comparator|Phase III - A|Patients in Phase III, Arm A receive 4-field box RT with concurrent cisplatin 40 mg/m2
3268799|NCT01554397|Experimental|Phase III - B|Patients in Phase III, Arm B receive IMRT with concurrent cisplatin 40 mg/m2
3268800|NCT01554410|Experimental|IMRT/Cisplatin/Gemcitabine|All patients get IMRT with concurrent cisplatin & gemcitabine, with the dose of gemcitabine varying according to cohort
3376804|NCT05006781|Experimental|tDCS+Dose B|Drug: DAOIB at dose B The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
3376805|NCT05006781|Experimental|tDCS+Dose C|Drug: DAOIB at dose C The DAOIB dose will be fixed during the 24 weeks duration. Device: tDCS tDCS
3376806|NCT05006781|Placebo Comparator|tDCS+placebo|Drug: Placebo Placebo Device: tDCS tDCS
3376807|NCT05005845|Active Comparator|0.5% NFX-179 gel|Topical gel applied once daily to target cNFs
3376808|NCT05005845|Active Comparator|1.5% NFX-179 gel|Topical gel applied once daily to target cNFs
3376809|NCT05005845|Placebo Comparator|Vehicle gel|Topical gel applied once daily to target cNFs
3268801|NCT01554423|Active Comparator|Testing and Counseling|One of the four RCT arms will be comprised of couples randomly assigned to testing and counseling on HIV and associated STI co-infections based on revised procedures developed by the CDC. Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences. Randomized trial studies of behavioral interventions have incorporated testing and counseling as a comparison condition and studies in the US and SSA countries have shown that testing and counseling on its own can help to reduce HIV/STI risk behaviors.
3376810|NCT05004935|Experimental|beetroot juice|single intake of beetroot juice containing 800mg nitrates
3376811|NCT05004935|Active Comparator|nitrates|single intake of 800mg nitrates (NaNO3)
3376812|NCT05003453|Experimental|1.5% Palmitoylethanolamide (PEA) sold as Levagen+|Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
3376813|NCT05003453|Placebo Comparator|Placebo comparator|A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
3376814|NCT05000216|Experimental|Cohort A, Arm A1: Moderna mRNA-1273 +IS (MMF or MPA)|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Moderna COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376815|NCT05000216|Experimental|Cohort A, Arm A2: BNT162b2 +IS (MMF or MPA)|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Pfizer-BioNTech COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376816|NCT05000216|Experimental|Cohort A, Arm A3: Ad26.COV2.S + IS (MMF or MPA)|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376817|NCT05000216|Experimental|Cohort A, Arm A4: Moderna mRNA-1273|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Moderna COVID-19 vaccine booster (1 dose), per protocol instruction.
3376818|NCT05000216|Experimental|Cohort A, Arm A5: BNT162b2|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Pfizer-BioNTech COVID-19 vaccine booster (1 dose), per protocol instruction.
3376819|NCT05000216|Experimental|Cohort A, Arm A6: Ad26.COV2.S|Participants who are taking MMF or MPA (without additional B cell depleting medications or MTX) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
3376820|NCT05000216|Experimental|Cohort B, Arm B1: Moderna mRNA-1273 + IS (MTX)|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Moderna COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376821|NCT05000216|Experimental|Cohort B, Arm B2: BNT162b2 + IS (MTX)|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Pfizer-BioNTech COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376822|NCT05000216|Experimental|Cohort B, Arm B3: Ad26.COV2.S + IS (MTX)|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376823|NCT05000216|Experimental|Cohort B, Arm B4: Moderna mRNA-1273|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Moderna COVID-19 vaccine booster (1 dose), per protocol instruction.
3376824|NCT05000216|Experimental|Cohort B, Arm B5: BNT162b2|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Pfizer-BioNTech COVID-19 vaccine booster (1 dose), per protocol instruction.
3376825|NCT05000216|Experimental|Cohort B, Arm B6: Ad26.COV2.S|Participants who are taking methotrexate (without additional B cell depleting medications or MMF/ MPA) for management of their underlying autoimmune disease will withhold their immunosuppressive medications (IS) before and after the Janssen COVID-19 vaccine booster (1 dose), per protocol instruction.
3376826|NCT05000216|Experimental|Cohort C, Arm C1: Moderna mRNA-1273 +IS (B cell depletion therapy)|Participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Moderna COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3268802|NCT01554423|Experimental|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use. Each module is delivered by the clinician using a two-sided laminated card that includes scripted questions and visual aids. Consistent with brief intervention models, the BMI intervention is delivered during one 45 minute session with advice giving as a primary characteristic. Motivational interviewing is also incorporated within the BMI intervention by using a client-centered method of communication to foster behavior change through five techniques of expressing empathy, developing discrepancy, avoiding argumentation, supporting self-efficacy, and motivational rules.
3268803|NCT01554423|Experimental|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present. The six IFCBT sessions are delivered during a 2-week period with two group couples' sessions and one individual couples' session each week.
3268804|NCT01554423|Experimental|BMI + IFCBT|Participants assigned to this experimental arm will receive Brief Motivational Interviewing combined with Integrated Family and Cognitive Behavioral Therapy.
3268805|NCT01554436|Experimental|patients in smoking cessation|patients in smoking cessation
3268806|NCT01554449|Experimental|Serious game|In this group, patients will have a session of conventional retraining with a serious game retraining.
3268807|NCT01554449|Active Comparator|control patients|In this group, patients will have the conventional retraining with an other conventional retrainning session. The difference between both groups of patients is the serious game session for one group and conventional session for the other group
3268808|NCT01554449|Placebo Comparator|controls|For the neurologic assessments, patients are compared to healthy patient (without stroke)
3268809|NCT01554462|Active Comparator|ADHD active|4 month intervention with EPA/DHA in ADHD group
3268810|NCT01554462|Placebo Comparator|ADHD Placebo|4 month dietary intervention with placebo in ADHD group
3268811|NCT01554462|Active Comparator|Active Healthy control|4 month dietary intervention with DHA/EPA in healthy control group
3268812|NCT01554462|Placebo Comparator|Healthy placebo|4 month dietary intervention with placebo in healthy control group
3268813|NCT01554501||Community sample|
3268814|NCT01554540|Experimental|Cutaneous iontophoresis of Treprostenil|
3268815|NCT01554540|Placebo Comparator|Cutaneous iontophoresis of placebo|
3268816|NCT01554553|Experimental|Posterior crural repair|
3268817|NCT01554553|No Intervention|No posteriorcrural repair|
3268818|NCT01554566|Experimental|honey, no honey|
3268819|NCT01554592|Experimental|Statin withdrawal|Participants will received a placebo for 12 weeks.
3268820|NCT01554592|Active Comparator|Stable statin therapy|Participants need to have been receiving statin therapy for at least 3 months and be on a stable dose.
3268821|NCT01554631|Experimental|Arm 1|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken without water
3268822|NCT01554631|Experimental|Arm 2|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT 100 mg; Day 1: oral sucrose load plus Glucobay ODT 100 mg taken with water
3268823|NCT01554631|Active Comparator|Arm 3|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet 100 mg; Day 1: oral sucrose load plus Glucobay standard tablet 100 mg taken with water
3268824|NCT01554644|Active Comparator|Prontosan Solution and Gel|ProntosanTM Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and ProntosanTM Wound Gel (PHMB 0.1%, Betaine 0.1%)
3268825|NCT01554644|Placebo Comparator|Saline Solution and Inert Gel|
3268826|NCT01554657|Experimental|5 Days|
3268827|NCT01554657|Placebo Comparator|7 days|
3268828|NCT01554670|No Intervention|arthroscopic subacromial decompression|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).
3268829|NCT01554670|Active Comparator|decompression+RF micro-tenotomy|A thorough subacromial decompression was performed as described by Neer (which include coracoacromial ligament resection, excision of the anterio-lateral tip of the acromion and thorough debridement of the bursa).an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
3268830|NCT01554696|Experimental|ASP015K lowest dose|ASP015K lowest dose daily in addition to concomitant weekly oral methotrexate
3268831|NCT01554696|Experimental|ASP015K low dose|ASP015K low dose daily in addition to concomitant weekly oral methotrexate
3268832|NCT01554696|Experimental|ASP015K medium dose|ASP015K medium dose daily in addition to concomitant weekly oral methotrexate
3268833|NCT01554696|Experimental|ASP015K high dose|ASP015K high dose daily in addition to concomitant weekly oral methotrexate
3268834|NCT01554696|Placebo Comparator|Placebo|Placebo daily in addition to concomitant weekly oral methotrexate
3268835|NCT01554709|Experimental|CardioGard Cannula|
3268836|NCT01554709|Active Comparator|Reference Cannula|
3268837|NCT01554722|Experimental|in plane needle placement|
3268838|NCT01554722|Experimental|out of plane needle placement|
3268839|NCT01554735|Experimental|lifestyle counselling|exercise and diet counselling for weight loss
3268840|NCT01554748|Other|Patient cohort|TMC total joint arthroplasty
3268841|NCT01554774||GOLD II|Will be included in this group the patients with COPD stage II
3268842|NCT01554774||GOLD III|Will be included in this group the patients with COPD stage III
3268843|NCT01554774||GOLD IV|Will be included in this group the patients with COPD stage VI.
3268844|NCT01554787|Experimental|Chinese Herb Astragalus membranaceus|
3268845|NCT01554787|Placebo Comparator|Placebo|
3268846|NCT01554800|Experimental|ACP-501|
3268847|NCT01554813|Experimental|Influenza split vaccine of 15μg HA|15μg HA/strain/0.5ml/vial
3268848|NCT01554813|Experimental|Influenza split vaccine of 15 μg HA|15μg HA/strain/0.5ml/syringe
3268849|NCT01554813|Active Comparator|Influenza split vaccine|15μg HA/strain/0.5ml/syringe
3268850|NCT01554826|Experimental|Influenza Split Vaccine|7.5μg HA/strain/0.25ml/syringe
3268851|NCT01554826|Active Comparator|Inactivated Influenza Vaccine|7.5μg HA/strain/0.25ml/syringe
3268852|NCT01554839|Experimental|Treatment Group|Treatment group participates in 1 hour online educational tool in addition to baseline and follow up surveys
3268853|NCT01554839|Placebo Comparator|Non Treatment Group|Non Treatment group participates in baseline and follow up surveys
3268854|NCT01554852|Active Comparator|Intensive pathway|"The intensive pathway is aimed at younger and fitter patients who will receive the standard dose of chemotherapy. The initial treatments will be followed by high-dose chemotherapy with a stem cell transplant which is generally standard practice.~Participants receive one treatment from each following stage in intensive pathway, depending on what they are randomised to (Protocol v6.0):~Induction treatment:~CRD regimen - cyclophosphamide, lenalidomide, dexamethasone~CTD regimen - cyclophosphamide, thalidomide, dexamethasone~CCRD regimen - carfilzomib, cyclophosphamide, lenalidomide, dexamethasone~Consolidation treatment (depending on response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~High-dose therapy and stem cell transplant~Maintenance treatment:~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (Protocol v5.0 only)"
3268855|NCT01554852|Active Comparator|Non-intensive pathway|"The non-intensive pathway is aimed at participants who are not deemed suitable for the stem cell transplant, and will receive lower doses of some of the drugs.~Interventions in each stage of non-intensive pathway (depending on what the participant has been randomised to) - from Protocol v6.0:~Induction treatment~CRDa regimen - cyclophosphamide, lenalidomide, dexamethasone attenuated~CTDa regimen - cyclophosphamide, thalidomide, dexamethasone attenuated~Consolidation treatment (depending on participant's response to induction treatment):~VCD regimen - bortezomib, cyclosphosphamide, dexamethasone~No consolidation treatment~Maintenance treatment~Lenalidomide maintenance~No maintenance~Lenalidomide plus vorinostat maintenance (*for participants recruited under Protocol v5.0 only*)"
3268856|NCT01554865|Active Comparator|conventional diet counselling|counselling given by dietician on diet modification and caloric restriction
3268857|NCT01554865|Active Comparator|partial meal replacement diet|calorie-restricted diet using 1-2 meal replacements
3268858|NCT01554878||knee surgery|
3268859|NCT01554917|Experimental|Iguratimod|
3268860|NCT01554930|Active Comparator|Western therapy|
3268861|NCT01554930|Experimental|Xiyanping injection plus western therapy|
3268862|NCT01554943|Active Comparator|CMF|adjuvant standard CMF given from 1988 to 1996
3268863|NCT01554943|Experimental|EC|Adjuvant EC chemotherapy given from 1988 to 1996
3268864|NCT01554943|Experimental|HEC|High dose epirubicin (HEC) given from 1988 to 1996
3268865|NCT01554956|Experimental|Human Plasminogen|Human Plasminogen Eye Drop treatment
3268866|NCT01554969|Experimental|capecitabine + ganetespib .|Capecitabine oral medication. Ganetespib IV medication
3268867|NCT01554995|Experimental|LCB01-0371|active
3268868|NCT01554995|Experimental|Linezolid|comparator
3268869|NCT01555008|Experimental|Treatment A|
3268870|NCT01555008|Placebo Comparator|LX4211 Placebo|
3268871|NCT01555021||Treatment as Usual (TAU)|"This group will provide blood samples to be analyzed at a later date for genotyping to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications.Treatment will be initiated based on the attending clinicians decision making absent genotyping results.~All subjects in the group will receive the following assessment instruments for diagnosis: SCID-I/P and the Mini International Neuropsychiatric Interview (MINI)~All subjects in the group will have the severity of their depression measured by the HAM D-17 (physician rating scale), the QIDS-SR-16 (patient rating). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the UKU. ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the TAU group will provide saliva samples for future GWAS analysis."
3268872|NCT01555021||Assay Guided Treatment (AGT)|"This group will provide blood samples for genotyping test to determine the activity of CYP-450 enzymes that are important in metabolizing antidepressant medications . This test result will be available within 3-5 days available to guide clinicians in their choice and dosing of antidepressant medications.~All subjects in the group will have the severity of their depression measured by the Hamilton Depression Rating Scale-17 (physician rating scale), the QIDS-SR-16 (patient rating scale). Clinical status will be measured by the CGI-S scale (1-7 with 7 being high functioning). Side effects ratings will be measured by the Udvalg for Kliniske Undersogelser (UKU). ATRQ will be used to assess the degree of treatment resistance by measuring the number of prior antidepressant trials.~Patients in the AGT group will provide saliva samples for future GWAS analysis."
3268873|NCT01555034|Active Comparator|intervention plus therapy|
3268874|NCT01555034|Active Comparator|intervention no therapy|exercise and nutrition
3268875|NCT01555047|Active Comparator|males who were not infected by mycoplasma|100 male patients whose spouse was going to conduct IUI, was not infected by mycoplasma.
3268876|NCT01555047|Experimental|infected by mycoplasma males|100 male patients whose spouse was going to conduct IUI, was infected by mycoplasma.
3268877|NCT01555047|No Intervention|fertile males|50 fertile males were chose as control samples
3268878|NCT01555060|Experimental|Iron supplements|Subjects who are randomized to receive daily iron supplements after donating blood
3268879|NCT01555060|No Intervention|Control|Subjects who are randomized not to receive daily iron supplements after donating blood
3268880|NCT01555086|Experimental|Limited pelvic Lymphadenectomy|
3268881|NCT01555086|Experimental|Extended pelvic Lymphadenectomy|
3268882|NCT01555099|Experimental|AZD5423|New study drug
3268883|NCT01555099|Active Comparator|Budesonide|Comparator to which the new study drug will be compared
3268884|NCT01555099|Placebo Comparator|Placebo|No drug to which both other arms will be compared
3268885|NCT01555112|Experimental|Topical AS101|15% AS101 ointment applied twice a day for treatment of external genital warts.
3268886|NCT01555177||Peri-operative NSTEMI patients|Patients with POMI undergoing cardiac catheterization within 72 hours of first troponin elevation and within 2 weeks of their non-cardiac surgery.
3268887|NCT01555177||Non-surgery related NSTEMI patients|Patients with NSTEMI undergoing cardiac catheterization within 72 hours of symptom onset.
3268888|NCT01555190|Active Comparator|myo-inositol 1500 gr|6 months treatment with myo-inositol 1500 gr
3268889|NCT01555190|Active Comparator|myo-inositol 2000gr + folic acid 200 mcg|
3268890|NCT01555203|Experimental|liveWell: A healthy foundation for life|
3268891|NCT01555216|Active Comparator|Posterior tibial nerve catheter|5 ml bolus of 0.5% ropivacaine. The catheter will then be connected to a portable pump delivering 3 ml/h of 0.2% ropivacaine with a 2ml bolus every two hours.
3268892|NCT01555216|Active Comparator|Single injection PTNB|Single injection posterior tibial nerve block (PTNB) of 0.5% ropivacaine
3268893|NCT01555229|Experimental|Intermittent drainage|Intermittent subglottic secretion drainage at -100 mmHg during 8 sec every 15 seconds.
3268894|NCT01555229|Active Comparator|Continuous drainage.|Continuous subglottic secretion drainage at -20 mmHg.
3268895|NCT01555242|Experimental|Aneustat (OMN54)|
3268896|NCT01555268|Experimental|Arm A (trebananib)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, and 22.
3268897|NCT01555268|Experimental|Arm B (trebananib, cytarabine)|Patients receive trebananib as in Arm A. Patients also receive cytarabine SC BID on days 1-14 of course 1 and days 1-7 of subsequent courses.
3268898|NCT01555281|Experimental|Nelfinavir and Lenalidomide/Dexamethasone|"Phase I: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose escalation in cohorts of 3 patients~Phase II: Cycles 1-4 (1 cycle = 28 days) Lenalidomide: 25 mg per day p.o., day 1 to 21 Dexamethasone: 40/20 mg per day p.o., days 1, 8, 15, 22 Nelfinavir: Dose established in phase I twice daily p.o., day 1 to 21"
3268899|NCT01555294||community-based cohort|"The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.~In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed."
3268900|NCT01555294||Familial Combined Hyperlipidemia|FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.
3268901|NCT01555307|Experimental|Balance group|Typical plus balance exercises
3268902|NCT01555307|Other|Typical group|Typical exercises
3268903|NCT01555320|Placebo Comparator|Qishen Yiqi dripping pills dummy|
3268904|NCT01555320|Experimental|Qishen Yiqi Dripping Pills|
3268905|NCT01555333|Experimental|Arbaclofen|Open Label Study
3268906|NCT01555346||High risk pregnant subjects undergoing an invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy scheduled to undergo an invasive procedure for fetal karyotype determination.
3268907|NCT01555346||High risk subjects electing not to undergo invasive procedure|Women with one or more high risk factors for fetal chromosome 21 aneuploidy who elect not to undergo an invasive procedure for fetal karyotype determination.
3268908|NCT01555359||Patients undergoing stem cell collection|
3268909|NCT01555372|Active Comparator|Hook Plate|20 participants will be enrolled in this group.
3268910|NCT01555372|Experimental|Locking Plates|20 paticipants will be enrolled in this group
3268911|NCT01555385|Active Comparator|Dietary supplement: high-protein breakfast|high-protein juice
3268912|NCT01555385|Active Comparator|Dietary supplement: high-carbohydrate breakfast|high-carbohydrate juice
3268913|NCT01555385|Placebo Comparator|Dietary supplement: low energy breakfast|low-calorie juice
3268914|NCT01555398|Experimental|Fasting conditions|Investigational product administrated under fasting condition.
3268915|NCT01555398|Active Comparator|Fed conditions|Investigational product administrated 30min after starting a high-fat breakfast.
3268916|NCT01555411||No treatment|
3268917|NCT01555424|Active Comparator|High dose|
3268918|NCT01555424|Active Comparator|Reference dose|
3268919|NCT01555450|Experimental|With Patient Navigator|People in this arm receive the Intervention of a Patient Navigator
3268920|NCT01555450|No Intervention|Control - Without Patient Navigator|People in this arm receive just the usual care of colorectal cancer screening
3268921|NCT01555476|Experimental|A-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
3268922|NCT01555476|Active Comparator|B-IBU|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
3268923|NCT01555502||low complications|Patients who had VATS lung resection for NSCLC, and have no or low grade (grade 1 and 2) post operative complications based on the Clavien classification system.
3268924|NCT01555502||High complications|Patients who had VATS lung resection for NSCLC, and have no or high grade (grade 3 and 4) post operative complications based on the Clavien classification system.
3268925|NCT01555515|Experimental|EPODURE Low dose|EPODURE pump secreting hEPO 18-25 IU/kg/day
3268926|NCT01555528||Growth Disorders|
3268927|NCT01555554|Experimental|Propranolol Hydrochloride|
3268928|NCT01555554|Placebo Comparator|Placebo Group|
3268929|NCT01555580|Experimental|GM-CSF|
3268930|NCT01555593|Experimental|COPD FEV1<70%pred feNO Cardioline Exp'air|COPD subjects with FEV1<70% of predicted value and Forced Expiratory Volume Forced to Forced Vital Capacity ratio (FEV1/FVC) less than 88% (males)or less than 89% (females) of Low Levels of Normality (LLN) entering the respiratory rehabilitation unit will undergo multiflow feNo measure with Cardioline Exp'air by Medi-soft - Sorinnes (B)
3268931|NCT01555606||Moderate to severe plaque psoriasis patients|The group includes adult patients (either male or female) diagnosed with plaque psoriasis for at least 6 months prior to screening with PGA value of greater than or equal to 3. The patients in the group needed are currently receiving treatment with conventional systemic agents, topical therapy and/or phototherapy or biologic therapy
3268932|NCT01555619||CRT-D System|St. Jude Medical (SJM) Promote® Q/Promote® Quadra/Unify Quadra™ CRT-D system.
3268933|NCT01555632|Placebo Comparator|Arm I (placebo)|Patients receive placebo PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3268934|NCT01555632|Experimental|Arm II (atorvastatin calcium)|Patients receive atorvastatin calcium PO QD for 6 months in the absence of disease progression or unacceptable toxicity.
3268935|NCT01555645|Experimental|Stress management Individual format|The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
3268936|NCT01555645|Experimental|Stress management Group format|Participants will meet for 2 hours every week for a total of 20 hours. In the intervals between the group meetings patients will be asked to do homework. Homework entails practicing problem-solving techniques, keeping a diary, practicing relaxation or physical activities. Each group meeting has a specific subject, i.e. What is stress and stress behaviors, Stress related symptoms, How to manage anger and negative thoughts, Self-registrations and behavioral changes, Future perspectives, Cancer, stress and relations, Expectations and demands, Body, pleasure and sexuality.
3268937|NCT01555658|Experimental|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Bivalirudin
3268938|NCT01555658|Experimental|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to Unfractioned Heparin.
3268939|NCT01555684|Experimental|venoplasty proceedures|Half of the participants receive treatment and the other half do not
3268940|NCT01555684|Placebo Comparator|Control - no treatment|
3268941|NCT01555710|Experimental|Palifosfamide-tris plus Carboplatin and Etoposide|Drug: palifosfamide-tris in combination with carboplatin and etoposide palifosfamide-tris: 130 mg/m2/day 3 days every 21 days for a max of 6 cycles. carboplatin: AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a max of 6 cycles.
3268942|NCT01555710|Active Comparator|Carboplatin plus Etoposide|Drug: carboplatin in combination with etoposide carboplatin: AUC 5mg/mL/min 1 day every 21 days for a maximum of 6 cycles. etoposide: 100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
3268943|NCT01555736|Active Comparator|preseasonal immunotherapy scheme|
3268944|NCT01555736|Active Comparator|perennial immunotherapy scheme|
3268945|NCT01555749|Experimental|NNC172-2021 low dose / Placebo|
3268946|NCT01555749|Experimental|NNC172-2021 high dose / Placebo|
3268947|NCT01555775|Experimental|P-CHO supplement|This group will drink the P-CHO supplement in the first trial and the fruit milk shake in the second.
3268948|NCT01555775|Experimental|Fruit Milk Sake|This group will drink the fruit milk shake in the first trial and the P-CHO supplement in the second.
3268949|NCT01555788|Experimental|Type 1 diabetic population|The only one arm (type 1 diabetic patients treated by basal-bolus insulin and external pumps) of this study will test an artificial pancreas system that uses the intraperitoneal route to deliver insulin (through DiaPort).
3268950|NCT01555801|Experimental|Submucosal injection combining with EUS|The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
3268951|NCT01555801|Placebo Comparator|ordinary endosonography(EUS)|The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
3268952|NCT01555814|Experimental|Amisulpride|For 4 weeks, all patients will be treated with amisulpride open label.
3268953|NCT01555827|Experimental|Alzheimer Disease|
3268954|NCT01555827|Active Comparator|Control|
3268955|NCT01555840|Other|patients requiring upper GI endoscopy|patients with upper abdominal complaints requiring upper GI endoscopy
3268956|NCT01555853|Experimental|Phase I-Dose Level 0|Abraxane 100 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3268957|NCT01555853|Experimental|Phase I-Dose Level 1|Abraxane 125 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3268958|NCT01555853|Experimental|Phase I-Dose Level 2|Abraxane 150 mg/m2 IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3268959|NCT01555853|Experimental|Phase II|Abraxane (dose to be determined in Phase I) IV on Days 1, 8, and 15 of each 28 day cycle for a maximum of 6 cycles.
3268960|NCT01555866|Experimental|Part 1 Subjects with End Stage Renal Disease (ESRD)|
3268961|NCT01555866|Experimental|Part 1 Healthy Subjects|
3268962|NCT01555866|Experimental|Part 2 Subjects with Mild Renal Impairment|
3268963|NCT01555866|Experimental|Part 2 Subjects with Moderate Renal Impairment|
3268964|NCT01555866|Experimental|Part 2 Subjects with Severe Renal Impairment|
3268965|NCT01555866|Experimental|Part 2 Subjects with no Renal Impairment|
3268966|NCT01555879||All patients|All patients in T3 who have used Abatacept for at least 3 months between 2009-03-17 and 2011-11-30.
3268967|NCT01555905|Experimental|Exercise|Threshold PEP or IMT device Phillips-Respironics
3268968|NCT01555918|Experimental|Isavuconazole single oral dose - Part 1|
3268969|NCT01555918|Experimental|Isavuconazole single intravenous (IV) dose - Part 1|
3268970|NCT01555918|Experimental|Isavuconazole multiple oral doses - Part 2|
3268971|NCT01555918|Experimental|Isavuconazole multiple intravenous (IV) doses -Part 2|
3268972|NCT01555970|Experimental|NAC|Patients allocated in this group will receive N-acetylcysteine 1200 mg (one 600 mg capsule twice a day) during the first week of the study. On day 8 this will increase to 4 capsules per day (2400 mg NAC; 2 capsules twice a day). Finally, on day 15 (after 1 week at 2400 mg) the dose will be increased to the target dose of 5 capsules per day (3000 mg; 2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
3268973|NCT01555970|Placebo Comparator|Placebo|Patients allocated in this group will receive one capsule of placebo twice a day during the first week of the study. On day 8 this will increase to 4 capsules per day (2 capsules twice a day). Finally, on day 15 the dose will be increased to the target dose of 5 capsules per day (2 capsules in the morning and 3 in the evening), at which dose it will be continued for the remainder of the study.
3268974|NCT01555996|Experimental|Early and intensive OT|
3268975|NCT01555996|Active Comparator|Standard non-pharmacological prevention|
3268976|NCT01556022|Experimental|ADRCs processed by the Celution System|400,000 adipose-derived regenerative cells (ADRCs) per kilogram (kg) of body weight not to exceed 40,000,000 cells.
3268977|NCT01556022|Placebo Comparator|Lactated Ringers and Subject's blood|Sterile Lactated Ringers Solution (3mL) mixed with ≤ 0.10 ml of the study Subject's own freshly drawn blood.
3268978|NCT01556035|Experimental|Lenalidomide treatment|
3268979|NCT01556048|Experimental|IMMEDIATE START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 1 of entry into the study
3268980|NCT01556048|Placebo Comparator|DELAY START GROUP|Randomized to participate in Behavioral Activation for pathological grief starting at Week 12 of entry into the study
3268981|NCT01556074|Experimental|Yoga treatment|
3268982|NCT01556087|Experimental|Distress Tolerance|7 sessions aimed at increasing distress tolerance skills
3268983|NCT01556087|Placebo Comparator|Health Education|7 didactic health education sessions
3268984|NCT01556113|Active Comparator|omega diet carrying CC/CG genotype|Subjects homozygous for the major allele of the rs73049 SNP or heterozygous (CC and CG)
3268985|NCT01556113|Active Comparator|omega diet carrying GG genotype|Subjects homozygous for the minor allele of the rs73049 SNP (GG)
3268986|NCT01556126|Experimental|Amphilimus eluting stent (Cre8)|Sirolimus formulated coronary eluting stent
3268987|NCT01556139|Experimental|Spirotiger|Patients belonging to this group perform 20 sessions of usual training (cyclette and calisthenic exercises) and additional 20 sessions of a specific training for respiratory muscles with Spirotiger
3268988|NCT01556139|No Intervention|Control|Control group with a placebo device
3268989|NCT01556152|Active Comparator|Treatment Arm 1|
3268990|NCT01556152|Active Comparator|Traetment Arm 2|
3268991|NCT01556152|Placebo Comparator|Treatment Arm 3|
3268992|NCT01556178||Children without central nervous system tumors|Children without central nervous system tumors between the ages of 1 year and 21 years who are undergoing a neurosurgical procedure to address hydrocephalus
3268993|NCT01556191|Experimental|Gefinitib + Fulvestrant (patient with EGFR mutations)|
3268994|NCT01556191|Active Comparator|Erlotinib (wild type patients)|
3268995|NCT01556191|Experimental|Erlotinib + Fulvestrant (wild type patients)|
3268996|NCT01556191|Active Comparator|Gefinib (patient with EGFR mutations)|
3268997|NCT01556217|Experimental|JNJ-39393406|
3268998|NCT01556217|Placebo Comparator|Placebo|
3268999|NCT01556230||Group I|The first group of subjects, Group I, will be followed in Protocol I and are a group of subjects with an apparent clinically nonfunctioning pituitary lesion who will be studied in a prospective study of conservative non-surgical management.
3269000|NCT01556230||Group II|A second group of subjects, Group II, are subjects who are undergoing surgical intervention for CNFA or radiotherapy for CNFA and these subjects will be studied in a prospectively follow up as part of Protocol II.
3269001|NCT01556243|Experimental|Breast conservation surgery and radiation therapy|Patients undergo breast conserving surgery. Patients receive adjuvant chemotherapy at the physician's discretion. Patients receiving chemotherapy will start treatment within 12 weeks following surgery. Patients receive radiation therapy within 8 weeks following the last dose of chemotherapy or within 10 weeks following surgery if not receiving chemotherapy. Patients receive endocrine therapy at the physician's discretion. Patient observation will occur every 6 months until 5 years after the end of radiation therapy.
3269002|NCT01556256|Experimental|Arm I (TMV)|See detailed description.
3269003|NCT01556256|Experimental|Arm II (TMV+P)|See detailed description.
3269004|NCT01556282|Experimental|Therasphere|
3269005|NCT01556295||Experimental|
3269006|NCT01556295||Control|
3269007|NCT01556308|Experimental|DM-EBS|
3376827|NCT05000216|Experimental|Cohort C, Arm C2: BNT162b2+IS (B cell depletion therapy)|Participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Pfizer-BioNTech COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3269008|NCT01556321|Experimental|Green tea, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
3269009|NCT01556321|Placebo Comparator|Placebo, normal weight|Subjects with a BMI 18.5-25 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
3269010|NCT01556321|Experimental|Green tea, overweight|Subjects with a BMI >30 kg/m2 will receive green tea capsules, which they have to consume daily for a period of twelve weeks
3376828|NCT05000216|Experimental|Cohort C, Arm C3: Ad26.COV2.S +IS (B cell depletion therapy)|Participants taking B cell depletion medication(s) for management of their underlying autoimmune disease, regardless of whether they are also taking MMF or MTX, will receive the Janssen COVID-19 vaccine booster (1 dose) and continue to take their immunosuppressive medications (IS) without alterations in schedule and dosing.
3376829|NCT04996875|Experimental|CGT9486|
3376830|NCT04991935|Experimental|Administration of CC-93538|Participants are administered CC-93538 dose subcutaneously once weekly
3376831|NCT04988321|Active Comparator|Primary motor cortex (M1)|Stimulation of the M1
3376832|NCT04988321|Active Comparator|Dorsolateral prefrontal cortex (DLPFC)|Stimulation of the DLPFC
3376833|NCT04987320|Experimental|Olpasiran Dose A|Participants will be administered Olpasiran dose A as a subcutaneous injection.
3269011|NCT01556321|Placebo Comparator|Placebo capsules, obese|Subjects with a BMI >30 kg/m2 will receive placebo capsules, which they have to consume daily for a period of twelve weeks
3376834|NCT04987320|Experimental|Olpasiran Dose B|Participants will be administered Olpasiran dose B as a subcutaneous injection.
3269012|NCT01556334|Experimental|Azithromycin|Azithromycin 1g po
3269013|NCT01556334|Active Comparator|Erythromycin|Erythromycin IV followed by po for a total of 5 days.
3269014|NCT01556373||severe sepsis|patients with severe sepsis
3269015|NCT01556373||Controls|Controls matched to patients on age, sex and cardiovascular risk factors
3376836|NCT04982926|Experimental|TAS2940 Dose Escalation|Dose escalation will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally.
3269016|NCT01556386||Pharmacogenetic analysis, ALL|
3269017|NCT01556399||Duodenal adenomas|Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
3376837|NCT04982926|Experimental|Dose Expansion Non-small Cell Lung Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
3376838|NCT04982926|Experimental|Dose Expansion Breast Cancer|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
3376839|NCT04982926|Experimental|Dose Expansion Gliblastoma|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
3376840|NCT04982926|Experimental|Dose Expansion Solid tumors|Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
3376841|NCT04981431|Experimental|Elinzanetant single dose step 1|Each participant will receive a single oral dose of elinzanetant or placebo.
3269018|NCT01556412||Chronic hepatopathy suspicious of PSC|"All patients with chronic hepatopathy of unknown origin and a high risk of primary sclerosing cholangitis as the underlying disease for chronic hepatopathy.~This group includes all patients with cholestatic hepatopathy (predominantly elevated gamma-glutamyltransferase and alkalic phosphatase) and positive ANCAs (Anti-neutrophil cytoplasmic antibodies) and/or inflammatory bowel disease in medical history.~Other explanations of cholestatic hepatopathy (like pancreatic tumor or cholelithiasis) must not be apparent in patients eligible for this study.~Furthermore, infection oder extrahepatic cholestasis already proven by laboratory results or percutaneous ultrasound, which make endoscopic retrograde cholangiography necessary, are exclusion criteria in this study."
3269019|NCT01556464|Experimental|ACPAP|Patients in the intervention group will be introduced to the auto-adjusting CPAP (ACPAP) (ResMed S9) during the day and placed on it at night with a nocturnal oximetry and ACPAP download to assess its effectiveness and pressure requirements. The intervention is the application of the ACPAP. The patients will be discharged on ACPAP pressure determined by the ACPAP download (95th percentile pressure in absence of significant air leak) and will be scheduled for an outpatient repeat diagnostic PSG and, if indicated, a full night titration study.
3376842|NCT04981431|Experimental|Elinzanetant single dose step 2|Each participant will receive a single oral dose of elinzanetant or placebo.
3376843|NCT04981431|Experimental|Elinzanetant single dose step 3|Each participant will receive a single oral dose of elinzanetant or placebo.
3376844|NCT04981431|Experimental|Elinzanetant single dose step 4|Each participant will receive a single oral dose of elinzanetant or placebo.
3376845|NCT04981431|Experimental|Elinzanetant multiple dose step 5|Each participant will receive multiple doses of elinzanetant or placebo administered once a day for 7 consecutive days.
3376846|NCT04980417|Experimental|concomitant cholecystectomy|concomitant cholecystectomy with bariatric procedure
3376847|NCT04980417|Active Comparator|delayed cholecystectomy|delayed cholecystectomy
3376848|NCT04980222|Experimental|Glofitamab + R-CHOP Immunochemotherapy|"Participants will receive step-up doses of glofitamab, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), then 30 mg glofitamab will be given every three weeks (Q3W) onwards, on Day 8 of Cycles 4-6 and on Day 1 of Cycles 7-10. (cycle length = 21 days)~Participants will receive rituximab, cyclophosphamide, doxorubicin, and vincristine Q3W on Day 1 of Cycles 1-6. Prednisone or prednisolone will be administered daily (QD) on Days 1-5 of Cycles 1-6. (cycle length = 21 days)"
3376849|NCT04979052|Active Comparator|Interferon-Gamma|Recombinant Interferon-Gamma 1b combined with standard therapy
3376850|NCT04979052|No Intervention|Standard of care|Standard of care antifungal therapy according tot ESCMID/EFISG (Europe) or ISDA (US) guidelines.
3269020|NCT01556464|No Intervention|Control|The control group will receive nocturnal oxygen or no therapy while in the hospital and after discharge at the discretion of the attending physician. They will be scheduled for outpatient repeat diagnostic PSG and then, if indicated, a full night titration study.
3269021|NCT01556477|Active Comparator|azacitidine|
3269022|NCT01556477|Experimental|azacitidine + lenalidomide|
3269023|NCT01556490|No Intervention|Control group|Standard-of-care sorafenib, with no added therapy
3269024|NCT01556490|Experimental|Treatment group|Standard-of-care sorafenib plus TheraSphere
3269025|NCT01556503||Pigmented Lesion|Patients identified as having a concerning pigmented lesion and the physician believes it is appropriate to biopsy to rule out melanoma.
3269026|NCT01556516||Women with Pompe Disease|
3269027|NCT01556529|Experimental|risk profile information|patient gets information on quantitative individual complication risk profile and patient gets standard T2DM DMP care
3269028|NCT01556529|Active Comparator|Control|Control group: patient gets standard T2DM DMP care
3269029|NCT01556542|Active Comparator|standard PTA|nitinol stent implantation
3269030|NCT01556542|Experimental|DEB|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
3269031|NCT01556555||Primary sclerosing cholangitis|Patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP.
3269032|NCT01556568|Experimental|MEK162|Patients will be treated with MEK162 only and will be uptitrated or down titrated based on safety and tolerability observed.
3269033|NCT01556607|Active Comparator|Experimental: MDT-637|
3269034|NCT01556607|Placebo Comparator|Placebo|
3269035|NCT01556646|Experimental|Tolvaptan|Open label study of tolvaptan. First 3 days as an inpatient then outpatient for the remainder of the study
3269036|NCT01556659|Active Comparator|Triple antithrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
3269037|NCT01556659|No Intervention|Triple anti-thrombotic therapy|Treatment with aspirin, P2Y12 inhibitors and vitamin K antagonist.
3269038|NCT01556672|Experimental|adalimumab|All patients will receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
3269039|NCT01556685|Active Comparator|Group 1 Avonex|Approximately 90 subjects treated with IFN beta 1a IM 30μg
3269040|NCT01556685|Active Comparator|Group 2 Jumtab|Approximately 90 subjects treated with IFN beta 1a IM biosimilar
3269041|NCT01556698|Experimental|NVN1000 Gel|NVN1000 Gel topically applied one daily at bedtime for 8 weeks
3269042|NCT01556698|Placebo Comparator|Vehicle Gel|Vehicle Gel topically applied once daily at bedtime for 8 weeks
3269043|NCT01556711||Head Injury|Males and females ages 18 to 80 (the entire age range), who are admitted to the ED, who are suspected of a traumatically induced structural brain
3269044|NCT01556711||Control|"A 'normal' control group will be recruited for comparison and will consist of ED patients (ED normal control group) who have sustained an injury but do not exhibit any trauma above the clavicle and no history of MVA requiring an ED visit or TBI within the past one (1) year, and no primary complaint of syncope"
3269045|NCT01556737|Experimental|Supplement|
3269046|NCT01556737|Placebo Comparator|Placebo|
3269047|NCT01556776|Experimental|Lenalidomide|lenalidomide maintenance following firstline treatment with FCR, BR, FR, or FC(if Rituximab is contraindicated)
3269048|NCT01556776|Placebo Comparator|Placebo|placebo
3269049|NCT01556789|Experimental|ONT-10 Vaccine|ONT-10 investigational agent
3269050|NCT01556802|Experimental|Minocicline|minocicline 100mg oral twice a day for 5 days
3269051|NCT01556802|Placebo Comparator|Placebo|Pills filled with vegetal fiber with similar presentation of the drug. Given one pill oral twice a day for five days
3269052|NCT01556815|Active Comparator|Group TACE|Patients who undergo TACE
3269053|NCT01556815|Experimental|Group Combination|Patients who are treated with sorafenib combined with TACE
3269054|NCT01556841|Experimental|TroVax®|TroVax® consists of a highly attenuated VV (Modified Vaccinia Ankara, MVA) containing the human TAA 5T4 under regulatory control of a modified VV promoter, mH5.
3269055|NCT01556841|Placebo Comparator|Placebo|
3269056|NCT01556867|Active Comparator|dry cord care|
3269057|NCT01556867|Active Comparator|antiseptic care|
3269058|NCT01556880|Experimental|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
3269059|NCT01556880|No Intervention|Standard usual care|
3269060|NCT01556893|Other|LASIK Flap Arm|This is a single arm study.
3269061|NCT01556919||Mucosal Impedance Probe|
3269062|NCT01556945|Experimental|Group A : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the GlaxoSmithKline (GSK) adjuvant system, number 2 (AS02) and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant concomitantly as separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3269063|NCT01556945|Experimental|Group B : FMP1/AS02 + RTS,S/AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with AS02 adjuvant at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3269064|NCT01556945|Experimental|Group C: FMP1/AS02 + AS02|FMP1 malaria vaccine given with the adjuvant AS02 and a second experimental malaria vaccine RTS,S also given with adjuvant AS02 adjuvant alone at one injection site and saline at the opposite site on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3269065|NCT01556945|Experimental|Group D : RTS,S/AS02 + AS02|RTS,S malaria vaccine given with the adjuvant AS02 and an adjuvant AS02 alone concomitantly at separate sites of injection on days 0, 28 and 84. Malaria challenge phase began 14-30 days after the last vaccine.
3269066|NCT01556945|Placebo Comparator|Control cohort|Infectivity controls (unvaccinated). Non-randomized infectivity controls were recruited specifically for the malaria challenge phase of the trial.
3269067|NCT01556958||Active Wheezing - age 5-12|
3269068|NCT01556958||Active Wheezing - under age 5|
3269069|NCT01556958||No Wheezing|
3269070|NCT01556971|Active Comparator|Botox|The study will be divided randomly into two groups of equal number; one arm will receive a Botox injection; the other will receive saline solution injection
3269071|NCT01556971|Placebo Comparator|Saline Solution|A saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
3269072|NCT01556984||DSA group|
3269073|NCT01556984||control group|
3269074|NCT01557010|Experimental|Treatment A|
3269075|NCT01557010|Experimental|Treatment B|
3269076|NCT01557010|Experimental|Treatment C|
3269077|NCT01557010|Placebo Comparator|Treatment D|
3269078|NCT01557023|Experimental|dienogest 2 mg/ethynilestradiol 30 mcg;|
3269079|NCT01557023|Active Comparator|Yasmin®|
3269080|NCT01557036||Aneurysms treated with Pipleline|Aneurysms treated with Pipleline. All patients independently treated according to the labeled indications for use with the Pipeline Embolization Device
3269081|NCT01557049|Experimental|Postural Reeducation Group|The participants, after obtaining a written informed consent, were randomized for one of the two groups: In the Global Postural Reeducation group (GPR), they were submitted 1 time per week, during 12 weeks, at GPR sessions. The duration of sessions was 60 minutes each, with the same physical Therapist of the study. After the intervention, subjects returned to assessment 3 months after, with the blinded assessor. All the 6 postures from GPR were used during the study. All outcomes measurements, in both groups, were validated for Portuguese language and applicable at baseline, 3 months and 6 months after baseline.
3269082|NCT01557049|No Intervention|Control Group|In the control group, no physical intervention was given during the study. After the study, 6 months after, all participants from control group received the same treatment given in GPR group, according to the Unifesp Ethics Committee orientations. All participants, of both groups, have a doctor from the study, if necessary.
3269083|NCT01557062|Other|Polysomnography|
3269084|NCT01557062|Other|Temperature measure|
3269085|NCT01557062|Other|Fibromyalgia Impact questionary|
3269086|NCT01557075|Active Comparator|Atorvastatin group|Atorvastatin 40 mg daily for 12 months after randomization
3269087|NCT01557075|Active Comparator|Pravastatin group|Pravastatin 20mg daily for 12 months after randomization
3269088|NCT01557101|Other|COLON CAPSULE ENDOSCOPY|
3269089|NCT01557101|Other|OPTICAL COLONOSCOPY|
3269090|NCT01557114|Experimental|radiation therapy with Ipilimumab|
3269091|NCT01557127||Group 1|
3269092|NCT01557140|Placebo Comparator|RASi plus placebo|RAS inhibition was optimized and after patients were randomly assigned to receive placebo
3269093|NCT01557140|Experimental|RASi plus carvedilol|RAS inhibition was optimized and after patients were randomly assigned to receive carvedilol
3269094|NCT01557153|Experimental|Amlodipine|
3269095|NCT01557153|Placebo Comparator|Placebo|
3269096|NCT01557179|Experimental|Hyaluronic acid vaginal gel (Hyalofemme)|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
3269097|NCT01557179|Active Comparator|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
3269098|NCT01557192|Active Comparator|Active LFMS treatment|20 minute exposure to the LFMS electromagnetic field treatment
3269099|NCT01557192|Placebo Comparator|Sham LFMS treatment|20 minute exposure to either the sham (inactive) electromagnetic field treatment
3269100|NCT01557218|Experimental|Cucumber|
3269101|NCT01557218|Experimental|Pepper|
3269102|NCT01557218|Experimental|Tomato|
3269103|NCT01557218|Experimental|Vegetable variety|
3269104|NCT01557218|Experimental|Apple|
3269105|NCT01557218|Experimental|Peach|
3269106|NCT01557218|Experimental|Pineapple|
3269107|NCT01557218|Experimental|Fruit variety|
3269108|NCT01557231||No treatment|OA
3269109|NCT01557257|Experimental|40 mg ALO-02 capsule|Single- and multiple-dose of 40 mg ALO-02 capsule under 50 mg naltrexone block
3269110|NCT01557257|Experimental|80 mg ALO-02 capsule|Single- and multiple-dose of 80 mg ALO-02 capsule under 50 mg naltrexone block
3269111|NCT01557257|Experimental|40 mg OxyContin tablet|Single- and multiple-dose of 40 mg OxyContin tablet under 50 mg naltrexone block
3269112|NCT01557270|Experimental|ropivacaine + dexmedetomidine|This group represents the standard of care drug (ropivacaine) plus the new additive to be studied (dexmedetomidine)
3269113|NCT01557270|Active Comparator|ropivacaine + saline|This group represents the current standard of care in peripheral nerve blockade
3269114|NCT01557296|Placebo Comparator|Diabetic diet|Control group. Subjects with Insulin Treated Diabetes Mellitus and Gastroparesis. Diet: Food of large particle size during 20 weeks.
3269115|NCT01557296|Active Comparator|Diet food in small particle size|Intervention group: Subjects with Insulin Treated Diabetes and Gastroparesis. Intervention Diet: Food of small particle size during 20 weeks.
3269116|NCT01557335|Experimental|Clopidogrel (Plavix®) and PA32540|PA32540 and Clopidogrel (Plavix®) tablet, 10 hours post PA32540
3269117|NCT01557335|Active Comparator|EC aspirin, EC omeprazole, Clopidogrel|
3269118|NCT01557361|Active Comparator|Standard RRT initiation|RRT is initiated >12 hours after eligibility determination. Once a decision is made to start RRT, a dialysis catheter will be placed and RRT initiated as soon as possible.
3269119|NCT01557361|Experimental|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility.
3269120|NCT01557374|Active Comparator|Maintenance Tocilizumab, Abatacept|No modification in biotherapy dose and administration frequency
3269121|NCT01557374|Experimental|Decrease Tocilizumab, Abatacept|Progressive decrease by predetermined pattern. Progressive injection interval increase (by stage)
3269122|NCT01557387||Patients with pseudopolyps.|No treatment involved in this study.
3269123|NCT01557413|Experimental|Intramedullary nail|Intramedullary nail
3269124|NCT01557413|Experimental|Locked plate|Locked plate
3269125|NCT01557426|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of their skin or soft tissue infection and an ultrasound to an uninfected portion of skin.
3269126|NCT01557439|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
3269127|NCT01557439|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
3269128|NCT01557478|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
3269129|NCT01557478|Active Comparator|Melatonin 20mg|20 mg melatonin gelatin capsule
3269130|NCT01557491|Active Comparator|Straight Incision|incision made perpendicular to scalp surface
3269131|NCT01557491|Active Comparator|Bevelled Incision|Incision made at 45 degrees to scalp surface
3269132|NCT01557608|Experimental|Photon stimulation|
3269133|NCT01557608|Placebo Comparator|Placebo treatment|
3269134|NCT01557621|Experimental|Collaborative Population-Based Recall-Phone/Mail Group|Collaborative Pop-Based R/R: Phone/Mail Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
3269135|NCT01557621|Experimental|Collaborative Population-Based Recall-Mail Only Group|Collaborative Pop-Based R/R: Mail-Only Group Private providers, local public health departments, and the state immunization registry (CIIS) collaborate to send notices to families whose children appear in need of an immunization.
3269136|NCT01557621|Active Comparator|Practice-based Recall|Practice-based Recall
3269137|NCT01557634|Experimental|Closed-loop with diluted insulin|Insulin pump therapy using diluted insulin (20 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
3269138|NCT01557634|Active Comparator|Closed-loop with non-diluted insulin|Insulin pump therapy using standard non-diluted insulin (100 IU/ml) will be driven by computer-based algorithm from 1700 on Day 1 until 0800 on Day 2
3269139|NCT01557647|Experimental|inhaled treprostinil|
3269140|NCT01557647|Placebo Comparator|placebo|
3269141|NCT01557660|Experimental|inhaled treprostinil|
3269142|NCT01557673|Active Comparator|NG bolus feeding over 5 min|Tube bolus (TB): feed administered via syringe through NG tube over 5 min.
3269143|NCT01557673|Placebo Comparator|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.
3269144|NCT01557712|Experimental|Ketamine+venlafaxine|one injection of 0.5 mg/kg of kentamine the first day plus venlafaxine (150-375 mg day) during 6 weeks
3269145|NCT01557712|Active Comparator|venlafaxine|venlafaxine (150-375 mg day) during 6 weeks
3269146|NCT01557725||THR/TKR patients|Any patients receiving fast-track THR or TKR in departments participating in the Lundbeck Foundation Centre for fast-track THR and TKR
3269147|NCT01557738|Experimental|Acute effects of flavanol consumption|The outcome measurements will be made on all study participants before and 2 hours after consumption of the high flavanol beverage.
3269148|NCT01557738|Placebo Comparator|Low Flavanol Trial; acute effects|Once again, the outcome measurements will be made on all study participants before and 2 hours after consumption of the low flavanol beverage.
3269149|NCT01557738|Experimental|Long-term effects of flavanol consumption|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a high flavanol beverage.
3269150|NCT01557738|Placebo Comparator|Low Flavanol Trial; long-term effects|Only those study participants over 60 years of age will continue with this arm of the trial. The same outcome measures will be performed following 4 weeks of daily consumption of a low flavanol beverage.
3269151|NCT01557764|Experimental|Treatment (enzyme inhibitor and monoclonal antibody)|Patients receive lapatinib PO QD on days 1-21 and trastuzumab IV over 90 minutes on day 1 of a 21-day cycle. Treatment continues in the absence of disease progression or unacceptable toxicity.
3269152|NCT01557777|Experimental|Navitoclax, ABT-263|
3269153|NCT01557803||Starting ART|Adult patients starting anti retroviral therapy for the first time
3269154|NCT01557816|Active Comparator|Naproxen|
3269155|NCT01557816|Sham Comparator|Placebo|
3269156|NCT01557829|Active Comparator|PEEK interbody cage|Posterior fusion with an interbody spacer (cage) made from polyetheretherketone (PEEK) plastic. The open space in the center of the cage is filled with local bone or bone harvested from the iliac crest.
3269157|NCT01557829|Experimental|Valeo OL ceramic cage|Posterior fusion with the Valeo OL cage, a silicon nitride ceramic interbody spacer. The center area of the cage is filled with autograft local bone or bone harvested from the iliac crest.
3269158|NCT01557907|Experimental|Intradermal - BD Research Catheter Set|Intradermal delivery of insulin (basal and bolus delivery) using the BD Research Catheter Set with 34G x 1.5 mm side-ported needle and the Animas Vibe insulin pump over a three day period.
3269159|NCT01557907|Active Comparator|Subcutaneous - Medtronic Quick-Set|Subcutaneous delivery of insulin (basal and bolus delivery) using the Medtronic Quick Set with 6 mm Teflon catheter and the Animas Vibe insulin pump over a three day period.
3269160|NCT01557933||ECT|All study subjects have consented to receive ECT.
3269161|NCT01557972||1. Morning HP and NT|Subjects based on HBP were divided into MH and MN patients
3269162|NCT01557972||2. Clinic HP and NT|Subjects based on CBP were divided into CH and CN patients
3269163|NCT01557985|Experimental|Transversus abdominis plane (TAP) Block|All participants in the study will receive a Transverses abdominis plane (TAP) Block in conjunction with their surgery.
3269164|NCT01557998|Other|Control - No intervention|PWID in the control arm will receive the behavioral survey, follow-up interviews, health education and training sessions on how to recruit peers, the rapid HIV and HCV test, and the point of care CD4 test but will not be assigned a peer case manager. Confirmed HCV viremic will receive HCV treatment.
3269165|NCT01557998|Experimental|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention. Confirmed HCV viremic will receive HCV treatment.
3269166|NCT01557998|Other|HCV+PWID|Control and Experimental Confirmed HCV viremic study subject will receive HCV treatment
3269167|NCT01558011|Experimental|chemotherapy|"Chemotherapy:~Drug: Capecitabine, Oxaliplatin, Docetaxel Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
3269168|NCT01558024||C1S patients|"18 Patients with venous insufficiency: C1S patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3269169|NCT01558024||C3 patients|"18 Patients with venous insufficiency: C3 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3269170|NCT01558024||C5 patients|"18 Patients with venous insufficiency: C5 patients according to the CEAP (Clinical-Etiology-Anatomy-Pathophysiology)classification."
3269171|NCT01558024||Sedentary volunteers|18 healthy volunteers with a sedentary lifestyle (< 2h of physical activity per week)
3269172|NCT01558024||Active volunteers|18 healthy volunteers with an active lifestyle (between 2 and 6 hours of physical activity per week)
3269173|NCT01558024||Athletic volunteers|18 healthy volunteers with an athletic lifestyle (over 6 hours of physical activity per week for at least one year)
3269174|NCT01558037||Main study|Main study patients are enrolled before or at time of solid organ transplant. Qualifying subjects either have tested positive for Cytomegalovirus or have a donor who has tested positive for Cytomegalovirus.
3269175|NCT01558037||Sub study|Subjects are enrolled to this arm who have begun replicating Cytomegalovirus post transplant. These subjects may or may not have been on the main study arm.
3269176|NCT01558050|Experimental|red rice|commercially available red rice nutritionial supplement
3269177|NCT01558050|Placebo Comparator|placebo|placebo capsules
3269178|NCT01558076||Subjects with sickle cell anemia|60 subjects with sickle cell anemia will be enrolled on the study.
3269179|NCT01558076||30 healthy controls|30 controls without sickle cell anemia or sickle cell trait will be enrolled on the study.
3269180|NCT01558115|Experimental|Denosumab - Group #1|Receive active drug for year 1 and year 2 of the study
3269181|NCT01558115|Placebo Comparator|Placebo - Group #2|Receive placebo for year 1 and active drug for year 2 of the study
3269182|NCT01558141|Active Comparator|Follicular flushing|Flushing follicles with embryo culture media prior to aspiration.
3269183|NCT01558154|Experimental|Chinese herb|Chinese herbs special for depression
3269184|NCT01558154|Experimental|acupuncture|
3269185|NCT01558154|Experimental|Psychotherapy|
3269186|NCT01558154|Experimental|physiotherapy|
3269187|NCT01558167|Experimental|Bendamustine, Rituximab,Lenalidomide|Dose modification treatment plan of lenalidomide
3269188|NCT01558180|Experimental|Telephone Care Management|calls from a registered nurse to educate caregivers about behavioral sleep strategies
3269189|NCT01558180|Placebo Comparator|Usual Care|It's a placebo comparator because individuals in this group will receive an educational handout on behavioral sleep strategies. This handout approximates standard of care.
3269190|NCT01558193|Placebo Comparator|Placebo|Two placebos consumed
3269191|NCT01558193|Active Comparator|Multi-vitamin/mineral|Subjects took multi-vitamin/mineral and placebo fatty acid capsule
3269192|NCT01558193|Active Comparator|Docosahexaenoic acid|Subjects took docosahexaenoic acid capsule and placebo vitamins/minerals
3269193|NCT01558193|Active Comparator|DHA plus vitamins/minerals|Subjects took both fatty acid and vitamin/mineral supplements
3269194|NCT01558206||Patients with impression of PTE|Those with signs and symptoms in favor of pulmonary thromboembolism.
3269195|NCT01558219|Experimental|acitive anticancer drug|single cytostatic agent, cabazitaxel every second week in the treatment of castration resistant metastatic prostate cancer after docetaxel
3269196|NCT01558232|Experimental|Tibion Arm|Arm of the study in which enrolled subacute post-stroke subjects undergo lower extremity physical therapy using the Tibion Bionic Leg.
3269197|NCT01558245|Experimental|Tissue kallikrein group|Patients in this group will be prescribed with intravenous infusion of TK (0.15 PNAU/d, dissolved in 100ml saline) for 7 days after stenting and then oral administration of pancreatic kallikrein enteric-coated tablet (240U, 3/d) to the end of study. As the foundation treatment, all the enrolled patients will receive aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
3269198|NCT01558245|No Intervention|Control group|Patients in control group will receive foundation treatment, including aspirin (100 mg/d), clopidogrel (75 mg/d), and atorvastatin (20 mg/d) for the first 6 months and continue with the combination of aspirin and atorvastatin at the previous dosage.
3269199|NCT01558258|Experimental|Mindfullness Meditation-based Intervention|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
3269200|NCT01558258|No Intervention|Wait-list control group|The wait-list control condition will control for naturally occurring changes in stress and other outcomes over the six-week intervention period. After the post-treatment assessments have been completed, those assigned to the wait-list control group will be able to participate in the MAP classes.
3269201|NCT01558310|Active Comparator|Group A|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52.The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
3269202|NCT01558310|Placebo Comparator|Group B|Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
3269203|NCT01558323|Experimental|LCQ908 (mild renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with mild renal impairment and will receive a single 40 mg dose of LCQ908.
3269204|NCT01558323|Experimental|LCQ908 (moderate renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with moderate renal impairment and will receive a single 40 mg dose of LCQ908.
3269205|NCT01558323|Experimental|LCQ908 (severe renal impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±15 years) and weight (±20%) to subjects with severe renal impairment and will receive a single 40 mg dose of LCQ908.
3269206|NCT01558336|Experimental|Praziguantel|tablet single dose
3269207|NCT01558349||Hospitalized controls|Patients that have been hospitalized at the Nîmes University Hospital and who do not have dermatological cancer.
3269208|NCT01558349||Metastatic melanoma|This cohort includes patients with metastatic melanoma.
3269209|NCT01558362|Experimental|123I-CMICE-013|Administration and analysis of alternative MPI radiotracer
3269210|NCT01558375|Placebo Comparator|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
3269211|NCT01558375|Experimental|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
3269212|NCT01558388|Experimental|Vaginal lactobacilli|
3269213|NCT01558388|Placebo Comparator|Placebo|
3269214|NCT01558401|Experimental|Physical activity program Group|The physical activity program consists of 123 sessions over 52 weeks. The initial assessment is followed by 12 weeks of physical activity. After this ten-week period, a second assessment is performed, followed by 3 weeks of rest. This is followed by a further 17 weeks of activities, 4 weeks of activities followed by 4 weeks of rest. Finally, there were 12 more weeks of activities.
3269215|NCT01558414|Experimental|SILS|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
3269216|NCT01558414|Experimental|FSIS|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
3269217|NCT01558414|Active Comparator|Conventional laparoscopy|Cholecystectomy performed by a conventional laparoscopic approach
3269218|NCT01558427|Experimental|Active clinical surveillance|Active monitoring of patients with low volume metastases with Prostate Specific Antigen (PSA) and sequential imaging.
3269219|NCT01558427|Experimental|Salvage treatment of metastases|Surgical or radiotherapy treatment of metastases.
3269220|NCT01558440|Active Comparator|Infant Formula|A diet that is being fed to the young infants
3269221|NCT01558440|Experimental|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
3269222|NCT01558440|Experimental|Diluted F-100|300 ml of water is added to 1000 ml of F-100
3269223|NCT01558453|Experimental|Eloxatin|Oxaliplatin
3269224|NCT01558466|Placebo Comparator|Group A - Placebo|iNO combined with placebo will be administered
3269225|NCT01558466|Active Comparator|Group B- Sildenafil|iNO combined with Sildenafil
3269226|NCT01558479||Case|Has a diagnosis of Parkinson's disease
3269227|NCT01558479||Control|No diagnosis of Parkinson's disease
3269228|NCT01558479||Family Member|Has a family history of Parkinson's disease. Can be affected or unaffected with Parkinson's disease
3269229|NCT01558505|Active Comparator|standard PTA|conventional balloon angioplasty
3269230|NCT01558505|Experimental|Drug-eluting balloon angioplasty|paclitaxel-eluting balloon angioplasty
3269231|NCT01558531||DEB|paclitaxel-eluting balloon angioplasty
3269232|NCT01558531||conventional PTA|historical conventional balloon angioplasty control group (patients referred to our institution between 2008 and 2009)
3269233|NCT01558544|Other|Use of high dose chemotherapy|Use of chemotherapy without removal of the disease ovary.
3269234|NCT01558557|Experimental|Gluten Free Diet|
3269235|NCT01558570||Schizophrenia|
3269236|NCT01558583|Other|Rating and Ranking Group|A group of individuals from the United States and Australia who complete a rating and ranking task.
3269237|NCT01558583|Other|Discrete Choice Group|A group of individuals from the United States and Australia who complete a discrete choice experiment task.
3269238|NCT01558583|Other|Balance Sheet Group|Individuals from the United States and Australia who will complete an implicit values clarification task
3269239|NCT01558622|Placebo Comparator|dexketoprofen trometamol|Dexketoprofen trometamol is a water-soluble salt of the dextrorotatory enantiomer of the nonsteroidal anti-inflammatory drug (NSAID) ketoprofen.
3269240|NCT01558622|Placebo Comparator|tramadol hydrochloride|Tramadol Hydrochloride is a well-known centrally acting opioid pain killer.
3269241|NCT01558622|Placebo Comparator|pethidine hydrochloride|Pethidine is a synthetic opioid analgesic which produces a pattern of effects similar to morphine the standard against which opioid analgesics are compared.
3269242|NCT01558622|Placebo Comparator|dexketoprofen trometamol + tramadol hydrochloride|
3269243|NCT01558622|Placebo Comparator|dexketoprofen trometamol + pethidine hydrochloride|
3269244|NCT01558622|Placebo Comparator|vitamin c|
3269245|NCT01558648||Pts having Minimally Invasive esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
3269246|NCT01558648||Pts having open esophagectomy|This is a prospective non-randomized study comprising two surgical cohorts of esophageal cancer patients. Patients will be assigned to each of the two intervention groups, MIE versus OE, based on a combination of patient referral patterns, patient preference, and surgeon preference/expertise.
3269247|NCT01558687|Experimental|Group A = Cilengitide Group|Cilengitide + SoC (Temolozomide + Radiotherapy)
3269248|NCT01558687|Active Comparator|Group B = Control Group|SoC (Temolozomide + Radiotherapy)
3269249|NCT01558713|Active Comparator|Group BFS|Group B: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3269250|NCT01558713|Active Comparator|Group RFS|Group R : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3269251|NCT01558713|Active Comparator|Group LFS|Group L: LEVO-BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY, FOLLOWED BY EPIDURAL ADMINISTRATION OF 10 ml N/S 0,9%
3269252|NCT01558713|Active Comparator|BupivacaineF|Group BupivacaineF: BUPIVACAINE 0,5% 2ml + 10μg FENTANYL(0,2ml) INTRATHECALLY
3269253|NCT01558713|Active Comparator|RopivacaineF|Group RopivacaineF : ROPIVACAINE 0,75% 2ml + 10μg FENTANYL ( 0,2ml) INTRATHECALLY.
3269254|NCT01558713|Active Comparator|LevobupivacaineF|Group LevobupivacaineF: LEVO-BUPIVACAINE 0,5% (2ml) + 10μg FENTANYL(0,2ml) INTRATHECALLY.
3269255|NCT01558726|Experimental|Case management|
3269256|NCT01558726|Active Comparator|Usual treatment|Usual treatment of the CAPSad
3269257|NCT01558765|Experimental|Intervention group|Patients receive integrated rehabilitation
3269258|NCT01558765|No Intervention|Control group|Patients receive usual follow-up care without physical exercise
3269259|NCT01558778|Experimental|Supportive care (whole body vibration)|Patients undergo mechanical stimulation over 20 minutes QD beginning on date of hospital admission and continuing through day 100 post-HCT, except for day 0 (date of transplant).
3269260|NCT01558804||Rapid Strep Positive|Children will be eligible for this study if they are ages 5 to 15 years and have been diagnosed to have acute pharyngitis caused by GAS with a positive Rapid Antigen Detection Test (RADT) and have not been treated with antibiotics in the last 30 days.
3269261|NCT01558817|Active Comparator|Informational brochure|Patients receive an informational brochure
3269262|NCT01558817|Experimental|Intervention|Patients receive physician-directed informed assent intervention regarding CPR and informational brochure.
3269263|NCT01558830|Placebo Comparator|sugar pill|one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
3269264|NCT01558830|Active Comparator|Ranolazine|500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
3269265|NCT01558843||traumatic brain injury|
3269266|NCT01558843||aneurysmal subarachnoid hemorrhage|
3269267|NCT01558843||intracerebral hematoma|
3269268|NCT01558843||brain tumor|
3269269|NCT01558856|Active Comparator|Unilateral testing|"Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves.~Intervention: Unilateral electrode placement and testing"
3269270|NCT01558856|Experimental|Bilateral testing|"Patients in this group will have bilateral testing for neuromodulation of the sacral nerves.~Intervention: Bilateral electrode placement and testing"
3269271|NCT01558869|Experimental|Arm 1|
3269272|NCT01558882||10 patients|The patients included desire tubal sterilization via the ESSURE technique.
3269273|NCT01558895|Experimental|Conventional Treatment and Infrared ray heat treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
3269274|NCT01558895|Active Comparator|conventional treatment group|conventional treatment consist of antiviral drugs, lowering aminotransferase and jaundice medicine.
3269275|NCT01558908|Experimental|Intramuscular injection of ERC|
3269276|NCT01558921|Experimental|B: 5x5Gy -> CAPOX -> surgery|experimental group (arm B) M1 scheme
3269277|NCT01558921|Active Comparator|A: 5 weeks chemoradiation -> surgery|control group (arm A) standard long course chemoradiotherapy
3269278|NCT01558934|Experimental|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume. If the therapeutic dose is not reached under 50% methadone reduction conditions, the methadone dose will be further reduced to 0 mg for 2 days followed by reintroduction of 25% of the starting dose on the 3rd day, and on such 3rd day lofexidine titration will resume again.
3269279|NCT01558947|Experimental|chemotherapy with ECX|chemotherapy with ECX
3269280|NCT01558947|Experimental|chemotherapy with XP|chemotherapy with XP
3269281|NCT01558960|Experimental|IVit Treatment group|Intravitreal injections of Melphalan
3269282|NCT01558973||Cocaine dependent|
3269283|NCT01558973||Opioid dependent|
3269284|NCT01558973||Alcohol dependent|
3269285|NCT01558973||Healthy controls|
3269286|NCT01558973||Adolescents|
3269287|NCT01558973||Pathological gamblers|
3269288|NCT01558986|Active Comparator|Treatment Arm|Patients to receive intravenous cefazolin 1 gram within 30 minutes prior to skin incision
3269289|NCT01558986|Placebo Comparator|Placebo Arm|Patients to receive sterile water only within 30 minutes prior to skin incision
3269290|NCT01558999|Experimental|High concentration SI-614|
3269291|NCT01558999|Experimental|Low concentration SI-614|
3269292|NCT01558999|Placebo Comparator|Vehicle|
3269293|NCT01559025|No Intervention|Insulin therapy|Patients will receive the conventional treatment with insulin
3269294|NCT01559025|Active Comparator|Vildagliptin|Patients will receive vildagliptin besides the conventional treatment with insulin
3269295|NCT01559038||adalimumab|Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
3269296|NCT01559038||DMARD (disease-modifying antirheumatic drugs)|Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
3269297|NCT01559051|Experimental|Intravenous Injection and Inhalation infusion of AD-SVF|AD-SVF harvested from Autologous Adipose Tissue will be deliver after processing via IV and Inhalation
3269298|NCT01559077|Active Comparator|ALN-TTR02|
3269299|NCT01559077|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3269300|NCT01559103|Experimental|MEDI5117|Intravenous infusion administered over 60 minutes
3269301|NCT01559103|Placebo Comparator|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
3269302|NCT01559142|Active Comparator|IFX TG|
3269303|NCT01559142|Active Comparator|IFX alone|
3269304|NCT01559155||Bullous pemphigoid|Patients in this cohort are newly diagnosed (or have not started treatment) with bullous pemphigoid
3269305|NCT01559155||Other bullous-like auto-immune|Patients in this cohort are newly diagnosed (or have not started treatment) with pemphigus (15 patients) or cutaneous lupus (15 patients)
3269306|NCT01559155||Control group|Patients in this cohort are hospitalized at the Nîmes University Hospital, and have no history of autoimmune, inflammatory or neoplastic disease. Patients are matched for age and sex with patients in the bullous pemphigoid cohort.
3269307|NCT01559168|Experimental|Prolapse patients recieving UpHold LITE|Non-pregnant female patients >= 50 years who are not considering future pregnancies, who are diagnosed with uterine or vault prolapse with ICS POP-Q score of stage 2 or greater, who are receiving the UpholdTM LITE mesh kit and who agree to be in the study.
3269308|NCT01559181||Exposure to intrauterine hyperglycemia|The study group includes the offspring of women with type 1 diabetes from the national diabetes birth registry (1993-99, n=900) with information of HbA1c prior to conception and/or 1st trimester HbA1c.
3269309|NCT01559181||Control group|The control group including offspring of women without diabetes who delivered during the same period matched with respect to gender and age of offspring and the family's postcode as an indirect marker of the socioeconomic background.
3269310|NCT01559194|Active Comparator|Low Fat Diet + Exercise|Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
3269311|NCT01559194|Active Comparator|Low Carbohydrate Diet + Exercise|Subjects were educated about a low carbohydrate diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
3269312|NCT01559207||Patients with VTE|"Group P is composed of all patients with a history of VTE. Group Px is a subgroup of 15 patients from group P. Members of Px are randomly selected from P."
3269313|NCT01559207||Healthy volunteers|"Group T: 15 healthy volunteers with no history of VTE will be included in this group."
3269314|NCT01559220|Experimental|Open Label|DBS Implant and stimulation
3269315|NCT01559233|Experimental|FPlus|
3269316|NCT01559246||Cardiac Arrhythmia|Subjects 18 years of age or greater that have indications for traditional cardiac(Holter) monitoring.
3269317|NCT01559272|Experimental|Panel A|Panel A consists of 2 treatment groups
3269318|NCT01559272|Experimental|Panel B|Panel B consists of 5 treatment groups
3269319|NCT01559272|Experimental|Panel C|Panel C consists of 1 treatment group
3269320|NCT01559272|Experimental|Panel D|Panel D consists of 4 treatment groups
3269321|NCT01559285|Active Comparator|0.375% ropivacaine|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3269322|NCT01559285|Active Comparator|0.75% ropivacaine|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3269323|NCT01559285|Active Comparator|0.2% ropivacaine|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
3269324|NCT01559298|Active Comparator|Aspirin + clopidogrel|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d) + clopidogrel (75 mg/d) following the TAVI procedure.
3269325|NCT01559298|Active Comparator|Aspirin|Patients will be randomized within the month prior to the TAVI procedure to receive aspirin (80 mg/d)
3269326|NCT01559324|Experimental|Bifrontal ECT (BF)|Formula-based low dose BF ECT
3269327|NCT01559324|Experimental|Right unilateral ECT (RU)|Formula-based high-dose RU ECT
3269328|NCT01559337|Other|Nerve repair|the dorsal branch of the proper digital nerve was used as a pedicle nerve for reconstructing PDN defects
3269329|NCT01559350||RGEA group|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
3269330|NCT01559350||SVG group|A saphenous vein grafting in the right coronary artery system during OPCAB
3269331|NCT01559363|Experimental|Cohort 1|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3269332|NCT01559363|Experimental|Cohort 2|Two 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
3269333|NCT01559363|Experimental|Cohort 3|Three 50mg KD019 (tesevatinib) tablets per day for 28 days and up to 24 months
3269334|NCT01559363|Experimental|Phase 2a Monday, Wednesday, Friday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday, Wednesday and Friday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
3269335|NCT01559363|Experimental|Phase 2a Monday and Thursday|An alternate KD019 (tesevatinib) dosing schedule of dosing on Monday and Thursday of each week for 24 months from their first dose or until the development of unacceptable toxicity, noncompliance, or withdrawal of consent by the subject, or investigator decision
3269336|NCT01559363|Experimental|Phase 2a, 50mg|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3269337|NCT01559363|Experimental|Phase 2a, 50mg (SILK Cohort)|One 50mg KD019 (tesevatinib) tablet per day for 28 days and up to 24 months
3269338|NCT01559376||Endoscopic radial artery harvest|
3269339|NCT01559376||Conventional open radial artery harvest|
3269340|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with an inspiratory oxygen fraction(FIO2) of 1.0, supplied by a continuous positive airway pressure of 10 centimeters of water(cmH2O), during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled CPAP and 100% oxygen.
3269341|NCT01559402|Experimental|Start O2 100% and CPAP 10, end O2 31%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, supplied by a continuous positive airway pressure of 10 cmH2O, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 0.3 is used. The intervention associated with this arm is labeled CPAP and 31% oxygen.
3269342|NCT01559402|Experimental|Start O2 100% and CPAP 0, end O2 100%.|This arm describes some aspects of ventilation during anesthesia for laparoscopic gastric bypass. Pre-oxygenation is with a FIO2 of 1.0, without a continuous positive airway pressure, during anesthesia a positive end-expiratory pressure of 10 cmH2O is used and during emergence from anesthesia a FIO2 of 1.0 is used. The intervention associated with this arm is labeled No CPAP and 100% oxygen.
3269343|NCT01559415|Experimental|Very Low Calorie Diet|
3269344|NCT01559415|Active Comparator|Low Calorie Diet|1250 kcal diet in which Modifast is given in combination with a normal diet
3269345|NCT01559428|Experimental|Plant sterol-enriched margarine|
3269346|NCT01559428|Experimental|Plant stanol-enriched margarine|
3269347|NCT01559428|Placebo Comparator|Control margarine|
3269348|NCT01559441|Experimental|Beetroot juice|
3269349|NCT01559441|Placebo Comparator|Carbohydrate control drink|
3269350|NCT01559467|Other|Routine clinical care plus early CMR|
3269351|NCT01559467|No Intervention|Routine clinical care|
3269352|NCT01559467|Other|Routine clinical care plus early CTA|
3269353|NCT01559480|Active Comparator|Desogestrel|
3269354|NCT01559480|Placebo Comparator|Placebo|
3269355|NCT01559493||FFR; iFR|Interventional Cardiology, Pressure wire, fractional flow reserve, coronary flow measurement
3269356|NCT01559519|Active Comparator|albumin|cirrhotic patients who underwent tips placement
3269357|NCT01559532||ATK patients|Patients from our institution that underwent cemented TKA for degenerative knee disorders.
3269358|NCT01559545|Active Comparator|Metronidazole|Immediate release metronidazole
3269359|NCT01559545|Experimental|Metronidazole-DRF1|Modified release metronidazole (DRF1)
3269360|NCT01559545|Experimental|Metronidazole-DRF2|Modified release metronidazole (DRF2)
3269361|NCT01559558||cystocele|
3269362|NCT01559584|Experimental|Phototherapeutic|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
3269363|NCT01559584|Active Comparator|Conventional therapy|One monthly injections of intralesional potent corticosteroids
3269364|NCT01559597|Active Comparator|Cold chain|Group vaccinated with tetanus toxoid vaccine kept in cold chain
3269365|NCT01559597|Experimental|CTC|Group vaccinated with tetanus toxoid vaccine kept in controlled temperature chain
3269366|NCT01559610|No Intervention|Control Group|Received preoperative guidance by a member of healthcare team with the aid of checklist
3269367|NCT01559610|Other|Group intervention|preoperative guideline by a nurse
3269368|NCT01559636|Active Comparator|Diarrhea|Infants with diarrhea will have blood and stool sample taken and receive zinc and ORS. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
3269369|NCT01559636|Active Comparator|Non-diarrhea|Infants without diarrhea will have blood and stool sample taken and receive multivitamins. They will then receive bivalent oral polio vaccine as the intervention. Four weeks later another blood sample will be drawn to measure seroconversion.
3269370|NCT01559662|Experimental|Sugared Chewing Gum|Patient asked to chew sugared chewing gum postoperative day 1 to 7, 3 times a day, 45 minutes at a time
3269371|NCT01559662|No Intervention|No Gum|No gum given, routine postoperative care provided
3269372|NCT01559688|Experimental|ART therapy group|Participants in this arm will receive 2-5 sessions of ART therapy, depending on individual progress. Each session will last 60-90 minutes over a 2-week period.
3269373|NCT01559688|Active Comparator|Waitlist|Participants in this group will receive 2 fitness assessment or career counseling sessions. Each session will last 60-90 minutes over a 2-week period. Upon completion of this arm, participants will be offered the choice to start ART therapy.
3269374|NCT01559701|Experimental|PF-00345439 (oxycodone)|PF-00345439 (oxycodone)
3269375|NCT01559714||Clinical HCM patients|Patients with an echocardiographically proven hypertrophic cardiomyopathy according to the ESC and ACCF/AHA guidelines
3269376|NCT01559714||Pre-clinical HCM patients|Individuals with a HCM associated mutation without the clinical characteristics of hypertrophic cardiomyopathy
3269377|NCT01559727|No Intervention|Control|The patients with symptomatic heart failure were treated with standard treatment.
3269378|NCT01559727|Experimental|15 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
3269379|NCT01559727|Experimental|30 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day.
3269380|NCT01559727|Experimental|60 mg prednisone group|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day.
3269381|NCT01559740|Experimental|0.25% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 1 receiving a TAP block with 0.25% bupivacaine with 1:200,000 epinephrine at a dose of 1 mL/kg.
3269382|NCT01559740|Experimental|0.125% Bupivacaine|All children will receive a single dose of 1 mcg/kg of Fentanyl intravenously prior to incision. Group TAP 2 will receive a TAP block with a total dose of 1 mL/kg given at a concentration of 0.125% bupivacaine with 1:200,000 epinephrine.
3269383|NCT01559753|Experimental|8 days of antibiotic treatment|Patients will receive a combination antibiotic during 5 days and then 3 days of a single Beta Lactam antibiotic
3269384|NCT01559753|Active Comparator|15 days antibiotic treatment|All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for 10 days according to the group. The beta-lactam antibiotics will be administered in high doses during the first 3 days of treatment. Aminoglycosides will be administered in a single daily dose, with a loading dose the first day of treatment.
3269385|NCT01559766||4-6 years old group|
3269386|NCT01559766||7-9 years old group|
3269387|NCT01559779||Normal glucose tolerance|Morbidly obese subjects with normal glucose tolerance undergoing gastric bypass surgery
3269388|NCT01559805|Experimental|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
3269389|NCT01559805|Active Comparator|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
3269390|NCT01559818|Experimental|IMM-101|IMM-101 1.0 mg administered intradermally
3269391|NCT01559831|Other|IXIARO|IXIARO, applied according to licensed dose, intramuscular
3269392|NCT01559870||patients with elective cardiac surgery|adult patients who had undergone elective cardiac surgery with CPB
3269393|NCT01559883||all eligible patients|there is only 1 Cohort in which all patients participating in this NIS are included
3269394|NCT01559896|Experimental|intervention and placebo|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
3269395|NCT01559909|Experimental|Socket wall height|
3269396|NCT01559961|Experimental|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
3269397|NCT01559974|Active Comparator|Vitamin D|
3269398|NCT01559974|Placebo Comparator|Placebo|
3269399|NCT01559987|Other|Control|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
3269400|NCT01559987|Other|Test|MTB + Floss
3269401|NCT01559987|Experimental|MTB + Waterpik Ultra Water Flosser High|MTB + Waterpik Ultra Water Flosser High
3269402|NCT01560000|Other|fiber|
3269403|NCT01560013|Experimental|Naltrexone|Treatment with naltrexone for two months together with psycho-social support
3269404|NCT01560026||ovarian preservation|endometrial cancer with ovarian preservation
3269405|NCT01560026||oophorectomy|endometrial cancer without ovarian preservation
3269406|NCT01560039|Active Comparator|Real EEG-NF|10 EEG based neurofeedback sessions modulating the activity of the primary motor cortex
3269407|NCT01560039|Sham Comparator|Sham EEG-NF|10 sessions of Sham EEG_NF of the motor cortex area
3269408|NCT01560039|Active Comparator|Transcrainal Magnetic Stimulation|10 dailt TMS stimulation sessions of M1
3269409|NCT01560052|Active Comparator|oral methylprednisolone|"oral methylprednisolone~Original Cohort:~Methylprednisolone group; start at 0.8mg/kg/day with a maximal 48mg/kg/day x 2months, taper by 8mg/day every month with optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~Low Dose Cohort:~Methylprednisolone group; start at 0.4mg /kg/day with a maximal dose of 32mg/day and a minimum dose of 24mg/day, reducing over 6-9months.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
3269410|NCT01560052|Placebo Comparator|placebo|"Original Cohort:~Matching placebo; Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines; Low Dose Cohort; Matching placebo: Optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines.~All participants will also receive standard guideline based care, without steroid therapy. Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months in the low-dose cohort, after randomisation, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
3269411|NCT01560065|Other|Normospermic patients|
3269412|NCT01560065|Other|Oligoasthenospermic patients|
3269413|NCT01560065|No Intervention|Control|
3269414|NCT01560091|Placebo Comparator|Group A|Patients will receive ESWL and no medication
3269415|NCT01560091|Active Comparator|Group B|Patients will receive Flomax after ESWL
3269416|NCT01560091|Active Comparator|Group C|Patients will receive silodosin after ESWL
3269417|NCT01560104|Experimental|veliparib and carboplatin and paclitaxel|Veliparib on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
3269418|NCT01560104|Placebo Comparator|placebo and carboplatin and paclitaxel|Placebo on Days 1-7 and carboplatin and paclitaxel on Day 3 of a 21 day cycle
3269419|NCT01560130|Active Comparator|Shape Up Rhode Island + Online Weight Loss + Incentives|
3269420|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program|
3269421|NCT01560130|Active Comparator|Shape Up Rhode Island + Online weight loss program + groups|
3269422|NCT01560169||Gluten challenge|Gluten containing or gluten-free study food in established celiac disease patients
3269423|NCT01560169||Observation|Observation in newly diagnosed celiac disease patients
3269424|NCT01560182|Experimental|OTL-200 Gene Therapy|CD34+ cells transduced ex vivo with lentiviral vector encoding ARSA cDNA
3269425|NCT01560195|Experimental|Pegylated rhG-CSF: 100µg/kg|Staged III or IV NSCLC patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
3269426|NCT01560195|Experimental|Pegylated rhG-CSF: 6mg|Staged III or IV NSCLC patients receiving chemotherapy and pegylated rhG-CSF 6mg
3269427|NCT01560195|Placebo Comparator|Placebo|Staged III or IV NSCLC patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF in cycle 2 to 4
3269428|NCT01560221|Experimental|Therapeutic Workplace|Participants will receive all standard services plus the Therapeutic Workplace intervention, in which access to stipend supported training and/or wage subsidies for community employment is contingent upon drug abstinence as verified by urinalysis.
3269429|NCT01560221|Active Comparator|Standard Services|Participants will receive methadone treatment or buprenorphine treatment, depending upon medical recommendations of their physicians, slot availability, and their own preferences. Participants who remain in treatment for at least 90 days will have the charge of prostitution that is pending against them dropped.
3269430|NCT01560247||Treatment Group|Subjects in whom a MindFrame Device was employed for restoration of flow and clot removal
3269431|NCT01560273||Aspen Spinous Process Fixation Device|The Aspen device provides supplemental posterior fixation for fusion
3269432|NCT01560299|Active Comparator|group one|This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
3269433|NCT01560299|Active Comparator|group two|methimazole stopped 48-72 hour before radioiodine therapy
3269434|NCT01560299|Active Comparator|group three|
3269435|NCT01560312|Experimental|Renal denervation|Renal denervation (Symplicity® Catheter System™) + conventional antihypertensive medical treatment without spironolactone (spironolactone can be taken only if started before randomization)
3269436|NCT01560312|No Intervention|Medical treatment|"Conventional antihypertensive treatment including spironolactone (if not contraindicated).~One year after randomization, renal denervation can be performed according to the physician's decision based on the BP levels and if patient desires the procedure."
3269437|NCT01560325|Experimental|CKD-516 inj.|CKD-516 Inj, 3.3~13mg/m2/day, D1, 4, 8, 11 every 3 weeks
3269438|NCT01560338||Pediatric after Cardiac Arrest|Pediatric patients greater than 3 kg. and less than 18 years suffering cardiac arrest who have been given or currently receiving morphine and/or midazolam and receiving hypothermia.
3269439|NCT01560351|Experimental|rTMS|Session of repeated low-frequency Transcranial Magnetic Stimulation
3269440|NCT01560351|Sham Comparator|Placebo|Sessions of sham rTMS
3269441|NCT01560364||Hemofilter|
3269442|NCT01560390|Other|Rémifentanil + Kétamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
3269443|NCT01560390|Other|Rémifentanil + Placebo|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
3269444|NCT01560442||buprenorphine|
3269445|NCT01560442||Methadone Hydrochloride|
3269446|NCT01560455|Active Comparator|single stent|single stent
3269447|NCT01560455|Active Comparator|dual stent|dual stent (culotte)
3269448|NCT01560468|Experimental|ITX 5061|Subjects will receive ITX 5061 for 28 days beginning at the time of liver transplantation for hepatitis C virus. 300mg will be administered on the day of surgery and for one week post transplant, followed by 150mg for an additional 21 days.
3269449|NCT01560481|Experimental|Step A: metformin glycinate 620 mg|620mg single dose by mouth
3269450|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg|1240mg single dose by mouth
3269451|NCT01560481|Experimental|Step A: metformin glycinate 2480 mg|2480mg single dose by mouth
3269452|NCT01560481|Active Comparator|Step A: metformin hydrochloride 1000 mg|1000mg single dose by mouth
3269453|NCT01560481|Experimental|Step A: metformin glycinate 1240 mg, food intake|1240mg single dose by mouth after food intake
3269454|NCT01560481|Experimental|Step B: metformin glycinate 620 mg BID|620mg BID for 8 days
3269455|NCT01560481|Active Comparator|Step B: metformin hydrochloride 500 mg BID|500mg tablets BID for 8 days
3269456|NCT01560494|Experimental|STAC curriculum|
3269457|NCT01560494|No Intervention|Conventional Curriculum|
3269458|NCT01560520||Accelerometer|
3269459|NCT01560533|Other|Treated by HIPEC|Patients treated by HIPEC for peritoneal cancer
3269460|NCT01560533|Other|Standard chemiotherapy|Patients treated by standard chemiotherapy for peritoneal cancer
3269461|NCT01560546|Active Comparator|Testim|
3269462|NCT01560546|Placebo Comparator|Placebo|Placebo for 24 weeks
3269463|NCT01560559|Experimental|Single Arm|Peroral endoscopic myotomy
3269464|NCT01560572|Active Comparator|standard immunosuupression|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg
3269465|NCT01560572|Experimental|steroidfree|maintenance immunosuppression with tacrolimus OD (target range 6-10 ng/ml), mycophenolic acid (2 dd 540 mg)
3269466|NCT01560572|Experimental|low dose tacrolimus|triple maintenance immunosuppression with tacrolimus OD (maintenance 6-10 ng/ml), mycophenolic acid 2 dd 540mg and prednisolone 7.5 mg. After 6 months lowering of tacrolimus OD maintenance 3-5 ng/ml
3269467|NCT01560585|Experimental|Open label|All participants will receive Isotretinoin for 24 weeks
3269468|NCT01560598||Reflux esophagitis|those with endoscopically proven reflux esophagitis
3269469|NCT01560598||Normal|those with normal GFS finding (without definite mucosal break at Z-line)
3269470|NCT01560611||High-risk cardiac surgery patient|
3269471|NCT01560637|Experimental|UT-15C|Open label access
3269472|NCT01560650|Experimental|high dose (35ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 35 mL/kg/h.
3269473|NCT01560650|Experimental|low dose (25ml/kg/h)|> = 18 years of age, CRRT indications for acute kidney injury (RIFLE criteria) patients with cardiac surgery, was given filtration at a rate of 25 mL/kg/h.
3269474|NCT01560663||Docetaxel Carboplatino|Doses of AUC 5-6 of carboplatin in combination with 75 mg/m2 of docetaxel are easily combined, being myelosuppression the most important toxicity. This combination has been studied in metastatic breast cancer as well as in the neoadjuvant setting. The combination of taxanes and platinum salts is increasingly used as neoadjuvant chemotherapy for TNBC. The docetaxel-carboplatin (TCb) regimen is an active and tolerable regimen in metastatic and locally advanced breast cancer, and the efficacy and toxicity characterization in the clinical setting are regaining interest in the era where the role of anthracyclines is controversial in the adjuvant setting. The avoidance of potentially serious long-term toxicities in specific breast cancer subtypes is a real challenge in an attempt to individualize therapies.
3376855|NCT04976127|Experimental|Talineuren dose escalation|14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg
3376856|NCT04976127|Experimental|Talineuren repeated dose|8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose)
3376857|NCT04975867|Experimental|Hypothermia group|Hypothermia group is then performed at a body temperature of 33±0.5 °C during 24 h using a surface cooling device as soon as possible after the HBO and research consent. After therapeutic hypothermia ended, rewarming is done slowly between 0.2℃ - 0.5℃/h for 12 hours. After rewarming, it will be held at 36.5 ℃ for 36 hours.
3376858|NCT04975867|Active Comparator|Normothermia group|For normothermia group, it will be held at 36.5±0.5 ℃ for 72 hours using a surface cooling device after the HBO and research consent.
3269475|NCT01560676|Active Comparator|HEALTH[e]TEEN|8 lessons over 6-8 weeks Education on healthy eating and physical activity Behavioral support for self-monitoring and goal setting
3269476|NCT01560676|Active Comparator|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks Education on healthy eating and coping skills training Behavioral support for self-monitoring and goal setting
3269477|NCT01560689|Active Comparator|BUDESONIDE/FORMOTEROL|
3269478|NCT01560689|Placebo Comparator|control|
3269479|NCT01560702|Active Comparator|Autologous blood|Patients will be injected by autologous blood at the edge of actively bleeding ulcer
3269480|NCT01560702|Other|Epinephrine injection|Patients will be injected by diluted epinephrine at the edge of actively bleeding ulcer
3269481|NCT01560715|Experimental|Experimental: Test group|Retinitis pigmentosa patients with best-corrected visual acuity (BCVA) worse than 20/200 or visual field less than 20 degrees
3269482|NCT01560728|Experimental|Trauma-Focused CBT|Adapted or modified Trauma-Focused Cognitive Behavioral Therapy
3269483|NCT01560728|No Intervention|Wait list|Monitored while waiting for intervention
3376868|NCT04969861|Experimental|BEMPEG + Pembrolizumab|Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
3376869|NCT04969861|Active Comparator|Pembrolizumab Monotherapy|Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
3376870|NCT04968288||Cohort 1|Subjects with KSHV-associated MCD
3376871|NCT04968028|Experimental|ACAF|Participants underwent anterior decompression of Anterior Controllable Antedisplacement and Fusion
3376872|NCT04968028|Experimental|Laminoplasty|Participants underwent posterior decompression of Laminoplasty
3376873|NCT04967742|Experimental|A group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 10 μg in V-122 study.
3376874|NCT04967742|Experimental|B group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 30 μg in V-122 study.
3376875|NCT04967742|Experimental|C group: 1 booster dose of UB-612 vaccine 100 μg|1 booster dose for subjects at UB-612 vaccine 100 μg in V-122 study.
3376876|NCT04964128|Experimental|meal gesture dosing for unannounced meals within the AHCL System|
3269484|NCT01560741|Active Comparator|Telemedicine Group|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be provided with a ventilator outfitted with a wireless transmitter to allow the remote data collection of compliance and efficacy information. While patient sleeps, data is collected. If abnormalities criteria will be detected, remote titration of ventilator settings will be done to optimise therapy. Patient will be monitored again and data analyzed. This procedure will be repeated until we obtained the optimal ventilator parameters for each patient in this group. Nocturnal oximetry under home mechanical non-invasive ventilation will be carried out after one week and one month of treatment. Subjects also receive pre-arranged telephone calls to assist with progress.
3376883|NCT04958239|Experimental|Arm A: BI 765179|
3376884|NCT04958239|Experimental|Arm B: BI 765179 + ezabenlimab|
3376885|NCT04958018|Experimental|Almond|57 g almonds each day in split doses (half in the morning, half in the afternoon)
3376886|NCT04958018|Active Comparator|Snack Bar|snack bar group will ingest a matched calorie, common snack bar in split doses (324 calories/day, Nutri-Grain cereal bars, 120 kcal each)
3269485|NCT01560741|Other|Usual care|Patients will be initiated and adapted on non-invasive home mechanical ventilation in Pulmonology Department of S. João Hospital, in an outpatient setting, according to the prevailing standard of care for Chronic Respiratory Diseases patients in this unit. Patients will be assessed by a hospital visit scheduled at the end of third month after their initial adaptation. In this hospital visit data provided by the ventilator will be transferred to research team computer so they could evaluate patient compliance and efficacy of ventilation criteria under the parameters used at home present at the time of assessment. If abnormality criteria will be detected, re-titration of ventilator settings will be made. Patients will be encouraged to call their respiratory consultant any time they had a problem or concern.
3269486|NCT01560754|Experimental|Transdermal nicotine patch|Subjects will apply a combination of 7 or 14 mg nicotine transdermal patches until reaching their highest well tolerated dose of 7 to 28 mg/day.
3269487|NCT01560754|Placebo Comparator|Transdermal placebo patch|Subjects will apply a combination of 7 or 14 mg placebo transdermal patches until reaching their highest well tolerated dose.
3269488|NCT01560767|Active Comparator|Femoral Nerve Block|levobupivacaine
3269489|NCT01560767|Active Comparator|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
3269490|NCT01560793|Experimental|VAX161B|Dose escalating study where subjects are treated with VAX161B at one of six dose levels. Subjects will be injected with VAX161B twice during the study at Day 0 and Day 21. The dosages are: 1 mcg; 2.5 mcg; 4 mcg; 6 mcg; 8 mcg; and 12 mcg.
3269491|NCT01560806|No Intervention|Conventional Healthcare services|People with high blood pressure detected during screening survey or opportunistically during study period will be referred to receive the conventional health care services for hypertension at district hospital or local commune health station
3269492|NCT01560806|Experimental|Commune Hypertension Management|People with high blood pressure were managed in commune-based hypertension management programme
3269493|NCT01560832||Laboratory (PCR)-confirmed C.difficile infection|patient who has experienced the passage of 3 or more unformed or loose stools [diarrhea] conforming to the shape of a container within a 24-hour period and has a positive laboratory test result confirmed by PCR.
3269494|NCT01560845|Experimental|ABMSCi plus surgery group|Autologous bone marrow stem cells infusion through hepatic artery in open abdominal portal hypertension surgery
3269495|NCT01560845|No Intervention|portal hypertension surgery group|only portal hypertension surgery for this group patients
3269496|NCT01560884|Active Comparator|Group B|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
3269497|NCT01560884|Active Comparator|Group C|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
3269498|NCT01560884|Active Comparator|Group D|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
3269499|NCT01560884|Active Comparator|Group A|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
3269500|NCT01560897|Experimental|C13|The dose of sodium [1-13C] acetate is calculated according to patient weight (27mg/kg) or (0.33 mmol / kg).
3269501|NCT01560962|Other|PI vs no intervention|In group one, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI twice daily for 10 days and the other eye with no intervention.
3269502|NCT01560962|Other|PI vs hygiene|In group two, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive warm soaked eyelid wash.
3269503|NCT01560962|Other|PI vs azasite|In group three, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive 1 drop of azithromycin ophthalmic solution twice daily for 10 days.
3269504|NCT01560962|Other|PI vs tobradex|In group four, 25 patients will be instructed to scrub the lid margin of one eye with 5% PI and the other eye will receive tobradex ointment applied to the lid margin.
3269505|NCT01561014|Experimental|Treatment (chemotherapy, enzyme inhibitor therapy)|"CHEMORADIOTHERAPY: Patients undergo radiation therapy QD, 5 days a week and receive fluorouracil IV continuously and erlotinib hydrochloride PO QD on days 1-38. Patients also receive oxaliplatin IV over 2 hours on days 1, 15, and 29.~SURGERY: Within 4-8 weeks after completion of chemoradiotherapy, patients with potentially resectable disease (i.e., complete response, partial response, or stable disease) undergo surgery to remove the tumor.~CONSOLIDATION CHEMOTHERAPY: Within 2-4 weeks after surgery, patients with tumors that demonstrate positive immunohistochemistry for EGFR and/or cyclin D1 (in the pretreatment biopsy or in the residual tumor in the esophagectomy specimen) receive consolidation chemotherapy comprising erlotinib hydrochloride PO QD for 12 weeks."
3269506|NCT01561027|Experimental|CNV1014802|CNV1014802 350mg on prescription (BID) for 21 days
3269507|NCT01561027|Placebo Comparator|Placebo|Placebo 350mg BID for 21 days
3269508|NCT01561040|Experimental|Omega 3, Vitamins A, D3 and E|Dry eye patients that have been screened with elevated osmolarity dispensed EZ Tears supplements containing Omega 3, Vitamins A, D3 and E to evaluate the change in dry eye conditions subjectively and objectively.
3269509|NCT01561066|Sham Comparator|conservative therapy|Conservative therapy includes orrection of electrolytic disturbances, suppression of gastric/intestinal secretion with octreotide, nutritional support.
3269510|NCT01561066|Active Comparator|Application of autologous PRFG|The application of the glues through the external opening of the fistula was controlled by the drainage tube, which was based on fistulography to assure total occlusion of the internal hole. To allow the adhesion of the fibrin glues patch, all fistulous tracts were debrided to produce a smooth surface. At the time of procedures, the two components were mixed together to yield a gelatinous substance. After the FG was instilled, any redundant glue was removed from the external openings.
3269511|NCT01561092|Active Comparator|Escitalopram|
3269512|NCT01561092|Placebo Comparator|Non active drug|
3269513|NCT01561105|Experimental|IMPACT|
3269514|NCT01561105|No Intervention|Care as Usual|Patients received all depression care available to them as part of care as usual in the participating primary care clinics.
3269515|NCT01561118|Experimental|Bicycle-Ergometer Training Group|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions).~In the second part of the study intervention will be prolonged for another 12 weeks."
3269516|NCT01561118|Other|Control|"No intervention during hemodialysis during the first 12 weeks of the study.~In the second part of the study a training program, according to that of the intervention group, will be performed with a performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes, with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions)."
3269517|NCT01561131|Active Comparator|Whey protein supplement|Whey protein
3269518|NCT01561131|Active Comparator|Whey protein enriched with calcium supplement|Whey protein enriched with calcium
3269519|NCT01561131|Active Comparator|Soy protein supplement|Soy protein
3269520|NCT01561131|Placebo Comparator|Control supplement|Maltodextrin
3269521|NCT01561157||Acute Intermittent Porphyria (AIP)|Patients with a documented diagnosis of AIP
3269522|NCT01561157||Hereditary Coproporphyria (HCP)|Patients with a documented diagnosis of HCP
3269523|NCT01561157||Variegate Porphyria (VP)|Patients with a documented diagnosis of VP
3269524|NCT01561157||Congenital Erythropoietic Porphyria (CEP)|Patients with a documented diagnosis of CEP
3269525|NCT01561157||Hepatoerythropoietic Porphyria (HEP)|Patients with a documented diagnosis of HEP
3269526|NCT01561157||Porphyria Cutanea Tarda (PCT)|Patients with a documented diagnosis of PCT
3269527|NCT01561157||Erythropoietic Protoporphyria (EPP)|Patients with a documented diagnosis of EPP
3269528|NCT01561157||X-Linked Protoporphyria (XLP)|Patients with a documented diagnosis of XLP
3269529|NCT01561157||Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)|Patients with a documented diagnosis of ALAD, ADP
3269530|NCT01561157||Homozygous Dominant Acute Hepatic Porphyria|Patients with a documented diagnosis of Homozygous Dominant AHP
3269531|NCT01561170||Chronically venous ulcer|A group of 36 patients
3269532|NCT01561183|Experimental|Indirect pulp capping (IPC)|Indirect pulp capping
3269533|NCT01561183|Experimental|Direct pulp capping (DPC)|Direct pulp capping
3269534|NCT01561183|Experimental|Miniature pulpotomy (MP)|Miniature pulpotomy
3269535|NCT01561183|Experimental|Full pulpotomy (FP)|Full pulpotomy
3269536|NCT01561196|Active Comparator|Ultrasound guided arterial cannulation|The arterial needle is placed using ultrasound monitoring for guiding the operator.
3269537|NCT01561196|Active Comparator|Conventional cannulation|the arterial needle is placed using the traditional method and lidocaine. The operator decides where to place the needle in the forearm
3269538|NCT01561209|Active Comparator|Amitryptiline|Amitryptiline 5 mg before bedtime
3269539|NCT01561209|Placebo Comparator|Placebo|Placebo pill
3269540|NCT01561222|Placebo Comparator|placebo|
3269541|NCT01561222|Experimental|Calcitriol|
3269542|NCT01561235|Active Comparator|Normal Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 14 E%, Fat: 30 E% and carbohydrate: 56E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3269543|NCT01561235|Experimental|Medium-high protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 25E%, Fat: 30 E% and carbohydrate: 45E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3269544|NCT01561235|Experimental|High Protein|"Energy content 3 or 4 MJ/meal, depending on the subject's individual daily energy requirements).~Macronutrient content: Protein: 50 E%, Fat: 30 E% and carbohydrate: 20E%. The fibre content was similar in all three test meals. The test meals were served as pork/rice/mushroom pâtés, flavoured with thyme in order to blind differences in taste."
3269545|NCT01561248|No Intervention|SOC-treatment|Patients with EHEC associated bloody diarrhoea (n=12) receiving standard of care treatment, consisting of intravenous fluids (2-3 liters/daily), analgetics, including paracetamol and metamizol and metoclopramid, if required.
3269546|NCT01561248|Experimental|PEG-Solution, daily bowel lavage|Patients with EHEC associated bloody diarrhoea (n=21)receiving SOC-treatment, consisting of i.v. fluids (2-3 liter/day), analgetics ( paracetamol and metamizol) or metoclopramid and orally administered polyethylene glycol-solution daily during the clinical course.
3269547|NCT01561274|Active Comparator|2 ml bupivacaine|2 ml of 0.75% hyperbaric bupivacaine, for a total of 15 mg of bupivacaine.
3269548|NCT01561274|Active Comparator|1.5 ml bupivicaine.|1.5 ml of 0.75% hyperbaric bupivacaine, for a total of 12.5 mg of bupivacaine.
3269549|NCT01561287|Experimental|Dermal Autograft|
3269550|NCT01561287|Experimental|AlloDerm|
3269551|NCT01561326|Experimental|Cognitive-affective barriers counseling delivered by phone|Standard care plus cognitive-affective barriers counseling delivered by phone , i.e., culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence
3269552|NCT01561326|Experimental|cognitive-affective barriers counseling via brochure|Standard care plus cognitive-affective barriers counseling delivered via mail-home print material
3269553|NCT01561326|Active Comparator|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
3269554|NCT01561352|Experimental|Factor VII|
3269555|NCT01561365|Experimental|Emergency|
3269556|NCT01561365|Experimental|Orthopedic residents|
3269557|NCT01561391|Experimental|Continuous infusion|
3269558|NCT01561391|Experimental|Bolus injection|
3269559|NCT01561391|Experimental|Control|
3269560|NCT01561404|Experimental|Everolimus|Conversion from calcineurin inhibitor (CNI) to MTOR inhibitor (everolimus)
3269561|NCT01561417|Active Comparator|CP-rFVIIa|
3269562|NCT01561417|Experimental|VII25|
3269563|NCT01561430|Experimental|15 mg LY2886721|LY2886721: 15 milligrams (mg), capsules, administered orally, once daily for 26 weeks.
3269564|NCT01561430|Experimental|35 mg LY2886721|LY2886721: 35 mg, capsules, administered orally, once daily for 26 weeks.
3269565|NCT01561430|Experimental|70 mg LY2886721|LY2886721: 70 mg, capsules, administered orally, once daily for 26 weeks.
3269566|NCT01561430|Placebo Comparator|Placebo|Placebo: 1 placebo capsule, administered orally, once daily for 26 weeks.
3269567|NCT01561456|Experimental|AXL1717|AXL1717
3269568|NCT01561456|Active Comparator|Docetaxel|Docetaxel
3269569|NCT01561482|Experimental|Metformin, Simvastatin|"Both metformin and simvastatin will be taken every day. Metformin will be taken as 1 pill in the morning and 1 pill before going to bed. Simvastatin will be taken as 1 pill before going to bed.~They will be taken until metastasis from the prostate cancer appears or until the subjects PSA has doubled from what it was before they started the study."
3269570|NCT01561508|Experimental|GABA|2/3 of participants will be randomized to the GABA treatment group. Dosage will be based on body weight and will be adjusted at each study visit.
3269571|NCT01561508|Placebo Comparator|Placebo|1/3 of participants will receive placebo.
3269572|NCT01561521|Experimental|AKF-1 0.025%|
3269573|NCT01561521|Experimental|AKF-1 0.035%|
3269574|NCT01561521|Placebo Comparator|AKF-1 0%|
3269575|NCT01561547|Experimental|Kangaroo Mother Care|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sterile water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
3269576|NCT01561547|Active Comparator|Sucrose|Two minutes before the painful procedure and at the moment of the procedure, the infant will be given 24% sucrose by mouth. The volume is determined by body weight and is not important in terms of efficacy, it is the percentage of sweetness that is important.
3269577|NCT01561547|Experimental|Combination Kangaroo Mother Care and Sucrose|Infant is held in skin-to-skin contact with mother at least 15 minutes prior to painful procedure, remains in that position throughout the procedure and after the procedure at least until heart rate returns to baseline. Infant is given sucrose water by mouth. This is for every heel lance and venipuncture, and if possible for tape removal.
3269578|NCT01561573|Other|Ultrasound colles fracture|This is a single arm study
3269579|NCT01561586|Active Comparator|A: Weekly cisplatin with RT|Weekly cisplatin 40mg/m2 six cycles concurrent to radiation therapy
3269580|NCT01561586|Experimental|B: Tri-weekly cisplatin with RT|Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
3269581|NCT01561599|Placebo Comparator|Normal saline|Placebo
3269582|NCT01561599|Active Comparator|BB3|Small molecule mimetic of hepatocyte growth factor/scatter factor
3269583|NCT01561612|Experimental|Intervention|Breastfeeding promotion according to World Health Organization's Baby Friendly Hospital Initiative
3269584|NCT01561612|No Intervention|Control|Usual care
3269585|NCT01561638|Active Comparator|group p|pulse radiofrequency lesioning
3269586|NCT01561638|Placebo Comparator|sham group|Controlled, conventional
3269587|NCT01561638|Active Comparator|group C|Pulse dose radiofrequency
3269588|NCT01561651|Experimental|Left Atrial Appendage Occlusion Group|Surgeon will close the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure device during the patient's cardiac surgery procedure.
3269589|NCT01561651|No Intervention|No Left Atrial Appendage Occlusion Group|Surgeon will not close the left atrial appendage during the patient's cardiac surgery procedure. Patient will be treated as per best medical practice for stroke prevention in atrial fibrillation. Treatment will be decided by the patient's primary care physician.
3269590|NCT01561664|Active Comparator|volunteers|not overweight Volunteers responding to the study criteria
3269591|NCT01561664|Experimental|overweight patients insulin sensitive|overweight patients insulin sensitive responding to the study criteria
3269592|NCT01561664|Experimental|overweight insulin resistant|overweight patients insulin resistant responding to the study criteria
3269593|NCT01561677|No Intervention|apnea/hypopnea index (AHI<5 : no OSAS)|
3269594|NCT01561677|No Intervention|apnea/hypopnea index (5≥AHI<15 : mild OSAS)|
3269595|NCT01561677|No Intervention|apnea/hypopnea index (15≤AHI<30 :moderate OSAS)|
3269596|NCT01561677|Active Comparator|apnea/hypopnea index ( AHI≥30 : severe OSAS treated).|Treated with CPAP
3269597|NCT01561677|Sham Comparator|apnea/hypopnea index ( AHI≥30:severe OSAS untreated).|Treated with sham CPAP (placebo)
3269598|NCT01561690|Experimental|ARRY-502|
3269599|NCT01561690|Placebo Comparator|Placebo|
3269600|NCT01561729|Experimental|Study group|This is the only arm of the study. All patients enrolled will have a nasogastric or orogastric tube placed. All will be assessed by both the RightSpot pH Indicator and chest radiograph.
3269601|NCT01561742|Experimental|Minocycline|
3269602|NCT01561742|Placebo Comparator|Placebo|
3269603|NCT01561768|Experimental|Group 1|
3269604|NCT01561768|Experimental|Group 2|
3269605|NCT01561768|Experimental|Group 3|
3269606|NCT01561768|Experimental|Group 4|
3269607|NCT01561768|Experimental|Group 5|
3269608|NCT01561781|Experimental|digoxin then digoxin + vandetanib|Digoxin alone followed by digoxin in combination with vandetanib
3269609|NCT01561794|Experimental|Ciprofloxacin|
3269610|NCT01561807|Experimental|787 low dose|VX-787 low dose capsule, taken orally for 5 days
3269611|NCT01561807|Experimental|787 high dose|VX-787 high dose capsule, taken orally for 5 days
3269612|NCT01561807|Experimental|Placebo low dose|Matching placebo low dose capsule, taken orally for 5 days
3269613|NCT01561807|Experimental|Placebo high dose|Matching placebo high dose capsule, taken orally for 5 days
3376887|NCT04954027||Patients with a use-related disorder weaning for a substance|
3376888|NCT04952597|Experimental|Arm A: Ociperlimab + Tislelizumab|Ociperlimab + tislelizumab + cCRT for 4 cycles followed by ociperlimab + tislelizumab
3269614|NCT01561820|Active Comparator|Buddy|Participant will be assigned a buddy that will meet with them at the gym for each of their exercise sessions. This person will serve as a source of support and motivation for them and will also help them remember and stick to the goals set for you. This person will also help them maintain their exercise logs and ensure they are correct. The buddy will not be exercising with them, but will just be there with them while you exercise.
3269615|NCT01561820|Placebo Comparator|Non Buddy|Participants will not be assigned a buddy (and are not allowed to bring someone with them as a buddy). They will be asked to exercise on their own and remember the goals set for them. They will also be responsible for filling out their own exercise logs and ensuring they are correct.
3269616|NCT01561846|Active Comparator|regular cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trialy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
3269617|NCT01561846|Experimental|CLA enriched cheese|
3269618|NCT01561859|Experimental|Cognitive enhancement therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups
3269619|NCT01561859|Active Comparator|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
3269620|NCT01561872||intervention group|"Rooms of the patient of the intervention group will be equipped of cameras"
3269621|NCT01561872||reference group|"Patient in the non-equipped group will have usual care"
3269622|NCT01561885|Active Comparator|Patients on Pathway Care|
3269623|NCT01561885|No Intervention|Patients on Usual Care|
3269624|NCT01561924|Experimental|Ex vivo|
3269625|NCT01561937|Experimental|Pre-warfarin treatment (trial part A)|
3269626|NCT01561937|Experimental|Post-warfarin treatment (trial part B)|
3269627|NCT01561950|Experimental|Factor VII|
3269628|NCT01561950|Placebo Comparator|Placebo|
3269629|NCT01562002|Experimental|Bone Marrow mesenchymal stem cell|Allogenic Bone Marrow mesenchymal stem cell in amniotic membrane transplant
3269630|NCT01562002|Active Comparator|Allogenic limbal stem cell Transplant|Stem Cell with Amniotic Membrane Transplant
3269631|NCT01562015|Experimental|Ganetespib|Ganetespib IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
3269632|NCT01562080|Experimental|Dietary supplement|red yeast, astaxanthin, berberine, policosanol, coenzyme Q10, folic acid
3269633|NCT01562080|Placebo Comparator|microcrystalline cellulose|
3269634|NCT01562093|Experimental|local nasal steroids|
3269635|NCT01562093|Placebo Comparator|placebo|
3269636|NCT01562106|Experimental|ICG Dye|Fluorescence-guided sentinel lymph node detection
3269637|NCT01562145||Patients with rotator cuff tears|Patients with ultrasound verified rotator cuff tears
3269638|NCT01562145||Healthy controls|Age and gender matched controls with ultrasound verified intact rotator cuff
3269639|NCT01562158|Placebo Comparator|Placebo|
3269640|NCT01562158|Experimental|Low dose|
3269641|NCT01562158|Experimental|Medium dose|
3269642|NCT01562158|Experimental|High dose|
3269643|NCT01562171|Experimental|Cooked Lentils|The study group will be asked to consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
3269644|NCT01562171|Active Comparator|Potato-Based Foods|The control group will be asked to consume one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
3269645|NCT01562184|Active Comparator|Active tDCS|Active tDCS
3269646|NCT01562184|Sham Comparator|Sham tDCS|Sham tDCS
3269647|NCT01562197|Experimental|Axitinib|axitinib treatment arm
3269648|NCT01562197|Experimental|Axitinib plus Lomustine|Axitinib plus Lomustine
3269649|NCT01562210|Experimental|Olaparib, radiation +/- Cisplatin|Olaparib and radiotherapy with or without Cisplatin
3269650|NCT01562223|Experimental|Repeatability Assessment|Gadolinium motexafin gadolinium All participants will undergo two consecutive DCE-MRI and DWI scans per same imaging parameters and subsequent comparison for repeatability.
3269651|NCT01562249|Experimental|Experimental group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients; adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
3269652|NCT01562249|Active Comparator|Instruction Group|Inclusion criteria were: Skeletal Class III orthognathic surgery patients, adults (age above 18 years), agreement to perform orthognathic surgery and to undergo all of the necessary procedures determined by the multidisciplinary team (i.e. orthodontic preparation, clinical orofacial myofunctional and electromyographic assessment, surgery, post surgery orthodontic treatment, post surgery clinical orofacial myofunctional and electromyographic assessment and orofacial myofunctional treatment when necessary). Exclusion criteria were: previous orthognathic surgery; previous head and neck surgery; neurologic and/or systemic diseases; facial trauma; syndromes; cognitive impairment; and communication and hearing deficits.
3269653|NCT01562249|No Intervention|Control group|Inclusion criteria for this group were: adults (age above 18 years); absence of stomatognathic system alterations; absence of alterations in the scapular region; complete permanent dentition (absence/extraction of the third molar was accepted); Skeletal and Angle's Class I facial pattern; and absence of malocclusion. Exclusion criteria were: previous orthodontic treatment; and history of previous oral motor intervention.
3269654|NCT01562262||CTR|Control group
3269655|NCT01562262||ASS|Apnea without complaints group
3269656|NCT01562262||ACS|SAOS Group
3269657|NCT01562288||Observational|Previously collected serum and DNA from peripheral blood mononuclear cell samples are analyzed for HER2-specific antibodies and FcγR genotype by ELISA and PCR.
3269658|NCT01562301|Experimental|Anvirzel + Carboplatin + Docetaxel|Anvirzel administered sublingually. A total of five dose cohorts evaluated (6, 12, 24, 36, 48 mg/m2/day; SL divided into 3 doses given every 8 hrs) with 3 patients per cohort. Patients receive the assigned dose (2, 4, 8, 12, or 16 mg/m2) of Anvirzel three times a day throughout each cycle for a total of 4 cycles of chemotherapy. Cycles occur every 21 days. Patients start with an AUC of 6 for Carboplatin and 75mg/m2 for docetaxel, and on subsequent cycles, modifications at the discretion of the treating team. Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
3269659|NCT01562340|Active Comparator|Pomegranate fruit extract|
3269660|NCT01562340|Active Comparator|Pomegranate juice|
3269661|NCT01562353||Case|Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain.
3269662|NCT01562353||Control|Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).
3269663|NCT01562366|Experimental|Group 1|
3269664|NCT01562366|Active Comparator|Group 2|
3269665|NCT01562392|Experimental|berries and vegetables|subjects include specific berries and vegetables in the diet
3269666|NCT01562392|Placebo Comparator|control product|Control product with equivalent amounts of carbohydrates but without vegetables and berries.
3269667|NCT01562405|Experimental|ACE-011 (sotatercept)|ACE-011, Lenalidomide or pomalidomide, Dexamethasone
3269668|NCT01562418|Experimental|Ergonomic consulting|Ergonomic consulting without biofeedback
3269669|NCT01562418|Experimental|Ergonomic consulting with biofeedback|Ergonomic intervention with biofeedback
3269670|NCT01562418|No Intervention|general instructions|general instructions with no intervention
3269671|NCT01562431|Other|Control|Participants complete the Signal-checklist BUT counselors do not obtain the results of the checklist
3269672|NCT01562431|Other|Intervention|Participants complete the Signal-checklist AND the counselor will get the results of the questionnaire
3269673|NCT01562457|Experimental|Low dose|
3269674|NCT01562457|Experimental|Medium dose|
3269675|NCT01562457|Experimental|High dose|
3269676|NCT01562470|Experimental|herbal-based cellulite cream|Trial subjects will apply the treatment cream to one thigh and placebo to the other thigh, by random allocation.
3269677|NCT01562483|Experimental|delta-9-tetrahydrocannabinol (namisol)|
3269678|NCT01562483|Placebo Comparator|Placebo|
3269679|NCT01562496|Experimental|Exercise|Twente patients will perform Aerobic exercise 3 times a week for at least 30 min
3269680|NCT01562496|No Intervention|Control|Fifteen patients will be listed as a control group and will be instructed to continue their previous level of activity throughout the study
3269681|NCT01562509|Active Comparator|Standard implementation strategy|Standard intervention
3269682|NCT01562509|Experimental|Innovative implementation strategy|Implementation tools
3269683|NCT01562522|Experimental|Intervention group|
3269684|NCT01562522|No Intervention|Control group|
3269685|NCT01562535|Experimental|Pronation group|In this group, participants will receive the pronation procedure. The technique is described below
3269686|NCT01562535|Active Comparator|Supination group|Participants in this group will be performed the supination technique. Description below.
3269687|NCT01562561|Experimental|Rep + NPH|
3269688|NCT01562561|Active Comparator|NPH|
3269689|NCT01562574|Experimental|Activated recombinant human factor VII|
3269690|NCT01562574|Placebo Comparator|Placebo|
3269691|NCT01562587|Experimental|Adults|
3269692|NCT01562587|Experimental|Paediatric|
3269693|NCT01562600||Nexium|
3269694|NCT01562626|Experimental|Dose escalation|
3269695|NCT01562639||Nexium|
3269696|NCT01562652|Experimental|Research|
3269697|NCT01562665||All Population|
3269698|NCT01562665||Sample of patients will be invited to complete Quality of Life|
3269699|NCT01562691|Experimental|Nasopore only|Packing using nasopore without airway integrated
3269700|NCT01562691|Active Comparator|nasopore with airway integrated|packing using airway integrated nasopore
3269701|NCT01562691|Active Comparator|airway-integrated Vaseline gauze|Nasal packing using airway-integrated Vaseline gauze
3269702|NCT01562704|Experimental|paracetamol|
3269703|NCT01562704|Placebo Comparator|placebo|
3269704|NCT01562717|Experimental|Ibuprofen|
3376889|NCT04952597|Experimental|Arm B: Tislelizumab|Tislelizumab + cCRT for 4 cycles followed by tislelizumab alone
3376890|NCT04952597|Experimental|Arm C: Concurrent Chemoradiotherapy (cCRT)|cCRT for 4 cycles
3269705|NCT01562717|Placebo Comparator|Placebo|
3269706|NCT01562730||No previous cardiovascular disease|Individuals without any history of cardiovascular disease
3269707|NCT01562730||Previous cardiovascular disease|Individuals with history of cardiovascular disease
3269708|NCT01562769||Standard precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
3269709|NCT01562769||contact precautions|"One selected part of the unit keep the usual procedure applied in our institution with contact precautions prescriptions when colonized patient is admitted with SA and/or ESBL bacteria.~Second selected part of the unit applies only standard precautions (even for patients colonized with multiple drug-resistant organisms).~After 8 months precaution procedures will be exchanged between the two sectors (cross over design)."
3269710|NCT01562795|Experimental|group 1|
3269711|NCT01562795|Experimental|group 2|
3269712|NCT01562795|Experimental|group 3|
3269713|NCT01562795|Other|group 4|
3269714|NCT01562821|Experimental|Low dose|
3269715|NCT01562821|Experimental|High dose|
3269716|NCT01562821|Placebo Comparator|Placebo|
3376892|NCT04950192||Prospective Observational|Prospective observational subjects undergoing planned cardiac procedures utilizing image guidance
3376895|NCT04948658||Patient 13-21|Adolescents (13 to age 21) who undergo puberty and menarche with subsequent premature ovarian insufficiency
3376896|NCT04948658||patient 4-12|Girls with Turner Syndrome and galactosemia age 4 to 12 who are at increased risk of early ovarian insufficiency
3376897|NCT04946851||non-treatment-seeking individuals|Participants across the spectrum of drinking (from non-drinkers to heavy drinkers) who are not interested in treatment for alcohol use disorder
3269717|NCT01562834|Experimental|Somatropin|
3376898|NCT04946851||treatment-seeking individuals with alcohol use disorder|Volunteers with an AUD diagnosis who are seeking treatment for the condition
3376899|NCT04946526|Active Comparator|Broccoli seed extract|A single dose dietary supplement made up of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR) and 100 mg vitamin C (as ascorbic acid).
3376900|NCT04946526|Experimental|Broccoli seed extract with mustard seed powder|A single dose dietary supplement made up of a mixture of 385 mg broccoli seed extract delivering 50 mg GR (115 umol GR), 145 mg mustard seed powder containing enough active myrosinase (enzyme) to fully hydrolyze the GR in the capsule to SF post-ingestion (~30 units myrosinase activity) and 100 mg vitamin C (as ascorbic acid).
3269718|NCT01562834|Placebo Comparator|Placebo|
3269719|NCT01562847||Nilotinib|
3269720|NCT01562860|Active Comparator|Carpal Tunnel and Pronator Teres Release|Patients enrolled in this arm of the study will have both surgical procedures performed at the same time
3269721|NCT01562860|Active Comparator|Carpal Tunnel Release only|Patients enrolled in this arm will have only Carpal Tunnel Release performed. In they still have symptoms of median nerve neuropathy, they will be scheduled for an additional procedure to release the pronator Teres in a separate surgery.
3269722|NCT01562899|Experimental|Dose escalation|Dose finding group chosen in order to establish a safe and tolerated dose of binimetinib in combination with ganitumab in patients with selected advanced solid tumors.
3269723|NCT01562899|Experimental|KRAS mutated colorectal adenocarcinoma|"Patients with KRAS mutant colorectal cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3269724|NCT01562899|Experimental|Metastatic pancreatic adenocarcinoma|"Patients with metastatic pancreatic cancer.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3269725|NCT01562899|Experimental|BRAF mutated melanoma|"Patients with mutant BRAF V600 melanoma.~The starting dose (30 mg bid) of binimetinib chosen for this study was a fraction of the MTD (60 mg bid) and the RP2D (45 mg bid) determined for single agent use. The starting dose for ganitumab was 12 mg/kg q2w which had been shown to be a well-tolerated dose in combination with other anti-cancer agents."
3269726|NCT01562912|Active Comparator|Control|Radiofrequency Ablation Procedure. Subjects who are undergoing AF ablation with traditional ablation technology at the same centers by the same operators. Control patients will be enrolled in a 1:2 ratio compared to the PVAC cohort. Intervention is the use of Radiofrequency Ablation.
3269727|NCT01562912|Experimental|PVAC Ablation Procedure|Intervention is the use of PVAC technology. The PVAC is deployed in the left atrium over a 0.032-inch guidewire inside the PV and advanced until it is wedged within the antrum proximal to the ostium. Energy is delivered through selected electrode pairs with local potentials as well as adjacent electrode pairs, allowing bipolar current to flow to the target electrode(s) from both sides. Each application lasts for 60 seconds. When the temperature does not rise above 50°C within 15 seconds, the application should be discontinued to improve position. The PVAC may be manipulated within the antrum to ablate in a pattern of overlapping circular lesions.
3269728|NCT01562925|Active Comparator|Red Wine|Patients assigned to red wine group will receive standard care plus two doses of red wine: the evening before contrast-medium use and the morning of contrast-medium exposure
3269729|NCT01562925|Active Comparator|White wine|
3269730|NCT01562925|Active Comparator|Beer|
3269731|NCT01562925|No Intervention|Control|Patients assigned to control group will receive standard care. Patients receive ordinary still water without alcohol the evening before(7.8 ml per kg bodyweight) and 60-120 minutes before contrast exposure (at least 3.9 ml per kg bodyweight)
3269732|NCT01562938|Placebo Comparator|Placebo|Placebo
3269733|NCT01562938|Active Comparator|MEDI-557 low-dose|
3269734|NCT01562938|Active Comparator|MEDI-557 high-dose|
3269735|NCT01562951|Placebo Comparator|PLACEBO|Treatment with placebo
3269736|NCT01562951|Active Comparator|ADALIMUMAB|Treatment with Adalimumab
3269737|NCT01562964|Experimental|Hypnotherapy|Hypnotherapy will be conducted at the Royal Brompton Hospital by a qualified practician (DF). Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
3269738|NCT01562964|Active Comparator|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min. Patients will be encouraged to talk about their physical symptoms and any emotional issues, and to discuss how these might be coped with in a better way.
3269739|NCT01562977|Other|no arms|no arms were present for the study, only 2 different cohorts:MCL and LDCGB
3269740|NCT01562990|Experimental|R-CMC544 and R-GEMOX|Treatment with R-CMC544 and R-GEMOX
3269741|NCT01563016|Experimental|Glucose & Depleting|participants will perform in a depleting task and receive a glucose drink
3269742|NCT01563016|Placebo Comparator|Glucose & non-depleting|participants will perform in a non-depleting task and receive a glucose drink
3269743|NCT01563016|No Intervention|Placebo & depleting|participants will perform in a depleting task and receive a placebo drink
3269744|NCT01563016|No Intervention|Placebo & non depleting|participants will perform in a non depleting task and receive a placebo drink
3269745|NCT01563042|Experimental|Cohort 1 GSK2434735|Cohort 1: Single intravenous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
3269746|NCT01563042|Experimental|Cohort 2 GSK2434735|Cohort 2: Single subcutaneous administration of GSK2434735 and Pharmacokinetic (PK) and Immunogenicity assessments up to 42 days post dose.
3269747|NCT01563068|Experimental|Calcipotriene Foam|Calcipotriene foam 0.005% administered under maximal-use conditions to adolescent patients with plaque psoriasis
3269748|NCT01563107|Experimental|High Salt Diet|POTS and healthy controls will be randomly assigned the order of dietary sodium levels. All procedures are performed at both levels.
3269749|NCT01563107|Experimental|Low Salt Diet|
3269750|NCT01563120|Active Comparator|metformin|metformin up to 2550mg per day
3269751|NCT01563120|Active Comparator|glybenclamide|glybenclamide up to 20mg per day.
3269752|NCT01563133|Other|Lymph nodes, pancreatic masses & cysts|
3269753|NCT01563146||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2006 and May the 31st 2007.
3269754|NCT01563159||Group A|All children ≤ 5 years old with a rotavirus detection test (inpatient and ambulatory tests) performed during the period of June the 1st 2010 and May the 31st 2011.
3269755|NCT01563211||Patients receiving endocrine treatment for breast cancer|Patients who are treated with tamoxifen, anastrozole or letrozole before or after surgery for breast cancer.
3269756|NCT01563211||Patients receiving chemotherapy for breast cancer|Patients receiving FEC (5-FU, cyclophosphamide, epiribicin) or FEC-D (FEC for 3 cycles, followed by 3 cycles of docetaxel).
3269757|NCT01563224|Experimental|single group, crossover, 3 interventions|
3269758|NCT01563250|No Intervention|Core Laboratory|Patients receiving serial routinely available cardiac biomarker testing in a core laboratory setting using Troponin T. (Roche Centaur)
3269759|NCT01563250|Active Comparator|Point of Care|Patients will receive the Point of Care testing intervention using serial cardiac biomarker testing at the bedside including myoglobin, Troponin I and CK-MB. (Triage Cardiac Panel, Alere)
3269760|NCT01563263|Active Comparator|IC43 100 mcg|IC43 100 mcg intramuscular injection, IC43 is a recombinant Pseudomonas aeruginosa fusion protein
3269761|NCT01563263|Placebo Comparator|Placebo|phosphate buffered saline solution containing 0,9 % NaCL
3269762|NCT01563276||Progressive Supranuclear Palsy|Patients with a diagnosis of probable or possible PSP as defined by the National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) diagnostic criteria.
3269763|NCT01563276||Parkinson's Disease|"Idiopathic PD according to the UK Parkinsons Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)"
3269764|NCT01563276||Healthy Control|
3269765|NCT01563289|Placebo Comparator|placebo|
3269766|NCT01563289|Experimental|Ibuprofen|
3269767|NCT01563302|Experimental|Group 1|IONIS-STAT3Rx
3269768|NCT01563315||Adults with CAP admitted to hospital|All adult patients with CAP admitted to Vestre Viken HF-Buskerud Hospital (VVHF-BH), a 400-bed community general hospital, between January 2008 og January 2011 were evaluated for inclusion in the study.
3269769|NCT01563328|Experimental|Cohort 1|DTG x 5 days followed by BCV + DTG x 10 days
3269770|NCT01563328|Experimental|Cohort 2|DTG x 5 days followed by TVR + DTG x 10 days
3269771|NCT01563341|Experimental|Deep Brain Stimulation|Parkinson's disease patients who would otherwise be undergoing subthalamic nucleus (STN) deep brain stimulation (DBS) will have dual hemispheric stimulation of the STN and globus pallidus interna (GPi).
3269772|NCT01563367|Active Comparator|Iron isomaltoside 1000 (Monofer®)|Iron isomaltoside 1000 (Monofer®) - Intravenous Infusion
3269773|NCT01563367|Placebo Comparator|0,9% sodium saline|Placebo (0.9% sodium saline) - Intravenous infusion
3269774|NCT01563380|Experimental|PRP arm|Platelet-rich plasma was applied over the wound including the capsule, medial and lateral recesses.
3269775|NCT01563380|No Intervention|Control Arm|
3269776|NCT01563393|Other|STAMP using|Relevant to the third part of the study. 30 Children between 1 and 17 years of age from internal medicine department will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale.
3269777|NCT01563393|Other|No STAMP using|Relevant to the third part of the study. Other 30 children that are not screened by dietitian and either not by STAMP
3269778|NCT01563419|No Intervention|Control|dialing up the selected dose of insulin pens without an indicator magnifying window
3269779|NCT01563419|Experimental|Magnifier|dialing up the selected dose of insulin pens clipped on an indicator magnifying window
3269780|NCT01563432|Experimental|febuxostat (TR)|
3269781|NCT01563432|Experimental|febuxostat (RT)|
3269782|NCT01563445|Experimental|activated recombinant human factor VII|
3269783|NCT01563445|Placebo Comparator|Placebo|
3269784|NCT01563458|Experimental|High dose|
3269785|NCT01563458|Experimental|Low dose|
3269786|NCT01563458|Placebo Comparator|Placebo|
3269787|NCT01563471|Experimental|Treatment sequence 1|
3269788|NCT01563471|Experimental|Treatment sequence 2|
3269789|NCT01563471|Experimental|Treatment sequence 3|
3269790|NCT01563471|Placebo Comparator|Treatment sequence 4|
3269791|NCT01563484||low-osmolar contrast media|Patients undergo TACE of low-osmolar contrast media on day 1.
3269792|NCT01563484||iso-osmolar contrast media|Patients undergo TACE of iso-osmolar contrast media on day 1.
3269793|NCT01563497|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
3269794|NCT01563497|Experimental|PF-05089771 TS formulation fasted|Tablets TS formulation- fasted
3269795|NCT01563497|Experimental|PF-05089771 TS formulation fed|Tablets TS formulation- fed
3269796|NCT01563510|Experimental|Laparoscopic operation|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
3269797|NCT01563510|Active Comparator|Open operation|The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
3269798|NCT01563523|Experimental|Activated recombinant human factor VII|
3269799|NCT01563523|Placebo Comparator|Placebo|
3269800|NCT01563562|Experimental|Bardoxolone Methyl 20 mg|
3269801|NCT01563575|Experimental|Intervention Group|fast-track implementation process
3269802|NCT01563575|No Intervention|Control Group|Continue usual routine
3269803|NCT01563588|Experimental|dietary and physical training|12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
3269804|NCT01563588|No Intervention|control|dietary counseling by a dietetician in the anticancer hospital
3269805|NCT01563601|Experimental|Obatoclax mesylate, Carboplatin and Etoposide (CEO)|
3269806|NCT01563601|Active Comparator|Carboplatin and Etoposide (CE)|
3269807|NCT01563614|Experimental|Treatment|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
3269808|NCT01563627|Experimental|Antiepileptic Drug resistant|Adult patients suffering from epilepsy drug-resistant and potentially surgical candidates
3269809|NCT01563627|Experimental|Antiepileptic drug Controlled group|epilepsy well controlled by antiepileptic drugs
3269810|NCT01563640|Placebo Comparator|normal school uniforms|washing only
3269811|NCT01563640|Experimental|insecticide-treated school uniforms|washing and insecticide treatment
3269812|NCT01563653|Experimental|Patients|Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.
3269813|NCT01563692||Paediatric health care workers|NHS members of staff who regularly care for children admitted with RSV infections, and who therefore have a higher rate of exposure.
3269814|NCT01563692||Non-paediatric health care workers|This is a comparator group made up of healthy adults who do not work in an occupation or have other risk factors for higher exposure to RSV.
3269815|NCT01563718|Experimental|PRE-release XR-NTX|Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
3269816|NCT01563718|Active Comparator|POST-release XR-NTX|Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
3269817|NCT01563731|Other|SBP < 145-135 mmHg and LDL-C 2.8 - 1.8 mmol/l|Highest SBP target. Higher LDL-C target. Control arm
3269818|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C 2.8 - 1.8 mmol/l|"Intermediate SBP target. Higher LDL-C target~."
3269819|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C 2.8 - 1.8 mmol/l|Lowest SBP target. Higher LDL-C target
3269820|NCT01563731|Active Comparator|SBP < 145-135 mmHg and LDL-C < 1.8 mmol/l|Highest SBP target. Lower LDL-C target.
3269821|NCT01563731|Active Comparator|SBP < 135-125 mmHg and LDL-C < 1.8 mmol/l|Intermediate SBP target. Lower LDL-C target.
3269822|NCT01563731|Active Comparator|SBP < 125 mmHg and LDL-C < 1.8 mmol/l|Lowest SBP target. Lower LDL-C target.
3269823|NCT01563744|Experimental|EGD-assisted colonoscopy prep|2 liters of polyethylene glycol instilled through the channel of the endoscope during EGD when colonoscopy expected the following day. Patients follow a clear liquid diet, then ingest an addition 1 liter polyethylene glycol 4 hours prior to colonoscopy. Patients are also given a tap water enema 1 hour prior to colonoscopy.
3269824|NCT01563744|Active Comparator|Standard Colonoscopy Prep|Split-dose polyethylene glycol (2 liters pm prior to colonoscopy, 1 liter 4 hours prior to colonoscopy)), clear liquid diet, metoclopramide 10 mg IV 30 minutes prior to procedure, tap water enema 1 hr prior to colonoscopy
3269825|NCT01563757||Fontan Patients with PLE and PB|Fontan Patients with Protein Losing Enteropathy and Plastic Bronchitis
3269826|NCT01563757||Fontan Patients w/out PLE & PB|Protein Losing Enteropathy and Plastic Bronchitis
3269827|NCT01563757||Glenn Physiology Patients|
3269828|NCT01563757||2 ventricle heart with ASD|2 ventricle heart with Atrial Septal Defect
3269829|NCT01563770|Experimental|Salvia miltiorrhiza extract (Danshen)|p.o. Salvia miltiorrhiza extract, 1.5 g twice daily for four consecutive weeks
3269830|NCT01563770|Placebo Comparator|placebo|p.o. placebo, twice daily
3269833|NCT01563796||TCC positive|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to have a bladder tumor confirmed by histopathology
3269834|NCT01563796||TCC negative|subjects with hematuria, dysuria or other irritative voiding symptoms, without evidence of other causative factors such as infections or stones that are found to NOT have a bladder tumor by histopathology or clinical observation.
3269835|NCT01563809|Active Comparator|Low androgens FSH+LH|Patients with androgens below threshold receiving FSH+LH for ovarian stimulation
3269836|NCT01563809|Active Comparator|High androgens FSH+LH|Patients with androgens above threshold receiving FSH+LH for ovarian stimulation
3269837|NCT01563809|No Intervention|High androgens FSH alone|
3269838|NCT01563809|No Intervention|Low androgens, FSH alone|
3269839|NCT01563822|Experimental|follicular fluid group|Follicular fluid group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is done.
3269840|NCT01563822|No Intervention|control group|Control group is the group in which flushing of the uterine cavity with follicular fluid after ovum pick-up is not done.
3269841|NCT01563835|Active Comparator|Epidural (PCEA)|bupivacaine, fentanyl
3269842|NCT01563835|Active Comparator|IV PCA|Intravenous fentanyl patient controlled analgesia
3269843|NCT01563848|Active Comparator|Group 1 (RFA CTI+Reveal)|assessing the incidence of atrial fibrillation in patients with atrial flutter
3269844|NCT01563848|Active Comparator|Group 2 (RFA CTI+Cryo PVI+Reveal)|efficacy of cryoablation in patients with atrial flutter
3269845|NCT01563887|Experimental|DD.com|Participants in this arm will receive the DiabetesDriving.com internet intervention intended to help reduce their risk of being in a future collision.
3269846|NCT01563887|Experimental|DD.com + MI|Participants will receive the DiabetesDriving Internet intervention and two 60 minute Motivational Interview (MI) sessions over the telephone. The MI sessions will take place once before and once following completion of the Internet intervention. This interview will focus on making explicit individual's ambivalence around changing behavior.
3269847|NCT01563900|Sham Comparator|sham-CPAP group|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp).
3269848|NCT01563900|Active Comparator|Auto-titration CPAP|This group will received an auto-titration CPAP, which will have a pressure range of 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
3269849|NCT01563926|Experimental|Somatropin|
3269850|NCT01563939|Active Comparator|Continuous infusion|Remifentanil administered by continuous IV infusion, with stepwise increase in infusion rates and placebo demand bolus of normal saline.
3269851|NCT01563939|Active Comparator|Demand Bolus|Demand bolus of remifentanil with stepwise increase in bolus dose and placebo continuous infusion of normal saline.
3269852|NCT01563952|Active Comparator|Non-IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3269853|NCT01563952|Experimental|IVUS guided endeavor-R group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3269854|NCT01563952|Active Comparator|Non-IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3269855|NCT01563952|Experimental|IVUS guided Nobori group|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
3269856|NCT01563965|Active Comparator|Conventional preoperative fast|Patients underwent surgery after 8h fast
3269857|NCT01563965|Experimental|Carbohydrate plus protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil).All the patients fasted for solids at least 8 hours from the operation
3269858|NCT01563991|Active Comparator|Standard fluid volume|Subject receives normal fluid volume during peri-operative period
3269859|NCT01563991|Experimental|Reduced Fluid Volume|Subject receives a reduced fluid volume during the peri-operative period
3269860|NCT01564004|Experimental|Clinical hypnosis|20 minutes tape recorded clinical hypnosis intervention
3269861|NCT01564004|Active Comparator|Neuro-linguistic programming|20 minutes tape recording of nouro-linguistic programming intervention
3269862|NCT01564017|Experimental|Allergovac depot. Group 1|Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3269863|NCT01564017|Experimental|Allergovac depot. Group 2|Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3269864|NCT01564017|Experimental|Allergovac depot. Group 3|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3269865|NCT01564017|Experimental|Allergovac depot. Group 4|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3269866|NCT01564017|Experimental|Allergovac depot. Group 5|Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
3269867|NCT01564017|Placebo Comparator|Allergovac depot placebo. Group 6|The same scheme of treatment as the active groups
3269868|NCT01564030|Other|Empty stomach|Patients have fasted for 8 hours.
3269869|NCT01564030|Other|Fluid|Patients have fasted for 8 hours, followed by the consumption of 250mL of apple juice.
3269870|NCT01564030|Other|Solid|Patients have fasted for 8 hours, followed by the consumption of their breakfast.
3269871|NCT01564043|Experimental|website and pedometer|
3269872|NCT01564056|Other|Arm A: ENDOCRINE TREATMENT|HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).
3269873|NCT01564056|Experimental|Arm B: CHEMOTHERAPY + ENDOCRINE TREATMENT|"HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II).~CHEMOTHERAPY regimen will be chosen amongst the following ones:~TC (docetaxel + cyclophosphamide)~AC (doxorubicin + cyclophosphamide)~MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)"
3269874|NCT01564069||IT opioids|Patients with IT pumps receiving IT opioids
3269875|NCT01564069||Systemic opioids|Patients taking oral or transdermal opioids for chronic pain
3269876|NCT01564069||Non-opioid management|Patients managing chronic pain without taking opioids
3269877|NCT01564082|Experimental|ETT first|Patients will have the endotracheal tube (ETT) introduced into the pharynx prior to GlideScope insertion, and then advanced under GlideScope guidance into the trachea.
3269878|NCT01564082|No Intervention|Control Group|Patients will have the GlideScope introduced into the pharynx. The endotracheal tube (ETT) will then be advanced under direct vision into the mouth/pharynx. The ETT will then be advanced into the trachea under GlideScope guidance.
3269879|NCT01564095|Experimental|Tacrolimus + HTK|Ex vivo Tacrolimus Rinse (20 ng/ml solved in 1000 ml HTK) of marginal liver grafts prior to implantation
3269880|NCT01564095|Placebo Comparator|HTK|Ex vivo Rinse (1000 ml HTK) of marginal liver grafts prior to implantation
3269881|NCT01564108|Experimental|Ranibizumab|Series of intravitreal injections of Ranibizumab
3269882|NCT01564134|Experimental|HepB 5ug|receive the vaccine with 5ug HBsAg
3269883|NCT01564134|Experimental|HepB 10ug|receive the vaccine with 10ug HBsAg
3269884|NCT01564134|Experimental|HepB 20ug|receive the vaccine with 20ug HBsAg
3269885|NCT01564134|Experimental|HepB 60ug|receive the vaccine with 60ug HBsAg
3269886|NCT01564147|Other|Immediate Education therapeutic|Access to the course of immediate therapeutic education
3269887|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
3269888|NCT01564160|Experimental|Arm 1: PCSO-524|PCSO-524
3269889|NCT01564160|Active Comparator|Arm 2: Fish Oil|Fish Oil
3269890|NCT01564173||VT Ablation|Patients undergoing epicardial mapping and ablation procedure for a ventricular tachycardia
3269891|NCT01564186||MulitPoint Pacing|
3269892|NCT01564186||BiV Conventional|
3269893|NCT01564199|Experimental|Treatment A|Salmeterol/fluticasone propionate with concomitant charcoal
3269894|NCT01564199|Experimental|Treatment B|Salmeterol/fluticasone propionate without concomitant charcoal
3269895|NCT01564212|Active Comparator|standard airflow and forced air warming|Subjects will lie on operating room bed with standard airflow and forced air warming.
3269896|NCT01564212|Active Comparator|laminar airflow with surgical drapes|Subjects will lie on operating room bed with laminar airflow device on and surgical drapes surrounding bed.
3269897|NCT01564212|Active Comparator|laminar aiflow with forced air warming|Subjects will lie on operating room bed with laminar airflow on and warming forced air.
3269898|NCT01564212|Active Comparator|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow and surgical drapes surrounding bed.
3269899|NCT01564225|Experimental|EDI200|
3269900|NCT01564238|Experimental|High calcium diets (1300 mg or higher)|
3269901|NCT01564238|Experimental|Low calcium diet (800 mg/d)|
3269902|NCT01564251|Experimental|Stage 1 Arm 1: GDC-0575 Monotherapy|Participants will receive escalating doses of GDC-0575, administered orally, for 3 consecutive days, starting on Days 1, 8, and 15 of each 21-day cycle.
3269903|NCT01564251|Experimental|Stage 1 Arm 2a: GDC-0575 + Gemcitabine (750 or 1000 mg/m^2)|Participants will receive gemcitabine 750 milligrams per meter square (mg/m^2) or 1000 mg/m^2, intravenously, on Days 1 and 8 followed by escalating doses of GDC-0575 orally, on Days 2 and 9 of each 21-day cycle.
3269904|NCT01564251|Experimental|Stage 1 Arm 2b: GDC-0575 plus Gemcitabine (500 mg/m^2)|Participants will receive gemcitabine 500 mg/m^2, intravenously, once weekly for approximately 2 consecutive weeks of any 3-week period and escalating doses of GDC-0575 orally approximately 24-hours after each gemcitabine dose.
3269905|NCT01564251|Experimental|Stage 2: GDC-0575 plus Gemcitabine|Participants will receive GDC-0575 in combination with gemcitabine intravenously (1000 mg/m^2 and/or 500 mg/m^2), at or below the MTDs for the combination treatments that are determined during Stage 1.
3269906|NCT01564264|Experimental|Sentinel Node Biopsy|Each participant will have both measurements, the new diagnostic test (sentinel node biopsy) and the gold standard (complete lymphadenectomy)
3269907|NCT01564290|Placebo Comparator|probiotic|Probiotic product with Sacharomices Boulardii
3269908|NCT01564290|Active Comparator|probiotic yogurt|Yogurt with Lactobacilus Rhamnonsus strain spp
3269909|NCT01564303|No Intervention|2. Acetylcysteine group (NAC+S) , aside with the saline, will|2. Acetylcysteine group (NAC+S) , aside with the saline, patients will be given orally Acetylcysteine at a dose of 600 mg twice daily, on the day before and on the day of administration of the contrast agent.
3269910|NCT01564303|Experimental|CAR+S , aside with the saline, carnitne will be adminstrated|Carnitine group (Car+S), aside with the saline, patients will be administrated with 20 mg/kg carnitine over 10 minutes 2 hours prior to the administration of the contrast agent and 8 hours after CT.
3269911|NCT01564303|Experimental|Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with|4. Phosphodiesterase type 5 inhibitor group (PDE5+S), aside with the saline patients will be given orally 20 mg tablets of PDE5 Tadalafil once daily 2 hours prior to the administration of the contrast agent and in the subsequent day.
3269912|NCT01564303|No Intervention|Control group (S) will be treated without any extra agents|Control group ( S ) , which will be treated without any extra agents, just Saline (0.9 %) will be given I.V. at a rate of 1 ml per kilogram of body weight per hour for 12 hours before and 12 hours after administration of the contrast agent.
3269913|NCT01564316||neurodegeneration patients|•neurodegeneration patients and control group include dementia patients visited the part of neurology
3269914|NCT01564329|Experimental|endostar2|CT Perfusion Imaging(CTPI) at D0, D21 of the first cycle、D6, D14 of the second cycle, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
3269915|NCT01564329|Experimental|endostar1|CT Perfusion Imaging(CTPI) at D0，D6, D14, D21 of the first period, measure blood flow ( BF ), blood volume ( BV ), mean transit time ( MTT ), start time ( TTS ), time to peak ( TTP ), Patlak blood volume ( pBV ), vascular permeability etc. before/after tumor tissue treatment.
3269916|NCT01564342|Other|wounds irrigated with sterile normal saline|Patients in this arm had their wounds irrigated with sterile normal saline
3269917|NCT01564342|Other|wound irrigation with tap water|Patients in the arm had their wounds irrigated with tap water
3269918|NCT01564355|Experimental|Systemic Steroid Group|Will receive post-operative oral steroids for 10 days as per usual protocol.
3269919|NCT01564355|Placebo Comparator|Placebo|Will receive placebo pills for 10 days post-operatively
3269920|NCT01564368|Experimental|Diffusion Weighted-MRI|Participants on all arms of the I-SPY II trial will undergo diffusion-weighted magnetic resonance imaging as described in the ACRIN 6698 protocol. The experimental component/intervention is whether DW-MRI can predict therapeutic response in neoadjuvant treatment for breast cancer.
3269921|NCT01564381|Experimental|Resveratrol|The capsules will contain 90mg of resveratrol.
3269922|NCT01564381|Experimental|ResA|ResA is a product produced by using patented technology that physically binds resveratrol to arginine, creating a novel conjugate. The capsules will contain 90mg of resveratrol.
3269923|NCT01564381|Placebo Comparator|Placebo|The placebo will be cellulose.
3269924|NCT01564420||Intrathecal morphine|Patients were randomized for general anesthesia, and allocated in the control group and morphine intrathecal group.
3269925|NCT01564420||Control group|
3269926|NCT01564433|Experimental|Gait trainer treatment|
3269927|NCT01564433|Active Comparator|Conventional group|
3269928|NCT01564446|Experimental|secure message regarding post-discharge medication|Participants will be sent a secure message to confirm compliance with post-discharge medication.
3269929|NCT01564472||PSG Scoring|Retrospective, de-identified PSG studies will be collected and scored by registered polysomnogrpahy technicians. The manually scored studies will be compared to the automatic scoring performed by the new Sleepware Software G3 Autoscoring Algorithm.
3269930|NCT01564498|Placebo Comparator|White potato|Participants will consume 300-500 g of cooked white potatoes per day
3269931|NCT01564498|Experimental|Purple Potato|Participants will consume 300-500 g of cooked purple potato per day
3269932|NCT01564498|Placebo Comparator|Orange carrots|Participants will consume 200-300 g typical varieties of orange carrots during the intervention
3269933|NCT01564498|Experimental|Purple Carrots|Participants will consume 200-300 g raw purple carrots instead of orange carrots in the control arm
3269934|NCT01564511|Experimental|Gait trainer treatment|Roboti gait training by mean of Gangtrainer I
3269935|NCT01564511|Sham Comparator|Conventional group|Convetional physical gait training
3269936|NCT01564550||type 2 diabetes|
3269937|NCT01564550||healthy subjects|
3269938|NCT01564563|Placebo Comparator|Placebo|
3269939|NCT01564563|Experimental|Low dose|
3269940|NCT01564563|Experimental|High dose|
3269941|NCT01564576|No Intervention|Conventional neuromuscular blockade|The dose of rocuronium (medication used for NMB during anesthesia)will be adjusted to maintain a depth of NMB of T1 of 10-20% as assessed by a nerve stimulator. At the end of surgery patients will receive neostigmine 2.5 mg and atropine 1 mg to reverse the effect of rocuronium. Extubation will be performed when train-of-four ratio ≥ 0.9.
3269942|NCT01564576|Experimental|Profound neuromuscular blockade|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
3269943|NCT01564602|Experimental|single port laparoscopic surgery|2-channel or multiple channel single port laparoscopic surgery in gynecologic disorders
3269944|NCT01564615|Experimental|AgION catheter|Patients in this arm received an AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
3269945|NCT01564615|Active Comparator|Non-impregnated polyurethane catheter|Patients in this arm received a non-impregnated polyurethane umbilical catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
3269946|NCT01564641||iDuo G2|iDuo G2 to be implanted in the patient.
3269947|NCT01564667|Experimental|Attention Bias Modification Treatment|Attention bias modification training using a computerized spatial attention task (dot-probe) designed to alter threat-bias attention patterns away from threat.
3269948|NCT01564667|Active Comparator|Attentional Control Training|Attention control training using a computerized spatial attention taks (dot-probe) counter balances training toward and away from threat.
3269949|NCT01564680|Experimental|Lornoxicam|Lornoxicam 16 mg will be given at skin closure and 8 mg will be given 12 hours postoperatively
3269950|NCT01564680|Placebo Comparator|Control|Patients will receive normal saline at skin closure, at 6, 12, 18 hours postoperatively.
3269951|NCT01564680|Experimental|Paracetamol|1 gm of paracetamol will be given at skin closure, 6, 12, 18 hours postoperatively
3269952|NCT01564719|Experimental|Immediate-intervention arm|This is a holistic health intervention. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
3269953|NCT01564719|Experimental|One-year waitlist arm|This holistic health intervention arm for Cohort 2 was the same as Cohort 1's, only the intervention delivery was smoother (e.g., Naturally Slim offered at more start times). Cohort 2 waited for one year before beginning the intervention.
3269954|NCT01564719|Experimental|Two-year waitlist arm|This holistic health intervention arm for Cohort 3 was the same as Cohort 2's, only Cohort 3 waited for two years and received the stress management program meQuilibrium rather than Williams LifeSkills.
3269955|NCT01564745|Other|Cough Determinants|
3269956|NCT01564771||Group one|Adults ≥18 years of age with chest X-ray confirmed CAP
3269957|NCT01564797|Active Comparator|Education Intervention|A series of 5 home-based lay health educator-led education sessions (Home Health Parties (HHP)), to educate a Hispanic population about diabetes, management of diabetes, and diet and exercise
3269958|NCT01564797|No Intervention|Control Arm|A delayed intervention where the intervention was delivered after the hA1c level was measured for the second time (3 months after the baseline measurement)
3269959|NCT01564810|Experimental|Arm A|patients received cetuximab in combination with chemotherapy
3269960|NCT01564810|Active Comparator|Arm B|Patients received chemotherapy (mFOLFOX6 or FOLFIRI) alone. mFOLFOX6 (day 1, oxaliplatin 85 mg/m², folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then 2400 mg/m² over 46 h continuous infusion) FOLFIRI (day 1, irinotecan 180mg/m2, folinic acid 400 mg/m², and fluorouracil 400 mg/m² intravenous bolus, then continuous infusion for 46 hours of 2400 mg/m2).
3269961|NCT01564823|Experimental|Metronidazole + Azathioprine.|Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.
3269962|NCT01564823|Active Comparator|Metronidazole + Adalimumab|Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.
3269963|NCT01564836|Experimental|Imatinib treatment discontinuing|
3269964|NCT01564849||chronic rhinitis,|
3269965|NCT01564849||chronic sinusitis|
3269966|NCT01564849||nasal polyps|
3269967|NCT01564849||control rhinitis|
3269968|NCT01564849||control sinusitis|
3269969|NCT01564849||control polyps|
3269970|NCT01564875|Experimental|Simvast CR|"Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.~Placebo with the same appearance and formulation as that of Zocor Tab, 1 tablet once daily to be administered between 6 and 9 p.m."
3269971|NCT01564875|Active Comparator|Zocor|"Placebo with the same appearance and formulation as that of Simvast CR Tab, 1 tablet once daily to be administered between 6 and 9 a.m.~Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m."
3269972|NCT01564888|Placebo Comparator|Patent hemostasis|Patent hemostasis is the technique for radial artery hemostasis after transradial catheterization, with proactive attempt to maintain radial artery hemostasis and radial artery patency.
3269973|NCT01564888|Active Comparator|Ulnar artery compression|Ulnar artery compression will involve radial artery hemostasis using patent hemostasis technique and compression of ulnar artery to the point of occluding flow, in an attempt to augment radial artery flow.
3269974|NCT01564901||Cohort|
3269975|NCT01564927|Experimental|Electroacupuncture to right LI4 and LI11|
3269976|NCT01564927|Sham Comparator|Electroacupuncture to knee caps|Electroacupuncture to knee caps
3269977|NCT01564927|Placebo Comparator|Sham electroacupuncture to LI4 & LI11|
3269978|NCT01564966||Living kidney donors|Those who donate kidneys
3269979|NCT01564979|Experimental|preseptal|
3269980|NCT01564979|Experimental|pretarsal|
3269981|NCT01564992||Parkinson disease|Identification of genes
3269982|NCT01565005||Microcephaly|Microcephaly Intellectual abilities Cranial MRI
3269983|NCT01565005||FANCONI ANEMIA|
3269984|NCT01565018|Experimental|Treatment A - Treatment B|"Treatment A: Test; drug product PR 2.2.1~Treatment B: Reference; drug product PR 2.1.4~Sequence of two single applications of Rotigotine transdermal patches (PR 2.2.1 first) for 24 hours separated by a Washout Period of 5 days."
3269985|NCT01565018|Experimental|Treatment B - Treatment A|"Treatment B: Reference; drug product PR 2.1.4~Treatment A: Test; drug product PR 2.2.1~Sequence of two single applications of Rotigotine transdermal patches (PR 2.1.4 first) for 24 hours separated by a Washout Period of 5 days."
3269986|NCT01565031||controlled asthmatics, down-titration|Adults (age between 18 and 80) with asthma under control (see definitions) during the last 3 months, treated with a combination of ICS and long-acting beta-agonist (LABA).
3269987|NCT01565044|Experimental|" AUTO  Group"|
3269988|NCT01565044|Sham Comparator|" CONTROL  Group"|
3269989|NCT01565057|Experimental|sedimenting meal|To assess whether rates of gastric emptying of a specifically formulated emulsion drink are significantly different from a control drink and that this in turn leads to differences in satiation (cessation in the desire to eat) and satiety (desire to limit further food intake) as measured by visual analogue scale (VAS) satiety questionnaire and blood CCK.
3269990|NCT01565070|Active Comparator|Biofreeze|
3269991|NCT01565070|Placebo Comparator|Placebo|Use of placebo ointment
3269992|NCT01565096|Experimental|Vildagliptin plus Metformin|Metformin (1000 mg BID) + Vildagliptin 50 mg twice daily
3269993|NCT01565096|Active Comparator|Glimepirid plus Metformin|Metformin (1000 mg BID) + Glimepiride (individual dosage)
3269994|NCT01565109|Experimental|Single arm study|"Docetaxel - Cisplatine - 5FU 2 cycles of Docetaxel - Cisplatine - 5 FU~Radiation: Radiation of 45 Grays on 5 weeks Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks"
3269995|NCT01565122||Cohort|
3269996|NCT01565135|Experimental|Intervention Practices|Intervention offices will adopt a multimodal vaccine program to increase their patients' vaccine rates.
3269997|NCT01565135|No Intervention|Control Practices|Control offices will offer usual health care related to immunizations throughout the duration of the study.
3269998|NCT01565161|Experimental|Home-Based Health Coaching|Intervention delivered in the home.
3269999|NCT01565161|Active Comparator|Control Arm|Mailed educational materials
3270000|NCT01565174||High activity COMT|Carriers of high activity COMT158Val allele who are expected to show higher THC-induced meso-limbic DA release
3270001|NCT01565174||Low activity COMT|Carriers of low activity COMT 158Met homozygotes are expected to release low amount of dopamine after smoking a cigarette with THC
3270002|NCT01565187||hand transplant candidates|Participants enrolled will be asked to complete behavioral questionnaires.
3270003|NCT01565200|Other|T-DM1|After an imaging phase, the patient will receive T-DM1 iv every 3 weeks until progression or toxicity
3270004|NCT01565213|Active Comparator|CBT cognitive behavioral therapy|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks
3270005|NCT01565213|Active Comparator|MMI Multimodal group intervention|group multimodal intervention
3270006|NCT01565213|Other|CAU|Care as usual given by the GPs
3270007|NCT01565226||Open|open, observational study
3270008|NCT01565239|Experimental|Fiix PT (Fiix-INR) monitoring and dosing of warfarin|The modified prothrombin time, sensitive only to factor II and X activity, will be used to monitor and dose warfarin.
3270009|NCT01565239|Active Comparator|PT (INR) monitoring and dosing of warfarin|The prothrombin time, sensitive to factors II, VII and X activity, will be used to monitor and dose warfarin.
3270010|NCT01565252|No Intervention|Stage 1|"Dietary regimens:~Stage1 - all participants (N=20) in first stage will receive two regular (high n-6 PUFA) hard-boiled eggs/day at breakfast for a three weeks period for each participant."
3270011|NCT01565252|Experimental|Stage 2|Stage 2 will be conduct after 3 weeks for wash-out with no eggs. All participants(N=20) in second stage will receive two high n-3 PUFA hard-boiled eggs/day at breakfast for a three weeks period for each participant.
3270012|NCT01565265|Active Comparator|GnRH agonist long protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with decapeptyl, which will be administered from the midluteal phase of the preceding menstrual cycle up to ovulation induction.
3270013|NCT01565265|Experimental|antagonist protocol|Pergoveris will be administered daily from cycle day 2 to ovulation induction together with Cetrotide, which will be administered from the day six up to ovulation induction.
3270014|NCT01565278|Experimental|Soybean oil + Fish oil|Intralipid (0.25 g/kg/TPN day) + Omegaven (0.4 g/kg/TPN day) for a period of 6 months.
3270015|NCT01565278|Active Comparator|Soybean oil (Standard treatment)|Standard treatment: Intralipid (0.25 g/kg/TPN day) for a period of 6 months
3270016|NCT01565304|Experimental|POWER Through Choices|10-session group-based sexual education curriculum
3270017|NCT01565304|No Intervention|Usual services|No intervention
3270018|NCT01565317|Experimental|Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
3270019|NCT01565317|No Intervention|Control Group|Matched control group will be recruited from obese patients with diabetes followed at Joslin Clinic. This group will receive the routine standard diabetes care.
3270020|NCT01565395|Experimental|Xeomin Injections|Fifteen units (0.15 ml) of incobotulinum toxin A injected into each parotid gland and 20 units (0.2 ml) to each submandibular gland for a total dose of 70 units using anatomical landmarks for ALS Twenty units (0.2ml) injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks for PD/parkinsonism
3270021|NCT01565395|Placebo Comparator|Placebo|0.15 ml sterile 0.9% saline injected into each parotid gland and 0.2 ml to each submandibular gland using anatomical landmarks for ALS 0.2ml injected into each parotid gland and 0.3 ml to each submandibular gland using anatomical landmarks for PD/parkinsonism
3270022|NCT01565408|Experimental|NNC0114-0006|
3270023|NCT01565408|Placebo Comparator|Placebo|
3270024|NCT01565447||Children with ALL or LL|Children diagnosed with ALL or LL will be recruited for this study
3270025|NCT01565460||pancreatic/biliary strictures|Sample Collection: Patients with pancreatic/biliary stricture undergoing intervention will have samples of brushings and bile taken during the procedure.
3270026|NCT01565473||Parkinson disease patients|
3270027|NCT01565473||Healthy normal controls|
3270028|NCT01565486|Other|Ultrasonic coagulation device|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
3270029|NCT01565486|Other|Bipolar Energy Sealing System|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
3270030|NCT01565512|Placebo Comparator|saline injection|saline injection
3270031|NCT01565512|Active Comparator|Bupivacaine injection|penile block with bupivacaine
3270032|NCT01565525|No Intervention|Bright Futures|This represents 'usual care' in the pediatric office. The anticipatory guidance regarding nutrition is based on the Bright Futures Pocket Guide.
3270033|NCT01565525|Experimental|Maternal focused intervention|Childhood obesity prevention was approached in this arm via anticipatory guidance aimed at maternal eating habits.
3270034|NCT01565525|Active Comparator|Ounce of Prevention|This is a program of anticipatory guidance given to mothers of infants ages 2 weeks to one year which focuses on serving size per age and tips for introducing new foods for the infant.
3270035|NCT01565577|Experimental|Bras A|
3270036|NCT01565590|Active Comparator|Propofol|
3270037|NCT01565590|Experimental|Dexmedetomidine|
3270038|NCT01565629|No Intervention|Waitlist Condition|Children in this condition will withhold from any type of intervention for a period of 12 weeks.
3270039|NCT01565629|Experimental|Computer Assisted CBT|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
3270040|NCT01565655|Experimental|ASP015K lowest dose|ASP015K lowest dose once daily
3270041|NCT01565655|Experimental|ASP015K low dose|ASP015K low dose once daily
3270042|NCT01565655|Experimental|ASP015K medium dose|ASP015K medium dose once daily
3270043|NCT01565655|Experimental|ASP015K high dose|ASP015K high dose once daily
3270044|NCT01565655|Placebo Comparator|Placebo|Matching placebo once daily
3270045|NCT01565681|Experimental|Arm A: ASKP1240 lowest dose|
3270046|NCT01565681|Experimental|Arm B: ASKP1240 second lowest dose|
3270047|NCT01565681|Experimental|Arm C: ASKP1240 third lowest dose|
3270048|NCT01565681|Experimental|Arm D: ASKP1240 fourth lowest dose|
3270049|NCT01565681|Experimental|Arm E: ASKP1240 fifth lowest dose|
3270050|NCT01565681|Experimental|Arm F: ASKP1240 middle dose|
3270051|NCT01565681|Experimental|Arm G: ASKP1240 sixth highest dose|
3270052|NCT01565681|Experimental|Arm H: ASKP1240 fifth highest dose|
3270053|NCT01565681|Experimental|Arm I: ASKP1240 fourth highest dose|
3270054|NCT01565681|Experimental|Arm J: ASKP1240 third highest dose|
3270055|NCT01565681|Experimental|Arm K: ASKP1240 second highest dose|
3270056|NCT01565681|Experimental|Arm L: ASKP1240 highest dose|
3270057|NCT01565681|Placebo Comparator|Arm M: Placebo|Sodium Chloride solution
3270058|NCT01565720|Experimental|Group 1|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole low dose once a day (QD) for 11 days
3270059|NCT01565720|Experimental|Group 2|Isavuconazole low dose 3 times per day (TID) for 2 days followed by isavuconazole high dose once a day (QD) for 11 days
3270060|NCT01565720|Placebo Comparator|Group 3|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 11 days
3270061|NCT01565720|Active Comparator|Group 4|Placebo 3 times a day (TID) for 2 days followed by placebo once a day (QD) for 10 days and then moxifloxacin on Day 13
3270062|NCT01565733||NovoMix® 30 users|
3270063|NCT01565746|Experimental|Radium-223 dichloride [50 kBq/kg]|
3270064|NCT01565746|Experimental|Radium-223 dichloride [100 kBq/kg]|
3270065|NCT01565746|Experimental|Radium-223 dichloride [expansion]|
3270066|NCT01565759|Experimental|Lithium|This will be a short-term longitudinal study of 4 weeks of duration. Twenty (20) healthy male subjects will be recruited and treated with lithium carbonate for 4 weeks. Lithium carbonate (150 mg, 300 mg, 600 mg) will be administered to the recruited subjects. The study will be performed in one centre at Capital District Health Authority - Dalhousie University, Halifax, Nova Scotia, Canada. Lithium serum levels will be tested at day 8, at day 14 and at the end of the treatment. Additional tests may be performed as necessary (as in the case of side effects).
3270067|NCT01565772|Experimental|Radiation, Chemotherapy and Surgery|Proton beam radiation, plus chemotherapy with cisplatin and etoposide, followed by surgery.
3270068|NCT01565785|Experimental|Discharge Prepartion with The FSM-DPI|25 families on each of 2 units will receive the will receive the Family Self-Management-Discharge Preparation Intervention (FSM-DPI). This scripted theory-based intervention is delivered by the study nurse using a e-mobile device. Eight elements of discharge preparation are addressed, the nurse assesses the family status and documents the additional care provided.
3270069|NCT01565785|No Intervention|control group|25 parents on each unit receiving standard of care in discharge preparation.
3270070|NCT01565798|Experimental|Copper Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with copper surfaced objects.
3270071|NCT01565798|No Intervention|Standard Surfaced Room|Patients sequentially randomized to this arm were admitted to an ICU room with standard surfaced objects
3270072|NCT01565811||Hepatic pedicle lymph node Involvement|Intervention Type: perihepatic lymphadenectomy(surgical procedure)
3270073|NCT01565824|Experimental|Web-based support|The subjects will get access to a website where they can store blood glucose levels, read specialized information concerning pregnancy and early motherhood, and access a discussion forum for peer support.
3270074|NCT01565824|No Intervention|Usual care|
3270075|NCT01565837|Experimental|Ipilimumab + SART|Patients with oligometastatic but unresectable malignant melanoma will receive induction ipilimumab plus concurrent SART followed by maintenance ipilimumab.
3270076|NCT01565863|Experimental|Progressive Goal Attainment Program|
3270077|NCT01565863|No Intervention|VA employment services|
3270078|NCT01565876|Experimental|study|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
3270079|NCT01565915|Experimental|Perlane-L|Perlane-L treatment
3270080|NCT01565915|Sham Comparator|Non-Treatment|Non-Treatment Arm
3270081|NCT01565967||Autotransfusion|All patients undergoing surgery which requires routine use of an autotransfusion system
3270082|NCT01566006|No Intervention|control group|group receiving the conventional treatment for DN
3270083|NCT01566006|Experimental|cellcept group|additional to the conventional treatment patients will receive cellcept
3270084|NCT01566006|Experimental|carnitine group|aside to the conventional treatment patients will receive carnitine
3270085|NCT01566006|Experimental|PDE5 group|aside to the conventional treatment patients will receive PDE5 inhibitor
3270086|NCT01566019|Experimental|Patients with non curable metastatic cancer|
3270087|NCT01566045|Active Comparator|Core Needle TRUS biopsy (Transrectal ultrasound)|Patient receiving core needle TRUS biopsy (Standard of care biopsy)
3270088|NCT01566045|Experimental|Core Needle MRI/US fusion guided biopsy|Patients receiving Standard of Care core needle TRUS biopsy will then receive the MRI / Ultrasound fusion core needle guided biopsy
3270089|NCT01566058|Experimental|With BB Box|"The mothers in this arm of the study will have access to a BB Box video system to maintain contact with their premature baby."
3270090|NCT01566058|Active Comparator|Without BB Box|"The mothers in this arm of the study will not have access to a BB Box video system to maintain contact with their premature baby. (Standard care)"
3270091|NCT01566097|Experimental|Intervention group|This study is cluster randomized trial, and the randomization level is physician. Current smokers seen by physician allocated into intervention group were provided with Smoking Cessation Decision Aids along with study questionnaires. The intervention was Smoking Cessation Decision Aids provided to current smokers.
3270092|NCT01566097|No Intervention|Control group|Current smokers seen by physician allocated into control group were provided with only study questionnaires and usual care.
3270093|NCT01566110|Experimental|Diet Intervention Group|
3270094|NCT01566110|No Intervention|Control Group|Subjects assigned to the control group will continue their usual diet. They will receive dietary teaching at each study visit as part of their diabetes management.
3270095|NCT01566123|Experimental|A|Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma
3270096|NCT01566136|No Intervention|Usual care|Current routine rehab care for persons with a hip fracture and CI lacks a well integrated care system within the local hospital network. The usual approach to care at the two sites differ in one major way: patients presenting with a hip fracture to Site 1 receive surgery locally, while those presenting to Site 2 receive surgery at a different hospital because of the absence of an operating suite at this site. Within 2 to 10 days 95% of patients presenting to either site hospital's emergency room with a hip fracture, receive internal fixation or arthroplasty surgery. Patients, including some with mild and moderate CI, are then transferred to in-patient rehabilitation beds at Site 1 or Site 2. Screening of patients for dementia or delirium is not routinely done.
3270097|NCT01566136|Experimental|Rehabilitation Model of Care|Staff will be introduced to five components of the Patient-Centred Rehabilitation Model of Care (PCRM-CI) in a one-day workshop prior to implementing the PCRM-CI model. They will then be provided with eight additional educational sessions throughout the year. A manual detailing all aspects of training, including specifics on how to present the material, ideas for stimulating discussion, and case vignettes to illustrate training concepts was developed for our pilot study and will be used here. We also produced a short video on care of elderly with CI in rehabilitation which will be utilized in the training session. The model will be tested over a one year period with a sustainability plan in place developed by the local hospital network and the two study sites.
3270098|NCT01566175|Experimental|Neovasc coronary sinus reducer|open label: Neovasc coronary sinus reducer
3270099|NCT01566188|Experimental|omega-3 from vegetal origin|
3270100|NCT01566188|Placebo Comparator|Placebo|
3270101|NCT01566201|Active Comparator|anakinra|
3270102|NCT01566201|Placebo Comparator|placebo|
3270103|NCT01566227|Experimental|number of implants|number of implants (1,2 or 3) used to retained an overdenture
3270104|NCT01566240|Active Comparator|Chemoradiation|Radiotherapy (external beam and brachytherapy) plus concurrent Cisplatin weekly for 5 weeks
3270105|NCT01566240|Experimental|Induction Chemotherapy + Chemoradiation|6 cycles of weekly Paclitaxel and Carboplatin followed by Chemoradiation as per Active Comparator
3270106|NCT01566253|Experimental|PCOA|The PCOA arm receiving oral self administered multimodal analgesic protocol (paracetamol, ketoprofen, morphine) by oral use.
3270107|NCT01566253|Active Comparator|Standard/ IV|The standard/IV arm will be received the analgesic treatment by intravenous use, administered by nursing staff.
3270108|NCT01566266|Experimental|Amoxicillin|
3270109|NCT01566266|Placebo Comparator|Placebo capsules|
3270110|NCT01566279|Other|everolimus|All patients in first part will receive everolimus 10mg q.d.
3270111|NCT01566292|Experimental|BOTOX|
3270112|NCT01566305|Experimental|Buttermilk with added egg yolk|
3270113|NCT01566305|Experimental|Buttermilk without added egg-yolk|
3270114|NCT01566305|Experimental|Skimmed milk with added egg-yolk|
3270115|NCT01566305|Placebo Comparator|Skimmed milk without added egg yolk|
3270116|NCT01566318|Experimental|Problem solving therapy (PST)|6-8 sessions of PST, with booster, delivered over 8 weeks
3270117|NCT01566318|No Intervention|Usual care|Usual agency care, monitored for mental health services
3270118|NCT01566344|Experimental|Routine heart failure therapy plus PVC suppression therapy|
3270119|NCT01566344|No Intervention|Routine heart failure therapy|
3270120|NCT01566357|No Intervention|Fluoride-free toothpaste|
3270121|NCT01566357|Active Comparator|Fluoride toothpaste|
3270122|NCT01566357|Active Comparator|Milk|
3270123|NCT01566357|Active Comparator|Fluoridated milk|
3270124|NCT01566357|Active Comparator|CPP-ACP|
3270125|NCT01566357|Active Comparator|Fluoridated CPP-ACP|
3270126|NCT01566357|Active Comparator|Fluoride mouthrinse|
3270127|NCT01566383|Experimental|Healthy Volunteers|Healthy volunteers who are matched (age, weight, gender) to the general patient population undergoing manometry and pH monitoring for GERD will undergo the same procedures to determine pH levels in people without reflux symptoms as compared to pH levels in those patients who have been diagnosed with reflux.
3270128|NCT01566396|Experimental|A3F|A3F, Fractional RF treatment
3270129|NCT01566422|Experimental|Vancomycin powder|80 randomized patients will be given vancomycin powder in the surgical sites prior to closure following spinal surgery.
3270130|NCT01566422|No Intervention|Control|80 participants who were not randomized to receive Vancomycin powder will receive no intervention at the conclusion of their surgery.
3270131|NCT01566474|Experimental|Melatonin + omeprazole|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
3270132|NCT01566474|Active Comparator|omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
3270133|NCT01566487|Experimental|Quetiapine fumarate tablets 300 mg|Quetiapine fumarate film-coated tablets 300 mg of Dr. Reddy's Laboratories Limited
3270134|NCT01566487|Active Comparator|Seroquel|Seroquel film-coated tablets 300 mg of Astrazeneca Pharmaceuticals, USA
3270135|NCT01566513|No Intervention|Treatment as usual|
3270136|NCT01566513|Experimental|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
3270137|NCT01566513|Experimental|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
3270138|NCT01566513|Experimental|Peer Case Manager|If a participant is randomized into this condition, they are offered the chance to work with a Case Manager, who is trained in strengths-based case management.
3270139|NCT01566552|Other|SINGLE DOSE AMBISOME|
3270140|NCT01566565|Active Comparator|Theophylline|
3270141|NCT01566565|Active Comparator|Bambuterol|
3270142|NCT01566578|Experimental|EGF Cream|
3270143|NCT01566578|Placebo Comparator|Placebo cream|
3270144|NCT01566591|Sham Comparator|Sham Treatment|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
3270145|NCT01566591|Active Comparator|Deep TMS Treatment|Deep TMS treatment is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions.
3270146|NCT01566617|Other|Standard Care|(1) group who will receive standard care
3270147|NCT01566617|Other|Standard Care and Pharmaceutical Care|(2) group who will receive standard care and pharmaceutical care
3270148|NCT01566643|Experimental|Hybrid-10|RA3-RACM7: rabeprazole + amoxicillin x 3 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days.
3270149|NCT01566643|Experimental|Hybrid-12|RA5-RACM7: rabeprazole + amoxicillin x 5 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
3270150|NCT01566643|Experimental|Hybrid-14|RA7-RACM7: rabeprazole + amoxicillin x 7 days, then rabeprazole + amoxicillin + clarithromycin + metronidazole x 7 days
3270151|NCT01566656|Experimental|TLI and anti-thymocyte globulin|
3270152|NCT01566669|Placebo Comparator|Normal Saline|Before incision, patients in controlled Group received NS
3270153|NCT01566669|Experimental|parecoxib sodium|Before incision, parecoxib patients received 40mg of parecoxib IV
3270154|NCT01566708|Experimental|treatment group|
3270155|NCT01566708|Active Comparator|waiting list group|
3270156|NCT01566708|Active Comparator|control group|
3270157|NCT01566734|Experimental|Cefazolin|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
3270158|NCT01566734|Experimental|Normal Saline|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients
3270159|NCT01566734|No Intervention|Control|
3270161|NCT01566760|Experimental|Treatment A, Cohort 1|
3270162|NCT01566760|Experimental|Treatment B, Cohort 2|
3270163|NCT01566760|Experimental|Treatment C, Cohort 1|
3270164|NCT01566760|Experimental|Treatment D, Cohort 2|
3270165|NCT01566760|Active Comparator|Treatment E, Cohort 1 and/or Cohort 2|
3270166|NCT01566786|Experimental|activated recombinant human factor VII|
3270167|NCT01566786|Placebo Comparator|Placebo|
3270168|NCT01566799|Experimental|Metformin|Patients will be receive 12 weeks of paclitaxel followed by 4 cycles of FAC combined with 500 mg/day of metformin p.o.
3270169|NCT01566812|Experimental|Breast feeding optimization|
3270170|NCT01566812|Active Comparator|Usual/routine care|
3270171|NCT01566825|Active Comparator|Amitriptyline|
3270172|NCT01566825|Placebo Comparator|white 8 mm Lichtenstein®|
3270173|NCT01566851||Patient|Patients with rheumatoid arthritis
3270174|NCT01566864|Experimental|Behavioral: Improve clinic based measurement of blood pressur|
3270175|NCT01566864|Experimental|Behavioral: Provider education system to promote patient-cent|
3270176|NCT01566864|Experimental|Behavioral: Introduce care management system in clinics|
3270177|NCT01566877|Active Comparator|AVI-7288|AVI-7288 is a phosphorodiamidate morpholino oligomer with positive charges (PMOplus™) that targets Marburg virus nucleoprotein (NP). AVI-7288 is supplied in 5 mL vials containing 5 mL AVI-7288 at a concentration of 50 mg/mL. The dose levels of AVI-7288 will vary in four cohort's.
3270178|NCT01566877|Placebo Comparator|Placebo|Placebo control consists of approximately 150 mL normal saline solution administered by IV infusion over 30 minutes once a day for 14 days.
3270179|NCT01566890|Experimental|Regadenoson ARM|Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
3270180|NCT01566890|Other|Sickle Cell Controls ARM|Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
3270181|NCT01566890|Other|Sickle Cell CEU ARM|Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
3270182|NCT01566890|Other|Healthy Control ARM|Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound
3270183|NCT01566890|Other|Technique Optimization Controls|Healthy volunteers will undergo contrast-enhanced ultrasound.
3270184|NCT01566903||arteriovenous malformations|
3270185|NCT01566903||Arterial stenosis|
3270186|NCT01566903||Post-treatment follow-up|Patient with an arteriovenous malformation for which treatment by embolization or radiosurgery is indicated
3270187|NCT01566916|Active Comparator|Total Hip Arthroplasty performed via direct anterior approach|
3270188|NCT01566916|Active Comparator|Total Hip Arthroplasty using anterolateral approach|
3270189|NCT01566929|No Intervention|IVF only|IVFtreatment
3270190|NCT01566929|Active Comparator|Weight reduction treatment and IVF|Dietary Supplement: Low calorie diet treatment and then IVFtreatment
3270191|NCT01566942|Active Comparator|FOLFOX|In this group, the patients will receive the adjuvant chemotherapy with mFOLFOX6.
3270192|NCT01566942|Experimental|FOLFIRI|in this arm, patients will receive adjuvant chemotherapy with FOLFIRI regimen for about 8 cycles
3270193|NCT01566955|Experimental|transgastric adnexectomy|patients are operated transgastric
3270194|NCT01566968||Healthy Volunteers|Adults between ages of 18-75 inclusive who have never smoked and have no history of any respiratory disease for which they are on regular treatment.
3270195|NCT01566968||Asthma|Adults between the ages on 18-75 inclusive who have a physician diagnosis of asthma and have no smoking history or minimal smoking history (less than 10 pack years or in other words less than 20 cigarettes per day for 10 years).
3270196|NCT01566968||COPD|Adults between the ages of 18-75 inclusive who have previously been smokers (at least 20 pack years) and have physician diagnosis and spirometry evidence of COPD.
3270197|NCT01566968||Healthy smokers|Adults between the ages of 18-75 inclusive who are currently smokers (at least 10 pack years history)but have no history of any respiratory disease and no evidence of COPD on spirometry.
3270198|NCT01566968||Chronic cough|Adults between ages of 18-75 inclusive who have history of dry cough for at least 8 weeks and have a normal chest x ray and no smoking history or minimal smoking history (less than 10 pack years).
3270199|NCT01566994|Experimental|TTM Tailored|
3270200|NCT01566994|Experimental|Motivational Enhancement Therapy|
3270201|NCT01566994|Experimental|Integrated Treatment|
3270202|NCT01567007|No Intervention|control|session of 15-20 minutes duration. It took place guidelines on physical activity, delivering a manual with general information about physical activity
3270203|NCT01567007|Experimental|Individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise steps. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
3270204|NCT01567007|Experimental|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices.
3270205|NCT01567007|Experimental|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill
3270206|NCT01567033|Experimental|Intervention|Intervention participants received HEALTH, which embedded a lifestyle intervention derived from DPP within the standard PAT curriculum
3270207|NCT01567046||Correlative studies|Archived DNA tissue samples are analyzed for frequency of genetic mutations, including SNPs, SNVs, and small deletions and/or insertions, by PCR and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.
3270208|NCT01567059|Experimental|Arm I (tosedostat and cytarabine)|Patients receive tosedostat PO QD on days 1-35 and cytarabine IV on days 1-5.
3270209|NCT01567059|Experimental|Arm II (tosedostat and decitabine)|Patients receive tosedostat PO QD on days 1-35 and decitabine IV on days 1-5.
3270210|NCT01567072|Experimental|NSAIDs in 7 days|NSAIDs (Ibuprofen) in 7 days
3270211|NCT01567072|Active Comparator|NSAIDs in 3 days|NSAIDs (Ibuprofen) in the first 3 days and placebo in the last 4 days
3270212|NCT01567072|Placebo Comparator|Placebo|Only placebo in 7 days
3270213|NCT01567098|Experimental|SILS appendectomy|Single incision laparoscopic appendectomy
3270214|NCT01567098|Active Comparator|3 Ports appendectomy|performing appendectomy through conventional 3 incisions on the abdomen
3270215|NCT01567111|Experimental|Subjects with PA|All study subjects have biochemically confirmed PA and undergo adrenal CT, AVS and MTO-PET to diagnose lateralization of aldosterone production.
3270216|NCT01567124|Other|Olanzapine|Participants taking olanzapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
3270217|NCT01567124|Other|Clozapine|Participants taking clozapine at the time of recruitment will continue to take this medication as part of standard care for schizophrenia.
3270218|NCT01567176|Other|Single Arm|
3270219|NCT01567189|Experimental|Hospital cardiac rehabilitation|The patients will perform physical training sessions in the hospital
3270220|NCT01567189|Active Comparator|Home cardiac rehabilitation|The patients will perform physical training sessions at home
3270221|NCT01567202|Experimental|Arm DC|In this arm, the patients will receive DC vaccination in addition to the standard therapy, including Surgery, Chemotherapy, and Radiotherapy.
3270222|NCT01567202|Placebo Comparator|Arm Placebo|In this arm, the patients will receive blank placebo instead of the DC vaccination in addition to the standard therapy.
3270223|NCT01567215|Experimental|Granuloma|
3270224|NCT01567228|No Intervention|routine counseling (control group)|Children will receive typical counseling for obesity prevention, dental caries prevention, or school problems per routine standards for pediatrician anticipatory guidance
3270225|NCT01567228|Experimental|CHICA GIS|In randomly assigned experimental clinics, physicians will counsel patients to increase physical activity, seek dental care, or seek academic support services such as tutoring; this counseling will be assisted by an experimental intervention which consist of an electronic medical record that prompts specific counseling in conjunction with a geographic information system. The enhanced electronic medical record will map community resources to support physician counseling and lifestyle modification
3270226|NCT01567241|Placebo Comparator|Relaxation music|
3270227|NCT01567241|Experimental|Clinical hypnosis|
3270228|NCT01567254|Experimental|guided imaginary|7 children receiving auditory guided imagery disk
3270229|NCT01567254|Active Comparator|music|6 children receiving music disk
3270230|NCT01567267|Experimental|Experimental educational intervention|Experimental educational intervention
3270231|NCT01567267|Active Comparator|Standard educational intervention|Standard educational intervention
3270232|NCT01567280||Controlled patients|Asthmatic patients with controlled asthma (according to ACQ score)
3270233|NCT01567280||Partly controlled/Uncontrolled patients|Patients with partly controlled or uncontrolled asthma (according to ACQ score)
3270234|NCT01567319|Experimental|Allergic Subjects|
3270235|NCT01567319|Active Comparator|Atopic Subjects|Patients sensitized to other allergenic sources but the allergen extracts under investigation.
3270236|NCT01567319|Active Comparator|No Atopic Subjects|Healthy volunteers.
3270237|NCT01567332|Experimental|rTMS active|
3270238|NCT01567332|Placebo Comparator|rTMS inactive (sham)|
3270239|NCT01567345|Active Comparator|Intrathecal pump with continuous flow|After placement of the implantable pump, continuous flow is scheduled by physician and the patient can't modify it.
3270240|NCT01567345|Experimental|Intrathecal pump with programmable flow.|After placement of the implantable pump, programmable flow is scheduled by physician and patient can do himself morphine bolus injections for a better control of acute episodes of pain.
3270241|NCT01567358|Experimental|NI-071|
3270242|NCT01567358|Active Comparator|Remicade|
3270243|NCT01567384|Experimental|Combination therapy with OSI and Pemetrexed|
3270244|NCT01567410|Other|traditional Classroom training|one group of nurses receive traditional classroom training to learn about the braden scale and pressure ulcer classification
3270245|NCT01567410|Other|e-learning|one group of nurses receive e-learning as a training method to learn about the braden scale and classification of pressure ulcer
3270246|NCT01567423|Experimental|Artesunate and Amodiaquine (ASAQ)|children receiving fixed-dose combination of artesunate and amodiaquine
3270247|NCT01567423|Active Comparator|Arthemeter and Lumefantrine (AL)|children receiving fixed-dose combination of arthemeter and lumefantrine
3270248|NCT01567449||the case group|The case group referred to SAH patients with aneurysm rebleeding
3270249|NCT01567449||the control group|the control group referred to SAH patients not with aneurysm rebleeding
3270250|NCT01567475|Experimental|Everolimus and rituximab|
3270251|NCT01567488|Experimental|Everolimus + Octreotide LAR treatment|
3270252|NCT01567501|Experimental|Levocetirizine Dihydrochloride tablets 5 mg|Levocetirizine dihydrochloride Tablets, 5 mg of M/s Ipca Laboratories Limited, India
3270253|NCT01567501|Active Comparator|Xyzal|XYZAL (levocetirizine dihydrochloride) 5 mg Tablets of M/s UCB Inc.,USA
3270254|NCT01567514|Active Comparator|Glass-ionomer cement lining|Presence of glass-ionomer cement lining in posterior resin composite restorations.
3270255|NCT01567514|No Intervention|No glass-ionomer cement lining|Absence of glass-ionomer cement lining in posterior resin composite restorations
3270256|NCT01567540|Experimental|DPPIV Inhibition|The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).
3270257|NCT01567553||Control group|Only unenhanced MR scanning will be performed in a control group of normal, age-matched subjects and after acceptance of the protocol by an independent ethical committee for the implication of a normal population in such an MRI research project.
3270258|NCT01567553||Experimental group|CIS at presentation (clinically isolated syndromes) will be recruited with MRI evidence of at least two asymptomatic brain MRI lesions. The group will compromise 50 CIS patients. These CIS patients will be included within three months after first clinical presentation.
3270259|NCT01567566|Active Comparator|Local lumbopelvic stabilizers|
3270260|NCT01567566|Experimental|Local lumbopelvic plus hip stabilizers|
3270261|NCT01567592|Experimental|Active Shockwave Therapy|Treatment group. Patients in this group receive actual shockwave therapy.
3270262|NCT01567605|Experimental|Lidocaine lubricant|In this arm, subjects will use lidocaine lubricant in their normal bowel care routine (rather than standard lubricating jelly).
3270263|NCT01567605|Placebo Comparator|Placebo lubricant|In this arm, subjects will use regular lubricant (AMG MedPro lubricating gel) in their normal bowel care routine.
3270264|NCT01567631|Experimental|intrahepatic Glisson's approach|
3270265|NCT01567631|Active Comparator|classical hepatectomy|
3270266|NCT01567644|Experimental|Active Shockwave Therapy|Patients in this group receive shockwave therapy.
3270267|NCT01567657|Active Comparator|Pethidin plus midazolam|Initial dose of 25 mg Pethidin iv. plus 1-2 mg Midazolam iv. Additional Bolus of Midazolam (1 mg wise iv.) if needed, until a maximal dose of 7 mg Midazolam iv.
3270268|NCT01567657|Active Comparator|Propofol|Initial dose of Propofol of 50-60 mg iv. for patients 50 years or younger. Initial dose of Propofol of 30-40 mg iv. for patients over 50 years. If needed additional Bolus of 20-30 mg Propofol iv. as usual until sedation is achieved.
3270269|NCT01567670|Active Comparator|Naloxone|nasal spray before binging, naloxone dose 2 mg, maximum daily dose 4 mg
3270270|NCT01567670|Placebo Comparator|nasal spray|nasal placebo (h2o) spray before binging, max sprays / day
3270271|NCT01567683|Experimental|Limtop solution (imiquimod), Vehicle solution for topical use|
3270272|NCT01567709|Experimental|Treatment (alisertib, vorinostat)|Patients receive alisertib PO BID on days 1-7 or days 1-3 and 8-10, and vorinostat PO BID on days 1-14 or days 1-5 and 8-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3270273|NCT01567722||HIV-positive diffuse large B-cell lymphoma cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and diffuse large B-cell lymphoma.
3270274|NCT01567722||HIV-positive lung cancer cases|Tissue collection for genomic sequencing from persons with a diagnosis of HIV and lung cancer.
3270275|NCT01567735|Experimental|TMC435|
3270276|NCT01567748||Hemodynamics Measured|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
3270277|NCT01567774|Active Comparator|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
3270278|NCT01567774|Active Comparator|Rosuvastatin|Patients will receive randomly rosuvastatin (10 mg per day) for 30 days
3270279|NCT01567787|Experimental|Proton Radiation for MPNST|Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
3270280|NCT01567787|Experimental|Proton Radiation for neurofibromas|Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
3270281|NCT01567800|Experimental|PET FAZA imaging|PET FAZA imaging of tumor hypoxia in patients with prostate cancer
3270282|NCT01567813||Regimen Initiators|Any male health plan member who receives at least one dose of GARDASIL™
3270283|NCT01567813||Regimen Completers|Regimen Initiators who complete the 3-dose vaccination regimen within 12 months
3270284|NCT01567813||Autoimmune cohort|Regimen Initiators who were members of the health plan during the 12-month period prior to their first dose of GARDASIL™
3270285|NCT01567878||ankylosing spondylitis|It will be held ultrasound exam in enthesis and joints in patients with ankylosing spondylitis and healthy subjects
3270286|NCT01567878||Healthy pelople|It will be held ultrasound exam in enthesis and joints of healthy subjects
3270287|NCT01567904|Experimental|Age group from 12 to 18 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3270288|NCT01567904|Experimental|Age group from 6 to 12 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3270289|NCT01567904|Experimental|Age group from 2 to 6 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3270290|NCT01567904|Experimental|Age group from 3 months to 2 (<) years|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3270291|NCT01567904|Experimental|Age group from birth to 3 (<) months|Semuloparin sodium, weight-adjusted dose once daily for 6-30 days
3270292|NCT01567917||Group A|"Patients who gave a permission to this study and underwent doppler US (Doppler US cohort~- Expected subject no.: 400 patients"
3270293|NCT01567917||Group B|"Patient who gave a permission to this study, but who did not receive doppler US (Although this group of patients did not undergo doppler US, these patients will be included as group B [simple observation cohort without doppler US examination])~- Expected subject no.: 200 patients"
3270294|NCT01567956|Experimental|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine
3270295|NCT01567956|Placebo Comparator|Placebo|Modified release tablets containing inert substances
3270296|NCT01567969|Experimental|IICAPS|Provision of Intensive In-home Child and Adolescent Psychiatric Service, a six to seven month family-focused in-home psychiatric intervention.
3270297|NCT01567969|Active Comparator|Home-based CTC|Provision of Home-based Child Treatment Coordination, a six to seven month child-focused case management service with monthly in-home visits with the child's parent/legal guardian.
3270298|NCT01567982|Experimental|smokers and nonsmokers|both smokers and nonsmokers will receive same tDCS
3270299|NCT01567995|Experimental|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
3270300|NCT01567995|Other|Vehicle (base cream)|Vehicle (base cream)
3270301|NCT01568060||Infanrix-IPV group|Infants and children who received at least one dose of Infanrix-IPV as a part of routine practice at a private clinic or hospital in korea
3270302|NCT01568086||AFFITOPE AD03 with adjuvant|
3270303|NCT01568086||AFFITOPE AD03 without adjuvant|
3270304|NCT01568099|Experimental|A: AFFITOPE® PD01A + Adjuvant|4 injections of 15µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
3270305|NCT01568099|Experimental|B: AFFITOPE® PD01A + Adjuvant|4 injections of 75µg AFFITOPE® PD01A/ adjuvanted, once every 4 weeks
3270306|NCT01568099|Other|Control|Untreated control group
3270307|NCT01568125||Incretin-related drugs|
3270308|NCT01568151|Active Comparator|Intervention Clinics|Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions(Clinic-directed intervention program)including: 1)provider-directed interventions; 2)office-based systems; and 3) waiting room materials. If the subjects have not undergone colorectal cancer screening after 12 months, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
3270309|NCT01568151|No Intervention|Usual Care Clinics|Subjects recruited at the Usual Care Clinics (Control Clinics) will not receive any study intervention. The results of how many subjects undergo colorectal cancer screening at the Usual Care Clinics will be compared to the number that undergo colorectal cancer screening at the Intervention Clinics.
3270310|NCT01568164|Experimental|Device Treatment|Treatment with the investigational device.
3270311|NCT01568177|Other|abnormal CRT|"40 subjects with microvascular coronary dysfunction (MCD) defined as abnormal CRT.~Visits 1, 2, and 3"
3270312|NCT01568177|Other|Cardiac Syndrome X|20 subjects with symptoms and normal stress tests, no MCD. Visits 1 and 2
3270313|NCT01568177|Other|normal reference controls|40 normal reference controls subjects Visits 1 and 2
3270314|NCT01568190|Experimental|AVANZ|AVANZ Mites
3270315|NCT01568203|Experimental|AMG 579|
3270316|NCT01568203|Placebo Comparator|Placebo|
3270317|NCT01568216|Experimental|AMG 747 - Dose 1|
3270318|NCT01568216|Experimental|AMG 747 - Dose 2|
3270319|NCT01568216|Experimental|AMG 747 - Dose 3|
3270320|NCT01568216|Placebo Comparator|Placebo Comparator|
3270321|NCT01568229|Experimental|AMG 747 - Dose 1|
3270322|NCT01568229|Experimental|AMG 747 - Dose 2|
3270323|NCT01568229|Experimental|AMG 747 - Dose 3|
3270324|NCT01568229|Placebo Comparator|Placebo Comparator|
3270325|NCT01568242|Experimental|Thermoprobe|Determination of vitreous temperature with a thermoprobe
3270326|NCT01568268|Experimental|Palonsetron|
3270327|NCT01568268|Placebo Comparator|Placebo|
3270328|NCT01568281|Experimental|1|2 way crossover
3270329|NCT01568281|Experimental|2|2 way crossover
3270330|NCT01568281|Experimental|3|2 way crossover
3270331|NCT01568281|Experimental|4|2 way crossover
3270332|NCT01568294|Experimental|pomalidomide|Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.
3270333|NCT01568333|Experimental|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
3270334|NCT01568346|Active Comparator|MRI|MRI
3270335|NCT01568346|No Intervention|No MRI|No MRI
3270336|NCT01568359||Group 1 - Acromegaly, Group 2 - control|Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)
3270337|NCT01568372|Experimental|Nurse telephone follow-up|This group received a telephone follow-up by a nurse following discharge from the hospital and up until the 10th postoperative day, which is considered as the usual period of healing for a tonsillectomy
3270338|NCT01568372|No Intervention|Standard care group|This group received the standard care which consisted of an informative session before discharge and no follow-up once discharged home.
3270339|NCT01568385|Experimental|TAK-438 20 mg QD|
3270340|NCT01568398|Experimental|TAK-438 20 mg QD|
3270341|NCT01568411|Active Comparator|TD-1211|
3270342|NCT01568411|Active Comparator|TD-1211+ itraconazole|
3270343|NCT01568437|Active Comparator|Conventional management|On the ward, patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg up to every 2 hours or iv morphine. Patients with contraindications to oxycodone will be prescribed oral hydromorphone 1-2 mg instead. This is the current standard of care at Toronto Western Hospital.
3270344|NCT01568437|Experimental|TAP Block+Conventional Management|The TAP block will be performed after the induction, before the surgery, by an anesthesiologist with experience of at least 10 successful TAP blocks.Also patients will be prescribed acetaminophen 1 g every 6 hours. If additional analgesia is required, patients will take oxycodone 5-10 mg(oral hydromorphone 1-2 mg) up to every 2 hours or iv morphine.
3270345|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, fasted)|
3270346|NCT01568450|Experimental|GL2907 XL 20mg (Oxycodone 20mg, after high fat meal)|
3270347|NCT01568450|Active Comparator|Oxycontin CR 10mg (Oxycodone 10mg, fasted)|
3270348|NCT01568476|Active Comparator|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
3270349|NCT01568476|Active Comparator|Interneural|sciatic nerve blockade at the site of bifurcation
3270350|NCT01568489|Experimental|HL-009 Liposomal Gel (0.07%)|
3270351|NCT01568489|Experimental|HL-009 Liposomal Gel (0.15%)|
3270352|NCT01568489|Experimental|HL-009 Liposomal Gel (0.30%)|
3270353|NCT01568489|Placebo Comparator|HL-009 Liposomal Gel (Placebo)|
3270354|NCT01568502||DSE|Patients, who underwent Dobutamine Stress Echocardiography (DSE)
3270355|NCT01568502||DSCMR|Patients, who underwent Dobutamine Stress Cardiac Magnetic Resonance (DSCMR)
3270356|NCT01568515|Experimental|Electronic Messages|Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months
3270357|NCT01568515|No Intervention|Standard of Care|Control group participants received standard of care at the student health center which included a card with their next appointment written on it.
3270358|NCT01568541|Active Comparator|Children' toothpaste|Children's toothpastes
3270359|NCT01568541|Active Comparator|Regular toothpastes|Regular toothpastes
3270360|NCT01568554||Group 1|Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
3376907|NCT04944940||Healthy Volunteers|Healthy male participants who are age and gender matched to the SBMA participants
3376908|NCT04944940||Patients with Spinal and bulbar muscular atrophy (SBMA)|Male participants with genetically confirmed SBMA
3270361|NCT01568554||Group 2 (Not Yet Enrolling)|Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
3270362|NCT01568554||Group 3|"Subjects in Group 3 will participate in the Follow Up Sub-Study. This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit."
3270363|NCT01568567|Active Comparator|Double dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
3376918|NCT04936464|Experimental|Intervention Group|
3376919|NCT04936464|Sham Comparator|Sham Group|
3376920|NCT04934007|Experimental|Active stimulation|Active rTMS stimulation , 2 session per day during 10 days.
3376921|NCT04934007|Sham Comparator|Sham Stimulation|Sham rTMS stimulation , 2 session per day during 10 days.
3376925|NCT04933227|Experimental|Atezo + Tira + XELOX|Atezolizumab plus tiragolumab in combination with XELOX (oxaliplatin and capecitabine) will be administered during Cycles 1-4 (each cycle is 21 days). During Cycle 5 and beyond atezolizumab and tiragolumab will be administered on Day 1 of each 21-day cycle. Participants will receive study treatment until disease progression, unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3376926|NCT04929938|Experimental|Inmediate UP plus Treatment As Usual|Treatment As Usual Plus Inmediate Virtual group Therapy applying the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders. The treatment consists in 15 weekly sessions of 120 minutes that combines cognitive-behavioural techniques to improve emotional self-regulation skills.
3376927|NCT04929938|Active Comparator|Waiting list plus Treatment As Usual|A waiting list for treatment with delayed UP after 7 months while receiving the treatment as usual (WL + TAU).
3376928|NCT04928742|Experimental|Treatment (9-week online CBT group)|Participants assigned to the treatment group will participate in a 9-week group CBT intervention for PPD delivered via Zoom by two public health nurses. This intervention was developed by Dr. Van Lieshout (PI) at the Women's Health Concerns Clinic (WHCC) at St. Joseph's Healthcare Hamilton. It was designed to be brief, simple, and applicable to women in community settings. It consists of 9 weekly 2-hour sessions where core CBT skills are learned and practiced, and a new psychoeducational topic is introduced and discussed by women each week. All participants in the treatment group will be mailed a hardcopy of the program manual.
3376929|NCT04928742|No Intervention|Control (treatment as usual)|The control group will receive standard postnatal care from Niagara Region Public Health, their obstetrician, midwife, and/or family physician.
3270364|NCT01568567|Active Comparator|Single dose|One stick pack with active ingredients contains 1.0 g contains 75% GOS (galactooligosaccharide), 25% L-Rhamnose, 1x108 live bacteria (CFU) Lactobacillus reuteri and silicon dioxide
3270365|NCT01568567|Placebo Comparator|Placebo|One stick pack with placebo contains 1.0 g maltodextrin and silicon dioxide
3270366|NCT01568580|Experimental|test drug|GreenGene
3270381|NCT01568749|Active Comparator|Standard paracetamol|Marketed formulation
3270382|NCT01568749|Experimental|Formulation 1|Paracetamol formulation 1
3270383|NCT01568749|Experimental|Formulation 2|Paracetamol formulation 2
3270384|NCT01568749|Experimental|Formulation 3|Paracetamol formulation 3
3270385|NCT01568749|Experimental|Formulation 4|Paracetamol formulation 4
3270386|NCT01568762|Experimental|VAK694|VAK694 was administered as a 1 hour intravenous infusion
3270387|NCT01568762|Placebo Comparator|VAK694 Placebo|VAK694 placebo was administered as a one hour intravenous infusion
3270388|NCT01568762|Experimental|QAX576|QAX576 was administered intravenously as a 2 hour infusion
3270389|NCT01568762|Placebo Comparator|QAX576 placebo|QAX576 placebo was administered as a 2 hour intravenous infusion
3270390|NCT01568775|Experimental|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
3270391|NCT01568788|Experimental|Inactivated Influenza Vaccine|15μg HA/strain/0.5ml/syringe, Hualan Biologicals
3270392|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of Pasteur|15ug HA/strain/0.5ml/syringe, Sanofi Pasteur
3270393|NCT01568788|Active Comparator|Inactivated Influenza Vaccine of GSK|15ug HA/strain/0.5ml/syringe, GSK
3270394|NCT01568801|No Intervention|Control Group|Individuals randomized into the control arm will receive usual community care services referred by the social worker from SGH and AH.
3270395|NCT01568801|Experimental|Intervention Group|Individuals in the intervention group will go through an integrated program of community based health and social care based on intake and ongoing evaluation by the SingaPACE team.
3270396|NCT01568814|Placebo Comparator|High volume PEG|Patients who are scheduled colonoscopy ingest high volume PEG(4L) for bowel preparation.
3270397|NCT01568814|Active Comparator|Low volume PEG with low residual meals|Patients who are scheduled colonoscopy ingest low volume PEG(2L) and have a prepackaged low residual meals for bowel preparation.
3270398|NCT01568840|Experimental|Global Postural Reeducation Group|Global Postural Reeducation
3270399|NCT01568840|Active Comparator|Segmental Exercises Group|Segmental Exercises
3270400|NCT01568879|Experimental|Gout Chronic Disease Management Program|
3270401|NCT01568879|Active Comparator|Usual Care|
3270402|NCT01568918|Experimental|Tamsulosin|Participants randomized to this arm will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
3270403|NCT01568918|Placebo Comparator|Placebo|Participants randomized to this arm will receive a daily placebo capsule matching the active study drug from 5 days prior to the operation until hospital discharge.
3270404|NCT01568931|Active Comparator|Urokinase|Patients will be randomized to to receive local bolus of 200,000 units urokinase
3270405|NCT01568931|Active Comparator|Saline|Patients will be randomized to to receive local bolus of intracoronary saline
3270406|NCT01568957|Experimental|Dual-task gait training|Gait training with simultaneous performance of cognitive tasks for 75% of training session.
3270407|NCT01568957|Active Comparator|Single-task gait training|Gait training (without simultaneous cognitive task performance)
3270408|NCT01568970|Experimental|Return to work follow-up|Regular contact between the patient and his/her caretaker at the rehabilitation center over a 6 month period, including joint communication between patient, caretaker at the rehabilitation center and stake holders such as social security office, general practitioner and workplace.
3270409|NCT01568970|Active Comparator|Standard follow-up|Standard follow-up of the patient after ended rehabilitation by the return-to-work stakeholders, ie. the general practitioner, social security office and the employer. Limited contact between the caretaker at the rehabilitation center and the patient and stakeholders.
3270410|NCT01568983|Placebo Comparator|Control|"12 weeks intake of 0.5 liter/day placebo juice containing sugar, aromas and salt corresponding to the berry juices in the other groups.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3270411|NCT01568983|Active Comparator|Mana-juice|"12 weeks intake of 0.5 liter/day of a commercially available berry juice (Mana blue) rich in polyphenols (grape, cherries, bilberries and aronia).~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3270412|NCT01568983|Active Comparator|Optijuice|"12 weeks intake of 0.5 liter/day of berry juice rich in polyphenols (grape, cherries, blueberry and aronia) and added extract from press cake of black currant.~Blood pressure will be taken at time point 0,6 and 12 weeks. Blood and urine samples will be collected and weight and bioelectric impedance will be monitored at time point 0 and 12 weeks."
3270413|NCT01568996|Experimental|Low dose BSE-SFN|BSE-SFN will be orally administered at 50 µmol SFN for 28 days.
3270414|NCT01568996|Experimental|Mid dose BSE-SFN|BSE-SFN will be orally administered at 100 µmol SFN for 28 days.
3270415|NCT01568996|Experimental|High dose BSE-SFN|BSE-SFN will be orally administered at 200 µmol SFN for 28 days.
3270416|NCT01569009||Observational|Patients are asked to continue with their normal daily activities.
3270417|NCT01569035|Active Comparator|warfarin|oral anti coagulant
3270418|NCT01569048|Active Comparator|remifentanil|
3270419|NCT01569048|Experimental|dexmedetomidine|
3270420|NCT01569061|Active Comparator|Active Laser Group (ALG)|
3270421|NCT01569061|Sham Comparator|Sham Laser Group (SLG)|
3270422|NCT01569113|Experimental|ellaOne + microgynon 30|
3270423|NCT01569113|Placebo Comparator|placebo + microgynon 30|
3270424|NCT01569139||GPRD MI|Myocardial infarction, as identified in the GPRD data.
3270425|NCT01569139||MINAP MI|Myocardial infarction, as identified in MINAP data.
3270426|NCT01569139||HES MI|Myocardial infarction, as identified in HES data.
3270427|NCT01569165|Experimental|washing after 30 min|washing with water after 30 min following APF treatment
3270428|NCT01569165|Experimental|washing after 15 min|washing with water after 15 min following APF treatment
3270429|NCT01569165|Experimental|immediately washing with water|immediately washing with water after APF treatment
3270430|NCT01569165|Experimental|cleansing teeth with cotton roll|cleansing teeth with cotton roll immediately following APF treatment
3270431|NCT01569165|No Intervention|no fluoride therapy|control group
3270432|NCT01569178|No Intervention|standard care|optimal standard care post myocardial infarction
3270433|NCT01569178|Experimental|Intracoronary Reinfusion of Cells|Bone marrow-derived progenitor cells aspiration and Intracoronary reinfusion of the cells
3270434|NCT01569204|Active Comparator|BrECAPP|modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
3270435|NCT01569204|Active Comparator|BrECADD|modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
3270436|NCT01569217||respiratory muscle dysfunction patients|Neuromuscular patients
3270437|NCT01569217||diaphragmatic dysfunction|patients who present orthopnea, recruitment of accessory muscles, abdominal paradox, respiratory dysfunction or dyssynchronous movement
3270438|NCT01569230|Experimental|Individualized acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
3270439|NCT01569230|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
3270440|NCT01569230|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
3270441|NCT01569230|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
3270442|NCT01569243|Other|Usual care group|Subjects in this group will receive the usual standard of care available at MGH.
3270443|NCT01569243|Experimental|Text messaging group|Subjects in this group will be enrolled to receive text messages aimed at providing bite-sized coaching based on measured step count to help improve activity levels and providing reminder, educational and motivation messages aimed at helping patients to meet their diabetes self-management goals.
3270444|NCT01569256|Active Comparator|Cabergoline administered group|"The patients in this group will have cabergoline (Dostinex tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days) for prevention of OHSS.~All patients were administered long luteal protocol for ovulation induction."
3270445|NCT01569256|No Intervention|Control arm|"The patients in the control group had no manipulation for prevention of OHSS and age-, BMI-matched with the active comparator group.~All patients were administered long luteal protocol for ovulation induction."
3270446|NCT01569269|Experimental|Yoga|See intervention description
3270447|NCT01569269|Experimental|Meditation|See intervention description
3270448|NCT01569269|Experimental|Reiki|see intervention description
3270449|NCT01569269|Active Comparator|Holistic Education|see intervention description
3270450|NCT01569282|Active Comparator|Double bypass|
3270451|NCT01569282|Active Comparator|Stent Strategy|
3270452|NCT01569321|Experimental|Breast cancer|
3270453|NCT01569334|Other|HTC with Cardiac allograft vasculopathy|HTC:heart transplanted recipients
3270454|NCT01569334|Other|HTR without Cardiac allograft vasculopathy|
3270455|NCT01569334|Other|untransplanted|
3270456|NCT01569347||1: Cocaine users|Adults, cocaine users
3270457|NCT01569360|Active Comparator|Corset|the patients are assigned the use of a custome made corset during daytime
3270458|NCT01569360|No Intervention|No corset|the patients do not use a corset during daytime
3270459|NCT01569373||Post allogeneic SCT patients|Patients who have undergone an allogeneic stem cell transplant.
3270460|NCT01569386|Experimental|low intensity physical activity|Daily low intensity physical activity by the half squat
3270461|NCT01569386|Active Comparator|stretch exercise and usual activity|They do whole body stretch exercise for 20 minute in a day
3270462|NCT01569399|Active Comparator|active rTMS|High frequency (10HZ) on the left DLPFC
3270463|NCT01569399|Placebo Comparator|sham rTMS|
3270464|NCT01569412|Experimental|Ertumaxomab|Ertumaxomab administration during two treatment cycles will follow a predefined dose escalation scheme, consisting of 5 ascending doses per cycle with each infusion lasting 3 hours.
3270465|NCT01569425|Experimental|Lifestyle counseling|Lifestyle counseling, with high calorie breakfast
3376930|NCT04928508|Experimental|SHetA2 capsule|SHetA2 (oral, BID) within a 21-days cycle
3270466|NCT01569425|Active Comparator|Life Counseling|Diet with high calorie dinner
3270467|NCT01569477|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
3270468|NCT01569477|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
3270469|NCT01569490|Experimental|Treatment incentives|Incentives for biochemical verification visits, treatment engagement, and abstinence
3270470|NCT01569490|Active Comparator|Attendance incentive|Incentives for only attending the biochemical verification visits
3270471|NCT01569503|Experimental|VSN|VNS therapy
3376948|NCT04925622||Control|No symptoms of neurological condition
3376949|NCT04925622||Parkinson's disease|Parkinson's disease diagnosis
3376950|NCT04925622||Non-PD Movement disorder|Non-PD with other movement disorder such as progressive supranuclear palsy, multiple system atrophy, essential tremor, corticobasal degeneration, vascular Parkinsonism, or Parkinsonian syndromes
3376951|NCT04925544|Experimental|VK-2019_arm|1800 mg VK 2019 once daily, cycles will be defined as 28 days of treatment, subjects will receive VK 2019 until progression or dose limiting toxicity, for up to 12 cycles.
3270472|NCT01569516|Experimental|low dose|1mg, tid
3270473|NCT01569516|Experimental|Moderate dose|2mg,tid
3270474|NCT01569516|Experimental|High dose|4mg,tid
3270475|NCT01569516|Placebo Comparator|Placebo|0 mg, tid
3270476|NCT01569581|Experimental|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
3270477|NCT01569581|Experimental|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
3376959|NCT04917419|Experimental|Luminotherapy and Psychoeducation Program|
3270478|NCT01569581|Experimental|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
3270479|NCT01569581|Experimental|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
3270480|NCT01569581|No Intervention|0U/0.5ml in infants (6-11 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 6-11 months old on day 0, 28
3376960|NCT04917419|Active Comparator|Psychoeducation Program|
3270481|NCT01569581|No Intervention|0U/0.5ml in infants (12-23 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1750 infants aged 12-23 months old on day 0, 28
3270482|NCT01569581|No Intervention|0U/0.5ml in children (24-35 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1500 children aged 24-35 months old on day 0, 28
3270483|NCT01569581|No Intervention|0U/0.5ml in children (36-71 months old)|0U/0.5ml (0Eu/0.5ml) placebo in 1000 children aged 36-71 months old on day 0, 28
3270484|NCT01569620|Active Comparator|Culturally targeted print materials|Best clinical practices plus culturally print materials
3270485|NCT01569620|Active Comparator|Standard print materials|Best clinical practices plus standard print materials
3270486|NCT01569620|Active Comparator|Best clinical practices alone|Best clinical practices alone: This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
3270487|NCT01569633|Placebo Comparator|Placebo|This group of infant will not receive any medication but sugar water or placebo
3270488|NCT01569633|Active Comparator|Metclopramide|This group of infants will receive Metoclopramide at 0.1mg/kg q8 hrs.
3270489|NCT01569633|Active Comparator|Erythromycin|mediaction used to treat feeding disorder
3270490|NCT01569659|Active Comparator|Standard dose of lurasidone|
3270491|NCT01569659|Experimental|High dose of lurasidone|
3270492|NCT01569672|Active Comparator|Intervention Clinic|Patient Navigator matched with subjects. Patient Navigators will be matched with subjects at the intervention clinics and will assist patients with questions, issues or concerns with their cancer treatment/diagnosis or abnormal test results and followup test or treatments
3270493|NCT01569672|Placebo Comparator|Control Clinics|Subjects are mailed informational/educational materials.
3270494|NCT01569685|Active Comparator|Venlafaxine|6 months treament vith Venlafaxine (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
3270495|NCT01569685|Active Comparator|Sertraline|6 months treament vith Sertraline (if patient has troubles sleeping in combination with Mianserine) in recommended dose in combination with Cognitive Behavioral Therapy
3270496|NCT01569698||extrarenal replacement therapy|Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
3270497|NCT01569711||Deep brain stimulation|
3270498|NCT01569724|Experimental|bexarotene|
3270499|NCT01569750|Experimental|Ibrutinib|"Part 1 (Dose Escalation): Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) until maximum tolerated dose is achieved.~Part 2: Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP."
3270500|NCT01569776|Experimental|New Amino Acid formula|
3270501|NCT01569776|Active Comparator|Control formula|Commercially available Amino Acid infant formula
3270502|NCT01569789|Active Comparator|Ear Stimulation|Comparing cytokine levels pre and post stimulation of the nerve in the ear
3270503|NCT01569789|Placebo Comparator|Calf Stimulation|Comparing cytokine levels pre and post stimulation of the placebo area on the calf
3270504|NCT01569802||screening|
3270505|NCT01569854||statin|
3270506|NCT01569893|No Intervention|Control group|Usual care: treatment as usual
3270507|NCT01569893|Experimental|Self-monitoring for patients with Dibetes mellitus type 2|Self-monitoring for patients with Dibetes mellitus type 2
3270508|NCT01569906||UVB|Children with moderate to severe atopic eczema who undertook a standard course of narrowband Ultraviolet B (NBUVB) phototherapy
3270509|NCT01569906||Controls|Children with moderate to severe atopic eczema who were offered UVB but were unable to undertake treatment
3270510|NCT01569919|Experimental|TroVax®|In this single-arm study, all participants will receive 9 injections of the TroVax® vaccine, plus standard cisplatin and pemetrexed chemotherapy.
3270511|NCT01569932||chemotherapy|Patients will be assessed both before and after they undergo treatment with chemotherapy.
3270512|NCT01569945|Active Comparator|Tablets|Clomifen (5 days) followed by Ethinyl Estradiol (5 days)
3270513|NCT01569945|Active Comparator|human menopausal gonadotropins|Daily Injections
3270514|NCT01569958|Active Comparator|tDCS|
3270515|NCT01569958|Sham Comparator|sham|
3270516|NCT01569971||Adolescents|Adolescents with SCD (all genotypes) age 12 years old up to 18 years old and currently receiving services through the St. Jude Children's Research Hospital Sickle Cell Disease Transition Program.
3270517|NCT01569971||Caregivers|Caregiver of an adolescent with SCD who has resided with the adolescent for at least two years prior.
3270518|NCT01569971||Young Adults|Young adults with SCD (all genotypes) age equal to 18 years up to and equal to 30 years of age who have transitioned to adult care.
3270519|NCT01569984|Experimental|Avastin, SBRT|2 treatments of avastin followed by 6 treatments of SBRT every other day.
3270520|NCT01569997|Other|Intervention group|Intervention group: nursing homes whose residents benefit from MDTM to identify the cases of dementia and to propose an adequate care project
3270521|NCT01569997|No Intervention|control group|Control group: nursing homes whose residents continue to benefit from usual care
3270522|NCT01570010|Experimental|Intervention group|
3270523|NCT01570010|Other|Control group|Counseling on physical activity only
3270524|NCT01570023|No Intervention|Standard Clinical Care|Standard swallowing intervention is that which is identified by the SLP as appropriate to treat the patient's dysphagia and is in common clinical practice. Such treatment would consist of dietary or postural compensatory strategies (i.e., chin down posture while swallowing).
3270525|NCT01570023|Experimental|Standard Clinical Care Plus Isometric Lingual Exercise|Standard Clinical Care Plus 8-week Isometric Lingual Exercise Regimen. The isometric tongue exercises will be completed using the Madison Oral Strengthening Therapeutic (MOST) device. Baseline maximum lingual pressure will be obtained at the anterior and posterior sensors independently by gathering two sets of data (3 MOST device trials) at each site (anterior and posterior) that differ by less that 5%. During week one of the regimen, the target value of each repetition will be 60% of the maximum baseline pressure. For the remaining seven weeks of the program, the target value will be increased to 80% of the maximum. At weeks three, five, and seven, the baseline will be re-measured by phone and the 80% target value re-calculated.
3270526|NCT01570049|Experimental|Bendamustine|Dose of 120 mg/m2/day on Day 1 and Day 2 of each treatment cycle (every 21 days), to a maximum of 8 cycles.
3270527|NCT01570062|Active Comparator|Indoor Air HEPA Filtration|HEPA filters will be placed in participant's main living area and bedroom. Actual filtration will occur during only one of the two 7-day sampling periods.
3270528|NCT01570062|Placebo Comparator|HEPA Filtration Placebo|For one of two 7-day sampling sessions, HEPA filters placed in participants' homes will be run without an actual filter in the housing unit.
3270529|NCT01570075|Experimental|RFA group|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3270530|NCT01570075|Experimental|HR group|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
3376963|NCT04912232||Trauma Patients|"Patients suffering blunt and/or penetrating trauma but without physiologic criteria suggestive of ongoing hemorrhage:~Awake and alert GCS >14~Admission systolic blood pressure greater than 90 and heart rate less than 120~Without signs of clinically significant ongoing external hemorrhage with no active bleeding documented on radiology/ultrasound and stable vital signs (no signs of hemodynamic deterioration) during initial evaluation (approximately 15 minutes post admission)"
3270531|NCT01570088|Active Comparator|Folic acid|
3270532|NCT01570088|Experimental|L-5-MTHF|
3270533|NCT01570088|Placebo Comparator|Placebo|
3270534|NCT01570101|Experimental|CE Marked Sapheon Closure System in GSV|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
3270535|NCT01570114||covered metallic stent|Endoscopically insertion of fully covered metallic stent on benign colonic strictures
3270536|NCT01570127|Experimental|Individualized Acupuncture|The patients in this group received individualized acupuncture prescribed by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on the pattern diagnosis, which is an unique diagnosis system of Oriental Medicine.
3270537|NCT01570127|Experimental|Standardized Acupuncture|The patients in this group received standardized acupuncture treatment using the same acupuncture points, applied by a certified Korean Medicine Doctor with more than 6 years of oriental medicine college education and 2 years of clinical experience. The acupuncture formulas were composed based on literature review of RCTs.
3270538|NCT01570127|Sham Comparator|Sham acupuncture|Non-penetrating acupuncture device, Park-sham acupuncture, was applied to the patients. The appearance of the acupuncture is same but the needles do not penetrate the skin.
3270539|NCT01570127|No Intervention|Waiting|No interventions were applied to the patients in this group. Only assessments were made at each visit.
3270540|NCT01570140||Web portal users|T2DM patients in the primary care setting, using the web portal.
3270541|NCT01570153||ADHF patients|
3270542|NCT01570166|Experimental|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
3270543|NCT01570166|Experimental|HR group|HR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
3270544|NCT01570179|Experimental|deep block ideal body weight|
3270545|NCT01570179|Active Comparator|deep block real body weight|
3270546|NCT01570179|Experimental|moderate block ideal body weight|
3270547|NCT01570179|Active Comparator|moderate block real body weight|
3270548|NCT01570205|Experimental|XG-102 10 µg/kg|
3270549|NCT01570205|Experimental|XG-102 40 µg/kg|
3270550|NCT01570205|Experimental|XG-102 80 µg/kg|
3270551|NCT01570205|Placebo Comparator|placebo|
3270552|NCT01570218|Experimental|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days.
3270553|NCT01570218|No Intervention|Control|
3270554|NCT01570231|Experimental|bilateral limb ischemic preconditioning (BLIPC)|5 minutes bilateral limb ischemic preconditioning treatment with an inflating tourniquets to 200 mmHg
3270555|NCT01570231|No Intervention|Control group|underwent equivalent medical treatments only
3270556|NCT01570257|No Intervention|control group|These patients receive a shunt with the valve preset and fixed at a Performance level of 1.0, corresponding to an opening/closing pressure of 35-55 mm H2O.
3270557|NCT01570257|Experimental|Intervention group|These patients receive a shunt with the valve preset at a Performance level (PL) of 2.5, corresponding to an opening/closing pressure of 135-155 mm H2O. The PL is allowed to be lowered until clinical improvement occurs.
3270558|NCT01570270|Experimental|regular cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks -1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. T
3270559|NCT01570296|Experimental|Gefitinib and BKM120|"Patients with NSCLC who progress on treatment with single-agent EGFR TKI (e.g., gefitinib or erlotinib), and meet the clinical definition of EGFR TKI resistance (Jackman et al., 2010):~A tumour that harbours an EGFR mutation known to be associated with drug sensitivity~Previous objective clinical benefit from treatment with an EGFR TKI~Patients should have systemic progression of disease (by RECIST) while on continuous treatment with gefitinib or erlotinib. Patients that have previously progressed on EGFR TKI (not in the preceding line of treatment) may also be enrolled and will receive gefitinib and BKM120 sequentially.~Patients with any solid tumour-type and activated PI3 kinase pathway and historically known to over express EGFR may also be recruited.~Once the RP2D is reached, an expansion cohort of 40 patients will be accrued for extended safety experience and to ascertain preliminary activity."
3270560|NCT01570374|Experimental|iCBT|Receives treatment.
3270561|NCT01570374|No Intervention|Waiting list control group|The waiting list control group initially receives no treatment, but do weekly screenings. After 9 weeks, the control group receives the same treatment as the other study arm.
3270562|NCT01570400|Experimental|CBM training program variant 1 + iCBT|Cognitive bias modification training program variant 1 combined with iCBT
3270563|NCT01570400|Experimental|CBM training program variant 2 + iCBT|Cognitive bias modification training program variant 2 combined with iCBT
3270564|NCT01570413|Active Comparator|Pelvic Exam|Subjects receive pelvic exam
3270565|NCT01570413|Experimental|No Pelvic Exam|Subjects do not receive pelvic exam
3270566|NCT01570426||Bipolar Disorder|Children, 7- 17 years-old, who meet diagnostic criteria for bipolar disorder, Type 1
3270567|NCT01570426||ADHD/ADD|Children, 7-17 years-old, who meet diagnostic criteria for attention deficit/hyperactivity disorder (ADHD) OR attention deficit disorder (without hyperactivity)
3270568|NCT01570426||Generalized Anxiety Disorder (GAD)|Children, 7-17 years-old, who meet diagnostic criteria for Generalized Anxiety Disorder (GAD)
3270569|NCT01570426||Health Controls|Children, ages 7-17 years-old, without a history of psychiatric diagnosis
3270570|NCT01570452||healthy volunteers|healthy subjects not affected by benign or malignant colonic disease
3270571|NCT01570452||benign colonic tumor patients|patients affected by benign colonic tumor such as adenoma
3270572|NCT01570452||cancer patient I-II stage|Patients affected by colonic cancer in I-II stage
3270573|NCT01570452||cancer patients III-IV stage|Patients affected by colonic cancer in III-IV stage
3270575|NCT01570478|Experimental|Foster® NEXThaler®|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
3270576|NCT01570478|Active Comparator|Seretide® Accuhaler®|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
3270577|NCT01570504|Experimental|ivermectin multiple doses|A dose of 200 mcg/kg of ivermectin given on days 1,2, 15 and 16
3270578|NCT01570504|Active Comparator|1 dose ivermectin|A single 200 mcg/kg dose of ivermectin
3270579|NCT01570517|Experimental|Device implantation|Subjects are implanted with the study device.
3270580|NCT01570530|Active Comparator|Atorvastatin|Patients treated with atorvastatin
3270581|NCT01570530|Other|Without Atorvastatin|Patients treated without atorvastatin
3270582|NCT01570543||orthopedic implants, no treatment|
3270583|NCT01570556|Active Comparator|Patients with positive culture, treatment group|These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
3270584|NCT01570556|No Intervention|Patients with positive culture, observation only|These asymptomatic patients with positive urine culture, will be observed only during the study period.
3270585|NCT01570569|Active Comparator|Omeprazole|
3270586|NCT01570569|Active Comparator|Losartan|
3270587|NCT01570569|Active Comparator|Dextromethorphan|
3270588|NCT01570569|Active Comparator|Caffeine|
3270589|NCT01570569|Active Comparator|Midazolam|
3270590|NCT01570582|Experimental|drug effect|"Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.~Subjects assigned to Arm II Gemcitabine and Latin Neople every week based on the first day of the outpatient / inpatient treatment receive it. The subjects first received Gemcitabine given over 30 minutes followed by 30 minutes will be administered Neople Latin week.~Gemcitabine and eighth day of the foreign / hospitalization are given over 30 minutes.~Regimen of the progression of the disease, the subject can not continue to deny or toxic dose every 3 weeks until at least 6 cycles should be administered to. Subjects completed six cycles of medication which responds subjects, the researchers believe it is necessary to sustain if the regimen is"
3270591|NCT01570595|Experimental|Web-Based Intervention|This group will be asked to participate in the online quit smoking program. At their first visit, they will be given an ID number to log in to the quit smoking program, and they will complete their first log in with the research assistant. The online program is made up of 8 separate online sessions that are supposed to be completed approximately once per week. Each sessions is written to take an average reader 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. At the first visit, participants are asked to provide an email address and/or cell phone number so reminders can be sent, by email or text message, to complete the sessions. If participants are late completing a session, they may receive call from clinic staff as a reminder.
3270592|NCT01570595|Active Comparator|Standard Care|"This group will receive standard care for their smoking, including advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
3270593|NCT01570608|Active Comparator|monotherapy arm|patients receiving 3 initial Ranibizumab injections, thereafter as needed
3270594|NCT01570608|Active Comparator|combined treatment arm|
3270595|NCT01570647||Healthy controls|
3270596|NCT01570647||Chronic low back pain|
3270597|NCT01570647||restricted hamstrings|
3270598|NCT01570647||systemic scleroderma|
3270599|NCT01570647||joint hyperlaxity|
3270600|NCT01570660|No Intervention|control group|parallel group without intervention
3270601|NCT01570673|Experimental|Group Urotherapy|Children in this arm wil receive group urotherapy in small groups with other children.
3376971|NCT04905069|No Intervention|No-Spacer Control|Subjects will receive radiotherapy without the use of the SpaceOAR Vue.
3376972|NCT04905069|Experimental|SpaceOAR Vue|Subjects will receive radiotherapy following injection of the SpaceOAR Vue hydrogel.
3270602|NCT01570673|Active Comparator|Individual urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
3270603|NCT01570699||2: patients included in METHADOSE study|includes opiate-dependent patients substituted by methadone
3270604|NCT01570699||1: opiate-non dependent patients|Will be included in the COM ON study subjects who have consumed illicit opiates (heroin, methadone, buprenorphine or morphine) more than 10 times in their life, without ever having the DSM-IV criteria for opiate dependence or abuse
3270605|NCT01570712|Experimental|Housing First Program|
3270606|NCT01570712|Active Comparator|traditional French services|
3270607|NCT01570725|Experimental|1|Virtual reality exposure to a relaxing virtual environment. The virtual experience will be provided using immersive equipment.
3270608|NCT01570725|Experimental|2|Exposure to relaxing music. The music will be selected between classical music tunes.
3270609|NCT01570764|Experimental|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
3270610|NCT01570764|Placebo Comparator|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
3270611|NCT01570777|Experimental|Renal denervation|
3270612|NCT01570777|Other|optimized medication regimen|optimized medication regimen
3270613|NCT01570790|Experimental|Cohort 1|
3270614|NCT01570790|Experimental|Cohort 2|
3270615|NCT01570790|Experimental|Cohort 3|
3270616|NCT01570803|Experimental|Complete SE Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus Complete-SE) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, patients were randomized to receive either clopidogrel group (clopidogrel will not be changed but continue) or cilostazol group (clopidogrel will be changed into cilostazol) in separate groups of SMART group and Complete SE group. Randomization procedure will be performed using a web-based program
3270617|NCT01570803|Active Comparator|SMART CONTROL Stent|same to Complete SE
3270618|NCT01570816|Experimental|Experimental|Volunteers are evaluated for appropriateness for inclusion in the study on an intent-to-treat basis. Qualifying candidates all receive the implanted neuroprosthesis and participate in post-operative training and follow-up procedures
3270619|NCT01570842|Other|Anthropometric Measurements; Tissue Samples|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity. Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
3270620|NCT01570881||Delirium,Nondelirium|those with delirium and those without delirium
3270621|NCT01570920|Experimental|walking|a cohort of stroke patients trained during 3 month, based on walking
3270622|NCT01570933|Experimental|NAVAfirst|Starting crossover by NIVnava mode
3270623|NCT01570933|Active Comparator|Cpap first|Start crossover by Cpap on nasal canula
3270624|NCT01570946|Experimental|Lifestyle modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
3270625|NCT01570946|No Intervention|Standard Care|Baseline 30-minute interview delivering personalised diet and exercise advice supplemented with educational material on diabetes.
3270626|NCT01570972|Other|MFG and GCBT|There is a single arm for this study. All participants will be able to participate in MFG and GCBT
3270627|NCT01570985|Active Comparator|Steroid injection Without distension|Group 1 consists of patients receiving Triamcinolone acetonide 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and a total of 4 ml solution.
3270628|NCT01570985|Active Comparator|Steroid with distension|Patients in group 2 will receive intraarticular Triamcinolone Acetonide 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
3270629|NCT01570985|No Intervention|Control|Group 3 will serve as control group and patients in this group could receive any other treatment other than corticosteroid injections or per oral corticosteroid medication. The control group will remain without treatment with corticosteroids, in injection or tablet form till 61 days, which is also the last day of the outcome measurements.
3270630|NCT01570998|Experimental|Treatment (IORT)|Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.
3270631|NCT01571011|Experimental|CURB Intervention|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
3270632|NCT01571011|Experimental|CURB Intervention (Wait List)|Same as the CURB Intervention arm, however, individuals assigned to this arm wait 3 months before receiving the intervention.
3270633|NCT01571024|Experimental|BKM120 + mFOLFOX6|BKM120 + mFOLFOX6 in patients with advanced solid tumors including metastatic pancreatic cancer.
3376973|NCT04903314|Experimental|Cohort I|Xcopri to be administered to ages 12 to < 18 years not to exceed 400 mg/day.
3376974|NCT04903314|Experimental|Cohort IIa|Xcopri to be administered to ages 6 to < 12 years not to exceed 400 mg/day.
3270634|NCT01571037|Other|inhaled nebulized Milrinone|"Drug: Inhaled, nebulized, Milrinone~1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation."
3270635|NCT01571050|Experimental|Fresh NaF/SiO2 toothpaste|
3270636|NCT01571050|Placebo Comparator|Purified water|
3270637|NCT01571050|Experimental|Aged NaF/SiO2 toothpaste|
3270638|NCT01571050|Experimental|Fresh MFP/CaCO3 toothpaste|
3270639|NCT01571050|Experimental|Aged MFP/CaCO3 toothpaste|
3270640|NCT01571063|Experimental|Vitamin D3|
3270641|NCT01571063|Placebo Comparator|Placebo|
3270642|NCT01571076|Experimental|Group B - Severe Male Factor|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
3270643|NCT01571076|Experimental|Group B - Advanced Age|PGS of day three biopsies and consequent embryo transfer on on Day 5 (blastocyst)
3270644|NCT01571076|Active Comparator|Group A - Advanced Age|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Advanced Age group
3270645|NCT01571076|Active Comparator|Group A - Severe Male Factor|Prolonged culture, no PGS, for Day 5 (blastocyst) embryo transfer for the Severe Male Factor group.
3270646|NCT01571089|Experimental|DBT-inspired exposure treatment|DBT-inspired exposure treatment.
3270647|NCT01571102|Active Comparator|physiotherapy|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
3270648|NCT01571102|No Intervention|Rest|
3270649|NCT01571102|Active Comparator|Home exercises|Promote mobility, strength and stability and exercises to reduce pain and swelling depending on the phase of tissue repair and evolution of the patient.
3270650|NCT01571115|Active Comparator|Insomnia Stretching Exercise|This group will realize stretching exercise
3270651|NCT01571115|No Intervention|Control|This group will not realize any type of intervention.
3270652|NCT01571115|Active Comparator|Insomnia Physical Exercise|This group will realize resistance physical exercise
3270653|NCT01571128|Experimental|Male-Specific Intervention Package|Gender-specific interventions targeted specifically for boys offered in an integrated services delivery modality. Cross-Sectional Arm.
3270654|NCT01571128|Experimental|Female-Specific Intervention Package|Gender-specific interventions targeted specifically for girls offered in an integrated services delivery modality. Cross-Sectional Arm.
3270655|NCT01571128|No Intervention|HIV Positive Cohort (Males and Females)|Behavioral data on HIV positive youth. Longitudinal Arm.
3270656|NCT01571128|Experimental|Pre-Exposure Prophylaxis (Females)|PrEP adherence and feasibility. Longitudinal Arm.
3270657|NCT01571128|Experimental|Cash Transfer Cohort (Females)|School attendance, behavioral data, and feasibility. Longitudinal Arm
3270658|NCT01571141|Experimental|Monogin|
3270659|NCT01571141|No Intervention|No intervention|
3270660|NCT01571167|Placebo Comparator|Placebo|
3270661|NCT01571167|Active Comparator|Varenicline 2 mg|
3270662|NCT01571167|Active Comparator|Varenicline 1 mg|
3270663|NCT01571180||Gastric Bypass|Obese patients who have scheduled a gastric bypass
3270664|NCT01571206|Active Comparator|CT-P13|infliximab
3270665|NCT01571219|Experimental|CT-P13|
3270666|NCT01571245||Veterans with PTSD|Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans who are ages 18 to 60 and currently in or about to start treatment for deployment-related Post-Traumatic Stress Disorder (PTSD) at the Central Arkansas Veterans Healthcare System Mental Health Clinics.
3270667|NCT01571258|No Intervention|Control|
3270668|NCT01571258|Experimental|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
3270669|NCT01571271|Experimental|Electrohydraulic lithotripsy|Electrohydraulic lithotripsy: Lithotripsy will be performed using electrohydraulic method
3270670|NCT01571271|Experimental|Laser Lithotripsy|Laser Lithotripsy: Lithotripsy will be performed using laser method
3270671|NCT01571297|Active Comparator|RM-131|
3270672|NCT01571297|Placebo Comparator|Placebo|
3270673|NCT01571310|Experimental|Omitted Breakfast|Experimental: The patients in Omitted Breakfast day will omit the breakfast and will continue the fast until noon. Thereafter will eat Lunch at 13;30 and Dinner at 19:00
3270674|NCT01571310|Active Comparator|Breakfast|The patients in Breakfast day will consume breakfast at 8:00 and then lunch at 13;30 and dinner at 19:00
3270675|NCT01571323|Active Comparator|Misoprostol|
3270676|NCT01571323|Active Comparator|Oxytocin|
3270677|NCT01571323|Active Comparator|Oxytocin and Misoprostol|
3270678|NCT01571349||chronic ITP group|ITP patients with elevated level of vWF, ITP patients with preserved MA of thromboelastography
3270679|NCT01571349||acute ITP group|ITP patients with normal level of vWF, ITP patients with decreased MA of thromboelastography
3270680|NCT01571375||FinnHEMS10|Patients Treated by Helsinki HEMS.
3270681|NCT01571375||FinnHEMS30|PAtients Treated by Tampere HEMS.
3270682|NCT01571388|Experimental|Group 1|Healthy Subjects to receive dacomitinib
3270683|NCT01571388|Experimental|Group 2|Subjects with mildly impaired hepatic function to receive dacomitinib
3270684|NCT01571388|Experimental|Group 3|Subjects with moderately impaired hepatic function to receive dacomitinib
3376975|NCT04903314|Experimental|Cohort IIb|Xcopri to be administered to ages 4 to < 6 years not to exceed 400 mg/day.
3376976|NCT04903314|Experimental|Cohort III|Xcopri to be administered to ages 2 to < 4 years not to exceed 400 mg/day.
3270685|NCT01571401|Experimental|Supervised PA plus Exercise Counselling|Participants will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, this group will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at fitness centre. In order to achieve the physical activity guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed. In addition to the supervised sessions, traditional exercise counselling will be provided to teach proper technique, how to monitor intensity, and to progress PA safely and effectively to achieve the public health physical activity guidelines
3270686|NCT01571401|Experimental|Supervised PA plus behavioural counselling|"In addition to the same supervised PA sessions as the SPA group, participants in this group will receive six individual face-to-face behavioural counselling sessions with a physical activity specialist. These counselling sessions will be combined with the supervised PA sessions, and will be provided directly following the supervised PA session. Counselling strategies will be based on the TPB and will target the unique benefits of PA for kidney cancer survivors, strategies for making PA enjoyable, for overcoming barriers, for including social support from family and friends, time management, self-monitoring, goal setting, and planning."
3376977|NCT04897347|Experimental|Robotic Trunk-Support-Trainer (TruST)|Postural-reaching control intervention with TruST
3376978|NCT04897347|Active Comparator|Static Trunk Support|Postural-reaching control intervention with Rigid Trunk Support
3376983|NCT04893096|Experimental|MOR202 (felzartamab) infusion|Participants will receive active treatment for a total of nine doses during 24 weeks.
3376988|NCT04888923||Healthy Controls|General public population, including females and males, who are over the age of 18, with a mixture of races and ethnicities representative of North Carolina.
3376989|NCT04888377||Antenatal exposure to low dose aspirin|Mothers in the Global Networks ASPIRIN trial were given 81 mg of Aspirin throughout their pregnancy with the follow-up studies participant.
3376990|NCT04888377||Antenatal exposure to Placebo|Mothers in the Global Networks ASPIRIN trial were given placebo throughout their pregnancy with the follow-up studies participant.
3376993|NCT04883359||Healthy Volunteers|From the Washington, D.C. metropolitan area
3376994|NCT04880642|Experimental|C21|50 mg capsules, oral administration twice daily,for 14 days
3376995|NCT04880642|Placebo Comparator|Placebo|placebo capsules, oral administration twice daily,for 14 days
3376996|NCT04880187|Experimental|AXA1125 22.6g|22.6 g AXA1125 administered orally BID with or without food
3376997|NCT04880187|Experimental|AXA1125 33.9g|33.9 g AXA1125 administered orally BID with or without food
3376998|NCT04880187|Placebo Comparator|Placebo|Matching Placebo administered orally BID with or without food
3376999|NCT04879160||1/ Cohort 1A|Clinician raters familiar with NF1
3377000|NCT04879160||2/ Cohort 1B|Clinician raters without specific NF1 familiarity
3377001|NCT04879160||3/ Cohort 2A|Non-clinician raters familiar with NF1
3377002|NCT04879160||4/ Cohort 2B|Non-clinician raters without specific NF1 familiarity
3377003|NCT04879160||5/ Cohort 3|Subjects with NF1
3270687|NCT01571414|Experimental|Arm 1A-EFV and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, EFV on Days 22 to 35, and EFV plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 34, and 41 to 42.
3270688|NCT01571414|Experimental|Arm 1B-EFV and PA-824|Participants will receive EFV on Days 1 to 14, EFV plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 13, 20 to 21, and 42.
3270689|NCT01571414|Experimental|Arm 2A-LPV/r and PA-824|Participants will receive PA-824 on Days 1 to 7, no study medication on Days 8 to 21, LPV/r on Days 22 to 35, and LPV/r plus PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 7, 35, and 42.
3377007|NCT04876248|Experimental|Treatment (belantamab mafodotin, lenalidomide)|Patients receive belantamab mafodotin IV over 30 minutes on day 1 and lenalidomide PO QD on days 1-28. Treatment repeats every 8 weeks for 6 cycles in the absence of disease progression or unacceptable toxicity.
3377008|NCT04872595|Experimental|P-rATG with total body irradiation, thiotepa, cyclophosphamide|"P-rATG days (always starting on Day -12 to -10)~Hyper fractionated total body irradiation (1375 - 1500cGy*) Day -9 to -6~Thiotepa (5mg/kg/day x 2 day) Day -5 to -4~Cyclophosphamide (60mg/kg/day x 2 days) Day -3 to -2~GCSF Day +7 *TBI dose in 125cGy fractions (with lung shielding) and total dose to be determined by treating physician/radiation oncology and is based off age, stage of disease, and anesthesia requirements."
3270690|NCT01571414|Experimental|Arm 2B-LPV/r and PA-824|Participants will receive LPV/r on Days 1 to 14, LPV/r plus PA-824 on Days 15 to 21, no study medication on Days 22 to 35, and PA-824 on Days 36 to 42. Inpatient study visits will occur at Days 14, 21, and 42.
3270691|NCT01571414|Experimental|Arm 3-RIF and PA-824|Participants will receive PA-824 on Days 1 to 7, RIF on Days 8 to 14, and RIF plus PA-824 on Days 15 to 21. Inpatient study visits will occur at Days 7 and 21.
3270692|NCT01571440|Placebo Comparator|No Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times daily.
3270693|NCT01571440|Active Comparator|12 g Soluble Corn Fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times daily
3270694|NCT01571466|Experimental|Vaccine group|Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef) (MVA HIV-B)
3270695|NCT01571466|Placebo Comparator|Placebo|
3270696|NCT01571479|No Intervention|2-mm mini-instrument (M-LC)|M-LC is three-port laparoscopic cholecystectomy using a 2-mm mini-instrument.
3270697|NCT01571479|No Intervention|conventional instrument(C-LC)|C-LC is conventional three port laparoscopic cholecystectomy
3270698|NCT01571492|Experimental|L2 Paravertebral peripheral nerve block|L2 paravertebral peripheral nerve block catheter will be placed.
3270699|NCT01571492|Active Comparator|Continuous Lumbar plexus peripheral nerve block|Continuous unilateral lumbar plexus peripheral nerve block catheter will be placed.
3270700|NCT01571505|Experimental|IPV vaccination|Randomized IPV vaccination to children at the age of 39 weeks.
3270701|NCT01571505|Placebo Comparator|OPV vaccination|Randomized OPV vaccination to children at the age of 39 weeks.
3270702|NCT01571518|Experimental|early injection|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
3270703|NCT01571518|Sham Comparator|late injection|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
3270704|NCT01571544|Experimental|Thermal suit|Randomly selected half of the patients will use thermal suit prior to anesthesia, during the surgery and post anesthesia care unit.
3270705|NCT01571544|Active Comparator|Conventional clothing|Randomly selected half of the patients will use conventional clothing prior to anesthesia, during the surgery and post anesthesia care unit.
3270706|NCT01571570|Experimental|Treatment A|Panel 1: single oral dose of 150 mg TMC435 150 mg capsule, fed
3270707|NCT01571570|Experimental|Treatment B|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fasted
3270708|NCT01571570|Experimental|Treatment C|Panel 1: single oral dose of 150 mg TMC435 oral suspension (20 mg/mL), fed
3270709|NCT01571570|Experimental|Treatment D|Panel 2: single oral dose of 150 mg TMC435 150 mg capsule, fed
3270710|NCT01571570|Experimental|Treatment E|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fasted
3270711|NCT01571570|Experimental|Treatment F|Panel 2: single oral dose of 150 mg TMC435 oral solution (10 mg/mL), fed
3270712|NCT01571570|Experimental|Treatment G|Panel 3: single oral dose of 150 mg TMC435 150 mg capsule, fed
3270713|NCT01571570|Experimental|Treatment H|Panel 3: single oral dose of 150 mg TMC435 capsule concept K, fed
3270714|NCT01571570|Experimental|Treatment I|Panel 3: single oral dose of 150 mg TMC435 capsule concept L, fed
3270715|NCT01571583|Experimental|Telaprevir+Peg-IFN-alfa-2a+Ribavirin|Patients will be treated for 12 weeks with telaprevir in combination with Pegylated interferon alfa-2a (Peg-IFN-alfa-2a) and ribavirin followed by 36 weeks of treatment with Peg-IFN-alfa-2a and ribavirin alone.
3270716|NCT01571609|Experimental|Carriers|
3270717|NCT01571609|Experimental|Non-carriers|
3270718|NCT01571622|Placebo Comparator|Water before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with 250 ml of water
3270719|NCT01571622|Experimental|Whey before breakfast|Each patient will consume a high-GI breakfast (white bread). Each subject will be pretreated 30 min before breakfast with Whey Protein Concentrate (WPC 80 %) 45 gr dissolved in 250 ml of water\
3270720|NCT01571635|Experimental|Sotatercept dose level 0.1mg/kg|Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270721|NCT01571635|Experimental|Sotatercept dose level 0.3mg/ kg|Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270722|NCT01571635|Experimental|Sotatercept dose level 0.5mg/kg|Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270723|NCT01571635|Experimental|Sotatercept dose level 0.75mg/kg|Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270724|NCT01571635|Experimental|Sotatercept dose level 1.0mg/kg|Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270725|NCT01571635|Experimental|Sotatercept dose level 1.5mg/kg|Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
3270726|NCT01571648|Experimental|Oral azacitidine|
3270727|NCT01571661|Experimental|Part A Treatment 1|GSK189075A 20mg
3270728|NCT01571661|Experimental|Part A Treatment 2|GSK189075A 50mg
3270729|NCT01571661|Experimental|Part A Treatment 3|GSK189075A 150mg
3270730|NCT01571661|Experimental|Part A Treatment 4|GSK189075A 500mg
3270731|NCT01571661|Experimental|Part A Treatment 5|GSK189075A 1000mg
3270732|NCT01571661|Placebo Comparator|Placebo|Placebo
3270733|NCT01571661|Experimental|Part B Low dose|low dose chosen from Part A
3270734|NCT01571661|Experimental|Part B High Dose|high dose chosen from Part A
3270735|NCT01571674|Experimental|Manipulation + Exercise Group|The treatment received by the manipulation+exercise group will differ from the exercise group for the first week only (two treatment sessions). During the first two sessions, patients in the manipulation+exercise group will receive cervicothoracic spine manipulations and range of motion (ROM) exercises only. Beginning on the third session these patients will receive the same exercise program as the exercise group.
3270736|NCT01571674|Active Comparator|Exercise Group|The exercise group will be treated with a stretching and strengthening program.
3270737|NCT01571687|Active Comparator|antioxidant supplements|800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
3270738|NCT01571687|Placebo Comparator|Placebo|identically appearing placebo
3270739|NCT01571700||Study|Patients with pulmonary hypertension.
3270740|NCT01571700||Control|ASD patients or patients with normal hearts
3270741|NCT01571713||Study|Pediatric patients with pulmonary hypertension
3270753|NCT01571765|Experimental|MNCH programming|protocols and training for data collection, referrals, and management for health district. Training in obstetrics, newborn care and management of sick children for health workers, Increased community health promotion such as training of CHWs, health centre management teams and bednet distribution
3270754|NCT01571765|No Intervention|no added MNCH activities|
3270755|NCT01571778|Experimental|Donning Gloves without Hand Hygiene|In this arm, healthcare workers will be assigned to don non-sterile gloves prior to patient contact WITHOUT first performing hand hygiene. Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3270756|NCT01571778|No Intervention|Hand Hygiene before donning Non-Sterile Gloves|In this arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (This is usual,expected practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
3270757|NCT01571791|Placebo Comparator|group SF|either saline infusion and intravenous fentanyl boluses
3270758|NCT01571791|Active Comparator|group KL|ketorolac-lidocaine infusion and intravenous saline boluses
3270759|NCT01571804|Active Comparator|pregabalin 150 mg group|one capsule of pregabalin 150 mg and one placebo capsule
3270760|NCT01571804|Active Comparator|pregabalin 300 mg group|two capsules of pregabalin 150 mg
3270761|NCT01571804|Placebo Comparator|placebo group|to receive two identical placebo capsules
3270762|NCT01571817|Experimental|Study intervention|endoscopically-guided intestinal submucosal transplantation of Isolated Human Pancreatic Islets in a type 1 diabetic patient
3270763|NCT01571843|Experimental|PHPT/ Walking + Forearm exercise|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
3270764|NCT01571843|Placebo Comparator|PHPT/ Walking alone|Ten participants with PHPT will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
3270765|NCT01571843|Active Comparator|Osteopenia/ Walking + Forearm exercise|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the forearm exercise program plus walking.
3270766|NCT01571843|Placebo Comparator|Osteopenia/ Walking alone|Ten healthy, postmenopausal women with osteopenia will be randomized to the intervention of 52 weeks of the walking program alone. Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks.
3270767|NCT01571856|Active Comparator|zinc sulfate|zinc sulphate solution.
3270768|NCT01571856|Placebo Comparator|cornstarch solution|cornstarch powder diluted in distilled water
3270769|NCT01571869|Experimental|1 = Tested product|
3270770|NCT01571869|Placebo Comparator|2 = Control product|
3270771|NCT01571882|Experimental|1 = Tested product 1|
3270772|NCT01571882|Experimental|2 = tested product 2|
3270773|NCT01571882|Active Comparator|3 = Active control product|
3270774|NCT01571895|Experimental|DF 2156A 150 mg|150 mg capsule twice a day (every 12 h) for a maximum of 14 days
3270775|NCT01571908|Experimental|Magnesium perfusion - Rocuronium|60 mg/kg of magnesium perfusion over 15 minutes before Anaesthesia. After Anaesthesia induction 0.6 mg/kg of Rocuronium intravenously
3270776|NCT01571908|Active Comparator|Placebo perfusion - Succinylcholine|1ml/kg of saline (placebo) over 15 minutes before Anaesthesia. After Anaesthesia induction 1 mg/kg of Succinylcholine intravenously
3270777|NCT01571921|Experimental|Gamma-Delta Tocotrienol|
3270778|NCT01571921|Active Comparator|TRF|
3270779|NCT01571934||Mild or moderate hemophilia A|Subjects with mild or moderate hemophilia A (fVIII activity 1-40%) who are scheduled to undergo surgery for which at least 5 consecutive days of fVIII replacement therapy is required.
3270780|NCT01571947|Active Comparator|SFA|
3270781|NCT01571947|Active Comparator|MUFA|
3270782|NCT01571947|Active Comparator|PUFA|
3270783|NCT01571947|Active Comparator|CARB|
3270784|NCT01571960|Experimental|Group 1: study vaccine|Participants in this arm will receive a 0.3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 224.
3270785|NCT01571960|Placebo Comparator|Group 1: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 224.
3270786|NCT01571960|Experimental|Group 2: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112, 168, and 303.
3270787|NCT01571960|Placebo Comparator|Group 2: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112, 168, and 303.
3270788|NCT01571960|Experimental|Group 3: study vaccine|Participants in this arm will receive a 3-mg dose injection of GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of MVA62B vaccine at Days 112 and 224.
3270789|NCT01571960|Placebo Comparator|Group 3: placebo vaccine|Participants in this arm will receive injections of placebo for GEO-D03 DNA vaccine at Days 0 and 56, followed by injections of placebo for MVA62B vaccine at Days 112 and 224.
3270790|NCT01571973|No Intervention|control group|outpatients receiving usual care
3270791|NCT01571973|Experimental|intervention group|outpatients receiving pharmaceutical care or pharmacotherapeutic follow-up by 6 months
3270793|NCT01571999|Experimental|Severe renally impaired subjects|Approximately 9 subjects will complete each treatment arm
3270794|NCT01571999|Experimental|Matched healthy volunteers|Matched to the severe renal impairment subjects based on gender, ethnicity, body mass index (±15%) and age (±5 years). Approximately 9 subjects will complete each treatment arm
3270795|NCT01572012|Experimental|Subcutaneous Administration|Ondansetron + Hylenex administered subcutaneously
3270796|NCT01572012|Experimental|Oral Administration|Ondansetron administered orally
3270797|NCT01572012|Experimental|Intramuscular Administration|Ondansetron administered intramuscularly
3270798|NCT01572012|Experimental|Intravenous Administration|Ondansetron administered intravenously
3270799|NCT01572025|Experimental|DHEA supplementation|
3270800|NCT01572025|Placebo Comparator|Control|
3270801|NCT01572051|Experimental|Group 1A (3month plus phone)|This group will attend to two courses with a 3 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270802|NCT01572051|Experimental|Group 1B (3month no phone)|This group will attend to two courses with a 3 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270803|NCT01572051|Experimental|Group 2A (2month plus phone)|This group will attend to two courses with a 2 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270804|NCT01572051|Experimental|Group 2B (2month no phone)|This group will attend to two courses with a 2 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270805|NCT01572051|Experimental|Group 3A (1month plus phone)|This group will attend to two courses with a 1 month interval between them This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270806|NCT01572051|Experimental|Group 3B (1month no phone)|This group will attend to two courses with a 1 month interval between them This group will NOT receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270807|NCT01572051|Experimental|Group 4A (no course plus phone)|This group will NOT attend to any courses This group will receive phone calls This group will receive printed material This group will be reassessed in 6 months
3270808|NCT01572051|Experimental|Group 4B (no course no phone)|This group will NOT attend to any courses This group will NOT receive phone calls This group will only receive printed material This group will be reassessed in 6 months
3270809|NCT01572077|Experimental|FTHA/GDF PET imaging|"This study plans to enrol 60 subjects with Type I pulmonary arterial hypertension (PAH) and 20 healthy, age and sex individuals to serve as normal controls. These subjects will have no known cardiac or pulmonary disease.~Both groups will undergo FTHA/FDG PET imaging."
3270810|NCT01572090|Active Comparator|Conventional weight loss: CONV-NG|"Obese normoglycemic (NG) patients evidenced by a body fat ≥ 35% in women and ≥ 25% in men and a 2-h oral glucose tolerance test.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
3270811|NCT01572090|Active Comparator|Conventional weight loss: CONV-T2D|"Obese type 2 diabetic (T2D) patients evidenced by a body fat >35% in women and ≥ 25% in men and proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice.~Conventional weight loss will be achieved by Lifestyle changes including advice on increasing physical activity and prescription of a hypocaloric diet providing a daily energy deficit of 500-1000 kcal/d as calculated from the determination of the resting energy expenditure through indirect calorimetry (Vmax29, SensorMedics Corporation, Yorba Linda, CA) and multiplication by the physical activity level factor to obtain the individual's total energy expenditure. Regular visits with the dietitian will be scheduled as in the surgical groups."
3270812|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing a sleeve gastrectomy (SG). The Sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach. Via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
3270813|NCT01572090|Active Comparator|Laparoscopic Sleeve gastrectomy: SG-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing a sleeve gastrectomy (SG). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
3377009|NCT04872595|Experimental|P-rATG with busulfan, melphalan and fludarabine|"P-rATG days (Appendix A - always starting on Day -12 to -10)~Busulfan -Day -9 to -7~Initial dose per table in Appendix B; doses 2-3 to be adjusted per PK for target cumulative exposure of 65 mg*h/L Melphalan (70mg/m2/day x 2 days) Day -6 to -5~Fludarabine (25mg/m2/day x 5 days) Day -6 to -2~GCSF Day +7"
3377010|NCT04870827||Affected Subjects|Subjects diagnosed with moderate- severe psoriasis
3377011|NCT04870827||Healthy Controls|Females and males 18 years of age or older
3377012|NCT04868240|Experimental|Concurrent Training Group|The experimental group will perform 16-weeks of the concurrent training exercise.
3377013|NCT04868240|No Intervention|Control Group|Maintain their usual habits/activities, including not participate in any type of physical exercise.
3377016|NCT04865289|Experimental|Lenvatinib + Pembrolizumab|Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.
3377017|NCT04865289|Active Comparator|Paclitaxel + Carboplatin|Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.
3377018|NCT04864886||Healthy volunteers|Control group
3377019|NCT04864886||Patients with atopic dermatitis|Physician-diagnosed atopic dermatitis
3377020|NCT04864886||Patients with primary immunodeficiency|Confirmed by genetic diagnosis or suspected by genetic variant of unconfirmed significance and a history consistent with immunodeficiency
3377021|NCT04864886||Patients with psoriasis|Physician-diagnosed psoriasis
3377024|NCT04859582|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
3377025|NCT04859582|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
3270814|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypass: RYGB-NG|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) normoglycemic (NG) patients (evidenced by a 2-h OGTT) undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
3377030|NCT04856215|Experimental|90-Yttrium-labelled anti-CD66 monoclonal antibody|"The medicinal product consists of the murine IgG1 anti-CD66 monoclonal antibody radio-labelled with 111In for imaging and dosimetry and with 90Y for therapy.~Dosage indications The [111In]-labeled anti-CD66 monoclonal antibody (MAb) will be given at an infused activity of 100MBq/sqm between 1-4 weeks before the therapeutic dose of radiolabelled antibody.~[90Y]-yttrium-labeled anti-CD66 MAb will be given as a single infusion on day - 14 prior to transplant. [90Y]-yttrium labelled anti-CD66 MAb will be given to target an absorbed dose to the bone marrow of 45 Gy +/- 10%. The maximum dose to be delivered to the liver and the kidneys is 15 Gy and 10 Gy, respectively."
3377035|NCT04852276||Control particpants|Control participants will be healthy volunteers, and may include unaffected relatives of immunodeficient/dysregulated participants
3377036|NCT04852276||Patients with immunodeficiencies and immune dysregulations|Affected patients with evidence of a primary or secondary immune deficiency or dysregulation
3377038|NCT04839354|Experimental|Arginine Hydrochloride|Arginine is a nutritional supplement in parenteral form
3377039|NCT04839354|Placebo Comparator|Placebo|Normal saline
3377045|NCT04836754||Case group|Pregnant women with Covid-19
3377046|NCT04836754||Control groups|Pregnant women who do not have Covid-19
3377047|NCT04835714|Experimental|Part A with Monotherapy dose escalation|
3377048|NCT04835714|Experimental|Part B with Combination therapy dose escalation|
3377049|NCT04835714|Experimental|Part C with Combination therapy dose confirmation|
3377050|NCT04835714|Experimental|Part D with Combination therapy dose expansion|
3377051|NCT04835441|Experimental|ALPN-101|
3377052|NCT04835441|Placebo Comparator|Placebo|
3377053|NCT04833855|Active Comparator|Group 1: Omalizumab|Participants naive to anti-IgE therapies will receive omalizumab.
3270815|NCT01572090|Active Comparator|Laparoscopic R-Y gastric bypss: RYGB-T2D|The intervention in this arm comprises obese (BMI ≥ 40 kg/m2 or ≥ 35 kg/m2 with comorbidities) type 2 diabetic (T2D) patients with proven documentation of T2D diagnosis, history and treatment in accordance with good clinical practice undergoing laparoscopic Roux-en-Y gastric bypass (RYGB). In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
3270816|NCT01572103|Experimental|Administration of coffee|Administration of 4 cups of coffee/day for 1 month
3270817|NCT01572103|No Intervention|Coffee abstinence|Total coffee and caffeine containing beverages abstinence
3270818|NCT01572116|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
3270819|NCT01572116|Active Comparator|Lidocaine with Epinephrine + sufentanil|
3270820|NCT01572129|Experimental|Reload|600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
3270821|NCT01572129|Placebo Comparator|Placebo|Placebo arm in addition to the chronic daily dose of 75 mg
3270822|NCT01572142||Parkinson disease group|Subjects with Parkinson disease
3270823|NCT01572155|No Intervention|Sham stimulation|No stimulation of nervus vagus
3270824|NCT01572155|Active Comparator|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
3270825|NCT01572155|Active Comparator|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
3270826|NCT01572168|Experimental|Acupuncture|Eight sessions of weekly acupuncture
3270827|NCT01572181|Experimental|Drugs|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
3270828|NCT01572220|Other|stress echocardiography|Comparative effectiveness
3270829|NCT01572220|Other|Myocardial SPECT|CER
3270830|NCT01572233|Experimental|Patient with HCV Infection|Personalized Physical Activity and Psycho-Education (PPAPE) Program will be tested on this group.
3270831|NCT01572233|No Intervention|usual care|waiting list group with usual care
3270832|NCT01572246||Non-cardiac above-the-waist surgery|Subjects with an implanted ICD who present for a non-cardiac above-the-waist surgical procedure involving monopolar electrocautery
3270833|NCT01572246||Cardiac surgery|Subjects with an implanted ICD who present for a cardiac surgical procedure involving monopolar electrocautery
3270834|NCT01572246||Below-the-waist surgery|Subjects with an implanted ICD who present for a below-the-waist surgical procedure involving monopolar electrocautery
3270835|NCT01572259|Experimental|interruption of the growth hormone treatment.|
3270836|NCT01572259|Experimental|Patients traited by grouth hormone|
3270837|NCT01572272||Open|Open group: Data derived from the Capnostream20p and displayed to the medical team. It will allow the treating physician and the nursing team to review the real time data and make clinical decisions based upon it if felt necessary.
3270838|NCT01572272||Masked|Data derived from the Capnostream20p will be recorded; however the medical staff will be masked from it and hence will not use it.
3270839|NCT01572285|Sham Comparator|Sham|Sham arm received a simulation of transforaminal injection using a non-penetrating needle
3270840|NCT01572285|Experimental|Transforaminal|Subjects received TF with infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
3270841|NCT01572311|Experimental|Exercise Intervention Group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of dual-task gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week)
3270842|NCT01572311|Active Comparator|Exercise Control group|For 26 weeks, attend Canadian Centre for Activity and Aging combined classes (75-minute or 60-minute classes, 2 to 3 days/week) and also complete 45 minutes of gait training (15 minutes for 3 days/week or 22.5 minutes for 2 days/week). Note: no dual-task challenges during gait training
3270843|NCT01572324|Experimental|Arterial infusion|
3270846|NCT01572350|Active Comparator|Grid laser|It's a reference standard as the treatment which is currently accepted for NTDDME
3270847|NCT01572350|Experimental|Triamcinolone 4 mg|
3270848|NCT01572350|Experimental|Bevacizumab|
3270849|NCT01572363|Experimental|Sildenafil|All patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
3270850|NCT01572376|Experimental|Bone marrow stem cells|Bone marrow was obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for infusion into the wound.
3270851|NCT01572402|Experimental|Patients with type 2 diabetes|Study group: 40 individuals with type 2 diabetes treated by diet and/or oral hypogylycemic agents, diabetes duration at least 1 year, both men and women, age 30-65 years, BMI 27-50 kg/m². The subjects will be explained aims, methods and risks of the study and they will sign informed consent
3270852|NCT01572402|Active Comparator|Healthy subjects|Mean and women, age 30-70 years, no diabetes, no metabolic syndrome
3270853|NCT01572441||12-14 year olds|No intervention administered. This is a longitudinal observational study including observation of behaviors and physiological responses.
3270854|NCT01572454|Experimental|Dexmedetomidine group|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
3270855|NCT01572454|Active Comparator|Remifentanil group|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
3377054|NCT04833855|Placebo Comparator|Group 2: Placebo|Participants naive to anti-IgE therapies will receive a placebo.
3377055|NCT04833855|Experimental|Group 3: Tezepelumab Dose 1|Participants naive to anti-IgE therapies will receive tezepelumab.
3377056|NCT04833855|Experimental|Group 4: Tezepelumab Dose 2|Participants naive to anti-IgE therapies will receive tezepelumab.
3377057|NCT04833855|Placebo Comparator|Group 5: Placebo|Participants previously treated with anti-IgE therapies will receive a placebo.
3270866|NCT01572519|Experimental|JNJ-40346527|
3270867|NCT01572532|Experimental|Intervention Screening and Treatment|"CHWs will collect urine and vaginal samples for all women enrolled. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison. Vaginal specimens will be collected via sterile self-administered vaginal swabs. The women will be instructed by the CHW to insert a Dacron swab ~4-5 cm into the vagina, allow the swab to stand for 15 seconds, and then rotate 360 degrees prior to withdrawal. The CHW will gently roll out the swab onto a plain glass slide and allow to air dry prior to transport to Sylhet field laboratory.~A midstream urine specimen will be obtained for urine culture. The mother will be instructed to separate the labia and collect 20-30mL of midstream urine into a sterile container which will be immediately refrigerated in a cool specimen box."
3270868|NCT01572532|No Intervention|Control Arm|Standard care will be administered, including antenatal and postnatal care. In the control clusters, every eighth woman enrolled will receive the screening-treatment protocol in order to determine the baseline prevalence of these infections in the control areas for comparison.
3270869|NCT01572545|Experimental|Denosumab|
3270870|NCT01572545|Experimental|Zoledronic Acid|
3270871|NCT01572558|Active Comparator|Appendectomy|Standard surgical treatment, appendectomy
3270872|NCT01572558|Experimental|Conservative, non-surgical treatment|Non-operative treatment with intravenous and oral antibiotics
3270873|NCT01572597|Experimental|Acetylcystein|10-day triple therapy plus N-acetyl-cystein to remove the biofilm.
3270874|NCT01572597|Active Comparator|Metronidazole|10-day triple therapy plus metronidazole (concomitant therapy) as active comparator
3270875|NCT01572610|Experimental|RTA 402|
3270876|NCT01572623|Active Comparator|Antiplatelet before carotid artery stenting|Clopidogrel 600 mg after carotid artery stenting
3270877|NCT01572623|Active Comparator|Statin therapy before carotid artery stenting|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
3270878|NCT01572636||Laronidase use in Hurler Syndrome|Laronidase receiving prior and post transplant
3270879|NCT01572649|Placebo Comparator|Placebo|1 single administration (volume matched to the dose lixisenatide: 50 µL or 100µL) once a day subcutaneously
3270880|NCT01572649|Experimental|Dose 1|1 single administration of 5 µg lixisenatide (50 µL) once a day subcutaneously
3270881|NCT01572649|Experimental|Dose 2|1 single administration of 10 µg lixisenatide (100 µL) once a day subcutaneously
3270882|NCT01572662|Experimental|Fludarabine + Busulfan|"Fludarabine administered by vein at dose of 40 mg/m2 in 100 ml of normal saline (NS) on Days -6 through -3.~First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
3270883|NCT01572688|Experimental|autologous stem cell transplant|
3270884|NCT01572701|Experimental|20 (±3) mCi of study drug|
3270885|NCT01572714|Active Comparator|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
3270886|NCT01572714|Active Comparator|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
3270887|NCT01572714|Active Comparator|Physical Activity Plus Fatigue|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
3270888|NCT01572753|Experimental|Post-dose fasting 120 mins/50 ml water|
3270889|NCT01572753|Experimental|Post-dose fasting 60 mins/50 ml water|
3270890|NCT01572753|Experimental|Post-dose fasting 30 mins/50 ml water|
3270891|NCT01572753|Experimental|Post-dose fasting 15 mins/50 ml water|
3270892|NCT01572753|Experimental|Post-dose fasting 120 mins/120 ml water|
3270893|NCT01572753|Experimental|Post-dose fasting 60 mins/120 ml water|
3270894|NCT01572753|Experimental|Post-dose fasting 30 mins/120 ml water|
3270895|NCT01572753|Experimental|Post-dose fasting 15 mins/120 ml water|
3377058|NCT04833855|Experimental|Group 6: Tezepelumab Dose 1|Participants previously treated with anti-IgE therapies will receive tezepelumab.
3270896|NCT01572766|Active Comparator|FRAX Assessment|FRAX Assessment Tool administered by a pharmacist. This group also receives a heel ultrasound and pharmacist counseling.
3270897|NCT01572766|No Intervention|Control group|Control group receives heel ultrasound and pharmacist counseling
3270898|NCT01572779|Experimental|Intervention|BSM device with bio-feedback
3270899|NCT01572779|Placebo Comparator|Control|The BSM device without feed-back
3270900|NCT01572805|Active Comparator|melatonin 3mg|
3270901|NCT01572805|Active Comparator|melatonin 6mg|
3270902|NCT01572805|Placebo Comparator|placebo|
3270903|NCT01572818|Experimental|Phlebotomy|phlebotomy associated with dietary and lifestyle counseling
3270904|NCT01572818|Active Comparator|Lifestyle counseling|dietary and lifestyle counseling
3270905|NCT01572831|No Intervention|standard care|Abx will be determined by the managing physician
3270906|NCT01572831|Experimental|experimental arm|Abx determined by normalization of PCT and basic clinical parameters
3270907|NCT01572857||first phase|"This first phase aims to study the variations in urinary excretion of FLC immunoglobulin during the day and night to determine the appropriate time of day for collection of urine.~20 patients hospitalized."
3270908|NCT01572857||Second phase|"Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row. This value will check the quality of urine collection for 24 hours during the study.~30 patients hospitalized."
3270909|NCT01572870||No ABPA nor Aspergillus infection|CF patients who had neither ABPA nor Aspergillus infection in the past (the control group)
3270910|NCT01572870||persistent Aspergillus infection, without ABPA|CF patients with persistent Aspergillus infection, without ABPA.
3270911|NCT01572870||Current or past ABPA infection|CF patients with current or past ABPA
3270912|NCT01572896|Experimental|Taking Charge Experimental Group|
3270913|NCT01572896|Active Comparator|Control Group|
3270914|NCT01572961|Active Comparator|Aspirin|Aspirin
3270915|NCT01572961|Placebo Comparator|Placebo|Placebo
3270916|NCT01572974||No Barrett's esophagus|Subject without columnar lined esophagus
3270917|NCT01572974||Nondysplastic BE|Subject with columnar lined esophagus and absence of dysplasia
3270918|NCT01572974||Low grade dysplastic BE|subject with columnar lined esophagus and presence of low grade dysplasia
3270919|NCT01572974||High grade dysplastic BE|subject with columnar lined esophagus and presence of high grade dysplasia
3270920|NCT01572987|Active Comparator|RFA arm|Under this arm, study patients will undergo radiofrequency ablation.
3270921|NCT01572987|Active Comparator|EMR arm|Under this arm, the individuals will undergo endoscopic mucosal resection.
3270922|NCT01573013|Active Comparator|NaFeEDTA treatment, biscuit|Group receives 10 mg of Fe in form of NaFeEDTA per day. wheat flour based biscuit
3270923|NCT01573013|Active Comparator|EDTA treatment, biscuit|Group receives Na2EDTA enriched biscuit
3270924|NCT01573013|Active Comparator|FeSO4 treatment, biscuit|Group receives 10 mg of iron as FeSo4 per day for 8 months
3270925|NCT01573013|Placebo Comparator|control treatment, biscuit|group receives a biscuit without additional iron
3270926|NCT01573065|Experimental|Single arm|
3270927|NCT01573078||Crohn's disease patient|Outpatients who carry a diagnosis of Crohn's disease made by a gastroenterologist.
3270928|NCT01573091||Heart failure patients|Patients with a CRT device according to current guidelines
3270929|NCT01573104|Experimental|Biomarker group|Patients undergoing CPB having proteomic assays, blood sampling and biomarker assays performed on D0, D1, D2 and D3
3270930|NCT01573117|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
3270931|NCT01573117|Active Comparator|RhinoChill|Nasopharyngeal cooling with the RhinoChill device (BeneChill, USA)
3270932|NCT01573130|Experimental|Initial treatment group|Group receives treatment.
3270933|NCT01573130|No Intervention|Waiting list control group|The waiting list control group receives treatment after 9 weeks, before which they do weekly ratings.
3270934|NCT01573143|Placebo Comparator|Sugar pill|Placebo
3270935|NCT01573143|Experimental|Rosuvastatin|Rosuvastatin (20 mg od)
3270936|NCT01573156|Experimental|VTP treatment to small renal mass|
3270937|NCT01573182|Experimental|Donor|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the intramuscular (IM) route 4 to 6 weeks prior to stem cell harvesting..
3270938|NCT01573195||All prescribing MDs at UWHC|Observational for accept, reject, or accept with modification of Best Practice Alers
3270939|NCT01573208|Experimental|Register|Register
3270940|NCT01573221||stroke|
3270941|NCT01573234|Experimental|MySkin patch|Hydrogel and polyurethane film
3270942|NCT01573234|Active Comparator|Traditional Dressing|
3270943|NCT01573247|Experimental|AKN-028|
3270944|NCT01573286|Experimental|Intestinal Failure in children (>1 year)|Children requiring parenteral nutrition for >30% of calories more than 1 year (365) days post surgery will be eligible for treatment with Glucagon-like peptide 2 (20 ug/kg/day) for 6 weeks
3270945|NCT01573286|Experimental|GLP-2 in Infants (<1 year of age)|Infants under one year of age with congenital anomalies, or intestinal resection, leaving them with anatomic short bowel syndrome (total remaining small intestine less than 40 % of predicted for gestational age) or with intestinal resection or repaired gastroschisis who have demonstrated dependence on parenteral nutrition at 45 days post operation with the requirement for >50% of calories by PN (independent of the length of remnant small intestine) will be eligible for treatment with Glucagon-like peptide 2, at a dose of 5, 10 or 20 ug/kg/day.
3270946|NCT01573299|Active Comparator|Early vertical positioning|
3270947|NCT01573299|Active Comparator|Progressively vertical positioning|
3270948|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 with ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 micrograms(mcg) of H5N1 hemagglutinin plus AS03 given intramuscularly in two doses 28 days apart.
3270949|NCT01573312|Experimental|Inactivated monovalent influenza A/H5N1 without ASO3 adjuvant|Ten subjects will be vaccinated with 3.75 mcg of H5N1 hemagglutinin alone, given intramuscularly, in two doses 28 days apart.
3270950|NCT01573338|Experimental|Arm 1|BAY1000394 will be administered in combination with chemotherapy (etoposide and cisplatin or carboplatin) for up to 6 cycles. BAY1000394 will continue beyond Cycle 6 of chemotherapy. Type of chemotherapy for each patient will be decided by the investigator case by case.
3270951|NCT01573351|Experimental|QUAD: Asunaprevir+Daclatasvir+Peg-interferon Alfa-2a+Ribavirin|"Asunaprevir: Capsule, Oral, 100 mg, Twice daily, 24 weeks~Daclatasvir: Tablet, Oral, 60 mg, Once daily, 24 weeks~Peg-interferon Alfa-2a: Injection, subcutaneous (SC), 180 mcg/0.5 mL, Once weekly, 24 weeks~Ribavirin: Tablet, Oral, 1000 mg/1200 mg (total daily dose), 24 weeks"
3270952|NCT01573377|Experimental|metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
3270953|NCT01573377|Experimental|Ethinylestradiol and Cyproterone Acetate|From the first day of the menstruation, oral administration of one pill daily for 21 days consecutively, then discontinue using the pill for seven days, and on the eighth day, restart taking the pill.
3270954|NCT01573390||1|Healthy participants.
3270955|NCT01573403|Experimental|Treatment 1|one dose of DLBS2411 @250 mg
3270956|NCT01573403|Experimental|Treatment II|two doses of DLBS2411 @250 mg
3270957|NCT01573403|Placebo Comparator|Treatment III|
3270958|NCT01573416|Placebo Comparator|Control group|
3270959|NCT01573416|Active Comparator|Intervention group|
3270960|NCT01573468|Experimental|Capecitabine-tesetaxel|21-day cycle; tesetaxel 27 mg/m2 orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
3270961|NCT01573468|Active Comparator|Capecitabine-placebo|21-day cycle; placebo orally once on Day 1; capecitabine 1750 mg/m2/day orally in 2 equally divided doses on Days 1-14
3270962|NCT01573481|Active Comparator|Pressure support ventilation|"Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure support ventilation mode. The level of the pressure support is the same as the previous day.~During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased)."
3270963|NCT01573481|Active Comparator|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min). During the day (9 AM to 10 PM), patients are ventilated with pressure support ventilation (the level of pressure support is progressively decreased).
3270964|NCT01573494|Experimental|Metastatic melanoma patients|Sampling of blood before and after chemotherapy
3270965|NCT01573507|Experimental|sodium lactate infusion|Continuous i.v. infusion of Sodium Lactate (2'400 mOsmol/L) over 3 hours
3270966|NCT01573520|No Intervention|usual care|
3270967|NCT01573520|Active Comparator|adherence intervention arm|Monitoring drug adherence to guide treatment
3270968|NCT01573546|Experimental|Aerobic Exercise|
3270969|NCT01573546|Experimental|DASH diet|
3270970|NCT01573546|Experimental|Combined aerobic exercise and DASH diet|
3270971|NCT01573546|Active Comparator|Health education control|
3270972|NCT01573559||ClearView/Predicate|
3270973|NCT01573585|Active Comparator|Usual care|The usual care will consist of strength training, endurance, range of motion, patient education, weight shifting in standing and gait re-training.
3270974|NCT01573585|Experimental|FAST protocol|The Fast muscle activation and stepping training will be the Experimental arm of this trial. This program will be exercises emphasizing speed of movement.
3270975|NCT01573598|Placebo Comparator|Placebo|Dose-matched placebo capsules, oral administration
3270976|NCT01573598|Experimental|Vilazodone 20mg|Vilazodone tablets, 20 mg per day, oral administration
3270977|NCT01573598|Experimental|Vilazodone 40mg|Vilazodone tablets, 40 mg per day, oral administration
3270978|NCT01573611|Experimental|Grape Powder|
3270979|NCT01573611|Placebo Comparator|Placebo Powder|
3270980|NCT01573637|Experimental|Raloxifene hydrochloride 60 mg|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
3270981|NCT01573637|Placebo Comparator|Lactosa (placebo)|"Patients fulfilling inclusion criteria and those giving the general informed consent for the study will be randomly allocated to one of the two groups in the trial (placebo or raloxifene) in a 1:1 proportion and in blocks of 4 patients, using the random number tables designed for this purpose.~The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Both drugs will be given orally in capsule form. The medication of each of the treatment groups (lactose as placebo, raloxifene) will be introduced into dark green gelatin capsules to guarantee the blinding."
3270982|NCT01573663|Experimental|Ambroxol and Levodropropizine|
3270983|NCT01573663|Active Comparator|Ambroxol|
3270984|NCT01573663|Active Comparator|Levodropropizine|
3270985|NCT01573676||Bariatric surgery patients|Candidates for bariatric surgery.
3270986|NCT01573715|Active Comparator|severe ARDS patients|
3270987|NCT01573715|Active Comparator|control group|
3270988|NCT01573715|Experimental|moderate SDRA patients|
3270989|NCT01573728|Active Comparator|Low Exercise Arm|Low dose exercise (50 Minutes)
3270990|NCT01573728|Experimental|Public Health Exercise|Public Health dose exercise (150 minutes)
3270991|NCT01573741|Experimental|ketamine,four hours monitoring hydrochloride injection|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
3270992|NCT01573754|Experimental|Hydroxychloroquine|Low-dose hydroxychloroquine 100 mg by mouth twice weekly
3270993|NCT01573754|Active Comparator|Phlebotomy|Phlebotomy 450 mL biweekly
3270994|NCT01573780|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive gemcitabine hydrochloride IV over 30 minutes and smac mimetic TL32711 IV over 30 minutes once weekly for 2 weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
3270995|NCT01573793|Active Comparator|Intervention|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
3270996|NCT01573793|Sham Comparator|Control|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
3270997|NCT01573806|Active Comparator|Exenatide|Subjects dosed with exenatide in Phase 2
3270998|NCT01573806|Placebo Comparator|Exenatide vehicle|Subjects dosed with exenatide vehicle in Phase 2
3270999|NCT01573819|Experimental|Cohort 1|A dose of 2mg per day for 10 days
3271000|NCT01573819|Experimental|Cohort 2|A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg
3271001|NCT01573819|Experimental|Cohort 3|a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
3271002|NCT01573832|Experimental|Diabetic Foot Ulcer Intervention|
3271003|NCT01573832|No Intervention|Diabetic Foot Ulcer Usual Care|
3271004|NCT01573832|Experimental|Pionidal Sinus Ulcer Intervention|
3271005|NCT01573832|No Intervention|Pionidal Sinus Ulcer Usual Care|
3271006|NCT01573845|Experimental|Healthy Eating + Eco-Friendly Campaign|
3271007|NCT01573845|Active Comparator|Healthy Eating Campaign|
3271008|NCT01573845|No Intervention|Control/Delayed Intervention|
3271009|NCT01573858|Experimental|Acupuncture treatment 1 plus CC|
3271010|NCT01573858|Active Comparator|Acupuncture treatment 2 plus CC|
3271011|NCT01573858|Active Comparator|Acupuncture treatment 1 plus CC placebo|
3271012|NCT01573858|Active Comparator|Acupucture treatment 2 and CC placebo.|
3271013|NCT01573871|Experimental|Hydrolyzed infant formula|Hydrolyzed infant formula to be fed ad libitum
3271014|NCT01573897||Foot-wound without SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) without sleep apnea syndrome
3271015|NCT01573897||Foot-wound with SAS|patients with diabetic foot wound(or at risk of diabetic foot wound) with sleep apnea syndrome
3271016|NCT01573923|Sham Comparator|Conventional therapy|only apply for conventional medical therapy without any cell therapy
3271017|NCT01573923|Active Comparator|mesenchymal stem cells|combination of conventional therapy with umbilical mesenchymal stem cells intravenous injection, (4x107/40ml, once per three months, four times in one year)
3271018|NCT01573936|Experimental|rehabilitation program|Rehabilitation program from January 2008 through July 2010, which consists of 40-minutes of many therapies for 1-2 days a week
3271019|NCT01573975|Experimental|Seq-Metronidazole|10-day sequential therapy with metronidazole
3271020|NCT01573975|Experimental|Seq-Tetracycline|10-day sequential therapy with tetracycline.
3271021|NCT01573975|Active Comparator|Control|10-day standard triple therapy.
3271022|NCT01573988|Other|non-obese volunteers|Volunteers with a BMI (Body Mass Index) between 20 and 25 kg/m2.
3271023|NCT01573988|Other|Obese volunteers|Volunteers with a BMI (Body Mass Index) between 30 and 35 kg/m2.
3271024|NCT01574001|Experimental|Antismoking intervention with minimal early follow-up|"an intervention according to the 5A's model with one follow-up visit within one week after discharge from the hospital; follow-up assessment will include two visits: 3 and 12 months after stroke"
3271025|NCT01574001|Active Comparator|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
3271026|NCT01574001|Experimental|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
3271027|NCT01574014|Active Comparator|1: CBGT & Hydrocortisone|
3271028|NCT01574014|Placebo Comparator|2: CBGT & Placebo|
3271029|NCT01574027|Placebo Comparator|Placebo|Some participants were given a placebo pill to take daily for the length of the study. The placebo patients were used as a control group to compare against those taking the Vitamin D supplement.
3271030|NCT01574027|Experimental|Vitamin D3 (cholecalciferol)|Other participants were administered Vitamin D3 (cholecalciferol) for the six month study duration to determine if it would decrease the number of aberrant crypt foci in the colon as compared to the baseline number.
3271031|NCT01574040|Experimental|Staff (and visitors) of the University Medical Centre Utrecht|This is a dynamic study population
3271032|NCT01574066|Experimental|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
3271033|NCT01574092|Experimental|Irinotecan plus Cisplatin combination|This is a open-label study with only one treatment experimental arm. The patients will be treated, in a weekly basis, with 30 mg/m2 of cisplatino plus 65 mg/m2 of irinotecán (one cycle), until a total of 16 cycles.
3271034|NCT01574118|Experimental|Brief Enhanaced Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting the Trauma memories~Processing the trauma memories~In vivo Exposure homework~*Use of a brief pre-exposure trauma memory retrieval trial~Exposure to video clips related to the patient's trauma~Compound extinction - simultaneously exposing patient to trauma video clips while they listen to their trauma script"
3271035|NCT01574118|Active Comparator|Standard Prolonged Exposure Therapy|"The following interventions are included in this arm:~Psycho-education addressing common reactions to trauma~Revisiting of the Trauma memories~Processing the trauma memories~Breathing retraining~In vivo Exposure homework"
3271036|NCT01574118|No Intervention|Delayed Treatment Control|Patients assigned to this arm receive assessment only (Week 0, 3, and 6) prior to receiving standard prolonged exposure therapy using the Foa et al treatment manual.
3271037|NCT01574131|Placebo Comparator|Sugar pill|pill
3271038|NCT01574131|Active Comparator|Fenofibrate|ppar-alpha agonist
3271039|NCT01574196||Young adult survivors of childhood cancer|Young adult survivors of childhood cancer diagnosed between 1987 and 1992 in the Rhône-Alpes and Auvergne regions of France.
3271040|NCT01574209||Celiac Disease|Patients suffering from coeliac diseases confirmed by small intestinal biopsy
3271041|NCT01574209||IBS patients|Patients suffering from irritable bowel syndrome (IBS) according to Rome III criteria
3271042|NCT01574209||Healthy subjects|Healthy subjects as control group
3271043|NCT01574222|Experimental|Arm 1|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling
3271044|NCT01574235||Curative or prophylactic Nivestim® treatment for FN|
3271045|NCT01574261|Active Comparator|Inositol|Patients will be randomized to receive Inositol 4 g/die per os for four months of treatment
3271046|NCT01574261|Placebo Comparator|Placebo|Patients will be randomized to receive placebo for four months
3271047|NCT01574274|Active Comparator|SC-PEG|SC-PEG
3271048|NCT01574274|Active Comparator|Oncaspar|Oncaspar
3271049|NCT01574300||Biospecimens and biofluids|"This is a multi-cohort parallel study in which tumor, plasma and serum samples will be collected prior to the start of any therapeutic intervention for stage IV lung cancer. These biospecimens will be correlated with treatment and clinical data and distributed for peer reviewed research purposes to academic and community centers in the U.S. and Europe.~The biospecimens collected in CASTLE will be analyzed for a panel of biomarkers, currently including:~tumor: epidermal growth factor receptor (EGFR), KRAS (Kirsten RAt Sarcoma) gene and EML4-ALK (echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase) translocations, and EGFR, TS (thymidylate synthase), ERCC1 (excision repair cross-complementing 1) and RRM1 (Ribonucleotide Reductase, M1 Subunit) gene expressions~serum: proteomics predictive for EGFR-TKI (tyrosine kinase inhibotors)response"
3271050|NCT01574313|Experimental|Stellate ganglion block|treated with SGB
3271051|NCT01574313|Active Comparator|Oral medication|treated with oral medications: 0.25mg of erispan@ (fludiazine) , 25mg cephadol@ (diphenidol), and 200mg kentons@ (tocopherol nicotinate).
3271052|NCT01574339|Experimental|Treatment Arm|
3271053|NCT01574365|Experimental|RTA402|
3271054|NCT01574365|Experimental|RTA402 Low|
3271055|NCT01574365|Experimental|RTA402 Medium-low|
3271056|NCT01574365|Experimental|RTA402 Medium-high|
3271057|NCT01574378|Active Comparator|Control arm|Control arm- conventional method of wound closure
3271058|NCT01574378|Experimental|V-Loc group|V-Loc 90 barbed sutures
3271059|NCT01574391|Active Comparator|EPIDRUM|EPIDRUM DEVICE IS USED TO SITE THE EPIDURALS IN THE PATIENTS RANDOMISED TO THIS ARM
3271060|NCT01574391|No Intervention|Control|This arm is the control where normal technique is used
3271061|NCT01574404|Experimental|Polar Body Biopsy with PGS|Polar Body Biopsy with Pre implantation genetic screening
3271062|NCT01574417|Experimental|Plant stanol-enriched margarine|
3271063|NCT01574417|Placebo Comparator|control margarine|
3271064|NCT01574430|Active Comparator|50% dose PDT|patients in this group was given 50% verteporfin dose PDT
3271065|NCT01574430|Experimental|30% dose PDT|patients in this group was given 30% verteporfin dose PDT
3271066|NCT01574443||epilepsy resection patients|Patients undergoing resection for refractory epilepsy
3271067|NCT01574456||7 patients diagnosed with dementia of the Alzheimer's type|
3271068|NCT01574456||13 patients with mild cognitive impairment|
3271069|NCT01574456||19 healthy controls|
3271070|NCT01574469|Active Comparator|1 = Tested product|
3271071|NCT01574469|Placebo Comparator|2 = Control product|
3271072|NCT01574482|Experimental|1 = Tested product|
3271073|NCT01574482|Placebo Comparator|2 = Control product|
3271074|NCT01574495|Experimental|Error Augmentation-Control|
3271075|NCT01574495|Experimental|Control-Error Augmentation|
3271076|NCT01574508|Experimental|Continuous Subcutaneous Insulin Infusion|CSII
3271077|NCT01574508|Active Comparator|Multiple Daily Insulin Injections|MDI
3271078|NCT01574521||Only father carrier|fetuses whose fathers were HBV carriers whereas mothers negatively.
3271079|NCT01574521||only mother carrier|fetuses whose mothers were HBV carriers whereas fathers negatively.
3271080|NCT01574521||both parents carriers|fetuses whose both parents were HBV carriers
3271081|NCT01574534|Experimental|Drug eluting balloon|paclitaxel-eluting SeQuent® Please balloon, B.Braun Melsungen AG, Berlin, Germany
3271082|NCT01574534|Active Comparator|Drug eluting stent|paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA or everolimus-eluting Xience® stent Abbott Vascular, Santa Clara, California, USA
3271083|NCT01574547||Cat Scratch Colon|Patients with mucosal tears during colonoscopy
3271084|NCT01574547||Control group|Patients without mucosal tears during the colonoscopy
3271085|NCT01574560|Active Comparator|Control Group - Health Education|This group is provided with information regarding secondhand smoke and creating a healthy home environment.
3271086|NCT01574560|Active Comparator|Treatment Group - Counseling|This group is provided with biomarker feedback on child exposure to secondhand smoke. Active participants receive 5 counseling sessions from a trained research counselor; 3 sessions in the home and 2 by phone. The counseling sessions focus on changing smoking behaviors and/or other behaviors that impact smoking.
3271087|NCT01574573|Experimental|Obese individuals with weight loss|Self support, group sessions
3271088|NCT01574573|Experimental|Obese individuals without weight loss|self support, group sessions
3271089|NCT01574586|Active Comparator|2-link stent Nobori|Bifurcation stenting
3271090|NCT01574586|Active Comparator|3-link stent Xience|Bifurcation stenting
3271091|NCT01574599|Experimental|Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
3271092|NCT01574599|No Intervention|Conventional Therapy Program|Typical therapy excluding robotics, RFE
3377059|NCT04833855|Experimental|Group 7: Tezepelumab Dose 2|Participants previously treated with anti-IgE therapies will receive tezepelumab.
3377063|NCT04832854|Experimental|Cohort A (PD-L1 High)|"Participants with high programmed death-ligand 1 (PD-L1) expression level will be enrolled in Cohort A and receive neoadjuvant atezolizumab plus tiragolumab for 4 cycles, followed by surgical resection and either adjuvant atezolizumab plus tiragolumab for 16 cycles or adjuvant chemotherapy for 4 cycles at the discretion of the investigator.~Chemotherapy may include:~cisplatin/carboplatin + pemetrexed (for non-squamous only)~cisplatin/carboplatin + gemcitabine (for squamous only)~carboplatin + paclitaxel"
3377064|NCT04832854|Experimental|Cohort B (PD-L1 All Comers)|"All comers, which are participants with any PD-L1 expression level, will be enrolled in Cohort B and receive neoadjuvant atezolizumab plus tiragolumab plus chemotherapy for 4 cycles, followed by surgical resection and adjuvant atezolizumab plus tiragolumab for 16 cycles.~Chemotherapy may include:~cisplatin/carboplatin + pemetrexed (for non-squamous only)~cisplatin/carboplatin + gemcitabine (for squamous only)~carboplatin + paclitaxel"
3377065|NCT04830709||PARPi maintenance cohort (PMC)|patients who received at least one dose of PARPi as 1L MTX after 1L platinum-based CTX
3271093|NCT01574625||Mosaic prosthetic heart valve|All patients who were enrolled and implanted with a Mosaic bioprosthesis in the Albertinen-Krankenhaus (Hamburg, Germany) during the previous Mosaic PMA study and who agree to participate in this long-term follow-up study by informed consent.
3271094|NCT01574638|Experimental|Arm 1B|Participants in Arm 1B will receive RPT based on weight at entry, at a dose of 20 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 10 mg/kg twice daily with low-fat meals.
3377066|NCT04830709||Bevacizumab maintenance cohort (BMC)|patients who continue to receive at least one dose of bevacizumab after 1L platinum-based CTX and who have not received PARPi MTX treatment
3377067|NCT04830709||No maintenance cohort (NMC)|patients who never received any 1L MTX treatment (PARPi or bevacizumab)
3271095|NCT01574638|Experimental|Arm 1A|Participants in Arm 1A will receive RPT based on weight at entry, at a dose of 10 mg/kg twice daily with low-fat meals, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 20 mg/kg once daily with a low-fat breakfast.
3271096|NCT01574638|Experimental|Arm 2A|Participants in Arm 2A will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a boiled egg, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 70, at a dose of 15 mg/kg once daily with a low-fat breakfast.
3377068|NCT04827394|Experimental|Intervention group|In the intervention group, the infant will be placed on the thermal mattress, then wrapped.
3377069|NCT04827394|No Intervention|Control group|In the non-intervention group, the infant will be delivered onto the sterile field as per standard of care.
3377071|NCT04822961|Experimental|Senaparib (IMP4297) 20 mg|During the treatment period, eligible patients will receive single agent of Senaparib at a dose of 100 mg once daily (QD), continuously on a 4-week cycle
3377072|NCT04822961|Placebo Comparator|Placebo|During the treatment period, eligible patients will receive placebo QD, continuously on a 4-week cycle
3377073|NCT04818346|Experimental|INCB054707 Dose A followed by Dose C|Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
3377074|NCT04818346|Experimental|INCB054707 Dose B|Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).
3377075|NCT04818346|Experimental|INCB054707 Dose C|Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).
3377076|NCT04818346|Placebo Comparator|Placebo followed by INCB054707 Dose C|Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).
3377077|NCT04816526|Experimental|Descartes 08|
3377080|NCT04812665||Qualitative sub-study (SS1)|One group of caregivers (n = 10) will engage with the mHealth solution during 1 month. Subsequently, an individual semi-structured interview with each of the participants will proceed to gather user experience qualitative information.
3377081|NCT04812665||Quantitative sub-study (SS2)|A different group of caregivers (n = 55) will engage with the mHealth solution during 3 months. As elaborated in the following sections, a quantitative approach will be adopted to assess different emotional and behavioral parameters before and after engaging with the mHealth solution (pre-post design).
3377085|NCT04807595||Retrospective cohort|Patients with confirmed diagnosis of HER2-neg, unresectable and/or mBC regardless of hormone status dating back from 31 December 2017 - but no older than 01 January 2015 - who progressed on any systematic anti-cancer therapy will be involved in this study.
3377086|NCT04806282||1/All Patients|Documented hearing instability
3377087|NCT04805671|Experimental|ADG20 IM|Participants will be dosed on Day 1 with ADG20 IM
3377088|NCT04805671|Placebo Comparator|Placebo IM|Participants will be dosed on Day 1 with placebo IM
3271097|NCT01574638|Experimental|Arm 2B|Participants in Arm 2B will receive RPT based on weight at entry, at a dose of 15 mg/kg once daily with a low-fat breakfast, on Days 1 to 14. Participants will not receive RPT on Days 15 to 42 and will resume receipt of RPT on Days 43 to 56, at a dose of 15 mg/kg once daily with a boiled egg.
3271098|NCT01574664||Subjects scheduled to undergo lumpectomy|
3271099|NCT01574677||Screening FIT positive|Patients aged 49-80, with a positive screening FIT, who are referred to colonoscopy, and who meet inclusion criteria.
3271100|NCT01574690||Heart failure patients|50 subjects (both male and female) Heart failure patients already receiving RHC as part of their usual care
3271101|NCT01574729|Active Comparator|Surgery plus post-surgery chemotherapy|Surgery plus post-surgery chemotherapy
3271102|NCT01574729|Experimental|Surgery combined with rAd-p53 gene therapy|Surgery combined with the surgery wound surface injection of rAd-p53 plus post-surgery chemotherapy
3271103|NCT01574742|Experimental|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
3271104|NCT01574781||Women with abnormal fetus|Women carrying fetus that is identified as chromosomally abnormal by CVS/Amniocentesis
3271105|NCT01574781||Women experiencing miscarriage|Women identified as miscarrying, prior to any D&C or D&E procedure
3271106|NCT01574781||Born children|The children born from women participating in other cohorts of the study.
3271107|NCT01574781||Male relatives|The male partners (and presumed biological father of any fetuses/children) of women participating in other cohorts of the study or the biological father's brother and/or father.
3271108|NCT01574781||Non-pregnant women|Healthy women who are not pregnant
3271109|NCT01574781||Pregnant women|
3271110|NCT01574794|Experimental|Strengthening Exercises|Recreational older runners recruited from local community
3271111|NCT01574794|Experimental|Stretching Exercises|Recreational older runners recruited from local community
3271112|NCT01574794|No Intervention|Control Group|Recreational older runners recruited from local community
3271113|NCT01574820|Placebo Comparator|placebo|
3271114|NCT01574820|Experimental|rosiglitazone (4 mg)/day|
3271115|NCT01574833|Active Comparator|PEMF|arm that receive PEMF treatment
3271116|NCT01574833|Sham Comparator|Sham|arm that receive sham treatment
3271117|NCT01574846||Vantas|
3271118|NCT01574859||hypopituitarism|group of patients with hypopituitarism
3271119|NCT01574872|Experimental|Aerosal|This arm include all patients treated with Aerosal®
3271120|NCT01574872|Placebo Comparator|Placebo|This arm include all patients treated with placebo
3271121|NCT01574885|Experimental|Aerosal|This arm include all patients treated with Aerosal®
3271122|NCT01574885|Placebo Comparator|Placebo|This arm include all patients treated with placebo
3271123|NCT01574898|Active Comparator|Niquitin® Fresh Mint 4 mg|
3271124|NCT01574898|Active Comparator|V0118 - B mg|
3271125|NCT01574898|Experimental|V0474 - C mg|
3271126|NCT01574898|Experimental|V0474 - B mg|
3271127|NCT01574898|Experimental|V0474 - A mg|
3271128|NCT01574911||healthy adults|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
3271129|NCT01574911||Adults Chronic venous insufficiency|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D laser scanning
3271130|NCT01574911||patients primary lymphedema|The objective of this project is the validation of real time reconstruction and calculation of limb volume using a 3 D laser scanner In each subject limb volume will be measured once by water - displacement and twice by 3D
3271131|NCT01574924||Medical residents|
3271132|NCT01574937|Experimental|Treatment Arm|Cabozantinib and abiraterone
3271133|NCT01574963||CAD Patients|Patients suffering from CAD requiring coronary artery bypass grafting
3271134|NCT01574963||Control Patients|Patients without CAD
3271135|NCT01574976|Active Comparator|control, no feeback|subjects without ADHD, probabilistic choices without feedback
3271136|NCT01574976|Active Comparator|control, feedback|subjects without ADHD, probabilistic choices with feedback
3271137|NCT01574976|Experimental|ADHD, no feedback|subjects with ADHD, probabilistic choices without feedback
3271138|NCT01574976|Experimental|adhd, feedback|subjects with ADHD, probabilistic choices with feedback
3271139|NCT01574989|Experimental|Active low-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, low-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3271140|NCT01574989|Experimental|Active high-frequency rTMS/sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the rTMS will be active, high-frequency, and the tDCS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3271141|NCT01574989|Experimental|Sham rTMS/active anodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, anodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3271142|NCT01574989|Experimental|Sham rTMS/active cathodal tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, however only one will be active. For this arm, the tDCS will be active, cathodal, and the TMS will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3271143|NCT01574989|Sham Comparator|Sham rTMS/Sham tDCS|Subjects will have both the rTMS and tDCS on their scalp during the session, and both interventions will be sham. They will undergo only one session of this condition, and it will last 20 minutes.
3271144|NCT01575002|Experimental|Active tDCS|Subjects will undergo 20 minutes of active tDCS stimulation.
3271145|NCT01575002|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham tDCS stimulation.
3271146|NCT01575015|Active Comparator|Standard intraoperative support (no CRRT)|
3271147|NCT01575015|Experimental|Intraoperative renal support (CRRT)|
3271148|NCT01575041|Active Comparator|Sodium|For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
3271149|NCT01575041|Active Comparator|Potassium|For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
3271150|NCT01575041|Placebo Comparator|Placebo|For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
3271151|NCT01575067||blood pressure monitor|Cuff circumference:22cm-42cm
3271152|NCT01575067||stethoscopy|Cuff circumference: 22cm-42cm
3271153|NCT01575119|Experimental|In-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
3271154|NCT01575119|Active Comparator|In-patient|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
3271155|NCT01575119|Experimental|Out-patient surgery|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
3271156|NCT01575119|Active Comparator|Out-patient|Standard of care information, including distributing a patient education brochure, to provide information regarding perioperative smoking
3271157|NCT01575132||Parkinson's Disease, DBS, 10-14 years|
3271158|NCT01575145|Experimental|Quitline facilitation intervention|brief quitline facilitation intervention given
3271159|NCT01575145|Active Comparator|Stop-smoking intervention|brief review of tips to maintain smoking abstinence, using brochure
3271160|NCT01575158|Experimental|citalopram|citalopram
3271161|NCT01575158|Active Comparator|clomipramnine|clomipramine
3271162|NCT01575158|Placebo Comparator|placebo|placebo
3271163|NCT01575171||"Intervention/Nudge"|"Individuals will be analyzed according to their assigned intervention group, to compare the effectiveness of an opt-out EHR decision support system to enhance the prescription of statins to those patients with an elevated LDL-C and to subsequently titrate the medication dose until LDL-C control is obtained. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
3271164|NCT01575184|Experimental|Shoulder traction|The ultrasonographic measurements with shoulder traction
3271165|NCT01575184|Active Comparator|No traction|The ultrasonographic measurements without shoulder traction
3271166|NCT01575210|Experimental|Group A_ washing procedure 1|This group will apply washing technique 1.
3271167|NCT01575210|Experimental|Group B_washing procedure 2|This group will apply washing technique 2.
3271168|NCT01575223|Active Comparator|High volume saline irrigation|Patients in this group will receive high volume saline irrigation (NeilMed sinus rinse)
3271169|NCT01575223|Placebo Comparator|Placebo|Patients in this group will receive low volume saline irrigation (Salinex)
3271170|NCT01575236|Experimental|Guardian|Guardian Laryngeal Mask
3271171|NCT01575236|Experimental|Supreme|Supreme Laryngeal Mask Airway
3271172|NCT01575249||Asymptomatic group|one hundred patients with a negative exercise stress echo for symptoms/ECG/wall motion abnormalities (WMA), negative spirometry test for pulmonary disease, without known CAD or other valvular diseases, in sinus rhythm and with a LVEF>55%
3271173|NCT01575249||Symptomatic group|one hundred patients with symptomatic AS (negative pulmonary tests but positive stress echo or prior CAD or other valvular diseases and a LVEF>55%
3271174|NCT01575262|Experimental|Incentive|Participants use their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of physical activity = 1 point; capped at 30 points per day) over the 12-week intervention period. Points are redeemed for rewards (extrinsic motivation) at week 6 and week 12.
3271175|NCT01575262|Active Comparator|No Incentive|Participants used their PAL card to self-monitor their physical activity levels (intrinsic motivation) over the 12-week intervention period but do not collect points or earn rewards.
3271176|NCT01575288|Placebo Comparator|Maltose|
3271177|NCT01575288|Experimental|High-dose trehalose|
3271178|NCT01575314|Experimental|stapling device|stapling device refer to patients who were randomized to use stapler for dividing lung parenchyma.
3271179|NCT01575314|No Intervention|hand sewn|hand sewn refer to patients who were randomized to use hand suturing for dividing lung parenchyma.
3271180|NCT01575327|Active Comparator|Fixed oxygen flow delivery|Oxygen flow delivery is adjusted by respiratory therapists. Standard medical treatment.
3271181|NCT01575327|Experimental|FreeO2 system|FreeO2 is a new system that automatically adjusts the oxygen flow delivered to patients in a closed-loop based on the SpO2 signal. This system is intended to maintain SpO2 in a predefined target and to adapt oxygen flow to patient's needs.
3271182|NCT01575340|Experimental|fish oil encapsuled|will receive the supplementation of 2 g / day of fish oil encapsulated for 9 weeks
3271183|NCT01575340|No Intervention|without supplementation|not will receive supplementation or encapsulated fish oil or placebo
3271184|NCT01575353|Active Comparator|Venturi mask|After extubation, patients will receive oxygen therapy through the standard Venturi mask (control)
3271185|NCT01575353|Active Comparator|Nasal high-flow|After extubation, patients will receive oxygen therapy through the nasal high-flow (intervention)
3271186|NCT01575366|Experimental|Slow tracking training|
3271187|NCT01575366|Experimental|Fast tracking training|
3271188|NCT01575392||Patients coming for creatinine clearance|For this single group study, all patients presenting at the laboratory facility for a 24-hour creatinine clearance and patients in the dialysis population of the Isala Clinics who came for their periodical KT/V control, were informed about the study and asked to participate. Moreover, 20 'healthy' volunteers (including the investigators of this study and staff working at the clinical chemistry department of the Isala clinics) participated in this study.
3271189|NCT01575405|Experimental|Rectal-specific formulation (RF) stage|During this stage, participants will receive seven rectally-administered doses of the rectal-specific formulation (RF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
3271190|NCT01575405|Active Comparator|Vaginal formulation (VF) stage|"During this stage, only one exposure to the vaginal formulation (VF) will be administered (as the seventh dose in the stage), but it will be coupled with six preceding exposures to the Universal HEC Placebo Gel to balance it out against the other three stages in the study.~First and last doses will be administered in clinic, and after the administration of the last dose, various specimens will be collected, including blood, vaginal and rectal fluid, and endoscopic biopsies. Additional blood and fluids will be collected at 2, 4, and 24 hours post seventh dose administration."
3271191|NCT01575405|Active Comparator|Reduced Glycerin Vaginal Formulation (RGVF) stage|During this stage, participants will receive seven rectally-administered doses of the reduced glycerin vaginal formulation (RGVF), with the first and last dose administered in clinic and five doses in between self-administered by a participant at home. Various specimens will be collected after administration of the last dose, including blood, vaginal and rectal fluids, and endoscopic biopsies. Blood and fluids will be additionally collected at 2hr, 4hr, and 24hr post-last-dose administration.
3271192|NCT01575418|Experimental|Rectal specific formulation (RF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3271193|NCT01575418|Active Comparator|Vaginal formulation (VF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3377094|NCT04794829||NIH staff|NIH staff who are 18 years and older. NIH staff may include employees and contractors, fellows and volunteers.
3377095|NCT04793217|Experimental|Improving AIDS Care after Trauma+|ImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. The ImpACT+ individual sessions will focus on coping skills and care engagement during an early critical period, while maintenance check-ins will serve to reinforce positive change and support the ongoing implementation of skills as new challenges arise.
3377096|NCT04793217|Active Comparator|Adapted Problem-Solving Therapy|Participants randomly assigned to the control condition will receive a brief adapted version of problem-solving therapy (PST), based on Problem Management Plus, a component of the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP). PST is a psychoeducational treatment focused on managing the negative effects of stressful life events. PST has been found to be effective for a range of problems, such as depression, and is recommended for implementation in low-resource settings.
3377097|NCT04789174|Active Comparator|Solriamfetol|Solriamfetol 75 mg/d Solriamfetol 150 mg/d
3377098|NCT04789174|Placebo Comparator|Placebo|
3377099|NCT04784715|Experimental|Arm A|Trastuzumab deruxtecan (T-DXd) with pertuzumab-matching placebo
3377100|NCT04784715|Experimental|Arm B|Trastuzumab deruxtecan (T-DXd) with pertuzumab
3377101|NCT04784715|Active Comparator|Arm C|Standard of care
3377102|NCT04784559|Experimental|Plitidepsin 1.5 mg arm|"Patients will receive plitidepsin 1.5 mg/day intravenous (IV) combined with dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) oral administration (PO)/IV from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution).~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
3377103|NCT04784559|Experimental|Plitidepsin 2.5 mg arm|"Patients will receive plitidepsin 2.5 mg/day intravenous (IV) combined with dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution).~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
3271194|NCT01575418|Active Comparator|Reduced glycerin vaginal formulation (RGVF) stage|Each participant will receive two inpatient doses of each radiolabeled study product. The first inpatient dose of each product will be administered without coital dynamics simulation (CDS), while the second inpatient dose will be followed by a CDS procedure at 1-hour post dose with instillation of radiolabeled autologous semen. There will be a washout period of at least 11 days between each dose.
3271195|NCT01575431||Stable angina|Patients who undergo an elective and successful single or multivessel percutaneous coronary intervention can be considered for the study.
3271196|NCT01575444||Home Based Vaginal Collection|Somali women who are randomized for Home based Vaginal Collection will be given a kit to perform the vaginal sample collection for HPV analysis, with detailed written instructions.
3271197|NCT01575444||Clinic Based Pap Test Collection|30 Somali women who are randomized for Standard Clinic Pap Group will be given a list of clinics that they can attend for cervical cancer screening using pap test. Follow-up will be done on test completion with the clinic at 3 months after enrollment.
3271198|NCT01575457|Experimental|Intervention|The Healthy Futures Program is an interactive, multi-session training program. The intervention participants will participate in College/vocational school, Job, and Career Planning activities with a career coach.
3271199|NCT01575457|Other|Comparison|The Healthy Futures Program is an interactive, multi-session training program. The comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
3271200|NCT01575470|Experimental|bone marrow mononuclear cells|a bone marrow harvest will be performed within 36 hours of injury followed by a single intravenous infusion of autologous bone marrow mononuclear cells (BMMNCs)
3271201|NCT01575483||Patients with T2DM|Patients with diagnosis of type 2 diabetes mellitus (T2DM) initiating Onglyza® treatment within the approved indications will be enrolled
3271202|NCT01575496|Active Comparator|Active tDCS|Subjects will receive 20 minutes of active tDCS.
3271203|NCT01575496|Sham Comparator|Sham tDCS|Subjects will receive 20 minutes of sham tDCS.
3271204|NCT01575548|Experimental|Arm I (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3271205|NCT01575548|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3271206|NCT01575574|Other|GADOXETIC ACID|Is a non comparative study. a magnetic resonance will be done using gadoxetic acid : 0.025mmol/Kg
3271207|NCT01575587|Experimental|Treatment A|
3271208|NCT01575587|Experimental|Treatment B|
3271209|NCT01575587|Experimental|Treatment C|
3271210|NCT01575587|Experimental|Treatment D|
3271211|NCT01575600|Active Comparator|10 mL/kg/h lactated Ringer's solution|Group 1, 10 mL/kg/h lactated Ringer's solution
3271212|NCT01575600|Experimental|30 mL/kg/h lactated Ringer's solution|Group 2, 30 mL/kg/h lactated Ringer's solution
3271213|NCT01575613|Experimental|Hotspot Targeting|Four hotspot-targeted interventions will be superimposed on ongoing control measures: hotspots will be targeted with a combination of IRS, long-lasting insecticide treated nets (LLINs), larviciding and a focal screening and treatment (FSAT)campaign.
3271214|NCT01575613|No Intervention|Control|Standard of care as determined by the Division of Malaria Control of the Kenyan Ministry of Health
3271215|NCT01575626|Active Comparator|first sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 0%, 7%, 4%
3271216|NCT01575626|Active Comparator|second sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 4%, 7%, 0%
3271217|NCT01575626|Active Comparator|third sevoflurane concentration|patients will be given 3 different end-tidal sevoflurane concentrations in the following order: 7%, 4%, 0%
3271218|NCT01575626|Active Comparator|Propofol|General anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model).Following tracheal intubation, concentration of propofol will be decreased till 0.
3271219|NCT01575639|Experimental|High dose|Oral Prednisolone will be given at dose of 4 mg/kg/day for 14 days
3271220|NCT01575639|Active Comparator|Usual dose|Oral prednisolone will be given at dose of 2 mg/kg/day for 14 days
3271221|NCT01575652|Active Comparator|ACE-I|Group using ACEIs
3271222|NCT01575652|No Intervention|ACE-I, 2|group not using ace-i
3271223|NCT01575665|Experimental|Partial Rebreathing Mask|A novel membrane breathing mask which facilitates a partial rebreathing of expired gas (thereby raising systemic CO2), while allowing a diffusion of oxygen from the atmosphere to the user, through the membranes.
3271224|NCT01575678|Active Comparator|Melatonin|
3271225|NCT01575678|Placebo Comparator|Lactose|
3271226|NCT01575704|Experimental|Sport|
3271227|NCT01575704|Other|Control|
3271228|NCT01575717|Experimental|Vitamin D 4000|Subjects taking 4000 IU of vitamin D
3271229|NCT01575717|Experimental|Vitamin D 2000|Subjects taking 2000IU of vitamin D
3271230|NCT01575717|No Intervention|No Intervention|
3271231|NCT01575730|Active Comparator|Oxaliplatin 37°C, high dose, 30 minutes|
3271232|NCT01575730|Placebo Comparator|Oxaliplatin 41 °C, high dose, 30 minutes|
3271233|NCT01575730|Active Comparator|Oxaliplatin 37°C, low dose, 90 minutes|
3271234|NCT01575743|Experimental|Aerobic Exercise|
3271235|NCT01575743|Other|healthy controls|
3271236|NCT01575782|Experimental|Chloroquine|
3271237|NCT01575795|Active Comparator|Ticagrelor 180mg loading dose|Ticagrelor 180mg loading dose
3271238|NCT01575795|Experimental|Ticagrelor 360mg loading dose|Ticagrelor 360mg loading dose
3271239|NCT01575821|Experimental|Eucalyptus honey ,|75 children
3271240|NCT01575821|Experimental|Labiatae honey|75 children allocated
3271241|NCT01575821|Experimental|Silan date extract (placebo)|75 children allocated
3271242|NCT01575821|Experimental|Citrus honey|75 children allocated
3271243|NCT01575847||Part I|"Part 1 will be a feasibility study conducted in the Emergency Department at UAMS and ACH. This Part will test the research use dipsticks and dipstick testing kit in subjects that are having APAP levels obtained as part of their medical evaluation.~Part 1 20 subjects~Part I~Inclusion Criteria:~Subject is 12-18 years of age. Subject has an APAP level ordered as part of clinical management.~Exclusion Criteria:~Previous recent history of APAP overdose in the previous 30 days."
3271244|NCT01575847||Part 2|"Part 2~Part 2 will be a non-intervention study in adults presenting to hepatology centers participating in the Acute Liver Failure Study Group (ALFSG). The dipstick will be tested in these subjects and the results will be compared to the HPLC-EC measurement of APAP protein adducts. The results of the dipstick testing will not be used for diagnosis or clinical decision-making.~Part 2 100 subjects~Part 2~Inclusion Criteria:~Subject is 18 years of age or older. Subject is enrolled in the ALFSG registry.~Exclusion Criteria:~None."
3377104|NCT04784559|Active Comparator|Control arm|"Dexamethasone phosphate 8 mg/day (equivalent to 6.6 mg dexamethasone base) IV on Days 1 to 3, followed by dexamethasone phosphate 7.2 mg (equivalent to 6 mg/day dexamethasone base) from Day 4 and up to a total cumulative dose of 60 mg of dexamethasone base (as per physician judgement according to patient clinical condition and evolution). Per local treatment guidelines, patients may receive a regulatory approved antiviral treatment, such as remdesivir (200 mg IV on Day 1 followed by 100 mg/day IV on Days 2 to 5) or favipiravir (1600 mg twice daily [BID] PO on Day 1, followed by 600 mg BID PO daily for 2 to 5 days). Antiviral to be used per approved product information in each country, different dosages could be used.~The study allows up to a total cumulative dose of 60 mg of dexamethasone base (calculation of the total dose will also include corticosteroids administered within 72 hours before the start of the study treatment and dexamethasone administered as premedication)."
3377107|NCT04775082|Experimental|Liraglutide 3.0 mg|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
3377108|NCT04775082|Placebo Comparator|Placebo|The treatment duration is 56 weeks and the follow-up period is 26 weeks.
3377109|NCT04774926|Experimental|Brolucizumab 6 mg|Participants will receive 3 monthly ocular injections followed by a q12w or q8w maintenance phase based on patient's disease activity (DA).
3377110|NCT04774289||1|Participants with NF1 seen at the NIH from 1/1/1998 to 1/1/2020
3377111|NCT04772742|Experimental|Eptinezumab|"Double-Blind Treatment Phase (at baseline): 100 mg eptinezumab by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
3377112|NCT04772742|Placebo Comparator|Placebo|"Double-Blind Treatment Phase (at baseline): Placebo by IV infusion~Open-Label Treatment Phase (at week 12): 100 mg eptinezumab by IV infusion"
3377120|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 1)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 1) according to 0.2-week schedule.
3377121|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 2)|Participants (n=330) aged 18-40 years old will received OCV-S (Lot 2) according to 0.2-week schedule.
3271245|NCT01575886|Experimental|Smoking cessation intervention|This group receives the teachable moment communication process intervention focused on smoking cessation and contributes data at baseline (Time 1) and post intervention (Time 2).
3377122|NCT04760236|Experimental|Oral Cholera Vaccine-Simplified (OCV-S) group (Lot 3)|Participants (n=935) aged 1-40 years old will received OCV-S (Lot 3) according to 0.2-week schedule.
3377123|NCT04760236|Active Comparator|Shanchol™ group|Participants (n=935) aged 1-40 years old will received Shanchol™ according to 0.2-week schedule.
3271246|NCT01575886|No Intervention|Delayed intervention group|This group serves as the comparison group for the evaluation of the smoking cessation intervention at Time 1 and Time 2 data collection to complete the group randomized trial. This group of clinicians then has Time 3 data collection focused on weight management receives a revised intervention focused on teachable moment communication for weight management and has Time 4 data collected to evaluate the teachable moment for weight management training as a pre-post design.
3271247|NCT01575925|Experimental|4 mg Oral POM + 40 mg Oral DEX|Oral POM at 4 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
3271248|NCT01575925|Experimental|2 mg Oral POM + 40 mg Oral DEX|Oral POM at 2 mg on days 1-21 of a 28-day cycle, Oral DEX at 40 mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on days 1, 8, 15 and 22 of a 28-day cycle
3271249|NCT01575938|Experimental|HIV group-based prevention intervention|The HIV prevention intervention is a 6-session group-based and manualized intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
3271250|NCT01575938|Active Comparator|Diet and nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
3271251|NCT01575938|No Intervention|Standard-of-care|This arm will receive HIV and STI testing and counseling only.
3271252|NCT01575951|Experimental|All patients|All participants enrolled.
3271253|NCT01575990|Experimental|Making A Decision About CRC Screening|A decision support intervention that is a literacy sensitive paper based tool with educational information targeted to the patient's age and gender.
3271254|NCT01575990|Placebo Comparator|Drivers 65 Plus|The placebo comparator is an attention control with information about driving tips for drivers age 65 and older.
3271255|NCT01576029|Active Comparator|Docetaxel|75 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
3271256|NCT01576029|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, every 3 weeks
3271257|NCT01576068|Other|High Risk Customers|Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
3271258|NCT01576081|Experimental|Unilateral orthotic intervention|The HEPHAISTOS orthotic was worn unilaterally for 56days by 11 healthy male subjects.
3271259|NCT01576094|Active Comparator|Milrinone|Milrinone (MR) lactate 1 mg/ml: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission; dose 3, after 2 hours of stability with dose 2, and maintained up to 48 hours. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
3271260|NCT01576094|Active Comparator|Levosimendan|
3271261|NCT01576107|Experimental|Physical activity|Exercise counseling (behavior change techniques)
3271262|NCT01576107|Experimental|Stress-management|Stress-management training
3271263|NCT01576133|Experimental|CAPABLE|Experimental group participants received up to 10 sessions; up to 6 with an OT, and up to 4 sessions with an RN, and ≤ $1200 of safety and functional modifications from a licensed handyman. These sessions happened in coordinated fashion over the course of 4 months.
3271264|NCT01576133|Active Comparator|Attention visits|Participants in the attention visit arm received 10 visits of one hour length spaced across 16 weeks. These visits included sedentary activities of their choice based on their goals and interests.
3271265|NCT01576185||Observational (xenograft models)|Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
3271266|NCT01576224|Experimental|Immediate mobilization|Patients start exercises immediately after osteosynthesis.
3271267|NCT01576224|Active Comparator|Later mobilization|Patients are allowed exercises after 14 days.
3271268|NCT01576237||healthy apheresis donors|healthy blood donors for blood cell aphereses
3271269|NCT01576250|Experimental|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
3271270|NCT01576263||Total knee arthroplasty|25 consecutive patients diagnosed for total knee arthroplasty.
3271271|NCT01576263||Total hip arthroplasty|27 patients diagnosed for total hip arthroplasty.
3271272|NCT01576289||Patients undergoing uppper endoscopy|Consecutive patients with and without symptoms of reflux disease who routinely undergo upper endoscopy from November 2011 through May 2012.
3271273|NCT01576302|Experimental|Diaphragmatic breathing|Training in diaphragmatic breathing as response incompatible with rumination.
3271274|NCT01576302|Active Comparator|Muscle relaxation|Patients in this arm of study will be taught muscle relaxation as intervention for rumination, instructed in habit-reversal paradigm to use after eating food or if urge to ruminate
3271275|NCT01576315|Experimental|itraconazole|"itraconazole 10 mg/mL oral solution~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
3271276|NCT01576315|Experimental|voriconazole|"voriconazole 40 mg/mL oral suspension :~patients > 40 kg body weight : 200 mg morning and evening.~patients < 40 kg body weight : 100 mg morning and evening.~dosage out of meal.~Without a loading dose"
3271277|NCT01576328|Experimental|Cohort 1|MPC dose 1 or Placebo
3271278|NCT01576328|Experimental|Cohort 2|MPC dose 2 or Placebo
3271279|NCT01576328|Experimental|Cohort 3|MPC dose 3 or Placebo
3271280|NCT01576354|Active Comparator|Prolonged-release Fampridine|
3271281|NCT01576354|Placebo Comparator|Placebo|
3271282|NCT01576380|Experimental|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
3271283|NCT01576393|Experimental|Home-Based family therapy|12 home-based family therapy sessions
3271284|NCT01576393|Active Comparator|Office-based family therapy|12 office-based family therapy sessions
3271285|NCT01576393|Placebo Comparator|Women's Health Education|12 womens's health education sessions
3271286|NCT01576419|Experimental|PG201 tablet|
3271287|NCT01576419|Active Comparator|Celecoxib capsule|
3271288|NCT01576432|Experimental|Breastfeeding + skin-to-skin contact|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
3271289|NCT01576432|Experimental|Sucrose + skin-to-skin contact|In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
3271290|NCT01576432|Experimental|Skin-to-skin contact|In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
3271291|NCT01576432|Active Comparator|Sucrose|In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother
3271292|NCT01576445|Experimental|Mid-vastus approach|
3271293|NCT01576445|Experimental|medial parapatellar approach|
3271294|NCT01576458|Active Comparator|ursodeoxycholic acid|10 pregant women with intrahepatic cholestasis of pregnancy
3271295|NCT01576458|Active Comparator|placebo|10 pregnant women with intrahepatic cholestasis of pregnancy
3271296|NCT01576497|Active Comparator|EUS-FNA with suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA with suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
3271297|NCT01576497|Active Comparator|EUS-FNA without suction|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
3271298|NCT01576510|Experimental|Prolonged Exposure (PE) treatment.|
3271299|NCT01576510|No Intervention|Trauma exposed healthy controls|Clinical assessments at baseline, 7 and 10 weeks. fMRI assessments at baseline and 10 weeks.
3271300|NCT01576562||Study Group - Control Group|VAD implantation (study group) or other cardiothoracic surgery (control group)
3271301|NCT01576601||Hopkins|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3271302|NCT01576601||Childrens Hospital of Philadelphia|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3271303|NCT01576601||Childrens Hospital Boston|Pediatric patients (0-18 yo) who are scheduled for craniotomy surgery under general anesthesia. This will include patients undergoing brain surgery for cancer, epilepsy, vascular malformations, and craniofacial reconstructive surgery. Patients will receive routine postoperative management and treated for pain based on institutional routine. We will follow patients for the first 5 post-operative days or until discharge, whichever comes first.
3271304|NCT01576614||Nurse-Physician Rounding by Phone|"The SICU's practice involves daily morning team rounding at the bedside. The team includes the critical care attending physician (AP), surgical resident physician, and critical care nurse. The AP is physically present in the SICU during these rounds and for the hours between approximately 7am and 7pm. During off-shift hours (7pm-7am), the AP is available by phone as the on-call attending physician. In addition to this on-call availability, the standard of practice in SICU for years has been that the on-call physician proactively places a telephone call to the SICU at least once every evening to perform telephone rounds with the resident physician aeach SICU patient."
3271305|NCT01576614||Nurse-Physican rounding by R T P|"Remote Telepresence Robotics (RTP) is a form of telemedicine that enables a fast and direct face-to-face response by a physician, located remotely, and may sometime utilize a mobile robot.~RTP provides the physician the ability to teleconference with patients and other healthcare providers using two way audio visual technology. The sophistication of these devices varies and can range from simple video conferencing to remote robotic control devices with audio visual conferencing capabilities. The robotic capabilities refer to ability of the physician to remotely direct or drive the device from one location to another.~The technology allows clinical experts to provide the right care at the right time and has become an accepted standard of care when used under appropriate circumstances."
3271306|NCT01576627|Experimental|zinc citrate|
3271307|NCT01576627|Active Comparator|zinc gluconate|
3271308|NCT01576627|Active Comparator|zinc oxide|
3271309|NCT01576640|Other|Replapse Prevention Therapy|
3271310|NCT01576653|Active Comparator|No IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do not fulfill EORTC/MSG IFI criteria will serve as negative controls.
3271311|NCT01576653|Active Comparator|IFI|Bronchoscopy will be performed routinely in most patients with clinical suspicion of IFI. IFIs in patients will be retrospectively graded in possible, probable, proven and no IFI according to revised EORTC/MSG criteria. Patients that do fulfill EORTC/MSG criteria of possible/probable/proven IFI will serve as study group.
3271312|NCT01576666|Experimental|LDE225 and BKM120 in combination|LDE225 and BKM120 in combination
3271313|NCT01576679|Experimental|tPA|tissue Plasminogen Activator
3271314|NCT01576679|Placebo Comparator|Placebo|Saline
3271315|NCT01576692|Experimental|Treatment|"Participants receive humanized anti-GD2 antibody, chemotherapy, cytokines, and natural killer cells.~Cells for infusion are prepared using the CliniMACS System."
3271316|NCT01576731|Active Comparator|Tenofovir + emtricitabine + lopinavir/r|Standard postexposure prophylaxis combination
3271317|NCT01576731|Experimental|Tenofovir + Emtricitabine + Raltegravir|new postexposure prophylaxis combination
3271318|NCT01576757||Heart failure|Patients with heart failure from any cause will be considered as potential participants given their clinical background meets eligibility criteria.
3271319|NCT01576770|Active Comparator|ethyl chloride vapocoolant spray|"Half of the patients will randomly be assigned to receive Gebauer's ethyl choride topical anesthetic vapo-coolant spray immediately prior to placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the ethyl chloride or the patch."
3271320|NCT01576770|Experimental|Synera Patch|"The other half of the patients will randomly be assigned to receive Synera Patches, to be applied to the dorsum of both hands, at least 30 minutes before placing a 22 gauge intravenous catheter.~Pain in this group will be evaluated at the time of IV placement by an independent observer (unblinded) and the patient on a 0-10 scale. Pain will again be evaluated when propofol is injected at anesthesia induction by a blinded observer and the staff anesthesiologist (also blinded) on a scale of 1-4.~Blinding will occur following IV placement by draping and securing the hand and IV site with Coban self-adherent elastic wrap to cover any skin changes due to the patch or ethyl chloride."
3271321|NCT01576822|Active Comparator|Low Dose|Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. Participants will be able to attend 9 consecutive sessions, should they wish.
3271322|NCT01576822|Active Comparator|High Dose|Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna). Participants will be able to schedule visits on any of 7 days per week. Maximum flexibility in hours of operation as well as flexibility in which days are attended will be utilized to increase likelihood of retention. A participant may attend visits for 15 consecutive days, should they wish.
3271323|NCT01576848|Experimental|GROUP 1 (OLD-PRO)|test drink contains intrinsically labeled protein alone
3271324|NCT01576848|Experimental|GROUP 2 (OLD-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
3271325|NCT01576848|Experimental|GROUP 3 (YOUNG-PRO)|test drink contains intrinsically labeled protein alone
3271326|NCT01576848|Experimental|GROUP 4 (YOUNG-PRO/CARB)|test drink contains intrinsically labeled protein and carbohydrate
3271327|NCT01576861|Experimental|GH replacement|Patients will receive 48 months of substitutive somatotropin (growth hormone) therapy at a dose of 0,012 mg/kg every second day, added to their background optimized CHF therapy
3271328|NCT01576861|No Intervention|Control CHF patients under optimized CHF therapy|
3271329|NCT01576887|Placebo Comparator|Placebo|
3271330|NCT01576887|Experimental|Bardoxolone Methyl|
3271331|NCT01576900||Desmopressin monotherapy|Control group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + simple instruction
3271332|NCT01576900||Combination group|"Study group: Desmopressin (Minirin Tablet 0.1-0.4mg/day) + SyBeMeP~* Patients will be randomized and assigned to each group at the ratio of 1:1."
3271333|NCT01576913|Active Comparator|Music pacing|Exercise testing with music pacing
3271334|NCT01576913|No Intervention|No music pacing|Exercise testing without music pacing
3271335|NCT01576926||surgery|patients with obstructive sleep apnea
3271336|NCT01576965|Experimental|Mechanical Bowel Prep Group|Half of the subjects will be randomized to a group that does mechanical bowel preparation with sodium phosphate enema. Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
3271337|NCT01576965|No Intervention|No Bowel Prep Group|Participants randomly assigned to this group will not have the bowel prep treatment before the surgery. All subjects will be instructed to restrict their diet to clear liquids the day prior to their surgery and to continue this diet after midnight, save a small sip of water for medications in the morning.
3271338|NCT01576978|Active Comparator|postural orientations|The group of postural orientations receive a pamphlet containing information about the sitting, standing and lying postures to be performed at home for 10 weeks.The marking of the note pain will be before and after 10 weeks.
3271339|NCT01576978|Active Comparator|hatha yoga exercises|The allocates women will participate in the Hatha yoga class for 10 weeks. At first in class, the women will make a note of pain according to VAS. Class Moments: heating ten minutes, forty minutes postures of stretching and strengthening exercises and breathing exercises, ten minutes of relaxation and meditation. Marking note of pain after practice.
3271340|NCT01576991||Oocyte collection|This is an observational study; there are no cohorts or groups
3271341|NCT01577004|Experimental|Omega-3 fatty acid supplement|Data obtained after the intervention was compared to baseline data
3271342|NCT01577017|Experimental|Letrozole|Group L will be assigned with Letrozole 5 mg on night on day 5 to day 9 of the cycle
3271343|NCT01577030|Experimental|Dairy|Add 4 daily servings of non-fat dairy to diet for a period of 4 weeks
3271344|NCT01577030|Active Comparator|Fruit|Add 4 daily servings of fruit to diet, remove all dairy from diet for a period of 4 weeks
3271345|NCT01577043|Active Comparator|Racecadotril|intestinal antisecretory
3271346|NCT01577043|Placebo Comparator|cornstach solution|Cornstarch powder diluted in distilled water
3271347|NCT01577056|Active Comparator|Fish oil|
3271348|NCT01577056|Placebo Comparator|Placebo|FH subjects with standard treatment (statin treatment)
3271349|NCT01577082|Experimental|CHF 1535 200/6µg|
3271350|NCT01577082|Active Comparator|BDP 100µg|
3271351|NCT01577095|Experimental|EA + Rosiglitazone|
3271352|NCT01577095|Placebo Comparator|Rosiglitazone|
3271353|NCT01577121|Placebo Comparator|placebo|
3271354|NCT01577121|Experimental|indomethacin|50 mg/ 6 hours of indomethacin oral use
3271355|NCT01577134|Experimental|Intervention to enhance physical activity|Participants in this arm have high motivation to be regularly physically active. Face-to-face group intervention includes behavior change techniques to enhance physical activity.
3271356|NCT01577134|Active Comparator|Active control intervention|Face-to-face group intervention includes behavior change techniques to enhance volunteering and improve attitudes towards volunteering.
3271357|NCT01577134|Other|Passive control intervention|Waiting-list control group, who receives all information (that the active groups got) via mail after completion of 8.5 months follow-up.
3271358|NCT01577147|Other|sample collection|Ovulation prediction products provided to aid conception
3271359|NCT01577173|Experimental|A: MEHD7945A|
3271360|NCT01577173|Active Comparator|B: Cetuximab|
3271361|NCT01577199|Active Comparator|High dose gonadotropins|High dose gonadotropins protocol compared to Low-dose Clomiphene
3271362|NCT01577199|Experimental|Low-dose Clomiphene|clomid-based, low dose gonadotropin protocol compared to High dose gonadotropins
3271363|NCT01577212|Experimental|Individualized dose escalation|Individualized dose escalation on the basis of the dose to the organs at risk.
3271364|NCT01577225|Experimental|OPSITE Post-Op Visible|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Dressing should be used right after surgery and changed as needed.
3271365|NCT01577225|Active Comparator|Tape&Gauze|Subject is randomized to OPSITE Post-Op Visible group or Tape&Gauze group. Tape and Gauze should be used right after surgery and changed as per routin practice.
3271366|NCT01577264||Cimzia treatment|
3271367|NCT01577290|Experimental|Mindfulness training|Group receives mindfulness training.
3271368|NCT01577290|Active Comparator|Discussion group|Group has access to a discussion group.
3271369|NCT01577303|Experimental|CBM training program variant 1|Attention training towards positive cues using words as stimuli
3271370|NCT01577303|Experimental|CBM training program variant 2|Attention training towards positive cues using words and faces as stimuli
3271371|NCT01577303|Experimental|CBM training program variant 3|Attention training towards negative using words as stimuli
3271372|NCT01577303|Experimental|CBM training program variant 4|Attention training towards negative using words and faces
3271373|NCT01577303|Experimental|Control training variant 1|Control training condition using words as stimuli
3271374|NCT01577303|Experimental|Control training variant 2|Control training condition using words and faces as stimuli
3271375|NCT01577316|Experimental|Pregnant Woman|Pregnant Woman
3271376|NCT01577316|Experimental|Nonpregnant women|2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
3271377|NCT01577342|Active Comparator|Moxifloxacin 0.5%|1 drop four times daily for 3 days in affected eye post intravitreal injection
3271378|NCT01577342|No Intervention|No antibiotic use|
3271379|NCT01577355|Experimental|[C14]-LY2784544|Single 30 mg oral dose containing 100 micro curies of LY2784544
3271380|NCT01577368|Experimental|Piperacillin continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours
3271381|NCT01577368|Active Comparator|Piperacillin intermittent infusion|Piperacillin-Tazobactam 4gr intermittent infusion 4gr every 8 hours
3271382|NCT01577394|Experimental|Early stage of dementia|oculomotor measurements
3271383|NCT01577407|Experimental|Nefopam|
3271384|NCT01577407|Placebo Comparator|placebo|
3271385|NCT01577420|Experimental|Group A|Reflexology Sessions: One session per week performed by certified reflexologist for four consecutive weeks.
3271386|NCT01577420|Placebo Comparator|Group B|Placebo Sessions: One session per week performed by research aide for four consecutive weeks.
3271387|NCT01577420|No Intervention|Group C|Control; no foot sessions
3271388|NCT01577433||Control Group|Historical control HeartMate II BTT and DT data
3271389|NCT01577433||Prospective and Retrospectively identified SSI|Prospectively and Retrospectively identified HeartMate II patients where the full length of the velour coated portion of the driveline is tunneled under the skin
3271390|NCT01577446|Experimental|CRT|The CRT group undergoes implantation of a CRT defibrillator
3271391|NCT01577446|No Intervention|no-CRT|The no-CRT group receives a dual-chamber defibrillator
3271392|NCT01577459|Experimental|TR-701 FA with PSE|TR-701 FA 200 mg oral with PSE
3271393|NCT01577459|Placebo Comparator|TR-701 FA Placebo with PSE|TR-701 FA Placebo 200 mg oral with PSE
3271394|NCT01577472|Active Comparator|High Dose Clomiphencitrat|450 IU Merional® plus 100mg Serophene®
3271395|NCT01577472|Active Comparator|Low Dose Clomiphencitrat|150 IU Merional® plus 100mg Serophene®
3271396|NCT01577472|Placebo Comparator|High Dose Placebo|450 IU Merional® plus Placebo
3271397|NCT01577472|Placebo Comparator|Low Dose Placebo|150 IU Merional® plus Placebo
3271398|NCT01577485|Experimental|Probiotic pastille|Test group
3271399|NCT01577485|Active Comparator|Control pastille|Control group
3271400|NCT01577511||30 Patients|"Patients with operable, stage III or IV, adenocarcino-type colorectal cancer treated at the Nîmes University Hospital.~Intervention: Samples and follow up"
3271401|NCT01577524|Active Comparator|Diluted Povidone Iodine Solution|
3271402|NCT01577524|Placebo Comparator|Normal Saline Wash|
3271403|NCT01577550|Experimental|i.v. BI 655066|A subject to receive a single i.v. dose of BI 655066
3271404|NCT01577550|Placebo Comparator|i.v. placebo|A subject to receive a single i.v. dose of placebo
3271405|NCT01577550|Experimental|s.c. BI 655066|A subject to receive a single s.c. dose of BI 655066
3271406|NCT01577550|Placebo Comparator|s.c. placebo|A subject to receive a single s.c. dose of placebo
3271407|NCT01577576||Upper-body athletes|This group includes swimmers, rowers or kayakers with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
3271408|NCT01577576||Lower-body athletes|This group includes runners (marathon or trail) and cyclists with a history of at least 10 years of intense training, and performance in regional competitions for the past five years.
3271409|NCT01577576||Sedentary volunteers|This group of healthy volunteers does not participate in athletic activity for more than two hours per week. They are matched by age and sex with the athletic groups.
3271410|NCT01577589|Experimental|A|600 mg ceftaroline fosamil in 50 ml infusion volume
3271411|NCT01577589|Placebo Comparator|B|Placebo in 50 ml infusion volume
3271412|NCT01577589|Experimental|C|600 ceftaroline fosamil in 250 ml infusion volume
3271413|NCT01577589|Placebo Comparator|D|Placebo in 250 ml infusion volume
3271414|NCT01577589|Experimental|E|600 mg ceftaroline in 100 ml infusion volume
3271415|NCT01577589|Placebo Comparator|F|Placebo in 100 ml infusion volume
3271416|NCT01577602|No Intervention|Standard practice|
3271417|NCT01577602|Experimental|Printed list intervention|Providing patients a list of their current medications before they see medical assistant and begin their visit.
3271418|NCT01577602|Experimental|Open ended question intervention|"Medical assistants begin the medication review with a scripted, open ended question (i.e., tell me about your medications)"
3271419|NCT01577602|Experimental|Combined intervention|
3271420|NCT01577615|Experimental|Patterned Experience Group|Infants in the patterned experience group will receive a patterned feeding experience with all feedings through discharge. They will receive a touch intervention at each gavage feeding. Once oral feedings are initiated, they will be offered an oral feeding at every scheduled feeding. They will be held for feedings. They will be observed twice a week utilizing the computer data acquisition system. Follow up visits will occur at 2,6 amd 24 months corrected age.
3271421|NCT01577615|No Intervention|Usual Care Group|In the usual care group infants usually are not held or contained during gavage feeding. Infants in the usual care group are orally fed at the discretion of the nurses or medical team. Once oral feedings are initiated, infants will be observed twice a week using the computer data acquisition system. Follow up visits will occur at 2,6 and 24 months corrected age.
3271422|NCT01577654|Experimental|Arm A: EC145 alone|EC145 alone
3271423|NCT01577654|Experimental|Arm B: EC145 + Docetaxel|EC145 + Docetaxel
3271424|NCT01577654|Active Comparator|Arm C: Docetaxel alone|Docetaxel alone
3271425|NCT01577667|No Intervention|Conventional ventilation|Usual ventilation is administered according to the protocols implemented in the unit
3271426|NCT01577667|Experimental|Intellivent|"Intellivent is a ventilatory mode included in ventilator S1, Hamilton Medical. Intervention: the patient is ventilated with the same ventilator than in the conventionnal group; but the ASV-Intellivent ventilation has to be activated via a dedicated key on the ventilator screen.~IntelliVent® activation requires selecting the kind of patient: ARDS, COPD and whether hemodynamic instability exists.~The initial settings are IntelliVent® by default settings (% MV: 110%, PEEP: 5 cm H2O, FiO2: 60% - 100% in case of ARDS).~Therefore modification of these various parameters is automatic. FiO2 and PEP are modified according to SpO2; %MV according to EtCO2."
3271427|NCT01577680|Experimental|Moderate Hepatic Impairment|Approximately 9 subjects will complete each of these treatment arms
3271428|NCT01577680|Experimental|Matched Healthy Volunteers|Matched to the moderate hepatic impairment subjects based on gender, ethnicity, body mass index (+/-15%) and age (+/-5 years) Approximately 9 subjects will complete each of these treatment arms
3271429|NCT01577693|Experimental|0.5 mg novel dose form (test)|0.5 mg novel dose form (test)
3271430|NCT01577693|Other|0.5 mg Soft Gel Capsule|0.5 mg Soft Gel Capsule (reference)
3271431|NCT01577719|Active Comparator|Multimedia Lifestyle Improvement|Multimedia lifestyle intervention
3271432|NCT01577719|Placebo Comparator|Usual Care|usual care
3271433|NCT01577771|Active Comparator|Child|1 dose of Prevnar13 at 2 to 4 years of age
3271434|NCT01577771|Experimental|Toddler 1 dose|Single dose of Prevnar13 at 12-15 months of age
3271435|NCT01577771|Active Comparator|Toddler 2 dose|2 doses of Prevnar13 2 months apart beginning at 12-15 months of age
3271436|NCT01577771|Experimental|Infants 2+1|Infants receiving Prevnar13 at 6 weeks, 14 weeks and 9 months. Note: This infant immunization schedule is used in many European countries and in South Africa and has been shown to be immunogenic and effective. However, few head-to-head comparisons of the 2+1 and 3+0 schedules have been conducted.
3271437|NCT01577771|Active Comparator|Infants 3+0|Infants receiving Prevnar13 at 6, 10 and 14 weeks
3271438|NCT01577784|Experimental|Pazopanib|800 mg / day of pazopanib in monotherapy
3271439|NCT01577797|Experimental|CBT-based text messages - Week 1 or 3|One week CBT-based text messages followed by a 1-week washout period (Week 2)
3271440|NCT01577797|Placebo Comparator|Placebo text messages - Week 3 or 1|
3271441|NCT01577823|No Intervention|No foley catheter|
3271442|NCT01577823|Active Comparator|Foley Catheter|
3271443|NCT01577836||Robotic assistance, Nîmes|The patients in this group will undergo robot-assisted radial prostatectomy at the University Hospital of Nîmes.
3271444|NCT01577836||Laparotomy, Marseilles|The patients in this group will undergo radical prostatectomy via traditional laparotomy at the University Hospital Marseillles.
3271445|NCT01577849|Active Comparator|Vitamin D3|
3271446|NCT01577849|Experimental|DP-R206|
3271447|NCT01577862|Active Comparator|Colistin|Colistin alone, 2 million units every 8 hours intravenously or according to renal function
3271448|NCT01577862|Experimental|Colistin plus Rifampicin|Colistin, 2 million units every 8 hours intravenously or according to renal function, plus Rifampicin, 600 mg every 12 hours intravenously
3271449|NCT01577875|No Intervention|control group|histologic prediction only with the narrow band imaging (without magnification)
3271450|NCT01577875|Other|test group|histologic prediction with narrow band imaging plus magnification
3271451|NCT01577888|Experimental|Lithotripsy Treatment|Shockwave System Treatment -Lithotripsy-enhanced, low-pressure balloon dilation of calcified, stenotic peripheral arteries.
3271452|NCT01577914|Experimental|Carvedilol Tablets USP 12.5 mg|Carvedilol Tablets USP 12.5 mg of M/s Ipca Laboratories Limited, India
3271453|NCT01577914|Active Comparator|Coreg®|Coreg® (Carvedilol Tablets) 12.5 mg of M/s GlaxoSmithKline
3271454|NCT01577927|Active Comparator|Usual home care|No assistance or care by PT.
3271455|NCT01577927|Experimental|PT-assisted home rehabilitation|Assisted home care is supported by a PT at least 2 times/month. Few brief educational lessons preceeded the training activity that the patient performs by himself at home.
3271456|NCT01577940|Experimental|Infusion of local anesthetic|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours.
3271457|NCT01577940|Placebo Comparator|Infusion of saline|TAP block with 20 ml of ropivacaine 0,5%, catheter with infusion of saline 5 ml/h 24 hours.
3271458|NCT01577953|Experimental|SB010|The drug SB010 is administered in phosphate-buffered saline solution, inhaled via a controlled breathing system over a 5 to 10 min.
3271459|NCT01577953|Placebo Comparator|Placebo|The placebo (phosphate-buffered saline) is administered as a solution inhaled via a controlled breathing system over a 5 to 10 min.
3271460|NCT01577979|Experimental|Reminder/Recall Strategy|The experimental group will consist of patients randomly selected from participating clinics. Patients from private practices and the safety net provider may be exposed to a reminder/recall strategy involving text messaging. Text messages will be used to notify parents that their child is due for an immunization or well-care visit. Parents will be able to reply with one of three response options. Patients presenting to the randomly selected experimental managed care clinics for the first HPV vaccination dose will be offered the ability to provide the clinic with their preferred contact method. The preferred method of contact will be used for the second and third HPV dose reminder/recalls.
3271461|NCT01577979|No Intervention|Usual Care|The patients in the usual care group will receive the clinic's usual care in terms of immunization and well-care reminder/recall.
3271462|NCT01577992|Experimental|Group 1: MSA disease|determination of objective and subjective pain threshold before and after levodopa intake
3271463|NCT01577992|Experimental|Group 2: Parkinson disease|determination of objective and subjective pain threshold before and after levodopa intake
3271464|NCT01577992|Other|Group 3: healthy volunteers.|one determination of objective and subjective pain threshold without treatment
3271465|NCT01578018|Other|Lung Cancer|Diagnostic
3271466|NCT01578018|Other|Lung Disease|Diagnostic
3271467|NCT01578057|Experimental|tasimelteon + placebo ethanol|
3271468|NCT01578057|Experimental|ethanol + placebo tasimelteon|
3271469|NCT01578057|Experimental|tasimelteon + ethanol|
3271470|NCT01578057|Experimental|placebo tasimelteon + placebo ethanol|
3271471|NCT01578070|Experimental|ViscoGel® and 0.2μg Act-HIB®|
3271472|NCT01578070|Experimental|0.2μg Act-HIB®|
3271473|NCT01578070|Experimental|ViscoGel® and 2μg Act-HIB®|
3271474|NCT01578070|Experimental|2μg Act-HIB®|
3271475|NCT01578070|Active Comparator|10μg Act-HIB®|
3271476|NCT01578083||Cognitive Impairment|With self-report cognitive impairment.
3271477|NCT01578083||No Cognitive Impairment|Without self-report cognitive impairment.
3271478|NCT01578096|No Intervention|Diabetes education|Group-based diabetes education delivered to participants through community health workers
3271479|NCT01578096|Experimental|Diabetes education plus stress management|Group-based diabetes education plus stress management delivered to participants through community health workers
3271480|NCT01578109|Experimental|Treatment (sorafenib tosylate and transplant)|Patients receive sorafenib tosylate PO BID beginning at least 30 days after completion of induction therapy and/or transplant and no more than 120 days after transplant continuing for up to 2 years after transplant in the absence of disease progression or unacceptable toxicity.
3271481|NCT01578122|Experimental|25mmHg ECS|Thigh-length graduated elastic compression stockings applying 25mmhg of targeted pressure at the ankle worn daily for two years
3271482|NCT01578122|Active Comparator|35mmHg ECS|Thigh-length graduated elastic compression stockings applying 35 mmhg of targeted pressure at the ankle worn daily for two years
3271483|NCT01578135||Phase I|
3271484|NCT01578135||Phase II|
3271485|NCT01578148|Experimental|Noxipoint Therapy|
3271486|NCT01578148|Active Comparator|Physical Therapy|
3271487|NCT01578161|Experimental|Dexmedetomidine0.25|dexmedetomidine 0.25 microg.kg(-1),(Group D0.25) ivs. for 10min.
3271488|NCT01578161|Experimental|Dexmedetomidine0.5|dexmedetomidine 0.5 microg.kg(-1),(group D0.5) ivs. for 10min.
3271489|NCT01578161|Experimental|Dexmedetomidine1.0|dexmedetomidine 1 microg.kg(-1) ivs. for 10min.
3271490|NCT01578161|Placebo Comparator|NormalSaline|Normal saline 10ml ivs. for 10min.
3271491|NCT01578174|Placebo Comparator|Control|
3271492|NCT01578174|Active Comparator|Dexmedetomidine|
3271493|NCT01578200|Experimental|Lanthanum carbonate|Patients are given Lanthanum Carbonate oral administration after meals three times per day in total daily dose of 750-2250mg.
3271494|NCT01578200|Active Comparator|Calcium Carbonate|Patients are given Calcium carbonate oral administration after meals three times per day in total daily dose of 3.0g.
3271495|NCT01578213|Experimental|Imatinib|
3271496|NCT01578226||Decompensated cirrhotic patients|Cirrhotic patients presenting with clinically detectable ascites (Grade 2 o Grade 3)
3271497|NCT01578252|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
3271498|NCT01578252|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
3271499|NCT01578265|Experimental|Ondansetron Tablets USP 8 mg|Ondansetron Tablets USP 8 mg of M/s Ipca Laboratories Limited, India
3271500|NCT01578265|Active Comparator|Zofran®|Zofran® (Ondansetron Hydrochloride) Tablets 8 mg of M/s GlaxoSmithKline
3271501|NCT01578291|No Intervention|No intervention|Parents given routine information by the medical staff.
3271502|NCT01578291|Active Comparator|Parental information|Parents are provided with an educational brochure of the study and the expectations of the discomfort.
3271503|NCT01578291|Active Comparator|Play Therapy|Child and the parents will spend time in the office with the child life therapist undergoing play therapy.
3271504|NCT01578304|Experimental|Imidafenacin|
3271505|NCT01578304|Active Comparator|Fesoterodine|
3271506|NCT01578343|Experimental|Vorinostat-FND|Vorinostat-fludarabine, mitoxantrone, dexamethasone Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
3271507|NCT01578356||Radical Retropubic prostatectomy (RRP)|Men who underwent open radical prostatectomy in the past at our centre.
3271508|NCT01578356||Robot-assisted laparoscopic prostatectomy (RALP)|Men who undergo robot-assisted laparoscopic prostatectomy at our centre.
3271509|NCT01578369|Experimental|Exercise group|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
3271510|NCT01578369|No Intervention|Control|Usual care
3271511|NCT01578382||Hypertensive ischemic leg ulcer|"Twenty consecutive patients with Martorell HYTILU as defined in:~Arch Dermatol 2010;146:961-968"
3271512|NCT01578382||Calciphylaxis|"Ten subjects with calciphylaxis (calcific uremic arteriolopathy) as described in:~Vasa 1998;27:137-143"
3271513|NCT01578382||Venous ulcer (controls)|"Twenty subjects with venous ulcers (CEAP C4-6) as described in:~J Vasc Surg. 2004 Dec;40(6):1248-52"
3271514|NCT01578395|Experimental|N-acetylcysteine|This arm consists of 30 patients who will receive 1200mg n-acetylcysteine dissolved in 50ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3271515|NCT01578395|Experimental|Ascorbic acid|This arm consists of 30 patients who will receive 3000 mg ascorbic acid dissolved in 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3271516|NCT01578395|Placebo Comparator|Sodium Chloride (NaCl)|This arm consists of 30 patients who will receive 50 ml NaCl 0.9% iv before either low-dose (10 patients) or high-dose (10 patients) radiation exposure, or no radiation exposure (10 patients)
3271517|NCT01578408|Active Comparator|Uncemented HA Coated Corail stem|Surgery with an inversed hybrid arthroplasty with an uncemented hydroxyapatite coated Corail stem and a cemented Marathon cup (DePuy).
3271518|NCT01578408|Active Comparator|Cemented Lubinus SPII stem (control arm)|Surgery with a totally cemented option with a Lubinus SPII stem and a IP cup (Link).
3271519|NCT01578421|Other|FX 100 dialyzer|
3271520|NCT01578421|Other|Polyflux 210 H dialyzer|
3271521|NCT01578421|Other|FXCorDiax 100 dialyzer|
3271522|NCT01578434|Active Comparator|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
3271523|NCT01578434|Active Comparator|Vitamin D|Vitamin D: 6 lakh IU single im dose
3271524|NCT01578434|Active Comparator|Vitamin D and Calcium|vitamin D and Calcium: combination of above two
3271525|NCT01578447|Other|Depo-SubQ Provera 104 in Uniject|
3271526|NCT01578447|Other|Intramuscular DMPA|
3271527|NCT01578460|Active Comparator|Control Group|Participants will self-select which group they wish to participate in at time of consent. The control group will use standard glucose meter testing to monitor their glucose levels.
3271528|NCT01578460|Experimental|Continuous Glucose Monitor (CGM) Group|Participants will self-select which group they wish to participate in at time of consent. The CGM group will utilize the iPro2 CGM to monitor their glucose levels during their 28, 32, and 36 week of gestation.
3271529|NCT01578473|Active Comparator|Vitamin D and E|Oral Vitamin D and E alone in men with penile curvature due to PD.
3271530|NCT01578473|Active Comparator|Testosterone Pellets and Vitamin D and E|Testosterone in combination with oral Vitamin D an E supplementation in men with penile curvature due to PD.
3271531|NCT01578512|Experimental|Face-to-Face|8 sessions of weekly group behavioral weight loss treatment
3271532|NCT01578512|Experimental|Web-based|Participants receive one group face-to-face session followed by 7 web-based lessons, reporting of key behaviors, and feedback on progress.
3271533|NCT01578512|Active Comparator|Single Session|Single session behavioral weight loss
3271534|NCT01578525|No Intervention|standard care|Standard care (by German definition), traditional care by physician and nurse on the ward
3271535|NCT01578525|Other|Intensified standard care|Intensified standard care: traditional care by physician and nurse, additional pharmaceutical care by a pharmacist during hospitalization
3271536|NCT01578538|Active Comparator|mesh used repair|mesh used hernia repair will be perform
3271537|NCT01578538|Active Comparator|nonmesh|nonmesh hernia repair techniques will be used
3271538|NCT01578564|Experimental|SOR-C13|
3271539|NCT01578590|Experimental|Subjects will consume lean minced meat|Subjects will perform resistance exercise and consume a piece of meat (135 grams, 35 g of protein)
3271540|NCT01578590|Active Comparator|Subjects will consume a milk beverage|Subjects will perform resistance exercise and consume a milk protein beverage
3271541|NCT01578603|Experimental|sugar substituted chewing gum A|
3271542|NCT01578603|Experimental|Sugar substituted chewing gum B|
3271543|NCT01578616||3 / non-CAD, ACS with or without TCFA|ACS patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
3271544|NCT01578616||non-CAD, ACS without TCFA, ACS with TCFA|Acute coronary syndrome (ACS) patients with thin cap fibroatheroma. ACS patients without thin cap fibroatheroma. Age-, gender-, and rate of hypertension or diabetes mellitus-matched patients who have never been diagnosed or treated for CAD are also enrolled as non-CAD patients
3271545|NCT01578629|Active Comparator|Healthy Volunteers|Healthy participants randomized into one of 6 groups that will take 4 capsules, twice a day of vitamin E tocotrienol (TCT) capsules ; Low Dose Aspirin or placebo capsule for 7 months.
3271546|NCT01578629|Active Comparator|Hyperlipidemic|hyperlipidemic patients randomized into one of 6 groups that will take 4 capsules, twice a day of Vitamin E Tocotrienol (TCT) capsules; Low Dose Aspirin or placebo vehicle control capsule for 7 months.
3271547|NCT01578642|Other|Single Arm open label|EndoStim LES Stimulation System
3271548|NCT01578655|Experimental|Cabazitaxel plus Custirsen|cabazitaxel, prednisone, and custirsen sodium
3271549|NCT01578655|Active Comparator|Cabazitaxel|cabazitaxel and prednisone
3271550|NCT01578668|Experimental|Erlotinib, pemetrexed, cisplatin|
3271551|NCT01578668|Experimental|erlotinib|
3271552|NCT01578681|Active Comparator|Airway clearance, bronchiectasis|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
3271553|NCT01578681|Placebo Comparator|bronchiectasis, stretching|"The patient would be selected randomly to one of the two groups (intervention or placebo). And follow up for one year with regular visits with the physician and the respiratory therapist.~Each patient will be visited 7 times. At each visit all the variable will be registered. Patient will have also a personal registration diary."
3271554|NCT01578694|Other|Patient Group|The patient group has been diagnosed by the surgeon as having femoro-acetabular impingement (FAI) of the hip and will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
3271555|NCT01578694|Other|Control healthy volunteers|The control group has not been diagnosed with any hip problems, but will undergo a magnetic resonance imaging (MRI) test, more specifically, T1-rho to examine articular cartilage.
3271556|NCT01578720|Other|IVT injection once every 8 weeks after 3 initial monthly doses|"Intravitreal aflibercept injection 2.0mg dosed every 4 weeks (monthly)for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection every eight weeks (2 months).~Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of greater than or equal to 5 letters from the previous visit."
3271557|NCT01578733|Experimental|protein intake|different levels of protein intake
3271558|NCT01578746|Active Comparator|Direct lateral approach|Patient operated using direct lateral approach.
3271559|NCT01578746|Active Comparator|Anterior approach|Patient operated using anterior approach.
3271560|NCT01578759|Experimental|Salpingectomy group|Participants in this group will have their fallopian tubes removed.
3271561|NCT01578759|No Intervention|No Salpingectomy Group|Participants in this group will not have their fallopian tubes removed.
3271562|NCT01578811|Placebo Comparator|Placebo|
3271563|NCT01578811|Experimental|SK-MS10 160mg t.i.d|
3271564|NCT01578811|Experimental|SK-MS10 320mg t.i.d|
3271565|NCT01578824|Active Comparator|Healthy Control|
3271566|NCT01578824|Active Comparator|Vitamin D resistant Rickets|Vitamin D resistant Rickets patients
3271567|NCT01578837|Experimental|Ginseng|Combined Rg3-enriched Korean Red Ginseng and American Ginseng capsule
3271568|NCT01578837|Placebo Comparator|Wheat Bran|100 % Natural Wheat Bran capsule
3271569|NCT01578863|Active Comparator|Intervention program|6 months intervention program to lose weight in obese children. Behavioral, emotional, physical, familial and demographic questioners will be fulfilled at the beginning and at the end of the program.
3271570|NCT01578863|No Intervention|Untreated obese children|Behavioral, emotional, physical, familial and demographic questioners will be fulfilled twice in a 6 month program.
3271571|NCT01578863|No Intervention|Normal weight children|Behavioral, emotional, physical, familial and demographic questioners will fulfill twice in the 6 month period.
3271572|NCT01578876|Experimental|CSWT for 3 month|A group
3271573|NCT01578876|Experimental|CSWT for 1 month|B group
3271574|NCT01578876|No Intervention|Control group|C group
3271575|NCT01578889|Experimental|Group 1: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine administered as 0.5 mL by intramuscular (IM) injection in both the left and right deltoids using the Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3271576|NCT01578889|Placebo Comparator|Group 1: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.5 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3271577|NCT01578889|Experimental|Group 2: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 250 mcg IL-12 pDNA adjuvant, and divided into two 0.55 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3271578|NCT01578889|Placebo Comparator|Group 2: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.55 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3271579|NCT01578889|Experimental|Group 3: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1,000 mcg of the IL-12 pDNA adjuvant and divided into two 0.75 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3271580|NCT01578889|Placebo Comparator|Group 3: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.75 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3271581|NCT01578889|Experimental|Group 4: Vaccine|At study entry and Months 1 and 3, participants will receive HIV-MAG vaccine admixed with 1500 mcg of the IL-12 pDNA adjuvant divided into two 0.9 mL IM injections administered in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive the VSV HIV gag vaccine by IM injection in both the left and right deltoids.
3271582|NCT01578889|Placebo Comparator|Group 4: Placebo|At study entry and Months 1 and 3, participants will receive placebo administered as 0.9 mL by IM injection in both the left and right deltoids using the Ichor Medical Systems TDS EP device. At Month 6, they will receive placebo by IM injection in both the left and right deltoids.
3271583|NCT01578915||Cases|Women with 4 or more sexual partners during the past year
3271584|NCT01578915||Controls|Women with only one sexual partner during the past year
3271585|NCT01578928|Experimental|SOM230|subjects with varying degrees of renal impairment along with subjects without renal impairment
3271586|NCT01578941|Placebo Comparator|Placebo|
3271587|NCT01578941|Active Comparator|Treximet|
3271588|NCT01578954|Experimental|Drug|Lenalidomide (25, 35, or 50 mg induction/10mg maintenance)
3271589|NCT01579019|Active Comparator|1000 mg 24 weeks|
3271590|NCT01579019|Active Comparator|1000 mg 26 weeks|
3271591|NCT01579019|Experimental|1500 mg 24 weeks|
3271592|NCT01579019|Experimental|1500 mg 26 weeks|
3271593|NCT01579032||CKD patients|
3271594|NCT01579058|Active Comparator|bisoprolol|bisoprolol 5mg qd
3271595|NCT01579058|Placebo Comparator|placebo|placebo
3271596|NCT01579071|Experimental|CO2 sufflation group|
3271597|NCT01579071|Experimental|Room air sufflation group|
3271598|NCT01579097|Active Comparator|compounded ternary parenteral nutrition|compounded ternary Parenteral Nutrition admixture
3271599|NCT01579097|Experimental|Oliclinomel N4 formulation|Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag
3271600|NCT01579110|Experimental|prednisolone + levamisole|
3271601|NCT01579110|Active Comparator|Prednisone|
3271602|NCT01579123|Active Comparator|Laser atherectomy|
3271603|NCT01579123|Active Comparator|Angioplasty|
3271604|NCT01579136|No Intervention|Control group|This group will not get a home blood pressure monitor.
3271605|NCT01579136|Experimental|Home monitors|This group will be given a home blood pressure monitor to use.
3271606|NCT01579149|Experimental|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg)
3271607|NCT01579149|Placebo Comparator|Placebo|
3271608|NCT01579175|No Intervention|Standard postoperative care|
3271609|NCT01579175|Experimental|Chewing gum arm|Sugar free (extra, spearment) chewing gum given to the patient to chew during waking hours every four hours for 15 minutes
3271610|NCT01579188|Experimental|GV1001|The adjuvant GM-CSF is administered first as an intradermal injection followed in 10-15 minutes by the GV1001 peptide injected into the same site.
3271611|NCT01579188|Placebo Comparator|Placebo|Placebo
3271612|NCT01579201|Experimental|Carbetocin|
3271613|NCT01579227||1-TOP group 1|TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
3271614|NCT01579227||TOP group 2|TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
3271615|NCT01579227||OTOP group-1|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
3271616|NCT01579227||OTOP group-2|OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
3271617|NCT01579227||TAM Group 1|TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
3271618|NCT01579227||Normal Skin|Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
3271619|NCT01579240|Experimental|program visits|visits to intervention program
3271620|NCT01579279|Experimental|ABT-652 6 mg|ABT-652 capsules - twice daily
3271621|NCT01579279|Experimental|ABT-652 12 mg|ABT-652 capsules twice daily
3271622|NCT01579279|Experimental|ABT-652 12 mg - 18 mg|ABT-652 capsules twice daily
3271623|NCT01579279|Placebo Comparator|Placebo|Placebo capsules twice daily
3271624|NCT01579279|Active Comparator|Duloxetine|Duloxetine capsules once daily
3271625|NCT01579292|Experimental|Physical Activity and Diet Intervention|5-month physical activity and diet intervention which includes 6 in-person sessions, mobile app, and pedometer
3271626|NCT01579292|Active Comparator|Pedometer only|Pedometer only
3271627|NCT01579331|Experimental|Dynamic Contour Tonometry|All recruited volunteers in present study, that underwent diurnal GAT tonometry (3 measures) and 5 DCT measurements.
3271628|NCT01579344|Active Comparator|Thyroid carcinoma, Radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma undergoing radioactive iodine therapy
3271629|NCT01579344|No Intervention|Thyroid carcinoma, without radioactive iodine therapy|50 patients (100 eyes) diagnosed with differentiated thyroid carcinoma not undergone radioactive iodine therapy
3271630|NCT01579357|Other|A|Capecitabine in week 1,2,4,5,7 and 8 Cetuximab in week 3 to 9 Oxaliplatin in week 7
3271631|NCT01579357|Other|B|Capecitabine in weeks 1,2,4,5,7, and 8 Cetuximab in weeks 1,8 and 9 Oxaliplatin in week 7
3271632|NCT01579370|Active Comparator|Quaternary ammonium|Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
3271633|NCT01579370|Experimental|Bleach|Rooms will be terminally cleaned using bleach-containing products.
3271634|NCT01579370|Experimental|Quaternary ammonium and UV-C light|Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
3271635|NCT01579370|Experimental|Bleach and UV-C light|Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.
3271636|NCT01579383|Experimental|Part A, Cohorts A - H|ALD403/Placebo
3271637|NCT01579383|Experimental|Part A, Cohort I|ALD403/Placebo
3271638|NCT01579383|Experimental|Part B|ALD403/Placebo/Sumatriptan
3377130|NCT04757961|Experimental|Lifestories|Participants in this condition will be actively participating in the online intervention for 4 weeks.
3377131|NCT04757961|No Intervention|Waitlist Control Condition|Participant in the waitlist group will be asked to not use other self-help websites or books for four weeks, after which they will be given weekly access to LifeStories modules. All participants will be asked to continue their antidepressant treatment as usual as directed by their primary care provider.
3271639|NCT01579396|Experimental|septeX|septeX CVVH for 12h after cardiac surgery
3271640|NCT01579396|Other|standard therapy|standard therapy according to local practice
3377132|NCT04756726|Experimental|Phase 1: Arm A - CFT7455|Participants with r/r NHL or r/r MM will be treated with oral CFT7455 QD
3377133|NCT04756726|Experimental|Phase 1: Arm B1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455 QD until the determination of maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
3377134|NCT04756726|Experimental|Phase 1: Arm B2 - CFT7455 in combination with dexamethasone|Participants with r/r MM will be treated with oral CFT7455 in combination with a fixed dose of oral dexamethasone in each cohort
3377135|NCT04756726|Experimental|Phase 1: Arm C - CFT7455|Participants with r/r NHL will be treated with oral CFT7455 QD in each cohort until determination of MTD/RP2D
3377136|NCT04756726|Experimental|Phase 2: Arm 1 - CFT7455|Participants with r/r MM will be treated with oral CFT7455
3377137|NCT04756726|Experimental|Phase 2: Arm 2 - CFT7455 in combination with dexamethasone|Participants with r/r MM treated with oral CFT7455 in combination with oral dexamethasone
3377138|NCT04756726|Experimental|Phase 2: Arm 3 - CFT7455|Participants with r/r mantle cell lymphoma (MCL) treated with oral CFT7455
3377139|NCT04756726|Experimental|Phase 2: Arm 4 - CFT7455|Participants with r/r peripheral T-cell lymphoma (PTCL) treated with oral CFT7455
3377140|NCT04755283|Experimental|Abelacimab (MAA868)|"Treatment group 1: Abelacimab middle dose subcutaneous (s.c.) monthly~Treatment group 2: Abelacimab high dose subcutaneous (s.c.) monthly"
3377141|NCT04755283|Active Comparator|Rivaroxaban|"Treatment group 3: Rivaroxaban 20 mg by mouth; orally (p.o.) once per day with the evening meal~Patients with a Creatinine Clearance (CrCl) ≤50 ml/min by the Cockcroft-Gault equation will have a dose adaptation to rivaroxaban 15 mg p.o. daily."
3377143|NCT04753164|Experimental|100 mg twice daily (b.i.d.) ACT-539313|
3377144|NCT04753164|Placebo Comparator|Placebo|
3377146|NCT04744363|Experimental|AVT04 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
3377147|NCT04744363|Active Comparator|US Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
3377148|NCT04744363|Active Comparator|EU Stelara 45 mg SC|Single dose Pre-filled syringe to be injected subcutaneously into thigh or abdomen
3377149|NCT04743661|Experimental|Recurrent Medulloblastoma|This arm aims to estimate event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 131I-omburtamab in patients with recurrent medulloblastoma. Patients with recurrent medulloblastoma will undergo surgery if feasible prior to study entry, followed by Induction Chemotherapy with irinotecan, temozolomide, and bevacizumab on study as per the Children's Oncology Group (COG) trial ACNS0821. Following 2 or 4 courses of chemotherapy and if radiographic disease status is stable or improved, patients will receive 2 therapeutic doses of 50 mCi cRIT 131I-omburtamab during Radioimmunotherapy. Following Radioimmunotherapy, patients may resume to Maintenance Chemotherapy with irinotecan, temozolomide, and bevacizumab for up to 12 total courses of chemotherapy or until disease progression, whichever occurs sooner.
3271641|NCT01579409|Other|1-25th percentile of the PNNS score|
3271642|NCT01579409|Other|75-100th percentile of the PNNS score|
3271643|NCT01579422|Experimental|social cognitive training|
3377150|NCT04743661|Experimental|Recurrent Ependymoma|This is a feasibility cohort. The primary objective is to assess feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma and to assess dosimetry. Patients must have progressed after initial surgery, radiation therapy, or other therapies. Patients will undergo surgery (if feasible) prior to study entry with the goal of achieving stable or better disease. Tumor tissue (archived or new) will be tested for B7H3 prior to enrollment. If positive, patients will enroll on Stratum 2 and receive one dosimetry dose (2 mCi) of cRIT 131I-omburtamab with nuclear medicine scintigraphy using SPECT during the Dosimetry Course (14 days in length). Following the Dosimetry Course and within 2 weeks of the dosimetry dose, patients may continue to Radioimmunotherapy to receive 2 therapeutic doses (50 mCi) of cRIT 131I-omburtamab.
3271644|NCT01579435|Experimental|Therapeutic tDCS|6 patients with essential tremor
3271645|NCT01579435|Experimental|Physiopathological tDCS|6 patients with essential tremor
3271646|NCT01579448|Experimental|Vaccine to past vaccinated participants|The first arm includes subjects, who were immunized with two Shanchol™ doses, five years prior. In this study, arm one will receive one Shanchol™ booster dose at baseline and one booster dose on day fourteen.
3271647|NCT01579448|Active Comparator|Vaccine to past placebo recipients|The second arm includes subjects, who received two placebo doses, five years prior. Arm two will receive a primary immunization series consisting of one Shanchol™ dose at baseline and one at day fourteen
3271648|NCT01579448|Placebo Comparator|No intervention to past placebo recipients|The third arm includes subjects, who received two placebo doses, five years prior. This third arm will not receive any intervention and will serve to represent a baseline immune response by vaccine naïve individuals exposed to natural exposure.
3271649|NCT01579461|Experimental|mild hepatic impairment|
3271650|NCT01579461|Experimental|moderate hepatic impairment|
3271651|NCT01579461|Experimental|healthy volunteers (matched with mild hepatic)|
3271652|NCT01579461|Experimental|healthy volunteers (matched with moderate hepatic)|
3271653|NCT01579500|Active Comparator|botulinum toxin A|
3271654|NCT01579500|Placebo Comparator|normal saline|
3271655|NCT01579526|Experimental|FP01 Dose 1|Drug
3271656|NCT01579526|Experimental|FP01 Dose 2|Drug
3271657|NCT01579526|Experimental|FP01 Dose 3|Drug
3271658|NCT01579526|Active Comparator|Comparator|Drug
3271659|NCT01579539|Experimental|Patients|Patients with moderate to severe thyroid-associated ophthalmopathy
3271660|NCT01579552|Experimental|Intervention Group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
3271661|NCT01579552|Active Comparator|attention control group|The EMPOWER intervention trial is a 12-month study of 360 women from the Childhood Cancer Survivor Study who have previously been treated with chest radiation, are 25 to 49 years of age at the time of enrollment, are 8 years or more since their chest radiation, and have not had a mammogram or other breast imaging study in the preceding two years. Following a baseline questionnaire, participants will be randomized to the attention control group (N=120) or the intervention group (N=240).
3271662|NCT01579591|Experimental|VSL#3 PROBIOTIC PREPARATION|
3271663|NCT01579591|Placebo Comparator|Placebo|
3271664|NCT01579604|Experimental|Surgical arm|"Nerve reconstruction:~Early nerve transfer (around 6-9 months post cervical spine injury) will be performed in this group of patients."
3271665|NCT01579604|No Intervention|Non-surgical (or observed)|Patients in this group will receive standard of care and be observed for up to two years post injury.
3271666|NCT01579617|Experimental|BUtiful|Intervention arm, 'BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved', has 8 website sessions focused on pregnancy and STI prevention
3271667|NCT01579617|Other|DIVAS|Attention control arm, 'DIVAS. Diversity, Individuality, Vitality, Activity and Strong', has 8 website sessions focused on general health and nutrition
3271668|NCT01579630|Experimental|Pemetrexed 500mg/m2 iv|
3271669|NCT01579630|Experimental|Pemetrexed 500 mg/m2 i.v. and Gefitinib 250 mg|
3271670|NCT01579643|Experimental|LALAK|
3271671|NCT01579643|Active Comparator|Penetrating Keratoplasty (KP)|
3271672|NCT01579656|Experimental|Salba|25g of ground Salba baked into a bran muffin
3271673|NCT01579656|Experimental|Poppy|25g of ground poppy seeds baked into a bran muffin
3271674|NCT01579656|Experimental|Flaxseed|25g of ground flaxseed baked into a bran muffin
3271675|NCT01579656|Experimental|Sesame|25g of ground sesame seeds baked into a bran muffin
3271676|NCT01579656|Placebo Comparator|Wheat Bran|Bran muffin matched for total available carbohydrates, total dietary fibre and calories
3271677|NCT01579682|Experimental|Psychotherapy|Family-Based Therapy (12 sessions)
3271678|NCT01579682|Experimental|Family-Based Therapy with Intensive Family-Focused Treatment|The patient will receive 4 sessions of Family-Based therapy, and if the participant does not make adequate weight gain within this time period, will be assigned to Intensive Family-Focused Therapy (IFT).
3271679|NCT01579695||Exposed Group will receive Tesamorelin|
3271680|NCT01579695||Control Group will not receive Tesamorelin|
3271681|NCT01579708|Experimental|Program SI! educational intervention|
3271682|NCT01579708|No Intervention|Control|
3271683|NCT01579721|Experimental|SILS-group|20 patients undergoing Single Incision Laparoscopic Surgery
3271684|NCT01579721|No Intervention|CLS-group|20 patients undergoing Conventional Laparoscopic Surgery for rectal cancer
3271685|NCT01579734|Placebo Comparator|Placebo|1 tablet day for 5 years
3271686|NCT01579734|Active Comparator|Tamoxifen|Tamoxifen 5 mg, (1 tablet) day for 5 years
3271687|NCT01579760|Experimental|aflibercept every 2 months|
3271688|NCT01579760|Experimental|aflibercept monthly|
3271689|NCT01579786|No Intervention|Acetaminophen|A group All patients will be treated only with drugs used for this type during the operation and post operative pain controlled with usual acetaminophen drug administration (maximum 3 g/day)
3271690|NCT01579786|Experimental|Acetaminophen and acupuncture|B group patients. All patients will receive the standard pharmacological treatment for the operation. Acetaminophen (maximum 3g/day) during all seven days after surgery and patients will be treated with acupuncture the first day after surgery and thirty minutes before the surgical procedure
3271691|NCT01579799|Active Comparator|Dose 0.5|
3271692|NCT01579799|Active Comparator|Dose 7.5|
3271693|NCT01579799|Active Comparator|Dose 3|
3271694|NCT01579799|Active Comparator|Dose 1.2|
3271695|NCT01579825|Experimental|Buffer|
3271696|NCT01579825|No Intervention|Control|
3271697|NCT01579838|Experimental|Eculizumab|Eculizumab will be administrated according to known protocols.
3271698|NCT01579851|Active Comparator|Propofol-Remifentanil|Anesthesia is maintained with Propofol and Remifentanil; myorelaxation is obtained with rocuronium
3271699|NCT01579851|Active Comparator|Sevoflurane-Remifentanil|Anesthesia is maintained with Sevoflurane and Remifentanil; myorelaxation is obtained with rocuronium
3271700|NCT01579864|Active Comparator|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary.
3271701|NCT01579864|Experimental|Rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
3271702|NCT01579877|Experimental|Yukmijihwang-tang|Yukmijihwang-tang: Real herbal extract granule
3271703|NCT01579877|Placebo Comparator|Yukmijihwang-tang_Placebo|Yukmijihwang-tang_Placebo: Placebo herbal extract granule
3271704|NCT01579903|Experimental|Sequence 1|Subjects randomized to receive Treatment A during Period 1, then Treatment B during Period 2.
3271705|NCT01579903|Experimental|Sequence 2|Subjects randomized to receive Treatment B during Period 1, then Treatment B during Period 2.
3271706|NCT01579929|Experimental|LDE225, Etoposide and Cisplatin|This is a single institution phase I trial of LDE225 combined with etoposide and cisplatin in patients with untreated, newly diagnosed extensive stage small cell lung cancer (ES-SCLC). LDE225 is an oral drug, which will be taken daily by patients. Patient self-reporting via STAR will be used in an evaluation of the extent to which patient-reported toxicity influences dose finding in phase I clinical trials. Specifically, STAR reports will be presented to clinicians in real-time at clinic visits, & clinicians will have an opportunity to either agree or modify the patient self-assessments & use this information in their grading & attribution of toxicities.
3271707|NCT01579942||Patients with Major Depressive Disorder|Patients who have Major Depressive Disorder and are taking a Selective Serotonin Re-uptake Inhibitor (SSRI) as part of another study at our clinic.
3271708|NCT01579942||Healthy Controls|Patient with no history of significant mental health problems.
3271709|NCT01579955||eptacog alpha users|
3271710|NCT01579968||eptacog alpha users|
3271711|NCT01579994|Experimental|Ganetespib (STA-9090) and crizotinib|This protocol is a phase I single arm, open label, single institution study of crizotinib and ganetespib (STA-9090) in patients with ALK+ advanced NSCLC who are crizotinib naïve.
3271712|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and active cholecalciferol|500 mg sodium phenylbutyrate (4-phenylbutyric acid, sodium salt) in tablet form twice daily and 5000 IU of cholecalciferol once daily will be given orally for 2 months
3271713|NCT01580007|Active Comparator|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Drug: Cholecalciferol Placebo: Sodium Phenylbutyrate
3271714|NCT01580007|Active Comparator|Active Sodium Phenylbutyrate and placebo cholecalciferol|Drug: Sodium Phenylbutyrate Placebo: cholecalciferol
3271715|NCT01580007|Placebo Comparator|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate Placebo cholecalciferol
3271716|NCT01580033|Experimental|A+C+hib Conjugate Vaccine|600 infants aged 3-5 months, will be vaccinated on day0, 28, 56
3271717|NCT01580033|Active Comparator|Walvax AC vaccine, Pasteur Hib vaccine|300 infants aged 3-5 months, will be vaccinated on day0, 28, 56
3271718|NCT01580046|Experimental|Iodixanol|
3271719|NCT01580046|Active Comparator|iopromide|
3271720|NCT01580085||Pulmonary embolism|Patients who were diagnosed with pulmonary embolism
3271721|NCT01580085||control group|age and sex matched adults with osa and no thromboembolism
3271722|NCT01580111|Experimental|Short storage|Short storage arm: Will receive blood (Packed red blood cells) of 1 (one) to 10 (ten) days in storage.
3271723|NCT01580111|Active Comparator|Long storage arm|Will be transfused with blood ( packed red cells) of storage age 21- 35 days.
3271724|NCT01580124|Active Comparator|PVI alone|Pulmonary vein isolation alone in persistent atrial fibrillation
3271725|NCT01580124|Active Comparator|PVI + Defragmentation + linear lesions|AF ablation continuation aiming for AF termination
3271726|NCT01580137||healthy conscripts|non allergic subjects who have not a history of recurrent rhinosinusitis
3271727|NCT01580137||subjects with recurrent rhinosinusitis|subjects who have experienced recurrent rhinosinusitis episodes (3 during the previous 3 years)
3271728|NCT01580150|Experimental|Berry meal|Carbohydrate meals with berries
3271729|NCT01580150|Active Comparator|Reference meal|Carbohydrate meals without berries
3271730|NCT01580163|Experimental|JITAI combined therapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
3271731|NCT01580163|Experimental|Methadone combined herapy group|The investigator will adopt JITAI combined psychological intervention and social support in Shanghai-related community.
3271732|NCT01580163|Experimental|JITAI therapy group|The investigator will adopt JITAI combined social support in Shanghai-related community and outside of Shanghai.
3271733|NCT01580176|Experimental|GlucoseMonitor|
3271734|NCT01580189|Active Comparator|Milk|Chocolate milk compared to protein supplement
3271735|NCT01580189|Active Comparator|Whey protein|Whey protein compared to milk
3271736|NCT01580189|Placebo Comparator|Sugar|Maltodextrin compared to treatments
3271737|NCT01580202|Active Comparator|Lamivudine|LAM (100 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
3271738|NCT01580202|Experimental|Entecavir|ETV (0.5 mg/day) will be started within 1 week prior to initiation of the 1st cycle of chemotherapy, and continued until 24 weeks after completion of the last chemotherapy.
3271739|NCT01580215||Main cohort|"Patients of both genders of at least 18 years of age~Who understand and voluntarily sign an informed consent form~FEV1 > 15% predicted and < 45% predicted~RV >180% predicted~Diagnosis of emphysema with CT evidence of hyperinflation~Absence of collateral ventilation according to Chartis Assessment System~Treated with Zephyr Endobronchial Valve (EBV)"
3271740|NCT01580228|Experimental|Dinaciclib|
3271741|NCT01580228|Active Comparator|Ofatumumab|
3271742|NCT01580241||Surgery group|Patients with pancreatic cancer who undergo surgical treatment only
3271743|NCT01580241||Chemotherapy group|Patients with pancreatic cancer who undergo chemotherapy treatment only
3271744|NCT01580241||Neoadjuvant group|Patients with pancreatic cancer who undergo neoadjuvant chemotherapy and surgery
3271745|NCT01580241||Adjuvant group|Patients with pancreatic cancer who undergo surgery followed by chemotherapy
3271746|NCT01580254|Active Comparator|IOPIZE© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is IOPIZE©
3271747|NCT01580254|Active Comparator|GALAXIA© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is GALAXIA©
3271748|NCT01580254|Active Comparator|Latanoprost RATIOPHARM© eyedrops|subjects will receive a IOP-lowering therapy with latanoprost eyedrops. Drug commercial name is Latanoprost RATIOPHARM©
3271749|NCT01580280|Experimental|Thrust manipulation|
3271750|NCT01580280|Active Comparator|Non-thrust mobilization and exercise|
3271751|NCT01580319|No Intervention|Control|Participants do not receive a physical exercise plan. Participants receive a simple orientations about lifestyle activities.
3271752|NCT01580319|Experimental|Exercise|Participants receive a physical exercise plan to play at home
3271753|NCT01580345|Active Comparator|Docosa-hexaenoic Acid (DHA)|
3271754|NCT01580345|Placebo Comparator|Placebo|Corn-Soy Oil
3271755|NCT01580358|Active Comparator|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
3271756|NCT01580358|Placebo Comparator|starch|Starch in the same granule as intervention group for this double-blind trial
3271757|NCT01580371|Experimental|Treatment|CKD-581
3271758|NCT01580384||Cohort|
3271759|NCT01580397|Experimental|INNO-206|
3271760|NCT01580436|Experimental|Tricuspid Valve Annuloplasty|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to concomitant tricuspid valve annuloplasty.
3271761|NCT01580436|No Intervention|Conservative arm|Patients, undergoing mitral valve surgery with no significant tricuspid valve regurgitation despite tricuspid annular dilation, randomized to mitral valve surgery without concomitant tricuspid valve annuloplasty.
3271762|NCT01580462||Children and Adolescent with type 1 diabetes on CSII|
3271763|NCT01580475|Experimental|Lifestyle (exercise training)|Training, detraining and retraining
3271764|NCT01580514|Active Comparator|Exenatide|"Drug: Exenatide~10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
3271765|NCT01580514|Placebo Comparator|Saline|"Drug: Saline~10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
3271766|NCT01580527|Active Comparator|total parenteral nutrition|
3271767|NCT01580527|Experimental|Early enteral nutrition|
3271768|NCT01580540||Group A, subjects with colorectal cancer|Subjects between ages 50 and 84 identified to have CRC. Blood and stool specimens are collected and tested after colonoscopy and prior to surgery or other interventions.
3271769|NCT01580540||Group B, subjects without CRC|Subjects between ages 50 and 84 who provide stool and blood specimens prior to colonoscopy.
3271770|NCT01580553|Placebo Comparator|Levocarnitine|
3271771|NCT01580553|Active Comparator|L-carnitine|
3271772|NCT01580566||Group 1 - Control|"Non-Q wave MI subjects with normal cardiac and renal function (defined as eGFR >60ml/min) not undergoing a cardiac procedure involving contrast will serve as control for renal injury subjects."
3271773|NCT01580566||Group 2 - stable CAD or non-Q wave MI|Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI with normal cardiac and renal function (defined as eGFR >60ml/min) will control for the contrast STEMI patients are likely to receive as part of their post-MI management
3271774|NCT01580566||Group 3 - Acute STEMI without chronic kidney disease|Acute STEMI patients (n=40), without chronic kidney disease (defined as eGFR ≥60ml/min).
3271775|NCT01580566||Group 4 - Acute STEMI with kidney disease|Acute STEMI patients (n=40), with evidence of background chronic kidney disease (eGFR <60ml/min).
3271776|NCT01580579||locally advanced lung cancer|Patients with locally advanced lung cancer who are candidates to chemoradiation
3271777|NCT01580605||Users of somatropin|
3271778|NCT01580631||BE with dysplasia.|Patients having Barrett's esophagus with dysplasia.
3271779|NCT01580631||BE without dysplasia.|Patients having Barrett's esophagus without dysplasia.
3271780|NCT01580644|Experimental|Period 1: formulation 1 oral solution|
3271781|NCT01580644|Experimental|Period 2: formulation 2 capsule|
3271782|NCT01580644|Experimental|Period 3: Selected formulation + food|
3271783|NCT01580644|Experimental|Period 4: Selected formulation at higher dose|
3271784|NCT01580657|Experimental|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
3271785|NCT01580657|Experimental|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
3271786|NCT01580657|Experimental|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
3271787|NCT01580657|Active Comparator|D. Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
3271788|NCT01580657|Active Comparator|E. General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
3271789|NCT01580657|Active Comparator|F. No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
3271790|NCT01580683|Experimental|Ascorbic acid|
3271791|NCT01580683|Placebo Comparator|Placebo|
3271792|NCT01580696|Active Comparator|Non-vaccine clinically matched control group|HLA-A2-negative patients and HLA-A2+ patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression.
3271793|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
3271794|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
3271795|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus E39 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39 6 and 12 months after completion of the primary vaccine series.
3271796|NCT01580696|Experimental|E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 100mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3271797|NCT01580696|Experimental|E39 peptide (500mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 500mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3271798|NCT01580696|Experimental|E39 peptide (1000mcg) /GM-CSF vaccine plus J65 booster|HLA-A2+ patients receive 1000mg E39 peptide/GM-CSF vaccine intradermally every 3-4 weeks for a total of up to six inoculations followed by 500mg booster inoculations of E39' (J65) 6 and 12 months after completion of the primary vaccine series.
3271799|NCT01580709|Active Comparator|Multimodality Approach|Patients in the multimodality arm will undergo a single brushing for routine cytology, a second brush sample for Fluorescence In Situ Hybridization and a cholangioscopy with site-directed biopsies for histology.
3271800|NCT01580709|Active Comparator|Multiple brush samples|In patients randomized to multiple brushing samples, subsequent brushings #2-7 will be labeled separately and consecutively and sent to cytology. The cytopathologist will review each specimen for cellularity using a previously validated scoring system and presence of malignancy (positive, highly suspicious, atypical, normal).
3271801|NCT01580722|Other|early|patients underwent < 8 weeks reconstruction after injury
3271802|NCT01580722|Other|delay|patients underwent > 8 weeks reconstruction after injury
3271803|NCT01580735|Experimental|ARQ 197|
3271804|NCT01580748|Experimental|Treatment arm|single arm study
3271805|NCT01580761|Experimental|Sleep restriction|Sleep restriction
3271806|NCT01580761|No Intervention|Normal sleep|Normal sleep
3271807|NCT01580774||Post-discharge phone call|All patients in this group will receive a phone call within 72-hours of being discharged from hospital.
3271808|NCT01580774||Usual care (no phone call)|
3271809|NCT01580787|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
3271810|NCT01580787|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
3271811|NCT01580800||Breast cancer survivors|Patients who have undergone breast cancer treatment (e.g. surgery, node dissection, chemotherapy and/or radiation therapy), and what affect this has had on their arm health.
3271812|NCT01580813|Experimental|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visi
3271813|NCT01580813|Placebo Comparator|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit
3271814|NCT01580826|No Intervention|raw milk|Infants who were assigned to the raw group received fresh or thawed milk from their own mother, cultured weekly with a semi-quantitative analysis. Raw milk was withheld if it contained any Gram-negative organisms, S. aureus or enterococci.
3271815|NCT01580826|Active Comparator|pasteurized milk|Infants who were assigned to pasteurization received own mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
3271816|NCT01580839|Experimental|intravenous tissue plasminogen activator|
3271817|NCT01580839|Placebo Comparator|Placebo|
3271818|NCT01580852|Active Comparator|Dead Sea Water|
3271819|NCT01580852|Sham Comparator|Pool Water|
3271820|NCT01580865|Active Comparator|Mycophenolate Mofetil (MMF)|MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. .
3271821|NCT01580865|Experimental|Tacrolimus (TAC)|TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter
3271822|NCT01580878|Experimental|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
3271823|NCT01580878|Active Comparator|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
3271824|NCT01580878|Placebo Comparator|Butenafine Vehicle|Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
3271825|NCT01580891|Experimental|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.)
3271826|NCT01580891|Active Comparator|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% (Merz Pharmaceuticals)
3271827|NCT01580891|Placebo Comparator|Placebo topical cream|Placebo topical cream (Taro Pharmaceuticals Inc.)
3271828|NCT01580917||Diabetic Test|Diabetic individuals with a history of previous plantar ulcer and a high risk of developing a foot ulceration
3271829|NCT01580917||Healthy Controls|Non-diabetic, healthy individuals with low risk of developing a neurogenic foot ulcer
3271830|NCT01580930|No Intervention|Control group|Group had outcome measures collected and were instructed to not change activity and sedentary time behavior
3271831|NCT01580930|Experimental|Exercise|Participants performed 5 days per week, 40 min per session of exercise training under direct supervision of personal trainer.
3271832|NCT01580930|Experimental|Sedentary time reduction|participants were give strategies to reduce sedentary time
3271833|NCT01580930|Experimental|exercise plus sedentary time reduction|Participants completed exercise training (5 days per week, 40 min per session) plus were given sedentary time reduction intervention
3271834|NCT01580943|Active Comparator|Antiplaque Efficacy|"This study was designed as a randomized, two group parallel, double-blind, 3-day non-brushing clinical trial. The sample size (50 participants) was determined using similar studies, making it a convenience sample.~Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds."
3271835|NCT01580943|Active Comparator|Taste and Side Effects|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
3271836|NCT01580956|Other|VARIABLE-PSV ventilatory mode|
3271837|NCT01580956|Other|STANDARD-PSV ventilatory mode|
3271838|NCT01581034|Active Comparator|Padma|
3271839|NCT01581034|Placebo Comparator|Placebo|
3271840|NCT01581047||Amoxicillin/Clavulanic Acid|Patients in the intensive care unit, with an infection which will be treated with Amoxicillin/Clavulanic Acid.
3271841|NCT01581047||Cefuroxime|Patients in the intensive care unit, with an infection which will be treated with Cefuroxime.
3271842|NCT01581060|Experimental|WX-554|
3271843|NCT01581073|Experimental|High Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 12.0g/dL and it should be maintained greater than or equal to 11.0g/dL and less than 13.0g/dL. If the patients do not have medical history of myocardial infarction, stroke, pulmonary embolism, unstable angina, or peripheral artery disease, the target Hb level will be greater than or equal to 12.0g/dL and less than 13.0g/dL. Maximum dose of darbepoetin alfa is 240 microgram per 4 weeks.
3271844|NCT01581073|Active Comparator|Low Hb group|Darbepoetin alfa is given to the patients. Target Hb level is 10.0g/dL and it should be maintained greater than or equal to 9.0g/dL and less than 11.0g/dL. If the Hb level exceeds 10.0g/dL in patients, reduce the dose amount or stop giving dose.
3271845|NCT01581099||Clinical treatment|Diabetic individuals refractory to medical treatment kept under clinical treatment guidelines and lifestyle
3271846|NCT01581099||Surgery|Diabetic individuals refractory to conservative clinical treatment subject to Digestive Adaptations III Surgery.
3271847|NCT01581099||Control|Healthy individuals (normal weight and no cardiovascular risk factors) will be used to evaluate the behavior incretin hormones in healthy individuals, serving as a benchmark to analyze the results obtained in other groups.
3271848|NCT01581112|Experimental|Heavy armpit odour|Subjects with heavy armpit odour.
3271849|NCT01581112|Experimental|Heavy foot odour|Subjects with heavy foot odour.
3271850|NCT01581125|Experimental|Sleep:wake 2|Sleep and wake durations for arm 2 for inpatient portion of protocol. .There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 1.
3271851|NCT01581125|Experimental|Sleep:wake 1|Sleep and wake durations for arm 1 of the inpatient portion of the protocol. There are a variety of sleep and wake durations during the protocol; some of these are longer and some are shorter and some are the same as in arm 2.
3271852|NCT01581138|Experimental|12 week treatment|
3271853|NCT01581138|Experimental|16 week treatment|
3271854|NCT01581151|Active Comparator|Monthly Ranibizumab|"• Patients will receive a ranibizumab intravitreal injection on day 0. During each other visit, patients will receive a ranibizumab intravitreal injection. The protocol will use the term monthly to represent a 30 day interval between treatments."
3271855|NCT01581151|Experimental|Dexamethasone intravitreal implant|"Patients will receive a dexamethasone intravitreal implant injection at day 0.~During monthly visits 1,2,3, and 5, patients will receive a ranibizumab intravitreal injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse. The injection procedure is described in the next section.~During monthly visit 4, patients will receive a dexamethasone intravitreal implant injection if the macula SD-OCT during that visit shows mean central foveal thickness ≥ 250 μm or the best-corrected visual acuity is 20/40 or worse."
3271856|NCT01581164||HSCT patients|Patients who have been treated with HSCT
3271857|NCT01581177|Experimental|T1|Two inhalations, one of Albuterol DPI 25 mcg/inh and one of Placebo DPI; Total Albuterol dose of 25 mcg
3271858|NCT01581177|Experimental|T2|Two inhalations of Albuterol DPI 25 mcg/inh; Total Albuterol dose of 50 mcg
3271859|NCT01581177|Experimental|T3|Two inhalations, one of Albuterol DPI 90 mcg/inh and one of Placebo DPI; Total Albuterol dose of 90 mcg
3271860|NCT01581177|Experimental|T4|Two inhalations of Albuterol DPI 90 mcg/inh; Total Albuterol dose of 180 mcg
3271861|NCT01581177|Placebo Comparator|P|Two inhalations Placebo DPI; Total Albuterol dose of 0 mcg
3271862|NCT01581177|Active Comparator|R1|One inhalation of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 90 mcg
3271863|NCT01581177|Active Comparator|R2|Two inhalations of Albuterol MDI 90 mcg/inh; Total Albuterol dose of 180 mcg
3271864|NCT01581190|Experimental|Bananas versus 6% carbohydrate beverage|
3271865|NCT01581203|Experimental|Arm 1: Null or Partial Responder to P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
3271866|NCT01581203|Experimental|Arm 2: Intolerant to or Ineligible for P/R (ASV + DCV)|"Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 Weeks"
3271867|NCT01581203|Experimental|Arm 3: Treatment naive (ASV + DCV)|"[Subjects will receive ASV + DCV for 24 weeks] followed by ASV + DCV for 24 weeks in protocol AI444026]~Subjects meeting prespecified rescue criteria in the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg/1200 mg (total daily dose) tablet by mouth for 24 or 48 weeks"
3271868|NCT01581203|Experimental|Arm 4: Null or Partial Responder to P/R (ASV + DCV) 24/48 week|"Subjects meeting prespecified rescue criteria in the null or partial responder cohort or active arm of the treatment naive cohort may have therapeutic rescue instituted with QUAD regimen (QUAD= ASV + DCV + P/R)~Asunaprevir 100 mg Capsules by mouth, Twice daily for 24 or 48 Weeks~Daclatasvir 60 mg Tablet by mouth, Once daily for 24 or 48 Weeks~Pegylated-interferon alfa 2a (PegIFN) 180 mcg/0.5 mL injection subcutaneously (SC), once weekly for 24 or 48 weeks~Ribavirin 1000 mg / 1200 mg (total daily dose) Tablet by mouth, for 24 or 48 weeks"
3271869|NCT01581216|Experimental|10 minute walk|10-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3271870|NCT01581216|Experimental|20 minute walk|20-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3271871|NCT01581216|Experimental|30 minute walk|30-minute walk and exercises for the upper limbs with 1 lb-dumbbells
3271872|NCT01581229|Experimental|NPPV|
3271873|NCT01581229|Active Comparator|Control|
3271874|NCT01581242|Experimental|A|
3271875|NCT01581242|Experimental|B|
3271876|NCT01581242|Experimental|C|
3271877|NCT01581255||Conventional lung protective ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the conventional lung protective ventilation arm of the OSCILLATE trial.
3271878|NCT01581255||High frequency oscillation ventilation|Critically-ill patients with the acute respiratory distress syndrome randomized to the high frequency oscillation ventilation arm of the OSCILLATE trial.
3271879|NCT01581320|Experimental|DP-R206|
3271880|NCT01581320|Active Comparator|Bonviva|
3271881|NCT01581333|Experimental|Experimental Arm|Empirical antimicrobial treatment discontinuation
3271882|NCT01581333|Active Comparator|Control Arm|Standard empirical antimicrobial treatment discontinuation
3271883|NCT01581346|Experimental|exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
3271884|NCT01581359|Active Comparator|GnRHa|Triptorelin acetate 3,75 mg subcutaneous injection administered on days 1, 28 and 56 after menstrual cycle.
3271885|NCT01581359|Placebo Comparator|Physiological serum|physiological serum subcutaneous injection with same delivery device and same volume that active comparator ) administered on days 1, 28 and 56 after menstrual cycle.
3271886|NCT01581372|Experimental|Pharmacist care|
3271887|NCT01581372|No Intervention|Usual care|
3271888|NCT01581385||Carotid endarterectomy|Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery.
3271889|NCT01581398|Experimental|A1(Genotype2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 800mg/day
3271890|NCT01581398|Active Comparator|A2(Genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 800mg/day
3271891|NCT01581398|Experimental|B1(Non-genotype 2/3)|Ypeginterferon alfa-2b 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight
3271892|NCT01581398|Active Comparator|B2(Non-genotype 2/3)|Pegasys 180μg/week, in combination with Ribavirin 1000-1200mg/day based on body weight.
3271893|NCT01581411|Experimental|IA t-PA|intra-ophthalmic artery injection of tissue plasminogen activator
3271894|NCT01581450|Experimental|Tested drug|Remifentanil at 0.1 µg/kg/min Tested drug (N2O 35%): 35%/15%/50% N2O/N2/O2
3271895|NCT01581450|Active Comparator|Gas Active control|Remifentanil at 0.1 µg/kg/min Gas active control (N2O 50%):50%/50% N2O/O2
3271896|NCT01581463|Active Comparator|Liothyronine, Sodium|Healthy adults.
3271897|NCT01581476|Active Comparator|Statin|Participants receive active statin and placebo ACE Inhibitor
3271898|NCT01581476|Active Comparator|Angiotensin-converting enzyme inhibitor|Participants receive active ACE Inhibitor and placebo statin
3271899|NCT01581476|Placebo Comparator|Placebo|Participants receive placebo ACE Inhibitor and placebo statin
3271900|NCT01581476|Other|Combination therapy|Participants receive both active ACE Inhibitor and active Statin
3271901|NCT01581489||Early cord clamping (ECC)|Early cord clamping consisted of early (=< 10 s) clamping of the umbilical cord at birth.
3271902|NCT01581489||Delayed cord clamping (DCC)|Delayed cord clamping consisted of delayed (>= 180 s) clamping of the umbilical cord at birth.
3271903|NCT01581502||NVAF, acute ischemic stroke/TIA|Consecutive acute ischemic stroke/TIA patients with nonvalvular atrial fibrillation; most of these patients begin to receive anticoagulant therapy after index stroke/TIA for secondary prevention
3271904|NCT01581515|Active Comparator|P-E group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
3271905|NCT01581515|Active Comparator|X-P group|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
3271909|NCT01581606||Group 1R and 1T AMD Screening|Group 1 patients will be collected through all referrals to any of the physician investigators with a provisional diagnosis of possible wet AMD. Any request for clinical evaluation of a patient for presumed wet AMD will be randomized into Group 1R (Routine Screening) and Group 1T (Tele-ophthalmology screening).
3377157|NCT04737096|Experimental|tDCS+DAOIB|
3377158|NCT04737096|Placebo Comparator|tDCS+placebo|
3377162|NCT04732806|No Intervention|Treatment as usual|
3377163|NCT04732806|Experimental|Intervention|Six months of ad lib Mightier play in home
3271910|NCT01581606||Group 2R and 2T Follow up|Group 2 patients will be collected from the patients previously treated for wet AMD within the practices of the physician investigators. All patients in whom the disease is inactive (not receiving active treatment) and who therefore require monitoring will be randomized into Group 2R (Routine Monitoring) and Group 2T (Teleophthalmology Monitoring).
3377164|NCT04732065|Experimental|Arm A: ONC206 for participants with diffuse midline gliomas + prior therapy|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3377165|NCT04732065|Experimental|Arm B: ONC206 + radiation therapy for newly diagnosed participants|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3377166|NCT04732065|Experimental|Arm C: ONC206 + radiation therapy, DMGs with evidence of first progression but previously untreated|Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3377167|NCT04732065|Experimental|Arm D: ONC206 Therapy, Primary malignant brain tumors with progression|Patients receive ONC206 PO QD on days 1, 8, 15, 22. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
3377170|NCT04725851|Experimental|High concentration Oxygen Therapy|12-15 Litre/min O2 delivery via Non-Rebreather Mask (NRM) consecutively for 24 hours.
3377171|NCT04725851|Placebo Comparator|Room air or low concentration oxygen|Room air or low concentration oxygen (0-2 Litre/min O2 ) consecutively for 24 hours.
3377173|NCT04718181|Experimental|Part 1|"Cohort A+B: participants will receive, in a five-period crossover way, a single oral dose of risdiplam oral solution 5 mg in fasted state and thereafter risdiplam/F21 or F22 dispersible tablet 5 mg as tablet in fasted and fed states; tablet dispersed in water in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations.~Cohort C+D: participants will receive, in a two-period fixed sequence design, a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state and omeprazole 40 mg once daily for 7 days + a single dose of risdiplam/F21 or F22 dispersible tablet 5 mg in fasted state, on the 7th day of omeprazole. There will be a 14-day wash-out between the two treatment periods.~Cohort E: participants will receive, in a two-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted and fed states, with a 14-day wash-out period in between the single-dose administrations."
3377174|NCT04718181|Experimental|Part 2 (optional)|"Group 1: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as swallowed tablet in fasted state; swallowed tablet in fed state.~Group 2: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as tablet dispersed in water in fasted state; tablet dispersed in water in fed state."
3377175|NCT04718181|Experimental|Part 3 (optional)|"Group 1: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as swallowed tablet in fasted state; swallowed tablet in fed state.~Group 2: participants will receive, in 3-period crossover design, a single oral dose of risdiplam oral solution 5 mg in fasted state and the selected dispersible tablet (F21 or F22) as tablet dispersed in water in fasted state; tablet dispersed in water in fed state."
3377176|NCT04717479|Other|Intervention|Participants will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
3377177|NCT04717479|Other|Wait-list Control|Participants will wait 8 weeks and then they will be paired with an English language learner and engage in 8 weeks, 1 hour videoconferencing sessions.
3271911|NCT01581632|Other|LipiScan/LipiScan IVUS|valuation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
3271912|NCT01581645|Experimental|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
3271913|NCT01581671||Patients having a first time angiogram|Patients who are coming to the Cardiac Cath Lab to have an angiogram for the first time
3271914|NCT01581697|Experimental|Oat bran|
3271915|NCT01581723|Active Comparator|Monopolar TUR|Monopolar diathermy is used to perform tranurethral resection of bladder tumor
3271916|NCT01581723|Experimental|Biploar TUR|Bipolar diathermy is used to perform transurethral resection of bladder tumor
3271917|NCT01581736|Experimental|Exercise|Proteomics of muscle after a single bout of exercise compared to baseline with U100 Humulin infusion at rate of 80 milliunits(mU)/m^2 surface area.
3271918|NCT01581749|Other|36.25Gy to prostate in 5 fractions|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
3271919|NCT01581762|Sham Comparator|Conventional 22G Needle|Device: EUS-FNA with conventional 22G Needle
3271920|NCT01581762|Active Comparator|22G Procore Needle|Device: EUS-FNA with 22G Procore Needle which has a reverse bevel at the tip of the needle to enhance tissue collection
3271921|NCT01581775|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
3271922|NCT01581775|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
3271923|NCT01581788|Experimental|Divalproex Sodium ER Tablets, 500 mg|Divalproex Sodium ER Tablets, 500 mg of Dr. Reddy's Laboratories Limited
3271924|NCT01581788|Active Comparator|Depakote ER Tablets, 500 mg|Depakote ER Tablets, 500 mg of Abbott Laboratories
3271925|NCT01581801|Other|Gastric Bypass|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo gastric bypass
3271926|NCT01581801|Other|Sleeve Gastrectomy|60 subjects obese subjects with complications or morbidly obese subjects will be assigned randomly to this arm to undergo sleeve gastrectomy
3271927|NCT01581814|Active Comparator|Metformin|31 subjects were randomized to receive 500 mg Metformin per 3/die
3271928|NCT01581814|Active Comparator|0.03 mg EE plus 3 mg of DRPS|
3271929|NCT01581814|Active Comparator|Metformin plus Yasmin|
3271930|NCT01581827||Study population|People at high risk of heart failure (from SCREEN-HF study)
3271931|NCT01581840|Experimental|5Fu-mitomycine-panitumumab + radiotherapy|5 FU = 400 or 600 or 80 or 1000 mg depending of phase I results, days 1 to 4 weeks 1, 5 and 8 mitomicyne = 10 mg/m² day 1 week 1 and days 1, weeks 5 and 8 Panitumumab = 3 or 6 mg/kg (depending of phase I results) days 1, weeks: 1, 3, 5, 8 and 10
3271932|NCT01581853|Other|Lopinavir/ritonavir 800 mg / 200mg|Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
3271933|NCT01581866|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
3271934|NCT01581866|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
3271935|NCT01581879|Experimental|Ziprasidone HCL Capsules, 20 mg|Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Laboratories Limited
3271936|NCT01581879|Experimental|Geodon Capsules, 20 mg|Geodon Capsules, 20 mg of Pfizer Inc
3271937|NCT01581892|Experimental|Bone marrow stem cells|Bone marrow is obtained by posterosuperior iliac crest aspiration under topical anesthesia. Mononuclear cells were isolated by Ficoll density gradient and will be resuspended in heparinized isotonic saline for mixing with osteogenic matrix.
3271938|NCT01581905|Active Comparator|LH Group|The LH Group includes individuals undergoing conventional laparoscopic hysterectomy, total or supracervical.
3271939|NCT01581905|Active Comparator|RH Group|The RH Group includes individuals undergoing Robot-Assisted laparoscopic hysterectomy, total or supracervical.
3271940|NCT01581944|No Intervention|No Treatment (Control)|Women were randomised to receive no gonadotropin-releasing hormone agonist prior to myomectomy.
3271941|NCT01581944|Experimental|2 Doses Goserelin|Women were randomised to receive 2 doses of 3.6mg of gonadotropin releasing hormone agonist prior to the myomectomy.
3271942|NCT01581944|Experimental|3 Doses Goserelin|Women were randomised to receive 3 doses of the gonadotropin-releasing agonist (3.6mg monthly injections).
3271943|NCT01581957|Active Comparator|Specific Enteral formulation|
3271944|NCT01581957|Placebo Comparator|Standard enteral formulation|
3271945|NCT01581983|Experimental|Internet Mindfulness Meditation|
3271946|NCT01581983|Experimental|Individual Mindfulness Meditation|
3271947|NCT01581996|Experimental|Lanthanum carbonate treatment|One Treatment arm. All patients will receive the following doses of lanthanum carbonate(Fosrenol)for 10-12 days each: 0 mg, 500 mg tid, 1000 mg tid and 1500 mg tid.
3271948|NCT01582022|Experimental|local anesthetic|local anesthetic agent
3271949|NCT01582022|Placebo Comparator|normal saline|comparator
3271950|NCT01582035|Experimental|Panel 1|TMC647055 in combination with TVR for 10 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
3271951|NCT01582035|Experimental|Panel 2|TMC647055 in combination with TVR for 10 or 14 days. Immediately followed by the extension phase: TVR at a dose of 750 mg every 8 hours for 12 weeks in combination with Peg IFN and RBV followed by either 12 or 36 weeks of PegIFN -RBV treatment alone.
3271952|NCT01582074||Cases|women with breast cancer
3271953|NCT01582074||Controls|Matched women without breast cancer
3271954|NCT01582087||acute or chronic hepatic failure|All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma
3271955|NCT01582113|Experimental|High Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 500 mg of citicoline, of which they will be instructed to take 500 mg daily. This will be done in a double-blind, randomized fashion.
3271956|NCT01582113|Experimental|Low Dose Citicoline|At visit 1 and again at visit 2, participants assigned to the experimental arm will receive a 14-day supply of 250 mg of citicoline, of which they will be instructed to take 250 mg daily. This will be done in a double-blind, randomized fashion.
3271957|NCT01582113|Placebo Comparator|Placebo|At visit 1 and again at visit 2, participants assigned to the placebo group will be given 14-day supplies of placebo to be taken daily throughout the study period. This will be done in a double-blind, randomized fashion.
3271958|NCT01582126|Experimental|Group balance training early start|
3271959|NCT01582126|Experimental|Group balance training late start|
3271960|NCT01582165|Active Comparator|Angina. IMR. Statin.|
3271961|NCT01582165|Placebo Comparator|Angina. IMR. Placebo.|
3271962|NCT01582191|Experimental|Treatment (vandetanib, everolimus)|Patients receive vandetanib PO QD and everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3271963|NCT01582204|Experimental|124IcG250|This is a pilot study of 124I-cG250-PET/CT in 25 evaluable patients with advanced and/or metastatic clear cell renal cell carcinoma (ccRCC) who are scheduled to begin treatment with sunitinib or pazopanib. 124I-cG250-PET/CT will be assessed for its ability to predict response in comparison to standard CT scan of the chest, abdomen, and pelvis.
3271964|NCT01582217||SA + 5mg prasugrel|Prasugrel 5 mg group: Patients with Intermediate or high bleeding risks and PRU ≥ 230 are Prescribed 5mg of prasugrel daily along with aspirin.
3271965|NCT01582217||ASA + 10 mg prasugrel|Prasugrel 10 mg group: Patients with Low bleeding risk and high ischemia risk and PRU ≥ 230 are prescribed 10 mg of prasugrel daily along with aspirin.
3271966|NCT01582217||ASA + 75 mg clopidogrel daily|Clopidogrel 75 mg group (control): PRU ≤ 230; high bleeding risk or high ischemic risk; patients with active malignancy, age >75; Wt< 60kg with previous CVA or TA are prescribed 75 mg of clopidogrel daily along with aspirin.
3271967|NCT01582230|Experimental|Vildagliptin|Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
3271968|NCT01582230|Placebo Comparator|Placebo|Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
3271969|NCT01582256||ASD+CNVs|
3271970|NCT01582256||ASD-CNVs|
3271971|NCT01582256||Unaffected siblings of ASD+CNVs|
3271972|NCT01582256||Unaffected siblings of ASD-CNVs|
3271973|NCT01582256||Neurotypicals for ASD+CNVs comparisons|
3271974|NCT01582256||Neurotypicals for ASD-CNVs comparisons|
3271975|NCT01582269|Experimental|LY2157299 monohydrate plus lomustine|"300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle.~First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2."
3271976|NCT01582269|Experimental|LY2157299 monohydrate|300 mg/day LY2157299, given orally for 14 days, followed by 14 days of rest, equaling a 28-day cycle (unblinded)
3271977|NCT01582269|Active Comparator|lomustine plus placebo|"First lomustine dose will be given as 100 mg/m2 on day 7 cycle 1. Remaining doses are based on the investigator's discretion and will be given orally once every 6 weeks in capsules to equal 100 to 130 mg/m2.~LY2157299 monohydrate-matched placebo, given orally as tablets for 14 days, followed by 14 days of rest, equaling a 28-day cycle."
3271978|NCT01582295|Experimental|Treatment Arm|Cabozantinib ( XL 184)
3271979|NCT01582321|Experimental|Part 1 Male|16 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
3271980|NCT01582321|Experimental|Part 1 Female|16 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 1, 3 and 4. At 24 and 72 hours prior to outcome measures on day 3 a cantharidin-soaked 1cm2 filter paper disc will be applied to participants forearm or back on leg for blister formation. Blister fluids will be harvested on day 3.
3271981|NCT01582321|Experimental|Part 2 Male|12 healthy male volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
3271982|NCT01582321|Experimental|Part 2 Female|12 healthy female volunteers will be recruited. Primary and secondary outcome measures will be made on day 0, 1 and 2. At 8 hours prior to outcome measures on day 1 intra-muscular typhoid vaccine will be administered.
3271983|NCT01582347|Experimental|RBP-6300|During the Double-Blind Transfer Period (Days 1-7), participants take RBP-6300 at a level (either 10, 20 or 30 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for Subutex®/Suboxone®. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
3271984|NCT01582347|Active Comparator|Subutex®/Suboxone®|During the Double-Blind Transfer Period (Days 1-7), participants take Subutex®/Suboxone® at a level (either 8, 16 or 240 mg/day) equivalent to dosing during the Run-In Period, plus Placebo for RBP-6000. This is followed by a 3-day Transition Period (Days 8-10) in which participants take active Subutex®/Suboxone® equal to the dose taken during the Run-In Period plus placebo matching RBP-6000.
3271985|NCT01582360||antiinfectiva: vancomycin|80 patients Completed.
3271986|NCT01582360||antiinfectiva: meropenem|80 patients recruiting
3271987|NCT01582360||antiinfectiva: flukonazol|80 patients
3271988|NCT01582360||antiinfectiva: cefotaxim|80 patients
3271989|NCT01582360||antiinfectiva: benzylpenicilline|80 patients
3271990|NCT01582360||antiinfectiva: tazobactam piperacillin|80 patients recruiting
3271991|NCT01582360||antiinfectiva: cloxacillin|80 patients
3271992|NCT01582360||antiinfectiva: ciprofloxacin|80 patients
3271993|NCT01582373|Experimental|Cognitive-behavioral couple therapy|The goals of CBCT are to enable participants to: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of their sexual functioning, reduce their sexual distress and increase their sexual satisfaction; (5) consolidate skills.
3271994|NCT01582399|Experimental|Arm A: ASKP1240 intravenous (IV) infusion|
3271995|NCT01582399|Experimental|Arm B: ASKP1240 subcutaneous (SC)|
3271996|NCT01582412|Experimental|Isavuconazole and digoxin|Isavuconazole three times per day (TID) on Days 15 and 16, and once daily (QD) on Days 17 thru 26. Digoxin single dose on Days 1 and 19.
3271997|NCT01582425|Experimental|Isavuconazole and methadone|Single dose of methadone on Days 1 and 20, isavuconazole 3 times a day (TID) on Days 16-17 as a loading dose, isavuconazole once a day (QD) on Days 18-28
3271998|NCT01582464||Older Adults in a Senior Community|Residents of a Continuing Care Retirement Community (CCRC) that is a part of The Be Group (previously known as Southern California Presbyterian Homes), with no exclusion other than being able to communicate in English and provide consent to participate.
3271999|NCT01582503|Experimental|MEMP1972A 150 mg|
3272000|NCT01582503|Experimental|MEMP1972A 300 mg|
3272001|NCT01582503|Experimental|MEMP1972A 450 mg|
3272002|NCT01582503|Placebo Comparator|Placebo|
3272003|NCT01582516|Experimental|Delta24-RGD|Intracerebral slow continuous infusion of study drug in increasing dose
3272004|NCT01582542|Experimental|Desmopressin|
3272005|NCT01582555|Experimental|saline irrigation|a control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation;
3272006|NCT01582555|Experimental|intervention arm (group B),|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
3272007|NCT01582568||Certolizumab|Subjects will take the study drug certolizumab for 8 weeks. They will undergo a endoscopy before study drug and then again after study is complete. The study doctor will be looking for complete closure of the peri-anal fistula identified at visit 1 after the use of certolizumab based on and endoscopic ultrasound (EUS).
3272008|NCT01582581|Active Comparator|Telephonic CBT|Computer guided, cognitive behavioral therapy (CBT) delivered by a clinician-administered telephone intervention.
3272009|NCT01582581|Sham Comparator|Wait List Control|Randomized wait list control with measurement of study outcomes at week 0, 3 and 5 after the initiation of waiting.
3272010|NCT01582607|Active Comparator|Group B|subarachnoid administration of 2.0 mL (10mg) plain bupivacaine hydrochloride 0.5%
3272011|NCT01582607|Active Comparator|Group R|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75%
3272012|NCT01582607|Active Comparator|Group LB|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5%
3272013|NCT01582607|Active Comparator|Group RF|subarachnoid administration of 2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl
3272014|NCT01582607|Active Comparator|Group BF|subarachnoid administration of 2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
3272015|NCT01582607|Active Comparator|Group LBF|subarachnoid administration of 2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl
3272016|NCT01582633|Experimental|0.1 ml ID dose|Dose of 0.1 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3272017|NCT01582633|Experimental|0.2 ml ID dose|Dose of 0.2 ml ID trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3272018|NCT01582633|Experimental|0.5 ml IM dose - needle-free|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by disposable needle-free jet injector
3272019|NCT01582633|Active Comparator|0.5 ml IM - needle and syringe|Dose of 0.5 ml IM trivalent 2012 influenza vaccine administered by needle and syringe
3272020|NCT01582646|Other|first period with terbutaline and second period with placebo|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
3272021|NCT01582646|Other|first period with placebo and second period with terbutaline.|The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
3272022|NCT01582659|No Intervention|No ekstra counseling|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made.
3272023|NCT01582659|Active Comparator|2 counseling sessions|Standardized information about childhood constipation is given and the child receives PEG 3350. 2 additional follow up appointments by telephone are made.
3272024|NCT01582659|Active Comparator|Web access|Standardized information about childhood constipation is given and the child receives PEG 3350. No additional follow up appointments are made but the family are given access to a website with information about childhood constipation.
3272025|NCT01582672|Experimental|AGS-003 + Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma. In addition, subjects will receive AGS-003.
3272026|NCT01582672|Active Comparator|Standard Treatment|Subjects on this arm will receive standard treatment for Renal Cell Carcinoma.
3272027|NCT01582685|Experimental|Exercise Group|The intervention is a structured walking program which will be performed partly in the Pavilion Physical Therapy clinic and partly at home. The participant will be instructed in how hard to exercise, how long to exercise, and how many times in a week to exercise. You will also be instructed in how to exercise safely.
3377178|NCT04717349||Family Members of PAG patients|Clinical evaluation of family members that would provide clinical information related to the diagnosis of a proband in future research.
3377179|NCT04717349||PAG patient|Pediatric and adolescent patients with gynecologic conditions.
3272028|NCT01582685|No Intervention|No Exercise|These participants will receive standard of care follow up.
3272029|NCT01582698|Experimental|Seropersistence evaluation + 2nd booster vaccination|Blood will be drawn to assess the seropersistence of TBE virus antibodies at 82, 94, 106 and 118 months after the first booster vaccination with FSME-IMMUN 0.5ml administered during the first precursor study. Timing of the second booster vaccination will depend on the level of serum TBE antibodies observed during the study. Blood will be drawn 21 - 35 days after vaccination to assess the booster response.
3272030|NCT01582711|Active Comparator|3HP Directly Observed Therapy (DOT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) under Directly Observed Therapy (DOT)
3272031|NCT01582711|Experimental|3HP Self Administered Therapy (SAT)|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT)
3272032|NCT01582711|Experimental|3HP SAT with SMS Reminders|900mg of isoniazid plus 900mg of rifapentine given weekly for 3 months (12 weeks, 12 doses) as patient Self Administered Therapy (SAT). In addition, patient receives phone Short Message Service (SMS) reminders weekly.
3272033|NCT01582724|Experimental|Self-care acupressure|1
3272034|NCT01582724|No Intervention|Usual care|2
3272035|NCT01582737||Group 1|Patients treated with Xarelto for the purpose of prevention of ischemic stroke and systemic embolism
3272036|NCT01582750||Local advanced rectal cancer EUS|
3272037|NCT01582763||GBS|Guillain-Barré syndrome >1000, follow-up 1-3 years
3272038|NCT01582763||NC|Normal controls (NC)
3272039|NCT01582763||IC|Infectious controls (IC)
3272040|NCT01582763||OND|Other neurological diseases (OND)
3272041|NCT01582776|Experimental|Lenalidomide and GA101|Ga101 and lenalidomide
3272042|NCT01582802||Pregnant women carrying multiples|
3272043|NCT01582815|Experimental|JNJ-40411813|
3272044|NCT01582815|Placebo Comparator|Placebo|
3272045|NCT01582828|Active Comparator|Epicardial (surgical) ablation|Epicardial Pulmonary vein isolation
3272046|NCT01582828|Experimental|Hybrid|Epicardial (surgical) ablation & Endocardial assessment
3272047|NCT01582841|Experimental|MSI testing|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI following surgery. Those with MSI-H results will receive a genetic counseling informational call.
3272048|NCT01582841|No Intervention|Usual care|These patients will be treated as usual by their oncologist and medical team. These patients receive a follow up letter a year after randomization, alerting them to the availability of clinical Lynch Syndrome screening.
3272049|NCT01582867|Experimental|HD and HDF|During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
3272050|NCT01582867|Experimental|HDF and HD|patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
3272051|NCT01582893|Experimental|HCO1100-P14L|HCO1100 is connected in row with low flux dialyzer P14L
3272052|NCT01582893|Active Comparator|P210H|High flux Filter P210H
3272053|NCT01582906||Control Group|Participants randomised to the control group would receive usual rehabilitation care via the existing referral pathways.
3272054|NCT01582906||Intervention Group|Participants randomised to the intervention group will be offered two rehabilitation appointments at three month intervals. They will complete the screening tool, the Distress (Concerns) Thermometer before the first appointment; this will be reviewed after three months. Appointments will make use of communication skills recognised to promote motivation via self-efficacy. Self efficacy is a person's belief in their ability to achieve a goal. Their sense of mastery will influence their behaviour, their perception of stress and the effort they put into achieving that goal.
3272055|NCT01582919|Experimental|Participant from AMI cohort|
3272056|NCT01582919|Active Comparator|Participant from 3Ccohort|
3272057|NCT01582932|Experimental|Calcipotriene 0.005% Foam|Foam is a vitamin D3 analog (calcipotriene) foam 0.005%. It is applied twice a day for 8 weeks to psoriasis lesions (except the face).
3272058|NCT01582958|Experimental|Treatment|This arm will receive the usual Pulmonary Rehabilitation Program plus OMT, the intervention.
3272059|NCT01582958|Placebo Comparator|placebo|Receives normal pulmonary rehabilitation care plus positioned to receive OMT but OMT is not provided.
3272060|NCT01582958|No Intervention|Control|This arm receives only pulmonary rehabilitation care.
3272061|NCT01582984|Active Comparator|iMedConsentTM and customized written handout group|iMedConsentTM and a customized written handout
3272062|NCT01582984|Experimental|iMedConsentTM, handout, and standard video g|iMedConsentTM, handout, and standard AAOS video
3272063|NCT01582984|Experimental|iMedConsentTM, handout, video, and formal education|iMedConsentTM, the handout, the video, and a formal education session
3272064|NCT01582997|Experimental|Dose Escalation Part|Dose escalation will be conducted to assess safety, tolerability, single and repeat dose PK profile and preliminary efficacy of GSK2118436 . The dose may be escalated to the overseas recommended phase III dose.
3272065|NCT01583010|No Intervention|Standard Treatment Group|Patients receiving ultrasound guided regional anaesthesia without using Advanced Needle Visualization Technology(R)
3272066|NCT01583010|Active Comparator|ANV ® Group|Patients receiving ultrasound guided regional anaesthesia with using Advanced Needle Visualization Technology(R)
3272067|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Sham rTMS|
3272068|NCT01583023|Experimental|Placebo + Lithium a/o Epival + Active rTMS|
3272069|NCT01583023|Experimental|Wellbutrin + Lithium a/o Epival + Active rTMS|
3272070|NCT01583036|Experimental|Session 1 digoxin alone, Session 2 retigabine plus digoxin|Session 1: Single administration of digoxin (0.25mg) and PK assessments up to 144hrs post-dose. Session 2: Retigabine up-titration to 1200mg (TDD) with co-administration of digoxin (0.25mg) at 3 doses or retigabine during the up-titration (600mg, 900mg and 1200mg) and PK assessments up to 144hrs post-dose following wach co-administration.
3272071|NCT01583062|Active Comparator|1|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
3272072|NCT01583062|Placebo Comparator|2|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
3272073|NCT01583075|Other|Circumferential ablation|
3272074|NCT01583075|Experimental|Single ring ablation|
3272075|NCT01583088|Experimental|phenic nerve stimulation|effective phenic nerve stimulation NeurX™ (Synapse Biomedical)
3272076|NCT01583088|Sham Comparator|sham|sham phenic nerve stimulation
3272077|NCT01583114|Experimental|perindopril|
3272078|NCT01583114|Placebo Comparator|placebo|same form, administration, posology, frequency and duration as perindopril
3272079|NCT01583127|Experimental|School-Wide (SW)-PBIS intervention|SW-PBIS intervention
3272080|NCT01583127|No Intervention|Control|Practice as usual
3272081|NCT01583140|Experimental|Exercise Intervention|Culturally-modified, individually tailored physical activity print materials
3272082|NCT01583140|Active Comparator|Control|Bilingual health education booklets
3272083|NCT01583153|Active Comparator|Hospital Inpatient Rehabilitation (HI)|
3272084|NCT01583153|Active Comparator|Hybrid Home Programme (HO)|
3272085|NCT01583192|Active Comparator|chloride-hexidine soluted in alcohol|"patients will have skin preparation with chloride-hexidine soluted in alcohol prior to their forefoot surgery.~Skin swabs will be taken prior to skin preparation, after skin preparation and after skin closure at the end of the operation"
3272086|NCT01583192|Active Comparator|povidine-jodine soluted in alcohol|skin perparation will be done with povidine-jodine soluted in alcohol prior to forefoot surgery.
3272087|NCT01583205|Experimental|Coping Effectiveness Training|Coping Effectiveness Training -ALS (CET-ALS) is an eight session intervention derived from Coping Effectiveness Training (CET), a manualized intervention based on stress and coping theory. It is designed to strengthen coping skills and alleviate distress for either the patient or care partner following a diagnosis of ALS.
3272088|NCT01583231|No Intervention|No Prewash|Level 1: participants will be swabbed, then application of brushless scrub, swabbed again
3272089|NCT01583231|Experimental|Prewash|Level 2: participants will be swabbed, perform a wash with soap and water for 1 minute, dry, apply brushless scrub, swabbed again
3272090|NCT01583244||Patients with active rheumatoid arthritis|Patients aged 6 years and over who have moderate-to-severe active rheumatoid arthritis
3272091|NCT01583257|Experimental|Active Video Gaming|An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.
3272092|NCT01583270|Experimental|Arabinoxylan|Porridge rich in arabinoxylan. 50 g available carbohydrate
3272093|NCT01583270|Experimental|rye kernels|Porridge made from rye kernels. 50 g available carbohydrate
3272094|NCT01583270|Experimental|arabinoxylan and rye kernels|Porridge made of rye kernels and arabinoxylan. 50g available carbohydrate
3272095|NCT01583270|Experimental|semolina|Semoline porridge. 50 g available carbohydrate
3272096|NCT01583283|Experimental|ACY-1215, Lenalidomide and Dexamethasone|Open label dosing cohorts will evaluate oral ACY-1215 (doses ranging from 40 - 480 mg days 1-5, 8-12, 15-19) in combination with oral Lenalidomide (doses ranging from 15 - 25 mg days 1-21) and oral Dexamethasone (40 mg once weekly).
3272097|NCT01583309|No Intervention|low-flux hemodialysis|
3272098|NCT01583309|Experimental|online pre-dilution hemofiltration|
3272099|NCT01583309|Experimental|online pre-dilution hemodiafiltration|
3272100|NCT01583322|Experimental|vargatef/Nintedanib|
3272101|NCT01583322|Placebo Comparator|placebo|
3272102|NCT01583335|Experimental|Improved lifestyle|
3272103|NCT01583335|No Intervention|Control group|The control group was seen at baseline and follow-up, but not in between.
3272104|NCT01583335|No Intervention|Shadow group|The shadow group was followed in registers exclusively
3272105|NCT01583348||Women with gallstones|30 women with symptomatic gallstone disease with an indication for elective cholecystectomy
3272106|NCT01583361|Experimental|Arm A:Neoadjuvant sox|Patients in arm a will receive (N=2-4) cycles of neoadjuvant SOX first, and then standard gastrectomy with D2 lymphadenectomy, and (8-N) cycles of adjuvant SOX adjuvant chemotherapy.
3272107|NCT01583361|Active Comparator|Arm B:Adjuvant SOX|Patients in arm B will receive standard gastrectomy with D2 Lymphadenectomy first, and 8 cycles of adjuvant SOX later.
3272108|NCT01583387|Other|1= Intervention|
3272109|NCT01583387|Other|2= Control|
3272110|NCT01583400|Active Comparator|RESPECT-D|The RESPECT-D Model: Collaborative Care depression treatment within primary care including care manager
3272111|NCT01583400|Experimental|RESPECT-D-E|RESPECT-D-E: Collaborative Care depression treatment within primary care including care manager plus on-line coaching, education and symptom, side effect and, medication adherence tracking with the digital health coaching program for depressive symptoms.
3272112|NCT01583413|Experimental|Opt Out Protocol|
3272113|NCT01583426|Experimental|nab-Paclitaxel|nab-Paclitaxel (125 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
3272114|NCT01583426|Active Comparator|Paclitaxel|Paclitaxel (80 mg/m² weekly, infusion) is applicated for 12 weeks, followed by epirubicin and cyclophosphamide, applicated 4 cycles 3-weekly . In case of HER2-positive tumor patients receive tarstuzumab and pertuzumab 3-weekly during all cycles.
3272115|NCT01583465|Experimental|Aquamantys Malleable Bipolar Sealer|In 100 patients randomly assigned, primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of the Aquamantys Malleable Bipolar Sealer with Light.
3272116|NCT01583465|Active Comparator|Standard Treatment|100 patients randomly assigned will undergo primary total hip arthroplasty via the anterior supine intermuscular approach performed with the assistance of standard electrocautery.
3272117|NCT01583478|Active Comparator|incobotulinumtoxinA 20 units|Three patients will be randomly assigned to receive 20 units total of incobotulinumtoxinA to the glabellar region.
3272118|NCT01583478|Active Comparator|incobotulinumtoxinA 40 units|Three patients will be randomly assigned to receive 40 units total of incobotulinumtoxinA to the glabellar region.
3272119|NCT01583478|Active Comparator|incobotulinumtoxinA 60 units|Three patients will be randomly assigned to receive 60 units total of incobotulinumtoxinA to the glabellar region.
3272120|NCT01583478|Active Comparator|incobotulinumtoxinA 80 units|Three patients will be randomly assigned to receive 80 units total of incobotulinumtoxinA to the glabellar region.
3272121|NCT01583478|Active Comparator|incobotulinumtoxinA 100 units|Three patients will be randomly assigned to receive 100 units total of incobotulinumtoxinA to the glabellar region.
3272122|NCT01583491|Active Comparator|prf group.peridontal problem|prf insert into surgical site immediate after surgery
3272123|NCT01583491|Placebo Comparator|control group|
3272124|NCT01583504|Experimental|High volume saline injection|Patients randomised to this trial arm will receive an ultrasound guided steroid and local anaesthetic injection around the achilles tendon in the same way as the control arm patients. In addition they will receive an injected bolus of normal saline (through the same needle) of between 14-25ml until the new vessels seen on ultrasound scan disappear. They will be then given a programme of stretching and strengthening exercises in the same way as patients on the control arm.
3272125|NCT01583504|Active Comparator|Control Arm|"Patients on this trial arm will receive an ultrasound guided injection of steroid and local anaesthetic between Kager's fat pad and the achilles tendon. They will then be given a programme of stretching and strengthening exercises.~Patients on this trial arm will be offered the high volume saline injection at their 6 week follow up appointment after outcome measures have been taken by the blinded assessor. The whole cohort of patients will then be followed up at 12 and 40 weeks"
3272126|NCT01583517|Active Comparator|Biliary sphincterotomy|Cutting of the biliary sphincter muscle alone
3272127|NCT01583517|Active Comparator|Dual sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
3272128|NCT01583517|Sham Comparator|Sham|Among patients with normal sphincter of Oddi manometry, patients will undergo no sphincterotomy (sham therapy).
3272129|NCT01583517|Active Comparator|Biliary sphincterotomy - Normal SOM|Among patients with normal SOM, patients may be randomized to empiric biliary sphincterotomy alone.
3272130|NCT01583556||Standard treatment|This study will employ a prospective, non-randomized design. After the questionnaires are filled the patients choose whether or not to schedule a second appointment for evaluation of their fracture: The first group will be scheduled for a second visit (standard treatment) as our daily practice after 1-3 months. They will be contacted after 2-6 months either by phone or email and will complete again some questionnaires (Quick DASH, satisfaction, return to work).
3272131|NCT01583556||Optional follow-up group|The alternative (Optional follow-up group) will be to take a handout describing the recovery and providing instructions for how to contact us should they get off course. The questionnaires will be repeated either by phone or email in 2-6 months.
3272132|NCT01583582|Experimental|Refined peptide concentrate, 1200 mg|Refined peptide concentrate, 1 200 mg, once a day
3272133|NCT01583582|Experimental|Refined peptide concentrate, 2 x 600 mg|Refined peptide concentrate, 600 mg, twice a day
3272134|NCT01583582|Placebo Comparator|Refined peptide concentrate, 0 mg|
3272135|NCT01583621|No Intervention|Placebo|Placebo group
3272136|NCT01583621|Experimental|Supplementation arm 1|cholecalciferol 18000 U/month for 4 months
3272137|NCT01583621|Experimental|supplementation arm 2|cholecalciferol 60000 U/month for 4 months
3272138|NCT01583621|Experimental|Supplementation arm 3|cholecalciferol 120000 U/month for 4 months
3272139|NCT01583634||Healthy volunteers|9 subjects (male and female)
3272140|NCT01583673|Experimental|Amino Acid Formula|Hypoallergenic baby formula
3272141|NCT01583673|Active Comparator|Amino Acid commercial formula|Hypoallergenic commercial amino acid formula
3272142|NCT01583699|Experimental|Endomicroscopy|All patients included into the study will undergo endomicroscopy of the upper GI-tract.
3272143|NCT01583712|Experimental|Endomicroscopy|All patients included in the study will undergo endomicroscopy of the upper GI-tract including the reachable parts of the small bowel.
3272144|NCT01583725|Experimental|Roux-en-Y Gastric Bypass|30 subjects who plan to undergo Roux-en-Y Gastric Bypass bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3272145|NCT01583725|Experimental|Gastric Banding (Lap-band)|30 subjects who plan to undergo Gastric Banding bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3272146|NCT01583725|Experimental|Formula Diet Weight Loss|30 subjects who plan to begin a formula diet to lose weight. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before subjects undertake a 12-week weight loss intervention (T1), at the end of the weight loss intervention (T2) and 18 months after they completed the weight loss intervention(T3).
3272147|NCT01583725|Experimental|No Treatment|30 subjects who do not undergo any treatment for weight loss. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed at baseline (T1) and at 3 months (T2) and 18 months (T3) later.
3272148|NCT01583725|Experimental|Sleeve Gastrectomy Surgery|30 subjects who plan to undergo Sleeve Gastrectomy bariatric surgery. Liquid meal responses and Behavioral fMRI responses to food-cues will be assessed before surgery (T1), 3 months (T2) and 18 months (T3) after surgery.
3272149|NCT01583738|Experimental|V0251|
3272150|NCT01583738|Placebo Comparator|Placebo|
3272151|NCT01583751|Experimental|control|excision and primer repair surgical technique will be perform
3272152|NCT01583777|Experimental|Belinostat|Open Label
3272153|NCT01583790||no group|laparoscopic sleeve gastrectomy
3272154|NCT01583803||Males|
3272155|NCT01583803||Females|
3272156|NCT01583816|Experimental|Resiquimod Gel 0.03% or placebo|Resiquimod gel 0.03% or placebo, once daily, 3x per week for 4 weeks, break of 8 weeks, repeated once
3272157|NCT01583816|Experimental|Resiquimod or placebo|Once daily, 7x within 2 weeks, break of 8 weeks, cycle repeated once
3272158|NCT01583816|Experimental|Resiquimod or vehicle|Once daily, 5x for 1 week, break of 8 weeks, cycle repeated once
3272159|NCT01583816|Experimental|Resiquimod gel 0.01%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
3272160|NCT01583816|Experimental|Resiquimod gel 0.03%|Once daily, 3x/week until occurrence of biological endpoint or for a maximum of 8 weeks (no repetition of cycle), 8 weeks follow-up
3272161|NCT01583829|Experimental|Neurofeedback|
3272162|NCT01583829|Experimental|Cognitive Training|
3272163|NCT01583829|Active Comparator|Waitlist Control|
3272164|NCT01583842|Experimental|124I-MIBG no-carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
3272165|NCT01583842|Experimental|124I-MIBG carrier added|Patients are 3 years of age and older with relapsed or refractory neuroblastoma who are currently enrolled on a treatment protocol with 131I-MIBG.
3272166|NCT01583842|Active Comparator|Imaging Only|Participants with high-risk neuroblastoma will receive imaging only without 124I-MIBG
3272167|NCT01583855|Active Comparator|Manual ablation|Patients will have their ablation performed manually.
3272168|NCT01583855|Active Comparator|Ablation using remote catheter system|Ablation for atrial fibrillation using the Amigo remote catheter system
3272169|NCT01583881|Experimental|Renal denervation|Renal denervation
3272170|NCT01583881|No Intervention|control|No intervention
3272171|NCT01583907||different dietotherapy strategies|
3272172|NCT01583920|Experimental|Focal salvage HDR prostate brachytherapy|
3272173|NCT01583933|Experimental|Essix retainer|
3272174|NCT01583933|Active Comparator|Hawley retainer|"Hawley retainer is a device composed of an acrylic base with built-in hooks and a labial arch wire 0.022 x0.036 and attached to the teeth. Its metal component consists of two adams hooks positioned from the first permanent molar right to left, a labial bow that progresses from lingual superface to distal of canine to integrate with the acrylic base."
3272175|NCT01583946||Male low past-oriented SWB|
3272176|NCT01583946||Male high past-oriented SWB|
3272177|NCT01583946||Female low past-oriented SWB|
3272178|NCT01583946||Female high past-oriented SWB|
3272179|NCT01583946||Black Female high past-oriented SWB|
3272180|NCT01583946||Black Female low past-oriented SWB|
3272181|NCT01583946||Black male low past-oriented SWB|
3272182|NCT01583946||Black male high past-oriented SWB|
3272183|NCT01583959|Active Comparator|Folic acid 30 mg per week|Patients will be administered 5 mg folic acid for 6 days a week, no tablet on the day they take methotrexate (5 mg x 6 days = 30 mg per week)
3272184|NCT01583959|Active Comparator|Folic acid 10 mg|Patients will be given folic acid 5 mg for two days per week and placebo tablets for four days a week, no tablet on the day they take methotrexate (Folic acid 5mg x 2 days = 10mg per week)
3272185|NCT01583972|Experimental|Vitamin A|50,000 IU vitamin A in edible oil
3272186|NCT01583972|Placebo Comparator|Placebo|edible oil used as diluent for vitamin A
3272187|NCT01583998|Active Comparator|e-MBC|Patients will receive e-MBC
3272188|NCT01583998|No Intervention|Treatment as Usual Control|Patients receive standard treatment
3272189|NCT01584011||Middle ear disease|
3272190|NCT01584037||Observational|This is a prospective, observational, exposure-registration and follow-up study of pregnant women exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral and their live born offspring through the first year of life. The intent of the Adenovirus Vaccine Pregnancy Registry, Protocol DR-501-401, is to collect observational data on pregnancy outcomes, including birth defects, in women who were exposed to Adenovirus Type 4 and Type 7 Vaccine, Live, Oral.
3272191|NCT01584050|Active Comparator|L-MTHF|
3272192|NCT01584050|Active Comparator|folic acid|
3272193|NCT01584050|Placebo Comparator|placebo (methyl cellulose)|
3272194|NCT01584063|No Intervention|Control|These women received general information about pregnancy and the postpartum period and tips for stress management. This information was delivered during 3 group meetings during pregnancy and 1 group meeting postpartum by trained staff from a local community mental health agency.
3272195|NCT01584063|Experimental|MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
3272196|NCT01584076|Experimental|Donepezil|
3272197|NCT01584102|Experimental|Group 1|
3272198|NCT01584102|Active Comparator|Group 2|
3272199|NCT01584115|Experimental|NY-ESO-1|NY-ESO-1 combined with MPLA vaccine
3272200|NCT01584128||Oxidized regenerated cellulose|Patients undergoing laparoscopic hysterectomy who have oxidized regenerated cellulose placed at the vaginal cuff at the time of their surgery.
3272201|NCT01584141||Cases|Asian cases with lymphoid or myeloid neoplasma
3272202|NCT01584141||Controls|Controls with selected non-cancer diagnosis who were hospitalized in Hong Kong, Chengdu and Tianjin of Mainland China, and Taiwan
3272203|NCT01584154|Experimental|cryoablation|
3272204|NCT01584154|Active Comparator|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
3272205|NCT01584167|Active Comparator|Cold infusions|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
3272206|NCT01584167|Active Comparator|EMCOOLS Flex.Pads|Passive surface cooling with 10 EMCOOLS Flex.Pads (Emergency Medical Cooling Systems AG, Wien, Austria)
3272207|NCT01584180|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
3272208|NCT01584180|Active Comparator|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad (Emergency Medical Cooling Systems AG, Wien, Austria)
3272209|NCT01584193|Experimental|US-guided subclavian vein puncture|
3272210|NCT01584193|Active Comparator|Cephalic vein dissection|
3272211|NCT01584206|Experimental|Ezetimibe|Compare on and off ezetimibe
3272212|NCT01584219||Women after cesarean section|Women after cesarean section
3272213|NCT01584219||pregnancy pathologies|pregnancy pathologies
3272214|NCT01584219||first/second trimester pregnancy|
3272215|NCT01584219||Women after vaginal delivery|Women after vaginal delivery
3272216|NCT01584258|Active Comparator|Laparoscopic Prostatectomy vs prostate SBRT|Patients for whom surgery is considered will be randomised to laparoscopic prostatectomy or prostate SBRT delivered with 36.25 Gy in 5 fractions.
3272217|NCT01584258|Active Comparator|Conventionally Fractionated RT vs Prostate SBRT|Patients for whom surgery is not considered or who refuse surgery will be randomised to either conventionally fractionated radiotherapy delivered to a dose of 78 Gy in 2 Gy fractions or SBRT delivered with 36.25 Gy in 5 fractions.
3272218|NCT01584271|Active Comparator|2 Dex-Otic ear drops|Dex-Otic(R) ear drops are used for pain relief and treating ears of AOE patients. It contains: Dexamethasone Sodium Phosphate 1 mg; Neomycin sulfate 5 mg; Polymyxin B sulfate 10,000 units. It
3272219|NCT01584271|Experimental|3 Ear Comfort(TM) ear drops|Natural Ear comfort(TM) ear drops contains Chamomile extract and Thyme oil in anhydrous glycerin for pain relief and ear healing.
3272220|NCT01584271|Active Comparator|1 Otidin(R) ear drops|Otidin(R): Ear drops containing Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin for pain relief in AOE patients.
3272221|NCT01584297|Experimental|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
3272222|NCT01584310|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
3272223|NCT01584310|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
3272224|NCT01584323|Active Comparator|Pomegranate pills|treatment with pomgranate pills to women suffering preterm premature rupture of membranes
3272225|NCT01584323|Placebo Comparator|placebo pills|treatment with placebo to women with preterm premature rupture of membranes
3272226|NCT01584336|Experimental|LATG group|It means the patients who will be enrolled in our study.
3272227|NCT01584362|Experimental|oxfendazole 0.3|administration of a single oral 0.3mg/kg dose of oxfendazole
3272228|NCT01584362|Placebo Comparator|placebo comparator|administration of a single oral dose of placebo
3272229|NCT01584362|Experimental|oxfendazole 1.0|administration of a single oral 1.0 mg/kg dose of oxfendazole
3272230|NCT01584362|Experimental|oxfendazole 3.0|administration of a single oral 3 mg/kg dose of oxfendazole
3272231|NCT01584362|Experimental|oxfendazole 10|administration of a single oral 10 mg/kg dose of oxfendazole
3272232|NCT01584362|Experimental|oxfendazole 20|administration of a single oral 20 mg/kg dose of oxfendazole
3272233|NCT01584362|Experimental|oxfendazole 30|administration of a single oral 30 mg/kg dose of oxfendazole
3272234|NCT01584375|Other|Flat midline head position|
3272235|NCT01584375|Other|Right flat lateral head position|
3272236|NCT01584414||normal samples|
3272237|NCT01584414||premalignant/carcinoma samples|
3272238|NCT01584427|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch.
3272239|NCT01584427|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans
3272240|NCT01584453|Experimental|Sodium Nitrite|
3272241|NCT01584453|Placebo Comparator|Placebo|
3272242|NCT01584466|Experimental|Paliperidone|
3272243|NCT01584492|Experimental|Treatment A|CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
3272244|NCT01584492|Experimental|Treatment B:|CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
3272245|NCT01584492|Experimental|Treatment C|CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
3272246|NCT01584492|Active Comparator|Treatment D|formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
3272247|NCT01584492|Placebo Comparator|Treatment E|placebo pMDI with spacer, 6 inhalations in the morning at the clinic
3272248|NCT01584505|Experimental|CHF5993 HFA pMDI dose 1, BID|CHF5993 HFA pMDI dose 1, BID
3272249|NCT01584505|Experimental|CHF5993 HFA pMDI dose 2, BID|CHF5993 HFA pMDI dose 2, BID
3272250|NCT01584505|Active Comparator|CHF1535 HFA pMDI + Placebo|CHF1535 HFA pMDI BID plus placebo BID
3272251|NCT01584531|Experimental|21-Day Regimen|560 mg oral rigosertib in the morning and 280 mg rigosertib in the afternoon on days 1 to 21 of 21-day cycle
3272252|NCT01584557|Active Comparator|Tolvaptan, Samsca|Tolvaptan, Samsca, uncoated tablet, 30 mg, once per day, up to 7 days.
3272253|NCT01584557|Placebo Comparator|sugar pill|placebo, sugar pill
3272254|NCT01584570|Active Comparator|Control|fentanyl 1 mcg/kg before induction
3272255|NCT01584570|Experimental|D 0.5 group|Dexmedetomidine 0.5 ug/kg + Propofol + Sevoflurane+ Vecuronium
3272256|NCT01584570|Experimental|D 1.0 group|Dexmedetomidine 1.0 ug/kg + Propofol + Sevoflurane+ Vecuronium
3272257|NCT01584583||blood pressure monitor|Cuff circumference:22cm-36cm
3272258|NCT01584583||stethoscopy|Cuff circumference: 22cm-36cm
3272259|NCT01584596|Experimental|Adapted Diet and Physical Activity|Adapted diet and physical activity guidelines sessions
3272260|NCT01584596|Active Comparator|Adapted Diet|Adapted dietary guidelines sessions
3272261|NCT01584635|Experimental|Peroral Endoscopic Myotomy (POEM)|Peroral Endoscopic Myotomy- a less invasive treatment for patients with Achalasia
3272262|NCT01584661||Compliance with nutritional care|"The Inclusion criteria comprise patients who were treated nutritionally with food enrichment supplements during their hospitalization in Bait Balev and were discharged to their homes with dietary recommendations. Participants who are willing to participate will sign an informed consent form. For patients with cognitive impairment or dementia, as reported in their medical records, their formal primary caregiver or proxy will sign the informed consent form."
3272263|NCT01584674|Experimental|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
3272264|NCT01584674|No Intervention|Control (untreated hemiface)|No treatment will be administered on the control hemiface
3272265|NCT01584687|Experimental|Omalizumab|All patients will receive omalizumab.
3272266|NCT01584700|Other|Renal Artery Denervation|Ontervention
3272267|NCT01584713|Experimental|Adipose derived Stem Cells|
3272268|NCT01584726|Other|magnesium sulfate arm|magnesium sulfate with standard therapy
3272269|NCT01584726|No Intervention|placebo arm|placebo with standard therapy
3272270|NCT01584739|Experimental|AZD8683|
3272271|NCT01584739|Placebo Comparator|Placebo to AZD8683|
3272272|NCT01584752||Fistula patients|Gore-BioA Fistula Plug
3272273|NCT01584765||Rechallenge|positive, negative, indeterminate and intermediate rechallenge subtypes
3272274|NCT01584765||Severe positive rechallenge|Subtype of positive rechallenge is defined as: ALT≥5 xULN or AP ≥2 xULN and bilirubin ≥2 xULN with one of the following: INR ≥1.5, Ascites, or Encephalopathy where time from liver chemistry elevation to INR≥1.5,ascites, or encephalopathy is less than 26 weeks in the absence of underlying cirrhosis; other organ failure considered due to DILI; liver-related hospitalization
3272275|NCT01584778||Behçet patients|
3272276|NCT01584778||Healthy controls|
3272277|NCT01584778||Allergic rhinitis (diseased) controls|
3272278|NCT01584791|Experimental|clopidogrel napadisilate + aspirin|
3272279|NCT01584791|Active Comparator|clopidogrel bisulfate + aspirin|
3272280|NCT01584804|Active Comparator|Monotherapy|Monotherapy with Su-Huang antitussive capsule
3272281|NCT01584804|Placebo Comparator|Sugar pill|Monotherapy with placebo
3272282|NCT01584817|No Intervention|normal education|patients in this arm was educated about bowel preparation on the day of reservation by nurse for 15 minutes and meanwhile a booklet was also sent to them.
3272283|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
3272284|NCT01584830|Experimental|Arm 1|
3272285|NCT01584830|Placebo Comparator|Arm 2|
3272286|NCT01584869|Experimental|capsule endoscopy|
3272287|NCT01584882|No Intervention|Control (Usual care)|Return patients seen within the data collection window in HealthPartners Dental Clinics (new patient exams were excluded) who were documented as using tobacco, specifically cigarettes, at their last dental encounter. Randomization was at the clinic level.
3272288|NCT01584882|Experimental|Tobacco Cessation Tool (CATI Tool)|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a 'CATI'[Computer Assisted Tobacco Intervention] tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
3272289|NCT01584895|Experimental|Rehab|Patients randomized into early cardiac rehabilitation
3272290|NCT01584895|No Intervention|Control|No cardiac rehabilitation until after 6 week post assessment.
3272291|NCT01584921|Placebo Comparator|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
3272292|NCT01584921|Active Comparator|Low dose Erythropoietin|
3272293|NCT01584921|Active Comparator|High dose Eryhropoietin|
3272294|NCT01584934|Experimental|Sodium oxybate|Patient group receives sodium oxybate as treatment.
3272295|NCT01584934|Placebo Comparator|Placebo|Patient group receives placebo as treatment.
3272296|NCT01584947|Placebo Comparator|Placebo lozenge|The patients will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards they start another two weeks treatment with the opposite type of lozenge from the first treatment period.
3272297|NCT01584947|Active Comparator|Bupivacaine lozenge|The patient will be randomized to start two weeks treatment with either a bupivacaine lozenge or a placebo lozenge (taken three times a day). The two weeks treatment is followed by a week without treatment. Afterwards the patient starts another two weeks treatment with the opposite type of lozenge from the first treatment period.
3272298|NCT01584960|Experimental|Prostate cancer, endurance training|Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention
3272299|NCT01584973||cruciate ligament group|
3272300|NCT01584973||control group|
3272301|NCT01584986|Active Comparator|ACP treated|Autologous angiogenic cell precursors (ACPs) were injected into the ischemic gastrocnemius muscle in addition to the conventional treatment.
3272302|NCT01584986|No Intervention|Control|Control patients were treated with the conventional therapy.
3272303|NCT01584999|Active Comparator|Fresh not-leukocyte-reduced RBCs|
3272304|NCT01584999|Active Comparator|Fresh RBCs leukocyte-reduced|
3272305|NCT01584999|Active Comparator|RBCs with storage longer than 15 days|
3272306|NCT01585012|Experimental|Cervical cap|Collection condom with cervical cap inserted
3272307|NCT01585051|Active Comparator|vitamin D|Intervention: Intramuscular injection of 300 000 U of 25(OH)vitamin D
3272308|NCT01585051|Placebo Comparator|placebo|administration of 0.9 % NaCl as a placebo
3272309|NCT01585064||DAS28-IOMS|Physicians randomized to the DAS28-IOMS will treat patients according to a protocol aimed at achieving a DAS28 score under 2.4.
3272310|NCT01585064||0SJ-IOMS|Physicians randomized to the 0SJ-IOMS will treat patients according to a protocol aimed at attaining a count of zero swollen joint (28 joints evaluated).
3272311|NCT01585064||Routine Care (RC)|Physicians randomized to the RC group will treat study patients as per routine care and according to their own judgment.
3272312|NCT01585077|Experimental|Naive volunteers|Volunteers without previous exposure to malaria, and negative antibody titers (<1:20) against native protein of P. vivax.
3272313|NCT01585077|Experimental|Pre-immune volunteers|Volunteers with previous exposure to malaria, and positive antibody titers against native protein of P. vivax
3272314|NCT01585090|Experimental|passive ankle dorsi ﬂexion|doing strengthening exercises of PFM in standing position with passive ankle dorsi ﬂexion (on wooden surface with 15 degree angle)
3272315|NCT01585090|Experimental|active ankle plantar ﬂexion with arm up|doing strengthening exercises of PFM in standing position with active ankle plantar ﬂexion with arm up (standing on toe)(n=20) and horizontal standing position
3272316|NCT01585090|No Intervention|horizontal standing position|doing strengthening exercises of PFM in standing position with horizontal standing position
3272317|NCT01585103|Experimental|Cytosponge/ brushing|
3272318|NCT01585142|Experimental|BabyNes system formula|
3272319|NCT01585181|Placebo Comparator|Placebo|
3272320|NCT01585181|Experimental|PXVX0200|
3272321|NCT01585220|Experimental|Neuramis|
3272322|NCT01585220|Active Comparator|Restylane®|
3272323|NCT01585233|Experimental|Cohort 1|ASKP1240 lowest dose
3272324|NCT01585233|Experimental|Cohort 2|ASKP1240 low dose
3272325|NCT01585233|Experimental|Cohort 3|ASKP1240 high dose
3272326|NCT01585233|Experimental|Cohort 4|ASKP1240 highest dose
3272327|NCT01585233|Placebo Comparator|Placebo|
3272328|NCT01585259|Active Comparator|Anfibatide|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
3272329|NCT01585259|Placebo Comparator|Placebo|Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h
3272330|NCT01585285|Experimental|LIMA to SVG Bridge|Patients will receive composite coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) and saphenous vein graft (SVG) Bridge for the anterolateral targets
3272331|NCT01585285|Active Comparator|Conventional CABG|Patients will receive conventional coronary artery bypass grafting (CABG) with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
3272332|NCT01585311||Subarachnoid Hemorrhage patients|SAH patients with hourly eMR values of Heart Rate
3272333|NCT01585337||patients with lumbar fusion|
3272334|NCT01585350|Experimental|Cohort 1|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
3272335|NCT01585350|Experimental|Cohort 2|"Vaccines will be administered subcutaneously, intradermally or transdermally in one skin location that is rotated to different sites on an extremity clinically uninvolved with melanoma.~Vaccines will be administered on days 1, 8, 15, 36, 57, and 78."
3272336|NCT01585402|Experimental|Etidronate|20 mg/kg oral 14 days on / 10 weeks off study drug
3272337|NCT01585415|Experimental|Single Arm|Two weeks prior to the start of the preparative regimen, patients will begin taking vemurafenib. Patients will then receive lymphocyte depleting preparative regimen of cyclophosphamide and fludarabine, followed by young TIL and high dose aldesleukin
3272338|NCT01585480|Experimental|weight gain prevention intervention|
3272339|NCT01585480|No Intervention|No treatment comparison group|
3272340|NCT01585493|Active Comparator|Treatment as usual|Treatment as usual
3272341|NCT01585493|Active Comparator|Care coordinator|
3272342|NCT01585493|Experimental|CHANGE|
3272343|NCT01585506||Questionnaire responders|
3272344|NCT01585519|No Intervention|(Group 1) Low Apple Diet|
3272345|NCT01585519|Experimental|(Group 2) 2 High Apples|
3272346|NCT01585519|Experimental|(Group 3) 2 Low Apples|
3272347|NCT01585519|Experimental|(Group 4) 2 x 4.4g apple granules|
3272348|NCT01585519|Experimental|(Group 5) 2 x Apple Extract Capsules|
3272349|NCT01585532||TB suspects with alternative final diagnosis|
3272350|NCT01585532||Confirmed tuberculosis patients|
3272351|NCT01585545||patients with NSCLC|
3272352|NCT01585571||Control|50 individuals of typical development with no known neuromuscular issues.
3272353|NCT01585571||Adults with CP|50 Individuals with a pediatric diagnosis of spastic, hemiplegic, diplegic or quadriplegic cerebral palsy.
3272354|NCT01585610|Experimental|DVD Program|
3272355|NCT01585610|Active Comparator|Standard Care Printed Materials|
3272356|NCT01585623|Experimental|Segment 1|two single doses of omeprazol/metoprolol/midazolam on day-1 and day 15 without food, SAR302503 500 mg once daily without food for 15 days
3377182|NCT04713137|Active Comparator|Erythritol|20 volunteers receive 50g erythritol dissolved in 300mL tap water as an oral pre-load.
3377183|NCT04713137|Active Comparator|Sucrose|20 volunteers receive 33.5g sucrose dissolved in 300mL tap water as an oral pre-load.
3377184|NCT04713137|Active Comparator|Sucralose|20 volunteers receive 0.0558g sucralose dissolved in 300mL tap water as an oral pre-load.
3377185|NCT04713137|Placebo Comparator|Water|20 volunteers receive 300mL tap water as an oral pre-load.
3272357|NCT01585623|Experimental|Segment 2|SAR302503 500 mg once daily without food in 28-day per cycle
3272358|NCT01585636|Experimental|5 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272359|NCT01585636|Experimental|10 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272360|NCT01585636|Experimental|20 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272361|NCT01585636|Experimental|50 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272362|NCT01585636|Experimental|100 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272363|NCT01585636|Experimental|200 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3272364|NCT01585636|Experimental|300 mg dose group|8 subjects: 6 received active drug, 2 received matching placebo
3377188|NCT04708431||Female subjects relatives who are carriers of the AR gene difference|We will enroll 50 female subjects relatives AIS subjects who are carriers of the AR gene difference
3272365|NCT01585636|Experimental|Food effect group|6 Subjects received single, 300 mg SQ109 after high-fat, high-calorie meal.
3272366|NCT01585649|Experimental|XM22, 100 μg/kg BW|
3272367|NCT01585662|Experimental|Naso-pancreatic tube|The patients enrolled in this group will be treated with modified naso-pancreatic tube drainage method.
3272368|NCT01585662|Experimental|Stents|The patients enrolled this group will be treated by placing the stents (at least 2 stents) between gastric and pancreatic pseudocyst.
3272369|NCT01585688|Experimental|hLL1-DOX|
3272370|NCT01585727|Experimental|TME with neuromonitoring|Total mesorectal excision with intraoperative neuromonitoring of pelvic autonomic nerves.
3272371|NCT01585727|Active Comparator|TME without neuromontoring|Total mesorectal excision without intraoperative neuromonitoring of pelvic autonomic nerves.
3272372|NCT01585740|Active Comparator|Normal Saline|250 patients in this arm assigned to receive normal saline as the study fluid
3272373|NCT01585740|Active Comparator|Ringer's Lactate|250 patients in this arm assigned to receive Ringer's Lactate as the study fluid
3272374|NCT01585753||Arm 1|NRTI and PI
3272375|NCT01585753||Arm 2|Maraviroc + PI
3272376|NCT01585753||Arm 3|maraviroc + NRTI
3272377|NCT01585792|Experimental|TAK-875 25 mg|
3272378|NCT01585792|Experimental|TAK-875 50 mg|
3272379|NCT01585792|Active Comparator|Glimepiride|
3272380|NCT01585792|Placebo Comparator|Placebo|
3272384|NCT01585818|Active Comparator|standard dietary intervention (SDI) arm|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre
3272385|NCT01585818|Experimental|LGI intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI. Participants will be provided with a list of low GI carbohydrates to consume during the intervention period and in addition, they will be provided with a supply of the staples for the same period
3272386|NCT01585844||Women with sleep apnea|
3272387|NCT01585844||Women without sleep apnea|
3272388|NCT01585857|Experimental|Group 1|2 x 10E6 ASC intra-articular injection (5 ml)
3272389|NCT01585857|Experimental|Group 2|10 x 10E6 ASC intra-articular injection (5 ml)
3272390|NCT01585857|Experimental|Group 3|50 x 10E6 ASC intra-articular injection (5 ml)
3272391|NCT01585870|Experimental|Sorafenib + Eribulin|
3272392|NCT01585883|Experimental|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session.
3272393|NCT01585883|Active Comparator|Standard of care|Patients in this condition will receive usual care as decided by their oncology clinic team or physician.
3272394|NCT01585896|Experimental|Self-help group|The facilitated self-help group, which represents an empirically supported intervention for hoarding (Frost et al., 2011).
3272395|NCT01585909|Other|Septic Shock|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with septic shock
3272396|NCT01585909|Other|SIRS|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients with SIRS
3272397|NCT01585909|Other|healthy/controls|Activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as brush border morphology determined from duodenal biopsies in patients without SIRS/septic shock
3272398|NCT01585922|Experimental|NPPV|Use the NPPV to treat moderate ARDS
3272399|NCT01585922|Active Comparator|IMV|Use invasive mechanical ventilation in treating the patients allocated to this group.
3272400|NCT01585935|Experimental|Smoflipid|SMOFLIPID will be used for parenteral lipid supply
3272401|NCT01585935|Active Comparator|Intralipid|INTRALIPID will be used for parenteral lipid supply
3272402|NCT01585948||Diabetes Mellitus|All patients undergoing coronary angiography who are diabetics.
3272403|NCT01585948||No diabetes mellitus|All patients undergoing coronary angiography that are non-diabetics.
3272404|NCT01585948||Coronary angiography patients|Diabetics and non-diabetics with or without known CV disease who are admitted in the Department of Cardiology in the University Hospital of Ioannina and the Catheterization Laboratory of 1st IKA Hospital in Athens and undergo coronary angiography for clinical purposes will be studied. The study will include subjects who 1) have suspected CAD and undergo a scheduled diagnostic angiogram for clinical reasons, and 2) are hospitalized because of an acute coronary syndrome and thus undergo diagnostic angiography (with or without previous history of CAD).
3272405|NCT01585974||Group 1|
3272406|NCT01586000|Experimental|10 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3272407|NCT01586000|Experimental|20 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3272408|NCT01586000|Experimental|40 µg/day E2|Two consecutive 3-month (90-day) rings will be used continuously for six months (180 days).
3272409|NCT01586013|Experimental|propofol infusion|Healthy adults scheduled for elective surgery will receive a computer controlled infusion until obtain the loss of counsiousness (BIS <50). After stoping the infusion we observe the emergency of anesthesia and the correspondant BIS curve. Using the complete loss and recovery curve of BIS we can describe the course of the effect of the drug. Venous sample will be taken during the study to evaluate the pharmacokinetic performance of the model.
3272410|NCT01586052|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
3272411|NCT01586065|Experimental|CGM|
3272412|NCT01586065|Other|Control|Fingerstick BGs only, no CGM
3272413|NCT01586104|Experimental|Treatment (IMRT)|Patients undergo cardiac-sparing whole lung IMRT.
3272414|NCT01586117|Experimental|Amifostine|intrarectal Amifostine assign to the Amifostine arm
3272415|NCT01586130|Other|isokinetic exercises in eccentric mode|
3272416|NCT01586130|Other|isokinetic exercises in concentric mode|
3272417|NCT01586143|Experimental|transbuccal paracetamol 125 mg|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
3272418|NCT01586143|Placebo Comparator|placebo|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
3272419|NCT01586182|Experimental|Stereotactic Boost|Escalating doses of stereotactic body radiation therapy (SBRT)
3272420|NCT01586208|Active Comparator|40mg/kg intial valproate bolus|Patient receives a 40mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
3272421|NCT01586208|Active Comparator|20mg/Kg intial bolus valproate|Patient receives a 20mg/kg valproate bolus with a maintenance of 1mg/kg/h, after benzodiazepine + phenytoin administration
3272422|NCT01586221|Other|Music & Physical Therapy|Subjects will received Music and Physical Therapy in a group setting.
3272423|NCT01586234|Experimental|DSAEK with graft shaping and smoothing|
3272424|NCT01586234|Active Comparator|Standard DSAEK|
3272425|NCT01586247|Experimental|Synbiotic|8g/day gluco-oligosaccharide + 109 CFU/day B. lactis BI07
3272426|NCT01586247|Experimental|Placebo|8g/day maltodextrin
3272427|NCT01586247|Experimental|Prebiotic|8g/day galacto-oligosaccharides (GOS)
3272428|NCT01586247|Experimental|Probiotic|109 CFU/day B. lactis BI07
3272429|NCT01586273|Experimental|MR-HIFU treatment|Subjects undergo a MR-HIFU treatment for pain palliation of bone metastases on their most painful metastasis.
3272430|NCT01586286|Placebo Comparator|Ointment Base|Patients in this arm will serve as the control and will undergo pelvic floor physical therapy and receive placebo (lanolin and mineral oil base).
3272431|NCT01586286|Active Comparator|Nifedipine Ointment|Patients in this arm will undergo pelvic floor physical therapy, but will receive compounded vaginal nifedipine.
3272432|NCT01586299|Experimental|ibuprofen|
3272433|NCT01586299|Active Comparator|acetaminophen|
3272434|NCT01586325|Experimental|Panel 1|Study participants will receive double-blind treatment with JNJ-47910382 30 mg or matching placebo. Participants in each of Panel will be treated sequentially (ie, participants in Panel 1 will be treated before participants in Panel 2, participants in Panel 2 will be treated before participants in Panel 3).
3272435|NCT01586325|Experimental|Panel 2|Study participants will receive double-blind treatment with JNJ-47910382 90 mg or matching placebo. Participants in each of Panel will be treated sequentially.
3272436|NCT01586325|Experimental|Panel 3|Study participants will receive double-blind treatment with JNJ-47910382 200 mg (maxiumum dose) or matching placebo. Participants in each of Panel will be treated sequentially.
3272437|NCT01586351||Patch and ACP Treatment|Patents who get an patch augmentation and ACP injection following an arthroscopic repair of the rotator cuff.
3272438|NCT01586377||CRPS Type 1|Patients with CRPS 1 affecting a single upper limb
3272439|NCT01586377||Healthy volunteers|Volunteers without the diagnosis of CRPS Type 1
3272440|NCT01586390|Experimental|MOK|Adjustable and removable brace made out of Softcast material
3272441|NCT01586390|Active Comparator|WRAP|Softcast ankle cast
3272442|NCT01586403|Experimental|Dose 1|Subjects in cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight
3272443|NCT01586403|Experimental|Dose 2|cohort 2 will receive 7.5 x 106 TIL 1383I TCR transduced T cells per kg body weight.
3272444|NCT01586403|Experimental|Dose 3|Subjects in cohort 3 will receive 2.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
3272445|NCT01586403|Experimental|Dose 4|Subjects will then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 107 TIL 1383I TCR transduced T cells per kg body weight.
3272446|NCT01586416|Experimental|Behavioral Intervention|Brief behavioral intervention on 2-3 sessions of tailored cognitive-behavioral therapy to support chemotherapy adherence and well-being of patients completing chemotherapy for colon cancer.
3272447|NCT01586429||Epidural|
3272448|NCT01586429||Femoral catheter|
3272449|NCT01586442|Active Comparator|Spironolactone|spironolactone 12.5mg once daily titrated to 25mg once daily
3272450|NCT01586442|Experimental|Eplerenone|Eplerenone 25mg once daily titrated to 50mg once daily
3272451|NCT01586455|Experimental|Group A|related cord blood with ≥3/6 HLA match to the patient and related HPDSC
3272452|NCT01586455|Experimental|Group B|unrelated cord blood with ≥ 4/6 HLA match to the patient and unrelated HPDSC
3272453|NCT01586455|Experimental|Group C|unrelated cord blood with ≥4/6 HLA match to the patient but related to HPDSC
3272454|NCT01586455|Experimental|Group D|double unrelated cord blood units with ≥4/6 HLA match to patient and each other and unrelated HPDSC
3272455|NCT01586468|Placebo Comparator|NaCl Solution|
3272456|NCT01586468|Experimental|WF10 0.5 ml/kg BW|
3272457|NCT01586481|Active Comparator|barouk|
3272458|NCT01586481|Experimental|sanidiab|
3272459|NCT01586494|Experimental|Group 1|
3272460|NCT01586494|Experimental|Group 2|
3272461|NCT01586507|Experimental|Group 1|
3272462|NCT01586507|Experimental|Group 2|
3272463|NCT01586520||Disease positive|Imaging or biopsy evidence of disease
3272464|NCT01586520||Disease negative|No evidence of disease
3272465|NCT01586533|Experimental|Zoenasa-1:4|
3272466|NCT01586533|Active Comparator|Mesalamine Enema|
3272467|NCT01586546|Experimental|Face-to-Face MBM Skills Group|
3272468|NCT01586546|Experimental|Online MBM Skills Group|
3272469|NCT01586546|Other|Waitlist Control I|This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
3272470|NCT01586546|Other|Waitlisted Control II|This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.
3272471|NCT01586559||Control group|Nulliparous women
3272472|NCT01586559||Diastasis|Patients after rectus sheath plication due to diastasis
3272473|NCT01586572|Experimental|mOPV1- Arm A|Arm A will be administered a second dose of mOPV1 seven days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at day 79.
3272474|NCT01586572|Experimental|mOPV1- Arm B|Arm B will be administered a second dose of mOPV1 fourteen days after after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 86 days.
3272475|NCT01586572|Experimental|mOPV1-Arm C|Arm C will receive the second dose of mOPV1 thirty days after the 42 day mOPV1 index dose.Second dose of tOPV2 will be given at 102 days.
3272476|NCT01586572|Experimental|Arm D- bOPV1,3|Arm D will be administered a second dose of bOPV1,3 thirty days after the 42 day bOPV1,3 index dose.Second dose of tOPV2 will be given at day 102.
3272477|NCT01586585||post cardiac surgery patients|
3272478|NCT01586598|No Intervention|control group|No intervention will be given to this control group. Spontaneous recovery of mandibular nerve will be assessed for sensory function.
3272479|NCT01586598|Experimental|sensory retraining group|Sensory retraining protocol will be applied this group. Any facilitation of sensory function in mandibular nerve will be assessed.
3272480|NCT01586611|Active Comparator|Gemcitabine|Cycles to be 4 weeks in length Gemcitabine 1000 mg/m2 IV weekly for 3 weeks then one week off
3272481|NCT01586611|Experimental|FOLFOX|Cycles to be 2 weeks in length Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
3272482|NCT01586637|Experimental|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
3272483|NCT01586637|Experimental|Walking|The group walked twice a week during one hour.
3272484|NCT01586650|Experimental|Aerobic training|The patients in this arm perform a 50-minute-walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
3272485|NCT01586650|Placebo Comparator|Stretching exercises|The control group perform global stretching exercises for approximately 20 minutes 3 times a week for 12 weeks.
3272486|NCT01586663|Experimental|Experimental Group|Splint group
3272487|NCT01586663|Active Comparator|Control Group|Drug treatment
3272488|NCT01586676|Experimental|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP)
3272489|NCT01586676|Active Comparator|Supervision-as-usual|Supervision-as-usual consists of the typical clinical supervision services provided to clinicians by their supervisors in their community programs.
3272490|NCT01586689|Experimental|Safe Haven|participants assigned to the Safe haven condition and agree to move into the A Safe Haven residential treatment facility
3272491|NCT01586689|Experimental|Usual aftercare|participants assigned to the control condition, and may or may not seek treatment on their own
3272492|NCT01586689|Experimental|Oxford House|participants who were assigned to the Oxford House condition and agree to move into an Oxford House
3272493|NCT01586702|No Intervention|Regular care|Consisting of structured information given at hospital discharge regarding stroke etiology and recommended secondary prevention plus regular outpatient care by general practitioners or family doctors.
3272494|NCT01586702|Active Comparator|Support program|In addition to regular care: Up to 8 appointments in outpatient clinics. Results of risk factor measurements and assessed adherence to medical recommendations are shared with the patients. In case that a patients fails to meet target values, preventive measures will be modified directly or via recommendation to GPs / family doctors. Patients are also offered assistance in finding appropriate physical activities or smoking cessation programs.
3272495|NCT01586715|Experimental|Autologous Stem Cells|
3272496|NCT01586728|Other|Air - oxygen|One period in room air and one period with nocturnal oxygen therapy, separated by a wash out period of 2 to 6 weeks.
3272497|NCT01586728|Other|Oxygen - Air|One period with nocturnal oxygen therapy and one period in room air, separated by a wash out period of 2 to 6 weeks.
3272498|NCT01586754||With Metabolic Syndrome|
3272499|NCT01586754||Without Metabolic Syndrome|
3272500|NCT01586767|Active Comparator|Proton beam therapy|Subjects treated at Massachusetts General Hospital with proton beam therapy
3272501|NCT01586767|Active Comparator|IMRT|Intensity-modulated radiation therapy at institutions other than Massachusetts General Hospital
3272502|NCT01586780|Experimental|Reference meal|
3272503|NCT01586780|Experimental|Whey protein|
3272504|NCT01586780|Experimental|Whey + 5 amino acids|
3272505|NCT01586780|Experimental|Whey + 6 amino acids|
3272506|NCT01586780|Experimental|Soy protein drink|
3272507|NCT01586780|Experimental|Soy + 5 amino acids|
3272508|NCT01586780|Experimental|Soy + 6 amino acids|
3272509|NCT01586793|Experimental|High Frequency rTMS|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
3272510|NCT01586793|Experimental|Low Frequency rTMS|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
3272511|NCT01586832||ED Nurses|"Nurses in the emergency department (ED) providing patient care using supplies found in the stocking towers"
3272512|NCT01586845|Experimental|Voclosporin|Voclosporin
3272513|NCT01586845|Active Comparator|Tacrolimus|Tacrolimus
3272514|NCT01586858||RAVE subjects|
3272515|NCT01586884|Experimental|Intervention|"Ten patients undergoing LV lead placement for either initial CRT device implant or revision of an existing system at Lancaster General Hospital who meet the inclusion and exclusion criteria will be screened and approached for enrollment in this safety and feasibility study. Study participants may have ischemic or non-ischemic cardiomyopathy; results for ischemic and non-ischemic patients will be analyzed separately. Any device system from any manufacturer may be used; the choice of device and leads will be at the implanting physician's discretion.~Post implant procedures will be the same as those for any CRT implant. Outpatient follow-up other than the 1-month follow-up will be per the implanting physician's usual practice."
3272516|NCT01586923|Active Comparator|Short-storage RBC|RBC transfusion using packed RBCs stored for 10 days or less.
3272517|NCT01586923|Active Comparator|Prolonged-storage RBC|RBC transfusion using packed RBCs stored for 25 days or more.
3272518|NCT01586936||eptacog alpha users|
3272519|NCT01586949|Experimental|Treatment|Intervention: Daily Challenge
3272520|NCT01586949|No Intervention|Control|Weekly Well-being, an email-based health information delivery service.
3272521|NCT01586988|Experimental|IMAGE Intervention|mothers are provided the IMAGE Parenting and Self-Care intervention
3272522|NCT01586988|No Intervention|Control|Standard care.
3272523|NCT01587053||AVK|patient with AVK treatment
3272524|NCT01587066|Active Comparator|Quetiapine fumarate|
3272525|NCT01587066|Active Comparator|Divalproex sodium|
3272526|NCT01587092|Placebo Comparator|Usual Working Condition Group|Participants assigned to the usual working condition control group will continue to work in their usual environment and accustomed manner. The control group participants will have access to the Workstations at the completion of study.
3272527|NCT01587092|Active Comparator|WorkStation Intervention Group|Participants will be asked to walk for up to 1.5 hours per day on the treadmill. This will be split into two 45 minute sessions per day. Behavioral support will focus on adherence to frequency (attending scheduled sessions). Participants self-select speed of walking and time (they have up to 45 minutes allotted, but may choose less as they like).
3272528|NCT01587131|Experimental|Group 1- DNA prime DNA boost|0.9 mg of FVH1 vaccine delivered ID followed by electroporation on Day 0, Week 15 and Week 27
3272529|NCT01587131|Experimental|Group 2 - DNA prime Seasonal Vaccine boost|0.9 mg FVH1 vaccine delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
3272530|NCT01587131|Placebo Comparator|Group 3 - sWFI prime Seasonal Vaccine boost|100 microliters of sterile water for injection delivered ID followed by electroporation on Day 0 and Trivalent Seasonal Influenza Vaccine delivered IM on Week 15
3272531|NCT01587144|Placebo Comparator|Placebo|Participants will receive a matching placebo as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
3272532|NCT01587144|Active Comparator|Lucanthone|Participants will receive Lucanthone as an adjunct in initial six weeks of concomitant therapy with TMZ and radiation, followed by a maintenance phase of six cycles of TMZ given on Days 1 to 5 of a 28-day cycle (+/- 3 days).
3272533|NCT01587157|Experimental|capnography|
3272534|NCT01587170||Uninjured control subjects|Uninjured, control subjects who are not taking any of the contraindicated drugs.
3272535|NCT01587170||Spinal-cord injured subjects|Patients who have suffered a spinal cord injury (>1year ago).
3272536|NCT01587183|Other|Educational materials control|Enhanced usual care
3272537|NCT01587183|Active Comparator|Group running style B|Basic running instruction using group based training.
3272538|NCT01587183|Experimental|Group running style A|Form focused running instruction using group based training.
3272539|NCT01587196|Experimental|Naltrexone Intervention|Eligible participants receive up to three monthly injections of 380 mg of naltrexone contained in dissolvable polymer microspheres and administered by deep intramuscular injection and slowly released over a period of approximately 4 weeks.
3272540|NCT01587209||Divers with decompression sickness|The sole group under study is SCUBA divers who have sustained decompression sickness
3272541|NCT01587222|Experimental|Albumin, Midodrine, Octreotide|
3272542|NCT01587235|Experimental|Vytorin|
3272543|NCT01587235|Active Comparator|Other Statin|
3272544|NCT01587248|Active Comparator|Electrocautery|Raising of the flaps with electrocautery
3272545|NCT01587248|Experimental|Harmonic|Dissection with harmonic scalpel in modified radical mastectomy
3272546|NCT01587261|Placebo Comparator|Placebo|Victims of severe thermal injury receiving placebo Lactated Ringers solution for the first 24 hours
3272547|NCT01587261|Experimental|Vitamin C|Victims of severe thermal injury receiving high-dose vitamin C 66 mg/kg/hr for the first 24 hours
3272548|NCT01587287||Corneal power measurement|All recruited volunteers in present study, that underwent corneal power measurement with 8 different instruments
3272549|NCT01587313|Experimental|Group 1|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 am
3377189|NCT04708431||Female subjects relatives who are not carriers of the AR gene|We will enroll 50 female subjects relatives of AIS subjects who are not carriers of the AR gene.
3377190|NCT04708431||Healthy male subjects relatives|We will enroll 50 healthy male subjects of AIS relative subjects
3377191|NCT04708431||Subjects with androgen receptor mutations|500 Subjects with confirmed androgen receptor mutations
3377194|NCT04706559|Experimental|Group A (Interventional group)|Along with below mentioned conventional treatment, the participants in group A (i.e. Interventional group) will receive conventional treatment of AD for a short duration along with probiotics for 8 weeks. One probiotic sachet twice a day will be prescribed. A sachet of 2 grams containing 1.25 billion cells per gram of 4 strains (Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, and Saccharomyces boulardii) will be used. The child will receive a total of 5 billion cells of probiotics per day.
3377195|NCT04706559|Active Comparator|Group B (Conventional group)|All patients (i.e. in both arms) with atopic dermatitis will be prescribed emollients and cleanser as a part of routine skin care. Topical corticosteroid (i.e. Fluticasone 0.05% cream) and topical calcineurin inhibitor (tacrolimus 0.1% ointment) for sensitive areas like periorbital regions, flexures and face, will be given once daily. All patients will be given an oral antihistamine (syrup/ tablet cetirizine 0.3mg/kg) at night. It is referred to as conventional treatment.
3272550|NCT01587313|Experimental|Group 2|ISDN/HYD 2 SR caps crossover to 1 IR cap at 5 pm
3272551|NCT01587313|Experimental|Group 3|ISDN/HYD 2 SR caps crossover to 1 IR cap at 8 pm
3272552|NCT01587313|Active Comparator|Group 4|ISDN/HYD 1 IR cap and two SR caps at 8 am crossover to Day 8: BiDil Tablet tid
3377196|NCT04705246|Experimental|Psychoeducation|The goal of the psychoeducation session is to provide insight in the hyperacusis symptoms, take away the fear of external noises, and encourage exposure to noise.
3377197|NCT04704674||0.5 - 5 years|Age bracket for infants/children up to age five years
3272553|NCT01587326|Experimental|Escitalopram|Escitalopram 10 mg/d to 20 mg/d
3272554|NCT01587339||Drug-resistant (or refractory) partial epilepsy of all types|Drug-resistant (or refractory) partial epilepsy of all types
3377198|NCT04704674||10 - 18 years|Age bracket for children 10 - 18 years
3377199|NCT04704674||19 + years|Age bracket for adults over 19 years
3377200|NCT04704674||5 - 10 years|Age bracket for children ages 5 - 10 years
3377201|NCT04700176|Experimental|Progressed on Daratumumab + Lenalidomide + Dexamethasone (Cohort A)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Len + Dex (Cohort A) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
3272556|NCT01587365|Experimental|Panel 1: BMS-962476 SC (0.01 mg/Kg) or Placebo|BMS-962476 0.01 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3272557|NCT01587365|Experimental|Panel 2: BMS-962476 SC (0.03 mg/Kg) or Placebo|BMS-962476 0.03 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3377202|NCT04700176|Experimental|Progressed on Daratumumab + Pomalidomide + Dexamethasone (Cohort B)|Patients with relapsed or refractory multiple myeloma who have progressed on the combination of Dara + Pom + Dex (Cohort B) to be treated with a combination of Dara + Pom + Dex + ATRA (All-Transretinoic Acid)
3377207|NCT04690816||Healthy Volunteers|Healthy Volunteers to have a comparative group,without an underlying autoimmune disease or other significant medical problems
3377208|NCT04690816||Systemic Autoimmune Diseases|Patients with associated systemic autoimmune diseases.
3377209|NCT04690387|Experimental|0.1 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen
3377210|NCT04690387|Experimental|0.33 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen
3272558|NCT01587365|Experimental|Panel 3: BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3272559|NCT01587365|Experimental|Panel 4: BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3377211|NCT04690387|Experimental|1.0 mg antigen, 0 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen
3377212|NCT04690387|Experimental|0.1 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 250 mcg GM-CSF
3272560|NCT01587365|Experimental|Panel 5: BMS-962476 IV (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
3272561|NCT01587365|Experimental|Panel 6: BMS-962476 IV (1.0 mg/Kg) or Placebo|BMS-962476 1.0 mg/kg or Placebo matching with BMS-962476 0 mg liquid intravenously (IV), Single Dose, 1 day
3272562|NCT01587365|Experimental|Panel 7: Statin + BMS-962476 SC (0.1 mg/Kg) or Placebo|BMS-962476 0.1 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3272563|NCT01587365|Experimental|Panel 8: Statin + BMS-962476 SC (0.3 mg/Kg) or Placebo|BMS-962476 0.3 mg/kg or Placebo matching with BMS-962476 0 mg liquid subcutaneously (SC), Single Dose, 1 day
3272564|NCT01587378|Experimental|metformin|
3272565|NCT01587378|Placebo Comparator|placebo|
3272566|NCT01587391|Experimental|BI 163538 XX|1 single dose per subject as oral solution
3272567|NCT01587391|Placebo Comparator|Placebo to BI 163538 XX|1 single dose per subject as oral solution
3272568|NCT01587404|Experimental|Constant Catheter Contact Force|No alteration of catheter contact force during recording period
3272569|NCT01587404|Experimental|Variable catheter contact force|change in contact force from low to high after 30seconds of recording.
3272570|NCT01587417|Experimental|BI 187004 CL|1 single dose per subject as oral solution
3272571|NCT01587417|Placebo Comparator|Placebo to BI 187004 CL|1 single dose per subject as oral solution
3272572|NCT01587430|Active Comparator|high dose ARA-C|High dose ARA-C will be applied after two 7+3 induction courses during the first and the second consolidation courses: ARA-C 1 g/m2 bid 1-3 days with idarubicin (8mg/m2 3-5 days)and mitoxantrone (10 mg/m2 3-5 days)
3272573|NCT01587430|Active Comparator|standard dose ARA-C|Standard dose ARA-C will be applied after two 7+3 induction courses the first and the second consolidation courses : ARA-C 100 g/m2 bid 1-7 days with idarubicin (8mg/m2 1-3 days)and mitoxantrone (10 mg/m2 1-3 days)
3272574|NCT01587443||Hemodialysis|
3272575|NCT01587443||Peritoneal dialysis|
3272576|NCT01587469||HIV-infected and -uninfected individuals|HIV-infected and -uninfected individuals with suspected TB infection
3272577|NCT01587482||drug eluting balloon|"In this observationnal study, the intervention of interest is the use of drug eluting balloon in stent restenosis.~Only the treated patients were included in this cohort."
3272578|NCT01587495|Experimental|Ertapenem|Women diagnosed with postpartum endometritis
3272579|NCT01587508|Active Comparator|meloxicam - Movatec®|
3272580|NCT01587508|Active Comparator|cyclobenzaprine - Miosan®,|
3272581|NCT01587508|Experimental|meloxicam/cyclobenzaprine hydrochloride|
3272582|NCT01587534|Experimental|pancreatic enzyme replacement therapy|The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
3272583|NCT01587534|No Intervention|Placebo|The placebo will match the active drug in appearance, taste, and weight and contained pharmacologically inactive substances.
3272584|NCT01587547||IVF and ICSI patients|Subjects undergoing IVF or ICSI treatment with a maximum of 2 embryos transferred
3272585|NCT01587560|Active Comparator|Pyrocarbon|Patients receiving a shoulder surface replacement implant made of pyrocarbon (the PyroTITAN Humeral resurfacing Arthroplasty)
3272586|NCT01587560|Active Comparator|CoCr|Patients receiving a shoulder surface replacement implant made of Cobalt-Chrome(CoCR) (the TITAN Humeral Resurfacing Arthroplasty)
3272587|NCT01587573||oral lesions|oral lesions suspicious for squamous cell carcinoma with saliva collection prior to clinically driven oral biopsy
3272588|NCT01587586|Active Comparator|PEGASYS 180 µg Q1W + ribavirin* for 48 weeks|Pegasys 180 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses(48)
3272589|NCT01587586|Experimental|P1101 180 µg Q1W + ribavirin* for 48 weeks|P1101 180 µg Q1W(subcutaneous injection)with Ribavirin, multiple doses
3272590|NCT01587586|Experimental|P1101 270 µg Q1W + ribavirin* for 48 weeks|P1101 270 µg Q1W(subcutaneous injection)+Ribavirin, multiple doses
3272591|NCT01587586|Experimental|P1101 450 µg Q2W + ribavirin* for 48 weeks|P1101 450 µg Q2W(subcutaneous injection)+Ribavirin, multiple doses
3272592|NCT01587599|Active Comparator|Pharmaceutical care|
3272593|NCT01587599|Placebo Comparator|Standard care|
3272594|NCT01587625|Experimental|High dose of oxytocin infusion|Oxytocin: High dose infusion
3272595|NCT01587625|Active Comparator|Low dose of oxytocin infusion|Oxytocin: Low dose infusion
3272596|NCT01587638||Hypertensive users of Beta blocker|Patients aged ≥18 years and at least 1 diagnosis of hypertension (ICD-9-CM: 401.xx-405.xx) during this time frame in a US Managed care population
3272597|NCT01587664|Experimental|NewBreez ILP|Implantation of a NewBreez ILP
3272598|NCT01587677||Confirmed tuberculosis|
3272599|NCT01587677||Confirmed non-tuberculous mycobacterial infection|
3272600|NCT01587677||Confirmed bronchial carcinoma|
3272601|NCT01587677||Suspected tuberculosis but confirmed alternative diagnosis|
3272602|NCT01587690||Healthy subjects|Self-explanatory
3272603|NCT01587690||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
3272604|NCT01587690||Treated Patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Interferon-beta-1a prior to enrollment
3272605|NCT01587716|Experimental|1. Inhaled GSK2339345/Placebo Single Dose (Cohort 1)|administered three ascending doses of GSK2339345 or placebo as a solution via an aqueous droplet inhaler over four treatment periods, with at least 5 days washout between doses
3272606|NCT01587716|Experimental|2. Inhaled GSK2339345/Placebo Repeat Dose (Cohort 2)|administered a dose of GSK2339345 or placebo, four times a day on two consecutive days. Each subject will receive either GSK2339345 or matching placebo as a solution administered via an aqueous droplet inhaler
3272607|NCT01587729||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
3272608|NCT01587729||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
3272609|NCT01587742||Patients with a diagnosis of any cancer type|All patients of the study population with a diagnosis of any cancer type based on Read codes and ICD-10 codes
3272610|NCT01587742||Patients with a diagnosis of breast cancer|All patients of the study population with a diagnosis of breast cancer based on Read codes and ICD-10 codes
3272611|NCT01587742||Patients with a diagnosis of prostate cancer|All patients of the study population with a diagnosis of prostate cancer based on Read codes and ICD-10 codes
3272612|NCT01587742||Patients with a diagnosis of colon cancer|All patients of the study population with a diagnosis of colon cancer based on Read codes and ICD-10 codes
3272613|NCT01587742||Patients without a diagnosis of any cancer type|All patients of the study population without a diagnosis of any cancer type
3272614|NCT01587755|Other|Topical Treatment Optimizing Program|Optimized care
3272615|NCT01587755|Other|non-Topical Treatment Optimizing Program|Standard care
3377213|NCT04690387|Experimental|0.33 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 250 mcg GM-CSF
3272616|NCT01587768||Patients with a definite case of acute liver injury|"The information recorded in the patients' medical record met all the criteria to be classified as idiopathic acute liver injury and the patient presents with at least with one of the following conditions (A+B or A+C):~A - A diagnosis of liver injury (codes listed in tables 1a, 1b, 1c) with a referral to a specialist or hospital.~Together with B - An increase of more than two times the upper limit of the normal range in alanine aminotransferase (ALT) or C - A combined increase in aspartate aminotransferase (AST), alkaline phosphatase (AP) and total bilirubin provided one of them is twice the upper limit of the respective normal range."
3272617|NCT01587768||Patients with a probable case of acute liver injury|The information recorded in the patients' medical file was compatible with idiopathic acute liver injury, but not fulfilling all conditions and criteria to be defined as definite case. For example, patients identified with a READ or ICPC code for acute liver injury with a hospitalization or visit to a specialist but without complete laboratory criteria or patients identified with a READ or ICPC code for acute liver injury without a referral to a hospital/specialist, and with or without complete laboratory data.
3272618|NCT01587768||Non-cases|Any potential or probable case that was excluded in one of the previous steps and those with insufficient data to determine their case status. Patients presenting normal liver function tests (LFTs), alcohol related problems, gallbladder disease, pancreatic disease, or other liver diseases with clear aetiology such as viral, alcoholic or autoimmune, or presence of other well defined pathology known to cause acute liver injury will be considered non-cases.
3272619|NCT01587794||retinal detachment group|Patients who were diagnosed with unilateral rhegmatogenous retinal detachment involving only the superior or inferior half of the retina and who underwent successful scleral buckling procedure or vitrectomy by a single surgeon between January 1, 2008 and April 1, 2010 were included in the study sample.
3272620|NCT01587807|Experimental|Cohort 1|single inhaled dose of GSK1995057 (dose 1) or placebo
3272621|NCT01587807|Experimental|Cohort 2|single inhaled dose of GSK1995057 (dose 2) or placebo
3377214|NCT04690387|Experimental|1.0 mg antigen, 250 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 250 mcg GM-CSF
3377215|NCT04690387|Experimental|0.1 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.1 mcg antigen, admixed with 500 mcg GM-CSF
3377216|NCT04690387|Experimental|0.33 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 0.33 mcg antigen, admixed with 500 mcg GM-CSF
3377217|NCT04690387|Experimental|1.0 mg antigen, 500 mcg GM-CSF|Dendritic cells previously incubated with 1.0 mcg antigen, admixed with 500 mcg GM-CSF
3377218|NCT04690335|Experimental|MV-012-968|Dose: 1 x10^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).
3377219|NCT04690335|Placebo Comparator|Placebo|Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.
3377222|NCT04684615||AmBiGen|Individuals who are enrolled in AmBiGen over the last 3 years
3377223|NCT04682847||Primary and metastatic liver tumors and hepatic cirrhosis|This study is a single arm prospective study that will enroll 25 patients with primary and metastatic liver tumors and hepatic cirrhosis eligible for liver SBRT who will be receiving treatment at a single center - Allegheny General Hospital.
3377226|NCT04676009|Experimental|Exercise arm :|"Patient randomized to the Exercise arm will receive physical activity recommendations at inclusion and nutritional assessment will be carried out during the first and last treatment cure. Patients will receive an acute physical exercise just before immunotherapy and chemotherapy infusion.They will have a home walking program and will have to wear an activity tracker during the 3 months of intervention.~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place before exercise (1), after exercise (2) and 12 hours after the start of treatment (3)."
3377227|NCT04676009|No Intervention|Control arm|"Patients will receive physical activity recommendations at inclusion and a nutritional assessment will be carried out during the first and last treatment cure. They will receive the usual care and standard treatment protocol (immunotherapy and chemotherapy).~3 blood sampling times (2 EDTAsx10 mL) will be specially added to the study and will take place 40 min before the administration of treatments (1), just before the administration of treatments (2) and 12 hours after the start of treatment (3)."
3377228|NCT04675996|Experimental|Phase 1/1b|"Phase 1: dose escalation phase with a 'hybrid' 3+3 design in all-comers cancer patients. Approximately 30 patients will be included.~Phase 1b: dose expansion phase in selected tumor types at the recommended phase 2 dose. Approximately 50 patients will be included."
3272622|NCT01587807|Experimental|Cohort 3|single inhaled dose of GSK1995057 (dose 3) or placebo
3272623|NCT01587807|Experimental|Cohort 4|single inhaled dose of GSK1995057 (dose 4) or placebo
3272624|NCT01587807|Experimental|Cohort 5|single inhaled dose GSK1995057 (dose 4) with bronchoalveolar lavage (BAL)sampling procedure conducted approximately 30 minutes post GSK1995057 dose
3272625|NCT01587807|Experimental|Cohort 6|high dose of GSK1995057 or placebo followed by an inhaled LPS challenge and BAL sampling procedure.
3272626|NCT01587820|Experimental|Intra-arterial cisplatin and radiation|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
3272627|NCT01587820|Active Comparator|Intravenous cisplatin and radiation|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
3272628|NCT01587833||Patients with a diagnosis of hip or femur fracture|All patients of the study population with a record/diagnosis of a first fracture of the hip or femur during the study period regardless of whether they have a history of past fractures. When the patient has a history of hip or hip/femur fracture, a minimum of 12 months should have elapsed between the two episodes for a current fracture to be considered a new event.
3272629|NCT01587833||Patients without a diagnosis of hip or femur fracture|All patients of the study population without a record/diagnosis of a fracture of the hip or femur during the study period
3272630|NCT01587846|Experimental|Probiotic/abdominal pain|Children with functional abdominal pain that will receive probiotic.
3272631|NCT01587846|Experimental|Placebo/abdominal pain|Children with functional abdominal pain that will receive placebo.
3272632|NCT01587846|Experimental|Probiotic/constipation|Children with chronic constipation tha will receive probiotic plus lactulose
3272633|NCT01587846|Experimental|Placebo/chronic constipation|Children with chronic constipation that will receive placebo plus lactulose
3272634|NCT01587859||Cohort|Patients submitted to laparoscopic surgery for Type II-IV hiatus hernia
3272635|NCT01587872|Experimental|DBC|Double balloon colonoscopy will be attempted in cases where conventional colonoscopy failed due to technical difficulties such as looping or redundant colonic segments.
3272636|NCT01587911|Active Comparator|Whey protein|Complete whey protein.
3272637|NCT01587911|Active Comparator|Whey-CMP|Complete whey protein missing the CMP (aka GMP) portion of the peptide.
3272638|NCT01587911|Placebo Comparator|Control|Placebo preload control, matched for energy.
3272639|NCT01587911|Active Comparator|CMP (casinomacropeptide)|Small peptide cleaved from complete whey protein.
3272640|NCT01587911|Active Comparator|MPI|Complete milk protein.
3272641|NCT01587911|Active Comparator|CPI (casein)|Preload containing casein.
3272642|NCT01587937|Experimental|Antibiotic stewardship intervention|Audit-and-feedback intervention to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antimicrobial
3272643|NCT01587937|No Intervention|Control|The pre-intervention period will serve as the control period on each medical and surgical service. The cross-over is uni-directional from control to intervention; all services receive the intervention by the end of the study. This is a stepped wedge design. The order of roll-out is randomized.
3272644|NCT01588002|Active Comparator|A danoprevir+ritonavir|
3272645|NCT01588002|Active Comparator|B efavirenz|
3272646|NCT01588002|Experimental|C combination|
3272647|NCT01588015|Experimental|Arm I (vaccine therapy)|Patients receive Tet-CMV + PF03512675 SC on days 28 and 56 post-HCT.
3272648|NCT01588015|Active Comparator|Arm II (control)|Patients undergo immune monitoring only.
3272649|NCT01588041||Vitreoretinal Interface Disease Group|A minimum of 50 subjects with vitreoretinal interface disease will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272650|NCT01588041||Macular Hole Group|A minimum of 50 subjects with macular hole with be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272651|NCT01588041||Retinal Detachment Group|A minimum of 50 subjects with retinal detachment will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272652|NCT01588041||Diabetic Retinopathy Group|A minimum of 50 subjects with diabetic retinopathy will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272653|NCT01588041||Rare Related Macular Disease Group|Up to 70 subjects with rare related macular diseases will be imaged with MIOCT prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272654|NCT01588041||Generation 2 MIOCT Transition Group|80 of the subjects recruited in years 1 through 5 (40 normal, 40 diseased) will be imaged with both the generation 1 MIOCT and the generation 2 MIOCT systems prior to surgery, during surgical maneuvers, during a normal pause in surgery, and at 2 post-operative follow-up visits.
3272655|NCT01588041||Endothelial Keratoplasty Group|150 subjects undergoing Descemet Stripping Endothelial Keratoplasty (DSEK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
3272656|NCT01588041||Anterior Lamellar Keratoplasty Group|150 subjects undergoing Deep Anterior Lamellar Keratoplasty (DALK) will be imaged with MIOCT at the conclusion of the surgical procedure and may be imaged during follow-up visits.
3272657|NCT01588054||adults, cervical deformity, surgical treatment|Adults 18years or older at time of enrollment, cervical deformity to include kyphosis (C2-7 greater than 10 degrees) or scoliosis (coronal cobb greater than 10 degrees), plans for surgical treatment of cervical deformity
3272658|NCT01588067||Medical|Patients treated for PAD medically or with exercise therapy
3272659|NCT01588067||Endovascular|Patients with PAD treated with endovascular therapy
3272660|NCT01588067||Surgery|Patients with PAD treated with surgery
3272661|NCT01588080|Placebo Comparator|SiPAP|
3272662|NCT01588080|Experimental|Neurally Adjusted Ventilatory Assist|
3272663|NCT01588093|Placebo Comparator|Saline|
3272664|NCT01588093|Active Comparator|Increlex|
3272665|NCT01588119||Dabigatran|in atrial fibrillation
3272666|NCT01588119||Rivaroxaban|in atrial fibrillation and VTE
3272667|NCT01588119||Apixaban|in atrial fibrillation and VTE
3272668|NCT01588119||Edoxaban|in atrial fibrillation and VTE
3272669|NCT01588132|Experimental|Single dose gourp 1|Anfibatide injection at the concentration of 0.33μg/60kg in healthy volunteers
3272670|NCT01588132|Experimental|Single dose group 2|Anfibatide injection at the concentration of 0.66μg/60kg in healthy volunteers
3272671|NCT01588132|Experimental|Single dose groups 3|Anfibatide injection at the concentration of1.0μg/60kg in healthy volunteers
3377231|NCT04669574||Group 1|Participants who are newly diagnosed and have initiated front-line treatment.
3377232|NCT04669574||Group 2|Participants who have previously had one progression.
3377233|NCT04669574||Group 3|Participants who have previously had a second recurrence.
3377234|NCT04669574||Group 4|Participants who are on imaging surveillance and not receiving anti-neoplastic treatment
3377235|NCT04665843|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab followed by tiragolumab every three weeks (Q3W) on Day 1 of each 21-day cycle.
3377236|NCT04665843|Placebo Comparator|Atezolizumab + Placebo|Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle.
3377237|NCT04665752||Affected Participants|Participants previously diagnosed with COVID-19.
3377241|NCT04661813|Experimental|EXTRA-CVD Virtual Care|"An adapted version of a Nurse-led intervention to EXtend the HIV TReatment CascAde for CardioVascular Disease prevention (EXTRA-CVD)."
3377242|NCT04659993||Telemental Group|The virtual group will be conducted within a secure platform such as Microsoft WebEx. Assessments (pre-, post-, mid-way) will be distributed through REDCap, a secure virtual platform, as will session handouts and forms.
3377244|NCT04652973||1/Prostate cancer dataset|Biopsy-proven prostate cancer patients who have abdomen CT studies that were available in the clinical PACS (picture archiving system) in the Clinical Center.
3377245|NCT04652973||2/Multiphase CT dataset|Men or women of all age and race, who have Multiphase abdomen-pelvic CT studies that were available in the PACS.
3377246|NCT04651296|Experimental|compassion meditation|10 week, group-based manualized compassion meditation training
3377247|NCT04651296|Active Comparator|health education|10 week, group-based manualized health education protocol
3377248|NCT04650815||1 - 5 Years|Infants and Children up to age 5 years in the Sabou Health District
3377249|NCT04650815||10 - 18 Years|Children ranging in age 10 to 18 years in the Sabou Health District
3377250|NCT04650815||19 + Years|Adults ranging in ages 19 years to 65 years in the Sabou Health District
3377251|NCT04650815||5 - 10 Years|Children ranging in age 5 years through 10 years in the Sabou Health District
3377252|NCT04650659||Part one of the project|83 patients with Systemic Sclerosis will perform three functional exercise tests on the same day. All 83 patients will be examined with NVC. Moreover, HRpQCT will be performed on all patients at baseline and after 1 year.
3272672|NCT01588132|Experimental|Single dose group 4|Anfibatide injection at the concentration of 1.5μg/60kg in healthy volunteers
3272673|NCT01588132|Experimental|Single dose group 5|Anfibatide injection at the concentration of 2.0μg/60kg in healthy volunteers
3272674|NCT01588132|Experimental|Single dose group 6|Anfibatide injection at the concentration of 3.0μg/60kg in healthy volunteers
3272675|NCT01588132|Experimental|Single dose group 7|Anfibatide injection at the concentration of 4.0μg/60kg in healthy volunteers
3377253|NCT04650659||Part two of the project|Half of the patients from part one of the project will be invited to repeat the three functional exercise tests approximately one week later in reverse order to determine test-retest reliability.
3377254|NCT04647396|Experimental|Intervention group|
3377255|NCT04647396|No Intervention|Control group|
3377256|NCT04647253|Experimental|AGENT DCB|Agent DCB is a Monorail Percutaneous Transluminal Coronary Angioplasty (PTCA) balloon catheter with a semi-compliant balloon coated with a formulation of paclitaxel (drug) and an excipient, Acetyl-Tri-n-butyl citrate (ATBC). The balloon catheter platform is based on the commercially available BSC Emerge™ PTCA balloon catheter system (K130391).
3377257|NCT04647253|Active Comparator|Commercially available, PTCA Dilation Catheter|
3377261|NCT04640142|Experimental|Newnorm|Newnorm is a 20% human normal immunoglobulin for SC infusion
3272676|NCT01588132|Experimental|Single dose group 8|Anfibatide injection at the concentration of 5.0μg/60kg in healthy volunteers
3272677|NCT01588132|Experimental|Multiple dose group 9|Give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours
3272678|NCT01588132|Experimental|Multiple dose group 10|Give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.
3272679|NCT01588132|Experimental|Multiple dose group 11|Give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours
3272680|NCT01588145|Experimental|HM61713|
3272681|NCT01588171|Active Comparator|Bemiparin|A new second generation Low Molecular Weight Heparin
3272682|NCT01588171|Active Comparator|Enoxaparin|A well known Low Molecular Weight Heparin
3272683|NCT01588171|No Intervention|control group|Risky group patients for VTE, but they will not receive any thromboprophylactic drug.
3272684|NCT01588210|Experimental|Glass Ionomer Cement group|a high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany)
3272685|NCT01588210|Experimental|Resin Based Fluoride Group|white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein)
3272686|NCT01588210|Placebo Comparator|Resin Based sealant|white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany)
3272687|NCT01588223|Experimental|Lipids|
3272688|NCT01588249|Experimental|Novel formulation of pasteurized maple cough syrup|
3272689|NCT01588249|Placebo Comparator|Placebo|
3272690|NCT01588262|Other|Stressmanagement counselling|
3272691|NCT01588262|No Intervention|Control|
3272692|NCT01588275|Active Comparator|MRA therapy|During 12 months patients will be treated with a bibloc MRA (SomnoDent® MAS, SomnoMed Australia/Europe AG). The MRA will be customized by certified dentists or dental-specialists experienced in the field of dental sleep medicine.
3272693|NCT01588275|Active Comparator|CPAP therapy|"During 12 months patients will be treated with Continuous positive airway pressure (CPAP).Treatment with CPAP prevents upper airway collapse by pneumatically splinting the upper airway during sleep."
3272694|NCT01588288|Experimental|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy
3272695|NCT01588301|Experimental|Group 1 : Further invitation by mail|Further invitation to attend for cervical cytology
3272696|NCT01588301|Experimental|Group 2 : Kit for Self-collected vaginal sample|Kit for Self-collected vaginal sample sent at home and then test for Human Papillomavirus (HPV)
3272697|NCT01588301|No Intervention|Group 3: Control|
3272698|NCT01588314|Active Comparator|gabapentin|
3272699|NCT01588314|Placebo Comparator|placebo|
3272700|NCT01588327||Experimental|Patient taking FDA approved dose of dabigatran
3272701|NCT01588327||Control group|Person not taking any form of anticoagulation.
3272702|NCT01588340|Active Comparator|MRI|The patient will have a rapid noncontrast MRI (magnetic resonance imaging) that will take approximately 15 minutes to complete.
3272703|NCT01588340|Active Comparator|Ultrasound exam|A noncontrast ultrasound examination
3272704|NCT01588379|Experimental|Girls and mothers dance together|African-American girls AND their mom's will participate in the Afro-centric dance program together and also receive weekly newsletter that focuses on health related issues.
3272705|NCT01588379|Experimental|Girls, alone|African-American girls will participate in the Afro-centric dance program alone. Girls and mom's will receive weekly newsletter that focuses on health related issues
3272706|NCT01588379|Active Comparator|No dancing|African-American girls and their mom's will only receive weekly newsletter that focuses on health related issues.
3272707|NCT01588392|Experimental|Short bouts of structured activity|
3272708|NCT01588392|Active Comparator|Unstructured physical activity|
3272710|NCT01588483||giant cell arteritis|patients with biopsy and/or scintigraphy proven GCA
3272711|NCT01588522|Experimental|dose-escalation of compound 31543|compound 31543 Calcitriol, Topical application, 0.25 mL to be applied to each of the four quadrants of the scalp twice daily, morning and night with 10-14 hours between applications
3272712|NCT01588535|Active Comparator|benzocaine solution|ear drops
3272713|NCT01588535|Placebo Comparator|Placebo|ear drops
3272714|NCT01588574|Active Comparator|BOTOX (registered trade mark)|
3272715|NCT01588574|Experimental|MT10109|
3272716|NCT01588587||DPP-IV inhibitors|
3272717|NCT01588600|Active Comparator|Control|Breakfast without fiber
3272718|NCT01588600|Experimental|Low-dose|Low-dose of fiber in breakfast
3272719|NCT01588600|Experimental|High-dose|high dose of fiber added to breakfast
3272720|NCT01588626|Experimental|AZD6140|single administration of 90 mg dose of AZD6140
3272721|NCT01588639||Group 1|
3272722|NCT01588665||Pregnant women and pregnant adolescents|
3272723|NCT01588678|Experimental|DS-3078a|"Part 1 - Dose escalation of DS-3078a to determine the maximum tolerated dose (MTD) will be guided by the modified continuous reassessment method (mCRM) using a Bayesian logistic regression model (BLRM) following escalation with overdose control (EWOC) principle.~Before starting mCRM, initial dose escalation will proceed following an accelerated titration in which single subjects will be enrolled into sequential dose levels with a dose increment of up to 100% from the previous dose.~Upon completion of Part 1 with established MTD and tentative recommended phase 2 dose (RP2D), the Dose Expansion (Part 2) will begin with the intention of further assessing the safety and tolerability of DS-3078a, confirming the RP2D, determining the Pharmacodynamic response in tumor samples, and evaluating preliminary efficacy of DS-3078a in subjects."
3272724|NCT01588691|Active Comparator|Low frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3272725|NCT01588691|Active Comparator|High frequency|Programming parameters with the Eon Mini will be set at a low frequency. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3272726|NCT01588691|Placebo Comparator|No stimulation|Programming parameters will be set to the lowest possible level and minimal power will be generated. Subjects will remain in this group for 3 weeks. If subject cannot tolerate this frequency, he/she will meet with the clinical designee for reprogramming.
3272727|NCT01588704|Experimental|Neoadjuvant Bevacizumab|Four cycles of neoadjuvant chemotherapy with pemetrexed, carboplatin and bevacizumab.
3272728|NCT01588717|Experimental|glycopyrrolate|glycopyrrolate 2 to 6 mg/day
3272729|NCT01588730|Experimental|Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours).
3272730|NCT01588730|Active Comparator|Static Splint|The control group will be treated with a static splint for a minimum of 6 4 hours each night while sleeping with the end goal of 6-8 hours.
3272731|NCT01588756|Experimental|AcSDKP-NH2 inuline|AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less
3272732|NCT01588756|Experimental|AcSDKP-NH2 Cr-EDTA|AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less
3272733|NCT01588769|Experimental|One arm|3 doses of ALECSAT cell based immunotherapy planned for all enrolled patients
3272734|NCT01588782|Experimental|Abiraterone acetate|All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.
3272735|NCT01588795|Experimental|Denervation + TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
3272736|NCT01588795|Active Comparator|TMNS|Patients are maintained on standardized anti-proteinuric medications
3272737|NCT01588808|Active Comparator|Immobilization with protein (elderly)|Immobilization with twice-daily protein supplementation - in the elderly
3272738|NCT01588808|Placebo Comparator|Immobilization without protein (elderly)|Immobilization without twice-daily protein supplementation - in the elderly
3272739|NCT01588808|Active Comparator|Immobilization without protein (young)|Immobilization without twice-daily protein supplementation - in the young
3272740|NCT01588847|Experimental|Regional anesthesia|
3272741|NCT01588847|Active Comparator|General anesthesia|
3272742|NCT01588873|Active Comparator|Oral contraceptive pill|
3272743|NCT01588873|Active Comparator|Contraceptive ring|
3272744|NCT01588886||with PPI|CKD with PPI use, follow up at least 5 years began PPI use
3272745|NCT01588886||with or without Pneumonia outcome|Patients were eligible for inclusion if they received any PPIs treatment between January 1, 1998 and December 31, 2002 and had been diagnosed with pneumonia between January 1, 1998 and December 31, 2008 in an inpatient setting.
3272746|NCT01588899|Experimental|MR-HIFU Treatment|Patients in this arm will receive MR-HIFU uterine fibroid treatment
3272747|NCT01588912|Experimental|Telbivudine-Tenofovir roadmap|
3272748|NCT01588912|Active Comparator|Entecavir|
3272749|NCT01588925|Experimental|Control group|Cochlear Implantation
3272750|NCT01588925|Active Comparator|Dexamethasone|Cochlear implantation using topical dexamethasone
3272751|NCT01588925|Active Comparator|Dexamethasone+Hyaluronic acid|Cochlear implantation using topical dexamethasone associated with hyaluronic acid
3272752|NCT01588964|Experimental|HIPEC|Surgery plus HIPEC
3272753|NCT01588977||All-Inside TightRope technique|
3272754|NCT01588977||ACL reconstruction with TLS system|
3272755|NCT01588977||Hamstring Tendon Graft Reconstruction of the ACL|
3272756|NCT01589003|Active Comparator|Low GI group|Low Glycaemic index growing up milk
3272757|NCT01589003|Other|High GI group|Hi Glycaemic index growing up milk
3272758|NCT01589016||PUL (pregnancy of unknown location),|
3272759|NCT01589016||EP ( ectopic pregnancies P)|
3272760|NCT01589016||IUP-singleton intrauterine pregnancies|
3272761|NCT01589029|Other|CANAKINUMAB (ILARIS®)|
3272762|NCT01589042||Above the Knee|Patients treated with the Chocolate balloon for a lesion located above the knee
3272763|NCT01589042||Below the Knee|Patients treated with the Chocolate balloon for a lesion located below the knee
3272764|NCT01589055|Active Comparator|Male Smokers|
3272765|NCT01589055|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3272766|NCT01589055|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3272767|NCT01589068|Active Comparator|Male Smokers|
3272768|NCT01589068|Active Comparator|Female Smokers (Follicular Phase)|
3272769|NCT01589068|Active Comparator|Female Smokers (Luteal Phase)|
3272770|NCT01589081|Active Comparator|Female Smokers (Luteal Phase)|
3272771|NCT01589081|Active Comparator|Female Smokers (Follicular Phase)|
3272772|NCT01589107|No Intervention|control group|usual care
3272773|NCT01589107|Experimental|Video Arm|
3272774|NCT01589120|No Intervention|control group|Verbal description of goals of care reflecting usual care
3272775|NCT01589120|Experimental|Video Arm|Video intervention group
3272776|NCT01589146|No Intervention|short heparin|
3272777|NCT01589146|Experimental|extended heparin|
3272778|NCT01589159|Experimental|Experimental|
3272779|NCT01589172||Pediatric Brain Trauma Patients|
3272780|NCT01589211|Active Comparator|Brief advice|A brief advice to stop smoking of about 10 min accompanied with self-help material
3272781|NCT01589211|Experimental|Compact cessation course|Cessation intervention of 2 x 120 min in a group setting
3272782|NCT01589211|Active Comparator|Standard cessation course|Cessation course in a group setting over 6 dates
3272783|NCT01589224||Healthy people|
3272784|NCT01589276||Emergency hernia repairs|
3272785|NCT01589276||Elective hernia repairs|
3272786|NCT01589289|Experimental|Phase 3 RDTs|The different interventions will be assessed for estimation of sensitivity, specificity and predictive values in the patients' cohort, for the respective target conditions. [To be noted that, in addition, also the predictive values of validated RDTs when used alone and in various combinations will be estimated].
3272787|NCT01589328|Experimental|Early Palliative care|"The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
3272788|NCT01589328|No Intervention|Contol: usual oncologic care|Patients randomly assigned to usual oncologic care were not scheduled to meet with the palliative care service unless a meeting was requested by the patient, the family, or the oncologist; those who were referred to the service did not cross over to the early palliative care group or follow the specified palliative care protocol.
3272789|NCT01589341||Correlative studies|Archived DNA samples are analyzed (laboratory biomarker analysis) for segmental chromosome aberrations by MLPA, a PCR-based technique. The following genomic regions are being studied: 1p, 1q, 3p, 4p, 7q, 9p, 11q, and 17q, as are the copy numbers of MYCN, NAG, DDX1, and ALK genes.
3272790|NCT01589354|Experimental|Interscalene brachial plexus block|
3272791|NCT01589354|Experimental|Intra-articular injection|
3272792|NCT01589367|Experimental|Arm1_ Metformin|Letrozole with concurrent metformin
3272793|NCT01589367|Placebo Comparator|Arm 2_ Letrole alone|Letrozole with placebo
3272794|NCT01589380|Placebo Comparator|Placebo Arm|Placebo: Capsule that is containing lactate hydrate, identically appearing with fimasartan will be administered to patient in placebo group, once daily. Same placebo drug which was used in phase 3 clinical trial of fimasartan will be provided by Boryoung Phamaceutical company. Dose titration will be done with same criteria of fimasartan group. 30mg form and 60 mg form of placebo will be identical in its morphology.
3272795|NCT01589380|Active Comparator|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
3272796|NCT01589393|Active Comparator|Early initiation of thromboprophylaxis|Early initiation of thromboprophylaxis with Enoxaparin between 36-48 hours post injury to day 5, followed by standard of care (DVT prophylaxis with Enoxaparin) starting day 6 post injury.
3272797|NCT01589393|Placebo Comparator|Late initiation of thromboprophylaxis|Initiation of placebo 36-48 hours post traumatic injury until day 5, then standard of care (DVT prophylaxis with Enoxaparin) starting on Day 6.
3272798|NCT01589406||group A group B|A:Patients for surgical intervention B:Patients for radiotherapy
3272799|NCT01589419|Experimental|veliparib and capecitabine and radiation|Veliparib on days 1-7, capecitabine and radiation on days 1-5
3272800|NCT01589432|Experimental|ABT-639|
3272801|NCT01589432|Placebo Comparator|Placebo|
3272802|NCT01589432|Active Comparator|Lidocaine|
3272803|NCT01589458|Placebo Comparator|Non-fluoride toothpaste|
3272804|NCT01589458|Experimental|NaF/SiO2 toothpaste|
3272805|NCT01589458|Experimental|MFP/CaCO3 toothpaste|
3272806|NCT01589471|Experimental|Botox-A|Intra-rectal (or intra-colic) injection of 100 U of Botox-A
3272807|NCT01589523|Experimental|GlycoCholic Acid, Study Drug|A Phase III, open label, single arm, non-randomized, non-comparative, treatment study of Glycocholic Acid in the treatment of defects of bile acid metabolism.
3272808|NCT01589536|Experimental|Interventiongroup|A Stationary psychocardiological interval-rehabilitation.
3272809|NCT01589536|No Intervention|controlgroup|The Patients in the control group receive a personal recommendation concerning psychotherapy outpatient counseling and therapy services at home and take therapeutic help.
3272810|NCT01589549|Experimental|Mesenchymal stromal cell therapy|Mesenchymal stromal cell therapy in addition to corticosteroid therapy
3272811|NCT01589549|Active Comparator|Corticosteroid therapy|
3272812|NCT01589562|Active Comparator|Megace 800mg/20ml|Fed condition
3272813|NCT01589562|Experimental|DW-ES(B) 625mg/5ml|Fed condition
3272814|NCT01589575||Spouses|This group of relatives includes the spouses of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
3272815|NCT01589575||Other relatives|This group of relatives includes the non-spouse relatives of ICU patients (over 16 years of age and intubated and under ventilation for at least 48 hours) meeting stated inclusion criteria.
3272816|NCT01589588|Experimental|Mask 1|
3272817|NCT01589588|Experimental|Mask 2|
3272818|NCT01589588|Experimental|Mask 3|
3272819|NCT01589588|Placebo Comparator|Mask 3, placebo|
3272820|NCT01589614|Experimental|PH-797804 6 mg|Subjects will receive a single 6 mg dose in the fed state
3272821|NCT01589614|Experimental|PH-797804 6 mg + erythromycin 800 mg|Subjects will receive multiple 800 mg doses of erythromycin and a single 6 mg dose of PH-797804 in the fed state
3272822|NCT01589627|Experimental|experimental|Patients will be treated with the Standard of Care physical therapy, NSAIDs as well as a Wrist Extension Dynasplint
3272823|NCT01589627|No Intervention|Control|Patients will receive standard of care physical therapy and NSAIDS
3272824|NCT01589640||Blink Tears|Blink Tears is an over the counter artificial tear
3272825|NCT01589640||Blink Gel Tears|Blink Gel Tears is an over the counter artifical tear product
3272826|NCT01589640||Systane Balance|Systane Balance is an over the counter artificial Tear product
3272827|NCT01589666|Experimental|Spray-dried S/D-treated plasma|"Resusix (Spray-Dried Solvent/Detergent-Treated Plasma) uses source plasma from U.S.-licensed facilities as the starting material. Source plasma donors are selected from the AB blood type, which is considered a universal product."
3272828|NCT01589679|Other|control/ standard of care|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study.
3272829|NCT01589679|Experimental|Dynasplint|ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day.
3272830|NCT01589692|Experimental|Internal Fixation|Open Reduction and Internal Fixation: Internal fixation with a volar locking plating system
3272831|NCT01589692|Experimental|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
3272832|NCT01589692|Experimental|Pinning|Percutaneous pinning with any number of Kirschner wires
3272833|NCT01589692|Active Comparator|No Surgery|Closed Reduction and casting: Closed reduction and immobilization with a cast and/or splint
3272834|NCT01589705||polycystic kidney ,no hypertension|The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
3272835|NCT01589718|Experimental|0.3mg Pegaptanib Sodium, Macugen|will receive Macugen intravitreal injection prior to surgery
3272836|NCT01589718|Sham Comparator|Sham injection|will receive a sham injection
3272837|NCT01589731||Allergic group|The first group (group A) included 45 patients (17 males; mean age: 46.2 years, SD: 12.2 years) with convincing clinical histories of reproducible adverse reactions to bovine milk. All subjects presented βs-IgE that were detectable by SDS-PAGE immunoblotting.
3272838|NCT01589731||Non Allergic group|The second group (group B) was used as a control for the immunoblotting analysis performed in the first group and included 20 individuals selected based on an evident tolerance to cow's milk, an absence of βs-IgE by ImmunoCAP assay and SPT non-reactivity to β-Lg or TgPolβ-Lg (6 males; mean age: 21.9 years, SD: 17.6 years).
3272839|NCT01589731||Atopic group|The third group (group C) included 49 subjects with atopic respiratory and/or dermatological diseases (19 males; mean age: 28.7 years, SD: 20.6 years) regardless of βs-IgE status. This group was used to compare the ex vivo cell-mediated immunoreactivity between β-Lg and TgPolβ-Lg by comparing the mean ex vivo antigenic challenge results determined using the leukocyte adherence inhibition test (LAIT).
3272840|NCT01589744|Experimental|Suction cup Hemostatic Intra-Uterin|The suction haemostatic cup will be positioned into the uterus, and the aim is to stop haemorrhage
3272841|NCT01589757|Placebo Comparator|Standard Care|Standard care dietary advice to emphasize high fiber foods with a moderate to high GI
3272842|NCT01589757|Experimental|Low GI Diet|Low GI dietary advice in addition to standard care
3272843|NCT01589783||Pregnant or newly post partum women|
3272844|NCT01589783||family practice physicians and obstetricians|
3272845|NCT01589796|Active Comparator|classic TAP|classic US-guided TAP block in a space between iliac crest and the costal margin in the region of the anterior axillary line
3272846|NCT01589796|Active Comparator|Medial TAP|US-guided TAP block in a space between iliac crest and the costal margin within 1 inch lateral to transversus abdominis muscle origination
3272847|NCT01589809|Experimental|Nicotinamide|Comparison is made within-subjects to different doses and no treatment
3272848|NCT01589835|Experimental|Lifestyle counseling|Green prescription with facilitator support
3272849|NCT01589835|Other|Usual care|
3272850|NCT01589848||von Willebrand women|Referred women who may have von Willebrand Disease
3272851|NCT01589861|Experimental|BKM120+Lapatinib|"BKM120 40, 60 or 80 mg/day per os for 28 days cycle~+ Lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle"
3272852|NCT01589874||acute ill patients|
3272853|NCT01589913|Experimental|Treatment as usual plus remote care|"The same treatment as described under treatment as usual plus participation in the intervention ICD-Forum."
3272854|NCT01589913|No Intervention|Treatment as usual|Standard information provided by hospitals on ICD-technology as well as consequences of ICD-implantation plus medical aftercare including cardiology appointments at 1, 3, and 6 months, and one year after ICD-implantation.
3272855|NCT01589952|Experimental|Pegylated Interferon, Entecavir|'Pegylated Interferon, Entecavir' arm will consist of 20 chronic hepatitis B patients who will receive Pegylated Interferon 90 micro gms subcutaneously once weekly in combination with entecavir 0.5 mg orally once daily for 24 weeks
3272856|NCT01589965|Experimental|Treatment group: T5|Small Lottery reward
3272857|NCT01589965|No Intervention|Control group|
3272858|NCT01589965|Experimental|Treatment group T1|High Lottery reward
3272859|NCT01589991|Placebo Comparator|Non-fluoride toothpaste|
3272860|NCT01589991|Experimental|Toothpaste 550 µg F/g (NaF/SiO2)|
3272861|NCT01589991|Experimental|Toothpaste 1100 µg F/g (NaF/SiO2)|
3272862|NCT01589991|Experimental|Toothpaste 1450 µg F/g (MFP/CaCO3)|
3272863|NCT01590030|Experimental|Laparoscopic mesial incision|
3272864|NCT01590030|Active Comparator|Laparoscopic antimesial incision|
3272865|NCT01590043||Control|Healthy 3-18 years old participants
3272866|NCT01590043||Inflammatory bowel disease|3-18 years old patients identified with inflammatory bowel disease
3272867|NCT01590043||Abdominal pain|3-18 years old patients suffering from abdominal pain not related to Inflammatory bowel disease
3272868|NCT01590056||PD patients|PD patients that are treated or are candidates for treatment with STN DBS
3272869|NCT01590069|Experimental|Treatment (aerosolized aldesleukin)|Patients receive aerosolized aldesleukin QD on days 1-21. Courses repeat every 28 days in the absence of disease progression of unacceptable toxicity.
3272870|NCT01590095|Active Comparator|Water quality|90 clusters, approx. 720 newborns
3272871|NCT01590095|Active Comparator|Sanitation|90 clusters, approx. 720 newborns
3272872|NCT01590095|Active Comparator|Hand washing|90 clusters, approx. 720 newborns
3272873|NCT01590095|Active Comparator|Combined WASH|90 clusters, approx. 720 newborns
3272874|NCT01590095|Active Comparator|Nutrition|90 clusters, approx. 720 newborns
3272875|NCT01590095|Active Comparator|Nutrition + Combined WASH|90 clusters, approx. 720 newborns
3272876|NCT01590095|No Intervention|Non-intervention|180 clusters, approx. 1,440 newborns
3272877|NCT01590108|Experimental|Apelin|Subject will perform cardiopulmonary exercise testing and receive (Pyr1)apelin-13 intravenously.
3272878|NCT01590108|Placebo Comparator|Control|Subject will take cardiopulmonary exercise testing with receive placebo
3272879|NCT01590121||Pateints with hereditary haemorrhagic telangiectasia|
3272880|NCT01590134|No Intervention|Control|"Following randomisation,to no active intervention, blood and urine samples will be collected at 6 stated intervals over a 48 hour period~Total number of participants in arm = 6"
3272881|NCT01590134|Active Comparator|Iron control|"Following randomisation, on each of two consecutive mornings, the participant will receive a single dose of ferrous sulphate 200mg. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Total number of participants in arm = 6"
3272882|NCT01590134|Experimental|Dietary supplement|"Following randomisation, on each of two consecutive mornings, the participant will receive the experimental dietary iron supplement. Blood and urine samples will be collected pre first dose, and at 5 further stated intervals over a 48 hour period.~Toal participants in arm = 6"
3272883|NCT01590147|Experimental|Arm 1 (YST)|Patients participate in three 15-minute YST sessions, comprising awareness meditation practice, movement practice, and breathing practice and relaxation. Patients also receive a CD recording of a 15-minute YST session and are instructed to practice the YST at home 4 times weekly.
3272884|NCT01590147|Active Comparator|Arm 2 (CE)|Patients participate in three 15-minute CE sessions, comprising empathic attention with an interventionist who allows patients to direct the flow of conversation and provides supportive comments according to standardized procedures. Patients also receive CDs with recorded information related to coping with colorectal cancer similar in length to the suggested practice time in Arm I.
3272885|NCT01590160|Experimental|Cisplatin/Pemetrexed|Cisplatin 75mg/m2, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
3272886|NCT01590160|Experimental|Carboplatin/Pemetrexed|Carboplatin AUC5, Day 1 every 21 days Pemetrexed 500mg/m2, Day 1 every 21 days
3272887|NCT01590173|Experimental|Prednisolone and Heparin during COH for IVF|
3272888|NCT01590173|Active Comparator|COH for IVF|
3272889|NCT01590199|Experimental|RAD001 + SOM230|
3272890|NCT01590225|Experimental|Part A: boceprevir + peginterferon alpha-2b + ribavirin|
3272891|NCT01590225|Experimental|Part B: boceprevir + peginterferon alpha-2b + ribavirin|
3272892|NCT01590251|Experimental|Yoga|Gentle yoga for chronic pain and opioid dependence
3272893|NCT01590251|Active Comparator|Educational Counseling|Educational counseling is a didactic, lecture-discussion format to supplement the information and advice provided in opioid agonist maintenance treatment.
3272894|NCT01590277|Experimental|ethanol and iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3272895|NCT01590277|Experimental|placebo ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3272896|NCT01590277|Experimental|active iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3272897|NCT01590277|Experimental|placebo iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil active ethanol + placebo iomazenil active ethanol + active iomazenil placebo ethanol + active iomazenil"
3272898|NCT01590290|Active Comparator|pay for performance|
3272899|NCT01590290|No Intervention|no pay for performance|
3272900|NCT01590303|Experimental|Vitamin C|Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit
3272901|NCT01590303|Placebo Comparator|placebo|placebo vehicle administered in same fashion as active treatment
3272902|NCT01590316|Experimental|Cerebral NIRS oximetry + treatment guideline based on reading|
3272903|NCT01590316|No Intervention|Blinded cerebral NIRS oximetry|
3272904|NCT01590329|Experimental|Micrografting|
3272905|NCT01590342|Active Comparator|Diclofenac|
3272906|NCT01590342|Placebo Comparator|Placebo|
3272907|NCT01590355|Active Comparator|Radiotherapy plus or minus Chemotherapy|Radiotherapy plus or minus chemotherapy with surgical treatment for salvage of persistent disease
3272908|NCT01590355|Experimental|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot. The spatula cautery will be used to remove the tumours with 1 cm margins. At the time of surgery circumferential margins will be taken and sent for frozen section analysis. The resection will proceed until negative margins are obtained if feasible.
3272909|NCT01590368|Other|Marketed electrode|The currently marketed electrodes using the current CE marked adhesive
3272910|NCT01590368|Active Comparator|Modified hydrogel|"Electrodes with the new modified adhesive - the test electrodes"
3272911|NCT01590381||personnel in medical training - COURSE 1|
3272912|NCT01590381||personnel in medical training - COURSE 2|
3272913|NCT01590381||personnel in medical training - COURSE 3|
3272914|NCT01590381||personnel in medical training - COURSE 4|
3272915|NCT01590381||personnel in medical training - COURSE 5|
3272916|NCT01590381||personnel in medical training - COURSE 6|
3272917|NCT01590381||personnel in medical training - COURSE 7|
3272918|NCT01590381||personnel in medical training - COURSE 8|
3272919|NCT01590381||personnel in medical training - COURSE 9|
3272920|NCT01590381||personnel in medical training - COURSE 10|
3272921|NCT01590407|Experimental|ALS-002200|
3272922|NCT01590407|Placebo Comparator|Placebo|
3272923|NCT01590420|Experimental|CPAP treatment|1000 patients with 3-years CPAP treatment after a PSG titration
3272924|NCT01590446|Placebo Comparator|Placebo|
3272925|NCT01590446|Active Comparator|BMN 111|
3272926|NCT01590459|Placebo Comparator|Placebo Arm|
3272927|NCT01590459|Experimental|VX-509 100 mg qd Arm|
3272928|NCT01590459|Experimental|VX-509 150 mg qd Arm|
3272929|NCT01590459|Experimental|VX-509 100 mg bid Arm|
3272930|NCT01590459|Experimental|VX-509 200 mg qd Arm|
3272931|NCT01590472||Mesothelioma|Individuals who have been diagnosed with mesothelioma
3272932|NCT01590485|Placebo Comparator|Starch capsule|starch with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
3272933|NCT01590485|Active Comparator|Saffron capsule|saffron with dose of 100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
3272934|NCT01590498||Salvage radiotherapy|local radiation to the prostate and metastasis following biochemical or clinical recurrence
3272935|NCT01590498||observation|did not receive salvage following biochemical or clinical recurrence
3272936|NCT01590511||The study population|Patients in the emergency room or intensive care in acute circulatory failure without ventilatory support.
3272937|NCT01590524|Experimental|CAM group|Subjects receiving the interventions and standard psychological care
3272938|NCT01590524|No Intervention|No-CAM group|Parents receiving only standard psychological care
3272939|NCT01590537||Group 1|
3272940|NCT01590537||Group 2|
3272941|NCT01590576||lower urinary tract symptoms and pelvic organ prolapse|
3272942|NCT01590589||REGISTRY participants|"Individuals~with manifest HD~unaffected but known to carry the HD mutation~unaffected but at risk of carrying the HD mutation~from HD families known not to carry the HD mutation~from outside HD families acting as control research participants (e.g., spouses)"
3272943|NCT01590602||JHD cases|All ages included, but must have an HD age of onset 25 or below
3272944|NCT01590615||Participants with chronic HBV infection|Participants with decompensated liver disease due to chronic HBV infection, who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy, will be included in the study.
3272945|NCT01590628|Experimental|NiCord|
3272946|NCT01590641|Experimental|0.3mg GS-9620|
3272947|NCT01590641|Experimental|1mg GS-9620|
3272948|NCT01590641|Experimental|2mg GS-9620|
3272949|NCT01590641|Experimental|4mg GS-9620|
3272950|NCT01590641|Experimental|0.3mg GS-9620 QW x 2 doses|
3272951|NCT01590641|Experimental|1mg GS-9620 QW x 2 doses|
3272952|NCT01590641|Experimental|2mg GS-9620 QW x 2 doses|
3272953|NCT01590641|Experimental|4mg GS-9620 QW x 2 doses|
3272954|NCT01590654|Experimental|0.3mg GS-9620|
3272955|NCT01590654|Experimental|1mg GS-9620|
3272956|NCT01590654|Experimental|2mg GS-9620|
3272957|NCT01590654|Experimental|4mg GS-9620|
3272958|NCT01590654|Experimental|0.3mg GS-9620 QW x 2 doses|
3272959|NCT01590654|Experimental|1mg GS-9620 QW x 2 doses|
3272960|NCT01590654|Experimental|2mg GS-9620 QW x 2 doses|
3272961|NCT01590654|Experimental|4mg GS-9620 QW x 2 doses|
3272962|NCT01590667|Active Comparator|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
3272963|NCT01590667|Placebo Comparator|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
3272964|NCT01590693|Experimental|Group 2|Children treated with four weeks of below knee walking casts and botulinum toxin A injections
3272965|NCT01590693|Active Comparator|Group 1|Children treated with four weeks of below knee walking casts.
3272966|NCT01590719|Experimental|Onartuzumab (MetMAb) with mFOLFOX6|Onartuzumab (MetMAb) in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
3272967|NCT01590719|Placebo Comparator|Placebo with mFOLFOX6|Placebo in combination with mFOLFOX6 (modified 5-fluorouracil, folinic acid [leucovorin], and oxaliplatin)
3272968|NCT01590732|Experimental|Treatment (romidepsin, ifosfamide, carboplatin, etoposide)|Participants receive romidepsin IV over 4 hours on days 1 and 4, ifosfamide IV over 24 hours on day 1, carboplatin IV over 1 hour on day 1, and etoposide IV over 2 hours on day 1-3. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3272969|NCT01590745|Placebo Comparator|Sham Ultrasound regimen|A switch in the transducer circuit allows mock ionisation as a result no ultrasound emitted.
3272970|NCT01590745|Active Comparator|Real Ultrasound therapy|Pulsed mode ultrasound therapy
3272971|NCT01590823|Other|Dabigatran etexilate 110 mg|Single dose of Dabigatran etexilate 110 mg po
3272972|NCT01590836|Experimental|IDeg-->IDegAsp|
3272973|NCT01590849|No Intervention|No hormonal contraception|
3272974|NCT01590849|Active Comparator|Hormonal Contraceptive|healthy women, users of COC containing 20 mcg EE and 3 mg DRSP (Yaz®), 24 days of active pills, 4 days of pill-free interval (n=40).
3272975|NCT01590862|Active Comparator|Deep Brain Stimulation On|We will assess Reward Motivation behavior with Deep Brain Stimulation on.
3272976|NCT01590862|No Intervention|Deep Brain Stimulation Off|We will assess Reward Motivation behavior with Deep Brain Stimulation off.
3272977|NCT01590901|Other|probucol in healthy male subjects|multiple oral doses of probucol in single group of healthy male subjects
3272978|NCT01590914|Experimental|Roux-En Y Gastric Bypass|40 subjects who plan to undergo Roux-En-Y Gastric Bypass bariatric surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
3272979|NCT01590914|Experimental|Gastric Banding|40 Subjects who plan to undergo Gastric Banding bariatric Surgery. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition Pre-Surgery and 3 months post Surgery.
3272980|NCT01590914|Experimental|Formula Diet Weight-Loss|40 subjects will undertake a 12-week liquid formula weight loss plan. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition pre-weight loss and 3 months after a 12-week weight loss plan.
3272981|NCT01590914|Experimental|No Treatment|40 subjects who do not undergo any treatment for weight loss. BOLD fMRI responses to food cues will be collected in the Fed Condition and Fasted Condition at baseline and after 3 months.
3272982|NCT01590927||20 healthy women|
3272983|NCT01590940||Parietex mesh|Enrolled patients who met criteria for inclusion would have undergone open inguinal hernia repair using the Parietex plug and patch hernia system
3272984|NCT01590966|Experimental|Patients with an active inflammatory joint disease|In total there will be 20 patients included: 5 patients with active rheumatoid arthritis, 5 patients with active early axial spondyloarthritis, 5 patients with active early peripheral spondyloarthritis and 5 patients with active ankylosing spondylitis.
3272985|NCT01590992|Experimental|Exposure-based Psychotherapy for Somatic Symptoms|First: 1-2 months waiting period; followed by: exposure-based psychotherapy
3272986|NCT01590992|Active Comparator|Relaxation Therapy|First: 1-2 months waiting period; followed by: relaxation therapy
3272987|NCT01591031|Active Comparator|sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane
3272988|NCT01591031|Active Comparator|rocuronium|anesthesia induction with propofol, remifentanil and rocuronium
3272989|NCT01591057|Experimental|2 Portions|
3272990|NCT01591057|Experimental|5 portions|
3272991|NCT01591057|Experimental|8 portions|
3272992|NCT01591070|No Intervention|vehicle twice weekly|
3272993|NCT01591070|Experimental|tacrolimus once weekly|
3272994|NCT01591070|Experimental|tacrolimus twice weekly|
3272995|NCT01591083|Active Comparator|Double oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days.
3272996|NCT01591083|Active Comparator|Regular oral dose|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
3272997|NCT01591083|Active Comparator|Control group|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients receive 40 mg oral esomeprazole once daily for 25 days.
3272998|NCT01591109||Bevacizumab including chemotherapy|Patients treated with bevacizumab including chemotherapy for metastatic liver tumor derived from colorectal cancer before metastasectomy.
3272999|NCT01591109||no adjuvant chemotherapy|Patients with no adjuvant chemotherapy including bevacizumab
3273000|NCT01591122|Experimental|Abiraterone acetate and prednisone|
3273001|NCT01591122|Active Comparator|Placebo and prednisone|
3273002|NCT01591135|Active Comparator|Cisplatin|Chemoradiotherapy with cisplatin and 5-fluorouracil for 2 cycles followed by adjuvant chemotherapy for 2 cycles.
3273003|NCT01591135|Experimental|Paclitaxel|Patients randomized in Arm B will receive chemoradiation with weekly paclitaxel and 5-fluorouracil for 5 weeks followed by adjuvant chemotherapy with paclitaxel and 5-fluorouracil for 2 cycles.
3273004|NCT01591148|Experimental|Morbidly obese subjects|Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
3273005|NCT01591148|Active Comparator|Control subjects (body mass index 20-25)|Normal weight subjects (body mass index 20-25) will be given propofol during induction of general anesthesia. Plasma samples will be collected over time to ascertain propofol plasma concentration.
3273006|NCT01591174||Functional Dyspepsia with PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and Clinics in the Abdominal Pain Clinic (APC)or in the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and have Postprandial Distress Syndrome (PDS).
3273007|NCT01591174||Functional Dyspepsia without PDS|Study participants 8-17 years of age will be recruited for this arm after an evaluation at Children's Mercy Hospital and clinics (CMH) Abdominal Pain Clinic (APC)or the Section of Gastroenterology, general, and diagnosed with FD, fail to respond to acid suppression therapy and do not have Postprandial Distress Syndrome (PDS).
3273008|NCT01591174||Control Group|Healthy participants 8-17 years of age recruited from internal advertising within Children's Mercy Hospital and Clinics.
3273009|NCT01591187||Cancer|Participants with a diagnosis of cancer.
3273010|NCT01591187||Sickle Cell Disease|"Participants with a diagnosis of sickle cell disease.~Interventions: Text messaging, Questionnaire, Interviews"
3273011|NCT01591200|No Intervention|Control|This arm will receive standard protocol of care alone
3273012|NCT01591200|Experimental|Stem cells high dose|This arm will receive high dose of Allogeneic Mesenchymal Stem Cells
3273013|NCT01591200|Experimental|Stem cells intermediate dose|This arm will receive intermediate dose of Allogeneic Mesenchymal Stem Cells
3273014|NCT01591200|Experimental|Stem cells low dose|This arm will receive low dose of Allogeneic Mesenchymal Stem Cells
3273015|NCT01591213||Healthy Volunteers|Fourth grade students enrolled in Memphis-area schools.
3273016|NCT01591226|Active Comparator|Caffeine|6mg per kg bodyweight ingested 60min before test
3273017|NCT01591226|Placebo Comparator|Placebo|Sodium chloride and mannitol as placebo are ingested by the athlete
3273018|NCT01591226|Active Comparator|Sodium Citrate|sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test
3273019|NCT01591226|Active Comparator|Caffeine and Sodium Citrate|sodium citrate 120-90min prior test capsules:60min prior test
3377264|NCT04639830||Children with a known risk|Children between 6 months and 76 months who are at risk for developing a neurodevelopmental disorder.
3377265|NCT04639830||Children with no known risk|Children between 6 months and 76 months who don't have a risk for neurodevelopmental disorders.
3273020|NCT01591239|Experimental|Home-Based Intervention|Parents will receive a 1-session training on how to deliver a 3-session intervention across a 3-week period. The intervention program begins with a 3 and a half hour training session delivered by the staff Trainer to the participating parent. At the conclusion of training, the parent will be given the intervention manual and supplemental materials. The trainer will phone the parent shortly before session 1, in between each intervention session, and after the third intervention (four phone calls total) to review the objectives and tasks associated with that week's intervention session and to help prepare for the coming session. At the final phone call between the parent and trainer (after the third week), the trainer will deliver to the parent the follow-up resources.
3377274|NCT04622553|Other|Cohort 1 and 2|7 patients aged 12 to < 18 years , inclusive in cohort-1 7 patients aged 6 to < 12 years, inclusive in cohort-2
3377277|NCT04618432||Patients|Patients at risk, suspected of having, have a history of, or currently have a diagnosed head and neck or communication disorder.
3377283|NCT04607148|Experimental|FHTR2163 20 mg Q4W|Participants will receive 20 milligrams (mg) FHTR2163 via ITV injection every 4 weeks (Q4W).
3377284|NCT04607148|Experimental|FHTR2163 20 mg Q8W|Participants will receive 20 mg FHTR2163 via ITV injection every 8 weeks (Q8W).
3377285|NCT04607148|Experimental|FHTR2163 10 mg Q4W|Participants will receive 10 mg FHTR2163 via ITV injection Q4W.
3377286|NCT04607148|Experimental|FHTR2163 10 mg Q8W|Participants will receive 10 mg FHTR2163 via ITV injection Q8W.
3377287|NCT04603521||Hypertrophic cardiomyopathy (HCM)|Survival after Myectomy Operation
3377288|NCT04600154|Experimental|MS-20|4ml, twice, daily
3377289|NCT04600154|Placebo Comparator|Placebo|4ml, twice, daily
3273021|NCT01591239|Active Comparator|Educational Group|Parents will receive a 2-hour, education-only psychoeducational curriculum (no parent-led intervention with their teen will occur.
3273022|NCT01591265|Active Comparator|Compensatory Extraction|Patients allocated to this group, both the upper FPM and lower FPM teeth will be extracted.
3273023|NCT01591265|Active Comparator|No Compensatory Extraction|Patients allocated to this group, only the lower FPM tooth will be extracted.
3273024|NCT01591278|Experimental|Pulp dressing agent|
3273025|NCT01591278|Active Comparator|Pulp dressing|MTA
3273026|NCT01591291|Experimental|Ondansetron|
3273027|NCT01591291|Placebo Comparator|Placebo|
3273028|NCT01591304|Active Comparator|Group A|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers at 0.25J and 0.20J energy settings, respectively.
3273029|NCT01591304|Active Comparator|Group B|Ulthera System Treatment provided using 1.5mm and 1.0mm transducers, at 0.18J and 0.15J energy settings, respectively.
3273030|NCT01591343|Experimental|Depigoid® (500 DPP/ml)|Patients will receive either Depigoid® Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), depending on their sensitization to one or both mites (Dermatophagoides pteronyssinus and Dermatophagoides farinae).
3273031|NCT01591356|Experimental|Treatment (EphA2-targeting DOPC-encapsulated siRNA)|Patients receive EphA2-targeting DOPC-encapsulated siRNA IV over 120 minutes on days 1 and 4. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3273032|NCT01591395|Active Comparator|Multiport TEP|Adult inguinal hernia patients who randomized to receive multiport endoscopic TEP repair
3273033|NCT01591395|Active Comparator|LESS TEP|Adult inguinal hernia patients who randomized to receive laparoendoscopic single-site TEP repair
3273034|NCT01591421|Experimental|BKM120 and Panitumumab|BKM120 will be given either daily starting day 1 cycle 1or 5 out of 7 days every week, depending on when patient is enrolled on the study, in combination with panitumumab given intravenously every two weeks starting day 1 cycle 1.
3273035|NCT01591434|Active Comparator|AQUACEL®|A sterile non-woven sheet of sodium carboxymethylcellulose (NaCMC).
3273036|NCT01591434|Active Comparator|AQUACEL® Extra™|A sandwiched construction of two layers of optimally textiled non-woven fabric, stitch-bonded together using Lyocel (Tencel™ regenerated cellulose) yarns.
3273037|NCT01591447|Experimental|Solithromycin (CEM-101)|A single oral dose of 1200 mg solithromycin
3273038|NCT01591447|Experimental|Solithromycin 1000 mg|A single oral dose of 1000 mg solithromycin
3273039|NCT01591473|Experimental|FluMist + Ampligen, Group 1|Nasal administration; dose group 1; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
3273040|NCT01591473|Experimental|FluMist + Ampligen, Group 2|Nasal administration; dose group 2; FluMist + Poly I:Poly C12U 200 ug; 3 doses separated by 28 days
3273041|NCT01591473|Experimental|FluMist + Ampligen, Group 3|Nasal administration; dose group 3; FluMist + Poly I:Poly C12U 500 ug; 3 doses separated by 28 days
3273042|NCT01591473|Experimental|FluMist + Ampligen, Group 4|Nasal administration; dose group 4; FluMist + Poly I:Poly C12U 50 ug; 3 doses separated by 28 days
3273043|NCT01591473|Experimental|FluMist + Ampligen, Group 5|Nasal administration; dose group 5; FluMist + Poly I:Poly C12U 1250 ug; 3 doses separated by 28 days
3273044|NCT01591473|Experimental|FluMist + Placebo, Group 6|Nasal administration; dose group 6; FluMist + placebo; 3 doses separated by 28 days
3273045|NCT01591486||Hp-negative cohort|"Hp-negative cohort~The second cohort consists of ASA users with ulcer bleeding but no current or past Hp infection, as evidenced by:~negative rapid urease test~negative histology for Hp infection on both initial and follow-up endoscopy~negative serology test~absence of intestinal metaplasia and atrophy on 4 random biopsies of the antrum and corpus~After ulcer healing, the Hp-negative cohort will receive enteric-coated ASA (<160 mg daily) without regular co-prescription of anti-ulcer drugs."
3273046|NCT01591486||Hp-eradicated cohort|Hp-eradicated cohort This cohort consists of ASA users with ulcer bleeding and Hp infection who have healed ulcers and successful eradication of Hp on follow-up endoscopy. They will receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs.
3273047|NCT01591486||Average-risk cohort|Average-risk cohort The third cohort consists of ASA-naive patients without a history of ulcer who attend the general outpatient clinic. They require long-term ASA for established cardiothrombotic diseases. They receive plain ASA (<160 mg daily) without co-prescription of anti-ulcer drugs. Hp status will not be determined in this cohort because Hp testing is not justified in average-risk asymptomatic patients.
3273048|NCT01591525||Uncontrolled Diabetic|Individuals who were previously diagnosed with Type II Diabetes, but have a HgA1C greater than 7.0%
3273049|NCT01591525||Newly diagnosed Type II Diabetic|Individuals who have never been diagnosed with Type II Diabetes, but have an HgA1c greater than 7.0%
3273050|NCT01591525||Newly diagnosised pre-diabetics|Individuals who have never been diagnosed with Type II Diabetes, but have a HgA1C of 6.0%-6.9%
3273051|NCT01591525||Controlled|Diabetic or non-diabetic individuals with RPCG of less than 130 mg/dl.
3273052|NCT01591538||lifestyle condition|
3273053|NCT01591551|Other|Natalizumab (Tysabri) naive|Patients who are newly prescribed Natalizumab (TYSABRI®), but have not received their first infusion, will be invited to participate.
3273054|NCT01591564|Other|therapy|All participants will receive the intervention.
3273055|NCT01591577|Experimental|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
3273056|NCT01591590|Experimental|All Patients|This is an Interventional, Non Therapeutic arm
3273057|NCT01591603|Experimental|Group 1|
3273058|NCT01591603|Experimental|Group 2|
3273059|NCT01591629|Placebo Comparator|Placebo and Placebo|
3273060|NCT01591629|Experimental|Active Naloxone and Placebo|
3273061|NCT01591629|Placebo Comparator|Placebo and Active Delta-9-THC|
3273062|NCT01591629|Experimental|Active Naloxone and Active Delta-9-THC|
3273063|NCT01591668|Experimental|0.3mg GS-9620|
3273064|NCT01591668|Experimental|1mg GS-9620|
3273065|NCT01591668|Experimental|2mg GS-9620|
3273066|NCT01591668|Experimental|4mg GS-9620|
3273067|NCT01591668|Experimental|0.3mg GS-9620 QW x 2 doses|
3273068|NCT01591668|Experimental|1mg GS-9620 QW x 2 doses|
3273069|NCT01591668|Experimental|2mg GS-9620 QW x 2 doses|
3273070|NCT01591668|Experimental|4mg GS-9620 QW x 2 doses|
3273071|NCT01591694||FamilyLive|Families with a history of intergenerational trauma (maltreatment, violence exposure, domestic violence, substance abuse, etc.)
3273072|NCT01591694||Yoga Based Psychotherapy|Children with a history of maltreatment and/or violence exposure
3273073|NCT01591694||Biofeedback|Children with a history of maltreatment and violence exposure and their caregivers
3273074|NCT01591694||TST-SA|Trauma Systems Therapy for Adolescent Substance Abuse
3273075|NCT01591707|Experimental|ISC+PRT Intervention|For the duration of at least one school year children will receive 45-90 minutes of intervention in the classroom in an attempt to increase social and communication skills.
3273076|NCT01591707|No Intervention|Instruction As Usual|For the duration of at least one year children will receive the typical classroom instruction
3273077|NCT01591720|Experimental|Tailored Internet-delivered CBT|The intervention is delivered within a primary care clinic.
3273078|NCT01591759|Experimental|Citicoline|8-week treatment of 2,000mg/day of citicoline
3273079|NCT01591759|Placebo Comparator|Placebo|
3273080|NCT01591772||diagnosed with ovarian that recieved chemo|
3273081|NCT01591772||healthy controls|
3273082|NCT01591798|Experimental|Robotic surgery|Proctectomy using robot
3273083|NCT01591798|Active Comparator|Laparoscopic surgery|Conventional laparoscopic rectal resection
3273084|NCT01591811|Experimental|Arm 1 Daily Boost of Radiation Therapy|Arm 1 of treatment, you will be receiving 15 daily radiation fractions of 2.7 Gy (measure of radiation dose) daily for three weeks to the entire breast with a daily concomitant boost of 0.5 Gy
3273085|NCT01591811|Experimental|Arm 2 Weekly Boost of Radiation Therapy|Arm 2 Weekly Boost will receive 15 daily radiation fractions of 2.7 Gy for three weeks to the entire breast with a weekly boost of 2.0 GY.
3273086|NCT01591824|Experimental|POLD TREATMENT|Patients who applies the treatment of resonant oscillation according to the Pold Concept
3273087|NCT01591824|Active Comparator|CONVENCIONAL: column exercise group|Patients who applied the conventional treatment of hospital
3273088|NCT01591850|Experimental|1 Ketoconazole DDI|
3273089|NCT01591850|Experimental|2 Rifampicin DDI|
3273090|NCT01591850|Experimental|3 ATZ/r DDI|
3273091|NCT01591876|Sham Comparator|Progressive muscle relaxation|As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
3273092|NCT01591876|Active Comparator|Aerobic exercise|Intervention -moderate intensity aerobic exercise.
3273093|NCT01591889|Active Comparator|tindamax|500 mg tablet
3273094|NCT01591889|Active Comparator|tinidazole|500 mg tablet
3273095|NCT01591902|Experimental|EGRIFTA Treatment Grop|Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient
3273096|NCT01591902|Placebo Comparator|Placebo|Placebo-controlled
3273097|NCT01591915|Experimental|MBSR self care program including weekly sessions|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week. Participants will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 hours.
3273098|NCT01591915|Experimental|MBSR self care program|Participants will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 minutes sessions, 6 days/week.
3273099|NCT01591915|No Intervention|Standard care|
3273100|NCT01591928||Infants with heterotaxy syndrome|
3273101|NCT01591941|Active Comparator|CON group|Control Group underwent a standard soccer warm-up
3273102|NCT01591941|Experimental|Core-PAC|Experimental took part in the Core position and control movement strategy (Core-PAC) warm-up
3273103|NCT01591967|No Intervention|Control|Control -- no intervention
3273104|NCT01591967|No Intervention|Placebo w/ sham|"Sham intervention with the adjusting tool turned off"
3273105|NCT01591967|Experimental|Activator treatment|Treatment with Activator
3273106|NCT01591980|Experimental|Pregabalin 100 mg|
3273107|NCT01591980|Experimental|pregabalin 150 mg|
3273108|NCT01591980|Sham Comparator|Placebo|
3273109|NCT01591993|Experimental|Test subject|To each subject, the investigators will randomly apply 10% lactic acid on one nasolabial fold, once.
3273110|NCT01591993|Placebo Comparator|Placebo|To each subject, the investigators will apply placebo (0.9% saline solution) on the contralateral nasolabial fold to the lactic acid, simultaneously.
3273111|NCT01592019|Experimental|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3273112|NCT01592019|Experimental|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3273113|NCT01592019|Experimental|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3273114|NCT01592019|Experimental|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2: A single dose of the patch will be applied. In addition, the Microdialysis probe consisting of three probes will be inserted to test for the amount of the drug diclofenace. This will determine whether the site of application affects the availability of the drug.
3273115|NCT01592032|Experimental|Vancomycin antimicrobial-lock|Vancomycin antimicrobial-lock solution. Dosage: 2 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3273116|NCT01592032|Experimental|Teicoplanin antimicrobial-lock|Teicoplanin antimicrobial-lock solution. Dosage: 10 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3273117|NCT01592032|Experimental|Linezolid antimicrobial-lock|Linezolid antimicrobial-lock solution. Dosage: 1.8 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3273118|NCT01592032|Experimental|Daptomycin antimicrobial-lock|Daptomycin antimicrobial-lock solution. Dosage: 5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3273119|NCT01592032|Experimental|Tigecycline antimicrobial-lock|Tigecycline antimicrobial-lock solution. Dosage: 4.5 mg/mL. Dosage form: liquid in syringe. Frequency: 1. Duration: from 1 to 10 days according to HPLC corrected by urea gradient.
3273120|NCT01592084||lipid lowering therapy|those with lipid lowering therapy those without lipid lowering therapy
3273121|NCT01592110|Experimental|Cohort 1|25 mg of risperidone-SABER administered as a SC injection of 0.25 mL (100 mg/mL concentration) in the abdominal region
3273122|NCT01592110|Experimental|Cohort 2|50 mg of ZX003 (risperidone-SABER-DosePro) administered as 0.5 mL (100 mg/mL concentration) via the DosePro Needle-free Delivery System in the abdominal region
3273123|NCT01592110|Experimental|Cohort 3|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL (100 mg/mL concentration) in the abdominal region
3273124|NCT01592110|Experimental|Cohort 4|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL (100 mg/mL concentration) in the abdominal region
3273125|NCT01592123||The participants with septal deviation|
3273126|NCT01592149||Group 1|
3273127|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 0|propofol 1% (Astra-Zeneca)plus remifentanil 0 ng/ml
3273128|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 2|propofol 1% (Astra-Zeneca)plus remifentanil 2 ng/ml
3273129|NCT01592162|Active Comparator|propofol 1% (Astra-Zeneca) - remi 4|propofol 1% (Astra-Zeneca)plus remifentanil 4 ng/ml
3273130|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 0|propofol 1% (Fresenius) plus remifentanil 0 ng/ml
3273131|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 2|propofol 1% (Fresenius) plus remifentanil 2 ng/ml
3273132|NCT01592162|Active Comparator|propofol 1% (Fresenius) - remi 4|propofol 1% (Fresenius) plus remifentanil 4 ng/ml
3273133|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 0|propofol 1% (B-Braun) plus remifentanil 0 ng/ml
3273134|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 2|propofol 1% (B-Braun) plus remifentanil 2 ng/ml
3273135|NCT01592162|Active Comparator|propofol 1% (B-Braun) - remi 4|propofol 1% (B-Braun) plus remifentanil 4 ng/ml
3273136|NCT01592188|Active Comparator|MT|Mindfulness training. Participants will be provided with once per week training in mindfulness meditation.
3273137|NCT01592188|Experimental|CBCT|Cognitively-based compassion training. Participants in this arm will be provided with once weekly training on the cognitively-based compassion training program.
3273138|NCT01592201|Experimental|Paliperidone ER|Immediate initiation of Paliperidone ER for a total of 12 weeks
3273139|NCT01592201|Experimental|Antipsychotics and paliperidone ER|Delayed initiation included previous atypical antipsychotics for 8 weeks and then be initiated on paliperidone ER at Day 56 for 4 weeks. The atypical antipsychotics includes aripiprazole, olanzapine and risperidone. These antipsychotics belongs to the class of second generation bipolar atypical antipsychotics.
3273140|NCT01592214|Experimental|Part 1 #2-XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|4 subjects: 2.0 mg/g concentrations of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 2.4 mg.
3273141|NCT01592214|Placebo Comparator|Part 2 #4-Placebo in 4% Klucel® gel, concentration 0 mg/g|12 subjects: a placebo in 4% Klucel® gel intranasally to both nares in a volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5.
3273142|NCT01592214|Active Comparator|Part 2 # 3-XF-73 in 4% Klucel® gel, concentration 0.5 mg/g:|12 subjects: a modified 4% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
3273143|NCT01592214|Experimental|Part 2 #2- XF-73 in 2% Klucel® gel, concentration 2.0 mg/g|12 subjects; a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 2.0 mg/g and volume of 0.3 mL/naris/dose,3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 3.6 mg on Day 1 and 2.4 mg on Days 2 to 5.
3273144|NCT01592214|Experimental|Part 2 #1- XF-73 in 2 % Klucel® gel, concentration 0.5 mg/g|12 subjects: a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares in a concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose, 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
3273145|NCT01592214|Experimental|Part 1 #1-XF-73 in 2% Klucel® gel, concentration 0.5 mg/g:|4 subjects: 0.5 mg/g concentration of a modified 2% Klucel® gel formulation of XF-73 intranasally to both nares twice in a single day in a volume of 0.3 mL/naris/dose and total daily dose of 0.6 mg.
3273146|NCT01592227|Active Comparator|Marketed paracetamol|Marketed paracetamol
3273147|NCT01592227|Experimental|Experimental paracetamol formulation|Experimental formulations
3273148|NCT01592266||AML|patients with AML prior and after treatment
3273149|NCT01592279|Experimental|liraglutide|
3273150|NCT01592279|Active Comparator|Insulin injections|
3273151|NCT01592305|Experimental|S1 P1 TDF + DNV/r|
3273152|NCT01592305|Experimental|S1/S2 P2 DNV/r + ATZ|
3273153|NCT01592305|Experimental|S2 P1 ATZ/r|
3273154|NCT01592318|Active Comparator|DNV + r reference|
3273155|NCT01592318|Experimental|DNV/r fixed dose combination|
3273156|NCT01592331|Placebo Comparator|Placebo|
3273157|NCT01592331|Experimental|RO5508887|
3377294|NCT04596072|No Intervention|control|basic treatment+ Cognitive rehabilitation training
3377295|NCT04596072|Experimental|treatment|basic treatment+ Cognitive rehabilitation training+Chinese traditional rehabilitation
3377296|NCT04595760||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
3377298|NCT04588727|Experimental|AZD3366 Dose 1 Part A|Randomized healthy subjects will receive Dose 1 of AZD3366.
3377299|NCT04588727|Experimental|AZD3366 Dose 2 Part A|Randomized healthy subjects will receive Dose 2 of AZD3366.
3377300|NCT04588727|Experimental|AZD3366 Dose 3 Part A|Randomized healthy subjects will receive Dose 3 of AZD3366.
3377301|NCT04588727|Experimental|AZD3366 Dose 4 Part A|Randomized healthy subjects will receive Dose 4 of AZD3366.
3377302|NCT04588727|Experimental|AZD3366 Dose 5 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 5 of AZD3366.
3377303|NCT04588727|Experimental|AZD3366 Dose 6 Part A|Randomized healthy subjects and healthy Japanese subjects will receive Dose 6 of AZD3366.
3377304|NCT04588727|Experimental|AZD3366 Dose 7 Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Dose 7 of AZD3366.
3377305|NCT04588727|Placebo Comparator|Placebo Part A|Randomized healthy subjects, healthy Japanese subjects, and healthy Chinese subjects will receive Placebo matched to AZD3366.
3377306|NCT04588727|Experimental|AZD3366 Dose X Part B|Randomized healthy subjects will receive Dose X of AZD3366 in conjunction with concomitant administration of ticagrelor and ASA.
3377307|NCT04588727|Placebo Comparator|Placebo Dose X Part B|Randomized healthy subjects will receive Dose X of placebo in conjunction with concomitant administration of ticagrelor and ASA.
3377308|NCT04584112|Experimental|Cohort A: Tiragolumab and Atezolizumab + Nab-paclitaxel|Participants with first-line metastatic TNBC will receive tiragolumab and atezolizumab on Day 1 of every 28-day cycle plus nab-paclitaxel on Days 1, 8, and 15 of every 28-day cycle.
3377309|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-carbo-AC|Participants with early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab every 2 weeks (Q2W) in combination with nab-paclitaxel weekly (QW) and carboplatin every 3 weeks (Q3W) for four cycles, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim) or granulocyte-macrophage colony-stimulating factor (GM-CSF) support for four doses.
3273158|NCT01592357|Experimental|Tai Chi|
3273159|NCT01592357|Sham Comparator|Sham Exercise|
3377310|NCT04584112|Experimental|Cohort B: Tiragolumab and Atezolizumab + Nab-pac-AC|Participantswith early TNBC in the neoadjuvant setting, who are eligible for surgery, will receive tiragolumab and atezolizumab Q2W in combination with nab-paclitaxel QW for 12 weeks, followed by tiragolumab and atezolizumab in combination with doxorubicin and cyclophosphamide Q2W with G-CSF (filgrastim or pegfilgrastim) or GM-CSF support for four doses.
3377311|NCT04582903||Biological Relative|Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
3377312|NCT04582903||Confirmed or Suspected SARS-CoV-2 infection|Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current),typically but not always supported by a positive PCR test for viral RNA
3377313|NCT04582903||Exposed but Uninfected|Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavyor extensive COVID-19 exposure in the workplace or home environment
3377317|NCT04579237||1/All Subjects|Data will be derived from primary studies on all subjects.
3273160|NCT01592370|Experimental|Nivolumab monotherapy (Dose Escalation)|"Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
3273161|NCT01592370|Experimental|Nivolumab + Ipilimumab|"Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort"
3273162|NCT01592370|Experimental|Nivolumab + Lirilumab|"Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort"
3377320|NCT04567615|Experimental|Arm A : Nivolumab|
3377321|NCT04567615|Experimental|Arm B : Nivolumab + Relatlimab Dose 1|
3377322|NCT04567615|Experimental|Arm C : Nivolumab + Relatlimab Dose 2|
3377326|NCT04565067||1|COVID-19 recovered adult patients
3377327|NCT04564742|Experimental|Dapagliflozin|Patients will be randomized 1:1 to either dapagliflozin or placebo
3377328|NCT04564742|Placebo Comparator|Placebo|Placebo matching dapagliflozin
3377329|NCT04564443|Experimental|(Medaxis Debritom+™) micro jet lavage|Medaxis Debritom+™ is a high-quality, micro water jet debridement device designed to remove fibrin, necrotic tissue, and biofilm from wound surfaces by mechanical cleaning and stimulation of the diabetic foot wound
3273163|NCT01592370|Experimental|Nivo + Dara + Pom + Dexa vs. Nivo + Dara|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants > 75 years old~Weeks with daratumumab dosing:~20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants > 75 years old~Enrollment is closed for this cohort"
3273164|NCT01592370|Experimental|Daratumumab vs. Nivolumab + Daratumumab|"Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 & beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 & beyond: 16 mg/kg Day 1"
3377330|NCT04564443|Active Comparator|Sharp Surgical Debridement|Use of a surgical scalpel or curette to remove fibrin, necrotic tissue and biofilm from wound surfaces by mechanically cleaning the wound
3377331|NCT04564339|Experimental|Ravulizumab: LN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
3273165|NCT01592422|Experimental|Immunotherapy|Subjects receive autologous cytokine-induced killer cell infusion every month
3273166|NCT01592422|Active Comparator|Best Supportive Care|Best Supportive Care
3377332|NCT04564339|Placebo Comparator|Placebo: LN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
3377333|NCT04564339|Experimental|Ravulizumab: IgAN Cohort|Eligible participants will receive ravulizumab IV infusion in combination with background therapy during both the Initial Evaluation Period (26 weeks) and Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
3377334|NCT04564339|Placebo Comparator|Placebo: IgAN Cohort|Eligible participants will receive placebo IV infusion in combination with background therapy during the Initial Evaluation Period (26 weeks) and will switch to ravulizumab for the Extension Period (24 weeks). During the Follow-up Period (36 weeks) participants will receive background therapy according to the standard of care.
3273167|NCT01592448||Usual Care|"Participants will be shown standard (defined as currently commercially available) over-the-counter and prescription medicine bottles and asked questions regarding safety and use. Participants will also be shown additional standard over-the-counter bottles and asked whether these comparison bottles could safely be taken in addition to the primary products shown."
3273168|NCT01592448||Written Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. This flier will be passively hanging within sight of the participant in the room, but no verbal explanation of the flier will be given to the participant. (This is designed to represent a passive education campaign such as posters in drug stores that may be used should these icons be adopted by manufacturers.)"
3377336|NCT04564274||1|patients with rare and common diseases
3377337|NCT04557969||1/ Cohort 1|Patients with histologically confirmed or clinical presentation suspicious of GIST
3377338|NCT04557813||IC before start of any treatment|Informed consent (IC) before start of any treatment after diagnosis of NTRK fusion-positive cancer. All data after diagnosis of NTRK fusion-positive cancer are collected prospectively.
3377339|NCT04557813||IC after start of any treatment|IC after start of any treatment after diagnosis of NTRK fusion-positive cancer. Data after study inclusion are collected prospectively and retrospectively.
3377340|NCT04557813||Deceased patients|Patients deceased prior to study inclusion (no IC required). All data are collected retrospectively.
3377341|NCT04557436|Other|Standard of care|"Follow-up period:~For patients achieving molecular remission by day 28, allo-HSCT will be scheduled as soon as practicable. Routine transplant care for 24 months will incorporate the disease monitoring and recording of adverse events of special interest and document elimination of PBLTT52CAR19 through the transplant conditioning period.~For patients with refractory disease at Day 56, the monitoring of adverse events of special interest, the disease outcome will be monitored monthly up to 24 months or until a palliative therapy approach is adopted.~Assessments will be carried out after the treatment period at the following time points: 1m, 2m, 3m, 6m, and 12m, 24m~Physical examination, ECOG~Laboratory tests~Vital signs (temperature, BP, HR, respiratory rate, weight)~Persistence of PBLTT52CAR19, VCN by qPCR in blood and bone marrow (if sampled)~Chimerism and MRD in blood and bone marrow (if sampled)~Adverse events~Concomitant treatments"
3377342|NCT04557085|Placebo Comparator|Placebo|Placebo
3377343|NCT04557085|Experimental|Cenobamate 100 mg/day|Cenobamate 100 mg/day
3273169|NCT01592448||Written + Verbal Orientation|"Participants will be exposed to over-the-counter and prescription bottles enhanced with an icon pertaining to active ingredient and asked questions regarding safety and use. Participants will be exposed to a flier describing the safe use of acetaminophen and orienting the participant towards the icon that is used to indicate the presence of acetaminophen in a product. Research personnel will also verbally go through the flier with the participant and answer any questions in a standardized fashion. (This is designed to represent an active education campaign such as pharmacist counseling that may be used should these icons be adopted by manufacturers.)"
3273170|NCT01592487||Lean BMI|BMI in the 25th - 75th percentile
3273171|NCT01592487||Overweight BMI|BMI in the 85th - 95th percentile
3273172|NCT01592513|No Intervention|Control|
3273173|NCT01592513|Experimental|BIS monitor|"Patients in this group will be monitored by BIS (placement of an electrode over the forehead before sedation).~Patients in this group will receive propofol (boluses of 10-20 mg) to reach a BIS target value of 80-90."
3273174|NCT01592526|Experimental|Untrained, healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
3273175|NCT01592526|Experimental|Well-trained healthy volunteers A|(Endotoxin) before (Endotoxin + Nicotine)
3273176|NCT01592526|Experimental|Untrained, healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
3273177|NCT01592526|Experimental|Well-trained healthy volunteers B|(Endotoxin + Nicotine) before (Endotoxin)
3273178|NCT01592539||Case|Patients with Type 1 Diabetes Mellitus
3273179|NCT01592539||Control|Age and sex matched healthy controls.
3273180|NCT01592552||Neurological Condition|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
3273181|NCT01592552||Control|Collect blood and other biospecimens like saliva, urine and CSF for research purposes.
3273182|NCT01592578|Active Comparator|Ligation and Cyanoacrylate Group|
3273183|NCT01592578|Experimental|Ligation plus Sclerotherapy and Cyanoacrylate Group|
3273184|NCT01592604|Experimental|Treatment A|Patients receive supportive compressive bandage for 4 weeks
3273185|NCT01592604|Experimental|Treatment B|Below knee walking plaster cast for 4 weeks
3273186|NCT01592617|Experimental|S-488410|
3273187|NCT01592630|Experimental|Ropivacaine|Subjects with TAP catheters attached to the On-Q pump with 0.2% ropivacaine
3273188|NCT01592630|Placebo Comparator|Saline|Subjects with TAP catheters attached to the On-Q pump with saline
3273189|NCT01592656|Active Comparator|Non-invasive ventilation (NIV)|30 patients will receive NIV during 6 months = group 1
3273190|NCT01592656|Placebo Comparator|Control group|10 patients will act as control group, they will not be treated with NIV = group 2
3273191|NCT01592669|Experimental|passive leg group|bilateral PLR was achieved by raising the patient's legs to a 45 angle.
3273192|NCT01592669|No Intervention|control|supine baseline position
3273193|NCT01592682|No Intervention|Usual care|Household pairs that are assessment only and receive usual care of local in-language smoking cessation resource referral including quitline.
3273194|NCT01592682|Experimental|Smokefree counseling|Household pairs assigned to smokefree counseling intervention, consisting of group education sessions, tobacco exposure lab report, individual follow-up phone calls.
3273195|NCT01592721|Experimental|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
3273196|NCT01592734|Experimental|PEG-only|Polyethylene glycol 4000 only (PEG-only).
3273197|NCT01592734|Active Comparator|PEG-EL|Polyethylene glycol 3350 with electrolytes (PEG-EL).
3273198|NCT01592812|Experimental|electrical stimulation|Evaluation of the effect of calf stimulation on flow and tissue oxygenation
3273199|NCT01592838||Hospitalized Group|Data collection for changes in hospital pattern pre- versus post-rotavirus vaccination, in children ≤15 years old hospitalised for any reason between June 2004 and May 2010.
3273200|NCT01592890|Experimental|[14C]-labeled RO4917523|
3273201|NCT01592903||Patients with symptomatic uterine fibroids.|Samples of human leiomyomas are obtained from patients undergoing laparoscopic myomectomy for symptomatic uterine fibroids. These leiomyomas are isolated and cultured for stem cells.
3273202|NCT01592916||Fibromyalgia|Women with fibromyalgia, aged 20-50 years
3273203|NCT01592916||Healthy controls|Women without severe disease, aged 20-50 years
3273204|NCT01592942|Experimental|glue fixation|Optilene™ mesh 60 g/m2 (B. Braun), fixation Histoacryl™ cyanoacrylate glue (price 14+37 euros)
3273205|NCT01592942|Active Comparator|self-gripping|ProGrip™ mesh 60 g/m2 (Covidien, USA) (price 113 euros)
3273206|NCT01592942|Active Comparator|suture fixation|Ultrapro™ mesh 28 g/m2 (Ethicon, USA) (price 45 euros) fixated by non-absorbable sutures
3273207|NCT01592955|Experimental|EYEOP1 device|cyclocoagulation HIFU
3273208|NCT01592968|Experimental|Arm I (SRS)|Patients undergo SRS on day 1.
3273209|NCT01592968|Experimental|Arm II (WBRT)|Patients undergo WBRT 5 days per week (7 days per week for inpatients) for 2 weeks.
3273210|NCT01592981|Experimental|bortezomib, cyclophosphamide, rituximab|"Bortezomib:1.6 mg/m2 s.c; days 1, 8, 15 of each cycle. Cyclophosphamide:250 mg/m2 oral; days 1, 8, 15 of each cycle. Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days. After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
3273211|NCT01592981|Active Comparator|fludarabine, cyclophosphamide, rituximab|"Fludarabine:40 mg/sq m, oral, days 1,2 and 3 of each cycle. Cyclophosphamide:250 mg/sq m; oral, days 1, 2 and 3 of each cycle. Rituximab: 375 mg/sq m i.v. infusion days 1, 8, 15 and 22 of cycles 2 and 5 only.~Cycle repeated every 28 days.After 3 cycles of treatment, patients are reassessed and those with evidence of progression stop trial treatment. All other patients continue with further 3 cycles (to a total of 6) unless a clear clinical contradiction to further treatment exist."
3377344|NCT04557085|Experimental|Cenobamate 200 mg/day|Cenobamate 200 mg/day
3377345|NCT04557085|Experimental|Cenobamate 400 mg/day|Cenobamate 400 mg/day
3377346|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 600 mg three times daily
3273212|NCT01592994|No Intervention|control|control participants received basic messages on the utility of condoms in protecting from HIV and other STIs, and they were informed about local HIV/STI counseling and testing services.
3273213|NCT01592994|Experimental|RHANI Wives Intervention|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT) and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
3273214|NCT01593007|Experimental|Inspiratory Muscle Training|Inspiratory Muscle Training
3273215|NCT01593007|Placebo Comparator|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
3273216|NCT01593033|Experimental|Fish oil and Micronutrient Supplementation|
3273217|NCT01593033|Experimental|Micronutrient Supplementation|
3273218|NCT01593033|Placebo Comparator|Placebo|
3273219|NCT01593046|Experimental|Run-in Period|Oral GSK1265744 30mg once daily for 14 days
3273220|NCT01593046|Experimental|Cohort 1|GSK1265744 LAP injection given subcutaneously once a month for 4 months
3273221|NCT01593046|Experimental|Cohort 2|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
3273222|NCT01593046|Experimental|Cohort 3|GSK1265744 LAP injection given intramuscularly once a month for 4 months. TMC278 LA + GSK1265744 given in Month 3 and 4.
3273223|NCT01593046|Experimental|Cohort 4|GSK1265744 LAP injection given intramuscularly once every 12 weeks.
3273224|NCT01593059||Orsiro DES|
3273225|NCT01593072|Active Comparator|AVI-7537|AVI-7537
3273226|NCT01593072|Other|Placebo|Normal Saline Solution (NSS)
3273227|NCT01593085||patients in palliative cares|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
3273228|NCT01593098||Exposed siblings|Siblings (age >40 and <70) of individuals diagnosed with advanced neoplasm on screening colonoscopy. Advanced neoplasm is defined as adenomas≥10mm size, >25% villous features, severe dysplasia or carcinoma-in-situ
3273229|NCT01593098||unexposed siblings|Siblings (age >40 and <70) of individuals diagnosed with no polyp on screening colonoscopy who is age and sex matched to case.
3273230|NCT01593111|Experimental|Environmental Intervention|If randomized to this part of the study the patient will receive an individualized homebased program. In addition to general handouts provided to at Visit 3, subjects in this arm will also receive home-based education by Intervention Counselors about how indoor allergens can affect asthma and the importance of strategies for removing allergens. The goal of the intervention is to provide the patient with the knowledge and skills necessary to remove allergens from their home, and to assist them with those clean up measures. Some of the measures implemented will be specifically based on data we have previously collected from them in the clinic and from their previous home visit, while others will be general to reduce all allergen level.
3273231|NCT01593111|No Intervention|Control Group|If assigned to this group the patient will receive general health/safety related counseling. At the counselor visit following randomization, the patient will receive handouts related to general health and safety issues. They will also have visits by the Home Evaluators for assessment of the home and collection of dust samples identical to those in the treatment group (week 28 and week 44).
3273232|NCT01593124|Active Comparator|Imiquimod, 2 doses, vaginally|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3273233|NCT01593124|Placebo Comparator|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3273234|NCT01593124|Active Comparator|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
3273235|NCT01593137|Experimental|Liraglutide + metformin|
3273236|NCT01593137|Active Comparator|glimepiride + metformin|
3273237|NCT01593150|Experimental|Conventional|Conventional treatment Pradaxa prior to DC cardioversion
3273238|NCT01593150|Experimental|TEE|Transesophageal echo prior to DC cardioversion (early DC)
3273239|NCT01593150|Active Comparator|Early versus Late DC cardioversion|Comparing early versus late DC cardioversion. Patients randomized to either early or late DC cardioversion, follow-up time after intervention 12 month.
3273240|NCT01593163|Experimental|EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
3273241|NCT01593163|Other|ST (standard treatment)|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
3273242|NCT01593176||Distal Femur Fracture, LISS Plate|Patients presenting with a distal femur fracture requiring surgical fixation with a Less Invasive Stabilization System (LISS) plate will have placement of RSA beads for analysis.
3273243|NCT01593189|Experimental|KITS Program|The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
3273244|NCT01593189|No Intervention|Services as usual|Families continued to receive any services that they had been receiving in the community.
3273245|NCT01593202|Experimental|Dialectical behavior therapy|Dialectical Behavior Therapy, delivered for 19 weeks, consisted of 1 weekly session of individual therapy (60 minutes), 1 weekly session of multifamily skills training (120 minutes), and family therapy sessions and Telephone coaching with individual therapists outside therapy sessions as needed.
3273246|NCT01593202|Active Comparator|Enhanced usual care|Enhanced usual care was 19 weeks of standard care (enhanced for the purpose of the study by requiring that EUC therapists agree to provide on average no less than 1 weekly treatment session per patient throughout the trial) delivered by therapists (4 psychiatrists, 16 clinical psychologists, 6 clinical social workers, 2 clinical pedagogues, 1 specialist nurse, and 1 psychology graduate student) not trained in or practicing DBT.
3273247|NCT01593228|Experimental|1|"Patients receiving iniparib alone or in combination with other anti-cancer agents as defined by the parental study. Interventions:~Drug: Iniparib monotherapy~Drug: Iniparib + gemcitabine + carboplatin~Drug: Iniparib + topotecan~Drug: Iniparib + irinotecan~Drug: Iniparib + paclitaxel~Drug: Iniparib + liposomal doxorubicin + carboplatin"
3273248|NCT01593267|Active Comparator|Endovascular|Subjects randomized to endovascular coil embolization will be treated by one of two neurosurgeons expert in such treatment. All endovascular coil embolization treatments will be accomplished using accepted techniques.
3273249|NCT01593267|Active Comparator|Surgical|Subjects randomized to surgical clip occlusion repair will receive treatment from one of two neurosurgeons expert in clip occlusion surgery for ruptured aneurysms.
3273250|NCT01593280|Active Comparator|TAP catheter|Indwelling TAP catheter placed at the end of c-section. It will be dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen OnQ C-block pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The catheters will run at 7cc/hr/side for 50 hrs.
3273251|NCT01593280|Active Comparator|intrathecal morphine|0.3 mg of intrathecal morphine
3273252|NCT01593293|Active Comparator|PemCarbo|Pemetrexed/Carboplatin arm
3273253|NCT01593293|Active Comparator|Pem only|Pemetrexed arm
3273254|NCT01593306|Experimental|cisplatin and paclitaxel with concurrent radiotherapy|weekly cisplatin at 30mg/m2 and paclitaxel at 50mg/m2 are given with concurrent radiotherapy at 2Gy per fraction at 5 fractions per week for 5 weeks followed by either low dose rate (LDR) Intracavitary (I/C) Brachytherapy or supplement Chemoradiotherapy (CRT); if not fit for I/C Brachytherapy
3273255|NCT01593306|Active Comparator|cisplatin with concurrent radiotherapy|weekly cisplatin @ 40mg/m2 is given along with concurrent radiotherapy at 2Gy per fraction with 5 fractions per week for 5 weeks followed by LDR I/C brachytherapy or supplement CRT; if not fit for I/C Brachytherapy
3273256|NCT01593319|Active Comparator|ropivacaine|
3273257|NCT01593319|Placebo Comparator|Natrium chloride|
3273258|NCT01593332|Active Comparator|Rituximab|
3273259|NCT01593332|Active Comparator|Methotrexate|
3273260|NCT01593345|Experimental|Mentor|
3273261|NCT01593345|Active Comparator|Guidebook|
3273262|NCT01593371|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3273263|NCT01593371|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3273264|NCT01593397|Experimental|Propofol and Fentanyl administration|Propofol and Fentanyl will be administered to all subjects. All subjects will have blood drawn to determine pharmacokinetic variables. Processed EEG will be used to determine pharmacodynamics. Plasma samples will be used to ascertain adiponectin levels and for DNA sampling for analysis of adiponectin single nucleotide polymorphisms.
3273265|NCT01593410|Experimental|Lenalidomide and dexamethasone|Cycle 1: 25 mg oral lenalidomide once daily on Days 1-21 every 28 Days and 40 mg oral dexamethasone on Days 8, 15, and 22. Cycle 2 and beyond: 25 oral lenalidomide once daily on Days 1-21 every 28 days and 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22.
3273266|NCT01593423|Experimental|Homestead Food Production plus small pond aquaculture|
3273267|NCT01593423|Active Comparator|plant-based Homestead Food Production|
3273268|NCT01593423|Sham Comparator|Control|
3273269|NCT01593436|Active Comparator|mindfulness training|mindfulness training for patients with insomnia
3273270|NCT01593436|No Intervention|polysomnography and actigraphy|The intention is to assess the sleep architecture of meditators and non meditators women without menopausal insomnia by polysomnographic , actigraphy, and questionnaires to assess sleep quality and emotional state
3273271|NCT01593449|Active Comparator|American Heart Association|Participants will receive handouts on increasing physical activity derived from the American Heart Association materials on increasing physical activity.
3273272|NCT01593449|Experimental|Dog Walking|The 6-month dog walking intervention involves 5 components to address the individual, interpersonal and community levels of the socio-ecological model: newsletters, pedometers, social networking website, neighborhood dog walks, and invitations to community events.
3273273|NCT01593462|Experimental|Pediatric Small Bowel Crohn's Disease|MRE (magnetic resonance enterography) performed 4 weeks after SBCD treatment begins, or ends or treatment changes, or at 6 months whichever comes first. One research MRE will be performed and one MRE may or may not be performed as part of your routine care.
3273274|NCT01593475|Experimental|Induction chemotherapy followed by CCRT|"In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during RT and CRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy.~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
3273275|NCT01593488|Experimental|Intrathecal liposomal cytarabine|
3377347|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine|N-Acetyl Cysteine 1,200 mg three times daily
3273276|NCT01593501|Active Comparator|High dose vitamin D|50,000 IU vitamin D3 every 15 days, with a loading dose of 50,000 IU per day for the first 15 days of an approximate 365-day treatment.
3273277|NCT01593501|Active Comparator|Low dose vitamin D|800 IU vitamin D3 every day of an approximate 365-day treatment.
3273278|NCT01593501|Placebo Comparator|Placebo|A pill that looks like the low/high dose vitamin D pills, but contains no vitamin D. Given to preserve the double-blind nature of the study.
3273279|NCT01593514|Active Comparator|Group 1 Conjugate-conjugate|Group I will receive 2 doses of the MenACWY-CRM conjugate vaccine (Novartis Vaccines) given 1 month apart. All vaccine doses are 0.5ml and will be administered intramuscularly into the deltoid.
3273280|NCT01593514|Experimental|Group 2 Polysaccharide-conjugate|"Group II will receive one full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.5 mL of MenACWY-PS vaccine will be administered subcutaneously and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
3273281|NCT01593514|Experimental|Group 3 Polysaccharide (subcutaneously)-conjugate|Group III will receive a full dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine subcutaneously, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.
3273282|NCT01593514|Experimental|Group 4: 1/5th dose Polysaccharide:conjugate|"Group IV will receive one fifth dose of MenACWY-PS polysaccharide vaccine meningococcal vaccine, followed by one dose of MenACWY-CRM conjugate vaccine given 1 month later.~0.1 mL of MenACWY-PS vaccine will be administered IM and 0.5 mL of the MenACWY-CRM vaccine will be administered intramuscularly into the deltoid."
3273283|NCT01593527|Experimental|Arm 1|Canakinumab 150 mg s.c.
3273284|NCT01593527|Experimental|Arm 2|Triamcinelone acetonide 40 mg i.m.
3273285|NCT01593540|Experimental|metal-free interdental brushes.|
3273286|NCT01593540|Active Comparator|metal-core interdental brushes|
3273287|NCT01593553|Experimental|ECG screening|Twice daily screening using intermittent ECG recorder (Zenicor) for two weeks
3273288|NCT01593553|No Intervention|Control group|Standard of care
3273289|NCT01593566|Active Comparator|0.25% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
3273290|NCT01593566|Active Comparator|0.5% bupivacaine|femoral nerve block using 0.25% bupivacaine versus 0.5% bupivacaine
3273291|NCT01593579||Patients with Melanoma|Patients with Melanoma that are enrolled in a clinical trial at the Vanderbilt Ingram Cancer Center (VICC) including an arm with an oral Akt inhibitor
3273292|NCT01593605|Active Comparator|Dietary Supplement/insulin sensitivity|The first study supplement contains resveratrol that may improve insulin sensitivity and Leucine.Resveratrol 50mg with leucine 1.11 g. - one tablet taken twice a day by mouth
3273293|NCT01593605|Placebo Comparator|Sugar Pill|Neutral treatment Placebo - one tablet taken twice a day by mouth
3273294|NCT01593605|Active Comparator|Dietary Supplement 2|2nd study supplement contains resveratrol and HMB which may stimulate protein building.
3273295|NCT01593618|Experimental|Web-Based Intervention|UMFollowUp - web-based internet resource for information about their diagnostic histories, recommendations for follow-up care, and tips to enhance their treatment, psychosocial and physical well-being.
3273296|NCT01593618|Active Comparator|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
3273297|NCT01593631|Active Comparator|2 billion lyoph. yoghurt bacteria|
3273298|NCT01593631|Active Comparator|3300 FCC acid lactase|
3273299|NCT01593631|Active Comparator|9000 FCC acid lactase|
3273300|NCT01593631|Active Comparator|Combination of Substances of arm 1 and 2|
3273301|NCT01593631|Placebo Comparator|Placebo|
3273302|NCT01593644|Experimental|adenosine + dypiridamole|
3273303|NCT01593657|Experimental|Mindful Movement and Breathing program|Mindful Movement and Breathing program implemented in a hospital room or clinic room three times by a yoga instructor: prior to surgery, one day and two days after surgery.
3273304|NCT01593683|Experimental|Psychological education program|Patients receive the psychological education program upon study enrollment.
3273305|NCT01593683|No Intervention|Waitlist|Participants are assigned to a 16-week wait-list period upon enrollment. Participants are invited to receive the psychological education program following the waitlist period.
3273306|NCT01593709||Cohort 1|Healthy adults; age 18 or older
3273307|NCT01593735|Experimental|Panel A: GT1, low dose|Participants with genotype 1 (GT1) Hepatitis C Virus (HCV) will receive low dose MK-2748 daily for 7 days.
3273308|NCT01593735|Experimental|Panel B: GT1, lower dose|Participants with GT1 HCV will receive lower dose MK-2748 daily for 7 days.
3273309|NCT01593735|Experimental|Panel C: GT1, dose based on Panels A+B|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose) and B (lower dose).
3273310|NCT01593735|Experimental|Panel G: GT1, dose based on Panels A+B+C|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), and C.
3273311|NCT01593735|Experimental|Panel H: GT1, dose based on Panels A+B+C+G|Participants with GT1 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels A (low dose), B (lower dose), C, and G.
3273312|NCT01593735|Experimental|Panel D: GT3, low dose (Omitted)|Participants with genotype 3 (GT3) HCV were to receive low dose MK-2748 daily for 7 days. Panel D was omitted from the study design and participants were not enrolled in this panel.
3273313|NCT01593735|Experimental|Panel E: GT3, high dose|Participants with genotype 3 (GT3) HCV will receive high dose MK-2748 daily for 7 days.
3273314|NCT01593735|Experimental|Panel F: GT3, dose based on Panel E|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panel E (high dose).
3273315|NCT01593735|Experimental|Panel I: GT3, dose based on Panels E+F|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose) and F.
3273316|NCT01593735|Experimental|Panel J: GT3, dose based on Panels E+F+I|Participants with GT3 HCV will be dosed with MK-2748 daily for 7 days based on the safety, pharmacokinetic, and/or pharmacodynamic data from Panels E (high dose), F, and I.
3273317|NCT01593761|Experimental|Single Arm for CG400549|All the patients will be administered with CG400549.
3273318|NCT01593774|Experimental|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group for eight week
3273319|NCT01593774|Placebo Comparator|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
3273320|NCT01593800|Experimental|open label probiotics|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
3273321|NCT01593826|Active Comparator|Charcoal and Symbicort Turbuhaler|
3273322|NCT01593826|Active Comparator|Symbicort Turbuhaler|
3273323|NCT01593826|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3273324|NCT01593826|Experimental|Budesonide/formoterol Easyhaler|
3273325|NCT01593865||BIMA Grafting Group|Group consists of patients who received bilateral internal mammary artery grafting for treatment of severe coronary disease since June 2012.
3273326|NCT01593865||Control Group|This Group consists of historical control patients who received conventional coronary artery bypass grafting (left mammary artery graft only plus great saphenous vein grafts) in the 2010-2012 period, and who are propensity-matched to the BIMA Group patients.
3273327|NCT01593878|Experimental|TV|Test taken with TV on
3273328|NCT01593878|No Intervention|Control|test taken in quiet
3273329|NCT01593930|Experimental|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
3273330|NCT01593930|Experimental|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
3273331|NCT01593930|Experimental|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
3273332|NCT01593930|Experimental|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
3273333|NCT01593943|No Intervention|Control Condition|
3273334|NCT01593943|Experimental|CHARM Intervention|CHARM will be conducted via three 30-minute counseling sessions delivered in a rural setting, with the first session being required and the subsequent sessions being optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
3273335|NCT01593956|Other|Concussed athletes|
3273336|NCT01593956|Other|Healthy controls|
3273337|NCT01593969|Active Comparator|Standard RUTF|Standard RUTF given according to National Guidelines
3273338|NCT01593969|Experimental|RUTF/Flax Oil|RUTF/Flax Oil is reformulated RUTF to increase n3 content
3273339|NCT01593969|Experimental|RUTF/Flax Oil plus additional Fish Oil|RUTF/Flax Oil plus additional Fish Oil is RUTF reformulated to increase n3. Fish oil to provide long chain n3
3273340|NCT01593982|Placebo Comparator|Sham rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Sham (placebo) rTMS delivered to the left dorsolateral prefrontal cortex.
3273341|NCT01593982|Active Comparator|Active rTMS|Drug-free patients, receiving 20 sessions (1 session daily) of Active rTMS delivered to the left dorsolateral prefrontal cortex.
3273342|NCT01593995|Experimental|EGF ointment|
3273343|NCT01594021|Experimental|High pre-emptive volume loading|
3273344|NCT01594021|Active Comparator|Low pre-emptive volume loading|
3273345|NCT01594034||no treatment|
3273346|NCT01594047|No Intervention|zero/morphine|Patient received a standard balance anaesthesia and morphine for post operative pain.
3273347|NCT01594047|Experimental|ketamine/morphine|patients received a balance anaesthesia supplemented by low dose of ketamine and Morphine by PCA device for postoperative pain
3273348|NCT01594047|Experimental|zero/metadone|patients received a standard balance anaesthesia and methadone by PCA device for postoperative pain
3273349|NCT01594047|Experimental|ketamine/methadone|Patients received a balance anaesthesia supplemented with low dose of ketamine and Methadone by PCA device for postoperative pain
3273350|NCT01594060|Active Comparator|sliding scale|
3273351|NCT01594060|Active Comparator|basal bolus|
3273352|NCT01594086|Experimental|green tea powder|Natural green tea powder
3273353|NCT01594099|Active Comparator|Radiotherapy alone|
3273354|NCT01594099|Experimental|Radiotherapy plus cisplatin|
3273355|NCT01594099|Experimental|Radiotherapy plus liposome paclitaxel|
3273356|NCT01594112||Patient with at least one ID|Patient with ICD who received at least one inappropriate diagnosis (with or without therapy) during the 15 months follow-up.
3273357|NCT01594138||Suicidal Subjects|Suicidal Subjects
3273358|NCT01594138||Non-Suicidal Control Subjects|Non-Suicidal Control Subjects
3273359|NCT01594177|Experimental|Treatment arm|Afatinib-Trastuzumab (6 weeks) followed by Afatinib*-Paclitaxel-Trastuzumab (12 weeks) followed by Epirubicin-Cyclophosphamide-Trastuzumab (12 weeks). *only 11 weeks.
3273360|NCT01594190|Active Comparator|Low Dose Training|15 minutes/day on a weight-bearing treadmill
3273361|NCT01594190|Active Comparator|High Dose Training|2x 30 minutes/day on a weight-bearing treadmill
3273362|NCT01594203||Advanced Soft Tissue Sarcoma|patients with advanced Soft Tissue Sarcoma
3273363|NCT01594216|Experimental|First Stage|Ruxolitinib at 25 mg orally, twice daily and Exemestane, 25 mg orally once daily
3273364|NCT01594216|Experimental|Second Stage|Ruxolitinib at 15 mg orally, twice daily and Exemestane, 25 mg orally once daily
3273365|NCT01594229|Experimental|Arm 1|Non-Hodgkin's Lymphoma (NHL)
3273366|NCT01594242|Experimental|Autophagy Induction After Bortezomib|"Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma).~The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment."
3273367|NCT01594255|Experimental|AEB071 300 mg|
3273368|NCT01594255|Experimental|AEB071 900 mg|
3273369|NCT01594255|Placebo Comparator|Placebo to AEB071|
3273370|NCT01594255|Active Comparator|Moxifloxacin|
3273371|NCT01594268|Other|Kidney transplantation patient|Kidney transplantation patient; single arm
3377348|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 20 mg three times daily
3273372|NCT01594307||blood pressure monitor|Cuff circumference:13.5cm-22cm
3273373|NCT01594307||stethoscopy|Cuff circumference: 13.5cm-22cm
3273374|NCT01594320|Experimental|Group A|
3273375|NCT01594320|Experimental|Group B|
3273376|NCT01594320|Experimental|Group C|
3273377|NCT01594320|Experimental|Group D|
3273378|NCT01594320|Experimental|Group E|
3273379|NCT01594320|Experimental|Group F|
3273380|NCT01594346|Placebo Comparator|Sugar Pill|
3273381|NCT01594346|Active Comparator|Alpha-Tocopherol|
3273382|NCT01594359|Active Comparator|High iron bean|High-iron bean
3273383|NCT01594359|Placebo Comparator|Low iron bean|Low-iron bean
3273384|NCT01594372|Active Comparator|Laparoscopic Repair|Laparoscopic supracervical hysterectomy with sacropexy
3273385|NCT01594372|Active Comparator|Vaginal Repair|Vaginal hysterectomy with uterosacral colposuspension
3273386|NCT01594437|Experimental|TCN-202|
3273387|NCT01594437|Placebo Comparator|Placebo|
3273388|NCT01594450|Experimental|biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
3273389|NCT01594450|Active Comparator|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization.
3273390|NCT01594463|Experimental|late ultrasound examination|late examination between 34+1 weeks to 35+6 weeks.
3273391|NCT01594463|Experimental|early ultrasound examination|early examination between 30+1 weeks to 31+6 weeks
3273392|NCT01594489|Experimental|Aminophylline|Additional Aminophylline therapy to hydration (sodium bicarbonate) and N-acetilcysteine
3273393|NCT01594489|Active Comparator|Control group|Control group treated with hydration (sodium bicarbonate) and N-acetilcysteine
3273394|NCT01594502||Dutasteride Year 2 PCa|Subject assigned to dutasteride, prostate cancer found on Year 2 biopsy.
3273395|NCT01594502||Placebo Year 2 no PCa, Year 4 PCa|Subject assigned to placebo, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
3273396|NCT01594502||Dutasteride Year 2 no PCa, Year 4 PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 biopsy, but prostate cancer found on Year 4 biopsy.
3273397|NCT01594502||Placebo, Year 2 and 4 no PCa|Subject assigned to placebo, no prostate cancer found on Year 2 or Year 4 biopsy.
3273398|NCT01594502||Dutasteride, Year 2 and 4 no PCa|Subject assigned to dutasteride, no prostate cancer found on Year 2 or Year 4 biopsy.
3273399|NCT01594502||Placebo, Year 2 PCa|Subject assigned to placebo, prostate cancer found on Year 2 biopsy.
3273400|NCT01594541||Patients Treated with CerefolinNAC®|
3273401|NCT01594541||Patients Not Treated with CerefolinNAC®|
3273402|NCT01594554||HCV Patients|A sample of 600 Han ethnic Chinese male or female who are ≥ 18 years old enrolled and completed in the study of AI452-009 (i.e., CCgenos cross sectional phase, ClinicalTrials.gov Identifier: NCT01293279).
3273403|NCT01594580|Experimental|Antimicrobial impregnated scrubs|Those randomized to this arm of the study will wear scrubs impregnated with an antimicrobial.
3273404|NCT01594580|Placebo Comparator|Non-impregnated scrubs|Those randomized to this arm of the study will wear scrubs not impregnated with an antimicrobial.
3273405|NCT01594593|Experimental|Acceptance and Commitment Therapy|Group-based behavioral workshop to address cancer-related distress
3273406|NCT01594593|No Intervention|treatment as usual|
3273407|NCT01594606|Experimental|Animal-assisted|This group receives the dog training program in which they will be teaching a dog basic obedience skills.
3273408|NCT01594606|Active Comparator|Dog Walking|This group will walk a different dog each week but will not engage in dog training.
3273409|NCT01594619|Experimental|A|Single dose naloxegol 25mg
3273410|NCT01594619|Active Comparator|B|Diltiazem 240mg once daily day 4-6
3273411|NCT01594619|Active Comparator|C|Diltiazem 240mg once daily day 7 and 8. Single dose naloxegol 25mg day 7
3273412|NCT01594632|Experimental|Jadelle|Contraception using Jadelle implant
3273413|NCT01594632|Active Comparator|Sino-implant (II)|levonorgestrel containing subdermal contraceptive implant [Zarin, Femplant, Trust or Simplant]
3273414|NCT01594645|Experimental|Spermatozoa election using a polscope|AR+ spermatozoa are selected for ICSI using a polscope
3273415|NCT01594645|Active Comparator|Control|Spermatozoa for ICSI are selected based on morphology and motion under conventional light microscopy
3273416|NCT01594658||Foam sclerotherapy|This arm corresponds to ultrasound-guided foam sclerotherapy of superficial venous reflux plus conservative management
3273417|NCT01594658||Conservative|This arm only has medical standard handling (healings performed by the nurse group)
3273418|NCT01594671|Experimental|Tranexamic acid|"Intravenous Tranexamic Acid Two dosage Tranexamic acid during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule Other Name: Amchafibrin"
3377349|NCT04545008|Experimental|High Dose N-Acetyl Cysteine Alone|N-Acetyl Cysteine 1,800 mg three times daily
3377350|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 20 mg three times daily
3377351|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 40 mg three times daily
3273419|NCT01594671|Active Comparator|Habitual haemostasia|The surgical habitual haemostasia.
3273420|NCT01594671|Experimental|Topical Tranexamic acid|Topical Tranexamic acid one dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
3273421|NCT01594684|Active Comparator|drug eluting balloon|treatment with drug eltuing balloon
3273422|NCT01594684|Placebo Comparator|uncoated balloon|treatment with uncoated balloon
3273423|NCT01594684|Active Comparator|double drug eluting balloon|if treatment fails 30 days or later
3273424|NCT01594697|Experimental|metformin|
3273425|NCT01594710||Apparently Health People|
3273426|NCT01594723|Experimental|120 mg LY2784544|120 milligram (mg) administered orally once daily for 6 cycles (168 days)
3273427|NCT01594736|Active Comparator|ORSIRO|
3273428|NCT01594736|Active Comparator|XIENCE PRIME DES|
3273429|NCT01594775|Active Comparator|nasal spray|
3273430|NCT01594775|Placebo Comparator|Placebo|
3273431|NCT01594801|No Intervention|Control|Subject continue their routine therapy
3273432|NCT01594801|Experimental|Test|Subjects using the InsuPad device
3273433|NCT01594814||RFA of AVNRT of AVRT|
3273434|NCT01594840|Experimental|Changing chat|Diapers will have tips on them
3273435|NCT01594840|Active Comparator|Control|Normal diapers
3273436|NCT01594866|Placebo Comparator|Escitalopram, 20mg, placebo|escitalopram 20mg + placebo (same taste, appearance, texture of escitalopram 10mg)
3273437|NCT01594866|Experimental|Escitalopram 20mg, escitalopram 10mg|Escitalopram 20mg + Escitalopram 10mg
3273438|NCT01594879|Experimental|Endometrial cancer, LNG-IUS with MPA|
3273439|NCT01594892|Experimental|Dose intensified SBRT|Depending on the modified Mizumoto Score (0-4 points or 5-9 points) patients will be treated with 10 fractions of 4.85Gy in involved parts of the vertebra and 3Gy in not-involved parts using a simultaneous integrated boost or with 5 fractions of 7Gy in involved parts of the vertebra and 4Gy in not-involved parts using a simultaneous integrated boost, respectively.
3273440|NCT01594905|Experimental|Entecavir 1.0mg + Tenofovir 300mg|All subjects will orally take investigational drugs once daily for 48 weeks.
3273441|NCT01594918|Experimental|Cabazitaxel, Mitoxantrone, Prednisone|
3273442|NCT01594957|Experimental|LCQ908 (mild hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with mild hepatic impairment and will receive a single dose of LCQ908.
3273443|NCT01594957|Experimental|LCQ908 (moderate hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with moderate hepatic impairment and will receive a single dose of LCQ908.
3273444|NCT01594957|Experimental|LCQ908 (severe hepatic impairment plus healthy volunteers)|Healthy subjects will be matched pair-wise by, sex, race, age (±10 years) and weight (±20%) to subjects with severe hepatic impairment and will receive a single dose of LCQ908.
3273445|NCT01594983|Experimental|LCQ908 1|LCQ908 (Diacylglycerol acyltransferase inhibitor)once daily for 12 weeks
3273446|NCT01594983|Experimental|LCQ908 2|LCQ908 once daily for 12 weeks
3273447|NCT01594983|Experimental|LCQ908 3|LCQ908 once daily for 12 weeks
3273448|NCT01594983|Active Comparator|Fenofibrate|Intervention Type: Drug Intervention Name: Fenofibrate
3273449|NCT01594983|Active Comparator|Fish Oil|Fish oil once daily for 12 weeks
3273450|NCT01594983|Placebo Comparator|Arm Label: Placebo|Intervention Type: other Intervention Name: other
3273451|NCT01594996||Seroquel XR group|
3273452|NCT01595009|Experimental|Everolimus (RAD001)|Participants received Everolimus 10 mg orally once daily until documented tumor progression, unacceptable toxicity or any other reason.
3273453|NCT01595022|Placebo Comparator|Flexi ring FR01|
3273454|NCT01595022|Placebo Comparator|Flexi ring FR20|
3273455|NCT01595022|Placebo Comparator|Ultra low dose LCS|
3273456|NCT01595035|Experimental|counselling|Patients who receive the Pain booklet and support by telephone
3273457|NCT01595035|No Intervention|Control|Standard care
3273459|NCT01595074||Ancillary-Correlative (laboratory biomarkre analysis)|Archived RNA and DNA samples are analyzed for gene expression, mutations, and variations by RT-qPCR, MassARRAY, molecular inversion probe assay, and microarray assays. Results are then compared with patients' clinical outcomes.
3273460|NCT01595087|Experimental|Osteodex, infusion|Osteodex
3273461|NCT01595126||Patients with Central Nervous System Tumors|
3273462|NCT01595139||NF-1 without evidence of glioma|
3273463|NCT01595139||NF-1 with evidence of glioma|
3273464|NCT01595152|Active Comparator|solifenacin succinate (10 mg OD)|
3273465|NCT01595152|Active Comparator|fesoterodine (8mg OD)|
3273466|NCT01595165|Placebo Comparator|Control|Control group receiving saline instead of ropivacaine
3273467|NCT01595165|Experimental|TAP|TAP group receiving ropivacaine total of 150 mg at TAP under US
3273468|NCT01595191|Active Comparator|Music by Mozart|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
3273469|NCT01595191|Active Comparator|Bach Music|"The sequence by which Bach, Mozart, or no music were administered (over 3 consecutive days) was determined by randomization using random numbers. Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel). The music was played using a music player at a volume of 65-70 dB with attached speakers which were placed at a distance of 30 cm from the infant's ears. According to the American Academy of Pediatrics recommendations (5): the volume did not exceed 75dB and the background noise near the infant's ears was maintained below 45 dB. Music (Mozart or Bach) was initiated 10 minutes prior to the beginning of the metabolic measurements and continued for 30 minutes while energy expenditure (EE) was recorded. In the same manner EE was recorded for each infant with no music therapy."
3273470|NCT01595204|Experimental|Diagnostic Laparoscopy|Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
3273471|NCT01595217|Experimental|MRCP and DWI using 3T MRI|MRCP and DWI using Magnetic resonance imaging（GE Signa,3.0 T )
3273472|NCT01595217|Experimental|MRCP only using 3T MRI|MRCP only using Magnetic resonance imaging（GE Signa,3.0 T )
3273473|NCT01595230|Experimental|Inertervention group_Clips to avoid internal herniation|LRYGB with closure of the defects with simple hernia stapler clips. Aim of this study is to evaluate the benefits and disadvantages of closing the mesenteric defects during gastric bypass in order to avoid internal herniation.
3273474|NCT01595230|No Intervention|Control group|conventional LRYGB without closure of the mesenteric defects
3273475|NCT01595243|No Intervention|control|patient with liver cancer in non-surgical treatment after discharge receive usual care
3273476|NCT01595243|Experimental|patient in experiment|patient in the experimental group will receive seven instances of telephone follow-up or face to face education
3273477|NCT01595256|Experimental|walking group|
3273478|NCT01595256|No Intervention|usual care|
3273479|NCT01595269|Placebo Comparator|Education mode 1 (control)|Education mode 1 (control) is comprised of participants educated using CHR's current traditional face-to-face delivery method, with printed materials and written log journals. These participants will be trained to use the University's web portal if they elect to access internet-based diabetes information. This allows for the tracking of the type and amounts of diabetes information accessed by participants.
3273480|NCT01595269|Active Comparator|Education mode 2 (static interface)|Education mode 2 (static interface) participants will be educated using digitized forms of the traditional materials provided by CHR as well as an electronic log journal (e-journal) where participants will record their diabetes-related outcomes and behavioural information. Education mode 2 will be assessed and approved by CHR.
3273481|NCT01595269|Active Comparator|Education mode 3 (dynamic interface)|Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
3273482|NCT01595295||Hypomethylating Agents|Patients treated with hypomethylating agents
3273483|NCT01595308|Experimental|Pomegranate juice|Pomegranate juice
3273484|NCT01595321|Experimental|SBRT and FOLFIRINOX|The first 6 patients will receive SBRT and FOLFIRINOX only.
3273485|NCT01595321|Experimental|Cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX|The last 12 patients will receive cyclophosphamide, Vaccine, SBRT, and FOLFIRINOX.
3273486|NCT01595334|Active Comparator|Study subjects desiring pregnancy|"Study subjects to be treated with rFSH, rLH throughout controlled ovarian hyperstimulation (COH) in appropriate dosages,considering age, body mass index (BMI), ovarian reserve, etc. and GnRH antagonist, cetrorelix in 0.25 mg/d when needed till the desired follicular maturity and the minimum required number of follicles are achieved.~INTRVENTIONS - Monitoring at regular intervals by transvaginal ultrasound and hormonal studies.Once pregnancy established by beta-human chorionic gonadotropin (hCG) and ultrasound will be supported by intervention of adequate luteal support by estrogen (E) + progesterone (P) for 12 weeks of gestation."
3273487|NCT01595334|Other|Control subjects desiring pregnancy|"Control subjects selected in randomized way,desiring pregnancy will be treated with gonadotrophins, rFSH and rLH in appropriate dosages considering age, BMI, ovarian reserve, etc. after standard downregulation with GnRH agonist, Leuprolide acetate, 1 mg/d under established 'Long Luteal Suppression Protocol' from the previous cycle.~INTERVENTIONS - Monitoring of response to treatment by hormonal study and sonography evaluation at regular intervals during COH till adequate number of mature follicles of minimum 18 mm mean diameter is achieved, to be followed by hCG trigger and ovum pick-up (OPU) and embryo transfer (ET). Chemical pregnancy by beta-hCG would be confirmed 14 days post-ET. Clinical pregnancy would be confirmed by sonography 6 weeks after ET (visibility of yolk sac and fetal heart-beat). Pregnancy support by E+P for 12 weeks would be provided."
3273488|NCT01595347|Active Comparator|Hyper-oxigenated fatty acid|Hyper-oxigenated fatty acid,Equisetum arvense, Hypericum perforatum
3273489|NCT01595347|Experimental|Olive oil's Cream|Cream with 60% extra virgin olive oil.
3273490|NCT01595360|Placebo Comparator|Placebo|Placebo
3273491|NCT01595360|Experimental|TT-173|TT-173
3273492|NCT01595373|Active Comparator|Ghrelin|Ghrelin
3273493|NCT01595373|Placebo Comparator|Placebo|Ringer acetate is used for placebo.
3273494|NCT01595399|Active Comparator|Atropine, fentanyl and succinylcholine|20 mcg/kg atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
3273495|NCT01595399|Placebo Comparator|placebo, fentanyl and succinylcholine|an equivalent volume of normal saline to atropine IV, 3 mcg/kg fentanyl slowly IV and 2 mg/kg succinylcholine IV.
3273496|NCT01595412|Active Comparator|Cohort 2|Cohort 2 (two) will consist of 120 patients with an external rectal prolapse (Oxford Grade V)treated by Laparoscopic Resection Rectopexy (LRR). These patients will be included in the US centers involved in this study and treated by LRR.
3273497|NCT01595412|Active Comparator|Cohort 1|Cohort one will consist of 120 patients with an external rectal prolapse (Oxford Grade V) which will be treated with Laparoscopic Ventral Rectopexy. As this is the standard treatment in the European centers involved in this study these patients will be selected in the participating centers in the Netherlands, Belgium and England.
3273498|NCT01595425|Experimental|D961H Sachet 20 mg|2 way crossover
3273499|NCT01595425|Experimental|D961HHPMC Capsule 20 mg|2 way crossover
3273500|NCT01595451|Active Comparator|Traditional Acupuncture|Acupuncture will be delivered to 12 points traditionally used to treat chronic low back pain.
3273501|NCT01595451|Placebo Comparator|Non-traditional Acupuncture|You will receive non-traditional acupuncture at 12 points for chronic low back pain.
3273502|NCT01595464|Experimental|Mind-Body Skills Groups|
3273503|NCT01595464|No Intervention|Control Group|
3273504|NCT01595477|Experimental|Mind-Body Skills Groups|
3273505|NCT01595477|No Intervention|Control Group|
3273506|NCT01595490|Experimental|Mind-Body Skills Groups|
3273507|NCT01595490|No Intervention|Control Group|
3273510|NCT01595542|Experimental|Intervention|Parents served by experimental school sites received intervention packets including modified vaccine consent form
3273511|NCT01595542|No Intervention|Control|Did not receive intervention materials
3273512|NCT01595555|No Intervention|Wait-list control|Group with no intervention. Only complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3273513|NCT01595555|Experimental|Stress Free Now|Participate in the 8 week online stress management program Stress Free Now. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3273514|NCT01595555|Experimental|Stress Free Now + Social Media|Participate in the 8-week Stress Free Now program and a discussion board that provides peer and moderator support. Complete questionnaires at baseline, week 8 and 12 and activity logs through the first 8 weeks
3273515|NCT01595568|Experimental|Learning to cope with your impulsivity|Cognitive-behavioural intervention targeting impulsive personality
3377352|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Low Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 20 mg three times daily
3273516|NCT01595568|Experimental|Learning to cope with your sensation seeking|Cognitive behavioural intervention designed to help sensation seeking youth manage their need for stimulation and excitement.
3273517|NCT01595568|Experimental|Learning to cope with your anxiety sensitivity|Cognitive behavioural intervention teaching anxiety sensitive youth to manager their sensitivity to threat and anxiety.
3273518|NCT01595568|Experimental|Learning to manage your negative thinking|Cognitive behavioural intervention targeting pessimistic and negative thinking in hopeless youth
3273519|NCT01595581|Experimental|Testosterone, standard-of-care rehabilitation|
3273520|NCT01595581|Placebo Comparator|Standard-of-care rehabilitation, Saline|
3273521|NCT01595594|Active Comparator|Systemic Doxycycline|
3273522|NCT01595594|Experimental|aPDT+ Placebo|
3273523|NCT01595607|Active Comparator|Typical American Diet|Participants will receive a typical American diet for 6 weeks.
3273524|NCT01595607|Experimental|Avocado Diet|Participants will receive a modified typical American diet in which avocado is substituted for foods that contain moderate and high amounts of saturated fat to allow the inclusion of avocado.
3273525|NCT01595620|Active Comparator|THC 0.01 mg/kg|
3273526|NCT01595620|Placebo Comparator|Placebo|
3273527|NCT01595620|Active Comparator|THC 0.03 mg/kg|
3273528|NCT01595633|Active Comparator|Adefovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Adefovir 10mg
3273529|NCT01595633|Experimental|Tenofovir, nucleoside analogues|Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg) + Tenofovir 300mg
3273530|NCT01595659|Placebo Comparator|no alcohol and passenger|Blood alcohol concentration (BAC) = 0.00% and risk accepting or averse passenger
3273531|NCT01595659|Experimental|low alcohol dose and passenger|BAC = 0.02% and risk accepting or averse passenger
3273532|NCT01595659|Experimental|moderate alcohol dose and passenger|BAC = 0.05% and risk accepting or averse passenger
3273533|NCT01595672|Active Comparator|EHVCVVH group|Patients receive conventional treatments recommended by guidelines with adjunctive early high-volume continuous veno-venous hemofiltration (EHVCVVH).
3273534|NCT01595672|Active Comparator|Control group|Patients receive conventional treatments recommended by guidelines only.
3273535|NCT01595685|Experimental|Telbivudine|Telbivudine 600 mg Daily Oral
3273536|NCT01595685|Active Comparator|Entecavir|Entecavir 0.5 mg Daily Oral
3273537|NCT01595698|Sham Comparator|Control|
3273538|NCT01595698|Experimental|Physical Exercise|
3273539|NCT01595711||Thoracotomized patients|
3273540|NCT01595724||Group 1|
3273541|NCT01595737|Experimental|Levosimendan|
3273542|NCT01595737|Placebo Comparator|Placebo|
3273543|NCT01595750|Placebo Comparator|Placebo|
3273544|NCT01595750|Active Comparator|Roflumilast|Roflumilast 500 mcg
3273545|NCT01595763||Deep Vein Thromobosis signs or symptoms|
3273546|NCT01595776|Experimental|single arm: autologous EPCs|
3273547|NCT01595789|Placebo Comparator|Placebo + metformin|
3273548|NCT01595789|Active Comparator|Liraglutide + metformin|
3273549|NCT01595802|Experimental|Subjects without Vasospasm|Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. Intervention with Nautilus NeuroWave recording to obtain baseline status.
3273550|NCT01595802|Experimental|Subjects with Vasospasm|"Transcranial Doppler (TCD) will be used to evaluate if subject has a vasospasm. If confirmed by TCD, the degree of vasospasm will also be evaluated and classified as mild, moderate and severe Vasospasm.~Intervention with Nautilus NeuroWave recording to obtain recordings with mild, moderate and severe Vasospasm."
3273551|NCT01595815|Active Comparator|Conventional ICSI|The couple showed complete fertilization failure after ICSI.
3273552|NCT01595815|Active Comparator|Convention ICSI|The couple showed a low fertilization rates after ICSI.
3273553|NCT01595828|Experimental|Pitavastatin 4mg daily|4 mg tablets of pitavastatin by oral route for a period of 6 months
3273554|NCT01595841|Experimental|Sirolimus|Participants will take sirolimus for 3 days prior to procedure and 30 days post procedure.
3273555|NCT01595841|No Intervention|Not taking Sirolimus|Participants will not change the standard of care.
3273556|NCT01595867|Placebo Comparator|Treatment A|Placebo
3273557|NCT01595867|Experimental|Treatment B|EMBEDA 30 mg crushed
3273558|NCT01595867|Active Comparator|Treatment C|Morphine Sulfate Controlled Release 30 mg crushed
3273559|NCT01595880|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg
3273560|NCT01595880|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 500mg
3273561|NCT01595893|Experimental|Vitamin D3|
3273562|NCT01595893|Placebo Comparator|Placebo|
3273563|NCT01595906|Experimental|The experiment subjects|"The subjects will undergo:~6 acclimatization days carried out by a standard protocol including a daily 2 hour effort performed in a climatic chamber, during which the subjects walk on a treadmill at 5km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH). Core (rectal) and skin temperatures and heart rate will be monitored continuously.~Three consecutive days including 3 scenarios:~Without a helmet b.With a helmet c.With a ventilated helmet During the experiment days the subjects will be exposed to the following protocol : A 5 minute sitting, performing cognitive tests on a computer for 15 min, 120 min walking on a treadmill at 5km/h on a 2% incline, at the end of the effort the same cognitive tests will be repeated for extra 15 min, 155 min in total."
3273564|NCT01595919|Experimental|1% Milk|
3273565|NCT01595919|Experimental|Regular Cola|
3273566|NCT01595919|Experimental|Diet cola|
3273567|NCT01595919|Experimental|Orange juice|
3273568|NCT01595919|Placebo Comparator|Water|
3273569|NCT01595932|Placebo Comparator|placebo|
3273570|NCT01595932|Experimental|α-galactosidase|
3273571|NCT01595945|Other|Gastric bypass|Subjects with planned gastric bypass surgery are followed-up in regard of resting metabolic rate.
3273572|NCT01595945|Other|Caloric restriction|Caloric restriction calculated by an online weight management program (based on subject's starting weight, start BMI, age, target weight and time span). Subjects are followed-up in regard to resting metabolic rate.
3273573|NCT01595958|Experimental|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
3273574|NCT01595958|Active Comparator|Control|usual care of cardiac arrest
3273575|NCT01595971|Experimental|continuing education|RESPIRANET is a multifaceted intervention directed at professionals of the Family Health Teams in the inner cities.Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
3273576|NCT01595971|Placebo Comparator|Usual Care|usual care
3273577|NCT01595984|Active Comparator|Cyclosporin + Mycophenolate mofetil|
3273578|NCT01595984|Experimental|Everolimus + mycophenolate mofetil|
3273579|NCT01595997|Placebo Comparator|Placebo|
3273580|NCT01595997|Experimental|DLX105|
3273581|NCT01596010|Experimental|New formulation|
3273582|NCT01596010|Active Comparator|Old formulation|
3273583|NCT01596023|Experimental|NIOV Ventilator|Breathe NIOV Ventilator under various volume augmentation settings
3273584|NCT01596036|Experimental|Early Appointment|Patients will receive an early appointment (within 10 days) from the time of their anticipated hospital discharge
3273585|NCT01596036|Placebo Comparator|Standard Referral|Patients will receive an appointment to cardiac rehabilitation at 5 weeks from the date of their anticipated hospital discharge. A routine referral to cardiac rehabilitation will also occur in parallel. Consequently, it is possible that some patients will attend cardiac rehabilitation earlier than their assigned 5 week appointment.
3273586|NCT01596049||Self-fixating Mesh|patients attributed to that arm, undergoing surgery of open inguinal unilateral hernia repair, using Self-fixating Mesh which is acceptable in the literature.
3273587|NCT01596075|Experimental|Oral Cannabidiol|Patients undergoing allogeneic SCT will receive standard GVHD prophylaxis consisting of a calcineurin inhibitor and methotrexate or mycophenolate mofetil. Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
3273588|NCT01596101||acute burns|
3273589|NCT01596101||rehab patients|
3273590|NCT01596114|Experimental|Stop treatment|TKI treatment will be stopped in CML patients with very deep molecular responses for at least one year and at least 3 years TKI treatment
3273591|NCT01596140|Experimental|Vemurafenib + Oral Everolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
3273592|NCT01596140|Experimental|Vemurafenib + Intravenous Temsirolimus|Vemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
3273593|NCT01596153|Placebo Comparator|Placebo|BID
3273594|NCT01596153|Active Comparator|Go Live Rx Probiotic|BID
3273595|NCT01596166|Experimental|Metoclopramide, Ketorolac|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Ketorolac 0.5 mg/kg (max 30 mg) IV"
3273596|NCT01596166|Placebo Comparator|Metoclopramide, Placebo|"10 mL/kg IV 0.9% sodium chloride~Metoclopramide 0.2 mg/kg (max 10 mg) IV~Placebo (normal saline)"
3273597|NCT01596179|Experimental|Interactive navigational support|Patients on the intervention arm are provided with a netbook computer and internet access with ongoing interaction with a nurse and a social worker navigators for a one year period.
3273598|NCT01596179|Active Comparator|control arm|Patients on the control arm are provided with a netbook computer, internet access and general website information but no interactive navigational support for a one year period.
3273599|NCT01596192||Patients with acute GVHD|Patients after allogeneic hematopoietic cell transplantation who have developed acute GVHD
3273600|NCT01596205|Experimental|Robot intervention|Participants were given baseline assessments and randomly assigned into 3 groups; 24 with robot assisted cognitive training group (Robot intervention group), 24 with experienced behavioral therapist group (Conventional intervention group), and 37 without cognitive training (Control group).It was explained that there was a waiting list, therefore, participants in control group had an opportunity to participate in cognitive training program after a delay of 12 weeks for the intervention.
3273601|NCT01596205|Active Comparator|Conventional intervention|conventional cognitive training group - pen and pencil with experienced behavioral therapists
3273602|NCT01596205|No Intervention|Control group|
3273603|NCT01596218|Experimental|Treatment Arm|Treatment Arm for all participants - Brentuximab vedotin
3273604|NCT01596244|Experimental|Microclinics training|Diabetic, pre-diabetic, or those with family members who are diabetic/pre-diabetic who participated in a 4 month long intervention with a focus on disease management, health behavior change, and social network supports in order to improve chronic disease risk factors.
3273605|NCT01596257|Active Comparator|bulk SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
3273606|NCT01596257|Experimental|fractionated SCT|Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months
3273607|NCT01596270|Experimental|Once daily dosing|escalating doses, once daily dosing every day, no eating for 2 hours prior and 1 hour after dose
3273608|NCT01596270|Experimental|Twice daily dosing|escalating doses, twice daily dosing every day, no eating for 2 hours prior and 1 hour after dose
3273609|NCT01596296|Active Comparator|Transcervical foley catheter|
3273610|NCT01596296|Active Comparator|Dinoprostone|
3273611|NCT01596309|Placebo Comparator|control group, placebo|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added
3273612|NCT01596309|Experimental|Intervention group, cocoa extract|This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
3273613|NCT01596322||UARTO|
3273614|NCT01596348||RA patients|Patients with Rheumatoid Arthritis
3273615|NCT01596387|Experimental|Propofol|20 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery.
3273616|NCT01596400|Experimental|Sancuso Arm|
3273617|NCT01596400|Active Comparator|IV Granisetron Arm|IV
3273618|NCT01596413|Experimental|Sancuso Arm|Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
3273619|NCT01596413|Active Comparator|IV Granisetron|"Aqueous solution for IV administration~1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)"
3273620|NCT01596426|Experimental|Sancuso Arm|patch
3273621|NCT01596426|Active Comparator|IV granisetron|IV
3273622|NCT01596465|Active Comparator|Control|Control arm
3273623|NCT01596465|Active Comparator|Intervention|Intervention arm
3273624|NCT01596478|Active Comparator|Treatment As Usual|The standard treatment usually provided at the clinic.
3273625|NCT01596478|Active Comparator|Cognitive Motivational Behavior Therapy|An approach that addresses motivation to change gambling and behavioral patterns related to gambling.
3273626|NCT01596478|Active Comparator|12-week wait list|Participant will start treatment 12 weeks from day of consent.
3273627|NCT01596491||patients with peripheral nerve injury|10 patients with neuropathic pain, because of peripheral nerve injury will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
3273628|NCT01596491||patients with postherpetic neuralgia|10 patients with neuropathic pain, because of postherpetic neuralgia will obtain a baseline-QST and after capsaicin-application a QST 2, 4, 6, 8 and every 2 weeks until re-occurrence of pain and/or recovery of the capsaicin-induced sensory deficits
3273629|NCT01596517|Experimental|Korean CHC|Two CHC patient groups. One is CHC patients who are treated with combination of peginterferon alfa-2a and ribavirin in a prospective, multicenter, industry-sponsored, open-label, uncontrolled, community-based clinical trial (Pegasys Expanded Access Program) conducted at 6 tertiary referral centers in Korea between 2003 and 2004. Another is a cohort of hepatitis C patients who were treated in a single tertiary referral hospital (Asan Medical Center, Seoul, Korea) between 2004 and 2008.
3273630|NCT01596530|Active Comparator|AZD8931|AZD8931
3273631|NCT01596530|Placebo Comparator|Placebo|Placebo
3273632|NCT01596543|Experimental|sleep deprivation|The research contains only one arm. The subjects will be tested with no sleep deprivation (which will be used as a control measurement) and with partial and complete sleep deprivation.
3273633|NCT01596556|Experimental|smokers|This arm consists of smokers.
3273634|NCT01596556|Active Comparator|non-smokers|non-smoking participants in the study
3273635|NCT01596569|Active Comparator|Active TMS and Cognitive Intervention|"Active TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
3273636|NCT01596569|Sham Comparator|Sham TMS and Cognitive Intervention:|"Sham TMS and Cognitive Intervention:~Repetitive Transcranial Magnetic Stimulation (rTMS) and Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory)."
3273637|NCT01596608|Experimental|Magnetic Seizure Therapy|
3377353|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 40 mg three times daily
3377354|NCT04545008|Experimental|Low Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 600 mg three times daily Famotidine 80 mg three times daily
3377355|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and Medium Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 40 mg three times daily
3377356|NCT04545008|Experimental|Medium Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,200 mg three times daily Famotidine 80 mg three times daily
3377357|NCT04545008|Experimental|High Dose N-Acetyl Cysteine and High Dose Famotidine|N-Acetyl Cysteine 1,800 mg three times daily Famotidine 80 mg three times daily
3377358|NCT04543838|Experimental|EEG & SSEP monitoring|Intervention will include standard of care pain management during the postoperative period. Participants in this arm will receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP). EEG will be used to manage blood pressure.
3273638|NCT01596634|Experimental|Supportive care (bovine lactoferrin)|Patients receive bovine lactoferrin PO (rinse or tablet) TID for 1 month. Treatment continues in the absence of unacceptable toxicity.
3273639|NCT01596647|Experimental|TKI258 (dovitinib)|dovitinib, 5 days on / 2 days off dose schedule
3377359|NCT04543838|Active Comparator|Standard of Care|Control will include standard of care pain management during the postoperative period. Participants in this arm will not receive an Electroencephalogram (EEG) and Somatosensory evoked potentials (SSEP).
3377361|NCT04536792|Experimental|Part 1: Single Ascending Dose (SAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once on Day 1. AG-946 will be given under fasted or fed conditions.
3377362|NCT04536792|Experimental|Part 2: Multiple Ascending Dose (MAD) Phase|Participants will receive a range of doses of AG-946 or placebo, orally, once daily (QD) for 14 days or using an alternative dosing regimen for 28 days under fasted conditions.
3377363|NCT04536792|Experimental|Part 3: Sickle Cell Disease (SCD) Phase|Participants will receive a range of selected ascending doses of AG-946, orally, QD or using an alternative dosing regimen for 28 days.
3273640|NCT01596660|Experimental|Bupivacaina|20 cc of bupivacaine 0.5% in 20 cc de saline solution and it is infiltrated 20 cc each side.
3377366|NCT04534738|Experimental|Mediterranean Diet|Participants in the Mediterranean Diet arm are asked to follow a Mediterranean Diet for 8 weeks. The diet is ad libitum. A combination of fresh, frozen, and shelf-stable meals are provided for the first 4 weeks. Also during the first 4 weeks, participants receive an education session to discuss how to effectively implement a Mediterranean Diet into their daily routine.
3377367|NCT04534738|No Intervention|Usual care|Participants in the usual care are will complete all the same study assessments as those in the intervention group. They will not receive any specific dietary advice, but they will be permitted to seek dietary advice outside the study. Data from this group are indispensable in understanding the nutritional habits and preferences of patients undergoing chemotherapy, and these data will be used to optimize nutritional interventions in future studies. At the end of the 8-week intervention, the participants in the usual care group will be provided the intervention materials gratis, including one-week of Mediterranean Diet food and education materials.
3377368|NCT04534400||Patients with SARS-CoV-2 infection|
3377369|NCT04534400||Patients with Postoperative hypoxemic respiratory failure|
3377370|NCT04532346|Experimental|Hydroxychloroquine|Hydroxychloroquine in a dose of 10 mg/kg*d, p.o., bid for 12 months. The maximum daily dose is 400mg.
3273641|NCT01596660|Placebo Comparator|saline solution|20 cc of saline solution 0.9% to infiltrate each side.
3377371|NCT04532346|No Intervention|control|control group which do not take hydroxychloroquine for treatment.
3377372|NCT04527874|Experimental|Intervention|Clusters in the intervention arm receive the VITAL intervention (see intervention)
3377373|NCT04527874|No Intervention|Control|Clusters in the control arm continue standard of care.
3377380|NCT04526002|Experimental|Concurrent TBS/fNIRS with iTBS and followed by cTBS after 1h|self-explanatory, see Arm Title
3377381|NCT04525885|Experimental|Gefapixant 45 mg twice daily (BID)|Participants will receive a gefapixant 45 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks).
3273642|NCT01596673|Experimental|BCAD Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet)."
3377382|NCT04525885|Experimental|Gefapixant 15 mg BID|Participants will receive a gefapixant 15 mg tablet BID during the main study period (24 weeks) and also during the extension period (28 weeks). This arm is not included in protocol amendment 5 or later.
3273643|NCT01596673|Experimental|CDBA Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet (matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet."
3377383|NCT04525885|Placebo Comparator|Placebo|Participants will receive a matching placebo tablet BID during the 24-week main study period and during the 28-week extension period.
3377384|NCT04524351|Active Comparator|Posiphen, 80mg|Posiphen Oral Capsule, 80mg, taken once per day for 25±2 days.
3377385|NCT04524351|Active Comparator|Posiphen, 40mg|Posiphen Oral Capsule, 40mg, taken once per day for 25±2 days.
3377386|NCT04524351|Active Comparator|Posiphen, 20mg|Posiphen Oral Capsule, 20mg, taken once per day for 25±2 days.
3377387|NCT04524351|Active Comparator|Posiphen, 10mg|Posiphen Oral Capsule, 10mg, taken once per day for 25±2 days.
3377388|NCT04524351|Active Comparator|Posiphen, 5mg|Posiphen Oral Capsule, 5mg, taken once per day for 25±2 days.
3377389|NCT04524351|Placebo Comparator|Placebo|Placebo Oral Capsule, taken once per day for 25±2 days.
3377390|NCT04522141|Experimental|Self-control treatment group|The self-control treatment group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit as well as a short interventional input targeting self-control.
3377391|NCT04522141|Active Comparator|Control group|The control group will wear a Fitbit step counter across 8 weeks. In addition, they will use the MindHike smartphone application across 8 weeks. Each day, the app sends the a reminder to wear the Fitbit.
3377392|NCT04519580||Patients with suspected polymyalgia rheumatica|The study investigates patients with suspected polymyalgia rheumatica (PMR). For Patients where the PMR diagnosis is dismissed, the study terminates after the first visit. Patients diagnosed with PMR will be treated with prednisolone with taper corresponding to usual care. At baseline all patients will have medical history taken, physical examination, blood drawn, Synacthen® test, PET/CT, and ultrasound performed. Physical examination, PET/CT, and ultrasound are repeated after 8 weeks of prednisolone treatment while the patients iare on 10 mg prednisolone as well as after prednisolone taper two weeks later, where Synachten® test is also performed. After 10 weeks prednisolone is restarted at 10 mg and the patient is followed by their general practitioner or at the department of rheumatology, where prednisolone is tapered according to usual care. Patients are invited to a follow up visit after one year.
3377393|NCT04514562|Other|Intervention|NeVa Stent Retrievers
3377394|NCT04513925|Experimental|Atezolizumab + Tiragolumab|Participants will receive atezolizumab administered intravenously (IV) on Day 1 of each 28-day cycle followed by tiragolumab administered IV on Day 1 of each 28-day cycle for a maximum of 13 cycles.
3377395|NCT04513925|Active Comparator|Durvalumab|Participants will receive durvalumab administered IV during each 28-day cycle for a maximum of 13 cycles.
3377396|NCT04512066|Experimental|150 mg Once Daily (QD) RO6889450|Participants will receive 150 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
3377397|NCT04512066|Experimental|45 mg QD RO6889450|Participants will receive 45 mg of RO6889450 QD for 4 weeks or 12 weeks or 48 weeks.
3377398|NCT04512066|Placebo Comparator|Placebo|Participants will receive oral placebo QD for 4 weeks. Participants from this arm that continue to the extension period will be randomized to either 45 mg or 150 mg QD of RO6889450 for up to an additional 8 weeks or additional 44 weeks (optional 36-Week Safety Extension Phase).
3377399|NCT04512066|Active Comparator|4 mg QD Risperidone|Participants will receive 4 mg of risperidone QD for 4 weeks or 12 weeks or 48 weeks.
3377400|NCT04506905|Experimental|Part 1 (Panel A) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg once daily (QD), orally, over a course of 7-day treatment.
3377401|NCT04506905|Experimental|Part 1 (Panel B) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated up to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panel.
3377402|NCT04506905|Experimental|Part 1 (Panel C) MK-8189|Young adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over a course of 7-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
3377403|NCT04506905|Experimental|Part 2 (Panel D) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
3377404|NCT04506905|Experimental|Part 2 (Panel E) MK-8189|Elderly adult participants with schizophrenia receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
3377405|NCT04506905|Experimental|Part 2 (Panel F) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 8 mg to 24 mg QD, orally, over the course of a 13-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
3377406|NCT04506905|Experimental|Part 2 (Panel G) MK-8189|Healthy elderly adult participants receive MK-8189 titrated from 16 mg to 24 mg QD, orally, over the course of 10-day treatment period with starting doses based on safety and tolerability of previous starting dose in previous panels.
3377407|NCT04506905|Placebo Comparator|Part 1 (Panels A, B, C) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
3377408|NCT04506905|Placebo Comparator|Part 2 (Panels D, E, F, G) Placebo|Oral tablets of dose-matched placebo to total daily dose of MK-8189.
3273644|NCT01596673|Experimental|DACB Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
3273645|NCT01596673|Experimental|ABDC Treatment Group|"Subjects in this group will receive study drug in the following sequence:~Treatment A - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B - 1 intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45 mg reconstituted in 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet.~Treatment D - 1 intact placebo tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet(matching the 45-mg hydrocodone bitartrate extended-release tablet).~Treatment C - 1 intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL of a noncarbonated flavored beverage, and 1 crushed placebo tablet."
3273646|NCT01596686|Active Comparator|sodium picosulphate and magnesium citrate (Picoprep)|
3273647|NCT01596686|Active Comparator|polyethylene glycol (Fortrans)|
3273648|NCT01596712|Experimental|QGE031 Dose 1|QGE031 Dose 1: subcutaneous injection, single dose
3273649|NCT01596712|Experimental|QGE031 Dose 2|QGE031 Dose 2: subcutaneous injection, single dose
3273650|NCT01596712|Experimental|QGE031 Dose 3|QGE031 Dose 3: subcutaneous injection, single dose
3273651|NCT01596712|Placebo Comparator|Placebo|Placebo to QGE031 : subcutaneous injection, single dose
3273652|NCT01596725|Experimental|Group A|
3273653|NCT01596725|Experimental|Group B|
3273654|NCT01596725|Experimental|Group C|
3273655|NCT01596725|Experimental|Group D|
3273656|NCT01596725|Experimental|Group E|
3273657|NCT01596725|Experimental|Group F|
3273658|NCT01596738|Experimental|Tranexamic Acid group|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
3273659|NCT01596738|Placebo Comparator|Placebo group|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
3273660|NCT01596764|Placebo Comparator|Treatment A|Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
3273661|NCT01596764|Placebo Comparator|Treatment B|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under loperamide-induced obstipation condition.
3273662|NCT01596764|Active Comparator|Treatment C|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), NLX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose naloxone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of naloxone.
3273663|NCT01596764|Active Comparator|Treatment D|Administration of LOP (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), MNTX-ER (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To describe the effects of repeated-dose methylnaltrexone in preventing loperamide-induced delay of WGT, OCT and CTT and measure pharmacokinetics of methylnaltrexone.
3273664|NCT01596777|Placebo Comparator|Treatment A|Administration of LOP placebo (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under placebo condition.
3273665|NCT01596777|Placebo Comparator|Treatment B|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX placebo (0 h). To asses the oro-cecal and whole-gut transit time under loperamide-induced obstipation condition.
3273666|NCT01596777|Active Comparator|Treatment C|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX 12 mg sc. (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after subcutaneous administration.
3273667|NCT01596777|Active Comparator|Treatment D|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX IR (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of immediate release capsule.
3273668|NCT01596777|Active Comparator|Treatment E|Administration of LOP 4 mg (-24 h, -12 h, -1 h, 12 h), Colon Transit (-24 h, -12 h, -1 h), SSP (+ 2 h) and MNTX ER (0 h). To assess the effects of methylnaltrexone in preventing loperamide-induced delay of the oro-cecal and whole-gut transit time and to measure pharmacokinetics of methylnaltrexone after oral administration of extended release capsule.
3273669|NCT01596790|Other|CTC assay|Detection & characterization of viable CTC in the peripheral blood.
3273670|NCT01596803|Active Comparator|vitamins minerals|VitE 400/d, vitC 500mg/d, Se 200µg/d (selenomethionine), Zn 25 mg/d gluconate Venous blood samples( analysis oxidative stress inflammatory markers) Needle biopsy of the vastus lateralis muscle (analysis oxidative stress inflammatory markers)
3273671|NCT01596803|Placebo Comparator|Placebo|Supplementation 17 weeks placebo venous blood samples (analysis of oxidative stress inflammatory markers) needle biopsy of the vastus lateralis muscle
3273672|NCT01596816|Experimental|Boost by CyberKnife|
3273673|NCT01596816|Experimental|Boost by linear accelerator|
3273674|NCT01596829|Active Comparator|Probiotic|Probiotic consumption during and after course of antibiotic
3273675|NCT01596829|Placebo Comparator|Placebo|Placebo consumed during and after course of antibiotic
3273676|NCT01596855|Experimental|FG-4592|Active Drug
3273677|NCT01596855|Active Comparator|Epoetin alfa|Standard of care
3273678|NCT01596868|Active Comparator|Gemcitabine and Cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT..
3273679|NCT01596868|Active Comparator|docetaxel and cisplatin|Drug: Docetaxel and cisplatin TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
3273680|NCT01596881||Multiple Sclerosis Patients|Physician-confirmed diagnosis of multiple sclerosis. Any subtype is acceptable. For example, relapsing-remitting, secondary progressive, primary progressive
3273681|NCT01596881||Healthy Normal Subjects|Volunteers with healthy eyes.
3273682|NCT01596894|Experimental|Azithromycin + Metronidazole|Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
3273683|NCT01596894|Active Comparator|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
3273684|NCT01596907|Active Comparator|Ephedrine and caffiene|"Drug treatment:~ephedrine sulfate 25-mg with caffeine 200-mg per capsule to be given three times per day 4 hours apart for 6 months after gastric bypass surgery. Weight loss rate, resting energy expenditure, fat free mass will be measured during the treatment."
3273685|NCT01596907|Placebo Comparator|placebo|one placebo capsule will be taken three times per day 4 hours apart, identical to the instructions for the active drug for approximately 6 months following gastric bypass surgery. Weight loss rate, resting energy expenditure and fat free mass will be measured during the treatment.
3273686|NCT01596920|Active Comparator|Grafix®|
3273687|NCT01596920|Placebo Comparator|Control (non-adherent dressing)|
3273688|NCT01596933|Experimental|omega-3 fatty acid supplementation|omega-3 fatty acid supplementation (echium oil)
3273689|NCT01596933|Placebo Comparator|standard nutritional support|sunflower oil supplementation
3273690|NCT01596946|Active Comparator|Contact tracing mode test at clinic|Conventional mode of contact tracing where the partners were asked by either the index patient or demanded by the counsellor to attend a clinic for C. trachomatis testing. The date of testing for chlamydia of the study subject i e a sexual partner to a chlamydia infected index patient was noted. Those partners being C trachomatis positive were referred to the STD-clinic for contact tracing and following the same study arm a the index patient.
3273691|NCT01596946|Experimental|Self-sampling at home|The intervention: Self-sampling of sexual partners to infected index patient for chlamydia by urine test or vaginal sampling at home. They sent the kit tube to a microbiological laboratorium for analysis. The test kit was sent by post by the counsellor at the STD-clinic or distributed via the index patient. The partner in this arm was informed about the test result from the STD-clinic and those tested C trachomatis positive were given an appointment for treating and contact tracing as soon as possible. Their partners were not randomised but following the same mode. The days from the counselling conversation with the index patient to the date of testing was measured and compared with partners tested following arm 1 mode.
3273692|NCT01596959|Active Comparator|ECI CONTACT-ACTIVE|Irrigated Radiofrequency ablation performed using the ECI contact data
3273693|NCT01596959|Placebo Comparator|ECI CONTACT-INACTIVE|irrigated RF ablation performed to the right atrium without the use of ECI contact data
3273694|NCT01596985|Experimental|Ablation using the PlasmaJet system|"Origin of cyst invagination is identified after lysis of adhesions between ovary and adjacent broad ligament, leading to characteristic chocolate fluid evacuation. Surgeon then attempts to turn cyst completely inside out via original invagination site of diameter averaging 1 to 2cm. Ablation of cyst's inner surface is performed using the PlasmaJet system in coagulation mode set at 40, at distance averaging 5mm from tip of handpiece, and with exposure time limited to 1 to 2s on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and corresponding peritoneal implants on adjacent broad ligament. When cyst reversion is not feasible, surgeon progressively exposes cyst interior to guide plasma beam at an angle perpendicular to the inner surface."
3273695|NCT01596985|Active Comparator|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
3273696|NCT01596998|Active Comparator|Levobupivacaine without epinephrine|
3273697|NCT01596998|Experimental|Levobupivacaine with epinephrine|
3273698|NCT01597011||Fibrin sealant group|Patients who have undergone laparoscopic inguinal hernia repair with fibrin sealant for mesh fixation
3273699|NCT01597011||Tissue-penetrating fixation group|Patients who have undergone laparoscopic inguinal hernia repair with the use of tacks, staples or sutures for mesh fixation
3273700|NCT01597024|Experimental|Phase 1: Breakfast Study|
3273701|NCT01597024|Experimental|Phase 2: fMRI Study|
3273702|NCT01597037|Active Comparator|High complexity, high feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
3273703|NCT01597037|Active Comparator|High complexity, low feedback|Scripts are one grade level higher than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
3273704|NCT01597037|Active Comparator|Low complexity, high feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is an opportunity for the participant to listen to his/her production and assess performance.
3273705|NCT01597037|Active Comparator|Low complexity, low feedback|Scripts are one grade level lower than the typical script that would be provided for the severity of aphasia; there is no opportunity for the participant to listen to his/her production and assess performance.
3273706|NCT01597063||low risk pregnancies|
3273707|NCT01597076|Experimental|60-240 mL/day|60 -240 mL/day dose group
3273708|NCT01597102||Liver transplantation|Patients with liver failure and liver transplantation
3273709|NCT01597115|Active Comparator|Duplex|Patients in this group will be examed by duplex ultrasonography at 2 and 4 weeks after surgery
3273710|NCT01597115|No Intervention|physical exam|According to the K/DOQI guideline, patients will be examed by vascular access surgeon at 2 and 4 weeks after surgery
3273711|NCT01597154|Experimental|Lifestyle counselling|Exercise, nutrition and self-efficacy based lifestyle training in a peer mentoring setting
3273712|NCT01597154|No Intervention|Control|Youth randomized to the control group will receive standard care for the first 16 weeks followed by 16 weeks of intervention
3273713|NCT01597167|Experimental|Magnesium sulfate crossover|IV infusion of magnesium sulfate followed by 5-day washout period and crossover to 5% dextrose (placebo)
3273714|NCT01597167|Placebo Comparator|Placebo crossover|IV infusion of 5% dextrose with 5 day washout and crossover to magnesium sulfate
3273715|NCT01597206|Experimental|Removable partial denture Group|Patients with a reduced posterior dental arch will be randomized into one of 2 Groups Group A will receive a removable partial denture prosthesis
3273716|NCT01597206|Active Comparator|Reduced Posterior Dental Arch Group|Patients with a reduced posterior dental arch and not receiving any Intervention will be compared to the removable partial denture group
3273717|NCT01597219|Experimental|Reduced intensity haploidentical transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
3273718|NCT01597219|Experimental|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
3273719|NCT01597232|Experimental|Transfusion trigger based on WCPTS|Determination of whether a patient need red blood cells transfusion or which hemoglobin level should be maintained is based on WCPTS.
3273720|NCT01597232|Active Comparator|Hemoglobin level 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively.
3273721|NCT01597232|Active Comparator|Transfusion trigger based on experience|Determination of whether a patient need red blood cell transfusion or which hemoglobin level should be maintained is base on the physician's experience.
3273722|NCT01597297|Experimental|Fampridine-PR|Prolonged-Release Fampridine (Fampridine-PR) 10 mg twice daily (every 12 hours) for up to 24 weeks.
3273723|NCT01597297|Placebo Comparator|Placebo|Matched placebo twice daily (every 12 hours) for up to 24 weeks.
3273724|NCT01597310|Experimental|Warfarin|25 mg Warfarin, Treatment Period 1 & Treatment Period 2
3273725|NCT01597310|Experimental|Dexpramipexole|150 mg BID Treatment Period 2
3273726|NCT01597323||Treatment Group|Healthy Male of Female between ages 35 and 60 with presence of mild to moderate facial photodamage (sun damage) and presence of mild to moderate facial wrinkling
3273727|NCT01597336|Active Comparator|Saline only flush of abscess|Saline alone used to flush abscess
3273728|NCT01597336|Experimental|Saline plus tPA flush of abscess|Saline plus tPA used for abscess flush
3273729|NCT01597349|Experimental|FP01 High dose|
3273730|NCT01597349|Experimental|FP01 Low dose|
3273731|NCT01597349|Placebo Comparator|Placebo|
3273732|NCT01597362|Other|Veress needle technique|
3273733|NCT01597362|Other|Direct trocar technique|
3273734|NCT01597362|Other|Open technique|
3273735|NCT01597401|Experimental|Aes-103 300 mg to 1000 mg (Group A)|Group A will consist of six subjects receiving a single dose of either a low dose of Aes-103 (300 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (1,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
3273736|NCT01597401|Experimental|Aes-103 2000 mg to 4000 mg (Group B)|Group B will consist of six subjects receiving an initial dose of either Aes 103 (2,000 mg) or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second, higher dose of Aes-103 (4,000 mg), and subjects initially randomized to placebo will receive a second dose of placebo without food.
3273737|NCT01597401|Experimental|Top Dose Expansion (Group C)|Once the top dose (i.e., highest tolerated) of Aes-103 has been determined, the size of this group will be expanded with an additional six subjects (Group C) for a total of 12 at that dose, distributed so that six subjects receiving hydroxyurea (HU) and six subjects not receiving HU (for the past 6 months) will receive study drug (five receiving Aes-103 and one receiving placebo in each of the HU and non-HU treated cohorts). This total of 12 subjects includes the initial six subjects who received the highest dose in the study plus six Group C subjects. These subjects will receive a single dose of the top dose of Aes-103 or placebo without food. After a minimum of a 1- to 2-week washout period and evaluation of blinded safety data, subjects initially randomized to Aes-103 will receive a second dose of the top dose of Aes-103 and subjects initially randomized to placebo will receive a second dose of placebo; all subjects will be administered a pre-dose, high fat, high protein meal.
3273738|NCT01597414|Active Comparator|Pertuzumab + trastuzumab (PH)|Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1
3273739|NCT01597414|Experimental|PH + metronomic chemotherapy (PHM)|Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1
3273740|NCT01597427|Sham Comparator|Clonidine|Administration of 2 μg/kg of intravenous clonidine.
3273741|NCT01597427|Placebo Comparator|Placebo|Injection of placebo solution.
3273742|NCT01597453|Other|Lifestyle counseling|There are no different arms, NOR-SYS is an observational study
3273743|NCT01597466|Experimental|Epidrum|Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
3273744|NCT01597466|Active Comparator|Loss of resistance technique|
3273745|NCT01597518|Experimental|Riluzole|
3273746|NCT01597518|Placebo Comparator|Placebo|
3273747|NCT01597531|Active Comparator|Liraglutide only|
3273748|NCT01597531|Active Comparator|Orlistat only|
3273749|NCT01597531|Active Comparator|Liraglutide + Orlistat|
3273750|NCT01597544|No Intervention|CISC instruction post-operatively|For those patients that are randomized to CISC instruction before surgery, instruction will begin on post-operative day one. One of the nurses from the hospital gynecology unit will teach and supervise the patients until they feel comfortable with the technique or until catheterization is no longer required (e.g. when the patient passes her voiding trial on two separate occasions). This is the protocol currently in use at our institution.
3273751|NCT01597544|Active Comparator|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
3273752|NCT01597570|Experimental|FASTSEAL® Bioabsorbable VCD|Fastseal® Bioabsorbable Vascular Access Closure System
3273753|NCT01597570|Active Comparator|Perclose® ProGlide SMC System|Perclose® ProGlide Suture-Mediated Closure System
3273754|NCT01597583|Experimental|Use of MobileMedMinder|
3273755|NCT01597583|No Intervention|Usual care|
3273756|NCT01597609|Experimental|Cohort A|- 600 Kcal deficit, Sibutramine placebo
3273757|NCT01597609|Experimental|Cohort B|- 600 Kcal deficit, Sibutramine 10 mg once daily
3273758|NCT01597609|Experimental|Cohort C|- 600 Kcal deficit, Moderate exercise (The energy expenditure will be equivalent to 30 minutes of brisk walking/5 times week i.e. ~1,000 Kcal/week) /sibutramine placebo
3273759|NCT01597648|Experimental|Sequence 1|Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast Washout Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.
3273760|NCT01597648|Experimental|Sequence 2|"Treatment B: 1 tablet of maraviroc 300 mg + 1 tablet of Combivir taken concurrently after an overnight fast.~Washout Treatment A: 1 tablet of GSK2838510 (maraviroc 300 mg, lamivudine 150 mg, and zidovudine 300 mg as a combined formulation) after an overnight fast"
3273761|NCT01597661||Malformed and population-based sample of non-malformed infants|Infants with any of a wide range of malformations are identified at tertiary care and birth hospitals in four study centers (Boston, Philadelphia, Toronto, San Diego) using approaches that include reviewing lists of discharge diagnoses available in medical records; contacting newborn nursery and/or labor and delivery rooms; reviewing admission/discharge lists; and reviewing clinic and surgical logs. A population-based random sample of non-malformed newborns in Massachusetts is also included. Information gathered on each subject includes name, address, telephone number, diagnostic information, and date of birth.
3273762|NCT01597700|Experimental|Acotral® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 day.
3273763|NCT01597700|Active Comparator|Zetia® ezetimibe 10mg|Subjects will be fasted overnight and receive one tablet by mouth in accordance with a randomisation list and venous blood samples will be taken at specified intervals over the ensuing 3 days.
3273764|NCT01597713|Experimental|Part 1, level 1-7 escalating doses|
3273765|NCT01597713|Experimental|Part 2, cross-over|
3273766|NCT01597726|Active Comparator|Misoprostol|
3273767|NCT01597726|Experimental|Laminaria|
3273768|NCT01597739|Experimental|JNJ-40346527|
3273769|NCT01597739|Placebo Comparator|Placebo|
3273770|NCT01597752|Experimental|1|"Blomia tropicalis allergen extract (four concentrations: 5, 0.5, 0.05, 0.005 mg/ml)~Positive control~Negative control"
3273771|NCT01597765|Experimental|Curcuminoids|The administrate curcuminoids is intervention for 30 patients
3273772|NCT01597765|Experimental|Vitamin E|The vitamin E is intervention for 30 patients
3273773|NCT01597804|Experimental|"Supportive care (Bathing Bundle)"|"Patients undergo preoperative preparation with the Bathing Bundle comprising CHG 4% skin prep solution and disposable wash cloths to bathe or shower with the night before and morning of surgery."
3273774|NCT01597817|Active Comparator|chitosan coated textile|Chitosan coated cotton long sleeved t-shirts and pants.
3273775|NCT01597817|Placebo Comparator|chitosan free cotton textile|Chitosan free cotton long sleeved t-shirts and pants.
3273776|NCT01597830|Experimental|active shoe|
3273777|NCT01597830|Sham Comparator|Control|
3273778|NCT01597882||Case managed patients|Patients aged 65 years and over receiving community case management.
3273779|NCT01597895|Active Comparator|Maraviroc|
3273780|NCT01597895|Experimental|Maraviroc + Boceprevir|
3273781|NCT01597895|Experimental|Maraviroc + Telaprevir|
3273782|NCT01597921||Breast cancer patient receiving RT|Total dose:2Gy/Fx
3273783|NCT01597934|Active Comparator|Group A:|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
3273784|NCT01597934|Experimental|Group B|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
3273785|NCT01597947|Experimental|Arm A|
3273786|NCT01597947|Placebo Comparator|Arm B|
3273787|NCT01597960|Active Comparator|Yoga 12 week programme|Usual care (standard cardiac rehabilitation programme) plus yoga intervention.
3273788|NCT01597960|No Intervention|Usual care|Usual care (standard cardiac rehabilitation programme) only.
3273789|NCT01597986|Experimental|Isavuconazole and oral contraceptive|Arm description(as needed): Subjects receive single dose of oral contraceptive consisting of ethinyl estradiol and norethindrone on Days 1 and 13 and oral doses of isavuconazole every 8 hours on Days 9 and 10 followed by a once a day dose in the mornings on Days 11 through 16.
3273790|NCT01597999|Other|No treatment|Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )
3273791|NCT01598012|Experimental|Ayurved Siriraj Prasaplai|
3273792|NCT01598012|Placebo Comparator|placebo|
3273793|NCT01598038|No Intervention|Afinitor|"The recommended dose of Afinitor is 10 mg everolimus once daily, at fixed hour.Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.~In case of frail patients, treatment could be initiated at a lower daily-dose (5mg/d for example) and then increase if tolerance is acceptable."
3273794|NCT01598051||Group 1|Patients treated with Xarelto under practical manner for SPAF.
3273795|NCT01598077|Experimental|Dose escalation and dose expansion|
3273796|NCT01598103|Placebo Comparator|Placebo to SAF312|
3273797|NCT01598103|Experimental|SAF312|
3273800|NCT01598142|Other|experienced assistant group|experienced endoscopist with an experienced assistant.
3273801|NCT01598142|Other|new trained assistant group|same experienced endoscopist with a new trained assistant
3273802|NCT01598155|Experimental|Supragingival biofilm control|
3273803|NCT01598155|Experimental|Supra- and subgingival biofilm control|
3273804|NCT01598168|Experimental|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
3273805|NCT01598181|Experimental|active tDCS|
3273806|NCT01598181|Sham Comparator|sham tDCS|tDCS fades out after 20 sec. administered double blind by coded program.
3273807|NCT01598220|Experimental|Computer-assisted cognitive remediation therapy|
3273808|NCT01598220|Placebo Comparator|attentional task|
3273809|NCT01598233|Experimental|Intragastric balloon|Patients submitted to six-month intragastric balloon
3273810|NCT01598246||Extubation Success|Patients who do not require re-intubation, upto 72 hours after a planned extubation in the pediatric intensive care unit.
3273811|NCT01598246||Extubation failure|Patients who required re-intubation within 72 hours after a planned extubation in pediatric intensive care unit. To be further classified as early <12 hour and late 12-72 hour, extubation failures.
3273812|NCT01598259|Experimental|melatonin|Subjects will receive melatonin
3273813|NCT01598259|Placebo Comparator|placebo|
3273814|NCT01598272|Experimental|Vitality product AM + Vitality product PM|"Dietary Supplement:~Proprietary blend of ginseng, cordyceps, and pomegranate + proprietary blend of broccoli seed, red orange, and grape seed taken twice a day for 8 weeks."
3273815|NCT01598272|Placebo Comparator|Placebo|Dietary Supplement: Placebo Placebo taken twice a day for 8 weeks
3273816|NCT01598324||escitalopram responders no augmentation|Participants who show a clinical response following 8 weeks on an SSRI will have a final magnetic resonance scan at the end of 8 weeks and will complete the study at that time.
3273817|NCT01598324||Ziprasidone augmentation|Participants who do not respond to escitalopram and are randomized to ziprasidone augmentation will have a final magnetic resonance scan following 8 weeks on ziprasidone.
3273818|NCT01598324||Placebo augmentation|Participants who do not respond to escitalopram and are randomized to placebo augmentation will have a final magnetic resonance scan following 8 weeks on placebo.
3273819|NCT01598337|Active Comparator|Aspirin alone|
3273820|NCT01598337|Experimental|Tirofoban|Patient assigned to this arm will receive tirofiban infusion starting approximately six hours post bypass surgery once hemomstasis established and no evidence of bleeding
3273821|NCT01598337|Experimental|Clopidogrel|Patients receive oral clopidogrel 75 mg 6-8 hours before coronary bypass surgery and continue daily mentenance dose as per instruction by investigators
3273822|NCT01598337|Experimental|Prasugrel|Patients started on prasugrel 6 hours post surgery 10 mg then continue on daily 10mg as per instruction by investigators
3273823|NCT01598363|Experimental|Digoxin 0.5mg, Bardoxolone Methyl 20mg and 60mg|
3273824|NCT01598363|Experimental|Rosuvastatin 20mg, Bardoxolone Methyl 20mg and 60mg|
3273825|NCT01598376|Active Comparator|5/0 gauge vicryl suture|Patients randomly assigned to 5/0 gauge test everting suture
3273826|NCT01598376|Active Comparator|7/0 gauge vicryl suture|Patients randomly assigned to 7/0 gauge test everting suture
3273827|NCT01598389|Experimental|Low energy-dense preload|
3273828|NCT01598389|Experimental|High energy-dense preload|
3273829|NCT01598389|Experimental|No preload|
3273830|NCT01598402|No Intervention|No prophylactic treatment|When a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics).
3273831|NCT01598402|Experimental|prophylactic treatment|Administration of prophylactic amoxicillin/clavulanic acid suspension, 625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT. If a lower airway infection is suspected cultures will be taken and a chest radiography will be made; after that the standard care will be given (in most patients admission to hospital and start of intravenous antibiotics)
3273832|NCT01598415|Experimental|SAR113945|TDU11685 selected dose
3273833|NCT01598415|Placebo Comparator|Placebo|
3273834|NCT01598441|Experimental|iloprost|Iloprost nebuliser solution 500 ng/kg inhaled
3273835|NCT01598441|Placebo Comparator|distilled water|aerosolized distilled water 1-2 ml
3273836|NCT01598454|Experimental|Racotumomab|
3273837|NCT01598467|Other|Women with pelvic organ prolapse|Women with pelvic organ prolapse (simplified POP-Q > stage 1)
3273838|NCT01598480|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze.
3273839|NCT01598480|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
3273840|NCT01598493|Active Comparator|Control|Flamazine is applied on the wound in the control group instead and then covered with sterile gauze
3273841|NCT01598493|Experimental|BCT Antimicrobial Dressing|The wound in the experimental group is first cleansed with normal saline and then applied with BCT Antimicrobial Dressing and covered by sterile gauze, and dressings will be changed every 3 days.
3273842|NCT01598519|Experimental|study group|1500 students are randomized to receive a universal suicide intervention apart from usual school psychology classes. Furthermore, high risk of suicidal students screened in study group will receive an indicated suicide intervention in addition to usual school psychology classes.
3273843|NCT01598519|No Intervention|control group|1500 students are randomized to receive usual school psychology classes. High risk of suicidal students screened in control group will receive usual psychology classes.
3273844|NCT01598558|Experimental|64Cu-DOTA|Subjects will be injected with less than 14 mCi of 64Cu-DOTA-Rituximab. This is a slow infusion, done over 20 minutes.
3273845|NCT01598571|Experimental|Fostamatinib 50 mg tablet|
3273846|NCT01598571|Experimental|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose|
3273847|NCT01598584|Placebo Comparator|placebo plus gemcitabine|we design placebo plus gemcitabine as control arm
3273848|NCT01598584|Experimental|Mirtazapine plus gemcitabine|We design Mirtazapine plus gemcitabine as experimental arm
3273849|NCT01598597||Cohort|
3273850|NCT01598623|Experimental|Oxytocin+ Non Specific Counselling|
3273851|NCT01598623|Experimental|Oxytocin + Social Skills training|
3273852|NCT01598623|Placebo Comparator|Placebo + Non Specific Counselling|
3273853|NCT01598623|Experimental|Placebo + Social Skills Training|
3273854|NCT01598636|Experimental|Lateral Tibial Tunnel technique|
3273855|NCT01598649|Experimental|Lupin protein|Lupin protein isolate (cultivar: Lupinus angustifolius Boregine; incorporated in study products) and placebo capsules with mannitol
3273856|NCT01598649|Active Comparator|Milk protein|Milk Protein Isolate (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and Placebo capsules
3273857|NCT01598649|Active Comparator|Milk protein and arginine|Milk Protein Isoalte (75% sodium caseinate (EM7; DMV international) and 25% whey protein (Megglosat HP; Meggle), incorporated in study products) and 1,6 g Arginin in four caspules per day
3273858|NCT01598675|Active Comparator|Control|Symmetric Gait. Dual-belted treadmill belts moving at the same belt speeds during training
3273859|NCT01598675|Experimental|Gait Asymmetry|Error Augmentation. Belts of a dual-belted treadmill may move at different belt speeds to amplify spatiotemporal gait asymmetry during training
3273860|NCT01598675|Experimental|Gait Symmetry|Error Minimization. Belts of a dual-belted treadmill may move at different belt speeds to encourage spatiotemporal gait symmetry during training
3273861|NCT01598688|Active Comparator|Blood collection immediately after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
3273862|NCT01598688|Experimental|Blood collection five minutes after interrupting the drug|Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
3273863|NCT01598714|Other|Darco shoe|Darco walking shoe provided
3273864|NCT01598714|Other|Podalux Shoe|Podalus shoe
3273865|NCT01598714|Other|Standard dressing shoe|Standard dressing shoe
3273866|NCT01598727|Experimental|Fluobeam(TM) Imaging System (Fluoptics)|Single arm observational pilot study
3273867|NCT01598766|Experimental|Diagnostic Coil|This coil is a lightweight, flexible coil which can be used for many pediatric MRI exams
3273868|NCT01598805|Experimental|roll out of eAlerts|Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
3273869|NCT01598818||Visual acuity|Comparison of best visual acuity and refraction using the First Sight Refractive System with autorefraction in subjects with refractive error.
3273870|NCT01598844||High risk patients with aortic stenosis|Transapical aortic valve implantation using a transcatheter heart valve for aortic stenosis.
3273871|NCT01598844||High risk patients with AI|Transapical aortic valve implantation using a transcatheter heart valve for aortic regurgitation.
3273872|NCT01598857|Experimental|Blisibimod|
3273873|NCT01598857|Placebo Comparator|Placebo|
3273874|NCT01598870||Patients with cirrhosis and ascites|Patients requiring diagnostic and/or therapeutic paracentesis.
3273875|NCT01598883|Other|ACT after initial heparin bolus less than 450|If a patients activated clotting time (ACT) is less than 450 after the bolus dose of heparin (350U/kg) they will be randomized to one of two interventions.
3273876|NCT01598883|Active Comparator|ACT after first intervention less than 450|
3273877|NCT01598909|Active Comparator|Arnica ointment|
3273878|NCT01598909|Placebo Comparator|Placebo ointment|
3273879|NCT01598909|No Intervention|Control|
3273880|NCT01598935|Placebo Comparator|Control|placebo
3273881|NCT01598935|Active Comparator|High protein intake|Nutrition - High protein
3273882|NCT01598935|Active Comparator|Low protein intake|Nutrition - Low protein
3273883|NCT01598935|Active Comparator|Medium protein intake|Nutrition - Medium protein
3273884|NCT01598948|Experimental|Mipomersen|Patients randomized to this arm will receive mipomersen 200 mg weekly
3273885|NCT01598948|No Intervention|Control|patients randomized to this arm will receive no additional drug
3273886|NCT01598961|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
3273887|NCT01598961|Active Comparator|T1/Tc amplitude group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
3273888|NCT01598961|Experimental|No neuromuscular blockade group|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
3273889|NCT01598974|Experimental|Traditional Acupuncture|Participants will receive acupuncture over 6 30-minute sessions.
3273890|NCT01598974|Experimental|Laser Acupuncture|Participants will receive laser acupuncture over 6 30-minute sessions.
3273891|NCT01598974|No Intervention|Wait-List|Subjects will be put on a 6 week wait-list and receive vouchers for acupuncture at a local clinic.
3273892|NCT01599000|Active Comparator|Efficacy arm|Supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
3273893|NCT01599000|Experimental|Effectiveness arm|Un-supervised administration of six doses of fixed-dose artemether-lumefantrine (Coartem, Novartis)
3273894|NCT01599013|Other|Vinflunine plus Gemcitabine|
3273895|NCT01599013|Other|Vinflunine plus Carboplatin|
3273896|NCT01599039||breast cancer patients with SN|1. Breast cancer patients with sentinel node biopsy (n=25)
3273897|NCT01599039||breast cancer patients with AD|2. Breast cancer patients with axillary dissection (n=25)
3273898|NCT01599039||colo-rectal patients|3. Colo-rectal patients as control group (n=25)
3273899|NCT01599052||Brain Tumour Patients|Newly diagnosed brain tumour patients aged between 5 and 13 years
3273900|NCT01599052||Cystic Fibrosis patients|Patients diagnosed with Cystic Fibrosis aged between 5 and 13 years
3273901|NCT01599052||Healthy control group|Healthy children aged between 5 and 13 years
3273902|NCT01599065||Magnet|group treated by disabling ICD during procedure
3273903|NCT01599065||Off-On|Group having ICD turned off during the procedure
3273904|NCT01599078|Placebo Comparator|Placebo|
3273905|NCT01599078|Active Comparator|Paclitaxel|
3273906|NCT01599091||Fibroblast's donors|Patients undergoing tooth extraction will be asked permission to use the anyway extracted teeth and gingiva in order to harvest fibroblasts for further basic research.
3273907|NCT01599117|Placebo Comparator|Placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3273908|NCT01599117|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3273909|NCT01599130|Active Comparator|entecavir|patients continue to use entecavir
3273910|NCT01599130|Experimental|peg-interferon|patients switch to sequential peg-interferon α-2a
3273911|NCT01599143|Experimental|Mindfulness-based Stress Reduction group|All eligible participants attend a 3-hour weekly session, for 8 consecutive weeks, to learn meditation and simple Hatha Yoga techniques, and incorporate them into their daily lives.
3273912|NCT01599156|Experimental|Reflexology|reflexology treatment, x2-3/week for 12 weeks
3273913|NCT01599169|Experimental|B-Back® verum|
3273914|NCT01599169|Placebo Comparator|B-Back® placebo|
3273915|NCT01599182||High-Risk Prostate Cancer|
3273916|NCT01599182||Intermediate-Risk Prostate Cancer|
3273917|NCT01599195||adults|adults audiodoc use to evaluate for carotid or femoral bruit
3273918|NCT01599208|Experimental|Single-pulse online stimulation|Online single-pulse online stimulation at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3273919|NCT01599208|Experimental|Repetitive online stim., 400ms, 10Hz|Repetitive online stimulation for 400ms at 10Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3273920|NCT01599208|Experimental|Repetitive online stim., 400ms, 20Hz|Repetitive online stimulation for 400ms at 20Hz at 120% of motor threshold to either the right or left MTL, in comparison to sham condition, in either -400/0/400/800 ms relatively to stimulus in either the study or test phases of a recognition test.
3273921|NCT01599208|Experimental|Repetitive offline stimulation at 10Hz|Repetitive offline stimulation at 10Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
3273922|NCT01599208|Experimental|Repetitive offline stimulation at 20Hz|Repetitive offline stimulation at 20Hz for 4 min before study or for 8 min before test (in accordance with the phase length), comprising 2-second stimulation trains and 20-second breaks. Stimulation will be given at 120% of motor threshold to either the right or the left MTL in comparison to sham condition.
3273923|NCT01599208|Experimental|Repetitive offline stimulation with iTBS|Repetitive offline stimulation with Intermittent Theta Burst Stimulation (iTBS) comprising 3 pulses at 50Hz, repeated at 5Hz for 2-second stimulation trains with 8-second breaks for 192 seconds. Stimulation will be given at 90% of motor threshold to either the right or the left MTL in comparison to sham condition.
3273924|NCT01599221||Subjects with EBA2|Subjects who have undergone surgery with EBA2 medical device for lateral proximal femoral fractures
3273925|NCT01599247||Suicidal ideation/behavior|
3273926|NCT01599260|Experimental|Resistance Exercise|Subjects will participate in a 16 week long resistance exercise program which will consist of 2 30-minute individually supervised sessions per week.
3273927|NCT01599273|Experimental|Triam inj|
3273928|NCT01599273|No Intervention|observation group|
3273929|NCT01599299||Ultrasound, internal jugular vein|All patients who will need a central venous access (into the right jugular vein) preoperative are included.
3273930|NCT01599312|Other|Classic Macintosh laryngoscope|Classic Macintosh laryngoscope (Karl Storz, Tuttlingen, Germany)
3273931|NCT01599312|Other|McGrath®|McGrath® (Aircraft Medical Ltd, Edinburgh, UK)
3273932|NCT01599312|Other|C-MAC®|C-MAC® (Karl Storz, Tuttlingen, Germany)
3273933|NCT01599312|Other|GlideScope® Cobalt|GlideScope® Cobalt (Verathon Medical, Bothell, WA, USA)
3273934|NCT01599338|Experimental|Liraglutide|Single Arm study. T2DM patients are studied before and after 3 months of Liraglutide treatment (1.2 mg/day).
3273935|NCT01599351|Active Comparator|Prone|Patients were in prone position along the ERCP procedure.
3273936|NCT01599351|Active Comparator|Left lateral decubitus|Patients were in left lateral decubitus along the ERCP procedure.
3273937|NCT01599364|Experimental|Switch|Switch to Atazanavir 300 mg with ritonavir 100 mg plus lamivudine 300 mg
3273938|NCT01599364|No Intervention|continue|Continue Atazanavir 300 mg with ritonavir 100 mg with the same NRTI backbone
3273939|NCT01599377|Experimental|Cohort 1|
3273940|NCT01599377|Experimental|Cohort 2|
3273941|NCT01599390||Influenza Group|
3273942|NCT01599403|Active Comparator|Paravertebral Block|Patients will receive 1 or 2 paravertebral catheters for ongoing infusion of local anesthestic
3273943|NCT01599403|No Intervention|Patient Controlled Anesthesia|Standard usual care
3273944|NCT01599403|Experimental|Epidural Block|"Intervention:~Patients will have epidural catheters placed for the infusion of local anesthetic solution to control pain (if qualified for this approach and randomized here)"
3273945|NCT01599403|Active Comparator|Intercostal Nerve Block|Patients will receive intercostal catheters for the infusion of local anesthetic solution to control pain(if qualified for this arm and randomized here)
3273946|NCT01599416|Active Comparator|U-relax Group|Day 1-5: take two capsuals of oral U-relax everyday before sleep Day 6-360: take one capsual of oral U-relax everyday before sleep
3273947|NCT01599416|Placebo Comparator|Placebo Group|Day 1-5: take two capsuals of oral placebo everyday before sleep Day 6-360: take one capsual of oral placebo everyday before sleep
3273948|NCT01599455||Inpatient|Youths admitted for inpatient rehabilitation training
3273949|NCT01599455||Outpatient|Youths visiting outpatient clinics
3273950|NCT01599455||Urodynamic study|Youths who undergo scheduled urodynamic study
3273951|NCT01599468|Experimental|tranexamic acid, post partum hemorrhage|
3273952|NCT01599468|Placebo Comparator|placebo|
3273953|NCT01599481|Experimental|Intervention|Standard Care (IAPT Therapy) + Individual Career Management (ICM)
3273954|NCT01599481|Active Comparator|Control|Standard Care (IAPT Therapy)
3273955|NCT01599494|Experimental|Single-Dose MK-8962 + recFSH|
3273956|NCT01599494|Active Comparator|Reference Group recFSH only|
3273957|NCT01599507|Experimental|FG-4592|Active Drug
3273958|NCT01599507|Placebo Comparator|Placebo|
3273961|NCT01599533|Other|abdominal aortic aneurysms|
3273962|NCT01599546||Full Term children|born >36 weeks, currently age 6 +/- 6 months
3273963|NCT01599546||Preterm children|born <35 weeks, age 6 +/- 6 months at the beginning of the study.
3273964|NCT01599559|Experimental|observation|Follow up visits are scheduled from randomization. Patients will be seen at 3-months intervals for 24 months, then every 6 months until 5 years from randomization.
3273965|NCT01599559|Active Comparator|mediastinal irradiation|Radiotherapy will be delivered in this phase III protocol, as alternative to observation, as consolidation treatment in patients achieving a CR status (PET/CT scan negative) at the end of R-chemotherapy, with a total dose of 30 Gy.
3273966|NCT01599572|Experimental|30mg/day zinc supplementation|30mg/day of zinc supplement provided for 3 months to zinc deficient elderly
3273967|NCT01599598|Active Comparator|Progressive Muscle Relaxation|A stress intervention where subjects will learn to regulate stress based on the tensing and releasing of the major muscle groups in the body, accompanied with relaxed breathing techniques.
3273968|NCT01599598|Active Comparator|Coherence Advantage|A stress intervention where subjects will learn to regulate stress by focusing on breathing and mindfulness techniques while recognizing physiological coherence by way of a portable biofeedback device.
3273969|NCT01599611||Exposed group|Children age 5-10 years old who had a total serum bilirubin > 450 umol/L in the neonatal period
3273970|NCT01599611||Non-exposed group|Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence
3273971|NCT01599624|Experimental|iPad-based SRTS|
3273972|NCT01599624|Experimental|iPad-based PMR program|
3273973|NCT01599663|Experimental|Intervention units|"A time period before the clinicians will be educated, trained and guided in the pain management algorithm, pre-test data will be collected in four ICU units.~The clinicians in three of the ICU units will be educated, trained and guided in the pain management algorithm. The algorithm will then be used to assess and treat pain in all consecutive ICU patients. Post-test data will be collected a time period after the intervention is implemented."
3273974|NCT01599663|No Intervention|Control unit|The clinicians in the fourth ICU (control unit) will not be educated, trained and guided in the pain management algorithm. They will continue to assess and treat pain in all consecutive ICU patients as before. The unit, which will be used as a comparison unit, will collect the same post-test data at the same time as data in intervention ICUs were collected.
3273975|NCT01599676|Sham Comparator|Not essential amino acid|"Non essential amino acid:~The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive 1 unit of an equivalent quantity of nonessential amino acids (alanine, aspartate, glycine, serine, histidine and proline in equimolar quantity) isonitrogenous to 10 g of citrulline, once in the morning for 12 weeks."
3377409|NCT04502823|No Intervention|Control Group|"Clinical practice: Management by Doppler and CTG findings.~In women allocated to the control group, the sFlt-1/PlGF result will be blinded to caregivers. Routine Doppler-based clinical care will be used to counsel women. Following the Doppler classification:~Fetuses with an EFW below the 3rd centile or below the 10th centile accompanied by any impaired fetoplacental Doppler, elective delivery will be recommended at at ≥37 weeks.~Fetuses with an EFW above the 3rd centile without any fetoplacental Doppler abnormality, elective delivery will be recommended at at ≥40 weeks."
3377410|NCT04502823|Experimental|Intervention Group|Management based on sFlt-1/PlGF values
3377411|NCT04501081||1|DFNA patients and their family members (affected)
3377412|NCT04501081||2|DFNA patients and their family members (unaffected)
3377413|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r)|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100 mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7
3377414|NCT04499677|Experimental|Favipiravir + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir at 1800 mg twice daily on Day 1, followed by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
3273976|NCT01599676|Experimental|Citrulline|The subjects will have a regimen of high-intensity progressive resistance training of the knee extensors 3 days per week for 12 weeks. The subjects will receive citrulline 10 g/day orally in the morning for 12 weeks.
3273977|NCT01599689|Experimental|Mirrors Intervention|Patients allocated to Mirrors will receive a structured, protocol-driven bedside mirrors intervention as part of their postsurgical ICU care. This intervention will commence as soon as all anaesthetic agents have been switched off and the patient is awake following surgery unless considered clinically inappropriate.
3273978|NCT01599689|No Intervention|Standard Care|Patients allocated to Standard Care will receive the usual postsurgical ICU care that does not include the use of mirrors.
3273979|NCT01599702|Experimental|Group A Monofer|Depending on the body weight, subjects in Treatment Group A will receive a total dose of 1,500 mg or 2,000 mg IV iron isomaltoside 1000 where 1,500 mg is administered as a single infusion and 2,000 mg is divided into 2 administrations: 1 administration of 1,500 mg at baseline and 1 administration of 500 mg 1 week later. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
3377415|NCT04499677|Experimental|Favipiravir placebo + Lopinavir/ritonavir (LPV/r)|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
3377416|NCT04499677|Placebo Comparator|Favipiravir placebo + Lopinavir/ritonavir (LPV/r) placebo|Oral favipiravir matched placebo at 1800 mg twice daily on Day 1, by 400 mg four (4) times daily from Day 2 to Day 7 PLUS Lopinavir/ritonavir (LPV/r) matched placebo at 400mg/100mg twice daily on Day 1, followed by 200mg/50mg four (4) times daily from Day 2 to Day 7.
3377418|NCT04492956|Experimental|Ecopipam HCl ~2mg/kg/day|Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks
3377419|NCT04492956|Placebo Comparator|Matching Placebo|Matching placebo tablets for daily, oral administration for 12 weeks
3377420|NCT04491526|Experimental|Tamsulosin Arm|p.o.
3377421|NCT04491526|Placebo Comparator|Placebo Arm|p.o.
3377422|NCT04490174||Healthy participants|Healthy adults without a current active COVID-19 infection or current symptoms consistent with COVID-19 at the first clinic visit
3377423|NCT04489719||Observational (biospecimen collection)|Patients receive standard of care radium Ra 223 dichloride given by IV bolus every 4 weeks for up to 6 cycles. Patients undergo collection of blood every 1-3 months during radium Ra 223 dichloride treatment.
3377424|NCT04488263||Cohort 1|Subjects with confirmed/suspected NENs.
3377425|NCT04488250|Other|Low-to-mid functioning HIV/AIDS patients|Low-to-mid functioning HIV/AIDS patients greater than 18 years of age with stroke co-morbidity.
3377426|NCT04488250|Other|Stroke survivors|Stroke survivors greater than 18 years of age with hemiplegia with and without HIV/AIDS.
3377427|NCT04484857|Experimental|Roxadustat|
3377428|NCT04481113|Experimental|Treatment (abemaciclib, niraparib)|Patients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
3377429|NCT04478994|Active Comparator|TEPEZZA 20mg/kg|Approximately 15 participants will receive 8 infusions of TEPEZZA q3W for a total of 21 weeks. TEPEZZA 10mg/kg will be administered on Day 1 and TEPEZZA 20mg/kg will be administered q3W for the remaining 7 infusions.
3377430|NCT04478994|Placebo Comparator|Placebo|Approximately 10 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
3377431|NCT04478266|Experimental|Amcenestrant with Letrozole-matching placebo Arm|Participants in Amcenestrant with Letrozole-matching placebo Arm will be administered: Amcenestrant dose, once daily, continuously. Letrozole-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle. Goserelin once every 4 weeks in pre/peri menopausal women and men
3377432|NCT04478266|Active Comparator|Letrozole with Amcenestrant matching placebo Arm|Participants in Letrozole with Amcenestrant-matching placebo Arm will be administered: Letrozole dose, once daily, continuously. Amcenestrant-matching placebo, once daily, continuously. Palbociclib dose once daily, days 1-21 of every 28-day cycle Goserelin once every 4 weeks in pre/peri menopausal women and men
3377433|NCT04477343|Experimental|Experimental: SX-682 and Nivolumab|"SX-682 Dose: 25, 50, 100, 200, 400mg BID taken as an oral pill~Nivolumab Dose: 240mg, every 2 weeks via intravenous infusion"
3273980|NCT01599702|Experimental|Group B Monofer|Depending on the body weight, Subjects in Treatment Group B will receive a total dose of 2,500 mg or 3,000 mg IV iron isomaltoside 1000 divided into 2 administrations; 1 administration of 1,500 mg and 8 weeks later a second administration of 1,000 mg or 1,500 mg.. All doses will be diluted in 100 ml normal saline (0.9 % sodium chloride) and administered by infusion over approximately 15 minutes.
3273981|NCT01599715|Other|Instructional DVD Intervention|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once
3273982|NCT01599715|Other|Bladder Health Class Intervention|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
3273983|NCT01599728|Other|Patients with heart failure|Assessing the response to infusion of intra-arterial Urocortin 2, 3 and Substance P in patients with heart failure
3273984|NCT01599728|Other|Healthy controls|Assessing response to intra-arterial infusions of Urocortin 2, 3 and Substance P in age and sex-matched healthy volunteers as controls.
3273985|NCT01599767|Experimental|Active tDCS|Subjects will undergo 20 minutes active tDCS.
3273986|NCT01599767|Sham Comparator|Sham tDCS|Subjects will undergo 20 minutes of sham stimulation.
3273987|NCT01599780||Full-Term Children|≥37 weeks gestation; 18 months old at the start of the study
3273988|NCT01599780||Preterm Children|<33 weeks gestation; 18 months old at the start of the study
3273989|NCT01599819|Experimental|Cohort 1|Low dose of ADVATE followed by low dose of BAX 855
3273990|NCT01599819|Experimental|Cohort 2|High dose of ADVATE followed by high dose of BAX 855
3273991|NCT01599845||Nanoparticle exposed|
3273992|NCT01599871|Experimental|Intervention|Inhaled corticosteroids and long-acting beta agonist + theophylline (Slophylline capsules 100 mg/Theo-dur Retard 100 mg b.i.d.)
3273993|NCT01599871|Placebo Comparator|Control|inhaled corticosteroids and long-acting beta agonist + Placebo
3273994|NCT01599884|Active Comparator|N-acetylcysteine|N-acetylcysteine, 1800 mg twice daily
3273995|NCT01599884|Placebo Comparator|Sugar pill|Identical to active drug
3273996|NCT01599897|Experimental|2 µg ID93 + 2 µg GLA-SE|Low dose and antigen and low dose of adjuvant.
3273997|NCT01599897|Experimental|10 µg ID93 + 2 µg GLA-SE|High dose of antigen and low dose of adjuvant.
3273998|NCT01599897|Experimental|2 µg ID93 + 5 µg GLA-SE|Low dose of antigen and high dose of adjuvant.
3273999|NCT01599897|Experimental|10 µg ID93 + 5 µg GLA-SE|High dose of antigen and high dose of adjuvant.
3274000|NCT01599897|Active Comparator|2 µg ID93 alone|Low dose of antigen alone.
3274001|NCT01599897|Active Comparator|10 µg ID93 alone|High dose of antigen alone.
3274002|NCT01599923|Experimental|Alacramyn|
3274003|NCT01599936|Experimental|Anascorp|Three vials of Anascorp® will be administered in a total volume of 50 mL, intravenous over not less than 10 minutes or as permitted by IV access
3274004|NCT01599949|Experimental|Ibrutinib|
3274005|NCT01599962|Experimental|Cinacalcet|
3274006|NCT01599962|Placebo Comparator|Sugar pill|
3274007|NCT01599975|Active Comparator|Group A: 2 tabs of 18 mg Concerta daily|20 subjects to receive active study drug in a blinded fashion x 2 weeks, then washout x 2 weeks, then cross over to receive matched placebo x 2 weeks.
3274008|NCT01599975|Placebo Comparator|Group B: Matched placebo, 2 tabs daily|Group B to receive matched placebo x 2 weeks, then washout x 2 weeks, then cross over to receive active drug in a blinded fashion x 2 weeks.
3274009|NCT01599988|Active Comparator|Milk protein isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
3274010|NCT01599988|Active Comparator|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.
3274011|NCT01600001|Experimental|Drug:KWA-0711 dose 1|
3274012|NCT01600001|Experimental|Drug:KWA-0711 dose 2|
3274013|NCT01600001|Experimental|Drug:KWA-0711 dose 3|
3274014|NCT01600001|Experimental|Drug:KWA-0711 dose 4|
3274015|NCT01600001|Placebo Comparator|Drug: Placebo|
3274016|NCT01600027|Placebo Comparator|Group B|received 1 ml/kg bupivacaine 0.25%.
3274017|NCT01600027|Active Comparator|group BD|received 1 ml/kg bupivacaine 0.25% with dexmedetomidine 2 μg/kg
3274018|NCT01600040|Other|Proton Radiation Therapy|This is a single arm study; all participants will receive proton radiation therapy.
3274019|NCT01600079||Vaccinated Cohort|Participants vaccinated with at least one dose of ZOSTAVAX™
3274020|NCT01600079||Unvaccinated Comparison Cohort|Participants who are not yet vaccinated with any zoster vaccine
3274021|NCT01600118|Active Comparator|ESWT|Extracorporeal shockwave therapy
3274022|NCT01600118|Placebo Comparator|ESWT Placebo|No extracorporeal shockwave therapy
3274023|NCT01600131|Experimental|Caregiver education and support|problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.cidrr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
3274024|NCT01600131|Other|Standard Care|Caregivers receiving standard of care
3274025|NCT01600144||data collection|
3274026|NCT01600157|Experimental|Laparoscopic Nephrectomy|
3274027|NCT01600183|Active Comparator|casting|subjects with MTA will be treated with cast for 20 weeks. casting is replaced during every study visit.
3274028|NCT01600183|Experimental|UNFO-s|subjects with MTA will be treated with the UNFO-s device for 12 weeks - will be worn day and night during first 6 weeks and only at night during next 6 weeks
3274029|NCT01600196|Experimental|Resection arm|Liver resection Plus Thrombectomy
3274030|NCT01600196|No Intervention|Best support care arm|Best supportive care
3274031|NCT01600209||Average risk patients|Subjects will be men and women, 50-84 years of age, inclusive, each with a screening colonoscopy resulting in normal findings.
3274032|NCT01600235|Experimental|Phenylephrine|Phenylephrine induced-hypertension arm
3274033|NCT01600235|No Intervention|Conventional treatment|Control arm
3274034|NCT01600248|Other|Treatment arm|This is an open-label pilot study with no control group. Participants pre-treatment scores are compared to their post-treatment scores.
3274035|NCT01600261||eye exam|
3274036|NCT01600274|Experimental|Diena|Dienogest-Ethinyl Estradiol (test product) tablet
3274037|NCT01600274|Active Comparator|Valette®|Dienogest-Ethinyl Estradiol (reference product) tablet
3274038|NCT01600300|Placebo Comparator|Sham|Treatment with inactivate Tesmac device
3274039|NCT01600300|Active Comparator|Tesmac|Treatment with active Tesmac device
3274040|NCT01600313|Experimental|treatment, control|
3274041|NCT01600339|Experimental|CABAZITAXEL|cabazitaxel at a starting dose of 25 mg/m
3274042|NCT01600365|Active Comparator|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
3274043|NCT01600365|Placebo Comparator|Ophthalmic gel (placebo)|ophthalmic gel (placebo)in the study eye
3274044|NCT01600391|Active Comparator|Usual Care|A task specific-based intervention that does not include use of visual cues to influence quality or adaptability of gait.
3274045|NCT01600391|Experimental|Overground visual cue training|Overground visual cue training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
3274046|NCT01600391|Experimental|Treadmill visual cue training|Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). Walking training will involve stepping to targets which are positioned to improve gait symmetry and speed. Training will include turning practice and the avoidance of obstacles for adaptability during straight walking.
3274047|NCT01600404||antimuscarinic treatment|antimuscarinic treatment
3274048|NCT01600404||no antimuscarinic treatment (control)|
3274049|NCT01600417||clinical suspicion of lumbar instability|
3274050|NCT01600430|Active Comparator|Oral Vitamin D--200 IU/day|Cholecalciferol 200 IU given orally once per day
3274051|NCT01600430|Placebo Comparator|Placebo|Identical-appearing treatment that does not contain the test drug given orally four times per day.
3274052|NCT01600430|Active Comparator|Oral Vitamin D--800 IU/day|Cholecalciferol 800 IU given orally once per day
3274053|NCT01600443|Experimental|LoFric - SC - SCCM|Study period 1: LoFric Study period 2: SpeediCath Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
3274054|NCT01600443|Experimental|LoFric - SCCM - SC|Study period 1: LoFric Study period 2: SpeediCath Compact Male Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
3274055|NCT01600443|Experimental|SC - SCCM - LoFric|Study period 1: SpeediCath Study period 2: SpeediCath Compact Male Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
3274056|NCT01600443|Experimental|SC - LoFric - SCCM|Study period 1: SpeediCath Study period 2: LoFric Study period 3: SpeediCath Compact Male In each study period three catheterizations are made, separated by at least 2 hours.
3274057|NCT01600443|Experimental|SCCM - LoFric - SC|Study period 1: SpeediCath Compact Male Study period 2: LoFric Study period 3: SpeediCath In each study period three catheterizations are made, separated by at least 2 hours.
3274058|NCT01600443|Experimental|SCCM - SC - LoFric|Study period 1: SpeediCath Compact Male Study period 2: SpeediCath Study period 3: LoFric In each study period three catheterizations are made, separated by at least 2 hours.
3274059|NCT01600456|Active Comparator|Choice: Prolonged exposure (PE)|"Participants randomized to choice who choose prolonged exposure (PE)."
3274060|NCT01600456|Active Comparator|Choice: PE plus sertraline|"Participants randomized to choice who choose PE plus sertraline."
3274061|NCT01600456|Active Comparator|No choice: Prolonged exposure (PE)|"Participants randomized to no choice who are then randomized to PE."
3274062|NCT01600456|Active Comparator|No Choice: PE plus sertraline|"Participants randomized to no choice who are then randomized to PE plus sertraline."
3274063|NCT01600469|Experimental|DAOI-B|
3274064|NCT01600469|Placebo Comparator|Placebo|
3274065|NCT01600508|Active Comparator|Traditional stoma care|Being discharged from a hospital with a stoma is a challenge to the patient's quality of life in many aspects. Optimal stoma function and care is essential to keep quality of life best possible. Videoconference can be a useful tool to help patients cope with stoma problems without travelling long distances to a surgical outpatient clinic.
3274066|NCT01600508|Experimental|Videoconference Stoma Consultations|Videoconference Stoma Consultations
3274067|NCT01600521|Active Comparator|Paeoniflorin + Polypeptides (PAE + CCPI)|Paeoniflorin (PAE), the extract from peony (Paeonia lactiflora), is an active ingredient with anti-inflammation properties. Polypeptides (3,000 - 10,000 dalton) in Cervus & Cucumis polypeptide injection (CCPI), the extract from Sika deer (Cervus nippon Temmick) bones and muskmelon (Cucumis melo L) seeds, are the active ingredients with bone healing, pain relieving, and anti-inflammation properties. PAE was administrated orally 600 mg twice a day for at least 12 months. CCPI was administered intravenously 8~12 mL daily with 250 mL 5% dextrose injection solution or 0.9% NaCl IV solution for 2 weeks, discontinued 1 week, and restarted for another 2 weeks.
3274068|NCT01600521|Active Comparator|Methotrexate (MTX) + Leflunomide (LEF)|DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months. MTX dose: 7.5 mg ~ 10mg / week, LEF dose: 10 mg ~ 20mg daily.
3274069|NCT01600521|Active Comparator|MTX + LEF + CCPI|The DMARDs and CCPI were administrated as in the above two groups.
3274070|NCT01600534|Experimental|Lifestyle counseling|Participants obtain access to an internet-based educational intervention.
3274071|NCT01600534|Other|Usual Care Lifestyle counseling|Self directed educational intervention
3274072|NCT01600547||fall clinic population|women, aged + 65 years
3274073|NCT01600547||control fallers|randomly selected community aged matched female controls with a fall episode
3274074|NCT01600547||control non fallers|randomly selected community aged matched female controls, with out fall episodes
3274075|NCT01600560||Social media|
3274076|NCT01600573|Experimental|pazopanib plus weekly topotecan|pazopanib in combination with weekly topotecan
3274077|NCT01600599|Active Comparator|IV & topical TA|patients in this group will receive both intravenous & topical tranexamic acid
3274078|NCT01600599|Placebo Comparator|IV tranexamic acid & Topical Saline|
3274079|NCT01600612|Active Comparator|Oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
3274080|NCT01600612|Active Comparator|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
3274081|NCT01600612|Active Comparator|misopristol|600 ug of misopristol sublingually will be given intravenously to patients with atonic postpartum hemorrhage
3274082|NCT01600625|Experimental|Minocycline treatment group|
3274083|NCT01600651|Sham Comparator|Recruitment maneuver (RM) sham group|when recruitment maneuver sequence precedes a sham evaluation period
3274084|NCT01600651|Sham Comparator|Sham Recruitment (RM) maneuver group|a group in which patients receive a sham sequence before the RM sequence
3274085|NCT01600664|Experimental|interactive computer game|"Participants will be using the interactive computer game- My Diabetic Friend, installed on Intel-powered convertible classmate PC."
3274086|NCT01600664|Active Comparator|Convertible PC|Participants will be using the convertible classmate PC without the interactive computer game
3274087|NCT01600690|No Intervention|Continue statin regimen|Patients randomized to this arm will continue their usual statin regimen and dose, without any intervention.
3274088|NCT01600690|Experimental|Statin withdrawal|Patients randomized to this arm will stop statin treatment for 5 days.
3274089|NCT01600742|Active Comparator|WBRT, placebo|
3274090|NCT01600742|Experimental|WBRT and concurrent vorinostat|
3274091|NCT01600768|Active Comparator|intermittent infusion|
3274092|NCT01600768|Experimental|extended infusion|
3274093|NCT01600781|Active Comparator|NutriniDrink/Fortini group|this group will receive 2 bottles of NutriniDrink/Fortini MF unflavoured daily (200 ml each) and standard dietary counselling for a period of 6 weeks.
3274094|NCT01600781|No Intervention|control group|this control group will only receive standard dietary counselling
3274095|NCT01600794||male/female, immunity or others factor infertility, IVF|
3274096|NCT01600807|Experimental|Gemcitabine, Erlotinib, OSI-906|Experimental treatment arm
3274097|NCT01600807|Active Comparator|Gemcitabine, Erlotinib|Standard treatment arm
3274098|NCT01600820|Experimental|1 = Tested product 1|
3274099|NCT01600820|Experimental|2 = tested product 2|
3274100|NCT01600820|Placebo Comparator|3 = Control product|
3274101|NCT01600833||Obese women|BMI>25
3274102|NCT01600833||Non obese women|BMI<25
3274103|NCT01600859|Experimental|E2609|
3274104|NCT01600859|Placebo Comparator|Placebo for E2609|
3274105|NCT01600872||Gruop 1|
3274106|NCT01600872||Group 2|
3274107|NCT01600898||Asymptomatic BMPR2 mutation carriers|Asymptomatic BMPR2 mutation carriers
3274108|NCT01600937|No Intervention|Control|Standard care including physician recommendations for daily PA
3274109|NCT01600937|Experimental|Exercise|Theoretical & practical exercise counseling including 2 sessions/ per wk for 1 month of supervised exercise training
3274110|NCT01600963|Experimental|Arm A|
3274111|NCT01600963|Placebo Comparator|Arm B|
3274112|NCT01600976|Experimental|Group 1|10 patients with moderate hepatic impairment (CPB [Child-Pugh score 7 to 9])
3274113|NCT01600976|Experimental|Group 2|10 healthy control patients with normal hepatic function. Each healthy control patient is matched to a patient in Group 1 with respect to sex, age (± 5 years) and body mass index (BMI) (± 15%)
3274114|NCT01600976|Experimental|Group 3|up to 4 patients with severe hepatic impairment (CPC [limited to Child Pugh score 10 to 12])
3274115|NCT01600989||Patients with severe sepsis / septic shock|30 Adult patients (age > 18years), with severe sepsis or septic shock as defined by the 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference guidelines at the time of admission to ICU.
3274116|NCT01600989||Healthy volunteers|Healthy volunteers
3274117|NCT01601002|Experimental|Mirtazapine|Mirtazapine in dosage of 7.5 mg to 45 mg/day
3274118|NCT01601015|Experimental|Manual therapy|Manual therapy of Suboccipital soft tissue Inhibition treatment aims to release the suboccipital muscle spasm that maintains the occiput-atlas-axis joint dysfunction.
3274119|NCT01601015|Experimental|Occiput-atlas-axis joint manipulation|Is bilaterally administered. The aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction
3274120|NCT01601015|Experimental|Combined treatment|The group receiving combined treatment received the two previous techniques exactly with the same sequence.
3274121|NCT01601015|Placebo Comparator|Control group|Control group not receive treatment and stayed in this position for 10 minutes
3274122|NCT01601028|Active Comparator|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o.
3274123|NCT01601028|Placebo Comparator|Placebo|Placebo
3274124|NCT01601041||urinary tract infection|urinary tract infection in male patients with neurogenic bladder dysfunction due to spinal cord injury managed by intermittent catheterization
3274125|NCT01601041||control group|less than three urinary tract infections / year
3274126|NCT01601054|Active Comparator|Anterior lumbar interbody fusion|Anterior lumbar interbody fusion using a tantalum cage. Cage will be inserted through a left sided retroperitoneal approach.
3274127|NCT01601054|Active Comparator|Posterior instrumentation alone|Posterior pedicle screw instrumentation
3274128|NCT01601093|Experimental|High dose|Ceftazidime 3g
3274129|NCT01601093|Experimental|Low dose|Ceftazidime 2g
3274130|NCT01601093|Active Comparator|CFP/SUB|Cefoperazone and sulbactam sodium for injection(2:1)
3274131|NCT01601106|Active Comparator|Liposomal prednisolone|
3274132|NCT01601106|Placebo Comparator|Placebo control|
3274133|NCT01601119||Rebif cohort|Subject will receive Rebif as the treatment medication as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
3274134|NCT01601119||Other DMT cohort|Subjects will receive DMT other than Rebif as per the standard or current practices or as directed by the healthcare professional. Allocation of subjects to a specific cohort was based on the first DMT they will be prescribed regardless of any subsequent treatment switches.
3274135|NCT01601145|Experimental|lozenges with Lactobacillus brevis CD2|Randomized group using lozenges for 6 weeks.
3274136|NCT01601145|Placebo Comparator|lozenges|Randomized group using lozenges for 6 weeks.
3274137|NCT01601158|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood infusion and Active Rehabilitation
3274138|NCT01601171||Patients|"Patients with reproductive disorders with or without cleft lip/palate will be recruited for:~completion of medical questionnaire and review of medical records~family tree (including questions on reproductive disorders and cleft lip/palate)~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing~hearing test~bone density~brain MRI~kidney, testicular/ovarian ultrasound"
3274139|NCT01601171||Family members|"Family members of Patients will be recruited for:~completion of medical questionnaire~specimen collection (DNA/RNA) from: serum/plasma/saliva/urine/buccal swab/hair follicles/sperm/skin biopsy~smell testing"
3274140|NCT01601184|Experimental|combination of vismodegib with temozolomide|"In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive~- Arm A: the combination of vismodegib (150 mg/day continuously) with temozolomide (150 mg/m2 during Cycle 1 [day 1 to day 5/ 28 day-cycle] and 200 mg/m2 during subsequent cycles) (6 patients)"
3274141|NCT01601184|Active Comparator|temozolomide alone|In the first step of the study (Phase I), 9 adult patients with relapsing or refractory medulloblastoma will be randomized (randomization ratio 2:1) to receive Arm B: temozolomide alone (150 mg/m2 day1 to day 5/ 28 day-cycle during Cycle 1 and 200 mg/m2 day 1 to day 5/ 28 day-cycle during subsequent cycles) (3 patients).
3274142|NCT01601184|Other|vismodegib alone|Considering the rarity of the disease, the few therapeutic options available and the promising results reported with vismodegib in adult medulloblastoma : the Sponsor will consider (on case by case basis) the enrolment of patients previously treated by temozolomide in a 3rd independent and parallel study arm
3274143|NCT01601197|Experimental|Tactile stimulation|Ipsilateral limb will be rubbed immediately before, during and after immunization injection(s)
3274144|NCT01601197|No Intervention|No tactile stimulation|There will be no tactile stimulation of ipsilateral limb before, during and after immunization injection(s)
3274145|NCT01601210|Placebo Comparator|Placebo|
3274146|NCT01601210|Active Comparator|2 grams of creatine|
3274147|NCT01601210|Active Comparator|4 grams of creatine|
3274148|NCT01601210|Active Comparator|10 grams of creatine|
3274149|NCT01601223||Surgical mechanically-ventilated|Surgical patients undergoing invasive mechanical ventilation for general anesthesia
3274150|NCT01601249|Experimental|Polscope based embryo grading|Embryos for transfer will be selected based on highest polscope scores, unless are not grade 1-2 by conventional morphology
3274151|NCT01601249|Active Comparator|Morphology based embryo grading|Conventional embryo grading and decision making
3274152|NCT01601262|Experimental|Open label|
3274153|NCT01601301|Experimental|PRECICE System|
3274154|NCT01601314|Experimental|magnesium sulphate|The patients who are going to receive Magnesium Sulphate
3274155|NCT01601314|Placebo Comparator|Control|Patients who are going to receive Sodium Chloride 0.9%
3274156|NCT01601327|Other|hypogonadism, treatment|77 patients with idiopathic hypogonadotropic hypogonadism were treated with testosterone gel, testosterone enanthate or human chorionic gonadotropin
3274157|NCT01601327|No Intervention|Control group|42 healthy controls
3274158|NCT01601340|Active Comparator|HQK-1001|
3274159|NCT01601340|Placebo Comparator|Placebo|
3274160|NCT01601353|Experimental|Treatment|Injection of adipose derived cells into penis
3274161|NCT01601353|No Intervention|Control|No intervention through 9 months
3274162|NCT01601366|Experimental|LNG-IUS (Mirena)|"Group I the LNG-IUS group where they will have a LNG IUS (mirena) inserted for them"
3274163|NCT01601366|Active Comparator|Combined oral contraceptives|"Group II COCs group where they will receive low dose combined oral contraceptive pills for 6 months"
3274164|NCT01601392|Experimental|Anodal tDCS|
3274165|NCT01601392|Active Comparator|Cathodal tDCS|
3274166|NCT01601392|Sham Comparator|Sham|
3274167|NCT01601457|Experimental|Activated recombinant human factor VII|
3274168|NCT01601457|Placebo Comparator|Placebo|
3274169|NCT01601483|Experimental|MC-1101 1% Ophthalmic Solution|
3274170|NCT01601483|Placebo Comparator|Vehicle control|
3274171|NCT01601509|Active Comparator|nasal spray with tramazoline and dexamethazone|
3274172|NCT01601509|Placebo Comparator|Placebo|
3274173|NCT01601522|Experimental|Desentization dose|500 mg Peanut Protein
3274174|NCT01601522|Placebo Comparator|Placebo|Oat flour
3274175|NCT01601548|Experimental|Intervention Arm|Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention. Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices. There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day. A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
3274176|NCT01601548|No Intervention|Control Arm|No intervention is administered. Health-related quality of life questionnaires will be completed.
3274177|NCT01601561|Experimental|High-dose insulin|
3274178|NCT01601561|No Intervention|Control|
3274179|NCT01601574|Experimental|Modified Weight Watchers program|
3274180|NCT01601574|Active Comparator|Standard Diabetes Counseling group|
3274181|NCT01601587|No Intervention|Treatment as usual|Patients will receive treatment as usual
3274182|NCT01601587|Other|Introduction Seminar|Psychoeducational group
3274183|NCT01601600|Placebo Comparator|Placebo|
3274184|NCT01601600|Experimental|BYM338|BYM338 active drug
3274185|NCT01601613|Experimental|rFVIIa|
3274186|NCT01601613|Placebo Comparator|placebo|
3274187|NCT01601639|Active Comparator|Argon Plasma Coagulation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
3274188|NCT01601639|Active Comparator|Endoscopic Band Ligation|Patients with GAVE and/or chronic anemia, active GI bleeding, blood transfusion requirements
3274189|NCT01601665||Toric High Cylinder Power IOL|Toric high cylinder power intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
3274190|NCT01601665||Monofocal IOL|Monofocal intraocular lens implanted during cataract surgery in the first operative eye, with the second operative eye implanted within 30 days of the first implantation.
3274191|NCT01601678|Active Comparator|Peroral Endoscopic Myotomy POEM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the POEM therapy group
3274192|NCT01601678|Active Comparator|Laparoscopic Heller Myotomy LHM|Patients with Achalasia, designated to receive a myotomy of the lower esophageal sphincter, who have been randomised into the LHM therapy group.
3274193|NCT01601717|Placebo Comparator|Sugar pill|
3274194|NCT01601717|Active Comparator|RTI-336|
3274195|NCT01601730|Placebo Comparator|Placebo|
3274196|NCT01601730|Active Comparator|Modafinil 200 mg + Escitalopram 20 mg|
3274197|NCT01601730|Active Comparator|Modafinil 200 mg|
3274198|NCT01601730|Active Comparator|Escitalopram 20 mg|
3274199|NCT01601743|Active Comparator|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
3274200|NCT01601743|Active Comparator|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
3274201|NCT01601743|Active Comparator|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
3274202|NCT01601756|Experimental|navigated revision total knee arthroplasty|revision total knee arthroplasty with the aid of a navigation system
3274203|NCT01601756|Active Comparator|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
3274204|NCT01601769|Active Comparator|Colposcopy|a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
3274205|NCT01601769|Experimental|Vitom|The VITOM system, consisting of the VITOM scope, xenon light source, HD camera system, AIDA HD documentation system, 1 monitor, and a mechanical support arm (all Karl Storz, Tuttlingen, Germany) is used for video exocolposcopy.
3274206|NCT01601795|Active Comparator|Sevoflurane|During cardiopulmonary bypass, sevoflurane will be administered through a vaporizer integrated into heart-lung-machine.
3274207|NCT01601795|Active Comparator|Isoflurane|During cardiopulmonary bypass, isoflurane will be administered through a vaporizer integrated into heart-lung-machine.
3274208|NCT01601808|Placebo Comparator|Gemcitabine and Placebo|Standard therapeutic arm. Placebo orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
3274209|NCT01601808|Experimental|Gemcitabine and vandetanib|Experimental arm. Vandetanib orally once a day continuously together with gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 7 consecutive weeks. This will then be followed by a one week break and then gemcitabine 1000mg/m2 weekly as a 30 minute infusion for 3 weeks followed by a one week break in subsequent cycles.
3274210|NCT01601834|Experimental|Cohort 1: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 1 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
3274211|NCT01601834|Experimental|Cohort 2: Experimental intervention: PF-06273340 or placebo|Subjects in Cohort 2 will receive single ascending doses of PF-06273340 or placebo to investigate the safety/tolerability and PK of PF-06273340. The effect of food on PK may also be investigated.
3274212|NCT01601886||Before SUPPORT|01/03-06/05
3274213|NCT01601886||During SUPPORT recruitment|07/05-02/09
3274214|NCT01601886||After SUPPORT|03/09-06/10
3274215|NCT01601899|Active Comparator|ARM A|Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3274216|NCT01601899|Active Comparator|ARM B|Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3274217|NCT01601899|Active Comparator|ARM C|TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
3274218|NCT01601912||Atomoxetine NRI|We will modulate endogenous adrenergic pain inhibitory mechanisms by using a selective norepinephrine reuptake inhibitor (NRI).
3274219|NCT01601912||Citalopram SSRI|We will modulate serotonergic pain inhibitory mechanisms by using a selective serotonin reuptake inhibitor (SSRI)
3274220|NCT01601925|Experimental|neck extended group|We measured the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck.
3274221|NCT01601938|Experimental|Selenium|500 mcg of selenium (10mL) daily for 7 days
3274222|NCT01601938|Placebo Comparator|Placebo|Placebo 10 mL (delivered from biosyn) for 7 days
3274223|NCT01601951||Hip Osteoarthritis|
3274224|NCT01601951||Knee Osteoarthritis|
3274225|NCT01601964||Follow-up or medical treatment.|medical treatment
3274226|NCT01601964||Surgical treatment|Surgical treatment
3274227|NCT01601990|Placebo Comparator|Placebo|
3274228|NCT01601990|Experimental|LC15-0444|
3274229|NCT01602003|Experimental|LC15-0444 25 mg bid|LC15-0444 25 mg bid(twice daily)added on Metformin therapy
3274230|NCT01602003|Experimental|LC15-0444 50 mg qd|LC15-0444 50 mg qd(once daily) added on Metformin therapy
3274231|NCT01602003|Active Comparator|Sitagliptin 100mg qd|Sitagliptin 100 mg qd (once daily) added on the Metformin therapy
3274232|NCT01602029|Active Comparator|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
3274233|NCT01602029|Active Comparator|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
3274234|NCT01602029|Placebo Comparator|Placebo|Placebo added to TAU
3274235|NCT01602029|Active Comparator|Odansetron Plus Simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
3274236|NCT01602055|Experimental|Azivol|
3274237|NCT01602055|Active Comparator|Zithromax|
3274238|NCT01602081||LIFT+Biodesign|
3274239|NCT01602094||Adequate antimeales antibody levels|ELISA test OD > 0.1
3274240|NCT01602094||Inadequate measles antibody levels|ELISA test OD < 0.1
3274241|NCT01602107|No Intervention|Control|Participants in the control group will not receive therapist-supervised intervention. An exercise sheet briefly describing pelvic floor muscle exercises will be provided, as would be the standard practice from most physicians.
3274242|NCT01602107|Experimental|Pelvic Floor Therapy|Participants in the experimental group undergo and assessment and treatment by a registered physiotherapist. Treatments will include two sessions of biofeedback training, therapist-assisted strengthening exercises, and will a prescribed home exercise program to strengthen their pelvic floor muscles.
3274243|NCT01602133|Experimental|one intervention arm|
3274244|NCT01602146||ultramarathon runner|People who do the Mont Blanc ultramarathon (31/08/12 to 02/09/12)
3274245|NCT01602159|Active Comparator|Open Bypass Surgery|Open Bypass Surgery
3274246|NCT01602159|Active Comparator|Angioplasty and Stenting|
3274247|NCT01602185|Experimental|memantine|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3274248|NCT01602185|Experimental|dextromethorphan|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3274249|NCT01602185|Placebo Comparator|placebo|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
3274250|NCT01602211|Experimental|Arm I (INSPIRE internet full program access)|Participants receive full access to the INSPIRE internet site comprising an individually tailored program with a greeting home page with links to each target area, a 'My Health Action Plan' health care guideline for transplant survivors, self-care tips and tool pages for each complication and major issues for HCT survivors, a section for each complication (mood, energy, heart health, strengthening bones, second cancers), resource pages, opportunities to send secure messages with questions or comments on any topic, opportunities to request additional assistance or information, mobile texting options, and social media links (Twitter/Facebook/Pinterest) maintained and monitored by the Social Media Specialist.
3274251|NCT01602211|Experimental|Arm II (delayed program access control)|Participants receive annotated website links to existing transplant and cancer survivor sites, followed by delayed access to the INSPIRE internet program after 1 year.
3274252|NCT01602237||Bakery workers|
3274253|NCT01602250|Placebo Comparator|levobupivacaine placebo|levobupivacaine placebo
3274254|NCT01602250|Experimental|levobupivacaine Intralipid®|levobupivacaine Intralipid®
3274255|NCT01602250|Experimental|ropivacaine Intralipid®|ropivacaine Intralipid®
3274256|NCT01602250|Placebo Comparator|ropivacaine placebo|ropivacaine placebo
3274261|NCT01602276|Experimental|Active Stimulation|Transcranial direct current stimulation using Anodal or Cathodal stimulation over the area of interest
3274262|NCT01602276|Sham Comparator|Sham Stimulation|Transcranial direct current stimulation (tDCS) that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS.
3274263|NCT01602289|Experimental|LY2875358|Part A. LY2875358 will be administered intravenously (IV) at escalating doses (700 mg up to 2000 mg) on Day 1 and Day 15 of a 28-day cycle, until any discontinuation criterion is met.
3274264|NCT01602289|Experimental|LY2875358+Erlotinib|Part B1. Erlotinib will be administered orally at 150 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B1 was added per protocol amendment in January, 2013.)
3274265|NCT01602289|Experimental|LY2875358+Gefitinib|Part B2. Gefitinib will be administered orally at 250 mg dose level each day. LY2875358 will be administered intravenously (IV) at recommended dose level in Part A on Day 1 and Day 15 of a 28-day cycle. (Part B2 was added per protocol amendment in January, 2013.)
3274266|NCT01602302|Experimental|single arm ( bDMARD withdrawal )|single arm (bDMARD withdrawal)
3274267|NCT01602328|Active Comparator|AC607|Treatment with AC607
3274268|NCT01602328|Placebo Comparator|Placebo|Treatment with Placebo
3274269|NCT01602354||Gram-negative Septic shock|Patients affected by Gram-negative septic shock
3274270|NCT01602367|Experimental|Arm 1: BMS-823778 (2mg)|
3274271|NCT01602367|Experimental|Arm2: BMS-823778 (6mg)|
3274272|NCT01602367|Experimental|Arm 3: BMS-823778 (15mg)|
3274273|NCT01602367|Experimental|Arm4: Placebo|
3274274|NCT01602393|Experimental|CHF 5074 1x|oral tablet, multidose
3274275|NCT01602393|Experimental|CHF 5074 2x|oral tablet, multidose
3274276|NCT01602393|Experimental|CHF 5074 3x|oral tablet, multidose
3274277|NCT01602406|Experimental|LJM716 in combination with trastuzumab|
3274278|NCT01602432||High Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is ≥ 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~Based on this method, the model includes 5 predictive variables as follows:~Site of cancer: classified as very high-risk (+2 points) or high-risk (+1 point).~Platelet count: (>350 x 109/L) (+1 point)~Hemoglobin level (<100 g/L) and/or use of erythropoiesis stimulating agents (+1 point)~Leukocyte count (> 11 x 109/L)(+1 point).~body mass index (≥ 35 Kg/m2) (+1 point)."
3274279|NCT01602432||Low high Risk Group|"Defined as patients whose primary malignancy is located in the brain, bladder, lung, testicle, stomach, pancreas and lymphatic system and whose risk score before the beginning of anticancer treatment is < 2 according to the Risk Stratification Method proposed by Khorana et al. (2008).~In order to confirm the patient low risk status, we will draw a blood sample to determine serum levels of D- dimer and soluble P selectin in patients of this low risk group according to Ay et al. (2010). If levels of D-dimer are ≥ 1.44 µg/mL and/or soluble P selectin ≥ 53.1 ng/mL, we will add one point for each one of the increased biochemical marker and the total score recalculated."
3274280|NCT01602445||Cancer patients|All cancer patients with a diagnosed acute symptomatic VTE episode.
3274281|NCT01602458|Other|Silicone Only Therapy (SOT)|Mepiform™ silicone will be utilized by SOT group.
3274282|NCT01602458|Other|Silicone Pressure Garment Therapy (SPGT)|Mepiform™ silicone and custom compression garments fabricated by Barton Carey™ will be utilized by SPGT group.
3274283|NCT01602497|Active Comparator|rTMS intervention group|The rTMS intervention group undergo ten session of real TMS therapy.
3274284|NCT01602497|Placebo Comparator|Sham group|Patients will undergo ten session of sham rTMS.
3274285|NCT01602523|Active Comparator|budesonide/formoterol|budesonide/formoterol 160/4.5 mcg (Symbicort)
3274286|NCT01602523|Placebo Comparator|Placebo|Symbicort placebo
3274287|NCT01602536|Experimental|Twitter|Experimental participants are assigned a 20-person twitter quit-smoking group to interact with, are instructed to use Twitter-enabled interactive peer messaging,and are sent daily messages to encourage interaction. The baseline intervention 'smoking cessation aides' is also provided.
3274288|NCT01602536|Active Comparator|Control|Control participants are not assigned to a twitter group. The baseline intervention 'smoking cessation aides' is also provided.
3274289|NCT01602575|Experimental|mindfulness treatment|Mindfulness based stress reduction is the intervention in this single arm trial
3274290|NCT01602588|Experimental|Arm B|Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.
3274291|NCT01602588|Active Comparator|Arm A: SCRT alone|Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy
3274292|NCT01602601||Cohort 1|Patients will have a single blood draw for the analysis of antibodies induced by idursulfase. Samples will be used to further evaluate whether the antibodies induced by idursulfase bind to GSK2788723 molecules in vitro and if these antibodies neutralize the bioactivity of GSK2788723 in vitro.
3274293|NCT01602627|Experimental|Treatment (enzyme inhibitor therapy)|Patients receive Hsp90 inhibitor AUY922 IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3274294|NCT01602640|Experimental|Morphine|
3274295|NCT01602640|Active Comparator|Fentanyl and Midazolam|Control
3274296|NCT01602653|Active Comparator|1|the first group of patients received an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
3274297|NCT01602653|Active Comparator|2|The second grouop of patients received 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
3274298|NCT01602705|Placebo Comparator|Usual care|
3274299|NCT01602705|Active Comparator|Usual care + feedback of practice performance|
3274300|NCT01602705|Active Comparator|Usual care + feedback + health psychology intervention|
3274301|NCT01602718|No Intervention|Physical Function/Activity|"cross-sectional comparison study of physical function/activity, frailty and inflammation measures in prevalent home Dx and prevalent in-center hemodialysis patients.~Subjects: Forty-five prevalent home dialysis patients will be recruited and tested once for all outcome measures. Forty-five prevalent in-center hemodialysis patients will be identified from prevalent patients in the University of Utah in-center dialysis system who are matched for gender, age, comorbidities and time on dialysis as the home dialysis patients who have been tested. Consenting patients will be tested for all outcome measures once and compared to the home dialysis group."
3274302|NCT01602718|No Intervention|Incident Patients|"Study 2: is a longitudinal cohort study of incident patients starting either home dialysis or in-center hemodialysis.~Consenting patients will be tested upon initiation of dialysis therapy and every 6 months for 18 months to track physical functioning /activity, frailty and inflammation over time."
3274303|NCT01602718|Other|Independent Home Exercise|pilot study of independent home exercise training in home dialysis (PD only) patients. Consenting patients will be tested at baseline, then randomized into exercise training or usual care (no prescribed change in activity levels) and retested after 3 months.
3274304|NCT01602757|Experimental|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
3274305|NCT01602770||Group 1|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
3274306|NCT01602783|Experimental|11C Acetate Imaging|11C acetate imaging
3274307|NCT01602796|Experimental|School-based intervention|
3274308|NCT01602796|No Intervention|Control|
3274309|NCT01602822|Other|Atazanavir, Ritonavir, Truvada|Open Label
3274310|NCT01602848|Experimental|Intervention enrollee|HIgh risk fee for service Medicaid recipients identified as eligible by the New York State Dept of Health and enrolled in the intensive care management and coordination intervention
3274311|NCT01602848|No Intervention|Eligible, not enrolled|Medicaid fee-for-service patients who are identified as eligible for the intervention but are not enrolled. These patients receive usual services provided by Medicaid.
3274312|NCT01602861|Experimental|Spironolactone|
3274313|NCT01602861|Placebo Comparator|Placebo|
3274314|NCT01602874|Experimental|A. Tigecycline|
3274315|NCT01602874|Active Comparator|B. Ceftriaxone regimen|
3274316|NCT01602887|Active Comparator|Reference|This is the reference formulation
3274317|NCT01602887|Experimental|NF1|This is a test formulation
3274318|NCT01602887|Experimental|NF2|This is a test formulation
3274319|NCT01602887|Experimental|SOL|This is a test formulation
3274320|NCT01602900|Experimental|GSK356278|Investigational drug
3274321|NCT01602913||Patients with diagnosis of Type II Diabetes|Patients indicating T2DM after the index date (ICD-9-CM 250.x), or 1 diagnostic code and 1 prescription of oral anti-diabetic medications or insulin (or Byetta and Victoza) after the index date
3274322|NCT01602913||Patients without diagnosis of Type II Diabetes|Patients not indicating T2DM
3274323|NCT01602926|Experimental|conventional surgery arm|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws.
3274324|NCT01602926|Experimental|minimally invasive technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal
3274325|NCT01602939|Experimental|2CDA+IFN|
3274326|NCT01602952|Experimental|Radotinib|"Phase 1 : 200mg/kg or 1200mg/m^2~Phase 2 : 400mg Bid"
3274327|NCT01603004||everolimus, sunitinib or traditional chemotherapy|A total of 30 patients with well differentiated pancreatic NETs who have known liver metastases and who are planned to initiate therapy with either targeted (everolimus or sunitinib) or traditional cytotoxic chemotherapy will be recruited for this study. We plan to recruit approximately 10 patients for each therapy (everolimus, sunitinib, cytotoxic chemotherapy). Evidence of metastatic disease will be determined at the discretion of the oncologist based on available imaging, surgical and pathologic evidence.
3274328|NCT01603017|Placebo Comparator|Placebo - no therapy|Patients who were blinded but did not receive therapy
3274329|NCT01603017|Experimental|MRI therapy|Patients receiving MRI therapy but blinded to it
3274330|NCT01603030|Experimental|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
3274331|NCT01603030|Active Comparator|moxifloxacin 0,5% + Prednisolone 1%|1 drop of each bottle, BID, 15 days
3274332|NCT01603069|Active Comparator|AZD3241, 300 mg|AZD3241 300 mg BID
3274333|NCT01603069|Active Comparator|AZD3241, 600 mg|AZD3241 600 mg BID
3274334|NCT01603069|Placebo Comparator|Placebo|Placebo to AZD3241
3274335|NCT01603095||Growth measurements|Approximately 500 patients will be enrolled. Patients from birth to <= 17 years on the date of consent will be enrolled. Approximately equal numbers of boys and girls will be enrolled.
3274336|NCT01603108|Experimental|Rifaximin Arm|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
3274337|NCT01603108|Placebo Comparator|Placebo Control Arm|Rifaximin placebo will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo will be taken twice daily for 90 days (+/- 10 days) post-LT.
3274338|NCT01603134|Experimental|Allopurinol 300 mg Tablets USP|Allopurinol 300 mg Tablets USP of M/s Ipca Laboratories Limited, India
3274339|NCT01603134|Active Comparator|Zyloprim®|Zyloprim® (Allopurinol) 300 mg Tablets manufactured by Catalytica Pharma Inc., USA for Prometheus Laboratories Inc., USA,
3274340|NCT01603147|Placebo Comparator|Saline|A total of 10 subjects will receive placebo
3274341|NCT01603147|Experimental|ch-mAb7F9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively.
3274342|NCT01603160||Emergency Department Staff|"Interventions put in place in the Emergency Department will effect most staff who work in the ED, but different sub-groups will be approached for participation in specific aspects of the study:~All ED attending and resident physicians and ED nurses will be invited to complete the SCD Attitudes survey.~Select ED Staff will be invited to be members of the QI team and will be invited to participate in the FMECA.~Members of the QI team will be invited to participate in a focus group."
3274343|NCT01603173|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
3274344|NCT01603173|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
3274345|NCT01603186|Experimental|Quetiapine Fumarate Tablets 25 mg|Quetiapine Fumarate Tablets 25 mg of M/s Ipca Laboratories Limited, India
3274346|NCT01603186|Active Comparator|Seroquel®|Seroquel® (Quetiapine Fumarate) Tablets 25 mg of M/s AstraZeneca Pharmaceuticals LP, USA
3274347|NCT01603199|Experimental|Primary biliary cirrhosis (Non-cirrhotic)|
3274348|NCT01603199|Experimental|Primary biliary cirrhosis (Cirrhotic)|
3274349|NCT01603212|Experimental|Vemurafenib + IL-2 + Interferon Alfa-2b|Starting dose of Vemurafenib 720 mg by mouth twice daily. Three dose levels of Vemurafenib evaluated in combination with interferon and IL-2. These doses are 480 mg, 720 mg and 960 mg. IL-2 given by continuous venous infusion at starting IL-2 dose of 7 million IU/m2 daily for 4 days (total of 96 hours, days 2-5) starting day 2. IL-2 dose levels are 5MU/m2/day, 7MU/m2/day and 9MU/m2 day. Doses of interferon remain constant at 5 MU/m2 subcutaneously daily for 5 days starting Day 1.
3274350|NCT01603225||Autism|Individuals with autism will have either Anodal, Cathodal, or Sham Transcranial Direct Current Stimulation (tDCS).
3274351|NCT01603238|Experimental|[14C]-LC15-0444|A single oral dose of [14C]-LC15-0444 50 mg , containing 4.9 MBq [14C] (batch number 110372/C/01).
3274352|NCT01603251|Active Comparator|Artemether-Lumefantrine|
3274353|NCT01603251|Experimental|Artemether-Lumefantrine + single dose Ivermectin|
3274354|NCT01603251|Experimental|Artemether-Lumefantrine + repeated dose Ivermectin|
3274355|NCT01603264|Experimental|A|PF-05280014
3274356|NCT01603264|Active Comparator|B|Trastuzumab-EU
3274357|NCT01603264|Active Comparator|C|Trastuzumab-US
3274358|NCT01603290||Hospitalized Leukemia Patients|leukemia patients with chemotherapy during hospitalization
3274359|NCT01603303|Other|Usual Care + Education Materials|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
3274360|NCT01603303|Experimental|Luvena Group|Luvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
3274361|NCT01603303|Experimental|Hyalo-Gyn Group|Hyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
3274362|NCT01603316|Active Comparator|Food Voucher Program (Voucher)|Food Voucher arm, each participant will receive a debit card specifically created for this program. Each month for the duration of study participation (6 months), the debit card will be credited with $128 & given to the patient in person or via mail. Patients will be instructed to use these cards only for food purchases. If patients are not able to use the debit card at their local grocery stores, patients will be provided with a money order of the same dollar value instead of the debit card. They will be counseled on using their vouchers only for healthful foods, in a way that stretches their food dollars. Purchases will be tracked by having patients bring their receipts in for review each month when they come in to pick-up their next monthly vouche, or by providing electronic copies of receipts. Patients will be provided with a receipt holder to assist in storing receipts for review. For voucher cards sent via mail, patients will receive a mailing letter accompanying each card.
3274363|NCT01603316|Experimental|Home Grocery Delivery (Delivery)|"In the Home Grocery Delivery arm, each participant will receive home grocery delivery from PeaPod grocery delivery service or from FreshDirect (depending on the participants zip code), worth $128 per month, for the duration of study participation (6 months). Patients in the Delivery arm will review a list of food categories and a subset of items in each category with a COA."
3274364|NCT01603316|Experimental|Medically-Tailored Hospital-Based Food Pantry (Pantry)|Patients in this arm will have access to the pantry for the duration of their study participation (6 months). Those accessing the medically-tailored food pantry will pick-up a pantry bag weekly or bi-weekly (per patient preference) at the hospital, either during one of their medical appointments or at another preferred time. Each patient's food prefereces will be assessed once during baseline and they will be given food bags, tailored when possible and when available to these preferences and to their medical needs and cultural preferences.
3274365|NCT01603329|Experimental|Comprehensive incentives + comprehensive communication|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
3274366|NCT01603329|Experimental|Comp incentives + comp communication + non-white paper|Physicians are given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication, and their patient reports are printed on non-white bright colored paper.
3274367|NCT01603329|Experimental|Focused incentives + focused com for oral diabetes medication|Physicians are given financial incentives for improving patient medication adherence for oral diabetes medication.
3274368|NCT01603329|Experimental|Foc incentives + foc comm for Diabetes + non-white paper|Physicians given financial incentives for improving patient medication adherence for oral diabetes medication and patient reports are printed on bright non-white paper.
3274369|NCT01603329|Experimental|Focused incentives + focused comm for hypertension meds|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication.
3274370|NCT01603329|Experimental|Foc incentives + comm for hypertension meds + non-white paper|Physicians are given financial incentives for improving patient medication adherence for hypertension (ACEI or ARB) medication with patient reports on non-white paper.
3274371|NCT01603329|Experimental|Focused incentives + focused comm for cholesterol meds|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication.
3274372|NCT01603329|Experimental|Foc incentives +comm for cholesterol meds + non-white paper|Physicians given financial incentives for improving patient medication adherence for cholesterol (statins) medication and patient reports are printed on non-white paper.
3274373|NCT01603329|Experimental|Comprehensive communiation|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication.
3274374|NCT01603329|Experimental|Comprehensive communication + non-white paper|Physicians are given communication emphasizing the importance of improving adherence to all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication and patient reports are printed on non-white paper.
3274375|NCT01603329|Experimental|Control Arm|Physicians and their patient adherence is tracked, but they receive no intervention.
3274376|NCT01603342|Experimental|clopidogrel|
3274377|NCT01603342|Placebo Comparator|Placebo|
3274378|NCT01603381|Experimental|CBT-I|Cognitive Behavioral Therapy for Insomnia
3274379|NCT01603381|No Intervention|Monitor Only (M.O.)|
3274380|NCT01603407|Experimental|Daily prednisone|daily prednisone (0.75 mg/kg/day)
3274381|NCT01603407|Experimental|Intermittent prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off)
3274382|NCT01603407|Experimental|Daily deflazacort|daily deflazacort (0.9 mg/kg/day
3274383|NCT01603433|Experimental|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
3274384|NCT01603446|Experimental|MELAS Patients|Three siblings with MELAS (A3243G) syndrome (1 male; 2 females) aged 17-23 years, followed or previously followed in the Neurometabolic Clinic at the Hospital for Sick Children will be studied.
3274385|NCT01603446|No Intervention|Control Group|Four age- and sex-matched controls and female controls will be matched according to phase in menstrual cycle corresponding with their age-matched MELAS subjects
3274386|NCT01603472||Subjects on Parenteral Nutrition|cases are those on Parenteral Nutrition >6 weeks for intestinal failure.
3274387|NCT01603472||Subjects not on Parenteral Nutrion|Controls are those who have never been on PN but can be fed via a feeding tube
3274388|NCT01603485|Experimental|Lersivirine|
3274389|NCT01603498|Experimental|Dexamethasone 8mg|
3274390|NCT01603498|Experimental|Methylprednisolone|Methylprednisolone 40mg
3274391|NCT01603524|Active Comparator|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
3274392|NCT01603524|Experimental|OMSC + Performance Feedback Group|The OMSC + Provider Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic.
3274393|NCT01603537||PHTLS|The exposure is defined from the dichotomization of the probability in each event/accident that at least one of the caring ambulance crew members was PHTLS certified.
3274394|NCT01603537||No PHTLS|Not exposed to PHTLS
3274395|NCT01603550|Experimental|Energy Restriction|
3274396|NCT01603550|Experimental|Sleep Deprivation|
3274397|NCT01603563|Experimental|Stepped Care TF-CBT|Patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
3274398|NCT01603563|Active Comparator|Standard TF-CBT|Patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
3274399|NCT01603576|Experimental|Suprachoroidal retinal prosthesis|
3274400|NCT01603589|Active Comparator|MiECC group|Patients operated for elective coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation (MiECC).
3274401|NCT01603589|Active Comparator|CECC group|Patients operated for elective coronary artery bypass grafting under conventional extracorporeal circulation (CECC).
3274402|NCT01603654|Experimental|sodium picosulphate/magnesium citrate|
3274403|NCT01603654|Active Comparator|low-volume PEG -ascorbic acid|
3274404|NCT01603667|Experimental|PG2 Injection 500 mg|PG2 Injection 500 mg
3274405|NCT01603667|Placebo Comparator|Placebo|Placebo
3274406|NCT01603680|Other|Circumferential (C)|"Circumferential(C) spread group will be defined as mepivacaine injectate visualized by ultrasonography all around the median and ulnar nerves imaged in short axis."
3274407|NCT01603680|Other|Non circumferential (NC)|Local anesthetic spread will be asymmetrical around the median and ulnar nerves, the mepivacaine will be partially in contact with the nerve
3274408|NCT01603693|Experimental|Bio-Oss|In this arm,GBR will be performed with DBBM (Bio-Oss, Geistlich) in 25 patients.
3274409|NCT01603693|Experimental|Bio-Oss and BondBone|In this arm, GBR will be performed using a combination of DBBM (Bio-Oss, Geistlich) and bi-phasic calcium sulphate (BondBone, Augma) in 25 patients.
3274410|NCT01603706|Active Comparator|Echo guided implantation group|Echo guided implantation group Patients undergoing speckle tracking based LV lead implantation.
3274411|NCT01603706|No Intervention|Conventional implantation group|Patients undergoing conventional LV lead implantation
3274412|NCT01603719|No Intervention|Standard Formula|Standard formula with no supplementation
3274413|NCT01603719|Experimental|experimental formula|infant formula with higher beta-palmitate and supplemented GOS
3274414|NCT01603732||Moms w HLHS or variant|Mom's fetal diagnosis Hypoplastic Left Heart Syndrome/variant
3274415|NCT01603732||Moms w/ Other congential heart defect)|Moms fetal diagnosis -other congenital heart defects
3274416|NCT01603732||Moms-fetal - echo normal|Moms echo fetal diagnosis is normal.
3274417|NCT01603732||Random Healthy Moms|Mom with healthy pregnancy.
3274418|NCT01603745|Active Comparator|NOMAC-valerate estradiol|E/P therapy
3274419|NCT01603745|Active Comparator|Drospirenone/ethinylestradiol|E/P therapy
3274420|NCT01603758|No Intervention|Observational Arm|Cholesterol metabolic parameters will be measured in 100 subjects in an observational study. Results will be related to circulating biomarkers and carotid intima-media thickness.
3274421|NCT01603758|Placebo Comparator|Ezetimibe Interventional Arm|Cholesterol metabolic parameters will be measured before and after ezetimibe or placebo intervention. Changes due to ezetimibe will be determined
3274422|NCT01603771||Combined|Participants assigned to this group have been randomized to the Combined group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month standardized aerobic training program at a local recreational center, 3 times per week for 1 hour. Participants in this group also perform an 8-week cognitive training program 3 days per week for 1 hour, during months 5 and 6. The cognitive training program is computer-based, and focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. The cognitive training is conducted on concurrent days with aerobic exercise training sessions, also on site at the recreational center.
3274423|NCT01603771||Control|Participants assigned to this group have been randomized to the Control group of the parent study, Combining Exercise and Cognitive Training to Improve Everyday Function(EXACT)(Unique Protocol ID 201102416). Participants perform a 6-month home exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes and record their activity on a calendar. Participants also attend weekly 1-hour Health Education sessions for 8 weeks, during months 5 and 6. These sessions cover topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and home energy conservation.
3274424|NCT01603784|Experimental|Combined|Aerobic Exercise + Cognitive Training
3274425|NCT01603784|Experimental|Exercise|Aerobic Exercise + Health Education
3274426|NCT01603784|Experimental|Cognitive|Home Exercise + Cognitive Training
3274427|NCT01603784|Experimental|Control|Home Exercise + Health Education
3274428|NCT01603797|Experimental|Internet delivered ACT|Internet delivered acceptance and commitment therapy (ACT), 7 weeks treatment
3274429|NCT01603797|Active Comparator|Online discussion forum|Active wait-list condition. Were offered to participate in a moderated online discussion forum. After post-treatment assessment the control group were offered treatment.
3274430|NCT01603810||BCC|Adult of any age or gender with capacity to give informed consent who has a basal cell carinoma requiring surgical excision and involving the periocular skin
3274431|NCT01603823||Healthy volunteers|
3274432|NCT01603823||St.p. Pars plana vitrectomy|
3274433|NCT01603836|Experimental|bone marrow concentrate|In forty cases, the posterolateral fusion was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
3274434|NCT01603849|Experimental|A Prophylactic Cranial Irradiation|Patients will received PCI 25 Gy in 10 fractions WBRT 4 weeks after initial treatment in the absence of disease progression.
3274435|NCT01603849|No Intervention|B Observation Group|Patients in this arm will be observed (not receiving WBRT)
3274436|NCT01603862|Experimental|ThinkingFit|
3274437|NCT01603888||healthy newborns, BNP, NT-proBNP|healthy newborns
3274438|NCT01603888||infants, BNP, NT-proBNP|infants
3274439|NCT01603888||children with heart disease, BNP, NT-proBNP|children with heart disease
3274440|NCT01603901|Experimental|Investigated Wounds|
3274441|NCT01603914|Experimental|scheduled wire-guided every six days|scheduled wire-guided every six days and a replacement of the catheter in a different place after 12 days from randomization.
3274442|NCT01603914|Experimental|Scheduled replacement every six days|Scheduled replacement every six days in a different location
3274443|NCT01603914|Experimental|replacement guided by clinical criteria|re change of catheter strategy guided by clinical suspicious of catheter-related bacteremia and replacement of the catheter in a different location.
3274444|NCT01603927||Colonoscopy with Narrow band imaging (NBI)|All patients attending for routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
3274445|NCT01603979|Experimental|Dose-escalation AV-203 Monotherapy|dose-escalation of monotherapy AV-203 (an ERBB3 inhibitory antibody) by IV every two weeks
3274446|NCT01604005|Experimental|PIT Arm|
3274447|NCT01604005|No Intervention|No PIT Arm|
3274448|NCT01604018||Placebo|Subjects previously randomized to receive placebo in study CP005 and completed CP005A.
3274449|NCT01604018||Cat-PAD Group 1|Subjects previously randomized to receive Cat-PAD dose 1 in study CP005 and completed CP005A.
3274450|NCT01604018||Cat-Pad Group 2|Subjects previously randomized to receive Cat-PAD dose 2 in study CP005 and completed CP005A.
3274451|NCT01604031|Experimental|B-CLL vaccine|Patients will receive doses of vaccine at 2 week intervals for 5 doses and at 4 week intervals for doses 6-16. The injection will be performed subcutaneously in the deltoid region of the upper arm.
3274452|NCT01604044|Active Comparator|HP-hMG|
3274453|NCT01604044|Active Comparator|rFSH plus rLH|
3274454|NCT01604057|Experimental|Low Dose Nasal Spray|
3274455|NCT01604057|Experimental|Mid Dose Nasal Spray|
3274456|NCT01604057|Experimental|High Dose Nasal Spray|
3274457|NCT01604057|Active Comparator|Forteo|20ug subcutaneous injection daily
3274458|NCT01604057|Placebo Comparator|Placebo Nasal Spray|
3274459|NCT01604070||Nextra fusion|group that has the nextra device
3274460|NCT01604070||k wire fixation|control group fixated with k wire
3274461|NCT01604096|Experimental|Intervention areas|Provinces of Modena and Parma (about 1.100.000 inhabitants - campaign targeted to the general population), in Northern Italy (Emilia-Romagna Region)
3274462|NCT01604096|No Intervention|Control|All the other provinces in the Emilia-Romagna Region (where the information campaign has not been implemented)
3274463|NCT01604135|Active Comparator|Corneal Collagen Crosslinking|The keratokonic eye which progresses most is included and randomized. Significant progression is defined in the eligibility criteria section. If randomized to the treatment arm the cornea is treated with collagen crosslinking as described below.
3274464|NCT01604135|No Intervention|Control group|The keratokonic eye which progresses most is included and randomized to either the treatment group (CXL) or the control group.
3274465|NCT01604148||HoLEP group|Holmium Laser Enucleation of Prostate Group
3274466|NCT01604161||Somatropin|
3274467|NCT01604174|Experimental|Interactive Virtual Telerehabilitation|Rehabilitation by IVT
3274468|NCT01604174|Active Comparator|Standard rehabilitation care|Standard care rehabilitation after total knee arthroplasty
3274469|NCT01604187|Active Comparator|Fentanyl|Ten minutes before the procedure fentanyl 100 mikrograms sublingual tablet will be given to the patient.
3274470|NCT01604187|Placebo Comparator|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
3274471|NCT01604200||Dentists|Dentists in practice
3274472|NCT01604213|Experimental|Vildagliptin+metformin|Oral Vildagliptin+metformin combination
3274473|NCT01604213|Active Comparator|Metformin only|Oral metformin only
3274474|NCT01604226||Gynecologic surgery group|Those undergoing gynecologic laparoscopic surgery with TIVA
3274475|NCT01604226||Urologic surgery group|Those undergoing urologic surgery with TIVA
3274476|NCT01604239|Experimental|Shinbaro|
3274477|NCT01604252||Cohort|
3274478|NCT01604304|Active Comparator|Extracorporeal shockwave lithotripsy|stone treatment using electroconductive technology
3274479|NCT01604304|Active Comparator|Flexible ureteroscopy|intra renal retrograde surgery with or without laser and stone extraction
3274480|NCT01604317|Active Comparator|Resuscitation-torso plastic bag|Resuscitation with plastic bag covering torso and lower extremities for first hour to assist with temperature regulation.
3274481|NCT01604317|Active Comparator|Resuscitation-partial-head plastic bag|Resuscitation with plastic bag covering torso, upper and lower extremities, and a portion of the head for first hour after birth to assist with temperature regulation.
3274482|NCT01604330|Experimental|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
3274483|NCT01604330|Placebo Comparator|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
3274484|NCT01604356|Experimental|Electro-acupuncture|
3274485|NCT01604369|Experimental|Cryoablation|
3274486|NCT01604382|Experimental|treatment|Receives General Anesthesia as described above
3274487|NCT01604382|Placebo Comparator|Placebo|Patients receives neuraxial anesthesia as described above
3274488|NCT01604395||growth hormone|
3274489|NCT01604421|Sham Comparator|Thermoregulation-standard care|Standard thermoregulation without a plastic bag from one hour after birth until discharge or 24 hours after birth, whichever comes first.
3274490|NCT01604421|Active Comparator|Thermoregulation-with plastic bag|Thermoregulation with plastic bag covering torso and lower extremities from one hour after birth until discharge or 24 hours after birth to assist with thermoregulation. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
3274491|NCT01604434|Sham Comparator|Incubator-no plastic bag|Placement into an incubator without a plastic bag
3274492|NCT01604434|Active Comparator|Incubator-torso bag|Placement into a plastic bag inside incubator
3274493|NCT01604447|Active Comparator|Incubator removal-torso bag|Use plastic bag covering the torso and lower extremities for temperature regulation with standard bundling practices when removing infant from incubator
3274494|NCT01604447|Placebo Comparator|Incubator removal-no plastic bag|Standard bundling practices when removing the infant from the incubator. No plastic bag used.
3274495|NCT01604460|Sham Comparator|Resuscitation-no plastic bag|Resuscitation per standard of care without a plastic bag
3274496|NCT01604460|Active Comparator|Resuscitation-torso bag|Use of plastic bag covering the torso and lower extremities for temperature regulation during and after resuscitation for the first hour after birth
3274497|NCT01604473||Chronic Kidney Disease|Individuals with Chronic Kidney Disease stages IV or V anticipating the need for hemodialysis access through an arterio-venous fistula.
3274498|NCT01604486||MI without ischaemic preconditioning|Myocardial infarction unheralded by any previous cardiovascular disease diagnosis and without symptoms of chest pain in the previous 90 days.
3274499|NCT01604486||MI with longstanding disease|Patients with myocardial infarction who have had diagnosed atherosclerotic disease for longer than 90 days preceding infarct.
3274500|NCT01604486||MI with only chest pain|Patients with chest pain in the 90 days preceding MI, but with no prior atherosclerotic disease diagnoses.
3274501|NCT01604486||MI with disease and chest pain|Myocardial infarction occurring with previously diagnosed atherosclerotic disease of longer than 90 days' duration, but with chest pain in 90 days preceding infarct.
3274502|NCT01604499|Experimental|Feedback only|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
3274503|NCT01604499|Experimental|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
3274504|NCT01604499|No Intervention|Control group|
3274505|NCT01604512|Experimental|Pts with a brain tumor|The study will prospectively enroll patients who have increasing size and/or enhancement of brain lesion(s) after brain radiation therapy for a neoplasm (either primary or metastatic), where. it is unclear if a lesion represents radiation injury or progressive tumor. At the discretion of PI the RSI sequence may be repeated at SOC FDG or other radiotracer imaging carried out while the patient is still on study, if deemed clinically necessary.
3274506|NCT01604525|Sham Comparator|Control|Participants randomized to this group received access to an untailored general interest/lifestyle website.
3274507|NCT01604525|Experimental|Tailored Health and Lifestyle Web|Participants randomized to this arm received tailored web content about health and wellness, with weekly goal-setting and feedback.
3274508|NCT01604525|Experimental|Tailored Web plus Peer Coaching|Participants randomized to this arm received access to weekly tailored health and wellness web content, plus weekly feedback from a peer health coach (videos uploaded to the web and phone calls).
3274509|NCT01604538||patients with acute pulmonary embolism|
3274510|NCT01604564||Colitis Ulcerosa|Colitis Ulcerosa With creation of IPAA
3274511|NCT01604564||Familial Adenomatous Polyposis|Familial Adenomatous Polyposis with creation of IPAA
3274512|NCT01604577|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
3274513|NCT01604577|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
3274514|NCT01604590||glioblastoma patients on bevacizumab|
3274515|NCT01604603||Control|
3274516|NCT01604603||Oligomenorrhea|
3274517|NCT01604603||Amenorrhea|
3274518|NCT01604603||premature ovarian failure|
3274519|NCT01604616||PCFL GROUP|patients in this group had the PFCL for a period of 7-10 days before it was replaced by SF6 gas or silicone oil
3274520|NCT01604616||control group|in thos group no PFCL was left in the eye and either SF6 or silicone oil was the definitive treatment at the time of the retinal detachment surgery repair.
3274521|NCT01604629|Experimental|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
3274522|NCT01604629|Active Comparator|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
3274523|NCT01604642|Other|cachectic versus no cachectic patients|blood tests, muscular biopsies
3274524|NCT01604655|Active Comparator|Coronary CT Angiography|Patient admitted with chest pain is randomized to CCTA for assessment.
3274525|NCT01604655|Active Comparator|Stress Test|Patients admitted with chest pain are randomized to a stress test (stress SPECT or Echocardiography) for assessment.
3274526|NCT01604668||RevF vs RevG vs Pronto-7|Comparison of hemoglobin levels derived by continuous hemoglobin sensor RevF versus continuous hemoglobin sensor RevG versus an intermittent hemoglobin level derived from the Pronto-7 hand-held device versus a hemoglobin derived from a blood sample.
3274527|NCT01604681|Placebo Comparator|placebo group|3 g of powdered gelatin encapsulated in opaque capsules.
3274528|NCT01604681|Experimental|Flaxseed oil group|Oil extracted from linseed by pressing the cold and encapsulated, providing 3g per day containing 1.75 g of alpha linolenic acid.
3274529|NCT01604694|Experimental|TAP Block with levobupivacaïne|
3274530|NCT01604694|Placebo Comparator|TAP Block with Placebo|
3274531|NCT01604707|No Intervention|Control group|Standard care
3274532|NCT01604707|Experimental|Medical Yoga|Group training with medical yoga in primary health care.
3274533|NCT01604733||HYPERCHOLESTEROLEMIC PATIENTS|
3274534|NCT01604746|No Intervention|Safety assessment|Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.
3274535|NCT01604759|Other|Polarized probe measurement.|All patients belong under this arm as all will be measured by the polarized probe and the data will be compared to the biopsy site's pathology results.
3274536|NCT01604798||Colorectal Cancer Patients|Patients with histologically confirmed colorectal cancer
3274537|NCT01604798||Healthy Controls|Healthy volunteers
3274538|NCT01604811|Experimental|Tested product|
3274539|NCT01604811|Active Comparator|Comparator|
3274540|NCT01604837||Pelvic malignancy group|those with diagnosis of gynecologic or urologic malignancy
3274541|NCT01604837||Pelvic chronic disease group|those with chronic pelvic pain with constitutional cause e.g. endometriosis
3274542|NCT01604863|Experimental|Arm A|HGS1036 + Paclitaxel + Carboplatin
3274543|NCT01604863|Experimental|Arm B|HGS1036 + Cisplatin + Etoposide
3274544|NCT01604863|Experimental|Arm C|HGS1036 + Docetaxel
3274545|NCT01604876|Experimental|light condition 1 + day night structure|exposure to 10.000 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
3274546|NCT01604876|Active Comparator|light condition 2 + day night structure|exposure to 200 lux light twice daily (morning + evening) for 30 minutes during 3 months at home.
3274547|NCT01604889|Experimental|Epacadostat 300 mg|300 mg twice daily (BID) in combination with ipilimumab
3274548|NCT01604889|Placebo Comparator|Placebo in combination with ipilimumab|
3274549|NCT01604889|Experimental|Epacadostat 25 mg|25 mg BID in combination with ipilimumab
3274550|NCT01604889|Experimental|Epacadostat 50 mg|50 mg BID in combination with ipilimumab
3274551|NCT01604889|Experimental|Epacadostat 75 mg|75 mg once a day (QD) in combination with ipilimumab
3274552|NCT01604902||Psoriasis vulgaris|Patients with psoriasis vulgaris who are going to be treated with biological drugs independent of this project(according to national guidelines).
3274553|NCT01604915|Placebo Comparator|Group R|Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered.
3274554|NCT01604915|Experimental|Group DR|Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
3274555|NCT01604928|Experimental|YM178 Dose 1|low dose
3274556|NCT01604928|Experimental|YM178 Dose 2|high dose
3274557|NCT01604928|Active Comparator|Tolterodine|Oral
3274558|NCT01604928|Placebo Comparator|Placebo|Oral
3274559|NCT01604954|Other|Non-obese|Non-obese women (BMI between 18.5 and 25 kg/m2)
3274560|NCT01604954|Other|Obese|Obese women (BMI between 30 and 40 kg/m2)
3274561|NCT01604980|Experimental|Protein Intakes|subjects will recieve differnt levels of protein intakes varying from 0.2 to2.0g/kg/day.
3274562|NCT01604993|Experimental|High nitrate dietary source|556 grams of high nitrate spinach soup that is orally consumed as a single dose for 7 days.
3274563|NCT01604993|Placebo Comparator|No Nitrate dietary source|556g low nitrate asparagus soup; orally consumed as a single does for 7 days.
3274564|NCT01605006|Other|NeuRx Diaphragm Pacing System (DPS)|Surgical implantation of the NeuRx DPS (on label use).
3274565|NCT01605045|Experimental|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique)versus
3274566|NCT01605045|Active Comparator|Standard technique|Coronary anatomy visualized and documented using cinematography alone (standard technique)
3274567|NCT01605084|Experimental|Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone|
3274568|NCT01605084|Experimental|Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone|
3274569|NCT01605110|Experimental|Hyperbaric oxygen therapy|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
3274570|NCT01605110|Sham Comparator|Air sham|We propose to study the effects of two HBOT treatments (one before and one after surgery) with patients who have undergone upper eyelid surgery. Reduction in swelling and bruising will be assessed at 3, 10, 21, 30 and 90 days post-surgery to determine if healing is accelerated by HBOT. Patients that volunteer to participate in this study will be exposed to two treatments of 100% oxygen at 2.0 atmospheres absolute (ATA) or air (sham) 1.2 ATA inside mono-place chambers for 90 minutes. By comparing oxygen treatment groups with a matched control group, we can accurately assess the effectiveness of this treatment for patients. By participating in this study, patients will help in establishing the best treatment practices of using HBOT to accelerate healing and reduce cost in surgical recovery.
3274571|NCT01605123||Lean children|n=100 (anticipated), n=70 currently Age: 6-25 years BMI-SDS: -1.88 to +1.23 , currently -0.25±0.77; Height-SDS: > - 2 SDS, currently 0.03±1.07;
3274572|NCT01605123||Obese children|n=106 Age: 6-25 years BMI-SDS: >1.23 , currently 2.41±0.52; Height-SDS: > - 2 SDS, currently 0.80±1.18;
3274573|NCT01605123||Obese Exercise Group|Obese children will engage in increased physical activity (one to two lessons per week) at 40-60 and 60-80% of maximal exercise capacity (n=50 each anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
3274574|NCT01605123||Classical Lifestyle Intervention|Obese children will receive a classical lifestyle intervention, including dietary, activity and psychosocial counselling (n=50 anticipated). Within the frame of the study we will assess the effect of the exercise on cardiovascular outcomes.
3274575|NCT01605149||Case|Patients with Type 1 Diabetes Mellitus
3274576|NCT01605162|Experimental|E7016 plus TMZ|
3274577|NCT01605201|Experimental|Implantation of cartilage graft|
3274578|NCT01605214||Bilateral Lung Transplant|All patients undergoing bilateral lung transplant for any indication will be considered for enrollment in the study. The characteristics of measurements of extravascular lung water will be compared following surgery in those who develop primary graft dysfunction compared to those who do not.
3274579|NCT01605240|Active Comparator|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
3274580|NCT01605240|Active Comparator|Acetaminophen and Ibuprofen|Following reduction of their fracture, these patients will receive acetaminophen (15mg/ml) and ibuprofen (10mg/ml) at regular dosing intervals.
3274581|NCT01605253|Active Comparator|Eszopiclone|The total study duration is 16 weeks, with subjects taking 3mg eszopiclone at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
3274582|NCT01605253|Placebo Comparator|Placebo|The total study duration is 16 weeks, with subjects taking placebo at bedtime for 12 weeks. There is one follow-up visit after the 12 week treatment phase.
3274583|NCT01605266||Nephrotic Syndrome|The cohort includes all children diagnosed with nephrotic syndrome between ages 1-18. Children and their caregiver must be willing to provide informed consent, complete questionnaires, and provide biospecimens of the child. Those with secondary causes of nephrotic syndrome and/or systemic disease are excluded.
3274584|NCT01605279|Experimental|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomised to receive dobutamine or placebo.
3274585|NCT01605279|Placebo Comparator|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo.
3274586|NCT01605305|Experimental|FOLFOX6|
3274587|NCT01605318|Experimental|IMMU-130|All patients receive IMMU-130 administered in 21-day treatment cycles consisting of once or twice weekly for 2 consecutive weeks followed by a 1-week rest period. Treatment can be continued in the absence of unacceptable toxicity for a period of up to 8 cycles until the first documentation of Progressive Disease by CT (physician discretion), but must terminate study treatment upon the second documentation of Progressive Disease.
3274588|NCT01605331|Experimental|sustained-release recombinant human GH (SR-rhGH)|12-week subcutaneous administration, 2mg/week
3274589|NCT01605344|Experimental|Arm A|ARM A subjects will receive atorvastatin 20 mg orally once daily given for two weeks prior to FOLFIRI. The last dose of atorvastatin will be taken day 1 of FOLFIRI. ARM A will then receive no statin for the next 2 weeks. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
3274590|NCT01605344|Experimental|Arm B|ARM B subjects will receive no atorvastatin prior to day 1 of FOLFIRI. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks prior to day 15 of FOLFIRI. The last dose of atorvastatin will be taken day 15 of FOLFIRI. Patients will receive FOLFIRI infusion on day 1 and day 15. Blood samples will be collected at baseline and periodically through 24 hours on day 1 and 15 of FOLFIRI.
3274591|NCT01605357|Active Comparator|Standard Care|Patients will be managed to maintain a goal serum sodium of > 135 mmol/L , a well recognized value in the management of severe traumatic brain injury.
3274592|NCT01605357|Experimental|Induced Hypernatremia|Patients will be treated with induced, sustained hypernatremia for 5 days following injury by using hypertonic saline to target a goal serum sodium of 150-160 mmol/L
3274593|NCT01605383|Experimental|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stem cells fixed in allogenic bone tissue (under Xcelia-GMP conditions)for osteonecrosis of the femoral head"
3274594|NCT01605383|Sham Comparator|Standard Treatment|Isolated core decompression
3274595|NCT01605409|Active Comparator|Standard ACLS|Patients in the standard ACLS group will be resuscitated until ROSC or termination of efforts. If ROSC is achieved they will be transported to the emergency department and treated according to ERC guidelines and GCP.
3274596|NCT01605409|Experimental|ECPB|"ACLS provided for 15 minutes by EMS personnel according to current guidelines of the ERC.~CPR during transportation will be performed by EMS personnel according to ERC guidelines.~At the ED cannulation will be performed percutaneously if feasible. The femoral artery will be cannulated with a 17-19 - Fr and the femoral vein will be cannulated simultaneously with heparin coated 19-25 - Fr catheter or a smart cannula. An antegrade 8 - Fr cannula will be placed to supply perfusion for the cannulated leg if feasible. The procedures will be performed ultrasound-guided and the size of the cannulae will be adapted according to vessel size. Correct placement of the venous cannulae will be verified via ultrasound. Cardiopulmonary bypass will be performed by using the Lifebridge(Sorin®) or the Cardiohelp(Maquet®) ECMO device, according to protocol."
3274597|NCT01605448|Experimental|MBSR|Mindfulness Based Stress Reduction
3274598|NCT01605448|No Intervention|Control Group|Continue in Usual care; offered the intervention at the end of the study
3274599|NCT01605474|Active Comparator|Outpatient Cervical Ripening|Patients who are randomized to this arm will be allowed discharged home for 12 hours after fetal status is assessed and noted to be reassuring with the foley bulb in place. They will return sooner if they experience rupture of membranes or enter active labor or if the foley bulb falls out.
3274600|NCT01605474|No Intervention|Inpatient Cervical Ripening|In this arm, the fetus will be assessed and a foley bulb placed but these patients will be kept in the hospital.
3274601|NCT01605487|Other|Rupatadine 20mg - Placebo - Rupatadine 40mg|
3274602|NCT01605487|Other|Rupatadine 20mg - Rupatadine 40mg - Placebo|
3274603|NCT01605487|Other|Placebo - Rupatadine 20mg - Rupatadine 40mg|
3274604|NCT01605487|Other|Rupatadine 40mg - Placebo - Rupatadine 20mg|
3274605|NCT01605487|Other|Placebo - Rupatadine 40mg - Rupatadine 20mg|
3274606|NCT01605487|Other|Rupatadine 40mg - Rupatadine 20mg - Placebo|
3274607|NCT01605500||Medtronic ICDs|Patients with Generation 2 Medtronic ICDs
3274608|NCT01605513|Experimental|recombinant interferon|PEG-IFN-SA 1.0μg/kg for 12 times, Peginterferon alfa-2a 180 μg for 12 times, PEG-IFN-SA 1.5 μg/kg for 12 times, PEG-IFN-SA 2 μg/kg for 12 times, PEG-IFN-SA 3 μg/kg for 12 times, PEG-IFN-SA 1.5μg/kg + ribavirin 0.45g/bid group for 12 times, Intergen 15μg/48hours for 7 times, ribavirin 0.45g/bid for 10 times
3274609|NCT01605526|Experimental|Single Arm|
3274610|NCT01605591|Active Comparator|the DLT bending to the right|
3274611|NCT01605591|Active Comparator|the DLT bending to the left|
3274612|NCT01605604|Experimental|recieves Buddhist mindfullness|
3274613|NCT01605630|Experimental|Family-based cancer literacy intervention|
3274614|NCT01605630|Active Comparator|Control|Standard of care
3274615|NCT01605656||Focus Groups + Interviews + Questionnaires|HIV-positive women recruited from the population of individuals seeking care at Thomas Street Health Center (TSHC) of the Harris County Hospital District (HCHD).
3274616|NCT01605682|Experimental|Berry extract 125|Fresh berry extract containing 125mg of polyphenols
3274617|NCT01605682|Experimental|Berry extract 250|Fresh berry extract containing 250mg of polyphenols
3274618|NCT01605682|Experimental|Berry extract 500|Fresh berry extract containing 500mg of polyphenols
3274619|NCT01605682|Placebo Comparator|Placebo|Berry flavoured juice containing no polyphenols
3274620|NCT01605695||Normal healthy adults|The concentration of iNOS will be measured in plasma samples obtained at the time of blood donation from normal healthy adult humans
3274621|NCT01605708|Experimental|Cohort 1|
3274622|NCT01605721|Experimental|XIENCE PRIMETM everolimus-eluting coronary stent|
3274623|NCT01605734|Active Comparator|Group TACE|TACE will be carried out with chemotherapeutic agents and lipiodol; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated if clinically indicated
3274624|NCT01605734|Experimental|Group Combination|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
3274625|NCT01605747|Experimental|Culturelle|
3274626|NCT01605747|Placebo Comparator|Placebo|
3274627|NCT01605760|No Intervention|non immunotherapy treatment|
3274628|NCT01605760|Active Comparator|sublingual immunotherapy course|
3274629|NCT01605773|Experimental|repaglinide|
3274630|NCT01605773|Active Comparator|glyburide|
3274631|NCT01605786|Experimental|PEBS Low dose|
3274632|NCT01605786|Experimental|PEBS High dose|
3274633|NCT01605786|Active Comparator|Control|
3274634|NCT01605812||high myopia|high myopia (axial length>26mm)
3274635|NCT01605812||emmetropia|emmetropia (22<axial length<25mm) as control group.
3274636|NCT01605851|Other|Closure, Foramen Ovale|Patients undergoing device closure of PFO
3274637|NCT01605929|Experimental|Retroclavicular Brachial Plexus Block|
3274638|NCT01605955||Fingertip Pulse Oximeter|SPO2 measurement range: 70%-99%
3274639|NCT01605955||CO-oximeter|SaO2 measurement range: 70%-99%
3274640|NCT01605968|Experimental|BCT Silver Bandage|
3274641|NCT01605968|Active Comparator|Aquacel® Ag. Dressing|
3274642|NCT01605981|Experimental|Nilotinib oral|Nilotinib oral dose of 400 mg BID (800 mg/day) continuous dosing for up to 24 months. Nilotinib oral dose of 300 mg BID (600 mg/day) continuous dosing in case of intolerance. Nilotinib oral dose of 400 mg QD (400 mg/day) continuous dosing in case of intolerance
3274643|NCT01605994|Experimental|Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution|"BMS-933043 2 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274644|NCT01605994|Experimental|Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution|"BMS-933043 5 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274645|NCT01605994|Experimental|Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution|"BMS-933043 10 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274646|NCT01605994|Experimental|Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution|"BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274647|NCT01605994|Experimental|Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution|"BMS-933043 50 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days~CSF sampling required"
3274648|NCT01605994|Experimental|Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution|"BMS-933043 100 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274649|NCT01605994|Experimental|Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution|"BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274650|NCT01605994|Experimental|Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose|"MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required~BMS-933043 25 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274651|NCT01605994|Experimental|Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose|"Japanese Subjects. CSF sampling not required.~BMS-933043 200 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274652|NCT01605994|Experimental|Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose|"BMS-933043 350 mg solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274653|NCT01605994|Experimental|CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose|"If Panel 5 does not run. CSF Sampling at steady state~BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days~OR~Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days~Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days"
3274654|NCT01606020|Active Comparator|Sleep deprivation First|"First night D7 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.~Second night D28 :~Overnight, the subjects stay in their homes. No intervention during this night."
3274655|NCT01606020|Active Comparator|sleep deprivation second|"First night D7 :~Overnight, the subjects stay in their homes. No intervention during this night.~Second night D28 :~Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep."
3274656|NCT01606033|Other|phase II non randomized study|"phase II non randomized study, Case : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
3274657|NCT01606033|Other|blind randomized phase II or III study|"blind randomized phase II or III study: control : 40 patients description of patients feeling by questionnaires :~Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~understanding of the implications of participating in a clinical trial"
3274658|NCT01606033|Other|open randomized phase II or III study|"open randomized phase II or III study : 40 patients description of patients feeling by questionnaires : Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction Survey~-understanding of the implications of participating in a clinical trial"
3274659|NCT01606033|Other|receiving standard treatment|"receiving standard treatment : 120 patients description of patients feeling by questionnaires :~-understanding of the implications of participating in a clinical trial"
3274660|NCT01606046|Active Comparator|vapocoolant spray|
3274661|NCT01606046|Active Comparator|topical anesthetic agent|
3274662|NCT01606046|No Intervention|Control|no interventions
3274663|NCT01606059|Active Comparator|DW-0919|
3274664|NCT01606059|Experimental|DW-0920|
3274665|NCT01606072|Experimental|Desmopressin|
3274666|NCT01606085|Experimental|HF-DM Self Care|educational counseling intervention about integrated HF-DM self care outcomes
3274667|NCT01606085|No Intervention|Usual Care|Usual Care provided by providers
3274668|NCT01606098|Active Comparator|Systemic treatment|First-line fluoropyrimidine-based chemotherapy with bevacizumab initiated within 4 weeks of randomization, followed by salvage therapy upon progression at the discretion of the local investigator. Surgery of primary tumour will be performed only when indicated by local signs or symptoms.
3274669|NCT01606098|Experimental|Surgery followed by systemic treatment|Surgery within 4 weeks of randomization followed by fluoropyrimidine-based chemotherapy with bevacizumab until progression or unacceptable toxicity, followed by salvage therapy upon progression at the discretion of the local investigator
3274670|NCT01606111|Placebo Comparator|0.9% NaCl, saline|
3274671|NCT01606111|Experimental|Cerebrolysin|
3274672|NCT01606163|Experimental|group 1|"Drug:GC1102~Amount:3ml (30,000IU)"
3274673|NCT01606163|Experimental|group 2|"Drug: GC1102~Amount: 5ml(50,000IU)"
3274674|NCT01606163|Experimental|group 3|"Drug: GC1102~Amount: 8ml (80,000IU)"
3274675|NCT01606163|Placebo Comparator|group 4|drug: JW normal saline
3274676|NCT01606215|Experimental|mesenchymal stem cells|1-2 x106 MSCs/kg administered at Week 0
3274677|NCT01606215|Sham Comparator|Placebo|Suspension media administered at Week 0
3274678|NCT01606241|Experimental|Treatment (cyclophosphamide and vaccine therapy)|Patients receive cyclophosphamide PO BID on days 1-7 and 15-21 of course 1. Within 3-5 days, patients receive multi-epitope folate receptor alpha peptide vaccine ID on day 1. Vaccine treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3274679|NCT01606267|No Intervention|Routine HEP|This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities.
3274680|NCT01606267|Experimental|HEP+ICCM|This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities.
3274681|NCT01606293||Carcinomas of the Cervix Survey|Women with small and large cell carcinomas of the cervix, who are members of the Facebook group found at the uniform resource locator https://www.facebook.com/SmallCellCC through an online link.
3274682|NCT01606332|No Intervention|Single in interscalene block|Single indwelling interscalene block with ropivacaine 0.5% 10ml
3274683|NCT01606332|Experimental|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
3274684|NCT01606345|Experimental|Phase I Dose Escalation|Dose escalation: 200 mg/75 ml effluent, 400 mg/75 ml effluent, 800 mg/75 ml effluent
3274685|NCT01606358||Ovarian Cancer|
3274686|NCT01606371|Placebo Comparator|Healthy-Placebo|Placebo (capsule) administered once, orally
3274687|NCT01606371|Experimental|Healthy-2.5 mg LY2409021|2.5 mg LY2409021 administered once, orally
3274688|NCT01606371|Experimental|Healthy-10 mg LY2409021|10 mg LY2409021 administered once, orally
3274689|NCT01606371|Experimental|Healthy-30 mg LY2409021|30 mg LY2409021 administered once, orally
3274690|NCT01606371|Experimental|Healthy-100 mg LY2409021|100 mg LY2409021 administered once, orally
3274691|NCT01606371|Experimental|Healthy-250 mg LY2409021|250 mg LY2409021 administered once, orally
3274692|NCT01606371|Experimental|Healthy-500 mg LY2409021|500 mg LY2409021 administered once, orally
3274693|NCT01606371|Placebo Comparator|Diabetic-Placebo|Placebo (capsule) administered once, orally
3274694|NCT01606371|Experimental|Diabetic-75 mg LY2409021|75 mg LY2409021 administered once, orally
3274695|NCT01606371|Experimental|Diabetic-200 mg LY2409021|200 mg LY2409021 administered once, orally
3274696|NCT01606371|Experimental|Diabetic-500 mg LY2409021|500 mg LY2409021 administered once, orally
3274697|NCT01606384|Placebo Comparator|Placebo|Twice daily
3274698|NCT01606384|Experimental|SSR149415 - 100mg|Twice daily
3274699|NCT01606384|Experimental|SSR149415 - 250mg|Twice daily
3274700|NCT01606397|Placebo Comparator|Placebo|Placebo administered orally once daily for 4 weeks
3274701|NCT01606397|Experimental|5 mg LY2409021|5 mg LY2409021 administered orally once daily for 4 weeks
3274702|NCT01606397|Experimental|30 mg LY2409021|30 mg LY2409021 administered orally once daily for 4 weeks
3274703|NCT01606397|Experimental|60 mg LY2409021|60 mg LY2409021 administered orally once daily for 4 weeks
3274704|NCT01606397|Experimental|90 mg LY2409021|90 mg LY2409021 administered orally once daily for 4 weeks
3274705|NCT01606410||young, sedentary|
3274706|NCT01606410||young, active|
3274707|NCT01606410||old, sedentary|
3274708|NCT01606410||old, active|
3274709|NCT01606423|Placebo Comparator|Placebo|Administered once, orally
3274710|NCT01606423|Experimental|10 mg LY2409021|10 mg LY2409021 administered once, orally
3274711|NCT01606423|Experimental|22.5 mg LY2409021|22.5 mg LY2409021 administered once, orally
3274712|NCT01606423|Experimental|60 mg LY2409021|60 mg LY2409021 administered once, orally
3274713|NCT01606423|Experimental|200 mg LY2409021|200 mg LY2409021 administered once, orally
3274714|NCT01606423|Experimental|500 mg LY2409021|500 mg LY2409021 administered once, orally
3274715|NCT01606436|Placebo Comparator|Sugar pill|Placebo matching pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3274716|NCT01606436|Experimental|400 mg pomaglumetad methionil|400 mg pomaglumetad methionil administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3274717|NCT01606436|Other|400 mg Moxifloxacin|Positive control, unblinded moxifloxacin administered orally once during 1 of 3 crossover periods, separated by a 2 day washout period.
3274718|NCT01606449||Group 1|Group 1 = Patients with type II Hiatal Hernia submitted to surgical therapy
3274719|NCT01606449||Group 2|Group 2 = Patients with type III Hiatal Hernia submitted to surgical therapy
3274720|NCT01606449||Group 3|Group 3 = Patients with type IV Hiatal Hernia submitted to surgical therapy
3274721|NCT01606462|Experimental|Oxytocin|one application of 24 IU oxytocin per volunteer
3274722|NCT01606462|Placebo Comparator|Placebo|sodium chloride solution, intranasal application, 3 puffs per nostril one application per volunteer
3274723|NCT01606488|Other|Surgical Group|"Subjects scheduled to undergo total knee or total hip replacement at the SFVAMC.~Subjects in this arm of the study will undergo the florbetapir PET scan once prior to their surgery.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
3274724|NCT01606488|Other|Non-surgical group|"Subjects being seen in at the SFVAMC orthopedic clinic for knee or hip pain but are not anticipating surgical intervention.~Subjects in this arm will not undergo the florbetapir PET scan.~Subjects in this arm of the study will undergo serial neurocognitive assessment, heart rate variability measurement, and blood draws for genetic and inflammatory markers."
3274725|NCT01606501||Limb Salvage patients|Patients undergoing limb salvage following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
3274726|NCT01606501||Transtibial Amputation patients|Patients undergoing transtibial amputation following severe distal tibia, ankle and/or foot injuries with major soft tissue, bone and/or ankle articular surface loss.
3274727|NCT01606514|Experimental|Child, Parenting, & Parent Web-Intervention|Bounce Back Now Child, Parenting, & Parent Psychoeducation & Self-Help Web-Intervention.
3274728|NCT01606514|Experimental|Child & Parenting Web-Intervention|Bounce Back Now Child & Parenting Psychoeducation and Self-Help Web-Intervention.
3274729|NCT01606514|No Intervention|Child & Parent Web-based Assessment|Bounce Back Now Web-Based Symptom Assessment
3274730|NCT01606527|Experimental|Ibuprofen|Ibuprofen 600mg taken three times daily for four days.
3274731|NCT01606527|Placebo Comparator|placebo|Avicel placebo capsules three times daily for four days
3274732|NCT01606540|Experimental|Reposition and immobilism|"The patient are under sedation before reposition. The patient will be injected with 8-10 ml 1% Lidocain.~After reposition the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after reposition."
3274733|NCT01606540|Active Comparator|Surgery|"The method of surgery is type bridging.~After surgery the patient is asked to fill in a questionnaire with information of experienced pain based on VAS score. The patient note down the experience of pain each day 14 days after operation."
3274734|NCT01606553|Experimental|High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a dual-vave prototype
3274735|NCT01606553|Active Comparator|Sham High-intensity IMT|High intensity short duration respiratory muscle training (IMT) using a sham dual-vave prototype
3274736|NCT01606566|Experimental|Amphinex induced PCI of bleomycin|"Drug: Amphinex induced PCI of bleomycin~Intervention:Intravenous administration of Amphinex (day 0) followed by intravenous administration of bleomycin and laser light application (day 4)"
3274737|NCT01606579|Experimental|Part I|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Acute Group patients. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
3274738|NCT01606579|Experimental|Part II|Single-agent MTD (or maximum dose to be studied) of PRI-724 will be determined in escalating dose cohorts of Non-Acute Group patients. Dosing will begin 2 dose levels below the Part I MTD. The MTD cohort will be expanded up to 10 patients to further evaluate tolerability.
3274739|NCT01606579|Experimental|Part III Arm A|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with low dose ara-C therapy (20 mg SC BID × 10d q 28d) for AML patients ≥ 65 years of age."
3274740|NCT01606579|Experimental|Part III Arm B|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 2 dose levels below the Part I MTD will be administered in combination with dasatinib (140 mg PO daily) to Acute Group patients with CML-AP or BC."
3274741|NCT01606579|Experimental|Part III Arm C|"Once the MTD is identified for each arm, that cohort will be expanded to a total of 10 patients each.~Escalating doses of PRI-724, beginning 1 dose level below the Part II MTD will be administered in combination with dasatinib (100 mg PO daily) to Non-Acute Group patients with CML-CP."
3274742|NCT01606592|Experimental|Randomized Panic Control Treatment|Patients who have been randomized to the randomization condition are assigned to PCT
3274743|NCT01606592|Experimental|Randomized Panic-Focused Psychodynamic Psychotherapy|Patients who have been randomized to the randomization condition are assigned to PFPP
3274744|NCT01606592|Experimental|Self-selected Panic Control Treatment|Patients who have been randomized to the self-selection condition choose PCT
3274745|NCT01606592|Experimental|Self-selected Panic-Focussed Psychodynamic Psychotherapy|Patients who have been randomized to the self-selection condition choose PFPP
3274746|NCT01606592|Experimental|Waiting-list|Patients who have been randomized to the waiting-list are offered sparse contact over telephone for 12 weeks and are then re-randomized to one of the other four arms
3274747|NCT01606605||Diffuse large B-cell lymphoma|Patients diagnosed and treated at the Samsung Medical Center
3274748|NCT01606618||Spina bifida aperta|
3274749|NCT01606618||Acquired traumatic spinal cord injury|
3274750|NCT01606631||Arm 1 : experimental (case)|Patients included in the study and admitted to the ICU either directly from UAA or after a hospitalization in a specialty, for a severe sepsis or septic shock on their infectious disease community.
3274751|NCT01606631||Arm 2 : control|Patients included in the study with an infectious disease community, admitted to a specialty, and have not progressed to severe sepsis or septic shock before hospital discharge.
3274752|NCT01606644|Experimental|HBO|30 90-minute hyperbaric oxygen sessions at 2.4 atm.
3274753|NCT01606644|No Intervention|No HBO|No intervention. No hyperbaric oxygen is administered. Otherwise, the patient will follow the examination program.
3274754|NCT01606657|Active Comparator|Irrigation|THE PATIENT IS TO HAVE IRRIGATION OF THE ABSCESS WITH NORMAL SALINE AS PART OF THE I&D PROCEDURE
3274755|NCT01606657|Placebo Comparator|No Irrigation|THE PATIENT IS NOT TO HAVE IRRIGATION OF THE ABSCESS AS PART OF THE I&D PROCEDURE
3274756|NCT01606683|Experimental|GROUP 1|Infant formula supplemented with with functional ingredients (galacto-oligosaccharides, beta-palmitate, fermented milk). Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae.
3274757|NCT01606683|Other|GROUP 2|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
3274758|NCT01606683|Other|CONTROL GROUP|Breast milk
3274759|NCT01606696|Experimental|HIIT|Higher intensity interval training.
3274760|NCT01606696|Active Comparator|Standard intensity non-interval training|Standard intensity non-interval training
3274761|NCT01606722||Darunavir-ritonavir monotherapy|HIV-infected patients with undetectable viral load for at least for 6 months on stable therapy and no darunavir related mutations in the HIV-protease gene
3274762|NCT01606774|Experimental|Low risk patients|Patients who agreed to 4 telemedicine obstetrical visits
3274763|NCT01606813|Active Comparator|Brief physician counseling (BPC) + Usual care (UC)|The participant will receive standard care. They will receive BPC from their PCP on weight loss by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss.
3274764|NCT01606813|Experimental|BPC + Internet Weight Control Program (IWCP)|The participant will receive BPC from their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program.
3274765|NCT01606813|Experimental|BPC + IWCP + Follow up email notes from PCP|The participant will receive BPC form their PCP by reviewing a goal setting worksheet and collaboratively setting a goal for weight loss. They will receive referral and access to an internet weight control program. And they will receive brief follow up email notes from PCPs on how their weight loss is going (from data collected from the weight loss website).
3274766|NCT01606826||Asthmatics|Subjects with active asthma.
3274767|NCT01606826||Healthy Controls|Subjects without any known pulmonary disease.
3274768|NCT01606865||elective and acute non-cardiac surgery|
3274769|NCT01606878|Experimental|Part A (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (oral solution) PO BID on days 1-21, cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
3274770|NCT01606878|Experimental|Part B (crizotinib, vincristine, dexrazoxane, doxorubicin)|Patients receive crizotinib (oral solution) PO BID as in Part A. Patients also receive vincristine sulfate IV on day 1, dexrazoxane hydrochloride IV on day 1, and doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)
3274771|NCT01606878|Experimental|Part C (crizotinib, cyclophosphamide, topotecan hydrochloride)|Patients receive crizotinib (capsule formulation) PO BID, cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
3274772|NCT01606891|Experimental|parent-targeted intervention|experimental
3274773|NCT01606891|No Intervention|Primary Care|Standard primary care
3274774|NCT01606904|Experimental|Weight loss counseling|Cognitive behavioral therapy - based weight loss program
3274775|NCT01606904|Other|Control|Short term weight loss counseling, control group
3274776|NCT01606917|Experimental|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity.
3274777|NCT01606917|No Intervention|Usual care|Usual care
3274778|NCT01606930|No Intervention|Usual Care Group|"Group will see their physician without receiving the activation instrument."
3274779|NCT01606930|Active Comparator|"Activated Group"|"Group will be given an activation instrument to complete before their appointment and instructed to refer to and use the instrument during their clinical encounter."
3274780|NCT01606956|Experimental|resting volume group|
3274781|NCT01606956|Active Comparator|half the maximum volume group|
3274782|NCT01606969|Experimental|Dex group|dexmedetomidine-lidocaine solution,
3274783|NCT01606969|Active Comparator|Control group|epinephrine-lidocaine solution
3274784|NCT01606995||Group 1|
3274785|NCT01607008|Other|MRI imaging|Use of MRI imaging in conjunction with standard radiation treatment
3274786|NCT01607021||Chinese children with HCV RNA positive|"A sample of 200 children with a recent confirmation of anti-HCV-antibody positive and HCV RNA positive. All the children were treated with antiviral therapy, and the course of treatment depend on HCV Viral genotyping(ie, genotype 1,2,3,4 subtypes).~Primary Outcome Measures:~Virologic response [ Time Frame: Weeks 2, 4, 6, 8, 10, and 12 ] Sustained virologic response (SVR, defined as plasma HCV RNA < lower limit of quantification [LLoQ] at 24 weeks after treatment cessation) following antiviral treatment.~Secondary Outcome Measures: Safety and tolerability of therapy. [ Time Frame: Up to 48 weeks ] measured by frequency of laboratory abnormalities , reported adverse events and discontinuations due to adverse events"
3274787|NCT01607034|Experimental|Sequence 1 - tablet-fast|150 mg Dexpramipexole (intact tablet) single dose under fasted condition
3274788|NCT01607034|Experimental|Sequence 2 - tablet-fed|150 mg Dexpramipexole (intact tablet) single dose under fed condition
3274789|NCT01607034|Experimental|Sequence 3 - water-fast|150 mg Dexpramipexole single dose dispersed in water under fasted condition
3274790|NCT01607034|Experimental|Sequence 4 - apple-fast|150 mg Dexpramipexole single dose crushed and mixed in applesauce under fasted condition
3274791|NCT01607060|Experimental|Lactulone|Patients receiving lactulone
3274792|NCT01607060|Active Comparator|Control|Observational group. Compare to lactulone group.
3274793|NCT01607086|Experimental|Group 1|To receive the sequence of investigational products in the order of AB where A is cherry lamotrigine ODT and B is cherry placebo.
3274794|NCT01607086|Experimental|Group 2|To receive the sequence of investigational products in the order of BA where A is cherry lamotrigine ODT and B is cherry placebo.
3274795|NCT01607099|Experimental|Pico Prep|Arm in which sodium- picosulfate/magnesium citrate is used for bowel cleansing
3274796|NCT01607099|No Intervention|Standard|The standard drug macrogol is used for bowel cleansing
3274797|NCT01607125|Experimental|Vortioxetine|
3274798|NCT01607125|Placebo Comparator|Placebo|
3274799|NCT01607138||Total laryngectomy|A group of patients who underwent total laryngectomy with trechea esophageal puncture (TEP)
3274800|NCT01607151|Active Comparator|Normothermia|Core temperature 36-37 C
3274801|NCT01607151|Experimental|Hypothermia|Core temperature 32-34 C
3274802|NCT01607164|Experimental|Online self-help mood management|"Healthy Mood Project Website~Online self-help automated mood management course available in Spanish and English via a website.~Intervention consisted of 8 cognitive-behavioral mood management lessons."
3274803|NCT01607177|Experimental|Text message group|Patients randomised to this group will receive daily text message reminders used to motivate them to exercise in the preoperative period. They will also receive an exercise information sheet to complement the text messages.
3274804|NCT01607177|No Intervention|No text message group|Patients randomised to this group will receive standardised exercise advice but will not receive the text message reminders or the exercise information sheet.
3274805|NCT01607190||Patients with diabetic retinopathy.|
3274806|NCT01607216||Premature Infant|Infants born 23 0/7 weeks gestation to 35 6/7 weeks gestation.
3274807|NCT01607216||Healthy Full Term Infants|Infants born between 37 0/7 weeks gestation to 41 6/7 weeks gestation.
3274808|NCT01607229||otherwise healthy with various BMI|
3274809|NCT01607242||patients|patients undergoing total thyroidectomy
3274810|NCT01607268||Pure Autonomic Failure|Pure autonomic failure is a type of primary autonomic failure characterized by peripheral autonomic nervous system impairment.
3274811|NCT01607268||Multiple System Atrophy|Multiple system atrophy is a type of primary autonomic failure characterized by central autonomic nervous system impairment.
3274812|NCT01607281||anesthesiologists, experience|There is one arm. All participating anesthesiologists wıll fulfill the questionary survey and show the imaginary puncture site by USG bilaterally.
3274813|NCT01607294|Experimental|ETC-1002|ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day
3274814|NCT01607294|Placebo Comparator|Placebo|Placebo daily 4 weeks
3274815|NCT01607307|Active Comparator|Oral/enteral TJ-100 solution|Oral/enteral TJ-100 solution
3274816|NCT01607307|Placebo Comparator|Oral/enteral placebo solution|Oral/enteral placebo solution
3274817|NCT01607333||Completed suicide|Patients who completed suicide
3274818|NCT01607333||Suicide attempt|Patients who have attempted suicide, or performed preparatory acts toward imminent suicidal behavior, suicidal ideation plus indeterminate or potentially suicidal events
3274819|NCT01607333||Not completed suicide|Patients who have not completed suicide
3274820|NCT01607359||dabigatran group|All patients receiving dabigatran as periprocedural anticoagulation during the study time period
3274821|NCT01607359||warfarin group|A randomly selected group of patients treated with warfarin during the study time period matching the number of dabigatran treated patients in the same time period.
3274822|NCT01607372|Experimental|GSK2245035 - 40 ng or placebo|Subjects will receive GSK2245035 - 40 nanogram (ng) or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3274823|NCT01607372|Experimental|GSK2245035 - 80 ng or placebo|Subjects will receive GSK2245035 - 80 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3274824|NCT01607372|Experimental|GSK2245035 - 120 ng or placebo|Subjects will receive GSK2245035 - 120 ng or placebo once per week for four treatment weeks. There will be washout period of 7 days between treatment periods. GSK medical monitor will review all available clinical and laboratory safety data and decide if subjects can proceed to the next scheduled dosing cohort.
3274825|NCT01607372|Experimental|GSK2245035 - 160 ng or placebo|Subjects will receive GSK2245035 - 160 ng or placebo once per week, for four treatment weeks. There will be washout period of 7 days between treatment periods.
3274826|NCT01607385|Active Comparator|GSK2330672|
3274827|NCT01607385|Placebo Comparator|Placebo|
3274828|NCT01607424|Experimental|RECOS: 42 hours CR, 14 week-treatment.|RECOS(Cognitive Remediation for Schizophrenia) exercises were designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 5 main cognitive functions. RECOS modules focus on the relevant cognitive domains, which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS was determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participated in the module corresponding to his/her most altered cognitive area.
3274829|NCT01607424|Active Comparator|CRT: 42 hours CR, 14 week-treatment|CRT (Cognitive Remediation Therapy) exercises are the ones used by Wykes et al (1999). The CRT method consists of 3 modules: flexibility, memory (A and B) and planning (A and B). Each module involves a series of paper and pencil exercises with parallel forms providing with gradual difficulty.
3274830|NCT01607463|Experimental|active TENS group|Two electrodes were attached to the radial side of dominant forearm. In the active TENS group, TENS was delivered via two electrodes on the venous cannulation site
3274831|NCT01607463|Placebo Comparator|Placebo group|"Two electrodes were attached to the radial side of dominant forearm. In the placebo group the TENS device had no current output although the power on indicator light remained active."
3274832|NCT01607489|Other|pulmonary vascular disease|Dual-energy computed tomography investigation
3274833|NCT01607502||Patients of our outpatient clinic|Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing
3274834|NCT01607515|Other|suspected PH|Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography
3274835|NCT01607528|Active Comparator|Probiotic|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
3274836|NCT01607528|Placebo Comparator|Placebo|A similar looking and tasting powder
3274837|NCT01607541|Experimental|Peer-driven intervention|"The PDI entails structured intervention sessions including a computerized CARE for Prevention tool and HIV pre-test and post-test counseling, the opportunity to educate three peers on core education messages, and navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and six months of navigation)"
3274838|NCT01607541|Active Comparator|Control|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
3274839|NCT01607580|Experimental|low-dose glucocorticoid|drug
3274840|NCT01607580|Other|no intervention after transplant|
3274841|NCT01607632|Experimental|loving-kindness meditation|
3274842|NCT01607671|Experimental|Timolol|This group will receive ophthalmic Timolol maleate 0.5%, 1 drop to the effected eye twice daily for 4 weeks.
3274843|NCT01607671|No Intervention|Standard Care|This group will be treated with current standard care. This does not include Timolol or other medications to reduce intraocular pressure.
3274844|NCT01607684|Other|Diabetes mellitus group|Subjects with Diabetes mellitus and symptoms of diabetic gastroparesis
3274845|NCT01607684|Other|Control group|Healthy volunteers as matched pairs according to gender and age
3274846|NCT01607697|Experimental|Mindfulness Training|Group received Mindfulness Training
3274847|NCT01607697|No Intervention|Waitlist Control|Group received Usual Care
3274848|NCT01607710||Generalized Anxiety Disorder|The group of participants diagnosed with generalized anxiety disorder.
3274849|NCT01607710||Nonclinical Control Group|The comparison group of participants with no psychiatric diagnoses.
3274850|NCT01607723|Other|NAVA ventilatory mode|
3274851|NCT01607723|Other|PAV+ ventilatory mode|
3274852|NCT01607736|No Intervention|Inactive Comparator|
3274853|NCT01607736|Experimental|Virtual Gait Training|
3274854|NCT01607749|Experimental|Educational Program|"Students in the intervention schools learn the educational program Asthma, Sport and Health in three sessions during a period of 6 weeks. The content of the educational program has been published elsewhere."
3274855|NCT01607749|No Intervention|Asthma information for teachers|Information about asthma the Ministry of Education to all schools in the community.
3274856|NCT01607762|Experimental|Cohort A: Aripiprazole|
3274857|NCT01607762|Experimental|Cohort B: Quetiapine|
3274858|NCT01607762|Experimental|Cohort C: Olanzapine|
3274859|NCT01607762|Experimental|Cohort D: Risperidone|
3274860|NCT01607762|Experimental|Cohort E: Paliperidone|
3274861|NCT01607775|Active Comparator|PEEK-cage|Patients will receive a PEEK-cage
3274862|NCT01607775|Experimental|PMMA-cage|
3274863|NCT01607801||non-absorbable suture NAS|having their umbilical hernia repaired with NAS
3274864|NCT01607801||Long-term-absorbable suture (LAS)|patients having their umbilical hernia repair with LAS
3274865|NCT01607801||Absorbable sutures (AS)|patients having their umbilical hernia repair with AS
3274866|NCT01607801||Mesh repair|Patients having umbilical hernia mesh repair
3274867|NCT01607814||Cirrhotic Patients|Patients affected by cirrhosis of any etiology and severity
3274868|NCT01607814||Control Group|Subjects age, sex and comorbidities matched
3274869|NCT01607827|Active Comparator|Polyp removal upon insertion and withdrawal|
3274870|NCT01607827|No Intervention|Polyp removal upon withdrawal only|
3274871|NCT01607840|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
3274872|NCT01607840|Experimental|Cathodal|transcranial direct current stimulation using cathodal stimulation over the brain area of interest
3274873|NCT01607840|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without actually delivering tDCS
3274874|NCT01607866|Experimental|Quadrant parotidectomy|Patients in this arm will receive excision of the parotid gland quadrant harboring the tumor
3274875|NCT01607866|Active Comparator|Superficial parotidectomy|Patients in this group will receive superficial parotidectomy
3274876|NCT01607879|Experimental|Standard of care ADT + (HMB + AG)|Standard of care androgen deprivation therapy plus the nutritional supplement HMB + arginine + glutamine (AG)
3274877|NCT01607879|Active Comparator|Standard of care ADT|Standard of care androgen deprivation therapy
3274878|NCT01607918|Experimental|Sequential therapy 10 days|Sequential therapy
3274879|NCT01607918|Active Comparator|Triple therapy 14 days|Triple therapy
3274880|NCT01607931|No Intervention|Resting Trial|a 1 hour period of rest immediately prior to OGTT or isoglycemic clamp
3274881|NCT01607931|Experimental|Exercise Trial|a 1 hour cycling exercise bout immediately prior to the OGTT or isoglycemic clamp
3274882|NCT01607944||Normal Glucose Tolerance|
3274883|NCT01607944||Type 2 Diabetes|
3274884|NCT01607970|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
3274885|NCT01607970|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
3274886|NCT01607983|Experimental|inhaled nitric oxide|
3274887|NCT01607996|Active Comparator|Patient controlled intravenous analgesia|Fentanyl (10 microg/ml) continuous intravenous infusion at a rate of 10 to 20 microg/h
3274888|NCT01607996|Experimental|Epidural anesthesia|Carbostesin (0.1%) and Fentanyl (2 microg/ml) at a continuous flow of 6 to 15 ml/hour
3274889|NCT01608009|Experimental|Pazopanib and paclitaxel|
3274890|NCT01608022|Experimental|PF804|
3274891|NCT01608035|Experimental|sciatic catheter|
3274892|NCT01608035|Active Comparator|Stump catheter|
3274893|NCT01608048|No Intervention|control|
3274894|NCT01608048|Experimental|TEAS|
3274895|NCT01608048|Experimental|EA:electro-acupuncture|
3274896|NCT01608074|Experimental|BRCA mutation carriers|"Women with BRCA1 or BRCA 2 mutation or a family history of breast/ovarian cancer.~Radical fimbriectomy. Histopathology SEE-FIM"
3274897|NCT01608126|Active Comparator|Combined Cervical Block|
3274898|NCT01608126|Active Comparator|Median Cervical Block US guided|
3274899|NCT01608139|Experimental|Curcumin + Sorafenib + Vorinostat|"Participant assigned to a dose level of the study drug combination based on when joined this study. Up to 9 dose levels of the study drug combination will be tested. Three (3) to 6 participants will be enrolled at each dose level of the study drug combination. During first cycle only, Curcumin initiated on Day 1, Vorinostat on Day 3 and Sorafenib on Day 5. Beginning with Cycle 1 Day 5, all agents administered continuously. Cycle of therapy is 28 days.~Starting dose of Curcumin: 4 grams by mouth per day on Day 1. Starting dose of Sorafenib: 200 mg by mouth daily beginning on Day 5. Starting dose of Vorinostat: 100 mg by mouth daily beginning on Day 3."
3274900|NCT01608152||Group I (focus group)|Patients attend a focus group for up to 1.5 hours and provide feedback on design elements, specific desirable features, and preferences for the initial prototype.
3274901|NCT01608152||Group II (access to the game)|Patients have access to the game for 3 weeks and then provide feedback on problems or questions regarding the use of the prototype.
3274902|NCT01608165|Other|Partial nephrectomy|Patients randomised to this arm will undergo a partial nephrectomy
3274903|NCT01608165|Other|Radiofrequency ablation|Patients randomised to this arm will undergo radiofrequency ablation
3274904|NCT01608165|Other|cryoablation|Patients randomised to this arm will undergo cryoablation
3274905|NCT01608191|No Intervention|Ordinary primary care follow up|Ordinary follow up after 24 weeks of LCD diet + reintroduction of food.
3274906|NCT01608191|Active Comparator|CBT follow up|11 weeks intervention programme with CBT conducted via internet.
3274907|NCT01608217|Active Comparator|Namisol|Namisol is a tablet containing delta-9-tetrahydrocannabinol, the main cannabinoid from Cannabis sativa L. Namisol is added to a standardized treatment with acetaminophen.
3274908|NCT01608217|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product. Placebo is added to a standardized treatment with acetaminophen.
3274909|NCT01608243|Experimental|SLIT tablets of HDM allergen extracts|
3274910|NCT01608243|Placebo Comparator|Placebo|
3274911|NCT01608256||mild cognitive impairment|men and women, aged 50 to 70. The inclusion criteria are:diagnosis of MCI (given by a neurologist), valid driver's license and driving experience of at least a year. the exclusion criteria are: people diagnosed with other neurological damage such as: dementia, CVA and head injury, people with sensory or motor impairment.
3274912|NCT01608256||Healthy people|Men and women, ages 50-70. the inclusion criteria are: healthy people with out neurological disease or psychiatric illness, have valid driver's license and driving experience of at least a year.
3274913|NCT01608269|Other|ABC/3TC (Epzicom), NRTI|
3274914|NCT01608282|Experimental|OPEN Intervention Group|Intervention group participants will receive an email prompt to access the OPEN website every two weeks for the first three months, with a short message about the ongoing projects at the Arthritis Research Centre of Canada. The OPEN website will remain accessible throughout the study, but no further prompting emails will be sent after Month 3. In addition, they will receive an education pamphlet produced by The Arthritis Society containing information about osteoarthritis, physical activity and other treatments.
3274915|NCT01608282|No Intervention|Control Group|Control group participants will receive, by email, the same Arthritis Society pamphlet as the Intervention group. Participants will also receive, by email, the same short message about the ongoing projects at the Arthritis Research Centre of Canada, every two weeks for the first three months (i.e. the same schedule as the intervention group receiving the prompting email so that the number of contacts is equal in both groups), but without the prompting to use the OPEN website.
3274916|NCT01608334|Experimental|group A|Fentanyl
3274917|NCT01608334|Active Comparator|Group B|Sufentanil
3274918|NCT01608347|Experimental|LMWH + Folic acid group|Daily 40 mg of enoxaparin (LMWH) (Clexane, Sanofi Aventis, Paris, France)subconsciously started once positive pregnancy test. Treatment will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tab once/daily until 13 weeks' of gestation.
3274919|NCT01608347|Active Comparator|Folic acid|500 microgram folic acid tab/day started once positive pregnancy test and will be continued until 13 weeks' of gestation.
3274920|NCT01608360|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3274921|NCT01608360|Placebo Comparator|Placebo control group|Patients in Group C (placebo control group) received normal saline intravenous injection
3274922|NCT01608373|Active Comparator|Intravenous lidocaine injection group|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
3274923|NCT01608373|Active Comparator|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc.
3274924|NCT01608373|Placebo Comparator|Intravenous normal saline group|The patients in Group C (placebo control group) received normal saline intravenous injection
3274925|NCT01608386|Experimental|anterior approach+IVC clamping|Use anterior approach combined with infrahepatic Inferior Vena Cava clamping in right hepatectomy for HCC patients.
3274926|NCT01608386|No Intervention|anterior approach|Only use anterior approach in right hepatectomy for HCC patients.
3274927|NCT01608399|Experimental|Metacognitive therapy|
3274928|NCT01608399|No Intervention|Waiting list control|
3274929|NCT01608412|Active Comparator|Tacrolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Tacrolimus"
3274930|NCT01608412|Active Comparator|Everolimus|"The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.~Intervention arm: Everolimus"
3274931|NCT01608425|No Intervention|Control|Control group. Regular treatment.
3274932|NCT01608425|Experimental|Diabetes ulcer monitoring|Receives a telemedicine intervention: Diabetes ulcer monitoring.
3274933|NCT01608438|Experimental|SCI Static|SCI group that practices with a static body-machine map
3274934|NCT01608438|Experimental|SCI Machine Learning|Spinal Cord Injury patients who practice with a body-machine map that is adapted using machine learning
3274935|NCT01608451|No Intervention|No additional treatment|No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
3274936|NCT01608451|Active Comparator|Inj. Proluton|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3274937|NCT01608451|Active Comparator|Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3274938|NCT01608451|Active Comparator|Inj. Proluton and Inj. Arachitol|Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
3274939|NCT01608464|Active Comparator|Arm A|Arm A: will receive combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
3274940|NCT01608464|Experimental|Arm B|"Arm B will receive combination of cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.~PET scan will be repeated 3-4 weeks after end of concurrent chemo-radiation therapy Patients in Arm A and B will go for esophagectomy 4-6 weeks after end of concurrent chemo-radiation therapy or chemotherapy"
3274941|NCT01608503|Experimental|respiration cycle|lung inflation and deflation
3274942|NCT01608516|Experimental|68Ga-NODAGA-RGD radiotracer|All patients will undergo a 68Ga-NODAGA-RGD PET/CT, a 18F-FDG PET/CT, a MRI and a US.
3274943|NCT01608529|Experimental|Cyclist group|
3274944|NCT01608542|Experimental|Fostamatinib 100mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 100mg single and multiple twice daily doses
3274945|NCT01608542|Experimental|Fostamatinib 200mg|Up to two cohorts of Japanese subjects are planned to receive fostamatinib 200mg single and multiple twice daily doses
3274946|NCT01608555|Experimental|inhaled tobramycin once-a-day|Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.
3274947|NCT01608568|Active Comparator|Interrupted suture|interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA)
3274948|NCT01608568|Active Comparator|Quill suture|self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada)
3274949|NCT01608581|Experimental|exposure to multi-media campaign|A multimedia campaign highlighting dangers of gasoline and fire was delivered to an intervention region in the state of Queensland
3274950|NCT01608594|Experimental|Ipilimumab 10 mg/kg + HDI|Ipilimumab 10 mg/kg + standard dose IFN alpha
3274951|NCT01608594|Experimental|Ipilimumab 3mg/kg + HDI|Ipilimumab 3mg/kg + standard dose IFN alpha
3274952|NCT01608633|Experimental|Spray and stretch|
3274953|NCT01608633|No Intervention|Control|
3274954|NCT01608646|No Intervention|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
3274955|NCT01608685||Renal transplant recipients|Inclusion criteria: All renal transplant recipients followed by the Division of Nephrology aged above 18 years, and having accepted study protocol after informed consent
3274956|NCT01608698|Experimental|Belara|The participants who receive OCP in combination of 30 mcg ethinylestradiol/2 mg chlormadinone acetate (Belara®).
3274957|NCT01608698|Experimental|Yasmin|The participants who receive OCP in combination of 30 mcg ethinylestradiol/3 mg drospirenone (Yasmin®).
3274958|NCT01608711|Experimental|AGS-1C4D4 plus gemcitabine|Subjects will receive a maintenance dose of AGS-1C4D4 every 3 weeks (Q3W) in addition to the gemcitabine administration.
3274959|NCT01608737|Experimental|2. BI 201335 for 24 weeks|BI 201335 once daily low dose for 24 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3274960|NCT01608737|Experimental|3. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in treatment-naive patients
3274961|NCT01608737|Active Comparator|1. PegIFN/RBV|PegIFN/RBV for 48 weeks in treatment-naive patients
3274962|NCT01608737|Active Comparator|4. PegIFN/RBV|PegIFN/RBV for 48 weeks in prior relapser patients
3274963|NCT01608737|Experimental|5. BI 201335 for 12 weeks|BI 201335 once daily high dose for 12 weeks, in combined with PegIFN/RBV for 24 or 48 weeks in prior relapser patients
3274964|NCT01608750|Experimental|pantoprazole|
3274965|NCT01608750|Placebo Comparator|folic acid|
3274966|NCT01608763|Experimental|Full personalized feedback|Participant provided with the full CYD personalized feedback summary.
3274967|NCT01608763|Experimental|Only normative feedback|Participant provided with just the normative feedback component of the CYD personalized feedback summary.
3274968|NCT01608763|Experimental|Just other personalized feedback|Participant provided with all the other personalized feedback components of the CYD intervention (i.e., no normative feedback).
3274969|NCT01608763|No Intervention|No intervention control|Participant provided with a list describing the components of the CYD intervention but not provided any personalized feedback.
3274970|NCT01608776|Active Comparator|SOC - Standard of Care|Wound cleansing and debridement as needed, moist wound healing dressing, and off-loading
3274971|NCT01608776|Active Comparator|SOC + MIST Therapy|Wound cleansing and debridement as needed, moist wound healing dressing, off-loading, and MIST treatment
3274972|NCT01608789|Experimental|Virtue® Male Sling|Patient implanted Virtue® Male Sling
3274973|NCT01608802|Active Comparator|Standard care|Standard care will be provided to the control group, i.e. existing HIV outpatient multiprofessional care, ART monitoring and adherence support.
3274974|NCT01608802|Experimental|Palliative care|Palliative care delivered by an existing nurse who has been provided with palliative care training, palliative care patient management planning records, and clinical supervision
3274975|NCT01608841|No Intervention|Gemcitabine|
3274976|NCT01608841|Experimental|Gemcitabine plus erlotinib|
3274977|NCT01608854||24 Hour Antibiotics|Patients were randomized to receive 24 hours of postoperative antibiotics following spine surgery
3274978|NCT01608854||Duration Antibiotics|Patients were randomized to receive antibiotics for the duration of time a spinal drain was in place following spinal surgery
3274979|NCT01608880|Placebo Comparator|Polysporin Control|Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
3274980|NCT01608880|Active Comparator|Nitroglycerin|Patients in treatment group will receive nitroglycerin ointment application
3274981|NCT01608893|Active Comparator|Metoprolol|The metoprolol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and metoprolol is dose titrated from 25 mg bid to a maximum of 50 mg bid over one month then patients are followed for 6 months.
3274982|NCT01608893|Active Comparator|Carvedilol|The carvedilol arm patients are stratified by the arrhythmia management strategy Rate or Rhythm control and carvedilol is dose titrated from 3.25 mg bid to maximum dose of 25 mg bid over one month then patients are followed for 6 months.
3274983|NCT01608919|No Intervention|diagnostic blood tests|We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
3274984|NCT01608932|No Intervention|Control Group|Treatment as usual
3274985|NCT01608932|Experimental|Telemonitoring for frail patients with chronic diseases|Telemonitoring for frail patients with chronic diseases
3274986|NCT01608945||steroid,liver function I/R|
3274987|NCT01608958|Active Comparator|IV infusion|Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.
3274988|NCT01608958|Active Comparator|IM Injection|Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.
3274989|NCT01608984|Active Comparator|RIPC-CABG|Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery with blood cardioplegia for cardiac arrest (CABG) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before induction of cardioplegic cardiac arrest and 5 to 10 Minutes after aortic unclamping during reperfusion of the myocardium. Blood samples are taken up to 72 hours postoperatively.
3274990|NCT01608984|Placebo Comparator|Control-CABG|Control group: Coronary artery bypass grafting without RIPC protocol
3274991|NCT01608984|Active Comparator|RIPC-OPCAB|Remote ischemic preconditioning (RIPC) protocol before Off-pump coronary artery bypass surgery (OPCAB) consists of 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 minutes of reperfusion after induction of anesthesia before coronary artery bypass surgery. For myocardial molecular analyses, left ventricular biopsies are taken before first coronary artery incision and 5 to 10 Minutes after completion of the coronary anastomoses. Blood samples are taken up to 72 hours postoperatively.
3274992|NCT01608984|Placebo Comparator|Control-OPCAB|Control group: Off-pump Coronary artery bypass surgery without RIPC protocol
3274993|NCT01609036||Cohort|
3274994|NCT01609049||Participants with Chronic Hepatitis C|Naive and previously treated participants who received peginterferon alfa-2a in combination with ribavirin as per local labeling requirements.
3274995|NCT01609075||Cohort|
3274996|NCT01609088|Experimental|Erythritol-containing beverage|
3274997|NCT01609101|Other|Coopdech® videolaryngoscope|
3274998|NCT01609101|Other|C-MAC® videolaryngoscope|
3274999|NCT01609101|Other|McGrath® Series 5 videolaryngoscope|
3275000|NCT01609101|Other|Glidescope® Cobalt videolaryngoscope|
3275001|NCT01609101|Other|King Vision® videolaryngoscope|
3275002|NCT01609101|Other|Venner® videolaryngoscope|
3275003|NCT01609101|Other|McGrath MAC® videolaryngoscope|
3275004|NCT01609114||control groups|chemotherapy (C/T) is applied in the morning. After 4-6 hrs, RT is delivered (according to the clinical practice).
3275005|NCT01609114||experimental groups|RT is delivered in the morning. After 4-6 hrs, C/T is applied.
3275006|NCT01609127|Experimental|Tesetaxel every 3 weeks|Tesetaxel 27 mg/m2 orally on Day 1 in a 21-day cycle
3275007|NCT01609127|Experimental|Tesetaxel weekly|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 in a 28-day cycle
3275008|NCT01609127|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 in a 21-day cycle
3275009|NCT01609140|Experimental|A|
3275010|NCT01609140|Experimental|B|
3275011|NCT01609140|Experimental|C|
3275012|NCT01609140|Experimental|D|
3275013|NCT01609140|Experimental|E|
3275014|NCT01609140|Placebo Comparator|F|
3275015|NCT01609153|Active Comparator|Olanzapine or Placebo|
3275016|NCT01609153|Active Comparator|Amisulpride or Placebo|
3275017|NCT01609153|Active Comparator|Olanzapine and Amisulpride|
3275018|NCT01609166|Experimental|Allopurinol 3% cream|Allopurinol 3% cream in one side of the body
3275019|NCT01609166|Placebo Comparator|Placebo cream|Placebo cream in the other side of the body
3275020|NCT01609179|Experimental|IPI-926|
3275021|NCT01609192|Experimental|hydroxyurea|
3275022|NCT01609205|Experimental|Arm 1|Adalimumab
3275023|NCT01609244|Active Comparator|Bilevel|Bilevel therapy
3275024|NCT01609244|Active Comparator|Servoventilation|servoventilation therapy
3275025|NCT01609270||CardioRoot|All subjects receive the CardioRoot graft at baseline implant procedure.
3275026|NCT01609283|Experimental|Autologous Mesenchymal Stem Cells|
3275027|NCT01609309|Experimental|Laparoscopic gastrectomy|Laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3275028|NCT01609309|Active Comparator|Open gastrectomy|Open distal subtotal gastrectomy with D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3275029|NCT01609322|Active Comparator|Education about falls|In-person education about falls with a health educator.
3275030|NCT01609322|Experimental|Activity, Balance, Learning, and Exposure|Intervention combining medication review, exercise, home safety evaluation, and exposure therapy.
3275031|NCT01609335|Other|Cognitively Normal Subjects|Study participation will consist of tests of memory and thinking, a MRI, and two PET scans. F-18 FDG and C-11 Pittsburgh compound B (PiB) are two drugs used in PET scans.
3275032|NCT01609361|No Intervention|1: Standard surgery + Standard care|standard surgery and Standard care after surgery
3275033|NCT01609361|Other|2: Laparoscopy + Rehabilitation program|Laparoscopic colorectal surgery with rehabilitation program
3275034|NCT01609374|Experimental|M6-C Artificial Cervical Disc|
3275035|NCT01609374|Active Comparator|Anterior Cervical Discectomy and Fusion|
3275036|NCT01609387|Experimental|Gastric Banding new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
3275037|NCT01609387|Active Comparator|Gastric Banding current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Band patients)
3275038|NCT01609387|Experimental|RYGB new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients
3275039|NCT01609387|Active Comparator|RYGB current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in RYGB patients)
3275040|NCT01609387|Experimental|Gastric sleeve new vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
3275041|NCT01609387|Active Comparator|Gastric sleeve current vitamins|Randomization between optimal multivitamins for bariatric surgery and normal over the counter multivitamins (in Gastric Sleeve patients)
3275042|NCT01609400||Breast enhancement|
3275043|NCT01609413|Experimental|AlgaeCal|Calcium supplements derived from ocean algae. One dose equals 3 capsules containing 180 mg calcium each.
3275044|NCT01609413|Active Comparator|Caltrate 600|Proprietary calcium supplement. One dose contains 600 mg of calcium.
3275045|NCT01609426||children with idiopathic nephrotic syndrome|children below 16 years of age with a steroid dependent nephrotic syndrome
3275046|NCT01609439|Placebo Comparator|Placebo|
3275047|NCT01609439|Experimental|Treatment|Pre-operative Vitamin D 800 units x 4 weeks
3275048|NCT01609452|Experimental|Blisibimod|
3275049|NCT01609452|Placebo Comparator|Placebo|
3275050|NCT01609465||Stable angina|
3275051|NCT01609491|Active Comparator|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) will be used in the syringes
3275052|NCT01609491|Active Comparator|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
3275053|NCT01609504|Experimental|Transanal Endoscopic Microsurgery|Patients were treated by TEM as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT (ELRR- Endo Luminal Loco Regional Resection)
3275054|NCT01609504|Active Comparator|Total Mesorectal Excision|
3275055|NCT01609517||Obese group|patients with BMI >= 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
3275056|NCT01609517||Non-obese group|patients with BMI < 30.0 kg/m2 who received spinal anesthesia with heavy marcaine
3275057|NCT01609530|Active Comparator|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
3275058|NCT01609530|Experimental|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
3275059|NCT01609569||coronary complication|"patients with coronary complication and patients without coronary complications.~pro-calcitonin will be measured in both groups to see if any correlation."
3275060|NCT01609595|Experimental|Treatment|Study drug treatment
3275061|NCT01609608|Experimental|vibration|
3275062|NCT01609608|Placebo Comparator|placebo|
3275063|NCT01609621||Retrograde access|
3275064|NCT01609634|Active Comparator|Key Group of interest|Subjects who started test product / control product 1 / control product 2 by 1-month of age
3275065|NCT01609634|Active Comparator|Other-fed Group|Subjects who started test product / control product 1 / control product 2 and continued on breast-feeding
3275066|NCT01609634|Active Comparator|Breast Fed Reference Group|Subjects who are exclusively breast-fed up to 4 months of age and not started on test product / control product 1 / control product 2.
3275067|NCT01609647|Experimental|Prasugrel|Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
3275068|NCT01609647|Active Comparator|Clopidogrel|Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
3275069|NCT01609660|No Intervention|Control group|No intervention at all
3275070|NCT01609660|Experimental|Study group|Use of Saccharomyces boulardii, 100mg for at least seven days before surgery
3275071|NCT01609673|No Intervention|Control|"35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day"
3275072|NCT01609673|Active Comparator|Intervention|"35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
3275073|NCT01609699|Experimental|Group A - will undergo 3 successive treatments, 1 week apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
3275074|NCT01609699|Experimental|Group B - will undergo 3 successive treatments, 2 weeks apart|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
3275075|NCT01609712||Patient with vertebral compression fracture|RF kyphoplasty is standard of care in our hospital for patients with osteoporortic compression fractures. We are intersetd, if it also can improve the lung function.
3275076|NCT01609725|Experimental|Comprehensive treatment|Test treatment group
3275077|NCT01609725|Other|Community treatment|Control treatment group
3275078|NCT01609738||Sinus node dysfunction|Patients with sinus node dysfunction and structurally normal hearts
3275079|NCT01609738||CRT indication|Patients with an indication for CRT (heart failure with an LVEF <35% and LBBB)
3275080|NCT01609751|Experimental|Yakult 62 ml daily|
3275081|NCT01609764|Experimental|Exercise|Follows the fitness program as described in the intervention
3275082|NCT01609764|No Intervention|Control|Will not follow any regular fitness activity during one year
3275083|NCT01609777|Other|Handover with SBAR|Handover with handover tool.
3275084|NCT01609803||Correlative studies|Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.
3275085|NCT01609816|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months
3275086|NCT01609855|Experimental|HBB- Hioscine Butyl Bromide|
3275087|NCT01609855|Placebo Comparator|Placebo arm|
3275088|NCT01609868|Active Comparator|control|infants in this arm will receive the current treatment that is standard of care for these infants, powder protein modular to achieve 4 gm/kg/day
3275089|NCT01609868|Experimental|experimental|this group will receive a liquid protein modular that recently became commercially avaliable, to achieve the same protein of 4 grm/kg/day as the powder comparision group
3275090|NCT01609881|Other|Acuvail|Acuvail as preventive for inflammation and possible decrease or prevent diabetic retinopathy. The study has four arms - diabetic ketorolac, diabetic control, normal eyes ketorolac, normal eyes control. patients are randomized to ketorolac or control.
3275091|NCT01609881|Placebo Comparator|Placebo|Placebo using artificial tear drops
3275092|NCT01609894|Experimental|Individualized fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches.~Modular products for individual adjustment of protein and/or carbohydrate and/or fat will be given in order to achieve target macronutrient level."
3275093|NCT01609894|Active Comparator|Routine fortification of breast milk|"Macronutrient content (for protein, carbohydrate and fat content) will be analyzed of native breast milk batches which had been prepared for 24 hr feeding.~Routine fortifier will be added to breast milk batches."
3275094|NCT01609907|Experimental|Sequence 1|
3275095|NCT01609907|Experimental|Sequence 2|
3275096|NCT01609907|Experimental|Sequence 3|
3275097|NCT01609907|Experimental|Sequence 4|
3275098|NCT01609907|Experimental|Sequence 5|
3275099|NCT01609907|Experimental|Sequence 6|
3275100|NCT01609920|Experimental|Gadofosveset MRL|
3275101|NCT01609959|Active Comparator|Azilsartan group|
3275102|NCT01609959|Active Comparator|Valsartan group|
3275103|NCT01609972|Experimental|Test|Subjects randomized to this arm will be trialed and implanted with the Nevro Senza System
3275104|NCT01609972|Active Comparator|Control|Subjects randomized to this arm will be trialed and implanted with a commercially available SCS system.
3275105|NCT01609998|Experimental|Group 1A (12-17yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3275106|NCT01609998|Experimental|Group 1B (6-11yrs):1 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3275107|NCT01609998|Experimental|Group 2A (12-17yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3275108|NCT01609998|Experimental|Group 2B (6-11yrs):4 mg DNA vaccine+TIV|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV at Week 18±2 wks
3275109|NCT01609998|Active Comparator|Group 3A: (12-17yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
3275110|NCT01609998|Active Comparator|Group 3B: (6-11yrs): TIV+TIV|Licensed 2012/13 TIV at Day 0 and Week 18±2 wks
3275111|NCT01610024|Active Comparator|Beetroot|
3275112|NCT01610050|Experimental|LFA102|
3275113|NCT01610089|Experimental|stable isotope infusion|Infusion of isotopes [15N2-ureido] arginine, [5-13C,4, 4, 5, 5-D4] citrulline, [15N]citrulline, 15N sodium nitrate and [15N][18O3] potassium nitrate,[18O][13C]urea.
3275114|NCT01610128||chronic urticaria patients|all patients suffering from chronic types of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
3275115|NCT01610141|Experimental|Genotype-guided warfarin dosing|A pharmacogenetic dosing algorithm including clinical factors and genotype information (VKORC1, CYP2C9 and CYP4F2) will be used to determine warfarin doses.
3275116|NCT01610141|Active Comparator|Non-genotype guided warfarin dosing|A fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
3275117|NCT01610180|Other|Eltrombopag Olamine|Eltrombopag Olamine Initial dose 50 mg/day for 14 days. Then adjusted according to platelet count
3275118|NCT01610193||Right sided abdominal pain|Patients that present at the Emergency Department with abdominal pain and a clinical suspicion of appendicitis.
3275119|NCT01610219|Active Comparator|Lifestyle Modification for Diabetes Prevention|Family based intervention utilizing Traffic Light Diet, self monitoring, parent behavioral skill training and tool kit of items promoting physical activity.
3275120|NCT01610219|Other|Nutrition and Physical Activity|Family based intervention providing education on healthy eating and physical activity but no behavioral skills training, goal setting, self monitoring or physical activity toolkit.
3275121|NCT01610232|Experimental|LED Group|Phototherapy associated with treadmill training
3275122|NCT01610232|Active Comparator|Exercise Group|Treadmill training
3275123|NCT01610232|No Intervention|Sedentary Group|Neither physical training nor phototherapy
3275124|NCT01610245|Active Comparator|Nitazoxanide|Two Nitazoxanide 300 mg tablets and one placebo capsule twice daily with food for 5 days
3275125|NCT01610245|Active Comparator|Oseltamivir|Two placebo tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
3275126|NCT01610245|Active Comparator|Nitazoxanide and Oseltamivir|Two nitazoxanide 300 mg tablets and one Oseltamivir 75 mg capsule twice daily with food for 5 days
3275127|NCT01610245|Placebo Comparator|Placebo|Two placebo tablets and one placebo capsule with food twice daily for 5 days
3275128|NCT01610310|Experimental|peginterferon beta-1a PFS/autoinjector|A single dose of peginterferon beta-1a 125 mcg administered by prefilled syringe (PFS) on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by autoinjector on Day 22.
3275129|NCT01610310|Experimental|peginterferon beta-1a autoinjector / PFS|A single dose of peginterferon beta-1a 125 mcg administered by autoinjector on Day 1, then by a single dose of peginterferon beta-1a 125 mcg by prefilled syringe (PFS) on Day 22.
3275130|NCT01610323|Experimental|Exercise group|Exercise intervention
3275131|NCT01610323|Other|Control group|Standard care
3275132|NCT01610362|Active Comparator|5-dose IM rabies vaccines, HRIG 20 IU/kg|Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg
3275133|NCT01610362|Experimental|5-dose IM rabies vaccines, HRIG 40 IU/kg|Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg
3275134|NCT01610375|Other|Telephone Follow-up|Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up. However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up. Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
3275135|NCT01610388|Experimental|Cohort A1|Single dose 60 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
3275136|NCT01610388|Experimental|Cohort A2|Single dose 30 minute infusion of 500mg IV GSK1322322/placebo followed by BID for 4 days
3275137|NCT01610388|Experimental|Cohort B|Initial single 1000mg oral GSK1322322/placebo dose, initial single dose 1000mg IV GSK1322322/placebo followed by BID for 4 days
3275138|NCT01610388|Experimental|Cohort C|Initial single 1500mg oral GSK1322322/placebo dose, initial single dose 1500mg IV GSK1322322/placebo followed by BID for 4 days
3275139|NCT01610388|Experimental|Cohort D|Single dose 2000mg IV GSK1322322J/placebo
3275140|NCT01610388|Experimental|Cohort E|Single dose 3000mg IV GSK1322322J/placebo
3275141|NCT01610388|Experimental|Cohort F|1000mg IV GSK1322322J/placebo followed by BID for 4 days
3275142|NCT01610401|Active Comparator|Pretreatment with metformin|Pretreatment with metformin 500 mg three times a day for 3 days.
3275143|NCT01610401|No Intervention|No pretreatment.|no intervention
3275144|NCT01610401|Active Comparator|Pretreatment with Metformin/caffeine|to study whether caffeine (4 mg/kg intravenously over 10 minutes) attenuates the protective effect of metformin (500 mg three times a day for 3 days) on FMD after ischemia/reperfusion
3275145|NCT01610401|Other|No metformin, only pretreatment with caffeine|No pretreatment with metformin, FMD measurement after forearm ischemia/reperfusion and infusion of caffeine (4 mg/kg intravenously over 10 minutes).
3275146|NCT01610440|Experimental|Intervention Group|Participants will be given rehabilitation therapy plus human umbilical cord mesenchymal stem cells transplantation with one year follow-up
3275147|NCT01610466|Experimental|Curriculum training group|Surgical residents in the curriculum training group will complete the entire curriculum. They will participate in a cognitive component, which will consist of self-directed readings and a faculty-led seminar. Participants will also train to proficiency in laparoscopic jejunojejunostomy and gastrojejunostomy using a laparoscopic box trainer with cadaveric porcine bowels. Finally, for the non-technical skills component participants will participate in an introductory lecture on non-technical skills in surgery, as well as a practice crisis scenario with a debriefing session.
3275148|NCT01610466|No Intervention|Conventional training group|Participants in the conventional training group will proceed through surgical residency training in the usual fashion.
3275149|NCT01610479|Experimental|TAS-114/S-1|TAS-114 plus S-1
3275150|NCT01610518|Experimental|250 mL medium viscosity|250 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
3275151|NCT01610518|Experimental|600 mL low viscosity|600 mL beverage containing 4g low molecular weight oat beta-glucan and 50g glucose
3275152|NCT01610518|Experimental|250 mL high viscosity|250 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
3275153|NCT01610518|Experimental|600 mL medium viscosity|600 mL beverage containing 4g high molecular weight oat beta-glucan and 50g glucose
3275154|NCT01610518|Placebo Comparator|250mL control|250 mL beverage containing 50g glucose
3275155|NCT01610518|Placebo Comparator|600mL control|600mL beverage containing 50g glucose
3275156|NCT01610609|Experimental|Population Health Management Intervention|Participants randomized to this arm will receive the population health management intervention.
3275157|NCT01610609|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
3275158|NCT01610635|Experimental|Male - 8 weeks|Male donors assigned to an 8 week donation interval frequency
3275159|NCT01610635|Experimental|Male - 10 weeks|Male donors assigned to 10 week donation interval frequency
3275160|NCT01610635|No Intervention|Male - 12 weeks|Male donors assigned to 12 week donation interval frequency
3275161|NCT01610635|Experimental|Female - 12 weeks|Female donors assigned to 12 week donation interval frequency
3275162|NCT01610635|Experimental|Female - 14 weeks|Female donors assigned to 14 week donation interval frequency
3275163|NCT01610635|No Intervention|Female - 16 weeks|Female donors assigned to 16 week donation interval frequency
3275164|NCT01610648||Patients presenting for a diagnostic sleep study|Patients presenting to the TMC sleep center for sleep study
3275165|NCT01610661|Other|Unrefined-carbohydrate|unrefined carbohydrate diet
3275166|NCT01610661|Other|Refined-carbohydrate|refined carbohydrate diet
3275167|NCT01610661|Other|Simple-carbohydrate|simple carbohydrate diet
3275168|NCT01610674|Experimental|Tailored improvement strategy|In 3 hospitals a tailored strategy to improve perioperative diabetes care is performed
3275169|NCT01610674|No Intervention|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals
3275170|NCT01610726|Active Comparator|enhanced recovery|
3275171|NCT01610726|No Intervention|conventional recovery|
3275172|NCT01610739|Other|Median nerve perfusion|Injection of indigocyanine green dye to evaluate perfusion of the median nerve with the SPY scope before and after carpal tunnel release
3275173|NCT01610765|Active Comparator|Novel Antiviral Drug|Subjects will be randomized to receive one of 3 oral doses of a Novel Antiviral Drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
3275174|NCT01610765|Placebo Comparator|Placebo|Subjects will be randomized to receive one of 3 oral doses of placebo matched in volume to active drug: 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for up to 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered
3275175|NCT01610778|Placebo Comparator|Placebo|
3275176|NCT01610778|Experimental|Supplement|
3275177|NCT01610804||CSCR-Patients|Patients suffering from Central Serous Chorioretinopathy
3275178|NCT01610804||Healthy Subjects|Healthy subjects with (assumed) normal choroidal thickness
3275179|NCT01610817||Patients with the InPAct intervention|The InPAct intervention will be presented to the last patients recruited by each general practitioner
3275180|NCT01610817||Patients without the InPAct intervention|The InPAct intervention will not be presented to the first patients recruited by each general practitioner
3275181|NCT01610830||Group A|have skin involvement +/- an extra renal disease (arthritis, digestive and/or HSP without renal disease. The absence of renal disease is defined by the absence of hypertension (BP <95th percentile for height in children, BP <140/90 mmHg in adults with no known history of hypertension), the absence of hematuria (<5 RBCs per mm3), the absence of proteinuria (proteinuria <0.1 g/24h) and the absence of renal dysfunction (MDRD> 80 ml / min).
3275182|NCT01610830||group B|"HSP with renal impairment, defined by the presence of renal dysfunction (calculated clearance <60 ml/min) and/or proteinuria (daily proteinuria greater than 0.3 g) and/or hematuria (more than 5000 RBC per ml or 5 RBC per mm3). We distinguish:~Group B1 patients with moderate renal disease if renal biopsy was not indicated or no evidence of histologic severity in renal biopsy (histological classification class 1 or 25)~Group B2 patients with severe renal impairment, with signs of histological severity in renal biopsy (class 3, 4 or 5)."
3275183|NCT01610856|Experimental|PEG - 4 L|4 Litres PEG bowel preparation given the day prior to colonoscopy with a clear fluid diet
3275184|NCT01610856|Active Comparator|Split Dose PEG|4 Litres of Colyte given as two split doses of 2L each either the day before colonoscopy 8 hours apart in the case of an AM colonoscopy or in the case of an afternoon colonoscopy given 5PM the day before and 6:00AM the day of the colonoscopy
3275185|NCT01610869|Experimental|Cyclophosphamide and BIBF-1120|Patients will receive oral BIBF 1120 (200mg bd) and cyclophosphamide (100mg) on a daily basis until disease progression or unacceptable toxicity.
3275186|NCT01610869|Placebo Comparator|Cyclophosphamide and placebo|Patients will receive oral BIBF 1120 (200mg bd) and placebo capsules on a daily basis until disease progression or unacceptable toxicity.
3275187|NCT01610882|Other|Panda first|Panda evaluation of post-operative pain first, followed by manual method of pain assessment.
3275188|NCT01610882|Other|Manual first|Manual evaluation of post-operative pain first followed by Panda pain assessment.
3275189|NCT01610895|Active Comparator|Split-dose PEG Based Lavage (2L + 2L) + Low-fiber Diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast, a low-fibre lunch by 2PM and then drink only clear fluids until after the procedure is completed.
3275190|NCT01610895|Placebo Comparator|Split-dose PEG Based Lavage (2L + 2L) + Clear fluid diet|Patients randomized to this arm will have a split-dose Polyethylene Glycol Based lavage (2L + 2L), have a low-fibre diet 4 days prior to Colonoscopy and the day before Colonoscopy, have a low-fibre breakfast and then drink only clear fluids until after the procedure is completed.
3377434|NCT04466553||NICO BrainPath™ Patients|"50 patients will be enrolled in Group A NICO BrainPath™ system.~The NICO BrainPath™ System has been proposed to reduce high morbidity and mortality associated with ICH through minimally invasive clot evacuation. Previous, single-center trials concluded evacuation of ICH using the BrainPath™ system as being safe and effective. Additionally, previous studies concluded that lesser ICH removal was correlated with mortality benefit and that the NICO BrainPath™ system approach was shown to be safe and effective with a high rate of clot evacuation and functional independence. This system warrants further research because of the need to optimize clinical outcome in these patients and to better define the role of hematoma evacuation in the care of these patients."
3377435|NCT04466553||Standard of Care|50 patients will be matched retrospectively of similar diagnosis, undergoing standard of care (e.g. no surgical intervention). These patients will be matched to the surgical patients based on age, gender, and location of hemorrhage.
3377436|NCT04465214||1/Cohort 1|Participants with a diagnosis of cancer who are under active treatment on a protocol at NIH
3377440|NCT04458935||Participants|Participants with retinal hemangioblastoma (RH) managed with trans-scleral cryotherapy at the NIH.
3377446|NCT04452877|Experimental|Dabrafenib in combination with trametinib|Dabrafenib 150 mg twice daily, trametinib 2 mg once daily
3275191|NCT01610908|Experimental|Schroth exercises|The experimental group receives the Schroth exercises treatment.Patients in this arm receive 5 individual sessions with a Schroth therapist for introduction to the approach. They they receive a home program consisting of 3-4 exercises to do at home everyday for 30-45 minutes. They come to weekly group therapy sessions to where exercise prescription is adjusted.
3377447|NCT04451044|Experimental|physiologically-guided arm|Physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy
3377448|NCT04451044|Active Comparator|angiographically-guided arm|Standard of care angiographically-guided PCI for determining the PCI strategy
3377449|NCT04450927||1|Data collection and treatment according to guidelines of standard of medical evaluation and care. No investigational treatments or procedures will be administered on this protocol.
3377450|NCT04447014||Cohort 1|Subjects with confirmed adrenocortical cancer (ACC)
3377451|NCT04446481|Experimental|MCI patients|Vets with mild cognitive impairment
3377452|NCT04446481|Active Comparator|NC|Normal healthy Veterans
3377453|NCT04445545|Experimental|Experimental group 1 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
3377454|NCT04445545|Experimental|Experimental group 2 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 50 J / cm2 in continuous emission (duty cycle 100%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
3377455|NCT04445545|Experimental|Experimental group 3 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
3377456|NCT04445545|Experimental|Experimental group 4 (HILT)|The group will receive treatment of high intensity laser therapy (HILT) with a dose of 25 J / cm2 in pulsed emission (duty cycle 25%).The group will receive, in addition to the laser intervention, a treatment with passive static stretching exercises of 5 sets of 30 seconds.
3377457|NCT04445545|Active Comparator|Control group|The group will receive only passive static stretching exercises of 5 sets of 30 seconds.
3377458|NCT04444427|Experimental|Part 1: Dose Escalation|Dose escalation cohorts are planned to determine the maximum tolerated dose or recommended phase 2 dose of GLR-2007, as well as expansion cohorts and a Phase 2 cohort.
3275192|NCT01610908|No Intervention|Standard of care|"The Standard of care is a control group that will continue receiving the standard North American treatment prescribed by a surgeon (observation or brace [if meeting SRS criteria]) for of 6 months. After 6 months, the participants will receive the Schroth exercises intervention for 6 months."
3275193|NCT01610908|Active Comparator|Global Postural Re-education (Montréal)|"The active group (in Montréal only) receives the Global Postural Re-Education exercises treatment.Patients in this arm come to weekly individual 1 hour long therapy sessions where exercise prescription is adjusted. Selection of posture exercises is based on scoliosis type, on muscular chain stiffness associated with posture alterations and on position increasing scoliosis or pain (lying, sitting, standing).~They they receive a 15-min home program consisting of 1 to 2 exercises to do at home everyday."
3275194|NCT01610921|Experimental|bronchial provocationtest|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
3275195|NCT01610934|Experimental|liraglutide|
3275196|NCT01610934|Active Comparator|glimepiride|
3275197|NCT01610947|Active Comparator|Maintain|Continuation of usual treatment with fixed intervals according to standard recommendations
3275198|NCT01610947|Active Comparator|Spacing|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.
3275199|NCT01610960|Active Comparator|HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
3275200|NCT01610960|Sham Comparator|Facemask|The facemask will be used by each patient.
3275201|NCT01610973|Experimental|Manual preparation|Manual preparation of the graft
3275202|NCT01610973|Active Comparator|Automatized preparation|Automatized preparation of the graft with microkeratoma
3275203|NCT01610986|Experimental|Glucose-fructose|Participants will take glucose-fructose drinks during training sessions
3275204|NCT01610986|Experimental|Water|Participants will take only water during training sessions
3275205|NCT01610999|Experimental|Cohort A|0.24 mg/kg plerixafor on day 1
3275206|NCT01610999|Experimental|Cohort B|0.24 mg/kg plerixafor daily on days 1 & 2
3275207|NCT01610999|No Intervention|Cohort C|"Six control subjects will have research bloods drawn but receive no plerixafor."
3275208|NCT01611038|Placebo Comparator|Placebo|Placebo given daily
3275209|NCT01611038|Experimental|Methylselenocysteine|Methylselenocysteine given daily
3275210|NCT01611051|Experimental|Pegylated rhG-CSF: 100µg/kg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 100µg/kg
3275211|NCT01611051|Experimental|Pegylated rhG-CSF: 6mg|Chemtherapy naive patients receiving chemotherapy and Pegylated rhG-CSF 6mg
3275212|NCT01611051|Active Comparator|rhG-CSF 5ug/kg/day|Chemtherapy naive patients receiving chemotherapy and rhG-CSF 5ug/kg/day
3275213|NCT01611064|Active Comparator|Oxygen|Volunteer receives oxygen at a rate of 10litres/minute by mask
3275214|NCT01611064|Placebo Comparator|Air|Volunteer receives normal air at a rate of 10litres/minute by mask
3275215|NCT01611077|Other|Single Arm|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days, then olmesartan 40 mg tablets once daily for 42 days, then olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
3275216|NCT01611103|Sham Comparator|Sham Stimulation|transcranial direct current stimulation that is ramped up and ramped down providing the sensation of tDCS without delivering the full amount of tDCS
3275217|NCT01611103|Experimental|Anodal Stimulation|transcranial direct current stimulation using Anodal stimulation over the area of interest
3275218|NCT01611129|Active Comparator|reading about hearing loss and its management|General self-reading reading about hearing loss and its management This would run for 30 days and the participants have to manage their own time.
3275219|NCT01611129|Experimental|Internet-based counseling|This would involve 4 stages of designated internet sessions and additional tasks which the patients can complete in their own time. This programme should be completed within 30 days.
3275220|NCT01611142|Experimental|KW-0761|
3275221|NCT01611168|No Intervention|Usual Care|
3275222|NCT01611168|Experimental|Intervention Group, treatment algorithms|
3275223|NCT01611181|Active Comparator|Hemoboost (iron supplementation)|A registered natural product containing specially haemolysed haemoglobin and iron dextran.
3275224|NCT01611181|Active Comparator|Kräuterblut (iron supplementation)|A registered natural product made from a number of herbs with ferrous gluconate as the active substance.
3275225|NCT01611181|Active Comparator|Ferrofumerat (iron supplementation)|Ferrous sulphate
3275226|NCT01611207|Experimental|Negative Pressure Wound Therapy|Used therapy systems
3275227|NCT01611207|Active Comparator|Standard Conventional Wound Therapy|Standard conventional wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
3275228|NCT01611220|No Intervention|Control|Standard cognitive behavior inpatient treatment
3275229|NCT01611220|Experimental|RePAN|Standard cognitive behavior inpatient treatment plus 8 dissonance relapse prevention groups
3275230|NCT01611233||DePuy ASR THA|Adults having received a Depuy ASR metal on metal hip system which is subject to a voluntary recall.
3275231|NCT01611246||Anesthetization|Anesthetization
3275232|NCT01611272||1|Unstable angina, Non ST-segment Elevation Myocardial Infarction or ST-segment elevation myocardial infarction including patients managed medically, and those who are managed with percutaneous coronary intervention or coronary artery by-pass grafting
3275233|NCT01611285||Robotic Sacrocolpopexy patients|Patients who underwent Robotic Sacrocolpopexy to treat pelvic organ prolapse between 2009 and 2010
3275234|NCT01611285||UPHOLD patients|Patients who underwent the UPHOLD procedure to treat pelvic organ prolapse from 2009-2010.
3275235|NCT01611311|Experimental|BI 409306 BS medium dose|Film-coated tablet
3275236|NCT01611311|Experimental|BI 409306 BS high dose|Film-coated tablet
3275237|NCT01611311|Placebo Comparator|Placebo|Film-coated tablet
3275238|NCT01611324|Experimental|Alkalinised anesthetic solution|
3275239|NCT01611324|Active Comparator|Non alkalinised anesthetic solution|
3275240|NCT01611337|Other|insight evaluation|insight evaluation using the Q8 scale
3275241|NCT01611350|Experimental|Health Marketing Message|Marketing message focused on health effects of cooking with wood on a three stone fire.
3275242|NCT01611350|Experimental|Savings Marketing Message|Marketing message focused on savings (both time and money) related to using an energy efficient cookstove.
3275243|NCT01611350|Experimental|Savings and Health Marketing Messages Combined|One group will receive both the savings and health marketing messages.
3275244|NCT01611350|Experimental|Novel Sales Offer|This group will receive a free trial and time payments when purchasing an energy efficient cookstove.
3275245|NCT01611350|Experimental|Early vs. Late Buyers|Of those who accept the Novel Sales Offer, half the buyers will randomly be selected to start their free trial within a few weeks of the sales meeting, while the other half- the late buyers- will start their free trial a within 2 months of the sales meeting.
3275246|NCT01611363|Experimental|Part A|Ipragliflozin (low dose) & Placebo
3275247|NCT01611363|Experimental|Part B|Ipragliflozin (high dose)
3275248|NCT01611389|Experimental|Long AV delay.|
3275249|NCT01611389|Active Comparator|Short AV delay.|
3275250|NCT01611415|Experimental|ipragliflozin|
3275251|NCT01611415|Experimental|furosemide|
3275252|NCT01611415|Experimental|ipragliflozin & furosemide|
3275253|NCT01611428|Experimental|Ipragliflozin - oral|open label
3275254|NCT01611428|Experimental|Ipragliflozin - i.v.|open label
3275255|NCT01611441||Patients with osteoarthritis of the knee|Patients with osteoarthritis of the knee undergoing total knee replacement surgery.
3275256|NCT01611467|Experimental|20 mg oral CC-223 with microtracer|A single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution
3275257|NCT01611467|Experimental|20 mg oral CC-223 fasting|A single 20-mg oral dose of CC-223 tablet under fasting conditions
3275258|NCT01611467|Experimental|20 mg oral CC-223 fed|A single 20-mg oral dose of CC-223 tablet under fed conditions
3275259|NCT01611493|Experimental|Osseotite Prevail Implant|The Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure.
3275260|NCT01611493|Active Comparator|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
3275261|NCT01611506|Experimental|Cetuximab, capecitabine, cisplatin based chemoradiation|"Induction chemotherapy:~3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.~Followed by:~Radio-chemo-immunotherapy:~Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week~Surgery:~Will be performed 4-6 weeks after neoadjuvant radiochemotherapy~Postoperative treatment:~3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator."
3275262|NCT01611519||Early (within 48 hours of surgery)|Patients will have their urinary catheter removed within 48 hours of surgery
3275263|NCT01611519||Late (6 hours after epidural removal)|Patients will have their urinary catheter removed 6 hours after their epidural is removed
3275264|NCT01611532||Acute pancreatitis|All adult patients (>18y.o.) requiring admission for acute pancreatitis (amylase >3 times the upper limit of normal and typical symptoms of abdominal pain and vomiting)
3275265|NCT01611545||Clopidogrel|Patients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
3275266|NCT01611584|Experimental|ALA|No arms for the trial. Participants will have proven or presumed lung cancer and will be assessed for participant by a research team member.
3275267|NCT01611610|Other|Ambulant SMA|
3275268|NCT01611610|Other|Non-ambulant SMA|
3275269|NCT01611623|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation based on safety outcomes
3275270|NCT01611649|Experimental|Dairy lipids and plant oils|
3275271|NCT01611649|Experimental|Plant oils|
3275272|NCT01611649|Experimental|Dairy lipids and plant oils, DHA+ARA|DHA: docosahexaenoic acid, ARA: arachidonic acid
3275273|NCT01611649|No Intervention|Human milk|
3275274|NCT01611675|Experimental|Treatment Arm|Leflunomide + Vemurafenib
3275275|NCT01611688|Experimental|Active|
3275276|NCT01611688|Placebo Comparator|Placebo|
3275277|NCT01611701|Active Comparator|Cryoballoon group|
3275278|NCT01611701|Active Comparator|RF group|
3275279|NCT01611714|Experimental|Audit-feedback|Arm 1: Audit-feedback only
3275280|NCT01611714|Experimental|CDS message|Arm 2: CDS message only
3275281|NCT01611714|Experimental|Both Interventions|Arm 3: Audit-feedback and CDS message
3275282|NCT01611714|No Intervention|Control|Arm 4: Control
3275283|NCT01611727|Experimental|Cisplatin|
3275284|NCT01611740||Preterm infants|Telemonitoring system prototype developed by INSERM U-642
3275285|NCT01611753|Active Comparator|liberal group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL.
3275286|NCT01611753|Active Comparator|restrictive group|Patients in the liberal group received transfusions immediately, as the objective was to maintain hemoglobin levels above 7.0 g/dL.
3275287|NCT01611766|Experimental|secondary cytoreductive surgery|SCR followed by chemotherapy
3275288|NCT01611766|Active Comparator|Salvage Chemotherapy|platinum-based chemotherapy
3275289|NCT01611805|Experimental|GSK1605786 250mg|Opaque Swedish orange body and cap.
3275290|NCT01611805|Placebo Comparator|Placebo|Opaque Swedish orange body and cap.
3275291|NCT01611805|Experimental|GSK1605786 500mg|Opaque Swedish orange body and cap.
3275292|NCT01611805|Experimental|GSK1605786 1000mg|Opaque Swedish orange body and cap.
3275293|NCT01611805|Experimental|GSK1605786 500mg in fed|Opaque Swedish orange body and cap.
3275294|NCT01611818|Other|Low intensity Internet-delivered psychotherapy|Low intensity Internet-delivered psychotherapy + improved treatment as usual by GP.
3275295|NCT01611818|Other|Self-guided Internet-delivered psychotherapy|Self-guided Internet-delivered psychotherapy + improved treatment as usual
3275296|NCT01611818|Other|Improved treatment as usual by GP|
3275297|NCT01611831|Experimental|ACT in group|Patients assigned to this arm will receive Acceptation and Commitment Therapy (ACT) in groups of 8-12 patients. Intervention has been protocolized. Therapy will be administered by two experienced therapists (psychologists).
3275298|NCT01611831|Active Comparator|Improved Treatment as usual by General practitioner|Patients assigned to this arm will receive treatment as usual by their General Practitioner in the Primary Care center. To enhance treatment, investigators participating in the trial will receive the Guidelines for fibromyalgia treatment in Primary Care handed by Health Service in Aragón.
3275299|NCT01611844|Experimental|Medical device : micro-needle BD 1.5 mm 30G|
3275300|NCT01611844|Active Comparator|Manthoux method: lance 26G X 16mm|
3275301|NCT01611896|Active Comparator|Selenium|
3275302|NCT01611896|Placebo Comparator|Placebo|
3275303|NCT01611909|Experimental|2% PMDO|
3275304|NCT01611909|Experimental|5% PMDO|
3275305|NCT01611909|Active Comparator|Mupirocin|
3275306|NCT01611922||Symptomatic Lens Wearers|Contact lens wearers reporting a habitual wear time of less than eight hours and a noticeable reduction in comfort over a wearing day
3275307|NCT01611922||Non-Symptomatic Contact Lens Wearers|Contact lens wearers reporting a comfortable wear time of more than 10 hours and minimal reduction in comfort over a wearing day
3275308|NCT01611922||Asymptomatic Non-Contact Lens Wearers|Non-contact lens wearers reporting a minimal reduction in ocular comfort over the course of a day
3275309|NCT01611961|Experimental|DT-LM|Docetaxel Lipid Microsphere (DT-LM)
3275310|NCT01611961|Active Comparator|Taxotere|Commerical Product
3275311|NCT01611987|Experimental|MSTEP|The MSTEP program is a 6 day tailored exercise program. It includes flexibility, aerobic, peripheral strengthening, core and balance training, power and speed training and push days.
3275312|NCT01611987|Active Comparator|General guideline approach|The general Guideline approach is the general guidelines that are recommended for people with MS by the Canadian Society Exercise Physiology.
3275313|NCT01612013|Active Comparator|Intravenous NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
3275314|NCT01612013|Active Comparator|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3275315|NCT01612013|Active Comparator|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3275316|NCT01612013|Placebo Comparator|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
3275317|NCT01612026||Ultrasound|
3275318|NCT01612026||Fluoroscopy|
3275319|NCT01612039|Experimental|ASP3291|
3275320|NCT01612039|Placebo Comparator|Placebo|
3275321|NCT01612052|Active Comparator|Cefazolin plus Daptomycin|
3275322|NCT01612052|Active Comparator|Cefazolin plus Vancomycin|
3275323|NCT01612065|Active Comparator|Misoprostol vaginally, 200 ug|200 ug misoprostol in the posterior vaginal fornix
3275324|NCT01612065|Active Comparator|Misoprostol vaginally, 400ug|Misoprostol in the posterior vaginal fornix
3275325|NCT01612078|Experimental|Droxidopa, antihypotensive drug, tablet|
3275326|NCT01612078|Placebo Comparator|placebo, tablet|
3275327|NCT01612091|Experimental|Monitoring Messenger|
3275328|NCT01612091|Active Comparator|Control|Traditional tools (monitors, paper records)
3275329|NCT01612104|Experimental|Psychological First Aid|Psychological material developed for children and adolescents, based on cognitive behavioral theory, used to structure therapeutic conversations and/or for self-help.
3275330|NCT01612117||consecutive, PCP patients|All patients requiring percutaneous coronary procedures, such as coronary angiography or intervention
3275331|NCT01612130|Experimental|Valeriana officinalis L (100mg)|100 mg of Valeriana officinalis L. (Valerian)
3275332|NCT01612130|Placebo Comparator|Placebo (100 mg)|Placebo 100mg
3275333|NCT01612143|Active Comparator|A: STV capsule (after high fat meal)|
3275334|NCT01612143|Active Comparator|B: STV capsule (fasted state)|
3275335|NCT01612143|Experimental|C: STV tablet (after high fat meal)|
3275336|NCT01612143|Experimental|D: STV tablet (fasted state)|
3275337|NCT01612169|No Intervention|Treatment as Usual (TAU) Group|"Participants assigned to the TAU group will receive the standard treatment provided at each hospital for linking patients to HIV and substance use care.~During the formal site selection process, a thorough assessment will be conducted of each site's standard practice for linkage to HIV care and substance use treatment. Throughout the course of the trial, hospital sites will be monitored for any potential changes that might occur in standard practice around linkage to HIV care and substance use treatment."
3275338|NCT01612169|Experimental|Patient Navigation (PN) Group|"The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.~After the initial four meetings, patient navigators will meet with PN group participants ideally twice monthly during months 2 and 3 and once monthly during months 4 - 6."
3275339|NCT01612169|Experimental|Patient Navigator Plus Contingency Management (PN+CM) Group|"Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM). Using the principles of contingency management, this combined intervention will incorporate viral load suppression as a target of reinforcement as well as several other behaviors (HIV clinical care, medication adherence, cessation or reduction of substance use) that are hypothesized to be moderators or mediators of the primary outcome.~For participants randomly assigned to the PN+CM study group, patient navigators will: 1) effectively communicate the incentive plan to the participant, 2) track each of the seven target behaviors that may earn participant incentives, 3) verify occurrence of the target behaviors, 4) deliver incentives according to the protocol, and 5) maintain a record of incentives delivered. PNs will use a computer-based tracking program to facilitate this work."
3275340|NCT01612182||ESBL(+) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(+) Klebsiella pneumonia in any site during hospitalization
3275341|NCT01612182||ESBL(-) Klebsiella pneumonia|All the patient who's the culture result showed ESBL(-) Klebsiella pneumonia in any site during hospitalization
3275342|NCT01612195|Experimental|Anal fistula plug|
3275343|NCT01612208||Distal femur fractures|(AO/OTA types 33-A and 33-C)
3275344|NCT01612234|Experimental|High palmitate or high oleate diet.|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
3275345|NCT01612234|Experimental|high palmitate or high oleate diet|This is a solid food diet in which vegetable oils are used to create a dietary fat composition similar to the average American/Western diet in which palmitic and oleic acid are ingested in approximately equal amounts (high palmitate diet) or a composition similar to the Mediterranean Diet (low palmitate, high oleate, using hazelnut oil as the source of fat). There are no interventions other than the diet itself.
3275346|NCT01612260|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. po for 12weeks
3275347|NCT01612260|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. po for 12weeks
3275348|NCT01612273|Experimental|Disgren|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
3275349|NCT01612273|Experimental|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
3275350|NCT01612286|Experimental|endostatin|chemotherapy concurrently with endostatin
3275351|NCT01612299|Active Comparator|Standard Immunosuppression|Tacrolimus + Myfortic®/Cellcept + Corticosteroids
3275352|NCT01612299|Experimental|Zortress®|Tacrolimus + Zortress® + Corticosteroids
3275353|NCT01612312|Active Comparator|Thrombectomy|
3275354|NCT01612312|Other|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
3275355|NCT01612325|Experimental|Holmium-166 MS radioembolization|Single radioembolization met Holmium-166 polylactic microspheres administered
3275356|NCT01612338|Experimental|Targeted|Targeted letter and booklet
3275357|NCT01612338|Experimental|Tailored|Tailored letter and booklet, enhanced family communication and support brochure
3275358|NCT01612364|Experimental|thoracic sympathetic block|Sympathetic block of upper limb via thoracic vertebra T3
3275359|NCT01612364|Active Comparator|control block|Same medication used in experimental group, but in dorsal subcutaneous
3275360|NCT01612377|Experimental|prednisolone-dipyridamole|
3275361|NCT01612377|Active Comparator|prednisone 5mg|
3275362|NCT01612377|Active Comparator|prednisone 7.5mg|
3275363|NCT01612390||group 1|receive 400 Mg sublingual misoprostol.
3275364|NCT01612390||group 2|receive 600 Mg sublingual misoprostol.
3275365|NCT01612390||group 3|receive 5IU of intravenous oxytocin.
3275366|NCT01612403||Single group|Single group: all participants receive same intervention throughout study (Non-randomised)
3275367|NCT01612416|Sham Comparator|Normal subjects|
3275368|NCT01612416|Active Comparator|Primary open angle glaucoma|
3275369|NCT01612416|Active Comparator|Normal tension glaucoma|
3275370|NCT01612429|Experimental|Amino acid supplementation|Up to 500 mL of 5.4% amino acid solution (NephrAmine) by intravenous infusion 3 x weekly for 6 weeks.
3275371|NCT01612442|Experimental|Integrated education|
3275372|NCT01612442|No Intervention|Control|
3275373|NCT01612442|Experimental|Nutrition education|
3275374|NCT01612455|No Intervention|Standard of Care|Control participants will receive the narcology hospital's standard of care. With regard to linkage to HIV medical care, patients will be given printed information about where to obtain HIV medical care - the outpatient clinic that is involved in the intervention. Control patients will be referred to outpatient narcology care as part of standard of care. If control participants are newly diagnosed with HIV infection at the addiction hospital, they will receive HIV post test counseling consistent with CDC recommendations (this represents an enhancement of the current standard of care in Russia).
3275375|NCT01612455|Experimental|LINC Case Management (Intervention)|LINC Case Management (study Intervention) - see Intervention description
3275376|NCT01612468|Experimental|Liraglutide|
3275377|NCT01612468|Placebo Comparator|Placebo|
3275378|NCT01612481|Active Comparator|chest radiography|clinical exam + chest radiography every 3 months during 2 years and every 6 months during 1 year
3275379|NCT01612481|Active Comparator|chest CT|clinical exam + Chest CT every 3 months during 2 years and every 6 months during 1 year
3275380|NCT01612507|Experimental|A|600 mg Ceftaroline fosamil 1 h infusion
3275381|NCT01612507|Experimental|B|Placebo 1 h infusion
3275382|NCT01612507|Experimental|C|600 mg Ceftaroline fosamil 2 h infusion
3275383|NCT01612507|Experimental|D|Placebo 2 h infusion
3275384|NCT01612520|Active Comparator|telecoaching|
3275385|NCT01612520|No Intervention|control|
3275386|NCT01612598|Experimental|Supportive Care (PCI)|"PCI PART I: Patients undergo comprehensive PC assessment based on baseline data and complete goals of care discussion.~PCI PART II: Following the first dose of phase I investigational treatment, patients meet with the IDT, where PC recommendations are made. This is followed by two patient educational sessions that will cover QOL-related domains, including physical, social, emotional, and spiritual well-being. Supportive care referrals are made based on IDT recommendations."
3275387|NCT01612611||a cohort using Shenmai injection|
3275388|NCT01612637|Experimental|Group 1|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and they will perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
3275389|NCT01612637|Active Comparator|Group 2|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
3275390|NCT01612650|Active Comparator|breast cancer histologically proven|Patient with breast cancer histologically proven, addressed to Oscar Lambret Center for treatment
3275391|NCT01612650|Active Comparator|surveillance of a treated breast cancer|surveillance of patient already treated for breast cancer must have annual mammography
3275392|NCT01612650|Active Comparator|diagnosis of a detected anomaly|patient addressed for diagnosis of a detected anomaly
3275393|NCT01612663|Active Comparator|deep needle non-site specific|
3275394|NCT01612663|Active Comparator|contralateral elbow to the knee pain|
3275395|NCT01612663|Active Comparator|Energy of Living Systems Needling|
3275396|NCT01612663|Placebo Comparator|Sham acupuncture|
3275397|NCT01612689|Experimental|Physiologic Data Collection|
3275398|NCT01612715||Study Population|Mild asthma, cat-allergic, 18-65 years old, males and females will be recruited for the study.
3275399|NCT01612728|Experimental|Women with Arthralgia|Women who develop joint pain on Aromatase Inhibitor therapy will be placed on the clinical algorithm, as specified in the protocol.
3275400|NCT01612728|Other|Women without Arthralgia|Women who do not develop arthralgia will continue to have their joint pain and strength measured, as well as their medication compliance. However, they will not be placed on the clinical algorithm which is meant for alleviation of joint pains.
3275401|NCT01612741||Group 1|
3275402|NCT01612754|No Intervention|Reference group - cloaked noise meters|"Reference group or phase 1~Theatre equipped with multiple sound meters disguised as CO2 meter for sound probing in the absence of a research clerk with personnel completely unaware of sound measurements."
3275403|NCT01612754|Sham Comparator|Control Noise AND Stress measurements|"Control Group - Phase 2~No intervention but research clerk is present in theatre to protocoll the operation and test for stress by collecting saliva cortisol and probing electrodermal activity"
3275404|NCT01612754|Experimental|Noise Reduction Intervention Group|"Intervention Group - Phase 3~A panel of noise reduction measures (staff workplace rules, technical devices as optical noise warners, optical telephones) is put into effect. Surgeons are monitored by biometry, psychometry and the outcome."
3275405|NCT01612806|Experimental|PriMatrix|PriMatrix Dermal Repair Scaffold
3275406|NCT01612806|Experimental|PriMatrix Ag|PriMatrix Ag Antimicrobial Dermal Repair Scaffold
3275407|NCT01612806|Active Comparator|Standard of Care|Standard of Care Moist Wound Therapy
3275408|NCT01612832|Experimental|Lyrica|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
3275409|NCT01612832|Active Comparator|Control|no liryca treatment
3275410|NCT01612845|Experimental|PRF|the group in which the PRF was administered
3275411|NCT01612845|Active Comparator|Control|repair without PRF
3275412|NCT01612871|Experimental|hormone therapy treatment|Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day
3275413|NCT01612897|Experimental|Computer based reminders to MD|Children in this arm attend a clinic that is randomly assigned to receive physician alerts to screen appropriate children for autism.
3275414|NCT01612897|No Intervention|Usual care arm|Children in this are receive usual care from a clinic randomly chosen to serve as a control.
3275415|NCT01612910|Experimental|microencapsulated diindolylmethane, lab. biomarker analysis|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
3275416|NCT01612923|Experimental|midwife|Gynecological exam and ultrasound performed by midwife, medical abortion service provided by midwife,contraceptive advice provided by midwife. Follow-up visit provided by midwife
3275417|NCT01612923|No Intervention|Physician|Gynecological exam and ultrasound and contraceptive advice provided by physician. Medical abortion service and follow-up visit provided by midwife
3275418|NCT01612936|Experimental|Allergic asthmatic, allergic nonasthmatic|Adults who are allergic asthmatics or allergic non-asthmatics will receive segmental allergen challenge to the lung
3275419|NCT01612949||easy to intubate, model derivation|easy to intubate, model derivation. photographing head and neck
3275420|NCT01612949||difficult to intubate, model derivation|difficult to intubate, model derivation.photographing head and neck
3275421|NCT01612949||easy to intubate, model validation|easy to intubate, model validation. photographing head and neck
3275422|NCT01612949||difficult to intubate, model validation|difficult to intubate, model validation. photographing head and neck
3275423|NCT01612949||Test|A group of unlabeled subjects (mix of easy and difficult intubations) to test the reproducibility of the derived and validated model(s)
3275424|NCT01612962||bony debridement or amputation|In this study, the investigators will perform a retrospective chart analysis of patients that underwent a bony debridement or amputation in the operating room at Georgetown University Hospital during 2009-2010 under Drs. Steinberg and Attinger
3275425|NCT01612975|Placebo Comparator|Placebo|This study arm will encompass the administration of a placebo (physically identical to Naproxen) orally to participants. Naproxen is a painkiller with intrinsic anti-inflammatory properties, while the placebo has no pharmacological properties associated with it. Participants will also be taking Pantoprazole to negate the gastrointestinal consequences of Naproxen (or the placebo). Participants will not know which arm of the study they belong to. In addition, they will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety.
3275426|NCT01612975|Experimental|Naproxen|Intervention arm involves administering 500mg Naproxen twice a day to participants and 40mg of Pantoprazole once a day in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
3275427|NCT01612988|Experimental|Chemotherapy BOMP|Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks
3275428|NCT01613001||DoD Beneficiaries|"Exclusion: Active Duty Air Force members with the following conditions will be excluded from the study:~Documented preexisting musculoskeletal injury/disease before onset of obesity~Hypothyroidism/Hyperthyroidism~Hyperparathyroidism~Osteopenia/Osteoporosis~Nicotine dependence~Alcohol dependence~Eating disorders (anorexia nervosa, bulimia nervosa)~Cancer requiring chemotherapy or radiation therapy~Status-post gastrectomy~Status-post bilateral oophorectomy~Crohn's Disease~Ulcerative Colitis~Celiac Disease~Cushing's Disease~Prior to or during the study period, more than 6 months of taking proton pump inhibitors, medroxyprogesterone acetate, bisphosphonates, methotrexate, selective serotonin reuptake inhibitors, or inhaled/intranasal corticosteroids~Prior to or during the study period, more than 1 month of taking fluoroquinolones, oral or intramuscular corticosteroids, oral or intramuscular testosterone, or leuprolide"
3275429|NCT01613040|Experimental|Treatment A|
3275430|NCT01613040|Experimental|Treatment B|
3275431|NCT01613040|Placebo Comparator|Treatment C|
3275432|NCT01613040|Placebo Comparator|Treatment D|
3275433|NCT01613066|Experimental|Treatment|Patients with high risk haematological malignancies
3275434|NCT01613079|Placebo Comparator|Methotrexate|Patients were treated with methotrexate alone.
3275435|NCT01613079|Experimental|T2|Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
3275436|NCT01613079|Experimental|MTX+T2|The patients were treated with methotrexate and T2.
3275437|NCT01613092|Experimental|Conventional|Preoperative Antibiotics
3275438|NCT01613092|Active Comparator|Aggressive (Incremental)|Preoperative antibiotics, antibiotic wash and post operative antibiotics
3275439|NCT01613105||Group 1|
3275440|NCT01613144||OsseoScrew|
3275441|NCT01613144||Fenestrated Screw|
3275442|NCT01613170|Experimental|Toviaz and Premarin Vaginal Cream|Toviaz 4 mg PO q day and premarin cream 1 g per vagina 2 times a week.
3275443|NCT01613170|Placebo Comparator|Toviaz , Placebo Premarin Vaginal Cream|Toviaz 4 mg PO q day and placebo cream 1 g per vagina 2 times a week.
3275444|NCT01613183|Experimental|Chinese Medicine group|Chinese Medicine prescription of one of three prestigious Chinese medicine clinicians
3275445|NCT01613183|Placebo Comparator|placebo group|
3275446|NCT01613196|Experimental|Positron Emission Tomography|Positron Emission Tomography
3275447|NCT01613209|Experimental|Olmesartan/Amlodipin fixed combination|
3275448|NCT01613235|No Intervention|No intervention|No induced hypertension (reference group)
3275449|NCT01613235|Active Comparator|Induced hypertension|Patients who are randomised to this arm will have their blood pressure raised with vasopressors and fluids. Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
3275450|NCT01613261|Experimental|TAK-733 and alisertib|
3275451|NCT01613274|Experimental|Gum chewing|Chewing mint flavored sugarless gum for 10-20 minutes three times a day following colon resection.
3275452|NCT01613274|Placebo Comparator|no gum chewing|no gum chewing
3275453|NCT01613287|Experimental|Immunoadsorption|Patients are treated with the TheraSorb® Ig flex adsorber used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy (5 treatments) performed over 5 to 8 consecutive days
3275454|NCT01613300|Experimental|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
3275455|NCT01613352|Experimental|Day surgery group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to ambulatory surgery group.
3275456|NCT01613352|Active Comparator|In-Patient group|Patients who underwent breast conserving surgery and sentinel node biopsy only and were randomized to in-patient group.
3275457|NCT01613365|Experimental|chlorhexidine gluconate|
3275458|NCT01613365|Experimental|placebo|
3275459|NCT01613391||RYGBP|Patients underwent Roux-en-Y Gastric Bypass for morbid obesity.
3275460|NCT01613391||LAGB|Patients underwent Laparoscopic Adjustable Gastric Banding for morbid obesity.
3275461|NCT01613404||Patients with nurse case manager|Patients will receive a dedicated nurse case manager (intervention group) in this group.
3275462|NCT01613404||Patients with no nurse case manager|Patients will not receive nurse case manager (control group) in this group.
3275463|NCT01613430|Active Comparator|Printed Educational Material (PEM) only|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
3275464|NCT01613430|Experimental|Coach Training (COACH)|The COACH intervention consists of the Printed Educational Materials (PEM) plus the addition of cancer-related training for participant-designated coaches.
3275465|NCT01613443||Control|Healthy volunteers without medication
3275466|NCT01613443||Phenprocoumon|Patients receiving Marcumar having target INR 2-3
3275467|NCT01613443||Dabigatran|Patients receiving therapeutic dosis of Pradaxa
3275468|NCT01613443||Rivaroxaban|Patients receiving therapeutic dosis of Xarelto
3275469|NCT01613456|Placebo Comparator|Placebo|Dicalcium phosphate, Maltodextrin and Magnesium stearate.
3275470|NCT01613456|Experimental|Saccharomyces cerevisiae CNCM I-3856|
3275471|NCT01613469|Other|5FU/Leucovorin- post distal rectal srgy|Assess complete clinical response rate following neoadjuvant chemoradiation in patients with distal rectal cancer
3275472|NCT01613482|Active Comparator|Arm A|Without cerebral prophylactic radiation
3275473|NCT01613482|Experimental|Arm B|With cerebral prophylactic radiation
3275474|NCT01613495|Placebo Comparator|Placebo|Normal Saline
3275475|NCT01613495|Active Comparator|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
3275476|NCT01613508|Active Comparator|Direct Anterior Approach|An oblique incision is made over the anterior margin of the tensor muscle. The fascia of the tensor muscle is identified and incised. The muscle is swept digitally laterally and a retractor is placed over the superior aspect of the femoral neck. The hip capsule is then incised and retracted.
3275477|NCT01613508|Active Comparator|Mini-Posterior Approach|The surgical approach involved a 7 to 9.5 cm incision along the posterior aspect of the femur starting at the tip of the greater trochanter and proceeding distally. The fascia of the gluteus maximus was split, and blunt dissection revealed the underlying abductor and external rotator musculature. The external rotators an the hip capsule were incised and preserved as one layer, with an attempt being made to preserve the insertion of the quadratus femoris on the femur. The hip was dislocated posteriorly and the femoral neck was cut in accordance with the preoperative plan.
3275478|NCT01613521|Experimental|DCE-MRI and 18F-FMISO PET|Each patient will undergo three DCE-MRI (dynamic contrast-enhanced MRI) studies: a baseline DCE-MRI within two weeks before chemoradiation; a second DCE-MRI after the second week of treatment (within a week); and a third DCE-MRI three months after treatment. As a pilot study in 10 patients, we will perform 18F-FMISO PET/CT on the same day of a baseline DCE-MRI before chemoradiation. Treatment decisions will not be based on DCE-MRI and 18F-FMISO PET/CT studies.
3275479|NCT01613534|Experimental|APC plus oral sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) administration for four weeks.
3275480|NCT01613534|Placebo Comparator|APC plus placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks.
3275481|NCT01613547|Active Comparator|Routine antibiotic prescription|Routine antibiotic prescription with amoxicillin (80 mg/kg/day for 7 days)
3275482|NCT01613547|Placebo Comparator|No routine antibiotic prescription|
3275483|NCT01613586|Experimental|Low dose ASP3652 twice daily|50 mg twice daily for 12 weeks
3275484|NCT01613586|Experimental|Medium dose ASP3652 twice daily|150 mg twice daily for 12 weeks
3275485|NCT01613586|Experimental|High dose ASP3652 twice daily|300 mg twice daily for 12 weeks
3275486|NCT01613586|Placebo Comparator|Placebo|Matching placebo twice daily for 12 weeks
3275487|NCT01613612|Sham Comparator|control group:core decompression|single core decompression
3275488|NCT01613612|Active Comparator|Treatment group: BMCs+core decompression|Enriched bone marrow cells combined with core decompression
3275489|NCT01613625|Experimental|Elastography|
3275490|NCT01613638|Other|Congenital malformations|"All livebirths, fetal deaths with gestational age (GA) ≥22 weeks and terminations of pregnancy (at any gestational age) after prenatal diagnosis of malformation.~born from mothers living in Brittany at delivery~with a congenital anomaly according to Eurocat criteria, diagnosed or suspected (and then confirmed) at birth~or with mild congenital heart defects, genital anomalies or hip dislocation diagnosed after birth (and before the age of one)"
3275491|NCT01613638|Other|control|2 controls per case will be included, corresponding to the first 2 births without congenital anomalies, with same sex and same birth place, following the case.
3275492|NCT01613651|Experimental|Arm I (RALP)|Patients undergo RALP.
3275493|NCT01613651|Experimental|Arm II (RALP and placement of pelvic drain)|Patients undergo RALP and placement of pelvic drain.
3275494|NCT01613664|Experimental|tisseel|tisseel will be applied during the surgery
3275495|NCT01613664|Placebo Comparator|no tisseel|no tisseel will be applied during the surgery
3275496|NCT01613677|Experimental|BKM120|
3275497|NCT01613690|Experimental|Healthy volunteers|control group receiving 100 μg NVA237
3275498|NCT01613690|Experimental|Mild renal impairment|(eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237
3275499|NCT01613690|Experimental|Moderate renal impairment|(eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237
3377459|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort A|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their non-small cell lung cancer (NSCLC) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
3275500|NCT01613690|Experimental|Severe renal impairment|(eGFR <30 mL/min1.73m2) receiving 100 μg NVA237
3275501|NCT01613690|Experimental|End-stage subjects requiring dialysis (ESRD)|receiving 100 μg NVA237
3275502|NCT01613703|Experimental|Experimental|
3275503|NCT01613729|Active Comparator|Rosuvastation 5 Initiator Arm|These patients will start the study with Rosuvastatin 5 mg and then after 12 weks they will be switched to Rosuvastatin 10 mg.
3275504|NCT01613729|Active Comparator|Rosuvastatin 10 initiator arm|These patients will continue with Rosuvastatin 10 mg and after 12 weeks they will be switched to Rosuvastatin 5 mg
3275505|NCT01613755|Active Comparator|Metformin therapy with concomitant use of dipyridamole|Metformin 500 mg twice daily for four days in combination with dipyridamole 200 mg twice daily for four days
3275506|NCT01613755|Active Comparator|Metformin therapy|Metformin 500 mg twice daily for four days
3275507|NCT01613781|Active Comparator|T1/Tc amplitude-guided group|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
3275508|NCT01613781|Active Comparator|TOF count-guided group|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
3275509|NCT01613794|No Intervention|No intervention|
3275510|NCT01613794|Experimental|Rosuvastatin|
3275511|NCT01613807|Experimental|Mix 50/50|3 doses of Mix 50/50 at mealtime
3275512|NCT01613807|Active Comparator|Usual insulin regimen|3 injections of Humalog(r) daily with meals; 3 injections of Humulin N (r) daily on rising, mid-afternoon, and at bedtime
3275513|NCT01613820|Experimental|Ketamine plus placebo|Subjects assigned to this paradigm will receive a 15 minute infusion of normal saline (placebo) followed by IV ketamine at 0.25mg/kg over 45 minutes twice a week for 3 weeks.
3275514|NCT01613820|Experimental|Scopolamine plus placebo|Subjects will receive a 15 minute infusion of IV scopolamine 2ug/kg followed by a 45 minute infusion of normal saline (placebo).
3275515|NCT01613820|Experimental|Ketamine plus scopolamine|Subject will receive an IV scopolamine infusion at a dose of 2ug/kg over 15 minutes, followed by an IV infusion of ketamine at a dose of 0.25mg/kg over 45 minutes.
3275516|NCT01613833||Primary OA Group|Subjects who are to undergo primary total knee arthroplasty due to primary OA which may include but is not limited to bilateral or peripheral involvement with no significant history of overuse or trauma to the joint.
3275517|NCT01613833||Secondary/Post-traumatic OA Group|Subjects who are to undergo primary total knee arthroplasty due to osteoarthritis of the knee that is secondary to injury or overuse of the joint.
3275518|NCT01613846|Experimental|Sorafenib followed by pazopanib|"Sorafenib 400 mg bid orally until progression or intolerable toxicity, followed by pazopanib 800 mg once daily orally until progression or intolerable toxicity.~During first- and second-line, treatment visits are scheduled in weeks 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
3275519|NCT01613846|Experimental|Pazopanib followed by Sorafenib|"Pazopanib 800 mg once daily orally until progression or intolerable toxicity, followed by Sorafenib 400 mg bid orally until progression or intolerable toxicity:~During first- and second-line, treatment visits are scheduled in weeks, 0,2,4,8,12, and every 4 weeks thereafter, with tumor assessments and electrocardiogram after every second cycle (every 8 weeks)."
3275520|NCT01613872|No Intervention|Control|Wait List Control
3275521|NCT01613872|Experimental|Mindfulness Based Stress Reduction|An 8 week standardized protocol of stress reduction using gentle yoga and meditation
3275522|NCT01613885||Twins|Twins that are ages 0 to 80 years, with or without allergy disease.
3275523|NCT01613898||CTX Group|
3275524|NCT01613911||Epileptics having invasive monitoring|People between 10 and 65 years of age with epilepsy and who are coming in to have invasive electrophysiological monitoring.
3275525|NCT01613924|Placebo Comparator|Heat based treatment/no treatment|Split face treatment with handheld acne heat based device and no treatment
3275526|NCT01613924|Active Comparator|Heat based treatment/benzoyl peroxide|Split face treatment with handheld acne heat based device and benzoyl peroxide 4%
3275527|NCT01613937|Experimental|Lifestyle|12 once weekly Lifestyle training program
3275528|NCT01613950|Experimental|BYL719 + AUY922|Dose finding study to estimate the maximum tolerated dose(s) (MTD) and/or recommended dose(s) for safety expansion (RDE) followed by an expansion phase to further assess the safety and preliminary activity of the combination. BYL719 tablets will be administered orally on a daily schedule (q.d.). a b.i.d. regimen may be explored. AUY922 will be administered by IV infusion once per week.
3275529|NCT01613963||Patients with ocular inflammation|Patients with ocular inflammation
3275530|NCT01613976|Experimental|Panobinostat and Azacitidine|combination regimen
3275531|NCT01613989|Active Comparator|Treatment 1|Reference group, installation of hip prothesis following standard procedure
3275532|NCT01613989|Active Comparator|Treatment 2|:treatment group,installation of hip prosthesis with assistance by computer based on imaging EOS
3275533|NCT01614002||carcinoma, Doce onkovis (Docetaxel)|treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region.
3275534|NCT01614015|Experimental|Supervision as Usual|Supervision as Usual
3275535|NCT01614015|Experimental|Observation Based Supervision|Behavioral
3275536|NCT01614028|Active Comparator|Total Hip Arthroplasty using Fitmore femoral stem|
3275537|NCT01614028|Active Comparator|Total Hip Arthroplasty using M/L Taper Femoral stem|
3275538|NCT01614041|Active Comparator|Control Group|Patient randomized to control group is administrated with usual dose of tandospirone treatment, 30 mg/day
3275539|NCT01614041|Experimental|Study Group|Comparative high dose of tandospirone treatment, 60 mg/day
3275540|NCT01614054|Experimental|Survey Group|Patients will receive a survey along with their meal tray, provided by Food and Nutrition Services. The survey will consist of questions related to smoking habits, desire for NRT and desire for assistance with smoking cessation. The results of these surveys will be collected by allied health professionals and forwarded to the CTU team. The CTU team will then be encouraged to use that information to engage in a discussion with the patient regarding prescription of NRT. It will then be left to the discretion of the HCP whether or not to prescribe NRT taking into account patient preference, absence of contraindications and clinical benefit. All those participating in the survey will be offered referral to a smoking cessation clinic upon discharge.
3275541|NCT01614054|No Intervention|Standard of Care|In the control arm, surveys will also be given out to all patients along with their meal trays. However, these surveys will include only questions related to smoking habits in order to get a baseline number of smokers. The surveys will then be collected by the allied health and nursing staff and forwarded only to the research team. The HCP taking care of the patients will still provide standard of care treatment with NRT and smoking cessation referral as clinically indicated.
3275542|NCT01614080||High sc-tPA/tc-tPA ratio group|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The High sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio higher than the median
3275543|NCT01614080||Low sc-tPA/tc-tPA ratio|A threshold value of the sc-tPA/tc-tPA ratio will be defined as the median value found in the population. The Low sc-tPA/tc-tPA ratio group will be defined as the group of patients with a sc-tPA/tc-tPA ratio lower than the median
3275544|NCT01614106|Experimental|Intervention|The Retention Clinic will incorporate HIV primary care and mental health services with on-site substance abuse treatment and patient navigation. The central components will include: Primary HIV Care; Mental Health Services; Skill-building; and On-Site substance abuse treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
3275545|NCT01614106|No Intervention|Treatment as Usual (TAU)|The treatment as usual (TAU) group condition will represent standard of care at both of the participating clinics. Standard of care at both clinics includes primary HIV care, the provision of mental health services, and the assignment of a clinic case manager. These case managers meet with patients when they first come to clinic and then meet with them as needed and typically offer substance-using patients a referral to substance abuse treatment in the community as needed. Case managers usually do not follow up to determine the uptake of these referrals.
3275546|NCT01614119|Experimental|Sportsmen|One single group of active healthy subjects was investigated
3275547|NCT01614132|Experimental|Vincristin, CCNU, cis-platin|"radiotherapy and concomitant chemotherapy (7 cycles of 7 days):~2 mg/m2 vincristin i.v.~55,0 Gy Posterior cranial fossa (M0)~55,0 Gy Posterior cranial fossa / cerebral metastases + 49,6 Gy spinal metastases (M1-M3)~maintenance chemotherapy (8 cycles of 42 days):~once at day 1 at each cycle: 70 mg/m2 cis-platin i.v. 75 mg/m2 CCNU oral 2 mg/m2 vincristin i.v.~once at day 8 and 15 at each cycle: 2 mg/m2 vincristin i.v."
3275548|NCT01614145||Proven/probable CNS IA|Immunocompromised patients with proven/probable invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
3275549|NCT01614145||Possible/No CNS IA|Immunocompromised patients with possible/NoIA invasive CNS Aspergillosis based on modified criteria by the EORTC/MSG
3275550|NCT01614158||acute N-AION (< 7 d)|"physical, intellectual and linguistic abilities, in order to understand the test requirements~willingness to comply with the protocol (4 visits)~45 - 80 years, informed consent~acute N-AION (< 7 d)~D-BCVA > 0.1 (2/20)~RAPD ≥ 0.3 logE steps (neutral density filters)"
3275551|NCT01614171|Experimental|Growth hormone therapy|Growth hormone treatment for 6 months
3275552|NCT01614184|Experimental|All patients|All patients enrolled in study.
3275553|NCT01614197|Experimental|Dose Level 1|This is the starting dose of temsirolimus at 7.5 mg/m^2 given IV. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
3275554|NCT01614197|Experimental|Dose Level 2|If Dose Level 1 is tolerated, the study will escalate to Dose Level 2 following the dose escalation schedule. Dose Level 2 will be administered via IV at 10 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
3275555|NCT01614197|Experimental|Dose Level 3|If Dose Level 2 is tolerated, the study will escalate to Dose Level 3 following the dose escalation schedule. Dose Level 3 will be administered via IV at 15 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8.
3275556|NCT01614197|Experimental|Dose Level 4|If Dose Level 3 is tolerated, the study will escalate to Dose Level 4 following the dose escalation schedule. Dose Level 4 will be administered via IV at 25 mg/m^2. First dose of temsirolimus will be administered on Day 1, followed immediately by the first dose of IV etoposide and IV cyclophosphamide. Etoposide (100mg/m^2) and cyclophosphamide (440 mg/m^2) are continued for the next four days (Day 1-5). A second dose of temsirolimus is given on Day 8. Temsirolimus will not be escalated beyond Dose Level 4.
3275557|NCT01614223|Active Comparator|ACP treatment|
3275558|NCT01614223|Active Comparator|Corticosteroid treatment|
3275559|NCT01614236|Active Comparator|control|patients will be randomized similarly but will undergo surgery under epidural analgesia
3275560|NCT01614236|Active Comparator|Lyrica|Patients will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
3275561|NCT01614262|Experimental|Continuous Glucose Monitoring|The Continuous Glucose Monitoring (CGM) arm will receive care based upon results from there CGM data; treatment decisions are based on algorithm and CGM data
3275562|NCT01614262|Active Comparator|Self Monitoring Blood Glucose|Subjects in the Self Monitoring Blood Glucose group will have treatment decisions based on self monitored blood glucose values and not CGM values, per current standard of care.
3275563|NCT01614275|Experimental|Technology-enhanced Parent Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training military parents of children with autism, regardless of their geographic location, to implement effective behavior management and teaching strategies with high procedural integrity (90% accuracy).
3275564|NCT01614275|Experimental|Technology-enhanced Tutor Training|The investigators will demonstrate that web-based instructional technologies provides an efficient and effective mechanism for training tutors to implement early intervention services that are commonly used with children diagnosed with autism with high procedural integrity (above 80%).
3275565|NCT01614275|Experimental|Technology-enhanced Early Intensive Behavioral Intervention|The investigators will demonstrate that technology-enhanced service delivery will provide remote access to efficient and effective EIBI services to military families affected by autism.
3275566|NCT01614275|Placebo Comparator|Wait-list No-intervention Control Group|Tutors and families will be assigned to treatment and control groups using the process of minimization, which has been recommended for small clinical trials because it minimizes differences between the groups on relevant covariables while guarding against bias in ways comparable to simple randomization. The control group will not receive intervention services.
3275567|NCT01614288|Active Comparator|Knee Arthroscopy + HTO|
3275568|NCT01614288|Active Comparator|HTO Alone|
3275569|NCT01614301|Experimental|Experimental Arm|Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+ Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory acting therapy, day 1+. Treatment until disease progression or toxicity
3275570|NCT01614301|Other|Controll Arm|Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks. The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
3275571|NCT01614314|Active Comparator|Auto-instructional guide|The subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
3275572|NCT01614314|Experimental|Preceptorship|The subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
3275573|NCT01614327||Retinal Screening; Diabetes 1 and 2|Patients diagnosed as either having Pre-Diabetes, Diabetes 1 or Diabetes 2
3275574|NCT01614340|Other|Usual Care|Usual Physical Therapy Plan of Care
3275575|NCT01614340|Other|Usual Care Plus Pain Management Program|Behavioral: Cognitive-Behavioral Pain Self-management Program.
3275576|NCT01614353||Study Cohort|All participants (N=30) will be asked to identify perceptions and behaviors surrounding the medication-taking process using technology-assisted prompts and recordings. Half (n=15) of the participants will participate in two hermeneutic interviews using an interpretive phenomenological approach to generate an interpretation of the meaning of medication taking.
3275577|NCT01614366|Active Comparator|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
3275578|NCT01614366|Experimental|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
3275579|NCT01614366|Experimental|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
3275580|NCT01614366|Experimental|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
3275581|NCT01614379||Healthy control subject|10 healthy control subjects for statistical comparison
3275582|NCT01614379||Type 1 diabetic patient|40 type 1 diabetic patients with diabetic foot ulcers.
3275583|NCT01614405|Placebo Comparator|Placebo|6 months therapy with blinded placebo followed by 6 months open label therapy with Kaletra and Truvada. Then there is an option for an 18 month follow-up study.
3275584|NCT01614405|Active Comparator|Truvada and Kaletra|Patients will be take Truvada and Kaletra for 6 months with the option of open label for additional 18 months.
3275585|NCT01614418|Experimental|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation using BARRX HALO90 catheter
3275586|NCT01614431|Experimental|N acetyl cysteine|NAC will be given to cystinosis patients and we will observe the renal function status and a marker of oxidative stress (TBARS)
3275587|NCT01614444|Active Comparator|Acupressure Treatment|
3275588|NCT01614444|Placebo Comparator|Placebo Acupressure Treatment|
3275589|NCT01614483|Experimental|Yellow cassava + placebo capsule|
3275590|NCT01614483|Placebo Comparator|White cassava + placebo capsule|
3275591|NCT01614483|Active Comparator|White cassava + B-carotene capsule|
3275592|NCT01614522|Experimental|HER-2 Amplified|
3275593|NCT01614522|Experimental|HER-1 & HER-2 Co-expression|
3275594|NCT01614535|Experimental|Female group|Female gender patients undergoing thyroidectomy
3275595|NCT01614535|Active Comparator|Male group|Male gender patients undergoing thyroidectomy
3275596|NCT01614548||all patients|We selected 9 cities (Zhengzhou, Luoyang, Kaifeng, Anyang, Xinyang, Zhoukou, Shangqiu, Nanyang, Zhumadian) by probability proportional to size sampling from geographical regions in central China. All cases with complete follow-up data of histological-proven prostate cancer treated in 2003 and 2008 at 14 department of urology in the 9 cities were retrospectively collected. Only patients with newly diagnosed prostate cancer were included in the study. Those with a history of prostate cancer who were treated for another disease were excluded from study.
3275597|NCT01614587||Cases|"Early, unexplained recurrence (within six months of procedure) after Sacrocolpopexy~The recurrence required treatment (surgery or pessary)"
3275598|NCT01614587||Controls|"Sacrocolpopexy during the same period~No recurrence, no reoperation, no retreatment to date (minimum of 12 months from surgery)"
3275599|NCT01614639|Experimental|Traditional Acupuncture|Traditional Acupuncture given at 2 visits.
3275600|NCT01614639|Experimental|Electroacupuncture|Electro-acupuncture given at 2 visits.
3275601|NCT01614652|Experimental|Parachute Implant and All Appropriate Medical Therapy (AAMT)|
3275602|NCT01614652|No Intervention|All Appropriate Medical Therapy (AAMT)|
3275603|NCT01614665|Active Comparator|Tacrolimus|Participants receive tacrolimus twice daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus twice daily up to end of Part B and C of the study.
3275604|NCT01614665|Experimental|Tacrolimus Prolonged Release|Participants receive tacrolimus prolonged release once daily starting from day 1 for 4 weeks for in Part A, and continue to receive tacrolimus prolonged release once daily up to end of Part B and of the study.
3275605|NCT01614678|Other|AIR OPTIX® COLORS Auto, then AIR OPTIX® COLORS Semi-auto|Lotrafilcon B contact lens with color, automated, worn first, with Lotrafilcon B contact lens with color, semi-automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
3275606|NCT01614678|Other|AIR OPTIX® COLORS Semi-auto, then AIR OPTIX® COLORS Auto|Lotrafilcon B contact lens with color, semi-automated, worn first, with Lotrafilcon B contact lens with color, automated, worn second. Each product worn on a daily wear basis approximately 8 hours a day, 5 days a week, for 2 weeks.
3275607|NCT01614691|Experimental|SPARC1203 low dose|
3377460|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort B|Participants who have received 2 or more second-line therapies, with at least 1 line of standard therapy, for their brain metastases of breast or NSCLC origin will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
3377461|NCT04444427|Experimental|Part 2: Dose Expansion - Cohort C|Participants experiencing their first recurrence glioblastoma multiforme (GBM) will be dosed the maximal tolerated dose of GLR2007 as determined in Part 1 until lack of tolerance or disease progression.
3377462|NCT04442477||Experimental: Enriched Protein Fractions|This group was given Infant formula with enriched protein fractions
3377463|NCT04442477||Active Comparator: Protein Fractions|This group was given Infant formula with protein fractions
3275608|NCT01614691|Experimental|SPARC1203 mid dose|
3275609|NCT01614691|Experimental|SPARC1203 high dose|
3377464|NCT04442425||1DF/NoPain_IV-VI_Female|Worst pain in past month = 0; Skin Type IVVI, Female
3377465|NCT04442425||1DM/NoPain_IV-VI_Male|Worst pain in past month = 0; Skin Type IVVI, Male
3377466|NCT04442425||1LF/NoPain_I-III_Female|Worst pain in past month = 0; Skin Type I-III, Female
3377467|NCT04442425||1LM/NoPain_I-III_Male|Worst pain in past month = 0; Skin Type I-III, Male
3377468|NCT04442425||2DF/MildPain_IV-VI_Female|Worst pain in past month = 1-3; Skin Type IVVI, Female
3377469|NCT04442425||2DM/MildPain_IV-VI_Male|Worst pain in past month = 1-3; Skin Type IVVI, Male
3377470|NCT04442425||2LF/MildPain_I-III_Female|Worst pain in past month = 1-3; Skin Type IIII, Female
3377471|NCT04442425||2LM/MildPain_I-III_Male|Worst pain in past month = 1-3; Skin Type IIII, Male
3377472|NCT04442425||3DF/ModPain_IV-VI_Female|Worst pain in past month = 4-6; Skin Type IVVI, Female
3377473|NCT04442425||3DM/ModPain_IV-VI_Male|Worst pain in past month = 4-6; Skin Type IVVI, Male
3377474|NCT04442425||3LF/ModPain_I-III_Female|Worst pain in past month = 4-6; Skin Type IIII, Female
3377475|NCT04442425||3LM/ModPain_I-III_Male|Worst pain in past month = 4-6; Skin Type IIII, Male
3275610|NCT01614691|Placebo Comparator|Placebo|
3275611|NCT01614704||Adjuvant treatment|Patients in this group will be offered the option of ovarien cryopreservation as well as the follow up of the follicule stock during chemotherapy.
3377476|NCT04442425||4DF/SeverePain_IV-VI_Female|Worst pain in past month = 7-10; Skin Type IVVI, Female
3377477|NCT04442425||4DM/SeverePain_IV-VI_Male|Worst pain in past month = 7-10; Skin Type IVVI, Male
3377478|NCT04442425||4LF/SeverePain_I-III_Female|Worst pain in past month = 7-10; Skin Type IIII, Female
3377479|NCT04442425||4LM/SeverePain_I-III_Male|Worst pain in past month = 7-10; Skin Type IIII, Male
3377480|NCT04439071|Experimental|PTC299 + Standard of Care (SOC)|"Participants will receive PTC299 at 200 milligrams (mg), administered orally, twice daily (BID) on Days 1 to 7, then at 50 mg administered orally, once daily (QD) on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
3377481|NCT04439071|Placebo Comparator|Placebo + SOC|"Participants will receive PTC299-matching placebo administered orally, BID on Days 1 to 7, then administered orally, QD on Days 8 to 14.~SOC will also be administered according to local, written policies or guidelines."
3377482|NCT04436380||Relapsed SAA Patients|Patients with Severe Aplastic Anemia who Relapsed after Immunosuppressive Therapy
3377483|NCT04436367||SAA patients with Monosomy 7|Severe Aplastic Anemia Patients who Developed High Risk Clonal Evolution with Chromosome 7 Abnormalities after Immunosuppressive Therapy
3377484|NCT04434846||1|Adults ages 18-55 with ZIKV, DENV, and/or CHIKV seroprevalence.
3377485|NCT04431024||Cancer patients|Individuals with history of cancer and detected or suspected germline mutation in BAP1 TPDS
3275612|NCT01614704||Neo adjuvant treatment|patients in this group will only have the follow up of the follicule stock.
3275613|NCT01614717|Active Comparator|Treatment Group|CRT-P Implant. Patients randomized in Treatment Group will have the device programmed to optimized DDD pacing
3275614|NCT01614717|Placebo Comparator|Control Group|CRT-P Implant. Patients randomized in the control Group will have the device programmed to back-up pacing AAI
3275615|NCT01614730|Sham Comparator|Modified Neurotech Vital Device|Checking to see no contraction is stimulated during treatment with the Modified Neurotech Device
3275616|NCT01614730|Active Comparator|Neurotech Vital Device|Checking to see a contraction is stimulated during treatment of the Neurotech Vital Device
3275617|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3275618|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.01 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.01 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3275619|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.03 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.03 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3275620|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.06 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.06 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3275621|NCT01614756|Experimental|Dose Escalation- BMS-981164 (0.1 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3377486|NCT04431024||Relatives of cancer patients|First- or second-degree relatives of a cancer patient (with or without cancer) with documented BAP1 tumor predisposition syndrome (TPDS)
3275622|NCT01614756|Experimental|Dose Escalation-BMS-981164 (0.3 mg/kg) or Placebo|"Part 1~Single dose of BMS-981164 0.3 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3275623|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg SC) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution subcutaneously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution subcutaneously"
3377487|NCT04431011||Participants|Healthy right-handed participants aged 18-50
3377488|NCT04429087|Experimental|BI 764532|
3275624|NCT01614756|Experimental|Dose Escalation-BMS-981164 (1 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 1 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3377489|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Margetuximab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~Paclitaxel- via IV, Day 1,8,15 of each cycle~Margetuximab via IV, Day 1 of each cycle~Pertuzumab via IV, Day 1 of each cycle"
3377490|NCT04425018|Experimental|Paclitaxel + Pertuzumab + Trastuzumab|"The research study procedures include screening for eligibility and study treatment including laboratory evaluations, two mandatory research biopsies and follow up visits.Cycle=21 days~Paclitaxel- via IV, Day 1,8,15 of each cycle~Pertuzumab via IV, Day 1 of each cycle~Trastuzumab via IV, Day 1 of each cycle"
3377491|NCT04421014|Active Comparator|HVMN Ketone Ester/ Arm 1|25 participants
3377492|NCT04421014|Placebo Comparator|Placebo/ Arm 2|25 participants
3377493|NCT04419870||Group 1a|Patients with mitochondrial disease who are ill with suspected or confirmed COVID19
3377494|NCT04419870||Group 1b|Patients with mitochondrial disease who are NOT ill with acute infection
3377495|NCT04419870||Group 2|Family members of patients with mitochondrial disease in Group 1
3377496|NCT04419519|Experimental|Venetoclax monotherapy|
3377497|NCT04419519|Experimental|Venetoclax with anti-CD20 monoclonal antibody|
3377498|NCT04417673||Sickle Cell Disease|Individuals with sickle cell disease
3377499|NCT04411147||Close Contacts|Individuals without COVID-19 diagnosis, lived in same home as a survivor during illness, were within 6 feet of a COVID-19 case for a prolonged period of time or had direct contact with secretions
3377500|NCT04411147||COVID-19 Survivor|Individuals with documented prior COVID-19 infection and who have recovered
3377503|NCT04408950||Patients with uncharacterized immune defects|Patients with uncharacterized immune defects
3377504|NCT04408950||Unaffected biological relatives|Unaffected biological relatives
3275625|NCT01614756|Experimental|Dose Escalation-BMS-981164 (3 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 3 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3275626|NCT01614756|Experimental|Dose Escalation-BMS-981164 (10 mg/kg IV) or Placebo|"Part 1~Single dose of BMS-981164 10.0 mg/kg solution intravenously~OR~Single dose of Placebo matching with BMS-981164 0 mg/kg solution intravenously"
3275627|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 1)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 3 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous or IV, 0 mg, once, single dose"
3275628|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 2)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3275629|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 3)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 0.1 mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3377511|NCT04401436||COVID 19 patients|Study participants will be adults who either have COVID-19 or who have recently recovered from the disease(recovered per Centers for Disease Control and Prevention guidelines).
3377512|NCT04394871||ALS4 Patients|Patients with ALS4 inherited defect in the senataxin (SETX) gene.
3377513|NCT04394871||Disease Control Participants|Disease control participants with mutation in other genes which alter RNA processing (e.g., RNASEH1+2 and loss of function SETX mutations in patients with ataxia and oculomotor apraxia type 2[AOA2]).
3377514|NCT04394871||Related, Unaffected Healthy Controls|Unrelated, unaffected healthy relatives of the ALS4 and disease control groups enrolled as controls.
3377515|NCT04394871||Unrelated, Healthy Controls|Unrelated, healthy volunteers who are age and sex matched to the affected ALS4 and disease control participants.
3377516|NCT04391816||Study Participants|Participants that were previously enrolled in the NIAAA Screening Protocol.
3275630|NCT01614756|Experimental|Dose Escalation- BMS-981164 or Placebo (dose group 4)|"Part 2~BMS-981164: Solution, Depending on dose level selected could be subcutaneous, ≤ 3.0 mg/kg and >1.0mg/kg, once, single dose~OR~Placebo matching with BMS-981164: Solution, Depending on dose level selected could be subcutaneous, 0 mg, once, single dose"
3275631|NCT01614782|Experimental|0.35 mg MK-5823 - Healthy Participants|
3275632|NCT01614782|Experimental|0.7 mg MK-5823 - Healthy Participants|
3275633|NCT01614782|Experimental|1.4 mg MK-5823 - Healthy Participants|
3275634|NCT01614782|Experimental|2.8 mg MK-5823 - Healthy Participants|
3377517|NCT04390178|Experimental|Convalescent plasma treatment|All participants will receive a bag of convalescent plasma. The bag volume will be 180-200 ml. The first 10 patients will receive 1, 5, 10, 50 and 134 ml of plasma at 30 minute intervals while being closely monitored for adverse events, especially allergic reactions. The remaining twenty patients will receive the convalescent plasma as a slow infusion according to normal routines.
3377519|NCT04386252|Experimental|Phase 1 Antigen Dose Exploration|AV-COVID-19 consisting of autologous DC loaded with 0.1 mcg, 0.33 mcg or 1.0 mcg SARS-CoV-2 spike protein, with or without GM-CSF
3377520|NCT04386252|Experimental|Phase 2|Separate cohorts of patients who have 0 or >1 risk factor related to poor outcome for COVID-19 infection will receive AV-COVID-19 consisting of optimal antigen and GM-CSF formulation.
3377521|NCT04384692|Experimental|Treatment (ruxolitinib, conditioning, HSCT, GVHD prophylaxis)|See detailed description.
3377522|NCT04383444||SARS-CoV-2 exposure|NIH staff exposed to SARS-CoV-2 or current or previous SARS-CoV-2 infection, but currently asymptomatic
3377523|NCT04381936|No Intervention|Standard Care|Patient receives usual hospital care
3377524|NCT04381936|Active Comparator|Low dose corticosteroids|"First (main) randomisation part A~[This arm is now closed to recruitment]"
3377525|NCT04381936|Active Comparator|Hydroxychloroquine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
3377526|NCT04381936|Active Comparator|Lopinavir-Ritonavir|"First (main) randomisation part A~[This arm is now closed to recruitment]"
3377527|NCT04381936|Active Comparator|Azithromycin|"First (main) randomisation part A~[This arm is now closed to recruitment]"
3377528|NCT04381936|Active Comparator|Convalescent plasma|"First (main) randomisation part B~[This arm is now closed to recruitment]"
3377529|NCT04381936|Active Comparator|Tocilizumab|"Participants with progressive COVID-19 (as evidenced by hypoxia and an inflammatory state) may undergo randomisation between Tocilizumab and no additional treatment.~(Children with COVID-19 pneumonia are not eligible for this comparison).~[This arm is now closed to adult recruitment]"
3377530|NCT04381936|Active Comparator|Intravenous Immunoglobulin|"First (main) randomisation part A (children only)~[This arm is now closed to recruitment]"
3377531|NCT04381936|Active Comparator|Synthetic neutralising antibodies|"First (main) randomisation part B.~[This arm is now closed to recruitment]"
3377532|NCT04381936|Active Comparator|Aspirin|"First (main) randomisation part C~[This arm is now closed to recruitment]"
3377533|NCT04381936|Active Comparator|Colchicine|"First (main) randomisation part A~[This arm is now closed to recruitment]"
3275635|NCT01614782|Experimental|1.4 mg MK-5823 - Participants with T2DM|
3275636|NCT01614782|Experimental|2.8 mg MK-5823 - Participants with T2DM|
3377534|NCT04381936|Active Comparator|Baricitinib|First (main) randomisation part D
3377535|NCT04381936|Active Comparator|Anakinra|"Randomisation for children only with PIMS-TS~(Children with COVID-19 pneumonia are not eligible for this comparison)."
3377536|NCT04381936|Active Comparator|Dimethyl fumarate|First (main) randomisation part A (UK adults only; early phase assessment)
3377537|NCT04381936|Active Comparator|High Dose Corticosteroids|First (main) randomisation part E
3377538|NCT04381936|Active Comparator|Empagliflozin|First (main) randomisation part F
3275637|NCT01614808||Observational|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance (NMR) spectroscopy and principal component analysis (PCA). Tumor tissue may also be examined by NMR and PCA.
3377539|NCT04381494|Other|Observational/Other|Patients will be enrolled after their treating physician has prescribed durvalumab and before they start durvalumab treatment. Patients will receive mobile and wearable devices alongside their durvalumab treatment without any additional interventions.
3275638|NCT01614834||chronic urticaria patients|all patients suffering from chronic forms of urticaria (chronic spontaneous urticaria as well as chronic inducible forms such as cold contact urticaria)
3275639|NCT01614873|Active Comparator|Pressure Support Ventilator|"Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden).~During pressure support the inspiratory muscles are assisted by a constant inspiratory pressure adjusted by the prescriptor and applied to the airway by either an invasive or a non invasive interface. Then the subject initiate the inspiratory effort and a constant pressure is delivered to the airway in order to assist inspiration. Three levels of pressure will be tested (5 cmH2O, 8 cmH2O and 12 cmH2O)"
3275640|NCT01614873|Experimental|NAVA|Spontaneous Breathing using Neurally Adjusted Ventilatory Assist with trigger adjusted on diaphragmatic electromyogram. Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). During NAVA the inspiratory muscles are assisted by a pressure which is proportional to this electrical activity. Then the subject initiate the inspiratory effort and a pressure proportional to the integrated EMG activity is delivered to the airway in order to assist inspiration. The adjustment of the level of NAVA (expressed in cmH2O/microvolt) will be adjusted in order to obtain a peak pressure similar to pressure support (5 cmH2O, 8 cmH2O and 12 cmH2O)
3377543|NCT04378920|Experimental|4L6715|exploring various doses of LEAF-4L6715
3275641|NCT01614938|Active Comparator|cisplatin-radiotherapy (CRT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent weekly cisplatin and radiotherapy
3275642|NCT01614938|Experimental|cetuximab-radiotherapy (ERT)|The arm receiving docetaxel-cisplatin neoadjuvant chemotherapy followed by concurrent cetuximab and radiotherapy
3275643|NCT01614951|Experimental|Pulmonary perfusion|
3275644|NCT01614951|Experimental|Pulmoplegia|
3275645|NCT01614951|Other|Control group|
3275646|NCT01614964|Experimental|AQ-13|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
3377546|NCT04366102|Experimental|Group A|Multisensory stimulation and soft tissue therapy
3377547|NCT04366102|Experimental|Group B|Routine Hospital care
3377550|NCT04362670|Experimental|OTX-CSI-Cohort 1|Formulation 2A-.36 mg
3377551|NCT04362670|Experimental|OTX-CSI-Cohort 2|Formulation 1- .36 mg
3377552|NCT04362670|Placebo Comparator|HV|"Cohort 2:~Formulation 2B"
3377553|NCT04362670|Experimental|OTX-CSI- Cohort 2|Formulation 2A- .36 mg
3377554|NCT04362670|Placebo Comparator|HV-2|"Cohort 2:~Formulation 3"
3377555|NCT04360278||Plasma Donors|Persons who have recovered from COVID-19 or have been immunized against SARS-CoV-2 who meet criteria to donate plasma.
3377556|NCT04358107||1|Medical records of subjects enrolled on various ACC studies conducted by CCR
3377557|NCT04354077|Experimental|NAc DBS|Subjects will receive bilateral DBS of the NAc
3377558|NCT04353791|Active Comparator|Experimental arm OST-122|24 subjects will be randomized to receive OST-122 orally daily for 28 days
3377559|NCT04353791|Placebo Comparator|Control arm Placebo|8 subjects will be randomized to receive placebo orally daily for 28 days
3377564|NCT04348240||Group 1|asymptomatic or mildly symptomatic high-risk subjects with unknown SARS-CoV-2 status but with known history of close personal contact with a COVID-19 positive person.
3377565|NCT04348240||Group 2|asymptomatic or mildly symptomatic (e.g., low grade fever, mild malaise, minor sore throat, runny nose, or sneezing) subjects who are COVID-19 positive.
3377566|NCT04348240||Group 3|COVID-19 positive individuals retesting negative can be enrolled to complete the electronic questionnaire(s) and allow evaluation of history of symptoms.
3377567|NCT04348240||Group 4|COVID-19 positive individuals enrolled and admitted to the NIH Clinical Center for other protocols.
3377568|NCT04341948|Active Comparator|Group 1 (Treatment)|Participants in Group 1 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and will receive electrical stimulation for 8 weeks.
3377569|NCT04341948|Sham Comparator|Group 2 (Control)|Participants in Group 2 will have Leads placed by the nerves of the mid to upper thigh. These participants will then use the SPRINT Peripheral Nerve Stimulation (PNS) System and receive 8 weeks of sham stimulation. Participants will then have the option to crossover and receive stimulation therapy.
3377570|NCT04340115||Participants treated with RINVOQ|Participants treated with upadacitinib in accordance with approved local label. Decision to treat with upadacitinib was made prior to offering participation in this study.
3377571|NCT04339790||New study participant|Individuals who respond to study website or advertisements for the study who have not previously been a NIMH study participant
3377572|NCT04339790||NIMH Study Participant|Individuals who have previously consented for a NIMH study
3377576|NCT04334954||Healthy Volunteers|Healthy Volunteers
3377577|NCT04328961|Placebo Comparator|Ascorbic Acid|Ascorbic acid 500 mg orally daily for 3 days, then 250 mg orally daily for 11 days
3377578|NCT04328961|Experimental|Hydroxychloroquine|Hydrochloroquine 400 mg orally daily for 3 days, then 200 mg orally daily for an additional 11 days
3377579|NCT04328740|Experimental|Monotherapy|TP-1454
3377580|NCT04328740|Experimental|Combination Therapy|TP-1454, ipilimumab and nivolumab
3275647|NCT01614964|Active Comparator|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention: Active Comparator: Coartem. Participants randomized to the Coartem arm will be treated with 80 mg artemether and 480 mg lumefantrine at the time of diagnosis and 8 hours later on day 1, the same doses (80 mg artemether and 480 mg lumefantrine) twice on day 2 (24 and 36 hours after diagnosis) and twice more on day 3 (48 and 60 hours after diagnosis) for total oral doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
3275648|NCT01614977|Experimental|Methylprednisolone|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days."
3275649|NCT01614977|No Intervention|Placebo|"Clarithromycin 15mg/Kg/day divided into 2 doses for 28 days.~Rifambutin 20mg/Kg/day divided into 2 doses for 28 days.~placebo pills with an identical outward appearance and volume prescribed according to the same schedule."
3275650|NCT01614990|Active Comparator|Macimorelin|
3275651|NCT01614990|Placebo Comparator|Placebo|
3275652|NCT01615003|Experimental|Xuesaitong soft capsule group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and Xuesaitong soft capsule.
3275653|NCT01615003|Placebo Comparator|control group|Patients who confirmed by coronary angiography and diagnosed blood stasis syndrome of coronary heart disease are given conventional Western medicine treatment and placebo.
3275654|NCT01615016|Experimental|MISurf|Minimally Surfactant application via small tube inserted into the trachea under CPAP therapy without formal intubation and without mechanical ventilation
3275655|NCT01615016|Active Comparator|InSurE|Surfactant application via Intubation - Surfactant Application - Extubation sequence
3275656|NCT01615042|Experimental|Dose Escalation/High Dose Lenalidomide|Subjects are given a single dose of the drug while they are observed and tested for a period of time. If they do not exhibit any adverse side effects the dose is escalated, and a new group of subjects is then given a higher dose.
3275657|NCT01615055|Experimental|Fluoxetine tablets|
3275658|NCT01615055|Placebo Comparator|Placebo tablets|
3275659|NCT01615068||Cohort|
3275660|NCT01615081|Active Comparator|Sucrose solution|75 g sucrose (75 g carbohydrate) desolved in 750 ml water
3275661|NCT01615081|Experimental|Malt extract solution|183 g malt extract (corresponding to 75 g carbohydrate and 103 ml water) desolved in 647 ml water
3275662|NCT01615094||High-risk Stage B Heart Failure Patients|American College of Cardiology/American Heart Association (ACC/AHA) asymptomatic Stage B patients with B-Type natriuretic peptide (BNP) ≥ 65pg/ml
3275663|NCT01615107|Experimental|GROUP 1: Oxytocin infusion alone|GROUP 1: Oxytocin infusion alone
3275664|NCT01615107|Experimental|double balloonand oxytocin|insertion of the double balloon and oxytocin
3275665|NCT01615146|Experimental|Therapeutic Platelet Transfusion Arm|Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions.
3275666|NCT01615146|Active Comparator|Prophylactic Platelet Transfusion Group|Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion (a single dose of random donor platelets (4 unit pool or random donor platelets or one apheresis unit) when the measured platelet count is < 10 x 109/L.
3275667|NCT01615159|No Intervention|Self directed control|
3275668|NCT01615159|Active Comparator|Behavior and lifestyle counseling|
3275669|NCT01615172|Active Comparator|Aortic cannulation|routine placement of aortic cannula
3275670|NCT01615172|Active Comparator|axilaris cannulation|new type of cannulation
3275671|NCT01615185|Experimental|sulpiride plus amisulpride|sulpiride 800mg/d + amisulpride 400mg/d
3275672|NCT01615185|Active Comparator|full-dose amisulpride|amisulpride 800mg/d
3275673|NCT01615211|No Intervention|Standard treatment|patients will receive standard treatment with 200mg Mifepristone and after 36-48 hours 800 mcg of misoprostol vaginally
3275674|NCT01615211|Active Comparator|trilostane|patients will receive Day 1: Mifepristone 200 mg and Trilostane 120mg 1 tablet twice and Day 2 Trilostane 240mg twice. On Day 3 800 mcg misoprostol will be given vaginally.
3275675|NCT01615211|Active Comparator|Letrozole|Patients will receive on Day 1 Mifepristone 200mg and Letrozole 2,5mg 3 tablets and on Day 2 Letrozole 2,5mg 3 tablets. On day 3 800mcg of misoprostol will be given vaginally
3275676|NCT01615224|No Intervention|single dose|Patients receive the standard treatment with 800mcg of vaginal misoprostol
3275677|NCT01615224|Experimental|repeated doses|patients receive 800mcg of vaginal misoprostol. In addition to this they receive repeated doses of 400mcg oral misoprostol after 3 and 5 hours. Women of more than 9 weeks pregnancy according to last menstrual period will be given a choice of vacuum aspiration or further medical treatment with 2 additional doses of misoprostol given after 7 and 9 hours after the initial vaginal treatment.
3275678|NCT01615237|Active Comparator|CBP + PF|Field sites randomly assigned to Arm 2 will receive as an intervention current best practices and quarterly audits and performance feedback reports (PF) on provider delivery of cessation services using chart audit procedures that we have used successfully in prior work. Depending on what is used at the site, paper or Electronic Dental Record, we will work with the site to create a registry of patients who are tobacco users.
3275679|NCT01615237|Active Comparator|CBP + PF + P4P|Field sites randomly assigned to this implementation condition (Arm 3) will receive current best practices (CBP), quarterly audit and performance feedback reports (PF), and financial incentives (pay for performance, P4P) for every documented (documentation in patient chart of counseling, prescription, or referral to the quit-line) delivery of adherence to clinical practice guidelines.
3275680|NCT01615237|Active Comparator|Current Best Practices (CBP)|All dental field sites will receive current best practices (CBP) for training and technical assistance in promoting adoption of clinical practice guidelines for treating tobacco dependence.
3275681|NCT01615250|No Intervention|Standard therapy|Treatment with standard therapy. Cardiospec shock-wave therapy
3275682|NCT01615250|Active Comparator|Stem cells|Group of of intramyocardial implantation of peripheral mononuclear cells with CD34+ stem cells in patient with ischemic cardiomyopathy after preparatory course of shock - wave therapy.
3275683|NCT01615276|Placebo Comparator|Protein ingestion|Protein ingestion directly after the contralateral leg received NMES
3275684|NCT01615276|Experimental|Protein ingestion after NMES|Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)
3275685|NCT01615289|Active Comparator|Green tea extract, 250 ml|Single intragastric instillation of 250 ml green tea extract
3275686|NCT01615289|Active Comparator|Green tea extract, 500 ml|Intragastric instillation of 500 ml green tea extract solution
3275687|NCT01615289|Placebo Comparator|Control solution, 250 ml|Intragastric instillation of 250 ml control solution
3275688|NCT01615289|Placebo Comparator|Control solution, 500 ml|Single intragastric instillation of 500 ml control solution
3275689|NCT01615302|Active Comparator|Mucosa advancement flap|
3275690|NCT01615302|Experimental|Mucosa advancement flap + PRP|Platelet rich plasma added to the mucosa advancement flap
3275691|NCT01615354|Placebo Comparator|Placebo|
3275692|NCT01615354|Experimental|Treatment|
3275693|NCT01615380|Active Comparator|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
3275694|NCT01615380|Experimental|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
3275695|NCT01615393|Active Comparator|Ribavirin capsule arm|
3275696|NCT01615393|Experimental|Ribavirin tablet arm|
3275697|NCT01615406|Experimental|Drug: 99mTc-MIP-1404|20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
3275698|NCT01615419||Cohort|
3275699|NCT01615445|Active Comparator|Resveratrol|Group A Participants will received resveratrol 500 mg twice daily for 1 week then 1000 mg twice daily for 3 weeks, according to tolerance. They will discontinue medication for 2 weeks. The will receive placebo for 4 weeks.
3275700|NCT01615445|Placebo Comparator|Placebo|Group B (n=6) Will receive placebo for 4 weeks, they will discontinue medication for two weeks. Then receive resveratrol for 4 weeks
3275701|NCT01615458|Active Comparator|Usual Care|Patients will receive their usual care from providers at the clinic.
3275702|NCT01615471|Active Comparator|Large Group|In person group sessions in large group format (up to 125 others)
3275703|NCT01615471|Active Comparator|Small group|Small group in person sessions (up to 25 other participants)
3275704|NCT01615497|Active Comparator|Standard Treatment as Usual (TAU)|Treatment that would normally be received at the clinic typically consisting of individual or group counseling sessions focusing on alcohol and substance abuse.
3275705|NCT01615497|Experimental|Web-based CBT4CBT for alcohol plus TAU|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug use, coping with cravings, etc. plus standard treatment as usual.
3275706|NCT01615497|Active Comparator|Web-based CBT with minimal clinical contact|A computerized program that teaches skills for stopping drug and alcohol use by increasing coping skills such as how to understand patterns of drug and alcohol use, coping with cravings, etc. plus 10 minute check in with clinician.
3275707|NCT01615510|Experimental|Capsaicin (topical)|300 µL of 0.6% capsaicin in 45% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
3275708|NCT01615510|Experimental|Menthol (topical)|1000 µL of 40% menthol in 90% ethanol, topically applied on the forearm intervention: tapentadol immediate release or placebo
3275709|NCT01615523||Children/adolescents born preterm|
3275710|NCT01615523||Control children and adolescents|
3275711|NCT01615536|Experimental|Canine fossa trephine group (CFT)|
3275712|NCT01615536|Active Comparator|Non Canine fossa trephine group (NonCFT)|
3275713|NCT01615549|Active Comparator|Free training|
3275714|NCT01615549|Experimental|Proficiency-based training|
3275715|NCT01615562||PCOS adolescents|Post-menarchal females ages 14-17 with and without PCOS (15 each group for a total of 30 subjects).
3275716|NCT01615562||PCOS women|Women ages 18-40 with and without PCOS (15 each group for a total of 30 subjects).
3275717|NCT01615575|Active Comparator|Haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and addiction of rectal mucopexy.
3275718|NCT01615575|Active Comparator|Stapler haemorrhoidopexy|Haemorrhoidopexy was performed with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA.)
3275719|NCT01615588|Experimental|honey|Manuka honey
3275720|NCT01615601||darunavir (PREZISTA)|PREZISTA co-administered with 100 mg ritonavir as per Canadian Product Monograph. (Observational Study)
3275721|NCT01615601||etravirine (INTELENCE)|INTELENCE co-administered with other antiretroviral medicinal products as per Canadian Product Monograph (Observational Study)
3275722|NCT01615614|Experimental|Treatment A|Rilpivirine 25 mg once daily will be administered for 11 days
3275723|NCT01615614|Experimental|Treatment B|Rilpivirine 50 mg once daily will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days
3275724|NCT01615614|Experimental|Treatment C|Rilpivirine (in a regimen to be determined based on an interim pharmacokinetic analysis of treatment A and B) will be administered for 11 days and rifabutin 300 mg once daily will be administered for 17 days.
3275725|NCT01615627|Experimental|Hypotonic Treprostinil Solution|Hypotonic Treprostinil Solution
3275726|NCT01615627|Active Comparator|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
3275727|NCT01615640||Osteosarcoma patients|Patients with an histologically proven osteosarcoma will be entered into the study.
3275728|NCT01615653|Active Comparator|EUS 1|
3275729|NCT01615653|Active Comparator|EUS 2|
3275730|NCT01615666||Healthy volunteers|Healthy volunteers who will undergo functional MRI (fMRI) to obtain fMRI index
3275731|NCT01615666||Alzheimer's disease|Individuals with Alzheimer's disease who will undergo functional MRI (fMRI) to obtain fMRI index
3275732|NCT01615666||Non-Alzheimer's dementia|Individuals with Non-Alzheimer's dementia who will undergo functional MRI (fMRI) to obtain fMRI index
3275733|NCT01615666||Amnestic mild cognitive impairment|Individuals with Amnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
3275734|NCT01615666||Nonamnestic mild cognitive impairment|Individuals with Nonamnestic mild cognitive impairment who will undergo functional MRI (fMRI) to obtain fMRI index
3275735|NCT01615692||36-mth follow up visit|The cohort will consist of original subjects of the SOX Trial who consent to participate in the extension to follow up sub study.
3275736|NCT01615705||Blood Draw|"SOX Subjects:~The cohort consists of original subjects from the SOX Trial who consented to participate in the sub study."
3275737|NCT01615718|Experimental|Active Electrical Stim/Active Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
3275738|NCT01615718|Sham Comparator|Sham Electrical Stim/Sham Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with sham transcranial ultrasound for 20 minutes.
3275739|NCT01615718|Active Comparator|Active Electrical Stim/Sham Ultrasound|Subjects will undergo active low-intensity transcranial electrical stimulation in conjunction with sham (placebo) transcranial ultrasound for 20 minutes.
3275740|NCT01615718|Active Comparator|Sham Electrical Stim/Active Ultrasound|Subjects will undergo sham (placebo) low-intensity transcranial electrical stimulation in conjunction with active transcranial ultrasound for 20 minutes.
3275741|NCT01615744||Surgical ORIF calcaneal fx|
3275742|NCT01615744||Conservative treatment calcaneal fx|
3275743|NCT01615757|Experimental|Arm B, Ara-c - 12 gm/m2|Arm B will receive HIDAC at 12 gm/m2/cycle for 3 cycles , i.e. 2 gm/m2 BD , Day 1,3,5
3275744|NCT01615757|Active Comparator|Arm A. Ara-c 18 gm/m2|Arm A will receive HIDAC at 18 gm/m2/cycle for 3 cycles , i.e. 3 gm/m2 BD , Day 1,3,5
3275745|NCT01615770|No Intervention|Open Label CBT and Pharmacotherapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label, this group received general supportive therapy delivered via four telephone calls made to participants over a 12-week period.
3275746|NCT01615770|Experimental|Behavioral: cognitive behavior therapy|All study participants received 8 weeks of cognitive and behavioral cessation and relapse prevention skills training (CBT) and nicotine patch therapy combined with 9 weeks of bupropion SR therapy. Following open-label treatment, half the participants received an additional 12 weeks of CBT that combined clinic-based skills training sessions, voicemail monitoring and telephone counseling
3275747|NCT01615783||Medicaid beneficiaries|Medicaid beneficiaries with at least one medical or pharmacy claim during each year in the identification period (2004-2006)
3275748|NCT01615796|Experimental|Cohort A1|GSK2140944 200mg single dose
3275749|NCT01615796|Experimental|Cohort A2|GSK2140944 600mg single dose
3275750|NCT01615796|Experimental|Cohort A3|GSK2140944 1200mg single dose
3275751|NCT01615796|Experimental|Cohort A4|GSK2140944 1800mg single dose
3275752|NCT01615796|Experimental|Cohort A5|GSK2140944 1800mg single dose
3275753|NCT01615796|Experimental|Cohort A6|GSK2140944 dose to be determined, single dose
3275754|NCT01615796|Experimental|Cohort B1|GSK2140944 400 mg repeat dose BID up to 7 days
3275755|NCT01615796|Experimental|Cohort B2|GSK2140944 750 mg repeat dose BID up to 7 days
3275756|NCT01615796|Experimental|Cohort B3|GSK2140944 1000 mg repeat dose BID up to 7 days
3275757|NCT01615796|Experimental|Cohort B4|GSK2140944 to be determined repeat dose BID up to 7 days
3275758|NCT01615796|Experimental|Cohort B5|GSK2140944 to be determined repeat dose TID up to 14 days
3275759|NCT01615796|Experimental|Cohort B6|GSK2140944 to be determined repeat dose TID up to 14 days
3275760|NCT01615848|Experimental|mediterranean diet restricted calorie|1500 k/calories 47-51% carbohydrate 14-17% protein 33-36% fat: 7-7.6% saturated fat 22-30% monounsaturated & polyunsaturated fat
3275761|NCT01615848|Experimental|high protein diet, restricted calorie|1500 k/calories 40 % carbohydrate 30% protein 30% fat
3275762|NCT01615861|Experimental|IOL implantation|Hydrophilic acrylic lens implantation through a micro-incision phacoemulsification and cataract surgery (MICS)
3275763|NCT01615874|Experimental|MF/F MDI 50/10 mcg BID|
3275764|NCT01615874|Experimental|MF/F MDI 100/10 mcg BID|
3275765|NCT01615874|Experimental|MF/F MDI 200/10 mcg BID|
3275766|NCT01615874|Active Comparator|BDP HFA 160 mcg BID|
3275767|NCT01615874|Active Comparator|Montelukast 5 mg QD (4 mg QD for 5-year-olds)|
3275768|NCT01615887|Experimental|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
3275769|NCT01615887|Placebo Comparator|Sugar pill|Placebo will be administered in the same fashion as the treatment arm
3275770|NCT01615900|Other|Teleconsultation|
3275771|NCT01615900|Other|Standard consultation|
3275772|NCT01615913|Experimental|3% terbinafine patch|A 10-cm2 patch containing 3 mg terbinafine and 2 mg ketoconazole
3275773|NCT01615913|Experimental|6% terbinafine patch|A 10-cm2 patch containing 6 mg terbinafine and 2 mg ketoconazole
3275774|NCT01615913|Experimental|8% terbinafine patch|A 10-cm2 patch containing 8 mg terbinafine and 2 mg ketoconazole
3275775|NCT01615952||Sitting Position (head of bed 90 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3275776|NCT01615952||Semi-sitting position (45 degrees)|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3275777|NCT01615952||Supine position|"Ultrasound measurements will be performed. A= skin to the pleura at the level lateral to the subclavian artery, B= skin to center of the subclavian artery, C= skin to first rib, D= skin to corner pocket"
3275778|NCT01615965|Experimental|micrometastases|Molecular biologic detection of micrometastases in lymph nodes of patients with localized prostate cancer treated with radical prostatectomy and lymphadenectomy.
3275779|NCT01615978|Experimental|Fixed dose: 5 mcg/kg|
3275780|NCT01615978|Experimental|Escalated dose: 10 mcg/kg|
3377581|NCT04321200||Cross-sectional-150 infants (atypical vs typical)|Arm (Study)1: To assess the concurrent validity of a multimodal instrumented gym with existing clinical tools. Here, using 150 infants, we will focus on converting data from an instrumented gym into estimates of the standard clinical tests.
3377582|NCT04321200||Longitudinal cohort - 50 infants (atypical vs typical)|Arm (Study) 2: To discover the features related to long-term motor development. Here we will convert data collected longitudinally from 50 infants, using both instrumented gym and video recordings, into estimates standard clinical tests change over time and track features over developmental timescales.
3377583|NCT04321200||Cross-sectional-1500 infants (atypical vs typical)|Arm (Study) 3: To develop a computer vision-based algorithm to quantify infant motor performance from a single-camera video. Here using video data from 1200 infants, plus those gathered from Arm 1 and Arm 2, we will extract pose data from single-camera video recordings and convert these into kinematic features and relevant scores needed to classify infant movement.
3377586|NCT04317781|Experimental|Treatment (tagraxofusp-erzs)|Within day 45 and 120 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3377587|NCT04316741|Experimental|Brief Intervention+Health Coaching|Brief intervention with social-media delivered health coaching
3377588|NCT04316741|No Intervention|Control|Enhanced usual care brochure plus attention control with social media messaging
3377592|NCT04316156|Experimental|Exercise using Uincare Homeplus|Uincare Homeplus
3275781|NCT01615991|Other|radiosynoviorthesis with yttrium-90 or rhenium -186|Patients suffering from arthritis or chronic inflammatory joint disease.
3377593|NCT04316156|Active Comparator|Exercise using brochure|brochure
3377594|NCT04314401||Ancillary-correlative (biospecimen collection, chart review)|Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 10 years.
3275782|NCT01616004|Experimental|N2O|N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes
3275783|NCT01616004|Sham Comparator|Air|
3377599|NCT04303195|Experimental|NG101 - 5 mg|NG101 5 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
3377600|NCT04303195|Experimental|NG101 - 10 mg|NG101 10 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
3275784|NCT01616030|Experimental|Strength training, fractured limb|"Knee-extension strength training of the fractured limb:~Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery."
3275785|NCT01616043|Experimental|Glyaderm + STSG|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds of the patients are covered with Glyaderm®. After 6-8 days the wounds are finally covered with a thin STSG.
3377601|NCT04303195|Experimental|NG101 - 20 mg|NG101 20 mg, capsules, orally, QID (4 times a day) for up to 12 weeks
3377602|NCT04303195|Placebo Comparator|Placebo|Placebo-matching, capsules, orally, QID (4 times a day) for up to 12 weeks
3377603|NCT04296305|Experimental|Group A (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes."
3377604|NCT04296305|Experimental|Group B (hydromorphone, placebo)|"TREATMENT PHASE I: Patients receive hydromorphone IV over 15 minutes and placebo IV over 2 minutes.~TREATMENT PHASE II: Patients receive hydromorphone IV over 2 minutes and placebo IV over 15 minutes."
3275786|NCT01616043|Other|STSG alone|All included patients in this arm will undergo full thickness removal of the burned skin or adequate debridement of all necrotic tissue. The wounds of the patients will be covered with glycerol preserved allografts for wound bed preparation. At the second operation, 5-7 days after the first operation, the allografts are removed. If the wound bed is not suitable for grafting, additional wound bed preparation with allografts is required until the wound bed is satisfactory. If the wound bed is suitable for grafting, the wounds are immediately covered with a thin STSG.
3275787|NCT01616069|Active Comparator|epinephrine|Assessment of systolic and diastolic heart function during CABAG with CPB with levosimendan using TEE.
3275788|NCT01616069|Active Comparator|levosimendan|Assessment of systolic and diastolic heart function during CABAG with CPB with epinephrine using TEE.
3275789|NCT01616095||Adults with Growth Hormone Deficiency|if multiple hormonal deficiences exist, long term adequate supplementation is provided and tightly monitored.
3275790|NCT01616095||Healthy Controls|matched for BMI, age, and gender
3275791|NCT01616108|Experimental|Bupivacaine Injection|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
3275792|NCT01616121|Active Comparator|Conventional Treatment Heart Failure|Conventional Treatment
3275793|NCT01616121|Experimental|Lung Impedance-Guided Therapy|Lung Impedance-Guided Therapy
3275794|NCT01616134|Active Comparator|Korea Red Ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks.
3275795|NCT01616134|Placebo Comparator|placebo contating constarch|
3275796|NCT01616147|Experimental|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
3275797|NCT01616147|Active Comparator|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
3275798|NCT01616186|Experimental|Everolimus/Sorafenib|Patients will be stratified by current smoking status (smoker: yes or no0, for each smoking stratum patients will be randomized in a 2:1 ratio
3275799|NCT01616186|Active Comparator|Sunitinib|"Sunitinib is the concurrent control group~Patients will be stratified by current smoking status (smoker: yes or no), for each smoking stratum patients will be randomized in a 2:1 ratio"
3275800|NCT01616199|Experimental|Phase 1 Dose Escalation of PX-866 + vemurafenib|PX-866 given with vemurafenib
3275801|NCT01616199|Experimental|Phase 2 Combination PX-866 + vemurafenib|PX-866 given with vemurafenib
3275802|NCT01616199|Active Comparator|Phase 2 Single-agent vemurafenib|vemurafenib given as a single agent
3275803|NCT01616212|Experimental|TX1|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
3275804|NCT01616212|Experimental|TX 2|Motivational Enhancement Therapy for adolescents
3275805|NCT01616212|Experimental|TX3|Drug Education for adolescents, Parenting Wisely for parents
3275806|NCT01616212|Experimental|TX4|Drug Education for adolescents
3275807|NCT01616225|Active Comparator|No Growth Hormone Supplementation|
3275808|NCT01616225|Experimental|Luteal Growth Hormone Start|Growth hormone starting in the luteal phase of the previous menstrual cycle.
3275809|NCT01616225|Experimental|Follicular Growth Hormone Start|Starting growth hormone during the follicular phase of the prior menstrual cycle.
3275810|NCT01616238|Experimental|Philadelphia Positive Patients|All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen
3275811|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive|Patients with Philadelphia negative ALL who are fit for intensive treatment will be allocated into this group.
3275812|NCT01616238|Experimental|Philadelphia -ve Patients- Intensive +|Patients with Philadelphia negative disease and who are fit for intensive treatment will be entered into this group
3275813|NCT01616238|Experimental|Philadelphia -ve Patients- Non Intensive|Patients with Philadelphia negative disease who are not fit for intensive chemotherapy will be entered into this group
3275814|NCT01616238|No Intervention|Registration only|Patients with either Philadelphia positive or negative ALL who do not wish to enter the study will be allocated to this group for data collection purposes only.
3275815|NCT01616251|Experimental|Vegetable protein meal|Vegetable protein meal based on legumes (3.6 MJ, 19E% protein, 28 g dietary fibers)
3275816|NCT01616251|Experimental|Egg protein meal + fibers|Protein meal based on eggs and added pea dietary fibers (3.6 MJ, 19E% protein, 28 g dietary fibers)
3275817|NCT01616251|Experimental|Egg protein meal|Protein meal based on egg without added dietary fibers (3.6 MJ, 19E% protein, 6 g dietary fibers)
3275818|NCT01616251|Experimental|Meat protein meal + fibers|Protein meal based on meat and added pea dietary fibers (3.6 MJ, 19E% protein, 29 g dietary fibers)
3275819|NCT01616277|Placebo Comparator|1|
3275820|NCT01616277|Placebo Comparator|2|
3275821|NCT01616277|Placebo Comparator|3|
3275822|NCT01616277|Placebo Comparator|4|
3275823|NCT01616277|Placebo Comparator|5|Repeat dose of PF-06252616, IV infusion, single dose - 10.0 miligram per kilogram
3275824|NCT01616277|Placebo Comparator|6|
3275825|NCT01616277|Placebo Comparator|7|
3275826|NCT01616303|Active Comparator|carboplatin & paclitaxel|first-line chemotherapy for ovarian cancer
3275827|NCT01616303|Experimental|carboplatin & paclitaxel & oregovomab|first-line chemotherapy for ovarian cancer plus oregovomab
3275828|NCT01616316|Experimental|subfascial flap|
3275829|NCT01616316|Experimental|Subplatysmal flap|
3275830|NCT01616329||Cases and Controls|Cases: alloantibody formers Controls: non-alloantibody formers
3275831|NCT01616342|Active Comparator|Comprehensive Medical Management|Comprehensive Medical Management will include analgesic management in accordance with guidelines and practices at the site.
3275832|NCT01616342|Active Comparator|Spinal Cord Stimulation (SCS)|Subjects assigned to Arm A, CMM + SCS, will be treated with electrical pulses from a surgically implanted Precision Plus® SCS System (Boston Scientific Corporation).
3275833|NCT01616368|Experimental|MEAL|Participation in an 8-week mindful eating course
3275834|NCT01616381|Active Comparator|Sildenafil|Sildenafil tablets 40 mg x 3 daily
3275835|NCT01616381|Placebo Comparator|Placebo|Placebo tablet x 3 daily
3275836|NCT01616394||children with congenital heart disease|
3275837|NCT01616407|Experimental|MDMA, methylphenidate, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject.
3275838|NCT01616420|No Intervention|Delayed aPS|
3275839|NCT01616420|Experimental|Immediate aPS|
3275840|NCT01616433|Active Comparator|Arthritis Foundation Exercise Program|
3275841|NCT01616433|Experimental|AFEP + 10 Keys to Healthy Aging|"Arthritis Foundation Exercise Program integrated with the 10 Keys to Healthy Aging"
3275842|NCT01616446||remission|Nephrotic patients in remission
3275843|NCT01616446||relapse|Nephrotic patients in recidive
3275844|NCT01616472||Incident diabetes cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with diabetes during follow-up, subsequent to SLE diagnosis.
3275845|NCT01616472||Incident diabetes controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of diabetes during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3275846|NCT01616472||Incident hypertension cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with hypertension during follow-up, subsequent to SLE diagnosis.
3275847|NCT01616472||Incident hypertension controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of hypertension during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3275848|NCT01616472||Incident cataract cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with cataract during follow-up, subsequent to SLE diagnosis.
3275849|NCT01616472||Incident cataract controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of cataract during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3275850|NCT01616472||Incident osteoporosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with osteoporosis during follow-up, subsequent to SLE diagnosis.
3275851|NCT01616472||Incident osteoporosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of osteoporosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3275852|NCT01616472||Incident avascular necrosis cases|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who are newly diagnosed with avascular necrosis during follow-up, subsequent to SLE diagnosis
3275853|NCT01616472||Incident avascular necrosis controls|Individuals with newly diagnosed SLE selected from the Hopkins Lupus Cohort (1987-2011) who have no record of avascular necrosis during follow-up time (years) since SLE diagnosis that is equivalent to length of case at-risk time. Controls are matched to cases on decade of SLE diagnosis: 1987-1989, 1990-1999, 2000-2009, 2010+
3275854|NCT01616485|Experimental|Treatment A|TA-1790 + glyceryl trinitrate
3275855|NCT01616485|Active Comparator|Treatment B|sildenafil citrate + glyceryl trinitrate
3275856|NCT01616485|Placebo Comparator|Treatment C|placebo + glyceryl trinitrate
3275857|NCT01616498||Lean|Comparison data from this lean cohort will be compared to the obese older adults are already being collected in an R01-funded study (Improving Muscle for Functional Independence Trial; IRB00009098; NCT01049698)
3275858|NCT01616511||Pathway CH-1 Subjects|
3275859|NCT01616524|Experimental|Arm 1: pegIFNλ + Ribavirin + Placebo matching Daclatasvir|
3275860|NCT01616524|Experimental|Arm 2: pegIFNλ + Ribavirin + Daclatasvir|
3275861|NCT01616524|Experimental|Arm 3: pegIFNα-2a + Ribavirin + Placebo matching Daclatasvir|
3275862|NCT01616550||Patients undergoing thoracic surgery|Assessment of postoperative pain management in patients undergoing elective thoracoscopy or thoracotomy in a teaching hospital
3275863|NCT01616589||Fragile X full mutation (affected)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed >200 CGG repeats with abnormal methylation pattern; interpretation is full mutation for fragile X syndrome
3275864|NCT01616589||Fragile X premutation (carriers)|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and molecular analysis for fragile X revealed 55-200 CGG repeats with normal methylation pattern; interpretation is premutation carrier of fragile X syndrome
3275865|NCT01616589||Fragile X intermediate|Individual whose previous blood specimen was tested at Esoterix Genetic Laboratories and fragile X molecular analysis revealed 45-54 CGG repeats; interpretation is intermediate, not a carrier of a fragile X expansion mutation
3275866|NCT01616602|Placebo Comparator|Left-sided Position|
3275867|NCT01616602|Experimental|Prone Position|
3275868|NCT01616615|Experimental|ASPIRIN|150 mg milligram(s)/ day oral use
3275869|NCT01616615|Placebo Comparator|PLACEBO|
3275870|NCT01616628|No Intervention|Wait listed control|Participants grocery shop without the intervention for extended baseline and have delayed entrance into the intervention period.
3275871|NCT01616628|Experimental|Rewards for purchases & topic education|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables.
3275872|NCT01616641||rheumatoid arthritis group|75 patients with rheumatoid arthritis
3275873|NCT01616641||control group|75 healthy women
3377607|NCT04283682|No Intervention|standard group|Feeding procedures follow clinical nursing practices
3275874|NCT01616667|Active Comparator|Modified direct lateral approach|The patients included is operated with a total hip arthroplasty using a modified direct lateral approach
3275875|NCT01616667|Active Comparator|Posterior approach|The patients included is operated with a total hip arthroplasty using posterior approach
3275876|NCT01616680|Experimental|Supportive care (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15.
3275877|NCT01616719|Other|DTRAX graft|
3275878|NCT01616732|Active Comparator|testosterone|against placebo
3275879|NCT01616732|Placebo Comparator|placebo|
3275880|NCT01616758|Experimental|GTx-024 9mg|GTx-024 dosage of three soft gels once daily to equal 9mg
3275881|NCT01616784|Active Comparator|Multiple daily injections plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
3275882|NCT01616784|Experimental|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
3275883|NCT01616797|Experimental|Computerized intervention|Participants will be asked to visit a customized website and engage in computerized exercises. Cognitive and emotion training games.
3275884|NCT01616797|Sham Comparator|Control|Participants will be asked to visit a customized website and engage in computerized games.
3275885|NCT01616810||observation|Healthy participants
3275886|NCT01616823||HIV Positive Women|HIV positive women in two downtown Toronto, Ontario academic-affiliated hospitals
3275887|NCT01616836|Active Comparator|continuous FNB|Bolus femoral nerve block (ropivacaine 0.5% 20 mL), continuous infusion 48 hours (ropivacaine 0.2%, 5 mL/h), placebo local infiltration
3275888|NCT01616836|Active Comparator|single FNB|femoral nerve block (ropivacaine 0.5% 20 mL), placebo femoral nerve block infusion, placebo local infiltration
3275889|NCT01616836|Active Comparator|LIA|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia
3275890|NCT01616849|Experimental|PF+ Nimotuzumab|Patients treated with cisplatin and 5-Fu combined with nimotuzumab
3275891|NCT01616862||Parents of PA positive CF children|parents of children with cystic fibrosis who are positive for Pseudomonas aeruginosa
3275892|NCT01616862||parents of Pa negative CF children|parents of children with cystic fibrosis who are negative for pseudomonas aeruginosa
3275893|NCT01616875|Experimental|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 Intravenous (IV)followed by Cisplatin 70mg/m2 IV on day 1 of each 21 day cycle for 4 cycles
3275894|NCT01616888|Active Comparator|Treatment arm|SFA angioplasty with In.Pact Admiral drug eluting balloon
3275895|NCT01616901|Experimental|Spontaneous breathing trial|
3275896|NCT01616914||delirium group|patients with delirium during ICU stay
3275897|NCT01616914||non-delirium group|patients without delirium during ICU stay
3275898|NCT01616927|No Intervention|standard care|Subjects in this arm will receive standard care
3275899|NCT01616927|Experimental|Lanreotide|
3275900|NCT01616940|No Intervention|Standard-of-care|Standard-of-care at 3 demonstration sites includes: HIV medical care, medical case management, and referral to substance abuse, mental health, and housing services.
3275901|NCT01616940|Experimental|Enhanced Peer Intervention|Provides emotional, informational, and instrumental peer support, in addition to Standard-of-Care.
3275902|NCT01616966|Active Comparator|Sevoflurane|Anesthesia was maintained with sevoflurane during surgery.
3275903|NCT01616966|Active Comparator|Anesthesia with propofol|Anesthesia was maintained with propofol during surgery.
3275904|NCT01616979||OPCAB surgery|Fifteen elective OPCAB surgery patients who undergo grafting in the left circumflex artery territory due to three-vessel disease
3275905|NCT01616992||Interstitial Cystitis|
3275906|NCT01616992||Myofascial Pelvic Pain|
3275907|NCT01616992||Healthy|
3275908|NCT01616992||First Degree Relative|
3275909|NCT01617018||Exposed group|Biotherapy
3275910|NCT01617018||Non-exposed group|Major conventional systemic therapy (methotrexate or cyclosporine)
3275911|NCT01617031||Diabetic patients with coronary artery disease|Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis >50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
3275912|NCT01617044|Experimental|Treatment|"iron 3 mg/kg/day elemental iron FeSO4 up to 45 mg (dose to be determined by PI)~+ vitamin C-250 mg chewable tab~+ probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)"
3275913|NCT01617044|Placebo Comparator|Control|"iron 3 mg/kg/day elemental iron FeSO4 to 45 mg~+ vitamin C-250 mg chewable tab~+ placebo (identical capsule)"
3275914|NCT01617057|Experimental|Skelid|tiludronic acid
3275915|NCT01617057|Placebo Comparator|Control|Placebo
3275916|NCT01617096|Experimental|Dapivirine Vaginal Ring|Vaginal ring containing 25mg dapivirine
3275917|NCT01617096|Placebo Comparator|Placebo Ring|Vaginal ring containing no drug substance
3275918|NCT01617109|Placebo Comparator|Placebo|
3275919|NCT01617109|Experimental|Ca/Vit D|
3275920|NCT01617122|Experimental|Bacteriophage|Subjects receive bacteriophage vaccinations and blood draws
3275921|NCT01617135|Experimental|CVT-301 Low Dose|CVT-Low; levodopa inhalation powder (LIP)
3275922|NCT01617135|Experimental|CVT-301 High Dose|CVT-High; levodopa inhalation powder (LIP)
3275923|NCT01617135|Placebo Comparator|Inhaled Placebo|Inhaled placebo powder
3275924|NCT01617135|Active Comparator|Oral Sinemet (carbidopa/levodopa)|Open-label oral carbidopa/levodopa (CD/LD)
3275925|NCT01617161|Active Comparator|PBT|Proton Beam Therapy
3275926|NCT01617161|Active Comparator|IMRT|Intensity Modulated Radiation Therapy
3377608|NCT04283682|Experimental|intervention group|At appropriate time to invite mothers of premature infants into the NICU for skin-to-skin and breastfeeding
3275927|NCT01617174||assessments completed by patients|"A single-arm observational study will be conducted at three institutions in the Prostate Cancer Clinical Trials Consortium (PCCTC): Memorial Sloan-Kettering Cancer Center; Johns Hopkins; and Oregon Health & Science University. MSKCC is the coordinating center. The target enrollment is 400 patients, with at least 250 experiencing moderate or worse pain intensity at baseline, defined as a score of ≥4, the preferred regulatory cutoff."
3275928|NCT01617200|Experimental|Asenapine 2.5 mg BID|
3275929|NCT01617200|Experimental|Asenapine 5 mg BID|
3275930|NCT01617200|Active Comparator|Olanzapine 15 mg QD|
3275931|NCT01617200|Experimental|Placebo switched to Asenapine 2.5 mg BID|
3275932|NCT01617213|Experimental|Maintenance Lenalidomide After Melphalan|
3275933|NCT01617226|Active Comparator|azacitidine|azacitidine (75mg/m2) by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. This should be delivered in a 5-2-2 schedule
3275934|NCT01617226|Active Comparator|azacitidine and vorinostat|Patients will receive (75mg/m2) azacitidine by SC injection on 7 consecutive days (excluding weekends), starting day 1 of 28-day cycles for up to 6 cycles. Azacitidine should be delivered in a 5-2-2 schedule. Vorinostat (300mg bid) will be taken orally for 7 consecutive days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles. (Day 3 is defined as the 3rd day of azacitidine administration).
3275935|NCT01617239|Experimental|Group 1|1 x standard dose (0.5 mL) on Day 1, Day 29, and Day 57
3275936|NCT01617239|Experimental|Group 2|1 x double standard dose (1.0 mL) on Day 1 and 1 x standard dose (0.5 mL) on Day 57.
3275937|NCT01617239|Experimental|Group 3|1 x triple standard dose (1.5 mL) on Day 1
3275938|NCT01617252|Experimental|Optiflow|
3275939|NCT01617252|Experimental|Facial mask|
3275940|NCT01617265|Experimental|Prevention of oversedation group|In this arm sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated intravenous (IV) hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
3275941|NCT01617265|Active Comparator|Conventional sedation group|In this arm, sedation will be administered according to the usual practices in each participating center.
3275942|NCT01617278|Experimental|I-Scan 1|I-Scan 1 modality will be used by the endoscopist for the entire procedure
3275943|NCT01617278|Experimental|HD Colon|High definition white light modality will be used by the endoscopist for the entire procedure
3275944|NCT01617278|Experimental|I-scan 2|I-Scan 2 modality will be used by th endoscopist through out the procedure
3275945|NCT01617291|Experimental|Induced Hypothermia|Induced hypothermia after the return of spontaneous circulation by the application of ice packs to the axilla and groin with cold IV fluids
3275946|NCT01617291|No Intervention|Regular Care|Treatment of the return of spontaneous circulation under standing paramedic protocol without the addition of induced therapeutic hypothermia
3275947|NCT01617304|Experimental|low AGE, glucose|Food prepared by boiling/steaming and 20 g of glucose 3 times a day in a water solution
3275948|NCT01617304|Experimental|low AGE, fructose|Food prepared by boiling/steaming and 20 g of fructose 3 times a day in a water solution
3275949|NCT01617304|Experimental|high AGE, fructose|Food prepared by frying/baking and 20 g of fructose 3 times a day in a water solution
3275950|NCT01617304|Experimental|high AGE, glucose|Food prepared by frying/baking and 20 g of glucose 3 times a day in a water solution
3275951|NCT01617317|Active Comparator|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG which contain no H1N1 2009 antibody (manufactured before 2009).
3275952|NCT01617317|Experimental|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG fractionated from convalescent plasma (H1N1 2009 antibody titer was 1:320 by hemagglutination inhibition and neutralizing antibody assays)
3275953|NCT01617330|Experimental|Diesel exhaust|2 hour exposure to diesel exhaust at 100 microgram per cubic meter during intermittent exercise
3275954|NCT01617330|Experimental|Filtered air exposure|2 hour exposure to filtered air during intermittent exercise
3275955|NCT01617343|No Intervention|Usual care|Patients in this control group will receive usual care following stroke including standard physiotherapy and occupational therapy.
3275956|NCT01617343|Experimental|HEP-OKS|
3275957|NCT01617356|Active Comparator|Dextrose Injection|
3275958|NCT01617356|Active Comparator|Sterile Water Injection|
3275959|NCT01617382||Registry|Patients with peritoneal carcinomatosis of colorectal origin, patients with pseudomyxoma peritonei (type DPAM or PMCA) and patients with peritoneal mesothelioma who are planned to undergo cytoreductive surgery and HIPEC because of a peritoneal surface malignancy
3275963|NCT01617473|Experimental|procedure/surgery|transplant with G-CSF mobilized PBSCs
3275964|NCT01617473|No Intervention|other|no intervention after transplant with mobilized BMPB
3275965|NCT01617486|Experimental|BALANCE|
3275966|NCT01617499||University employees|Participants will include employees of Washington University in St. Louis. Recruitment will be directed to staff employees of the Central Fiscal Unit (CFU) on the Danforth campus.
3275967|NCT01617525|Experimental|Korean Recommended Diet|A dietary pattern that follows the recommendations by the Korean Rural Development Administration.
3275968|NCT01617525|Active Comparator|US Recommended Diet|Diet based on recipes and menus developed by the USDA Dietary Guidelines for Americans intramural team.
3275969|NCT01617525|Active Comparator|Typical American Diet|Diet based on data from the NHANES surveys, as summarized in the USDA report What We Eat in America.
3377611|NCT04274361|Experimental|Ketamine arm|Early ketamine infusion therapy at a rate of 3 mcg/kg/min. All ketamine infusions will be calculated based on ideal body weight (IBW), unless actual body weight is less than ideal. Ketamine infusion therapy will be continued for 48 hours. At 2-4 hours post-infusion the patient's pain will be reassessed. If the NPS is more than 5 the infusion will be increased to 5mcg/kg/min. Following each change in the infusion rate the patient's pain will be reassessed at 2-4 hours and adjustments made accordingly. Maximum infusion rate will be set at 9mcg/kg/min. Conversely, The RAAPS team should be notified if neurologic symptoms (hallucinations, delusions, disturbing dreams, vertigo) are developing and, at the discretion of the RAAPS service, a single dose of lorazepam or midazolam may be utilized. The infusion can be decreased from in 2 mcg/kg/min increments if there are symptoms believed to be related to the infusion that do not respond to benzodiazepines.
3377612|NCT04274361|Placebo Comparator|Placebo arm|The 65 patients randomized to the control arm will receive placebo saline solution at a rate equivalent.
3377613|NCT04268784|Experimental|DNL343|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
3377614|NCT04268784|Placebo Comparator|Placebo|Cohort A: Single-ascending dose; Cohort B: Multiple-ascending doses
3275970|NCT01617538|Experimental|Atorvastatin|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment before stroke.in this study ,we will give them atorvastatin 40mg treatment for 24 weeks and monitor and evaluate the change of intracranial hemodynamics after treatment.
3275971|NCT01617538|No Intervention|compare|30 patients who had MCA infarction within 6 months prior to screening, and has not received any statins treatment.we will monitor and evaluate the intracranial hemodynamics as a baseline.
3377615|NCT04267861||1|Medical records of subjects enrolled on NCI protocols 15-C-0179 and 18-C-0056
3377620|NCT04265261|Placebo Comparator|Group A|Participants will receive an oral dose of placebo matched to RG7774 once daily (QD)
3275972|NCT01617551|Experimental|Renal denervation|Patient group randomized to renal denervation
3275973|NCT01617551|Sham Comparator|Sham|Patients randomized to sham procedure
3275974|NCT01617564|Active Comparator|Bupivacain|
3275975|NCT01617564|Sham Comparator|Sodium Chloride|
3275976|NCT01617590|Experimental|leflunomide|Leflunomide 10-20 mg/d
3377621|NCT04265261|Experimental|Group B|Participants will receive a low oral dose of RG7774 QD
3377622|NCT04265261|Experimental|Group C|Participants will receive a high oral dose of RG7774 QD
3377623|NCT04263792|Other|Biodistribution cohort|The Biodistribution cohort will include up to 5 patients who will undergo a series of vertex to mid-thigh (or feet if indicated) biodistribution [18F]fluoropropyl-trimethoprim PET/CT scans over a period of approximately 4 hours.
3377624|NCT04263792|Other|The Dynamic cohort|The Dynamic cohort will include up to 15 patients who will undergo approximately 60 minutes of dynamic scanning followed by up to 2 static skull base to mid-thigh (or feet if indicated) scans post injection of [18F]fluoropropyl-trimethoprim.
3377625|NCT04261088||Experts in Swiss assisted suicide|Persons in Switzerland who are experts in how assisted suicide is practiced. We will beexamining already collected interviews.
3275977|NCT01617590|Active Comparator|methotrexate|MTX 7.5-15 mg/week
3275978|NCT01617616||Normal tilt test|Patients with normal tilt table testing (they may have symptoms which precipitated the tilt, but in the end did not qualify as POTS, NMH, ETC.)
3275979|NCT01617616||confirmed POTS diagnosis|after review of tilt table results, this group will be the confirmed postural orthostatic tachycardic syndrome group patient
3275980|NCT01617616||Neurocardiogenic syncope on tilt|This group is comprised of patients with confirmed diagnosis of neurocardiogenic syncope on tilt
3275981|NCT01617616||Neurally-mediated hypotension|Patients with confirmed diagnosis neurally mediated hypotension
3377626|NCT04259996||MODIFIED NATURAL CYCLE|"The term 'modified natural cycle' refers to a natural cycle in which ovulation is triggered by exogenous hCG administration in order to provide optimal timing scheduling embryo transfer. In contrast to the natural cycle, the applied hCG may lead to a different luteal phase profile. Luteal phase support is common clinical practice in those cycles.~On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
3377627|NCT04259996||STIMULATED CYCLE|"On the day of embryo transfer (ET), eligible patients being transferred one or two good quality embryos on day 5 of development according to the Spanish ASEBIR classification will be informed about the nature of the study, read the informed consent (IC) form and decide if entering into the study. After signing the IC form, a blood test will be performed in a time frame between 1 and 2 hours before the ET.~The only intervention will be a single determination of serum P and E2 levels immediately before the embryo transfer."
3377628|NCT04259047|Experimental|Diabetes Regulation for Eyesight and Memory (DREAM)|DREAM is a behavioral treatment for diabetes mellitus (DM), as well as a secondary prevention strategy for dementia. DREAM acts to reinforce DM self-care and address negative beliefs about medications and physicians, which compromise glycemic control in African Americans (AAs). In DREAM, race-concordant community health workers (CHWs) will: 1) deliver in-home DM education tailored to AAs with MCI; 2) use action plans to reinforce diabetes self-care; 3) facilitate telehealth visits with a DM nurse educator to improve DM self-care and address participants' health beliefs; and 4) increase primary care physicians' (PCP) awareness of participants' cognitive deficits and health beliefs to optimize treatment of DM. .
3377629|NCT04259047|Active Comparator|Enhanced Usual Care (EUC)|EUC consists of home visits by a CHW in which general DM education is provided.
3275982|NCT01617642||Control group|Healthy control group, matched for age and gender
3275983|NCT01617642||Acute intermittent porphyria|Patients with acute intermittent porphyria.
3275984|NCT01617694|Experimental|group R|continuation of remifentanil target controlled infusion (TCI) at effect-site concentration of 2 ng/ml during anesthetic recovery until extubation.
3275985|NCT01617694|Active Comparator|group D|remifentanil TCI discontinuation and dexmedetomidine 0.5 mg/kg intravenous injection before 10 min of the end of surgery
3275986|NCT01617707|Active Comparator|conventional sedation group|midazolam
3275987|NCT01617707|Experimental|BPS group|midazolam plus propofol
3275988|NCT01617733|Experimental|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
3275989|NCT01617746|Experimental|Ambrisentan|5mg od ambrisentan
3275990|NCT01617746|Experimental|Bosentan|62.5mg bosentan
3275991|NCT01617746|Placebo Comparator|Placebo|
3275992|NCT01617772|Experimental|Atorvastatin|20mg atorvastatin daily
3275993|NCT01617772|Experimental|Carnitine|1000mg L-carnitine daily
3275994|NCT01617772|Experimental|Atoral|1000mg L-carnitine and 20mg atorvastatin
3275995|NCT01617772|Placebo Comparator|Placebo|Identically looking placebo
3275996|NCT01617785||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
3275997|NCT01617785||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization
3275998|NCT01617785||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
3275999|NCT01617798|Placebo Comparator|Control-- furosemide (lasix) only|"Control arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix).~No actual placebo is administered."
3276000|NCT01617798|Active Comparator|Study Arm|Study arm receives evolving standard of care diuresis with furosemide and metolazone.
3276001|NCT01617824|Experimental|Linagliptin|Linagliptin 5 mg tablets daily for 4 days
3276002|NCT01617824|Placebo Comparator|Placebo|Placebo tablets 1 daily for 4 days
3276003|NCT01617837|Active Comparator|P6 acupressure group|"In the end of the operation Sea-Band®, a single-sized elastic acupressure band with a plastic button, was placed unilaterally at the place of P6 (the P6 Neiguan acupoint, located about 3 cm proximal to the distal wrist, between the tendons of the flexor carpi radialis and the palmaris longus)to apply acupressure."
3276004|NCT01617837|Placebo Comparator|Placebo group|In the end of the operation an identical Sea-Band® with no button and thereby no acupressure was placed unilaterally at the place of P6.
3276005|NCT01617850|Experimental|optimized physical exercise training|Intervention: Supervised physical exercise training x3 weekly for 12 weeks
3276006|NCT01617850|Active Comparator|conventional group|Intervention: Supervised physical exercise training x2 weekly for 8 weeks
3276007|NCT01617889|Active Comparator|Powdered milk-based formula, standard fat blend|
3276008|NCT01617889|Experimental|Powder milk-based formula, alternate fat blend|
3276009|NCT01617928|Experimental|veliparib (ABT-888)|
3276010|NCT01617941|Experimental|BGG492|At Baseline 60 patients will be randomized to receive BGG492 for the upcoming 12 weeks (dose: 75 mg BID administered in approx. 12 hours +/- 2 hours intervals).
3276011|NCT01617941|Placebo Comparator|Placebo|At Baseline 30 patients will be randomized to receive Placebo for the upcoming 12 weeks (matching a dose of 75 mg BID BGG492 administered in approx. 12 hours +/- 2 hours intervals).
3276012|NCT01617954||Subjects with MammaPrint Result|
3276013|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
3276014|NCT01617993||Women undergoing IVF treatment|Women undergoing IVF treatment
3276015|NCT01618006|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period.
3276016|NCT01618006|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3276017|NCT01618006|Experimental|Aspirin 81mg four times daily|Patients will receive ASA 81mg four times daily until postoperative day 7 or end of hospitalization
3276018|NCT01618032|Experimental|HVLA|High velocity and low amplitude traction manipulation on the ankle joint
3276019|NCT01618032|Experimental|MWM|Mobilization with movement on ankle joint as Mulligan
3276020|NCT01618032|Sham Comparator|placebo|Contact without therapeutic effect
3276021|NCT01618045||Fermented Papaya Preparation (FPP)|This a is single arm study - all participants will receive and take fermented papaya preparation (FPP) for a total of 6 weeks. Participants will take 3 grams of FPP three times per day (a total of 9 grams per day).
3276022|NCT01618058||ARV-Treated Participants|Those participants who received dapivirine during HIV seroconversion
3276023|NCT01618058||ARV-Naive Participants|Those participants who received placebo during HIV seroconversion
3276024|NCT01618071|Active Comparator|Oleic acid|75 g high oleic acid sunflower oil.
3276025|NCT01618071|Active Comparator|Linoleic acid|75 g high linoleic acid sunflower oil.
3276026|NCT01618071|Experimental|Eicosapentaenoic acid and docosahexaenoic acid|5 g EPA and DHA derived from fish oil, made up to a total of 75 g with high oleic sunflower oil.
3276027|NCT01618071|Experimental|Docosahexaenoic acid|5 g DHA derived from algal oil, made up to a total of 75 g with high oleic sunflower oil.
3276028|NCT01618084|Experimental|Tritanium cup|
3276029|NCT01618084|Active Comparator|Trident HA cup|
3276030|NCT01618097|Experimental|DVD Decision Aid|Patient assigned to watch DVD decision aid.
3276031|NCT01618097|Experimental|Internet Based Decision Aid|Patient assigned to watch OA specific internet based decision aid.
3276032|NCT01618110|Active Comparator|Treatment Group|
3276033|NCT01618110|Sham Comparator|Sham group|Sham TMS coil (same noise, minimal magnetic field)
3276034|NCT01618123||All CPU subjects|All subjects admitted to the CPU with low to moderate probability for CAD and negative troponin, will undergo the following tests upon arrival following clinical evaluation and their consenting to the study: resting ECG, EndoPAT testing and then after stress nuclear imaging or stress echocardiography. Except for EndoPAT testing, all other tests were conducted according to the routine CPU protocol.
3276035|NCT01618136|Experimental|E7449|
3276036|NCT01618136|Active Comparator|E7449 plus TMZ|
3276037|NCT01618136|Active Comparator|E7449 plus carboplatin and paclitaxel|
3276038|NCT01618149||severe knee OA who are indicated for total knee arthroplasty|the woman who are indicated for TKR and are post menopausal will be recruited in this study. We will excluded the patients who had immune disease ,previous fracture of femur and end stage of renal disease
3276039|NCT01618175|Experimental|Home oxygen therapy|Infants with acute bronchiolitis of low to moderate severity will be discharged home with supplemental oxygen and monitored by phone calls and home visits.
3276040|NCT01618188|Experimental|Formulation A|
3276041|NCT01618188|Experimental|Formulation B|
3276042|NCT01618188|Active Comparator|Insulin Aspart|
3276043|NCT01618201||50 subjects with migraine without aura|Inflammation Migraine Headache
3276044|NCT01618201||50 subjects with migraine with aura|Inflammation Migraine Headache
3276045|NCT01618201||50 subjects with tension headache and cluster headache|Inflammation Migraine Headache
3276046|NCT01618201||50 healthy subjects|Inflammation Migraine Headache
3276047|NCT01618253|Experimental|Radiation therapy with concurrent sorafenib|
3276048|NCT01618279||Tryptase|Patients with clinical manifestations have been discovered and documented symptoms of coronary heart
3276049|NCT01618292||Robotic-assisted sacrocolpopexy patients|Patients who underwent robotic-assisted laparoscopic sacrocolpopexy between January 2007 and August 2011.
3276050|NCT01618318||General asthma population|People with asthma, aged 18 years and over, non smoker, all severities of disease, regardless of treatment, broad inclusion and few exclusion criteria.
3276051|NCT01618331|Active Comparator|Protein supplementation|Patients consume a drink after each exercise session. The drink consist of whey protein, maltodextrin, and flavors mixed in water.
3276052|NCT01618331|Placebo Comparator|Placebo supplement|Patients consume a drink after each exercise session. The drink consist of flavors mixed in water.
3276053|NCT01618331|No Intervention|Control|Patients will be tested before and after a none-intervention period of 12 weeks.
3276054|NCT01618357|Experimental|Intervention|All subjects will receive pre-operative Neo-Adjuvant Chemotherapy (NAC) but only those with an incomplete response to NAC will be treated with the PARPi experimental portion of the trial explained below. Those with a complete response will be treated per standard of care.
3276055|NCT01618370|Experimental|Radium-223 dichloride|
3276056|NCT01618383|Other|Colonic biopsies|Colonic biopsies obtained during the course of colonoscopy or rectosigmoidoscopy
3276057|NCT01618409|Experimental|PictureRx cards|Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
3276058|NCT01618409|No Intervention|Control|Usual care
3276059|NCT01618435|Active Comparator|Fusion, allograft|Allograft used for fusion in the operation site
3276060|NCT01618435|Experimental|Fusion, i-FACTOR|i-FACTOR used for fusion in the operation site
3276061|NCT01618448|Experimental|Placebo|Placebo once daily
3276062|NCT01618448|Experimental|Tolvaptan|Tolvaptan 15mg once daily
3276063|NCT01618461|No Intervention|Text instructions|Medication instructions displayed in text format
3276064|NCT01618461|Experimental|Drug indication icons|Icons illustrate the purpose of each medication
3276065|NCT01618461|Experimental|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
3276066|NCT01618461|Experimental|Icons + Structured instructions|Icons illustrate the purpose of each medication, and a graphical format shows what time(s) of day each medication should be taken
3276067|NCT01618474|Experimental|DX|DX: Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
3276068|NCT01618474|Active Comparator|XELOX|XELOX: oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
3276069|NCT01618487|Active Comparator|Arthroscopic tenotomy|Patients who are in this group will have arthroscopic tenotomy. A scope is used to see the tendon and release it.
3276070|NCT01618487|Active Comparator|Open tenotomy|Patients in this group will undergo open tenotomy. This involves opening the skin to expose the muscle and tendon, and then the tendon is released.
3276071|NCT01618487|Active Comparator|Debridement and repair|The patients in this group will undergo an arthroscopic technique (scope and small incision) to go in and remove any tissue that is diseased/does not belong and repair the tear(s) in the tendon.
3276072|NCT01618500||INPH-patients|"Inclusion criteria~Older than 60 years of age Probable INPH according to the NIH guidelines Planned shunt surgery based on a diagnosis of INPH.~Exclusion criteria~Known cause for hydrocephalus (i.e., secondary NPH). Medical condition preventing cognitive testing (e.g. deafness, blindness).~Patients not considered for shunt operation."
3276073|NCT01618513|Experimental|SA monitored by GH|
3276074|NCT01618513|Experimental|SA monitored by IGF-I|
3276075|NCT01618513|No Intervention|Control|Control, patients who have achieved sufficient disease control by surgery alone.
3276076|NCT01618526|Active Comparator|Healthy Carbohydrate Diet|4 weeks of intervention with a diet rich in Arabinoxylans and Resistent Starch
3276077|NCT01618526|Placebo Comparator|Western Style Diet|4 weeks of intervention with a diet with low content of Resistent Starch and Arabinoxylans.
3276078|NCT01618552|Experimental|SEE IT training (interviewing skills)|Intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) with patients who have coexisting depression and diabetes
3276079|NCT01618552|Active Comparator|Control (knowledge enhancement)|Brief video clip designed to increase primary care physician awareness of new medication treatments for patients with diabetes
3276080|NCT01618565|Experimental|Hands-On Training|30 minutes hands-on training of maneuvers to manage shoulder dystocia
3276081|NCT01618565|Active Comparator|Demonstration|30 minutes passive training by watching an expert instructor explain and perform maneuvers to manage shoulder dystocia
3276082|NCT01618578||Patients with CRPS|24 patients with CRPS of the upper limb type 1 were included into the study.
3276083|NCT01618578||Patients with unilateral upper limb pain|21 patients with unilateral upper limb pain served as controls.
3276084|NCT01618578||healthy subjects|24 healthy subjects were age- and sex matched to patients with CRPS.
3276085|NCT01618591|Experimental|Acute Watery Diarrhea|
3276086|NCT01618591|Experimental|Acute Dysentery/Febrile|
3276087|NCT01618604||Healthy|26 healthy voluntary probands
3276088|NCT01618617|Experimental|Probiotic, high dose|High dose Multistrain probiotic, 100 billion cfu/day
3276089|NCT01618617|Experimental|Probiotic, low dose|Low dose Multistrain probiotic, 15 billion cfu/day
3276090|NCT01618617|Placebo Comparator|Placebo|Placebo
3276091|NCT01618630|Experimental|EAA Supplementation + Exercise Training|Drink an amino acid supplementation during exercise training.
3276092|NCT01618630|Placebo Comparator|Placebo + Exercise Training|Drink a placebo supplementation during exercise training.
3276093|NCT01618643||Acetic acid chromoendoscopy|"Patients with known Barrett's metaplasia under surveillance~Patients with Barrett's metaplasia who had undergone endoscopic treatment for neoplasia previously and were under surveillance for metachronous neoplasia~Patients suspected of neoplasia referred for endoscopic mucosal resection or other targeted endoscopic treatment of the lesion"
3276094|NCT01618656|Active Comparator|PF-04457845|2/3 of subjects will be randomized to fatty acid amide hydrolase (FAAH) inhibitor 4mg
3276095|NCT01618656|Placebo Comparator|Placebo (sugar pill)|1/3 of subjects will be randomized to placebo
3276096|NCT01618682||Hand Transplant Patients|These will be subjects who have undergone a hand transplant.
3276097|NCT01618682||Hand Replant Patients|These will be patients who have undergone a hand replant procedure.
3276098|NCT01618734||Romiplostim and eltrombopag in ITP|ITP patients who received alternatively romiplostim or eltrombopag with at least two months of follow-up for each period.
3276099|NCT01618747||Cohort|
3276100|NCT01618760|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
3276101|NCT01618760|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
3276102|NCT01618786|Experimental|Compliant Flooring (CF)|Compliant flooring
3276103|NCT01618786|Placebo Comparator|Control (CON)|Non-compliant flooring
3276104|NCT01618799|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
3276105|NCT01618799|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
3276106|NCT01618812||Pes plano valgus|Children with painful flatfeet
3276107|NCT01618825|Active Comparator|LAMICTAL®|Lamictal® (Lamotrigine) Tablets 25 mg of GlaxoSmithkline, USA
3276108|NCT01618825|Experimental|Lamotrigine Tablets 25 mg|Lamotrigine Tablets 25 mg of M/s Ipca Laboratories Limited, India
3276109|NCT01618851|Experimental|IMRT with SBRT Boost|Patients with clinically localized prostate cancer will be treated with three radiosurgical treatments (6.5 Gy per fraction to PTV) followed by IMRT (45 Gy in 25 fractions) over 6-7 weeks.
3276110|NCT01618877|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) infusion.
3276111|NCT01618877|Placebo Comparator|Placebo infusion|
3276112|NCT01618890|Experimental|HVPG-propranolol arm|"A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.~A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices."
3276113|NCT01618890|No Intervention|Propranolol arm|Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.
3276114|NCT01618903|Experimental|Levetiracetam iv infusion|Levetiracetam intravenous (iv) 45 min infusion administered as one single dose.
3276115|NCT01618903|Experimental|Levetiracetam oral tablet|Levetiracetam oral tablet administered as one single dose.
3276116|NCT01618929|Active Comparator|asthma with food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design).
3276117|NCT01618929|Active Comparator|asthma without food allergy|The study will be performed in 2 groups of patients (Patients with and without food allergy) parallel to each other at the same time and within each group the patients will take montelukast and placebo (one after another in a double-blind design)
3276118|NCT01618981|Experimental|first active|
3276119|NCT01618981|Experimental|first inactive|
3276120|NCT01618994||Expert Surgeons|Gynecologic robotic surgeons, each averaging >75 robotic cases per year
3276121|NCT01618994||Study Surgeons|Gynecologic surgeons who are completely naive to robotics
3276122|NCT01618994||Control Surgeons|Gynecologic surgeons with full robotic privileges but were not averaging more than 2 cases a month and had never used the simulator
3276123|NCT01619007||Group 1|
3276124|NCT01619007||Group 2|
3276125|NCT01619020|Active Comparator|Flaxseed Lignans|Capsules
3276126|NCT01619020|Placebo Comparator|Placebo|Capsules
3276127|NCT01619033|Experimental|impaired renal function subjects|impaired renal function subjects
3276128|NCT01619033|Other|Healthy volunteers|matched with impaired renal function subjects on ethnic group, sex, age (+/- 5 years), and BMI (+/- 20%)
3276129|NCT01619046|Active Comparator|PK substudy|A cohort of 13-18 subjects will be included in the pharmacokinetic (PK) evaluation of GreenGene™ F and an approved recombinant Factor VIII product (Refacto AF); a minimum of 13 of these subjects will be re-evaluated at study end (50 exposure day).
3276130|NCT01619046|Experimental|Prophylaxis safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding during prophylaxis over ≥ 50 exposure days.
3276131|NCT01619046|Experimental|On-demand safety and efficacy substudy|Hemostatic efficacy of GreenGene™ F will be assessed by its effectiveness in controlling spontaneous or traumatic bleeding episodes and by the rate of breakthrough bleeding in a minimum of 10 on demand treated subjects during 50 exposure days.
3276132|NCT01619046|Experimental|Surgical substudy|Peri-operative hemostatic control of GreenGene™ F in surgery or invasive procedures will be assessed in at least 10 surgeries, some of them major, in at least five subjects
3276133|NCT01619072|Active Comparator|Misoprostol|800 mcg sublingual misoprostol + referral to higher level care
3276134|NCT01619072|Placebo Comparator|Placebo|Placebo + referral to higher level care
3276135|NCT01619098|Experimental|Patient Navigator|Hospital-based Patient Navigator (a bilingual community health worker) engaged in discharge planning and made outreach phone calls to patients for 30 days after discharge and assisted patints with follow-up appointments, obtaining and taking medications, transportation, financial barriers, and linkages to community resources
3276136|NCT01619098|No Intervention|Usual Care|Home care plan at discharge, outreach phone call from RN at patient's primary care clinic
3276137|NCT01619111|Active Comparator|standard therapy|standard chemo- or endocrine therapy
3276138|NCT01619111|Experimental|standard therapy + lapatinib|standard chemo- or endocrine therapy + lapatinib
3276139|NCT01619137|Active Comparator|Povidone-iodine And normal salin|40 patients with complaint of ununion wound of laparatomy or episiotomy coming to Gynecologist's office or hospital enrolled to this study randomly recieve Povidone-iodine And normal salin treatment.
3276140|NCT01619137|Active Comparator|water and soap|40 patients coming to Gynecologist's offices or hospital with complaint of ununion wound of laparatomy or episiotomy in Bandarabbas enrolled to this study and randomly recieve water and soap to irrigation of the wound (it's not require to be at hospital), washing is for each 6-8 hours per day. and if not difference seen after 4 day, treatment change to Povidone-iodine And normal salin.
3276141|NCT01619150|Other|Etoricoxib, followed by placebo|4 weeks of treatment with etoricoxib, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with placebo.
3276142|NCT01619150|Other|Placebo, followed by etoricoxib|4 weeks of treatment with placebo, followed by a wash out period of at least 6 days, followed by another 4 weeks of treatment with etoricoxib.
3276143|NCT01619163|Experimental|prednisolone|
3276144|NCT01619163|Placebo Comparator|Placebo|
3276145|NCT01619176|Experimental|Acupuncture|Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
3276146|NCT01619176|Active Comparator|Control|Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
3276147|NCT01619189|Experimental|Tranplantation of cultured LSC in stage 3 limbal deficiency|Transplantation of Allogeneic or Autologous Limbal Epithelial Stem Cells Cultured on Human Amniotic Membrane with no Feeders in stage 3 unilateral or bilateral limbal stem cell deficiency.
3276148|NCT01619202|Experimental|Risk Anticipation-Perception Training|Complete the Risk Anticipation-Perception Training (RAPT) program
3276149|NCT01619202|No Intervention|No training program|Does not complete the Risk Anticipation-Perception Training (RAPT) program
3276150|NCT01619215||Bariatric Surgery|As the number of patients dropping out during follow-up, we had difficulty achieving our secondary outcomes, and so the team decided to continue the recruitment until all our outcomes are reached. Main part of the primary outcomes is finalised and published The effects of bariatric surgeries on nonalcoholic fatty liver disease. Aldoheyan T, Hassanain M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Al-Khalidi H. Surg Endosc. 2016 Jul 12
3276151|NCT01619228||Premature Infants|Infants born at < 37 weeks gestational age
3276152|NCT01619228||Full Term Infants|Infants born at equal to or greater than 37 weeks gestational age
3276153|NCT01619228||Adults|Adults are parents of infants enrolled in the study
3276154|NCT01619241||advanced non-small cell lung cancer|
3276155|NCT01619254|Experimental|Hand hygiene|Hand washing with soap measures will be carried out as an intervention activity
3276156|NCT01619254|Experimental|Hand finger nail hygiene|Hand finger nail clipping activities
3276157|NCT01619254|Experimental|Hand and finger nails hygiene|Both hand washing with soap and hand finger nail clipping activities will be implemented
3276158|NCT01619254|Placebo Comparator|Customary practice|No hand washing with soap and nail clipping activities. House holds and children assigned to the control group will not have the interventions (hand washing with soap and nail clipping activities)
3276159|NCT01619267||device associated infection|patients with proven device associated infection
3276160|NCT01619267||control group|patients without device associated infection
3276161|NCT01619280|Experimental|Nebulized sodium nitroprusside|
3276162|NCT01619293||Epidural H.|patients with hematoma epidurale
3276163|NCT01619293||Subdural H.|patients with hematoma subdurale
3276164|NCT01619293||Subarachnoidal H.|patients with hematoma subarachnoidale
3276165|NCT01619293||Intracerebral H.|patients with hematoma intracerebrale
3276166|NCT01619293||E. cerebri|patients with edema cerebri
3276167|NCT01619293||Concussion|patients with concussion
3276168|NCT01619319|Experimental|Cognitive Remediation Therapy|A computerised cognitive remediation intervention called the Brain Fitness program is compared against a placebo intervention consisting of computer games
3276169|NCT01619319|Active Comparator|computer games|computer games
3276170|NCT01619332|Experimental|LEZ763|Part I- Healthy volunteers enrolled into 6 single-ascending dose cohorts Part II- Healthy volunteers enrolled into 5 multiple-ascending dose cohorts. Part III- LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
3276171|NCT01619332|Placebo Comparator|Placebo|Part I : Healthy volunteers enrolled in 6 single ascending dose cohorts to receive matching placebo of LEZ763. Part II: Healthy volunteers enrolled in 5 multiple ascending dose cohorts to receive matching placebo of LEZ763. Part III- Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
3276172|NCT01619332|Active Comparator|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
3276173|NCT01619345|Experimental|Period 1: NN9924 with 50 mL water|
3276174|NCT01619345|Experimental|Period 2: NN9924 with 240 mL water|
3276175|NCT01619371||Lactating women|Lactating women willing to use a breast pump.
3276176|NCT01619384|No Intervention|Treatment as Usual|Usual VA care
3276177|NCT01619384|Experimental|MBSR|participation in an 8-week stress reduction course (mindfulness-based stress reduction)
3276178|NCT01619397|Other|Condom|Test condom with new Xanthan gum condom coating
3276179|NCT01619436|Active Comparator|clonidine|clonidine 2 mg/kg IV
3276180|NCT01619436|Placebo Comparator|ringer lactato 1 ml|Ringer lactato 1 ml IV as Placebo
3276181|NCT01619449|Experimental|Renal replacement therapy|Liver transplant recipients who receive continuous renal replacement therapy intra-operatively.
3276182|NCT01619449|Active Comparator|No CRRT|This arm consists of standard of care without CRRT in the OR for OLT
3276183|NCT01619462|Other|Synflorix or PCV10|130 children will receive Synflorix at 1-2-3 months
3276184|NCT01619462|Other|Prevenar 13|130 children will receive Prevenar 13 at 1-2-3 months
3276185|NCT01619475||Prospective|Individuals approved as liver donors and recipients shortly Pre-donation/Pre-transplant at the study sites.
3276186|NCT01619475||Long-Term Follow-up|"Donors and recipients enrolled in the original A2ALL Cohort study.~Donors and LDLT recipients whose donation/transplant occurred during the period of time that began with the end of enrollment into the original Cohort study (Aug. 31, 2009) and ended with the opening of the enrollment in the current core protocol; this is referred to as the Gap Era.~LDLT recipients and donors who were not in the original Cohort study or from the Gap Era will enter the study at time proximate to time of living donation."
3276187|NCT01619475||HCV-Infected Liver Transplant Recipients|Male and female HCV-infected adult liver transplant recipients from those enrolled in the A2ALL-1 Cohort study and from those concurrently transplanted at the new A2ALL-2 centers (University of Toronto, University of Pittsburgh, Lahey Clinic).
3276188|NCT01619488|Experimental|Gastric Banding|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
3276189|NCT01619527|Experimental|Treatment A|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fasted condition)
3276190|NCT01619527|Experimental|Treatment B|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fasted condition).
3276191|NCT01619527|Experimental|Treatment C|Single-dose co-administration of 800 mg darunavir and 150 mg cobicistat as single agents (under fed condition - standardized breakfast).
3276192|NCT01619527|Experimental|Treatment D|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - standardized breakfast).
3276193|NCT01619527|Experimental|Treatment E|Single-dose co-administration of the fixed dose combination darunavir/cobicistat 800/150-mg (under fasted condition).
3276194|NCT01619527|Experimental|Treatment F|Single-dose co-administration of the fixed dose combination darunavir/cobicistat (800/150-mg) (under fed condition - high-fat breakfast).
3276195|NCT01619540|Other|acute heart failure|control arm
3276196|NCT01619540|Experimental|COPD exacerbation|COPD exacerbation
3276197|NCT01619553||affected|individuals with keloids
3276198|NCT01619553||unaffected|unrelated unaffected controls or unaffected family members
3276199|NCT01619566|No Intervention|Control|Control subjects undergo a skin biopsy.
3276200|NCT01619566|Experimental|Treatment|Subjects in the treatment arm also undergo a skin biopsy, followed by 8 week treatment with Duloxetine.
3276201|NCT01619592|Active Comparator|Intervention group|webbased education (telemonitoring)
3276202|NCT01619592|No Intervention|control group|standard care
3276203|NCT01619605|Experimental|Shrim|
3276204|NCT01619631|Experimental|12-week Tai Chi intervention|
3276205|NCT01619631|Active Comparator|Education control group|After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
3276206|NCT01619631|No Intervention|Waitlist control group|The waitlist control will not receive any intervention during the duration of the study. After 24 weeks, and upon completion of the study, each participant will be offered twelve weeks of Tai Chi twice weekly.
3276207|NCT01619644|Experimental|Sodium Valproate|Group of 40 patients receiving one year of sodium valproate
3276208|NCT01619644|Placebo Comparator|Placebo|Group of 20 patients receiving one year of placebo
3276209|NCT01619657|Experimental|Hypertonic Saline|Inhalation with 6% Hypertonic Saline twice daily over 1 year
3276210|NCT01619657|Active Comparator|Isotonic Saline|Inhalation with 0.9% Isotonic Saline twice daily over 1 year
3276211|NCT01619670|No Intervention|no intervention|standard wound care
3276212|NCT01619670|Active Comparator|Apligraf|non adhesive layer with apligraf
3276213|NCT01619683|Experimental|Androxal|
3276214|NCT01619683|Placebo Comparator|Placebo|
3276215|NCT01619696|Experimental|Intervention|
3276216|NCT01619709|Other|lobar hemorrhage group|PET AV-45 in patients with cortical or corticosubcortical hemorrhage (involving predominantly the cortex and underlying white matter)
3276217|NCT01619709|Other|deep hemorrhage group|PET AV-45patients with subcortical hemorrhage (involving predominately the basal ganglia, periventricular white matter, or internal capsule).
3276218|NCT01619735||Fragments basketed|"Active extraction is whereby the ureteroscope is passed back and forth into the kidney to remove all visible stone fragments."
3276219|NCT01619735||Fragments dusted|"Dusting is whereby the stones are broken into tiny fragments or dust with the intention that achieving such a small stone size will allow the stones to pass spontaneously."
3276220|NCT01619748||Untreated OSA patients|Patients with obstructive sleep apnoea who are untreated
3276221|NCT01619748||OSA patients highly compliant with CPAP|OSA patients established on CPAP therapy (high compliance, > 80% nightly use for ≥ 4 h per night)
3276222|NCT01619748||OSA patients poorly compliant with CPAP|OSA patients established on CPAP therapy (poor compliance, 10% < nightly use < 50% or < 4 h per night)
3276223|NCT01619748||Age and BMI-matched controls|Age and BMI-matched controls without OSA
3276224|NCT01619761|Experimental|Treatment Plan 1 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -8 to -2, fludarabine phosphate IV over 1 hour on days -7 to -4, and melphalan IV over 30 minutes on day -4. CD20 positive patients also receive rituximab IV over 6 hours on days -8 to -4.
3276225|NCT01619761|Experimental|Treatment Plan 2 (NK cells, umbilical cord blood transplant)|Patients receive high-dose lenalidomide PO QD on days -7 to -2, cyclophosphamide IV over 3 hours on day -7, and undergo TBI on day -3. Patients also receive rituximab and fludarabine phosphate as in Treatment Plan 1.
3276226|NCT01619813|Active Comparator|Docetaxel, Reolysin and Prednisone|
3276227|NCT01619813|Active Comparator|Docetaxel and Prednisone|
3276228|NCT01619826|Experimental|Treatment Group|Participants randomized to the physical activity-based afterschool intervention
3276229|NCT01619826|Placebo Comparator|Wait List Group|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
3276230|NCT01619891|Active Comparator|Vitamin D|Vitamin D 100mcg per day
3276231|NCT01619891|Placebo Comparator|Placebo|Standard optimal therapy
3276232|NCT01619904|Experimental|Goal-Directed Therapy|
3276233|NCT01619904|Active Comparator|Standard Therapy|
3276234|NCT01619917|Active Comparator|Proximal|location of the scar proximal to heart
3276235|NCT01619917|Experimental|Distal|location of scar distal to heart
3276236|NCT01619930|Experimental|1a|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
3276237|NCT01619930|Experimental|1b|"In phase 1, group 1 undergoes physical activation without added motivation interviewing. Post-treatment (phase 2), group 1 is divided by randomization into group 1a and 1b, where 1a receives relapse prevention and 1b does not. Both 1a and 1b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 1 + 12 from waiting list control group)"
3276238|NCT01619930|Experimental|2a|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
3276239|NCT01619930|Experimental|2b|"In phase 1, group 2 undergoes physical activation with added motivation interviewing. Post-treatment (phase 2), group 2 is divided by randomization into group 2a and 2b, where 2a receives relapse prevention and 2b does not. Both 2a and 2b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 2 + 12 from waiting list control group)"
3276240|NCT01619930|Experimental|3a|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
3276241|NCT01619930|Experimental|3b|"In phase 1, group 3 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 3 is divided by randomization into group 3a and 3b, where 3a receives relapse prevention and 3b does not. Both 3a and 3b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 3 + 12 from waiting list control group)"
3276242|NCT01619930|Experimental|4a|"In phase 1, group 4 undergoes behavioral activation without added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
3276243|NCT01619930|Experimental|4b|"In phase 1, group 4 undergoes behavioral activation with added motivation interviewing. Post-treatment (phase 2), group 4 is divided by randomization into group 4a and 4b, where 4a receives relapse prevention and 4b does not. Both 4a and 4b undergo post-treatment measurements as previously described.~n = 50 + 12 = 62 (50 from group 4 + 12 from waiting list control group)"
3276244|NCT01619930|No Intervention|Phase 1 Waiting list control group|Control group during phase 1, in parallel with treatment groups 1-4. Weekly self-report measurements, the results of which are conveyed in the form of individualized feedback. After 12 weeks, the participants of the control group (n = 100) are randomized to one four phase 1 active treatment groups (1-4) and receive treatment accordingly.
3276245|NCT01619943||Patients with minor head injury|MHI is defined as a blunt trauma to the head within 24 hours with a Glasgow Coma Scale (GCS) score of 13 to 15 and at least one of the following: history of loss of consciousness, short-term memory deficit, amnesia for the traumatic event, post-traumatic seizure, vomiting, headache, external evidence of injury above the clavicles, confusion, and neurologic deficit.
3276246|NCT01619956|Experimental|OSFE with grafting|OSFE with grafting (autogenous bone chips+xenograft material with a ratio of 1:4)
3276247|NCT01619956|Active Comparator|OSFE without grafting|OSFE without grafting. No grafting materials or autogenous bone chips were used.
3276248|NCT01619969|Experimental|Celgosivir|
3276249|NCT01619969|Placebo Comparator|Placebo|
3276250|NCT01620008|No Intervention|Immediate Cord Clamping (ICC)|The infant will be placed on the maternal abdomen and the umbilical cord will be clamped immediately after birth (routine care).
3276251|NCT01620008|Experimental|Delayed Cord Clamping (DCC)|At birth, infants will be placed on the maternal abdomen and the cord clamping will be delayed for 5 minutes. If the provider is unable to delay the cord clamping, the cord will be milked 5 times.
3276252|NCT01620021||Healthy|Ten healthy volunteers with no history of gait and balance issues will be recruited to participate in the study.The participants must be between 18 and 65 years of age.
3276253|NCT01620034|Active Comparator|11 Day Arm|
3276254|NCT01620034|Experimental|4 Day Arm|
3276255|NCT01620073|Other|Partner friendly arm|Proportion of males counseled and tested using routine standards of prenatal care
3276256|NCT01620073|Experimental|Home based arm|Proportion of male partners accepting HIV counseling and testing following home visits for couple HIV counseling and testing during pregnancy
3276257|NCT01620099|Experimental|Asthmatic nonsmokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who never smoked. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
3276258|NCT01620099|Active Comparator|Asthmatic smokers|Asthmatic patients aged 18-50 years old, at stage 2-3 according to GINA international guidelines, on inhaled treatment (ICS alone or combination ICS/LABA) other than extrafine formulations, will be enrolled. This group includes patients who smoked with a smoking habit ranging from 10 to 20 pack/years. Following the initial evaluation (cross-sectional - primary outcome) patients will be switched to an extrafine equipotent dose of the same compound (BDP-HFA if the patient was on ICS) or combination (BDP-HFA/F if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
3276259|NCT01620112|Active Comparator|low clonidine concentration|clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus
3276260|NCT01620112|Active Comparator|lidocaine 20 ml 1,5%|lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery
3276261|NCT01620112|Active Comparator|high clonidine concentration|clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus
3276262|NCT01620112|Active Comparator|40 ml lidocaine 1,5%|40 ml of lidocaine 1,5% without clonidine for upper brachial plexus
3276263|NCT01620125|Other|Lactobacillus reuteri|Dietary supplementation with Lactobacillus reuteri DSM 17938
3276264|NCT01620151|No Intervention|No extended neck|Patient will not undergo thyroid surgery with extended neck
3276265|NCT01620151|Experimental|Extended neck|Patients who undergoing thyroid surgeries are positioned with extended neck by using pillow under shoulder in order to facilitate neck exposure and make the surgery easier.
3276266|NCT01620164|Other|Parkinsonian patients OFF/ON|9 patients will be evaluated with psychophysical measurements of 3D perception, in OFF then ON conditions
3276267|NCT01620164|Other|healthy subjects|Healthy subjects will be evaluated with psychophysical measurements of 3D perception, without treatment
3276268|NCT01620164|Other|Parkinsonian patients ON/OFF|9 patients will be evaluated with psychophysical measurements of 3D perception, in ON and then OFF conditions
3276269|NCT01620229|Experimental|Treatment (brentuximab vedotin)|Patients receive brentuximab vedotin IV on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3276270|NCT01620242|Experimental|Cabazitaxel|All patients are treated with Cabazitaxel.
3276271|NCT01620268|No Intervention|Control Group|Patients receive standard of care.
3276272|NCT01620268|Experimental|Treatment Group|Dose adjusted leflunomide plus 600 mg orotic acid.
3276273|NCT01620281|Experimental|Immediate treatment (IT)|Subjects from this group will receive the device immediately. Subjects will be instructed to treat themselves daily for 3 weeks, in up to three 10-minutes sessions. All subjects will receive a diary to record details of the daily use of the device (time of day, position of legs, and number of daily uses), degree of pain, a weekly ODI questionnaire, and record of any back/pain related events. After 3 weeks the subjects from the IT group will return the device and at 6 weeks they will visit again for the final evaluation.
3276274|NCT01620281|Other|Waiting List Control (WLC)|The WLC group will go through the same evaluations at the same time intervals but will begin treatments 3 weeks later during which they will fill the diary daily but not use the device.
3276275|NCT01620294|Experimental|triclosan|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3276276|NCT01620294|Experimental|uncoated|Two arms are separated by computer randomization at abdominal wall closure: application of triclosan-coated and non-coated PDS suture (PDS vs. PDS-Plus).
3276277|NCT01620307|Active Comparator|with Rapamune treatment|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were received Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
3276278|NCT01620307|Placebo Comparator|Without Rapamune treatment.|"All patients were treated with Oseltamivir (Tamiflu, Roche) 50 mg twice a day for 10 days and oral prednisolone 20 mg/day for 14 days. At ICU admission, patients started on empiric antimicrobial therapy with moxifloxacin 500 mg per day until results of microbiological studies were available.~Each patient received best support treatment including mechanical ventilator, fluid resuscitation, gastrointestinal and thromboembolic prophylaxis, and enteral nutrition for most aspects of care. After radomization, patients were not to receive Sirolimus (Rapamune 2mg/day, Pfizer)for a course of 14 days."
3276279|NCT01620320||Stress echography|Nine to twelve months after their left main angioplasty, patients will go through a stress echo and then the usual control angiography (done routinely in most patient in our center). Patients will act as their own control.
3276280|NCT01620333|Experimental|Treatment period 1|
3276281|NCT01620333|Experimental|Treatment period 2|
3276282|NCT01620346|Active Comparator|ICSI group|This group was provided with conventional intracytoplasmic sperm injection (ICSI). This treatment is routinely used to treat infertility. Sperm selection in the ICSI group is analysed under a magnification of 400x using an inverted microscope.
3276283|NCT01620346|Experimental|Intracytoplasmic morphologically selected sperm injection|Intracytoplasmic morphologically selected sperm injection (IMSI) is an established modified ICSI procedure. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
3276284|NCT01620359|Experimental|ExAblate|
3276285|NCT01620372||Treatment cohort (chemo/radiotherapy)|- those who have survived at least 5 years from the date of diagnosis
3276286|NCT01620372||Self-questionnaire cohort|- those with a complete address, who come of age, are still alive and sent back a signed consent agreement
3276287|NCT01620372||Medical Insurance cohort|- those who come of age and authorize the access to the medical facilities of the French Health Insurance Information System
3276288|NCT01620385|Experimental|ciPDA|
3276289|NCT01620398|Experimental|BALANCE group|BALANCE Program is composed by 3 concepts: a) a diet composed of 50-60% of energy from carbohydrate, 10-15% of energy from protein; 25-35% of energy from fat (<7% saturated fatty acid; <10% polyunsaturated fatty acid; <20% monounsaturated fatty acid, <1% trans fatty acid), <200 mg/day of cholesterol, 20-30 g/day of fiber and <2400 mg/day of sodium; b) Nutrition education program based on ludic strategies and indication of affordable foods; c) An intense follow up by individual and group visits and phone calls.
3276290|NCT01620398|Active Comparator|Control Diet group|generalized advices to follow a low fat, low energy, low sodium and low cholesterol diet are given.
3276291|NCT01620411|Experimental|Comprehensive Medical Management (CMM)|This arm will receive standard of care treatment for injuries sustained while on active duty. Non-Invasive.
3276292|NCT01620411|Experimental|CMM + Spinal Cord Stimulator (SCS)|This arm will combine comprehensive medical management with placement of a spinal cord stimulator.
3276293|NCT01620424|Experimental|Dosing visit 1|
3276294|NCT01620424|Experimental|Dosing visit 2|
3276295|NCT01620437|Experimental|Formulation A|
3276296|NCT01620437|Experimental|Formulation B|
3276297|NCT01620450|Experimental|NN2000|
3276298|NCT01620450|Active Comparator|NN-X14|
3276299|NCT01620463|Experimental|NNC 90-1170|
3276300|NCT01620463|Placebo Comparator|Placebo|
3276301|NCT01620476|Experimental|5 mcg/kg|
3276302|NCT01620476|Experimental|10 mcg/kg|
3276303|NCT01620476|Experimental|15 mcg/kg|
3276304|NCT01620502|Active Comparator|EPA 3.5 g/day|
3276305|NCT01620502|Placebo Comparator|Placebo capsules|oleic oil
3276306|NCT01620502|Experimental|DHA 1.75 g/day|DHA 1.75 g/day
3276307|NCT01620515|No Intervention|Active Surveillance|Subjects with low risk localized (T1c) prostate cancer who are being followed with active surveillance and not undergoing active treatment for prostate cancer.
3276308|NCT01620515|Experimental|NX-1207 2.5 mg|
3276309|NCT01620515|Experimental|NX-1207 15 mg|
3276310|NCT01620541||Preference, Ankle Arthrodesis|
3276311|NCT01620541||Preference, Ankle Arthroplasty|
3276312|NCT01620554|Experimental|BF2.649 5mg|
3276313|NCT01620554|Experimental|BF2.649 10mg|
3276314|NCT01620554|Experimental|BF2.649 20mg|
3276315|NCT01620554|Experimental|BF2.649 40mg|
3276316|NCT01620554|Placebo Comparator|Placebo|
3276317|NCT01620580|Active Comparator|Self Management Strategies|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3."
3276318|NCT01620580|Active Comparator|Dietary Information|Control arm
3276319|NCT01620606|Experimental|SLCBT|Social Learning and Cognitive Behavioral Therapy
3276320|NCT01620606|Experimental|SLCBT-R|Phone-based Social Learning and Cognitive Behavioral Therapy
3276321|NCT01620606|Active Comparator|ES|Education and Support
3276322|NCT01620619|Active Comparator|Arthroscopic Bankart Repair & Rotator Interval Closure|
3276323|NCT01620619|Active Comparator|Arthoscopic Bankart Repair alone|
3276324|NCT01620632||Altered gastric anatomy|Patients who have an altered gastric who need an ERCP
3276325|NCT01620645||COPD, GOLD II severity or above|
3276326|NCT01620671|Active Comparator|Conventional surgery|The patients who will have a conventional surgical treatment will be included.
3276327|NCT01620671|Active Comparator|Fast-track surgery|The patients who will have fast-track surgery will be included.
3276328|NCT01620684|Active Comparator|metyrapone|Overnight metyrapone treatment (total dose of 30 mg/kg)
3276329|NCT01620684|Placebo Comparator|sugar pill|Overnight treatment with placebo capsules
3276330|NCT01620697||Perirenal fat|
3276331|NCT01620710|Other|prostate bed|"irradiation of the prostatic bed only (no higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy)~This arm has already finished recruitment"
3276332|NCT01620710|Other|prostate bed & lymph nodes|irradiation of the prostatic bed and the pelvic lymphatic drainage (in patients with higher risk of lymph node recurrence); helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
3276333|NCT01620723|Experimental|New breastfeeding programme|"The breastfeeding programme consists of four core elements:~breastfeeding is a parental task~skin to skin contact during the first three days~frequent breastfeeding at least 8 times a day~good positioning, preferable in a laid back position~Moreover communication was supposed to enhance breastfeeding self-efficacy, using Banduras theory of self-efficacy"
3276334|NCT01620723|Active Comparator|Treatment as usual|Breastfeeding counselling uses the national handbook of breastfeeding as reference
3276335|NCT01620736|Experimental|Raltegravir|Treatment with raltegravir for 8 wks
3276336|NCT01620749|Experimental|MEL050|
3276337|NCT01620775|Experimental|Knee osteoarthritis (MRI, surveys, pain testing)|Subjects previously diagnosed with knee osteoarthritis will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3276338|NCT01620775|Active Comparator|Healthy controls (MRI, surveys,pain testing)|Healthy volunteers will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3276339|NCT01620775|Experimental|diabetic peripheral neuropathy|Subjects previously diagnosed with diabetic peripheral neuropathy will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3276340|NCT01620775|Experimental|chronic low back pain|Subjects previously diagnosed with chronic low back pain will have an MRI with imaging that measures brain metabolites. There are surveys to complete and a session of pain tolerance testing.
3276341|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 50mg|
3276342|NCT01620788|Experimental|Indapamide 1.5mg / Losartan 100mg|
3276343|NCT01620788|Active Comparator|Hyzaar® (Losartan 50mg/Hydrochlorothiazide12,5mg)|
3276344|NCT01620788|Active Comparator|Hyzaar® (Losartan 100mg/Hydrochlorothiazide 25mg)|
3276345|NCT01620801|Experimental|Low dose|AAV8-hFIX19
3276346|NCT01620801|Experimental|Middle dose|AAV8-hFIX19
3276347|NCT01620801|Experimental|High dose|AAV8-hFIX19
3276348|NCT01620814|Experimental|Dinoprostone and misoprostol|"For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.~After drugs administration, cervical canal will be again evaluated with above mentioned way by bougie before hysteroscopy"
3276349|NCT01620814|Experimental|Misoprostol and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
3276350|NCT01620814|Experimental|dinoprostone and control|For the purpose of cervical ripening none procedure will be performed to Group 1, while vaginal misoprostole of 200 mg and vaginal dinoprostone will be applied to Group 2 and 3, respectively. While misoprostol will be implanted 3 hours before procedure, but dinoprostone will be implanted 6 hours before procedure. Before drug implantation for determination of the cervical insufficiency and measure of the cervical canal's opening, bougies will be applied toward to back from 8 no- hegar bougie.
3276351|NCT01620827|Active Comparator|Hospital Landline|Subjects in this arm have all of their follow-up phone calls placed from a hospital landline number.
3276352|NCT01620827|Active Comparator|Private Cell Phone|Subjects in this arm have all of their follow-up phone calls placed from a private cell phone number.
3276353|NCT01620840||Lacosamid-i.v. treatment|
3276354|NCT01620866|Experimental|EMDR|
3276355|NCT01620866|No Intervention|TAU|Treatment as usual (TAU)
3276356|NCT01620892||Unicondylar knee replacement|This is a non-intervational, retrospective, observational study of a case series cohort of patients who received a particular surgical operation during a specified time period.
3276357|NCT01620905|Experimental|Cervical spine manipulation|Subjects received cervical spine manipulation
3276358|NCT01620931|Experimental|RO5469754|
3276359|NCT01620931|Placebo Comparator|Placebo|
3276360|NCT01620944|Experimental|Arm1: ATV/RTVHS+3TC|
3276361|NCT01620944|Active Comparator|Arm2: ATV/RTVHS+TDF/FTC|
3276362|NCT01620957||Coma patients|
3276363|NCT01620970|Experimental|PF03446962|Investigational study drug, administered intravenously every 2 weeks until disease progression or unacceptable toxicity.
3276364|NCT01620996|Active Comparator|1|Duffus Street Medical Centre
3276365|NCT01620996|Active Comparator|2|Sydney Family Practice
3276366|NCT01620996|No Intervention|no counseling|HRA assessment pre and post but no counselling
3276367|NCT01621022|Active Comparator|Active bupropion-Active gum|150 mg bupropion twice daily + 4 mg nicotine gum as needed (up to 12 pcs/day)
3276368|NCT01621022|Active Comparator|Active bupropion-Placebo gum|150mg bupropion twice daily + placebo gum as needed (up to 12 pcs/day)
3276369|NCT01621022|Active Comparator|Placebo medication-Placebo gum|Placebo bupropion, twice daily, plus placebo gum as needed (up to 12 pcs/day)
3276370|NCT01621035||elderly (> 70 y)|
3276371|NCT01621061||High altitude pulmonary hypertension|Highlanders with high altitude pulmonary hypertension
3276372|NCT01621061||High altitude control|Healthy highlanders
3276373|NCT01621061||Low altitude control|Healthy lowlanders
3276374|NCT01621074|Active Comparator|Sodium bicarbonate|
3276375|NCT01621074|Placebo Comparator|Placebo|
3276376|NCT01621087|Experimental|Safflower oil|
3276377|NCT01621087|No Intervention|Control group (no diet instruction)|
3276378|NCT01621100|Experimental|OROS hydromorphone|Once-Daily OROS (Osmotic release oral system [a controlled release oral drug delivery system in the form of a tablet]) hydromorphone
3276379|NCT01621113|Experimental|Locomotor Training + Dalfampridine|Subjects randomized to this group will undergo 10 weeks of double-blind treatment with extended release dalfampridine tablets (10 mg twice daily) while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
3276380|NCT01621113|Placebo Comparator|Locomotor Training + Placebo|Subjects randomized to this group will undergo identical treatment, but will take placebo tablets while simultaneously receiving locomotor training therapy (5 sessions per week x 10 weeks = 50 sessions total).
3276381|NCT01621139|Experimental|Real acupuncture|Real acupuncture group
3276382|NCT01621139|Sham Comparator|Sham acupuncture|Sham acupuncture group
3276383|NCT01621152|Other|Conventional management arm|Patients with AKI receive standard of care in the conventional manner by the primary clinicians
3276384|NCT01621152|Active Comparator|AKI sniffer instigated AKI management|primary clinicians for the AKI patients in this arm receive a verbal alert and reminder of KDIGO guidelines.
3276385|NCT01621165|Active Comparator|prazosin|Add prazosin to usual medications and monitor manic symptoms and for adverse effects
3276386|NCT01621165|Placebo Comparator|Placebo|
3377631|NCT04253626|Experimental|Intravenous iron|Participants will receive 510mg intravenous iron ferumoxytol, with a maximum of 2 doses based on the baseline hemoglobin level. The ferumoxytol is administered as an infusion for approximately 15 - 30 minutes.
3276387|NCT01621204|Experimental|Eltrombopag|Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
3276388|NCT01621204|Active Comparator|IVIG infusion|Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.
3276389|NCT01621217|Experimental|Cetuximab, Mitomycin C, Fluoruracil|
3276390|NCT01621243|Placebo Comparator|nab-paclitaxel, gemcitabine, placebo|"Part A: Not applicable.~Part B: nab-paclitaxel, gemcitabine, and placebo. Placebo administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
3276391|NCT01621243|Experimental|nab-paclitaxel, gemcitabine, necuparanib|"Part A: Following a single-dose of necuparanib and a 7-day follow-up period, necuparanib was administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle. Dose escalation of necuparanib proceeded by cohort in a 3+3 design.~Part B: A fixed dose of necuparanib will be administered daily along with nab-paclitaxel and gemcitabine administration on Day 1, Day 8, and Day 15 of each 28-day cycle."
3276392|NCT01621256|Experimental|Ancrod|Ancrod
3276393|NCT01621256|Placebo Comparator|Saline solution|Saline solution
3276394|NCT01621269|Experimental|Fingolimod|
3276395|NCT01621282|Experimental|Education|Departments passed 6-month interactive educational course
3276396|NCT01621282|No Intervention|No Education|Departments not passed 6-month interactive educational course
3276397|NCT01621308||IP insulin|Patients treated with continuous intraperitoneal insulin infusion using a implantable pump
3276398|NCT01621308||SC insulin|Patients treated with subcutaneous insulin, both multiple daily injections and continuous subcutaneous insulin infusion
3276399|NCT01621321|Experimental|Steroid group|
3276400|NCT01621321|Experimental|Voriconazole group|
3276401|NCT01621334|Experimental|Motivational Enhancement Therapy|Motivational Enhancement Therapy
3276402|NCT01621334|Other|Educational brochure|Intimate Partner Violence, Substance Abuse, and HIV risky behaviors Education
3276403|NCT01621360|Active Comparator|Arthroscopic surgery|Arthroscopic surgery of the hip plus optimized medical management
3276404|NCT01621360|Active Comparator|Conservative management|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
3276405|NCT01621373|Other|propofol|All patients receive propofol. Dose will be defined based on response of previous patient in the same stratum.
3276406|NCT01621386|Experimental|All Participants|Participants (male or female) that are between 18-65 years of age with a clinical diagnosis of asthma will take montelukast for 2 weeks (treatment period 1) and then take prednisone for 2 weeks (treatment period 2)
3276407|NCT01621399|Placebo Comparator|Vehicle|Treatment with the vehicle (placebo)
3276408|NCT01621399|Experimental|Product 55394|Treatment with product 55394
3276409|NCT01621425||TAC regimen|Female subject diagnosed with breast carcinoma and will receive docetaxel treatment according to standard hospital protocol
3276410|NCT01621425||PRODOC regimen|male subject diagnosed with metastatic castration-resistant prostate carcinoma and will receive docetaxel treatment according to standard hospital protocol
3276411|NCT01621451|Active Comparator|immediate|Patients who receive pantoprazole plus aspirin and/or clopidogrel within 3~4 days after EMR/ESD
3276412|NCT01621451|Active Comparator|2 weeks|Patients who receive pantoprazole plus aspirin and/or clopidogrel at 2 weeks after EMR/ESD
3276413|NCT01621464|Placebo Comparator|Control|Pacemaker implanted but NO pacing (mode DDI, 30 bpm and sub-threshold)
3276414|NCT01621464|Experimental|CLS group|pacemaker implanted programmed with the contractility sensor activated (mode DDD-CLS)
3276415|NCT01621516||Healthy controls|10 healthy volunteers
3276416|NCT01621516||Solitary small bowel transplant patients|3
3276417|NCT01621516||Liver/small bowel transplant patients|3
3276418|NCT01621555||PSOASS Patients|Patients undergoing elective arthroscopic shoulder surgery
3276419|NCT01621568|Experimental|Arm 1|Single Group Assignment for Thymoma and Thymic Carcimoma
3276420|NCT01621581|Experimental|Single Arm|AAV2-GDNF vector will be delivered to each patient
3276421|NCT01621620|Experimental|yohimbin|
3276422|NCT01621646|Placebo Comparator|egg white (control)|egg whites, 4 ounces per day for six months
3276423|NCT01621646|Experimental|eggs|eggs, 2 large per day for 6 months
3276424|NCT01621659|Experimental|multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
3276425|NCT01621659|No Intervention|Observational arm|Participants randomized to observational arm will receive usual care.
3276426|NCT01621685|Experimental|Spirometry, auscultation, questionnaire|>12% fall in FEV1, wheezing on auscultation, symptom questionnaire score >4
3276427|NCT01621698|Active Comparator|Early paravertebral block|The early group will have Local anaesthetic placed at the start of surgery and have normal saline placed at the close.
3276428|NCT01621698|Active Comparator|Late paravertebral block|The late group will have normal saline placed at the start of surgery and local anaesthetic placed at the close.
3276429|NCT01621711|No Intervention|Usual Care|Usual CD treatment, including therapy groups and individual counseling sessions, and six 45-min medical education groups. Physician appointments, pharmacotherapy, and SUD medications were be available as needed.
3276430|NCT01621711|Experimental|Linkage patient activation intervention|Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
3276431|NCT01621724|Experimental|Single arm cohort study|WT1 TCR-transduced T cells
3276432|NCT01621750|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
3276433|NCT01621750|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
3276434|NCT01621763|Experimental|Clopidogrel|Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
3276435|NCT01621763|Active Comparator|Plavix|Clopidogrel Tablet 300 mg
3276436|NCT01621789|Experimental|dye of lutein, zeaxanthin, trypan blue|during the surgery will be evaluated if the dye is suitable for dyeing anterior lens capsule
3276437|NCT01621815|Active Comparator|Anxiety and Depression|Adolescents diagnosed with anxiety and/or depression
3276438|NCT01621815|Active Comparator|ADD|Adolescents diagnosed with ADD (without hyperactive element)
3276439|NCT01621815|Active Comparator|ADHD, Behavioral|Adolescents diagnosed with ADHD (with hyperactivity), with or without behavioral problems
3276440|NCT01621815|Active Comparator|PDD|Adolescents diagnosed with PDD Spectrum Disorders
3276441|NCT01621815|Active Comparator|Control|Adolescents without a psychiatric diagnosis
3276442|NCT01621828|Other|video|video showing a patient's pathway into the operating room.
3276443|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
3276444|NCT01621841||Glaucoma subjects|
3276445|NCT01621841||heathly subjects|
3276446|NCT01621854|Experimental|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
3276447|NCT01621867|Active Comparator|pGM169/GL67A (CFTR Gene/Lipid Vector)|
3276448|NCT01621867|Placebo Comparator|Placebo|
3276449|NCT01621893||BML of the Knee|Subject has single bone marrow lesion of tibia, single BML of femur, or adjoining BML's of tibia & femur on which a Subchondroplasty procedure is performed
3276450|NCT01621906|Experimental|Cohort 1|Cohort 1 will include the first ten patients treated with WBRT concomitantly with sorafenib (on a separate phase I trial). We will perform a pilot study of serial FLT-PET imaging of the brain at baseline (< 4 weeks prior to initiation of WBRT), up to 7-10 days post-WBRT and 10-12 weeks after WBRT in patients with metastatic breast cancer to the brain (N=20) treated with WBRT with or without sorafenib.
3276451|NCT01621906|Experimental|Cohort 2|Cohort 2 will include patients treated with standard WBRT alone. Patients in both these cohorts will also be assessed with standard non-invasive MRI in addition to [18F] FLT PET at baseline (< 4 weeks of WBRT) and 10-12 weeks after completion of WBRT.
3276452|NCT01621932|Active Comparator|Surgical approach 1|Direct anterior surgical approach with capsulectomy
3276453|NCT01621932|Active Comparator|Surgical approach 2|Direct anterior approach without capsulectomy
3276454|NCT01621945||Bras A|children, born between the 06/04/2004 and the 17/04/2008, living around Neufchatel en Bray, before the fourth dose of MenBVac
3276455|NCT01621958|Experimental|Motor training|
3276456|NCT01621958|Placebo Comparator|Intensity control|
3276457|NCT01621971|Experimental|milrinone inhalation|inhaled milirinone and IV placebo (0.9% normal saline 0.05 ml/kg) are administered in Group IH.
3276458|NCT01621971|Active Comparator|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an IV bolus of milrinone (50 μg/kg) are administered in Group IV
3276459|NCT01621984|Experimental|Therapeutic Riding/ Hippotherapy|12 week Therapeutic Riding program that focused on gross motor function, gross motor performance, balance, spasticity, posture and quality of life
3276460|NCT01621984|No Intervention|without Therapeutic Riding/ Hippotherapy|
3276461|NCT01621997|Experimental|operation inspection|During retraining the patients performed bag exchange under the supervision of a nurse. The nurse ensured that each error listed in the NAC form should be avoided, thus immediately corrected any wrong steps if only.
3276462|NCT01621997|Experimental|verbal education|"Patients in the oral education group also underwent retraining every 2 months. A nurse would address all items in the NAC form one by one, to remind the patient of the key points of bag exchange. Scores calculated by the sum of error items during the bag exchange for patients in technique inspection group, or by the sum of yes in the interactive quiz for patients in verbal education group."
3276463|NCT01621997|Experimental|usual care|Patients in the usual care group did not receive any retraining
3276464|NCT01622023|Experimental|Study group|intrauterine insemination after 24 hours
3276465|NCT01622023|Active Comparator|Control group|intrauterine insemination after 48 hours
3276466|NCT01622036||Cancer patients undergoing first medical oncology visit.|
3276467|NCT01622049||TTTS treatment method|This is an observational trial. Patients who meet eligibility criteria and give written informed consent will have SLPCV. All subjects will receive ongoing standard-of-care prenatal care for the duration of their pregnancy from their referring perinatologist or obstetrician.
3276468|NCT01622062|Experimental|Group 1|"Patients with WHO Category II exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3276469|NCT01622062|Experimental|Group 2|"Patients with WHO Category III exposure receive PEP with PVRV using one-week, 4-site (4-4-4-0-0) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3276470|NCT01622062|Active Comparator|Group 3|"Patients with WHO Category III exposure receive PEP with PVRV using the updated 2-site TRC (2-2-2-0-2) ID vaccination regimen and pERIG Favirab®, and a single-visit, 4-site booster vaccination with PVRV 5 years later"
3276471|NCT01622075|Experimental|SeQuent® Please|Paclitaxel Drug-eluting Coronary Artery Balloon Catheter
3276472|NCT01622075|Active Comparator|Taxus Liberte|Paclitaxel Drug-eluting Coronary Stent and Conveying System
3276473|NCT01622088|Experimental|Dexpramipexole|
3276474|NCT01622101|Experimental|zantrex|The test compound was administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules).
3276475|NCT01622101|Placebo Comparator|Control|The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or appearance.
3276476|NCT01622114|Experimental|Menstralean group|"Represents a program which is designed to induce weight loss by taking into account the physiology of each menstrual phase in terms of adjusting diet and physical activity to the body's cyclic changes in energy demands.~The diet will be adjusted to match one menstrual cycle in duration (approx. 1 month) and will be separated into three phases corresponding to three menstrual phases: menstruation (days 1-5), the follicular phase (days 6-14), and the luteal phase (days 15-28). All women in this group will start the program at day 1 in their cycle. The diet will be repeated six times for each woman, which equals six months."
3276477|NCT01622114|Active Comparator|Control Group:|"Represents a program where subjects engage in a similar diet and exercise program as the Menstralean Group, specifically based on the educational diet system Eat for Life. Importantly, the subjects in Control group will start the program at a random time in their menstrual cycles.~Eat for Life is a simple tool for controlling the energy content and nutritional composition of your diet. The method is based on a system of counters that ensure strict control of the diet whilst still allowing a great deal of freedom of choice. The subjects in the Control Group will also receive exactly the same attention and undergo the same visits and measurements as the Menstralean Group."
3276478|NCT01622127||incisional hernias|
3276479|NCT01622153|Placebo Comparator|Formocresol (control)|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Cotton pellets are saturated with conventional 1:5 dilution of Buckley's formocresol into the canal orifice for 5 minutes for complete hemostasis. IRM (Zinc Oxide Eugenol) cement will then be placed to seal the pulp chamber. A stainless steel crown will be cemented with Ketac Cement that was triturated for 10 seconds to complete the pulpotomy procedure and final restoration.
3276480|NCT01622153|Active Comparator|Laser|This will consist of patients who are ASA I or II status, 3-8 years old, males and females, and present with restorable primary molars with reversible pulpitis and free of clinical radiographic signs of pulp pathology. From these study participants, they will be randomly assigned to this or other group. Patients in this group will receive a pulpotomy. Then a GENTLEray 980 Soft Tissue diode laser (Power: 3.0W, Mode: PW, Fiber: 300µm, Ton: 100ms, Toff: 100ms, Timer: cont) will be used to vaporize the residual pulp tissue and complete hemostasis. IRM (Zinc Oxide Eugenol) cement is then placed to seal the pulp chamber. A stainless steel crown cemented with Ketac Cement for the full coverage final restoration completes the pulpotomy procedure.
3276481|NCT01622166|Experimental|art therapy|12 sessions of art therapy / 6 weeks
3276482|NCT01622166|No Intervention|TAU|treatment as usual / 6 weeks
3276483|NCT01622179|Experimental|Indirectly|The epitenon was repaired and sewed indirectly.
3276484|NCT01622179|Placebo Comparator|Directly|The epitenon was unrepaired and sewed directly.
3276485|NCT01622192|Experimental|Automated probe|
3276486|NCT01622205|Experimental|Active|Early supported discharge
3276487|NCT01622205|Other|Control|Ordinary rehabilitation
3276488|NCT01622218|Experimental|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers.
3276489|NCT01622218|No Intervention|Control|Assessment of child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect on the total consumption of analgesics and on the post- surgery inflammatory markers.
3276490|NCT01622244|Experimental|Intervention arm|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
3276491|NCT01622244|Active Comparator|Counseling and Resource Education (CARE)|Participants will receive care as usual in the community. In addition, participants in this arm will receive an educational session and resource guide outlining available community-based services
3276492|NCT01622283|Experimental|Levocetirizine oral solution 5 mg|Levocetirizine oral solution 5 mg
3276493|NCT01622283|Active Comparator|Cetirizine dry syrup 10 mg|Cetirizine dry syrup 10 mg
3276494|NCT01622309|Active Comparator|eggplant meal|13 g meal of eggplant/day
3276495|NCT01622309|Placebo Comparator|cassava meal|13 g of placebo/day
3276496|NCT01622322|Experimental|Nitrous oxide|Subjects will receive General anesthesia with Nitrous Oxide.
3276497|NCT01622322|Placebo Comparator|Oxygen|Subjects will receive General anesthesia with oxygen.
3276498|NCT01622335|Placebo Comparator|General anesthesia with oxygen|General anesthesia and Air
3276499|NCT01622335|Experimental|nitrous oxide and general anesthesia|General anesthesia with Nitrous Oxide
3276500|NCT01622361|Active Comparator|Chemotherapy Group|Chemotherapy Adriamycin+Cyclophosphamide>Docetaxel
3276501|NCT01622361|Experimental|Endocrine therapy group|Endocrine therapy(GnRHa with Tamoxifen) group
3276502|NCT01622374|Active Comparator|Silence|the subjects received 10 minutes of silence through headphone
3276503|NCT01622374|Experimental|Music for the mind|
3276504|NCT01622374|Experimental|Mozart music|
3276505|NCT01622374|Experimental|Iranian traditional music|
3276506|NCT01622387|Experimental|Radial artery|Use of the radial artery as a conduit in CABG surgery
3276507|NCT01622387|Active Comparator|Long saphenous vein|Use of long saphenous vein as a conduit in CABG surgery
3276508|NCT01622400|Experimental|Therapeutic education HTA Vasc|125 subjects who participate in the therapeutic education program
3276509|NCT01622400|No Intervention|Control group|125 subjects who don't participate in the therapeutic education program
3276510|NCT01622413|Experimental|Endscopy|
3276511|NCT01622413|Active Comparator|Microsurgery|
3276512|NCT01622426|Active Comparator|New formula IgE mediated testing|Children with IgE-mediated CMA performed oral food challenge with the new formula
3276513|NCT01622426|Active Comparator|New formula non-IgE-mediated testing|Children with non-IgE-mediated CMA performed oral food challenge with the new formula
3276514|NCT01622439|Experimental|Single, open labeld.|
3276515|NCT01622465|Experimental|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises.
3276516|NCT01622465|Active Comparator|Conventional exercises|Patients will participate only of the conventional exercises program.
3276517|NCT01622478||Clinically node-positive patients before NAC|"Patients with clinically positive lymph node receiving neoadjuvant chemotherapy~Clinically negative-node after NAC~Clinically positive-node after NAC"
3276518|NCT01622491||Case control|A case-control study with cases (individuals hospitalized with influenza or pneumonia during the second wave of the pandemic) and controls (non-hospitalized individuals) identified using the MH Hospital Separation Abstract Database and the MH Population Registry, respectively. Information on receipt of vaccines will be obtained by record linkage to the MIMS.
3276519|NCT01622504|Experimental|Test Product Dose 1|
3276520|NCT01622504|Experimental|Test Product Dose 2|
3276521|NCT01622504|Active Comparator|Comparator Product|
3276522|NCT01622530||Amputees|upper limb amputees
3276523|NCT01622530||Non-amputees|No longer recruiting non-amputees
3276524|NCT01622556|Experimental|Reduced Intensity Conditioning with UCB Transplant|
3276525|NCT01622608|Experimental|Kiosk Users|
3276526|NCT01622608|No Intervention|Non-Kiosk Users|
3276527|NCT01622621|Active Comparator|Randomized Sublobar Resection|Randomized by computer to receive a sublobar resection.
3276528|NCT01622621|Active Comparator|Randomized SBRT|Randomized by computer to receive Stereotactic Body Radiotherapy (SBRT).
3276529|NCT01622621|Active Comparator|Observation Sublobar Resection|Patient decides with doctor to undergo a sublobar resection.
3276530|NCT01622621|Active Comparator|Observation SBRT|Patient decides with doctor to undergo SBRT.
3276531|NCT01622634|Active Comparator|Higher Protein Diet (PRO)|
3276532|NCT01622634|Active Comparator|Higher Carbohydrate Diet (CARB)|
3276533|NCT01622634|Active Comparator|PRO & Interval Exercise (PRO+EX)|
3276534|NCT01622634|Active Comparator|CARB & Interval Exercise (CARB+EX)|
3276535|NCT01622647|Active Comparator|NCPAP Group|Group of patients that do receive NCPAP treatment
3276536|NCT01622647|No Intervention|No NCPAP|subjects will not receive NCPAP
3276537|NCT01622686|No Intervention|Traditional prescription drug labels|Routine drug labels provided by the participating pharmacies
3276538|NCT01622686|Experimental|Reformatted medication labels|Prescription drug container labels that follow a new format and also include illustrations
3276539|NCT01622712|Experimental|Unilateral inguinal hernia|A Nitinol containing large pore polypropylene mesh will be placed in patients with unilateral inguinal hernia.
3276540|NCT01622725|Experimental|Resorbable mesh|Long-term resorbable mesh implanted to treat primary and secondary ventral hernia.
3276541|NCT01622725|Active Comparator|Non-resorbable mesh|Non-resorbable synthetic mesh implanted to treat primary and secondary ventral hernia.
3276542|NCT01622764|Experimental|Molecular imaging with 89Zr-RO5323441|
3276543|NCT01622777|Experimental|Rosuvastatin|20 mg daily of oral rosuvastatin
3276544|NCT01622777|Placebo Comparator|Placebo|
3276545|NCT01622790|Experimental|Arm 1|33 subjects will receive a single dose of each of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 1followed by dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3276546|NCT01622790|Experimental|Arm 2|33 subjects will receive dolutegravir 50 mg plus EPZICOM (abacavir 600mg/lamivudine 300 mg) in Period 1 followed by a single dose of a tablet formulation of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg in Period 2. Approximately 6 of these subjects will return for a third period where they will receive a single dose of dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg after a high fat breakfast. There will be a screening visit within 30 days prior to first dose and a follow-up visit 7-14 days after the last dose.
3276547|NCT01622803|Active Comparator|parallel stent|parallel stent insertion group
3276548|NCT01622803|Active Comparator|Y-stent|Y-stent insertion group
3276549|NCT01622829|Experimental|group1|"Usual Physiotherapy, additional: Prescription for Activity with a structured fitness program and individual instructions to become more active in the daily living situation"
3276550|NCT01622829|Experimental|group 2|"usual Physiotherapy , additional: Prescription for Activity without instructions"
3276551|NCT01622829|No Intervention|group 3|control, usual physiotherapy
3276552|NCT01622842||Bioimpedance|8 females and 8 males BMI from 19 to 46 SBP from 119 to 182
3276553|NCT01622855|Experimental|PPRS video|Prevention of post sexual assault stress
3276554|NCT01622855|No Intervention|Standard care|Receipt of standard services
3276555|NCT01622881|Active Comparator|Nefopam|
3276556|NCT01622881|Placebo Comparator|Control|
3276557|NCT01622907||Pts Symptomatic Recurrent Persistent AF|Patients with Symptomatic Recurrent Persistent AF or Long standing AF,for > 1-year < 5 years duration
3276558|NCT01622920|Other|ultrasound enamel thickness measurements|Enamel thickness will be measured with ultrasound
3276559|NCT01622933|Experimental|Vaccine + IFN|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines. Approximately 30 days after the last vaccine subjects will receive IFN intravenously 5 days a week for 4 weeks.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and after the IFN treatment."
3377632|NCT04253626|Active Comparator|Oral iron|Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin < 9.
3276560|NCT01622933|Experimental|Vaccine only|"Subjects will receive the investigational vaccine, intradermally, every other week for a total of 3 vaccines.~Leukapheresis will be required to be performed for each subject to be able to produce the investigational vaccine and for research testing. Leukapheresis and biopsies will be performed before the first vaccine, after the 3rd vaccine, and again approximately 2 months after the last vaccine."
3276561|NCT01622946|Active Comparator|Placebo|The patients who receive placebo form the control group. The results can be compared with the results of the patients who did receive TXA
3276562|NCT01622946|Placebo Comparator|Tranexamic acid|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
3276563|NCT01622959|Active Comparator|acupuncture|"Inclusion criteria:~Traumatic and non traumatic acute pain with visual analog pain scale ( VAPS) > 40 (on a scale 0-100) Age ≥18 years Presigned consentement to participate in the study.~Exclusion criteria:~Temperature > 37.7° C, Anticoagulation medication use or the presence of a mechanical heart valve, Skin infections that would preclude certain acupuncture points being used, Refusal, inability to consent or communication difficulties, Acute major trauma, Any form of analgesia up to 60 minutes prior to study start, An initial pain score ≤ 40 on the pain scale (score range 0-100), Opiate contraindication, Pregnancy, Presentation to the ED > 4 times in the previous 3 months with the same condition."
3276564|NCT01622959|Sham Comparator|morphine|drug:5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%.
3276565|NCT01622972|Experimental|Group 1|Healthy volunteers in Group 1: To give sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2
3276566|NCT01622972|Experimental|Group 2|Healthy volunteers in group 2: To give 2x sachet's A and B made up to 2 litres with tap water on day 1.
3276567|NCT01622972|Experimental|Group 3|Patients with functional constipation and irritable bowel syndrome characterized by constipation: To give sachet's A and B made up to 1 litre with tap water once on day 1
3276568|NCT01622998|Active Comparator|Standard transdermal NRT group (UC)|10 week standard transdermal nicotine replacement therapy patch protocol
3276569|NCT01622998|Experimental|Titrated transdermal NRT group (EXP)|10 week titrated transdermal nicotine replacement therapy patch dose regimen based on smoking history with the option to increase dose, if withdrawal symptoms are unmanageable.
3276570|NCT01623011|Experimental|Arthroscopic Sub-acromial Decompression|Arthroscopic sub-acromial decompression surgery.
3276571|NCT01623011|Active Comparator|Shoulder Arthroscopy|Shoulder arthroscopy only.
3276572|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Active monitoring with specialist reassessment - non-operative control.
3276573|NCT01623024|Experimental|Vitamin D and Lifestyle counseling|
3276574|NCT01623024|Active Comparator|Lifestyle counseling|
3276575|NCT01623063|Experimental|Infertile|patients from our human reproduction center
3276576|NCT01623063|Active Comparator|Fertile|patients with comproved fertility
3276577|NCT01623076||Neuromyelitis Optica Spectrum Disorder|Patients diagnosed with NMOSD based on revised diagnostic criteria. Seronegative, anti-AQP4 seropositive and ant-MOG seropositive patients will be included
3276578|NCT01623076||Transverse Myelitis and Optic Neuritis|Patients who have had one demyelinating event, not diagnosed with multiple sclerosis and whom are considered at risk for NMO or NMOSD.
3276579|NCT01623076||Healthy Controls|patients without a history of CNS inflammation
3276580|NCT01623076||Neuromyelitis Optica|patients diagnosed with NMO
3276581|NCT01623089||severe asthma|
3276582|NCT01623102|Experimental|Arm I: bevacizumab plus chemotherapy|Patients in the experimental arm receive cisplatin and gemcitabine combination with Bevacizumab. GP chemotherapy (gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) plus bevacizumab (7.5 mg/kg IV on D1 of every 21-day cycle).
3276583|NCT01623102|Active Comparator|Arm II: chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy((gemcitabine 1250mg/m2 IV D1 and D8 plus cisplatin 75mg/m2 IV D1, every 21-day cycle) ) every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3276584|NCT01623128|Experimental|Breastfeeding video|Participants randomized to this arm view the intervention video - Injoy Videos Better Breastfeeding video.
3276585|NCT01623128|Placebo Comparator|Sham video|Participants randomized to this arm view the sham video Injoy Videos Your Healthy Pregnancy: Prenatal Nutrition and Exercise video.
3276586|NCT01623141||Patients with CRPS|18 patients with unilateral CPRS of the upper limb were included to the study
3276587|NCT01623141||Patients with limb pain of other origin|17 patients with unilateral upper limb pain of other origin served as control group
3276588|NCT01623141||Healthy subjects|18 healthy subjects were included to establish reference data for the pressure pain thresholds
3276589|NCT01623180|Experimental|BioFreedom™ Drug Coated Stent (DCS)|BA9 drug coated stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 mm and 4.0 mm.
3276590|NCT01623180|Active Comparator|Gazelle™ Bare Metal Coronary Stent (BMS)|GAZELLE™ bare metal stent implantation for improving coronary luminal diameter in patients with de novo lesions in native coronary arteries with a reference vessel diameter between 2.25 and 4.0 mm.
3276591|NCT01623193|Active Comparator|Control|Patients receive standard 4:1 cardioplegia for myocardial protection during cardiac surgery
3276592|NCT01623193|Experimental|Treatment|Patients receive all-blood cardiolpegia for myocardial protection during surgery
3276593|NCT01623206|Experimental|Desmopressin|Four dose levels and two dosing schedules with 3 patients in each group.
3276594|NCT01623219|Experimental|TeleMedicine Prolonged Exposure|Veterans will receive prolonged exposure therapy (PE)delivered via telemedicine instead of in person. For this study 9 weekly 90 minute sessions will be given over a period of up to 3 months. The first 2 sessions of each treatment will involve education, rational and treatment preparation. Sessions 3-9 will consist of recounting the traumatic event out loud and repeatedly. The purpose of this study is to determine if this treatment is effective when given through telehealth.
3276595|NCT01623232|Experimental|adjuvant plus 1 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 1 �g of HA antigen
3276596|NCT01623232|Experimental|adjuvant plus 3 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 3 �g of HA antigen
3276597|NCT01623232|Experimental|adjuvant plus 5 �g of HA antigen|MAS-1-adjuvant-formulated influenza vaccine, at three HA antigen dose levels containing 5 �g of HA antigen
3276598|NCT01623232|Active Comparator|licensed influenza vaccine|licensed, inactivated, standard dose influenza vaccine without adjuvant
3276599|NCT01623245||Hypertrophic Cardiomyopathy|In the population of Hypertrophic Cardiomyopathy patients, patients suffering from a cardiac amyloidosis
3276600|NCT01623258||Standard of Care|Standard histopathological evaluation using conventional paraffin embedding, sectioning and hematoxylin and eosin staining and microscopy without sentinel lymph node ultrastaging
3276601|NCT01623258||Research|SOC with sentinel lymph node analysis
3276602|NCT01623284|Experimental|PiB and FDG positron emission tomography (PET)|All subjects will receive PiB and FDG PET diagnosis on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
3276603|NCT01623297||Laparoscopic colon surgery|Patients over age 65 having laparoscopic colon resection for colonic adenocarcinoma
3276604|NCT01623297||Open colon surgery|Patients over age 65 having open colon resection for colonic adenocarcinoma
3276605|NCT01623336|Active Comparator|Pegasys ®|Patients will receive Pegasys ® (peginterferon alfa-2a 40kDa) at a dose of 180 micrograms, subcutaneously, once a week, associated with ribavirin at a dose 1000-1250 mg,daily. For genotype 1 treatment time is 48 to 72 weeks and for genotypes 2 and 3, 24 weeks.
3276606|NCT01623336|Experimental|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48, 180 micrograms a week, SC, for the same period as Pegasys ®.
3276607|NCT01623349|Experimental|Arm BKM|BKM120 and Olaparib
3276608|NCT01623349|Experimental|Arm BYL|BYL719 and Olaparib
3276609|NCT01623362|Experimental|Low-fluoride acidic dentifrice|
3276610|NCT01623362|No Intervention|Conventional dentifrice|1100µgF/g-pH7.0
3276611|NCT01623362|Experimental|neutral pH and low-fluoride dentifrice|550 ppm pH 7
3276612|NCT01623375|Experimental|s.c.|
3276613|NCT01623375|Experimental|i.v.|
3276614|NCT01623388||Phase I|
3276615|NCT01623401|Experimental|TR-701 FA|TR-701 FA 200 mg oral once daily
3276616|NCT01623414||Healthy schoolchildren|
3276617|NCT01623427|Experimental|Vacuum|the group of patients assigned to application of vacuum to the wound dressing
3276618|NCT01623427|Active Comparator|Control|The dressing for the umbilical port site will be the same as the experimental group, except for the application of vacuum. The control group will have no vacuum applied to the wound dressing.
3276619|NCT01623440||Placebo/Naltrexone and fMRI|A placebo or Naltrexone will be given before fMRI. All participants will undergo both procedures. Naltrexone/placebo are not used as an intervention.
3276620|NCT01623453||Low dose group|Group1. Low dose group
3276621|NCT01623453||High dose group|Group2. High dose group
3276622|NCT01623492||diagnosis of Eisenmenger Syndrome|subjects with diagnosis of Eisenmenger Syndrome
3276623|NCT01623505|Experimental|Champix|
3276624|NCT01623505|Experimental|Long & Combination patch treatment|
3276625|NCT01623505|Experimental|Standard patch treatment|
3276626|NCT01623518|Experimental|ChAdOx1-NP+M1|
3276627|NCT01623544||Symbicort|BFC patients new to ICS/LABA combination therapy
3276628|NCT01623544||Advair|FSC patients new to ICS/LABA combination therapy
3276629|NCT01623557|Active Comparator|Group 1: ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
3276630|NCT01623557|Active Comparator|Group 2: ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
3276631|NCT01623557|Active Comparator|Group 3: Unvaccinated Infectivity Controls|
3276632|NCT01623570|Experimental|Pergoveris: 150IU r-hFSH+ 75IU r-hLH|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Pergoveris arms can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women.
3276633|NCT01623570|Experimental|Menopur: hMG-HP (150IU)|This is a prospective randomized study using two in-label treatments for the patient disease: Pergoveris and Menopur. Menopur can be considered as experimental for the aim of the study, anyway it is standard routine practice for HH women
3276634|NCT01623583|Experimental|Enhanced Needle Phobia Intervention|Patients will receive enhanced needle phobia intervention comprising the standard intervention plus demonstration of Synera
3276635|NCT01623583|Active Comparator|Standard Needle Phobia Intervention|Patients will receive the standard intervention for needle phobia
3276636|NCT01623609|Experimental|A|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fasted conditions
3276637|NCT01623609|Experimental|B|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation under fed conditions
3276638|NCT01623609|Experimental|C|Naloxegol film-coated IR tablet 25 mg Phase III formulation under fasted conditions
3276639|NCT01623622|Experimental|HC-58 low dose|Low dose
3276640|NCT01623622|Experimental|HC-58 high dose|High dose
3276641|NCT01623622|Placebo Comparator|Placebo|
3276642|NCT01623635|Experimental|Case - adnexal|
3276643|NCT01623635|Placebo Comparator|placebo - adnexal|
3276644|NCT01623635|Experimental|case - uterine|
3276645|NCT01623635|Placebo Comparator|placebo - uterine|
3276646|NCT01623648|Experimental|Arm 1 Whey Breakfast|The arm 1 will be assigned to eating Whey protein in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein namely from whey at breakfast
3276647|NCT01623648|Active Comparator|Arm 2: No Whey Breakfast|The arm 2 will be assigned to intake other proteins (No Whey) in the breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 42 g protein from other sources at breakfast
3276648|NCT01623648|Placebo Comparator|Arm 3: Low Protein Breakfast|The arm 3 will be assigned to intake low protein and high carbohydrate breakfast (660 kcal), lunch (560 cal) and dinner (280 cal), with 22 g protein from other sources at breakfast
3276649|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0% (7 ml/kg)
3276650|NCT01623687|Active Comparator|Regenerex|
3276651|NCT01623687|Active Comparator|Lub cup|
3276652|NCT01623687|Active Comparator|SP II|
3276653|NCT01623687|Active Comparator|Corail|
3276654|NCT01623700||dual antiplatelet treatment 12 months after ACS event|
3276655|NCT01623700||dual antiplatelet treatment 6 months after ACS event|
3276656|NCT01623700||dual antiplatelet treatment 3 months after ACS event|
3276657|NCT01623713|Active Comparator|Risperidone|
3276658|NCT01623713|Experimental|iloperidone|
3276659|NCT01623726|Experimental|tDCS active|Active tDCS as foreseen in research protocol: daily sessions for 10 days with 2mA intensity stimulation during 20 minutes.
3276660|NCT01623726|Placebo Comparator|tDCS sham|Sham tDCS : as foreseen in research protocol: sham stimulation with initial stimulation followed by turning off the device during the same time of intervention as to guarantee blinding
3276661|NCT01623778||Add on ADV|Patients with inadequate response to interferon at 24 weeks received interferon add on ADV optimized therapy
3276662|NCT01623778||Switch to LDT|Patients with inadequate response to interferon at 24 weeks received switching to LDT therapy
3276663|NCT01623791||Group 1|Group 1: mild pre-eclamptic group Mild and severe pre-eclampsia were defined American College of Obstetrics and Gynecology criteria (ACOG practice bulletin no. 33: diagnosis and management of preeclampsia and eclampsia. January 2002.)
3276664|NCT01623791||Group 2|Group 2: severe pre-eclamptic group
3276665|NCT01623804|Active Comparator|Low intensity, pulsed ultrasound|
3276666|NCT01623804|Sham Comparator|Sham ultrasound|
3276667|NCT01623817|No Intervention|Vancomcyin, maintain dose|This arm is received only maintain dose of vancomycin (15mg/kg twice a day or 1g twice a day).
3276668|NCT01623817|Experimental|Vancomycin loading|This group is received loading dose 30mg/kg. Subsequent doses of vancomycin are considered standard of care.
3276669|NCT01623843|Active Comparator|Arthroscopic Lavage|Participants have three hip portals (antero-lateral, mid anterior, distal antero-lateral) with limited capsulotomy allowing for a complete assessment of the central and peripheral compartments. The participant has a diagnostic arthroscopy and lavage of the hip joint with three litres of normal saline. No osteochondroplasty or rim resection is completed in this group. No instruments are used to treat minor cartilage or labral damage. The labrum should only be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The labrum will be refixated only if the above criteria for labral instability is met.
3276670|NCT01623843|Experimental|Arthroscopic Osteochondroplasty|After establishing standard portals, an inter-portal capsulotomy will be completed to allow for complete evaluation of the central compartment of the hip. Significant and obvious labral tears and cartilage damage will be addressed. The labrum will be repaired if mechanically unstable once probed with visible displacement or chondrolabral separation. The acetabular rim will be evaluated and any evident Pincer lesion will be resected using an arthroscopic burr under fluoroscopic guidance. Following this resection, the labrum will be refixated only if the criteria for labral instability is met. Following this, a limited capsulotomy will be completed along the head-neck junction of the femoral neck to allow for visualization and treatment of the impingement lesion in the peripheral compartment. For the FIRST-EPIC sub-study, participants will receive the osteochondroplasty intervention as per standard of care.
3276671|NCT01623856||Observational|DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.
3276672|NCT01623908|Experimental|Zoledronate|
3276673|NCT01623921|Other|control|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3276674|NCT01623921|Active Comparator|Celecoxib|Group 2: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3276675|NCT01623921|Active Comparator|rosuvastatin|Group 3: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3276676|NCT01623921|Active Comparator|Combined therapy|Group 4: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
3276677|NCT01623934||Phase 1: Pregnant women|
3276678|NCT01623934||Phase 2: Mother-offspring dyad|
3276679|NCT01623947|Placebo Comparator|Placebo|
3276680|NCT01623947|Active Comparator|2.8 g Sustamine|
3276681|NCT01623947|Active Comparator|19.6 g Sustamine|
3276682|NCT01623973|Experimental|With restraint|The group with restraint underwent specific training of paretic upper limb and use of restraint.
3276683|NCT01623973|Active Comparator|no restraint|"The group control without restraint submitted only to the specific training of paretic upper limb"
3276684|NCT01623986||St. Michael's Hospital Patients|Patients who are referred to the St. Michael's Hospital echocardiography (ECHO) lab.
3276685|NCT01624012|Active Comparator|NIV NAVA|Noninvasive ventilation in this group is practiced with NIV NAVA
3276686|NCT01624012|Active Comparator|ncpap|Patients randomized to this arm will receive noninvasive ventilation with continuous nasal CPAP as routinely in neonatal intensive care unit.
3276687|NCT01624025|Experimental|HER2 positive|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)
3276688|NCT01624025|Active Comparator|HER2 negative|"Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.~(Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks)"
3276689|NCT01624038|Active Comparator|Hydroxyurea,blood transfusion|Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
3276690|NCT01624038|Experimental|Hydroxyurea, Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued. White cell count and platelet count were determined on a monthly basis. Side effects such as nausea, vomiting, diarrhea, rashes, and malaise, experienced during the first 6 h after taking the HU will be considered as clinical toxicity.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
3276691|NCT01624051|Active Comparator|Body Surface Area Dosing|Standard dosing arm based on body surface area
3276692|NCT01624051|Experimental|Lean Body Mass Dosing|Experimental dosing arm based on individual lean body mass
3276693|NCT01624064|Active Comparator|Enalapril, Proteinuria < 1g/day|
3276694|NCT01624064|Placebo Comparator|Calcium, Proteinuria < 1g/day|
3276695|NCT01624064|Active Comparator|Enalapril, Proteinuria > 1g/day|
3276696|NCT01624064|Placebo Comparator|Calcium, Proteinuria > 1g/day|
3276697|NCT01624077|Experimental|Regulatory T cells|Naïve CD4+ T cells isolated from peripheral blood mononuclear cells were stimulated with GMP anti-CD3/CD28 coated beads in the presence of IL-2 ,TGF-β.
3276698|NCT01624103|Experimental|Elderly (32 mL LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 32 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
3276699|NCT01624103|Experimental|Elderly (20 ml LA volume)|Population over age of 65 undergoing upper limb surgery using US-SCB receiving 20 ml of LA (50:50 mixture of 0.5% levobupivacaine and 2% lidocaine).
3276700|NCT01624116|Active Comparator|Diet and lifestyle measures alone.|Type 2 diabetic subjects on lifestyle counselling as part of diabetes treatment would continue as such during Ramadan. They would receive acarbose on one day to be followed by CGMS for a 24 hour period
3276701|NCT01624116|Active Comparator|Metformin monotherapy|Type 2 diabetics on biguanide treatment.
3276702|NCT01624116|Active Comparator|Metformin + Sulphonylurea.|Type 2 diabetics on dual oral hypoglycaemics-metformin and glimepiride.
3276703|NCT01624116|Active Comparator|Metformin + Sitagliptin|Type 2 diabetics managed on dual oral hypoglycaemic therapies: metformin and sitagliptin.
3276704|NCT01624129||eosinophilic esophagitis|patients with histopathological defined eosinophilic esophagitis
3276705|NCT01624155|Experimental|Women taking teratogens|Women taking teratogens
3276706|NCT01624207|Experimental|Atorva|generic formulation (Atorva®) of atorvastatin 20mg once daily
3276707|NCT01624207|Active Comparator|Lipitor|branded formulation (Lipitor®) of atorvastatin 20mg once daily
3276708|NCT01624220|Experimental|Hypofractionated Radiation|"All patients receive CT-guided spinal SBRT using IMRT to maximize conformality of treatment plan to target volume, while sparing normal structures. Dose given to tumor and number of treatments received determined by patient's doctor.~In second stage, characterize tolerance of esophagus to hypofractionated radiation doses through prospective constraint relaxation and toxicity monitoring. Data collected from Group 1 in first stage will give data on dose delivered to esophagus. Second stage of protocol will begin accrual once Group 1 has filled. Dose constraints used for Groups 3 allow higher dose. Dose constraints for Group 4 represent modest increase of esophageal dose maximums."
3276709|NCT01624220|Experimental|ExacTrac Positioning System|Analysis performed of ExacTrac positioning system with and without fiducial guidance. Four dimensional CT datasets for simulation will allow use of data from this portion of protocol to characterize degree to which organ at risk (OAR) motion is relevant at each spinal level. 20 patients accrued in two groups of 10, with 10 patients in each rostral-caudal position in the spine (Group 1: T4-T12, Group 2: L1-L5). Imaging done with fiducial markers for this study will not impact patient management. Patients will treated with standard dose constraints to normal tissues.
3276710|NCT01624246|Experimental|Ceftaroline fosamil/Avibactam|
3276711|NCT01624272|No Intervention|Control|Usual care
3276712|NCT01624272|Experimental|Threshold Inspiratory Muscle Training|Inspiratory muscle training regime
3276713|NCT01624272|Experimental|Controlled breathing exercises|Yoga Pranayama breathing exercises
3276714|NCT01624285|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO BID.
3276715|NCT01624285|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID.
3276716|NCT01624298|No Intervention|Wait List Control Group|The wait list control group will be asked to wait for approximately 4 1/2 months before being reassessed and then, unless found to be ineffective or harmful, receive the intervention being provided by the counselor.
3276717|NCT01624298|Experimental|Intervention Group|Children randomized into the intervention group will immediately receive the Trauma Focused Cognitive Behavioral Therapy with a trained counselor for 12 weeks.
3276718|NCT01624311|Experimental|Adjunct Hypothermia Arm|Patients that receive adjunct therapeutic hypothermia in addition to standard of care therapy
3276719|NCT01624311|Other|Historic Controls|Patients that were treated with standard of care therapy for the same conditions at the sponsoring institution over the past 10 years.
3276720|NCT01624337|Experimental|DHA-piperaquine|DHA-piperaquine monthly 2 day treatment course
3276721|NCT01624337|Placebo Comparator|Placebo|Matching placebo control
3276722|NCT01624376|Active Comparator|DLX105|DLX105 local injection into the identified fistula(s)
3276723|NCT01624376|Placebo Comparator|Placebo Injection|
3276724|NCT01624389|Experimental|F18-AV45|
3276725|NCT01624402|Experimental|Ecosystem Focused Therapy (EFT)|Ecosystem Focused Therapy (EFT) follows a structured personalization approach based on the model of adaptive functioning, in which behavior is a function of the person's competence and the demands of the environment.
3276726|NCT01624402|Active Comparator|Education on Stroke and Depression (ESD)|Education on Stroke and Depression (ESD) is home-delivered and imparts education about depression, stroke, and the role of available treatments.
3276727|NCT01624428|Active Comparator|varenicline|
3276728|NCT01624428|Placebo Comparator|Placebo|
3276729|NCT01624441|Experimental|Treatment (dinaciclib and epirubicin hydrochloride)|Patients receive dinaciclib IV over 2 hours on day 1 and epirubicin hydrochloride IV over 30 minutes on day 2. Treatment repeats every 21 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3276730|NCT01624454|Active Comparator|large volume|bowel cleansing with PEG
3276731|NCT01624454|Active Comparator|Osmotic|
3276732|NCT01624493|Experimental|Phase II Arm A|Phase II Arm A will randomize patients to treatment regimen of carboplatin and gemcitabine without BNC105P
3276733|NCT01624493|Experimental|Phase II Arm B|Phase II Arm B will randomize patients to treatment regimen of carboplatin and gemcitabine and will include BNC105P
3276734|NCT01624519|Other|1|
3276735|NCT01624532|Experimental|GC1109|"Step1: GC1109 0.3 mL or 0.5 mL or 0.1mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
3276736|NCT01624532|Placebo Comparator|Placebo of GC1109|"Step1: Placebo of GC1109 0.5mL administered in Multi Intramuscular Doses (3 times) to Healthy Subjects~Step2: Placebo of GC1109 1.0 mL administered in Multi Intramuscular Doses (4 times) to Healthy Subjects"
3276737|NCT01624545|Active Comparator|1|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
3276738|NCT01624545|No Intervention|2|Patients in this study arm will undergo neurological evaluation on day 2 and day 30 without follow-up CT scan.
3276739|NCT01624558|Experimental|Treatment (filter in circuit)|After baseline use of volatile anesthetic, this group will have carbon filter placed in-line.
3276740|NCT01624558|No Intervention|No Intervention Control|After baseline use of volatile anesthetic, this group will NOT have carbon filter placed in-line.
3276741|NCT01624571|Experimental|Group 1|300mg/day
3276742|NCT01624571|Experimental|Group 2|600mg/day
3276743|NCT01624571|Experimental|Group 3|900mg/day
3276744|NCT01624571|Placebo Comparator|Placebo|Control Group
3276745|NCT01624584|Experimental|Experimental treatment|6 sessions of anxiety treatment
3276746|NCT01624584|Active Comparator|Traditional Treatment|Six sessions of anxiety treatment
3276747|NCT01624597|No Intervention|Usual Care|Participants will have a passive in-vehicle video device installed in their car to measure driving errors and safety behaviors.
3276748|NCT01624597|Experimental|In-vehicle video feedback|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors.
3276749|NCT01624597|Experimental|In-vehicle video feedback, parent communication|Participants will receive feedback from an in-vehicle video system. A light on the system will blink when a driving event has been recorded. Parents will receive a weekly report card of driving errors. Parents will participate in an intervention that provides input on teaching and communicating about driving skills and safety behaviors.
3276750|NCT01624610|Active Comparator|Diet 1|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 1 can be used to control their IBS symptoms.
3276751|NCT01624610|Active Comparator|Diet 2|Patients randomized to this arm will receive both written and face-to-face advice about how the components of Diet 2 can be used to control their IBS symptoms.
3276752|NCT01624636|Placebo Comparator|Placebo|
3276753|NCT01624636|Experimental|LFG316: 10 mg/kg (2 doses in cohort 1)|
3276754|NCT01624636|Experimental|LFG316: 20 mg/kg (2 doses in cohort 1, 3 doses in cohort 2).|
3276755|NCT01624649||Patients with ADHD|Patients will receive methylphenidate hydrochloride or atomoxetine. The methylphenidate hydrochloride is available in three forms. 1) Immediate release 2) Extended release 3) Osmotic release oral system
3276756|NCT01624675|Experimental|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
3276757|NCT01624675|Placebo Comparator|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
3276758|NCT01624701|Experimental|Expanded|'Ex vivo expanded cord blood cells
3276759|NCT01624714|Experimental|Alemtuzumab Naive|Alemtuzumab Subjects (30) with prior treatment refractoriness and treatment experience EDSS 3.0-7.0 inclusive, without contraindications to alemtuzumab
3276760|NCT01624714|Experimental|Alemtuzumab Experienced|Subjects with treatment refractory MS and prior alemtuzumab therapy (30)
3276761|NCT01624727|No Intervention|Usual care|Those randomized to usual care will continue to follow the care provided by their cardiologist. They will have all the follow-up phone calls, visits and testing which the intervention group has.
3276762|NCT01624727|Active Comparator|Lovaza (Omega 3 ethyl esters)|
3276763|NCT01624753|Experimental|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
3276764|NCT01624766|Experimental|Arm I (everolimus, anakinra)|Participants receive everolimus PO daily and anakinra SC daily on days 1-28. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
3276765|NCT01624766|Experimental|Arm II (everolimus, denosumab)|Participants receive everolimus PO daily on days 1-28 and denosumab SC on day 1. Treatment repeats every 28 days in absence of disease progression or unacceptable toxicity.
3276766|NCT01624792|Experimental|Healthy older adults|Healthy controls will receive each intervention (olive oil or fish oil with 3.5 g EPA+DHA) one time and for only one day per intervention .
3276767|NCT01624792|Experimental|COPD patients|COPD patients will receive one out of three possible interventions (olive oil or fish oil with 3.5 g EPA+DHA or fish oil and placebo with 2 g EPA+DHA) for 4 (+/- 7 days) weeks.
3276768|NCT01624805|Experimental|Treatment (methylprednisolone, hATG, cyclosporine, G-CSF)|Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
3276769|NCT01624818|Experimental|Group 2, 6-7 years|18 children (6-7 years) with heart disease participating in a rehabilitation programme in Geilomo childrens hospital
3276770|NCT01624818|Experimental|Group 1, 11-12 years|18 children(11-12 years) with heart disease participating in a rehabilitation programme at Geilomo childrens hospital.
3276771|NCT01624831||Individuals with Longstanding Psychosis|Individuals with symptoms of psychosis that have been present for 5 or more years
3276772|NCT01624844|Experimental|Calculation of dural sac volume|
3276773|NCT01624857|Placebo Comparator|control group|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
3276774|NCT01624857|Active Comparator|statin group|Rosuvastatin 20mg/d for at least 5 days before the CABG surgery, then continue to take for a month
3276775|NCT01624935|Experimental|psychotherapy|psychotherapy
3276776|NCT01624935|Other|treatment as usual|TAU control
3276777|NCT01624961|Experimental|50 PfSPZ IV|PfSPZ Challenge
3276778|NCT01624961|Experimental|200 PfSPZ IV|PfSPZ Challenge
3276779|NCT01624961|Experimental|800 PfSPZ IV|PfSPZ Challenge
3276780|NCT01624961|Experimental|3200 PfSPZ IV|PfSPZ Challenge
3276781|NCT01624961|Experimental|2500 PfSPZ ID|PfSPZ Challenge
3276782|NCT01624987|Experimental|NET for Forensic Offender Rehabilitation|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)
3276783|NCT01625026|Active Comparator|Morbid Obesity OCA|Obeticholic acid 25 mg/day in three weeks
3276784|NCT01625026|Placebo Comparator|Morbid Obesity Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3276785|NCT01625026|Active Comparator|Gallstones OCA|Obeticholic acid 25 mg/day in three weeks
3276786|NCT01625026|Placebo Comparator|Gallstones Placebo|Obeticholic acid 25 mg/day matching placebo in three weeks
3276787|NCT01625039|Experimental|Intervention|Participated in weekly educational workshops
3276788|NCT01625039|Active Comparator|Control group|Received once off educational session and materials
3276789|NCT01625052|Experimental|Baska|
3276790|NCT01625065||pain patients|patients from a specific pain management department, patients with long duration of pain, mostly insufficiently treated pain
3276791|NCT01625065||pre-surgical patients|patients from a surgical outpatient department with current pain
3276792|NCT01625078|Experimental|Baska mask|
3276793|NCT01625117|No Intervention|Control Group|
3276794|NCT01625117|Experimental|A variant of Narrative exposure therapy|
3276795|NCT01625130|Active Comparator|broccoli sprout homogenate (BSH)|Two hundred grams of BSH is equivalent to approximately 111 grams fresh sprouts (about one 4 oz package). Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water.
3276796|NCT01625130|Placebo Comparator|alfalfa sprout homogenate|Two hundred grams of commercially available alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
3276797|NCT01625143||Observational|Archived bone marrow samples, collected at the time of diagnosis and relapse, are analyzed for gene expression and histone modifications by microarray, chromatin immunoprecipitation (ChIP) sequencing, and quantitative real-time polymerase chain reaction (qRT-PCR).
3276798|NCT01625156|Experimental|Treatment (tivantinib, temsirolimus)|Patients receive tivantinib PO BID and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22 (days 8, 15, 22, and 29 of course 1). Courses repeat every 28 days (35 days in course 1) in the absence of disease progression or unacceptable toxicity.
3276799|NCT01625195|Placebo Comparator|Omega-3 fatty acid supplement|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with eachthe breackfast and two capsules with dinner. The daily treatment will provide 1.4 g/d of DHA and 1.8 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain orange flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
3276800|NCT01625195|Active Comparator|Placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg capsules/d, two capsules with each of the main daily meals. The placebo will be composed of 50:50% corn/soybean oil as used in other randomized placebo-controlled trials.
3276801|NCT01625208|Experimental|Combined nerve block|Participants in this group will receive a supraclavicular brachial plexus block plus a median or ulnar nerve block.
3276802|NCT01625208|Active Comparator|Single nerve block|Participants in this group will receive a supraclavicular brachial plexus block only.
3276803|NCT01625234|Experimental|Phase I: X-396 (ensartinib)|Dose escalation starting at 25 mg, oral once or twice a day, 28-day cycle. Number of Cycles: until progression or unacceptable toxicity develops
3276804|NCT01625234|Experimental|Phase II: X-396 (ensartinib)|RP2D 225mg stratified based on prior treatment and CNS activity
3276805|NCT01625247|Experimental|1 arm|Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc.
3276806|NCT01625247|Active Comparator|2 arm|Patients under LC. Allocation to sham drain,
3276807|NCT01625260|Experimental|Gemcitabine in combination with ALT-801|
3276808|NCT01625273|No Intervention|IF (Infant formula)|
3276809|NCT01625273|Experimental|IF with L. paracasei strain F19|
3276810|NCT01625299|Experimental|Gluten and Milk group|Subject on a gluten and dairy free diet will receive supplement of gluten and dry milk daily
3276811|NCT01625299|Placebo Comparator|Rice flour|Subjects will be on a gluten and dairy free diet and receive daily supplement of rice flour (placebo)
3276812|NCT01625312||CABG group|Three-vessel disease patients undergoing CABG at index hospitalization
3276813|NCT01625312||PCI group|Three-vessel disease patients undergoing PCI at index hospitalization.
3276814|NCT01625312||OMT group|Three-vessel disease patients undergoing no revascularization at index hospitalization
3276815|NCT01625325||extremely obese|BMI ≥35kg/m2
3276816|NCT01625325||obese|BMI 30-34.9kg/m2
3276817|NCT01625351|Experimental|Treatment|"Participants to undergo transplantation. They receive alemtuzumab, fludarabine, sirolimus, busulfan, melphalan, and stem cells.~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy.~Cells for infusion are prepared using the CliniMACS System."
3276818|NCT01625364|Experimental|Open Airways for Schools|OAS is a school-based non-academic asthma health education program for elementary students with asthma and their parents.
3276819|NCT01625364|Experimental|SHARP program|The Staying Health-Asthma Responsible & Prepared (SHARP) program is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregiver.
3276820|NCT01625390|Experimental|Arm 1|
3276821|NCT01625390|Active Comparator|Arm 2|
3276822|NCT01625390|Experimental|Arm 3|
3276823|NCT01625403|Experimental|rhBNP treated|standard of care with rhBNP
3276824|NCT01625403|Active Comparator|standard of care|standard of care
3276825|NCT01625429|Experimental|neoadjuvant|
3276826|NCT01625442|Active Comparator|Saffron|Saffron treatment group received saffron tablets daily for 45 days
3276827|NCT01625442|Active Comparator|Barberry|Barberry group received barberry tablets daily for 45 days
3276828|NCT01625442|Placebo Comparator|Placebo|Placebo group received placebo tablets daily for 45 days
3276829|NCT01625468|No Intervention|Control|Participant receives usual care
3276830|NCT01625468|Experimental|Intervention|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
3276831|NCT01625481|Experimental|Seal-V|A vascular sealant intended to achieve adjunctive hemostasis by mechanically sealing areas of potential leakage in surgical reconstruction of large blood vessels.
3276832|NCT01625494|Experimental|Irbesartan/Amlodipine 150/5 mg fixed combination|"1 tablet once daily in the morning for 4 weeks Patient will be first treated with irbesartan 150mg or amlodipine 5mg, 1 tablet /day for 4 weeks.~If OBPM is controlled on monotherapy at week 4 (SBP <140 mmHg and DBP<90 mmHg), patient will be withdrawn from the study"
3276833|NCT01625494|Experimental|Irbesartan/Amlodipine 150/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks
3276834|NCT01625494|Experimental|Irbesartan/Amlodipine 300/5 mg fixed combination|1 tablet once daily in the morning for 4 weeks
3276835|NCT01625494|Experimental|Irbesartan/Amlodipine 300/10 mg fixed combination|1 tablet once daily in the morning for 4 weeks. If OBPM is controlled at week 12, patients will continue on the same therapy until the end of the study
3276836|NCT01625520|Experimental|SOM230 alone or in combination with RAD001|Patients with progressive metastatic or postoperative persistent medullary thyroid cancer will start the study treatment as a mono therapy with SOM230. Patients benefiting from the treatment will continue with the monotherapy (stable disease or better according to RECIST). Patients progressing will be switched to the combination therapy with SOM230 and RAD001.
3276837|NCT01625533||SA group|Patients using SA for the diagnosis of coronary artery disease are assigned to the SA group.
3276838|NCT01625533||DARCA group|Patients using DARCA for the diagnosis of coronary artery disease are assigned to the DARCA group.
3276839|NCT01625546|Experimental|High intensity whole-body infrared heating|Subjects will be induced to levels of heat that increases core body temperature to approximately 37.5-38.5 °C using the Whole Body Hyperthermia system.
3276840|NCT01625546|Sham Comparator|Low intensity whole-body infrared heating|Subjects will be induced to levels of heat that causes only a minor increase in body temperature using Whole Body Hyperthermia system.
3276841|NCT01625559|Experimental|50,000 cells|Biological: MA09-hRPE Cellular therapy
3276842|NCT01625572|No Intervention|general anesthesia and epidural catheter (control)|"General anaesthesia~total intravenous anaesthesia with propofol 5-10 mg / kg / h,~remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~use of a bispectral index~monitoring with a target range of 40-60~at the end of the anaesthesia all patients get 0.1 mg / kg morphine intravenously epidural catheter~plant of the epidural catheter under sterile conditions at the intervertebral space of the vertebral body 8-10 of the thoracic spine• local anaesthesia with lidocaine 1%~puncture with a Tuohy 18 G- needle, Lost of resistance technique~after a negative test dose with bupivacaine 0,5% isobar we inject fractional ropivacaine 10 ml 0,2%, after that continuous administration of ropivacaine 0,2% via patient-controlled-analgesia-device with a sweep rate of 6 ml/h, all Patients also receive an intravenous morphine-patient-controlled-analgesia-device"
3276843|NCT01625572|Experimental|general anesthesia and regional anesthesia|"General anesthesia~anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~Bispektralindex monitoring with a target range of 40-60~at the end of the anesthesia all patients get 0.1 mg / kg morphine intravenously Transversus abdominis plane blockade~ultrasound visible needles, a special pin detection software~under visual control the needle moves into the space between Musculus obliquus internus and M. transversus abdominis~Under sonographic control we inject a local anesthetic depot (30 ml of ropivacaine 0.375%)~puncture is performed under constant protective nerve stimulation with a current of 1 mA, pulse duration 0.1 ms, frequency 2 Hz All Patients receive an i.v. Morphine-patient-controlled-analgesia-device"
3276844|NCT01625572|Experimental|general anaesthesia and intravenous pain therapy|"General anaesthesia~total intravenous anesthesia with propofol 5-10 mg / kg / h, remifentanil 0.1 to 0.3 micrograms / kg / min and muscle relaxation with cis-atracurium~we use a of BIS monitoring with a target range of 40-60~at the end of the aneasthesia all patients get 0.1 mg / kg morphine intravenously intravenous pain therapy with~Morphine-patient-controlled-analgesia-device"
3276845|NCT01625585||Consecutive patients undergoing SBE for OGIB|
3276846|NCT01625598||People with diabetes|People with diabetes who are referred to an ophthalmologist for a dilated eye examination
3276848|NCT01625624|Placebo Comparator|Control Food Product|
3276849|NCT01625624|Experimental|Experimental Food Product|
3276850|NCT01625637|Experimental|AAT-avoid cigarette condition|Adolescent smokers are trained to avoid tobacco in a training AAT
3276851|NCT01625637|Placebo Comparator|AAT-no contingency continued assessment|
3276852|NCT01625650||Rheumatology|Patients who present at enrolling sites across the US are invited to enroll if eligible.
3276853|NCT01625663||Barth syndrome|Children (8-17 yrs) and adults (18-35 yrs)
3276854|NCT01625663||Controls|Children (8-15 yrs) and adults (18-35 yrs)
3276855|NCT01625676|Experimental|CIAT-Group|Patients received a modified constraint-induced therapy schedule
3276856|NCT01625676|Active Comparator|standard treatment group|patients received a standard aphasia therapy
3276857|NCT01625702|Experimental|cisplatin plus capecitabine|gastric cancer patients treated with capecitabine/cisplatin
3276858|NCT01625702|Experimental|capecitabine plus paclitaxel|gastric cancer patients treated with capecitabine/paclitaxel
3276859|NCT01625715|No Intervention|Case control|Routine therapy during peanut desensitization
3276860|NCT01625715|Experimental|ketotifen|rising doses of ketotifen
3276861|NCT01625728||Experimental group.|Participants are either student teachers or practicing teachers.
3276862|NCT01625728||Control Group.|Participants are no students teachers or practicing teachers.
3276863|NCT01625741|Experimental|rituximab|4 monthly administrations of rituximab
3276864|NCT01625754||Cardiac rehabilitation|This study recruits individuals that are currently participating in a cardiac rehabilitation exercise program.
3276865|NCT01625767|Experimental|Approach Avoidance Task experiment|Approach Avoidance Task experiment
3276866|NCT01625780|Experimental|Study group: 3-layer block|Patients in this group will receive the 3-layer ilioinguinal nerve block.
3276867|NCT01625780|Active Comparator|Control: single-shot block|Patients in this group will receive a standard, single-shot ilioinguinal nerve block.
3276868|NCT01625793|Active Comparator|HCV Interferon-alpha group|Subjects receiving treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection.
3276869|NCT01625793|Placebo Comparator|HCV Control Group|Subjects delaying the start of treatment with interferon (IFN)-alpha for chronic hepatitis C virus infection by 7 weeks.
3276870|NCT01625806|Active Comparator|RO4602522|
3276871|NCT01625806|Experimental|RO4602522 + ketoconazole|
3276872|NCT01625819|Experimental|Tai Chi|32 1-hour group sessions of Tai Chi instruction
3276873|NCT01625819|Active Comparator|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
3276874|NCT01625819|Placebo Comparator|Health Education|32 1-hour bi-weekly group sessions of health education
3276875|NCT01625819|No Intervention|Care as Usual|Receive usual cardiology care for 4 months between pre- and post-treatment testing
3276876|NCT01625832|Experimental|1|CSO first
3276877|NCT01625832|Experimental|2|CSO second
3276878|NCT01625858||Supreme / other pediatric SGA|pediatric patients undergoing general anesthesia being treated with LMA Supreme or another pediatric supraglottic airway device
3276879|NCT01625871|Experimental|artemether-lumefantrine|tablets (containing 20mg artemether and 120 mg lumefantrine) for three days
3276880|NCT01625949|Active Comparator|Control Arm (Standard Therapy)|Control Arm Receiving The Standard Therapy including successful coronary intervention and stenting
3276881|NCT01625949|Experimental|Intracoronary stem cells|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting
3276882|NCT01625962||mTBI|"Service members who have sustained impact-induced mTBI or blast-induced mTBI (n = 74 completers)"
3276883|NCT01625962||ECI|Service members who have sustained an extracranial injury (ECI) with no evidence of TBI (n = 32 completers)
3276884|NCT01625975||Growth modulation with Eight plate|Pediatric patients undergoing growth modulation with the Eight plate system
3276885|NCT01626001|Experimental|Cohort 1|Cohort of 18 subjects evaluated. Subject will receive 4DCT cine acquisition gated using a respiratory signal from real-time position management (RPM) gating system. Maximum number of allowable images that may be acquired increased from 3000 to 5999 images. Total imaging time for each subject < 60 minutes.
3276886|NCT01626001|Experimental|Cohort 2|Reproducibility of optimal 4DCT acquisition method determined from cohort 1 tested with cohort of 18 study subjects. Three 4DCT images acquired, all with acquisition method determined from cohort 1. Cohort also receives two spiral-mode 4DCT acquisitions.
3276887|NCT01626014|Experimental|Intervention Group|Using the Prototype System website: An interactive educational system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
3276888|NCT01626014|Active Comparator|Control Group|Using the Usual Care Educational Website : a website which will contain information regarding ovarian cancer however it will not be interactive. It will contain pdf documents of the material handed out in clinic (usual care).
3276889|NCT01626040||PEG-P prep|Children taking the one day polyethylene glycol powder preparation for outpatient colonoscopy
3276890|NCT01626053|No Intervention|control group|
3276891|NCT01626053|Experimental|lifestyle counseling|These participant received the ASMART interventions.
3276892|NCT01626066|Experimental|LUM015|Receive single dose of LUM015 through a vein in the arm the day prior to surgery
3276893|NCT01626131|Experimental|Exercise treatment|Aerobic and resistance training
3276894|NCT01626131|Experimental|Stretching treatment|
3276895|NCT01626144||Breast cancer, exemestane treatment|Breast cancer patients receiving standard of care exemestane
3276896|NCT01626170||Correlative (laboratory biomarker analysis)|Archived tissue samples of matched primary-relapsed and non-matched primary are analyzed for genomic DNA, DNA methylation profiles, RNA sequencing, differences between alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcoma (ERMS), gene expression profiles, target-of-rapamycin complex 1 (TORC1) and TORC2 pathway intermediates, and paired box 3 (PAX3)/forkhead box O1 (FOXO1) translocation by microarray, immunohistochemical staining, and fluorescence in situ hybridization (FISH).
3276897|NCT01626196||Colonoscopy patients|Patients undergoing with bowel cleansing procedures according to the clinics' usual routine
3276898|NCT01626209|Experimental|BKM120 at: 80 and 100mg/day dose levels|
3276899|NCT01626222|Experimental|Everolimus & Exemestane|This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
3276900|NCT01626235||NSAID only|Subjects have their pain treated post-ED care with NSAID medication alone
3276901|NCT01626235||Opioid only|Subjects have their pain treated post-ED care with opioid medication alone
3276902|NCT01626235||NSAID + Opioid|Subjects have their pain treated post-ED care with NSAID medication and opioid as PRN rescue analgesia
3276903|NCT01626248||Group A TX Naive|Patient decided to start disease modifying treatment, either interferon beta-1a, glatiramer acetate or natalizumab. If interested and consented they would be assigned to Group A. Patient would have blood specimens taken up to 5 times over the next 19 months: Day 0; Day 28; Day 84: Day 336 and Day 508.
3276904|NCT01626248||Group B TY 4-12 doses|Patient is currently prescribed and is taking natalizumab, has 4 to 12 doses. If interested patient could be consented and assigned to Group B. Patients will have their blood drawn Day 0; and around the time of the patient's 18th dose.
3276905|NCT01626248||Group C 18 plus TY|Patient currently or close to being at 18 doses or 18 plus doses of natalizumab. If interested patient consented and assigned to Group C. Patient will have their blood drawn once: Day 0.
3276906|NCT01626248||Group D Other DMT 18 plus|Patient is close to or currently at 18 doses or more of interferon beta-1a or glatiramer acetate. If interested patient consented and assigned to Group D. Patient will have their blood drawn once: Day 0.
3276907|NCT01626248||Group E - Non-MS|10 participants without Multiple Sclerosis or other immunological illness. If interested participants consented and assigned to Group E. Participants will have their blood drawn once: Day 0.
3276908|NCT01626261||cardiac pacemaker|
3276909|NCT01626274|Experimental|Device: in-ear sensor|Patients who routinely undergo a polysomnography night (1 night) are monitored via in-ear sensor which will be embedded in the auditory canal. During this night vital signs parameters are monitored, processed and subsequently compared to the polysomnography data.
3276910|NCT01626287|Experimental|Black tea bag|
3276911|NCT01626287|Active Comparator|ice packs|20 randomly chosen participants will be given frozen ice packs for perineal pain relief
3276912|NCT01626313|Active Comparator|Immediate intervention|Subjects are randomized to receive immediate intervention of the 8 session FOCUS IFRT
3276913|NCT01626313|Active Comparator|Waitlisted|Subjects are randomized to be waitlisted for 4 months, re-assessed and then receive intervention of the 8 session FOCUS IFRT
3276914|NCT01626326||Stop smoking app|Stop smoking iPhone research app provided at no charge via the iTunes store
3276915|NCT01626365|Active Comparator|non-thermosoftening|Double-lumen tube is put into a bottle of normal saline at room temperature (25°C) before intubation.
3276916|NCT01626365|Experimental|thermosoftening|Double-lumen tube is put into a bottle of warm normal saline (40°C) before intubation.
3276917|NCT01626378|Experimental|TRx0237 200 mg/day group|
3276918|NCT01626378|Placebo Comparator|Placebo|
3276919|NCT01626404||Patients enrolled|All patients enrolled in the study
3276920|NCT01626417|No Intervention|Patient Population|Chronic post-stroke subjects with varied impairment level, who have completed routine rehabilitative physical therapy.
3276921|NCT01626430|Experimental|200 mg gd-TRF|
3276922|NCT01626430|Experimental|400 mg gd-TRF|
3276923|NCT01626430|Experimental|Placebo|
3276924|NCT01626443|Active Comparator|Folic acid|
3276925|NCT01626443|Experimental|Inofolic Combi|
3276926|NCT01626469|Active Comparator|Arm A|Captopril 25 mg (Admission 1, Day 1, low salt diet) Matched Placebo (Admission 1, Day 2, low salt diet) Captopril 25 mg (Admission 2, Day 1, high salt diet) Matched Placebo (Admission 2, Day 2, high salt diet)
3276927|NCT01626469|Placebo Comparator|Captopril|Matched Placebo (Admission 1, Day 1, low salt diet) Captopril 25 mg (Admission 1, Day 2, low salt diet) Matched Placebo (Admission 2, Day 1, high salt diet) Captopril 25 mg (Admission 2, Day 2, high salt diet)
3276928|NCT01626482|Placebo Comparator|Sham tape|
3276929|NCT01626482|Experimental|Kinesio Tape|
3276930|NCT01626508||breast-milk bank|breast milk collected and processed by the breast-milk bank before being used
3276931|NCT01626508||breast milk|breast milk used without any treatment, directly by children
3276932|NCT01626521||COPD Exacerbation|Patients admitted to hospital with COPD exacerbation
3276933|NCT01626534|Active Comparator|clopidogrel group|
3276934|NCT01626534|Experimental|tricagrelor group|
3276935|NCT01626560|Other|Daptomicina|
3276936|NCT01626560|Other|Vancomycin|
3377633|NCT04252014|No Intervention|Non-Tobacco Messages|Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
3377634|NCT04252014|Experimental|Hookah Tobacco Messages|Participants in the hookah tobacco messaging group will receive hookah tobacco public education messages delivered online through 4 brief study communications. Messages will communicate about the risks of hookah tobacco use in the following theme areas: 1) Health Harms; 2) Addictiveness; 3) Social Use; 4) Flavorings. The order of message themes delivered in each study communication will be randomized.
3377635|NCT04248517|Experimental|mHealth intervention group|participants in the mHealth Group will download the app on to their smartphone and complete ecological momentary assessments on 3 consecutive weekdays every 2 weeks for 6 months.
3377636|NCT04248517|No Intervention|Treatment as Usual group|participants will undergo their routine treatment.
3377639|NCT04246086|Experimental|Mosunetuzumab + Lenalidomide (Non-randomized)|Participants will receive treatment with mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
3377640|NCT04246086|Experimental|Glofitamab + Lenalidomide (Non-randomized)|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
3276937|NCT01626573|Experimental|Itacitinib 400 mg twice a day|Itacitinib 400 mg twice a day
3276938|NCT01626573|Placebo Comparator|Itacitinib 400 mg placebo twice a day|Itacitinib 400 mg placebo twice a day
3377641|NCT04246086|Experimental|Glofitamab + Obinutuzumab + Lenalidomide (Non-randomized)|Participants will receive obinutuzumab pretreatment, followed by treatment with glofitamab plus lenalidomide and obinutuzumab for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
3377642|NCT04246086|Experimental|Arm A: IV Mosunetuzumab + Len (Randomized)|Participants will receive treatment with IV mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
3377643|NCT04246086|Experimental|Arm B: SC Mosunetuzumab + Len (Randomized)|Participants will receive treatment with SC mosunetuzumab plus lenalidomide for 12 cycles total (cycle length = 21 days for Cycle 1, 28 days from Cycle 2 onward)
3276939|NCT01626573|Experimental|Itacitinib 100 mg twice a day|This dose group will be studied twice during the study.
3276940|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo twice a day|This dose group will be studied twice during the study.
3276941|NCT01626573|Experimental|Itacitinib 100mg once a day|Itacitinib 100mg once a day
3377644|NCT04243512|Experimental|Time-restricted eating|Participants will be asked to follow a TRE meal pattern for 14 consecutive days. Participants will be encouraged to consume food and beverages only within a 10-h time window for the 14-day intervention, with the exception of water, which will be encouraged at any time.
3377645|NCT04235764||1/ Cohort 1|Bladder Cancer Patients
3377646|NCT04228575|Experimental|Extended Contact|Clients in the Extended Contact condition will be asked at the 6 week mark if they like they can extend their treatment and receive up to 12 weeks of support. They will be informed that this may be helpful if they feel they have fallen behind in reviewing of the materials, if they would like to receive support while they work on supplementary resources or if they would like extended support while they work on core lessons. If they would like additional support, participants will answer questions presented on the website about their desire for this additional support what they would like to focus on during this time. Those clients who indicate that they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks. Those that do not request the additional support will end treatment as planned at the end of 8 weeks.
3377647|NCT04228575|Experimental|8 Week ICBT no Booster|In the standard condition, clients will receive 8 weeks of therapist support. They will not be given the option to extend their treatment and support to 12 weeks. The booster course will not be offered in this condition.
3377648|NCT04228575|Experimental|Extended Contact with Booster|"Clients in the Extended Contact condition will receive an email at the 6 week mark letting them know that they if they like they can extend their treatment and receive up to 12 weeks of support. At week 6, clients will answer questions on the website about whether they would like this additional support or not and what they would like to focus on during this time. Clients who indicate they would like this extended support will automatically have their therapists check-in with them for up to 12 weeks.~They will also be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks."
3276942|NCT01626573|Placebo Comparator|Itacitinib 100 mg placebo once a day|Itacitinib 100 mg placebo once a day
3276943|NCT01626573|Experimental|Itacitinib 200 mg twice a day|Itacitinib 200 mg twice a day
3276944|NCT01626573|Placebo Comparator|Itacitinib 200 mg placebo twice a day|Itacitinib 200 mg placebo twice a day
3276945|NCT01626573|Experimental|Itacitinib 300 mg once a day|Itacitinib 300 mg once a day
3276946|NCT01626573|Placebo Comparator|Itacitinib 300 mg placebo once a day|Itacitinib 300 mg placebo once a day
3276947|NCT01626573|Experimental|Itacitinib 600 mg once a day|Itacitinib 600 mg once a day
3276948|NCT01626573|Placebo Comparator|Itacitinib 600 mg placebo once a day|Itacitinib 600 mg placebo once a day
3276949|NCT01626586|Experimental|Group Therapy|"This study includes having an initial assessment completed; participating in a 6 session group therapy intervention over a 7 week time period; and returning at 2 and 4 months after group therapy intervention for booster follow-up sessions. During the group intervention sessions, the parent group and the youth group will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
3276950|NCT01626586|Active Comparator|Individual Arm|"This study includes having an initial assessment completed; participating in a 6 session individual therapy intervention over a 7 week time period; and returning at 2 months after the individual therapy intervention for the booster follow-up session. During the individual intervention sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15 to 20 minutes."
3276951|NCT01626586|Active Comparator|Recently Diagnosed Arm|"This study includes enrolling patients with Type 1 Diabetes, who are recently diagnosed (<1 year) to participate in a 4 session group therapy intervention over a 4 week time period; and returning at 2 months after the last group session for the booster follow-up session. During the group sessions, the youth and the parents will each meet for about 45 minutes and then the families will come together to work on family goals for the last 15-20 minutes."
3276952|NCT01626599|Other|Assess product useability|All subjects participate in the same arm. This arm completes the primary objective of product usability.
3276953|NCT01626612|Experimental|a strategy based on de-escalation|
3276954|NCT01626612|Active Comparator|a conservative strategy|
3276955|NCT01626625|Experimental|stem cells|stem cells + hydroxy apatite
3276956|NCT01626625|Active Comparator|autograft|
3276957|NCT01626638|Experimental|Experimental|
3276958|NCT01626651|Experimental|Ibrutinib and Ketoconazole|
3276959|NCT01626677|Experimental|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
3276960|NCT01626677|Active Comparator|Microfracture|conventional treatment method
3276961|NCT01626703|Experimental|intervention|remiding call
3276962|NCT01626703|No Intervention|Control|No intervention
3276963|NCT01626716|Experimental|case management|patients who assigned to the intervention group will take 7 times phone calls from case manager
3276964|NCT01626716|No Intervention|control|usual care
3276965|NCT01626729|Experimental|Traffic Light|
3276966|NCT01626729|Experimental|Traffic Light+|
3276967|NCT01626729|Experimental|Facts Up Front|
3276968|NCT01626729|Experimental|Facts Up Front+|
3276969|NCT01626729|Placebo Comparator|No front of package label|
3276970|NCT01626742|Placebo Comparator|Ready to drink flavored beverage|
3276971|NCT01626742|Experimental|Ready to drink flavored beverage w/ AN 777|
3276972|NCT01626755|Experimental|Nerve block|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: infusion of local anesthetic."
3276973|NCT01626755|Active Comparator|Control|"Optimized intravenous pain treatment during surgery and for 7 days postoperatively.~Definition: strong opioid patient-controlled analgesia, non-opioids, ketamine intravenously.~Sciatic nerve block: saline infusion."
3276974|NCT01626768||Enrolled patients|
3276975|NCT01626794|Experimental|VARIVAX™ VEP|
3276976|NCT01626794|Active Comparator|VARIVAX™ 2007 Process|
3276977|NCT01626807|Experimental|Walking school bus|
3276978|NCT01626807|No Intervention|Usual care|
3276979|NCT01626833|Active Comparator|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx®
3276980|NCT01626833|Placebo Comparator|Placebo|Placebo
3276981|NCT01626846||NF1 teenagers|
3276982|NCT01626898|Experimental|HOLA en Grupos|The Spanish language HOLA en Grupos intervention consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants.
3276983|NCT01626898|Active Comparator|General health intervention|The Spanish language comparison condition consists of four 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
3276984|NCT01626911|Experimental|CRAI|CRAI of LMWH in the celiac trunk
3276985|NCT01626911|Other|Conservative treatment|Conservative treatment without CRAI, control group
3276986|NCT01626924|Experimental|2-Iminobiotin|
3276987|NCT01626937|Experimental|Non invasive ventilation with conventional treatment|
3276988|NCT01626937|Active Comparator|conventional medical treatment|
3276989|NCT01626950||Cases - Stage III-IV breast cancer|The women in this group have been diagnosed with stage III-IV incident cancer.
3276990|NCT01626950||Controls: Stage I-II breast cancer|The women in this group have been diagnosed with stage I-II incident cancer.
3276991|NCT01626963|Experimental|SPA|Single-port access surgery
3276992|NCT01626963|Active Comparator|CL|Conventional Laparoscopic access
3276993|NCT01626976|Experimental|Cohort 1|
3276994|NCT01626976|Experimental|Cohort 2|
3276995|NCT01626976|Experimental|Cohort 3|
3276996|NCT01626976|Experimental|Cohort 4|
3276997|NCT01626976|Experimental|Cohort 5|
3276998|NCT01627015|Experimental|Modified infant follow-on formula|Infants are fed a modified infant follow-on formula (modified carbohydrate composition) for 4 weeks, according to protocol
3276999|NCT01627015|Active Comparator|Standard infant follow-on formula|Infants are fed a commercial follow-on formula for 4 weeks, according to protocol
3277000|NCT01627041|Experimental|Arm I (daunorubicin hydrochloride, cytarabine)|Patients receive induction chemotherapy comprising daunorubicin hydrochloride IV daily on days 1-3 and cytarabine IV continuously on days 1-7 in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
3277001|NCT01627041|Experimental|Arm II (decitabine, daunorubicin hydrochloride, cytarabine)|Patients receive decitabine IV over 1 hour on days -5 to -1. Patients then receive induction chemotherapy as in arm I in the absence of disease progression or unacceptable toxicity. Patients who do not achieve a CR after the first induction-chemotherapy course receive a second identical induction course.
3277002|NCT01627054|Experimental|AT7519M|
3277003|NCT01627080||Cardiac Biomarkers|Patients with histologically proven esophageal cancer to be treated with radiation therapy with concurrent chemotherapy to a final dose of >/=40 Gy included in this study at UT MD Anderson Cancer Center in Houston, Texas.
3277004|NCT01627093||Observational (questionnaire, medical chart review)|Patients complete questionnaires over 30 minutes before treatment begins, at each visit during treatment, and again at all follow-up visits related to treatment. Patients also have their medical records reviewed.
3277005|NCT01627106|Experimental|Vernakalant|
3277006|NCT01627106|Active Comparator|Amiodarone|
3277007|NCT01627119||Gastric cancer patients|Gastric cancer patients who receive curative surgery at National Taiwan University Hospital
3277008|NCT01627132|Experimental|dasatinib|
3277009|NCT01627145|Experimental|antimuscariniz drug|
3277010|NCT01627158|Experimental|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
3277011|NCT01627158|Active Comparator|Symbicort Turbuhaler|Symbicort Turbuhaler
3277012|NCT01627158|Experimental|Charcoal and Budesonide/formoterol Easyhaler|
3277013|NCT01627158|Active Comparator|Charcoal and Symbicort Turbuhaler|
3277014|NCT01627171|Active Comparator|PEG Lyte|PEGlyte to be reconstituted with 4L of water and taken in the evening before the colonoscopy.
3277015|NCT01627171|Experimental|Pico Salax Split|Two sachets of Pico-Salax with 1 taken the night before colonoscopy and the second taken the morning of colonoscopy.
3277016|NCT01627171|Experimental|Pico Salax Night Before|2 sachets of Pico Salax mixed with water taken about 4 hours apart the night before colonoscopy
3277017|NCT01627184||Athletes with diabetes mellitus|Athletes who are insulin-requiring and insulin-dependent diabetics undergoing high levels of activity over extended period of time
3277018|NCT01627197|Active Comparator|Intraaterial chemotherapy|"This is an open-label, prospective, multicenter, randomized, controlled phase 3 two-arm study.Patients with locally advanced TCC of the bladder are randomized to 1 of 2 treatment arms~Arm 1 (treatment):'Surgery of percutaneous catheter system for arterial chemotherapy is done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique.Gemcitabine 800 mg/m2 intra-arterial,cisplatin 25 mg/m2 intra-arterial once a week for 3 weeks followed by 1-week rest period. Maximum of 3 cycles. Treatment begins between 1-5 weeks after radical operation (within 40 days is recommended)."
3277019|NCT01627197|No Intervention|Watchful waiting|Arm 2 (control): No immediate post-surgery treatment. Patients undergo observation followed by cisplatin and gemcitabine as in arm I at local relapse, or receive intravenously chemotherapy with cisplatin and gemcitabine at multiple metastases
3277020|NCT01627223|Experimental|Lamivudine 100 mg p.o. q.d.|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
3277021|NCT01627223|Experimental|Entecavir 0.5 mg p.o. q.d|"To target 88 evaluable subjects, approximately 98 patients should be recruited into this trial. After enrollment, all eligible subjects will be randomly assigned to one of the antiviral treatments below.~Cohort 1: Lamivudine 100 mg p.o. q.d.~Cohort 2: Entecavir 0.5 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
3277022|NCT01627236|Experimental|glucocorticoid treatment group|
3277023|NCT01627236|No Intervention|conventional treatment|
3277024|NCT01627262|Placebo Comparator|Placebo|
3277025|NCT01627262|Experimental|Mesalamine|
3277026|NCT01627275|Experimental|DLI from HLA-identical donor|Naive T Cell Depleted Donor Lymphocyte Infusion from HLA matched family member donor or 8/8 HLA matched unrelated donor.
3277027|NCT01627301|Experimental|Device-guided Breathing (DGB)|Participants randomized to the DGB group use a device to guide their breathing to a slow breathing rate.
3277028|NCT01627301|Sham Comparator|Sham DGB|Participants randomized to the sham DGB group use a device identical to the DGB device but respiratory rates are not guided lower than the physiological rate.
3277029|NCT01627301|Experimental|Transcutaneous Vagal Nerve Stimulation (tVNS)|Participants randomized to use a tVNS device to deliver mild electrical stimulation to the vagal nerve.
3277030|NCT01627301|Sham Comparator|Sham tVNS|Participants randomized to use the sham tVNS device which vibrates but does not stimulate the vagal nerve.
3277031|NCT01627353|Active Comparator|Standard of Care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
3277032|NCT01627353|Experimental|Pre-emptive wound infiltration|The Wound Infiltration Group will receive 100 mL 0.25% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
3277033|NCT01627366|Experimental|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
3277034|NCT01627366|No Intervention|Usual care|Receipt of usual medical care.
3277035|NCT01627379|Active Comparator|Arm A: Cisplatin, 5-Fluorouracil|Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
3277036|NCT01627379|Experimental|Arm B: Cisplatin, 5-Fluorouracil and Panitumumab|Chemotherapy plus Panitumumab will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled.
3277037|NCT01627392|Experimental|Smoking abstinence|
3277038|NCT01627418|Experimental|Voucher|"Receive the intervention (Energy Voucher) the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
3277039|NCT01627418|Other|Control|"Receive the intervention the second winter enrolled in the study (thus No intervention : control arm). The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy."
3277040|NCT01627431|Other|Antiplatelet therapy|Patients underwent peripheral revascularization procedures undergoing a double antiplatelet therapy
3277041|NCT01627444|Experimental|ear acupuncture|
3277042|NCT01627444|Placebo Comparator|Placebo acupuncture|No needle insertion, only stickers on acupuncture points.
3277043|NCT01627457|Experimental|GEx Training|CAD Patients in cardiac rehabilitation phase II (inpatient) and phase III (at home)in order to analyze data for quality of heart rate measurement and data acquisition by device as well as for practicability and technical problems at home.
3277044|NCT01627470||Cohort|Emergency Patients with applied arterial blood pressure measurement
3277045|NCT01627483|Experimental|Medication review|Assessment of risks of falls and fractures, medication review
3277046|NCT01627483|No Intervention|Controll|
3277047|NCT01627522|Active Comparator|Finastide low dose|2 weeks of daily 5mg finastride before operation
3277048|NCT01627522|Active Comparator|Finastide high dose|4 weeks of daily 5mg finastride before operation
3277049|NCT01627522|No Intervention|Control|Control
3277050|NCT01627535|Experimental|Optical Imaging|Patients undergo i2DOS
3277051|NCT01627548|Active Comparator|Waitlisted Intervention|Couple will be consented, assessed and randomized to a waitlist of 4 months. The couple will be reassessed at 8 weeks and prior to initiating intervention.
3277052|NCT01627548|Active Comparator|Immediate Intervention|Eligible couples who are randomized to immediate intervention will begin sessions with a trained interventionist within weeks of consent and initial assessments
3277053|NCT01627561|Experimental|Cervarix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received two doses of Cervarix vaccine at Day 0 and Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
3277054|NCT01627561|Active Comparator|Priorix + Infanrix Group|Healthy female subjects aged between, and including, 4 and 6 years, who received one dose of Priorix vaccine at Day 0 and one dose of Infanrix vaccine at Month 6, administered intramuscularly in the deltoid muscle of the left upper arm.
3277055|NCT01627587|Experimental|Ketoconazole-Part A|Healthy Female volunteers of child bearing potential will receive Treatment A, B and C
3277056|NCT01627587|Experimental|Food-Part B|Healthy Female Volunteers of child bearing potential will receive Treament D and E
3277057|NCT01627600||Atahualpa residents aged ≥ 40 years|All Atahualpa residentes aged 40 ≥ years will be screened by field questionnaires. Then, those with suspected stroke or ischemic heart disease will be evaluated by neurologists and cardiologists. Cardiovascular health metrics will be evaluated in those negative for stroke or ischemic heart disease.
3277058|NCT01627613|Experimental|AP301|Treatment group
3277059|NCT01627613|Placebo Comparator|saline solution|Placebo group
3277060|NCT01627626|Experimental|0.1% pilocarpine mouthwash|0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline
3277061|NCT01627626|Placebo Comparator|0.9% saline mouthwash|0.9% saline as a mouthwash
3277062|NCT01627639|Active Comparator|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
3277063|NCT01627639|Placebo Comparator|Placebo|Placebo
3277064|NCT01627652|Experimental|altitude|subjects will be studies at sea level and at high altitude
3277065|NCT01627665|Active Comparator|D->R->C+R|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with rivaroxaban
3277066|NCT01627665|Active Comparator|D->R->C+D|sequence of treatment: Dabigatran after rivaroxaban after chlarythromycin in association with Dabigatran
3277067|NCT01627665|Active Comparator|R->D->C+D|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with Dabigatran
3277068|NCT01627665|Active Comparator|R->D->C+R|sequence of treatment: rivaroxaban after Dabigatran after chlarythromycin in association with rivaroxaban
3277069|NCT01627678|Experimental|Arm 1= Arm A: Vacc-C5 /GM-CSF.|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
3277070|NCT01627678|Experimental|Arm 2=Arm B: Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
3277071|NCT01627704|Other|Fluoroestradiol (18F)|
3277072|NCT01627717|Experimental|Maraviroc Boceprevir|
3277073|NCT01627730|Experimental|3th year medical students|
3277074|NCT01627730|Experimental|nurses in critical care units|
3277075|NCT01627743||COPD patients grade C and D|
3277076|NCT01627756|Experimental|Ventilation Group|Volume controlled ventilation was done during the whole surgery.
3277077|NCT01627756|Active Comparator|Non-ventilation Group|In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
3277078|NCT01627769||second degree blisters patients|blister fluids of second degree burns
3277079|NCT01627769||cryotherapy blisters|blister fluids of cryosurgery wounds
3277080|NCT01627795|Experimental|Oshadi D and Oshadi R|anti cancer agents
3277081|NCT01627821|Active Comparator|Jarvik 2000 Treatment|Jarvik 2000 VAS, Post-Auricular Cable
3277082|NCT01627821|Active Comparator|HeartMate II Control|HeartMate II VAS Control
3277083|NCT01627834|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
3277084|NCT01627834|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
3277085|NCT01627847|Experimental|Ropinirole|Ropinirole Hydrochloride ER tablets 2 mg of Dr. Reddy's Laboratories Limited
3277086|NCT01627847|Active Comparator|Requip|Requip XL Tablets 2 mg of Glaxosmithkline, USA
3277087|NCT01627873|Experimental|Remifentanyl|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
3277088|NCT01627873|Active Comparator|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
3277089|NCT01627886|Experimental|Ibandronate sodium tablets 150 mg|Ibandronate sodium tablets 150 mg of Dr. Reddy's Laboratories Limited
3277090|NCT01627886|Active Comparator|Boniva|Boniva Tablets 150 mg of Roche Laboratories Inc, USA
3277091|NCT01627925|Experimental|Face mask and nasal mask without PEEP|Face mask ventilation and nasal mask ventilation without PEEP
3277092|NCT01627925|Experimental|Nasal mask and face mask with PEEP|Nasal mask ventilation and face mask ventilation with PEEP
3277093|NCT01627938|Experimental|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1
3277094|NCT01627938|Placebo Comparator|Placebo plus Mitoxantrone (MX)|Placebo + MX (12 mg/m2)
3277095|NCT01627951|Active Comparator|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3277096|NCT01627951|Experimental|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3277097|NCT01627951|Experimental|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
3277098|NCT01627964||normal heart function|normal heart function
3277099|NCT01627964||abnormal heart function|abnormal heart function
3277100|NCT01627977|Experimental|Dye of Lutein/Zeaxanthin/Brilliant Blue|during the surgery will be evaluated if the dye is suitable for dyeing the internal limiting membrane as well as the epiretinal membrane
3277101|NCT01628003|Active Comparator|healthy persons|
3277102|NCT01628003|Experimental|patients after moderate-severe TBI|
3277103|NCT01628029|Experimental|Arm I (methylphenidate, melatonin, light therapy, CBT)|Patients undergo CBT comprising 3 30-minute counseling sessions between baseline and day 14. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
3277104|NCT01628029|Experimental|Arm II (placebo, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
3277105|NCT01628029|Experimental|Arm III (methylphenidate, melatonin, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
3277106|NCT01628029|Experimental|Arm IV (methylphenidate, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
3277107|NCT01628029|Experimental|Arm V (placebo, melatonin, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo light therapy over 30 minutes for 15 days.
3277108|NCT01628029|Experimental|Arm VI (placebo, placebo, light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and melatonin placebo PO QD, and undergo light therapy over 30 minutes for 15 days.
3277109|NCT01628029|Experimental|Arm VII (methylphenidate, placebo, sham light therapy, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate hydrochloride PO BID and melatonin placebo PO QD, and undergo sham light therapy over 30 minutes for 15 days.
3277110|NCT01628029|Experimental|Arm VIII (placebo, melatonin, sham light intervention, CBT)|Patients undergo CBT as in Arm I. Patients also receive methylphenidate placebo PO BID and therapeutic melatonin PO QD, and undergo sham light therapy over 30 minutes for 15 days.
3277111|NCT01628055|Experimental|Privigen|The IVIG preparation to be used is 10% liquid (Privigen). IVIG will be applied at a dose of 1.0g/kg, which is approximately 1/2 of the optimal dose used for other immuno/inflammatory indications. The infusion will start at 0.5 ml/kg/hr for the first 30 minutes, to watch for the signs of hypersensitivity to immunoglobulins, and then increased to 2.5 ml/kg/hr, two times slower than the recommended rate indicated in the product package insert (5 ml/kg/hr). Such a low, single dose has not been associated with hyperviscosity and together with a slow infusion will safeguard against occurrence of adverse events related to IVIG infusions. They will receive a total of 1g/kg and depending on patient's weight, it will take between 3.5 to 4+ hours to infuse that amount.
3277112|NCT01628055|Placebo Comparator|Normal Saline|The placebo is the normal saline. Since saline solution will be infused at the volume equivalent to that in which the intended dose of immunoglobulin molecules will be delivered, the placebo (comparator) arm will also serve as a control for the volume of fluid infused to the treatment arm participants.
3277113|NCT01628068|Active Comparator|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
3277114|NCT01628068|No Intervention|Oral anticoagulation|Oral anticoagulation
3277115|NCT01628081|Experimental|Alga Dunaliella bardawil|After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo.
3277116|NCT01628081|Placebo Comparator|Placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
3277117|NCT01628094|Experimental|A: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3277118|NCT01628094|Experimental|B: GT1a 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3277119|NCT01628094|Experimental|C: GT1a 2DAA|including RO5466731, RO5190591, ritonavir and ribavirin [Copegus]
3277120|NCT01628094|Experimental|D: GT1b 3DAA|including RO5466731, RO5190591, ritonavir, ribavirin [Copegus] and RO5024048
3277121|NCT01628094|Experimental|E: GT1b 2DAA|including RO54664731, RO5190591, ritonavir and ribavirin [Copegus]
3277122|NCT01628094|Experimental|Part II|
3277123|NCT01628133||blood transfusion group|
3277124|NCT01628146|Experimental|SUPRACOR LASIK treatment|SUPRACOR LASIK treatment
3277125|NCT01628172|Experimental|Biosense Webster Celcius Thermacool catheter|These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
3277126|NCT01628172|No Intervention|renal angiogram only|Control Group: Control arm will not receive intervention but will be followed for 1 year.
3277127|NCT01628185||Pain Observations|Adult ICU patients who are not comatose with Richmond Agitation-Sedation Scale (RASS) score of -3 to 4 and unable to self-report pain. Patients will be excluded for neurological deficits (acute or chronic) that prevent observation of the muscle tonus or movement
3277128|NCT01628211|Experimental|Second look laparoscopy|Second look laparoscopy to evaluate for and treat peritoneal carcinosis
3277129|NCT01628211|No Intervention|standard follow up|
3277130|NCT01628224||CCATT Team|Measurements will be taken on groups of 3 people each. There will be a total of 16 such teams, with total membership of 48 individuals
3277131|NCT01628237|Active Comparator|Monocolumn spinal cord stimulation|Specify 5-6-5 Lead (only one column)
3277132|NCT01628237|Experimental|Multicolumn spinal cord stimulation|Specify 5-6-5 Lead
3277133|NCT01628263|Experimental|Follow up Clinic|Participants will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse.
3277134|NCT01628263|No Intervention|Control|Participants will not receive an offer of a follow up clinic
3277135|NCT01628276|Experimental|Rehab first|
3277136|NCT01628276|Experimental|Rehab Second|
3277137|NCT01628276|No Intervention|Non Rehab|
3277138|NCT01628289|Other|free screening group|Subjects in this group receive free diabetic retinopathy screening.
3277139|NCT01628289|Other|Pay screening group|Subjects in this group receive diabetic retinopathy screening with charging a co-payment.
3277140|NCT01628302|No Intervention|Normal salt diet|The group had normal salt diet (250mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had low salt diet (50mmol) at the last 3 weeks of the study.
3277141|NCT01628302|Experimental|Low salt diet|The group had low salt diet (50mmol)for three weeks. Subjects had normal salt diet in their daily routine life for the following 2 weeks.According to crossover nature of the study, the group had normal salt diet at the last 3 weeks of the study.
3277142|NCT01628315||Mulitple Sclerosis|Patients with relapsing-remitting MS who had a MRI as part of their participation in the ASA study.
3277143|NCT01628328||Stenting|patient who received colonic stenting for obstructive colorectal cancer
3277144|NCT01628328||Control|patients who had only colonoscopy without obstruction and without stenting
3277145|NCT01628341||Patients with diabetes (type 1 and 2)|
3277146|NCT01628380|Active Comparator|CRS + HIPEC|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy with CDDP+Paclitaxel
3277147|NCT01628380|Active Comparator|CRS alone|Cytoreductive Surgery alone
3277148|NCT01628406||Patients treated at the neurosurgery department|Patients treated at the neurosurgery department
3277149|NCT01628419|Experimental|Health intervention program|Health promotion intervention program will be implemented at each workplace and will include: exercise program, nutritional counseling for the kitchen service, lectures on different topics (physical activity, nutrition, sleeping behaviour etc.).
3277150|NCT01628432|Experimental|conservative hysterectomy I|bilateral salpingectomy during hysterectomy with conservation of the ovaries
3277151|NCT01628432|Active Comparator|conservative hysterectomy II|standard conservative hysterectomy with conservation of both ovaries and tubes
3277152|NCT01628445|Active Comparator|liraglutide|liraglutide 1.8 mg injected once daily
3277153|NCT01628445|Placebo Comparator|Placebo injection|
3277154|NCT01628458|Experimental|radiofrequency ablation|
3277155|NCT01628471|Experimental|Decitabine + genistein single arm|decitabine injectable, by infusion, 5 ascending doses (60 to 500 mg/m2) genisteine capsules, 3 x 50 mg capsules twice a day
3277156|NCT01628484|Other|Skin Preparation Testing|The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
3277157|NCT01628497||Positive filariasis test|Those testing positive for filariasis
3277158|NCT01628497||Filariasis negative|
3277159|NCT01628536|Experimental|Black cohosh|
3277160|NCT01628562|Active Comparator|GroupE/Esmolol infusion|Heart rate control, Beta blocker
3277161|NCT01628562|Experimental|GroupR/Remifentanil infusion|Heart rate control, opioid
3277162|NCT01628575||PAO|patients undergoing orthodontic treatment with the addition of pretreatment periodontal surgery for bone decortication.
3277163|NCT01628627|Experimental|FREMS|Frequency Modulated Neural Stimulation (FREMS)
3277164|NCT01628627|Sham Comparator|Control|
3277165|NCT01628640|Experimental|Arm A (viral therapy in single tumor location)|Patients with hepatocellular carcinoma or advanced solid tumor with liver lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in a single tumor location on day 1.
3277166|NCT01628640|Experimental|Arm B (viral therapy in multiple locations)|Patients with advanced solid tumor with subcutaneous/cutaneous lesions receive recombinant vesicular stomatitis virus expressing interferon beta intratumorally in up to 5 cutaneous, subcutaneous, or soft tissue tumor lesions on day 1.
3277167|NCT01628653|Experimental|U-SMART|U-SMART (Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training)
3277168|NCT01628666|Experimental|Conventional|Preoperative Antibiotics: Cefazolin preoperative, vancomycin in penicillin allergic patients.
3277169|NCT01628666|Experimental|Incremental|Preoperative antibiotics (Cefazolin and Vancomycin) Bacitracin pocket wash and 2 days of oral Cefalexin post operative.
3277170|NCT01628679|Experimental|physical therapy treatment|
3277171|NCT01628705|Sham Comparator|Nutritional intervention|The subjects were undergoing nutritional intervention.
3277172|NCT01628705|Experimental|Nutritional intervention with green tea|The subjects were undergoing nutritional intervention complemented with green tea.
3277173|NCT01628731|Active Comparator|furosemide|furosemide, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
3277174|NCT01628731|Active Comparator|ethacryinic acid|ethacrynic acid, 0.2 mg/kg/h up to 0.8 mg/kg/h for 72 hours
3277175|NCT01628744||Patients with mycobacterial infection|
3277176|NCT01628757||neoadjuvant chemotherapy|
3277177|NCT01628770|Experimental|parenteral iron|dose will be calculated according to Ganzoni's formula, and will be administered by intravenous infusion
3277178|NCT01628770|Active Comparator|oral iron|oral iron in form of ferrous sulphate 200 mg twice daily
3277179|NCT01628783|Placebo Comparator|Placebo|Microgranular cellulose in gelatine capsules.
3277180|NCT01628783|Experimental|Escitalopram 10 mg|Escitalopram in gelatine capsule
3277181|NCT01628809|Active Comparator|Rest and Relaxation|three-day relaxation retreat without mindfulness components
3277182|NCT01628809|Experimental|Mindfulness-Based Meditation|three-day mindfulness-based meditation retreat
3277183|NCT01628822|Experimental|Active relaxation|
3277184|NCT01628822|Placebo Comparator|Placebo relaxation|
3277185|NCT01628835|Experimental|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided.
3277186|NCT01628835|Active Comparator|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
3277187|NCT01628861|Active Comparator|education only|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided.
3277188|NCT01628861|Experimental|prompt + education|"A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet with the same message is also provided. Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
3277189|NCT01628887|Experimental|Supportive Care (BBCEI)|Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.
3277190|NCT01628900|Active Comparator|ambulatory|Patient will be treated for 7 days at home, then 3 follow-up visit at hospital.
3277191|NCT01628900|Active Comparator|hospitalisation|7 days for mono-antibiotherapy at hospital.
3277192|NCT01628939||current low back pain|subjects with current low back pain (i.e. more than 30 days of low back pain in the last three months)
3277193|NCT01628939||controls|subjects with less than 30 days of low back pain in the last three months
3277194|NCT01628952|Experimental|TAP|
3277195|NCT01628952|Active Comparator|curare|Patients will be randomized into two parallel groups. One group will receive curare, another benefit of a bilateral TAP block
3277196|NCT01628978||Auscultation group|The depth of endotracheal tube placement is determined by auscultation.
3277197|NCT01628978||Ultrasonography group|The depth of placement of endotracheal tube placement is determined by ultrasonographic finding of pleural sliding sign.
3277198|NCT01628991|Experimental|behavioural intervention|Recieving interventional behavioural program
3277199|NCT01628991|Experimental|vaginal cone|intravaginal device insertion(vaginal cone)
3277200|NCT01629004|Other|Non-responders|"Non-responders to an initial mailed CRC screening invitation from their family physician.~FOBT kit. Mailed invitation."
3277201|NCT01629004|Other|Recall patients|"Those who responded to the initial mailed CRC screening invitation and are now due for repeat screening (i.e., recall patients).~FOBT kit. Mailed invitation."
3277202|NCT01629030||Coronary Artery Bypass Graft Group|Those underwent coronary artery bypass graft surgery with median sternotomy in Samsung Medical Center during the period of January 2008 and December 2011.
3277203|NCT01629056|Active Comparator|Contact ECI active|Contact ECI active
3277204|NCT01629056|Placebo Comparator|Contact information deactivated|RF ablation without contact data
3277205|NCT01629069|Active Comparator|Participant in MBRT|6 sessions of Mindfulness Based Resilience Training
3277206|NCT01629095||NAFLD|Patients who have already undergone liver transplantation for a confirmed diagnosis of NAFLD or cryptogenic cirrhosis are also eligible to participate.
3277207|NCT01629095||NASH|Patients with radiologic evidence of fatty liver and/or cirrhosis in which other causes havebeen ruled out are eligible to participate.
3277209|NCT01629121|Experimental|education intervention|The intervention delivered education about the benefits of bicycle helmet use and safety and was designed to be sensitive to the age and educational level of the study participant.
3277210|NCT01629121|No Intervention|control|Printed materials were given to the control group, along with a helmet for each participant.
3277211|NCT01629147|Experimental|Biogaia|5 drops containing Lactobacillus reuteri Protectis
3277212|NCT01629147|Placebo Comparator|Placebo|- 5 drops identical in appearance and taste
3277213|NCT01629173|Experimental|Dynamic impression insole|We sequentially padded P-cell, Ethylene Vinyl Acetate, and Multiform on the 9-mm thick plastazote under daily walking compression to make dynamic impression insole.
3277214|NCT01629173|Experimental|Custom molded insole|The custom molded insole was made by sequentially padded Multiform, P-cell, EVA, and cork on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
3277215|NCT01629173|Experimental|9-mm uncompressed Plastazote insole|We used 9-mm flat Plastazote as an insole
3277216|NCT01629173|Experimental|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) as an insole
3277217|NCT01629186|Experimental|outcome|"Cardiopulmonary parameters were measured and recorded at baseline, just before and at every minute during NC-AC, and at the end of the FB session. In infants who already had an arterial line, arterial blood gas (ABG) analyses were taken for study. Data was represented as mean ± SD. The results obtained from the baseline and different stages. The values were considered statistically significant only when p < 0.05.~Technique failure was defined as: any vital signs of hypoxia did not return to accepted levels(HR>100 beat/min, SpO2>90%, mean BP>50 mmHg)within 2 minutes of the experimental CPR technique. Then traditional CPR procedures involving bag-mask ventilation, endotracheal intubation, Ambu bag ventilation or even chest compressions were substituted."
3277218|NCT01629199|Experimental|rhEGF(recombinant human Epidermal Growth Factor)|BID
3277219|NCT01629199|Placebo Comparator|placebo|BID
3277220|NCT01629212|Experimental|Tiropramide HCl|
3277221|NCT01629212|Active Comparator|Octylonium bromide|
3277222|NCT01629225|No Intervention|candesartan|All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
3277223|NCT01629238||group 1|group 1 = consumers of marketed drinkable low fat fermented milk enriched with plant sterol
3277224|NCT01629238||group 2|group 2 = non-consumers of marketed drinkable low fat fermented milk enriched with plant sterol
3277225|NCT01629251|Active Comparator|Closed-loop with standard meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard meal insulin dosing will be performed at each meal, following individual standard clinical practice.
3277226|NCT01629251|Experimental|Closed-loop with reduced meal insulin bolus|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. The standard meal insulin dose will be reduced by 20 to 50%.
3277227|NCT01629277|Active Comparator|Control|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
3277228|NCT01629277|Experimental|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
3277229|NCT01629303|Experimental|Arm on-off|"After the definitive implantation, stimulators are placed in position OFF during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks"
3277230|NCT01629303|Experimental|Arm off-on|"After the definitive implantation, stimulators are placed in position ON during 8 weeks.~Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks"
3277231|NCT01629316|Experimental|Text reminders, counseling, link coordinator|Text reminders, counseling, link coordination
3277232|NCT01629316|Active Comparator|Standard of care - control arm|
3277233|NCT01629342||Transient Ischemic Attack Patients|Patients discharged after a Transient Ischemic Attack
3277234|NCT01629355||Schizophrenia|Five patients with diagnosed schizophrenia will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with schizophrenia will then be studied blindly to evaluate the predictive value of the test.
3277235|NCT01629355||ADHD|Five patients with diagnosed ADHD will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern.
3277236|NCT01629355||Bipolar disorder|Five patients with diagnosed Bipolar disorder will be used to map changes in ABR/SD-BERA potentials compared to controls to establish the disease-specific pattern. Twelve patients with Bipolar disorder will then be studied blindly to evaluate the predictive value of the test.
3277237|NCT01629355||Healthy controls|Fifteen healthy controls will be used to define normal pattern of ABR/SD-BERA potentials. Another twelve normal controls will be studied blindly to evaluate the predictive value of the test.
3277238|NCT01629368|Experimental|Dosing Period 1|
3277239|NCT01629368|Experimental|Dosing Period 2|
3277240|NCT01629394|Active Comparator|Group A: Sugammadex CBW-open|Group A patients will undergo open surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
3277241|NCT01629394|Active Comparator|Group B: Sugammadex IBW-open|Group B patients will undergo open surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3277242|NCT01629394|Active Comparator|Group C: Neostigmine CBW-open|Group C patients will undergo open surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
3277243|NCT01629394|Active Comparator|Group D: Neostigmine-IBW|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3277244|NCT01629394|Active Comparator|Group E: Sugammadex CBW-Lap|Group E patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)] when T2 arises in adductor pollicis.
3277245|NCT01629394|Active Comparator|Group F: Sugammadex IBW-Lap|Group F patients will undergo laparoscopic surgery and will receive sugammadex 2mg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3277246|NCT01629394|Active Comparator|Group G: Neostigmine CBW-Lap|Group C patients will undergo laparoscopic surgery and will receive neostigmine 50μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]when T2 arises in adductor pollicis.
3277247|NCT01629394|Active Comparator|Group H: Neostigmine IBW-Lap|Group D patients will undergo open surgery and will receive neostigmine 50μg/kg ( ideal body weight ) when T2 arises in adductor pollicis.
3277248|NCT01629407||Glaucoma|Patients with glaucoma
3277249|NCT01629420|Experimental|Drug:KLH-2109 lower dose|
3277250|NCT01629420|Experimental|Drug:KLH-2109 higher dose|
3277251|NCT01629433||botulinum A toxin|18 patients with neurogenic DO and 7 with idiopathic DO All the patients had overactive bladder (OAB) symptoms and DO refractory to conventional anticholinergics.
3277252|NCT01629446|Experimental|Lofexidine HCl with 14C tracer|
3277253|NCT01629459|Experimental|Resistance exercise training|Participants will undergo resistance exercise training 3x/wk for 12 weeks at a physical therapy or cardiac rehabilitation facility near the participant's home.
3277254|NCT01629472|Experimental|VSLA + gender dialogue groups: treatment|
3277255|NCT01629472|Active Comparator|VSLA only: control|
3277256|NCT01629485|Experimental|Whole Task|Trainees will undergo whole task mastery training in the TEP simulator after completing the video curriculum portion.
3277257|NCT01629485|Experimental|Part Task|Trainees will undergo a random part task mastery training in the TEP simulator after completing the video portion of the curriculum.
3277258|NCT01629498|Experimental|Arm I (image-guided IMRT)|Patients undergo image-guided IMRT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
3277259|NCT01629498|Experimental|Arm II (image-guided IMPT)|Patients undergo image-guided IMPT SIB QD 5 days a week for up to 6 weeks in the absence of disease progression or unacceptable toxicity.
3277260|NCT01629511|Experimental|Treatment (combination chemotherapy, stem cell transplant)|Participants receive gemcitabine IV over 10-25 minutes on days -6 and -4, clofarabine IV over 1 hour and busulfan IV over 3 hours on days -6 to -3. Participants with matched unrelated donors also receive anti-thymocyte globulin IV over 4 hours on days -3 to -1. Starting day -2, participants receive tacrolimus PO daily for up to 6 months. Participants undergo hematopoietic allogeneic stem cell transplant on day 0, then receive methotrexate IV over 15 minutes on days 1, 3, 6 and 11, and filgrastim SC QD beginning 1 week after transplant until blood cell levels return to normal.
3277261|NCT01629524||Colorectal cancer patients|Colorectal cancer patients undergoing elective colorectal resection
3277262|NCT01629537|Other|Placebo|Subjects 1 month post in the placebo group who demonstrate either the same level of PTSD severity at enrollment or worsening of the condition (i.e., CAPS score greater than or equal to 40) will be offered SGB treatment and crossed over to active treatment. Patients who cross over from placebo to active SGB treatment will be followed one week, one month and three months after cross over.
3277263|NCT01629537|Experimental|Stellate Ganglion Block (SGB)|Subjects assigned to SGB arm will undergo SGB procedure and be followed one week, one month and three months after procedure or until CAPS score is below 40.
3277264|NCT01629550|Active Comparator|PVI paint|5% alcoholic povidone iodine paint
3277265|NCT01629550|Active Comparator|PVI scrub and paint|detersion with 4% povidone iodine scrub followed by 5% alcoholic povidone iodine paint
3277266|NCT01629550|Active Comparator|Chlorhexidine paint|2% alcoholic chlorhexidine paint
3277267|NCT01629550|Active Comparator|chlorhexidine scrub and paint|Detersion with 4% chlorhexidine scrub followed 2% alcoholic chlorhexidine paint
3277268|NCT01629576|No Intervention|control group|
3277269|NCT01629576|Experimental|low reward|economic incentive
3277270|NCT01629576|Experimental|high reward|economic incentive
3277271|NCT01629602|Experimental|vascularized nerve graft|The investigators combined the nerve branch with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
3277272|NCT01629628|Experimental|Adalimumab|
3277273|NCT01629628|Active Comparator|6-mercaptopurine|
3277274|NCT01629641||Normals|Texas Woman's University students from the School of Physical Therapy - Houston campus will be recruited to participate in this study. The participant will be excluded if they have pain in the shoulder on the day of testing, less than 90 degrees of active or passive shoulder abduction, less than 90 degrees of active or passive elbow flexion, have had any previous surgeries or procedures to either shoulder or identify by self-report any reason that they should not perform active external rotation at the shoulder.
3277275|NCT01629654|Experimental|Lifestyle counseling|Testing of the teory- and evidence based health promotion program. Patients will participate in a 13 weeks program.
3277276|NCT01629680|Experimental|Healthy subjects I|
3277277|NCT01629680|Placebo Comparator|Healthy subjects II|
3277278|NCT01629732|Experimental|Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)"
3277279|NCT01629732|Experimental|Arm 2: Daclasasvir + BMS-986094 (200 mg)|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)"
3277280|NCT01629732|Experimental|Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)"
3377649|NCT04228575|Experimental|8 week ICBT with Booster|Clients in the booster condition will be told that at 16 weeks they will have access to a booster session (online materials that go over core skills such as thought challenging, deep breathing, behavioural activation, and graded exposure). At 16 weeks, they will be sent an email reminder to log in for the booster course. The therapist will send a supportive email to the client offering to assist with any challenges the client reports in the check-in questionnaire by email or phone call over the next 2 weeks.
3377650|NCT04224870||Surgical Incision|A single cohort study, of 12 participants with a scheduled surgical procedure, of at least 4 hours, for up to six (6) timed tissue sampling at surgical incision. No investigational therapy is planned.
3277281|NCT01629732|Experimental|Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin|"Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)~Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)"
3277282|NCT01629732|Experimental|Arm 5: Daclasasvir + BMS-986094 (200 mg)|Genotype 1 PI-failure subjects
3277283|NCT01629732|Experimental|Arm 6: Daclasasvir + BMS-986094 (200 mg)|Genotype 4 naive subjects
3377653|NCT04210349|Experimental|Group A: 6 to 35 months, previously unvaccinated, step 1|Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
3277284|NCT01629732|Experimental|Arm 7: Daclasasvir + BMS-986094 (200 mg)|Genotype 2/3 NR/relapse Subjects
3377654|NCT04210349|Experimental|Group 1: 6 to 35 months, step 2|Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3277285|NCT01629758|Experimental|Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3277286|NCT01629758|Experimental|Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558|Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3377655|NCT04210349|Experimental|Group 2: 3 to 8 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
3377656|NCT04210349|Experimental|Group 3: 9 to 17 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
3377657|NCT04210349|Experimental|Group 4: 18 to 60 years, step 2|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
3377658|NCT04210349|Experimental|Group 5: >=61 years|Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
3377663|NCT04192136|Experimental|Nicotinamide Riboside (NR)|"Investigators will use Good Manufacturing Process (GMP)-grade 300 mg capsules of the dietary supplement nicotinamide riboside (ChromaDex, Irvine CA). Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
3377664|NCT04192136|Placebo Comparator|Placebo|"Matched placebo will contain the same excipients without the active supplement and is generally recognized as safe. The placebo will be covered in an identical capsule (NR will be covered in the same capsule). Doses of placebo will match the body weight schema for dosing of NR. Investigators dose based on body weight, and monitor for adverse effects (AEs).~For individuals with weight > 72 kg: 900 mg po qd x 12 wks.~For individuals with weight > 48 kg and ≤ 72 kg: 600 mg po qd x 12 wks.~For individuals with weight 24 ≤ 48 kg: 300 mg po qd x 12 wks."
3377665|NCT04192136|Experimental|Exercise Intervention and NR|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the NR."
3377666|NCT04192136|Experimental|Exercise Intervention and Placebo|"The exercise program consists of at-home training sessions: 3 aerobic sessions per week on the in-home bike trainer, and 2 resistance exercise sessions per week using resistance bands. All sessions will begin with stretching and brief aerobic warm-up exercise on the in-home bike trainer. On resistance training days, subjects will be given instructions to complete circuits of resistance exercises.~Participants in this arm will receive both the Exercise Intervention and the Placebo."
3277287|NCT01629758|Experimental|Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558|Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years
3277288|NCT01629849|Experimental|BI 1021958 qd|Multiple rising dose
3277289|NCT01629849|Placebo Comparator|Placebo to BI 1021958 qd|Matching placebo as tablets
3277290|NCT01629849|Experimental|BI 1021958 bid|Multiple rising dose
3277291|NCT01629849|Placebo Comparator|Placebo to BI 1021958 bid|Matching palcebo as tablet
3277292|NCT01629875|Experimental|DWP450|
3277293|NCT01629875|Active Comparator|Botox|
3277294|NCT01629888|Experimental|1 = Tested product|
3277295|NCT01629888|Placebo Comparator|2 = Control product|
3277296|NCT01629927||HED-affected males|Male subjects affected by HED
3277297|NCT01629927||Male controls|Male subjects not affected by HED
3277298|NCT01629940||Male HED-Affected Individuals|Male subjects affected by HED
3277299|NCT01629940||Male controls|Male subjects not affected by HED
3277300|NCT01629979|Experimental|A: Grafting of autologous epidermal harvested cells and UVB|"Grafting with epidermal cells: A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
3277301|NCT01629979|Active Comparator|UVB treatment|UVB treatment twice a week during 3months
3277302|NCT01629992|Experimental|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
3277303|NCT01629992|No Intervention|Control|The control group received no preoperative counseling either oral or written.
3277304|NCT01630005|Experimental|Talk therapy|A cohort of 25 patients
3277305|NCT01630018|Active Comparator|Topotecan|Topotecan
3277306|NCT01630018|Active Comparator|Camtobell|Belotecan
3277307|NCT01630031||Control group|Use of the THERMOCOOL SF or EZ STEER THERMOCOOL Catheter, Biosense Webster, Inc.
3277308|NCT01630031||CF group|Use of THERMOCOOL SMARTTOUCH Catheter, Biosense Webster, Inc.
3277309|NCT01630044|Experimental|TNM device, active treatment|This is an active-only assessment of the experimental neuromodulation device
3277310|NCT01630057|Experimental|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
3277311|NCT01630057|Active Comparator|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
3277312|NCT01630070|Experimental|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
3277313|NCT01630083|Active Comparator|EOX Treatment|Participants will receive up to 8 cycles of epirubicin, oxaliplatin and capecitabine (EOX) chemotherapy treatment alone (50 mg/m^2 epirubicin intravenously on day 1 of each cycle, 130 mg/m^2 oxaliplatin intravenously on day 1 of each cycle, 625 mg/m^2 capecitabine orally twice daily on days 1 to 21 of each cycle). The first dose of capecitabine to be taken in the evening of day 1.
3277314|NCT01630083|Experimental|EOX+zolbetuximab 800/600 mg/m^2|Participants will received up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab administered as loading dose of 800 mg/m^2 intravenously on day 1 of cycle 1 followed by 600 mg/m^2 intravenously on day 1 of each subsequent cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (600 mg/m^2 every 3 weeks to be administered intravenously as a 2-hour infusion) until progressive disease (PD), withdrawal of consent or unacceptable toxicity. PD per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study, an absolute increase of at least 5mm must also be demonstrated, unequivocal progression of existing non-target lesions and appearance of one or more new lesions is considered progression.
3277315|NCT01630083|Experimental|EOX+zolbetuximab 1000 mg/m^2|Participants will receive up to 8 cycles of EOX chemotherapy treatment in combination with zolbetuximab 1000 mg/m^2 intravenously on day 1 of each cycle. Zolbetuximab to be administered prior to EOX chemotherapy. After completion of the EOX treatment phase, participants will be permitted to continue zolbetuximab monotherapy (1000 mg/m^2 every 3 weeks administered intravenously as a 2-hour infusion ) until PD, withdrawal of consent or unacceptable toxicity.
3277316|NCT01630096|Active Comparator|Nu-Lytely|Bowel prep solution.
3277317|NCT01630096|No Intervention|Control|Standard of care.
3277318|NCT01630122||patients newly diagnosed non small cell lung cancer|patients with presumed newly diagnosed non small cell lung cancer, where radiographic studies and clinical description favor a probable diagnosis of non small cell lung cancer
3277319|NCT01630148|Active Comparator|Bemiparin|group one will be women who are risky for venous thromboembolic diseases after benign gynaecological surgeries, each will receive Bemiparin
3277320|NCT01630148|No Intervention|control group|women will undergo benign gynaecological surgeries and are risky for venous thrombosis, they will not receive any intervention. The patients will be followed up to 30 days after surgery.
3277321|NCT01630161|Active Comparator|Usual Care|Participants randomized to the Usual Care condition will receive standard care following recruitment.
3277322|NCT01630161|Active Comparator|Relapse-Prevention Intervention|Participants randomized to the Smoking Relapse Prevention for Cancer Patients (SRP-CaP) intervention will receive standard care plus our self-help smoking-relapse prevention materials.
3277323|NCT01630187|Active Comparator|Carbetocin 100 mcg|
3277324|NCT01630187|Experimental|Carbetocin 50 mcg|
3277325|NCT01630213|Active Comparator|Vitamin D3 + fish oil/placebo|Vitamin D3 2000 IU/day and fish oil (840 omega 3-fatty acids; Omacor)(or fish oil placebo)/day
3277326|NCT01630213|Placebo Comparator|Vitamin D3 placebo + fish oil/placebo|Vitamin D3 placebo + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo
3277327|NCT01630226|Experimental|Neoadjuvant Cisplatin Chemotherapy|
3277328|NCT01630239|Experimental|Visualise Thermal Therapy System|
3277329|NCT01630252|Active Comparator|Part A2 - Active Treatment arm|PGL5001 for 8 weeks + one DMPA injection
3277330|NCT01630252|Placebo Comparator|Part A2 - Placebo Treatment arm|PGL5001 matching placebo for 8 weeks + one DMPA injection
3277331|NCT01630252|Active Comparator|Part B - Active treatment arm|PGL5001 for 20 weeks + two DMPA injections
3277332|NCT01630252|Placebo Comparator|Part B - Placebo Treatment arm|PGL5001 matching placebo for 20 weeks + two DMPA 150mg injections
3277333|NCT01630252|Experimental|Part A1 - Active Treatment arm|PGL5001 for 8 weeks + one unique DMPA 150 mg injection
3277334|NCT01630265|Active Comparator|Written Discharge Instructions|Group of caregivers who read written discharge instructions that are the standard discharge instructions given in our pediatric ED
3277335|NCT01630265|Experimental|Video Discharge Instructions|Group of caregivers who watched the 3-minute video covering the information in the standard written discharge instructions
3277336|NCT01630278|No Intervention|Small ductus|
3277337|NCT01630278|Experimental|Large ductus ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
3277338|NCT01630278|Placebo Comparator|Large ductus placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
3277339|NCT01630291|Experimental|Electrical stimulation|
3277340|NCT01630304|Experimental|WelTel SMS service|"In addition to standard care, weekly text messages will be delivered to participants randomized to this arm for a one year period. Participants will be requested to respond to the outgoing message Mambo? within 48 hours; they may respond that they are doing well (sawa) or that they have a problem (shida). A clinician will call to follow-up with all participants who respond indicating a problem or who do not respond within 48 hours."
3277341|NCT01630304|No Intervention|Standard care|This arm will receive standard clinical care.
3277342|NCT01630317|Experimental|Peripheral acces|
3277343|NCT01630317|Placebo Comparator|Central access|
3277344|NCT01630330|Active Comparator|Contact Force Known|Ablation with contact force data known
3277345|NCT01630330|Experimental|Contact Force Not Known|Contact Force data unavailable during ablation
3277346|NCT01630343|Experimental|Regular oral Panadol and Tramadol|Geriatric (age >65) Patient having traumatic hip fracture will have three weeks of regular prescription of oral Panadol(500mg) and tramadol (50mg) three times a day. Operation will be done within 3 days usually followed by rehabilitation period.
3277347|NCT01630343|Experimental|Panadol and tramadol oral in prn basis|Control group is that patient having geriatric hip fracture will have oral analgesics ( Panadol 500mg Q4H and tramadol 50mg Q4H ) in prn basis.
3277348|NCT01630356|Experimental|Intervention group|
3277349|NCT01630356|Active Comparator|Control group|
3277350|NCT01630369|Experimental|Human Insulin|Dosage of human insulin (Insuman Basal/Comb/Rapid) will be individually adjusted in accordance with the Summary of Product Characteristics (SmPC). Patients will follow the titration algorithm recommended by the physician.
3277351|NCT01630395|No Intervention|conventional|Two-lung ventilation: tidal volume = 10 ml/kg, no PEEP. One-lung ventilation: tidal volume = 10 ml/kg, no PEEP
3277352|NCT01630395|Active Comparator|Protective|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O.
3277353|NCT01630395|Active Comparator|Recruitment|Two-lung ventilation: tidal volume 8 ml/kg, PEEP of 5 cmH2O. One-lung ventilation: tidal volume 6 ml/kg, PEEP of 5 cmH2O. Recruitment maneuver will be applied during one-lung ventilation.
3277354|NCT01630408|Experimental|Paricalcitol|Paricalcitol oral capsules (1 mcg per day for 48 weeks)
3277355|NCT01630421||affected, unaffected|Individuals with diagnosed ACC
3277356|NCT01630434|Experimental|OCS Lung (Treatment Group)|The OCS Lung, which is a portable, integrated platform designed to maintain adult donor lungs in a normothermic state through continuous normothermic perfusion and ventilation, will be used to preserve and transport donor lungs.
3277357|NCT01630434|Active Comparator|Cold flush and storage (Control Group)|Donor lungs will be preserved using cold flush and storage (control group)
3277358|NCT01630473|Experimental|Corticotomy-assisted orthodontics|This group of patients will receive corticotomy surgical procedure at day 0. Orthodontic activation will start immediately after surgery.
3277359|NCT01630473|Active Comparator|Conventional orthodontics|This group of patients will receive conventional orthodontics starting at day 0.
3277360|NCT01630486||glomerulonephritis|adult CKD patients, whose underlying etiology is glomerulonephritis, either clinically diagnosed or pathologically proven
3277361|NCT01630486||hypertensive nephropathy|adult CKD patients, whose underlying etiology is hypertensive nephropathy
3277362|NCT01630486||polycystic kidney disease|adult CKD patients, whose underlying etiology is autosomal dominant polycystic kidney disease
3277363|NCT01630486||diabetic nephropathy|adult CKD patients, whose underlying etiology is diabetic nephropathy
3277364|NCT01630499|Experimental|Tailored Lifestyle Intervention (TLI)|Participants randomized to the TLI condition will receive a 3-month weight management program tailored to the specific needs of women in remission from breast cancer.
3277365|NCT01630499|Active Comparator|Commercial Weight Loss Program (CLWP)|Participants randomized to the CWLP condition will receive a 3-month commercial weight loss program (i.e., Weight Watchers) at no cost.
3277366|NCT01630512|Experimental|MBCT|
3277367|NCT01630512|Experimental|CBT|
3277368|NCT01630512|No Intervention|Waitlist|
3277369|NCT01630525||Prodromal AD participants|
3277370|NCT01630525||Typical AD participants|
3277371|NCT01630525||Control participants|
3277372|NCT01630538|Experimental|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days (26 weeks) adjusted for renal function.
3277373|NCT01630551|Active Comparator|Fishoil nutritional supplement|90 day supply of daily oral administration of a fish oil nutritional supplement (TheraTears Nutrition; Advanced Vision Research, Woburn, MA)
3277374|NCT01630551|Placebo Comparator|Olive oil capsules|90 day supply of a daily dose of placebo olive oil capsules
3277375|NCT01630564|Experimental|Treatment (T-cell infusion)|Patients undergo ex vivo-expanded umbilical cord blood progenitor cell donor T cell infusion with aldesleukin 11-14 days after T-cell co-stimulation begins.
3277376|NCT01630577|Experimental|responder to fluid challenge|fluid challenge
3277377|NCT01630590|Experimental|Cabozantinib + Androgen Ablation Therapy|Patients receive Cabozantinib at starting dose of 60 mg by mouth every day. Study cycles 3 weeks in duration. Patients stay on treatment as long as they are benefitting. Patients receive androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration. Study doctor will decide what hormone therapy patient will receive.
3277378|NCT01630603||mother infants pairs|
3277379|NCT01630629||African-American Lactating Women|Healthy African-American women who are exclusively breast-feeding.
3277380|NCT01630629||Caucasian Lactating Women|Healthy Caucasian women who are exclusively breast-feeding.
3277381|NCT01630668|Experimental|One-a-Day L. reuteri NCIMB 30242 supplement capsule|
3277382|NCT01630668|Placebo Comparator|One-a-Day placebo capsule|
3277383|NCT01630681|Experimental|Internet-based stepped care|Internet-based stepped care comprises interactive support (Step 1) and Cognitive Behavioral Therapy (CBT; Step 2). Step 1 starts directly after randomization and extends over a 24 months period. Step 2 extends to a period of ten weeks.
3277384|NCT01630681|No Intervention|Standard care|
3277385|NCT01630720|Active Comparator|vitamin C|vitamin C 500 mg twice daily
3277386|NCT01630720|Active Comparator|vitamin D|vitamin D 5000 IU daily
3277387|NCT01630733|Experimental|Custirsen + Docetaxel|Custirsen: Three loading doses of custirsen 640mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
3277388|NCT01630733|Active Comparator|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle Continue treatment until disease progression, unacceptable toxicity, withdrawal of consent or protocol specified parameters to stop treatment.
3277389|NCT01630746|Experimental|TAK-438 20 mg/day|
3277390|NCT01630746|Experimental|TAK-438 40 mg/day|
3277391|NCT01630759|Experimental|Telemonitoring|The telemonitoring group will receive usual care but be asked to download their blood sugar readings and take a blood pressure and weight measurement each week. This will be reviewed by their diabetes health care team to assess the possibility of replacing alternate anti-natal/diabetes clinics with telemonitoring review in a future study. Acceptability to staff and patients will be assessed through a questionnaire (patients only) and qualitative interviews.
3277392|NCT01630759|Active Comparator|Control group|Control group will consist of usual care and review at clinic.
3277393|NCT01630785||IONM patients|all patients where surgery requires IONM
3277394|NCT01630798|Experimental|Application of peptide|
3277395|NCT01630824|Other|Education|Kidney transplant recipients, who undergo the structured education program
3277396|NCT01630824|No Intervention|Control|Kidney transplant recipients without structured education programm
3277397|NCT01630837|Other|12h|Frequency of oral hygiene was 12 to 12 hours.
3277398|NCT01630837|Other|24h|Frequency of oral hygiene was 24 to 24 hours.
3277399|NCT01630837|Other|48h|Frequency of oral hygiene was 48 to 48 hours.
3277400|NCT01630837|Other|72h|Frequency of oral hygiene was 72 to 72 hours.
3277401|NCT01630850|Experimental|Allogenic islet cells (human, U. Chicago)|
3277402|NCT01630863|Experimental|50% group|power of PDT is applied to the patients at 50% of the full energy based on TAP study.
3277403|NCT01630863|Experimental|40% group|Decreasing power of PDT is applied to the patients at 40% of the full energy based on TAP study.
3277404|NCT01630863|Experimental|30% group|Decreasing power of PDT is applied to the patients at 30% of the full energy based on TAP study.
3277405|NCT01630876|Sham Comparator|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only.
3277406|NCT01630876|Experimental|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection.
3277407|NCT01630928|Experimental|Renal sympathetic denervation|Patients with treatment resistant hypertension
3277408|NCT01630941|Active Comparator|Denosumab|1 ml (60 mg) subcutaneous injection Denosumab give in the posterior part of the upper arm after surgery followed by another injection 6 months later
3277409|NCT01630941|Placebo Comparator|saline|1 ml subcutaneous injection 0.9% saline give in the posterior part of the upper arm after surgery followed by another injection 6 months later
3277410|NCT01630954|Active Comparator|Single evacuation of mole,|
3277411|NCT01630954|Active Comparator|Double evacuation of mole|
3277412|NCT01630967|Experimental|Degarelix|Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.
3277413|NCT01630993|Experimental|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
3277414|NCT01630993|No Intervention|Immediate Cord Clamping|At birth, the infant will be held at the level of the placenta and umbilical cord will be clamped within 10 seconds (routine practice).
3277415|NCT01631006|Sham Comparator|Low CPAP pressure|Patients are submmited to a CPAP with low pressure for 20 minutes
3277416|NCT01631006|Active Comparator|High CPAP pressure|Patients are submmited to a high pressure of CPAP for 20 minutes
3277417|NCT01631019|Active Comparator|with mobile phone assistance|In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
3277418|NCT01631019|Placebo Comparator|with free walk|Patients in the control group were educated the same exercise protocol, but were only verbally asked to freely take the walking exercise training at home. The adherence to the walking exercise at home was reported by the patients themselves at every return visits. All the patients received ISWT, spirometry and blood sample for inflammatory biomarkers at baseline, 1, 2, 3 and 6 months.
3277419|NCT01631032|Placebo Comparator|Control|control group receive placebo capsule with same look, smell and flavor compared with experiment group. The scheme for medication is 3 times a day, 3gm each time, total 9gm per day.
3277420|NCT01631032|Experimental|Chinese herbal products (CHP)|CHP group receive Qi-tonifying Chinese herbal products capsule, 3 times a day, 3gm each time, total 9gm per day
3277421|NCT01631045||15 min|Subjects post-meal brain MRI will be 15 minutes after breakfast.
3277422|NCT01631045||30 min|Subjects post-meal brain MRI will be 30 minutes after breakfast.
3277423|NCT01631045||60|Subjects post-meal brain MRI will be 60 minutes after breakfast.
3277424|NCT01631045||120|Subjects post-meal brain MRI will be 120 minutes after breakfast.
3277425|NCT01631045||180|Subjects post-meal brain MRI will be 180 minutes after breakfast.
3277426|NCT01631045||240|Subjects post-meal brain MRI will be 240 minutes after breakfast.
3277427|NCT01631045||300|Subjects post-meal brain MRI will be 300 minutes after breakfast.
3277428|NCT01631058|Experimental|Everolimus|"Number of patients: 45 Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
3277429|NCT01631084|Experimental|JADE|Patients randomized to the JADE group will be followed according to protocol-driven diabetes care based on their individual risk levels, using a web-based disease management program. In addition to their annual comprehensive assessments at baseline, year 1 and year 2, all subsequent follow-up visits will be documented and entered into the JADE portal, which will then issue reports to both patients and doctor to promote sharing of information and informed decisions.
3277430|NCT01631084|Active Comparator|DIAMOND|Patients will receive a comprehensive assessment at baseline, year 1 and year 2. In the interim between these time points patients will be managed according to 'usual care' procedures.
3277431|NCT01631123|Experimental|Diet interventions|Sequential dietary intervention
3277432|NCT01631136|Active Comparator|Continuous maintenance Therapy|Induction chemotherapy by cisplatin + pemetrexed and maintenance therapy by pemetrexed
3277433|NCT01631136|Experimental|Maintenance according to the response of induction|"Induction chemotherapy by cisplatin + gemcitabine followed by :~continuous maintenance therapy by gemcitabine if response disease~switch maintenance therapy by pemetrexed if stable disease"
3277434|NCT01631162|No Intervention|lung disease|
3277435|NCT01631175|Experimental|(PO-Bado, FBK-R10, PHQ) Active Comparator|
3277436|NCT01631201|Experimental|Rifalazil 25 milligram|
3277437|NCT01631201|Active Comparator|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
3277438|NCT01631240||Adults 18-39 years|Healthy adults aged 18-39 years
3277439|NCT01631253|Active Comparator|single-port access laparoscopic ovarian cyst enucleation|Procedure: Operative laparoscopic ovarian cyst enucleation was performed only through an umbilical single port. ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with three 5mm trocars inserted into three fingers was draped around the rim of the wound retractor.)
3277440|NCT01631253|Active Comparator|two-port laparoscopic access ovarian cyst enucleation|Procedure: Operative access laparoscopic ovarian cyst enucleation was performed using an umbilical single port ( 2 cm longitudinal incision was made within the umbilicus and an wound retractor (Alexis Wound Retractor XS) was inserted into the wound opening. A surgical glove with two 5mm trocars inserted into two fingers was draped around the rim of the wound retractor.) and one 5-mm trocar in the lower abdomen.
3277441|NCT01631253|Active Comparator|four-port access laparoscopic ovarian cyst enucleation|Procedure: : Operative laparoscopic ovarian cyst enucleation was performed through insertion of a 12-mm subumbilical trocar and three 5-mm trocars in the lower abdomen.
3277442|NCT01631266|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3277443|NCT01631266|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3277444|NCT01631279|Experimental|PR610|
3277445|NCT01631292|Placebo Comparator|600 IU D3|
3277446|NCT01631292|Active Comparator|2000 IU D3|
3277447|NCT01631292|Active Comparator|4000 IU D3|
3277448|NCT01631305|Experimental|Levothyroxine|3 mcg/kg/day
3277449|NCT01631305|Placebo Comparator|Control|Calcium magnesia.
3277450|NCT01631318|Experimental|Diagnostic (3D contrast-enhanced ultrasound imaging)|Patients undergo 3D dynamic contrast-enhanced ultrasound imaging before initiation of chemotherapy and at 2 weeks.
3277451|NCT01631344|No Intervention|Physical Therapy|Conventional Physical Therapy
3277452|NCT01631344|Experimental|Daily physical activity consultation, Using Stage of change|
3277453|NCT01631357|Experimental|Arm 1: CIK+CT|Arm 1: We design chemotherapy combination with CIK cell immunotherapy as a experimential arm.
3277454|NCT01631357|Active Comparator|Arm 2: CT|Arm 2: We design chemotherapy alone as a control arm
3277455|NCT01631370|Experimental|Renal denervation|The patients will be examined prior to renal denervation and 6 months after. Thus the patients are their own controls.
3377667|NCT04190550|Experimental|Treatment (AMG 232, cytarabine, idarubicin)|Patients receive AMG 232 PO QD on days 1-7, cytarabine IV over 3 hours BID on days 1-7, and idarubicin IV over 10-15 minutes on days 1-3. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease may receive cytarabine IV BID over 3 hours for 5 days and idarubicin IV over 10-15 minutes for 2 days starting between days 14-21 of cycle 1 or the second cycle of AMG 232, cytarabine, and idarubicin. Patients who achieve a CR or a CRi in either cycle 1 or 2 may receive cytarabine IV BID over 3 hours on days 1, 3, and 5 for 3-4 additional 28 to 35-day cycles in the absence of disease progression or unacceptable toxicity.
3277456|NCT01631383|Placebo Comparator|Placebo|
3277457|NCT01631383|Active Comparator|l-THP|
3377674|NCT04173065|Placebo Comparator|Placebo|
3377675|NCT04173065|Experimental|1.0 mg|
3377676|NCT04173065|Experimental|2.5mg|
3377677|NCT04173065|Experimental|5.0 mg|
3277458|NCT01631396||Patients recieving Sugammadex|Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
3277459|NCT01631396||Patients recieving Neostigmine|Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body.
3277460|NCT01631409||Cohort 0|"Cohort 0 is allocated for the following two patient groups:~The patients with suspicion of angina although in whom the thorough investigation has not revealed CHD and the pain syndrome has been received the extracardiac interpretation (e.g. vertebral osteochondrosis, left side humeroscapular periarthritis, herpes zoster, intercostal neuralgia Tietze syndrome etc.)~The patients with subclinical manifestation of coronary atherosclerosis without angina (Class 0 angina, here and further is according to the Canadian Cardiovascular Society Angina Classification). This subgroup of the patients is recommended the proper diet, life style modification, lipid targeting medications in some cases, and no antianginal treatment."
3277461|NCT01631409||Cohort I|Represents patients with Class 1 angina, who receive OMT.
3377678|NCT04173065|Experimental|10 mg|
3377679|NCT04172025||Patients with colonization or infections with a pathogen|All patients with either colonisations or infections with either a bacterial or a viral pathogen, where whole genome sequencing data and available minimal epidemiological, demographic and clinical data
3377680|NCT04171765|Placebo Comparator|Fixed Dose: Placebo|Participants will receive a fixed dose of placebo matched to BFKB8488A.
3377681|NCT04171765|Placebo Comparator|Individualized Dose: Placebo|Participants will received a dose of placebo matched to BFKB8488A.
3277462|NCT01631409||Cohort II|"Comprises the patients with Class 2-4 angina, they are on MAAMT. The cohort is further divided in two groups:~The patients for whom MAAMT is effective.~The patients for whom MAAMT is not effective or not sufficiently effective, although those patients have not received any invasive, surgical or CSWT interventions yet.~They are those patients who then form cohorts III-VI."
3377682|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose A|Participants will receive BFKB8488A.
3377683|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose B|Participants will receive BFKB8488A.
3277463|NCT01631409||Cohort III|Consists of patients already received PCA. They also continue various MAAMT.
3377684|NCT04171765|Experimental|Fixed Dose: BFKB8488A Dose C|Participants will receive BFKB8488A.
3377685|NCT04171765|Experimental|Individualized Dose: BFKB8488A|Participants will receive increasing doses of BFKB8488A up to the highest tolerated dose .
3377686|NCT04166409|Active Comparator|Arm I (vincristine sulfate, carboplatin)|"INDUCTION: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, 15, 22, 29, 36, 43, 50, 57, and 64, and carboplatin IV over 60 minutes on days 1, 8, 15, 22, 43, 50, 57, and 64 in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive vincristine sulfate IV over 1 minute on days 1, 8, and 15, and carboplatin IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 42 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity."
3377687|NCT04166409|Experimental|Arm II (selumetinib sulfate)|Patients receive selumetinib sulfate PO BID on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity.
3377688|NCT04163809|No Intervention|Control Group (no VR)|Patients will be randomly allocated to the control group, which receives no Virtual Reality (VR) during the regional anesthesia procedure.
3377689|NCT04163809|Experimental|Experimental Group (VR)|Patients will be randomly allocated to the the experimental group, which receives VR during the regional anesthesia procedure.
3377690|NCT04154787|Experimental|LNP023|LNP023
3377691|NCT04154787|Active Comparator|Rituximab|Rituximab
3277464|NCT01631409||Cohort IV|Includes the patients after CABG. They also are on various MAAMT.
3277465|NCT01631409||Cohort V|Incorporates the patients who have already underwent CSWT. They also receive individualized MAAMT.
3377692|NCT04145141||1/ Cohort 1|Subjects with a diagnosis or suspicion of PLC
3377694|NCT04142983|Experimental|Study Group|Participants will receive a single dose of Tdap vaccine (Adacel) every 3 months for a total of 5 immunizations over a period of 12 months.
3377695|NCT04142788|No Intervention|Standard dose MRA|Participants in this arm will have titration to guideline-recommended doses of MRA attempted.
3377696|NCT04142788|Experimental|Patiromer and high dose MRA|Participants assigned to patiromer may be titrated to 200mg/day spironolactone or the highest licensed dose of eplerenone (50mg/day).
3277466|NCT01631409||Cohort VI|"The cohort is composed of the patients who for various reasons have not been exposed to any intervention except MAAMT and continue to be on it.~The algorithm of the cohort formation is graphically demonstrated in the Diagram The logic tree of the cohort formation (see the link at the bottom of the protocol)."
3277467|NCT01631422|Experimental|Single Arm|
3277468|NCT01631448|No Intervention|Control|Patients fron this group do not receive the fibrin sealant
3277469|NCT01631448|Active Comparator|Fibrin group|Patients from this group will receive the fibrin sealant
3277470|NCT01631461||1. Deep pain group|1. Deep pain group; Pain in the breast
3277471|NCT01631461||2. Superficial pain group|Pain on the nipple and/or aereola
3277472|NCT01631461||3. Control group|No pain or other breastfeeding problems
3277473|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 1)|
3277474|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 1)|
3277475|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 1)|
3277476|NCT01631487|Experimental|Caucasian Group 1: JNJ-39439335/placebo (Part 1)|
3277477|NCT01631487|Experimental|Caucasian Group 2: JNJ-39439335/placebo (Part 1)|
3277478|NCT01631487|Experimental|Caucasian Group 3: JNJ-39439335/placebo (Part 1)|
3277479|NCT01631487|Experimental|Japanese Group 1: JNJ-39439335/placebo (Part 2)|
3277480|NCT01631487|Experimental|Japanese Group 2: JNJ-39439335/placebo (Part 2)|
3277481|NCT01631487|Experimental|Japanese Group 3: JNJ-39439335/placebo (Part 2)|
3277482|NCT01631500|Other|Conventional treatment|Patients receive usual treatments provided at primary care settings, e.g. antidepressants, sessions with a curator or psychotherapist and physiotherapy.
3277483|NCT01631500|Experimental|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
3277484|NCT01631500|Active Comparator|Terapeutic acupuncture|Therapeutic acupuncture alone, eight individual sessions, once a week. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
3277485|NCT01631513|Experimental|Nucynta ER|Nucynta ER will be 100 to 250 mg every 12 hours
3277486|NCT01631526|Experimental|Vitamin D|vitamin D 20,000 IU per day for 2 weeks followed by 10,000 IU per day for a further 7 days
3277487|NCT01631539|Other|Chemoembolization|chemoembolization with DC Bead™ loaded with Irinotecan
3277488|NCT01631565|No Intervention|Standard care|Usual care given to the patients. Treatment, follow-up.
3277489|NCT01631565|Experimental|Early Palliative Care|"Intervention: Early allocation to palliative care. Intervention: Nutritional counseling. Intervention: patient and care-taker psychoeducation, depression and anxiety evaluation.~Standard of care: Oncological treatment according to stage of disease (IIIb/IV).~Treatment: Chemotherapy (platins, taxans, TKIs) Baseline: BMI, and anthropometric characteristics (weight, height). Follow-up: During 6 chemotherapy circles with: Quality of Life (EORTC qlq-c30), HADS, ESAS and ZARIT."
3277490|NCT01631578|Experimental|Injection of mitochondrial concentrate|A small volume of mitochondrial concentrate will be injected together with the spermatozoon during ICSI.
3277491|NCT01631578|Active Comparator|Control|ICSI will be performed conventionally.
3277492|NCT01631591||eosinophilic esophagitis|PATIENTS WITH A CURRENT DIAGNOSIS OF eosinophilic esophagitis.
3277493|NCT01631591||GERD|PATIENTS WITH A DIAGNOSIS WITH GERD.
3277494|NCT01631617|Active Comparator|1A/Cephalexin|Cephalexin + Placebo bleach
3277495|NCT01631617|Active Comparator|1B/TMP/SMX|TMP/SMZ DS 800 /160 orally every 12 hours for 14 days
3277496|NCT01631617|Active Comparator|1C/Doxycycline 100|Doxycycline 100 mg orally every 12 hours for 56 days
3277497|NCT01631617|Active Comparator|1D/Doxycycline 20|Doxycycline 20 mg orally every 12 hours for 56 days
3277498|NCT01631617|Active Comparator|2A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
3277499|NCT01631617|Placebo Comparator|2B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
3277500|NCT01631617|Placebo Comparator|2C/Placebo capsules + Dilute bleach|Placebo capsules + dilute bleach study bath liquid
3277501|NCT01631617|Placebo Comparator|2D/Placebo capsules + Placebo bleach|Placebo capsules + placebo study bath liquid
3277502|NCT01631617|Active Comparator|3A/Cephalexin + Dilute bleach|Systemic antibiotics (Cephalexin) + dilute bleach study bath liquid
3277503|NCT01631617|Placebo Comparator|3B/Cephalexin + Placebo bleach|Systemic antibiotics (Cephalexin) + placebo study bath liquid
3277504|NCT01631669|Experimental|Celebrex|Receive Celebrex
3277505|NCT01631669|No Intervention|Control|no placebo administered
3277506|NCT01631708|Active Comparator|Erythrocytapheresis|"Erythrocytapheresis is a procedure whereby whole blood is drawn from an individual and all elements except erythrocytes are returned to the donor. An automated filtration process removes the erythrocytes.~Those in arm 1 will have third weekly erythrocytapheresis until their SF is returned to the normal range."
3277507|NCT01631708|Sham Comparator|Plasmapheresis|"In plasmapheresis, the plasma is removed by the automated filtration process whilst other blood elements including erythrocytes are returned to the subject.~Those in arm 2 will have plasmapheresis with the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm."
3277508|NCT01631721||Cohort 1|Cohort of adolescents recruited in 2012-2013 of study
3277509|NCT01631721||Cohort 2|Cohort of adolescents recruited in year 2013-2014 of study
3277510|NCT01631721||Cohort 3|Cohort of adolescents recruited in year 2014-15 of study
3277511|NCT01631760||MicroRNA ages 5-12 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3277512|NCT01631760||MicroRNA ages 13-55 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3277513|NCT01631760||MicroRNA ages 56-85 yrs old|As a prospective study, we would like to look for the differential expression of microRNA in different age groups (ages 5 to 12, 13 to 55, and 56 and older) of asthma patients with exacerbation. At least 20 patients for each group is anticipated.
3377697|NCT04137289|Experimental|Phase Ia: BI 905711 - dose escalation|
3277514|NCT01631773||subjects w/ Nasal polyps & AERD disease|subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
3277515|NCT01631773||subjects w/ nasal polyps without AERD|subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
3277516|NCT01631786||Preserved ovaries|Ovaries or ovarian segments that have been fixed in 10% Formalin
3277517|NCT01631786||Fresh/non-preserved ovaries|Ovaries that have been surgically removed and placed in sterile saline
3277518|NCT01631799|Active Comparator|Femoral Block|One group received a femoral block for analgesia after surgery. Ropivacain was administered continuously for three days.
3277519|NCT01631799|Active Comparator|Epidural Analgesia|One group received an epidural analgesia after surgery for three days.
3277520|NCT01631838|Experimental|Tocotrienol-rich fraction 400mg|
3277521|NCT01631838|Experimental|Placebo|
3277522|NCT01631851|Experimental|Cognitive behavior therapy|
3277523|NCT01631877|Experimental|enoxaparin with acenocoumarol|Patients will receive enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg with titration of dose to maintain a target INR of 2-3.intially the INR will be monitored twice weekly with gradual escalation of dose to achieve target INR.After achieving the target INR this is to be repeated every 4th weekly. The Doppler Ultra Sonography screening will be done every 3monthly to assess the recanalization of portal vein thrombus but the medications will be continue for one year irrespective of recanalization.
3277524|NCT01631877|Placebo Comparator|Placebo|Injection placebo will be given for 5 days along with placebo tablets.
3277525|NCT01631890|Active Comparator|standard endotherapy|
3277526|NCT01631890|Experimental|Endoscopic Ultrasound assisted endoscopic glue injection|
3277527|NCT01631903|Experimental|Arm 2 (3mg)|
3277528|NCT01631903|Experimental|Arm 3 (6 mg)|
3277529|NCT01631903|Experimental|Arm 4 (12 mg)|
3277530|NCT01631903|Experimental|Arm 5 (24 mg)|
3277531|NCT01631903|Experimental|PK arm (12 mg)|PK arm requires one additional 24 hour PK assessment at V3 and daily visits between visits 2 and 3 for drug trough sample collection
3277532|NCT01631916|Experimental|Corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
3277533|NCT01631916|No Intervention|Control|No intervention
3277534|NCT01631942|Experimental|Low dose (healthy subjects)|
3277535|NCT01631942|Experimental|Medium dose (subjects with haemophilia)|
3277536|NCT01631942|Experimental|High dose (subjects with haemophilia)|
3277537|NCT01631955||Cystitis|female with cystitis symptoms
3277538|NCT01631968|Experimental|Cement with erytromycin and colistin|In this group the knee arthroplasty was fixed with cement with erythromycin and colistin.
3277539|NCT01631968|Placebo Comparator|Cement without antibiotic|In this group the knee arthroplasty was fixed with standard cement, without any antibiotics.
3277540|NCT01631981|Experimental|PGL2001|PGL2001 + NETA followed by NETA-only follow-up period
3277541|NCT01631981|Placebo Comparator|Placebo|Placebo + NETA followed by NETA-only follow-up period
3277542|NCT01631994|Experimental|Oral Dissolving metoclopramide|Patient's in this arm will receive the oral dissolving metoclopramide along with the capsule during capsule endoscopy.
3277543|NCT01631994|No Intervention|control group|This is the control group that will only ingest the capsule during video capsule endoscopy.
3277544|NCT01632007|Experimental|SYR-472 100 mg|
3277545|NCT01632007|Active Comparator|Alogliptin 25 mg|
3277546|NCT01632007|Placebo Comparator|Placebo|
3277547|NCT01632033||Investigation for lower limb arteries|Patients referred for investigation of assumed peripheral artery disease (PAD)
3277548|NCT01632046|Active Comparator|BicaVera, dialysis|Two Parallel arms. If patient randomised to the BicaVera arm he will be dialysed with bicarbonate based PD fluid (BicaVera) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
3277549|NCT01632046|Active Comparator|Balance, dialysis|If patient is randomised to the Balance arm, he will be dialysed with lactate based PD fluid (Balance) for 10 months. Dialysis prescription is determined according to clinical needs, dialysate glucose concentrations are 1.5, 2.3 and 4.25 %.
3277550|NCT01632059||septical patients|inclusion criteria are severe sepsis and septical shock and must be > 18 y/o
3277551|NCT01632072|Experimental|Nutritional counseling|Dietary supplement
3277552|NCT01632072|No Intervention|No nutritional counceling|
3277553|NCT01632085|Other|Group SU (Single use or Laryngobloc ®) ®)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Laryngobloc ®.
3277554|NCT01632085|Other|Group R (Reusable handle)|In order to avoid an order effect, the patient acting as his own control, will randomly undergo a laryngoscopy with each laryngoscopes, the intubation being performed during the second laryngoscopy, here with the Disposable Metal Blade.
3277555|NCT01632098||extremely obese|BMI ≥35kg/m2
3277556|NCT01632098||obese|BMI 30-34.9kg/m2
3277557|NCT01632137|Placebo Comparator|Placebo (vehicle)|
3277558|NCT01632137|Experimental|Rebamipide 2% ophthalmic suspension|
3277559|NCT01632163|Experimental|Lixisenatide|24-week treatment with lixisenatide once daily on top of basal insulin with or without metformin (at least 1.0g/day)
3277560|NCT01632163|Placebo Comparator|Placebo|24-week treatment with placebo once daily on top of basal insulin with or without metformin (at least 1.0g/day)
3277561|NCT01632176|No Intervention|Standard of care|Patients in the control group will not receive any intervention, but will receive standard care for dating abuse issues.
3277562|NCT01632176|Experimental|Intervention|Patients in the intervention group will participate in brief, motivational interview and one booster session to prevent adolescent dating abuse.
3277563|NCT01632189|Experimental|Varenicline|Varenicline will be used at the same dosage regimen as used for smoking cessation, i.e. 0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily. The total duration of Varenicline treatment will be three months.
3277564|NCT01632228|Experimental|Onartuzumab + Bevacizumab|All participants will receive onartuzumab intravenous (IV) infusion followed by bevacizumab IV infusion every 3 weeks.
3277565|NCT01632228|Active Comparator|Placebo + Bevacizumab|All participants will receive placebo matched with onartuzumab followed by bevacizumab IV infusion every 3 weeks.
3377698|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 1|
3377699|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 2|
3277566|NCT01632254||Patients with ≥70% carotid artery stenosis|
3277567|NCT01632293|Experimental|exercise|Individuals with multiple sclerosis and age and gender matched healthy controls will participate in a supervised exercise program for 12 weeks.
3277568|NCT01632319|Experimental|MI + CBT|Motivational Interviewing (MI) and cognitive behavioral therapy (CBT). In this course of therapy students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms.
3377700|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 3|
3377701|NCT04137289|Experimental|Phase Ib: BI 905711 - dose level 4|
3277569|NCT01632319|Active Comparator|CBT|Cognitive behavior therapy (CBT)
3377704|NCT04135352|Experimental|V938 Dose A + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose A of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously once every 3 weeks (Q3W) beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
3377705|NCT04135352|Experimental|V938 Dose B + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
3377706|NCT04135352|Experimental|V938 Dose C + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
3277570|NCT01632332|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID every 28 days for up to 6 courses in the absence of disease recurrence or unacceptable toxicity.
3277571|NCT01632358|Experimental|TAP311 capsules|Patients will receive TAP311 capsule orally once daily for 14 days.
3277572|NCT01632358|Placebo Comparator|Placebo of TAP311 capsules|Matching placebo to TAP311 capsule, once daily for 14 days
3277573|NCT01632371|Experimental|Paclitaxel Eluting Balloon + Scoring Balloon|Dilatation of the lesion with an Paclitaxel Eluting Balloon before the utilization of a Scoring Balloon
3277574|NCT01632371|Active Comparator|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon
3277575|NCT01632397|Experimental|CBT-based counseling|Cognitive behavioral based intervention to promote PrEP adherence.
3377707|NCT04135352|Experimental|V938 Dose D + delayed pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 2 for a maximum of 35 cycles. Each cycle is 21 days.
3377708|NCT04135352|Experimental|V938 Dose B + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose B of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
3377709|NCT04135352|Experimental|V938 Dose C + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose C of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
3377710|NCT04135352|Experimental|V938 Dose D + immediate pembrolizumab|This arm will enroll participants with advanced/metastatic or recurrent solid tumors. Participants receive Dose D of V938 intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
3377711|NCT04135352|Experimental|Dose Expansion Arm A, Melanoma|This arm will enroll only participants with with a diagnosis of stage III (unresectable) and Stage IV melanoma (any line of therapy). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
3277576|NCT01632397|Active Comparator|Health education and supportive counseling|Time matched supportive counseling
3277577|NCT01632410||Study group 1|"Post hemispheral ischemic stroke cognitively intact. Exclusion: Subjects with severe visual or hearing impairments, stroke location brain steam.~The group will be divided in to 4 goups acording to stroke specific location as demonstrated in MRI."
3277578|NCT01632410||Control|Control: Healthy subjects resemble in age and sex
3277579|NCT01632410||Study -3|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3277580|NCT01632410||Stydy -2|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3377712|NCT04135352|Experimental|Dose Expansion Arm B, HNSCC|This arm will only enroll participants with a diagnosis of advanced/metastatic head and neck squamous cell carcinoma (HNSCC). Participants receive V938 at the recommended Phase 2 Dose, determined by analysis of the Dose A-C arms, intratumorally in cycles 1-7. Participants also receive 200 mg of pembrolizumab intravenously Q3W beginning with cycle 1 for a maximum of 35 cycles. Each cycle is 21 days.
3377713|NCT04128319|Experimental|T-Guard Treatment|Patients will receive T-Guard for treatment of steroid-refractory acute GVHD.
3377715|NCT04120714|Experimental|Active tDCS group|Active tDCS
3377716|NCT04120714|Placebo Comparator|Placebo tDCS group|Inactive tDCS
3277581|NCT01632410||Stydy- 4|As explained the subjects will be divided into 4 groups acording to the stroke location. this is in order to evaluat the relationship between location and autonomic responed.
3277582|NCT01632436|Experimental|Stage 1 -Moderate Hepatic Impairment|Pixantrone
3377719|NCT04105855||Older Infants|Infants age 6-12 months presenting for routine healthy visits
3377720|NCT04105855||Pregnant Women|Women 18 years and older (and emancipated minors) presenting for routine antenatal visits
3377721|NCT04102423||CCUS|All participants meeting the criteria for CCUS
3277583|NCT01632436|Experimental|Stage 2 - Severe Hepatic Impairment|Pixantrone
3277584|NCT01632449|Experimental|1|Test product
3377722|NCT04102423||CHIP|Subjects will be split into five cohorts depending on specific mutations
3377723|NCT04095026||Patients|Patients age >18 years and <= 65 years enrolled in 11-N-0051 Epilepsy Surgery
3277585|NCT01632449|Experimental|2|Reference product
3277586|NCT01632462|Active Comparator|VSL#3 arm|15 patients with a diagnosis of Crohn's disease will be exposed to VSL#3 for 8 weeks
3377725|NCT04091893|Active Comparator|Usual care/wait list|
3377726|NCT04091893|Experimental|Art Rx|
3277587|NCT01632462|Placebo Comparator|placebo group|15 patients affected by Crohn's disease will be exposed to a placebo for 8 weeks
3277588|NCT01632475||Pneumostem®|Low Dose Group (3 subjects): 1.0 x 10^7 cells/kg, High Dose Group (6 subjects): 2.0 x 10^7 cells/kg
3277589|NCT01632488||Irritable bowel syndrome|Patients admitted to outpatient department with symptoms meeting Rome III criteria of irritable bowel syndrome.
3377727|NCT04091893|Experimental|Artful Meditation|
3377728|NCT04091893|Experimental|Art Rx + Artful Meditation|
3377729|NCT04088578|Experimental|Vagus nerve stimulation (VNS)|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. VNS will be delivered when a minimum level of accuracy has been achieved.
3377730|NCT04088578|Sham Comparator|Sham stimulation|Stroke and control subjects will undergo 3 testing sessions and 8 training sessions in these experiments. Subjects will hold a force transducer between the index finger and thumb to control the path of an object through targets displayed on a computer monitor. Sham stimulation will be delivered when a minimum level of accuracy has been achieved.
3377731|NCT04088565|Experimental|PAS+VNS|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with VNS in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
3377732|NCT04088565|Sham Comparator|PAS+Sham|Paired-associative stimulation (PAS) targeting primary motor cortex will be administered with sham stimulation in individuals with hemiparesis secondary to stroke and neurologically-intact, age-matched controls.
3277590|NCT01632488||Inflammation|Patients with long standing history or short onset of inflammatory bowel disease.
3277591|NCT01632488||Normal controls|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3377735|NCT04086121|Experimental|All Subjects|
3377736|NCT04084366|Experimental|OBI-999 Escalation phase|Part A: Five cohorts at escalating dose levels 0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg (capping calculations at a maximum at 100 kg) of OBI-999 liquid form via IV infusion to establish maximum tolerated dose (MTD) and Recommended phase 2 dose (RP2D).
3377737|NCT04084366|Experimental|OBI-999 Expansion Phase|Part B: Five cohorts of patients at RP2D of OBI-999 liquid form, as determined from Part A, via IV infusion.
3377738|NCT04076579|Experimental|Olaparib + Trabectedin|"There are 2 cohorts. Both cohorts receive the same treatment:~Cohort 1: Leiomyosarcoma and liposarcoma~Cohort 2: Other bone or soft tissue sarcoma histologies~Treatment consists of 21-day cycles for a maximum of 18 months."
3377739|NCT04069637||Early onset Scoliosis|Patients with early onset scoliosis treated with growth-sparing instrumentation (TGR, MCGR, and, VEPTR).
3377740|NCT04069637||Control group|Patients with operative fractures.
3377741|NCT04061031|Experimental|Parent-Child Interaction Therapy|
3277592|NCT01632514|Active Comparator|Vitamin D deficiency treatment|subjects with 25OHD < 20 ng/mL that will receive 100,000U of cholecalciferol weekly for 4 weeks before surgery
3277593|NCT01632514|No Intervention|Vitamin D deficiency observation|subjects with 25OHD < 20 ng/mL that will not receive cholecalciferol before surgery
3377742|NCT04061031|Active Comparator|Child-Centered Therapy with Parent Education|
3277594|NCT01632514|No Intervention|Vitamin D sufficiency|controls with 25OHD >= 20 ng/mL that will not receive cholecalciferol before surgery
3277595|NCT01632527|Experimental|HuCNS-SC|HuCNS-SC cells
3277596|NCT01632540||Perennial Allergic Rhinitis patients|
3277597|NCT01632553||Cases|women who have experienced DVA
3277598|NCT01632553||Controls|women who have not experienced DVA
3277599|NCT01632592|Experimental|Growth Hormone Releasing Hormone|Growth Hormone Releasing Hormone analogue, 2mg subcutaneously every day for 12 months.
3277600|NCT01632592|Placebo Comparator|Placebo|
3277601|NCT01632605|Experimental|Sirolimus|Daily single oral dose of 1-3mg sirolimus with an initial loading dose of 6mg.
3277602|NCT01632618|Experimental|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
3277603|NCT01632618|Active Comparator|Passive control intervention|Passive physical therapy interventions, including moist heat, ultrasound, massage and flexibility exercises
3277604|NCT01632631||PROcedure rehearsal|PROcedure rehearsal performed before real EVAR procedure No intervention
3277605|NCT01632631||No PROcedure rehearsal|no PROcedure rehearsal performed before real EVAR procedure No intervention
3277608|NCT01632657|Experimental|Sumatriptan|Subcutaneous injection of sumatriptan (6 mg)
3277609|NCT01632657|Placebo Comparator|Placebo|Matching placebo (0.9% saline)
3277610|NCT01632670|Experimental|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
3277611|NCT01632670|No Intervention|No music therapy|
3277612|NCT01632696|Experimental|I-124 PGN650 for PET/CT|
3277613|NCT01632722|Active Comparator|ArmA|
3277614|NCT01632722|Active Comparator|ArmB|
3277615|NCT01632748|Experimental|Modified Neurotech Vital Device|Checking to observe stimulation delivered using this device
3277616|NCT01632748|Active Comparator|Neurotech Vital Device|Checking to see if stimulation observed using this device
3277617|NCT01632761|Active Comparator|Vitamin D + fish oil|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
3277618|NCT01632761|Active Comparator|Vitamin D + fish oil placebo|Dietary Supplement: Vitamin D3 (cholecalciferol), 2000 IU per day. Other Name: cholecalciferol Dietary Supplement: Fish oil placebo Fish oil placebo
3277619|NCT01632761|Active Comparator|Vitamin D placebo + fish oil|"Drug: omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).~Dietary Supplement: Vitamin D3 placebo Vitamin D placebo"
3277620|NCT01632761|Active Comparator|Vitamin D placebo + fish oil placebo|Dietary Supplement:Vitamin D3 placebo Vitamin D placebo Dietary Supplement: Fish oil placebo Fish oil placebo
3277621|NCT01632813||CHD group|Seven-year-old children with CHD who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). The children of the CHD-group underwent cardiac surgery as infants (=<1year).
3277622|NCT01632813||Control group|Seven-year-old healthy control children who were four years old when they participated in Paediatric ICU follow-up study (i.e. first follow-up time point) (Neurocognitive development of children four years after critical illness and treatment with tight glucose control, Clinical Trials # NCT00214916). These children have never undergone cardiac surgery.
3277623|NCT01632839||Vaginal surgery +prothesis +sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are sexually active.
3277624|NCT01632839||Vaginal surgery +prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse with placement of a prothesis; these patients are NOT sexually active.
3277625|NCT01632839||Vaginal surgery -prothesis + sexuality|The 50 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are sexually active.
3277626|NCT01632839||Vaginal surgery -prothesis -sexuality|The 25 patients included in this group will have undergone vaginal surgery for pelvic organ prolapse WITHOUT placement of a prothesis; these patients are NOT sexually active.
3277627|NCT01632839||Abdominal surgery +sexuality|The 50 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are sexually active.
3277628|NCT01632839||Abdominal surgery -sexuality|The 25 patients included in this group will have undergone abdominal surgery for pelvic organ prolapse; these patients are NOT sexually active.
3277629|NCT01632839||Urinary incontinence surgery + sexuality|The 50 patients included in this group will have surgery for urinary incontinence; these patients are sexually active.
3277630|NCT01632839||Urinary incontinence surgery - sexuality|The 25 patients included in this group will have surgery for urinary incontinence; these patients are NOT sexually active.
3277631|NCT01632852|Experimental|CSL362|See Intervention Description
3277632|NCT01632865|Experimental|recanalization and stenting|
3277633|NCT01632917|Experimental|ATX-101 - EU|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
3277634|NCT01632917|Experimental|ATX-101 - US|Open Label study in which subjects will receive ATX-101 (one of the two formulations) in one dosing session in the submental area
3277635|NCT01632930|Experimental|Results of urinary PCA3 test will be available|In this arm, physicians will have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion is likely to be influenced by urinary PCA3 test results
3277636|NCT01632930|Active Comparator|Results of urinary PCA3 test will not be available|In this arm, physicians will not have knowledge of urinary PCA3 test results. How they subsequently manage patients with prostate cancer suspicion will therefore not be influenced by urinary PCA3 test results
3277637|NCT01632943|Experimental|Symplicity renal denervation system|
3277638|NCT01632956||in-person support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
3277639|NCT01632956||virtual support group|This is a 1 year pilot study of the feasibility of participation in both in-person and virtual information-based, culturally tailored support groups for Chinese breast cancer patients.
3277640|NCT01632969||families or next-of-kin of deceased patients|The families of deceased patients treated at MSKCC for non-cutaneous squamous cell carcinomas of the upper aerodigestive tract for whom contact information is available will be recruited by mail and by phone.
3277641|NCT01632982|Other|standard treatment|the standard drug counseling offered to patients in methadone maintenance treatment at the study site
3277642|NCT01632982|Experimental|Mobile Therapeutic System (MTS)|The Mobile Therapeutic System (MTS) is a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
3277643|NCT01632982|Active Comparator|mobile control|a mobile phone-based application that directs participants to the NIDA website's home page
3277644|NCT01633008|Experimental|1|Attend three 2-hour sessions held over two consecutive days
3277648|NCT01633047|Experimental|Electrical stimulation|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training) associated with electrostimulation.
3277649|NCT01633047|Active Comparator|Physical therapy exercises|The subjects on this group will be submitted to a conventional rehabilitation (ROM increase, strength recovery, functional training).
3277650|NCT01633073|Active Comparator|LMA Supreme|
3277651|NCT01633073|Active Comparator|i-gel|
3277652|NCT01633086|Active Comparator|nitric oxide gel|"st gel: sodium nitrites~nd gel: maleic/ascorbic acids"
3277653|NCT01633086|Placebo Comparator|Placebo gel|"st gel: phosphate-buffered saline~nd gel: maleic/ascorbic acids"
3277654|NCT01633099|Other|Decitabine, CR rate,OS,EFS,RFS|Therapeutic effect and safety of 10 days of decitabine. Acute myeloid leukemia,no acute promyelocytic leukemia.
3277655|NCT01633125|Experimental|Group music therapy|Participants in the experimental group will take part in biweekly group music therapy for 10 weeks (20 sessions). Each group will be formed by 6 to 8 people, and each session will last for 90 minutes.The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The active techniques will include musical improvisation as a medium to work with participants according to therapeutic goals and participants' needs.
3277656|NCT01633125|No Intervention|No music therapy|Participants assigned to the control group will not receive any specific treatment in this study. The usual care that is normally available at the prison will continue to be available for all participants during the study.Due to ethical considerations, the control group will receive group music therapy or psychotherapy by academically qualified therapists for 5 weeks after the study is finished.
3277657|NCT01633138|Active Comparator|CRT-S|Cognitive Remediation Therapy - Standard
3277658|NCT01633138|Experimental|CRT-CM|Cognitive Remediation Therapy plus Contingency Management
3277659|NCT01633151||20 volunteers|
3277660|NCT01633164|Experimental|SCI Reinvention Protocol Participants|This group will receive 6 instructor-led 2 hour long didactic presentations regarding 8 key principles of self-efficacy and experiential exercises, including goal setting and problem solving with extensive group discussion. At the end of each session, tasks are assigned to participants to be completed outside the group during the week between sessions. Experiences from these activities and practice implementing the intervention principles will be shared and discussed each week, providing additional opportunities for problem solving and positive feedback.
3277661|NCT01633164|Other|Waitlist Group|This group will include individuals randomized to receive no treatment for the 30 weeks during which the interventional group will receive the active treatment and have their progress tracked.
3277662|NCT01633177|Active Comparator|Vitamin D and Omega-3|
3277663|NCT01633177|Active Comparator|Vitamin D and Omega-3 placebo|
3277664|NCT01633177|Active Comparator|Vitamin D placebo and Omega-3|
3277665|NCT01633177|Placebo Comparator|Vitamin D placebo and Omega-3 placebo|
3277666|NCT01633190||Rotavirus|- Children (0-16 years of age)admitted to hospital (through to December 31, 2020)
3277667|NCT01633203||locally advanced gastric cancer|Patients with resectable, locally advanced cT3-4 and/or N+ gastric carcinoma treated with 3 perioperative epirubicin cisplatin capecitabine polychemotherapy
3277668|NCT01633216|Active Comparator|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
3277669|NCT01633216|Active Comparator|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
3277670|NCT01633216|Active Comparator|Monovalent OPV 2week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
3277671|NCT01633216|Active Comparator|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
3277672|NCT01633216|Active Comparator|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
3277674|NCT01633281|Experimental|acupuncture treatment|
3277675|NCT01633294|Active Comparator|Antibiotic group|women submitted to antibiotic prophylaxis
3277676|NCT01633294|No Intervention|Control group|
3277677|NCT01633307|Experimental|Experimental|Intervention (Teaching program)
3277678|NCT01633307|No Intervention|Control group|No teaching program
3277679|NCT01633333|Experimental|Water exchange|Colonoscopy with water exchange as the sole modality to reach the cecum. Carbon dioxide can be used in case of intubation failure with the test method.
3277680|NCT01633333|Active Comparator|Carbon dioxide insufflation|Carbon dioxide insufflation will be used in standard fashion to reach the cecum.
3277681|NCT01633346||Tocilizumab treated patients|Rheumatoid arthritis patients
3277682|NCT01633359|Experimental|Intensive statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Intensive Atorvastatin protocol indicates that 80mg Atorvastatin will be administrated before CAG, and then are followed with 20mg Atorvastatin during the entire study period."
3277683|NCT01633359|Experimental|Routine statin|"Fifty CAD subjects will receive intensive Atorvastatin administration and 50 CAD patients receiving the routine Atorvastatin administration as controls.~All subjects will receive the follow-up for 1 year, and peripheral blood VSELs, SDF-1/CXCR4 are tested, and the MACE (major adverse cardiovascular events) are recorded including angina, repeat myocardial infarction, repeat revascularization, major organ dysfunction, and death.~the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period."
3277684|NCT01633372|Experimental|itacitinib 100 mg|itacitinib 100 mg twice a day
3277685|NCT01633372|Experimental|itacitinib 200 mg|itacitinib 200 mg twice a day
3277686|NCT01633372|Experimental|itacitinib 300 mg|itacitinib 300 mg once a day
3277687|NCT01633372|Experimental|itacitinib 400 mg|itacitinib 400 mg once a day
3277688|NCT01633372|Experimental|itacitinib 600 mg|itacitinib 600 mg once a day
3277689|NCT01633385||Subject-Group|Patients suffering from doctors diagnosed bronchiolitis obliterans
3277690|NCT01633385||Control Group|age- and sex matched to subject-group
3277691|NCT01633411||Cohort A|Subjects in Cohort A will receive 6 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3277692|NCT01633411||Cohort B|Subjects in Cohort B will receive 8 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3277693|NCT01633411||Cohort C|Subjects in Cohort C will receive 10 seconds of treatment to dysplastic esophageal tissue using the Focal CryoBalloon Ablation System.
3277694|NCT01633437|Placebo Comparator|Sugar pill|
3277695|NCT01633437|Experimental|CX157|CX157 is a reversible monoamine oxidase inhibitor (RIMA) in Phase II development for the treatment of depression.
3277696|NCT01633450|Experimental|Zinc biofortified rice|
3277697|NCT01633450|Active Comparator|Rice extrinsically fortified with zinc|
3277698|NCT01633476|Active Comparator|Valaciclovir|Active treatment with valaciclovir
3277699|NCT01633476|No Intervention|No additional treatment|No additional treatment
3277700|NCT01633489||LAL Deficiency patients|Patients are those with a diagnosis of LAL Deficiency (living and deceased), irrespective of treatment status or treatment choice.
3277701|NCT01633502|Placebo Comparator|Conventional circulatory support|Patients randomized to conventional circulatory support.
3277702|NCT01633502|Active Comparator|Impella|Patients randomized to Impella CP
3277703|NCT01633515|Other|Intralesional cryotherapy|10 BCC (skin lesions) in the lower extremity of elderlies with risk factors for surgical complications.
3277704|NCT01633528|Experimental|Asprin|With the onset of endometrial preparation and estrogen treatment, the study group will receive 100 mg of oral aspirin.
3277705|NCT01633528|Placebo Comparator|placebo|With the onset of endometrial preparation and estrogen treatment, the control group will receive placebo
3277708|NCT01633554||Chronic Hepatitis B Group|Patients with chronic hepatitis B
3277709|NCT01633554||Cirrhosis|Patients with liver cirrhosis
3277710|NCT01633554||Control Group|Control Group: Healthy Volunteers
3277711|NCT01633567|Experimental|Culturally Targeted Cessation Program|The culturally targeted program will include the same cognitive and behavioral approaches and smoking education content that is used in the standard program. As such, we will maintain the integrity of the core program. However, cultural targeting of that program has been informed by local LGBT focus group input and testing, the available literature on LGBT smoking rates and behaviors, feedback from a panel of LGBT health experts, and data collected as part of a previous study.
3277712|NCT01633567|Active Comparator|Non-Targeted Cessation Program|Non-culturally targeted program with cognitive and behavioral approaches and smoking education content.
3277713|NCT01633580|Placebo Comparator|Day 2 group|Patients undergo a standard treatment with a classical start of corifollitropin alfa in a GnRH antagonist protocol.
3277714|NCT01633580|Active Comparator|Day 4 group|Patients undergo an ovarian stimulation, but start on day 4 with corifollitropin alfa
3277715|NCT01633593|Experimental|donepezil|Donepezil 5mg/day during 2 weeks
3277716|NCT01633593|Placebo Comparator|placebo|placebo comparator to donepezil (double blind)
3277717|NCT01633606||Acute patients|Patients admitted to the surgical and general ICU (including burn unit), to the coronary care unit, to the emergency department high care zone, to the medical ICU, to the medical medium care unit
3277718|NCT01633632|Active Comparator|Cognitive behavioral therapy|This group will receive a standardized, 8-session cognitive behavioral therapy course that is offered to the public at our practice.
3277719|NCT01633632|Experimental|Cognitive behavioral therapy + yoga|This group will receive the standardized, 8-session cognitive behavioral therapy course + 8 sessions of Hatha yoga.
3277720|NCT01633632|Experimental|Hatha yoga|This group will receive 8 sessions of Hatha yoga and printed materials to assist with their quit attempt
3277721|NCT01633645|Experimental|Velcade/GEM/CDDP|Bortezomib / Gemcitabine / Cisplatin
3277722|NCT01633658|Active Comparator|Vitamin D Cholecalciferol|A single dose of 2500 micrograms cholecalciferol
3277723|NCT01633658|Experimental|25(OH)D|A single dose of 625 micrograms 25(OH)D
3277724|NCT01633671||Suspected APE|Post-surgical patients with clinically suspected acute pulmonary embolism
3277725|NCT01633684||Diabetes|patients with Type 1 Diabetes Mellitus
3277726|NCT01633684||Control|Age and sex matched control subjects
3277727|NCT01633697|Experimental|Education-Pranayama|Subjects will receive education about COPD with special attention to breathing techniques
3277728|NCT01633697|Sham Comparator|Education-Control|Subjects will receive education alone about COPD.
3277729|NCT01633723|Experimental|DA-6886|
3277730|NCT01633723|Placebo Comparator|DA-6886 placebo|
3277731|NCT01633736|Experimental|home progressive resistance exercise|
3277732|NCT01633749|Experimental|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
3277733|NCT01633762|Experimental|meropenem, gentamicin, vancomycin|
3277734|NCT01633775||Ahmed glaucoma implant|
3277735|NCT01633775||Trabeculectomy with mitomycin C (MMC)|
3277736|NCT01633801|Other|High flows|
3277737|NCT01633801|Other|oxygen therapy|
3277738|NCT01633840|Active Comparator|Elemental E028 with added food allergens|
3277739|NCT01633840|Placebo Comparator|Elemental E028|
3277740|NCT01633866||Advances in Radio Frequency for MRI|advances in radio frequency (RF) coil magnetic resonance imaging (MRI)
3277741|NCT01633879|Experimental|parent education|audio-CD parent EDC supporting positive parenting practices
3277742|NCT01633879|Experimental|parent and school intervention|health and success parent and school intervention
3277743|NCT01633879|No Intervention|print materials|brochures to parents
3277744|NCT01633905||alcohol-dependent patients|22 recently detoxified participants diagnosed as alcohol-dependant on the basis of DSM-IV criteria who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
3277745|NCT01633905||control group|22 healthy controls without any psychiatric or neurological diagnosis who will performed an emotion-detection task on unimodal (visual or auditory) or crossmodal (visuo-auditory) stimulations presented centrally or peripherally
3277746|NCT01633918|Experimental|Internet-supported FeetEnergy approach|Schools which integrate Internet-supported approach with two home works in three health education lessons on physical activity
3277747|NCT01633918|Active Comparator|Usual health education|Schools which follow their usual practices in carrying out health education classes on physical activity
3277748|NCT01633957|Experimental|Genotype-based Warfarin Initiation|
3277749|NCT01633957|Active Comparator|clinical factor-based warfarin initiation|
3277750|NCT01633970|Experimental|A: Atezolizumab + Bevacizumab|Participants will receive atezolizumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion (or a selected dose level not to exceed the single agent MTD or MAD determined in Study PCD4989g) with bevacizumab 15 mg/kg every 3 weeks (q3w). After establishment of MTD or MAD, participants will receive bevacizumab 15 mg/kg IV infusion on Day 1 of Cycle 1 followed by atezolizumab 1200 mg IV infusion q3w after Days 5-7 and then atezolizumab 1200 mg q3w and bevacizumab 15 mg/kg q3w on Day 1 of all subsequent cycles until disease progression or unacceptable toxicity.
3277751|NCT01633970|Experimental|B: Atezolizumab + Bevacizumab + FOLFOX|Participants will receive FOLFOX IV infusion (oxaliplatin [85 milligrams per square meter {mg/m^2}], leucovorin [400 mg/m^2], 5-FU [400 mg/m^2]) on Day 1 of Cycle 1 and then atezolizumab 800 mg IV infusion every 2 weeks (q2w), bevacizumab 10 mg/kg IV infusion q3w and FOLFOX q2w on Day 1 of all subsequent cycles as per institutional guidelines until disease progression or unacceptable toxicity.
3277752|NCT01633970|Experimental|C: Atezolizumab + Carboplatin + Paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with paclitaxel 200 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) until disease progression or unacceptable toxicity.
3277753|NCT01633970|Experimental|D: Atezolizumab + Carboplatin + Pemetrexed|Participants will receive atezolizumab 1200 mg IV infusion q3w in combination with premetrexed 500 mg/m^2 IV infusion q3w and then carboplatin IV q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
3277754|NCT01633970|Experimental|E: Atezolizumab + Carboplatin + Nab-paclitaxel|Participants will receive atezolizumab 1200 mg IV infusion q3w (on Day 1 of every 3-week cycle) in combination with nab-paclitaxel 100 mg/m^2 IV infusion once weekly (qw) (on Days 1, 8 and 15 of every 3-week cycle) and then carboplatin IV infusion q3w (on Day 1 of every 3-week cycle) to achieve an initial target AUC of 6 mg/mL*min until disease progression or unacceptable toxicity.
3277755|NCT01633970|Experimental|F: Atezolizumab + Nab-paclitaxel|Participants will receive atezolizumab 800 mg IV infusion q2w (Days 1 and 15) in combination with nab-paclitaxel 125 mg/m^2 IV infusion qw (on Days 1, 8 and 15 of every 3-week cycle) until disease progression or unacceptable toxicity.
3277756|NCT01633983|Experimental|Methotrexate|Chronic CSC will be given an immediate MTX treatment
3277757|NCT01633983|Experimental|Delayed treatment|Acute CSC will be followed for 3 months for a spontaneous resolution before the treatment is offered
3277758|NCT01633996|Experimental|Acupuncture|All participants received open acupuncture augmentation treatment per the uniform acupuncture treatment protocol that we developed according to Traditional Chinese Medicine (TCM) principles for treating depression (see Intervention Description).
3277759|NCT01634009|Active Comparator|Standard RUTF (control)|Children will receive standard RUTF in this arm and will be considered as control arm
3277760|NCT01634009|No Intervention|Standard RUTF|Will act as control
3277761|NCT01634022|Experimental|Acupuncture|Adults with depression who are not currently taking an antidepressant medication.
3277762|NCT01634035||diabetic hemodialysis|all patient diabetic and on hemodialysis were involved if they are on hemodialysis for more than 3 months
3277763|NCT01634061|Experimental|Dose escalation: BEZ235 + Zytiga®|BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3277764|NCT01634061|Experimental|Dose escalation: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3277765|NCT01634061|Experimental|Dose expansion: BEZ235 + Zytiga®|"BEZ235 oral twice daily: 200 mg, 300 mg, and 400 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate~Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label"
3277766|NCT01634061|Experimental|Dose Expansion: BKM120 + Zytiga®|BKM120 oral once daily: 60 mg, 80 mg and 100 mg dose levels to be tested in the dose escalation part in combination with abiraterone acetate Zytiga® abiraterone acetate oral once daily: 1000 mg taken with low dose prednisone as per the label
3277767|NCT01634074||OSA patients|Patients with Obstructive Sleep Apnea (OSA), or suspected OSA
3277768|NCT01634087|Experimental|100 mg QD Itacitinib|
3277769|NCT01634087|Experimental|100 mg QD Placebo|
3277770|NCT01634087|Experimental|200 mg QD Itacitinib|
3277771|NCT01634087|Experimental|200 mg QD Placebo|
3277772|NCT01634087|Experimental|200 mg BID Itacitinib|
3277773|NCT01634087|Experimental|200 mg BID Placebo|
3277774|NCT01634087|Experimental|600 mg once a day Itacitinib|
3277775|NCT01634087|Experimental|600 mg once a day Placebo|
3277776|NCT01634126|Active Comparator|1 FIT kit|
3277777|NCT01634126|Active Comparator|2 FIT kit|
3277778|NCT01634204|Experimental|KiloCoach|Study subjects use the KiloCoach program on at least 4 days per week within the first half of the 6 months intervention period. In the second half, program usage is ad libitum.
3277779|NCT01634204|No Intervention|Control|Study subjects try to reduce body weight on their own, without participating in an organized weight loss program, over a period of 6 months.
3277780|NCT01634217|Experimental|Cohort 1|Administered 3 x 10^6 iTregs/kg infusion
3277781|NCT01634217|Experimental|Cohort 2|Administered 3 x 10^7 iTregs/kg infusion
3277782|NCT01634217|Experimental|Cohort 3|Administered 3 x 10^8 iTregs/kg infusion
3277783|NCT01634217|Experimental|Cohort 4|Administered 10 x 10^8 iTregs/kg infusion
3277784|NCT01634217|Experimental|Cohort 5 Extension|Administered 10 x 10^8 iTregs/kg or best available dose using sirolimus/MMF as graft-versus-host disease (GVHD) prophylaxis. Immunosuppression will consist of a combination of sirolimus and mycophenolate mofetil (MMF). Sirolimus will be administered starting at day -3 with 8mg-12mg oral loading dose followed by single dose 4 mg/day. MMF will be administered starting on day -3 at a dose of 3 gram/day divided in 2 or 3 doses. Intravenous (IV) route between days -3 and +5, then may change to PO between days +6 and +30. Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
3277785|NCT01634282|Experimental|OPC-262|
3277786|NCT01634295|Experimental|CKD-828 2.5/40, 2.5/80, 5/80mg|
3277787|NCT01634295|Active Comparator|S-Amlodipine 2.5, 5mg|
3277788|NCT01634308|Experimental|Novosis(bongros/BMP-2)|
3277789|NCT01634308|Active Comparator|Bio-oss|
3277790|NCT01634321|Experimental|Luphere|
3277791|NCT01634334|Experimental|Real-time Intervention|
3277792|NCT01634334|Active Comparator|Usual Education|Participants will receive usual education about secondhand and thirdhand smoke.
3277793|NCT01634347|Experimental|Propranolol and memory reactivation|
3277794|NCT01634347|Placebo Comparator|Placebo and memory reactivation|
3277795|NCT01634412|Experimental|SL TNX-102 at pH 3.5|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5
3277796|NCT01634412|Experimental|SL TNX-102 at pH 7.1|2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1
3277797|NCT01634412|Active Comparator|Cyclobenzaprine tablets|5 mg cyclobenzaprine tablet once
3277798|NCT01634412|Active Comparator|Cyclobenzaprine IV|2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4
3277799|NCT01634425|No Intervention|Group 1 - no pre-hospital biomarkers|Standard of Care
3277800|NCT01634425|Experimental|Group 2 - pre-hospital biomarkers|Troponin and BNP measured on a POC meter in the ambulance on the way to the hospital.
3277801|NCT01634438|Experimental|low dose heparin|30 units per kilogram of unfractionated heparin
3277802|NCT01634438|Active Comparator|High dose heparin|70 units per kilogram of unfractionated heparin (UFH) intravenously
3277803|NCT01634451|Active Comparator|Education Package|2 ICUs; one large and one small. Randomised to receive bespoke education package for the 9 month intervention period
3277804|NCT01634451|Active Comparator|Education and Feedback|2 ICUs; one large and one small. Randomised to receive a bespoke education package and real-time,site specific, outcome process feedback they will disseminate to their staff for the 9 month intervention period.
3277805|NCT01634451|Active Comparator|Education and Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
3277806|NCT01634451|Active Comparator|Education, Feedback, Sedation Monitoring|2 ICUs; one large and one small. Randomised to receive a bespoke education package, real-time,site specific, outcome process feedback they will disseminate to their staff and a new novel sedation (responsiveness) monitor for the 9 month intervention period.
3377747|NCT04049604||1/Cohort 1|Women with prenatal testing results that suggest an incidental detection of maternal neoplasia
3377748|NCT04049604||2/Cohort 2|Women undergoing active treatment or surveillance for known malignancy
3377749|NCT04047472|Experimental|Brolucizumab 6 mg|
3377750|NCT04047472|Active Comparator|Aflibercept 2 mg|
3377751|NCT04044365||1/Project 1 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=20 child/parent dyads
3377752|NCT04044365||2/Project 1 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=20 child/parent pairs
3377753|NCT04044365||3/Project 1 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=20 child/parent pairs
3377754|NCT04044365||4/Project 2 Child/caregiver-proxy|Children age 5-7 with cGVHD and their caregiver, n=40 child/parent pairs
3377755|NCT04044365||5/Project 2 Child/caregiver-proxy|Children age 8-12 with cGVHD and their caregiver, n=40 child/parent pairs
3377756|NCT04044365||6/Project 2 Child/caregiver-proxy|Children age 13-17 with cGVHD and their caregiver, n=40 child/parent pairs
3377759|NCT04031846|Experimental|V114|Full-term infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of V114 at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
3277807|NCT01634464||Control group|women with 18.5 > BMI < 25
3377760|NCT04031846|Active Comparator|Prevenar 13™|Full-term infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 4, and 11-15 months of age (Study Day 1, Month 2, and Month 9-13). Preterm infants received a 0.5 mL intramuscular injection of Prevenar 13™ at approximately 2, 3, 4, and 11-15 months of age (Study Day 1, Month 1, Month 2, and Month 9-13). All infants also received intramuscular injection of 0.5 mL Infanrix™ hexa at approximately 2, 3, 4, and 11-15 months of age and 1.5 mL oral dose of Rotarix™ at 2 and 4 months of age.
3377761|NCT04028362||Neuromuscular blockade|Patients who will receive neuromuscular blockade during their ICU length stay will be follow until day 28 or their hospital discharge.
3277808|NCT01634464||Pregnant women with overweight|BMI≥25 before the pregnancy
3277809|NCT01634464||Pregnant women with obesity|BMI≥30 before the pregnancy
3377765|NCT04013269|Active Comparator|CytoSorb-Therapy|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy in combination with haemadsorption using CytoSorb-Adsorber
3377766|NCT04013269|No Intervention|Standard of care|Therapy of septic shock using guideline directed standard of care, including continuous renal replacement therapy
3377767|NCT03998540||Patients with myopathy suspected of titinopathy|Patients with myopathy in which one or more potentially pathogenic TTN variants have been previously identified (index cases and related cases affected). Muscle biopsy performed previously
3377768|NCT03995901|Experimental|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
3377769|NCT03995901|No Intervention|Control|"Standard induction therapy followed by a maintenance regimen of tacrolimus, mycophenolate, and corticosteroids after kidney transplant.~Control donors are not followed beyond randomization."
3377770|NCT03986021||At-risk girls|Girls with first degree relative diagnosed with Polycystic Ovary Syndrome (PCOS) age 8-<15
3377771|NCT03986021||Healthy control women|Women age >18-34 without PCOS at least 3-years post-menarchal with regular menstrual cycles every 21-35 days
3377772|NCT03986021||post-menarche girls|Healthy, early post-menarchal girls age 8-<15
3377773|NCT03986021||Women with PCOS|Women diagnosed with PCOS >18-34 at least 3-years post-menarchal with irregular menstrual cycles
3377774|NCT03983863||IRB|Our target study population consists of all members/staff of NIH IRBs and IRB panels that fall under the NIH Intramural Federal Wide Assurance (FWA).
3377775|NCT03978637|Experimental|Itacitinib 300 mg|Phase 1: Itacitinib 300 mg twice daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
3377776|NCT03978637|Experimental|Itacitinib 400 mg|Phase 1: Itacitinib 400 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration.
3377777|NCT03978637|Experimental|Itacitinib 600 mg|Phase 1: Itacitinib 600 mg once daily. There can be required dose adjustments in the protocol for concurrent CYP3A administration
3377778|NCT03978637|Experimental|Itacitinib|Phase 2: Itacitinib administered orally at the recommended dose from Phase 1.
3277810|NCT01634464||Pregnant women with gestational diabetes|Gestational diabetes
3277811|NCT01634477||HIV-infected patients group|HIV positive
3277812|NCT01634477||HIV-uninfected patients group|HIV negative
3277813|NCT01634490||infants receiving extensively hydrolysed casein formula|infants receiving extensively hydrolysed casein formula as substitutive formula
3277814|NCT01634490||extensively hydrolysed casein formula with Lactobacillus GG|infants receiving extensively hydrolysed casein with LGG as substitutive formula
3277815|NCT01634490||infants receiving rice hydrolyzed formula|infants receiving rice hydrolyzed formula as substitutive formula
3277816|NCT01634490||infants receiving soy-based formula|infants receiving soy-based formula as substitutive formula
3277817|NCT01634490||infants receiving amino-acid based formula|infants receiving amino-acid based formula as substitutive formula
3277818|NCT01634503|Experimental|1mg of GX-188E by electroporation|
3277819|NCT01634503|Experimental|2mg of GX-188E by electroporation|
3277820|NCT01634503|Experimental|4mg of GX-188E by electroporation|
3277821|NCT01634516|Experimental|Dietary support|Face to face intervention plus subsequent telephone support
3277822|NCT01634516|Placebo Comparator|No dietary support|No face to face intervention plus subsequent telephone support
3277823|NCT01634529|Experimental|Single Ascending Dose|Single ascending doses of V158866 compared to Placebo
3277824|NCT01634529|Experimental|Multiple ascending doses|Multiple ascending doses of V158866 compared to Placebo
3277825|NCT01634542||Cohort|
3277826|NCT01634568|Experimental|Single Ascending Dose|Single Ascending Doses of V81444 compared to placebo
3277827|NCT01634568|Experimental|Multiple Ascending Doses|Multiple ascending doses of V81444 compared to placebo
3277828|NCT01634594|Experimental|sevoflurane-remifentanil (group R)|Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC
3277829|NCT01634594|Active Comparator|sevoflurane-nicardipine (group N)|Continuous infusion of nicardipine at 1 ~ 7 mcg/kg/min with sevoflurane concentration of 1 MAC
3277830|NCT01634594|Active Comparator|sevoflurane-dexmedetomidine (group D)|Continuous infusion of dexmedetomidine at 0.2 ~ 1.0 mcg/kg/hr with sevoflurane concentration of 1 MAC
3277831|NCT01634607||HIV uninfected|HIV negative patients
3277832|NCT01634607||HIV-infected, HAART naïve, high CD4 count|HIV positive patients with high CD4 and not on HIV treatment
3277833|NCT01634607||HIV-infected with planned to start HAART group|HIV positive patients who will start HIV treatment
3277834|NCT01634646|Placebo Comparator|Overweight, elevated total cholesterol|All individuates enrolled in this study are at least 15 lbs over their ideal weight as described on a BMI chart. Each individual must also have a total cholesterol of at least 200 mg/dl, or higher.
3277835|NCT01634672||hemodialysis patients|
3277836|NCT01634672||Peritoneal dialysis patients|
3277837|NCT01634685|Experimental|Bavituximab, Capecitabine, Radiation|one arm
3277838|NCT01634698|Experimental|RDR test (1500 UI vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 1500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
3277839|NCT01634698|Experimental|RDR test (2500 IU vitamin A)|81 patients with several etiologies of liver cirrhosis at different stages in the progression of the disease received 2500 UI retinyl palmitate dosage at T0 (blood sample taken following a 12-hour fast). Following supplementation, we took further blood samples five and seven hours later (T5 and T7).
3277840|NCT01634724|Experimental|GnRH agonist withdrawal|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (0.05mg/d) was withheld in the study group.
3277841|NCT01634724|No Intervention|control group|All the patients received a midluteal long GnRH agonist (GnRH-a) and a gonadotropins (recombinant FSH) stimulation protocol. In the control group, GnRHa (triptorelin, 0.05mg/d,)was used to the day of ovulation trigger.
3277842|NCT01634737||Patients with shellfish allergy|Patients with symptoms of allergy to shellfish (OAS-Oral allergy syndrome and/or systemic symptoms) and circulating IgE positive for the extract of shrimp (> 0.10 kU/L)
3277843|NCT01634737||Patients with respiratory allergy|Patients with respiratory allergy and IgE positive to dust mites, asymptomatic for shrimp or other shellfish and circulating IgE positive for shrimp
3277844|NCT01634750|Experimental|ManNac|
3277845|NCT01634750|Placebo Comparator|Placebo|
3277846|NCT01634763|Experimental|Dose-escalation|Open-label dose escalation study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase (ALK)
3277847|NCT01634763|Experimental|Dose-expansion|Open-label study of LDK378, administered orally in Japanese patients with tumors characterized by genetic alterations in ALK to see further safety, anti-tumor activity, and PK data in patients who has progressed since prior therapy with alectinib
3277848|NCT01634776|Placebo Comparator|Corn oil|1288 mg/day corn oil
3277849|NCT01634776|Experimental|Flaxseed oil|1200 mg/day flaxseed oil
3277850|NCT01634789|Experimental|Test Treatment 1: bazedoxifene|Test Treatment 1
3277851|NCT01634789|Experimental|Test Treatment 2: bazedoxifene|Test Treatment 2
3277852|NCT01634789|Experimental|Test Treatment 3: bazedoxifene|Test Treatment 3
3277853|NCT01634789|Experimental|Reference Treatment: bazedoxifene/conjugated estrogens|Reference Treatment
3277854|NCT01634802|No Intervention|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
3277855|NCT01634802|Experimental|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
3277856|NCT01634815|Experimental|lactate group|
3277857|NCT01634828||Minimal blood loss patients|
3277858|NCT01634828||Moderate to heavy blood loss patients|
3277859|NCT01634841|Active Comparator|Walnut group|This group will have their habitual diet supplemented with 30 to 45g (1 to 1.5 oz) of walnuts daily.
3277860|NCT01634841|Active Comparator|Control group|This group will eat their habitual diet and refrain from eating walnuts.
3277861|NCT01634867||Intraosseous (IO) drug delivery|patients in whom intraosseous (IO) vascular access has been established for rapid sequence intubation drug delivery.
3277862|NCT01634867||Peripheral intravenous (IV) drug delivery|patients in whom peripheral intravenous (IV) vascular access has been established for rapid sequence intubation drug delivery.
3277863|NCT01634880|Experimental|Postoperative Radiotherapy and Panitumumab|
3277864|NCT01634893|Experimental|Sorafenib plus Hydroxychloroquine|"Dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
3277865|NCT01634906|Experimental|Discontinuation of statin therapy|
3277866|NCT01634919||Chronic hepatitis C|Chronic hepatitis C
3277867|NCT01634932|Experimental|regular-iron millet|
3277868|NCT01634932|Experimental|iron-biofortified millet|
3277869|NCT01634932|Experimental|Post-harvest iron-fortified millet|
3277870|NCT01634945|Placebo Comparator|Placebo|Placebo
3277871|NCT01634945|Experimental|FeFum porridge + IPT of malaria|
3277872|NCT01634945|Experimental|IPT of malaria|
3277873|NCT01634945|Experimental|FeFum porridge|
3277874|NCT01634945|Experimental|FePP porridge|
3277875|NCT01634958|Experimental|10.000 DPP/ml suspension for s.c. inj.|
3277876|NCT01634958|Experimental|5.000 DPP/ml suspension for s.c. inj.|
3277877|NCT01634958|Experimental|1.000 DPP/ml suspension for s.c. inj.|
3277878|NCT01634958|Experimental|100 DPP/ml suspension for s.c. inj.|
3277879|NCT01634971|No Intervention|External Drainage of pancreatic duct|External Drainage of pancreatic duct was used in PD.
3277880|NCT01634971|Experimental|Internal Drainage of Pancreatic Duct|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
3277881|NCT01635010|No Intervention|Control|
3277882|NCT01635010|Experimental|Obstructive sleep apnea|
3277883|NCT01635023|Experimental|AZD6244 white capsule|75mg AZD6244 white (current Phase II) capsule
3277884|NCT01635023|Experimental|AZD6244 blue capsule|75mg AZD6244 blue (planned Phase III) capsule
3277885|NCT01635023|Experimental|AZD6244 solution|35mg AZD6244 oral solution
3277886|NCT01635036||Women undergoing IVF treatment|Women undergoing IVF treatment
3277887|NCT01635049||Women undergoing IVF treatment and CCS|•Women undergoing fresh IVF treatment and undergoing CCS, as recommended based on medical need by the clinical site reproductive endocrinologist.
3277888|NCT01635075|Experimental|Exercise|1-mile treadmill walk
3277889|NCT01635075|Placebo Comparator|Passive|20 min inactivity
3277890|NCT01635088|Other|Mometasone furoate 220 vs. Mometasone furoate 440|
3277891|NCT01635088|Active Comparator|Mometasone 220 mcg vs. 440 mcg|Inhaled steroid
3277892|NCT01635114|Active Comparator|resVida (resveratrol)|
3277893|NCT01635114|Placebo Comparator|Placebo|
3277894|NCT01635127|Experimental|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
3277895|NCT01635127|Placebo Comparator|Placebo|Constituent, inactive
3277896|NCT01635140|Experimental|Hypofractionated arm|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
3277897|NCT01635140|Other|Conventional arm|The same planning and treatment procedures will be performed with the established conventional regimen: 54 Gy in 30 fractions giving 1.8 Gy per fraction.
3277898|NCT01635166|Other|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement
3277899|NCT01635179|Experimental|Cricoid pressure|A cricoid pressure of 30 N is done to occlude esophagus under a rapid sequence induction.
3277900|NCT01635192|Active Comparator|VSL#3|
3277901|NCT01635192|Placebo Comparator|Inactive treatment|
3277902|NCT01635205|Experimental|paraspinous block|Paraspinous anesthetic block in the thoracolumbar region, in sensitized segments
3277903|NCT01635205|Sham Comparator|control|Subcutaneous puncture with no anesthetic effect
3277904|NCT01635231|Active Comparator|thiazide, diuretic|1.25 mg thiazide twice daily for 5 days
3277905|NCT01635231|Active Comparator|amiloride, diuretic|5 mg of amiloride twice daily
3277906|NCT01635231|Placebo Comparator|calcium|placebo twice daily for 5 days
3277907|NCT01635257||suspected pulmonary embolism patients|patients with clinical suspicion of PE and with a simplified Well's score>4 (PE likely) or with a D-dimer value ≥500ng/ml presenting to the emergency departments of Careggi University Hospital (Firenze), of San Luigi Gonzaga University Hospital (Torino) of Ospedale Pierantoni-Morgagni (Forlì)
3277908|NCT01635270|Experimental|midP arm|Patients treated with midP radiotherapy strategy.
3277909|NCT01635270|Active Comparator|ITV arm|Patient treated with radiotherapy ITV strategy
3277910|NCT01635296|Experimental|A: Previously untreated|
3277911|NCT01635296|Experimental|B: Relapse/Refractory|
3277912|NCT01635309||Non-cardiac surgical patients|>= 45 years old, undergoing non-cardiac surgery requiring regional or general anaesthetic and an overnight stay with cardiac risk factors
3277913|NCT01635322||Lumbar or thoraco-lumbar Adult Deformity|Lumbar or thoraco-lumbar Adult Deformity
3277914|NCT01635335|Experimental|HIV-specific|7-hour multiple family workshop focused on providing information and skills related to HIV prevention. Specific focus on parent-adolescent communication and parental monitoring.
3277915|NCT01635335|Active Comparator|General Health Promotion|7-hour multiple family workshop focused on providing information related to various adolescent health risk behaviors, including smoking, alcohol, violence, nutrition, and exercise.
3277916|NCT01635348|Experimental|motor skill gait exercise arm|motor skill gait exercise intervention: stepping and walking patterns, and speed interval treadmill-assisted walking to enhance timing and coordination in walking
3277917|NCT01635348|Active Comparator|aerobic gait exercise arm|aerobic gait exercise intervention: treadmill-assisted and overground walking exercise to enhance walking practice and improve endurance in walking
3277918|NCT01635361|Experimental|NMS|Patients in this arm will receive the full NMS service
3277919|NCT01635361|No Intervention|Current Practice|Patients in this arm will receive the normal advice with their new medicine as dictated by current professional practice
3277920|NCT01635374|Experimental|Per-Oral Endoscopic Esophagomyotomy|Patients will have a standard pre-operative work-up that may include upper endoscopy (EGD), endoscopic ultrasound (EUS), upper GI X-rays, high-resolution manometry, pH, FLIP and impedance measurement studies. Once a diagnosis of esophageal motility disorder is confirmed, patients will be offered POEM or standard treatment. Patients undergoing POEM will review and sign the study consent prior to their procedure. Patients will return and be evaluated two weeks following their procedure. At this visit, any post-operative complications will be noted in the patient's medical record. Also, at this visit and at the preoperative visit, patients will complete a standardized Quality of Life assessment. Perceived pain levels and type and frequency of pain medications will be recorded in the patient's medical record. Patients will then return at 6 weeks post-op to complete a second set of questionnaires and have a high resolution manometry performed to assess residual LES pressure.
3277921|NCT01635387|Experimental|Aliskiren|
3277922|NCT01635387|Placebo Comparator|Placebo|
3277923|NCT01635400|Other|UGT1A1 wild type (6/6)|
3277924|NCT01635400|Other|UGT1A1 heterozygous genotype (6/7)|
3277925|NCT01635400|Other|UGT1A1 homozygous genotype(7/7)|
3277926|NCT01635413|Experimental|Arm I (strength training)|Patients attend strength training classes for 1 hour 2 days per week.
3277927|NCT01635413|Experimental|Arm II (tai chi)|Patients attend tai chi classes for 1 hour 2 days per week.
3277928|NCT01635413|Active Comparator|Arm III (control)|Patients attend supervised stretching and relaxation classes for 1 hour 2 days per week.
3277929|NCT01635426|Active Comparator|Aspirin|
3277930|NCT01635426|Active Comparator|Clopidogrel|
3277931|NCT01635452||Patients treated with Esmya|
3277932|NCT01635465||Observation group:vinorelbine plus capecitabine|
3277933|NCT01635465||Control group:docetaxel plus capecitabine|
3277934|NCT01635517||Tolvaptan|Tolvaptan administration
3277935|NCT01635530|Active Comparator|Ceftriaxone|Treatment of intravenous ceftriaxone (2 g/day), three weeks
3277936|NCT01635530|Experimental|Doxycycline|Treatment with oral doxycycline (200mg / day), four weeks
3277937|NCT01635543||Crohn's Disease with peri-anal fistulas|Identifying Crohn's Disease patients with peri-anal fistulas and suffering from sexual dysfunction.
3277938|NCT01635569|Active Comparator|OCD-affected subjects (Group 1)|OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
3277939|NCT01635569|Active Comparator|OCD-affected subjects (Group 2)|Waitlist affected-controls awaiting a treatment spot.
3277940|NCT01635582|Active Comparator|Control group|Conventional hand exercise program
3277941|NCT01635582|Experimental|Experimental group|Computer gaming hand exercise regimen'
3277942|NCT01635595||Patients with BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia with preoperative diagnosis of BIM underwent subtotal esophagectomy and gastric pull up.
3277943|NCT01635595||Patients without BIM|Patients affected by adenocarcinoma of the distal esophagus and cardia without preoperative diagnosis of BIM underwent subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy.
3277944|NCT01635608|Active Comparator|non-caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml non-caloric water immediately before administration after overnight fasting
3277945|NCT01635608|Active Comparator|caloric water|500 mg paracetamol, 50 mg talinolol and 500 mg amoxicillin dissolved in 240 ml caloric water immediately before oral administration after overnight fasting
3277946|NCT01635621|Experimental|OKZ 120 mg|
3277947|NCT01635621|Experimental|OKZ 240 mg|
3277948|NCT01635621|Experimental|OKZ 120 mg with 480 mg loading dose at Week 0|
3277949|NCT01635621|Placebo Comparator|Placebo|
3277950|NCT01635634|Sham Comparator|Sham Cupping|Dry Cupping Therapy 5 serial treatments twice weekly 4-8 cups at the upper and lower back
3277951|NCT01635634|Experimental|Cupping Therapy|Dry Cupping 5 serial treatments twice weekly 4-8 cups at the upper and lower back
3277952|NCT01635634|No Intervention|Wait list|Wait list control no specific intervention for 3 weeks study period
3277953|NCT01635647|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3277954|NCT01635647|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
3277955|NCT01635660|Active Comparator|C-MAC System|
3277956|NCT01635660|Active Comparator|AP Advance|
3277957|NCT01635660|Active Comparator|King Vision|
3277958|NCT01635673|No Intervention|Control Group|A group that continues with their normal daily activities for the duration of the study
3277959|NCT01635673|Experimental|Exercise Group|This group exercises 3 times each week
3277960|NCT01635686|Experimental|DWP422|
3277961|NCT01635686|Active Comparator|ENBREL|
3277962|NCT01635712|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days on a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level
3277963|NCT01635738|Experimental|LP GMNL-133 group|Arm: LP GMNL-133 group One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
3277964|NCT01635738|Experimental|LF GM-090 group|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
3277965|NCT01635738|Experimental|LP GMNL-133+LF GM-090 group|One capsule with 2x10^9 (cfu) LP GMNL-133+ 2x10^9 (cfu)LF GM-090, once daily, PO
3277966|NCT01635738|Placebo Comparator|Placebo|
3277967|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(fasted)|
3277968|NCT01635751|Experimental|GLA5PR GLARS tablet 150mg(after high fat meal)|
3277969|NCT01635751|Active Comparator|Lyrica Capsule 75mg(fasted)|
3277970|NCT01635777|Experimental|12 weeks|miltefosine 12 weeks
3277971|NCT01635777|Experimental|8 weeks|miltefosine 8 weeks
3277972|NCT01635790|Active Comparator|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
3277973|NCT01635790|Active Comparator|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
3277974|NCT01635803|Active Comparator|Ranibizumab|Monthly injections with ranibizumab during 6 months
3277975|NCT01635803|Active Comparator|Bevacizumab|Monthly injections with bevacizumab during 6 months
3277976|NCT01635816|Active Comparator|JE Vaccine existing facilities|will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
3277977|NCT01635816|Active Comparator|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3277978|NCT01635816|Active Comparator|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3277979|NCT01635816|Active Comparator|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
3277980|NCT01635829|Experimental|Panel 1|Part 1 of Panel 1: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 1: Participants will receive phenytoin 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.
3277981|NCT01635829|Experimental|Panel 2|"Part 1 of Panel 2: Participants will receive telaprevir 750 mg every 8 hours from Day 1 to Day 9 followed by a single 750-mg dose in the morning on Day 10. Part 2 of Panel 2: Participants will receive carbamazepine 200 mg every 12 hours from Day 1 to Day 16 followed by a single 200-mg dose in the morning on Day 17; and telaprevir 750 mg every 8 hours from Day 8 to Day 16 followed by a single 750-mg dose in the morning on Day 17.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
3277982|NCT01635868||umbilical hernia repair|patients having umbilical or epigastric hernia repair from 2008-2010 in Zealand
3277983|NCT01635894|Experimental|nurse specialist|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
3277984|NCT01635894|Experimental|practice nurse|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment and training and were followed-up for their final assessment at 3 months."
3277985|NCT01635894|No Intervention|Control|"Women were screened for a weak pelvic floor (modified Oxford score, MOS, ≤ 2) before being invited into the trial. The women were seen monthly after their initial assessment (but no training given) and were followed-up for their final assessment at 3 months."
3277986|NCT01635907|Experimental|Dovitinib|
3277987|NCT01635946|Experimental|Isavuconazole and atorvastatin|Atorvastatin on Days 1 and 12, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 15
3277988|NCT01635959||Patients with Gastrointestinal Trackt Symptoms|
3277989|NCT01635972|Experimental|Isavuconazole and bupropion|Bupropion hydrochloride on Days 1 and 15, Isavuconazole three times per day (TID) on Days 8 and 9, and once daily (QD) on Days 10 thru 20.
3277990|NCT01635985|Experimental|1|AZD5423 iv
3277991|NCT01635985|Experimental|2|AZD5423 inhalation, Spira
3277992|NCT01635985|Experimental|3|AZD5423 inhalation I-neb
3277993|NCT01635985|Experimental|4|AZD5423 oral
3277994|NCT01635985|Experimental|5|AZD5423 inhalation Turbuhaler
3277995|NCT01635985|Experimental|6|AZD5423, New Dry Powder Inhaler
3277996|NCT01636011|Experimental|OMM Treatment|In this group the subjects are given 5 different OMM treatments addressing the thoracic cage.
3277997|NCT01636011|Sham Comparator|Light Touch sham|In this group the physician uses the dorsum of his hand to the same areas and for the same time that the OMM treatment arm receives.
3277998|NCT01636024|Experimental|1|Subjects will participate in 1 of up to 9 groups in Part A (single ascending dose part) or 1 of 4 groups in Part B (multiple ascending dose part). Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
3277999|NCT01636024|Placebo Comparator|2|Subjects will participate in 1 of up to 9 groups in Part A or 1 of 4 groups in Part B. Ratio of subjects receiving AZD7594 versus placebo is 6:2 in part A and 6:3 in Part B.
3278000|NCT01636037|Experimental|L-Dopa (Sinemet)|Augmentation of current antipsychotic treatment with oral L-Dopa (levodopa/carbidopa) up to 900mg daily for 8 weeks
3278001|NCT01636050|Experimental|Training group|
3278002|NCT01636050|Experimental|Control group|
3278003|NCT01636089|Experimental|bicarbonates|sodium bicarbonates 1,4%
3278004|NCT01636089|Active Comparator|saline|sodium chloride 0,9%
3278005|NCT01636128|Experimental|Sulindac first (Treatment Sequence B)|Sulindac alone, washout, DFMO alone, then combination of sulindac and DFMO
3278006|NCT01636128|Experimental|DFMO first (Treatment Sequence A)|DFMO alone, followed by washout, sulindac alone, then combination of DFMO and sulindac
3278007|NCT01636141|Placebo Comparator|Placebo gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
3278008|NCT01636141|Active Comparator|OLT1177 Gel|Each study group consists of 6 subjects randomized in a 5:1 ratio to receive OLT1177 Gel or placebo gel in both Part A and B of the study. Eighteen subjects will be enrolled in Part A and 18 in Part B. A total of 30 subjects will receive OLT1177 Gel and 6 subjects will receive placebo gel.
3278009|NCT01636154|No Intervention|The basic treatment|Comply to the Chinese guidelines of acute ischemic stroke in 2010
3278010|NCT01636154|Other|Clearing heat|Treat with KDZ injection on the basis of the basic treatment
3278011|NCT01636154|Other|Promoting blood circulation|Treat with Xueshuantong injection on the basis of the basic treatment
3278012|NCT01636154|Experimental|Clearing heat & Promoting blood circulation|Treat with both KDZ injection and Xueshuantong injection on the basis of the basic treatment
3278013|NCT01636180|Experimental|Clopidogrel - Repeated Loading Dose|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
3278014|NCT01636180|Active Comparator|Clopidogrel - standard of care|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
3278015|NCT01636193||Rota Group|Subjects will receive Rotarix® as per routine practice.
3278016|NCT01636232||ICU sepsis group|The ICU sepsis group consisting of 105 critically-ill cases diagnosed with sepsis upon admission and sampled within the first 24h of their ICU stay.
3278017|NCT01636232||ICU control group|the ICU control group including 51 critically-ill cases in whom sepsis was clinically excluded and from whom samples were taken upon admission.
3278018|NCT01636232||healthy control group|the healthy control group composed of 50 healthy control outpatients. For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
3278019|NCT01636245|Experimental|Lot 1|inactivated vaccine (Lot 1) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3278020|NCT01636245|Experimental|Lot 2|inactivated vaccine (Lot 2) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3278021|NCT01636245|Experimental|Lot 3|inactivated vaccine (Lot 3) against EV71 of 400U /0.5ml in 350 infants aged 6 months to 5 years old on day 0,28
3278022|NCT01636245|Placebo Comparator|Placebo|Placebo in 350 infants aged 6 months to 5 years old on day 0,28
3278023|NCT01636271||Group 1: subjects from LPL100601|randomized subjects in study LPL100601
3278024|NCT01636271||Group 2: subjects from SB480848/033|randomized subjects in study SB480848/033
3278025|NCT01636310|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3278026|NCT01636310|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3278027|NCT01636323|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3278028|NCT01636323|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3278029|NCT01636336|Active Comparator|Female Smokers (Mid-Luteal Phase; cycle days 18-22)|
3278030|NCT01636336|Active Comparator|Female Smokers (Early Follicular Phase; cycle days 4-8)|
3278031|NCT01636349|Experimental|Recreational soccer training|12 men participate in recreational soccer training for 6 months
3278032|NCT01636349|No Intervention|Control group|10 subjects serve as a control group with no change in lifestyle in the study period
3278033|NCT01636388|Experimental|Allogeneic Stem Cell Transplantation|Reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma.
3278034|NCT01636401|Active Comparator|aclidinium bromide|
3278035|NCT01636401|Placebo Comparator|Placebo|
3278036|NCT01636440|Other|Reliability|The same testing procedure is repeated after a delay of 7 days to test the reliability of the measure
3278037|NCT01636479|Experimental|SAR405838|SAR405838 in escalating doses
3278038|NCT01636492|Experimental|Bitopertin|
3278039|NCT01636492|Placebo Comparator|Placebo|
3278040|NCT01636505|Active Comparator|short protocol|gnrh agonist versus gnrh antagonist
3278041|NCT01636505|Active Comparator|long protocol|
3278042|NCT01636518||Atrial Fibrillation|Patients with Atrial Fibrillation that undergo standard of care procedure at the University of Kansas Hospital
3278043|NCT01636531|Experimental|HCLF|
3278044|NCT01636531|Active Comparator|LyoF|
3278045|NCT01636544|Experimental|contralateral healthy tissue biopsy|
3278046|NCT01636557|Experimental|Sirukumab and 5-probe cocktail|The 5-probe cocktail will consist of oral doses of midazolam, warfarin/vitamin K, omeprazole, and caffeine.
3278047|NCT01636570|Active Comparator|Vitamin D3 (cholecalciferol)|10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
3278048|NCT01636570|Placebo Comparator|Sugar Pill|Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.
3278049|NCT01636583|Experimental|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
3278050|NCT01636583|Active Comparator|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
3278051|NCT01636583|Active Comparator|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
3278052|NCT01636609|Experimental|Arm I (tosedostat, cytarabine)|Participants receive tosedostat PO QD on days 1-28 and cytarabine SC BID on days 1-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3278053|NCT01636609|Experimental|Arm II (tosedostat, azacitidine)|Participants receive tosedostat PO QD on days 1-28 and azacitidine IV over 10-40 minutes or SC on days 1-7. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3278054|NCT01636622|Experimental|Vemurafenib + Carboplatin + Paclitaxel|"All 3 study drugs will start on day 1 of cycle 1. Cycle defined as 3 weeks. On day 1, paclitaxel and carboplatin will be administered first, and the vemurafenib administration will start in the evening that day.~Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.~Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.~Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle."
3278055|NCT01636635|Active Comparator|Young (18-45 years)|Obese young women (18-45y) undergoing calorie restriction.
3278056|NCT01636635|Experimental|Older (>60 years)|Obese older women (>60y) undergoing calorie restriction.
3278057|NCT01636700|Active Comparator|tramadol infiltration|infiltration of tramadol 2mg/kg
3278058|NCT01636700|Placebo Comparator|Saline solution|Infiltration of saline
3278059|NCT01636726||Patients with AMI|All patients of the study population with a record/diagnosis of AMI during the study period
3278060|NCT01636726||Patients without AMI|All patients of the study population without a record/diagnosis of AMI during the study period
3278061|NCT01636739||Rota Group|Subjects will receive Rotarix® as per routine practice
3278062|NCT01636752|Experimental|Deprexis|Online self-help with and without e-mail-support
3278063|NCT01636752|No Intervention|Control|
3278064|NCT01636791|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
3278065|NCT01636791|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
3278066|NCT01636791|Experimental|CBT and Return to work|Participants randomized to this arm will receive a combination of cognitive behavior therapy and the return to work treatment. This arm is included in the study as the clinically most relevant therapy, would the return to work treatment be effective in reducing sick leave, is a treatment were patients are provided support to return to work but also is clinically effective in reducing psychiatric symptoms.
3278067|NCT01636804||Quicksite and Quickflex|Patients who have received the leads affected by the medical product advisory
3278068|NCT01636817|Experimental|60 mg|
3278069|NCT01636817|Experimental|120 mg|
3278070|NCT01636817|Experimental|240 mg|
3278071|NCT01636817|Placebo Comparator|Placebo|
3278072|NCT01636830|Active Comparator|Toothbrush type - medium|This is a crossover study, where the person used either a soft brush (control) and the medium brush (test).
3278073|NCT01636830|Active Comparator|Toothbrush type - soft|This is a crossover study, where the person used either a soft brush (control)and the medium brush(test).
3278074|NCT01636843|Experimental|60 mg|
3278075|NCT01636843|Experimental|120 mg|
3278076|NCT01636843|Experimental|240 mg|
3278077|NCT01636843|Experimental|Placebo|
3278078|NCT01636856|Active Comparator|1|Oropharyngeal exercises and oropharyngeal functions
3278079|NCT01636856|Sham Comparator|2|Nasal dilator, respiratory exercise, nasal lavage
3278080|NCT01636869|Experimental|bupicavaine|
3278081|NCT01636895|Experimental|SP-IPTp efficacy|Efficacy of suphladoxine/pyrimethamine as IPTp
3278082|NCT01636908|Experimental|Kinase inhibitor|Patients are cohort-wise treated with a registered (tyrosine) kinase inhibitor
3278083|NCT01636973|Experimental|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
3278084|NCT01636999|Experimental|Butorphanol|The main study arm will be examining how well a 50% Nitrous Oxide/50% Oxygen gas mixture is in reducing labor pains in term labor patients with less than 5 cm cervical dilation, compared to 2mg of Butorphanol (a common synthetic opiod used for labor pains in this setting).
3278085|NCT01637012|Experimental|ALEX stent arm|implantation of ALEX stent during index procedure
3278086|NCT01637025|Experimental|Traumastem - oxidized cellulose strip|
3278087|NCT01637025|Active Comparator|Surgicel® Original - oxidized regenerated cellulose strip|
3278088|NCT01637038|No Intervention|Control Group|no intervention
3278089|NCT01637038|Experimental|RIPC group|Those undergoing remote ischemic postconditioning
3278090|NCT01637051|Other|Zimmer NexGen®, Trabecular Metal Technology (TMT) Monoblock|The tibial component has a monoblock design
3278091|NCT01637051|Other|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|The tibial component has a modular design
3278092|NCT01637103|Experimental|Cognitive therapy of depression|
3278093|NCT01637103|Experimental|Bright light therapy|
3278094|NCT01637103|No Intervention|Waiting list|
3278095|NCT01637116||autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who also test positive in a cell activating assay (BHRA OR CD 63 activation of healthy donor basophils) and who exhibit anti-FcεRI and/or anti-IgE autoantibodies (=autoimmune chronic spontaneous urticaria).
3278096|NCT01637116||autoreactive, non-autoimmune chronic spontaneous urticaria|Patients with chronic spontaneous urticaria with a positive ASST, who test negative in cell activation assay or who do not exhibit anti-FcεRI or anti-IgE autoantibodies (=autoreactive, non-autoimmune chronic spontaneous urticaria)
3278097|NCT01637116||non-autoreactive chronic spontaneous urticaria|Patients with chronic spontaneous urticaria and a negative ASST (= non-autoreactive chronic spontaneous urticaria)
3278098|NCT01637129|Active Comparator|Magnetic Stimulation|Active Magnetic Stimulation with repetitive transcranial magnetic stimulation
3278099|NCT01637129|Placebo Comparator|No Intervention|Sham Magnetic Stimulation
3278100|NCT01637155|Experimental|Cholecalciferol|
3278101|NCT01637168|Experimental|Test Group|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin - 1 tablet, 2 times a day (12/12 hours).
3278102|NCT01637168|Active Comparator|Comparator Group|Ginkgo Biloba (Tebonin ®) - 1 tablet, 2 times a day (12/12 hours).
3278103|NCT01637181|Active Comparator|EVLA 940 nm|
3278104|NCT01637181|Active Comparator|EVLA 1470 nm|
3278105|NCT01637194|Experimental|Treatment (enzyme inhibitor, monoclonal antibody therapy)|Patients receive everolimus PO QD on days -14 and then 1-28. Patients also receive cetuximab IV over 60-120 minutes on days -7 and then once weekly beginning on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3278106|NCT01637207|Experimental|palpation|
3278107|NCT01637207|Experimental|ultrasound|
3278108|NCT01637220||case, control|Blood volume collected specifically for this study
3278109|NCT01637233||NRTI + PI|This is the randomisation of the main study, Arm 1
3278110|NCT01637233||maraviroc + PI|this is the randomisation of the main study, Arm 2
3278111|NCT01637233||maraviroc + NRTI|this is the randomisation of the main study, Arm 3
3278112|NCT01637259|Active Comparator|NRTI + PI|arm 1
3278113|NCT01637259|Active Comparator|PI + maraviroc|arm 2
3278114|NCT01637259|Active Comparator|NRTI + maraviroc|arm 3
3278115|NCT01637285|Experimental|PF-04856883 Treatment Arm 1|
3278116|NCT01637285|Experimental|PF-04856883 Treatment Arm 2|
3278117|NCT01637285|Experimental|PF-04856883 Treatment Arm 3|
3278118|NCT01637285|Experimental|PF-04856883 Treatment Arm 4|
3278119|NCT01637311|Experimental|Failed HM|Patients were eligible for enrollment in the study if they were age greater than 18 years and had recurrence/persistence of symptoms after primary HM with an Eckardt symptom score ≥ 4.
3278120|NCT01637337|Active Comparator|laparoscopic pyelolithotomy|
3278121|NCT01637337|Sham Comparator|percutaneous nephrolithotomy|
3278122|NCT01637350||Subtotal gastrectomy , BillrothⅠ|
3278123|NCT01637350||Subtotal gastrectomy , BillrothⅡ|
3278124|NCT01637350||total gastrectomy, jejunal interposition|
3278125|NCT01637350||total gastrectomy , Roux-en-Y|
3278126|NCT01637363|No Intervention|Regular treatment|This group is offered regular treatment from the job center i.e. exercise, mindfulness
3278127|NCT01637363|Experimental|Psychoeducation|6 x 2 hours of psychoeducation
3278128|NCT01637389|No Intervention|Control Arm|All communities (independent units/clusters) start in the control and have no intervention. All control communities cross-over to the intervention in a randomized sequence over the course of 12-15 month study.
3278129|NCT01637389|Experimental|Basic Safe Water Program|The Basic program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Basic program.
3278130|NCT01637389|Experimental|Enhanced Safe Water Program|The Enhanced program represents a variation in the implementation of the overall intervention: a community level safe-water program that is initiated with promotional meetings and followed by the offer to install Mesita Azul disinfection systems at the household level. Communities (independent units/cluster) cross-over from the control group to the intervention group in a randomized stepped-wedge fashion -- within each crossover group of 4 clusters, 2 are randomized to the Enhanced program.
3278131|NCT01637441|Experimental|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
3278132|NCT01637441|Experimental|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
3278133|NCT01637454|Active Comparator|Terlipressin and Type-2 HRS|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour.
3278134|NCT01637454|Active Comparator|Noradrenaline and Type-2 HRS|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
3278135|NCT01637467|Experimental|EMS intervention|The experimental group will received EMS at a therapeutic level.
3278136|NCT01637467|Sham Comparator|Sham|The sham group will receive EMS at a sub-therapeutic level.
3278137|NCT01637480|Experimental|Patellofemoral Pain Syndrome|Participants with Patellofemoral Pain Syndrome
3278138|NCT01637480|Active Comparator|Healthy control|Age- and gender-matched participants without Patellofemoral Pain Syndrome
3278139|NCT01637493|Experimental|Pegfilgrastim, 30mcg/kg|
3278140|NCT01637493|Experimental|Pegfilgrastim, 60mcg/kg|
3278141|NCT01637493|Experimental|Pegfilgrastim, 100mcg/kg|
3278142|NCT01637493|Experimental|Pegfilgrastim, 200mcg/kg|
3278143|NCT01637506||Study group|"Age > 19~Radiological evidence indicating presence of a current renal or ureteric stone"
3278144|NCT01637506||Control group|"Age > 19.~No history of kidney stone disease"
3278145|NCT01637519||Ureteral stone|Ten (10) patients with a unilateral, mid- or distal, ureteral (tube connecting kidney and bladder in the urinary system) stone will be enrolled and brought to completion in this study.
3278146|NCT01637532|Other|Group 1|Carboplatin/Caelyx
3278147|NCT01637532|Experimental|Group 2|Carboplatin/Caelyx or doxorubicin plus Tocilizumab
3278148|NCT01637532|Experimental|Group 3|Carboplatin/Caelyx or doxorubicin plus Tocilizumab plus Peg-Intron
3278149|NCT01637545|Active Comparator|Preop. ramosetron 0.3mg i.v.|G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery
3278150|NCT01637545|Active Comparator|Postop. ramosetron 0.3mg i.v.|G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
3278151|NCT01637545|Active Comparator|No Ramosetron|G3 - No medication but regular antiemetics injection if the patient wants
3278152|NCT01637558|No Intervention|Main TB cohort|Children with tuberculosis 0-12 years of age
3278153|NCT01637558|Experimental|Lopinavir/Ritonavir - Cases|children 3-20 kg with tuberculosis and indication for LPV/r-based ART
3278154|NCT01637558|Experimental|Lopinavir/Ritonavir - Controls|Children 3-20 kg on LPV/r-based ART; no TB
3278155|NCT01637558|Experimental|Nevirapine arm|children with TB and indication for nevi rapine-based ART
3278156|NCT01637571|Active Comparator|Dexilant|60mg of Dexilant QD for 12 weeks
3278157|NCT01637571|Placebo Comparator|Placebo|60mg of Dexilant placebo QD for 12 weeks
3278158|NCT01637610||PPROM|All women presenting to assessment at the labour and delivery unit at RUH with suspected PPROM between 16+0 and 36+6 weeks gestation.
3278159|NCT01637636|Experimental|Rifampin|
3278160|NCT01637636|Experimental|Ketoconazole|
3278161|NCT01637649||Stroke patients with dysphagia|Stroke patients with confirmed evidence of aspiration and severe dysphagia tha would require modified diet or nasogastric tube feeding
3278162|NCT01637649||Stroke patients without dysphagia|Stroke patients but with no gross evidence of dysphagia or with mild dysphagia with a Penetration aspiration scale of less than 4
3278163|NCT01637649||healthy volunteer group|healthy volunteers with no prior history of dysphagia or stroke and who are not included in the exclusion criteria
3278164|NCT01637662|Experimental|Healthy subjects|
3278165|NCT01637675|Active Comparator|20 mg sildenafil citrate tablets by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
3278166|NCT01637675|Experimental|sodium tanshinone IIA sulfonate, sildenafil citrate tablets|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection also permitted if necessary) 250ml ivdrip once a day for 8 weeks,20mg sildenafil citrate tablets by mouth three times a day for the same duration
3278167|NCT01637688||Amino acid formula|Comparison of growth between subjects who are fed with a newly innovated amino acid formula (NAAF) and who are fed with either Neocate or nutramigen AA.
3278168|NCT01637701|Active Comparator|PkEP|Patients in this group undergo PkEP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
3278169|NCT01637701|Active Comparator|B-TURP|Patients in this group undergo B-TURP using the Gyrus plasmakinetic tissue management system (Gyrus Medical Ltd,Bucks,UK).
3278170|NCT01637714|Experimental|Multi-strain probiotics|
3278171|NCT01637714|Placebo Comparator|Placebo powder|
3278172|NCT01637727||GDM1|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
3278173|NCT01637727||GDM|The study group will include women who gave birth in Shaare Zedek Medical Center between the years 2000 and 2010. Women with a GDM history will be identified based on the gestational diabetes clinic files. Women without a history of GDM who will be the control group will be identified from the Shaare Zedek Medical Center birth registration records.
3278174|NCT01637740||eyes with pseudoexfoliation syndrome|cataract myopic eyes with pseudoexfoliation syndrome
3278175|NCT01637740||eyes without pseudoexfoliation syndrome|cataract myopic eyes without pseudoexfoliation syndrome
3278176|NCT01637753|Experimental|Carmustine Sustained Release Implant|
3278177|NCT01637753|Sham Comparator|Surgical control group|
3278178|NCT01637766|Experimental|Selective intra-arterial chemotherapy|Subjects recruited to this study will receive intra-arterial injections of chemotherapy (melphalan) in the branches of the arteries feeding the metastatic spinal tumor. Subjects will receive general anesthesia or conscious sedation. A catheter will be guided using X-ray from the femoral artery at the top of the leg to the arteries of the spine. A dye will be injected through the catheter to show the arteries in greater detail. The chemotherapy is then injected into the tumor. We will inject the maximum systemic dose adjusted to white blood count and platelet count. Subjects will undergo three cycles of chemotherapy three to six weeks apart.
3278179|NCT01637779|Experimental|fact sheet review|mothers will review a fact sheet containing information about pain management during immunization then complete a knowledge test afterward
3278180|NCT01637779|Placebo Comparator|control unrelated material|mothers will review material unrelated to pain management during immunization then complete a knowledge test
3278181|NCT01637779|Experimental|pre-test, review of fact sheet|mothers do a pre-test, then read a fact sheet about how to manage immunization pain, then repeat the test
3278182|NCT01637779|Placebo Comparator|pre-test, control unrelated information|mothers do a pre-test, then read unrelated material, then repeat the test
3278183|NCT01637792|Experimental|Three 2-liter exchanges group|A group of randomly assigned patients undergoing three 2-liter exchanges daily CAPD.
3278184|NCT01637792|Active Comparator|Four 2-liter exchanges group|A group of randomly assigned patients undergoing four 2-liter exchanges daily CAPD.
3278185|NCT01637805|Experimental|AAV-DC-CTL|
3278186|NCT01637818|Other|Lichtenstein's Operation|
3278187|NCT01637818|Other|Mesh Plug Repair|
3278188|NCT01637831|Experimental|Patients with OSA and IPF|Participants with Obstructive Sleep Apnea (OSA)and Idiopathic Pulmonary Fibrosis (IPF).This arm will complete pre-treatment questionnaires assessing sleep and quality of life, undergo six months of Continuous Positive Airway Pressure (CPAP) to treat OSA, and complete post-treatment the same questionnaires 1, 3 and 6 months later.
3278189|NCT01637844|Experimental|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation start to orally take telbivudine (600 mg/day) until 4 weeks after delivery. Newborn infants receive standard immunoprophylaxis.
3278190|NCT01637844|No Intervention|Control|Infants of HBsAg- and HBeAg-positive women who are not treated with telbivudine and any other antiviral agents serve as controls. The infants are administered standard immunoprophylaxis against mother-to-infant transmission of HBV, 100-200 IU hepatitis B immunoglobulin (HBIG) within 12 hours after birth and three doses hepatitis B vaccine at 0, 1 and 6-month schedule.
3278191|NCT01637857|Sham Comparator|lifestyle counseling|Group of patients treated with sham oligoantigenic diet
3278192|NCT01637857|Experimental|oligoantigenic diet|Treatment with oligoantigenic diat
3278193|NCT01637883|No Intervention|nothing|nothing will be dripped on the cuff of the endotracheal tube in the control group
3278194|NCT01637883|Experimental|benzydamine HCl|benzydamine HCl will be dripped on the cuff of the endotracheal tube 5 minutes before induction of general anesthesia
3278195|NCT01637896|Experimental|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
3278196|NCT01637896|Active Comparator|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
3278197|NCT01637909|Active Comparator|general management|
3278198|NCT01637909|Experimental|The treatment group1|Korean DASH diet with sodium reduction intervention
3278199|NCT01637909|Experimental|The treatment group2|Korean DASH diet with sodium reduction intervention and excersize intervention
3278200|NCT01637948|Active Comparator|Listerine|essential oil mouthrinse
3377779|NCT03976375|Experimental|Pembrolizumab+Lenvatinib|Participants receive pembrolizumab at 200 mg, every 3 weeks (Q3W) via intravenous (IV) infusion on Day 1 of each 21-day cycle, in combination with lenvatinib at 20 mg, once daily (QD) via oral capsule. Pembrolizumab will be administered for up to 35 treatment cycles (~2 years). Lenvantinib will be administered until progressive disease or unacceptable toxicity.
3377780|NCT03976375|Active Comparator|Docetaxel|Participants receive docetaxel at 75 mg/m^2, Q3W via IV infusion over 1-hour infusion on Day 1 of each 21-day cycle. Docetaxel will be administered until progressive disease or unacceptable toxicity.
3377781|NCT03976375|Experimental|Lenvatinib Monotherapy|Participants receive lenvatinib at 24 mg, QD via oral capsule. Lenvantinib will be administered until progressive disease or unacceptable toxicity.
3377782|NCT03971071|Placebo Comparator|Placebo|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
3377783|NCT03971071|Active Comparator|Erenumab 70 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70 mg or 140 mg) or placebo.
3377784|NCT03971071|Active Comparator|Erenumab 140 mg|After subjects complete the baseline period and are found eligible, they will be enrolled and randomized in a 1:1:1 ratio to either erenumab (70mg or 140 mg) or placebo.
3377785|NCT03963843|Experimental|SCI internet delivered cognitive behavioural therapy|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
3377786|NCT03963843|Active Comparator|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
3278201|NCT01637948|No Intervention|Negative control|without intervention
3278202|NCT01637948|Experimental|Chinese medicine mouthrinse|5% Fructus Mume extract and 2% sodium bicarbonate
3278203|NCT01637974|Experimental|with INTERCOAT|injection of intercoat into the euterine cavity at the end of hysteroscopy
3278204|NCT01637974|No Intervention|without INTERCOAT|without INTERCOAT
3377793|NCT03946670|Experimental|MBG453 + hypomethylating agents|Patients will take MBG453 plus hypomethylating agents
3377794|NCT03946670|Placebo Comparator|Placebo + hypomethylating agents|Patients will take placebo plus hypomethylating agents
3377795|NCT03945448|Experimental|Single dose liposomal Amphotericin and fluconazole|"Experimental:~Single dose Ambisome 10mg/kg and Fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months. (standard of care therapy)"
3377796|NCT03945448|Active Comparator|fluconazole (standard of care)|Standard of care pre-emptive treatment fluconazole 800mg for two weeks ,400mg for 8 weeks and 200mg upto 6 months
3448449|NCT04065022|Experimental|Head stimulation|Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
3278205|NCT01637987|Active Comparator|Unassisted vein visualization|
3278206|NCT01637987|Active Comparator|Wee Sight Transilluminator|
3278207|NCT01637987|Active Comparator|Near Infra-red light (VeinViewer)|
3278208|NCT01638026|Experimental|Gnrh agonist , hcg|Gnrh agonist for final oocyte maturation, hcg for luteal support
3278209|NCT01638039|Active Comparator|Diarrheal disease|
3278210|NCT01638039|Active Comparator|Control|Samples of stool, blood, urine saliva
3278211|NCT01638065||Standard|Standard IV Access without device
3278212|NCT01638065||VeinViewer|IV access with VeinViewer device
3278213|NCT01638078|Active Comparator|Thalidomide|Thalidomide
3278214|NCT01638078|Placebo Comparator|Placebo|Placebo
3278215|NCT01638091|Experimental|All participating endoscopists|All endoscopists will undergo ex vivo training and will participate in in vivo practice-based learning.
3278216|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min (with low sodium diet)|0.001 dose unit equal to 1 millionth of a gram of an ANX-042 preparation / 1 kilogram of body mass administered / unit of time equal to 1 minute(mcg/kg/min), w/ diet restricted to 2.5 grams (gm) per day sodium (Na+) and 2.1 liters (L) fluid total daily intake
3278217|NCT01638104|Experimental|ANX-042: 0.001 mcg/kg/min|0.001 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278218|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min (low sodium diet)|0.003 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3278219|NCT01638104|Experimental|ANX-042: 0.003 mcg/kg/min|0.003 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278220|NCT01638104|Experimental|ANX-042: 0.0065 mcg/kg/min (low sodium diet)|0.0065 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3278221|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min (low sodium diet)|0.01 mcg/kg/min ANX-042 with diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3278222|NCT01638104|Experimental|ANX-042: 0.01 mcg/kg/min|0.01 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278223|NCT01638104|Experimental|ANX-042: 0.03 mcg/kg/min|0.03 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278224|NCT01638104|Experimental|ANX-042: 0.1 mcg/kg/min|0.1 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278225|NCT01638104|Experimental|ANX-042: 0.3 mcg/kg/min|0.3 mcg/kg/min ANX-042 with diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278226|NCT01638104|Placebo Comparator|Placebo (low sodium diet)|Placebo and diet restricted to 2.5 gm per day Na+ and 2.1 L fluid total daily intake
3278227|NCT01638104|Placebo Comparator|Placebo|Placebo and diet restricted to 4 gm per day Na+ and 3.6 L fluid total daily intake
3278228|NCT01638117|Placebo Comparator|PAC14028-Vehicle|PAC-14028 Cream Vehicle
3278229|NCT01638117|Experimental|PAC14028-0.1|PAC-14028 Cream 0.1%
3278230|NCT01638117|Experimental|PAC14028-0.3|PAC-14028 Cream 0.3%
3278231|NCT01638117|Experimental|PAC14028-1.0|PAC-14028 Cream 1%
3278232|NCT01638117|Placebo Comparator|Placebo|Saline
3278233|NCT01638117|Active Comparator|Positive control|Sodium Lauryl Sulfate, 0.5%
3278234|NCT01638143|Active Comparator|Gnosis P-1000 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Gnosis, Italy).
3278235|NCT01638143|Active Comparator|Gnosis M1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source Gnosis, Italy).
3278236|NCT01638143|Active Comparator|MenaQ7 M-1500 capsules|MK-7 capsules containing 75 µg of MK-7 (source: Nattopharma, Norway)
3278237|NCT01638169||20 children with DMD|
3278238|NCT01638182|Active Comparator|vitamin K1 capsules|27 participants received for three months 1 vitamin K1-capsule per day containing 52 µg of K1
3278239|NCT01638182|Active Comparator|Vitamin K2-capsules|27 participants received for three months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
3278240|NCT01638182|Placebo Comparator|Placebo capsules|27 participants received for 3 months 1 placebo capsule per day
3278241|NCT01638195|Experimental|Externally Focused Ultrasound|
3278242|NCT01638208|Experimental|VSL#3|Patients with IBS-D as per ROME III
3278243|NCT01638208|No Intervention|Healthy Controls|Healthy controls
3278244|NCT01638221||heavy weight mesh|Surgipro mesh is a heavier weighted mesh with less flexibility after surgery
3278245|NCT01638221||light weight mesh|UltraPro mesh is a lighter weighted mesh with theoretically less stiffness and more flexibility compared to heavier weighted meshes
3278246|NCT01638234|Placebo Comparator|Starch pill|
3278247|NCT01638234|Experimental|Melatonin|
3278248|NCT01638247|Active Comparator|Tamoxifen|Tamoxifen alone (daily).
3278249|NCT01638247|Experimental|Tamoxifen and GnRH analogue|Tamoxifen (daily) + GnRH analogue (at randomisation and after three months).
3278250|NCT01638247|Experimental|Exemestane and GnRH analogue|Exemestane (daily) + GnRH analogue (at randomisation and after three months).
3278251|NCT01638260|Placebo Comparator|Liraglutide|Subjects will inject liraglutide once daily for 26 weeks
3278252|NCT01638260|Active Comparator|Liraglutide and NEAT|Subjects will inject liraglutide once daily and combine this treatment with activating lifestyle, by increasing NEAT.
3278253|NCT01638273|Experimental|GLA5PR GLARS tablet 150mg(mealed)|Pregabalin 150mg
3278254|NCT01638273|Active Comparator|Lyrica Capsule 75mg(mealed)|Pregabalin 75mg
3278255|NCT01638286||Eperisone|
3278256|NCT01638286||Aceclofenac|
3278257|NCT01638286||Eperisone hydrochloride, Aceclofenac|
3278258|NCT01638299|Experimental|Hypo-Hyper Minimizer (HHM) System|
3278259|NCT01638325|Active Comparator|Insulin Lispro|15 international units (IU) insulin lispro administered once subcutaneously (SC) during 1 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
3278260|NCT01638325|Experimental|BC106 Insulin Lispro|15 up to 30 IU BC106 insulin lispro administered once SC during 2 of 3 dosing periods. There is a minimum 7 day washout between dosing periods.
3278261|NCT01638338|Experimental|Web site|"A specific web site for randomization and risky alcohol consumption counseling will be beta tested and created. Risky drinkers allocated to this arm will receive web assisted brief motivational interview.~They will first be assessed towards risky alcohol consumption and Quality of life (AUDIT and EQ5D). Personal health status will also be assessed with a Likert scale. Brief Intervention will be administered following a consistent number of web pages reporting brief motivational interview Web assisted brief motivational interview on risky drinking"
3278262|NCT01638338|Experimental|Face to Face|Risky drinking brief motivational interview provided by the GP.
3278263|NCT01638351|Active Comparator|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
3278264|NCT01638351|Experimental|Resistance exercise|Progressive resistance training, 3 times a week for 12 weeks
3278265|NCT01638364|Active Comparator|alcoholic beverage|95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
3278266|NCT01638364|Placebo Comparator|non-alcoholic beverage|Orange juice and tonic water.
3278267|NCT01638377|Experimental|Naltrexone|Drug: Naltrexone 50 mg/day for 24 weeks.All participants will receive medical intervention in the form of medical management (MM) which will be delovered by a trained health care professional.
3278268|NCT01638377|Placebo Comparator|Control|Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
3278269|NCT01638403|Experimental|BF2.649|BF2.649 (pitolisant) is a novel, highly potent, selective, orally active histamine H3 receptor antagonist/inverse agonist (Ki of 0.3 nM) at the human receptor.
3278270|NCT01638403|Active Comparator|Vigil|"Therapeutic indications Narcolepsy with and without cataplexy. Moderate to severe obstructive sleep apnoea syndrome with excessive daytime sleepiness despite adequate CPAP therapy.~Moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients who work rotating night shifts, if other sleep hygiene measures did not lead to a satisfactory improvement."
3278271|NCT01638403|Placebo Comparator|Placebo|
3278272|NCT01638442|Experimental|Treatment A|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
3278273|NCT01638442|Experimental|Treatment B|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
3278274|NCT01638455|Experimental|Test Group|All subjects will be enrolled in the test group and will receive the noninvasive device
3278275|NCT01638481||Group #1 - Burns affecting less than 10% BSA|
3278276|NCT01638481||Group #2 - Burns affecting 10%-30% TBSA|
3278277|NCT01638481||Group #3 - Burns affecting 31%-50% TBSA|
3278278|NCT01638481||Group #4 - Burns affecting 51%-70% TBSA|
3278279|NCT01638481||Group #5 - Burns affecting >70% TBSA|
3278280|NCT01638494|Experimental|Colecalcium testing|administration of Colecalcium
3278281|NCT01638520|Experimental|Pascolizumab|The dose of study medication will be calculated using the patient's body weight and the appropriate dosing regimen based on the cohort of enrollment. The medication will be administered by slow intravenous infusion over 1 hour under close medical supervision.
3278282|NCT01638520|Placebo Comparator|Placebo|For patients randomized to placebo, Sterile 0.9% w/v Sodium Chloride will be used for Injection, using the same volume that would have been prepared if the patient had been randomized to receive pascolizumab.
3278283|NCT01638572||neuroblastoma patients|
3278284|NCT01638585|No Intervention|standard therapy|patients receiving standard therapy for diabetic foot syndrome with critical limb ischemia, i. e. structured therapy of lesions with antibiosis, pressure relief and therapy of risk factors according to the relevant guidelines.
3278285|NCT01638585|Active Comparator|urokinase|patients receiving urokinase short infusions in addition to standard therapy
3278286|NCT01638598|Experimental|BI 1021958 dose group 1|subject to receive a tablet containing dose group 1 BI 1021958 single dose
3278287|NCT01638598|Experimental|BI 1021958 dose group 2|subject to receive a tablet containing dose group 2 BI 1021958 single dose
3278288|NCT01638598|Experimental|BI 1021958 dose group 3|subject to receive a tablet containing dose group 3 BI 1021958 single dose
3278289|NCT01638598|Experimental|BI 1021958 dose group 4|subject to receive a tablet containing dose group 4 BI 1021958 single dose
3278290|NCT01638598|Experimental|BI 1021958 dose group 5|subject to receive a tablet containing dose group 5 BI 1021958 single dose
3278291|NCT01638611|Active Comparator|HIP2B|Six subjects per dosing cohort will receive HIP2B
3278292|NCT01638611|Placebo Comparator|Placebo|Two subjects per dosing cohort will receive placebo.
3278293|NCT01638624|Active Comparator|Propofol|Propofol infusion group: Under spinal anesthesia, a continuous intravenous infusion (2mg/kg/h) of propofol will be use during the operation
3278294|NCT01638624|Placebo Comparator|Control group|Placebo group: Under spinal anesthesia, a continuous intravenous infusion of volume-equivalent placebo will use during the operation
3278295|NCT01638637||Specimen Collection|
3278296|NCT01638650|Experimental|Single Arm|
3278297|NCT01638663|Active Comparator|Tolvaptan|Oral administration of 15 mg Tolvaptan on each examination day.
3278298|NCT01638663|Placebo Comparator|Placebo|Oral administration of 15 mg Unikalk tablet on each examination day.
3278299|NCT01638676|Experimental|Vemurafenib and Metformin|
3278300|NCT01638702|Active Comparator|Right sided PICC placement|Insertion of PICC on the right arm
3278301|NCT01638702|Placebo Comparator|Left sided arm placement|Insertion of PICC on the left arm
3278302|NCT01638715|Experimental|Infliximab|Infliximab (Remicade®) will be administered i.v.at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
3278303|NCT01638715|Experimental|Abatacept|Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c.application at a dose of 125mg weekly.
3278304|NCT01638715|Experimental|Tocilizumab|Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
3278305|NCT01638715|Experimental|Rituximab|Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26. Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©).
3278306|NCT01638728||Endotracheal tube|
3278307|NCT01638767|Experimental|NuvaRing|Patients in the NuvaRing group will be inserting the vaginal ring for a period specified by the administrative nurse, ranging from 14 to 35 days.
3278308|NCT01638767|Active Comparator|Marvelon|Patients on Marvelon will be taking the medication for a period ranging from 14 to 21 days. This period will be determined by the administrative nurse.
3278309|NCT01638780|Placebo Comparator|placebo|A placebo will be given for 30 days, twice daily. One pill will be provided with lunch and the other pill will be provided with dinner.
3278310|NCT01638780|Active Comparator|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill of 75 mg will be provided with dinner. So in total 150 mg/day of resveratrol will be given.
3278311|NCT01638793|Experimental|Capnography|Capnographic respiration monitoring
3278312|NCT01638793|Active Comparator|Pulse-Oxymetry|pulse-oxymetric respiration monitoring
3278313|NCT01638806|Experimental|Group I: PPCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
3278314|NCT01638806|No Intervention|Conventional: Group II|Patients are treated as today: Admission to local hospital, Low-molecular-weight heparin (LMWH), Aspirin, ADP-blocker and within 72 hours transfer for angiography/angioplasty. Patients with a Grace score > 140 will be transferred for angiography/angioplasty within 24 hours. Patients with refractory angina, severe heart failure, life-threatening ventricular arrhythmias or haemodynamic instability will be transferred acutely for angiography/angioplasty according to the european guidelines.
3278315|NCT01638845|Active Comparator|continuous perineural catheter|
3278316|NCT01638845|No Intervention|Control|
3278317|NCT01638858|Experimental|Lucentis (Ranibizumab)|
3278318|NCT01638871|Experimental|Intervention Group|Study arm will complete the 8-week Internet-based pain coping skills program.
3278319|NCT01638871|No Intervention|Control Group|This study arm will only provide demographic and pain-related information.
3278320|NCT01638884|Experimental|Young Healthy Subjects|
3278321|NCT01638884|Experimental|Middle age Healthy Subjects|
3278322|NCT01638884|Experimental|Elderly Healthy Subjects|
3278323|NCT01638884|Experimental|Mild Cognitive Impairment patients|
3278324|NCT01638884|Experimental|Alzheimer Disease patients|
3278325|NCT01638910|Experimental|EV/DNG (Qlaira, BAY86-5027)|
3278326|NCT01638923|Experimental|Arm 1|
3278327|NCT01638923|Placebo Comparator|Arm 2|
3278328|NCT01638936|Experimental|BT062|BT062 administered intravenously on days 1, 8 and 15 of each 28-day cycle, and lenalidomide or pomalidomide and dexamethasone administered orally to subjects with relapsed or relapsed/refractory MM
3278329|NCT01638949|Experimental|Young controls|
3278330|NCT01638949|Experimental|Middle age controls|
3278331|NCT01638949|Experimental|Elderly controls|
3278332|NCT01638949|Experimental|Asymptomatic subjects|Asymptomatic subjects from families carrying a genetic mutation with an autosomal dominant transmission
3278333|NCT01638949|Experimental|Subjectif Cognitive Impariment patients|
3278334|NCT01638949|Experimental|Mild Cognitive Impairment patients|
3278335|NCT01638949|Experimental|Alzheimer Disease patients|
3278336|NCT01638949|Experimental|Non degenerative amnsesic syndrome|
3278337|NCT01638962|Experimental|NEMEX|NEuroMuscular EXercise
3278338|NCT01638962|Active Comparator|PHARMA|PHARMAcological pain relief
3278339|NCT01638975|Experimental|Computerized response inhibition training|Participants in this condition receive 8 computerized training sessions over a 4 week period.
3278340|NCT01638975|No Intervention|Waitlist Control|Participants assigned to this condition wait without an intervention until the second assessment (4 weeks after the baseline assessment).
3278341|NCT01638988|Experimental|Metformin|
3278342|NCT01638988|Active Comparator|Clomiphene Citrate|
3278343|NCT01639014|Experimental|F2695|
3278344|NCT01639014|Placebo Comparator|placebo|
3278345|NCT01639027|Active Comparator|Drotaverine|Women who will receive 40 mg Drotaverine hydrochloride (Do-Spa) IV injection.
3278346|NCT01639027|Placebo Comparator|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V.
3278347|NCT01639053||Gel Participants|
3278348|NCT01639053||Control Participants|
3278349|NCT01639066|Experimental|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
3278350|NCT01639066|Active Comparator|Tenofovir monotherapy|Tenofovir 300 mg/day orally
3278351|NCT01639079|No Intervention|Usual Care for Smoking|Usual care for smoking cessation with access to the web site after 6 months
3278352|NCT01639079|Experimental|Internet Smoking Cessation Web Site|"Internet Stop Smoking site (TC5) offers a menu of several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are:~English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx"
3278353|NCT01639092|Experimental|Tenofovir monotherapy|Tenofovir 300 mg/day orally
3278354|NCT01639092|Active Comparator|Tenofovir plus Entecavir combination|Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
3278355|NCT01639105|Experimental|treated half of the scar|
3278356|NCT01639105|No Intervention|untreated half of the scar|
3278357|NCT01639131|Experimental|ARM I|Patients will receive intravenous gemcitabine 800mg/m2 on days 1 and 8 and docetaxel 70mg/m2 on day 8 of each 21 day cycle. Patients will receive filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle.
3278358|NCT01639170|Experimental|subjects undergoing abdominal surgery|"Subjects who undergone abdominal intervention and reported major symptoms and signs suggestive of gastrointestinal perforation (abdominal pain, leukocytosis, fever) within the third postoperative day.~Exclusion criteria: inability to consent to the study, age ≤18 yr, certain or probable pregnancy, inability to remain in upright position for more than 10 minutes."
3278359|NCT01639183|Experimental|Rotating-oscillating Power Toothbrush|Nursing home residents will be randomly assigned to receive power toothbrushing twice daily by their caregivers using a rotating-oscillating power toothbrush.
3278360|NCT01639183|Active Comparator|Standard Care|This arm comprises the control group where nursing home residents will receive standard daily oral care as usual.
3278361|NCT01639196|Experimental|Self-compassion writing|
3278362|NCT01639196|Active Comparator|Self-efficacy writing|
3278363|NCT01639209|Experimental|Vitrectomy|
3278364|NCT01639209|Experimental|Pneumatic retinopexy|
3278365|NCT01639248|Experimental|ENMD-2076 Treatment|ENMD-2076
3278366|NCT01639274|Other|COPD|
3278367|NCT01639287||Painless|"Painless synovitis group(called cold synovitis)"
3278368|NCT01639287||Painful|Painful synovitis group
3278369|NCT01639300|Experimental|GNbAC1|
3278370|NCT01639300|Placebo Comparator|GNbAC1 placebo|
3278371|NCT01639326|Experimental|Irinotecan high doses|Patients will receive irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
3278372|NCT01639326|Active Comparator|Irinotecan standard doses|Patients will receive irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours
3278373|NCT01639378|Experimental|Renal Denervation|Subjects are treated with renal denervation after randomisation and maintained on heart failure medications
3278374|NCT01639378|No Intervention|Control group|Subject will have a sham procedure and not receive renal denervation. They will continue with the heart failure medications
3278375|NCT01639391|Experimental|patients|
3278376|NCT01639404|Experimental|Umbilical Cord Blood and Rehabilitation|Allogeneic Umbilical Cord Blood Administration and Active Rehabilitation
3278377|NCT01639430||Geriatric patients ED|Consecutive patients >= 75 years in the emergency department.
3278378|NCT01639456|Experimental|Patients Using CD3-/CD19- NK cell product|Patients receive the apheresis product (collected day -1: enriched for NK cells using the CliniMACS® CD3 and CD19 Reagent System in combination with the large-scale tubing set (Miltenyi Biotec) to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19- natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
3278379|NCT01639456|Experimental|Patients Using CD3-/CD56+ purified NK cell product|Patients receive the apheresis product (collected day -1): purified for NK cells using the CliniMACS® CD3 Reagent System (Miltenyi Biotec) in combination with the large-scale tubing set to deplete CD3+ cells and then use the CliniMACS® CD56 Reagent System to enrich CD56+ NK cells (CD3-CD56+ natural killer cells). Patients will also receive Cyclophosphamide, Fludarabine and Aldesleukin.
3278380|NCT01639482||Citalopram|Patients with bipolar disorder
3278381|NCT01639482||Placebo|Patients with bipolar disorder
3278382|NCT01639508|Experimental|Cabozantinib|This will be a single-institution, open label, two-stage, single agent trial of cabozantinib in patients with advanced NSCLCs.atients in GROUP A will have tumors with a RET fusion. Patients in GROUP B will have tumors with an NTRK fusion, or MET or AXL overexpression, amplication, or mutatation. Patients in GROUP C will have tumors with a ROS1 fusion. Patients in GROUP D will have tumors with a RET fusion and have progressed on a selective RET TKI.
3278383|NCT01639521|Experimental|Arm A (gemcitabine hydrochloride, cisplatin)|Patients receive cisplatin IV on day 1 and gemcitabine hydrochloride IV over 1 hour on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3278384|NCT01639521|Experimental|Arm B (MVAC)|Patients receive methotrexate IV on day 1 and vinblastine IV, doxorubicin hydrochloride IV, and cisplatin IV on day 2. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3278385|NCT01639534||Biomarkers, Carotid Stenting, Blood sample|Subjects requiring Carotid Stenting Procedure at Virginia Commonwealth University/Medical College of Virginia Health Systems
3278386|NCT01639547|Experimental|PEGASYS® plus ROBATROL® for 36 weeks|
3278387|NCT01639547|Active Comparator|PEGASYS® plus ROBATROL® for 48 weeks|
3278388|NCT01639586|Active Comparator|D|Impact of the day care on health profit of patient
3278389|NCT01639586|Active Comparator|C|No access to a respite structure
3278390|NCT01639586|Active Comparator|B|Respite platform
3278391|NCT01639612|Experimental|ALD-451|Autologous bone marrow derived ALD-451 cells administered intravenously following surgery, radiation therapy and temozolomide
3278392|NCT01639625|Experimental|CIGB300|
3278393|NCT01639638|Placebo Comparator|Placebo|
3278394|NCT01639638|Experimental|CIGB-300 - 5 mg|
3278395|NCT01639638|Experimental|CIGB-300 - 15 mg|
3278396|NCT01639651|Active Comparator|Control Group|
3278397|NCT01639651|Experimental|Mobilization Group|
3278398|NCT01639677|Experimental|Laparoscopic gastric bypass|
3278399|NCT01639677|Active Comparator|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
3278401|NCT01639716||Lymphoma group|
3278402|NCT01639716||healthy group|
3278403|NCT01639716||IL-10 high|
3278404|NCT01639716||IL-10 low|
3278405|NCT01639716||IL-4 high|
3278406|NCT01639716||IL-4 low|
3278407|NCT01639716||lymphopenia|
3278408|NCT01639768|Placebo Comparator|SUBLIVAC FIX Birch 0 AUN/ml|
3278409|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 3,333 AUN/ml|
3278410|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 10,000 AUN/ml|
3278411|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Birch 20,000 AUN/ml by an independent safety committee
3278412|NCT01639768|Active Comparator|SUBLIVAC FIX Birch 40,000 AUN/ml|Start of SUBLIVAC FIX Birch 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Birch 20,000 AUN/ml arm evaluated by an independent safety committee
3278413|NCT01639781|Active Comparator|flavanol rich intervention|flavanol rich drink
3278414|NCT01639781|Placebo Comparator|flavanol free intervention|flavanol free drink
3278415|NCT01639794||Male patients with non-neurogenic LUTS taking VESITRIM|Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
3278416|NCT01639807|Active Comparator|latanoprost 2-8˚ C|latanoprost(0.005%)stored at 2-8˚ C
3278417|NCT01639807|Experimental|SLT|Selective laser Trabeculoplasty
3278418|NCT01639820|Experimental|Strategy A|Only identification of sentinel nodes (without pelvic lymph-node dissection)
3278419|NCT01639820|Other|Strategy B|Identification of sentinel nodes + full pelvic lymph-node dissection
3278420|NCT01639846|Experimental|RX-10045 active arm|RX-10045 Ophthalmic Solution, 0.09%
3278421|NCT01639846|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
3278422|NCT01639859|Experimental|Elastography|
3278423|NCT01639885|No Intervention|Group 1|Patients will receive standard care (gemcitabine)
3278424|NCT01639885|Experimental|Group 2|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron)
3278425|NCT01639885|Experimental|Group 3|Patients will receive standard care (gemcitabine) combined with interferon-alpha 2b (Peg-Intron) and p53 SLP vaccin
3278426|NCT01639898|Experimental|"Group 1 (2-cycles trial)"|"The 2-cycles trial will be available to patients who can be treated by radiation or intensive treatment (75 % of cases occurring in front line); they will then undergo 2 cycles of the lenalidomide-dexamethasone combination before radiation or intensive treatment (Group 1)."
3278427|NCT01639898|Experimental|"Group 2 ( 9 cylces Trial)"|"The 9-cycles trial will be available to all other front-line patients (25 % of front-line patients) or patients in relapse or resistant, they will undergo 9 cycles of the lenalidomide-dexamethasone combination followed by maintenance therapy with lenalidomide alone for one year (Group 2)."
3278428|NCT01639911|Experimental|Treated Patients with Solid Tumor|Patients will receive alisertib orally twice a day for the first 7 days of a 21 day cycle. Patients will also receive pazopanib orally once a day continuously. Treatment continues until disease progression, unacceptable toxicity or patient refusal. The study consists of two components which are the dose finding component and optimally tolerated dose extension with pharmacokinetics component.
3278429|NCT01640002|Active Comparator|Propantheline|
3278430|NCT01640002|Placebo Comparator|Placebo|
3278431|NCT01640015|Experimental|low frequency diet|Participants will be assigned to a low frequency diet (fixed energy intake)
3278432|NCT01640015|Experimental|High frequency diet|
3278433|NCT01640041|Experimental|Implanted|All participants.
3278434|NCT01640067|Experimental|Human Neural Stem Cells Suspension|50,000 cells/µl. Patients received either unilateral or bilateral hNSCs microinjections (3 microinjections on each side) into the lumbar spinal cord. Each microinjection consisted of 15 µl of the above 50,000cells/µl suspension, yielding a total of 750,000 cells per injection site.
3278435|NCT01640080|Experimental|Esketamine (Group 1)|
3278436|NCT01640080|Experimental|Esketamine (Group 2)|
3278437|NCT01640080|Placebo Comparator|Placebo|
3278438|NCT01640093|Experimental|Treatment B|Abiraterone acetate (500 mg), 2 coated, reformulated tablets.
3278439|NCT01640093|Experimental|Treatment C|Abiraterone acetate (250 mg), 4 coated, reformulated tablets.
3278440|NCT01640093|Experimental|Treatment D|Abiraterone acetate (500 mg), 2 coated, reformulated tablets, showing slower in vitro dissolution.
3278441|NCT01640093|Active Comparator|Treatment A|Abiraterone acetate (250 mg), 4 uncoated, current commercial tablets.
3278442|NCT01640106|Experimental|Omega-3|Treatment arm, using the omega-3 product (fish oil/paste)
3278443|NCT01640106|Placebo Comparator|Control|Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste
3278444|NCT01640119|Placebo Comparator|no intervention|
3278445|NCT01640119|Experimental|Bicarbonate|
3278446|NCT01640145|Placebo Comparator|Carbohydrate|
3278447|NCT01640145|Active Comparator|Protein continous boluses|
3278448|NCT01640145|Active Comparator|Protein 2 boluses|
3278449|NCT01640158|Experimental|Experimental Treatment|Computerized plasticity-based adaptive cognitive training, up to 65 hours
3278450|NCT01640158|Active Comparator|Active Comparator|Commercially available computerized training, up to 65 hours
3278451|NCT01640223|Experimental|D-3 sensor|patients will be equiped with 2 Dexcom sensors 3 days before hospitalization
3278452|NCT01640223|Experimental|D-1 sensor|patients will be equiped with 2 Dexcom sensors one day before hospitalization
3278453|NCT01640262||localized prostate cancer|Danish men with localized prostate cancer
3278454|NCT01640275|Active Comparator|Propofol based intravenous anesthesia|patients will receive propofol based intravenous anesthesia
3278455|NCT01640275|Experimental|Isoflurane Based Inhaled Anesthesia|patients will receive isoflurane based inhaled anesthesia
3278456|NCT01640301|Experimental|Arm I (high-risk for relapse after HCT)|Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
3278457|NCT01640301|Experimental|Arm II (relapsed after HCT)|Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.
3278458|NCT01640392|Experimental|HIV prevention groups|Participants randomly assigned to the MyLife Intervention arm receive three 1.5-hour HIV behavioral risk-reduction group sessions over a 1-3 week period.
3278459|NCT01640392|No Intervention|Wait-list control|Participants randomly assigned to the Wait-list Control arm receive the MyLife MyStyle group sessions once they have completed a 6-month follow-up assessment.
3278460|NCT01640405|Active Comparator|Control|modified FOLFOX6 + bevacizumab
3278461|NCT01640405|Experimental|Experimental|FOLFOXIRI+bevacizumab
3278462|NCT01640418|Experimental|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
3278463|NCT01640418|No Intervention|Standard Care|Standard Care
3278464|NCT01640431|Experimental|Lumbar stabilization exercises|In the Segmental Stabilization group exercises the focus is on the transversus abdominis and lumbar multifidus muscles.
3278465|NCT01640431|Experimental|TENS group|In this group, patients are treated with TENS in the lumbar region for an hour.
3278466|NCT01640444|Experimental|A|FOLFIRI+bevacizumab
3278467|NCT01640444|Experimental|B|FOLFIRI + cetuximab
3278468|NCT01640457|Experimental|NDplus|NOVOCART® Disc plus (Autologous Disc Chondrocyte Transplantation System)
3278469|NCT01640457|Placebo Comparator|NDbasic|NOVOCART® Disc basic (media with no active cell component)
3278470|NCT01640457|No Intervention|Sequestrectomy only (SC)|Sequestrectomy (standard of care)
3278471|NCT01640470|Experimental|Assistive technology|The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will include recommendations for assistive technology, possibly entailing financial assistance to repair or to acquire new AT, and training. New equipment will likely include devices such as bathroom grab bars, raised toilet seats, walkers, and bath chairs.
3278472|NCT01640470|Active Comparator|Customary care|Participants in this arm will receive customary care.
3278473|NCT01640496|Active Comparator|Vitamin D|Subjects will take 1 pill per day for 8 weeks.
3278474|NCT01640496|Placebo Comparator|Placebo|Subjects will be asked to take 1 pill per day for 8 weeks.
3278475|NCT01640509|Experimental|synchrotron radiation|treated by synchrotron radiation
3278476|NCT01640522|Experimental|Collaborative Care Intervention|Care coordinator facilitates the assessment and treatment of cancer-related symptoms
3278477|NCT01640522|Active Comparator|Enhanced Usual Care|Upon evaluation of symptoms the patient will be referred for further assessment or treatment if indicated
3278478|NCT01640535|Experimental|Test arm|Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg
3278479|NCT01640535|Active Comparator|Comparator arm I|Matching placebo of Montelukast sodium 10mg + Levocetirizine dihydrochloride 5 mg
3278480|NCT01640535|Active Comparator|Comparator arm II|Montelukast sodium 10mg + matching placebo of Levocetirizine dihydrochloride 5mg
3278481|NCT01640561|Experimental|MISC|The Mediational Interventions for Sensitizing Caregivers (MISC) model developed by Professor Pnina Klein (consultant) has been used to enhance the development of children throughout the developing world, with the support of such international aid agencies as the World Health Organization (WHO), UNICEF, Norwegian Agency for Development Cooperation (NORAD), and Redd Barna (Norway).
3278482|NCT01640561|Active Comparator|Enhanced Treatment as Usual|
3278483|NCT01640574|Experimental|DHA-P 7 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
3278484|NCT01640574|Experimental|DHA-P 14 days|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
3278485|NCT01640574|Active Comparator|Chloroquine 7 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
3278486|NCT01640574|Active Comparator|Chloroquine 14 days|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
3278487|NCT01640587|Experimental|DP|2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
3278488|NCT01640587|Active Comparator|MAS3|4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2
3278489|NCT01640600||Children exposed to SSRIs in utero|This group are comprised of children whose mothers used antidepressants during pregnancy and who were therefore exposed to antidepressants in utero.
3278490|NCT01640600||Children exposed to nicotine in utero|This group is comprised of children whose mothers smoked cigarettes during pregnancy and who were therefore exposed to nicotine in utero.
3278491|NCT01640600||Children exposed to neither nicotine nor SSRIs|This group is comprised of children who were exposed to neither nicotine nor SSRIs in utero.
3278492|NCT01640626|Active Comparator|Health Education|Deworming will be conducted in both schools. A health education package will be introduced to schoolchildren in the intervention school (School A) only. Both schools will be followed up for 6 months.
3278493|NCT01640626|No Intervention|Control|Schoolchildren in school B will serve as a control group. No intervention (Health education package) will be given after complete deworming at baseline.
3278494|NCT01640639|Active Comparator|Thalidomide|Thalidomide
3278495|NCT01640639|Placebo Comparator|Placebo|Placebo
3278496|NCT01640652|Experimental|Low dose vaccine arm|To investigate safety, tolerability and immunogenicity of 25 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
3278497|NCT01640652|Experimental|High dose vaccine arm|To investigate safety, tolerability and immunogenicity of 50 µg of the serogroup B meningococcal protein vaccine MenPF-1 in healthy adults aged 18 to 50 years of age when given three doses of vaccine with 8 weeks interval.
3278498|NCT01640665|Experimental|Sorafenib and Capecitabine|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses. Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days
3278499|NCT01640678|Experimental|ReCell epidermal cell suspension grafting|CO2 laser abrasion + ReCell epidermal cell suspension + UV-therapy
3278500|NCT01640678|Active Comparator|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
3278501|NCT01640678|No Intervention|No treatment + UV-therapy|
3278502|NCT01640691|Experimental|Study vaccine (AdimFlu-W)|0.5 mL/dose, a total of 2 doses, 21 days apart
3278503|NCT01640730|Experimental|Kanglaite injection|
3278504|NCT01640743|Experimental|Evertwist 1|Tacrolimus (10-14 ng/ml) + Methylprednisolone (16 mg).
3278505|NCT01640743|Experimental|Evertwist 2|Tacrolimus (4-6 ng/ml) + Everolimus (8-10 ng/ml) + Methylprednisolone (8 mg).
3278506|NCT01640756|Experimental|AqueSys Microfistula Implant|
3278507|NCT01640769|Active Comparator|Image guided delivery of pacing leads|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm) versus standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
3278508|NCT01640769|Placebo Comparator|Standard delivery of pacing leads|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
3278509|NCT01640782|Experimental|Sequential regimen|Sequential treatment with CPT-11 plus Fluorouracil (FU), folinic acid (LV) and Docetaxel (TXT) plus Cisplatin (CDDP)
3278510|NCT01640782|Active Comparator|De Gramont regimen|Fluorouracil (5-FU), folinic acid (LV)
3278511|NCT01640821|Experimental|Intervention group (CdM?)|This group will be composed of women that are seeking help for weight-related problems that have been referred to the CdM? program.
3278512|NCT01640821|No Intervention|Control group|This group will be composed of women that are seeking help for weight-related problems but that are actually on the waiting list for participating to the CdM? program.
3278513|NCT01640847|Experimental|Arm RT: HIFU plus ThermoDox|Index lesion has been treated with EBRT and is currently painful, but these subjects have already received their maximum cumulative EBRT dose.
3278514|NCT01640847|Experimental|Arm NRT: HIFU plus ThermoDox|Subjects have no yet received any radiation to the index lesion.
3278515|NCT01640886||Standard of Care|"Comparison of S. aureus to the reference methods for S. aureus (tube coagulase and Staphaurex.)~Comparison to the reference method (30 ug cefoxitin disc diffusion)."
3278516|NCT01640886||KeyPath Test Group|All specimens collected that meet the inclusion criteria will be tested using the KeyPath BTA Test.
3278517|NCT01640899|Other|Single-arm study|This is a single-arm study. Just one group (i.e. the patients)
3278518|NCT01640912|Experimental|RXI-109|
3278519|NCT01640912|Placebo Comparator|Placebo|
3278520|NCT01640977||Open PLIF|The PLIF procedure achieves access to the degenerated disc from the back of the spine, and is performed through a single midline posterior incision that is typically expanded bilaterally past the facet joints to expose bony landmarks for pedicle screw fixation, which are traditionally placed in a trajectory from lateral to medial, requiring a more lateral starting point.
3278521|NCT01640977||MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach, avoiding the far lateral exposure typical of the traditional PLIF.
3278522|NCT01640990|Experimental|Cohort 1|slow IV infusion over 6 hours consisting of saline for 30 minutes (run in period), 8 mcg/h GW328267X for 1.5 hours (total dose of 12mcg), and 10 mcg/h GW328267X for 4 hours (total dose of 40 mcg)
3278523|NCT01640990|Experimental|Cohort 2|Dose to be determined after analysis of Cohort 1
3278524|NCT01641003||Fresh tumor specimen|Fresh tumor specimen taken immediately after surgery of patients diagnosed with pancreatic cancer, GBM and Breast cancer. These specimens will be taken immediately to the lab isolate and grow CSC using the described methods. No specific intervention done regarding the patients- the samples taken will be processed in the lab.
3278525|NCT01641016|Active Comparator|Continuous Therapy|Continue with current antiretroviral therapy regime as per standard care
3278526|NCT01641016|Experimental|Short Cycle Therapy|Take current antiretroviral therapy 5 days a week (2 days off) as instructed by clinician
3278527|NCT01641029||pyelonephritis|Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.
3278528|NCT01641055|Experimental|Salmon protein hydrolysate|
3278529|NCT01641055|Experimental|Herring protein hydrolysate|
3278530|NCT01641055|Sham Comparator|Cod protein|
3278531|NCT01641055|Placebo Comparator|Milk protein|
3278532|NCT01641068|Experimental|Arm I (memory and thinking skills workshop)|Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
3278533|NCT01641068|Active Comparator|Arm II (Education Workshop)|Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
3278534|NCT01641146|Experimental|Enhanced Sexual Health Intervention for Men|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
3278535|NCT01641146|Active Comparator|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
3278536|NCT01641172|Active Comparator|Patients|Patients with disseminated testicular cancer
3278537|NCT01641172|Placebo Comparator|Healthy volunteers|Healthy men, age 18-50 years old
3278538|NCT01641185|Experimental|protons|irradiation 20 x 3,3 GyE protons
3278539|NCT01641185|Experimental|carbon ions|irradiation 20 x 3,3 GyE carbon ions
3278540|NCT01641211|Experimental|Video intervention|Group that will watch the Meducation inhaler device technique videos.
3278541|NCT01641211|Other|Control|This group will watch a nutrition video.
3278542|NCT01641224|Active Comparator|TCM (Traditional Chinese medicine)|Formula for pain and diarrhea, Atractylodes (~10-15g), Paeonia Lactiflora (~15-30g), Tangerine Peel (~10g), Ledebouriella Root (~10g), Radix codonopsitis (~10-15g), Radix curcumae (~10g), Fingered citron (~10g), Tuckahoe (~15g), etc.
3278543|NCT01641224|Active Comparator|Pinaverium|
3278544|NCT01641224|Placebo Comparator|Placebo|Placebo is blindly given to patients
3278545|NCT01641250|Experimental|Part A: RO5429083|
3278546|NCT01641250|Experimental|Part B: RO5429083 + cytarabine|
3278547|NCT01641263|Experimental|Cognitive Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
3278548|NCT01641263|Active Comparator|Sleep Seminar|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
3278549|NCT01641276|Experimental|hepatitis|hepatitis B carriers patients
3278550|NCT01641276|Experimental|hepatocellular carcinoma patients|hepatites B carriers patients with associated hepatocellular carcinoma
3278551|NCT01641289|Experimental|Paracetamol|">50kg: Paracetamol 1gm PO/NG q6hourly for 72 hours and febrile for 24 hours (maximum total dose 4g/24 hours) plus intravenous Artesunate~<50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72 hours and febrile for 24 hours (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate"
3278552|NCT01641289|Active Comparator|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
3278553|NCT01641302||Patients undergoing robot-assisted laparoscopic prostatectomy|Patients undergoing robot-assisted laparoscopic prostatectomy under general anesthesia
3278554|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,28 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 28 with equine rabies immunoglobulin 40 IU/Kg on day 0.
3278555|NCT01641315|Experimental|Rabies vaccine, IM day 0,3,7,14 with RIG|Healthy volunteers received rabies vaccination intramuscularly on day 0,3,7 and 14 with equine rabies immunoglobulin 40 IU/Kg on day 0.
3278556|NCT01641315|Active Comparator|Rabies vaccine, IM Day 0,3,7,14,28 with RIG|Rabies exposed victims receive rabies vaccination intramuscularly on Day 0,3,7,14,28 with equine rabies immunoglobulin 40 IU/Kg on day 0
3278557|NCT01641328|Active Comparator|Waitlist Control / Home-based training|This group will serve as a waitlist control group while the active group is performing training. Following assessment at the end of the active group period, this group will begin home-based training and will be assessed at the end of that 10 week period.
3278558|NCT01641328|Experimental|Cognitive Activation Group|This group will attend the 3/week group intervention meetings over 10 weeks.
3278559|NCT01641341|Placebo Comparator|Placebo capsule|Placebo capsule (sugar pill with no active medication)
3278560|NCT01641341|Active Comparator|Active treatment|"Active treatment will consist of the following interventions:~Bowel Dysbiosis - probiotics Bifidobacterium infantis,~Maldigestion/Malabsorption - Pancrelipase~Parasitic infection/presence - Nitazoxanide"
3278561|NCT01641393|Experimental|EUR-1008 then Kreon|"EUR-1008 during Treatment Period 1 (29 days ±2 days) and~Kreon during Treatment Period 2 (29 days ±2 days)."
3278562|NCT01641393|Experimental|Kreon then EUR-1008|"Kreon during Treatment Period 1 (29 days ±2 days) and~EUR-1008 during Treatment Period 2 (29 days ±2 days)."
3278563|NCT01641406|Experimental|ER- (Triple Neg. and ER- PR+ Her 2 -)|Experimental chemotherapy using neoadjuvant approach
3278564|NCT01641406|Experimental|Her 2 +|Experimental chemotherapy using neoadjuvant approach
3278565|NCT01641406|Experimental|ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)|Experimental chemotherapy using neoadjuvant approach
3278566|NCT01641419|Placebo Comparator|Placebo|Ropivacaine 0.5% plus 2ml of normal saline used for nerve block
3278567|NCT01641419|Active Comparator|Dexamethasone 4 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 4 mg used for nerve block
3278568|NCT01641419|Active Comparator|Dexamethasone 8 mg|Ropivacaine 0.5% plus 2ml of dexamethasone 8 mg used for nerve block
3278569|NCT01641432|Experimental|TAPAT|Computerized Tonic and Phasic Attention training consisting of visual, auditory, and spatial stimuli that requires sustained attention (24 minutes). Training is followed by a computerized cognitive exercise (12 minutes).
3278570|NCT01641432|Active Comparator|Active Comparator|Computerized conventional board-games that lack the therapeutic effect of the TAPAT exercises. Active control has stimulus parameters similar to the TAPAT exercises (eg. stimuli is presented on the computer, participant responses are collected, session time and improvement is measured).
3278571|NCT01641458|Experimental|fluoropyrimidine-based chemotherapy|DPYD-genotype and TDM-driven dosing of 5FU/Capecitabine
3278572|NCT01641484|Experimental|local control 19.8Gy|local control at 19.8 Gy, at Day 14
3278573|NCT01641497|Active Comparator|3D conformational radiotherapy|25 * 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
3278574|NCT01641497|Experimental|Intensity-Modulated Radiation Therapy|25 * 1.8 Gy in 5 weeks (=45 Gy). IMRT
3278575|NCT01641510|Experimental|Prasugrel|Loading and maintenance dose of prasugrel
3278576|NCT01641510|Active Comparator|Clopidogrel|Loading and maintenance dose of clopidogrel
3278577|NCT01641523||Hydroxyapatite Cranioplasty|patient underwent to cranioplasty reconstruction with customized hydroxyapatite prosthesis
3278578|NCT01641523||polymethylmethacrylate|patient underwent to cranioplasty reconstruction with polymethylmethacrylate prosthesis
3278579|NCT01641523||autologous bone|patients underwent to cranioplasty reconstruction by autologous bone repositioning
3278580|NCT01641536|Experimental|1mg of HB-110|The subjects in this group will be administered 1 mg of HB-110 according to the protocol.
3278581|NCT01641536|Experimental|2mg of HB-110|The subjects in this group will be administered 2 mg of HB-110 according to the protocol.
3278582|NCT01641536|Experimental|4mg of HB-110|The subjects in this group will be administered 4 mg of HB-110 according to the protocol.
3278583|NCT01641549|Experimental|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
3278584|NCT01641549|Active Comparator|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent
3278585|NCT01641562||TAXANES|patients with early breast cancer, scheduled to receive taxanes, with doses according to the stage of the disease
3278586|NCT01641575|Experimental|CO-1.01 and Cisplatin|
3278587|NCT01641614|Experimental|Beating heart surgery|Group A (Beating heart) surgery was performed under normal temperature (36⁰ C) ,once CPB was established, the patient was placed in Trendelenburg position and a retrograde perfusion catheter was inserted into the coronary sinus and ligated by a simple suture line. Aorta cross clamping was immediately established and blood was oxygenated and delivered continuously through a catheter Mitral valve was exposed using the left atrial retractor. Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
3278588|NCT01641614|Active Comparator|heart surgery Group B|Group B (arrested heart) surgery was performed under moderate hypothermia (32⁰C) as technique requirement (3). After cardiac arrest, during the period of cross clamping, the aortic root was perfused through the cardioplegias's cannula with oxygenated blood at a rate between 200 mL/min to 300 mL/min for 2 minutes with 15 minutes intervals.Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture De Vegas' technique.
3278589|NCT01641627|Experimental|vibration|proprioceptive stimulation of the lower limb using vibration and plantar pressure boots
3278590|NCT01641666|Experimental|Peg2b + Ribavirin + Boceprevir|Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
3278591|NCT01641679||Suspected recurrent DTC|100 patients with biochemically suspected recurrent DTC
3278592|NCT01641705||Control Group|Group of nonsmokers individuals without respiratory disease.
3278593|NCT01641705||RA patients 1|RA patients nonsmokers with up to five years of disease.
3278594|NCT01641705||RA group 2|RA patients nonsmokers with six to ten years of disease.
3278595|NCT01641705||RA group 3|RA patients nonsmokers with eleven to fifteen years of disease.
3278596|NCT01641705||RA group 4|RA patients nonsmokers with sixteen or more years of disease
3278597|NCT01641718|Experimental|Single sided glue|Mesh is fixed with Tisseel for single sided inguinal hernias.
3278598|NCT01641718|Active Comparator|Single sided stapled|Mesh is fixed with staples for single sided inguinal hernias.
3278599|NCT01641718|Other|Bilateral glue right|"For bilateral inguinal hernias mesh on the right side is fixed with Tisseel, on the left with staples.~Experimental treatment and active comparator in the same patient."
3278600|NCT01641718|Other|Bilateral glue left|"For bilateral inguinal hernias mesh on the left side is fixed with Tisseel, on the right with staples.~Experimental treatment and active comparator in the same patient."
3278601|NCT01641731|Active Comparator|Cow's milk|
3278602|NCT01641731|No Intervention|Control group|
3278603|NCT01641744|Experimental|Group Attachment Based Intervention (GABI)|
3278604|NCT01641744|Active Comparator|Systematic Training for Effective Parenting (STEP)|
3278605|NCT01641757|Experimental|periodontal treatment group|non surgical periodontal therapy will be given to study subjects which will be selected by randomization from total study sample. at the end of study, serum albumin levels of both study and control groups will be compared.
3278606|NCT01641770|Experimental|Dietary Counseling + ONS|
3278607|NCT01641770|Active Comparator|Dietary Counseling|
3278608|NCT01641783|Experimental|nanoparticle Albumin-bound paclitaxel|evaluate one dose level of nab-paclitaxel:125mg/m2
3278609|NCT01641848|Experimental|Arthritic and injured ankles|InBone TAA
3278610|NCT01641874|Experimental|Specific directional exercise|During the assessment a specific exercise will be identified for this group. The exercise will consist of a repeated specific end range movement of the knee
3278611|NCT01641874|Active Comparator|Evidence based exercise|Quadriceps strengthening and advice on aerobic exercises will be given
3278612|NCT01641874|No Intervention|No intervention|Patient waits on the surgeons waiting list for next appointment or for planned knee surgery
3278613|NCT01641887||GERD patients|Patients who have GERD will be recruited for this study.
3278614|NCT01641913|Experimental|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
3278615|NCT01641965|Active Comparator|early non invasive ventilation|Patients assigned to this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB)immediately after randomization (when their FVC reaches the threshold of the 75% of the predicted value)
3278616|NCT01641965|Active Comparator|standard|patients in this arm will start non invasive ventilation with home pressure ventilator model Vivo 40 (BREAS Medical AB) when they fulfil at least one of the following criteria: (i) FVC < 50% predicted, (ii) orthopnea, and/or (iii) PaCO2 > 45 mmHg.
3278617|NCT01642017|Experimental|Pazopanib|Pazopanib : 3 dose levels are defined : 400, 600 and 800 mg per day.
3278618|NCT01642030|Other|Methadone Maintenance|
3278619|NCT01642030|Other|Buprenorphine Maintenance|
3278620|NCT01642069||Observational|Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or MLL-rearrangements, and other gene expression profiling by RT-PCR and karyotyping or FISH. Results are then compared with each patient's outcome data.
3278621|NCT01642095||Basic science (FAK expression)|Archived tumor tissue samples are analyzed for FAK expression by IHC. IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.
3278622|NCT01642108|Other|Sitagliptin|
3278623|NCT01642121||Observational|Samples and controls are sorted and re-sorted for CD34, CD38, and CD55 subsets by single-cell PCR analysis, flow cytometry, and reverse-transcriptase PCR. Sorted cell subsets are then transplanted into NSG mice. Beginning 6 weeks after transplantation, peripheral blood samples are collected and analyzed for human lymphoid- and myeloid-lineage cells by FACS.
3278624|NCT01642134|Active Comparator|Duoplavin|Both active substances in DuoPlavin: clopidogrel and acetylsalicylic acid, are inhibitors of platelet aggregation. Clopidogrel stops the platelets aggregating by blocking ADP. Acetylsalicylic acid the platelets aggregating by blocking the prostaglandin cyclo oxygenase.
3278625|NCT01642134|Sham Comparator|acenocumarol|
3278626|NCT01642160|Active Comparator|Standard of care|Participants randomized to this arm will have the usual follow up care without any additional information.
3278627|NCT01642160|Active Comparator|Additional Education|This arm will receive a weekly text message or e-mail asking participants to sign on to the web page that we will provide. Once they sign on, they will see additional educational materials and questions regarding their CPAP use. Based on their response, they will be directed to suggestion or sites to help improve their compliance with their CPAP.
3278628|NCT01642173|Other|OCT at baseline|"Subjects enrolled in the NIH funded and IRB approved (08-008161) protocol Lp-PLA2 and Coronary Atherosclerosis in Humans with a positive diagnosis of coronary artery endothelial dysfunction will be studied using Optical Coherence Tomography during the angiogram at baseline."
3278629|NCT01642173|Other|OCT following 6 month Lp-PLa2 inhibition|"Subjects who are enrolled in IRB 10-000044 Lp-PLA2 and Coronary Atherosclerosis in Humans Aim III a study in which the investigators are examining the impact of long-term inhibition of Lp-PLA2, with a specific novel inhibitor or placebo, on Lp-PLA2 activity and improvement in coronary endothelial function will be studied using Optical Coherence Tomography during the 6 month return angiogram."
3278630|NCT01642186|Experimental|Arm A everolimus|"Everolimus will be administered at the following doses:~Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
3278631|NCT01642186|Experimental|Arm B letrozole plus leuprolide|"Day 1 of Cycle 1: Leuprolide 7.5 mg IM will be administered by a nurse in clinic.~Letrozole will be dispensed and will be taken at home. Patients will be instructed to take letrozole at the same time each day, consistently with food or without food, and swallowed whole with a glass of water. If the patient is randomized to everolimus alone (1) or leuprolide and letrozole (2) and the cancer continues to grow, they may have the option to receive all three drugs together."
3278632|NCT01642186|Experimental|Arm C combination everolimus, letrozole and leuprolide|"Patients with a BSA ≤ 1.5 m2 will receive everolimus 5 mg PO QD.~Patients with a BSA > than or = to 1.5 m2 will receive everolimus 7.5 mg PO QD. Leuprolide 7.5 mg IM will be given every 4 weeks (+/- 7 days). Everolimus and letrozole will be administered continuously using the same dose, schedule and administration. Everolimus, letrozole and leuprolide should be administered concurrently at all times."
3278633|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|
3278634|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|
3278635|NCT01642199|Active Comparator|Reduced Intensity Behavioral Weight Loss|
3278636|NCT01642264|No Intervention|Control (Delayed Training) Condition|Participants in this condition were assessed at 1 week, 1 month and 3 months post-enrollment, and were provided access to the WeBREATHe training website upon completion of their 3-month assessment.
3278637|NCT01642264|Experimental|Intervention (Training) Condition|In this condition, participants used the WeBREATHe training program website for 1 week, and completed assessments at 1 week, 1 month, and 3 months post-training.
3278638|NCT01642303|Experimental|vodcasting|students who listen to downloaded vodcasting
3278639|NCT01642303|No Intervention|control|listen to the student book listening file
3278640|NCT01642316|Experimental|washback|students received 8 specific related formative test for that lesson plus a pre-test and post-test, Michigan English language proficiency test
3278641|NCT01642316|Other|control|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
3278642|NCT01642342|Experimental|Weekly Treatment (sEphB4-HSA)|Patients receive recombinant albumin fusion protein sEphB4-HSA IV over 60 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3278643|NCT01642342|Experimental|Every 2 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3278644|NCT01642342|Experimental|Every 3 Weeks Treatment (sEphB4-HSA)|Patients receive recombinant EphB4-HSA fusion protein IV over 60 minutes on days 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3278645|NCT01642355|No Intervention|Usual Care|Usual care includes physician assistant and/or nurse based medical and lifestyle recommendations in consultation with cardiac catheterization attending or patient's clinical cardiologist to potentially improve the patient's medical and lifestyle regimen. Relevant educational material is routinely distributed to patients.
3278646|NCT01642355|Active Comparator|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
3278647|NCT01642355|Active Comparator|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
3278648|NCT01642368|Placebo Comparator|Regular Diet|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3278649|NCT01642368|Active Comparator|Medium Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3278650|NCT01642368|Active Comparator|High Omega-3 Group|If you are accepted into the study, you will be randomized into one of 3 treatment arms which only differ according to the foods consumed. All groups will receive smoothies with these diets.
3278651|NCT01642381|Active Comparator|Psychotherapy|
3278652|NCT01642381|No Intervention|"Self-Change Control (SCC)"|SCC participants will be told that they should attempt to reduce their drinking over the course of 8 weeks. (If unsuccessful, they will be offered Full Motivational Interviewing therapy sessions.)
3278653|NCT01642394|No Intervention|Standardized care|The control group will receive usual care for secondary prevention of type 2 diabetes according to usual care in Osakidetza's primary care.
3278654|NCT01642394|Experimental|Self-management education programme|Attendees will receive the Diabetes Self-Management Programme in spanish version (Manejo personal de la diabetes).
3278655|NCT01642420||Mild cognitive impairment|Patients diagnosed with mild cognitive impairment
3278656|NCT01642420||Alzheimers disease|Patients diagnosed with mild Alzheimers disease
3278657|NCT01642420||Healthy control persons|Age matched healthy persons
3278658|NCT01642433|Placebo Comparator|Sugar pills|
3278659|NCT01642433|Active Comparator|Prazosin pills|
3278660|NCT01642446|Experimental|surgery|Precise hepatectomy
3278661|NCT01642446|Active Comparator|combined intervention|transcatheter hepatic arterial chemoembolization and/or ablation
3278662|NCT01642459|Experimental|Same direction cannulation|The inserted direction of arterial needle is same as the direction of blood flow.
3278663|NCT01642459|Active Comparator|Opposite direction cannulation|The inserted direction of arterial needle is opposite to the direction of blood flow.
3278664|NCT01642472|Experimental|Ulipristal Acetate (PGL4001) 10mg|Ulipristal Acetate (PGL4001)10mg daily administration
3278665|NCT01642498|Experimental|Group A|ROX Coupler + continuing standard antihypertensive medications
3278666|NCT01642498|No Intervention|Group B|Continuing standard antihypertensive medications
3278667|NCT01642511|Active Comparator|Control Group|conventional technique: 99mTc-labeled Sulfur Colloid was injected into the tumor quadrant 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
3278668|NCT01642511|Experimental|Study Group|modified technique: 99mTc-labeled Sulfur Colloid was injected into 2 quadrants of the breast 3-24 hours before surgery, lymphoscintigraphy was performed 30min before surgery. Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery. Axillary sentinel lymph node biopsy and Internal mammary sentinel lymph node biopsy was performed during surgery. Axillary lymph node dissection was performed if ASLN was positive.
3278669|NCT01642524|Experimental|hypertonic saline mixed Dextran|hypertonic saline mixed Dextran
3278670|NCT01642524|Placebo Comparator|Placebo controlled|Saline solution
3278671|NCT01642537|Other|Rhythmia Mapping System & Catheter|This is a single arm diagnostic feasibility study with the Rhythmia Mapping System and the Rhythmia Mapping Catheter
3278672|NCT01642550|Active Comparator|RM-131|Active study drug - RM-131
3278673|NCT01642550|Placebo Comparator|Placebo|Placebo comparator
3278674|NCT01642563|Experimental|Pathogen reduced platelets|Transfusion
3278675|NCT01642563|Active Comparator|Standard platelets|Transfusion
3278676|NCT01642576|Experimental|diet modification|counselling on caloric restriction and healthy eating
3278677|NCT01642576|Experimental|weight management program|dietician and sports trainer, physician counselling on weight loss
3278678|NCT01642628|Experimental|Body Image/Mirror Education|Participants in the mirror arm will receive a mirror and mirror viewing education from oncology nurse navigators.
3278679|NCT01642628|No Intervention|Standard Care|Patients allocated to the control group will receive the usual pre and post-op standard care that does not include the use or discussion of mirrors.
3278680|NCT01642641|Active Comparator|Non-surgical subgingival debridement|
3278681|NCT01642641|Active Comparator|Simplified Papilla Preservation Flap|
3278682|NCT01642641|Active Comparator|Resective Flap with Osseous Recontouring|
3278683|NCT01642654|Active Comparator|Control|
3278684|NCT01642654|Experimental|Treatment|
3278685|NCT01642667|Placebo Comparator|primary PCI|
3278686|NCT01642667|Active Comparator|prouk-PCI|
3278687|NCT01642680|Experimental|Physical activity during chemotherapy|This group will start with a physical activity program 3 months before the end of their chemotherapeutic regimen. After chemotherapy they will continue the PA program for another 3 months.
3278688|NCT01642680|Active Comparator|Physical activity after chemotherapy|This group will start with a physical activity program after the end of their chemotherapeutic regimen. The physical activity program wil take 6 months to complete.
3278689|NCT01642693|Experimental|Teeth with intrusive movement and low power laser|Histological changes and root resorption were assesed in Teeth with intrusive movement after a low power laser application
3278690|NCT01642693|Experimental|Teeth with intrusive movements with no laser|Histological changes and root resorption in Teeth with intrusive movements with no laser
3278691|NCT01642706||RA patients|Patients affected by Rheumatoid arthritis.
3278692|NCT01642706||Control|"Subjects affected by either :~mechanical pathology~systemic auto-immune pathology~other inflammatory rheumatism"
3278693|NCT01642719|Placebo Comparator|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline
3278694|NCT01642719|Experimental|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks. For example, if they spend 9 hr TIB during baseline, they will reduce their TIB to 8 hr.
3278695|NCT01642745|Experimental|Methacholine (Provocholine) with deep inhalation|
3278696|NCT01642745|Experimental|Mannitol (Aridol)|
3278697|NCT01642745|Active Comparator|Methacholine (Provocholine) tidal breathing|
3278698|NCT01642758|Experimental|Sodium 2,2 dimethylbutyrate|A single dose (20 mg/kg/day) of study drug will be taken once per day by mouth.
3278699|NCT01642771|Active Comparator|5-Fu/epirubicin/CTX following Docetaxel|Docetaxel for the first 3 cycles of chemotherapy followed by 3 cycles of FEC (Fluorouracil, epirubicin and cyclophosphamide) chemotherapy
3278700|NCT01642771|Experimental|Docetaxel/capecitabine followed by XEC|Docetaxel/ capecitabine (TX) for the first 3 cycles of chemotherapy followed by 3 cycles of capecitabine/epirubicin/cyclophosphamide (XEC) chemotherapy
3278701|NCT01642784||Culprit lesion IRA revascularization|Culprit lesion IRA revascularization
3278702|NCT01642784||Complete IRA revascularization|Complete IRA revascularization
3278703|NCT01642797|Experimental|CLE-TB|Confocal laser endomicroscopy with Targeted Biopsy
3278704|NCT01642797|Experimental|WLE-SB|Standard White-light endoscopy with Standard Biopsy
3278705|NCT01642810|Active Comparator|Treatment-as-usual|Participants continue their pre-study treatment plan, based on their physician/other professional recommendations
3278706|NCT01642810|Experimental|Online ABBT treatment + TAU|Participants to complete a 6-unit online Acceptance-based behavioural treatment including training in pacing, mindfulness, acceptance, cognitive defusion, willingness, and exercise while also maintaining their pre-study treatment.
3278707|NCT01642823||retinablastoma tumor tissue|
3278708|NCT01642836|Experimental|multi-component, multi-level, multi-setting (MMM)|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
3278709|NCT01642836|Active Comparator|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
3278710|NCT01642849|Experimental|high protein diet|12 subjects will be place on a high protein diet
3278711|NCT01642849|Experimental|high carbohydrate diet|12 subjects will be put on a high carbohydrate diet for 6 months
3278712|NCT01642862|Experimental|Liquid formulation of Simvastatin|
3278713|NCT01642862|Active Comparator|Tablet formulation of Simvastatin|
3278714|NCT01642875|Experimental|EN|early enteral nutrition with standard enteral formulas administered through a nasojejunal tube
3278715|NCT01642875|Active Comparator|PerOs|early oral nutrition with hospital diets and oral formulas
3278716|NCT01642888|Experimental|0.1 µg/0.1 mL C-Tb|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3278717|NCT01642888|Active Comparator|2 T.U. Tuberculin PPD RT 23 SSI|The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3278718|NCT01642901|Experimental|Zoledronic Acid 5 mg IV infusion|Single infusion of 5 mg intravenous zoledronic acid given within 21 days of acute traumatic spinal cord injury.
3278719|NCT01642901|Placebo Comparator|normal saline 0.9%|Infusion of normal saline of equivalent volume to reconstituted zoledronic acid, given only once and run over 2 hours, to occur within 21 days of acute traumatic spinal cord injury.
3278720|NCT01642927||Intra-Aortic Balloon Pump (IABP) Group|Advanced Heart Failure and/or pre-LVAD surgical patient with IABP
3278721|NCT01642927||IABP/LVAD Group|Post-LVAD surgical patients with IABP
3278722|NCT01642927||Post-LVAD Group|LVAD patients 3 months or greater post-implantation undergoing echocardiography
3278723|NCT01642927||LVAD Event Group|LVAD patients who have developed LVAD thrombosis or GI hemorrhage related to LVAD
3278724|NCT01642927||Arrhythmia group|LVAD patient with an irregular heartbeat.
3278725|NCT01642927||Valvular disease group|LVAD patient with valvular heart disease
3278726|NCT01642927||Normal control group|Healthy participant without any known heart disease (Control group).
3278727|NCT01642940|Active Comparator|Prasugrel|
3278728|NCT01642940|Experimental|Ticagrelor|
3278729|NCT01642953|Experimental|Early recovery|"Patients who enroll in this arm are supplied a liquid diet one day before surgery without bowel preparation.~After gastric cancer surgery, they start sips of water on postoperative first day, and they are discharged once they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination."
3278730|NCT01642966|Active Comparator|Prasugrel|Prasugrel 10mg/day for 15 days
3278731|NCT01642966|Experimental|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
3278732|NCT01642979|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
3278733|NCT01642979|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
3278734|NCT01642979|Active Comparator|Glucocorticoids|Glucocorticoids
3278735|NCT01642992||Coronary bifurcation lesion|
3278736|NCT01643005|Active Comparator|Active Control Group|For the active control group we will use Nurturing Parenting Groups currently being run by the community collaborator.
3278737|NCT01643005|Experimental|Relationship Strengthening HIV Prevent.|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
3278738|NCT01643018|Experimental|laparoscopic surgery|-Laparoscopic surgery group describes the patients treated with laparoscopic surgery
3278739|NCT01643018|Active Comparator|Open Surgery|-open surgery group describes the patients treated with traditional open surgery
3278740|NCT01643031|Experimental|Ticagrelor|Patients randomized to the ticagrelor group will receive ticagrelor at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient will be invited to a special research clinic in the hospital and his treatment will be switched back to clopidogrel (to complete 1 year of treatment).
3278741|NCT01643031|Active Comparator|Continued Clopidogrel|Patients randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
3278742|NCT01643057||Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
3278743|NCT01643070|Active Comparator|XELOX RT|Concurrent XELOX-RT
3278744|NCT01643070|Active Comparator|Induction XELOX|Induction XELOX followed by XELOX-RT
3278745|NCT01643083|Active Comparator|Rifaximin|
3278746|NCT01643083|Placebo Comparator|Placebo|
3278747|NCT01643096|Other|sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
3278748|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
3278749|NCT01643109|Experimental|CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
3278750|NCT01643109|No Intervention|Comparison|Standard therapy.
3278751|NCT01643122||Group 1|
3278752|NCT01643122||Group 2|
3278753|NCT01643135|Active Comparator|tranexamic acid|Tranexamic acid (15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will given before induction and the second dose(15 mg/kg in 0.9% NaCl and the total volume is 100 ml) will be given at 3 hours after the first dose.
3278754|NCT01643135|Placebo Comparator|0.9% NaCl|0.9% NaCl 100 ml will be given as a placebo before induction and 3 hours after the first dose
3278755|NCT01643148||breast cancer patients (cases)|36 subjects
3278756|NCT01643148||controls|36 subjects
3278757|NCT01643161|Experimental|TAU+GSH|Treatment As Usual plus Guided Self Help.
3278758|NCT01643161|Active Comparator|TAU|Treatment AS Usual.
3278759|NCT01643174||Surgical treatment|
3278760|NCT01643187|Experimental|Fortified beverage|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
3278761|NCT01643187|Active Comparator|Group receiving lactose-free milk|A group of children with some degree of malnourishment considered by a Z-score < -1 for weight for height, height for age or weight for age.
3278762|NCT01643226|Experimental|riboflavin solution and KXL System|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by UVA irradiation for 4 minutes
3278763|NCT01643226|Placebo Comparator|placebo solution and KXL System|Subjects will receive 0.0% riboflavin ophthalmic solution (Placebo) followed by UVA Irradiation for 4 minutes
3278764|NCT01643239|Experimental|Hospital-based mCIT with individualized intervention|Hospital-based modified constraint-induced therapy(mCIT)
3278765|NCT01643239|Experimental|Hospital-based mCIT with group therapy|Hospital-based modified constraint-induced therapy(mCIT)
3278766|NCT01643239|Other|Hospital-based TR|Hospital-based traditional rehabilitation (TR)
3278767|NCT01643252|Placebo Comparator|Placebo and UVA light exposure|
3278768|NCT01643252|Active Comparator|Riboflavin drops and UVA light exposure|
3278769|NCT01643265|Active Comparator|Whey Milk Protein|
3278770|NCT01643265|Experimental|Bovine Albumin Concentrate|
3278771|NCT01643278|Experimental|Treatment (dasatinib and ipilimumab)|Patients receive dasatinib PO QD for 7 days. Patients then receive dasatinib PO QD and ipilimumab IV once on weeks 1, 4, 7 and 10. Beginning on week 24, patients then receive dasatinib PO QD and ipilimumab IV once every 12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
3278772|NCT01643291|Experimental|Ultrasound|
3278773|NCT01643304||Group 1|
3278774|NCT01643330|Experimental|AAV1/SERCA2a (MYDICAR)|Intracoronary infusion
3278775|NCT01643330|Placebo Comparator|Placebo|Intracoronary infusion
3278776|NCT01643343||Typically Developing|Typically developing toddler volunteers between the ages of 8 months and 3 years
3278777|NCT01643343||Autism|Children between the ages of 8 months and 6 years with a diagnosis of an autism spectrum disorder
3278778|NCT01643356|Active Comparator|Fiber Cereal|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided high fiber cereal to manage hunger.
3278779|NCT01643356|No Intervention|Control Group|Women assigned to this arm of the study will receive routine clinical care and no additional interventions.
3278780|NCT01643356|Active Comparator|Resistant Starch|Women assigned to this arm will receive the group based behavioral intervention plus the recommendation to consume provided resistant starch to control hunger
3278781|NCT01643369|Experimental|Compassion Meditation Group|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
3278782|NCT01643369|Active Comparator|Health Education and Wellness Group|Eight week training in health and wellness, using a curriculum developed specifically for this study.
3278783|NCT01643369|Experimental|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
3278784|NCT01643395|Experimental|vertebroplasty|
3278785|NCT01643395|Other|conservative therapy (brace)|
3278786|NCT01643421|Experimental|Deep inspiration and expiratory positive airway pressure|The protocol of deep inspiration combined to expiratory positive airway pressure will be applied in asthmatic subjects.
3278787|NCT01643421|No Intervention|Control|
3278788|NCT01643434|Active Comparator|Spironolactone|
3278789|NCT01643434|Active Comparator|Clonidine|
3278790|NCT01643447|Active Comparator|Diammonium glycyrrhizinate|Conventional drugs protect liver
3278791|NCT01643447|Experimental|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
3278792|NCT01643460|Experimental|98% Ethanol with Paclitaxel injection|
3278793|NCT01643486|Experimental|iTouch phosphate counting program|All patients will have an iTouch that will help them to calculate the required number of phosphate binders to be taken with each meal
3278794|NCT01643486|Active Comparator|Usual Care|Participants in the active comparator group will document their meals in the iTouch but continue to take their phosphate binders as prescribed by their MD/dietician
3278795|NCT01643499|Experimental|Treatment (mFOLFIRINOX)|Patients receive oxaliplatin IV over 2 hours on, irinotecan hydrochloride IV over 1.5 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3278796|NCT01643538|Active Comparator|Control Arm|"Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.~Subjects in the Control Group will only receive pedometers and weekly feedback on their performance through the same mechanisms and with the same frequency as participants in the other three study arms. There will be no financial incentives or charity donations in this group."
3278797|NCT01643538|Experimental|Personal Financial Incentives Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, if pedometer is used and walking goal is met for 5 out of 7 days, participant will receive $20. Financial incentive is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3278798|NCT01643538|Experimental|Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week participants will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity. Charity donation is terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3278799|NCT01643538|Experimental|Combined Financial Incentives & Social Goals Arm|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will receive money and/or be notified that a donation of the selected amount has been sent to the charity, depending on their selected preference. Incentives are terminated after 4 months. Daily use of pedometer continues for an additional 4 weeks.
3278800|NCT01643551||LVAD Group|18 years and older Planning to undergo VAD implantation
3278801|NCT01643551||Cardiac Surgery Group|18 years or older Planning to undergo valve or coronary bypass surgery
3278802|NCT01643564||Group 1|Heart Transplant Recipients with Unexplained Graft Dysfunction
3278803|NCT01643564||Group 2|Normal Control
3278804|NCT01643564||Group 3|Class III-IV Heart Failure
3278805|NCT01643564||Group 4|Heart Transplant Recipients with Normal Graft Function
3278806|NCT01643577|Active Comparator|Acupuncture protocol for gastroparesis|Patients randomized to this arm will receive an acupuncture protocol that with points designed to treat gastroparesis
3278807|NCT01643577|Placebo Comparator|Acupuncture for musculoskeletal pain|Patients randomized to this arm will receive acupuncture therapy consisting of points designed to treat musculoskeletal pain.
3278808|NCT01643590|Placebo Comparator|Placebo|
3278809|NCT01643590|Experimental|15 mg dose of JVS-100|15 mg dose of JVS-100
3278810|NCT01643590|Experimental|30 mg dose of JVS-100|30 mg dose of JVS-100
3278811|NCT01643603|Experimental|Dasatinib|This is a phase 1 dose escalation study, using a standard 3+3 design. Dasatinib is administered orally once daily in the outpatient setting. Patients who are day 100-180 post transplant will be eligible. The treatment will be started as close to day 100 as possible. The range of days is provided to ensure that patients have recovered from toxicities associated with ASCT and are not deemed ineligible if they were recovering from any toxicity associated with ASCT at day 100.The starting dose of dasatinib is 20 mg daily. The increment of dose escalation is 20 mg per dose level. Thus, there will be 5 dose levels (20 mg, 40 mg, 60 mg, 80 mg and 100 mg, respectively) with 3 patients in each cohort. Patients will continue on dasatinib for 6 months.
3278812|NCT01643629|Other|Study arm A|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
3278813|NCT01643629|Other|Control Arm B|Control arm B will include subjects receiving Standard therapy
3278814|NCT01643642|Experimental|Cognitive behavioral treatment/farmacotherapy intervention|Brief intervention; intake, cognitive behavioral treatment/farmacotherapy (SSRI) and ROM
3278815|NCT01643642|Other|Treatment As Usual|Control group, TAU
3278816|NCT01643655|Experimental|Autologous Adipose Tissue Derived MSCs|
3278817|NCT01643681|Experimental|AdMSC|Autologous Adipose Tissue derived Mesenchymal Stem Cells
3278818|NCT01643694|Experimental|Electronic intervention|Completion of 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks
3278819|NCT01643694|No Intervention|control group|Completion of baseline and 3 mo survey
3278820|NCT01643720||Autism Spectrum Disorders|Children with Autism Disorders and their parents
3278821|NCT01643720||Typically Developing|Typically Developing children and their parents
3278822|NCT01643733|Experimental|Transonics Arm|Intervention will be guided by flow through the fistula as guided by Transonics flow measurements
3278823|NCT01643733|No Intervention|Control arm|Patient will undergo normal fistula intervention guided only by angiographic assessment
3278824|NCT01643746|Active Comparator|Supera stent|The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.
3278825|NCT01643746|Active Comparator|LifeStent|LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.
3278826|NCT01643759|Experimental|buprenorphine transdermal system|buprenorphine transdermal system
3278827|NCT01643785|Experimental|with Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] plus 20,000 units of pronase (endonase), BID for 7 days
3278828|NCT01643785|No Intervention|without Endonase|Second-line quadruple therapy [PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg) Bid, tetracycline 500 mg QID, metronidazole 500mg Tid, tripotassium dicitrate bismuthate 300mg QID] for 7 days
3278829|NCT01643811||Gastrectomy|Patients who underwent gastrectomy for early gastric cancer
3278830|NCT01643811||Endoscopic submucosal dissection|Patients who underwent endoscopic submucosal dissection for early gastric cancer
3278831|NCT01643824|Experimental|Proton Beam Therapy|"Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
3278832|NCT01643837|No Intervention|Standard|Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.
3278833|NCT01643837|Sham Comparator|Light Touch (LT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~Light touch protocol."
3278834|NCT01643837|Experimental|Osteopathic Manipulative Treatment (OMT)|"Standard treatment follow-up: 1. monthly history 2. monthly clinical breast examination.~OMT Protocol."
3278835|NCT01643863||Cohort|
3278836|NCT01643889|Experimental|Sequence group ADBC|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3278837|NCT01643889|Experimental|Sequence group BACD|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3278838|NCT01643889|Experimental|Sequence group CBDA|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3278839|NCT01643889|Experimental|Sequence group DCAB|Treatment A: domperidone 10 mg; Treatment B: domperidone 20 mg; Treatment C: placebo; Treatment D: moxifloxacin.
3278840|NCT01643915|Active Comparator|Control group|Patients with conventional treatment. No distraction method during the treatment visits.
3278841|NCT01643915|Experimental|Experimental group 1|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
3278842|NCT01643915|Experimental|Experimental group 2|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
3278843|NCT01643941|Experimental|1|SA4Ag vaccine low dose
3278844|NCT01643941|Experimental|2|SA4Ag vaccine mid dose
3278845|NCT01643941|Experimental|3|SA4Ag vaccine high dose
3278846|NCT01643941|Experimental|4|SA3Ag vaccine
3278847|NCT01643941|Placebo Comparator|5|Placebo
3278848|NCT01643954|No Intervention|Arm A|Patients with prostate cancer who have undergone robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center.
3278849|NCT01643954|Other|Arm B|Patients with prostate cancer that will undergo robotic radical prostatectomy at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center .
3278850|NCT01643967|Experimental|Ozone therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
3278851|NCT01643967|Active Comparator|sunflower oil|"The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.~Other Names:~Sunflower oil"
3278852|NCT01643980|Experimental|Vaginal micronized progesterone|200 mg vaginal route per day
3278853|NCT01643980|Active Comparator|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
3278854|NCT01643993|Experimental|hCG at Time of Embryo Transfer|Patients will have hCG and media (for a total of 20 microliters) inserted during a mock embryo transfer immediately prior to actual embryo transfer.
3278855|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
3278856|NCT01644006|Experimental|Device: Teleconsultation|"In cases of suspected acute coronary syndrome (including STEMI), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3278857|NCT01644006|No Intervention|Historical Matched Pairs|Historical matched pairs were searched from local protocols. During this phase no teleconsultation system was existent.
3377797|NCT03939585|Experimental|NK/γδ T cell-enriched cell therapy product|"This study will treat 10 participants with the donor NK/TCR-γδ T cell product. Of those 10 participants, 5 would have 10/10 HLA matched sibling donors (MSD) while 5 would have partially matched, related (haplo) donors.~27 days post transplant, the participant's donor will undergo a second, non-mobilized leukapheresis to obtain peripheral blood mononuclear cells (PBMCs).~Donor PBMCs will be processed next day (Day T+28) to obtain the NK cell/TCRγδ T cell product for same day infusion if the participant remains aGVHD free and clinically stable.~Participants will continue routine post-transplant and GVHD monitoring, as well as disease assessment at 56 days, 100 days, 6 months and 1 year following transplant.~Blood samples will be obtained on T=0, T+7, 14, 21 and 28 days and then weekly until T + 56 days, then on T+100 days, + 6 months and + 12 months. If immune-mediated adverse events occur (GVHD, CRS etc) additional blood samples will be obtained at onset and resolution."
3377799|NCT03937804||asthmatics|persons with asthma
3377800|NCT03937804||control|persons without asthma
3377801|NCT03933735|Experimental|Arm A: Dose Escalation|Up to 15 cohorts of subjects receiving sequentially ascending doses of TNB-383B are planned until maximum tolerated dose is reached or recommended phase 2 dose is identified.
3377802|NCT03933735|Experimental|Arm B: Dose Expansion|An expansion cohort will be enrolled after maximum tolerated dose or recommended phase 2 dose is established.
3278858|NCT01644019|Experimental|Device: Teleconsultation|"In cases of suspected acute stroke (including intracranial hemorrhage), if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, neurological diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3377804|NCT03926741|Experimental|GSNOR Challenge testing|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
3377809|NCT03917407|Active Comparator|Arm1: DUR-928 treatment for moderate alcoholic hepatitis|Enrolled alcoholic hepatitis patients would have MELD of 11-20; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with moderate alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
3377810|NCT03917407|Active Comparator|Arm 2: DUR-928 treatment for severe alcoholic hepatitis.|Enrolled alcoholic hepatitis patients would have MELD of 21-30; and have met inclusion and exclusion criteria. DUR-928 as a novel study treatment would be administered in patients with severe alcoholic hepatitis (AH) as determined by the absence of suspected unexpected serious adverse reaction (SUSAR).
3377818|NCT03910465||1/Cohort 1|Subjects with confirmed chordoma.
3377819|NCT03909334|Active Comparator|Arm A (Osimertinib and Ramucirumab)|Osimertinib and Ramucirumab
3377820|NCT03909334|Active Comparator|Arm B (Osimertinib)|Osimertinib
3278859|NCT01644032|Experimental|Device_ Teleconsultation|"Six ambulances from five different Emergency Medical Service (EMS) districts are equipped with a portable telemedicine system. In cases of emergencies, where intravenous analgesia is necessary, if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team and can delegate the application of morphine and other analgesics. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene.~The safety, efficacy and the quality of analgesia should be compared with regular EMS."
3278860|NCT01644032|No Intervention|Historical Control Period|After completion of the study arm, matched pairs from a historical phase (without the ability of teleconsultation) were searched. Local cases were always matched with comparable controls from the same location.
3278861|NCT01644045|Experimental|Device: Teleconsultation|"In cases of acute obstructive, respiratory emergencies if patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician who has an audio-connection to the EMS team and receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. The transmission of still pictures (taken with a smartphone), 12-lead-ECGs and video streaming from the inside of the ambulance can also be carried out, if indicated. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular EMS."
3278862|NCT01644071|Experimental|arm 1|application of three treatments and three masurements within 3 weeks
3278863|NCT01644084|Experimental|HA (priming)-HES (up to 15 ml/kg after CPB)|
3278864|NCT01644084|Active Comparator|HES (priming)-HES (up to 15 ml/kg after CPB)|
3278865|NCT01644084|Active Comparator|HA (priming)-nonHES (only crystalloids after CPB)|
3278866|NCT01644097|Experimental|Arm I (probiotic mix)|Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
3278867|NCT01644097|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID 9 weeks. Treatment continues in the absence of unacceptable toxicity.
3278868|NCT01644110|Experimental|ruxolitinib/pomalidomide|"Cohort 1 (Patient 1 - Patient 41): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be 0.5 mg once daily.~Cohort 2 (Patient 42 - Patient 90): ruxolitinib treatment will be started at 10 mg twice daily up to 25 mg twice daily, whereas the dose of pomalidomide will be started at 0.5 mg once daily up to 2 mg once daily."
3278869|NCT01644123||Nursing home residents|
3278870|NCT01644136|Experimental|Supportive care (microsphere-mediated lymphocele prevention)|Patients undergo standard robotic assisted laparoscopic prostatectomy with pelvic lymph node dissection. After lymph node dissection, patients undergo microsphere-mediated lymphocele prevention to the lymph node basin on one side of the pelvis.
3278871|NCT01644162|Other|iVAPS ventilation|3 months of ventilator use in iVAPS mode with data monitoring
3278872|NCT01644201|Active Comparator|High viscosity non-starch polysaccharide, PolyGlycopleX®-PGX®|
3278873|NCT01644201|Placebo Comparator|Placebo (Rice Flour)|
3278874|NCT01644214|No Intervention|Pessary Check at 3 months|Patients seen at 3 month intervals for pessary check-ups is the most common interval check in our clinic so this arm is considered the control group.
3278875|NCT01644214|Experimental|6 month Pessary Check|Those that will be seen at 6 month follow-up visits for pessary maintenance will be considered the experimental group of the study.
3278876|NCT01644253|Experimental|Cohort 1 - Previously Untreated CLL|20 mg/kg TRU-016 + Rituximab
3278877|NCT01644253|Experimental|Cohort 2 - Relapsed CLL|20 mg/kg TRU-016 + Rituximab
3278878|NCT01644253|Experimental|Cohort 3 - Previously Untreated CLL|10 mg/kg TRU-016 + Rituximab
3278879|NCT01644253|Experimental|Cohort 4 - Previously Untreated CLL|20 mg/kg TRU-016 20 + Obinutuzumab
3278880|NCT01644253|Experimental|Cohort 5 - Relapse CLL|20 mg/kg TRU-016 + idelalisib + rituximab
3278881|NCT01644253|Experimental|Cohort 6 - With CLL on ibrutinib with no complete response|20 mg/kg TRU-016 + ibrutinib
3278882|NCT01644253|Experimental|Cohort 7 - With CLL on ibrutinib with stable disease|20 mg/kg TRU-016 + ibrutinib
3278883|NCT01644253|Experimental|Cohort 8 - With relapsed or refractory PTCL|20 mg/kg TRU-016 + 90 mg/m2 bendamustine
3278884|NCT01644279||Young|Young (age 20-35 years old)
3278885|NCT01644279||Old high-functioning|Old high-functioning (age 70-99 years old)
3278886|NCT01644279||Old low-functioning|Old low-functioning (age 70-99 years old)
3278887|NCT01644305||Polycystic Ovary Syndrome|
3278888|NCT01644305||Idiopathic hirsutism|
3278889|NCT01644305||Control|
3278890|NCT01644318||authoimmıne thyroiditis and habitual abortus|
3278891|NCT01644318||authoimmune thyroiditis|
3278892|NCT01644318||healthy controls|
3278893|NCT01644344|Active Comparator|X-ray|Control group: patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks. Each time radiographs are completed, the surgeon or resident will document if a change in fixation position is noted and if a change in patient management will be entertained (addition, modification or maintenance of cast or splint use, modification of or decision not to advance activity level, need for further surgery to adjust fixation or fracture reduction). The patients' time spent in clinic will be recorded upon arrival and upon completion of the patient-physician interaction.
3278894|NCT01644344|Active Comparator|No X-ray|
3278895|NCT01644357|No Intervention|Dispensing only|Non clinical pharmacists will dispense drugs to patients and usual care will be offered.
3278896|NCT01644357|Experimental|Pharmaceutical care|Patients on experimental group will receive counseling and education on the asthma condition, medication and lifestyle issues. In all visits, the inhaler technique will be reviewed, adherence to treatment and drug related problems were checked. If necessary the patient will be referred to the respiratory specialist to change the medication or to prescribe dose adjustment. Pharmacists document their initial and monthly follow up encounters using a specified form.
3278897|NCT01644370|Other|HIV positive with aeroallergen|positive for aeroallergen at baseline
3278898|NCT01644370|Other|HIV positive without aeroallergen|negative for aeroallergen at baseline
3278899|NCT01644370|No Intervention|control|HIV negative children (n=10)
3278900|NCT01644383|Experimental|Treatment arm (logotherapy)|Participants in Arm I will attend the logotherapy group sessions by the trained psychologist for 4 visits (see Table II, III). The number of participants in group sessions will be 20 participants per group.
3278901|NCT01644383|No Intervention|Control arm (general health education)|Participants in Arm II will attend the routine health education by the nurse. The number of participants in group session will be 20 participants per group.
3278902|NCT01644422|Other|Study arm A|Subjects will receive hair follicles transplants that are dipped in HPL before transplant
3278903|NCT01644422|Other|Study arm B|Subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection one week after transplant
3278904|NCT01644422|Other|Control arm C|Subject will receive Standard hair follicle transplant
3278905|NCT01644435|Other|Study arm A|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
3278906|NCT01644435|Other|Study arm B|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring.
3278907|NCT01644448|Other|Study arm A|Subjects will receive one dose of 5 ml of Autologous Human Platelet Lysate with simultaneous micro-needling on day 2
3278908|NCT01644448|Other|Control Arm B|Topical Applications of the standard therapy as directed by the investigator
3278909|NCT01644461|Other|Study Group|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
3278910|NCT01644487|Experimental|Primary stenting|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
3278911|NCT01644487|Active Comparator|Balloon only|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
3278912|NCT01644513||Positive Responders|Have received at least one injection with no evidence of residual subretinal or intra-retinal fluid present on Spectral Domain Optical Coherence Tomography (SDOCT) one month (+/- 1 week) following most recent injection.
3278913|NCT01644513||Suboptimal Responders|Have received three or more injections in last six months with residual subretinal or intra-retinal fluid present on SDOCT one month (+/- 1 week) following most recent injection; Have not demonstrated complete resolution of fluid following any of the injections in the last 6 months Show leakage on Fluorescein Angiography (FA) or Indocyanine Green (ICG) imaging at some time during last 12 months
3278914|NCT01644526|Experimental|Hemoaccess Valve System|Valve system for use with AV graft
3278915|NCT01644539|Other|Control|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion of 500 ml non caloric load consisting of water and thickening agent (guar gum), over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml non caloric load consisting of water and thickening agent (guar gum) in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3278916|NCT01644539|Other|Oral ingestion|"Subjects participated in a 35 min fmri scan. Intervention: Oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk, over 5 min.~Time frame while scanning:~-5 - 0 min : baseline fmri scan 0 - 5 min: oral ingestion (through a tube, while drinking and swallowing on command) of 500 ml caloric load consisting of Nutricia Chocolate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3278917|NCT01644539|Other|Intra Gastric|"Subjects participated in a 35 min fmri scan. Intervention: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk, over 5 min.~While scanning:~-5 - 0 min : baseline scan 0 - 5 min: intra-gastric infusion (naso-gastric tube) of 500 ml caloric load consisting of Nutricia Cholate Milk in a time frame of 5 minutes while being scanned (fmri) 5 - 30 min: fmri scan continues while subject lays still~At t = 0, 2.5, 5, 10, 15 and 30 blood will be drawn and appetite ratings will be given."
3278918|NCT01644552||eye examinations|
3278919|NCT01644578|Other|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
3278920|NCT01644591|Experimental|Treatment (SRS)|Patients undergo SRS on day 1.
3278921|NCT01644604|Experimental|Renal denervation|Subjects are treated with the renal denervation procedure after randomization and are maintained on baseline anti-hypertensive medications.
3278922|NCT01644604|No Intervention|Control Group|Subjects are maintained on baseline anti-hypertensive medications
3278923|NCT01644630|Active Comparator|Cemented single crowns|Cemented single crown: zirconia abutment (Straumann Cares abutment) with an all-ceramic lithium disilicate crown
3278924|NCT01644630|Active Comparator|Screw-retained single crown|Screw-retained single crown: zirconia abutment (Straumann Cares abutment), directly veneered with veneering ceramic
3278925|NCT01644656|Experimental|acoustic radiation force impulse (ARFI)|Imaging of liver and spleen using modified ultrasound
3278926|NCT01644669|Experimental|Intra-operative Radiation Therapy - IORT|Intra-operative Radiation Therapy
3278927|NCT01644682|Experimental|Arm-1|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IWFPL intervention.
3278928|NCT01644682|Experimental|Arm-2|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive IDWL intervention.
3278929|NCT01644682|Experimental|Arm-3|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will receive ITN intervention.
3278930|NCT01644682|No Intervention|Control|In each country, this arm constitute with 6 clusters where 2 from high, 2 from medium and 2 from low shadfly destiny. Each cluster has 50 households. It will not receive any intervention, Control group
3278931|NCT01644708||Overweight, obese adult patients|Patients following a self empowerment group will be included in the study
3278932|NCT01644721|Experimental|Early measles vaccine|An additional measles vaccine at 4 months of age, at least 28 days after the third dose of pentavalent vaccine
3278933|NCT01644721|No Intervention|Control|Follows the normal vaccination schedule
3278934|NCT01644747|Active Comparator|active tDCS|a group named G1 and treated by medication with SSRIs (Selective Serotonin Reuptake Inhibitors) or SNRIs (Serotonine-Norepinephrine Reuptake Inhibitors) for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and 10 sessions of active anodal tDCS at 2 sessions per day (1 morning and 1 afternoon with a gap of 3h) for 5 days with an electric current 2 mA.
3278935|NCT01644747|Sham Comparator|sham tDCS|a group named G2 and treated by medication with SSRIs or SNRIs for 48 unipolar patients or with Lithium for 12 bipolar patients stabilized for at least 4 months and sham tDCS.
3377831|NCT03893929||Chinese patients with clinical suspicious of prostate cancer|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
3377832|NCT03889249|Active Comparator|Tenecteplase (tNK-TPA)|The intervention group will receive intravenous tenecteplase as a single bolus as per the standard manufacturers' instructions for use. The dose administered will be 0.25 mg/kg body weight (maximum dose 25 mg) over 10-20 seconds as soon as possible after randomization. Tenecteplase has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.
3377833|NCT03889249|Active Comparator|Alteplase ( tPA)|The control group will receive standard of care dosing of intravenous alteplase (0.9 mg/kg body weight, 10% bolus and 90% infusion as per standard care, maximum dose 90 mg).
3278936|NCT01644760|Experimental|Study population|Healthy subjects with spontaneous ventilation, 18 to 50 years of age.
3278937|NCT01644773|Experimental|Chemotherapy|Research participants with high grade glioma or diffuse intrinsic pontine glioma will receive crizotinib and dasatinib.
3278938|NCT01644799|Experimental|lenalidomide and idelalisib|"Lenalidomide:~Lenalidomide will be administered orally on days 1-21 followed by 7 days of rest, every 28 days. A treatment cycle will be considered 28 days in length. In the absence of intolerable toxicity or disease progression, lenalidomide will be given for a total of 12 cycles.~Idelalisib:~Dosing is fixed in all cohorts receiving idelalisib at 150 mg orally (twice daily) for 12 cycles, with the exception of dose modifications for toxicity."
3278939|NCT01644812|Active Comparator|Aerobic exercise|The exercise intervention is a 12-week program involving 150 minutes of moderate intensity exercise (65-69% of participant's age-predicted [220-age] maximum heart rate) each week. Participants will complete one 50-minute supervised treadmill exercise session in the laboratory and 100 minutes of exercise on their own. These exercises may include walking, jogging, biking, or other forms of aerobic exercise. The at-home exercise regimen will be individualized for each participant.
3377834|NCT03888742||ADT Group|Participants received continue ADT treatment for at least more than 6 months
3377835|NCT03888742||RRP Group|Participants have radical prostatectomy performed more than 6 months ago.
3377836|NCT03885908|Active Comparator|In-person geriatric co-management group|"In-person geriatric consults to be done via telemedicine due to the current pandemic and consideration for patient safety."
3377837|NCT03885908|Experimental|Automated geriatric co-management program group|
3377842|NCT03867448||Adults with Endocrine Disorder|Adults referred to NIH with posssible endocrine conditions.
3377843|NCT03867305|Experimental|MOBIDERM group|
3377844|NCT03867305|No Intervention|Control group|
3377845|NCT03866174|Experimental|Psilocybin|Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting protocol. Psilocybin is administered orally as a capsule and taken with water.
3377846|NCT03866174|Active Comparator|Niacin|Participants will receive a single 100 mg dose of niacin along with the Set and Setting protocol. Niacin is administered orally as a capsule and taken with water.
3278940|NCT01644812|Sham Comparator|stretching|The exercise intervention is a 12-week program involving 150 minutes of stretching each week (one 50-minute stretching session in the laboratory and 100 minutes of stretching at home). Participants in the stretching condition will work with a facilitator to create a stretching regimen for 100 minutes of home stretching throughout the week. The facilitator will provide a list of potential stretches with descriptions on how to perform them.
3278941|NCT01644825|Experimental|paclitaxel and pazopanib|
3278942|NCT01644825|Active Comparator|paclitaxel|
3278943|NCT01644838|Experimental|Promethazine|25 mg of promethazine
3278944|NCT01644838|Experimental|Hyoscine|20 mg of hyoscine
3278945|NCT01644851|Experimental|Executive function training|Executive function training
3278946|NCT01644851|Placebo Comparator|Word game training|Computer-based training in tasks related to verbal processing.
3278947|NCT01644864|Placebo Comparator|Placebo|saline injection
3278948|NCT01644864|Experimental|Experimental|0.375% ROPIVACAINE
3278949|NCT01644877|Experimental|DAS181|DAS181-F02, 4.5 mg qd x 10 days
3278950|NCT01644877|Placebo Comparator|Lactose Placebo|placebo, 4.5 mg qd x 10 days
3278951|NCT01644916|Other|Usual control|Usual control will be provided with usual standard management of COPD and psychiatric comorbidities.
3278952|NCT01644916|Other|Integrated care|Integrated care will be provided with integrated care management.
3278953|NCT01644929|Experimental|1 tDCS-Sham|tDC stimulation for 3 weeks, then cross-over to sham stimulation
3278954|NCT01644929|Experimental|2 Sham-tDCS|Sham stimulation for 3 weeks, then cross over to tDCS stimulation
3278955|NCT01644929|Sham Comparator|3 Sham-Sham|Treatment for 6 weeks daily with sham stimulation
3278956|NCT01644942|Other|Insulin sensitive patients|
3278957|NCT01644942|Other|Insulin resistant patients|
3278958|NCT01644955|Experimental|Treatment (carboplatin)|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room and then receive carboplatin administered intracerebrally by convection enhanced delivery.
3278959|NCT01644968|Experimental|KLH + anti-OX40|Day 1: KLH + anti-OX40; Day 3: anti-OX40; Day 4: anti-OX40; Day 29: Tetanus vaccine
3278960|NCT01644968|Experimental|Tetanus vaccine + anti-OX40|Day 1: Tetanus vaccine + anti-OX40; Day 3: anti-OX40; Day 5: anti-OX40; Day 29: KLH
3278961|NCT01644981||VLBW infants|
3278962|NCT01644994|Experimental|intracavitary cisplatin-fibrin|single dose local intracavitary cisplatin-fibrin application after pleurectomy/decortication
3278963|NCT01645033|Experimental|TAU plus computerized CBT|Standard treatment (TAU) plus a short session using a computer program containing computerized CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
3278964|NCT01645033|Active Comparator|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
3278965|NCT01645046|Active Comparator|Coenzyme A 200mg|Coenzyme A 200mg per day.
3278966|NCT01645046|Placebo Comparator|Placebo|Capsule without coenzyme A.
3278967|NCT01645046|Active Comparator|Coenzyme A 400mg|Coenzyme A 400mg per day.
3278968|NCT01645072|Experimental|Low glycemic index diet|The patients will be started on low glycemic index diet.
3278969|NCT01645072|Other|Control group|Standard care. The control group will receive their usual diet without any alteration. No changes will be made to the patients' antiepileptic medication during the 4-week baseline or the 3-month study periods in both the intervention and control groups, unless medically indicated; e.g. drug side effects, or status epilepticus; in which case appropriate changes will be made to their medications and same will be documented.
3278970|NCT01645085|Experimental|Treatment A|100mg MCC-based 13% drug-loaded tablets
3278971|NCT01645085|Experimental|Treatment B|100mg mannitol-based 38% drug-loaded tablets
3278972|NCT01645085|Experimental|Treatment C|150mg MCC-based 13% drug-loaded tablets
3278973|NCT01645085|Experimental|Treatment D|150mg mannitol-based 38% drug-loaded tablets
3278974|NCT01645124|Active Comparator|Cytoreduction for HCT < 45%|Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
3278975|NCT01645124|Experimental|Cytoreduction for HCT between 45 and 50%|Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
3278976|NCT01645137|Experimental|OMT|patients under usual medical care plus osteopathic treatment
3278977|NCT01645137|Other|control|patients under usual medical care
3278978|NCT01645150|Experimental|Strength training group|12 weeks of progressive strength training
3278979|NCT01645150|No Intervention|Control group|No intervention
3278980|NCT01645163|Experimental|Mobile phone counselling|
3278981|NCT01645189|Experimental|Test drug|Idursulfase-beta
3377851|NCT03854227|Experimental|Dose Escalation|Participants will receive PF-06939999 orally at escalating doses in 28 day cycles on a continuous basis
3377852|NCT03854227|Experimental|Non small cell lung cancer monotherapy|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
3377853|NCT03854227|Experimental|Urothelial carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
3377854|NCT03854227|Experimental|Head and neck squamous cell carcinoma|Participants will receive PF-06939999 at the recommended Phase 2 dose in 28 day cycles on a continuous basis
3377855|NCT03854227|Experimental|Non small cell lung cancer PF-06939999 plus docetaxel|Participants will receive PF-06939999 on a continuous basis in combination with docetaxel
3377856|NCT03854227|Experimental|Non small cell lung cancer dose finding|Participants will receive PF-06939999 on a continuous basis at escalating doses in combination with docetaxel
3377857|NCT03845218||single arm|participants with and without RP
3377858|NCT03838770|Experimental|Active|
3377859|NCT03838770|Placebo Comparator|Sham|
3377860|NCT03837314|Experimental|Deep Brain Stimulation|"Deep Brain stimulation using a novel device. Bioinduction Picostim Deep Brain Stimulation system"
3278982|NCT01645202|Active Comparator|TAVI with Edwards Sapien XT valve|
3278983|NCT01645202|Active Comparator|TAVI with Medtronic CoreValve|
3377863|NCT03830229||1/Germline positive mesothelioma|Individuals with mesothelioma who have a BAP1 or other DNA repair/cancer predisposition mutation regardless of CLIA confirmation
3278984|NCT01645215|Experimental|Fruquintinib capsule|cohort 1: fruquintinb continuous oral dosing (1mg once a day) cohort 2: fruquintinb continuous oral dosing (2mg once a day) cohort 3: fruquintinb continuous oral dosing (4mg once a day) cohort 4: fruquintinb continuous oral dosing (6mg once a day) cohort 5: fruquintinb continuous oral dosing (5mg once a day) cohort 6: fruquintinb oral dosing, 3 weeks on/1 week off (5mg once a day) cohort 7: fruquintinb oral dosing, 3 weeks on/1 week off (6mg once a day)
3278985|NCT01645228||significant coronary artery stenosis|anyone coronary segment > 50% diameter stenosis
3278986|NCT01645241|Experimental|Lutheal phase ovarian stimulation|Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.
3278987|NCT01645254|Experimental|Argemone mexicana|"Argemone mexicana is traditional medicinal plant known as having an antimalarial activity.~The aerial part of this plant is used. The decoction of the powder of the plant will be used."
3377864|NCT03830229||2/CLIA confirmed germline mutation without mesothelioma|Individuals with a CLIA confirmed BAP1 or other DNA repair/cancer predisposition mutation who do not have a diagnosis of mesothelioma
3377865|NCT03829722|Experimental|Nivolumab, Carboplatin/Paclitaxel, Radiotherapy|Therapy will continue for 21 weeks total. This includes 4 doses of of nivolumab (240mg/m2) before and concurrent with RT/carboplatin/paclitaxel and 4 adjuvant nivolumab doses (480mg/m2) after the end of RT.
3377866|NCT03827343||1|Retrospective chart review of children and adults with cancer enrolled on immunotherapy treatment protocols in the NCI.
3278988|NCT01645267|Experimental|Osteotomy|Using hydroxyapatite bone graft material
3278989|NCT01645293|Experimental|Genetically modified T cells #1138|
3278990|NCT01645319||White, non-hispanic - Medication Treatment Pathway|
3278991|NCT01645319||White, non-Hispanic - Laser Surgery Treatment Pathway|
3278992|NCT01645319||White, non-Hispanic - Incisional/Other Treatment Pathway|
3278993|NCT01645319||Hispanic - Medication Treatment Pathway|
3278994|NCT01645319||Hispanic - Laser Surgery Treatment Pathway|
3278995|NCT01645319||Hispanic - Incisional/Other Surgery Treatment Pathway|
3377867|NCT03818399|Experimental|overdose patients|subjects that receive acute administration of SUBOXONE sublingual film in the ED followed by SUBLOCADE administration in the ED and referral to an affiliated outpatient treatment clinic, and receive monthly SUBLOCADE injections for 6 months in the context of outpatient treatment.
3377868|NCT03816683||Single cohort (registry) of MCL patients|Patients diagnosed with MCL who have initiated a novel therapy meeting inclusion/exclusion criteria in the past 6 months and treatment is ongoing at the time of enrollment.
3377869|NCT03811665|Experimental|Stereotactic body radiation therapy (SBRT)|
3377870|NCT03811665|Active Comparator|Radiofrequency Ablation (RFA)|
3377871|NCT03809000|Active Comparator|Salvage Radiation Therapy + Standard ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.
3377872|NCT03809000|Experimental|Salvage Radiation Therapy + Enhanced ADT|Salvage RT will be given 66.0 - 70.2 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.
3278996|NCT01645319||Asian - Medication Treatment Pathway|
3278997|NCT01645319||Asian - Laser Surgery Treatment Pathway|
3278998|NCT01645319||Asian - Incisional/Other Surgery Treatment Pathway|
3377874|NCT03794999||Benralizumab-exposed group|Pregnant women with asthma exposed to benralizumab anytime during pregnancy or within 8 weeks prior to last menstrual period
3377875|NCT03794999||Asthmatic comparison group|Pregnant women currently treated for asthma not exposed to benralizumab during pregnancy or within 8 weeks prior to last menstrual period
3377876|NCT03794999||Non-asthmatic comparison group|Pregnant women who are not diagnosed with asthma, have not had exposure to a known human teratogen, and have not taken benralizumab during pregnancy.
3278999|NCT01645319||Black - Medication Treatment Pathway|
3279000|NCT01645319||Black - Laser Surgery Treatment Pathway|
3279001|NCT01645319||Black - Incisional/Other Surgery Treatment Pathway|
3279002|NCT01645332|Placebo Comparator|Treatment I (control)|Placebo of DLBS3233 once daily for 12 weeks + lifestyle modification
3279003|NCT01645332|Experimental|Treatment II|100 mg DLBS3233 once daily for 12 weeks + lifestyle modification
3279004|NCT01645345|Other|RF Pixel handpiece treatment|There is only one arm, and that is a treatment arm. For patients with wrinkles and acne scars, they are being treated with the RF Pixel handpiece to decrease the appearance of these cosmetic deficiencies. The improvement is documented in before and after photographs.
3279005|NCT01645358|Experimental|Helmet to deliver NIV|
3279006|NCT01645358|Active Comparator|Total Face to deliver NIV|
3279007|NCT01645371||Subjects with opioid induced constipation|
3279008|NCT01645384|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
3279009|NCT01645384|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
3279010|NCT01645397||Asthma, elevated exhaled NO|Children with asthma with elevated exhaled NO at initial evaluation (>25ppb)
3279011|NCT01645410|Experimental|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
3279012|NCT01645410|Active Comparator|Lipitor® 40 mg Tablets|Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals
3279013|NCT01645423|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
3279014|NCT01645423|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
3279015|NCT01645436|Experimental|treatment (exercise)|combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
3279016|NCT01645436|No Intervention|control (usual care)|Usual hospital care with no exercise
3279017|NCT01645449|Experimental|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
3279018|NCT01645449|Active Comparator|Lipitor 80 mg Tablets|Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
3279019|NCT01645475|Experimental|Desmopressin lyophilisate (Melt)|Patients receiving Desmopressin lyophilisate (Melt).
3279020|NCT01645566|Experimental|intervention|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
3279021|NCT01645566|No Intervention|Control|No instructions
3279025|NCT01645722|Other|Procedure/Surgery: Enriched Fat grafting|Enriched Fat grafting
3279026|NCT01645748|Experimental|S-1, induction chemotherapy|Cisplatin and 5-FU is the standard treatment for patients with head and neck cancer. Recently,docetaxel was used into CF, and it showed the prolongation of survival. Oral 5-FU showed similar or enhanced response rate, safety than intravenous 5-FU. S-1 showed promising preliminary result in combination with cisplatin in head and neck cancer. In patients with gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid, 60mg/m2 (D1) and 60mg/m2 (D1), respectively. And weekly docetaxel can reduce adverse events compared to 3 week regimen. The aim of this study was to evaluate the efficacy and safety of weekly docetaxel, cisplatin and S-1 combination chemotherapy
3279027|NCT01645761|Experimental|PPI-based triple therapy with endonase|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week) plus 20,000 units of endonase twice daily for one week.
3279028|NCT01645761|No Intervention|PPI-based triple therapy|7-day standard proton pump inhibitor-based triple therapy (the standard dosage of PPI, 1,000 mg of amoxicillin and 500 mg of clindamycin twice daily for one week)
3279029|NCT01645774|Experimental|10s injections duration|10s injections duration
3279030|NCT01645774|Experimental|10s injection duration , waiting 10s|10s injection duration and waiting 10s before withdrawing the needle
3279031|NCT01645774|Experimental|15s injection duration,waiting 5s|15s injection duration and waiting 5s before withdrawing the needle
3279032|NCT01645774|Experimental|5s injection duration , waiting 15s|5s injection duration and waiting 15s before withdrawing the needle
3279033|NCT01645787|Active Comparator|4-aminopyridine (Ampyra)|10 mg tab/ 1 tab twice daily
3279034|NCT01645787|Placebo Comparator|Sugar pill|Placebo 1 tab /twice daily
3279035|NCT01645800|Experimental|Lysozyme hydrochloride|
3279036|NCT01645800|Placebo Comparator|Placebo|
3279037|NCT01645826|Experimental|Diltiazem|The study agent will be Diltiazem and will start at 60 mg po BID then titrated up every two weeks until at a maximum dose of 180mg po BID.
3279038|NCT01645826|Placebo Comparator|Sugar Pill|The placebo group of patients will be treated with Drug A (sugar pill) PO bid and titrated up every two weeks for next titration dose (actually will be an unchanged concentration).
3279039|NCT01645839|Experimental|Systemic treatment with Depocyte|Intrathecal injection of Liposomal Cytarabine (Depocyte®) every 14 ± 2 days for a total of 5 cycles and then every 28 ± 4 days until progression.
3279040|NCT01645839|No Intervention|Systemic treatment without Depocyte|No intrathecal injection.
3279041|NCT01645852|No Intervention|Control|No specified diet for one week prior to hepatic resection.
3279042|NCT01645852|Active Comparator|Low calorie diet|Low calorie diet (five units of Optifast 800 {Nestle Nutrition, Vevey, Switzerland} plus an unlimited volume of calorie free fluids per day) for one week prior to hepatic resection.
3279043|NCT01645865||Control|
3279044|NCT01645865||Intervention|
3279045|NCT01645878|Experimental|Hands on|breast feeding instructed by direct help of instructor
3279046|NCT01645878|Experimental|hands off|
3279047|NCT01645878|Other|Control|Routin breast feeding education
3279048|NCT01645891|Active Comparator|CDO with standard MWT|CDO (continuously supply pure oxygen) with standard Moist Wound Therapy
3279049|NCT01645891|Sham Comparator|Moist Wound Therapy|Moist Wound Therapy. De-activated Sham device placed to wound in order to blind patient and study staff.
3279050|NCT01645904||Group 1|Patients participate in audiotaped focus group regarding web-based program, and fill out demographics questionnaire.
3279051|NCT01645904||Group 2|Patients come to Behavioral Research and Treatment Center (BRTC) at MD Anderson to use initial version of My Family Garden website. Completion of Website Analysis and MeasureMent Inventory (WAMMI), and demographics questionnaires.
3279052|NCT01645904||Group 3|Patients use final version of My Family Garden website, and are interviewed which will be audiotaped. Completion of Website Analysis and MeasureMent Inventory (WAMMI), questionnaire and demographics questionnaire.
3279053|NCT01645917|Experimental|Ablation|Ablation with Arctic Front Advance Cardiac CryoAblation system
3279054|NCT01645943|No Intervention|Conservative|Coronary angiogram only if recurrent ischemia or peristent heart failure or inducible ischemia in predischarge stress test if perfomed
3279055|NCT01645943|Active Comparator|Invasive|Routine coronary angiogram
3279056|NCT01645956||Single group|
3279057|NCT01645969||Cohort|
3279058|NCT01645995|Experimental|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
3279059|NCT01645995|Experimental|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
3279060|NCT01646008||respiratory|
3279061|NCT01646034|Experimental|intensified alkylating chemotherapy|a course chemotherapy with high dose cyclophosphamide, G-CSF and peripheral blood progenitor cell (PBPC) harvest followed by tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
3279062|NCT01646034|Active Comparator|three cycles of chemotherapy|"three cycles of chemotherapy depending on previously received agents~chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclophosphamide previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
3279063|NCT01646047|Experimental|supplement - no retinopathy|subjects receiving active supplement and with no retinopathy based on clinical examination
3279064|NCT01646047|Placebo Comparator|placebo - no retinopathy|patients receiving placebo and who have no diabetic retinopathy based on clinical examination
3279065|NCT01646047|Experimental|supplement - retinopathy|patients receiving the active supplement and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
3279066|NCT01646047|Placebo Comparator|placebo - retinopathy|patients receiving placebo and who have mild to moderate non-proliferative diabetic retinopathy based on clinical examination
3279067|NCT01646060|Experimental|Blood Draw|
3279068|NCT01646086|Experimental|weekly weight tracking|12 month behavioral weight loss intervention
3279069|NCT01646086|Active Comparator|daily weight tracking|12 month behavioral weight loss intervention
3279070|NCT01646086|Active Comparator|no weight tracking|12 month behavioral weight loss intervention
3279071|NCT01646099|Experimental|Sun Protection Education|Distribution of the internet-based sun protection educational program.
3279072|NCT01646099|No Intervention|Control|Distribution of general skin care information.
3279073|NCT01646164||Dill seed|used dill seed infusion (1 tablespoon whole dill seed seeped in a half or whole cup boiling water for 3-4 min)
3279074|NCT01646164||No used Dill seed|those who had not used any herbal drugs were placed at the control group
3279075|NCT01646190|Active Comparator|Standard care|Preoperative: Fasting state after midnight, no intake of oral carbohydrate load Preanesthetic medication No preoperative utilization of inspirex Intraoperative: Effective perioperative analgesia Routine nasogastric tube and abdominal drainage at surgeon discretion Postoperative: Removal of the nasogastric tube after return of bowel function removal of abdominal drainage at surgeon discretion or if volume <50cc Oral liquids and stepwise oral nutrition (water to others liquids to progressive normal or low-fiber nutrition Switch to oral medication after oral nutrition tolerance Urinary catheter removal when the mobilization is satisfactory Mobilization: non standardized and encouraged stepwise mobilization Discharge criteria discussed at surgeon discretion
3279076|NCT01646190|Experimental|FT perioperative care|Preoperative carbohydrate load No preanesthetic medication General anesthesia and intravenous analgesia Transoesophageal US-Doppler for individualized i.v fluids therapy POD 0: No Nasogastric tube postoperatively Oral liquids 0.3-0.5L 6h after extubation First mobilization 6h after surgery (2h) Stimulation of inspirex utilization (6-8t/d) POD 1: Free oral liquids; progressive normal or low-fiber diet Switch to oral medication Urinary catheter removal Mobilization: >4 h out of bed (walking, chair) inspirex utilization POD 2: Free oral liquids; normal or low-fiber diet Mobilization: >6 h out of bed (walking, chair), inspirex utilization POD 3: Complete mobilization as preoperatively First evaluation of discharge criteria in the afternoon
3279077|NCT01646229|Active Comparator|Polymyxin-B hemoperfusion|In the HEMOPERFUSION group, a veno-venous dialysis catheter type GamCath 12 F, 3 lumen will be inserted instead of a regular double or triple-lumen central venous catheter, and connected to the Toraymyxin® (PMX-20-R) device for endotoxin adsorption by hemoperfusion with the DECAPSMART pump. The length of the hemoperfusion will be a minimum of 120 min and started just before the beginning of the surgical intervention in the OR and stopped at the end of surgery.
3279078|NCT01646229|Active Comparator|Control|"In the CONTROL group, the administration of fluids (250 to 500ml crystalloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP between > 8 and 12 < mmHg, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mMol/L, normalisation of the BE.~At the discretion of the attending anaesthesiologist with the FMH level, a PiCCO monitoring, a transoesophageal echography, or a pulmonary artery catheter, will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
3279079|NCT01646242|Experimental|Cold snare polypectomy|
3279080|NCT01646242|Experimental|Double biopsy polypectomy|
3279081|NCT01646281|Active Comparator|Flecainide|Patients randomized to flecainide will receive a 10-minute infusion of 2 mg/kg (maximal 150 mg) flecainide. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
3279082|NCT01646281|Active Comparator|Vernakalant|Patients randomized to vernakalant will receive a 10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given. If the patient is still in AF 1 hour after the infusion, electrical cardioversion will be performed according to protocol.
3279083|NCT01646294|Experimental|OCAS-F|YM178 OCAS tablet (OCAS-Fast) taken orally under fasted and fed condition
3279084|NCT01646294|Experimental|OCAS-S|YM178 OCAS tablet (OCAS-Slow) taken orally under fasted and fed condition
3279085|NCT01646294|Experimental|OCAS-M|YM178 OCAS tablet (OCAS-Medium) taken orally under fasted and fed condition
3279086|NCT01646307|Placebo Comparator|standard care group|patients receive atorvastatin 20 mg/d
3279087|NCT01646307|Active Comparator|intensive rosuvastatin|administrated with rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI
3279088|NCT01646307|Active Comparator|intensive atorvastatin|patients will be administrated with atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI;
3279089|NCT01646333|Active Comparator|Supportive Therapy|The supportive therapy offers patients and support persons the opportunity to discuss and reflect upon both Parkinson's Disease and non-Parkinson's Disease related problems.
3279090|NCT01646333|Experimental|Memory and Problem-Solving Intervention|The memory and problem solving training consists of a day calendar manual and note taking system and problem solving techniques. The neurocognitive memory intervention was adapted from a 6-week manualized day calendar and note taking system previously evaluated in an amnestic MCI sample and a brain tumor sample. The problem solving intervention was adapted from an originally 12-week intervention, which was later adapted into a 6-week brain tumor sample.
3279091|NCT01646359|Experimental|corrected flow time|
3279092|NCT01646372|Active Comparator|Control Group|This group gets a simulation based ACLS refresher as treatment, but no access to cognitive aids for any of the tests.
3279093|NCT01646372|Active Comparator|2nd Control Group|This group receives a standard Simulation based ACLS refresher as the intervention, like the control group. No mention is made of Cognitive Aids in the teaching, but they are available during the post-test and retention post-test.
3279094|NCT01646372|Experimental|Cognitive Aid Group|This group receives Cognitive Aid based teaching as the intervention. They also have access to cognitive aids for post-test and retention post-test
3279095|NCT01646411||assorted acute infection|300 patients diagnosed with assorted acute infection.
3279096|NCT01646437|Experimental|Polycap vs. matching placebo|Polycap is a once daily capsule containing thiazide (25mg), atenolol (100mg), ramipril (10mg) and simvastatin (40mg) vs. matching placebo
3279097|NCT01646437|Experimental|Aspirin vs. matching placebo|Once daily 75mg tablet of Aspirin vs. matching placebo
3279098|NCT01646437|Experimental|Vitamin D vs. matching placebo|Monthly oral dosage of 60,000IU vs. matching placebo
3279099|NCT01646450|Experimental|Icotinib|Icotinib: 125mg, oral administration, three times per day.
3279100|NCT01646463|Experimental|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills is the standard CenteringPregnancy prenatal healthcare intervention combined with mindfulness meditation and mindful movement/yoga applied to pregnancy, childbirth, and parenting.
3279101|NCT01646463|Active Comparator|CenteringPregnancy|CenteringPregnancy is group-based prenatal healthcare delivered according to the guidelines of the American College of Obstetrics and Gynecology. It includes assessment, support, and health education delivered in a healthcare empowerment framework.
3279102|NCT01646476|Active Comparator|Covered stent (Bona stent, pyloric/duodenal covered)|WAVE covered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
3279103|NCT01646476|Active Comparator|Uncovered stent (Bona stent, pyloric/duodenal)|uncovered self-expandable metallic stent (BONASTENT, Standard Sci Tech, Ltd., Seoul, Korea)
3279104|NCT01646489|Experimental|Miravirsen sodium|
3279105|NCT01646489|Active Comparator|Telaprevir|
3279106|NCT01646502|Experimental|Esp-supplemented standard wound care|500 pmol Esp protein will be added to the standard wound care protocol.
3279107|NCT01646502|Active Comparator|Standard wound care|"The standard treatment protocol established at the Vancouver Wound Healing Clinic is based on the Best Clinical Practice Guidelines for Venous Leg Ulcers from the Canadian Association of Wound Care."
3279108|NCT01646515|Placebo Comparator|placebo arm|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3279109|NCT01646515|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3279110|NCT01646528||Consecutive patients for CLE examination|
3279111|NCT01646541||Asymptomatic|No dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class I]
3279112|NCT01646541||Symptomatic|Dyspnea with exertion greater than 6 months after mitral valve surgery [New York Heart Association (NYHA) Functional Class II, III, or IV]
3279113|NCT01646554|Active Comparator|Arm A: modified FOLFOX6 and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Oxaliplatin 85 mg/m² IV 2-h infusion~Hour 0: Folinic Acid 400 mg/m² (DL form) or 200 mg/m2 (L form) IV 2-h infusion~Hour 2: 5-FU 400 mg/m² IV bolus over 2-4 minutes~Hour 2: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~On day 1 of a 14 day cycle"
3279114|NCT01646554|Experimental|Arm B: modified FOLFOX6 + Aflibercept and Surgery|"6 cycles before and 6 cycles after surgery consisting in:~Hour 0: Aflibercept 4 mg/kg intravenous infusion 1-h~Hour 1: Oxaliplatin 85 mg/m2 2-h infusion~Hour 1: Folinic Acid 400 mg/m2 (DL form) or 200 mg/m2 (L form) 2-h infusion~Hour 3: 5-FU bolus 400 mg/m2 IV bolus over 2-4 minutes~Hour 3: 5-FU 2400 mg/m² given as a continuous infusion over 46h.~Day 1 of a 14 day cycle~Aflibercept should be given in all cycles, except cycle 6 of pre-operative treatment."
3279115|NCT01646567|Experimental|SHP-141C & Placebo & Calcipotriol & Betamethasone Valerate|A 100 mg dose of SHP-141C cream at three concentrations (0.5%, 1.0% and 2.0%), a matched placebo cream and two reference treatments: Calcipotriol 0.005% cream and Betamethasone Valerate 0.02% cream, applied topically to a selected plaque on each subject, six times per week over 28 days for a total of 24 doses.
3279116|NCT01646580|Experimental|ciclopirox|
3279117|NCT01646606|Active Comparator|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be measured at a frequency determined by the responsible physician (as is current practice). The reading will be displayed on the bedside monitor in the participants' room.
3279118|NCT01646606|Experimental|Intermittent oxygen monitoring|
3279119|NCT01646619|Active Comparator|Hypothermia + Magnesium Sulphate|
3279120|NCT01646619|Placebo Comparator|Hypothermia+ Placebo|
3279121|NCT01646632|Experimental|Physical exercise intervention|Progressive resistance training, balance training, functional training
3279122|NCT01646632|Placebo Comparator|Lifestyle counseling|Recreational sessions
3279123|NCT01646684|Experimental|SOM230|
3279124|NCT01646697|Experimental|Diagnostic (cytopathologic evaluation)|Patients undergo cytopathologic sample collection during pancreatic resection during which slides are gently pressed against the cut edge of the pancreas, the surgical bed, and along the superior mesenteric artery, and finally against the tumor itself.
3279125|NCT01646710|Experimental|Food Based Recommendations|Developing and pretesting tool for FBRs for infants 9 to 11 months old
3279126|NCT01646723|Experimental|VALID Intervention|Volunteers Adding Life in Dementia (VALID) Program
3279127|NCT01646736|Placebo Comparator|GC+CYC|Patients were treated with Glucocorticosteroid and Cyclophosphamide.
3279128|NCT01646736|Experimental|GC+T2|Patients were treated with Glucocorticosteroid and oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
3279129|NCT01646749|Experimental|Protein intake of 5 energy percent (En%)|
3279130|NCT01646749|Experimental|Protein intake of 15 En%|
3279131|NCT01646749|Experimental|Protein intake of 30 En%|
3279132|NCT01646775|Experimental|Epidural bupivacaine|
3279133|NCT01646775|Active Comparator|Epidural bupivacaine and fentanyl|
3279134|NCT01646788|Experimental|Experimental|NMB's PTA Balloon catheter with Paclitaxel drug
3279135|NCT01646801|Experimental|Experimental|NMB's Paclitaxel Drug ejecting balloon catheter
3279136|NCT01646840|Experimental|PF-04958242 capsule|
3279137|NCT01646840|Active Comparator|PF-04958242 oral solution|
3279138|NCT01646853|Experimental|Concurrent radiochemotherapy|
3279139|NCT01646866||Siblings of Children with Autism Spectrum Disorders|This group is comprised of 6-12 month old siblings of a child with an expert clinical diagnosis of autism spectrum disorders.
3279140|NCT01647178|Active Comparator|Manual closure|Patients are closed with a manual, straight wire, conventional closure technique
3279141|NCT01647178|Active Comparator|TORQ closure|Patients are undergo a TORQ assisted sternal closure
3279142|NCT01647191|Experimental|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
3279143|NCT01647191|Active Comparator|control group|The investigators will adopt previous treatment in the clinics to intervent the patients without any type of target intervention for this group.
3279144|NCT01647204|No Intervention|usual mealtime care|patients admitted to the control ward receiving no intervention but usual mealtime help from ward staff
3279145|NCT01647204|Experimental|mealtime assistance|Additional lunchtime help from trained volunteer mealtime assistants to supplement help from the ward staff
3279146|NCT01647243|Experimental|Preoperative strength training|Progressive strength training on group basis four weeks before the operation and progressive strength training on group basis four weeks after the operation
3279147|NCT01647243|No Intervention|Living as usual|The patients are living as usual the last 4 weeks before operation
3279148|NCT01647256|Experimental|Nikkomycin Z fed - fasting|"Period 1:~Day 1: Nikkomycin Z 500 mg with high fat breakfast~Period 2:~Day 1: Nikkomycin Z 500 mg under fasted conditions"
3279149|NCT01647256|Experimental|Nikkomycin Z fasting - fed|"Period 1:~Day 1: Nikkomycin Z 500 mg under fasted conditions~Period 2:~Day 1: Nikkomycin Z 500 mg with high fat breakfast"
3279150|NCT01647269|Experimental|DBS Off first|
3279151|NCT01647269|Experimental|DBS On First|
3279152|NCT01647308|Active Comparator|ISIS-APOCIIIRX|
3279153|NCT01647308|Placebo Comparator|Placebo|
3279154|NCT01647321|Active Comparator|Active cycling|Individuals will receive functional electrical stimulation while on the stationary bike and instructed to actively pedal.
3279155|NCT01647321|Sham Comparator|Passive cycling|Individuals will receive active functional electrical stimulation (FES) while on the stationary bike and instructed to relax their legs, allowing the FES to move their legs on the stationary bike.
3279156|NCT01647334|Experimental|Shrinking Target Adaptive Radiotherapy|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
3279157|NCT01647347|Experimental|test treatment|"Test treatment:~1 min mouthwash with 10% PVP-iodine~1 min subgingival rinsing with 10% PVP-iodine~1 min ultrasonic debridement with 10% PVP-iodine as cooling liquid~blood sampling from the V.mediana cupidi"
3279158|NCT01647347|Placebo Comparator|Control group|"Control:~1 min mouthwash with water~1 min subgingival rinsing with water~1 min ultrasonic debridement with water as cooling liquid~blood sampling from the V.mediana cupidi"
3279159|NCT01647360||Women with Heavy Menstrual Bleeding (HMB)|
3279160|NCT01647386||MBT Revision Component|
3279161|NCT01647399||Phenotypic Clusters|500 urban youth
3279162|NCT01647412|Active Comparator|Growth Hormone, Exclusion Diet, and Nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered recombinant human growth hormone (rhGH) for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet nutraceutical therapy for the remaining 26 weeks of the study.
3279163|NCT01647412|Placebo Comparator|rhGH placebo, Exclusion diet, and nutraceutical therapy|The experimental group will receive the exclusion diet and nutraceutical therapy (DNT) and daily subcutaneously administered placebo injections for the first 26 weeks. After 26 weeks this group will continue on the exclusion diet and nutraceutical therapy for the remaining 26 weeks of the study.
3279164|NCT01647425||head and neck or lung cancer|patient with a first head and neck cancer or first lung cancer
3279165|NCT01647451|Experimental|Active|
3279166|NCT01647451|Placebo Comparator|Placebo|
3279167|NCT01647477|Active Comparator|questionnaires|4 questionnaires to answer at baseline 45 minutes approx.
3279168|NCT01647477|Experimental|interview|semi directive interview 105 patients
3279169|NCT01647490|Active Comparator|Right Ventricular Apex (RVA)|In the RVA group the right ventricular pacing lead will be implanted in the apex region of the right ventricle
3279170|NCT01647490|Experimental|Right Ventricular Septum (RVS)|In the RVS group the right ventricular pacing lead will be implanted in the septal region (mid septum) of the right ventricle
3279171|NCT01647503||Tumor group|Parathyroid adenoma, hyperplasia and carcinoma
3279172|NCT01647503||Normal|Normal parathyroid samples
3279173|NCT01647529|Experimental|Ganciclovir|Treatment with topical ganciclovir ointment
3279174|NCT01647555||patient with epidermoid cancer|receiving Cetuximab and radiotherapy
3279175|NCT01647568||Control|Patients who are not on any anti-platelet/anti-coagulant therapy and present to our lab for a elective colonoscopy.
3279176|NCT01647568||Thienopyridine Users|Patients on Clopidogrel or prasugrel when they present for an elective colonoscopy.
3279177|NCT01647594|Active Comparator|Young Women's Intervention (YWI)|
3279178|NCT01647594|Active Comparator|Physical Activity Intervention (PAI)|
3279179|NCT01647607|Experimental|Young Women's Intervention (YWI)|This arm involves administration of an educational intervention that focuses on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
3279180|NCT01647607|Active Comparator|Physical Activity Intervention (PAI)|This arm involves administration of an educational intervention that focuses on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
3279181|NCT01647620|Active Comparator|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily
3279182|NCT01647620|Placebo Comparator|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
3279183|NCT01647633|Experimental|Calcium Glycerophosphate Nasal Wash|Nasal spray wash twice daily and up to four additional times per day as needed for nasal allergy symptoms
3279184|NCT01647646|Active Comparator|Symbicort|"We will evaluate the efficacy fot Symbicort use. The usage was 2 doses bid for one year period.~Intervention drug: Seretide fixed doses therapy"
3279185|NCT01647646|Experimental|Seretide|In non-well asthma controlled patients, experimental study with Seretide regular doses (125 2 doses bid for one year) and higher doses (250 2 doses bid) for one year
3279186|NCT01647659|Experimental|GSK1120212 tablet|GSK1120212 tablet
3279187|NCT01647659|Experimental|GSK1120212 powder for oral solution|GSK1120212 powder for oral solution
3279188|NCT01647672|Experimental|Abraxane|Abraxane for neoadjuvant chemotherapy
3279189|NCT01647685|Active Comparator|Nanocort|Two weekly IV infusions of 144 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
3279190|NCT01647685|Active Comparator|Methylprednisolone|Methylprednisolone sodium succinate 125 mg infusion.
3279191|NCT01647685|Placebo Comparator|Saline|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
3279192|NCT01647698|Experimental|Early training group|The early training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. They will continue training on the adaptive working memory training task for 5 weeks, after which they will continue for 5 weeks using a non-adaptive working memory task (active control task).
3279193|NCT01647698|Experimental|Late training group|The late training group will consist of 10 randomly assigned participants who will engage in a non-adaptive working memory training task (i.e. an active control task) immediately after baseline assessment for 5 weeks. After the initial 5 weeks of the active control task they will then switch to the adaptive working memory task (the intervention) for 5 weeks. This is a randomized controlled cross-over design.
3279194|NCT01647698|Placebo Comparator|No training group|The no training group will engage in no training over the course of the pilot study, but will still participate in baseline, 5 week, 10 . This will allow us to determine if changes in the outcome and assessment variables are due to the working memory training or progression in the disease itself.
3279195|NCT01647724||control 1|standard recall letter to perform HPV test at the clinic
3279196|NCT01647724||Intervention 1|direct mailing of the self sampling device at home
3279197|NCT01647724||intervention 2|invitation to retire the self sampling device in local pharmacy
3279198|NCT01647750|Other|Lower dose of levothyroxine|Participants may be randomised to receive a lower dose of levothyroxine (lower than their usual dose) to achieve a target TSH level of 4.1 - 8.0 mU/L
3279199|NCT01647750|Other|Standard dose of levothyroxine|Patients may be randomised to receive their usual dose of levothyroxine (target TSH level 0.4 - 4.0 mU/L)
3279200|NCT01647763|Experimental|HAL/RAR|hemorrhoidal artery ligation with rectoanal repair
3279201|NCT01647763|Active Comparator|Stapled hemorrhoidopexy|"procedure for prolapse and hemorrhoids (PPH)~Resection using a circular stapler"
3279202|NCT01647776||Individuals without colon polyps|
3279203|NCT01647776||Individuals with colon polyps|
3279204|NCT01647789|Experimental|CFG920|
3279205|NCT01647802|Experimental|Turner-Vertic'Easy-Tina|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Vertic'Easy; (3) Tina.
3279206|NCT01647802|Experimental|Turner-Tina-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Turner; (2) Tina; (3) Vertic'Easy.
3279207|NCT01647802|Experimental|Vertic'Easy-Turner-Tina|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Turner; (3) Tina.
3279208|NCT01647802|Experimental|Vertic'Easy-Tina-Turner|Standing will be attempted with the three devices in the following order: (1) Vertic'Easy; (2) Tina; (3) Turner.
3279209|NCT01647802|Experimental|Tina-Turner-Vertic'Easy|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Turner; (3) Vertic'Easy.
3279210|NCT01647802|Experimental|Tina-Vertic'Easy-Turner|Standing will be attempted with the three devices in the following order: (1) Tina; (2) Vertic'Easy; (3) Turner.
3279211|NCT01647815|Experimental|50 healthy volunteers|The study population consists of healthy volunteers aged 18 to 50 years and without previous surgery, trauma, or thrombosis of the axilla or the shoulder girdle.
3279212|NCT01647828|Experimental|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel|OMP-59R5 plus Gemcitabine and Nab-Paclitaxel
3279213|NCT01647828|Experimental|Gemcitabine and Nab-Paclitaxel plus Placebo|Gemcitabine and Nab-Paclitaxel plus Placebo
3279214|NCT01647841||Pregnant women and infants|HIV+ and HIV- pregnant women, HIV-exposed and HIV-unexposed infants, ARV-exposed and ARV-unexposed infants
3279215|NCT01647854|Experimental|Device: Teleconsultation|"If patients give informed consent the paramedics can use this system to contact a so called tele-EMS physician with an audio-connection to the EMS team who receives vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) in real-time. Also 12-lead-ECGs can be transmitted to the tele-EMS physician. The transmission of still pictures - taken with a smartphone - and video streaming from the inside of the ambulance can be carried out, if meaningful. The tele-EMS physician supports the EMS team in obtaining all relevant medical history, ECG diagnosis, general diagnosis and can delegate the application of medications. This can be carried out to bridge the time to the arrival of an EMS physician or in less severe cases without an EMS physician on-scene. The safety and efficacy of the introduction and operation of this system should be evaluated."
3279216|NCT01647867|Experimental|Met analysis|Met analysis on tissue and blood Western Blot Immunohistochemistry ELISA test
3279217|NCT01647880|Experimental|Fingolimod (Gilenya®)|0,5 mg once a day in the morning, oral
3279218|NCT01647880|Active Comparator|Interferon beta-1b (Extavia®)|every second day, s.c.
3279219|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.375mg/kg, single-dose|
3279220|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, single-dose|
3279221|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 1.5mg/kg, single-dose|
3279222|NCT01647893|Experimental|CTB-001 or placebo(mannitol) 0.75mg/kg, and dose escalation|
3279223|NCT01647919|Experimental|cogniVida™ 100 mg/day|
3279224|NCT01647919|Placebo Comparator|Placebo|
3279225|NCT01647932|Active Comparator|Loop plus thiazide-type diuretic|Loop diuretic plus hydrochlorothiazide
3279226|NCT01647932|Placebo Comparator|Loop diuretic plus placebo|Loop diuretic plus placebo
3279227|NCT01647971|Experimental|ublituximab|"Phase I:~4 cohorts with IV ublituximab starting with 450 mg followed by 600 mg, 900 mg or 1200 mg in each cohort (3 - 6 patients per cohort). Infusions will be on days 1, 8, 15 and 22 of cycle 1 followed by a planned maintenance with a single infusion monthly starting cycle 3. Patients with CLL or SLL will have infusions on Days 1, 8 and 15 of cycle 1 & 2 followed by a planned maintenance with a single infusion monthly starting cycle 3. Expansion of patient enrollment in select cohorts will apply."
3279228|NCT01647984|Placebo Comparator|Placebo|Inert Placebo - Vitamin B complex + diet
3279229|NCT01647984|Active Comparator|Ritmonutra|Omega-3 polyunsaturated fatty acids, Hawthorn, Astaxanthin, Vitamin E, Vitamin B complex + diet
3279230|NCT01647997|Experimental|study 1a|whole body lactate production after bacterial endotoxin challenge
3279231|NCT01647997|No Intervention|study 1b|basal whole body lactate production
3279232|NCT01647997|Experimental|study 2a|muscle lactate concentration after bacterial endotoxin challenge
3279233|NCT01647997|No Intervention|study 2b|basal muscle lactate concentrations
3279234|NCT01648010|Experimental|TC-3 gel|TC-3 gel group undergo intravesical instillation of the investigatory device
3279235|NCT01648010|Experimental|MMC- gel|MMC gel group undergo intravesical instillation of the reverse thermal gelation device mixed with MMC
3279236|NCT01648023|Experimental|Randomization to LC OR ONCOZENE Bead with Gem-Cis or Gem-Carbo|Transarterial Chemoembolization (LC or ONCOZENE Bead) with Gem-Cis or Gem-Carbo
3279237|NCT01648023|Active Comparator|Randomization to Gem-Cis or Gem-Carbo|Gem-Cis or Gem-Carbo alone
3279238|NCT01648036|Experimental|Unfractionated Heparin|
3279239|NCT01648036|Active Comparator|Dalteparin|Standard of care
3279240|NCT01648049|Experimental|CBT|Cognitive behavior therapy for both insomnia and depression featuring stimulus control and cognitive therapy.
3279241|NCT01648049|Active Comparator|Treatment as Usual|No additional treatment besides regular care.
3279242|NCT01648062|Active Comparator|Arousal reduction using guided imagery|Sleep Self-Regulation Using Mental Imagery: Participants in the arousal reduction condition were instructed to imagine wearing a backpack loaded with their worries, then putting the heavy backpack down, and then experiencing the relief and freedom from tension.
3279243|NCT01648062|Active Comparator|Mental simulation of sleep behavior|Sleep Self-Regulation Using Mental Imagery: Participants in this condition received instructions to visualize a specific behavioral plan designed to meet the goal of obtaining quality sleep each night through the practice of certain behaviors. To form the behavioral plan, participants visualised changing into comfortable clothes and taking time to relax prior to going to bed, the time they planned to go to sleep, where they planned to sleep, and the bedtime routine they follow to help them to get to sleep. At bedtime, they were instructed to mentally run through a checklist of these behaviors and then do any behaviors that they had not yet completed.
3279244|NCT01648062|Active Comparator|Combination|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to practice a combination of the guided imagery (for relaxation) and mental simulation imagery for sleep-related behaviour
3279245|NCT01648062|Sham Comparator|Control|Sleep Self-Regulation Using Mental Imagery: Participants in this condition were asked to imagine a typical post work activity
3279246|NCT01648075|Experimental|Experimental: Probiotic enriched milk|150 ml of skimmed milk enriched with probiotic (Lactobacillus rhamnosus LRH08) once a day
3279247|NCT01648075|Placebo Comparator|Skimmed Milk|150 ml of skimmed milk once a day
3279248|NCT01648088||Pre-op THA and TKA patients|Patients who are scheduled for total joint arthroplasty
3279249|NCT01648114|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
3279250|NCT01648114|Experimental|Antenatal Breastfeeding Intervention|Antenatal intervention group will receive usual care plus a 20 to 30-minute one-to-one educational intervention about breastfeeding.
3279251|NCT01648127|Experimental|Ceftaroline|Ceftaroline intravenous 600 mg single dose
3279252|NCT01648153|Active Comparator|GSK1070806 0.25mg/kg|TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
3279253|NCT01648153|Active Comparator|GSK1070806 5mg/kg|Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
3279254|NCT01648153|Placebo Comparator|Placebo (Saline)|Two IV administrations of saline 4 weeks apart
3279255|NCT01648179|Experimental|GSK1322322 IV formulation|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via IV formulation
3279256|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fasted)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fasted)
3279257|NCT01648179|Experimental|GSK1322322 Oral mesylate salt solution|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Oral mesylate salt solution
3279258|NCT01648179|Experimental|GSK1322322 Wet milled Tablet (Fed)|Subjects will be randomized in a cross over fashion to receive the GSK1322322 administered via Wet milled Tablet (Fed)
3279259|NCT01648192|Experimental|2.5 mg|Losmapimod for single dose
3279260|NCT01648192|Experimental|7.5 mg|Losmapimod for single dose
3279261|NCT01648192|Experimental|20 mg|Losmapimod for single dose
3279262|NCT01648192|Placebo Comparator|Placebo|Placebo
3279263|NCT01648192|Experimental|7.5 mg BID|Losmapimod for repeat dose (14 days)
3279264|NCT01648192|Placebo Comparator|Placebo BID|Placebo
3279265|NCT01648205|Active Comparator|Ranolazine|Ranolazine 1000 mg bid
3279266|NCT01648205|Placebo Comparator|Placebo|Matching Placebo
3279267|NCT01648218|Active Comparator|Neutral protamine hagedorn (NPH) insulin|"Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
3279268|NCT01648218|Experimental|Regular or Aspart insulin|"Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid."
3279269|NCT01648218|Experimental|Insulin glargine|"Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid."
3279270|NCT01648231|Other|Treatment Period 1|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
3279271|NCT01648231|Other|Treatment Period 2|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
3279272|NCT01648231|Other|Treatment Period 3|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
3279273|NCT01648244|Experimental|Computer-Assisted Decision Support|These providers will use the CADS program to treat their enrolled patients.
3279274|NCT01648257|Experimental|GSK1265744 Na Salt Tablets|Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.
3279275|NCT01648257|Experimental|GSK1265744 Free Acid Nanomilled Capsules|Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
3279276|NCT01648257|Experimental|GSK1265744 Free Acid Micronized Capsules|Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.
3279277|NCT01648309||TAVI|patients with significant aortic stenosis that are candidates for transvascular aortic valve implantation
3279278|NCT01648335|Active Comparator|immobilization of the shoulder in internal rotation|
3279279|NCT01648335|Experimental|Immobilization of the shoulder in external rotation|
3279280|NCT01648465|Experimental|Everolimus|
3279281|NCT01648478|Experimental|Single Arm|
3279282|NCT01648504|Experimental|Intervention with eGuide to colonoscopy|The investigators will prospectively enroll and follow patients who receive the eGuide to Colonoscopy and determine benefit and satisfaction with the intervention as part of a pilot study.
3279283|NCT01648517|Experimental|Arm A|Genomic-driven dual agent chemotherapy Chemotherapy will consist of the assigned two drugs according to ERCC1 and RRM1 mRNA expression level A1: docetaxel + vinorelbine (DV) A2: gemcitabine + vinorelbine (GV) A3: docetaxel + carboplatin (DC) A4: gemcitabine + carboplatin (GC)
3279284|NCT01648517|Active Comparator|Arm B|standard of care All control arm patients received standard platinum-based doublet chemotherapy with docetaxel plus carboplatin
3279285|NCT01648543|Active Comparator|block method: angle|The entry angle of angular method which is one method of lumbar sympathetic ganglion block is 30 degree of anterior-posterior view of C-arm.
3279286|NCT01648543|Active Comparator|block method: distance|The entry point of modified Reid method which is popular method of lumbar sympathetic ganglion block is 7~7.5cm from midline of spinous process of lumbar spine.
3279287|NCT01648556|Other|patients with a thrombopenia isolated|Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
3279288|NCT01648595|Experimental|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention.
3279289|NCT01648595|No Intervention|Without Fentanyl|The control group did not receive Fentanyl.
3279290|NCT01648608|Experimental|Exemestane|Exemestane for neoadjuvant chemotherapy
3279291|NCT01648621|Experimental|Case Management|In addition to usual care, the intervention group will receive case management that includes: 40 minute standardized education session, an individualized action plan, an individualized care plan for management of COPD and comorbidities, standardized reinforcement/motivational interviewing and action plan teach-back sessions and assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions), tele-home monitoring, coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and CCAC facilitated by the case manager, priority access to ambulatory clinics.
3279292|NCT01648621|Active Comparator|Usual care|Usual care for these patients comprises: Dictated patient summary, referral to an 8 week in-hospital rehabilitation and self-management education program, referral to a smoking cessation program (as applicable), individualized action plan developed with treating respirologist at the discretion of the attending respirologist, Referral to web based educational materials and resources.
3279293|NCT01648634|Experimental|Nebivolol|
3279294|NCT01648634|Placebo Comparator|Placebo|
3279295|NCT01648660|Active Comparator|D2x - D1x|"Cross Over from double dosage to single dosage:~daily supplementation with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FAabout two years after one year with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA"
3279296|NCT01648660|Active Comparator|D1x - D2x|"Cross Over from double dosage to single dosage:~daily supplementation with 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA"
3279297|NCT01648660|Active Comparator|D1x - D1x|single dosage: daily supplementation about two years after one year with 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA (dosage remains existing)
3279298|NCT01648686|Active Comparator|Women treated by bisphosphonate|Postmenopausal osteoporotic women treated by alendronate 70 mg weekly per os
3279299|NCT01648686|Sham Comparator|Women didn't treat by bisphosphonate|Postmenopausal osteoporotic women untreated by bisphosphonates
3279300|NCT01648712|Other|Balance Circuit|24 patients will be assigned to the Balance group , using a non -heparin extracorporeal pediatric device for operation . The intervention is to use the Balance circuit for this arm
3279301|NCT01648712|Other|Carmeda Circuit|"24 patients will be assigned to the Carmeda group, using a coated heparin extracorporeal pediatric device for operation.~The intervention is to use the Carmeda circuit for this arm. The intervention is the Carmeda circuit."
3279302|NCT01648725|Experimental|Hypnosis|standard care plus hypnosis followed by closed-loop administration of propofol for anesthesia induction
3279303|NCT01648725|Active Comparator|Control|standard care without hypnosis followed by closed-loop administration of propofol for anesthesia induction
3279304|NCT01648738|Experimental|Spa therapy, exercise and educational therapy|Spa therapy, exercise and educational therapy
3279305|NCT01648738|Active Comparator|Usual care and counselling (Back book)|Usual care and counselling (Back book)
3279306|NCT01648751|Experimental|Vaginal estrogen|Patients in the experimental group will receive vaginal estrogen cream
3279307|NCT01648751|Placebo Comparator|Placebo cream|Patients in the comparison group will receive placebo vaginal cream
3279308|NCT01648777|Experimental|L bupivacaine|Drug (L bupivacaine) and device (catheter) 750 patients undergoing cardiac surgery with sternotomy are treated with L-bupivacain in the multiperforated catheter of analgesia
3279309|NCT01648777|Placebo Comparator|placebo|Isotonic Nacl 9°/00 solution 750 patients undergoing cardiac surgery with sternotomy are treated with isotonic NaCl solution (placebo) in the multiperforated catheter of analgesia
3279310|NCT01648816||postpartum depression|caucasian mothers with postpartum depression
3279311|NCT01648816||control|caucasian mothers without depression
3279312|NCT01648829|Active Comparator|Atorvastatin|os, 20 mg, once per day, for 30 days
3279313|NCT01648829|Active Comparator|Pitavastatin|os, 4 mg, once per day, for 30 days
3279314|NCT01648842||Pregnant women|
3279315|NCT01648855||Preterm babies|Intra uterine growth restricted preterm babies born before 30 weeks of gestational age from mother with preeclampsia
3279316|NCT01648868|Experimental|Excitatory effects of rTMS|Study excitatory effects of rTMS applied to the STS in patients with autism
3279317|NCT01648868|Active Comparator|Inhibitory effects of rTMS|Study inhibitory effects of rTMS applied to the STS in healthy controls
3279318|NCT01648894|Experimental|11 weeks|The cancer surgery is practice 11 weeks after neoadjuvant radio-chemotherapy
3279319|NCT01648894|Other|7 weeks|The cancer surgery is practice 7 weeks after neoadjuvant radio-chemotherapy
3279320|NCT01648907||SPONDYLARTHRITIS COHORT|
3279321|NCT01648933|Experimental|Sarcoidosis|"Rubidium PET:~Myocardial Perfusion Imaging"
3279322|NCT01648946|Active Comparator|Liberal Transfusion Strategy|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
3279323|NCT01648946|Active Comparator|Restrictive Transfusion Strategy|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
3279324|NCT01648972|Experimental|Gastrografin|
3279325|NCT01648972|Placebo Comparator|Placebo|
3279326|NCT01648985||Acute stroke and TIA patients|Cohort of acute stroke patients, admitted to the Stroke Unit Danderyd hospital 2010 - 2012
3279327|NCT01648998|Experimental|Fludrocortisone|Fludrocortisone 500 mg in capsule
3279328|NCT01648998|Placebo Comparator|Placebo|Placebo capsule, single dose, main ingredient lactose
3279329|NCT01649011||Scores of the ODI and RMQ for low back pain|
3279330|NCT01649024|Experimental|single arm of Tremelimumab|Tremelimumab is administered at 15 mg/kg on day 1 every 12 weeks for 4 doses
3279331|NCT01649037|Experimental|nor adrenaline and terlipressin|
3279332|NCT01649037|Active Comparator|step up terlipressin|
3279333|NCT01649050|Experimental|BGG492|BGG492 tablets administered orally
3279334|NCT01649050|Placebo Comparator|Placebo|Matching placebo administered orally
3279335|NCT01649063||the shape and frequency of uterine contractions in delivery|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
3279336|NCT01649063||the shape and frequency of uterine contractions in cesarean|Uterine contractions were recorded by using fetal monitoring system (Model FC1400) at the beginning of the active phase (cervical dilatation 3-4 cm) for 30 min in two groups.
3279337|NCT01649089|Experimental|Treatment (cone biopsy/lymphadenectomy or hysterectomy)|Patients undergo cone biopsy and pelvic lymphadenectomy or simple hysterectomy and pelvic lymphadenectomy.
3279338|NCT01649102|Experimental|Palindroom catheter|Insertion of Palindroom catheter
3279339|NCT01649102|Experimental|Hemoglide Bard Catheter|Insertion of Hemoglide Bard Catheter
3279340|NCT01649115|No Intervention|Usual Care|The Usual Care arm, will not be receiving the interactive nutrition education. They will be meeting with the Registered Dietitian twice in person after the participants are randomized in each arm, and once on the phone. The first meeting, they will be receiving pamphlets and handouts, which are typically given as part of usual care. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool. The second meeting and the follow-up phone call are both the same for usual care and the Healthy Lifestyles Passport arm.
3279341|NCT01649115|Experimental|Healthy Lifestyles Passport|The Healthy Lifestyles Passport arm will be receiving the intervention. They will be meeting with the Registered Dietitian twice in person after the participants are randomized into each arm, and once on the phone. The first meeting, they will be receiving the Healthy Lifestyles Passport, including the interactive nutrition education. The second meeting is a post-test assessment and Newest Vital Sign Assessment Tool.
3279342|NCT01649141|Experimental|Treatment Group|Trauma-Focused Cognitive Behavioral Therapy
3279343|NCT01649154|Active Comparator|Ligasure Small-JAW|
3279344|NCT01649154|Active Comparator|Harmonic Focus|
3279345|NCT01649154|Active Comparator|Clamp-and-Tie technique|
3279346|NCT01649167||Overweight/obesity|Pregnant women with overweight/obesity
3279347|NCT01649167||gestational diabetes|Pregnant women with gestational diabetes
3279348|NCT01649167||normal weight|Pregnant women with normal weight
3279349|NCT01649193||Chronic Respiratory Disease|Any patient with a chronic respiratory disease referred for pulmonary rehabilitation
3279350|NCT01649206|Experimental|Group A: RTA|Percutaneous Radiofrequency Thermal Ablation (RTA).
3279351|NCT01649206|No Intervention|Group B: untreated|No treatment, only follow-up
3279352|NCT01649219|Experimental|Exercise intervention|3-month supervised exercise intervention 3 times per week; 60min per time.
3279353|NCT01649219|No Intervention|No intervention|Standard couselling at baseline
3279354|NCT01649245|Experimental|Reiferon retard plus ribavirin|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses
3279355|NCT01649258|Experimental|Supportive care (antiemetics)|Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.
3279356|NCT01649310|Experimental|WVB Training|
3279357|NCT01649336|Experimental|MEK162 + paclitaxel|
3279358|NCT01649401|Active Comparator|Standard nubulizer|"Nebulizer sessions for the patients in this arm will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
3279359|NCT01649401|Experimental|Experimental nebulizer|"Nebulizer sessions for the patients in this arm will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
3279360|NCT01649440||Normal control|Healthy volunteers
3279361|NCT01649440||SIRS|"temperature >38 ℃ or <36℃;~pulse rate>90 beats/min;~ventilatory rate>20 breaths/min or hyperventilation with partial pressure of arterial carbon dioxide (PaCO2)<32mmHg;~white blood cell count>12,000μL-1 or <4000μL-1 or >10% immature cells"
3279362|NCT01649440||sepsis|sepsis is defined as SIRS plus confirmed infection.
3279363|NCT01649440||severe sepsis|"sepsis associated with organ dysfunction, hypoperfusion, or hypotension.~sepsis with arterial hypotension, despite adequate fluid resuscitation."
3279364|NCT01649440||death|sepsis patients within 48 hours before death.
3279365|NCT01649453||Cancer of uncertain primary|
3279366|NCT01649466|Experimental|Vildagliptin|Patients randomized to the vildagliptin group will receive 50mg vildagliptin once daily add-on to their current glimepiride monotherapy for 24 weeks. No dose titrations are permitted during the study.
3279367|NCT01649466|Active Comparator|Protaphane|Patients randomized to the Protaphane group will receive a individualized dose of Protaphane once daily as bedtime dose. The Protaphane dose will be titrated within the first 4 weeks to reach fasting plasma glucose values below 100 mg/dl.
3279368|NCT01649479|Other|Suspected Obstetrical APS; confirmed APS|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients have APS.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3279369|NCT01649479|Other|Sus. Obst. APS, confirmed thrombophilia|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork later confirms that these patients are thrombophilic.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3279370|NCT01649479|Other|Suspected Obstectrical APS; unconfirmed|"The patients included in this study are women actively addressed to the participating departments because of clinical symptoms corresponding to suspected obstetrical anti-phospholipid syndrome.~Bloodwork cannot confirm APS, nor thrombophilia.~All patients included in this study will have the following interventions:~antiphospholipid antibody tests~thrombophilia bloodwork~psychiatric evaluation"
3279371|NCT01649492|No Intervention|diclofenac without pineapple juice|single dose of diclofenac 25 mg without pre-exposure to pineapple juice
3279372|NCT01649492|Active Comparator|diclofenac with pineapple juice|single dose of diclofenac 25 mg with pre-exposure to pineapple juice
3279373|NCT01649531|Active Comparator|Test group|1 Implant, to be placed in the position with greater vertical bone height with a mesial or distal cantilever.
3279374|NCT01649531|Active Comparator|Control group|2 Implants
3279375|NCT01649544|Experimental|EPICOR|"Cardiac ablation system EPICOR (CE n°0344).~ablation device EpicorTM UltraCinchTM LP (Class III device)~Positioning system and calibration EpicorTM LP (LP PASTM; device Class IIa)~Cable connection EpicorTM LP (unsterile)~Ablation Control System EpicorTM LP (Class IIb)"
3279376|NCT01649544|Active Comparator|Amiodarone|"Cordarone :~400 mg/d during the 2 first months 200 mg/d from 3th to 18th month"
3279377|NCT01649570|Experimental|Insulin aspart|
3279378|NCT01649583|Experimental|Jaw Dynasplint System|
3279379|NCT01649583|No Intervention|Control Arm|
3279380|NCT01649622|Experimental|Bendamustine|"Patients receive Bendamustine at dose of 75 mg/m2 by vein over 30 minutes twice daily for four days (Days 1-4). Bendamustine dose based on actual body weight.~Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses."
3279381|NCT01649635|Experimental|Cabazitaxel|25 mg/m2, administered as a 1-hour intravenous infusion, on Day 1 of each cycle, every 21 days Prednisone: 10 mg daily throughout the treatment with cabazitaxel Ciprofloxacin: at a dose of 500 mg for 8 days twice daily (total dose 1.0 g) Granulocyte-Colony Stimulating Factors: maximum dose of 600ug for 7 days or until Absolute Neutrophils Count reaches level ≥ 10.000/mm3
3279382|NCT01649648|Experimental|Intervention|Autologous cord blood cells arm
3279383|NCT01649661||premenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
3279384|NCT01649661||postmenopausal women|Only women already scheduled for a breast MRI will be included in the study, no additional MRIs will be scheduled for study purposes.
3279385|NCT01649674|Active Comparator|PEG|polyethylene glycol solution 2 liters
3279386|NCT01649674|Active Comparator|NapP|Sodium picosulphate and magnesium citrate solution 300 ml
3279387|NCT01649687|Experimental|Mesenchymal stem cells(MSC) treatment|All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells
3279388|NCT01649700|Experimental|Mesenchymal stem cells treatment|All subjects will receive autologous adipose-derived mesenchymal stem cells
3279389|NCT01649713|Experimental|Fluval AB vaccination|In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
3279390|NCT01649726|Other|Standard strategy|Apnea test according to recommendations
3279391|NCT01649726|Experimental|CPAP strategy|Apnea test with CPAP connection
3279392|NCT01649739|Experimental|Levitra|
3279393|NCT01649752|Experimental|Differentiated stem cell therapy group|After ovum pick-up, MSC differentiated to endometrium is deposited in the uterine cavity.Embryo transfer will be done at day 5 at the blastocyst stage.
3279394|NCT01649752|Experimental|undifferentiated stem cell therapy group|Immediately postmenstrual undifferentiated MSC is deposited in the uterine cavity. Ovum pick-up will be done as usual.Embryo transfer will be done at day 5 at the blastocyst stage.
3279395|NCT01649752|No Intervention|Control group|ovum pick-up as usual and embryo transfer at day 5 at the blastocyst stage.
3279396|NCT01649778||Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
3279397|NCT01649817||Cohort|
3279398|NCT01649830|Experimental|Radiotherapy plus adjuvant temozolomide|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
3279399|NCT01649830|Active Comparator|Radiotherapy|Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
3279400|NCT01649843|Experimental|EA|Patients were eligible for enrollment in the study if they had an Eckardt symptom score ≥ 4. The diagnosis of achalasia was made on the basis of the absence of peristalsis and on impaired relaxation of the LES on established methods (barium swallow, manometry, esophagogastroduodenoscopy (EGD)).
3279401|NCT01649882|Experimental|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
3279402|NCT01649895|Experimental|D-Cycloserine|D-Cycloserine, 5 pills (50mg), once per week in 5 weeks.
3279403|NCT01649895|Placebo Comparator|Placebo|Placebo: 5 pills for 5 weeks, once per week.
3279404|NCT01649908||sectional cross clamping|
3279405|NCT01649908||simultaniously cross clamping|
3279406|NCT01649908||EVAR|
3279407|NCT01649921|Active Comparator|Interferon-gamma|
3279408|NCT01649921|Placebo Comparator|Saline 0.9%|
3279409|NCT01649934|No Intervention|Scheduling as Usual|Participants will be subject to the current appointment scheduling procedures.
3279410|NCT01649934|Experimental|Contact Clinic|This group will be required to contact the clinic themselves to make appointments.
3279411|NCT01649934|Experimental|Implementation Intentions|This group will create Implementation Intentions to contact the clinic to make their appointments and to attend those appointments.
3279412|NCT01649960|Other|Rapamycin|Oral rapamycin was given during the nonrandomized phase of the study. The doses that were used of rapamycin were 0.5mg, 1mg, or 2mg.
3279413|NCT01649986|Active Comparator|Non-pharmacologic intervention|Patients assigned by their own general practitioner to have non-pharmacologic intervention and prevention strategies will be given details on lifestyle approaches and dietary strategies
3279414|NCT01649986|Active Comparator|Nutraceuticals|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
3279415|NCT01649999|Experimental|ASP015K lowest dose|Oral
3279416|NCT01649999|Experimental|ASP015K low dose|Oral
3279417|NCT01649999|Experimental|ASP015K medium dose|Oral
3279418|NCT01649999|Experimental|ASP015K high dose|Oral
3279419|NCT01649999|Placebo Comparator|Placebo|Oral
3279420|NCT01650012|Experimental|Eplerenone|Target of 50 mg/day
3279421|NCT01650012|Placebo Comparator|Placebo|Matching placebo
3279422|NCT01650025|Placebo Comparator|VSL#3 placebo|The placebo comparator is administered in the same form and dose as the active ingredient. The patient will take 2 sachets a day for 4 months.
3279423|NCT01650025|Active Comparator|VSL#3 active probiotic|VSL#3 is a probiotic preparation containing 8 different strains of lactic acid bacteria and bifidobacteria. Each sachet contains 450 billion bacteria and the patient will be requested to take 2 sachets a day for 4 months
3279424|NCT01650038|Active Comparator|faecal transplantation; donor faeces|2 times treatment with faecal transplantation: faeces from a healthy donor processed for duodenal tube infusion. after bowel lavage with macrogol.
3279425|NCT01650038|Placebo Comparator|faecal transplantation; placebo|2 times treatment with (own) faecal transplantation: faeces from the patient processed for duodenal tube infusion. after bowel lavage with macrogol.
3279426|NCT01650051|Placebo Comparator|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|
3279427|NCT01650051|Experimental|Phenazopyridine Hydrochloride Tables, USP 200 mg|
3279428|NCT01650090|Experimental|ILC|Inhaled Lipid Cisplatin (ILC) will be administered every two weeks via nebulization and inhalation.
3279429|NCT01650129|Experimental|BIAsp|
3279430|NCT01650129|Experimental|BHI|
3279431|NCT01650142||NF1GeneModif Cohort|Adult patients with neurofibromatosis 1
3279432|NCT01650155|Experimental|BI 1005273 i.v.|single dose i.v. infusion
3279433|NCT01650155|Placebo Comparator|BI 1005273 i.v. Placebo|single dose i.v. infusion (Placebo)
3279434|NCT01650155|Experimental|BI 1005273 s.c.|single dose s.c. injection
3279435|NCT01650155|Placebo Comparator|BI 1005273 s.c. Placebo|single dose s.c. injection (Placebo)
3279436|NCT01650168||NOMAC-E2|New users of NOMAC-E2
3279437|NCT01650168||LNG-COCs|New users of levonorgestrel-containing COCs
3279438|NCT01650181|Active Comparator|Metformin|Patients treated with diet, exercise and metformin
3279439|NCT01650181|Active Comparator|Suplement|Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).
3279440|NCT01650207|Experimental|EA group|To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes.
3279441|NCT01650207|Experimental|TENS group|The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes.
3279442|NCT01650207|Sham Comparator|sham-acupuncutre|The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16).
3279443|NCT01650220||Veterans with a history of PTSD|
3279444|NCT01650220||Veterans without a history of PTSD|
3279445|NCT01650233|Experimental|Mindfulness-based stress reduction|The mindfulness-based stress reduction (MBSR) program was previously adapted for urban youth and here further adapted to 12 weekly 50-minute classes for use in school.
3279446|NCT01650233|Placebo Comparator|Healthy Topics|An age-appropriate health education curriculum was used as a non-specific group comparison for the MBSR program to control for the effects of: positive adult instruction, interactive peer group instruction, learning new material, group size and location, time, and attention.
3279447|NCT01650272|Experimental|5%Minoxidil solution|"This arm AGA patient receive 5%Minoxidil solution ( Propylene glycol solvent ) to use for 6 month.~Record efficacy and safety as described."
3279448|NCT01650272|Experimental|5%Minoxidil milky lotion|This arm AGA patient receive 5%Minoxidil milky lotion to use for 6 month. Record efficacy and safety as described.
3279449|NCT01650311||Healthy controls|Healthy control group will include participants consenting prior to colorectal cancer screening.
3279450|NCT01650311||CD patient groups|The patient groups will include patients with clinical diagnosis of CD.
3279451|NCT01650311||UC patient group|The patient groups will include patients with clinical diagnosis of UC.
3279452|NCT01650337|Experimental|Smartphone Application|Patients will be given access to a smartphone application for weight loss and instructed on how to use it.
3279453|NCT01650337|No Intervention|Usual primary care|
3279454|NCT01650363|Active Comparator|Acupuncture, homeopathy, osteopathy and reflexology|patients will receive combinations of acupuncture, homeopathy, osteopathy and reflexology
3279455|NCT01650363|Placebo Comparator|homeopathic placebo medication|
3279456|NCT01650376|Experimental|Olaparib plus carboplatin and paclitaxel|
3279457|NCT01650389|Experimental|MVA85A|1 x 10(superscript'8') pfu MVA85A vaccine intradermal within 96 hours of birth
3279458|NCT01650389|Active Comparator|Candin|Equal volume intradermal administration within 96 hours of birth
3279459|NCT01650415|Experimental|Erythropoietin and Rehabilitation|recombinant human erythropoietin injection and active rehabilitation
3279460|NCT01650415|Placebo Comparator|Placebo and Rehabilitation|Placebo erythropoietin and rehabilitation
3279461|NCT01650428|Experimental|FOLFOX & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
3279462|NCT01650428|Experimental|FOLFOXIRI & Bevacizumab|"Bevacizumab - 5 mg/kg IV over 30-90 minutes (cycles 1-5 only), Irinotecan - 165 mg/m2 IV over 1 hour, Oxaliplatin - 85 mg/m2 IV over 2 hours, Folinic acid - 350 mg IV over 2 hours, 5-Fluorouracil - 3200 mg/m2 IV continuous infusion over 48 hour.~Treatment given every 2 weeks for 12 weeks (for 6 cycles)"
3279463|NCT01650441|Experimental|beclomethasone dipropionate + formoterol fumarate|All patients will be treated with the active product. No placebo arm will be used. The active product is a fixed combination containing extra-fine beclometasone dipropionate and formoterol fumarate in a new dry powder inhaler device, NEXThaler® (Chiesi Farmaceutici, Parma, Italy).
3279464|NCT01650454|Experimental|Patients from Memento cohort.|"Patients with mild cognitive impairment included in MEMENTO cohort.~These patients will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12."
3279465|NCT01650454|Experimental|Patients with memory disorders|Patients with mild cognitive impairment not included in MEMENTO cohort. For these patients a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
3279466|NCT01650454|Active Comparator|Healthy volunteers|Healthy volunteers matched in age, sex and educational level with patients. For these volunteers a virtual reality test, and a subjective evaluation of sleep and somnolence will be performed at Inclusion (Month 0)
3279467|NCT01650454|Active Comparator|control group|this group is composed with Healthy volunteers these volunteers will have a 2 night polysomnography, a battery of neuropsychological tests, a virtual reality test, and a subjective evaluation of sleep and somnolence at inclusion (Month 0) and Month 12.
3279468|NCT01650467||Healthy controls|60 healthy controls with no hematological pathologies
3279469|NCT01650467||Imatinib optimal response|30 CML patients who are optimal responders to imatinib treatment
3279470|NCT01650467||Imatinib primary resistance|30 CML patients who have primary resistance to imatinib treatment
3279471|NCT01650480|Experimental|Intervention group|
3279472|NCT01650480|No Intervention|Control group|
3279473|NCT01650493||Group A|Clinpro 5000
3279474|NCT01650493||Group B|MI Paste Plus
3279475|NCT01650493||Group C|Toms of Maine
3279476|NCT01650506|Experimental|Erlotinib + Metformin|This is a single arm phase 1 study. All patients will receive erlotinib and metformin.
3279477|NCT01650532|Experimental|Yoga Condition|Participants will be instructed to learn yoga postures as well as yoga based breathing and meditative practices by certified yoga instructors. Primary Hatha yoga postures will be performed using props like yoga mats, blocks, belts and blankets. Classes will be held 3 times a week for 8 weeks.
3279478|NCT01650532|Active Comparator|Stretching Condition|Exercises focusing on stretching and strengthening for all muscle groups will be performed at one-hour long sessions held 3 times a week for 8 weeks. Classes are led by trained exercise specialists.
3279479|NCT01650597|Experimental|Part 1 - Panel 1|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
3279480|NCT01650597|Experimental|Part 1 - Panel 2|The participants will receive 3 or 4 ascending doses (2.5, 10, 30, 100, 250, 500 mg) of JNJ-42165279 and placebo during the study.
3279481|NCT01650597|Experimental|Part 2 (parallel)- additional cohort|The participants will receive repeated daily dosing of 100 mg JNJ-42165279 or placebo for 6 consecutive days.
3279482|NCT01650610|Experimental|Gait training executive functions tasks|This group will perform a gait training associated with the tasks that require the main executive functions.
3279483|NCT01650623|Experimental|Gait training executive functions tasks|The experimental group will perform a gait training associated with the tasks that require the main executive functions (dual-task condition).
3279484|NCT01650623|Active Comparator|Gait training alone|The control group will perform a gait training alone, without associated tasks (single-task condition).
3279485|NCT01650649|Active Comparator|Lofexidine Titration in Methadone Maintained Subjects|Methadone maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their methadone dose reduced by 50% and lofexidine titration efforts will resume.
3279486|NCT01650649|Placebo Comparator|Placebo titration in methadone maintained subjects|Methadone maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc) to mimic titration for subjects randomized to lofexidine.
3279487|NCT01650662|Experimental|Cyclosporine A|"The investigational active treatment is CsA, an immunosuppressant indicated for the prevention of acute rejection after organ transplant, including cardiac transplantation.~The preparation used in the trial will be Sandimmun IV, containing CsA 50 mg/ml, Cremophor® EL and 94% ethyl alcohol in a 5 ml vial.~Patients will received Cyclosporine A on the top of recommended standard care for acute myocardial infarction."
3279488|NCT01650662|Experimental|Control group|The control group received on the top of recommended standard care for acute myocardial infarction.
3279489|NCT01650675|Placebo Comparator|Control|Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
3279490|NCT01650675|Experimental|Indirect intervention|Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
3279491|NCT01650688||Epiblepharon|subjects demonstrating prominent corneal touch by cilia and/or related subjective symptoms
3279492|NCT01650701|Experimental|Lenalidomide + Rituximab|"Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles~Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles."
3279493|NCT01650701|Active Comparator|Control|• ONE of the following: Rituximab - CHOP, Rituximab - CVP, Rituximab - Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
3279494|NCT01650714|Experimental|Full thickness gastric biopsy|Full thickness gastric biopsy
3279495|NCT01650727|Experimental|Dinaciclib + Rituximab|"Rituximab will be administered in Cycles 1 and 3-13.~Dinaciclib will be administered in Cycles 2-13."
3279496|NCT01650740|Experimental|Open-label duloxetine|12 week treatment with duloxetine
3279497|NCT01650740|Experimental|Open-label Placebo|4 weeks of open label placebo with option to continue or switch to duloxetine for remaining 8 weeks.
3279498|NCT01650740|Experimental|Supportive clinical management|4 weeks of supportive clinical management visits with option to continue or switch to duloxetine for remaining 8 weeks.
3279499|NCT01650753|Experimental|Probiotic Powder|Probiotic: Bifidobacterium longum subsp longum AH1206
3279500|NCT01650753|Placebo Comparator|Placebo Powder|Equivalent amount (same volume) of maltodextrin
3279501|NCT01650792|Active Comparator|Aspirin|Aspirin 300mg per day for 7 days in patients with HITS on transcranial Doppler monitorization
3279502|NCT01650792|No Intervention|Best medical treatment|Best medical treatment including drugs for heart failure and hypertension will be given to both groups.
3279503|NCT01650818|Experimental|Aerobic exercise training|
3279504|NCT01650818|Active Comparator|Standard physical therapy|
3279505|NCT01650870|Active Comparator|Evening Only (full-dose)|The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
3279506|NCT01650870|Experimental|Split-dose|The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.
3279507|NCT01650883|Experimental|Cholecaliferol 50,000 IU PO Q10 days x 40 days|Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3. They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
3279508|NCT01650883|Experimental|Cholecalciferol 5,000 IU PO daily x 40 days|Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU. These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
3279509|NCT01650896|No Intervention|General Medicine|
3279510|NCT01650896|Active Comparator|Geriatric Medicine|Daily medical review, adjust medications, treat infection, occupational therapy
3279511|NCT01650935|Active Comparator|Oxalate restricted|After a run-in period of 3 weeks patients are allocated into 2 groups. The Oxalate restricted group is prescribed an oxalate restricted diet. They are instructed to avoid oxalate-rich foods such as spinach, rhubarb, beets, chocolate, cereals, nuts, tea, wheat bran, and strawberries and to drink water in amounts of roughly 2 L during cold weather and 3 L during warm/hot weather.
3279512|NCT01650935|Active Comparator|DASH diet|The second group is asked to follow a calorie-controlled DASH diet plan. DASH is an eating pattern recommended by the 2005 Department of Health and Human Services Dietary Guidelines for Americans as a model of healthy eating for the majority of individuals in the population. This group eats a diet which includes higher fruit, vegetables, and low-fat dairy products and lower in saturated fat, total fat, and cholesterol, containing more whole grains and fewer refined grains, sweets, and red meat.
3279513|NCT01650948||AMD subjects with GA and/or RPED|All subjects will have AMD and GA and/or RPED.
3279514|NCT01650948||AMD subjects with CNV alone|All subjects will have the CNV form of AMD only.
3279515|NCT01650961|Experimental|Palonosetron|Intravenous administration of palonosetron 0.075 mg before the induction of general anesthesia
3279516|NCT01650961|Placebo Comparator|Control|Intravenous administration of normal saline before the induction of general anesthesia
3279517|NCT01650974|No Intervention|conventional oxygen therapy|conventional nasal prong with FiO2 ~0.4
3279518|NCT01650974|Experimental|HFNOT|high flow nasal oxygen therapy with starting FiO2 0.4 and Flow 40 L/min
3279519|NCT01650974|Sham Comparator|sham-HFNOT|same device with FiO2 ~0.4, NO high flow
3279520|NCT01650987||Col 1|Patient with uterus adenocarcinoma, treated by surgery, then surveillance without complementary treatment
3279521|NCT01650987||Col 2|Patient with uterus adenocarcinoma, treated by surgery then adjuvant radiotherapy
3279522|NCT01650987||Col 3|patient with uterus adenocarcinoma, treated by surgery then curietherapy of vaginal dome
3279523|NCT01650987||Endometrial 4|patient with cervix carcinoma stage IA2 to IIB, treated by surgery only
3279524|NCT01650987||endometrial 5|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy
3279525|NCT01650987||endometrial 6|patient with cervix carcinoma stage IA2 to IIB, treated by surgery then curietherapy and radiotherapy
3279526|NCT01651013||metastatic colorectal cancer|
3279527|NCT01651026||rectal cancer|
3279528|NCT01651065|Experimental|Microclinics Group A|Subjects will be receiving a 10/9-month Microclinic Diabetes Education Program (Team Up 4 Health) and 6 months of follow up. In the intervention these subjects will engage in the Microclinic Program support groups. The intervention program consists of 25 event sessions. Sessions are offered weekly the first month, and biweekly thereafter.
3279529|NCT01651065|Placebo Comparator|Group C Controls|Individuals will receive screening by clinical staff. Control group subjects will receive clinic screenings only; they will not participate in program activities.
3279530|NCT01651091|Experimental|Meditation Awareness Training|
3279531|NCT01651091|Active Comparator|Treatment as Usual|
3279532|NCT01651130|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg, once following delivery of the fetal head.
3279533|NCT01651130|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg, once following delivery of the fetal head.
3279534|NCT01651130|Active Comparator|Carbetocin 15mcg|Carbetocin 15mcg, once following delivery of the fetal head.
3279535|NCT01651130|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg, following delivery of the fetal head.
3279536|NCT01651130|Active Comparator|Carbetocin 5mcg|Carbetocin 5mcg, following delivery of the fetal head.
3279537|NCT01651130|Active Comparator|Carbetocin 2mcg|Carbetocin 2mcg, following delivery of the fetal head.
3279538|NCT01651143|Experimental|SAR100842|"Core part: SAR100842 300 mg, oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
3279539|NCT01651143|Placebo Comparator|Placebo|"Core part: Placebo (for SAR100842), oral administration twice daily, for 8 weeks~Extension part: SAR100842 300 mg, oral administration twice daily, for 16 additional weeks"
3279540|NCT01651156|Placebo Comparator|placebo|Frequency: once per day Duration: 7days
3279541|NCT01651156|Experimental|Tolvaptan|Tolvaptan tablet Frequency: once per day Duration: 7days
3279542|NCT01651169|Experimental|methylphenidate tablets (10mg), ADHD|Fifteen patients of ADHD
3279543|NCT01651169|Experimental|methylphenidate tablets, Methamphetamine abusers and ADHD|Fifteen patients of ADHD with Methamphetamine abuse for at least 2 years plus
3279544|NCT01651182|Placebo Comparator|Standard Care|No tranexamic acid
3279545|NCT01651182|Experimental|Dose 1|1 g bolus + 1 g infusion from induction over 8 hours
3279546|NCT01651182|Experimental|Dose 2|1 g bolus + 10 mg/kg/hr from induction until end of surgery
3279547|NCT01651221|Experimental|Olfactory|Habituation of olfactory response
3279548|NCT01651221|Experimental|gustatory|Habituation of gustatory response.
3279549|NCT01651221|Experimental|olfactory and gustatory|Habituation of olfactory and gustatory response
3279550|NCT01651234|Experimental|Active|
3279551|NCT01651234|Placebo Comparator|Placebo|
3279552|NCT01651247||Group A|Subjects received 3 doses of the combination DTaP-HepB-IPV vaccine or separately administered DTaP, HepB, and IPV vaccines at 2, 4, and 6 months of age, in a previous study (217744/085).
3279553|NCT01651247||Group B|Subjects received a single dose of the combination DTaP-IPV vaccine or separately administered DTaP and IPV vaccines at 4-6 years of age, in a previous study (213503/048).
3279554|NCT01651273|Experimental|Arm 1: BMS-852927 (0.25 mg)|
3279555|NCT01651273|Experimental|Arm 2: BMS-852927 (1.0 mg)|
3279556|NCT01651273|Experimental|Arm 3: BMS-852927 (2.5 mg)|
3279557|NCT01651273|Placebo Comparator|Arm 4: Placebo|
3279558|NCT01651286|Experimental|nasal mask|when the patient is apneic after the injection of anesthetics in the operating room, a nasal mask will be applied with positive pressure ventilation for 1 min. Then the nasal mask will be replaced with a full face mask for 1 min. Subsequently, the face mask will be replaced with the nasal mask.
3279559|NCT01651286|Active Comparator|full face mask|when the patient is apneic after the injection of anesthetics in the operating room, a full face mask will be applied with positive pressure ventilation for 1 min. Then the full face mask will be replaced with a nasal mask for 1 min. Subsequently, the nasal mask will be replaced with the full face mask.
3279560|NCT01651312|Experimental|14C-labeled YM178|Single oral administration of 14C-labeled YM178
3279561|NCT01651325|Experimental|Isavuconazole and dextromethorphan|Dextromethorphan on Day 1and Day 10, Isavuconazole three times per day (TID) on Days 6 and 7, and once daily (QD) on Days 8 thru 12.
3279562|NCT01651338|Experimental|accupuncture,|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
3279563|NCT01651364|Placebo Comparator|Placebo|
3279564|NCT01651364|Active Comparator|Cabergoline|
3279565|NCT01651377|Placebo Comparator|Placebo|
3279566|NCT01651377|Active Comparator|Pramipexole|
3279567|NCT01651390|Experimental|Drug coated balloon|Percutaneous coronary intervention with the Pantera Lux drug coated balloon.
3279568|NCT01651390|Active Comparator|Drug eluting stent|Percutaneous coronary intervention with the Orsiro drug eluting stent.
3279569|NCT01651416|Active Comparator|HMM using short-acting ACT|Home management of malaria using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs
3279570|NCT01651416|Experimental|HMM using short-acting ACT plus SMC|Home management of malaria using using Artemether-lumefantrine combination (a short-acting ACT) for treatment in children with malaria diagnosed using RDTs plus seasonal malaria chemoprevention with Amodiaquine plus sulphadoxine-pyrimethamine combination.
3279571|NCT01651416|Experimental|HMM using a long-acting ACT|Home management of malaria using Dihydroartemisinin Piperaquine combination (a long-acting ACT) for treatment in children with malaria diagnosed using RDTs
3279572|NCT01651429|Experimental|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation, 17 of which will be spent in the laboratory.
3279573|NCT01651455||Cohort first decade|Patients born between 01/01/1979 and 12/31/1984
3279574|NCT01651455||Cohort second decade|Patients born between 01/01/1991 and 12/31/1996
3279575|NCT01651468|Experimental|HEMOFIX|3 grams a day
3279576|NCT01651481|Experimental|TR|HCP1102(Singulair and Xyzal combination tablet) -> coadministration of Singulair and Xyzal
3279577|NCT01651481|Experimental|RT|coadministration of Singulair and Xyzal -> HCP1102(Singulair and Xyzal combination tablet)
3279578|NCT01651494|Active Comparator|DAS181-F04|DAS181-F04: 20 mg single-dose each day via inhalation for 3 days; 6 subjects
3279579|NCT01651494|Placebo Comparator|Placebo|Placebo: 20 mg single-dose each day via inhalation for 3 days; 3 subjects
3279580|NCT01651507||HLP|Patients with pulmonary LCH from eight teaching hospitals evaluated between June 1989 and February 2005 were considered for this study, if they were followed for at least 6 months and evaluated by ≥ 2 lung HRCT and lung function tests at the same time or within a 2 months period
3279581|NCT01651520|Experimental|Relapsing patients < 5 years|Relapsing patients < 5 years
3279582|NCT01651520|Experimental|relapsing patients < 10 years|relapsing patients < 10 years
3279583|NCT01651520|Experimental|primary progressive patients < 10 years|primary progressive patients < 10 years
3279584|NCT01651520|Other|healthy volunteers|healthy volunteers
3279585|NCT01651533|Experimental|Experimental: Mental Practice Group|
3279586|NCT01651533|Active Comparator|Active Comparator: Active Control Group|
3279587|NCT01651546|Other|Cohort|Patients with dysvoiding function and chronic urinary retention, with an indication to CISC.
3279588|NCT01651572|Experimental|Cisatracurium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl.~Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
3279589|NCT01651572|Experimental|Rocuronium|"Induction and maintaining of anaesthesia with Propofol. Analgesia either with Fentanyl or Fentanyl+Remifentanyl~Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)~At the end of the surgical operation, patients will be administered Neostigmine 0.04 mg/kg and Atropine 0.02 mg/kg.~Patients will be extubated with a TOF-Ratio of at least 0.90."
3279590|NCT01651585|Experimental|Valacyclovir arrow|Experimental : Valacyclovir arrow 500mg give Valacyclovir arrow to all participants (open phase)
3279591|NCT01651598|Experimental|BI 144807|Subjects receive multiple BID doses of BI 144807 solution
3279592|NCT01651598|Placebo Comparator|Placebo|Subjects receive multiple BID doses of Placebo solution
3279593|NCT01651611|Experimental|Extensive TTA interaction|Persons interested in quitting smoking will receive multiple in-person visits from a peer Tobacco Treatment Advocate (TTA) who will provide motivational interviewing, basic smoking cessation counseling assistance, navigation to smoking cessation resources, and social support.
3279594|NCT01651611|Active Comparator|Minimal TTA interaction|Persons interested in quitting smoking will receive a single in-person visit from a peer Tobacco Treatment Advocate (TTA) who will provide basic smoking cessation counseling assistance.
3279595|NCT01651624|Experimental|Computed tomographic colonography (CTC), reduced prep|Subjects invited to undergo CTC with reduced cathartic preparation
3279596|NCT01651624|Experimental|Computed tomographic colonography (CTC), standard prep|Subjects invited to undergo CTC with standard bowel preparation
3279597|NCT01651624|Active Comparator|Faecal occult blood test (FOBT)|Subjects invited to undergo FOBT
3279598|NCT01651624|Experimental|Colonoscopy|Subjects invited to undergo colonoscopy
3279599|NCT01651637|Experimental|Synthetic Surfactant|Cohort Design
3279600|NCT01651650|Other|Inhalation of Placebo Dry Powder|Each patient will perform at least two inhalations using the Chiesi NEXThaler DPI device containing placebo dry powder. There is no comparator and all patients will receive the same study treatment.
3279601|NCT01651663|Experimental|Arbidol (Umifenovir)|
3279602|NCT01651663|Placebo Comparator|placebo|
3279603|NCT01651663|Experimental|Arbidol (Umifenovir) prophylaxis|
3279604|NCT01651663|Placebo Comparator|placebo prophylaxis|
3279605|NCT01651676|Experimental|COPD arm|"VQ11 validation:~Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire"
3279606|NCT01651689||Scalp biopsy|Subjects are on scadule list for hair transplantation in Siriraj hospital. Scalp biopsy with punch biopsy No.4 Scalp biopsy by punch biopsy No.4 at occipital area was done in subjects who have hair transplantaion.
3279607|NCT01651702|Active Comparator|Carto|Patients in whom Carto system will be used
3279608|NCT01651702|Active Comparator|Ensite|Patients in whom Ensite system will be used
3279609|NCT01651715|Experimental|TAO1, oral homeopathic antibodies|TAO1 is an investigational medicinal product containing homeopathic dilutions (<10-24M) of antibodies purified from the serum of rabbit immunised against a synthetic peptide with an amino acid sequence selected in the human toll-like receptor type 3 sequence (anti-TLR3). It is intended for the treatment of viral Upper Respiratory Tract Infections (URTIs) such as common cold, influenza or influenza-like illnesses.
3279610|NCT01651715|Placebo Comparator|Placebo|Same characteristics as investigational medicinal Product except for homeopathic dilutions of oral antibodies to the TLR3 FYW peptide
3279611|NCT01651728|Experimental|Simvastatin|Tablet 20 mg once daily for 30 days
3279612|NCT01651728|Placebo Comparator|Placebo|Placebo tablet once daily for 30 days
3279613|NCT01651741|Experimental|Seaweed and Duolac7S|Seaweed: Real Seaweed granule, Duolac7S: Real probiotics
3279614|NCT01651741|Placebo Comparator|Seaweed and Duolac7S-P|Seaweed: Real Seaweed granule, Duolac7S-P: Placebo probiotics
3279615|NCT01651754|Other|Seasonal influenza vaccination|
3279616|NCT01651767|Experimental|Panel I|Patients will be randomized to receive JNJ-47910382 at a dose of 30 mg or placebo as monotherapy once daily for 5 days.
3279617|NCT01651767|Experimental|Panel II|Patients will be randomized to receive JNJ-47910382 at a dose of 90 mg or placebo as monotherapy once daily for 5 days.
3279618|NCT01651767|Experimental|Panel III|Patients will be randomized to receive JNJ-47910382 at a dose of 300 mg or placebo as monotherapy once daily for 5 days.
3279619|NCT01651767|Experimental|Panel IV|Patients will be randomized to receive JNJ-47910382 at a dose of 400 or 450 mg once daily or 300 mg twice daily (morning dose only on Day 5) or placebo as monotherapy for 5 days.
3279620|NCT01651819|Experimental|Urological physical therapy|Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.
3279621|NCT01651832|No Intervention|usual care|routine care and case management
3279622|NCT01651832|Experimental|SCAN-Intervention|
3279623|NCT01651845||Image Guided Intervention|Standard of care white light visual wound assessment followed by fluorescence image-guided wound assessment
3279624|NCT01651858|Experimental|Nurigra Chewable tablet|
3279625|NCT01651858|Active Comparator|Viagra|
3279626|NCT01651871|Experimental|Treatment Group 1|
3279627|NCT01651871|Experimental|Treatment Group 2|
3279628|NCT01651871|Experimental|Treatment Group 3|
3279629|NCT01651871|Active Comparator|Treatment Group 4|
3279630|NCT01651871|Placebo Comparator|Treatment Group 5|
3279631|NCT01651884|Experimental|High-Definition tDCS|
3279632|NCT01651884|Experimental|Sponge tDCS|
3279633|NCT01651897||Delirious in the ED|Patients who were delirious in the ED at either the 0-hour or 3-hour delirium assessment.
3279634|NCT01651897||Non-Delirious in the ED|Patients who were non-delirious in the ED at both the 0-hour or 3-hour delirium assessment.
3279635|NCT01651910||Controlled Pain|Participants who have controlled pain; requiring regular painkillers which are maintaining the pain as none - mild with no breakthrough pain episodes.
3279636|NCT01651910||Uncontrolled Pain|Participants who have uncontrolled pain; pain that is moderate to severe whether on painkillers or not
3279637|NCT01651910||Breakthrough pain|Participants who have breakthrough pain; pain that is controlled but the patient has episodes when the pain intermittently 'flares up'.
3279638|NCT01651923|Other|Group A|"First periody: Heparin Test Drug (Blau Farmacêutica S/A)~Secundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
3279639|NCT01651923|Other|Group B|"First periody: Heparin Comparator Drug (APP Pharmaceuticals)~Secundy periody: Heperin Test Drug (Blau Farmacêutica S/A)"
3279640|NCT01651962|Experimental|Terbutaline|Terbutaline 0.125mg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3279641|NCT01651962|Active Comparator|Fentanyl|Fentanyl 100mcg i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3279642|NCT01651962|Placebo Comparator|Placebo|0.9% NaCl i.v. x 1 dose prior to positioning for epidural placement; may repeat x1 PRN
3279643|NCT01651975|Other|Thickenup|
3279644|NCT01651988|Active Comparator|Ketofol 1:1|1. Anesthesia-sedation KETOFOL 1-1: Two milligrams per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:1 (one milligram of ketamine per one milligram of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedures previously defined in the inclusion criteria.
3279645|NCT01651988|Experimental|Ketofol 1:2|2. Anesthesia-sedation KETOFOL 1-2: One milligram per kilogram of ketamine plus two milligrams per kilogram of propofol in a solution 1:2 (one milligram of ketamine per two milligrams of propofol) was given to those patients randomly asigned to this group, who were scheduled for any short surgical procedure previously defined in the inclusion criteria.
3279646|NCT01652014|Experimental|Arm I|"Double UCB transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo double allogeneic UCB transplant on day 0."
3279647|NCT01652014|Experimental|Arm II|"Sub-threshold single UCB + irradiated PBMCs transplantation~Patients receive conditioning comprising fludarabine phosphate IV over 30 minutes on days -6 to -2, cyclophosphamide IV over 1 hour on day -6, and undergo TBI on day -1. Patients also receive GVHD prophylaxis comprising tacrolimus IV continuously or PO beginning on day -3 with taper and mycophenolate mofetil PO BID days 1-30. Patients undergo single allogeneic UCB transplant on day 0. Patients also undergo irradiated allogeneic PBMC transplant within 8 hours following the UCB infusion."
3279648|NCT01652027||Previously Untreated Patients with Hemophilia A|
3279649|NCT01652053||Disc Nucleus Replacement|Disc Nucleus Replacement (InterCushion DNP)
3279650|NCT01652066|Placebo Comparator|Placebo|oral consumption, once per day in the morning, fasting, with a glass of water
3279651|NCT01652066|Experimental|Mixture of probiotics|"at least 10x7 cfu/tablet of a mixture of probiotics~oral consumption, once per day in the morning, fasting, with a glass of water"
3279652|NCT01652079|Experimental|Treatment Arm|CRLX101
3279653|NCT01652092|Other|Arm A: Fully Myeloablative regimen|For use in patients with diseases including Wiskott-Aldrich syndrome, MHC Class II deficiency, hypomorphic SCID, etc. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, cyclophosphamide 50 mg/kg IV plus MESNA on days -9 through -6, busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2 and stem cell infusion on day 0.
3279654|NCT01652092|Other|Arm B: Reduced Toxicity Ablative Regimen|For use in patients with diseases including SCID, CGD, CHS and other CID. Receives Alemtuzumab 0.3 mg/kg intravenously (IV) on days -12 through -10, busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6, fludarabine phosphate 40 mg/m^2 IV on days -5 through -2 and stem cell infusion on day 0.
3279655|NCT01652092|Other|Arm C: Reduced Intensity Conditioning|For use in patients with diseases including HLH. Receives Alemtuzumab 0.2 mg/kg intravenously (IV) on days -14 through -10, fludarabine phosphate 30 mg/m^2 IV on days -8 through -4, melphalan 140 mg/m^2 IV on day -3 and stem cell infusion on day 0.
3279656|NCT01652092|Other|Arm D: No Preparative Regimen|For use in patients with complete SCID phenotype with no evidence of maternal engraftment or residual immune function who will be receiving their stem cell transplantation from a genotypically matched donor.
3279657|NCT01652105|Experimental|Diet|New developed diet
3279658|NCT01652105|Active Comparator|Prodimed|Standard VLCD
3279659|NCT01652118|Active Comparator|Clarithromycin|Fist group treated with clarithromycin which is include 10 days application.
3279660|NCT01652118|Placebo Comparator|placebo|Second group treated with salin as same as amount of clarithromycine volume
3279661|NCT01652131|Other|Tetrastarch (130/0.4)|In obese patients candidates to laparoscopic gastrojejunal bypass an infusion of Tetrastarch (130/0.4)) of 15mL/kg (of corrected weight) will be initiated after protocoled induction of general anesthesia. Blood samples will be taken at time 0 (after induction of anesthesia and before initiating infusion) and then every 5 minutes for half an hour and then every 15 minutes up to 90 minutes. Blood samples will be processed in the Institution's laboratory. Urine will be measured at the end of the intervention. With these data kinetic parameters will be estimated for each patient.
3279662|NCT01652144|Experimental|AT7519M|AT7519M: 27 mg/m2 IV injection, 1 hour infusion, 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
3279663|NCT01652157||Cystic fibrosis (CF) patients in the CF Patient Registry|Patients diagnosed with cystic fibrosis at participating sites who are providing data to the Cystic Fibrosis Patient Registry
3279664|NCT01652183|Placebo Comparator|Group Control (n=32):iv 1.5 ml/kg 0.9% NaCl|
3279665|NCT01652183|Active Comparator|Group Paracetamol(n=32):iv 15mg/kg paracetamol|The patients were randomly divided into two groups: Group P (Paracetamol group, n=32) received intravenous 15mg/kg paracetamol during the surgery and Group C (Control Group, n=32) received intravenous 1.5 ml/kg 0.9% NaCl solution 30 minutes before the of surgery.At the end of the surgery, all patients had an nephrostomy catheter and the insertion site was infiltrated with 20 ml 0.25% bupivacaine infiltration for postoperative analgesia. Each patient received patient-controlled intravenous analgesia by meperidine (10 mg bolus, 20-minute lock-out, no infusion dose and 4 hour limit) for postoperative analgesia. All patients were planned to receive tenoxicam 20 mg intravenously as a rescue analgesic when visual analogue scale (VAS) was >3.
3279666|NCT01652196|Experimental|Aflibercept (combination chemotherapy)|Patients receive aflibercept and fluorouracil and then continuously over 46 hours on days 1 and 15.If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted. Correlative Studies are required to be available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.DCE MRI (dynamic contrast-enhanced magnetic resonance imaging)images at weeks 0, and after 8 weeks +/- 1 week of treatment(after Cycle 2). 18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG).FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers,including colorectal cancer (99-102).
3279667|NCT01652209|No Intervention|Control|"After implementing PCI, contemporary drug treatment is conducted.~*Contemporary drug treatment is a general drug treatment (Unfractionated heparin, Low Molecular Weight Heparin, Glycoprotein llb/llla inhibitor, Aspirin, clopidogrel or Ticlopidine, Nitrate, ACE inhibitor or ARB, β-blocker, CCB, Diuretics, Statin, etc.)"
3279668|NCT01652209|Experimental|Single dose of Hearticellgram-AMI|Within 30 days (+ / -7 days) after aspirating bone-marrow, approximately 1×10^6/kg (refer to usage/dosage according to mass) of autologous bone marrow-derived mesenchymal stem cells are adminstered into the infarct coronary artery using balloon tipped catheter. Furthermore, contemporary drug treatment is conducted.
3279669|NCT01652222|Experimental|CONEM-BETA + socio-educational training|"Caregivers will receive 4 socioeducational training sessions during an 8 week period. These sessions will focus on the description and process of the Alzheimer's disease (AD), and will also provide to the caregivers resources and strategies to cope with AD. During the last 4 weeks, they will also systematically play with the patient at home with the CONEM-BETA game.~After that period, caregivers will use the game based on their preference and frequence during a period of 6 more weeks."
3279670|NCT01652222|Active Comparator|Socio-educational training only|Caregivers will receive the same 4 socioeducational training sessions as the experimental group, during an 8 week period.
3279671|NCT01652222|No Intervention|Control|Caregivers of this group will behave with his/her patient during the trial as they have been doing so far, but will receive no intervention
3279672|NCT01652235|Experimental|Endovascular|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
3279673|NCT01652248|Placebo Comparator|Standard generator replacement|Standard generator replacement
3279674|NCT01652248|Active Comparator|Upgrade to cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
3279675|NCT01652261|Experimental|experimental arm|"An experimental arm (early FDG-PET/CT-response adapted), where all patients are initially treated with a single cycle of ABVD. Very early FDG-PET/CT-negative patients continue on ABVD therapy to a total of six cycles. Very early FDG-PET/CT-positive patients receive 3 cycles of BEACOPPesc followed by another 3 cycles of BEACOPPesc. Mid-treatment evaluation is performed after 4 cycles. In case of treatment failure (less than partial remission (PR)), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
3279676|NCT01652261|Active Comparator|standard arm|"A standard arm, where patients are treated with four cycles of BEACOPPesc followed by 2 cycles of BEACOPPesc. FDG-PET/CT is performed after one cycle, but with no therapeutic consequences. Mid-treatment evaluation is performed after four cycles. In case of treatment failure (less than PR), the patient goes off protocol treatment.~Only patients with residual FDG-PET/CT-positive disease after chemotherapy will receive radiotherapy (36 Gy/18 fractions on the FDG-PET/CT-positive residual mass(es))."
3279677|NCT01652274||Mother|study objectives to Mother only
3279678|NCT01652274||Father|study objectives to Father only
3279679|NCT01652300|Experimental|test group|For test group intervention was two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
3279680|NCT01652300|Other|control|received no education
3279681|NCT01652313|Experimental|Rasagiline|
3279682|NCT01652326||Benzodiazepine-resistant|those patients with either 1) a requirement of either 200 mg of diazepam (or diazepam equivalents) in 4 hrs; 2) >40mg of diazepam (or diazepam equivalents) in 1 hr; or 3) an individual dose of 40 mg or greater of intravenous diazepam for control of agitation
3279683|NCT01652339|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
3279684|NCT01652339|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
3279685|NCT01652352||Individuals with Disability|Power wheelchair-bound individuals with conditions which affect upper and lower body mobility, strength, or dexterity. Such conditions may include but are not limited to spinal cord injury, Multiple Sclerosis, Cerebral Palsy, or other conditions which affect overall mobility.
3279686|NCT01652352||Able-Bodied Individuals|Those who possess no condition or injury resulting in loss of mobility.
3279687|NCT01652365|Experimental|RDT Training and Subsidy Offered|Licensed drug shops within villages selected randomly to be in this arm will be invited to training on RDTs and offered access to subsidized RDTs available for purchase at a local wholesale pharmacy in Mbale, Uganda.
3279688|NCT01652365|Experimental|Information/Education Campaign|Community meetings describing RDTs and encouraging community members to be diagnosed prior to taking malaria treatment will be held in villages randomly assigned to this treatment arm.
3279689|NCT01652365|Experimental|RDT Training/Subsidy + Information/Education Campaign|Includes both the training and subsidy component and the information/education campaign component.
3279690|NCT01652365|No Intervention|Control|
3279691|NCT01652378||Cocaine-Addicted Participants|Group of participants diagnosed with cocaine dependence
3279692|NCT01652378||Control Participants|healthy control volunteers
3279693|NCT01652391|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
3279694|NCT01652391|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
3279695|NCT01652404|Experimental|Procalcitonin-guided treatment|The duration of antibiotics will be determined by the procalcitonin levels.
3279696|NCT01652404|Active Comparator|Conventional treatment|The duration of antibiotics will be determined by the treating physician.
3279697|NCT01652417|No Intervention|oral prednisone|Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
3279698|NCT01652417|Experimental|methylprednisolone bolus|methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12.
3279699|NCT01652430||PTSD cohort|
3279700|NCT01652430||No PTSD cohort|
3279701|NCT01652456|Experimental|Group A|
3279702|NCT01652456|No Intervention|Group B|
3279703|NCT01652482|Active Comparator|FOLFIRI + Cetuximab|
3279704|NCT01652482|Experimental|FOLFIRI + MEHD7945A|
3279705|NCT01652508|Placebo Comparator|Control|Participants are given printed self-help leaflet on smoking cessation developed by the Department of Health, Hong Kong.
3279706|NCT01652508|Experimental|Acceptance and Commitment Therapy|All participants are given a self-help leaflet on smoking cessation. Participants are also given an initial session of face-to-face ACT at a primary health service clinic. In addition, two more subsequent ACT sessions are provided by telephone at one week and one month after the initial intervention.
3279707|NCT01652521||candidates for pleural fluid drainage|patients who are candidates for pleural fluid drainage.
3279708|NCT01652534|Active Comparator|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day
3279709|NCT01652534|Placebo Comparator|placebo|Sugar Pill
3279710|NCT01652547|Experimental|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs), switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
3279711|NCT01652547|Experimental|Pasireotide long acting release|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
3279712|NCT01652560||bevacizumab combined neoadjuvant chemotherapy|
3279713|NCT01652586|Experimental|dexmedetomidine-remifentanil|intravenous infusion of 0.2-0.7 µg/kg/h of dexmedetomidine after a loading dose of 1 µg/kg over 10 min
3279714|NCT01652586|Active Comparator|midazolam-remifentanil|remifentanil 3.6-7.2 mcg/kg/h midazolam 1-2mg
3279715|NCT01652599|Experimental|Eltrombopag and dexamethasone|
3279716|NCT01652612|No Intervention|Control|zero PEEP
3279717|NCT01652612|Experimental|OLV strategy: PEEP|1. apply 8 cm H2O positive end expiratory pressure during one lung ventilation and until the end of surgery
3279718|NCT01652612|Experimental|OLV strategy: PEEP followed by AR|"alveolar recruitment strategy before one lung ventilation~8 cmH2O positive end expiratory pressure during one lung ventilation and until the end of surgery"
3279719|NCT01652625|Experimental|Yunnan Baiyao toothpaste|The toothpaste containing 6.5 milligrams of Yunnan Baiyao was used twice daily as part of the patient's routine oral hygiene for 5 days.
3279720|NCT01652625|Active Comparator|placebo toothpaste|One gram of placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
3279721|NCT01652638|Experimental|Group A|"First periody: Test Drug (Heparin Blau Farmacêutica S/A)~Secundy periody: Comparator Drug (Heparin APP Pharmaceuticals)"
3279722|NCT01652638|Experimental|Group B|"First periody: Comparator Drug (Heparin APP Pharmaceuticals)~Secundy periody: Test Drug (heparin Blau Farmacêutica S/A)"
3279723|NCT01652651|Experimental|Psychological Intervention|
3448450|NCT04065022|Experimental|Arm stimulation|Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.
3279724|NCT01652677|Experimental|Low-frequency stimulation|Stimulation mode: 1 Hz, 100% MT, 20 minutes, unaffected hemisphere
3279725|NCT01652677|Experimental|High frequency stimulation|Stimulation mode: 10 Hz, 80% MT, 2 seconds - stimulation, 58 seconds - rest. - 8 session; affected hemisphere
3279726|NCT01652677|Sham Comparator|Sham stimulation|Patients will receive standard treatment (kinesotherapy, physiotherapy) and simulate of transcranial magnetic stimulation. Also patients will not know about simulation (blind group)
3279727|NCT01652677|Experimental|Both hemispheric stimulation|Stimulation mode: low-frequency to unaffected hemisphere than high-frequency to affected.
3279728|NCT01652742|Experimental|BI 135585 XX|one single dose
3279729|NCT01652755||AKI group|patients with AKI after cardiopulmonary bypass surgery
3279730|NCT01652755||non-AKI group|patients without AKI during study period
3279731|NCT01652768|Active Comparator|Arm A: Usual Care Group|Usual care is defined as standard post-operative care on a surgical unit in University Hospitals Case Medical Center. Discharge planning will be provided by the assigned in-patient social worker. Referrals to the assigned outpatient social worker will be made as appropriate. Patients and caregivers will be seen in the ambulatory medical oncology setting about three to six weeks after surgery, depending on post-operative recovery time. The research assistant will administer the research questionnaires at week one post-surgery and 8-10 weeks post surgery.
3279732|NCT01652768|Experimental|Arm B: PRESENCE Intervention|The unique features of the PRESENCE Project (PP) Intervention are 1) the early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse); 2) an educational information session for patients and caregivers; and 3) frequent (every two week and as needed) telephone or clinic visits during the first ten weeks post operatively (Figure 1). In usual care, the patient and caregiver receive little supportive care until they begin cancer treatment. The intervention provides aggressive supportive care from the time of diagnosis.
3279733|NCT01652781|Experimental|5-day arm|azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care
3279734|NCT01652781|Active Comparator|7-day arm|azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
3279735|NCT01652794|Experimental|Treatment (carboplatin, gemcitabine hydrochloride, and SBRT)|Patients also receive carboplatin IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on day 1 and undergo SBRT on days 2-4.
3279736|NCT01652807|Experimental|Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching.
3279737|NCT01652807|No Intervention|Waitlist (Delayed Yoga)|Participants assigned randomly to the control condition will provided an identical free two-month membership to Bikram Yoga Dallas after the week following their post-intervention session.
3279738|NCT01652820|Experimental|Docetaxel +Carboplatin +concomitant chemoradiation|Docetaxel 20 mg/m2/weekly plus carboplatin AUC 2/weekly (first, docetaxel will be administered and after that, carboplatin will be administered) and concomitant chemoradiation (total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
3279739|NCT01652820|Experimental|C) Docetax+ gemcit +concom. docetax + carbopl. + RDT concom|Docetaxel 40 mg/ m2 days 1, 8, 21 y 28 plus gemcitabine 1200 mg/ m2 days 1, 8, 21 y 28 followed by concomitant treatment Docetaxel 20 mg/m2/week plus carboplatin AUC 2/weekly and concomitant chemoradiation total dose of 60 Gy: 2 Gy/day, 5 days(week for 6 weeks)
3279740|NCT01652833||Round 1|survey of 150 oncologists
3279741|NCT01652833||Round 2|survey of 150 oncologists approximately 12 months after round 1
3279742|NCT01652833||Round 3|survey of 150 oncologists approximately 24 months after round 1
3279743|NCT01652859|Experimental|Liposomal Amphotericin B|Generic drug
3279744|NCT01652859|Active Comparator|AmBisome|RLD
3279745|NCT01652898|Active Comparator|Esmolol hydrochloride|Esmolol hydrochloride administered as intravenous bolus injection at low (0,5mg/kg), medium (1mg/kg) and high dose (1,5mg/kg) in 15/30/45 seconds once per subject
3279746|NCT01652898|Active Comparator|ONO LDL50|ONO LDL50 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
3279747|NCT01652898|Experimental|AOP LDLA202|AOP LDLA202 administered as intravenous bolus injection at low (0,1mg/kg), medium (0,2mg/kg) and high dose (0,3mg/kg) in 15/30/45 seconds once per subject
3279748|NCT01652911|Experimental|Cell Pouch|Participants with Type-1 diabetes will receive the Sernova Cell Pouch™ implanted in the subcutaneous site, two to approximately twelve weeks prior to transplantation of islets into the Cell Pouch™.
3279749|NCT01652924|Experimental|Mechanical ventilation|1: Active Comparator Children 1 month-14 years of age Intervention:Mechanical ventilation with facial mask during anesthetic induction
3279750|NCT01652924|Active Comparator|Manual ventilation|2: Active Comparator Children 1 month-14 years of age Intervention: Manual ventilation with facial mask during anesthetic induction
3279751|NCT01652937|Placebo Comparator|Placebo + Background Therapy|Background therapy including DMARD(s) approved by protocol
3279752|NCT01652937|Experimental|BIIB057 Dose 1 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3279753|NCT01652937|Experimental|BIIB057 Dose 2 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3279754|NCT01652937|Experimental|BIIB057 Dose 3 + Background Therapy|Background therapy including DMARD(s) approved by protocol
3377879|NCT03792659||Neurological Outpatients|Participants in this group will be recruited from the outpatient clinical population at the Yale University Department of Neurology. Treating physicians will make the initial determination of patients' potential eligibility to participate in the study.
3279755|NCT01652950|Experimental|Vitality Wellness program Direct Payment|In addition to the base program and supplementary communication, members of the Direct Payment group received a gift voucher, corresponding to their level of engagement. Members received payouts at the end of each month of registration, for 5 different levels of engagement. The payout for the lowest level of engagement corresponded to about 25% of the monthly subscription for the wellness program. The payout for the highest level of engagement was 3 times more than the monthly subscription for the wellness program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3279756|NCT01652950|Experimental|Vitality Wellness Program Lottery Incentive|Members of the Lottery Incentive group were entered into a cash-prize draw at the end of each month following registration, if they achieved physical activity targets. The chance of winning was set at one in fifty with an expected value identical to the direct payment group. Four lottery payouts corresponding to the member's levels of engagement were made at the end of each month following registration. Enrollment took place over a period of 5 months, and the intervention took place over a period of 12 months following registration.
3377880|NCT03784924||Initial prostate biopsy|Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.
3377881|NCT03783143||Clinical Cohort|This study population will consist of patient volunteers that visit one of our clinical sites withan undiagnosed febrile illness.
3377882|NCT03783143||Cross-sectional Cohort|Cross sectional study participants are volunteers from the general population selected from census lists.
3279757|NCT01652950|Experimental|Vitality Wellness Program Charity Incentive|Members of the Charity Incentive Group were offered a selection of charities to which earned rewards could be donated. Nominated charities received the payouts at the end of each month of registration, for 5 different levels of engagement of the individual members. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3279758|NCT01652950|Experimental|Vitality Wellness Program Choice Incentive|Members of the Choice Incentive Group were asked to choose one of the three aforementioned incentive options on enrollment to the study. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3377883|NCT03782636|Experimental|Aldesleukin|Ultra-low dose aldesleukin injected subcutaneously, at a dose of 0.2 x 106 IU/m2 twice-weekly , three days apart, for 6 months.
3377884|NCT03782636|Placebo Comparator|Placebo|Placebo sc, at a similar dose (expressed in ml) to the active drug
3377887|NCT03763422|Experimental|Early Treatment arm|Radiotherapy + Temozolomide
3377888|NCT03763422|Active Comparator|Active surveillance arm|Treatment as per local practice
3377891|NCT03761810|Experimental|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks
3377892|NCT03761810|Placebo Comparator|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
3377893|NCT03761784|Experimental|S6G5T-3|Participants will topically apply S6G5T-3 cream, once daily to face for 12 weeks.
3377894|NCT03761784|Placebo Comparator|S6G5T-8 Vehicle Cream|Participants will topically apply S6G5T-8 vehicle cream, once daily to face for 12 weeks.
3279759|NCT01652950|Other|Vitality Wellness Program Standard of Care|The Vitality Wellness program is the incentive-based wellness initiative of Discovery Health Medical Aid Scheme, a national private health insurer in South Africa. The standard program includes membership to three national gym chains, which is subsidized to 80% of the normal monthly subscription cost. Members have the opportunity to earn points by attending gyms, which contribute, together with points earned from engagement in other wellness and preventive activities, to tier status (Blue, Bronze, Silver, Gold and Diamond). Tier status allows members to receive increasing discounts on a range of goods and services from commercial partners. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
3279760|NCT01652950|Active Comparator|Vitality Wellness Program Enhanced Communication|"In this group, members were offered the base program and, in addition, were sent bi-weekly communications by alternating email and text messaging which included information on the importance of physical activity, tips on accumulating fitness points on the base program, a status update of points earned and information on benefits and rewards offered on the program. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration."
3279761|NCT01652963|No Intervention|Control task|The no-intervention control task consists of a presentation of the stimuli used in the training task. Participants will see situations and listen to the simultaneous voice recordings. Unlike in the training task participants will not receive instructions to link situations and emotions. There is no task requirement, just a presentation of the situation stimuli to assure that potential training effects are due to the training programme and not merely to the presentation of scenarios. The duration of the presentation of stimulus materials in the control group will range between fifteen and thirty minutes. The variable duration is necessary so the primary investigator cannot assume a participant's intervention group based on the duration of the intervention task.
3279762|NCT01652963|Experimental|Reed and Clements Training Task|The training task consists of 2 blocks of 6 items with items presented randomly within each block and blocks being counterbalanced between participants. Block 1 presents a situation and prompts participants to identify whether they would feel happy or sad in the given situation. Block 2 presents an emotion (happy or sad) and prompts the participant to identify which of two situations (positive or negative) most likely preceded this emotion. Within each block there will be at least one and maximum three training rounds. The second and third training rounds will only consist of the items to which the participant responded incorrect in the previous round. Each item in rounds 2 and 3 will be followed by feedback.
3279763|NCT01652989|Experimental|Weight loss maintenance intervention delivered via DVD|Weight loss maintenance intervention delivered via DVD (without a peer facilitator) to employee participants within the respective worksites randomized to this arm. Using DVD technology, a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period will be delivered to the participants of this arm using DVD-produced lessons of PILI Maintenance
3279764|NCT01652989|Experimental|Weight loss maintenance intervention Face-to-Face|The PILI Maintenance delivered face-to-face in a group setting by trained peer facilitators to employee participants within the respective worksites randomized to this arm. The trained peer facilitator will deliver a total of 11 additional sessions (designed for weight loss maintenance) over a 9-month period, meeting bi-weekly for the first 2 months and then monthly for the remaining 7 months with a group of 8 to 15 participants.
3279765|NCT01653002||Lung cancer with lymph node involvement|
3279766|NCT01653015|Experimental|Influenza vaccine LAIV|Live attenuated influenza vaccine (LAIV).
3279767|NCT01653015|Active Comparator|Influenza vaccine TIV|Trivalent inactivated vaccine (TIV).
3279768|NCT01653041|Experimental|Everolimus|Single arm
3279769|NCT01653054|Experimental|IBD patients ON Immunosuppression|
3279770|NCT01653054|Experimental|IBD Patients OFF Immunosuppression|
3279771|NCT01653067|Experimental|Rituximab, Temsirolimus, DHAP, intravenous|"This is a multicenter, open label, single arm, phase II study. There will be no placebo usage within this trial. In the part I, dose escalation part, of this trial 6 patients will be included in each dose level. There will be 4 cohorts, administering up to a maximum of 4 cycles 25 mg, 50 mg, 75mg or 100mg Temsirolimus in combination with Rituximab and DHAP.~Treatment regimen part I:~Part I - Cohort A, B, C, D, X Temsirolimus 25 (A), 50 (B), 75 (C),100 (D) or 15 (X) mg, Day 1, 8, Rituximab (375 mg/m² day 2) Dexamethasone 40mg day 3-6 Cisplatine 100 mg/m² day 3 Cytarabine 2x2 g/m² day 4~...repeat day 22, up to a maximum of 4 cycles~In the part II of the trial 40 patients will be included to receive the full target dose, established within the part I of the study."
3279772|NCT01653080|Experimental|Dynamic contrast-enhanced MRI|Patients undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
3279773|NCT01653093|Experimental|Diagnostic (3T MRI)|Patients undergo 3T MRI, including DCE-MRI, diffusion-weighted MRI, amide-proton-transfer MRI, and MR spectroscopy scans. Patients may undergo an additional 3T MRI scan at least 24 hours after the initial scan.
3279774|NCT01653106|Experimental|Arm I (cryotherapy 120 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 120 minutes.
3279775|NCT01653106|Active Comparator|Arm II (cryotherapy 360 minutes)|Beginning fifteen minutes before melphalan treatment, patients receive 1 ounce of shaved ice in their mouth, allow it to melt and then replenish it immediately for 360 minutes.
3279776|NCT01653119|Active Comparator|High loading dose of rosuvastatin|rosuvastatin 20mg/d×1w
3279777|NCT01653119|Active Comparator|Routine rosuvastatin therapy|rosuvastatin 10mg/d×1w
3279778|NCT01653145|Active Comparator|Diet A|Low Fat High Energy Density (1.6 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
3279779|NCT01653145|Active Comparator|Diet B|High Fat Low Energy Density (1.05 kcal/g)-50% Fat, 35% Carbohydrate, and 15% Protein
3279780|NCT01653145|Active Comparator|Diet C|High Carbohydrate Low Energy Density (1.05 kcal/g)-20% Fat, 65% Carbohydrate, 15% Protein
3279781|NCT01653171|No Intervention|Control|Standard upper endoscopy withouth premedication
3279782|NCT01653171|Placebo Comparator|Water|100 mL of water, 20 minutes before upper endoscopy
3279783|NCT01653171|Experimental|Simethicone|Simethicone 200 mg, in water for up to 100 mL, to take 20 minutes prior to examination
3279784|NCT01653171|Experimental|N-acetylcysteine 500 mg + Simethicone|N-acetylcysteine 500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
3279785|NCT01653171|Experimental|N-acetylcysteine 1000 mg + Simethicone|N-acetylcysteine 1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
3279786|NCT01653184|Experimental|Experimental: AREDS 2 Vitamin formula 1g|"Patients will receive oral supplementation with the commercially available AREDS2 vitamin formula (PreserVision AREDS 2 Eye Vitamin and Mineral Supplement. Bausch + Lomb Incorporated), consisting of vitamins C, E, zinc, lutein, zeaxanthin and 1g of omega-3 fatty acids in the ethyl ester formulation"
3279787|NCT01653184|Experimental|Eye Omega Advantage 2g|Patients will receive a similar vitamin combination in the second arm (Eye Omega Advantage® and Macular Vitamin Benefit. Physician Recommended Nutriceuticals) with 2g of omega-3 fatty acids in the triglyceride formulation (see attached document for supplement details)
3279788|NCT01653197|Experimental|Control|"On top of reminder, state: Here's a fun fact to cheer you on your way: and include a curiosity-inducing question and answer (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space? // A: Texas)"
3279789|NCT01653197|Experimental|Curiosity|"On top of reminder, state: Here's a fun fact to cheer you on your way. and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)."
3279790|NCT01653197|Experimental|Curiosity linked to Action|"On top of reminder, state: Here's a fun fact to cheer you on your way. Reward yourself by scratching off the answer only after you've made your [colonoscopy/mammogram/etc.] appointment! and include a curiosity-inducing question (e.g., Q: Which is the only state that allows you to cast absentee ballots from outer space?) Place the answer under a scratch-off patch (A: Texas)"
3279791|NCT01653223|No Intervention|control|untreated
3279792|NCT01653223|Experimental|short statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 7 days postoperatively.
3279793|NCT01653223|Experimental|long statin|Simvastatin (20 mg) was administered every day for the 5-7 days preoperatively, but not the day of surgery in the statin group. Then simvastatin was re-administered at the second day until 6 months postoperatively.
3279794|NCT01653236|Experimental|Experimental Arm B|48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg
3279795|NCT01653236|Active Comparator|Control Arm|48 weeks of peginterferon alfa-2b and ribavirin
3279796|NCT01653249|Experimental|vaccination|an escalating dose study of a vaccine consisting of four HPV-16 E6 peptides in combination with Candin® to determine the clinically optimum dose (COD), immunologically optimal dose (IOD), and maximum tolerated dose (MTD). An additional 30 subjects will be vaccinated at the final dose (apparent COD) for further assessment of clinical response.
3279797|NCT01653275|Experimental|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
3279798|NCT01653301|Experimental|XELOX-RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
3279799|NCT01653301|Active Comparator|XELAC-RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
3279800|NCT01653314|Experimental|Megavec|
3279801|NCT01653314|Active Comparator|Glivec|
3279802|NCT01653340|Experimental|High Frequency Spinal Cord Stimulation through Senza™|"During the trial implant of Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine, the 2 leads will be positioned to cover the C2-C3 cervical levels.~Over the following 2 weeks, the investigator will optimize therapy delivery by identifying the stimulation settings providing maximal headache pain relief.~The subject will be asked to attend the clinic at the end of the trial period. Together with his/her physician, the subject will discuss his/her experience over the past 2 weeks (satisfaction with the therapy), and decide whether or not move forward with a Nevro Senza IPG.~The Nevro Senza IPG will be implanted in the buttock or abdomen area as outlined in the Physician's Manual. Fluoroscopy and impedance measurements may be used during the procedure to confirm lead placement and location.~Before hospital discharge, the IPG will be programmed with the optimal settings identified during the trial phase."
3279803|NCT01653353|Experimental|Entire group|A peer-applied guideline will be applied to the physicians.
3279804|NCT01653366|Experimental|Arm A-Pedometer and Goal setting|"Physical Activity Goal Setting~Patients receive physical therapy (PT) consult, educational materials, and telephone calls and are contacted weekly/monthly for physical activity (PA) goal setting with registered nurse (RN). Physical Activity completed is measured with pedometers and recorded on patient log."
3279805|NCT01653366|No Intervention|ARM B|Patients receive standard physical activity recommendations and follow up.
3279806|NCT01653379|Experimental|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
3279807|NCT01653392||Anthrax Vaccine Adsorbed|Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry.
3279808|NCT01653431|Experimental|Transcranial direct current stimulation|Transcranial direct current stimulation combined with cognitive training
3279809|NCT01653431|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation combined with cognitive training
3279810|NCT01653444|Experimental|GC1119 0.5 mg/kg|0.5 mg/kg biweekly
3279811|NCT01653444|Experimental|GC1119 1.0 mg/kg|1.0 mg/kg biweekly
3377898|NCT03745144|Experimental|First Cladribine, Then Placebo|Participants will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
3377899|NCT03745144|Experimental|First Placebo, Then Cladribine|Participants 5-day once daily cladribine matched placebo treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 1 followed by will receive 5-day once-daily cladribine treatment along with Microgynon® tablet once daily from Day 1 to Day 21 in period 2.
3279812|NCT01653457|Placebo Comparator|Placebo|
3279813|NCT01653457|Active Comparator|Memantine|
3377905|NCT03739099|Active Comparator|Closed-loop insulin delivery 24/7, day and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
3377906|NCT03739099|Other|Closed-loop insulin delivery 7/7, dinner and night|Closed-loop subcutaneous insulin infusion driven by continuous glucose monitoring through an algorithm
3377908|NCT03733080||1|ages 18 and older
3377911|NCT03729245|Experimental|Combination of bempegaldesleukin + nivolumab|Patients in Arm A will receive bempegaldesleukin in combination with nivolumab.
3377912|NCT03729245|Active Comparator|sunitinib or cabozantinib|Patients in Arm B will receive the Investigator's choice of either one of two treatment options.
3377913|NCT03726554||Comp. Rev. Porous Augmented Glenoid|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Porous Augmented Glenoid.
3377914|NCT03726554||Comp. Rev. Mini Humeral Tray|Subjects with a grossly deficient rotator cuff in need of a reverse shoulder arthroplasty who met the inclusion/exclusion criteria and received the Comprehensive Reverse Mini Humeral Tray
3377915|NCT03724032|Active Comparator|TMD Patients Active Group: Active Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 20 minute sessions, once daily for 10 days (M-F for 2 weeks).
3377916|NCT03724032|Sham Comparator|TMD Patients Sham Group: Sham Comparator|30 TMD patients will be randomized (Taves method) to receive high-definition transcranial direct current stimulation (HD-tDCS*) as 30-second administrations at the beginning and end of each 20 minute session, once daily for 10 days (M-F for 2 weeks).
3377917|NCT03724032|No Intervention|Healthy Control Group|"20 Healthy Volunteers will be asked to undergo baseline assessments only (including imaging, but no brain stimulation).~Healthy volunteer data (n </= 10) may be used from a prior study (NIDCR-R56-DE022637 project [IRBMED #HUM00080911; Dr. Alexandre DaSilva, Principal Investigator]). Consent to use data for a future study was obtained in the informed consent document at the time of participation."
3377920|NCT03703778||bilateral orchidectomy|Patients with advanced prostate cancer who receive surgical androgen deprivation therapy - bilateral orchidectomy
3377921|NCT03703778||GnRH agonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH agonist
3377922|NCT03703778||GnRH antagonist|Patients with advanced prostate cancer who receive medical androgen deprivation therapy - GnRH antagonist
3377923|NCT03702283|Experimental|Penicillin Allergic ICU Patients|The intervention will provide access to a best-practices alert containing a penicillin allergy risk stratification tool and recommendations on whether to use an oral amoxicillin test dose challenge order set for patients who stratify as low risk.
3377924|NCT03690427|Experimental|Endothelial function|Brachial artery flow-mediated dilation will be used to measure endothelial function
3377925|NCT03690427|Experimental|Arterial Stiffness|Pulse wave velocity will be used to measure arterial stiffness
3279814|NCT01653470|Experimental|Arm A: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
3279815|NCT01653470|Experimental|Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024|5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity
3279816|NCT01653470|Experimental|Arm C: Carboplatin/Paclitaxel + BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity
3279817|NCT01653470|Experimental|Arm D: Paclitaxel + BMS-906024|Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity
3279818|NCT01653470|Experimental|Arm F: Carboplatin/Paclitaxcel and BMS-906024|Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity
3279819|NCT01653483|Experimental|GSK573719|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
3279820|NCT01653483|Placebo Comparator|GSK573719 matched-placebo|Placebo
3279821|NCT01653496|Experimental|Enhanced recovery after surgery|Patients who receive ERAS program after gastric cancer surgery
3279822|NCT01653522|Experimental|Triptan|
3279823|NCT01653522|Experimental|Doxycycline|
3279824|NCT01653522|Experimental|Triptan + Doxycycline|
3279825|NCT01653522|No Intervention|Control|
3279826|NCT01653535|Experimental|Fast Track Eligible|"Participants in the Experimental group received the Fast Track intervention. Intervention included school-based curriculum attended by high-risk children, parents, program staff, and occasionally teachers, home visiting, the the in-class PATHS prevention program."
3279827|NCT01653535|No Intervention|Control Group|Participants in the Control group were not eligible to receive the Fast Track intervention. These children received other services as usual, and served as the randomized comparison group for examining Fast Track program impacts
3279828|NCT01653548|Experimental|HR training + Portable HR|100 subjects who receive Habituation Reminder training and who have access to the HR via a cellular phone.
3279829|NCT01653548|Experimental|HR Training + no portable HR|50 subjects who receive Habituation Reminder training and who do not have access to the HR via a cellular phone.
3279830|NCT01653548|Experimental|No HR training|50 subjects who do not receive HR training.
3279831|NCT01653561|Experimental|Apatinib|Apatinib 500mg/d
3279832|NCT01653574|Experimental|Famitinib Malate|Famitinib 25mg/d
3279833|NCT01653600|Experimental|LifeStent|same to SMART CONTROL Stent
3279834|NCT01653600|Active Comparator|SMART CONTROL Stent|study design is 2x2 randomization design. First, before randomization, stratification will be performed according to lesion length 15cm criteria at web-based computerized program. Patients will be randomized in a 1:1 manner according to different two (SMART versus LifeStent) stents. And then, patients received aspirin and clopidogrel during one month. After one month from index procedure, clopidogrel will be stopped and changed into cilostazol. Patients were randomized to receive cilostazol 100mg bid either 11 month duration or 5 month duration in separate groups of SMART stent group and LifeStent group. Randomization procedure will be performed using a web-based program
3279835|NCT01653626|Experimental|package|
3279836|NCT01653639|Experimental|Arm 1|
3279837|NCT01653639|Experimental|Arm 2|
3279838|NCT01653652|Placebo Comparator|Placebo|maltodextrin powder to be taken daily
3279839|NCT01653652|Active Comparator|Probiotic|Probiotic blended in maltodextrin powder to be taken daily
3279840|NCT01653665|Active Comparator|Leukine (Sargramostim, GM-CSF)|Participants in dose finding study will receive either 3 or 6 micrograms per kilo per day as a daily subcutaneous injection for either 4 or 7 days. Within the Randomised controlled trial, participants will receive the dose as chosen following the dose finding study.
3279841|NCT01653665|Placebo Comparator|Placebo (normal saline)|Participants in the randomised controlled trial may be randomised to receive a daily subcutaneous injection of normal saline (placebo) for 4 or 7 days as decided following the results of the dose finding study
3279842|NCT01653678|Active Comparator|Vitamin D + fish oil|
3279843|NCT01653678|Active Comparator|Vitamin D + fish oil placebo|
3279844|NCT01653678|Active Comparator|Vitamin D placebo + fish oil|
3279845|NCT01653678|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3279846|NCT01653691|Active Comparator|Pulse Dye Laser, burn scars|A scar will be located on the study subject's torso or thigh and divided in half. Some subjects will receive laser to both sides of their scar, while others will not receive any intervention to one side and laser to the other side. Each side will be evaluated during outpatient visits. 12 months after treatment is completed, 2 burn experts will rate each side of the scar without knowing its treatment.
3279847|NCT01653691|Sham Comparator|No treatment to half of scar|A scar on the child's torso or thigh will be divided in half. One side will receive laser treatment and the other half will receive laser or sham treatment.
3279848|NCT01653717|Experimental|T-Cell Infusion + Chemotherapy|Peripheral blood mononuclear cells (PBMC) collected via venipuncture or steady state leukapheresis after enrollment. Clinically successful T-cell production defined as amount of T-cells required for dose level for which the patient is enrolled. Fludarabine 25 mg/m2 by vein on Days -5 to Day -3. Cyclophosphamide 250 mg/kg by vein on Days -5 to -3. Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
3279849|NCT01653730|Experimental|Eclipse 3 portable oxygen concentrator|Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3279850|NCT01653730|Experimental|iGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3279851|NCT01653730|Experimental|EverGo portable oxygen concentrator|Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
3279852|NCT01653730|No Intervention|Control portable oxygen concentrator|6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
3279853|NCT01653756|Active Comparator|IPI-145|Capsules
3279854|NCT01653756|Placebo Comparator|Placebo|Capsules
3279855|NCT01653795|Active Comparator|LMA Unique|
3279856|NCT01653795|Active Comparator|LMA Supreme|
3279857|NCT01653808|Experimental|Elisio-210H with HD|hemodialysis patients treated with conventional hemodialysis (HD) modality using Elisio-210H dialyzer
3279858|NCT01653808|Active Comparator|Elisio-210H with on line HDF|hemodialysis patients treated with on line hemodiafiltration (HDF) modality using Elisio-210H dialyzer
3279859|NCT01653821|Experimental|Carotid body excision|Patients undergoing unilateral or bilateral removal of carotid body.
3279860|NCT01653834|Experimental|Lymphocyte harvesting & reinfusion|Patients with a newly diagnosed high grade glioma (Grade III or IV), have a post-operative treatment plan that includes standard radiation and temozolomide, and have normal bone marrow function with Hematocrit ≥ 30%, platelet ≥ 100K, ANC ≥ 1000, and absolute lymphocyte count ≥ 1000 prior entry to this study are eligible for enrollment.
3279861|NCT01653860|Experimental|The Brøset anger management model|Group treatment
3279862|NCT01653860|Active Comparator|ordinary group treatment|Group treatment
3279863|NCT01653886|Experimental|Pilot Group 1|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3279864|NCT01653886|Experimental|Pilot Group 2|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3279865|NCT01653886|Experimental|Pilot Group 3|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3279866|NCT01653886|Experimental|Pilot Group 4|Each Participant completed taste tests at breakfast, lunch and dinner consisting of the 4 menus (baseline, high fat-high energy density, high fat-low energy density, and high carbohydrate-low energy density).
3279867|NCT01653899|Experimental|IDN-6556|Drug
3279868|NCT01653925|Experimental|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids.
3279869|NCT01653925|Experimental|Drug intervention first|Intake of 5α-Reductase Inhibitor
3279870|NCT01653938|No Intervention|control group|
3279871|NCT01653938|Experimental|Video Arm|Use of video decision aid in the experimental arm.
3279872|NCT01653951|Experimental|Nurse-led care management|Nurse-led care management involves a nurse care manager who performs a comprehensive assessment of the patient then presents those assessment findings to an interdisciplinary team. The team makes care recommendations that are implemented by the care manager in collaboration with the patient's PCP.
3279873|NCT01653951|Experimental|peer-led self managment|Peer-led self management follows the chronic disease self management model where peer counselors lead self management classes for 6 weeks, then conduct monthly support groups
3279874|NCT01653977|Active Comparator|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
3279875|NCT01653977|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
3279876|NCT01653990|Experimental|moxifloxacin, pill|Oral dose of 400mg moxifloxacin
3279877|NCT01653990|Placebo Comparator|moxifloxacin-placebo,pill|A pill of moxifloxacin-placebo
3279878|NCT01654003|Active Comparator|CONTROL|"In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.~At the discretion of the attending anaesthesiologist with the FMH level, a pulmonary artery catheter, a transoesophageal Doppler flow probe or the PiCCO monitor will be inserted to complement the standard hemodynamic monitoring if deemed necessary."
3279879|NCT01654003|Active Comparator|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
3279880|NCT01654016|Active Comparator|Detralex|Detralex 500 mg twice daily for three month prior to surgery
3279881|NCT01654016|No Intervention|Not taking Detralex|Not taking Detralex for three months prior to surgery
3279882|NCT01654029|No Intervention|Control group receiving usual care|Usual care consists of speech language therapy for some patients. Most care is focused on swallowing assessments.
3279883|NCT01654029|Experimental|PCCI Intervention|The Patient-Centred Communication Intervention consists of 1) development of a communication care plan; 2)a workshop for staff focused on communication and behavioural management strategies,: and 3) implementing a staff support system.
3279884|NCT01654042|No Intervention|Standard interval between PT testing|Prothrombin time (PT) is tested every 4 weeks, according to American College of Chest Physicians (ACCP) Guidelines up to 2008 for stable patients on warfarin.
3279885|NCT01654042|Experimental|Prolonged interval between PT testing|Prothrombin time (PT) is tested every 12 weeks, according to suggestion in American College of Chest Physicians (ACCP) Guidelines of 2012 for stable patients on warfarin.
3279886|NCT01654081|Experimental|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
3279887|NCT01654094|Experimental|P6 Low Adherent Dressing|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
3279888|NCT01654094|Active Comparator|Standard of Care (SOC)|All participants will serve as their own control. All participants will receive both the P6 Low Adherent Dressings and the Standard of Care (SOC).
3279889|NCT01654120|Experimental|liraglutide plus insulin|Patients were randomized to receive liraglutide plus insulin (LIRA) for 12 months.
3279890|NCT01654120|Active Comparator|Insulin titration only|Patients were randomized to receive insulin only (control) for 6 months. The controls were then crossed over to receive liraglutide plus insulin for 6 months after the initial control period.
3279891|NCT01654133|Experimental|endovascular repair TAAA|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using Branched stent grafts
3279892|NCT01654146|Active Comparator|Arm 1 (Control Arm)|Carboplatin and paclitaxel on day 1 of a 21-day cycle for 6 cycles
3279893|NCT01654146|Experimental|Arm 2 (Research arm)|Carboplatin on day 1 and dose-fractionated weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles
3279894|NCT01654146|Experimental|Arm 3 (Research arm)|Dose-fractionated weekly carboplatin and weekly paclitaxel on day 1, 8 and 15 of a 21-day cycle for 6 cycles.
3279895|NCT01654159|Placebo Comparator|Monofocal|"Monofocal IOL Implant~Manufacturers of IOLs used as monofocal comparator are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3279896|NCT01654159|Experimental|Multifocal|"Multifocal IOL~Manufacturers of multifocal IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3279897|NCT01654159|Experimental|Toric|"Toric IOL~Manufacturers of toric IOLs under investigation are Alcon, AMO, Bausch and Lomb, Lenstec, Oculentis, Ophthec, Physiol and Zeiss"
3279898|NCT01654172|Experimental|High Flavanol Cocoa|"Cocoa drink containing ~450mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
3279899|NCT01654172|Placebo Comparator|Low Flavanol Cocoa|"Cocoa drink containing ~25mg cocoa flavanols and 10g carbohydrate per serving.~Subject consumes 2 servings per day, for 7 days."
3279900|NCT01654185|Experimental|AI plus Dimethyldiguanide|AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
3279901|NCT01654185|Active Comparator|Aromatase Inhibitor|AI monotherapy
3279902|NCT01654198||Psoriatic arthritis|
3279903|NCT01654211|Experimental|Part 1: iv danoprevir|
3279904|NCT01654211|Placebo Comparator|Part 1: placebo|
3279905|NCT01654211|Experimental|Part 2 A: iv danoprevir|
3279906|NCT01654211|Active Comparator|Part 2 B: oral danoprevir|
3279907|NCT01654211|Active Comparator|Part 2 C: ritonavir|
3279908|NCT01654211|Experimental|Part 3 D: iv danoprevir|
3279909|NCT01654211|Experimental|Part 3 E: iv danoprevir + cyclosporine|
3279910|NCT01654237|No Intervention|Muskind|three questionnaires to be completed by the subjects
3279911|NCT01654328|Experimental|Arm A: sodium chloride tablets|Arm A: sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
3279912|NCT01654328|Active Comparator|B: isotonic saline intravenously|Sodium chloride solution (isotonic saline (NaCl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
3279913|NCT01654341|No Intervention|Usual Care Group|Subjects undergo usual standard of care
3279914|NCT01654341|Experimental|Intervention Group|Intervention with exercise, dietary and educational programs
3279915|NCT01654367|Experimental|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors for Adjuvant Therapy
3279916|NCT01654393|Experimental|OAR group|Patients with ankle injuries who are assessed by OAR trained triage nurses applying the OAR.
3279917|NCT01654393|No Intervention|Control for OAR Triage Nurses|Patients with ankle injuries that are seen by OAR triage nurses but not assessed in accordance with the OAR.
3279918|NCT01654406|Active Comparator|Control|Pulsed dye laser (V-beam)
3279919|NCT01654406|Experimental|Experimental group|Fractional CO2 laser(eCO2)and pulsed dye laser (V-beam)
3279920|NCT01654419|Active Comparator|Class II elastics alone|Use of class II elastics alone to correct class II dental malocclusions
3279921|NCT01654419|Experimental|Class II elastics with Sliding Jig|Class II elastics with Sliding Jig for correction of dental class II malocclusion
3279922|NCT01654432|Placebo Comparator|General anaesthesia and sham nerve block|Breast cancer surgery under general anaesthesia
3279923|NCT01654432|Active Comparator|Paravertebral Blocks (PVB)|Breast cancer surgery under ultrasound-guided paravertebral blocks plus general anesthesia
3279924|NCT01654458|Experimental|Immediate Treatment Condition|Receives the 12-week GyneGals Support Group within a month of completing the baseline assessment.
3279925|NCT01654458|No Intervention|Waitlist Control Condition|Waitlist control group receives the 12-week GyneGals Support Group only after its involvement in the study has ended, as a courtesy.
3279926|NCT01654471||Medical treatment|only medical treatment (regardless of the kinds of medicine)
3279927|NCT01654471||Surgical or endovascular treatemnt group|patients underwent surgery or endovascular therapy
3279928|NCT01654484|Experimental|Low Dose DE-117|Monotherapy
3279929|NCT01654484|Experimental|Medium Dose DE-117|Monotherapy
3279930|NCT01654484|Experimental|High Dose DE-117|Monotherapy
3279931|NCT01654484|Experimental|Low Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3279932|NCT01654484|Experimental|Med. Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3279933|NCT01654484|Experimental|High Dose DE-117 and 0.0015% tafluprost|Adjunctive Therapy
3279934|NCT01654484|Active Comparator|0.0015% tafluprost|Monotherapy
3279935|NCT01654484|Placebo Comparator|Placebo|Monotherapy
3279936|NCT01654497|Experimental|Dexanabinol|
3279937|NCT01654510|Experimental|Cognitive Behavioral Therapy Group|
3279938|NCT01654510|Active Comparator|Vocational Services as Usual Control|Vocational services typically present in a comprehensive vocational service center.
3279939|NCT01654562|Experimental|CHM|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
3279940|NCT01654562|Active Comparator|Age-matched controls|Administration of 40mg simvastatin daily, orally for 5 weeks (4-6 weeks window), followed by 5 week (4-6 week window) washout period.
3279941|NCT01654575|Experimental|Methotrexate|25mg/week orally
3279942|NCT01654575|Active Comparator|Placebo|"Placebo-sugar tablets identical in colour and shape to methotrexate given once a week for 16 weeks."
3279943|NCT01654614||Forme Fruste Keratoconus Group (FFKG)|Forme Fruste Keratoconus Group (FFKG) included patients diagnosed with FFK.
3377926|NCT03690427|Experimental|Biomarkers of|Prooxidant and inflammatory plasma biomarkers will be used to assess oxidative stress and inflammatory status
3279944|NCT01654614||Control Group (CG)|Control group(CG) was formed by refractive surgery candidates.
3279945|NCT01654627|Experimental|Regenecure AMCA GBR Dental membrane|16 patients will undergo the guided bone regeneration procedure using the Regenecure AMCA Membrane
3279946|NCT01654627|Active Comparator|Collagen membrane|16 patients will undergo the guided bone regeneration procedure using a commercially available collagen membrane
3279947|NCT01654640|Experimental|Metformin group|Metformin 500mg 1 tablet p.o. bid
3279948|NCT01654640|Placebo Comparator|Placebo group|1 tablet p.o. bid
3279949|NCT01654653|Experimental|HSL(Totilac)|Hypertonic Sodium Lactate
3279950|NCT01654653|Active Comparator|6% HES (Voluven)|6% Hydroxyethyl Starch
3279951|NCT01654679|Active Comparator|wIRA irradiation|Patients in Group A received local water-filtered infrared A (wIRA) irradiation once for 20 min preoperatively.
3279952|NCT01654679|Sham Comparator|visible light only|Patients assigned to Group B only received normal visible light application for 20 min prior to surgery.
3279953|NCT01654692|Experimental|Single arm of ipilimumab and fotemustine|Ipilimumab in combination with Fotemustine
3279954|NCT01654705|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
3279955|NCT01654705|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
3279956|NCT01654718|Experimental|Pantoprazole Sodium Delayed release tablets|Pantoprazole Sodium Delayed release tablets USP 40 mg of OHM Laboratories Inc.,USA
3279957|NCT01654718|Active Comparator|Protonix® Delayed Release 40 mg tablets|Protonix® Delayed Release 40 mg tablets of Wyeth Pharmaceuticals Inc.USA
3279958|NCT01654731|Experimental|Bezafibrate|400 mg/Day
3279959|NCT01654731|Placebo Comparator|Placebo|1 tablet/ day
3279960|NCT01654770|Active Comparator|video capsule endoscopy|Video capsule endoscopy is performed every recruited patient.
3279961|NCT01654770|Active Comparator|double balloon enteroscopy|Double balloon enteroscopy is performed after video capsule endoscopy in every recruited patient. (Tandem study)
3279962|NCT01654783||5-ASA|Patient's treated with oral 5-ASA
3279963|NCT01654809|Experimental|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3279964|NCT01654809|Active Comparator|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3279965|NCT01654809|Active Comparator|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
3279966|NCT01654822|Placebo Comparator|olive oil with 10% d-limonene|Topical spray one-time administration 2 puffs of 100µl
3279967|NCT01654822|Experimental|AV2-DM antiviral spray|Topical spray one-time application 2 puffs of 100µl
3279968|NCT01654835|Active Comparator|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
3279969|NCT01654835|Placebo Comparator|no low blood pressure alert|The Low Blood Pressure condition will be monitored by treatment team, but additional alert will not be sent to treatment team.
3279970|NCT01654848||orthotopic Liver Transplantation|consecutive inclusion of all recipients
3279971|NCT01654874|Experimental|Preparation A|20 (±3) mCi 99mTc-MIP-1404 (preparation A)
3279972|NCT01654874|Experimental|Preparation B|20 (±3) mCi 99mTc-MIP-1404 (preparation B)
3279973|NCT01654900||Patients age >75 y who underwent open hear surgeary|The cohort study consist of all patients > 75 y, undergoing open heart surgery between 2008-2011 at Hadassah medical center.
3279974|NCT01654913|Experimental|surgical patients|patients studied just before induction of anesthesia
3279975|NCT01654926||Heart Failure patients|
3279976|NCT01654939|Experimental|rifaximin|All patients will be taking rifaximin 550 mg twice daily
3279977|NCT01654965|Experimental|Treatment (tivantinib, topotecan hydrochloride, pegfilgrastim)|Patients receive tivantinib PO BID on days 1-21, topotecan hydrochloride IV over 30 minutes on days 1-5, and pegfilgrastim SC on day 6. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3279978|NCT01654991|Active Comparator|Clinic-Based Testing|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
3279979|NCT01654991|Experimental|Home-Based Testing|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
3279980|NCT01655004|Experimental|exemestane standard treatment|Patients will receive exemestane 25mg daily orally after a meal until progression of disease, intolerable toxicities, voluntary withdrawal or termination of the study.
3279981|NCT01655017|Experimental|biopsy|Obesity with BMI> 40 kg/m² or obesity with BMI between >35 kg/m² with comorbidities (OSA, type 2 diabetes, hypertension etc…)
3279982|NCT01655017|No Intervention|healthy volunteers|biopsy during a surgery
3279983|NCT01655030|Experimental|creatine monohydrate|6g qd for 6 weeks
3279984|NCT01655030|Placebo Comparator|placebo|6g qd for 6 weeks
3279985|NCT01655056|Experimental|low male dose|Japanese and Caucasian males
3279986|NCT01655056|Experimental|medium male dose|Japanese and Caucasian males
3279987|NCT01655056|Experimental|high male dose|Japanese and Caucasian males
3279988|NCT01655056|Experimental|high female dose|Japanese and Caucasian females
3279989|NCT01655056|Experimental|highest male dose|Japanese and Caucasian males
3279990|NCT01655082|Experimental|V0116|One patch per day (during 24 hours) for 21 days
3279991|NCT01655082|Active Comparator|Reference|One patch per day (during 24 hours) for 21 days
3279992|NCT01655095|Experimental|PEG and Prucalopride|
3279993|NCT01655095|Experimental|Picosalax and Prucalopride|
3279994|NCT01655108|Placebo Comparator|Saline|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the placebo group, thirty women will be subjected to intradermal application (mesotherapy) of saline; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
3279995|NCT01655108|Active Comparator|Minoxidil 0.5% /2ml|After having been properly diagnostic as having androgenetic alopecia, through biopsy of the scalp, trichogram and trichoscopy and randomized in the drug active group, thirty women will be subjected to intradermal application (mesotherapy) of minoxidil 0.5%/2ml; ten sessions will be held at weekly intervals. Eight weeks after the last session will be repeated all the tests for comparison of results.
3279996|NCT01655121|Experimental|Autoimmune hepatitis (Non-cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
3279997|NCT01655121|Experimental|Autoimmune hepatitis (Cirrhotic)|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
3279998|NCT01655147|Experimental|Abiraterone acetate + Rifampicin|Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 1 of Period 1. Rifampicin 600 mg (2 x 300 mg) on Days 8 to 13, and Abiraterone acetate 1,000 mg (4 x 250 mg) on Day 14 of Period 2.
3279999|NCT01655160|Experimental|mirror therapy treatment|Three groups will be involved in this part of the whole project:MT with low-intensity group (MT-LI), MT with moderate-intensity group (MT-MI), MT with high-intensity group (MT-HI)
3280000|NCT01655160|Active Comparator|control intervention group|The part of this project will involve 1 treatment groups:control intervention group (CI)
3280001|NCT01655173|Experimental|Cognitive behaviour therapy|36 weekly sessions (1 calendar year) of Cognitive behaviour therapy in a group setting.
3280002|NCT01655173|Active Comparator|Recreational activity intervention|36 sessions (1 calendar year) of a group intervention to enable social interaction and to break social isolation.
3280003|NCT01655186|Placebo Comparator|Placebo|Oral, once daily
3280004|NCT01655186|Experimental|Bardoxolone Methyl|Oral, once daily
3280005|NCT01655199|Experimental|COPD group|Moderate and/or severe COPD patients, corresponding to GOLD stages II and III.
3280006|NCT01655212|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
3280007|NCT01655212|No Intervention|Control|Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remains unchanged.
3280008|NCT01655225|Experimental|Part A: LY3023414 Once Daily|LY3023414 administered orally once daily (QD) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
3280009|NCT01655225|Experimental|Part A2: LY3023414 Twice Daily|LY3023414 administered orally twice daily (BID) at escalating doses for two 21 day cycles to participants with advanced/metastatic cancer (including lymphoma); participants receiving benefit may continue until disease progression or discontinuation.
3280010|NCT01655225|Experimental|Part B1 : LY3023414 + Midazolam|LY3023414 administered orally BID for two 21 day cycles to participants with advanced/metastatic cancer; participants receiving benefit may continue until disease progression or discontinuation. Dose based on Part A. 0.2 milligrams (mg) midazolam administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
3280011|NCT01655225|Experimental|Part B2: LY3023414 + Fulvestrant|LY3023414 administered orally BID for two 28 day cycles to participants with advanced/metastatic breast cancer; participants receiving benefit may continue until disease progression or discontinuation. 500 mg fulvestrant administered IM once every 28 days.
3280012|NCT01655225|Experimental|Part B3: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation.
3280013|NCT01655225|Experimental|Part B4: LY3023414 + pemetrexed/cisplatin|LY3023414 administered orally BID for two 21 day cycles to participants with malignant mesothelioma; participants receiving benefit may continue until disease progression or discontinuation. 500 mg/m2 pemetrexed and 75 mg/m2 administered IV once every 21 days.
3280014|NCT01655225|Experimental|Part B5: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with indolent non-Hodgkin's lymphoma; participants receiving benefit may continue until disease progression or discontinuation.
3280015|NCT01655225|Experimental|Part B6: LY3023414|LY3023414 administered orally BID for two 21 day cycles to participants with squamous NSCLC; participants receiving benefit may continue until disease progression or discontinuation.
3280016|NCT01655225|Experimental|Part B7: LY3023414 + Abemaciclib + Letrozole|LY3023414 administered orally BID with abemaciclib administered orally BID and letrozole administered orally once a day for two 28 day cycles to participants with breast cancer; participants receiving benefit may continue until disease progression or discontinuation.
3280017|NCT01655238||95-99% BMI ASC|Patients having a BMI between 95-99% who are seen in the ambulatory surgery centers.
3280018|NCT01655238||95-99% BMI NCH main OR|Patients having a BMI between 95-99% who are seen in the main operating rooms.
3280019|NCT01655238||>99% BMI NCH main OR|Patients having a BMI >99% who are seen in the main operating rooms.
3280020|NCT01655251|Experimental|Intervention|Video (DVD) discharge instructions
3280021|NCT01655251|No Intervention|Control|
3280022|NCT01655264|Active Comparator|Home-based self training exercises|The control group will receive home-based self-training exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
3280023|NCT01655264|Experimental|Tele-rehabilitation exercises|The experimental group will receive tele-rehabilitation treatment of comparable duration and intensity to those in the home-based self training exercise group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
3280024|NCT01655277|Experimental|Adductor Canal block first|This arm received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
3280025|NCT01655277|Experimental|Femoral nerve block first|This arm received an ultrasound guided femoral nerve block with 15mL of chloroprocaine 3% followed by motor, sensory and balance assessments. Then the patients received an ultrasound guided adductor canal block with 15mL of chloroprocaine 3% followed by sensory and motor assessments.
3280026|NCT01655290|Experimental|Gadobutrol|first session gadobutrol second session gadobenate dimeglumin
3280027|NCT01655290|Experimental|Demeglumin|first session gadobenate dimeglumin second session gadobutrol
3280028|NCT01655303|Experimental|Metoprolol Per Oral|50 mg Metoprolol
3280029|NCT01655303|Experimental|Verapamil|40 mg Verapamil Per Oral
3280030|NCT01655303|Experimental|Propranolol|40 mg Propranolol Per Oral
3280031|NCT01655303|Experimental|Diltiazem|60 mg Diltiazem Per Oral
3280032|NCT01655316|Experimental|Verapamil|40 mg Verapamil Per Oral
3280033|NCT01655342||formocresol|
3280034|NCT01655355||Revison of the hip joint|
3280035|NCT01655368|Experimental|Interventional: STEM modules|8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module (for schizophrenia or depression)
3280036|NCT01655368|Other|Interventional Control|11 sessions + 1 booster session of psychoeducation for schizophrenia or depression)
3280037|NCT01655407|Experimental|Treatment|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
3280038|NCT01655407|Active Comparator|Control|All patients will receive both Autologous Engineered Skin Substitute (ESS-W) and Split-Thickness Autograft (AG).
3280039|NCT01655420||LASIK|Individuals aged 21 to 84 years planning to undergo refractive surgery using LASIK for myopia, hyperopia, or astigmatism
3280040|NCT01655433|Experimental|Therapeutic Hypothermia Treatment|
3280041|NCT01655433|Active Comparator|No Hypothermia Treatment|control group is no hypothermia treatment
3280042|NCT01655446|Experimental|Robotic Rehabilitation with FES|Robotic rehabilitation combined Functional Electrical Stimulation (FES)
3280043|NCT01655446|Experimental|Mirror Therapy|Mirror Therapy (MT)
3280044|NCT01655446|Active Comparator|Conventional Rehabilitation|Conventional Rehabilitation (CR) mainly focuses on occupational therapy training
3280045|NCT01655446|Experimental|Robotic Rehabilitation|Robotic Rehabilitation (RR)
3280046|NCT01655446|Placebo Comparator|Robotic Rehabilitation with PI|Robotic rehabilitation with Placebo Intervention (RR-PI)
3280047|NCT01655459||Ultrasound exam of upper airway|Following Internal Review Board approval(4-2011-0800) and written informed consent, total 100 patients(ASA I and II children aged 1 month to 6years) undergoing infra-umblicular urologic surgeries were included in the study. Children with upper respiratory tract infection, restricted mouth opening, congenital heart disease and those at risk for aspiration were excluded.
3280048|NCT01655472|Active Comparator|healthy parents|
3280049|NCT01655472|Active Comparator|schizophrenic parents|
3280050|NCT01655485|Experimental|Patient teaching|ipad application for social script book
3280051|NCT01655511|Experimental|Period 1|240 mg tafamidis arm
3280052|NCT01655511|Experimental|Period 2|480 mg arm
3280053|NCT01655511|Experimental|Period 3|TBD dose
3280054|NCT01655524|Experimental|ASSUAGE Protocol|There is only one arm in this cross-over design trial. Patients who had a standard regadenoson stress test will be invited to enroll in the study. All enrolled subjects will undergo an investigational (ASSUAGE) regadenoson stress test. Imaging scans from the same patients (scan 1 and scan 2) will be compared.
3280055|NCT01655550|Other|Standard of Care|Patients will get routine CT scans with Oral and Intravenous contrast prior to their CT scan as is routine, standard practice
3280056|NCT01655550|Experimental|Withold Oral Contrast|Subjects will not drink oral contrast, but instead water (in itself a type of contrast agent) prior to their CT. Intravenous contrast will be administered as is routine
3280057|NCT01655576|No Intervention|Routine clamping|After delivery of the newborn, umbilical cord at mothers end, will be left clamped until delivery of the placenta.
3280058|NCT01655576|Experimental|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
3280059|NCT01655602|Experimental|upper edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of upper edge of linear incision before wound closure
3280060|NCT01655602|Experimental|lower edge trimming|Surgery: trichophytic closure The 1-millimetre trimming of lower edge of linear incision before wound closure
3280061|NCT01655602|Experimental|Both edge trimming|Surgery: trichophytic closure The 0.5-millimetre trimming of both edge of linear incision before wound closure
3280062|NCT01655615|Experimental|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
3280063|NCT01655628|Experimental|GC chemotherapy plus CIK cells|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks); however,the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus 8 cycles CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
3280064|NCT01655628|Active Comparator|GC chemotherapy|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. After the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
3280065|NCT01655641|Experimental|Tranexamic acid arm|"Along with the standard of care (routine surgical care involved in preventing blood loss during surgery) this arm will receive drug Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV for non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
3280066|NCT01655641|Active Comparator|Standard of care arm|Includes routine surgical care involved in preventing blood loss during and after surgery.
3280067|NCT01655654|No Intervention|Cohort 1|All employees within the acute care hospital that signed the informed consent form and provided their individual data.
3280068|NCT01655654|Active Comparator|Cohort 2|All subjects of cohort 1 who also are considered hypertensive and participated in one or more study interventions, which include behavioral interventions (an increase in physical activity, or dietary changes) or who have a primary care provider visit to discuss hypertension.
3280069|NCT01655667||Chronic Obstructive Pulmonary Disease|All patients with a coded diagnosis of COPD entered into their electronic clinical record between 1990 and 2009.
3280070|NCT01655680|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
3280071|NCT01655680|Experimental|ABT-126 Middle Dose|ABT-126 Middle Dose
3280072|NCT01655680|Experimental|ABT-126 High Dose|ABT-126 High Dose
3280073|NCT01655680|Placebo Comparator|Placebo|Placebo
3280074|NCT01655706|Active Comparator|escitalopram (10-20mg)|Patients are on escitalopram for 8 weeks. At Week 8, patients will be assessed as 'responders' or 'non-responders'. 'Responders' will continue on escitalopram until study endpoint.
3280075|NCT01655706|Active Comparator|aripiprazole (2-10mg)|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
3280076|NCT01655732|Experimental|Atraumatic Restorative Treatment|ART is Atraumatic Restorative Treatment involving removal of soft carious enamel and dentine by hand instruments only and then restore the resulting cavity and adjacent pits and fissures with an adhesive restorative material.
3280077|NCT01655745|Experimental|FDG PET/MR, No Chemotherapy Arm|Patients that are NOT receiving chemotherapy but are only completing surgical intervention.
3280078|NCT01655745|Experimental|FDG PET/MR, Chemotherapy Arm|Patients that are receiving chemotherapy prior to completing surgical intervention. These patients will receive a FDG PET/MR prior to chemotherapy and after completion of chemotherapy (at the time of pre-op, before surgical intervention).
3280079|NCT01655758|Active Comparator|timolol|60-day treatment phase with 0.5% timolol eyedrops, b.i.d.
3280080|NCT01655758|Active Comparator|'timolol-dorzolamide fixed combination'|60-day treatment phase with the fixed combination of 0.5% timolol-2% dorzolamide, eyedrops, b.i.d.
3280081|NCT01655758|Active Comparator|xalatan|60-day treatment phase with 0.005% latanoprost, eyedrops, QD
3280082|NCT01655758|Active Comparator|travatan|60-day treatment phase with 0.004% travoprost, eyedrops, QD
3280083|NCT01655758|Active Comparator|lumigan|60-day treatment phase with 0.03% bimatoprost, eyedrops, QD
3280084|NCT01655771|Experimental|Elderly|TD-1211 Dose 1
3280085|NCT01655771|Experimental|Younger|TD-1211 Dose 2
3280086|NCT01655797|Experimental|CBT|The treatment group received manualized CBT-I using a adapted version of a manual designed for use by primary care personnel. Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
3280087|NCT01655797|No Intervention|Wait-list|A deferred treatment wait-list condition, with no restrictions placed on the usual care.
3280088|NCT01655810|Active Comparator|Vitamin D 4000 IU|PO daily
3280089|NCT01655810|Active Comparator|Vitamin D 600 IU|PO daily
3280090|NCT01655836|Experimental|Treatment (HDR brachytherapy, SBRT)|Patients undergo HDR brachytherapy on day 0 followed by SBRT on days 15-30
3280091|NCT01655849|Experimental|Z160|375mg BID
3280092|NCT01655849|Placebo Comparator|placebo|matching placebo control
3280093|NCT01655862||OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
3280094|NCT01655875|Experimental|bone marrow transplant|
3280095|NCT01655888|Experimental|single arm with Tremelimumab|Tremelimumab: 10mg/Kg ev day 1 every 4 weeks for 6 doses in induction phase, then every 12 weeks in maintenance phase until disease progression of severe toxicity
3280096|NCT01655914|Active Comparator|Arm A|"Sequence of Exposure:~Sequence A (N=5) Week 1: S/L 1.1 mg Week 2: S/L 2.2 mg Week 3: IV 0.2 mg Week 4: S/L 2.2 mg with 240 ml water"
3280097|NCT01655914|Active Comparator|Arm B|Sequence B (N=5) Week 1: IV 0.2 mg Week 2: S/L 2.2 mg Week 3: S/L 1.1 mg Week 4: S/L 2.2 mg with high fat diet
3280098|NCT01655927|Experimental|Tranexamic Acid|15 mg/Kg Tranexamic Acid IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
3280099|NCT01655927|Placebo Comparator|Saline (Placebo)|15 mg/Kg of Saline IV after anesthesic induction,and continues with a dose of 1mg/kg/h intraoperatory
3280100|NCT01655940||Cardiac bypass patients|
3280101|NCT01655953|Experimental|Campaign 1|
3280102|NCT01655953|Experimental|Campaign 2|
3377930|NCT03684785|Experimental|Dose Escalation Phase 1b|Determine the recommended Phase 2 dose of cavrotolimod in combination with pembrolizumab.
3377931|NCT03684785|Experimental|Dose Expansion Phase 2; Merkel cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on an anti-PD-1 / anti-PD-L1 therapy.
3377932|NCT03684785|Experimental|Dose Expansion Phase 2, cutaneous squamous cell carcinoma|Determine the safety and preliminary efficacy of cavrotolimod and cemiplimab in patients with advanced cutaneous squamous cell carcinoma that have progressed on an anti-PD-1.
3377933|NCT03684785|Experimental|Exploratory Phase 2, Merkel cell carinoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with advanced Merkel cell carcinoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
3377934|NCT03684785|Experimental|Exploratory Phase 2, Subcutaneous Dosing Cohort|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with no cutaneous, subcutaneous, or accessible nodal tumor lesions amenable that have progressed on anti-PD-1 / anti-PD-L1 therapy.
3377935|NCT03684785|Experimental|Exploratory Phase 2, Melanoma|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with locally Advanced or Metastatic Melanoma that have progressed on anti-PD-1 / anti-PD-L1 therapy.
3377936|NCT03684785|Experimental|Exploratory Phase 2, Liver Lesion|Determine the safety and preliminary efficacy of cavrotolimod and pembrolizumab in patients with metastatic solid tumors with liver metastases that have progressed on anti-PD-1 / anti-PD-L1 therapy.
3377937|NCT03677154|Experimental|Consolidation Therapy (Cohort A)|Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).
3377938|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Monotherapy (Cohort B)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).
3377939|NCT03677154|Experimental|Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)|Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.
3377940|NCT03675737|Experimental|Pembrolizumab + FP or CAPOX|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5-fluorouracil (5FU) 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally twice a day (BID) on Days 1 to 14 Q3W. Participants who complete 35 administrations or achieve a complete response (CR) but progress after discontinuation can initiate a second course of pembrolizumab for up to 17 cycles (approximately 1 additional year).
3377941|NCT03675737|Active Comparator|Placebo + FP or CAPOX|Participants receive placebo for pembrolizumab IV on Day 1 Q3W for up to 35 cycles (approximately 2 years) + physicians' choice of either cisplatin 80 mg/m^2 IV on Day 1 Q3W and 5FU 800 mg/m^2/day via continuous IV infusion on Days 1 to 5 Q3W OR oxaliplatin 130 mg/m^2 IV on Day 1 Q3W + capecitabine 1000 mg/m^2 orally BID on Days 1 to 14 Q3W.
3377942|NCT03642795||Patients with rheumatoid polyarthritis|
3377943|NCT03632239||GAPP|Individuals undergoing phenotyping by GAPP
3377944|NCT03627208||1|Retrospective chart review of children and young adults with ALL/LBL enrolled on treatment protocols in the POB
3377945|NCT03625141|Experimental|Cohort 1- cobimetinib and atezolizumab|Participants with BRAFV600 wild-type disease will be administered cobimetinib on Days 1-21 of each 28-day cycle; and atezolizumab on Days 1 and 15 of each treatment cycle.
3377946|NCT03625141|Experimental|Cohort 2 - cobimetinib, atezolizumab and vemurafenib|Participants with BRAFV600 mutation-positive disease will be administered cobimetinib, atezolizumab and vemurafenib in 28-day treatment cycles. Treatment includes a 28-day run-in period where participants will receive cobimetinib and vemurafenib only. Upon completion of the 28-day run-in period, atezolizumab will be added to their treatment regimen.
3280103|NCT01655966|Active Comparator|Standard of care|Group A: comprises 40 treatment-naive chronic hepatitis c patients who will receive the standard of care treatment: peginterferon Alfa 2a 160 ug once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3280104|NCT01655966|Experimental|Triple therapy|Group B: comprises 40 treatment-naive chronic HCV patients who will receive oral vitamin D 1mcg once daily plus peginterferon alfa-2a (160ug once weekly) and weight-based ribavirin 1000-1200 mg daily (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses for 48 weeks.
3280105|NCT01655979|Experimental|MEP-1|
3280106|NCT01655979|Experimental|MEP-2|
3280107|NCT01655992|Experimental|S1 generic|40mg／m2 bid four weeks on two weeks off
3280108|NCT01655992|Active Comparator|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
3280109|NCT01656005|Experimental|Carvedilol|Beclometasone/Formoterol Beclometasone Tiotropium
3280110|NCT01656005|Active Comparator|Bisoprolol|Beclometasone/Formoterol Beclometasone Tiotropium
3280111|NCT01656018|Experimental|Arm 1A|Female participants will receive a single dose of long acting TMC278 1200 mg intramuscularly (IM) at baseline (Day 0) in Arm 1A.
3280112|NCT01656018|Experimental|Arm 1B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline in Arm 1B.
3280113|NCT01656018|Experimental|Arm 2A|Female participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2A.
3280114|NCT01656018|Experimental|Arm 2B|Male participants will receive a single dose of long acting TMC278 600 mg IM at baseline in Arm 2B.
3280115|NCT01656018|Experimental|Arm 3A|Female participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3A.
3377955|NCT03580616|Experimental|L-Serine|L-Serine 15 grams orally twice a day as tolerated for 6 months
3377956|NCT03576261|Experimental|Preoperative echo + fluids|20 individuals investigated by preoperative transthoracic echocardiography. Preoperative colloid fluid bolus (Gelofusine, Fresenius Kabi AB, Sweden) 6 ml/kg lean body weight, is infused intravenously immediately before anesthesia induction.
3377957|NCT03576261|Active Comparator|Preoperative echo, control|20 individuals investigated by preoperative transthoracic echocardiography. No intravenous fluids are infused before anesthesia induction.
3377958|NCT03575221||Enrollees|Individuals with Osteogenesis Imperfecta
3377959|NCT03571984|Experimental|Moving on ABC Plus|Moving on ABC Plus is combination of two interventions. The culturally adapted CBT and Moving on ABC. CBT will be integrated with The Moving on After Breast Cancer (ABC), which has been developed by Dr Anneela Saleem who suffered from breast cancer. The integrated intervention will consist of 12 sessions (60-90 minutes). The first 8 sessions will be delivered weekly and the last four sessions will be delivered fortnightly
3377960|NCT03571984|No Intervention|Routine Care|This will consist of routine assessment and management as usually conducted by oncology clinics and general practice. GP's will be informed about the psychiatric diagnosis.
3377961|NCT03548779|Experimental|Pre-visit prep / usual care + exome seq|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care and will be offered research exome sequencing."
3377962|NCT03548779|Experimental|Pre-visit prep / usual care|"Participants randomized to pre-visit prep will receive a study packet with educational materials and a question prompt list. These participants will be instructed to review the materials, discuss them with family members if desired, use the question prompt list to select questions they would like to ask at clinic visit 1, and bring the list to their clinic visit 1 appointment.~Participants will receive usual care."
3377963|NCT03548779|Experimental|No prep / usual care + exome seq|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care and will be offered research exome sequencing."
3377964|NCT03548779|No Intervention|No prep / usual care|"Participants in the no pre-visit preparation arm will receive a mailed card reminding them about their upcoming clinic visit.~Participants will receive usual care."
3377965|NCT03541317|Experimental|Stage 1: Optimal First Line Implementation Strategy|"All schools enrolled will first be randomized to an optimal first line treatment in order to compare REP vs. REP + Coaching. Schools assigned to Stage 1 treatment REP will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation. Schools assigned to Stage 1 treatment REP + Coaching will receive the REP components plus weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
3377966|NCT03541317|Experimental|Stage 2: Added Value of Providing Facilitation|"After 2 months, schools will be assessed to determine whether they could benefit from augmenting their current strategy with a step-up strategy called Facilitation. Schools identified as potentially benefiting will be re-randomized to compare the added value of augmenting their current strategy with Facilitation, compared to continuing with their same strategy. Stage 2 treatment strategy: step-up will include provision of an additional implementation strategy called Facilitation. A full-time Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support school professionals in strategic thinking and leadership skills to address organizational barriers. Sites receiving Facilitation will receive regular calls for up to a minimum of 10 weeks from the Facilitator. All schools will also continue to receive their first line treatment (i.e. REP or REP + Coaching)."
3377967|NCT03538665||Cases|Women undergoing clinically-indicated hysterectomy for endometrial cancer or precursors
3280116|NCT01656018|Experimental|Arm 3B|Male participants will receive 3 bi-monthly injections of long acting TMC278 1200 mg IM at baseline, Months 2 and 4 in Arm 3B.
3280117|NCT01656018|Experimental|Arm 4A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4A.
3280118|NCT01656018|Experimental|Arm 4B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 900 mg at Months 2 and 4 in Arm 4B.
3377968|NCT03538665||Controls|Women undergoing clinically-indicated hysterectomy for benign conditions
3377969|NCT03538639||1|Adult index cases (affected) and relatives (affected and unaffected)
3280119|NCT01656018|Experimental|Arm 5A|Female participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5A.
3377970|NCT03538639||2|Child index cases (affected) and child relatives (affected and unaffected)
3377971|NCT03538639||3|Healthy adult volunteers
3377972|NCT03538600||Healthy Volunteers|healthy volunteers
3377973|NCT03534245||1|Healthy children aged 2 - 9 years
3280120|NCT01656018|Experimental|Arm 5B|Male participants will receive a single dose of long acting TMC278 1200 mg IM at baseline followed by TMC278 600 mg at Months 2 and 4 in Arm 5B.
3280121|NCT01656044|Active Comparator|Arm I (SSD)|Patients receive SSD over their closed laparotomy incision at the conclusion of their surgery.
3280122|NCT01656044|Experimental|Arm II (NPT)|Patients receive NPT dressing over their closed laparotomy incision at the conclusion of their surgery.
3280123|NCT01656057|Experimental|Acetaminophen+saline|Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
3280124|NCT01656057|Experimental|Acetaminophen+CCK|Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3280125|NCT01656057|Experimental|Metformin+saline|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + i.v. saline
3280126|NCT01656057|Experimental|Metformin+CCK|Metformin tablet 1500 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3280127|NCT01656057|Experimental|Colesevelam+saline|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. saline
3280128|NCT01656057|Experimental|Colesevelam+CCK|Colesevelam tablet 3750 mg + Acetaminophen tablet 1500 mg via nasogastric tube + iv. CCK-8, 24 pmol/kg/hour
3280129|NCT01656070|Experimental|Vitamin D|"oral cholecalciferol 1000000 UI (vitamin D3).~At 0, 3, 6 and 9 months, the vitamin D group received orally 100000 IU of cholecalciferol suspended in 2 mL of olive oil in sealed plastic syringes labeled with the unique identification numbers."
3280130|NCT01656070|Placebo Comparator|placebo|"placebo~At 0, 3, 6 and 9 months, the placebo group received 2 mL of olive oil, in sealed plastic syringes labeled with the unique identification numbers."
3280131|NCT01656083||SM intervention + varenicline|In intervention group, SM is delivered by a standard designed SM platform system. The interactive SM supports are involved and trained professional staff will provide guidance regularly. The drug usage in two groups are the same.
3280132|NCT01656083||Non-SM intervention group: varenicline|varenicline only
3280133|NCT01656096|Experimental|Renal sympathetic denervation|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)
3280134|NCT01656096|Sham Comparator|Sham procedure|Sham procedure mimicking the renal sympathetic denervation procedure in the experimental arm
3280135|NCT01656109|Experimental|PI-experience group|Using PI-based HAART for ≥6 months at the screening visit HIV-RNA viral load < 50 copies/ml at the screening visit No history of HIV-RNA ≥ 1,000 copies/ml while using PI-based HAART
3280136|NCT01656109|Experimental|PI-naïve group|Never been exposed to any PI-containing regimen HIV-RNA viral load ≥ 1,000 copies/ml at the screening visit
3280137|NCT01656122|Experimental|PK|PK of abacavir and lamivudine
3280138|NCT01656135|Other|Reference Group|"Basiliximab (Simulect®):~Day 0: 20mg IV ≤2h prior to surgery~Day 4: 20mg IV~Prednisolone:~Day 0: 500mg IV (250mg pre-op, 250mg intra-op)~Day 1: 125mg IV~Day 2 - 14: 20mg/day oral~Week 3 - 4: 15mg/day oral~Week 5 - 8: 10mg/day oral~Week 9 - 12: 5mg/day oral~Week 13 - 14: 2.5mg/day oral~Week 15 - Study End: Cessation~Steroid tapering should not proceed if graft rejection has occurred or if renal dysfunction is observed.~Mycophenolate Mofetil (MMF, or biologic equivalent):~Treatment with MMF should commence one day prior to transplantation (on Day -1) and should continue indefinitely, with a dose reduction after two weeks:~Day -1 - 14: 2g/day oral~Day 15 - Study End 1.5g/day oral (750mg twice daily)~Tacrolimus (or biologic equivalent):~Day -4 - 14: 3-12ng/ml~Week 3 - 12: 3-10ng/ml~Week 13 - 36: 3-8ng/ml~Week 37 - Study End: 3-6ng/ml"
3280139|NCT01656148|Experimental|Fampridine-SR|Initially all participants receive Fampridine-SR 10 mg BID in an open label enrichment phase lasting four weeks. Those 40% responding the most by SSST will go onto phase two. 50% of these will receive 10 mg Fampridine-SR BID for four weeks.
3280140|NCT01656148|Placebo Comparator|Placebo|In the intervention phase 50% will receive placebo BID
3280141|NCT01656174||No Treatment|
3280142|NCT01656213|Experimental|visual-feedback handgrip exercise|Subjects allocated to treatment will be trained in the laptop-based exercise that takes 20 minutes/session. Subjects will be encouraged to perform the exercise 2-3 times per dialysis session
3280143|NCT01656213|No Intervention|Control Arm|"60 similar ESRD stroke patients will be randomly assigned to the non-intervention arm. These patients will receive standard advice during dialysis (rest or gentle activity, e.g. reading).~Note that both groups of patients will also receive standard multidisciplinary rehabilitation care following a stroke, including therapy sessions at times other than receiving dialysis"
3280144|NCT01656226|Experimental|Eryfotona AK-NMSC® cream|
3280145|NCT01656226|Other|Sunscreen SPF 50+|
3280146|NCT01656239|Experimental|fedovapagon 1 mg|Once daily oral dose of 1 mg fedovapagon for 12 weeks
3280147|NCT01656239|Experimental|fedovapagon 2 mg|Once daily oral dose of 2 mg fedovapagon for 12 weeks
3280148|NCT01656239|Experimental|fedovapagon 4 mg|Once daily oral dose of 4 mg fedovapagon for 12 weeks
3280149|NCT01656239|Placebo Comparator|sugar pill|Once daily oral dose of placebo for 12 weeks
3280150|NCT01656265|Experimental|ARQ 197|
3280151|NCT01656278|Active Comparator|Conventional biochemical and clinical examinations|Biochemical and clinical examinations
3280152|NCT01656278|Experimental|Conventional biochemical and clinical examinations and MRI.|Biochemical and clinical examinations and MRI.
3280153|NCT01656317|Active Comparator|Mobilisation of patients after SAH|"Patients which were treated after SAH in 2012 will receive early multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~Mobilisation will be initiated and completed according to mobilisations guidelines which are developed and adjusted to the patients in early stage after aneurysmal SAH."
3280154|NCT01656317|No Intervention|Patients after SAH from 2011|Patients after SAH from 2011 which did not receive early rehabilitation and mobilisation will be followed up 3-6 annd 12 months after SAH and outcome measures compared with patients from 2011.
3280155|NCT01656330|Experimental|Rivaroxaban + Profilnine SD|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Profilnine SD 50 IU/kg.
3280156|NCT01656330|Experimental|Rivaroxaban + Beriplex P/N|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single bolus dose of Beriplex 50 IU/kg.
3280157|NCT01656330|Experimental|Rivaroxaban + Saline|Rivaroxaban 20 mg twice a day on Days 1-4 followed by rivaroxaban 20 mg once a day on Day 5 administered 4 hours before a single 100cc bolus of saline.
3280158|NCT01656343||Belatacept treated kidney-only transplant recipients|
3280159|NCT01656343||CNI treated kidney-only transplant recipients|
3280160|NCT01656356|Active Comparator|A/17/turkey/Turkey/05/133 (H5N2)|
3280161|NCT01656356|Placebo Comparator|Placebo|
3280162|NCT01656369|Active Comparator|Group I delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed. Postoperatively, minimal pain medication was required. Early ambulation was encouraged, and patients' diets were advanced as tolerated.
3280163|NCT01656369|Active Comparator|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
3280164|NCT01656382|Active Comparator|5 mg/kg/d ABLC x 14 days|5 mg/kg/d of Amphotericin B Lipid Complex for 14 days
3280165|NCT01656382|Experimental|10/kg/kg/d x 7 days|10 mg/kg/d of Amphotericin B Lipid Complex for 7 days
3280166|NCT01656421||COPD|Patients with Chronic Obstructive Pulmonary Disease, including mild, moderate, severe and very severe airflow obstruction
3280167|NCT01656421||Comparators|Current or ex-smokers free from from Respiratory Disease
3280168|NCT01656447||Patients with Scleroderma|Patients who have been diagnosed at any point in their life with Scleroderma will compose the cohort.
3280169|NCT01656473|Experimental|MI and DBT|Individual Motivational Interview session followed by 12-week Dialectical Behaviour Therapy skills group
3280170|NCT01656499|Active Comparator|Arabinoxylanoligosaccharides (AXOS)|AXOS (2 x 5g WBE/day)
3280171|NCT01656499|Placebo Comparator|Maltodextrine (placebo)|Maltodextrine (2 x 5g/day)
3280172|NCT01656512|Active Comparator|Arm ( A)|Arm ( A) : patients will receive calcium & vitamin D
3280173|NCT01656512|Experimental|Arm (B)|we will give calcium and Vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
3280174|NCT01656525|Experimental|1|
3280175|NCT01656525|Experimental|2|
3280176|NCT01656525|Experimental|3|
3280177|NCT01656525|Experimental|4|
3280178|NCT01656538|Experimental|Paclitaxel plus Reolysin|Paclitaxel given weekly on days 1, 8, 15 every 4 weeks plus reolysin days 1, 2, 8, 9, 15 and 16.
3280179|NCT01656538|Active Comparator|Paclitaxel|Paclitaxel given weekly on days 1, 8 and 15 every 4 weeks.
3280180|NCT01656551|Active Comparator|A: Gemcitabine|Single agent gemcitabine dose 1200 mg/m2 days 1 and 8, every 3 weeks
3280181|NCT01656551|Experimental|B: Gemcitabine + Cisplatin|Gemcitabine dose 1000 mg/m2 days 1 and 8, every 3 weeks
3280182|NCT01656551|Active Comparator|C: Pemetrexed|
3280183|NCT01656551|Experimental|D: Pemetrexed + Cisplatin|
3280187|NCT01656590|Other|High Protein and Exercise therapy along-with Nocturnal Enteral|
3280188|NCT01656603|Experimental|unlicensed CBU|The Principal Investigators will be the transplant physicians at participating US transplant centers
3280189|NCT01656616||EMS cyanide exposure patients|
3280190|NCT01656642|Experimental|Cohort 1 (C1): Ate+Vem - No Run-in|Participants will receive atezolizumab (Ate) 1200 milligrams (mg) every 3 weeks (q3w) along with vemurafenib (Vem) 720 mg twice daily (BID) for 21 days in each cycle followed by 7 days off treatment (28-day cycle). Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of consent occurs.
3280191|NCT01656642|Experimental|Cohort 2 (C2): Ate+Vem (56 Day Run-in)|Run-in period (56 days): participants will receive vemurafenib 960 mg orally BID from Day 1 to 49 and vemurafenib 720 mg orally BID from Day 50 to 56. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg intravenous (IV) q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
3280192|NCT01656642|Experimental|Cohort 3 (C3): Ate+Vem (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days. Combination treatment period: Participants will receive fixed dose of atezolizumab 1200 mg IV q3w in combination with vemurafenib 720 mg orally BID in 21 days cycle.
3280193|NCT01656642|Experimental|Cohort 4 (C4): Ate+Vem+Cob (28 Day Run-in)|Run-in period (28 days): participants will receive vemurafenib 960 mg orally BID for 21 days, then vemurafenib 720 mg orally BID for 7 days in combination with cobimetinib (Cob) 60 mg IV once daily, 21 days on/7 days off schedule (21/7). Combination treatment period: Participants will receive fixed dose of atezolizumab 800 mg IV every 2 weeks (q2w) in combination with vemurafenib 720 mg orally BID and cobimetinib 60 mg orally once daily 21/7 in 28 days cycle.
3280194|NCT01656642|Experimental|ECA: Ate+Vem+Cob (Mandatory Biopsy PD)|Expansion Cohort A (ECA): Approximately 10 participants who experienced disease progression (PD) after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab plus (+) vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
3280195|NCT01656642|Experimental|ECB: Ate+Vem+Cob (Mandatory Biopsy)|Expansion Cohort B (ECB): Approximately 20 participants will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections of accessible lesions will be mandatory for all participants. The doses will be decided based on the results of Cohorts 1-4.
3280196|NCT01656642|Experimental|ECC: Ate+Vem+Cob (No Mandatory Biopsy)|Expansion Cohort C (ECC): Approximately 10 participants who experienced disease progression after receiving prior checkpoint inhibitor therapy will be enrolled and treated with atezolizumab + vemurafenib + cobimetinib. Serial biopsy tissue sample collections will be optional for all participants enrolled in this cohort. The doses will be decided based on the results of Cohorts 1-4.
3280197|NCT01656655||PTSD group|Patients with PTSD
3280198|NCT01656655||Control Group|non PTSD group
3280199|NCT01656668|Experimental|BC1036|BC1036 300 mg capsule capsule by mouth, twice daily, for 14 days.
3280200|NCT01656668|Placebo Comparator|Sugar Pill|Sugar placebo capsule by mouth, twice daily, for 14 days.
3280201|NCT01656681|Experimental|THIAA|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to THIAA arm additionally receive the THIAA tablet, 3 times a day."
3280202|NCT01656681|Active Comparator|Placebo|"Stage 1 (the first 12 weeks of the study): all subjects participate in a structured lifestyle change program featuring a high-protein, high-phytonutrient food plan (HP2). Those randomized to Placebo arm receive the placebo tablet, 3 times a day.~Stage 2 (the subsequent 52-week study): All qualified subjects (i.e. those who have lost at least 7.5% of their body weight in Stage 1) participate in a less restrictive lifestyle change program featuring a Mediterranean-style Low-glycemic-load food plan (MLGL). Those randomized to Placebo arm receive the placebo tablet, 3 times a day."
3280203|NCT01656707|Experimental|ACRA|Ten weekly 60-minute sessions of Adolescent Community Reinforcement Approach (ACRA) will be provided as an Adaptive treatment condition.
3280204|NCT01656707|Experimental|Cognitive Behavioral Therapy (CBT)|Ten weekly, 60-minute sessions of augmented individualized Cognitive Behavioral Therapy (CBT)will be provided as an Adaptive Treatment condition
3280205|NCT01656720|Placebo Comparator|Placebo|Placebo 2g Suppository
3280206|NCT01656720|Active Comparator|NRL001 5mg|5mg NRL001 in a 2g suppository
3280207|NCT01656720|Active Comparator|NRL001 7.5mg|7.5mg NRL001 in a 2g suppository
3280208|NCT01656720|Active Comparator|NRL001 10mg|10mg NRL001 in a 2g suppository
3280209|NCT01656746|Experimental|Treatment (single incision laparoscopic surgery)|Patients undergo single incision laparoscopic surgery with GelPort® attachment.
3280210|NCT01656785|Experimental|Brain 68Ga-BNOTA-PRGD2|We will perform brain 68Ga-BNOTA-PRGD2 PET/CT on stroke patients to determine its value.
3280211|NCT01656798|Experimental|fasted condition|
3280212|NCT01656798|Experimental|fec condition|
3280213|NCT01656811|Experimental|levalbuterol 90 mcg|levalbuterol 90 mcg delivered via metered dose inhaler (MDI)
3280214|NCT01656811|Experimental|levalbuterol 180 mcg|levalbuterol 180 mcg delivered via MDI
3280215|NCT01656811|Active Comparator|racemic albuterol 180 mcg|racemic albuterol 180 mcg delivered via MDI
3280216|NCT01656811|Placebo Comparator|Placebo|Placebo delivered via MDI
3280217|NCT01656837|Experimental|MST-BSF|MST-BSF integrates two models with empirical support for their effectiveness, MST-CAN for child maltreatment (Swenson, Schaeffer, Henggeler, Faldowski, & Mayhew, 2012) and RBT for adult substance abuse (Tuten, Jones, Schaeffer, Wong, & Stitzer, 2012) into one comprehensive treatment package. MST-BSF is intended to be comprehensive. The major interventions within the MST-BSF arm include safety planning and implementation, functional analysis of the abuse incident, cognitive behavioral interventions for PTSD symptomatology and low anger management, family communication and problem solving, abuse clarification, and Reinforcement Based Treatment for adult substance abuse. RBT is an incentive-based drug treatment program for adults who abuse opiates, cocaine, or other illicit drugs.
3280218|NCT01656837|Experimental|Comprehensive Community Treatment|Families randomized to the CCT condition receive an array of services consistent with existing DCF practices. Project Safe community providers offer individual, couples, and family therapy for substance abuse/dependence, early intervention groups, treatment for co-occurring disorders, gender-specific trauma/substance abuse groups, and relapse prevention groups. The DCF caseworker also is responsible for coordinating care for the behavioral and mental health needs of the children. Services include individual outpatient treatment, family therapy, intensive in-home treatment, extended day programs, intensive outpatient, partial and inpatient hospitalization, residential programs/temporary housing (safe homes, shelters), emergency mobile psychiatric services, and crisis stabilization.
3280219|NCT01656863||Parents|Parents reporting to the emergency room with dehydrated children
3280220|NCT01656876|Experimental|Mirror therapy|mirror box training with or without sham mesh glove stimulation
3280221|NCT01656876|Experimental|Mirror therapy + Mesh glove stimulation|Mirror therapy combined with mesh glove stimulation
3280222|NCT01656876|Active Comparator|Controlled intervention|conventional interventions
3280223|NCT01656902|Experimental|N3D plus|NOVOCART® 3D plus (Autologous Chondrocyte Transplantation System)
3280224|NCT01656902|Active Comparator|Microfracture|Microfracture is the standard care surgery.
3280225|NCT01656915||Healthy men|Healthy male subjects with normal weight
3280226|NCT01656915||Compromised men|pre-diabetic overweight, male subjects
3280227|NCT01656928|Other|Waiting-list control|Allocation to waiting-list Control. Receives intervention 6 months later.
3280228|NCT01656928|Active Comparator|Intervention|Allocation to intervention. Directly starts with nutritional intervention.
3280229|NCT01656941||d-Transposition of the Great Arteries|Neonates with d-transposition of the great arteries (dTGA) undergoing the arterial switch operation with cardiopulmonary bypass
3280230|NCT01656941||Single ventricle cardiac disease|Neonates with single ventricle cardiac disease (SVCD) undergoing stage I surgical palliation (Norwood) with cardiopulmonary bypass
3280231|NCT01656954||Anticipated volume/blood administration|Patients who may receive IV fluid boluses or blood products for restoration of vascular volume. Prior to receiving IV fluid boluses or blood products, the patient will undergo a passive leg raise. (PLR)
3280232|NCT01656980|Experimental|Carmustine Sustained Release Implant|For subjects in this group, they will accept intracranially implanted carmustine intraoperatively.
3377975|NCT03527186|Experimental|Risperidone ISM® 100 mg|A single intramuscular (IM) dose of 100 mg risperidone ISM® will be administered deeply into the gluteal muscle. A total of 4 IM doses will be given; each dose will be separated by 4 weeks
3448451|NCT04063917|Experimental|Sequence 1|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device ON for the first half and OFF for the second half."
3280233|NCT01656980|Sham Comparator|Tumor Resection Surgery|For subjects in this control group, they accept no implants while gliomas maximally be resected.
3280234|NCT01656993||ASA activity|Participants (age 2.0 days to 12 months) undergoing cardiac surgery for a shunt and planned treatment with aspirin
3280235|NCT01657045|Experimental|Cohort 1|Subjects will be randomized to receive injections JVS-100 or placebo.
3280236|NCT01657045|Experimental|Cohort 2|Subjects will be randomized to receive injections JVS-100 or placebo.
3280237|NCT01657045|Experimental|Cohort 3|Subjects will be randomized to receive injections of JVS-100 or placebo.
3280238|NCT01657058|Experimental|Treatment # 1|Soluble viscous fibre blend powder in hydrophobic matrix
3280239|NCT01657058|Experimental|Treatment # 2|Soluble viscous fibre blend in pre hydrated form
3280240|NCT01657058|Placebo Comparator|Control # 1|No soluble viscous fibre blend
3280241|NCT01657058|Experimental|Treatment # 3|Soluble viscous fibre blend premixed with ½ carbohydrate gel
3280242|NCT01657058|Placebo Comparator|Control # 2|No soluble viscous fibre blend, ½ carbohydrate jello
3280243|NCT01657071|Experimental|Group A|
3280244|NCT01657071|Active Comparator|Group B|
3280245|NCT01657084|Experimental|Tonic-clonic seizures|Patients with tonic-clonis seizures are observed in a video/EEG room. In the case of seizures, the treatment mask or dummy mask are administered, according to a randomized cross-over study design.
3280246|NCT01657084|Experimental|Generalized Paroxysms|Patients with generalized epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
3280247|NCT01657084|Experimental|Group 3|Patients with epileptic paroxysms are observed by EEG during baseline, treatment mask and dummy mask use, according to a randomized cross-over study design.
3280248|NCT01657097|Experimental|INCS|Fluticasone propionate 400 microgram daily
3280249|NCT01657097|Placebo Comparator|Placebo|Placebo
3280250|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
3280251|NCT01657123|Placebo Comparator|placebo|
3280252|NCT01657123|Experimental|hydrocortisone stress dosage|
3280253|NCT01657136|Active Comparator|Ivabradine|Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).
3280254|NCT01657136|Active Comparator|Beta blocker (Bisoprololo)|Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR > 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).
3280255|NCT01657149|Experimental|Research Group|receive lymphatic massage and individual physiotherapy
3280256|NCT01657149|Active Comparator|Control group|receive individual physiotherapy only
3280257|NCT01657175|Experimental|Supportive care|The patients randomized to the supportive care arm get an extended supportive care during the first year after surgery.
3280258|NCT01657175|No Intervention|Control|"The patients randomized to the control group get care as usual"
3280259|NCT01657188||Heart failure, sleep-disordered breathing|Patients with stable heart failure NYHA ≥ II, EF ≤ 45% with or without central sleep apnea (apnea-hypopnea index ≥ 15/h) with or without adaptive servoventilation
3280260|NCT01657201|Experimental|Sequence 1|SYP-1018 200mg → Voriconazole 200mg
3280261|NCT01657201|Experimental|Sequence 2|Voriconazole 200mg → SYP-1018 200mg
3280262|NCT01657214|Experimental|Dose escalation|SAR125844 will be administered as weekly IV infusion. Four weekly administrations are considered as 1 cycle. The starting dose will be either 1 dose level (DL) below the highest cleared dose level in a European TED11449 ongoing study or DL4 (260 mg/m^2), if the highest cleared dose in TED11449 is >340 mg/m^2.
3280263|NCT01657227|Experimental|Intervention to Patients|Only patients receive intervention
3280264|NCT01657227|Experimental|Intervention to healthcare Professionals|Primary care physicians and nurses practitioners receive the intervention. Their associated patients do not receive direct intervention although indirect intervention through professionals
3280265|NCT01657227|Experimental|Mixed Intervention|Patients and healthcare professionals (primary care physicians and nurses practitioners) associated with these patients receive intervention
3280266|NCT01657227|Other|Control|Patients receive usual care
3280267|NCT01657240|Experimental|PRO-118|pro-118 ophthalmic solution, instill one drop in each eye once a day for 21 days
3280268|NCT01657240|Active Comparator|Olopatadine Hydrochloride|Olopatadine Hydrochloride ophthalmic solution 2%, instill one drop in each eye once a day for 21 days
3280269|NCT01657279|Experimental|Randomized clinical scenarios|Clinicians are randomized to a sequence of 5 clinical scenarios
3280270|NCT01657318||Chronic Wound Group|Treatment with Olivamine containing wound care products
3280271|NCT01657331|Experimental|Brentuximab Vedotin / Bendamustine|Subjects with relapsed or refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma will receive Brentuximab Vedotin in combination with Bendamustine, and prophylactic Neulasta
3280272|NCT01657357||PAO, osteoarhritis, THA|
3280273|NCT01657383||Hepatopancreaticobiliary (HPB) Surgery Patients|Patients undergoing surgical HPB procedures
3280274|NCT01657396|Active Comparator|Standard Oral Hygiene|Oral hygiene provided by current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
3280275|NCT01657396|Active Comparator|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
3280276|NCT01657396|Active Comparator|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
3280277|NCT01657409|Experimental|BoNT-A (10 injection)|100 U in 10ml, 1.0ml for each injection, totally 10 injections at bladder body
3280278|NCT01657409|Experimental|BoNT-A (20 injections)|100 U in 10ml, 0.5ml for each injection, totally 20 injections at bladder body
3280279|NCT01657409|Experimental|BoNT-A (40 injections)|100 U in 10ml, 0.25ml for each injection, totally 40 injections at bladder body
3280280|NCT01657422|Experimental|PACE+ Intervention|Intervention Group
3280281|NCT01657422|No Intervention|Sun Protection|Control / Comparison group. Patients assigned to the comparison group will receive intervention strategies over a the course of 2 years including: (1) completion of a 30-minute office-based computer program resulting in on-screen feedback to address excess sun exposure prevention, and (2) 4 phone calls and 4 mailings over a 24-month period conducted by PACE+ staff members.
3280282|NCT01657435||Ceramax COC 28mm Acetabular Cup|The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.
3280283|NCT01657448|Experimental|Methenamine, Methylthioninium|
3280284|NCT01657448|Active Comparator|Phenazopyridine|
3280285|NCT01657474|Experimental|Weekly Application of EpiFix|Weekly application of EpiFix plus standard of care
3280286|NCT01657474|Experimental|Biweekly application of EpiFix|Biweekly application of EpiFix plus standard of care
3280287|NCT01657487|Experimental|Fluticasone/salmeterol high dose|COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)
3280288|NCT01657487|Active Comparator|Fluticasone/Salmeterol medium dose|COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)
3280289|NCT01657500|Active Comparator|Life 4°C media for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
3280290|NCT01657500|Active Comparator|Optisol GS|Donor cornea is stored in the Optisol GS media prior to implantation.
3280291|NCT01657513|Experimental|tnf-alfa treatment (infliximab, adalimumab, or etanercept)|This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug
3280292|NCT01657526|Experimental|Group A|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 1 of the study
3280293|NCT01657526|Placebo Comparator|Group B|Subjects in this group will receive placebo in Step 1 of the study
3280294|NCT01657526|Experimental|Group C|Subjects in this group will receive GSK Biologicals' NTHi candidate vaccine in Step 2 of the study
3280295|NCT01657526|Placebo Comparator|Group D|Subjects in this group will receive placebo in Step 2 of the study
3280296|NCT01657539|Experimental|Probiotics|Group of patients using yogurt containing probiotics during the experimental phase of the study.
3280297|NCT01657539|Placebo Comparator|Control Yogurt|Group of patients that will use a placebo yogurt for providing comparison with the experimental group.
3280298|NCT01657552|Experimental|Eltrombopag|Subjects will receive single oral dose of eltrombopag 200 mg in Period 1 with moderate-fat, low-calcium meal.
3280299|NCT01657552|Experimental|Boceprevir|Subjects will receive boceprevir 800 mg orally every 8 hours (hrs) for 10 days in Period 2 with moderate-fat meals.
3280300|NCT01657552|Experimental|Telaprevir|Subjects will receive telaprevir 750 mg orally every 8 hours hrs for 10 days in Period 2 with moderate-fat meals.
3280301|NCT01657552|Experimental|Eltrombopag and Broceprevir|Subjects will receive eltrombopag 200 mg as single oral dose and boceprevir 800 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
3280302|NCT01657552|Experimental|Eltrombopag and Telaprevir|Subjects will receive eltrombopag 200 mg as single oral dose and telaprevir 750 mg orally every 8 hrs for a day in Period 3 with moderate-fat meals.
3280303|NCT01657565||open appendectomy|
3280304|NCT01657565||laparscopic appendectomy|
3280305|NCT01657578|Experimental|neonates of less than 32 weeks gestational age|omeprazole
3280306|NCT01657578|Experimental|neonates born between 32 and 35 weeks of GA|omeprazole
3280307|NCT01657578|Experimental|neonates of more than 36 weeks of GA|omeprazole
3280308|NCT01657591|Experimental|Dose Escalation|The treatment period will include dosing (taking a certain amount on a regular schedule) with vemurafenib along with the study drug, XL888. Everyone in the study will receive both drugs, but the XL888 will be given at different doses (different amounts). Everyone in this study will be given vemurafenib at the standard dose (the amount of the drug that is given as standard treatment) of 960 milligrams (mg) twice per day, unless the first people in the study have severe side effects when taking the lowest dose of XL888 along with vemurafenib. If that happens, the next people in the study may be given a lower dose of vemurafenib (720 mg twice per day) along with the lowest dose of XL888.
3280309|NCT01657604|Experimental|Nilotinib+IFN|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with Peginterferon α2b at a starting target dose of 30μg/week.
3280310|NCT01657604|Active Comparator|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily.
3280311|NCT01657630||Accu-Chek Combo|15 type 1 young patients under 6 years old who begin to use the Accu-Chek Combo System
3280312|NCT01657643|Placebo Comparator|Placebo|Every day for 12 weeks, subjects are asked to eat 5 grams of a placebo (strawberry-flavored candy powder)
3280313|NCT01657643|Experimental|Probiotics|Every day for 12 weeks, subjects are asked to eat 5 grams of a strawberry-flavored candy that contains probiotics [daily dose minimum of 1 billion CFU of each Lactobacillus rhamnosus LGG® (LGG®), and Bifidobacterium animalis ssp lactis BB-12® (BB-12®)]
3280314|NCT01657656|Experimental|Vitamin D group|Vitamin D supplement by Tishcon
3280315|NCT01657656|Placebo Comparator|Control group|Identically appearing capsules
3280316|NCT01657669|Other|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).
3280317|NCT01657682|Experimental|Cohort A - No prior FLT3 TKI exposure|Will enroll relapsed/refractory AML patients with FLT3 activating mutations who progressed on one or more prior chemotherapy regimens excluding any FLT3 TKI.
3280318|NCT01657682|Experimental|Cohort B - Prior therapy with FLT3 TKI|Will enroll relapsed/refractory AML patients with FLT3 activating mutations whose leukemia has progressed and have history of prior therapy with one or more FLT3 TKIs.
3280319|NCT01657708|Other|Shared Desicion Making Model|
3280320|NCT01657721|No Intervention|Wait-list Control|"Participants randomized to this group will not undergo The Cogmed Working Memory Training Program during the 5 week period, but will receive weekly phone calls from a member of the research team to review progress and advice on general time management, organization, and mnemonic strategies.~After a 5-week period, participants in this arm will have access to the working memory training."
3280321|NCT01657721|Experimental|15 Minute Training|Participants will receive a low intensity version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 15 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
3280322|NCT01657721|Experimental|30 Minute Training|Participants will receive the standard-length version of The Cogmed Working Memory Training Program. This involves undergoing 25 training sessions for 30 minutes per day, 5 days a week for 5 weeks. Participants will also receive weekly phone calls from a CogMed Coach to review progress and adjust the training as needed.
3280323|NCT01657734||HGG2003|"**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial~Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy)."
3280324|NCT01657734||HGG2010|"**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial~prospective double blind placebo controlled randomised clinical trial HGG-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy)."
3280325|NCT01657747|No Intervention|Not applicable (imaging study)|
3280326|NCT01657773||colorectal cancer, without nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had not been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination.
3280327|NCT01657773||colorectal cancer, with nonalcoholic fatty liver disease|Patients were performed colonoscopy examination for colorectal cancer and who had been foud colorectal cancer proven by biopsy.Then the colorectal cancer patients who had been diagnosed with nonalcoholic fatty liver disease was based on blood tests and abdomen ultrasound examination ultrasonography.
3280328|NCT01657786|Experimental|Ondansetron administration group|
3280329|NCT01657812|Experimental|dexmedetomidine|Drug:dexmedetomidine,dexmedetomidine 1.0μg/kg intravenous injection within 15 minutes before the induction of general anesthesia and followed by Dex 0.4μg/kg/h until 40min before the end of surgery
3280330|NCT01657812|Active Comparator|epidural|Epidural:continuous epidural block (T8-9) 4 mL of 1.6% lidocaine as a test dose and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery
3280331|NCT01657812|Placebo Comparator|control|Drug: normalsaline
3280332|NCT01657825|Experimental|Isavuconazole and warfarin|Isavuconazole three times daily (TID) for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20
3280333|NCT01657838|Experimental|Arm 1: isavuconazole only|Single dose of isavuconazole on Day 1
3280334|NCT01657838|Experimental|Arm 2: isavuconazole + ketoconazole|Single dose of isavuconazole on Day 4 and ketoconazole twice daily (BID) for 24 days
3280335|NCT01657851|Experimental|dutasteride/tamsulosin|The present study is planned to establish bioequivalence of Duodart® 0.5mg/0.4mg manufactured by GlaxoSmithKline to concomitant dosing with separate capsules of dutasteride 0.5 mg and tamsulosin hydrochloride 0.4 mg formulations commercially available in Russia.
3280336|NCT01657851|Active Comparator|dutasteride|Dutasteride (Avodart®) is an approved potent dual type I and II, 5-alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery.
3280337|NCT01657851|Active Comparator|tamsulosin|Tamsulosin (Omnic®) is an alpha-1A-adrenocepter blocking agent approved for the treatment of signs and symptoms of benign prostatic hyperplasia
3280338|NCT01657864||Patients with aseptic meningitis|All patients of the study population with a record/diagnosis of aseptic meningitis during the study period
3280339|NCT01657864||Patients without aseptic meningitis|All patients of the study population without a record/diagnosis of aseptic meningitis during the study period
3280340|NCT01657890|Experimental|Arm 1: Isavuconazole in healthy non-elderly male subjects|age 18 to 45 years
3280341|NCT01657890|Experimental|Arm 2: Isavuconazole in healthy non-elderly female subjects|age 18 to 45 years
3280342|NCT01657890|Experimental|Arm 3: Isavuconazole in healthy elderly male subjects|age 65 years and older
3448452|NCT04063917|Experimental|Sequence 2|"Participants allocated to Sequence 1 will complete the overnight sleep study with the ZENS device OFF for the first half and ON for the second half"
3448453|NCT04064008||Primary Total Hip Arthroplasty|Single study group from a single site previously implanted with the PROFEMUR® Z Revision Femoral Stem
3280343|NCT01657890|Experimental|Arm 4: Isavuconazole in healthy elderly female subjects|age 65 years and older
3280344|NCT01657916||5 year sling implants|Patients who underwent implant of the Align Urethral Support System between June 2007 and December 2008
3280345|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given ID|
3280346|NCT01657929|Experimental|20 µg H5-VLP + 2.5 µg GLA-AF given IM|
3280347|NCT01657929|Active Comparator|20 µg H5-VLP alone given ID|
3280348|NCT01657929|Active Comparator|20 µg H5-VLP + 1 mg Alhydrogel(R) given IM|
3280349|NCT01657929|Active Comparator|90 µg licensed H5N1 vaccine|
3280350|NCT01657942|Experimental|ExABlate MR Guided Focus Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
3280351|NCT01657955|Experimental|Bendamustine Hydrochloride Injection|d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles.
3280352|NCT01657955|Active Comparator|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC≥4×109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC<4×109 /L at d12-d14 );
3280353|NCT01657968||Acute tonsillitis|Patients with acute tonsillitis aged 15 to 40 years meeting at least two of Centors criteria.
3280354|NCT01657968||Healthy control patients|Control patients aged 15 to 40 years.
3280355|NCT01657981|Experimental|Treatment arm 1|
3280356|NCT01657994|Experimental|therapy plus fes|robotic gait training plus functional electrical stimulation
3280357|NCT01658007|Experimental|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leuk
3280358|NCT01658033|Experimental|Avastin + mFOLFOX6|Avastin plus FOLFOX6 regimen in the management of her-2 negative breast cancer patients.
3280359|NCT01658046|Experimental|NMES group|10 weeks neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
3280360|NCT01658046|Sham Comparator|Control group|10 weeks sham neuromuscular electrical stimulation plus endurance training and quadriceps strength training.
3280361|NCT01658085||Study group: HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
3280362|NCT01658085||Control group: ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
3280363|NCT01658098||4-6 weeks after delivery|all patients on their 4th-6th weeks after delivery
3280364|NCT01658111|Active Comparator|Traditional physiotherapy|Each subject will receive 4 weeks of traditional upper limb rehabilitation treatment (20 sessions, 5 days a week for 4 weeks).
3280365|NCT01658111|Experimental|Robot Group|Each subject will be asked to perform five sessions per week goal-directed, planar reaching tasks, which emphasizes shoulder and elbow movements, moving from the centre target to each of 8 peripheral targets equally spaced on a 0.14 m radius circumference around a centre target using the InMotion2 (IM2) system (20 sessions- 5 days a week for 4 weeks).
3280366|NCT01658124|Experimental|Tranexamic acid|(total dose 8 grams)
3280367|NCT01658124|Placebo Comparator|Placebo|(Sodium Chloride 0.9%)
3280368|NCT01658137|Active Comparator|Typical Western Diet|"The comparator dietary pattern (Typical Western Diet) approximates the inflammatory dietary pattern typically consumed by North Americans. It contains refined grains, processed foods, dairy fat, meats, sugar and high glycemic index foods, and few fruits, nuts, legumes, and vegetables. The fruits and vegetables are highly processed (e.g. juices) and lower in micronutrients than those in the intervention diet. The saturated fat content of this diet does not meet national guidelines for health. The polyunsaturated fat:saturated fat ratio is ~0.5 (low)."
3280369|NCT01658137|Experimental|Prudent Diet|"The experimental dietary pattern (Prudent Diet) is based on intakes of foods hypothesized to have beneficial effects on inflammation and long-term health. This dietary pattern includes micronutrient and macronutrient levels consistent with healthy eating in epidemiological studies and randomized controlled trials. The diet is constructed with low-fat dairy products, fish, chicken, and lean meats to minimize saturated fat and increase protein and calcium. The diet is rich in fruits, vegetables, whole grains, nuts, legumes, and seeds that are good sources of potassium, magnesium, and dietary fiber. This diet provides a 'favorable' macronutrient profile that is low in saturated fat, has a polyunsaturated/saturated fat ratio of ~1.0 (high), and low in high glycemic index carbohydrates."
3280370|NCT01658176|Experimental|PF-04691502 + Exemestane|PF-04691502 in combination with Exemestane
3280371|NCT01658176|Active Comparator|Exemestane|Exemestane alone
3280372|NCT01658202|Other|Sequence 1|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
3280373|NCT01658202|Other|Sequence 2|"After a 24h washout period free of any nicotine exposure, subjects will be randomly assigned to one of 2 treatment-sequence groups, separated by a 48h-intervals.~Each patch will be applied for 24h."
3280374|NCT01658215|Other|Sequence 1|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
3280375|NCT01658215|Other|Sequence 2|"Subjects will be randomly assigned to one of 2 treatment-sequence groups with 2 treatment periods. The duration of each treatment period will be 3 days.~Each patch will be applied for 24 hours."
3280376|NCT01658241|Experimental|Single Arm Main population|
3280377|NCT01658254|Experimental|Survey by email|One arm of investigators will receive the survey to answer by email, reminding the necessity of posting basic results
3280378|NCT01658254|No Intervention|Non interventional arm|This arm will receive no intervention (no email with the survey)
3280379|NCT01658267|Experimental|Nutritional Supplement|Instructions and techniques to improve the quality of the diet to meet the child's daily nutritional requirements will be provided.
3280380|NCT01658280|Active Comparator|Conventional TBNA + ROSE|"Patients allocated in this group will undergo conventional TBNA, performed in a bronchoscopy suite by the same operator under conscious sedation, using 19-G needle size. Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.~In case of samples obtained from conventional TBNA defined as non diagnostic, the operator will shift to the EBUS procedure.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs"
3280381|NCT01658280|Experimental|EBUS-TBNA + ROSE|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
3280382|NCT01658293|Experimental|thermal stimulation|The experimental group receiving heat and cold-water stimulation, 30 minutes a session, five sessions a week for six weeks.
3280383|NCT01658293|Active Comparator|control group|The control group receiving the similar intensity of ergometer exercise as the experimental group.
3280384|NCT01658306|Experimental|remote ischemic preconditioning|Receiving remote ischemic preconditioning (RIPC) treatment with pressure set at 200 mmHg.
3280385|NCT01658306|Sham Comparator|placebo remote ischemic preconditioning|Receiving sham RIPC treatment with pressure set at 50 mmHg
3280386|NCT01658319|Experimental|Treatment (chemotherapy)|Patients receive fludarabine phosphate IV over 30 minutes on days 1-5 and methoxyamine IV over 1 hour on day 1 (day 2 of course 1). Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3280387|NCT01658332|Experimental|specific procedure|Circulating tumor cells will be search with the Veridex method at inclusion and after the third chimiotherapy
3280388|NCT01658358|Experimental|Phase I part :Systemic Therapy|"Drug: Lapatinib~Drug: Lipo-Dox"
3280389|NCT01658358|Experimental|Phase II part|"Drug: Lapatinib~Drug: Lipo-Dox Patients will receive recommended dose according to phase I study result. at least 8 cycles, then, with continue combination treatment cycles or single lapatinib treatment (start with 1500 mg per day) at investigator's discretion."
3280390|NCT01658371||efavirenz|HIV patients on efavirenz
3280391|NCT01658384||cognitive evolution, observational,MS|multiple sclerosis tysabri treated patients
3280392|NCT01658397|Experimental|Fasting|Ten day fast
3280393|NCT01658410|Active Comparator|BQ-123|
3280394|NCT01658410|Placebo Comparator|NaCl|
3280395|NCT01658423||Junior high school student|All subjects participated in measurements of body composition, muscle strength and motor fitness
3280396|NCT01658449|Experimental|group A|
3280397|NCT01658449|Experimental|group B|
3280398|NCT01658462|Experimental|Arm A|Docetaxel + Nintedanib
3280399|NCT01658462|Active Comparator|Arm B|Docetaxel + increase of the dose
3280400|NCT01658475||periodontitis|those with periodontitis and those without periodontitis
3280401|NCT01658488|Other|Regular Rice|2 servings per day of non-fortified rice
3280402|NCT01658488|Other|Iron-fortified Rice|2 servings per day of Rice enriched in iron for women with iron-deficient anemia to restore their blood counts more efficiently than the standard rice not enriched with iron.
3280403|NCT01658501|Experimental|Diet and Exercise|Diet and exercise only.
3280404|NCT01658501|Experimental|Metformin|Metformin only
3280405|NCT01658501|Experimental|Sulfonylurea|Sulfonylurea only
3280406|NCT01658501|Experimental|Metformin and Sulfonylurea|Metformin and Sulfonylurea combination therapy
3280407|NCT01658501|Experimental|PB1023|PB1023 weekly SC injection
3280408|NCT01658501|Placebo Comparator|Placebo Comparator|Placebo (0.9% Sodium Chloride) weekly SC injection
3280409|NCT01658501|Active Comparator|Active Comparator|Active Comparator (Victoza) daily SC injection
3280410|NCT01658527|Experimental|Orteronel, 300 mg twice daily|
3280411|NCT01658527|Active Comparator|Bicalutamide 50 mg per day|
3280412|NCT01658553|Experimental|GSK1120212 Qtc study|Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects with Solid Tumors
3280413|NCT01658592|Experimental|NAC-VC Deep Brain Stimulation|The contractors located in NAc and VC are ON at the same time
3280414|NCT01658592|Sham Comparator|Placebo A|Stimulator setting is OFF
3280415|NCT01658592|Experimental|Placebo B|The contractor located in NAc is on
3280416|NCT01658592|Experimental|Placebo C|The contactor located in VC is on
3280417|NCT01658605|Experimental|GSK1605786|Administered orally for 16 weeks in a 2:1 ratio
3280418|NCT01658605|Placebo Comparator|Placebo|Administered orally for 16 weeks in a 2:1 ratio
3280419|NCT01658631||Anesthesia|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during the induction of anesthesia
3280420|NCT01658631||Intensive Care Unit patients|Arterial pressure measurement using Nexfin (a noninvasive finger cuff system) during a passive legs raising test
3280421|NCT01658644|No Intervention|Group A|Patients participating in group A, will not be exposed to any interventions, they will partake in the typical hospital and communication experience.
3280422|NCT01658644|Experimental|Group B (text handout)|Patients assigned to group B will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will NOT be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
3280423|NCT01658644|Experimental|Group C (text & image handout)|Patients assigned to group C will be provided with a paper or electronic version displaying a list of the names and roles of their clinical care staff; each name will also be accompanied by the respective photograph of each clinician. This document will be presented to the patient at the earliest possible time after admission to the hospital.
3280424|NCT01658670|Active Comparator|Enhanced Usual Care (EUC) exercise group|The EUC group is provided paid access to the exercise facility and has access to regular facility staff for the 18 month study period.
3280425|NCT01658670|Experimental|HEART Camp (HC) Intervention group|The HC intervention group will be provided paid access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
3280426|NCT01658683|Experimental|Exercise Facilitator Intervention|The intervention employs small group counseling teleconferences (5),personal telephone contacts (3) and community Heart Wise Exercise program demonstrations.
3377976|NCT03517813||Cohort 1|"Asymptomatic women at increased risk of breast cancer referred clinically for high risk screening breast MRI or women with newly diagnosed primary unilateral breast cancer referred for evaluation of extent of disease (EOD) in the index breast and screening of the contralateral breast.~All women enrolled on study will complete a clinical breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
3377977|NCT03517813||Cohort 2|"Women receiving MRI for any indication and for whom percutaneous biopsy with ultrasound or MRI guidance has been recommended.~All women enrolled on study will complete a standard breast MRI and research contrast enhanced mammogram. Abbreviated MRI images will be extracted from the standard breast MRI exam."
3377978|NCT03517540|Experimental|Arm A: Tropifexor (LJN452) - Dose 1|tropifexor 140 mcg, once daily; given orally
3377979|NCT03517540|Experimental|Arm B: Cenicriviroc (CVC)|CVC 150 mg, once daily; given orally
3377980|NCT03517540|Experimental|Arm C: Tropifexor (LJN452) Dose 1 + CVC|tropifexor 140 mcg + CVC 150 mg, once daily; given orally
3377981|NCT03517540|Experimental|Arm D: Tropifexor Dose 2 + CVC|tropifexor 90 mcg + CVC 150 mg, once daily; given orally
3377982|NCT03511794||hep B vaccine|1. Patient must have received at least one dose of the hepatitis B vaccine
3280427|NCT01658683|No Intervention|Usual Care|Usual care for cardiac rehab graduates provided by the University of Ottawa Heart Institute Minto Prevention & Rehabilitation Centre and the Cardiovascular Rehabilitation and Prevention Centre at the University Health Network.
3280428|NCT01658696|Active Comparator|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3280429|NCT01658696|Placebo Comparator|Rabies vaccine|2 x 2.5IU Verorab
3280430|NCT01658709||Ankle Injured|Volunteers with an ankle injury
3280431|NCT01658709||Healthy|Healthy Volunteers
3377988|NCT03500237|Experimental|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will provide support within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
3377989|NCT03500237|Active Comparator|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychological intervention will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
3377990|NCT03498521|Experimental|Molecularly-Guided Therapy|Participants will be assigned to molecularly-guided therapy based on genomic profile.
3377991|NCT03498521|Active Comparator|Platinum-Based Chemotherapy|Participants will receive platinum-based chemotherapy (Carboplatin or Cisplatin in combination with Gemcitabine or Paclitaxel).
3377992|NCT03495661|Active Comparator|Surgical (Decompression)|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
3377993|NCT03495661|No Intervention|Non-surgical|"Physical therapy according to the Östersund model: training on stationary bicycle 30 min, 3 times/week under 4 months."
3280432|NCT01658722||Observational|Long term follow-up
3280433|NCT01658748|Active Comparator|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will have stimulators turned on approximately 1 week after the 3-4 week post-surgery EEG telemetry session that determines safety parameters for stimulator settings. Subjects will be followed weekly for the next 12 weeks, with adjustments in stimulator settings according to prescribed protocol based on changes in rating scale scores (CAPS, CGI-I, ADIPS, LFIPS, HAMA, MADRS, YMRS).
3377996|NCT03480139||Pregnant Women|Pregnant women aged 18 years and older
3377998|NCT03478839||CRF completion|Individuals with a diagnosis of GACI or ARHR2 with sufficient chart data to be included in the study will be eligible for enrollment, as well as all their siblings and parents.
3377999|NCT03473223|Experimental|CSL112|Apolipoprotein A-I [human]
3378000|NCT03473223|Placebo Comparator|Placebo|25% albumin solution diluted to 4.4%
3378001|NCT03457129|Active Comparator|Fycompa 2 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for two weeks, then up-titrated by 2 mg every two weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
3280434|NCT01658748|Sham Comparator|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Patients randomized to this arm will undergo the same procedures and same visit frequency as those in the week 0 stimulation arm, except that the actual stimulation settings will be kept at 0 V, 0 Hz, and the patient, study psychiatrist who does the ratings, and study neurosurgeon who does neurological clinical assessments will be blind to whether the subject is receiving actual or sham stimulation. Only the study neurophysiologist will know whether the patient is in the active or sham stimulation arm during these 12 weeks. After week 12, subjects in this week will begin to receive active stimulation according to pre-specified protocol.
3280435|NCT01658761|Experimental|Myopic traction maculopathy|The 71 eyes of 64 patients (14 men and 50 women) with myopic traction maculopathy in highly myopic eyes (refractive errors ≤-8.0 diopters and axial length ≥26.0 mm) who underwent vitrectomy were retrospectively reviewed.
3280436|NCT01658774|Active Comparator|Albendazole & Vitamin C|Anthelmintics. A single dose of Albendazole (400mg) at month 0 and single dose of Vitamin C (500 mg) at 3, 6, 9 and 12 months.
3280437|NCT01658774|Experimental|Albendazole|Anthelmintics. A single does of Albendazole (400mg) every three months for 12 months
3280438|NCT01658787||Endovascular aortic repair|Patients treated with Gore Endovascular Aortic Products.
3280439|NCT01658800|Experimental|VAX161C vaccine|Subjects will be injected into the arm on 2 occasions during the study, once on Day 0 and then again on Day 21 with the vaccine VAX161C
3280440|NCT01658826|Experimental|AIC316|100 mg once daily for 28 days
3280441|NCT01658826|Active Comparator|Valacyclovir|500 mg once daily for 28 days
3280442|NCT01658852|Active Comparator|Metronidazole|active drug: metronidazole 500mg three time per day for 10 days
3280443|NCT01658852|Placebo Comparator|Placebo|Placebo three times per day for 10days
3280444|NCT01658865||Transnasal endoscopy|Healthy volunteers and patients with esophageal motor symptom will be enrolled and esophageal motility assessed by transnasal endoscopy according to clinical and manometric diagnosis
3280445|NCT01658878|Experimental|Non-infected: Nivolumab|Nivolumab intravenous solution on specific days
3280446|NCT01658878|Experimental|HCV-infected: Nivolumab|Nivolumab intravenous solution on specific days
3280447|NCT01658878|Experimental|HBV-infected: Nivolumab|Nivolumab intravenous solution on specific days
3280448|NCT01658878|Experimental|Nivolumab|Nivolumab intravenous solution on specific days
3280449|NCT01658878|Active Comparator|Sorafenib|Sorafenib tablets on specific days
3280450|NCT01658878|Experimental|Nivolumab plus Ipilimumab Combination|Nivolumab intravenous solution + Ipilimumab intravenous solution on specific days
3280451|NCT01658878|Experimental|Child-Pugh B|Nivolumab intravenous solution on specific days
3280452|NCT01658878|Experimental|Nivolumab plus Cabozantinib Combination|Nivolumab intravenous solution + cabozantinib oral tablets on specific days
3280453|NCT01658878|Experimental|Nivolumab plus Ipilimumab plus Cabozantinib|Nivolumab intravenous solution + Ipilimumab intravenous solution + cabozantinib oral tablets on specific days
3280454|NCT01658891|Experimental|CHF 1535 50/6 µg|
3280455|NCT01658891|Active Comparator|beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|
3280457|NCT01658930|Active Comparator|Radical Hysterectomy|
3280458|NCT01658930|Experimental|Simple Hysterectomy|
3280459|NCT01658956|Experimental|Subcutaneous GCSF 5 µg/kg days 8 and 12|Prophylactic administration of GCSF on days 8 and 12 following chemotherapy
3280460|NCT01658956|No Intervention|No intervention|
3280461|NCT01658982||cirrhotic patients|cardiopulmonary exercise testing
3280462|NCT01659008|Experimental|estradiol|estradiol PO 0.5mg 2 tabs three times a day for 2 days
3280463|NCT01659008|Experimental|Lysteda|Lysteda 650mg PO 2 tabs three times a day for 2 days
3280464|NCT01659034|Experimental|Thienopyridine|Thienopyridine treatment for 3 months after implantation of everolimus-eluting Stents
3280465|NCT01659047|Experimental|GS-1101|GS-1101 (oral; 150 mg BID)
3280466|NCT01659060|Experimental|Dark chocolate|
3280467|NCT01659060|Placebo Comparator|Placebo chocolate|
3280468|NCT01659073|Experimental|Caloric Vestibular Stimulation|Caloric vestibular stimulation performed by a modified stethescope ear attachment attached to an MRI compatible infusion pump.
3280469|NCT01659086|Experimental|Group A|Subjects will receive the investigational vaccine GSK2654911A formulation 1 and placebo
3280470|NCT01659086|Experimental|Group B|Subjects will receive the investigational vaccine GSK2654911A formulation 2 and placebo
3280471|NCT01659086|Experimental|Group C|Subjects will receive the investigational vaccine GSK2654911A formulation 3 and placebo
3280472|NCT01659086|Experimental|Group D|Subjects will receive the investigational vaccine GSK2654911A formulation 4 and placebo
3280473|NCT01659086|Experimental|Group E|Subjects will receive the investigational vaccine GSK2654909A and placebo
3280474|NCT01659086|Experimental|Group F|Subjects will receive the investigational vaccine GSK2654911A formulation 5
3280475|NCT01659086|Experimental|Group G|Subjects will receive the investigational vaccine GSK2654911A formulation 6
3280476|NCT01659086|Experimental|Group H|Subjects will receive the investigational vaccine GSK2654911A formulation 7
3280477|NCT01659086|Experimental|Group I|Subjects will receive the investigational vaccine GSK2654911A formulation 8
3280478|NCT01659086|Experimental|Group J|Subjects will receive the investigational vaccine GSK2654909A
3280479|NCT01659086|Placebo Comparator|Placebo Group|Subjects will receive Placebo
3280480|NCT01659099|Experimental|GA101|GA101 - Chemotherapy (ACVBP or CHOP)
3280481|NCT01659099|Active Comparator|Rituximab|Rituximab - Chemotherapy (ACVBP or CHOP)
3280482|NCT01659112|Experimental|Stabilization Group|A core stabilization plus traditional upper extremity rehabilitation approach was performed.
3280483|NCT01659112|Active Comparator|Control Group|A traditional upper extremity rehabilitation-only approach was performed.
3280484|NCT01659138|Experimental|SAR339658|SAR339658 at Weeks 0, 2, 4, and 6
3378002|NCT03457129|Experimental|Fycompa 3 week titration intervals|Perampanel oral tablet: 2mg by mouth every 24 hours for three weeks, then up-titrated by 2 mg every three weeks to a target dose of 6 mg/day. Minimum total daily dose = 2 mg/day. Maximum daily dose is 12 mg/day. Total daily dose will be determined by the Investigator based on tolerability and seizure control.
3378003|NCT03454295|Experimental|Part I|Focus group (Part 1) of four to ten GBM ICs bereaved at least one year to help determine our recruitment strategy. Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received. Should consensus among participants be reached (e.g., if the majority report that being approached at time of their loved one's cancer recurrence would have been the optimal time for enrollment), we will target our enrollment timeline to this point (and this timeline will be reflected in amended inclusion criteria). If no consensus is reached, the study staff will enroll ICs at all points in the caregiving trajectory and revisit the appropriateness of various points of contact during the Part 2 individual interviews.
3378004|NCT03454295|Experimental|Part II|In Part 2, we will recruit 60 ICs of patients with GBM who will be randomized to receive either MCP-C or EUC. MCP-C will be delivered individually over 7 1-hour-long sessions within 7 - 14 weeks.
3378007|NCT03446352|Experimental|Psychomotor exercise program|The experimental group 1 (EG1) intervention comprises a psychomotor program. The program integrates 3 sessions / week of 75 minutes on alternated days. The psychomotor intervention includes exercises promoting simultaneous motor and cognitive stimulation (interval training).
3378008|NCT03446352|Experimental|Combined exercise program|The experimental group 2 (EG2) intervention combines the psychomotor program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.
3378009|NCT03446352|No Intervention|Control Group|Usual care. After the study, control group (CG) participants will be offered the opportunity to integrate a similar fall prevention program.
3378010|NCT03443700|Active Comparator|sLT|Standard neurorehabilitation locomotor training during the whole study period (8 weeks).
3378011|NCT03443700|Experimental|sLT + EX-T|Standard neurorehabilitation locomotor training (sLT) during the whole study period (8 weeks), plus a training with a new-generation robotic anthropomorphic exoskeleton (EKSO-GT locomotor training) during the first 4 study weeks.
3378012|NCT03439774|Other|Adults 18 years old or older|
3280485|NCT01659138|Placebo Comparator|Placebo|Placebo at Weeks 0, 2, 4, and 6
3378013|NCT03438357||Patients with multiple sclerosis|
3378014|NCT03434080||Autism Spectrum Disorder|The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)
3378015|NCT03434080||Cerebral Palsy|The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)
3378016|NCT03434080||Typical Development toddlers infants|The control group will consist of 50 healthy volunteers with TD
3378017|NCT03429036||1|Subjects must be diagnosed with a disorder of the head and neck region
3378018|NCT03427424||AUD-E|Early-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP within 2 months of starting treatment (AUD-E)
3280486|NCT01659151|Experimental|Combination Therapy|Combination Chemotherapy and Immunotherapy. The combination of vemurafenib followed by lymphodepletion with chemotherapy, Adoptive Cell Therapy (ACT) with Tumor Infiltrating Lymphocytes (TIL) infusion, and High Dose Interleukin-2 (IL-2).
3280487|NCT01659164|Experimental|Group treatment (uncontrolled)|Psychological treatment in group for adults with ADHD (pilot) during 14 weeks with focus on decreasing disabilities due to the condition.
3378019|NCT03427424||AUD-L|Long-term-in-treatment, healthy alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (AUD-L)
3378020|NCT03427424||Characterization|substance use disorder participants currently enrolled in PHP, not eligible for main imaging study
3378021|NCT03427424||CON|healthy, non-drug using control participants (CON)
3378022|NCT03427424||POAUD-E|Early-in-treatment, healthy dual prescription opioid and alcohol and use disorder participants currently enrolled in PHP within 2 months of starting treatment (POAUD-E)
3378023|NCT03427424||POAUD-L|Long-term-in-treatment, healthy dual prescription opioid and alcohol use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POAUD-L)
3280488|NCT01659177|Experimental|LY2140023 fasting|Single oral dose of 80 mg LY2140023 given in fasted state
3280489|NCT01659177|Experimental|LY2140023 + food|Single oral dose of 80 mg LY2140023 given after standardized high-fat breakfast
3280490|NCT01659190|Experimental|Oiled-limestone liniment|the removal of the collecting bag is made with the Oiled-limestone liniment.
3378024|NCT03427424||POUD-E|Early-in-treatment, healthy prescription opioid use disorder participants currently enrolled in physician health program (PHP) within 2 months of starting treatment (POUD-E)
3280491|NCT01659190|No Intervention|without Oiled-limestone liniment|the removal of the collecting bag is made without any special precautions
3280492|NCT01659203|Experimental|Treatment Arm IMPT|IG-IMPT with SIB to the high risk margin
3280493|NCT01659203|Experimental|Treatment Arm IMRT|IG IMRT with SIB to the high risk margin
3280494|NCT01659216||patients improved by EPNS; follow-up|Ninety female UFS patients with ≥50% symptom improvement at the end of EPNS treatment (Jul. 2001 to Jun. 2005) were followed up by a telephone questionnaire for at least 5 years.
3280495|NCT01659229||PFC CR 150 total knee implant|Study group implant: PFC CR 150 Control group implant: PFC CR standard
3280496|NCT01659229||PFC CR Standard|study group implant: PFC CR 150 control group implant: PFC CR Standard
3280497|NCT01659242|Active Comparator|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
3280498|NCT01659242|Active Comparator|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
3280499|NCT01659281|Active Comparator|1|2-day oral treatment with: Artesunate 6mg/kg at 0 and 24 hours Mefloquine 25 mg/kg total dose split into 2 doses of 15 mg/kg at 0 hours and and 10 mg/kg given 6-24 hours later Primaquine 0.5 mg/kg single dose at 24 hours
3378025|NCT03427424||POUD-L|Long-term-in-treatment, healthy prescription opioid use disorder participants currently enrolled in PHP more than 2 months and less than 5 years (POUD-L)
3378026|NCT03407066||In-person|200 in-person healthy volunteers.
3378027|NCT03407066||On-line|10,000 online healthy volunteers
3378028|NCT03400943|Experimental|Vilaprisan (A1)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3280500|NCT01659281|Active Comparator|2|3 days oral treatment with: Artesunate 4 mg/kg/day for 3 days Mefloquine 8 mg/kg/day for 3 days Primaquine 0.5 mg/kg single dose at 24 hours
3280501|NCT01659294|Experimental|nurse case management|nurse case management of diabetic variables
3280502|NCT01659294|Active Comparator|standard diabetologist care|standard diabetologist care
3280503|NCT01659307|Active Comparator|Aspirin 75mg|Aspirin 75mg once daily for 7 days. Administered by mouth.
3280504|NCT01659307|Active Comparator|Aspirin 1200mg|Asprin 600mg twice daily for 7 days. Administered by mouth.
3378029|NCT03400943|Experimental|Vilaprisan (A2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and in treatment period 2 for 12 weeks without a break.
3378030|NCT03400943|Experimental|Placebo+Vilaprisan (B1)|Placebo in treatment period 1 for 12 weeks, and vilaprisan (2 mg) in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3378031|NCT03400943|Experimental|Vilaprisan+Placebo (B2)|Vilaprisan (2 mg) in treatment period 1 for 12 weeks and placebo in treatment period 2 for 12 weeks, separated by 1 bleeding episode.
3378032|NCT03400917|Experimental|AV-GBM-1|Autologous dendritic cells loaded with tumor associated antigens from a short-term cell culture of autologous tumor cells. AV-GBM-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
3378033|NCT03397602|No Intervention|standard care|Participants do not participate in a on site structured exercise training program.
3378034|NCT03397602|Experimental|standard care + MICE|standard care + moderate-intensity continuous exercise training (MICE)
3378035|NCT03397602|Experimental|standard care + HIIT|standard care + high-intensity interval training (HIIT)
3280505|NCT01659307|Placebo Comparator|Lactose powder|Placebo for 7 days. Administered by mouth.
3280506|NCT01659333||Peritoneal dialysis, hypervolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
3378039|NCT03389828||1|The study population will consist of approximately 340 focus groups participants.
3378040|NCT03388606||Adolescents with Major Depression|Adolescents with a current or past history of meeting full critieria for major depressive disorder
3378041|NCT03388606||Adolescents with sub-threshold Major Depression|Adolescents with no past or current history of major depression who meet criteria at initialenrollment of sub-threshold major depression as defined in the protocol
3378042|NCT03388606||Health volunteer adolescents|Adolescents with no history of significant psychiatric or medical disorders (as defined in the protocol) currently or in the past.
3378049|NCT03374215||Adult AA with primary aldosteronism|Adult invdiviuals (age 18 or older) with HTN and discrete adrenal masses or bilateral hyperplasia of the adrenal glands, with outpatient positive ARR or string clinical suspicion for PA
3378050|NCT03374215||Family members age >= 7 of participants|DNA from relatives of patients (age 7 or older)
3378051|NCT03374137||obinutuzumab|Participants with follicular lymphoma or previously untreated chronic lymphocytic leukemia will be treated with obinutuzumab.
3378052|NCT03372057|Experimental|Dose Optimization Phase: Cohort 1|Duvelisib PO BID at a starting dose of 25 mg, with potential escalation on a per-patient basis to 50 mg and then 75 mg, based on the patient's response to and tolerance of therapy, in 28-day cycles.
3378053|NCT03372057|Experimental|Dose Optimization Phase: Cohort 2|Duvelisib 75 mg PO BID, administered in 28-day cycles.
3378054|NCT03372057|Experimental|Expansion Phase|Duvelisib administered in 28-day cycles (dose determined in Optimization Phase)
3378055|NCT03369223|Experimental|Part 1A: BMS-986249|
3378056|NCT03369223|Experimental|Part 1B: BMS-986249 + nivolumab (nivo)|
3378057|NCT03369223|Experimental|Part 2A Arm C: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
3378058|NCT03369223|Experimental|Part 2A Arm D: ipilimumab + nivo then nivo|Previously untreated unresectable stage III-IV melanoma
3280507|NCT01659333||Peritoneal dialysis, normovolemia|All calculations are automatically performed by the software of the BCM device. Absolute over hydration (OH) is the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative over hydration (Rel. OH) is defined as the OH to ECW ratio. Normohydration is defined when OH is between the 10th and the 90th percentile for healthy, age- and gender-matched individuals from the reference population, i.e., between 10th percentile (-1.1 L) to 90th percentile (+1.1 L), while volumes below and above this range define underhydration and overhydration, respectively.
3280508|NCT01659346|Experimental|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication
3280509|NCT01659346|Active Comparator|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
3280510|NCT01659359|Experimental|virtual reality glasses and Lidocaine|virtual reality glasses and 5 ml Lidocaine 2%
3280511|NCT01659359|Experimental|Lidocaine|5 cc Lidocaine2%
3280512|NCT01659372|Experimental|Low level laser therapy|this arm recieves low level laser therapy treatment for 12 sessions.
3280513|NCT01659372|Experimental|naproxen|this arm takes naproxen 500 mg twice daily for 3weeks
3280514|NCT01659398|Experimental|Enhanced external counterpulsation (EECP)|
3280515|NCT01659398|No Intervention|Subjects not receiving EECP|Control group to measure data from experimental group against.
3280516|NCT01659411||Adult CHD Patients|observational
3280517|NCT01659424|Other|Single Arm|This is a single arm study.
3280518|NCT01659437|Active Comparator|SR8|Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
3280519|NCT01659437|Experimental|CR8|Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks
3280520|NCT01659450|Experimental|Low energy dense|Diet of the LED group contained 30%fat, 15% protein and 55% carbohydrate. Most of the consumed carbohydrates in the LED diet group were fruits, vegetables and whole grains. In addition, this group received more servings of vegetables groups daily in the form of liquid diets or some menus contain more vegetables
3280521|NCT01659450|Experimental|control|In the group with a control diet, 35% of the energy was provided by fat, 15% by protein and 50% by carbohydrate
3280522|NCT01659463|Experimental|ICON - low viscosity resin|APPLICATION OF A LOW VISCOSITY RESIN IN EARLY PROXIMAL CARIES LESIONS
3280523|NCT01659463|Active Comparator|INSTRUCTIONS ORAL HYGIENE|INSTRUCTION ORAL HYGIENE AND DIET AND TOOPICAL FLUORIDE APPLICATIONS
3280524|NCT01659476|Experimental|Asthma|Individuals diagnosed with asthma.
3280525|NCT01659476|Experimental|Cough Variant Asthma|Individuals diagnosed with cough variant asthma.
3280526|NCT01659476|Experimental|Mch-induced cough w/normal airway sensitivity|Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.
3280527|NCT01659476|Experimental|Normal|Individuals with no history of asthma or chronic cough
3280528|NCT01659489||women undergoing laproscopy fo rsuspected adnexal torsion|
3280529|NCT01659502|Experimental|TL-118 alone or with pancreas cancer chemotherapy|
3280530|NCT01659541|Experimental|Procedure & Device|Procedure/Surgery: Implantation of device; Device: Expiratory Muscle Stimulator
3280531|NCT01659580|Experimental|T89 high dose|T89 225mg bid
3280532|NCT01659580|Experimental|T89 low dose|T89 150mg bid
3280533|NCT01659580|Experimental|Sanqi+Bingpian|225mg bid
3280534|NCT01659580|Placebo Comparator|Placebo|225mg bid
3280535|NCT01659593|Experimental|procog|cognitive remedial program 13 sessions over a 6-month period
3280536|NCT01659593|Placebo Comparator|DISINT|Interactive discussion program of 13 group sessions in a 6-month period
3280538|NCT01659619|Experimental|erythromycin|
3280539|NCT01659619|No Intervention|saline|
3280540|NCT01659645|Experimental|FACBC|
3280541|NCT01659658|Experimental|IXAZOMIB 4 mg + Dexamethasone 20 mg/day|IXAZOMIB 4 mg, capsules, orally, once on Days 1, 8, and 15; plus dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15, and 22 of each 28-day cycle; dexamethasone may be increased up to 40 mg/day after 4 weeks, if tolerated. Participants may continue to receive treatment until Progressive Disease (PD) or unacceptable toxicity, whichever comes first.
3280542|NCT01659658|Active Comparator|Physician's Choice|"Participants will receive one of the following treatment options as selected by the physician:~Dexamethasone 20 mg/day: dexamethasone 20 mg/day, orally, on Days 1-4, 9-12 and 17- 20 of each 28-day cycle.~Dexamethasone 20 mg/day + Melphalan 0.22 mg/kg: dexamethasone 20 mg/day, orally, on Days 1-4 of each 28-day cycle; plus melphalan 0.22 mg/kg, orally, on Days 1-4 every 28 days.~Dexamethasone 20 mg/day + Cyclophosphamide 500 mg: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus cyclophosphamide 500 mg, orally, on Days 1, 8 and 15 every 28 days.~Dexamethasone 20 mg/day + Thalidomide 200 mg/day: dexamethasone 20 mg/day, orally, weekly Days 1, 8, 15 and 22 of each 28-day cycle; plus thalidomide total dose up to 200 mg/day, orally.~Dexamethasone 20 mg/day+ Lenalidomide 15 mg/day: dexamethasone 20 mg/day, orally, weekly on Days 1, 8, 15 and 22 of each 28-day cycle; plus lenalidomide 15 mg/day, orally, for 21 days every 28 days."
3280543|NCT01659671|Active Comparator|Uvulopalatopharyngoplasty|One arm is Uvulopalatopharyngoplasty(intervention group of 32 patients), one arm is expectancy (control group of 33 patients). After six months the controls have delayed surgery and then both groups are followed for two years
3280544|NCT01659671|Active Comparator|Control|After six months the controls have delayed surgery then are followed for 2 year
3280545|NCT01659684|Experimental|standard intravenous immunoglobulin|Single arm evaluation of neurological consequences of congenital CMV infection in comparison with historical untreated controls.
3280546|NCT01659697||Intensive Lifestyle counseling|
3280547|NCT01659697||usual lifestyle counseling|
3280548|NCT01659710||Study Babies|Study video at 50-55 weeks gestational age, motor assessments at 24m (+/- 6 months) and again at 4 years (+/- 1 year).
3280549|NCT01659710||Control Babies|Video at 50-55 weeks gestational age, motor assessment at 24 months (+/- 6 months).
3378059|NCT03369223|Experimental|Part 2A Arm F: BMS-986249 + nivo|Previously untreated unresectable stage III-IV melanoma
3280550|NCT01659723|Active Comparator|A - Immediate start|Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
3280551|NCT01659723|No Intervention|B - delayed start|Delayed start: Start of treatment not before 6 months of inclusion in the study. No intervention is given during the initial period.
3280553|NCT01659762|Experimental|autologous mesenchymal stromal cells|
3280554|NCT01659775|Experimental|Sancuso patch|
3280555|NCT01659775|Active Comparator|Zofran|
3280556|NCT01659788|Experimental|Coenzyme Q10 concomitant treatment|"Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment~Dose: 600 mg by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the CoEnzyme Q10 if conceives or when the study is completed.~Other name: Ubiquinone"
3280557|NCT01659788|Placebo Comparator|Placebo|1 capsule by mouth daily beginning 3 months prior to IVF cycle. Patient will stop taking the placebo when she conceives or when the study is completed.
3280558|NCT01659814||Individuals with Major Depressive Disorder|
3280559|NCT01659814||Healthy Control Individuals|
3280560|NCT01659827|Sham Comparator|Control|Initial injections of Marcaine and Saline (one each)
3280561|NCT01659827|Experimental|0.5cc AmnioFix Injectable|Initial injections of Marcaine and 0.5cc AmnioFix (one each)
3280562|NCT01659827|Experimental|1.25cc AmnioFix Injectable|Initial injections of Marcaine and 1.25cc AmnioFix (one each)
3280563|NCT01659840|Other|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
3280564|NCT01659840|Other|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
3280565|NCT01659879|Experimental|multimedia information|Health information concerning the child's diagnosis, treatment and recovery time after evaluation by the pediatrician, using a 15 minutes long standardized health information package with multimedia elements from the Norwegian website www.syktbarn.no (English version: www.childhealthguide.com)
3280566|NCT01659879|Active Comparator|verbal information|Verbal health information by a nurse in the acute ward concerning the child's diagnosis, treatment and recovery time, after the evaluation by the pediatrician
3280567|NCT01659892|Active Comparator|Montelukast|5 mg Chewable Tablet
3280568|NCT01659892|Active Comparator|Singulair|5 mg Chewable Tablet
3280569|NCT01659905|Active Comparator|Montelukast|5 mg Chewable Tablet
3280570|NCT01659905|Active Comparator|Singulair|5 mg Chewable Tablet
3280571|NCT01659918|Active Comparator|Montelukast|10 mg Tablet
3280572|NCT01659918|Active Comparator|Singulair|10 mg Tablet
3280573|NCT01659931|Active Comparator|Montelukast|10 mg Tablet
3280574|NCT01659931|Active Comparator|Singulair|10 mg Tablet
3280575|NCT01659944|Experimental|Metoprolol alone then eliglustat + metoprolol|In Period 1 all participants will receive a single oral dose of metoprolol 50 mg on Day 1. In Period 2, participants will receive repeat oral doses of eliglustat 150 mg twice a day from Day 3 to Day 8 and a single oral dose of metoprolol 50 mg on Day 7.
3280576|NCT01659957|Experimental|Group Couples Couseling|Patients randomized to this arm will receive group couples counseling plus 12-step oriented alcoholism counseling.
3280577|NCT01659957|Experimental|One-on-One Couples Couseling|Patients randomized to this arm will receive one-on-one couples counseling plus 12-step oriented alcoholism counseling.
3280578|NCT01659970||Cohort|
3280579|NCT01659983|Experimental|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
3280580|NCT01659983|Active Comparator|Delayed primary wound closure|A wound will be left open with saline-soaked gauze packing after the operative procedure and will be sutured around day 3 to 7 after operation
3280581|NCT01660009|Experimental|Hypoglycemia First|Individuals will undergo a hyperinsulinemic hypoglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
3280582|NCT01660009|Experimental|Euglycemia First|Individuals will undergo a hyperinsulinemic euglycemic clamp in their 1st study visit after passing screening, and a euglycemic clamp in their second visit.
3280583|NCT01660048|Experimental|SILS TEP repair|Half of the patients will undergo laparoscopic total extraperitoneal inguinal hernia repair using a single port (Triport)
3280584|NCT01660048|Active Comparator|Multiports TEP repair|Half of the patients will undergo the conventional multiports total extraperitoneal inguinal hernia repair
3280585|NCT01660061||APS patients|Patients with antiphospholipid syndrome requiring long-term anticoagulant therapy with vitamin-K antagonists
3280586|NCT01660061||Controls|Patients without antiphospholipid antibodies requiring anticoagulant therapy with vitamin-K antagonists
3280587|NCT01660074|Experimental|Test food, reference food|Test food group of subject need to comsume 50g available carbohydrate of test food. One test food for one ocassion. Reference food need to comsume same 50g available carbohydrate of reference food, usually white bread or glucose syrup.
3280588|NCT01660100|Active Comparator|Pulmonary vein antrum isolation (PVAI)|Pulmonary vein antrum isolation (PVAI)
3378060|NCT03369223|Experimental|Part 2B Cohort 1: BMS-986249 + nivo|Advanced hepatocellular carcinoma (HCC)
3280589|NCT01660100|Active Comparator|PVAI plus left atrial posterior wall (LAPW) isolation|PVAI plus left atrial posterior wall (LAPW) isolation
3280590|NCT01660126|Active Comparator|Levothyroxine|Oral Levothyroxine, starting dose 25 or 50 micrograms increased to a maximum of 150 micrograms once daily.
3378061|NCT03369223|Experimental|Part 2B Cohort 2: BMS-986249 + nivo|Metastatic castration-resistant prostate cancer (CRPC)
3378062|NCT03369223|Experimental|Part 2B Cohort 3: BMS-986249 + nivo|Unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)
3378063|NCT03369223|Experimental|Part 2A Arm A: BMS-986249 + nivo then nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
3378064|NCT03369223|Experimental|Part 2A Arm B: BMS-986249 + nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
3378065|NCT03369223|Experimental|Part 2A Arm E: Nivo|"Previously untreated unresectable stage III-IV melanoma~Enrollment is closed for this Arm"
3378066|NCT03366168||Group 1|Ages 18-39 years
3280591|NCT01660126|Placebo Comparator|Placebo|Matched placebo
3280592|NCT01660139||Dermatology Clinic Patients|Patient attending dermatology clinics
3280593|NCT01660139||Primary Clinic Patients|Patient attending primary care clinics
3280594|NCT01660152|Experimental|Group A (vacuum therapy, holding erection for 2 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 2 minutes after undergoing RALP. Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
3378067|NCT03366168||Group 2|Ages 40-59 years
3378068|NCT03366168||Group 3|Ages 60 years and older
3378070|NCT03361865|Experimental|Pembrolizumab 200 mg + epacadostat 100 mg BID|Pembrolizumab + epacadostat
3378071|NCT03361865|Active Comparator|Pembrolizumab 200 mg + placebo BID|Pembrolizumab + placebo
3378072|NCT03354416||1/ Cohort 1|Subjects with an increased risk of prostate cancer or a diagnosis of prostatic cancer or suspicious for prostatic cancer lesions.
3378073|NCT03354390|Experimental|1|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLA-A*11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six hasexperienced a dose limiting toxicity (DLT).
3378074|NCT03344835||Prostate Cancer|Patients diagnosed with prostate cancer
3378076|NCT03320070|Experimental|Acthar Gel|Participants receive Acthar Gel as a 1 mL injection under the skin twice weekly
3378077|NCT03320070|Placebo Comparator|Placebo|Participants receive Placebo as a 1 mL injection under the skin twice weekly
3378078|NCT03307317||Adult pilots|Healthy adults between the ages of 18-65 years
3378079|NCT03307317||AR infants|Infants with 12 months of age (+/- 2 weeks) with one of the following: observed developmental delay, sibling of a child with autism, premature birth, small for gestational age.
3378080|NCT03307317||TD infants|Healthy infants with 9 months of age (+/- 2 weeks)
3378081|NCT03307304||Family members|Unaffected family members of individuals diagnosed with CLN3-Batten
3378082|NCT03307304||Proband/Affected Individuals|Individuals diagnosed with CLN3-Batten
3378083|NCT03304704||DSF Cohort|Accrual/Screening up to 1800 will include volunteers between the ages of 5 and 17 years and will be enrolled for genotyping and monthly blood sampling
3378084|NCT03304704||Genotype Cohort|Accrual/Screening up to 1500 will complete a single visit with blood draw for genotyping for future fidelity assessments with blood-fed, spray wild-caught mosquitoes.
3378085|NCT03304704||Parasite Surveillance Cohort|Accrual/Screening up to 1500 will be enrolled for genotyping and a minimum of six monthly blood sampling and mosquito wild catches wild-caught mosquitoes within their compound
3378088|NCT03304678||taking sirolimus|Subjects will come to the NIH and begin taking sirolimus 2mg
3378089|NCT03304600|Experimental|Active stimulation|10 sessions (1 per day during 2 week) of active tDCS stimulation
3378090|NCT03304600|Sham Comparator|Sham Stimulation|10 sessions (1 per day during 2 week) of sham stimulation
3378093|NCT03300830||group 1|Viral-assoc. cancer; HIV-neg pts with cancer that occurs in HIV pos; KSHV-assoc. cancer or related diseases e.g. multicentric Castleman disease; retrovirus-induced cancer; Idiopathic Castleman disease
3378094|NCT03294304|Experimental|Nivolumab, Cisplatin, & Gemcitabine|
3378098|NCT03285971|Experimental|CPP Alert Group|Device: Electronic CPP pager alert anesthesia providers will receive a pager alert when CPP decreases below 60 mmHg (median value over 5-minute epochs)
3378099|NCT03285971|No Intervention|Control|This arm will not receive the automated pager alerts.
3378100|NCT03278912||IBD|-Patients with IBD without a diagnosed PIDD.-First- or second-degree relatives of patients with a PIDD of interest who do not have a PIDD themselves, but have diagnosed or suspected IBD.
3378101|NCT03278912||Non-PIDD/non-IBD (healthy volunteers)|healthy volunteers
3378102|NCT03278912||PIDD|CGD cohort; IPEX syndrome cohort; CTLA4 haploinsufficiency cohort; LRBA deficiency and hypomorphic RAG deficiency cohorts
3378103|NCT03275103|Experimental|Arm A: Single Step Dose Escalation for Cevostamab|Study drug will be administered intravenously on a 21-day cycle. The step-up dose will be given on Cycle 1 Day 1 and the target dose will be given on C1D8. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
3280595|NCT01660152|Experimental|Group B (vacuum therapy, holding erection for 5 minutes)|Patients receive daily vacuum therapy over 10 minutes while holding erection for 5 minutes after undergoing RALP. Patients complete erection process 2 times.Patients complete erection process 5 times. SHIM questionnaire administration will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
3280596|NCT01660165||Observational|Pregnant women
3280597|NCT01660204|Active Comparator|Betalactam monotherapy|Preferred empirical treatment for patients in this arm is Beta-lactam monotherapy e.g. co-amoxiclav or ceftriaxone
3280598|NCT01660204|Active Comparator|Betalactam combination with macrolide|Preferred empirical treatment for patients in this arm is beta-lactam combination therapy with a macrolide e.g. ceftriaxone and erythromycin
3280599|NCT01660204|Active Comparator|Quinolone monotherapy|Preferred empirical treatment for patients in this arm is quinolone monotherapy e.g. moxifloxacin or levofloxacin
3280600|NCT01660217|Experimental|Initial Verbal Instruction Group|"The group who initially received only verbal instruction, and then later (in the crossover portion) received a written Eczema Action Plan (EAP)"
3280601|NCT01660217|Experimental|Written Eczema Action Plan (EAP)|The group given a written EAP after verbal instruction
3280602|NCT01660243|Active Comparator|MT-9938 2.5μg|
3280603|NCT01660243|Active Comparator|MT-9938 5μg|
3280604|NCT01660243|Active Comparator|MT-9938 10μg|
3280605|NCT01660243|Placebo Comparator|Placebo|
3280606|NCT01660295|Experimental|Certoparin control|Participants receive Certoparin 3,000 IU during period 1. Participants will receive 8,000 IU during period 2, if qualified as per medical criteria.
3280607|NCT01660295|Experimental|Certoparin Renal|"Participants receive dose escalation upon medical criteria qualification at each period:~Certoparin 3,000 IU once a day during period 1. Certoparin 3,000 IU twice a day during period 2. Certoparin 8,000 IU once a day during period 3. Certoparin 8,000 IU in the morning and 3,000 IU in the evening during period 4 OR Certoparin 8,000 IU twice a day during period 4."
3280608|NCT01660308||Tumor induced osteomalcia|
3280609|NCT01660347|Experimental|Supportive care (allogeneic PBSCT boost)|Patients undergo allogeneic PBSCT boost from cells selected for CD34+ using the CliniMACS CD34 Reagent System.
3280610|NCT01660360|Experimental|Tanibirumab|The total dose of Tanibirumab for each patient will depend on dose level assignment and the patient's weight. Dose levels to be potentially tested in Phase I include: 1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg, 16 mg/kg, and 20 mg/kg.
3280611|NCT01660373|Experimental|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
3280612|NCT01660373|Active Comparator|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
3280613|NCT01660386|Experimental|Sitagliptin|the subjects are asked to take one pill of sitagliptin(100mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3280614|NCT01660386|Experimental|Saxagliptin|the subjects are asked to take one pill of saxagliptin(5mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3280615|NCT01660386|Experimental|Glimepiride|the subjects are asked to take one pill of glimepiride(2mg po once) in 7am of experimental day then start bi-phase hyperglycaemic clamp at 9am.
3280616|NCT01660386|Other|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
3280617|NCT01660399|Experimental|Docetaxel/Boanmycin|Docetaxel 75mg/m2, intravenous infusion, day 1; Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
3280618|NCT01660399|Placebo Comparator|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1, 21days a cycle.
3280619|NCT01660425|No Intervention|treatment as usual with MPH|In the first twelve months of intervention the children receive treatment as usual with MPH and do not get any further intervention. Afterwards, the families get the opportunity to take part in the program which is then conducted for a duration of four months. Measurements are performed at the beginning of the program, after six moths, after 12 months and additionally after 16 months.
3280620|NCT01660425|Active Comparator|Psychosocial intervention|Parenting Enhancement Training as a form of psychosocial intervention is a guided program. Parents get the opportunity to discuss written information with a therapist in 20 minutes telephone calls. 14 telephone calls are offered. The whole intervention lasts for a period of one year. Booklets are mailed via post within the first 4 months. First 9 telephone calls are also within the first 4 months, usually every two weeks. Telephone calls 10 and 11 are within 5th or 6th month, telephone calls 12 to 14 are within 7th to 12th month with a two monthly time period in between.
3280621|NCT01660438||Stress urinary incontinence|Stress urinary incontinence
3280622|NCT01660464|Experimental|ADHD-Team|Intervention
3280623|NCT01660477|Experimental|Arm 1: isavuconazole only|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13
3280624|NCT01660477|Experimental|Arm 2 : LPV/RTV only|Lopinavir/ritonavir (LPV/RTV) twice daily (BID) on Days 1-12 and once on Day 13
3280625|NCT01660477|Experimental|Arm 3: isavuconazole and LPV/RTV|Isavuconazole three times per day (TID) on Days 1-2, and once daily (QD) on Days 3 thru 13 in combination with lopinavir/ritonavir twice daily (BID) on Days 1-13
3280626|NCT01660490||Proximal femur fractures with ORIF|Proximal femur fractures treated with ORIF
3280627|NCT01660503|Placebo Comparator|No SCF|Twice daily consumption of snack foods containing no SCF.
3280628|NCT01660503|Experimental|10 grams SCF|Twice daily consumption of snack foods, each containing 5 grams SCF
3280629|NCT01660503|Experimental|20 grams SCF|Twice daily consumption of snack foods, each containing 10 grams SCF
3280630|NCT01660516||Tea|Black tea ingestion
3280631|NCT01660529|Experimental|hTERT/Survivin Multi-Peptide Vaccination|single-arm Phase I study for patients with metastatic breast cancer who have failed at least one regimen for metastatic disease
3280632|NCT01660542|Experimental|doxorubicin/cyclophosphamide|Neoadjuvant Chemotherapy with Docetaxel(Monotaxel®) after Doxorubicin plus Cyclophosphamide
3280633|NCT01660555||Patiënts scheduled for colonoscopy|Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale <3
3280634|NCT01660568||relapsed or refractory NK/T cell lymphoma with gemcitabine|
3378104|NCT03275103|Experimental|Arm B: Multistep Dose Escalation for Cevostamab|In Cycle 1, participants will receive 2 step-up doses and a target dose. The step-up dose will be given on Cycle 1 Day 1 and C1D8. The target dose will be given on C1D15. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
3280635|NCT01660581|Experimental|CD133+|intramyocardial injection (electromechanical mapping based) of autological CD133+ cells, isolated from bone marrow
3280636|NCT01660581|Placebo Comparator|Placebo|intramyocardial injection (electromechanical mapping based) of placebo - 0,9% NaCl plus 0,5% solution of patients' serum
3280637|NCT01660594||Stable chest pain|All patients presenting with stable chest pain and referred by their general practitioners to the chest pain clinic in the hospital who had CT calcium scoring performed besides standard assessment.
3280638|NCT01660607|Experimental|Dose escalation|For the Phase I arm of the study the addition of planned numbers and ratios of Treg compared to Tcon will occur at defined time points after hematopoietic cell infusion. Each cohort will have 3 patients per group. The initial doses and ratios utilized will be 1 x 10^6/kg of T reg cells to 3x10^6/kg of Tcon cells at a 1:3 ratio. In order to progress to the next dose level, there must be no evidence of grade 3 or 4 acute GVHD.
3280639|NCT01660620|Experimental|betaxolol|betaxolol 0.25% 2 per day for 3 weeks
3280640|NCT01660620|Placebo Comparator|placebo|masked labeling also 2 per day administration
3280641|NCT01660633|Other|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|Subjects will receive only High-Dose Melphalan HCL for Injection (Propylene Glycol-free) at 200mg/m2 (100mg/m2/day for two days).
3280642|NCT01660646|Other|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
3280643|NCT01660646|No Intervention|control|
3280644|NCT01660659|Experimental|cooking with Biomass Briquettes and Rocket Stove|cooking with Biomass Briquettes and Rocket Stove
3280645|NCT01660659|No Intervention|standard cooking|standard way of cooking
3280646|NCT01660685|Experimental|Tracking + Journaling + Website|In addition to standard care, participants will complete daily tracking and journaling and receive weekly feedback based on their individual entries.
3280647|NCT01660685|Active Comparator|Enhanced Usual Care|Participants receive standard care
3280648|NCT01660724|Experimental|Ultrasound guided arterial puncture|Patients randomised to the this arm has arterial puncture performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
3280649|NCT01660724|Active Comparator|Conventional arterial puncture technique|Patients randomised to the active comparator arm has arterial puncture performed using the conventional technique
3280650|NCT01660750|Experimental|Carfilzomib, Cyclophosphamide, Dexamethasone|All eligible subjects will receive Carfilzomib, Cyclophosphamide, and Dexamethasone.
3280651|NCT01660776||DLBCL (diffuse large B-cell lymphoma)|DLBCL (diffuse large B-cell lymphoma)
3280652|NCT01660776||Hodgkin's lymphoma|Hodgkin's lymphoma
3280653|NCT01660776||metastatic breast cancer|metastatic breast cancer or with lymph node involvement
3280654|NCT01660776||immune thrombocytopenia (ITP)|immune thrombocytopenia (ITP)
3280655|NCT01660776||healthy volunteers|healthy volunteers
3280656|NCT01660776||non-small cell lung cancer|non-small cell lung cancer
3280657|NCT01660789|Other|Lifestyle intervention|Lifestyle intervention.
3280658|NCT01660828|Active Comparator|Intensive cycling test preceded by RIPC|Intensive cycling test preceded by a RIPC protocol.
3280659|NCT01660828|No Intervention|No intervention/ RIPC|Intensive cycling test not preceded by a RIPC protocol.
3280660|NCT01660841|Experimental|Arm 1|
3280661|NCT01660854|Experimental|Heterologous challenge|"Biological: Heterologous challenge with 5 infected mosquito bites (NF135) after previous CPS immunization and challenge.~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
3280662|NCT01660854|Active Comparator|Challenge control|"Biological: Plasmodium falciparum mosquito challenge by the bites of 5 Plasmodium falciparum infected mosquitoes (NF135).~Drug: Malarone treatment When thick smear positive, of at day 21 after challenge, all volunteers will be treated with malarone.~Other Name: atovaquone/proguanil"
3280663|NCT01660867|Placebo Comparator|0.9% saline + oral placebo|nebulized epinephrine + 0.9% saline + placebo => epinephrine + 0.9% saline
3280664|NCT01660867|Experimental|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
3280665|NCT01660867|Active Comparator|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
3280666|NCT01660880||aripiprazole|Patient group who is treated with aripiprazole
3280667|NCT01660919|Placebo Comparator|placebo|placebo
3280668|NCT01660919|Active Comparator|rosuvastatin 5|rosuvastatin 5 mg
3280669|NCT01660919|Active Comparator|rosuvastatin 10|rosuvastatin 10 mg
3280670|NCT01660919|Active Comparator|rosuvastatin 20|rosuvastatin 20 mg
3280671|NCT01660932|Placebo Comparator|placebo|placebo
3280672|NCT01660932|Active Comparator|omega 1|omega 1 gm
3280673|NCT01660932|Active Comparator|omega 2|omega 2 gm
3280674|NCT01660932|Active Comparator|omega 4|omega 4 gm
3280675|NCT01660945|Placebo Comparator|placebo|placebo
3280676|NCT01660945|Active Comparator|vytorin 10|vytorin 10 mg
3280677|NCT01660945|Active Comparator|vytorin 20|vytorin 20 mg
3280678|NCT01660958|Experimental|Infants: MNP|• Infants will receive sachets of multiple micronutrient powder (MNP) vs. placebo.
3280679|NCT01660958|Experimental|Infants: Early Learning|• Infant will receive early learning messages delivered in the home by village level workers vs. routine care.
3280680|NCT01660958|No Intervention|Infants: No intervention|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Infant phase. Routine care - no early learning intervention"
3280681|NCT01660958|Experimental|Infants: MNP/Early Learning|"Infants receive the MNP plus early learning intervention by receiving MNP sachets~Caregivers receive early learning messaged delivered at home biweekly for one year"
3280682|NCT01660958|Experimental|Preschoolers:MNP/High qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
3280683|NCT01660958|No Intervention|Preschoolers:Placebo/High qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as high quality preschools."
3378105|NCT03275103|Experimental|Arm C: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
3378106|NCT03275103|Experimental|Arm D: Multistep Dose Expansion for Cevostamab|The multistep dose expansion stage of the study may use the dosing and assessment schedule from the multistep dose escalation arm in Cycle 1, based on data from Arm B.
3378107|NCT03275103|Experimental|Arm E: Expansion Phase for Tocilizumab Pretreatment|All participants will receive a single dose of tocilizumab intravenously. An additional dose of tocilizumab may be instituted as premedication for subsequent Cycle 1 dose(s) of cevostamab and Cycle 1 cevostamab doses for other treatment arms.
3280684|NCT01660958|Experimental|Preschoolers:MNP/Low qual preschool|"Preschoolers will receive MNP fortified food in their Anganwadi Centers at the mid-day meal.~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
3280685|NCT01660958|No Intervention|Preschoolers:Placebo/Low qual preschool|"Placebo intervention include exposure to a single vitamin (B2 or riboflavin), plus the filler (maltodextrin).~Preschool quality will be assessed through observations using the Indian-modified ECERS and HOME Inventory for preschools. Using a median split, preschools will be classified as high/low quality. Using a randomization procedure, MNP vs. placebo will be assigned, nested within high/low-quality preschools.~Preschools that are classified as low quality preschools."
3280689|NCT01661075||mTBI|These individuals will have had an mTBI during their respective collegiate athletic season.
3280690|NCT01661075||healthy controls|Recruitment of healthy controls who have not suffered an mTBI for balancing testing.
3280691|NCT01661101|Experimental|Dabigatran|Dabigatran 110 mg capsule taken twice daily
3280692|NCT01661101|Experimental|Omeprazole|Omeprazole 20 mg capsule taken once daily
3280693|NCT01661101|Placebo Comparator|Placebo (dabigatran)|Dabigatran placebo taken twice daily
3280694|NCT01661101|Placebo Comparator|Placebo (omeprazole)|Omeprazole placebo taken once daily
3280695|NCT01661153||Cohort|
3280696|NCT01661166|Experimental|Fesoterodine 4mg|Fesoterodine 4mg, Oral once daily for three months
3280697|NCT01661166|Placebo Comparator|Placebo|Placebo Oral once daily for three months
3280698|NCT01661192|Experimental|AAT( Alpha 1 Antitrypsin)|Subjects who maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L will continue treatment with AAT according to the dosage group they were allocated to at the previous study(40mg/kg or 60mg/kg or 80mg/kg), intravenously, once a week for 6 consecutive weeks, at 24-week intervals for a duration of ~54 weeks.
3280699|NCT01661192|No Intervention|Follow up group|Subjects who have not maintained peak stimulated C-peptide secretion ≥ 0.2nmol/L or subjects with peak stimulated C -peptide secretion ≥ 0.2nmol/L who are reluctant to receive additional study drug, will be followed up only with no administration of investigational product
3280700|NCT01661218||complications|catheter-related venous thrombosis catheter-related infections
3280701|NCT01661231|Experimental|Investigational Stents|Device: Astron/Pulsar-18 Stents Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease.
3280702|NCT01661244|Experimental|Part A - Single dose escalation|
3280703|NCT01661244|Experimental|Part B - 14 day repeat dose escalation|
3280704|NCT01661257|Experimental|TIM-3|T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) is a novel transmembrane protein that is involved in the regulation of Th1-cell-mediated immunity.
3280705|NCT01661296|Active Comparator|Sodium stibogluconate|Intralesional SSG was administered in dose of 50 mg cm -2 of lesion once a week for 6 weeks (total six injections)
3280706|NCT01661296|Active Comparator|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia (1% lidocaine) using a current field radio-frequency generator (ThermoMed 1.8, Thermosurgery Inc).
3280707|NCT01661309|Placebo Comparator|Inactive lozenge|Inactive lozenge containing 2mg sucrose dissolved in the mouth taken after a meal every other day for 16 weeks
3280708|NCT01661309|Experimental|Methylcobalamin|Methylcobalamin 1mg lozenge dissolved in the mouth following a meal taken every other day for 16 weeks.
3280709|NCT01661322|Active Comparator|Intensive antiplatelet therapy|Participants in the intensive antiplatelet group will receive Aspirin+Dipyridamole+Clopidogrel triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
3280710|NCT01661322|No Intervention|Guideline antiplatelet therapy|This may be one or two antiplatelet drugs, as per standard treatment. Clopidogrel or aspirin and dipyridamole.
3378108|NCT03275103|Experimental|Arm F: Single Step Dose Expansion for Cevostamab|The single step dose expansion stage of the study may use the dosing and assessment schedule from the single dose escalation arm in Cycle 1, based on data from Arm A.
3378109|NCT03275103|Experimental|Arm G: Multistep Dose Expansion for Cevostamab|The multistep dose expansion stage of the study may use the dosing and assessment schedule from the multistep dose escalation arm in Cycle 1, based on data from Arm B.
3378110|NCT03269578||1|Patients with advanced, refractory cancers being treated on NCI/DTC studies
3280711|NCT01661335|Experimental|Ondansetron, dexamethasone, aprepitant|Arm A: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
3378111|NCT03258606||Individuals with affected capacity to consent|Individuals with who were unable to consent and were allowed by protocol to give surrogate consent.
3378112|NCT03253705||Controls|Healthy Controls
3378113|NCT03253705||Research Subjects|Research Subjects already enrolled on other NIH protocols
3378114|NCT03253692||Patients|People ages 18 years and older who need a computed tomography (CT) scan of the heart.
3378115|NCT03252847|Experimental|Low dose AAV2/5-RPGR|Single, subretinal administration of low dose AAV2/5-RPGR
3378116|NCT03252847|Experimental|Intermediate dose AAV2/5-RPGR|Single, subretinal administration of intermediate dose AAV2/5-RPGR
3378117|NCT03252847|Experimental|High dose AAV2/5-RPGR|Single, subretinal administration of high dose AAV2/5-RPGR
3378118|NCT03252756|Placebo Comparator|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
3378119|NCT03252756|Experimental|Phytocannabinoid cannabidiol (CBD)|600mg CBD/day (PO) for 4 weeks, immediately followed by 1200mg CBD/day (PO) for an additional 4 weeks (8 total weeks).
3378120|NCT03251989||1/Patient with a rare CNS diagnosis|A diagnosis of rare CNS Tumors
3378123|NCT03246126|Experimental|Valiant™Thoracoabdominal Stent Graft System|The implantation of the Valiant™ Thoracoabdominal Stent Graft System is conducted under fluoroscopic/angiographic guidance
3378124|NCT03240016|Experimental|Pembrolizumab and Abraxane|Pembrolizumab 200mg IV D1 Abraxane 100mg/m^2 IV D1 and D8 21 Day Cycles
3378125|NCT03233204|Experimental|Treatment (olaparib)|Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
3378126|NCT03226704||1|Patients 3-39 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy.
3378127|NCT03225196||Samples|We seek to measure a 665 exRNAs spanning a variety of classes in plasma from 4095 young to middle-aged adult participants in the Third Generation cohort of the FHS
3378128|NCT03225183||1|Framingham Heart Study participants
3378129|NCT03225157||1|Adult patients with head and neck squamous cell carcinoma of the upper aerodigestive tractwho will undergo cisplatin chemotherapy with concurrent radiation.
3378131|NCT03225131||0|participants without AMD meaning no large drusen (= 125 microns) or advanced AMD in either eye
3378132|NCT03225131||1|participants with large drusen (= 125 microns) in the study eye and no large drusen or advanced AMD (choroidal neovascularization (CNV) or geographic atrophy (GA)) in the fellow eye
3378133|NCT03225131||2|participants with bilateral large drusen (= 125 microns) with or without retinal pigment epithelial hypo/hyperpigmentary changes
3378134|NCT03225131||3|participants with large drusen (= 125 microns) in the study eye and advanced AMD (CNV or GA) in the fellow eye
3378135|NCT03225131||4|participants with findings of reticular pseudodrusen (RPD) in the study eye, without advanced AMD in the study eye, and any level of AMD in the fellow eye
3378137|NCT03217266|Experimental|Treatment (MDM2 inhibitor KRT-232, radiation therapy)|Patients receive MDM2 inhibitor KRT-232 PO on day 2, days 2 and 4, days 2-4, days 2-5, or days 1-5 of weeks -1 to 5. Patients also undergo radiation therapy daily on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity.
3378138|NCT03213704|Experimental|Treatment (larotrectinib sulfate)|Patients receive larotrectinib sulfate PO or via NG- or G-tube twice per day (BID) on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3378139|NCT03213652|Experimental|Treatment (ensartinib)|Patients receive ensartinib PO QD on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
3378140|NCT03210714|Experimental|Treatment (erdafitinib)|Patients receive erdafitinib PO QD on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
3378141|NCT03206099||Biological relatives|Biological relatives of probands, who may or may not also be co-enrolled on the proband's referring protocol.
3378142|NCT03206099||Healthy volunteers|Select internal controls
3378143|NCT03206099||Probands|Participants with a disease under investigation by another NIAID protocol on which they are enrolled, either at the NIH or CNHS.
3378144|NCT03203330|Active Comparator|Active Treatment (TG-C)|TG-C at 3 x 10e7 cells per single 2 mL intraarticular injection
3378145|NCT03203330|Placebo Comparator|Placebo Control (Normal Saline)|Normal saline, single 2 mL intraarticular injection
3378146|NCT03195322|Experimental|Pre-pectoral Tissue Expander|Pre-pectoral immediate tissue expander breast reconstruction with complete AlloDerm® coverage to reinforce breast tissues.
3280712|NCT01661335|Placebo Comparator|Ondansetron, Dexamethasone, placebo|Arm B: Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
3280713|NCT01661348||Prevena System placement|Subjects randomized to this group will receive standard skin preparation and closure followed by application of Prevena Incision Management System (Kinetic Concepts, Inc; San Antonio, TX) negative pressure wound therapy unit (experimental group).
3280714|NCT01661348||Standard of care postoperative care|Subjects randomized to this group will receive a standard surgical skin preparation, closure, and dressing (control group).
3280715|NCT01661361||vancomycin cohort|
3280716|NCT01661374||Mechanically Ventilated|
3280717|NCT01661374||Chronic obstructive pulmonary disease (COPD).|
3280718|NCT01661387||Plenadren|Modified release hydrocortisone
3280719|NCT01661387||Other Glucocorticoid Replacement Therapy|
3280720|NCT01661400|No Intervention|Control|No intervention
3280721|NCT01661400|Experimental|Metronomic Cyclophosphamide|Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children < 40kg or 100 mg daily for children > 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86
3280722|NCT01661400|Experimental|Thalidomide|Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86
3280723|NCT01661413||Acute Leukemia|Children diagnosed with acute leukemia, undergoing chemotherapy. Patients with acute leukemia will receive intrathecal methotrexate on day 1 plus intravenous vincristine on day 1 plus oral steroid on days 1-5 plus their regularly scheduled and ongoing daily oral 6-mercaptopurine at the start of a maintenance therapy cycle.
3280724|NCT01661426|Active Comparator|Low-Carbohydrate Diet first, then Low-Fat Diet (IR)|Participants who were more insulin resistant based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
3280725|NCT01661426|Active Comparator|Low-Fat Diet first, then Low-Carbohydrate Diet (IS)|Participants who were more insulin sensitive based on the median AUC for insulin concentrations measured from OGTT prior to randomization.
3280726|NCT01661439||Low molecular weight heparin|SC LMWH IN patients with recurrent pregnancy loss
3280727|NCT01661452||patients in UAB ER,|
3280728|NCT01661478||Emergency Department personnel|survey
3280729|NCT01661478||Department of Psychiatry personnel|survey
3280730|NCT01661491||Cystic Fibrosis|Infants and toddlers with Cystic Fibrosis
3280731|NCT01661491||Non-cystic fibrosis controls|Infants and toddlers without Cystic Fibrosis
3280732|NCT01661504|No Intervention|Referral Card Only|Women participants at control clinics will be given a referral card containing general information on IPV and a list of resources specific to their community
3280733|NCT01661504|Experimental|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions at 3 months post-baseline / initial counseling
3280734|NCT01661517|Experimental|Lifestyle Counseling|motivational interviewer
3280735|NCT01661530|Experimental|Vitamin E enhanced diet|Range of three vitamin E enhanced soups (400g/tin) containing 18-20mg vitamin in natural food form. Three portions per week
3280736|NCT01661530|Placebo Comparator|Non-enhanced dietary intervention|Range of three similar looking and tasting soups (400g/tin) with naturally low (<3mg) vitamin E content. Three portions per week
3280737|NCT01661543|Experimental|Bean consumption to lower cholesterol|This arm will consume 90 grams of beans per day for 5 out of 7 days for 6 weeks.
3280738|NCT01661543|Placebo Comparator|Control (rice) consumed to show results|The control group will consume 90 grams of rice per day for 5 out of 7 days for 6 weeks.
3280739|NCT01661543|Experimental|Peas consumed to lower cholesterol|This arm will consume 90g of peas per day for 5 days out of each week for 6 weeks.
3280740|NCT01661556|Experimental|Miconazole|OTC topical prescription used for fungal treatment that can be useful to the treatment of melasma due to its depigmenting properties.
3280741|NCT01661556|Active Comparator|Hydroquinone|Hydroquinone 4% cream (Topical use) a depigmenting agent used as reference will be used as control. It will be applied twice a day for 9 weeks.
3280742|NCT01661556|Placebo Comparator|Placebo|Moisturizer cream without pharmacological effects will be used as a control.
3280743|NCT01661569|Experimental|Headspace On-the-go app|Participants were given access to a 45-day mindfulness meditation programme via the Headspace smartphone app
3280744|NCT01661569|No Intervention|Waitlist control|Participants will be asked to wait for 8 weeks before starting the intervention
3280745|NCT01661582|Placebo Comparator|Filtered Air Exposure|Subjects will be exposed to filtered air for 1 hour during intermittent exercise in a purpose-built exposure facility
3280746|NCT01661582|Experimental|Dilute Diesel Exhaust Exposure|Subjects will be exposed to dilute diesel exhaust (~300 mcg/m3) for 1 hour during intermittent exercise in a purpose-built exposure facility
3280747|NCT01661608|Experimental|EOS|Collecting data on the use of the EOS for gastric tissue approximation during primary gastric restrictive procedures
3280748|NCT01661634|Experimental|Ularitide|Ularitide, lyophilizate for i.v. infusion, 15 ng/kg BW/min, for 48 hours
3280749|NCT01661634|Placebo Comparator|Placebo|Placebo lyophilizate for i.v. infusion
3280750|NCT01661647|Experimental|3D knee kinematic assessment|3D knee kinematic assessment under local anesthesia
3280751|NCT01661660|Active Comparator|Control subjects|Control subjects were people with memory complaints coming for a consultation and prevention.
3280752|NCT01661660|Experimental|Predementia / MCI patients|Subjects at predementia stage or MCI stage
3280753|NCT01661660|Experimental|Dementia patient|Subjects at demential stage
3280754|NCT01661673|Experimental|Arm 1|10 mg EVP-0962 Orally administered once daily for 14 days
3280755|NCT01661673|Experimental|Arm 2|50 mg EVP-0962 Orally administered once daily for 14 days
3280756|NCT01661673|Experimental|Arm 3|100 mg EVP-0962 Orally administered once daily for 14 days
3280757|NCT01661673|Experimental|Arm 4|200 mg EVP-0962 Orally administered once daily for 14 days
3280758|NCT01661673|Placebo Comparator|Arm 5|Placebo orally administered for 14 days
3280759|NCT01661699||Sleep apnea|Those suspected of sleep apnea and scheduled for polysomnography and treated with CPAP therapy.
3280760|NCT01661725|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5ml/ vial
3280761|NCT01661738|Experimental|Group ACYW135 Meningococcal Polysaccharide Vaccine|0.5 ml/ vial
3280762|NCT01661751|Experimental|ACYW135 Meningococcal Vaccine|0.5 ml/ dose, containing 50 μg of each antigen; lot No.: 20040601, manufacturing date: June 9, 2004 and the expiration date: till June 2006
3280763|NCT01661751|Active Comparator|A+C Meningococcal Vaccine|0.5 ml/ dose; each ampoule or dose contains 100 μg (one single human dose) and 50 μg of each antigen; lot No.: 20050805 and the expiration date: Aug. 24, 2007
3280764|NCT01661777|Other|Nasal steroid and Antihistamine|Patients with ETD will be given nasal steroid and antihistamine for 8 weeks.
3280765|NCT01661777|Active Comparator|Myringotomy tubes|Patients who fail nasal steroid and antihistamine treatment will have myringotomy tubes placed.
3280766|NCT01661777|Active Comparator|Low salt diet and diuretic|Patient's who fail to improve with myringotomy tubes will be treated with low salt det and diuretic
3280767|NCT01661803||group-A and group-B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
3280768|NCT01661803||group-A and group--B|Group-A (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15kg) and Group-B (0.5% hyperbaric bupivacaine 0.4 mg/kg for 5-15 kg or 0.3mg/kg for >15 with 1 mcg/kg preservative free clonidine).
3280769|NCT01661816||Within chemotherapy|30 couples, interviewed within chemotherapy (6 to 8 months after diagnosis)
3280770|NCT01661816||within Herceptin|30 couples, within herceptin treatment (the first year after diagnosis)
3280771|NCT01661816||within hormonotherapy|30 couples, within hormonotherapy (between 2 and 7 years after diagnosis)
3280772|NCT01661816||without hormonotherapy|30 couples, did not received hormonotherapy (1 year after diagnosis)
3280773|NCT01661816||end of treatment|30 couples, after end of treatments for patients who did received hormonotherapy (7 years after diagnosis)
3280774|NCT01661829||Biofeedback|Patients will undergo biofeedback therapy between 1st adjuvant chemotherapy and stoma closure(= after 3rd ajduvant chemotherapy)
3280775|NCT01661829||Kegel|Patients will be trained to take excersise for their anal sphincter by Kegel.
3280776|NCT01661842|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 96 study visit."
3280777|NCT01661842|Experimental|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 96 study visit.
3280778|NCT01661855|Active Comparator|Riluzole|
3280779|NCT01661855|Placebo Comparator|Placebo|
3280780|NCT01661868|Active Comparator|PARP Inhibitor Naive|Patients with no prior PARP inhibitor treatment
3280781|NCT01661868|Active Comparator|Prior PARP Inhibitor|Patients previously treated with a PARP inhibitor other than olaparib
3280782|NCT01661894|Active Comparator|Intervention|Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
3280783|NCT01661894|No Intervention|Wait-List Control|The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
3280784|NCT01661907|Experimental|Combined Epi-GA/PCEA|"Patients assigned to this group (experimental group) will receive combined epidural-general anesthesia (combined Epi-GA) and patient-controlled epidural analgesia (PCEA).~An epidural catheter will be placed before anesthesia induction. General anesthesia will be induced and maintained in the same manner as in the control group, with the addition of a continuous infusion or intermittent boluses of 0.375%-0.5% ropivacaine given through the epidural catheter for analgesia maintenance. Patient-controlled epidural analgesia will be provided for postoperative analgesia (established with 0.12% ropivacaine and 0.5 μg/mL sufentanil in 250 mL normal saline, programmed to deliver a 2-mL bolus with a lockout interval of 20 minutes and a background infusion of 4 mL/hr)."
3280785|NCT01661907|Active Comparator|GA/PCIA|"Patients assigned to this group (control group) will receive general anesthesia (GA) and patient-controlled intravenous analgesia (PCIA).~General anesthesia will be induced with midazolam, sufentanil, propofol and rocuronium. Anesthesia will then be maintained by inhalation of sevoflurane with or without nitrous oxide, and/or continuous intravenous infusion of propofol. Sufentanil and rocuronium will be given when needed. Patient-controlled intravenous analgesia will be provided for postoperative analgesia (established with 50 mg morphine in 100 mL normal saline, programmed to deliver a 2-mL bolus with a 6-10 minutes lockout interval and a 1 mL/hr background infusion)."
3280786|NCT01661920|Experimental|INTERVENTION GROUP|Patients with diagnosis of CAP with shorten treatment, defined as 5 days antibiotic treatment.
3280787|NCT01661920|Active Comparator|CONTROL GROUP|Patients with diagnosis of CAP which antibiotic treatment duration will be not modified by their doctors.
3280788|NCT01661959||Non-Operative|
3280789|NCT01661959||Operative|
3280790|NCT01661985|Active Comparator|Drug: Azithromycin 1g|Azithromycin 1 g,single dose (per os)
3280791|NCT01661985|Active Comparator|Drug: Doxycycline/lymecycline 9/10days|Tetracycline either as Doxycycline or during June and July lymecycline (due to lower risk of photo-sensitivity) given for treatment in 9(10)days (per os).
3280792|NCT01661985|Active Comparator|Azithromycin 1.5 g|Patients not randomized but receiving the first line treatment when a confirmed Mg infection
3280793|NCT01661998||Harms Study Group|
3280794|NCT01662011|Experimental|NAVA group|Patients ventilated with the mode of neurally adjusted ventilatory assist
3280795|NCT01662011|Active Comparator|PSV group|Patients ventilated with the mode of pressure support ventilation.
3280796|NCT01662037|Experimental|Bosentan group|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
3280797|NCT01662037|No Intervention|Routinely group|Routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
3280798|NCT01662050|Experimental|One arm for all patients.|Rituximab, Bendamustine, Cytarabine
3280799|NCT01662076|Experimental|Sublingual or Oral Liquid Homeopathy|The homeopathic remedy will be administered as 1 lactose/sucrose globule 2.5 mm in diameter to be administered sublingually up to 3 times per day or as 0.2 ml of a 30% ethanol based liquid homeopathic remedy administered orally up to 3 times per day. The homeopathic remedy and/or the homeopathic remedy potency can be changed on a daily basis during the course of treatment. However, only one homeopathic remedy and potency will be administered at a given time.
3280800|NCT01662089|Experimental|Chelate zinc suppliment|15mg Chelate zinc suppliment : additional to standard 5% minoxidil
3280801|NCT01662089|Placebo Comparator|Placebo drug|Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil
3280802|NCT01662128|Experimental|Xeloda|Xeloda
3280803|NCT01662154|Experimental|Nerve stimulator|Patients in this group will have their nerve blocks assessed with a common nerve stimulator (Stimuplex HNS 12, B.Braun, Germany).
3280804|NCT01662154|Active Comparator|Neurometer|Patients in this group will have their nerve block assessed using the Neurometer.
3280805|NCT01662167|Experimental|Multiple dose mtx|mtx
3280806|NCT01662167|Experimental|Single Dose|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
3280807|NCT01662180||Subfertile couples|"Subfertile couples presenting at fertility clinics with an indication for IUI in stimulated cycles~All patients will receive a fixed 75 IU recombinant follicle stimulating hormone per day conform normal stimulation protocol starting from cycle day 3, 4 or 5. Once the dominant follicle(s) reach a mean diameter of 16-18 mm, hCG (5000IU or 250 mcg) will be applied and insemination will be scheduled 36-42 hours later. Patients will be followed for the time of one menstrual cycle."
3280808|NCT01662193|Experimental|vitamin D3|vitamin D3 supplement 50000 IU vitamin D3 per week
3280809|NCT01662193|Experimental|calcium supplement|calcium supplement 1000 mg calcium carbonate daily
3280810|NCT01662193|Experimental|vitamin D and calcium supplement|vitamin D3 and calcium supplementation 50000 IU vitamin D3 per week and 1000 mg calcium carbonate daily
3280811|NCT01662193|Placebo Comparator|placebo|placebo
3280812|NCT01662206|Experimental|Probiotic|Capsules containing Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum
3280813|NCT01662206|Placebo Comparator|Placebo|Capsules containing placebo
3280814|NCT01662219|Experimental|superficial cervical plexus block|superficial cervical plexus block for experimental group
3280815|NCT01662219|No Intervention|No Block|no superficial cervical plexus block for the no intervention group
3280816|NCT01662232|Active Comparator|Green tea beverage|200 mg EGCG as green tea beverage.
3280817|NCT01662232|Active Comparator|Green tea extract|200 mg EGCG as green tea extract and same volume water as for tea beverage.
3280818|NCT01662232|Active Comparator|Epigallocatechin-3-gallate (EGCG)|200 mg EGCG and same volume water as for tea beverage.
3280819|NCT01662232|Placebo Comparator|Placebo (Water)|Same volume water as for all intervention arms.
3280820|NCT01662258|Experimental|Point-of-Care diagnostic laboratory test|Adult patients with community-acquired pneumonia (CAP) who are in the Targeted strategy group will undergo point-of-care (POC) diagnostic laboratory tests.
3280821|NCT01662258|No Intervention|Empiric therapy|Option of no application of POC laboratory tests
3280822|NCT01662271||adolescents with extreme obesity|BMI ≥35kg/m2
3280823|NCT01662271||adolescents with obesity|BMI 30-34.9kg/m2
3280824|NCT01662284||Triple Negative Breast|124I-NM404 in triple negative breast cancer
3280825|NCT01662284||Prostate|124I-NM404 in prostate cancer
3280826|NCT01662284||Colorectal|124I-NM404 in colorectal cancer
3280827|NCT01662284||Gastric|124I-NM404 in gastric cancer
3280828|NCT01662284||Ovarian|124I-NM404 in ovarian cancer
3280829|NCT01662284||Pancreatic|124I-NM404 in pancreatic cancer
3280830|NCT01662284||Esophageal|124I-NM404 in esophageal cancer
3280831|NCT01662284||Sarcoma|124I-NM404 in soft tissue sarcoma
3280832|NCT01662284||Head & Neck|124I-NM404 in head and neck cancer
3280833|NCT01662323|Active Comparator|Training of the GP's, intervention|General practitioners are trained to diagnose and treat heart failure according the recommendations of the NHG-standard.
3280834|NCT01662323|Active Comparator|Controle|General practitioners giving care as usual to their heart failure patients.
3280835|NCT01662349|Experimental|Plasma|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
3280836|NCT01662375||MIII|
3280837|NCT01662388|Experimental|automatrix band, Separation ring|The prepared teeth received Automatrix band (similar to the control group, product code# 62422513). The Automatrix was burnished against the adjacent tooth gently. Anatomical wedges were applied in the proximal area and then the separation ring (BiTine® round ring by Palodent systems, Dentsply International, DE, USA product # 659040) placed with the help of retainer forceps.
3280838|NCT01662388|Active Comparator|automatrix band|Teeth received Automatrix band alone (Wide-Regular type, dimensions 7.9 mm height and 0.05mm thickness, product code # 62422513). It was secured on the prepared tooth and burnished against the adjacent tooth gently. Anatomical wedges were placed in the inter-proximal area gingival to the cavity preparation.
3280839|NCT01662401|Experimental|Peripheral Nerve Block|bilateral rectus sheath and ilioinguinal nerve blocks under ultrasound guidance after induction of general anesthesia administered to subject
3280840|NCT01662401|Experimental|local anesthetic infiltration|local anesthetic infiltration will be administered after induction of general anesthesia
3378148|NCT03188796|Placebo Comparator|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
3280841|NCT01662414|Active Comparator|HMS 90®|
3280842|NCT01662414|Placebo Comparator|Placebo (Soy protein)|
3280843|NCT01662427||Questionniare|
3280844|NCT01662453||SUDEP Group|The SUDEP group refers to epileptic patients that had a sudden unexplained death; excludes trauma, drowning, status epilepticus, or other known cause, but there is often evidence of an associated seizure.
3280845|NCT01662453||Control Group|We will recruit living patients with epilepsy for the control group. In particular, epileptic patients with Dravet Syndrome of Idic 15.
3280846|NCT01662466|Active Comparator|DHEA+Testosterone|These patients will be administered the testosterone cream along with standard DHEA supplements
3280847|NCT01662466|Placebo Comparator|DHEA+Placebo|These patients will receive the placebo cream along with her DHEA supplements. In other words, no testosterone will be administered.
3280848|NCT01662518|Experimental|DDS-25|Intravitreal injection of DDS-25(Dexamethasone drug delivery system )
3280849|NCT01662544|Experimental|HHFNC|Heated High Flow arm
3280850|NCT01662544|Active Comparator|Standard Nasal Cannula|Standard treatment
3280851|NCT01662557|Active Comparator|Family Behavior Modification|Family-based behavior modification with parent and child using goal setting, self monitoring, reinforcement, behavioral skills training, and tasting opportunities.
3280852|NCT01662557|Other|Minimal Nutrition Information|Weekly mailings emphasizing healthy eating guidelines for families.
3280853|NCT01662570|Active Comparator|Beverage Choice Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake.
3280854|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included.
3280855|NCT01662622|Experimental|Sevoflurane|Anaesthesia was induced by 8% sevoflurane. Cisatracurium 0.15mg kg-1 was administered after loss of the lash reﬂex, then ventilated manually until the amplitude of T1 decreased to 0. Intubation was performed and switched to mechanical ventilation with a fresh gas flow 2L min-1. Gas concentrations were analysed using a gas analyser.The end-tidal concentration of carbon dioxide was maintained at 4.7kPa; an esophageal temperature probe was inserted and a warming unit was used if necessary to maintain normothermia (35.5°-38.5°). The surgical incision was performed at least 30min after tracheal intubation. When arterial blood pressure (MAP) decrease exceeding 20% of baseline values. Phenylephrine 0.1mg was administered intravenously if necessary to maintained MAP and recorded.
3280856|NCT01662661|Experimental|Arm AB|Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension followed by Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet, administered on Day 1.
3280857|NCT01662661|Experimental|Arm BA|Treatment B: 200 mg JNJ-47910382 formulated as an uncoated tablet followed by Treatment A: 200 mg dose of JNJ-47910382 formulated as a suspension, administered on Day 1.
3280858|NCT01662674|Experimental|G+M|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg
3280859|NCT01662674|Experimental|C|Combination of gemigliptin50mg/metformin HCl extended release 1000mg
3280860|NCT01662687|Experimental|Sancuso patch|
3280861|NCT01662687|Active Comparator|Kytril|
3280862|NCT01662700|Experimental|AS2|"Artesunate 2 mg/kg/day for 5 days Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
3280863|NCT01662700|Active Comparator|Chloroquine|"CH25: Chloroquine 25 mg/kg: 15 mg base/kg on the first days (D0), followed by 5 mg base/kg daily on the second and third day (day1-2) (total 25 mg base/ kg).~Combine with~Primaquine 15 mg is given daily for 14 days.~Or primaquine 45 mg is given once a week for 8 weeks in G6PD deficiency patients."
3280864|NCT01662713|Experimental|NMSC Imaging|Optical Frequency Domain Imaging (OFDI) will be used to look at non melanoma skin cancer (NMSC) lesion(s).
3280865|NCT01662726|Experimental|Irosustat|Irosustat 40mg OD for a minimum of 2 weeks until follow up FLT-PET/CT. For those patients consented to a repeat tumour biopsy, treatment will be extended to that day before the procedure.
3280866|NCT01662804|Experimental|hu3F8 and rIL-2|This phase I single arm trial assesses the toxicity of escalating doses of hu3F8 (day 1 and day 8) in the presence of 6 × 10^6 U rIL-2/m^2/d x 5 days sc (day 8 through day 12). These 2 doses of hu3F8 and 5 doses of rIL-2 constitute a treatment cycle.
3280867|NCT01662817||Intervention|Intervention group primary care physician (PCP) receives one day training in depression screening guidelines and uses guidelines for six months
3280868|NCT01662817||Control|Control group PCP manages depression in the usual way for six months
3280869|NCT01662830||MWCC clients|This study will be a systematic retrospective chart review of clients participating in the Jump Start (5 & 1) Plan at three different MWCC locations in Texas during the years 2007 - 2010.
3280870|NCT01662843||BRIPPED scan|Patients presenting with undifferentiated shortness of breath who receive the ultrasound scan in addition to standard of care
3280871|NCT01662843||Control|Patients who only receive the standard of care for undifferentiated shortness of breath
3280872|NCT01662869|Experimental|Onartuzumab+mFOLFOX6|Participants will receive onartuzumab 10 milligrams per kilogram (mg/kg) intravenous (IV) infusion + mFOLFOX6 (oxaliplatin, folinic acid, and 5-fluoruracil) regimen. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with onartuzumab. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with onartuzumab will continue treatment with onartuzumab until disease progression, unacceptable toxicity, or death.
3280873|NCT01662869|Placebo Comparator|Placebo+mFOLFOX6|Participants will receive onartuzumab matching placebo + mFOLFOX6. Participants will receive a maximum of 12 cycles (each cycle is 14 days) of mFOLFOX6 with placebo. Participants whose disease has not progressed after 12 cycles of mFOLFOX6 with placebo will continue treatment with placebo until disease progression, unacceptable toxicity, or death.
3280874|NCT01662921|Active Comparator|NPH and insulin lispro|Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average.
3280875|NCT01662921|Active Comparator|NPH and insulin glulisine|Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average.
3280876|NCT01662934|Sham Comparator|Sham|Using not functioning device
3280877|NCT01662934|Experimental|Experimental|Using functioning device
3280878|NCT01662947|Experimental|DUT Arm|"DUT: Transtek Wrist Blood Pressure Monitor TMB-1117~Measurement: Blood Pressure~Groups/Cohorts: DUT"
3280879|NCT01662947|Experimental|Reference Arm|"Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.~Measurement: Blood Pressure~Groups/Cohorts: Reference"
3280880|NCT01662973|Experimental|Conventional plus UC-MSC treatment|"Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit.~Participants will then be followed until the week 48 study visit."
3280881|NCT01662973|Placebo Comparator|Conventional plus placebo treatment|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
3280882|NCT01663025|Experimental|Hand Reflexology|Participants in this condition will receive hand reflexology, performed by a trained reflexologist during their treatment. This will be in addition to usual standard care therefore the surgeon will speak to the participant occasionally to ensure they are comfortable.
3280883|NCT01663025|No Intervention|Control|Participants in condition will form the control group for the study. They will receive usual standard care during treatment which will involve the surgeon speaking to them occasionally to ensure that they are comfortable.
3280884|NCT01663038|Active Comparator|Clopidogrel and Aspirin|
3280885|NCT01663038|Experimental|Copidogrel|
3280886|NCT01663051||Stent|Stent
3280887|NCT01663064|Experimental|Endovascular|Endovascular treatment
3280888|NCT01663077|Experimental|Clozapine|Clozapine tablet 150 mg at the day and 150 mg in the evening by mouth per day for 3 month
3280889|NCT01663090|Experimental|Nanoparticle enhanced MRI|
3280890|NCT01663116|Experimental|Treatment|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
3280891|NCT01663116|Placebo Comparator|Placebo|Lactate Ringer´s solution
3280892|NCT01663129||Leukemia Patient Group|Acute Lymphoblastic Leukemia (ALL)
3280893|NCT01663129||Rheumatic Disease Patient Group|"Juvenile Idiopathic Arthritis (JIA)~Systemic Lupus Erythematosis~Juvenile Dermatomyositis~Scleroderma~Overlap Syndromes~Sjogren's syndrome~Sarcoidosis~Systemic Vasculitis (excluding Kawasaki's disease and Henoch-Schonlein Purpura)~Systemic vasculitis as defined by the Chapel Hill Concensus Conference on Nomenclature. Other forms of systemic vasculitis, including Giant cell (temporal) arteritis, Takayasu's arteritis, Polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome, Microscopic polyangiitis, Essential cryoglobulinemic vasculitis, Cutaneous leukocytoclastic angiitis, Behcet's disease, Other vasculitis~Other rheumatic disease"
3280894|NCT01663129||Nephrotic Syndrome Patient Group|"Nephrotic syndrome will be classified according to the following categories:~Idiopathic nephrotic syndrome, without renal biopsy histology, presumed minimal change disease (MCD), Focal segmental glomerulosclerosis (FSGS), confirmed on biopsy, Minimal change disease, confirmed on biopsy Nephrotic syndrome with Henoch-Schonlein Purpura (HSP)."
3280895|NCT01663142||Patients who receive surgical resection for intestinal in CD|
3280896|NCT01663155||all enrolled subjects|Intervention is chest x-ray and CT scan. The chest x-ray image is read first without computer aided detection (CAD) and then a second time with computer aided detection (CAD) the CT scan is read by one reader. Subjects are asked to contribute breath and blood samples.
3280897|NCT01663168|Active Comparator|Rifabutin three times a week|Rifabutin 150mg tablet three times a week (Mon-Wed-Fri) in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
3280898|NCT01663168|Experimental|Rifabutin daily|Rifabutin 150mg tablet daily in combination with daily lopinavir/ritonavir taken as part of second-line ART for duration of TB treatment (24 weeks)
3280899|NCT01663181||urogynecologic patients undergoing outpatient cystoscopy|
3280900|NCT01663181||urogynecologic patients undergoing outpatient-urodynamics|
3280901|NCT01663194||N/L ratio tertile 2|patients were divided in to the tertiles
3280902|NCT01663194||N/L ratio tertile 3|patients were divided in to the tertiles
3280903|NCT01663194||N/L ratio tertile 1|patients were divided in to the tertiles
3280904|NCT01663207||obese individuals with prediabetes|
3280905|NCT01663220||obese individuals with type 2 diabetes mellitus|
3280906|NCT01663246|Active Comparator|Healthy Adults|Healthy adults over the age of 18, with no history of surgery to the salivary glands, or cancer therapy.
3280907|NCT01663246|Active Comparator|Radiation for Head and Neck Cancer|History of radiation therapy for head and neck cancer.
3280908|NCT01663298||Control group|Subjects must have never smoked and must be non-diabetic.
3280909|NCT01663298||Smoking group|Subjects must have had at least 5 pack-years of self-reported smoking history, must be currently smoking and must be non-diabetic.
3280910|NCT01663298||Diabetic group|Subjects must have type 2 diabetes. The condition must be diagnosed subjects must be treated by medications and/or insulin. A HbA1C test result either within past 3 months or performed in the first visit must be available. They must have never smoked.
3280911|NCT01663311|Experimental|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
3378149|NCT03188796|Experimental|High Dose Vitamin D3|"oral/enteral pharmacological dose of cholecalciferol (vitamin D3) - total dose 900,000~loading dose of 540,0000 (dissolved in 37.5 ml of medium chain triglycerides - MCT)~followed by 4000 IU daily (10 drops) for the entire active study period (90 days)"
3378150|NCT03188354|Experimental|CNS lymphoma patients|Patients included in the study will be examined with both 18F-FDG and 18F-Fluciclovine as well as standard MRI in the PET/MRI scanner on two consecutive days, both in primary staging and for therapy assessment
3280912|NCT01663311|Experimental|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
3280913|NCT01663324|Experimental|single site rTMS|"Low frequency temporoparietal transcranial magnetic stimulation~Intervention: Device: rTMS intervention 1"
3280914|NCT01663324|Experimental|multisite rTMS|"Combined high frequency dorsolateral prefrontal (unilateral) and low frequency temporoparietal (bilateral) stimulation~Intervention: Device: rTMS Intervention 2"
3378151|NCT03179436|Experimental|Escalation: Dose Level (DL) 1 Quavonlimab + Pembro: Cohort 1|On Cycle 1, Day 1 of the Dose Escalation Phase, advanced solid tumor participants receive a single monotherapy dose lead-in with quavonlimab at dose level 1 (DL1). On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL1 in combination with pembrolizumab (pembro) at pembrolizumab dose level 1 (PDL1) according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
3378152|NCT03179436|Experimental|Escalation: DL 2 Quavonlimab + Pembro: Cohort 2|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL2. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
3378153|NCT03179436|Experimental|Escalation: DL 3 Quavonlimab + Pembro: Cohort 3|On Cycle 1, Day 1 of the Dose Escalation Phase, participants with advanced solid tumors except NSCLC receive a single monotherapy dose lead-in with quavonlimab at DL3. On Cycle 2, Day 1, and for 3 subsequent cycles on Day 1 (Cycles 3 to 5), these participants receive quavonlimab at DL3 in combination with pembrolizumab at PDL1 according to Schedule 1. For all subsequent cycles (starting with Cycle 6), all participants receive pembrolizumab monotherapy according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
3378154|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm A|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1, both according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
3280915|NCT01663337|Active Comparator|Cognitive Processing Therapy (CPT)|
3280916|NCT01663337|Active Comparator|Relapse Prevention Therapy (RP)|
3280917|NCT01663337|No Intervention|Assessment Only (AO)|AO functions as a benchmark comparison condition. Consists of baseline assessment, daily interactive voice response (IVR) monitoring, and immediate post-test assessment. Not an active treatment
3378155|NCT03179436|Experimental|Confirmation: DL 1 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm B|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL1 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL1 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
3378156|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (NSCLC): Arm C|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and at DL2 quavonlimab according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
3378157|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 2 + Pembro (SCLC): Arm D|On Cycle 1, Day 1 of the Dose Confirmation Phase, participants with SCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1. On all subsequent cycles, participants receive pembrolizumab at PDL1 according to Schedule 1 and quavonlimab at DL2 according to Schedule 2. Participants will be treated for up to 35 cycles total on study.
3280918|NCT01663350||All-risk pregnant women|All-risk pregnancies undergoing conventional forms of prenatal screening
3280919|NCT01663389|Experimental|GSK1322322 1000 mg IV|On Day 1 of Period 1, after an overnight fast, subjects will receive GSK1322322 1000 mg IV single dose (containing approximately 45.5 microcurie [μCi] radioactive 14C-GSK1322322) for intravenous infusion over 60 minutes.
3280920|NCT01663389|Experimental|GSK1322322 1200 mg Oral Solution|On Day 1 of Period 2, after an overnight fast, subjects will receive GSK1322322 1200 mg oral solution single dose (containing approximately 54.5 μCi radioactive 14C-GSK1322322).
3280921|NCT01663415|Experimental|Enzalutamide|
3280922|NCT01663428|Experimental|Sup-ER Splint|Experimental group that will receive Sup-ER splint.
3280923|NCT01663428|Active Comparator|Control (Currently accepted treatment)|Control group that will receive the currently accepted treatment.
3280924|NCT01663441|Experimental|A1|"Patients in this treatment group will receive NL201(5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(7.5μg/kg).~Only for Dose-finding in Phase Ⅲa."
3280925|NCT01663441|Experimental|A2|"Patients in this treatment group will receive NL201(7.5μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201(5μg/kg).~Only for Dose-finding in Phase Ⅲa."
3280926|NCT01663441|Active Comparator|A|"Patients in this treatment group will receive NL201（optimal dosing dose）in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive rhIL-11(25μg/kg).~Only in Phase Ⅲb."
3280927|NCT01663441|Active Comparator|B|"Patients in this treatment group will receive rhIL-11(25μg/kg) in the first Chemotherapy cycle.Then，in the second Chemotherapy cycle，receive NL201（optimal dosing dose）.~Only in Phase Ⅲb."
3280928|NCT01663454|Experimental|Cogmed Robomemo working memory training|Participants will complete 25 sessions (5 weeks) of Cogmed Robomemo (Pearson assessment) working memory training
3280929|NCT01663467|Active Comparator|Ginkgo biloba only|control group Ginexin-F 80mg tablet will be given twice a day for 6 months.
3280930|NCT01663467|Experimental|Ginkgo biloba + modified TRT|"experimental group modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
3280931|NCT01663493|Other|Fine needle aspiration needle|standard Beacon FNA needle
3280932|NCT01663493|Other|fine needle biopsy needle|SharkCore fine needle biopsy needle
3280933|NCT01663519|Experimental|Prefabricated insoles|Prefabricated insoles with support in medial arch and metatarsal pad. A 2 mm top layer of cushioned material.
3280934|NCT01663519|Experimental|Custom made insoles 35 shore|Custom made insoles formed over an individual cast positive. 35 shore of hardness in material Ethyl Vinyl Acetate
3280935|NCT01663519|Experimental|55 shore Custom made insoles|Custom made insoles formed over an individual cast positive. 55 shore of hardness in material Ethyl Vinyl Acetate
3280936|NCT01663558|Active Comparator|imiquimod|"i. Each subject will use an imiquimod anal suppository three times weekly (overnight on Monday, Wednesday, Friday) for 12 weeks.~ii. Each subject will be asked to abstain from receptive anal sex during therapy period (12 weeks).~iii. If local imiquimod adverse effects are severe, a 7-day period off of treatment will be permitted.~iv. During 12 week therapy period, each subject will be evaluated 2, 4, 8, and 12 weeks after starting therapy. At each visit, subject will complete a therapy questionnaire and undergo anal Pap, HRA with biopsies as indicated, and anal HPV testing.~v. After therapy completed (12 weeks), subject will enter 12 month observation period."
3280937|NCT01663558|Active Comparator|ablative|"i. Subject will be referred to colorectal surgeon, will complete a therapy questionnaire, and will be treated in accordance with treatment algorithm which is already in use.~ii. Subject will be asked to abstain from receptive anal sex for 12 weeks after ablative therapy.~iii. After therapy, subject will enter 12 month observation period."
3280938|NCT01663558|No Intervention|Observation|"i. Given lack of accepted guidelines and outcome data on dysplasia management, the study PI will thoroughly discuss risks and benefits of observation/monitoring and treatment of dysplasia.~ii. If treatment is chosen, subject will be randomized to 1) ablative group, or 2) imiquimod group and begin therapy. Observation subjects will continue observation visits (observation questionnaire, anal Pap, HRA with biopsies as indicated, and anal HPV testing) every 3 months for 12 months (4 additional study visits)."
3280939|NCT01663597||Cohort 1|40 subjects with high grarde myopia ranging from -10 diopters to -4.01 diopters
3280940|NCT01663597||Cohort 2|40 subjects with moderate myopia ranging from -4 diopters to -1.01 diopter
3280941|NCT01663597||Cohort 3|40 subjects with emmetropia, -1 diopter to +1 diopter
3280942|NCT01663597||Cohort 4|40 subjects with hyperopia, +1.01 diopter and more
3280943|NCT01663610|Experimental|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
3280944|NCT01663610|No Intervention|Wait List Control (CONT)|Weekly registrations only. After 6 weeks the Internet-based course without therapist support well be offered (SelfSMART)
3280945|NCT01663649|Experimental|Deprexis|Deprexis (Web-based intervention deprexis consists of ten online modules (plus one introductory and one summary module) representing different psychotherapeutic strategies with a strong focus on evidence-based cognitive-behavioral techniques (e.g. interpersonal skills). Each module lasts approximately 10-60 minutes (e.g. depending on the user´s reading speed). Modules are sequential and organized as simulated dialogues. Each module refers and builds upon previous one. The program is delivered at no cost to participants.)
3280946|NCT01663649|Active Comparator|Wait-list|Wait-list group (Subjects receive access to deprexis after six months)
3280947|NCT01663662|Active Comparator|Tolvaptan Arm|"Tolvaptan 30 mg qd x 3 days and Low Dose Loop Continuous Infusion - Initial Dosing:~Furosemide - 10 mg/hr Bumentanide - 0.25 mg/hr Torsemide - 5 mg/hr"
3280948|NCT01663662|Placebo Comparator|Placebo|Placebo x 3 days and standard of care continuous infusion diuretic
3280949|NCT01663675||Trisomy 21 (Down syndrome)|Trisomy 21 (Down syndrome)
3280950|NCT01663688||Normative Data Collection|
3280951|NCT01663701|Active Comparator|Usual care|Patients are managed according to admitting doctors' orders. Blood cultures are drawn in all patients. Antibiotics are specified by the admitting doctors.
3280952|NCT01663701|Experimental|Simplified Severe Sepsis Protocol|This protocol consists of an early aggressive fluid strategy, early blood cultures and antibiotics, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings. Antibiotics are specified by the admitting doctors.
3280953|NCT01663753|Experimental|18F-FDG-PET|The 18F-FDG-PET will be performed 8 weeks following completion of brachytherapy (date of inclusion)
3280954|NCT01663766|Experimental|Milatuzumab|Milatuzumab will be added to the standard GVHD reduced intensity consitioning and prophylaxis regimen of fludarabine, busulfan, tacrolimus and low-dose methotrexate.
3280955|NCT01663792|Placebo Comparator|Placebo|5 g/d placebo (maltodextrin)in 10 500-mg capsules for 1 month
3280956|NCT01663792|Experimental|Seaweed|Seaweed (Undaria pinnatifida) given orally in ten 500-mg capsules for 1 month
3280957|NCT01663792|Placebo Comparator|Placebo2|5 g/d placebo in 10 500-mg capsules for one month
3280958|NCT01663805|Active Comparator|Everolimus|SCD/ECD: BXB (2x20mg, D1 and D4) + EVL (3.0 -8.0ng/ml) + MYF (1440mg/d)+ Prednisone
3280959|NCT01663805|No Intervention|mycophenolate sodium|SCD/ECD: BXB (2x20mg, D1 and D4) + TAC + MYF (1440mg/d)+ Prednisone
3280960|NCT01663818|Experimental|Treatment group|Treatment with Tack-IT Endovascular Staple
3280961|NCT01663831|Experimental|Topical Repellent & LLIN|
3280962|NCT01663831|No Intervention|Long Lasting Insecticidal Nets|"Brand Name LLIN: Olyset Net~Active ingredient: permethrin"
3280963|NCT01663844|Experimental|(Study 1) ICBT for insomnia and depression|
3280964|NCT01663844|Active Comparator|(Study 1) ICBT for depr. plus placebo insomnia intervention|
3280965|NCT01663844|Experimental|(Study 2) ICBT for insomnia with added support|
3280966|NCT01663844|Active Comparator|(Study 2) ICBT for insomnia with regular level of support|
3280967|NCT01663870||Breast Cancer Survivors|Patients in the LBJ General Hospital Cancer Survivorship Clinic.
3280968|NCT01663870||Clinic Stakeholders|Survivorship clinic stakeholders include clinic nurses, physicians, case managers, oncology patient navigators currently working with those in active treatment, information technology support professionals from the Harris County Hospital District (HCHD).
3280969|NCT01663883|Experimental|Healthy subjects|
3280970|NCT01663909|No Intervention|Standard care|
3280971|NCT01663909|Experimental|Guided imagery|
3280972|NCT01663948||Patients with Plastic bronchitis|
3280973|NCT01663961|Experimental|YM178 OCAS + digoxin|
3280974|NCT01663974||Bipolar disorder patients|
3280975|NCT01664000|Experimental|Kevetrin|thioureidobutyronitrile intravenous once/week for 3 weeks/ cycle
3280976|NCT01664013|Experimental|Neuronox|Neuronox® is a botulinum toxin type A (BoNT/A) product developed by Medytox Inc. (Medytox) of Korea. Neuronox® was first approved by the Korean Food and Drug Administration in 2006, and by Thai Food and Drug Administration in 2008.
3280977|NCT01664026|No Intervention|Control|Subjects assigned to the usual care group will receive general lifestyle recommendations as per their country standards of care.
3280978|NCT01664026|Experimental|Web|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
3280979|NCT01664026|Experimental|Web+|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
3280980|NCT01664065|Experimental|AZ drug: A|200 mg Ceftaroline fosamil 1h infusion
3280981|NCT01664065|Experimental|AZ drug: B|600 mg Ceftaroline fosamil 1h infusion
3280982|NCT01664143|Placebo Comparator|Placebo|
3280983|NCT01664143|Experimental|RO5508887|
3280984|NCT01664156|Experimental|Korean red ginseng|The patients will receive Korean red ginseng(Korean Red Ginseng Powder Capsule®; Korea Ginseng Corporation, Daejeon, Korea). Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
3280985|NCT01664156|Placebo Comparator|placebo|Placebo Korean red ginseng capsule contain cornstarch powder with the same color and taste as Korean red ginseng. Patients will be requested to take 6 capsules 2 times a day (1h after breakfast and dinner).
3280986|NCT01664169||Single group|"The samples required for this study are stored in the CALGB Pathology Coordinating Office at The Ohio State University from patients enrolled on protocol CALGB-80303. No additional samples are required from patients.~The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3, IL-8, bFGF, PDGF-C, ICAM-1, and PlGF."
3280987|NCT01664182|Experimental|Arm I (trebananib monotherapy)|Patients receive trebananib IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3280988|NCT01664182|Experimental|Arm II (trebananib and anti-VEGF therapy)|Patients receive trebananib as in Arm I and either bevacizumab IV over 30-90 minutes on days 1, 15, and 29, pazopanib hydrochloride PO QD on days 1-42, sorafenib tosylate PO BID on days 1-42, or sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity.
3280989|NCT01664195|Other|Group A|Epoetin alfa Test drug in the first period and comparator drug in the second period.
3280990|NCT01664195|Other|Group B|Epoetin alfa Comparator Drug in the first period and test drug in the second period
3280991|NCT01664221|Experimental|Eritromax|Eritromax (Epoetin alfa) intravenous administration, dose: 100 IU/kg
3280992|NCT01664221|Active Comparator|Eprex|Eprex (Epoetin alfa) intravenous administration: 100 IU/kg
3280993|NCT01664234|Experimental|laryngoscopy with simultaneous insufflation of oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
3280994|NCT01664234|Placebo Comparator|laryngoscopy without simultaneous oxygen insufflation|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
3280995|NCT01664260|Experimental|N-acetylcysteine + Escitalopram|The subjects with posttraumatic stress disorder, treated with N-acetylcysteine in addition to escitalopram
3280996|NCT01664260|Placebo Comparator|Placebo + Escitalopram|The subjects with posttraumatic stress disorder, treated with placebo in addition to escitalopram
3280997|NCT01664507|Active Comparator|conventional dose epinephrine|L-epinephrine (1:1000) 0.5 mL/kg (maximum 5mL) + normal saline : total 5mL
3280998|NCT01664507|Experimental|low dose epinephrine|L-epinephrine (1:1000) 0.1 mL/kg (maximum 1mL) + normal saline : total 5mL
3280999|NCT01664520|Experimental|Dexmedetomine infusion|
3281000|NCT01664546||Molecular blastocyst karyotype|Trophectoderm biopsy for genetic study by aCGH
3281001|NCT01664572||Healthy subjects|
3281002|NCT01664585|Experimental|Training group|"The rationale and means for the exercise program are to~Motivate and teach participants for postural and motor control and strengthening exercises~Monitor and motivate to continue exercise training, and to increase their physical activity~Training is organised six times as a 60-min session during six months: two individually supervised sessions, and four following training sessions will be accomplished in groups of 10 participants guided by an experienced physical therapist. Three weekly similar home training sessions are recommended for participants. Information on amount of exercise sessions per week and repetitions of each exercise will be collected via exercise diary. To perform home training, a DVD and/or booklet will be provided to participants in the training group."
3281003|NCT01664585|Sham Comparator|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0), and the participants in this group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
3281004|NCT01664598|Experimental|RoActemra/Actemra|
3281005|NCT01664611|Experimental|Treatment arm|Participants in this arm will receive remote ischaemic conditioning on a daily basis for 4 weeks post MI
3281006|NCT01664611|Sham Comparator|Sham arm|Participants in this arm will receive sham ischaemic conditioning on a daily basis for 4 weeks post MI
3281007|NCT01664637|Experimental|TZP-102 three times a day|10 mg TZP-102 will be taken 30 minutes prior to each main meal for a total of three daily doses.
3281008|NCT01664637|Placebo Comparator|Placebo three times a day|Placebo will be taken 30 minutes prior to each main meal for a total of three daily doses.
3281009|NCT01664650|Placebo Comparator|Lifestyle counseling|Placebo tablets. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3281010|NCT01664650|Experimental|Genistein|Genistein 54 mg/day in 2 tablets for 12 months. All participants were counseled on an moderate hypocaloric, Mediterranean-style diet composed of 25% to 30% energy from fat, less than 10% energy from saturated fatty acids, 55% to 60% energy from carbohydrates, and 15% energy from protein, with a cholesterol intake less than 300 mg/d and fiber intake of 35 g/d or greater.
3281011|NCT01664663|Active Comparator|Arm A:Standard radiochemotherapy|Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
3281012|NCT01664663|Experimental|Arm B Escalated radiochemotherapy|Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.
3281013|NCT01664676|Experimental|Liraglutide|1.2 mg liraglutide sc. (single-dose)
3281014|NCT01664676|Placebo Comparator|Placebo-liraglutide|Placebo liraglutide sc. (single-dose)
3281015|NCT01664689|Active Comparator|DiscoVisc|microcoaxial phacoemulsification performed with discovisc
3281016|NCT01664689|Active Comparator|Healon 5|microcoaxial phacoemulsification using healon 5
3281017|NCT01664689|Active Comparator|Celoftal|microcoaxial phacoemulsification using celoftal
3281018|NCT01664702|Experimental|Recommended dairy diet|Recommended servings of dairy products per day
3281019|NCT01664702|Experimental|Low dairy diet|One or fewer dairy servings per day
3281020|NCT01664715|Active Comparator|150 Minutes per Week|Performs 150 minutes of physical activity per week.
3281021|NCT01664715|Active Comparator|225 Minutes per Week|Performs 225 minutes of physical activity per week.
3281022|NCT01664715|Active Comparator|300 Minutes per Week|Performs 300 minutes of physical activity per week.
3281023|NCT01664728|Experimental|Abiraterone acetate|
3281024|NCT01664754|Experimental|Treatment (exemestane, pemetrexed disodium, and carboplatin)|Patients receive exemestane PO QD on days 1-28 and pemetrexed disodium IV over 15 minutes and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3281025|NCT01664767|Experimental|Thermal water inhalation|Patients will perform 12 days of sulfur thermal water inhalation
3281026|NCT01664767|Placebo Comparator|Isotonic saline inhalation|Patients will perform 12 days of isotonic saline inhalation
3281027|NCT01664780||Patients after liver transplantation|
3281028|NCT01664819|Active Comparator|Antioxidant supplementation|Randomized to receive antioxidant supplementation (vitamin C, 500 mg; beta carotene, 15 mg; and alpha-tocopherol, 400 IU) three times per week for five years.
3281029|NCT01664819|Placebo Comparator|Placebo|Randomized to receive placebo three times per week for five years
3281030|NCT01664832|Experimental|S-nIMV|nIMV synchronized using abdominal pressure capsule sensor device
3281031|NCT01664832|Placebo Comparator|nIMV|non-synchronized nasal intermittent mandatory ventilation group
3281032|NCT01664845|Active Comparator|metformin, pegylated-IFN, ribavirin|metformin,pegylated-IFN and ribavirin
3281033|NCT01664845|Placebo Comparator|Pegylated-IFN and ribavirin|pegylated -IFN and ribavirin
3281034|NCT01664871|Experimental|Levels of SIlver and Fluoride in Plasma|
3281035|NCT01664884||Bipolar Disorder Patients|Bipolar Disorder Patients, with age between 18 to 40 years old, at euthymic phase.
3281036|NCT01664884||Schizophrenia Patients|Schizophrenia Patients, with age between 18 to 40 years old, with minimum or none positive symptoms.
3281037|NCT01664910|Experimental|Treatment (transplant)|Patients receive inotuzumab ozogamicin IV over 1 hour on day -13, and fludarabine phosphate IV over 1 hour and bendamustine hydrochloride IV over 30 minutes to 1 hour on days -5 to -3. Patients with CD20-positive disease also receive rituximab IV over 4-6 hours on days -6, 1, and 8 and patients with MUD receive anti-thymocyte globulin IV over 3-4 hours on days -2 to -1. All patients also receive tacrolimus IV over 24 hours continuously or PO daily beginning on days -2 to 180 followed by taper in the absence of GVHD and methotrexate IV over 30 minutes on days 1, 3, and 6 (1, 3, 6, and 11 in patients with MUD). Patients undergo allogeneic BM or PBSC transplant on day 0.
3281038|NCT01664936||pts receiving a PET/CT scan with Metastatic LNs|This study seeks to optically image the Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I in a cohort of patients with primary tumor sites and from pathologic lymph nodes after routine 18F-FDG PET 31I radiotherapy and/or investigational study scans. We will include a subset of patients with normal lymph nodes during screening. This subset of patients will be imaged as a negative control for this study.
3281039|NCT01664962||Patients|Women with severe Vulvodynia
3281040|NCT01664962||Healthy controls|Women without vulvodynia
3281041|NCT01664988|Experimental|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
3281042|NCT01664988|Experimental|breath control|include deep diaphragmatic breathing and decrease breath rate to 6-10/min
3281043|NCT01664988|Other|control|received routine care of clinic or health center and control their blood pressure weekly and use drugs if necessary
3281044|NCT01665001|Experimental|Multiagent induction-consolidation|Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
3281045|NCT01665014|Experimental|Total marrow irradiation|Double autologous hematopoietic stem cell transplantation using TMI and HD-Mel
3281046|NCT01665027|Experimental|vacuum|Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head. He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers).
3281047|NCT01665027|Experimental|routine manual maneuvers for fetal head extraction|"Procedure/Surgery:~fetal head techniques like fundal pushing, pulling technique or reverse breech extraction"
3281048|NCT01665066|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
3281049|NCT01665066|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
3281050|NCT01665066|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
3281051|NCT01665066|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
3281052|NCT01665066|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
3281053|NCT01665079|Experimental|Propofol|14 obese patients(IMC>35 kg m-2) scheduled for laparoscopic bariatric surgery
3281054|NCT01665105|Experimental|Zusanli Group|electroacupuncture at both Zusanli on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3281055|NCT01665105|Active Comparator|Yanlingquan Group|electroacupuncture at both Yanglingquan on the leg, and record simultaneously the pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3281056|NCT01665105|Sham Comparator|Sham Group|acupuncture without electrical stimulation at non-acupoint on the leg, and record simultaneously pulse rate variability as well as take the skin blood flow and skin temperature recordings at Hoku's and Zhongzhu's region of right hand.
3281057|NCT01665118|Experimental|Treated Thigh|Trusculpt (Radio Frequency) Device
3281058|NCT01665118|No Intervention|Untreated Contra-lateral Thigh|To be used as the self control in this split body study.
3281059|NCT01665131|Experimental|Subcutaneous ICD group|
3281060|NCT01665183|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
3281061|NCT01665196|Experimental|18F-FDG PET/CT scanning|18F-FDG PET/CT scanning will be performed in patients with IgG4RD to determine the pictorial characteristics and measure the standardized uptake values (SUVs) of the lesions and their response to treatment.
3281062|NCT01665209|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
3281063|NCT01665209|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
3281064|NCT01665222|Experimental|Morphine Sulfate 60mg Extended-release tablets|A single oral dose of Morphine Sulfate 60mg Extended-release tablets of Ohm Laboratories Inc.
3281065|NCT01665222|Active Comparator|MS Contin® 60 mg Controlled-release tablets|A single oral dose of MS Contin® 60 mg Controlled-release tablets of Purdue Pharma L.P.
3281066|NCT01665235|Active Comparator|amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
3281067|NCT01665235|Experimental|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
3281068|NCT01665248|Other|stable angina pectoris or acute coronary syndrome|
3281069|NCT01665274|Active Comparator|XELOX adjuvant group|"D2 resection~XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 6 cycles"
3281070|NCT01665274|Experimental|XELOX neoadjuvant|"XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy before operation.~D2 resection~After operation:~CR/PR: XELOX (Drug: Capecitabine 1,000 mg/m² twice daily. Film coated tablets of 500 mg. d1-14 q3w Drug: Oxaliplatin IV infusion, 130mg/m² d1 q3w) 3 cycles chemotherapy after operation. SD/PD:,ST(Drug: S-1，40-75mg twice daily. d1-14 q3w Drug: Paclitaxel IV infusion 135mg/m2 d1; q3w) 3 cycles chemotherapy after operation."
3281071|NCT01665313||participants|Full-time faculty with morning and afternoon outpatient clinics on the same day in SNUH
3281072|NCT01665326||Infantile Pompe disease|Individuals with a confirmed diagnosis of Infantile Pompe disease
3281073|NCT01665339|Experimental|preload|subjects in preload group consumed salad, yogurt and water 15 minutes before the main meal.
3281074|NCT01665339|Experimental|control|subjects in control group consumed salad and yogurt with meal.
3281075|NCT01665352|Experimental|TTP054 400 mg|
3281076|NCT01665352|Experimental|TTP054 200 mg|
3281077|NCT01665352|Experimental|TTP054 800 mg|
3281078|NCT01665352|Placebo Comparator|Placebo|
3281079|NCT01665365|Experimental|1. Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention (intervention group).
3281080|NCT01665365|No Intervention|2.|Primary percutaneous coronary intervention (control group).
3281081|NCT01665378|Experimental|Multiple micronutrient - 1|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
3281082|NCT01665378|Active Comparator|Iron and folic acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
3281083|NCT01665378|Placebo Comparator|Folic Acid - 1|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
3281084|NCT01665378|Experimental|Multiple Micronutrient - 2|"The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Multiple micronutrient groups 1 and 2 receive:~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
3281085|NCT01665378|Active Comparator|Iron and Folic Acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Iron and folic acid groups 1 and 2 receive: iron (60mg) and folic acid (2800μg), based on current WHO recommendations for WRA.
3281086|NCT01665378|Placebo Comparator|Folic acid - 2|The study population has been divided into 6 arms receiving 3 different pre-pregnancy interventions. The study uses a double blind design therefore the supplements are differentiated by a letter and a color: P/Purple, Q/Black, S/Brown, M/Green, T/Orange, H/Red. Folic acid groups 1 and 2 receive: 2800 μg FA once a week during the pre-pregnancy period.
3281087|NCT01665391|Experimental|fresolimumab 1 mg/kg total body weight|
3281088|NCT01665391|Experimental|fresolimumab 4 mg/kg total body weight|
3281089|NCT01665391|Placebo Comparator|Placebo|
3281090|NCT01665404|Experimental|Dosing Period 1|
3281091|NCT01665404|Experimental|Dosing Period 2|
3281092|NCT01665417|Experimental|Experimental Icotinib|Icotinib: 125mg, oral administration, three times per day.
3281093|NCT01665417|Active Comparator|Chemotherapy Regimen 1|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
3281094|NCT01665417|Active Comparator|Chemotherapy Regimen 2|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
3281095|NCT01665456||Cases (women with complications)|Cases are women aged 15-49 years who delivered within 12 months prior to data collection and had experienced obstetric complication(s) that either necessitated treatment or hospitalization in order to prevent the likelihood of death of the mother.
3281096|NCT01665456||Control (women who did not experience any complications)|Controls are women aged 15-49 years who delivered within 12 months prior to data collection. They did not have or develop any of the complications which cases experienced or suffered from.Although controls did not have complications, they were individually matched on the basis of age and location. The idea was to compare how many cases were exposed versus how many controls were exposed.
3281097|NCT01665469|Placebo Comparator|Placebo|Soft gel capsule without test material
3281098|NCT01665469|Experimental|Tomato extracted lycopene|Soft gel cups for oral use
3281099|NCT01665482|Active Comparator|Saturated fat rich diet|
3281100|NCT01665482|Active Comparator|Monounsaturated fat rich diet|
3281101|NCT01665482|Active Comparator|Carbohydrate/ Low fat diet|
3281102|NCT01665495|No Intervention|Pericardiocentesis|Pericardial fluid drained by simple echo-guided pericardiocentesis
3281103|NCT01665495|Active Comparator|Extended pericardial drainage|Extended pericardial drainage will include pericardiocentesis followed by an intermittent pericardial catheter drainage. Pericardial drainage will be kept till daily fluid return<30ml
3281104|NCT01665521|Experimental|HEART Pathway|The HEART Pathway will be used for real time clinical decision making. Physicians will receive care recommendations according to the HEART Pathway, based on HEART score and serial cardiac biomarkers. This will help physicians identify low-risk patients for early discharge with no objective cardiac testing.
3281105|NCT01665521|No Intervention|Usual Care|Conventional Care cardiac testing. Patients will undergo cardiac testing as determined by their treating physicians.
3281106|NCT01665534|Experimental|Effect of salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks. During the low salt intake period, patients received a 10-20 mmol sodium diet + placebo tablets for two weeks.
3281107|NCT01665547|Active Comparator|l-carnitine|adding 3gm l-carnitine from day 1 to day 12 of induced the menstrual cycle by 50 mg clomiphene
3281108|NCT01665560||Smokers--Currently Smoking|Individuals that are right handed, and not claustrophobic were recruited. This same group was used for the smoking-group and refrain from smoking was evaluated by CO2 evaluation. To be classified as smokers, they had to report smoking 3-10 cigarettes daily for at least the last year and have a carbon monoxide reading of CO >10 ppm.
3281109|NCT01665560||Non-Smoker|Healthy individuals meeting the inclusion criteria who claim to not smoke. This is confirmed w/ CO testing.
3281110|NCT01665573|Active Comparator|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
3281111|NCT01665573|Placebo Comparator|Placebo|Placebo
3281112|NCT01665586|Placebo Comparator|Group C|: Spinal anesthesia with 6mg bupivacaine and intrathecal placebo(normal saline) added
3281113|NCT01665586|Active Comparator|Group F|: Spinal anesthesia with 6mg bupivacaine and intrathecal small dose of fentanyl(20micro gram)
3281114|NCT01665612|Experimental|MPDS1|Contact lens care solution
3281115|NCT01665612|Active Comparator|MPDS2|Contact lens care solution
3281116|NCT01665612|Active Comparator|MPDS3|Contact lens care solution
3281117|NCT01665625|Experimental|regional interventional chemotherapy group|
3378158|NCT03179436|Experimental|Confirmation: DL 2 Quavonlimab Schedule 1 + Pembro (NSCLC): Arm E|On Cycle 1, Day 1 of the Dose Confirmation Phase and during all subsequent cycles, participants with NSCLC receive quavonlimab at DL2 in combination with pembrolizumab at PDL1 according to Schedule 1. Participants will be treated for up to 35 cycles total on study.
3378159|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2+PDL2 Pembro Schedule 2: Arm F|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 in combination with pembrolizumab at pembrolizumab dose level 2 (PDL2). Both quavonlimab and pembrolizumab will be administered according to Schedule 2 for up to 24 months on study.
3378160|NCT03179436|Experimental|Expansion: DL1 Quavonlimab Schedule 2 Monotherapy: Arm G|On Cycle 1, Day 1 of the Efficacy Expansion Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive quavonlimab at DL1 according to Schedule 2 for up to 24 months on study. Participants who demonstrate radiographically confirmed progressive disease in Arm G will be eligible to receive combination therapy with pembrolizumab (crossover).
3378161|NCT03179436|Experimental|Coformulation: Pembrolizumab/Quavonlimab Schedule 2: Arm I|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with advanced/metastatic solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
3378162|NCT03179436|Experimental|Coformulation Phase: Pembrolizumab/Quavonlimab Schedule 2: Arm J|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants with PD-1/PD-L1 refractory melanoma receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
3378163|NCT03179436|Experimental|Coformulation Phase in China: Pembrolizumab/Quavonlimab Schedule 2: Arm K|On Cycle 1, Day 1 of the Coformulation Phase and during all subsequent cycles, participants in mainland China with advanced solid tumors receive pembrolizumab/quavonlimab according to Schedule 2 for up to 24 months on study.
3378164|NCT03178552|Experimental|Cohort A: Alectinib 600 Milligrams (mg)|"This cohort includes participants with anaplastic lymphoma kinase (ALK) positive NSCLC. Participants will receive alectinib 600 mg orally twice in a day (BID) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort A is complete."
3378165|NCT03178552|Experimental|Cohort B: Dose Finding Phase (DFP) Alectinib|"This cohort includes participants with rearranged during transfection (RET) positive NSCLC. Participants may receive alectinib 900 or 1200 mg orally BID until disease progression, unacceptable toxicity, withdrawal of consent or death if the recommended phase 2 dose (RP2D) is not established in any other clinical study. Participants may receive 750 mg or 600 mg, if it is unsafe to pursue the higher starting dose.~Enrollment to Cohort B is complete."
3378166|NCT03178552|Experimental|Cohort B: Dose Expansion Phase (DEP) Alectinib|"This cohort includes participants with RET positive NSCLC. Participants will receive alectinib at the RP2D established in the DFP of Cohort B or a separate clinical study. Participants will continue receiving study treatment until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort B is complete."
3378167|NCT03178552|Experimental|Cohort C: Atezolizumab 1200 mg|"This cohort includes participants with bTMB positive NSCLC. Participants will receive atezolizumab at a dose of 1200 mg administered by IV infusion every 21 days (Q21D) until disease progression, loss of clinical benefit, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort C is complete."
3378168|NCT03178552|Active Comparator|Cohort C: Pemetrexed, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, non-squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Carboplatin at a dose of area under the concentration-time curve (AUC) of 5 or 6 IV or cisplatin at a dose of 75 milligrams per meter square (mg/m^2) IV on Day 1 of each cycle combined with pemetrexed at a dose of 500 mg/m^2 IV on Day 1 of each cycle. Pemetrexed may be continued as maintenance therapy every 21 days (Q21D) as per local standard of care.~Enrollment to Cohort C is complete."
3378169|NCT03178552|Active Comparator|Cohort C: Gemcitabine, Cisplatin or Carboplatin|"This cohort includes participants with bTMB positive, squamous NSCLC. Participants will receive 4 or 6 cycles of treatment, with each cycle being 21 days in duration. Gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of every cycle and cisplatin 75 mg/m^2 IV on Day 1 Q21D or gemcitabine 1000 mg/m^2 IV on Days 1 and 8 of every cycle and carboplatin AUC 5 IV on Day 1 Q21D.~Enrollment to Cohort C is complete."
3281118|NCT01665625|No Intervention|systemic chemotherapy|
3281119|NCT01665638|Experimental|Treatment Sequence Group AB|
3281120|NCT01665638|Experimental|Treatment Sequence Group BA|
3281121|NCT01665651|Placebo Comparator|kidney Yin deficiency with placebo|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules placebo treatment besides basic treatment.
3281122|NCT01665651|Placebo Comparator|kidney Yang deficiency with placebo|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules placebo treatment besides basic treatment.
3281123|NCT01665651|Experimental|kidney Yin deficiency with Zuogui|chronic renal insufficiency patients with kidney Yin deficiency evaluated with traditional Chinese medicine will be given Zuogui granules treatment besides basic treatment.
3281124|NCT01665651|Experimental|kidney Yang deficiency with Yougui|chronic renal insufficiency patients with kidney Yang deficiency evaluated with traditional Chinese medicine will be given Yougui granules treatment besides basic treatment.
3281125|NCT01665664|Other|Hypocaloric feeding group|intervention - Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
3281126|NCT01665664|No Intervention|Full energy feeding group|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 100% of REE will be provided.
3281127|NCT01665677|Experimental|Atorvastatin calcium (Lipitor)|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
3281128|NCT01665677|Experimental|Unrelated Donor|"Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.~Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin."
3281129|NCT01665690|Experimental|Intervention period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
3281130|NCT01665690|No Intervention|Control Period|The study will include 23 WA state local health jurisdictions (LHJ). Each LHJ will be a randomized unit and a unit in which we will measure outcomes. (LHJs are governmental administrative units that usually correspond with a county.) Because this is a stepped-wedge randomized trial, the study will have two groups (intervention and control). However, each LHJ will be in both groups depending on the time period.
3281131|NCT01665703|Experimental|FDG PET/MR|Participents will undergo a gadolinium enhanced FDG PET/MR study.
3281132|NCT01665729||artery-artery embolus|There is no hypoperfusion ( contralateral compensatory is good )
3281133|NCT01665729||Hypoperfusion|Contralateral compensatory not sufficient
3281134|NCT01665729||Hypoperfusion and embolus amotic|Hypoperfusion and embolus amotic
3281135|NCT01665742|Active Comparator|Anti-inflammatory supplement|"8-weeks of daily supplementation with:~1 x fruit juice fortified with fish oil, and 4 x film-coated tablets containing vitamin C, alpha-tocopherol, green tea extract and lycopene~in conjunction with a weight management programme"
3281136|NCT01665742|Placebo Comparator|Placebo supplement|"8 weeks of daily supplementation with:~1 x fruit juice fortified with high-oleic sunflower oil, and 4 x film-coated placebo tablets~in conjunction with a weight management programme"
3281137|NCT01665755|Experimental|Precompression|Control arm
3281138|NCT01665755|Active Comparator|Upstroke Compression|Intervention arm
3281139|NCT01665781|Experimental|Erythropoietin|Erythropoietin 10,000U, weekly, for 4 weeks Last dose: 1 week before departure (10days before high altitude)
3281140|NCT01665781|No Intervention|Control|No erythropoietin
3281141|NCT01665794|Experimental|PdC Group|Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
3281142|NCT01665794|Experimental|PdC + Dara Group|Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
3281143|NCT01665820||Auscultate with mechanical stethoscope|Cardiologist & Medical Resident auscultate using mechanical stethoscope
3281144|NCT01665820||Auscultate with electronic stethoscope|Cardiologist & Medical Resident auscultate using electronic stethoscope
3281145|NCT01665846|Experimental|Ferumoxotyol|Brain MRI will be performed before and 48 +/- 8 hours after ferumoxytol administration.
3281146|NCT01665859||Danish Ventral Hernia Database|Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010
3281147|NCT01665885|Active Comparator|Endovascular cooling|Endovascular cooling using the cooling device ZOLL Thermogard XP with ZOLL Quattro cooling catheter
3281148|NCT01665885|Active Comparator|Surface cooling|Surface cooling using the cooling device BARD/Medivance Arctic Sun 5000 with BARD/Medivance Arctic Gel Pads
3281149|NCT01665885|No Intervention|Control group|Best medical treatment following international stroke guidelines
3281150|NCT01665898|Active Comparator|Cold biopsy forceps|Cold biopsy forceps for removal of colon polyps
3281151|NCT01665898|Active Comparator|Cold Snare Biopsy|Cold snare biopsy for removal of colon polyps
3281152|NCT01665924|Experimental|40-50 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
3281153|NCT01665924|Experimental|65-74 years old|GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
3281154|NCT01665924|Experimental|75 years and older|GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
3281155|NCT01665937|Experimental|STA-9090|Patients receiving STA-9090
3281156|NCT01665963|Active Comparator|TopClosure(c) Treated Wound|Pressure Bandage using the TopClosure(C) System
3281157|NCT01665963|Active Comparator|Traditional Wound Closure Treatment|Pressure Bandage
3281158|NCT01665976|Experimental|A: film coated tablets, fasted condition|
3281159|NCT01665976|Experimental|B: film coated tablets, fed condition|
3281160|NCT01665976|Experimental|C: hard gelatin capsules|
3281161|NCT01665976|Experimental|D: oral suspension|
3281162|NCT01665989|Experimental|Group Lifestyle program|The group lifestyle program used in the IDOLc study is adapted from the first 6 months of the Look AHEAD program and will include 19 group sessions offered over a six month period. Each of 2 groups will contain up to 15 patients with type 2 diabetes and will last 1-1.5 hours. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. The program fosters the development of knowledge and lifestyle skills to change diet and exercise habits through use of goal setting, problem solving, stimulus control and other behavioral techniques that have resulted in weight loss, weight maintenance and improved glycemic control.
3281163|NCT01665989|Active Comparator|Usual Care|A research assistant will provide the usual care group participants with brief (~15-20 minutes) counseling which reviews an educational handout emphasizing that modest weight loss (5 - 10%) via caloric restriction and gradual adoption of moderate increases in daily physical activity (equivalent to brisk walking for 30 minutes daily) is safe and effective in managing diabetes; and refer them to Nutrition Services for follow up.
3281164|NCT01666015|Experimental|Exercise (EX)|This group will perform two phases of an EX program.
3281165|NCT01666015|Active Comparator|Standard Care|This group will follow the standard care without any EX prescription.
3281166|NCT01666028|Experimental|Closed Loop Glucose control|Subject's glucose level is controlled by the automated closed loop glucose control system
3281167|NCT01666028|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
3281168|NCT01666041|Placebo Comparator|placebo|placebo
3281169|NCT01666041|Active Comparator|fenofibrate/omega|fenofibrate/omega
3281170|NCT01666041|Active Comparator|fenofibrate|fenofibrate
3281171|NCT01666054|Active Comparator|Proportional Assist Ventilation (PAV)|Proportional Assist Ventilation (PAV+ on the PB840 ventilator) will be used according to a weaning algorithm. If patients develop distress despite maximum levels of support on PAV+, they will be temporarily switched to assist control mode.
3281172|NCT01666054|Active Comparator|Pressure Support Ventilation (PSV)|Pressure Support Ventilation on the PV840 ventilator will be used according to a weaning algorithm. If patients develop distress despite maximal level of support on PSV, they will be temporarily switched to assist-control mode.
3281173|NCT01666067|Active Comparator|placebo|placebo
3281174|NCT01666067|Active Comparator|vytorin|vytorin
3281175|NCT01666067|Active Comparator|simvastatin|simvastatin
3281176|NCT01666080|Other|Reduced Intensity Conditioning|Includes patients receiving a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using reduced intensity conditioning (RIC). Patients will receive busulfan, fludarabine, total body irradiation and stem cell transplant. Keppra will be given for seizure prophylaxis.
3281177|NCT01666093|Other|revascularization group|patients will revascularized after a conservative treatment failure of at least 4 weeks
3281178|NCT01666106||Subjects with cancer and ONJ|Subjects with cancer and positively adjudicated ONJ
3281179|NCT01666132|Experimental|Intramyocardial injection of BM cells|
3281180|NCT01666132|Experimental|Intramyocardial / intracoronary injection of BM cells|
3281181|NCT01666132|Other|control|
3281182|NCT01666158|Active Comparator|Exercise|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. Additionally, these patients will be given a specific physical exercise program before and after surgery by kinesiologist.
3281183|NCT01666158|No Intervention|Standard nutrition counselling|Patients in this group will follow standard MUHC protocol of nutritional counseling and supplementation as needed in order to maintain caloric and protein requirements in the preoperative period. This group will receive general instructions on exercises (breathing, ankle rotation) to be done during hospital stay by kinesiologist.
3281184|NCT01666223|Experimental|Colesevelam|
3281185|NCT01666223|Experimental|Chenodeoxycholic acid|
3281186|NCT01666223|Experimental|Colesevelam + chenodeoxycholic acid|
3281187|NCT01666223|Experimental|Placebo|
3281188|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
3281189|NCT01666249|Experimental|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
3281190|NCT01666262|Experimental|A/17/CA/2009/38 (H1N1)|
3281191|NCT01666262|Placebo Comparator|Stabilizer|
3281192|NCT01666275||Aspirin desensitization|This group of patients has AERD (aspirin exacerbated respiratory disease) and is undergoing aspirin desensitization.
3281193|NCT01666288||IT Anaphylaxis|Blood samples will be taken from patient that develop anaphylaxis to routine outpatient allergen or venom immunotherapy.
3281194|NCT01666301|Active Comparator|C.E.R.A.|C.E.R.A. every 4 and then every 2 weeks
3281195|NCT01666301|Active Comparator|Darbepoetin|Darbepoetin alfa every 4 and then every 2 weeks
3281196|NCT01666327|Experimental|MT-1303|
3281197|NCT01666353|Experimental|Therapeutic response for solid tumors|Adult patients, with documented metastatic melanoma, RCC or NSCLC, about to initiate any line of immune checkpoint blockade therapy will receive a FDG PET scan during mid treatment to check for change in disease.
3281198|NCT01666366|Active Comparator|In Situ Bilateral mammary grafting|Coronary artery bypass grafting: BITA in situ (LITA to the LAD and RITA to the marginal branches into the transverse sinus)
3281199|NCT01666366|Active Comparator|Y composite Bilateral mammary grafting|Coronary artery bypass grafting: BITA Y (LITA to the LAD and RITA to the marginal branches but anastomozed proximally to the LITA in a Y configuration
3281200|NCT01666379|Experimental|Fentanyl|
3281201|NCT01666379|Placebo Comparator|placebo|
3281202|NCT01666392|Experimental|Fish oil (Omega-3 fatty acid)|2 capsules/day of ProOmega providing 650mg EPA and 450mg DHA
3281203|NCT01666392|Placebo Comparator|Soybean oil|2 capsules/day
3281204|NCT01666405|Experimental|Urgent(R) PC Neuromodulation System|Urgent(R) PC Neuromodulation System
3281205|NCT01666418|Other|Pazopanib/Paclitaxel|
3281206|NCT01666431|Other|Lapatinib|
3281207|NCT01666457||Pre-SOFFI infants|Infants discharged from the NICU prior to the implementation of the SOFFI infant driven feeding program with NICU staff.
3281208|NCT01666457||Post SOFFI infants|Subject infants discharged from the NICU at least 6 months after the implementation of the SOFFI infant driven feeding program and
3281209|NCT01666470||Drug allergy patients|Patients with a history of drug allergy in Thailand
3281210|NCT01666483|Active Comparator|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
3281211|NCT01666483|Active Comparator|laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip.Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
3281212|NCT01666496|Experimental|Experimental Video Game|Participants will play the experimental videogame for 6 weeks. The intervention will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
3281213|NCT01666496|Other|Off the Shelf Video Game|Participants will play the off the shelf videogame for 6 weeks. The intervention be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
3281214|NCT01666509|Experimental|Rossoseq™|Gel, topically applied twice daily
3378170|NCT03178552|Experimental|Cohort D: Entrectinib 600 Milligrams (mg)|"This cohort includes participants with c-ros oncogene 1 positive (ROS1+) NSCLC. Participants will receive entrectinib 600 mg orally once a day (QD) until disease progression, unacceptable toxicity, withdrawal of consent or death.~Enrollment to Cohort D is complete."
3378171|NCT03178552|Experimental|Cohort E: Atezolizumab, Vemurafenib, and Cobimetinib|This cohort includes participants with BRAF V600 mutation. Participants will receive: atezolizumab 1680 mg IV Q4W after the run-in period; cobimetinib 60 mg orally (PO) QD on Days 1-21 of each cycle during the run-in and triple-combination periods; and vemurafenib 960 mg PO twice daily (BID) on Days 1-21 of the initial run-in period, then 720 mg PO BID on Days 1-22 of the initial run-in period and on Days 1-28 of each cycle during the triple-combination period.
3281215|NCT01666509|Placebo Comparator|Vehicle|Gel, topically applied twice
3281216|NCT01666522|Experimental|Vitamin D|vitamin D-oral cholecalciferol 2000 IU/day for 4 months
3281217|NCT01666522|Active Comparator|Physical activity|A 3-day/week exercise programme lasting 60 minutes each day for 4 months was instigated.
3281218|NCT01666522|Experimental|Vitamin D and Physical activity|Vitamin D -oral cholecalciferol 2000 IU/day and Physical activity-60-minute 3-day/week exercise programme
3281219|NCT01666522|Placebo Comparator|Control|The control group was provided with health education using videotaped presentations, physician talks on topics concerning bone and muscle health.
3378172|NCT03178552|Experimental|Cohort F: Atezolizumab, Bevacizumab, Carboplatin, and Pemetrexed|This cohort includes participants with EGFR exon 20+ NSCLC. Participants will receive atezolizumab + bevacizumab + carboplatin + pemetrexed for 4 or 6 induction cycles (cycle = 21 days). After induction therapy, participants will continue maintenance treatment with atezolizumab + bevacizumab + pemetrexed until disease progression, unacceptable toxicity, withdrawal of consent, or death.
3378173|NCT03156114|Experimental|Part I - Dose--Escalation|
3378174|NCT03156114|Experimental|Part II - Dose-Expansion|
3378175|NCT03155347|Experimental|Tocilizumab + MTX|Participants will receive tocilizumab SC injections Q2W along with MTX orally every week (QW) for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase, irrespective if they achieve or do not achieve DAS28 low activity (DAS28-ESR <= 3.2).
3378176|NCT03155347|Experimental|Tocilizumab + Placebo Matched to MTX|Participants will receive tocilizumab SC Q2W along with placebo matched to MTX for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
3378177|NCT03155347|Active Comparator|Placebo Matched to Tocilizumab + MTX|Participants will receive placebo matched to tocilizumab along with MTX orally QW for 24-week double-blind treatment phase. Participants who complete the 24-week double-blind treatment phase may continue treatment until Week 48 in the extension phase. In the extension phase up to Week 48, participants who achieve DAS28 low activity (DAS28-ESR <= 3.2) will remain on the same treatment they received in double-blind phase. Participants who do not achieve DAS28-ESR <= 3.2 will receive treatment with tocilizumab 162 mg SC Q2W + MTX from Week 26 to Week 48.
3378178|NCT03152760||Abstinent Group (AB)|Current AUD diagnosis, currently abstaining from alcohol
3378179|NCT03152760||Current Drinking Group (CD)|Current AUD diagnosis, not seeking AUD treatment
3378180|NCT03152760||Healthy Control Group (HC)|NO current or past AUD diagnosis
3378181|NCT03143556|Experimental|Magnetic Stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for magnetic stent group will receive magnetic stent and the removal of stent would be done by help of magnetic device.
3281220|NCT01666535|Other|Influenza vaccination Timing #1|Influenza vaccination administered on the same day as infliximab administration (Day 0 to 4).
3281221|NCT01666535|Other|Influenza vaccination Timing #2|Influenza vaccination administered at the mid-point between infliximab infusions (Day 21 to 28)
3281222|NCT01666561|Experimental|Breakfast Test Cereal 1, Oat based|"Test cereal 1, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3281223|NCT01666561|Experimental|Breakfast Test Cereal 2, Oat-based|"Test Cereal 2, Oat-based breakfast cereal. You will be randomly presented with a breakfast consisting of either:~Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat oat brand cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3281224|NCT01666561|Experimental|Ready-to-eat cereal|"Ready-to-eat cereal, Oat based breakfast cereal- you will be randomly presented with a breakfast consisting of either:~one Oat-based breakfast cereal with lactose-free, fat-free milk to drink or ready-to-eat cereal in lactose-free, fat -free milk with water to drink. Then you will complete a visual analog scale at 30, 60, 120. 180, and 240 minutes following the start of breakfast meal."
3281225|NCT01666574|Experimental|Test cereal 1, Oat-based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based cereal will cause people to eat less at lunch.
3281226|NCT01666574|Experimental|Test Cereal 2, Oat based|The purpose of this arm is to determine if a breakfast containing 250 kcal of Oat based ready-to-eat cereal will cause people to eat less at lunch.
3281227|NCT01666587|No Intervention|control|Control trial to determine the impact of the ischemic injury on vascular function without intervention
3281228|NCT01666587|Experimental|Antioxidant load|Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery
3281229|NCT01666587|Experimental|Prostaglandin inhibition|Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery
3281230|NCT01666587|Experimental|Combined|Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery
3281231|NCT01666600|Experimental|BIBF 1120 + reirradiation|2 x minimal tolerated dose BIBF 1120 per day in combination with radiotherapy (2 Gy / fraction; 36 Gy in total)
3281232|NCT01666600|Active Comparator|reirradiation alone|radiotherapy (2 Gy / fraction; 36 Gy in total)
3281233|NCT01666613|Experimental|1|AZD8683 iv
3281234|NCT01666613|Experimental|2|AZD8683 oral
3281235|NCT01666613|Experimental|3|AZD8683 inhalation New Dry Powder Inhaler
3281236|NCT01666613|Experimental|4|AZD8683 inhalation Turbuhaler™
3281237|NCT01666626||Crohn's Inpatients|Crohn's Inpatients, with clinical small bowel obstruction All undergo ultrasound stiffness imaging (USI) of distal affected ileum.
3281238|NCT01666626||Crohn's Outpatients|Crohn's Outpatients, starting anti-TNF therapy All undergo ultrasound stiffness imaging (USI) at week 0, 6, 14
3281239|NCT01666639|Active Comparator|Control Group|
3281240|NCT01666639|Experimental|Intervention Group|
3281241|NCT01666665|Active Comparator|metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
3281242|NCT01666665|Placebo Comparator|Sugar pill|sugar pill up to 3 times per day for 12 months
3281243|NCT01666678|Experimental|Arm 1|
3281244|NCT01666678|Active Comparator|Arm 2|
3281245|NCT01666678|Active Comparator|Arm 3|
3281246|NCT01666678|Experimental|Arm 4|
3281247|NCT01666691|Placebo Comparator|Placebo|ZGN-440 sterile diluent
3281248|NCT01666691|Experimental|0.3 mg Beloranib|0.3 mg ZGN-440 for injectable suspension
3281249|NCT01666691|Experimental|0.6 mg Beloranib|0.6 mg ZGN-440 for injectable suspension
3281250|NCT01666691|Experimental|1.2 mg Beloranib|1.2 mg ZGN-440 for injectable suspension
3281251|NCT01666691|Experimental|2.4 mg Beloranib|2.4 mg ZGN-440 for injectable suspension
3281252|NCT01666691|Experimental|3.2 mg Beloranib|3.2 mg ZGN-440 for injectable suspension
3281253|NCT01666704|Experimental|Treatment A: BMS-823778 (2mg)|
3281254|NCT01666704|Experimental|Treatment B: BMS-823778 (15mg)|
3281255|NCT01666704|Placebo Comparator|Treatment C: Placebo|
3281256|NCT01666717||Healthy controls (HC)|HC
3281257|NCT01666717||Inflammatory Bowel Disease (IBD) patients|Crohn's disease (CD), Ulcerative colitis (UC) and pouchitis
3281258|NCT01666743|Experimental|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
3281259|NCT01666756|Experimental|Treatment (Chinese herbal formulation PHY906 and sorafenib)|Patients receive Chinese herbal formulation PHY906 PO BID on days 1-4, 8-11, 15-18, 21-24 and sorafenib tosylate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3281260|NCT01666769|Other|Treatment Dosing|Age group: 0 - <2y, Micafungin 8 mg/kg/day IV
3281261|NCT01666769|Other|Prophylaxis dosing|Age group: 0-<2y, Micafungin 4 mg/kg/day IV
3281262|NCT01666769|Other|Standard of care Dosing|Age group: 2-17.85 y, Micafungin standard of care dosing (decided by treating physician)
3281263|NCT01666795||IVIG therapy in ITP|IVIG therapy in untreated adults with severe ITP
3281264|NCT01666808|Experimental|FACBC PET scan|A trial group in which anti-3-[18F]FACBC PET-CT is used to guide radiotherapy decisions and radiotherapy treatment volumes.
3281265|NCT01666808|Active Comparator|Radiation therapy|A control group whose treatment decisions will be made based on conventional imaging - bone scan and abdominopelvic CT and/or MR scan.
3281266|NCT01666821||early and intermediate-stage AMD|Follow-up observation was implemented in whose fundus examination show lesions in the early and intermediate-stage AMD
3281267|NCT01666847|Experimental|Cord Milking|Infant receiving cord milking intervention before umbilical cord clamped.
3281268|NCT01666847|No Intervention|Immediate Cord Clamping|Infant whose umbilical cord is immediately clamped after delivery.
3281269|NCT01666860||Anterior Lumbar Interbody Fusion procedure|
3281270|NCT01666873||total knee prosthesis|Patients that undergo a total knee prosthesis.
3281271|NCT01666886|Experimental|Mandibular Advancement Device (MAD)|Mandibular advancement during therapy with a mandibular advancement device (MAD) in 90% of maximal protrusion
3281272|NCT01666899|Experimental|Skin and blood vessel procedures|All patients will be placed into Arm 1. They will undergo punch biopsies of the breast skin at the time of mastectomy and at 2, 4, 6, 8 and 12 months after completion of radiation therapy. Three more biopsies will be taken at 3, 6, and 12 months after completion of reconstruction. Patients will also undergo skin blood flow studies with a laser imaging device prior to each biopsy procedure. Ultrasound studies of the chest vessels will be performed 4 times over the course of the study- once prior to radiation and at 2, 6 and 12 months after radiation.
3281273|NCT01666925|Experimental|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime-boost immunisation
3281274|NCT01666925|Active Comparator|Rabies vaccine|2 x 2.5IU Verorab
3281275|NCT01666938|Experimental|Diabetes Education Group & Telephone counseling|This step was done for four months.
3281276|NCT01666938|Active Comparator|Telephone counseling about physical activity|This step was done for four months.
3281277|NCT01666964||3 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 3 months prior to enrollment, 50% mild, 50% moderate and severe
3281278|NCT01666964||6 months post-injury|Male and female combat veterans age 18 years and older with the diagnosis of Traumatic Brain Injury caused by a blast that occurred 6 months prior to enrollment, 50% mild, 50% moderate and severe
3281279|NCT01666977|Experimental|Arm A|Arm A: AMG 386 placebo IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3281280|NCT01666977|Experimental|Arm B|Arm B: AMG 386 15 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3281281|NCT01666977|Experimental|Arm C|Arm C: AMG 386 30 mg/kg IV QW, pemetrexed 500 mg/m2 IV Q3W, carboplatin AUC 6 IV Q3W, for up to 6 cycles
3281282|NCT01666990|Experimental|TwHF, lifestyle counseling|Participants will receive TwHF (20mg each time, 3 times per day, for 48 weeks) from Day 0 through the Week 48 study visit.
3281283|NCT01666990|Placebo Comparator|placebo, Lifestyle|Participants will receive placebo treatment (20mg each time, three times per day for 48 weeks) from Day 0 through the Week 48 study visit.
3281284|NCT01667003||Orsiro DES|
3281285|NCT01667016||Orsiro DES|
3281286|NCT01667042||Without Interstitial lung disease (ILD)|
3281287|NCT01667042||With Interstitial lung disease (ILD)|
3281288|NCT01667055||Patients with suspected drug allergy|Patients with a history of hypersensitivity reaction to beta-lactam antibiotics
3281289|NCT01667068||Regional Ruhrgebiets Cohort|HIV-positive patients in the German Ruhr-Region from out-patient clinics of hospitals and HIV-physicians pratices
3281290|NCT01667081||Grazoprevir|Participants who previously received grazoprevir as study treatment on a prior study.
3281291|NCT01667094|Active Comparator|Intermittent, short infusion|"Infusion over 30 minutes of either:~Cefepime 1g q8/24 OR Ceftazidime 2g q8/24 OR Meropenem 1g q8/24 OR Piperacillin-Tazobactam 4.5g q8/24 OR Ticarcillin-clavulanate 3.1g q6/24~Antibiotic chosen by treating physician"
3281292|NCT01667094|Experimental|Continuous infusion|"Continuous infusion of either:~Cefepime 1.5g over 12h, q12/24 after initial loading dose of 500mg OR Ceftazidime 3g over 12h, q12/24 after initial loading dose 1g OR Meropenem 1.5g over 12h, q12/24 after initial loading dose 500mg OR Piperacillin-tazobactam 13.5g over 24h after initial loading dose 2.25g OR Ticarcillin-clavulanate 12.4g over 24h after initial loading dose 1.55g~Antibiotic chosen by treating physician"
3281293|NCT01667120|Placebo Comparator|Placebo|Postoperative surgical neonates will receive an equivalent volume of 0.9% normal saline as placebo.
3281294|NCT01667120|Experimental|Ketorolac|Postoperative ketorolac 0.5mg/kg intravenously every 8 hrs for 72hrs will be administered.
3281295|NCT01667133|Experimental|Phase 1 dose escalation|Phase 1
3281296|NCT01667133|Experimental|Phase 2 expansion|Phase 2
3281297|NCT01667146|Experimental|PHARLAP ventilation group|PHARLAP mechanical ventilation strategy
3281298|NCT01667146|Active Comparator|Control group ventilation|Control group mechanical ventilation strategy
3281299|NCT01667159|Experimental|Integrated Cognitive Behavioral Therapy|Adolescents and their parent(s) will receive integrated cognitive behavioral therapy.
3281300|NCT01667159|Active Comparator|Standard Care|Adolescents and their parent(s) will receive treatment as usual through a community intensive outpatient program.
3281301|NCT01667172|Other|point-of-care test for CRP|
3281302|NCT01667185||Pediatric subjects with diabetes mellitus|
3281303|NCT01667198|Experimental|Train the leaders course|
3281304|NCT01667198|Active Comparator|Audit and feedback|
3281305|NCT01667211|Experimental|albumin-bound paclitaxel plus nedaplatin|albumin-bound paclitaxel plus nedaplatin: Intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
3281306|NCT01667237|Experimental|Pulmonary rehabilitation|
3281307|NCT01667263|Experimental|All-trans retinoic acid ＆Danazol|Danazol 400mg po and ATRA 10mg bid po
3281308|NCT01667263|Active Comparator|Danazol|Danazol 400mg po
3281309|NCT01667289|Active Comparator|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
3281310|NCT01667289|Experimental|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
3281311|NCT01667302|Experimental|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
3281312|NCT01667315|Experimental|Bupivacaine|Bupivacaine 0,375%
3281313|NCT01667328|Experimental|Massage therapy|This group will received presurgical massage
3281314|NCT01667328|Placebo Comparator|Control|Standard of care with no massage
3281315|NCT01667341|Experimental|Low Dose GEN-003 with Matrix M-2|10µg GEN-003, 50µg Matrix M-2 Adjuvant
3281316|NCT01667341|Experimental|Mid Dose GEN-003 with Matrix M-2|30µg GEN-003, 50µg Matrix M-2 Adjuvant
3281317|NCT01667341|Experimental|High Dose GEN-003 with Matrix M-2|100µg GEN-003, 50µg Matrix M-2 Adjuvant
3281318|NCT01667341|Experimental|Low Dose GEN-003 Only|10µg GEN-003
3281319|NCT01667341|Experimental|Mid Dose GEN-003 Only|30µg GEN-003
3281320|NCT01667341|Experimental|High Dose GEN-003 Only|100µg GEN-003
3281321|NCT01667341|Placebo Comparator|Placebo|0.5 mL phosphate buffered saline
3281322|NCT01667354|Experimental|Intervention Clinics|Providers in intervention clinics will receive a training followed by telephone coaching and follow-up visits for six months.
3281323|NCT01667354|No Intervention|Control Clinics|Control clinics will receive all intervention materials at the completion of the study.
3281324|NCT01667367|Placebo Comparator|Placebo|
3281325|NCT01667367|Experimental|RG1662|
3281326|NCT01667380||Cohort|
3281327|NCT01667393|Experimental|IDEV SUPERA Stent|Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.
3281328|NCT01667393|Active Comparator|Percutaneous Transluminal Angioplasty|The target lesion will be treated by PTA alone.
3281329|NCT01667445|Experimental|epimorph|single dose administration of 150mcg epimorph
3281330|NCT01667445|Active Comparator|spinal analgesia|spinal alone
3281331|NCT01667458||Cohort|
3281332|NCT01667484|Placebo Comparator|Placebo|treatment group #1
3281333|NCT01667484|Active Comparator|Adderall XR 5mg|treatment group #2
3281334|NCT01667484|Active Comparator|Adderal XR 10mg|treatment group #3
3281335|NCT01667497|Experimental|Fampridine SR|Fampridine SR 10mg BID
3281336|NCT01667497|Placebo Comparator|Placebo|non-drug
3281337|NCT01667510|Experimental|Cardio Mato|Soft gel capsule for oral use (Grade A Lyc-O-Mato, a tomato extracted lycopene)
3281338|NCT01667510|Placebo Comparator|Placebo|Soft gel capsule without test material, for oral use
3281339|NCT01667523|Experimental|Capsaicin|
3281340|NCT01667523|Experimental|Cinnamaldehyde|
3281341|NCT01667523|Placebo Comparator|Placebo|Physiological saline
3281342|NCT01667575|Experimental|10 day Quadruple Therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 10 days
3281343|NCT01667575|Active Comparator|10 day Triple therapy|Esomeprazole 20mg, Amoxicillin 1.0g,and Clarithromycin 500mg, twice a day, for ten days
3281344|NCT01667575|Active Comparator|14 day quadruple therapy|Esomeprazole 20mg, Amoxicillin 1.0g, Clarithromycin 500mg and Bismuth Potassium Citrate 220mg,twice a day for 14 days
3281345|NCT01667588||Pre-Dialysis|
3281346|NCT01667588||Dialysis|
3281347|NCT01667601|Experimental|Mindfulness-based program|A structured, researcher-designed mindfulness-based psycho-education program (6 months), comprised of 12 bi-weekly, 2-hour group sessions (10-12 patients per group). The program was based on the psycho-education programs by Chien et al. (2010) and Lehman et al. (2004), as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn (1990).
3281348|NCT01667601|Other|Routine Care|Routine psychiatric outpatient care, including medication, psychiatric consultation in outpatient clinic, brief education by psychiatric nurses, financial and social welfare advices by social workers, and individual counseling by clinical psychologist.
3281349|NCT01667601|Active Comparator|Psychoeducation group|"A psychoeducation group program (12 sessions, bi-weekly) based on Dr. Macpherson's Family Psychoeducation Program in 1996 and Chien and Bressington's one in 2014/15 will be used.~References:~Chien WT, Bressington D. A randomized controlled trial of a nurse-led structured psychosocial intervention program for people with first-onset mental illness in psychiatric outpatient clinics. Psychiatry Res 2015;229:277-86.~Macpherson R, Jerrom B, Hughes AA. controlled study of education about drug treatment in schizophrenia. Br J Psychiatry 1996;168:709-17."
3281350|NCT01667614|No Intervention|ACE/ARB|In 62 patients previously treated with enalapril (10-30 mg daily) + losartan (50-100 mg daily), this regimen was continued.
3281351|NCT01667614|Active Comparator|Spironolactone/ARB|spironolacone 25 mg tablets added to losartan
3281352|NCT01667627|Active Comparator|BIO-25, Probiotic-mixture|Two capsules a day.
3281353|NCT01667627|Placebo Comparator|Placebo|Identical to the Bio-25 capsule: same taste, same colour, same appearance
3281354|NCT01667640|Active Comparator|whole brain irradiation|whole brain irradiation with 40 Gy, with fixation mask, radiation of the entire brain, skull base and meninges
3281355|NCT01667640|Experimental|sector irradiation|irradiation of the resection margin plus 5 mm safety margin with 30 Gy in 5 fractions
3281356|NCT01667653|Experimental|Augmentin/Probiotic|Participants are provided in double blinded fashion probiotic to take with antibiotics
3281357|NCT01667653|Experimental|Augmentin/placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
3281358|NCT01667666|Experimental|Nebulized HTS|The first 5 patients will receive 3% Nebulized hypertonic saline, the second 5 patients will receive 4.5% Nebulized hypertonic saline, the third group 6% Nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% Nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
3281359|NCT01667692|Experimental|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics. It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
3281360|NCT01667692|Experimental|clarithromycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
3281361|NCT01667705||SkyCeiling during CT-Suite visit|Patients in the trial group are exposed to the SkyCeiling during their procedure.
3281362|NCT01667705||No SkyCeiling during CT-Suite visit|Patients in the trial group are not exposed to the SkyCeiling during their procedure.
3281363|NCT01667718|Active Comparator|Levofloxacin-triple therapy|Lansoprazole (Proton Pump Inhibitor), Levofloxacin, Amoxicillin
3281364|NCT01667718|Experimental|Levofloxacin-quadruple therapy|Lansoprazole (Proton Pump Inhibitor),Bismuth, Levofloxacin, Amoxicillin
3281365|NCT01667744|Placebo Comparator|Placebo|Placebo pill
3281366|NCT01667757||low post DES FFR group (<0.9)|the patient with FFR values less than 0.9 after DES procedure
3281367|NCT01667757||high post DES FFR group (≥0.9)|the patient with FFR values greater than 0.9 after DES procedure
3281368|NCT01667770|Active Comparator|surgery - autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using autologous graft
3281369|NCT01667770|Active Comparator|surgery - non-autologous graft|surgical intervention: decompression of Chiari malformation by suboccipital craniectomy using using non-autologous graft
3281370|NCT01667783|Active Comparator|Gastric Banding|Laparoscopic Adjustable Gastric Banding
3281371|NCT01667783|Active Comparator|Medical Weight Loss|Medical Weight Loss using a comprehensive lifestyle intervention consisting of diet (meal replacements), physical activity and behavioral techniques
3281372|NCT01667783|Active Comparator|Gastric Bypass|Roux-en-Y Gastric Bypass
3281373|NCT01667809|Active Comparator|Cognitive Behavior Therapy|As the trial will include several different common subclinical mental disorders, the cognitive behavior therapy used in the study will be based on the protocols with best empirical support. Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
3281374|NCT01667809|Experimental|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
3281375|NCT01667822|Active Comparator|Continued guided self help CBT|Continued guided self help CBT. Participants will receive CBT through self-help books with minimal therapist contact (3 sessions in total).
3281376|NCT01667822|Experimental|CBT individual therapy|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
3281377|NCT01667835|Experimental|Yoga Intervention|
3281378|NCT01667835|No Intervention|Control|
3281379|NCT01667861||(Wind) musicians|Members of (professional) orchestras, especially wind instrument players.
3281380|NCT01667874|No Intervention|No Collatamp sponge|Joint infection treated without the use of the Collatamp G sponge.
3281381|NCT01667874|Experimental|Collatamp G sponge|Use of Collatamp G Gentamicin impregnated sponge for the treatment of early total joint infections
3281382|NCT01667887||Femur Fractures|Patients with Distal Femur Fractures
3281383|NCT01667913|No Intervention|6 minutes walking test|
3281384|NCT01667939|Experimental|pregnancy diet|Healthy Eating Index (HEI) in supervised pregnancies
3281385|NCT01667939|No Intervention|unsupervised pregnancy|women attending the obstetrics unit who did not follow a supervised diet
3281386|NCT01667952||Cancer Survivors|The purpose of this study is to establish a registry of survivors of cancer, tumors,or a related illness. The registry will include detailed family history and germline DNA. Ultimately, we hope to improve our understanding of genetic susceptibility to secondary malignant neoplasms and other late effects among survivors of cancer, tumors, or a related illness.
3281387|NCT01667965||pts receiving palliative radiation therapy|The design of the study will be a prospective non-randomized cohort study with structured questionnaires administered to all enrolled patients at two or three time-points.
3281388|NCT01668043|Experimental|Antibody UB-421 Cohort 1|10 mg/kg BW, 8 weekly doses for 8-week treatment period
3281389|NCT01668043|Experimental|Antibody UB-421 Cohort 2|25 mg/kg BW, 4 biweekly doses for 8-week treatment period
3281390|NCT01668056|Active Comparator|Control|Patients will be stimulated according to the conventional flexible GnRH antagonist protocol for IVF. Alfa follitropin (150IU a day) will be started on the third day of the menstrual cycle. Treatment monitoring will be done with transvaginal ultrasound scans and serum determinations of estradiol and progesterone 5 days after the start of gonadotropins and every each day thereafter. Once the leading follicle reaches 13 mm in mean diameter 0,25mg of cetrorelix acetate will be administered daily. Once at least two follicles reach 18mm or more in mean diameter 250 micrograms of choriogonadotropin alfa will be administered and 36 hours latter patients will undergo follicle aspiration for IVF. Embryos will be cryopreserved (vitrification) on the third or fifth day of development. Two months after women will undergo uterine preparation for embryo transfer.
3281391|NCT01668056|Experimental|Ovulation induction|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will receive 250 micrograms of choriogonadotropin alfa subcutaneously. Daily transvaginal ultrasound scans will be done starting two days after the administration of the medication until a cohort of ovarian follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
3281392|NCT01668056|Experimental|Dominant follicle aspiration|Patients will be monitored with daily transvaginal ultrasound scans from the tenth day of the menstrual cycle on. When the dominant follicle reaches a mean diameter of 16mm or more, patients will then undergo aspiration of the dominant and all follicles greater than 10mm in mean diameter. aspiration will be transvaginal ultrasound guided and under sedation, as for oocyte retrieval. Oocytes eventually obtained at this first aspiration will not be used for IVF. Daily transvaginal ultrasound scans will be done starting the day after the follicular aspiration until a cohort of follicles between 4-6 mm is seen (follicular wave emergence). From this point on patients will undergo the same stimulation protocol as Controls, i.e., flexible GnRH antagonist protocol.
3281393|NCT01668069|Experimental|Ondansetron|study drug
3281394|NCT01668069|No Intervention|Doxylamine and Pyridoxine (vitamin B6)|other nausea treatment in use
3281395|NCT01668082|Experimental|surgical resection of a brain tumor|"The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.~--------------------------------------------------------------------------------"
3281396|NCT01668095||Ancillary-Correlative (biomarker analysis)|Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
3281397|NCT01668108||carcinoma, Paclitaxel onkovis (Paclitaxel)|treatment in mono- or combination therapy with Paclitaxel of breast-, non-small cell lung- and ovarial cancer.
3281398|NCT01668121|Experimental|Symbicort Turbohaler|Symbicort Turbohaler
3281399|NCT01668121|Active Comparator|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
3281400|NCT01668134|Experimental|Stereotactic radiation|
3281401|NCT01668160|Experimental|Revision Total Hip|patients recieving a revision total hip replacement will be assessed for implant stability and wear using RSA. Tantalum beads will be placed in the polyethylene and surrounding pelvic and femoral bone.
3281402|NCT01668186||Patients diagnosed with PBD|Collection of medical records and images (ultrasounds, X-rays, MRIs, CT scans, ophthalmic images), Next-generation panel, Drug screening, and Consultation
3281403|NCT01668199|Experimental|14C TZP-101|
3281404|NCT01668212||natural In Vitro Fertilization cycle|Patient doing following natural In Vitro fertilization cycle
3281405|NCT01668225||G-CSF FIV nat|Patient following a natural In Vitro Fecondation cycle
3281406|NCT01668238||malignant tumor|Inpatients with malignant tumors of thyroid and breast
3281407|NCT01668238||benign tumor|Inpatients with benign tumors of thyroid and breast
3281408|NCT01668238||Healthy volunteers|Volunteers without thyroid or breast tumors
3281409|NCT01668251||Fetal ascertainment|Girls who are diagnosed with Turner syndrome because of concerns raised by an abnormal fetal ultrasound.
3281410|NCT01668251||Maternal ascertainment|Girls who are diagnosed with Turner syndrome because their mothers had an amniocentesis for a reason other than an abnormal fetal ultrasound concerning for Turner syndrome. For example an amniocentesis was done because of advanced maternal age or because of an abnormal triple screen or because another condition was being screened for such as trisomy 21.
3281411|NCT01668264|Experimental|Magnetic Resonance Imaging (MRI)|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
3281412|NCT01668264|Experimental|Echocardiograph|Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
3281413|NCT01668277|Experimental|3 ml/kg 7.2% NaCl|The test fluids 7.2% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3281414|NCT01668277|Active Comparator|3 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 3 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3281415|NCT01668277|Active Comparator|20 ml/kg 0.9% NaCl|The test fluids 0.9% NaCl 20 ml/kg will be infused over 10 min. The hemodynamic parameters will be determined before and after infusion by a cardiologist blinded to the type of infusion.
3281416|NCT01668290||Stress Echocardiography|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Stress Echocardiography.
3281417|NCT01668290||SPECT|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Single Photon Emission Computed Tomography (SPECT)
3281418|NCT01668290||CCTA|Patients will be randomized to one of three imaging modalities. One imaging modality thay can be randomized to is Cardiac Computed Tomographic Angiography (CCTA)
3281419|NCT01668303|Experimental|Miami Juvenile Drug Court-MDFT|Multidimensional family therapy (MDFT) is primarily a family-based approach (Liddle, 2002)which conducts individual sessions with the teen and parent[s] but not peer-group sessions.
3281420|NCT01668303|Other|Miami Juvenile Drug Court -TAU|The Treatment as Usual (TAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions.
3281421|NCT01668316|Experimental|Weight loss|12 week weight loss program with biweekly meetings with a Registered Dietitian. Participants will be given a nutrition prescription and asked to record dietary intake online. Participants will be given a pedometer and record daily physical activity.
3281422|NCT01668316|No Intervention|Control|Participants asked to not change dietary and physical activity habits.
3281423|NCT01668342|Experimental|SMS assessments & feedback|Daily symptom assessments of headaches, trouble ocncentrating and irritability/anxiety with self-care feedback based on response severity.
3281424|NCT01668342|No Intervention|Control|Standard of care
3281425|NCT01668368|Other|Esophageal balloon group|"Esophageal balloon will be inserted, and esophageal pressure will be measured in patients with acute respiratory failure.~Intervention - PEEP and Inspiratory pressure will be adjusted according to the measured esophageal pressure."
3281426|NCT01668381||HCC patients|Hepatocellular carcinoma patients treated by radiofrequency ablation
3281427|NCT01668394|Active Comparator|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
3281428|NCT01668394|Placebo Comparator|Control arm|Usual care. Teaching style: deductive.
3281429|NCT01668407|Experimental|Robot-Assisted Gait Training (RAGT)|Robot-Assisted Gait Training (RAGT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
3281430|NCT01668407|Active Comparator|Treadmill Gait Training (TT)|Treadmill Gait Training (TT): Subjects (at least 40) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
3281431|NCT01668420|Experimental|noxious thermal stimulation|Heat-pain:46-47°C and Cold-pain:2-3°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
3281432|NCT01668420|Active Comparator|thermal stimulation (innocuous)|Heat:40-41°C and Cold:23-24°C alternately (intervention) 3 times /week and total 24 TS while conventional rehabilitation program was given
3281433|NCT01668433|Active Comparator|G6PD Normal|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
3281434|NCT01668433|Experimental|G6PD deficiency|Subjects will be given either primaquine, 45 mg single dose or methylene blue, 600 mg single dose with a washout period of 7 days then followed by either methylene blue, 600 mg single dose or primaquine, 45 mg single dose.
3281435|NCT01668446|Experimental|sildenafil|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
3281436|NCT01668446|Experimental|Sildenafil and estradiol valerat|"One of two group to prepare the endometrium give estradiol by step up method with menstruation.~From first to fourth day of menstrual cycle, estradiol valerat tablet 2 mg daily From Fifth to eighth day of menstrual cycle, estradiol valerat tablet 4 mg daily From Ninth to twelfth day of menstrual , estradiol valerat tablet 6 mg daily The second group in addition to the above treatment protocol from First day of cycle until day of starting progesterone will be given sildenafil tablets(50 mg) daily."
3281437|NCT01668459|Experimental|Cabazitaxel|6 cycles (3 weekly) of 25 mg/m^2 IV infusion
3281438|NCT01668459|Other|Best Supportive Care|Best supportive care including single agent chemotherapy as determined by the patient's study doctor
3281439|NCT01668485|Experimental|Islet transplant recipients|Hypoglycemic and euglycemic glucose clamp
3281440|NCT01668485|Placebo Comparator|Type 1 diabetic subjects|Hypoglycemic and euglycemic glucose clamp.
3281441|NCT01668485|Active Comparator|Non-diabetic subjects|Hypoglycemic and euglycemic glucose clamp
3281442|NCT01668498|Experimental|Erythromycin|Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
3281443|NCT01668498|Active Comparator|Doxycyline|Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks
3281444|NCT01668511|Experimental|Group 1|Randomized 7 drug/2 placebo by group
3281445|NCT01668511|Experimental|Group 2|Randomized 7 drug/2 placebo by group
3281446|NCT01668511|Experimental|Group 3|Randomized 7 drug/2 placebo by group
3281447|NCT01668511|Experimental|Group 4|Randomized 7 drug/2 placebo by group
3281448|NCT01668524|Experimental|Single Arm: ATS907|Single-cohort, dose-escalation
3281449|NCT01668563|Active Comparator|Endovascular management|Endovascular treatment will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
3281450|NCT01668563|Active Comparator|Surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
3281451|NCT01668641|Experimental|capsule, 30mg GLPG0634 once a day|3 capsules of 10 mg once a day
3281452|NCT01668641|Experimental|capsules, 75mg GLPG0634 once a day|3 capsules of 25mg once a day
3281453|NCT01668641|Experimental|capsules, 150mg GLPG0634 once a day|3 capsules of 50mg once a day
3281454|NCT01668641|Experimental|capsules, 300mg GLPG0634 once a day|3 capsules of 100mg once a day
3281455|NCT01668641|Placebo Comparator|capsules, placebo once a day|3 capsules placebo once a day
3281456|NCT01668680|Experimental|LDM anti-angiogenic chemotherapy|LDM (Low Dose Metronomic) anti-angiogenic chemotherapy includes daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE.
3281457|NCT01668680|No Intervention|observation|observation only
3281458|NCT01668693|Active Comparator|RIF ERA Receptive 1|"With the receptive results from the first Endometrial Receptivity Array (ERA), the patients will undergo embryo transfer on Day 5 of Progesterone administration in the cycle following the ERA diagnosis."
3281459|NCT01668693|Experimental|RIF ERA Non Receptive|"The Non Receptive results of the ERA diagnotic tool will indicate how many more days of Progesterone are necesary in order to obtain the Receptive daignosis. A second ERA will take place to confirm receptivity and in the following cycle, the personalized embryo transfer will take place on the day predicted by this diagnostic tool."
3281460|NCT01668706||Methadone maintenance treatment (MMT)|
3281461|NCT01668706||Buprenorphine-Naloxone treatment (BNT)|
3281462|NCT01668706||Medication-free ex-addicts(MF)|
3281463|NCT01668706||Normal control (NC)|
3281464|NCT01668732||community heroin addicts|
3281465|NCT01668745|Experimental|Early measles vaccine|The intervention is about to administer an early standard dose of Edmonston-Zagreb (EZ) measles vaccine in addition to the conventional dose. As such children will be randomised to receive either an early measles vaccine at 4 months after DTP3 or not. Thereafter both groups of children will receive the recommended EZ measles vaccine at 9 months of age according to WHO policy.
3281466|NCT01668745|No Intervention|Control|
3281467|NCT01668810||Beijing region|include six hospitals
3281468|NCT01668810||Guangdong Province|include 3 hospitals
3281469|NCT01668810||Jiangsu province|include 3 hospitals
3281470|NCT01668810||Hebei province|include 6 hospitals
3281471|NCT01668810||Hubei Province|include 7 hospitals
3281472|NCT01668810||Shanxi province|include 3 hospitals
3281473|NCT01668810||Jiangxi province|include 3 hospitals
3281474|NCT01668810||Jilin province|include 6 hospitals
3281475|NCT01668810||Sichuan province|include 3 hospitals
3281476|NCT01668810||Shaanxi province|include 3 hospitals
3281477|NCT01668823|Experimental|Treatment (PDT using HPPH)|Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.
3281478|NCT01668849|Experimental|1 - Grape extract|Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.
3281479|NCT01668849|Active Comparator|2 - Lortab, Fentanyl patch, mouthwash|Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.
3281480|NCT01668862|Other|Study arm A|Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
3281481|NCT01668862|Other|Control Arm B|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
3281482|NCT01668875|Experimental|Treatment condition|In intervention period patients were received head-down 30 degree postural drainage position for 10 min.
3281483|NCT01668875|Experimental|Sham condition|In intervention period patients were received horizontal supine lying for 10 min.
3281484|NCT01668888||Apparently Helathy Subjects|
3281485|NCT01668901|Experimental|warfarin|medication
3281486|NCT01668901|Active Comparator|aspirin|medication
3281487|NCT01668914|Experimental|clinically positive axillary nodes|3~18 hours before surgery, under ultrasonographic guidance, 0.5~1.0 mCi 99mTc-SC in sterile saline (total volume 0.2~2.0 mL) is injected intraparenchymally into 2 quadrants of breast. Subsequently, LSG is performed 0.5~1.0 hour before surgery. Methylthioninium was injected intraparenchymally. IM-SLNB is performed during the surgery and the IMSLNs were sent to histologic examination
3281488|NCT01668927|Experimental|tetracycline/furazolidone|one of the four empirical rescue therapies
3281489|NCT01668927|Experimental|amoxicillin/tetracycline|one of the four empirical rescue therapies
3281490|NCT01668927|Experimental|amoxicillin/furazolidone|one of the four empirical rescue therapies
3281491|NCT01668927|Active Comparator|tetracycline /metronidazole|Classical rescue therapy
3281492|NCT01668953|Experimental|Platelet Rich Plasma (PRP) Injection|Patients in this arm will receive a platelet rich plasma injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
3281493|NCT01668953|Active Comparator|Whole Blood Injection|Patients in this arm will receive a whole blood injection at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises.
3281494|NCT01668953|Active Comparator|Dry Needle Fenestration|Patients in this arm will receive 15-25 gentle strokes of dry needling (piercing of the tendon) at the site of their lateral epicondylitis, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
3281495|NCT01668953|Placebo Comparator|Sham Injection|Patients in this arm will receive a sham injection, followed by post-treatment physical therapy exercises. No blood will be injected into the tendon.
3281496|NCT01668979||new system to detect Near Falls|the new system comprises of a treadmill and a virtual reality simulation that will be used to induce Near Falls in healthy older adults with a history of falls.
3281497|NCT01668992|Experimental|Family intervention|Families receive 12-week program on parenting skills, discipline methods and family communication.
3281498|NCT01668992|No Intervention|Waitlist control|Families are on a waitlist and receive the intervention only after the trial is complete.
3281499|NCT01669005||Bone marrow transplant unit patients|hospitalized patients in the bone marrow transplant unit for an autologous or allogeneic hematopoietic stem cells transplantation or induction/consolidation chemotherapy
3281500|NCT01669018|Active Comparator|Lumbar ultrasound trident (LUT)|Lumbar plexus block using LUT technique
3281501|NCT01669018|Experimental|Supra Sacral Parallel Shift (SSPS)|Lumbar plexus block using SSPS technique
3281502|NCT01669031|No Intervention|Control Group|No practice tests are performed in this arm
3281503|NCT01669031|Experimental|Practice Program|"At the 3 study visits exposed to a training session (simulated visual field test on a computer).~Visit 1 they get 2 simulated tests tests per eye. At visits 2 and 3 they get 1 simulated test per eye. Each simulated test takes 3-15 minutes"
3281504|NCT01669044||dexmedetomidine,hemodynamics,injection|Group 1:when the patient can be roused after major abdominal surgery ，we will inject dexmedetomidine at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
3281505|NCT01669044||propofol,hemodynamics,injection|Group 2 :when the patient can be roused after major abdominal surgery ，we will inject propofol at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg.h for 6 to 24hours.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores
3281506|NCT01669057||Congenital heart defect（CHD） group|
3281507|NCT01669057||Normal control group|
3281508|NCT01669070|Experimental|FF 50 mcg powder inhalation|Each subject will receive a single dose of 300 mcg FF (6 inhalations of 50 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 50 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3281509|NCT01669070|Experimental|FF 100 mcg powder inhalation|Each subject will receive a single dose of 600 mcg FF (6 inhalations of 100 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 100 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3281510|NCT01669070|Experimental|FF 200 mcg powder inhalation|Each subject will receive a single dose of 1200 mcg FF (6 inhalations of 200 mcg FF) on Day 1 of the respective period per randomization sequence, followed by 200 mcg FF once daily for 7 days, on Days 3-9 inclusive, administered from the NDPI.
3281511|NCT01669070|Experimental|FF 250 mcg IV|Each subject will receive a single dose of 250 mcg FF, administered as an IV infusion over 20 minutes on Day 1 of the respective period per randomization sequence.
3281512|NCT01669083|Experimental|Cohort 1: GSK557296 10 mg|GSK557296 10 mg single dose on Day 1 followed by repeat dosing (4 times a day) on Days 2-6
3281513|NCT01669083|Experimental|Cohort 2: GSK557296 150 mg|GSK557296 150 mg as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in treatment A) on Days 9-13
3281514|NCT01669083|Experimental|Cohort 3|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 2. Subjects in this optional Cohort 3 will receive GSK557296 (dose to be determined) as a single dose on Day 1 followed by repeat nominal dosing of the same dose (either 2, 3 or 4 times a day based on half-life demonstrated in Cohort 1 and Cohort 2) on Days 2-6
3281515|NCT01669083|Experimental|Cohort 4|This study had an adaptive design and additional cohorts may be added depending on the PK profiles of Cohort 1 and Cohort 1. Subjects in this optional Cohort 4 will receive GSK557296 (dose to be determined) by PK of prior doses, 10-150 mg single dose on Day 1 followed by repeat dosing (either 2, 3 or 4 times a day dependent on half-life demonstrated in prior groups) on Days 2-6
3281516|NCT01669109|Experimental|Hatha yoga|"10 weeks of Hatha yoga, designed for patients with colorectal cancer, as a group intervention~1 weekly class (90 minutes)"
3281517|NCT01669109|No Intervention|Usual care|Patients continue their self-directed usual care
3281518|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|The cerebral oxygen saturation of the right and left frontal lobe as well as the thigh oxygen saturation are monitored during spinal anesthesia by means of the near-infrared spectroscopy. Hemodynamic variables were recorded at the same time points.
3281519|NCT01669161|Experimental|VNS|VNS (vagus nerve stimulation) paired with rehabilitation as provided by the Vivistim System.
3281520|NCT01669161|Active Comparator|Rehab Only|Rehabilitation only (no implant, no VNS)
3281521|NCT01669187|Active Comparator|Education brochure|The control group will receive a standard education brochure which will be provided pre-operatively to the participants.
3281522|NCT01669187|Experimental|Live education and exercise instruction|The intervention group will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
3281523|NCT01669200|Placebo Comparator|Placebo Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
3281524|NCT01669200|Experimental|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group versus the control group at one month and six months with respect to BHB and insulin levels, and at six months with respect to cognitive scores.
3281525|NCT01669213|Active Comparator|ramosetron 0.3 mg|preparation of ramosetron 0.3 mg
3281526|NCT01669213|Active Comparator|ondansetron 8 mg|preparation of ondansetron 8mg
3281527|NCT01669213|Active Comparator|ondansetron 4 mg|preparation of ondansetron 4mg
3281528|NCT01669213|Placebo Comparator|non 5-HT3 receptor antagonist|preparation of normal saline 5 ml
3281529|NCT01669226|Experimental|Regimen B, PEip and TCiv therapy|Weekly IP cisplatin plus etoposide followed by IV paclitaxel plus carboplatin or docetaxel plus carboplatin
3281530|NCT01669226|Active Comparator|Regimen A: Standard TCiv therapy|IV paclitaxel plus carboplatin or docetaxel plus carboplatin
3281531|NCT01669239|Experimental|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
3281532|NCT01669252|Experimental|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
3281533|NCT01669265||OSNA|Patient cases with cT1-3, N0 early breast cancer, who previously had intraoperative sentinel lymph node (SLN) evaluation by one-step nucleic acid amplification (OSNA) assay with a complete axillary dissection.
3281534|NCT01669278|No Intervention|Traditional flexible nasopharyngolaryngoscopy|No sheath procedure
3281535|NCT01669278|Active Comparator|Sheath flexible nasopharyngolaryngoscopy|Flexible nasopharyngolaryngoscopy using endosheath
3281536|NCT01669291|Active Comparator|Bravelle & Menopur Agonist Long Protocol|Patients will use an LH agonist (Lupron) starting on day 18 of the oral contraceptive pill (OCP), 5 units b.i.d. followed by 5 units q.d. beginning on day one of stimulation medications. The 5 units q.d. dose will continue until the day of hCG administration.Patients will administer Bravelle and Menopur for ovarian stimulation.
3281537|NCT01669291|Active Comparator|Bravelle & Menopur Antagonist Protocol|Patients will complete standard dose of oral contraceptive pill (OCP) and will then administer GnRH antagonist (ganirelix acetate or cetrorelix acetate) 0.25 mg q.d. during the stimulation phase when the lead follicle size reaches 12mm. The antagonist will continue until the day of hCG administration. Patients will administer Bravelle and Menopur for ovarian stimulation.
3281538|NCT01669304|Experimental|Verapamil|Verapamil extended release oral tablets administered in a flexible dose format ranging from 120 mg to 360 mg daily, as determined by severity of headache and dizziness.
3281539|NCT01669304|Experimental|Sertraline|Sertraline oral tablets administered in a flexible dose format ranging from 25 mg to 150 mg daily depending on severity of headache and dizziness.
3281540|NCT01669317|Experimental|Cherry Juice Standardized|You will be given an 8-ounce glass of cherry juice to drink when you arrive at the Sleep Laboratory.
3281541|NCT01669317|Placebo Comparator|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice to drink when you arrive at the Sleep Laboratory.
3281542|NCT01669330|Active Comparator|Total fundoplication|Procedure: Laparoscopic Nissen fundoplication
3281543|NCT01669330|Active Comparator|Anterior partial fundoplication|Procedure: Laparoscopic anterior partial fundoplication
3281544|NCT01669356|Experimental|PN supplement|Parenteral supplement with enteral nutrition for patients after esophagectomy
3281545|NCT01669356|Active Comparator|EN alone|Enteral nutrition alone for patients after esophagectomy
3281546|NCT01669369|Placebo Comparator|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
3281547|NCT01669369|Experimental|Lithium Carbonate|Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
3281548|NCT01669382|Active Comparator|Exo Seal system|Percutaneous coronary intervention
3281549|NCT01669382|Active Comparator|AngioSeal system|percutaneous coronary intervention
3281550|NCT01669395|Experimental|Early homebased rehabilitation|After discharge from the hospital patients are offered a homebased rehabilitation program lasting 6 weeks.
3281551|NCT01669395|Experimental|control group: Ususal care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
3281552|NCT01669408|Active Comparator|Cold infusions|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
3281553|NCT01669408|No Intervention|Control group|Best medical treatment following international stroke guidelines
3378182|NCT03143556|No Intervention|Routine stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure and randomized for routine stent would receive routine stent and the removal of stent would be done by cystoscopy
3281554|NCT01669447|Experimental|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
3281555|NCT01669460|Experimental|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink: two (250mL) cans per day for 28 days
3281556|NCT01669473|Experimental|Intervention Arm|"EHR Based Strategy to promote Safe and Appropriate Drug Use~Patients randomized to the intervention arm will be given (3) print tools to assist in safe and appropriate medication use. These include a Medreview, Medsheet,and Medlist."
3281557|NCT01669473|No Intervention|Standard Care Arm|The control group will receive regular standard care at the Clinic. They will not receive any print tools.
3281558|NCT01669486||ICU patients|All patients admitted to ICU for a minimal hospitalization of 24 hours, invasive mechanically ventilated, will be evaluated with CPOT and BPS scores, during nurses work, in particular before and after nurses manoeuvers.
3281559|NCT01669499|Placebo Comparator|Placebo|Placebo on day 0-3
3281560|NCT01669499|Active Comparator|Dexamethasone acetate day 0|8 mg dexamethasone on day 0
3281561|NCT01669499|Active Comparator|Dexamethasone acetate day 0-3|8 mg dexamethasone on day 0-3
3281562|NCT01669512|Active Comparator|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56 6 Volunteers
3281563|NCT01669512|Experimental|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56 8 Volunteers
3281564|NCT01669512|Experimental|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56 8 Volunteers
3281565|NCT01669525||No treatment|Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.
3281566|NCT01669551||Structural or Valvular Heart Disease|
3281567|NCT01669564|Active Comparator|Activated Patients|Will use HIT patient feedback to activate patients.
3281568|NCT01669564|Other|Control patients|Patients will not receive HIT patient feedback.
3281569|NCT01669564|Other|Intervention Physicians|Will use HIT patient feedback to activate patients.
3281570|NCT01669564|Other|Control Physicians|Patients will not receive HIT patient feedback.
3281571|NCT01669590||old (60-75yr)|
3281572|NCT01669590||young (18-35y)|
3281573|NCT01669668|Experimental|RFA|Patients undergo laparoscopic ultrasound followed by RFA.
3281574|NCT01669681||Included in the cohort COBRA|
3281575|NCT01669694||Women with Pelvic Pain|Women with Pelvic Pain undergoing pelvic floor PT in the Beaumont Women's Urology Center
3281576|NCT01669707|Experimental|Endostar -Continued Pumping into+GP|Endostar that is Continued Pumping into vein Combining With Gemcitabine -Cisplatin
3281577|NCT01669707|Active Comparator|Endostar -injecting into +GP|Endostar that is injecting into vein with Gemcitabine -Cisplatin
3281578|NCT01669733|Experimental|Live/Recorded Music Group|The music therapist will prepare a preferred song to be performed live in the preoperative room. Subjects in the live music group will listen to recorded music intraoperatively.
3281579|NCT01669733|Experimental|Recorded Music Group|Recorded music group will be given an iPod and headphones and will listen to a recorded version of a preferred song.
3281580|NCT01669733|Active Comparator|No Music (Standard of care)|The control group will receive standard of care and no music.
3281581|NCT01669746|Experimental|Treatment|
3281582|NCT01669759||fatigue|
3281583|NCT01669772|Other|DA-9701 and placebo|Administer DA-9701 for 1week and assess the study outcomes. After 1 week of washout period, administer placebo for 1week and assess the outcomes again.
3281584|NCT01669772|Other|Placebo and DA-9701|Administer placebo for 1 week and study the outcome parameters. After 1 week of washout, administer DA-9701 for 1 week and assess the outcome parameters again.
3281585|NCT01669824||Group 1|
3281586|NCT01669837||Patient group|Administration of surgical tissue glue.
3281587|NCT01669850|Experimental|Clipped anastomosis|A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
3281588|NCT01669850|Active Comparator|Handsewn anastomosis|A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.
3281589|NCT01669876|Active Comparator|Dietary Supplement: Anatabloc(R)|Study product, as mint-flavored lozenge (3 mg anatabine per lozenge) to be taken 2-3 times each day
3281590|NCT01669876|Placebo Comparator|Placebo|Placebo, as mint-flavored lozenge, to be taken 2-3 times each day
3281591|NCT01669889||Cohort|
3281592|NCT01669941|Experimental|IPTp-DP|At each ANC visit, women will be given treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
3378183|NCT03122431|Other|SLE/cutaneous lupus with thalidomide|This subproject includes only one arm of lupus patients with active and refractory cutaneous disease and eligible for Thalidomide 100mg/day for 12 months.
3378184|NCT03122431|Active Comparator|Inactive SLE with standard dose of HCQ|This subproject includes one arm of lupus patients with inactive disease, in which will be maintained on standard dose of Hydroxychloroquine (400mg/day).
3378185|NCT03122431|Active Comparator|Inactive SLE with reduced dose of HCQ|This subproject includes one arm of lupus patients with inactive disease: in which the dose will be reduced to 400mg 3 times a week (Hydroxychloroquine reduced).
3378186|NCT03119363|Experimental|Experimental Light|The experimental systematic light exposure consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses (AYO) each morning for 4 weeks. The AYO light glasses is a lightweight pair of glasses that emits light from LEDs at a distance of 15 millimeters (15mm, 0.015m) from the eye.
3378187|NCT03119363|Active Comparator|Comparison Light|The active comparator condition consists of exposure to light to reduce cancer-related fatigue. This group will self-administer 30 minutes of light from commercially available light glasses each morning for 4 weeks.
3378188|NCT03111745||1|Retrospective chart review of patients who have underwent hematopoietic stem celltransplantation (HSCT)
3378189|NCT03107104|Experimental|Medical need for FA imaging|Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera
3378190|NCT03099746|Experimental|INVOLVE|"The first study condition, called Interactive Virtual Decision Support for End-of-Life and Palliative Care (INVOLVE) will consist of exposures to an avatar-based decision support technology that will be administered via tablet computer and allow SDMs opportunities to practice their communication and decision making skills through interactions with avatars that portray a decision coach and various healthcare providers."
3378191|NCT03099746|Experimental|Informational Support|The second condition, called Informational Support (IS), will also be administered via tablet computers and expose SDMs to educational resources of INVOLVE without the experiential components.
3378192|NCT03099746|Experimental|Usual Care|The third condition, usual care (UC), will expose SDMs to the routine communication and decisional support practices provided by the healthcare team.
3378193|NCT03099356|Experimental|Cyclophosphamide and Sirolimus|Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
3378198|NCT03092505||Females|Females participants who are about to start first line antiretroviral therapy.
3378199|NCT03092492||Participants with bilateral early AMD|Participants with bilateral early AMD
3378200|NCT03092492||Participants with large RPD|Participants with large RPD
3378201|NCT03092492||Participants with small or medium-sized drusen|Participants with small or medium-sized reticular pseudodrusen (RPD)
3378202|NCT03092492||Unaffected Age-matched controls|Healthy age-matched controls
3378203|NCT03084939|Experimental|Trastuzumab Emtansine|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with trastuzumab emtansine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
3378204|NCT03084939|Active Comparator|Control (lapatinib + capecitabine)|Participants with HER2-positive, unresectable LABC or MBC who have experienced disease progression after treatment with trastuzumab and a taxane will be treated with lapatinib plus capecitabine. Participants may continue to receive study treatment until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor.
3378205|NCT03080714|Active Comparator|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
3378206|NCT03080714|Active Comparator|Subjects presenting with Retinal Disease|Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
3378207|NCT03080714|Active Comparator|Subjects presenting with Glaucoma|Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro
3378208|NCT03059121||HIV-infected ART-naïve|HIV-infected subjects ≥ 16 years who are ART-naïve starting their first antiretroviral regimen
3378209|NCT03049475||Control|Healthy, between age 18-80, African/African decent
3378210|NCT03049475||Subjects in steady State|Steady state is defined as the period from at any time 8 weeks prior to or after a crisis and samples obtained during this time would be considered steady state samples .
3378216|NCT03027440||CPP Cohort|offspring born to historic CPP cohort participant mothers between 1959 and 1966 who were known to be alive at age 7 (if still alive at the time of NDI search, ages 50 to 57 years old)
3378217|NCT03027310||Healthy Volunteers|adult healthy volunteers
3378218|NCT03027310||tremor patients|adult patients with tremor
3378219|NCT03022383|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be scanned on the DRI OCT Triton Plus device
3448454|NCT04063904|Experimental|Mifepristone and misoprostol|Mifepristone 200 mg orally, followed 24-48 hours later by misoprostol 400mcg sublingually every three hours until the abortion occurs. The experimental part of the regimen is that the first dose of misoprostol will be taken 1-2 hours before arriving at the clinic for continued dosing, monitoring and abortion completion.
3448455|NCT04064060|Experimental|ACE-536|Luspatercept will be administered as a subcutaneous (SC) injection to subjects by the study staff at the clinical site and administration will be documented in the subject's source record.
3448456|NCT04063865|Active Comparator|Control Arm|Tacrolimus as maintenance immunosuppression
3448457|NCT04063865|Experimental|Study Arm|Everolimus monotherapy maintenance immunosuppression
3281593|NCT01669941|Experimental|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if they test positive, will be treated with dihydroartemisinin-piperaquine (DP). Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
3281594|NCT01669941|Active Comparator|IPTp-SP|Treatment with a single dose of three tablets of sulfadoxine-pyrimethamine, each containing sulfadoxine (500 mg) and pyrimethamine (25 mg) at each FANC visit. This is the standard regimen.
3281595|NCT01669954||Controls, females|Controls who are presumed HIV uninfected, females, aged 18 or above
3281596|NCT01669954||Controls, males|Controls presumed HIV uninfected, males, aged 18 or above
3281597|NCT01669954||HIV infected patients, males|HIV patients, males, aged 18 or above
3281598|NCT01669954||HIV patients,|HIV patients, females, aged 18 or above
3281599|NCT01669967|Placebo Comparator|Diphenhydramine(Benadryl)|
3281600|NCT01669967|Active Comparator|Lidocaine|
3281601|NCT01669980|Experimental|Ceftaroline fosamil|
3281602|NCT01669980|Active Comparator|IV Ceftriaxone and Vancomycin|
3281603|NCT01670006|Experimental|Cochlear Implantation|Cochlear Nucleus Cochlear Implant System
3281604|NCT01670032|Experimental|CD07223 1.5 % Topical Gel BID|Drug: 1.5% CD07223 Topical Gel applied BID for 7 days
3281605|NCT01670032|Experimental|CD07223 1.5% Topical Gel TID|Drug: 1.5% CD07223 Topical Gel applied TID for 7 days
3281606|NCT01670032|Placebo Comparator|CD07223 vehicle gel BID|Drug: CD07223 Vehicle Topical Gel applied BID for 7 days
3281607|NCT01670032|Placebo Comparator|CD07223 vehicle gel TID|Drug: CD07223 Vehicle Topical Gel applied TID for 7 days
3281608|NCT01670058||Belatacept treated adult kidney-only transplant recipients|All adult kidney-only transplant recipients treated with Nulojix (Belatacept)
3281609|NCT01670058||CNIs at transplantation|
3281610|NCT01670071|Experimental|Paliperidone extended-release|
3281611|NCT01670071|Active Comparator|Risperidone immediate-release|
3281612|NCT01670084|Experimental|Treatment (nilotinib, combination chemotherapy)|See Detailed Description
3281613|NCT01670123|Experimental|Mobile Phone Condition|This arm will involve daily self-monitoring with an electronic mobile device with responses to survey questions about mood status. Mood status reports are linked with personalized coping strategies.
3281614|NCT01670123|Placebo Comparator|Paper-and-pencil condition|This arm will complete a paper-and-pencil mood chart on a daily basis
3281615|NCT01670136|No Intervention|sildenafil, standard of care|Infants receiving sildenafil as standard of care
3281616|NCT01670136|Other|sildenafil administered for study|1 dose of sildenafil administered for study
3281617|NCT01670149|Placebo Comparator|Placebo|Identical looking tablet
3281618|NCT01670149|Active Comparator|Rifaximin , Xifaxanta™|2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),
3281619|NCT01670162|Experimental|3 loading doses, then every 2 months|All patients will receive 3 monthly intravitreal aflibercept injections followed by mandatory dosing every 3 months. If needed, patients can be treated monthly.
3281620|NCT01670175|Experimental|Sirolimus, Cyclophosphamide, Topotecan|Sirolimus, Cyclophosphamide, Topotecan Patients accrued to dose levels in cohorts of 3 (3+3 design). Patients will receive daily oral sirolimus and cyclophosphamide days 1-21 in 28-day cycle, combined with oral topotecan given on days 1-14. Sirolimus will be dosed based on steady-state plasma trough concentrations.
3281621|NCT01670214|Active Comparator|Pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions phase 1 treatment and added 6 sessions for phase 2 treatment (3 sessions per week)
3281622|NCT01670214|Placebo Comparator|pulsed electromagnetic field|patients are placed under off instrument while who is kept blind to know it for 6 sessions (3 sessions per week).
3281623|NCT01670227|Experimental|PARENTCORPS|ParentCorps is a school-based, family-focused universal intervention designed to attenuate the multiple risks associated with urban poverty, on children's health and development
3281624|NCT01670227|Other|Control Condition|No intervention
3281625|NCT01670240|Active Comparator|Adalimumab|Every second week, mg: 160-80-40-40-40-40 12 weeks in all
3281626|NCT01670240|Placebo Comparator|Placebo|Given as the active comparator, every second week
3281627|NCT01670253|No Intervention|Group 2|6 hours of total fast for all solid and liquid food / drinks
3281628|NCT01670253|Experimental|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
3281629|NCT01670266|Experimental|Experimental Arm 1|Experimental Eye drops 3.0 µg/mL QD both eyes on Day 1, 5-18
3281630|NCT01670266|Experimental|Experimental Arm 2|Experimental Eye drops 10.0 µg/mL QD both eyes on Day 1, 5-18
3281631|NCT01670266|Experimental|Experimental Arm 3|Experimental Eye drop 30.0 µg/mL QD both eyes on day 1, 5-18
3281632|NCT01670266|Experimental|Experimental Arm 4|Experimental Eye drop, 2 sequence crossover Cohort [1 dose; 1-30 µg/mL]to be determined and placebo
3281633|NCT01670266|Placebo Comparator|Placebo Arm|Matched placebo eye drops dosed in same manner as ONO-9054
3281634|NCT01670305|Experimental|Residual pocket - PDT|Photosensitizer plus diiodo laser
3281635|NCT01670305|Placebo Comparator|Residual pocket - Photosensitizer|Photosensitizer alone
3281636|NCT01670305|Active Comparator|Residual pocket - SRP|scaling and root planing alone
3281637|NCT01670305|Experimental|Furcation - PDT+SRP|Photosensitizer plus diiodo laser associated with scaling and root planing
3281638|NCT01670305|Active Comparator|Furcation - SRP|Photosensitizer associated with scaling and root planing
3281639|NCT01670318|Experimental|platinum chromium everolimus-eluting stent|
3281640|NCT01670331|Active Comparator|Psychological preparation|Patients undergo 3 seminar sessions with the bariatric psychologist prior to their surgery. These will aim to prepare them for the lifestyle changes that will occur / they will have to make after surgery
3281641|NCT01670331|No Intervention|Surgery as usual|Patients will proceed to surgery as usual. They will complete psychological assessment forms at their follow up clinic sessions.
3281642|NCT01670344|Other|A|Treatment with investigational method (virtual implant positioning system)
3281643|NCT01670344|Other|B|Treatment with surgical standard of care
3281644|NCT01670357|Experimental|DA-6034 Low dose|DA-6034 3%
3281645|NCT01670357|Experimental|DA-6034 High dose|DA-6034 5%
3281646|NCT01670357|Placebo Comparator|Placebo|DA-6034 Placebo
3281647|NCT01670370|Experimental|Rituximab+Gemcitabine+oxaliplatin (R-GemOx)|Rituximab: 375 mg/m2 IV day1, Gemcitabine 1g/m2 IV day 2, oxaliplatin 100mg/m2 IV day2(every 14 days)
3281648|NCT01670383||Postresuscitation group|Adults (age over 16 years old) who have survived from nontraumatic cardiac arrest and admitted to ICU.
3281649|NCT01670383||Sepsis group|Adults (age over 16 years old) who satisfy the sepsis criteria (SIRS>=2 and infection is suspected for a cause) and admitted to the ICU.
3281650|NCT01670396||in-stent restenosis|
3281651|NCT01670396||non-in-stent restenosis|
3281653|NCT01670435||Group 1|
3281654|NCT01670448|Active Comparator|PECBLOCK performed with bupivacaine|Active drug given through PECBLOCK in these patients.
3281655|NCT01670448|Placebo Comparator|PECBLOCK performed with NaCl 0.9%|Placebo drug given through PECBLOCK in these patients
3281656|NCT01670461|Experimental|FACE Advance Care Planning|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
3281657|NCT01670461|Other|Standard of Care (SOC) Control|Standard of Care Control: Advance Directive Information Booklet plus Advance Directive Checklist.
3281658|NCT01670474|Experimental|fmDLC and rt-PA (2mg/2mL actilysis)|"Surface thrombogenicity of film-coated domain structured double lumen catheters (fmDLC) consisting of a novel reactive polyurethane copolymer coating will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3281659|NCT01670474|Active Comparator|polyDLC and rt-PA (2mg/2mL actilysis)|"The same procedure will be assessed in the polyurethane double lumen catheter (polyDLC)as with the fmDLC. Indeed, surface thrombogenicity of polyDLC will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3281660|NCT01670474|Active Comparator|siDLC and rt-PA (2mg/2mL actilysis)|"Same procedure as the previous catheters. Surface thrombogenicity of silicone double lumen catheter (siDLC) will be assessed by measurement of thrombin-antithrombin (TAT) III complex in vitro after the use of rt-PA (2mg/2mL) in each lumen of the catheter for 45 minutes.~Each lumen of the thrombosed (dysfunctional) catheter will be locked with the exact volume (luminal volume) of rt-PA (rt-PA (2mg/2mL) actilysis) during 45 min."
3281661|NCT01670513|Experimental|IDP-118 Low Strength|IDP-118 Low Strength
3281662|NCT01670513|Experimental|IDP-118 High Strength|IDP-118 High Strength
3281663|NCT01670539|Experimental|Telemonitor|"In addition to routine care, the HomMed Telemonitor wireless telemonitoring system (intervention)will be used in the patient's home for 14 days to alert the clinical research nurse to changes in patients conditions in order to contact them to teach self-management. The Honeywell HomMed Genesis™ DM Remote Patient Care Monitor will be used to measure temperature, pulse, oxygen level,weight and blood pressure. The telemonitor will also ask for a YES or NO response to questions on symptoms such as difficulty breathing. Research nurses review the data daily and call the participant for 2 weeks, and continue to monitor outcomes for 2 months."
3281664|NCT01670539|No Intervention|Routine care for patients with lungCa|Traditional physician ordered post-hospital care for patients with lung CA in rural WV requires patients to make an outpatient office/ clinic visit two to three weeks after discharge;a few patients receive homecare service referrals. No attempt to change care - just monitor what is used and collect study data at Discharge, 2 weeks, one month and two months.
3281665|NCT01670552|Experimental|Nimesulide + Pantoprazole|Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
3281666|NCT01670552|Active Comparator|Naproxen + Esomeprazole|Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
3281667|NCT01670565|Experimental|Mycophenolate mofetil + Belimumab|All patients who enroll in this trial will FIRST receive mycophenolate mofetil (MMF, Cellcept), which is a drug commonly given to patients with scleroderma in clinical practice. This drug will be given at no cost to the patient. After the patient has been titrated to 2 grams of MMF per day, the patient will receive EITHER a 10 mg/kg belimumab (Benlysta) intravenous infusion OR a placebo (saline) infusion. This medication and infusion will of course be covered by the study.
3281668|NCT01670565|Placebo Comparator|Mycophenolate Mofetil + Saline (placebo)|In order to observe the difference between belimumab/MMF compared to MMF alone, half of the patients will receive a normal saline infusion that appears identical to the belimumab infusion.
3281669|NCT01670578|Experimental|PRP Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
3281670|NCT01670578|Active Comparator|Hyaluronan Group|Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
3281671|NCT01670591|Experimental|PS - Prevention in School|Teachers learn to use the core program components (defining and teaching school rules and the handling of rule breakings, principles of positive behavior support)with help from external consultants during approximately 1.5 years.
3281672|NCT01670591|No Intervention|Business as usual|
3281673|NCT01670604|Experimental|VOL group|patients will receive 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
3281674|NCT01670604|Experimental|TET group|patient will receive 6% HES 130/0.42 in a balanced electrolyte containing Na+140 mmol/L, Cl- 118 mmol/L, K +4 mmol/L, Ca++ 2.5 mmol/L, Mg++ 1 mmol/L, acetate- 24 mmol/L and malate-- 5 mmol/L
3281675|NCT01670617|Other|DeNovo NT Graft|DeNovo NT Graft stratified by lesion location - femur or patella
3281676|NCT01670630|Active Comparator|Sheathed speculum|"Investigators will perform a vaginal speculum examination with either a sheathed or a standard (non sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception."
3281677|NCT01670630|Active Comparator|Standard speculum examination|Investigators will perform a vaginal speculum examination with either a standard or a sheathed speculum in a randomized comparison to estimate the degree of cervical visualization and subject pain perception.
3281678|NCT01670643||Video camera magnifier|
3281679|NCT01670669|Active Comparator|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
3281680|NCT01670682|Active Comparator|fascia fixation group|procedure: ischia spinous fascia fixation
3281681|NCT01670682|Active Comparator|mesh group|Procedure: Modified Pelvic Floor Reconstruction Surgery with mesh
3281682|NCT01670695||IgG4-RD|Patients with IgG4-RD, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis (Mikulicz disease and Küttner's tumor), inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions.
3281683|NCT01670708|Experimental|HOPE|Participation in HOPE program
3281684|NCT01670708|Active Comparator|Probation as Usual|Participation in probation as usual
3281685|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - mild hepatic function|Injection through subcutaneous (SC) administration in patients with mild hepatic function
3281686|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - moderate hepatic function|Injection through subcutaneous (SC) administration in patients with moderate hepatic function
3281687|NCT01670734|Experimental|alirocumab SAR236553 (REGN727) - normal hepatic function|Injection through subcutaneous (SC) administration in patients with normal hepatic function
3281688|NCT01670747||ARDS|Sedated and mechanically ventilated patients admitted to ICU
3281689|NCT01670773|Experimental|CAT-1004 Dose #1|Single dose #1
3281690|NCT01670773|Active Comparator|Salsalate + DHA|Single dose #2
3281691|NCT01670773|Placebo Comparator|Placebo|Single Dose #3
3281692|NCT01670786|Experimental|Iodopovidone 1%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
3281693|NCT01670786|Experimental|Iodopovidone 2%|The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
3281694|NCT01670799|Experimental|Ketorolac|"All patients will receive a single dose of IV ketorolac for pain management for the indication of post-operative pain control. Patients less than 65 years of age and in otherwise good health will receive a 30mg IV single dose. Patients 65 years of age or greater, or who have mild renal insufficiency or are of low weight (as per section 3.2) will receive a single 15 mg dose IV ketorolac.~In patients who have a clinical pain response and have no contraindications to multi-dose (every 6 hours over 24 hours), additional doses will be given per physician discretion based on clinical indication. Patients receiving 24 hour dosing will be eligible for sample time points after 24 hour dosing."
3281695|NCT01670812|Experimental|FFP+HDMP+Rituximab|Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5.
3281696|NCT01670838||subarachnoid haemorrhage|nontraumatic subarachnoid haemorrhage
3281697|NCT01670851||Strattice|eLAPE
3281698|NCT01670864|Experimental|Counseling group|Study participants in the counseling group will receive a brief on-site face-to-face smoking cessation counseling from our trained smoking cessation counselor on the study site after signing the consent form. They will receive advice on quitting smoking and specific warning about the hazardous effects of smoking on health. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
3281699|NCT01670864|Experimental|SMS intervention group|Study participants in the SMS group will receive SMS text messages on smoking cessation advice and warning on the hazardous effects of smoking on health. The participants will receive a total of 16 tailored SMS messages after recruitment.
3281700|NCT01670864|No Intervention|Control group|Study participants in the control group will not receive any quitting assistance other than the self-help materials from the recruitment sites.
3281701|NCT01670877|Experimental|Part I: met HER2- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3281702|NCT01670877|Experimental|Part II: met HER2- ER- BC w/HER2 mutations|"Patients will receive neratinib PO daily on Days 1-28. Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3281703|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-naive|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3281704|NCT01670877|Experimental|Part II: met HER2- ER+ BC w/HER2 mutations, fulvestrant-tx|"Patients will receive neratinib PO daily on Days 1-28 and fulvestrant on Day 1 of each cycle (and C1D15). Each cycle is 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.~If a participant experiences disease progression following neratinib, trastuzumab (or FDA approved biosimilar) may be added to the treatment regimen. Trastuzumab may be administered intravenously with a loading dose of 6 mg/kg then 4 mg/kg every 2 weeks. A cycle will be defined as 28 days."
3281705|NCT01670890|Active Comparator|TMZ group|patients were treated with TMZ alone
3281706|NCT01670890|Experimental|TMZ plus CDDP group|patients were treated with TMZ plus CDDP
3281707|NCT01670903||ARBs|Hypertensive patients treated with ARBs
3281708|NCT01670903||ACE inhibitors|Hypertensive patients treated with ACE inhibitors
3281709|NCT01670903||non ARB/ACE|Hypertensive patients treated with non ARBs or ACE inhibitors meds
3281710|NCT01670916||Probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
3281711|NCT01670916||Control|Probiotics never given
3281712|NCT01670929|Active Comparator|Progesterone group|progesterone (400 mg pessary, once daily)
3281713|NCT01670929|Placebo Comparator|Placebo group|Placebo (pessary, once daily)
3281714|NCT01670942||Traumatic Pneumothorax1|hypobaric chamber
3281715|NCT01670955|Active Comparator|Jobelyn + Ferrous Sulphate + Folic Acid|Caps Jobelyn 250mg, 12 hourly + Ferrous Sulphate 600mg thrice daily + Folic Acid 5mg daily
3281716|NCT01670955|Active Comparator|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
3281717|NCT01670981|Experimental|ixmyelocel-T|Ixmyelocel-T delivered by catheter-based intramyocardial injection procedure.
3281718|NCT01670981|Placebo Comparator|Placebo|Placebo delivered by catheter-based intramyocardial injection procedure.
3281719|NCT01670994|Experimental|ALT-801|
3281720|NCT01671020|Active Comparator|(R)(T)|Period 1: Fimasartan 60mg → Period 2: Fimasartan 30mg
3281721|NCT01671020|Active Comparator|(T)(R)|Period 1: Fimasartan 30mg → Period 2: Fimasartan 60mg
3281722|NCT01671033|Experimental|Muscle Relaxation|The patients of this arm practice on-line muscle relaxation every day.They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
3281723|NCT01671033|Experimental|Muscle Relaxation with Biofeedback|The patients of this arm practice on-line muscle relaxation with finger temperature biofeedback every day. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR(APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Clinical Global Impression (CGI) were performed by well-trained clinicians.
3281724|NCT01671033|No Intervention|Waiting-List|The patients of this arm waited for four weeks. They complete the Brief Symptom Rating Scale(BSRS), Family APGAR (APGAR), the Chinese-version of the Medical Outcomes Study 36-Item Short Form Health Survey(SF-36), and the panic diary via internet browser. The Panic Disorder Severity Scale(PDSS)and Impressions-Improvement(CGI) were performed by well-trained clinicians.
3281725|NCT01671046||Cohort|
3281726|NCT01671072|Experimental|TissueGene-C|Single intra-articular injection to the damaged knee joint a dose of 1.8 x 10^7 cells
3281727|NCT01671072|Placebo Comparator|Normal Saline|Single intra-articular injection to the damaged knee joint at the same volume
3281728|NCT01671098||Control|Healthy adults
3281729|NCT01671098||Balloon Sinuplasty|Patients who had balloon sinuplasty
3281730|NCT01671098||FESS-Uncinectomy|Patients who had FESS-Uncinectomy
3281731|NCT01671124||Soline capsule|Salvia divinorum, Lycium, Chenpi and Dihuang
3281732|NCT01671137|Active Comparator|Lactobacillus Rhamnosus Strain GG|LGG (6 × 109 colony forming units)
3281733|NCT01671137|Placebo Comparator|Placebo|Placebo
3281734|NCT01671150|Placebo Comparator|Placebo control|half of the participants will receive a placebo control
3281735|NCT01671150|Active Comparator|Endotoxin (Inflammatory challenge)|
3281736|NCT01671163||Subjects requiring fiducial placement|Endoscopic Ultrasound (EUS) for fiducial placement
3281737|NCT01671189|Experimental|SMS Appointment Reminders|150 patients will be randomly assigned to the intervention arm of the study and receive text reminders about their upcoming appointments.
3281738|NCT01671189|No Intervention|Existing Reminder Protocol|150 patients will be randomly assigned to the control arm of the study and will not receive SMS reminders about their upcoming appointments. They will, however, be subject to the clinics' existing reminder protocol (phone call reminders by either clinic personnel or computer machine).
3281739|NCT01671228|Experimental|decision aid|The Yorkshire Dialysis Decision Aid (YoDDA). Delivered as a leaflet in clinic and a web resource outside the NHS.
3281740|NCT01671228|Experimental|Decision Aid + values task|The Yorkshire Dialysis Decision Aid (YoDDA) + values clarification questions. delivered as a leaflet in clinic and a web-based resource outside the NHS.
3281741|NCT01671228|Experimental|Decision Aid + patient stories|The Yorkshire Dialysis Decision Aid (YoDDA) + patient stories. Delivered as an web-based resource outside the NHS.
3281742|NCT01671228|No Intervention|usual predialysis education|The consultations and information usually provided by the predialysis health professionals
3281743|NCT01671241|Experimental|Total body polyethylene wrap (body plus head)|The entire body surface (body plus head) is covered by a polyethylene wrap
3281744|NCT01671241|Active Comparator|Polyethylene wrap (body)|A polyethylene wrap covers the patient's body up to the neck
3281745|NCT01671254|Active Comparator|FishOil + placebo|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule
3281746|NCT01671254|Experimental|FishOil + CBE75|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)
3281747|NCT01671254|Experimental|FishOil + CBE150|Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)
3281748|NCT01671267|Experimental|Strength training|Strength training of the shoulder, arm and hand muscles for 3 x 10 minutes a week.
3281749|NCT01671267|Active Comparator|Ergonomic|Receives counseling on workstation adjustment and optimal use of the work tools.
3281750|NCT01671306||Collateral, coronary disease|Patients are grouped into 2: Good and poor collateral development
3281751|NCT01671306||collateral|Patients are grouped into 2: Good and poor collateral development
3281752|NCT01671358||Isolation Rooms for MRSA|Rooms that currently have a patient in them that are in isolation status due to MRSA
3281753|NCT01671358||Non-isolation rooms|Rooms that have not been occupied by a patient in isolation due to MRSA for 14 days
3281754|NCT01671371|Other|Immediate Ultrasound|A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
3281755|NCT01671371|Other|Delayed Ultrasound|A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization
3281756|NCT01671384|Active Comparator|Valproate, levocarnitine|"The patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
3281757|NCT01671384|Placebo Comparator|Placebo|"All patients will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)"
3281758|NCT01671397|Experimental|Diet, exercise, sleep hygiene counseling|Subjects will meet with a dietitian and a physician and receive counseling on diet restriction, exercise goals, and good sleep hygiene. Subjects will identify goals in each domain and keep a calendar of the success with achieving these goals.
3281759|NCT01671397|Active Comparator|Diet and exercise counseling|Subjects will meet with a dietitian and a physician and receive counseling on calorie restriction and exercise. They will identify goals in each domain and keep a calendar to determine their success with achieving these goals.
3281760|NCT01671410|Experimental|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
3281761|NCT01671410|Active Comparator|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
3281762|NCT01671436|Experimental|Central Meditation and Imagery Therapy|Intervention involved Central Meditation, may be characterized by a voluntary, regulated attentional set towards a specific stimulus or set of stimuli and visualization exercises utilized within CMIT, which primarily involves two types of thought experiments: 1) creating mental models of how a person fits into the larger world and universe according to evolutionary biology and modern cosmology, in order to gain a larger perspective on emotions and thought patterns, and 2) backcasting, the generation of a desirable future coupled with mental time travel back to the present to determine how to create that future with present-day actions.
3281763|NCT01671449|Active Comparator|S-1 plus Cisplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Cisplatin: 60 mg/ m2/day, i.v., day 1~Every 3 weeks"
3281764|NCT01671449|Experimental|S-1 plus Oxaliplatin|"S-1: 40 mg/m2, twice daily, p.o., day 1-14 (see Table 6 for dose calculation of S-1 according to body surface area)~: If S-1 is started on the evening of day 1, last dose of S-1 will be administered at the morning of day 15.~Oxaliplatin: 130 mg/ m2/day, i.v., day 1~Every 3 weeks"
3281765|NCT01671475|Experimental|Routine care plus microEEG|Subjects allocated to this group will undergo an EEG using microEEG device in addition to their routine care. The microEEG device will be used with commercially available electrodes in a headpiece configuration.
3281766|NCT01671475|No Intervention|Routine care only (control group)|Subjects allocated to the control group will receive routine care without microEEG. The treating physician may request a standard EEG, which will be performed by the hospital EEG laboratory, if available.
3281767|NCT01671501|Experimental|Motivational Interviewing|The intervention consists of one 45-minute in-person session followed by two 20-minute telephone sessions.The first telephone MI session will occur approximately 10 days after the in-person session. The second call will occur 30 days after the first call. The same research clinician will conduct both the in-person session and phone sessions. The calls will include a review of material covered in the initial session, questions on alcohol use, open-ended questions regarding patients' current motivational level, and a review of the patient's initial goals regarding alcohol consumption and will last about 20 minutes. If after six months hazardous drinking is noted, three more motivational interviewing phone sessions will be delivered by the research clinician.
3281768|NCT01671501|Experimental|Email Feedback|Each participant will receive up to three detailed emails, (if participants respond to a first, initial email with information on alcohol use risks). The initial and subsequent emails will be brief in length, and will include specific information on hazardous drinking levels, standard drink size; as well as advice to reduce drinking to non-hazardous levels. Each email will conclude with contact numbers for patients to receive further information and assistance if needed, including information on how to easily access SU treatment; and will encourage participants to respond to the research clinician with questions. If after six months hazardous drinking is detected, up to 3 more detailed emails will be delivered to the participant.
3281769|NCT01671501|Other|Usual Care|Participants in this arm will receive routine primary care services only. Usual care in this health care setting may include alcohol screening, brief intervention and referral to treatment (SBIRT) delivered by usual care clinic staff
3281770|NCT01671514|Experimental|Sedentary|The sedentary arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
3281771|NCT01671514|Experimental|Heart failure/diabetes|The heart failure/diabetes arm will be randomly assigned to either epicatechin-enriched dark chocolate or low-epicatechin dark chocolate as a placebo. Participants will take one square of chocolate per day for 90 days.
3281772|NCT01671527||Cervical Dystonia: DBS Subjects|Subjects who have undergone or plan to undergo DBS surgery for cervical dystonia
3281773|NCT01671527||Cervical Dystonia: Control Subjects|Subjects who DO NOT plan to undergo DBS surgery for cervical dystonia
3281774|NCT01671527||Healthy Controls|Healthy control subjects who do not have dystonia.
3281775|NCT01671540|Experimental|Intrapulmonary percussive ventilation|IPV is applied for 1 week (once a day) during the physical therapy treatment of the patient
3281776|NCT01671540|Active Comparator|standard airwy claerance regime|The standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises
3281777|NCT01671553|Experimental|Counseling group|Study participants in the intervention group were received an intensive smoking cessation telephone counselling with 2-weeks free and 6-weeks discount nicotine replacement therapy (NRT).
3281778|NCT01671553|No Intervention|Control group|Study participants in the control group were not received any quitting assistance other than the self-help materials provided by Hong Kong Council on Smoking and Health (COSH).
3281779|NCT01671566|Experimental|Home based interval training|12 weeks home based interval training
3281780|NCT01671566|No Intervention|Control group|No structured exercise training.
3281781|NCT01671579|Other|Pediatric small bowel Crohn disease|Subjects with previously diagnosed PSBCD (pediatric small bowel Crohn disease)who are scheduled for a clinically MRE (magnetic resonance enterography)imaging exam.
3281782|NCT01671592|Experimental|Day 1 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
3281783|NCT01671592|Experimental|Day 3 MRI with low dose vaccine|DC vaccine at 3 x 10e6 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
3281784|NCT01671592|Experimental|Day 1 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 1 of the course.
3281785|NCT01671592|Experimental|Day 3 MRI with high dose vaccine|DC vaccine at 3 x 10e7 per course which consists of 3 daily intradermal doses per course with the MRI on day 3 of the course.
3281786|NCT01671631||Acute Coronary Syndrome|Patients with Acute Coronary Syndrome and multivessel coronary artery disease undergoing functional evaluation of non-culprit lesions.
3281787|NCT01671644||Eeva Test Group|Day 3 embryo transfers that used Eeva predictions with morphology grading.
3281788|NCT01671644||Matched case control group|Day 3 embryo transfers using morphology grading only (from a matched concurrent control group).
3281789|NCT01671657||Eeva Test Group|Day 3 embryo transfers that used Eeva with morphology grading (Test Group).
3281790|NCT01671657||Matched case control group|Day 3 embryo transfers using morphology grading only (from concurrent Control Group).
3281791|NCT01671670|Experimental|acupuncture group|use traditional acupuncture to treat functional dyspepsia
3281792|NCT01671670|Sham Comparator|sham acupuncture group|use penetrating sham acupuncture to manage functional dyspepsia
3281793|NCT01671709|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
3281794|NCT01671709|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
3281795|NCT01671722|Experimental|Montelukast sodium tablets|Montelukast sodium tablets 10mg of Dr. Reddy's Laboratories Limited
3281796|NCT01671722|Active Comparator|SINGULAIR|(containing Montelukast sodium) tablets 10mg of Merck Sharp & Dohme Ltd., USA
3281797|NCT01671735|Experimental|VA DPP|Pre-Diabetic Participants eligible for VA DPP receive a curriculum based life-style intervention program tailored off of the original DPP but in a group format
3281798|NCT01671735|No Intervention|VA DPP-eligible MOVE!|Pre-Diabetic participants who screen and are eligible for VA DPP but bc of class being filled - have been assigned to MOVE!
3281799|NCT01671761||young adults|19-24 years old
3281800|NCT01671761||adolescents|15-18 years old
3281801|NCT01671774|Experimental|IMAB362 + ZA|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1.
3281802|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (1 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
3281803|NCT01671774|Experimental|IMAB362 + ZA + IL-2 (3 million IU)|Participants received IMAB362 on Day 1 of each 3-week cycle (every 3 weeks). Participants received ZA on Day 1 and IL-2 on Days 1 to 3 of Cycles 1 and 3 only.
3281804|NCT01671774|Active Comparator|IMAB362|Participants received IMAB362 only on Day 1 of each cycle every 3 weeks.
3281805|NCT01671787|Experimental|GS-7340 8mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3281806|NCT01671787|Experimental|GS-7340 25mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3281807|NCT01671787|Experimental|GS-7340 40mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3281808|NCT01671787|Experimental|GS-7340 120mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3281809|NCT01671787|Experimental|Tenofovir disoproxil fumarate 300mg|After Screening procedures, eligible subjects will be randomized 1:1:1:1:1 to receive either open-label GS-7340 8, 25, 40, or 120 mg (3 x 40 mg), or open-label TDF 300 mg for 28 days.
3281810|NCT01671800|Experimental|Botulinum Type B (Myobloc)|Each vial of active drug will contain 5000 unit/ml of Myobloc, with a total volume of 1 mL. The injections will be spaces 6 cm apart and will cover the entire area to be injected. Each site will receive a volume of 0.08 ml (400 units).
3281811|NCT01671800|Placebo Comparator|Saline solution|The volume to be injected will be calculated assuming the injectate is an active drug, and will therefore be an equivalent volume as an active drug (i.e. 0.08 mL per injection site with a 6 cm spacing interval)
3281812|NCT01671813|Experimental|Brentuximab vedotin Treatment|Participants will have screening tests up to 4 weeks before study treatment and dosing for up to 48 weeks. Brentuximab vedotin will be given with a dose of 1.8 mg (per kilogram of participant's body weight) intravenously (an IV through their vein) every 21 days, over 30 minutes for 16 cycles. Follow-up assessments will be performed up to 104 weeks (2 years).
3378220|NCT03021746|Experimental|Parish Nurse plus Peer Leader|The focus of this approach is for Peer Leaders (PL) to provide Diabetes Self Management Support (DSMS) with the oversight of Parish Nurses (PN). The first component starts with group-based Diabetes Self Management Education (DSME) provided by Certified Diabetes Educators (CDE), co-facilitated by PN and PL and held at the church. PL will also facilitate activities including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit, with oversight of PN. As the study progresses, PL and PN will have progressive leadership responsibilities. Following DSME, participants will be invited to attend 12 months of monthly DSMS support groups led by the PL, with oversight from the PN. This approach allows for PN to provide direct supervision to PL in areas of clinical content, educational methods, and group facilitation and communication skills.
3378221|NCT03021746|Experimental|Peer Leader Only|This approach will contain the same elements as the PN plus PL approach, except that a PN will not be used. Rather, PL will provide all aspects of DSMS, including behavioral goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. This approach will be delivered in a group setting. DSME will be provided by CDEs and co-facilitated by a PL to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 monthly DSMS groups led by PL. Following the group sessions, participants will transition into a period of ongoing support. During this time, participants and PL will be encouraged to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. If needed, PL may contact the CDE for additional information
3378222|NCT03021746|Experimental|Parish Nurse Only|The main focus of this approach will contain all of the same elements as the PN plus PL approach, except that PL will not be used. Rather, the PN will provide all aspects of Diabetes Self Management Support (DSMS), including facilitation of goal setting, monthly phone contacts, and preparation for a diabetes-related health care visit. Diabetes Self Management Education (DSME) will be provided by CDEs and co-facilitated by a PN to ensure consistency in the DSME content. Following DSME, participants will be invited to attend 12 months of monthly, DSMS support groups led by the PN. Following support sessions, participants will transition into a period of ongoing support, where the participants and PN will be encouraged to continue to foster DSMS through programs and initiatives that are meaningful to them, utilizing the existing church infrastructure. The PN may answer clinical questions and may contact the CDE for additional information if needed.
3378223|NCT03009201|Experimental|Treatment (ribociclib, doxorubicin hydrochloride)|"Patients receive ribociclib PO daily on days 1-7, and doxorubicin hydrochloride IV on day 10. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive ribociclib PO daily on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3281813|NCT01671826||above 65 years old|
3281814|NCT01671852|Active Comparator|Nasonex|The intervention group will receive mometasone nasal sprays at the dosage outlined below for 8 weeks. For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks.
3281815|NCT01671852|Placebo Comparator|Saline|The placebo group will receive saline nasal sprays for 8 weeks.
3281816|NCT01671878|Other|Reference Glucose|Glucose standard
3281817|NCT01671878|Experimental|Test Food 1|Cereal
3281818|NCT01671878|Experimental|Test Food 2|Biscuit
3281819|NCT01671891||rectal cancer with stage II-IV|rectal cancer with stage II-IV intervention: pelvic radiotherapy (45-55Gy) concurrent chemotherapy using capecitabine and oxaliplatin
3281820|NCT01671904|Experimental|1L CLL BR+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
3281821|NCT01671904|Experimental|1L CLL BG+V|Participants with first-line (1L)/previously untreated CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and obinutuzumab (BG). Participants received six 28-day cycles of BG+V. Participants with 1L CLL received 6 months of single-agent venetoclax for a total of 1-year treatment duration. Single-agent venetoclax could be extended if there was detectable minimal residual disease (MRD) in the bone marrow and/or partial response (PR) after 1 year of treatment and upon the request of the treating physician.
3281822|NCT01671904|Experimental|R/R CLL BR+V|Participants with relapsed/refractory (R/R) CLL were administered escalating doses of venetoclax (V) in combination with fixed dose bendamustine and rituximab (BR). Participants received six 28-day cycles of BR+V. Participants with R/R CLL continued single-agent venetoclax until disease progression, death, or unacceptable toxicity.
3281823|NCT01671917|Experimental|Educational and exercise program|
3281824|NCT01671917|Active Comparator|Usual care|
3281825|NCT01671930||cardiac computed tomographic angiography|Patients refered for cardiac computed tomographic angiography by a cardiologist.
3281826|NCT01671943|Experimental|Breast carcinoma up to 2.0 cm|
3281827|NCT01671956|Experimental|Bertilimumab|Bertilimumab 10 mg/kg will be administered by IV infusion over 30 minutes
3281828|NCT01671956|Placebo Comparator|Placebo|Phosphate buffered saline (PBS) placebo will be administered by IV infusion over 30 minutes.
3281829|NCT01671969|Experimental|very low calorie diet|
3281830|NCT01671982|Experimental|Tenofovir-containing HAART|
3281831|NCT01671995|Experimental|Nurse monitored heart failure program|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
3281832|NCT01671995|Active Comparator|Standard primary health care|To assess whether a nurse monitored management programme at the hospital outpatient clinic would improve quality of life, as compared to standard primary health care.
3281833|NCT01672008|Experimental|NOX-100/Placebo|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
3281834|NCT01672008|Experimental|Placebo/NOX-100|"After enrollment, subjects will be randomly assigned to one of the following treatment sequences in a 1:1 ratio.~Sequence A: NOX-100 treatment phase followed by Placebo treatment phase Sequence B: Placebo treatment phase followed by NOX-100 treatment phase"
3281835|NCT01672021|Other|PET/MRI|PET/MRI
3281836|NCT01672034||Obese, BMI > 35|
3281837|NCT01672047|Experimental|Treament|Intervention Vitamin D2
3281838|NCT01672047|No Intervention|Control|Not take Vitamin D2
3281839|NCT01672060|Experimental|Nurse-Family Partnership (NFP)|
3281840|NCT01672060|Active Comparator|Existing services|
3281841|NCT01672086||Stelkast Surpass Patients|
3281842|NCT01672099|Active Comparator|nutrient enriched dairy|Yoghurt product which contains vitamin K2 and extra dairy nutrients; all in a concentration of 15% of the recommended allowed daily intake (RDI)
3281843|NCT01672099|Placebo Comparator|Basic dairy|2 basic yoghurt products
3281844|NCT01672112|Other|Codeine|Oral Codeine 60mg 6hrly/prn
3281845|NCT01672112|Active Comparator|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
3281846|NCT01672125||women who have completed treatments|women who have completed breast cancer treatments, with a diagnosis of unilateral arm lymphedema, in the intensive phase of lymphedema treatment
3281847|NCT01672125||women who have completed treatment in maintenance phase|women who have completed breast cancer treatment and are in the maintenance phase of lymph edema treatment
3281848|NCT01672125||healthy women|healthy women adjusted in age and BMI
3281849|NCT01672138|Active Comparator|Control|Pulmonary Vein Antrum Isolation (PVAI) + isolation of left atrial posterior wall
3281850|NCT01672138|Active Comparator|Study I|PVAI+ scar homogenization
3281851|NCT01672138|Active Comparator|Study II|PVAI + isolation of left atrial posterior wall + non-PV triggers ablation
3281852|NCT01672164||Liver Transplant Recipients|
3281853|NCT01672177|No Intervention|Control|Individuals in the control group will not receive any training.
3281854|NCT01672177|Experimental|Intervention|Individuals in the intervention group will receive two hour long weekly training sessions for seven to eight months. The content of the training focuses on health promotion, health seeking behaviours and chronic disease management.
3281855|NCT01672190|Experimental|Yoga Therapy|Women in the Yoga Therapy Group will receive twice weekly yoga classes for 6 weeks.
3281856|NCT01672190|No Intervention|Control|Women in the Control Group will wait 6 weeks before receiving a gift certificate for yoga classes at an external yoga studio in the San Francisco Bay Area
3281857|NCT01672203||PE peripheral with fibrinolysis|Patients with peripheral PE who received fibrinolysis therapy
3281858|NCT01672203||PE peripheral, no fibrinolysis|Patients with peripheral PE who did not receive fibrinolysis
3281859|NCT01672203||PE central with fibrinolysis|Patients with central PE who received fibrinolysis therapy
3281860|NCT01672203||PE central, no fibrinolysis|Patients with central PE who did not receive fibrinolysis
3281861|NCT01672216|Experimental|Triple Target Treatment|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
3281862|NCT01672216|Active Comparator|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
3281863|NCT01672229|Experimental|Dose-escalation|Bortezomib starting dose is 0.2 mg/m2 subcutaneously which will be given weekly with incremental increase of 0.2 mg/m2 every other week, if no improvement is seen, and no dose limiting toxicities are observed to the maximum dose of 1.6 mg/m2. Bortezomib will be administered in the outpatient clinic.
3281864|NCT01672255|Active Comparator|Trial 1-SSRI|90 minute exercise baseline with 6 weeks treatment with SSRI (Prozac). Repeat 90 minute exercise after 6 week treatment.
3281865|NCT01672255|Placebo Comparator|Trial 2-Placebo|90 minute exercise at baseline with 6 weeks treatment with placebo. Repeat 90 minute exercise after 6 weeks treatment of placebo.
3281866|NCT01672268|Active Comparator|Standard TAVI procedure|Patients without Cardiac CT measures before TAVI
3281867|NCT01672268|Experimental|Cardiac CT scan before TAVI procedure|patients with cardiac CT measures before TAVI
3281868|NCT01672281|Experimental|vibrox training|
3281869|NCT01672281|Experimental|resistance training|
3281870|NCT01672307|Experimental|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
3281871|NCT01672307|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
3281872|NCT01672320||Phase II|An evaluation of long-term outcomes, patient reported outcomes, and radiographic analysis will be conducted prospectively on 500 patients
3281873|NCT01672320||Phase I|An analysis of post-operative component positioning will be evaluated for 500 patients, retrospectively.
3281874|NCT01672333|Experimental|Pathological Response|
3281875|NCT01672346|Active Comparator|Arm I|PVAI with ablation of posterior wall contained within pulmonary veins using energy up to 30 watts and post-ablation adenosine challenge
3281876|NCT01672346|Active Comparator|Arm II|AF ablationPVAI with ablation of posterior wall contained within pulmonary veins using energy up to 40 watts and post-ablation adenosine challenge
3281877|NCT01672359|Experimental|Ginkgo Synergy® and Choline|Ginkgo Synergy® (120 mg/day Ginkgo biloba leaf with 80 mg/day Ginkgo biloba whole extract combined with 40 mg/day Grape Seed extract) and Choline (700 mg choline/day)
3281878|NCT01672359|Experimental|OPC Synergy® and Catalyn|OPC Synergy® (100 mg/day of Grape Seed extract with 50 mg/day Green Tea extract (60% catechins)) and Catalyn® (1,248 IU/day of Vitamin D, 4,800 IU/day of Vitamin A, combined with vitamin C, thiamine, riboflavin, and vitamin B6)
3281879|NCT01672359|Placebo Comparator|Placebo|cellulose pills to simulate actual products
3281880|NCT01672372|Placebo Comparator|Placebo Max Stress B|oil/water emulsion with food coloring to simulate actual product
3281881|NCT01672372|Experimental|Max Stress B|whole-nutrient natural source extract from probiotic colonies that contains vitamins B1, B2, B5, B6, B12, and folate, PABA, biotin, inositol, purified water and certified organic alcohol.
3281882|NCT01672385|Experimental|Intervention Group|Telemonitoring plus self-management support
3281883|NCT01672385|No Intervention|Usual Care Group|Usual Care
3281884|NCT01672398|Experimental|Intervention Group|Telemonitoring plus self-management support
3281885|NCT01672398|No Intervention|Usual Care Group|Usual Care
3281886|NCT01672424||Group P: High Protein Drink|Patients receiving the high protein drink with 30 grams of protein in 11 fluid ounces.
3281887|NCT01672424||Group C: Ice Chips|The control group consisting patient receiving 11 ounces of ice chips
3281888|NCT01672437|Experimental|Birth and parent preparation|"The following subjects will be covered in the sessions:~Session 1 (25 weeks gestation):~Common challenges in the transition to parenthood and in the relationship~Couple communication~Session 2 (33 weeks gestation):~Expectations in relation to birth~The normal course of labour~Obstetric intervention~Pain relief,coping strategies~Partner support~Session 3 (35 weeks gestation):~Feeding a newborn~Interpreting the newborn's signs, symptoms and behaviour~Taking care of a newborn~Mood swings, postnatal depressive symptomatology~Session 4 (5 weeks post-partum):~Birth experiences~Mood swings, postnatal depressive symptomatology~The first time at home with a newborn~Couplehood - partner support, communication, division of household tasks"
3281889|NCT01672437|No Intervention|control group|The control group are offered two lectures in an auditorium during pregnancy - one on breastfeeding and one on labour. This is standard care.
3281890|NCT01672450|Experimental|All patients|All participants in this study will receive the same treatment.
3281891|NCT01672463|Experimental|All patients|All participants enrolled in this study
3281892|NCT01672476|Placebo Comparator|Placebo|1 capsule/day of placebo will be orally administered for the study period (8 weeks)
3281893|NCT01672476|Active Comparator|Valsartan 80mg|(As reference group) 80mg/day of Valsartan will be orally administered for the study period (8 weeks)
3281894|NCT01672476|Experimental|Fimasartan 30mg|30mg/day of Fimasartan will be orally administered for the study period (8 weeks)
3281895|NCT01672502|Experimental|Intervention|Firefighters in this group will receive at the beginning of the study an introduction to the study, sleep education, sleep disorder screening survey, health survey, increased sleep opportunities at their fire department, followed later by physiological monitoring of a portion of the firefighters, and then finally an 'end of year' survey at the end of the study.
3281896|NCT01672502|Active Comparator|Control|Firefighters in this group will only receive an introduction to the study and a health survey, followed later by physiological monitoring of a portion of the firefighters, and then at the end of the study will receive the sleep disorders screening survey, sleep education (Intervention group received screening survey and education much earlier at the beginning of the study), and an 'end of year' survey. None of these firefighters will receive the increased sleep opportunities as the Intervention group will.
3281897|NCT01672515|Experimental|RIPC group|RIPC treatment was performed by the inflating tourniquets to 200mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
3281898|NCT01672515|Sham Comparator|Control group|RIPC sham was performed by the inflating tourniquets to 60mmHg on bilateral arms with 5 cycles of 5min inflation and 5min relax alternation for the total of 30 consecutive days.
3281899|NCT01672528||Cardiac arrhythmia patients|Patients with cardiac arrhythmias consented to and awaiting a cardiac ablation procedure or post ablation.
3281900|NCT01672541|Experimental|Dating Matters Comprehensive Approach|Schools randomly assigned to the comprehensive approach will: implement 6th, 7th, and 8th grade student curricula in English to all the students in these grades; offer parent programs for parents of 6th, 7th, and 8th graders;implement a communications campaign involving brand ambassadors, a text message campaign, and social media campaign;encourage all educators to take an online training about teen dating violence for educators;be supported in assessing and informing local school or community policies relevant to teen dating violence.
3281901|NCT01672541|Active Comparator|Standard of Care Safe Dates Approach|Schools randomly assigned to the standard of care approach will implement Safe Dates as it is published in their schools 8th grade classes.
3281902|NCT01672554|Other|Seroquel XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
3281903|NCT01672567|Experimental|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
3281904|NCT01672567|Experimental|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
3281905|NCT01672567|Experimental|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
3281906|NCT01672580|Active Comparator|Random-Cloro|exposure to water chlorination
3281907|NCT01672580|Active Comparator|Random-Vitamin|exposure to vitamin use
3281908|NCT01672580|Experimental|Indegree-Cloro|high in-degree, exposure to water chlorination
3281909|NCT01672580|Experimental|Indegree-Vitamin|high in-degree, exposure to vitamin use
3281910|NCT01672580|Experimental|Nominated-Cloro|nominated by random, exposure to water chlorination
3281911|NCT01672580|Experimental|Nominated-Vitamin|nominated by random, exposure to vitamin use
3281912|NCT01672593|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the autologous PRFG(platelet-rich fibrin glue) group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
3281913|NCT01672593|Active Comparator|Bioseal treatment|The commercial fibrin sealants used in the study were purchased from Guangzhou Bioseal Biotech Co. Ltd, Guangzhou, China. Upon application, two components, fibrinogen and thrombin, were placed separately in two syringes which were joined by a Y-shaped connector. The trunk of the Y-shaped connecter was connected to a single lumen catheter.
3281914|NCT01672606|Experimental|Rocuronium|Intravenous infusion of rocuronium with the goal of TOF 0.70 and >0.90
3281915|NCT01672619||children with craniosynostosis|children with craniosynostosis aged 6 months to 13
3281916|NCT01672632|Experimental|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
3281917|NCT01672645|Experimental|PF-05402536|
3281918|NCT01672645|Experimental|PF-06413367|Intramuscular, multiple dose
3281919|NCT01672645|Placebo Comparator|Placebo|Intramuscular
3281920|NCT01672671|Experimental|Neoadjuvant platinum-based chemotherapy|Doxorubicin, Paclitaxel, Cisplatin
3281921|NCT01672684|Experimental|Arm I (experimental arm)|Participants complete at-home group video calling sessions for 1 1/2 hours once weekly for 8 weeks.
3281922|NCT01672684|Active Comparator|Arm II (control arm)|Participants receive an educational workbook journal.
3281923|NCT01672697|Experimental|Physical & Behavioral Therapy Group|"Intervention Group: Randomized to Physical Therapy (PT)~2-week visit which includes: Demographic Data, Physical Exam, ehavioral Therapy (BT) handouts Functional questionnaires administered Physiologic measurements obtained~Follow-up Evaluation-6-week visit PT session #1 Functional questionnaires administered~Follow-up Evaluation-8-week visit PT session #2~Follow-up Evaluation-10-week visit PT session #3~Study Completion Visit-12-week visit Functional questionnaires administered PT session #4 Physiologic measurements Physical Exam~Long-term Follow-up-24-weeks Functional questionnaires administered by mail"
3281924|NCT01672697|No Intervention|Control Group|"Control Group:~Baseline Data obtained at 2-week visit Demographic Data General Physical Exam findings Functional questionnaires administered in person (FIQOL, FISI, SF-12, FSFI, UDI-6, IIQ-7) Physiologic measurements obtained (Vaginal EMG, Anal-rectal manometry)~Follow-up Evaluation at 6-week visit Functional questionnaires administered in person at patient's previously scheduled postpartum office visit with primary Ob/Gyn or by mail~Study Completion Visit at 12-week visit Functional questionnaires administered Physiologic measurements obtained Physical Exam findings~Long-term Follow-up at 24-weeks - Functional questionnaires administered by mail"
3281925|NCT01672749||Spine based dual growing rod or VEPTR|Patients treated with the TROLLEY system will be compared with patients from the Chest Wall and Spine Deformity Study Group (CWSDSG) and the Growing Spine Study Group (GSSG) treated with a spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America). For each patient in the TROLLEY group a patient from each of the databases will be selected to be matched based on diagnosis, age, gender, and spine deformity classification.
3281926|NCT01672749||TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs). The TROLLEY system is CE marked at the time of the study conduct.
3281927|NCT01672762|Experimental|ASP1941 group|oral
3281928|NCT01672775|Experimental|Cohort 1 AGS-16C3F highest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281929|NCT01672775|Experimental|Cohort 0 AGS-16C3F higher dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281930|NCT01672775|Experimental|Cohort (-1) AGS-16C3F high dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281931|NCT01672775|Experimental|Cohort (-2) AGS-16C3F middle dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281932|NCT01672775|Experimental|Cohort (-3) AGS-16C3F low dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281933|NCT01672775|Experimental|Cohort (-4) AGS-16C3F lowest dose|Renal Cell Carcinoma subjects with clear and non-clear histology
3281934|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Clear Cell Histology|Expansion Cohort
3281935|NCT01672775|Experimental|AGS-16C3F in RCC Subjects with Papillary Histology|Expansion Cohort
3281936|NCT01672814|Active Comparator|Keraflex combined with Crosslinking|Vedera KXS microwave system used in conjunction with corneal collagen crosslinking performed with VibeX (Riboflavin ophthalmic solution)and the KXL UV System
3281937|NCT01672814|Active Comparator|Corneal collagen crosslinking alone|Corneal collagen crosslinking alone performed with VibeX (Riboflavin Ophthalmic Solution)and the KXL UV system
3281938|NCT01672840|Experimental|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
3281939|NCT01672840|Experimental|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
3281940|NCT01672931||BMI over 30|Women undergoing IVF with BMI over 30
3281941|NCT01672931||BMI 20-25|Women undergoing IVF treatments with BMI between 20-25
3281942|NCT01672944|Experimental|TBCCN-developed educational materials|"Biobanking educational DVD and booklet kit developed by the Tampa Bay Community Network (TBCCN) Center. English kit is entitled Biobanking Hope for a Cancer Cure, and Spanish kit is entitled Biobanco: Una esperanza de cura para el cancer."
3281943|NCT01672944|Other|Control Group|"Biobanking educational Brochure developed by the National Cancer Institute. English brochure is entitled Providing your Tissue for Research: What you need to Know, Spanish brochure is entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
3281944|NCT01673035|Experimental|internet-based CBT|Cognitive behavior therapy delivered via the internet: 12 weeks, therapist-guided
3281945|NCT01673035|Active Comparator|internet-based BSM|behavioral stress management delivered via the internet: 12 weeks, therapist-guided
3281946|NCT01673048|Active Comparator|Femoral fracture, ESIN|"Prospectively all patients treated with the 3-nail-configuration for dislocated femoral shaft fractures were enrolled; 25 patients are planned, 18 could be enrolled Comparison will be with own previous data of patients treated with the classical 2-C-shaped ESIN-osteosynthesis"
3281947|NCT01673087|Experimental|laboratory HPA probes|"All subjects will be studied with multiple probes of HPA axis function over the course of one to two months:~Metyrapone, oral, 750 mg, administered twice 3.5 hrs apart; Dexamethasone, oral, 1.5 mg administered once; oral, 0.25 mg administered once; Corticorelin ovine triflutate (CRH), intravenous, 100 mcg, administered once over 30 seconds; Cortrosyn (ACTH), intravenous, 250 mcg, administered once by bolus."
3281948|NCT01673100|Experimental|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. These messages will be tips to help them engage in physical activity and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
3281949|NCT01673100|No Intervention|Atttention Control|Subjects in the attention control group will receive only general health messages on their study cell phone (not physical activity promoting messages). They also will receive any usual post-PCI procedure care that all get.
3281950|NCT01673139|Experimental|Moderate exercise|Moderate exercise
3281951|NCT01673139|Experimental|Control|Control group
3281952|NCT01673139|Experimental|Interval exercise|interval exercise
3281953|NCT01673152|Placebo Comparator|Maltodextrin|
3281954|NCT01673152|Experimental|Oligofructose|Orafti P95, Beneo-Orafti, Belgium,
3281955|NCT01673165|Active Comparator|Specialized Formula|25 infants of mothers who do not have breast milk or do not want to use the skimming technique. These infants will receive our standard of care - specialized formula for the treatment of chylothorax
3281956|NCT01673165|Experimental|Skimmed mother's milk|25 infants of mothers who have breast milk and who also want to learn the skimming technique will be taught the technique. The infants will then receive the skimmed breast milk for the treatment of chylothorax
3281957|NCT01673204|Experimental|Calcitriol|Calcitriol
3281958|NCT01673204|Placebo Comparator|Placebo|Placebo
3281959|NCT01673217|Experimental|Treatment (chemotherapy and vaccine therapy)|Patients receive decitabine IV over 3 hours on day 1, pegylated liposomal doxorubicin hydrochloride IV on day 8, and NY-ESO-1 peptide vaccine emulsified in incomplete Freund's adjuvant and sargramostim subcutaneously on day 15. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.
3281960|NCT01673230|Other|Ventricular dysfunction|cardiac surgery for ventricular dysfunction
3281961|NCT01673243||Cancer|Parents of children with cancer will complete a questionnaire.
3281962|NCT01673243||Sickle cell disease|Parents of children with sickle cell disease will complete a questionnaire.
3281963|NCT01673243||Survivors|Parents of survivors of childhood cancer will complete a questionnaire.
3281964|NCT01673269|Experimental|ERCP with direct examination of the CBD|
3281965|NCT01673295|Experimental|RTX group|Subjects will receive a RTX infusion (1g) at w0, w2, w24, w48 and w72.
3281966|NCT01673295|Active Comparator|Control group|Subjects will not receive RTX infusions and will be followed in standard of care
3281967|NCT01673308|Experimental|Treatment arm|Lenalidomide treatment arm
3281968|NCT01673321|Experimental|Non-fat Yogurt-Plain flavored|Protein to carbohydrate ratio: 2.30
3281969|NCT01673321|Experimental|Skim milk|Protein to carbohydrate ratio: 0.69
3281970|NCT01673321|Experimental|Non-fat Yogurt with honey-Plain flavored|Protein to carbohydrate ratio: 1.24
3281971|NCT01673321|Experimental|Orange juice|Protein to carbohydrate ratio: 0.07
3281972|NCT01673321|Experimental|Non-fat Yogurt-Strawberry flavored|Protein to carbohydrate ratio: 0.79
3281973|NCT01673334|Experimental|Fine Needle Aspiration and Core Biospsy|Patients will undergo both FNA and core biopsy during EUS evaluation of a solid pancreatic tumor.
3281974|NCT01673360||Elevate PC|Subjects implanted with Elevate PC
3281975|NCT01673360||Mini Arc Pro|Subjects implanted with Mini Arc Pro
3281976|NCT01673360||RetroArc|Subjects implanted with RetroArc
3281977|NCT01673399|Active Comparator|Atosiban|Patients receive a bolus injection of 6.75mg atosiban and following an atosibaninfusion at 18mg/u during 3 hours.
3281978|NCT01673399|Placebo Comparator|placebo|Patients receive a placebo bolus injection (NaCl 0.9%)and an infusion of NaCl 0.9% during 3 hours
3281979|NCT01673412|Experimental|interventional arm|Psychological tests
3281980|NCT01673438|Experimental|Aldoxorubicin plus doxorubicin|Aldoxorubicin dosages of 175, 240, and 320 (doxorubicin equivalents of 130, 180, and 240 mg/m2) will be administered as a 30 minutes IVI on Day 1 of each cycle. In addition 35 mg/m2 of doxorubicin HCl will be administered as an IVI over > 3 minutes no later than 3 hours, but no more than 6 hours before the start of aldoxorubicin infusion.
3281981|NCT01673451|Placebo Comparator|Placebo comparator|
3281982|NCT01673451|Experimental|E2006|
3281983|NCT01673464||High School Athletes|
3281984|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx flex|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
3281985|NCT01673503|Active Comparator|Carl Zeiss Meditech VisuMax laser - ReLEx smile|>30 patients will receive treatment for myopia with a VisuMax femtosecond laser from Carl Zeiss. The laser can cut with two different settings, called ReLEx flex and ReLEx smile. One eye will recieve ReLEx flex, and the other ReLEx smile
3281986|NCT01673516|Active Comparator|group Co|"group Co receives intensive medical therapy utilizing integrated hemodynamic management calculated by impedance cardiography of The HOTMAN® System"
3281987|NCT01673516|Active Comparator|group RDN|"For patients who will be randomly assigned to undergo renal denervation by The SymplicityTM Renal Denervation System, the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Symplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm."
3281988|NCT01673529|Experimental|study population|All subjects will receive 1%, 3%, 5% (w/w) of SB705498 and a placebo comparator
3281989|NCT01673542|Experimental|Lidocaine-Prilocaine 5%|
3281990|NCT01673542|Placebo Comparator|Dexeryl|
3281991|NCT01673555|Experimental|GSK1278863 5mg|GSK1278863 5mg
3281992|NCT01673555|Experimental|GSK1278863 100mg|GSK1278863 100mg
3281993|NCT01673555|Placebo Comparator|Placebo|Placebo
3281994|NCT01673581||Low risk prostate cancer|
3281995|NCT01673633||SSc|Sacroiliitis
3281996|NCT01673633||Rheumatoid arthritis|Sacroiliitis
3281997|NCT01673633||Healthy controls|Sacroiliitis
3281998|NCT01673659|Experimental|Test product|Mometasone furoate 50 mcg/actuation Nasal Spray
3281999|NCT01673659|Active Comparator|Reference product|Nasonex Nasal Spray
3282000|NCT01673659|Placebo Comparator|Placebo Nasal Spray|vehicle of the test product
3282001|NCT01673672|Placebo Comparator|Placebo|7 weekly/biweekly injections of a placebo buffer
3282002|NCT01673672|Experimental|CYT003 low dose|7 weekly/biweekly injections of CYT003 low dose
3282003|NCT01673672|Experimental|CYT003 medium dose|7 weekly/biweekly injections of CYT003 medium dose
3282004|NCT01673672|Experimental|CYT003 high dose|7 weekly/biweekly injections of CYT003 high dose
3282005|NCT01673685|Placebo Comparator|Portable Oxygen Cylinder|Portable Oxygen Cylinder
3282006|NCT01673685|Active Comparator|Portable Oxygen Concentrator|Portable Oxygen Concentrator
3282007|NCT01673711||Basic Science (deuterated phenanthrene tetraol)|Patients receive deuterated phenanthrene tetraol PO and collect urine for 6 hours after dosing.
3282008|NCT01673724|Experimental|pramipexole|dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks
3282009|NCT01673724|Active Comparator|Bromocriptine|bromocriptine dosage form: white round tablet
3282010|NCT01673737|Experimental|Part A Monotherapy|Dose escalation of daily or twice daily SAR260301 within a 28-day cycle, followed by an expansion phase at the maximal tolerated dose
3282011|NCT01673737|Experimental|Part B Combination|Dose escalation of twice-daily SAR260301 within a 28-day cycle and in combination with 720 or 960 mg twice daily of Vemurafenib, followed by an expansion phase at the maximal tolerated dose of SAR260301 in combination
3282012|NCT01673750||Participants|Participants will have documented HIV infection and are aware of their diagnosis. They will complete a one-time questionnaire.
3282013|NCT01673763|Active Comparator|Stent|Stent insertion into the main pancreatic duct
3282014|NCT01673763|No Intervention|No stent|No stent insertion into the main pancreatic duct
3282015|NCT01673776|No Intervention|K group|commonly used therapy
3282016|NCT01673776|Experimental|M group|multimodal intervention
3282017|NCT01673789|Experimental|Stem Cell Educator|The collected lymphocytes are transferred into the device for exposure to CB-SCs, and other blood components are automatically returned to the patient. The Stem Cell Educator functions as part of a closed-loop system that circulates a patient's blood through a blood cell separator, briefly co-cultures the patient's lymphocytes with CB-SCs in vitro, and returns the educated lymphocytes to the patient's circulation. CB-SCs tightly attached to interior surfaces in the device, and only the CB-SC-educated autologous lymphocytes are returned to the subjects. The Stem Cell Educator therapy requires only two venipunctures with minimal pain, and does not introduce stem cells or reagents into patients.
3282018|NCT01673815|Experimental|1st: R eye video. 2nd: L eye no video|The right eye will be examined first with video, followed by the left eye without video.
3282019|NCT01673815|Experimental|1st: R eye no video. 2nd: L eye video|The right eye will be examined without video, followed by the left eye with video.
3282020|NCT01673815|Experimental|1st: L eye video. 2nd: R eye no video|The left eye will be examined first with video, followed by the right eye without video.
3282021|NCT01673815|Experimental|1st: L eye no video. 2nd: R eye video|The left eye will be examined first without video, followed by the right eye with video.
3282022|NCT01673841||Relative + absolute cerebral oxygen saturation.|
3282023|NCT01673880|Other|E2006 2.5 mg|
3282024|NCT01673880|Other|E2006 10mg|
3282025|NCT01673880|Other|E2006 25 mg|
3282026|NCT01673906|Experimental|Diagnostic work up|The patients enrolled in the study (see below), with a consistent clinical suspicion of a primary duodenal-pancreatic NET.
3282027|NCT01673932|Experimental|Group A - UCBMC Early Treatment Group|Group A subjects will receive transplant of UCBMC isolated from HLA-matched umbilical cord blood at Day 0.
3282028|NCT01673932|Experimental|Group B - UCBMC Delayed Treatment Group|Group B subject will partipate in 6 months observation and then receive the UCBMC transplant at month 6.
3282029|NCT01673945|Active Comparator|EUS-FNA with the CLA-EUS|patients examined with the CLA-EUS
3282030|NCT01673945|Experimental|EUS-FNA With the FV-EUS|patients examined with the FV-EUS
3282031|NCT01673958|Experimental|Stair descending group|Stair descending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
3282032|NCT01673958|Experimental|Stair ascending group|Stair ascending exercise. Participants will carry out six weeks of stair descending training consisting of three exercise sessions per week.
3282033|NCT01673971||Natural History|
3282034|NCT01673971||Treatment|
3282035|NCT01673997|Experimental|Metoprolol Succinate ER Tablets, 200 mg|Metoprolol Succinate ER Tablets, 200 mg of Dr.Reddy's Laboratories Ltd
3282036|NCT01673997|Active Comparator|TOPROL-XL ER Tablets 200 mg|TOPROL-XL ER Tablets 200 mg of AstraZeneca
3282037|NCT01674023||human vitreous, human blood serum, PCR|"human vitreous and blood serum sampling, PCR~1ml of human vitreous and 3ml of human blood serum of patients with various vitreoretinal diseases"
3282038|NCT01674036|Experimental|Part 1 (GZFD00111/TDU12766): Genz-682452|Participants will receive a single oral dose of Genz-682452. Six ascending single doses and an optional seventh dose under fasted conditions will be used.
3282039|NCT01674036|Placebo Comparator|Part 1 (GZFD00111/TDU12766): Placebo|Participants will receive a single oral dose of placebo.
3282040|NCT01674036|Experimental|Part 2 (GZFD00211/FED12767): Genz-682452|Participants will receive two single doses of Genz-682452 separated by a 7-day wash-out period, one dose given under fed (standardized high-fat breakfast) and one under fasted conditions. The dose will be based on the blind review of the safety/tolerability/pharmacokinetic data of single dose level cohorts in Part 1.
3282041|NCT01674049|Experimental|Exercise and Immediate Nutrition|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk immediately after the exercise bout
3282042|NCT01674049|Active Comparator|Exercise and Nutrition 3 hours Post-Bout|40 min of circuit-style resistance exercise and 600g low-fat chocolate milk three hours after the exercise bout
3282043|NCT01674075||Healthy adult volunteers|Healthy adult volunteers will be administered a J-Tip to the dorsum of his/her hand.
3282044|NCT01674088||Irritable Bowel Syndrome|Subjects meeting Rome III criteria will be included as the group Irritable Bowel Syndrome
3282045|NCT01674088||Healthy Controls|Subjects not meeting Rome III criteria and meeting clinical definitions of general good health will be considered as Healthy Controls
3282046|NCT01674101|Experimental|Physical Therapy|"The intervention group will receive PT 3 times per week for 60 minutes each session. The therapy sessions will include endurance, strengthening, and stretching exercises.~Exercise time and resistance will be progressed per individual's medical status and per participant's tolerance. All participants will be given a tailored home exercise program (HEP).~Participants will participate in PT 10 weeks prior to surgery and 10-12 weeks after surgery. Subjects will be seen by the physical therapist both when inpatient and outpatient. Patients will not be seen for PT if platelet count is less than 20,000mm3 and/or hemoglobin is less than 8g/dL."
3282047|NCT01674114|Experimental|TAP block|transversus abdominis plane block (TAP block). Ultrasound guided TAP-block at the end of surgery using 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml bilaterally by the anaesthesiologist, and 20 ml NaCl intracutaneously in the operating wound performed by the obstetrician
3282048|NCT01674114|Active Comparator|control|Ultrasound guided TAP block at the end of surgery with 20 ml NaCl bilaterally and 20 ml bupivacaine 0,25% with Adrenaline 5mcg/ml intracutaneously in the surgical wound(standard practice)
3282049|NCT01674127|Experimental|Methyldopa|In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.
3282050|NCT01674127|Placebo Comparator|placebo|
3282051|NCT01674140|Placebo Comparator|Arm I|Patients receive an approved endocrine therapy comprising tamoxifen citrate*, goserelin acetate** or leuprolide acetate**, or an aromatase inhibitor (anastrozole, letrozole, or exemestane) for 2-5 years. Patients also receive a placebo PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
3282052|NCT01674140|Experimental|Arm II|Patients receive an approved endocrine therapy regimen as in arm I. Patients also receive everolimus PO daily for 1 year in the absence of disease progression or unacceptable toxicity.
3282053|NCT01674153|Experimental|HD-Exercise-HDF|Prescribe intra-dialytic exercise of three bouts in 4 hours dialysis session.
3282054|NCT01674166|Experimental|prucalopride|single dose 0.03 mg/kg prucalopride open label
3282055|NCT01674179||ACR diagnosis of Fibromyalgia|
3282056|NCT01674179||Patients without Fibromyalgia|
3282057|NCT01674192|Experimental|prucalopride|single dose of 2 mg prucalopride
3282058|NCT01674205|Experimental|Group 1 (Inpatient, H2N3 MO 2006/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.2 mL being delivered by Accuspray device (0.1 mL per nostril).
3282059|NCT01674205|Experimental|Group 2 (Inpatient, H9N2 G9/AA ca)|Participants will receive one dose of vaccine on Day 0, with 0.5 mL being delivered as nose drops (0.25 mL per nostril) using a sterile, needle-less tuberculin syringe.
3282060|NCT01674205|Experimental|Group 3 (Outpatient, seasonal LAIV [FluMist®])|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)
3282061|NCT01674205|Placebo Comparator|Group 4 (Both inpatient and outpatient, placebo)|Participants will receive either the L-15 placebo delivered by nose drops or the FluMist® placebo delivered as a nasal spray.
3282062|NCT01674218|Experimental|Treatment E|PA-824 400 mg plus moxifloxacin 400 mg
3282063|NCT01674218|Active Comparator|Treatment D|PA-824 placebo plus moxifloxacin 400 mg
3282064|NCT01674218|Experimental|Treatment C|PA-824 1000 mg plus moxifloxacin placebo
3282065|NCT01674218|Experimental|Treatment B|PA-824 400 mg plus moxifloxacin placebo
3282066|NCT01674218|Placebo Comparator|Treatment A|PA-824 placebo and moxifloxacin placebo
3282067|NCT01674231|Active Comparator|Grape|Grapes in the form of a Freeze-dried Whole Grape Powder. 60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
3282068|NCT01674231|Placebo Comparator|Sugar|Grape Powder Placebo. 60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
3282069|NCT01674244|Experimental|Integrative Exercise|Subjects will exercise for 12 weeks (3 times weekly, with each total workout being approximately 60 minutes in length). The exercise protocol will incorporate elements of mindfulness, cardiovascular strengthening, and controlled breathing.
3282070|NCT01674244|Active Comparator|Monitor Only Waitlist|Monitor Only Waitlist
3282071|NCT01674257||Carotid Endarterectomy|Patients due to undergo carotid endarterectomy for symptomatic carotid artery stenosis will undergo an 18F-Fluoride PET/CT, an 18F-Flurodeoxyglucose PET/CT and a USPIO (ferumoxytol)-enhanced MRI scan (2 MRI scans).
3282072|NCT01674270|Experimental|Degarelix|Degarelix Alone
3282073|NCT01674270|Experimental|Degarelix + Casodex|Degarelix and Casodex
3282074|NCT01674270|Active Comparator|LHRH Agonist + Casodex|LHRH Agonist and Casodex
3282075|NCT01674283|Experimental|Glucagon|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of Glucagon.~The second recording is doing the same way 10 minutes after the Glucagon injection, just before the embryo transfer."
3282076|NCT01674283|Placebo Comparator|Sodium chloride 0.9%|"The first recording is a transvaginal ultrasound in midsagittale position for the measurement of the basic uterine contractility 2 minutes before the injection of the placebo.~The second recording is doing the same way 10 minutes after the placebo injection, just before the embryo transfer."
3282077|NCT01674296||Group 1 (2012-2013)|Monitoring of Dietary Intake, Physical Activity and Stress
3282078|NCT01674296||Group 2 (2013-2014)|Monitoring of Dietary Intake, Physical Activity and Stress
3282079|NCT01674309|Other|single arm study/ non randomized trial|FOLFORINOX
3282080|NCT01674322|Experimental|Ibrutinib|All participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
3282081|NCT01674335|No Intervention|Delayed-Intervention|A total of 120 participants with fibromyalgia will be randomly assigned to one of four intervention groups (Operant Learning (OL), Energy Conservation (EC), delayed-OL and delayed-EC). The delayed groups will receive the AP intervention 3 months later and will serve as a Usual Care control group. All groups will continue to receive any concomitant interventions that they are receiving (pharmacological and non-pharmacological) at the time of enrollment.
3282082|NCT01674335|Active Comparator|Operant Learning|
3282083|NCT01674335|Active Comparator|Energy Conservation|
3282084|NCT01674348|Active Comparator|P2202|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
3282085|NCT01674348|Placebo Comparator|Placebo|"Two treatment arms in Stage I- P2202 (1000 mg) and placebo~Four treatment arms in stage II- P2202 (suggested dose levels 750 mg, 500 mg or 250 mg) or placebo"
3282086|NCT01674361|Experimental|Bitopertin 30 mg|"Participants in Stratum 1 will receive bitopertin 30 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 30 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
3282087|NCT01674361|Experimental|Bitopertin 10 mg|"Participants in Stratum 1 will receive bitopertin 10 mg from Day 1 to Week 16 in addition to their background therapy with an SSRI.~Participants in Stratum 2 will receive placebo from Day 1 and will then start bitopertin 10 mg at the Week 2 until Week 16 in addition to their background therapy with an SSRI."
3282088|NCT01674361|Placebo Comparator|Placebo|Participants (both Stratum 1 and Stratum 2) will receive placebo from Day 1 to Week 16 in addition to their background therapy with an SSRI.
3282089|NCT01674374|Experimental|Arm I (SAMITAL)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules PO QID. Patients may continue to receive Vaccinium myrtillus extract/Macleaya cordata alkaloids/Echinacea angustifolia extract granules for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
3282090|NCT01674374|Placebo Comparator|Arm II (placebo)|Beginning as soon as symptoms arise during chemoradiotherapy, patients receive placebo PO QID. Patients may continue to receive placebo for up to 4 weeks after completion of radiation therapy for a maximum of 11 weeks.
3282091|NCT01674387|Experimental|acupuncture|56 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral cervical Jiaji (EX-B2),and two trigger points.Bilateral Jianzhongshu (SI15) and Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
3282092|NCT01674387|Other|comprehensive treatment|Other 56 patients (the matched group) receive the comprehensive treatment, including traction and TENS(Transcutaneous Electrical Nerve Stimulation) therapy. Each treatment 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
3282093|NCT01674413|Placebo Comparator|Placebo/Step-Down|1 syringe of placebo SC q 2 weeks.
3282094|NCT01674413|Active Comparator|PRNLOAD Arm|160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38)
3282095|NCT01674413|Active Comparator|Maintenance Arm|Adalimumab 40 mg q 2 weeks.
3282096|NCT01674426|Experimental|Cognitive behavior therapy|Cognitive behavior therapy consisting of 16 sessions over 20 weeks
3282097|NCT01674426|Placebo Comparator|observation|Subjects were called by telephone but were not given cognitive behavior therapy until the study phase was completed
3282098|NCT01674439|Experimental|With supplementation of ADRC|Fat graft with supplementation of ADRC
3282099|NCT01674439|Active Comparator|Without supplementation of ADRC|Fat grafts without supplementation of ADRC
3282100|NCT01674452|Experimental|home-based group|
3282101|NCT01674452|Active Comparator|supervised exercise group|
3282102|NCT01674452|No Intervention|control|Control group:no intervention
3282103|NCT01674465||CNI-induced nephrotoxicity|Hypoxyprobe-1
3282104|NCT01674491|Experimental|4.5g/day black soy peptide|4.5 g/day, 8weeks
3282105|NCT01674491|Placebo Comparator|placebo|similar appearance to the black soy peptide tablet, 8 weeks
3282106|NCT01674504|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
3282107|NCT01674504|Active Comparator|SINGTJLAIR ®|SINGTJLAIR ® (containing Montelukast sodium)chewable tablets 5mg of Merck Sharp & Dohme Ltd., USA
3282108|NCT01674517|Experimental|Montelukast sodium|Montelukast sodium chewable tablets 4mg and 5mg of Dr. Reddy's Laboratories Limited
3282109|NCT01674517|Active Comparator|SINGULAIR®|SINGULAIR®(containing Montelukast sodium) chewable tablets 4mg and 5mg of Merck Sharp & Dohme Ltd., USA
3282110|NCT01674530|Experimental|Lubiprostone|Manufactured by Dr Reddy's Laboratories Ltd( 24 mcg administered for 7 days )
3282111|NCT01674530|Active Comparator|AMITIZA®|Manufactured by Sucampo Pharmaceuticals(24 mcg administered for 7 days)
3282112|NCT01674530|Placebo Comparator|Placebo|Manufactured by Dr Reddy's Laboratories Ltd ( 24 mcg adminstered for 7 days )
3282113|NCT01674543|Experimental|Resistance training|
3282114|NCT01674543|Experimental|Concurrent training|
3282115|NCT01674543|Sham Comparator|Control Group|
3282116|NCT01674556|Experimental|Contrast-enhanced ultrasound (CEUS)|
3282117|NCT01674582|Other|MRI, Neuropsychological testing|
3282118|NCT01674595|Experimental|Immunotherapy|AVANZ
3282119|NCT01674660||volume status|volume status:group1 over volume status,group2 normal volume status,group3 low volume status
3282120|NCT01674660||night blood pressure|night blood pressure：group1 nondipper,group2 dipper,group3 extreme dipper,group4 riser
3282121|NCT01674660||interdialysis weight gain|interdialysis weight gain:group1 >5% dry weight,group2 <5% dry weight
3282122|NCT01674686|Experimental|A|Sarpogrelate versus placebo
3282123|NCT01674686|Experimental|B|Atorvastatin 80mg versus no statin or simvastatin 20 mg if LDL > 130 mg/dl
3282124|NCT01674699||EXCOR|Pediatric candidates age 0 - 21 with severe isolated left ventricular or biventricular dysfunction who are candidates for cardiac transplant and require circulatory support may be treated using the EXCOR® Pediatric.
3282125|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevacizumab|Stratum A
3282126|NCT01674738|Experimental|Pemetrexed, Cisplatin, Bevazizumab|Stratum B:
3282127|NCT01674751|Experimental|Immediate intervention|Group begins the 4 week Pre-Ordering Program intervention immediately following a 4-wk baseline period.
3282128|NCT01674751|Other|Wait-listed control|Group begins the 4 week Pre-Ordering Program intervention following an 8-wk baseline period.
3282129|NCT01674764||Early surgical intervention = Cohort 1|≤ 12 hours after the tSCI
3282130|NCT01674764||Late surgical intervention = Cohort 2|> 12 hours and < 14 days after the tSCI
3282131|NCT01674777|Experimental|under fasting condition group|Subjects will receive a single dose of ASP1941 under fasting condition
3282132|NCT01674777|Experimental|before meal group|Subjects will receive a single dose of ASP1941 before meal
3282133|NCT01674777|Experimental|after meal condition|Subjects will receive a single dose of ASP1941 after meal
3282134|NCT01674790|Experimental|AEROBIC group|6-week program of one 20-min session of aerobic training and one 20-min session of ROM exercise 5 days/week.
3282135|NCT01674790|Experimental|COGNITIVE group|6-week program of one 20-min session of cognitive training and one 20-min session of ROM exercise 5 days/week.
3282136|NCT01674790|Experimental|AEROBIC + COGNITIVE group|6-week program of one 20-min session of aerobic training and one 20-min session of cognitive training 5 days/week.
3282137|NCT01674790|Experimental|CONTROL group|6-week program of one 20-min session of ROM exercise and one 20-min session of unstructured mental activity 5 days/week.
3282138|NCT01674803|Active Comparator|Orsiro|
3282139|NCT01674803|Active Comparator|Synergy|
3282140|NCT01674803|Active Comparator|Resolute Integrity|
3282141|NCT01674816|Active Comparator|Repeated Measurements of Knee Alignment and Kinematics|Patients in the Repeated Measurements Arm will have the kinematic measurement protocol repeated twice before and twice after the surgical procedure; the procedure itself will be performed with the traditional technique, i.e without guidance by the system.
3282142|NCT01674816|Active Comparator|Computer Guidance of Surgical Actions|Patients in the Computer Guidance of Surgical Actions Arm will have the kinematic measurement protocol performed only once before and once after the surgical procedure; the procedure itself will be performed with guidance by the system.
3282143|NCT01674829|Experimental|Biological: MA09-hRPE Cellular therapy|"Biological: MA09-hRPE Cellular therapy~Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
3282144|NCT01674842|Experimental|Cisplatin + Radiation Therapy|Cisplatin concurrently with radiation therapy
3282145|NCT01674855|Experimental|DA-3031|PEG-G-CSF
3282146|NCT01674855|Active Comparator|Leucostim®|G-CSF
3282147|NCT01674868|Experimental|Fluoxetine|Subjects will take 20 mg fluoxetine daily for 90 days after stroke
3282148|NCT01674868|Placebo Comparator|placebo|Subjects will take one pill daily for 90 days after stroke.
3282149|NCT01674881|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|This group will receive MBCT for 8 consecutive weeks.
3282150|NCT01674881|Other|Waitlist control group|This group is a waitlist control group.
3282151|NCT01674894||Group 1|Women treated with Menopur
3282152|NCT01674894||Group 2|Women treated with Menopur and Bravelle
3282153|NCT01674907||Cohort|
3282154|NCT01674920|Experimental|Choices|"The 3-month twelve-session intervention, Choices, included topics on nutrition, physical activity, and resiliency. Parents, boys and girls met separately. The sessions were developed for delivery by a family physician, two family medicine residents, and a nutritionist, who received training in positive psychology and resilience skills. All children were measured on the same dates, but children were randomly assigned to two cohorts, beginning 6 months apart, to facilitate statistical analysis by having one group experience normal growth on study prior to intervention."
3282155|NCT01674933|Active Comparator|treatment as usual|any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing
3282156|NCT01674933|Experimental|Duraphat® Fluoride Varnish|treatment as usual (ie any treatment from the family dentist, plus the preventive intervention programme offered to nursery school children, including daily supervised toothbrushing) plus up to 4 six-monthly applications of Duraphat Fluoride Varnish in the nursery school setting.
3282157|NCT01674946|Placebo Comparator|ID saline|ID saline by feeding tube
3282158|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
3282159|NCT01674946|Active Comparator|ID + CDCA (15 mmol/L)|CDCA = chenodeoxycholic acid (primary bile acid)
3282160|NCT01674946|Active Comparator|ID saline + oleanolic acid (1 mmol/L)|
3282161|NCT01674946|Active Comparator|ID saline + CDCA (5 mmol/L) + oleic acid|
3282162|NCT01674946|Placebo Comparator|ID saline + oleic acid (20 mmol/L)|
3282163|NCT01674959|Experimental|concurrent chemoradiation|"• Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative current chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
3282164|NCT01674972||NAFLD|Patients with biopsy proven NAFLD
3282165|NCT01674972||Control|Matched healthy control subjects
3282166|NCT01674985|Experimental|Decitabine and cytarabine|induction therapy：decitabine 25mg/m2 daily for 4 days with cytarabine 150 mg/m2 daily for 7 days consolidation：decitabine 25mg/m2 daily for 4 days with cytarabine 2g/m2 q12h for 3 days
3282167|NCT01675024|Experimental|Rotigotine, Period 1|In Period 1 (Day 1 to Day 3) all 24 subjects will receive only 1 dose 2 mg / 24 hours.
3282168|NCT01675024|Experimental|Rotigotine, Period 2|In Period 2 (Day 7 to Day 14) all 24 subjects will receive 2 mg / 24 hours for 3 days then 4 mg / 24 hours for 3 days.
3282169|NCT01675037||obstructive|obstructive hydrocephalus in children and adults with biological evaluation
3282170|NCT01675076|Experimental|Continued NOAC|- Patients continue on their chronic dose of Dabigatran or Rivaroxaban or Apixaban throughout
3282171|NCT01675076|Active Comparator|Interrupted NOAC|"Interrupted Dabigatran:~Discontinue Dabigatran 1 day before surgery if GFR > 50 mL/min or discontinue 2 days before surgery if GFR 30-50 mL/min~Resume Dabigatran at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Rivaroxaban:~Discontinue Rivaroxaban 1 full day before surgery~Resume Rivaroxaban at next regular dose timing >or = 24 hours after the end of surgery~Interrupted Apixaban:~Discontinue Apixaban 1 full day before surgery~Resume Apixaban at next regular dose timing >or = 24 hours after the end of surgery"
3282172|NCT01675089|Experimental|Zoledronic acid|Intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement.
3282173|NCT01675089|No Intervention|Control|The control group will receive only vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
3282174|NCT01675115|Active Comparator|BNG-1 plus Aspirin|BNG-1 3 grams TID plus Aspirin 100mg QD for 4 weeks
3282175|NCT01675115|Sham Comparator|Aspirin|Aspirin 100mg QD for 4 weeks
3282176|NCT01675180|Other|Information|Women randomized to the intervention will recieve information and counseling on oral health care during pregnancy
3282177|NCT01675180|No Intervention|Control|
3282178|NCT01675193|No Intervention|Current screening protocol|Eye screening at age 1-2, 3-4, 6-9, 14-24, 36, 45 and 54-60 months
3282179|NCT01675193|Other|Disinvestment protocol|No eye screening at 6-9 and 14-24 months
3282180|NCT01675206|Active Comparator|360 µg Vit K2|Administration of 360 µg of Vitamin K2 thrice weekly
3282181|NCT01675206|Active Comparator|720 µg Vit K2|Administration of 720 µg of Vitamin K2 thrice weekly
3282182|NCT01675206|Active Comparator|1080 µg Vit K2|Administration of 1080 µg of Vitamin K2 thrice weekly
3282183|NCT01675219|Experimental|Group B|Blue light TUR-BT with no adjuvant instillations
3282184|NCT01675219|Active Comparator|Group A|White light TUR-BT with no adjuvant instillations
3282185|NCT01675219|Experimental|Group C|White light TUR-BT with six weekly optimized mitomycin-C instillations.
3282186|NCT01675219|Experimental|Group D|Blue light (PDD) TUR-BT with six weekly optimized mitomycin-C instillations.
3282187|NCT01675232|Active Comparator|Soak and smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment immediately to wet skin once a day and dry skin once a day.
3282188|NCT01675232|Active Comparator|Dry smear|Application of hydrocortisone 2.5% ointment or triamcinolone acetonide 0.1% ointment to dry skin twice a day.
3282189|NCT01675245||Velcade|Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks.
3282190|NCT01675258||Control|Healthy adults above the age of 18 years
3282191|NCT01675258||Study|Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer
3282192|NCT01675271|Active Comparator|individual exercise|individualized exercise program
3282193|NCT01675271|Active Comparator|general exercise|general exercise program
3282194|NCT01675271|No Intervention|control|No exercise and dietary counselling
3282195|NCT01675284|Experimental|Low Dosage AT-301|7.5 µg hemagglutinin (HA)
3282196|NCT01675284|Experimental|Middle Dosage AT-301|15 µg hemagglutinin (HA)
3282197|NCT01675284|Experimental|High Dosage AT-301|30 µg hemagglutinin (HA)
3282198|NCT01675310|Experimental|medical nutrition therapy + metformin|medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)
3282199|NCT01675310|Active Comparator|medical nutrition therapy|medical nutrition therapy without trans-gestational metformin
3282200|NCT01675323||RLS Patients|Participants who have diagnosed RLS with diagnosis confirmed by study investigators.
3282201|NCT01675323||Healthy Controls|Participants without RLS who are generally healthy and matched for gender, age, educational level, and race to patients in the RLS group.
3282202|NCT01675349|Experimental|Chenopodium album allergen extract|Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test.
3282203|NCT01675362|Placebo Comparator|Control group|They will receive placebo
3282204|NCT01675362|Active Comparator|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
3282205|NCT01675362|Active Comparator|Calcium channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
3282206|NCT01675362|Active Comparator|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
3282207|NCT01675375|Experimental|Eye shield|Eye shield place on post Laser Vision Correction eye
3282208|NCT01675388|Experimental|Hypothermia|Hypothermia to 33.5 deg Centigrade
3282209|NCT01675401|Experimental|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
3282210|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
3282211|NCT01675440||Severe (≥3-4+) Mitral Valve Regurgitation|Mitral valve regurgitation ≥3-4+
3282212|NCT01675440||Severe (≥3-4+) Tricuspid Valve Regurgitation|Tricuspid valve regurgitation ≥3-4+
3282213|NCT01675440||End Stage Renal Disease (ESRD)|End stage renal disease requiring renal replacement therapy or a creatinine clearance (CRCL) <20 cc/min, but not on dialysis
3282214|NCT01675440||Low Gradient Low Output Aortic Stenosis|Low gradient low output aortic stenosis
3282215|NCT01675440||Failed Bioprosthetic Surgical Aortic Valve|Stenosed, insufficient or combined bioprosthetic surgical aortic valve failure
3282216|NCT01675440||2 or More Conditions|2 or more of the listed conditions
3282217|NCT01675466|Active Comparator|early laparoscopy|early laparoscopy, aiming to achieve this within 12 hours
3282218|NCT01675466|Placebo Comparator|active observation|"standard management - the wait and see approach with serial examinations and investigations as deemed necessary"
3282219|NCT01675505||Patients|"Inclusion criteria:~Patients with first-diagnosed colon cancer. Age 18-60 y.o.~Exclusion criteria:~Metastatic colon cancer. Former psychiatric history. Substance use. Previous serious medical conditions."
3282220|NCT01675518|Experimental|Part-1 dose 1|
3282221|NCT01675518|Experimental|Part-1 dose 2|
3282222|NCT01675518|Experimental|Part-1 dose 3|
3282223|NCT01675518|Experimental|Part-1 dose 4|
3282224|NCT01675518|Experimental|Part-1 dose 5|
3282225|NCT01675518|Experimental|Part-1 dose 6|
3282226|NCT01675518|Placebo Comparator|Part-1 placebo|
3282227|NCT01675518|Experimental|Part-2 fed|
3282228|NCT01675518|Experimental|Part-2 fasted|
3282229|NCT01675557|Active Comparator|Vitamin D2|a single oral dose of vitamin D2
3282230|NCT01675557|Placebo Comparator|Placebo|a single oral dose of a placebo
3282231|NCT01675557|Experimental|Vitamin D3|A single oral dose of vitamin D3
3282232|NCT01675570|Experimental|RX-10045 active arm|RX-10045 Opththalmic Solution, 0.09%
3282233|NCT01675570|Placebo Comparator|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution
3282234|NCT01675583||Standard Care Group|Subjects who will undergo only standard wound care management.
3282235|NCT01675583||Hyperbaric Oxygen Therapy Group|Subjects who are selected for adjunctive hyperbaric oxygen therapy in addition to standard wound care intervention.
3282236|NCT01675609|Placebo Comparator|Placebo|
3282237|NCT01675609|Experimental|Brimonidine Tartrate 0.025%|
3282238|NCT01675648|Experimental|Lofexidine & Diazepam Placebo|"Initial Lofexidine dosage starts from 0.8mg per day, it will be gradually increased by increments of 0.4 to 0.8mg per day up to a maximum of 2.2mg daily. After 3 peak dose days, the dosage will be gradually decreased by 0.2 to 0.6mg per day till to 0.2mg of the last lofexidine dosage in Day 10.~The Diazepam placebo will be administrated to the patients with the same frequency, time and number tablets of diazepam in the active comparator arm."
3282239|NCT01675648|Active Comparator|Diazepam & Lofexidine Placebo|"The initial dosage of Diazepam is 10 mg per day on Day 1&2, the dosage will be increased to 15 mg per day on Day 3&4, subsequently decreased to 10mg per day on Day 5, 5mg per day on Day 6&7, 2mg per day on Day 8&9&10.~The Lofexidine placebo will be administrated to the patients with the same frequency, time and number tablets of lofexidine in the experimental arm."
3282240|NCT01675674||Dried blood spot test for MPS|"For the prospective study, subjects will be drawn from all children (aged 6 months to 18 years) with a history of presenting to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria).~For the retrospective chart review, subjects will be drawn from all children who were 6 months to 18 years of age at the time of first presentation to selected clinics (pediatric rheumatology, pediatric hand, or skeletal dysplasia clinic), with at least ONE highly suspicious symptom or at least TWO less suspicious symptoms that may be indicative of an MPS disorder (see inclusion criteria)."
3282241|NCT01675687|Experimental|Internet|"Participants of this intervention group get follow up support via Internet.~They have access to new inputs biweekly consisting of~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~News and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be available each month.~Tailored feedback of their behaviour will be given by documentation on spreadsheets."
3378230|NCT02991027|Experimental|Subjects Presenting With Normal Eyes|Subjects with no known ocular diseases will be imaged using 2 different light sources using the DRI Triton
3378231|NCT02990377|Experimental|RL-supported IVR intervention|Participants in the intervention group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED plus the RL-supported IVR intervention.
3378232|NCT02990377|No Intervention|Enhanced Usual Care|Participants in the enhanced usual care group receive brief, non-tailored information related to decreasing opioid analgesic risk via pamphlets given at the ED.
3378233|NCT02982174|Experimental|Normal Eyes|Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
3378234|NCT02982083|Active Comparator|Evista|20 postmenopausal women suffering from rheumatoid arthritis that take raloxifene hydrochloride 60 mg oral tablets every day for one year.
3378235|NCT02982083|Placebo Comparator|Placebo|20 postmenopausal women suffering from rheumatoid arthritis that take placebo pills every day for one year.
3378236|NCT02978326|Experimental|Part A: SAGE-217 15/20 mg Oral Solution|Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
3378237|NCT02978326|Placebo Comparator|Part B: Placebo|Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
3378238|NCT02978326|Experimental|Part B: SAGE 217 30 mg Capsules|Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.
3378239|NCT02974608||Children 0-10 years|Children living in selected villages surrounding the district of Ouelessebougou
3378240|NCT02974608||Pregnant Women + Newborns|Pregnant women of any age and their newborn children
3378241|NCT02974608||Women of Child Bearing Age Potential|Non-pregnant women of child-bearing age
3378242|NCT02974595||1|Participants age 0-99 will have a known autoinflammatory disease
3378243|NCT02974595||2|Unaffected relatives age 3-99 years
3378244|NCT02974595||3|Healthy Volunteers age 18-99 years
3378245|NCT02956382|Experimental|Phase I - Dose Level 0|"Ibrutinib (capsule) - 420mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
3378246|NCT02956382|Experimental|Phase I - Dose Level 1|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 400mg~Each medication is taken daily. Treatment cycles are 28 days long."
3378247|NCT02956382|Experimental|Phase I - Dose Level 2|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 600mg~Each medication is taken daily. Treatment cycles are 28 days long."
3378248|NCT02956382|Experimental|Phase I - Dose Level 3|"Ibrutinib (capsule) - 560mg Venetoclax (tablet) - 800mg~Each medication is taken daily. Treatment cycles are 28 days long."
3378249|NCT02956382|Experimental|Phase II Dose|The Phase II dose will be the maximum tolerated dose as determined in the Phase I portion.
3378250|NCT02952248|Experimental|BI 754091|
3378251|NCT02941263||Affected Participants|Participants with unilateral or bilateral GA associated with AMD.
3378252|NCT02939404||healthy volunteers|non-diabetic healthy volunteers at a stable weight
3378253|NCT02937142|Experimental|Cognitive behavior group therapy|Cognitive behavior group therapy in weekly 1,5 hour sessions during 12 weeks, 8 participants and 2 therapists per group, in addition to education on ADHD, and ADHD medication if indicated.
3378254|NCT02937142|Other|Controls|Treatment as usual: Education on ADHD, and ADHD medication if indicated.
3378255|NCT02936843|Experimental|Salsalate|Salsalate, 1 gram by mouth, 3 times daily (3 grams per day) for 12 months.
3378256|NCT02936843|Placebo Comparator|Comparator|Placebo for Salsalate, 2 tablets by mouth, 3 times daily for 12 months
3378257|NCT02929056|Placebo Comparator|SOC alginate dressing|SOC absorptive alginate primary dressing in conjunction with a class II multi-layer compression wrap and standard debridement
3378258|NCT02929056|Experimental|AmnioExCel dressing|AmnioExCel dressing in conjunction with a class II multilayer compression wrap and standard debridement
3378261|NCT02911129||Healthy Volunteer|Inclusion Criteria for Healthy Volunteers/Age-matched Controls
3378262|NCT02911129||Patients|Patients with neglect after a right hemisphere brain lesion
3378263|NCT02911077||AUD population|The participants/group were treatment-seeking AUD individuals admitted to the NIH CC 1SE Addictions Unit.
3378264|NCT02898194||1/Patient Surrogates|Any eligible participant who have acted as a surrogate medical decision-maker.
3282242|NCT01675687|Experimental|Printed Manual|"Participants of this intervention group get follow up support via a printed manual.~The manual consist of all the same inputs as are available to the Internet follow up group.~Thematic inputs and instructions (e.g. advice on shopping, cooking, regular exercise on daily routine, motivation and more)~assignments promoting self-awareness and introspection~spreadsheets promoting self-monitoring~All inputs will be given at once at the beginning of the follow up intervention, only news and updates (e.g. recipes, gymnastic classes, meetings of self support groups and more) will be sent per mail each month.~There is no tailored feedback of their behaviour as the paper-pencil documentation on spreadsheets can't be monitored by the psychologists."
3282243|NCT01675700|Experimental|Myofascial trigger point|Patients diagnosed with myofascial trigger points who will receive a nitroglycerin patch over the trigger point.
3282244|NCT01675713|Experimental|Lifestyle intervention|10-14 weeks intensive lifestyle intervention
3282245|NCT01675713|No Intervention|Controls|No treatment, waiting list
3282246|NCT01675726|Other|quality of life|
3282247|NCT01675739|Active Comparator|No-SMS group|In No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy without SMS.
3282248|NCT01675739|Experimental|SMS group|Patients in SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled short message service(SMS)
3282249|NCT01675791|Placebo Comparator|ALK tree AIT Placebo|1 AIT administered sublingually every day
3282250|NCT01675791|Experimental|ALK tree AIT 0.5 DU|1 AIT administered sublingually every day
3282251|NCT01675791|Experimental|ALK tree AIT 1 DU|1 AIT administered sublingually every day
3282252|NCT01675791|Experimental|ALK tree AIT 2 DU|1 AIT administered sublingually every day
3282253|NCT01675791|Experimental|ALK tree AIT 4 DU|1 AIT administered sublingually every day
3282254|NCT01675791|Experimental|ALK tree AIT 7 DU|1 AIT administered sublingually every day
3282255|NCT01675791|Experimental|ALK tree AIT 12 DU|1 AIT administered sublingually every day
3282256|NCT01675804|Experimental|Computerized cognitive rehabilitation|-Computer-assisted cognitive rehabilitation (CACR): 20 Ninety-minute sessions of CACR.
3282257|NCT01675804|Placebo Comparator|Placebo CACR [PCACR]|-PCACR group simultaneously received 20 Ninety-minute sessions of Placebo CACR.
3282258|NCT01675804|Experimental|Ritalin|-2 to 3 doses of 10 mg Ritalin tablets per day during two months.
3282259|NCT01675843|Experimental|Group A|controlled ovarian hyperstimulation (COH) and intrauterine insemination (IUI)
3282260|NCT01675843|No Intervention|Group B|Controlled ovarian hyperstimulation (COH)+ Timed Intercourse (TI)
3282261|NCT01675856|Active Comparator|Urgent endoscopy|Oesophagogastroduodenoscopy done within 6hours of first GI specialists consultation
3282262|NCT01675856|Placebo Comparator|Early endoscopy|Oesophagogastroduodenoscopy done within 24hours of first GI specialists consultation
3282263|NCT01675869|Experimental|ETAM group|Executive Function/Metacognitive Training Program: An 8-week program, which addresses major areas of deficit in ADHD; namely, attention (the ability to concentrate and focus), inhibition (the ability to control ones behaviors), and memory (the ability to remember information).
3282264|NCT01675869|Active Comparator|Attention Control|Attention control group: An 8-week program which provides education regarding several topics relevant for preschool children including nutrition, sleep, temperament, etc.
3282265|NCT01675895|Experimental|Group Levobupivacaine lidocaine|Group Levobupivacaine lidocaine Spinal anesthesia with 1.5 ml hyperbaric levobupivacaine (6.75 mg) + 0.3 ml 2 % lidocaine
3282266|NCT01675895|Active Comparator|Group Control|Group Control levobupivacaine spinal anesthesia with levobupivacaine (6.75 mg) + saline
3282267|NCT01675908|Active Comparator|Metal stent|Patients randomized to one cohort will undergo placement of fully covered self expandable metal stents. The rates (%) of stent dysfunction and complications will be evaluated.
3282268|NCT01675908|Active Comparator|Plastic Stent|At ERCP, a 10Fr plastic stent will be placed in the bile duct. The rates (%) of stent dysfunction and complications will be evaluated.
3282269|NCT01675921|No Intervention|Control|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to this study website at the start and at the end of the study."
3282270|NCT01675921|Experimental|Facebook group|"Participants will continue to receive medical care from their doctor as usual.~Participants will have access to the study website at all times throughout the study.~Participants will have access to the secret study group on Facebook for 12 months.~Participants will take the ACT survey once a month for 12 months."
3282271|NCT01675934|Active Comparator|Adult colonoscope|Use of the adult colonoscope.
3282272|NCT01675934|Active Comparator|Pediatric colonoscope|Use of the pediatric colonoscope.
3282273|NCT01675947|Experimental|Sirolimus|Monthly 20 μL (440 μg) intravitreal injection of sirolimus
3282274|NCT01675947|Sham Comparator|Lidocaine|Monthly subconjunctival injection of 2% lidocaine
3282275|NCT01675973|Experimental|Subjects with severe renal impairment|Cohort B (subjects with severe RI): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
3282276|NCT01675973|Experimental|Subjects with normal renal function|Cohort A (healthy subjects with normal renal function): Approximately 10 subjects will be enrolled to obtain approximately 8 evaluable subjects.
3282277|NCT01675986|Experimental|Pregabaline|Groups PREGABALINE : 150 mg de LYRICA®
3282278|NCT01675986|Experimental|Hydroxyzine|Groups HYDROXYZINE : 75 mg d'ATARAX®
3282279|NCT01675986|Placebo Comparator|Lactose|Groups placebo : 4 g de lactose
3282280|NCT01675999|Experimental|1|"Perioperative simplified FOLFOX-4 chemotherapy~- Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by simplified FOLFOX-4 (8 cycles)."
3282281|NCT01675999|Experimental|2|Perioperative FOLFOX4+Cetuximab chemotherapy Simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h)+ Cetuximab (IV 500 mg/m2 every 2 weeks) for 4 cycles followed by colectomy (3 to 5 weeks after), followed by simplified FOLFOX-4 + Cetuximab (8 cycles).
3282282|NCT01675999|Other|3|Surgery followed by FOLFOX4 chemotherapy No preoperative chemotherapy Colectomy (maximum 4 weeks after randomization) followed by simplified FOLFOX-4 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-FU 400 mg/m2 and IV infusional 5-FU 2400 mg/m2 over 46h) for 12 cycles.
3378265|NCT02896855|Active Comparator|Arm A: Placebo + Trastuzumab + Docetaxel|Placebo matched to pertuzumab, trastuzumab (8-milligrams per kilogram [mg/kg] loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-milligrams per square meter [mg/m^2]) were administered by intravenous (IV) infusion every 3 weeks until disease progression or unacceptable toxicity.
3378266|NCT02896855|Experimental|Arm B: Pertuzumab + Trastuzumab + Docetaxel|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles), trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles), and docetaxel (75-mg/m^2) were administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
3378267|NCT02890342||Affected Patients with Propionic Acidemia|Patients with Propionic Acidemia, standard adult, parental permission
3378268|NCT02890342||Healthy Volunteers|Healthy Volunteers, standard adult, parental permission
3282283|NCT01676025|Experimental|PRA|Persons who get PRA surgery.
3282284|NCT01676025|Experimental|LA|Persons who get LA surgery.
3282285|NCT01676038|Active Comparator|Pinless-Navigated Total Knee Arthroplasty|The patients underwent total knee arthroplasty using a Pinless-Navigated system that is designed to restore the mechanical alignment of the lower limb.
3378269|NCT02890342||Unaffected Family Members|Unaffected family members
3378270|NCT02881203|Experimental|Breathe Well + RPM|Participants will receive Breathe Well audiovisual feedback in addition to the RPM system
3378271|NCT02881203|Active Comparator|RPM|Varian's RPM system is the current standard of care at Royal North Shore Hospital where this trial is to be run.
3378272|NCT02871778|Experimental|Part A: VX-371 in Hypertonic Saline (HS), Then HS|Participants received 85 microgram (mcg) VX-371 diluted in 3 milliliter (mL) 4.2 percent (%) HS twice daily through oral nebulized inhalation from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
3378273|NCT02871778|Experimental|Part A: HS, Then VX-371 in HS|Participants received 3 mL 4.2% HS through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
3282286|NCT01676038|Active Comparator|Conventional Total Knee Arthroplasty|The patients underwent total knee arthroplasty using conventional technique.
3282287|NCT01676051||Chloraprep|
3378274|NCT02871778|Experimental|Part A: VX-371, Then Placebo|Participants received 85 mcg VX-371 diluted in 3 mL 0.17% Saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
3378275|NCT02871778|Experimental|Part A: Placebo, Then VX-371|Participants received 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily from Day 1 through Day 29 in treatment period 1 followed by a 28 day washout period (from Day 29 through Day 56) and then received 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2.
3378276|NCT02871778|Experimental|Part B: VX-371 in HS + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
3282288|NCT01676051||Duraprep|
3282289|NCT01676051||Betadine only|
3282290|NCT01676064|Active Comparator|liberal fluid group|during surgery 7 ml/kg/hr RL during first intraoperative hr, 5 ml/kg/hr for the subsequent hours.After surgery ( PACU) 1,5 ml/kg/hr;After operation ward on the day of surgery 1,5 ml/kg/hr; Postoperative day 1- 1,5 ml/kg/hr RL, oral fluids;Postoperative day 2-oral fluids and solid food according to surgical allowance.
3282291|NCT01676064|Active Comparator|restrictive fluid group|"during surgery-RL according to 4-2-1 4 ml/kg/hr for first 10 kg (=40ml/hr) then 2 ml/kg/hr for next 10 kg (=20ml/hr)then 1 ml/kg/hr for any kg over 20 kg of weight. This always gives 60ml/hr for first 20 kg then you add 1 ml/kg/hr for each kg over 20 kg.~After surgery (PACU):4-2-1 rule. After operation ward on the day of surgery 1,5 ml/kg/hr.Postoperative day 1:1,5 ml/kg/hr RL, oral fluids. Postoperative day 2:oral fluids and solid food according to surgical allowance."
3282292|NCT01676077||Patients with a genetically confirmed dysferlinopathy|
3282293|NCT01676103|Experimental|Tyrosine|Tyrosine supplementation (500 mg 2x daily) for 7 days
3282294|NCT01676103|Placebo Comparator|Sugar pill|Placebo sugar pills (2x daily) for 7 days
3282295|NCT01676129|Experimental|Nocipoint Therapy|"Nocipoint therapy (NT) follows rules of TENS stimulation in each session, all within the general FDA guidelines of TENS uses. The key points of Nocipoint Therapy include the following:~The stimulation pads are located at the skin surface location of the nociceptors of the muscle/tissue in pain (i.e., Nocipoint)~The intensity is set to induce C-fiber response during the stimulation~The duration of stimulation (about 1.5-4 minutes for each tissue stimulation)~Stimulations for different tissues (muscles, ligaments) are sequenced such that later stimulations will not cause re-injury of previously treated tissues.~Patient are instructed not to use the newly recovered muscle/tissue too much for an estimated rest period depending on his/her age."
3282296|NCT01676129|Active Comparator|Physical Therapy|"Patients in this group will be treated with comprehensive physical therapy program including typical electrical stimulation using a standard transcutaneous electrical nerve stimulation (TENS) device, manual myofascial release and postural correction exercise.~The application of TENS will follow general physical therapy guidelines, especially for TMD. Manual myofacial release will be applied on orofacial muscles and neck muscles.~TENS will serve both as a part of the standard of care and as placebo, as the same TENS device is used in both arms."
3282297|NCT01676142||Patients with NTM pulmonary infection|
3282298|NCT01676142||Patients with other pathogen related lung infection|
3282299|NCT01676142||Patient with NTM pulmonary colonization|
3282300|NCT01676155||Patient with active tuberculosis|
3282301|NCT01676155||Patients with diagnosis of latent tuberculosis infection|
3282302|NCT01676155||Patient without latent tuberculosis or active tuberculosis|
3282303|NCT01676168||hypertrophic scar|1x1cm2 hypertrophic scar of post-burn patients are taked by visiting staff when they accept scar-reconstructive surgery.
3282304|NCT01676168||normal skin|When the patient accept skin grafting surgery, visiting staff will take 1x1cm2 normal skin.
3282305|NCT01676181|Active Comparator|Adenotonsillectomy|Total removal of tonsils and adenoids with cold steel
3282306|NCT01676181|Active Comparator|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
3282307|NCT01676194|Experimental|Intra-arterial administration of DC BeadsR|Intra-arterial administration of DC BeadsR, (1 vial of 100-300 µm) as selectively as possible loaded with doxorubicin (50 mg per procedure) and mixed with an equal volume of contrast medium. The first injection will be performed within 21 days following enlisting and repeated 1-2 times until LT (only if hypervascularized vital tumor tissue is again visible on CT Scan and if liver function remains within Child A stage) or until complete response
3282308|NCT01676194|No Intervention|Control|Usual care
3282309|NCT01676207||1|CAD
3282310|NCT01676207||2|no CAD
3282311|NCT01676233|Experimental|Sequence 1|Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal
3282312|NCT01676233|Experimental|Sequence 2|Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal
3282313|NCT01676246|Active Comparator|flupirtine per os single dose|100 mg flupirtine per os, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
3282314|NCT01676246|Active Comparator|flupirtine intravenous|100 mg flupirtine intravenous, pharmacokinetics of flupirtine, induce delayed onset of muscle soreness (DOMS), electric pain measurement
3282315|NCT01676246|Active Comparator|flupirtine per os steady state|400 mg flupirtine per os, pharmacokinetics of flupirtine, electric pain measurement
3282316|NCT01676259|Experimental|siG12D-LODER + chemotherapy|Eight siG12D-LODER+Gemcitabine+nab-Paclitaxel or Eight siG12D-LODER+Folfirinox or Eight siG12D-LODER+modifide Folfirinox
3282317|NCT01676285|Active Comparator|Metoprolol succinate|Metoprolol succinate
3282318|NCT01676285|Placebo Comparator|Placebo|Placebo
3282319|NCT01676285|No Intervention|Follow up|Group without cirrhotic cardiomyopathy, only follow up without randomization.
3282320|NCT01676324||Inflammatory Bowel Disease|Those with Inflammatory Bowel Disease (known) and those with no Inflammatory Bowel Disease (not previously diagnosed)
3282321|NCT01676337|No Intervention|Control|Patients randomized to the control arm will not receive text message reminder regarding their upcoming appointment.
3282322|NCT01676337|Experimental|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
3282323|NCT01676350|No Intervention|Standard of care|If you are assigned to this group, ultrasound-guided IV will be used to obtain vascular access.
3282324|NCT01676350|Experimental|'IO access using EZ-IO®|If you are assigned to this group, you will receive an IO line in the humeral head of the shoulder. IO lines are placed using an FDA-approved device called an EZ-IO®.
3282325|NCT01676363|Experimental|Diflunisal|
3282326|NCT01676376|Active Comparator|eSVS Mesh treated saphenous vein graft|Each subject will be randomized to an eSVS Mesh treated SVG to the right or left coronary system.
3282327|NCT01676376|Sham Comparator|Control saphenous vein graft|Each subject will be randomized to an untreated (no eSVS Mesh) SVG to the right or left coronary system.
3282328|NCT01676376|Active Comparator|Single Vessel Treatment|Each subject with receive one SVG with eSVS Mesh either to the right or left coronary system.
3282329|NCT01676389|Experimental|OMM Hands-On Treatment|The Osteopathic Manual Medicine (OMM) Hands-On Treatment group will be receiving an osteopathic structural exam along with 7 gentle, non-thrusting techniques during each treatment session that lasts 20-30 minutes. The Sham treatment group will be receiving only an osteopathic structural exam that will be slowed down in order to be a similar duration to the full treatment group session (approximately 20-30 minutes).
3282330|NCT01676389|Placebo Comparator|Sham OMM|Sham Osteopathic Manual Medicine (OMM)
3282331|NCT01676402|Experimental|Group 1: HA DNA + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV ID at Week 14±2 wks
3282332|NCT01676402|Experimental|Group 2: HA DNA + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) at Day 0 and licensed 2012/13 TIV IM at Week 14±2 wks
3282333|NCT01676402|Experimental|Group 3: TIV ID + TIV ID|licensed 2012/13 TIV ID at Day 0 and licensed 2013/14 TIV ID at Week 44±2 weeks
3282334|NCT01676402|Experimental|Group 4: TIV IM + TIV IM|2012/13 licensed TIV IM at Day 0 and licensed 2013/14 TIV IM at Week 44±2 weeks
3282335|NCT01676402|Experimental|Group 5: (HA DNA and TIV ID) + TIV ID|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV ID at Day 0 followed by licensed 2013/14 TIV ID at Week 44±2 weeks
3282336|NCT01676402|Experimental|Group 6: (HA DNA and TIV IM) + TIV IM|2012/13 seasonal influenza DNA Vaccine (VRC-FLUDNA063-00-VP) and licensed 2012/13 TIV IM at Day 0 followed by licensed 2013/14 TIV IM at Week 44±2 weeks
3282337|NCT01676428|Experimental|Radiotherapy|"The interventional treatment will be prescribed as a 2-tiered dose scheduled dependant of target size.~For lesions <5cm, a single fraction of 26 Gy will be prescribed. For lesions ≥5cm a fractionated course of 15Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
3282338|NCT01676441|Experimental|cellgram-spine|posterior cervical laminectomy and Mesenchymal stem cells tranplantation. After laminectomy, 1.6X10^7 and 3.2 X10^7 Autologous Mesenchymal stem cells is injected into the intramedullary and intrathecal space respectively
3282339|NCT01676454||Vasopressin levels.|"Cohort will consist of subjects with a minor injury or injuries defined as:~no episodes of systolic blood pressure < 90 mmHg between occurrence of injury and admission;~no blood transfusion requirement;~base deficit < 5 mEq/L;~no requirement for mechanical ventilation other than transiently during orthopedic surgery."
3282340|NCT01676467||Smoking asthma on steroids|Smokers with persistent asthma on background steroid therapy
3282341|NCT01676467||Smoking asthma steroid naïve|Smokers with persistent asthma, steroid naive
3282342|NCT01676467||asthma on steroids|Non-Smokers with persistent asthma on background steroid therapy
3282343|NCT01676467||asthma, steroid naïve|Non-smokers with persistent asthma, steroid naive
3282344|NCT01676467||Healthy smoking|Healthy smoking control subjects
3282345|NCT01676467||Healthy non-smoking|Healthy non-smoking control subjects
3282346|NCT01676480|Experimental|ADT group|
3282347|NCT01676480|Experimental|Control group|
3282348|NCT01676493|Experimental|Codeine|Codeine Sulfate Oral Solution and Tablet
3282349|NCT01676519||PCI|diabetic patients undergoing percutaneous coronary intervention
3282350|NCT01676545||Chronic Periodontitis|
3282351|NCT01676545||Control|
3282352|NCT01676558|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3282353|NCT01676571|Experimental|Lu AA21004|
3282354|NCT01676584|Placebo Comparator|Placebo|
3282355|NCT01676584|Experimental|RO6811135|
3282356|NCT01676597|Experimental|rifaximin and pentoxifylline|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
3282357|NCT01676597|Active Comparator|pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
3282358|NCT01676610||Infants presenting to the Clinic|Infants presenting to the Bilal and Bhains Colony Health Center. Devices used to measure Pulse Oximetry (PO) include Rad-5v by Masimo, TuffSat by GE, N-65 by Nellcor, PRO2 by Conmed, and Lifebox by Acare.
3282359|NCT01676623|Active Comparator|Comparison area, only standard government services|This intervention arm will receive the standard government services offered at CHCs all over Vietnam. In addition, participants in this arm will be exposed to the nationwide mass media campaign.
3282360|NCT01676623|Experimental|A&T Franchise|In this arm, the 20 CHCs will offer Alive & Thrive branded franchise services with enhanced quality of IYCF counseling through interpersonal contact between health workers at the commune level and clients who use the commune health services. In addition, the clients could also be exposed to the mass media campaign.
3282361|NCT01676636||Pregnant Women|Women who are 13 to 30 weeks pregnant. Each participant will take all 4 different calcium vehicles and decide which one they prefer.
3282362|NCT01676649|Experimental|A|Arm A: Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 4, week 7, week 10, and week 13)
3282363|NCT01676649|Experimental|B|Carboplatin (week 1, week 4, week 7, week 10, and week 13) Paclitaxel (week 1, week 4, week 7, week 10, and week 13) Ipilimumab (week 5, week 8, week 11, and week 14)
3282364|NCT01676662|Experimental|Treatment on Day 0|Subjects who are treated with the Solace Bladder Control System upon entry into the trial.
3282365|NCT01676662|Sham Comparator|Sham Treatment on Day 0|Patients who undergo a sham procedure upon entry into the trial, with treatment with the Solace Bladder Control System at 3 months after the sham procedure.
3282366|NCT01676675|Experimental|7.5μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adolescents aged 12-17 years old on day 0, 21
3282367|NCT01676675|Experimental|15μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
3282368|NCT01676675|Experimental|30μg/0.5ml in subjects(12-17 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adolescents aged 12-17 years old on day0,21
3282369|NCT01676675|Experimental|7.5μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3282370|NCT01676675|Experimental|15μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3282371|NCT01676675|Experimental|30μg/0.5ml in subjects(18-60 years old)|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml in 30 adults aged 18-60 years old on day 0, 21
3282372|NCT01676675|Placebo Comparator|0/0.5ml in adolescents (12-17 years old)|0/0.5ml placebo in 30 adolescents aged 12-17 years old on day 0, 21
3282373|NCT01676675|Placebo Comparator|0/0.5ml in adults(18-60 years old)|0/0.5ml placebo in 30 adults aged 18-60 years old on day 0, 21
3282374|NCT01676740|Placebo Comparator|Mild anemia, normal hematinics|Mild anemia, normal iron studies, serum folate and vitamin B12 levels - will receive placebo
3282375|NCT01676740|Experimental|Anemia, normal hematinics|Mild anemia, deficient iron, folate or vitamin B12 levels Iron supplement will be given
3282376|NCT01676740|Other|Deficeicnt hematinics|Iron supplement will be provided
3282377|NCT01676753|Experimental|Dinaciclib & Pembrolizumab Treatment|Dinaciclib is administered on days 1 and 8 of a 21-day cycle in combination with pembrolizumab administered on day 1 of each 21-day cycle.
3282378|NCT01676779|Experimental|Arm A dendritic cell therapy|Arm-A, patients will receive Dendritic Cell therapy during one year following randomization.
3282379|NCT01676779|Experimental|Arm B Dendritic cell therapy|Arm-B, patients will initiate Dendritic Cell therapy only after documented recurrence of the melanoma that cannot be salvaged by local therapy.
3282380|NCT01676792|Experimental|Lesion reduction|
3282381|NCT01676844|Experimental|Oral thin film therapy|One or more oral thin films (OTFs) containing potassium acid phosphate administered to the inside cheek, tongue or palate at a dose of 0.5 mmol/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Where more than one OTF is required to achieve a dosage of 0.5mmol/kg, strips will be administered consecutively with time allowed between doses to allow for complete dissolving of the previous strip. Treatment will continue until the participant has received OTF therapy for 14 consecutive days.
3282382|NCT01676844|Active Comparator|Standard therapy|Standard oral phosphate supplementation as per NHS Greater Glasgow and Clyde Guidelines. An oral solution containing potassium acid phosphate (1 mmol/mL) will be administered at a dosage of 0.5 mM/kg body weight twice daily. Dosages will be rounded to the nearest 0.1 mM/kg. Standard therapy will continue until the participant has received treatment for 14 consecutive days.
3282383|NCT01676857||CP/CPPS group|The Study population will include patients diagnosed with CPPS (equal numbers of CPPS IIIa and CPPS IIIb) at least 18 years of age, recruited from Northwestern urology clinical site practices. All CPPS participants will be male and will have pelvic pain symptoms. Men who are at least 18 years of age and who had been seen by a physician for symptoms of CP/CPPS within the previous 2 years will comprise the patient population
3282384|NCT01676857||Control group|Adult male volunteers who are male, at least 18 years of age and meet inclusion and exclusion criteria
3282385|NCT01676870|Experimental|1x4 aerobic interval training|1x4min aerobic interval training (1-AIT), 3 times a week
3282386|NCT01676870|Experimental|4x4 aerobic interval training|4x4min aerobic interval training (4-AIT), vigorously exercise according to today's guidelines, 3 times a week
3282387|NCT01676870|Active Comparator|traditional moderate training|traditional moderate training (CME), moderate exercise at least 30 min, 5 days a week or more, according to today's guidelines
3282388|NCT01676883|Experimental|body composition assessment|Bioelectric impedance measurement pre- and post removal of calluses and corns (pedicure), then air-displacement plethysmography (gold standard)
3282389|NCT01676922||Cohort|
3282390|NCT01676935|Experimental|ABT-126|ABT-126 Open-label dose
3282391|NCT01676948|Experimental|Canakinumab - Cohort 1, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
3282392|NCT01676948|Experimental|Canakinumab - Cohort 1, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
3282393|NCT01676948|Experimental|Canakinumab - Cohort 2, 2mg|2 mg/kg q4wk (followed by taper to 1 mg/kg q4wk and drug discontinuation if appropriate)
3282394|NCT01676948|Experimental|Canakinumab - Cohort 2, 4mg|4 mg/kg q8wk (followed by taper to 4 mg/kg q12wk and drug discontinuation if appropriate)
3282395|NCT01676948|Experimental|Cohort 2 - canakinumab dose reduction|
3282396|NCT01676948|Experimental|Cohort 1 - canakinumab dose reduction|
3282397|NCT01676974||Travelers|Travelers and their family members
3282398|NCT01676987|Experimental|Fixed Combination of Budesonide and formoterol|Group 1 (experimental): Fixed Combination of Budesonide and formoterol
3282399|NCT01676987|Active Comparator|Budesonide|Group 2 (comparator): Budesonide
3282400|NCT01677013|No Intervention|Oral medication treatment|type 2 diabetics with only oral medications
3282401|NCT01677013|Experimental|Oral medication plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
3282402|NCT01677013|No Intervention|Oral medication plus insulin treatment|Type 2 diabetics who need insulin therapy with oral medications
3282403|NCT01677013|Experimental|Oral medication plus insulin plus BMMCT|Collect mononuclear cells from bone marrow aspiration, administer to pancreas via selective catheterization to splenic artery.
3282404|NCT01677039|Active Comparator|Treatment A|
3282405|NCT01677039|Experimental|Treatment B|
3282406|NCT01677039|Experimental|Treatment C|
3282407|NCT01677065||Treatment A|Controlled release oxycodone test formulation 40 mg
3282408|NCT01677065||Treatment B|Immediate release oxycodone reference drug 20 mg
3282409|NCT01677078|Experimental|Neuronavigation system|"10 sessions of rTMS coupled with a neuronavigation system~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~rTMS: System Mag Pro (Magventure, Denmark)~Neuronavigation system: Syneika One (Syneika, France)"
3282410|NCT01677078|Sham Comparator|Standard localisation method|"10 sessions of rTMS with manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')~Description of 1 session of the rTMS protocol :~Frequency: 20Hz~Intensity: 110% of motor threshold~80 train of 2 seconds duration~10 seconds between two trains~3200 pulses~Devices :~- rTMS: System Mag Pro (Magventure, Denmark)"
3282411|NCT01677091|Active Comparator|Control group|This group will benefit from conventional rehabilitation
3282412|NCT01677091|Experimental|Cervical vibration|This group will benefit from a daily 20 minutes session, with vibration of neck muscles during 10 minutes
3282413|NCT01677091|Experimental|Prism adaptation|This group will benefit from a daily 20 minutes session, with prism adaptation during 10 minutes
3282414|NCT01677091|Experimental|Cervical vibration + Prism adaptation|This group will receive a daily 30 minutes session, with cervical vibration during 10 minutes + prism adaptation during 10 minutes
3282415|NCT01677104|Active Comparator|DPP-IV inhibitor|Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
3282416|NCT01677104|Placebo Comparator|Placebo pill|One placebo tablet before microinjection
3282417|NCT01677143|Active Comparator|bupivacaine|Injection of 5 ml bupivacaine, 5mg/ml in each port site.
3282418|NCT01677143|Placebo Comparator|Placebo|Injection of 5 ml saline in each port site.
3282419|NCT01677156||Receiving Corus CAD (ASGES)|Patients receiving Corus CAD (ASGES) to aid in the diagnosis of obstructive CAD
3282420|NCT01677169|Experimental|59 mL noni juice|Ingestion of 59 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) twice daily (118 mL daily total) for 30 days.
3282421|NCT01677169|Placebo Comparator|Placebo|Ingestion of 59 mL of placebo (mixture of grape and blueberry juices and natural cheese flavor) twice daily (118 mL daily total) for 30 days.
3282422|NCT01677169|Experimental|29.5 mL noni dose|Ingestion of 29.5 mL of Tahitian Noni® juice (mixture of noni juice and grape and blueberry juices) daily for 30 days.
3282423|NCT01677208|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3282424|NCT01677208|Placebo Comparator|placebo|Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3282425|NCT01677234||Pregnant women|Pregnant women undergoing a cesarean section
3282426|NCT01677247|Experimental|Group I (Test)|Test : glimepiride 4 mg tablet of PT Dexa Medica
3282427|NCT01677247|Active Comparator|Group II (Reference)|Reference : glimepiride (Amaryl) 4 mg tablet of PT Sanofi-Aventis, Indonesia
3282428|NCT01677260|Experimental|Group I|500 mg metformin hydrochloride extended release caplet (PT Ferron Par Pharmaceuticals)
3282429|NCT01677260|Active Comparator|Group II|500 mg metformin hydrochloride prolonged release tablet (PT Merck Pharmaceuticals)
3282430|NCT01677273|Active Comparator|Hydrolyzed casein|Hydrolyzed casein
3282431|NCT01677273|Active Comparator|Intact casein|Intact casein
3282432|NCT01677273|Active Comparator|Intact whey protein|Intact whey protein
3282433|NCT01677325|Experimental|Chinese herb|Chinese herb
3282434|NCT01677338|Experimental|13C-uracil and 99mTc sulfur colloid|Subjects will consume the Semi-solid Test Meal containing 500 uCi 99mTc sulfur colloid and 100 mg of 13C-uracil.
3282435|NCT01677338|Experimental|99mTc sulfur colloid|Subjects will consume the Solid Test Meal containing 500 uCi 99mTc sulfur colloid.
3282436|NCT01677351|Active Comparator|group 2: clonidine 4mcg.kg|this group (group 2) will receive 4mcg.kg-1 of clonidine 20 minutes before surgery.
3282437|NCT01677351|Placebo Comparator|Group 1: sterile saline solution|this group (Group 1) will receive a sample injection of sterile saline solution 20 minutes before surgery
3282438|NCT01677364|Active Comparator|induction of labour|drug- infusion of 30U oxytocin diluted in 500ml normal saline given at rate of 3mU/min and subsequently dose increased 3mU/min every 45 min
3282439|NCT01677364|No Intervention|Spontaneous Labour|patients were allowed to go into spontaneous labour
3282440|NCT01677390|Experimental|Arm 1|SGN-75, everolimus
3282441|NCT01677403|Active Comparator|Nebulised Tobramycin|Nebulised Tobramycin
3282442|NCT01677403|Placebo Comparator|Nebulised 0.9% Saline|Nebulised 0.9% Saline
3282443|NCT01677416||Rheumatoid Arthritis Group|RA with at least one year since diagnosis, asymptomatic feet, and age between 18 and 65 years
3282444|NCT01677416||Control group|Absence of known osteoarticular disease
3282445|NCT01677429|Experimental|VR movie + balance challenge|VR-based balance training
3282446|NCT01677429|Sham Comparator|still pictures from VR|Exposure to still pictures from the same VR scene but no balance challenge
3282447|NCT01677429|Active Comparator|Cognitive Behavioral Therapy|Standard CBT protocol for the treatment of panic disorder
3282448|NCT01677442|Experimental|no-intubated group|Experimental: no-intubated thoracic epidural anesthesia Thoracic epidural anesthesia at the T5/T6 thoracic interspace
3282449|NCT01677442|Active Comparator|intubated group|Active Comparator:double-lumen endotracheal intubated anesthesia
3282450|NCT01677455|Experimental|HER2+ breast cancer|
3282451|NCT01677455|Experimental|Triple negative breast cancer|Closed to enrollment
3282452|NCT01677455|Experimental|ER/PR+ Refractory to Prior Hormonal Treatment|
3282453|NCT01677468|Experimental|Intermediate embolization|TACE with substatsis using gelfoam
3282454|NCT01677468|Active Comparator|Complete embolization|TACE with complete embolization using gelfoam
3282455|NCT01677481||Femoral|Coronary angiography procedures performed using transfemoral access
3282456|NCT01677481||Left radial access|Coronary angiography procedures performed using left radial access site.
3282457|NCT01677481||Right radial Access|Coronary angiography procedures performed using Right radial access site.
3282458|NCT01677494||heart failure with preserved ejection fraction|- Inclusion Elevated BNP EF > 50%
3282459|NCT01677520||18-30 yrs, 31-50 yrs, 51-70 yrs|No intervention
3282460|NCT01677533|Active Comparator|PM-Data|Team will receive data only.
3282461|NCT01677533|Experimental|PM-Support|Team will receive data and panel management support
3282462|NCT01677533|Experimental|PM-Education|Team will receive data, panel management support, and educational interventions.
3282463|NCT01677546|Experimental|CSII+BC+CL|Patients using insulin pump (CSII) bolus calculator (BC) wirelessly connected with blood glucose meter Contour Link (CL)
3282464|NCT01677546|Experimental|CSII+BC|Patients using insulin pump (CSII) bolus calculator (BC) without wireless connection with blood glucose meter (CL)
3282465|NCT01677546|No Intervention|CSII (insulin pump only)|Patients using insulin pump (CSII) without BC and connection with CL
3282466|NCT01677559|Experimental|Dose Level 0|"MLN8237 20 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3282467|NCT01677559|Experimental|Dose Level 1|"MLN8237 30 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3282468|NCT01677559|Experimental|Dose Level 2|"MLN8237 40 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3282469|NCT01677559|Experimental|Dose Level 3|"MLN8237 50 mg BID Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3282470|NCT01677559|Experimental|MTD Expansion Phase|"MLN8237 as determined during the dose escalation phase on Days 1, 2 and 3 of each week for 3 weeks out of a 4 week cycle.~nab-Paclitaxel 100 mg/m2 IV Day 1 of each week for 3 weeks out of a 4 week cycle."
3282471|NCT01677572|Experimental|Low-dose #1 Aducanumab|Intravenous doses of low-dose level #1 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282472|NCT01677572|Experimental|Low-dose #2 Aducanumab|Intravenous doses of low-dose level #2 Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282473|NCT01677572|Placebo Comparator|Placebo (low dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
3282474|NCT01677572|Experimental|Mid-dose Aducanumab|Intravenous doses of mid-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282475|NCT01677572|Placebo Comparator|Placebo (mid dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282476|NCT01677572|Experimental|High-dose Aducanumab|Intravenous doses of high-dose Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282477|NCT01677572|Placebo Comparator|Placebo (high dose group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose administered approximately 4 weeks apart for up to an additional 112 doses.
3282478|NCT01677572|Experimental|Aducanumab Titration|Intravenous doses of Aducanumab administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
3282479|NCT01677572|Placebo Comparator|Placebo (Titration Group)|Intravenous doses of placebo administered approximately 4 weeks apart over approximately 52 weeks (a total of 14 doses). Qualifying participants can continue into the long-term extension at a dose approximately 4 weeks apart for up to an additional 112 doses.
3282480|NCT01677598||Patients with plaque psoriasis|Patients with plaque psoriasis using ustekinumab in Asia-Pacific countries.
3282481|NCT01677611|Experimental|Resveratrol|Trans-resveratrol extract from Polygonum Cuspidatum (Mega Resveratrol, Danbury, USA) was used in the trial.Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of either resveratrol.The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia. Subjects were instructed to abstain from foods with high resveratrol content during the entire duration of the trial.
3282482|NCT01677611|Placebo Comparator|Placebo|All subjects underwent a 2-week run-in period during which placebo was administered. The placebo was manufactured so that it was not distinguishable by color, form, or taste from the active drug. Following the run-in period, subjects who were tolerant of the placebo would proceed to the treatment period. Subjects were given a starting dose of 500 mg daily of matching placebo and instructed to abstain from foods with high resveratrol content during the entire duration of the trial. The dose was increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
3282483|NCT01677637||All measurements|Total measured population
3282484|NCT01677650|Active Comparator|Methadone 0.5 mg/kg|Methadone 0.5 mg/kg
3282485|NCT01677650|Experimental|Methadone 0.4 mg/kg|Methadone 0.4 mg/kg
3282486|NCT01677650|Active Comparator|Methadone 0.3 mg/kg|Methadone 0.3 mg/kg
3282487|NCT01677650|Active Comparator|Methadone 0.2 mg/kg|Methadone 0.2 mg/kg
3282488|NCT01677650|Active Comparator|Methadone 0.15 mg/kg|Methadone 0.15 mg/kg
3282489|NCT01677676|Active Comparator|Group 2|FP-01.1 (250µg/peptide)
3282490|NCT01677676|Active Comparator|Group 3|FP-01.1-Adjuvant (150µg/peptide / 10.8mg)
3282491|NCT01677676|Active Comparator|Group 4|FP-01.1-Adjuvant (250µg/peptide / 18mg)
3282492|NCT01677676|Active Comparator|Group 1|FP-01.1 (150µg/peptide)
3282493|NCT01677689|Placebo Comparator|Control Group|Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal
3282494|NCT01677689|Experimental|Study Group|Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
3282495|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
3282496|NCT01677702|Active Comparator|Yili Lactoferrin ShuHua Milk (lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
3282497|NCT01677702|Placebo Comparator|Recombined low-protein milk|Total 250mL placebo milk will be taken once per day at 10am daily during the 84 days intervention.
3282498|NCT01677715|Active Comparator|"Yili Mei Yi Tian lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
3282499|NCT01677715|Placebo Comparator|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
3282500|NCT01677728||arm A|patients received chemotherapy alone
3282501|NCT01677728||arm B|patients received target therapy combined with chemotherapy
3282502|NCT01677754|Placebo Comparator|Placebo|Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3282503|NCT01677754|Experimental|RO4602522 1 milligram (mg)|Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3282504|NCT01677754|Experimental|RO4602522 5 mg|Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
3378277|NCT02871778|Experimental|Part B: HS + Ivacaftor|Participants who were on 3 mL 4.2% HS through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
3282505|NCT01677780|Experimental|RO5045337|Participants will continue the most similar dose and formulation available (which does not exceed the MTD or the maximum safely administered dose for that formulation during Phase 1) and the same schedule of RO5045337 treatment that they were receiving at the time of transitioning from their respective parent clinical study protocols: NO21279 (NCT00623870), NO21280 (NCT00559533), NP25299 (NCT01164033), NP28021 (NCT01605526) or NP28023 (NCT01635296).
3282506|NCT01677793||Child and adolescent population|
3282507|NCT01677806|Experimental|Percutaneous vertebroplasty|
3282508|NCT01677806|Active Comparator|Conservative therapy|
3282509|NCT01677832||ADHD/Taiwan|
3282510|NCT01677832||Control/Taiwan|
3282511|NCT01677832||ADHD/Germany|
3282512|NCT01677832||Control/Germany|
3282513|NCT01677845|Experimental|Radiation Therapy|Radiation Therapy
3282514|NCT01677871|Experimental|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
3282515|NCT01677871|Active Comparator|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
3282516|NCT01677871|Experimental|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
3282517|NCT01677871|Active Comparator|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
3282518|NCT01677884|Experimental|Patients with metastatic CRC|
3282519|NCT01677897|Experimental|Metformin|Metformin 2x1000mg orally per day
3282520|NCT01677923|No Intervention|Control without Metformin|Conventional management of obesity including basic instructions on diet and physical activity
3282521|NCT01677923|Experimental|Control with Metformin|Conventional management of obesity including basic instructions on diet and physical activity plus Metformin treatment
3282522|NCT01677923|Experimental|Intervention with Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian plus Metformin treatment.
3282523|NCT01677923|No Intervention|Intervention without Metformin|Intensive physical activity course twice per week and monthly diet control by dietitian
3282524|NCT01677949|Experimental|ALL patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute lymphoblastic leukemia (ALL) along with Clofarabine, Etoposide and Cyclophosphamide.
3282525|NCT01677949|Experimental|AML patients receiving transplant|Patients intent on receiving an allogeneic hematopoietic cell transplantation (allo-HCT) with the diagnosis of acute myeloid leukemia (AML) along with Clofarabine, Etoposide and Cyclophosphamide.
3282526|NCT01677962|Experimental|dendritic cell and Poly-ICLC vaccination|Dendritic cell and Poly-ICLC vaccination will be administered directly into the tumor on Day 0 and Day 14 of Treatment Phase. Subjects will then have standard of care procedures along with injections of Poly-ICLC and dendritic cells for the remainder of the study.
3282527|NCT01677975|Experimental|ultrasound, dynamic lymphscintigraphy|
3282528|NCT01678001|Active Comparator|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
3282529|NCT01678001|Placebo Comparator|Placebo|Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
3282530|NCT01678014|Experimental|Anorexia|Anorexia patients
3282531|NCT01678027|Placebo Comparator|Placebo|Placebo for LAC triple therapy
3282532|NCT01678027|Active Comparator|LAC triple therapy|PPI (Lansoprazole), Clarithromycin, Amoxicilline
3282533|NCT01678040||Cardiac Magnetic Resonance|"The CMR examinations will be performed in the cardiac MRI scanner (Siemens Avanto, 1.5 Tesla, Erlangen, Germany) at the Hospital for Sick Children. A brief echocardiogram will be performed using a GE Vivid 7 or Vivid E9 machine (General Electric Medical Systems, Wisconsin, USA) We will image from standard parasternal long axis and apical four-chamber before and after completed hydration."
3282534|NCT01678053|Experimental|PPI and BOTOX|onabotulinumtoxinA (BOTOX), injection, 10 units, one time; omeprazole 40mg po bid (standard of care) for 3 months
3282535|NCT01678053|Other|Proton pump inhibitor only|omeprazole 40mg po bid for 3 months(standard of care)
3282536|NCT01678066||Bilateral cardiac output|This is a prospective, non-randomized study to collect data from two noninvasive FDA-approved cardiac output monitors simultaneously in pediatric patients under general anesthesia in the operating room from age 1 month old to 8 years old with all types of medical conditions. We will enroll 50 male and female pediatric patients who are having lower abdominal and lower extremity surgery in this study so that the additional 8 EKG leads placed on the patients do not interfere with the surgical site or patient positioning.
3282537|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (500 mg/day)|Encapsulated Calcium
3282538|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)|Encapsulated Calcium
3282539|NCT01678079|Experimental|Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)|Encapsulated Calcium
3282540|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (500 mg/day)|Non-capsulated Calcium
3282541|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1000 mg/day)|Non-capsulated Calcium
3282542|NCT01678079|Active Comparator|Micronutrient Powder, Uncoated Calcium (1500 mg/day)|Non-capsulated Calcium
3282543|NCT01678105|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
3282544|NCT01678118||minority smokers|A single arm ABA design will be used to pilot a tobacco-focused patient navigation (TPN) intervention for low income, minority smokers.
3282545|NCT01678157||Documented symptomatic paraesophageal hernia|"Documented symptomatic paraesophageal hernia.~Greater than 5 cm hiatal hernia on upper gastrointestinal study.~Evidence that the stomach or other viscera is present in the hernia and does not spontaneously reduce from the mediastinum.~Significant symptoms or signs of a paraesophageal hernia including but not limited to heartburn,dysphagia, chest pain, shortness of breath, postprandial abdominal pain, early satiety, odynophagia, or chronic anemia.~Consenting adult 19 years of age or older~Must be able to participate in follow-up evaluation.~Free of cognitive impairment"
3282546|NCT01678183|Experimental|Monthly Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension, and hypercholesterolemia at the pharmacy on time. The intervention is the cash incentive.
3282547|NCT01678183|Experimental|Monthly and Final Incentive|Subjects in this arm will receive a cash incentive each month when they pick up their medications for diabetes, hypertension and hypercholesterolemia at the pharmacy on time, as well as an additional financial incentive for each full percentage point of decrease in their hemoglobin A1c over the eight-month course of the study. The two cash incentives are the intervention.
3282548|NCT01678183|No Intervention|Control|These subjects will complete the enrollment process for the study but will be randomized to a group that receives usual care.
3282549|NCT01678235|Experimental|GLU_ASP|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin glulisine~Second day: insulin aspart"
3282550|NCT01678235|Experimental|ASP_GLU|"Pre-breakfast insulin was given as a standard bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The carbo-insulin ratio on both study days was identical to the patient's ratio when entering trial.~First day: insulin aspart~Second day: insulin glulisine"
3282551|NCT01678261||1a Turner syndrome 45,X|Blood from 50 persons with Turner syndrome an karyotype 45,X
3282552|NCT01678261||1b Controls for TS 45,X|50 healthy aged female controls matched to the TS 45,X cohort
3282553|NCT01678261||2a Turner syndrome 45,X mosaics|Blood from 50 persons with Turner syndrome an karyotype 45,X mosaics
3282554|NCT01678261||2b Controls for TS 45,X mosaics|50 healthy aged female controls matched to the TS 45,X mosaics cohort
3282555|NCT01678261||3a Paraffin embedded aortic tissue TS|3a Paraffin embedded samples of aortic tissue from 10 persons with TS
3282556|NCT01678261||3b Paraffin embedded aortic tissue from 10 controls|3b Paraffin embedded samples of aortic tissue from 10 controls who did not die from aortic aneurism
3282557|NCT01678261||4a 70 47,XXY men|4a Blood from 70 men with Klinefelter syndrome (47,XXY)
3282558|NCT01678261||4b 70 controls matching group 4a|4b 70 male controls matching group 4a with respect to age.
3282559|NCT01678261||5a 5 persons with double Y-syndrome|5a Blood from 5 persons with double Y-syndrome (47,XYY)
3282560|NCT01678261||5b 20 controls matching 5a|5b 20 healthy controls matching group 5a with respect to age
3282561|NCT01678261||6a 5 persons with triple X-syndrome|6a Blood from 5 persons with triple X-syndrome (47,XXX)
3282562|NCT01678261||6b 20 controls matching 6a|6b 20 healthy controls matching group 6a with respect to age.
3282563|NCT01678261||7 10 biological parents of cohort 1a.|7 Blood from 10 biological parents of individuals in cohort 1a
3282564|NCT01678274||Turner syndrome|Females with Turner syndrome
3282565|NCT01678274||Control group|age matched females acting as controls
3282566|NCT01678287|Experimental|Arm 1 Non elderly receiving ASP1941|healthy subjects age 18 to 45 years receiving ASP1941
3282567|NCT01678287|Experimental|Arm 2 Non elderly receiving placebo|healthy subjects age 18 to 45 years receiving placebo
3282568|NCT01678287|Experimental|Arm 3 Elderly receiving ASP1941|healthy subjects age ≥ 65 years receiving ASP1941
3282569|NCT01678287|Experimental|Arm 4 Elderly receiving placebo|healthy subjects age ≥ 65 years receiving placebo
3282570|NCT01678326|Active Comparator|EUS-Rendezvous or direct intervention|EUS rendezvous or direct intervention involves: (1) using endoscopic-ultrasound technology to access the bile duct with a small needle and manipulate a wire across the biliary orifice and into the duodenum to be then retrieved endoscopically for ERCP (rendezvous ERCP), or (2) using endoscopic-ultrasound technology to directly puncture and perform intended biliary therapy
3282571|NCT01678326|Active Comparator|Advanced ERCP Biliary Access Techniques|Advanced ERCP techniques involve the following: precut access sphincterotomy and needle-knife fistulotomy. These are accepted techniques for biliary access in cases of difficult cannulation.
3282572|NCT01678339||1|
3282573|NCT01678352|Experimental|Cohort 1|Patients must have undergone surgery or biopsy alone (no postoperative radiation or chemotherapy) and have a baseline MRI scan (within 4 weeks of the first vaccine) that shows stable disease or regression (no progression from the initial surgery/biopsy).
3282574|NCT01678352|Experimental|Cohort 2|Patients received surgery or biopsy and radiation therapy (RT) (including fractionated external beam radiation therapy and/or stereotactic radiosurgery), which was completed ≥ 6 months prior to enrollment, and have a baseline MRI scan within 4 weeks prior to the first vaccine that shows stable disease or regression.
3282575|NCT01678352|Experimental|Cohort 3|Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy. Patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of Temozolomide or PCV-based chemotherapy). With regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease. The intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses). If the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse.
3282576|NCT01678365|Experimental|ceftriaxone and metronidazole for complicated appendicitis.|Children with complicated appendicitis treated with single daily dose of ceftriaxone and metronidazole.
3282577|NCT01678365|Active Comparator|Ampicillin, gentamicin, and metronidazole|Children with complicated appendicitis treated with ampicillin, gentamicin, and metronidazole
3282578|NCT01678378|Experimental|SHARP Intervention|School health centers randomized to the SHARP Intervention will be trained to address adolescent relationship abuse with school health center clients.
3282579|NCT01678378|No Intervention|Control|School health centers randomized to Control will provide standard of care.
3282580|NCT01678391|Experimental|Patients with common bile duct stones.|Common bile duct stone removal without fluoroscopy
3282581|NCT01678404|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3282582|NCT01678417|Experimental|131I-rituximab|131I-rituximab treatment interval at least 4 weeks up to maximum 6 cycles
3282583|NCT01678430|Active Comparator|Ofatumumab-Chlorambucil|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Chlorambucil: 10mg/m2 po days 1-7
3282584|NCT01678430|Experimental|Ofatumumab-Bendamustine|Ofatumumab cycle 1: 300mg iv day 1, 1000mg iv day 8; cycle 2 onwards: 1000mg iv day 1 Bendamustine: 70mg/m2 iv days 1 and 2
3282585|NCT01678469|Other|blood sample|
3282586|NCT01678482|Experimental|lession count reduction post treatment|"A total of 50 subjects were included.~The majority are female (62 %)~At baseline the average number of lesions was 20.5±7.1, ranging from 6 to 36 lesions.~All subjects demonstrated a reduction in lesion count.~The average improvement after one month was 56.7%±8.9%, and remained similar also after 3 months 57.7%±9.4%.~The percent of responders (with at least 40% of reduction) was 94% after 1 month and 96% after 3 months~The Percent of responders is similar for males & females and similar for cheeks & front."
3282587|NCT01678495|Experimental|Sonothrombolysis + microbubbles|"rtPA+ sonovue. SonoVue sulphur hexafluoride microbubbles 8 microlitres/ml Powder and solvent for dispersion for injection 1 vial containing 25 mg lyophilized powder to be reconstituted with 5 ml sodium chloride 9 mg/ml (0.9%) solution for injection~1 pre-filled syringe containing sodium chloride 9 mg/ml (0.9%) solution for injection~1 Mini-Spike Plus 6/8 (CE 0123) transfer system.~1 ml of the reconstituted dispersion contains 8 microlitres sulphur hexafluoride microbubbles."
3282588|NCT01678495|Active Comparator|Standard intravenous thrombolysis|Patients in thecontrol group will use thehelmetbut without U.S continuous U.S wave emission. Serial monitoring of the status ofrecanalizationaccording to theschedule set will be carried out according to theestablished schedule
3282589|NCT01678521||Hypercholesterolemic patients|Hypercholesterolemic Patients with documented CAD and poor- or non responders or intolerant to pharmacological treatment (statins) on chronic LDL-apheresis treatment
3282590|NCT01678534|Placebo Comparator|Placebo|In patients randomly assigned to the placebo arm will receive a intravenous solution (containing the vehicle) with the same appearance as the drug under investigation. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.
3282591|NCT01678534|Experimental|Allogeneic stem cells from adipose tissue|The experimental drug is a solution of mesenchymal stem cells from adipose tissue. It will be administered as a single intravenous dose within the first two weeks after the onset of stroke symptoms.Dose: 1 million units/kg
3282592|NCT01678547|Experimental|Robot G-EO|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling.
3282593|NCT01678547|Active Comparator|Treadmill Training|Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) consisting of a treatment cycle using the treadmill system device, according to individually tailored exercise scheduling.
3282594|NCT01678547|Active Comparator|Ground treatment|Ground Control Group (cCG): Each subject will be asked to perform 15 sessions (3 to 5 days a week for 4 up to 5 weeks) of traditional lower limb physiotherapy treatment.
3282595|NCT01678573|Experimental|Sequence 1: abiraterone acetate|"Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule ABC under fasted conditions."
3282596|NCT01678573|Experimental|Sequence 2: abiraterone acetate|"Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule BAC under fasted conditions."
3282597|NCT01678573|Experimental|Sequence 3: abiraterone acetate|"Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule CBA under fasted conditions."
3282598|NCT01678586|Active Comparator|True Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute acupuncture treatments.
3282599|NCT01678586|Sham Comparator|Sham Acupuncture|Pain subjects with radicular pain receiving 6, 30 minute sham acupuncture treatments.
3282600|NCT01678586|Active Comparator|Gabapentin|Pain subjects with radicular pain receiving gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
3282601|NCT01678586|Sham Comparator|Sham Gabapentin|Pain subjects with radicular pain receiving sham gabapentin. Medication treatment groups will titrate up to the standard clinical treatment dosage for one week and maintain that dosage for 1.5 weeks.
3282602|NCT01678599|Other|Benznidazol|This is a single arm, open label study; therefore, all subjects enrolled will receive benznidazol.
3282603|NCT01678612|No Intervention|Non copper standard surfaced objects|Rooms assigned to standard surfaced objects
3282604|NCT01678612|Experimental|Copper-alloy surfaced objects|Rooms furnished with copper surfaced objects, i.e. bed rails, bed rail levers, IV poles, nurse workstation, clipboards, sink handles.
3282605|NCT01678625||Acceleromyography group|Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
3282606|NCT01678625||Electromyography group|Train-of-four ratio calculation (T4-EMG)
3282607|NCT01678638|Active Comparator|Early inguinal hernia (IH) repair|IH repair before NICU discharge
3282608|NCT01678638|Active Comparator|Late inguinal hernia (IH) repair|IH repair as outpatient at approximately 55-60 weeks post-menstrual age
3282609|NCT01678651|Active Comparator|Human FSH|Human FSH
3282610|NCT01678651|Active Comparator|Recombinant FSH|Recombinant FSH
3282611|NCT01678664|Experimental|embolization or chemoembolization plus everolimus|After 2 sessions of embolization with microsphere of 100 to 500 µm or chemoembolization with 100 mg of doxorubicine and 10 ml of lipiodol, administered every day, 10 mg of everolimus during 24 months or until progression (hepatic and other site).
3282612|NCT01678677|Experimental|Group A|Subjects in this group will receive formulation 1 of NTHi vaccine.
3282613|NCT01678677|Experimental|Group B|Subjects in this group will receive formulation 2 of NTHi vaccine.
3282614|NCT01678677|Experimental|Group C|Subjects in this group will receive formulation 3 of NTHi vaccine.
3282615|NCT01678677|Experimental|Group D|Subjects in this group will receive formulation 4 of NTHi vaccine.
3282616|NCT01678677|Experimental|Group E|Subjects in this group will receive formulation 5 of NTHi vaccine and a placebo.
3282617|NCT01678677|Experimental|Group F|Subjects in this group will receive formulation 6 of NTHi vaccine and a placebo.
3282618|NCT01678677|Experimental|Group G|Subjects in this group will receive formulation 7 of NTHi vaccine and a placebo.
3282619|NCT01678677|Experimental|Group H|Subjects in this group will receive formulation 8 of NTHi vaccine and a placebo.
3282620|NCT01678677|Placebo Comparator|Group Placebo 1|Subjects in this group will receive placebo.
3282621|NCT01678677|Placebo Comparator|Group Placebo 2|Subjects in this group will receive placebo.
3282622|NCT01678690|Experimental|Gemcitabine HCl Oral Formulation|Subjects will be treated with Gemcitabine HCl Oral Formulation according to assigned cohort (2 mg or 5 mg or 10 mg) on Day 1 of the 7-day study treatment period
3282623|NCT01678703|Active Comparator|Laminaria group|Patients in this group will have cervical preparation with laminaria MedGyn Products, Inc. USA overnight the day before the abortion
3282624|NCT01678703|Active Comparator|Misoprostol group|Patients in this group will have cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
3282625|NCT01678716|Active Comparator|Essential Health Care (EHC) only|This arm is the basic comparison arm, which will receive the standard package of health services offered through BRAC's essential health care (basic antenatal care, basic counseling on health and nutrition through health worker home visits. In addition, a nationwide mass media campaign on IYCF practices will ensure exposure to some messages about IYCF behaviors in this arm.
3282626|NCT01678716|Experimental|EHC + Micronutrient Powders|This arm will be based on the EHC platform but will also include EHC platform health workers promoting and selling the micronutrient powders.
3282627|NCT01678716|Experimental|EHC + BCC|This arm will have a behavior chance communications intervention to improve infant and young child feeding practices. The intervention will be delivered primarily by the frontline health workers who will visit mothers in their homes and counsel them on essential IYCF practices.
3282628|NCT01678716|Experimental|EHC + BCC + Micronutrient powders|This arm will contain both the behavior change communication and the micronutrient powder sales intervention.
3282629|NCT01678742|Experimental|High-protein diet|
3282630|NCT01678742|Active Comparator|Standard diet|
3282631|NCT01678755|Experimental|ABT-126 Low Dose|ABT-126 Low Dose
3282632|NCT01678755|Experimental|ABT-126 High Dose|ABT-126 High Dose
3282633|NCT01678755|Placebo Comparator|Placebo|Placebo
3282634|NCT01678781||One patient group|Patients suffering from irritable bowel syndrome
3282635|NCT01678872|Other|Long Term Follow up|Long Term follow up of patients who received RetinoStat in a previous study.
3282636|NCT01678937||Control Group|"Ten Healthy individuals will have blood drawn (4 green top tubes(40 ml = 8 tsp.)) at one time point at Northwestern for control purposes. Blood will be drawn to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
3282637|NCT01678937||Monotherapy Group|"Monotherapy patients [cyclosporine (CyA) (10 patients), Tacrolimus (5 patients), mycophenolate mofetil (MMF) (10 patients), rapamycin (10 patients)]: Blood will be drawn at one time point (4 green top tubes (40 ml = 8 tsp.)) to conduct the following tests:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells), and~HLA microchimerism & HLA G."
3282638|NCT01678937||Conversion Group|Ten CNI monotherapy/dual therapy (CNI + MMF) patients pre-selected for conversion to rapamycin or wean to MMF monotherapy. Assays performed 2 weeks prior to conversion, 3-6 months following successful conversion. Liver function/drug levels monitored weekly during conversion until stable levels achieved. Patients converting from CNI monotherapy to rapamycin monotherapy (2-4 wks.): CNI discontinued when 2 therapeutic rapamycin levels (5-10) reached, graft function stable (clinical care protocol). MMF conversion: MMF dose slowly increased to 3 g/day (max.) while CNI therapy reduced by 1-2 mg/day (FK506) or 25-50 mg/day (CyA) monthly until CNI discontinued (1-6 months) (clinical care protocol). Monthly liver function/drug levels performed after successful conversion (standard of care).
3282639|NCT01678963|Experimental|Squalamine|Squalamine eye drop 0.2%
3282640|NCT01678963|Placebo Comparator|Vehicle Control|Eye drop vehicle control
3282641|NCT01678989||Patient group|Children with BD, (20 children) 12-18 year-old who agreed to participate in the study will be established.
3282642|NCT01678989||Risk group|Twenty healthy children of 12-18 years old who have mothers and/or fathers who previously assessed by an adult psychiatrist and diagnosed as BD according to DSM-IV diagnostic criteria, and who agreed to participate in the study. The age and gender of the groups will be matched.
3282643|NCT01678989||Healthy control group|Twenty participants between the ages of 12-18 who agree to participate in the study and whose family members do not have BD. The age and the gender of the groups will be matched.
3282644|NCT01679015||Dry Eyes, Eye Allergies|Patients with ocular allergies and those with dry eyes.
3282645|NCT01679041|Experimental|Single Arm|Conditioning regimens with Alemtuzumab, Fludarabine, and Cyclophosphamide will be used for all patients.
3282646|NCT01679054||EOX|Epirubicin + Oxaliplatin + Capecitabine (EOX) Epirubicin 50 mg/m2 iv bolus d1 q3w x 8 cycles Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hours d1 q3w x 8 cycles Capecitabine (Xeloda) 625 mg/m2 po bid x 6 months
3282647|NCT01679054||FOLFOX4|FOLFOX4 Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
3282648|NCT01679067||HIV-GALT|
3282649|NCT01679080|Experimental|Zolendronic acid, 3 yr + placebo teriparatide, 2 yr|yearly intravenous infusion of 5mg active zoledronic acid in 3 yr
3282650|NCT01679080|Experimental|teriparatide 2 yr; active zol in 3rd yr|daily injection of one dose active teriparatide for two years, active zoledronic acid in year 3.
3282651|NCT01679080|Placebo Comparator|No active treatment|Observation in three years, no treatment
3282652|NCT01679093|Active Comparator|ONDANSETRON (OS)|patients receiving ondansetron at the beginning of the surgery to prevent postoperative nausea and vomiting (PONV); and paracetamol at the end of the surgery for postoperative analgesia.
3282653|NCT01679093|Active Comparator|DROPERIDOL (DRO)|patients receiving droperidol at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
3282654|NCT01679093|Active Comparator|DEXAMETHASONE (DEXA)|patients receiving dexamethasone at the beginning of the surgery to prevent PONV; and paracetamol at the end of the surgey for postoperative analgesia.
3282655|NCT01679106|Placebo Comparator|Fentanyl IV PCA and placebo TAP catheter|Patients will receive Fentanyl IV PCA and placebo TAP catheter.
3282656|NCT01679106|Active Comparator|TAP catheter with continuous infusion of Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine for up to 48 hours after surgery.
3282657|NCT01679119|Experimental|IO-R-CVP|Inotuzumab Ozogamicin plus Rituximab and CVP (Cyclophosphamide, vincristine & prednisolone).
3282658|NCT01679119|Active Comparator|Gem-R-CVP|Gemcitabine plus Rituximab and CVP (Cyclophosphamide, Vincristine and Prednisolone).
3282659|NCT01679145||Alcohol- dependent patients|Detoxified alcohol- dependent patients in an inpatient setting
3282660|NCT01679145||Control group|Age- and gender matched healthy controls
3282661|NCT01679158|Experimental|Continuous Horizontal row|Use the IOP system from USGI to install suture anchors running from the distal body into the proximal antrum
3282662|NCT01679158|Experimental|"Reduction in ring opening"|"Use the IOP system from USGI to install suture anchors to reduce the ring opening to the antrum"
3282663|NCT01679158|Experimental|Control Arm|Use the IOP system from USGI to install suture anchors in the Current V shape in distal body
3282664|NCT01679210|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
3282665|NCT01679210|No Intervention|Health and Wellness|HW served as the comparison group and received the same number of in-person sessions, telephone calls, and mailings at the same time points as LI. Content was limited to general information available to the public from the ACOG and the American Academy of Pediatrics and did not mention exercise behavior change.
3282666|NCT01679223||<40 years|subjects aged less than 40 years
3282667|NCT01679223||40-60 years|subjects aged 40-60years
3282668|NCT01679223||> 60 years|subjects aged greater than 60 years
3282669|NCT01679249||Hemodialysis patients|Stable prevalent patients on 3-times-per-week hemodialysis
3282670|NCT01679262|Other|Optimal size of OPAs|
3282671|NCT01679275|Other|measuring cerebral oxygenation|NIRS: Measurement of cerebral oxygenation using Near Infrared Spectroscopy (NIRS) during the pre-operative phase in neonates with congenital heart disease.
3282672|NCT01679288|Experimental|ultrasound arm|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
3282673|NCT01679327|Experimental|Bevacizumab plus chemotherapy（XELOX or FOLFOX）|Bevacizumab plus XELOX (Bevacizumab 7.5mg/kg d1;Xeloda 2g/m2 d1-14 divided into two times;Oxaliplatin 130mg/m2 d1;repeated in 21 days) Bevacizumab plus FOLFOX (Oxaliplatin 85mg/ m2 ivgtt d1;CF 200mg/ m2 ivgtt d1;Bevacizumab 5mg/kg ivgtt d1 5-FU 400mg /m2 ivgtt d1;5-FU 2400mg/m2 CIV 48h;repeated in 14 days)
3282674|NCT01679340|Experimental|S-1+oxaliplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d oxaliplatin: 65mg/m2, D1,D8, 3weeks/cycle after 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
3282675|NCT01679340|Active Comparator|S-1+cisplatin|S-1: 80mg/m2, 3weeks/cycle(take for 14d, rest for 7d) cisplatin: 75mg/m2, D1, every 3 weeks After 6 cycles, then mono S-1 for 2-4 cycles, total 8-10 cycles.
3282676|NCT01679353|Placebo Comparator|placebo group|normal saline 0.5ml
3282677|NCT01679353|Experimental|magnesum group|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
3282678|NCT01679366|No Intervention|Penicillin G|hospitalization of 30 patients given penicilline intraveniously for 72 hours
3282679|NCT01679366|Placebo Comparator|Placebo|30 hospitalized patients will be given placebo with a regular penicillin treatment
3282680|NCT01679366|Experimental|Probiotic|Probiotics will be given to 30 hospitalized patients with regular penicillin treatment
3282681|NCT01679379|Active Comparator|Absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture].
3282682|NCT01679379|Active Comparator|Non absorbable suture group|Include women who have their skin closed with subcuticular stitches using [Polypropylene non absorbable monofilament suture].
3282683|NCT01679392|Experimental|Ropivacaine|Unilateral transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
3282684|NCT01679418|Active Comparator|Drain placement (Group A)|Patients in group A received a wound drain after surgery.
3282685|NCT01679418|Sham Comparator|No-drain placement (group B)|Patients assigned to group B, did not receive a wound drain after surgery.
3282686|NCT01679431||Patients with aortic stenosis|"Patients have every year: 1) an assessment of cardiometabolic risk profile with measure of body mass index, waist circumference and fasting blood sample and 2) a comprehensive Doppler-echocardiography exam.~Computed tomography and magnetic resonance imaging are performed every 2 years."
3282687|NCT01679457|Experimental|ACT-Focused ERP|One Session.
3282688|NCT01679457|Active Comparator|TAU-ERP|One Session.
3282689|NCT01679483|Experimental|FloSeal group|This group will undergo appropriate cancer surgery for each patient with pelvic lymph node dissection +/- para-aortic lymph node dissection. At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
3282690|NCT01679483|No Intervention|No FloSeal group|All surgical procedures of control group is the same with study group except that Floseal is not applicated in control group.
3282691|NCT01679496|Experimental|Food items|Food items low in saturated fat and high in polyunsaturated fat
3378278|NCT02871778|Experimental|Part B: VX-371 + Ivacaftor|Participants who were on 85 mcg VX-371 diluted in 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
3282692|NCT01679496|Placebo Comparator|Control food items|Food items containing saturated fat and polyunsaturated fat according to a traditional Norwegian diet
3282693|NCT01679509|Experimental|Single-port surgery group|Single-port laparoscopic adnexal surgery
3282694|NCT01679509|Active Comparator|Three-port surgery group|Three-port laparoscopic adnexal surgery
3282695|NCT01679522|Experimental|Single-port surgery group|Single-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
3282696|NCT01679522|Active Comparator|Four-port surgery group|Four-port laparoscopic surgical staging including total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
3282697|NCT01679535|Experimental|Intervention|nutrition and hygiene education by community health workers
3282698|NCT01679548|Experimental|Single-port LAVH group|single-port laparoscopic assisted vaginal hysterectomy
3282699|NCT01679548|Active Comparator|Three-port LAVH group|three-port laparoscopic assisted vaginal hysterectomy
3282700|NCT01679561|Experimental|intralipids|Two hundreds patients (group1) with abnormal NK activity results (NKa)will receive intralipids 20% i.v. (9 mg/mL total blood volume -corresponds to 2 mL of intralipids 20% diluted in 250 mL saline; or 18 mg/mL - corresponds to 4 mL of intralipids 20% diluted in 250 mL saline) infusions and their NKa will be tested periodically. The determination of NK cell function will be performed by flow cytometry using K562 cells as targets,then follow up of the patients by the Doppler of endometrial blood follow at the time of luteal phase,and the clinical pregnancy rate.Group(2)of 180 patients will receive placebo.
3282701|NCT01679574|Experimental|letrozole|Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
3282702|NCT01679574|Active Comparator|Metformin and clomiphene|".Drug: metformin (Cidophage®; CID,Cairo, Egypt) metformin 1500 daily for 3 months~Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation"
3282703|NCT01679587|Experimental|Molidustat, 80 mg|Subjects received a single oral dose of 80 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
3282704|NCT01679587|Experimental|Molidustat, 120 mg|Subjects received a single oral dose of 120 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week.
3282705|NCT01679587|Experimental|Molidustat, 40 mg|Subjects received a single oral dose of 40 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
3282706|NCT01679587|Experimental|Molidustat, 160 mg|Subjects received a single oral dose of 160 mg BAY 85-3934 in the first period and placebo in the second period, separated by a wash-out period of at least 1 week. This is an optional dose escalation step.
3282707|NCT01679639|Experimental|Aleglitazar|
3282708|NCT01679652|Experimental|Nebivolol|Tablet Nebivolol 5 mg (oral use) for 5 days
3282709|NCT01679652|Placebo Comparator|Placebo|Inactive placebo given as tablet for 5 days
3282710|NCT01679665|Experimental|320U /0.5ml in children (from 2 to 5 years old)|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml in 48 children aged 2-5 years old on day 0,28
3282711|NCT01679665|Placebo Comparator|0/0.5ml placebo in children (from 2 to 5 years old)|0/0.5ml placebo in 24 children aged 2-5 years old on day 0, 28
3282712|NCT01679678|Experimental|PolyHeal 2|Negatively charged 5-micron polystyrene microspheres in Water For Injection
3282713|NCT01679678|Active Comparator|PolyHeal|Negatively charged 5-micron polystyrene microspheres suspended in Dulbecco's Modified Eagle's Medium (DMEM)
3282714|NCT01679691|No Intervention|Control group|Control group in whom no epidural anesthesia will be applied
3282715|NCT01679691|Active Comparator|Epidural Anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
3282716|NCT01679704|Other|Food products|Ten food products will be given to all subjects
3282717|NCT01679717|Active Comparator|Early mobilisation after CMC1-surgery|Mobilisation at two weeks after operation. The participants will wear a soft splint for six weeks.
3282718|NCT01679717|Other|Conservative treatment after CMC1-surgery|Current standard procedure: Mobilisation at six weeks after operation. The participants will wear a rigid splint for six weeks.
3282719|NCT01679730||irritable bowel syndrome patients|
3282720|NCT01679743|Experimental|A|Breast Cancer Cohort
3282721|NCT01679743|Experimental|B|Non-Small Cell Lung Cancer Cohort
3282722|NCT01679756|Experimental|Intracorporeal anastomosis|Laparoscopic right hemicolectomy for cancer. .For the IA group, colon, transverse mesocolon, ileum and terminal ileum mesentery will be resected intracorporeally through a 45 mm endoscopic linear stapler with vascular cartridge. Then, the linear stapler will inserted through two small enterotomies and a mechanical ileo-transverse, side-to-side isoperistaltic intracorporeal anastomosis performed using the vascular cartridge with six rows of closely placed staples. The enterotomies will be then closed using a double layered continuous intra corporeal manual suture with 3-0 Polyglactin 910. The mesenteric defects will be left open. The specimen will be placed in a protective plastic bag and then extracted through a Pfannestiel incision.
3282723|NCT01679756|Active Comparator|Extracorporeal anastomosis|"Laparoscopic right hemicolectomy for cancer. In the EA group, the bowel will be externalized by widening the incision of one of the trocars or by performing a mini-laparotomy at another location (subcostal, suprapubic) protected with a plastic sheet. The ileum and colon will be then resected through a 45 mm endoscopic linear stapler with vascular cartridge (staple height = 3.85 mm) and a side-to-side isoperistaltic mechanical anastomosis will be then performed using the same vascular cartridge. The enterotomies will be then closed using a double layered continuous manual suture using a 3-0 Polyglactin 910.~In both groups, a drain will not routinely inserted."
3282724|NCT01679782||COPD nocturnal desaturator|COPD patients who spend 30% of the nigth with a SaO2 < 90%.
3282725|NCT01679782||COPD no nocturnal desaturator|COPD patients who spend less than 30% of the night with a SaO2 < 90%
3282726|NCT01679782||control group|healthy sedentary subjects
3282727|NCT01679795|Experimental|Tibolone|patientes will use tibolone 2,5mg/day during 30 days
3282728|NCT01679795|Placebo Comparator|Placebo use|Patients will use placebo for 30 days
3282729|NCT01679821||Dental students|Seventy dental students of State University of West of Paraná - UNIOESTE. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. A questionnaire and a clinical examination were employed.
3282730|NCT01679821||Removable partial denture|Seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous). Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary were not included in the research. A questionnaire and a clinical examination were employed.
3282731|NCT01679821||Double complete denture|Seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Patients wearing just one complete denture were not included in the research. A questionnaire and a clinical examination were employed.
3282732|NCT01679834||Cohort|
3282733|NCT01679860|Experimental|Clin A|Clin A. CHOP-Campath (CHOP-C) for 2 cycles , Hyper-C-Hidam for 2 cycles and auto-SCT (stem cell transplantation) or RIC allo-SCT in advanced stage PTCL pts ≥ 18 and ≤ 60 years
3282734|NCT01679860|Experimental|Clin B|Clin B: CHOP-Campath (CHOP-C) for 6 cycles . It is a combined immunochemotherapy approach in a subset of elderly pts aged > 60 ≤ 75 years
3282735|NCT01679873|Placebo Comparator|Control group|Assess abstract not reporting funding sources or conflicts of interest
3282736|NCT01679873|Experimental|Funding sources|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources only.
3282737|NCT01679873|Experimental|Funding sources/Conflicts of Interests|Assess one type of abstract in the randomized arm. Assess abstract reporting funding sources and conflicts of interest
3282738|NCT01679886|Experimental|Rubidium PET|Rubidium PET
3282739|NCT01679899|Experimental|Vildagliptin|Vildagliptin 50 mg bid for 12 months
3282740|NCT01679899|Active Comparator|Gliclazide MR|Gliclazide MR 60 or 120mg once a day for 12 months
3282741|NCT01679912|Experimental|1: phone to call center|recommendations to phone to the call center for all the patients who have an acute attack
3282742|NCT01679912|No Intervention|2: usual strategy|usual strategy. No intervention (patients does not change their practice)
3282743|NCT01679938|Experimental|primary obesity prevention|"The intervention will involve four main components:~Training of child care providers.~Curriculum sessions for children.~Family outreach activities.~Maintenance activities."
3282744|NCT01679938|No Intervention|Control group|For the control group, usual care will be provided
3282745|NCT01679951|Placebo Comparator|Placebo|
3282746|NCT01679951|Experimental|JNJ-38518168 (3 mg/d)|
3282747|NCT01679951|Experimental|JNJ-38518168 (10 mg/d)|
3282748|NCT01679951|Experimental|JNJ-38518168 (30 mg/d)|
3282749|NCT01679964|Other|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
3282750|NCT01679977|Active Comparator|Legpress|"Subjects in the LP group train on a custom built, computer controlled, linear electric motor powered leg press device. The so called swinging vibrational-proprioceptive mode is used, which means that constant velocity of the pedals (0.3 m/s and 0.2 m/s for concentric and eccentric phase, respectively) are interrupted by short stops (every 8 mm), resulting in short force peaks appearing throughout the movement. Training load is progressively increased throughout the training."
3282751|NCT01679977|Active Comparator|E-Stim|ES training is performed with a custom-built battery-powered stimulator. The subject are seated over the edge of the therapeutic table with the trunk upright and lower legs freely swinging. Two conductive rubber electrodes covered by wet sponge are placed on the anterior thigh on each side of the body. The electrode pairs are connected to the independent channels of the stimulator and the left and the right thigh are stimulated in an alternative manner. Each repetition (i.e. ES evoked muscle contraction) is evoked by a 3.5 s train (60 Hz) of electrical pulses (rectangular, biphasic, width 0.6 ms). Consecutive contractions of the same thigh are separated by 4.5 s off intervals. Maximal tolerable intensity should be used and is monitored during the training sessions. In all the subjects this should induce a tetanic contraction of the stimulated muscles.
3282752|NCT01679977|No Intervention|Control|This group only perform the same measurements as the intervention groups and lives their live as usual in between.
3282753|NCT01679990|Experimental|PLX-PAD Low dose|PLX-PAD double low doses
3282754|NCT01679990|Active Comparator|PLX-PAD high doses|PLX-PAD double high dose
3282755|NCT01679990|Placebo Comparator|Placebo|Double Placebo doses
3282756|NCT01679990|Experimental|PLX-PAD high dose +Placebo|High dose+Placebo
3282757|NCT01680003|Experimental|Hepar-P|Hepar-P: Two capsules (250mg x 2), three times daily, orally
3282758|NCT01680003|Placebo Comparator|Placebo for Hepar-P|Placebo: Two capsules, three times daily, orally
3282759|NCT01680029|Experimental|PBASE-system 2.0|
3282760|NCT01680042|Active Comparator|phenytoin paste|this group receives phenytoin paste after oral biopsy
3282761|NCT01680042|Placebo Comparator|usual mucoadhesive paste|this group receives the usual mucoadhesive paste without phenytoin after oral biopsy
3282762|NCT01680055||AA-ATG|Acquired Aplastic Anemia Patients Treated with Antithymocyte Globulin plus Cyclosporine
3282763|NCT01680068|Experimental|Pars plana vitrectomy and postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
3282764|NCT01680081|Experimental|CT perfusion group|
3282765|NCT01680094|Experimental|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
3282766|NCT01680107|Experimental|d-cycloserine|oral, capsule, 250 mg, once
3282767|NCT01680107|Placebo Comparator|sugar pill|oral, capsule, once
3282768|NCT01680120|Experimental|Continuous spinal anaesthesia|
3282769|NCT01680133||NGT|Normal glycaemic healthy control men, age between 45-65, BMI 25-35 kg/m2
3282770|NCT01680133||T2D|Type 2 diabetic men, age 45-65 yrs, BMI 25-35, diagnosed >5yrs and Hba1c 7-9%
3282771|NCT01680146|Active Comparator|PRO|Subjects will ingest 20 g of intrinsically labeled casein dissolved in water
3282772|NCT01680146|Experimental|PRO+FAT|Subjects will ingest 20 g of intrinsically labeled casein plus 26.7 g of anhydrous milk fat dissolved in water
3282773|NCT01680185|Active Comparator|Sensor-augmented Insulin Pump|Continuous subcutaneous sensor-augmented insulin-pump therapy (SAPT) with an insulin pump from Medtronic (Paradigm® Velo) for a period of approximately 3 months post-transplantation.
3282774|NCT01680185|Active Comparator|Basal insulin|NPH insulin titration regimen, as specified in the IPT-NODAT study
3282775|NCT01680185|Active Comparator|Standard of care|Patients assigned in this arm will receive standard of care following their kidney transplantation
3282776|NCT01680198|Placebo Comparator|Placebo|Placebo capsules daily for 12 weeks.
3282777|NCT01680198|Experimental|Paracalcitol|"see Intervention description for details."
3282778|NCT01680211|Experimental|Salacia bark extract (SR-B-01) and TLC|Capsules containing 250mg of salacia bark extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3282779|NCT01680211|Experimental|Sesame seeds extract (SI-S-01) and TLC|Capsules containing 250mg of sesame seed extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3282780|NCT01680211|Experimental|Salacia leaf extract (SR-L-01) and TLC|Capsules containing 250mg of salacia leaf extract,two times a day along with Therapeutic Lifestyle Change (TLC)
3282781|NCT01680211|Placebo Comparator|Placebo and TLC|Capsules containing 250mg of placebo,two times a day along with Therapeutic Lifestyle Change (TLC)
3282782|NCT01680224|Active Comparator|Healthy Weight|The main goal of the Healthy Weight intervention is to make small, sustainable changes to input and output on a weekly basis to achieve a balance between caloric intake and output. All sessions begin with a brief review of what was covered in the previous session, presentation of educational handouts, careful review of previous behavior change goals, and the development of healthy behavior change plans for the next session. Home exercises for all sessions consist of following individualized diet and exercise goals, and keeping a food and exercise log to determine areas for future healthy changes.
3282783|NCT01680224|Experimental|Project Health|Project Health adds dissonance-inducing activities, discussions, and homework activities to the Healthy Weight basic intervention. Each session begins with a verbal commitment to participate (to underscore the voluntary nature of participation), includes discussions of completed home practice assignments and in-session writing/sharing exercises (to create accountability), and concludes with home exercises (to increase level of effort). Completed home assignments are videotaped in subsequent sessions to increase accountability.
3282784|NCT01680224|Placebo Comparator|Control|"Some participants will be randomized to control condition whereby they will be given an psychoeducational video (Weight of the World)to view."
3282785|NCT01680237|Active Comparator|Cognitive behavior therapy|"Identification of bodily sensations, cognitions and safety behaviors characteristic of the individual patient~Modification of dysfunctional beliefs and assumptions using socratic questioning and behavioral experiments~Exposure in-vivo~Relapse prevention"
3282786|NCT01680237|Active Comparator|Exposure in-vivo|"Preparation of a brief behavior analysis of the individual case and construction of a hierarchy of relevant (internal and external) phobic situations~Exposure with internal stimuli~Exposure with external stimuli~Relapse prevention~Remark: In this condition there is no active work with the patient's catastrophic cognitions"
3282787|NCT01680250|Experimental|Sirolimus|Sirolimus administration group starting dose: 2mg/day target trough level: 4-10 ng/dL
3282788|NCT01680263|Experimental|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1 week interval"
3282789|NCT01680263|Active Comparator|NSAIDs/Physical therapy|treatment was done with NSAIDs and 10 sessions of daily physical therapy.
3282790|NCT01680276|Experimental|PBS based staff training|"The training, which will be supported by a treatment manual will comprise the following sections:~Functional Behavioural Assessment and formulation skills~• Brief Behavioural Assessment Tool for brief functional analyses~Primary Prevention~Secondary Prevention and Reactive Strategies~Periodic Service Review and Problem Solving~Developing individualised periodic service reviews~Trouble shooting"
3282791|NCT01680276|Other|Treatment as usual|Most community intellectual disability services provide a range of health interventions that include but are not limited to psychiatric assessment and management, nursing support, psychology, speech and language therapy, occupational therapy and counselling. There may be some variation in resources but service users with challenging behaviour are likely to receive a range of broadly defined behavioural management and pharmacological interventions. Staff is routinely supervised by their clinical managers weekly.
3282792|NCT01680289|Experimental|Three adhesive coats|Consecutive application of three one-bottle adhesive coats
3282793|NCT01680289|Active Comparator|Two adhesive coats|Consecutive application of two one-bottle adhesive coats
3282794|NCT01680302|Experimental|High intensity exercise|High intensity exercise(Borg 16) in intervals.
3282795|NCT01680302|Experimental|Moderate intensity exercise|Moderate intensity exercise 3 times a week.
3282796|NCT01680302|Experimental|Control group|Exercise on their own. Follow current guidelines.
3282797|NCT01680315|Experimental|Calorie information|"Low calorie yogurt~High calorie yogurt~with low calorie information sheet"
3282798|NCT01680315|Experimental|Calorie information (high)|"Low calorie yogurt~High calorie yogurt~High calorie information sheet"
3282799|NCT01680354|Active Comparator|ReLEx|One eye is treated with ReLEx the other with LASIK
3282800|NCT01680354|Active Comparator|LASIK|One eye is treated with ReLEx the other with LASIK
3282801|NCT01680367|Experimental|Arm I (control)|Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery.
3282802|NCT01680367|Experimental|Arm II (native collagen wound dressing)|Patients receive native collagen wound dressing after surgery.
3282803|NCT01680380||At-Home|Overnight sleep at home
3282804|NCT01680393|Experimental|Sequential compression device|During arthroscopic shoulder surgery, an SCD device will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
3282805|NCT01680393|Experimental|TED stockings|During arthroscopic shoulder surgery, TED stockings will be applied to the patients legs during surgery. Cerebral oxygenation and circulatory parameters will be recorded continuously throughout the surgery. Recordings will be hidden to the primary caregiver.
3282806|NCT01680393|No Intervention|Control|no stockings will be applied to the patients legs
3282807|NCT01680406|Active Comparator|Artemether-lumefantrine|Weight-based dose to be administered as fixed-dose combination twice daily for three days.
3282808|NCT01680406|Experimental|Artemether-lumefantrine and primaquine|"Artemether-lumefantrine will be given in a weight-based dose to be administered as fixed-dose combination twice daily for three days.~Primaquine will be given beginning on day 2 of artemether-lumefantrine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
3282809|NCT01680406|Active Comparator|Chloroquine|Chloroquine will be given in a weight-based dose to be administered once daily for three days.
3282810|NCT01680406|Experimental|Chloroquine and primaquine|"Chloroquine will be given in a weight-based dose to be administered once daily for three days.~Primaquine will be given beginning on day 2 of chloroquine to patients with a normal G6PD test; dose is weight-based to be administered once daily for 14 days."
3282811|NCT01680419|Experimental|Mission Reconnect only|Autonomous use of the Mission Reconnect multimedia instructional program at home.
3282812|NCT01680419|Active Comparator|PREP only|Participation in a standard PREP for Strong Bonds weekend retreat program.
3282813|NCT01680419|Active Comparator|PREP plus Mission Reconnect|Participation in a standard PREP for Strong Bonds weekend retreat followed by autonomous use of the Mission Reconnect multimedia instructional program at home.
3282814|NCT01680419|No Intervention|Wait-list control|No intervention, followed by delivery of the Mission Reconnect multimedia program materials for home use after the end of the study period.
3282815|NCT01680432|Experimental|Probiotic cheese|The group received, for 30 days, was instructed to eat 30 g/day of probiotic fresh cheese enriched with Bifidobacterium lactis Bi-07.
3282816|NCT01680432|Placebo Comparator|Regular Cheese|The group placebo received, for 30 days, was instructed to consume 30g/day of regular fresh cheese.
3282817|NCT01680471|Experimental|Midazolam 0.03mg/kg|This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
3282818|NCT01680471|Experimental|Midazolam 0.05mg/kg|This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
3282819|NCT01680471|Placebo Comparator|Placebo|This group will be injected intravenous normal saline five minutes before the end of surgery.
3282820|NCT01680484|Active Comparator|Bitter chocolate|50 grams Ülker Golden %70 bitter chocolate, İstanbul, Turkey
3282821|NCT01680484|Active Comparator|Orange juice|Ülker İçim Orange Juice 250 cc, İstanbul, Turkey
3282822|NCT01680484|No Intervention|Control|Sit and rest
3282823|NCT01680510|Experimental|Alga Dunaliella Bardawil 9-cis beta Carotene Rich Powder|50 patients will receive first the capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder and after 24 weeks of washout period will receive capsule containing placebo (Starch).
3282824|NCT01680510|Placebo Comparator|Placebo (Starch)|The other 50 Patients will receive first the placebo (Starch) capsules and after 24 weeks of washout period will receive capsules containing the alga Dunaliella Bardawil 9-cis beta-Carotene rich powder .
3282825|NCT01680523|Experimental|RH group|Radical hysterectomy followed by tailored adjuvant therapy
3282826|NCT01680523|Active Comparator|CCRT group|Primary concurrent chemoradiation therapy
3282827|NCT01680536|Experimental|Maraviroc, darunavir, ritonavir|Single-arm,assessing cerebrospinal fluid inflammatory markers after addition of maraviroc to patients stable on monotherapy darunavir/ritonavir
3282828|NCT01680562||skin cancer|Skin cancer patients with scheduled tumor excision and subsequent histopathological analysis of the tumor.
3282829|NCT01680575||Training cohort|This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.
3282830|NCT01680575||Validation cohort|"This is a retrospective cohort for validation of a risk prediction model developed using training cohort.~This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation."
3282831|NCT01680588|Experimental|[18F]NAV4694|Single intravenous injection of 8.1 millicuries of [18F]NAV4694
3282832|NCT01680601|Experimental|RIPC group|Patients assigned to this arm will go through a remote ischaemic preconditioning (RIPC)protocol
3282833|NCT01680601|Placebo Comparator|Control|Patients assigned to this arm will not receive the intervention, however the protocol will be applied to a wooden block in order to maintain blinding to relatives and investigators.
3282834|NCT01680614||At Risk Adult Drinkers|CASI
3282835|NCT01680627||ADOLESCENT|
3282836|NCT01680679|Experimental|Inactivated Trivalent Influenza Vaccine|Inactivated trivalent influenza vaccine (TIV), split virion
3282837|NCT01680679|Placebo Comparator|Inactivated Polio Vaccine|Inactivated poliovirus vaccine (IPV), trivalent
3282838|NCT01680679|No Intervention|Surveillance arm|Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members.
3282839|NCT01680692|Active Comparator|Continuous femoral and single shot sciatic nerve block|Will receive pre-operative continuous femoral catheter & post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine & 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
3282840|NCT01680692|Experimental|Continuous femoral and tibial peripheral nerve catheters|Patients will receive pre-operative continuous femoral catheter & post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) & 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
3282841|NCT01680705|Active Comparator|Frequency: Once Daily|Patients will use high volume saline irrigation once daily post operatively.
3282842|NCT01680705|Active Comparator|Frequency: Twice Daily|Patients will use high volume saline irrigation twice daily post operatively.
3282843|NCT01680705|Active Comparator|Frequency: Three Times Daily|Patients will use high volume saline irrigation three times daily post operatively.
3282844|NCT01680718|Experimental|Intranasal oxytocin|Participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
3282845|NCT01680718|Experimental|Intranasal vasopressin|Participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
3282846|NCT01680718|Placebo Comparator|Intranasal placebo|2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010). Participants will self-administer 5 puffs per nostril.
3282847|NCT01680731||Forceps assisted vaginal delivery|Forceps assisted vaginal delivery within 1-5 years without any interval delivery
3282848|NCT01680731||Vacuum assisted vaginal delivery|Vacuum assisted vaginal delivery within 1-5 years without any interval delivery
3282849|NCT01680731||Elective cesarean delivery|Elective cesarean vaginal delivery within 1-5 years without any interval delivery done prior to labor
3282850|NCT01680731||Spontaneous vaginal delivery|Spontaneous vaginal delivery within 1-5 years without any interval delivery
3282851|NCT01680744|Experimental|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
3282852|NCT01680744|No Intervention|Standard Treatment|
3282853|NCT01680757|Experimental|LAA exclusion with LARIAT & Accessories|Permanent exclusion of the LAA using the LARIAT Suture Delivery Device and Accessories
3282854|NCT01680770||Hypotensive patients in shock|
3282855|NCT01680796|Experimental|Active Treatment|"Dovitinib will be given at up to four different dose levels beginning with dose level 1 on a 5 days on/2 days off dosing schedule of each 21-day cycle.~Bortezomib will be given at two different dose levels intravenously on Days 1 and 8 of each 21-day cycle.~Dexamethasone will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle."
3282856|NCT01680809|Experimental|Compression stocking 15-20mmHg|Compression stocking 15-20mmHg
3282857|NCT01680809|Experimental|Compression stocking 20-30mmHg|Compression stocking 20-30mmHg
3282858|NCT01680822||NTM patient|confirmed NTM patient
3282859|NCT01680874|Experimental|Probiotic|"This arm will receive a probiotic combination which will consist of equal amounts of Lactobacillus acidophilus NCFM® (ATCC 700396), Lactobacillus paracasei Lpc-37 (ATCC SD5275), Bifidobacterium lactis Bi-07 (ATCC SC5220), and Bifidobacterium lactis Bl-04 (ATCC SD5219).~The probiotic will be taken orally, once a week, for 4 weeks."
3282860|NCT01680874|Placebo Comparator|Placebo|A placebo will be taken orally, once a day, for 4 weeks.
3282861|NCT01680913|Experimental|Spinal with ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
3282862|NCT01680913|Active Comparator|Spinal by palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
3282863|NCT01680926|Experimental|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
3282864|NCT01680939|Experimental|Morphine|Receives morphine for post-surgical pain
3282865|NCT01680939|Experimental|Ibuprofen|Receives ibuprofen for post-surgical pain
3282866|NCT01680952|Active Comparator|A) TEST|
3282867|NCT01680952|Experimental|B) CONTROL|
3282868|NCT01680978|Experimental|Aleglitazar|
3282869|NCT01680978|Placebo Comparator|Placebo|
3282870|NCT01681017|Other|Facilities|Have appropriate staff trained in HBB and have HBB equipment provided
3282871|NCT01681017|Other|Master Trainers|Receive appropriate HBB training
3282872|NCT01681017|Other|Facilitators|Receive appropriate HBB training
3282873|NCT01681017|Other|Learners|Receive appropriate HBB training
3282874|NCT01681043|No Intervention|24 hour PSG under ordinary conditions|24 hour PSG in 46 patients under ordinary (routine) conditions
3282875|NCT01681043|Active Comparator|24 hours PSG under protocol 'Quiet in the room'|24 hour PSG in the same 46 patients with protocol 'Quiet in the room' from 10 p.m. til 6 a.m.
3282876|NCT01681056|Experimental|Autosuggestion|
3282877|NCT01681056|No Intervention|Standard medical theraphy|
3282878|NCT01681082|Experimental|Tai Chi Training|"Subjects will be recruited from the University of Wisconsin-Madison course, Introduction to Martial Arts: Tai Chi."
3282879|NCT01681082|No Intervention|Control|"Subjects will be recruited from the University of Wisconsin-Madison course Introduction to Psychology."
3282880|NCT01681108|Other|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
3282881|NCT01681134|Experimental|Advagraf followed by Prograf|
3282882|NCT01681134|Experimental|Prograf followed by Advagraf|
3282883|NCT01681147|No Intervention|Group One|Standard postpartum care after a pregnancy with gestational diabetes
3282884|NCT01681147|Experimental|Group Two|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes"
3282885|NCT01681147|Experimental|Group Three|"Standard postpartum care after a pregnancy with gestational diabetes~2 online nutrition and exercise education classes~Self monitoring of blood glucose levels"
3282886|NCT01681160|Experimental|MAGGOT THERAPY & conventional therapy T|Maggot therapy,ADMINISTERED TWO TIMES AS A NEW METHODS OF DRESSING in experimental group.conventional therapy ,administered two times in control group
3282887|NCT01681173|Experimental|Drink enriched in fibers|7,5g enriched fiber drinks, BID
3282888|NCT01681173|Experimental|Placebo drink|Placebo drink, BID
3282889|NCT01681199|Experimental|Fluvastatin extended release tablet|Fluvastatin extended release tablet 80mg/day
3282890|NCT01681225|Experimental|EPVent|"The overall goals for the EPVent group (esophageal-pressure guided mechanical ventilation) are to employ an open-lung strategy that includes low tidal volumes and maintenance of a positive transpulmonary pressure at end-expiration [Ptpexp]. Fraction of inspired oxygen [FiO2] and transpulmonary pressure pressure during an expiratory hold will be changed to achieve values shown in one of the columns of a protocol-specified table to meet the oxygenation target."
3282891|NCT01681225|Active Comparator|Control|The overall goals for the Control group are similar to those for the EPVent group: to employ an open-lung strategy that includes low tidal volumes using an alternative high positive end-expiratory pressure [PEEP] strategy. The control group PEEP and tidal volume will be managed without reference to the esophageal pressure measurements, and instead will follow an empiric high PEEP mechanical ventilation strategy. PEEP and FiO2 will be raised or lowered to achieve the oxygenation target level specified in a study table.
3282892|NCT01681238|Other|Protocol group 1|Using standard hemodynamic therapy
3282893|NCT01681238|Experimental|Protocol group 2|Using goal-directed therapy
3282894|NCT01681251|Experimental|Intervention|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%
3282895|NCT01681251|Active Comparator|Control|Fluid titrated at the discretion of the attending anesthesiologist.
3282896|NCT01681264|Active Comparator|Morphine:Placebo|
3282897|NCT01681264|Active Comparator|Morphine:Guanfacine 1mg|
3282898|NCT01681264|Active Comparator|Morphine:Guanfacine 2mg|
3282899|NCT01681264|Active Comparator|Placebo:Guanfacine 2mg|
3282900|NCT01681264|Placebo Comparator|Placebo:Placebo|
3282901|NCT01681290|Experimental|CBX129801 High Dose|Solution for injection, 2.4 mg, weekly for 52 weeks
3282902|NCT01681290|Experimental|CBX129801 Low Dose|Solution for injection, 0.8 mg, weekly for 52 weeks
3282903|NCT01681290|Placebo Comparator|Placebo|Solution for injection, vehicle with no active, weekly for 52 weeks
3282904|NCT01681303|Experimental|AST-120 group|Administration of AST-120
3282905|NCT01681303|No Intervention|2|
3282906|NCT01681316|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3282907|NCT01681316|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
3282908|NCT01681329|Experimental|Cognitive-behavioral therapy with interpretation training|14 sessions of cognitive-behavioral therapy combined with computerized interpretation modification training
3282909|NCT01681329|Active Comparator|Cognitive-behavioral therapy with non-active training|14 sessions of cognitive-behavioral therapy combined with computerized non-active training
3282910|NCT01681355|Experimental|Intervention group|Healthy infants receiving standard cow's milk-based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition.
3282911|NCT01681381|Active Comparator|Firebird2® DES|Device:Firebird2® DES The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length.
3282912|NCT01681381|Experimental|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length.
3282913|NCT01681394|Active Comparator|Product 1|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
3282914|NCT01681394|Placebo Comparator|Control product|250 g of chocolate cream
3282915|NCT01681407||Depressed Patients|Patients: Group of patients that are diagnosed for having depression, and are suitable for SSRI treatment.
3282916|NCT01681407||Non-Depressed Controls|Controls: Volunteers that had clinical screening with no depression diagnosis.
3282917|NCT01681407||Patients Relatives|Patient Relatives (Optional group for later stage): First degree relatives with no depression diagnosis.
3282918|NCT01681420|Experimental|Approved Intervention Counseling|Approved blood donors randomized to intervention and choosing HIV counseling option with no donation.
3282919|NCT01681420|Experimental|Approved Intervention Donation|Approved blood donors randomized to intervention and choosing donation with no HIV counseling.
3282920|NCT01681420|Experimental|Deferred Intervention|Deferred blood donors randomized to intervention with HIV counseling.
3282921|NCT01681446|Active Comparator|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 30 μg three times a week or 50 μg twice a week for 18 months
3282922|NCT01681446|No Intervention|control|no anti-cancer interventions were assigned
3282923|NCT01681485||NSCL cancer patients|Surgery, chemotherapy and/or radiation therapy
3282924|NCT01681498||Pregnancy|
3282925|NCT01681524|Experimental|Flurpiridaz F18|Open-label study of a single injection of flurpiridaz F18 for PET MPI compared to SPECT MPI in patients with suspected or known coronary artery disease referred for coronary cathertization
3282926|NCT01681537|Experimental|Treatment Arm|Lenalidomide and re-induction chemotherapy
3282927|NCT01681550|Other|Incretin theapy combined with insulin|
3378279|NCT02871778|Placebo Comparator|Part B: Placebo + Ivacaftor|Participants who were on 3 mL 0.17% saline (placebo) through oral nebulized inhalation twice daily for 28 days (from Day 57 through Day 85) in treatment period 2 continued their inhaled study drug regimen from Treatment Period 2 and also received ivacaftor 150 mg tablet twice daily for 28 days (from Day 85 through Day 113) in treatment period 3.
3282928|NCT01681563|Experimental|Pentostatin/Cyclophosphamide/Ofatumumab|Subjects will receive up to 6 cycles of pentostatin, cyclophosphamide, and ofatumumab given every 21 days (+/- 4 days).
3282929|NCT01681602|Active Comparator|Intervention group|16 weeks of aerobic exercise
3282930|NCT01681602|No Intervention|Control group|Usual care.
3282931|NCT01681615|Active Comparator|Acetylsalicylate|Acetylsalicylic Acid Eyedrops
3282932|NCT01681615|Placebo Comparator|isotonic NaCl|Saline Eyedrops
3282933|NCT01681641|Experimental|Lifestyle counseling|Patients and spouses in the intervention group are offered 3 targeted meetings with the DBS nurse, focusing on goal setting for each individual, following DBS, based on patients and spouses own expectations, challenges and goals for everyday life after DBS.
3282934|NCT01681641|No Intervention|Control group|Patients and spouses enrolled in a control group
3282935|NCT01681654|Experimental|Immediate Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
3282936|NCT01681654|Experimental|Immediate Lifestyle Intervention - No Maintenance Program|Patients will begin the 12-week lifestyle intervention during treatment. Patients will not receive a maintenance support following the 12-week intervention.
3282937|NCT01681654|Experimental|Delayed Lifestyle Intervention - Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment (12 weeks after diagnosis). Patients will then receive maintenance support following the 12-week program.
3282938|NCT01681654|Experimental|Delayed Lifestyle Intervention - No Maintenance Program|Patients will receive a 12-week lifestyle intervention program following treatment completion (12 weeks following diagnosis). Patients will not receive maintenance support following the 12-week program.
3282939|NCT01681667|Active Comparator|ibuprofen|liquid ibuprofen 400mg compared to tablet ibuprofen 400mg
3282940|NCT01681667|Placebo Comparator|sugar pill or liquid|
3282941|NCT01681680|Other|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
3282942|NCT01681693|Experimental|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
3282943|NCT01681719|Experimental|WBV and resistance|used both interventions
3282944|NCT01681719|Experimental|WBV & resistance sham|used the vibrating platform and sham for resistance training
3282945|NCT01681719|Experimental|Resistance & sham WBV|used resistance exercises and sham for vibrating platform
3282946|NCT01681732|Experimental|Personalized Care Plan|A personalized plan based on baseline clinic visit data
3282947|NCT01681732|Active Comparator|Control|This arm will be standard care
3282948|NCT01681758|Active Comparator|PPV|use PPV to guide fluid therapy
3282949|NCT01681758|Placebo Comparator|standard care|fluids according to standard care
3282950|NCT01681797|Experimental|add-on fluorescence angiography|"The surgeon will prescribe the usual morphological assessment of the proposed flap:~CT angiography for an anterolateral thigh flap or an epigastric inferior flap~A Doppler ultrasonography for a fibula flap.~In addition to the usual radiological technique used to locate the perforating arteries, the patient will have a fluorescence angiography prior to surgery, another just after the end of surgery and then one every six hours during the next 4 days."
3282951|NCT01681823|Experimental|PectaSol-C Modified Citrus Pectin (MCP)|Treatment with 4.8 grams PectaSol-C Modified Citrus Pectin three times a day, away from meals for six months.
3282952|NCT01681862|Experimental|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
3282953|NCT01681875|Experimental|0.8 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.8 (±0.15) mg nicotine with 9 (±1.5) mg tar (standard nicotine and tar yields of commercially-available cigarettes; control condition)"
3282954|NCT01681875|Experimental|0.26 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.26 (±0.06) mg nicotine with 9 (±1.5) mg tar"
3282955|NCT01681875|Experimental|0.12 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.12 (±0.03) mg nicotine with 9 (±1.5) mg tar"
3282956|NCT01681875|Experimental|0.07 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.07 (±0.02) mg nicotine with 9 (±1.5) mg tar"
3282957|NCT01681875|Experimental|0.03 mg nicotine with 9 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.03 (±0.01) mg nicotine with 9 (±1.5) mg tar"
3282958|NCT01681875|Experimental|0.04 mg nicotine with 13 mg tar|"very low nicotine content cigarettes~SPECTRUM Cigarette: 0.04 (±0.02) mg nicotine with 13 (±2) mg tar"
3282959|NCT01681875|Other|Usual brand|"very low nicotine content cigarettes~Usual brand cigarettes (control condition)"
3282960|NCT01681888|Experimental|Surface EMG Biofeedback|
3282961|NCT01681901||Diagnostic (ultrasound)|Patients undergo breast ultrasound imaging.
3282962|NCT01681914||Anemia|Ambulatory, HIV-infected adult patients with hemoglobin <10 g/dL will be evaluated and managed in accordance with Mozambique's new anemia guideline for non-physician clinicians. The basic steps recommended by the guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral blood smear) and treat if indicated; evaluate for adverse drug reactions and manage per Mozambican national guidelines; consider nutritional deficiencies and intestinal parasites; evaluate response to therapy at <=1 month.
3282963|NCT01681914||Fever or History of Fever|Ambulatory, HIV-infected adult patients with measured axillary temperature >=37.5 C or history of fever within the past 24 hours will be evaluated and managed in accordance with Mozambique's new fever guideline for non-physician clinicians. The basic steps of the fever guideline are: screen for danger signs and stabilize or admit if indicated; perform rapid malaria antigen test (and/or peripheral smear) and treat if indicated; treat any other cause of fever identified through history and physical examination; re-evaluate at next scheduled clinical visit (sooner if worse or if not improving within 48 hours of initiating treatment). Although blood cultures are seldom performed in Mozambican health centers, venipuncture specimens will also be cultured for bacterial pathogens at the first study visit.
3282964|NCT01681914||Anemia and Fever/History of Fever|Patients who meet eligibility criteria for both the anemia and fever arms will be evaluated and managed using both the new Mozambican anemia guideline and the new Mozambican fever guideline, as above.
3282965|NCT01681927||1.4kg wt gain 8AM -10 PM|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
3282966|NCT01681927||>1.4kg wt gain 8AM - 10PM no nocturia.|Complete a questionnaire. Measure and record weight in AM and PM.Record for one week,number of times urinated after bedtime and before waking up.
3282967|NCT01681927||> 1.4 kg wt gain 8AM -10PM with nocturia|Complete a questionnaire. Measure and record weight in AM and PM. Record the number of times and collect all urine passed overnight in separate containers for one week.Collection of blood and interstitial fluid samples, fluorescein dye angiography, and bioimpedance study.
3282968|NCT01681940|Experimental|Lamazym|1 mg/kg body weight
3282969|NCT01681953|Active Comparator|Lamazym|1 mg Lamazym/kg body weight
3282970|NCT01681953|Placebo Comparator|Placebo|Placebo is formulated as an isotonic phosphate buffer with glycine and mannitol
3282971|NCT01681966|Experimental|Application of PRF110- oily solution|Post operative application of new extended release PRF110- oily solution (Ropivacaine)
3282972|NCT01681979||Women with asthma during pregnancy|Women with asthma during pregnancy will be identified based on one of the following: 1) an asthma related medical code recorded anytime before the pregnancy start date and at least one prescription for an asthma medicine in the 6 months before the pregnancy start date or during pregnancy; 2) no asthma related medical code but at least 6 prescriptions for an asthma medicine in their record before the pregnancy start date, including one in the 6 months before the pregnancy start date or during pregnancy.
3282973|NCT01682005||Complete RV vaccination|Subjects had received 2 doses of Rotarix or 3 doses of Rotateq/mixed within the vaccination window and the observation time is from the end of the vaccination window (8 months old) to end of observation.
3282974|NCT01682005||Incomplete RV vaccination|Subjects received at least one vaccination but less than complete vaccination has been received within the vaccination window and the observation time from 8 months old (if still observed) to end of observation.
3282975|NCT01682005||Any RV vaccination before 8 months|Subjects received any vaccination within the vaccination window and the observation time from 6 weeks old to earliest of end of observation or 8 months old.
3282976|NCT01682005||Historical unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and the observation time is from 6 weeks old (if still observed and on/before 12/31/06) to earliest of: 12/31/2006, end of observation, or 8 months old.
3282977|NCT01682005||Historical unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 8 months old (if still observed and on/before 12/31/2006) to earliest of: 12/31/2006 or end of observation.
3282978|NCT01682005||Contemporary unvaccinated on/before 8 months old|Subjects did not receive any RV vaccination within the vaccination window and observation time is from 6 weeks old (if on/after 01/01/2007) to earliest of: end of observation, or 8 months old.
3282979|NCT01682005||Contemporary unvaccinated after 8 months old|Subjects did not receive any RV vaccination within the vaccination window observation time is from 8 months old (if on/after 01/01/2007) to end of observation.
3282980|NCT01682018|Experimental|intervention group|Patients that underwent dingle lung transplantation due to emphysema and developed native lung overinflation as demonstrated by chest CT and decline in pulmonary lung function tests (FEV1 ) shall undergo valves placement to the native lung
3282981|NCT01682057|Experimental|Group A|ROX Anastomic Coupler System (ACS) + continuing standard antihypertensive medications
3282982|NCT01682070|Placebo Comparator|SUBLIVAC FIX Phleum prat. 0 AUN/ml|
3282983|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 3,333 AUN/ml|
3282984|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 10,000 AUN/ml|
3282985|NCT01682070|Experimental|SUBLIVAC FIX phleum prat. 20,000 AUN/ml|Evaluation of the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml by an independent safety committee
3282986|NCT01682070|Experimental|SUBLIVAC FIX Phleum prat. 40,000 AUN/ml|Start of SUBLIVAC FIX Phleum prat. 40,000 AUN/ml arm depends on safety in the SUBLIVAC FIX Phleum prat. 20,000 AUN/ml arm evaluated by an independent safety committee
3282987|NCT01682096|Active Comparator|Computed coronary angiography (CTA)|Patients will undergo a MDCT as the initial diagnostic test to rule out Acute Coronary Syndrome
3282988|NCT01682096|Active Comparator|Exercise stress echocardiography|Patients will undergo exercise stress echocardiography as the initial diagnostic test to rule out acute coronary syndrome.
3282989|NCT01682109|Experimental|new paediatric valacyclovir formulation|Newly developed formulation
3282990|NCT01682109|Active Comparator|reference valacyclovir formulation|Formulation derived from FDA label information
3282991|NCT01682122||Newborns|Healthy newborns in Regular and Observation nurseries who are between 0-72 hrs of age. Infants with gestational age > or = 35weeks and birth weight > 2500g, who are hemodynamically stable, have no cardiorespiratory abnormalities and have no evidence of sepsis. If a blood culture was drawn due to the presence of maternal risk factors (e.g. maternal fever, prolonged rupture of membranes), patients will be included only if the blood culture result is negative and in case of intrapartum antibiotic treatment, ancillary blood tests (CBC with differential, CRP) are also within the normal range
3282992|NCT01682161|Experimental|Group 1 (Immediate switch)|Paliperidone palmitate will be administered immediately after randomization and will be continued throughout the treatment phase.
3282993|NCT01682161|Experimental|Group 2 (Delayed switch)|Current oral antipsychotics will be continued until Week 8, and later on paliperidone palmitate will be administered.
3282994|NCT01682174|Placebo Comparator|Control Test Drink|control drink
3282995|NCT01682174|Experimental|Experimental Test Drink|Experimental Drink
3282996|NCT01682187|Experimental|LY2157299 (Part A)|Administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part A dose escalation will have starting dose of 40 mg/day and may increase up to 360 mg/day.
3282997|NCT01682187|Experimental|LY2157299 + Lomustine (Part B)|"LY21547299 will be administered orally by tablet twice daily for two weeks followed by two weeks of no treatment for two 28-day cycles. Part B dose expansion will have starting dose of 80 mg twice daily and may increase up to 150 mg twice daily.~Lomustine will be administered orally by capsule once on Day 7 of Cycle 1 after receiving LY2157299, and once after receiving LY2157299 on Day 21 of Cycles 2, 5, 8, 11, and every 4th cycle thereafter."
3282998|NCT01682200|Experimental|ProOxy, Effects and Side Effects in treating acne|Patients are instructed to clean the face with ProOxy facial cleanser and then spray on the face wet enough but not dripping twice daily (upon waking up and before bedtime) for 3 months.
3282999|NCT01682226|Experimental|A: standard risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
3283000|NCT01682226|Experimental|B: high risk group|This is a 2 arm phase 2 study to obtain an estimate of the speed of neutrophil recovery after myeloablative CBT with abrogation of prolonged cytopenia by infusion of haploidentical family member T-cell depleted PBSC in patients with high-risk or advanced hematologic malignancies.
3283001|NCT01682239|Experimental|RVAP lead|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV apex. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
3283002|NCT01682239|Experimental|RVSP arm|"Pacemaker lead implantation:~Pacemaker leads will be placed in specific predefined RA and RV sites according to randomization. In this arm pacemaker leads will be placed in the RV septum. The successful lead positioning at its target location will be verified by surface ECG and by fluoroscopy."
3283003|NCT01682252||musculoskeletal tumors|all patients undergoing surgery for musculoskeletal tumors
3283004|NCT01682265|Experimental|Stretta procedure|"Patient randomized in Stretta procedure arm will be hospitalized to have endoscopy and esophagus will receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
3283005|NCT01682265|Sham Comparator|Sham procedure|"Patient randomized in Sham procedure arm will be hospitalized to have endoscopy. Material necessary to perform Stretta procedure will be inserted (like in Stretta procedure arm) BUT esophagus will not receive radiofrequency.~Control visits will then take place until Month 6. At this visit endoscopic control will take place."
3283006|NCT01682278||Amalgam cohort|Patients with medically unexplained physical symptoms attributed to dental amalgam restorations which the patient wish to have removed.
3283007|NCT01682278||MUPS-cohort|Patients with medically unexplained physical symptoms without attribution to amalgam and no explicit wish to remove amalgam.
3283008|NCT01682278||Dental cohort|Healthy comparison group: Subjectively healthy without diagnosed chronic disease or prescribed medication.
3283009|NCT01682291|Active Comparator|Life-style modifications|"Lifestyle modifications will include:~Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)"
3283010|NCT01682291|Active Comparator|Dietary supplements|Life-style modifications along with a novel combination of dietary supplements that includes: Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
3283011|NCT01682304||History of Preeclampsia|Chronic hypertension with history of preeclampsia Chronic hypertension without history of preeclampsia
3283012|NCT01682317|Experimental|Three Meal|Participants in this condition will be instructed to limit their number of eating frequency to three meals per day.
3283013|NCT01682317|Experimental|Grazing|Participants in the increased eating frequency condition will be instructed to eat > 100 kcals every 2-3 hours.
3283014|NCT01682330||Fitness|
3283015|NCT01682330||Whole-body vibration|
3283016|NCT01682330||Control|
3283017|NCT01682343|Placebo Comparator|Placebo|Breakfast consisting of milk-based porridge with a normal calcium content.
3283018|NCT01682343|Experimental|High-Calcium|As control, but with a high-calcium content.
3283019|NCT01682356|Placebo Comparator|BRJ crossover to placebo|Beetroot Juice without nitrate.s Patients will be studied before and after ingestion of beetroot juice
3283020|NCT01682356|Active Comparator|Beetroot Juice|Beetroot Juice with nitrates. Patients will be studied before and after ingestion of beetroot juice with nitrates
3283021|NCT01682369|Other|Group 1 a - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283022|NCT01682369|Other|Group 1 b - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Agrippal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Agrippal)~V3-(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283023|NCT01682369|Other|Group 1 c - TIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine TIV (Aggripal) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine TIV (Aggripal)~V3-(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283024|NCT01682369|Other|Group 2 a - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+1)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283025|NCT01682369|Other|Group 2 b - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+3)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283026|NCT01682369|Other|Group 2 c - ATIV|"V1- Day 0- Administer a dose of 0.25ml of vaccine ATIV (Fluad) + Collect blood sample (up to 6.0 ml)~V2- Day 28 (26-35)- Vaccination 2nd dose, Administer a dose of 0.25ml of vaccine ATIV (Fluad)~V3- V3(Day V2+7)- Collect blood sample (up to 6.0 ml)~V4- V4 Day V2+28 (26-35)- Collect blood sample (up to 6.0 ml)"
3283027|NCT01682382||choroidal neovascular (CNV) AMD subjects|Subjects diagnosed with CNV (AREDS Grade 4b)
3283028|NCT01682382||dry AMD subjects|Subjects diagnosed with dry AMD (AREDS Grade 3)
3283029|NCT01682382||age-matched controls|Subjects without AMD (AREDS Grade 1)
3283030|NCT01682395|Active Comparator|G-SV Resection and colostomy|Gangrenous sigmoid volvulus patients randomized to undergo resection with colostomy and delayed anastomosis
3283031|NCT01682395|Experimental|G-SV Resection and anastomosis|Gangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
3283032|NCT01682395|Active Comparator|NG-SV resection and anastomosis|Nongangrenous sigmoid volvulus subjects randomized to undergo resection and anastomosis
3283033|NCT01682395|Experimental|NG-SV mesosigmoidopexy|Nongangrenous sigmoid volvulus subjects randomized to undergo mesosigmoidopexy
3283034|NCT01682408|Active Comparator|Part A1|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), fed 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
3283035|NCT01682408|Active Comparator|Part A2|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference) 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed 150 mg ranitidine
3283036|NCT01682408|Active Comparator|Part B1|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
3283037|NCT01682408|Active Comparator|Part B2|1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)
3283038|NCT01682408|Active Comparator|Part B3|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
3283039|NCT01682421|Experimental|Weak steroid|Initial treatment with dexamethasone 6x per day for two weeks, followed by Fluorometholone 4x per day for 2 months, 3x per day for 2 months, 2x per day for 2 months, and finally 1x per day continually during 2 years.
3283040|NCT01682421|Experimental|Potent steroid|Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month - giving a total of 4,5 months of steroid treatment.
3283041|NCT01682434|Active Comparator|Wavefront-guided LASIK|One eye will be randomized to wavefront-guided treatment. The other receives conventional LASIK.
3283042|NCT01682434|Active Comparator|Conventional LASIK|One eye will receive wavefront-guided LASIK. The other eye receives conventional treatment.
3283043|NCT01682447|Experimental|Extensive Pulmonary Rehabilitation (ERP)|Participants in this group are measured on primary and secondary outcome measures before and after a 12 week extensive pulmonary rehabilitation program.
3283044|NCT01682447|No Intervention|Waiting List Control group|Participants in the waiting list control group are measured on primary and secondary outcome measures before and after waiting time for the extensive pulmonary rehabilitation program and start with this program after the second moment of measurement.
3283045|NCT01682473|Experimental|Arm 1: 5/2 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 5 days on drug and 2 days off drug.
3283046|NCT01682473|Experimental|Arm 2: 21/7 Dosing|Subjects will receive oral ZSTK474 at a fixed once daily dose administered in 4-week (28-day) cycles of 21 days on drug and 7 days off drug.
3283047|NCT01682486|Experimental|BIP ETT, Bactigaurd coated endotracheal tube|
3283048|NCT01682486|Placebo Comparator|Standard ETT, un-coated endotracheal tube|
3283049|NCT01682499|Experimental|Calcium and Magnesium Infusion|
3283050|NCT01682525|Experimental|Ovarian tissue cryopreservation|The ovarian tissue is cryopreserved and stored at Boston IVF, which is an FDA compliant and American Association of Tissue Banks accredited long term storage facility for reproductive tissue.
3283051|NCT01682551|Experimental|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
3283052|NCT01682551|Placebo Comparator|Acetazolamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
3283053|NCT01682564|Experimental|Candemore tablet|"Candemore tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
3283054|NCT01682564|Active Comparator|Atacand tablet|"Atacand tablet~Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
3283055|NCT01682577|Experimental|Perindopril 4 mg tablets of PT Dexa Medica|"Group I (Test product): each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril tablet of PT Dexa Medica was given to each of study subjects."
3283056|NCT01682577|Active Comparator|Perindopril 4 mg tablets of Servier|"Group II (Reference product) : each tablet contains perindopril tert-butylamine salt 4 mg.~A single dose of perindopril (Prexum) tablets of Servier was given to each of study subjects."
3283057|NCT01682590|Experimental|Early initiation of RRT|Start of RRT within a maximum of 12 hours after randomisation.
3283058|NCT01682590|Active Comparator|Deferred RRT|Start of RRT between 48 and 60 hours after randomisation.
3283059|NCT01682616|Experimental|Arm 1|Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
3283060|NCT01682629|No Intervention|Non-Scripted Debriefing, Low Realism Simulation|A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. In this arm, novice instructors were provided the scenario learning objectives but NO SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing. The simulation scenario itself was conducted with an infant simulator. The low realism group had the simulator with the compressor turned off, thus eliminating the functionality of physical findings.
3283061|NCT01682629|Experimental|Scripted debriefing, Low Realism|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The lo realism group had the simulator with the compressor turned on, thus eliminating the functionality of physical findings.
3283062|NCT01682629|Experimental|non-Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITHOUT A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing WITHOUT USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
3283063|NCT01682629|Experimental|Scripted Debriefing, High Realism Simulation|In this arm, novice instructors were provided the scenario learning objectives WITH A DEBRIEFING SCRIPT, and asked to observe the simulation and conduct a 20 minute debriefing USING THE SCRIPT. The hi realism group had the simulator with the compressor turned on, thus activating the functionality of physical findings.
3283064|NCT01682668|Experimental|Frequency of subthalamic stimulation|Comparison between healthy controls and PD patients
3283065|NCT01682694|Experimental|Glucosamine and Chondroitin|Glucosamine and Chondroitin
3283066|NCT01682694|Placebo Comparator|Placebo|Inactive ingredients
3283067|NCT01682707|Active Comparator|Laryngoscopy|Laryngoscopy Track Light teaqueal intubation
3283068|NCT01682707|Active Comparator|Track Light|
3283069|NCT01682733|Experimental|Botulinum toxin at injection site|All subjects will have gastroplasty performed using the Overstitch Endoscopic Suturing System. Botulinum toxin will be injected in every other suture site in half of the randomly patients selected.
3283070|NCT01682746|Experimental|Treatment|Photofrin (porfimer sodium) photodynamic therapy.
3283071|NCT01682772|Experimental|Olaparib 400mg|Oral Olaparib at a dose of 400mg twice daily, continuously on a 28 day cycle
3283072|NCT01682772|Experimental|Olaparib 300mg|Oral Olaparib at a dose of 300mg twice daily, continuously on a 28 day cycle
3283073|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 1) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
3283074|NCT01682798|Placebo Comparator|Placebo yoghurt|100g of placebo yoghurt (normal yoghurt) will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
3283075|NCT01682798|Active Comparator|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|"100g of Yili Chang Qing Pro-ABB yoghurt (Formula 2) will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
3283076|NCT01682824||Group I (questionnaire, nutritional assessment)|Patients complete the TFEQ-R18v2 questionnaire, a dietary intake assessment, and the EQ-EMA questionnaire online.
3283077|NCT01682824||Group II (questionnaire, nutritional assessment)|Patients complete the EQ-EMA questionnaire, a dietary intake assessment and the TFEQ-R18v2 questionnaire.
3283078|NCT01682850|Active Comparator|Intervention|The Intervention Arm will receive 10 sessions of Mindfulness Based Pulmonary Rehabilitation prior to lung surgery
3283079|NCT01682850|Placebo Comparator|Usual Care|The Usual Care Arm will receive the normal care that a patient with severe COPD having a lung surgery would receive.
3283080|NCT01682889|Placebo Comparator|Placebo|NaCl 0.9% intravenously for 24 hours after induction of anaesthesia
3283081|NCT01682889|Active Comparator|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours after induction of anaesthesia
3283082|NCT01682902|Experimental|Formulation 1|
3283083|NCT01682902|Experimental|Formulation 2|
3283084|NCT01682902|Active Comparator|Insulin aspart (NovoLog®)|
3283085|NCT01682915||Group 1: ADHD+DAT1, Probands|30 ADHD probands with DAT1 variants
3283086|NCT01682915||Group 2: ADHD+DAT1, Unaffected sibling|30 same-sex unaffected siblings of Group 1
3283087|NCT01682915||Group 3: ADHD Drug-naïve, Probands|30 ADHD probands without DAT1 gene variants, who were age-, sex-, and IQ-matched to Group 1
3283088|NCT01682915||Group 4: ADHD Drug-naïve, unaffected sibling|30 same-sex unaffected siblings of Group 3
3283089|NCT01682915||Matched controls|30 age-, sex- and IQ-matched TD controls for each of 4 groups
3283090|NCT01682941|Active Comparator|Soy Bread Intervention|Arm I Soy Bread
3283091|NCT01682941|Experimental|Soy -Almond Bread Intervention|Arm II Soy-Almond Bread
3283092|NCT01682967||Experimental group|Patients suffering from PDPH would form this group
3283093|NCT01682967||Control group - Epidural|Patients who received an epidural during labour but did not have symptoms of PDPH would form this reference group
3283094|NCT01682967||Control Group without Epidural analgesia|Patients in labour who did not receive an EDA would form this cohort of controls
3283095|NCT01682980|Experimental|Strength training|The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.
3283096|NCT01682980|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 75% of maximal heart rate (calculated with formula for maximal heart rate reserve).
3283097|NCT01682980|No Intervention|Control group|The control group will do as usual.
3283098|NCT01682993|Active Comparator|Corneal Cross Linking|Patients will receive a standard corneal cross linking treatment
3283099|NCT01682993|Experimental|Corneal Cross Linking and Topo Laser|Patients will receive a topography guided laser treatment in combination with a standard corneal cross linking treatment in the same session.
3283100|NCT01683006|Active Comparator|Neuromuscular blocker group|"Continuous application of neuromuscular blockers during therapeutic hypothermia.~Bolus application of placebo in case of shivering."
3283101|NCT01683006|Placebo Comparator|Placebo group|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of neuromuscular blockers in case of shivering."
3283102|NCT01683032|Experimental|Experimental: Healthy adults|Participants, aged 21-40 years, will be recruited through an advertisement posted at the University of Haifa (including the website of Haifa University).
3283103|NCT01683045|Experimental|The Estech COBRA® Surgical System|
3283104|NCT01683084|Active Comparator|Telmisartan|One 40mg telmisartan pill given once daily for 24 months
3283105|NCT01683084|Placebo Comparator|Placebo|One 40mg placebo pill given once daily for 24 months
3283106|NCT01683097|No Intervention|Control|Questionnaire
3283107|NCT01683097|Experimental|Intervention|Standardized explanation followed by questionnaire
3283108|NCT01683136|Experimental|Deep TMS treatment|
3378280|NCT02858323||1|Previously selected HLA-alloimmunized platelet refractory, clinical, patients.
3378281|NCT02855242|Other|Intervention Program Group|Lifestyle Counseling
3378282|NCT02855242|Active Comparator|Controls Group|No lifestyle counseling
3283109|NCT01683136|Sham Comparator|inactive stimulation|
3283110|NCT01683149|Experimental|Combination Chemotherapy|"Combination Chemotherapy: Topotecan and Sorafenib. Participants will receive the treatment in cycles. Every cycle is 28 days long. For the first cycle participants will get the chemotherapy drugs:~Topotecan PO (by mouth) once daily on days 1-5 and days 8-12~Sorafenib PO (by mouth) twice daily (BID), continuously on days 2-28 of cycle one and days 1-28 on each additional cycle.~Level -1: Topotecan 1.0 mg/m^2: Sorafenib 100 mg/m^2 BID~Level -2: Topotecan 0.8 mg/m^2: Sorafenib 100 mg/m^2 BID~Level 1: Topotecan 1.0 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 2: Topotecan 1.4 mg/m^2: Sorafenib 150 mg/m^2 BID~Level 3: Topotecan 1.4 mg/m^2: Sorafenib 200 mg/m^2 BID~Level 4: Topotecan 1.8 mg/m^2: Sorafenib 200 mg/m^2 BID"
3283111|NCT01683162|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
3283112|NCT01683162|Experimental|MCT/LCT lipid emulsion|the MCT/LCT lipid emulsion is Lipofundin
3283113|NCT01683162|Experimental|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
3283114|NCT01683175|Experimental|Arm 1|Erlotinib 150mg daily oral up to 2 years
3283115|NCT01683175|Active Comparator|Arm 2|NP Chemotherapy for 4 cycles
3283116|NCT01683188|Other|Cohort 1|Patients who have received less than 7 weeks vemurafenib dosing prior to treatment with HD IL-2
3283117|NCT01683188|Other|Cohort 2|Patients who have receive >7 weeks to 18 weeks vemurafenib dosing prior to treatment with HD IL-2
3283118|NCT01683201|Experimental|Functional exercise class|Functional exercise class 45 mins twice weekly from week 12 to week 18
3283119|NCT01683201|Placebo Comparator|Usual Care Group|Usual Care
3283120|NCT01683227|Experimental|Screening/motivational drug intervention|Screening and brief intervention counseling matched to patient's risk level delivered in the ER
3283121|NCT01683227|Placebo Comparator|Motivational placebo intervention|Screening and brief intervention for driving and traffic safety
3283122|NCT01683240|Experimental|Frimberger cholangioscope|Patients with need for cholangioscopy due to gallstones or histological evaluation of strictures
3283123|NCT01683253|Experimental|Levodopa/Carbidopa(200mg/50mg)|
3283124|NCT01683253|Experimental|Control A (dopaminergic agonist )|Parkinson patients treated with anti-Parkinson drug over 6 months.
3283125|NCT01683253|No Intervention|Control B (no drug)|Parkinson diseased patients not treated.
3283126|NCT01683279|Experimental|CAR+ T cells|Subjects will receive two days of cyclophosphamide for a total of 3g/m^2 followed several days later by a single dose of Autologous CD19 CAR+ EGFTt + T cells
3283127|NCT01683292|Experimental|Inhaled VR040|Inhaled apomorphine, dry powder, VR040 at fine particle doses (FPD) of 0.2mg, 0.5mg and 0.8mg. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
3283128|NCT01683292|Placebo Comparator|Placebo|Inhaled dry powder. A single dose, followed by a second dose at 12 minutes if efficacy end point was not attained.
3283129|NCT01683305||Subjects who have no mammographically detectable tumors|This group will be evaluated for marker presence in NAF. no drugs administered
3283130|NCT01683305||Subjects who have non-cancerous growths|This group will be evaluated to study whether marker(s) detected in NAF are also expressed in non-cancerous tumors. No drugs administered
3283131|NCT01683305||subjects who have cancerous growths|In this group, any markers detected in NAF could also be detected in tumor tissues. No drugs administered.
3283132|NCT01683318|Experimental|Treatment|Patients will undergo Thermal Pulsation treatment of Meibomian Gland Dysfunction using the TearScience System (Lipiflow).
3283133|NCT01683357||Multiple Bilobar CLM|Patients selected for hepatectomy because carrier of multiple (> or = to 4), bilobar CLM
3283134|NCT01683370||Patients|Pediatric patients with cancer, receiving standard chemotherapy, and receiving standard supportive therapy in case of fever in neutropenia (FN) (No intervention for study purposes)
3283135|NCT01683396|Placebo Comparator|Placebo|
3283136|NCT01683396|Experimental|gevokizumab|
3283137|NCT01683435|Experimental|hylauronin binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
3283138|NCT01683461|Experimental|Enhanced Counseling|Women in the intervention arm receive: (1) a standardized health education video before HIV pre-test counseling; (2) HIV pre- and post-test counseling sessions that prepare women for decisions related to testing, serostatus disclosure and anti-retroviral (ARV) prophylaxis and help women plan strategies for sexual risk behavior change; (3) two additional post-test counseling sessions postpartum focused on legal education and referral, partner testing, sexual risk behavior change and family planning decisions and; (4) an active referral system to post-test support groups run by a clinically trained staff psychologist and (5) an active referral system to legal services run by a lawyer at the clinic.
3283139|NCT01683461|Active Comparator|Standard of Care|Women in the control arm receive the standard of care in terms of HIV counseling and testing during pregnancy. The standard of care for HIV counseling adheres to guidelines provided by the US Centers for Disease Control and the World Health Organization. Women receive one individual pre-test counseling session immediately before they are tested for HIV, and one individual post-test counseling session the same day that they are tested.
3283140|NCT01683474|Experimental|Venus A-Valve|single arm with intervention that percutaneous implantation of the Venus MedTech Aortic Valve Prosthesis
3283141|NCT01683500|Experimental|shock wave therapy|intervention: shock wave therapy with Modulith SLK (Storz)
3283142|NCT01683513|No Intervention|humaan chorion gonadotropine|ovulation induction with 5000E hCG
3283143|NCT01683513|Active Comparator|GnRH agonist + 1500E hCG|ovulation induction with GnRH agonist and 1500E hCG one hour after egg retrieval
3283144|NCT01683539|Experimental|The Thinking Skills for Work Program|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
3283145|NCT01683539|Active Comparator|The Cognitive Skills for Work Program|The Cognitive Skills for Work Program includes 4 components delivered by a Cognitive Specialist who works with the consumer's Employment Specialist: a) assessing the consumer's cognitive strengths and weaknesses their relation to job history b) teaching coping strategies for cognitive challenges associated with job search or maintenance c)job search planning, in which the consumer and the Cognitive and Employment Specialists help identify job leads based on the consumer's interests, and identify cognitive coping strategies and supports the consumer may need to succeed at the workplace; and d) job support consultation, in which the Cognitive and Employment Specialists consult with the consumer on additional cognitive coping strategies to enable the consumer to meet the demands of the job.
3283146|NCT01683552|Other|Aprepitant|Aprepitant is administered in patients ,affected by solid tumors treated with biological therapy, who did not receive any treatment for severe pruritus
3283147|NCT01683552|Other|Aprepitant after anti-itch standard therapy|Aprepitant will be administered in patient affected by severe itch resistant to standard treatment (steroids and/or antihistamines) administered for at least one week
3283148|NCT01683578|Active Comparator|Variable Ventilation|Variable tidal volumes with mean at 8 mL/kg of predicted body weight
3283149|NCT01683578|No Intervention|Non-variable Ventilation|Conventional mechanical ventilation with tidal volume 8 mL/kg of predicted body weight
3283150|NCT01683591||High-risk aspiration group|Among the consecutive stroke patients, categorized to high-risk group in the patient (1) was not on alert mentality (from drowsy to comatose mentality), (2) was not able to sit upright or control his/her head, and (3) failed to pass indirect water swallow test.
3283151|NCT01683591||Low-risk aspiration group|Patents without oropharyngeal neurologic signs
3283152|NCT01683591||Intermediate-risk aspiration group|If any one of following was positive, categorized to intermediate-risk group; (1) dysarthria, (2) motor aphasia, (3) inability to close and open lips or (4) facial weakness, (5) tongue deviation or (6) uvula deviation, (7) loss of gag reflex, and (8) inability to cough voluntarily.
3283153|NCT01683617|Experimental|A treatment based on CBT and new technologies|Individuals will receive a treatment based on cognitive behavioral therapy and new technologies (virtual reality, virtual reality combined to biofeedback and mobile phones). Relaxation will be induced through the immersion in different virtual environments (e.g., lake) which will be customized with different pre-recorded audio narratives that describe the specific setting and that guide the execution of a series of relaxation exercises. During biofeedback exercises a wearable biosensor system will provide suggestions to the trainer based on the reactions of the participants, and the biosensor data will directly modify the virtual reality experience in real time.
3283154|NCT01683617|Active Comparator|Traditional treatment based on CBT|Participants will receive a treatment based on traditional cognitive behavioral therapy techniques for stress management, without the use of new technologies. Relaxation will be induced by guided imagery, through auditory narratives.
3283155|NCT01683643|Experimental|SBIRT Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Experimental subjects, in addition to their risk score and informational materials, will also receive a brief intervention and a referral to treatment appropriate to their risk score from trained health educators. The health educators will be provided by Homeless Health Care, Los Angeles.
3283156|NCT01683643|Active Comparator|Control Group|Baseline demographic data will be collected. Subjects will be screened for substance use risk using The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) developed by the World Health Organization. Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
3283157|NCT01683656|Active Comparator|ER Niacin/laropipant|ER niacin/laropiprant 1g/20 mg for the first 4 weeks and 2g/40mg from week 5 to the end of the study.
3283158|NCT01683656|Placebo Comparator|ER Niacin/laropipant Placebo|ER niacin/laropiprant placebo p.m.
3283159|NCT01683669|Other|Noisy-PSV 1|different levels of variable pressure support
3283160|NCT01683669|Other|Noisy-PSV 2|different levels of variable pressure support
3283161|NCT01683682|Experimental|BIBF 1120, Vinorelbine, Carboplatin|"To determine the 'Maximum Toleraetd Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
3283162|NCT01683695|Active Comparator|AMG 557|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
3283163|NCT01683695|Placebo Comparator|AMG 557 Matching Placebo|All will receive AMG 557 on Day 1, Day 8, Day 15, Day 29, Day 43, Day 57, Day 71, Day 85, Day 99, Day 113, Day 127, Day 141 and Day 155.
3283164|NCT01683708||Symbiotic group|Jaundiced patients who have symbiotic therapy
3283165|NCT01683708||No Symbiotic therapy|Jaundiced patients who not have symbiotic therapy
3283166|NCT01683721||Winx|
3283167|NCT01683734||Renal Function Observation|
3283168|NCT01683747|Experimental|Tranexamic acid|Study group receives enteral tranexamic acid in normal saline in addition to usual care.
3283169|NCT01683747|Placebo Comparator|Control group|Control group receives vehicle (normal saline) without study drug and usual care.
3283170|NCT01683760|Experimental|Population PK|
3283171|NCT01683773|Experimental|Group A|Two doses of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
3283172|NCT01683773|Experimental|Group B|One dose of AERAS-402 (1x10^11 vp intramuscular injection) followed by one dose of MVA85A (1x10^8 pfu intradermal injection)
3283173|NCT01683773|Experimental|Group C|Three doses of AERAS-402 (1x10^11 vp intramuscular injection)
3283174|NCT01683786|Experimental|Pegintron + Riba for 36 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 24 weeks (36 weeks in total HCV treatment)
3283175|NCT01683786|Active Comparator|Pegintron + Riba for 48 wks in total|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day for 36 weeks (48 weeks in total HCV treatment)
3283176|NCT01683799|Experimental|Insomnia treatment|Cognitive Behavioral Therapy for Insomnia
3283177|NCT01683799|No Intervention|Control|
3283178|NCT01683825|Experimental|F-18 florbetapir PET-Amyloid Subjects|Individuals with documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
3283179|NCT01683825|Other|F-18 florbetapir PET-Healthy Controls|Individuals without documented cardiac amyloidosis will undergo F-18 florbetapir (Trade Name: Amyvid) positron emission tomography (PET).
3283180|NCT01683877|Experimental|FloSeal group|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
3283181|NCT01683877|Active Comparator|Electrocautery group|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
3283182|NCT01683890||Simple hysterectomy group|Patients will undergo simple hysterectomy due to benign uterine disease.
3283183|NCT01683903||Non coronary patients (NC)|Patient with myocardial infarction with non-coronary (NC) etiology
3283184|NCT01683903||Coronary patients (C)|Patients with myocardial infarction due to coronary disease
3283185|NCT01683929|Active Comparator|Oral glucose tolerance test|The participants will consume a beverage containing 75 gram glucose During the meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes. Also, they will record their macronutrient\caloric consumption during the 24 hour following the test.
3283186|NCT01683929|Placebo Comparator|Artificial sweetner|"participants will consume a beverage containing 0.42 gram artificial sweetener (Aspartame) During each meeting, the participants will drink the sweetened drink followed by blood work, at 0, 30, 60, 120, 180 minutes.~Also, they will record their macronutrient\caloric consumption during the 24 hour following the test."
3283187|NCT01683955|Experimental|Tranexamic Acid|Topical tranexamic acid (2g/100mL) applied during unilateral total hip arthroplasty.
3283188|NCT01683955|Placebo Comparator|Placebo|100mL 0.9% NS, applied topically
3283189|NCT01683968||Sickle cell|Patient who are admitted with sickle cell crises
3283190|NCT01683981|Experimental|L-Citrulline, Exercise Capacity|L-Citrulline malate, 1gr, oral, divided 3 times a day,for 2 weeks
3283191|NCT01684059||Single group|Single group: each participant receive same intervention (zinc sulfate) throughout study (non-randomized)
3283192|NCT01684072|Experimental|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3283193|NCT01684072|Active Comparator|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3283194|NCT01684085|Placebo Comparator|Encouragement to sleep|Encouraging explanation to sleep, rest and receiving Lorazepam 1mg in the first night post trauma
3283195|NCT01684085|Experimental|Encouragement to deprived sleep|Encouraging explanation to deprived sleep in the first night post trauma
3283196|NCT01684098|Other|Tc 99m EC20|
3283197|NCT01684111|Experimental|BIBF 1120, Vinorelbine|"To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.~Under certain conditions the dose level will be escalated to 200mg bid in a second cohort."
3283198|NCT01684124|Placebo Comparator|standard care|normal treatment
3283199|NCT01684124|Active Comparator|conservative O2 therapy|a value of 90-92% O2 saturation will be targeted
3283200|NCT01684137|Active Comparator|Joalis Bambi Bronchi & Joalis Bambi Analerg|10 days, 2 times per day 2,5/5 ml
3283201|NCT01684137|Placebo Comparator|Placebo & Placebo|10 days, 2 times per day 2,5/5 ml
3283202|NCT01684150|Experimental|EPZ-5676 Extension cohort|
3283203|NCT01684163|Placebo Comparator|Placebo injection|Normal saline
3283204|NCT01684163|Experimental|GLYX-13, 5 mg/kg|Low dose of GLYX-13
3283205|NCT01684163|Experimental|GLYX-13, 10 mg/kg|High dose of GLYX-13
3283206|NCT01684176|Experimental|Complex tailored intervention|"The intervention consists of 3 elements:~Medication review with recommendations focused on antithrombotics and adherence to guidelines and patient´s adherence to medications.~Discharge consultation with an pharmacist using motivational interviewing techniques.~Follow-up telephone calls one week, two months and six months after discharge."
3283207|NCT01684176|Placebo Comparator|Usual care|Usual care
3283208|NCT01684189||Patient registry|Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry
3283209|NCT01684241|Experimental|RBL001/RBL002 intranodal administration|"All participants will be treated with RBL001/RBL002 after allocation to one of the four escalating dose cohorts:~Cohort-1 50 µg RBL001 and 50 µg RBL002~Cohort-2 100 µg RBL001 and 100 µg RBL002~Cohort-3 300 µg RBL001 and 300 µg RBL002~Cohort-4 600 µg RBL001 and 600 µg RBL002"
3283210|NCT01684254||Children with Cerebral Palsy (CP)|
3283211|NCT01684267|Experimental|Healthy|Healthy individuals
3283212|NCT01684267|Experimental|Post-stroke|Chronic stroke survivors
3283213|NCT01684280||gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
3283214|NCT01684293|Experimental|Cognitive Rehabilitation|Occupational therapy-based cognitive rehabilitation
3283215|NCT01684293|Placebo Comparator|Psychoeducation/games|Psychoeducation/games
3283216|NCT01684306|Experimental|Placebo|Study subjects received, in a double blind fashion, a placebo pill identical to the drug.
3283217|NCT01684306|Experimental|Modafinil|"Modafinil (Provigil), a drug on the market since 1997, is employed for the treatment of narcolepsy and other sleep disorders. In recent years, modafinil has also been used off-label to treat cognitive dysfunction in psychiatric disorders such as schizophrenia and Attention Deficit/Hyperactivity Disorder (ADHD).~Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil."
3283218|NCT01684319|Placebo Comparator|Infant formula milk|Infant formula milk adapted to age of infant
3283219|NCT01684319|Active Comparator|Formula milk free of milk proteins|Milk-free formula milk adapted to age of infant
3283220|NCT01684332|Experimental|High Sugar (HS)|Study of the postprandial effects after consuming 60g of strawberry jam with high sugar content
3283221|NCT01684332|Experimental|Low Sugar (LS)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content
3283222|NCT01684332|Experimental|Low Sugar + Antioxidant (LSA)|Study of the postprandial effects after consuming 60g of strawberry jam with low sugar content and an antioxidant extract from strawberry pulp
3283223|NCT01684345|Placebo Comparator|Placebo|
3283224|NCT01684345|Experimental|Dose 1 gevokizumab|
3283225|NCT01684345|Experimental|Dose 2 gevokizumab|
3283226|NCT01684358|Experimental|Immediate implant|Sino-implant (II) inserted at enrollment visit
3283227|NCT01684358|Active Comparator|Delayed implant|Sino-implant (II) inserted at 3-month follow-up visit
3283228|NCT01684371||Blue Dotted Elmore Oil|Patients applied the above oil 3 times daily for four weeks and on the fifth week stopped the application completely for the flush out period before switching to Orange Dotted Elmore Oil
3283229|NCT01684371||Orange Dotted Elmore Oil|Patients give this oil applied it three times daily on the affected knees for four weeks and on the fifth week, stopped the application totally for the flush out period before switching to the Blue Dotted Elmore Oil.
3283230|NCT01684384|Experimental|No treatment|CT-scans will be taken in the study. The EC of the University hospital antwerp considers this as an intervention.
3283231|NCT01684397|Experimental|Treatment (pazopanib hydrochloride and bevacizumab)|Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.
3283232|NCT01684449|Experimental|Phase 2: Experimental Arm|Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
3283233|NCT01684462|Experimental|Human Serum Albumin 20|Human Serum Albumin 20% 100cc intravenously infused over 4~8h
3283234|NCT01684462|Placebo Comparator|0.9 % Normal saline|Treatment with same volume of normal saline
3283235|NCT01684475|Experimental|Treatment with CJH1|
3283236|NCT01684488|Active Comparator|Waitlist+EducAid|Immediately following enrollment, participants do not immediately receive any intervention. At 3 months, they are enrolled in EducAid educational programming for the 2012-2013 academic year.
3283237|NCT01684488|No Intervention|Waitlist|Participants do not receive any intervention throughout the trial period. Once the trial has concluded, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
3283238|NCT01684488|Experimental|YRI only|Immediately following enrollment, participants complete the YRI. They are then placed on a waitlist for the remainder of the trial. At the end of the trial, participants are invited to enroll in EducAid educational programming for the 2013-2014 academic year.
3283239|NCT01684488|Experimental|YRI+EducAid|Immediately following enrollment, participants complete the YRI. Participants are then immediately enrolled in EducAid educational programming for the 2012-2013 academic year.
3283240|NCT01684501||Amputees|Adults with history of traumatic unilateral transtibial amputation
3283241|NCT01684514|Experimental|colitis, ulcerative|Enrolled patients will be examined by conventional colonoscopy and confocal laser endomicroscopy before and after initiation of topical treatment, respectively.
3283242|NCT01684514|Sham Comparator|Control group|A control group will be examined by conventional colonoscopy and confocal laser endomicroscopy.
3283243|NCT01684527||Children Suffering From Bronchiolitis|Respiratory secretions obtained from children suffering from Bronchiolitis
3283244|NCT01684527||Healthy Children|Respiratory secretions obtained from children with no respiratory infection
3283245|NCT01684553|Experimental|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
3283246|NCT01684553|Active Comparator|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
3283247|NCT01684579|Experimental|Exercise and psychosocial counseling|Patients will participate in a psychosocial counseling session, 1 day/week for 20 weeks. Patients will be invited to participate in a progressive aerobic and resistance exercise program designed to achieve moderate and then vigorous levels of exercise, 5 days/week for 20 weeks.
3283248|NCT01684605|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3283249|NCT01684605|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3283250|NCT01684618|Experimental|Cerebral NIRS oximetry + CPAP|Cerebral NIRS oximetry, using the INVOS Cerebral/Somatic Oximeter, and changes in regional cerebral oxygen saturation, rSO2, during induced changes in CPAP flow pressure
3283251|NCT01684631||Hip arthroplasty|Patients implanted with a PINNACLE® ULTAMET™ Metal-on-Metal implant for conventional total hip arthroplasty for the treatment of a severe hip disease or true femoral cervical fracture.
3283252|NCT01684644|Experimental|New Forest Parenting Programme|The New Forest Parenting Programme is a parent training programme specifically developed to treat ADHD in preschool children. The programme is delivered as an 8 week intervention for individual parents and their child.
3283253|NCT01684644|Other|Treatment as Usual|Treatment as usual for preschool ADHD consists of psychoeducation groups for parents.
3283254|NCT01684657|Placebo Comparator|Placebo|This is the comparator. Placebo will be matched to color, taste, size, and smell.
3283255|NCT01684657|Experimental|Asenapine|This is an atypical antipsychotic that blocks dopamine and increases serotonin. The dosage will be from 2.5 to 10mg daily throughout the study.
3283256|NCT01684670|Experimental|Behavioral speech treatment|
3283257|NCT01684683|Experimental|Theophylline|Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks
3283258|NCT01684683|Placebo Comparator|placebo|Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks
3283259|NCT01684696|Experimental|mHealth TLC|"The mhealth TLC group will meet with a nurse before each of 4 clinician visits and use the mHealth TLC on an iPad with an interactive 3-dimensional intervention that allows individuals to experience virtual visits with their clinicians. Key aspects of mHealthTLC include informational videos about lung cancer and LCS. Blame and self-blame will be addressed, information about the role of addiction, social/cultural factors, and tobacco industry influence on smoking behaviors will be highlighted. Patients will experience practiced interaction in ever increasing complex situations with avatars (i.e., receptionist, medical assistant, and clinician). A virtual coach will accompany the patient through the virtual visit and will provide information and coaching (as needed)."
3283260|NCT01684696|Active Comparator|Attention Control|Attention control group (ACG) - Patients assigned to the ACG will meet with a nurse and receive only the informational videos on an iPad before 4 clinician visits with assessments after each clinician visit. An effort will be made to match the intervention condition on salience, credibility, and contact time.
3283261|NCT01684709|Experimental|Telemonitoring + self-management support|Automated assessment calls with follow-up by a Care Manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up.
3283262|NCT01684709|No Intervention|Usual Care|Usual Care
3283263|NCT01684735||women with breast cancer and chemotherapy|women recently diagnosed with breast cancer and selected to start with neo-adjuvant chemotherapy (6 cycles) before surgery/therapy
3283264|NCT01684761|Experimental|Tcelna|30-45 x 10E6 total cells in 2 ml. Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).
3283265|NCT01684761|Placebo Comparator|Placebo|Tcelna inactive ingredients (without cells) totaling 2 ml per dose. Administered subcutaneously with same two year treatment regimen as experimental treatment arm.
3283266|NCT01684774||I. USG|Patients receiving Ultrasound-guided Ankle Block
3283267|NCT01684774||II. ALG|Patients receiving Anatomic Landmark-guided Ankle Block
3283268|NCT01684787|Experimental|1|Peginterferon alfa-2a + ribavirin in normal ALT
3283269|NCT01684787|Active Comparator|2|peginterferon alfa-2a + ribavirin in elevated ALT
3283270|NCT01684800|Active Comparator|A. Desmopressin 10 microgram|
3283271|NCT01684800|Active Comparator|B. Desmopressin 25 microgram|
3283272|NCT01684800|Placebo Comparator|C. Placebo|
3283273|NCT01684813|Active Comparator|Clopidogrel|This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
3283274|NCT01684813|Experimental|Prasugrel|This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).
3283275|NCT01684865||Non-Hodgkin's Lymphoma Participants|Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will receive rituximab for maximum two years or until disease progression. Participants will be followed for one year after last dose of rituximab administered as maintenance.
3283276|NCT01684891|Experimental|RG1662|
3283277|NCT01684904|Experimental|Proton radiation|Proton radiation
3283278|NCT01684956|Experimental|Intradermal first|Intradermal injection experiment first, followed by subcutaneous injection experiment
3283279|NCT01684956|Experimental|Subcutaneous first|Subcutaneous injection experiment first, followed by intradermal injection experiment
3283280|NCT01684969|Active Comparator|intravenous haloperidol|intravenous haloperidol pharmacokinetics
3283281|NCT01684969|Placebo Comparator|Placebo|
3283282|NCT01684982|Experimental|everolimus eluting stent|second generation drug eluting stent
3283283|NCT01684982|Active Comparator|sirolimus eluting stent|first generation drug eluting stent
3283284|NCT01684995|Active Comparator|Minimal|Brief physician advice to quit smoking plus nicotine patch
3283285|NCT01684995|Experimental|Tailored|
3283287|NCT01685034|Experimental|Allergy Immunotherapy Group|There is only one active experimental group as this is a pilot study comparing clinical/histologic/endoscopic changes before and after treatment.
3283288|NCT01685086||Patients with severe chronic kidney disease|
3283289|NCT01685086||Patient with peritoneal dialysis|
3283290|NCT01685086||Patients with hemodialysis|
3283291|NCT01685099||Group with tuberculous pleurisy|
3283292|NCT01685099||Group with non-tuberculous pleurisy|
3283293|NCT01685112||Conventional Group|Patients who developed refractory shock, but didn't received ECMO as salvage treatment
3283294|NCT01685112||ECMO group|Patient who have septic shock, and progreseed to have ECMO as salvage therapy
3283295|NCT01685125|Active Comparator|Arm A (abiraterone acetate, prednisone)|Abiraterone acetate 1000 mg PO QD and Prednisone 5 mg PO BID on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3283296|NCT01685125|Experimental|Arm B (abiraterone acetate, prednisone, dasatinib)|Abiraterone acetate 1000 mg PO QD, Prednisone 5 mg PO BID, and dasatinib 100 mg PO QD on days 1-28. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3283297|NCT01685151|Experimental|Ramelteon SL (Dose 1)|Ramelteon SL tablets, sublingual, once daily, at night time for up to 12 months.
3283298|NCT01685151|Experimental|Ramelteon SL (Dose 2)|Ramelteon SL tablets, sublingual, once daily, at nigh time for up to 12 months
3283299|NCT01685151|Placebo Comparator|Placebo|Ramelteon SL placebo-matching tablets, sublingual, once daily, at night time for up to 12 months.
3283300|NCT01685164||LNG-IUS|Nulliparous women
3283301|NCT01685164||Cu-IUD|Nulliparous women
3283302|NCT01685177||SADI|Patients submitted to a second-step operation after a failed sleeve on which a single-anastomosis duodena-ileal bypass at 250 cm from the cecum is performed.
3283303|NCT01685190|Active Comparator|Prostate Alone IMRT|Participants will receive standard prostate Intensity Modulated Radiotherapy (IMRT) of 74Gy in 37 fractions delivered over 7.5 weeks.
3283304|NCT01685190|Experimental|Prostate & Pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
3283305|NCT01685255|Active Comparator|Epacadostat|Subjects randomized to Arm A (epacadostat) will take epacadostat tablets at a dose of 600 mg BID, beginning on Day 1.
3283306|NCT01685255|Active Comparator|Tamoxifen|Subjects randomized to Arm B (tamoxifen) will take tamoxifen tablets at a dose of 20 mg BID, beginning on Day 1.
3283307|NCT01685268|Experimental|Part A, Regimen 1|AT13387 given as a 1-hr IV infusion at a starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
3283308|NCT01685268|Experimental|Part A, Regimen 2|At13387 administered as a 1-hr IV infusion at a starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle, in combination with abiraterone acetate 1000 mg by mouth (PO) daily (QD) and prednisone or prednisolone 5 mg PO twice daily.
3283309|NCT01685281|Active Comparator|Metadoxine (MG01CI) 1400 mg|single dose of Metadoxine (MG01CI) 1400 mg
3283310|NCT01685281|Active Comparator|Metadoxine (MG01CI) 700 mg|Single dose of Metadoxine (MG01CI) 700 mg
3283311|NCT01685281|Placebo Comparator|Placebo|Single dose of Placebo
3283312|NCT01685294|No Intervention|Treatment as Usual (TAU)|Standard prison mental health treatment instead of the research groups, including individual therapy, medication, etc.
3283313|NCT01685294|Experimental|Group Interpersonal Psychotherapy (IPT) for Depression + TAU|Participants will receive Group IPT for Depression + TAU.
3283314|NCT01685307|Experimental|intense cooking process|Test meal: 150g of beef cooked at intense temperature. Beef proteins are intrinsically labelled with 15 N protein
3283315|NCT01685307|Experimental|mild cooking process|Test meal: 150 g of beef cooked at moderate intensity. Beef proteins are intrinsically labeled with 15N.
3283316|NCT01685333|Other|Group A|First Period: Test Drug (Epoetin Alfa) Second Period: Comparator Drug
3283317|NCT01685333|Other|Group B|First period: Comparator drug Second Period: Test drug (Epoetin alfa)
3283318|NCT01685346|Experimental|Biofeedback|biofeedback-mediated stress management (BFSM)
3283319|NCT01685359|Experimental|Test Drug|Test Drug (Human Recombinant Epoetin alfa - Blau) dosage: 100 IU/kg intravenous administration
3283320|NCT01685359|Active Comparator|Eprex|Eprex (Janssen-Cilag, Epoetin alfa) dosage: 100 IU/kg intravenous administration
3283321|NCT01685385|Active Comparator|Diagnostic intervention group A|Patients who will receive the BNP test
3283322|NCT01685385|No Intervention|Group B|Patients who will not receive the BNP test.
3283323|NCT01685398|Placebo Comparator|normal saline|normal saline 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
3283324|NCT01685398|Experimental|0.5% timolol maleate eye drop|0.5% timolol maleate solution 1-2 drops put on the hemangioma lesion 4 times a day and rub over the entire lesion with a finger
3283325|NCT01685424||Etoricoxib Prescription (Period 1)|First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005
3283326|NCT01685424||Etoricoxib Prescription (Period 2)|First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015
3283327|NCT01685424||Repeat Etoricoxib Prescription|One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2.
3283328|NCT01685450|Other|Intracranial pressure|
3283329|NCT01685476|Other|Intracranial pressure|
3283330|NCT01685489|Experimental|Docetaxel, PSK®|A 21-day lead-in oral PSK alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 evey 3 weeks for three cycles. After the third dose of docetaxel, study drug will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
3283331|NCT01685489|Placebo Comparator|Docetaxel, Placebo|A 21-day lead-in oral placebo alone is followed by the addition of standard intravenous docetaxel at 75 mg/m2 every 3 weeks for three cycles. After the third dose of docetaxel, the placebo will be discontinued on day 14 to allow for a 7-day washout period before a fourth dose of docetaxel is administered.
3283332|NCT01685502||Group 1|Patients treated with Glucobay OD under practical manner
3283333|NCT01685515|Experimental|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Tetrahydrouridine
3283334|NCT01685515|Placebo Comparator|Placebo|Placebo
3283335|NCT01685528|Experimental|CBT|
3283336|NCT01685541|Experimental|Maximum AVS Content|AVS includes patient name, visit date, chief complaining, allergies, immunizations, vital signs, medications, problem list, lab order, physician contact information, referrals, instructions
3283337|NCT01685541|Experimental|Intermediate AVS content|AVS includes patient name, visit date, vital signs, medications, diagnosis, problem list, physician contact information, referrals, instructions
3283338|NCT01685541|Experimental|Minimum AVS content|AVS contains patient name, visit date, medications, diagnosis, physician contact information, referrals, instructions
3283339|NCT01685541|Active Comparator|Control Group (Usual AVS)|Content differed by clinic site
3283340|NCT01685554|Active Comparator|normothermic CPB|cardiopulmonary bypass with maintenance of normal body temperature
3283341|NCT01685554|Active Comparator|hypothermic CPB|cardiopulmonary bypass using mild hypothermia
3283342|NCT01685580|Experimental|Manufacturer VPAP ST|7 days minimum non-invasive ventilation at 2 levels of pressure (BPAP) to the intervention.
3283343|NCT01685580|No Intervention|No intervention|usual advice
3283344|NCT01685593|Sham Comparator|regular bandage|no abdominal binder
3283345|NCT01685593|Experimental|abdominal binder|binder
3283346|NCT01685619||AML Cohort|This cohort is comprised of participants who have acute myelogenous leukemia (AML).
3283347|NCT01685619||MDS Cohort|This cohort is comprised of participants who have myelodysplastic syndrome (MDS).
3283348|NCT01685632|Active Comparator|Surgery with IPCH|Patients having an IPCH (Intra Peritoneal Chemo Hyperthermia) during the surgery time
3283349|NCT01685632|Sham Comparator|patients without IPCH|Patients recused for the surgery due to intraoperative contraindication
3283350|NCT01685645|Experimental|Study population|"The study population consists of male and female patients admitted for programmed major knee surgery (arthroplasty) with a truncal analgesic block (femoral nerve block with a sciatic block) and operated under general anesthesia.~See inclusion and exclusion criteria.~Intervention: AlgiScan"
3283351|NCT01685658|Active Comparator|Ketaprofen|"Patients randomized to this arm will receive intravenous ketaprofen when treating renal colic.~Intervention: intravenous ketaprofen"
3283352|NCT01685658|Experimental|Paracetamol|"Patients randomized to this arm will receive intravenous paracetamol when treating renal colic.~Intervention: intravenous paracetamol"
3283353|NCT01685671|Active Comparator|NESP 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3283354|NCT01685671|Experimental|CKD-11101 60μg|Prefilled syringe filled with Darbepoetin alfa 60μg
3283355|NCT01685710|Experimental|GTN patch|GTN patch 5mg, in situ 24hrs
3283356|NCT01685710|Placebo Comparator|Placebo patch|Placebo patch, in situ for 24hrs
3283357|NCT01685723|Experimental|Counseling group|"Subjects in this group will receive a face-to-face individualized brief advice based on risk communication for 15-30 minutes from the nurse counselors and a booster intervention (10-15 minutes) at 1 week.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone.Ten subjects from the intervention group who have not quitted will be invited for a process evaluation in the form of face-to-face interviews by research assistants at 12-month follow-up."
3378283|NCT02851706||1/Patients with CNS Tumors|Patients with CNS tumors (or a history) including those with undiagnosed imaging abnormalities in the CNS; and patients with known genetic syndromes at high risk of developing CNS Cancers.
3283358|NCT01685723|Sham Comparator|General supporting|"Subjects in this group will receive standard care without risk communication.~Data collection will be conducted at 1 week, 1, 3, 6, 9, 12 months via telephone."
3283359|NCT01685749||Enrolled participants|The targeted study population will include all people at Seal Beach who have been identified by the Seal Beach Lifeguards to have been stung by a jellyfish over the course of one year who are adults or children whose parent or guardian is present at the time of the injury. Children and pregnant women are included in the group.
3283360|NCT01685762|Experimental|Metformin|Metformin once daily for 4 weeks (weeks 1-4) and then twice daily for 8 weeks (weeks 5-12).
3283361|NCT01685775|Experimental|Transvaginal/transumbilical cholecystectomy|Transvaginal/transumbilical group: we will use a 5 mm trocar in the umbilicus and a 10 mm trocar together with a 5 mm seizing forceps through the posterior vaginal vault to perform the cholecystectomy in the Zornig style
3283362|NCT01685775|Active Comparator|Needlescopic cholecystectomy|Needlescopic cholecystectomy with 3 trocars: we will use two 2-3 mm working trocars and one 10 mm optic trocar, its access is also used for extraction of the gallbladder
3283363|NCT01685788||study participants|
3283364|NCT01685814|Active Comparator|single stem cell transplant, 3-year lenalidomide maintenance|Arm A
3283365|NCT01685814|Experimental|tandem autologous transplant, lenalidomide maintenance|Arm B
3283366|NCT01685814|Active Comparator|allogeneic stem cell transplant, lenalidomide maintenance|Arm C
3283367|NCT01685814|Experimental|tandem autologous transplant|Arm D
3283368|NCT01685827|Active Comparator|NECT (Nifurtimox Eflornithine Combination Therapy)|"Nifurtimox tablets will be given orally three times a day, at the daily dose of 15 mg/kg/day, for 10 days.~Eflornithine (400 mg/kg/day) will be given twice daily for 7 days, as a 2-hour IV infusion."
3283369|NCT01685827|Experimental|Fexinidazole|"Fexinidazole, 600 mg tablets given by oral route, after the main daily meal (within 30 minutes from the start of the meal), at the daily dose of:~1 800 mg (3 tablets) once a day for 4 days,~Followed by 1 200 mg (2 tablets) once a day for 6 days. Total duration of treatment will be 10 days."
3283370|NCT01685853|Active Comparator|PEG 4 litres split|Polyethylene glycol with electrolytes (PEG)
3283371|NCT01685853|Experimental|Bisacodyl plus PEG-CS|Bisacodyl plus PEG-CS: Bisacodyl plus Polyethylene glycol with citrate and simethicone (PEG-CS)
3283372|NCT01685866|Other|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
3283373|NCT01685866|No Intervention|no medical device|in the second arm, we use no medical device
3283374|NCT01685879|Experimental|High Amylose Rice 1|Test rice with high dietary fiber content
3283375|NCT01685879|Experimental|High Amylose Rice 2|Test rice with high dietary fiber content
3283376|NCT01685879|Placebo Comparator|Control Rice|Rice portion that contains 50 g carbohydrate.
3283377|NCT01685879|Placebo Comparator|Glucose beverage|Glucose beverage with 50 g carbohydrate
3283378|NCT01685892|Experimental|Dose-Finding: Schedule A: Relapsed/Refractory CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
3283379|NCT01685892|Experimental|Dose-Finding: Schedule B: Relapsed/Refractory CLL|In 4 cohorts of participants with relapsed/refractory CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
3283380|NCT01685892|Experimental|Dose-Finding: Schedule A: Previously Untreated CLL|All 4 cohorts will begin venetoclax administration after the ramp-up period of 5 weeks. In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule A, venetoclax will be introduced before obinutuzumab. Schedule A will be explored prior to Schedule B.
3283381|NCT01685892|Experimental|Dose-Finding: Schedule B: Previously Untreated CLL|In 4 cohorts of participants with previously untreated CLL escalating doses of venetoclax will be administered in combination with fixed dose obinutuzumab in the dose-finding stage. In Schedule B, venetoclax will be introduced after obinutuzumab. Schedule A will be explored prior to Schedule B.
3283382|NCT01685892|Experimental|Safety Expansion: Relapsed/Refractory CLL|In participants with relapsed/refractory CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
3283383|NCT01685892|Experimental|Safety Expansion: Previously Untreated CLL|In participants with previously untreated CLL a recommended dose of venetoclax will be administered in combination with obinutuzumab in the safety expansion stage. Schedule A or B will be used for the expansion cohort after a review of available safety data from the dose finding stage.
3283384|NCT01685931|Experimental|Paliperidone Palmitate|
3283385|NCT01685944|Placebo Comparator|Placebo|
3283386|NCT01685944|Experimental|Live Pediococcus pentosaceus LP28|
3283387|NCT01685944|Experimental|Heat-killed Pediococcus pentosaceus LP28|
3283388|NCT01685957|Active Comparator|Standard dietary treatment (STD)|Dietary treatment - 6 individual sessions with a registered dietitian
3283389|NCT01685957|Experimental|"Ned i vaegt (NIV)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
3283390|NCT01685957|Experimental|"Verdens bedste kur (VBK)"|Dietary treatment - 3 individual sessions and 3 group sessions. All sessions with a registered dietitian.
3283391|NCT01685970|Placebo Comparator|High volume Split-dose PEG|Patients who are scheduled afternoon colonoscopy ingest high volume split-dose PEG for bowel preparation
3283392|NCT01685970|Active Comparator|2 sachets of picosulfate|Patients who are scheduled afternoon colonoscopy ingest 2 sachets of picosulfate at the day of colonoscopy.
3283393|NCT01686009|Experimental|Intra-nasal ketamine|0.5 mg/kg ketamine intra-nasally; then 0.25 mg/kg repeat dose after 10 minutes if necessary
3283394|NCT01686022||Pollen Allergy|Pollen allergy and control will have the same intervention, ie. Skin prick test and collect serum samples.Then measure the specificIgE, immunoblot, and ELISA inhibition
3283395|NCT01686061||Blepharospasm Survey Group|
3283396|NCT01686074||Chronic fatigue syndrome|
3283397|NCT01686074||fibromyalgia|
3283398|NCT01686074||chronic fatigue syndrome + fibromyalgia|
3283399|NCT01686074||healthy sedentary control|
3283400|NCT01686087|Active Comparator|Continuation of SRI|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to stay on SRI. They will receive 45 minute EX/RP booster sessions once per month.
3283401|NCT01686087|Placebo Comparator|Replace SRI w/placebo|Patients who achieve minimal to mild OCD symptoms and are not currently depressed at end of preparatory phase will be randomized to gradual replacement with pill placebo. They will receive 45 minute EX/RP booster sessions once per month.
3283402|NCT01686100|Active Comparator|No touch vein grafts|The grafts were harvested with there surrounding tissues.
3283403|NCT01686100|Active Comparator|Conventional vein grafts.|The grafts were stripped from surrounding tissue.
3283404|NCT01686113|Experimental|NEFA|Participants swish and spit 5 mL of an oleic acid solution everyday for 10 days.
3283405|NCT01686113|Active Comparator|Control|Participants swish and spit 5 mL of sucrose solution everyday for 10 days.
3283406|NCT01686126|Experimental|Mirena + Metformin|Metformin tablets, 500mg twice daily orally, 6 months Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
3283407|NCT01686126|Experimental|Mirena|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months
3283408|NCT01686126|Experimental|Mirena + Weight Loss Intervention|Levonorgestrel (Mirena®) 52mg Intrauterine drug delivery system, 6 months Weight Loss Intervention will be delivered via Weight Watchers
3283409|NCT01686139|Experimental|ABDM-MSC|"The patient will receive multiple injections in one session during the study. The injections will take place in the chronic wound bed and in the third distal part of the treated shin (in the form of a ring).~Maximal amount of ABMD-MSC cells injected: 10-20*10^6 cells (up to volume of 20mL, depending on the wound size & patient weight)."
3283410|NCT01686178|Experimental|Anti-smoking social marketing campaign|"In prior research, a high risk subpopulation of young adults was identified in San Diego, CA: the hipster subculture. We developed a yearlong pilot social branding intervention to decrease smoking among this group, using social events and social leaders to promote a strong nonsmoking lifestyle. The intervention rationale is based on utilizing industry market research tools to define the target audience and directly countering tobacco industry lifestyle marketing strategies. We now propose to extend this intervention to three other cities (tailoring the intervention to a high-risk subpopulation of young adults in each city) and evaluate it in a multicenter quasi-experimental controlled trial."
3283411|NCT01686178|No Intervention|Control|Survey research data will be collected in control cities with the same schedule as data collection in the cities where the intervention is taking place.
3283412|NCT01686191||Cardiac transplant recipients|
3283413|NCT01686204|Active Comparator|Non-obese individuals|Daily consumption of 12 oz lowfat yogurt or soy pudding for 9 weeks.
3283414|NCT01686204|Experimental|Obese individuals|Consumption of 12 oz of soy pudding or low fat dairy yogurt daily for 9 weeks.
3283415|NCT01686217|Experimental|Dose Group 1 Treatment A|Lowest per tablet dose of ASP015K Extended Release (ER) tablets under fasted conditions
3283416|NCT01686217|Active Comparator|Dose Group 1 Treatment B|Medium per tablet dose ASP015K Immediate Release (IR) tablets under fasted conditions for comparison to lowest dose ER fasted conditions
3283417|NCT01686217|Experimental|Dose Group 1 Treatment C|Lowest per tablet dose of ASP015K ER tablets under fed conditions
3283418|NCT01686217|Experimental|Dose Group 2 Treatment D|Medium per tablet dose of ASP015K ER tablets under fasted conditions
3283419|NCT01686217|Active Comparator|Dose Group 2 Treatment E|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to medium dose ER fasted conditions
3283420|NCT01686217|Experimental|Dose Group 2 Treatment F|Medium per tablet dose of ASP015K ER tablets under fed conditions
3283421|NCT01686217|Experimental|Dose Group 3 Treatment G|Highest per tablet dose of ASP015K ER tablets under fasted conditions
3283422|NCT01686217|Active Comparator|Dose Group 3 Treatment H|Medium per tablet dose of ASP015K IR tablets under fasted conditions for comparison to highest dose ER under fasted conditions
3283423|NCT01686217|Experimental|Dose Group 3 Treatment I|Highest dose of ASP015K ER tablets under fed conditions
3283424|NCT01686230|Experimental|acupoints on specific meridian|Acupuncture plus foundation treatment。 We Select specific acpupoints on the heart and pericardium meridian.
3378284|NCT02851147||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
3378285|NCT02840448||Case|Subjects with WS/SVAS
3283425|NCT01686230|Active Comparator|acupoints on the other meridian|Acupuncture plus foundation treatment。We choose the acupoints on the other meridian。
3283426|NCT01686230|Sham Comparator|sham acupoints|Acupuncture plus foundation treatment。We use sham acupoints。
3283427|NCT01686230|Other|waiting-list|wait for the treatment，Only basic treatment, We will not treat the participants until they complete all the observations.
3283428|NCT01686243|Experimental|"echogenic 17G tuohy needles  Pajunk TuohySono"|Epidural will be placed with the aid of ultrasound and echogenic 17G Tuohy needles (Pajunk TuohySono).
3378286|NCT02840448||Controls|Healthy Volunteers
3283429|NCT01686243|Placebo Comparator|standard epidural needles|Epidural will be placed in standard practice with standard needles.
3378287|NCT02839733||Cerebral Palsy|Children and young adults with Cerebral Palsy.
3378288|NCT02839733||Healthy Volunteers|Children and young adults healthy volunteer
3378289|NCT02830308||Adults with known or suspected endocrine or metabolic dissorde|Adults with known or suspected endocrine or metabolic dissorders
3378290|NCT02821806||Cohort 1|Healthy Volunteers
3378292|NCT02810405||1/Patient Samples|Patients treated at NCI with available tissue samples
3378293|NCT02796261|Experimental|Eflornithine + Lomustine|Eflornithine dosed on a 2 weeks on, 1 week off schedule + Lomustine dosed every 6 weeks
3378294|NCT02796261|Active Comparator|Lomustine|Lomustine dosed every 6 weeks
3283430|NCT01686256|Experimental|Tc 99m EC20|A Phase 1, multi-center, open-label, single-treatment group, baseline-controlled (for safety) study designed to verify product safety, determine optimal imaging time, gather efficacy data for the radioactive drug product (Technetium Tc 99m EC20), and assay masses for presence of folate receptors, in women with suspected ovarian or endometrial cancer. Twelve subjects will be enrolled, with a minimum of five malignant cases, as determined by histopathological evaluation.
3283431|NCT01686282|Placebo Comparator|Placebo|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
3283432|NCT01686282|Experimental|Blueberry|8 weeks of freeze-dried blueberry powder taken in two doses of 22g each per day.
3283433|NCT01686295|Experimental|iRestore Hair Rejuvenation System|Seventy six (76) subjects will be enrolled in the 24-week study; of which 38 will be male and 38 will be female using the iRestore hair growth device
3283434|NCT01686295|Sham Comparator|Sham Device Arm|This study arm will use a sham device consistent with the experimental device with 12 men and 12 women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
3283435|NCT01686308|Active Comparator|Conventional Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
3378296|NCT02774746|Active Comparator|35-week delivery group|Subjects to be delivered at 35 0/7 weeks through 35 6/7 weeks.
3378297|NCT02774746|Active Comparator|38-week delivery group|Subjects to be expectantly managed to spontaneous delivery, delivered by 38 0/7 weeks through 38 6/7 weeks.
3378298|NCT02771236||Affected Participants|Participants with inherited eye diseases
3378299|NCT02771236||Unaffected family members|Family members without eye disease
3283436|NCT01686308|Experimental|Yellow Intra Ocular Lens (IOL)|Standard minimal incision cataract surgery by phacoemulsification and posterior intraocular lens implantation.
3283437|NCT01686321|Experimental|Bendamustine and subcutaneous Rituximab|single-arm non randomized
3283438|NCT01686334|Experimental|DC vaccine|Vaccination with autologous WT1 mRNA-electroporated DCs plus follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment in combination with DC vaccination.
3283439|NCT01686334|No Intervention|Control arm|Follow-up care. Patients receiving low-intensity chemotherapy are allowed to continue this treatment during the follow-up care
3283440|NCT01686347|Other|fetal cardiac rhythm abnormally|patient at term, in spontanous labor with fetal cardiac rythm abnormally which occurs 30 minutes after the epidural analgesia induction
3283441|NCT01686347|Other|control group|patient at term, spontaneous labor, without any fetal cardiac rhythm abnormalies during the 30 minutes after the epidural analgesia induction
3283442|NCT01686360|No Intervention|Control group 1: pre/post-test|Group receives pre and post test questions only.
3283443|NCT01686360|Experimental|Control group 2: tool and pre/post-test|Group receives decision tool without personalized information. (Behavioral: Decision Aid)
3283444|NCT01686360|Experimental|Gail score in a percentage format|Group receives Gail score in a percentage format. (Behavioral: Decision Aid)
3283445|NCT01686360|Experimental|Gail score in a frequency format|Group receives Gail score in a frequency format. (Behavioral: Decision Aid)
3283446|NCT01686360|Experimental|Frequency + Average 50 year old|Group receives Gail score in a frequency format as well as information about risk of breast cancer for the average 50 year old woman. (Behavioral: Decision Aid)
3378301|NCT02769117|Active Comparator|Ultrasound on fractured bone|An ultrasound technique will be used to record the acoustic response of the fractured bone at each clinical visit until the fracture is healed. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm on either sides of the fracture. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fracture and on the unaffected (contralateral) bone as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
3378302|NCT02769117|Active Comparator|Ultrasound on contralateral intact bone|An ultrasound technique will be used to record the acoustic response of the intact bone as control at each clinical visit. The ultrasound probe and a small hydrophone are placed on the exposed portion of the forearm or clavicle. The ultrasound intensity will be at the safe level according to the FDA regulation. Investigators will conduct the tests on the fractured forearm/clavicle and on the unaffected (contralateral) forearm/clavicle as the control. Typically this is at 1-, 2-, 4-, and 6- weeks following the fracture.
3283447|NCT01686360|Experimental|Frequency + Mammography Data|Group receives Gail score in a frequency format as well as information about the risks of mammography. (Behavioral: Decision Aid)
3283448|NCT01686360|Experimental|Frequency + Mortality Data|Group receives Gail score in a frequency format as well as information about mortality benefit of mammography. (Behavioral:Decision Aid)
3283449|NCT01686360|Experimental|Frequency + Avg 50 year old + Mamm Data + Mortality Data|Group receives Gail score in a frequency format as well as information about breast cancer risk for the average 50 year old woman, information about the risks of mammography, risk of breast cancer for the average 50 year old woman, and information about the mortality benefit associated with mammography. (Behavioral: Decision Aid)
3283450|NCT01686386|Experimental|Dose escalation benda lena dexa|"Phase I: Participants will be treated in groups (cohorts) of three to six subjects per cohort, according to a modified Fibonacci design. The dose of Bendamustine and Lenalidomide (from 0 to 5) will be increased from one cohort to the next. Regardless of the treatment cohort, participants will receive treatment in cycles lasting 28 days. In the first phase of the study, the dose of B and L given with will be gradually escalated to reach the MTD.~Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days."
3283451|NCT01686399|Experimental|The study has a single arm|The study has one arm The whole population of the campus will be exposed to the intervention. the effectiveness will be assessed using a random selection twice - before and after the intervention
3283452|NCT01686412|Active Comparator|Healthy patients|
3283453|NCT01686412|Active Comparator|Oncology patients|
3283454|NCT01686425|Active Comparator|Percutaneous Transhepatic cholangiography|
3283455|NCT01686425|Active Comparator|Endoscopic Ultrasound guided biliary drainage|
3283456|NCT01686464|Experimental|Magnetic - Oxygen|Magnetic and Oxygen Treatment for Bell's Palsy
3283457|NCT01686464|Active Comparator|prednisone - valacyclovir|prednisone and valacyclovir treatments for bell palsy
3283458|NCT01686477|Active Comparator|Unfortified Human Donor Milk|Used to make up any shortfall in mother's own milk
3283459|NCT01686477|Active Comparator|Fortified Human Donor Milk|Used to make up any shortfall in mother's own milk
3283460|NCT01686477|Active Comparator|Preterm Formula|Used to make up any shortfall in mother's own milk
3283461|NCT01686490|Other|D.|The focus is evaluation of LifeSkills Video/Workbook for patients about to receive an AICD. Patients who now have received their AICD were given a video/workbook pre-implantation as an intervention to reduce their concerns/distress. After implantation, they will be asked what was and was not helpful about the materials they received.
3283462|NCT01686529|Experimental|One subconjunctival injection|Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
3283463|NCT01686529|Experimental|Two subconjuctival injections|Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
3283464|NCT01686529|Active Comparator|Conventional treatment|Autoconjunctival grafting without subconjuntival bevacizumab injection
3283465|NCT01686542|Experimental|CPVI+RSM group|Circumferential pulmonary vein isolation (CPVI) plus renal sympathetic modification for atrial fibrillation ablation.
3283466|NCT01686542|Active Comparator|CPVI group|Circumferential pulmonary vein isolation is done alone for atrial fibrillation.
3283467|NCT01686555|Experimental|Single Dose|Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
3283468|NCT01686555|Experimental|Multiple Dose|Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)
3283469|NCT01686594|Active Comparator|PUVA maintenance treatment|Psoralen plus UVA (PUVA) treatment. The patients receive a standardized dose of oral 8-methoxypsoralen (Oxsoralen) 1 hour before UVA exposure
3283470|NCT01686594|No Intervention|No maintenance treatment|observation
3283471|NCT01686607||1) parenteral micafungin users|patients who had been treated with parenteral micafungin
3283472|NCT01686607||2) other parenteral antifungal users|patients who had been treated with a parenteral antifungal agent (not micafungin)
3283473|NCT01686620|Experimental|BIOD-123|BIOD-123 used as prandial insulin
3283474|NCT01686620|Active Comparator|Lispro (Humalog)|Lispro (Humalog) used as prandial insulin
3283475|NCT01686659|Experimental|SpHb Arm|These are the patients whose primary anesthesiologists have been allocated to treat them while having access to data from a continuous noninvasive hemoglobin monitoring device
3283476|NCT01686659|No Intervention|Control Arm|These are the patients whose primary anesthesiologists have been allocated to treat them without having access to data from a continuous noninvasive hemoglobin monitoring device
3283477|NCT01686672|Experimental|Web Intervention|BeInCharge has two components: an electronic diet tracker and a 7 session intervention. The 7 treatment sessions are designed to be completed over a 7 to 10 week period. Each treatment module includes both a nutrition education and child behavior management component. Treatment sessions should be completed every 7 to 10 days, while the electronic diet tracker requires daily input.
3283478|NCT01686672|No Intervention|Usual Care|Participants will receive usual care and be assessed at baseline and week 10 for study outcomes.
3283479|NCT01686698|Active Comparator|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) sachets containing 450 x 109 bacteria, 1 sachet every 12 hours during 3 months (n=20).
3283480|NCT01686698|Placebo Comparator|Placebo|Placebo sachets, 1 sachet every 12 hours during 3 months (n=20).
3283481|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 15 mg|
3283482|NCT01686711|Experimental|SYR-322 25 mg , AD-4833 30 mg|
3283483|NCT01686711|Placebo Comparator|SYR-322 25 mg , AD-4833 placebo|
3283484|NCT01686724|Other|Business as Usual (BAU)|This group receives services as usual in their schools. They will receive the intervention after follow-up measures are gathered.
3283485|NCT01686724|Experimental|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
3378303|NCT02769000|Experimental|Subjects 1-30|15 subjects in each RT dose schedule 10 GY in 5 daily fractions 20 GY in 10 daily fractions
3283486|NCT01686737|Experimental|Yoga|"Iyengar Yoga~12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
3283487|NCT01686737|Active Comparator|Aerobic exercise|"Walking~12 weeks of walking~2 weekly sessions of 60 minutes"
3283488|NCT01686737|No Intervention|Usual Care|
3283489|NCT01686763||subarachnoid hemorrhage disease|subarachnoid hemorrhage patients
3283490|NCT01686776|Active Comparator|123 I-HSA + 125 I-HSA|Healthy Volunteers, N=16
3283491|NCT01686776|Experimental|123 I- HSA + 125 I-HSA|Patients, planned for elective Major Abdominal Surgery, N=16
3283492|NCT01686776|Experimental|123-I-HSA+125 I-HSA|Patients, with a acute pancreatitis or cholecystitis, N=16
3283493|NCT01686789|Active Comparator|Pegylated interferon alpha-2a plus standard dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus standard dose ribavirin 100-1200 mg/day for 48 weeks
3283494|NCT01686789|Experimental|Pegylated interferon alpha-2a 180 mcgs adjusted dose ribavirin|Pegylated interferon alpha-2a 180 mcg weekly plus adjusted dose ribavirin for 48 weeks
3283495|NCT01686802|Active Comparator|ibuprofen|ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
3283496|NCT01686802|Active Comparator|oral morphine|oral morphine 0.5 mg/kg (max 20 mg) every 6 hours as needed for pain (maximum 8 doses) from the time the patient is discharged from hospital as deemed by the physician to a maximum of 48 hours.
3283497|NCT01686815||Olanzapine|Olanzapine-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3283498|NCT01686815||Risperidone|Risperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3283499|NCT01686815||Iloperidone|Iloperidone-treated patients with serious mental illness, such as schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, psychosis NOS, delusional disorder or paranoid disorder.
3283500|NCT01686841|Experimental|Fat Reduction|
3283501|NCT01686854|Experimental|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
3283502|NCT01686854|Active Comparator|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
3283503|NCT01686867|Experimental|Commercially-made followed by locally-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. Four months later the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
3283504|NCT01686867|Experimental|Locally-made followed by commercially-made improved cookstove|Following a four month run-in period using their traditional, open-fire cookstoves, the investigators will install a locally-made improved, ventilated cookstove in each patient's kitchen. Four months later the investigators will install a commercially-made improved, ventilated cookstove (Envirofit G-3300/G-3355) in each patient's kitchen. During each of the two periods, the investigators will request that the patient uses the improved, ventilated cookstove installed for that period.
3283505|NCT01686880|Experimental|Preoperative aTARE|The patients in this arm will receive Sirsphere trans-arterial radioembolization before surgery
3283506|NCT01686893|Active Comparator|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
3283507|NCT01686893|Active Comparator|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
3283508|NCT01686906|Experimental|Bowman layer graft implantation|
3283509|NCT01686919|Experimental|milk-free|morbidly obese patients with irritable bowel syndrome (IBS) eligible for gastric bypass surgery
3283510|NCT01686945|Experimental|Healthy - 20 mg|
3283511|NCT01686945|Experimental|Healthy - 40 mg|
3283512|NCT01686945|Experimental|Healthy - 60 mg|
3283513|NCT01686945|Experimental|T2D - 20/40/60 mg|
3283514|NCT01686971||questionaire|patients will receive a questionaire and speak to a nurse regarding their needs and/ or demands.
3283515|NCT01686984|Experimental|Altered breath|The group where the investigators alter the inspiratory and expiratory aspects of a ventilated breath.
3283516|NCT01686997|Active Comparator|Primairy long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic Limb 150 cm
3283517|NCT01686997|Active Comparator|Redo Long biliopancreatic limb RYGB|Roux limb 75 cm and Biliopancreatic limb 150 cm
3283518|NCT01686997|Active Comparator|Primairy standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
3283519|NCT01686997|Active Comparator|Redo standard RYGB|Roux limb 150 cm and Biliopancreatic limb 75 cm
3283520|NCT01687023||Tai Chi|Healthy Tai Chi practitioners
3283521|NCT01687049|Experimental|red yeast rice (RYR)|Two RYR capsules three times daily for a minimum of 6 months
3283522|NCT01687062|Active Comparator|FeSO4 + high phytate|injera test meal 1 labeled with a 4 mg staple iron isotope tag
3283523|NCT01687062|Experimental|FeSO4 + medium phytate|injera test meal 2 labeled with a 4 mg staple iron isotope tag
3283524|NCT01687062|Experimental|FeSO4 + low phytate|injera test meal 3 labeled with a 4 mg staple iron isotope tag
3283525|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:1) + high phytate|injera test meal 4 labeled with a 4 mg staple iron isotope tag
3283526|NCT01687062|Experimental|FeSO4 + NaFeEDTA (1:3) + high phytate|injera test meal 5 labeled with a 4 mg staple iron isotope tag
3283527|NCT01687075|Experimental|CR8|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
3283528|NCT01687127|Experimental|Folic acid supplementation|Folic acid will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism.
3378304|NCT02767986||Spanish-speaking Latinas|Women who speak Spanish as their primary language
3283529|NCT01687127|Experimental|5-MTHF supplementation|"The calcium salt of 5-methyltetrahydrofolate (5-MTHF; Brand name Metafolin) will be given orally in form of tablets. A supplement of 1 mg will be taken daily for 12 weeks. Thereafter, a supplement of 5 mg will be taken daily for 12 weeks (i.e., until Week 24). At baseline, Week 12, and Week 24, subjects will receive a 9-hour primed constant infusion of amino acids in saline solution for quantification of kinetics of one-carbon metabolism."
3283530|NCT01687140|Placebo Comparator|Placebo|Participant takes one pill of placebo a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
3283531|NCT01687140|Active Comparator|DCS|Participant takes one pill of D-Cycloserine a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
3283532|NCT01687192|Experimental|Girls and young womens receiving immunosuppressive treatment|
3283533|NCT01687205|Active Comparator|Group 1|Single Dose/1 hour before and 1 hour after sex (BAT) Cohort
3283534|NCT01687205|Active Comparator|Group 2|Multiple Dose Cohort
3283535|NCT01687231|No Intervention|Neutropenic Diet|This arm is the control and subjects will receive the standard of care neutropenic diet.
3283536|NCT01687231|Experimental|Non-neutropenic Diet|This arm is interventional and subjects will receive a non-neutropenic diet without restriction.
3283537|NCT01687309|Other|Cohort A fed session|GSK2586184 800mg single dose with food
3283538|NCT01687309|Other|Cohort A fasted session|GSK2586184 single dose without food
3283539|NCT01687309|Active Comparator|Cohort B active study medication|GSK2586184 800mg single and twice daily dose for 13 days
3283540|NCT01687309|Placebo Comparator|Cohort B placebo|Placebo-to-match single and twice daily dose for 13 days
3283541|NCT01687322||total hip replacement, quality of life, functioning|
3283542|NCT01687335||cancerous patients|the patients benefiting from treatment by chemotherapy.
3283543|NCT01687348|Experimental|lidocaine|lidocaine traitment
3283544|NCT01687361|Experimental|branched-chain amino acids (BCAA) supplementation|
3283545|NCT01687361|Placebo Comparator|PLACEBO|
3283546|NCT01687374|Placebo Comparator|Placebo|
3283547|NCT01687374|Experimental|Parathyroid hormone|
3283548|NCT01687426|Active Comparator|Brimonidine Tartrate 0.025%|
3283549|NCT01687426|Placebo Comparator|Vehicle|
3283550|NCT01687439|Experimental|Treatment|Eligible patients receive one cycle of Endostar monotherapy, two cycles of Endostar combined with chemotherapy (vinorelbine plus cisplatin) treatment, followed by Endostar plus radiotherapy treatment.
3283551|NCT01687452|Experimental|Groupe A|Infected by the HIV Innocents of antiretroviral treatment, with a viral plasmatique load > 1000 copies / ml
3283552|NCT01687452|Experimental|group B|Infected by the HIV whith antiretroviral treatment for at least 6 months,, with a viral plasmatique load > 40 copies / ml
3283553|NCT01687452|Placebo Comparator|group C|Healthy volunteers
3283554|NCT01687465|Active Comparator|Argon laser trabeculoplasty|Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.
3283555|NCT01687465|Active Comparator|selective laser trabeculoplasty|Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
3283556|NCT01687491|Active Comparator|Enoxa|ENOXA® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
3283557|NCT01687491|Active Comparator|Lovenox|LOVENOX® Anti-Xa/kg 100 IU by subcutaneous injection every 12 hours
3283558|NCT01687517|Experimental|Patient|90 patients suffering from sarcoidosis
3283559|NCT01687517|Active Comparator|Volunteer|100 volunteers
3283560|NCT01687530|Experimental|AMCA bone membrane|AMCA Bone is manufactured from Polyethylene Glycol 400 and Ammonio Methacrylate copolymer type A (Eudragit RL 100) materials.
3283561|NCT01687543|Experimental|Probiotics|Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups
3283562|NCT01687543|Placebo Comparator|Control|Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups
3283563|NCT01687556|Active Comparator|Topical EGCG 1%|Seventeen subjects were designated to use 1% EGCG .Since baseline visits, affected areas of randomly allocated half sides were treated with 1% solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
3283564|NCT01687556|Experimental|topical EGCG 5%|Eighteen subjects were designated to use 5% EGCG, to evaluate a dose-response relationship. Since baseline visits, affected areas of randomly allocated half sides were treated with 5% EGCG solution twice daily, whereas those of the opposite sides were treated with vehicle only (3% ethanol).
3283565|NCT01687569|Placebo Comparator|Control Cracker|Base cracker snack
3283566|NCT01687569|Experimental|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
3283567|NCT01687569|Experimental|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
3283568|NCT01687582|Experimental|GLP-1 analog|Liraglutide, 0.6 to 1.8 mg per day or Exenatide, 5 to 10 µg twice a day.
3283569|NCT01687608|Experimental|AskBio009 Dose Escalation|Single Dose of a Self-Complementing Optimized Adeno-associated Virus (AAV) Serotype 8 Factor IX Gene Therapy
3283570|NCT01687621||Neonates, 1 to 10 days old|Neonates between day 1-10 of life presenting to hospitals and community health centers in Southern Province, Zambia, with no prior diagnosis of omphalitis, whose guardian, aged 15 and above, is willing to allow their newborn to participate in the study.
3283571|NCT01687634|Experimental|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
3283572|NCT01687634|Experimental|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
3283573|NCT01687647|Other|Screening|Paired-design: low-dose CT scan, sputum sample and blood test will be performed on all subjects.
3283574|NCT01687660|Experimental|acupoint-meridian group|Apply traditional acupuncture to prevent the migraine attack according to TCM theory
3283575|NCT01687660|Other|sham-acupoint group|sham-acupoint will be penetrated for migraine prophylaxis.
3283576|NCT01687660|No Intervention|waiting list|No acupuncture nor other methods will be conducted in this group.
3283577|NCT01687686||All cohort|Initially healthy patients in General Practise Research Database (GPRD) meeting the inclusion criteria at any point between 1st January 2001 and 25th March 2010
3283578|NCT01687699|Experimental|spironolactone|
3283579|NCT01687725||Renal denervation|Renal denervation using Symplicity Catheter system
3283580|NCT01687738|Experimental|Communication Intervention|Specially trained communicator addresses factual understanding and elicits other barriers to care
3283581|NCT01687738|Experimental|Real Time Registry and data feedback only|Patients are enrolled in registry and clinicians receive warnings about delayed or missed care.
3283582|NCT01687751|Experimental|Dexmedetomidine|Dexmedetomidine 0.2 to 1.1 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
3283583|NCT01687751|Active Comparator|Midazolam|Midazolam 10 to 100 mcg/kg/hr by continuous subcutaneous infusion for up to 10 days
3283584|NCT01687764|Experimental|CBGT+ABMT(active)|
3283585|NCT01687764|Experimental|CBGT+ABMT(placebo)|
3283586|NCT01687764|Experimental|PCI+ABMT(active)|
3283587|NCT01687764|Placebo Comparator|PCI+ABMT(placebo)|
3283588|NCT01687777|Active Comparator|Mesenchymal stem cells (MSCs)|Mesenchymal stem cells with a collagen type I membrane (OrthoADAPT)
3283589|NCT01687777|Placebo Comparator|OrthADAPT|Membrane of collagen type I (OrthoADAPT)
3283590|NCT01687803|Experimental|Physical Activity|Physical activity intervention will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
3283591|NCT01687803|Other|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
3283592|NCT01687816||No interventions to be administered|Only a nasal swab is collected, no therapeutic interventions
3283593|NCT01687829||ILM-on group|patients were scheduled to undergo macular hole surgery without internal limiting membrane (ILM) peeling
3283594|NCT01687829||ILM-off group|patients were scheduled to undergo macular hole surgery with internal limiting membrane (ILM) peeling
3283595|NCT01687842||Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
3283596|NCT01687855||OSAHS group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
3283597|NCT01687855||normal group|Subjects that underwent night Ultrafast Magnetic Resonance Imaging with obtaining a series of midline sagittal images of the upper airway .
3283598|NCT01687868|Experimental|dexmedetomidine continuous infusion|
3283599|NCT01687881|Sham Comparator|Sham Chiropractic|Sham Chiropractic manipulative therapy.
3283600|NCT01687881|No Intervention|Control group|No intervention: Control group.
3283601|NCT01687881|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active intervention: Chiropractic Spinal Manipulative Therapy
3283602|NCT01687894||Vasopressins & propofol|Administer vasopressin 0.05 or 0.07 IU/kg before sitting position during propofol anesthesia.
3283603|NCT01687894||Placebo & propofol|Administer saline 10 ml (placebo) 2 min before beach chair position during propofol anesthesia
3283604|NCT01687894||Vasopressins & sevoflurane|Administer vasopressin 0.05 or 0.07 IU/kg 2 min before beach chair position during sevoflurane anesthesia
3283605|NCT01687894||Placebo & sevoflurane|Placebo (saline 10 ml) for vasopressin is administered 2 min before beach chair position during sevoflurane anesthesia
3283606|NCT01687907|Active Comparator|Fear of childbirth, music|Patients referred to the motherhood out-patient clinic because of fear of childbirth. Advised to active music listening. Followed up by weekly and monthly diaries and three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
3283607|NCT01687907|No Intervention|Fear of childbirth, control|Patients referred to the motherhood out-patient clinic because of fear of childbirth. No intervention. Followed up by three questionnaires (when recruiting, just after the delivery and 6 months after the delivery).
3283608|NCT01687907|Active Comparator|Nulliparous, music|300 nulliparous women recruited from the ultrasound screening. Advised to active music listening. Three questionnaires like the other arms, weekly and monthly diaries like the other music group. Screening questionnaires about fear of childbirth.
3283609|NCT01687907|No Intervention|Nulliparous, control|300 nulliparous women recruited from ultrasound screening. No intervention. 3 Questionnaires as all the other groups. Screening questionnaire about fear of childbirth.
3283610|NCT01687920|Experimental|BAY94-8862 (1.25mg)|single dose BAY94-8862 IR tablet 1.25mg
3283611|NCT01687920|Experimental|BAY94-8862 (2.5mg)|single dose BAY94-8862 IR tablet 2.5mg
3283612|NCT01687920|Experimental|BAY94-8862 (5mg)|single dose BAY94-8862 IR tablet 5mg
3283613|NCT01687920|Experimental|BAY94-8862 (7.5mg)|single dose BAY94-8862 IR tablet 7.5mg
3283614|NCT01687920|Experimental|BAY94-8862 (10mg)|single dose BAY94-8862 IR tablet 10mg
3283615|NCT01687933|Experimental|three-dimensional glasses (Virtual Reality glasses)|Women in case group used the glasses for 30 minutes
3283616|NCT01687933|Experimental|usual care|Women in control group did not use the glasses.
3283617|NCT01687946||Pulmonary fibrosis in aged individuals|"Group A and B:~Patients with UIP (histologically and/or radiologically proven) providing informed consent. According to functional and radiological assessment, the disease may be either limited (Group A) or advanced (Group B). The patients are usually older than 55 years."
3283618|NCT01687946||Pulmonary fibrosis and inflammation|"Groups C and D:~Patients with HP (histologically and radiologically proven) providing informed consent. According to functional and radiological assessment, the disease will be either acute or chronic. The patients will be significantly younger (mean > 10 years) than in groups A and B."
3283619|NCT01687946||Regular wound healing in lung|Patients receiving lung biopsy or bronchoscopy for reasons other that the study and volunteers providing informed consent. The group will consist of young (18-40 years) and old individuals (older than 55 years).
3283620|NCT01687959|Active Comparator|activity of peritoneal fibrinolysis|measurements of peritoneal fibrinolysis using tissue-type plasminogen activator and its specific activity, urokinase-type plasminogen activator, and plasminogen activator inhibitor type 1
3283621|NCT01687959|Active Comparator|surgical outcomes|surgical outcomes of laparoscopic cholecystectomy
3283622|NCT01687985|Experimental|BLI801 laxative - low dose|BLI801 laxative - oral solution
3283623|NCT01687985|Experimental|BLI801 laxative - high dose|BLI801 laxative - oral solution
3283624|NCT01688011||Lower-Risk Myelodysplastic Syndromes (LR MDS)|Newly diagnosed lower risk MDS patients as determined by International Prognostic Scoring System (IPSS).
3283625|NCT01688011||Higher-Risk Myelodysplastic Syndromes (HR MDS)|Newly diagnosed higher risk MDS patients as determined by International Prognostic Scoring System (IPSS).
3283626|NCT01688011||Acute Myeloid Leukemia (AML)|Newly diagnosed AML patients (≥55 years old, excluding patients with acute promyelocytic leukemia (APL).
3283627|NCT01688011||Myelofibrosis (MF)|Newly treated MF patients receiving treatment for MF or MF-related cytopenias. This cohort also includes patients with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap syndromes, excluding juvenile myelomonocytic leukemia (JMML).
3283628|NCT01688011||Idiopathic cytopenia of undetermined significance (ICUS)|Newly diagnosed ICUS patients.
3283629|NCT01688024|Experimental|Mitomycin C|Up to 10 mg administered during each standard of care endoscopic retrograde cholangiography. No more than five mitomycin C applications per every twelve months will be given.
3283630|NCT01688024|Placebo Comparator|Normal saline|Given during each standard of care endoscopic retrograde cholangiography. No more than five normal saline applications per every twelve months will be performed.
3283635|NCT01688089|Experimental|ODM-103|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
3283636|NCT01688089|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
3283637|NCT01688089|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
3283638|NCT01688115|Experimental|Procedure|
3283639|NCT01688115|Active Comparator|Standard Care|
3283640|NCT01688128|Experimental|Intervention_Control group|Phase I: U-SMART for 4 weeks (2 session/week); Washout: for 2 weeks; Phase II: No intervention for 4 weeks
3283641|NCT01688128|Experimental|Control_Intervention group|Phase I: No intervention for 4 weeks; Washout: for 2 weeks; Phase II: U-SMART for 4 weeks (2 session/week)
3283642|NCT01688154|Active Comparator|Product 1|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)
3283643|NCT01688154|Placebo Comparator|Control product|2 empty capsules
3283644|NCT01688167|Experimental|Intervention|Experimental condition clinics offer the MC and sexual risk reduction intervention: four group counseling sessions focused on male circumcision and sexual risk reduction.
3283645|NCT01688167|No Intervention|Standard of Care|"Male participants in the standard of care control condition CHCs will receive counseling per the VCT protocol guidelines. Participants will attend four video-based time-equivalent attention-control group sessions on endemic disease prevention strategies (e.g., TB, malaria, cholera, waterborne diseases). Female partners will be invited to participate in a similar four session program devoted to endemic disease risk reduction."
3283646|NCT01688167|No Intervention|Observational|"3 CHC sites will be randomly assigned as observation only; only aggregated clinic VCT and circumcision data will be collected."
3283647|NCT01688193||HCP 1004|
3283648|NCT01688193||Vimovo 500/20mg|
3378305|NCT02762773|Experimental|Experimental|Patients will undergo non-dissection of the inferior rectus sheath at time of primary cesarean delivery
3378306|NCT02762773|Placebo Comparator|Control|Patients will undergo standard practice which is dissection of the superior and inferior rectus sheath at time of cesarean delivery
3378307|NCT02756208|Experimental|300 ug FLSC vaccine|Subjects will be vaccinated with 300 ug FLSC vaccine (highest vaccine dose) on study days 0, 28, 56 and 168.
3378308|NCT02756208|Experimental|150 ug FLSC vaccine|Subjects will be vaccinated with 150 ug FLSC vaccine (middle vaccine dose) on study days 0, 28, 56 and 168.
3283649|NCT01688206|Experimental|Vanucizumab|Participants will receive escalating doses of vanucizumab and fixed dose of vanucizumab, intravenously every 2 weeks.
3283650|NCT01688206|Experimental|Vanucizumab + Atezolizumab|Participants will receive fixed dose of vanucizumab along with atezolizumab, intravenously every 2 weeks.
3283651|NCT01688245|No Intervention|Control|No SMS dialog
3283652|NCT01688245|Active Comparator|SMS Assessments|Weekly post-weekend drinking outcome assessments
3283653|NCT01688245|Experimental|SMS Assessments & Feedback|Weekly pre-weekend drinking intention & post-weekend drinking outcome assessments with personalized feedback and harm-reduction support
3283654|NCT01688271||Anesthesiologists|
3378309|NCT02756208|Experimental|75 ug FLSC vaccine|Subjects will be vaccinated with 75 ug FLSC vaccine (lowest vaccine dose) on study days 0, 28, 56 and 168.
3378310|NCT02756208|Placebo Comparator|Placebo|Subjects will be vaccinated with placebo (control group) on study days 0, 28, 56 and 168.
3378312|NCT02743468||Healthy Volunteers|Healthy Volunteers
3283655|NCT01688284|Active Comparator|No treatment|patients with recurrent miscarriages
3283656|NCT01688284|Active Comparator|OFFICE HYSTEROSCOPY|Office hysteroscopic endometrial biopsy at the luteal phase of the menestrual cycle
3283657|NCT01688297|Experimental|Low Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet formulation.
3283658|NCT01688297|Placebo Comparator|VXA Placebo Tablet|Oral tablets of the same size and number as the vaccine tablet doses. Placebo arms were included during enrollment of each of the experimental dose groups to maintain the double-blind study design.
3283659|NCT01688297|Experimental|Medium Dose VXA-A1.1 Oral Vaccine|Two doses of replication incompetent adenovirus vaccine given in an oral tablet
3283660|NCT01688297|Experimental|High Dose VXA-A1.1 Oral Vaccine|One dose of replication incompetent adenovirus given in an oral tablet dose. This dose was studied under protocol VXA02-003.
3283661|NCT01688323||Elderly Chemorads|Elderly patients with Head and Neck Cancer who are Undergoing Chemotherapy
3283662|NCT01688349|Experimental|Cushing group|AT biopsy during partial nephrectomy
3378315|NCT02714218|Experimental|Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV|Specified dose on specified days
3283663|NCT01688349|Other|Controls1|normal weight metabolic healthy patients having partial nephrectomy with small AT Biopsy.
3283664|NCT01688349|Other|Controls2|obese individuals already included and having biopsies of VAT and SCAT stocked.
3283665|NCT01688362|Experimental|platelet-rich plasma protein (PRP)|Subjects in this group will receive 2 injections with PRP. Each injection separated by two weeks.
3283666|NCT01688362|Active Comparator|Corticosteroid|Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later.
3283667|NCT01688375|Experimental|Ursodeoxycholic acid|Ursodeoxycholic acid administration UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
3378316|NCT02714218|Experimental|Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV|Specified dose on specified days
3283668|NCT01688388|Experimental|IORT Arm|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure.
3283669|NCT01688401|Experimental|IA melphalan|IA melphalan is administered via the basilar artery.
3283670|NCT01688414|Experimental|Diagnostic (fluorescence imaging, PAI)|Patients undergo fluorescence imaging and PAI during robot assisted laparoscopic surgery.
3378317|NCT02714218|Experimental|Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg|Specified dose on specified days
3283671|NCT01688427|Experimental|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper.
3378320|NCT02702115|Experimental|Cohort 1: SB-318: Starting Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
3378321|NCT02702115|Experimental|Cohort 2: SB-318 at Next Ascending Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
3378322|NCT02702115|Experimental|Cohort 3: SB-318 at Next Ascending Dose|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
3378324|NCT02692885||Healthy Volunteers|Individuals known to have brown adipose tissue, identified by PET/CT following participation/scanning in other clinical studies
3378325|NCT02692885||Surgical Patients|Individuals undergoing planned, clinically-indicated surgeries
3378326|NCT02692846||Control participants with connective tissue disease|Not have a diagnosis of WS. Have a clinical or molecular diagnosis of connective tissue disease, between the ages of 1 and 70 years old
3283672|NCT01688427|Experimental|Standard DOVE intervention|The standard DOVE intervention has already been developed and tested (NR009093). The standard DOVE intervention is a brochure based 10 minute intervention that the home visitor reviews with the women. It consists of information about IPV, its effects on pregnancy and infant health, community resources and a plan for individual safety options. For the eMOCHA DOVE intervention, the DOVE 10 minute brochure intervention will be converted from the paper format to a visually colorful interactive presentation loaded into the home visitor device using the eMOCHA application. The format will be completely activated and implemented by the women. She uses small ear buds and a touch screen, so how she responds and interacts with the media enhanced eMOCHA DOVE intervention is private.
3283673|NCT01688440|Experimental|#1 Respiratory Care Solution|Low sodium physiologically based airway care solution.
3283674|NCT01688453|Active Comparator|Group 1:|Socially advantaged overweight or obese adolescents are allocated to the standard care management.
3283675|NCT01688453|Experimental|Group 2|Socially less advantaged overweight or obese adolescents are allocated to the standard care management.
3283676|NCT01688453|Experimental|Group 3|Socially less advantaged overweight or obese adolescents are allocated to the strengthened care management.
3283677|NCT01688479|Experimental|Calendula Weleda® cream (Weleda)|Calendula Officinalis (marigold plant) is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
3283678|NCT01688479|Active Comparator|Essex® cream (Schering-Plough)|Essex cream is applied twice daily on the skin in the radiated area during the entire treatment period and until the skin reaction subsided
3283679|NCT01688492|Experimental|ipilimumab|This multi-institution open label study has a Phase 1 and Phase 2 component. The Phase 1 dose escalation stage is to establish the tolerability of ipilimumab to be used in combination with the standard clinical dose of abiraterone acetate plus prednisone in chemotherapy and immunotherapy-naïve patients with progressive metastatic CRPC. Due to the overlapping potential hepatic toxicity between abiraterone and ipilimumab, a Lead in Therapy with abiraterone plus prednisone for 2 cycles will assess for adverse events related to the abiraterone plus prednisone. Patients, who tolerate well the Lead in therapy as defined by Grade 1 or less AEs, will pursue Combination Therapy. Patients with AEs Grade ≥ 2 after Lead in Therapy will be excluded and replaced. The Phase 2 stage will assess efficacy and confirm an acceptable safety profile of the recommended dose.
3283680|NCT01688505||Visit-to-visit BP variability|The highest, intermediate, and the lowest visit-to-visit BP variability (Tertile grouping)
3283681|NCT01688518|Active Comparator|Synera® for 30min & Lidoderm® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
3283682|NCT01688518|Active Comparator|Lidoderm® for 30min & Synera® for 4 hours|Heated Lidocaine/Tetracaine (Synera®)applied to one forearm for either 30 minutes or 4 hours and a 5% Lidocaine (Lidoderm®) patch applied to the alternate forearm for the alternate time period.
3283683|NCT01688531|Experimental|CD0271 0.1%/CD1579 2.5% gel|Split-face design, one application a day for 6 months
3283684|NCT01688531|Placebo Comparator|CD0271 0.1%/CD1579 2.5% gel vehicle|Split-face design, one application a day for 6 months
3283685|NCT01688544|Experimental|Ilaprazole|"Before Ilaprazole dosing, 24 hours intragastric pH monitoring is performed as baseline value.~After 7 days dosing of Ilaprazole 10 mg, 24 hours intragastric pH monitoring, serum gastrin level check, and pharmacokinetic sampling is performed"
3283686|NCT01688557|Experimental|Innovative colonoscopy|Innovative colonoscopy performed using narrow band imaging and dual focus function (NBI + Dual Focus).
3283687|NCT01688557|Active Comparator|Conventional colonoscopy|Conventional colonoscopy performed without innovative techniques assessed in this study.
3283688|NCT01688570|Active Comparator|Duloxetine|Neuromuscular fatigue testing with duloxetine dose
3283689|NCT01688570|Active Comparator|Cyproheptadine|Neuromuscular fatigue testing with cyproheptadine dose
3283690|NCT01688570|Placebo Comparator|Placebo|Neuromuscular fatigue testing with placebo dose
3283691|NCT01688583||Fentanyl matrix|
3283692|NCT01688622|Other|Exercise|obese women who are volunteers for the 3 months exercise programs
3283693|NCT01688648|Experimental|Lidocaine group|a bolus dose of lidocaine 1.5 mg/kg after anesthetic induction with following lidocaine infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
3283694|NCT01688648|Experimental|Dexmedetomidine group|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
3283695|NCT01688648|Experimental|Combined infusion group|Combined lidocaine and dexmedetomidine infusion with the dose specified in single infusion group
3283696|NCT01688648|No Intervention|Control group|The group without infusion of lidocaine or dexmedetomidine
3283697|NCT01688674|Placebo Comparator|Bolus arm|two hourly dextrose boluses administered via an intravenous cannula
3283698|NCT01688674|Experimental|infusion|10% dextrose infusion by burettes
3283699|NCT01688687||Superficial gastric neoplasia|Patients with superficial gastric neoplasia on diagnostic endoscopy, recieved both conventional endoscopic forcpes biopsies and pCLE. All patients were subject to endoscopic resection of the lesion.
3283700|NCT01688700|Experimental|Nimotuzumab plus chemotherapy|
3283701|NCT01688713|Experimental|Icotinib,Brain metastases|
3283702|NCT01688752||Sibling Controls|Healthy siblings of acute lymphoblastic leukemia (ALL) subjects frequency matched by age and sex.
3283703|NCT01688752||Acute Lymphoblastic Leukemia Survivors|Survivors of acute lymphoblastic leukemia (ALL) who recently completed therapy.
3283704|NCT01688765||First Episode Psychosis Patients|
3283705|NCT01688765||Healthy Controls|
3283706|NCT01688778|Experimental|Telemedicine|Monthly video consultations with a nurse as add-on to standard treatment.
3283707|NCT01688778|No Intervention|Standard treatment|Standard diabetes control at a Diabetes Clinic or GP
3283708|NCT01688791|Experimental|Part A: Vintafolide BIW|Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
3283709|NCT01688791|Experimental|Part A: Vintafolide TIW|Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle
3283710|NCT01688791|Experimental|Parts B & C: Vintafolide Single Dose & Weekly (QW)|Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.
3283711|NCT01688804|Experimental|Behavioral intervention|Behavioral intervention to reduce sedentary time delivered via mobile smartphone
3283712|NCT01688817|Other|Physician's counseling|
3283713|NCT01688817|Active Comparator|Information leaflet|
3283714|NCT01688869||Mild TBI|Patients who have been diagnosed with a mild brain injury.
3283715|NCT01688908|No Intervention|Control Arm|Participants in this arm will not accept the endoscopic screening and only baseline and follow-up interview will be conducted in this arm.
3283716|NCT01688908|Experimental|Screening Arm|Participants in this arm will accept a baseline endoscopic screening, questionnaire investigation and follow-up interview. Subsequent re-examination and further medical services would be arranged among individuals who already have high-grade lesions found at baseline screening.
3283717|NCT01688934|Experimental|V116517 - 50 mg|V116517 50-mg tablets
3283718|NCT01688934|Experimental|V116517 - 30 mg|V116517 30-mg tablets
3283719|NCT01688934|Active Comparator|Naproxen 500 mg|Naproxen 500-mg capsules
3283720|NCT01688934|Placebo Comparator|Placebo|Placebo
3283721|NCT01688947|Experimental|V116517 - 50 mg|V116517 50-mg tablets
3283722|NCT01688947|Experimental|V116517 - 30 mg|V116517 30-mg tablets
3283723|NCT01688947|Active Comparator|Pregabalin|Pregabalin capsules
3283724|NCT01688947|Placebo Comparator|Placebo|Placebo
3283725|NCT01688960|Experimental|Cohort 1|
3283726|NCT01688960|Experimental|Cohort 2|
3283727|NCT01688960|Experimental|Cohort 3a|
3283728|NCT01688960|Experimental|Cohort 3b|
3283729|NCT01688960|Experimental|Cohort 4|
3283731|NCT01689025|Experimental|NNC0114-0006|
3283732|NCT01689025|Placebo Comparator|Placebo|
3283733|NCT01689038|Experimental|Tested product|
3283734|NCT01689051|Active Comparator|Healthy subjects|
3283735|NCT01689051|Active Comparator|Patients with type 2 diabetes|
3283736|NCT01689064|Active Comparator|Posterior Septectomy|Patient will be randomized to a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
3283737|NCT01689064|Experimental|Stamm Approach|Patient will be randomized a study arm. The patient will be blinded to the approach. The surgeon will have performed at least 10 procedures previous for each approach. The surgeon will maintain the following surgical practives: preservation of both middle turbinates, preservation of one superior turbinate (to minimize olfactory injury), elevation of a nasoseptal flap, the use of a combination of gelform, surgicel and nasapore dissolvable spacer placed within the surgical defect. These practices are all standard of care. Patient will start Neilmed high volume low pressure saline irrigation three times daily starting on post operative day five. Patients will receive prophylactic antibiotics for fourteen days post operatively.
3283738|NCT01689077|Active Comparator|24 hours hypothermia|24 hours hypothermia
3283739|NCT01689077|Experimental|48 hours hypothermoa|48 hours hypothermia
3283740|NCT01689090|Experimental|Hypoxia|Inhaling hypoxic gas mixture to induce hypoxemia during recordings of diameter changes of retinal vessels. Recording are performed during hypoxia alone and in combination with the associated interventions at two examination days.
3283741|NCT01689090|Experimental|Normoxia|Breathing atmospheric air during recordings of diameter changes of retinal vessels. Recording are performed during normoxia alone and in combination with the associated interventions at two examination days.
3283742|NCT01689103|Experimental|Alliance Feedback to Therapist|Alliance feedback provided to therapist
3283743|NCT01689103|Placebo Comparator|No alliance feedback to therapist|No alliance feedback provided to therapist
3283744|NCT01689116|Experimental|Bardoxolone Methyl 20mg|
3283745|NCT01689116|Experimental|Bardoxolone Methyl 80mg|
3283746|NCT01689116|Placebo Comparator|Bardoxolone Methyl Placebo|
3283747|NCT01689116|Active Comparator|Moxifloxacin|
3283748|NCT01689129|Experimental|New formulation of insulin glargine|once daily in the evening on-top of mealtime insulin
3283749|NCT01689129|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of mealtime insulin
3283750|NCT01689142|Experimental|New formulation of insulin glargine|once daily in the evening on-top of oral antihyperglycemic drug (OADs)
3283751|NCT01689142|Active Comparator|Lantus (insulin glargine)|once daily in the evening on-top of OADs
3283752|NCT01689168|Experimental|Counseling plus chiropractic adjustments|
3283753|NCT01689168|Active Comparator|Counseling alone|
3283754|NCT01689181||chronic schizophrenic patients|
3283755|NCT01689181||healthy volunteers|
3283756|NCT01689194|Experimental|genexolPM + cisplatin|
3283757|NCT01689220|Experimental|SP-02L|
3283758|NCT01689233|Experimental|TRx0237 200 mg/day|
3283759|NCT01689233|Placebo Comparator|Placebo|
3283760|NCT01689246|Experimental|TRx0237 250 mg/day|
3283761|NCT01689246|Placebo Comparator|Placebo|
3283762|NCT01689246|Experimental|TRx0237 150 mg/day|
3283763|NCT01689259|Experimental|SL TNX-102 at 2.4 mg|1 x TNX-102 SL Tablets at 2.4 mg
3283764|NCT01689259|Experimental|SL TNX-102 at 4.8 mg|2 x TNX-102 SL Tablets at 2.4 mg
3283765|NCT01689259|Experimental|SL TNX-102-A at 2.4 mg|1 x TNX-102-A (without phosphate) SL Tablet at 2.4 mg
3378327|NCT02692846||Unaffected Control participants|Not have a diagnosis of WS or other connective tissue disease, between the ages of 1 and 70 years old
3283766|NCT01689259|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
3283767|NCT01689272|Experimental|Kidney transplantation|Kidney transplantation from alive relative donor.
3283768|NCT01689285|Active Comparator|valacyclovir tablet|Administration of 500 mg once daily on day 1 (group A) or on day 8 (group B)
3283769|NCT01689285|Experimental|valacyclovir oral solution|Administration of 500 mg once daily on day 1 (group B) or on day 8 (group A)
3283770|NCT01689298|Active Comparator|No drug pre-treatment|A control sample from each patient (no uterotonic drug will be applied during pre-treatment) will be measured concurrently with samples pre-treated with oxytocin. Controls will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given oxytocin for pre-treatment.
3283771|NCT01689298|Active Comparator|Drug pre-treatment|A sample from each patient will be pre-treated with oxytocin 10-5mol/L. These samples will undergo the same dose response of oxytocin or carbetocin after pre-treatment period as the groups given no drug for pre-treatment (controls).
3283772|NCT01689311|Experimental|Treatment|All samples will undergo dose response treatment (increasing concentrations) of one of the four uterotonic drugs: oxytocin, ergonovine, prostaglandin F2alpha, or misoprostol.
3283773|NCT01689389||Main study population|"All eligible patients receiving Quetiapine XR for the first time in the inclusion period regardless the diagnosed disease or the patients' age.~Patients aged 18 years and over and diagnosed with bipolar disorder or schizophrenia according to DSM-IV criteria will be followed during 12 months."
3283774|NCT01689389||Schizophrenia SoC sample|Patients would have to be prescribed for the first time with a new (not used during the preceding 3 months) atypical antipsychotic other than Quetiapine XR (irrespective this new atypical antipsychotic is preceded or not by another atypical antipsychotic).
3283775|NCT01689389||Bipolar SoC sample|Patients would have to be prescribed a new (not used during the preceding 3 months) antidepressant [N06A], antipsychotic (other than Quetiapine XR) [N05A] or mood stabilizer (including lithium [N05AN], valproate [N03AG01], and lamotrigine [N03AX09].
3283776|NCT01689402||Intracerebral Hemorrhage Patients|Patients admitted with acute intracerebral hemorrhage within 72 hours after symptom onset.Patients are included in the study for MRI studies
3283777|NCT01689428||IVF treatment EmbryoGen|Embryo culture in EmbryoGen medium
3283778|NCT01689428||IVF treatment ISM1|Embryo culture in ISM1 medium
3283779|NCT01689454||IVF treatment ISM1|Embryo culture in ISM1 medium
3283780|NCT01689454||IVF treatment EG|Embryo culture in EmbryoGen medium
3283781|NCT01689467|Experimental|Fermented Velvet Antler extract|
3283782|NCT01689467|Placebo Comparator|Placebo|
3283783|NCT01689480||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) can be included in this study.
3283784|NCT01689493|No Intervention|usual care|usual care arm, without SMS reminder
3283785|NCT01689493|Active Comparator|patient education and daily SMS|Multifaceted patient centered intervention including : collaborative care, patient education , and daily SMS.
3283786|NCT01689506|Experimental|Volulyte|Volulyte 6%-supplemented arm: 6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (solution for infusion)
3283787|NCT01689506|Active Comparator|Human Serum Albumin|5% Albumin-supplemented arm: Human Serum Albumin (HSA 50g/L, solution for infusion)
3283788|NCT01689545|Experimental|Individual level|
3283789|NCT01689545|Experimental|Structural level|
3283790|NCT01689545|Experimental|Combined individual & structural level|
3283791|NCT01689545|Active Comparator|Standard of Care|
3283792|NCT01689558|Experimental|Recombine Endostatin|Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
3283793|NCT01689571|Placebo Comparator|Placebo DPI|Placebo by inhalation for 9 days
3283794|NCT01689571|Experimental|CHF6001 DPI Dose 2|CHF6001 by inhalation for 9 days
3283795|NCT01689571|Experimental|CHF6001 DPI Dose1|CHF6001 by inhalation for 9 days
3283796|NCT01689584|Other|Covar|
3283797|NCT01689597|Active Comparator|Low dose epidural morphine|One dose of 1.25 mg epidural morphine
3283798|NCT01689597|Active Comparator|High dose epidural morphine|One dose of 2.5 mg epidural morphine
3283799|NCT01689597|Placebo Comparator|Saline|One dose of 10 ml saline administered through an epidural catheter
3283800|NCT01689610||Adult female patients with MBC|This is an observational study, no interventions are specified
3283801|NCT01689623|Experimental|Panel I|Each participant will be administered a single oral 40-mg atorvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
3283802|NCT01689623|Experimental|Panel II|Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
3283803|NCT01689636|Experimental|Single-center, open-label|"The study was designed as a single-center, open-label clinical study to evaluate the safety, pharmacokinetics, dosimetry and metabolism of Tc 99m EC20 in normal volunteers and in patients with known or suspected ovarian cancer.~Eight subjects were to be enrolled at one center: four normal subjects, four patients with ovarian cancer. Each subject was to receive a single injection of Tc 99m EC20 complex composed of 0.1 mg ligand (EC20) and 15 - 20 mCi of Tc 99m. Two (2) of the 4 normal subjects and 2 of the 4 patients were to receive an injection of 0.25-2.0 mg folic acid 1-2 minutes prior to the injection of Tc 99m EC20."
3283804|NCT01689662|Experimental|Tc 99m EC20|"Subjects will receive two intravenous injections 1-3 minutes apart:~1 mg of folic acid~1-2 mL injection of 0.1 mg of EC20 labeled with 15-25 mCi of technetium-99m"
3283805|NCT01689675|Experimental|Computer based pain management|The computer-based self-management program (CBSM) intervention will be administered over 8 sessions during the average 4 week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute CBSM intervention. The primary goals of treatment include developing skills for managing acute injury and related pain including: reducing fear avoidance beliefs and catastrophizing, improving mood, increasing perceptions of control and self-efficacy, maintaining activity and reducing pain. Skills are presented and modeled by computer-based video during sessions, audio will be used to explain models and teach skills such as relaxation training.
3378328|NCT02692846||WS participants|Have diagnosis of WS, between the ages of 5 and 70 years old. Be able to tolerate blood pressure measurements.
3378329|NCT02689466||cervical dystonia|clinically documented cervical dystonia (focal cervical or segmental with neck involvement)established by history and physical/neurological examination, at least 18 years old.
3283806|NCT01689675|Active Comparator|Education control|The computer exposure will be administered over 8 sessions during the average 4-week period patients are receiving their standard on-site rehabilitation care. Patients will come to the center to receive their standard care and then interact with the computer for the 25-30 minute control condition. The primary goal of this condition is to provide a control for computer exposure. Briefly, the first session will concentrate on establishing the patient's ability to interact with the computer. The materials will provide general education regarding the injury and methods for preventing re-injury. This condition will not provide teaching and practice of specific pain management and coping management skills. This control computer education activity will equalize the computer exposure of the two groups and the duration of time devoted to injury care.
3283807|NCT01689688||EES-XIENCE V|Groups who were treated with XIENCE V® everolimus eluting stent
3283808|NCT01689714|Experimental|Tc 99m EC20|Patients received 2 intravenous (IV) injections: 1 mg of folic acid (to reduce the uptake of FolateScan in normal tissues), followed 1 to 3 minutes later by 0.1 mg of EC20 labeled with 15 to 25 mCi of technetium-99m (99mTc) over 30 seconds in a total injection volume of 1 to 2 mL.2 Each injection was given as a slow IV push via a free-flowing indwelling IV catheter in an upper extremity vein (i.e., in the antecubital fossa).
3283809|NCT01689727|Other|Technetium Tc 99m EC20|
3283810|NCT01689753|Experimental|TEGO® connector|The TEGO® connector is used during 3 consecutive hemodialyse. After each dialysis session, the dead space of the catheter is flushed with NaCl 0.9%.
3283811|NCT01689753|Active Comparator|Trisodium citrate|After each dialysis, the dead space of the catheter is filled with trisodium citrate 46.7% (Citralock®).
3283812|NCT01689766|Other|Technetium Tc 99m EC20|
3283813|NCT01689792|Active Comparator|CitraFleet|Administration of CitraFleet
3283814|NCT01689792|Experimental|MOVIPREP|Administration of MOVIPREP
3283815|NCT01689805||Patients with atopic dermatitis|
3283816|NCT01689805||Non-atopic controls|
3283817|NCT01689818|Experimental|exercise training|exercise training program which included aerobic exercise for 3 times per week.
3283818|NCT01689818|No Intervention|control|lifestyle counseling
3283819|NCT01689831|Experimental|Aplisol, potency determination|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.
3283820|NCT01689831|Active Comparator|Reference standard PPD-S2, reference|Reactivity of Aplisol compared to reference standard PPD-S2.
3283821|NCT01689844|Active Comparator|Behavioral, DASH Plus - Dietary advice|This group will receive DASH diet advice and guided ordering of fruits, vegetables, nuts and beans that are high in potassium from a local supermarket.
3283822|NCT01689844|Other|DASH - C|DASH C Group will receive brief DASH diet advice and will be able to make non- guided purchases of food products from the local supermarket.
3283823|NCT01689870|Experimental|Phase 1 Cohort 1|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.1 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3283824|NCT01689870|Experimental|Phase 1 Cohort 2|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.2 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3283825|NCT01689870|Experimental|Phase 1 Cohort 3|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered at 0.4 mg/kg over 60 minutes only in the first week on Days 1, 3 and 5.
3283826|NCT01689870|Experimental|Phase 2 Cohort 4|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1. Anti-OX40 will be administered i.v. at the Phase 1 Maximum Tolerated Dose over 60 minutes only in the first week on Days 1, 3 and 5.
3283827|NCT01689883|Other|Current stimulator|The investigators have developed a device to deliver very small currents to the arm. The device will be used while subjects perform upper-limb movements using a device for upper-limb rehabilitation. Subjects will perform multiple trials of movement. During half of the trials, they will receive actual stimulation. During the other half, they will receive sham stimulation.
3283828|NCT01689896|Active Comparator|Testosterone Gel|Testosterone Gel
3283829|NCT01689896|Placebo Comparator|Placebo Gel|Placebo Gel
3283830|NCT01689922||AlterG and Physical therapy|2) Standard postoperative rehabilitation program with addition of lower body positive pressure (LBPP) treadmill training
3283831|NCT01689922||Control group|1) Standard postoperative rehabilitation program
3283832|NCT01689935|No Intervention|Control|No drug, no treatment
3283833|NCT01689935|Active Comparator|ALA-PDT|Drug- topical 20% Aminolevulinic acid - ALA followed by red light irradiation - conventional photodynamic therapy -PDT
3283834|NCT01689935|Experimental|i-PDT|Drug - topical 20% Aminolevulinic acid - followed by inhibitory light during incubation time, then red light for photodynamic therapy
3283835|NCT01689935|Active Comparator|Red Light only|Red light only - no drug
3283836|NCT01689935|Active Comparator|Blue light only|Blue light only - no drug
3283837|NCT01689948|Experimental|Home rehabilitation therapy|12 weekly sessions of Home rehabilitation therapy
3283838|NCT01689961|Experimental|Nutrition+Exercise Intervention|"Structured + monitored nutrition and exercise intervention:~The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence"
3378330|NCT02689466||healthy volunteers|age and sex matched healthy volunteers, atleast 18 years old.
3378331|NCT02682667||1/Cohort 1|Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency.
3378332|NCT02664402||Adults|English speaking, physician diagnosed with a life threatening illness.
3378333|NCT02659956||Individuals without known CNS disease|Family members of patient participants
3378334|NCT02659956||Patient Controls|a target population of 20 patient controls will also be enrolled. These individuals will have diseases that share clinical, imaging, or biological features with MS.
3378335|NCT02659956||Patients with multiple sclerosis|Up to 100 adults (age greater than or equal to 18) with MS, diagnosed by applicable consensus criteria, and by the best judgment of the investigators, at the time of enrollment.
3378336|NCT02656381||Anterior Uveitis|Participants with AU at entry
3378337|NCT02656381||Intermediate Uveitis|Participants with IU at entry
3378338|NCT02656381||Other|Participants not fitting above criteria
3283839|NCT01689961|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health services. In addition, they will be asked to attend 2 focus group sessions exploring women's experiences with exercise, nutrition, and weight gain in pregnancy. Women will receive information about healthy pregnancy from Health Canada.
3283840|NCT01689987|Experimental|Treatment (HCQ, sirolimus, cy/dex)|Patients receive hydroxychloroquine PO daily on days 1-28 (days 5-28 of course 1), sirolimus PO on days -2 to 4, and cyclophosphamide IV continuously and dexamethasone PO on days 1-4. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3283841|NCT01690013||Klinefelter|Men with Klinefelter syndrome
3378339|NCT02656381||Posterior/Pan Uveitis|Participants with non-infectious posterior or pan-uveitis
3378341|NCT02639312||1|hemifacial microsomia
3283842|NCT01690013||Control|Men from the general population, matched by age, education and zipcode.
3283843|NCT01690026|Other|Brief intervention|Motivational intervention based brief intervention
3283844|NCT01690026|Other|Standard intervention|Standard intervention condition
3283845|NCT01690039||All study participants|Furosemide-Fludrocortisone-Test and Ammonium chloride-Loading Test will be performed in renal stone patients.
3283846|NCT01690065|Experimental|Nilotinib+AD induction|"Nilotinib plus AD induction chemotherapy~AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)~Nilotinib 400mg bid PO (continuous without interruption from D8 of induction chemotherapy)~Re-induction chemotherapy AD regimen : Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 5 days (D 1-5) plus Daunorubicin 45 mg/m2/day iv daily for 2 days (D 1-2)"
3283847|NCT01690078||Cross sectional|Cross sectional study where subjects with PRS, micrognathia, or SGS will have a single study visit that will be scheduled within 14 days of a clinically indicated upper airway endoscopy. CT scans of the neck or maxillofacial CT will be obtained in all subjects. During upper airway endoscopy, airway measurements will be conducted. Cohort may include subjects who have previously undergone medical or surgical intervention for their airway obstruction, or who are currently undergoing multidisciplinary team management. The following data will be collected: clinical parameters, Obstructive Sleep Apnea (OSA)OSA-18 (quality of life) questionnaire, and lung function tests (subjects > 4 years of age). Clinically indicated swallowing studies and voice evaluations will be collected.
3378342|NCT02639312||2|mandibular prognathism
3378343|NCT02633670|Experimental|Hemopatch|The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion.
3378344|NCT02633670|Active Comparator|Standard technique|Standard hemostatic agents (floseal, tisseal).
3378345|NCT02629107||Healthy Volunteers|Healthy volunteers, age 18-34.
3378346|NCT02621151|Experimental|Pembrolizumab, Gemcitabine, and RT|"Lead-in single dose Pembrolizumab 200 mg, intravenously (IV)~Transurethral Resection of Bladder Tumor (TURBT) at pre-RT (maximal) and completion of therapy (diagnostic)~External Beam Radiation Therapy (EBRT) - 52 Gy in 20 fractions over 4 weeks (1 fraction = 2.6 Gy)~Gemcitabine 27 mg/m^2 IV twice weekly for 4 weeks concurrent with EBRT~Pembrolizumab 200 mg IV every 3 weeks for total 3 doses starting day 1 of EBRT"
3378347|NCT02620826|Experimental|Indirect pulp therapy|Primary molars will be treated with indirect pulp therapy using resin-modified glass ionomer (Vitrebond Plus).
3378348|NCT02620826|Active Comparator|Pulpotomy|Primary molars treated with MTA pulpotomy.
3378350|NCT02601209|Experimental|Arm I (sapanisertib)|Patients receive sapanisertib as in Phase I. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3283848|NCT01690078||Longitudinal|The prospective, longitudinal cohort arm of the study is designed to describe the effects of treatment on clinical and computational model endpoints. This is performed in a subset of subjects with PRS, micrognathia, or SGS who are scheduled for clinically indicated upper airway endoscopy and who are scheduled to complete a definitive treatment course which necessitates multiple endoscopic evaluations and follow-up imaging. Subjects will have an entry visit comparable to the cross-sectional entry visit. Longitudinal subjects will have up to 3 additional study visits over a 12 to 15-month period.
3378351|NCT02601209|Experimental|Arm II (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may crossover to Arm I.
3283849|NCT01690078||Normal Control Data|Normal de-identified control data is retrospectively collected from clinically indicated CT scans of the neck and maxillofacial CT scans in children less than 18 years of age.
3283850|NCT01690091|Experimental|Metformin|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration: 3 months
3283851|NCT01690091|Placebo Comparator|Placebo|500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening), duration:3 months
3283852|NCT01690104|Active Comparator|Rifampicin|Rifampicin 600 mg daily
3283853|NCT01690104|Placebo Comparator|Placebo|Placebo daily
3283854|NCT01690156||Parallel Probe Position|Performing the simulated interscalene block with the ultrasound probe parallel to the shoulders of the person performing the block
3283855|NCT01690156||Perpendicular Probe Position|Performing the simulated interscalene block with the ultrasound probe perpendicular to the shoulders of the person performing the block
3283856|NCT01690169|Experimental|NNC0113-0987|
3283857|NCT01690169|Placebo Comparator|Placebo|
3283858|NCT01690182|Experimental|Study test meal 1|High volume, high energy density test meal. Volunteers will be given 490 mL of a high energy test meal once in the morning
3283859|NCT01690182|Experimental|Study test meal 2|High volume, low energy density test meal. Volunteers will be given 490 mL of a high volume low energy density test meal once in the morning
3283860|NCT01690182|Experimental|Study test meal 3|A low volume, high energy test meal. Volunteers will be given 140 mL high energy density test meal once in the morning.
3283861|NCT01690195|Experimental|ABT-126|ABT-126 Open-label dose
3283862|NCT01690208|Experimental|EMERALD|Patients assigned to the EMERALD group will be invited to join the multi-component program which will last for 1 year. This program will be held on a 4-weekly basis for the first 3-4 months followed by a maintenance program involving 2-4 group activities every year. Between clinic visits, patients in this group will also receive telephone reminders from the staff and peer supporters to reinforce compliance and for social support.
3283863|NCT01690208|Active Comparator|Usual Care|"Irrespective of the assignment group, all patients will undergo a baseline comprehensive assessment using the JADE portal disease management system. All patients will also receive a 2-hour session on how to interpret their individualised JADE report and risk profiles, whilst the importance of achieving targets and optimizing self care will be reinforced.~Patients assigned to the UC group will be followed up in their usual clinic according to the 'standard' practice."
3283864|NCT01690221|Experimental|VEN 307|diltiazem hydrochloride 2% cream
3283865|NCT01690221|Placebo Comparator|Placebo|Placebo Cream
3283866|NCT01690234|Experimental|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
3283867|NCT01690234|Active Comparator|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
3283868|NCT01690247|Experimental|Conventional plus UC-MSC|Participants will receive conventional treatment plus a dose of UC-MSC from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit
3283869|NCT01690247|Placebo Comparator|Conventional plus placebo|Participants will receive conventional plus placebo treatment from day 0 through the week 12 study visit. Participants will then be followed until the week 48 study visit.
3283870|NCT01690260|Experimental|Bone Morphogenetic Protein 2|Condition of bone healing will be evaluated at serial radiological examinations and by clinical results according to a standard score system.
3283871|NCT01690260|Experimental|Autologous bone graft|Condition of bone healing will be evaluated at serial radiological examinations after 1,2,3,4,5,6,9 and 12 months. Blood tests and urine samples will also be examined for monitoring the bone healing process.
3283872|NCT01690286|Experimental|Group 1: JNJ-38518168 3 mg/ ketoconazole|
3283873|NCT01690286|Experimental|Group 2: JNJ-38518168 30 mg/ ketoconazole|
3283874|NCT01690286|Experimental|Group 3: JNJ-38518168 10 mg/ ketoconazole (optional)|
3283875|NCT01690312|Experimental|1 (Dietary Supplement - Fish Oil)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
3283876|NCT01690312|Experimental|2 (Placebo)|"On Day 1 & Day 29, the researcher will obtain anthropometric measurements as specified in the study protocol. A venous catheter will be inserted and a fasted blood sample will be drawn, which will be analyzed for study primary and secondary endpoints. Participants will consume a Breakfast Meal (which will represent t0) and will have blood drawn at a total of 7 time points. Blood samples drawn at30, t60, t120, and t180 will be analyzed for glucose and insulin; blood samples drawn at t60, t120, t180, t240, t300 and t360 will be analyzed for triglycerides. Upon completion of the 6 hour blood draw period, the venous catheter will be removed.~On Day 15, the researcher will obtain anthropometric measurements as specified in the study protocol."
3283877|NCT01690325|Experimental|Docetaxel, Avastin, Herceptin; adjuv. Epirubicin, Cyclophos.|Arm A: Neoadjuvant: 6 cycles of Docetaxel every 21 days together with 6 cycles of Avastin and Herceptin; Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days together with 12 cycles of Herceptin every 21 days.
3283878|NCT01690325|Experimental|Docetaxel, Avastin; adjuvant Epirubicin, Cyclophosphamid|Arm B: neoadjuvant: 6 cycles of Docetaxel and Avastin every 21 days. Adjuvant: 4 cycles of Epirubicin and Cyclophosphamid every 21 days.
3283879|NCT01690338|Active Comparator|Vecuronium Bromide|Patients who will be performed general anesthesia and tracheal intubation. Vecuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3283880|NCT01690338|Active Comparator|cisatracurium|Patients who will be performed general anesthesia and tracheal intubation. Cisatracurium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3283881|NCT01690338|Active Comparator|rocuronium|Patients who will be performed general anesthesia and tracheal intubation. Rocuronium will be used during surgery and tracheal extubation is scheduled when surgery is over.
3283882|NCT01690351|Experimental|PF-05089771 Oral Dispersion fasted|Oral dispersion TS formulation- fasted
3283883|NCT01690351|Experimental|PF-05089771 TS formulation fasted|Capsules TS formulation- fasted
3283884|NCT01690364|Experimental|Cisatracurium Group|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
3283885|NCT01690364|Active Comparator|Vecuronium Group|MEP monitoring with continuous infusion of vecuronium during general anesthesia
3283886|NCT01690377|Experimental|1|PDC or myDC
3283887|NCT01690390|Active Comparator|Icotinib of Routine Dose|Oral Drug icotinib 125 mg three times per day
3283888|NCT01690390|Experimental|Icotinib of High Dose|Oral Drug icotinib 250 mg three times per day
3283889|NCT01690403|Experimental|cohort 1|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 1).
3283890|NCT01690403|Experimental|cohort 2|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 2).
3283891|NCT01690403|Experimental|cohort 3 (optional)|Period 1 (15 days) : ATRIPLA™ Period 2 (21 days) : ATRIPLA™ + oral rifapentine (regimen 3).
3283892|NCT01690416|Active Comparator|Ultrasound DNTP|the catheter will be placed using ultrasound and DNTT and Lidocaine as local anesthesia, by the same fellow as the one who performs the puncture with the traditional method
3283893|NCT01690416|Active Comparator|Traditional palpation technique|arteria cannulation by traditional palpation technique, using preprocedural lidocaine for anesthetic and palpation method by a fellow
3283894|NCT01690429|Other|OSA Patients|
3283895|NCT01690442|Experimental|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
3283896|NCT01690442|Active Comparator|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
3283897|NCT01690455||Cohort|
3283898|NCT01690468|Experimental|Triciribine & Carboplatin|"Phase I/II: 25mg/m^2 Triciribine and Carboplatin AUC 4. Triciribine escalated to 30, 35, 45mg/m^2 if toxicities are not encountered.~Phase II: Recommended phase II dose of triciribine and carboplatin."
3283899|NCT01690494|Experimental|PACT + TAU|4-session PACT delivered to both partners together + standard treatment of care services (TAU) delivered to the male participant
3283900|NCT01690494|Active Comparator|TAU|TAU control condition delivered to the male participant
3283901|NCT01690507|Other|DCAG plus HLI|
3283902|NCT01690533||Group 1|
3283903|NCT01690559||Group 1|Patient treated with Ciproxan without dilution treatment in daily clinical practice
3283904|NCT01690572|Active Comparator|Paclitaxel coated balloon catheter|"Paclitaxel coated balloon catheter IN.PACT Falcon"
3283905|NCT01690572|Active Comparator|uncoated balloon catheter|"uncoated balloon catheter sprinter legend"
3283906|NCT01690585|Experimental|Ferinject 1000 mg|Intravenous Administration of 1000 mg of ferinject Volume of infusion : 250 mL
3283907|NCT01690585|Placebo Comparator|Placebo|Intravenous administration of 250 ml of sodium chlorure 0.9 %
3283908|NCT01690598|Experimental|Veliparib and Topotecan|
3283909|NCT01690611|Experimental|Walking & Visual Feedback|Individuals in this arm will walk on a treadmill while viewing real time visual feedback regarding their body motions and use the visual feedback to correct their body motions.
3283910|NCT01690611|Active Comparator|Walking & No Visual Feedback|Individuals in this arm will walk on a treadmill without viewing real time visual feedback regarding their body motion.
3283911|NCT01690624|Experimental|Patients with relapsed or refractoryAML|Patients with acute myeloid leukemia who have relapsed after 1 prior treatment.
3283912|NCT01690637|Active Comparator|Oseltamivir phosphate suspension|Participants assigned to the oseltamivir phosphate treatment arm will receive the appropriate weight-based dose of oseltamivir phosphate every 12 hours for 10 doses. For children 0-11 months of age, oseltamivir phosphate will be dosed as 3mg/kg/dose every 12 hours. For children 12 months and older, oseltamivir phosphate will be dosed as follows: 30 mg every 12 hours for children up to 15kg, 45mg every 12 hours for children greater than 15kg up to 23 kg, 60mg every 12 hours for children greater than 23 up to 40kg, and 75mg every 12 hours for children greater than 40kg.
3283913|NCT01690637|Placebo Comparator|Placebo|
3283914|NCT01690650|Experimental|Oxygen + Cerebral NIRS|Induced changes in oxygen supply (100% vs. room air). Continuously monitoring of cerebral oxygen saturation.
3283915|NCT01690676|Active Comparator|Epicatechin|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
3283916|NCT01690676|Placebo Comparator|Microcrystalline cellulose|The subjects will receive the study product and corresponding placebo once a day for 4 weeks in randomised order. There will be a four to five-weeks wash-out between the treatment periods.
3283917|NCT01690689|Experimental|Surgery|Implant surgery
3283918|NCT01690702|Active Comparator|dtEC-dtD|Epirubicin and Cyclophosphamide with a tailored dose 4 cycles q2w followed by one additional week followed by Docetaxel with a tailored dose 4 cycles q2w.
3283919|NCT01690702|Experimental|EnPC|Epirubicin 150mg/qm 3 cycles q2w followed by nabPaclitaxel 260-330mg/qm (to be determined in run-in-phase) 3 cycles q2w followed by Cyclophosphamide 2000mg/qm 3 cycles q2w
3283920|NCT01690715||Hepatocellular carcinoma underwent surgery|
3283921|NCT01690728|Active Comparator|Physical Activity|40 min exercise supervised by physiotherapists two times weekly in six month.
3283922|NCT01690728|No Intervention|Control Group|These participants follows the standard post surgery follow-up consisting of counseling by dietitians, nurses and doctors.
3283923|NCT01690741|Experimental|Nerofe|Nerofe administered intravenously 3x/week
3283924|NCT01690754|No Intervention|Control|This arm will receive the regular standard of care given by TB clinics.
3283925|NCT01690754|Experimental|Interactive Reminders|Patients randomized to this arm will receive Interactive SMS reminders daily.
3283926|NCT01690767|Experimental|Topical and intraurethral 2% lidocaine|2% lidocaine gel will be applied for 5 minutes to the external urethral opening. This will be followed immediately by 2% lidocaine gel administration into the urethra using a 24 gauge angiocath for 5 minutes prior to catheterization for urine specimen collection. Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc, respectively.
3283927|NCT01690767|Active Comparator|Standard of care|According to standard nursing practice, the urethra will be catheterized without anaesthetic gel but using lubricant gel only. Intervention is Health Care Lubricating Jelly.
3283928|NCT01690780|Active Comparator|Ibuprofen|
3283929|NCT01690780|Experimental|Oral morphine|
3283930|NCT01690806||dexamethasone|Patients who receive dexamethasone (8 mg; Decadron; Merck Sharp & Dohme) intravenously 90 min before skin incision
3283931|NCT01690806||placebo|Patients who receive saline placebo intravenously 90 min before skin incision
3283932|NCT01690819|Active Comparator|Conventional Ventilatory Strategy|Conventional Ventilatory Strategy
3283933|NCT01690819|Experimental|Protective Ventilatory Strategy|Protective ventilatory strategy
3283934|NCT01690832|Active Comparator|standard saline infusion|standard i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure.
3283935|NCT01690832|Active Comparator|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure.
3283936|NCT01690845|No Intervention|Control|Patients with severe HH will be treated with standard medical therapy (i.e. vasopressor support with norepinephrine in refractory hypotension = RR mean < 65 mmHg, positive inotropic support with dobutamine if the central venous oxygen saturation < 70%, renal replacement therapy in case of severe metabolic acidosis and/or renal failure, antibiotic treatment in case of suspected or proven infection, mechanical ventilation in case of severe hypoxemia or hypercapnia and/or GCS <= 8.
3283937|NCT01690845|Experimental|MARS-Group|20 patients will be allocated by randomization to the MARS arm. Additionally to standard medical therapy they will receive 4 MARS sessions on three consecutive days, MARS® therapy will be applied for at least 12 hours per session. Thereafter, MARS® treatment will be continued if the patient still has increasing aminotransferase levels, requires vasopressor support or suffers from cholestasis (defined as serum bilirubin levels > 5 mg/dL) for 3 sessions again. There will be a maximum of 7 MARS ® sessions per patient.
3283938|NCT01690858||females with medical history of repeated foetal losses|The females can be pregnant
3283939|NCT01690858||females without medical history of repeated foetal losses|The females can be pregnant
3283940|NCT01690871|Experimental|BEZ235|BEZ235 will be supplied in 200mg, 300mg and 400mg sachets packaged in boxes. Each box will contain only sachets of one strength.
3283941|NCT01690884|Placebo Comparator|Placebo|To determine if there is an increase in adenosine interstitial levels in the forearm.
3283942|NCT01690884|Active Comparator|Dipyridamole|To determine if there is an increase in adenosine interstitial levels in the forearm.
3283943|NCT01690884|Experimental|Ticagrelor|To determine if there is an increase in adenosine interstitial levels in the forearm.
3283944|NCT01690897|Experimental|MBCT group|Women randomized into the MBCT group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the mindfulness-based treatment.
3283945|NCT01690897|Active Comparator|Support group|Women randomized into the support group will undergo pre-treatment testing (questionnaires, saliva sample collection, and physiological assessment) within 2.5 months of beginning the sex therapy, education, and support treatment.
3283946|NCT01690936|Experimental|Breakfast|Almonds (43g/day) were consumed with breakfast for four weeks.
3283947|NCT01690936|Experimental|Morning snack|Almonds (43g/day) were consumed alone as morning snacks for four weeks.
3283948|NCT01690936|Experimental|Lunch|Almonds (43g/day) were consumed with lunch for four weeks.
3283949|NCT01690936|Experimental|Afternoon snack|Almonds (43g/day) were consumed alone as afternoon snacks for four weeks.
3283950|NCT01690936|No Intervention|Control no nuts|Avoided all nuts and seeds
3283951|NCT01690949|Experimental|PUR118 low dose|
3283952|NCT01690949|Experimental|PUR118 mid dose|
3283953|NCT01690949|Experimental|PUR118 high dose|
3283954|NCT01690962|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
3283955|NCT01690962|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
3283956|NCT01690975|Placebo Comparator|Placebo|Placebo Control
3283957|NCT01690975|Experimental|Benzonatate|Benzonatate Active
3283958|NCT01691001|Experimental|dexmedetomidine|
3283959|NCT01691001|Placebo Comparator|placebo group|normal saline
3283960|NCT01691040|Experimental|Open-label pilot group|Twice weekly administration of NOX-H94
3283961|NCT01691053|Active Comparator|Spironolactone|
3283962|NCT01691053|Placebo Comparator|Placebo|
3283963|NCT01691066|Experimental|Infant Toddler Years PRT|Infant Toddler PRT in an evidence-based, manualized treatment for children with autism spectrum disorder that involves specific motivational behavioral procedures adapted to be developmentally appropriate for 12-15 month old infants who present with developmental delays.
3283964|NCT01691066|No Intervention|Community Treatment|Community Treatment includes the treatments offered by early intervention services (e.g., speech-language therapy, special education instruction).
3283965|NCT01691118|Active Comparator|Fimasartan|Fimasartan 60mg qd added on conventional antihypertensive treatment for 10 months.
3283966|NCT01691118|Placebo Comparator|Placebo|Conventional antihypetensive treatment
3283967|NCT01691131|Other|Exercise training on land|High intensity exercise training on land.
3283968|NCT01691131|Other|Exercise training on water|High intensity exercise training on water.
3283969|NCT01691144||recently treated patients|
3283970|NCT01691144||2-3 years after treatment|
3283971|NCT01691157|Active Comparator|Usual physiotherapy without exercise|Will receive 6 sessions of modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
3283972|NCT01691157|Experimental|Exercise|Will receive an evidence based exercise protocol but no other physiotherapeutic modalities
3283973|NCT01691170|Active Comparator|Quadriceps Strengthening|
3283974|NCT01691170|Active Comparator|Stretching Hamstring|
3283975|NCT01691183||Study Subjects|Subjects with or without orbital disease that present to clinic for scheduled appointments.
3283976|NCT01691209|Experimental|Phoenix|Application over 29 days twice daily
3283977|NCT01691209|Active Comparator|Hydrocortison|Application over 29 days twice daily
3283978|NCT01691209|No Intervention|Untreated skin|Participants will be observed over 29 days without study treatment
3283979|NCT01691222|Other|Double lumen endotracheal tube tracheostomy|Tracheostomy with a dedicated double lumen endotracheal tube
3283980|NCT01691235||Arm 1|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) dispensed using the Simpill device. The study staff will have access to data from the device during therapy and will be able to give subjects feedback on adherence during the course of therapy. The study team will refill the device as the medication is needed. The device will be configured to remind a subject each time a dose is missed. Subjects in this study arm will receive a text message each time a dose of medication is missed. This message will only go to the telephone number specified by the subject and will not go to members of the study team.
3283981|NCT01691235||Arm 2|Subjects in this arm will receive their medication (telaprevir, interferon and ribavirin) as standard of care therapy where the SIMpill device will not be used.
3283982|NCT01691261|Experimental|Treatment|PF-05206388 Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane
3283983|NCT01691274|Experimental|PF-04895162|
3283984|NCT01691274|Placebo Comparator|Placebo|
3283985|NCT01691287|Experimental|Michael Method|14 group meeting, taking place once a week during 14 consecutive weeks
3283986|NCT01691300|Experimental|ACT PET/CT|Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)
3283987|NCT01691352|Active Comparator|Wick|Patients with wick placed in their wound at the time of ostomy reversal
3283988|NCT01691352|Sham Comparator|No wick|patients with non-wicked dressing placed on their wound
3283989|NCT01691365|Active Comparator|vitamins pills|"antioxidant and B vitamins vitamins vitamin~--------------------------------------------------------------------------------"
3283990|NCT01691365|Placebo Comparator|pills|MICROCRYSTALLINE CELLULOSE
3283991|NCT01691391||Advanced CRC, candidates for anti-EGFR antibody monotherapy|Patients with histopathologically confirmed advanced CRC with K-Ras and BRAF wild type, aged ≥ 18 years, with a life expectancy of at least 12 weeks, who are candidates for anti-EGFR antibody monotherapy (3rd line palliative treatment).
3283992|NCT01691404|Active Comparator|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
3283993|NCT01691404|Active Comparator|Quercetin|Subjects will be asked to consume supplements containing 160mg of quercetin-3-glucoside daily
3283994|NCT01691404|Placebo Comparator|Placebo|Subjects will be asked to consume capsules containing a placebo (cellulose) daily
3283995|NCT01691417|Experimental|Pneumatic Sleeves|
3283996|NCT01691417|Experimental|Congestive Heart Failure Patients|
3283997|NCT01691443|Experimental|Use of the glove|The subject wear the glove for the time of the trial
3283998|NCT01691456|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
3283999|NCT01691456|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
3284000|NCT01691469|Experimental|Montelukast Sodium Oral Granules|Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
3284001|NCT01691469|Active Comparator|SINGULAIR|(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
3284002|NCT01691495||Superficial Vein Thrombosis (SVT)|A representative of geographical regions of patients with Superficial Vein Thrombosis (SVT) who live in several EU countries.
3284003|NCT01691547|Experimental|UMEC/VI+FF|UMEC (500 µg)/VI(100 µg) (blended together) and FF (400 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3284004|NCT01691547|Experimental|UMEC+VI|UMEC (500 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3284005|NCT01691547|Experimental|FF+VI|FF (400 µg) and VI (100 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3284006|NCT01691547|Experimental|FF+UMEC|FF (400 µg) and UMEC (500 µg) will be administered as single dose (4 inhalations); as dry powder in NDPI device once in 7 days in one of the 4 Treatment Periods of the study.
3284007|NCT01691586|Experimental|Remote patient management|Remote patient management system + yearly in-clinic follow-up
3284008|NCT01691586|Other|In-Clinic follow-up|In-clinic follow-up according to standard practice (every 3-6 months)
3284009|NCT01691599||Tibia fractures|Patients with open and closed tibia fracture treated with internal fixation in India
3284010|NCT01691625|Experimental|concurrent chemoradiotherapy plus DC-CIK immunotherapy|patients will receive concurrent chemoradiotherapy plur DC-CIK immunotherapy
3284011|NCT01691625|Active Comparator|Concurrent chemoradiation only|patients will receive concurrent chemoradiotherapy only
3284012|NCT01691638||Periodontitis|
3284013|NCT01691638||Control|
3284014|NCT01691651|Active Comparator|Botulinum toxin type A|The group that will be subjected to the injection of botulinum toxin (subcutaneous injection of botulinum toxin type A).Subcutaneous botulinum toxin A injection will be performed in this group, (2.5 units per point application), at two points in a nasal and temporal extent of the orbicularis muscle.
3284015|NCT01691651|No Intervention|Control|The group that will not be subjected to any intervention.
3284016|NCT01691664|Active Comparator|Only radiation therapy|Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
3284017|NCT01691664|Experimental|Radiation therapy plus DC-CIK cellular therapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 50Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~DC-CIK cellular therapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before radiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the radiation intermittent period."
3284018|NCT01691677|Experimental|beclomethasone dipropionate|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days
3284019|NCT01691677|Placebo Comparator|placebo|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days
3284020|NCT01691703|Experimental|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
3284021|NCT01691716|Experimental|Tendoactive|Tendoactive dosage: 3 capsules per day
3284022|NCT01691716|Active Comparator|Eccentric training|Protocol published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
3284023|NCT01691716|Active Comparator|Tendoactive and eccentric training|Tendoactive dosage: 3 capsules per day. Eccentric training: protocol described by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
3284024|NCT01691729|Other|Ostomy 1|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy AccessoryProduct/Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2
3284025|NCT01691729|Other|Ostomy 2|3 Ostomy Accessory Devices with the order of wear being Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1
3284026|NCT01691729|Other|Ostomy 3|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product
3284027|NCT01691729|Other|Ostomy 4|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product
3284028|NCT01691729|Other|Ostomy 5|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #1/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #2
3284029|NCT01691729|Other|Ostomy 6|3 Ostomy Accessory Devices with the order of wear being Ostomy Accessory Marketed Product #2/Investigative Ostomy Accessory Product/Ostomy Accessory Marketed Product #1
3284030|NCT01691742|Placebo Comparator|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
3284031|NCT01691742|Active Comparator|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
3284032|NCT01691755|Placebo Comparator|Placebo|
3284033|NCT01691755|Experimental|aleglitazar|
3284034|NCT01691807|Experimental|Arm A|bendamustine and ofatumumab treatment of NHL
3284035|NCT01691807|Experimental|Arm B|ofatumumab only treatment of NHL
3284036|NCT01691846|Experimental|aleglitazar|
3284037|NCT01691846|Placebo Comparator|placebo|
3284038|NCT01691872|Experimental|Japanese|Retigabine 300mg single-dose
3284039|NCT01691872|Experimental|Caucasian|Retigabine 300mg single-dose
3284040|NCT01691911|Experimental|Remote preconditioning|Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
3284041|NCT01691911|No Intervention|Remote preconditioning control|Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
3284042|NCT01691924|Placebo Comparator|Placebo|Placebo capsules: solid microcrystalline cellulose c.s.p
3284043|NCT01691924|Experimental|PBF-509|The initial dose-escalation scheme includes the following eight doses: 10 mg, 20 mg, 40 mg,80 mg, 160 mg, 320 mg, 480 mg and 620 mg. This dose-escalation scheme has been built with the aim to reach the Minimum Intolerated Dose (MID), i.e. when investigator should stop escalating, and consequently the MTD.
3284044|NCT01691937|Experimental|PVB + PCA|Continuous Paravertebral block with ropivacaine and Patient-controlled analgesia with sufentanil
3284045|NCT01691937|Placebo Comparator|Placebo PVB + PCA|Continuous Paravertebral Block with Saline and Patient-controlled analgesia with sufentanil
3284046|NCT01691963|No Intervention|Control group|"In the control group, anaesthesia will be induced in the same way as mentioned above for the intervention group. Also in this group, intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula. The glottic view will be scored in this position using the Cormack and Lehane classification system. If correct laryngoscope positioning cannot be achieved with a size 3 blade, a size 4 blade will be used. Hereafter, the patient's trachea will be intubated once the optimal view of the larynx had been obtained. Intubation attempts will be scored in the same way as mentioned above for the intervention group."
3284047|NCT01691963|Experimental|Epiglottic downfolding|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
3284048|NCT01691976|No Intervention|Controls|Age-matched male patients with benign prostatic hyperplasia, otherwise healthy, as controls
3284049|NCT01691976|Active Comparator|LHRHa|Prostate cancer patients receiving androgen deprivation therapy by luteinising hormone releasing-hormone agonists (LHRHa)
3284050|NCT01691976|Experimental|Oestrogen|Prostate cancer patients recruited from the Prostate Adenocarcinoma TransCutaneous Hormones (PATCH) Trial, randomised to receive ADT via transdermal oestrogen patches.
3284051|NCT01691989|Experimental|aleglitazar|
3284052|NCT01691989|Experimental|placebo|
3284053|NCT01692002|Placebo Comparator|Sodium chloride pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
3284054|NCT01692002|Experimental|Sodium propionate pill|Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test
3284055|NCT01692015|Experimental|Diet and nosebleed questionnaire|Participants will only be required to fill in two paper questionnaires, one on dietary history, and one on nosebleed severity.
3284056|NCT01692015|Experimental|Weighed food diary arm|Participants will be required to weigh their food for one week to generate a food dairy, and have a single blood test, in addition to filling in the two paper questionnaires, one on dietary history, and one on nosebleed severity.
3284057|NCT01692041|Active Comparator|Ivy leave|active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks
3284058|NCT01692041|Placebo Comparator|Placebo|Ivy leave placebo 5 ml twice daily p.o. for four weeks
3284059|NCT01692054||Alcohol intoxicated adolescents|Adolescents who were hospitalized due to acute alcohol intoxication
3284060|NCT01692054||Control group|adolescents who were hospitalized due to other medical conditions but not alcohol intoxication
3284061|NCT01692067||D0|Not deployed
3284062|NCT01692067||D1|Deployed to combat-related regions once
3284063|NCT01692067||D2|Deployed to combat related regions more than once
3284064|NCT01692067||D3|Deployed outside of the continental US but not to combat related regions
3284065|NCT01692080||Asthma Screenings and Camps|Children, ages 5-17 years who participate in one of the asthma screenings or camps are eligible to participate in this study.
3284066|NCT01692093|Experimental|KM110329|Participants will receive KM110329 for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
3284067|NCT01692093|Placebo Comparator|Control|Participants will receive placebo drug for eight weeks. Participants will take 2 tablets by mouth with water two times a day after meals.
3284068|NCT01692106|Experimental|peroral endoscopic myotomy (POEM)|The Procedure: per oral endoscopic myotomy (POEM)will be performed on all patients in this single arm study.
3284069|NCT01692132||Prucalopride|
3284070|NCT01692145|Experimental|KCT-0809 ophtalmic solution|
3284071|NCT01692145|Placebo Comparator|Placebo|
3284072|NCT01692158|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
3284073|NCT01692158|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
3284074|NCT01692171|Experimental|Teste|Enoxalow (Heparin, Low-Molecular-Weight) - Blau Farmacêutica S/A.
3284075|NCT01692171|Active Comparator|Comparador|Clexane (Heparin, Low-Molecular-Weight)- Sanofi-Aventis
3284076|NCT01692184|Experimental|50 mg of AVL-292 and Placebo|50 mg AVL-292 (2 x 25 mg AVL-292 capsules and 6 placebo capsules) once daily for 7 days administered orally under fasted condition
3284077|NCT01692184|Experimental|100 mg of AVL-292 and Placebo|100 mg AVL-292 (4 x 25 mg AVL-292 capsules and 4 placebo capsules) once daily for 7 days administered orally under fasted condition
3284078|NCT01692184|Experimental|200 mg AVL-292|8 x 25 mg AVL-292 capsules orally once daily for 7 days under fasted condition
3284079|NCT01692184|Experimental|350 mg of AVL-292|350 mg AVL-292 (14 x 25 mg AVL-292 capsules) once daily for 7 days administered orally under fasted condition
3284080|NCT01692184|Placebo Comparator|Placebo - 8 capsules|8 placebo capsules once daily for 7 days administered orally under fasted condition
3284081|NCT01692184|Placebo Comparator|Placebo - 14 capsules|14 placebo capsules once daily for 7 days administered orally under fasted condition
3284082|NCT01692210||Blood Draw Pre and Post Surgery|Patients within the UT MD Anderson Cancer Center who are scheduled for breast cancer surgery.
3284083|NCT01692223||Unaffected Relatives|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
3284084|NCT01692223||Pts with history of cancer|We will use a prospective, observational cohort design, we will invite a sample of individuals who have indicated willingness to be re-contacted for future studies (from existing protocols involving cancer survivors and their unaffected relatives employing mixed methods -qualitative interviews coupled with validated measures - to assess: the proportion of participants experiencing psychological distress from Whole genome/exome sequencing (WGS/WES) results.
3284085|NCT01692223||Participants whose genomes/exomes are not sequenced|We will also recruit an additional group of participants from the general public (with or without a cancer history) who have not had their genomes or exomes sequenced to participate in focus groups to inform us about their perceptions of the hypothetical utility of learning of incidental results from their genome or exomes. For our sampling purposes, this group of participants is referred to as the 'focus group participants (sample #3-hypothetical group)
3284086|NCT01692249|Experimental|immediate spa therapy|group (A) received immediate spa treatment, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
3284087|NCT01692249|No Intervention|control group|in group (B), spa therapy was delayed for 6 months (control group).
3284088|NCT01692262|Experimental|Part A Group 1 Intermittent|Recruitment suspended and will not be re-opened. See intervention description below.
3284089|NCT01692262|Experimental|Part A Group 2 Intermittent|Recruitment complete. See intervention description below.
3284090|NCT01692262|Experimental|Part B|This part of the study will not be conducted following a review of data from Part A. See intervention description below.
3284091|NCT01692288|Experimental|Offered First Born® Program services|Family and first-born child are selected to be offered First Born® Program home visiting services.
3284092|NCT01692288|No Intervention|Not offered First Born® Program services|Family and first-born child are not selected to be offered First Born® Program home visiting services.
3284093|NCT01692314|Experimental|Obese adolescents is being compared to control ones|Patients underwent to resistance training, three times a week, during three months.
3284094|NCT01692327|Other|Obese Group|Obese group with fat overload intake.
3284095|NCT01692327|Other|Control Group|Control Group + fat overload intake
3284096|NCT01692327|Other|Glucose Intolerance|glucose intolerance + fat overload intake
3284097|NCT01692353||Exclusive cigarette smokers (SMK)|Subject's usual brand (UB) of cigarettes
3284098|NCT01692353||Exclusive moist snuff consumers (MSC)|Subject's usual brand (UB) of moist snuff
3284099|NCT01692353||Non-tobacco consumers (NTC)|No use of tobacco or nicotine-containing products of any kind
3284100|NCT01692366|Experimental|SAR302503 300mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 300mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3284101|NCT01692366|Experimental|SAR302503 400 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 400 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3284102|NCT01692366|Experimental|SAR302503 500 mg|SAR302503 will be self-administered, orally, once daily, as a single agent, in consecutive, 28-day cycles at the dose level of 500 mg. SAR302503 will be taken on an empty stomach at approximately the same time each day
3284103|NCT01692379|Experimental|Endovascular treatment|Mechanical embolectomy with Solitaire FR device
3284104|NCT01692379|Active Comparator|Medical treatment|Medical treatment (standard of care in acute ischemic stroke)including intravenous thrombolysis
3284105|NCT01692392||Pectus carinatum|Patients who have undergone surgical repair of pectus carinatum.
3284106|NCT01692405|No Intervention|Standard method|Standard method- shaking the biopsy needle into a formalin container.
3284107|NCT01692405|Active Comparator|Download onto a biopsy sponge pad|Samples will be downloaded by moving the needle notch on a biopsy sponge pad.
3284108|NCT01692405|Experimental|Dowloading the biopsy cores using NavigoBx system|Downloading the biopsy cores using NavigoBx™ system. The NaviGoBx™ device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.
3284109|NCT01692418|Experimental|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
3284110|NCT01692418|Placebo Comparator|Placebo|Normal saline will be administered as an i.v. infusion (100ml normal saline) over a minimum of 15 minutes
3284111|NCT01692431|Experimental|DHA|High fat meal containing DHA rich oil.
3284112|NCT01692431|Experimental|EPA|High fat meal containing EPA.
3284113|NCT01692431|Placebo Comparator|Control|High fat meal with no/negligable omega-3 fatty acid content.
3284114|NCT01692444||COPD|15 patients with COPD from 1 to 4 according to the GOLD 2011
3284115|NCT01692444||Non smoker Control|15 patients without COPD and no smoking history
3284116|NCT01692444||Smoker Control|15 patients without COPD but a smoking history
3284117|NCT01692457||Golimumab|Patients will be taking golimumab as per the dosing regimen given on product insert approved in Philippines.
3284118|NCT01692470||rilpivirine hydrochloride|Patients will be taking 1 tablet of 25 mg rilpivirine hydrochloride is administered once daily orally in combination with other anti-retroviral (ARV) medications.
3284119|NCT01692483||Abiraterone acetate plus prednisone|
3284120|NCT01692509||Patients requiring NIV|Patients requiring NIV because of acute respiratory failure
3284121|NCT01692522|Experimental|Ambu Aura-i|intubation
3284122|NCT01692522|Active Comparator|AirQ|intubation
3284123|NCT01692535|Experimental|GlideScope|intubation
3284124|NCT01692535|Experimental|Airtraq|intubation
3284125|NCT01692535|Experimental|McGrath MAC|intubation
3284126|NCT01692535|Experimental|King Vision|intubation
3284127|NCT01692535|Experimental|A.P. Advance|intubation
3284128|NCT01692535|Experimental|C-MAC|intubation
3284129|NCT01692548|Experimental|Neurofeedback|Neurofeedback: two sessions per week, 30 sessions total.
3284130|NCT01692548|No Intervention|Control|
3284131|NCT01692561||normaL|Healthy subjects without symptoms of dysautonomia.
3284132|NCT01692561||Neurocardiogenic syncope|Fainting due to sudden drop in blood pressure.
3284133|NCT01692561||Orthostatic hypotension|Sudden decrease in blood pressure while standing.
3284134|NCT01692561||Postural Orthostatic Tachycardic Syndrome|Increased heart rate when standing.
3284135|NCT01692574|Experimental|Combined|Group cognitive-behavior therapy for depression combined with behavior modification for weight loss
3284136|NCT01692574|Active Comparator|GCBT-ND|Group cognitive-behavior therapy for depression combined with an alternative approach to weight loss
3284137|NCT01692574|Active Comparator|DSE|Behavior modification for weight loss combined with depression support and education.
3284138|NCT01692587|No Intervention|Control|No changes in dietary group
3284139|NCT01692587|Experimental|Protein restrictive diet|reduced protein diet
3284140|NCT01692600||healthy volunteers|Age-matched with the patient group, with no oral pathologies and comorbidities
3284141|NCT01692600||Late oral radiation toxicity patients|Head-and-neck cancer patients who had undergone radiation therapy and developed late radiation side ffects
3284142|NCT01692652|Experimental|Lotemax with warm compress group|topical loteprednol etabonate (lotemax 0.5%) qid and warm compress & ocular massage (a minimum of four times, once or twice a daily) for 2months
3284143|NCT01692652|Active Comparator|warm compress only group|warm compress only group
3284144|NCT01692665||stage 3 or stage 4 meibomiang gland dysfunction patients|stage 3 or stage 4 meibomiang gland dysfunction patients
3284145|NCT01692678|Experimental|Trabectedin (Part 1 and Part 2)|Trabectedin will be administered at a dose of 1.5, 1.2 or 1.0 mg/m2 as a 24-hour intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
3284146|NCT01692678|Active Comparator|Dacarbazine (Part 2)|Dacarbazine will be administered at a dose of 1 g/m2 as a longer than 30-minute intravenous infusion on Day 1 of each 21-day treatment cycle (ie, each treatment cycle being at least 21 days apart).
3284147|NCT01692704|Experimental|HAI with FUDR & systemic cisplatin and gemcitabin|FUDR: 0.2mg/kg/day continuously i.a. for 14 days Cisplatin: 25mg/m2 i.v. Gemcitabin: different doses according to dose level 600, 800, or 1000 mg/m2 i.v.
3284148|NCT01692717|Active Comparator|Atorvastatin|Citalor (Atorvastatin) - Pfizer
3284149|NCT01692717|Active Comparator|Hydrochlorothiazide + Losartan|Hyzaar (Hydrochlorothiazide + Losartan) - Merck Sharp & Dohme
3284150|NCT01692717|Experimental|Atorvastatin + Hydrochlorothiazide + Losartan|Polipílula (Atorvastatin + Hydrochlorothiazide + Losartan) - Lab Hypermarcas
3284151|NCT01692769|Active Comparator|Normal Saline|Patients will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
3284152|NCT01692769|Active Comparator|Ringer's Lactate|Patients will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
3284153|NCT01692795||MI patients|
3284154|NCT01692808|No Intervention|Exclusive Enteral Nutrition|This group is one of the non interventional group. As enteral nutrition is one of the usual therapy of Crohn disease at diagnosis.
3284155|NCT01692808|Experimental|EEN + Vitamin D3 3000 UI daily|Exclusive Enteral Nutrition + Vitamin D3 3000 UI daily for one month This arm will be one of the two experimental arms.
3284156|NCT01692808|No Intervention|Corticosteroïd|Corticosteroids (1mg/kg/day) associated with usual vitamin and calcium supplementation: vitamin D 800 IU of vitamin D3 + 1000 mg calcium per day) for one month
3284157|NCT01692808|Experimental|Corticosteroids + Vitamin D3 4000 UI|Corticosteroids (1mg/kg/day) associated with vitamin D3 4000 UI daily and calcium 1000 mg daily for one month
3284158|NCT01692808|Experimental|Vitamin D3 4000 UI|Vitamin D3 4000 UI /day . This arm is intended for those children in remission with or without immunosuppressant. Vitamin D will be administered in adjunction to usual therapy.
3284159|NCT01692821|Experimental|100% oxygen breathing|
3284160|NCT01692821|Experimental|15% oxygen in N2 breathing|
3284161|NCT01692821|Experimental|12% oxygen in N2 breathing|
3284162|NCT01692834|Active Comparator|Cyclosporine in Cremophor EL®|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
3284163|NCT01692834|Active Comparator|Cyclosporine in lipid emulsion|Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.
3284164|NCT01692847||RRT calls prior to IGS use|Patients who triggered ACT/RRT calls prior to the installation of the IGS (Intellivue Guardian System)
3284165|NCT01692847||RRT calls during IGS use|Patients who triggered ACT/RRT calls after the installation of IGS. All patients on the study ward receive the same care in both groups. The only difference is the system used to collect vital signs and to inform the staff about patient deteriorations. In Group 2, the IGS (FDA approved and CE marked) is the vital signs collection and information system.
3284166|NCT01692860|Experimental|High protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of 1.5g/kg/d
3284167|NCT01692860|Placebo Comparator|Normal protein consumption|Intervention, energy restriction. This arm has a dietary protein intake of .8g/kg/d
3284168|NCT01692873|Experimental|suspected pancreatic tumor|Realization of pancreatic tumor biopsy and blood samples
3284169|NCT01692886|Active Comparator|7vPnC (3-, 4-, 5-, 12-Month)|
3284170|NCT01692886|Experimental|13vPnC (3-, 4-, 5-, 12-Month)|
3284171|NCT01692886|Experimental|13vPnC (2-, 4-, 6-, 12-Month)|
3284172|NCT01692886|Experimental|13vPnC (3-, 5-, 12-Month)|
3284173|NCT01692899||Etanercept|Etanercept: administered as first line biotherapy in RA during the period of the study
3284174|NCT01692899||Adalimumab|Adalimumab: administered as first line biotherpy in RA during the period of the study
3284175|NCT01692899||Infliximab|Infliximab: administered as first line biotherpy in RA during the period of the study
3284176|NCT01692912|Active Comparator|Intensive Care (IC)|Rheumatologists treating to target of DAS28<2.6
3284177|NCT01692912|No Intervention|Routine Care (RC)|Participants treated in the routine manner by their rheumatologist (not treated to the target of DAS28<2.6)
3284178|NCT01692925|Experimental|Lot A|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3284179|NCT01692925|Experimental|Lot B|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3284180|NCT01692925|Experimental|Lot C|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3284181|NCT01692925|Experimental|Lot D|Each subject will receive two single doses of turocotocog alfa from two lots of trial product on two separate days.
3284182|NCT01692977|Experimental|Alzheimer disease patients|Alzheimer disease patients
3284183|NCT01692977|Active Comparator|control|healthy control subjects.
3284184|NCT01692990|Experimental|Fish oil|5 g/d in 10 capsules, providing 3.5 g of long-chain n-3 fatty acids
3284185|NCT01692990|Placebo Comparator|Soy bean oil|5 g/d in 10 capsules
3284186|NCT01693003|Experimental|Indacaterol first|"Indacaterol 150 µg d.o. during the first 3-week period followed by other 3-week period of tiotropium bromide 5 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
3284187|NCT01693003|Experimental|Tiotropium first|"Tiotropium bromide 5 µg d.o. during the first 3-week period followed by other 3-week period of Indacaterol 150 µg d.o. separated by a wash-out phase of at least 5 to 14 days between each treatment period"
3284188|NCT01693016|Other|inhalation group|20 children Taking blood samples and SpHb-measurement was made under inhalational anesthesia
3284189|NCT01693016|Other|non-inhalational|40 children Taking blood samples and SpHb measurements in awake and spontaneous breathing children.
3284190|NCT01693042|Active Comparator|Single intracoronary cell application|Single intracoronary application of autologous bone marrow derived mononuclear cells
3284191|NCT01693042|Active Comparator|repeated (2 times) intracoronary cell application|2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells
3284192|NCT01693055|Experimental|UltheraTM|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
3284193|NCT01693081|Active Comparator|VR040/Aspirair® inhaler|VR040 was administered as an inhaled dry powder, in a dosage of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
3284194|NCT01693081|Placebo Comparator|Placebo|Placebo was administered as an inhaled dry powder, matching to active comparator at dosages of 1.5, 2.3, 3.0 and 4.0mg, single dose given at each dose level.
3284195|NCT01693094|No Intervention|No decision aid|One cohort will not receive the decision aid, and instead will receive only a brochure as standard treatment.
3284196|NCT01693094|Active Comparator|Decision Aid|One cohort will receive a decision aid.
3284197|NCT01693107||Operator Blinded to Contact Force|Physicians performing the ablation will be blinded to the contact force data
3284198|NCT01693133|Other|Control|Standard of Care: Moist Wound Therapy and Offloading
3284199|NCT01693133|Experimental|EpiFix plus Standard of Care|Weekly application of EpiFix (up to 12 week) and standard of care (moist wound therapy and offloading)
3284200|NCT01693146|Active Comparator|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
3284201|NCT01693146|Active Comparator|Nasal oxygen insufflation with a TNI® 20 oxy device|Device: TNI®20 oxy Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
3284202|NCT01693159|Experimental|ECA: Ethyl-2-cyanoacrate|Application of ethyl-2-cyanoacrylate (ECA) for painful cetuximab-induced rhagades
3284203|NCT01693159|Active Comparator|Standard treatment of the institution|Standard treatment of the institution to treat painful cetuximab-induced rhagades
3284204|NCT01693172|Active Comparator|early postoperative mobilization|Early postoperative supervised aerobic exercise, resistance and flexibility training
3284205|NCT01693172|No Intervention|Standard|Standard rehabilitation care
3284206|NCT01693211|Experimental|Group A|Capsulorhexis and pre-fragmentation of the nucleus are performed by the femtosecond laser.
3284207|NCT01693211|Active Comparator|Group B|The Capulorhexis and nuclear fragmentation are performed manually.
3284208|NCT01693237|Active Comparator|Group psychotherapy|20 sessions of systemic and narrative group psychotherapy
3284209|NCT01693237|Experimental|Group psychotherapy with feedback|20 sessions of systemic and narrative group psychotherapy with session-to-session feedback to patient and therapist.
3284210|NCT01693263||brachiocephalic fistula placed|Subjects are being asked to participate in this study because they have end-stage renal disease and they are undergoing dialysis, and their doctor has recommended that they will have brachiocephalic fistula placed for their dialysis access.
3284211|NCT01693263||Sub-study participants|As part of this study there is an additional sub-study. The researchers would like to collect more information about the vascular access from 50 subjects. For the purposes of this sub-study the following will take place: Intravenous Ultrasound (IVUS) and Hand Held Doppler
3284212|NCT01693276|Experimental|Gemzar/Abraxane and Radiation Therapy|Patients will receive 2 cycles of gemcitabine and abraxane prior to the start of chemoradiation. Chemoradiation will commence 2 week after the completion of second cycle of gemcitabine/abraxane. Patients will receive an additional 2 cycles of gemcitabine and abraxane to start 2-4 weeks after the completion of chemoradiation. After the last two cycles of chemotherapy, if well tolerated with continued tumor response additional cycles of chemotherapy may be given.
3284213|NCT01693289|Experimental|Metformin plus letrozole|metformin :850mg tablets twice daily for 6 months letrozole :5mg tablets twice daily form day 3to7 of cycle
3284214|NCT01693289|Experimental|ovarian drilling|bilateral diathermy ovarian drilling, four drills each ovary
3284215|NCT01693302|Experimental|-20 minute insulin|Insulin for the meal is given 20 minutes prior to starting the meal.
3284216|NCT01693302|Experimental|0 minute insulin|Insulin for the meal is given immediately before starting to eat.
3284217|NCT01693302|Experimental|+20 minute insulin|Insulin is given 20 minutes after the start of the meal.
3284218|NCT01693315|Experimental|Cohort 1 - AMA0076 Dose A (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
3284219|NCT01693315|Experimental|Cohort 2: AMA0076 Dose B (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (12 active : 3 placebo).
3378357|NCT02578875||Sample|Discarded patient samples and autopsy material
3284220|NCT01693315|Experimental|Cohort 3: AMA0076 Dose C (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
3284221|NCT01693315|Experimental|Cohort 4: AMA0076 Dose D (or vehicle)|Consecutive, eligible subjects who meet the inclusion/exclusion criteria in each cohort will be randomized to active or placebo (vehicle) in a 4:1 allocation ratio (20 active : 5 placebo).
3284222|NCT01693328||PecFent®|
3284223|NCT01693341|Active Comparator|Care-giver mediated training|Each patient and the caregiver of the intervention group received weekly home training and exercise counseling by a physical therapist about the caregiver mediated home exercise skill for stroke patient. The training program were progress weekly based on the patient's need.
3284224|NCT01693341|No Intervention|Standard-care|Maintain the inherent standard-care
3284225|NCT01693354|Active Comparator|HF dialysis|HF (high-flux) dialysis is standard hemodialysis treatment performed by using a high permeability dialyzer instead of a low permeability one.
3284226|NCT01693354|Experimental|Mid-dilution HDF|Mid-dilution is a newly developed hemodiafiltration therapy able to allow a simultaneous pre- and post-dilution infusion.
3284227|NCT01693380|Experimental|Influenza vaccine|"Schoolchildren from 6 to 8 years received two intra-muscular doses of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009.~Schoolchildren above 8 years received one intra-muscular dose of 0.5 ml of inactivated influenza vaccine, of the Southern Hemisphere, 2009."
3284228|NCT01693380|Sham Comparator|Control vaccine|"Schoolchildren received one intra-muscular dose of 0.5 ml of Meningococcal C conjugate vaccine.~Schoolchildren under nine years of age received also one intra-muscular dose of 0.5 ml of varicella vaccine one month after the Meningococcal C vaccine."
3284229|NCT01693393|Other|Cyclosporine A|All patients will receive Cyclosporine A in a dose of 2mg/kg/BW daily for 16 weeks
3284230|NCT01693406||Normal Weight|Normal weight and normoglycemic women: Pre-pregnancy BMI between 18.5 - 24.9 kg/m2.
3284231|NCT01693406||Overweight/Obese|Overweight and normoglycemic women: Pre-pregnancy BMI between > 25 kg/m2.
3284232|NCT01693406||Gestational Diabetes|Women who develop gestational diabetes and return to normal glucose control after delivery.
3284233|NCT01693406||Type 2 Diabetes|Women who are overweight and have Type 2 Diabetes that was diagnosed before pregnancy: Pre-pregnancy BMI > 25 kg/m2.
3284234|NCT01693419|Experimental|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
3284235|NCT01693432|Experimental|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
3284236|NCT01693445|Experimental|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7 Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
3284237|NCT01693458|Experimental|Lifestyle counseling|Appreciative Inquiry Change Agents (CA) Program (NAMWEZA)
3284238|NCT01693458|Placebo Comparator|Control group|Since the design is a stepped-wedge randomized trial, those in the control group will eventually receive the intervention later in the study.
3284239|NCT01693471||SEARCH Study Group|
3284240|NCT01693497|Experimental|Dialogical exposure therapy|Psychotherapy based on a manual integrating Gestalt principles with cognitive-behavioral techniques.
3284241|NCT01693497|Active Comparator|Cognitive Processing Therapy|Cognitive Processing Therapy, a cognitive behavioral psychotherapy for PTSD patients. Based on a German manual adapted from Resick and Schnicke, 1993.
3284242|NCT01693510|Experimental|Exercise and Nutrition Intervention|Nutrition intervention: The proposed nutrition plan is a high protein (25% energy) diet providing low fat dairy foods and individualized to energy needs. Dairy foods are accepted by women during pregnancy as a healthy choice (from pilot study) and in our recent birth cohort study, women consumed an average of 3 or more servings of dairy per day. Exercise intervention: Most previous studies and published guidance focus on aerobic exercise such as walking as it is the easiest physical activity to implement in pregnancy in terms of setting goals of steps and monitoring of adherence using accelerometer-type devices. Walking is also the most practical since women reduced moderate and vigorous physical activity during pregnancy but levels of walking were maintained.
3284243|NCT01693510|No Intervention|Usual Prenatal Care|Mothers in the Control Group will be followed by their primary care provider and have usual access to public health. In addition, women will have the opportunity to attend one focus group session exploring women's experiences with nutrition, exercise, and weight gain in pregnancy.
3284244|NCT01693536|Experimental|Lifestyle counselling|"Three dietician visits focussed on education to find food with sodium less than 120mg/100gms.~Two physiotherapist visits focussed on teaching personalised sustainable practical exercise."
3284245|NCT01693536|No Intervention|Control|Control group was offered free skin cancer check and wait listed for the same lifestyle counselling after the six months of the study.
3284246|NCT01693549|Experimental|Cabazitaxel|Cabazitaxel(XRP6258) will be administered on day 1 of each cycle, every 21 days, at a dose of 25 mg/m² by i.v. route in 1 hour. Treatment can be continued until patient's consent withdrawal, intolerable toxicity or documented disease progression.
3284247|NCT01693575|Experimental|Pupil expansion with APX 100 device|Use of APX 100 device during standard phacoemulsification cataract extraction surgery in patients with small pupil diameter (<4.5 mm) or with documented intraoperative floppy iris syndrome in previous eye.
3284248|NCT01693588|Experimental|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
3284249|NCT01693601|Experimental|Panobinostat and Ruxolitinib|Combination of Panobinostat and Ruxolitinib
3284250|NCT01693627|Active Comparator|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
3284251|NCT01693627|Active Comparator|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
3284252|NCT01693627|Active Comparator|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
3284253|NCT01693627|Active Comparator|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
3284254|NCT01693640|Experimental|abatacept|
3284255|NCT01693666|Experimental|Lifestyle intervention group|The LIFE program emphasizes improved nutritional quality, moderate physical activity, and weight maintenance (±10 lb) in obese pregnant women using a contingency management (CM) approach to reinforce behavior change. Participants will meet with the study dietitian and exercise physiologist every 2-4 weeks to develop and maintain individualized nutrition and physical activity plans, reinforced by CM. When the subject meets with the interventionists at their regular appointments, they will review the diet and exercise requirements, and provide vouchers earned as reinforcement from the previous study period. Diet requirements include at least 5 days of food logs each week. Exercise requirements include objective verification of up to 5 exercise sessions per week (as prescribed).
3284256|NCT01693666|No Intervention|Routine care group|Participants in the Routine Care (RC) control group will receive no additional intervention beyond standard of care.
3284257|NCT01693679|Experimental|antiviral drug|Telbivudine team,Telbivudine,600mg/d,oral,60 patients. non-Tebivudine team,Lamivudine,100mg/d,oral,20 patients.Adefovir,10mg/d,oral,20 patients.Enecavir,0.5mg/d,oral,20 patients.
3284258|NCT01693692|Experimental|TD-9855 Group 1|Group 1 to be dosed with TD-9855
3284259|NCT01693692|Experimental|TD-9855 Group 2|Group 2 to be dosed with TD-9855
3284260|NCT01693692|Placebo Comparator|Placebo|Group to be dosed with Placebo
3284261|NCT01693705||Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated and who underwent tracheostomy
3284262|NCT01693705||Non-Tracheostomy Patients|Critical care patients with respiratory failure who were mechanically ventilated but did not undergo tracheostomy
3284263|NCT01693731||Aromatase Inhibitor|Postmenopausal women with breast cancer taking Arimidex, Aromasin, or Femara
3284264|NCT01693731||No Treatment|Healthy volunteer postmenopausal women not taking Aromatase Inhibitors
3284265|NCT01693744||Dialysis patients|Patients with stage 5 chronic kidney disease undergoing haemodialysis
3284266|NCT01693744||Chronic kidney disease patients|Stage 1-4 Chronic kidney disease patients
3284267|NCT01693744||Control group|Patients with normal renal functions
3284268|NCT01693757||BPTB group|Bone-patellar tendon-bone
3284269|NCT01693757||STG group|Semitendinosus and gracilis tendon
3284270|NCT01693757||Control|Healthy
3284271|NCT01693770|Other|MRgFUS|High intensity focused ultrasound energy, delivered under the guidance of the MR images (MgFUS) allows for a predefined amount of energy to be delivered in the desired target (Metastasis). Bone readily absorbs focused ultrasound energy resulting in a thermo-related neurolysis of the periostium with consequent pain palliation. The amount of energy delivered can be modulated with the objective to penetrate cortical space and obtain necrosis of the metastasis thus preventing local recurrence.
3284272|NCT01693783|Experimental|Treatment (ipilimumab)|Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
3284273|NCT01693809|Experimental|Caffeine|Caffeine 420mg, one time
3284274|NCT01693822|Experimental|Axitinib|Axitinib - oral tablet twice daily until disease progression. Starting dose 5mg.
3284275|NCT01693835||Patients|Patients with metastatic colorectal cancer
3284276|NCT01693835||Healthy subjects|Age and sec-matched healthy subjects
3284277|NCT01693848||Patients|Patients with metastatic colorectal cancer scheduled for metastatic surgery
3284278|NCT01693848||Control patients|Patients with metastatic colorectal cancer scheduled for general anesthesia without metastatic surgery
3284279|NCT01693861||Patients|Patients with metastatic colorectal cancer treated with chemotherapy
3284280|NCT01693874|Experimental|Mindfulness Based Stress Reduction|All participants in this arm receive Mindfulness Based Stress Reduction (MBSR).
3284281|NCT01693874|Active Comparator|control|All participants in this arm receive an attention control
3284282|NCT01693887||empirical therapy|immediate initiation of antifungal therapy; Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid)
3284283|NCT01693887||preemptive therapy|Dynamic monitoring of fungal infection, initiation antifungal therapy when clinical diagnosis ( microbial + experiment +, G/GM, CT typical change ) approveled in two weeks Itraconazole :1-14day,iv；(400mg/day bid 1-2day, 200mg/day q.d 3-14day) 15-28day,p.o(400mg/day bid) If within two weeks without obtaining positive results, researchers determine whether initiation of antifungal therapy。
3284284|NCT01693913|Experimental|Cognitive-behavioral|Those participating in a cognitive behaviorally supported exercise and nutrition treatment will receive a cognitive behavioral exercise and nutrition over 50 weeks
3284285|NCT01693913|Active Comparator|Nurtition education|This arm will participate in nutrition and exercise education
3284286|NCT01693926|Experimental|Acute physical activity intervention|25 min of moderate physical activity
3284287|NCT01693926|Placebo Comparator|Placebo|25 min of reading (instead of physical activity)
3284288|NCT01693939|Other|FS200 Femtosecond Laser|The LASIK flap will be created using the FS200 Femtosecond Laser
3284289|NCT01693952|Experimental|blood samples|
3284290|NCT01693965|Other|sputum samples|
3284291|NCT01693978|Experimental|Reinforced Prolonged Exposure (RPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks. RPE participants will receive voucher-based reinforcement contingent on attendance to scheduled Prolonged Exposure therapy sessions.
3284292|NCT01693978|Active Comparator|Standard Prolonged Exposure (SPE)|All participants will be scheduled to attend a weekly Prolonged Exposure therapy session for 12 consecutive weeks, and followed for 12 additional weeks.
3284293|NCT01693991|Experimental|Meaning-Making intervention (MMi)|Patients in this arm will be receiving the Meaning-Making intervention (MMi) as per intervention manual (Lee, 2006).
3284294|NCT01693991|Placebo Comparator|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
3284295|NCT01693991|No Intervention|Control Group|Patients in this group will only be receiving treatment as usual.
3284296|NCT01694004|Experimental|Benzocaine Infusion into Duodenum|The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid traces and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow the investigators to determine if LCFA can alter nutrient absorption and glucose and amino acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK, GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs) will be measured during all infusion periods.
3284297|NCT01694017|Active Comparator|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
3284298|NCT01694017|Active Comparator|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
3284299|NCT01694030|Experimental|Neutral Condition|Participants in the neutral (control) condition of the attachment security priming experiment will be asked to spend time visualising neutral events (e.g., supermarket shopping)for 3-10 minutes at a time.
3284300|NCT01694030|Experimental|Secure condition|Participants in the attachment security priming condition will be asked to complete visualisation tasks where they think about a secure attachment figure for between 3 - 10 minutes.
3284301|NCT01694043|Experimental|Non-Food Related Commercials|Participants will watch a 30-minute Saturday Night Live television show with non-food related commercials embedded.
3284302|NCT01694043|Experimental|Healthy Food Commercials|Participants will watch a 30-minute Saturday Night Live television show with healthy food commercials embedded.
3284303|NCT01694043|Experimental|Unhealthy Food Commericlas|Participants will watch a 30-minute Saturday Night Live television show with unhealthy food commercials imbedded.
3284304|NCT01694056|Experimental|Soy protein diet|High mixed protein diet (20 en%) with 25gr of soy protein per day
3284305|NCT01694056|Active Comparator|Control diet|High mixed protein diet (20 en%)
3284306|NCT01694069|Active Comparator|Intermittent Infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
3284307|NCT01694069|Experimental|Continuous infusion piperacillin-tazobactam|Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily
3284308|NCT01694082|Experimental|THRIVE replication|Participants in this condition receive THRIVE with a full list of direct and indirect protective behavioral strategies to reduce alcohol consumption.
3284309|NCT01694082|Experimental|THRIVE direct strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are directly related to alcohol drinking.
3284310|NCT01694082|Experimental|THRIVE indirect strategies|Participants in this condition receive THRIVE including a subset of protective behavioral strategies that are indirectly related to alcohol drinking.
3284311|NCT01694082|Sham Comparator|Brief brochure and assessment control|Participants will answer the same survey questions as participants in the THRIVE conditions, but will receive a brief alcohol-related brochure with only didactic content rather than the intervention components received by participants randomized to THRIVE conditions.
3284312|NCT01694095||Patients with geographic atrophy|
3284313|NCT01694134|Active Comparator|Corticoids|A group of patients will receive an intradiscal injection of Hydrocortancyl.
3284314|NCT01694134|Sham Comparator|Local anaesthetic|A group of patients will receive an intradiscal injection of Lidocaine.
3284315|NCT01694147||patients with sepsis related ALI/ARDS.|Consecutive septic patients with ALI/ARDS in medical intensive care units (ICUs) will be enrolled. EVLWI will be measured by PiCCO monitoring system.
3284316|NCT01694160|Experimental|Paricalcitol|Paricalcitol 2 ug/daily for 48 weeks
3284317|NCT01694160|No Intervention|no intervention|
3284318|NCT01694173|Experimental|Stem cell therapy - SPD artery|Stem cells will be infused into the superior pancreaticoduodenal artery.
3284319|NCT01694173|Active Comparator|Stem cell therapy - splenic artery|Stem cells will be infused into the splenic artery.
3284320|NCT01694173|Active Comparator|Stem cell therapy-intravenous|Stem cells will be given intravenously.
3284321|NCT01694173|Placebo Comparator|Normal saline placebo -sham procedure|Sham procedure with infusion of normal saline.
3284322|NCT01694212|Experimental|Diclofenac|Patients with diabetic retinopathy having preoperative treatment with diclofenac
3284323|NCT01694212|Placebo Comparator|Placebo|Control group having placebo treatment
3284324|NCT01694225|Experimental|bubble package for monthly prescription|use of bubble packaging for monthly prescription
3284325|NCT01694238|Active Comparator|Cruciate incision|Cruciate incision in the abdominal wall fascia
3284326|NCT01694238|Experimental|Circular incision|Circular incision in the fascia
3284327|NCT01694238|Experimental|Mesh enforced cruciate incision|Mesh enforcement and then cruciate incision in the abdominal wall fascia
3284328|NCT01694264|Experimental|Experimental Group|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
3284329|NCT01694264|Placebo Comparator|Control Group|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
3284330|NCT01694277|Experimental|Masitinib|Participants receive masitinib (12 mg/kg/day), given orally twice daily.
3284331|NCT01694277|Active Comparator|Sunitinib|Participants receive sunitinib, given at 50 mg/day for 4 consecutive weeks out of 6 weeks, orally
3284332|NCT01694290|Experimental|Chemical Ice packs to neck, groin, axillae|Chemical ice packs will be changed out every 9 minutes
3284333|NCT01694290|Experimental|Chemical Ice Packs to cheeks, palms, soles|Chemical Ice packs will be changed out every 9 minutes
3284334|NCT01694290|No Intervention|no chemical ice packs|
3284335|NCT01694303|Active Comparator|Engaging computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3284336|NCT01694303|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3284337|NCT01694316|Active Comparator|Engaging in Computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3284338|NCT01694316|Experimental|Neurobehavioral computerized tasks|Participants will log into a personalized website and engage in computerized tasks online.
3284339|NCT01694329||2006-2010 cohort|cohort of children born between 2006 and 2010, and living in Nunavik
3284340|NCT01694355|Experimental|Vitamin D treatment|We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.
3284341|NCT01694381|Experimental|mutant pro-urokinase (M5) alone|In the first study part subjects in cohorts of 4 will receive ascending doses of either M5 (3 subjects) or M5-placebo (1 subject) without C1-inhibitor.
3284342|NCT01694381|Experimental|Mutant pro-urokinase (M5) and its inhibitor, C1 inhibitor|"In the second study part subjects in cohorts of 5 will receive ascending doses of either M5 or M5-placebo, preceded by a single intravenous dose of C1-inhibitor or C1-inhibitor-placebo. Each subject will randomly be allocated to one of the following treatment arms within one cohort:~C1-inhibitor followed by M5 (3 subjects);~C1-inhibitor followed by M5-placebo (1 subject);~C1-inhibitor-placebo followed by M5-placebo (1 subject).~Dose levels of both M5 and C1-inhibitor within each cohort will be chosen based on the available safety, pharmacokinetic and pharmacodynamic data of the preceding cohorts."
3284343|NCT01694394||Cohort|Single arm cohort will receive a St. Jude Medical Implantable Cardiac Monitor (Confirm ICM model 2102) for continuous monitoring over the study follow-up period to determine incidence of sub-clinical atrial fibrillation.
3284344|NCT01694407|Active Comparator|TFV Alone Vaginal Tablet|
3284345|NCT01694407|Active Comparator|Emtricitabine (FTC) Alone Vaginal Tablet|
3284346|NCT01694407|Active Comparator|TFV Combined with FTC Vaginal Tablet|
3284347|NCT01694407|Placebo Comparator|Placebo Vaginal Tablet|
3284348|NCT01694446|Experimental|Intraduodenal glucose or fructose|
3284349|NCT01694459|Active Comparator|Standard dose heparin|Bolus of 100 UI/Kg of heparin. Activated clotting time (ACT) > 300 sec. during the procedure
3284350|NCT01694459|Experimental|Low-dose heparin|Bolus of 50 UI/Kg heparin with a target ACT during the procedure of >200 sec.
3284351|NCT01694472|Experimental|MAGE-A4 TCR Gene-Modified T Cells|
3284352|NCT01694498|Active Comparator|A. Desmopressin 25 µg|1 orally disintegrating tablet every night during study period
3284353|NCT01694498|Active Comparator|B. Desmopressin 50 µg|1 orally disintegrating tablet every night during study period
3284354|NCT01694498|Placebo Comparator|C. Placebo|1 orally disintegrating tablet every night during study period
3284355|NCT01694511|Active Comparator|Introductory conventional endoscopy|Conventional endoscopy followed by HRME+CVC after 30 days.
3284356|NCT01694511|Active Comparator|Introductory HRME+CVC|HRME+CVC followed by conventional endoscopy after 30 days.
3284357|NCT01694537|Placebo Comparator|placebo|The comparison drug is placebo, which is made with same size and shape with study drug. DLBS1033 and placebo is produced by PT Dexa Medica. Placebo will taken 3 times 1 tablet per day for 7 days. Wash out period before enter another arm is 7 days.
3284358|NCT01694537|Experimental|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction. The drug will taken 3 times 490 mg per day for 7 days. Wash out period before enter another arm is 7 days.
3284359|NCT01694550||Pacemaker mode programming|High grade AV-block
3284360|NCT01694576|Experimental|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients will receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
3284361|NCT01694576|No Intervention|Observation|Patients will be followed up without adjuvant chemotherapy after concurrent chemoradiation
3284362|NCT01694589|Experimental|LDE-225|LDE-225: dose - 800 mg, taken by mouth once daily for 2 weeks.
3284363|NCT01694602||Newly Diagnosed NSCLC patients|In this study, newly diagnosed NSCLC patients who are not candidates for curative resection, will receive a (non-radioactive) oral dose of deuterated 3-methylhistidine (D-3MH).
3284364|NCT01694615|Active Comparator|Cryoprobe biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
3284365|NCT01694615|Active Comparator|Forceps Biopsy|All patients enrolled will undergo standard forceps biopsies followed by cryoprobe biopsies and results will be compared
3284366|NCT01694628|Experimental|CLIMB (COPD Lifestyle, Mood, and Behavior)|Counseling sessions for COPD and depression
3284367|NCT01694628|No Intervention|Control|Usual Care
3284368|NCT01694680|Active Comparator|Lutein-enriched-egg beverage|Powder in sachets is provided and dissolved to prepare Lutein-enriched-egg beverage
3284369|NCT01694680|Placebo Comparator|Placebo|Powder in sachet to prepare beverage
3284370|NCT01694693||RA patients treated by Orencia|RA patients treated by Orencia according to usual practice from June 1st 2007
3284371|NCT01694719|Experimental|Behavioral Activation + Cognitive Control Training|Participants will receive 5 sessions of behavioral activation therapy concurrent with 4 sessions of cognitive control training, a computerized intervention which targets cognitive control processes such as working memory and attention.
3284372|NCT01694719|Active Comparator|Behavioral Activation Therapy plus Control Task|Participants will receive 5 sessions of behavioral activation therapy and 4 sessions of a non-active, computerized control task.
3284373|NCT01694732|Experimental|varenicline with counselling|Active varenicline associated with intensive smoking cessation counselling
3284374|NCT01694732|Placebo Comparator|Placebo with counselling|Placebo of varenicline associated with intensive smoking cessation counselling
3284375|NCT01694758||Patients with diabetes type 2|
3284376|NCT01694784|Experimental|Quantitative|In the quantitative arm, we will present harms as absolute risks in the Quantitative Information Sheet. Compared with other risk formats, absolute risks have been shown to improve understanding relative to other common risk formats.
3284377|NCT01694784|Active Comparator|Qualitative|In the qualitative arm, we will describe harms using verbal descriptors (such as rare, uncommon, fairly common, and common) in the Qualitative Information Sheet.
3284378|NCT01694784|Experimental|Narrative|In the narrative arm, we will present harms using patient narratives (i.e. descriptions in which patients describe their experience with decision making about potentially harmful screening services)in the Narrative Information Sheet. To address concerns in the literature that characteristics of the narrator independently influence narrative effect, we will present narratives in paper format with a banner of culturally diverse age-appropriate pictures shown at the top.
3284379|NCT01694784|Experimental|Framed|In the framed arm, we will frame not screening with potentially harmful services as beneficial (i.e. use a gain frame). In the Framed Information Sheet, we will highlight the harms that could be avoided by not getting screened.
3284380|NCT01694797|Experimental|Metoprolol Succinate ER Tablets, 50 mg|Metoprolol Succinate ER Tablets, 50 mg of Dr.Reddy's Laboratories Ltd
3284381|NCT01694797|Active Comparator|TOPROL-XL ER Tablets 50 mg|TOPROL-XL ER Tablets 50 mg of AstraZeneca
3284382|NCT01694810|Experimental|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
3284383|NCT01694810|Experimental|4% NVN1000 Topical Gel|4% NVN1000 4% Topical Gel once daily for 4 weeks
3284384|NCT01694810|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel once daily for 4 weeks
3284385|NCT01694810|Experimental|8% NVN1000 Topical Gel|8% NVN1000 8% Topical Gel applied once daily for 4 weeks
3284386|NCT01694823|Experimental|CS-ACI|"Group/Cohort Label： pretherapy post-treatment~Group/Cohort Description ：The CS-ACI is used to prepare cell sheet and implant to the Cartilage defects.The arm of safety and efficacy are compared preoperative observation with postoperative observation."
3284387|NCT01694836|Experimental|Depigoid Birch 5.000 DPP/ml|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
3284388|NCT01694836|Placebo Comparator|Placebo|"Suspension for s.c. injection. Treatment schedule:~Build-up phase (1 day: 0,2 ml+0,3 ml at interval of 30 minutes)~Maintenance phase (3 years: 0,5 ml at intervals of 4-6 weeks)"
3284389|NCT01694849|Experimental|GFT505 80mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
3284390|NCT01694849|Experimental|GFT505 120mg|Hard gelatin capsules dosed at 40mg, oral administration, 3 capsules per day before breakfast with a glass of water.
3284391|NCT01694849|Placebo Comparator|Placebo|hard gelatin capsules, oral administration, 3 capsules per day before breakfast with a glass of water.
3284392|NCT01694862|Experimental|Integrated FP /PNC service delivery|Clinic or district identified as 'intervention' in which FP and PNC services are (theoretically) being provided together with HIV services (counselling, testing, treatment etc.) and in which the procedural intervention has been applied.
3284393|NCT01694862|No Intervention|Non-integrated FP/PNC service delivery|Clinic or district where FP and PNC services are not (theoretically) being provided together with HIV services, and in which no procedural intervention has been applied.
3284394|NCT01694875||No Treatment|
3284395|NCT01694888|Experimental|midwifery students|all midwifery students studying at last term (except one who was absent) (27) in Mashhad school of nursing and midwifery in April 2011
3284396|NCT01694901||SmartPilot® system|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia using the SmartPilot® system
3284397|NCT01694901||Standard arm|50 patients scheduled for elective surgery (general/abdominal surgery; traumatological/orthopedic surgery, gynecology, urology) in general anesthesia according to the standard operating procedures of the department, i.e. manually controlled clinical anesthesia and EEG-derived parameters of anesthetic depth
3284398|NCT01694914|Experimental|Animal Compound Free Medium|Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium
3284399|NCT01694914|Active Comparator|organ culture medium containing 2% of fœtal calf serum|Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum
3284400|NCT01694927|Experimental|Mesenchymal Stem cells|
3284401|NCT01694940||Mitochondrial Disease Patients|Patients with possible or known mitochondrial disorders. Patients who are known carriers of mitochondrial or nuclear DNA mutations involved in mitochondrial function.
3284402|NCT01694953||Patients with MNGIE|Patients of all races of any gender who are at least 5 years of age with a defect in thymidine phosphorylase may participate in this natural history study.
3284403|NCT01694979||Single group: pelvic floor and breathing|This is a single group with repeated measures during variable breathing effort
3284404|NCT01694992|Experimental|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after stroke, five times per week for 30 plus a time spent out of bed (sitting).
3284405|NCT01694992|No Intervention|Control|The Control Group will follow within the routines of the hospital as is usually done.
3284406|NCT01695005|Experimental|LY3039478 - Dose Escalation|Part A: LY3039478 administered orally three times per week (TIW) at escalating doses (2.5 milligrams [mg] to 100 mg) for two 28 day cycles. Participants receiving benefit may continue until disease progression
3284407|NCT01695005|Experimental|LY3039478 - Cohort Expansion|Part B, C, D and E: LY3039478 administered orally three times per week (TIW) at a fixed dose determined in Part A for two 28 day cycles. Participants receiving benefit may continue until disease progression.
3284408|NCT01695005|Experimental|Dose 1 LY3039478 + Prednisone|Part F1: LY3039478 administered orally TIW for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only (28 day cycles). Participants receiving benefit may continue until disease progression.
3284409|NCT01695005|Experimental|Dose 2 LY3039478 + Prednisone|Part F2: LY3039478 administered orally TIW (twice a week in cycle 1) for 28 day cycles. Prednisone will be co-administered with LY3039478 for the first 2 weeks in cycle 1 only. Participants receiving benefit may continue until disease progression.
3284410|NCT01695018||p16 methylation positive|48 patients with mild or moderate oral epithelial dysplasia containing methylated p16.
3284411|NCT01695018||p16 methylation negative|104 patients with p16 mild or moderate oral epithelial dysplasia NOT containing methylated p16.
3284412|NCT01695031|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions of web-based, tailored asthma management
3284413|NCT01695031|Active Comparator|Generic web-based education|Teens in the control group will receive generic, web-based asthma education.
3284414|NCT01695057|Experimental|Treatment (vorinostat and surgery)|Patients receive vorinostat 400 mg daily PO on days 1-21 followed by surgery within 14 days.
3284415|NCT01695070|Experimental|Melatonin|Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.
3284416|NCT01695096|Experimental|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
3284417|NCT01695096|Placebo Comparator|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to > 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
3284418|NCT01695109|Placebo Comparator|Placebo|
3284419|NCT01695109|Active Comparator|Liraglutide|
3284420|NCT01695122|Experimental|valproic acid|
3284421|NCT01695148|Active Comparator|White Maize Flour|Children will receive 2 meals a day (~200 g of white maize flour), 6 days a week for 6 months.
3284422|NCT01695148|Experimental|β-Carotene Biofortified Maize|Children will receive 2 meals a day (~200 g of beta-carotene biofortified maize flour), 6 days a week for 6 months.
3284423|NCT01695148|No Intervention|Non-Intervened|Children will receive no food for the duration of the study, but families in this group will receive an equivalent ration of food items at the end of the trial.
3284424|NCT01695161||mucopolysaccharidosis|mucopolysaccharidosis
3284425|NCT01695161||Fabry disease|Fabry disease
3284426|NCT01695161||healthy controls|healthy controls
3284427|NCT01695174|Experimental|Xifaxan|Xifaxan 550 mg two times per day for three months
3284428|NCT01695187|Experimental|NB-001 (0.3%)|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and two surfactants: polysorbate (Tween) 20 and cetylpyridinium chloride (CPC).
3284429|NCT01695187|Placebo Comparator|Vehicle|NB-001 is an oil-in-water emulsion composed of nanometer-sized, positively charged droplets (average particle size = 180nm). NB-001 is composed of highly refined soybean oil, purified water, ethanol, edetate disodium dihydrate (EDTA) and one surfactant: polysorbate (Tween) 20.
3284430|NCT01695200|Experimental|Omega-3 Fatty Acids|15ml omega-3 liquid form, twice a day for 12 weeks (Total daily dosage:840mg DHA and 192mg EPA)
3284431|NCT01695213|Active Comparator|HA-Omnifit|Patients who receive a HA-Omnifit uncemented hip stem
3284432|NCT01695213|Active Comparator|Symax hip stem|Patients with the Symax uncemented hip stem
3284433|NCT01695226|Placebo Comparator|placebo|pre-operative placebo twice daily for two to three weeks
3284434|NCT01695226|Experimental|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
3284435|NCT01695252|No Intervention|S-Sup|Standard supervision
3284436|NCT01695252|Experimental|MEMOS|Patient informed clinical outcomes supervision
3284437|NCT01695265|Experimental|Exercie oronasal breathing (ONB)|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with oronasal breathing (ONB) (Without FeelBreathe device)
3284438|NCT01695265|Experimental|Exercie nasal breathing through the FB|Exercise protocol was walking on a treadmill for 10 minutes at a constant rate at 50% of VO2peak with nasal restriction using FeelBreathe device.
3284439|NCT01695278|Active Comparator|Standard Care|Participants will receive standard care from physicians for monitoring and treating their diabetes. They are placed on a wait list to receive the intervention.
3284440|NCT01695278|Experimental|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
3284441|NCT01695317|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine tablets
3284442|NCT01695317|Placebo Comparator|Sugar pills|Glucose with lemon acid
3284443|NCT01695343|Experimental|KB001-A|KB001-A administered up to 5x intravenously (IV) at 10 mg/kg up to a maximum dose of 800 mg per dose.
3284444|NCT01695343|Placebo Comparator|Placebo Comparator|Placebo administered up to 5x intravenously
3284445|NCT01695356|Active Comparator|290-400 nm sunscreen|"Sunscreen containing Mexoryl SX, Mexoryl XL, Titanium Dioxide, Octocrylene, Tinosorb S, Avobenzone, and Ethylhexyl triazone.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
3284446|NCT01695356|Experimental|290-800 nm sunscreen|"Sunscreen containing Benzophenone-3, Octinoxate, Octocrylene, Titanium Dioxide, Zinc Oxide, and iron oxide.~Fluid vehicle administered daily, from 8AM to 5PM every 3 hr, for 12 weeks."
3284447|NCT01695382|Experimental|Navigation|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy. In addition they will have 5 navigator initiated home visits to review the educational materials and help patients and families address barriers to palliative care through education, advocacy, and activation.
3284448|NCT01695382|No Intervention|Control|Participants randomized to the control arm of the study will receive a packet of written materials that are appropriate linguistically and written for individuals with low health literacy.
3284449|NCT01695395||Intellectual disabled adults without a mental disorder|
3284450|NCT01695395||Intellectual disabled adults with a mental disorder|
3284451|NCT01695421|Experimental|Functional electrical stimulation|Burst modulated alternating rectified current with a 10 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
3284452|NCT01695421|Experimental|Medium-frequency alternating current|Burst modulated alternating current with a 2500 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts
3284453|NCT01695421|Experimental|Burst-modulated alternating current|Burst modulated alternating current with a 4000 Hz carrier frequency, 400 microsecond pulse duration and 50 Hz bursts.
3284454|NCT01695421|Placebo Comparator|Placebo|Training with the intensity of 5 mA.
3284455|NCT01695434||Copaxone MRI|Patients with relapsing-remitting multiple sclerosis who take Copaxone will have a MRI.
3284456|NCT01695434||Healthy Controls MRI|Subjects who are otherwise healthy, without neurological disorders, will have a MRI.
3284457|NCT01695447|Experimental|duct-to-mucosa|duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
3284458|NCT01695447|Active Comparator|invagination|invagination technique is used for pancreaticojejunostomy after pancreaticoduodenectomy
3284459|NCT01695460|Active Comparator|Vitamin D|"The active treatment consists of vitamin D and is given in tablets of the brand D3 Vitamin ®, supplied by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.~The tablets contain the vitamin D in the form of vitamin D3, also known as cholecalciferol.~D3 Vitamin ® consists of small white tablets, which are easy to swallow.~D3 Vitamin ® contains 25 micrograms vitamin D3 (colecalciferol) per tablet, equivalent to 1000 IU (International Units).~Tablet Excipients: Cellulose, dicalcium phosphate, magnesium stearate, silicon dioxide and talc. Vitamin D3 ® contains no gluten, soy, gelatin or other animal products."
3284460|NCT01695460|Placebo Comparator|Placebo|Placebo tablets to match D3 Vitamin ®, were produced. They are identical to the D3 Vitamin ® in appearance, ie small white tablets. These tablets do not have a therapeutic effect. Placebo tablets produced and delivered by D3 Pharmacy Ltd., Bispensgade 22, 9000 Aalborg.
3284461|NCT01695499||Immunosuppressed ICU Patients with lung infiltrates|Immunosuppressed ICU Patients with lung infiltrates
3284462|NCT01695499||Control Group|BAL and blood aliquots of 20 immunocompetent pts (suffering from lung diseases) will be collected and tested identically as a control population.
3284463|NCT01695512||Immunocompromised Patients|Patients with acute leukemia undergoing induction chemotherapy or undergoing allogeneic stem cell transplantation
3284464|NCT01695512||Control Group|Patients underdoing bronchoscopy and diagnostic BAL without immunosuppression and without signs of infection (Sarcoidosis, Lung Cancer)
3284465|NCT01695525|Experimental|Yoga|Participants will be asked to practice Yoga 3 times per week at a minimum, and daily at a maximum. Participants will receive training in different Yoga techniques including breathing exercises, postures and meditation. Participants will be asked to practice 1 hour Yoga sessions comprised of breathing exercises, postures and meditation.
3284466|NCT01695538|Experimental|Yoga|Participants will be asked to practice yoga 3 days per week, at a minimum and encouraged to practice 7 days per week, for 1 year.
3284467|NCT01695551||Ventricular Tachycardia|Participants in cohort will have implantable defibrillators in-situ and are undergoing ablation procedure for ventricular tachycardia.
3284468|NCT01695564||WATCHMAN|Patients that had the WATCHMAN device implanted
3284469|NCT01695564||LARIAT LAA Device|patients that had LARIAT LAA device implanted
3284470|NCT01695577|Experimental|Multidisciplinary evaluation and VR|Vestibular rehabilitation and balance training. Twice a week for eight weeks.Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
3284471|NCT01695577|Active Comparator|Multidisciplinary evaluation and no VR|Multidisciplinary evaluation. Outcome measures and tests at baseline, after 8 weeks and 6 months after the injury.
3284472|NCT01695590|Experimental|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle
3284473|NCT01695603|No Intervention|Standard mode of controlled ventilation|Each brain injured patient will be ventilated during two hours with a standard mode of controlled ventilation.
3284474|NCT01695603|Experimental|Intellivent arm|Each brain injured patient will be ventilated during two hours with an automated mode of ventilation, the Intellivent mode.
3284475|NCT01695616|Placebo Comparator|Placebo|Patients enrolled in this arm will take a tablet twice a day
3284476|NCT01695616|Active Comparator|Passiflora incarnata and isoflavona combination|Patients enrolled in this arm will take a tablet twice a day
3284477|NCT01695629||None to Mild|Subjects with Diabetes with none to mild peripheral neuropathy
3284478|NCT01695629||Severe|Subjects with diabetes with severe neuropathy
3284479|NCT01695642||Microkeratome|mechanical microkeratome
3284480|NCT01695642||Intralase|femtosecond laser
3284481|NCT01695655||PKP|Subjects undergoing penetrating keratoplasty
3284482|NCT01695681|Other|Dietary instruction|Gluten-free diet
3284483|NCT01695694|Active Comparator|community support group|
3284484|NCT01695694|Experimental|supporting positive and healthy relationships|
3284485|NCT01695707|Placebo Comparator|Placebo|"Subjects randomized to placebo will receive opaque size 00 gelatin capsules containing 240mg lactose. As with the intervention group, 1 capsule will be taken by each day throughout the treatment period."
3284486|NCT01695707|Experimental|Pioglitazone|"Subjects randomized to pioglitazone will receive opaque size 00 gelatin capsules containing pioglitazone. For the first 3 weeks, capsules will contain 30 mg pioglitazone. For the remaining 9 weeks of the treatment period, capsules will contain 45 mg pioglitazone unless subjects are unable to tolerate this increased dose.~One capsule will be taken by each day throughout the treatment period."
3284487|NCT01695720|Experimental|VisionScope Imaging (VSI) Exam|A VisionScope Imaging (VSI) Exam is diagnostic arthroscopic procedure. Through a natural or surgical opening, an endoscope is inserted through a cannula to illuminate and visualize the interior cavity of a joint.
3284488|NCT01695733|Experimental|Schedule A|Influenza vaccination on the first day of chemotherapy
3284489|NCT01695733|Experimental|Schedule B|Influenza vaccination 1 week (+/- 1 day) prior to chemotherapy
3284490|NCT01695759|Experimental|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
3284491|NCT01695759|Active Comparator|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
3284492|NCT01695785||Healthy weight|greater than or equal to the 5th to less than the 85th BMI percentile
3284493|NCT01695785||Obese|greater than or equal to the 95th BMI percentile
3284494|NCT01695798|No Intervention|Chronic malnourished bOPV|This arm will receive only bOPV
3284495|NCT01695798|Experimental|Malnourished IPV+bOPV|This arm will receive IPV and bOPV
3284496|NCT01695798|No Intervention|Normally nourished bOPV|This arm will receive only bOPV
3284497|NCT01695798|Experimental|Normally nourished IPV+bOPV|This arm will receive both IPV and bOPV
3284498|NCT01695811||FLAK|FLAK
3284499|NCT01695811||PKP|Retrospective
3284500|NCT01695824|Active Comparator|LAA occluder|
3284501|NCT01695824|Active Comparator|Warfarin|
3284502|NCT01695837|Experimental|Group A-dietary counseling month 0-6|"Group A Visit #1 - Weight, height, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the primary care physician (PCP) reviewed the results of the fasting lipid panel and diet test with the patient; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #2 - Same as visit #1. Weekly automatic emails sent to patient reminding to visit the counseling website.~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
3284503|NCT01695837|Other|Group B- Dietary counseling month 3-6|"Group B Visit #1: Weight, height, blood pressure and pulse were measured at the beginning of the visit. Follow up visit and lab order were scheduled for 3 months. No blood test or diet test results were reviewed with the patient.~Visit #2 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the two fasting lipid panels ; the PCP provide the patient with written educational materials and access to the counseling website. Weekly automatic emails sent to patient reminding to visit the counseling website~Visit #3 - Weight, blood pressure and pulse were measured at the beginning of the visit. During a focused office visit the PCP reviewed the results of the new fasting lipid panel and diet test with the patient."
3284504|NCT01695850|Experimental|MZRW|MZRW is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo).
3284505|NCT01695850|Active Comparator|Senna|Senna is a stimulant laxative which facilitates the passage of stools by altering intestinal electrolyte transport and increasing intestinal motor activity.
3284506|NCT01695850|Placebo Comparator|Placebo|Placebo MZRW and Placebo Senna
3284507|NCT01695863|Experimental|miralax|miralax with dulcolax and gatorade efficacy evaluated by colonoscopy and patient satisfaction evaluated by patient questionnaire
3284508|NCT01695863|Experimental|moviprep split dose|Efficacy of split dose moviprep on cleansing colon for colonoscopy and patient satisfaction with the regimen
3284509|NCT01695876|Experimental|AMG 357|AMG 357 is a small molecule for treatment of inflammatory disease
3284510|NCT01695876|Placebo Comparator|Placebo|Matching placebo to AMG 357 containing no active drug
3284511|NCT01695902|Experimental|Levosert-20|Levosert is a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG in a cylindrical-shaped reservoir. The reservoir is mounted on the vertical arm of a T-shaped plastic frame and is covered with a release rate controlling membrane.
3284512|NCT01695902|Active Comparator|Mirena®|Mirena® IUS, Bayer-Schering, a LNG-releasing Intrauterine Delivery System (IUS) containing 52 mg of LNG.
3284513|NCT01695915||Healthy|Transabdominal ultrasound
3284514|NCT01695915||Constipated|Transabdominal ultrasound
3284515|NCT01695928|Active Comparator|Extracorporeal shockwave therapy (ESWT)|Active treatment
3284516|NCT01695928|Placebo Comparator|ESWT Placebo|No extracoporeal shockwave therapy
3284517|NCT01695967|Experimental|Turbinate Cauterization|Turbinate Cauterization will be completed.
3284518|NCT01695967|No Intervention|control|no turbinate cauterization
3284519|NCT01695980|Experimental|LMA with modified retractor|LMA with modified retractor
3284520|NCT01695980|Active Comparator|ETT with non modified retractor|ETT with non modified retractor
3284521|NCT01696019|Experimental|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
3284522|NCT01696019|Active Comparator|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
3284523|NCT01696019|Active Comparator|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
3284524|NCT01696019|Placebo Comparator|Contact and testing only|The fourth group received no intervention. Contact was maintained by phone during the intervention period to reduce dropout. Participants were called four times during the 40 weeks intervention period by the study coordinator.
3284525|NCT01696097|Other|Dietary Counseling|Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure
3284526|NCT01696110|Experimental|Bivalirudin|Bivalirudin will be started in the cath lab, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per h infusion; if ACT<225s 5min after bolus, an additional dose of 0.3mg/kg bolus should be given. After procedure, a prolonged infusion (1.75mg/kg per h) will be given for at least 30 min (totally no more than 4 h) followed by a reduced dose infusion (0.2mg/kg per h) up to 20 h.
3284527|NCT01696110|Active Comparator|Heparin monotherapy|100 IU/kg intravenous bolus. If ACT <225s 5 min after bolus injection, additional dose of heparin (20U/kg) will be given.
3284528|NCT01696110|Active Comparator|heparin plus tirofiban|heparin 60 IU/kg intravenous bolus and Tirofiban: 10μg/kg intravenous bolus followed by 0.15μg/kg per min infusion for up to 36h.
3284529|NCT01696123|Experimental|MLC601|MLC601 (NeuroAid, Moleac Pte. Ltd, Singapore) (0.4 g per capsule) was prescribed as one capsule three times daily without an escalation dose.
3284530|NCT01696136|Active Comparator|AF-Ablation with Multi-electrode catheter|Regular AF-ablation with a multi-electrode ablation catheter
3284531|NCT01696136|Active Comparator|AF-Ablation with single-tip electrode|Regular AF-ablation with a regular single-tip ablation catheter
3284532|NCT01696149|Experimental|electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz transcutaneous electrical nerve stimulation session, a 110 Hz transcutaneous electrical nerve stimulation session, and a control (off-transcutaneous electrical nerve stimulation) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period
3284533|NCT01696162|Active Comparator|PDF exercise sheets|Participants in this arm will receive a PDF sheet of 6 exercises that are commonly administered for the treatment of anterior knee pain. They will be asked to perform the exercises three times a week for 6 weeks. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
3284534|NCT01696162|Active Comparator|Limited Exercise Videos|"Participants in this arm will receive the same six exercises as provided in the PDF sheet in arm 1 in a video format. They will be asked to perform the exercises three times per week for 6 weeks.~A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety."
3284535|NCT01696162|Experimental|Algorithm based Exercise Videos|Participants in this arm will be provided a 6 week regimen of exercise videos for their anterior knee pain. Following each exercise session, the participant will be asked for their input concerning each exercise. The algorithm will adjust the exercise regimen for the next session based on the participants input. A questionnaire will be administered at the three, six and twelve week mark to evaluate efficacy, compliance and safety.
3284536|NCT01696175||PICU admittance|Children equipped with an arterial and a central venous catheter within 12 hours after admittance to a Dutch PICU
3284537|NCT01696201|No Intervention|Control group|Sedentary pregnant women
3284538|NCT01696201|Experimental|Exercise group|Exercise program
3284539|NCT01696227||Nissle 1917|In vitro, Nissle 1917's ability to adversely affect the growth of uropathogens associated with urinary catheters and those with a known GI resevoir will be measured.
3284540|NCT01696240|Placebo Comparator|Placebo|Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3284541|NCT01696240|Active Comparator|Udenafil|Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
3284542|NCT01696253||Subjects at risk for Alport sydrome|
3284543|NCT01696253||Newly identified subjects with Alport syndrome|
3284544|NCT01696266||Insulin-treated patients with diabetes|
3284545|NCT01696305|Experimental|Hyalobarrier|ACP200 (Auto-crosslinked polysaccharide:inner ester of hyaluronic acid) 30mg/ml*10ml/syringe and 5cm-cannula
3284546|NCT01696305|Active Comparator|Guardix-SG|Poloxamer/sodium alginate mixture 6g/syringe
3284547|NCT01696318|No Intervention|Educational program|Educational Program with Professional Physical Education, Pharmacist and Nutritionist
3284548|NCT01696318|Experimental|Educational program and individual care|Educational program and individual care with professional Physical Education; Pharmacist and Nutritionist
3284549|NCT01696331|Experimental|Text Message Reminder|
3284550|NCT01696344||Cohort 1|No additional ablation after AF termination(PVAI only)
3284551|NCT01696344||Cohort 2|Additional ablation of extra-PV triggers before and after isoproterenol-challenge after AF termination (PVAI + ablation of extra-PV triggers)
3284552|NCT01696370|Active Comparator|Trimetazidine|
3284553|NCT01696370|Placebo Comparator|Placebo capsule|
3284554|NCT01696383|Experimental|DuoTrav|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
3284555|NCT01696409||Arm A|400 IU vitamin D3 once a day for 2 months
3284556|NCT01696409||Arm B|2000 IU Vitamin D3 once/day for 2 months
3284557|NCT01696422|Experimental|Step A: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Two doses with a six-months interval, SC
3284558|NCT01696422|Active Comparator|Step A:dengue liquid vaccine|TetraVax-DV Vaccine - Admixture TV003 Two doses with a six-months interval, SC
3284559|NCT01696422|Placebo Comparator|Step A: Placebo|Placebo comparator Two doses with a six-months interval, SC
3284560|NCT01696422|Experimental|Step B: dengue lyophilized vaccine|Dengue 1,2,3,4 (attenuated) vaccine Single dose, SC
3284561|NCT01696422|Placebo Comparator|Step B: Placebo|Placebo comparator Single dose, SC
3284562|NCT01696435|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3284563|NCT01696435|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3284564|NCT01696435|Active Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~Fish oil placebo"
3284565|NCT01696435|Active Comparator|Vitamin D + fish oil|"Vitamin D3 (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3284566|NCT01696448|Experimental|Experimental Group|CAR-191: Berberine 200mg, Alpha-lipoic Acid 150mg, Picrorhiza 100mg each in a separate capsule, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
3284567|NCT01696448|Placebo Comparator|Control Group|3 placebo capsules, to be taken 3 times a day, 30 minutes before breakfast, lunch and dinner. Total 9 capsules per day.
3284568|NCT01696461|Experimental|Related donors receiving plerixafor|Collection of sufficient CD34+ cells using plerixafor as the mobilizing agent.
3284569|NCT01696474|Experimental|Bortezomib therapy|A single course of Bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11. Prophylaxis of HZ reactivation will be given with oral acyclovir at the dosage of 400 mg twice daily for one month after the end of Bortezomib.
3284570|NCT01696487|Experimental|Healthy Volunteers|Volunteers will be challenged with oral 150g Fructose per day for 28 days.
3284571|NCT01696487|No Intervention|NAFLD|Patients with confirmed fatty liver (imaging positive) will be compared at baseline with other arms.
3284572|NCT01696487|No Intervention|NASH|Patients with confirmed non-alcoholic steatohepatitis (biopsy proven) will be compared at baseline with other arms.
3284573|NCT01696487|No Intervention|Hepatitis C genotype 1 (HCV-GT1)|Patients with confirmed hepatitis C genotype 1 will be compared at baseline with other arms and act as different liver disease control group
3284574|NCT01696500|Experimental|NPB-01|
3284577|NCT01696526|Experimental|vitamin D fortified fish|Human volunteers receiving vitamin D fortified fish, 4 weeks
3284578|NCT01696526|Placebo Comparator|conventional fish|consumption of conventional fish , 4 weeks
3284579|NCT01696539|Experimental|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
3284580|NCT01696539|Active Comparator|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
3284581|NCT01696552|Active Comparator|TKR with Positioning Guides (PSPG)|Use of PSPG (Signature, Materialise) in TKR (Vanguard Total Knee System, Biomet)
3284582|NCT01696552|Active Comparator|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet), Conventional Technique
3284583|NCT01696565|Experimental|125 mg/day Treatment Arm|125 mg/day PG2 treatment continuously for 7 days
3284584|NCT01696565|Experimental|250 mg/day Treatment Arm|250 mg/day PG2 treatment continuously for 7 days
3284585|NCT01696565|Experimental|500 mg/day Treatment Arm|500 mg/day PG2 treatment continuously for 7 days
3284586|NCT01696578|Experimental|BF-CBT and group physiotherapy|Multivitamin+10 sessions of biofeedback supported cognitive behavioral therapy (BF-CBT) and 10 sessions of group physiotherapy
3284587|NCT01696578|Active Comparator|Waiting list|The waiting list group receives only multivitamin pills while being waiting and will receive the same intervention 3 months later
3284588|NCT01696591||NEUROSTEM®-AD|"A single administration of human umbilical cord blood-derived mesenchymal stem cells through a brain surgery~DOSE A - 250,000 cells per entry site, 3 million cells per brain; DOSE B - 500,000 cells per entry site, 6 million cells per brain"
3284589|NCT01696591||Control Group|"A group of subjects with comparable demographics (age and gender) and disease characteristics [Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB)] as the NEUROSTEM®-AD-treated group, but did not receive the treatment with NEUROSTEM®-AD and were continued on conventional therapy. Restrictions in the concurrent use of drug therapy are as follows:~Patients are, in principle, permitted to continue the drug therapy they were on prior to the enrollment, for the treatment of concurrent illnesses other than Dementia, such as hypertension, diabetes mellitus, or hyperlipidemia.~For drugs used in the treatment of dementia, behavior-modifying drugs can be added to the pharmacological regimen of a subject during the course of the study. However, adding a new cognitive enhancer, such as donepezil, memantine, galantamine, rivastigmine, is not permitted while dose adjustment is permitted given that the drug had been in use prior to the initiation of the study."
3284590|NCT01696604|Experimental|Part A: Cohort 1-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.01, 0.03, 0.1, and 0.3 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period.
3284591|NCT01696604|Experimental|Part A: Cohort 1-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
3378365|NCT02564263|Experimental|Pembrolizumab|Participants received pembrolizumab 200 mg, intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 25 months).
3378366|NCT02564263|Active Comparator|Chemotherapy|Participants received Investigator's choice of paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 19 months).
3378374|NCT02534727||Sputum and blood participants|These participants will contribute both blood and sputum to the study
3378375|NCT02534727||Sputum only participants|These participants will only contribute sputum to the study
3378380|NCT02511015||Family Member Control Subjects|Family members, of enrolled EOPD subjects, who themselves do not have Parkinson disease or Parkinsonism can be enrolled as controls on this study.
3378381|NCT02511015||Healthy Control Subjects|Age 18 years to 80 years old with no history or family history of Parkinson disease or Parkinsonism.
3378382|NCT02511015||Parkinson Subjects|Age 18 years to 80 years old with a history of early onset Parkinson disease or Parkinsonism (Presentation within the first five decades of life).
3284592|NCT01696604|Experimental|Part A: Cohort 2-GSK2849466|The subjects will receive single planned dose of GSK284946 in ascending order (0.3, 1, 3, and 10 mg) in ratio of 3:1.with placebo within each of 4 treatment periods. The dose will not be allowed to exceed 30 mg over a 24-hour period in one of the 4 treatment periods.
3284593|NCT01696604|Experimental|Part A: Cohort 2-Placebo|The subjects will receive single dose of matching placebo in one of the 4 treatment periods.
3284594|NCT01696604|Experimental|Part B: Cohort 3-GSK2849466 (Repeat dose 1)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo.
3284595|NCT01696604|Experimental|Part B: Cohort 3-Placebo (Repeat dose 1)|The subjects will receive repeat dose of matching placebo.
3284596|NCT01696604|Experimental|Part B: Cohort 4-GSK2849466 (Repeat dose 2)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo. In Cohort 4 subjects will be dosed in the fasted state on Days 1 and 14 and in the fed state on Day 7.
3284597|NCT01696604|Experimental|Part B: Cohort 4-Placebo (Repeat dose 2)|The subjects will receive repeat doses of matching placebo.
3284598|NCT01696604|Experimental|Part B: Cohort 5-GSK2849466 (Repeat dose 3)|The selection of appropriate doses for Part B will be performed upon consideration of available safety and tolerability and PK data from Part A and/or any preceding repeat dose cohorts. The subjects will receive GSK2849466 in ratio of 3:1.with placebo
3284599|NCT01696604|Experimental|Part B: Cohort 5-Placebo (Repeat dose 3)|The subjects will receive repeat doses of matching placebo.
3284600|NCT01696617|Experimental|Aripiprazole 8-week group|Adjunctive aripiprazole 8-week treatment
3284601|NCT01696617|Active Comparator|Aripiprazole 6-week group|Adjunctive aripiprazole 6-week treatment
3284602|NCT01696630|Active Comparator|Desflurane|Desflurane 6.5% (+/-0.5%) in association with a thoracic epidural analgesia in maintenance phase
3284603|NCT01696630|Experimental|Xenon|Xenon 60% (+/-5%) in association with a thoracic epidural analgesia in maintenance phase
3284604|NCT01696656||Intestinal insufficiency|Patients with variable categories of major intestinal resection due to benign diseases,suffering from intestinal insufficiency and maintained with home nutritional support. Only clinically stable and nonhospitalized subjects will be recruited.
3284605|NCT01696669|Experimental|Chemotherapy + Surgery + Radiotherapy|"Standard risk patients: MP6 Treatment:~CHEMOTHERAPY: 2 cycles of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide. SURGERY: Ideally within 21 days after chemotherapy.~CHEMOTHERAPY: 1 cycle of vincristine-doxorubicin + dexrazoxane-cyclophosphamide, 1 cycle of ifosfamide-etoposide.~RADIOTHERAPY: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%.~High risk patients:~CHEMOTHERAPY: Window phase with 2 cycles of gemcitabine + docetaxel. MP6 TREATMENT. CHEMOTHERAPY: Maintenance therapy for 1 year with gemcitabine + docetaxel."
3284606|NCT01696682|Experimental|Narrow Gastric Conduit|The group in which narrowed gastric conduit will be performed during minimally invasive esophagectomy
3284607|NCT01696682|Experimental|Wide Gastric Conduit|The group in which widened gastric conduit will be performed during minimally invasive esophagectomy
3284608|NCT01696708|Other|Patients|31-Phosphorus RMN Spectroscopy
3284609|NCT01696708|Other|Volunteers|31-Phosphorus RMN Spectroscopy
3284610|NCT01696721||Pediatric Patients Treated with Protons|Proton Radiation Therapy
3284611|NCT01696734|Experimental|Treatment (domperidone)|Patients receive domperidone PO TID or QID. Treatment continues in the absence of disease progression or unacceptable toxicity.
3284612|NCT01696747||Diabetic|participants with a primary etiology of diabetic gastroparesis
3284613|NCT01696747||Idiopathic|participants with a primary etiology of idiopathic gastroparesis
3284614|NCT01696747||Post-Nissen|participants with a primary etiology of post-Nissen fundoplication gastroparesis
3284615|NCT01696786|Experimental|Oocyte cryopreservation|
3284616|NCT01696799|Experimental|Econazole Nitrate Foam|Investigational Drug Product
3284617|NCT01696799|Placebo Comparator|Vehicle Foam|Vehicle Foam Comparator
3284618|NCT01696799|Active Comparator|Econazole Nitrate Cream|Active comparator cream product
3284619|NCT01696812|Experimental|electrode position, STN DBS, Parkinson' disease|To determine the electrode positions with the relationship of the STN from the fused images of the preoperative MRI and the postoperative CT via web-site.
3284620|NCT01696825|Experimental|Diazepam Tablet, 5 mg, Vaginal|
3284621|NCT01696825|Experimental|Diazepam Suppository, 5 mg, Vaginal|
3284622|NCT01696825|Experimental|Diazepam Cream, 5 mg, Vaginal|
3284623|NCT01696825|Active Comparator|Diazepam Tablet, 5 Mg, Oral|
3284624|NCT01696838|Experimental|EA group|Electroacupuncture group
3284625|NCT01696838|Experimental|MOX group|Herbs-partitioned moxibustion group
3284626|NCT01696851||wheelchair rugby players with tetraplegia|
3284627|NCT01696851||other routine sport participants with tetraplegia|
3284628|NCT01696864|Experimental|stroke patients - hand|stroke patients with the ability to move their hand
3284629|NCT01696864|Experimental|stroke patient - arm|stroke patients with the ability to move their arms
3284630|NCT01696890|Active Comparator|integrated care|telemonitoring-assisted follow-up with intensive collaboration between general practitioner and specialized Heart failure clinic.
3284631|NCT01696890|Active Comparator|standard care|telemonitoring- assisted follow-up with usual care by general practitioner, without supervision of heart failure clinic
3284632|NCT01696903|No Intervention|Conventional anastomosis|"Conventional anastomosis: The pancreaticojejunostomy is carried out in a traditional way according to Cattell's duct-to-mucosa technique."
3284633|NCT01696903|Active Comparator|Novel anastomosis|Novel anastomosis: This the active comparator to the conventional anastomosis. A new pancreaticojejunostomy technique is used for the reconstruction. The pancreas is intubated into the jejunum.
3284634|NCT01696916|Experimental|exercise testing|6-minute walking test with pCO2 and pO2 measurement
3284635|NCT01697007|Experimental|2 injections of DNA administered by Zetajet|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml
3284636|NCT01697007|Experimental|2 injections DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given as 2 injections using the Zetajet device each injection will comprise of 0.1 ml at a concentration of 3mg/ml followed by electroporation using the Derma Vax device.
3284637|NCT01697007|Experimental|1 injection DNA by Zetajet and electroporation|This arm will receive 600 micrograms of HIVIS DNA given in 1 injection using the Zetajet device the injection will comprise of 0.1 ml at a concentration of 6mg/ml followed by electroporation using the Derma Vax device.
3284638|NCT01697020|Experimental|Arm 1|Mercaptopurine 20mg/ml Oral Suspension
3284639|NCT01697020|Active Comparator|Arm 2|Mercaptopurine 50mg tablets
3284640|NCT01697046|Experimental|Isentress+Truvada|All participants will receive the intervention
3284641|NCT01697059|Experimental|Piperacillin + Amoxicillin|Piperacillin/Tazobactam (Zosyn®) 100 mg/kg, up to adult dose of 3 g, i.v. q 6 hours x 2 doses, followed by Ampicillin/Clavulanate (Augmentin®) 50 mg/kg/d p.o. in 3 divided doses for 1 week.
3284642|NCT01697072|Experimental|Rilotumumab|Rilotumumab (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
3284643|NCT01697072|Placebo Comparator|Placebo|Rilotumumab-placebo (15 mg/kg, IV every 21 days) plus Epirubicin, Cisplatin and Capecitabine (ECX)
3284644|NCT01697085|Experimental|Sea buckthorn oil|3 g (6 capsules)/day for three months
3284645|NCT01697085|Placebo Comparator|Placebo oil|3 g (6 capsules)/day for three months
3284646|NCT01697098|Experimental|12 hours Dexamethasone|Those patient will be given 12 hours dexamethasone after randomization
3284647|NCT01697098|Experimental|24 hours Dexamethasone|Those patient will be give 24 hours dexamethasone after randomization
3284648|NCT01697111|Experimental|Arm 1|
3284649|NCT01697111|Experimental|Arm 2|
3284650|NCT01697111|Active Comparator|Arm 3|
3284651|NCT01697124|Experimental|SPARK-EC|SPARK-EC curriculum for preschoolers offered instruction and practice in a comprehensive program designed to promote motor development through increased physical activity.
3284652|NCT01697137|No Intervention|Usual Care|Following enrollment, participants will visit with their primary care provider per usual.
3284653|NCT01697137|Experimental|Participant Video and Provider Cueing|Participants will watch a video prior to meeting with their provider. Participants will then cue their providers to discuss organ donation with them.
3284654|NCT01697150|Experimental|Control to Range Testing|Subjects will spend two nights in a non hospital setting while the DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is remotely monitored from an adjacent room. DiAs Diabetes Assistant Wearable Artificial Pancreas Platform is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
3284655|NCT01697163||Iressa|Lung cancer patients with EGFR mutation
3284656|NCT01697189|Experimental|Fatigue management training|Experimental group subjects participated in a single half-day fatigue management training session.
3284657|NCT01697189|No Intervention|No fatigue management training|The control group subjects did not participate in the fatigue management training.
3284658|NCT01697202||no intervention|
3284659|NCT01697215||Oral or nasal endotracheal intubation|Oral or nasal endotracheal intubation, anticipated to last at least 48 hours Adults that require ETT internal diameter sizes of 6.5 - 9.0 mm Subject must be at least 18 years old (no upper age limitation) English speaking patients/decision makers.
3284660|NCT01697228|Other|Immediate treatment group|This group will receive vitamin D supplementation for the first 6 months, then will be monitored off vitamin D for the next 6 months.
3284661|NCT01697228|Other|Delayed treatment group|This group will be monitored for the first 6 months, and then will be given vitamin D for the next 6 months.
3284662|NCT01697241|Experimental|Supervised exercise and patient education|The entire duration of the intervention is 12 weeks, and consists of 24 sessions each lasting 60-70 minutes. Patients will receive two types of exercises, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX) in groups with progression guided by the patient's neuromuscular function (12 sessions). The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load (12 sessions).
3284663|NCT01697241|Other|Patient Education|The patient education program is designed to educate the patients about hip OA during 3 sessions of 90 min. duration
3284664|NCT01697267|Experimental|Rituximab Maintenance|Rituximab maintenance: 1g at 4, 8, 12, 16 & 20 months with standardised steroid taper
3284665|NCT01697267|Active Comparator|Azathioprine Maintenance|Azathioprine Maintenance: 2mg/kg/day with standardised steroid taper, from month 4 (randomisation) (200 mg maximum daily dose). Azathioprine withdrawn at month 27.
3284666|NCT01697280|Experimental|Educational messages only|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization
3284667|NCT01697280|Experimental|Immunization status verification only|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
3284668|NCT01697280|Experimental|Education and vaccine verification|EPI vaccinators/volunteers will educate mothers/care-providers of infants less than 12 months old months about the benefits of routine immunization, identify and record details of un/under-vaccinated children in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
3284669|NCT01697280|No Intervention|Status quo|No interventional activity will take place in this group. Therefore, the status quo (routine services) will be maintained during Polio NID
3284670|NCT01697293|Experimental|Treatment (chemotherapy, surgery)|"COURSES A 1-12 (PHASE I & II): Patients receive triciribine phosphate IV over 60 minutes on days 1, 8, and 15, 29, 36, 43, 57, 64, and 71 and paclitaxel IV over 1 hour on days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 79. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.~COURSES B 1-4 (PHASE II): Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.~SURGERY (PHASE II): Eligible patients undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy."
3284671|NCT01697306|Active Comparator|Gemcitabine-arm|7-15 days after TUR patients received six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline. Maintenance consisted in monthly instillations up to 1 year
3284672|NCT01697306|Active Comparator|BCG-arm|7-15 days after TUR patients received an induction cycle of six weekly instillations of Connaught strain Bacillus Calmette-Guerin (BCG Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline. Maintenance consisted of 3 weekly instillations at 3, 6 and 12 months
3284673|NCT01697371|Experimental|Proton Radiation|
3284674|NCT01697384|Experimental|one histrelin acetate 50 mg implant|The test product was a histrelin acetate 50 mg hydrogel implant surgically placed subdermally into the inner aspect of the upper arm.
3378384|NCT02504879||Melorheostosis patients|Patients aged > 18 years with possible and confirmed melorheostosis.
3378385|NCT02504879||Relatives of patients with melorheostosis|Relatives of patients with melorheostosis may be included for genetic testing only.
3378390|NCT02504840||healthy volunteers|healthy volunteers
3378391|NCT02504840||patient controls|Participants with diseases that share features with MS.
3284675|NCT01697410|Experimental|terlipressin|
3284676|NCT01697410|Active Comparator|norepinephrine|
3378392|NCT02504840||patients with suspected or confirmed multiple sclerosis|Participants with definite, probable, or possible MS.
3284677|NCT01697423|Experimental|platelet-rich plasma|
3284678|NCT01697423|Active Comparator|durolane|
3284679|NCT01697436|Experimental|Crossover Period 1|
3378400|NCT02501018|Experimental|CLI Due to ASO with CLBS12 + SOC|This group of subjects with CLI due to ASO will be administered with CLBS12 + SOC for collecting efficacy and safety data.
3378401|NCT02501018|Active Comparator|CLI Due to ASO with SOC|This group of subjects with CLI due to ASO will be administered with SOC only.
3378402|NCT02501018|Experimental|CLI Due to BD with CLBS12|CLBS12 will be administered to patients with CLI due to BD for collecting safety and efficacy data.
3378403|NCT02473757||1/Cohort 1|Subjects who have received treatment on an NCI Surgery Branch CAR T-cell gene therapy protocols.
3378405|NCT02471365||Healthy Volunteers|Non-pregnant and non-nursing females between 35 and 74 who usesa high number (e.g., 15 or more products a day) of consumer products.
3284680|NCT01697436|Experimental|Crossover Period 2|
3284681|NCT01697436|Experimental|Crossover Period 3|
3378406|NCT02471352||1/ Skin disease or at risk|Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease
3378407|NCT02471352||2/ Healthy Volunteers|Healthy Volunteers
3378408|NCT02469662|Experimental|Retrospective|Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available
3378409|NCT02469662|Experimental|Prospective|Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow
3284682|NCT01697436|Experimental|Crossover Period 4|
3284683|NCT01697475|Experimental|Intervention Group|Motivational text messaging
3284684|NCT01697475|No Intervention|Control Group|Step count
3284685|NCT01697488||Cohort|Overall sample
3284686|NCT01697488||Subgroup|Patients aged >/= 70 years
3284687|NCT01697514|Experimental|Part A: LY2940680 (Dose Escalation)|LY2940680 administered orally once daily at escalating doses (92.5 milligrams per square meter [mg/m^2] up to 370 mg/m^2) for two 28 day cycles. Lower dose levels (23 mg/m^2 and 46 mg/m^2) may also be explored, if necessary. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
3284688|NCT01697514|Experimental|Part B: LY2940680 (Dose Confirmation)|LY2940680 administered orally once daily for two 28 day cycles. Dose based on Part A. Participants receiving benefit may continue until disease progression, unacceptable toxicity, or discontinuation.
3284689|NCT01697553|Experimental|Home automation pack coupled to teleassistance service|
3284690|NCT01697553|Active Comparator|Home without automation pack coupled to teleassistance service|
3284691|NCT01697566|Experimental|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
3284692|NCT01697566|Experimental|Placebo + Lifestyle Intervention|Placebo taken by mouth twice daily for 4, 30 day cycles. Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
3284693|NCT01697566|Experimental|Metformin + Lifestyle Intervention|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg.~Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period."
3284694|NCT01697566|Placebo Comparator|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
3284695|NCT01697605|Experimental|BGJ398|Eligible participants received oral BGJ398 once daily or twice daily. Patients may continue treatment with BGJ398 until the patient experiences unacceptable toxicity or progressive disease.
3284696|NCT01697618|Experimental|BIAsp 30|
3284697|NCT01697618|Active Comparator|BHI 30|
3284698|NCT01697631|Experimental|BIAsp|
3284699|NCT01697631|Experimental|Insulin aspart|
3284700|NCT01697644|Experimental|Low dose|
3284701|NCT01697644|Experimental|High dose|
3284702|NCT01697657|Experimental|Detemir|
3284703|NCT01697657|Active Comparator|NPH|
3284704|NCT01697670|Experimental|Photodynamic therapy with Gliolan|Intervention: Laser light illumination with a cylindrical light diffuser (Model RD, Medlight SA) is performed 3 hours after administration of 15 mg/kg 5-aminolevulinic acid (5-ALA, Gliolan)
3284705|NCT01697683|Active Comparator|Probiotic Rhamnosus Lactobacilli|
3284706|NCT01697683|Placebo Comparator|Sugar pill|
3284707|NCT01697722||Step-up as FDC ICS/LABA|ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).
3284708|NCT01697722||Step up as separate therapies|ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).
3284709|NCT01697722||Qvar step-up|ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate
3284710|NCT01697735|Experimental|Berberine;Atorvastatin or Rosuvastatin|Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
3284711|NCT01697735|Active Comparator|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
3284712|NCT01697761|Experimental|Treatment Group|treat by moxibustion and acupuncture
3284713|NCT01697761|Experimental|Control Group|treat by Sham acupuncture and moxibustion
3284714|NCT01697787|Other|Amodiaquine-Artesunate|ASAQ is produced by Sanofi-Aventis as CoarsucamTM and as artesunate-amodiaquine Winthrop®
3284715|NCT01697787|Other|Artemether-Lumefantrine|AL (tablets containing 20 mg of artemether and 120 mg of lumefantrine) is produced by Novartis
3284716|NCT01697826|Active Comparator|ClinSupV3 -soft gelatin capsule|Soft gelatin capsule containing 100mg Clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days
3284717|NCT01697826|Active Comparator|ClinSupV3ER- Extended release tablet|ER tablets containing 100mg clindamycin and 200mg clotrimazole administered per vaginally for 3 consecutive days.
3284718|NCT01697852|Experimental|LLIN plus IRS|LLIN by universal coverage campaign 2 rounds of indoor residual spraying with bendiocarb insecticide
3284719|NCT01697852|Active Comparator|LLIN only|LLIN by universal coverage campaign
3284720|NCT01697865|Active Comparator|Transfer group|The first surgical technique includes a concomitant latissimus and teres major transfer (transfer group).
3284721|NCT01697865|Active Comparator|Control group|The second technique does not include a concomitant latissimus and teres major transfer (control group).
3284722|NCT01697878|Experimental|Randomization Group 1|CPAP first followed by standard of care
3284723|NCT01697878|Active Comparator|Randomization group 2|Standard of care followed by CPAP
3284724|NCT01697891|Experimental|ALTENS|Patients in this arm will be treated with Acupuncture-like Transcutaneous Electrical Nerve Stimulation using Codetron (Codetron ALTENS)
3284725|NCT01697904|Experimental|Low Oxygen Strategy|"Resuscitation was initiated with room air (21% O2) for LOX infants. Supplemental oxygen was given if 1) the heart rate (HR) was less than 100 bpm after 30 seconds of effective ventilation, 2) the lower limits of goal saturations were not met. Targeted goal Pre-ductal saturations after birth were derived by approximation of the interquartile values for healthy term infants as reported by Kamlin et al and Dawson et al.FiO2 was increased or decreased by 10% in 30 second intervals as needed. If HR < 60 bpm after 30 seconds of effective ventilation , FiO2 was increased to 100% until the heart rate was stabilized.~Targeted Pre-ductal SpO2 After birth~min 60%-65%~min 65%-70%~min 70%-75%~min 75%-80%~min 80%-85%~10 min 85%-94%"
3284726|NCT01697904|Active Comparator|Traditional Oxygen strategy ( TOX)|Resuscitation for TOX infants was started with 100% O2 and adjusted every 30 seconds by 10% to meet the target oxygen saturation range of 85-94%
3284727|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
3284728|NCT01697930|Experimental|[18F] 4-L-Fluoroglutamine (2S,4R)|This pilot, first in-human microdose PET trial of the positron-emitting agent [18F] 4-L-Fluoroglutamine (2S,4R) will be an open-label study. The [18F] 4-L-Fluoroglutamine (2S,4R) agent will be administered by bolus intravenous injection. In all study patients, the pharmacokinetics, metabolism, and biodistribution of [18F] 4-L-Fluoroglutamine (2S,4R) will be evaluated by non-invasive blood- and PET-based assays, at multiple time points (see Table 1,) during one day. Eligible patients optionally can participate in the study twice, on a separate date, receiving a second radiotracer microdose of [18F] 4-L-Fluoroglutamine (2S,4R), followed by non-invasive blood- and PET-based assays. At the discretion of the investigator, scan 3 can be waived.
3284729|NCT01697943|Experimental|Roux-En-Y Pouch Reconstruction or Roux-En-Y Reconstruction|
3284730|NCT01697982|Experimental|Living with Hope Program|"Participants will receive the Living with Hope Program (LWHP). The LWHP involves viewing a short film and choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
3284731|NCT01697982|Experimental|LWH Film|Participants will viewing a short film entitled Living with Hope (LWH), which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope
3284732|NCT01697982|No Intervention|Usual Care|Participants in the usual care group will not receive an intervention. Data collection for outcome variables will be the same as the participants in the other arms.
3284733|NCT01697995||Lexiscan-Echo echo subjects|No Intervention: Observational study
3284734|NCT01697995||Lexiscan-Echo control subjects|No intervention: observational study
3284735|NCT01698034|Experimental|Volunteering|Weekly volunteering with elementary school children in after school programs
3284736|NCT01698034|No Intervention|Control|Wait-list control
3284737|NCT01698047|Experimental|Resiliency Class|"Resiliency Classes (study group) Study participant randomized to the Resiliency classes will be offered and assigned a time and date to attend the classes. Each class will have up to 10 participants. Classes will be 90-120 minutes in duration and will be held weekly for six weeks. At the classes, participants will be offered a copy of the Resiliency Class Manual. And at each class, light snacks and refreshments will be offered.~The Resiliency Class manual covers the following topics:~Session 1 - What Affects Your Mood and Resilience; Session 2 - Pleasant Activities Can Help Improve Your Mood and Make You Resilient; Session 3 - What Gets In The Way of Pleasant Activities: Harmful Thoughts and How to Change Them; Session 4 - How to Increase Your Resilience Through Support from Others; Session 5 - My Personal Resiliency Plan: Goal Setting; Session 6 - Celebrate Your Resiliency: Graduation"
3284738|NCT01698047|Active Comparator|Case Management|Case management phone calls (control group) Study participants randomized to the case management phone calls will be told that they will receive two calls over two months by study staff to offer them referrals based on their perceived need for services to local health care, mental health, substance use, social services, child welfare, housing, and food. In addition, study participants in this arm of the study will be told that if the study determines that the resiliency classes are better at improving mood than the case management calls, they will receive a call to invite them to participate in resiliency classes for free at the B-RICH partner agencies.
3284739|NCT01698060|Experimental|Intestinal Delivery|ND1.1
3284740|NCT01698073|Experimental|mCOL|mCircle of Life is a culturally-based HIV-prevention intervention designed for American Indian and Alaska Native 10-12 year-olds. It includes both online and facilitated material.
3284741|NCT01698073|Active Comparator|AS+|After-School Science Plus is a curriculum designed for youth to teach science and literacy using everyday materials. It helps youth see how science is a part of everyday life and provides role models of scientists who come from different backgrounds and ethnicities.
3284742|NCT01698086|Experimental|Experimental group|Participants who are randomized to the Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions (Figure 1). The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report.
3284743|NCT01698086|No Intervention|Wait-listed Control group|The Wait-listed Control group will not receive treatment; however, participants in the Wait-listed Control group will undergo the same outcome measurement plan as the Experimental group. If interested, participants from this group will be placed on a wait-list and will have the opportunity to receive instructions in how to perform the vestibular rehabilitation program following their completion of the study.
3284744|NCT01698112|Experimental|Flaxseed High Dose|
3284745|NCT01698112|Experimental|Flaxseed Low Dose|
3284746|NCT01698112|No Intervention|Flaxseed control|
3284747|NCT01698125||Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
3284748|NCT01698138|Placebo Comparator|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
3284749|NCT01698138|Active Comparator|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
3284750|NCT01698164|Active Comparator|estradiol plus MPA|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 4mg medroxyprogesterone acetate, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box medroxyprogesterone acetate, 2mg*100/bottle"
3284751|NCT01698164|Experimental|estradiol plus progesterone|"1 mg estradiol valerate, once a day, for 28 days, since the 17th day of taking estradiol valerate adding 200mg progesterone capsule, once a day, for 12 days. 28 days forms one cycle. The anticipated duration is 24cycles.~estradiol valerate, 1mg*21/box progesterone capsule, 100mg*6/box"
3284752|NCT01698164|Experimental|Ximingting tablet|1 tablet of cimicifuga rhizoma extract, tid 100mg*15*2/box The anticipated duration is 2 years.
3284753|NCT01698177|Active Comparator|Group A|This group will receive the influenza vaccine preoperatively.
3284754|NCT01698177|Active Comparator|Group B|Group B will receive the influenza vaccine postoperatively, prior to hospital discharge.
3284755|NCT01698177|No Intervention|Group C|Group C subjects have already received the seasonal flu vaccine.
3284756|NCT01698177|Placebo Comparator|Group D|Group D subjects have refused the vaccine, but agree to have serum titers drawn.
3284757|NCT01698190|Active Comparator|Fine needle aspiration (FNA)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a standard FNA needle
3284758|NCT01698190|Active Comparator|Fine needle biopsy (FNB)|Endoscopic ultrasound guided needle tissue acquisition: Tissue acquisition using a new Core needle (Procore; Fine Needle Biopsy).
3284759|NCT01698203|Experimental|ropivacaine|
3284760|NCT01698203|Placebo Comparator|placebo|
3284761|NCT01698216||Consta Sustenna switching|The patients group who switched to paliperidone palmitate from risperidone long acting injection
3284762|NCT01698229||Group 1|Study cohort is comprised of healthy children, ages 2yrs - 8yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
3284763|NCT01698242|Experimental|Enhanced Training|The Enhanced Training intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. Randomization occurs at the PCP-level, that is, patients are assigned to the Enhanced Training group only if their PCP has been enrolled and randomized to this group. Descriptions of the intervention on the PCP-level and patient-level are provided in the intervention section.
3284764|NCT01698242|Active Comparator|Enhanced Education|The Enhanced Education intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention strategy revolves around providing nominal information through the mail. Randomization occurs at the PCP-level; that is, patients are assigned to the Enhanced Education group only if their PCP already has been enrolled and randomized to this group. Description of the intervention on the PCP-level and patient-level is provided in the intervention section.
3284765|NCT01698255|Experimental|ENGAGE|"ENGAGE is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression. The steps of ENGAGE are:~basic social and physical engagement, which has been found to be a very effective depression strategy for most older adults;~the addition of strategies to address clinical features of depression interfering with treatment engagement, namely affect regulation, pessimism, and disorganization."
3284766|NCT01698255|Active Comparator|Standard of Care Psychotherapy|The comparison group for this study will be the current standard of care psychotherapy offered by Westchester Jewish Community Services (WJCS) therapists. This type of psychotherapy is often supportive or eclectic in nature. Therapists will focus on helping the subject to express feelings and focus on strengths and abilities in working through current difficulties and transitions. Therapists assigned to provide standard psychotherapy to eligible participants will receive training and supervision from WJCS staff consistent with agency practice.
3284767|NCT01698281|Experimental|Arm A: AEZS-108|Intervention: AEZS-108 (267 mg/m^2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle). Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone
3284768|NCT01698281|Active Comparator|Arm B: Standard (SCCC)|"commercially available standard single agent cytotoxic chemotherapy (SSCC): - doses below the recommended package insert at the discretion of treating oncologist;~- on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle)."
3284769|NCT01698294|Experimental|Group I (flaxseed)|"Participants receive flaxseed PO daily for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group II."
3284770|NCT01698294|Active Comparator|Group II (usual diet)|"Participants maintain a usual diet for 6 weeks. After a usual diet washout period of 8 weeks, patients crossover to Group I."
3284771|NCT01698346|No Intervention|control|50 unvaccinated pregnant women
3284772|NCT01698346|Active Comparator|Pertussis vaccine (Boostrix®, GSK Biologicals, Rixensart)|50 pregnant women vaccinated with pertussis vaccine
3284773|NCT01698372|Experimental|Prevena device (Group A)|Group A will have the VAC Prevena portable device applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
3284774|NCT01698372|No Intervention|Conventional dressing (Group B)|Group B will have conventional dry dressing applied to the saphenous vein harvest site after standard wound closure following coronary artery bypass surgery.
3284775|NCT01698385|Active Comparator|Lifestyle counseling|
3284776|NCT01698385|No Intervention|Control, just measurements|
3284777|NCT01698398|Experimental|CF-LVAD pumpspeed.|Optimal pumpspeed setting of CF-LVAD during exercise on ergometric bicycle.
3284778|NCT01698437|Other|Transcranial MR-Guided Focused Ultrasound for Brain Tumors|
3284779|NCT01698450|Other|Focused Ultrasound for Movement Disorders|
3284780|NCT01698476|Active Comparator|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
3284781|NCT01698476|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
3284782|NCT01698515||Anti-TNF subgroup|"anti - TNF subgroup~20 subjects with RA, who are starting TNF inhibitors based on the decision of their treating rheumatologist, will be recruited from the clinic. Patients will be starting commercially available anti-TNF agents that have already been authorized for insurance coverage. We are not requesting anti-TNFs or other drugs specifically for patients enrolled in this study from any pharmaceutical company. Patients will also continue on their background MTX and corticosteroids if they are taking these agents, and MTX will be required for patients taking Infliximab or Golimumab as per approved indication. No medications will be supplied through the study.~--------------------------------------------------------------------------------"
3284783|NCT01698541|Experimental|Tacni|Tacrolimus administered as generic formulation Tacni in accordance with standard protocol at the transplant center
3284784|NCT01698541|Active Comparator|Prograf|Tacrolimus administered as Prograf in according to standard protocol at the transplant center
3284785|NCT01698567|Active Comparator|Antithrombin III|"Product- Antithrombin III is derived from pooled human plasma~ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)~a."
3284786|NCT01698567|Placebo Comparator|Placebo|placebo (normal saline)
3284787|NCT01698580|Active Comparator|usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
3284788|NCT01698580|Experimental|Multifactorial Falls Prevention Program|12 week intervention for 10 to 12 participants with sessions once a week, lasting for 2 hours, consisting of: On-site exercises (progressive body balance exercise program),Home-based exercise program, Educational and Behavioural sessions and management of modifiable risk factors.
3284789|NCT01698593|Active Comparator|Ring Finger Nerve Block|
3284790|NCT01698606|Active Comparator|Secondary lifestyle intervention arm|6-month wait list group. Second arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling, following of completion of main 6-month intervention for arm 1.
3284791|NCT01698606|Experimental|Primary lifestyle intervention arm|First arm to receive multidisciplinary, family-centered lifestyle intervention with behavioral counseling
3284792|NCT01698619||Climbers on Mount Aconcagua|The Cohort consists of volunteers climbing Mount Aconcagua.
3284793|NCT01698632||benign-looking adnexal masses|
3284794|NCT01698645||PecFent®|
3284795|NCT01698658|Experimental|Diagnostic (SoftVue ultrasound tomography)|Patients undergo ultrasound tomography using SoftVue. Some patients also undergo MRI of the breast.
3284796|NCT01698671|Other|InterGard Synergy Vascular Graft|
3284797|NCT01698697|Active Comparator|U100|
3284798|NCT01698697|Experimental|U200|
3284799|NCT01698723|Active Comparator|Ribavirin|1000 mg (5 capsules)
3284800|NCT01698723|Placebo Comparator|Placebo|5 capsules of placebo
3284801|NCT01698736|Active Comparator|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
3284802|NCT01698736|Experimental|Semiselective IA + membrane filtration|Semiselective immunoadsorption (GAM peptide adsorber) in combination with membrane filtration
3284803|NCT01698749|Experimental|Ozurdex in diabetic macular edema|Intravitreal ozurdex given in patients with diabetic macular edema and patients followed up for change in central macular thickness and visual acuity over period of 6 months
3284804|NCT01698762||Osteoarthritis (OA)|"One OA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3284805|NCT01698762||Osteoporosis (OP)|"One OP group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One OP group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3284806|NCT01698762||Rheumatoid Arthritis (RA)|"One RA group will watch a DVD - Multimedia Patient Decision Aids (MM-PtDAs) of information about their disease type.~One RA group will read a booklet - Comparative Effectiveness Research Summary Guide (CERSG) about their disease type.~Questionnaires completed at baseline, 3, and at 6 months."
3284807|NCT01698788|Experimental|TPHM removal without ozurdex|Comparison of taut posterior hyaloid removal with (Group B)and without intraoperative ozurdex(Group A)
3284808|NCT01698788|Experimental|TPHM removal with ozurdex|Comparison of TPHM removal with (Group B) and without (Group A)Ozurdex
3284809|NCT01698827||Kangaroo|"20 patients managed by Kangaroo gastrostomy tubes. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3284810|NCT01698827||Cook|"20 patients receiving Wilson Cook gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3284811|NCT01698827||Silmag|"20 patients managed by Silmag gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3284812|NCT01698827||Freka|"20 patients carrying Freka gastrostomy tubes.Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3284813|NCT01698827||Bard|"20 patients using the Bard gastrostomy tube. Patients will be submitted to initial screening and tube replacement, followed tube assessment visits every two months, till 6 months."
3284814|NCT01698840|Experimental|Investigational Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Investigational Nutrition group will receive vitamin D drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
3284815|NCT01698840|Placebo Comparator|Routine Nutrition|Starting between post menstrual age (PMA) 34 0/7 to 38 6/7 weeks, infants in the Routine Nutrition group will receive placebo drops that are added to transitional formula daily through hospital discharge and at home until the outpatient follow-up visit at 52 weeks PMA.
3284816|NCT01698866|Experimental|vaccin GenHevac B Pasteur|vaccin GenHevac B Pasteur (Suspension for injection in pre-filled syringe / 20 μg microgram(s)Per day). In total, 3 injections at M0, M1 and M6
3284817|NCT01698892|Experimental|I.V. sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation
3284818|NCT01698892|Active Comparator|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
3284819|NCT01698918|Experimental|Everolimus + letrozole/exemestane|Enrolled patients will receive everolimus in combination with letrozole in the first line setting until disease progression, unacceptable toxicity or withdrawal of consent. Following disease progression in the first line setting, patients will be offered everolimus in combination with exemestane. Patients who discontinue treatment in the first line setting due to unacceptable toxicity or due to withdrawal of consent will not be offered everolimus plus exemestane. Those patients treated in the second line setting will continue treatment until disease progression, unacceptable toxicity or withdrawal of consent.
3284820|NCT01698931|Experimental|Treatment period 1|
3284821|NCT01698931|Active Comparator|Treatment period 2|
3284822|NCT01698931|Placebo Comparator|Treatment period 3|
3284823|NCT01698944|Experimental|Somatropin|
3284824|NCT01698957||UA Doppler Velocimetry|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
3284825|NCT01698970|Experimental|1 = Tested product|
3284826|NCT01698970|Placebo Comparator|2 = Control product|
3284827|NCT01698996|Active Comparator|No Packing|No Packing
3284828|NCT01698996|Experimental|Packing|Packing
3284829|NCT01699009|Experimental|Vegan diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks.
3284830|NCT01699009|Placebo Comparator|Supplement group|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
3284831|NCT01699035||stroke survivors|stroke survivors who have either returned to work, have thought about returning to work, or have tried to return to work
3284832|NCT01699048|Other|Hybrid group|Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with the left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50)
3284833|NCT01699048|Other|PCI|Multi-vessel PCI with DES (MV-PCI group, n=50)
3284834|NCT01699048|Other|CABG|Coronary artery bypass graft (CABG) treatment (CABG group, n=50)
3284835|NCT01699061|Placebo Comparator|Placebo|Placebo tablet administered with a meal twice a day on Day 1
3284836|NCT01699061|Experimental|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
3284837|NCT01699074|Experimental|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
3284838|NCT01699074|Experimental|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
3284839|NCT01699074|Experimental|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
3284840|NCT01699074|Placebo Comparator|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
3284841|NCT01699074|Active Comparator|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
3284842|NCT01699100|Experimental|device|In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
3284843|NCT01699126|Experimental|CPAP, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP on OSA
3284844|NCT01699126|Active Comparator|CPAP and statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after CPAP plus statin on OSA patients
3284845|NCT01699126|Active Comparator|OSA, statin, Hypertension|evaluate the effect on FMD, blood pressure and inflammation after statin treatment on OSA
3284846|NCT01699126|No Intervention|Placebo|We will also measure the FMD, blood pressure and inflammation on patients with only life style modification as in all other patients
3284847|NCT01699139|Active Comparator|positional device|
3284848|NCT01699139|Sham Comparator|lumbar corset|
3284849|NCT01699152|Experimental|TG02 citrate|TG02 citrate capsules given orally.
3284850|NCT01699165|Sham Comparator|Placebo Nasal filter|Placebo treatment
3284851|NCT01699165|Active Comparator|Nasal Filter|Active treatment
3284852|NCT01699191|Active Comparator|Probiotic Mixture|Probiotic mixture
3284853|NCT01699191|Placebo Comparator|Placebo|Placebo
3284854|NCT01699204|Placebo Comparator|Filtered air with placebo|Exposure for 2 hours to filtered air and placebo tablets 3 times daily for 6 days
3284855|NCT01699204|Active Comparator|Diesel exhaust with placebo|Exposure for 2 hours to diesel exhaust and placebo tablets 3 times daily for 6 days
3284856|NCT01699204|Experimental|Diesel exhaust with N-acetylcysteine|Exposure for 2 hours to diesel exhaust and N-acetylcysteine tablets (600 mg) 3 times daily for 6 days
3284857|NCT01699230|Experimental|Omega 3 supplemented patients|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
3284858|NCT01699230|No Intervention|Control group|
3284859|NCT01699243||Epidural|subjects under epidural anesthesia
3284860|NCT01699256|Experimental|Enhanced strategy|Enhanced implementation strategy
3284861|NCT01699256|Active Comparator|Strategy as usual|Normal implementation strategy
3284862|NCT01699269|Other|brain tumor|
3284863|NCT01699282|Experimental|Group thorough VKA (antivitamin K)education|
3284864|NCT01699282|Active Comparator|control group|
3284865|NCT01699295|Experimental|A+PAAC|Lessons delivered using A+PAAC
3284866|NCT01699295|Active Comparator|CON|Regular sedentary lessons
3284867|NCT01699308|Experimental|Genotropin|10 persons with TBI and GHD will receive daily rhGH injections titrated to bring their GH levels into the normal range for one year. Treatment is initiated using Genotropin (rhGH) at an initial daily dose of 200mcg/day subcutaneously with a titration schedule calling for an increase in daily dosage by 200 mcg every two months until the target daily dose, 600 mcg/day, is achieved. The 10 GHD subjects will be assessed at baseline with EEG, fMRI and DTI and neuropsychological measures, again at 6 months, and a third time at 12 months.
3284868|NCT01699308|No Intervention|Control|5 demographically-matched TBI with normal GH subjects will be assessed at baseline (with EEG, fMRI and DTI, and neuropsychological measures) and at 12 months.
3284869|NCT01699321|Experimental|Your Move (physical activity)|The Your Move intervention is a multi-level, theory and evidence-based intervention that will include the following components: monthly handbills with community resources, newsletters, contests (shop and customer level), tailored health feedback report, and monthly phone calls from the research team.
3284870|NCT01699321|Other|Your Money (financial empowerment)|The Your Money program is an attention control intervention. Owners and barbers will receive 3 workshops that focus on financial health. Customers will receive monthly handbills and newsletters about different financial health topics.
3284871|NCT01699334|Experimental|Psychoeducational video|
3284872|NCT01699334|Active Comparator|Relaxation video|
3284873|NCT01699347|Experimental|OK432|Intracystic injection of OK432 under US guiding
3284874|NCT01699360|Experimental|Cyclosporine A, Tacrolimus, Sirolimus|"Cyclosporine A：soft capsule,2-6mg/kg/d, the same twice daily dose at least five days.~Tacrolimus:capsule,0.15-0.3mg/kg/d, the same twice daily dose at least five days.~Sirolimus:tablet,2mg/d, once a day."
3284875|NCT01699386|Active Comparator|Control Study Formula|protein hydrolysate formula
3284876|NCT01699386|Experimental|Experimental Study Formula|free-amino acid-based medical food
3284877|NCT01699399|Experimental|water immersion|infuse water during insertion phase of colonoscopy instead of air insufflation; remove the water during withdrawal phase.
3284878|NCT01699399|Experimental|water exchange|infuse and remove water during the insertion phase of colonoscopy. Air insufflation is used only in the withdrawal phase
3284879|NCT01699399|Active Comparator|air insufflation|standard colonoscopy using traditional air insufflation during insertion
3284880|NCT01699412|Experimental|Dexamethasone|Patients under topical treatment with solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL
3284881|NCT01699412|Experimental|Clobetasol|Patients under topical treatment with solution of clobetasol 0.05% associated with nystatin 100,000 UI/mL
3284882|NCT01699425|Experimental|Ajust|Experimental group: surgery to treat stress urinary incontinence with the sling Ajust®
3284883|NCT01699425|Active Comparator|Classical transobturator tape|Control group: surgery to treat stress urinary incontinence with the Align® sling.
3284884|NCT01699438|Experimental|Mesalazine|
3284885|NCT01699438|Placebo Comparator|Placebo|
3284886|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.7%|AR-12286 Ophthalmic Solution 0.7%, both eyes
3284887|NCT01699464|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% both eyes
3284888|NCT01699464|Active Comparator|Timolol maleate ophthalmic solution 0.5%|Timolol maleate ophthalmic solution 0.5% both eyes
3284889|NCT01699477|Other|Trancranial MRg Focused Ultrasound for Neuropatic Pain|
3284890|NCT01699490|Experimental|Fluoxetine + Valsartan|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to 40 mg per day of valsartan"
3284891|NCT01699490|Active Comparator|Fluoxetine + Placebo|"The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 60 mg.~Add-on treatment to placebo"
3284892|NCT01699516||Intestinal graft vs host disease|Patients with biopsy-proven intestinal acute GVHD in the setting of an allogenic transplant
3284893|NCT01699516||Control group|In the setting of an allogenic bone marrow transplant: patients with biopsy-proven stomach GVHD without intestinal symptoms and patients with neutropenic enterocolitis. Normal volunteers.
3284894|NCT01699529|Experimental|Renal Denervation|
3284895|NCT01699555|Experimental|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
3284896|NCT01699555|Placebo Comparator|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
3284897|NCT01699568|Experimental|Vulcano Actives|Implants 4mm x 10mm Vulcano Actives (anodized surface)(AR Torque Vulcano actives), Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
3284898|NCT01699568|Active Comparator|Porous|Implants 4mm x 10mm Porous (dual acid-etched surface treatment)(AR Torque Porous, Conexão Sistemas de Prótese, Arujá, Brasil)will be placed on edentulous area in maxilla
3284899|NCT01699581|Experimental|Nestle Impact Advanced Recovery|"Nestle Impact Advanced Recovery~1 dose of Nestle Impact Advanced Recovery orally three times a day"
3284900|NCT01699594|Experimental|Mannitol|This arm will assess the allergen induced change in airway responsiveness to mannitol bronchoprovocation.
3284901|NCT01699594|Active Comparator|Methacholine Chloride|This arm will assess the allergen induced change in airway responsiveness to methacholine bronchoprovocation.
3284902|NCT01699620|Experimental|Dermatome|BAHA implant insertion with Dermatome technique
3284903|NCT01699620|Experimental|Linear incision|BAHA implant insertion with linear incision
3284904|NCT01699646|Active Comparator|CTG + FBS|intrapartum surveillance with CTG+FBS
3284905|NCT01699646|Active Comparator|Neoventa S 21 ST-ANalysis of fetal heart|intrapartum surveillance with CTG + STAN
3284906|NCT01699672|Experimental|Group and Individual information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
3284907|NCT01699672|No Intervention|Individual information|Standard information about disease and treatment from doctor and nurse given at 2 occasions.
3284908|NCT01699711|Active Comparator|Dietary Supplement: Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
3284909|NCT01699711|Placebo Comparator|Placebo|No active treatment is given.
3284910|NCT01699724|Active Comparator|JZoloft|Oral tablet of sertraline hydrochloride (Japanese commercial tablet: JZoloft ® tablet) 50 mg as a single oral dose under fasted conditions
3284911|NCT01699724|Experimental|ODT without water|sertraline ODT 50 mg without water as a single oral dose under fasted conditions
3284912|NCT01699724|Experimental|ODT with water|sertraline ODT 50 mg with water as a single oral dose under fasted conditions
3284913|NCT01699737|Experimental|JTT-851 Dose 1|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3284914|NCT01699737|Experimental|JTT-851 Dose 2|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3284915|NCT01699737|Experimental|JTT-851 Dose 3|JTT-851 Tablets and Placebo comparator capsule, administered once daily for 12 weeks
3284916|NCT01699737|Active Comparator|Glimepiride Dose 1|Active Comparator Capsule and Placebo Tablets, administered once daily for 12 weeks
3284917|NCT01699737|Placebo Comparator|Placebo active & Placebo comparator|Placebo Tablets for study drug and Placebo Capsule for active comparator, administered once daily for 12 weeks
3284918|NCT01699776|Active Comparator|Ivabradine|Ivabradine, 7,5 mg b.id. by mouth for 14-16 weeks.
3284919|NCT01699776|Active Comparator|Digoxin|Digoxin 0.125 mg once a day, 5 times per week, for 12-14 weeks by mouth.
3284920|NCT01699802|Experimental|Inhaled anaesthetic agent|The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
3284921|NCT01699828|Experimental|Buspirone 120 mg|Buspirone 120 mg (encapsulated).
3284922|NCT01699828|Experimental|Buspirone 60 mg|Buspirone 60 mg (encapsulated)
3284923|NCT01699828|Placebo Comparator|Placebo|Placebo (encapsulated)
3284924|NCT01699828|Experimental|Buspirone 30 mg|Buspirone 30 mg (encapsulated).
3284925|NCT01699841||HIV+ and HIV- mothers and their infants|
3284926|NCT01699854|Active Comparator|capsaicin patch|
3284927|NCT01699854|Placebo Comparator|placebo patch|
3284928|NCT01699880||conventional high FiO2 bag reservoir facemask|this group of patients is intubated according to our current practice that requires the use of a high FiO2 nonrebreathing with bag reservoir facemask to ensure preoxygenation in patients requiring tracheal intubation. a small nasal catheter is inserted just before laryngoscopy to ensure a low oxygen flow to allow oxygenation during laryngoscopy.
3284929|NCT01699880||high flow nasal cannula oxygen|we wish to change our standard practice of preoxygenation and expand our use of high flow nasal cannula oxygen therapy to the tracheal intubation setting. Currently, used of high flow oxygen nasal cannula oxygen therapy to ensure oxygenation during intubation is limited to the patients already under high flow nasal cannula oxygen. the change of practice consists in the systematic use of high flow nasal cannula oxygen therapy in all patients requiring tracheal intubation in the ICU.
3284930|NCT01699893|Experimental|unique arm|"At V0: 1500 will be screened~At V1: 1000 subjects will be performed following samples: blood, nasal swab,stool. 500 subjects among 1000 will be performed one additional sample (Skin Biopsy)~At V2: only the 500 subjects having performing the skin biopsy at V1 will come at V2 to perform blood, nasal swab and stool samples"
3284931|NCT01699906|Experimental|Dietary intervention|Diet regimen to induce weight loss
3284932|NCT01699919|Active Comparator|intravenous lignocaine|Intravenous lignocaine will be given as a bolus of 1.5mg/kg at the time of intubation followed by an infusion at a rate of 1.5mg/kg/hr throughout surgery and till one hour post surgery.
3284933|NCT01699919|Placebo Comparator|normal saline|Normal saline will be given as a bolus at the time of intubation and saline infusion given to patients in the control group during the surgery and till one hour post surgery.
3284934|NCT01699932|Experimental|Arm 1|24-week treatment period: starting dose will be of 2/1000 mg or 4/2000 mg of glimepiride/metformin fixed combination (Amaryl M® ) depending on the previous treatment and dose. The Interventional medicinal product's dose will be increased every 2 weeks up to the maximum tolerated dose of 8/2000 mg of Amaryl M® , and adjusted throughout the 24-week treatment period according to fasting Self Monitored Plasma Glucose (SMPG) values in the objective to obtain fasting SMPG values ≤ 130mg/dL (7.2mmol/L) and > 70 mg/dL (3.9mmol/L) without symptomatic hypoglycemia.
3284935|NCT01699945||Verbal Autopsies|The study involves filling of verbal autopsies for still births and deaths in women of reproductive age group.
3284936|NCT01699958|Experimental|Problem-solving intervention|2 individual sessions teaching problem-solving skills with the use of videos, handouts, and worksheets.
3284937|NCT01699958|No Intervention|Control: Standard Care|Control arm participants will receive standard of care from their primary care provider.
3284938|NCT01699971|Active Comparator|Lichtenstein|Hernia repair with lichtenstein propylene mesh
3284939|NCT01699984||Hospitalized patients|All patients hospitalized in 4 inpatient facilities in Northern Italy during 4 index-months.
3284940|NCT01699997|Experimental|Oxytocin|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of OXT Spray, which contains approximately 40 international units (IU) of OXT
3284941|NCT01699997|Placebo Comparator|Placebo vial|Each treatment will consist of 10 insufflations (5/nostril alternating between nostrils) of placebo Spray, which contains all OXT Spray ingredients except for oxytocin.
3284942|NCT01700010|Experimental|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
3284943|NCT01700023||patients with leg-edema|patients with decompensated heart failure presenting with leg-edema
3284944|NCT01700062|Experimental|Medium calorie|
3284945|NCT01700062|Experimental|standard calorie|
3284946|NCT01700075|Active Comparator|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
3284947|NCT01700075|Experimental|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
3284948|NCT01700088||Oxygen cannular|After lung resection surgery,every patient will received supplementary oxygen 5 L/minutes via oxygen cannular for 120 minutes
3284949|NCT01700127|Other|Breastfeeding|Breastfeeding Encouraged
3284950|NCT01700127|Active Comparator|Breastfeeding Withheld|Breastfeeding Withheld
3284951|NCT01700153|Experimental|Experimental: Robotic-assisted therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of robotic-assisted therapy.
3284952|NCT01700153|Active Comparator|Classical therapy|All patients will receive a similar classical rehabilitation as a basis. the 10 patients of this group will receive a supplement of classical rehabilitation.
3284953|NCT01700166|Experimental|Biologic; Cord Blood Stem Cells; Intravenous injection|Autologous Human Umbilical Cord Blood derived Stem Cell injection
3284954|NCT01700218|Other|telemonitoring|patients in the telemonitoring arm will record vital parameters (blood pressure, heart rate, body weight) and transmit these parameters together with wellbeing and daily dose of heart failure medication
3284955|NCT01700218|Other|control|patients in the control arm will not record any vital parameter
3284956|NCT01700231||Liver resection ,Liver Dysfunction|100 patients will be monitored perioperatively, in a subset of 40 patients hepatic venous pressure gradient will be monitored
3284957|NCT01700244|Experimental|Pacemaker|
3284958|NCT01700257|Other|CT scan & Early CDT Lung test|Every study participant receives a CT scan & Early CDT-Lung test (biomarker blood test) for lung cancer screening purposes.
3284959|NCT01700270|Experimental|dovitinib (TKI258)|dovitinib, 5 days on / 2 days off dose schedule
3284960|NCT01700283|Experimental|exercise education and walking program|
3284961|NCT01700283|No Intervention|maintain their daily activity|
3284962|NCT01700296|No Intervention|Standard Care|"Standard Care: finishing treatment for AECOPD in hospital and after hospital discharge to further control by the GP. In case of severe symptoms and / or airway obstruction (measured by FEV1) refer patients for follow-up in lung clinic. The subjects are recorded with the same subjective, clinical, paraclinical and invasive parameters as the Best care group"
3284963|NCT01700296|Experimental|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
3284964|NCT01700309|No Intervention|Control group|Treatment as usual
3284965|NCT01700309|Experimental|Young and Active|This arm will recieve web-based health counselling through the web-site Young and Active.
3284966|NCT01700322|Active Comparator|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
3284967|NCT01700322|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
3284968|NCT01700322|Active Comparator|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
3284969|NCT01700361||No treatment|This is an observational study. Women in this study are not receiving any treatments.
3284970|NCT01700374||Women without Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 0 or 1 adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
3284971|NCT01700374||Women with Prepubertal Adversity|"At 8-17 weeks gestational age, 1,500 pregnant women will complete:~Adverse Childhood Events (ACE) Questionnaire;~Perceived Stress Scale (PSS);~A general health and demographic questionnaire.~All women who are screened will be asked if they would be willing to allow the study team to access their delivery report.~Women who report 2 or more adverse childhood experiences will be invited to continue in the study as part of the Women without Prepubertal Adversity cohort. We aim to have 125 women in this cohort."
3284972|NCT01700400|Experimental|Experimental Phase I Dose Escalation|"Pemetrexed: intravenous; 500 mg/m² for Dose Levels 1, 2 and 3~Carboplatin: intravenous; 5 AUC for Dose Level 1; 6 AUC for Dose Levels 2 and 3~Bevacizumab: intravenous; 15 mg/kg for Dose Levels 1, 2, and 3~Everolimus: oral, 2.5 mg/day for Dose Levels 1 and 2; 5.0 mg/day for Dose Level 3"
3284973|NCT01700413|Experimental|Idarubicin|Cohort 1: Idarubicin 14 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 2: Idarubicin 16 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day Cohort 3: Idarubicin 18 mg/m2 (day 1-3), Cytarabine 200 mg/m2 (Days 1-7), G-CSF 150 mcg/m2/day
3284974|NCT01700426|Active Comparator|iron|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
3284975|NCT01700426|Active Comparator|iron 2|"Sixty-eight subjects found to have ID or IDA will be consented and randomized to one of the two treatment regimens (34 subjects per group). Liquid supplement preparations of iron (both groups), Vitamin E (test) and placebo (control) will be distributed by the research pharmacy at Children's Hospital Colorado.~A commercial ferrous sulfate solution (Fer-In-Sol, 15 mg elemental Fe/mL; Mead Johnson, Inc, Evansville, IN) will be distributed to all qualifying participants for the study by the research pharmacy at Children's Hospital Colorado. The volume of the suspension will be individualized by the pharmacy to the infant's weight, to maintain consistent iron dosing at 6 mg/kg/day."
3284976|NCT01700452||patients suspected of having lung cancer|Subjects presenting with 0.8 - 3 cm solitary pulmonary nodules with high probability for malignance. The subject must be scheduled for a lung biopsy procedure to determine clinical diagnosis.
3284977|NCT01700465||Hemodialysis|Patients undergoing hemodialysis
3284978|NCT01700478|Experimental|Misoprostol + vasopressin, Vasopressin|Misoprostol 400ug given rectally one hour before surgery.
3284979|NCT01700491|Active Comparator|Epidural Catheter 0.2% ropivacaine|Patients will receive an infusion of 0.2% ropivacaine at a range of 0-10 mL/hr through an epidural catheter. They will also receive an infusion of saline at a rate of 0-10 mL/hr through a paravertebral catheter.
3284980|NCT01700491|Active Comparator|Paravertebral Catheter 0.4% ropivacaine|Patients will receive an infusion of 0.4% ropivacaine at a range of 0-10mL/hr through a paravertebral catheter. They will also receive an infusion of saline at a range of 0-10mL/hr through an epidural catheter.
3284981|NCT01700504|Experimental|Gentamicin lavage|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
3284982|NCT01700504|Active Comparator|Normal saline lavage|Patients undergoing 2 axillary lavages with 500ml of normal saline
3284983|NCT01700543||1|Patients indicated for hemi or total shoulder arthroplasty with good bone stock who fulfill all inclusion and none of the exclusion criteria.
3284984|NCT01700556|Active Comparator|Usual Care|"150 patient-caregivers will receive a light support in the form of paper brochures and 3 preventive home visits by a nurse"
3284985|NCT01700556|Experimental|UP Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker and receiving 3 preventive home visits by a nurse
3284986|NCT01700556|Experimental|UP-TECH Protocol|150 patient-caregivers provided with the systematic and comprehensive support of a case manager social worker, receiving an intervention based on assistive technologies and 3 preventive home visits by a nurse
3284987|NCT01700569|Experimental|Folinic Acid|"Folinic acid is given orally every day during the radiation therapy (47 days), then 5 days at each of the 6 maintenance cycle of temozolomide. The dose is escalated in a 3x3 method and the levels are: 5mg, 10mg, 15mg, 30mg, 60mg."
3284988|NCT01700582||Patients with advanced lung cancer|Patients with advanced lung cancer
3284989|NCT01700595|Experimental|new technical intervention|''new technical intervention'' represents the surgical procedure which is applied for the patients assigned to this group because of their certain characteristics. Namely, pediatric patients with broad axillary, anterior chest wall, mammary and neck scars are treated with this surgical approach.
3284990|NCT01700608||plerixafor treated patients|lymphoma and myeloma patients
3284991|NCT01700634||OA patients with HIGH central sensitization|Central sensitization will be defined by the presence of both spreading sensitization and temporal summation to repeated pressure pain stimulation (Arendt-Nielsen et al. 2010, Graven-Nielsen et al. 2010, Woolf 2010, Imamura et al. 2008, Nijs et al. 2010).
3284992|NCT01700634||OA patients with LOW central sensitization|
3284993|NCT01700634||Control subjects|
3284994|NCT01700647||smoking controls|patients referred for bronchoscopy who have detailed axamination and do not have any dysplasia proven by bronchoscopy and laryngoscopy Breath test- sampling using ENose
3284995|NCT01700647||In Situ carcinoma larynx|Biopsy proven in situ carcinoma larynx proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
3284996|NCT01700647||Advanced Larynx Cancer|Biopsy proven stage 3/4 larynx cancer proven by laryngoscopy and bronchoscopy Breath test- sampling using ENose
3284997|NCT01700660||VIO|Patients operated under VIO.
3284998|NCT01700660||Control|Patients operated without VIO.
3284999|NCT01700686||Obese subjects|Meal test and dexa scan
3285000|NCT01700699||Sorafenib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sorafenib
3285001|NCT01700699||Axitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Axitinib
3285002|NCT01700699||Pazopanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Pazopanib
3285003|NCT01700699||TKI|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with different type of tyrosine kinase inhibitor
3285004|NCT01700699||Motesanib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Motesanib
3285005|NCT01700699||Sunitinib|Assessment of percentage of BRAFV600E in tissue specimens of MRR-DTC patients treated with Sunitinib
3285006|NCT01700712|Active Comparator|L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU|2 tablets a day for 2 weeks
3285007|NCT01700712|Placebo Comparator|Sugar pill|2 tablets a day for 2 weeks
3285008|NCT01700738|Experimental|gastric ring surgery|in this group a gastric ring will be put by surgery.
3285009|NCT01700738|Active Comparator|nutritional help|the usual treatment of obesity in France with nutritional care will be dispensed for this arm
3285010|NCT01700751|Experimental|Dose Level 0 (starting dose)|brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
3285011|NCT01700751|Experimental|Dose Level 1|brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
3285012|NCT01700751|Experimental|Dose Level 2|brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
3285013|NCT01700751|Experimental|Dose Level 3|brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
3285014|NCT01700751|No Intervention|Control Dose Level|The first 3 patients will not receive brentuximab vedotin.
3285015|NCT01700777|Experimental|Intensive rehab group|"A group of children will beneficiate of HABIT-ILE treatment in an intensive way (camp) for 90h."
3285016|NCT01700777|Active Comparator|Regular treatment group|A group of children with hemiplegic cerebral palsy will beneficiate from conventional training at a regular frequency (1 to 6 hours / week) for 90hours.
3285017|NCT01700790|Experimental|Lopinavir/ritonavir and ritonavir|Two tablets of twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 tablets of ritonavir 100 mg of twice daily given with rifampin 600 mg daily.
3285018|NCT01700803|Experimental|Povidone Iodine 10%|Using Povidone Iodine 10% hand scrub before caesarian section
3285019|NCT01700803|Experimental|Povidone Iodine 7.5% hand scrub|Using Povidone Iodine 7.5% hand scrub before caesarian section
3285020|NCT01700855|Experimental|Electroacupuncture|Patients received electroacupuncture stimulation
3285021|NCT01700855|Sham Comparator|Non-electroacupuncture|Patients received sham electroacupuncture
3285022|NCT01700868|Experimental|Vegan Group|Participants in the intervention group will follow a low-fat, vegan diet for 20 weeks, and will attend nutrition classes in the form of a weekly support group.
3285023|NCT01700868|Active Comparator|American Diabetes Association guidelines|Participants will follow ADA diet according to ADA regulations. This group will also receive weekly nutrition classes.
3285024|NCT01700881|Experimental|Plant-based diet|The diet group will be asked to follow a low-fat, vegan diet for 16 weeks
3285025|NCT01700881|Placebo Comparator|Supplement|The supplement group will follow an unrestricted diet, but will be given a pill containing a small, clinically insignificant amount of omega- 3 oils and vitamin E, which will serve as a placebo.
3285026|NCT01700894|Experimental|Walking Program + motivational interviewing calls|"The Women's Walking Program (WWP) core included a lifestyle PA prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every week for 5 weeks in the 1st 24 weeks and 1 3 months later) targeted to increase lifestyle PA in AA women.~Participant in the WWP plus motivational interviewing telephone call arm receives 11 motivational interviewing telephone calls from an interventionist, with two calls in between each of the group-visits. Motivational interviewing calls are tailored to the individual and intended to sustain intervention effects between group-visits"
3285027|NCT01700894|Experimental|Walking Program + automated calls|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP plus automated telephone call arm receive 11 automated calls with two calls sent between each group-visit. The automated calls are intended to supplement and sustain the intervention effects of the group-visits."
3285028|NCT01700894|Experimental|Walking Program|"The Women's Walking Program (WWP) core, including a lifestyle physical activity prescription with an accelerometer for self-feedback and monitoring and 6 group visits (1 every 5 weeks during the first 24 weeks and 1 3 months later) targeted to increase lifestyle physical activity in African American women.~Participants in the WWP receive no telephone calls."
3285029|NCT01700920|Experimental|Mesenchymal Stem Cell|"Cell suspension mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They employ a minimum dose of 0.5 x 106 MSC / kg and a maximum of 1, 0x106 CSM / kg of patient weight.~Pharmaceutical form: Suspension cell Route of administration: local implant intraosseous injection with trocar in the femoral head."
3285030|NCT01700933|Active Comparator|High-dosage-group|
3285031|NCT01700933|Active Comparator|Low-dosage-group|
3285032|NCT01700946|Active Comparator|Standard Risk|"Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
3285033|NCT01700946|Active Comparator|High Risk|"Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone~Cells for infusion are prepared using the CliniMACS System."
3285034|NCT01700972|Experimental|Imaging at 10-minute vs. 30-45-minutes|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
3285035|NCT01700998|Placebo Comparator|Placebo|250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr for 3 days repeated during ICU stay if hypomagnesemia occurs.
3285036|NCT01700998|Experimental|Magnesium|48 mEq Magnesium diluted in 250 ml saline 0.9% for 24 hours in an infusion rate solution of 10.4 ml / hr. Therapy is continued for 3 days and repeated if hypomagnesemia occurs during ICU stay
3285037|NCT01701050||Blood collection|Female patients 18 years or older with estrogen receptor (ER) positive, HER2 negative, progressive metastatic breast cancer after one or more lines of endocrine therapy (ET) who are initiating a new ET will be enrolled into the study. Patients must have immunohistochemistry (IHC) proven ER positive disease, IHC and/or fluorescence in-situ hybridization (FISH) proven HER2 negative disease, and an ECOG performance status of 0-2. Patients with brain metastases only or those who are progressing on fulvestrant are not eligible for the study.
3285038|NCT01701076|Experimental|Bendamustine|All patients are treated with bendamustine in combination with lenalidomide and dexamethasone for a maximum of 6 cycles.
3285039|NCT01701089|Experimental|RO4602522 Group 1|
3285040|NCT01701089|Experimental|RO4602522 Group 2|
3285041|NCT01701128|Experimental|Speed TT|Walk on treadmill with progressive increases in speed
3285042|NCT01701128|Experimental|Mixed TT|Walk on treadmill with progressive increases in speed and incline
3285043|NCT01701128|Active Comparator|Control|Light-intensity exercise group, work flexibility and coordination
3285044|NCT01701141||Individuals with MDD|Individuals with current MDD as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment.
3285045|NCT01701141||Healthy Controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment
3285046|NCT01701154||Pompe|Adults and children with Pompe disease.
3285047|NCT01701180|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
3285048|NCT01701180|Placebo Comparator|Placebo|Intranasal application, sodium chloride solution, 3 puffs per nostril
3285049|NCT01701206|Experimental|HIV intervention Group|Experimental arm receives peer-led HIV information on social media
3285050|NCT01701206|No Intervention|Control arm|
3285051|NCT01701219|Other|Cohort A|S. aureus on at least 1 blood culture within 72 hours of beginning study drug
3285052|NCT01701219|Other|Cohort B|MRSA on a baseline blood culture and on at least 1 additional blood culture after at least 72 hours of vancomycin and/or daptomycin treatment
3285053|NCT01701232|Active Comparator|MabThera|Reference rituximab at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
3285054|NCT01701232|Experimental|BCD-020|Proposed rituximab biosimilar at a dose of 375 mg/m2 intravenously once a week for four weeks (on days 1, 8, 15 and 22)
3285055|NCT01701284|Experimental|Right-Sided Low-Frequency rTMS|Participants will have rTMS administered at 1Hz to the right dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
3285056|NCT01701284|Experimental|Left-Sided High-Frequency rTMS|Participants will have rTMS administered at 10Hz to the left dorsolateral Prefrontal Cortex (dlPFC) once a day for 40 minutes, 5 days a week, for a total of six weeks.
3285057|NCT01701297|Active Comparator|Co-trimoxazole|Co-trimoxazole 960mg daily po
3285058|NCT01701297|Experimental|VSL#3 active|VSL#3 active 2 sachets/daily
3285059|NCT01701297|Placebo Comparator|VSL#3 placebo|VSL#3 placebo 2 sachets/daily
3285060|NCT01701310|Experimental|Ferric carboxymaltose|
3285061|NCT01701310|Active Comparator|Ferrous Sulphate|
3285062|NCT01701323|Experimental|Treatment (Ex-vivo expanded cord blood progenitors)|Patients receive filgrastim SC or IV on days 1-7, fludarabine phosphate IV QD over 30 minutes on days 2-6, cytarabine IV QD over 4 hours on days 2-6, and ex-vivo expanded cord blood progenitor cells IV over 30 minutes on day 8.
3285063|NCT01701336|Experimental|Unique Arm|"Ad6NSmut~MVA-NSmut~15 subjects receiving 2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination"
3285064|NCT01701349|Active Comparator|Fosbretabulin + paclitaxel + carboplatin|"Six 21 day cycles of:~Fosbretabulin (60 mg/m2) IV on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC 6) IV on Day 2"
3285065|NCT01701349|Placebo Comparator|Placebo + paclitaxel + carboplatin|"Six 21-day cycles of:~Placebo (formulated and packages to match fosbretabulin)on Day 1, 8, 15 Paclitaxel (200 mg/m2) IV on Day 2 Carboplatin (AUC6) IV on Day 2"
3285066|NCT01701388|Experimental|Ekso Safety and Efficacy|Observational study on the first time use of a robotic exoskeleton.
3285067|NCT01701427||1|1. Healthy, un-operated, groin-hernia free, pain-free and medicinal free males
3285068|NCT01701453|Experimental|6 months group|6 months duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
3285069|NCT01701453|Experimental|12 months or longer group|12 months or longer duration of P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) treatment
3285070|NCT01701466|Experimental|Arm B: standard of care plus NeoVIDERM cream|Patients will apply NeoVIDERM cream to the treatment area everyday one week before starting radiotherapy, throughout treatment and for two weeks post treatment. Patients will also perform standard of care skin treatment.
3285071|NCT01701466|Active Comparator|Arm A: standard skin care|Patients will be asked to apply Aveeno cream twice a day starting the day of their treatment until two weeks after the end of their treatments. If they develop dry desquamation, they will be asked to apply Flamazine twice a day until dermatitis resolves.
3285072|NCT01701479|Experimental|Experimental arm|"Subcutaneous aldesleukin (IL-2) will be given at a dose of 6 x 106 IU/m2/day in two 5 day blocks (days 1-5 and 8-12).~A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
3285073|NCT01701479|Active Comparator|Comparator arm|"A continuous infusion of ch14.18/CHO is started on day 8. The duration of the infusion is dependent on the assigned infusion schedule. The duration will range from 10 to 21 days. Three dose levels will be considered with respect to daily dose (7 mg/m2, 10 mg/m2, 15 mg/m2), which relates to total doses of 100 mg/m2,150 mg/m2 and 210 mg/m2.~Patients will receive isotretinoin (13-cis-RA) 160 mg/m²/day divided into two equal doses given orally twice a day for 14 days after the completion of the ch14.18/CHO infusion. The starting day is dependent on the duration of ch14.18/CHO infusion and may be either day 19, 23, 24 or 30."
3285074|NCT01701492||Stem Cell Transplant Survivors|All participants enrolled on this study will complete a questionnaire and undergo neurocognitive evaluation.
3285075|NCT01701492||Normal control participants|Control participants in the community without a history of serious illness, matched on age, gender, race/ethnicity and socioeconomic status. They will complete a questionnaire and undergo neurocognitive evaluation.
3285076|NCT01701518|Other|Ozurdex|Intra-operative Ozurdex (biodegradable 0.7mg dexamethasone implant) post-vitrectomy for epiretinal membrane
3285077|NCT01701531|Experimental|RBCPF|Treatment intervention arm
3285078|NCT01701544|Sham Comparator|NBM DBS Off|NBM DBS switched off
3285079|NCT01701544|Active Comparator|NBM DBS On|NBM DBS Switched On
3285080|NCT01701557|Active Comparator|slow fluid rate|bolus 10 ml/kg of NS followed by 1.25 times maintenance rate
3285081|NCT01701557|Active Comparator|Fast fluid rate|bolus 20 ml/kg of NS followed by 1.5 times maintenance rate
3285082|NCT01701570|Active Comparator|An Active Comparator exercise training intervention|The Active Comparator Groupwill participate in an exercise training intervention to distinguish the relative roles of objective factors (lactate level) and subjective factors (self-efficacy) in mediating pre-post change in RPE during low, moderate, and vigorous exercise.
3285083|NCT01701570|Placebo Comparator|A Placebo Attention Control|The placebo attention control group will receive monthly diabetes education and phone calls phone calls to monitor their blood glucose levels. Participants will receive an accelerometer to wear for one week.
3285084|NCT01701583|Experimental|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
3285085|NCT01701596|Experimental|Rotational atherectomy (RA)|Immediate rotational atherectomy (RA) in the treatment with nondilatable calcified lesion complicated by coronary dissection
3285086|NCT01701596|Active Comparator|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
3285087|NCT01701609|Experimental|Cognitive Remediation Therapy|CRT: Frontal/Executive Program. The program has a duration of 40 sessions, with two session for week. Is is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding in a context of learning without errors.
3285088|NCT01701635|Experimental|Disclosure intervention|In the disclosure intervention plus usual care arm the adherence and disclosure specialist will meet with caregiver at each clinic visit and provide information, education, disclosure skills, and support till disclosure occurs.
3285089|NCT01701635|Active Comparator|Usual care|"In the enhanced usual care (control) arm the disclosure specialist will meet with caregiver at each clinic visit and provide them will general health education and no mention or effort will be made to improve disclosure skills of caregiver."
3285090|NCT01701648|Active Comparator|1|
3285091|NCT01701661|Active Comparator|conservative treatment|Compression stockings class II
3285092|NCT01701661|Active Comparator|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refloating trunk
3285093|NCT01701687||Decompensated Alcoholic Cirrhosis|Recruited patients will have diagnosed liver cirrhosis (histological, radiological or accepted clinical parameters)admitted with an episode of decompensation. Patients must still be drinking hazardous alcohol quantities (>14 units for women, >21 units for men) at study enrollment
3285094|NCT01701700|Experimental|portable electronic magnifier|Use of a prescribed electronic magnifier plus existing optical aids for a period of 2 months
3285095|NCT01701700|Active Comparator|optical aids|Use of existing optical aids for 2 months
3285096|NCT01701713|Experimental|TDCS - DKI ED2011|TDCS with DKI ED2011 session is followed by a behavioral naming therapy with different cues
3285097|NCT01701713|Sham Comparator|Sham-TDCS|Sham-TDCS session is followed by a behavioral naming therapy with different cues
3285098|NCT01701726|Experimental|Acupuncture|Two types of acupuncture are given, one is acupuncture at affected meridian points, the other is at non-affected. For the first type, We select the acupoints from the affected meridians.Patients in this group are divided into two subgroups according meridian syndrome differentiation(jue-yin style,yang-ming style).Patients pertaining to Jue-yin-style are treated with taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6) .Patients pertaining to Yang-ming-style: taichong(LR3), renying(ST9), zusanli(ST36), quchi(LI11). For the second,We select the acupoints from the non-affected meridians.Patients assigned into the non-affected meridian acupuncture group will be treated with Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), xuehai (SP10).
3285099|NCT01701726|Sham Comparator|Sham acupuncture|"we use sham acupoints:~The edge of the tibia (1-2cm lateral and horizontal to the zusanli (ST36))~Half way between the tip of the elbow and the axilla~On the ulnar side of the arm, half way between the epicondylus medialis of the humerus and the ulnar side of the wrist.~2cm superior to fu tu(LI18)"
3285100|NCT01701726|No Intervention|Waiting list|Participants who will be randomized into the waiting-list group will not receive any acupuncture treatment throughout 13-week observation period. At the end of trial, if the participant would like to be treated with acupuncture, it will be provided three times weekly for 6 weeks.
3285101|NCT01701739|Experimental|aleglitazar / digoxin|
3285102|NCT01701752|Active Comparator|Group 1|Day 1: FP-01.1 + Placebo ; Day 29: FP-01.1
3285103|NCT01701752|Active Comparator|Group 2|Day 1: FP-01.1 + TIV ; Day 29: FP-01.1
3285104|NCT01701752|Active Comparator|Group 3|Day 1: FP-01.1-Adjuvant + Placebo ; Day 29: FP-01.1-Adjuvant
3285105|NCT01701752|Active Comparator|Group 4|Day 1: FP-01.1-Adjuvant + TIV ; Day 29: FP-01.1-Adjuvant
3285106|NCT01701752|Active Comparator|Group 5|Day 1: Adjuvant + TIV ; Day 29: Placebo
3285107|NCT01701752|Active Comparator|Group 6|Day 1: Placebo + TIV ; Day 29: Placebo
3285108|NCT01701765||Patients in residential facilities|All patients staying in September 2010 in 23 medium-long term RFs of the St John of God Order in Northern Italy with a primary psychiatric diagnosis and younger than 65 years recruited.
3285109|NCT01701778|Experimental|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
3378450|NCT02450851||Undiagnosed disorders|Patients with rare, undiagnosed disorders.
3285110|NCT01701778|Experimental|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg~Anesthesia was induced and maintained with sevoflurane"
3285111|NCT01701778|Placebo Comparator|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline~Anesthesia was induced and maintained with sevoflurane"
3285112|NCT01701791|Experimental|Computerized Decision Support System (CDSS)|GPs will use a CDSS with treatment algorithms, supervision from a consultant psychiatrist, and despatch to patients of reminders via mobile texting or automatic mobile (or landline) phone calls to improve adherence to the treatment prescribed.
3285113|NCT01701791|No Intervention|Treatment as usual|GPs will provide TAU, will make their own decisions and will therefore not use the CDSS. Patients will not receive any reminders.
3285114|NCT01701804||integrative treatment|
3285115|NCT01701817||Patients with Atrial Fibrillation (AF)|(1) patients with new onset/first detected Atrial Fibrillation (AF) diagnosed within the 6 months preceding the baseline visit; or (2) patients with AF who had initiation or transition to a FXa (Factor Xa) inhibitor or a direct thrombin inhibitor within the preceding 3 months.
3285116|NCT01701830||Case Group|Patients with chronic kidney disease of stage 3-4.
3378451|NCT02450331|Experimental|Atezolizumab|Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
3378452|NCT02450331|No Intervention|Observation|Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).
3378453|NCT02447120|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the Maestro device
3378454|NCT02444039||Any Willing and Able Person for Ocular Imaging|Any Willing and Able Person for Ocular Imaging
3285117|NCT01701830||Control group|30 healthy subject
3285118|NCT01701843|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion left bodyside), Cromoglicate (on a lesion on right bodyside)
3285119|NCT01701843|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion right bodyside), Cromoglicate (on a lesion on left bodyside)
3285120|NCT01701856|Experimental|Interferon beta-1b|Interferon beta-1b 250 mcg s.c. every other day
3285121|NCT01701869||NTHi positive|No intervention, this is an observational study
3285122|NCT01701869||NTHi negative|No intervention, this is an observational study
3285123|NCT01701869||Healthy Control|No intervention, this is an observational study
3285124|NCT01701882|Experimental|tenofovir/emtricitabine/rilpivirine|A one pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily.
3285125|NCT01701921|Experimental|Pregabalin 75|Pregabalin 75mg by mouth one hour before surgery
3285126|NCT01701921|Active Comparator|Pregabalin 150|Pregabalin 150mg by mouth one hour before surgery
3285127|NCT01701921|Placebo Comparator|Sugar pill|Placebo : Sugar pill manufactured to mimic pregabalin capsule by mouth one hour before surgery
3285128|NCT01701934|Experimental|Roflumilast|Roflumilast 500 mcg, once daily for 6 months
3285129|NCT01701934|Placebo Comparator|Placebo pill|Placebo pill, once daily for 6 months
3285130|NCT01701960||Group 1|This cohort will be injected with 1% lidocaine with 1:100,000 of epinephrine into the nasal mucosa at the time of nasal surgery
3285131|NCT01701960||Group 2|This group will be injected with 1% lidocaine with 1:200,000 of epinephrine into the nasal mucosa at the start of nasal surgery.
3285132|NCT01702012|Experimental|Almased Meal Replacement Powder|Participants assigned to this arm will receive the Almased meal replacement powder and will be asked to replace one meal per day during the first 6 months of participation. During the second 6 months, participants will be allowed to choose whether to continue using the product to replace a meal or to use the product as a supplement prior to meals.
3285133|NCT01702012|Active Comparator|Lifestyle Intervention|Participants randomized to this group will receive 5 group sessions in the first two months of participation and 5 additional group sessions in the last two months. These group sessions will focus on lifestyle behavior changes for weight loss and management including goal-setting, calorie balance, general nutrition, and physical activity.
3285134|NCT01702038|Experimental|Rituximab|Participants will receive an intravenous infusion of rituximab on Days 0 and 14
3285135|NCT01702051||1|patients with chronic pancreatitis treated with total or subtotal pancreatectomy
3285136|NCT01702051||2|patients underwent completion pancreatectomy because of anastomotic leak after partial pancreatectomy
3285137|NCT01702051||3|patients underwent pancreatoduodenectomy in which pancreatic anastomosis was made impracticable by technical difficulties and/or high risk of leakage
3285138|NCT01702051||4|patients underwent extensive distal pancreatectomy for pancreatic lesions located at the neck
3285139|NCT01702064|Experimental|Nilotinib with Ruxolitinib|"The starting dose of ruxolitinib will be 5mg by mouth (PO) twice a day (BID) and will increase by 5 mg increments in each cohort, to a maximum dose of 15 mg PO BID. Nilotinib will be given at a dose ranging from 300 mg PO BID to 400 mg PO BID, depending on the participant's dose prior to enrollment on the trial.~Dose Level 1: Ruxolitinib 5 mg twice a day (BID); Nilotinib 300 mg or 400 mg BID.~Dose Level 2: Ruxolitinib 10 mg BID; Nilotinib 300 mg or 400 mg BID.~Dose Level 3: Ruxolitinib 15 mg BID; Nilotinib 300 mg or 400 mg BID."
3285140|NCT01702077|Experimental|Neurofeedback first|Neurofeedback then sham feedback
3285141|NCT01702077|Experimental|Sham first|Sham feedback then neurofeedback
3285142|NCT01702090|Experimental|TMC114/ritonavir|
3285143|NCT01702103|Experimental|Mometasone|Mometasone, nasal spray for 8 weeks, 2 actuations each nostril in the morning.
3285144|NCT01702103|Active Comparator|Nasonex®|Nasonex nasal spray for 8 weeks 2 actuations each nostril in the morning.
3285145|NCT01702116|Experimental|extralevator APR|"This is a modified and more extensive procedure that is used to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
3285146|NCT01702116|Active Comparator|standard APR|conventional abdominoperineal resection (APR)
3285147|NCT01702129|Experimental|anti-EGFR Immunoliposomes|anti-EGFR immunoliposomes loaded with doxorubicin. Dose escalating study. 3 patients per dose level. Dose levels: 5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2.
3285148|NCT01702142||NIATx Only|NIATx (Network for the Improvement of Addiction Treatment) organization change model only
3285149|NCT01702142||NIATx and Advancing Recovery|Organizational and system changes
3285150|NCT01702155|Experimental|DFP-10917|"7-day continuous infusion (in the vein): Starting dose 4 mg/m^2~14-day continuous infusion (in the vein): Starting dose 10 mg/m^2~Phase II Only: 6 mg/m^2 for the 14-day continuous infusion (in the vein)"
3285151|NCT01702168||CBT Training|
3285152|NCT01702181|Placebo Comparator|Placebo|Matching placebo.
3285153|NCT01702181|Active Comparator|Tacrolimus|Tacrolimus 0.1% ointment twice daily for 28 days.
3285154|NCT01702181|Experimental|OPA-15406|
3285155|NCT01702194|Experimental|TD-1211 IV [C14]|TD-1211 IV [C14]
3285156|NCT01702194|Experimental|TD-1211 PO [C14]|TD-1211 PO [C14]
3285157|NCT01702207|Active Comparator|Once Daily Tacrolimus|Treatment Arm - Subjects are switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
3285158|NCT01702207|Active Comparator|Twice Daily Tacrolimus|Control Arm - Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
3285159|NCT01702220|Experimental|CBT|
3285160|NCT01702220|Active Comparator|Enhanced Community Care (ECC)|
3285161|NCT01702272||Dengue Virus|
3285162|NCT01702285|Experimental|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
3285163|NCT01702324|Experimental|DD-25|A concentration of 0.025% of topical DD-25 cream.
3285164|NCT01702337||HPV-1 Group|Hypothetical group of women vaccinated with HPV-1 vaccine in Taiwan.
3285165|NCT01702337||HPV-2 Group|Hypothetical group of women vaccinated with HPV-2 vaccine in Taiwan.
3285166|NCT01702350|Experimental|Study Drug Formulation A|Enterric Coated Tablet Formulation of GSK2251052
3285167|NCT01702350|Experimental|Study Drug Formulation B|Modified Release Table Formulation of GSK2251052
3285168|NCT01702350|Experimental|Study Drug Formulation C|Enterric Coated Powder for Oral Suspension Formulation of GSK2251052
3285169|NCT01702350|Experimental|Study Drug Formulation D|Immidiate Release Table Formulation of GSK2251052
3285170|NCT01702350|Experimental|Study Drug Formulation E|Oral Solution Formulation of GSk2251052
3285171|NCT01702376|Experimental|Retosiban 100 mg|Each subject will be randomized to single dose of retosiban 100 mg in one of the four treatment sequences.
3285172|NCT01702376|Experimental|Retosiban 800 mg|Each subject will be randomized to single dose of retosiban 800 mg in one of the four treatment sequences
3285173|NCT01702376|Placebo Comparator|Placebo|Each subject will be randomized to single dose of matching placebo in one of the four treatment sequences
3285174|NCT01702376|Active Comparator|Moxifloxacin 400 mg|Each subject will be randomized to single dose of moxifloxacin 400 mg in one of the four treatment sequences
3285175|NCT01702389|Experimental|Remifentanil|The study has only one arm. Same group of volunteers will receive remifentanil infusion with abrupt withdrawal, remifentanil infusion with gradual dose reduction and saline infusion at three separate trials.
3285176|NCT01702402|Experimental|Intervention Arm|Intervention activities will include behaviour change communications on healthy timing and spacing of pregnancy, couples counselling, social networking and expansion of contraceptive options for postpartum women, including provision of oral contraceptive pills and condoms in the home.
3285177|NCT01702402|Other|Comparison|A comparison area received standard government health services.
3285178|NCT01702415|Placebo Comparator|Placebo|Placebo
3285179|NCT01702415|Experimental|Zoledronic acid|Active IMP
3285180|NCT01702441|Experimental|AKB-9778|Up to 4 dose levels of subcutaneous AKB-9778 will be evaluated. Doses will be administered daily for 28 days.
3285181|NCT01702467|Experimental|GSK2647544|The starting dose of GSK2647544 is 0.5 mg. The escalating doses to be administered will be determined based on study results from previous dose (s).
3285182|NCT01702467|Placebo Comparator|Placebo|Matching placebo
3285183|NCT01702480|Experimental|Part 1: GSK2981710 10 gram (g)|Eight subjects will receive single dose of GSK2981710 in the form of 10 g medium-chain triglycerides (MCT) powder daily for 14 days.
3285184|NCT01702480|Experimental|Part 1: GSK2981710 20 g|Eight subjects will receive single dose of GSK2981710 in the form of 20 g MCT powder daily for 14 days.
3285185|NCT01702480|Experimental|Part 1: GSK2981710 30 g|Eight subjects will receive single dose of GSK2981710 in the form of 30 g MCT powder daily for 14 days.
3285186|NCT01702480|Experimental|Part 1: GSK2981710 40 g|Eight subjects will receive single dose of GSK2981710 in the form of 40 g MCT powder daily for 14 days.
3285187|NCT01702480|Placebo Comparator|Part 1: Placebo|Eight subjects will receive single dose of matching placebo daily for 14 days.
3285188|NCT01702480|Experimental|Part 2: GSK2981710 (dose to be decided from Part 1)|The subjects will receive single dose of GSK2981710 in the form of MCT powder (dose to be decided from Part 1) daily for 14 days.
3285189|NCT01702480|Placebo Comparator|Part 2: Placebo|The subjects will receive single dose of matching placebo daily for 14 days..
3285190|NCT01702493|Active Comparator|Part 1: Cap SRT2104|500 mg SRT2104 (in the form of two, 250 mg capsules) will be administered as a single oral dose in the fasting state
3285191|NCT01702493|Experimental|Part 1: Tab SRT2104 (slow release)|500 mg SRT2104 (in the form of two, 250 mg slow release tablets) will be administered as a single oral dose in the fasting state.
3285192|NCT01702493|Experimental|Part 1: Tab SRT2104 (intermediate release)|500 mg SRT2104 (in the form of two, 250 mg intermediate release tablets) will be administered as a single oral dose in the fasting state.
3285193|NCT01702493|Experimental|Part 1: Tab SRT2104 (fast release)|500 mg SRT2104 (in the form of two, 250 mg fast release tablets) will be administered as a single oral dose in the fasting state.
3285194|NCT01702493|Experimental|Part 2A: SRT2104 500 mg single-dose|500 mg SRT2104 (formulation selected from Part 1) will be administered as a single oral dose in the fed state.
3285195|NCT01702493|Experimental|Part 2B: SRT2104 single alternative dose|An alternative dose (other than 500 mg, but not to exceed 2000 mg) of SRT2104 (formulation selected from Part 1) will be administered as a single oral dose.
3285196|NCT01702493|Experimental|Part 2C: SRT2104 500 mg daily for 7 days|500 mg SRT2104 (formulation selected from Part 1) will be administered daily for 7 days.
3285197|NCT01702506|Experimental|Fasted|Dacomitinib administered under fasted conditions
3285198|NCT01702506|Experimental|Fed|Dacomitinib administered under fed conditions
3285199|NCT01702506|Experimental|Antacid|Dacomitinib administered under antacid treatment
3285200|NCT01702584||stent assisted embolization|stent assisted embolization of intracranial aneurysm
3285201|NCT01702597|Experimental|WBV|Patients will receive supervised physical therapy using a whole body vibration device (Galileo® Med M Plus, Novotec, Pforzheim, Germany) twice a week, 30 minutes per session, for 6 weeks.
3285202|NCT01702597|Active Comparator|Physiotherapy|Patient will receive the current gold standard treatment protocol: supervised physical therapy, twice a week, 30 minutes per session, for 6 weeks.
3285203|NCT01702610|Experimental|Temozolomide, Accelerated Hypofractionated RT|Patient will receive two weeks of neo-adjuvant Temozolomide followed by Accelerated Hypofractionated RT for a total of 20 fractions for a total of 60Gy followed by Temozolomide for 12 cycles.
3285204|NCT01702623|Active Comparator|Oxcarbazepine first, then Trileptal|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period)
3285205|NCT01702623|Active Comparator|Trileptal first, then Oxcarbazepine|Single dose of oxcarbazepine suspension, 600 mg, then single dose of trileptal suspension, 600 mg (after washout period
3285206|NCT01702636|Active Comparator|Tranexamic Acid|Intravenous tranexamic acid 1000 mg in 100 mL 0.9% NaCl over 10 minutes followed by 1000 mg in 500 mL 0.9% NaCl infusion over 8 hours.
3285207|NCT01702636|Placebo Comparator|Placebo|Intravenous placebo in 100 mL 0.9% NaCl over 10 minutes followed by 500 mL 0.9% NaCl infusion over 8 hours.
3285208|NCT01702649|Experimental|RPX2003 (Biapenem)|Single and multiple dose of RPX2003 (Biapenem).
3285209|NCT01702649|Placebo Comparator|Normal Saline|Single and multiple doses of normal saline.
3285210|NCT01702662|Experimental|Photopill treatment|Photopill treatment, 2 minutes per cm rectal mucosa (3cm) 10 times
3285211|NCT01702675|Experimental|ACH15 - 50mg capsule|ACH15 50mg capsule by mouth single dose (Group 1)
3285212|NCT01702675|Experimental|ACH15 - 250 mg capsule|ACH15 250mg capsule by mouth as single dose(Group 2)
3285213|NCT01702675|Experimental|ACH15 - 500mg capsule|ACH15 500mg capsule by mouth in a single dose(Group 3)
3285214|NCT01702675|Experimental|ACH15 - 1000 mg (two 500mg capsule)|ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
3285215|NCT01702675|Experimental|ACH15 - 2000 mg (four 500 mg capsule)|ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
3285216|NCT01702675|Experimental|ACH15 - 500 mg (twice a day for 7 days)|ACH15 500mg capsule by mouth twice a day for seven days (Group 6)
3285217|NCT01702675|Placebo Comparator|Placebo - 250 mg capsule|Placebo 250mg capsule by mouth single dose (Group 2)
3285218|NCT01702675|Placebo Comparator|Placebo - 500 mg capsule|Placebo 500mg capsule by mouth in a single dose(Group 3)
3285219|NCT01702675|Placebo Comparator|Placebo - 1000 mg (two 500mg capsule)|Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)
3285220|NCT01702675|Placebo Comparator|Placebo 2000 mg (four 500mg capsule)|Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)
3285221|NCT01702675|Placebo Comparator|Placebo - 500 mg (twice a day for 7 days)|Placebo 500mg capsule by mouth twice a day for seven days (Group 7)
3285222|NCT01702701|Active Comparator|Montelukast|patients will receive 10 mg po montelukast daily for 12 weeks.
3285223|NCT01702701|Active Comparator|Fluticasone|patients will receive 440mcg fluticasone po bid for 12 weeks
3378457|NCT02438969||Cohort 1|Treatment-seeking or non-treatment-seeking individuals with AUD and ELS exposure
3285224|NCT01702714|Experimental|RO5083945 + carboplatin + paclitaxel|
3285225|NCT01702714|Experimental|RO5083945 + cisplatin +gemcitabine|
3285226|NCT01702727|Experimental|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
3285227|NCT01702727|Active Comparator|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
3285228|NCT01702727|Experimental|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
3285229|NCT01702740|Experimental|Part A, 1 mg/kg CNTO 136|
3285230|NCT01702740|Experimental|Part A, 4 mg/kg CNTO 136|
3285231|NCT01702740|Experimental|Part A, 10 mg/kg CNTO 136|
3285232|NCT01702740|Experimental|Part B, 10 mg/kg CNTO 136/placebo|
3285233|NCT01702753|Active Comparator|Bifidobacterium animalis subsp. lactis|
3285234|NCT01702753|Placebo Comparator|Placebo|
3285235|NCT01702766|Active Comparator|Bifidobacterium animalis subsp. lactis|
3285236|NCT01702766|Placebo Comparator|Placebo|
3285237|NCT01702779|Other|optiflow|
3285238|NCT01702779|Other|O2|
3285239|NCT01702792|Experimental|Tumor Vaccine|1 x 107 TCE tumor lysate in 0.5 ml Lactated Ringers Solution (approximately 1 mg of tumor lysate protein) and equivalent volume of adjuvant will be injected 2 weeks and 3 weeks (2 vaccinations) after surgery in the intradermal skin of the upper thigh. There will be 2 vaccine administrations and patients will be followed for 2 months after inguinal node removal for any possible vaccine/study-related toxicity.
3285240|NCT01702805|Active Comparator|Low Threshold Transfusion|Transfusions will be administered using a lower threshold hemoglobin value. The low threshold values reflect more common practice, so this is considered the 'usual treatment' group
3285241|NCT01702805|Active Comparator|High Threshold Transfusion|Transfusions will be administered using a higher threshold hemoglobin value.
3285242|NCT01702818||HSDD group|Women with a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
3285243|NCT01702818||Control Group|Women without a diagnosis of Hypoactive Sexual Desire Disorder (HSDD).
3285244|NCT01702831|Experimental|BuMel + lenalidomide Maintenance|I.V. Busulfan + I.V. Melphalan for conditioning prior ASCT, followed by Lenalidomide maintenance at day 100 after ASCT.
3285245|NCT01702857|Experimental|TDENV-PIV alum4|4 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3285246|NCT01702857|Experimental|TDENV-PIV AS03B|1 µg TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3285247|NCT01702857|Placebo Comparator|Placebo|Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days
3285248|NCT01702857|Experimental|TDENV-PIV alum1|1 µg TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3285249|NCT01702857|Experimental|TDENV-PIV AS01E|1 µg TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days
3285250|NCT01702870||Suspected myositis|Participants with suspected myositis based on clinical criteria (Bohan and Peters criteria) referred for Magnetic resonance imaging
3285251|NCT01702870||Controls|Normal volunteers without myositis, who will undergo MR imaging to establish normal ranges of MR signal in health muscle
3285256|NCT01702974|Active Comparator|Vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
3285257|NCT01702974|Placebo Comparator|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
3285258|NCT01703052|Experimental|CHF 6001 SD or placebo|Single administration of CHF 6001 dose levels 1 to 7 or placebo
3285259|NCT01703052|Experimental|CHF 6001 MD or placebo|Multiple administration of CHF 6001 dose levels 1 to 5 or placebo
3285260|NCT01703078|Active Comparator|Ingenol mebutate gel 0.05%|once daily for two consecutive days
3285261|NCT01703078|Experimental|Ingenol derivative concentration 1|once daily for two consecutive days
3285262|NCT01703078|Experimental|Ingenol derivative concentration 2|once daily for two consecutive days
3285263|NCT01703078|Experimental|Ingenol derivative concentration 3|once daily for two consecutive days
3285264|NCT01703104|Active Comparator|Paludrine + Folic Acid|This arm uses routine drugs, Paludrine + Folic Acid
3285265|NCT01703104|Active Comparator|Paludrine + Folic Acid + Jobelyn|This group uses Paludrine + Folic Acid + Jobelyn
3285266|NCT01703130|Experimental|Local Anesthestic Dose|
3285267|NCT01703143|Experimental|Laser Ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
3285268|NCT01703156|Experimental|Non-Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. The dosages of aspirin, b-blocker and statin will be left to the discretion of the treating physician. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a patient has contraindications to any medications, they will not be administered. If a statin contraindication exists, other cholesterol-lowering medications may be administered. Appendix 4 shows the detailed management of low risk ACS patients randomized to the non-stress group.
3285269|NCT01703156|Active Comparator|Stress Group|Medical therapy will be implemented and will include the following: aspirin, clopidogrel, b-blockers, and statins. Statins will be initiated irrespective of LDL unless contraindicated. Clopidogrel will be taken for at least one month and ideally up to one year. Sublingual nitroglycerin will be provided to all patients. Other anti-ischemic medications including long-acting nitrates, calcium channel blockers, and ranolazine may be provided at the treating physicians' discretion. If a statin contraindication exists, other cholesterol-lowering medications may be administered. All patients will undergo noninvasive stress testing. Results of individual stress tests will be reviewed by a cardiologist. Based on the myocardium deemed at risk and patient symptoms, further testing with angiography and revascularization using percutaneous techniques and/or coronary artery bypass grafting may be considered. Likewise, medical treatment may be adjusted.
3285270|NCT01703182||leg amputation|Patients undergoing below-knee and above ankle amputation for vascular reasons will receive transcutaneous oximetry and transcutaneous carbon dioxide measurement
3285271|NCT01703195|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Patients receive Magnetic Resonance Imaging (MRI) and Diffusion Weighted Magnetic Resonance Imaging (DWMR) imaging pre-treatment and 4-6 weeks post-treatment.
3285272|NCT01703234|Experimental|Ramipril|
3285273|NCT01703247|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
3285274|NCT01703247|Active Comparator|PVI+GP|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
3285275|NCT01703273|Experimental|low key intervention|
3285276|NCT01703273|Active Comparator|routine care|
3285277|NCT01703299||imipenem-treated patients|imipenem-treated patients
3285278|NCT01703299||ertapenem-treated patients|ertapenem-treated patients
3285279|NCT01703312|Experimental|QGE031|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses). Three dose levels of QGE031 will be offered during the study: low, medium, and high. Participants will be randomized to receive one of these dose levels for all dosing visits.
3285280|NCT01703312|Active Comparator|omalizumab|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses) or once every four weeks (total of three doses). The dose that a participant receives will depend upon the participant's body weight and IgE level; dosage will be determined based upon local omalizumab dosing charts.
3285281|NCT01703312|Placebo Comparator|placebo|During the 10-week treatment period, participants will receive a dose of study drug subcutaneously once every two weeks (total of six doses).
3285282|NCT01703325|Active Comparator|triamcinolone injection (10 mg/ml)|"Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection"
3285283|NCT01703325|Active Comparator|Topical 0.05% clobetasol ointment|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Apply Topical 0.05% clobetasol propionate ointment on the nail fold twice daily for 6 months
3285284|NCT01703325|No Intervention|Controlled group|Three finger nails are chosen from the equally average Targeted NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C Controlled group
3285285|NCT01703338||Lumbar spinal surgery|The study included participants who were diagnosed by a neurological surgeon and received lumbar surgery according to relevant imaging findings
3285286|NCT01703351|Experimental|Drug: 0.5% ropivacaine|
3285287|NCT01703351|Active Comparator|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|
3285288|NCT01703364|Experimental|Lenalidomide/Fludarabine/Rituximab|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
3285289|NCT01703390|Experimental|ERCC-1 low|modifiedFOLFOX6 + Cetuximab oxaliplatin 85 mg/m2 on day 1, 15 q d29 for 6 cycles folinic acid (FA) 400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus day 1 + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
3285290|NCT01703390|Experimental|ERCC-1 high|FOLFIRI + Cetuximab irinotecan 180 mg/m² on day 1, 15 q d29 for 6 cycles folinic acid (FA)400 mg/m2 on days 1 and 15 and q d29 for 6 cycles fluorouracil (5-FU) 400 mg/m2 bolus + 2400 mg/m2 46-hour infusion on days 1, 2 and 15, 16 and q d29 for 6 cycles or until unacceptable toxicity Cetuximab will be administered as a 120- minute intravenous infusion at 500 mg/m2 on day 1 then 500 mg/m2 bi-weekly
3285291|NCT01703416||1|
3285292|NCT01703429||Individuals with MS|
3285293|NCT01703442||Ovarian cancer patients|Perioperative primary epithelial ovarian cancer patients
3285294|NCT01703455|Experimental|Sorafenib 400 mg twice daily|Sorafenib 400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
3285295|NCT01703468|Active Comparator|Oxcarbazepine then Trileptal|600 mg suspension
3285296|NCT01703468|Active Comparator|Trileptal then Oxcarbazepine|600 mg suspension
3285297|NCT01703481|Experimental|Part 1|Dose Escalation, Part 1: Participants will be enrolled in sequential cohorts to determine recommended Phase 2 doses (RP2D).
3285298|NCT01703481|Experimental|Part 2|Dose Confirmation, Part 2: Tumor biopsy cohorts will confirm RP2D.
3285299|NCT01703481|Experimental|Part 3, Cohort A|First dose expansion, Part 3: Participants with squamous non-small cell lung cancer.
3285300|NCT01703481|Experimental|Part 3, Cohort B|First dose expansion, Part 3: Participants with small cell lung cancer.
3285301|NCT01703481|Experimental|Part 3, Cohort C|First dose expansion, Part 3: Participants with breast cancer.
3285302|NCT01703481|Experimental|Part 3, Cohort D|First dose expansion, Part 3: Participants with solid tumors (consisting of one of the following: gastric, head and neck, lung adenocarcinoma, urothelial, glioblastoma multiforme [GBM], ovarian or prostate).
3285303|NCT01703481|Experimental|Part 4, Cohort E|Second dose expansion, Part 4: Participants with non-small cell lung cancer.
3285304|NCT01703481|Experimental|Part 4, Cohort F|Second dose expansion, Part 4: Participants with solid tumors (consisting of one of the following: breast, urothelial, GBM).
3285305|NCT01703494|Active Comparator|Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal Microbiota Transplant (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
3285306|NCT01703494|Sham Comparator|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute severe C. difficile infection, subjects will receive a 300 mL infusion of a sham (autotransfusion) fecal solution at colonoscopy.
3285307|NCT01703520||Male Finasteride Users|Male finasteride users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3285308|NCT01703520||Male Finasteride Non-users|Country-matched male finasteride non-users aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3285309|NCT01703520||Men with Breast Cancer|Breast cancer cases among men aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3285310|NCT01703520||Men without Breast Cancer|Country- and age-matched controls: men without breast cancer aged 35 years and above in the registries of Denmark (1995-2013), Finland (1994-2013), Norway (2008-2013), and Sweden (2005-2013).
3285311|NCT01703533|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3285312|NCT01703533|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water for Injection
3285313|NCT01703546|Experimental|LAGB & LGCP|"All study patients will have the following surgical procedure: Laparoscopic Adjustable Gastric Banding and Gastric Plication (LAGB & LGCP).~The percent of Excess Body Weight Loss will be monitored at all post op visits."
3285314|NCT01703559|Placebo Comparator|Placebo|Administered once daily in both eyes for 15 days
3285315|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 0.5%|Administered once daily in both eyes for 15 days
3285316|NCT01703559|Experimental|Phentolamine Mesylate Ophthalmic Solution 1.0%|Administered once daily in both eyes for 15 days
3285317|NCT01703572|Experimental|OMP-52M51|
3285318|NCT01703585||metastatic breast cancer|
3285319|NCT01703585||metastatic colorectal cancer|
3285320|NCT01703585||metastatic gynecological cancer|
3285321|NCT01703585||metastatic melanoma|
3285322|NCT01703611|Experimental|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBPGN) (www.guidelines.gov)
3285323|NCT01703611|Active Comparator|Usual Nutrition Care|Visits for usual nutrition therapy (diet and lifestyle changes) provided by dietitians over a 12 month period.
3285324|NCT01703624|Experimental|glycopyrronium bromide 12.5mcg|glycopyrronium bromide 12.5mcg single dose via pressurised metered dose inhaler (pMDI)
3285325|NCT01703624|Experimental|glycopyrronium bromide 25mcg|glycopyrronium bromide 25mcg single dose via pressurised metered dose inhaler (pMDI)
3285326|NCT01703624|Experimental|glycopyrronium bromide 50mcg|glycopyrronium bromide 50mcg single dose via pressurised metered dose inhaler (pMDI)
3285327|NCT01703624|Experimental|glycopyrronium bromide 100mcg|glycopyrronium bromide 100mcg single dose via pressurised metered dose inhaler (pMDI)
3285328|NCT01703624|Placebo Comparator|placebo|placebo single dose via pressurised metered dose inhaler (pMDI)
3285329|NCT01703637|Experimental|Sitagliptin|Drug: sitagliptin sitagliptin 100mg tablet by mouth , once daily for 12 weeks
3285330|NCT01703637|Experimental|Vildagliptin|Drug: vildagliptin saxagliptin 50mg tablet by mouth , twice daily for 12 weeks
3285331|NCT01703637|Experimental|Saxagliptin|Drug: saxagliptin saxagliptin 5mg tablet by mouth , once daily for 12 weeks
3285332|NCT01703650||Resectable pancreas cancer|patients with resectable pancreas adenocarcinoma or neuroendocrine tumor underwent perfusion CT after intravenous iopromide administration
3285333|NCT01703650||Locally advanced Pancreas cancer|Patients with locally advanced pancreas cancer underwent perfusion CT after intravenous iopromide administration before and after chemotherapy.
3285334|NCT01703676||Patients|Klinefelter Patients
3285335|NCT01703676||Parents|Parents of Klinefelter Patients
3285336|NCT01703676||Controls M|Healthy Male Control with normal karyotype
3285337|NCT01703676||Controls F|Healthy female controls
3285338|NCT01703689|Experimental|strong intervention group (SIG)|Nursing homes that received audit and feedback information on quality indicators and benefited of cooperative work meetings with hospital geriatricians
3285339|NCT01703689|Active Comparator|intervention group (LIG)|Nursing homes that only received audit and feedback information on quality indicators
3285340|NCT01703715||Patients aged 65 years and over|All patients aged 65 years and over admitted to acutely to medical wards
3285341|NCT01703728||Highly purified menotropin (HP-hMG) treatment|Cohort of women from 18 to 36 years old treated by HP-hMG for controlled ovarian stimulation (COS) for a first or second cycle of IVF / ICSI.
3285342|NCT01703754|Experimental|Ad-RTS-hIL-12 and veledimex|Experimental study drug monotherapy arm (A)
3285343|NCT01703754|Experimental|Ad-RTS-hIL-12 and Palifosfamide|Study drug combination therapy arm (C)
3285344|NCT01703767||Gulf War 1 Veterans|Persian Gulf War 1 Veterans (GW1V) who are currently treated by a primary care physician at the VA Salt Lake City Health Care System. GW1V will assess their primary care satisfaction before and after their providers receive a Provider Education Workshop.
3285345|NCT01703780||resistant hypertension|blood pressure remaining above goal (< 140/90 mm Hg for the general population and < 130/80 mm Hg for patients with diabetes or renal disease) despite using optimal doses of 3 antihypertensive agents of different classes(including a diuretic) for half to one year.
3285346|NCT01703780||controllable hypertension|blood pressure can reach 130/80 mm Hg or less in half year by use of optimal dose of less than 3 antihypertensive agents of different classes
3285347|NCT01703780||healthy control|"Age>50 years old~Blood pressure ≤ 120/80 mm Hg( 24-hour blood pressure monitor or home blood pressure measurement at 6-9 am and 5-8pm, twice)~No cardiovascular diseases: coronary artery disease(coronary angiography or CTA), cerebrovascular diseases(history, MRI-Lacunar brain stem), Carotid ultrasound~No peripheral angiopathy (ABI<0.9 or lower extremity vessels Doppler ultrasound)~No major cardiovascular risk factors:~Dyslipidemia~Diabetes~Smoke within one year"
3285348|NCT01703793|Placebo Comparator|Vehicle|Vehicle (placebo) treatment, twice a week for four weeks.
3285349|NCT01703793|Experimental|Test Product 10156|Product 10156 treatment, twice a week for four weeks.
3285350|NCT01703793|Experimental|Test Product 49778|Product 49778 treatment, twice a week for four weeks.
3285351|NCT01703806||Conventional Treatment|Patients in the conventional treatment group will be treated according to the 2006 ACC/AHA guidelines and they will be referred for surgery if they experience any symptoms, and referred for surgery if exertional dyspnea, LV ejection fraction <0.60, LV end-systolic dimension >40 mm, Doppler estimated pulmonary artery pressure > 50 mmHg, or atrial fibrillation develops.
3285352|NCT01703806||Early Surgery|Patients in the early surgery group should undergo mitral valve surgery within 6 months of enrollment.
3285353|NCT01703884|Experimental|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy women will be systematically evaluated with RDT for whether they have malaria parasites and treated effectively.
3285354|NCT01703884|No Intervention|SP|At ANC and labor wards for women in the control area, there will be no change from routine approaches.
3285355|NCT01703897||Obese patients|
3285356|NCT01703910|Active Comparator|Arm A|Control treatment and will be treated with any of the schemes used in the study according to the discretion of the physician.
3285357|NCT01703910|Experimental|Arm B|Treatment guided by the gene expression profiles obtained from the CTC
3285358|NCT01703923|Experimental|FP01 6mg or Placebo|FP01 6mg Oral
3285359|NCT01703923|Experimental|FP01 12mg or Placebo|FP01 12mg Oral
3285360|NCT01703936|Experimental|agricultural training program|Three to four month residential agriculture and life skills training program.
3285361|NCT01703936|No Intervention|Control group|
3285362|NCT01703949|Experimental|Arm A (brentuximab vedotin)|Patients receive brentuximab vedotin IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3285363|NCT01703949|Experimental|Arm B (brentuximab vedotin, nivolumab)|Patients receive brentuximab vedotin IV over 30 minutes and nivolumab IV over 30-60 minutes on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3285364|NCT01703962||Patients with IDH1 R132H or wild type IDH1/IDH2 glioma|
3285365|NCT01703975|No Intervention|Single training|Students training alone on the simulator
3285366|NCT01703975|Experimental|Training in pairs (Dyad Training)|Students training in pairs on the simulator
3285367|NCT01704001|Experimental|Renal impairment grade 0|
3285368|NCT01704001|Experimental|Renal impairment grade 1|
3285369|NCT01704001|Experimental|Renal impairment grade 2|
3285370|NCT01704001|Experimental|Renal impairment grade 3|
3285371|NCT01704014||α1-ARA Group|All patients on α1-ARA(α1-adrenergic receptor antagonists) medication who underwent cataract surgeries.
3285372|NCT01704014||Control Group|Age and sex-matched control subjects
3285373|NCT01704027|Experimental|Radiotherapy|Patient will receive a pelvic and prostatic simultaneous integrated boost intensity-modulated arctherapy (SIB-IMAT) in combination with three years of androgen deprivation
3285374|NCT01704040|Experimental|Part 1: Healthy participants (CNTO 3157 + HRV-16)|
3285375|NCT01704040|Placebo Comparator|Part 1: Healthy participants (placebo + HRV-16)|
3285376|NCT01704040|Experimental|Part 2: Asthmatic patients (CNTO 3157 + HRV-16)|
3285377|NCT01704040|Placebo Comparator|Part 2: Asthmatic patients (placebo + HRV-16)|
3285378|NCT01704092||Group High-dose|Dexmedetomidine loading dose 1μg/kg Dexmedetomidine maintenance dose 0.6μg/kg/h
3285379|NCT01704092||Group Low-dose|Dexmedetomidine loading dose 0.6μg/kg Dexmedetomidine maintenance dose 0.3μg/kg/h
3285380|NCT01704092||Group Control|Dexmedetomidine loading dose and Dexmedetomidine maintenance dose were placed with the same amount of 0.9% saline as placebo
3285381|NCT01704105|Active Comparator|Water Quality|100 clusters, approximately 1,000 newborns
3285382|NCT01704105|Active Comparator|Sanitation|100 clusters, approximately 1,000 newborns
3285383|NCT01704105|Active Comparator|Handwashing|100 clusters, approximately 1,000 newborns
3285384|NCT01704105|Active Comparator|Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
3285385|NCT01704105|Active Comparator|Nutrition|100 clusters, approximately 1,000 newborns
3285386|NCT01704105|Active Comparator|Nutrition + Combined Water, Sanitation, and Handwashing|100 clusters, approximately 1,000 newborns
3285387|NCT01704105|No Intervention|Active control arm|200 clusters, approximately 2,000 newborns. Village-level promoter will visit household and will strictly engage in recording the child's MUAC, which will also be conducted in all active comparator arms as well.
3285388|NCT01704105|No Intervention|Passive control arm|100 clusters, approximately 1,000 newborns. No intervention.
3285389|NCT01704118|Experimental|I-gel|I-gel (Intersurgical Ltd, Wokingham, Berkshire, UK) is a disposable supraglottic airway device with a non-inflatable cuff in which part of that is fixed on glottis is made of thermoplastic elastomer, unlike other laryngeal masks
3285390|NCT01704118|Active Comparator|ProSeal Laryngeal mask|ProSeal laryngeal mask (PLMA) (LMA North America, Inc., San Diego, USA) is a modified type of LMA (larger and deeper bowl and enlarged and softer cuff) with gastric drainage tube.
3378458|NCT02438969||Cohort 2|Treatment-seeking or non-treatment-seeking individuals with AUD without ELS exposure
3378459|NCT02438969||Cohort 3|Healthy volunteers with ELS exposure
3378460|NCT02438969||Cohort 4|Healthy volunteers without ELS exposure
3285391|NCT01704131||children > 6 months|children > 6 months of age
3285392|NCT01704131||children < 6 months|children < 6 months
3285393|NCT01704157|Other|Open Treatment|Treatment with Cryo-Touch III Device
3285394|NCT01704170|Experimental|Renal Denervation Using Externally Focused Ultrasound Therapy|
3285397|NCT01704222||Child in nursery|Children older than 3 months and less than 6 years kept in nurseries retained, regardless of the duration of custody of the child in the manger concerned.
3285398|NCT01704235||Primary health care providers|medical physicians and nurse practitioners
3285399|NCT01704248|Placebo Comparator|Routine self-instillation technique|The participants first use the Routine self-instillation technique for two weeks and then switch to the Eye Drop Guide technique for another two weeks.
3285400|NCT01704248|Experimental|Eye Drop Guide technique|The participants first use the Eye Drop Guide technique for two weeks and then switch to the Routine self-instillation technique for another two weeks.
3285401|NCT01704274|Placebo Comparator|Placebo|Placebo patch
3285402|NCT01704274|Experimental|Low dose GTN 0.0285 mg/hr|Low dose GTN
3285403|NCT01704274|Experimental|High Dose GTN 0.057 mg/hr|High Dose GTN
3285404|NCT01704300||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
3285405|NCT01704313|Experimental|Interrupted|Interrupted suturing technique used around heel of anastomosis
3285406|NCT01704313|Active Comparator|Continuous|Continuous suturing technique used for the anastomosis
3285407|NCT01704339|Experimental|QUTENZA|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
3285408|NCT01704352|Active Comparator|CBT-I|Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment consisting of sleep restriction therapy, psychoeducation about sleep, stimulus control, stabilizing circadian rhythm and challenging beliefs and perception of sleep.
3285409|NCT01704352|No Intervention|Treatment as usual|Treatment as usual (TAU) consists of pharmacological and supportive psychosocial treatment according to the needs of the patient.
3285410|NCT01704365|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
3285411|NCT01704365|Experimental|Group B|Low dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
3285412|NCT01704365|Experimental|Group C|Low dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
3285413|NCT01704365|Experimental|Group D|Low dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
3285414|NCT01704365|Experimental|Group E|High dose RSV-F Vaccine with Adjuvant (Day 0 and Day 28)
3285415|NCT01704365|Experimental|Group F|High dose RSV-F Vaccine with Adjuvant (Day 0); Placebo (Day 28)
3285416|NCT01704365|Experimental|Group G|High dose RSV-F Vaccine without Adjuvant (Day 0 and Day 28)
3285417|NCT01704365|Experimental|Group H|High dose RSV-F Vaccine without Adjuvant (Day 0); Placebo (Day 28)
3285418|NCT01704365|Experimental|Group J|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing] (Day 0 & Day 28)
3285419|NCT01704365|Placebo Comparator|Group K|Placebo (Day 0 and Day 28)
3285420|NCT01704378|Experimental|BIAsp|
3285421|NCT01704391||Aortic aneurysm patients|10 patients with a CT verified diagnosis of aortic aneurysm demanding open elective surgical correction with insertion of vascular prosthesis
3285422|NCT01704391||Aortic occlusive disease patients|10 patients with CT verified aortic occlusive disease demanding open elective surgical correction with insertion of vascular prosthesis
3285423|NCT01704417|Experimental|IDeg followed by IGlar|
3285424|NCT01704417|Experimental|IGlar followed by IDeg|
3285425|NCT01704430|Experimental|Glutamine|Oral/enteral glutamine 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
3285426|NCT01704430|Placebo Comparator|Maltodextrin|Oral/enteral maltodextrin 0.5 g/kg satisfactory body weight per day (divided doses every 8 hours) starting 6 hours post-operatively
3285427|NCT01704443|Experimental|Immediate treatment|Women in the Immediate treatment arm will receive the Group Psychoeducational treatment in the next available group. There will be 8-9 womenper group and each session will be 2.25 hours in duration and there will be 4, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
3285428|NCT01704443|Experimental|Waitlist Control- delayed treatment|Women in the Waitlist Control arm will receive no treatment for a period of approximately 8 weeks. After the waitlist period they will receive the same Group Psychoeducational treatment as the participants in the immediate treatment arm of the study.
3285429|NCT01704469|Experimental|The local anesthetic injection group|
3285430|NCT01704482|Experimental|N-acetylcysteine|N-acetylcysteine bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
3285431|NCT01704482|Placebo Comparator|Glucose 5%|equivalent volume over the same period.
3285432|NCT01704508|Active Comparator|Artemether-lumefantrine|6-dose regime will be used:
3285433|NCT01704508|Active Comparator|Dihydroartemisinin-piperaquine|A 3 dose regime will be used
3285434|NCT01704534|Experimental|Ustekinumab|Ustekinumab 45 mg or 90 mg (dependent on patient's weight) administered on weeks 0-4-16-28
3285435|NCT01704560|Experimental|Coversheet to Informed Consent|Coversheet attached to Informed Consent.
3285436|NCT01704560|No Intervention|No Coversheet|Standard, full permission form, without the coversheet.
3285437|NCT01704573||NMR by abstinence status|"This study uses a mixed design with one between-subject factor (NMR: continuous variable) and one within-subject factor (session: 24 hours abstinent vs. smoking as usual) to examine NMR by abstinence status interactions on α4β2* nAChR availability using 2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine (2-[18F]FA) PET imaging.~Subjects will participate in two one-hour PET sessions: a) after smoking as usual (smoking exposure standardized) and b) the other following 24 hours of smoking abstinence.~All participants who complete both PET scans will also complete an anatomical MRI scan."
3285438|NCT01704586|Active Comparator|Radioiodine|Standard procedures using only I-131. All patients in this arm will have assigned I-131 ablation, followed by periodic I-131 diagnostic re-evaluations after 4-6 months as needed.
3285439|NCT01704586|Active Comparator|I-124|I-124 PET/CT guided concept following ATA guideline recommendations after total thyroidectomy. Uptake outside of thyroid bed constitutes I-131 therapy for remnant ablation and metastasis therapy based on I-124 dosimetry. Remnant mass and/or metastasis mass will be estimated by a diagnostic CT scan simultaneously while doing PET at the optimum time point 2-3 days after administration of I-124. If there is no uptake outside of thyroid bed, no ablation will follow in stage I disease according to AJCC with the possibility of lymph node involvement but no distant metastasis and no microscopical residual disease (Patient age <45y: any T, any N, M0; Patient age 45y or older: T1, N0, M0). Periodic follow-up may include I-124 PET/CT when indicated to determine whether or not another I-131 therapy has to follow. Thyroglobuline increase also constitutes I-124 PET/CT imaging.
3285440|NCT01704612|Active Comparator|Diabete group|Patient with type 2 diabete received 20 mL ropivacaine
3285441|NCT01704612|Sham Comparator|Control group|no diabete reveived 20 mL ropivacaine
3285442|NCT01704625|Experimental|Osteopathic Manipulative Treatment|The osteopathic treatment group will have performed on them 3 standardized osteopathic manipulative treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT
3285443|NCT01704625|Sham Comparator|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments. If at any time the patient is unable to tolerate a treatment secondary to pain that particular study will be stopped. If the patient's nurse enters the room with medication, the study will be stopped and patient will not be included in the study. At no time will the patient's medical treatment in the emergency department be delayed to perform OMT.
3285444|NCT01704638|Experimental|2677TT|Plasma kinetics of fluvoxamine and digoxin in this genotype
3285445|NCT01704638|Other|2677GG|plasma kinetics of fluvoxamine and digoxin in this genotype
3285446|NCT01704664|Active Comparator|I - Nutritional therapy only during the postoperative period.|Postoperative nutritional therapy administered in group I will not include immunomodulating factors. Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb), starts 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
3285447|NCT01704664|Active Comparator|II - parenteral glutamine in postoperative time|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
3285448|NCT01704664|Active Comparator|III - perioperative oral immunonutrition|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they will be administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will be increased gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
3285449|NCT01704664|Active Comparator|IV - Perioperative parenteral immunonutrition|Nutritional therapy of group IV will be based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids will be administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will be started at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition will be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
3285450|NCT01704677|Experimental|Surgery|Replacement of the degenerative intervertebral lumbar disc with an artificial lumbar disc device (degeneration had to be restricted to the two lower levels (L4/L5 and/or L5/S1))
3285451|NCT01704677|Active Comparator|Multidiciplinary rehabilitation|
3285452|NCT01704690|Experimental|S-1 and Paclitaxel|Patients in these arm will receive combination treatment of S-1 and paclitaxel. S-1, 80-120mg po, bid, from day 1 to day 14 Paclitaxel, 175mg/m2, IV infusion on day 1 Repeated every 21 days
3285453|NCT01704690|Active Comparator|Paclitaxel and Cisplatin|"Patients in these arm will receive combination treatment of paclitaxel and cisplatin.~Paclitaxel, 175mg/m2, IV infusion on day 1 Cisplatin, 30 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days"
3285454|NCT01704690|Active Comparator|5-FU and Cisplatin|Patients in these arm will receive combination treatment of 5-FU and cisplatin. 5-FU, 2500mg/m2, continue iv infusion for 120 hours Cisplatin, 35 mg/m2, IV infusion on day 1 and day 2 Repeated every 21 days
3285455|NCT01704703|Experimental|Experimental|FOLFIRI + panitumumab
3285456|NCT01704716|Experimental|R0: COJEC plus G-CSF|Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.
3285457|NCT01704716|Active Comparator|R0: COJEC|Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF
3285458|NCT01704716|Active Comparator|R1: BuMel MAT|"The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.~In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)"
3285459|NCT01704716|Experimental|R1: CEM MAT|The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course
3285460|NCT01704716|Active Comparator|R2: ch14.18/CHO|ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses
3285461|NCT01704716|Experimental|R2: ch14.18/CHO plus Aldesleukin|Patients randomised to receive ch14.18/CHO plus Aldesleukin
3285462|NCT01704716|Active Comparator|R3: COJEC Induction|"Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:~Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide"
3285463|NCT01704716|Experimental|R3: Modified N7|The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).
3285464|NCT01704716|Active Comparator|R4: cnt inf ch14.18/CHO|ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO
3285465|NCT01704716|Experimental|R4: cnt inf ch14.18/CHO plus Aldesleukin|"ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.~In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion"
3285466|NCT01704729|Other|group2|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
3285467|NCT01704729|Other|group3|"Cycloplegic subjective refraction by a vision technician trained in the Zhongshan Ophthalmic Center's Rural Refractionist Program"
3285468|NCT01704729|Other|group4|Cycloplegic subjective refraction by an experienced optometrist or ophthalmologist
3285469|NCT01704729|Other|group1|Non-cycloplegic self-refraction using First Generation, Child-Specific fluid-filled adjustable spectacles and updated self-refraction protocol
3285470|NCT01704742||No treatment|
3285471|NCT01704768|Experimental|COPE/Healthy Lifestyles TEEN Program|COPE is a manualized 15-session educational and cognitive-behavioral skills building program guided by Cognitive Behavioral Theory with physical activity as a component of each session.
3285472|NCT01704768|Placebo Comparator|Healthy Teens Attention Control Program|Healthy Teens is an attention control program that controls for the time spent with the adolescents in the COPE group is essential to determining the efficacy of the experimental program.
3285473|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (500mg)|Folic acid 5mg given twice daily. Paludrine 50mg to 20mg daily. Jobelyn 500mg once daily.
3285474|NCT01704794|Active Comparator|Folic Acid + Paludrine +Jobelyn (250mg.)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 250mg daily
3285475|NCT01704794|Active Comparator|Folic Acid + Paludrine + Jobelyn (2mg)|Folic Acid 5mg daily Paludrine 20 - 40mg daily Jobelyn 2mg daily
3285476|NCT01704807|Active Comparator|Intervention, Custom Orthotics|Wearing custom foot orthotics
3285477|NCT01704807|Sham Comparator|Sham Foot Orthotic|Wearing sham or flat shoe insoles
3285478|NCT01704820|Experimental|Retroflexion arm|Retroflexion arm: retroflexion in the cecum or proximal ascending colon and slow withdrawal to the hepatic flexure with removal of all visible colon polyps
3285479|NCT01704820|Placebo Comparator|Forward view arm|Colonoscope is slowly withdrawn from the proximal colon to the hepatic flexure and all visible colon polyps are removed.
3285480|NCT01704833|Experimental|Cognitive Behavioral Therapy|This group receives 15 weeks of Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) in addition to standard care.
3285481|NCT01704833|No Intervention|Treatment as Usual|This group receives standard care only.
3285482|NCT01704859|Placebo Comparator|Vitamin D placebo + fish oil placebo|
3285483|NCT01704859|Active Comparator|Vitamin D placebo + fish oil|
3285484|NCT01704859|Active Comparator|Vitamin D + fish oil placebo|
3285485|NCT01704859|Active Comparator|Vitamin D + fish oil|
3285486|NCT01704872|Experimental|dose level finding ch14.18/CHO|A dose escalation design based on Phase I rules starting at 10 mg/m2/day ch14.18/CHO. This is 50% below the dose of ch14.18/SP2/0 used in a large cohort of patients. Dose escalation will be adapted to a modified Fibonacci series aiming at 10, 20 and 30 mg/m2 of ch14.18/CHO. Since this study is a bridging study aiming at a reassessment of the toxicity and determination of the pharmacokinetics of ch14.18/CHO, only a limited number of dose escalation steps (3) is implemented in the design.
3285487|NCT01704885|Sham Comparator|Active Control Group|Children in the active control group will play with puzzles, a building toy, or color. The play facilitator will praise the child and interact at a similar rate to control for interaction with a caring adult.
3285488|NCT01704885|Experimental|Play Intervention|"children in the play intervention group will be given 3 story stems that they are asked to play out with the goal of helping the main character feel better (see session scripts). The play facilitator will play with the child, modeling and praising use of positive coping skills. In the first session the play facilitator will focus on positive self-statements, in the second session the play facilitator will focus on problem-solving, and a combination of these two approaches will be used in the final session. The child will be allowed to make up a story about whatever they want before ending each session."
3285489|NCT01704898|Other|Efavirenz 600 Test-Stocrin 600 Reference|Efavirenz 600 mg will be randomly assigned.
3285490|NCT01704898|Other|Stocrin 600 Reference-Efavirenz 600 Test|Stocrin 600 mg will be randomly assigned.
3285491|NCT01704911|Experimental|Transradial Coronary Intervention|Transradial Coronary Intervention
3285492|NCT01704911|Experimental|Transfemoral Coronary Intervention|Transfemoral Coronary Intervention
3285493|NCT01704924|Active Comparator|Prevena|Incision with prevena device overlying
3285494|NCT01704924|Active Comparator|Standard of Care dressing|Prevena device is not used
3285495|NCT01704937|Experimental|Colonoscopy|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via colonoscopy"
3285496|NCT01704937|Experimental|Nasogastric Tube (NGT)|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via NGT"
3285497|NCT01704963|Experimental|PCI-32765|Patients will receive oral doses of PCI-32765 in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be given before administration of daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
3285498|NCT01704989|Active Comparator|Laser pathway|Arm in which patients first randomised to receive SLT laser
3285499|NCT01704989|Active Comparator|Topical therapy|Arm in which patients first selected to receive drops (Prostagladin analogue as first-line)
3285500|NCT01705002|Experimental|Cohort A: Promitil 0.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285501|NCT01705002|Experimental|Cohort B: Promitil 1.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285502|NCT01705002|Experimental|Cohort C: Promitil 1.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285503|NCT01705002|Experimental|Cohort D: Promitil 2.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285504|NCT01705002|Experimental|Cohort E: Promitil 2.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285505|NCT01705002|Experimental|Cohort F: Promitil 3.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285506|NCT01705002|Experimental|Cohort G: Promitil 3.5 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285507|NCT01705002|Experimental|Cohort H: Promitil 4.0 mg/kg|Three treatment cycles, intravenous infusion of Promitil
3285508|NCT01705002|Experimental|Expanded Cohort|"Patients treated with the selected RP2D of PROMITIL (3 mg/kg) intravenously administered on their first cycle and reduced dose of 2 mg/kg from cycle 2 and onwards.~Only for mCRC patients."
3285509|NCT01705002|Experimental|Combination Cohort|"Patients treated with one cycle of 2.5mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21 followed by two cycles of 2.0 mg/kg Promitil day 1 together with Capecitabine 1,000 mg bid po days 1-21, at four-week intervals.~Only for mCRC patients."
3285510|NCT01705002|Experimental|Triple combination Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 5 mg/kg Bevacizumab i.v on day 1 together with Capecitabine 1,000 mg bid p.o days 1-14 at four-week intervals.~Only for mCRC patients."
3285511|NCT01705002|Experimental|3 Weekly Cohort|"Patients treated with one cycle of 2mg/kg Promitil I.v and 7.5 mg/kg Bevacizumab i.v on day 1 together at three-week intervals.~Only for mCRC patients."
3285512|NCT01705015|Experimental|UCFit plus direct feedback about exercise|Subjects assigned to higher feedback will be encouraged to look at the summary of daily data about pedaling and will be encouraged to progress activity - more repetitions per minute (RPM range from 10-60), more frequent sessions (up to 3 times daily), longer sessions (from 5-20 minutes), and exertion against larger forces (no resistance, mild, moderate) for the legs. These subjects will also be encouraged to carry out pedaling with the upper extremities once a day, if the arms are free of lines that could be damaged. Progression of leg exercises would be within the capability and motivation of each subject, but would not exceed increments of 10% from one day to the next in any one of these parameters. Graphical displays that can be used for feedback will be available at the patient's bedside. The staff, patient and family will be able to view these bar graphs.
3285513|NCT01705015|Placebo Comparator|UCFit plus encouraged exercise|These subjects will receive a graph of the total number of minutes cycled each day and the average RPMs. The coordinator will only encourage these subjects to try to increase their total cycling time. These bar graphs will not be posted, but will be left by the bedside.
3285514|NCT01705041|Experimental|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
3285515|NCT01705054||Outpatient Coronary Artery Disease Patient|CAD patients being seen in a participating cardiology office for a scheduled clinic visit who agree to take the survey.
3285516|NCT01705093|Experimental|Flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
3285517|NCT01705093|Placebo Comparator|macronutrient- matched control powder|50g macronutrient-matched control powder that will lack strawberry flavonoids
3285518|NCT01705119|Experimental|Mechanically Ventilated|
3285519|NCT01705158|Experimental|carboplatin and liposomal doxorubicin|carboplatin and liposomal doxorubicin in ovarian cancer in realapse
3285520|NCT01705171||IBS patients with fructose intolerance|analysis of biopsies
3285521|NCT01705171||Control group: no IBS or fructose intolerance|analysis of biopsies
3285522|NCT01705184|Experimental|BUCiL|"Sequence 1 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab if disease control. If progression --> Sequence 2~Sequence 2 : 3 cycles of cisplatin-pemetrexed-bevacizumab, then maintenance by bevacizumab-pemetrexed if disease control"
3378463|NCT02432898||Normal Healthy Eyes|Normal healthy eyes with no known ocular diseases
3285523|NCT01705197|Active Comparator|Avanfil 100 or 200mg|All subjects, who are judged to be suitable to the clinical trial after 4-week free run-in period was completed, should be administered with Avanafil 100mg(study group) or placebo 100mg(control group) for the first 4 weeks after randomization. When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed. For subjects with a sufficient improvement effect on ED at 100mg, no dosage increase is allowed, and the previous 100mg administration should be maintained until the termination of the study.
3285524|NCT01705197|Placebo Comparator|Placebo 100mg or 200mg|When there are no moderate to severe adverse events at the 4 weeks evaluation after administration, and when it is decided by the researcher that the effect of Avanafil or placebo 100mg against erectile dysfunction is insufficient, a dosage increase to 200mg is executed.
3285525|NCT01705210||Diabetes mellitus type 2 (DM2)|
3285526|NCT01705210||metabolic syndrome (MetS)|
3285527|NCT01705210||healthy controls|
3285528|NCT01705223|Experimental|group A|DNA vaccine prime at week 0,4,8 and rTV boost at week 16
3285529|NCT01705223|Experimental|group B|DNA vaccine prime at week 0,4,8 and rTV boost at week 24
3285530|NCT01705223|Experimental|group C|DNA vaccine prime at week 0,4,8 and rTV boost at week 32
3285531|NCT01705223|Experimental|group D|DNA vaccine prime with the addition of electroporation at week 0, 4, 8 and rTV boost at week 24
3285532|NCT01705249|Experimental|estradiol / norethisterone acetate|
3285533|NCT01705262||u-65 M|Male patients under 65
3285534|NCT01705262||u-65 K|Female patients under 65 years old
3285535|NCT01705262||o-65 -K|Female patients over 65 years
3285536|NCT01705262||O-65 M|Male patients over 65 years
3285537|NCT01705275|Experimental|ONO-8539 BID|ONO-8539
3285538|NCT01705275|Placebo Comparator|Placebo BID|0mg
3285539|NCT01705301||Deep Brain Stimulation|Patient's undergoing the clinical procedure of Deep Brain Stimulation will have the experimental protocol that involves, after implantation of the DBS electrodes, a single electrochemical recording electrode, from the WINCS system, implanted along the same trajectory path as the electrophysiology and the DBS electrode
3285540|NCT01705314|Experimental|vitamin D supplements|children and adolescents that are randomized to the intervention will receive 7 mls of D-drops (14,000U/week of vitamin D) for eight months
3285541|NCT01705314|Placebo Comparator|vitamin D placebo|children and adolescents that are randomized to placebo will receive 7 mls of placebo drops for eight months
3285542|NCT01705327||Parkinson's Disease Subjects|
3285543|NCT01705327||Healthy Control Subjects|
3285544|NCT01705340|Experimental|Treatment (MK2206, lapatinib ditosylate, trastuzumab)|Patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15; lapatinib ditosylate PO QD on days 1-21 or on days 1-3, 8-10, and 15-17; and trastuzumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3285545|NCT01705366||Knee Arthroplasty|"Patients undergoing total knee arthroplasty. This may be Non-MAKO® Robot Assisted Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty or MAKO® Robot Assisted Medial and PF Knee Arthroplasty~The Non-MAKO® Robot Assisted Total Knee Arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System. The MAKO® Robot Assisted Arthroplasty uses the RESTORIS Multicompartmental Knee System ."
3285546|NCT01705379||MenACWY-CRM|2 years of age and older
3285547|NCT01705392|Experimental|Bevacizumab plus propranolol|Bevacizumab 10mg/kg q2w plus propranolol 80 mg x 1
3285548|NCT01705392|Experimental|Bevacizumab plus enalapril|Bevacizumab 10mg/kg q2w plus enalapril 5 mg x 1
3285549|NCT01705392|Active Comparator|Dacarbazine|Dacarbazine 1000mg/m2 q3w
3285550|NCT01705405|Experimental|medical device|medical device to acquire ultrasound and endoscopic images during surgery
3285551|NCT01705431|Experimental|Support for students with EBD|
3285552|NCT01705431|No Intervention|Control|Participants continue with services as usual
3285553|NCT01705444|Other|Foley catheter and The Spanner Insertion|Quality of life questionnaire after using the Foley catheter and the Spanner
3285554|NCT01705457|Active Comparator|with Multiple Sclerosis, vitamin A|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
3285555|NCT01705457|Placebo Comparator|with multiple sclerosis,placebo|Patients with Multiple Sclerosis confirmed Relapsing Remitting Type
3285556|NCT01705470|Experimental|arm1|will receive 60 mg (6 ml) of intra-venous furosemide before administration of the blood transfusion (250-300 ml of packed cells).
3285557|NCT01705470|Experimental|arm2|will receive 6 ml of normal saline (NaCl 0.9%) before administration of the blood transfusion (250-300 ml of packed cells).
3285558|NCT01705483|Experimental|Part 1: ASP9853 with docetaxel|2 docetaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
3285559|NCT01705483|Experimental|Part 2: ASP9853 with paclitaxel|Starting dose for ASP9853 determined as one dose level below maximum tolerated dose (MTD) determined in Part 1, 2 paclitaxel dose levels and starting dose of ASP9853 followed by escalation of ASP9853 with additional dose cohorts
3285560|NCT01705522||IBD patients|patients with ulcerative colitis or crohn's disease, in remission
3285561|NCT01705535|Experimental|Pelvic floor muscle exercises|Individual supervised pelvic floor muscle exercises. Standard information and guidance
3285562|NCT01705535|Active Comparator|Masage of the neck and back|Massage of the neck and back. Standard information and guidance
3285563|NCT01705548|Experimental|Hypofractionated Radiosurgery|"HR (Hypofractionated Radiosurgery) delivered in 5 fractions, with a minimum of 2 and a maximum of 3 fractions being delivered per week, to patients with brain metastases or resection cavity greater than 3 cm and less than 6 cm.~Dose escalation will proceed according to the Escalation with Overdose Control (EWOC) method with a planned total enrollment of 24 patients, in 8 patient cohorts with 3 patients per cohort. A 4 month observation period will occur for each completed cohort prior to dose escalation, with a goal timeline for trial completion of 4 years from first patient enrollment."
3285564|NCT01705600|Experimental|Pain Verbalization Repression Rules|This group will wear a bracelet with a set of rules which will restrict ones verbalization of pain complaints
3285565|NCT01705626||Participants diagnosed with small fiber polyneuropathy|Participants aged between 18 and 85 years, diagnosed with small fiber polyneuropathy of no obvious etiology, without diagnosis of alcoholism and not undergoing chemotherapy for cancer
3285566|NCT01705639|Experimental|Melatonin|melatonin 4mg od for 3 months
3285567|NCT01705665||Aspirated Coronary Thrombi During AMI|
3285568|NCT01705678|Active Comparator|Krill oil|Krill oil will be compared to fish oil as an active comparator
3285569|NCT01705678|Active Comparator|Fish oil|Fish oil 500 mg of DHA/EPA
3285570|NCT01705704||Cohort|
3285571|NCT01705743|Active Comparator|Group 1 Sevoflurane+Nitrous oxide|
3285572|NCT01705743|Active Comparator|Group 2 Sevoflurane|
3285573|NCT01705756|Placebo Comparator|Vehicle|•Patients randomized to placebo will receive syringes identical to active drug (100 mg prefilled syringes for subcutaneous injection) filled with drug vehicle
3285574|NCT01705756|Experimental|Kineret (Anakinra)|Patients randomized to active drug will receive Kineret (Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
3285575|NCT01705769|Experimental|RUTF-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company
3285576|NCT01705769|Experimental|RUTF-Locally produced|Ready to Use Therapeutic Food-Locally produced by the study team at each study site
3285577|NCT01705769|Active Comparator|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
3285578|NCT01705782|No Intervention|Saline|Only saline is given.
3285579|NCT01705782|Placebo Comparator|+ Saline|Endotoxin is given + Placebo (Saline)
3285580|NCT01705782|Active Comparator|+ amino acids|Endotoxin is given + amino acids (intravenously)
3285581|NCT01705795|Active Comparator|Mepolizumab|Mepolizumab 750 mg four times one month apart.
3285582|NCT01705795|Placebo Comparator|Placebo|Placebo (saline) four times one month apart
3285583|NCT01705808|Experimental|Protein C concentrate|
3285584|NCT01705808|Placebo Comparator|Placebo|
3285585|NCT01705821||Skull Base Surgery Candidate|Patient with a skull base lesion will undergo use of standard surgical curette with force sensor built into shaft. 6-axis force and torque data will be collected during the surgical procedure.
3285586|NCT01705834||Arthritis patients|Patients with Rheumatoid Arthritis
3285587|NCT01705847|Experimental|GS-9820|Participants will be sequentially enrolled at progressively higher dose levels to receive GS-9820 administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
3285588|NCT01705860||Assessment|All subjects will receive same assessments.
3285589|NCT01705873||LPV/r|LPV/r based HAART
3285590|NCT01705873||Efavirenz|EFV first line based HAART
3285591|NCT01705886||Knee Arthroplasty|"Patients undergoing knee replacement surgery. This may be a Total Knee Arthroplasty or MAKO® Robot Assisted Medial Knee Arthroplasty.~The MAKO® Robot Assisted surgeries use the RESTORIS Multicompartmental Knee System.~The total knee arthroplasty uses the Depuy Knee Replacement System or the Stryker® Knee Replacement System."
3285592|NCT01705899|Experimental|Subjects with preserved kidney function|Subjects with preserved renal function that have not previously received a kidney transplant will be treated with Human Pancreatic Islets (in the form of islets alone - IA).
3285593|NCT01705899|Experimental|Subjects with prior kidney transplant|Subjects with renal failure secondary to diabetes who have received a prior kidney transplant at least 6 months previously and have stable renal function on a steroid-free immunosuppressive regimen will receive Human Pancreatic Islets (in the form of islets after kidney - IAK).
3285594|NCT01705912|Experimental|Training|Complete intervention i.e. basic intervention + individual training program.
3285595|NCT01705912|Active Comparator|Control|Basic intervention.
3285596|NCT01705938|Active Comparator|Group 1|SP-333 0.1 mg & Placebo, one tablet by mouth, single dose
3285597|NCT01705938|Active Comparator|Group 2|SP-333 0.3 mg & Placebo, 3 tablets by mouth, single dose
3285598|NCT01705938|Active Comparator|Group 3|SP-333 1 mg & Placebo, one tablet by mouth, single dose
3285599|NCT01705938|Active Comparator|Group 4|SP-333 3 mg & Placebo, 3 tablets by mouth,single dose
3285600|NCT01705938|Active Comparator|Group 5|SP-333 10 mg & Placebo, 1 tablet by mouth, single dose
3285601|NCT01705938|Active Comparator|Group 6|SP-333 30 mg & Placebo, 3 tablets by mouth, single dose
3285602|NCT01705938|Active Comparator|Group 7|SP-333 60 mg & Placebo, 6 tablets by mouth, single dose
3285603|NCT01705951|Experimental|Group 1: Resistance Training/Nicotine Replacement|
3285604|NCT01705951|Experimental|Group 2: Resistance Training only|
3285605|NCT01705951|Experimental|Group 3: Nicotine Replacement Therapy only|
3285606|NCT01705951|No Intervention|Group 4: Control; no RT and no NRT|
3285607|NCT01705990|Experimental|Group A: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
3285608|NCT01705990|Experimental|Group B: SeV-G(NP) followed by Ad35-GRIN|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10^10 vp at Month 4. (Vaccine/Placebo = 12/4)
3285609|NCT01705990|Experimental|Group C: Ad35-GRIN followed by SeV-G(NP)|Ad35-GRIN (IM) at 1x10^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
3285610|NCT01705990|Experimental|Group D: SeV-G(NP) only|SeV-G(NP) (IN) at 2x10^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)
3285611|NCT01706016|Experimental|Patients with breast cancer smaller than 20mm|
3285612|NCT01706042|Placebo Comparator|white bread|White bread (based on 35 g available carbohydrates)
3378464|NCT02431923||EVD Close Contacts|At least one of the following:-Household contact of survivor at time of or since EVD event-Sexual contact with survivor since EVD event-Other selected contacts
3378465|NCT02431923||EVD Survivors|Subject listed on the Ministry of Health registry for Ebola survivors
3378466|NCT02431923||Non Contact Controls|Selected Controls
3378467|NCT02427256||Non-Pathologic Adults age 18-28 yrs|
3378468|NCT02427256||Non-Pathologic Adults age 29-80 yrs|
3378469|NCT02427256||Pathologic Adults age 29-80 yrs|
3285613|NCT01706042|Active Comparator|Legume meal|Legumes are consumed as a late evening meal(based on 35 g available carbohydrates)
3285614|NCT01706055||Group 1|
3285615|NCT01706094|Experimental|lying flat head position|positioning the head of the bed at zero degrees during the first 48 hours from admission of patients with acute ischemic stroke Active Comparator: upright position of the head of the bed during 48 hours from admission of patients with acute ischemic stroke
3285616|NCT01706120|Other|First-line chemotherapy with bevacizumab|"Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks for up to 22 cycles~Paclitaxel 175 mg/m2 on Day 1 every 3 weeks for up to 6 cycles~Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles"
3285617|NCT01706133|No Intervention|Basal phase|Integrated measurement of all variables involved impact and frequency of prior use of health services and specifically to the emergency room, service access, patient characteristics, features for the classification of frailty, cognitive impairment and depression, why consultation, triage scale level on admission to the service and to the service variables in terms of length of stay, diagnosis and medical management, and related services with internal consultants percentage of inpatients discharged or deceased, in further analysis the researchers undertake group estimating frequency of use and the identification of factors associated with the use of emergency departments and adverse events
3285618|NCT01706172|Active Comparator|Dextrose 20 % Injection|Injecting 20 % Dextrose and 0.2 % lidocaine intra-articularly into the TM Joint
3285619|NCT01706172|Active Comparator|Sterile Water Injection|Injection of Sterile water in 0.2 % lidocaine intra-articularly into the TM joint
3285620|NCT01706185||Cancer Group|
3378471|NCT02423031||Caregivers|caregivers of pediatric patients with cancer and other serious illnesses
3378472|NCT02423031||pediatric patients|pediatric patients with cancer and other serious illnesses
3378473|NCT02421341|Experimental|Drug - Fentanyl|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
3378474|NCT02421341|Placebo Comparator|Placebo|Study visit 1 you will be asked to get a blood draw, DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. Study visits 2 and 3 you will be asked to again exercise at maximal exertion while breathing into a mouth piece. During these two visits you will be receiving an intrathecal injection of either fentanyl or placebo, randomly selected and you will be blinded as to which you are receiving. Catheters will also be placed in an artery in your arm and a vein in your leg, helping us to measure blood flow, blood pressure and draw blood. You will also perform a chemosensitivity test, breathing in and out your own air, after you are done exercising.
3378477|NCT02417740||Adult with absence of Portal Hypertension|Confirmed absence of Portal Hypertension will have no findings suggestive of non cirrhotic portal hypertension on liver biopsy and on portal pressure measurements on confirmatory examination.
3378478|NCT02417740||Adult with presence of Portal Hypertension|Confirmed Presence of Noncirrhotic Portal Hypertension, through confirmatory testing, tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5mmHg).
3378479|NCT02417740||Minors likely to have the absence of Portal Hypertension|Minors identified as Confirmed Absence of Noncirrhotic Portal Hypertension will have no abnormal findings on confirmatory examination.
3378480|NCT02417740||Minors likely to have the presence of Portal Hypertension|Minors identified as Confirmed Presence of Noncirrhotic Portal Hypertension, have shown they have the disease with a tissue diagnosis by liver biopsy and/or portal hypertension (HVPG >5).
3378481|NCT02417714||Body CT group|100 subjects for a body CT
3378482|NCT02417714||Chest Ct Group|100 subjects for a chest CT
3378483|NCT02400216||Group A|Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)
3285621|NCT01706211|Experimental|BRL 49653C|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
3378484|NCT02400216||Group B|Patients with minimal fibrosis (Ishak score 0-1).
3378485|NCT02392455||A|
3378486|NCT02392442|Experimental|1 - Endotoxin|6 hour lavage post endotoxin
3378487|NCT02392442|Experimental|2 - Endotoxin|24 hour lavage post endotoxin
3378488|NCT02392442|Experimental|3 - Endotoxin|48 hour lavage post endotoxin
3378489|NCT02392442|Placebo Comparator|4 Placebo comparator|6 hour control lavage
3378491|NCT02379429||1/ Participants|Adults with biopsy-proven or suspected urothelial cancer who require diagnostic or therapeutic intervention
3378492|NCT02379429||2/Healthy Volunteers|Healthy volunteers from whom blood, saliva and urine samples are easily obtainable.
3378493|NCT02376868|Other|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
3378494|NCT02376868|Other|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
3378495|NCT02376868|Other|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
3378496|NCT02342665|Experimental|Copanlisib (BAY80-6946)|Dose escalation/safety evaluation cohort and objective tumor response (OR) expansion cohort
3378497|NCT02340221|Experimental|Taselisib + Fulvestrant|Participants received taselisib 4 milligrams (mg) taken orally QD beginning at Cycle 1, Day 1 and fulvestrant 500 mg by IM injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
3378498|NCT02340221|Placebo Comparator|Placebo + Fulvestrant|Participants received placebo taken orally once daily (QD) beginning at Cycle 1, Day 1, and fulvestrant 500 mg administered by intramuscular (IM) injection at Cycle 1, Days 1 and 15, and then on Day 1 of each subsequent 28-day cycle until disease progression, unacceptable toxicity, or study termination by the Sponsor.
3378499|NCT02339740|Experimental|Treatment (tretinoin, arsenic trioxide, chemotherapy)|See Detailed Description
3378507|NCT02338986||Healthy Volunteers|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases
3378508|NCT02327897||1|Asthamatic
3378509|NCT02327897||2|Non-asthmatic
3378510|NCT02322177||1|Participants are women with inborn errors of metabolism who have been pregnant
3378511|NCT02317328||Affected participants|Participants with ocular conditions
3378512|NCT02317328||Healthy Volunteers|Healthy volunteers
3378513|NCT02315599||1|Patients screening for, participating in, or have participated in a POB gene therapy clinical trial and have received/or be scheduled to receive a genetically engineered cellular therapy.
3378514|NCT02315586||1|Participants will be enrolled at the NIH Clinical Center.
3378515|NCT02315586||2|IPF subjects will be recruited from the INOVA Fairfax Advanced Lung Disease Program
3378517|NCT02304991|Experimental|Peanut (liquid peanut extract) SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
3378518|NCT02304991|Placebo Comparator|Placebo Glycerin SLIT|After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to placebo glycerin SLIT will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
3378519|NCT02293174||Normal Healthy Eyes|Willing and able subjects with normal and healthy eyes
3378520|NCT02290392||1|African Americans age 30-55 years with severe controlled HTN or severe resistant HTN.
3378521|NCT02289313|Experimental|Youth Healthy Living Program|Youth attending the Rochester Alternative Learning Center (ALC) will be enrolled in a youth healthy living program at the ALC.
3378522|NCT02281747||affected with arthritis|arthritis may be either rheumatoid, osteoarthritis, or ankylosing spondylitis
3378523|NCT02281747||unaffected with arthritis|in some analyses, the comparison is by arthritis status. in other analyses, it is within arthritisstatus by clinically relevant subgroups.
3378524|NCT02257892||Patients|Affected patients, with symptoms or genetic mutation
3378525|NCT02257892||Unaffected/healthy relatives|Relatives without symptoms or genetic mutation
3378526|NCT02257866||Healthy Volunteers|Patients without known auto immune diseases
3378527|NCT02257866||Vasculitis|Patients with known or suspected vasculitis age 5 or older
3378528|NCT02231840||Not treatment-seeking participants|Individuals who meet current or past DSM 5 criteria for AUD but are not seeking treatment. Healthy volunteers and other volunteers.
3378529|NCT02231840||Treatment-seeking Patients|Individuals who meet current DSM 5 criteria for AUD and are seeking treatment for it.
3378533|NCT02221778|Experimental|SBRT|SBRT according to the intervention description
3285622|NCT01706211|Placebo Comparator|placebo|Eligible patients may enter the study at visit 1 according to the inclusion/exclusion criteria. At the screening visit, patients will enter a single blind placebo run-in period to establish baseline characteristics. Patients must have been stable on sulphonylurea therapy for at least 2 months prior to the screening visit to be included. For the duration of the run-in period, patients will receive BRL 49653C placebo in addition to their constant dose of sulphonylurea. Patients eligible to enter the double-blind phase of the study will be randomized in equal numbers at visit 2, to one of two treatment groups (BRL 49653C 2 mg bid. or placebo bid). Patients will then continue to take their study medication arid the constant dose of sulphonylurea through visits 3 to 8 (weeks 4 to 24).
3285623|NCT01706224||Group A|Subjects in this group will be all physicians actively working at hospital centres in Spain.
3285624|NCT01706224||Group B|Subjects in this group will be all nurses actively working at hospital centres in Spain.
3285625|NCT01706224||Group C|Subjects in this group will be all ancillary nursing professionals actively working at hospital centres in Spain.
3285626|NCT01706224||Group D|Subjects in this group will be all midwives actively working at hospital centres in Spain.
3285627|NCT01706237|Experimental|Shield|A shield (similar to a contact lens) is placed on the eye after myopic LASIK procedure.
3285628|NCT01706289||diabetic mellitus screen|
3285629|NCT01706302||Cohort Group|
3285630|NCT01706315|Experimental|Cohort 1 - GSK2140944 400 mg|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days
3285631|NCT01706315|Placebo Comparator|Cohort 1 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
3285632|NCT01706315|Experimental|Cohort 2 - GSK2140944 800 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 2 will be decided based on the safety and PK data from six subjects in Cohort 1
3285633|NCT01706315|Placebo Comparator|Cohort 2 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 BID or matching placebo for approximately 15 days
3285634|NCT01706315|Experimental|Cohort 3 - GSK2140944 1500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 3 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 2
3285635|NCT01706315|Placebo Comparator|Cohort 3 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
3285636|NCT01706315|Experimental|Cohort 4 - GSK2140944 2500 mg|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) BID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 4 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 3
3285637|NCT01706315|Placebo Comparator|Cohort 4 - Placebo|Subjects will be randomized in 12:4 ratio to receive either GSK2140944 bid or matching placebo for approximately 15 days
3285638|NCT01706315|Experimental|Cohort 5 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 12 subjects dosed at the Cohort 4
3285639|NCT01706315|Placebo Comparator|Cohort 5 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
3285640|NCT01706315|Experimental|Cohort 6 - GSK2140944 TBD|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 (Day 1: Single oral dose Days 3 to 16: (14 Days) TID oral doses) or placebo for approximately 15 days. GSK2140944 dose in Cohort 5 will be decided on the safety data and available PK data from at least 6 subjects dosed at the Cohort 5
3285641|NCT01706315|Placebo Comparator|Cohort 6 - Placebo|Subjects will be randomized in 6:2 ratio to receive either GSK2140944 TID or matching placebo for approximately 15 days
3285642|NCT01706341|Active Comparator|acetate Ringer's solution|Administering acetate Ringer's solution that contains no glucose as an initial infusion A total infusion volume of acetate Ringer's solution is 1500ml
3285643|NCT01706341|Active Comparator|acetate Ringer's solution with 1% glucose|Administering the acetate Ringer's solution that contains 1% glucose as an initial infusion A total infusion volume of the acetate Ringer's solution containing 1% glucose is 1500ml (containing 15g of glucose)
3285644|NCT01706354|Active Comparator|Local anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
3285645|NCT01706354|Experimental|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
3285646|NCT01706367|Experimental|Low dose C diff vaccine|
3285647|NCT01706367|Experimental|Low dose C diff vaccine + adjuvant|
3285648|NCT01706367|Experimental|Mid dose C diff vaccine|
3285649|NCT01706367|Experimental|Mid dose C diff vaccine + adjuvant|
3285650|NCT01706367|Experimental|High dose C diff vaccine|
3285651|NCT01706367|Experimental|High dose C diff vaccine + adjuvant|
3285652|NCT01706380|Experimental|Interactive voice response with personal feedback|Interactive voice response follows the client twice weekly for 3 months with respect to symptoms and substance use, in both arms. This intervention group also receives a personalized and automated feedback describing whether the symptom status of the patient is better, worse or equal, compared to the preceding follow-up.
3285653|NCT01706380|Active Comparator|Interactive voice response without personal feedback|This control group is also followed with identical interactive voice response follow-up, addressing symptoms and substance use, but without the personal feedback.
3285654|NCT01706393|Experimental|probiotics|"Probiotics supplementation group. Probiotics intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Probiotics is composed of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium lactis, L. rhamnosus, B. longum and B. bifidum."
3285655|NCT01706393|Placebo Comparator|placebo|"Placebo group. Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.~Placebo is composed of starch.Probiotics and placebo were similar in appearance, taste."
3285656|NCT01706406|Experimental|1 treatment|"Women randomized into the treatment group will undergo pre-treatment testing (questionnaires and physiological assessment)within 14 days of beginning treatment"
3285657|NCT01706406|Other|2 waitlist|"Women randomized to the waitlist group will undergo initial testing (questionnaires and physiological testing) and receive no treatment until the next scheduled group (4 months). They will undergo pretreatment testing and treatment on the same schedule as women in the treatment group."
3285658|NCT01706419|No Intervention|no school meal|control group receiving no school meal
3285659|NCT01706419|Placebo Comparator|normal school meal|school meal without fortified rice, placebo group
3285660|NCT01706419|Experimental|cold extruded fortified rice|school meal with fortified rice using cold extrusion kernels
3285661|NCT01706419|Experimental|warm extrusion|school meal with fortified rice using warm extrusion kernels
3285662|NCT01706419|Experimental|hot extruded|school meal with fortified rice using hot extrusion kernels
3285664|NCT01706445|No Intervention|Control|
3285665|NCT01706445|Other|intervention|Exercise training
3285666|NCT01706471|Experimental|Everolimus + Low dose CsA +PD|
3285667|NCT01706471|Active Comparator|Myfortic+ Standard CsA + PD|
3285668|NCT01706484|Experimental|80 mg BNO 1016 und placebo|2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily
3285669|NCT01706484|Experimental|160 mg BNO 1016|2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily
3285670|NCT01706484|Placebo Comparator|placebo|2 tablets (each without BNO 1016) by mouth 3 times daily
3285671|NCT01706510|Experimental|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
3285672|NCT01706510|Active Comparator|Clopidogrel|Clopidogrel 600 mg Loading Dose followed by 75 mg Daily for 7 days ± 2 days
3285673|NCT01706523|Experimental|STX209|Active treatment with STX209
3285674|NCT01706562||Itraconazole|
3285675|NCT01706601||Hemorrhoids|Patient with hemorrhoids
3285676|NCT01706627|Placebo Comparator|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
3285677|NCT01706627|Active Comparator|Drug: 10 mg Melatonin|10 mg melatonin gelatin capsule
3285678|NCT01706627|Active Comparator|Drug: 20 mg Melatonin|20 mg melatonin gelatin capsule
3285679|NCT01706653|Active Comparator|Intervention 1|Polyphenol-enriched fruit-based drink - low
3285680|NCT01706653|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - medium
3285681|NCT01706653|Active Comparator|Intervention 3|Polyphenol-enriched fruit-based drink - high
3285682|NCT01706653|Placebo Comparator|Intervention 4|Very low polyphenol fruit based drink (control)
3285683|NCT01706679|Active Comparator|Maximum therapeutic dose of ATX-101|ATX-101 10 mg/ml
3285684|NCT01706679|Active Comparator|Supratherapeutic dose of ATX-101|ATX-101 20 mg/ml
3285685|NCT01706679|Active Comparator|Moxifloxacin|moxifloxacin (400mg)
3285686|NCT01706679|Placebo Comparator|Placebo vehicle|placebo vehicle (PBS)
3285687|NCT01706692||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
3285688|NCT01706692||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
3285689|NCT01706692||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
3285690|NCT01706692||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
3285691|NCT01706692||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
3285692|NCT01706692||Fumaric acids|Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
3285693|NCT01706692||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
3285694|NCT01706692||Other anti-psoriatic systemic treatments|e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
3285695|NCT01706705|Experimental|Brachytherapy Treatment Planning|"MRI-compatible intracavitary applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.~Computed tomography (CT) scan and a magnetic resonance imaging (MRI) scan performed after the implant is placed in the operating room. The CT scan should take about 20 minutes and the MRI about 45 minutes."
3285696|NCT01706718|Placebo Comparator|Control white bread|
3285697|NCT01706718|Experimental|Beetroot bread|
3285698|NCT01706731|Active Comparator|TAU plus Cognitive-behavioral Therapy|Participants randomized to this group will receive treatment as usual plus cognitive behavioral therapy (CBT) provided by trained Buddhist monks.
3285699|NCT01706731|Sham Comparator|TAU plus routine counselling|Participants randomized into this group will receive treatment as usual (TAU) plus plus routine psychological support from non-CBT monks.
3285700|NCT01706744|Experimental|Intermediate care unit|Follow-up treatment and care in a intermediate care unit after discharge from hospital
3285701|NCT01706744|Active Comparator|Local health care 1|Discharge from hospital to usual care as provided by the local health and social care (Verdal)
3285702|NCT01706744|Active Comparator|Local health care 2|Discharge from hospital to usual care as provided by the local health and social care (Stjørdal)
3285703|NCT01706757|Experimental|with go-cart|conducts exercises with the help of a go-cart
3285704|NCT01706757|No Intervention|without go-cart|conduct exercises without go-cart
3285705|NCT01706783|Experimental|NNC0195-0092 (somapacitan)|
3285706|NCT01706783|Active Comparator|Norditropin NordiFlex®|
3285707|NCT01706796|Experimental|PF-06273340 Oral Solution Fasted|
3285708|NCT01706796|Experimental|PF-06273340 Immediate Release Tablet Fasted|
3285709|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fasted|
3285710|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fasted|
3285711|NCT01706796|Experimental|PF-06273340 Modified Release (MR1) Tablet Fed|
3378545|NCT02192359|Experimental|Treatment (hCE1m6-NSCs and irinotecan hydrochloride)|Patients receive carboxylesterase-expressing allogeneic neural stem cells intracranially over 1.5-4.5 hours on days 1 and 15 (day 1 only for patients at dose level 1) and irinotecan hydrochloride IV over 90 minutes on days 3 and 17. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3285712|NCT01706796|Experimental|PF-06273340 Modified Release (MR2) Tablet Fed|
3285713|NCT01706809||Biomarkeres|
3378546|NCT02190266||Patients|Patients with confirmed refractory and/or disseminated coccidioidomycosis.
3378547|NCT02190253||Organ transplant recipients|Recipients of either liver, kidney, liver and kidney, and small bowel transplants
3285714|NCT01706835|Experimental|Aldoxorubicin|Aldoxorubicin dosages of 230 mg/m2 or 350 mg/m2 will be given as a 30 minute infusion every 3 weeks for 8 cycles.
3285715|NCT01706848|Active Comparator|Celotres|Scar halves randomized to treatment with device, opposite side treated per standard of care.
3285716|NCT01706848|Active Comparator|Standard surgical wound closure|Scar halves randomized to treatment with device, opposite side treated per standard of care.
3378548|NCT02190253||Waitlist patients|Patients on waitlist for liver, kidney or intestinal transplantation
3378549|NCT02185443|Experimental|SBRT|
3378550|NCT02181569||Treatment seeking participants with alcohol dependence|Treatment seeking individuals with alcohol dependence who are admitted into a 28-day inpatient treatment program.
3285717|NCT01706861|Other|Celotres|Celotres following surgical removal of earlobe keloid.
3285718|NCT01706874||Periodontal prophylaxis|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.
3285719|NCT01706874||Control|Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients
3285720|NCT01706887|Experimental|Diet Amiloride|One week Low Na diet (10 mmol/d) followed by ine week high Na diet (200 mmol/d) followed by 2 weeks administration of amiloride (10 mg the 1 st week and the 20mg).
3285721|NCT01706900|Placebo Comparator|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
3285722|NCT01706900|Experimental|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
3285723|NCT01706913|No Intervention|No consult|Those who are in the control group will follow internal medicine hospitalist recommendations alone which will include when and what type of post-discharge follow-up appointments the patient will have. We would like to emphasize that as part of the standard of care, patients in the control arm may still receive a dermatology consult if it is deemed necessary and/or requested. We will not prevent patients or the patient's team of caregivers from requesting a dermatology consultation during the course of hospitalization. A follow-up phone call will be performed two weeks after discharge for patients in the control group in order to confirm the patient's outcome. There will also be a medical record review one month after the patient's initial discharge from the hospital to assess for readmission
3285724|NCT01706913|Active Comparator|Dermatology Consult|The patients randomized to the treatment group will obtain a dermatology evaluation within 24 hours of being admitted to MGH for their cellulitis. The skin and lymph node exam performed by the dermatologist on patients in the treatment group will be documented in the LMR for the subjects' medical records. Patients who are readmitted for cellulitis within one month of being discharged from the hospital will be considered treatment failures. Patients in the treatment group will have a follow-up visit in dermatology clinic within two weeks after being discharged. There will also be a medical record review performed one month after the patient's initial discharge from the hospital to assess for readmission.
3285725|NCT01706939|Experimental|Reduced Dose Radiation|Patients randomized to receive a reduced (5600 cGy) dose radiotherapy with weekly Carboplatin
3285726|NCT01706939|Active Comparator|Standard Dose Radiation|Patients randomized to receive a standard (7000 cGy) dose radiotherapy with carboplatin
3285727|NCT01706991||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3285728|NCT01706991||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3285729|NCT01706991||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3285730|NCT01707017|Active Comparator|High-load strength training|
3285731|NCT01707017|Active Comparator|Low-load strength training|
3285732|NCT01707017|Active Comparator|Low-load + moderate-load strength training|
3285733|NCT01707056|Active Comparator|Black coffee|Synthroid will be administered with 12 ounces of black coffee for a period of 6 weeks.
3285734|NCT01707056|Active Comparator|Coffee with Milk|Synthroid will be administered with 12 ounces of coffee and 2 ounces of 2% milk for a period of 6 weeks.
3285735|NCT01707056|Active Comparator|Black Tea|Synthroid will be administered with 12 ounces of black Lipton tea for a period of 6 weeks.
3285736|NCT01707056|Placebo Comparator|Water|Synthroid will be administered with 12 ounces of water for a period of 6 weeks.
3285737|NCT01707069|Experimental|Group 1: 4mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who are skin test negative to Japanese Red Cedar pollen or Mountain Cedar pollen and have no reactive Cry J 2 antibodies.~Group 1: will receive 4mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered to be the optimal DNA vaccine dose based on historical clinical data from other DNA vaccine studies). The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) of a 4 mg dose at 14 day intervals."
3285738|NCT01707069|Experimental|Group 2: 2mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four half (2 mg) dose dosing regimen.~Group 2: will receive 2 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection(considered ½ of the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive three (3) additional 2 mg doses at 14 day intervals between doses (4 doses in total)."
3285739|NCT01707069|Experimental|Group 3: 4 mg CryJ2-DNA-LAMP plasmid vaccine|"Healthy male and female subjects 18 to 63 years of age, who have lived in Japan, are Skin test positive to Japanese Red Cedar pollen or Mountain Cedar pollen and/or have reactive Cry J 2 antibodies, and have a history of allergic rhinitis symptoms during the Japanese Red Cedar or Mountain Cedar season will receive a total of four full (4 mg) dose dosing regimen.~Group 3: will receive 4 mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection (considered the optimal plasmid vaccine dose based on historical clinical data from studies with other antigens). The dosing regimen for this group will be to receive 3 additional 4 mg doses at 14 day intervals between doses (4 doses in total)."
3285740|NCT01707082|Experimental|Part A Cohort 1|
3285741|NCT01707082|Experimental|Part A Cohort 2|
3285742|NCT01707082|Experimental|Part A Cohort 3|
3285743|NCT01707082|Experimental|Part A Cohort 4|
3285744|NCT01707082|Experimental|Part A Cohort 5|
3285745|NCT01707082|Experimental|Part B Cohort 1|
3285746|NCT01707082|Experimental|Part B Cohort 2|
3285747|NCT01707121||Surgical patients|Patients with planned surgery for breast cancer, colorectal cancer and gall bladder disease
3285748|NCT01707134|Experimental|insulin aspart|
3285749|NCT01707134|Active Comparator|human insulin|
3285750|NCT01707160|Experimental|Treatment period 1|
3285751|NCT01707160|Active Comparator|Treatment period 2|
3285752|NCT01707173|Other|Standard Education|Control group participants will receive standard educational materials published by the CDC or American Academy of Pediatrics as an intervention along with a generic infant safety DVD
3285753|NCT01707173|Experimental|Tailored education|Parents/caregivers will receive educational materials tailored to their specific beliefs and barriers about infant supine sleep along with a DVD detailing standard guidelines along with specific solutions and facilitators to infant supine sleep as the intervention.
3285754|NCT01707186||Group 1A|Early phase, requiring change in treatment
3285755|NCT01707186||Group 2|Established phase, stable treatment
3285756|NCT01707186||Group 2A|Established phase, requiring a change in treatment
3285757|NCT01707186||Group 1|Early phase, stable treatment
3285758|NCT01707199|Experimental|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
3285759|NCT01707212|Experimental|Pain management education|Education about pain management during infant immunization
3285760|NCT01707212|Other|No pain management education|Control - general information about immunization only
3285761|NCT01707251|Experimental|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
3285762|NCT01707251|Placebo Comparator|Saline|IV saline every 6 hours starting preoperatively (5 doses).
3285763|NCT01707264|Experimental|NEOD001|NEOD001 will be administered intravenously once every 28 days. The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for single agent NEOD001. Approximately 20 additional subjects will be treated with the maximum tolerated dose.
3285764|NCT01707277|Experimental|Inspiratory muscle training|Inspiratory muscle training for improving maximum inspiratory pressure plus phrmacological treatment Pharmacological treatment (usual care)
3285765|NCT01707277|Active Comparator|Usual care|Pharmacological treatment
3285766|NCT01707303|Other|Usual Care|Usual hospital rehabilitative services
3285767|NCT01707303|Experimental|Early ICU Rehabilitation Strategy|Early ICU physical therapy will be applied in this arm
3285768|NCT01707316|Experimental|Sequence 1: Treatment A-B-C|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3285769|NCT01707316|Experimental|Sequence 2: Treatment B-C-A|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3285770|NCT01707316|Experimental|Sequence 3: Treatment C-A-B|The study consists of 3 single-dose treatment periods. Each treatment period will be 5 days in duration. Successive treatment periods will be separated by a washout period (with no medication) of 10 days.
3285771|NCT01707329|Active Comparator|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
3285772|NCT01707329|Experimental|Icotinib+Chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
3285773|NCT01707342|Experimental|Simeprevir (TMC435)|Treatment A: single oral dose of simeprevir (TMC435) 50 mg; and Treatment B: single oral dose of simeprevir (TMC435) 150 mg. A single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram will be followed 5 hours later after administration of Treatment A and Treatment B in Period 1 and Period 2, respectively.
3285774|NCT01707355|Active Comparator|invention with poster|intervention - poster
3285775|NCT01707355|No Intervention|control|control - no poster
3285776|NCT01707394|Experimental|Group 1: Apixaban (low dose)|
3285777|NCT01707394|Experimental|Group 2A: Apixaban (low dose)|
3285778|NCT01707394|Experimental|Group 2B: Apixaban (low dose)|
3285779|NCT01707394|Experimental|Group 3: Apixaban (low dose)|
3285780|NCT01707394|Experimental|Group 4: Apixaban (low dose)|
3285781|NCT01707394|Experimental|Group 5: Apixaban (low dose)|
3285782|NCT01707394|Experimental|Group 2A (higher dose): Apixaban (low dose)|
3285783|NCT01707407|Experimental|Pomalidomide|
3285784|NCT01707407|Experimental|Pomalidomide plus Ketoconazole|
3285785|NCT01707407|Experimental|Pomalidomide plus Ketoconazole plus Fluvoxamine|
3285786|NCT01707407|Experimental|Pomalidomide plus Carbamazepine|
3285787|NCT01707433||Diagnosis of hip disease|Diagnosed with spondyloepiphyseal dysplasia or multiple epiphyseal dysplasia or bilateral Legg-Calve-Perthes disease, or bilateral proximal femoral epiphyseal dysplasia
3285788|NCT01707446|Active Comparator|Near-infrared reflectance spectroscopy|Bilateral NIRS (The INVOS® Cerebral/Somatic Oximeter)will be used to measure rSO2 intraoperatively and during the 24h postoperative period in the intensive care unit. In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established.
3285789|NCT01707446|No Intervention|Blinded Near-infrared reflectance spectroscopy|In the control group, the NIRS monitor screen will be electronically blinded, however, the recording will be continuous after verification of the signal strength and baseline value by an independent observer trained in NIRS application and unaware of the study design.
3285790|NCT01707498|Experimental|Tetraplegic patients|Scanning device RoBIK Brain-Computer Interface
3285791|NCT01707498|Experimental|Healthy volunteers|RoBIK Brain-Computer Interface
3285792|NCT01707524|Experimental|Trans-radial approach|Randomized left versus right radial artery approach
3285793|NCT01707524|No Intervention|Trans-femoral approach|Observational
3285794|NCT01707537|Experimental|Euvichol|Euvichol is a homogeneous suspension of inactivated suitable strains of Vibrio cholera serogroup O1 and O139. Euvichol is Yellow to yellowish colour.
3285795|NCT01707550||Cohort|
3285796|NCT01707563|Other|Marfan patients|Study participants were recruited between 11/2009 and 10/2011, among adult patients consulting in the Multidisciplinary Marfan Clinic of our University Hospital, and having a known mutation in the FBN1 gene. There, patients are evaluated by geneticists, rheumatologists, cardiologists, and ophthalmologists. Systematic slit-lamp examination, cardiac ultrasonography, and radiological investigations are also performed. A skin punch biopsy was used to establish a fibroblast cell culture. We determined mRNA levels for FBN1 and compared it to the clinical involvement.
3285797|NCT01707563|Other|control patients|Fibroblasts were obtained from non Marfan patients (cell bank). We determineed mRNA level for FBN1 for each allele.
3285798|NCT01707576|Other|screening of adolescent mental suffering. Management|screening of adolescent mental suffering consultant to emergencies. Management and later monitoring
3285799|NCT01707589|Experimental|Neonates admitted to the NICU|Neonates admitted to the NICU for a variety of medical reasons will be the cohort group. Those whose parents give informed consent will compose the subjects of the study
3285800|NCT01707602|Experimental|Arm A|Type Vaccine Name: INTANZA® 15 T Description : transcutaneous vaccination
3285801|NCT01707602|Active Comparator|Arm B|Type: Vaccine Name: INTANZA® 15ug Description : intradermal vaccination
3285802|NCT01707602|Active Comparator|Arm C|Type : Vaccine Name: Vaxigrip® Description :Intramuscular vaccination
3285803|NCT01707615|Other|control group|In the control group, all patients were enrolled in a lifestyle intervention
3378553|NCT02166463|Active Comparator|Arm I (ABVE-PC)|Patients receive doxorubicin hydrochloride IV over 1-15 minutes on days 1-2, bleomycin sulfate IV over 10 minutes or SC on days 1 and 8, vincristine sulfate IV over 1 minute on days 1 and 8, etoposide IV over 60-120 minutes on days 1-3, prednisone PO BID or methylprednisolone IV on days 1-7, and cyclophosphamide IV over 30-60 minutes on days 1 and 2. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
3378554|NCT02166463|Experimental|ARM II (Bv-AVEPC)|Patients receive brentuximab vedotin IV over 30 minutes on day 1. Patients also receive doxorubicin hydrochloride, etoposide, prednisone or methylprednisolone, and cyclophosphamide as in Arm I and vincristine sulfate IV over 1 minute on day 8. Treatment repeats every 21 days for 5 cycles in the absence of disease progression or unacceptable toxicity.
3285804|NCT01707615|Active Comparator|GSPE group|GSPE 240 mg/day (120mg bid) in addition to the same lifestyle intervention.
3285805|NCT01707628|Active Comparator|Early group after rituximab|"Patients who received rituximab last dose 3-6 months before influenza vaccination will be the early group."
3285806|NCT01707628|Active Comparator|Late group after rituximab|"Patients who received rituximab last dose 9-12 months before influenza vaccination will be the late group."
3378555|NCT02156115||healthy volunteers|healthy volunteers
3378556|NCT02156115||lymphatic patients|lymphatic patients
3378557|NCT02156115||relatives|relatives
3378558|NCT02156102||Microbiome with active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants with active leg ulcers and sickle cell disease.
3378559|NCT02156102||Microbiome with no active Leg Ulcer|We will recruit and obtain microbiome samples from male or female adult participants without active leg ulcers but do have sickle cell disease.
3378560|NCT02156102||Non-microbiome participants|We will recruit but not obtain microbiome samples from participants with sickle cell disease
3285807|NCT01707628|Active Comparator|Control group|Healthy individuals will be receive vaccination with influenza vaccine and will serve as controls.
3285808|NCT01707641|Active Comparator|CD#2|patients will be asked to melt slowly in the mouth 6 lozenges per day, containing Lactobacillus brevis CD2
3378561|NCT02154035||Group 1|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
3378562|NCT02154035||Group 2|HIV-infected patients on ART with suppressed viral loads, defined as <40 copies per ml over a period of 10-18 months.
3378563|NCT02154022||1|Patients with cancer who are currently enrolled in IRB approved NIH Intramural Research Program clinical trial
3378564|NCT02149121|Experimental|CT-P10|rituximab, CT-P10(experimental drug), 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
3285809|NCT01707641|Active Comparator|bicarbonate sodium mouthwash|patients will be asked to wash their mouth with bicarbonate several times per day
3285810|NCT01707680||Dexmedetomidine|Here, patients to be included are those being sedated with dexmedetomidine as primary sedative.
3378565|NCT02149121|Active Comparator|Rituxan|US-licensed referece product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
3378566|NCT02149121|Active Comparator|MabThera|EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusions
3285811|NCT01707680||Propofol|Here, patients to be included are those being sedated with propofol as primary sedative.
3285812|NCT01707680||Midazolam|Here, patients to be included are those being sedated with midazolam as primary sedative
3378567|NCT02147405||ARV naive|Patients that have not started or have ever been on ARV therapy.
3378568|NCT02147405||IRIS|Patients that are on medication but are possibly experiencing an IRIS event.
3378569|NCT02146170||Single group|Patients with histologically or cytologically confirmed NSCLC, SCLC, ESCC, PNET, and TET
3378570|NCT02138279||Male and female adults 18+ years of age|
3378571|NCT02138266||Non-Pathologic Adults age 18-28 yrs|Non-Pathologic Adults age 18-28 yrs
3378572|NCT02138266||Non-Pathologic Adults age 29-80 yrs|Non-Pathologic Adults age 29-80 yrs
3285813|NCT01707706|Experimental|Traditional Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3285814|NCT01707706|Active Comparator|Minimal Acupuncture|"Patients will be treated superficially at points away from classic acupoints. The points include bilateral Forearm [1 inch lateral to the middle point between HE3 and HE7] , Upper arm [1 inch lateral to LU 3 ], and Lower leg [0.5 inch dorsal to GB39]; for head, the non-acupoints include bilateral Head [middle point between GB8 and ST8], Forehead [middle point between ST8 and GB14], Neck [middle point between TB16 and SI17], and Ear [the point on the helix, inferior to the apex]. The points selected have been used in previous acupuncture studies as sham control. De qi is avoided during needling. The treatment procedure, electric-stimulation, frequency, duration and number of treatment sessions will be the same for the Traditional Acupuncture group."
3378573|NCT02138266||Pathologic Adults age 29-80 yrs|Pathologic Adults age 29-80 yrs
3378574|NCT02124057||Healthy female control|Age-matched healthy control women
3378575|NCT02124057||Healthy male control|Age-matched healthy control men
3378576|NCT02124057||Other Motor Neuron Disease Patients|Male participants with other motor neuron disease
3378577|NCT02124057||SBMA Patients|Men with genetically confirmed SBMA
3285815|NCT01707706|Placebo Comparator|Placebo Acupuncture|Placebo needles designed by Streitberger (1998) will be used. The placebo needles are blunt needle that will not penetrate the skin during needle insertion. The handles of these placebo needles will slide over the needle when it is compressed, giving it the appearance of penetrating the skin. The placebo needles are inserted to the site 1 inch beside the acupoints in order to avoid the acupressure effect. The needles are held by a surgical tape or hair pin in hairy region to imitate the retention of needles. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of the treatment sessions, and the intervention procedure will be the same for electro-acupuncture and placebo acupuncture.
3378578|NCT02124057||SMBA|SBMA carrier women
3285816|NCT01707719||Alzheimer's disease|
3285817|NCT01707719||Non demented subjects|
3285818|NCT01707732|Active Comparator|Enoxaparin 40mg/ day|Enoxaparin administrated at the following dose : 40mg/ day
3285819|NCT01707732|Experimental|Enoxaparin 60 mg/day|Enoxaparin administrated at the following dose : 60 mg/day
3378579|NCT02116764||Cross Sectional|3 years after Transplant
3378580|NCT02116764||No Transplant|These patients were diagnosed with CGD but have not been transplanted
3285820|NCT01707745|Other|Avastin|Bevacizumab(Avastin) 0.75mg in 0.03 ml
3285821|NCT01707758||pancreatic cancer|This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
3378581|NCT02116764||Prospective|Prior to Transplant Conditioning
3285822|NCT01707771|Active Comparator|Roux-en-Y gastric bypass|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
3285823|NCT01707771|Active Comparator|diet and lifestyle modifications|Both sexes, age between 30 and 60 years, BMI =/> 35 kg/m2
3285824|NCT01707784||Women with gestational diabetes|Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3285825|NCT01707784||Women without gestational diabetes|Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing
3285826|NCT01707797||Healthy children aged 9-15 months|Healthy children aged 12 months (± 3 months) at baseline stratified by Medicaid status and/or race/ethnicity to ensure a diverse representation. Each child will be paired with the primary caregiver, whom the investigators expect to most likely be the adult parent or legal guardian.
3285827|NCT01707810|Sham Comparator|Conventional method|In the conventional method IVC was clamped during the anhepatic phase and venous return was maintained by a portal femoral axillary venovenous bypass with a centrifugal pump. In these cases, IVC reconstruction was performed by end-to-end anastomosis above and below the liver.
3285828|NCT01707810|Experimental|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
3285829|NCT01707823|Experimental|Prevention (acetylsalicylic acid)|Patients receive acetylsalicylic acid PO for 7 days.
3285830|NCT01707836||Family|Families with a child with Neurofibromatosis Type 1 who has been diagnosed with a brain tumor.
3285831|NCT01707849|Active Comparator|MMF arm|"MMF arm (n=20)~They will receive immunosuppression as stipulated by hospital protocol:~Tacrolimus (levels 8-10ng/mL) and Mycophenalate mofetil 1mg bid(levels 1-3ng/mL)."
3285832|NCT01707849|Experimental|EVL arm|"EVL arm (n=20):~Tacrolimus (levels 8-10ng/ml) + everolimus 1mg bid (levels 2-4 ng/mL)"
3285833|NCT01707875||fetal ventricle brain asymmetry|
3285834|NCT01707888||major lung resection|Patients undergo major lung resection by thoracoscopy/VATS.
3285835|NCT01707901|Experimental|ONO-8539|ONO-8539
3285836|NCT01707901|Placebo Comparator|Placebo|Placebo
3285837|NCT01707914|Experimental|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
3285838|NCT01707914|Placebo Comparator|Placebo|Consume 500 mL placebo/d (250 mL placebo twice daily)
3285839|NCT01707927||Trifecta|Degenerated aortic valve with indication for aortic valve replacement
3285840|NCT01707927||mosaic Ultra|Need a aortic valve replacement
3285841|NCT01707940|Experimental|BI 144807|subjects receive an oral single dose of BI 144807
3285842|NCT01707940|Experimental|BI 144807 plus Ketoconazole|subjects receive bid ketoconazole plus an oral single dose of BI 144807
3285843|NCT01707953|Experimental|Midodrine|Midodrine Hydrochloride (5mg) administered as capsule 5 and 23 hours after end of surgery.
3285844|NCT01707953|Placebo Comparator|Placebo|Placebo administered as capsule 5- and 23 hours after end of surgery.
3285845|NCT01707966|Experimental|Orteronel and best supportive care|Arm A: 300mg Orteronel twice daily and best supportive care until occurrence of an event.
3285846|NCT01707966|Placebo Comparator|Placebo and best supportive care|Arm B: Placebo twice daily and best supportive care until occurrence of an event.
3285847|NCT01707979||Diabetic neuropathy|Male participants, type1 diabetic with diabetic neuropathy
3285848|NCT01707979||Diabetes without neuropathy|Male participants, type1 diabetic without diabetic neuropathy
3285849|NCT01707979||Non diabetic control|Male participants, control group non diabetic
3285850|NCT01708005|Active Comparator|Intervention|80 participants start the oral intake of Lecitone®Se-Vitamin D3 the day after inclusion and during 24 weeks
3285851|NCT01708005|Placebo Comparator|Placebo|"80 participants in this arm start the oral intake of placebo the day after inclusion and during 12 weeks.~Then, they start the oral intake of Lecitone®Se-Vitamin D3 12 weeks after inclusion until the 24th week."
3285852|NCT01708018|No Intervention|Control group|Prior and post intervention period (on days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). Survey concerning birth.
3285853|NCT01708018|Experimental|Intervention group|Prior and post intervention (days 1 and 4) and final control (day 8): ultrasound examination of position of the fetus and amount of amniotic fluid. On these days plus weekly (until birth) questionnaires (QoL: SF-36, EQ-5D-5L, stress: PSS, psychological wellbeing: MDBF, current stress and pain: VAS). After the second intervention(day 4): qualitative questionnaire for intervention-group only. Survey concerning birth.
3285854|NCT01708031|Experimental|stress inducing task|Normal subjects without history medication presently will be participated. Stress induced through stress inducing task (mental arithmetic task), the physiological signals collected before and during the task simultaneously. All the subjects will be participating only once in this MAT based study. Because, the stress will not be possible to induce when the subject is more familiar with the stress inducing task.
3285855|NCT01708044|Experimental|Pramlintide 6 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 6 mcg for each unit of insulin.
3285856|NCT01708044|Experimental|Pramlintide 9 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 9 mcg for each unit of insulin.
3285857|NCT01708044|Experimental|Pramlintide 12 mcg per unit of insulin dose|The pramlintide dose will be calculated based on the subjects' individual insulin units. Dose ratio to be examined is pramlintide 12 mcg for each unit of insulin.
3285858|NCT01708044|Placebo Comparator|Placebo|
3285859|NCT01708070|Active Comparator|Asthma self-management experimental|The intervention will involve a self-management workbook, contracting to improve self-management behaviors, instruction in using of a peak flow meter, and follow-up discussions based on the workbook.
3285860|NCT01708070|Other|Asthma self-management control|The control state will involve a self-management workbook and contracting to improve self-management behaviors.
3285861|NCT01708083||Type 2 Diabetes and BMI>35|Patients with type 2 diabetes and body mass index 35 or more.
3285862|NCT01708083||BMI>35|Patients undergoing surgery, gastric bypass or cholecystectomy, without diabetes type 2 and body mass index 35 or more
3285863|NCT01708083||BMI 18-27|Patients undergoing surgery, cholecystectomy or reflux, without type 2 diabetes and body mass index between 18-27
3285864|NCT01708096|Active Comparator|Modifast|treated with VLD Modifast 1000 kcal/day in 2 weeks before gastric by-pass,
3285865|NCT01708096|Placebo Comparator|Normal diet|normal diet 2 weeks before gastric by-pass surgery
3285866|NCT01708109|Experimental|Biliary calculus remain|biliary calculus, less than or equal to 6 mm, remains
3285867|NCT01708109|Experimental|Biliary calculus removed|biliary calculus, less than or equal to 6 mm, removed
3285868|NCT01708135|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in preparing for bariatric surgery.
3285869|NCT01708148|Active Comparator|Lactobacilli|30 Participants with verum
3285870|NCT01708148|Placebo Comparator|Placebo|30 Participants
3285871|NCT01708200|Experimental|Memory Intervention|Two types of memory protocols (psychoeducational vs computerized) will be compared in a population of individuals with mental illness.
3285872|NCT01708226|Experimental|Attention Modification Program|Attention Modification Program
3285873|NCT01708239||Pregnant women|Pregnant women with suspected DVT assessed by the LEFt rule, D-dimer measurement and complete ultrasonography.
3285874|NCT01708252|Experimental|Ulthera treatment group|All subjects will receive an Ulthera System Treatment
3285875|NCT01708265|Active Comparator|Early mitral valve repair|Early mitral valve repair
3285876|NCT01708265|Active Comparator|Watchful waiting|Watchful waiting
3285877|NCT01708304|Other|RDAD|Exercise training for caregiver and care recipient. Behavior modification training for caregiver.
3285878|NCT01708330|Placebo Comparator|Placebo gel|Placebo gel applied topically to the cervix
3285879|NCT01708330|Experimental|Lidocaine gel|2% lidocaine gel applied topically to the cervix
3285880|NCT01708343|Sham Comparator|Placebo-sham|Placebo-sham twice a week during four weeks
3285881|NCT01708343|Active Comparator|Lidocaine injection|Lidocaine 0.2-0.5 mL of 1% injected each time into the trigger point. Twice a week during four weeks
3285882|NCT01708343|Experimental|DIMMST|"DIMMST include the combination of trigger point deep dry needling (TrP-DDN) is combined with paraspinal deep intramuscular stimulation (PDIMS) and needle rotation (NR).~Twice a week during four weeks"
3285883|NCT01708356|Experimental|Normal cycling|Cycling on a residential and downtown route (crossover design)
3285884|NCT01708369|Active Comparator|Oseltamivir & Placebo|Oseltamivir 150 mg orally will be administered 15 minutes after subjects consume orange juice
3285885|NCT01708369|Experimental|Oseltamivir & Ethanol|Oseltamivir 150 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
3285886|NCT01708369|Active Comparator|Aspirin & Placebo|Aspirin 650 mg orally will be administered 15 minutes after subjects consume orange juice
3285887|NCT01708369|Experimental|Aspirin & Ethanol|Aspirin 650 mg and ethanol targeted to blood alcohol concentration 0.08 g/dl
3285888|NCT01708382|Experimental|Ultherapy treatment on the elbows|All enrolled subjects will receive one Ultherapy treatment to the elbows.
3285889|NCT01708395||Cohort 1|First 50 patients
3285890|NCT01708395||Cohort 2|2nd group of 50 patients
3285891|NCT01708408||community|
3285892|NCT01708434|Experimental|Ulthera® treatment of the knees|Bilateral treatment of the knees using the Ulthera® System
3285893|NCT01708447|Active Comparator|Topical anesthetic - L.M.X.4.® cream|Topical anesthetic cream, L.M.X.4.® cream, applied to one side of the face and neck prior to Ulthera System treatment.
3285894|NCT01708447|Placebo Comparator|Placebo cream|A placebo cream with similar consistency and color will be applied to the other side of the face and neck prior to Ulthera System treatment.
3285895|NCT01708460|Experimental|Ulthera-treated subjects|All enrolled subjects will receive one Ultherapy treatment to one side of the body in the lateral buttock region. Following study completion, subjects may elect to receive a balancing treatment to the other side of the body.
3285896|NCT01708473|Active Comparator|Advil with Ultherapy|Subjects randomized to this study arm will receive Advil prior to an Ulthera System Treatment.
3285897|NCT01708473|Active Comparator|Lortab with Ultherapy|Subjects randomized to this study arm will receive Lortab prior to an Ulthera System Treatment.
3285898|NCT01708486||Adolescents' with asthma using inhalation devices|Asthmatic adolescents will record their opinion for their inhalation devices by replying to FSI-10 questionnaire
3285899|NCT01708499|Experimental|Study treatment|All enrolled subjects will receive one Ulthera System Treatment.
3285900|NCT01708512|Experimental|Ultherapy™ study treatment|Each subject will receive a customized, high-density, vectored Ulthera System Treatment.
3285901|NCT01708538|Active Comparator|Epithelium on|Epi not removed during CXL treatment
3285902|NCT01708538|Active Comparator|Epithelium off|Epi removed before CXL treatment
3285903|NCT01708551|Active Comparator|Group A|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
3285904|NCT01708551|Active Comparator|Group B|Subjects who were non-responders to a prior Ultherapy™ treatment for hyperhidrosis will receive bilateral Ulthera System treatments; dual depth treatment at 4.5mm and 3.0mm.
3285905|NCT01708551|Active Comparator|Group C|Subjects will receive one double-density Ulthera System treatment; dual depth treatment at 4.5mm and 3.0mm.
3285906|NCT01708551|Active Comparator|Group D|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and standard energy level.
3285907|NCT01708551|Active Comparator|Group E|Subjects naïve to Ultherapy™ for treatment of hyperhidrosis will receive bilateral Ulthera System treatments at 2.0mm treatment depth and adjusted energy level.
3285908|NCT01708564|Experimental|Cohort 1|10 patients administered a single low dose of rhFVIIa
3285909|NCT01708564|Experimental|Cohort 2|10 patients administered a single intermediate dose of rhFVIIa
3285910|NCT01708564|Experimental|Cohort 3|10 patients administered a single high dose of rhFVIIa
3285911|NCT01708577|Experimental|IPANEMA validation without water intake|The one group is restricted to the water intake during the Indoor phase during testing the IPANEMA measurement system. The other group is not restricted to the water intake.
3285912|NCT01708577|Experimental|IPANEMA validation with water intake|The one group is restricted to the water intake during the Indoor phase, the other group is not restricted to the water intake.
3285913|NCT01708616|Placebo Comparator|Placebo + risperidone|
3285914|NCT01708616|Placebo Comparator|Placebo +placebo|
3285915|NCT01708616|Active Comparator|RO5285119 + placebo|
3285916|NCT01708616|Experimental|RO5285119 + risperidone|
3285917|NCT01708642|Experimental|Adrenaline|Intraoperative low-dose adrenaline infusion
3285918|NCT01708642|Placebo Comparator|Placebo|Placebo: Isotonic Saline
3285919|NCT01708655|Other|Sweat Evaporimeter measurement|"0.1 ml Carbachol, intraocular solution - diluted to 0.1 µg/ml in normal saline- dose 0.01 µg~0.2 ml Atropine sulphate, injection solution - diluted to 44 µg/ml in normal saline - dose 8.8 µg.~0.2 ml of the Beta cocktail injection solution diluted to 44 µg/ml atropine, 22 µg/ml isoproterenol and 4.6 mg/ml aminophylline in normal saline - dose:~4.4 µg Isoproterenol hydrochloride, injection solution~0.93 mg Aminophylline injection solution~8.8 µg Atropine, injection solution"
3285920|NCT01708668|Active Comparator|1|Epidural analgesia (EA) with continuous epidural infusion(CEI)
3285921|NCT01708668|Active Comparator|2|Combined spinal-epidural analgesia (CSEA) with continuous epidural infusion(CEI)
3285922|NCT01708668|Active Comparator|3|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
3285923|NCT01708668|Active Comparator|4|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
3285924|NCT01708668|Active Comparator|5|Epidural analgesia (EA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
3285925|NCT01708668|Active Comparator|6|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 2.5 mL bolused every 15 minutes)
3285926|NCT01708668|Active Comparator|7|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 5ml bolused every 30 minutes)
3285927|NCT01708668|Active Comparator|8|Combined spinal-epidural analgesia (CSEA) with intermittent epidural bolus (IEB, 10ml bolused every 60 minutes)
3285928|NCT01708681|Experimental|Lean seafood|Cross-over design, half of the subject will receive lean seafood in study period I and the other half in study period II
3285929|NCT01708681|Active Comparator|Meat, egg, milk|Cross-over design, half of the subject will receive meat, egg, milk in study period I and the other half in study period II
3285930|NCT01708694|Placebo Comparator|Placebo Starch|Yogurt with about 45 g/day of placebo starch (amylopectin).
3285931|NCT01708694|Experimental|Experimental Starch|Yogurt with about 45 g/day of slowly digestible starch (amylose).
3285932|NCT01708707|Active Comparator|Oral morphine sulfate|Oral morphine sulfate 0.4 mg/kg/day morphine every 3-4 hours as needed for Finnegan scores suggestive of Neonatal Abstinence Syndrome Other Name: morphine
3285933|NCT01708707|Experimental|Buprenorphine|Sublingual Buprenorphine 15.9 µg/kg per day in 3 divided doses, titrated up or escalated down based upon standardized scoring for neonatal abstinence syndrome
3285934|NCT01708720|Experimental|Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, and 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose
3285935|NCT01708720|Experimental|Adjuvanted Sabin-IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, and 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose, adjuvanted with 0.5 mg aluminium hydroxide
3285936|NCT01708720|Active Comparator|IPV|Single intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose
3285937|NCT01708733|Placebo Comparator|KSY diluted|KSY diluted, 100mg decoction by mouth per day for 6 weeks
3285938|NCT01708733|Experimental|KSY|KSY, 100mg decoction by mouth per day for 6 weeks
3285939|NCT01708746||Enrolled subjects|
3285940|NCT01708746||Historic control|
3285941|NCT01708759||Sepsis|Forty patients developed septic complication during ICU stay (sepsis group).
3285942|NCT01708759||SIRS|Forty patients were critically ill without evidence of infectious organism (SIRS group).
3285943|NCT01708772||Sepsis|Forty five patients developed septic complication during ICU stay (sepsis group).
3285944|NCT01708772||SIRS group|Forty five patients were critically ill without evidence of infectious organism (SIRS group).
3285945|NCT01708785|Active Comparator|Single context|Subjects will be exposed to food cues in a single context.
3378582|NCT02116764||Retrospective|1 year after Transplant
3378585|NCT02108041||Physicians that interact with the black/High SES avatar patien|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income and Black/African American.
3378586|NCT02108041||Physicians that interact with the black/Low SES avatar patient|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low-Middle Income and Black/African American.
3378587|NCT02108041||Physicians that interact with the white race/high SES avatar|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is Upper-Middle Income White andCaucasian.
3378588|NCT02108041||Physicians that interact with the white race/low SES avatar p|Medical residents will then be randomized to be exposed to a virtual patient with one of 4 race/SES profiles, this one being a female patient who is low Income White and Caucasian.
3285946|NCT01708785|Experimental|Multiple contexts|Subjects will be exposed to food cues in multiple contexts.
3285947|NCT01708785|Active Comparator|8 treatment sessions|Subjects receive 8 treatment sessions.
3285948|NCT01708785|Experimental|16 treatment sessions|Subjects receive 16 treatment sessions
3378597|NCT02077894||Participants with retinal disease|Participants with retinal disease
3378598|NCT02077894||Unaffected family members|Members of the participant's family that do not have eye disease
3378599|NCT02066181|Experimental|Arm I (sorafenib tosylate)|Patients receive sorafenib tosylate PO QD on days 1-28.
3378600|NCT02066181|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.
3378601|NCT02063464||Cohort 1|Subjects w/ovarian, primary peritoneal or fallopian tube ca who are not currently on therapy and are screening for trials, being seen in consultation, or presenting for enrollment on a trial.
3378602|NCT02055248||Subjects with Moebius or related syndromes and their family me|Subjects with Moebius or related syndromes and their family members and healthy volunteers.
3378603|NCT02055222||Lung disease (IPF) and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
3378604|NCT02055222||Lung disease COPD and smoking history|50 IPF and 50 COPD patients, and 30 subjects with early interstitial lung abnormalities seen on previous radiographs
3378605|NCT02055222||Normal Volunteers- Non-smokers, and Smokers|50 smoking and 30 non-smoking controls
3378606|NCT02055209||1|Adults only, all genders, US-born African American
3378607|NCT02045823||Normal|Normal results from clinical exam and free of ocular pathology
3378608|NCT02045823||Glaucoma|Clinical exam with results consistent with glaucoma and visual field defects consistent with glaucoma
3378609|NCT02045823||Retina|clinical exam with results consistent with retina pathology
3285949|NCT01708798|Placebo Comparator|Placebo|"One tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: one tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to one tablet by mouth daily."
3285950|NCT01708798|Experimental|Eplerenone|"Eplerenone 25 mg tablet by mouth daily. If serum potassium level is <5.0 mmol/L at four weeks, increase to two 25 mg tablets by mouth daily.~If estimated glomerular filtration rate (eGFR) is between 30-49 ml per min per 1.73m2, initial dose is: eplerenone 25 mg tablet by mouth every other day. If serum potassium level is <5.0 mmol/L at four weeks, increase to 25 mg tablet by mouth daily."
3285951|NCT01708824|Experimental|dietary|"Dietary intervention to meet the target of~1.<5 servings of red/processed meat weekly; <2 servings would be processed meat 2.2 servings of refined grains daily"
3285952|NCT01708824|Experimental|physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
3285953|NCT01708824|Experimental|dietary and physical activity|Meeting both the dietary and physical activity targets
3285954|NCT01708824|No Intervention|usual care|Follow the general lifestyle advice in accordance with the recommendations of the Department of Health in Hong Kong available in the public domain
3285955|NCT01708837|Other|deep anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 30-45
3285956|NCT01708837|Other|light anesthesia group|Propofol infusion rate is titrated to maintain the target BIS values in 45-60
3285957|NCT01708850|Other|Rivaroxaban|Rivaroxaban 15 mg po bid x 3 weeks, followed by rivaroxaban 20 mg po daily x 9 weeks. Then up to discretion of investigator to decide regarding further anticoagulation as study length is limited to 12 weeks.
3285958|NCT01708863||Children with Hypoplastic Left Heart Syndrome (HLHS)|HLHS patients requiring Stage II Glenn surgery
3285959|NCT01708876|Active Comparator|Artesunate-mefloquine|3 doses artesunate-mefloquine - daily over 3 days (dosage according to bodyweight - 4mg/kg and 8.3mg/kg respectively).
3285960|NCT01708876|Active Comparator|Chloroquine|4 doses chloroquine over 3 days - total dose 25mg/kg. 10mg/kg at 0 hours, 5mg/kg at 6-8, 24, 48 hours.
3285961|NCT01708889|Experimental|Group 1: BMS-914143 (eGFR ≥ 80 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with normal renal function with eGFR ≥ 80 mL/min/1.73 m2
3285962|NCT01708889|Experimental|Group 2: BMS-914143 (eGFR 60 to 79 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with mild renal dysfunction with eGFR 60 to 79 mL/min/1.73 m2
3285963|NCT01708889|Experimental|Group 3: BMS-914143 (eGFR 30 to 59 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with moderate renal dysfunction with eGFR 30 to 59 mL/min/1.73 m2
3285964|NCT01708889|Experimental|Group 4: BMS-914143 (eGFR 15 to 29 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with severe renal dysfunction with eGFR 15 to 29 mL/min/1.73 m2
3285965|NCT01708889|Experimental|Group 5: BMS-914143 (eGFR < 15 mL/min/1.73 m2)|BMS-914143 (Peginterferon Lambda-1a) single 180 µg Solution, Subcutaneous injection for subjects with end-stage renal dysfunction with eGFR < 15 mL/min/1.73 m2 (on hemodialysis [HD] or non-HD)
3285966|NCT01708928|Active Comparator|Group A|Subjects who have previous history of submentoplasty and or rhytidectomy
3285967|NCT01708928|Active Comparator|Group B|Subjects naïve to submentoplasty and or rhytidectomy
3285968|NCT01708980|Experimental|Six different strength training exercises|Six different strength training exercises are investigated. Four repetitions of each exercise are performed with a relative loading of 10 RM.
3285969|NCT01708993|Active Comparator|Arm A: Pemetrexed and Reolysin (and safety run-in)|
3285970|NCT01708993|Active Comparator|Arm B: Pemetrexed|
3285971|NCT01708993|Active Comparator|Arm C: Docetaxel and Reolysin (and safety run-in)|
3285972|NCT01708993|Active Comparator|Arm D: Docetaxel|
3285973|NCT01709006|Other|Radiation therapy|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
3285974|NCT01709019|Experimental|Group A|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3285975|NCT01709019|Experimental|Group B|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3285976|NCT01709019|Experimental|Group C|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3285977|NCT01709019|Experimental|Group D|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
3285978|NCT01709019|Placebo Comparator|Group E|Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
3285979|NCT01709045||Patients scheduled for CEA|All patients who are scheduled for carotid endarterectomy (CEA)
3285980|NCT01709058|Experimental|Intramuscular/paravertebral injections of Oxygen-Ozone|"This group will be treated with Intramuscular/paravertebral injections of Oxygen-Ozone twice a week for six weeks"
3285981|NCT01709058|Other|Simulated treatment|"The Simulated intramuscular/paravertebral injections will mimic the Oxygen-Ozone injections in the area to be treated by pricking the skin with the needle without drilling. These simulated injections will be performed twice a week for six weeks."
3285982|NCT01709071|Experimental|Low dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285983|NCT01709071|Experimental|Low dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 2.5, 4, 8 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285984|NCT01709071|Experimental|Middle dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285985|NCT01709071|Experimental|Middle dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 5, 8, 16 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285986|NCT01709071|Experimental|High dose Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 20, 32, 64 D-antigen units respectively of Sabin-1,-2 and -3 per dose.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285987|NCT01709071|Experimental|High dose adjuvanted Sabin-IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 10, 16, 32 D-antigen units respectively of Sabin-1,-2 and -3 per dose adjuvanted with 0.5 mg aluminium hydroxide.~Infants receive three vaccinations with an interval of 8 weeks between doses."
3285988|NCT01709071|Active Comparator|Conventional IPV|"Intramuscular injection of 0.5 ml of Inactivated Poliomyelitis Vaccine containing 40, 8, and 32 D-antigen units respectively of Mahoney, MEF-1 and Saukett poliovirus per dose.~Infants receive three injections with an interval of 8 weeks between doses."
3285989|NCT01709097||With Med-O-Wheel™|Kidney Transplant Recipient with Med-O-Wheel™
3285990|NCT01709097||With out Med-O-Wheel™|Kidney Transplant Recipient with out Med-O-Wheel™
3378610|NCT02042430|Experimental|Treatment (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-14 and undergo surgery on day 15. Treatment continues in the absence of disease progression or unacceptable toxicity. In circumstances where there are medical or administrative reasons for delaying surgery, treatment with IDO1 inhibitor INCB024360 may continue for up to 3 weeks.
3285991|NCT01709123|Placebo Comparator|placebo|Placebo supplementation in pill form for 3 months following randomization after a placebo run-in period.
3285992|NCT01709123|Experimental|chromium niacinate|Chromium niacinate supplementation (200ug or 500ug/day) in pill form for 3 months following randomization after a placebo run-in period
3285993|NCT01709175|Experimental|Once-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the once-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet ONCE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
3285994|NCT01709175|Experimental|Twice-a-week Strength Training|After completing the introduction to strength training (two sessions in the first week), participants randomized to the twice-a-week group will receive 12 additional weeks of progressive strength training. Participants will meet TWICE-A-WEEK to strength train in a supervised exercise group. The program includes nine exercises.
3285995|NCT01709188|Experimental|Musical Dual Task Training|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the Musical Dual Task Training session, participant will be asked to sing familiar songs, play simple percussive musical instruments such as paddle drums and shakers, sing while walking, and play instruments while walking.
3285996|NCT01709188|Active Comparator|Walking and Talking|60 minute individual session once a week across 2 months for a total of 8 sessions.Each session will be led by a qualified music therapist. Within the walking and talking session, participant will be asked to read a newspaper article prior to a walk and have a conversation with the music therapist based on the content of the news while walking.
3285997|NCT01709201|No Intervention|Treatment as Usual|Those in the Treatment as Usual group will not receive the brief intervention for substance use but will receive a brief health education brochure.
3285998|NCT01709201|Experimental|Brief Intervention|Those in the Brief Intervention group will receive a brief motivational intervention aimed at encouraging the participant to decrease their substance use.
3285999|NCT01709214|Experimental|Cebranopadol (GRT6005) Low-Dose Range|Once daily GRT6005, flexible dosing 200, 300 or 400 micrograms, and once daily Placebo; oral administration for 15 weeks
3286000|NCT01709214|Experimental|Cebranopadol (GRT6005) High-Dose Range|Once daily GRT6005, flexible dosing 400, 600 or 800 micrograms, and once daily Placebo; oral administration for 15 weeks
3286001|NCT01709214|Placebo Comparator|Placebo|Twice daily Placebo, oral administration for 15 weeks
3286002|NCT01709214|Active Comparator|Oxycodone CR|Twice daily Oxycodone CR, flexible dosing 10, 20, 30, 40 or 50 milligrams; oral administration for 15 weeks
3286003|NCT01709240|Experimental|BioWeld1 System|
3286004|NCT01709253|Experimental|Arm 1|27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk)
3286005|NCT01709253|Experimental|Arm 2|27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk)
3286006|NCT01709253|Experimental|Arm 3|27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk)
3286007|NCT01709253|Experimental|Arm 4|27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk)
3286008|NCT01709266|Experimental|Probiotics|Capsule containing 5x10E9 CFU probiotics. Twice daily for 2 weeks.
3286009|NCT01709266|Placebo Comparator|Placebo|Capsule containing carrier material powder of identical appearance. Twice daily for 2 weeks.
3286010|NCT01709279|Other|adipose tissue derived stromal cells|
3286011|NCT01709292|Experimental|Vemurafenib - (Presurgery)|All Groups: Vemurafenib 960 mg by mouth 2 times a day for 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56 +/- 7 days).
3286012|NCT01709292|Experimental|Vemurafenib (Post Surgery) - Group A|Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
3286013|NCT01709292|No Intervention|Post Surgery - Group B|Post Surgery - Group B: Patients discontinue vemurafenib after surgery but will be restaged with CT neck 8 weeks after surgery.
3286014|NCT01709292|Experimental|Vemurafenib - Group C|Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56, Vemurafenib 960 mg by mouth twice a day unless there is evidence of progressive disease on day 56 CT scan. Patients evaluated for resectability after each CT scan is performed. If scheduled for resection, patient continues vemurafenib until surgery and follows same treatment schema as patients in Groups A and B.
3286015|NCT01709344|Experimental|PS-OT|Problem-solving Occupational Therapy
3286016|NCT01709344|Other|Usual care|Access to all supportive and rehabilitative services available at DHMC
3286017|NCT01709357|Experimental|Muscle energy technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the muscle energy technique of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3286018|NCT01709357|Experimental|Ischemic compression technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed ischemic compression technique on the latent trigger point.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3286019|NCT01709357|Experimental|Passive stretching technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, the therapist performed the passive stretching of the upper trapezius muscle.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3286020|NCT01709357|Sham Comparator|Sham technique|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next, for the sham technique, the therapist only contacted with his hands the head and the shoulder of the subject, without executing any movement, for 30 seconds.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3286021|NCT01709357|No Intervention|No intervention group|"In each volunteer, the therapist identified the latent trigger point on the upper trapezius. A questionnaire about general information was performed. And the maximum homolateral side flexion of the trigger point was measured.~On the following week, the blind assessor performed the pre-intervention measurements of pressure pain threshold, pressure pain perception and cervical range of motions.~Next,the subject was lying for 30 seconds, without intervention.~Then, all measurements, before described, were repeated, by the assessor, after 10 minutes, 24 hours and one week."
3286022|NCT01709370|Experimental|Letrozole plus PD 0332991|Drug: Letrozole 2.5mg/d for 16 weeks before surgery plus PD 0332991 (CDK-4/6 inhibitor) 125 mg/d for 3 out of 4 weeks in repeated cycles for 16 weeks before surgery
3286023|NCT01709396|Experimental|18 cGY ED-TBI|18 cGY ED-TBI followed by an allogenic done marrow transplant
3286024|NCT01709435|Experimental|Treatment (cabozantinib S-malate)|Patients receive cabozantinib S-malate PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3286025|NCT01709487|Experimental|HIPEC surgery with chemotherapy|"3 courses of pre-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks~Debulking surgery~HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery~3 courses of post-operative chemotherapy: carboplatin AUC = 5 IV + paclitaxel 175 mg/m2 IV every 3 weeks"
3286026|NCT01709526|Other|Improvement after psychiatric inpatient treatment|
3286027|NCT01709539|Experimental|Diagnostiskt Centrum|Investigation at the primary care center followed by further investigation at Diagnostiskt Centrum, Kristianstad General Hospital
3286028|NCT01709539|No Intervention|Existing diagnostic procedures|Investigation at the primary care center followed by further investigation at Helsingborg General Hospital
3286029|NCT01709552|Experimental|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
3286030|NCT01709552|Sham Comparator|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
3286031|NCT01709565||No hepatic dysfunction|No hepatic dysfunction, total plasma bilirubin ≤ 2.0 mg/dl
3286032|NCT01709565||Hepatic dysfunction|Hepatic dysfunction, total plasma bilirubin > 2.0 mg/dl
3286033|NCT01709591|No Intervention|No Prenatal education|These subjects will be randomized to receive routine prenatal epidural class (control group).
3286034|NCT01709591|Active Comparator|Receives Prenatal Education|Subjects randomized to this group will receive educational video addressing the cultural and perceptions regarding the myths on epidural in either English or Spanish (Keeping an Open Mind: choices in Labor Anaglesia: an educational produce of the Society for Obstetric Anesthesia and perinatology)
3286035|NCT01709604||continuous venovenous hemofiltration|Continuous venovenous hemofiltration(CVVH):blood access was achieved by placing a double lumen catheter in the femoral or internal jugular vein. Continuous diffusive solute transport is achieved by infusing a dialysis fluid that runs counter-current to blood at an ultrafiltration rate of 35 ml/h/Kg.
3286036|NCT01709604||Standardized therapy regimens|The standardized therapy regimens included reduce absorption, accelerate the elimination and prevent the complications in patients with paraquat poisoning.
3286037|NCT01709617|Experimental|Glucose-glucose|Glucose ingestion
3286038|NCT01709617|Active Comparator|Glucose-Fructose|glucose-fructose ingestion
3286039|NCT01709617|Active Comparator|disaccharide|Disaccharide ingestion
3286040|NCT01709630||Neonatal|Neonates born to pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection.
3286041|NCT01709630||Maternal|Pregnant women exposed to magnesium sulfate for preeclampsia, tocolysis, or neuroprotection
3286042|NCT01709643|Other|High fat breakfast lean subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
3286043|NCT01709643|Other|High fat breakfast,obese subjects|Subjects will consume a high fat breakfast, containing of sausage rolls. Energy content of the breakfast will be set to 50 % of the recommended daily calorie intake (BMR times 1.3).
3286044|NCT01709643|Other|HF breakfast with protein,lean subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
3286045|NCT01709643|Other|HF breakfast with protein,obese subjects|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls. The amount of added proteins will be calculated to assure that the total energy content from proteins in the breakfast equals 20 %,
3286046|NCT01709656|Experimental|MSC plus NSAID|"human mesenchymal stem cells:1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment, plus non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os).~Duration of treatment:24 weeks for follow up. collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
3378611|NCT02038140|Other|Zimmer TM Total Ankle System|Primary or revision total ankle arthroplasty subjects that receive the Zimmer Trabecular Metal Total Ankle System
3378612|NCT02033616|Experimental|AVOVA-1|Autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells. AVOVA-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
3286047|NCT01709656|Experimental|NSAID|"non-steroid anti-inflammatory drugs (NSAID: celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up;collect peripheral blood (PBMCs and serums)of those patients at baseline and every 4 weeks for basic study after they signed informed consent."
3286048|NCT01709669||Enrolling by invitation|
3286049|NCT01709682|Active Comparator|AAD therapy|Recurrent episodes were pharmacologically managed by conventional AAD therapy (propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure) according to AF management guidelines.
3378613|NCT02033616|Placebo Comparator|MC|Autologous monocytes will serve as the control arm. MC is admixed with GM-CSF as an adjuvant, prior to injection.
3378614|NCT02019654||1|Mild or moderate TBI within the past 30 days
3378615|NCT02015078||African Americans|Targets are family members attending African American family reunions.
3378616|NCT02014246||1|Participants with confirmed or suspected movement disorder or dementia diagnosis and their affected and unaffected family members will be potential candidates for the study, well as unrelated, healthy individuals (known as control samples.
3378617|NCT02014246||2|We plan to enroll 12,000 study subjects (10,000 patients, 1,000 asymptomatic family members, 1,000 neurological normal controls) for this study
3378618|NCT01995396|Active Comparator|APE with intersphincteric dissection|Abdominoperineal excision with intersphincteric dissection and a stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
3378619|NCT01995396|Active Comparator|Hartmann´s procedure|Hartmann´s operation and stoma is performed in patients with rectal cancer and fecal incontinence and/or severe co-morbidity
3378620|NCT01994382|Experimental|cerdulatinib (PRT062070)|Intervention: Drug: cerdulatinib (PRT062070) or cerdulatinib (PRT062070) plus rituximab
3378621|NCT01986478||Normal|Normal results from clinical exam and free of ocular pathology
3378623|NCT01976715||HIV-1|Subjects (greater than or equal to 18 years) with human immunodeficiency virus type 1 (HIV-1) who have documented virologic failure.
3378624|NCT01967563||overweight and class I obese adult male volunteers|Adult Male Subjects (18-50) will be recruited in order to determine the effects on energy expenditure of transitioning from an energyand macronutrient-balanced standard baseline diet (50% carbohydrate, 35% fat, 15% protein) to a eucaloric ketogenic diet (5% carbohydrate, 80% fat, 15% protein).
3378625|NCT01953016||immunodeficiency|Individual of all ages, gender, and races with an immunodeficiency disorder from NIH studies, will be accepted for registration.
3378626|NCT01952171||Congenital Heart Disease|Congenital Heart Disease
3378627|NCT01950624||Down syndrome cohort|Individuals who have a diagnosis of complete trisomy 21, translocation down syndrome and Mosaic Down syndrome
3378628|NCT01950572||1/Eligible cancer diagnosis|Subjects with mesothelioma, thymic carcinoma, pancreatic or biliary adenocarcinoma or lung, gastric or ovarian cancers
3378629|NCT01950377||Healthy Adults|Healthy adults healthy adults - male and female
3378630|NCT01935921|Experimental|Treatment (cetuximab, IMRT, and ipilimumab)|Patients receive cetuximab IV over 60-120 minutes on days 1, 8, 15, and 22. Treatment with cetuximab repeats every 4 weeks for 2 courses. Beginning in week 2 of course 1, patients undergo concurrent IMRT 5 days per week for 7 weeks. Beginning in week 4 (day 1 of course 2) patients also receive ipilimumab IV over 90 minutes once every 21 days for 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may undergo surgery after completion of therapy.
3378631|NCT01934660||Group 1|Healthy volunteers
3378632|NCT01934660||Group 2|Subjects diagnosed with diabetes
3378633|NCT01934660||Group 3|Subjects diagnosed cardiovascular disease
3378634|NCT01933932|Experimental|Selumetinib + Docetaxel|Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle
3378635|NCT01933932|Experimental|Placebo + Docetaxel|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3378636|NCT01933620||Patient|Patients who might become colonized or infected with a multi drug-resistant organism
3378643|NCT01927419|Experimental|Nivolumab + Ipilimumab|Participants received (Part 1) 1 mg/kg of nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) 3 mg/kg of nivolumab intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
3378644|NCT01927419|Experimental|Placebo + Ipilimumab|Participants received (Part 1) placebo-matching nivolumab + 3 mg/kg of ipilimumab solution intravenously every 3 weeks for 4 doses (4 cycles), then (Part 2) placebo-matching nivolumab solution intravenously every 2 weeks until documented disease progression, toxicity, withdrawal of consent, or study completion.
3378645|NCT01925196||C9ORF72|Participants with C9ORF72 mutation
3378646|NCT01919099||Post-transplant|Patients receiving allogenic stem cell transplants at the NIH CC
3286050|NCT01709682|Active Comparator|re-ablation procedure|"Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.~The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity. Only in patients with induced left atrial flutter, additional RF ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs."
3286051|NCT01709734|Experimental|Dose Confirmation|"Dose A - galeterone tablets once daily PO for three months + extension~Dose B - galeterone tablets once daily PO for three months + extension~Dose C - galeterone tablets once daily PO for three months + extension"
3286052|NCT01709734|Experimental|Dose Expansion|Single dose expansion (from part 1) of galeterone tablets once daily PO for three months + extension
3286053|NCT01709760|Experimental|methotrexate & ENIA11|ENIA11 25 mg, sc twice weekly
3286054|NCT01709760|Active Comparator|methotrexate & Placebo|Placebo, sc twice weekly
3286055|NCT01709773|Experimental|Focal treatment arm|
3286056|NCT01709812|Other|1 standard care|standard care
3286057|NCT01709812|Experimental|2 individualized PSP|individualized patient support program
3286058|NCT01709825|Placebo Comparator|Sugar Pill|Sugar Pill will be taken as a capsule once daily for 6 weeks.
3286059|NCT01709825|Experimental|Probiotic- Bifidobacterium bifidum|Bifidobacterium bifidum (Supplement A) will be taken as a capsule once daily for 6 weeks.
3286060|NCT01709825|Experimental|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus (Supplement B) will be taken as a capsule once daily for 6 weeks.
3286061|NCT01709825|Experimental|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C)will be taken as a capsule once daily for 6 weeks.
3286062|NCT01709851||Type 1 Diabetes - vMD and sMD|Patients will undergo vascular (vMD) and subcutaneous microdialysis (sMD) using the GMD-system (GlucoMen(R)Day-system)
3286063|NCT01709851||Type 1 diabetes - vMD|Patients will undergo vascular microdialysis (vMD) using the GMD-system (GlucoMen(R)Day-system)
3286064|NCT01709877|Active Comparator|Traditional multiport laparoscopic cholecystectomy|Standard laparoscopic cholecystectomy performed by the traditional multiport technique
3286065|NCT01709877|Experimental|Single port laparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using the reusable ENDOCONE system with dedicated curved coaxial instruments
3286066|NCT01709890||Airway catheter during sedation|
3286067|NCT01709916||Glaucoma patients|Glaucoma patients treated with eye drops to lower the IOP.
3286068|NCT01709929|Experimental|Insulin detemir|
3286069|NCT01709942|Experimental|degarelix group|group of patients treated with long acting GnRH antagonist
3286070|NCT01709942|Active Comparator|Cetrorelix 0.25mg|patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol
3286071|NCT01709955|Experimental|Gucomannan|
3286072|NCT01709955|Placebo Comparator|Placebo pill|
3286073|NCT01709968|Experimental|MAGNOX 520®|MAGNOX 520® (un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks.
3286074|NCT01709968|Placebo Comparator|Similarly looking placebo.|Similarly looking placebo. Oral administration once daily for 4 weeks.
3286075|NCT01709994|Active Comparator|aspirin|Aspirin dosage 100 mg/day
3286076|NCT01709994|No Intervention|standard medication|the patients will continue with standard medication
3286077|NCT01710007|Experimental|1PC002|2 mg 1PC002 once daily for 12 weeks.
3286078|NCT01710007|Active Comparator|Lipitor|10 mg atorvastatin once daily for 12 weeks.
3286079|NCT01710059|Experimental|Experimental: Intervention Group|"Experimental: Intervention Group~1) Asthma Supervision; 2) Mobile Phone with talking, texting, and data plan; 3) Inhaled Corticosteroid Mobile Phone Application to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated; and 4) Beta2-adrenergic agonist Mobile Phone Application to monitor real time patterns of use of beta2-adrenergic agonist medication for asthma."
3286080|NCT01710072|Experimental|aspirin|aspirin 81 mg po every day
3286081|NCT01710072|No Intervention|no aspirin|
3286082|NCT01710085|Experimental|Diffusion weighted imaging, Recurrence|
3286083|NCT01710098||Degarelix|adult male patients with advanced hormone dependent prostate cancer who receive 240 mg as a start dose and then monthly 80mg Firmagon® for one year
3286084|NCT01710111|Experimental|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
3286085|NCT01710111|No Intervention|Control Recipients|No face shield and no repeat hand hygiene measures
3286086|NCT01710124|Experimental|Incentive|Subjects in this group will receive financial incentives for using grocery coupons to purchase healthy foods.
3286087|NCT01710124|No Intervention|No incentive|Subjects in this group will receive no financial incentives.
3286088|NCT01710150|Placebo Comparator|CTI ablation only|subjects undergoing cavo-tricuspid isthmus (CTI) ablation alone for Atrial flutter
3286089|NCT01710150|Active Comparator|CTI ablation and PVI.|subjects undergoing cavo-tricuspid isthmus (CTI) ablation for Atrial flutter and pulmonary vein isolation (PVI) for Atrial Fibrillation.
3286090|NCT01710163|Experimental|Lithium|Potentiation of previous treatment (Quetiapine monotherapy) with Lithium (0.5 - 0.8 mEq/L)
3286091|NCT01710163|Experimental|Aripiprazole|Potentiation of previous treatment (Quetiapine monotherapy) with Aripiprazole (10 - 15 mg)
3286092|NCT01710189|Experimental|TicoVac immunisation - right deltoid muscle|IM immunisation right deltoid muscle
3286093|NCT01710189|Experimental|TicoVac immunisation - upper anterolateral thigh|IM: right upper anterolateral thigh
3286094|NCT01710202||Placebo|Control group who will not receive hydrocortisone. Will act as a comparison group to the hydrocortisone group.
3286095|NCT01710202||Experimental: Hydrocortisone|Group will receive 20mg oral hydrocortisone
3286096|NCT01710215|No Intervention|Usual Care|"No outreach mailed invitations.~Ordering of colonoscopy or FIT for screening at the discretion of the primary provider.~Follow up of abnormal tests and results reporting to the patient at the discretion of primary and specialty providers."
3286097|NCT01710215|Experimental|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
3286098|NCT01710215|Experimental|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
3286099|NCT01710228|Placebo Comparator|Methylprednisolone placebo|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
3286100|NCT01710228|Experimental|methylprednisolone|"subjects will be randomized 1:1 to receive either:~Methylprednisolone placebo or~Methylprednisolone"
3286101|NCT01710267||Observation group|This group includes all volunteers of this observation study.
3286102|NCT01710280|Active Comparator|Native palm olein|75 g native palm olein
3286103|NCT01710280|Experimental|Interesterified palm olein|75 g interesterified palm olein
3286104|NCT01710293|Experimental|Communication of Patients Lost to Follow-up to Providers|This intervention will consist of two related, continuous steps over at least a 12-month period. In the first step, the investigators will query the VA's Corporate Data Warehouse (CDW, a repository of near real-time patient data from all VA medical centers) weekly to identify possible lost to follow-up events in a pre-specified time period and for a random sample of about half of the providers at the investigators' study sites. These identified patient charts will be reviewed by Facility Recipients/Cancer Trackers at each site who will then communicate patients truly found to be lost to follow-up to the appropriate provider/care team.
3286105|NCT01710293|No Intervention|Usual Care|In the usual care group, providers will continue to use the existing notification system to receive abnormal test results in accordance with institutional norms, policies, and procedures. There are no formal patient-tracking programs currently at our study sites for all abnormal test results. The investigators will apply our computerized surveillance tools in the usual care arm only when the investigators are ready to conduct the final chart reviews on intervention patients and identify these patients in similar time periods as in the intervention arm. If persistent delays are found, the investigators will inform the patients' primary care providers.
3286106|NCT01710319||smoker with lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and have lung cancer
3286107|NCT01710319||smoker without lung cancer|patients that smoke greater than 45 pack years or have end organ damage due to cigarette smoking and do not have lung cancer
3286108|NCT01710319||nonsmoker with lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and have lung cancer
3286109|NCT01710319||nonsmoker without lung cancer|patients that have smoked less than 100 cigarettes in their lifetime and do not have lung cancer
3286110|NCT01710371|Experimental|Arginine Stimulation Testing|Establish the methodology for glucose enhanced arginine stimulation testing (AST).
3286111|NCT01710371|Experimental|PET Imaging|Determine if pancreatic PET-determined binding measures of 18F-AV-133 differ in up to 60 subjects determined to be at one of four stages of the natural history of Type 2 Diabetes: Healthy Overweight/obese Volunteers (HOV), Subjects with Pre-diabetes (PD) and Type 2 Diabetes mellitus (T2DM).
3286112|NCT01710384|Experimental|betamethasoneb, 34-36 weeks, preterm labor|betamethasone 12 mg 2 injections will be given 24-hours apart.
3286113|NCT01710384|No Intervention|preterm labor, 34-37 weeks|betamethasone 12 mg 2 injections will be given 24-hours apart.
3286114|NCT01710397|No Intervention|Standard group, non-pregnant adults|Comparison group (prospective enrollment)
3286115|NCT01710397|No Intervention|Standard group, pregnant women|Comparison group (retrospective record review)
3286116|NCT01710397|Experimental|Rapid group, non-pregnant adults|Rapid ART initiation
3286117|NCT01710397|Experimental|Rapid group, pregnant women|Rapid ART initiation
3286118|NCT01710410|Experimental|DLPFC tDCS (left anode/right cathode)|Active transcranial Direct Current Stimulation (tDCS) administered to the left DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
3286119|NCT01710410|Experimental|DLPFC tDCS (left cathode/right anode)|Active transcranial Direct Current Stimulation (tDCS) administered to the right DLPFC. Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
3286120|NCT01710410|Sham Comparator|DLPFC tDCS|Sham transcranial Direct Current Stimulation (tDCS) delivered to the DLPFC. Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
3286121|NCT01710423|Experimental|Immediate Intervention|Peer mentoring intervention ('Cooking with Friends')
3286122|NCT01710423|No Intervention|Delayed Entry Control|
3286123|NCT01710436||Low dose - Wild genotype (LW)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
3286124|NCT01710436||Low dose - Variant genotype (LV)|75mg Qd > 7d Clopidogrel pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
3286125|NCT01710436||High dose - Wild genotype (HW)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 wild genotype
3286126|NCT01710436||High dose - Variant genotype (HV)|300mg Clopidogrel loading dose pre-treatment before PCI, according to the reality; CYP2C19 variant genotype
3286127|NCT01710449|Experimental|Normal|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
3286128|NCT01710449|Experimental|Lung Disease|The subjects will receive the gas by breathing perfluorinated gas/oxygen mixture using either a disposable Mouthpiece without Bite blocks or Disposable oral-nasal (full Face) Non Invasive Ventilation with no Anti Asphyxia Vents no vent CAPA/NPPV Face mask and a standard Douglas Bag system.
3286129|NCT01710462|Experimental|Pantoprazole + Domperidone|The combination of pantoprazole and domperidone provided for the study will be the new incremental formulation produced by Eurofarma. For this study will be used doses of capsules containing 20 mg pantoprazole, 20 mg of domperidone.
3286130|NCT01710462|Active Comparator|Pantozol® (Takeda)|The Pantozol® may be presented in boxes of coated tablets of 20 mg or 40 mg. For this study will be used 20 mg tablets.
3286131|NCT01710488|Active Comparator|Levofloxacin 1 tablet 500 mg once a day|Levofloxacin 1 tablet 500 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
3286132|NCT01710488|Experimental|Prulifloxacin 1 tablet 600 mg once a day|Prulifloxacin 1 tablet 600 mg once a day for 7-10 days. It will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients
3286133|NCT01710540|Other|Metformin GSK 850mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 850mg
3286134|NCT01710540|Other|Glucophage 850mg|open label, crossover, two period, two treatment, two sequence, single dose
3286135|NCT01710553|Other|Metformin GSK 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Metformin 1000mg
3286136|NCT01710553|Other|Glucophage 1000mg|open label, crossover, two period, two treatment, two sequence, single dose of Glucophage 1000mg to asset bioequivalence
3286137|NCT01710566|Experimental|Group 1|600 mcg oral misoprostol
3286138|NCT01710566|Experimental|Group 2|10 IU oxytocin in Uniject
3286139|NCT01710579|Other|ARM 1 Healthy Volunteers|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3286140|NCT01710579|Other|ARM 2: Patients with fecal incontinence|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3286141|NCT01710579|Other|ARM 3 Patients with constipation|Ano-rectal 3D high resolution manometry, ano-rectal radial endsonography, dynamic ano-rectal endosonography
3286142|NCT01710592|Active Comparator|Epirubicin, Oxaliplatin, Capecitabine|"Epirubicin 50mg/m2 (day 1) bolus injection~Oxaliplatin 130mg/m2 (day 1) in 250mls of 5% dextrose. i.v. over 2 hours~Capecitabine 625mg/m2 (days 1-21) b.d. orally~8 x 3-weekly cycle"
3286143|NCT01710592|Active Comparator|Docetaxel, Oxaliplatin|"Docetaxel 20mg/m2 (days 1, 8 & 15)in 250mls of 5% dextrose. i.v. over 30mins (Dexamethasone 8mg i.v, Chlorpheniramine 10mg i.v,Ranitidine 50mg i.v. to be given 30 minutes prior to Docetaxel)~Oxaliplatin 85mg/m2 (days 1 & 15)in 250mls of 5% dextrose. i.v. over 2 hours~6 x 4-weekly cycle"
3286144|NCT01710605|Active Comparator|Standard|Treatment choices (hormonotherapy or chemotherapy) are done according to standard of each center based on clinical, radiological and biological information.
3286145|NCT01710605|Experimental|Circulating Tumor Cells|"Treatment choices (hormonotherapy or chemotherapy) are done according to the number of CTC / 7.5 ml of blood at baseline :~If <5 CTC : Hormonotherapy If 5 or more CTC : chemotherapy"
3286146|NCT01710631|Experimental|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
3286147|NCT01710631|Placebo Comparator|placebo|placebo tablet
3286148|NCT01710644|Experimental|Burlulipase|Burlulipase orally, per meal
3286149|NCT01710644|Placebo Comparator|Placebo (Caramel in sterile water)|Placebo orally, per meal
3286150|NCT01710670|Experimental|Ethanol + Brivaracetam|Treatment A: Ethanol + Brivaracetam
3286151|NCT01710670|Experimental|Ethanol Placebo + Brivaracetam|Treatment B: Ethanol Placebo + Brivaracetam
3286152|NCT01710670|Experimental|Ethanol + Brivaracetam Placebo|Treatment C: Ethanol + Brivaracetam Placebo
3286153|NCT01710683||Control group|Median age 45 years, 18-63.
3286154|NCT01710683||Intervention group|Median age 46 years, 18-62.
3286155|NCT01710696|Experimental|Individual dose|
3286156|NCT01710696|Experimental|Fixed dose|
3286157|NCT01710722|Experimental|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
3286158|NCT01710722|Experimental|leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
3286159|NCT01710722|Experimental|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
3286160|NCT01710735|Experimental|Dry needling (deep)|Subjects receive dry needle insertion deeper than 1,5cm below the skin of the Trapezius.
3286161|NCT01710735|Active Comparator|Dry needling (superficial)|Insertion of dry needle less than 1cm.
3286162|NCT01710748|Active Comparator|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
3286163|NCT01710748|Experimental|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
3286164|NCT01710761|Active Comparator|Nitrate supplement with caffeine|
3286165|NCT01710761|Placebo Comparator|Placebo|
3286166|NCT01710774|No Intervention|Traditional follow-up|Traditional follow-up with standard consultations at the Section of Endocrinology. For some patients, this will include follow-up from nurses in the home care or general practice office related to wound care. However, this is not the standard procedure and will not take place in combination with telemedicine follow-up.
3286167|NCT01710774|Active Comparator|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
3286168|NCT01710813||pompe safety sub-registry|patients are selected from those who are enrolled in the Pompe Registry, and will be followed for safety evaluation in this sub-registry
3286169|NCT01710826|Experimental|Genz-682452|This study will include three cohorts for doses of Genz-682452: Dose 1, Dose 2, Dose 3. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
3286170|NCT01710826|Placebo Comparator|Placebo|Placebo comparator taken by participants randomized to the placebo arm in each of the three cohorts. Each cohort will include 12 participants, 9 of whom will be administered Genz-682452 and 3 will be administered placebo.
3286171|NCT01710852|Experimental|Group A|ISIS CRP Rx followed by Placebo
3286172|NCT01710852|Experimental|Group B|Placebo followed by ISIS CRP Rx
3286173|NCT01710865|Experimental|Ultraseal Sealant|Both Ultraseal XT Hydro and Ultraseal XT Plus will be applied on patients.
3286174|NCT01710878|Other|Intergard Synergy Graft|
3286175|NCT01710917||Targinact® (oxycodon/naloxon)|
3286176|NCT01710930|Experimental|Study of predictive factors|
3286177|NCT01710943|Experimental|Web-based Cognitive Behavioral Treatment|"Participants who are randomly assigned to the treatment condition will receive the same standard care as those in the control condition and they will also receive access to the web-based CBT intervention. Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial."
3286178|NCT01710943|No Intervention|Treatment as Usual|TAU consists of the usual Veterans Integrated Service Network 2 (VISN) primary care services. As we have described, all of the participants will be recruited from patients presenting for treatment typically for physical complaints in primary care clinics in VA's VISN 2 (Upstate NY). VISN 2 officially practices a co-located, collaborative care model of integrated (behavioral health and physical health) in its primary care clinics. This integrated model has been implemented widely in both VA and non-VA primary care clinics in the United States .
3286179|NCT01710956|Experimental|Arm 1(with twice-daily TRT)|
3286180|NCT01710956|Experimental|Arm 2 (with once-daily TRT)|
3286181|NCT01710969|Experimental|Individual Intervention|behavioral - children receive the Coping Power program in an individual, face-to-face format
3286182|NCT01710969|Experimental|Group Intervention|behavioral - children receive the Coping Power program in a small group format (5-6 children per group)
3286183|NCT01710982|Active Comparator|TZP-101|TZP-101
3286184|NCT01710982|Placebo Comparator|Placebo|Placebo
3286185|NCT01710995|Active Comparator|Zegerid 20mg capsule|Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
3286186|NCT01710995|Active Comparator|Zegerid 20mg powder for oral suspension|Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
3286187|NCT01710995|Active Comparator|Losec 20mg capsule|Losec 20mg capsule (20mg omeprazole)
3286188|NCT01711008|Placebo Comparator|No Breakfast|Water only
3286189|NCT01711008|Active Comparator|20g Cereal|20g Kelloggs Special K cereal with 83ml semi-skimmed milk
3286190|NCT01711008|Active Comparator|40g Cereal|40g Kelloggs Special K cereal with 166ml semi-skimmed milk
3286191|NCT01711021|Active Comparator|d-Amphetamine Transdermal System|d-Amphetamine Transdermal System
3286192|NCT01711021|Placebo Comparator|Placebo patch|Placebo patch
3286193|NCT01711034|Experimental|OPB-111077|"In escalation stage of study, treatment with a once daily dose of OPB-111077 during cycles 1 and 2 on day 1, followed by 2-day treatment free interval, and then resuming daily dosing on day 4 through day 28. For cycle 3 and beyond, OPB-111077 will be administered for 28 continuous days per cycle until MTD is reached.~In expansion portion of study, established dose of 250mg administered once daily for 28 consecutive days for each cycle. Patient in expansion are defined as those who meet eligibility criteria and have a diagnosed malignancy that is presumed to be susceptible to inhibition by OPB-111077"
3286194|NCT01711047|Active Comparator|PVI + Linear ablation|Arm A: patients have PVI and roof and mitral isthmus lines
3286195|NCT01711047|Active Comparator|PVI + linear ablation + CFAE|Arm B: patients have PVI + roof and mitral isthmus lines and CFAE ablation
3286196|NCT01711060|Experimental|oxytocin|
3286197|NCT01711060|Experimental|balloon catheter|Dufour 1859H18
3286198|NCT01711073|Experimental|Mobilization with G-CSF plus Mozobil|Patients will receive G-CSF (Filgrastim) plus Mozobil (Plerixafor)
3286199|NCT01711086|Active Comparator|Inspiromatic followed by Aerolizer|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Inspiromatic dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Aerolizer dry powder inhaler.
3286200|NCT01711086|Active Comparator|Aerolizer followed by Inspiromatic|volunteers will perform lung function pre and post Formoterol (a bronchodilator) inhalation. They will use either the Aerolizer dry powder inhalers the delivery device. 3-60 days later participants will receive the same drug through the Inspiromatic dry powder inhaler.
3286201|NCT01711099|Experimental|ESMR treated|
3286202|NCT01711112|Experimental|docetaxel|Days 1 & 8 Docetaxel 35 mg/m2 IV
3286203|NCT01711125|Experimental|Arm 1|Baclofen low dose
3286204|NCT01711125|Experimental|Arm 2|Baclofen high dose
3286205|NCT01711125|Placebo Comparator|Arm 3|Placebo
3286206|NCT01711138||Intervention|Intervention group is geographically located near a built environment intervention (neighbourhood redevelopment).
3286207|NCT01711138||Comparison|Comparison group is not exposed to the built environment intervention according to their geographic location.
3286208|NCT01711151||Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
3286209|NCT01711151||Non Idiopathic Pulmonary Fibrosis|Questionnaire evaluation
3286210|NCT01711151||Sarciodosis|Questionnaire evaluation
3286211|NCT01711151||Healthy Controls|Questionnaire evaluation
3286212|NCT01711164||patients|Chronic HCV patients who undergo antiviral therapy
3286213|NCT01711164||Healthy controls|healthy controls who are willing to give blood and liver tissue samples
3286214|NCT01711203|Experimental|Motor Control|"Pilates-based exercise with verbal cues to facilitate motor control Plank progression, use of feedback tool VERBAL CUES FOR MOTOR CONTROL GROUP (could also include above cues) Maintain neutral spine Not too arched, not too flexed Remember your pilates position Inhale, exhale Let me hear your breath"
3286215|NCT01711203|Active Comparator|General strengthening|"Patient group that will receive active strengthening without specific verbal cueing to recruit deeper abdominal musculature. Core strengthening and lower quarter strengthening is the focus of this group.~Verbal cuing will include:~VERBAL CUEING FOR NON-MOTOR CONTROL GROUP~Keep your back straight Don't slouch Don't arch your back Don't let your body move Nothing should move but your arms tighten up your abs suck in your stomach feet shoulder-width apart, knees bent, shoulders back, hold your stomach tight Time will be kept the same as the intervention group."
3286216|NCT01711229|Active Comparator|Group I: IV acetaminophen|Group I will receive 1 gram IV acetaminophen 15 minutes prior to going to the operating room for arthroscopic rotator cuff repair
3286217|NCT01711229|Active Comparator|group 2|Group 2 will receive 1.5grams of oral acetaminophen immediately prior to proceeding to the operation groom for arthroscopic rotator cuff surgery
3286218|NCT01711242|Experimental|capecitabine/Oxaliplatin/radiotherapy|"sequence chemoradiotherapy following radical resection~sequence chemoradiotherapy two cycles of XELOX + concurrent chemoradiotherapy + two cycles of XELOX.~Postoperative radiotherapy regimen: Radiotherapy consisted of 4500 centigray of radiation at 180 centigray per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Concurrent chemotherapy regimen: capecitabine 825 mg/m² twice daily Postoperative chemotherapy regimen: see arm 2"
3286219|NCT01711242|Active Comparator|capecitabine/Oxaliplatin|"chemotherapy alone following radical resection~Drug: chemotherapy alone following radical resection Postoperative chemotherapy regimen: The XELOX regimen was administrated: Oxaliplatin, 130mg/m2/day on day1, i.v. 2h; Capecitabine 1000mg/m²/day twice daily d1-14; every 21 days repeated, for 4 cycles."
3286220|NCT01711255||Multiple Sclerosis|Subjects who have been diagnosed with clinically definite or probable multiple sclerosis as defined and recorded by board certified neurologist.
3286221|NCT01711255||Healthy controls|Adults age 18 and older who have not been diagnosed with any neurological, endocrine, or other chronic health condition. They must also be free of any recent acute illness that can impact inflammation/clotting.
3286222|NCT01711281|Experimental|Intracardiac Impedance Measurement|
3286223|NCT01711307|Experimental|non-operative|cast applied within 48 hours
3286224|NCT01711307|Active Comparator|operative|cast applied within 48 hours and surgery within 14 days
3286225|NCT01711320|Placebo Comparator|Placebo|oral dose of Placebo combined with two dose of Metformin (OGTTs)
3286226|NCT01711320|Experimental|Omeprazole|oral dose of Omeprazole (80 mg) combined with two dose of Metformin (OGTTs)
3286227|NCT01711333|Experimental|Pletaal SR capsule|
3286228|NCT01711346|Experimental|S303 Red Blood Cells (RBCs)|Participants will be assigned to S303 Red Blood Cells (RBCs) and then to Conventional, Untreated Red Blood Cells (RBCs).
3286229|NCT01711346|Active Comparator|Conventional, Untreated Red Blood Cells (RBCs)|Participants will be assigned to Conventional, Untreated Red Blood Cells (RBCs) and then to S303 Red Blood Cells (RBCs).
3286230|NCT01711385|No Intervention|Standard practice|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the basic/control intervention, are informed that it is important to follow-up with their physician regarding their test results. They are contacted by phone once to schedule their 6-month recall visit."
3286231|NCT01711385|Experimental|Enhanced intervention|"Study patients are notified of their diagnostic test result within 72 hours. Those identified as potentially pre-diabetic or diabetic and randomized to the enhanced group, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results. They are given a letter to take to their physician and receive a call at month two and then again at month four if necessary to inquire if they have followed-up with their physician and encouragement to do so, if they have not, prior to their six month follow-up study visit."
3286232|NCT01711398|Experimental|IPP204106N|
3286233|NCT01711437|Experimental|PEG-S|polyethylene glycol 4000 solution with simethicon
3286234|NCT01711437|Experimental|PEG-CS + Bisacodyl|PEG-CS is a new sulphate-free iso-osmotic formulation of PEG-4000 with citrates and simethicone
3286235|NCT01711437|Experimental|PEG-ASC|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
3286236|NCT01711437|Experimental|picoprep|sodium picosulphate plus magnesium oxide and citric acid
3286237|NCT01711450|Experimental|Paravertebral block|Paravertebral space will be needled and an anesthetic agent will be injected.
3286238|NCT01711450|Placebo Comparator|Control sham procedure|Paravertebral space will be needled, but only normal saline injected.
3286239|NCT01711463|Experimental|FF/VI|50/25 mcg, 100/25 mcg or 200/25 mcg
3286240|NCT01711463|Placebo Comparator|Placebo|matching placebo
3286241|NCT01711476|Active Comparator|Lifestyle counseling ARM 1|Arm 1 Breakfast Diet The arm 1 will be assigned to eat High calorie breakfast (800kcal) and reduced dinner (200 kcal) During 90 days from baseline to the end of the trial (day 90)
3286242|NCT01711476|Placebo Comparator|Lifestyle counseling ARM 2|Lean PCOS women in the Arm 2 will be assigned to do a dinner diet from day 0 to day 90 of the trial
3286243|NCT01711489|Experimental|isavuconazole and mycophenolate mofetil|Single dose of MMF on Day 1, isavuconazole three times daily (TID) on Days 9 and 10, isavuconazole once daily (QD) Days 11-16, a single dose of MMF on Day 13
3286244|NCT01711502||Female patients diagosed with metastatic breast cancer|
3286245|NCT01711515|Experimental|Treatment (cisplatin, radiation therapy, and ipilimumab)|Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36, undergo extended beam radiation therapy 5 days a week for 6 weeks, and then undergo intracavitary brachytherapy for approximately 2 weeks. Within 2 weeks, patients receive ipilimumab IV over 90 minutes once every 3 weeks for 12 weeks.
3286246|NCT01711528|Experimental|Schedule I (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours and bortezomib SC or IV (if patients do not tolerate SC injection) on days 1, 8, and 15 and dexamethasone PO QD on days 1, 2, 8, 9, 15, and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3286247|NCT01711528|Experimental|Schedule II (dinaciclib, bortezomib, dexamethasone)|Patients receive dinaciclib IV over 2 hours on day 1; bortezomib SC on days 1 and 8; and dexamethasone PO QD on days 1, 2, 8, and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3286248|NCT01711554|Experimental|Treatment (lenalidomide, dinutuximab, isotretinoin)|Patients receive lenalidomide PO QD on days 1-21, dinutuximab IV over 10 hours on days 8-11, and isotretinoin PO BID on days 15-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3286249|NCT01711567|Active Comparator|entecavir|standard drugs
3286250|NCT01711567|Active Comparator|tenofovir|study drugs
3286251|NCT01711580||Re-irradiation, high grade glioma|EORTC QLQ-C30 EORTC QLQ-BN20 Hopkins Verbal Learning Test-Revised (HVLT-R) Trail Making Test (TMT) Stroop color-word test Controlled oral word association test (COWA) Jamar hand dynamometer EORTC QLQ- FA13 Short Form health survey (SF-36)
3286252|NCT01711593|Experimental|Allergic Asthmatic, Non-allergic non-asthmatics(HC)|Track 1: Adult subjects who are allergic asthmatics or non-allergic non-asthmatics(Healthy Controls) will not receive segmental allergen challenge to the lung but will have their blood drawn at 1 time point. Track 2: Adult subjects who are allergic asthmatics will receive segmental allergen challenge to the lung and have their blood drawn at 2 time points.
3286253|NCT01711606||unselected Fragile-X patients|
3286254|NCT01711632|Experimental|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days).
3286255|NCT01711671|Experimental|DKN-01 300mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
3286256|NCT01711671|Experimental|DKN-01 600mg|DKN-01 plus lenalidomide (Revlimid)/dexamethasone
3286257|NCT01711671|Active Comparator|Standard of Care|Lenalidomide (Revlimid)/dexamethasone
3286258|NCT01711684|Experimental|Diphenylcyclopropenone (DPCP)|Subjects will have DPCP in a topical gel formulation applied to their cutaneous metastatic lesions.
3286259|NCT01711697|Experimental|Treatment (radiation therapy, carboplatin, paclitaxel, SBRT)|Patients undergo radiation therapy daily and receive carboplatin and paclitaxel weekly for 4.5 weeks. Patients then undergo 2 boost SBRT treatments 2-3 days apart.
3286260|NCT01711710|Experimental|Cohesive Gel Breast Implant|Cohesive Silicone Gel-Filled Breast Implant
3286261|NCT01711723|Experimental|Renal Impaired Group|Subjects with renal impairment received darapladip 160 mg daily for 10 consecutive days.
3286262|NCT01711723|Experimental|Healthy Control Group|Healthy volunteers matching with renal impairment subjects for gender, age and BMI; received darapladip 160 mg daily for 10 consecutive days.
3286263|NCT01711749|Active Comparator|Sequence 1|01 tablet, single dose, of Reference Product in period 1 and 01 tablet, single dose, of Test Product in period 2.
3286264|NCT01711749|Active Comparator|Sequence 2|01 tablet of Test Product in period 1, and 01 tablet, single dose, of Reference Product in period 2.
3286265|NCT01711762|Experimental|GDC-0973 Single Arm|
3286266|NCT01711775|Experimental|Aleglitazar|
3286267|NCT01711788|Experimental|Intrabone umbilical cord blood tranplant|Intrabone infusion of umbilical cord blood stem cells
3286268|NCT01711801|Placebo Comparator|Part 1: Placebo|
3286269|NCT01711801|Experimental|Part 1: RO5545965|
3286270|NCT01711801|Experimental|Part 2: Food effect|
3286271|NCT01711814|Experimental|ASP015K|Experimental
3286272|NCT01711827|Experimental|Isavuconazole and Prednisone|Single dose of prednisone on Days 1 and 9, isavuconazole 3 times a day (TID) on Days 5-6, isavuconazole once a day (QD) on Days 7-10
3286273|NCT01711840||Symbicort|
3286274|NCT01711892|Active Comparator|Soccer Training|12 weeks of soccer training. (2 times per week for the first 8 weeks and 3 times per week in the last 4 weeks. Training will consist of 15 minutes warm-up and 2 x 15 minutes matches for the first 4 weeks and of 15 minutes warm-up and 3 x 15 minutes matches for the last 8 weeks). After 12 weeks assessments participants in the intervention group will continue bi-weekly supervised training for additional 20 weeks at the end of which tests will be repeated.
3286275|NCT01711892|No Intervention|Control group|Usual care
3286276|NCT01711905|Experimental|Vitamin D3|cholecalciferol 20 µg per day for 12 weeks
3286277|NCT01711905|No Intervention|Placebo|Placebo for 12 weeks
3286278|NCT01711931|Active Comparator|Everolimus-eluting bioresorbable vascular scaffold stents|
3286279|NCT01711931|Active Comparator|Everolimus-eluting stent|
3286280|NCT01711931|Active Comparator|Biolimus-eluting stent|
3286281|NCT01711944|Experimental|Online PSST|An online version of Problem-Solving Skills Training (PSST) will be compared to standard (face-to-face) PSST
3286282|NCT01711944|Active Comparator|Face-to-Face PSST|This is an 8-session face-to-face Problem-Solving Skills Training intervention
3286283|NCT01711957||Liver disease and liver transplantation|Patient with end stage liver disease and/or primary liver tumor undergoing liver transplantation
3286284|NCT01711970|Experimental|VB-111|
3286285|NCT01711996||UPJO|0-3 year old hydronephrosis patients without ureter dilatation who undergo pyeloplasty
3286286|NCT01711996||Hydronephrosis|0-3 year old hydronephrosis patients without ureter dilatation who does not meet the indication of pyeloplasty
3286287|NCT01711996||Normal|0-3 year old children without hydronephrosis
3286288|NCT01712022||Dry Eye|clinical diagnosis of dry eye
3286289|NCT01712022||Contact Lens|routine wear of contact lens
3286290|NCT01712022||Normal|Not having history of dry eye or contact lens wear or corneal pathology or surgery
3286291|NCT01712035||Treatment-active NVAMD|Patients with NVAMD who have received treatment with an anti-VEGF agent (Avastin, Lucentis, Macugen, or Eylea) 6 weeks prior enrollment visit
3286292|NCT01712035||Treatment-naive NVAMD|Individuals who have not received any treatment for neovascular AMD in the study eye
3286293|NCT01712048|Active Comparator|Submucosal Injection EMR|"For patients who are randomized to the submucosal injection arm polypectomy will be performed with selective saline injection to the layer of tissue underneath the polyp in order to create a safety cushion for resection."
3286294|NCT01712048|Active Comparator|Underwater EMR|"For patients who are randomized to the underwater arm polypectomy with water will be performed under full water emersion without the use of submucosal injection."
3286295|NCT01712087||MedStream System Implants|All subjects presenting for a de novo programmable pump implant or replacement of an implantable, programmable infusion pump for the treatment of severe spasticity with intrathecal Baclofen.
3286296|NCT01712100|Experimental|irbesartan|300 mg tablet
3286297|NCT01712100|Active Comparator|Avapro|300 mg tablet
3286298|NCT01712113|Experimental|irbesartan|300 mg tablet
3286299|NCT01712113|Active Comparator|Avapro|300 mg tablet
3286300|NCT01712126|Experimental|Irbesartan and Hydrochlorothiazide|300 mg and 25 mg tablet
3286301|NCT01712126|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg
3286302|NCT01712139|Active Comparator|Avalide|irbesartan 300 mg and hydrochlorothiazide 25 mg tablet
3286303|NCT01712139|Experimental|Irbesartan and Hydrochlolothiazide|300 mg irbesartan and 25 mg hydrochlorothiazide tablet
3286304|NCT01712165|Active Comparator|ANMUM Materna|75g milk powder in 400 ml water daily for 12 weeks.
3286305|NCT01712165|Placebo Comparator|Control|75g of milk powder in 400 ml water for 12 weeks.
3286306|NCT01712191|Experimental|NUsurface Meniscus Implant|
3286307|NCT01712217|Experimental|AT13387 and Crizotinib|Part A is a single-arm, Phase 1, open-label, dose-escalation design in patients with NSCLC who have already been receiving crizotinib 250 mg by mouth (PO) twice daily (BID) for at least 8 weeks and are still tolerating treatment at that dose. Patients will continue treatment with crizotinib + escalating doses of AT13387 IV weekly for 3 weeks in a 4-week cycle. Each cohort will consist of at least 6 patients until the maximum tolerated dose (MTD) is reached. An additional 12 patients will be treated at the MTD level of AT13387 in combination with crizotinib to confirm the safety profile of the combination at that dose level.
3286308|NCT01712217|Active Comparator|Crizotinib versus crizotinib + AT13387|Part B is a Phase 2, open-label, randomized continuation design comparing crizotinib alone versus the combination of crizotinib + AT13387 at the MTD established in Part A. Part B will enroll 128 patients with NSCLC who have been treated with crizotinib for at least 8 weeks and are still tolerating treatment without evidence of disease progression.
3286309|NCT01712217|Active Comparator|AT13387 or AT13387 + crizotinib|Part C is an open-label, randomized, Phase 2, Simon's 2-stage design of AT13387 administered alone once weekly for 3 weeks (QW×3) or in combination with crizotinib at the MTD established in Part A.
3286310|NCT01712243|Active Comparator|Dim light|15 minutes of very dim (<1 lux) light during the night
3286311|NCT01712243|Active Comparator|Room light|15 minutes of normal room light (~100 lux) during the night
3286312|NCT01712243|Experimental|Colored light|15 minutes of colored light during the night
3286313|NCT01712269|Experimental|Weight-loss (bariatric) surgery|All subjects enrolled will undergo bariatric surgery to assist weight-loss
3286314|NCT01712282|Experimental|High dose training|2 x 30 minutes/day on a weight-bearing treadmill
3286315|NCT01712295|Experimental|17% Salicylate with Ethyl Pyruvate|Subjects with plantar wart(s) will apply the product to warts twice a day for up to 16 weeks.
3286316|NCT01712295|Active Comparator|17% salicylate|subjects will apply 17% salicylate (standard of care treatment) to plantar skin wart(s) twice a day for up to 16 weeks
3286318|NCT01712321|Experimental|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth for up to 12 weeks
3286319|NCT01712321|Placebo Comparator|Placebo|Placebo to match Vilazodone 20mg or 40mg, taken once daily by mouth for up to 12 weeks
3286320|NCT01712347||mCRC Participants|mCRC participant will receive bevacizumab as per approved label with the approved first-line fluoropyrimidine based chemotherapy, as per physician discretion. The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
3286321|NCT01712373|Active Comparator|Ginseng|Ginseng, tablet, 250 mg, twice, 3 months
3286322|NCT01712373|Placebo Comparator|Placebo|Placebo, tablet
3286323|NCT01712386|Experimental|COPD|
3286324|NCT01712412|Experimental|IW-9179|Oral IW-9179 taken daily for two weeks
3286325|NCT01712412|Placebo Comparator|Placebo|Oral placebo taken daily for two weeks
3286326|NCT01712425|Experimental|0-24 week prime/boost regimen (ARM A)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-24 week prime/boost regimen
3286327|NCT01712425|Experimental|0-8 week prime/boost regimen (ARM B)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines, delivered intramuscularly, 0-8 week prime/boost regimen
3286328|NCT01712425|No Intervention|Arm A control (ARM C)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
3286329|NCT01712425|No Intervention|Arm B control (ARM D)|Start antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
3286330|NCT01712451|Experimental|LIPO-102, Low|
3286331|NCT01712451|Experimental|LIPO-102, Mid|
3286332|NCT01712451|Experimental|LIPO-102, High|
3286333|NCT01712451|Experimental|LIPO-102; Placebo|
3286334|NCT01712451|Experimental|salmeterol xinafoate|
3286335|NCT01712464|Other|Cross over Oxytocin and Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
3286336|NCT01712464|Other|Cross over Placebo and Oxytocin|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
3286337|NCT01712477|Active Comparator|Intravenous sedation with propofol|Traumatic brain injured patient, already requiring sedation. Intervention is sedation with intravenous propofol during mechanical ventilation
3286338|NCT01712477|Active Comparator|Intravenous sedation with midazolam|Patients with traumatic brain injury requiring mechinical ventilation. Intervention is intravenous midazolam for sedation at variable doses to achieve adequite sedation levels
3286339|NCT01712503|Experimental|Toric intraocular lens|TFlex Lens (623T)
3286340|NCT01712503|Placebo Comparator|Monofocal intraocular lens|Superflex Aspheric Lens (920H)/Cflex Aspheric Lens (970C)
3286341|NCT01712529|Experimental|Supervised physical exercise|Walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
3286342|NCT01712529|No Intervention|No supervised physical exercise|No intervention for 16 weeks
3286343|NCT01712555|Experimental|fat grafting with PRP to anophthalmic orbits|There is only one arm to this study. People with orbital atrophy and loss of an eye are to be injected with autologous fat mixed with autologous PRP (platelet rich plasma) and observed for at least one year for evidence of retention of the injected fat
3286344|NCT01712568|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
3286345|NCT01712568|Experimental|Reference Product|Drug: Ropinirole REQUIP XL Tablets (Ropinirole hydrochloride CR 2mg)commercial formulation under fasting conditions
3286346|NCT01712581|Experimental|Healthy volunters|175 Healthy volunters in the cohorte divided in 7 groups of age: 18-19 years old (ratio M/F: 1/1) 20-24 years old (ratio M/F: 1/1) 25-29 years old (ratio M/F: 1/1) 30-39 years old (ratio M/F: 1/1) 40-49 years old (ratio M/F: 1/1) 50-59 years old (ratio M/F: 1/1) 60-69 years old (ratio M/F: 1/1)
3286347|NCT01712594|Active Comparator|Closed Loop Procedure AB|Closed loop procedure with normal calibration first followed by closed loop procedure B with calibration error induced.
3286348|NCT01712594|Active Comparator|Closed loop Procedure BA|Closed loop procedure with an induced calibration error first followed by closed loop procedure with normal calibration.
3286349|NCT01712607|Experimental|Warm-Up|Surgery after warm-up task Preoperative Warm-Up training
3286350|NCT01712607|No Intervention|No Warm-up|Surgery without warm-up exercise
3286351|NCT01712620|Experimental|Group A|Spironolactone
3286352|NCT01712620|Placebo Comparator|Group B|Placebo
3286353|NCT01712659|Experimental|1- CLOSED|Ruxolitinib 20mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
3286354|NCT01712659|Experimental|2- Dose Escalation|Ruxolitinib 30-50 mg orally twice daily for 28 days to determine the maximum tolerated dose (MTD). Patients may continue to receive treatment until PD or unacceptable toxicity.
3286355|NCT01712659|Experimental|3- Dose Expansion|Ruxolitinib at the MTD orally twice daily for 28 days. Patients may continue to receive treatment until PD or unacceptable toxicity.
3286357|NCT01712698||Cervical spinal cord injury|Those patients with an acute cervical spinal cord injury evaluated with DTI MRI
3286358|NCT01712724|Active Comparator|Aerobic Training|Walking, elliptical, stationary recumbent or upright cycling will be the modes of AT prescribed depending on individual ability and access to equipment when away from the Centre. Treadmill or overground walking will be considered for those who can sustain high enough speeds and durations to achieve aerobic benefit. Cycle ergometer exercise (upright or recumbent) will be prescribed to patients in addition to walking when stroke-related deficits preclude a sufficient walking speed. The AT group will complete AT 5 d∙wk-1.
3286359|NCT01712724|Experimental|Combined Resistance and Aerobic Training|The AT+RT group will complete AT 3 d∙wk-1 + RT 2 d∙wk-1.The RT exercises will be task specific, incorporating muscle actions that are performed during daily activities. Resistance will be provided by hand-held dumbbells, exercise bands (wrist/ankle attachments), or patients' body weight. A weight load equivalent to 50-60% of 1 repetition maximum will be prescribed on the non-affected limb. On the hemiparetic limb ≥50% of 1 repetition maximum and/or a resistance rated as 13-14 on the Rating of Perceived Exertion scale on the last repetition of the set will be prescribed
3286360|NCT01712737|Experimental|Snack foods: raisins|children were given ad libitum access to raisins for 15 min
3286361|NCT01712737|Experimental|Snack foods: grapes|children were given ad libitum access to grapes for 15 min
3286362|NCT01712737|Experimental|Snack foods: a mix of almonds with raisins|children were given ad libitum access to a mix of almonds with raisins for 15 min
3286363|NCT01712737|Experimental|Water control|children were given ad libitum access to water
3286364|NCT01712750||VOT on bypass|
3286365|NCT01712763|Experimental|Degarelix|50 women will be treated with degarelix 80mg in one administration
3286366|NCT01712763|Active Comparator|Goserelin|goserelin 3.6mg monthly for three months
3286367|NCT01712789|Experimental|Pomalidomide plus Dexamethasone|Pomalidomide 4mg by mouth (PO) daily days 1 through 21 of a 28 day cycle and dexamethasone 40mg/day PO for those ≤75 years of age or 20mg/day for those greater than 75 years of age on Days 1, 8, 15 and 22 of a 28 day cycle.
3286368|NCT01712802|Experimental|Denture Adhesives: Cream|Parallel arm that receives application of Cream denture adhesives.
3286369|NCT01712802|Experimental|Denture Adhesives: Powder|Parallel arm that receives application of powder denture adhesive.
3286370|NCT01712802|Placebo Comparator|control|Parallel arm that receive placebo.
3286371|NCT01712815|Experimental|Diagnostic (fluorine F 18-clevudine PET/CT)|Patients receive fluorine F18-clevudine IV over 1 minute and then undergo PET/CT scan at baseline. Patients with HER2+ breast cancer also undergo fluorine F 18-clevudine PET/CT scan 2-3 weeks after the first course of treatment and after completion of treatment.
3286372|NCT01712828|Experimental|Lenalidomide plus Quinidine|
3286373|NCT01712828|Experimental|Lenalidomide plusTemsirolimus and Diphenhydramine|
3286374|NCT01712841||Severe NEAMD|Presence of definite central or noncentral geographic atrophy within 3000 microns of the foveal center
3286375|NCT01712841||Moderate/Intermediate NEAMD|Presence of large drusen (>125µ) and pigmentary changes without geographic atrophy
3286376|NCT01712841||Mild/Early NEAMD|Presence of small or medium drusen without geographic atrophy
3286377|NCT01712867|Experimental|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
3286378|NCT01712867|Active Comparator|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
3286379|NCT01712880|Active Comparator|open debridement with modular exchange|
3286380|NCT01712880|Active Comparator|one stage exchange|
3286381|NCT01712893|Experimental|Zoladex combined with chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the test group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,all patients will receive Tamoxifen after chemotherapy
3286382|NCT01712893|Active Comparator|Zoladex after chemotherapy|After signing informed consent, patients will be screened, eligible patients were randomly divided into 2 groups, the control group should use Zoladex 3.6mg once a month up to 2-3 years after chemotherapy,all patients will receive Tamoxifen after chemotherapy
3286383|NCT01712906|Experimental|3.50±0.25logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3286384|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3286385|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in adults|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 adults aged 16-59 years old on day 0.
3378648|NCT01905865||Parent|Persons aged 18 years or older who have a child with an undiagnosed medical condition, who have applied to the Undiagnosed Diseases Network, and have been assigned to the NIH.
3378649|NCT01905826||Patient Relatives|Blood relatives of enrolled patients.
3378650|NCT01905826||Patients|Patients with known mutations in GATA2 or those with clinical and laboratory characteristics strongly consistent with GATA2 deficiency.
3286386|NCT01712906|Placebo Comparator|0 logCCID50/ml in adults|0 logCCID50/ml in 18 adults aged 16-59 years old on day 0.
3286387|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 5-15 years old on day 0.
3378656|NCT01889186|Experimental|Main Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 79 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
3378657|NCT01889186|Experimental|Safety Expansion Cohort|Participants received ABT-199 tablets once daily (QD) orally for up to 68 months. The starting dose was 20 mg daily, increasing over a period of 5 weeks up to the daily dose of 400 mg.
3378658|NCT01888913||Adult Women|Adult Women aged 18-50
3378659|NCT01878045||American Indians with type 2 diabetes|previously enrolled in OH95-DK-N037
3378660|NCT01875588||DOD|Participants that are from IDCRP
3378661|NCT01875588||HIV negative controls|Participants that do not have HIV infection
3378662|NCT01875588||HIV positive|Participants that have HIV infection
3378663|NCT01868711|Active Comparator|*Cognitive behavior therapy|Depressed patients will receive 12 virtual sessions of cognitive behavior therapy (CBT) for depression. CBT Includes behavior activation, correcting distorted thoughts, and other tools to reduce symptoms.
3378664|NCT01868711|Other|Supportive psychotherapy|Supportive psychotherapy aims to strengthen the patient's ability to cope effectively with various life stressors. Specifically, in our study, supportive psychotherapy will be geared towards reducing or alleviating symptoms of depression. The sessions will be administered virtually.
3378665|NCT01867411||ex-smokers|former smokers who have quit
3378666|NCT01867411||never smokers|never smoked
3378667|NCT01867411||non-treatment seeking smokers|smokers not interested in quitting smoking
3378668|NCT01867411||Treatment seeking smokers|smokers interested in quitting smoking
3286388|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
3286389|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (5-15 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 5-15 years old on day 0.
3286390|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (5-15 years old)|0 logCCID50/ml in 18 children aged 5-15 years old on day 0.
3286391|NCT01712906|Experimental|3.50±0.25logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 children aged 2-4 years old on day 0.
3286392|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
3286393|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in children (2-4 years old)|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 children aged 2-4 years old on day 0.
3286394|NCT01712906|Placebo Comparator|0 logCCID50/ml in children (2-4 years old)|0 logCCID50/ml in 18 children aged 2-4 years old on day 0.
3286395|NCT01712906|Active Comparator|Attenuated Mumps vaccine in children (2-4 years old)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 children aged 2-4 years old on day 0.
3286396|NCT01712906|Experimental|3.50±0.25logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3378671|NCT01862107||Healthy Volunteer|Any healthy volunteer getting a lumbar puncture done for either clinical care or research purposes.
3378672|NCT01862107||Patient|Any patient getting a lumbar puncture done for either clinical care or research purposes.
3286397|NCT01712906|Experimental|4.25±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3286398|NCT01712906|Experimental|5.00±0.25 logCCID50/ml in infants|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in 16 infants aged 8-23 months old on day 0.
3286399|NCT01712906|Placebo Comparator|0 logCCID50/ml in infants|0 logCCID50/ml in 18 infants aged 8-23 months old on day 0.
3286400|NCT01712906|Active Comparator|Attenuated Mumps vaccine in infants|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in 18 infants aged 8-23 months old on day 0.
3286401|NCT01712919|Experimental|cetuximab|Patients will be given intensity-modulated radiotherapy,2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin,and weekly cetuximab during radiation therapy.
3286402|NCT01712945|Experimental|Palifermin (and Alemtuzumab)|Palifermin (Kepivance®), at the maximum identified tolerated dose will be administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose. Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
3286403|NCT01712945|Placebo Comparator|Placebo (and Alemtuzumab)|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
3286404|NCT01712971||OPD|standard open pancreaticoduodenectomy
3286405|NCT01712971||LPD|laparoscopic pancreaticoduodenectomy
3286406|NCT01712997|Experimental|Combination therapy|combine inhaled iloprost, 10μg, 4-6times/day with bosentan,125mg,po,bid.
3286407|NCT01712997|Active Comparator|monotherapy|Bosentan,125mg,po,bid.
3286408|NCT01713023|Experimental|Glucose solution|Solution containing 75g of glucose diluted in 200 mL of water
3286409|NCT01713023|Experimental|Fructose solution|Solution containing 75g of fructose diluted in 200 mL of water
3286410|NCT01713049|Other|18F-FLT|18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
3286411|NCT01713062||Vitelene|Plasmacup DC® with Vitelene® inlay manufactured by UHMWPE-XE (Ultra High Molecular Weight Polyethylene highly cross-linked with 0.1% Vitamin E) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
3286412|NCT01713062||XLPE|Plasmacup DC® with a standard polyethylene inlay manufactured by UHMWPE-X (Ultra High Molecular Weight Polyethylene highly cross-linked) in combination with one of four different Aesculap® stems (Bicontact®, TRJ®, Metha®, Excia®)
3286413|NCT01713075||Symbicort|
3286414|NCT01713088|Experimental|Multisystemic therapy|MST is a family- and community-based intervention that establishes close contact with families to understand and deal with the factors that cause the young person's antisocial behaviour. The intervention targets the individual's adjustment, family relationships, school functioning and peer group affiliations. Therapists help caretakers develop skills to intervene and operate changes in important domains such as young person's individual adjustment, their family relationships, school functioning, and peer group affiliations.
3286415|NCT01713088|Active Comparator|YOT (usual services)|YOT intervention consisted of services currently available to young offenders in accordance with the Youth Justice Board National Standards.These services included supporting the young person to re-engage with education, with substance misuse problems and anger management; training them in social problem-solving skills; and programs to decrease vehicle-crime, violent-offending and knife crime. The treatments were delivered by professional social workers, specialist therapists or probation officers.
3286416|NCT01713101|Experimental|Early intravenous tranexamic acid administration|"Early intraveous administration of tranexamic acid~(1g IV bolus over 10 minutes followed by 1g slow infusion over 8 hours"
3286417|NCT01713101|Placebo Comparator|Placebo group|Normal saline (placebo) administration instead of tranexamic acid solution
3286418|NCT01713114|Experimental|Low carbohydrate|
3286419|NCT01713114|Experimental|Moderate carbohydrate|
3286420|NCT01713114|Experimental|Higher Carbohydrate|
3286421|NCT01713114|Placebo Comparator|Meal Skipping|
3286422|NCT01713127|Placebo Comparator|Placebo|5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
3286423|NCT01713127|Active Comparator|remifentanil|0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth
3286424|NCT01713140|Experimental|1 strength training set performed until contraction failure|Knee extensions until contraction failure will be performed, using a relative loading of 10 repetition maximum (RM).
3286425|NCT01713153|Experimental|Misoprostol|600 mcg oral misoprostol administered during the third stage of labor
3286426|NCT01713153|Experimental|UnijectTM|10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
3286427|NCT01713166|Active Comparator|Plasmalyte solution|Plasmalyte solution infusion to meet the fluid requirements.
3286428|NCT01713166|Experimental|Hextend|6% Hetastarch administeration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
3286429|NCT01713179|Experimental|ambroxol|"Ambroxol hydrochloride (Mucopect®, trans-4[2-amino-3.5-dibrombenzylamino]-cyclohexanhydro-chloride, 60 mg, Boehringer Ingelheim) was administered orally to subjects in the ambroxol group immediately after initial examination (10 AM).~one dose for one day"
3286430|NCT01713179|No Intervention|control|
3286431|NCT01713192||Cardiac surgery|
3286432|NCT01713218|Experimental|Gemcitabine+Vismodegib|Neoadjuvant chemotherapy combining gemcitabine and Vismodegib during 4 weeks before surgery
3286433|NCT01713231|Active Comparator|standard-dose vitamin D|one group of 30 participants will be randomized to receive vitamin D3 at a dose of 400 international units per day ('standard-dose group').
3286434|NCT01713231|Experimental|high-dose vitamin D|One group of 30 participants will be randomized to receive vitamin D3 at a dose of 2000 international units per day ('high-dose group').
3286435|NCT01713244|Active Comparator|Hepatectomy|Using Hepatectomy for the treatment of advanced HCC
3286436|NCT01713244|Experimental|RFA assisted Hepatectomy|Ablating the liver tissue around the tumor before hepatectomy.
3286437|NCT01713257|Experimental|Immunoenhancing diet|Immunoenhancing diet feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
3286438|NCT01713257|Active Comparator|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
3286439|NCT01713270|Experimental|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter was introduced into each renal artery. This was then maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 60 seconds each were performed in both renal arteries. After renal sympathetic denervation, patients with persistent AF accepted direct-current cardioversion immediately.
3286440|NCT01713270|Active Comparator|drug therapy|Patients in the drug treatment group will be followed-up at 3, 6, 9 and 12 months after randomization. All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. Antiarrhythmic drugs treatment is consistent in both arms.
3286441|NCT01713296|Experimental|Pazopanib|
3286442|NCT01713309|Active Comparator|Filgrastim|Filgrastim 300 microgr/day subcutaneously for 7 days
3286443|NCT01713309|Placebo Comparator|NaCl 0.9%|Corresponding placebo once daily, subcutaneously for 7 days
3286444|NCT01713322|Experimental|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
3286445|NCT01713322|Other|No pain management education|Control - parents receive general information about childhood immunization.
3286446|NCT01713361|Experimental|ISIS-FXIRx Dose 2|Group B: ISIS-FXIRx Dose #2
3286447|NCT01713361|Experimental|ISIS-FXIRx Dose 3|Group C: ISIS-FXIRx Dose #3
3286448|NCT01713361|Active Comparator|Enoxaparin|Enoxaparin (40mg)
3286449|NCT01713374|Active Comparator|Myogenic activation|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of myogenic activation
3286450|NCT01713374|Active Comparator|Cold pressure test|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of cold pressure test
3286451|NCT01713374|Active Comparator|mental stress|Subjects will undergo endothelial function assessment at rest and, after a 45 minutes pause, 1 minute after begin of mental stress
3286452|NCT01713374|Active Comparator|Control|Control visit - no intervention performed - subjects will undergo endothelial function measurement twice at a distance of 45 minutes
3286453|NCT01713387|Experimental|gemcitabine , S-1|Level-2 Gem 800mg/msq, S-1 50mg/msq Level-1 Gem 800mg/msq, S-1 65mg/msq Level 1 Gem 1000mg/msq, S-1 65mg/msq Level 2 Gem 800mg/msq, S-1 80mg/msq
3286454|NCT01713413|Active Comparator|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
3286455|NCT01713413|Active Comparator|nasal cannula|Using first the conventional nasal cannula and 24 h later the Oxymizer
3286456|NCT01713426|Experimental|Qutenza|Cutaneous patch
3286457|NCT01713426|Active Comparator|Pregabalin|Oral capsule
3286458|NCT01713439|Experimental|Injection of allogeneic neuroblastoma cells|Retrovirally transduced allogeneic neuroblastoma cell lines secreting the human interleukin-2 and lymphotactin genes are frozen and, when needed, are thawed, mixed and irradiated. Relapsed or refractory patients are then treated with a course of four injections of their gene-modified tumor cells according to the following schedule: The first two injections will be given at week 1 and week 2. Patients will then have a two-week rest and the remaining two injections will be given at week 4 and week 5. A complete evaluation for evidence of toxicity and response will be performed at week 8 after a 3 week rest. At the 8 week evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received.
3286459|NCT01713452|Active Comparator|Purse string closure|Patients undergo a purse string closure of their old stoma site.
3286460|NCT01713452|Active Comparator|Primary closure|Patients have their stoma sites close primarily with staples.
3286461|NCT01713465|Experimental|1 CBMP|CBMP: Computer based Metabolic syndrome program
3286462|NCT01713478|Experimental|cirrhotic patients|"Study will include 50 cirrhotic patients, divided in 2 subgroups: 25 with alcoholic cirrhosis, and 25 with viral cirrhosis~Routine blood samples~Electrocardiogram (12 leads)~Specific biomarkers: proBNP, troponin, myocardial fibrosis (β cross laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6, IL 10, TNFα); oxidative stress: carbonyl in plasmatic proteins, and the antioxidant capacity of plasma.~Comprehensive Echocardiography"
3286463|NCT01713478|Active Comparator|normal controls|50 normals subjects with the same procedures as cirrhotic patients: echocardiography, ECG, biomarkers
3286464|NCT01713491||Cognitively normal|Patients with IQCODE score of 52 or less
3286465|NCT01713491||Cognitively impaired - no dementia|IQCODE score 53 - 63
3286466|NCT01713491||Demented|IQCODE score 64 or more
3286467|NCT01713504|Experimental|Hypereosinophilic syndrome unexplained|
3286468|NCT01713504|Active Comparator|Hypereosinophilic syndrome explained|
3286469|NCT01713504|Sham Comparator|Normal rate of eosinophilic|
3286470|NCT01713517|Active Comparator|Universal coverage of Long Lasting Insecticidal Nets (LLIN)|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons
3286471|NCT01713517|Experimental|LLIN Plus Indoor Residual Spraying|Distribution of long lasting insecticidal nets to all community members in the study arm allowing for at least one net per 2 persons plus indoor residual spraying with insecticide of interior walls of all houses twice yearly.
3286472|NCT01713543|Experimental|Intervention Group|The intervention consists of a tailored physical therapy focused on progressive strength, balance and gait training for a period of 3 months.
3286473|NCT01713543|No Intervention|Control Group|Usual care by physician.
3286474|NCT01713556|Experimental|Propranolol + reactivation|they have a script-driven mental imagery of the traumatic event white drug
3286475|NCT01713556|Placebo Comparator|Placebo + reactivation|They have a script-driven mental imagery of the traumatic event with placebo
3286476|NCT01713569|Active Comparator|Subject 1|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 1.2 Joules and 30 Watts on the Left side versus 0.9 Joules and 30 Watts on the Right side.
3286477|NCT01713569|Active Comparator|Subject 2|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 1.05 Joules and 25 Watts on the Left side versus 0.75 Joules and 25 Watts on the Right side.
3286478|NCT01713569|Active Comparator|Subject 3|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm depth transducer at 0.45 Joules and 15 Watts on the Left side versus 0.35 Joules and 14 Watts on the Right side.
3286479|NCT01713569|Active Comparator|Subject 4|Ulthera treatment will be administered to both pre-auricular regions using a 10 MHz, 1.5mm depth transducer at 0.25 Joules and 5 Watts on the Left side versus 0.18 Joules and 5 Watts on the Right side.
3286480|NCT01713569|Active Comparator|Subject 5|Ulthera treatment will be administered to both pre-auricular regions using a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus 7 MHz, 4.5mm 0.9 Joules and 25 Watts on the Right side.
3286481|NCT01713569|Active Comparator|Subject 6|Ulthera treatment will be administered to both pre-auricular regions using a 7 MHz, 3.0mm transducer at 0.35 and 14 Watts, and a 4 MHz, 4.5mm depth transducer at 0.9 Joules and 30 Watts on the Left side versus a 7 MHz, 3.0mm depth and 4.5mm depth transducer at 2.0 Joules and 40 Watts on the Right side.
3286482|NCT01713595|Experimental|Hypertonic Saline Aerosol|a single 5ml dose of 7% Saline aerosol
3286483|NCT01713634|Experimental|Low Apro/K Diet|Subjects consume a prescribed diet for 4 days with a low ratio of animal protein to potassium (0.3-0.6 g/mEq).
3286484|NCT01713634|Experimental|High Apro/K Diet|Subjects consume a prescribed diet that has a high ratio of animal protein to potassium (1.0-1.3 g/mEq) for 4 days.
3286485|NCT01713647|Experimental|LOSANET AM PLUS (10/100/12.5 mg) of PHARMALINE, Lebanon|"Subjects will be fasted overnight and receive one tablet by mouth in accordance with randomization table, and blood samples will be taken at specified intervals over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
3286486|NCT01713647|Active Comparator|NORVASC & HYZAAR (100/12.5 mg)|"Subjects will be fasted overnight and receive one tablet of Norvasc &HYZAAR by mouth in accordance with randomization table, and blood samples will be taken over 3 days~intervention: Drug: LOSANET AM PLUS Amlodipine/ Losartan/Hydrochlorothiazide Other Name: NA"
3286487|NCT01713673|Experimental|Active Treatment|Subjects receive Ulthera System Treatments according to the pre-defined Ulthera® System energy settings.
3286488|NCT01713673|Sham Comparator|Sham Treatment|Subjects will receive Sham treatments using the Ulthera® System with the energy set to 0.00 Joules.
3286489|NCT01713699|Other|diagnostic|Using extra CSF material received by clinically indicated lumbar punctures to determine the sensitivity and specificity of CTCs in CSF (5ml CSF). Standard material of 5 ml CSF for cytology and 2 ml CSF for cell count and chemistry is being regularly used and processed.
3286490|NCT01713712|No Intervention|Routine Obstetric Care|
3286491|NCT01713712|Experimental|Nutritional Counseling|Patients will receive an initial 90 minute nutritional consult followed by 60 minute follow up consults every 2 weeks to monitor weight gain and nutritional status.
3286492|NCT01713725|Active Comparator|Omalizumab 300 mg|"Subcutaneous route~300 mg dose (independent from total IgE, weight or high)"
3286493|NCT01713725|Placebo Comparator|Placebo|"Saline serum~Subcutaneous route~0.6 ml saline serum with same volume as an active treatment"
3286494|NCT01713738|Experimental|rituximab|
3286495|NCT01713751|Active Comparator|Interrupted suturing Group|Includes women who have their skin closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
3286496|NCT01713751|Active Comparator|Subcuticular suturing Group|Includes women who have their skin closed with subcuticular stitches using non-absorbable polypropylene [Prolene®].
3286497|NCT01713764|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate diet: carbohydrate intake 10-50 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3286498|NCT01713764|Active Comparator|American Diabetes Association Diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3286499|NCT01713777|Experimental|"Lamotrigine Generic A/Generic B"|"Crossover trial. Each arm will receive generic A for two periods and generic B for two periods."
3286500|NCT01713777|Experimental|"Lamotrigine Generic B/Generic A"|"Crossover trial. Each participant will have two periods of generic A and two periods of generic B"
3286501|NCT01713790|Experimental|Training group|T0 - Intervention program 3x/ week over 10 weeks: Stochastic resonance whole-body vibration + Exergame + leg press - T1
3286502|NCT01713803|Placebo Comparator|Sugar pill|
3286503|NCT01713803|Experimental|buprenorphine and nalaxone|
3286504|NCT01713816||Elderly control|Healthy elderly subjects age and gender matched to the AD cohort, predominantly male
3286505|NCT01713829|Experimental|Cranberry Beverage|Cranberry Beverage is provided in an 8 oz daily beverage consumed once daily for 12 weeks
3286506|NCT01713829|Placebo Comparator|Placebo Beverage|The placebo beverage looks like the active arm and is given in the same way but contains no active ingredient.
3286507|NCT01713842|Experimental|TCZ|Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion
3286508|NCT01713881||post-registry|"Registry Group:~Select 500 consecutive patients from the polyp registry who were found to have a tubular adenoma on a colonoscopy done between 2007-2008 from the polyp registry.~Quantify the completion rate and time between index and surveillance colonoscopy after the establishment of the polyp surveillance program (2006-2013)."
3286509|NCT01713881||pre-registry|Pre-registry Group: Select 380 consecutive patients who were found to have a tubular adenoma on a colonoscopy done between April 2004-Nov 2006.
3286510|NCT01713894|Other|Decision Aid|In this arm of the study, parents will be counseled using a decision aid.
3286511|NCT01713894|Other|Standard|In this arm of the study, parents will be counseled using current standard methods.
3286512|NCT01713907|Experimental|Ulthera® treatment|All enrolled subjects will receive one full face and neck Ulthera® treatment.
3286513|NCT01713920|Experimental|SEVIKAR|Subjects who are eligible for the inclusion and exclusion criteria will be treated with Sevikar 5/20mg for 4 weeks. If subjects fail to reach the SBP threshold of SeSBP≥ 140mmHg after 4-week treatment, they will receive Sevikar 5/40mg for 4 weeks. At the end of 4-week treatment, subjects who fail to reach SBP threshold will receive Sevikar 10/40mg for 4 weeks. Subjects who can reach SBP threshold will continue to treat with current dose until 12 weeks.
3286514|NCT01713959|Experimental|Group A - Split Body Treatment|Active treatment of one axilla with the Ulthera System Treatment; Sham treatment of one axilla.
3286515|NCT01713959|Active Comparator|Group B: Ulthera System Treatment w lido|Subjects receive a bilateral Ulthera System Treatment, with one axilla receiving a subcutaneous lidocaine injection.
3286516|NCT01713972|Experimental|Treatment (dabrafenib, pazopanib hydrochloride)|Patients receive dabrafenib PO BID on days 1-28 (once daily on day 1 and BID on days 3-28 of course 1), and pazopanib hydrochloride PO QD on days 1-28 (days 2-28 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3286517|NCT01713972|Other|Correlative Studies|"Pharmacokinetic studies: Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
3286518|NCT01713985|Active Comparator|Group A|Ulthera System Treatment Right, Thermage Left
3286519|NCT01713985|Active Comparator|Group B|Ulthera System Treatment Left, Thermage Right
3286520|NCT01714011|Active Comparator|Ziprasidone|Ziprasidone is a psychotropic agent with chemical name: 5-[2-[4-(1,2-benzisothiazole-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one.Ziprasidone is a potent antagonist of both serotonin 5-HT2A and dopamine D2 receptors, although its affinity for 5-HT2A receptors is about 10 times higher than for D2 receptors.
3286521|NCT01714011|Active Comparator|Aripiprazole|Aripiprazole is a psychotropic drug that is available as tablets for oral administration. Aripiprazole is 7-[ 4-[ 4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3-4-dihydrocarbostyril. Aripiprazole exhibits high affinity for dopamine D2 and D3, serotonin 5-HT1A and 5-HT2A receptors, moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha 1-adrenergic and histamine H1 receptors and moderate affinity for serotonin reuptake site (Ki = 98nM).
3286522|NCT01714037|Experimental|Cisplatin, Pemetrexed, Debio 0932|Cisplatin, Pemetrexed, Debio 0932
3286523|NCT01714037|Experimental|Cisplatin, Gemcitabine, Debio 0932|Cisplatin, Gemcitabine, Debio 0932
3286524|NCT01714037|Experimental|Docetaxel, Debio 0932|Docetaxel, Debio 0932
3286525|NCT01714050|Experimental|Cognitive-Behavioral Therapy (CBT)|"The CBT is a SAD-tailored version of Beck et al.'s (1979) cognitive therapy for depression called Coping with the Seasons (Rohan, 2008). The rationale addresses environmental changes, thoughts, and behaviors in SAD onset and maintenance. It seeks to change behaviors and thoughts to improve coping with winter. Behaviors that promote enjoyment in the winter are increased. Negative thoughts that interfere with self-esteem and negative thoughts about winter are identified and addressed. A relapse-prevention component addresses early identification of negative anticipatory thoughts about winter and SAD-related behavior changes, using the CBT skills learned to cope with subsequent winter seasons, and development of a personalized relapse-prevention plan. The CBT sessions are administered twice a week over 6 weeks (total of 12 sessions) with 4-8 participants per group. The CBT is led by one of three licensed Ph.D.-level psychologists working on the project."
3286526|NCT01714050|Experimental|Light Therapy (LT)|LT will be initiated at 30-minutes in the morning at home, first thing upon awakening, using a light box with an ultraviolet shield that emits 10,000-lux of white fluorescent light. After the first week, an M.D. light therapy consultant will recommend individually-tailored, clinical adjustments to the duration and timing of light use to maximize response and reduce any reported side effects. For each of the 6-weeks of LT, LT participants will complete a Light Therapy Side Effects Questionnaire to assess side effects attributed to LT. Participants will keep daily LT compliance diaries to record the timing and duration of LT. After the 6-weeks of monitoring, participants may choose to continue using the light box through April. We will offer LT participants who wish to use light therapy in the next fall/winter season access to our light boxes if they agree to followup with a physician or other qualified professional for monitoring and side effects management.
3286527|NCT01714076||cohort isolation|patients with bronchiolitis are cohorted together irrespective of viral agent diagnosed, thus respiratory syncytial virus (RSV)-positive patient stay in the same room as RSV-negative patients
3286528|NCT01714089|Experimental|RNS60 125 ml|125 ml of RNS60 administered weekly by IV infusion
3286529|NCT01714089|Experimental|RNS60 250 ml|250 ml of RNS60 administered weekly by IV infusion
3286530|NCT01714089|Active Comparator|Interferon beta-1a|Weekly dose of 30 mcg Interferon beta-1a (Avonex) administered by intramuscular injection.
3286531|NCT01714102|Placebo Comparator|Placebo|Placebo for 30 days
3286532|NCT01714102|Active Comparator|Resveratrol|1000 mg PO BID for 30 days
3286533|NCT01714128|Other|Optional Diagnostic Imaging|Optional diagnostic imaging FES-PET/CT imaging
3286534|NCT01714141|Experimental|Multi-component, technology based intervention|2 tailored, computer-delivered motivational interviewing sessions targeting adherence to asthma control medications + tailored text messaged reminders to take medications between sessions.
3286535|NCT01714141|Active Comparator|Asthma education active control|Control condition consists of active control matched to intervention for delivery-method and time-- 2 sessions of computer-delivered asthma education + daily text messaged facts about asthma.
3286536|NCT01714154|Experimental|A: setrobuvir|
3286537|NCT01714154|Experimental|B: setrobuvir + DNV/r|
3286538|NCT01714167|Active Comparator|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient plus conventional treatment include rehabilitation
3286539|NCT01714167|No Intervention|conventional treatment|Control group receive conventional stroke treatment that include rehabilitation
3286540|NCT01714180||Obese Patients|
3286541|NCT01714180||Non-obese Patients|
3286542|NCT01714193|Experimental|Canagliflozin + oral contraceptive|Each volunteer will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of an oral contraceptive containing ethinyl estradiol and levonorgestrel in combination with a single dose of canagliflozin.
3286543|NCT01714206|Active Comparator|Treatment A|Each volunteer will receive digoxin once daily on Days 1 through 7.
3286544|NCT01714206|Experimental|Treatment B|Each volunteer will receive digoxin once daily on Days 1 through 7 in combination with canagliflozin (JNJ-28431754) once daily on Days 1 through 7.
3286545|NCT01714219|Experimental|Posterior reconstruction|"New posterior reconstruction, which entails opposition of the median dorsal fibrous raphe solely to the posterior counterpart of the detrusor apron~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
3286546|NCT01714219|No Intervention|No posterior reconstruction|"No posterior reconstruction~Vesicourethral anastomosis using the van Velthoven method~Anterior reconstruction, which involved opposing the anterior detrusor apron to the remaining puboprostatic ligaments and dorsal vascular complex"
3286547|NCT01714258|Experimental|non invasive cardiac output measure|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients 20 times, throughout a period of about 45 min
3286548|NCT01714271|Experimental|Home environs-based lifestyle counseling|Home environs-based lifestyle counseling Involves Spanish-speaking community health workers interacting with intervention subjects in home visits and phone calls - 12 contacts overall. The counseling focuses on promoting subject adherence to the Dietary Guidelines for Americans (DGA) and the Physical Activity Guidelines for Americans (PAGA) with special attention devoted to changing the home environment to make it optimally supportive of the lifestyle choices consistent with the DGA and PAGA. Study participants will also be provided 4 group education sessions that will be devoted to improving subject adherence to the DGA and PAGA.
3286549|NCT01714271|Experimental|Cancer early detection|Cancer Early Detection Spanish-speaking health educators will interact with study participants via a home visit and four telephone calls. The focus of the health education will be on practical strategies to detect cancer early to help prevent death from cancer. Cancer sites of interest will be: breast, cervical, skin, colon, prostate and testicular cancers. In addition, study participants will be provided two group education classes that will focus on the basics of the cancer process and why early detection and intervention can be life-saving.
3286550|NCT01714284|Experimental|Diet and Exercise|
3286551|NCT01714284|Sham Comparator|Informative|
3286552|NCT01714297|Active Comparator|dalteparin 5000IU s.c.|5000IU dalteparin s.c. injected the evening before cemented total hip arthroplasty
3286553|NCT01714297|Placebo Comparator|saline|Syringes of Saline with the same volume as in the dalteparin injections are injected the evenings before total hip arthroplasty. Dalteparin 5000IU are injected 6 hours after surgery and the concomitant 33 days
3286554|NCT01714349|Experimental|Nerve Transfer|Surgical - Nerve transfers for patients with stable cervical spinal cord injuries
3286555|NCT01714375|Active Comparator|QuietDose device VOLUNTARY|"This group of employees will voluntarily use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
3286556|NCT01714375|No Intervention|No QuietDose device|"This group of employees will not use the QuietDose units and maintain use of their regular hearing protection which may be either ear plugs or ear muffs."
3286557|NCT01714375|Active Comparator|QuietDose Device REQUIRED|"This group of employees will be required to use the QuietDose units in place of their regular hearing protection, which may be either ear plugs or ear muffs."
3286558|NCT01714388|Experimental|Remifentanil, Vagotonic response|1 microgram/kg remifentanil given iv over at least 30 sec. at the beginning of induction of general anaesthesia
3286559|NCT01714401|Active Comparator|Salbutamol 2,5 mg|25 mechanically ventilated patients to receive 2,5mg of nebulised salbtamol (Ventolin) duration of nebulisation - 20 minutes
3286560|NCT01714401|Active Comparator|Salbutamol 5mg|25 mechanically ventilated patients 5 mg of nebulised salbutamol (Ventolin) duration of nebulisation - 20 minutes
3286561|NCT01714414|Experimental|FZD 600mg twice daily|FZD 3 tablets (600mg) twice daily / 3TC 1 tablet (150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3286562|NCT01714414|Experimental|FZD 800mg once daily|FZD 4 tablets (800mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3286563|NCT01714414|Experimental|FZD 1200mg once daily|FZD 6 tablets (1200mg) once daily / 3TC 2 tablets (150mg) once daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3286564|NCT01714414|Active Comparator|AZT twice daily|1 tablet Combivir(AZT 300mg/3TC 150mg) twice daily / EFV 1 capsule (600mg) once daily for the duration of 24 weeks
3286565|NCT01714427|Active Comparator|Dexamethasone|
3286566|NCT01714427|Placebo Comparator|Sterile isotonic saline|
3286567|NCT01714440||Transplant Recipients Cohort|Main Study Cohort: Kidney (or kidney-pancreas) transplant recipients. Enrollment for this cohort is closed.
3286568|NCT01714440||Transplant Donors Cohort|Main Study Cohort: The kidney donor for transplant recipients in this study. Enrollment for this cohort is closed.
3286569|NCT01714440||Activity&mRNA Expression Substudy Cohort|A subset of subjects enrolled in the main study who will receive tacrolimus, cyclosporine or mycophenolate as part of maintenance immunosuppression therapy. This group has a prospective observational cohort design. Enrollment into the Activity and messenger ribonucleic acid (mRNA) Expression Cohort, occurring concurrently with enrollment of the rest of the study, will continue until either the required sample size of 600 is achieved or the protocol team terminates enrollment. Participants in the Activity and mRNA Expression Cohort have additional blood draws up to 2 weeks prior to transplant, at week 1, Month 3 and Month 6 post-transplant.
3286570|NCT01714466|Experimental|Part A, arm 1|Evening dose of TF048. Morning dose of TF043
3286571|NCT01714466|Experimental|Part A, arm 2|Evening dose of TF043. Morning dose of TF048
3286572|NCT01714466|Experimental|Part A, arm 3|Evening dose of TF047. Morning dose of TF043
3286573|NCT01714466|Active Comparator|Part A, arm 4|MOVIPREP (Both evening and morning dose)
3286574|NCT01714466|Experimental|Part B, arm 1|IMP selected based on the optimal dosing sequence and volume identified from Part A
3286575|NCT01714466|Experimental|Part B, arm 2|IMP as used in Part B, arm 1, with a differing amount of additional clear fluid being consumed
3286576|NCT01714466|Active Comparator|Part B, arm 3|IMP as used in Part B, arm 1, except for a reduced amount of ascorbate
3286577|NCT01714466|Experimental|Part B, arm 4|MOVIPREP used in both evening and morning dose
3286578|NCT01714479|Placebo Comparator|Load Carriage - Control|Load Carriage - with a calorie-free placebo
3286579|NCT01714479|Experimental|Load Carriage - leucine-enriched nutrition supplement|Load Carriage with leucine-enriched amino acid supplementation
3286580|NCT01714479|Placebo Comparator|Conventional Exercise - Control|Conventional Exercise with a calorie-free placebo
3286581|NCT01714479|Active Comparator|Conventional Exercise - Leucine-enriched Nutrition Supplement|Conventional Exercise with leucine-enriched Amino Acid supplementation
3286582|NCT01714518||ILD diagnosis|Patients subjected to Cryobiopsy and/or VATS for diagnosis of interstitial lung disease
3286583|NCT01714531|Experimental|Telephone-Based Goal Management Training|The GMT intervention targets cognitive deficits in executive functioning that impact a person's ability to carry out daily tasks. Participants learn how to recognize and stop absentmindedness and automatic pilot and how to reduce daily errors and 'slips' through goal setting. The telephone-based GMT condition includes 7 sessions delivered over the phone for 10 weeks.
3286584|NCT01714531|Active Comparator|Telephone-Based Attention-Control|The attention group receives an educational intervention that is matched to the GMT intervention in terms of session length and contact with the study therapist. The telephone-based attention condition includes 7 sessions delivered over 10 weeks. Sessions address education on brain function and cognitive principles of memory, attention, language, perception, and motor skills. Education on stress reduction, sleep hygiene, energy management, exercise, communication, and nutrition are also provided
3286585|NCT01714531|No Intervention|Usual Care Control|Participants in the control group will receive usual care as determined by the treating surgeon. Usual care may include referral to a physical therapist, occupational therapist, psychiatrist, and/or psychologist and utilization of health services will be recorded during follow-up assessments.
3286586|NCT01714557|No Intervention|No prophylaxis|
3286587|NCT01714557|Active Comparator|piperacillin|
3286588|NCT01714557|Experimental|piperacillin/tazobactam|
3286589|NCT01714570|Experimental|piperacillin/tazobactam|
3286590|NCT01714570|Active Comparator|imipenem/cilastatin|
3286591|NCT01714583||High PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) greater than or equal to 12cm.
3286592|NCT01714583||Low PEEP|Cohort of participants with positive end-expiratory pressure (PEEP) less than 12cm.
3286593|NCT01714596|Active Comparator|Oral Antibiotic|Oral Antibiotic Arm; Participants assigned to this group will receive oral antibiotics as prescribed by their treating physician.
3286594|NCT01714596|Active Comparator|IV Antibiotic|Participants assigned to this group will receive intravenous (IV) antibiotics as prescribed by their treating physician.
3286595|NCT01714622||metabolic syndrome|gastric cancer patients with metabolic syndrome
3286596|NCT01714622||metabolic disease|gastric cancer patients with metabolic disease
3286597|NCT01714622||normal|gastric cancer patients without metabolic syndrome or metabolic disease
3286598|NCT01714648|Experimental|OHSS high risk patients|Triptorelin 0.2 mg
3286599|NCT01714661|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3286600|NCT01714661|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3286601|NCT01714661|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
3286602|NCT01714674|Placebo Comparator|Placebo beverage|the impact of placebo (no active substance) on exercise-induced cTnT release
3286603|NCT01714674|Active Comparator|Dietary nitrate beverage|The impact of dietary nitrate (active substance) on exercise-induced cTnT release
3286604|NCT01714700|Active Comparator|High protein diet, Resistance exercise|High protein diet, Resistance exercise total calories 2400 Kcal/day, 55% carbohydrate, 30% protein, and 15% fat
3286605|NCT01714700|Placebo Comparator|Standard diet, Resistance exercise|total calories 2400 Kcal/day, 60% carbohydrate, 15% protein, and 25% fat; ST group
3286606|NCT01714713|Experimental|EVP-6124 low dose|low dose Tablet, Once Daily, Day 1 through Day 182
3286607|NCT01714713|Experimental|EVP-6124, high dose|high dose Tablet, Once Daily, Day 1 through Day 182
3286608|NCT01714739|Experimental|Part 1|Dose Escalation and Initial Signal Detection in Multiple Solid Tumors - Nivolumab with Lirilumab
3286609|NCT01714739|Experimental|Part 2 and 3: Cohort Expansion|In platinum-refractory recurrent or metastatic SCCHN - Nivolumab with or without Lirilumab
3286610|NCT01714739|Experimental|Part 4: Cohort Expansion|Additional Signal Detection in Solid Tumors - Nivolumab with Lirilumab (Study Part 4 Removed; No Subjects Enrolled)
3286611|NCT01714739|Experimental|Part 5 and 6|Safety Lead-In and Additional Signal Detection in Solid Tumors -- Nivolumab Plus Ipilimumab with Lirilumab (Study Part 6 Removed; No Subjects Enrolled)
3286612|NCT01714752|Experimental|exercise|Patients perform exercise and pression measure is performed
3286613|NCT01714765|Other|Dovitinib and Everolimus|No Arms
3286614|NCT01714778||e-Cigarette|Smokers attempting to quit with behavioural support and e-Cigarettes.
3286615|NCT01714791|Active Comparator|Usual care|Patients following the outpatient cardiac rehabilitation program.
3286616|NCT01714791|Experimental|Usual care and Osteopathic treatment|Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.
3286617|NCT01714817|Experimental|BMS-188667 + Mycophenolate mofetil + Prednisone|BMS-188667 30 mg/kg injection by intravenous on Days 1,15, 29, and 57, followed by a weight-tiered dose approximating 10mg/kg injection by intravenous every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 weeks
3286618|NCT01714817|Placebo Comparator|Placebo + Mycophenolate mofetil + Prednisone|Placebo matching with BMS-188667 injection by intravenous on Days 1,15, 29, and 57, followed by every 4 weeks, Mycophenolate mofetil 1.5 g tablet by mouth and Prednisone up to 60 mg tablet by mouth Daily for 104 Weeks
3286619|NCT01714830|Sham Comparator|sham group|the same protocol is applied but with the probe being turned off.
3286620|NCT01714830|Sham Comparator|treatment group|patients will be treated by ESWT once a week for 4 weeks
3286621|NCT01714843|Experimental|ASP0456 lowest dose group|oral
3286622|NCT01714843|Experimental|ASP0456 low dose group|oral
3286623|NCT01714843|Experimental|ASP0456 middle dose group|oral
3286624|NCT01714843|Experimental|ASP0456 high dose group|oral
3286625|NCT01714843|Placebo Comparator|placebo group|oral
3286626|NCT01714856|Experimental|Test Product|Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fed conditions
3286627|NCT01714856|Experimental|Reference Product|Single oral dose of REQUIP XL Tablets 2mg under fed conditions
3286628|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
3286629|NCT01714882|Experimental|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
3286630|NCT01714882|Active Comparator|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
3286631|NCT01714895|Other|High plasma insulin-Low plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a High insulin glucose clamp and on the second day a Low insulin glucose clamp (sequence 'AB')
3286632|NCT01714895|Other|Low plasma insulin-High plasma insulin|Seven out of the 14 subjects recruited in the study have been randomized to receive on the first study day a Low insulin glucose clamp and on the second day a High insulin glucose clamp (sequence 'BA')
3286633|NCT01714908|Experimental|Erlotinib w Concurrent Radiotherapy|erlotinib 150mg oral daily up to 2 years concurrent radiotherapy total dose 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, and 5 fractions per week.
3286634|NCT01714908|Active Comparator|etoposide/cis-platin (EP) w Concurrent Radiotherapy|etoposide 50mg/m2 on D1-5 and D29-33 cis-platin 50mg/m2 on D1, D8, D29 and D36 concurrent radiotherapy total 60-66 Gray (Gy) in 2 Gray (Gy) fractions. One fraction per day, 5 fractions per week.
3286635|NCT01714934||IPF|IPF patients diagnosed according to clinical and radiological findings
3286636|NCT01714934||NON IPF|Other interstitial lung diseases such as sarcoidosis or hypersensitivity pneumonitis diagnosed as per clinical and radiological findings
3286637|NCT01714960|Experimental|Healthy volunteers low dose|MRZ-99030 eye drops (5mg/mL), 1-3 drops three times per day, duration: 16 days.
3286638|NCT01714960|Experimental|Healthy volunteers high dose|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
3286639|NCT01714960|Experimental|Glaucoma patients|MRZ-99030 eye drops (20mg/mL), 1-3 drops three times per day, duration: 16 days.
3286640|NCT01714960|Placebo Comparator|Placebo|Placebo eye drops, 1-3 drops three times per day, duration: 16 days.
3286641|NCT01714973|Experimental|ST266 intact|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The first cohort will receive ST266 and saline placebo applied to intact skin beginning immediately following the first radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
3286642|NCT01714973|Experimental|ST266 inflamed|Ten (10) patients will be randomized before the first radiation treatment to receive ST266 (4ml) and saline placebo (4ml), one to the medial segment and the other to the lateral segment. The area of the breast will be divided into two, roughly equal parts, medial and lateral. The randomization scheme will be equal in each of two cohorts. The second cohort will receive ST266 and saline placebo applied to inflamed skin (after inflammation is first noted) beginning immediately following the radiation treatment, to continue immediately following each of ten (10) consecutive radiation treatments.
3286643|NCT01714986|Active Comparator|Affect School|Psychological group education intervention
3286644|NCT01714986|Active Comparator|Body Awareness Therapy|Physiotherapeutic psychosomatic intervention
3286645|NCT01714999|Experimental|Bursectomy: Vienna|At the Department of Trauma Surgery, Medical University of Vienna, bursectomy is considered the gold standard in case of traumatic laceration of the OB or PB bursa.
3286646|NCT01714999|Experimental|Bursal reconstruction: Munich|At the Department of Trauma Surgery, Medical University of Munich, the treatment regime is a primary bursa-preserving therapy.
3286647|NCT01715012|Experimental|ST266|ST266 sprayed to the skin graft and donor site
3286648|NCT01715012|Placebo Comparator|Saline|Saline (placebo)sprayed to the skin graft and donor site
3286649|NCT01715025|Experimental|E2/Nomac|Women with demonstrated HMB at baseline will be assigned to 3 cycles of a E2/Nomac combined pill 1 daily for 24 days followed by 1 placebo pill daily for 4 days per cycle.
3286650|NCT01715038|Experimental|Comprehensive|"Comprehensive LNS: LNS-PLW provided daily to mothers during pregnancy and postpartum lactation (a total of at least 11 months, starting by 20 weeks gestation and ending at 6 months post-partum) and LNS developed for infants and young children (LNS-child) provided daily to their infants (beginning at 6 months of age for a period of 18 months i.e., from 6-24 months of age)."
3286651|NCT01715038|Experimental|Child-only LNS|"Child-only LNS: Daily LNS-child supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
3286652|NCT01715038|Experimental|Child-only MNP|"Child-only MNP: Daily MNP supplementation of the child starting at 6 months of age and ending at 24 months of age (18 months total). Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum."
3286653|NCT01715038|Active Comparator|Control: IFA|Control: No additional nutrient supplementation for the child will be provided through the study, but the regular nutrition education and visits provided by the program frontline staff will continue. Women will be provided with iron and folic acid (IFA) tablets during pregnancy and for 3 months postpartum.
3286654|NCT01715051|Active Comparator|D-serine|Participants randomized to D-serine will receive 500 mg tablets of D-serine based on the participant's weight in addition to weekly cognitive behavioral therapy (CBT). The number of capsules prescribed will be based on the target ~60 mg/kg per day dose. In practice, the mg/kg daily dose will range between approximately 55 mg/kg and 65 mg/kg. Dosing will be bid.
3286655|NCT01715051|Placebo Comparator|Placebo|The number of placebo capsules prescribed to a study participant per day will be based on the participant's weight and will be bid dosing to match the dosing of D-serine.
3286656|NCT01715077|Experimental|Ipilimumab|The recommended induction dose of ipilimumab is 3 mg/kg administered intravenously over a 90-minute period every 3 weeks for a total of four doses, as guided by laboratory tests and patient assessment.
3286657|NCT01715090|Experimental|Web-based insulin titration|An online web-based insulin titration algorithm to guide patients in self-titration
3286658|NCT01715090|No Intervention|Standard care|
3286659|NCT01715103|Other|Healthy women volunteers|Healthy women volunteers with vaginal swabs by washing and cytobrush
3286660|NCT01715103|Other|HIV-1 infected women|HIV-1 infected women with vaginal swabs by washing and cytobrush
3286661|NCT01715116|Experimental|Enhanced ICD programming|
3286662|NCT01715142|Experimental|Gemcitabine+Abraxane|Chemotherapy combining gemcitabine and Abraxane during 4 weeks (1 cycle) before surgery (cohort 1: resectable patients) and during at least 8 weeks (2 cycles or more in case of response of stable disease) (cohort 2: locally advanced and metastatic patients)
3286663|NCT01715155||Female patients diagnosed with metastatic breast cancer|Patients newly diagnosed with metastatic breast cancer, either De Novo or having progressed from a non-metastatic stage.
3286664|NCT01715168|Active Comparator|DOXIL/CAELYX or Doxorubicin Hydrochloride (Lipspome)|Current Standard of care and/or reference product in Europe (Caelyx) and US (Doxorubicin Hydrochloride (Liposome) and Doxil)
3286665|NCT01715168|Experimental|ATI-0918|Investigational drug arm which will be compared to Doxil/Caelyx and Hydrochloride Doxorubicin (Liposome) arms for bioequivalence analysis
3286666|NCT01715181|No Intervention|Usual care|Individuals will receive usual care
3286667|NCT01715181|Experimental|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
3286668|NCT01715194|Active Comparator|Telemedicine intervention|"In the telemedicine intervention arm, a telemetry device is instructed and attached to the CPAP. Patients are instructed to use CPAP every night. Data of the CPAP are downloaded to the internet once daily. On week days, a nurse is checking the downloaded data three times per week. The nurse contacts the patient if~CPAP was used <4h/ night for 2 consecutive night~the median leakage was above 0.4 L/sec on 2 consecutive nights The nurse informs the patient of the problem observed, asks for explanations and gives advice on possibilities to solve the problem. The common problems and the respective solutions are discussed according to the ELF facts sheet (Dry mouth/throat, nasal congestion, skin irritation, conjunctivitis, headache, loss of benefits, appendix 1). The patient is encouraged to use CPAP every night. In the case of regular use and acceptable leakage, a congratulatory message is sent to the patient via sms or e-mail (for procedural rules, see appendix 4)."
3286669|NCT01715194|No Intervention|Control (without telemedicine)|In the control arm, no device is attached to the CPAP machine, but data stored in the CPAP machine are collected at the follow-up visit after 1 month of CPAP use.
3286670|NCT01715220|Active Comparator|Sublingual nitroglycerine|Sublingual nitroglycerine followed by pain assessment and if necessary second dose of sublingual nitroglycerine
3286671|NCT01715220|Placebo Comparator|placebo|sublingual placebo followed by pain assessment and if necessary second dose of sublingual placebo
3286672|NCT01715246|Placebo Comparator|Starter infant formula without HMO|Volumes of feed depend on age, weight and appetite.
3286673|NCT01715246|Active Comparator|Starter infant formula with 2 HMOs|Volumes of feeds depend on age, weight and appetite
3286674|NCT01715246|No Intervention|Breasfed reference group|
3286675|NCT01715259|Experimental|Abiraterone acetate|
3286676|NCT01715272|Active Comparator|Fleet enema|This group will receive Fleet enema as their treatment
3286677|NCT01715272|Experimental|TF037|This group will receive TF037 as their treatment
3286678|NCT01715311|Experimental|Indacaterol|Indacaterol once daily
3286679|NCT01715311|Placebo Comparator|Placebo|Placebo for indacaterol and placebo for tiotropium once daily
3286680|NCT01715311|Active Comparator|Tiotropium|Tiotropium
3286681|NCT01715324|Experimental|Growth Hormon|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.
3286682|NCT01715324|No Intervention|Control|The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).
3286683|NCT01715337|Other|pulmonary rehabilitation|
3378673|NCT01861314|Experimental|Treatment (bortezomib, sorafenib tosylate, decitabine)|"STEP A: Patients receive bortezomib SC on days 1 and 4, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~STEP B: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 9-18 or 12-21.~STEP C: Patients receive bortezomib SC on days 1, 4, and 8 or 1, 4, 8 and 11, sorafenib tosylate PO BID on days 1-14, and decitabine IV over 1 hour on days 5-14.~Treatment repeats every 28 days for up to 4 courses in the absence of unacceptable toxicity. Patients achieving CR or CRi receive maintenance therapy comprising decitabine IV on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3378674|NCT01859299||Affected|Participants with various types of uveitis
3378675|NCT01859299||Healthy controls|Participants without uveitis
3378676|NCT01851447||Fragile Sarcolemmal Muscular Dystrophy|patients with early adulthood or late onset of a genetic disorder FSMD (LGMD 2B-F, I, L, MM, BMD and MMD3)
3286684|NCT01715350|Placebo Comparator|Placebo group|"• Drug : Placebo 2 tablet~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3286685|NCT01715350|Experimental|Dose group 1|"Drug : Placebo 1 tablet + Study drug 1 tablet~Study drug(650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3378677|NCT01851434||healthy volunteers|age- and sex-matched to the participants with unilateral optic neuritis and a brain MRI suggestive of MS
3378678|NCT01851434||Patients with unilateral optic neuritis|Recruitment will proceed until 10 participants with a brain MRI suggestive of MS (obtained at any time point during the study) have completed the study.
3378679|NCT01851395||1/Thoracic malignancies|Patients with histologically or cytologically confirmed metastatic NSCLC, SCLC, EPCC, pNET, thymic epithelial tumor (thymoma, thymic carcinoma) or mesothelioma.
3378680|NCT01851395||2/Genitourinary malignancies|Patients with genitourinary malignancies
3286686|NCT01715350|Experimental|Dose group 2|"Drug : Study drug 2 tablet~Study drug (650-mg PM012 tablet)~The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water."
3286687|NCT01715363|Experimental|FOLFOX + surgery + FOLFOX|"Systemic chemotherapy (modified FOLFOX 4) 48 hours before surgery~resection of the colorectal tumor during surgery~Resumption of FOLFOX within the month after surgery (post operative administration of 4 course of treatment and assessment of the response)"
3286688|NCT01715376||Integrative Chinese and western medicine|Integrative Chinese and western medicine group treat with western medical therapy for CHD refering to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.TCM should be confirmed by the physicians, according to the syndrome differentiation and the treat plan recommended in this study.
3286689|NCT01715376||Western medicine|western medical therapy for CHD can refer to the 'Chronic stable angina pectoris diagnosis and treatment guide'which is published by Chinese society of Cardiology, Chinese Medical Association in March, 2007, including the anti-ischemia treatment(nitric acid ester,β-blocker,calcium antagonist,ACEI), anti platelet therapy(aspirin and/or clopidogrel) and other statins.
3378681|NCT01851395||3/ACT|Patients treated with an adoptive cellular therapy
3378682|NCT01851395||4/Ovarian|Patients with ovarian cancer
3378683|NCT01851382||Cohort 1|Healthy volunteers.
3378684|NCT01850004|Experimental|Dasatinib|Dasatinib 50, 80, 100, 140, 180 mg tablets by mouth, once daily, up to 60 months
3378685|NCT01849263|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease at the end of course 2 may continue on therapy until the end of course 5 at the discretion of the treating physician.
3378686|NCT01844505|Experimental|Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab|Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Ipilimumab 0 mg/kg solution intravenously on weeks 1, 4 and Placebo matching with Nivolumab on weeks 4 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3378687|NCT01844505|Experimental|Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab|Nivolumab 1 mg/kg solution intravenously combined with Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses then Nivolumab 3 mg/kg solution intravenously every 2 weeks plus Placebo matching with Nivolumab on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
3378688|NCT01844505|Experimental|Arm C: Ipilimumab+Placebo for Nivolumab|Ipilimumab 3 mg/kg solution intravenously every 3 weeks for a total of 4 doses plus Placebo matching with Nivolumab 0 mg/kg solution intravenously on weeks 3 and 5 for cycles 1 and 2, until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends (Placebo matching with Nivolumab is no longer required)
3378689|NCT01834001||1/Untreated prostate cancer|Patients with untreated prostate cancer
3378690|NCT01834001||2/Radiotherapy treated prostate cancer|Patients with prostate cancer who have already received definitive radiotherapy and have experienced biochemical failure
3378691|NCT01829724||Healthy volunteer|The control groups for each participant cohort will consist of up to 50 individuals spanning Objectives 1 and 2, for a total recruitment of up to 100 healthy volunteers within the same age range.
3378692|NCT01829724||Individuals with childhood-onset brain or peripheral injury|The childhood-onset brain injury group 120 individuals spanning the three objectives.
3378693|NCT01829568|Experimental|Treatment (lenalidomide, ibrutinib, and rituximab)|Patients receive lenalidomide PO QD on days 1-21 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 18 courses in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 and once weekly at weeks 13, 21, 29, and 37.
3378694|NCT01809704||Normal|Normal results from clinical exam and free of ocular pathology.
3286690|NCT01715389|Experimental|Intervention|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
3286691|NCT01715389|No Intervention|Control|The control group will be signed up for MyChart but not use the MyAsthma Patient Portal. This group will be referred to asthma educational content on the CHOP website, complete study measures and otherwise, receive standard care.
3378695|NCT01809704||Glaucoma|Clinical exam results consistent with glaucoma and visual field defects consistent with glaucoma.
3378696|NCT01809704||Retina|Clinical exam results consistent with retina pathology
3378697|NCT01809288||1|Healthy African, African-American, and white women between 30 and 65 years of age who are federal employees or contractors.
3286692|NCT01715402||operated patients|this cohort includes patients who underwent a liver surgery whatever the pathology and whatever the surgical procedure
3286693|NCT01715428||Liraglutide|administration of liraglutide at 1.2 mg/daily
3286694|NCT01715441|Active Comparator|Irinotecan monotherapy|Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression.
3286695|NCT01715441|Active Comparator|Sorafenib monotherapy|Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression
3286696|NCT01715441|Experimental|Sorafenib and irinotecan combination|"Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m² at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m² at C3 in the same conditions~Oral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
3286697|NCT01715480|Experimental|Broccoli sprout homogenate ingestion|Subjects will ingest broccoli sprout homogenate in the form of a shake.
3286698|NCT01715493|Experimental|Lysozyme 90 mg|
3286699|NCT01715493|Placebo Comparator|Placebo|
3286700|NCT01715506|Experimental|Educational intervention|Educational intervention with two days of lecture/course for the whole staff in the selected department in each nursing home and six monthly sessions of counselling in smaller groups
3286701|NCT01715519|Experimental|Treatment (Viibryd)|10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.
3286702|NCT01715519|Placebo Comparator|Placebo|will be compared to the treatment group (viibryd)
3286703|NCT01715532|Experimental|Huachansu + TACE|Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
3286704|NCT01715532|Active Comparator|TACE|Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment.
3286705|NCT01715545||day-3 poor quality embryos|
3286706|NCT01715545||developmental stage|day3 poor quality embryos day4 morular day-5/6 blastocyst
3286707|NCT01715558||RYTHMIQ study group|
3286708|NCT01715558||Historical control from OPTI-MIND|
3286709|NCT01715584|Other|Angiotensin Converting Enzyme Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)will make up this arm.~Preoperative Exposure to any of the following Angiotensin Converting Enzyme Inhibitors Enalapril (Vasotec/Renitec) Ramipril (Altace/Prilace/Ramace/Ramiwin/Triatec/Tritace) Quinapril (Accupril) Perindopril (Coversyl/Aceon) Lisinopril (Listril/Lopril/Novatec/Prinivil/Zestril) Benazepril (Lotensin) Imidapril (Tanatril) Zofenopril (Zofecard) Trandolapril (Mavik/Odrik/Gopten) Fosinopril (Fositen/Monopril)"
3286710|NCT01715584|Other|Angiotensin Receptor Blocker Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients exposed to Angiotensin Receptor Blocking Agents (ARBs).~Preoperative Exposure to any of the following Angiotensin II Receptor Blocking Agents Losartan(Cozaar) Candesartan (Atacand) Valsartan (Diovan) Irbesartan (Avapro) Telmisartan (Micardis) Eprosartan (Teveten) Olemisartan (Benicar) Azilsartan (Edarbi)"
3286711|NCT01715584|Other|Non ACE/ARB Exposed|"Sevoflurane/oxygen/air/nitrous oxide~Hypertensive patients not exposed to angiotensin converting enzyme inhibitors or Angiotensin receptor blocking agents will be put into this arm."
3286712|NCT01715597|Experimental|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 2hours before the operation
3286713|NCT01715597|Placebo Comparator|Control|Normal saline 500ml IV infusion for 2hour
3286714|NCT01715610|Active Comparator|Antibiotic Clavulin or Clindamycin|Patient's in this arm are randomized by random-number generator to receive antibiotics. This is for a 7 day course of antibiotics. Those that are allergic to penicillin will receive clindamycin. Randomization occurs after knowledge of the patient's allergy status.
3286715|NCT01715610|Placebo Comparator|Placebo|Patient's randomized to this arm post-drainage will receive placebo and not receive antibiotics
3286716|NCT01715623||Children with HSP|children with Purpura of Henoch-Schönlein with or without renal complication
3286717|NCT01715623||healthy volunteers|healthy volunteers without allergy
3286718|NCT01715623||subjects with allergy|subjects with peanut allergy or hymenoptera venom allergy
3286719|NCT01715623||lymphoma|lymphoma-proliferation with chromosome 14 translocation
3286720|NCT01715636|Other|Eviplera|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
3286721|NCT01715649|No Intervention|Control-usual care|Nurse care coordination in a telephonic diabetes disease management program
3286722|NCT01715649|Experimental|Intervention paired testing and remote monitoring|Telehealth remote patient monitoring, structured blood glucose and usual care Paired testing-weekly remote monitoring Data analysis Virtual visits in EHR
3286723|NCT01715662|Experimental|Wii.n.Walk|Subjects (n=12) in the experimental arm (Wii.n.Walk) will be trained using the Wii Fit for 40-minute sessions, 3 times a week for a period of 4 weeks. Subjects will stand on the Wii Fit balance board and interact with the games through weight shifting or using the Wii remote controller. The intervention protocol includes: 1) Yoga (static single and double leg exercises), 2) Balance games (lateral and poster/anterior weight shifting exercises in standing), 3) Aerobics (running on spot and step class), and 4) Strength training (dynamic single and double leg exercises). The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic training sessions, a trained research assistant will administer the intervention and will provide external cueing and correction of the pose if the participants use unsafe technique.
3286724|NCT01715662|Placebo Comparator|Control|Subjects (n=12) in the control arm will play cognitive computer games using Wii Big Brain for the same frequency and duration as the Wii.n.Walk arm. The sessions will start in the clinic with a group of 3 participants and will graduate to individualized in-home training starting from week 2. For the in-clinic sessions, a research assistant will administer the intervention and will provide supervision. Wii Big Brain is a low-cost commercially available gaming software to improve cognitive function.
3286725|NCT01715675|Active Comparator|plant stanol|
3286726|NCT01715675|Placebo Comparator|control|
3286727|NCT01715688|Active Comparator|Alkalinized lidocaine|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with alkalinized lidocaine. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
3286728|NCT01715688|Placebo Comparator|Saline|"The endotracheal tube cuff will be pre-filled at least 90 minutes before intubation with saline. Endotracheal tube cuff will be emptied before intubation and then re-filled with the same mixture following intubation to secure the position of the endotracheal tube. (cuff will be inflated until there is no air leak around the tube).~During emergence, when the expired fraction of desflurane reaches 0.2 MAC, the patient will be asked to open his eyes every 30 seconds. Any coughing effort before 0.2 MAC will be considered as a treatment failure and the patient will be treated according to the attending anaesthesiologist."
3286729|NCT01715701|Experimental|Paravertebral nerve blockade|A multilevel thoracic paravertebral nerve block will be performed by the anaesthesiologist prior to the induction of general anesthesia. Prior to the block, the anaesthesiologist will locate and mark each level and then, infiltrate the skin with lidocaine 2% (0.5-1 mL). Subsequently, using a Tuohy needle 22G, 5 mL of ropivacaine 0.5% will be injected at each level between T4 and T8. At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
3286730|NCT01715701|Active Comparator|Intercostal nerve blockade|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will also infiltrate the skin with lidocaine 2% (0.5-1 mL). A multilevel intercostal nerve block will be performed by the surgeon at the end of surgery before skin closure. Five mL of ropivacaine 0.5% will be injected at each level between T4 and T8. A PCA device will be installed upon arrival in the recovery room.
3286731|NCT01715701|Active Comparator|Patient Controlled Analgesia (PCA)|Prior to the induction of general anaesthesia, a paravertebral block will be simulated by measuring, marking the patient's skin and applying mild pressure at each level (T4-T8). To preserve the blind, the anaesthesiologist will infiltrate the skin with lidocaine 2% (0.5-1 mL). At the end of surgery, before skin closure, a multilevel intercostal nerve block will be performed by the surgeon using 5 mL of saline at each level between T4-T8. A PCA device will be installed upon arrival in the recovery room.
3286732|NCT01715714|Active Comparator|Statin Recapture Therapy|Oral statin reload of patients at 12 and 2 hours before CABG using the maximal dose of the chronically prescribed statin* on admission. (*simvastatin 80 mg, atorvastatin 80 mg, fluvastatin 80 mg or pravastatin 40 mg)
3286733|NCT01715714|Placebo Comparator|Placebo|Placebo given orally 12 hrs and 2 hrs before CABG
3286734|NCT01715727||Parkinson's Disease for follow-up|"Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Early to moderate stage defined as Hohen and Yahr stage 1-3,"
3286735|NCT01715727||"Parkinsonss Disease with severity match"|"Parkinsonss Disease with severity match: 30 subjects~Patients should fulfill the National Institute of Neurological Disorders and Stroke in USA ( NINDS ) Diagnostic Criteria for Parkinson Disease(37) for probable PD, except for the age of onset.~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent.~Severity matched with PSP (subjects = 15)/MSA (subjects= 15), the severity was judged by Hohen and Yahr stage"
3286736|NCT01715727||Healthy age matched controls|"Healthy age matched controls: subjects = 112~Healthy subjects without a clinically significant abnormal laboratory values, and/or clinically significant or unstable medical or psychiatric illness.~Able to understand and provide signed informed consent.~Age range and gender matched with Parkinsonss Disease for follow up."
3286737|NCT01715727||Parkinson Plus Syndrome Group M|"MSA Patients should fulfill the NINDS Consensus statement for the clinical diagnosis of probable MSA~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent"
3286738|NCT01715727||Parkinson Plus Syndrome Group P|"PSP Patients should fulfill the NINDS-SPSP and Litvan criteria(4) for probable PSP~Able to tolerate the disability during the drug-off state, at least for 12 hours.~Able to understand and provide signed informed consent."
3286739|NCT01715740|Experimental|Chinese herbal medicine (CHM)|Subject in CHM group will receive CHM capsules, 8 capsules (4 gm) four times a day, total 16 gm a day, combined with levocetiricine 1PC once a day for 1 month.
3286740|NCT01715740|Placebo Comparator|Control|Subjects in control group will receive the placebo capsules, which has the similar look, smell and taste. The dosage, frequency and duration are the same as CHM group, in which 8 placebo capsule (4gm) 4 times a day, total 16 gm a day, combined with levocetiricine 1PC once a day, for 1 month.
3286741|NCT01715753|Active Comparator|Weight Loss Control|Diet counseling and group education lessons. Subjects follow a calorie-reduction diet for a weight loss of ≥10%.
3286742|NCT01715753|Experimental|Weight Loss-High Protein|Protein supplementation. Subjects follow a calorie-reduction diet for a weight loss of ≥10%, with a high proportion of protein, including substantial amounts of supplemental protein provided as lean beef. Intakes of > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
3286743|NCT01715779||Patients who experienced a thromboembolic event|Patients who experienced a thromboembolic event during participation in the ENABLE clinical trials.
3286744|NCT01715792||Group 1|Subject defined as acceptable in the CPRD GOLD with at least one solid organ transplant rejection reported during the overall study period (01 September to 31 October 2010).
3286745|NCT01715818|Experimental|Aleglitazar|
3286746|NCT01715818|Placebo Comparator|Placebo|
3286747|NCT01715844|Active Comparator|L-citrulline|3-gr/day of L-citrulline effervescent powder mix
3286748|NCT01715844|Placebo Comparator|Placebo|3 gr of Placebo/day matching L-citrulline effervescent powder
3286749|NCT01715870||"Population of the Epidemiological study on AMD."|
3286750|NCT01715909|Experimental|Oseltamivir: Standard dose|Participants will receive standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight. Infants <1 year of age will receive oseltamivir at a dose of 3 milligrams per kilogram (mg/kg).
3286751|NCT01715909|Experimental|Oseltamivir: Triple dose|Participants will receive three times the standard dose of oseltamivir capsules or suspension orally for 5 to maximum of 20 days depending on weight and age. Infants <1 year will receive standard dose at 3 mg/kg.
3286752|NCT01715922|Other|oral treatment|"Drug: Fluconazole and flucytosine~Induction treatment for 2 weeks:~Fluconazole (1600mg/j) + flucytosine (100 mg/kg/j) lumbar punctures to control intracranial pressure Consolidation treatment for 8 weeks: fluconazole (800 mg/j)"
3286753|NCT01715935|Experimental|everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
3286754|NCT01715961|Other|anthropometric measurement|"The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months~anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)~albuminemia, transthyretin, orosomucoid, CRP~functional test to attest the muscular strength: hand grip test, unipodal test, up and go test~hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2~OS and PFS at 18 and 24 months~GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis"
3286755|NCT01715974|Placebo Comparator|CONTROL|patients with recurrent implantation failure treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
3286756|NCT01715974|Experimental|G-CSF group|patients with recurrent implantation failure treated with G-CSF (60 micrograms/day) from the day of embryo transfer through the day of beta hCG test
3286757|NCT01715987||Tenofovir Disoproxil Fumarate|Patients who are taking Tenofovir Disoproxil Fumarate.
3286758|NCT01715987||Entecavir|Patients who are taking Entecavir.
3286759|NCT01716000|Experimental|2 mL vaginal gel|2 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
3286760|NCT01716000|Experimental|4 mL vaginal gel|4 mL gel inserted vaginally for completion of vaginal gel imaging and computer aided self interview.
3286761|NCT01716026|Active Comparator|3 Month Load with 9 month p.r.n.|3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit
3286762|NCT01716026|Experimental|Single Dose Load Phase|Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol
3286763|NCT01716091||saline irrigation|irrigation group:saline irrigation after uterine wall closed control group:no irrigation after uterine wall closed
3286764|NCT01716130||IM vaccine in the past 3 years|Those subjects that received the Fluzone ID influenza vaccine, and reported having received the IM influenza vaccine in the past three years.
3286765|NCT01716130||no IM vaccine in the past 3 years|Patients that received the Fluzone ID vaccine and reported not receiving the IM influenza vaccine in the past 3 years.
3286766|NCT01716130||vaccine administrators|Those experienced vaccine administrators that administered the Fluzone ID vaccine, and were then surveyed concerning safety and overall satisfaction with the ID vaccine in comparison to the IM vaccine.
3286767|NCT01716143|Other|catheter ablation|
3286768|NCT01716182||transacral lumbar interbody fusion procedure|
3286769|NCT01716182||transforaminal lumbar interbody fusion procedure (TLIF)|
3286770|NCT01716247|Experimental|pts at risk for breast cancer|Women at increased risk for breast cancer who are being referred for screening MRI will be offered and consented for CESM at the same time. The 2 examinations will be performed on the same day when at all possible and if not we will make every attempt to perform CESM before MRI. Patients with outside MRI performed within 30 days and of adequate quality will also be eligible for CESM.
3286771|NCT01716260||Chloroquine and Primaquine|Chloroquine (CQ)10mg/kg for day 1, 2 and 5mg/kg for day 3 Primaquine (PQ)0.25mg/kg/day for 14 days
3286772|NCT01716273|Experimental|Chronic & Acute infected wounds|Wound will be cleaned with normal saline or tap water and Granulated sugar will be applied directly to the wound and covered with an absorbent pad and held in place with a bandage and tape.
3286773|NCT01716273|Active Comparator|Chronic and Acute infected wounds|Wound will be cleaned with normal saline or tap water and an appropriate debridement dressing (Aquacel or Sorbsan) is applied to the wound and secured with a bandage and surgical tape.
3286774|NCT01716286|Experimental|yoghurt type|low fat yoghurt vs. essence yoghurt
3286775|NCT01716312|Placebo Comparator|1|Subjects who were randomized to the placebo arm originally will receive 600 mg omalizumab by subcutaneous injection
3286776|NCT01716312|Active Comparator|2|Subjects in the omalizumab arm will receive 300 mg omalizumab by subcutaneous injection in a doubleblinded fashion
3286777|NCT01716325|Experimental|Weight loss - ICT support|Weight loss - ICT support
3286778|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
3286779|NCT01716338|Active Comparator|Glyburide|1.5 mg (lowest dose) by mouth every day with breakfast for 7 days
3286780|NCT01716338|Placebo Comparator|Sugar Pill (Capsule)|Matching placebo capsule by mouth every day with breakfast for 7 days
3286781|NCT01716351|Experimental|Adapted Yoga Intervention Group|Patients received the Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients and a call from a cardiac research nurse once monthly for five months.
3286782|NCT01716351|No Intervention|Control|Patients received usual care and a call from a cardiac research nurse once monthly for five months to control for attention.
3286783|NCT01716364|Experimental|Anti-LeY- scFv-CD28-ζ vector.|Anti-LeY- scFv-CD28-ζ vector, a non-pathogenic, replication-incompetent retroviral vector specifically designed for this study and produced by EUFETS under GMP-conditions.
3286784|NCT01716377|Placebo Comparator|Placebo|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
3286785|NCT01716377|Active Comparator|Venlafaxine|37.5mg QD 1 week 75mg QD 1 week 150mg QD 8 weeks 75mg QD 1 week 37.5mg QD 1 week
3286786|NCT01716390|Active Comparator|Drink that contains plant stanols|Dietary supplement: Plant stanol
3286787|NCT01716390|Placebo Comparator|Placebo drink|Dietary supplement: Placebo
3286788|NCT01716403||HCV tritherapy and anemia|HCV-genotype 1 infected patients
3286789|NCT01716416|Experimental|Dose Level 1|"Pazopanib 200 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3286790|NCT01716416|Experimental|Dose Level 2|"Pazopanib 400 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3286791|NCT01716416|Experimental|Dose Level 3|"Pazopanib 600 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3286792|NCT01716416|Experimental|Dose Level 4|"Pazopanib 800 mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3286793|NCT01716416|Experimental|Part 2 Dose|"Pazopanib (dose to be determined in Part 1 of study) mg PO QD~Cetuximab 400 mg/m^2 (cycle 1 week 1 only) followed by weekly maintenance doses of 250 mg/m^2"
3286794|NCT01716429|Active Comparator|Low Calorie|Participants in this arm will be instructed on how to reduce their caloric intake and follow a low calorie diet
3286795|NCT01716429|Experimental|Vegan diet|Participants in this arm will follow a very low fat diet (~10% kcals from fat) and also a diet that has a low glycemic index and is free of animal products (vegan)
3286796|NCT01716442|Active Comparator|steroid-resistant|Steroid-resistant group: n=27 , enroll all for treatment
3286797|NCT01716442|Active Comparator|steroid-dependent-rituximab|steroid-responsive group: n=38
3286798|NCT01716442|Placebo Comparator|steroid-dependent-placebo|steroid-responsive group: n=23
3286799|NCT01716481|Experimental|Mesenchymal stem cell treatment|
3286800|NCT01716481|No Intervention|Standard treatment|
3286801|NCT01716494||Severe Asthma|Subjects with severe asthma (SARP protocol definition)
3286802|NCT01716494||Well controlled asthma|Subjects with well controlled asthma
3286803|NCT01716494||Normal control|Subjects that are healthy normals
3286804|NCT01716507|Other|20 gauge pars plana vitrectomy|20 gauge pars plana vitrectomy for retinal detachment repair
3286805|NCT01716507|Other|23 gauge pars plana vitrectomy|23 gauge pars plana vitrectomy for retinal detachment repair
3286806|NCT01716546|Experimental|1|Panitumumab plus DCF
3286807|NCT01716572|Active Comparator|gastric lavage|gastric lavage by nasogastric tube with 1 liter saline before the endoscopy
3286808|NCT01716572|Active Comparator|erythromycin|administration of 250mgr of erythromycin before the endoscopy
3286809|NCT01716598|Experimental|Treatment|Targeted Lung Denervation Therapy (TLD Therapy)
3286810|NCT01716611|Active Comparator|Tolvaptan group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
3286811|NCT01716611|Placebo Comparator|Placebo group|Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days
3286812|NCT01716624|Active Comparator|Oxybutynin|
3286813|NCT01716624|Experimental|Botulinum Toxin A injection|
3286814|NCT01716637|Active Comparator|Etanercept|25 mg administered weekly for 6 weeks
3286815|NCT01716637|Active Comparator|Nutritional Supplements|Nutritional supplements administered daily for 6 weeks in each period as well as an additional 12 weeks following visit 15.
3286816|NCT01716650||Saphenous nerve block|Data collection after saphenous nerve block placement
3286817|NCT01716676|Active Comparator|Standard CPAP follow-up|
3286818|NCT01716676|Experimental|Telemedicine CPAP follow-up|
3286819|NCT01716689|Experimental|Patients with advanced sarcoma|
3286820|NCT01716702|Experimental|Couples Prostate Cancer Support Group|"The participants in the support group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
3286821|NCT01716702|No Intervention|Wait-List Control|Participants will be asked to complete questionnaires at three time points: 1)week 1 2) week 7, and 3) week 13.
3286822|NCT01716728|No Intervention|Enzyme analysis|Patients invited for evaluation will undergo lysosomal acid lipase enzyme analysis
3286823|NCT01716741|Other|Enzyme analysis|Patients invited for evaluation will undergo glucocerebrosidase enzyme analysis
3286824|NCT01716767|Experimental|Menthol|Biofreeze topical gel containing 3.5% menthol
3286825|NCT01716767|Placebo Comparator|Placebo|Topical gel containing a menthol scent, but no active menthol
3286826|NCT01716780|No Intervention|Routine care|"Patients allocated to the control group will undergo their 'usual care'; they will be given pain medication when they specifically request it or when their oncology doctor/ nurse or GP considers it appropriate to prescribe it, either at the oncology clinic visit or at any time during the course of the study."
3286827|NCT01716780|Experimental|Intervention|"Patients allocated to the intervention group will be reviewed by the pain/palliative care team and will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care."
3286828|NCT01716793|Other|Risk-adapted postremission treatment|Ara-C, autologous transplantation, Allogeneic HLA-identical sibling transplantation depending on risk factors (cytogenetics, courses to CR)and availability of an HLA-identical sibling, CD34+ selection.
3286829|NCT01716806|Experimental|Part A: Brentuximab Vedotin in HL Patients|
3286830|NCT01716806|Experimental|Part B: Brentuximab Vedotin + Dacarbazine in HL Patients|
3286831|NCT01716806|Experimental|Part C: Brentuximab Vedotin + Bendamustine in HL Patients|
3286832|NCT01716806|Experimental|Part D: Brentuximab Vedotin + Nivolumab in HL Patients|
3286833|NCT01716806|Experimental|Part E: Brentuximab Vedotin in HL Patients|
3286834|NCT01716806|Experimental|Part F: Brentuximab Vedotin in PTCL Patients|
3286835|NCT01716819|Other|Abdominal obesity|"Single arm, follow up cohort in patient with abdominal obesity. No comparator: description of interventions :~Composition of body mass by Dual x-ray absorptiometry Pulse wave velocity Electrocardiogram Urine sample Blood sample (and biological collection) Assessment of sleep apnea syndrome Glucose tolerance test Echocardiography Echotracking cardiac and abdominal magnetic resonance imaging Ambulatory blood pressure monitoring"
3286836|NCT01716832|Experimental|Mindfulness walking|
3286837|NCT01716832|No Intervention|No intervention (waiting list)|
3286838|NCT01716845||Development group 1|
3286839|NCT01716845||Development group 2|
3286840|NCT01716845||Development group 3|
3286841|NCT01716845||Validation group|
3286842|NCT01716858|Experimental|A single-arm study|
3286843|NCT01716871|Active Comparator|cryotherapy using Cold pack®|"patients with lateral ankle sprain who have been randomized in the cold packs® group.~Application of cryotherapy with Cold pack® or ice-cubes pack in the sprained ankle during 20 minutes 4 times a day, 3 days long."
3286844|NCT01716871|Active Comparator|cryotherapy using Neurocryostimulation|"Patient with lateral ankle sprain randomized in the neurocryostimulation group.~Application of neurocryostimulation with Duo-cryo® device during 1 minute on the sprained ankle, 2 times a day, 3 days long"
3286845|NCT01716897|Other|50 mg E2609 capsule formulation in fasted state|50 mg E2609 capsule formulation
3286846|NCT01716897|Other|50 mg E2609 tablet formulation in fasted state|50 mg E2609 tablet formulation in fasted state
3286847|NCT01716897|Other|50 mg tablet formulation in fed state|50 mg E2609 tablet formulation in fed state
3286848|NCT01716910|Placebo Comparator|Maltodextrin|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day
3286849|NCT01716910|Active Comparator|Synbiotic|'Combination of Lactobacillus acidophilus NCFM and cellobiose', Sachet, 5 g/day + 10e9 CFU
3286850|NCT01716923|Experimental|S-303 Treated Red Blood Cells|Patients receive S-303 treated red blood cells (RBCs).
3286851|NCT01716923|Active Comparator|Conventional, untreated Red Blood Cells|Patients receive conventional, untreated red blood cells (RBCs).
3286852|NCT01716936||MAGEC Implant|All patients implanted with the MAGEC System will be reviewed for inclusion into this retrospective study.
3286853|NCT01716949|Experimental|HyRec|Radiotherapy, Hyperthermia, 5-Fluorouracil (may be replaced by Capecitabine), Capecitabine (may be replaced by 5-Fluorouracil), Oxaliplatin
3286854|NCT01716962||ARDS with acute circulatory failure|acute respiratory distress syndrome with acute circulatory failure with infusion of 6% tetrastarch for a total of 500ml
3286855|NCT01716975|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day -14 through Day 182
3286856|NCT01716975|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3286857|NCT01716975|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3286858|NCT01716988||Micafungin|
3286859|NCT01717027|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3286860|NCT01717027|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3286861|NCT01717027|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3286862|NCT01717027|Experimental|Treatment D|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3286863|NCT01717066|Experimental|the ginsenoside Rg3|320 HCCs,the ginsenoside Rg3 capsule,4-8 weeks after surgery, will be taken, 2 capsules, BID, 8 weeks as one cycle, continue taking it until the tumor recurs or until the end date of the study for patients without recurrence
3286864|NCT01717066|Placebo Comparator|the placebo|160 HCCs as control group with patients who don't receive any adjuvant therapy after liver resection, to compare with the treatment group
3286865|NCT01717079|Active Comparator|Effective arm|Effective coil
3286866|NCT01717079|Placebo Comparator|Placebo arm|Placebo coil
3286867|NCT01717092||Consecutive patients with acute PE|
3286868|NCT01717105||metastatic non-small cell lung cancer|Only epidermal growth factor receptor (EGFR) M+ patients will be eligible for the study assessments
3286869|NCT01717118|Active Comparator|Tetravalent Vaccine|"Month 2 visit: May be scheduled on the appropriate month +/- 3 weeks.~Month 6, 21, 60 and 61 visit (vaccination scheme 0, 2, 6): May be programmed on the appropriate month +/- 4 weeks.~Month 7 and 61 visit (vaccination scheme 0, 6, 60): The time interval between the month 6/60 visit and the month 7/61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
3286870|NCT01717118|Active Comparator|Bivalent Vaccine|"Month 1 visit: May be scheduled 21 to 62 days after the Day 0 visit.~Month 6 visit: May be scheduled 161 to 216 days after the Day 0 visit.~Month 6 visit: The time interval between the month 6 visit and the month 7 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination.~Month 21, 60 and 61 visit (vaccination scheme 0, 1, 6): May be scheduled on the appropriate month +/- 4 weeks.~Month 61 (vaccination scheme 0, 6, 60) The time interval between the month 60 visit and the month 61 visit must be at least 3 weeks and maximum 7 weeks from the previous vaccination"
3286871|NCT01717131|Active Comparator|Surgery for standard axillary node dissection|Standard axillary dissection
3286872|NCT01717131|Experimental|No axillary lymph node dissection|No surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial)
3286873|NCT01717144|No Intervention|traditional medical care|patients benefiting of a traditional medical care
3286874|NCT01717144|Experimental|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
3286875|NCT01717157|Experimental|Treatment sequence 1 (AEBD)|
3286876|NCT01717157|Experimental|Treatment sequence 2 (BACE)|
3286877|NCT01717157|Experimental|Treatment sequence 3 (CBDA)|
3286878|NCT01717157|Experimental|Treatment sequence 4 (EDAC)|
3286879|NCT01717157|Experimental|Treatment sequence 5 (DECA)|
3286880|NCT01717157|Experimental|Treatment sequence 6 (EADB)|
3286881|NCT01717157|Experimental|Treatment sequence 7 (ABEC)|
3286882|NCT01717157|Experimental|Treatment sequence 8 (BCAD)|
3286883|NCT01717170|Experimental|Tocilizumab (4 mg/kg)|Tocilizumab (4 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
3286884|NCT01717170|Experimental|Tocilizumab (8 mg/kg)|Tocilizumab (8 mg/kg) as an intravenous infusion over 1 hour at day 0, 30, 60, 90, 120, and 150.
3286885|NCT01717183|Experimental|URGO 310 3113 dressing - new|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
3286886|NCT01717183|Placebo Comparator|URGO 310 3113 dressing|flexible, conformable, non-adhesive and non-occlusive lipido-colloid matrix that does not adhere to the wound.
3286887|NCT01717196|Experimental|DIFFERENT VOLUME ASPIRATION BIOPSY|The needle system was in all cases the 22 gauge EUS-FNA (Expect needle). After the puncture the stylet was removed, and we performed three punctures with a 22 G needle with both volume aspiration 10 and 20 cc and without syringe for each lesion. The sequence of different volume aspiration Biopsy/ FNA (10cc, 20cc, no aspiration) was randomly assigned by sealed envelope system.
3286888|NCT01717222|Active Comparator|Intraperitoneal (IP) group|Patients will receive 100 ml of 0.2% Lignocaine as intraperitoneal lignocaine irrigation in the gall bladder fossa along with a placebo of normal saline of volume equivalent to 1.5 mg/kg of intravenous lignocaine at induction and normal saline of volume equivalent to 2 mg/kg/hour of intravenous lignocaine as continuous infusion until one hour postoperatively to ensure blinding
3286889|NCT01717222|Active Comparator|Intravenous (IV) group|Patients will receive 1.5mg/kg of intravenous lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lignocaine until one hour after surgery and 100 ml of saline intraperitoneally as placebo to ensure blinding.
3286890|NCT01717235|Experimental|Test Product|Drug: Ropinirole Single oral dose of Ropinirole hydrochloride CR 2mg Tablets under fasting conditions
3286891|NCT01717235|Experimental|Reference Product|REQUIP XL Tablets (containing Ropinirole hydrochloride CR 2mg Tablets)under fasting conditions
3286892|NCT01717248|Experimental|GCS-100|GCS-100 will be administered once weekly by a ten minutes injection.
3286893|NCT01717261|Experimental|Single Pre-Operative Radiation Therapy|
3286894|NCT01717274|Experimental|Hot saline irrigation|Hot saline is prepared by first placing 2 litres of sterile normal saline (0.9%) into a basin (IntraTemp Therma BasinTM) that is wrapped in a sterile disposable drape (IntraTemp Therma Basin DrapeTM). The basin is then placed in a medical grade warmer (IntraTemp Fluid Warming SystemTM). The warmer is set to heat the saline up to a temperature of 50 degrees Celsius. An external digital thermometer is placed in the saline at all times to ensure that the temperature is between 45-50 degrees.
3286895|NCT01717274|No Intervention|Room temperature saline irrigation|Room temperature saline is prepared in the same manner as the experimental arm except that the warmer is switched off and the temperature of the saline in the basin is left to equilibrate to the temperature of the operating room.
3286896|NCT01717300|Experimental|Anacetrapib 100 mg|
3286897|NCT01717300|Experimental|Anacetrapib 25 mg|
3286898|NCT01717300|Placebo Comparator|Placebo|
3286899|NCT01717339|Other|Normal Subjects|Non-OSA (Obstructive sleep apnea) patients
3286900|NCT01717339|Other|OSA subjects|(Obstructive sleep apnea) OSA subjects
3286901|NCT01717352|Active Comparator|Weight Loss Education|Provides participants with important information about weight control and healthy eating prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
3286902|NCT01717352|Active Comparator|Sleep and Eating Routine|Establish a consistent sleep and eating routine prior to treatment to prepare participants for participation in a weight loss program and enhance outcomes.
3286903|NCT01717365||OTs|Occupational therapists
3286904|NCT01717378||Potential research participants|UCSF Registry represents a single recruitment pool of individuals who have consented to be contacted about future studies for which they may be eligible based on self-reported health information.
3286905|NCT01717404|Experimental|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
3286906|NCT01717417||group 1|Patient treated with Trans Palatal Arch as anchorage for canine traction
3286907|NCT01717417||Group 2|Patient treated with miniscrew as anchorage for canine traction
3378700|NCT01780142||asthmatics|Subjects with confirmed diagnosis of asthma without other lung disease followed for collection of clinical data &amp; specimens
3378701|NCT01780142||non-asthmatic healthy volunteers|Healthy volunteers in whom asthma has been ruled out and without other lung disease followed for comparison to asthmatics
3378702|NCT01778569||Group 1|Patient with a diagnosis of chronic plaque psoriasis, psoriatic arthritis, or pustular psoriasis
3378703|NCT01778543||Coloboma|Participants with Coloboma and their family members.
3286908|NCT01717430||Corticosteroid injection|Consecutive patients receiving initial or repeated sacroiliac joint or single or multi-level epidural corticosteroid injections as part of their management plan for SI joint, neck, back, or radicular pain. Injections will be performed using 0.5 mL bupivacaine 0.25% and 15 mg dexamethasone sodium phosphate.
3286909|NCT01717443||Women, renal disease, transplantation|Women with end-stage renal disease, whose eligibility for renal transplantation is assessed
3286910|NCT01717469|Active Comparator|RV Pacing|Right ventricular pacing
3286911|NCT01717469|Experimental|LV Pacing|Left ventricular pacing through coronary sinus tributaries
3286912|NCT01717495||Implantation Procedures|Patients submitted to initial pacemaker or ICD implantation
3286913|NCT01717495||Reoperation Procedures|Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
3286914|NCT01717508|Other|Cognitive Behavioral Therapy|12 weekly sessions of cognitive behavioral therapy
3286915|NCT01717508|No Intervention|Healthy Controls|
3286916|NCT01717534|Experimental|Heat-treated lactobacilli|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
3286917|NCT01717534|Placebo Comparator|Maltodextrin|"One sachets (1 gram of content) will be consumed once a day, and will be suspended in a provided milk powder to be reconstituted with water.~The duration of the treatment is 5 months."
3286918|NCT01717547|Experimental|Yoga|Yoga-based treatment - manualized group treatment - classes will be held twice per week for approximately 85 minutes for a period of eight weeks.
3286919|NCT01717560|Experimental|Collaborative multidisciplinary integrated care|Collaborative, multidisciplinary, integrated care for hepatitis C
3286920|NCT01717573|Active Comparator|Deferred stenting|During primary PCI in STEMI, when TIMI 3 flow has been re-established with guide-wire, aspiration thrombectomy and/or balloon angioplasty, stenting is then deferred for a period of 4-16 hours following reperfusion. During this time, patients remain in the Coronary Care Unit and will receive intravenous tirofiban and subcutaneous low molecular weight heparin (enoxaparin 1 mg/kg)
3286921|NCT01717573|Sham Comparator|Conventional treatment|Conventional treatment in STEMI, with immediate stenting
3286924|NCT01717599|Experimental|Diclofenac group|
3286925|NCT01717599|Placebo Comparator|Placebo(normal saline) group|
3286926|NCT01717612|Active Comparator|Histoacryl group|the injected agents consisted of n-butyl-2-cyanoacrylate (Histoacryl; B.Braun, Melsungen AG, Germany) 0.5ml mixed with 1.5 ml Lipiodol ultra-fluide (Guerbet, Bois Cedex, France). The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
3286927|NCT01717612|Experimental|thrombin group|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
3286928|NCT01717625|Experimental|Montelukast|"montelukast sodium~dosage~< 1000g : 0.5 mg/D QD~1000g~1500g : 1.0 mg/D QD~1500g~2000g : 1.5 mg/D QD~> 2000g : 2mg/D QD~medication period : to discharge or GA 36wks"
3286929|NCT01717625|No Intervention|Control|Standard treatment of BPD and preterm infants
3286930|NCT01717651||CPM device|a CPM (continuous passive motion) device attached to one of your legs intermittently over the next three days.
3286931|NCT01717664|Experimental|RHB-104|5 RHB-104 capsules administered orally BID
3286932|NCT01717677|Experimental|radical prostatectomy|Procedure/Surgery: radical prostatectomy
3286933|NCT01717677|Experimental|percutaneous radiation therapy|Radiation: percutaneous radiation therapy
3286934|NCT01717677|Experimental|permanent seed implantation|Radiation: permanent seed implantation
3286935|NCT01717677|Experimental|Active Surveillance|Procedure/Surgery: Active Surveillance
3286936|NCT01717690|Active Comparator|CHG antiseptic body cleanser|"One randomly selected intervention unit in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with an antiseptic body cleanser (CHG).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed.~Antiseptic body cleanser - 2% Chlorhexidine Gluconate in a non-alcohol and non-alkaline base, delivered to skin surface through the bath cloths impregnated with this antiseptic solution."
3286937|NCT01717690|No Intervention|Non-antiseptic body cleanser|"Two control units in Complex Continuing Care program where all patients (MRSA-positive and MRSA-negative) will be bathed daily with a non-antiseptic body cleanser (Comfort Bath ®).~Only MRSA-negative patients at enrollment will be included in the study analysis, and only their outcomes (MRSA status and time to conversion) will be analyzed."
3286938|NCT01717703|Experimental|Water Control|Water Control
3286939|NCT01717703|Experimental|Fruit drink|Fruit drink
3286940|NCT01717703|Experimental|Cola|Cola
3286941|NCT01717703|Experimental|1% chocolate milk|1% chocolate milk
3286942|NCT01717716|Experimental|Calorie-free control|Calorie-free control
3286943|NCT01717716|Experimental|HFCS-55 drink|HFCS-55 drink
3286944|NCT01717716|Experimental|Glucose drink|Glucose drink
3286945|NCT01717716|Experimental|Sucrose drink|Sucrose drink
3286946|NCT01717729|Experimental|RFA-125I group|The combination RFA and 125I (RFA-125I) (n = 68; 42 men, 26 women; mean age, 50.7 years; age range, 29-73 years) In this group, patients were accepted not only radiofrequency ablation (RFA) but also iodine-125.
3286947|NCT01717729|Active Comparator|RFA-only group|(n = 68; 47 men, 21 women; mean age, 48.9 years; age range, 30-74 years) In tis group,the patient were just peformed radiofrequency ablation alnoe.
3378706|NCT01757535|Experimental|Oral Azacitidine|300 mg oral azacitidine on days 1 to 14 of each 28-day treatment cycle.
3378707|NCT01757535|Placebo Comparator|Placebo|Identically matching placebo tablets on days 1 to 14 of each 28-day treatment cycle.
3378708|NCT01750281|Experimental|Selumetinib 75 mg twice daily +Docetaxel 75 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3378709|NCT01750281|Experimental|Selumetinib 75 mg twice daily + Docetaxel 60 mg/m2|Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 60 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3378710|NCT01750281|Experimental|Placebo twice daily + Docetaxel 75 mg/m2|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
3378711|NCT01736293||Affected Patients|Participants with ABCA4-related retinopathies.
3378712|NCT01734369||Healthy Control Subjects|Military service members active duty or no longer in duty, military contractors, and civilians working for the military. Controls should be without a recognized autoimmune or chronic muscle disease.
3378713|NCT01734369||Myositis Subjects|Diagnosis of myositis during military service or service as a military contractor or civilian working for the military with polymyositis, dermatomyositis, or inclusion body myositis.
3286948|NCT01717755|No Intervention|Best medical management.|"Best medical management consists of the standard of care of patients with acute ischemic stroke according to existing local protocols and guidelines, and may include IV thrombolysis.~If treated with IVT as part of BMM, IVT should be started within 4.5 hours of estimated time of BAO."
3286949|NCT01717755|Experimental|Additional intra-arterial treatment.|Best medical management followed by intra-arterial treatment and best medical management
3378719|NCT01721720||1|children and adolescents and adults with ADHD
3378720|NCT01712672||1|Healthy participants
3378721|NCT01702922||1/Active Cancer Parents|Must have been in a partnership at the time child was diagnosed with cancer &amp; must have been diagnosed at least 3 months prior to enrollment on this study &amp; be currently receiving treatment
3378722|NCT01702922||2/Complete Cancer Parents|Must have been in a partnership at the time the child was diagnosed with cancer and the child has completed treatment at age 21 or younger (without evidence of disease) within the previous 3 years
3378723|NCT01702922||3/NF1 Parents|Must have been in a partnership at the time the child was diagnosed with NF1 and the child must have been diagnosed with NF1 at least 3 months prior to enrollment on this study.
3378725|NCT01676805||1|Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy
3378726|NCT01676805||2|Patients without a known lymphoid malignancy or precursor disease to a lymphoid malignancy
3378727|NCT01661010||Control|Family members can serve as control group
3378728|NCT01661010||Sex-linked genes|Patients previously identified through outside research or diagnostic labs as having sex-chromosome variants causing deletion/duplication of sex-linked genes or entire sex chromosomes.
3378729|NCT01660984||Parents/caregivers|Parents or caregivers of study patients to assess their psychosocial experiences and needs.
3378730|NCT01660984||Patients|Children and adults with MTC and MEN2B, other non-tumor manifestations of MEN2, and patients with MEN2 who do not demonstrate MTC. Characterize the biology and manifestations of their disease.
3378731|NCT01660971|Experimental|Treatment (gemcitabine, dasatinib, erlotinib)|Patients receive gemcitabine hydrochloride IV over 30-60 minutes on days 1, 8, and 15, and dasatinib PO QD and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3378732|NCT01660451|Experimental|Copanlisib (indolent NHL)|Part A: Participants in this arm will be patients with indolent NHL.
3378733|NCT01660451|Experimental|Copanlisib (aggressive NHL)|Part A: Participants in this arm will be patients with aggressive NHL.
3378734|NCT01660451|Experimental|Copanlisib (indolent B-cell NHL)|Part B: Participants in this arm will be patients with indolent B-cell NHL.
3378735|NCT01658917||Primary|Patients greater than or equal to 18 years of age who have premalignant, primary or metastatic solid tumors based upon either radiographic or biochemical testing, or histological/cytological analysis
3378736|NCT01656564||Healthy Controls|Individuals with no known history of HIV
3378737|NCT01656564||Healthy Controls - Questionnaire Group|Individuals with no known history of HIV
3378738|NCT01656564||HIV|Individuals who acquired HIV in early life
3378739|NCT01639950||Adults Group 1|Adults patients with cancer or neurofibromatosis 1 (NF1)
3378740|NCT01639950||Adults Group 2|Adults with sickle cell disease (SCD)
3378741|NCT01639950||Children|Children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
3378742|NCT01639950||Parents|Parents of children with with neurofibromatosis 1 (NF1), genetic tumor predisposition syndromes (GTPS), malignant solid tumor, or leukemia. -closed
3378743|NCT01639924||Study Cohort|Patients with known or suspected gastrointestinal disease
3378744|NCT01633268||Healthy Volunteers|Healthy men and women aged 18-65
3378745|NCT01633021||Diabetes|Self/Family member affected by type-2 diabetes (plus self-referred family-members)
3378746|NCT01633021||Heritable Cancer Screen-Positive|Person who has screened-positive for heritable cancers on genetic tests (plus referred family-members)
3378747|NCT01633021||Sickle Cell (Trait/Disease/Related)|Self/Family member affected by Sickle Cell Trait or Sickle Cell Disease (plus self-referred family-members)
3286950|NCT01717781|Experimental|Thunderbeat|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to incise the bladder peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to dissect the bladder and develop rectovaginal septum, to unroof the ureter, to cut parametria, and to divide the uterosacral ligaments. Monopolar hook is used in the culdotomy. Thunderbeat is also used to perform pelvic lymphadenectomy."
3286951|NCT01717781|Active Comparator|Standard|"Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3286952|NCT01717794|Active Comparator|Standard bipolar electrosurgery|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with standard bipolar electrosurgery.~A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope.~Two additional 5 mm ports are placed under direct visualization. One more 5-mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system."
3286953|NCT01717794|Experimental|Thunderbeat technology|"Laparoscopic total hysterectomy with pelvic lymphadenectomy are performed with Thunderbeat technology: using Thunderbeat technique, surgeons can avoid changing instruments during surgery since Thunderbeat combines bipolar energy for haemostasis and ultrasound for dissection and cut.~Thunderbeat is used to coagulate the fallopian tubes, to coagulate and divide the round ligaments, to seal ovarian pedicles, to open the anterior and posteriors leaves of the broad ligaments peritoneum, to develop the paravesical and pararectal spaces, to seal uterine arteries and uterine pedicles, to incise the bladder peritoneum, to dissect the bladder, to develop rectovaginal septum, to cut parametria, and to divide the uterosacral ligaments. Thunderbeat is also used to perform the pelvic lymphadenectomy and, if necessary, the para-aortic lymphadenectomy."
3286954|NCT01717807||lung cancer; advanced pancreatic cancer|
3286955|NCT01717820|Experimental|Freeze-dried whole-grape powder|Freeze-dried whole-grape powder (46g/day)will be provided to participants for 12 weeks.
3286956|NCT01717833|Experimental|NEMS group|
3286957|NCT01717833|Sham Comparator|Sham group|
3286958|NCT01717846|Experimental|Arm 1|Orencia Group is for RA patients who have not received any other biologic treatment, including abatacept previously, and whose doctor has determined that it is appropriate to treat their RA with Abatacept. If you are in Group 1, you will receive the study drug, Abatacept, given in an intravenous (IV - injected into a vein) as well as subcutaneous form. Abatacept, given in an intravenous injection is approved by the FDA for the treatment of RA.
3286959|NCT01717846|Other|Arm 2 or group 2|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
3286960|NCT01717885||HIV+children on LPV/r|HIV+ children who are stabilized on a LPV/r based ART regimen
3286961|NCT01717885||HIV+ children on nevirapine|HIV+ children who are stabilized on an nevirapine based ART regimen
3286962|NCT01717885||HIV+ children on efavirenz|HIV+ children who are stabilized on an efavirenz based ART regimen
3286963|NCT01717885||HIV+ pregnant women on LPV/r|HIV+ pregnant women who are stabilized on an LPV/r based ART regimen
3286964|NCT01717885||HIV+ pregnant women on NVP|HIV+ pregnant women who are stabilized on an nevirapine based ART regimen
3286965|NCT01717885||HIV+ pregnant women on EFV|HIV+ pregnant women stabilized on an efavirenz based ART regimen
3286966|NCT01717885||HIV negative children|HIV negative children that will serve as a control for HIV positive children on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
3286967|NCT01717885||HIV negative adults|HIV negative adults that will serve as a control for comparing results to HIV negative children and HIV negative pregnant women
3286968|NCT01717885||HIV negative pregnant women|HIV negative pregnant women who will serve as a control for HIV positive pregnant women on either a LPV/r, NVP or EFV based ART regimen and will be compared to HIV negative non-pregnant adults
3286969|NCT01717911|Active Comparator|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
3286970|NCT01717911|Experimental|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
3286971|NCT01717911|Experimental|Insulin|In the insulin therapy group (Insulin glargine), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Daily dose was administrated before breakfast.
3286972|NCT01717924|Active Comparator|peri-operative chemotherapy|Neoadjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5 fluoro-uracil (oral or intra-veinous) Surgery within 3 and 6 weeks after the end of neoadjuvant chemotherapy Adjuvant chemotherapy with 3 cycles of the same chemotherapy within 6 and 12 weeks after surgery
3286973|NCT01717924|Experimental|surgery first with adjuvant chemotherapy|Surgery first Adjuvant chemotherapy with 3 cycles of Epirubicin/Cisplatin/5FU within 6 and 12 weeks after surgery No neoadjuvant chemotherapy
3286974|NCT01717937||PVOCT|Subjects will receive fluorescein angiography (FA) as part of their normal clinical evaluation and will undergo phase variance optical coherence tomography (PV-OCT) as the study intervention. This involves having subjects undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images.
3286975|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel®|
3286976|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
3286977|NCT01717950|Experimental|30 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
3286978|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel®|
3286979|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 2.5 µg GLA-AF|
3286980|NCT01717950|Experimental|100 µg Na-APR-1 (M74)/Alhydrogel® plus 5.0 µg GLA-AF|
3286981|NCT01717963|Experimental|Naltrexone intramuscular suspension|Extended release naltrexone injections 380mg
3286982|NCT01717963|Active Comparator|Buprenorphine-naloxone|Flexible oral dose 4-24 mg daily
3286983|NCT01718002|Other|Educational video on oral hygiene|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
3286984|NCT01718015||Patients with diabetic polyneuropathy|
3286985|NCT01718015||Patients with diabetes without peripheral nerve disorder|
3286986|NCT01718015||Patients with polyneuropathies not due to diabetes|
3286987|NCT01718015||Patients not suffering from diabetes or nerve disease|Control subjects
3286988|NCT01718015||Patients with unspecified nerve disease|
3286989|NCT01718041|Experimental|VRS-317|Active treatment arm
3286990|NCT01718054|Active Comparator|vascular|In this intervention period children will receive a vascular ready-to-use supplementary food with added L-Arginine & L-Citrulline plus daily chloroquine
3286991|NCT01718054|Active Comparator|regular|In this intervention period children will receive a regular ready-to-use supplementary food plus weekly dose of chloroquine
3286992|NCT01718067|Experimental|Vakum|VAKÜM system (Free Aspire, MPR, Legnano-I) added to the conventional manual ELTGOL technique
3286993|NCT01718067|Active Comparator|Control|conventional manual ELTGOL technique
3286994|NCT01718080||Group A|Healthy lean children before puberty
3286995|NCT01718080||Group B|Otherwise healthy overweight children before puberty
3286996|NCT01718080||Group C|Healthy lean adolescents in mid to late puberty
3286997|NCT01718080||Group D|Otherwise healthy overweight adolescents in mid to late puberty
3286998|NCT01718093|Active Comparator|Insulin plus sitagliptin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily
3286999|NCT01718093|Active Comparator|Insulin plus metformin|The subjects continued their usual insulin regimen throughout the study. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
3287000|NCT01718093|Active Comparator|Insulin plus sitagliptin and metformin|The subjects continued their usual insulin regimen throughout the study. Sitagliptin was started and continued at 50 mg orally twice daily. Metformin was started at 500 mg orally daily. The dose was increased over a 2 week period up to 2,000 mg per day as tolerated.
3287001|NCT01718106|Active Comparator|Single long bioabsorbable polymer DES|Patients with long coronary stenosis treated by a single long bioabsorbable polymer DES
3287002|NCT01718106|Active Comparator|Two bioabsorbable polymer DES in overlapping|patients with long coronary artery stenosis tretaed by 2 bioabsorbable polymer DES with minimal overlapping
3287003|NCT01718119|Experimental|DA-3803|subjects treated with DA-3803(r-hCG)
3287004|NCT01718119|Active Comparator|Ovidrel|subjects treated with Ovidrel(r-hCG)
3287005|NCT01718132||postoperative patients|
3287006|NCT01718145|Experimental|Arm 1: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Naive cohort"
3287007|NCT01718145|Active Comparator|Arm 2: Telaprevir + pegIFNα-2b + Ribavirin|"Telaprevir 750 mg tablets by mouth three times daily, pegIFNα-2b 1.5 μg/kg solution by Subcutaneous weekly & Ribavirin 600- 1000 mg Capsules by mouth twice daily for 24 Weeks~- Naive cohort"
3287008|NCT01718145|Experimental|Arm 3: Daclatasvir + Asunaprevir|"Daclatasvir 60 mg tablets by mouth once daily and Asunaprevir 200 mg capsules by mouth twice daily for 24 weeks~- Relapser cohort"
3287009|NCT01718158|Experimental|Peginterferon Lambda-1a + Ribavirin + Daclatasvir|"Peginterferon Lambda-1a 180 µg solution for subcutaneous injection, once a week for 24 Weeks~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 weeks~Daclatasvir 60 mg tablets by mouth, once a day for 12 weeks"
3287010|NCT01718158|Experimental|Peginterferon Alfa-2a + Ribavirin + Telaprevir|"Peginterferon Alfa-2a 180 µg solution for subcutaneous injection, once a week for 24 to 48 weeks depending on response~Ribavirin 200 mg tablets [1000-1200 mg total daily dose: subjects should take either 400 mg (2 tablets for subjects < 75 kg) or 600 mg (3 tablets for subjects ≥ 75 kg) in the morning with food and 600 mg (3 tablets) in the evening with food] by mouth, twice daily, for 24 to 48 weeks depending on response~Telaprevir 375 mg tablets [2250 mg total daily dose: subjects should take 750 mg (two 375 mg tablets) orally three times a day, approximately 7-9 hours apart) for 12 weeks"
3287011|NCT01718171||Group I, Group II, Group III, Group IV|Values and results of the Systemic Inflammatory Response and C-reactive protein to appendicitis
3287012|NCT01718184|Experimental|Sulcoflex|Sulcoflex intraocular lens implantation
3287013|NCT01718197||Mild-to-Moderate Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3287014|NCT01718197||Severe Asthma|"Major Criteria: (1 required)~Treatment with oral corticosteroids for at least 6 of the previous 12 months~Treatment with high-dose inhaled corticosteroids (ICS) for at least 10 of the previous 12 months~Minor Criteria: (2 required)~Daily treatment with an asthma controller medication in addition to ICS, or~Asthma symptoms requiring short-acting bronchodilator use on a daily or near daily basis, or~Persistent airway obstruction with baseline FEV1 <80% predicted, or~≥ 1 urgent visits for asthma in the previous 12 months, or~≥ 3 systemic corticosteroid bursts in the previous 12 months, or~Prompt deterioration with a reduction in oral or inhaled corticosteroid dose, or~A near-fatal asthma event (i.e., intubation) in the past"
3287015|NCT01718197||Healthy Controls|Those without asthma or other chronic lung disease.
3287016|NCT01718210|Experimental|GM-CSF medium|patient's embryos are incubated after fertilization with mediun supplemented with GM-CSF
3287017|NCT01718210|Placebo Comparator|CONTROL|50 women with recurrent implantation failure (at leat three previous IVF attempts failed with at least 8 good embryos transferred in uterus)that the obtained with IVF are incubated with a standard medium for IVF, and utilized as control group.
3287018|NCT01718223|Experimental|Treatment (interstitial photodynamic therapy using temoporfin)|Patients receive temoporfin IV over at least 6 minutes on day 1 and undergo interstitial photodynamic therapy on day 3. Within 4-6 weeks, patients undergo surgical resection.
3287019|NCT01718236|Experimental|Rocuronium + sugammadex|Intubation after rocuronium administration and reversal of blockade after administration of sugammadex
3287020|NCT01718236|Experimental|Succinylcholine + Neostigmine|Intubation after succinylcholine administration, neuromuscular block is than maintained by rocuronium administration and reversal of block is by neostigmine + atropine administration
3287021|NCT01718249|Other|deep brain stimulation|
3287022|NCT01718275||Non-operative Group|Patients and caregivers who agree to receive non-operative management with antibiotics alone
3287023|NCT01718275||Surgery Group|Patients and caregivers who decide to undergo appendectomy that permit us to track their standard treatment course
3287024|NCT01718288|Experimental|iloprost + standard treat.(aspirin)|1B - patients unsuitable to surgical or endovascular vascular therapy: treatment with iloprost intravenous infusions for 10 days every 3 months, in addition to conventional treatment
3287025|NCT01718288|Active Comparator|Standard Treatment (aspirin....)|"1A - patients unsuitable to surgical or endovascular vascular therapy: conventional treatment~Conventional Treatments:correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin / low molecular weight heparin, hemorheological / vasodilators such as pentoxifylline / buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
3287026|NCT01718288|Experimental|Vascular surgery patients + iloprost|2B - patients suitable to vascular surgical or endovascular therapy: treatment with intravenous infusions iloprost for 10 days every 3 months, in addition to conventional treatment
3287027|NCT01718288|Active Comparator|Vasc. Surg.+ standard treat. (aspirin..)|2A - patients suitable to vascular surgical or endovascular therapy + standard treatment (aspirin...)
3287028|NCT01718301|Experimental|boceprevir + ribavirin + peginterferon|boceprevir 800 mg three times a day (v.o.) in combination with peginterferon (alfa-2b or alfa-2a) and ribavirin
3287029|NCT01718314|Experimental|Sublingual Misoprostol & Lidocaine placebo|Misoprostol 200 µg sublingually single dose and Lidocaine spray placebo
3287030|NCT01718314|Experimental|Lidocaine Pump Spray & Misoprostol placebo|Lidocaine Pump spray, 6 sprays to cervix (60 mg totally) and sublingual misoprotol placebo
3287031|NCT01718327|Experimental|open label, single arm|single arm: sunitinib until progresion or unacceptable toxicity
3287032|NCT01718340|Experimental|Metformin|The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive
3287033|NCT01718366|Experimental|ferritin level >300ng/ml and < 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level >300ng/ml and < 1000ng/ml, will be included in Group 1.~Interventions: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 5mg/kg/d Cohort 2: Deferasirox: 10mg/kg/d Cohort 3: Deferasirox: 15mg/kg/d"
3287034|NCT01718366|Experimental|ferritin level > 1000ng/ml|"Patients will be included in 2 groups according to the ferritin level at time of inclusion.~Patients with the ferritin level > 1000ng/ml, will be included in Group 2. Intervention: Deferasirox, Vitamin D (100000/week) and Azacitidine (75 mg/kg/day Day1 today 7)~5 patients in each cohort: Cohort 1: Deferasirox: 10mg/kg/d Cohort 2: Deferasirox: 15mg/kg/d Cohort 3: Deferasirox: 20mg/kg/d"
3287035|NCT01718379|Experimental|Arm A|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses.~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
3287036|NCT01718379|Experimental|Arm B|"Lenalidomide 10 mg/day for 21 days every 28 days for 4 courses combined with weekly subcutaneous injections of Epoetin beta (60,000 Units/w).~Evaluation of response at the end of 4 months according to IWG 2006 and IWG 2000 criteria.~Maintenance: responders will continue to follow the corresponding treatment arm until relapse occurs; non responders at cycle 4 in arm A will be considered in failure of treatment and the introduction of Epoetin beta is at the discretion of the physician.~The patients will be followed every 3 months for 12 months"
3287037|NCT01718392|Experimental|Training|24 weeks combined exercise programme (supervised)
3287038|NCT01718392|No Intervention|Control|sedentary/habitual lifestyle
3287039|NCT01718405|Experimental|Exercise Group|Each individual subject will give a blood sample for genetic analysis and undertake an exercise session and a rest session as a control. Cognitive function will be tested before and after each session.
3287040|NCT01718418|Experimental|+ ind.CHO + prebiotics|test meal: intrinsic indigestible carbohydrates in combination with a combined probiotic supplement.
3287041|NCT01718418|Experimental|+ ind.CHO - prebiotics|test meal: intrinsic indigestible carbohydrates in combination with placebo probiotic supplement.
3287042|NCT01718418|Experimental|- ind.CHO - prebiotics|reference: no ind. carbohydrates and no probiotic supplement
3287043|NCT01718431|Experimental|indigestible carbohydrates|test meal: indigestible carbohydrates
3287044|NCT01718431|Experimental|reference|reference meal: no indigestible carbohydrates
3287045|NCT01718457|Experimental|Endobarrier device insertion|
3287046|NCT01718470|Active Comparator|Endotracheal tube|At the end of surgery, emerge from anesthesia with the ETT still in place
3287047|NCT01718470|Active Comparator|Laryngeal mask|At the end of surgery,emerge from anesthesia after ETT had been replaced by an LMA.
3287048|NCT01718496|Active Comparator|Morphine|Patient with advance COPD who will randomly receive single dose oral Morphine
3287049|NCT01718496|Placebo Comparator|Placebo|patient with advanced COPD who will receive Placebo
3287050|NCT01718548|Active Comparator|CS and Lingzhi|CS liquid (each dosage is a bottle of liquid containing 30 ml: comprising 75% of CS, 6% Lingzhi, 6% shitake, 5% bamboo shoot, 2% honey, 0.1% potassium sorbet and 5.9% pure water) and Lingzhi capsule (each capsule contains 620mg of: 52.42% Lingzhi, 28.23% CS, and 19.35% soy gel ) ; one quarter bottle of CS to be ingested twice a day, and the Lingzhi capsule to be taken once a day, both for a period of 28 days.
3287051|NCT01718548|Placebo Comparator|Placebo|Liquid tea ingested twice a day and flour-filled capsules ingested once a day over a period of 28 days
3287052|NCT01718561|No Intervention|Control|Usual clinical airway evaluation and usual registration in Danish Anaesthesia Database (without SARI registration)
3287053|NCT01718561|Experimental|SARI|Registration of Modified SARI score and predictors for difficult mask ventilation in Danish Anaesthesia Database
3287054|NCT01718574|Experimental|Self-help book|
3287055|NCT01718574|No Intervention|Usual Care Control|
3287056|NCT01718587|Experimental|stem cell transplantation therapy|umbilical cord mesenchyma stem cell transplantation through interventional procedures do in liver cirrhosis patients.
3287057|NCT01718587|Active Comparator|antiviral therapy|"Antiviral therapy: lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).~Supportive therapy are allowed to use on patients not including intravenous infusions of plasma or albumin."
3287058|NCT01718600||Neuroimaging Correlates|Carotid revascularization can significantly reduce the risk of stroke in patients with severe carotid stenosis; however, it has been associated with cognitive decline in 25% of the older adults who undergo the procedure. Neuroimaging techniques that characterize white matter integrity and regional hypoperfusion have the potential to provide sensitive brain structure indicators that may be associated with memory decline following revascularization procedures. In this proposal, we hope to determine the risk factors and cognitive effect of microembolization following carotid revascularization procedures.
3287059|NCT01718613|Active Comparator|Norepinephrine|
3287060|NCT01718613|Active Comparator|Vasopressin|
3287061|NCT01718626|Active Comparator|S1+Docetaxel|
3287062|NCT01718626|Experimental|S1+Docetaxel followed by S1|
3287063|NCT01718639|Active Comparator|IQP-LH-101 tablet|4 chewable tablets to be chewed thoroughly before swallowing
3287064|NCT01718639|Active Comparator|IQP-LH-101 liquid|2 liquid sachets to be emptied into the mouth and consumed.
3287065|NCT01718639|Placebo Comparator|Placebo|1 tablet to be swallowed with water.
3287066|NCT01718652|Experimental|Canagliflozin + cyclosporine|Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7.
3287067|NCT01718678|Active Comparator|Melatonin|Melatonin, Tablet, 3 mg, once, one month
3287068|NCT01718678|Placebo Comparator|Placebo|Placebo, tablet
3287069|NCT01718704|Experimental|Viberect device|Men in this group will begin using the Viberect device 3 days after Foley catheter removal after surgery on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting.
3287070|NCT01718704|No Intervention|No Viberect|Men in this group will not be provided with the Viberect device
3287071|NCT01718717|Active Comparator|6 days TEA|Postoperative analgesia for the first six postoperative days with TEA and daily monitoring for arrhythmia
3287072|NCT01718717|Active Comparator|3 days TEA and 3 days intravenous morphine|Postoperative analgesia for the first three postoperative days with TEA followed for the next three days with intravenous morphine, and daily monitoring for arrhythmia
3287073|NCT01718730||Mild depression|Subjects with mild, but clinically significant depression
3287074|NCT01718730||Moderate to Severe MDD|Subjects with moderate to severe major depressive disorder who have not yet initiated treatment with an SSRI
3287075|NCT01718730||MDD with response to SSRI|Subjects with moderate to severe major depressive disorder that has responded to an SSRI
3287076|NCT01718730||MDD without response to SSRI|Subjects with moderate to severe major depressive disorder which has not responded to treatment with an SSRI
3287077|NCT01718743|Experimental|Treatment (ixazomib citrate, lenalidomide)|Beginning 60-180 days post-transplant, patients receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3287078|NCT01718756|Placebo Comparator|Placebo|The placebo group received 12 hourly boluses of 0.9% saline, followed by a constant infusion for 48 hrs after surgery.
3287079|NCT01718756|Active Comparator|Scheduled|They received a 12 hourly boluses of lornoxicam followed by a constant infusion of 0.9% saline, for 48 hrs after surgery
3287080|NCT01718756|Active Comparator|Continuous infusion|They received boluses of lornoxicam 0.8 mg/mL before induction of anaesthesia followed by a 12 hourly boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery.
3287081|NCT01718769|Active Comparator|STAMP using|100 boys and girls aged 1 to 6, attending Clalit Health Care Services Pediatric Centers, will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
3287082|NCT01718769|Placebo Comparator|No STAMP using|150 files shall be reviewed in the beginning of the research and after 6 months in order to estimate the change in medical staff's attention to nutritional status, by way of noting relevant diagnoses, reference to nutritional status- related tests and recording of anthropometric measurements.
3287083|NCT01718782|Active Comparator|laryngeal mask Ambu AuraOnce|laryngeal mask Ambu AuraOnce
3287084|NCT01718782|Active Comparator|laryngeal mask LMA Supreme|laryngeal mask LMA Supreme
3378753|NCT01602263||Controls|Healthy Controls with no known cognitive impairment will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3378754|NCT01602263||Individuals with schizophrenia|Individuals with schizophrenia and first-degree relatives will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3378755|NCT01602263||Individuals with aphasia|Individuals with aphasia will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3378756|NCT01602263||Individuals with high-functioning autism|Individuals with high-functioning autism will have Transcranial Direct Current Stimulation (tDCS) administered and receive either Anodal, Cathodal or Sham tDCS.
3378757|NCT01581554||Patients with HBeAg negative chronic hepatitis B|Patients with HBeAg negative chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
3378758|NCT01581554||Patients with HBeAG positive chronic hepatitis B|Patients with HBeAg positive chronic hepatitis B who have received a minimum of 4 years of oral nucleoside therapy with a serum HBV DNA level less than 500 IU/ml in the 6 months prior to withdrawal.
3287085|NCT01718795|Active Comparator|Bag-valve mask ventilation|"Bag-valve mask ventilation during CPR, i.e. traditional ventilation during CPR. Airway management with bag-valve mask ventilation and efficient ventilation: yes or no?~Intervention is Bag-valve mask ventilation during CPR"
3287086|NCT01718795|Active Comparator|Laryngeal Tube|"Laryngeal Tube Ventilation during CPR, i.e. the alternative ventilation technique to be compared to the traditional technique. Airway management with laryngeal tube and efficient ventilation: yes or no?~Intervention is Ventilation through laryngeal tube during CPR"
3287087|NCT01718808|Active Comparator|Arm A: Cetuximab|Cetuximab 500 mg/m2 every 2 weeks
3287088|NCT01718808|Active Comparator|Arm B: Cetuximab and Capecitabine|"Cetuximab 500 mg/m2 every 2 weeks plus Capecitabine 1000 mg/m2 (*) bid d1-14 every 3 weeks~* 750 mg/m2 if creatinine-clearance 30-50 ml/min"
3287089|NCT01718821||Advanced upper GI cancer patients|Upper GI cancers include: esophageal cancer, gastric cancer, ampulla vater cancer, pancreatic cancer and cholangiocarcinoma.
3378773|NCT01568671||1|Male 18-35 White 18.5-25.0 (Phase 1)
3378774|NCT01568671||2|Male 18-35 White 18.5-25.0 (Phase 2)
3378775|NCT01568671||3|Male 18-35 White 30.0-40.0
3378776|NCT01568671||4|Female 18-35 White 18.5-25.0
3287090|NCT01718834|Active Comparator|prophylactic vaccine|6 monthly doses each of 648 ug of prophylactic vaccine subcutaneously injected to healthy volunteers
3287091|NCT01718834|Active Comparator|therapeutic vaccine|6 monthly doses each of 648 ug subcutaneously injected to chronic HCV patients
3287092|NCT01718847|Experimental|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
3378777|NCT01568671||5|Male 55-75 White 18.5-25.0
3287093|NCT01718860||Postoperative Residual Paralysis|Patients with train-of-four ratio less than 0.9 measured in the postanesthesia care unit
3287094|NCT01718860||No Postoperative Residual Paralysis|Patients with train-of-four ratio greater than 0.9 measured in the postanesthesia care unit
3287095|NCT01718873|Experimental|bevacizumab before chemotherapy|Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
3287096|NCT01718873|Active Comparator|bevacizumab with chemotherapy|Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)
3287097|NCT01718886||Obalon Gastric Balloon|Patients received 1-3 Obalon Gastric Balloons over a period of 12 weeks
3287098|NCT01718899|Experimental|PVX-410, .4 mg dose|Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
3287099|NCT01718899|Experimental|PVX-410, .8 mg dose|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
3378778|NCT01568671||6|Male 18-35 African American 18.5-25.0
3287100|NCT01718899|Experimental|PVX-410 plus lenalidomide|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of an .8 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will also receive 3 cycles of lenalidomide. Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
3287101|NCT01718912|Other|Metronidazole-nystatin oral rinse, regular oral hygiene|Week 1: daily brushing with suction brush. Week two: daily brushing with a mixture of metronidazole-nystatin suspension.
3287102|NCT01718925||Inflammatory Bowel Disease|Ulcerative Colitis and Crohns's disease patients will be recruited from sqeduled outpatient follow-up
3287103|NCT01718925||Irritable Bowel Syndrome|Irritable Bowel patients will be recruited from sqeduled outpatient follow-up
3287104|NCT01718925||Rheumatoid Arthritis|Rheumatoid Arthritis patients will be recruited from sqeduled outpatient follow-up
3287105|NCT01718925||Diabetes Mellitus|Diabetes mellitus patients will be recruited from sqeduled outpatient follow-up
3287106|NCT01718938|Experimental|Sequence 1|3-way crossover of velusetrag or placebo
3287107|NCT01718938|Experimental|Sequence 2|3-way crossover of velusetrag or placebo
3287108|NCT01718938|Experimental|Sequence 3|3-way crossover of velusetrag or placebo
3287109|NCT01718938|Experimental|Sequence 4|3-way crossover of velusetrag or placebo
3287110|NCT01718951|Active Comparator|golimumab|golimumab 50mg subcutaneous every 4 weeks
3287111|NCT01718951|Active Comparator|pamidronate|Pamidronate (60mg) intravenously every 4 weeks
3287112|NCT01718964|Other|A|Cortisol 20 mg /Placebo Mannitol
3287113|NCT01718964|Other|B|Placebo Mannitol/Cortisol 20mg
3287114|NCT01718977|Experimental|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
3287115|NCT01718977|Active Comparator|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
3287116|NCT01718990||Patients with Idiopathic Pulmonary Fibrosis (IPF)|Sixty patients with IPF will be included in this prospective cohort;15 IPF patients per year for years 1-4.
3287117|NCT01718990||Healthy Volunteers|Sixty normal controls will be recruited from volunteers.
3287118|NCT01719016||Cardiac PET, Coronary catheterization|"Cardiac PET scan:~Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.~Injection of Lexiscan.~Coronary catheterization:~Pressure and flow readings using Combowire~Injection of Adenosine."
3287119|NCT01719029|Experimental|Conventional Diet|Low carbohydrate/higher fat diet: 40% carbohydrate, 45% fat, 15% protein
3287120|NCT01719029|Experimental|Complex Carbohydrate Diet|High complex carbohydrate/lower fat diet: 60% complex carbohydrate, 25% fat, 15% protein
3287121|NCT01719042|Active Comparator|Zofran (8mg)|Participant will take Zofran (8mg) once per day before taking their antibiotic regimen
3287122|NCT01719042|Active Comparator|Ensure|Subject will drink a can of Ensure before taking their antibiotic regimen
3287123|NCT01719068||Workers exposed to asbestos|
3287124|NCT01719081|Experimental|Ultrasound Guided SIJ Injection|Needle placement will be performed under US guidance. Fluoroscopy will be used to confirm needle placement prior to medication injection.
3287125|NCT01719081|Active Comparator|Xray Guided SIJ Injection|Needle placement will be performed under fluoroscopy.
3287126|NCT01719094||Childhood Cancer Surviviors|
3287127|NCT01719094||Adolescent/young adults with no cancer history|
3287128|NCT01719094||Newly diagnosed cancer patients|
3287129|NCT01719107|Active Comparator|L. reuteri DSM 17938 chewable tablets|The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri DSM 17938 is 1x108 live bacteria (CFU)/tablet.
3287130|NCT01719107|Placebo Comparator|Placebo chewable tablets|The placebo study product consists of an identical formulation in all respects except that the live bacteria are excluded.
3287131|NCT01719120|Experimental|Self-help CBT with tel. consultation|Self-help CBT with tel. consultation (SHTC)group will receive telephone consultation provided by the investigator in addition to self-help cognitive-behavioral therapy once per week for 6 consecutive weeks.During the consultation, the investigator will answer questions about the treatment content, monitor whether the subjects read the assigned materials and comply with the tasks and procedures, and provide encouragement and support.
3287132|NCT01719120|Experimental|Self-help CBT|The subjects will receive self-help cognitive-behavioral therapy (SH)once per week for 6 consecutive weeks.
3287133|NCT01719120|No Intervention|Waiting-list control (WL)|Subjects in this group will not receive any kind of treatment during the waiting period. They will receive the treatment identical to the self-help group within 3 months from the baseline.
3287134|NCT01719133|Other|All subjects|placebo histamine T1 T2 T3 T4 T5 T1-T2-T3 T4-T5
3287135|NCT01719146||UofL Subjects|Subjects undergoing Specimen Collection at University Kidney Center, University of Louisville, Louisville, KY
3287136|NCT01719146||Duke Subjects|Subjects undergoing Specimen Collection at Duke University, Durham, NC
3287137|NCT01719146||WNERTA Subjects|Subject undergoing Specimen Collection at Western New England Renal and Transplant Associates, Springfield, MA
3287138|NCT01719159|Experimental|Rituximab|Rituximab, 25 mg, is administrated intrathecal three times one week apart
3287139|NCT01719185|Experimental|Phentermine and B12|Those in the experimental group will take 37.5 mg of phentermine daily as well as receive 1000 mg intramuscular injections of B12 weekly.
3287140|NCT01719185|Active Comparator|Phentermine|Those in the control group will take phentermine 37.5 mg daily as well as receive 1000 mg intramuscular injections of saline weekly.
3287141|NCT01719237|Active Comparator|Ropivacine and Cholroprocaine mixture|20 ml's of 1% ropivacaine + 10 ml's of 3% 2-chloroprocaine + 0.1 ml of 1 mg/ml epinephrine
3287142|NCT01719237|Sham Comparator|Ropivacine only|30 ml syringe with either 20 ml's of 1% ropivacaine + 10 ml's of normal saline + 0.1 ml of 1mg/ml epinephrine
3287143|NCT01719250|Experimental|Treatment (buparlisib)|Patients receive buparlisib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3287144|NCT01719263|Experimental|Treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System and Optimal Medical Therapy
3287145|NCT01719263|Active Comparator|Optimal Medical Therapy|Patients will be treated according to Optimal Medical Therapy
3287146|NCT01719276|Active Comparator|Graded Activity|Exercise treadmill, Strengthening of the lower limbs and trunk
3287147|NCT01719276|Active Comparator|Supervised exercises|Stretching, Strengthening, Motor Control
3287148|NCT01719289|Experimental|PROGRAVIDA|All women in this arm receive a stepped-care program for depression based on psycho-education and problem solving techniques.
3287149|NCT01719289|No Intervention|Treatment as usual|Primary health care professionals in charge of prenatal care are notified by the research team about all women with depression receiving pre-natal care and included in the trial. Primary health care professionals decide how to treat these women without any interference from the research team.
3287150|NCT01719302|Experimental|cohort 1|
3287151|NCT01719315||MDD with Hypersomnia|Participants with Major Depressive Disorder and co-morbid hypersomnia
3287152|NCT01719315||MDD without hypersomnia|Participants with Major Depressive Disorder but without co-morbid hypersomnia
3287153|NCT01719315||BPAD with hypersomnia|Participants with Bipolar Affective Disorder and co-morbid hypersomnia
3287154|NCT01719315||BPAD without hypersomnia|Participants with Bipolar Affective Disorder without co-morbid hypersomnia
3287155|NCT01719315||Primary Hypersomnia|Patients with primary hypersomnia (idiopathic hypersomnia)
3287156|NCT01719315||Primary Insomnia|Patients with primary insomnia
3287157|NCT01719315||Narcolepsy|Subjects with narcolepsy
3287158|NCT01719315||Healthy Controls|healthy participants
3287159|NCT01719328|Experimental|Vinyasa yoga|Group administered 60 minute vinyasa yoga classes delivered twice weekly for 8 weeks
3287160|NCT01719354|Experimental|Community Health center|Aftercare in a community Health center
3287161|NCT01719354|Active Comparator|Control|AFtercare as usual in hospital/Mental health centers of District Psychiatric Service (DPS.
3287162|NCT01719406|Experimental|Intervention, behavioral lifestyle education|Pregnant women will participate in 20 educational sessions designed to promote daily exercise, vegetable and fruit intake, maintain a diet that is relatively lower in fat and rich in whole grains.
3287163|NCT01719406|No Intervention|Control|Standard medical care
3287164|NCT01719419|Experimental|Placebo|Fatty food intake on the day the Modified sham feeding technique with placebo compared to the day modified sham feeding with orlistat.
3287165|NCT01719419|Experimental|Orlistat|Fatty food intake on the day of the modified sham feeding technique with orlistat compared to the day with placebo.
3287166|NCT01719432||Obese patients|
3287167|NCT01719432||Non-obese patients|
3287168|NCT01719445||RFPM/Paper and Pen Method|
3287169|NCT01719458||Alcohol|Subjects diagnosed with alcohol dependence
3287170|NCT01719458||Obese|Subjects diagnosed with obesity
3287171|NCT01719458||Healthy|Subjects deemed to be medically healthy
3287172|NCT01719471||Smokers|Nicotine dependent individuals otherwise medically healthy
3287173|NCT01719471||Healthy|Medically healthy individuals who do not smoke
3287174|NCT01719484||Healthy|Subjects deemed to be medically healthy
3287175|NCT01719484||Obese|Subjects deemed to be medically obese
3287176|NCT01719497||Alcohol|Subjects diagnosed with alcohol dependence
3287177|NCT01719497||Obese|Subjects diagnosed with obesity
3287178|NCT01719497||High Stress|Subjects diagnosed with high stress
3287179|NCT01719497||Healthy|Subjects deemed medically healthy
3287180|NCT01719510|Other|Positive Group B Streptococcus vaginal sample|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For all women included will be achieved in the delivery room:~a blood sample to the mother and a sampling of umbilical cord blood. Newborns will have a search for GBS (standard culture) in the stools and the pharynx.~For mothers, the collection of milk when breastfeeding."
3287181|NCT01719523|Experimental|EPI-743|EPI-743- Participants will receive 200mg three times a day of EPI-743 for 2 weeks and then receive 300mg of EPI-743 for an additional 2 weeks.
3287182|NCT01719536|Experimental|Icotinib|Icotinib 125mg is administered orally three times per day.
3287183|NCT01719536|Active Comparator|Chemotherapy|Patients in this arm will receive pemetrexed/cisplatin for 4 cycles, of who don't progress will receive maintenance treatment with pemetrexed.
3287184|NCT01719549|Experimental|Dovitinib|
3287188|NCT01719575|Other|Motilitone|take motilitone 30mg three times daily for the first week After 7 day wash-out period, take placebo three times daily for the second week
3287189|NCT01719575|Other|Placebo|take placebo three times daily for the first week After 7 day wash-out period, take motilitone 30mg three times daily for the second week
3287190|NCT01719588||Prolonged release tapentadol|Patients will be taking prolonged release tapentadol hydrochloride as per the product insert approved in Philippines.
3287191|NCT01719601||Immediate release tapentadol|Patients will be taking immediate release tapentadol hydrochloride as per the product insert approved in Philippines.
3287192|NCT01719614|Experimental|Rilpivirine+Metformin|All participants will receive study medications in two sessions in a fixed, sequential order as a session 1 (a single dose of metformin on Day 1) followed by washout period (period when no treatment is received) of 4 days and then session 2 (rilpivirine on Day 5 to Day 17 with a single dose of metformin on Day 15).
3287193|NCT01719627|Experimental|MVC 300 mg|MVC 300 mg in unique dose
3287194|NCT01719627|Active Comparator|TVD 300/200 QD|TVD 300/200 QD during 7 days.
3287195|NCT01719627|Experimental|Maraviroc 600mg|MVC 600mg in unique dose
3287196|NCT01719640|Experimental|BMMSC+BMMNC|infusion of BMMSC+BMMNC and insulin injection
3287197|NCT01719640|Active Comparator|BMMNC|infusion of BMMNC and insulin injection
3287198|NCT01719640|Active Comparator|Insulin|insulin injection
3287199|NCT01719666|Other|isolated MPFL reconstruction|
3287200|NCT01719666|Experimental|MPFL reconstruction and Lateral retinaculum release|
3287201|NCT01719679|Experimental|School Located Vaccine (SLV) Program|A vaccine program carried out by a community vaccinator will be conducted in a limited number of participating schools. The program will be open to the students enrolled at the participating schools
3287202|NCT01719679|No Intervention|no School Located Vaccine (SLV) Program|Schools that are part of the non-intervention arm of the study will not have a school-located vaccine program.
3287203|NCT01719692|Experimental|Rituximab A group|375mg/m2 for once
3287204|NCT01719692|Active Comparator|Rituximab B group|100mg/week for four weeks
3287205|NCT01719705|Placebo Comparator|Placebo|receive two identical placebo capsules
3287206|NCT01719705|Active Comparator|Pregabalin 150 mg group|one capsule of pregabalin 150 mg
3287207|NCT01719705|Active Comparator|Pregabalin 300 mg group|two capsules of pregabalin 150 mg
3287208|NCT01719718|Active Comparator|Closure|
3287209|NCT01719718|Sham Comparator|Non-Closure|
3287210|NCT01719731|Placebo Comparator|Non-Education|This group will not receive the psychosocial education.
3287211|NCT01719731|Active Comparator|Education|This group will receive the psychosocial education
3287212|NCT01719770|Active Comparator|Rocuronium|Continuous infusion of rocuronium with 0,25mg/kg (blinded) for 29 hours after initiation of mild therapeutic hypothermia
3287213|NCT01719770|Placebo Comparator|Placebo|Continuous infusion of sodium-chloride (placebo) and rocuronium bolus (0,25mg/kg)in case of shivering episode (blinded)
3287214|NCT01719796|Experimental|Bilateral TAP catheter|Ultrasonography guided bilateral TAP catheter insertion.
3287215|NCT01719796|No Intervention|No TAP catheter|
3287216|NCT01719822|No Intervention|Usual Care|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week and a written home exercise plan/diary.
3287217|NCT01719822|Experimental|Intervention|Standard 8-week pulmonary rehabilitation programme with 2 supervised sessions per week. In addition they will receive a pedometer with a daily step count target set by a physiotherapist and a written home exercise plan/diary.
3287218|NCT01719835|Experimental|Chemotherapy GEM-P|Gemcitabine, Methylprednisolone, Cisplatin
3287219|NCT01719835|Active Comparator|Chemotherapy CHOP|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
3287220|NCT01719848||Preoperative airway examination|patients undergoing general anesthesia for any surgery
3287221|NCT01719874|Experimental|TCN-032|single-dose, administered intravenously
3287222|NCT01719874|Placebo Comparator|Placebo (saline)|single-dose, administered intravenously
3287223|NCT01719887|Active Comparator|Conservative treatment|Conservative treatment with functional brace and physiotherapy.
3287224|NCT01719887|Experimental|Operative treatment|Operative treatment with open reduction and internal fixation with 4,5mm locking compression plate. Physiotherapy at 3 and 9 wks.
3287225|NCT01719913|Active Comparator|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
3287226|NCT01719913|Placebo Comparator|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
3287227|NCT01719926|Experimental|Capecitabine/Oxaliplatin|Patients receiving Capecitabine/Oxaliplatin chemotherapy
3287228|NCT01719926|Experimental|Cisplatin + Xeloda(Capecitabine) or Gemcitabine|Patients receiving Cisplatin regimen
3287229|NCT01719952|Experimental|Carbetocin|Carbetocin 100 µg, given as an intravenous bolus over 30 seconds others names are: duratocin, pabal
3287230|NCT01719952|Active Comparator|Oxytocin|Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
3287231|NCT01719965||Health Workers|"Worked in SMRU for at least 6 months~Clinic assistants, medics or home visitors"
3287232|NCT01719965||Researchers|"Worked in SMRU for at least 6 months~Physician or scientist"
3287233|NCT01719965||CAB members|- Member of the CAB for at least 3 months
3287234|NCT01719965||Community members|- Lived in the border area (area served by SMRU or Mae Sot) for at least 6 months
3287235|NCT01719965||Research subjects|- Participants who are currently enrolled in an SMRU study
3287236|NCT01719978|Active Comparator|Hyaluronidase|Lower Third Molar Extraction -- 3.6mL 2% Mepivacaine with 1:100,000 epinephrine + Hyaluronidase
3287237|NCT01719978|Placebo Comparator|Placebo|Lower Third Molar Extraction -- Anesthetic: 3.6 mL of the LA 2% HCl mepivacaine with 1:100,000 epinephrine + Placebo (0.9% saline)
3287238|NCT01719991|Experimental|Nurse case management and self-management support|The first component of the intervention is the monitoring offered under the case management process. The second component of the intervention consists of group meetings (10-12 people) for self-management support in accordance with the stanford model. A sample of patients in each of the four FMGs (n = 126) will be recruited. These patients will receive the intervention for six months.
3287239|NCT01719991|No Intervention|Control group|Patients in the control group (n = 121) will receive the usual care for six months and then the same intervention as the experimental group for the next five months (waiting list control group).
3287240|NCT01720004|Experimental|Repeated Use of Hands-and-Knees|The intervention was repeated use of hands-and-knees position during labour. Participants were asked to try it for at least 15 minutes every hour, from randomization until delivery. They were not required to use it for delivery.
3287241|NCT01720004|No Intervention|Usual care|Participants were asked to refrain from using hands-and-knees position at any time from randomization to delivery. They were free to use any other position.
3287242|NCT01720017|Active Comparator|Inservice Training Only|Inservice training will include review of a product information handout and a video demonstration. Specific attention will be given to (1) describing each system component and its operation, (2) attaching the wireless camera head and coordinating channel selection with the monitor, (3) turning on the Airtraq Avant light and device preparation for use, (4) Airtraq Avant insertion into the patient's mouth and advancement into the hypopharynx (deep in the throat) to obtain a view of the vocal cords, (5) use of standard lift and rotation movements to optimize the vocal cord view, (6) tracheal tube advancement through the vocal cords tracheal intubation, (7) standard methods for confirmation of correct tracheal tube placement, (8) tracheal tube removal from the Airtraq Avant and the Airtraq Avant removal from the patient's mouth, and (9) disposal of the disposable blade and cleaning of the reusable optics insert.
3287243|NCT01720017|Experimental|Inservice and Manikin Training|Study subjects in this group will receive the standard inservice training described above, as well as, preclinical manikin training on use of the Airtraq Avant and Wireless Monitor System in simulated difficult airway conditions (swollen tongue and cervical collar). During the preclinical manikin training, each subject will perform 10 intubations. Performance characteristics including attempts for successful Airtraq Avant insertion, glottic view obtained, ease of insertion, ease of tracheal intubation, time required for tracheal intubation, and attempts for successful tracheal intubation will be recorded for each intubation.
3287244|NCT01720030|Placebo Comparator|Conventional therapy|Standard of care as protocolized locally
3287245|NCT01720030|Experimental|Levosimendan|The experimental group receives standard treatment supplemented by levosimendan (0.2 µg/kg/min) for 24 hours within 36 hrs following onset of AKI.
3287246|NCT01720056|Active Comparator|Verapamil|Verapamil 2.5 mg/mL injection sc intralesionally
3287247|NCT01720056|Active Comparator|Kenalog 10|Kenalog 10 mg/mL injection sc intralesionally
3287248|NCT01720082|Active Comparator|Single incision laparoscopic appendectomy|Acute appendicitis with surgical indication
3287249|NCT01720082|Active Comparator|Multiport Laparoscopic appendectomy|Acute appendicitis with surgical indication
3287250|NCT01720095|Experimental|Niaspan|these are the first episode psychosis patients that are randomized to receive niaspan
3287251|NCT01720095|No Intervention|healthy control|this is the group of healthy controls for cognitive outcome measures
3287252|NCT01720095|No Intervention|first episode control group|first episode psychosis patients who are randomized to no intervention
3287253|NCT01720108|Active Comparator|rivaroxaban|rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
3287254|NCT01720108|Experimental|ASA|ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients
3287255|NCT01720121|No Intervention|Control group|The control group received the guidelines orientation provide by nursing team
3287256|NCT01720121|Experimental|Guidelines printed group|The patient received the informative material in details about the cardiac catheterization provide by the researchers
3287257|NCT01720121|Experimental|Guidelines digital video disc group|Guidelines digital video disc group: The patient received the informative provide by digital video disc in details about the cardiac catheterization
3287258|NCT01720134||after legislation 1st july 2003|2003-2006
3287259|NCT01720134||before legislation 1st july 2003|1999-2003
3287260|NCT01720160|Experimental|Device|1) BAROSTIM NEO System and 2) standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
3287261|NCT01720160|Active Comparator|Medical Management|Standard of care medical management therapy for heart failure (American Heart Association [AHA] / American College of Cardiology [ACC] guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
3287262|NCT01720186|Experimental|SPI Medical device|SPI medical device used during PET/CT 4D imaging in a synchronized mode centered on the thorax.
3287263|NCT01720186|Active Comparator|reference medical device : RPM|Reference medical device (RPM) used simultaneously during PET/CT 4D imaging in a synchronized mode centered on the thorax.
3287264|NCT01720199|Experimental|Intervention group|Preadolescents allocated to the Diario della Salute (DDS) intervention.
3287265|NCT01720199|No Intervention|Control group|
3287266|NCT01720212|Experimental|Single dose group|
3287267|NCT01720212|Experimental|Multiple dose group|
3287268|NCT01720238||Group 1|Entecavir Therapy
3287269|NCT01720238||Group 2|Lamivudine plus Adefovir Dipivoxil Therapy
3287270|NCT01720290|Experimental|Rep|
3287271|NCT01720290|Active Comparator|Met|
3287272|NCT01720290|Active Comparator|Rep + met|
3287273|NCT01720303|Experimental|Rep + NPH|
3287274|NCT01720303|Active Comparator|Premixed insulin/NPH|
3287275|NCT01720329|Active Comparator|Probiotics|Participants randomized to probiotics will receive 2 capsules supplemented with 10 billion cfu of Lactobacillus rhamnosus GG on a daily basis for six months
3287276|NCT01720329|Placebo Comparator|Probiotic placebo|Participants randomized to placebo will receive 2 capsules of matching placebo on a daily basis for six months
3287277|NCT01720342||Aortic valve stenosis, aortic valve insufficiency|Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.
3287278|NCT01720368||1st Group of 50 patients|
3287279|NCT01720368||2nd Group of 50 patients|
3287280|NCT01720394|Experimental|Cervical ripening balloon|primary treatment with the cervical ripening balloon on day 1. removal of the balloon latest after 12 h. If no progression of labor (Bishop Score ≥ 9 and/or cervical opening ≥ 3 cm) continuing of standard treatment using dinoprostone vaginal-inserts on day 2 and if necessary on day 3.
3287281|NCT01720394|Active Comparator|Propess|Primary treatment using dinoprostone-vaginal-inserts on day 1-3 if no progression of labor (Bishop Score ≥ 9 and/or cervical dilatation ≥ 3 cm)
3287282|NCT01720407|Experimental|Imiquimod|
3287283|NCT01720407|Placebo Comparator|Placebo|
3287284|NCT01720420|Experimental|Mandible|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
3287285|NCT01720420|Experimental|Maxilla|NobelReplace CC NobelProcera Implant Bar Titanium Overdenture (lab-made)
3287286|NCT01720433|Experimental|intervention|In the intervention group, in addition to the above, the patient was placed in the Trendelenburg position (30°) and a pulmonary recruitment maneuver utilized, consisting of two manual inflations to a maximum pressure of 60 cm H2O. This was performed by the Anaesthetist, who held each positive pressure inflation for five seconds, with the valves on the operative ports fully open.
3287287|NCT01720433|No Intervention|control arm|In the control group residual carbon dioxide pneumo-peritoneum was evacuated at the end of the procedure by passively allowing the abdomen to decompress by opening the operative ports.
3287288|NCT01720459|Active Comparator|Micronized trans-resveratrol|Micronized trans-resveratrol
3287289|NCT01720459|Placebo Comparator|Placebo|
3287290|NCT01720472||Community, Physical Performance|
3287291|NCT01720485|Experimental|Desloratadine + Prednisolone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the test medication(Desloratadine 5 mg + Prednisolone 20 mg) + 1 tablet of placebo control medication.~Afternoon: 1 tablet of placebo test medication + 1 tablet of placebo control medication.~Night: 1 tablet of placebo test medication + 1 tablet of placebo control medication."
3287292|NCT01720485|Active Comparator|Dexchlorpheniramine + Betamethasone|"The patients will take 2 tablets three times a day, as follows:~Morning: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Afternoon: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication.~Night: 1 tablet of the control medication(Dexchlorpheniramine 2mg + Betamethasone 0.25mg) + 1 tablet of placebo test medication."
3287293|NCT01720498|Experimental|Male|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3287294|NCT01720498|Experimental|Female|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3287295|NCT01720511|Experimental|Purple Rice|Twice a day given purple rice with 5mg of resveratrol.
3287296|NCT01720511|Active Comparator|Brown RIce|Plain Purple rice given twice a day
3287297|NCT01720537|Experimental|Cohort 1|
3287298|NCT01720537|Experimental|Cohort 2|
3287299|NCT01720537|Experimental|Cohort 3|
3287300|NCT01720537|Experimental|Cohort 4|
3287301|NCT01720537|Experimental|Cohort 5|
3287302|NCT01720537|Experimental|Cohort 6|
3287303|NCT01720550|Experimental|PG2 High Dose|Astragalus Polysaccharides 500 mg
3287304|NCT01720550|Experimental|PG2 Low Dose|Astragalus Polysaccharides 250 mg
3287305|NCT01720563|Placebo Comparator|Control|Placebo
3287306|NCT01720563|Experimental|Treatment|Astragalus polysaccharides 500 mg
3287307|NCT01720576|Experimental|Cohort 1|Dose 1 of REGN1033 (SAR391786) or Placebo
3287308|NCT01720576|Experimental|Cohort 2|Dose 2 of REGN1033 (SAR391786) or Placebo
3287309|NCT01720576|Experimental|Cohort 3|Dose 3 of REGN1033 (SAR391786) or Placebo
3287310|NCT01720589|Experimental|Melt (test oil)|Participants will consume a muffin containing 20 g of dietary fat provided by the test oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the test oil and their food intake at an ad libitum meal will be measured 1 hour later.
3287311|NCT01720589|Active Comparator|Corn oil (control)|Participants will consume a muffin containing 20 g of dietary fat provided by the control oil and their energy expenditure will be measure post-prandially for 6 hours. At the end of the measurement period, participants will consume a cookie containing 10 g of fat provided by the control oil and their food intake at an ad libitum meal will be measured 1 hour later.
3287312|NCT01720615|No Intervention|Propofol or Sevoflurane|General anesthesia
3287313|NCT01720628||Behçet's patients|Serum levels of angiogenin, bFGF, VEGF levels in Behçet's patients with ocular involvement group, without ocular involvement group and control group
3287314|NCT01720641|No Intervention|Control|Standardized partner notification counseling
3287315|NCT01720641|Experimental|Internet Notification|Standardized partner notification counseling and referral to internet-based partner referral website.
3287316|NCT01720641|Experimental|Referral Card|Standardized partner notification counseling and provision of 5 printed partner referral cards.
3287317|NCT01720641|Experimental|Internet and Referral Card|Standardized partner notification counseling and referral to internet-based partner referral website and provision of 5 printed partner referral cards.
3287318|NCT01720654|No Intervention|Control|Standardized partner notification counseling.
3287319|NCT01720654|Experimental|EPT|Standardized partner notification counseling and provision of 5 partner treatment (EPT) packets.
3287320|NCT01720693|Experimental|hypoperfusion|Hypoperfusion of the renal artery
3287321|NCT01720706|Experimental|Acute|The RFA Loosely wound thermal coil electrode will be inserted directly or percutaneously into the lesion, depending on the imaging modality (US or CT guidance) and deployed with same method as previously described in the 'delayed group'. Energy will be delivered using the single timed heating cycle. Treatment will be monitored with B mode US. Once the cycle is completed, the probe will be removed and the planned surgery will continue with partial or radical nephrectomy.
3287322|NCT01720706|Experimental|Delayed|Using an electrically insulated 12ga introducer with trocar is inserted percutaneously into the renal tumor. The needle tip will be placed 20mm from the center of the target. The trocar is removed and co-axially (i.e. within the introducer), a core biopsy of the lesion is performed with a 14-18 gauge needle. The radiofrequency applicator with a 14ga cannula containing the RFA Loosely wound thermal coil electrode is then optimally positioned and locked into the introducer. On approximately day 6-10, a partial or radical nephrectomy will be performed in the usual way.
3287323|NCT01720719|Active Comparator|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
3287324|NCT01720719|Experimental|Atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
3287325|NCT01720732|Experimental|Lifeline NET|Lifeline-NET (Short Version of NET)
3287326|NCT01720732|No Intervention|TAU|Treatment as Usual
3287327|NCT01720745||EUS FNA|Patients undergoing endoscopic ultrasound for solid mass lesions with a 22 G needle at University of Minnesota Medical center and Aurora St.Luke's Medical Center, Milwaukee, WI
3287328|NCT01720771|Active Comparator|Probiotic tablet|a tablet with three probiotic streptococci strains (S. uberis KJ2, S. oralis KJ3 and S. rattus JH145) at a concentration of 3x108 CFU
3287329|NCT01720771|Placebo Comparator|Sugar pill|The same tablet but without active probiotic bacteria
3287330|NCT01720784|Placebo Comparator|Placebo|
3287331|NCT01720784|Experimental|Low dose (1.5 g DF)|
3287332|NCT01720784|Experimental|High dose (2.25 gDF)|
3287333|NCT01720823|Experimental|home polysomnography and standard polysomnography|home polysomnography (GETEMED) and standard polysomnography (BRAINNETII) are both carried out in children during 1 night.
3287334|NCT01720836|Experimental|Stage IA or I/II NSCLC|Resection or radiotherapy without adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
3287335|NCT01720836|Experimental|Stage IB/II/IIIA|Resection and adjuvant chemotherapy followed by 3 cycles of vaccine + PolyICLC.
3287336|NCT01720836|Experimental|Stage IIIA or IIIB|Concomitant chemo-irradiation followed by 3 cycles of vaccine + PolyICLC.
3287337|NCT01720849||Fampyra group|
3287338|NCT01720862||Episodic migraineurs|Those with migraines >2 and < 12 times per month.
3287339|NCT01720862||Chronic migraineurs|Those with migraines greater than 14 days per month.
3287340|NCT01720862||Controls|Those without headaches other than occasional hangover, cold, flu headaches.
3287341|NCT01720875|Experimental|Vorinostat Velcade Dexamethasone (VVD)|"Up to 8 cycles of VVD followed by vorinostat maintenance until disease progression.~Cycles 1-8 (21-day cycle)~Velcade: 1.3mg/m2 (subcutaneous) on days 1, 4, 8 and 11~Dexamethasone: 20 mg (PO) on days 1, 2, 4, 5, 8, 9, 11 and 12~Vorinostat: 400mg (PO) on days 1-4, 8-11, 15-18 Maintenance (28-day cycle)~Vorinostat: 400mg PO on 1-4 and 15-18"
3287342|NCT01720888|No Intervention|Maximal medical therapy|Maximal medical therapy which comprises of optimal pharmacological therapy
3287343|NCT01720888|Experimental|Maximal medical therapy and BM-MSCs|Autologous Bone marrrow-derived mesenchymal stem cells implantation
3287344|NCT01720901|Experimental|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
3287345|NCT01720914||Critically ill patient|
3287346|NCT01720927||Acute Pharyngitis|Subjects presenting with acute pharyngitis
3287347|NCT01720940|Experimental|continuous vancomycin infusion|
3287348|NCT01720940|Active Comparator|intermittent vancomycin infusion|vancomycin in this arm will be administered as intermittent infusion
3287349|NCT01720953||Healthy control subjects|Matched healthy control subjects will be assessed at 6 month intervals to compare changes in DNA methylation, BDNF serum levels, salivary cortisol levels, and neuropsychological test performance. Healthy control subjects will within the 1-year study period also undergo continuous assessment for comparative changes in symptoms of dissociation, depression, and personality dysfunction.
3287350|NCT01720966||Laparoscopy|Patients who will undergo liver resection who have a laparoscopically performed colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
3287351|NCT01720966||Laparotomy|Patients who will undergo liver resection who have an open colorectal resection in history. Assignment to cohort is on intention to treat of the primary operation.
3287352|NCT01720979||Patients with traumatic injuries|Children that were admitted to the hospital after traumatic injuries to body parts below the clavicles (traumatic control injury) and children that were admitted to the hospital after traumatic brain injury as diagnosed by a physician (TBI).
3287353|NCT01720992|Experimental|Group A|A theory-based action planning toolkit will be distributed to Group A participants.
3287354|NCT01720992|Other|Group B|Group B is a wait list control
3287355|NCT01721005|Other|pulse palpation education|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model
3287356|NCT01721018|Experimental|HSV1716|Single Arm Phase I/II study of intra-pleural HSV1716 administration.
3287357|NCT01721031|Experimental|DPNB|Patients receive DPNB 30min before extubation at the end of operation.
3287358|NCT01721031|Active Comparator|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
3287359|NCT01721083|Experimental|Z-Track immunization|Subject receives Intramuscular injection by z-track method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
3287360|NCT01721083|Active Comparator|Bunch immunization|Subject receives Intramuscular injection by bunch method during flu vaccination given by employee health Registered Nurse into deltoid muscle.
3287361|NCT01721135|Experimental|GSK2190915 100mg|GSK2190915 100mg on days 1-5; moxifloxacin placebo on day 5
3287362|NCT01721135|Experimental|GSK2190915 1000mg|GSK2190915 1000mg on days 1-5; moxifloxacin placebo on day 5
3287363|NCT01721135|Active Comparator|moxifloxacin 400mg|placebo tablet on days 1-5; moxifloxacin 400mg on day 5
3287364|NCT01721135|Placebo Comparator|placebo|placebo tablet on days 1-5; moxifloxacin placebo on day 5
3378784|NCT01552356|Experimental|Treatment (pazopanib hydrochloride)|Patients receive pazopanib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Course length can be extended to 56 days at the discretion of the treating physician after 12 courses (1 year) of treatment on study.
3287365|NCT01721148|Other|Cohort Dose Escalation|open label dose escalation study of ASLAN002 administered orally on a once daily schedule to subjects with advanced or metastatic solid tumours, who have either progressed on standard therapy or for whom standard therapy is not known
3287366|NCT01721174|Active Comparator|SEMS only|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. An uncovered self expanding metallic stent (SEMS) would be inserted to bypass the site of narrowing (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea)
3287367|NCT01721174|Active Comparator|EBRFA and SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the length of the biliary stricture, diameter, and position. The radiofrequency ablation (EBRFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter with energy delivered by an RFA generator would be used to apply RFA to the entire length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. Patients would undergo 2 sessions of EBRFA 2 weeks apart. A plastic stent would be inserted in between the 2 sessions. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after the second EBRFA.
3287368|NCT01721187||Low disinhibition|fMRI during fed and fasted states
3287369|NCT01721187||High disinhibition|fMRI during fed and fasted states
3287370|NCT01721213||Patients using Trobalt™|Use of Trobalt™ current use or at least one prescription filled within the previous three months.
3287371|NCT01721213||Physicians prescribing AEDs|Physicians (neurologists) who prescribed AEDs at least once in the three months prior to the survey.
3287372|NCT01721213||Physicians Prescribing Trobalt™|Physicians (neurologists) who have had experience of prescribing Trobalt™ specifically, from among those who have prescribed AEDs at least once in the three months prior to the survey.
3287373|NCT01721239|No Intervention|Control group|No intervention
3378795|NCT01510184|Experimental|Zevalin|Participants received rituximab 250 milligram per meter square (mg/m^2) by intravenous infusion on Day 1. If required by the governing regulatory agency, rituximab was to be followed 4 hours later by In-111-Zevalin 5.0 millicurie (mCi) on Day 1. And on Days 7-9: participants received rituximab 250 mg/m^2 by intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 millicurie/kilogram (mCi/kg) 10-minute intravenous push (0.3 mCi/kg in participants with a platelet count in 100,000/ microliter [μL] to 149,000/μL).
3378796|NCT01510184|No Intervention|Observation|Participants who were randomized in this arm group did not receive any anti-lymphoma therapy unless they had a relapse of their disease.
3287374|NCT01721239|Experimental|Standardized Followup program|Standardized written information, patient photos and three follow-up consultations.
3287375|NCT01721291|Experimental|SALBUTAMOL 1.5 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3287376|NCT01721291|Experimental|SALBUTAMOL 3 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3287377|NCT01721291|Experimental|SALBUTAMOL 6 MICRONS|DOSAGE FORM- SALBUTAMOL INHALED VIA RESEARCH NEBULISER;DOSAGE- 30 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT THREE VISITS (ONE VISIT INHALE SLOWY, ANOTHER VISIT INHALE FAST, ANOTHER VISIT INHALE SLOW AT 15 MICROGRAMS)
3287378|NCT01721291|Active Comparator|SALBUTAMOL 200 MICROGRAMS|DOSAGE FORM- SALBUTAMOL INHALED VIA METERED DOSE INHLAER;DOSAGE- 200 MICROGRAMS, ONCE SINGLE INHALATION ONLY; FREQUENCY- AT ONE VISIT INHALE SLOWY)
3287379|NCT01721304|Experimental|Adaptive Conjoint Analysis|Computerized survey to elicit preferences
3287380|NCT01721304|No Intervention|Usual care|Patients are counseled by their physician as usual
3287381|NCT01721343|Experimental|Arm I (enhanced usual care)|Patients undergo enhanced usual care comprising telephonic monitoring with monthly status reports provided to their oncology care teams for 6 months.
3287382|NCT01721343|Experimental|Arm II (enhanced usual care, RCM)|Patients undergo enhanced usual care as in Arm I and participate in an individualized conditioning program delivered telephonically by the Fitness Care Manager (FCM) and adapted, as required, by a local physical therapist for 6 months.
3287383|NCT01721343|Experimental|Arm III (enhanced usual, RCM, PCM)|Patients undergo enhanced usual care as in Arm I, participate in an individualized conditioning program coordinated by the FCM as in Arm II, and receive optimized pain management through a nurse Pain Care Manager (PCM) for 6 months.
3287384|NCT01721356||Healthy individuals|Healthy individuals ranging in age, race, ethnicity, socioeconomic status, and years of education
3287385|NCT01721382|Experimental|Sitagliptin|Treatment with sitagliptin
3287386|NCT01721395|Placebo Comparator|Colored, Flavored water|The placebo will be colored to approximate the reddish amber color of the agave syrup. The placebo will use the same flavoring used in the agave syrup. The placebo will be created in a GMP facility
3287387|NCT01721395|Experimental|Agave Syrup|The formulation of pasteurized agave syrup consists of pasteurized agave syrup and natural flavoring.
3287388|NCT01721395|Sham Comparator|Air-filled oral syringe|Air-filled oral syringe to match experimental and placebo arm
3287389|NCT01721421|Experimental|Extended Treatment time|Extended treatment time of 6 hours
3287390|NCT01721421|Active Comparator|standard treatment time|Standard Treatment time of 4 hours
3287391|NCT01721434|Experimental|Levosimendan|Levosimendan 0.2 ug/kg/min intravenous for a single 7 hours.
3287392|NCT01721434|Placebo Comparator|Placebo|Similar coloured placebo intravenous for a single 7 hours
3287393|NCT01721499|Experimental|Mindfulness intervention|"The mindfulness intervention consists of weekly group format mindfulness instruction and skills development, weekly individual therapy sessions, and 6 nutritional sessions.~The control group receives 6 nutritional sessions only."
3287394|NCT01721499|Active Comparator|Nutrition Control Group|The control group receives 6 nutritional counseling sessions.
3287395|NCT01721512||Breast-fed infants|80 infants of mothers who plan to exclusively breastfeed for at least 6 months.
3287396|NCT01721512||Formula-fed infants|"Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.~Mother consents to her infant receiving trial infant formula for 12 months"
3287397|NCT01721525|Experimental|afatinib, ribavirin, and weekly carboplatin/paclitaxel|This will be a single institution phase I study with an expansion cohort. Up to 2 dose levels of daily afatinib will be studied: 30 mg/day and 40 mg/day. The doses of ribavirin, carboplatin, and paclitaxel are fixed. A standard 3 + 3 phase I dose escalation design will be used.
3287398|NCT01721538|Experimental|Therapy arm|Non-drug therapeutic weight reduction program (15 weeks)
3287399|NCT01721538|Placebo Comparator|Control arm|Lecture on healthy nutrition (1 hour)
3287400|NCT01721551|Experimental|Exercise training|HD patients will receive a 9 months intradialytic exercise training program
3287401|NCT01721551|Placebo Comparator|No exercise|HD patients will not participate in any type of systematic exercise training
3287402|NCT01721577|Experimental|AXL1717|In the first phase, 10-20 patients will be enrolled and treated with 300-520 mg BID of AXL1717 for 28 days. The primary endpoint of the first phase is to determine the recommended Phase 2 dose (RP2D) of AXL1717 and to assess the safety and toxicity of AXL1717. The study has a 3+3 design and the first cohort will be treated with 400 mg AXL1717 BID for 28 days repeated in up to 5 cycles. The highest dose level without DLT or with maximally one DLT out of 6 patients will be the RP2D. Non-progressing patients may be treated for a total of five 28-day cycles (24 weeks).
3287403|NCT01721590|Placebo Comparator|Control|Placebo，3 capsules/time，3times/day for 1 year
3287404|NCT01721590|Experimental|Tongxinluo|Tongxinluo 3 capsules/time 3times/day for 1 year
3287405|NCT01721616|Active Comparator|Cefazolin|single antibiotic
3287406|NCT01721616|Active Comparator|Cefazolin + Azitrhromycin|double antibiotic
3287407|NCT01721629|Other|Sudden wean of nasal CPAP|The CPAP is taken off at the morning ward round. If the discontinuation of the CPAP fails according to prespecified failure criteria, CPAP is recommenced and continued for at least 24 hours. Then a new evaluation takes place and if the infant again meets the inclusion criteria another attempt of sudden wean can be undertaken. Infants are considered successfully weaned if they are off CPAP for three days.
3287408|NCT01721629|Other|Gradual wean of nasal CPAP pressure|The reduction of the CPAP pressure begins at the morning ward round and the pressure is reduced in steps with 1 cmH2O maximum once a day. Each time the pressure is to be reduced the infant needs to be evaluated according to the inclusion criteria and only if these are still met, will the pressure be reduced. When a CPAP pressure at 4 cmH2O is reached the infant is treated with this pressure for 24 hours and then the CPAP is discontinued. Infants are considered successfully weaned if they are off CPAP for three days.
3287409|NCT01721642|Experimental|Apica Cardiovascular ASC Device|Access, stabilisation and closure with the Apica Cardiovascular ASC Device
3287410|NCT01721655|Active Comparator|Spironolactone|Oral spironolactone suspension dosed at 3 mg/kg/day will be administered once-daily to the patients assigned to the treatment arm.
3287411|NCT01721655|Placebo Comparator|Placebo suspension|An oral placebo suspension dosed at 3 mg/kg/day administered once-daily will be given to patients in the placebo arm.
3287412|NCT01721668|Experimental|MSR - Music Supported Rehabilitation|Behavioral: Music Supported Rehabilitation
3287413|NCT01721668|Active Comparator|CU/ET|Experimental: CU/ET (Conventional Upper Extremity Therapy)
3287414|NCT01721694|Experimental|azithromycin 1.5%/Loteprednol 0,5% + placebo|fixed combination of azithromycin 1.5% / Loteprednol 0,5% eye drops + placebo eye drops
3287415|NCT01721694|Active Comparator|azithromycin 1.5% + Loteprednol 0,5% (separately)|azithromycin 1.5% + Loteprednol 0,5% eye drops (separately)
3287416|NCT01721707|Experimental|Latanoprost+Brinzolamide combination|Latanoprost 0.005%(50 mg/ml)+brinzolamide 1%(10mg/ml) eye drops
3287417|NCT01721707|Active Comparator|Latanoprost|Latanoprost 0.005% (50 mg / ml)
3287419|NCT01721733|Placebo Comparator|Placebo|Each patient will receive a volume of placebo based on weight
3287420|NCT01721733|Active Comparator|EPI-743 15 mg/kg|Each subjects dose will be based on their weight. 15 mg/kg with a maximum dose of 200 mg per dose, t.i.d., will be administered in this treatment arm.
3287421|NCT01721733|Active Comparator|EPI-743 5 mg/kg|Each subjects dose will be based on their weight. 5 mg/kg with a maximum dose of 100 mg per dose, t.i.d., will be administered in this treatment arm.
3287422|NCT01721785||Primary staging group I|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group I are patients that will be stratified for direct surgery (TME) or a short-course of radiotherapy (5x5 Gy) followed by immediate TME.~Group I will undergo only a staging MRI, including gadofosveset-enhanced MRI."
3287423|NCT01721785||Restaging group II|"All patients will be treated according to standard practice of the concerning hospital.~Patients in group II are patients that will be stratified for a long course of chemoradiotherapy.~Group II will undergo a staging MRI, a re-staging MRI and a optional sigmoidoscopy as part of restaging. MRI includes diffusion-weighted imaging and gadofosveset-enhanced MRI."
3287424|NCT01721798|Active Comparator|Copper T-380a IUD|Copper T-380a IUD
3287425|NCT01721798|Active Comparator|Mirena Levonorgestrel IUD|Mirena levonorgestrel IUD
3287426|NCT01721811|Experimental|Healthy|Healthy study participanats
3287427|NCT01721811|Experimental|Diabetes|Patients with diabetes
3287428|NCT01721824|Experimental|IPS-MA|"The IPS-MA method consists of five basic services for the participants. 1)Individual mentor support, based on psychiatric knowledge. 2)Coordination by the mentor of activities, internal as well as from external providers. 3)Career counseling aimed at people with mental illnesses. 4)Impartial help to clarify private economy. 5) Contact to employers to help participants obtain jobs, and keep them.~Participants will receive the IPS-MA method in addition to treatment as usual."
3287429|NCT01721824|No Intervention|Control group|"Participants randomised to the control group will receive treatment as usual only. This means the standard support offered by the social- and health services in Denmark."
3287430|NCT01721850|Active Comparator|control formula|infants are fed a commercial stage 1 infant formula during the first 4 months of life, according to protocol
3287431|NCT01721850|Experimental|intervention formula 1 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
3287432|NCT01721850|Experimental|intervention formula 2 group|infants are fed hydrolyzed infant formula containing pre- and probiotics during the first 4 months of life, according to protocol
3287433|NCT01721863|Experimental|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
3287434|NCT01721863|No Intervention|control group|Control group conducted the usual care
3287435|NCT01721889||Radiostereometric analysis - Intact fusion|Clinically fused per classical radiographic assessment (≤ 2 degrees angular motion and evidence of bone bridging)
3287436|NCT01721889||Radiostereometric analysis - Symptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis (not fused, ˃ 2 degrees angular motion or absence of bone bridge) and scheduled for surgical exploration
3287437|NCT01721889||Radiostereometric analysis - Asymptomatic pseudoarthrosis|Definitive clinical evidence of pseudarthrosis without scheduled surgical exploration.
3287438|NCT01721902|Active Comparator|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of autologous CD133+ cells in suspension.
3287439|NCT01721902|Placebo Comparator|Carrier Solution|Intra-myocardial inception of carrier solution.
3287440|NCT01721915|Experimental|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
3287441|NCT01721915|Placebo Comparator|Placebo|the placebo group will receive oily drops without vitD
3287442|NCT01721928||ICU patients with AKI|ICU patients with AKI treated with continuous venovenous hemodialysis
3287443|NCT01721928||ICU patients without AKI|ICU patients without AKI defined as RIFLE group O and R
3287444|NCT01721941|Experimental|Phase I dose level -1|TH-302 25mg; Doxorubicin 50mg
3287445|NCT01721941|Experimental|Phase I Dose level 1|TH-302 50mg; doxorubicin 50mg
3287446|NCT01721941|Experimental|Phase I Dose level 2|TH-302 100mg; doxorubicin 50mg
3287447|NCT01721941|Experimental|Phase 1 Dose level 3|TH-302 150mg; Doxorubicin 50mg
3287448|NCT01721980|Other|50 mg GLPG0974 or placebo|50 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3287449|NCT01721980|Other|100 mg GLPG0974 or placebo|100 mg GLPG0974 dose as oral capsule or placebo oral capsule, daily for 14 days
3287450|NCT01721980|Other|200 mg GLPG0974 or placebo|200 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3287451|NCT01721980|Other|400 mg GLPG0974 or placebo|400 mg GLPG0974 dose as oral capsule or placebo capsule, daily for 14 days
3287452|NCT01721993|Experimental|T121E01F|
3287453|NCT01721993|Active Comparator|zoledronic acid IV|
3287454|NCT01722006||Pairing group|Paired, high reward, oral methamphetamine (20 mg) vs placebo Paired, low reward, oral methamphetamine (20 mg) vs placebo Paired, no reward, oral methamphetamine (20 mg) vs placebo Unpaired, oral methamphetamine (20 mg) vs placebo
3287455|NCT01722019|Active Comparator|radiofrequency ablation with VNUS closure fast|Radiofrequency ablation will be performed with VNUS closure fast.
3287456|NCT01722019|Experimental|laser ablation and Tulip fiber|Laser ablation with a 1470 nm wave length in combination with a new fiber, the Tulip fiber.
3287457|NCT01722032|Experimental|Treatment|"The intervention centers' menus were modified to include more fresh fruit, fresh vegetables, low-fat (1%) or skim milk, water, less juice, and less simple carbohydrate snacks. The centers were also encouraged to incorporate fresh fruits and vegetables as often as possible for snack and meal time.~Physical Activity. Physical activity was promoted for at least 60 minutes per day. TV viewing, watching movies and playing computer games were logged and limited to 30 minutes or less per day. Schools adopted Best-Practice Policies."
3287458|NCT01722032|No Intervention|Control|Those schools randomized to the control arm received a safety curriculum and some child care center locations received an attention control consisting of three visits from the University of Miami Safety Van which provided parents and teachers with home, car and child seat safety information. The control group received all the same pre-post measures as the intervention arms. They also received the same incentives as the intervention arms to foster involvement and ensure retention/reduce loss to follow up.
3287459|NCT01722058|Experimental|peptide application|
3287460|NCT01722084|Experimental|Community-eùbedded reproductive health interventions|Members of communities that belonged to the intervention arm were exposed to complex interventions addressing different target groups (adolescents, parents, authorities and health providers) and focusing on various behaviours that were related to communication about sexuality, information seeking, access to health care and safe sexual intercourse.
3287461|NCT01722084|No Intervention|Community members without intervention|
3287462|NCT01722110|Experimental|Indomethacin Extended-Release Capsules USP 75 mg|Indomethacin Extended-Release Capsules USP 75 mg of Ipca Laboratories Limited, India
3287463|NCT01722110|Active Comparator|Indomethacin Extended Release Capsules USP 75 mg|Indomethacin Extended Release Capsules USP 75 mg of Epic Pharma, USA.
3287464|NCT01722123|No Intervention|DLST Only|Patients will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
3287465|NCT01722123|Experimental|Contemplate only|Patients will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
3287466|NCT01722123|Experimental|Decide with advice|Patients will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, patients will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
3287467|NCT01722123|Experimental|Decide without advice|Patients will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
3287468|NCT01722136|Experimental|Low Dosage|Exercise dose of 8kcal/kg/week
3287469|NCT01722136|Experimental|High Dosage|Exercise dose 14kcal/kg/week
3287470|NCT01722149|Experimental|Adoptive Transfer of re-directed T cells|Adoptive Transfer of re-directed FAP specific T cells in the pleural effusion
3287471|NCT01722175|Experimental|Arm I (ALPPS)|Patients undergo Associating Liver Partition with Portal Vein Ligation (ALPPS) step 1 surgery on day 0 and step 2 surgery 7-14 days later, based on patient's liver size.
3287472|NCT01722175|Active Comparator|Arm II (PVO)|Patients undergo portal vein occlusion (PVO) step 1 on day 0 and step 2 surgery 6-8 weeks later, based on patient's liver size.
3287473|NCT01722188||Optim Leads|
3287474|NCT01722201|Experimental|Risperidone Tablet 1 mg|Risperidone Tablet 1 mg of M/s Ipca Laboratories Limited, India
3287475|NCT01722201|Active Comparator|Risperdal®|Risperdal® (Risperidone) Tablet 1 mg of Janssen Pharmaceutica Products, USA
3287476|NCT01722214|Experimental|Group Adalimumab|A total of 53 patients with moderate to severe psoriasis will randomized in the adalimumab group. At Day 0 patients will receive adalimumab. It will be administered sub-cutaneously as described in the Canadian product monograph (80mg followed by 40mg at Week 1 and 40mg every other week). At Week 16, all patients will received two injections of placebo. As of Week 17, patients randomized to the adalimumab group will receive 40 mg adalimumab every other week until Week 51.
3287477|NCT01722214|Placebo Comparator|Placebo Group|A total of 53 patients with moderate to severe psoriasis will be randomized in the placebo group. At Day 0 these patients will receive the placebo. It will be administered sub-cutaneously as described in the Canadian product monograph of adalimumab. At Week 16, all these patients will received two injections of adalimumab. As of Week 17, patients randomized to the placebo group will receive 40 mg adalimumab every other week until Week 67.
3287478|NCT01722227|Active Comparator|Liraglutide 0.6mg|Daily Injection
3287479|NCT01722227|Placebo Comparator|Placebo|Daily Injection
3287480|NCT01722240|Active Comparator|Liraglutide 1.8mg|Daily Injection
3287481|NCT01722240|Placebo Comparator|Placebo|Daily Injection
3287482|NCT01722253||placebo, electroacupuncture|"Electroacupuncture before and after surgery (40min and 60 min respectively) with frequency 2 Hz, and 'frequency scanning mode'.~Placebo electroacupuncture, in which the needles are secured (without penetrating the skin) and connected to the electrical device, which is not functional."
3287483|NCT01722279||Bariatric surgery patients, at least 5 years post-surgery|Survey participants had bariatric surgery at the St. Vincent Bariatric Center of Excellence at least 5 years before completing survey.
3287484|NCT01722305|Experimental|Treatment (pomalidomide, dexamethasone)|Patients receive pomalidomide PO on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3287485|NCT01722344|Experimental|Individual Placement and Support (IPS)|
3287486|NCT01722344|Experimental|IPS plus|Individual Placement and Support plus cognitive remediation and work-related social skills training
3287487|NCT01722344|No Intervention|Standard intervention|
3287488|NCT01722357|Experimental|Pedometer + Exercise Counseling|
3287489|NCT01722357|Experimental|Pedometer|
3287490|NCT01722357|No Intervention|Usual Care|"Self-help information provided on physical activity (WIN:Weight Control Network Active At Any Size provided by National Institute of Diabetes and Digestive and Kidney Diseases, 2006)."
3287491|NCT01722370|Placebo Comparator|Medical air equivalent|Oxygen-nitrogen mix equivalent to medical air when inhaled from a cylinder at 2l/min
3287492|NCT01722370|Experimental|Oxygen|Ambulatory oxygen delivered at 2l/min on any activity performed by the patient, using a blinded cylinder
3287493|NCT01722383||Chronic kidney disease|Stages 3-5 chronic kidney disease (pre-dialysis)
3378809|NCT01496599||Healthy Volunteers|Subjects without PD diagnosis
3378810|NCT01496599||Parkinsons Disease subjects|Subjects fitting the MSD Clinical Diagnostic Criteria for PD
3378811|NCT01496599||Prodromal Parkinson disease|Subjects fitting the MDS prodromal criteria for PD
3378812|NCT01471444|Experimental|Flu + Bu|Fludarabine 40 mg/m2 intravenous (IV) over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours. Both delivered for 4 consecutive days (days -6 to -3). Stem cell transplant Day 0.
3378813|NCT01471444|Experimental|Flu +Clo + Bu|Fludarabine 10 mg/m2 over 1 hour. Clofarabine 40 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, infused over 1 hour. Busulfan dose calculated to achieve a systemic exposure dose of 6000 µMol-min IV over 3 hours every 24 hours, immediately after Clofarabine. All delivered on 4 consecutive days (days -6 through -3). Stem cell transplant Day 0.
3378814|NCT01464177|Active Comparator|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
3378815|NCT01464177|Experimental|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~the dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
3378816|NCT01445483||1/Cohort 1|KPS>70; Age =65; controlled primary tumor and no extracranial metastases
3287494|NCT01722396|Experimental|Vitamin D|
3287495|NCT01722409|No Intervention|sevoflurane and saline infusion|After induction of general anesthesia, Group S received a placebo infusion of normal saline.
3287496|NCT01722409|Experimental|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
3287497|NCT01722409|Experimental|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
3287498|NCT01722422|Placebo Comparator|normoxia and isotonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
3287499|NCT01722422|Active Comparator|normoxia and 3% hypertonic saline|Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with 3% hypertonic saline during 3 days.
3287500|NCT01722422|Active Comparator|hyperoxia and isotonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with isotonic saline during 3 days."
3287501|NCT01722422|Active Comparator|hyperoxia and 3% hypertonic saline|"Administration of oxygen with FiO2 = 100% during the first 24 hours and after switch oxygen administration to usual care.~Fluid resuscitation if needed with 3% hypertonic saline during 3 days."
3287502|NCT01722448|Experimental|Choline|Phosphatidyl choline
3287503|NCT01722448|Placebo Comparator|Placebo|Vegetable oil
3287504|NCT01722461|Experimental|Active treatment|Ulthera System treatment
3287505|NCT01722461|Sham Comparator|Sham treatment|Ulthera System delivering no ultrasound energy
3287506|NCT01722474|Experimental|ASI Device|Study Participants will attend the research clinic one time (one visit) for the vascular testing. Each instrument/assessment will be run sequentially starting with the Arterial Stiffness Screening Device, then followed by SphygmoCor system, which will then be followed by the CR-2000 CV Profiler, then finally the VP-1000.
3287507|NCT01722500||10 year old children|500 children with mean age 10.5 years from each of 12 countries
3287508|NCT01722513|Experimental|Alprostadil, Control|Alprostadil interventions: Alprostadil 40 ug + 1cc/kg/hr normal salin 6 hour before and after angiography AND Control interventions:Normal salin 1cc/kg/hr before and after angiography
3287509|NCT01722526|Experimental|Recombinant human acid sphingomyelinase|Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart.
3287510|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine|"Sulfadoxine-Pyrimethamine every Four months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3287511|NCT01722539|Experimental|Sulfadoxine-Pyrimethamine+Piperaquine|"Sulfadoxine-Pyrimethamine every 4 months Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more; Piperaquine every four months Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.~Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3287512|NCT01722539|Active Comparator|Control|"Albendazole oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.~Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up."
3287513|NCT01722565|Experimental|Mesh Group|Patients receiving conventional sigmoid end colostomy plus a preperitoneal lightweight mesh Physiomesh® by laparoscopic procedure
3287514|NCT01722565|No Intervention|Control Group|Patients receiving conventional sigmoid end colostomy by laparoscopic procedure, without mesh
3287515|NCT01722578|Experimental|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
3287516|NCT01722578|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water, 6 ampuoles of 10 ml each) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
3287517|NCT01722591|Experimental|Cardiapex device|Use of the Cardiapex device in the context of transapical TAVI procedures
3287518|NCT01722617|No Intervention|DAS 28|Patients in this group will be asked to fill basic questionnaires, but without the FLARE questionnaires.
3287519|NCT01722617|Active Comparator|DAS 28 + FLARE questionnaires|Patients in this group will be asked to fill basic questionnaires and FLARE questionnaires.
3287520|NCT01722617|Active Comparator|DAS 28+FLARE + information to doctor|Patients in this group will fill basic and FLARE questionnaires which then will be transmitted to physician.
3287521|NCT01722630|No Intervention|control|Patients received intravenously saline solution at 5 ml/Kg/h
3287522|NCT01722630|Experimental|dopamine|Patients received intravenously saline solution at 5 ml/Kg/h and dopamine at 3 mcg/Kg/min
3287523|NCT01722630|No Intervention|crystalloids|Patients received intravenously saline solution at 10 ml/Kg/h
3287524|NCT01722656|Other|Aflibercept|All subjects will receive aflibercept
3287525|NCT01722682|Active Comparator|A: intraportal islet infusion|Patients will received islet into the liver through the portal venous circulation (standard procedure)
3287526|NCT01722682|Experimental|B: intra BM islet infusion|Patients will received an intra BM islet infusion at the level of the iliac crest. The direct intra BM administration will be performed following the same procedures that our institution utilizes for administration of cord-blood cells in patients with acute leukemia (Lancet Oncol. 2008;9:831). The procedure is easy and reproducible: a standard needle for BM aspiration is inserted in the iliac crest and cells are gently infused.
3287527|NCT01722695|Other|Revaclear followed by FX|
3287528|NCT01722695|Other|FX followed by Revaclear|
3287529|NCT01722708|Experimental|clindamycin|
3287530|NCT01722708|Experimental|metronidazole|
3287531|NCT01722747|Experimental|Intervention Condition|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)
3287532|NCT01722747|No Intervention|Delayed Intervention Control condition|Receives abbreviated 3-month delayed intervention after final data collection time point
3287533|NCT01722760||Term and preterm infants|Term and preterm infants
3287534|NCT01722773|Active Comparator|Bipap|Bipap
3287535|NCT01722773|No Intervention|Standard of care|No intervention
3287536|NCT01722786||DOA|"Expected number of patients estimated by study duration~N= 90 patients treated with direct oral anticoagulants (DOA) with acute bleeding~N= 40 patients treated with direct oral anticoagulants (DOA) with urgent surgical intervention"
3287537|NCT01722786||VKA|"Expected number of patients estimated by study duration~N= 90 treated with vitamin K antagonists (VKA) with acute bleeding~N= 40 patients treated with vitamin K antagonists (VKA) with urgent surgical intervention"
3287538|NCT01722799|Experimental|Drug elluting Balloon (DEB)|Is a coronary dilating device with Paclitaxel ® drug delivery, for dilatation and provisional spot bare metal stenting (BMS).
3287539|NCT01722799|Active Comparator|Drug elluting coronary stent (DES)|The Resolute Integrity Zotarolimus-Eluting Coronary Stent System is indicated for improving coronary luminal diameters in patients, including those with diabetes mellitus, with symptomatic ischemic heart disease due to de novo lesions of length ≤ 27 mm in native coronary arteries with reference vessel diameters of 2.25 mm to 4.20 mm.
3287540|NCT01722812|Other|Placebo (left) / Cromoglicate (right)|Placebo (on a lesion on left bodyside), Cromoglicate (on a lesion on right bodyside)
3287541|NCT01722812|Other|Placebo (right) / Cromoglicate (left)|Placebo (on a lesion on right bodyside), Cromoglicate (on a lesion on left bodyside)
3287542|NCT01722825|Experimental|LY2157299|80 up to 150 milligrams of LY2157299 administered orally, twice daily for 14 days, followed by 14 days with no study drug (2 weeks on/2 weeks off schedule) for at least two 28 day cycles. Participants receiving clinical benefit may continue receiving treatment until discontinuation criterion is met.
3287543|NCT01722838|Experimental|B-ME intervention|Men will receive behavioral HIV prevention intervention, B-ME.
3287544|NCT01722838|No Intervention|Control Arm|Men in this arm will receive monthly text or telephone voice messages relaying general health messages.
3287545|NCT01722851||Cohort 1|All newly diagnosed breast cancer patients who are scheduled to undergo neoadjuvant chemotherapy
3287546|NCT01722851||Cohort 2|All breast cancer patients who present with metastatic disease, disease recurrence or progression, who are commencing up-front chemotherapy ± hormonal therapy
3287547|NCT01722851||Cohort 3|All breast cancer patient who present with metastatic disease who are commencing hormonal therapy only.
3287548|NCT01722864|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 10 to 35 days.
3287549|NCT01722890||Cohort 1|TNM stage II-IV breast cancer patients with highly trastuzumab-sensitive tumours.
3287550|NCT01722890||Cohort 2(Control Group)|TNM stage II-IV breast cancer patients with trastuzumab-refractory disease.
3287551|NCT01722903||Stage IV colorectal cancer|CTCs will be drawn during liver and/or lung metastasectomy for colorectal cancer
3287553|NCT01722942|Active Comparator|ICD group|ICD implantation will be performed according to the Institution protocol of each participating center; single-chamber devices are preferred and programming should prioritize the patient's own pace, avoiding ventricular stimulation.
3287554|NCT01722942|Active Comparator|Amiodarone Group|"Patients randomized for this group will receive amiodarone hydrochloride (once a day) according to the following regimen:~Initial oral loading dose of 600 mg/day for 10 days on an outpatient basis;~After the loading period, an oral dose between 200 and 400 mg/day should be maintained until study termination. The determination of the optimal maintenance dose will be left at the discretion of each investigator; this dose may be based on the therapeutic response on 24-hour Holter monitoring, resting heart rate (HR), side effects, prolonged corrected QT interval (QTc), etc. Dose adjustments will be allowed throughout the study period provided the maintenance dose is kept between 200 and 400 mg/day. If the patient cannot tolerate the minimum 200 mg/day dose, amiodarone should be discontinued permanently and treatment should be considered interrupted."
3287555|NCT01722955|Experimental|Pre-warmed fluids|Pre-warmed fluids will be prepared for 8hous in 41℃ set hot cabinet.
3287556|NCT01722955|Experimental|Room temperature fluids|Room temperature fluids will be stored at ambient temperature.
3287557|NCT01722968|Active Comparator|Arm A|Arm A and feasibility phase: Bevacizumab 15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly.
3287558|NCT01722968|Active Comparator|Arm B|Arm B: Paclitaxel 80mg/m2 iv weekly.
3287559|NCT01722981|Active Comparator|Direct laryngoscopy|Performing percutaneous tracheostomy as accepted in our institute: By placing the tube higher up near the vocal cords by direct laryngoscopy. In the second stage tracheal perforation by a needle will be carried out by palpation of the anatomical placement of the neck.
3287560|NCT01722981|Active Comparator|Real time sonography|"Percutaneous tracheostomy will be guided by real time sonography (with the visualization of the needle path) using acoustic shadows of the cricoid and the tracheal rings.~In both methods, in order to identify the anatomic location of the needle prick- after passing the guide wire, the front elevation will be verified by optical means, which will be drawn out immediately afterwards."
3287561|NCT01722981|Active Comparator|Bronchoscopy|Percutaneous tracheostomy will be guided by bronchoscopy. Initially, the tube will be placed according to the desired height observed by the bronchoscope, phase two will be tracheal perforation by a needle under trans illumination and real-time view on the income of the needle and the passage of the guide wire.
3287562|NCT01723007|Experimental|Other: Apple|Women were supplemented with apples. Sixteen women were asked to ingest three apple daily between meals ( approximately 120g kcal) between meals (breakfast, lunch and dinner).
3287563|NCT01723007|Active Comparator|Other: oatmeal cookies|A another group with nineteen women were asked to ingest three oatmeal cookies a day, approximately 60g and similar caloric content to experimental group (approximately 120 kcal) between meals (breakfast, lunch and dinner).
3287564|NCT01723007|Active Comparator|Other: Pear|Women were supplemented with pear. Sixteen women were asked to ingest daily three pears (approximately 120 kcal) between meals daily (breakfast, lunch and dinner).
3287565|NCT01723020|Experimental|AMG 232|AMG 232 is an anti-cancer agent.
3287566|NCT01723033||EEG acquisition|15 PTSD patients and 15 OCD patients who will, while wearing a net of electrodes for EEG acquisition on their heads, perform three error detection tasks.
3287567|NCT01723033||Control|Previously collected healthy student's data
3287568|NCT01723046|Experimental|Training with the device|Training with new upper limb robot assisted therapy device
3287569|NCT01723046|No Intervention|Control group|The control group is treated with conventional therapy.
3287570|NCT01723059|Other|Standard triple therapy|Gold standard for management of H pylori is amoxicillin 1 gm twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 10 days.
3287571|NCT01723059|Active Comparator|Sequential Therapy|Amoxicillin 1 gm twice daily and omeprazole 20 mg twice daily for 5 days followed by metronidazole 500 mg twice daily, clarithromycin 500 mg twice daily, and omeprazole 20 mg twice daily for 5 days.
3287572|NCT01723085||Open myomectomy|All patients belong to the same group Description includes the surgical technique
3287573|NCT01723098|No Intervention|Control|Sedentary pregnant women
3287574|NCT01723098|Experimental|Exercise group|
3287575|NCT01723111||Peritoneal dialysis|start PD
3287576|NCT01723111||Hemodialysis|start HD
3287577|NCT01723124|Experimental|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
3287578|NCT01723137||In pain|Patients who report pain greater than or equal to 3 out of 10 are eligible for this study.
3287579|NCT01723150|Experimental|Oral antibiotics|The intervention arm switched to oral antibiotics to complete 4 weeks of therapy. Oral antibiotics will be ciprofloxacin (or trimethoprim/sulfamethoxazole if the isolate is resistant).
3287580|NCT01723150|Active Comparator|Intravenous antibiotics|The active comparator arm continues intravenous antibiotics to complete 4 weeks of therapy. Intravenous antibiotics will be ceftriaxone (or ertapenem if the isolate is resistant).
3287581|NCT01723176||Patients in Cardiopulmonary Failure|patients in cardiopulmonary failure
3287582|NCT01723189||Central Apnoeas Patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of central apnoea (central apnoea index> 10 / h, or Cheyne-Stokes breathing for more than 30% of total sleep time or mixed apneas with central apnoeas> 50% of total apneas)
3287583|NCT01723189||Obstructive apnoea patients|• 30 patients diagnosed with TIA / ischemic stroke within 7 days of admission and evidence at polysomnography of obstructive sleep apnea (apnea-hypopnea index> 20 / h)
3287584|NCT01723189||No SDB patients|• 30 patients diagnosed with TIA / stroke within 7 days of admission and no evidence of sleep respiratory disorders at polysomnography
3378817|NCT01445483||2/Cohort 2|KPS>70 and at least one of the following: age >65, uncontrolled or synchronous primary disease, or extracranial metastases
3287585|NCT01723189||Healthy controls|• 30 healthy controls matched for age, sex, race and BMI.
3287586|NCT01723202|Experimental|Arm A: GSK2118436|Patients receive dabrafenib orally 2 twice a day on days 1-28. Patients with disease progression may cross over to arm II.
3287587|NCT01723202|Experimental|Arm B: GSK2118436 and GSK1120212|Patients receive dabrafenib orally twice a day and trametinib orally once a day on days 1-28.
3287588|NCT01723202|Other|Correlative Studies|Tumor pharmacodynamics (PD) evaluation,BRAF mutation quantification in circulating plasma DNA,Tumor mutation screening/Mechanisms of Drug Resistance,Predictive Markers of Response (Archival Tumor Block),Pharmacokinetics(PK,Pharmacogenetics (PGx)
3378818|NCT01445483||3/Cohort 3|KPS<70
3378820|NCT01445288||1|Pediatric Patients with Central Nervous System Tumors
3287589|NCT01723215|Active Comparator|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
3287590|NCT01723215|Active Comparator|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
3287591|NCT01723215|No Intervention|Control|Control: will not receive any intervention
3287592|NCT01723215|Placebo Comparator|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
3287593|NCT01723241|Experimental|XAF5|
3287594|NCT01723241|Placebo Comparator|Placebo|
3287595|NCT01723267|Active Comparator|3D follicles assessment|During IVF treatment all ultrasound examinations will use 3D- SonoAVC technology. Timing of hCG injection and oocyte collection will be based on follicle volume and 3D-volume based diameter.
3287596|NCT01723267|Active Comparator|2D follicles assessment|During IVF treatment all ultrasound examinations will use standard 2D ultrasound. Timing of hCG injection and oocyte collection will be based on follicle diameter.
3287597|NCT01723280||80% oxygen group|
3287598|NCT01723280||30% oxygen group|
3287599|NCT01723293|No Intervention|Control|Sedentary pregnant women
3287600|NCT01723293|Experimental|Exercise group|
3287601|NCT01723306|Experimental|2nd Generation Designer T Cells|All participants will receive gene modified T cells, with concomitant IL2 for 30 days post infusion.
3287602|NCT01723319|Experimental|1|deep TMS treatment
3287603|NCT01723319|Sham Comparator|2|inactive treatment
3287604|NCT01723332|Experimental|Intervention|Clinical based educational and self management intervention.
3287605|NCT01723332|No Intervention|Usual Care|Youth seen in the Cardiology clinic see a nurse only to measure weight, height, and blood pressure. They rely on their cardiologist for information about their heart condition. The approach and amount of time taken by each cardiologist with a youth varies.
3287606|NCT01723345|Active Comparator|omega 3|receive omega 3 in addition to standard treatment
3287607|NCT01723345|No Intervention|control|just receive standard treatment
3287608|NCT01723358|Experimental|Neuromuscular electrical stimulation (NMES)|
3287609|NCT01723371|Experimental|Carvedilol|
3287610|NCT01723410|Experimental|Writing condition|Subjects will be asked to write about other individuals in their lives.
3287611|NCT01723410|Placebo Comparator|Writing|Subjects will be asked to write about places or objects in their lives.
3287612|NCT01723423||Expander/Implant|Patients receiving expander/implant breast reconstruction procedures.
3287613|NCT01723423||Lat Dorsi|Patients receiving latissimus dorsi breast reconstructions with or without implant.
3287614|NCT01723423||PTRAM|Patients receiving pedicle transverse rectus abdominis musculocutaneous (PTRAM)breast reconstruction.
3287615|NCT01723423||FTRAM|Patients receiving free transverse rectus abdominis musculocutaneous (FTRAM.)
3287616|NCT01723423||DIEP|Patients receiving deep inferior epigastric perforator (DIEP) breast reconstructions.
3287617|NCT01723423||SIEA|Patients receiving superficial inferior epigastric artery (SIEA)breast reconstruction.
3287618|NCT01723423||S-GAP|Patients receiving superior gluteal artery perforator breast reconstruction.
3287619|NCT01723423||I-GAP|Patients receiving inferior gluteal artery perforator breast reconstruction.
3287620|NCT01723436|No Intervention|DLST Only|Surrogates will complete the Stroop test then answer the hypothetical life sustaining therapy (LST)
3287621|NCT01723436|Experimental|Contemplate only|Surrogates will contemplate each of the 3 scenarios but not make any decisions, then complete the Stroop test and answer the hypothetical LST question
3287622|NCT01723436|Experimental|Decide with advice|Surrogates will make decisions on 4 scenarios with physician advice, then complete the Stroop test and answer the hypothetical LST question. Within this arm, surrogates will receive two positive recommendations (i.e. to go ahead with the intervention) and two negative recommendations (i.e. to decline the intervention). These positive and negative recommendations will be randomly assigned upon study enrollment. With four hypothetical scenarios, there are six possible options for recommendation variations.
3287623|NCT01723436|Experimental|Decide without advice|Surrogates will make decisions on 4 scenarios without physician advice, then complete the Stroop test and the hypothetical LST question.
3287624|NCT01723475|Experimental|BAY2010112 (s.c.)|
3287625|NCT01723475|Experimental|BAY2010112 (c.i.v.)|
3287626|NCT01723488|Experimental|Tau diagnostic|Experimental: Tau diagnostic [F18] T808
3287627|NCT01723501|Placebo Comparator|sterile water|sterile water wipes
3287628|NCT01723501|Experimental|0.25% chlorhexidine|0.44% chlorhexidine digluconate wipes which will release 0.25% free chlorhexidine
3378825|NCT01441089||1/Cancer Patients|Patients enrolled on IRB approved NIH Intramural Research Program (IRP) therapeutic clinical trials
3378839|NCT01417533||GNE|Patients with a diagnosis of GNE myopathy
3378840|NCT01417533||GNE-Related Diseases|Patient with a GNE related disease
3378841|NCT01417533||non-GNE|Subjects that are a carrier family member or a caregiver of a patient on the study are eligibleto participate.
3378842|NCT01399411||AHS Cohort|licensed pesticide applicators and their spouses from Iowa and North Carolina already enrolled in the Agricultural Health Study (AHS)
3378843|NCT01386437||Fungal Infection|Patients with or without inherited or acquired abnormalities of immune function manifesting mucocutaneous and/or invasive fungal infections
3378844|NCT01353521|Experimental|Contrast-enhanced ultrasound|
3378850|NCT01352949||Healthy Volunteers|Healthy volunteers without scoliosis or obesity
3378851|NCT01352949||Obesity|Healthy volunteers with obesity
3378852|NCT01352949||Scoliosis|Healthy volunteers with scoliosis but no obesity
3378853|NCT01350648||HBV and HCV Co-infection|HBV and HCV Co-infection
3378854|NCT01350648||Hepatitis B|Hepatitis B alone
3378855|NCT01350648||Hepatitis C|Hepatitis C alone
3378856|NCT01350648||HIV and HBV and HCV Tri-Infection|HIV and HBV and HCV Tri-Infection
3378857|NCT01350648||HIV and HBV Co-infection|HIV and HBV Co-infection
3378858|NCT01350648||HIV/HCV Co-Infection|HIV and HCV Co-infection
3378859|NCT01332968|Active Comparator|Rituximab+Chemotherapy|Participants will receive either 8 cycles of rituximab along with 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) (21-day cycle) or 8 cycles of rituximab along with 8 cycles of cyclophosphamide, vincristine, and prednisone (CVP) (21-day cycles) or 6 cycles of rituximab along with 6 cycles of bendamustine (28-day cycle) during the induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive rituximab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
3378860|NCT01332968|Experimental|Obinutuzumab+Chemotherapy|Participants will receive either 8 cycles of obinutuzumab along with 6 cycles of CHOP (21-day cycle) or 8 cycles of obinutuzumab along with 8 cycles of CVP (21-day cycles) or 6 cycles of obinutuzumab along with 6 cycles of bendamustine (28-day cycle) during induction period. The induction period will be followed by either a maintenance or observation period for responders or non-responders, respectively. Responders will receive obinutuzumab monotherapy every 2 months for 2 years during the maintenance period. Non-responders will receive no protocol specified treatment during the 2-year observation period. Finally, participants will be followed during a 5-year follow-up period. The chemotherapy regimen (CHOP or CVP or bendamustine) for individual participant will be chosen by the site prior to initiation of the study.
3287629|NCT01723527|Experimental|Therapeutic Workplace|Participants assigned to this condition will receive the standard services and requirements for diversion as described for the usual care group, and will also be eligible to attend the three-phase Therapeutic Workplace (TW) intervention. All phases of this intervention include employment-based drug abstinence reinforcement contingencies. Under these contingencies, participants can work and earn wages or wage subsidies contingent upon drug abstinence as verified by urinalysis. Phase 1 of the TW intervention is expected to increase cocaine abstinence and to prepare participants for employment. Phase 2 of the TW intervention is expected to maintain abstinence while participants are employed in an onsite model workplace. Phase 3 is designed to increase employment in community jobs and to maintain abstinence while participants are employed in offsite community workplaces.
3378861|NCT01324206||Healthy Volunteers|Healthy Volunteers 18 years or older
3287630|NCT01723527|Active Comparator|Diversion to treatment (Usual Care)|Participants in this condition will be offered the standard treatment services available in community methadone and buprenorphine programs, including medication (methadone or buprenorphine, respectively), counseling services, HIV testing, and case management. All services will be provided in the treatment clinics. There are a number of clinics within easy walking distance from the research site, and others throughout the city that are reachable by public transportation from the research site. In addition, all participants will receive referrals to the Re-Entry Center, a One-Stop Career Center tailored to the needs of offenders, at all intake and monthly assessments. As mentioned in detail above, participants will be required by the court to stay enrolled in treatment for 90 days. It is important to note that all diverted individuals will receive these services and requirements, independent of whether they agree to participate in the pilot study.
3287631|NCT01723540|Experimental|Minilaparotomy cholecystectomy with ultrasonic scissors|Minilaparotomy vs laparoscopy
3287632|NCT01723540|Active Comparator|Laparoscopic cholecystectomy|Minilaparotomy vs laparoscopy
3287633|NCT01723553|Experimental|PiB positron emission tomography (PET)|All subjects will receive PET imaging with C-11 PiB on approximately day 1 or day 2 of study to determine if they have beta-amyloid deposits in their brains.
3287634|NCT01723579|Experimental|NOMAC-E2 2.5 mg/1.5 mg|Participants will receive combined oral contraceptive NOMAC-E2 2.5 mg/1.5 mg tablet for 13 consecutive 28-day cycles. Each 28-day cycle with consist of 24 active tablets and 4 placebo tablets taken at approximately the same time each day.
3287635|NCT01723592|Placebo Comparator|Placebo|30 participants in this group receive a oral lactose placebo
3287636|NCT01723592|Active Comparator|Probiotics|"30 participants in this group receiving oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains belonging to the species:~L.rhamnosus/ LbV96 (DSM 22560)~L.jensenii /LbV 116 (DSM 22567)~L.crispatus/ Lbv88 (DSM 22566)~L.gasseri /LbV 150N (DSM 22583)"
3287637|NCT01723605|Experimental|insitu repair|insitu repair of the uterine incision during caeserean section
3287638|NCT01723605|Active Comparator|exteriorisation of the uretus|uterine closure during caeserian section with exteriorisation of the uterus
3287639|NCT01723618|Experimental|CRD007 10 mg|CRD007, 10 mg tablet, single dose
3287640|NCT01723618|Experimental|CRD007 25 mg|CRD007, 25 mg tablet, single dose
3287641|NCT01723618|Experimental|CRD007 40 mg|CRD007, 40 mg tablet, single dose
3287642|NCT01723631|Other|Relapsing Multiple Sclerosis- group 1|Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
3287643|NCT01723631|Other|Relapsing Multiple Sclerosis- group 2|Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
3287644|NCT01723631|Other|secondary progressive multiple sclerosis- Group 3|Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
3287645|NCT01723631|Other|primary progressive multiple sclerosis- group 4|Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
3287646|NCT01723631|Other|control 1|healthy volunteers
3287647|NCT01723631|Other|Control 2|Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
3287648|NCT01723631|Other|Control 3|Patients having an autoimmune pathology
3287649|NCT01723644|Other|PCT guidance|"Group of patient  Procalcitonin  where the initiation and the stop of the antibiotic treatment are made according to a strategy guided by the PCT"
3287650|NCT01723644|Other|clinical reassessment|Group of patient where the initiation and the stop of the antibiotic treatment make following on clinical criteria and paraclinic not including the PCT.
3287651|NCT01723657|Other|Risk-adapted postremission treatment.|Ara-C, G-CSF, Autologous peripheral blood stem cell transplantation, Allogeneic matched related or unrelated donor transplant, G-CSF Priming, CD34+ selection, Myeloablative or reduced intensity conditioning, Mylotarg purging before autologous PBSC transplantation.
3287652|NCT01723670|Experimental|CHF 5074 1x|oral tablet, multidose
3287653|NCT01723670|Experimental|CHF 5074 2x|oral tablet, multidose
3287654|NCT01723670|Placebo Comparator|Placebo|placebo, oral tablet, multidose
3287655|NCT01723683|Experimental|MISTCPAP group|MISTCPAP group: Surfactant will be instillated via the Angio-Cath without endotracheal intubation and followed by CPAP.
3287656|NCT01723683|Active Comparator|INSURE group|INSURE group: The procedure of surfactant treatment should be according to the conventional surfactant treatment which involves intubation, surfactant divided to 4 liquors to inject into 4 positions followed by amubagging and then extubation to CPAP.
3287657|NCT01723735|Experimental|Alirocumab + Ezetimibe Placebo|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe placebo
3287658|NCT01723735|Experimental|Alirocumab + Ezetimibe|Subcutaneous (SC) injections of alirocumab added to oral administration of ezetimibe
3287659|NCT01723735|Experimental|Alirocumab + Fenofibrate|Subcutaneous (SC) injections of alirocumab added to oral administration of fenofibrate
3287660|NCT01723748|Active Comparator|surgery treated|"10 patients with well-controlled acromegaly for at least 6 months after surgery alone.~Stimulated with genotropin"
3287661|NCT01723748|Active Comparator|SA treated|10 patients with well-controlled acromegaly for at least 6 months after SA treatment Stimulated with genotropin
3287662|NCT01723774|Experimental|Arm 1: PIK3CA Wild Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3287663|NCT01723774|Experimental|Arm 2: PIK3CA Mutant Type Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycle 0 is 28 days of anastrozole PO daily and, if premenopausal, goserelin SC every 28 days.~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3287664|NCT01723774|Experimental|Arm 3: Endocrine Resistant Cohort|"Tumor biopsy for testing/research at baseline and Cycle 1 Day 15~Cycles 1-5: PD 0332991 combined with anastrozole (and goserelin if premenopausal) is to be (4) 28-day cycles followed by a 5th cycle of 10-12 days duration consisting of daily PD 0332991 and anastrozole (last dose day before surgery)~Standard surgery will be performed per institutional standards 2-4 weeks following the completion of Cycle 4 in those who did not receive Cycle 5. In patients who receive Cycle 5, surgery occurs on Day 11, 12, or 13 of Cycle 5.~Patients who derived benefit from the therapy have the option of taking PD 0332991 in combination with endocrine therapy for 23 cycles after surgery and adjuvant chemotherapy and radiation if indicated. It should be re-started at least 4 weeks after the completion of chemotherapy and radiation therapy if these treatments were planned."
3287665|NCT01723787||Infantile Spasms|Participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
3287666|NCT01723787||biological parents|Biological parents of participants retrospectively identified to have been treated with ACTH according to FDA-approved protocol for Infantile Spasms
3287667|NCT01723800|Experimental|Treatment (pemetrexed, carboplatin, PI3K inhibitor BKM120)|Patients receive pemetrexed disodium IV over 10 minutes followed by carboplatin IV over 30 minutes on day 1, and PI3K inhibitor BKM120 PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may receive courses of PI3K inhibitor BKM120 alone or PI3K inhibitor BKM120 and pemetrexed disodium after 4-6 courses with carboplatin in the absence of unacceptable toxicity or disease progression.
3287668|NCT01723813|Experimental|Group 1 : peptides + GM-CT-01 IV|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections
3287669|NCT01723813|Experimental|Group 2 : peptides + GM-CT-01 IV+PT|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2 plus Galectin-3 inhibitor: GM-CT-01 systemic injections and Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
3287670|NCT01723839|Other|FCR with Lenalidomide|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - 19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity. If there are at least 5 CRs after 4 cycles of FCR plus lenalidomide the study will accrue an additional 35 subjects.
3287671|NCT01723852|Active Comparator|Vitamin D supplement|Vitamin D supplement according to national guidelines (10 ug/day) from 2 weeks to 2 years of age
3287672|NCT01723852|Active Comparator|Vitamin D supplement at 30 ug/day|Vitamin D supplement at 30 ug/day from 2 weeks to 2 years of age
3287673|NCT01723865||Conventional|Patients with heart failure having an ICD-CRT implanted, followed by conventional visits.
3287674|NCT01723865||Remote Monitoring|Patients with heart failure having an ICD-CRT implanted, followed by remote monitoring.
3287675|NCT01723878||Cohort|
3287676|NCT01723891|Active Comparator|Surfolase capsule & HT-002-01|
3287677|NCT01723891|Active Comparator|HT-002-01 & Surfolase capsule|
3287678|NCT01723917|Experimental|PhytoSERM 50 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
3287679|NCT01723917|Experimental|PhytoSERM 100 mg tablet|Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks
3287680|NCT01723917|Placebo Comparator|Placebo tablet|Dietary supplement: placebo tablet to be taken once per day for 12 weeks
3287681|NCT01723943|Active Comparator|Arm I (educational booklet)|"Participants receive the What's Happening to the Woman I Love? booklet, which focuses on ways to understand and deal with marital communication and relationship issues arising from breast cancer diagnosis."
3287682|NCT01723943|Experimental|Arm II (Helping Her Heal program)|"Participants undergo the Helping Her Heal educational counseling program comprising 5 1-hour sessions 2 weeks apart.~SESSION I: Participants learn stress management skills and discover ways stress affects themselves and their partner.~SESSION II: Participants practice attentive listening and reduce the tendency to try to distract patients from talking about sad or difficult aspects of the cancer experience.~SESSION III: Patients learn to help their spouse talk when she is quiet or withdrawn, to add to their understanding of what she is thinking and feeling, and to add to their ways of supporting her during especially difficult times with the cancer.~SESSION IV: Participants learn strategies for physically reconnecting with spouses.~SESSION V: Participants review skills from prior sessions, identify strategies he or she will continue to use to manage their personal stress, and identify ways to maintain connection and support."
3287683|NCT01723956|Active Comparator|Arm B|LEEP treatment of CIN 2/3 cervical lesion in HIV positive women (standard of Care)
3287684|NCT01723956|Experimental|Arm A|Cryotherapy treatment of CIN 2/3 cervical lesions
3287685|NCT01723969||Colo-rectal cancer|Tumour markers testing in patients with advanced or metastatic colo-rectal cancer
3287686|NCT01723982|Experimental|A. FE 200440|Barusiban (FE 200440) Solution for Injection for Subcutaneous use
3287687|NCT01723982|Placebo Comparator|B. Placebo|Placebo Solution for Injection for Subcutaneous use
3287688|NCT01723995|Experimental|low-level laser on nipples|Application of laser light from the device in direct contact with the nipple injury, equipment connected and set up at a dose of 5J/cm2 (Epoint = 0.2J/cm2) for both groups, three consecutive doses of 5J/cm2 (ETotal = 0.6J/cm2) along the entire length of the injury.
3287689|NCT01723995|Placebo Comparator|low-level laser off on nipples|Laser with modified standard operation - shutdown of InGaAIP semiconductor diode and installation of a visible red light emitting diode with optical power of 0mW (LED - Light Emitting Diode - maximum power with standard nozzle).
3287690|NCT01724034|Experimental|Daily Lung Ultrasound|"If there is no lung sliding - evaluation for pneumothorax or mainstream intubation.~If lung ultrasound shows normal pattern - search for reversible airway obstruction or venous embolism. If the patient has COPD, non invasive ventilation must be used as mode of discontinuing mechanical ventilation.~If lung ultrasound shows intersticial syndrome - evaluate the need to negativate hydric balance before the next spontaneous breathing trial.~If findings are asymmetrical - search for new or uncontrolled infection. If there is simple pleural effusion - researchers should determine a negativation of hydric balance or perform thoracocentesis.~If there are signs of complicated pleural effusion - a new image technique should be performed as evaluated by the surgical team."
3287691|NCT01724034|No Intervention|Control Group|
3378863|NCT01322581||observational cohort|This observational-cohort study of individuals (3 months and 40 years of age) will be conducted in the rural village of Kalifabougou, Mali, where Pf transmission is intense and seasonal
3378864|NCT01316783||Healthy Volunteers|African ancestry and whites (who will serve as a comparison group)
3287692|NCT01724047|Experimental|Playground Intervention|Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed 2) Waitlist treatment, where the training will begin the following school year. The initial delivery will occur for 30 minutes three times for a period of two to three weeks, then 30 minutes two times for a period of two weeks, then 30 minutes once a week for up to 16 sessions, within a period of 3 months, then a 30 minute follow up will occur 3 months later. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment, and 3-month follow-up. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
3378872|NCT01287000||1|Workers and volunteers engaged or potentially engaged in oil spill clean-up operations in the Gulf of Mexico
3378879|NCT01264055||1|Adults with idiopathic bronchiectasis
3378881|NCT01247597||Controls|People without pathogenic DICER1 germline variation
3378882|NCT01247597||DICER1 (cases)|People with pathogenic DICER1 germline variation or history of DICER1-associated tumors
3378883|NCT01238211|Experimental|Treatment (daunorubicin hydrochloride, cytarabine, dasatinib)|"INDUCTION THERAPY (course 1): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 168 hours on days 1-7, and dasatinib PO QD on days 8-21. Patients with responsive disease on day 21 undergo consolidation therapy, and patients with non-responsive disease on day 21 (bone marrow cellularity >= 20% and leukemia blasts >= 5%) receive a second course of induction therapy.~INDUCTION THERAPY (course 2): Patients receive daunorubicin hydrochloride IV on days 1-3, cytarabine IV continuously over 120 hours on days 1-5, and dasatinib PO QD on days 6-19. Patients achieving complete response receive consolidation therapy.~CONSOLIDATION THERAPY: Patients receive high-dose cytarabine IV over 3 hours on days 1, 3, and 5, and dasatinib PO QD on days 6-26 or 7-27. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients in complete remission receive continuation therapy."
3378892|NCT01212055||Cohort 1|Patients with DOCK8 deficiency, LAD-1, or GATA2 Deficiency
3287693|NCT01724047|Experimental|STAT Intervention|Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. The intervention will be over a period of 6 weeks, with baseline, treatment, and a follow up visit totaling 18 weeks at the school site. Each visit is approximately 30 minutes. A systematic fading of intervention using performance feedback, coaching, and consultation. Outcome measures will be administered at entry, end of treatment. Entry diagnostic, exit and follow up assessments will last 1.5- 2 hours and participants will be assessed after school or in their homes.
3287694|NCT01724047|No Intervention|Playground Waitlist Control|Waitlist Control
3287695|NCT01724047|No Intervention|STAT Waitlist Control|Waitlist Control
3287696|NCT01724073|Experimental|Leafy vegetable-fish sauce|one meal per day, 6 days a week, with leafy vegetable-fish sauce + tô, a local cereal-based paste
3287697|NCT01724073|Experimental|Leafy vegetable-fish/liver sauce|one meal per day, 6 days a week, 5 days with leafy vegetable-fish sauce + tô, 1 day with leafy vegetable-liver sauce + tô
3287698|NCT01724073|Experimental|Misola|one meal per day, 6 days a week, with gruel prepared with the fortified Misola flour
3287699|NCT01724073|No Intervention|no test food|control group receiving no test food
3287700|NCT01724086|Experimental|Panel 1|10 chronic HCV genotype 1a (GT1a) infected treatment-naive patients/prior relapsers who will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
3287701|NCT01724086|Experimental|Panel 2 Arm 1|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir and ribavirin.
3287702|NCT01724086|Experimental|Panel 2 Arm 2|10 chronic HCV GT1b infected treatment-naive patients/ prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
3287703|NCT01724086|Experimental|Panel 3 - Arm 1|8 chronic HCV GT1a infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir + ribavirin.
3287704|NCT01724086|Experimental|Panel 3 - Arm 2|8 chronically HCV GT1b infected treatment naïve patients/prior relapsers will receive TMC435 + TMC647055 + low-dose ritonavir.
3287705|NCT01724086|Experimental|Panel 4 - Arm 1|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (30 mg once daily)
3287706|NCT01724086|Experimental|Panel 4 - Arm 2|20 chronic HCV GT1a or GT1b infected treatment-naive patients/ prior relapsers will receive 12 weeks of treatment with TMC435 + TMC647055 + low-dose RTV + GSK2336805 (60 mg once daily)
3287707|NCT01724099|Experimental|Euiiyin-tang|powder type, 3 times per day before the meal, 12 weeks total
3287708|NCT01724099|Placebo Comparator|Placebo|powder type, 3 times per day before the meal, 12 weeks total
3287709|NCT01724112|Experimental|LY2940094|40 mg administered orally as 1 capsule QD for 8 weeks.
3287710|NCT01724112|Placebo Comparator|Placebo|Administered orally as 1 capsule QD for 8 weeks.
3287711|NCT01724125|Experimental|Case|Assigned a Personal Electronic Health Record
3287712|NCT01724125|Active Comparator|Control: Usual Care|Assigned to control arm, continued to receive care as usual in community. Was issued information on community health resources, but did not use research study personal health record.
3287713|NCT01724138|Experimental|Deferasirox|The study will provide PK, safety, tolerability and efficacy data collected during 48 weeks of treatment with deferasirox in Chinese pediatric patients with transfusion dependent -thalassemia major, aged 2 to <6 years at enrollment. The target patient pool consists of 20 patients with evidence of iron overload measured by serum ferritin level at the start of study. Patients will start their deferasirox treatment with a dose of 20 mg/kg/day. Serum ferritin will be monitored every month and the dose of deferasirox will be adjusted if necessary every 3 months based on the trends in serum ferritin. Other possible dose adjustments will be based on the patient's safety assessments.
3287714|NCT01724151||Healthy adults|Healthy adults, over 45 years old
3287715|NCT01724151||Mild cognitive impairment|subjects with mild cognitive impairment
3287716|NCT01724151||Alzheimer's disease|subjects with Alzheimer's disease
3287717|NCT01724164|Experimental|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
3287718|NCT01724164|Experimental|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
3287719|NCT01724164|Active Comparator|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
3287720|NCT01724164|Experimental|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
3287721|NCT01724164|Placebo Comparator|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
3287722|NCT01724190|Active Comparator|Vitamin D|Subjects will receive oral vitamin D supplementation, 3000 IU daily over the course of 9 months.
3287723|NCT01724190|Placebo Comparator|Placebo|Subjects will receive a placebo solution daily over the course of 9 months.
3287724|NCT01724203|Active Comparator|Lactobacillus rhamnosus|Formula containing 1 million CFU/g Lactobacillus rhamnosus HN001 (trademarked DR20) at least three times daily for 12 weeks.
3287725|NCT01724203|Active Comparator|Bifidobacterium animalis subsp. lactis|Formula containing 1 million CFU/g Bifidobacterium animalis subsp. lactis HN019 (trademarked DR10) at least three times daily for 12 weeks.
3287726|NCT01724203|Placebo Comparator|Placebo|Placebo formula without probiotics at least three times daily for 12 weeks.
3287727|NCT01724229|Other|treatment with OTC drug products|"Body Wash & Shampoo applied directly to the skin or cloth; soiled area gently wiped clean. No rinsing necessary.~Moisture Barrier Cream: Once area cleansed and dried thoroughly, a thin coat is gently applied to the area of the skin exposed to moisture twice daily for two weeks or as directed by doctor.~2-in-1 Cleanser: applied directly to the skin or a cloth and skin gently wiped clean. No rinsing necessary.~Antifungal Cream: Once reddened area cleansed and dried thoroughly a thin layer is applied over the affected area twice daily for two weeks or as directed by doctor."
3287728|NCT01724242|Experimental|Vaginal DHEA|Vaginal DHEA 0.5%(6.5mg)inserted nightly
3287729|NCT01724242|Placebo Comparator|Placebo|
3287730|NCT01724255||staple removal day 4 dressing removal day 1|early staple removal and early dressing removal
3287731|NCT01724255||staple removal day 4 dressing removal day 4|early staple removal and day 4 dressing removal
3287732|NCT01724255||staple removal day 7, dressing removal day 1|late staple removal and early dressing removal
3287733|NCT01724255||staple removal day 7, dressing removal day 7|late staple removal and late dressing removal
3287734|NCT01724255||staple removal day 7, dressing removal day 4|late staple removal and day 4 dressing removal
3287735|NCT01724268|Experimental|Pred + Meth|"Prednisolone : 10 mg daily~+ Methotrexate : 25 mg/ day~ARM 1 Treatment Arm"
3287736|NCT01724268|Active Comparator|Anti TNF + Meth|"Etanrcept: 50 mg; Adalimumab: 40 mg; Infliximab: 3mg/kg~+ Methotrexate 25 mg per day Control Arm"
3287737|NCT01724281||pregnant women between 19-30 weeks gestational age|No intervention, only follow up
3287738|NCT01724294||Cohort|
3287739|NCT01724307|Active Comparator|Asthma positive to Methacholine Challenge Testing|Asthma diagnosis by positive Methacholine Challenge Testing
3287740|NCT01724307|Active Comparator|Asthma positive to Eucapnic voluntary hyperventilation testing|Asthma diagnosis by positive Eucapnic voluntary hyperventilation testing
3287741|NCT01724320|Experimental|OTX008|Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
3287742|NCT01724333||Group 1- in active treatment|Questionnaires only
3287743|NCT01724333||Group 2 - 2-6 months post-treatment|Questionnaires only
3287744|NCT01724333||Group 3 - 6 mos-3yrs post-treatment|Questionnaires only
3287745|NCT01724333||Group 4 - Palliative treatment|Questionnaires only
3287746|NCT01724333||Group 5 - Referred to dentist/oral team|Questionnaires only
3287747|NCT01724346|Other|Arm A Post-Chlorambucil Therapy Followup|Patients randomized to Chlorambucil in the parent study(PCYC-1115-CA) who have not progressed at the time of parent study closure will be transferred to this Arm. Follow-up will continue until PD, unacceptable toxicity, or other reason for treatment discontinuation.
3287748|NCT01724346|Experimental|Arm B Ibrutinib|Patients randomized to Ibrutinib in the parent study (PCYC-1115-CA) who have not experienced PD at the time of parent study closure will be transferred to this Arm to continue on Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
3287749|NCT01724346|Experimental|Arm C Second-line Ibrutinib|Patients who received Chlorambucil in the parent study (PCYC-1115-CA) and experienced PD are transferred to this Arm for Ibrutinib treatment. Treatment will continue until PD, unacceptable toxicity, or other reasons for treatment discontinuation.
3287750|NCT01724346|Other|Arm D Alternative Anticancer Therapy|At the Investigator's discretion, alternative anticancer treatment is a therapeutic option for patients who experienced PD during Ibrutinib treatment or during or after Chlorambucil treatment. This Arm can also be considered if drug is discontinued for other reasons (e.g., intolerability or adverse event [AE]) or prior to experiencing PD).
3287751|NCT01724372|Experimental|Antidepressant|Fluoxetine
3287752|NCT01724372|Active Comparator|Antipsychotic|Aripiprazole
3287753|NCT01724385|Experimental|intravitreal bevacizumab injection|intravitreal injection of bevacizumab 1.25 mg
3287754|NCT01724398|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 48 study visit.
3287755|NCT01724398|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC and then be followed until the week 48 study visit.
3287756|NCT01724398|Experimental|Conventional plus PE treatment|Participants will receive conventional treatment plus plasma exchange and then be followed until the week 48 study visit.
3287757|NCT01724398|Experimental|Conventional plus UC-MSC and PE therapy|Participants will receive conventional treatment plus umbilical cord mesenchymal stem cells transplantation combined with plasma exchange. Participants will then be followed until the week 48 study visit.
3287758|NCT01724411|Experimental|Resistant Starch 3|Resistant Starch Type 3:dose of 26g/day males and 22g/day female during 11 days of the maintenance period. (C ActiStar 11700, Tapioca Maltodextrin, Cargill, Belgium)
3287759|NCT01724411|No Intervention|Control Non- RS3|Non-Resistant Starch type 3 food items during 11 days of the maintenance period.
3287760|NCT01724424|Experimental|melatonin 20mg|2 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3287761|NCT01724424|Experimental|melatonin 30mg|3 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3287762|NCT01724424|Experimental|Melatonin 50mg|5 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3287763|NCT01724424|Experimental|Melatonin 100mg|10 x 10mg capsules of melatonin, single dose. Blood sampling and physiological measures (blood pressure, ECG, oxygen saturation) every 30 mins for 6 hours.
3287764|NCT01724437|Active Comparator|Loss of pace capture|Pulmonary vein isolation: Ablation along the ablation line is continued until loss of pace capture along the ablation line is achieved
3287765|NCT01724437|Active Comparator|Conventional|Pulmonary vein isolation: Ablation is discontinued when electrical isolation of the pulmonary veins is achieved.
3287766|NCT01724450|Active Comparator|Carvedilol|
3287767|NCT01724450|Placebo Comparator|Control|
3287768|NCT01724463||Electronically Screened Sepsis Patients|Patients between the ages 1 month and 18 years admitted to the hospital or presenting to the Emergency Department (ED) with clinical signs of Systemic Inflammatory Response Syndrome (SIRS) electronically screened for severe sepsis. Patients screened as positive will receive an evidence based goal directed severe sepsis management bundle.
3287769|NCT01724476|Active Comparator|folate with B12|Subjects randomized to the folate with B12 group will take 1 capsule of 400mcg per day of folate with B12.
3287770|NCT01724476|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 1 capsule of placebo per day.
3287771|NCT01724502|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3287772|NCT01724502|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3287773|NCT01724502|Experimental|Healthy Control Subjects|All subjects on this arm will undergo exercise and muscle biopsies.
3287774|NCT01724515|Experimental|Obese Non-Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3287775|NCT01724515|Experimental|Type 2 Diabetic Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3287776|NCT01724515|Experimental|Healthy Control Subjects|All subjects on this arm will undergo lipid infusion and muscle biopsies.
3287777|NCT01724554|Experimental|Every Month Treatment|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the 12 month duration of the study.
3287778|NCT01724554|Experimental|Every Month, then Every Other Month|Patients will receive Intravitreal Aflibercept Injection (IAI) every month for the first 6 months, then every other month for the next 6 months. Retreatment criteria will allow for patients to be treated every month in the second 6 months if needed.
3287779|NCT01724567|Experimental|Weight Loss|12 weeks of Low Calorie Diet to obtain a 10 - 15 % weight loss. Followed by 40 weeks on a weight maintenance diet and interval training 2 times a week.
3287780|NCT01724567|Experimental|Interval Training|12 weeks of interval training 3 times a week followed by 40 weeks of interval training 2 times a week.
3287781|NCT01724593||Observational Cohort|No Intervention
3287782|NCT01724606|Experimental|Radiotherapy with Sorafenib|This is a single institution, open label, prospective, phase I clinical trial using standard 3+3 design. Histologically confirmed metastatic adenocarcinoma of the breast with radiologic evidence of new and/or progressive brain metastases (BM) with a clinical indication for WBRT will be enrolled.
3287783|NCT01724619|Experimental|Healthy Volunteers|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
3287784|NCT01724619|Experimental|Prostate Cancer Patients|F-18] fluorinated dihydrotestosterone (FDHT) PET/CT
3287785|NCT01724632|Active Comparator|Group Treatment|Participants who are assigned to group treatment will attend group meetings weekly for the first 6 months, then every 2 weeks for 6 months, and then monthly for the final 6 months. Participants will be weighed individually at the start of each group meeting.
3287786|NCT01724632|Active Comparator|Individual Treatment|Participants who are assigned to individual treatment will attend one-on-one sessions with a weight loss counselor every month for 18 months.
3287787|NCT01724632|Experimental|Smartphone Treatment|Participants who are assigned to smartphone treatment will use a smartphone to learn and practice weight loss skills. They will also attend one-on-one sessions with a weight loss counselor every month for 18 months.
3287788|NCT01724645|Experimental|Korean traditional diets|Korean traditional diets (calorie 2,100kcal) for 12weeks
3287789|NCT01724645|Active Comparator|Control group|"Control group : told to eat as usal diet) for 12weeks"
3287790|NCT01724658|Experimental|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week plus progynova 1mg oral daily
3287791|NCT01724658|Placebo Comparator|placebo|placebo twice a week with progynova 1 mg oral daily
3287792|NCT01724671||Cefatroline|Investigators will retrospectively capture patient cases that have been treated for MRSA with ceftaroline. Cases will only be included if the isolate was tested against vancomycin and ceftaroline
3287793|NCT01724671||Vancomycin|Investigators will retrospectively capture patient cases that were been treated for MRSA with Vancomycin.
3287794|NCT01724684|Other|Telehealth program|Telehealth program service
3287795|NCT01724684|Other|Usual care|Usual care service
3287796|NCT01724697|Active Comparator|conventional treatment|conventional treatment & antivrial treatment.
3287797|NCT01724697|Experimental|BMSC transplantation|conventional treatment & antiviral treatment & autologous bone marrow stem cell transplantation via hepatic artery
3287798|NCT01724710||chronic ulcer|1x1cm2 tissue from chronic ulcer wound
3287799|NCT01724710||normal skin|1x1x0.1 cm3 normal skin from graft
3287800|NCT01724723|Experimental|Entecavir group|Study treatment for only treatment group: entecavir (BARACLUDE®) 0.5 mg per day during and within 6 months after anti-tuberculous treatment.
3287801|NCT01724723|No Intervention|Control group|Not receiving entecavir (BARACLUDE®)
3287802|NCT01724736|Placebo Comparator|Placebo Comparator:|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
3287803|NCT01724736|Active Comparator|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
3287804|NCT01724749||Healthy control subjects|"Age: 21 - 80 years~No prior history or symptoms of cardiovascular disease~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80."
3287805|NCT01724749||Subjects with cardiovascular disease|"Age: 21 - 80 years~HeartSCORE > 0%~Symptoms of angina pectoris~The investigators aim to include equal numbers of females and males. Furthermore, the investigators aim to include patients in six different age strata: 21-30, 31-40, 41-50, 51-60, 61-70, 71-80. Also, the investigators aim to include patients in 3 strata of HeartSCORE risk: low risk (1-4%), mild risk (5-9%) and high risk (> 9%)"
3287806|NCT01724762|Experimental|Nursing orientation|Patients who received nursing orientation and read the informative manual concerning bed bath
3287807|NCT01724775||CME surgery for colon cancer|
3287808|NCT01724775||non-CME surgery for colon cancer|
3287809|NCT01724788|Experimental|Furosemide PO - IV|Oral furosemide allocated at the beginning of Period 1, then cross-over to IV furosemide (a minimum 7-day diuretic free washout period required between the two periods)
3287810|NCT01724788|Experimental|Furosemide IV - PO|IV furosemide allocated at the beginning of Period 1, then cross-over to oral furosemide (a minimum 7-day diuretic free washout period required between the two periods)
3287811|NCT01724801|Experimental|icotinib|icotinib administered orally at a dose of 125 mg 3 times daily
3287812|NCT01724801|Active Comparator|Whole brain irradiation|Whole brain irradiation 30Gy/3Gy/10 fractions plus concurrent or sequential chemotherapy for 4-6 cycles
3287813|NCT01724814|Experimental|Cohort S1|HM12460A Dose 1 (1.2 nmol/kg) or placebo
3287814|NCT01724814|Experimental|Cohort S2|HM12460A Dose 2 (2.4 nmol/kg) or Placebo
3287815|NCT01724814|Experimental|Cohort S3|HM12460A Dose 3 (4.8 nmol/kg) or Placebo
3287816|NCT01724814|Experimental|Cohort S4|HM12460A Dose 4 (9.6 nmol/kg) or Placebo
3287817|NCT01724814|Experimental|Cohort S5|HM12460A Dose 5 (14.4 nmol/kg) or Placebo
3287818|NCT01724814|Experimental|Cohort S6|HM12460A Dose 6 (19.2 nmol/kg) or Placebo
3287819|NCT01724827|Active Comparator|ceramic|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
3287820|NCT01724827|Active Comparator|composite|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
3287821|NCT01724840|Experimental|GraftJacket|GraftJAcket is used as interpositional material
3287822|NCT01724840|Active Comparator|Tendon Interposition|Flexor carpi radialis tendon is used as interpositional material
3287823|NCT01724853|Other|Surgery|Preferred surgery
3287824|NCT01724853|Other|Conservative|Conservative treatment
3287825|NCT01724866|Experimental|Single-dose HM10460A (45 μg/kg)|Single-dose HM10460A (45 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3287826|NCT01724866|Experimental|Single-dose HM10460A (135 μg/kg)|Single-dose HM10460A (135 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3287827|NCT01724866|Experimental|Single-dose HM10460A (270 μg/kg)|Single-dose HM10460A (270 μg/kg) should be administered on Day 2 of each cycle, approximately 24 hours (±2 hours) after TC chemotherapy.
3287828|NCT01724866|Active Comparator|Pegfilgrastim 6 mg|Pegfilgrastim (Neulasta®) is not to be administered between 14 days before or 24 hours after TC chemotherapy. Pegfilgrastim (Neulasta®) will be administered according to the manufacturer's Prescribing Information (6 mg subcutaneously once per chemotherapy cycle).
3287829|NCT01724879|Experimental|Dasatinib and chemotherapy|Dasatinib, QD p.o. administration, day 1 to EOS
3287830|NCT01724892|Active Comparator|Loteprednol etabonate|Topical Loteprednol etabonate eye drop 0.5%, 4 times a day, 3 weeks
3287831|NCT01724892|Active Comparator|Dexamethasone|Topical Dexamethasone eye drop 0.1%, 4 times a day, 3 weeks
3287832|NCT01724905|Experimental|Modified Stop Light Diet|
3287833|NCT01724905|Active Comparator|Recommended Care for Weight Reduction|
3287834|NCT01724918|Other|100 mg IV|100 mg IV lacosamide infused over 30 minutes
3287835|NCT01724918|Other|200 mg IV|200 mg IV lacosamide infused over 30 minutes
3287836|NCT01724918|Other|400 mg IV|400 mg IV lacosamide infused over 30 minutes
3287837|NCT01724931|Placebo Comparator|Placebo|Placebo once weekly
3287838|NCT01724931|Experimental|3 mg LD-Aminopterin|3 mg LD-aminopterin once weekly
3287839|NCT01724931|Experimental|1 mg LD-aminopterin|1 mg LD-aminopterin once weekly
3287840|NCT01724944|Experimental|Systematic Lymphadenectomy|
3287841|NCT01724957||Patients with coronary bifurcation lesions|Only one group will be studied. The patient will be a slef-reference.
3287842|NCT01724970|Experimental|PLMA|ProSeal
3287843|NCT01724970|Experimental|SLMA|Supreme LMA
3287844|NCT01724983|Experimental|ketamine|patients will receive ketamine at induction
3287845|NCT01724983|Active Comparator|fentanyl|patients will receive fentanyl at induction
3287846|NCT01725009|Experimental|Levetiracetam IV infusions in Japanese|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects
3287847|NCT01725009|Experimental|Levetiracetam IV infusions in Caucasian|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects
3287848|NCT01725022|Experimental|Home Care|This is the arm for patients who receive their transplant care in their homes.
3287849|NCT01725022|No Intervention|Hospital Care|Standard of care for stem cell transplant recipients where the aftercare is done in hospital.
3287850|NCT01725022|No Intervention|Clinic Care|Standard of care for stem cell transplant recipients who live at home but receive aftercare in the daily outpatient clinic.
3287851|NCT01725035||Fatty liver|
3287852|NCT01725035||Non Fatty liver|
3287853|NCT01725048|Active Comparator|Mirtazapine|Treatment with oral mirtazapine, dosed once daily, for 9 weeks, with starting dose of 7.5 milligrams (mg) daily up to 30mg daily.
3287854|NCT01725048|Active Comparator|Citalopram|Treatment with Citalopram, once daily, for 9 weeks, with dosages starting at 10mg once daily to 40mg once daily.
3287855|NCT01725074|Experimental|"Case Management CM CHD"|The intervention consists of a biweekly telephone or personal contact by trained case managers over the first 6-months and monthly contact over the second 6-months to assess well-being, everyday life (positive, neutral and negative daily events), and to inquire after health and personal problems on which basis the case manager offers practical or emotional support or a referral to the general practitioner if deemed necessary. During the contacts also medical control measures like blood pressure or weight are taken, and other study outcome measures like need for medical treatment.
3287856|NCT01725074|Experimental|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures.
3287857|NCT01725074|No Intervention|Control Group|Patients assigned to the control group received usual care (no additional contact/support) and therefore stays under the standard supervision of the general practitioner i.e. as participant in the normal disease management program for CHD (quarterly check-ups).
3287858|NCT01725087|Placebo Comparator|Matching Placebo|Twice daily oral administration of matching placebo for 14 weeks
3287859|NCT01725087|Experimental|Low Dose GRT6005|Once daily GRT6005 low dose oral administration for 12 weeks with a titration period of 2 weeks.
3287860|NCT01725087|Experimental|Medium Dose GRT6005|Once daily GRT6005 medium dose oral administration for 12 weeks with a titration period of 2 weeks.
3287861|NCT01725087|Experimental|High Dose GRT6005|Once daily GRT6005 high dose oral administration for 12 weeks with a titration period of 2 weeks.
3287862|NCT01725087|Active Comparator|Tapentadol|Twice daily oral administration of Tapentadol for 12 weeks with a titration period of 2 weeks.
3287863|NCT01725100|Experimental|Treatment A: GSK1120212B (Standard DMSO content)|Subjects will receive Treatment A in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
3287864|NCT01725100|Experimental|Treatment B: GSK1120212B (Lower DMSO content)|Subjects will receive Treatment B in Period 1 or 2 as single oral dose on Day 1 of Period 1 or 2 in fasting condition with water.
3287865|NCT01725113|Experimental|Calcitriol|Patients will be converted from paricalcitol to calcitriol according to published package inserts which describe a 10mcg:3mcg ratio.
3287866|NCT01725113|Active Comparator|Paricalcitol|Continuation of intravenous paricalcitol that patient was originally on at the time of recruitment.
3287867|NCT01725139|Experimental|Cohort 1-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 (0.25 mg twice daily [bid]) or placebo for approximately 8 days (7 to 10 days dosing)
3287868|NCT01725139|Placebo Comparator|Cohort 1-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing)
3287869|NCT01725139|Experimental|Cohort 2-GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 1 and which could be escalated or deescalated or repeated from Cohort 1 dosing.
3287870|NCT01725139|Placebo Comparator|Cohort 2-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3287871|NCT01725139|Experimental|Cohort 3- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 2 and which could be escalated or deescalated or repeated from Cohort 2 dosing.
3287872|NCT01725139|Placebo Comparator|Cohort 3-Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3287873|NCT01725139|Experimental|Cohort 4- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 3 and which could be escalated or deescalated or repeated from Cohort 3 dosing.
3287874|NCT01725139|Placebo Comparator|Cohort 4- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3287875|NCT01725139|Experimental|Cohort 5- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 4 dosing.
3287876|NCT01725139|Placebo Comparator|Cohort 5- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3287877|NCT01725139|Experimental|Cohort 6- GSK2126458|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or placebo for approximately 8 days (7 to 10 days dosing). GSK2126458 dose will be decided from Cohort 4 and which could be escalated or deescalated or repeated from Cohort 5 dosing.
3287878|NCT01725139|Placebo Comparator|Cohort 6- Placebo|Subjects will be randomized in 3:1 ratio to receive either GSK2126458 bid or matching placebo for approximately 8 days (7 to 10 days dosing).
3287879|NCT01725152|Experimental|Ganaxolone|3 mg/kg up to 12 mg/kg, with maximum of 1500 mg/day
3287880|NCT01725152|Placebo Comparator|Placebo|non active
3287881|NCT01725165|Experimental|Arm I (immediate LCT)|Patients undergo ablation of all residual local and metastatic sites of disease by surgery and/or EBRT. After completion of LCT, patients undergo either surveillance or maintenance treatment at the discretion of the treating physician.
3287882|NCT01725165|Active Comparator|Arm II (delayed/no LCT)|Patients undergo standard maintenance therapy or clinical observation, based on physician choice. Patients may cross-over to Arm I due to RECIST progression or toxicity at the treating physician's discretion.
3287883|NCT01725178|No Intervention|Standard care|No intervention besides usual care
3287884|NCT01725178|Active Comparator|Cognitive and physical training|Patients will undergo the comprehensive program of cognitive and physical training.
3287885|NCT01725191|Experimental|Treatment (tivantinib)|Patients receive tivantinib PO BID on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
3287886|NCT01725204|Experimental|Dasatinib + PegIFN|Dasatinib 100mg OD for three months single drug, with subsequent addition of PegIFN 15 μg/ week for 3 months. If well tolerated (less than grade 2 non-hematological or grade 3 hematological AE) the dose should be increased to 25μg weekly for the remaining 9 months on combination treatment. Thereafter dasatinib will be given as monotherapy. Patients will be followed for 24 months totally.
3287887|NCT01725230|Experimental|Rosuvastatin|Single, oral dose of rosuvastatin 20mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of rosuvastatin 20 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
3287888|NCT01725230|Experimental|Simvastatin|Single, oral dose of simvastatin 40 mg in first period and in second period (after wash out) fostamatinib 100 mg twice daily, then single oral dose of simvastatin 40 mg plus continued oral dosing of fostamatinib 100 mg twice daily, then continue fostamatinib 100 mg twice daily
3287889|NCT01725243|Active Comparator|Carbetocin 10mcg|Carbetocin 10mcg IV, once following delivery.
3287890|NCT01725243|Active Comparator|Carbetocin 20mcg|Carbetocin 20mcg IV, once following delivery.
3287891|NCT01725243|Active Comparator|Carbetocin 40mcg|Carbetocin 40mcg IV, once following delivery.
3287892|NCT01725243|Active Comparator|Carbetocin 60mcg|Carbetocin 60mcg IV, once following delivery.
3287893|NCT01725243|Active Comparator|Carbetocin 80mcg|Carbetocin 80mcg IV, once following delivery.
3287894|NCT01725243|Active Comparator|Carbetocin 100mcg|Carbetocin 100mcg IV, once following delivery.
3287895|NCT01725243|Active Comparator|Carbetocin 120mcg|Carbetocin 120mcg IV, once following delivery.
3287896|NCT01725243|Active Comparator|Carbetocin 140mcg|Carbetocin 140mcg IV, once following delivery.
3287897|NCT01725256|Experimental|80mg AIR001 four times daily|80mg AIR001 nebulized four times daily for 16 weeks
3287898|NCT01725256|Experimental|46mg AIR001 four times daily|46mg AIR001 nebulized four times daily for 16 weeks
3287899|NCT01725256|Experimental|80mg AIR001 once daily|80mg AIR001 nebulized once daily for 16 weeks
3287900|NCT01725269|Experimental|80mg AIR001, nebulized four times daily|AIR001, 80 mg into nebulizer
3287901|NCT01725269|Experimental|46 mg AIR001, nebulized four times daily|AIR001, 46 mg into nebulizer
3287902|NCT01725269|Experimental|80mg AIR001, nebulized once daily|AIR001, 80 mg into nebulizer
3287903|NCT01725295|Experimental|NST|A form of physical therapy to relieve symptoms of fibromyalgia
3287904|NCT01725295|Active Comparator|Hydrotherapy|An alternate form of physical therapy to relieve symptoms of fibromyalgia
3287905|NCT01725321||Narrow band imaging|Colonoscopy with new narrow band imaging
3287906|NCT01725334|Experimental|Nucleus Accumbens/Ventral Striatum (NAcc/VS) Stimulation|The first 3 patients will have the DBS device target the NAcc/VS, which has been found to be hypoactive in patients with primarily negative symptoms.
3287907|NCT01725334|Experimental|Ventral Tegmental Area (VTA) Stimulation|For 3 patients, the DBS device will target the VTA, which has been found to be hypoactive in patients with primarily negative symptoms.
3287908|NCT01725347||African American Girls|-25% of sample is African American Girls
3287909|NCT01725347||African American Boys|-25% of sample is African American Boys
3287910|NCT01725347||Hispanic American Girls|-25% of sample is Hispanic American Girls
3287911|NCT01725347||Hispanic American Boys|-25% of sample is Hispanic American Boys
3287912|NCT01725360|Experimental|montelukast|A leukotriene receptor antagonist (LTRA, montelukast) is added to a basic treatment of inhaled corticosteroids (ICS) + long-acting betamimetics (LABA) in well-controlled patients with asthma.
3287913|NCT01725373||Angioplasty of left main|"Patients with:~stable or unstable angina and/or documented ischemia~de novo ≥50% stenosis in the left main stem referred for angioplasty"
3287914|NCT01725399|Placebo Comparator|Water|Water will be given as the study subject's first oral intake after emergence from general anesthesia.
3287915|NCT01725399|Experimental|Apple Juice|Apple juice will be given as the study subject's first oral intake after emergence from general anesthesia.
3287916|NCT01725412|Experimental|Thiamine Supplementation|
3287917|NCT01725412|Placebo Comparator|Placebo|
3287918|NCT01725425|Experimental|Control|Participants will receive equal amounts of foods.
3287919|NCT01725425|Experimental|Increase Portion Size|Participants will receive increased portion sizes.
3287920|NCT01725425|Experimental|Decrease Portion Sizes|Participants will receive decreased portion sizes.
3287921|NCT01725425|Experimental|Mixed Portion Sizes|Participants will receive mixed portion sizes.
3287922|NCT01725438|Experimental|Pregnant women accepting an invasive prenatal diagnosis|Pregnant women accepting an invasive prenatal diagnosis and a sample blood (non invasive diagnosis)
3287923|NCT01725464|Experimental|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
3287924|NCT01725477|Experimental|Dye& normal saline/ 20ml methylene blue +50 ml normal saline|first arm:20 ml methylene blue washing with50 ml normal saline
3287925|NCT01725477|Active Comparator|injection of 20ml metheylen blue|20 ml methylene blue injected without washing
3287926|NCT01725490|Experimental|metformin 500mg daily (arm A)|
3287927|NCT01725490|Experimental|metformin 1500mg daily (arm B)|
3287928|NCT01725490|Placebo Comparator|an identical- appearing placebo (arm C)|
3287929|NCT01725503|Experimental|Creatine and amino acid supplement|
3287930|NCT01725516|Experimental|Myofascial release technique|
3287931|NCT01725542|Experimental|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|"Lead-in Phase: day 0 to week 4 PegInterferon alpha-2a + Ribavirin~Quadruple therapy: week 4 to week 28 Asunaprevir + Daclatasvir + PegInterferon alpha-2a + Ribavirin"
3287932|NCT01725555|Experimental|Fasted treatment|
3287933|NCT01725555|Experimental|Fed treatment|
3287934|NCT01725568||Implantable cardiac monitor diagnostics|Patients has standard indication for implantable cardiac monitor diagnostic.
3287935|NCT01725581||Inexperienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
3287936|NCT01725581||Experienced students|Final year medical students at the end of the Obstetrics and Gynaecology placement
3287937|NCT01725581||Junior Doctors|Pre Royal College of Obstetric and Gynaecology registered junior doctors with experience in Obstetrics and Gynaecology
3287938|NCT01725594|Experimental|Cohort A1, Dose Level 1: CAT 2003 or placebo fasting|Single dose
3287939|NCT01725594|Experimental|Cohort A2, Dose Level 2: CAT 2003 or placebo fasting|Single dose
3287940|NCT01725594|Experimental|Cohort A3, Dose Level 3: CAT 2003 or placebo fasting|Single dose
3287941|NCT01725594|Experimental|Cohort A4, Dose Level 4: CAT 2003 or placebo fasting|Single dose
3287942|NCT01725594|Experimental|Cohort A5, Dose Level 5: CAT 2003 or placebo fasting|Single dose
3287943|NCT01725594|Experimental|Cohort A2: Dose Level 2: CAT 2003 or placebo fed|Single dose
3287944|NCT01725594|Experimental|Cohort A3: Dose level 3:CAT 2003 or placebo fed|Single dose
3287945|NCT01725594|Experimental|Cohort B1: Dose level 6: CAT 2003 or placebo|Multiple dose for 14 days
3287946|NCT01725594|Experimental|Cohort B2: Dose level 7: CAT 2003 or placebo|Multiple dose for 14 days
3287947|NCT01725594|Experimental|Cohort B3: Dose level 8: CAT 2003 or placebo|Multiple dose for 14 days
3287948|NCT01725594|Experimental|Cohort B4: Dose level 9: CAT 2003 or placebo|Multiple dose for 14 days
3287949|NCT01725607|No Intervention|the control group (Group C)|general anesthesia
3287950|NCT01725607|Experimental|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
3287951|NCT01725607|Experimental|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
3287952|NCT01725620|Experimental|Group 1|Enbrel, LBEC0101
3378905|NCT01164241||1|Eczema
3287953|NCT01725620|Experimental|Group 2|LBEC0101, Enbrel
3378906|NCT01164241||2|unaffected relatives
3378907|NCT01164241||3|healthy volunteers
3378908|NCT01164241||4|other allergic phenotypes
3378909|NCT01150721||1/PNMI|Adult patients with Pulmonary Nontuberculous Mycobacterial Infection
3378910|NCT01150721||2/Healthy Volunteers|Healthy Volunteer adults
3378911|NCT01150708||Chiari 1 with syringomyelia|Chiari I malformation with syringomyelia.
3378912|NCT01150708||Chiari 1 without syringomyelia|A Chiari I Malformation without syringomyelia is defined as descent of the cerebellar tonsils > 5 mm below the foramen magnum 79 without associated syringomyelia.
3378913|NCT01150708||Syringomyelia without chiari|A syrinx or syringomyelia is defined as an intramedullary cyst that extends / length > 1spinal segment.
3287954|NCT01725646|Active Comparator|Omacor® 4 g|Subjects in this group will take 4 g of Omacor® everyday.
3287955|NCT01725646|Active Comparator|Omacor® 2 g|Subjects in this group will take 2 g of Omacor® and 2 g of placebo everyday.
3378919|NCT01145196||Affected|Participants affected by Paquenil induced retinal toxicity
3378920|NCT01145196||Unaffected|control participants without Plaquenil induced retinal toxicity
3378921|NCT01143532||1|Kidney transplant recipient of black African descent.
3378922|NCT01143532||2|Kidney transplant donor of black African descent.
3378923|NCT01143519||FLT1 C-677T|SNP
3287956|NCT01725646|Placebo Comparator|Placebo|Subjects in this group will take 4 g of placebo everyday.
3287957|NCT01725659|Experimental|Motor Learning|subjects are provided with intensive motor learning training of the upper limb
3287958|NCT01725659|Experimental|Robotics and Motor Learning|subject are provided with intensive motor learning and robotics training of the upper limb
3378924|NCT01143519||MDM2 rs2279744|SNP
3378925|NCT01143519||p53 rs1042522|SNP
3378926|NCT01143519||RMM1 rs1465952|SNP
3378927|NCT01143519||TLR8 rs3761624|SNP
3287959|NCT01725659|Experimental|Motor learning and FES|subjects are provided with intensive motor learning and surface FES (Functional Electrical Stimulation) of the upper limb
3287960|NCT01725672|Active Comparator|Part A and B:Arm 1: 500 mg metformin XR / 1 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 500 mg metformin XR and 1 mg glimepiride IR on Day 1 of the respective period per randomized sequence
3287961|NCT01725672|Active Comparator|Part A and B:Arm 2: 1000 mg metformin XR / 2 mg glimepiride IR|In Part A and Part B of the study, subjects will receive single dose oral tablets of 1000 mg metformin XR and 2 mg glimepiride IR on Day 1 of the respective period per randomized sequence
3287962|NCT01725672|Experimental|Part A:Arm 3: 500 mg metformin XR and 1 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
3378944|NCT01141816|Experimental|Contrast-Enhanced Ultrasound|
3378947|NCT01132937||Healthy Controls|Accrual Ceiling: 20. Healthy, uninjured, subjects are used to match to those suspected of head injury. 10 subjects have been enrolled to date in the PET arm
3378948|NCT01132937||Suspected of Head Injury|Accrual Ceiling: 1000. Subjects enrolled with 48hrs of suspected head injury in emergency department of local hospitals, Suburban Hospital Center or Washington Hospital Center
3287963|NCT01725672|Experimental|Part A:Arm 4: 1000 mg metformin XR and 2 mg glimepiride XR|In Part A of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC1) film coated tablet containing release controlling polymers on Day 1 of the respective period per randomized sequence
3287964|NCT01725672|Experimental|Part B:Arm 5: 500 mg metformin XR and 1 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 500 mg metformin XR and 1 mg glimepiride XR (FDC3) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
3287965|NCT01725672|Experimental|Part B:Arm 6: 1000 mg metformin XR and 2 mg glimepiride XR|In Part B of the study subjects will receive single oral dose of 1000 mg metformin XR and 2 mg glimepiride XR (FDC4) tablet coated with release controlling polymers on Day 1 of the respective period per randomized sequence
3287966|NCT01725685|Experimental|Treatment A - FF 400 microgram (mcg)|Subjects will be randomized to single dose of FF 400 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3287967|NCT01725685|Experimental|Treatment B - UMEC 500 mcg|Subjects will be randomized to single dose of UMEC 125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3287968|NCT01725685|Experimental|Treatment C - FF/UMEC 400/500 mcg|Subjects will be randomized to single dose of FF/UMEC 100/125 mcg in either of the three treatment period, which is separated by a wash-out period of 7 to 10 days.
3287969|NCT01725698|Experimental|Stemcell|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant
3287970|NCT01725711|Experimental|Implant System|
3287971|NCT01725724|Active Comparator|Allogeneic blood|Allogeneic blood transfusion. Patients in this group will receive allogeneic red cell transfusions.
3287972|NCT01725724|Experimental|Autologous blood|Autologous blood transfusion. Patients in this arm will receive per- and postoperatively collected autologous blood collected with the Sangvia Blood Collection System. If teh amount of autologous blood is too small for the clinical need, additional allogeneic blood will be transfused.
3287973|NCT01725737|Placebo Comparator|Placebo|
3287974|NCT01725737|Active Comparator|GlyTI-M|GlyTI-M: 0.03gm/kg/day
3287975|NCT01725763|Other|suspected PH|60 minute Cardiac MRI
3287976|NCT01725776|Experimental|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg(as for the injectable solution)
3287977|NCT01725789|Experimental|Ferinject® Group|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
3287978|NCT01725789|Placebo Comparator|Placebo Group|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with 7g/dl≤Hb<10g/dl at 5 - 7 days after gastrectomy for gastric cancer.
3287979|NCT01725802|Experimental|levodopa and carbidopa|levodopa and carbidopa solution
3287980|NCT01725802|Placebo Comparator|placebo to levodopa and carbidopa|saline
3287981|NCT01725828|Experimental|External Palpation group|External Palpation group will consist of 109 patients, who's CTM will be marked using traditional palpation technique of identifying the Cricothyroid membrane.
3287982|NCT01725828|Experimental|Ultrasound group|"Ultrasound group will consist of 114 patients, who's CTM will be marked using, ultrasonography to identify the CTM.~The Intervention by using the Ultrasound to determine the CTM."
3287983|NCT01725854|Experimental|Relaxation Response Training|The Military tailored RR training program will consist of six weekly small group sessions which involve group presentations, in-group skill building exercises, and at-home assignments. Groups will contain 5-8 participants who are active-duty Soldiers enrolled in either Respect-MIL or the Interdisciplinary Pain Management Center (IPMC).
3287984|NCT01725854|No Intervention|Standard of Care|Participants randomized to the control group will receive standard care through their providers at Respect-MIL or at the IPMC. Participants randomized to the control group will remain on the wait list for further standard care. After the collection of the final data point, these participants will also have the option to participate in an abbreviated, two-hour version of the RR training.
3287985|NCT01725867|Experimental|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
3287986|NCT01725867|Active Comparator|Splint group|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
3287987|NCT01725880||No treatment|Observation
3287988|NCT01725906|Active Comparator|Empirical therapy|selection of antibiotic according to medication history
3287989|NCT01725906|Experimental|Genotypic resistance guided therapy|selection of antibiotics according to genotypic resistance
3287990|NCT01725919|Experimental|Immediate CI therapy|
3287991|NCT01725919|Active Comparator|Delayed CI therapy|
3287992|NCT01725932|Experimental|Culturally adapted CBT based Self Help|Culturally sensitive cbt based self help intervention, which consists of 6 regular chapters and 2 additional chapters. The self help intervention involves family to improve compliance with the intervention
3287993|NCT01725932|No Intervention|Care As Usual|Control Group
3287994|NCT01725945|No Intervention|Usual Care|Usual Care
3287995|NCT01725945|Experimental|DASH Intervention|Dietary Approaches to Stop Hypertension dietary pattern. Usual care in combination with a DASH intervention consisting of 8 group and 3 individual sessions over 3 months, followed by 3 monthly phone consultations.
3287996|NCT01725958|Experimental|Dietary Supplement|"Treatment Regimen~-The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake."
3287997|NCT01725971||Control group|Group of nonsmokers individuals without respiratory disease.
3287998|NCT01725971||normal exam|subjects with silicosis , but with normal spirometric data
3287999|NCT01725971||mild obstruction|subjects with silicosis with mild obstruction in spirometric data
3288000|NCT01725971||moderate to severe obstruction|subjects with silicosis with moderate to severe obstruction in spirometric data
3288001|NCT01725997|Active Comparator|Operative treatment|Operative treatment with hook plate.
3288002|NCT01725997|Active Comparator|Conservative treatment|Physiotherapy
3288003|NCT01726010|Experimental|22-G Procore Needle|
3288004|NCT01726062|Experimental|Motivational Interviewing plus Incentives|
3288005|NCT01726062|Other|Conventional Care (CC)|
3288006|NCT01726075|Experimental|COLIRIOBCN070660|COLIRIOBCN070660 Somatostatin 1mg/mL Eye drops, solution. One drop/eye administered twice a day.
3288007|NCT01726075|Placebo Comparator|Placebo|Placebo Eye drops, solution. One drop/eye administered twice a day.
3288008|NCT01726075|Experimental|Brimonidine|Brimonidine tartrate 2mg/mL One drop/eye administered twice a day.
3288009|NCT01726088|Active Comparator|modafinil|Study participants randomized to the active arm of the study will take modafinil 100mg capsules orally each day for 4 weeks.
3288010|NCT01726088|Placebo Comparator|Sugar Pill|Study participants randomized to the placebo arm of the study will take matching capsules orally each day for 4 weeks.
3288011|NCT01726114|Experimental|Non-invasive Optical Glucose Monitor™|Test device
3288012|NCT01726127|Experimental|Broccoli and Brussels Sprouts|Subjects will consume broccoli or Brussels sprouts (40g daily) for 8 weeks.
3288013|NCT01726127|Experimental|Cruciferous Complete|Subjects will take Cruciferous CompleteTM supplements (2 capsules, 3 times daily) for 8 weeks.
3288014|NCT01726127|Placebo Comparator|Placebo|Subjects will take placebo capsules (2 capsules, 3 times daily) for 8 weeks.
3288015|NCT01726140|Experimental|TREATMENT|Helmet CPAP
3288016|NCT01726140|Active Comparator|CONTROL|Venturi Mask
3288017|NCT01726153|No Intervention|Web sites|Individuals assigned to this arm are given a list of websites where they can view additional information relating to condom use.
3288018|NCT01726153|Experimental|Condom-HIM|Individuals assigned to this arm must follow an on-line one session tailored intervention.
3288019|NCT01726166|Active Comparator|Suprapubic Aspiration|A trained physician or neonatal nurse practitioner utilizing U/S guidance at the bedside will perform the SPA. An U/S machine is readily available for use in each NICU.
3288020|NCT01726166|Active Comparator|Urinary Catheterization|"The infants will have the procedure done by NICU nurses who have been trained in performing this procedure.~If the randomly assigned infant passes urine spontaneously during a UC attempt after complete perineal cleansing and the urine is collected as a clean catch sample, then this infant will be analysed in the assigned group (intention to treat)."
3288021|NCT01726179|Experimental|Icon infiltration|Icon infiltration regarding instructions for use
3288022|NCT01726179|Active Comparator|control|conventional non invasive treatment
3288023|NCT01726192|Active Comparator|HLOC|Placement of a femoral catheter with the hydrolocalization technique
3288024|NCT01726192|Active Comparator|NS|Placement of a femoral neurostimulating catheter
3288025|NCT01726205|Active Comparator|pregabalin|perioperative pregabalin starting the evening before surgery, and for five days postoperatively
3288026|NCT01726205|Active Comparator|pregabalin and continuous wound infusion|Pregabalin as previous group and continuous infusion of ropivacaine 0.2% via a wound catheter
3288027|NCT01726205|Placebo Comparator|placebo|Placebo drug and normal saline infusion
3288028|NCT01726218||Stroke patients|
3288029|NCT01726218||Healthy Control|
3288030|NCT01726244|No Intervention|Control group|Habitual Clinical Practice
3288031|NCT01726244|Experimental|Intervention Group|Multidisciplinary intervention consisting in controlling disease and stress associated to it, and modifying eating habits. A Nurse, nutritionist and a psychologist will be the responsible of these educational sessions. it will be three educational sessions. Patients with a BMI lower than 20 or bigger than 30 will be receive a closer follow up by nutritionist. In addition, patients with a score of 9 or more in the Patients Health Questionnaire-9 questionnaire will be also a closer follow up with the psychologist.
3288032|NCT01726257|Experimental|Nellix System|Nellix Endovascular Aneurysm Sealing System is the only arm for this study. This is a single arm study.
3288033|NCT01726283||low risk subjects for developing post-operative ectasia|Patients undergoing vision correction surgery who are not at a higher risk for developing post-op ectasia
3288034|NCT01726283||Subjects at Risk for Ectasia|Patients undergoing vision correction surgery who are at a higher risk for developing post-operative ectasia
3288035|NCT01726296|Experimental|Health services research (educational intervention)|Health care providers complete an educational intervention based on NCCN guidelines in CRC and NSCLC survivorship care comprising a power point presentation reviewing evidence and prompts for addressing survivorship care components; and an electronic paper copy sample survivorship care plan that can be adapted and distributed at each participating site.
3288036|NCT01726309||Stage IV CRC|
3288037|NCT01726309||Stage IV NSCLC|
3288038|NCT01726348||Darunavir|Patients will be taking darunavir as per the dosing regimen given on product insert approved in Philippines.
3288039|NCT01726361|Experimental|MTFC|Out of home placement in MTFC family program
3288040|NCT01726361|Active Comparator|TAU|Other kind of out of home placement
3288041|NCT01726374|Experimental|One cycle adjuvant BEP(500)|Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15
3288042|NCT01726387|Experimental|Psychosocial Counseling|A Counseling Assistant offers a low-threshold intervention (self-management support, counseling, active guidance). This nurse practitioner collaborates extensively with the general practitioner, re-adjusting the intervention in order to meet the patient's needs.
3288043|NCT01726387|Placebo Comparator|Usual Care|Depending on the conditions, patients get usual care of their general practitioner.
3288044|NCT01726400||Interferon and ribavirin|Treatment with standard of care pegylated interferon alpha and ribavirin.
3288045|NCT01726413|Experimental|Test Arm|GRC17356 for daily administration
3288046|NCT01726413|Placebo Comparator|Placebo|Matching placebo for daily administration
3288047|NCT01726426|Experimental|Patients of palmer arsenical keratosis|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3288048|NCT01726426|Active Comparator|Arsenic exposed controls|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3288049|NCT01726426|Active Comparator|Heathy volunteers|Probiotics Capsule (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
3288050|NCT01726439||CHB patients who are naive to NUC treatment|CHB patients who are naive to NUC at enrollment and be treated at hospitals at tier 2 cities in China
3288051|NCT01726452|Experimental|A (Modified MAGIC) OR Arm A: FLOT|"Modified MAGIC: The modified MAGIC regimen encompasses 3 cycles of chemotherapy pre-surgery and 3 cycles post-surgery. The regimen is a combination of epirubicin, cisplatin or oxaliplatin and a choice of 5-fluorouracil or capecitabine. Each cycle lasts 21 days.~FLOT: The FLOT regimen encompasses 8 cycles of chemotherapy in total , 4 cycles of chemotherapy pre-surgery and a further 4 cycles of chemotherapy post-surgery. Each cycle of chemotherapy lasts 14 days/2 weeks."
3288052|NCT01726452|Experimental|B (CROSS)|Arm B consists of the multimodal CROSS arm, which includes a combination of chemotherapy and radiotherapy prior to surgery. The patient will receive four and a half (4.5) weeks of radiation therapy (41.4 Gy/23 fractions), and 5 weekly cycles of chemotherapy. The chemotherapy and radiotherapy will run concurrently over a 4 and a half-week period. Chemotherapy is given by intravenous infusion on days 1, 8, 15, 22 and 29. The radiation will generally commence on the 1st day of treatment and will run for 4 and a half weeks as follows: days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31 inclusive.
3288053|NCT01726465|Experimental|N-acetylcysteine|Patients were randomized to this arm will receive a bolus of N-acetylcysteine in an hour of 150 mg/kg after the beginning of the operation. After the bolus will start a 6-hour infusion of 50mg/kg/h of N-acetylcysteine.
3288054|NCT01726465|Experimental|Methylprednisolone|Patients were randomized to this arm will receive a bolus of methylprednisolone in an hour of 500 mg after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
3288055|NCT01726465|Placebo Comparator|Placebo|Patients were randomized to this arm will receive placebo (Ringer's acetate) in an hour after the beginning of the operation. After the bolus will start a 6-hour infusion of placebo (Ringer's acetate).
3288056|NCT01726478|Active Comparator|2.5 units oxytocin|Administration of 2.5 units of oxytocin intravenously after clamping of umbilical cord
3288057|NCT01726478|Placebo Comparator|10 units oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
3288058|NCT01726491||Insulin resistance epigenetics|"This experiment will use the Infinium methylation assay to perform epigenome mapping and define patterns of DNA methylation in skeletal muscle and whole blood tissue of metabolically well-characterized lean healthy, obese nondiabetic, and type 2 diabetic volunteers. We will test the hypotheses that~(1) There is an increased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation and altered methylation of promoters of genes coding for extracellular matrix and cytoskeletal proteins in insulin resistance, (2) The altered methylation patterns observed correspond to protein and mRNA expression changes, and (3) There are coordinated patterns of DNA methylation between the skeletal muscle and whole blood tissues in insulin resistance."
3288059|NCT01726491||Single bout of exercise|"This experiment will test the hypotheses in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~Increased methylation of the PGC-1α promoter predicts a decreased response of this gene to a single bout of exercise, and~Altered methylation of promoters of nuclear encoded mitochondrial genes predicts a decreased response of this gene to a single bout of exercise."
3288060|NCT01726491||Eight weeks of exercise|"This experiment will test the hypothesis in lean healthy, obese non-diabetic and type 2 diabetic volunteers that~There is decreased methylation of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and the altered methylation corresponds to protein and mRNA (messenger ribonucleic acid) expression changes,~There is altered methylation of genes involved in inflammation and cytoskeletal structure."
3288061|NCT01726530|Active Comparator|Transdermal fentanyl patch|Transdermal fentanyl patch, 50 mcg/hour, was attached to the patient's chest wall at 10 pm the day before surgery
3288062|NCT01726530|Placebo Comparator|Placebo|Placebo patch was attached to the patient's chest wall at 10 pm the day before surgery
3288063|NCT01726543|Active Comparator|Canaloplasty and phacoemulsification|
3288064|NCT01726543|Active Comparator|Non-penetrating deep sclerectomy and phacoemulsification|
3288065|NCT01726556|Active Comparator|Rigid thoracoscopy|Rigid thoracoscopy would be done using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany.
3288066|NCT01726556|Active Comparator|Semirigid thoracoscopy|The semirigid thoracoscope employed is a model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan.
3288069|NCT01726582|Other|Pre surgery targeted chemo|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm A:~Targeted chemotherapy prior to surgery: 8 weeks targeted chemotherapy; restaging:~see link to protocol Figures A & C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288070|NCT01726582|Other|Pre surgery cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm B:~Before surgery: Chemoradiotherapy (cRXT); restaging:~see link to protocol Figure C and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288071|NCT01726582|Other|Pre surgery targeted chemo, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C1:~Before surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging~see link to protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288072|NCT01726582|Other|Pre surgery FOLFIRINOX, then cXRT|"Depending on the tumor biopsy, treatment prior to surgery will follow arm A or B or C1 or C2.~Arm C2:~standard FOLFIRINOX chemotherapy prior to surgery: 8 weeks FOLFIRINOX (standard chemotherapy); restaging; standard chemoradiotherapy (cXRT); restaging:~see link at protocol Figures B and C at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288073|NCT01726582|Other|After surgery targeted chemo, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D1:~After surgery: 8 weeks targeted chemotherapy; restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288074|NCT01726582|Other|After surgery Gemcitabine, then cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm D2:~Gemcitabine after surgery: 8 weeks standard Gemcitabine (chemotherapy); restaging; chemoradiotherapy (cXRT); restaging:~see link to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3378949|NCT01132924||EPS Study Participants|Women who participated in the 1982-1986 North Carolina Early Pregnancy Study (EPS)
3288075|NCT01726582|Other|After surgery cXRT|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm E:~After surgery: chemoradiotherapy (cXRT); restaging:~see lint to protocol Figures A and D at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288076|NCT01726582|Other|After surgery targeted chemo|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F1:~Targeted chemotherapy after surgery: 8 weeks targeted chemotherapy; restaging; 8 weeks targeted chemotherapy; restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288077|NCT01726582|Other|After surgery Gemcitabine|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm F2:~Gemcitabine after surgery : 8 weeks Gemcitabine (chemotherapy); restaging; 8 weeks Gemcitabine (chemotherapy); restaging:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288078|NCT01726582|Other|After surgery no additional treatment|"Depending on the tumor removed during surgery, treatment after surgery will follow arm D1 or D2 or E or F1 or F2 or G.~Arm G:~No additional therapy after surgery:~see link to protocol Figure E and Figure A or B at:~http://www.mcw.edu/surgery/patientinfo/Pancreatic-Cancer-Trial.htm"
3288079|NCT01726595||severe sepsis|Patients with severe sepsis or septic shock
3288080|NCT01726595||non-infected critically ill|Patients with severe non-infectious systemic inflammatory response syndrome
3288081|NCT01726595||healthy|healthy volunteers
3288082|NCT01726608|Active Comparator|Radiofrequency neurotomy|Active Radiofrequency Neurotomy
3288083|NCT01726608|Placebo Comparator|Sham|Sham radiofrequency neurotomy
3288084|NCT01726634|Experimental|Elastic Tapping|
3288085|NCT01726647||No product is tested|No intervention
3288086|NCT01726660|Experimental|IMT Robotic Arm Therapy: Aim training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for aim training, 3x/week for 12 weeks.
3288087|NCT01726660|Experimental|IMT Robotic Arm Therapy: Smoothness Training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for smoothness training, 3x/week for 12 weeks.
3288088|NCT01726660|Experimental|IMT Robotic Arm Therapy: Impairment training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole-arm, impairment training, 3x/week for 12 weeks.
3288089|NCT01726660|Experimental|IMT Robotic Arm Therapy: Functional training|Alternating sessions of planar (shoulder/elbow) and wrist robotic therapy programmed for whole arm, functional training, 3x/week for 12 weeks.
3288090|NCT01726686|Active Comparator|Ropivacaine in the pump|The intra-articular Continuous Infusion Pump is filled with Ropivacaine,10 mg/ml, set at 2 ml/hour for 48 hours postoperatively.
3288091|NCT01726686|Placebo Comparator|Placebo in the pump|The intra-articular Continuous Infusion Pump is filled with NaCl, set at 2 ml/hour for 48 hours postoperatively.
3288092|NCT01726699||Cancer Diagnosis|
3288093|NCT01726712|No Intervention|Routine Care|
3288094|NCT01726712|Active Comparator|Supportive Contact|
3288095|NCT01726725||hemifacial spasm, lateral spread, motor evoked potentials|EMG recordings from facial muscles of HFS patients during MVD surgery will be compared during total intravenous anesthesia (propofol), 0.5 MAC desflurane and 1.0 MAC desflurane
3288096|NCT01726751|Other|Early off-stimulation (group B)|Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
3288097|NCT01726751|Other|Early on-stimulation (group A)|Early SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group A starting with SCS for a period of six weeks (A) followed by a period of no SCS (off-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
3288098|NCT01726764|Experimental|Metformin|"7 days of pretreatment with metformin before full pharmacokinetics and other goals are investigated.~Minimum 1 week of washout after this period. 3 weeks of pretreatment with St John's Wort and the last 7 days metformin is ingested again, and the same effect parameters as described above is performed again"
3288099|NCT01726777|Placebo Comparator|Control|30g normal cheddar cheese once per week
3288100|NCT01726777|Experimental|Vitamin D|30g cheddar cheese containing 28,000IU vitamin D once per week
3288101|NCT01726816|Experimental|Probucol 250mg/day|Probucol 250mg group: probucol 250mg 2 tablets, 16 weeks
3288102|NCT01726816|Experimental|Probucol 500mg/day|Probucol 500mg group: probucol 250mg 2 tablets, 16 weeks
3288103|NCT01726816|Placebo Comparator|Placebo|Placebo group: placebo 2 tablets, 16 weeks
3288104|NCT01726829|Experimental|MD-Logic Artificial Pancreas (MDLAP) system|four consecutive outpatients overnight sessions at home under closed loop MD-Logic Artificial Pancreas (MDLAP) system
3288105|NCT01726829|Active Comparator|Standard treatment with sensor augmented pump therapy|four consecutive outpatients overnight sessions at home under standard treatment with sensor augmented pump therapy
3288106|NCT01726842||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3288107|NCT01726842||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3288108|NCT01726842||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3288109|NCT01726855||dorsal fascial flap|combined with standard modified Kessler technique and vascularized finger dorsal fascial flap pedicled with dorsal cutaneous branch of proper digital artery ,which is transported to finger palmar for placement of a mechanical barrier between flexor digitorum superficialis /profundus tendons.
3288110|NCT01726855||standard modified Kessler technique|
3288111|NCT01726868|Experimental|Liposorber LA-15 System|
3288112|NCT01726881|Experimental|Fresh Spinal Cord Injury patients|Spinal Cord Injury patients that are currently admitted to the rehabilitation unit with three weeks or less since injury that will over go several tests and will fill out several questionnaires.
3288113|NCT01726881|Experimental|Chronic Spinal Cord Injury patients|Spinal Cord Injury patients with one year or more since injury that will over go several tests and will fill out several questionnaires
3288114|NCT01726881|Active Comparator|Healthy volunteers|Healthy subjects that will over go several tests and will fill out several questionnaires
3288115|NCT01726894|Experimental|Irreversible Electroporation|
3288116|NCT01726907|Experimental|Robotic SMG resection|Robot-assisted SMG resection
3288117|NCT01726907|Active Comparator|Endoscopic SMG resection|Endoscope-assisted SMG resection
3288118|NCT01726920|Experimental|naratriptan + naproxen|Fixed-dose combination of naratriptan + naproxen
3288119|NCT01726920|Active Comparator|naratriptan|
3288120|NCT01726920|Active Comparator|naproxen|
3288121|NCT01726933|Experimental|LAS41008|up to 6 tablets/ day for 16 weeks double blind treatment period, randomized gastric resistant tablet
3288122|NCT01726933|Placebo Comparator|Placebo|up to 6 tablets/ day for 16 weeks randomized, double blind gastric resistant tablet
3288123|NCT01726933|Active Comparator|LASW1835|double blind, randomized gastric resistant tablet up to 6 tablets/ day for 16 weeks
3288124|NCT01726946|Experimental|VX-135 High Dose with ribavirin|12 weeks of a high dose of VX-135 in combination with ribavirin
3288125|NCT01726946|Experimental|VX-135 Low Dose with ribavirin|12 weeks of a low dose of VX-135 in combination with ribavirin
3288126|NCT01726959||Methotrexate|Methotrexate for rheumatic diseases, 2.5 - 25 mg weekly
3288127|NCT01726985||Patients hospitalized with CHF|Patients hospitalized with CHF Parameter Based Clinical Disposition
3288128|NCT01726998|Experimental|Lokomat Group|
3288129|NCT01726998|Active Comparator|conventional gait training group|
3288131|NCT01727037|Experimental|BIABI arm|Patients will undergo intrabullous autologous blood instillation
3288132|NCT01727050|Active Comparator|Mechanical stapling|
3288133|NCT01727050|Active Comparator|Fibrin sealant spray|
3288134|NCT01727063|Experimental|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
3288135|NCT01727063|No Intervention|Placebo|Saline injection
3288136|NCT01727076|Experimental|Treatment (recombinant interleukin-15)|Patients receive recombinant interleukin-15 SC daily on days 1-5 of weeks 1 and 2. Treatment repeats every 28 days (4 weeks) for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3288137|NCT01727115|Active Comparator|NUTRAMIGEN®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Nutramigen® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Nutramigen®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
3288138|NCT01727115|Experimental|ALTHERA®|"Subjects are orally fed ad libitum (following guidelines printed on the labels).~Subjects will receive the Althera® formula for a 4 week period~Then depending of the result of the challenge test we have the following possibilities:~If the test is positive: The children continue the formula Althera®~If the test is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
3288139|NCT01727128|Experimental|Mild Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - mildly hepatically impaired
3288140|NCT01727128|Experimental|Moderate Hepatic Impaired group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - moderately hepatically impaired
3288141|NCT01727128|Experimental|Severe Hepatic Impaired Group|Subjects can only be enroled into this group if they fit the Child -Pugh score criteria of severity category - Severely hepatically impaired
3288142|NCT01727128|Experimental|Control Group|Matching healthy control subjects who do not have hepatic impairment and are matched to the hepatic impaired subjects by sex, age, gender and BMI
3288143|NCT01727193|Active Comparator|Azathioprine|cholinesterase inhibitors+Glucocorticoid +Azathioprine
3288144|NCT01727193|Active Comparator|Leflunomide|cholinesterase inhibitors+glucocorticoid+Leflunomide
3288145|NCT01727206|Experimental|Tocilizumab|Tocilizumab 8 mg/kg intravenously every month for six months
3288146|NCT01727232||Standard regimen|Patients received the standard regimen (i.e 4 weekly infusions of 375 mg/m2)of rituximab
3288147|NCT01727232||Rheumatoid arthritis regimen|Patients received the RA regimen (i.e two infusions of 1000 mg, 2 weeks apart) of rituximab
3288148|NCT01727245|Other|Obese|Obese patients undergoing gastric by-pass surgery
3288149|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
3288150|NCT01727271|Active Comparator|Tenofovir Monotherapy|Tenofovir 300 mg tablet, orally (PO) once daily for 8 weeks, then Tenofovir 300 mg tablet, PO, once daily for an additional 96 weeks (total treatment duration 104 weeks)
3288151|NCT01727271|Experimental|PegIFN-2b/Tenofovir Sequential Therapy|Tenofovir 300 mg tablet, PO, once daily for 8 weeks, then PegIFN-2b, 1.5 mcg/kg subcutaneously (SC), once weekly, for 24 weeks, then Tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
3288152|NCT01727271|Experimental|Peg-IFN-2b + Tenofovir Combination Therapy|Tenofovir 300 mg tablet, PO once daily for 8 weeks, then pegIFN-2b, 1.5 mcg/kg SC once weekly and tenofovir 300 mg tablet, PO, once daily for 24 weeks, and then tenofovir 300 mg tablet, PO, once daily for 72 weeks (total treatment duration 104 weeks)
3288153|NCT01727284|Other|MR-guided cryoablation (freezing of tissue and/or tumors)|
3288154|NCT01727349|Other|Type 2 diabetic subject|Subject with type 2 diabetes
3288155|NCT01727349|Other|healthy subject|Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
3288156|NCT01727362|Active Comparator|Usual care + acupuncture|
3288157|NCT01727362|Active Comparator|Usual care|
3288158|NCT01727375|No Intervention|Standard light|In this arm patients receive standard lightening conditions
3288159|NCT01727375|Experimental|Ciradian light|In this arm patients receive artificial ceiling light (circadian light) at the bedside.
3288160|NCT01727388|Experimental|lateral decubitus|The digital rectal examination is performed in lateral decubitus i.e. curled up position . The patient in left lateral decubitus if the examiner is right handed and right lateral decubitus if the examiner is left handed.
3288161|NCT01727388|Active Comparator|supine decubitus|The digital rectal examination is performed supine, spread legs, feet on the examination table. The examiner is in the patient's right side if he is right handed and in the patient's left side if he is left-handed.
3288162|NCT01727401|Experimental|Fondaparinux|Drug: fondaparinux once daily sc injections 2.5 mg if renal clearance of creatinine above 50 ml/min once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
3288163|NCT01727427||Anticoagulants, aspirin|Parenteral or oral anticoagulants: heparin, fondaparinux, vitamin-K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors; aspirin. Any dosage, frequency and duration
3288164|NCT01727453|Active Comparator|Bemiparin|Group 1 (low molecular weight heparin: bemiparin), which is the study group: after passing the bleeding episode, will receive low molecular weight heparin (bemiparin) in anticoagulant dose. Check should be made by measurement of anti-factor Xa.
3288165|NCT01727453|Active Comparator|Warfarin|which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
3288166|NCT01727466|Experimental|Facing Your Fears|FYF is a group CBT approach to managing anxiety symptoms in children with high-functioning autism spectrum disorders and anxiety.
3288167|NCT01727479|Experimental|Ribose|After each of the 3km time trial (3 in total), consumption of ribose incorporated in a sports drink.
3288168|NCT01727479|Placebo Comparator|Placebo|After each of the 3km time trial (3 in total), consumption of placebo incorporated in a sports drink.
3288169|NCT01727492|Placebo Comparator|sugar pill|
3288170|NCT01727492|Active Comparator|Antioxidantia|Dosage: 600mg n-acetylcystein and 200mg magnesium intake: 1 hour before leisure noise exposure above 100dB of at least 30 minutes frequency: 4 separate events (2x placebo, 2x antioxidants)
3288171|NCT01727518||Reference Population|No Intervention
3288172|NCT01727531|Experimental|CQ Arm|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks.
3288173|NCT01727544|Active Comparator|Surgical Group|patients will undergo a primary transmastoid and tegmen mini-craniotomy cartilage cap occlusion surgery.
3288174|NCT01727544|No Intervention|Non Surgical Group|patients meet the same criteria but will elect not to undergo surgery
3288175|NCT01727557|Active Comparator|Local anesthesia|
3288176|NCT01727557|Active Comparator|regional anesthesia|
3288177|NCT01727570|No Intervention|Nutrition Counselling|Patients will be asked to fill out a three day record of all food and drink consumed. Patients will be given an appointment with the nutritionist approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of their diet
3288178|NCT01727570|Active Comparator|Nutrition Supplementation|Patients will be asked to fill out a three day record of all food and drink consumed. An appointment with the nutritionist will be given approximately 4 weeks before surgery to go over their regular diet and advice will be given on how to improve the nutritional quality of the diet. Patients will also be given a supply of nutritional supplements to take orally (by mouth) every day. These supplements include a whey protein isolate (Immunocal®, Immunotec Inc), omega-3 fatty acids from fish oil, and vitamins/minerals.
3288179|NCT01727583|Active Comparator|Lipid 1|Meal intake
3288180|NCT01727583|Placebo Comparator|Lipid-free|Maltodextrine + proteins
3288181|NCT01727583|Active Comparator|Lipid 2|Meal intake
3288182|NCT01727583|Active Comparator|Lipid 3|Meal intake
3288183|NCT01727583|Active Comparator|Lipid 4|meal intake
3288184|NCT01727596|Experimental|1|
3288185|NCT01727609|Active Comparator|Slower milk feed increment|Increase milk feeds by 18 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
3288186|NCT01727609|Experimental|Faster milk feed increment|Increase milk feeds by 30 ml/kg/day until on full milk feeds (tolerating 150 ml/kg/day for 3 consecutive days)
3288187|NCT01727622||Controls|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
3288188|NCT01727622||Mild Cognitive Impairment|ASL-MRI and FDG-PET will be compared for ability to discriminate between Control subjects and adults with Mild Cognitive Impairment (prodromal AD). A lumbar puncture will be obtained in a proportion of the participants.
3288189|NCT01727635|Experimental|counseling|body-mind-spirit group therapy
3288190|NCT01727648|Experimental|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
3288191|NCT01727648|Experimental|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
3378961|NCT01132859||1|Volunteers of 18 years of age or older willing to donate blood and tissue specimens and participate in imaging studies to evaluate the components of the immune system
3378962|NCT01130545||Volunteers|Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
3378963|NCT01125228||Arm 1|Zidovudine 200mg by mouth every 4hr
3378964|NCT01125228||Arm 2|-Zidovudine 200mg by mouth every 4hr -Alpha Interferon 1 million units once a day, escalating
3378965|NCT01125228||Arm 3|-Alpha Interferon 1 million units once a day, escalating
3378966|NCT01123499||Healthy Volunteers|Any healthy volunteers that are eligible to donate blood.
3378967|NCT01109420||1/ Cohort 1|Affected with non-medullary thyroid cancer
3378968|NCT01109420||2/Cohort 2|Non-affected members of families with non-medullary thyroid cancer
3378969|NCT01109394||1/Cohort 1|Adult or Pediatric subjects, with any malignancy, pre-malignancy, suspected malignancy, family history of malignancy, or without malignancy undergoing surgery or well visit.
3378970|NCT01109394||2/Cohort 2|Human samples, specimens and data collected on IRB approved protocols that are now closed
3378971|NCT01109394||3/Cohort 3|Parent/caregiver of a participating pediatric or adult subject who is being treated for, or who has previously been treated for any form of pediatric cancer.
3378972|NCT01087333||1|Patients with hematologic malignancy, including HCL, CLL, CTCL, ATL, NHL, ALL, or solid tumor, including mesothelioma.
3378973|NCT01087333||2|Normal Donors who are defined as individuals without a diagnosis of or history of any cancer.
3378974|NCT01087333||3|Samples transferred from protocols 07-C-0130 and 08-CN-013
3378975|NCT01087320||Genetic Disorders|Patients or family probands with genetic cause of disorders that are intractable or difficult to identify with existing technique.
3378977|NCT01087281||1|Neurologically normal healthy volunteers in good general health.
3378978|NCT01087281||2|Patients with unilateral or bilateral focal lesions of prefrontal, parietal, occipital or temporal cortex, or amygdala.
3378979|NCT01071577||Healthy Volunteers|Healthy volunteers wanting to donate BMSC for allogeneic use
3378980|NCT01071577||Patients|Patients donating BMSC for autologous use
3378981|NCT01036685||370-bench-control|healthy control who will only do behavioral tasks
3378982|NCT01036685||379-bench-other-psych-diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who will only dobehavioral tasks
3378983|NCT01036685||379-bench-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who will only do behavioral tasks
3378984|NCT01036685||379-bench-user|someone with a DSM-V substance use disorder on a substance other than nicotine who will only do behavioral tasks
3378985|NCT01036685||379-control|healthy control who can do MRI and tDCS
3378986|NCT01036685||379-other-psych -diagnosis|someone with a DSM-V disorder, stable and in treatment (i.e., no medication changes in the previous four weeks and a clearly identified treating psychiatrist) who can do MRI and tDCS
3378987|NCT01036685||379-smoker|daily smoker of tobacco cigarettes for at least one year (excluding quit attempts)who can do MRI and tDCS
3378988|NCT01036685||379-user|someone with a DSM-V substance use disorder on a substance other than nicotine who can do MRI and tDCS
3378995|NCT00978003||1/Healthy Volunteers|Adults age 18-55.
3378996|NCT00976014||Intensive Lipid-lowering therapy|Subjects on intensive long-term lipid lowering therapy (lowering LDL-C plus raising of HDL-C).
3378997|NCT00976014||Usual Care|"Subjects with Atherosclerosis who have been on conventional standard of care treatment."
3379000|NCT00943514||1|chronic or recurring respiratory infections including pulmonary nontuberculous mycobacterial disease
3379001|NCT00943514||2|Relatives
3288192|NCT01727648|Experimental|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
3379004|NCT00936325||Healthy volunteers|healthy volunteers to act as controls.
3379005|NCT00936325||Patients with SCLS|patients who have been diagnosed, or are suspected of having systemic capillary leak syndrome.
3379006|NCT00936325||Relatives|relatives of patients who have systemic capillary leak syndrome.
3379010|NCT00923507||Patients|Patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstr(SqrRoot)(Delta)m macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).
3379011|NCT00923442||1|Patients (from birth to 75 years old) diagnosed with any hematologic malignancy or pre malignant condition
3379022|NCT00895271||Healthy Volunteers|Up to 50 subjects as healthy controls
3379023|NCT00895271||Immunodeficiency|Up to 150 subjects with poorly defined, rare inherited immunodeficiency or immunodysregulation disorders
3379027|NCT00867269||Blood Relatives|Blood Relatives of ICL subjects
3379028|NCT00867269||Household Contacts|Household contacts of ICL subjects
3379029|NCT00867269||ICL Subjects|Patients with confirmed idiopathic CD4 lymphocytopenia
3379030|NCT00858728|Experimental|1|5 portions fruit and vegetables/day
3379031|NCT00858728|Other|2|2 portions fruit and vegetables/day
3379034|NCT00843375||Higher risk, no neoplasia|"Negative study colonoscopy and one or more of the following:~Subjects with a personal history of adenomas (confirmed by pathology) with none present on qualifying colonoscopy~Subjects with a personal history of colorectal cancer (CRC) (longer than 3 years ago because of exclusion criteria of cancer within last 3 years) with none present at time of qualifying colonoscopy~Any family history of CRC (1st degree relative)~Current positive screening stool test for blood, for DNA or for both within 12 months with no follow up intervention"
3379035|NCT00843375||Adenoma|"Pathologically confirmed adenomas, both non-advanced adenoma and advanced. Advanced adenoma includes any of the following:~Sessile serrated adenoma~Tubulovillous adenoma~Villous adenoma~Sessile serrated polyp/adenoma~Traditional serrated adenoma~Any adenoma ≥1 cm"
3379036|NCT00843375||Colorectal adenocarcinoma|Pathologically confirmed colorectal cancer either present at time of stool collection or discovered during colonoscopy
3379037|NCT00843375||Average risk, no neoplasia|"No neoplasia found at colonoscopy and:~No prior history of adenomas or sessile serrated adenomas~No prior history of CRC~No first degree family history of CRC~Negative colorectal cancer screening test (if performed) for blood, for DNA or for both within 12 months."
3379038|NCT00837122||Control|Control subjects are nondiabetics ethnically matched to patients
3379039|NCT00837122||T2D|Patients with confirmed T2D who are newly diagnosed or on treatment in Ibadan, Nigeria
3379040|NCT00814827||Group 1|Patients with nontuberculous mycobacteria (NTM) alone.
3288193|NCT01727648|Active Comparator|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
3288194|NCT01727661||type 1 diabetes mellitus|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
3288195|NCT01727661||healthy controls|"exercise testing with near-infrared spectroscopy~lung function testing~quality of life"
3288196|NCT01727687|Experimental|Patients with Parkinson's disease|Using simulated traffic scene system to help patients with Parkinson's disease improve crossing road behaviors.
3288197|NCT01727739|Active Comparator|PLLA bioscrew|poly-L-lactic acid bioscrew
3288198|NCT01727739|Active Comparator|PLLA+TCP bioscrew|poly-l-lactic acid with beta tricalcium phosphate bioscrew
3288199|NCT01727752|Active Comparator|Surgical decompression|Surgical decompression
3288200|NCT01727752|Active Comparator|coflex Interlaminar Technology|Surgical decompression followed by implantation of coflex Interlaminar Technology.
3288201|NCT01727778|Experimental|Antibody treatment|Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
3288202|NCT01727804|Experimental|Laser|
3379041|NCT00814827||Group 2|Patients with non-NTM opportunistic infection, either with or without concurrent NTM infection.
3379042|NCT00814827||Group 3|Patients with pulmonary mycobacterium tuberculosis (MTB).
3379043|NCT00814827||Group 4|Patients with disseminated mycobacterium tuberculosis (MTB).
3379044|NCT00814827||Group 5|Blood Specimen Donors.
3379047|NCT00789009||Group 1|Consist of HIV positive patients recruited from the Washington DC metropolitan area who will receive long-term care for their HIV infection through the NIAID/CCMD HIV clinic
3379048|NCT00789009||Group 2|Patients with known or suspected HIV infection, referred to a NIAID/CCMD investigator for reasons such as testing to diagnose or exclude HIV disease or assistance with HIV-related problems.
3379049|NCT00787423||COHORT 1|Individuals from 18 to 75 years of age who are current heroin users seeking treatment for addiction and who spend most of their time in Baltimore city.
3379050|NCT00776412||HIV Negative|Healthy Volunteer Cohort
3379051|NCT00776412||HIV Positive INR|HIV Positive INR Cohort
3379052|NCT00776412||HIV Positive Standard|HIV Positive Standard Cohort
3288203|NCT01727817|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in Control to Range (CTR) or in Safety Only mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct for hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3379053|NCT00775853||PD Risk Individuals|Individuals who may be at risk for developing PD, because of genetic risk; olfactory dysfunction; symptomatic rapid eye movement (REM) sleep behavior disorder (RBD); or orthostatic hypotension.
3379054|NCT00767312||Patients|HIV-infected patients who are 18 years of age or older, have been enrolled in another NIH protocol.
3379059|NCT00702533||Healthy Volunteers|Healthy volunteers between the ages of 18 and 60 years of age
3379060|NCT00702533||Patients with gastric acid and secretory disorders|18 years of age who have been diagnosed with Zollinger-Ellison Syndrome or acid hypersecretion.
3379061|NCT00687882|Experimental|Intervention: A|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
3379062|NCT00687882|Active Comparator|B|Patients with non-occlusive thrombus or resolved thrombosis at 6 weeks.
3379063|NCT00687882|Other|Parallel Cohort: Persistent Occlusive Thrombosis|Patients with completely occlusive thrombosis at 6 weeks.
3379064|NCT00687882|Other|Parallel Cohort: Persistent Antiphospholipid Antibody|Patients with persistent Positive Antiphospholipid Antibody at 6 weeks.
3379073|NCT00598351||Patients|Patients must have the diagnosis of NF2 by established clinical criteria or genetic testing.
3379075|NCT00568243||1|normal adult volunteers and patients with eye movement problems
3379076|NCT00557726||1|patients with a variety of infectious and inflammatory diseases
3379077|NCT00555646|Experimental|1|Each subject's study plaque areas will be assigned by the investigator to two PH-10 treatment plaque areas and one control plaque area.
3379078|NCT00545766|Experimental|Interventional|
3379079|NCT00542230||Healthy Volunteers|Healthy Volunteers
3288204|NCT01727817|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3288205|NCT01727843|Experimental|tranexamic acid|3000mg/mL tranexamic acid in saline applied directly to the wound at the end of the surgical procedure.
3288206|NCT01727843|Placebo Comparator|saline|3000mg/mL saline applied directly to the wound at the end of the surgical procedure
3288207|NCT01727856||Rehabilitation Measurement Tool|This single arm consists of all subjects which will interact with the tool under invstigation.
3288208|NCT01727869|Experimental|Cohort 1|Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3288209|NCT01727869|Experimental|Cohort 2|Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3288210|NCT01727869|Experimental|Cohort 3|Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab
3288211|NCT01727882|Experimental|Daily Assessments & Brief Feedback|Daily assessments during 30 days after parole and a feedback intervention based on these daily assessments.
3288212|NCT01727882|Active Comparator|Daily assessments|Daily assessments during 30 days after parole.
3288213|NCT01727908|No Intervention|Endoscopy without staining of the mucosa|
3288214|NCT01727908|Experimental|Endoscopy with staining of the mucosa.|
3288215|NCT01727921|Active Comparator|22 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 22 gauge ProCore biopsy needle.
3288216|NCT01727921|Active Comparator|25 gauge ProCore needle biopsy|EUS-guided pancreatic or peripancreatic mass biopsy with 25 gauge ProCore biopsy needle.
3288217|NCT01727934|Experimental|Miravirsen sodium|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg then 4 every other week doses at 5 mg/kg.
3288218|NCT01727947|Experimental|MSOME|Couples in which the sperm cells were analysed through MSOME
3288219|NCT01727960||Korean Male Adolescents|students from two academic high schools
3288220|NCT01727973|Experimental|Doxycycline|Tablets Doxycycline 50 mg PO per day for 12 weeks
3288221|NCT01727986|Experimental|RoActemra/Actemra|
3288222|NCT01727999||TPO responder|Patients with therapeutic response to TPO
3288223|NCT01727999||TPO non-responder|Patients not responding to TPO agonists
3288224|NCT01728012||eGFR >=60ml/min/1.73m2|Patients with an estimated glomerular filtration rate of >=60 ml/min/1.73m2.
3288225|NCT01728012||eGFR 45-60ml/min/1.73m2|Patients with estimated glomerular filtration rate >=45 ml/min/1.73m2 and <60ml/min/1.73m2.
3288226|NCT01728025|Experimental|Ranolazine|Ranolazine 500-1000 mg twice a day as tolerated
3288227|NCT01728038|Experimental|Cessation Counseling|Parental smokers will be given a brief cessation intervention consisting of counseling, nicotine replacement therapy and Quitline connection.
3288228|NCT01728064|Placebo Comparator|Placebo|Placebo capsules three times daily
3288229|NCT01728064|Active Comparator|EPI-743 400 mg|EPI-743 at a dose of 400 mg three times daily
3288230|NCT01728064|Active Comparator|EPI-743 200 mg|EPI-743 at a dose of 200 mg three times daily
3288231|NCT01728090|Experimental|Hand sanitizer|"Intervention classrooms received alcohol-based hand sanitizer and a programme educational.~Characteristics of the hydroalcoholic gel (ALCO ALOE GEL): chlorhexidine digluconate at 20% solution, phenoxyethanol 1%, benzalkonium chloride 0.%. aloe Barbadensis 5%, Renat ethyl alcohol 70%, excipients c.s.p. 100 ml. Alcohol of between 65 - 70% degrees, pondus Hydrogenium (pH) = 7-7,5."
3288232|NCT01728090|No Intervention|Control|No hand sanitizer or educational programme were used
3288233|NCT01728103||No Treatment|
3288234|NCT01728129|Experimental|Concussed|Subjects who are diagnosed with a concussion by a clinician will be assessed with the MACE and DANA Rapid every 24 hours for up to 72 hours post-injury.
3288235|NCT01728129|Active Comparator|Non-concussed|Subjects will have been exposed to a potentially concussive event but be clinically evaluated and found not to have sustained a concussion. Control subjects from this arm will take both the MACE and DANA Rapid twice: once within 24 hours of potentially concussive event, and again on the day of return to duty.
3288236|NCT01728142|Active Comparator|Non-concussed|Control group; individuals assigned to this group will be either healthy volunteers or individuals sustaining an injury that does not involve concussion. Participants will take both the ANAM and DANA Brief twice at minimum.
3288237|NCT01728142|Experimental|Concussed|Individuals who have been diagnosed with a concussion by a clinician. Participants will take both the DANA and ANAM twice at minimum.
3288238|NCT01728155|No Intervention|Group1|initial observation (chemotherapy is only given if there is subsequent progression)
3288239|NCT01728155|Active Comparator|Group 1: chemotherapy|chemotherapy and surgery
3288240|NCT01728155|Experimental|Group 2|chemotherapy and surgery
3288241|NCT01728155|Experimental|Group 3|chemotherapy and surgery
3288242|NCT01728155|No Intervention|Group 4|Observation
3288243|NCT01728155|Experimental|Group 5|chemotherapy
3288244|NCT01728155|Experimental|Group 6|chemotherapy and surgery
3288245|NCT01728155|Experimental|Group 7|chemotherapy and surgery
3288246|NCT01728155|Experimental|Group 8|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
3288247|NCT01728155|Experimental|Group 9|chemotherapy, surgery, radiotherapy and 13 cis-retinoic acid
3288248|NCT01728155|Experimental|Group 10|chemotherapy, surgery,
3288249|NCT01728168||Atopic|Subjects with either documented allergy, neurodermatitis, allergic asthma, allergic rhinitis, and/or a positive atopic score based on the criteria of Erlangen (>10 points).
3288250|NCT01728168||Non-atopic|Subjects without atopy.
3288251|NCT01728181|Experimental|Phase I|Will receive Tivozanib and Erlotinib treatment.
3288252|NCT01728181|Other|Phase II Group 1 (Standard of Care)|"Group 1: VeriStrat® predicts the chance of no benefit from erlotinib~• The patient will get standard-of- care"
3288253|NCT01728181|Active Comparator|Phase II Group 2 (arm 1)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 1: Patient will get the study drugs Erlotinib and Tivozanib"
3288254|NCT01728181|Placebo Comparator|Phase II Group 2 (arm 2)|"Group 2: VeriStrat® predicts the chance of benefit from Erlotinib~• Arm 2: Patient will get the study drug erlotinib and placebo"
3379080|NCT00542230||Sickle Cell Trait|Patient with sickle cell trait or disease
3288255|NCT01728207|Experimental|IMMU-114|IMMU-114 will be administered subcutaneously (under the skin) once or twice weekly for 3 weeks followed by one week of rest. Treatment cycles will continue until disease worsening or toxicity. Various dose levels will be studied.
3288256|NCT01728220|Active Comparator|Inhaled NO @ 0.003 mg/kg/ ideal body weight (IBW)/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
3288257|NCT01728220|Active Comparator|Inhaled NO @ 0.010 mg/kg/IBW/hr (Part A)|Inhaled NO using 3.0 mg/L [2440 ppm] NO minicylinder
3288258|NCT01728220|Active Comparator|Inhaled NO @ 0.015 mg/kg/IBW/hr (Part A)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3288259|NCT01728220|Placebo Comparator|Placebo random @ 0.003, 0.010 or 0.015 mg/kg/IBW/hr (Part A)|Placebo using 99.999% N2 minicylinder
3288260|NCT01728220|Active Comparator|Inhaled NO @ 0.030 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3288261|NCT01728220|Active Comparator|Inhaled NO @ 0.075 mg/kg IBW/hr (Part B)|Inhaled NO using 6.0 mg/L [4880 ppm] NO minicylinder
3288262|NCT01728220|Active Comparator|Placebo random @ 0.030 or 0.075 mg/kg/IBW (Part B)|Placebo using 99.999% N2 minicylinder
3288263|NCT01728233|Experimental|Dacomitinib (PF-00299804)|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
3288264|NCT01728259|Experimental|Treatment (pomalidomide, bortezomib, and dexamethasone)|Patients receive pomalidomide PO on days 1-21; bortezomib IV or SC on days 1, 8, and 15; and dexamethasone PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3288265|NCT01728272|Experimental|blood concentration of metoprolol|how does off-pump miniperfusion and perfusion CABG influence the absorption of metoprolol after CABG
3288266|NCT01728285|Active Comparator|Electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) using an electronic compliance device (Memozax®)
3288267|NCT01728285|No Intervention|No electronic compliance device|Patients with grass allergy treated with allergen specific immunotherapy (GRAZAX®) without any electronic compliance device (Memozax®)
3288268|NCT01728298|Active Comparator|SLITone ULTRA low dose|SLITone ULTRA HDM immunotherapy
3288269|NCT01728298|Active Comparator|SLITone ULTRA medium dose|SLITone ULTRA HDM immunotherapy
3288270|NCT01728298|Active Comparator|SLITone ULTRA high dose|SLITone ULTRA HDM immunotherapy
3288271|NCT01728311|Experimental|Arm 1|
3288272|NCT01728350|Experimental|Treatment|Participants in this arm will participate in a novel structured volunteering intervention called HOPE - Helping Others through Purpose and Engagement. This intervention involves orientation, training, volunteer placement assistance, and problem solving and support.
3288273|NCT01728350|No Intervention|Control|Participants who are randomized to the control arm will be offered the HOPE intervention at the conclusion of study.
3288274|NCT01728363|Experimental|Ticarcillin-clavulanate antibiotic|"Cohort Gestational Age (GA) Postnatal Age (PNA) Dose~<30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses~<30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses~Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better."
3288275|NCT01728363|Experimental|Rifampin generic antibiotic|"Cohort GA PNA Dose~<32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses~<32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses~≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses~The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis."
3288276|NCT01728363|Experimental|Clindamycin Generic Antibiotic|"Cohort GA PNA Dose~<30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses~<30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses~<30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses~The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections."
3288277|NCT01728389|Experimental|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
3288278|NCT01728402||Blood Draw|
3288279|NCT01728415|Experimental|A: Exercise|High intensity interval exercise training (3 x 3 minutes of intensity abow 85% og Heart rate peak)
3288280|NCT01728415|Active Comparator|B: Execise|Moderate continuous exercise training
3288281|NCT01728415|No Intervention|C: Controll|Usual care without exercise training
3288282|NCT01728441|Experimental|Paclitaxel Eluting Stent|Patients randomized to treatment with paclitaxel eluting stent will receive the Zilver® PTX® stent.Primary stenting should be performed covering the full lesion. Post-dilatation is at the investigator's discretion.
3288283|NCT01728441|Active Comparator|Paclitaxel Eluting Balloon|For patients randomized to treatment with drug eluting balloon (DEB), angioplasty (ballooning) should be performed covering the full lesion.
3288284|NCT01728467|Experimental|RVX000222, 200 mg daily|
3288285|NCT01728467|Placebo Comparator|Placebo|
3288286|NCT01728480|Experimental|Treatment (entolimod, IMRT, cisplatin)|Patients undergo IMRT 5 times per week for 7 weeks, receive cisplatin IV once weekly for 7 weeks, and entolimod SC on days 1, 8, 15, 22, 29, 36, and 43.
3288287|NCT01728493||Part 1|- newly diagnosed hypertensive patients in general practice
3288288|NCT01728493||Part 2:|"newly diagnosed hypertensive patients with primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
3288289|NCT01728493||Part 3:|"newly diagnosed hypertensive patients with normokalemic primary aldosteronism~newly diagnosed hypertensive patients with essential hypertension"
3288290|NCT01728506|Experimental|Weight Loss & Exercise|Single arm intervention of a 24 week weight loss and exercise intervention.
3288291|NCT01728519|Experimental|AllerT SC|AllerT subcutaneous injections
3288292|NCT01728519|Placebo Comparator|Placebo SC|placebo subcutaneous injections
3288293|NCT01728519|Experimental|AllerT ID|AllerT intra-dermal injections
3288294|NCT01728519|Placebo Comparator|Placebo ID|placebo intra-dermal injections
3379081|NCT00533182||Immunocompromised|Immunocompromised individuals
3379082|NCT00533182||Non-Immunocompromised|Non-immunocompromised individuals
3379083|NCT00533182||Pregnant|Pregnant women
3288295|NCT01728532|Active Comparator|Pulp Canal Sealer (Kerr)|zinc oxide eugenol sealer
3288296|NCT01728532|Experimental|PA0903|type C implant according to ISO 7405:2008 and ISO 10993 guidelines.
3288297|NCT01728558|Other|Early Goal Directed Sedation|"Early Goal Directed Sedation process of care involves:~Early delivery of proposed intervention, shortly after initiating mechanical ventilation;~Effective analgesia provided simultaneously and early (analgesia first).~Regular and frequent assessment of patient wakefulness/sedative state;~Avoidance of benzodiazepines and minimisation of use of propofol;~Reduced overall sedation depth with targeted light sedation; Patients randomised to the EGDS arm will receive a sedative infusion of Dexmedetomidine withor without minimal propofol in order to maintain a RASS of -2 to +1.~Dexmedetomidine infusion will be continued until sedation is no longer clinically indicated up to a maximum of 28 days after enrolment."
3288298|NCT01728558|Active Comparator|Standard care Sedation Arm|Patients randomised to the standard care sedation arm will receive process of care sedation directed by the treating clinician. Based on the information from our observational study and the EGDS Pilot trial, most patients in this group are likely to receive midazolam and /or propofol. These agents will be infused to achieve the default target of Light sedation (RASS -2 to +1) whenever clinically appropriate and as specified by the treating clinician. The use remifentanil or dexmedetomidine for initial and maintenance sedation will be precluded.
3288299|NCT01728571|Active Comparator|Vitamin D3 + fish oil|Dietary Supplement: vitamin D3 Drug: omega-3 fatty acids (fish oil)
3288300|NCT01728571|Active Comparator|Vitamin D3 + fish oil placebo|Dietary Supplement: vitamin D3 Dietary Supplement: fish oil placebo
3288301|NCT01728571|Active Comparator|Vitamin D3 placebo + fish oil|Drug: omega-3 fatty acids (fish oil) Dietary Supplement: vitamin D3 placebo
3288302|NCT01728571|Placebo Comparator|Vitamin D3 placebo + fish oil placebo|Dietary Supplement: vitamin D3 placebo Dietary Supplement: fish oil placebo
3288303|NCT01728597||healthy volunteers|MR compliant volunteers with no history of cardiovascular diseases
3288304|NCT01728610|Active Comparator|Active high|Probiotic, high dose
3288305|NCT01728610|Active Comparator|Active low|Probiotic, low dose
3288306|NCT01728610|Placebo Comparator|Placebo|Placebo
3288307|NCT01728649|No Intervention|Normothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA approved devices. After which patient will be started on normothermia attempting to keep core body temp between 38 and 36.5 degrees centigrade. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
3288308|NCT01728649|Experimental|Mild Hypothermia|As part of standard of care, an interventional reperfusion procedure will be performed on all subjects using current FDA cleared device. Patient will also have a Quattro catheter placed in the femoral vein and temperature brought to 33 degrees centigrade as quickly as possible. They will stay in mild hypothermia for 12 hours and then be rewarmed very slowly. Patients will also undergo blood draws for biomarkers before reperfusion is achieved the immediately, 6 hours then 24 hours after reperfusion.
3288309|NCT01728662|Experimental|ELVR Procedure|A single subsegmental AeriSeal System treatment consists of the administration of 10 mL Foam Sealant administered through a standard fiberoptic bronchoscope via an administration syringe and bronchoscopic catheter into the target area of damaged lung
3288310|NCT01728675|Experimental|Young group|Participants will underwent two isokinetic eccentric exercise sessions
3288311|NCT01728675|Experimental|Elderly group|Participants will underwent two isokinetic eccentric exercise sessions
3288312|NCT01728688|Active Comparator|Conventional|conventional treatment & antiviral treatment
3288313|NCT01728688|Experimental|conventional & PBSC transplantation|After three days G-CSF mobilization, Patients randomized to the intervention arm will receive autologous PBSCs transplantation at day1, and receive conventional treatment and antiviral treatment through the one year study visit and followed until one years study visit.
3288314|NCT01728701|Experimental|Grp 1: 75,000 PfSPZ Challenge, 3 immunizations|Grp 1 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 1 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 1 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
3288315|NCT01728701|Placebo Comparator|Grp 2: Normal Saline (NS)|Grp 2 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 2 gets ID injections of normal saline, on days 8, 36 & 64 (immunizations 1, 2 & 3). 33 days after last dose of CQ, Grp 2 will have CHMI by bites of 5 mosquitoes infected with Pf NF54 strain.
3288316|NCT01728701|Experimental|Grp 3: 75,000 PfSPZ Challenge, 3/4 immunizations|Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
3379085|NCT00495300||1|Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program
3288317|NCT01728701|Placebo Comparator|Grp 4: Normal Saline (NS)|Grp 4 (5 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 wks(98 days). In this time, Grp 4 gets ID injections of NS, on days 8, 36 & 64 (immunizations 1, 2 & 3). Grp 4 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If <75% of Grp 1 are protected against homologous Pf CHMI, Grp 4 will receive 1 additional immunization (immunization 4), consisting of ID injections of NS, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 4 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
3288318|NCT01728714||Adults over 18 years old|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months submitted to an educational programme during 1 year
3288319|NCT01728714||Adults with HbA1c <= 8,5%|Adults over 18 years old, with type 2 diabetes, HbA1c <= 8,5%, treated with oral antidiabetics at least for 6 months followed according to normal clinical practice during 1 year
3288320|NCT01728727|Active Comparator|conventional|conventional treatment & antiviral treatment
3288321|NCT01728727|Experimental|UC-MSC transplantation|Participants will receive umbilical cord derived mesenchymal stem cell treatment at day 1 and conventional treatment and antiviral treatment through the one year study visit. Participants will then be followed until one years study visit
3288322|NCT01728740|Experimental|Acarbose/Metformin FDC|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Acarbose/Metformin FDC; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose/Metformin FDC (containing 50 mg Acarbose and 500 mg Metformin)
3288323|NCT01728740|Active Comparator|Acarbose+Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without loose combination of Acarbose and Metformin; Day 1: oral sucrose load plus single dose of 1 tablet each of a loose combination of Acarbose 50 mg and Metformin 500 mg
3288324|NCT01728740|Active Comparator|Acarbose|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Acarbose 50 mg
3288325|NCT01728740|Active Comparator|Metformin|Day 0: oral sucrose load (75 g sucrose dissolved in 225 mL water) without comedication; Day 1: oral sucrose load plus single dose of 1 tablet Metformin 500 mg
3288326|NCT01728753|Placebo Comparator|Placebo|Placebo
3288327|NCT01728753|Experimental|T-705 A|Favipiravir regimen 1: 1200 mg 3x daily (TID) on Day 1, then 600 mg TID on Days 2-5
3288328|NCT01728753|Experimental|T-705 B|Favipiravir regimen 2: 2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
3288329|NCT01728753|Experimental|T-705 C|Favipiravir regimen 3: 1800 mg BID on Day 1, then 800 mg BID for Days 2-5
3288330|NCT01728766||Infants under-6 months and their mothers|Small for gestational age at delivery. Post-term Infant, Not Heavy-for-dates.
3288331|NCT01728818|Experimental|Arm A|
3288332|NCT01728818|Active Comparator|Arm B|
3288333|NCT01728857|Experimental|Fat Reduction|
3288334|NCT01728870|Experimental|Unique Diet+Partial Enteral Nutrition|"Unique Diet+Partial Enteral Nutrition (PEN): This group will receive as follows:~Weeks 1-6: 50% of dietary needs from PEN (Modulen, Nestle) and 50% from a limited whole food diet.~Weeks 7-12: 25% of dietary needs from PEN (Modulen, Nestle) and 75% from a limited whole food diet."
3288335|NCT01728870|Active Comparator|Exclusive Enteral Nutrition (Modulen)|"Exclusive Enteral Nutrition(EEN): This group will receive as follows:~Weeks 1-6: EEN(100% of dietary needs from Modulen) Weeks 7-12: 25% of dietary needs from Modulen and 75% from a free diet."
3288336|NCT01728883||Diagnosed DR/DME requiring treatment|Patients diagnosed as diabetic retinopathy(DR) and/or diabetic macular edema (DME) and requiring treatment at the time they are recruited into the Study. Patients will be home vision monitoring using myVisionTrack®.
3288337|NCT01728896|Experimental|Patient-controlled oral refeeding|Patients will be allowed to drink and eat hospital food freely as tolerated.
3288338|NCT01728896|No Intervention|Conventional management|
3288339|NCT01728909|Experimental|Oxytocin|40 IU Oxytocin
3288340|NCT01728909|Placebo Comparator|Saline Nasal Spray|Placebo Comparator
3288341|NCT01728922|Active Comparator|Healthy control - 5,000 IU vitamin D|13 healthy controls will be administered 5,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
3288342|NCT01728922|Active Comparator|Healthy control - 10,000 IU vitamin D|13 healthy controls will be administered 10,000 IU vitamin D. Primary outcome and safety outcome measures will be assessed.
3288343|NCT01728922|Placebo Comparator|CIS - placebo|15 patients will be administered placebo and all outcome measures will be assessed.
3288344|NCT01728922|Active Comparator|CIS - 5,000 IU vitamin D|15 patients will be administered 5,000 IU vitamin D and all outcomes will be assessed.
3288345|NCT01728922|Active Comparator|CIS - 10,000 IU vitamin D|15 patients will be administered 10,000 IU of vitamin D and all outcome measures assessed.
3288346|NCT01728922|Placebo Comparator|Healthy control - placebo|13 control participants who will be administered placebo. These will be assessed for the primary outcome and safety outcomes only.
3288347|NCT01728935|Other|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
3288348|NCT01728948||Group 1|
3288349|NCT01728961|Active Comparator|ARM A: AL + NVP -based ARV treatment|AL given to children who test positive for malaria and are already taking NVP as prescribed by their healthcare provider
3288350|NCT01728961|Active Comparator|ARM B: AL with No ARV treatment|AL given to children who do not meet national guidelines for beginning ARV treatment
3288351|NCT01728974|Experimental|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
3288352|NCT01728987|Active Comparator|cholecalciferol|vitamin d (cholecalciferol) will be given as a capsule of 20.000 Iu twice a week
3288353|NCT01728987|Placebo Comparator|placebo|the placebo capsules are looking identical to the vitamin d capsules and contain medium chain triglycerides and arachis oil
3288354|NCT01729000|No Intervention|Hand hygiene|All staff that have interaction with subjects will perform hand hygiene with all patient contact and before all contact with the intravenous line.
3288355|NCT01729000|Experimental|Hand hygiene plus gloving|All staff that have interaction with subjects will perform hand hygiene and wear gloves with all patient contact and before all contact with the intravenous line.
3288356|NCT01729013||subjects previously given placebo|
3288357|NCT01729013||subjects previously given vitamin D|
3288358|NCT01729052|Experimental|Acupuncture and standard treatment|"Acupuncture at Neiguan (Pericardium-6) bilaterally with Seirin needles no 3 (0.20x15 mm) to a depth of approximately 7 mm will be performed on the children immediately after induction of anaesthesia and removed before they are fully awake.~Standard treatment: general anaesthesia"
3288359|NCT01729052|No Intervention|Standard treatment|General anaesthesia
3288360|NCT01729065|No Intervention|Home Program|Participants perform home program only.
3288361|NCT01729065|Experimental|Physical Therapy Intervention|Physical therapy intervention provided for first 12 weeks following surgery.
3288362|NCT01729078|Experimental|high fat ( MUFA) diet|intervention using high fat diet.
3288363|NCT01729078|Experimental|high carb/high fiber|diet using high carb-high fiber with dry beans
3288364|NCT01729078|Experimental|high carb/low fat|Habitual diet
3288365|NCT01729104|Experimental|Phase I: Carfilzomib + Lenalidomide + Rituximab|Phase I: Four primary dose levels of carfilzomib plus lenalidomide (carfilzomib 20 mg/27 mg + lenalidomide 20 mg, carfilzomib 20 mg/36 mg + lenalidomide 20 mg, carfilzomib 20mg/45 mg + lenalidomide 20 mg, carfilzomib 20 mg/56 mg + lenalidomide 20 mg,) evaluated with a fixed dose of rituximab (375 mg/m2 weekly for 4 weeks). Alternate dose levels using 15 mg of lenalidomide in combination with carfilzomib and rituximab evaluated if MTD is exceeded with 20 mg of lenalidomide.
3288366|NCT01729104|Experimental|Phase II: Mantle Cell Lymphoma Group|"Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
3288367|NCT01729104|Experimental|Phase II: Follicular, Marginal Zone, DLBCL Group|"Group consists of : Patients with follicular lymphoma (FL) grade 1 - 3, marginal zone lymphoma (MZL), or non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL).~Phase II: Patients enrolled at recommended dose level (MTD) of Carfilzomib established in Phase I of the study.~Phase II Lenalidomide Dose: 20 mg by vein on Days 1-21 of each cycle.~Phase II Rituximab Dose: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months."
3288368|NCT01729117|Other|Meal Replacement|Meal Replacements will be provided to participants randomized to the MR group
3288369|NCT01729117|Other|Standard Care|Standard Care participants will receive standard care but no meal replacements
3288370|NCT01729130||Group 1 Pancreas/kidney transplant|Group 1 of patients with End Stage Renal Disease (ESRD) and Diabetes Mellitis who will receive a pancreas and kidney transplant. An adipose tissue biopsy and blood samples are collected at time of transplant surgery. A repeat adipose tissue needle biopsy and blood samples are collected between 3-12 months post transplant.
3288371|NCT01729130||Group 2 DM with kidney transplant|Group 2 are patient with DM and ESRD and who will receive only a kidney transplant.
3288372|NCT01729130||Group 3 No DM and kidney transplant|Group 3 will be patients who do not have DM but do have the diagnosis of ESRD and will receive only a kidney transplant.
3288373|NCT01729143|Active Comparator|Black pepper|During the black pepper study day, subjects consumed 1.5g of black pepper (0.5g/meal) in 60.8g of vegetable juice. Black pepper was consumed was a meal on each occasion. 24-hour energy expenditure and substrate utilization will be measured.
3288374|NCT01729143|Placebo Comparator|No pepper control|During the no pepper control study day, subjects consumed an identical menu without black pepper. 60.8g of vegetable juice (vehicle) was consumed at each of the three study meals. 24-hour energy expenditure and substrate utilization will be measured.
3288375|NCT01729169||Sarcoidosis patients|Patients with biopsy proven sarcoidosis suspected of having cardiac sarcoidosis
3288376|NCT01729182||Nexium|
3288377|NCT01729195|Experimental|Single-arm|The syndesmosis injury of the patients will be fixed with a ciprofloxacin containing bioabsorbable PLGA bone screw or a stainless steel metal screw
3288378|NCT01729221||HCV infected patients treated by stem cell therap|Hepatitis C virus infected patients treated by stem cell therapy
3288379|NCT01729221||HCV infected patients treated by standared line of care|Hepatitis C virus infected patients treated by standared line of care
3288380|NCT01729234|Experimental|Nitrate|150µmol /Kg bodyweight /day
3288381|NCT01729234|Placebo Comparator|PLacebo|150µmol /Kg bodyweight /day
3288382|NCT01729260|Experimental|Mebendazole|All study participants will receive study drug; Mebendazole.
3288383|NCT01729273|Experimental|Diet and Exercise Intervention|"Tests will include EndoPAT analysis to assess endothelial function, applanation tonometry to assess arterial stiffness, carotid artery imaging to assess the wall thickness of the carotid arteries, exercise testing to assess the physical exercise capacity of these children and blood work to evaluate the lipid profile and inflammation status (CRP).~The Home Exercise Program will be 3 days a week for 12 weeks and participants will connect with the trainer to perform 45-60 minutes of a combination of strength training and aerobic activity via Skype. The Dietary Approaches to Stop Hypertension(DASH) eating pattern will be prescribed to all participants in the treatment group and specific strategies to achieve goals will be discussed weekly by the participant over the phone."
3288384|NCT01729286|Active Comparator|PriMatrix Moist Wound Therapy|sharp debridement, Primatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
3288385|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
3288386|NCT01729299|Placebo Comparator|saline|Saline: 0.9% saline solution
3288387|NCT01729299|Experimental|ghrelin and exendin (9-39)|Ghrelin+Ex-9: Combination of ghrelin and Ex-9,
3288388|NCT01729299|Experimental|Exendin (9-39)|Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min
3288389|NCT01729299|Experimental|ghrelin|synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,
3288390|NCT01729325|Experimental|Preventive Narrative Exposure Therapy|Treatment with Pre-NET before deployment in peace-keeping mission
3288391|NCT01729325|No Intervention|No treatment control|
3288392|NCT01729351||IPDI EF HFA-BDP|Patients initiating inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3288393|NCT01729351||IPDI FP|Patients initiating inhaled corticosteroid therapy as FP via pMDI at the index date
3288394|NCT01729351||IPDI NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
3288395|NCT01729351||IPDA EF HFA-BDP|Patients increasing inhaled corticosteroid therapy as extra-fine HFA-BDP MDI at the index date
3288396|NCT01729351||IPDA FP|Patients increasing inhaled corticosteroid therapy as FP MDI at the index date
3288397|NCT01729351||IPDA NEF HFA-BDP|Patients initiating inhaled corticosteroid therapy as non-extra-fine HFA-BDP via pMDI at the index date
3288398|NCT01729364|Experimental|crystalloid|crystalloid fluid administration, Ringer-acetat 20ml/kg under 30 minutes
3288399|NCT01729364|Experimental|colloid|colloidal fluids administration, HES 6% (130/0,4) 7ml/kg under 30 minutes
3288400|NCT01729377||Suicidal older persons and their families|Suicidal older persons and their families will be interviewed
3288401|NCT01729390|Experimental|Std ED Control|100% energy density and 133% portion size
3288402|NCT01729390|Experimental|Inc ED Control|133% energy density and 133% portion size
3288403|NCT01729390|Experimental|Std ED and Std PS|100% energy density and 100% portion size
3288404|NCT01729390|Experimental|Std ED and Inc PS|100% energy density and 133% portion size
3288405|NCT01729390|Experimental|Inc ED and Inc PS|133% energy density and 133% portion size
3288406|NCT01729390|Experimental|Inc ED and Std PS|133% energy density and 100% portion size
3288407|NCT01729403|Experimental|Aleglitazar|
3288408|NCT01729403|Placebo Comparator|Placebo|
3288409|NCT01729416|Experimental|Water Exchange Colonoscopy|The intervention will be water exchange colonoscopy in patients who are randomized to have screening colonoscopy with water exchange colonoscopy.
3288410|NCT01729416|Active Comparator|Air colonoscopy|The intervention will be colonoscopy using the traditional air method in patients who are randomized to have screening colonoscopy with air colonoscopy.
3288411|NCT01729429|Active Comparator|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
3288412|NCT01729429|Experimental|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
3288413|NCT01729442|Other|Patients referred for first-line prostate HIFU ablation|10 patients
3288414|NCT01729442|Other|Patients referred for first-line HIFU hemi-ablation|10 patients
3288415|NCT01729442|Other|Patients referred for salvage HIFU after radiotherapy|10 patients
3288416|NCT01729468|Experimental|Aspirin|Aspirin 160 mg per day
3288417|NCT01729468|Placebo Comparator|Placebo|Placebo 160 mg per day
3288418|NCT01729481|Experimental|RASH positive|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~Thereafter Treatment in patients with RASH-positve outcome after 4 weeks."
3288419|NCT01729481|Active Comparator|RASH-negative|"Run-In-Phase during 4 weeks:~Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly~RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:~Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion"
3288420|NCT01729507|Active Comparator|Treatment with tDCS|This group will receive 7x verum treatment with tDSC. All participants receive standardised behavioural therapy ('The smoke-free programme')
3288421|NCT01729507|Placebo Comparator|7x sham treatment|This group will receive 7x sham treatment. All participants will receive standardised behavioural therapy ('The smoke-free programme')
3288422|NCT01729520|Experimental|Knee extension strength training|
3288423|NCT01729533|Active Comparator|ICSI|In this arm, patients will be provided with standard intracytoplasmic sperm injection (ICSI), in which sperm selection is performed under an overall magnification of x400.
3288424|NCT01729533|Experimental|IMSI|In this arm, patients will be provided with a modified intracytoplasmic sperm injection (ICSI) procedure, the IMSI, in which sperm selection is performed under an overall magnification of x6600.
3288425|NCT01729572|Experimental|Experimental: Tele-medicine monitoring|Tele-medicine monitoring of medication adherence will be given to the study group as an add-on to routine out-patient treatment
3288426|NCT01729572|No Intervention|No Intervention: Control Rutine out-patient treatment|routine out-patient treatment will be given to the control group
3288427|NCT01729585|No Intervention|control group|control group
3288428|NCT01729585|Active Comparator|Massage therapy|Treatment group receives pre-determined massage therapy protocol x 5 over 10-12 weeks. massage therapy protocol includes a blend of Swedish strokes and myofascial trigger point therapy. Initially, dosing will be more frequent. Treatments will be spaced out to determine the ability of the body to maintain a more efficient musculoskeletal system, especially related to respiratory and postural efforts. Each session will end with resting hands and relaxation strokes to signal the end of the session. This protocol invites increased mobility in the musculoskeletal system. The ultimate goal is to return connective tissue (including muscles and fascia) to a more relaxed and neutral state, thus allowing expansion and ease of movement of the areas of the musculoskeletal system being worked.
3288429|NCT01729611||Scleroderma|60 patients with scleroderma - 30 with and 30 without Pulmonary Arterial Hypertension
3288430|NCT01729611||Cirrhosis|60 patients with cirrhosis - 30 with and 30 without Pulmonary Arteria Hypertension
3288431|NCT01729650|Experimental|Physical and diet educational group|group educational PA program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks), carried out by mental health nurses.
3288432|NCT01729650|No Intervention|Usual clinical care|
3288433|NCT01729663|Active Comparator|Interferon alpha 2 b|Interferon alpha 2b treatment will consist of s.c. injection of 10 MU (5 t/w) for four weeks and then 5 MU (3t/w) for 23 months.
3288434|NCT01729663|Experimental|CSF470 vaccine, BCG, Molgramostim|"CSF470 vaccine, BCG, Molgramostim~CSF-470 treatment will consist of four vaccine doses id injection (three weeks apart), then one dose every two months for the first year and them every three months for the second year.~Each vaccine consist of a mixture of 17,6.106 melanoma cells , from four melanoma cell lines, not genetically modified and lethally irradiated. As adjuvant BCG (120 µg prot) the first day and rhGM-CSF (Molgramostim 400 µg, fractionated in four days doses) will be used."
3288435|NCT01729676||Group A|Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice
3288436|NCT01729689|Experimental|Supportive care (cognitive behavioral therapy)|Participants undergo cognitive behavioral therapy over 1 hour once weekly for a total of 6 sessions. Sessions are tailored to patient and caregiver cognitions and approach and avoidance behaviors.
3288437|NCT01729702|Other|single group - consecutive patients|
3288438|NCT01729715|Experimental|Internet|Internet site that offers parents tips on promoting sleep in infants and toddlers
3288439|NCT01729715|Experimental|DVD|DVD that offers parents tips on promoting sleep in infants and toddlers
3288440|NCT01729715|No Intervention|No treatment|
3288441|NCT01729741|No Intervention|No drain|No drain was inserted after Thyroid surgery
3288442|NCT01729741|Experimental|Drain|A drain was inserted after thyroid surgery
3288443|NCT01729767|Experimental|Acyclovir|Acyclovir 400 mg tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
3288444|NCT01729767|Placebo Comparator|Placebo|Placebo tablets by mouth 5 times a day for the first month, 3 times a day for next 10 days, and 2 times a day for the last 10 days.
3288445|NCT01729780|Sham Comparator|Sham EEG-NF|Subjects who will undergo sham EEG-NF.
3288446|NCT01729780|Active Comparator|True EEG-NF|Subjects who will undergo true EEG-NF training in order to lessen their anxiety symptoms.
3288447|NCT01729793|Active Comparator|Digestive Enzyme #2|A proprietary blend of dietary supplement enzymes in a capsule
3288448|NCT01729793|Placebo Comparator|Placebo|Capsule identical to active arm containing only microcrystalline cellulose
3288449|NCT01729806|Experimental|Arm A (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 1, 4, 7, and 10. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3288450|NCT01729806|Experimental|Arm B (ipilimumab and rituximab)|Patients receive rituximab IV over 2-6 hours once weekly in weeks 1-4 and ipilimumab IV over 90 minutes once weekly in weeks 3, 6, 9, and 12. Patients then receive ipilimumab IV over 90 minutes and rituximab IV over 2-6 hours once every 12 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.
3288451|NCT01729832|Experimental|Supportive care (image-guided breast reconstruction)|Patients undergo DIEP flap breast reconstruction using the StealthStation navigation system.
3288452|NCT01729884|Experimental|Treatment (HER-2/neu peptide vaccine)|Patients receive HER-2/neu peptide vaccine ID once monthly for 3 months.
3288453|NCT01729897|Experimental|Etomidate & Fentanyl|"4 min before procedure: fentanyl 1 μg/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, etomidate was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of etomidate would be administrated separately when duration of procedure was prolonged."
3288454|NCT01729897|Placebo Comparator|Propofol & Fentanyl|"4 min before procedure: fentanyl 1 g/kg (0.02 ml/kg), intravenous injection~After injection of fentanyl, propofol was infused intravenously at rate of 200 ml/h for 30 seconds with unified injection pump, then after interval time of 30 seconds, infusion rate was altered to 500 ml/h and infusion was sustained until patients fell asleep.~Additional dose of propofol would be administrated separately when duration of procedure was prolonged."
3288455|NCT01729910|Experimental|Parent education / behavioral counseling|Parents of children in the intervention group will be invited to participate in four group visits and two individual visits with their primary care provider as well as four follow-up phone calls with study personnel (project coordinator or registered dietician). Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls.
3288456|NCT01729910|Placebo Comparator|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
3288457|NCT01729936|Experimental|Sitting time Change Intervention|"Sitting time Change Intervention: recommendation to substitute Sitting time by doing the regular activities standing or walking.~Duration: 6 month. Frequency: 1 time each 15 days during the first 4 month and 1 time each month the last 2 months."
3288458|NCT01729936|No Intervention|Active Control|Control visits to the Primary Health Care Center
3288459|NCT01729949|Active Comparator|Active Treatment Beverage|Strawberry powder and Blackcurrent extract
3288460|NCT01729949|Placebo Comparator|Placebo Treatment Beverage|Placebo Beverage
3288461|NCT01729962||Agreement Cohort|All subjects in the agreement portion of the study will have a single measurement performed with each device, the Nidek optical biometer, predicate device and ultrasound reference device. Each device will be operated by a different operator.
3288462|NCT01729962||Precision Cohort|All subjects in the precision portion of the study will each be paired with one Nidek optical biometer and with one predicate device for a total of three Nidek optical biometer/predicate device pairs. Each of the three device pairs will be designated one and only one operator. All subjects in the precision portion of the study will have their measurements repeated three times on each of three Nidek optical biometer and predicate device pairs.
3288463|NCT01729975||18-28 years old Non-pathologic|
3288464|NCT01729975||29-80 years old Non-Pathologic|
3288465|NCT01729975||29-80 years old pathologic corneal disease|
3288466|NCT01729988|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
3288467|NCT01730001|Active Comparator|Early Intubation|Early intubation is defined as prehospital intubation on the scene of the patient illness/injury, or where the EMS physician first meets the patient (e.g en route to hospital). Intubation includes drug assisted and/or rapid sequence intubation (RSI) with endotracheal tube.
3379090|NCT00471250||1|Healthy Volunteers
3288468|NCT01730001|Active Comparator|Late intubation|Late intubation is defined as on-scene prehospital high-flow (> 10 L/min) supplemental oxygen by mask, assisted bag-mask-ventilation by EMS physician if required and stable recovery position during transport to hospital. Intubation should be done on arrival in the emergency department.
3288469|NCT01730014|Experimental|Trial part 1|
3288470|NCT01730014|Experimental|Trial part 2, treatment A|
3288471|NCT01730014|Experimental|Trial part 2, treatment B|
3379091|NCT00471250||2|NIH patients with known or suspected susceptibility to infection.
3288472|NCT01730027|Experimental|ADC3680|ADC3680 oral once daily
3288473|NCT01730027|Placebo Comparator|Placebo|Placebo oral once daily
3288474|NCT01730027|Active Comparator|montelukast|montelukast oral once daily
3288475|NCT01730066|Experimental|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria preoperatively and given the same study product enterally postoperatively
3288476|NCT01730066|No Intervention|Control|No intervention.What has been the standard procedure so far
3288479|NCT01730118|Experimental|1/Part I dose escalation|AdHER DC vaccine administered at escalating doses
3288480|NCT01730118|Experimental|2/Part I dose expansion|AdHER DC vaccine administered at a next lower dose or the highest dose
3288481|NCT01730118|Experimental|3/Part II dose escalation|AdHER DC vaccine administered at Dose Level 1
3288482|NCT01730118|Experimental|4/Part II dose expansion|AdHER DC vaccine administered at Arm 1 MTD
3379092|NCT00469339||cohort of Mexican-American households|cohort of Mexican-American households
3379093|NCT00451022||Cohort 1|Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
3288486|NCT01730157|Experimental|Treatment (yttrium Y 90 glass microspheres, ipilimumab)|Patients undergo radioembolization with yttrium Y 90 glass microspheres via hepatic arterial infusion on day 1. Beginning on day 29, patients also receive ipilimumab IV over 90 minutes. Treatment with ipilimumab repeats every 3 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3288487|NCT01730170||Pregnant Women without Epilepsy|Women in their first trimester of pregnancy who are not diagnosed with epilepsy
3288488|NCT01730170||Nonpregnant Women with Epilepsy|Women diagnosed with epilepsy and not currently pregnant.
3288489|NCT01730170||Pregnant Women with Epilepsy|Women in their first trimester of pregnancy and diagnosed with epilepsy
3288490|NCT01730183|Experimental|Bone marrow derived stem cells|Autologous Bone Marrow derived Stem Cells(BMSC) transplanted intrathecally into patients with spinal cord injury.
3288491|NCT01730196|Experimental|Fit Body and Soul|Faith-based adaptation of the Group Life Style Program
3288492|NCT01730196|Active Comparator|Wellness education|A health education program developed from the list of topics provided by the Centers for Disease Control and Prevention (CDC) Guide to Community Prevention Services
3288493|NCT01730209|Experimental|Everolimus|Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml
3288494|NCT01730209|Placebo Comparator|Placebo|Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.
3288495|NCT01730222|Experimental|PAXG regimen|cisplatin at 30 mg/m2 on days 1 and 15, nab-paclitaxel at the RP2D on days 1 and 15, capecitabine at 1250 mg/ m2 days 1-28, gemcitabine at 800 mg/ m2 on days 1 and 15 every 4 weeks
3288496|NCT01730222|Active Comparator|gemcitabine + nab-paclitaxel|gemcitabine at 1000 mg/ m2 on days 1, 8 and 15 every 4 weeks + nab-paclitaxel at 125 mg/ m2 on days 1, 8 and 15 every 4 weeks
3288497|NCT01730235||Case Group|Group receiving access to MyMediHealth web site.
3288498|NCT01730235||Control Group|Children completing baseline and week two measures, but without any additional intervention.
3288499|NCT01730248|Experimental|JAK Inhibitor Naive|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period ( 6 or more cycles of 28 days, with visits every 28days for 6 cycles and then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine maximum tolerated dose (MTD) / Recommended Phase II dose (RPIID) & an Expansion Phase
3288500|NCT01730248|Experimental|Prior JAK Inhibitor|Two treatment periods applicable to all patients; Treatment Period (6 cycles / 28 days per cycle) and Extension Period (6 or more cycles of 28 days, with visits every 28 days for 6 cycles then visits every 12 weeks) following the treatment period dependent on patient continued eligibility. Two Study Phases: Dose Escalation Phase to determine MTD / RPIID & an Expansion Phase
3288501|NCT01730261|Experimental|Online Emotional Regulation Treatment|Participants will receive 24 treatment sessions, with baseline, post-treatment screening and follow-up screening, and bi-weekly assessments
3288502|NCT01730274||patients|children operated on a cerebellar tumor
3288503|NCT01730274||healthy subjects|healthy volunteers
3288504|NCT01730287|Experimental|Control|No lining applied in group1.
3288505|NCT01730287|Experimental|CEM cement|CEM cement applied over remained caries in group4.
3288506|NCT01730287|Experimental|Mineral Trioxide Aggregate (MTA)|MTA applied over remained caries in group3.
3288507|NCT01730287|Experimental|Calcium Hydroxide|Calcium Hydroxide applied over remained caries in group2.
3288508|NCT01730313|Experimental|Pyridoxine (B6)|Oral pyridoxine, 30- 50 mg/kg/day in one daily dose (powder form)for a period of four weeks followed by cross-over to Phenytoin arm for another four weeks
3288509|NCT01730313|Experimental|Phenytoin|Phenytoin Oral, 5 mg/kg/day in two equally divided doses(powder form)for a period of four weeks and then cross-over to Pyridoxine arm for another four weeks
3288510|NCT01730313|Experimental|Sodium Valproate|Sodium valproate oral, 10 - 15 mg/kg/day once daily powder form)for a period of four weeks and then cross-over to placebo arm for another four weeks
3288511|NCT01730313|Placebo Comparator|Placebo|Placebo will consist of an inert substance (e.g., gelatin) with an appearance similar to medication in similar dosage as the study arms for a period of 4 weeks and subsequent cross-over to Sodium Valproate arm
3288512|NCT01730326|Experimental|Paracetamol|Paracetamol which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
3288513|NCT01730326|Active Comparator|Dexketoprofen|Dexketoprofen which will be given after randomization will be diluted in serum physiologic and will be given as intravenous rapid infusion.
3288514|NCT01730352|No Intervention|H. pylori no treatment|Observational group, with clinical and platelet count follow-up
3288515|NCT01730352|Experimental|H. pylori triple therapy|Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.
3288516|NCT01730365||Histological biopsy procedures|Patients with a suspicious lesion in lung or liver or breast who are planned for a standard core biopsy procedure. And patients planned for percutaneous RFA (Radiofrequency Ablation) of colorectal liver metastasis
3288517|NCT01730391||Study cohort|Subjects visiting the hospital with suspected bacterial meningitis in The Philippines and Vietnam.
3288518|NCT01730404|Experimental|CHF6001|CHF6001 DPI (Dry Powder Inhaler) once daily
3288519|NCT01730404|Active Comparator|Roflumilast|Roflumilast, tablet, once daily
3288520|NCT01730404|Placebo Comparator|placebo|Placebo
3288521|NCT01730417|Experimental|Radiation dosimetry|no carrier added metaiodobenzylguanidine
3288522|NCT01730430||Collection of CSF|"Those with Alzheimer's disease~Those with non-Alzheimer's disease dementia~Healthy elderly volunteers"
3288523|NCT01730443||On progesterone treatment|The group assigned to progesterone treatment.
3288524|NCT01730443||group assigned to placebo|The group that will not be receiving progesterone treatment
3288525|NCT01730456|Experimental|RoActemra/Actemra|
3288526|NCT01730469|Experimental|AT1001 150 mg|Each subject will receive a single oral dose of AT1001 150 mg administered orally with 240 mL room temperature water after at least a 4-hour fast
3288527|NCT01730482|Experimental|[14C] AT1001 Arm|Each subject will receive a single oral dose of 150 mg of [14C] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.
3288528|NCT01730495|Experimental|Etanercept|
3288529|NCT01730508||Chronic Hepatitis B Participants|Hepatitis B e antigen (HBeAg) chronic hepatitis B (CHB) participants who received treatment with pegylated interferon alfa (peginterferon alfa) according to China labeling and China standard of care and were followed up to 1 year after treatment cessation.
3288530|NCT01730521||Difference in Iron bioavailabilty exercise and resting phase|the subjects will act as their own control during the study
3288531|NCT01730547|Active Comparator|Early treatment with mesenchymal stem cells|
3288532|NCT01730547|Active Comparator|Delayed treatment with mesenchymal stem cells|
3288533|NCT01730560|Experimental|Arm 1:Treatment A|Treatment A (active) followed by treatment B (neutral)
3288534|NCT01730560|Experimental|Arm 2: Treatment B|Treatment B (neutral) followed by treatment A (active)
3288535|NCT01730573|Active Comparator|Interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
3288536|NCT01730573|Active Comparator|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
3288537|NCT01730599||PD patients|PD patients carriers of the G2019S mutation in the LRRK2 gene
3288538|NCT01730625|Experimental|ABMT + CBT|CBT and ABMT
3288539|NCT01730625|Other|CBT Alone|CBT alone (compare/control group)
3288540|NCT01730625|Placebo Comparator|ABMT placebo + CBT|ABMT placebo training and CBT
3288541|NCT01730651|Experimental|Tomotherapy|"Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
3288542|NCT01730664|Experimental|ertapenem|single dose ertapenem
3288543|NCT01730677|Experimental|Lapatinib+Vinorelbine|lapatinib 1000mg, once daily vinorelbine 20mg/m2, D1 and D8, every 3 weeks
3288544|NCT01730677|No Intervention|Vinorelbine|vinorelbine 30mg/m2, D1 and D8, every 3 weeks
3288545|NCT01730703||Adults ages 65 and older|
3288546|NCT01730716|Experimental|Surgery|There will be 5 sequential cohorts (Groups A-E) with 3 subjects in each cohort. Each cohort will follow a dose escalation plan. New patients will be enrolled into each group. No control group is included. All patients will received spinal cord injections of HSSC.
3288547|NCT01730742|Experimental|Sleep deprivation|Total sleep deprivation: participants were required to stay up for the entire night before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
3288548|NCT01730742|Experimental|Sleep|Sleep: participants had an 8-h sleep opportunity before a 'Blood Sample' was taken and the 'Neuroeconomics task' and 'Portion size task' were performed
3288549|NCT01730768|Experimental|AQW051 10 mg/day|Two 5mg AQW051 capsules will be taken orally daily by patients from Day 1 until Day 84.
3288550|NCT01730768|Placebo Comparator|Placebo to AQW051|Matching placebo administered orally.
3288551|NCT01730781||Schizophrenia|Patients diagnosed with schizophrenia both on medication and off medication
3288552|NCT01730781||Cannabis dependence|Frequent users of cannabis
3288553|NCT01730781||Family history of alcoholism|Healthy volunteers with a first degree relative with alcoholism
3288554|NCT01730781||Prodrome for psychotic illness|Not meeting full criteria for psychotic illness but exhibiting prodromal symptoms
3288555|NCT01730781||Healthy Volunteers|Healthy volunteers with no current or past major medical or psychiatric history
3288556|NCT01730781||PTSD-Post Traumatic Stress Disorder|Patients diagnosed with Post Traumatic Stress Disorder
3288557|NCT01730781||Opioid Use Disorder|Patients diagnosed with Opioid Use Disorder
3288558|NCT01730794|Other|Conventional Lung Protective Ventilation|In this group, patients will be ventilated in either volume A/C, pressure A/C, pressure support, pressure regulated volume control or volume support based on the discretion of the medical team with TV 4-8 ml/kg PBW range and PP or pressure (control or support) level <30 cmH2O.
3288559|NCT01730794|Other|NAVA Ventilation Group|In the NAVA group, NAVA level will be set initially at zero, then the maximum Edi will be determined as the average level over the next 3 to 5 breaths without ventilatory support or PEEP. The actual NAVA level will then be titrated by the clinician to achieve the following: 1) an Edi equal to approximately 50% of the maximum Edi, 2) an average tidal volume of between 4 to 8 ml/kg predicted body weight (PBW), and 3) an average respiratory rate between about 15 and 40 per minute. In addition, the trigger sensitivity should be set as sensitive as possible without causing auto-triggering and the maximum pressure limit in NAVA should be set at 40 cm H2O.
3288560|NCT01730807|Experimental|IntellaTip XP MiFi|Patients with Atrial Flutter will receive ablation treatment with the IntellaTip MiFi XP catheter
3288561|NCT01730833|Experimental|Treatment (pertuzumab, trastuzumab, nab-paclitaxel)|Patients receive pertuzumab IV over 30-60 minutes on day 1, trastuzumab IV over 30-90 minutes and paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes on days 1, 8, and 15. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3288562|NCT01730859|Experimental|Balance exrercise and ankle taping|"Balance Exercises:Balance exercises for 6 weeks, 3 sessions per week and each session was 40 minutes for training group.~Ankle taping: Ankle joint taping was performed for 6 weeks and was renewed three times a week."
3288563|NCT01730885|Other|BGStar|Comparision
3288564|NCT01730898|Active Comparator|Control capsule|2 capsules
3288565|NCT01730898|Experimental|Experimental capsule|2 capsules
3288566|NCT01730911|No Intervention|ParaGard, paper diaries|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries on paper.
3288567|NCT01730911|Active Comparator|ParaGard, text message|Women who have chosen ParaGard IUDs as their contraception, and randomized to submit bleeding diaries via text message.
3288568|NCT01730911|No Intervention|Mirena, paper diaries|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries on paper.
3288569|NCT01730911|Active Comparator|Mirena, text message|Women who have chosen Mirena IUDs as their contraception, and randomized to submit bleeding diaries via text message.
3288570|NCT01730924|Other|Contact force available|
3288571|NCT01730924|Other|Contact force not available|
3288572|NCT01730937|Experimental|Arm 1 (sorafenib tosylate)|Patients receive sorafenib tosylate orally PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3288573|NCT01730937|Experimental|Arm 2 (SBRT and sorafenib tosylate)|Patients undergo SBRT every 24-72 hours for a total of 5 fractions over 5 to 15 days. Within 1-5 days post-SBRT, patients receive sorafenib tosylate PO BID on days 1-28. Treatment repeats every 28 days for up to 5 years in the absence of disease progression or unacceptable toxicity.
3288574|NCT01730963||Pregnant, Preterm, In Labor|Gestation Age at or less than 36 weeks, clinically determined to be in labor
3288575|NCT01730963||Pregnant, Preterm, Nonlaboring|Gestation Age at or less than 36 weeks, clinically determined to not be in labor
3288576|NCT01730963||Pregnant, Term, Nonlaboring|Gestation Age more than 36 weeks, clinically determined to not be in labor
3288577|NCT01730976|Experimental|Vitamin D 2,000 I.U. daily|Study subjects will take 2,000 I.U. vitamin D daily for three months
3288578|NCT01730989|Experimental|Estromineral Serena Plus|"Estromineral Serena Plus is an association of soy isoflavones, Lactobacillus sporogenes, magnolia, chaste tree, Vitamin D3, calcium and magnesium.~1 tablet oad for 12 weeks"
3288579|NCT01730989|Active Comparator|Estromineral|"Estromineral is an association of soy isoflavones, Lactobacillus sporogenes, Vitamin D3, and calcium.~1 tablet oad for 12 weeks"
3288580|NCT01731015|Experimental|Normal Subject|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
3288581|NCT01731015|Experimental|Subjects with Lung/or Airway Disease|Each subject will receive oxygen as a contrast agent to visualize the airway and alveolar spaces in their lungs using magnetic resonance imaging of inert gas/oxygen mixtures. The subjects will receive the gas by breathing room air interleaved with oxygen using a standard Douglas Bag system. No additional drug products, investigational or otherwise will be provided in this study.
3288582|NCT01731028||Somatropin|Children with growth hormone deficiency treated with somatropin as Zomacton® according to the marketing authorization
3288583|NCT01731067|Active Comparator|CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors|Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs
3288584|NCT01731067|Active Comparator|CYP2D6 and P-gp inhibitor|Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs
3288585|NCT01731067|Active Comparator|CYPs and P-gp inducer|Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs
3288586|NCT01731067|Experimental|Probe cocktail alone|"Oral intake of the cocktail probe drugs :~bupropion 25 mg~flurbiprofen 25 mg~omeprazole 5 mg~dextromethorphan 5 mg~midazolam 1 mg~fexofenadine 25mg~Caffeine (a cup of coffee)"
3288587|NCT01731080||Pseudoxanthoma Elasticum|Patients with genetically and clincally proven PXE
3288588|NCT01731080||chronic kidney disease|Type 2 diabetic patients with mediacalcosis and matched to PXE patients for gender and age (+/- 5 yrs).
3288589|NCT01731080||Diabetes|patients with chronic kidney disease and matched to PXE patients for gender and age (+/- 5 yrs).
3288590|NCT01731093|Experimental|AT-001|AT-001
3288591|NCT01731093|Placebo Comparator|Placebo|Matching placebo.
3288592|NCT01731132||Group 1|
3288593|NCT01731145|Experimental|SNUMAP assessment|Uses SNUMAP motion sensing system to quantify tremor symptom.
3288594|NCT01731158|Other|arm A|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), Afinitor (second-line) and a TKI (Sutent, Nexavar or Votrient) (third-line)"
3288595|NCT01731158|Other|arm B|"sequential therapy with approved drugs~Avastin in combination with Roferon-A (first-line), a TKI (Sutent, Nexavar or Votrient) (second-line) and Afinitor (third-line)"
3288596|NCT01731184|Experimental|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
3288597|NCT01731184|Placebo Comparator|Placebo|Placebo at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
3288598|NCT01731197|Experimental|Test ISP-10|10 grams of the test ISP will be consumed as a dry-blended beverage
3288599|NCT01731197|Experimental|Test ISP-20|20 grams of the test ISP will be consumed as a dry-blended beverage
3288600|NCT01731197|Active Comparator|Control ISP-10|10 grams of the control ISP will be consumed as a dry-blended beverage
3288601|NCT01731197|Active Comparator|Control ISP-20|20 grams of the control ISP will be consumed as a dry-blended beverage
3288602|NCT01731223|Experimental|Group treatment for insomnia|Group treatment for insomnia.
3288603|NCT01731223|No Intervention|No intervention|Treatment as usual
3288604|NCT01731236|Active Comparator|Carnitine (No antibiotics, No aspirin)|L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
3288605|NCT01731236|Active Comparator|Choline (No Antibiotics, No aspirin)|Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.
3288606|NCT01731236|Active Comparator|Antibiotics|"Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)~Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)~Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)~Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)"
3288607|NCT01731236|Active Comparator|Choline and Aspirin|"Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
3288608|NCT01731236|Active Comparator|Carnitine and Aspirin|"Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)~Other Names:~Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin"
3288609|NCT01731249|Placebo Comparator|Placebo|Placebo sublingual solution
3288610|NCT01731249|Experimental|Birch pollen allergen extract|Sublingual Solution of Birch pollen allergen extract 300IR once daily 5 months per year and during 2 years
3288611|NCT01731262||RA group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
3288612|NCT01731262||control group|expression of Shh pathway associated factors from peripheral blood mononuclear cells or synovial tissues will be detected
3288613|NCT01731275|Experimental|E6011|
3288614|NCT01731275|Placebo Comparator|E6011 Matching Placebo|
3288615|NCT01731288||vulvodynia|Women with vulvodynia
3288616|NCT01731288||control|Women without vulvar pain
3288617|NCT01731301|Experimental|Ribavirin, peginterferon, boceprevir|The efficacy and safety of HCV treatment in patients with ESRD will be assessed with a maximal tolerated dose of ribavirin, peginterferon and boceprevir.
3288618|NCT01731327|Experimental|Experimental Treatment A|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
3288619|NCT01731327|Experimental|Experimental Treatment B|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
3288620|NCT01731340|Active Comparator|Supplemental Calcium|"750 mg Calcium Citrate per day~800 IU Vitamin D3 per day~Low Dietary Calcium (450 mg per day)"
3288621|NCT01731340|Active Comparator|Dietary Calcium|"400 IU Vitamin D3 per day~High Dietary Calcium (1200 mg per day)"
3288622|NCT01731340|No Intervention|Usual Diet|"400 IU Vitamin D3 per day~Unrestricted Dietary Calcium"
3288623|NCT01731353||Emerging fungal infections|Web-based registry of invasive infections by emerging fungi
3288624|NCT01731366|Placebo Comparator|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
3288625|NCT01731366|Active Comparator|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
3288626|NCT01731379||Surgical resections|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy, patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
3288627|NCT01731392|Experimental|Milk with Bifidobacteria|duration of the treatment is 5 months
3288628|NCT01731392|Active Comparator|Milk with non replicating lactobacilli|duration of the treatment is 5 months
3288629|NCT01731392|Placebo Comparator|Semi skimmed milk|duration of the treatment is 5 months
3288630|NCT01731405||Formats A,B,C; medicines Ritalin, Morphine Sulfate, Aranesp|All patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
3288631|NCT01731405||There is not another group|
3288632|NCT01731418|Other|Treamtent-as-usual|Treatment-as-usual can be defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive psychotherapy.
3288633|NCT01731418|Experimental|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a standardized short-term approach based on the principles of cognitive behavioral exposure therapy and testimony therapy for the treatment of PTSD resulting from organized violence.
3288634|NCT01731431|Active Comparator|Insulin|standard protocol of insulin treatment for gestational diabetes
3288635|NCT01731431|Experimental|Glyburide|initial dose 2.5 mg per day increased if necessary until 10mg twice a day if glycemia is not controlled
3288636|NCT01731444|Experimental|Phenylephrine|20 ug/cc
3288637|NCT01731444|Active Comparator|Epinephrine|1:1000000
3288638|NCT01731457|Experimental|Etanercept|
3288639|NCT01731457|No Intervention|Control|
3288640|NCT01731496|Experimental|Telephone reminder|Telephone message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
3288641|NCT01731496|Experimental|Text Message reminder|Text message reminder to parents of adolescents whose child is due for a 2nd or 3rd dose of HPV vaccine.
3288642|NCT01731496|No Intervention|Control: Telephone|
3288643|NCT01731496|No Intervention|Control: Text Message|
3288644|NCT01731509|Active Comparator|Standard FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 26 0/7 weeks and 28 6/7 weeks.
3288645|NCT01731509|Experimental|Early FETO|Group of fetus that undergo fetal endoscopic tracheal occlusion between 22 0/7 weeks and 24 6/7 weeks.
3288646|NCT01731522|Experimental|EF condition|
3288647|NCT01731535||Prior bisphosphonate users|Patients with record of using bisphosphonate medication
3288648|NCT01731548|Experimental|study arm|"For patients who are randomized to study arm, (i.e. to irradiate the post-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the post-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy（1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks）"
3288649|NCT01731548|Active Comparator|control arm|"For patients who are randomized to control arm, (i.e. to irradiate the pre-chemotherapy tumor extent) the clinical target volume-tumor (CTV-T) includes the pre-chemotherapy gross tumor volume-tumor (GTV-T) with a margin of 0.8 cm.~Chemotherapy includes etoposide 100mg/m2 d1-d3 combine with cisplatin 80mg/m2 d1 at 21-day interval for 4 cycles.~Radiotherapy will be administered with cycle 3 chemotherapy (1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks)."
3288650|NCT01731561|Experimental|Rituximab infusion according biological parameters|Rituximab infusion based on ANCA and CD19 lymphocytes
3288651|NCT01731561|Active Comparator|Systematic rituximab infusion|Semestrial rituximab infusion until 18 months
3288652|NCT01731574|Active Comparator|Dapivirine Ring + Miconazole|Dapivirine Ring + miconazole
3288653|NCT01731574|Experimental|Dapivirine Ring|Dapivirine Ring
3288654|NCT01731587|Experimental|L-BLP25 plus Cyclophosphamide (CPA)|
3288655|NCT01731613|Active Comparator|Standard Fortification|receive human milk fortified with human milk fortifier(HMF) in the standard amount (4 packs /100 ml of HM) throughout the study
3288656|NCT01731613|Experimental|Adjustable fortification|encompasses increasing/decreasing the amount of human milk fortifier(HMF) and adding supplemental protein guided by periodic determinations of the protein concentration of human milk (PCHM), body weight, blood urea nitrogen(BUN)
3288657|NCT01731639|Experimental|MSOME|The samples will be evaluated under high magnification
3288658|NCT01731652|Experimental|TMX-101|TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
3288659|NCT01731665||The Songpa-Kangdong cohort of IBD|Incident cases of IBD in the Songpa-Kangdong district, a well-defined administrative area in Seoul, the capital of Korea, beginning in 1986, when the first patient with IBD was diagnosed, until 2017. For the prevalent cases, the inhabitants with IBD at Dec 31, 2007 in the Songpa-Kangdong district are included.
3288660|NCT01731704|Active Comparator|Stereotactic Radiosurgery (SRS)|Radiation Therapy: Radiosurgical (SRS) technique via Gamma Knife Perfexion radiosurgical system
3288661|NCT01731704|Active Comparator|Whole Brain Radiation Therapy (WBRT)|whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
3288662|NCT01731717|Experimental|Stepped care intervention (SCM)|"Patients within the stepped care intervention are screened by general physician using the PHQ-9 (inclusion criterion: >4 points) and diagnosed according to International Classification of Diseases (ICD-10) criteria. Patients receive differentially intensive treatment according to depression severity.~Patients with mild depression receive:~Step I: Active monitoring or Step II: II.a. Bibliotherapy or II.b. Online self-help (Deprexis®) or II+: Telephone-based psychotherapy~Patients with moderate depression receive:~Step III: III.a. Outpatient psychotherapy or III.b. Psychopharmacological treatment~Patients with severe depression receive:~Step IV: Combined psychotherapy and psychopharmacological treatment, optionally in inpatient setting."
3288663|NCT01731717|Active Comparator|Control group: treatment as usual|Patients in the control group are screened by their general physician using the PHQ-D-9 depression scale. Patients included in the study then receive treatment as usual from general physician or other health service providers.
3288664|NCT01731730|Placebo Comparator|Placebo (Vehicle) Injection|Single Intrathecal (spinal) administration of Placebo Injection just prior to intrathecal administration of spinal anesthetic for knee surgery
3288665|NCT01731730|Experimental|AYX1 Injection 110 mg|Single Intrathecal (spinal) administration of AYX1 Injection (110 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
3288666|NCT01731730|Experimental|AYX1 Injection 330 mg|Single Intrathecal (spinal) administration of AYX1 Injection (330 mg) just prior to intrathecal administration of spinal anesthetic for knee surgery
3288667|NCT01731743|Other|implantation of a trifocal IOL (AT LISA tri 839MP)|
3288668|NCT01731756|Experimental|Palmer arsenical keratosis (study)|Leaf extract of A. indica plus salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
3288669|NCT01731756|Placebo Comparator|Palmer arsenical keratosis (control)|Salicylic acid (6%) in petroleum jelly base will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks
3288670|NCT01731769|Active Comparator|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
3288671|NCT01731769|Experimental|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
3288672|NCT01731782|Active Comparator|bupivacaine|bupivacaine-0.5ml/kg of 25% bupivacaine for maximum of 30ml
3288673|NCT01731782|Placebo Comparator|normal saline|Normal saline placebo-0.5ml/kg of 0.9% normal saline (max of 30ml)to mimic bupivacaine
3288674|NCT01731795|No Intervention|No dexamethasone|Patients will be treated with conventional treatment
3288675|NCT01731795|Active Comparator|Dexamethasone|Conventional treatment plus dexamethasone
3288676|NCT01731808|No Intervention|Standard care|All participants received three specially-developed brochures with information regarding the diabetic foot condition. The brochures contained explanations to a) the cause and warning signs of diabetic foot ulcers, b) the precautions patients can take in their daily life, and c) helpful foot gymnastics to be practiced at home. The participants who were randomized in the control group received standard care. Standard care consisted of either physician-prescribed inpatient or outpatient wound care.
3288677|NCT01731808|Experimental|Nursing counseling|
3288678|NCT01731821|Experimental|Nonstented stump-closed anastomosis|Nonstented stump-closed anastomosis is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3288679|NCT01731821|Active Comparator|Duct-to-mucosa anastomosis|Duct-to-mucosa technique is used for pancreaticojejunostomy after pancreaticoduodenectomy.
3288680|NCT01731834|Active Comparator|Aspiration of secretion|10 children are evaluated at rest, during and after aspiration technique secretion
3288681|NCT01731834|Experimental|Vibrocompression|10 children will be assessed at rest, during and after the maneuver vibrocompression
3288682|NCT01731847|Experimental|The combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
3288683|NCT01731860|Experimental|Patients receiving PET/CT|Patients already scheduled for a clinically necessary PET/CT scan.
3288684|NCT01731899||agomelatine|patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
3288685|NCT01731925|Experimental|Sunitinib|Sunitinib 37.5 mg daily. Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
3288686|NCT01731925|Placebo Comparator|Placebo|Placebo (for sunitinib). Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
3288687|NCT01731964|Experimental|WA- NG Telescope Prothesis|Implantable Miniature Telescope for end stage AMD
3288688|NCT01731977|Experimental|Strengths-based family psychoeducation|Family psychoeducation in addition to treatment as usual
3288689|NCT01731977|No Intervention|Waiting list|Treatment as usual
3288690|NCT01732003|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3288691|NCT01732003|Placebo Comparator|Placebo Pill|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3288692|NCT01732016|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric (sea-level atmospheric pressure) hypoxia (low oxygen) by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (around 4500 m).
3288693|NCT01732029|Other|Normobaric hypoxia chamber|Study subjects will be put into a hypoxic state by exposing them to normobaric hypoxia by administrating an air mix containing a reduced O2 concentration. This is achieved in a hypoxia chamber where O2 concentration is gradually reduced to simulate high altitude (about 4500 m).
3288694|NCT01732055|Active Comparator|Partner-Assisted Interpersonal Psychotherapy|Partner-Assisted Interpersonal Psychotherapy is an 8-week series of psychotherapy sessions attended by the patient and her identified partner.
3288695|NCT01732055|Other|Treatment as Usual|Treatment prescribed for subjects by the UNC Perinatal Psychiatry clinic physicians according to the clinic algorithm.
3288696|NCT01732068|Experimental|Corifollitropin alfa+hMG|
3288697|NCT01732081||Patients with chronic hepatitis B virus infection|Patients chronically infected with hepatitis B virus (HBV), and followed in university hospital of Strasbourg, France
3288698|NCT01732094|Experimental|Corifollitropin Alfa + hMG|
3288699|NCT01732120|Experimental|Off-clamp partial nephrectomy|Partial nephrectomy will be performed without clamping of the renal blood vessels.
3288700|NCT01732120|No Intervention|Traditional partial nephrectomy|Partial nephrectomy will be performed with clamping of the renal blood vessels.
3288701|NCT01732133|Experimental|Measurement of arterial pressure|
3288702|NCT01732146|Active Comparator|Erythropoietin beta|1000 to 1500 U/kg/dose X 3 every 24 hours
3288703|NCT01732146|Placebo Comparator|Placebo|0.2 ml saline solution X 3 given every 24 hours
3288704|NCT01732159|Experimental|Administration of the checklist|Patients will be contacted by phone for administration of the checklist
3288705|NCT01732159|No Intervention|No contact by phone|Patients who will not be contacted by phone
3288706|NCT01732172|Experimental|Patient Group|Patient with urethritis
3288707|NCT01732172|Other|Control group|Subjects with no urethritis and no history urogenital infection
3288708|NCT01732185|Other|Patient|congenital cystic adenomatoid malformations
3288709|NCT01732198|Experimental|NU300 and Prevnar 13|NU300 at a single dose of 0.5 mL IM
3288710|NCT01732198|Active Comparator|ActHIB and Prevnar 13|ActHIB at a dose of 0.5 ml IM
3288711|NCT01732224|Experimental|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
3288712|NCT01732224|Active Comparator|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
3288713|NCT01732237|Experimental|JNJ-42396302|Patients will receive JNJ-42396302 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3288714|NCT01732237|Experimental|JNJ-42692507|Patients will receive JNJ-42692507 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3288715|NCT01732237|Experimental|JNJ-53773187|Patients will receive JNJ-53773187 100 micrograms as a single oral dose after an overnight fast of at least 10 hours.
3288716|NCT01732250|Experimental|Colistin and Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
3288717|NCT01732250|Active Comparator|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function
3288718|NCT01732276|Experimental|gefitinib|gefitinib tablet 250mg/day by mouth until disease progression
3288719|NCT01732289|Experimental|A|
3288720|NCT01732302|Experimental|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
3288721|NCT01732302|No Intervention|Delayed educational intervention|Primary health care centers in the delayed intervention group will receive the same intervention as described above with 9 months delay.
3288722|NCT01732315|Experimental|Vaccination Email Reminder|This group of parents in the study will receive email notifications about due/overdue vaccines for their adolescents. Vaccination records will be reviewed to identify adolescent patients in both practices who are newly eligible for a vaccine and/or overdue for a vaccine at the start of every other month. Email notifications will then be sent to the parents of these children.
3288723|NCT01732315|No Intervention|Usual Care|This group of parents in the study will not receive email notifications about due/overdue vaccines for their adolescents.
3288724|NCT01732328|Placebo Comparator|placebo|Inactive pill (microcrystalline cellulose and corn starch) taken daily
3288725|NCT01732328|Active Comparator|Calcium plus vitamin D|600mg of calcium and 200 international units (IU) vitamin D taken daily
3288726|NCT01732341|Experimental|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
3288727|NCT01732341|Active Comparator|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
3288728|NCT01732367|Active Comparator|Lamivudine plus adefovir|Continue lamivudine/adefovir add on treatment (standard treatment)
3288729|NCT01732367|Experimental|Tenofovir|Switch from lamivudine/adefovir add on treatment to tenofovir monotherapy
3288730|NCT01732380|Active Comparator|Radiotherapy|Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
3288731|NCT01732380|Experimental|Raltitrexed/Oxaliplatin Plus Radiotherapy|Raltitrexed 2.5mg/㎡ d1,Oxaliplatin 100mg/㎡ d1,q21d Plus Radiotherapy 2.0Gy/day, 5 times/week,6 weeks In Subjects With Inoperable esophageal cancer
3288732|NCT01732393|Active Comparator|oral quercetin capsules|Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks
3288733|NCT01732393|Placebo Comparator|oral placebo capsules|Patients in the placebo group received two placebo capsules containing lactose .
3288734|NCT01732497|Experimental|Single Group miraDry Treatment|This is a single group study where each enrolled subject will receive active miraDry treatment in each axilla.
3288735|NCT01732523||No treatment|No intervention
3288736|NCT01732562|No Intervention|Control|Patient receives the standard of care.
3288737|NCT01732562|Experimental|Patient e-Learning educational tool|Patient receives the standard of care and access to patient e-Learning educational tool.
3288738|NCT01732575|Experimental|Enrichment|Enrichment with meaning-generating activities
3288739|NCT01732575|No Intervention|Rehabilitation as usual|The ongoing, normal day center program.
3288740|NCT01732601|Experimental|Intensive Outpatient CBT|Intensive CBT for both parents and adolescents as well as family sessions to increase communication.
3288741|NCT01732601|Active Comparator|Standard Care|Standard Treatment in the Community
3288742|NCT01732614|Experimental|Topcon Endpoint Management Laser|
3288743|NCT01732653|Experimental|TT+VR|The training will consist of walking on the treadmill while negotiating obstacles in a virtual reality simulation.Training will be provided3 times a week for a duration of 6 weeks (total of 18 sessions).
3288744|NCT01732653|Active Comparator|TT alone|The training will consist of walking on the treadmill 3 times a week for a duration of 6 weeks (total of 18 sessions).
3288745|NCT01732666|Placebo Comparator|group L|receives 100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
3288746|NCT01732666|Placebo Comparator|group H|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
3288747|NCT01732666|Experimental|group N|20mg of nefopam mixed in 100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
3288748|NCT01732679||stroke patients|specialized rehabilitation in a multidisciplinary team, Sunnaas International Network
3288749|NCT01732705|Experimental|HIT (trained leg) DM|High intensity interval training for one leg (trained leg) (randomized) in patient with type 2 diabetes
3288750|NCT01732705|No Intervention|Control leg, DM|Control leg (untrained leg)in patient with type 2 diabetes
3288751|NCT01732705|Experimental|HIT (trained leg), Control subject|High intensity interval training for one leg (trained leg) (randomized) in control subject
3288752|NCT01732705|No Intervention|Control leg, Control subject|Control leg (untrained leg)in control subject
3288753|NCT01732731|Experimental|treadmill training|children will receive home-based treadmill training with supervision from a physical therapist
3379095|NCT00445627||Healthy Lean Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
3379096|NCT00445627||Overweight Obese Controls|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
3379097|NCT00445627||Type 1 Diabetes|Cross-sectional analyses of continuous variables (e.g. hormonal measurements, inflammatory markers, lipids, BMI, and body composition measurements) will be compared using ANOVA
3288754|NCT01732731|No Intervention|no treadmill training|children will not receive treadmill training
3288755|NCT01732744|Placebo Comparator|Physiological solution|"1)Negative Control: physiological solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3288756|NCT01732744|Active Comparator|Sodium hypochlorite|"2)active Comparator 1: Sodium hypochlorite, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3288757|NCT01732744|Active Comparator|Peroxide alkaline|"2)Active Comparator 2: Alkaline peroxide (Polident), for 5 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3379102|NCT00410241||A1|Self-referred individuals 45-65 at enrollment, 25% of whom had coronary artery disease
3379103|NCT00410241||A2|Individuals 45-65 at enrollment who self-identified as African, African-American, or Afro-Caribbean
3379104|NCT00410241||A3|Adults aged 18-65 at the time of enrollment, including subjects of both sexes, who have been identified as likely to return for follow up
3379105|NCT00410241||B|Family members of Group A1, A2, or A3
3379106|NCT00397280||1|Any healthy donors meeting inclusion/exclusion criteria
3379113|NCT00368446||1|Normal
3379114|NCT00368446||2|Patients with Genetic Disorders of Mucociliary Clearance
3379115|NCT00362843||healthy volunteers|healthy volunteers
3379116|NCT00362843||patients|Patients with Fragile X Syndrome
3379117|NCT00361829||Ecologic/Community|Married women, infants, caregivers, Japanese-American, Argentine-American
3379118|NCT00359684||Cystinosis|Patients with a diagnosis of cystinosis
3379120|NCT00353782||Dyslipidemia|Dyslipidemia
3379121|NCT00352924||Cohort of Agricultural Workers|Cohort of Agricultural Workers
3379125|NCT00342888||Childhood Leukemia Cases|Cases were diagnosed at 9 hospitals in Northern California
3379126|NCT00342888||Matched Controls|Controls were matched on age, gender and race/ethnicity from birth certificates in Northern California
3379127|NCT00342797||Retinoblastoma cohort|Retinoblastoma patients treated at two hospitals in New York and one hospital in Boston from 1914-2006 who survived at least one year after their retinoblastoma diagnosis.
3379128|NCT00342732||non-diabetic volunteers|non-diabetic volunteers aged 18-65 who are healthy as determined by medical history, physical examination, and laboratory tests
3379129|NCT00342667||1|patients with preterm labor/contractions and preterm premature rupture of membranes
3379131|NCT00342589||Healthy Volunteers|Individuals exposed to environmental or person- to-person sources of organisms, including healthy volunteers, health care professionals, patient families, or other patients in health care facilities
3379132|NCT00342589||Patients|Patients immunosuppressed with acute pneumonia and are undergoing or have undergone a clinically indicated procedure to obtain a respiratory sample for diagnostic purposes.
3379133|NCT00342550||Pregnant Women|Pregnant women aged 15 and older between 20 and 35 weeks with singleton gestation
3379135|NCT00342277||Pregnant Women|Consecutive pregnant women admitted with either: Preterm labor/delivery/PROM. Termdelivery without labor/spontaneous labor /chorioamnionitis/failed labor leading to c-section
3379136|NCT00342264||1|The study cohort will be comprised of underground, and surface workers (excluding administrative workers) who have been employed in the candidate non-metal mines for at least one year during the period between the date of dieselization of each mine and December 31, 1996.
3288758|NCT01732744|Experimental|Castor bean solution|"3)Experimental: castor bean solution, for 20 minutes~All the volunteers used one of the four chemical methods (interventions) in a random sequence for a period of 07 days each. Between each period of use, there was a one week wash out period during which the patient performed his/her habitual cleaning procedure, in order to avoid a carry-over effect."
3288759|NCT01732848||Subjects treated with BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of BMS-986094/INX-08189 was administered
3288760|NCT01732848||Subjects treated with Placebo matching BMS-986094/INX-08189|Subjects who participated in a clinical trial in which at least 1 dose of Placebo matching BMS-986094/INX-08189 was administered
3288761|NCT01732861|Experimental|CC-292 + Lenalidomide|
3288762|NCT01732887|Other|Immediate cognitive fitness training|"After the initial baseline evaluation, the immediate treatment group participants will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants in this group will switch to a 20 week no intervention period where they receive only standard of care treatment."
3288763|NCT01732887|Other|Delayed cognitive fitness training|"After the initial baseline evaluation, the delayed cognitive fitness training group participants will receive only standard of care for 10 weeks (no intervention period). Starting in week 11, participants in this arm will receive individualized multi-domain cognitive training and standard of care. Cognitive training includes at least 1/2 hour per session, 3 days per week, throughout the 10 week interval. After 10 weeks of cognitive fitness training, participants will go for another 10 weeks with only standard of care treatment."
3288764|NCT01732900|Active Comparator|Morphology|Embryos selected for transfer will be based on morphology alone.
3288765|NCT01732900|Experimental|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
3288766|NCT01732939||AT|Docetaxel 75 mg/m2, day 1 or paclitaxel 175mg/m2 day 1 plus Epirubicin 75 mg/m2, day 1 or doxorubicine 50mg/m2 day 1 for 6-8 cycles
3288767|NCT01732939||AT-NP|docetaxel 75mg/m2,day 1 or paclitaxel 175mg/m2,day 1 plus doxorubicine 50mg/m2,day 1 or epirubicin 75mg/m2, day 1,for3-4 cycles then switch to vinorelbine 25mg/m2, day 1 and day 8 plus cisplatinum 75mg/m2, day 1 for 3-4 cycles
3288768|NCT01732952||regions,hospitals,age, gender, risk levels, comorbidity,|
3288769|NCT01732965|Placebo Comparator|NB-UVB phototherapy|NB-UVB alone
3288770|NCT01732965|Experimental|phototherapy and photochemotherapy|NB-UVB and PUVA
3288771|NCT01732978|Other|Babies|Any child born in the University Hospital of Saint Etienne (inborn) whatever its term birth, hospitalized in a neonatal unit at the time of registration (after 37 weeks of gestation for preterm infants) or maternity
3288772|NCT01732991|Experimental|prostatic photo-vaporization|prostatic photo-vaporization (PVP) surgery with laser Greenlight
3288773|NCT01733004|Experimental|Arm A|MM-141 monotherapy
3288774|NCT01733004|Experimental|Arm B|MM-141 and Everolimus
3288775|NCT01733004|Experimental|Arm C|MM-141 and Abraxane and Gemcitabine
3288776|NCT01733017|Experimental|sodium reduction, omega-3, lycopene|combination of dietary sodium restriction with supplementation of omega-3 capsules and lycopene containing juices or foods
3288777|NCT01733017|Placebo Comparator|Control|Limited nutritional counseling, juice without lycopene, rice oil capsules
3288778|NCT01733030||250 mg Seromycin|Healthy adults who will receeve one administration of 250 mg of Seromycin prior to the start of the study.
3288779|NCT01733030||500 mg Seromycin|Healthy adults who will recieve one administration of 500 mg of Seromycin prior to the start of the study.
3288780|NCT01733030||Placebo|Healthy adults who will receive one administration of a placebo pill prior to the start of the study.
3288781|NCT01733043|Experimental|Dexmedetomidine infusion|Dexmedetomidine 0.5 mcg/kg loading dose administered over 20 minutes, followed by 0.6 mcg/kg/hr infusion for 1 hour and 40 minutes
3288782|NCT01733043|Placebo Comparator|Placebo|Normal saline infusions will be administered over 4 hours at rates mimicking the DEX infusion rate
3288783|NCT01733082||Cohort|
3288784|NCT01733095|Experimental|ambrisentan|In all patients with clinically significant PoPH, ambrisentan will be administered orally using a low ascending dose regime (see below). Duration of treatment will be 12 months.
3288785|NCT01733108|Experimental|Canagliflozin (JNJ-28431754) + glyburide|Each volunteer will receive a single dose of glyburide on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 4 through 8. On Day 9 volunteers will receive a single dose of glyburide in combination with a single dose of canagliflozin.
3288786|NCT01733134|Experimental|Standard therapy plus Tolvaptan|Patient in the interventional group will receive tolvaptan in addition to standard therapy
3288787|NCT01733134|Placebo Comparator|Standard therapy plus placebo|
3288788|NCT01733147|Placebo Comparator|Placebo|Subjects will be placed on 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal.
3288789|NCT01733147|Active Comparator|Omega-3 free fatty acids|Subjects will be placed on 3 capsules a day of Omega 3 free fatty acids taken orally for six months. Subjects will take 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
3288790|NCT01733173||mass in posterior fossa, either benign or malignant|A pilot study will be performed. We will perform fMRI and DTI in children before and after surgery for posterior fossa brain tumors. Each subject will receive the standard of care for their brain tumors in terms of surgical resection, radiation therapy and/or chemotherapy.
3288791|NCT01733199|Experimental|BA-|Patient with no secondary behavioural addiction
3288792|NCT01733199|Experimental|BA+/DDS-|Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
3288793|NCT01733199|Experimental|BA+/DDS+|Patients with secondary behavioural addiction and dopamine dysregulation syndrome
3288794|NCT01733290|Experimental|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
3288795|NCT01733290|Placebo Comparator|Control arm-Normal saline instillation|Normal saline instillation
3379137|NCT00341939||1/Cancer Patients|Cancer patients previously enrolled on IRB approved clinical trials at NCI
3288796|NCT01733303|Experimental|Exercise|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality.
3288797|NCT01733342|Active Comparator|Celsite|patients received celsite chemoport implantation under local anesthesia
3288798|NCT01733342|Experimental|Humanport|patients received Humanport chemoport implantation under local anesthesia
3288799|NCT01733355|Experimental|Tau diagnostic|[F18] T807
3288800|NCT01733381||Barefoot runners|This group of individuals will run in minimally shod foot ware. For the purposes of this study we have defined this to be Vibram Five Finger shoes. Participants will be runners who consistently run in these shoes at least 20 miles per week.
3288801|NCT01733381||Shoed runners|This group of individuals will run in normal running shoes. Participants will be runners who consistently run in regular running shoes (that are not considered by industry standards to be minimal shoes) at least 20 miles per week.
3288802|NCT01733394|Experimental|Generic A - Generic B - Brand - Generic A - Brand - Generic B|Sequence 1
3288803|NCT01733394|Experimental|Generic B - Brand - Generic A - Generic B - Generic A - Brand|Sequence 2
3288804|NCT01733394|Experimental|Brand - Generic A - Generic B - Brand - Generic B- Generic A|Sequence 3
3288805|NCT01733446|No Intervention|Standard anesthesia regimen|Positive pressure ventilation will be stopped at the same time infusions of anesthetic agents and spontaneous ventilation employed until emergence from anesthesia is observed. (This is standard protocol for everyday anesthesia management of this population.)
3288806|NCT01733446|Experimental|Continuation of High Frequency Jet Ventilation ( HFJV)|In Group B after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
3288807|NCT01733459|Experimental|Treatment I|1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)
3288808|NCT01733459|Active Comparator|Treatment II|1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)
3288809|NCT01733485|Active Comparator|Aspirin|
3288810|NCT01733485|Active Comparator|Indomethacin|
3288811|NCT01733485|No Intervention|Control|
3288812|NCT01733511||admitted to emergency department|
3288813|NCT01733511||patients admitted to surgical ward|
3288814|NCT01733524|Sham Comparator|Picture of a fish|Participants will receive a picture of a betta fish.
3288815|NCT01733524|Active Comparator|Pet fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
3288816|NCT01733537|Experimental|Vest and Education|Motorcycle Taxi Drivers provided with a reflective, fluorescent vest and basic education about recommended measures to increase their visibility
3288817|NCT01733537|Other|Education Alone|Motorcycle Taxi Drivers provided with basic education about recommended measures to increase their visibility
3288818|NCT01733550||Glaucoma patients|Intraocular pressure is measured by Home iCare performed by the study nurse, by the patient it self and by Goldmann applanation tonometry.
3288819|NCT01733563|Experimental|fructose sweetened beverage|"Soft drink consumption:~Subjects have to drink a fructose sweetened beverage (3x 200ml per day, 13.3g fructose/100ml) during 7 weeks"
3288820|NCT01733563|Experimental|glucose sweetened beverage|"Soft drink consumption:~Subjects have to drink a glucose sweetened beverage (3x 200ml per day, 13.3g glucose/100ml) during 7 weeks"
3288821|NCT01733563|Experimental|sucrose sweetened beverage|"Soft drink consumption:~Subjects have to drink a sucrose sweetened beverage (3x 200ml per day, 13.3g sucrose/100ml) during 7 weeks"
3288822|NCT01733563|Experimental|No change of eating habits|"No Soft drink consumption (no soft drink diet):~Subjects do not change their eating habits during 7 weeks"
3288823|NCT01733576|Sham Comparator|Sham HD-tDCS|
3288824|NCT01733576|Active Comparator|Active HD-tDCS 1|
3288825|NCT01733576|Active Comparator|Active HD-tDCS 2|
3288826|NCT01733576|Active Comparator|Active HD-tDCS 3|
3288827|NCT01733589|Experimental|Recombinant Human Endostatin|All patients received recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7. During week 2 through 8, patients received etoposide 50mg/m2 days 1-5 and cisplatin 50mg/m2 on day 1,8, every 4 weeks for two cycles with concurrent thoracic radiation at 60~66Gy in 30~33 fractions for 6~7 weeks.
3288828|NCT01733602|Experimental|active tDCS and cognitive training|Transcranial direct current stimulation combined with cognitive training
3288829|NCT01733602|Active Comparator|sham tDCD and cognitive training|Sham transcranial direct current stimulation combined with cognitive training
3288830|NCT01733615||Mucopolysaccharidosis IVA|Patients with the condition.
3288831|NCT01733654|Active Comparator|RO4995819 5mg|RO4995819 5mgX6wks
3288832|NCT01733654|Active Comparator|RO4995819 15mg|RO4995819 15mg X 6 weeks
3288833|NCT01733654|Active Comparator|RO4995819 30mg|RO4995819 30mg X 6 weeks
3288834|NCT01733654|Placebo Comparator|Placebo|Placebo X 6 weeks
3288835|NCT01733667|Experimental|MediENT|Right or left sinus cavity where MediENT will be place after randomization.
3288836|NCT01733667|Active Comparator|MeroPack|Right or left sinus cavity where MeroPack will be placed after randomization of MediENT is assigned.
3288837|NCT01733693|Experimental|Buprenorphine|Oral sublingual tablet, 8-32 mg per day, administered daily for duration of 4 months
3288838|NCT01733693|Active Comparator|Methadone|Oral sublingual tablet, 60-100 mg per day, administered daily for duration of 4 months
3288839|NCT01733706|Active Comparator|Standard counseling|a psychologist will provide standard counseling
3288840|NCT01733706|Experimental|No nicotine electronic cigarette|patients will receive standard counseling as well as an electronic cigarette
3288841|NCT01733719|Active Comparator|ER plus RFA|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or RadioFrequency Ablation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
3288842|NCT01733719|Active Comparator|ER plus APC|Initial Endoscopic Resection of visible neoplasia/HGD in Barrett's esophagus followed by 4 x 2 monthly interventions (either ER of residual/metachronous visible lesions or Argon Plasma Coagulation of 'flat' dysplastic or non-dysplastic Barrett's esophagus)
3288843|NCT01733771||CAM with standard care|Symptomatic hospitalized people referred by the medical team to CAM treatments on top of standard of care
3288844|NCT01733771||Standard care only|Symptomatic patients who are referred to CAM treatments but are not interested in such treatments
3288845|NCT01733784|Experimental|Viscoelastic properties of the airway|
3288846|NCT01733797|Experimental|Wooden spatula|
3288847|NCT01733797|Experimental|Therabite|
3288848|NCT01733810|Experimental|Reflux Patients|Patients with reflux and a prior history of reflux esophagitis are being enrolled. The intervention is cessation of acid-suppressing medications.
3288849|NCT01733823|Experimental|Group A|Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3288850|NCT01733823|Experimental|Group B|PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3288851|NCT01733823|Experimental|Group C|PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3288852|NCT01733823|Experimental|Group D|PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
3288853|NCT01733836|Experimental|Metformin|850mg BID
3288854|NCT01733836|Placebo Comparator|Placebo|
3288855|NCT01733849||Group Bulgaria|Subjects in this group include infants/children from Bulgaria, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
3288856|NCT01733849||Group Latvia|Subjects in this group include infants/children from Latvia, less than five years of age with home visits by the GP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for the treatment of AGE.
3288857|NCT01733862||Group Japan|Children less than five years of age, hospitalized for RV GE or AGE and children with outpatient or emergency room visits for RV GE or AGE, between November 2007 and October 2016 (i.e., before and after the introduction of RV vaccination in Japan) in any of the selected hospitals.
3288858|NCT01733875|Experimental|CC-220 0.03 mg|
3288859|NCT01733875|Experimental|CC-220 0.1 mg|
3288860|NCT01733875|Experimental|CC-220 0.3 mg|
3288861|NCT01733875|Experimental|CC-220 1 mg|
3288862|NCT01733875|Experimental|CC-220 2 mg|
3288863|NCT01733875|Experimental|Placebo|In each arm, 6 subjects will receive a dose of CC-220 and 2 subjects will receive placebo depending on the randomization schedule.
3288864|NCT01733875|Experimental|CC-220 4 mg|
3288865|NCT01733875|Experimental|CC-220 6 mg|
3288866|NCT01733875|Experimental|CC-220 1 mg (Part 2 only)|
3288867|NCT01733888|Active Comparator|Office Bleaching|
3288868|NCT01733888|Experimental|Resin Infiltration|
3288869|NCT01733888|Experimental|Resin Infiltration twice|
3288870|NCT01733888|Experimental|Office Bleaching + Resin Infiltration|
3288871|NCT01733901|Active Comparator|RSD+PCI+Medicine|We will recruit 300 randomised CHD patients who meet the inclusion criteria. First undergo percutaneous coronary intervention, and then perform the renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. After renal sympathetic denervation traditional secondary prevention of coronary heart disease is recommend. Finally we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
3288872|NCT01733901|Placebo Comparator|PCI+Medicine|We aslo will recruit 300 randomised CHD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will perform percutaneous coronary intervention firstly, then give traditional secondary prevention of coronary heart disease just like the RSD+PCI+Medicine group. Third we will conduct a clinic follow-up every six month and a telephone follow-up every three month(Total 24 months).
3288873|NCT01733914|Experimental|Acupuncture|Experimental group
3288874|NCT01733914|Sham Comparator|Waiting list|Control group
3288875|NCT01733927|Experimental|Rapid testing for HIV|The intervention consisted in administer an oral rapid test for HIV (OQA) to people that also had taken an ELISA test to compare their tests results. Group 1 consisted of 344 participants who did not know their HIV status; Group 2 consisted of 153 participants who were previously confirmed to be HIV positive. The participants were instructed to obtain their own oral fluid sample using the testing devices provide by the OQA rapid test kits. Project team members, certified to interpret OQA results, registered each test outcome on a data form using the same code number that the participant was assigned for the ELISA test.
3288876|NCT01733940|Experimental|"Tegaderm CHG Dressing"|This arm is receiving a clorhexidine dressing for intravascular catheters.
3288877|NCT01733940|Active Comparator|"Tegaderm IV dressing"|Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.
3288878|NCT01733966|Experimental|Secnidazol-Ciprofloxacin|2g(single dose) of Secnidazol associated with 1g(2 doses of 500mg)of Ciprofloxacin during 3 days
3288879|NCT01733966|Active Comparator|Amoxicillin-Clavulanic Acid|3g (3 doses of 1g) of Amoxicillin-Clavulanic acid during 10 days
3288880|NCT01733979|Experimental|Heme-Iron Polypeptide|
3288881|NCT01733979|Placebo Comparator|Placebo|
3288882|NCT01733979|Active Comparator|Heme-Iron|
3288883|NCT01733979|Active Comparator|Organic Iron|
3288884|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3288885|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3288886|NCT01733992|Active Comparator|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single (1 day) and multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3288887|NCT01733992|Placebo Comparator|Placebo|Placebo, single (1 day) or multiple ascending dose (13 days) followed by a single dose on the fourteenth day.
3288888|NCT01734005|Experimental|Red Ginseng|
3288889|NCT01734005|Placebo Comparator|Placebo|
3288890|NCT01734018||Cohort|
3288891|NCT01734044|Experimental|combination treatment group|100 enrolled patients are randomly picked up to take rhTPO in combination with dexamethasone at the indicated dose.
3288892|NCT01734044|Active Comparator|single treatment group|100 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
3288893|NCT01734057|Experimental|combinant treatment group|120 enrolled patients are randomly picked up to take Rituximab in combination with rhTPO at the indicated dose.
3288894|NCT01734057|Active Comparator|single treatment group|120 enrolled patients are randomly picked up to take dexamethasone at the indicated dose.
3288895|NCT01734070|Experimental|Cherry consumption|Volunteers will supplement their diets with 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories. We will prefer that the subjects split the cherries into three equal portions and consume one with each meal; however, this will not be mandatory.
3288896|NCT01734083|Experimental|Whole body vibration exercise|The experimental group will receive 2 sessions of whole body vibration exercise training and conventional exercise per week for a period of 9 weeks. The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration frequency and amplitude used will be 30 Hz and 1 mm, respectively.
3288897|NCT01734083|Active Comparator|Conventional exercise|This group will receive 2 sessions of conventional exercise training per week for a period of 9 weeks.
3288898|NCT01734096|Active Comparator|control group|healthy volunteer
3288899|NCT01734096|Active Comparator|obesity group|Patients with BMI >30 Kg/m2
3288900|NCT01734096|Active Comparator|white coat hypertension group|Patients with office blood pressure >140/90 mmHg and ambulatory daytime blood pressure <135/85 mmHg
3288901|NCT01734096|Active Comparator|Resistant hypertension|Patients with ambulatory blood pressure > 135/85 mm Hg (day) or >120/70 mm Hg (night) with 3 antihypertensive drugs with direct observance of drug taking.
3288902|NCT01734109|Placebo Comparator|Standard of Care - Wound Care|Standard, acceptable local wound care management, consisting of topical treatments, chemical debriders, or light bedside debridement.
3288903|NCT01734109|Active Comparator|Quantum NPWT|Intervention with Quantum NPWT to Standard III/IV pressure ulcers for 12 weeks.
3288904|NCT01734109|Active Comparator|Quantum NPWT with Irrigation|NPWT with the Quantum device, with the addition of simultaneous irrigation using 0.25% acetic acid.
3288905|NCT01734122||Essential Tremor|Patients with severe, medication-refractory Essential Tremor
3288906|NCT01734122||Parkinsonian Tremor|Patients with severe, medication-refractory, tremor-dominant Parkinsons
3288907|NCT01734135|No Intervention|Usual Care|Usual care
3288908|NCT01734135|Experimental|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
3288909|NCT01734148|Experimental|Experimental group (RELAX TO SLEEP program)|
3288910|NCT01734148|No Intervention|Control group (Usual Care)|
3288911|NCT01734174||cardiac patients|Patients having elective coronary artery bypass grafting surgery, valve repair or replacement surgery, aortic repair or replacement surgery, or any combination of these surgeries will be recruited for this study to validate measurements of left ventricular volume and ejection fraction (a quantitative measure of general heart function) as assessed by 3-dimensional transesophageal echocardiography (3D TEE) as compared to 3-dimensional transthoracic echocardiography (3D TTE). Secondarily, we will also compare the 3D TEE assessment to the 2D TEE and TTE assessment, which is routinely performed simultaneously. Last, we will compare this assessment to a third method of quantification of cardiac function via a pulmonary artery catheter using thermodilution.
3288912|NCT01734187|Experimental|Fermented Cinnamon Vine Powder|
3288913|NCT01734187|Placebo Comparator|Placebo|
3288914|NCT01734200|Experimental|Eriobotyra Japonica Lindley Extract|
3288915|NCT01734200|Placebo Comparator|Placebo|
3288916|NCT01734213|Experimental|Eriobotyra Japonica Lindley Extract|
3288917|NCT01734213|Placebo Comparator|Placebo|
3288918|NCT01734226|Experimental|Prunus Mume Extract|
3288919|NCT01734226|Placebo Comparator|Placebo|
3288920|NCT01734252|No Intervention|Standard Treatment|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be contin-ued and, if necessary increased. Hereby the maximum heparin dose is 1.500 IU per hour.
3288921|NCT01734252|Experimental|Treatment with Argatroban|If a Heparin resistance appears and the patient meets the inclusion and exclu-sion criteria, he/she will be enrolled. The Heparin administration will be stopped and Argatroban will be given and adjusted until the target aPTT-range is achieved.
3288922|NCT01734265|Experimental|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|Depigoid 50%Grasses/ 50% Olea europaea (2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
3288923|NCT01734265|Experimental|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|Depigoid 50%Grasses/ 50% Parietaria judaica(2.000 DPP/ml) The administration regimen will consist of a rush build-up regimen: 0.2 ml followed by 0.3 ml after 30 minutes if no adverse events occur a second maintenance dose of 0,5 ml 4 weeks later.
3288924|NCT01734278||Asenapine|Patients prescribed asenapine for any indication.
3288925|NCT01734291|Active Comparator|Family psychoeducation plus TAU|Family psychoeducational therapy in addition to treatment as usual for the patients.
3288926|NCT01734291|Placebo Comparator|Treatment as usual(TAU)|Treatment as usual administered by physician and counseling administered by nurse.
3288927|NCT01734304|Experimental|DC vaccination|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
3288928|NCT01734330|Experimental|Cognitive behavior therapy|Cognitive behavior therapy for 6 weeks associated to nicotine replacement for 12 weeks
3288929|NCT01734330|Other|Nicotine replacement|Nicotine replacement for 12 weeks
3288930|NCT01734343|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
3288931|NCT01734343|Other|PhysIOL microAY|eyes with implanted intraocular lens PhysIOL microAY
3288932|NCT01734356|Other|inherited arrhythmias|6 patient with inherited arrhythmias
3288933|NCT01734356|Other|valvulopathies|6 patient with valvulopathies
3288934|NCT01734356|Other|controle|8 healthy people for these pathologies
3288935|NCT01734408|Experimental|alum-adjuvant 160U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 160U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
3288936|NCT01734408|Placebo Comparator|placebo A|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 160U/0.5ml EV71 vaccines one year before.
3288937|NCT01734408|Experimental|alum-adjuvant 320U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 320U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
3288938|NCT01734408|Placebo Comparator|placebo B|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 320U/0.5ml EV71 vaccines one year before.
3288939|NCT01734408|Experimental|alum-adjuvant 640U /0.5ml EV71 vaccine|A booster dose of alum-adjuvant 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
3288940|NCT01734408|Placebo Comparator|placebo C|A 0/0.5ml placebo in 80 children whom had received two doses of alum-adjuvant 640U/0.5ml EV71 vaccines one year before.
3288941|NCT01734408|Experimental|adjuvant-free 640U /0.5ml EV71 vaccine|A booster dose of adjuvant-free 640U /0.5ml EV71 vaccine in 160 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
3288942|NCT01734408|Placebo Comparator|placebo D|A 0/0.5ml placebo in 80 children whom had received two doses of adjuvant-free 640U/0.5ml EV71 vaccines one year before.
3288943|NCT01734421|Other|Control group|Habitual deshabituation in the control group following the guidelines of the primary health care institution.
3288944|NCT01734421|Active Comparator|Cell phone Aplication for Smarth Phone|Cell phone 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation which includes mobile APPs application
3288945|NCT01734447|Experimental|1.2, continuous treatment|
3288946|NCT01734447|Experimental|1.2, non-continuous treatment|
3288947|NCT01734447|Experimental|2.4, non-continuous treatment|
3288948|NCT01734460||third trimester pregnant women|no intervention
3288949|NCT01734473|Experimental|Study day 1|Hydrolyzed casein protein. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3288950|NCT01734473|Experimental|Study day 2|Hydrolyzed casein protein + carbohydrates. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3288951|NCT01734473|Experimental|Study day 3|Hydrolyzed casein protein + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3288952|NCT01734473|Experimental|Study day 4|Hydrolyzed casein protein + carbohydrates + leucine. On each study day participants receive one out of 4 protein meals (interventions). The 4 interventions are given in a randomized order.
3288953|NCT01734473|Experimental|Study Day 5|4 levels of hydrolyzed casein protein + carbohydrates
3288954|NCT01734486|Experimental|Low dose|
3288955|NCT01734486|Experimental|High dose|
3288956|NCT01734499|Experimental|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. Quality of Life survey completed at 5 time points after informed consent."
3288957|NCT01734499|Active Comparator|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program, (2)Local support groups centered at community cancer centers, (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation.Quality of Life surveys completed at 5 time points after informed consent.
3288958|NCT01734538|Experimental|Omega-3 Complete|Oral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories, Ltd., Windsor, Ontario, Canada) per day for 12 weeks.
3288959|NCT01734538|Placebo Comparator|Placebo Capsule|Oral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
3288960|NCT01734564|Experimental|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
3288961|NCT01734564|Experimental|Hiltonol, dendritic cells and radiation|Hiltonol, dendritic cells and radiation.
3288962|NCT01734577|Active Comparator|Dry needling|Monofilament needles will be inserted into each subject's left multifidus muscle and stimulated mechanically for a local twitch response
3288963|NCT01734577|Sham Comparator|Sham needling|Monofilament tubes will be pressed into the left multifidus muscle and mechanically manipulated to give the sensation that needling is occuring.
3288964|NCT01734590|Experimental|Carbohydrate based food mix 1|Slowly digestible carbohydrate
3288965|NCT01734590|Experimental|Carbohydrate based food mix 2|Slowly digestible carbohydrate
3288966|NCT01734590|Active Comparator|Control carbohydrate based food|Rapidly digestible carbohydrate
3288967|NCT01734603|Active Comparator|conventional rehabilitation program|conventional rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with complete rest.
3288968|NCT01734603|Experimental|experimental rehabilitation program|experimental rehabilitation program 20 patients are expected in this arm. Patients perform walking treadmill exercises with active recovery (no stop walking).
3288969|NCT01734616|No Intervention|Young|Young subjects to be controlled to older individuals with interventions
3288970|NCT01734616|No Intervention|Old|Older individuals to compare to young and other older intervention groups
3288971|NCT01734616|Experimental|Old Exercise|Older individuals studied after an intervention of 20 weeks fully-supervised resistance exercise training
3288972|NCT01734616|Experimental|Old Acute Cocoa|Older individuals studied with the addition of cocoa flavanols during their acute study
3288973|NCT01734616|Experimental|Old 7 Day Cocoa|Older individuals studied after 7 day supplementation of cocoa flavanols
3379138|NCT00341874||1|Subjects with hearing loss consisting of both nonsyndromic and syndromic forms of deafness of genetic etiology
3288974|NCT01734629||Coronary CT Spirometry Cohort|Patients refereed to coronary CT enrolled in the study.
3288975|NCT01734642||PATIENT HOSPITALIZED|ALL THE PATIENTS HOSPITALIZED IN THE INVOLVED UNITS WHO GAVE THEIR INFORMED CONSENT. PATIENTS HOSPITALIZED DURING THE WEEK-END WILL BE ENROLLED ON the next MONDAY
3288976|NCT01734681|Experimental|Treatment with G-202|G-202 will be administered by intravenous infusion over one hour on Days 1, 2 and 3 of a 28-day treatment cycle. The G-202 dose will be 40 mg/m2 on Day 1 and 66.8 mg/m2 on Days 2 and 3.
3288977|NCT01734694|Active Comparator|Vancomycin|
3288978|NCT01734694|Active Comparator|Comparator|
3288979|NCT01734707|Active Comparator|Allicor|Allicor 150 mg tablet by mouth two times a day
3288980|NCT01734707|Placebo Comparator|Sugar pill|Placebo tablet 150 mg by mouth two times a day
3288981|NCT01734720||common bile duct stone|Patients undergoing cholecystectomy
3288982|NCT01734733|Experimental|NTCELL|"NTCELL 40 microcapsules (+/- 20%)~The NTCELL microcapsules are drawn up into a catheter system and introduced intracranially by stereotactic insertion into the brain under guidance by neuroimaging."
3288983|NCT01734759|Experimental|Taste Test|
3288984|NCT01734798|Experimental|Arm 1|post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks
3288985|NCT01734798|Experimental|Arm 2|adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
3288986|NCT01734798|Experimental|Arm 3|Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy
3288987|NCT01734824|Active Comparator|Teriparatide|daily subcutaneous injection of teriparatide 20µg for three months
3288988|NCT01734824|Placebo Comparator|Placebo Teriparatide|daily subcutaneous teriparatide placebo injection
3288989|NCT01734824|Active Comparator|Denosumab|one subcutaneous injection of denosumab
3288990|NCT01734824|Active Comparator|Placebo Denosumab|one subcutaneous injection of denosumab placebo
3288991|NCT01734863|Experimental|Radiotherapy Arm|"this study arm will take External Beam radiotherapy as follows :~Radiotherapy Technique: Conformal radiotherapy, Intensity modulated radiotherapy [IMRT] is allowed.~Radiotherapy Dose: 45 Gy/25 fractions/5 weeks (1.8 Gy/fraction). , the inclusion criteria are as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
3288992|NCT01734863|No Intervention|No Radiotherapy Arm|"this arm will not take radiotherapy and their inclusion criteria as following:~Age < 18 years old.~Non-metastatic Ewing Sarcoma patients who will undergo surgery and show poor histologic response to neo-adjuvant chemotherapy.~Negative surgical margins.~Patients show good safety profile and acceptable performance status."
3288993|NCT01734876|Experimental|Tactile Touch|Tactile Touch is given to the active arm
3288994|NCT01734876|Active Comparator|Rest To Music|Rest to Music. Rest for 30-60 minutes, aroma therapy, quit music in the background, well temepered room, lying position
3288995|NCT01734915||NSCLC|Subjects with advanced NSCLC, will undergo blood draw
3288996|NCT01734928|Experimental|Pomalidomide, Bortezomib and Low Dose Dexamethasone|4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression.
3288997|NCT01734928|Active Comparator|Bortezomib and Low Dose Dexamethasone|1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day [≤ 75 years old]or 10 mg/day [> 75 years old] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
3288998|NCT01734941|Active Comparator|TSO 2500|2500 TSO every other week
3288999|NCT01734941|Active Comparator|7500 TSO|7500 TSO every other week
3289000|NCT01734941|Placebo Comparator|Placebo|placebo every other week.
3289001|NCT01734954|Experimental|Sciatic nerve blockade at bifurcation|Ultrasound-guided block at the bifurcation of the sciatic nerve
3289002|NCT01734954|Experimental|Sciatic block 2 cm beyond bifurcation|Ultrasound-guided block of the sciatic nerve 2 cm beyond of the bifurcation
3289003|NCT01734967|Experimental|needle based CLE & EUS-FNA|The study will prospectively include patients referred to our department for EUS and EUS-FNA of suspected pancreatic masses during a 12 months period. The indication for this investigation will be based on the patient's clinical history and previous imaging studies (abdominal ultrasound, CT scan, MRI).
3289004|NCT01734980|Experimental|Endobronchial Ultrasound|EBUS-TBNA is a procedure that allows accurate sampling of mediastinal lymph nodes and peribronchial lesions
3289005|NCT01735006|Experimental|HPV vaccine|This dosage contains 40μg HPV 16 virus-like particle antigen and 20μg HPV 18 virus-like particle antigen adsorbed in alum-adjuvant
3289006|NCT01735006|Placebo Comparator|HEV vaccine|commercialized HEV vaccine which contains 30μg HEV antigen adsorbed in alum-adjuvant
3289007|NCT01735019|Experimental|group 1|administration of remifentanil with target-controlled infusion (TCI) system at a given concentration during anesthetic emergence
3289008|NCT01735045|Experimental|Test Group myopia control|Subjects wearing contact lenses made of LSH (mangofilcon A) Soft (hydrophilic) Contact Lens for myopia control
3289009|NCT01735045|Active Comparator|Myopia Control|Subjects wearing Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens for myopia control
3289010|NCT01735058|Active Comparator|Sodium hyaluronate|Ultrasound guided injection of sodium hyaluronate
3289011|NCT01735058|Placebo Comparator|Normal saline|Ultrasound guided injection of normal saline
3289012|NCT01735071|Experimental|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
3289013|NCT01735071|Experimental|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1-6, bevacizumab given as 1 hour infusion will be followed by carboplatin area under curve 4 (AUC 4) and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
3289014|NCT01735084|Experimental|Prevenar13|The booster dose of Prevenar13 is 0.5 mL given intramuscularly only, with care to avoid injection into or near nerves and blood vessels. The preferred sites are anterolateral aspect of the thigh (vastus lateralis muscle) in infants or the deltoid muscle of the upper arm in young children.
3289015|NCT01735084|Experimental|Synflorix|The booster vaccination schedule consists of one dose of 0.5 ml with an interval of at least 1 month between doses.
3289016|NCT01735097|Experimental|Arsenical keratosis (Study)|Vitamin E (200 mg, soft capsule) plus Nigella sativa (500 mg, soft capsule) twice daily, orally for 12 weeks
3289017|NCT01735097|Active Comparator|Arsenical keratosis (Control)|Vitamin E (200 mg, soft capsule) plus Placebo (refined oil in soft capsule with same size and color as that contains N sativa) twice daily, orally for 12 weeks
3289018|NCT01735110|Active Comparator|Femoral approach group|PCI through Femoral approach
3289019|NCT01735110|Experimental|radial approach group|PCI through radial approach
3289020|NCT01735123|Experimental|extensively hydrolyzed casein formula|The investigators plan to randomize 60 out of 120 infants to be weaned to an extensively hydrolyzed casein formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
3289021|NCT01735123|Experimental|cow's milk based infant formula|The investigators plan to randomize 60 out of 120 infants to be weaned to a cow's milk based infant formula. Recruited mothers are encouraged to breast-feed. The dietary intervention will be applied until 9 months of age. The minimum exposure time to the study formula should be 90 days. Signs of beta-cell autoimmunity, i.e. diabetes-associated autoantibodies, will be monitored in the study participants, although the study will not have sufficient power to detect statistically significant differences in the seroconversion rate between the groups due to the limited number of infants randomized.
3289022|NCT01735136|Experimental|InSan Bamboo Salt|
3289023|NCT01735136|Placebo Comparator|Placebo|
3289024|NCT01735149|Experimental|Kochujang Pills|
3289025|NCT01735149|Placebo Comparator|Placebo|
3289026|NCT01735162||Very high risk|Very high risk PICU patients are on mechanical ventilation and at least one inotrope or vasopressor at time of admission
3289027|NCT01735162||High Risk|High risk PICU patients have a history of transplantation (solid organ or bone marrow)
3289028|NCT01735162||Moderate risk|Moderate risk PICU patients are all other admissions to the ICU (may have either mechanical ventilation or inotropy/vasopressor use but not both). Cannot have a history of transplant. Minimum expected stay 48 hours.
3289029|NCT01735188||Living|
3289030|NCT01735188||Deceased|
3289031|NCT01735227|Experimental|omeprazole group|omeprazole group:all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and taking omeprazole 20mg/d(1 month).on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization due to cardiovascular disease , bleeding events) .
3289032|NCT01735227|Experimental|pantoprazole group|pantoprazole group: all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term),taking pantoprazole 20mg/d(1 month).
3289033|NCT01735240|Experimental|First AZD5069, then Ketoconazole + AZD5069|AZD5069 in first period (on 1 day) and in second period (after wash out) ketoconazole alone (on 2 days) then ketoconazole + AZD5069 (on 1 day), then again ketoconazole alone (on 2 days)
3289034|NCT01735253|Experimental|gastric bypass, duodenojejunal bypass|
3289035|NCT01735266|Active Comparator|Air colonoscopy|Air was insufflated during whole procedure of colonoscope insertion.
3289036|NCT01735266|Experimental|Whole-colon water exchange colonoscopy|The air pump was turned off before colonoscopy. During the whole procedure of the scope insertion, residual air in lumen was suctioned and 37°C (maintained with a water bath) water was infused with a peristaltic pump to obtain lumen visualization. Air was insufflated until cecum was reached or appendix opening was seen.
3289037|NCT01735266|Experimental|left-colon water exchange colonoscopy|In the left side of colon (including descending colon, sigmoid colon and rectum), water was infused instead of air to obtain lumen visualization as described above in whole-colon water exchange colonoscopy group.
3289038|NCT01735305||Antiplatelet therapy|patients with coronary artery disease receiving any antiplatelet therapy, without any intervention by the investigators.
3289039|NCT01735318|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
3289040|NCT01735318|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
3289041|NCT01735331||VEGF level|VEGF level in hysteroscopic endometrial biopsy of the patients with recurrent pregnancy loss.
3289042|NCT01735331||control group|Patients with Abnormal Uterine Bleeding
3289043|NCT01735344|Experimental|Lisinopril Tablets 40 mg|Lisinopril Tablets 40 mg of Ipca Laboratories Limited, India
3289044|NCT01735344|Active Comparator|Zestril® (Lisinopril) 40 mg Tablets|Zestril® (Lisinopril) 40 mg Tablets of AstraZeneca Pharmaceuticals LP USA
3289045|NCT01735357|Placebo Comparator|Olive oil (BP specification)|5g per day
3289046|NCT01735357|Experimental|DHA-rich oil|Fish oil supplement (total = 5g/day) providing 3.1g/day of DHA triacylglycerol, blended with olive oil
3289047|NCT01735357|Experimental|EPA-rich oil|Fish oil supplement (total = 5g/day) providing 2.9g/day of EPA triacylglycerol, blended with olive oil
3289048|NCT01735370|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
3289049|NCT01735370|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
3289050|NCT01735383|Experimental|Etodolac Tablets USP 500mg|Etodolac Tablets USP 500 mg of Ipca Laboratories Limited, India
3379144|NCT00341276||1|First, several hundred cases of esophageal cancer and gastric cancer (both cardia and body) ascertained in Taiyuan at the Shanxi Cancer Hospital.
3289051|NCT01735383|Active Comparator|Etodolac Tablets USP 500 mg|Etodolac Tablets USP 500 mg of Taro Pharmaceutical Industries Ltd., USA
3289052|NCT01735409|Experimental|1-day regimen|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
3379147|NCT00340405||Tin Miners in China at risk of lung cancer|Tin Miners in China at risk of lung cancer
3289053|NCT01735409|Experimental|2-day regimen|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
3289054|NCT01735409|Experimental|3-day regimen|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
3289055|NCT01735422|Experimental|r-hLH (825 International Units [IU])|
3379151|NCT00340015||AARP|Members of the AARP, aged 50-71 years, and who resided in one of six states
3289056|NCT01735422|Experimental|r-hLH (2750 IU)|
3379152|NCT00340002||Pregnant women|Pregnant women aged 18 years and older
3379153|NCT00339924||Physicians|Currently practicing, board certified general internists, both allopathic and osteopathic, whose offices are in the United States.
3379155|NCT00339482||American Indians|Residents of the Gila River Indian Community
3379156|NCT00339287||Healthy volunteers|Healthy adult volunteers at least 18 years of age.
3379157|NCT00339235||Non-pregnant women|Non-pregnant women aged 18 years and older
3379158|NCT00339235||Pregant women|Pregnant women aged 18 years and older
3379159|NCT00331331||Participants|Participants who were previously enrolled as part of the MUST study and patients who participate in other intramural NIH studies and agreed to participate in this study.
3379163|NCT00319579||Observation|Living Kidney Donors with controls who have not donated a kidney and meet certain criteria at the time of the donor's donation (i.e. no hypertension, no kidney disease, etc.).
3289057|NCT01735422|Experimental|r-hLH (5500 IU)|
3289058|NCT01735422|Experimental|r-hLH (11000 IU)|
3289059|NCT01735422|Experimental|r-hLH (22000 IU)|
3289060|NCT01735422|Active Comparator|u-hCG (5000 IU)|
3289061|NCT01735435|No Intervention|Group 2 (Control group)|Group 2(Control group)-patients in this group received nutrition according to the standard hospital dietary regimen.
3289062|NCT01735435|Experimental|Group 1 (Indirect Calorimetry)|Group 1(Indirect Calorimetry)-The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
3289063|NCT01735448||Aboriginal smoker, male, Adelaide|Focus group: Aboriginal smoker, male from Adelaide
3289064|NCT01735448||Aboriginal smoker, female, Adelaide|Focus group: Aboriginal smoker, female, from Adelaide
3289065|NCT01735448||Aboriginal ex/non-smoker, male, Adelaide|Focus group: Aboriginal ex/non-smoker, male, from Adelaide
3289066|NCT01735448||Aboriginal ex/non-smoker, female, Adelaide|Focus group: Aboriginal ex/non-smoker, female, from Adelaide
3289067|NCT01735448||Healthcare workers, Adelaide|Focus group: Healthcare workers who are based in Adelaide and work with Aboriginal patients
3289068|NCT01735448||Healthcare workers, Murray Bridge|Focus group: Healthcare workers who are based in Murray Bridge and work with Aboriginal patients
3289069|NCT01735448||Aboriginal smoker, male, Murray Bridge|Focus group: Aboriginal smoker, male, from Murray Bridge
3289070|NCT01735448||Aboriginal smoker, female, Murray Bridge|Focus group: Aboriginal smoker, female, from Murray Bridge
3289071|NCT01735448||Aboriginal ex/non-smoker, male, Murray Bridge|Focus group: Aboriginal ex/non-smoker, male, from Murray Bridge
3289072|NCT01735448||Aboriginal ex/non-smoker, female, Murray Bridge|Focus group: Aboriginal ex/non-smoker, female, from Murray Bridge
3289073|NCT01735448||Key community stakeholders|One-on-one interviews with 10 key Aboriginal community stakeholders
3289074|NCT01735448||Respiratory physicians|One-on-one interviews with 10 Respiratory physicians
3289075|NCT01735448||Consultants and General Practitioners|One-on-one interviews with 10 consultants and/or GP's
3289076|NCT01735461|Experimental|Dietary supplement|Calcium Carbonate
3289077|NCT01735474|Placebo Comparator|Placebo|30 people are recruited in order to the inclusion criteria for the study. Placebo controlled.
3289078|NCT01735474|Active Comparator|Manual technique|30 people are recruited in order to the inclusion criteria for the study. Experimental group.
3289079|NCT01735487|Active Comparator|Own Brand cigarette|Smoke Own Brand cigarette, 15 puff of cigarette.
3289080|NCT01735487|Experimental|One High 2,4% nicotine|Smoke electronic cigarette One High 2,4% nicotine for a day, 15 puff of e-cigarette.
3289081|NCT01735487|Experimental|Original 7,4 mg nicotine|Smoke electronic cigarette Original 7,4 mg nicotine for a day. 15 puff of e-cigarette.
3289082|NCT01735487|Placebo Comparator|Nicotine Free|Smoke electronic cigarette nicotine free (15 puff)
3289083|NCT01735487|Experimental|EGO 9mg|Smoke electronic cigarette EGO for a day (15 puff)
3289084|NCT01735500||CAG without PCI|
3289085|NCT01735500||CAG with PCI|
3289086|NCT01735513|Experimental|Transaortic TAVI with EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation with the use of the embolic protection device EmbolX"
3289087|NCT01735513|Active Comparator|Transaortic TAVI without EmbolX|"Subjects are randomized into this arm to receive a transaortic transcatheter aortic valve implantation without the use of the embolic protection device EmbolX"
3289088|NCT01735539|Experimental|Old Bolus|15g EAA bolus
3289089|NCT01735539|Experimental|Old Arginine|15g EAA Bolus supplemented with 3g Arginine
3289090|NCT01735539|Experimental|Young Bolus|15g EAA bolus
3289091|NCT01735539|Experimental|Young Pulse|4 x 3.75g Mixed EAA Pulses
3289092|NCT01735539|Experimental|Old Pulse|4 x 3.75g Mixed EAA Pulses
3289093|NCT01735552||Infants requiring PRBCs|Premature infants who require PRBCs for anemia that is not related to sepsis, surgery, NEC or immunologic abnormalities.
3289094|NCT01735565||Post bone marrow transplant|Patients who are undergoing bone marrow transplant, as well as patients who have completed a bone marrow transplant within the previous year.
3289095|NCT01735578||Premature infants with anemia|Inpatient premature infants at the University of Utah Neonatal Intensive Care Unit (NICU) with Hct < or = to 28 who are being fed and are stable.
3289096|NCT01735591|Experimental|Probiotic|Capsules with 3x10^9 colony forming units (Lactococcus lactis PB 411 - 50%; Lactobacillus casei PB 121 - 25%; Lactobacillus acidophilus PB 111 - 12,5%; Bifidobacterium bifidum PB 211 - 12,5%). 1 capsule a day from inclusion until liver transplantation
3289097|NCT01735591|Placebo Comparator|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
3289098|NCT01735604|Experimental|anti-CD20-CAR T cell|Arm 1 Patients receive anti-CD20-CAR lentiviral vector-transduced autologous T cells with 41BB vector for 3-5 days in the absence of disease progression or unacceptable toxicity.
3289099|NCT01735643|Experimental|interactive videogame intervention|
3289100|NCT01735643|Experimental|waiting group|
3289101|NCT01735656|Experimental|DK-culotte & Resolute stents|Double kissing culotte technique for true bifurcation lesion with Resolute stents
3289102|NCT01735656|Active Comparator|DK-crush & Resolute stents|Double kissing crush technique for true bifurcation lesion with Resolute stents
3289103|NCT01735669|Experimental|Remifentanil|External cephalic version at term under Remifentanil perfusion
3289104|NCT01735669|Active Comparator|Nitrous oxide|External cephalic version at term under Nitrous oxide inhalation
3289105|NCT01735682|Experimental|Whole body vibration|This group will receive whole body vibration and conventional exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
3289106|NCT01735682|Active Comparator|Conventional exercise|This group will receive convention exercise training (1 hour per session, 3 sessions per week, for 8 consecutive weeks).
3289107|NCT01735682|Active Comparator|Control|This group will have exercise training that involve only the upper limbs (about 30 minutes per session, 3 sessions per week, for 8 consecutive weeks).
3289108|NCT01735708|Placebo Comparator|Health Education|Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
3289109|NCT01735708|Active Comparator|HIVPASS Intervention|Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.
3289110|NCT01735721|Active Comparator|Open Sinus Lift with DFDBA|In each patient, one sinus was chosen at random and filled with DFDBA (Tissue Regeneration Corporation, Iran).
3289111|NCT01735721|Experimental|Open Sinus Lift with Algipore|The contra lateral sinus was filled with Algipore (Dentsply, USA).
3289112|NCT01735734||Capillary malformation|
3289113|NCT01735747|Experimental|Temozolomide, Nedaplatin, Vincristine, Radiotherapy|The newly diagnosed PCNSL patients will be given concurrent temozolomide (75mg/m2, orally) daily during WBRT. Then, the TNV regimen will be given after four weeks. TNV regimen consisted of temozolomide (200mg/m2 orally, days 1-5), nedaplatin (80mg/m2 i.v., day 1), vincristine (1.4mg/m2 i.v., day 1). Each cycle was 4 weeks and a maximum of six cycles were applied.
3289114|NCT01735760||Palpation|The group using palpation as primary attempt at localizing the cricothyroid membrane
3289115|NCT01735760||Ultrasonography|The group using ultrasound for their primary approach to localizing the cricothyroid membrane
3289116|NCT01735773||Hemodialysis group|Patients on chronic hemodialysis program
3289117|NCT01735773||Peritoneal dialysis group|Patients on chronic peritoneal dialysis program
3289118|NCT01735773||Pre-dialysis group|Patients with chronic kidney disease stage-4
3289119|NCT01735773||Control group|Healthy volunteers
3289120|NCT01735786||Treatment group|Subjects in this group will received Endoclot treatment immediately after EMR.
3289121|NCT01735786||Control group|Subjects in this group will not received any hemostasis treatment after EMR.
3289122|NCT01735812|Experimental|symptomatic UF|
3289123|NCT01735825|Experimental|paclitaxel-coated balloon|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter (iopomide coating)
3289124|NCT01735825|Active Comparator|drug eluting stent|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
3289125|NCT01735825|Other|seal-wing paclitaxel-eluting balloon catheter|"Observational, non-randomised arm:~Pts with ISR treated by seal-wing paclitaxel-eluting balloon catheter"
3289126|NCT01735851|Active Comparator|Thoracic epidural analgesia|Group 1 will receive a catheter congruent TEA. The epidural space will be identified using the loss of resistance technique. After a test dose to rule out intravascular and intrathecal placement of the catheterthe initial block will be made with 0.25% bupivacaine 5 mL followed by 3 mL aliquots administered every 5 minutes to establish a block between T8 and T12. An infusion will be started at 8 mL/hour with 0.1 % bupivacaine with 10microgram/mL of dilaudid and continued for 72 hours. Additional nurse administered boluses of 5-10mL of the standard solution will be allowed via the epidural catheter every 6hourly for poor pain control followed by an increase in the basal infusion rate up to a maximum of 14mL/hr. Patients will be allowed to self administer additional boluses of 3mL of the standard infusate every 20minutes (PCEA)
3289127|NCT01735851|Experimental|Bilateral Paravertebral block|Group 2 will have bilateral PVB catheters inserted using the ultrasound with patients prone. A high-frequency linear probe will used to visualize the transverse process, pleura and the internal intercostal membrane. A 17 guage Tuohy needle will be inserted to puncture the internal intercostal membrane. Injection of local anesthetic will push the pleura away, which will be the end point of needle position. A curved pigtail catheter will be inserted and further 5mL of local anesthetic will be injected while observing further movement of pleura. A similar procedure will be done on the contralateral side at the same level. Infusion of 0.2% ropivacaine will be continued for the next 72 hours. They will also receive IVPCA and additional nurse administered boluses of 5-10mL of ropivacaine 0.2% in the PVB every 6 hourly to the side of maximal pain.
3289128|NCT01735864|Active Comparator|Indirubin 200 μg/g|per gram of ointment contains 200 μg of indirubin
3289129|NCT01735864|Active Comparator|Indirubin 100 μg/g|per gram of ointment contains 100 μg of indirubin
3289130|NCT01735864|Active Comparator|Indirubin 50 μg/g|per gram of ointment contains 50 μg of indirubin
3289131|NCT01735864|Active Comparator|Indirubin 10 μg/g|per gram of ointment contains 10 μg of indirubin
3289132|NCT01735890|Experimental|CJ Amlodipine/Valsartan 10/160mg|
3289133|NCT01735890|Active Comparator|Novartis Exforge 10/160mg|
3289138|NCT01735955|Experimental|AMN107 (nilotinib)|AMN107
3289139|NCT01735968|Experimental|STI571 (imatinib mesylate) and BYL719|The study will comprise of 2 parts. A dose escalation and a dose expansion part. All patients in the dose escalation part will have a pharmacokinetic (PK) run-in period of 7 days receiving imatinib monotherapy. Patients will receive increasing doses of BYL719 (200, 300, 400 mg) in combination with 400mg imatinib daily until maximum tolerated dose (MTD) and rapid phase 2 dose (RP2D) is determined. Approximately 35 patients will enter the expansion phase.
3289140|NCT01736007|Sham Comparator|Liquid light guide tip on laser|Excimer laser treatment with 308-nm excimer laser with guide tip applied to alopecia patch twice a week.
3289141|NCT01736007|Active Comparator|308-nm excimer laser to alopecia patch|Laser treatment with 308-nm excimer laser procedure to alopecia patch twice a week with increasing fluence as tolerated.
3289142|NCT01736020|Placebo Comparator|Placebo|Placebo
3289143|NCT01736020|Experimental|Dexmedetomidine|Dexmedetomidine intravenous infusion during scan.
3289144|NCT01736020|Experimental|Propofol|Propofol intravenous infusion during scan.
3289145|NCT01736020|Experimental|Ketamine|Ketamine intravenous infusion during scan.
3289146|NCT01736020|Experimental|Nitrous Oxide|Nitrous Oxide inhalation during scan.
3289147|NCT01736033|Placebo Comparator|Tamsulosin + Placebo|Tamsulosin 0.2mg + Placebo 5 mg daily until clinical progression
3289148|NCT01736033|Active Comparator|Tamsulosin + Finasteride|Tamsulosin 0.2mg + Finasteride 5 mg daily until clinical progression
3289149|NCT01736046||Crohn's Disease patients|All patients referred for CT Enterography will be undergo both standard and low dose CT Enterography
3289150|NCT01736059|Experimental|Stem cell treated|
3289151|NCT01736072|Active Comparator|Laparoscopic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Standard Laparoscopic Surgery.
3289152|NCT01736072|Active Comparator|Robotic Resection of Rectal Cancer|Research Subjects will be randomized to Surgical Resection of Rectal Cancer by Robotic Assisted Laparoscopic Surgery.
3289153|NCT01736098|Experimental|High Energy Flux|Energy Flux Exercise Intervention: 7kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
3289154|NCT01736098|Experimental|Medium Energy Flux|Energy Flux Exercise Intervention: 3.5kcal/kg/day at 5 days/week of energy expenditure and matching energy intake
3289155|NCT01736098|No Intervention|Low Energy Flux|No Intervention: maintain normal lifestyle
3289156|NCT01736111|Experimental|Personal feedback|"This arm will receive all intervention components of Active Comparator group, plus the following:~Text messages to prompt participant to reply with self-monitoring entries~Human coach uses system to send personalized text messages with feedback on self-monitoring entries"
3289157|NCT01736111|Active Comparator|One Way Text|"Printed handouts from the Aim for a Healthy Weight booklet, which is published by National Heart, Lung, and Blood Institute and is frequently included in control conditions in primary care-based weight loss studies.~Other handouts will discuss the use of prepackaged foods as well as setting goals for calorie intake, physical activity, and weight loss.~One to three text messages per week, based on topics from Aim for a Healthy Weight and other sources. The text messages will be pre-scheduled, automated, non-tailored, and one-way (no reply will be requested). The total dose of contact will be low because each text message is limited to 160 characters. The condition is comparable in intensity to control conditions in other weight loss trials in the primary care setting.~Usual medical care from the PCP.~Education on symptoms of hypoglycemia, hypotension, and cardiovascular disease, with instructions to contact their PCP in the event of those symptoms."
3289158|NCT01736137||Chronic Heart failure group|All chronic heart failure group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
3289159|NCT01736137||Control Group|All control group participants will perform two walk tests at the same day, with a heart rate monitor, and answer questionnaires about their perception of quality of life. Tests will be conducted on a single day, without follow up of patients. The six minute walk test will be performed according the American Thoracic Society Statement (2002).
3289160|NCT01736150|Experimental|Sevelamer carbonate|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
3289161|NCT01736150|Placebo Comparator|Placebo|Subjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
3289162|NCT01736163||Thyrogen and 131I|Patients were previously treated with Thyrogen in conjunction with a high ablative activity of 131I.
3289163|NCT01736163||Thyroid Hormone Withdrawal and 131I|Patients were previously treated with Thyroid hormone withdrawal (THW) in conjunction with a high ablative activity of 131I.
3289164|NCT01736202|Active Comparator|Palm oil orally|oral fat load
3289165|NCT01736202|Active Comparator|Canola oil orally|Oral fat load
3289166|NCT01736202|Placebo Comparator|Water orally|oral water administration as control
3289167|NCT01736228|Experimental|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
3289168|NCT01736280|Other|1|Standard of Care. Participants will be evaluated and treated for their particular digestive disorder or presenting symptoms.
3289170|NCT01736306||Volunteers|Volunteer milk donors
3289171|NCT01736345||Telephone Disclosure|Telephone Disclosure: Participants randomized to telephone disclosure will be asked to provide a personal identifier that the participant will be asked at the time of their telephone disclosure to ensure their identity.
3289172|NCT01736345||In Person Disclosure|Individuals opting out of randomization but still willing to participate in the research will be placed in the self-select in-person arm.
3289173|NCT01736371|Sham Comparator|Total Intravenous Anesthesia|Only propofol infusion is used for maintenance of anesthesia keeping Bispectral Index (BIS) between 45-55.
3289174|NCT01736371|Active Comparator|1% Sevoflurane|1% Sevoflurane with propofol infusion is used for maintenance. BIS is kept between 45-55 by adjusting propofol infusion.
3289175|NCT01736371|Active Comparator|Sevoflurane|Only Sevoflurane is used for maintenance keeping BIS between 45-55
3289176|NCT01736384||Obesity|Gastric bypass surgery and non-obese controls undergoing cholecystectomy
3289177|NCT01736410|Other|IHC method|
3289178|NCT01736410|Other|FISH method|
3289179|NCT01736423|Experimental|Female Patients with D-IBS|
3289180|NCT01736436|Experimental|100 mg APG101 weekly over 12 weeks|Single arm open label study. Patient receive 100 mg APG101 i.v. weekly over 12 weeks with a 6 monthly follow-up phase
3289181|NCT01736449|Placebo Comparator|Pterygium Excision Alone|
3289182|NCT01736449|Experimental|Pterygium Excision with Bevacizumab Injection|
3289183|NCT01736462|Experimental|Mapracorat|Mapracorat ophthalmic suspension, 3%
3289184|NCT01736488|Experimental|Fimasartan 60mg|60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
3289185|NCT01736488|Active Comparator|Atenolol 50mg|50mg/day of Atenolol will be oral administered for the study period (8 weeks)
3289186|NCT01736501|No Intervention|Baseline1-demographics|Baseline survey- demographics only
3289187|NCT01736501|Other|Baseline1 w/genetics|Genetics education, baseline interest in genome screening - 1
3289188|NCT01736501|Other|Baseline2-demographics|Baseline survey- demographics only
3289189|NCT01736501|Other|Baseline2 w/genetics|Genetics education, baseline interest in genome screening - 2
3289190|NCT01736514|Experimental|febuxostat group|oral
3289191|NCT01736514|Active Comparator|allopurinol group|oral
3289192|NCT01736592|Other|Long Term Follow up|Long term follow up in all patients who received SAR422459 in previous study TDU13583
3289193|NCT01736605|Active Comparator|Massage|Daily massage for 20 minutes the first 3 days following surgery.
3289194|NCT01736605|Active Comparator|Massage combined with meditation|Daily massage for 20 minutes combined with meditation the first 3 days following surgery.
3289195|NCT01736618||S-ICD System Implant Attempt|
3289196|NCT01736631|Experimental|Cognitive behavioural therapy|Cognitive behavioural therapy for social phobia in people with bipolar disorder
3289197|NCT01736644|Placebo Comparator|Electrocautery|Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
3289198|NCT01736644|Active Comparator|Bipolar Sealer Aquamantys|Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
3289199|NCT01736670|Experimental|Acute Steroid Responsive dermatitis|10 patients with acute steroid-responsive dermatoses
3289200|NCT01736670|Experimental|Chronic Steroid Responsive Dermatits|10 patients with chronic steroid-responsive dermatoses
3289201|NCT01736670|Active Comparator|Control, Otherwise healthy|10 healthy controls
3289202|NCT01736709|Experimental|trivalent seasonal influenza vaccine|2012-2013 trivalent seasonal influenza vaccine in 60 infants with two-dose regimen, 21 days interval trivalent seasonal influenza vaccine in 60 adults and 60 old people with single-dose regimen
3289203|NCT01736722|Experimental|MRI-guided laser induced thermal therapy|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
3289204|NCT01736735|Experimental|CLP|CLP BID
3289205|NCT01736735|Placebo Comparator|Placebo|BID powder
3289206|NCT01736748|Experimental|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
3289207|NCT01736748|Other|Traditional PA counseling|In this arm, while children will wear the same sensors as in the intervention arm, the intervention will not rely on data gathered using the wearable sensors. Rather, a traditional physical activity counseling strategy will be adopted in this control group.
3289208|NCT01736761|Experimental|Darunavir, Ritonavir, Rilpivirine|Darunavir 800 mg once daily, Ritonavir 100 mg once daily and Rilpivirine 25 mg once daily
3289209|NCT01736774|Experimental|Usual care intervention|Primary care as required including medication
3289210|NCT01736774|Experimental|Physiotherapy treatment|Exercise and manipulative therapy
3289211|NCT01736787|Experimental|Cauliflower Mushroom extract|
3289212|NCT01736787|Placebo Comparator|Placebo|
3289213|NCT01736800|Experimental|Temozolomide/Topotecan|Temozolomide pills are to be taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule. Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
3289214|NCT01736813||CCR5-inhibitor at 300 mg/bid|colorectal cancer patients with liver metastases (twelve patients treated with 300 mg/bid)
3289215|NCT01736826||Group P: pregnancy w/complications|"The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism).~100 patients will be included.~Interventions to be administered: Bloodwork, baseline"
3289216|NCT01736826||Group T1: Healthy volunteers|"Healthy volunteers with no history of chronic or neoplastic disease.~30 healthy volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
3289217|NCT01736826||Group T2: Pregnancy, no complications|"Pregnant patients with no identifiable pregnancy complications, and no history of chronic or neoplastic disease.~50 pregnant volunteers will be included.~Interventions to be administered: Bloodwork, baseline"
3289218|NCT01736826||Group T1x: 15 Healthy volunteers|"15 Healthy volunteers selected from group T1 (the first 15). These patients will have 2 additional months of follow up.~Interventions to be administered: Blood work, Months 1 & 2"
3289219|NCT01736826||Group T2x: 15 Pregnancy, no complications|"15 patients selected from group T2 (the first 15); these patients will have 7 months of follow up during pregnancy.~Interventions to be administered: Bloodwork, Months -1 to -6"
3289220|NCT01736839||CF adults colonized with Pseudomonas aeruginosa|
3289221|NCT01736878|Experimental|Sorafenib tablets|Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity
3289222|NCT01736878|Placebo Comparator|Placebo tablets|Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator
3289223|NCT01736891|Experimental|Rasagiline|Rasagiline 0.5 mg by mouth every day for 2 weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
3289224|NCT01736891|Placebo Comparator|Placebo|placebo 0.5 mg by mouth every day for two weeks, then 1 mg by mouth every day for 12 weeks, then switch to 0.5mg by mouth every day for remainder of the study (approximately 16 weeks total)
3289225|NCT01736904|Active Comparator|FOLFIRI|FOLFIRI regimen
3289226|NCT01736904|Experimental|wXELIRI regimen|wXELIRI
3289227|NCT01736956|Experimental|Fetal Aortic Valvuloplasty|Subjects will undergo fetal aortic valvuloplasty
3289228|NCT01736956|No Intervention|Control|Control group. Will receive standard prenatal and postnatal care.
3289229|NCT01736969|Experimental|RD047-023|RD-047-023
3289230|NCT01736969|Active Comparator|Predicate Device|legally marketed predicate device
3289231|NCT01736982|Active Comparator|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)], breath sample monitoring, standard smoking cessation counseling
3289232|NCT01736982|Experimental|Standard of Care plus Contingency Management|Standard smoking cessation intervention plus contingency management
3289233|NCT01736995|Experimental|Motivational/Cog Beh Tx-Contingency Mgmt|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
3289234|NCT01736995|Experimental|Functional Family Tx- Contingency Mgmt|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. The additional inclusion of contingency management (CM) methods will provide immediate, tangible reinforcers to the family as a consequence delivered contingently upon evidence of abstinence from substance use or other desirable behavior.
3289235|NCT01736995|Experimental|Motivational/Cog Beh Tx|The group Motivational Enhancement Tx/Cognitive Behavioral Tx (MET/CBT) treatment is a peer-focused, multi-component intervention involving 2 initial individual motivational sessions followed by 12 group sessions that includes a functional analysis of behavior to identify antecedents and consequences of drug use and skills training for coping with cravings, enhancing assertive communication, drug refusal, managing negative moods, problem-solving, decision-making, and relapse prevention.
3289236|NCT01736995|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills.
3289237|NCT01737008|Experimental|Dacomitinib with Radiotherapy|Dacomitinib, 15mg to 45mg orally, once daily. Radiotherapy, once daily (Monday to Friday) over six weeks.One day on weeks 2 to 6 the participants will receive treatment twice daily (bid).
3289238|NCT01737008|Experimental|Dacomitinib and Chemoradiotherapy|Dacomitinib: 15mg to 45mg orally, once daily. Radiotherapy: Once daily (Monday to Friday) over seven weeks. Twice daily (bid) treatments may be introduced to compensate for treatment days missed due to statutory holidays, or machine maintenance. Cisplatin: 100mg/m2 intravenously; weeks 1, 4, and 7.
3289239|NCT01737034|Experimental|low GI, low GI|low GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
3289240|NCT01737034|Experimental|low GI, high GI|low GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
3289241|NCT01737034|Experimental|high GI, low GI|high GI diet (semi starvation phase) followed by low GI diet in the refeeding phase
3289242|NCT01737034|Experimental|high GI, high GI|high GI diet (semi starvation phase) followed by high GI diet in the refeeding phase
3289243|NCT01737047||HIV positive over 50 years of age|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
3289244|NCT01737047||HIV positive under the age of 50|"All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.~Blood sample collections for the determination of the plasma concentrations of tenofovir and the third agent (i.e. a non-nucleoside reverse transcriptase, protease, entry or integrase inhibitor) in the patient's regimen will be drawn"
3289245|NCT01737047||HIV negative over the age of 50|All study subjects will undergo a whole body DEXA scan (dual energy X-ray absorptiometry). at the beginning and end of the study.
3289246|NCT01737060|Active Comparator|Angular stable plate Philos|Open Reduction and Osteofixation with Philos plate and TiCron cerclages
3289247|NCT01737060|Experimental|Reverse Total Shoulder Artroplasty|Intervention group
3289248|NCT01737073|Experimental|IVR self management|cognitive behavioral based self management training for chronic pain delivered by interactive voice response (IVR)
3289249|NCT01737073|Experimental|Opioid monitoring|monthly interactive voice response (IVR) monitoring of prescription opioid use with feedback to the prescribing physician
3289250|NCT01737073|Experimental|IVR self management plus opioid monitoring|Cognitive behavioral based self management training for chronic pain delivered by IVR plus monthly IVR monitoring of prescription opioid use with feedback to the prescribing physician
3289251|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tips via IVR
3289252|NCT01737086|Experimental|ORS with probiotic and zinc|Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
3289253|NCT01737086|Placebo Comparator|Standard ORS|Standard oral rehydration solution
3289254|NCT01737099|Experimental|DHA-O|
3289255|NCT01737099|Active Comparator|Fish oil|
3289256|NCT01737099|Placebo Comparator|Placebo|
3289257|NCT01737112|Experimental|99mTc-3PRGD2 SPECT/CT scanning|Determine if 99mTc-3PRGD2 SPECT/CT is safe and effective in diagnosis and evaluation of lung cancer patients.
3289258|NCT01737138|Active Comparator|RSD+Medicine|The investigators will recruit 50 randomised CKD patients who meet the inclusion criteria. First undergo renal artery angiography procedure to confirm anatomy. If renal artery meet the inclusion criteria, give the renal sympathetic denervation. At the same time, we will use optimal medication to protect renal function. Then we will conduct a clinic follow-up and a telephone follow-up e(Total 36 months).
3289259|NCT01737138|Placebo Comparator|Medicine|The investigators aslo will recruit 50 randomised CKD patients who meet the inclusion criteria. There are no significant differences in age, gender, race, past medical history,personal history and so on between the two groups. In this group we will use optimal medication just like the RSD+Medicine group. Third we will conduct a clinic and a telephone follow-up(Total 36 months).
3289260|NCT01737151|Active Comparator|Arm I (standard stereotactic body radiation therapy (SBRT)|Patients undergo standard daily fractions of SBRT over 7-8.5 weeks
3289261|NCT01737151|Experimental|Arm II (four fraction split-course SBRT)|Patients undergo 2 fractions of SBRT in weeks 1 and 4
3289262|NCT01737164|Experimental|Aerobic Exercise - Older Subjects|Subjects aged 65 and higher will perform 16 weeks of moderate intensity exercise
3289263|NCT01737164|Experimental|Aerobic Exercise - Young Subjects|Subjects 18-30 years old will perform 16 weeks of moderate intensity exercise
3289264|NCT01737177|Experimental|Bendamustina, Lenalidomide, Rituximab|1 arm for all patients
3289265|NCT01737190|Experimental|PEEP guided by Esophageal pressure + Recruitment maneuver.|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
3289266|NCT01737203|Active Comparator|Viagra|Oral tablet of sildenafil citrate (Japanese commercial tablet: Viagra® tablet) 50 mg as a single oral dose under fasted conditions
3289267|NCT01737203|Experimental|ODT without water|Sildenafil ODT 50 mg without water as a single oral dose under fasted conditions
3289268|NCT01737203|Experimental|ODT with water|Sildenafil ODT 50 mg with water as a single oral dose under fasted conditions
3289269|NCT01737216|Experimental|Zoledronic acid plus First-line chemotherapy|
3289270|NCT01737216|Active Comparator|First-line chemotherapy|
3289271|NCT01737229|Experimental|Direct pulp capping/carious exposure|symptomatic (provoked pain) or asymptomatic mature or immature tooth that presented pulp exposure when scraping out carious lesions or performing cavity preparation.
3289272|NCT01737229|Experimental|Direct pulp capping/dental trauma|• Permanent mature or immature single-root tooth having suffered traumatic injury < 72 hours, with amelodentinal coronal fracture causing pulp exposure.
3289273|NCT01737229|Experimental|Repairing root canals/pulp chamber floor|"Iatrogenic perforation of the pulpal floor, with or without LEO.~Iatrogenic perforated root canals following post space preparation involving dentin matrix, with or without LEO.~Iatrogenic perforated root canals with stripping not involving dentin matrix, with or without LEO."
3289274|NCT01737229|Experimental|Retrograde endodontic surgery - adults|"Failure of endodontic treatment or retreatment, evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling looks to be of sufficiently good quality, provided that a working coronal restoration is in place.~Failure of endodontic treatment evidenced by recent or persistent clinical or radiological signs of LEO and/or symptoms on a tooth in which the root canal filling is inadequate, when orthograde retreatment does not offer a more favorable risk-benefit ratio than the surgery option"
3289275|NCT01737229|Experimental|Pulpotomy in primary molars - children (3 to 12 years )|"Molar presenting deep carious lesion without irreversible pulpal disease, as the molar has to stay on the dental arch for at least 3 years.~Pulp exposure during excision of a carious lesion on a temporary molar that does not present irreversible pulp disease. The molar has to stay of the dental arch for at least 3 years."
3289276|NCT01737229|Experimental|Apexification - children (7 to 18 years) + adults|"Permanent immature single-root tooth having suffered periodontal or dentoalveolar injury causing pulp necrosis with or without periapical disease (LEO) in children, teenagers or adult patients.~Permanent immature single-root tooth presenting pulp necrosis with or without periapical disease (LEO) in children.~Apical Root Resorption"
3289277|NCT01737255||TP53 mutation carriers|Carriers of TP53 mutation not known to be low penetrance
3289278|NCT01737255||Population controls|Population controls will be sex and aged matched (+/- 5 years) to the TP53 mutation carrier group, with no personal history of cancer and no family history of cancer diagnosed under 50 years
3289279|NCT01737294||Treatment with QUTENZA|Patients with Peripheral Neuropathic Pain
3289280|NCT01737307|Experimental|Fluoride Varnish|Fluoride varnish was used once in this group. Fluoride varnish(NaF 5%,Sultan,USA)
3289281|NCT01737307|Experimental|Oral hygiene|Oral hygiene followed twice daily. No F varnish or CPP-ACP applied.
3289282|NCT01737307|Experimental|CPP-ACP|CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
3289283|NCT01737320|Experimental|short-course|antibiotic treatment stopped on day 7 if the patient has been afebrile for 48 hours and clinically stable. Continued hospitalization will be left to the discretion of the treating physician. Antibiotics will be restarted if fever recurs in at least 2 consecutive measurements above 38 or in cases of clinically or microbiologically documented infections.
3289284|NCT01737320|Active Comparator|accepted prolonged antibiotic treatment|"antibiotic treatment continued for 14 days according to accepted hospital local guidelines. Duration of hospital stay will also be left to the discretion of the treating physician.~Type of empiric antibiotic treatment and later, specific antibiotic treatment, will be chosen by the treating physicians in consultation with the infectious diseases unit.~The decision on timing of switch to oral antibiotic therapy will also be left to the discretion of the treating physician."
3289285|NCT01737346|Experimental|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
3289286|NCT01737359|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3289287|NCT01737359|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3289288|NCT01737359|Active Comparator|tenofovir DF 300 mg qd|in combination with zidovudine 300 mg bid for 12 weeks; lopinavir/ritonavir (400 mg/100 mg) bid is added on week 3
3289289|NCT01737372||Secondary Progressive MS (SPMS)|Secondary Progressive MS participants
3289290|NCT01737372||Clinically Isolated Syndrome (CIS)|Clinically isolated syndrome participants
3289291|NCT01737372||Healthy participants|No immunological or neurological illnesses.
3289292|NCT01737385||Type 1|One segment fracture
3289293|NCT01737385||Type 2|Two segment fracture
3289294|NCT01737385||Type 3|Three segment fracture
3289295|NCT01737385||Type 4|Four segment fracture
3289296|NCT01737411|Active Comparator|solifenacin|10 mg solifenacin per day for three months
3289297|NCT01737411|Experimental|cesa/vasa|repair of USL
3289298|NCT01737424|Placebo Comparator|Placebo|Placebo
3289299|NCT01737424|Experimental|LC28-0126|LC28-0126(IV)
3289300|NCT01737437|Experimental|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
3289301|NCT01737437|Placebo Comparator|group C|0.9% normal saline was applied to trachea and laryngoscope blade in Group C.
3379173|NCT00233272||Healthy Volunteers|Healthy volunteers over a wide age-range
3289302|NCT01737437|Experimental|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
3289303|NCT01737437|Experimental|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
3289304|NCT01737450|Experimental|BKM120|Full dose=100 mg/day (oral route) One study cycle equals 28 days. Patients will be treated until disease progression, unacceptable toxicity, or willingness to stop.
3289305|NCT01737463|Active Comparator|Group A|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was inserted immediately after the excision."
3289306|NCT01737463|Active Comparator|Group B|"Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope (JF-240, TJF-240, JF-260, TJF-260; Olympus Optical Co, Ltd, Tokyo, Japan).~A pancreatic duct stent was not inserted immediately after the excision."
3289307|NCT01737476|Sham Comparator|control|control-sham
3289308|NCT01737476|Active Comparator|Deep TMS PFC Lt|Deep TMS PFC left
3289309|NCT01737476|Active Comparator|DEEP TMS PFC Rt|DEEP TMS PFC Rt
3289310|NCT01737476|Active Comparator|Superficial TMS PFC Lt|Superficial TMS PFC Lt
3289311|NCT01737476|Active Comparator|superficial TMS PFC Rt|superficial TMS PFC Rt
3289312|NCT01737489|Active Comparator|LACE ( Listening And Communication Enhancement )|use the commercially available auditory training program which is administered by computer as daily lessons.
3289313|NCT01737489|Active Comparator|NOOK (Electronic reader)|will use an electronic reader (NOOK device) to do speech tracking
3289314|NCT01737489|No Intervention|Control|
3289315|NCT01737515||Main group|Consecutive patients undergoing colorectal surgery for benign or malignant colorectal disease without any diversion from the standard of care
3289316|NCT01737528||TAVR Patients|Will include all patients 18 years or over who undergo Transcatheter Aortic Valve Replacement (TAVR) for severe aortic stenosis. The sample size will include all patients entered into the Registry.
3289317|NCT01737541|Experimental|Fluoxetine|fluoxetine per os 20 mg daily
3289318|NCT01737541|Placebo Comparator|Placebo|per os daily
3289319|NCT01737554||Participants|"Participants include children with cancer and hematologic disorders who, as part of their standard clinical care, have a central venous access device (CVAD) used for infusion, withdrawal of blood, or hemodynamic monitoring.~Intervention: Catheter resistance monitoring"
3289320|NCT01737567|Experimental|Bright Narrow Band Imaging|Use of B-NBI to detect colonic adenomas.
3289321|NCT01737567|Active Comparator|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
3289322|NCT01737580|Active Comparator|Intanza+resiquimod gel|Intanza 15mcg intradermal injection + resiquimod gel applied to the vaccination site immediately post vaccination.
3289323|NCT01737580|Placebo Comparator|Intanza + placebo gel|Intanza 15mcg intradermal injection + placebo gel applied to the vaccination site immediately post vaccination.
3289324|NCT01737606|Experimental|echography|Fast Cerebral Pulsatility Imaging
3289325|NCT01737632|Experimental|Multidimensional Family Therapy (MDFT)|MDFT is an intensive, in-home family-based drug abuse treatment for adolescent substance abusers. MDFT views family factors in their context -in terms of the network (individual, familial, peer, community) or multiplicity of influences on drug use and change.
3289326|NCT01737632|Other|Adolescent Residential Treatment|"The Adolescent Treatment Program (ATP) is a residential dual diagnosed substance abuse treatment program that is staff secure. It is based on a social learning approach which emphasizes positive reinforcement for appropriate coping behavior and social skills, and incorporates a levels system which allocates privileges and responsibilities according to the individual's behavioral capacities."
3289327|NCT01737645||obese patients|BMI (body mass index) more than or equal to 35 kg/m2 (weight in kilograms divided by the square of the height in metres)
3289328|NCT01737645||Thin patients|BMI less than or equal to 30 kg/m2
3289329|NCT01737658|Other|Exercise Program upon enrollment|Subject will receive exercise intervention immediately upon enrollment to study
3289330|NCT01737658|Other|Exercise Program 6 months after enrollment|Subject will be enrolled into study and then receive exercise intervention 6 months after enrollment.
3289331|NCT01737671|Experimental|Methotrexate Infusion|3 consecutive cycles of intraventricular methotrexate infusions into implanted fourth ventricle catheter/Ommaya reservoir following surgical catheter placement into fourth ventricle, each cycle is 4 consecutive daily doses of intraventricular methotrexate with minimum 2 weeks between cycles. If any serum methotrexate level is > 0.3 micromolar, then Leucovorin therapy administered (5 mg/square meter per dose) every 6 hours by vein or mouth.
3289332|NCT01737723||Study population|Stroke patients
3289333|NCT01737736||Patients undergoing cartoid endarterectomy surgery|
3289334|NCT01737749||Patients undergoing cardiac surgery|
3289335|NCT01737775|Experimental|Abdominal laparoscopic surgery (C group)|
3289336|NCT01737775|Experimental|Abdominal surgery by laparotomy (L group)|
3289337|NCT01737775|Experimental|Head and neck surgery (O group)|
3289338|NCT01737788|Experimental|Therapeutic Trial|Therapeutic cervical cerclage with or without cervical occlusion in women presenting with short cervix (<25mm)
3289339|NCT01737788|Experimental|Prophylactic Trial|Prophylactic cervical cerclage with or without cervical occlusion in women with a history of cervical insufficiency
3289340|NCT01737801|Experimental|Lung function test|Lung function test
3289341|NCT01737814|Experimental|MST-188|MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
3289342|NCT01737814|Placebo Comparator|Saline|Saline administered as a continuous infusion for up to 49 hours
3289344|NCT01737853||Ganfort's Group|"Ganfort® QD for patients under Krytantek®~For patients assigned to the Ganfort's group, instructions for applying one drop QD (8:00 PM ± 30 minutes)"
3289345|NCT01737853||Krytantek's Group|"Krytantek® BID for patients under Ganforti®~For patients assigned to the Krytantek's group, application schedule will be BID (8:00 AM ± 30 minutes and 8:00 PM ± 30 minutes)"
3289346|NCT01737866|Experimental|Group 1|End Stage Renal Diseas (ESRD) requiring hemodialysis
3289347|NCT01737866|Experimental|Group 2|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
3289348|NCT01737866|Experimental|Group 3|Mild decrease in GFR (eGFR 60-79 mL/min/1.73m^2)
3289349|NCT01737866|Experimental|Group 4|Moderate decrease in GFR (eGFR 30-59 mL/min/1.73m^2)
3289350|NCT01737866|Experimental|Group 5|Severe decrease in GFR (eGFR 15-29 mL/min/1.73m^2)
3289351|NCT01737866|Experimental|Group 6|Normal renal function (eGFR >or = 80mL/min/1.73m^2)
3289352|NCT01737892|Experimental|Arm T-Epinephrine Inhalation Aerosol HFA|Experimental arm utilizing Epinephrine HFA-MDI (E004)
3289353|NCT01737892|Active Comparator|Arm C-Epinephrine Inhalation Aerosol CFC|Active comparator arm utilizing Epinephrine CFC-MDI
3289354|NCT01737905|Experimental|Arm T|Experimental arm utilizing Epinephrine HFA-MDI (E004)
3289355|NCT01737905|Placebo Comparator|Arm P|Placebo comparator arm utilizing Placebo-HFA
3289356|NCT01737918|Experimental|trans obturatorial tape (TOT)|placement of a sub-urethral tape
3289357|NCT01737918|Active Comparator|solifenacin|10 mg per day
3289358|NCT01737957|Experimental|Low-fluence|Low-fluence pan-retinal photocoagulation in a single session for proliferative diabetic retinopathy
3289359|NCT01737957|Active Comparator|Full-fluence|Full-fluence pan-retinal photocoagulation for proliferative diabetic retinopathy
3289360|NCT01737983|Experimental|Lactobacillus reuteri (LR) ATCC55730|The tested probiotic, Lactobacillus reuteri, was administered in 5 drops per day (10^10 colony-forming units) for 6 months
3289361|NCT01737983|Placebo Comparator|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation for 6 months During the test period, patients were not allowed to consume any other product that contained probiotics or prebiotics
3289362|NCT01738009|Experimental|Induction of flow limitation|Flow limitation will be induced by sustained reductions in continuous positive airway pressure during sleep
3289363|NCT01738022|Experimental|Gas mixture administration|Subjects will breathe different gas mixtures with different densities and viscosity for brief periods in order to promote changes in peak inspiratory flow
3289364|NCT01738035|Experimental|NEFECON 8 mg/day|NEFECON 8 mg/day (2 active + 2 placebo capsules daily) for 9 months
3289365|NCT01738035|Experimental|NEFECON 16 mg/day|NEFECON 16 mg/day (4 active capsules daily) for 9 months
3289366|NCT01738035|Placebo Comparator|Placebo|Placebo (4 placebo capsules daily) for 9 months
3289367|NCT01738048||Mastectomy|Patients treated with mastectomy without reconstruction
3289368|NCT01738048||Reconstruction|Patients treated with mastectomy followed by reconstruction
3289369|NCT01738061|No Intervention|reference group|They continued their daily routine.
3289370|NCT01738061|Experimental|Multidimensional lifestyle intervention|The multidimensional lifestyle intervention program received motivational activities to improve awareness of the impact of lifestyle on chronic diseases and the importance of self-health management.
3289371|NCT01738074|Experimental|trivalent rotavirus genetic reassortment vaccine|2ml of rotavirus genetic reassortment vaccine by mouth every month for three month
3289372|NCT01738074|Placebo Comparator|Placebo|2ml of placebo by mouth every month for three month
3289373|NCT01738087|Experimental|NEXThaler 100/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 100/6 mcg DPI: total dose 400/24 mcg
3289374|NCT01738087|Experimental|NEXThaler 200/6 mcg DPI|Single dose (4 inhalations)of NEXThaler 200/6 mcg DPI: total dose: 800/24 mcg
3289375|NCT01738087|Placebo Comparator|NEXThaler placebo|Single dose (4 inhalations)
3289376|NCT01738087|Experimental|NEXThaler 100/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 100/6 mcg administered with activated charcoal (Charcoal Block): total dose 400/24 mcg
3289377|NCT01738087|Experimental|NEXThaler 200/6 mcg plus CB|Single dose (4 inhalations) NEXThaler 200/6 mcg administered with activated charcoal (Charcoal Block): total dose 800/24 mcg
3289378|NCT01738087|Active Comparator|Flixotide Accuhaler 500 mcg|Single dose (2 inhalations) of fluticasone propionate
3289379|NCT01738100|Experimental|Ticagrelor + Intracoronary Morphine|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Intracoronary Morphine Sulfate 3 mg + Saline 3 ml mix.
3289380|NCT01738100|Experimental|Ticagrelor + Intracoronary Saline|180 mg loading pre-PCI followed by 90 mg bid for 5 days. Saline 3 ml intracoronary injection.
3289381|NCT01738100|Experimental|Clopidogrel + Intracoronary Morphine|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Morphine Sulfate 3 mg + Saline 3 ml mix intracoronary injection.
3289382|NCT01738100|Active Comparator|Clopidogrel + Intracoronary Saline|600 mg loading pre-PCI followed by 75 mg qd for 5 days. Saline 3 ml intracoronary injection.
3289383|NCT01738113|Experimental|open kinetic chain exercise|Open kinetic chain exercise
3289384|NCT01738113|Experimental|Closed Kinetic chain exercise|Closed kinetic chain exercise
3289385|NCT01738139|Experimental|Treatment (ipilimumab, imatinib mesylate)|Patients receive ipilimumab IV over 90 minutes on day 1 and imatinib mesylate PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3289386|NCT01738152|Experimental|HLA treatment|This is a single arm prospective longitudinal clinical trial investigating the feasibility of a hyaluronic acid (HLA) vaginal gel (HyaloGYN®; Cebert Pharmaceuticals, Inc.; Birmingham, Alabama) to improve estrogen deprivation vaginal and vulvar health symptoms in post-menopausal women with a history of hormone-receptor positive cancer with estrogen deprivation symptoms of vaginal dryness and discomfort.
3289387|NCT01738178|Placebo Comparator|Control - Placebo|These participants will receive placebo tablets during the first 5 years
3289388|NCT01738178|Active Comparator|Caffeine group|This group of participants will receive caffeine tablets.
3289389|NCT01738204||Females with endometriosis|Females with a surgical diagnosis of endometriosis or who undergoing surgery for suspected endometriosis. At this time, we are only recruiting patients of Boston Children's Hospital and Brigham and Women's Hospital for this group.
3289390|NCT01738204||Females without surgical diagnosis of endometriosis|Females do not need to be patients of Boston Children's Hospital or Brigham and Women's Hospital.
3289391|NCT01738217|Experimental|Fluobeam|
3289392|NCT01738243|Experimental|Unilateral Upper Eyelid Retraction|"This arm will consist of participants with unilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel Injection or Saline injection"
3289393|NCT01738243|Experimental|Bilateral Upper Eyelid Retraction|"This arm will consist of participants with bilateral upper eye lid retraction secondary to thyroid eye disease (TED).~Patients enrolled will be randomized 1:1 to Hyaluronic Acid Gel injection or Saline injection"
3289394|NCT01738256|Experimental|Face-to-Face|Group meetings face-to-face using intervention for wellbeing with ACT principles.
3289395|NCT01738256|Experimental|Mobile|Intervention for wellbeing via mobile phone application with ACT principles.
3289396|NCT01738256|Experimental|Internet|Intervention for wellbeing via Internet (Virtual Health Check and Coaching).
3289397|NCT01738256|Experimental|Control|Control group, no intervention.
3289398|NCT01738269||Apparently healthy subjects|
3289399|NCT01738269||Non-malignant conditions subjects|
3289400|NCT01738269||Malignant conditions subjects|
3289401|NCT01738282|Experimental|Baclofen|Baclofen 20mg tablet. Titration:increasing dosage regimen to reach the target dosage of 180 mg (9 tablets)in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
3289402|NCT01738282|Placebo Comparator|Placebo|Placebo tablet Titration:increasing dosage regimen to reach the target dosage of 9 tablets in 7 weeks Maintenance period with a constant dosage during 17 weeks Progressive decrease and stop of study treatment in 2 weeks
3289403|NCT01738295|Active Comparator|Donepezil|Donepezil administration. In this group Donepezil (Aricept pill, 5 mg) will be orally administrated 3h before each experiment (1 week intervals)
3289404|NCT01738295|Placebo Comparator|Lactose pill|Placebo administration. In this group, placebo (lactose pill) will be orally administrated 3h before each experiments (1 week intervals)
3289405|NCT01738308|Experimental|Healing Touch Treatment|"Healing Touch Treatment~When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
3289406|NCT01738308|Sham Comparator|Sham Healing Touch Treatment|Usual standard of post operative care plus a sham Heal Touch treatment upon entering the post anesthesia care unit. Treatment done by untrained study staff using same hand locations.
3289407|NCT01738308|No Intervention|Control- No treatment done|Usual standard of post operative care with no additional intervention
3289408|NCT01738334|Active Comparator|Healthy subjects|"The active control group of healthy individuals was subjected to the practice of meditation for eight weeks."
3289409|NCT01738334|No Intervention|Standby|The control group of participants (patients and healthy subjects) who was not practice anything for eight weeks.
3289410|NCT01738334|Experimental|Meditation|A Group of Patients with ADHD was participate of the meditation practices for eight weeks.
3289411|NCT01738347|Experimental|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
3289412|NCT01738360|Experimental|Arsenic trioxide|Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day).
3289413|NCT01738399|Experimental|Coffee|Subjects take 4 cups of coffee mix per day for 24 weeks
3289414|NCT01738399|Placebo Comparator|Placebo|Subjects take 4 cups of placebo per day for 24 weeks
3289415|NCT01738412||Study population|Stroke patients
3289416|NCT01738425|Experimental|GIC-1001 oral tablets|GIC-1001; 125 mg oral tablets; Single ascending doses (SAD) from 125 mg to 1000 mg; multiple ascending dose (MAD) from 125 mg to 500 mg TID over 7 successive days
3289417|NCT01738425|Placebo Comparator|GIC-1001 matching placebo|Matching placebo, single or multiple dosing
3289418|NCT01738451|Experimental|Part 1(Cohort 1): GSK2118436 225 mg|GSK2118436 (3 capsules of 75 mg) will be administered orally at the dose of 225 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal.
3289419|NCT01738451|Experimental|Part 1(Cohort 2): GSK2118436 300 mg|GSK2118436 (4 capsules of 75 mg) will be administered orally at the dose of 300 mg BID from Day 1 to 7 (and single dose on Day 8) under fasted conditions, either 1 hour before or 2 hours after a meal. If 225 mg BID is not tolerated in Part 1 /Cohort 1, then Part 1/Cohort 2 will not be initiated and 150 mg BID will be used in Part 2.
3289420|NCT01738451|Experimental|Part 2: GSK2118436 300 mg (or highest tolerated dose)|Subjects will receive a single dose of GSK2118436/placebo (4 capsules of 75 mg/highest tolerated dose) orally on the first 2 days of the study followed by 2 doses daily for 6 days and a single dose on the 9th day. There will be 1 day when a placebo will be given. All doses will be administered under fasted conditions, either 1 hour before or 2 hours after a meal.
3289421|NCT01738464||Pelvic Pain|Interstitial Cystitis or Chronic Prostatitis/Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, and Overactive Bladder patients will be compared to Healthy and Depressed patients.
3289422|NCT01738464||Controls|Healthy patients will be used as controls to compare to patients diagnosed with Interstitial Cystitis, Chronic Prostatitis, Chronic Pelvic Pain Syndrome, Lower Urinary Tract Symptoms, Overactive Bladder, and Depressed patients.
3289423|NCT01738464||Major Depression|Major Depression patients will be compared to Controls and Pelvic Pain cohorts.
3289424|NCT01738490|Other|Wide diameter implant|Bone anchored hearing implant For the wide diameter arm (test group), the Ponto wide implant (diameter 4,5mm, length 4mm) and abutment 6mm developed by Oticon Medical AB (Gothenburg, Sweden) will be installed.
3289425|NCT01738490|Other|Control group|Bone anchored hearing implant For the control group, the previous generation Ponto implant (diameter 3,75mm, length 4mm) and 6mm abutment (Oticon Medical AB, Gothenburg, Sweden) will be installed.
3289426|NCT01738516|Other|epileptic patients|Electroencephalography
3289427|NCT01738516|Other|Healthy Volunteers|Electroencephalography and additional experimental tasks
3289428|NCT01738529|Active Comparator|CLE ileocolonoscopy on Crohn patients|Patients known with Crohn´s disease
3289429|NCT01738529|Sham Comparator|CLE ileocolonoscopy on control patients|CLE ileocolonoscopy on patients without known IBD
3289430|NCT01738542|Experimental|Antiaggregants & Statins & Antihypertensives & Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks) plus Antiaggregant therapy (AAS 100mg/d or Clopidogrel 75mg/d), Statins and Antihypertensive therapy
3289431|NCT01738542|Active Comparator|Antiaggregants & Statins & Antihypertensives|Antiaggregant therapy (AAS 100 mg/d or Clopidogrel 75 mg/d), Statins, Antihypertensive therapy
3289432|NCT01738555|Experimental|amdoxovir 300 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
3289433|NCT01738555|Experimental|amdoxovir 500 mg bid|in combination with zidovudine 300 mg bid and lopinavir/ritonavir (400 mg/100 mg bid) for 36 weeks.
3289434|NCT01738568|Experimental|Exercise|Aerobic exercise
3289435|NCT01738607|Placebo Comparator|Placebo|"basic recipe for juice and muffin recipe~abbreviated PLB"
3289436|NCT01738607|Experimental|Carboxymethylcellulose|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated CMC"
3289437|NCT01738607|Experimental|Gum Arabic|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated GA"
3289438|NCT01738607|Experimental|Psyllium|"The supplements were prepared as two fruit juice mixtures (each 270 ml) providing 7 g total fiber/d) and two small muffins providing 9 g total fiber/d for 16 g of toal fiber daily.~abbreviated as PSY"
3289439|NCT01738620|Experimental|psychological counseling+prevention of sleep disorders in ICU|patients will receive both psychological counseling and interventions to prevent sleep disorders during their ICU stay
3289440|NCT01738620|Experimental|psychological counseling|patients will receive psychological counseling
3289441|NCT01738620|Experimental|prevention of sleep disorders in ICU|interventions to prevent sleep disorders during their ICU stay
3289442|NCT01738620|No Intervention|standard care|patients will receive standard care
3289443|NCT01738633|Experimental|nutritional + respirology counseling|patients will receive both nutritional and respirology counseling
3289444|NCT01738633|Experimental|nutritional counseling|patients will receive nutritional counseling alone
3289445|NCT01738633|Experimental|respirology counseling|patients will receive respirology counseling alone
3289446|NCT01738633|No Intervention|standard care|patients will receive standard care
3289447|NCT01738659|Experimental|normal sodium diet (120 mmol/die)|active comparator: low sodium diet (80 mmol/die)
3289448|NCT01738685|Other|Control.|Nutritional Education.
3289449|NCT01738685|Other|Behavioral Intervention|Behavioral Intervention.
3289450|NCT01738711|Active Comparator|Cognitive Behavioural Therapy|Patient in this arm receive 2-6 sessions of cognitive behavioural therapy
3289451|NCT01738711|Placebo Comparator|Written information on CBT|Patients in this arm do not receive sessions of CBT but receive written information on anxiety control as per standard practice
3289452|NCT01738724|Experimental|Dienogest|Dienogest 2mg pills daily during 6 months
3289453|NCT01738724|Experimental|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
3289454|NCT01738724|Active Comparator|Desogestrel|Desogestrel 75mcg pills daily during six months
3289455|NCT01738763|Experimental|Low dose (2.5 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3289456|NCT01738763|Experimental|Intermediate dose (4.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3289457|NCT01738763|Experimental|High dose (6.0 g of pinitol)|Each subject completed two 1-day trials separated by a 1-week interval. The subjects were randomized by alternation method to belong to the group of low, intermediate or high dose, containing 2.5, 4.0 or 6.0 g of pinitol, respectively. Each subject was newly randomized (1:1) and cross-over into one of two groups: one that received the pinitol-enriched beverage, and the other a placebo beverage. In this way, each dose and its corresponding placebo were studied in 10 normoglycaemic subjects.
3289458|NCT01738776||Cases|Hip fracture patients participating in a randomised controlled trial (RCT) of orthogeriatric care (ClinicalTrials.gov NCT01009268)
3289459|NCT01738776||Controls|A group of voluntary elderly persons without a history of hip fracture, recruited specifically for this purpose
3289460|NCT01738802|Experimental|Anti-oxidant and micronutrient|This group will take the anti-oxidant and micronutrient supplement.
3289461|NCT01738802|Placebo Comparator|Placebo|This group will take the placebo.
3289462|NCT01738815|Experimental|valproic acid|Patients will be administered valproic acid (Depakote ER) for up to 30 days prior to tumor resection
3289463|NCT01738828||Subjects with CAD|
3289464|NCT01738828||Subjects without CAD|
3289465|NCT01738841||Cohort Group|Children aged 12 months to 12 years will receive Priorix-Tetra as prescribed by the physician.
3289466|NCT01738854|Experimental|intra-cuff pressure 40 cmH2O|
3289467|NCT01738854|Active Comparator|intra-cuff pressure 60 cmH2O|
3289468|NCT01738854|Active Comparator|intra-cuff pressure 80 cmH2O|
3289469|NCT01738867|Placebo Comparator|Treatment A|Subject will receive oral dose of matching placebo once daily for 5 days in one of the 3 treatment periods.
3289470|NCT01738867|Experimental|Treatment B|Subject will receive 25 mg orally once daily for the first two days and 50 mg once daily for 3 days in one of the 3 treatment periods.
3289471|NCT01738867|Experimental|Treatment C|Subject will receive 10 mg orally once daily for 5 days in one of the 3 treatment periods.
3289472|NCT01738880|Active Comparator|group C|intraoperative fluid management based on CVP
3289473|NCT01738880|Experimental|group S|intraoperative fluid management based on SVV
3289474|NCT01738893|Experimental|A (test)/ B (reference)|initial administration of test and cross-over to reference
3289475|NCT01738893|Experimental|B (reference/ A (test)|initial administration of reference and cross-over to test
3289476|NCT01738906|Experimental|Alcohol placebo and MSF|175 mL orange juice with 31 g Fantomalt maltodextrin and modified sham feeding of 40 g butter cake
3289477|NCT01738906|Experimental|Alcohol and MSF|65 mL vodka with 135 mL orange juice (ca 20 g alcohol)and modified sham feeding of 40 g butter cake
3289478|NCT01738906|Experimental|Alcohol placebo and consumption|175 mL orange juice with 31 g maltodextrin and consumption of 40 g butter cake
3289479|NCT01738906|Experimental|Alcohol and consumption|65 mL vodka with 135 mL orange juice and consumption of 40 g butter cake
3289480|NCT01738906|Experimental|Alcohol placebo and control|175 mL orange juice with 31 g maltodextrin and no oral exposure to butter cake
3289481|NCT01738906|Experimental|Alcohol and control|65 mL vodka with 135 mL orange juice and no oral exposure to butter cake
3289482|NCT01738932||Patients|women with histologically verified endometriosis
3289483|NCT01738932||Controls|Healthy Danish blood donors
3289484|NCT01738945|Other|Amlodipine|Amlodipine 10 mg/day for 12 weeks
3289485|NCT01738958|Active Comparator|Probiotic lactobacilli|L. reuteri, two times a day for 6 weeks
3289486|NCT01738958|Placebo Comparator|Placebo|Placebo tablets, two times a day for 6 weeks
3289487|NCT01738997|Experimental|Group A|Dilation 10 sec
3289488|NCT01738997|Active Comparator|Group B|Dilation 2 min
3289489|NCT01739023|Experimental|Autologous Human Schwann Cells|
3289490|NCT01739036|Active Comparator|Group 4|Unvaccinated control volunteers who undergo controlled human malaria infection.
3289491|NCT01739036|Active Comparator|Group 3|Controlled human malaria infection administered at an interval of approximately 8-12 months after the initial controlled human malaria infection that the volunteers received in the VAC045 clinical trial.
3289492|NCT01739036|Active Comparator|Group 2|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp and ChAd63 AMA1 5 x 1010 vp followed by intramuscular administration of a mixture of MVA ME-TRAP 1.33 x 108 pfu and MVA CS 1.33 x 108 pfu and MVA AMA1 1.33 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
3289493|NCT01739036|Active Comparator|Group 1|Intramuscular administration of a mixture of ChAd63 ME-TRAP 5 x 1010 vp and ChAd63 CS 5 x 1010 vp, followed by intramuscular administration of a mixture of MVA ME-TRAP 2 x 108 pfu and MVA CS 2 x 108 pfu eight weeks later, followed by controlled human malaria infection 17-24 days later.
3289494|NCT01739049|Experimental|Liraglutide and lifestyle counselling|"Liraglutide 0.6mg od for 1st week, then 1.2mg od for 2nd week then 1.8mg od until 12 weeks.~Diet and Exercise"
3289495|NCT01739049|Active Comparator|Lifestyle counselling|Diet and Exercise
3289496|NCT01739062|Experimental|Genetic risk assessment|At least 40 SNP (single nucleotide polymorphisms)increase the risk of PCa. The individual risk of PCa accumulates with the increasing number of these genetic variants. The risk is doubled if patient has familial disposition as well. In retrospective studies, non-genetic risk-prediction models were compared to risk-prediction models containing both non-genetic factors and SNPs analyses. The genetic models had a significantly higher specificity than the non-genetic models. It has been argued that genetic PCa risk assessment could reduce the inexpedient use of PSA tests, saving it for patients at high risk of PCa.
3289497|NCT01739062|No Intervention|Familial disposition risk assessment|
3289498|NCT01739088|Experimental|Remote ischemic preconditioning stimulus|The remote ischemic pre-conditioning arm of the study is the experimental one. Patients in this arm will receive a remote ischemic pre-conditioning stimulus at 24-48 hours pre-operatively, and again intra-operatively before CPB.
3289499|NCT01739088|Sham Comparator|Sham Ischemic Pre-conditioning|In the control (sham-RIPC) group the cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the the control group.
3289500|NCT01739101|Experimental|Intervention group|The intervention group answered a baseline questionnaire in the waiting room and received the intervention (Reproductive Life Plan) in addition to standard care.
3289501|NCT01739101|No Intervention|Control group 1|The control group 1 answered a baseline questionnaire in the waiting room and received standard care.
3289502|NCT01739101|No Intervention|Control group 2|The control group 2 received standard care.
3289503|NCT01739114|Experimental|"SI group"|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cm H2O.~After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cm H2O and PEEP of 5 cm H2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided."
3289504|NCT01739114|Active Comparator|IPPV group|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
3289505|NCT01739127||Aripiprazole|Participants receiving treatment with at least 10mg aripiprazole per day, as prescribed to them by their psychiatrists.
3289506|NCT01739127||Risperidone/Quetiapine|Participants receiving treatment with either risperidone or quetiapine, as prescribed to them by their psychiatrists.
3289507|NCT01739127||Control|Healthy participants who are not taking any antipsychotic medications.
3289508|NCT01739140|Experimental|Yoga|Study Participants will receive: 12 weekly yoga classes, a book and a home practice audio recording.
3289509|NCT01739153|Experimental|CARB diet|The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
3289510|NCT01739153|Experimental|CHEESE diet|The CHEESE diet will contain cheese in amounts corresponding to 120 g/day on a 10 MJ diet (approx. 1.8 MJ from cheese). A high dose of cheese is chosen to provoke effects within this short time frame. The cheese types used in this study will be Danbo (45+) and Cheddar (50+) which will be supplied in equal amounts. The CHEESE diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
3289511|NCT01739153|Experimental|MEAT diet|The MEAT diet will be a diet without dairy products. In this diet cheese is mainly replaced by high-fat mixed meat products to achieve saturated fat content and protein quality similar to that of the CHEESE diet. The MEAT diet will have the same macronutrient composition as that of the average Danish diet (15 E% from protein, max 35 E% from fat, and max 15 E% from saturated fat).
3289512|NCT01739166|Experimental|Practice-tailored intervention - Early/Phase 1|During the 6 month Intervention Phase the Practice Facilitator works with each practice to create changes that are tailored to their individual preferences and methods of operation. Sites randomized to Early/Phase 1 start their 6 month intervention immediately after randomization.
3289513|NCT01739166|Experimental|Practice-tailored intervention - Late/Phase 2|The Phase 2 group will start the practice-tailored intervention with the study facilitator 4 months post-randomization and continue through post-randomization month 10.
3289514|NCT01739179||1|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter
3379174|NCT00182858||1|Participants will be 18 years or older that are Healthy Volunteers or have been identified by the investigator and/or physician to have a condition of interest for exploratory studies related to the participant s illness or other feature that offers the possibility of creating information that leads to scientifically useful and important studies.
3379175|NCT00156767||Bone Marrow Transplant|Patients enrolled in an NCI protocols for bone marrow transplant for breast cancer using prednisone treatment.
3379176|NCT00156767||Cirrhosis|Adults on NIDDK protocol 91-DK-0213 with evidence of chronic liver disease with class A or B cirrhosis secondary to viral hepatitis
3379177|NCT00156767||Critical Care|Patients with a diagnosis of sepsis by the primary clinical provider in the Emergency room of ICU
3379178|NCT00156767||Healthy Volunteer|Healthy adult volunteers
3379179|NCT00156767||Known Adrenal Insufficiency|patients with known diagnosis of Adrenal Insufficiency
3289515|NCT01739179||2|VP Shunt Surgery for open insertion of the peritoneal catheter
3289516|NCT01739192|Placebo Comparator|Arm 1|Placebo oral daily for approximately six (6) weeks.
3379180|NCT00156767||Nephrotic Syndrome|Adults enrolled in NIDDK protocols with diagnosis of nephrotic syndrome
3379181|NCT00156767||Post Surgical Treatment for Cushings|Patients with transient adrenal insufficiency secondary to successful surgical treatment of cushing's syndrome
3289517|NCT01739192|Experimental|Arm 2|Naltrexone (25 mg) oral daily for approximately six (6) weeks.
3379182|NCT00128960||1|Participants with different types of diseases and conditions who have undergone an allogeneic (donor) stem cell transplant.
3289518|NCT01739192|Experimental|Arm 3|Naltrexone (50 mg) oral daily for approximately six (6) weeks.
3289519|NCT01739205|Experimental|Lifestyle counseling|"CALM-D Intervention Session Topic Weekly~I Welcome to the CALM-D Program. Getting Started Being Active, Losing Weight and Managing Stress~I Negative Thoughts and Emotions~G Where's the Fat?/Three Ways to Eat Less Fat~G Taking Your Medications/Stress and You Bi weekly~G Move Those Muscles/Being Active: A Way of Life~G Challenging and Changing Negative Thoughts~G Healthy Eating~G Problem Solving Monthly~G Four Keys to Healthy Eating Out~G Social Support/Communication~G Take Charge of What's Around You/Tip the Calorie Balance~G The Slippery Slope of Lifestyle Change~G Jump Start Your Activity Plan~G Assertiveness/Make Social Cues Work for You.~G You Can Manage Stress~G Life Goals~G Ways to Stay Motivated Abbreviations: I = Individual session; G = Group session"
3379187|NCT00114647||1|Healthy Volunteers
3379188|NCT00114647||2|HIV
3379189|NCT00111384||Group A|Affected participants, must have a correct clinical diagnosis of NF1.
3289520|NCT01739218|Experimental|Carboplatin + Paclitaxel + Bevacizumab|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered during both the neoadjuvant and the adjuvant treatment periods in Cycles 1 to 26 (no treatment in Cycles 4 and 5).
3379190|NCT00111384||Group B|Unaffected individuals greater than 2 years of age who are relatives of participants.
3379191|NCT00106925||1|allogeneic stem cell transplant recipients
3379192|NCT00106925||2|Donors
3379193|NCT00104325||1|white blood cells obtained through cytapheresis by healthy males and females 18 years and older
3379194|NCT00092235||Cohort 1|Patients who have undergone an allogeneic stem cell transplant and are diagnosed withcGVHD
3379195|NCT00092235||Cohort 2|Pediatric patients who have undergone an allogeneic stem cell transplant and arediagnosed with cGVHD
3379196|NCT00092235||Cohort 3|Patients who have undergone an allogeneic stem cell transplant and choose to submitbiopsy, blood and urine samples only
3289521|NCT01739218|Active Comparator|Carboplatin + Paclitaxel|Participants will receive 4 cycles of neoadjuvant therapy prior to IDS and 22 cycles of adjuvant therapy before entering long-term follow-up. Each cycle will be 3 weeks in length. Carboplatin and paclitaxel will be administered during Cycles 1 to 8. Bevacizumab will be administered only during the adjuvant treatment period in Cycles 6 to 26.
3289522|NCT01739244|Experimental|SYL040012 eye drops dose A|Ocular topical administration of SYL040012 eye drops dose A
3289523|NCT01739244|Experimental|SYL040012 eye drops dose B|Ocular topical administration of SYL040012 eye drops dose B
3289524|NCT01739244|Experimental|SYL040012 eye drops dose C|Ocular topical administration of SYL040012 eye drops dose C
3289525|NCT01739244|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
3289526|NCT01739257|Experimental|Theater|"1-hour dramatic reading of The Most Massive Woman Wins"
3289527|NCT01739257|Active Comparator|Lecture|1-hour lecture on the medical management of obese patients
3289528|NCT01739270|Active Comparator|dexamethasone with levobupivacaine|25ml 0.5% levobupivacaine plus 4mg Dexamethasone are given for supraclavicular brachial plexus block for upper extremity surgery
3289529|NCT01739270|Active Comparator|levobupivacaine|25ml 0.5% levobupivacaine plus 1ml 0.9% saline are given for supraclavicular brachial plexus block for upper extremity surgery
3289530|NCT01739283|Experimental|hyperglycemia|Hyperglycemic clamping
3289531|NCT01739283|Experimental|hypoglycemia|Hypoglycemic clamping
3289532|NCT01739296|Experimental|Wedge|Lateral wedge insole with subtalar strapping Use of lateral wedge insoles with subtalar strapping for 5 to 10 hours daily
3289533|NCT01739296|Sham Comparator|Neutral|Neutral insole with subtalar strapping (sham) Use of neutral insoles with subtalar strapping for 5 to 10 hours daily
3289534|NCT01739322|Experimental|1|"Four concentrations of Platanus acerifolia allergen extract (10, 1, 0.1, 0.01 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
3289535|NCT01739374|Experimental|Device - Reduced mesh implants|Patients treated with reduced mesh implants for POP reconstruction
3289536|NCT01739387||Breath actuated inhaler (BAI)|Placebo. Two to nine puffs on one day only
3289537|NCT01739387||Flutiform® pMDI|Placebo. Two to nine puffs on one day only
3289538|NCT01739413|Active Comparator|General Anesthesia|Patients will receive general anesthesia alone followed by intravenous morphine for postoperative pain control. This techniques is safe and is standard procedure for colorectal surgery.
3289539|NCT01739413|Experimental|Epidural Anesthesia|Patients will receive general anesthesia plus epidural anesthesia followed by epidural analgesia for postoperative pain control. This techniques is safe and standard procedure for colorectal surgery.
3289540|NCT01739426|Experimental|Study population|"The population is composed of patients with a confirmed Zenker's diverticulum.~Intervention: Repair w/LigaSure"
3289541|NCT01739439|Experimental|Treatment (chemoradiation and radiosurgery)|Patients receive gemcitabine hydrochloride IV over 30 minutes once weekly and undergo hyperfractionated IMRT 5 days a week in weeks 1-3. Patients then undergo a single fraction of radiosurgery boost in week 5 and then receive gemcitabine hydrochloride IV over 30 minutes once weekly in weeks 6-8. Treatment continues in the absence of disease progression or unacceptable toxicity.
3289542|NCT01739452||erythropoiesis-stimulating agents|Patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1), treated with erythropoiesis-stimulating agents.
3289543|NCT01739452||Transfusion support|A control group of patients who received only transfusional support.
3289544|NCT01739465|Active Comparator|Self expanding metallic stent （SEMS ）placement only|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
3289545|NCT01739465|Experimental|Endoscopic radiofrequency ablation plus SEMS|Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) would be performed to confirm the position and length of the biliary malignant. The radiofrequency ablation (RFA) catheter (EMcision, London, United Kingdom) would be placed under fluoroscopic guidance across the biliary stricture. Radiofrequency energy will be delivered to the malignant site. After that,A self expanding metallic stent (SEMS) would be placed to bypass the site of narrowing
3289546|NCT01739465|Experimental|Photodynamic therapy plus SEMS|Photofrin is injected 3 days prior to laser activation of the agent.Endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) will be carried out to determine the length and positon of the biliary malignant. Delivery Fiber used along with the laser system to activate the photosensitizing agent and induce tumor tissue necrosis. A self expanding metallic stent (SEMS) will be placed the site of biliary narrowing
3289547|NCT01739478|Experimental|Non-packing of abscess cavity|
3289548|NCT01739478|Other|Packing of abscess cavity|Current practice
3289549|NCT01739491||Bendamustine hydrochloride|Adult Filipino patients with chronic lymphocytic leukemia will be taking bendamustine hydrochloride as per the dosing regimen given on product insert approved in Philippines.
3289550|NCT01739504|Experimental|Autologous Adipose-derived Stromal Vascular Fraction infusion|Intervention: AD-SVF infusion directly into affected joints.
3289551|NCT01739517|Experimental|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
3289552|NCT01739530|Experimental|Repaircell|allogenic differentiated adipocyte
3289553|NCT01739543|Experimental|Investigational|Subject receives Hem-Avert Device.
3289554|NCT01739543|No Intervention|Control|Subject does not receive Hem-Avert Device.
3289555|NCT01739556|Experimental|Intervention Arm|Antiplatelet regimen modification will be guided by assessment of the on-treatment platelet reactivity. Low responders to aspirin will receive 200 mg aspirin for 30 days. Low responders to clopidogrel will receive 180 mg ticagrelor for 1 year.
3289556|NCT01739556|No Intervention|Standard Treatment|Patients enrolled in the Standard Treatment arm will receive standard antiplatelet regimen including 100 mg aspirin and 75 mg clopidogrel without assessment of on-treatment platelet reactivity.
3289557|NCT01739569|Experimental|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
3289558|NCT01739569|No Intervention|Habitual meals|Dietary treatment with habitual diet
3289559|NCT01739582|Experimental|Androxal|Androxal (enclomiphene citrate) 12.5 mg, once daily, oral capsule. Subjects will be up-titrated to 25 mg if testosterone levels remain below 450 ng/dL at visit 2.
3289560|NCT01739608|Experimental|CT Colonography (CTC)|Invitation to screening. Subject who consent to participate in the study undergo to low dose CTC examination with limited bowel preparation.
3289561|NCT01739608|Active Comparator|Sigmoidoscopy (FS)|Invitation to screening. Subjects who consent to participate in the study undergo to FS.
3289562|NCT01739621|Experimental|Proellex 12 mg|Telapristone acetate, 1 vaginally inserted capsule, once a day, for 4 months
3289563|NCT01739621|Experimental|Proellex 24 mg|Telapristone acetate, 1 vaginally inserted capsule, twice a day, for 4 months
3289564|NCT01739634|Experimental|Active Drug|After a 1 week run-in period CASAD will be administered TID for 1 week. Each dose will be 2 500mg CASAD capsules. Patients will be followed for two weeks post active drug administration.
3289565|NCT01739647|Experimental|AZD3293|Up to 11 sequential cohorts of healthy young and healthy elderly subjects are planned, with single ascending doses ranging from 1mg to a maximum of 1000mg
3289566|NCT01739647|Placebo Comparator|Placebo|Placebo given (2 subjects in each cohort)
3289567|NCT01739660|Experimental|Pegloticase|Pegloticase 8 mg single intraveneous dose
3289568|NCT01739673|Experimental|Ultraviolet-A and riboflavin|
3289569|NCT01739686|Experimental|CASA Intervention|"The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
3289570|NCT01739686|No Intervention|Usual Care|Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. If patients self-report depression on baseline surveys, this information will be given to their provider, and patients will be given resources. Patients will have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency.
3289571|NCT01739712|Experimental|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
3289572|NCT01739712|Sham Comparator|Fixed Sleep Duration|All youth in this condition are asked to maintain their baseline sleep duration.
3289573|NCT01739725|Experimental|Helical stent insertion|Study participants will receive the helical stent
3289574|NCT01739738||no Ureteral Stent - control group|non-stented volunteers to receive ultrasound for peristalsis changes detection
3289575|NCT01739738||Ureteral stent|patients who receive stent, and to receive ultrasound for peristalsis changes detection in their stented and non-stented ureter
3289576|NCT01739751|No Intervention|Control Group|Patients without feedback of a pedometers, followed for 3 months
3289577|NCT01739751|Experimental|Pedometers|With a program of physical activity enhancement using pedometers as a feedback
3289578|NCT01739777|Experimental|ucMSC|Umbilical cord derived mesenchymal are injected intravenously to Patients.
3289579|NCT01739777|Placebo Comparator|Controls|Intravenous placebo solution are administrated to Patients.
3289580|NCT01739816|No Intervention|Control group|Patients get no intervention at study start, but only at study end after seven months.
3289581|NCT01739816|Active Comparator|Intervention group|At the beginning and at the end of the study, this group receives a pharmacist's led medication review focusing on daily medicines use (= Polymedication Check).
3289582|NCT01739816|Other|Observational arm|If participants after recruitment violate inclusion criteria (e.g. change from autonomous medication management to external home care) or insists on intervention despite being randomised to control group or patient condition forces pharmacist to provide a PMC.
3289583|NCT01739829|Experimental|DIABECELL group 1|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
3289584|NCT01739829|Experimental|DIABECELL group 2|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
3289585|NCT01739842|Active Comparator|Kudzu extract treatment|"Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day for a total dose of 3 grams of kudzu."
3289586|NCT01739842|Placebo Comparator|Placebo|"Placebo will be administered as a pretreatment 2 ½ hours before a drinking session.~During the medication week, participants will take 2 capsules three times a day."
3289587|NCT01739855|Active Comparator|Calcium/Vitamin D|"All subjects will receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery as follows:~daily: 500 mg oral calcium (calcium carbonate) weekly: 16.000 IU oral vitamin D3 (calciferol)"
3289588|NCT01739855|No Intervention|No Calcium/Vitamin D|All subjects will not receive calcium/vitamin D supplementation after laparoscopic bariatric gastric bypass surgery.
3289589|NCT01739894|Experimental|IP Paclitaxel|Paclitaxel will be administered intraperitoneally at 40mg/m2 on Days 1 and 8 in a 21-day cycle in patients receiving intravenous oxaliplatin 100mg/m2 on Day 1 and capecitabine 1000mg/m2 twice daily on Days 1-14.
3289590|NCT01739907|Experimental|Iron-fortified dairy product|Consumption of an iron-fortified flavoured skimmed milk as part of the usual diet
3289591|NCT01739907|Experimental|Iron and vitamin D dairy product|Consumption of an iron and vitamin D fortified flavoured skimmed milk as part of the usual diet
3289592|NCT01739920|Experimental|Povidone-iodine|1 drop of povidone-iodine 5% will be instilled at time zero, 20-minute and 28-minute study period.
3289593|NCT01739920|Active Comparator|Povidone-iodine and Saline Solution|1 drop of saline solution 0.9% will be instilled at time zero and 20-minute. At 28-minute will be instilled 1 drop of Povidone-iodine 5%.
3289594|NCT01739946||Implanted subject|Subjects with Interstim implanted
3289595|NCT01739946||Controls|Subjects without Interstim implanted
3289596|NCT01739959||Necrotizing fasciitis proven|Histological evidence of necrotizing fasciitis at initial surgical debridement
3289597|NCT01739959||Not necrotizing fasciitis|A composite of those with no histological tissue necrosis at initial surgical debridement, and those clinically judged not to be a necrotizing infection who therefore did not undergo surgery.
3289598|NCT01739972|Active Comparator|Levothyroxine|Levothyroxine in the capsule form, once daily, appropriate dosage to keep TSH at the normal range.
3289599|NCT01739972|Active Comparator|Desiccated thyroid extract|Desiccated thyroid extract in capsule form, once daily, appropriate dosage to keep TSH in the normal range.
3289600|NCT01739985|Active Comparator|Dexamethasone + ondansetron + Placebo|dexamethasone + ondansetron + Placebo
3289601|NCT01739985|Experimental|Dexamethasone + ondansetron + Droperidol|dexamethasone + ondansetron + Droperidol
3289602|NCT01739998|Experimental|functional oil|Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15% EPA) Orange flavour] during the day by 8 weeks.
3289603|NCT01739998|Placebo Comparator|Placebo|Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks
3289604|NCT01740011|Experimental|Group A|Laparoscopic surgery with AirSeal CO2 pressure insufflation
3289605|NCT01740011|Active Comparator|Group S|Laparoscopic surgery with standard CO2 pressure insufflation
3289606|NCT01740024|Experimental|1 (Dose-Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations Positive control Negative control
3289607|NCT01740037|Experimental|Specialized AF-clinic|Management of AF patients in specialized outpatient AF Clinics according to the principles of an integrated chronic care program (ICCP) performed by a nurse practitioner/ physician assistant/ specialised cardiovascular nurse, cardiologist, supported by an ICT decision support tool based on professional guidelines (CardioConsult AF®). The use of a web-based patient centered management of patient's own medication (Medication manager TM) was optional. A standardized diagnostic, treatment and follow-up pathway was performed within the ICCP. In addition, the intervention is based on identifying risk factors and potential problems in patients, and addressing needs through dynamic use of personalized education and adjustment of treatment.
3289608|NCT01740037|Active Comparator|Usual Care|Usual care provided by cardiologists at the regular outpatient clinic.
3289609|NCT01740050|Active Comparator|Roux- and Y bypas surgery (RYGB)|"One subject group will lose 10% of initial body weight using RYGB. RYGB is an operation that first divides the stomach into a small upper pouch and a much larger lower remnant pouch and then re-arranges the small intestine to connect to both, in this way bypassing part of the small intestine."
3289610|NCT01740050|Active Comparator|Laparoscopic adjustable gastric banding (LAGB)|One subject group will lose 10% of initial body weight using LAGB. With LAGB an inflatable band is placed around the upper part of the stomach to create a smaller stomach pouch. This slows and limits the amount of food that can be consumed at one time giving the opportunity for the sense of satiety to be met. It does not decrease gastric emptying time.
3289611|NCT01740050|Active Comparator|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
3289612|NCT01740063|Experimental|DAS181-F02 formulation|DAS181 10 mg dose for three days of the F02 formulation
3289613|NCT01740063|Experimental|DAS181-F04 formulation|DAS181 20 mg dose group for three days of the F04 formulation,
3289614|NCT01740063|Placebo Comparator|Placebo|placebo group
3289615|NCT01740076|Experimental|soy nuts|25 g of soy nuts provided daily to the subjects and they were counseled to replace 25 g of protein in their therapeutic lifestyle change (TLC) diet with the soy. TLC diet consisted of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
3289616|NCT01740076|Other|Therapeutic lifestyle change diet|Counseling on therapeutic lifestyle change diet consisting of 30% of energy from total fat (<7% saturated fat, 12% monounsaturated fat and 11% polyunsaturated fat), 15% from protein and 55% from carbohydrate; less than 200 mg of cholesterol per day and 1200 mg of calcium and 2 fatty fish meals per week. Those ingesting suboptimal dietary calcium were given calcium carbonate supplementation.
3289617|NCT01740102|Experimental|RIPC|Remote ischemic preconditioning (RIPC) in the operating theatre after induction of anaesthesia and before surgery.
3289618|NCT01740102|No Intervention|No RIPC|Patients in the control group will not receive remote ischemic preconditioning before the surgery.
3289619|NCT01740141|Other|Plexus before surgery|Plexus brachialis before surgery
3289620|NCT01740141|Other|Plexus after surgery|Plexus brachialis performed after surgery
3289621|NCT01740167|Experimental|Lifestyle program|health promotion lifestyle program : individual counseling, once a month, total 3 times.
3289622|NCT01740180||CLIPPERS patients|"The population concerned by this study consists of patients diagnosed according to CLIPPERS criteria (see inclusion and exclusion criteria).~Intervention: Data entry"
3289623|NCT01740193|Active Comparator|TAP Block|
3289624|NCT01740193|Active Comparator|Ilioinguinal/iliohypogastric blockade|
3289625|NCT01740219|Experimental|Capacity Enhancement|
3289626|NCT01740219|Active Comparator|Standard Dissemination|
3289627|NCT01740232|Active Comparator|Trephination|A 1 x 10 mm pricker are used for the trephination of the meniscus before normal meniscal repair.
3289628|NCT01740232|Placebo Comparator|Normal meniscal repair|standard operation. Normal meniscalrepair.
3289629|NCT01740245|Active Comparator|Chlorhexidine|
3289630|NCT01740245|Experimental|Polyhexamethylene biguanide|
3289631|NCT01740271|Experimental|Epirubicin|Following genetic analysis, depending on results, participants will receive either standard or increased epirubicin dosing for cycles 2 - 4.
3289632|NCT01740284|Active Comparator|Grazax + Aerius|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (desloratidine) 2.5 mg
3289633|NCT01740284|Placebo Comparator|Grazax + Placebo|1 tablet (oral lyophilisate ) on Day 14 and Day 28 of Grazax (Phleum Pratense grass pollen allergen extract) 75.000 SQ-T and 1 tablet (melting tablet)of Aerius (Placebo)
3289634|NCT01740310|Experimental|High Elaboration Video Arm|Women randomized to this arm will be exposed to a handheld/electronic tablet device-based video with detailed vaccine-related information designed to invoke a high level of attention to the message and thought (elaboration) while processing information.
3289635|NCT01740310|Experimental|High Elaboration Interactive Tutorial Arm|Women will be exposed to a handheld/electronic tablet device-based intervention designed to invoke a high level of attention to the message and thought (elaboration) while processing information through an interactive question/answer format.
3289636|NCT01740310|Placebo Comparator|Low Elaboration / Control Arm|Women randomized to the control arm will be provided standard CDC vaccine information statements that will likely lead to low elaboration information processing.
3289637|NCT01740336|Experimental|A: Paclitaxel, GDC-0941|Participants will receive GDC-091 260 milligrams (mg) orally in repeated rounds of once daily (QD) dosing for 5 consecutive days followed by 2 consecutive days during which GDC-0941 will not be administered (5/7-day schedule). This 5/7-day schedule will be repeated weekly in each 28-day cycle until disease progression or intolerable toxicity. Participants will receive 90 milligrams per square meter (mg/m^2) intravenously (IV) weekly for 3 out of 4 weeks in every 28-day cycle.
3289638|NCT01740336|Placebo Comparator|B: Paclitaxel, Placebo|Participants will receive placebo matching to GDC-0941 on the 5/7-day schedule along with 90 mg/m^2 IV weekly for 3 out of 4 weeks in every 28-day cycle.
3289639|NCT01740349||30 children with UC|This prospective pilot study of 30 pediatric subjects, that are indicated for standard colonoscopy due to follow-up of ulcerative colitis (UC), examines the Given Diagnostic System and the PillCam Colon Capsule in comparison to standard colonoscopy.
3289640|NCT01740375|No Intervention|Arm B: observation:|No additional treatment after concurrent chemoradiotherapy. However, esophagectomy will be considered as a salvage treatment for local recurrence during observation.
3289641|NCT01740375|Experimental|Arm A: esophagectomy|Esophagectomy will be performed preferentially within 8 weeks (maximum 12 weeks) after completion of concurrent chemoradiotherapy
3289642|NCT01740453|No Intervention|Single (no catheter)|ropivacaine single injection : 5 mg/ml 15 ml
3289643|NCT01740453|Experimental|Continuous infusion|Single injection with continuous injection ropivacaine 2 mg/ml 8 ml/h
3289644|NCT01740466||Ocular diseases|Observational
3289645|NCT01740479|Active Comparator|Complete Revascularization Strategy|"Complete Revascularization Strategy (Staged Non-Culprit Lesion PCI plus Optimal Medical Therapy): Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose acetylsalicylic acid (ASA) and ticagrelor)."
3289646|NCT01740479|No Intervention|Optimal Medical Therapy Alone|"Culprit lesion only Revascularization Strategy (Optimal Medical Therapy Alone): No further revascularization of non-culprit lesions.~All patients, regardless of randomized treatment allocation will receive optimal medical therapy consisting of risk factor modification and use of evidence-based therapies (including low dose ASA and ticagrelor)."
3289647|NCT01740492|Experimental|LDK1: Low dose Ketamine (0.15mg/kg)|"Participants randomized to the first group, LDK1, will receive an intravenous injection of low dose ketamine (0.15mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
3289648|NCT01740492|Experimental|LDK2: Low dose Ketamine (0.3mg/kg)|"Participants randomized to the second group, LDK2, will receive an intravenous injection of low dose ketamine (0.3mg/kg).~All participants, regardless of the group, will receive a dose of morphine(0.15mg/kg) at the same time the study drug is administered."
3289649|NCT01740492|Placebo Comparator|0.9% Normal Saline|This group will receive a placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
3289650|NCT01740505|Experimental|Timing and Coordination|
3289651|NCT01740505|Experimental|Aerobic Walking|
3289652|NCT01740505|Active Comparator|Stretching and Relaxation|
3289653|NCT01740518||PEG + ascorbic acid|Those who taken PEG 2L + ascorbic acid
3289654|NCT01740518||PEG 4L|Those who taken PEG 4L alone
3289655|NCT01740531|Experimental|S-303 Treated Red Blood Cells (RBC)|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
3289656|NCT01740531|Active Comparator|Conventional, untreated Red Blood Cells|Patients will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible patients are randomly assigned to receive Test RBCs followed by Control RBCs or Control RBCs followed by Test RBCs. Each patient will complete both treatment periods.
3289657|NCT01740544|Experimental|Cathodal tDCS in young study participants|Cathodal tDCS in young study participants
3289658|NCT01740544|Experimental|Cathodal tDCS in elderly study participants|Cathodal tDCS in elderly study participants
3289659|NCT01740544|Sham Comparator|Sham tDCS in young study participants|Sham tDCS in young study participants
3289660|NCT01740544|Sham Comparator|Sham tDCS in elderly study participants|Sham tDCS in elderly study participants
3289662|NCT01740570|Experimental|Cabazitaxel|"Cabazitaxel by vein on day 1 of each 3 week cycle.~Phase I: Up to 5 dose levels of cabazitaxel tested. Two (2) dose levels will be given over 60 minutes, and 3 will be given over 30 minutes. First group of participants receive the lowest dose level. Each new group receives a higher dose level of cabazitaxel than the group before it, if no intolerable side effects were seen.~Phase II: Cabazitaxel at the highest dose that was tolerated in Phase I."
3289663|NCT01740583|Experimental|annuloplasty|All patients will receive treatment with the Mitralign Percutaneous Annuloplasty System (MPAS).
3289664|NCT01740596|Experimental|C-Pulse® System|C-Pulse® System Counterpulsation
3289665|NCT01740596|No Intervention|Control Arm|Optimal Medical Therapy
3289666|NCT01740609|Placebo Comparator|1. Placebo|Placebo
3289667|NCT01740609|Experimental|2.0|
3289668|NCT01740622|Experimental|Injury Intervention Group|In homes of children who are randomized to the injury intervention arm of the trial, a comprehensive survey of injury hazards in living spaces will be undertaken. In addition to quantifying hazards, the area of living spaces will be obtained to allow the determination of both the number and density (number of hazards per 100 sq.ft.) of injury hazards. If one or more injury hazards are identified, they will be removed and/or modified to reduce exposure and injury risk. The intervention is focused on areas in living spaces below 1-meter (~39 inches) in height from (the 75th percentile in height or eye-level for a 3-year old US male toddler) which might be easily reached or climbed on by children less than 4 years.
3289669|NCT01740622|No Intervention|Control Group|Participants who are assigned to the control group will have their medical claims examined related to injury in the home. Households in this control condition will also be provided with information sheets on child safety developed by the American Academy of Pediatrics, The Injury Prevention Program (TIPP). These age-based recommendations for child safety are provided as standard of care at many pediatric offices.
3289670|NCT01740635|Experimental|EPIC WheelS Training Program|The EPIC WheelS program includes a comprehensive, structured library of educational material and training activities, organized in a hierarchy from simple to complex. Experimental group subjects will attend 2 training sessions with an expert Trainer. The Trainer will individualize a structured home training program, delivered via a computer tablet, and subjects will train at home for 1 month.
3289671|NCT01740635|No Intervention|Cognitive games|To provide a comparable level of investigator attention, control group subjects will receive two 1-hour social visits. To control for Trainer bias, the experimental and control groups will have separate Trainers. During social visits, the Trainer will discuss subjects' current community activities and their experience using the wheelchair, and provide verbal information related to barriers encountered. Subjects will receive a computer tablet with cognitive stimulation games to account for activity and tablet device exposure. Participants in the extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week (total 75 minutes/week) and document these on a simple calendar-style form provided. To minimize attrition, control subjects will receive a DVD with a condensed MWC skills education program after the post-intervention data collection is complete.
3289672|NCT01740648|Experimental|Treatment (trametinib, fluorouracil, radiation, surgery)|"Patients receive trametinib PO (by mouth) QD (daily) on days -14 through -10 and 1-38 and fluorouracil IV continuously 5 days a week from days 1-38. Patients also undergo radiation therapy 5 days a week on days 1-33. Patients then undergo surgery 6-10 weeks later.~Patients achieving negative surgical margins after complete resection of tumor receive postoperative chemotherapy comprising leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15 OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3289673|NCT01740661|Experimental|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
3289674|NCT01740661|Placebo Comparator|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
3289675|NCT01740674|Experimental|Electronic data collection|The group of participants who will complete questionnaires via the internet
3289676|NCT01740674|No Intervention|Paper data collection|The group of participants who will continue to complete paper based questionnaires, as has been the practice for this longitudinal study.
3289677|NCT01740687||Essure+NovaSure|The group of women relying on Essure micro-inserts for permanent birth control when NovaSure is performed following a successful Essure Confirmation Test
3289678|NCT01740700|Experimental|p-Branch®|
3289679|NCT01740739||Cardiac Risk|Patients, as part of their standard of care, who are recommended for and who complete a test resulting in a Coronary Calcium Score, lipid test, hs-CRP and MPO result.
3289680|NCT01740752|Experimental|UCAN+CBT|This condition includes 22 UCAN sessions and 22 CBT sessions, totaling 44 psychotherapy sessions. UCAN is a manualized, 22-session Cognitive Behavioral Couple Therapy (CBCT) intervention that engages the couple to target the core psychopathology of AN and address the uniquely challenging stress that AN places on intimate relationships. The CBT proposed for this study is a 22 session adaptation of the manualized intervention that has been employed successfully as an outpatient post-hospitalization therapy and in an National Institute of Mental Health multisite study of fluoxetine with elements from the CBT manual used in McIntosh et al (PubMed 15800147).
3289681|NCT01740752|Experimental|CBT|"In this condition, participants will receive a higher dose of individual CBT, with 44 total sessions. Our experience with patients in the pilot strongly suggests that a higher dose of CBT will allow for further, fruitful discussion and exploration of key individual issues and is unlikely to be experienced as diluted or a slow approach to treatment. Most of these patients have complicated histories, long-standing eating disorders, and complex comorbid conditions."
3289682|NCT01740765|Experimental|Eucaloric Feeding|Subjects will complete an initial eucaloric feeding study day. During this study day, subjects will receive 100% of their calorie requirements. 24-hour energy expenditure will be measured.
3289683|NCT01740765|Experimental|Underfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the underfeeding study arm, subjects will receive 50% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
3379197|NCT00092235||Cohort 4|Patients who have undergone an allogeneic stem cell transplant and are not diagnosed withcGVHD
3379198|NCT00091871||Affected family members|Family members with peripheral blood eosinophilia
3289684|NCT01740765|Experimental|Overfeeding|Following the eucaloric feeding study day, subjects will undergo the underfeeding and overfeeding arms in random order. During the overfeeding study arm, subjects will receive 150% of their calorie requirements (as determined during the initial eucaloric study day) for 3 days. 24-hour energy expenditure will be measured.
3289685|NCT01740778||Study Group 1|Aurora vs. Microlet 2
3289686|NCT01740778||Study Group 2|Aurora vs. SoftClix
3289687|NCT01740778||Study Group 3|Aurora vs. One Touch Comfort
3289688|NCT01740778||Study Group 4|Aurora vs. Multiclix
3289689|NCT01740830|Active Comparator|Anodal tDCS|
3289690|NCT01740830|Sham Comparator|Sham tDCS|
3289691|NCT01740843|Active Comparator|Low intensity anodal tDCS|tDCS will be administered for 10 min at 1mA
3289692|NCT01740843|Experimental|High intensity anodal tDCS|tDCS will be administered for 10 min at 2.5mA
3289693|NCT01740843|Sham Comparator|Sham tDCS|Sham will be administered for 10 min at 0 mA
3289694|NCT01740856|Experimental|Rest three hours|Rest three hours
3289695|NCT01740856|Experimental|Rest five hours|Rest five hours
3289696|NCT01740869|Experimental|Experimental: Patients|Children who will receive intrathecal autologous stem cells
3289697|NCT01740869|Other|Control/Crossover|We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time.
3289698|NCT01740908||Hyperbaric Oxygen Treatment|Six healthy adult individuals (18-65 yrs), with no current, ongoing infection or chronic disease will be recruited for this study. Treatment study subjects will undergo a daily exposure to 2.0 ATA, 100% Oxygen for 90 minutes over 5 days.
3289699|NCT01740908||Baseline|Two healthy study subjects with no current, ongoing infection or chronic disease will be rectuited to serve as a baseline group. Study subjects will not be exposed to HBO, but will have blood drawn at the same time as the treatment group.
3289700|NCT01740921|Active Comparator|Liraglutide|Liraglutide (Victoza) daily injections
3289701|NCT01740921|Placebo Comparator|diet|reduction in calorie intake
3289702|NCT01740921|Placebo Comparator|Aspirin|Aspirin 300mg once daily
3289703|NCT01740934|Active Comparator|Anatabloc Cream|Twice daily use of active facial cream
3289704|NCT01740934|Placebo Comparator|Placebo Cream|Twice daily use of placebo facial cream
3289705|NCT01740947|No Intervention|Standard treatment|Standard treatment for colorectal cancer
3289706|NCT01740947|Experimental|Selective decontamination of the digestive tract (SDD)|"Standard treatment + SDD perioperatively 4 times daily 10 ml of SDD suspension, consisting of 100mg colistin sulfate, 80mg tobramycin and 500mg of amphotericin B.~SDD treatment starts 3 days before surgery and is continued until at least 3 days postoperatively."
3289707|NCT01740960|Active Comparator|delta-9-tetrahydrocannabinol|Subjects will be randomized to receive 3 doses Namisol® (3 mg, 5 mg, 6,5 mg)
3289708|NCT01740960|Placebo Comparator|Placebo|The control product is placebo, consisting of a tablet with similar appearance and taste of the test product.
3289709|NCT01740973||SILC cholecystectomy|No intervention. 239 SILC having a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
3289710|NCT01740973||and conventional lap. cholecystectomy|no intervention.Patients are also mailed a prospective questionnaire and clinical follow-up, if the patient suspects an umbilical hernia.
3289711|NCT01740986|Experimental|SA09012 Low dose|
3289712|NCT01740986|Experimental|SA09012 High dose|
3289713|NCT01740986|Placebo Comparator|Placebo|
3289714|NCT01740999|Experimental|silicone arthroplasty|silicone arthroplasty
3289715|NCT01740999|Active Comparator|arthrodesis|arthrodesis
3289716|NCT01741025|Experimental|iFuse Implant System|Surgical placement of iFuse implants in the affected SI joint
3289717|NCT01741025|Active Comparator|conservative management|Medications, physical therapy, information
3289718|NCT01741038|Experimental|AlloStim® treatment|The treatment schedule includes: (1) the priming step with two ID AlloStim® injections (Days 0 and 3), an additional two ID injections followed by IV infusion of AlloStim® (Days 7 and 10); (2) the vaccination step with cryoablation of a single metastatic lesion followed by injection of AlloStim® into the ablated tumor and IV infusion of AlloStim® on protocol day 14, followed by IV infusion of AlloStim® on Day 17 (3) the activation step with an IV study drug infusion on Day 21 and (4) the booster step with IV booster infusions of AlloStim® on days 49 and 77. Additional booster infusions can be administered monthly at the discretion of the Investigator.
3289719|NCT01741038|Other|Physician's Choice (PC)|All subjects will be assigned Physician's Choice (PC) therapy. PC can consist of best supportive care (BSC) or any US-FDA-approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated.
3289720|NCT01741051|Experimental|HEPA Filter|HEPA filter(s) placed in the participant's home from approximately 10 weeks gestation until birth.
3289721|NCT01741051|No Intervention|Control|
3289722|NCT01741064||PTH below target iPTH in CKD|iPTH at one year post transplantation below target range of iPTH by stage of CKD (KDOQI-guidelines).
3289723|NCT01741064||iPTH within target range of iPTH in CKD|iPTH at one year post transplantation within target range of iPTH by stage of CKD (KDOQI-guidelines).
3289724|NCT01741064||iPTH above target range of iPTH in CKD|iPTH at one year post transplantation above target range of iPTH by stage of CKD (KDOQI-guidelines).
3289725|NCT01741077||pregnant women|pregnant women taking 1 mg folic acid;
3289726|NCT01741077||non-pregnant women|non-pregnant women taking 0mg folic acid;
3289727|NCT01741077||non-pregnant women 2|non-pregnant women taking 1 mg folic acid
3289728|NCT01741077||non-pregnant women 3|non-pregnant women taking 5 mg folic acid
3289729|NCT01741090|Experimental|MSC injection|This study is designed as single interventional arm without comparative arm. MSC injection means hepatic artery catheterizations and mesenchymal stem cell injection through catheter.
3289730|NCT01741103|Experimental|Sitagliptin|
3289731|NCT01741103|Placebo Comparator|Placebo|
3379199|NCT00091871||Unaffected family members|Family members without peripheral blood eosinophilia
3289732|NCT01741116|Experimental|TKI258, inhibitor of RTKs|"Intervention: TKI258~Investigational drug, TKI258, will be administered to all of the patients after enrollments. Treatment will initially be administered as 28-day cycles as follows:~- Daily 500mg of TKI258 will be self-administered orally by the patient for 5 days, followed by 2 days of treatment off."
3289733|NCT01741129|Active Comparator|Nasal Continuous Positive Airway Pressure (CPAP)|"After 2 hours evaluation:~Infants needed invasive MV (mechanic ventilation) or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of >88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
3289734|NCT01741129|Active Comparator|Nasal Intermittent Mandatory Ventilation (IMV)|"After 2 hours evaluation:~Infants needed invasive MV or Required a fraction of inspired oxygen of >40% to maintain the targeted saturation of > 88% to 92%.~Non-invasive surfactant treatment (Curosurf®) 100 mg/kg per dose"
3289735|NCT01741142|Experimental|ABT-436|Subject receiving ABT-436
3289736|NCT01741142|Active Comparator|Escitalopram|Subject receiving escitalopram.
3289737|NCT01741142|Placebo Comparator|Placebo|Subject receiving placebo
3289738|NCT01741155|Experimental|Single Arm Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 IV followed by docetaxel 75 mg/m2 IV. Cycles will continue every 3 weeks until progression or intolerable toxicity.
3289739|NCT01741155|Experimental|Randomized Part: SPI-1620 & Docetaxel|Patients will receive 11 μg/m^2 of SPI-1620 intravenous (IV) followed by docetaxel 75 mg/m^2 IV administered in 3-week cycles until progression or intolerable toxicity.
3289740|NCT01741155|Active Comparator|Randomized Part: Docetaxel|Patients will receive 75 mg/m^2 docetaxel in 3-week cycles until progression or intolerable toxicity.
3289741|NCT01741168|Active Comparator|TLSO|TLSO brace 8-10 weeks
3289742|NCT01741168|Experimental|No Orthosis|No Orthosis
3289743|NCT01741181|Active Comparator|Vitamin D supplementation|Vitamin D3 tablets (cholecalciferol)
3289744|NCT01741181|Placebo Comparator|Placebo pill|Placebo pill
3289745|NCT01741194|Experimental|AC-1204|Powder formulation (40 g) mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed. Each dosing unit of AC-1204 contains 20 g of the active ingredient, caprylic triglyceride.
3289746|NCT01741194|Placebo Comparator|Placebo|Placebo is an isocaloric formulation prepared to be virtually identical to AC-1204 in appearance, odor and taste. Powdered formulation is mixed with 4-8 ounces of water, other liquid or soft food as preferred, and shaken or blended until fully mixed.
3289747|NCT01741207|No Intervention|control|control This group is without N-acetylcystein : just receives standard treatment
3289748|NCT01741207|Active Comparator|N-acetylcystein|receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
3289749|NCT01741220||anesthetists|German-speaking intensive-care providers and anesthetists
3289750|NCT01741233|Experimental|UV-B irraditation|VitDgen
3289751|NCT01741246||Control|Headache-free subjects.
3289752|NCT01741246||Episodic migraine|Patients with less that 15 headache days per month that fulfill International Classification of Headache Disorders 2R (ICHD-2nd edition Revised)- criteria for Episodic Migraine.
3289753|NCT01741246||Chronic migraine|Patients that fulfill International Classification of Headache Disorders (ICHD)-2R criteria for chronic migraine (more than 15 days per month).
3289754|NCT01741285|Active Comparator|Fluticasone|Two weeks treatment with HFA-Fluticasone 250 microgram twice daily
3289755|NCT01741285|Active Comparator|Clenil|Two weeks treatment with HFA-Clenil 200 microgram 2 inhalations twice daily.
3289756|NCT01741285|Experimental|QVAR|Two weeks treatment with QVAR 2 times 100 microgram twice daily
3289757|NCT01741298|Experimental|Lifestyle counseling|CHARMS Intervention Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
3289758|NCT01741311|Experimental|3H+ Group|3H+ (Holistic for HIV) group patients will receive the standard of drug treatment care (i.e., methadone maintenance treatment and case management) plus four weekly 60-minute HIV risk reduction groups, and a 60-minute booster session at 12 weeks, led by two facilitators trained and supervised by a licensed clinical psychologist. 3H+ is an HIV risk reduction and ART adherence intervention that provides coping skills training and is delivered in a group modality, addressing high risk drug- and sex-related HIV risk behaviors and ART adherence for opioid-dependent individuals living with HIV.
3289759|NCT01741311|Active Comparator|HHRP+ Group|HHRP+ (Holistic Health Recovery Program) is comprised of 12 two-hour weekly manual-guided group sessions with comprehensive HIV risk reduction content that addresses the medical, emotional, and spiritual needs of opioid-dependent individuals living with HIV. Each session is designed to last 2 hours and is co-facilitated by two trained facilitators, who address potential motivational conflicts of HIV+ individuals by providing them with self-protective as well as altruistic reasons for examining and changing their HIV risk behaviors and improving adherence behavior. Material is presented using cognitive remediation strategies.
3289760|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3289761|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
3289762|NCT01741324|Active Comparator|Umeå, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per dag.
3289763|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3289764|NCT01741324|Experimental|Malmö, vitamin D 25 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3289765|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3289766|NCT01741324|Active Comparator|Malmö, vitamin D 10 microg/d, light skin|Participants with light skin will be randomized to a milk drink providing 10 microg vitamin D3 per day.
3289767|NCT01741324|Placebo Comparator|Malmö, placebo, dark skin,|Participants with dark skin will be randomized to a milk drink without added vitamin D (placebo).
3289768|NCT01741324|Placebo Comparator|Malmö, placebo, light skin|Participants with light skin will be randomized to a milk drink without added vitamin D (placebo).
3289769|NCT01741324|Experimental|Umeå, vitamin D 25 microg/d, dark skin|Participants with dark skin will be randomized to a milk drink providing 25 microg vitamin D3 per day.
3289770|NCT01741337|Experimental|Patients treated by ventilation|Adaptive servo-ventilation post-operative treatment for 6 months
3289771|NCT01741337|No Intervention|Patients not treated by ventilation|Patients not treated during 6 months by an adaptive servo-ventilation
3289772|NCT01741363|Experimental|one-day sampling with one-year interval|FIT one-day sampling with one-year interval
3289773|NCT01741363|Active Comparator|one-day sampling with two-year interval|FIT one-day sampling with two-year interval
3289774|NCT01741363|Experimental|two-day sampling with one-year interval|FIT two-day sampling with one-year interval
3289775|NCT01741363|Experimental|two-day sampling with two-year interval|FIT two-day sampling with two-year interval
3289776|NCT01741363|Experimental|Hp stool antigen (HpSA)+FIT|HpSA for detection of upper gastrointestinal tract diseases and upper endoscopy for H. pylori carriers; HPSA combined with FIT
3289777|NCT01741376|Placebo Comparator|Placebo + Placebo|Two placebos are given for 84 days.
3289778|NCT01741376|Active Comparator|Progesterone + Placebo|Progesterone (200 mg twice daily) and a placebo are given
3289779|NCT01741389|Placebo Comparator|Sleep only|Placebo given at night to tetraplegic individuals before going to sleep,
3289780|NCT01741389|Active Comparator|Melatonin|Melatonin given at night to tetraplegic individuals before going to sleep.
3289781|NCT01741402|Experimental|Virtual Reality Training|The virtual reality training was done by experimental group with ten games of Nintendo Wii Fit.
3289782|NCT01741402|Active Comparator|Physical Therapy|The Control Group was trained by conventional Physical Therapy exercises.
3289783|NCT01741415|Experimental|SIDI|Skills for Improving Distress Intolerance treatment protocol: individual, manualized treatment aimed at improving distress intolerance
3289784|NCT01741415|Placebo Comparator|SC|supportive counseling; psychological placebo/talk therapy - aimed at controlling for non-specific therapeutic factors
3289785|NCT01741428|Active Comparator|Intervention (INT1)|The participants will join a 5-days course at the Feiring Heart Clinic.
3289786|NCT01741428|No Intervention|Control (KTR1)|The participants in the Control Group will receive care as usual at their local Doctors Office
3289787|NCT01741428|Active Comparator|Subgroup Intervention (INT2)|Subgroup of 200 participants from the (INT1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
3289788|NCT01741428|No Intervention|Subgroup control (KTR2)|Subgroup of 200 participants from the (KTR1)where multiple, known CVD risk factors are studied: Physical Activity, Physical Condition (O2-consumption), Quality of life, Biochemical markers (fasting Glucose, Insulin, Apo Lipoprotein A (ApoA), Apo Lipoprotein B (ApoB), micro-C reactive protein (CRP), Total-, LDL- and HDL-cholesterol, Triglycerides and HbA1C.
3289789|NCT01741441||WAR and MR patients|Consecutive patients with MR and WAR selected for laparoscopic total fundoplication (LTF) were included in a prospective clinical study. Gastroesophageal function was assessed by clinical validated questionnaires, upper endoscopy, esophageal manometry and 24-h impedance pH monitoring before and 12 and 60 months after LTF. Gastric scintigraphy was preoperatively performed in all patients.
3289790|NCT01741467|Experimental|RT-CGM|Patients using the RT-CGM for the intervention portion of the study.
3289791|NCT01741493|Experimental|Healthy Volunteers (ABT-494)|Multiple dosing of ABT-494 in healthy volunteers
3289792|NCT01741493|Experimental|Rheumatoid Arthritis Patients|Multiple dosing of ABT-494 in patients with rheumatoid arthritis
3289793|NCT01741493|Placebo Comparator|No treatment|Placebo administration in healthy volunteers and patients with rheumatoid arthritis
3289794|NCT01741493|Other|Healthy Volunteers (tofa)|Multiple dosing of tofacitinib in healthy volunteers
3289795|NCT01741506|Experimental|Dalteparin (Fragmin®)|Dalteparin (Fragmin®) 5000 IU (International Unit) once daily
3289796|NCT01741506|No Intervention|No treatment|No treatment
3289797|NCT01741506|Other|Open surgery arm|Dalteparin (Fragmin®) 5000 IU once daily
3289798|NCT01741519|Experimental|LDLL600|Landiolol hydrochloride, intravenous infusion of 10, 20 and 40 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
3289799|NCT01741519|Active Comparator|Brevibloc|Esmolol, intravenous infusion of 50, 100 and 200 µg/kg/min for 2 h each followed by 18 h long-term infusion of best tolerated dose.
3289800|NCT01741558|Experimental|Methotrexate|Established treatment associated with methotrexate
3289801|NCT01741558|Placebo Comparator|Placebo (Riboflavin)|Established treatment associated with placebo (riboflavin sodium fosfate 0.1%). We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
3289802|NCT01741571|Active Comparator|EBUS guided FNA with suction|"Device/procedure: lymph node tissue collection using fine needle aspiration with suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
3289803|NCT01741571|Experimental|EBUS guided FNA without suction|"Device/procedure: lymph node tissue collection using fine needle aspiration without suction applied.~Four fine needle aspirations will be taken sequentially from each lymph node. Two with suction and two without suction applied."
3379200|NCT00090662||Healthy volunteer|Healthy volunteer
3289804|NCT01741584|Experimental|stationary bike exercise|6 months of exercise (60% of anaerobic threshold)
3289805|NCT01741584|Placebo Comparator|aerobic|6 months of exercise <30% anaerobic threshold
3289806|NCT01741597|Experimental|Diagnostic (DCE-MRI, tumor-homing peptide iRGD)|Patients undergo DCE-MRI on day 1 and undergo tumor-homing peptide iRGD DCE-MRI on day 2.
3289807|NCT01741610|Placebo Comparator|No coloading (Group E)|Placebo comparator
3289808|NCT01741610|Active Comparator|Cristalloid (Lactated Ringer) Coloading|Cristalloid (Lactated Ringer's) Coloading (Group L)
3289809|NCT01741610|Active Comparator|Colloid (HES) coloading|Colloid (HES) coloading (Group C)
3289810|NCT01741623|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
3289811|NCT01741623|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
3289812|NCT01741636|Experimental|Supportive care (survivorship plan)|Patients undergo Survivorship Care Planning comprising disease surveillance, management of potential long-term and late effects, psycho-social-spiritual issues, and healthy living recommendations.
3289813|NCT01741649|Experimental|Clorhexidine|Skin prior to the surgical incision will be cleaned for five minutes with Clorhexidine.
3289814|NCT01741649|Experimental|Povidone|Skin prior to surgical incision will be cleaned for five minutes with a povidine solution.
3289815|NCT01741662|Other|group psychopathological|
3289816|NCT01741675|Experimental|Monetary incentive|The intervention group will receive a postal questionnaire together with a voucher worth €15 for the largest supermarket chain in Denmark. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
3289817|NCT01741675|Other|Control|The control group will only receive a postal questionnaire. Non-responders will after three weeks receive a reminder together with another copy of the questionnaire. In both cases the questionnaire will be sent with a cover letter and a reply paid return envelope.
3289818|NCT01741714|Active Comparator|Chiropractic Spinal Manipulative Therapy|Active chiropractic spinal manipulative treatment
3289819|NCT01741714|Sham Comparator|Sham manipulation|Sham chiropractic manipulative therapy
3289820|NCT01741714|No Intervention|Control group|No intervention, follow headache diary
3289821|NCT01741727|Experimental|ABT-414|Subjects with solid tumors (Phase 1) and squamous non-small cell lung cancer (NSCLC) (Phase 2)
3289822|NCT01741740||retrospective surgical patients|consecutive elective umbilical hernia repair patients during two years from two hospitals,- retrospective id with prospective follow up
3289823|NCT01741753|Experimental|Treatment Arm|BKM120+Abiraterone+Prednisone
3289824|NCT01741766|Experimental|Stretching Training|Whole body stretching exercises 3 times per wk for 8 weeks
3289825|NCT01741766|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 8 wk.
3289826|NCT01741779|Experimental|Hypocaloric diet|This arm involves 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
3289827|NCT01741779|No Intervention|Control|This arm involves not making any change to the subject's lifestyle at the moment of the start of the intervention and for 12 wk.
3289828|NCT01741779|Experimental|Whole body vibration training & diet|Lower-body exercise training on a vibration platform and diet
3289829|NCT01741779|Experimental|Whole body vibration training|Lower-body exercises 3 times per wk for 12 wk in a vibration platform
3289830|NCT01741805||Severe Asthma|Patients with severe asthma as specified under inclusion, exclusion criteria
3289831|NCT01741818||Group B|CVP less than 8cmH2o
3289832|NCT01741831||Darunavir|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking darunavir as per recommended doses.
3289833|NCT01741844||Etravirine|Patients having Acquired Immune Deficiency Syndrome (AIDS) will be taking etravirine as per recommended doses.
3289834|NCT01741857|Experimental|human umbilical cord derived MSC|human umbilical cord derived MSC transplantation for SLE
3289835|NCT01741870|Placebo Comparator|Control|No intervention was given. All subjects received routine care
3289836|NCT01741870|Active Comparator|Received nutrition supplement as needed|Subjects in this group received 50 g/day soy protein-based nutritional supplement (containing 9.5 g protein, 250 kcal energy and all essential micro-nutrients) whenever subjects BMI is below 24 and MNA score also below 24.
3289837|NCT01741883|No Intervention|Standard Medical Care and Information|Patients receive standard treatment protocol for breast cancer patients and additional oral and written information about adjuvant endocrine treatment.
3289838|NCT01741883|Experimental|Side effect prevention training (SEPT)|Patients receive standard medical care and a brief behavioral intervention that targets patients' response and coping expectations while starting with adjuvant endocrine treatment.
3289839|NCT01741883|Active Comparator|Attention Control group (ACG)|Patients receive standard medical care and a comparable amount of therapist´s attention (common and unspecific factors) to the intervention group without targeting patients´ expectations.
3289840|NCT01741896|Active Comparator|RIPC|Patients in the RIPC arm will undergo a period of upper limb ischaemic preconditioning before their contrast enhanced CT scan. The RIPC stimulus involves four cycles of ischaemia/reperfusion (5 minutes of blood pressure cuff induced upper limb ischaemia with 3 minutes reperfusion). This will start at a time of 30 - 40 minutes before the administration of contrast. The cuff is inflated to 15mmHg above systolic pressure at each inflation.
3289841|NCT01741896|No Intervention|Control arm|Patients in the control arm will undergo no extra intervention.
3289842|NCT01741909|Experimental|Before, After|The intervention is educational
3289843|NCT01741922|Experimental|ASA evening&placebo morning|Patients will receive acetylsalicylic acid (100 mg)in the evening and placebo in the morning.
3289844|NCT01741922|Active Comparator|ASA morning&placebo evening|Patients will receive acetylsalicylic acid (100 mg) in the morning and placebo in the evening
3289845|NCT01741948||First time users of hormonal contraceptive|
3289846|NCT01741961||glaucoma, surgery, Ahmed valve|Patients with uncontrolled glaucoma undergoing Ahmed glaucoma valve implantation for intraocular pressure reduction.
3289847|NCT01741974|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
3289848|NCT01741974|Placebo Comparator|Sugar pill|Placebo tablet 500 mg by mouth three times a day
3289849|NCT01741987|Active Comparator|optive® eye drop|
3289850|NCT01741987|Placebo Comparator|fresh tears ® eye drop|
3289851|NCT01742000|Active Comparator|Karinat|Karinat 500 mg tablet by mouth three times a day
3289852|NCT01742000|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
3289853|NCT01742013|Placebo Comparator|Placebo|NaCl 0.9%, s.c., 4ml (2ml x 2), 3 times per a week, 6 weeks
3289854|NCT01742013|Experimental|GCJBP Laennec Inj.|GCJBP Laennec Injection,s.c., 4ml(2ml x 2)/day, 3 times per a week, 6 weeks
3289855|NCT01742026||High Risk Oncohematological Patients|Detection Aspergillus PCR technique and Aspergillus AGA technique
3289856|NCT01742039||b-blocker|
3289857|NCT01742039||amiodarone|
3289858|NCT01742039||atrial pacing|
3289859|NCT01742039||amiodarone plus atrial pacing|
3289860|NCT01742052|Experimental|MT-1303-Low|MT-1303-Low Dose
3289861|NCT01742052|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3289862|NCT01742052|Experimental|MT-1303-High|MT-1303-High Dose
3289863|NCT01742052|Placebo Comparator|Placebo|Placebo
3289864|NCT01742130|Experimental|Sodium bicarbonate|Sodium Bicarbonate (154 mEq/L in dextrose and H2O) 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3289865|NCT01742130|Active Comparator|Saline|Sodium Saline 3 mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after the procedure
3289866|NCT01742156||Presence of coronary disease|All patients with or without coronary disease who are followed in coronary clinics or wards
3289867|NCT01742156||coronary disease|Is coronary disease associated with tortuosity of vessels Patients seen in cardiology clinics
3289868|NCT01742169|Experimental|Outreach and Reminder Intervention|Participants randomized to this arm will receive the Outreach and Reminder intervention.
3289869|NCT01742169|No Intervention|Usual Care|Patients assigned to this arm will receive usual care.
3289870|NCT01742182|No Intervention|Control|
3289871|NCT01742182|No Intervention|PD patients without sleep problems|
3289872|NCT01742182|Active Comparator|PD patients with sleep problems|light exposure
3289873|NCT01742182|Placebo Comparator|PD patients with sleep problem|light exposure
3289874|NCT01742195|Other|Nasal EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the nose.
3289875|NCT01742195|Other|Oral EBUS insertion|Patients in this arm will undergo a linear endobronchial ultrasound with the bronchoscope inserted through the mouth.
3289876|NCT01742221|Experimental|HemaMax|Single subcutaneous 12 microgram dose of HemaMax
3289877|NCT01742221|Placebo Comparator|Placebo|Single subcutaneous dose
3289878|NCT01742234||Kidney Donors|People who will donate a kidney at the University of Minnesota, Mayo Clinic, or University of Alabama
3289879|NCT01742234||Lung Donors|People who will donate a lung at the Washington University School of Medicine or the University of Southern California
3289880|NCT01742247|Experimental|Physiogel, Laser therapy, Moisturizer|"Experimental: Physiogel treated & Non-treated~1 Palmitoylethanolamide, Physiogel 3 times a day for 2 weeks"
3289881|NCT01742260|Experimental|Repair of cranial defect|Repair of cranial defects by tissue engineering
3289882|NCT01742273|No Intervention|standard treatment (usual care)|standard treatment (usual care)
3289883|NCT01742273|Experimental|Vitamin K1|Vitamin K1 (phylloquinone), thrice weekly p.o. (5mg)
3289884|NCT01742299|Experimental|imatinib mesylate|The starting dose of imatinib should be the same as the last dose that was given in the parent imatinib study (400 mg/day to 600 mg/day). After this, the dose of imatinib is based on the investigator's judgment.
3289885|NCT01742312||oesophageal adenocarcinoma|DEXA scan cardio-pulmonary exercise testing (CPEX) muscle biopsy
3289886|NCT01742325|Other|Lifestyle counseling|To test an intervention program (two 20-minute sessions of walking around the nurse's station daily, five days a cycle) to reduce the symptoms of fatigue and pain and increase quality of sleep.
3289887|NCT01742338|Active Comparator|Low Dose Corticosteroids|"10 mg IV q8hrs x 3 days*, then prednisone 40 mg PO daily x 4 days, then prednisone 30 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then prednisone 10 mg daily x 1 day, then stop.~*If patient unable to receive IV medications, will give prednisone 20 mg PO bid for the first 3 days."
3289888|NCT01742338|Experimental|High Dose Corticosteroids|Methylprednisolone 40 mg IV q8hrs x 3 days*, then prednisone 80 mg PO daily x 4 days, then prednisone 60 mg daily x 1 day, then prednisone 40 mg daily x 1 day, then prednisone 20 mg daily x 1 day, then stop. *If patient unable to receive IV medications, will give prednisone 40 mg PO bid for the first 3 days.
3289889|NCT01742351|Experimental|Guided internet-based cognitive behavior therapy (CBT)|
3289890|NCT01742377||Patients with GerdQ positive|Gerd Q positive was defined as score equal or more than eight.
3289891|NCT01742377||Patients with GerdQ negative|Gerd Q neegative was defined as score less than eight.
3289892|NCT01742377||Normal volunteers|Normal volunteers was defined as population without dyspeptic symptom.
3289893|NCT01742390|Experimental|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
3289894|NCT01742390|Active Comparator|risperidone or paliperidone|Stay on risperidone (RIS) or paliperidone (PALI)
3289895|NCT01742403|Experimental|R/T gating kV intrafraction monitoring|"Intervention: Recruitment will be performed in 2 phases:~Phase I will include the first 10 patients. All patients will be treated on a standard fractionation protocol with 40 fractions. This will allow 400 potential fractions to be auto-segmented in real time. Once Phase I is successfully completed we will aim to continue recruitment of a further 20 patients as Phase II. For this phase we will open recruitment to patients with lymph node positivity, hypofractionation (as per Department protocols) and intermittent imaging (imaging less frequently than every fraction)."
3289896|NCT01742416|Experimental|Ultrasound|
3289897|NCT01742416|Active Comparator|Palpation Method|
3289898|NCT01742429|Experimental|Levofloxacin-bismuth therapy|14 day levoﬂoxacin and bismuth-containing therapy:PPI,bismuth, amoxicillin, levoﬂoxacin
3289899|NCT01742429|Active Comparator|classical quadruple therapy|14 day classical quadruple therapy:PPI,bismuth, metronidazole, tetracycline
3289900|NCT01742442||Older cancer patients|Older cancer patients 70 years or older referred to specialist oncology outpatient clinics
3289901|NCT01742468|Experimental|Dietary supplement: n-3 LC-PUFA|Name: microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany; rich in docosahexaenoic acid (DHA); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
3289902|NCT01742468|Placebo Comparator|Dietary supplement: sunflower oil|Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
3289903|NCT01742481|Experimental|Education and empowerment program|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
3289904|NCT01742481|Placebo Comparator|self-guided empowerment and education|participants have information packet but receive no individualized support or assistance
3289905|NCT01742494|Active Comparator|Water-jet POEM|POEM were performed by the use of Erbe Hybrid knife (WJ group)
3289906|NCT01742494|Active Comparator|Conventional POEM|POEM were performed by the conventional technique using injection and triangle tip knife (C group).
3289907|NCT01742507|Active Comparator|Medtronic Resolute Integrity Stent|Medtronic Resolute Integrity Stent
3289908|NCT01742507|Active Comparator|Biomatrix stent|Biomatrix stent
3289909|NCT01742520|Active Comparator|Formula or Breast Milk|Breast milk or formula prior to every painful procedure.
3289910|NCT01742520|Active Comparator|Multiple doses of sucrose|Infants in this group will be treated with Sucrose 24% 0.5-1ml on the anterior pat of the tongue 1-3min prior to every invasive procedure
3289911|NCT01742533|Experimental|Group1 : HRT plus hUCMSCs treatment:|Participants will be given HRT plus human cord mesenchymal stem cells transplantation with a 12 menstrual Cycle follow-up.
3289912|NCT01742533|Experimental|Group 2: HRT plus hCBMNCs and hUCMSCs therapy|Participants will be given HRT plus combination of hCBMNCs together with hUCMSCs transplantation with a 12 menstrual Cycle follow-up.
3289913|NCT01742533|Experimental|Group3 : HRT plus hCBMNCs treatment:|Participants will be given HRT plus human cord blood mononuclear cells transplantation with a 12 menstrual Cycle follow-up.
3289914|NCT01742533|Experimental|Group 4:Hormone Replacement Therapy|Participants will be given conventional therapy only with a 12 menstrual Cycle follow-up.
3289915|NCT01742546|Experimental|Therapeutic ultrasound combine TENS|"Use therapeutic ultrasound with simultaneous TENS for 10 minutes/session for 10 sessions/course.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius), this device has treatment head described by the manufacturers as having surface area as 5.8 cm2, ERA (Effective Radiating Area) of 5.0 cm2 and BNR (Beam Non-uniform Ratio) as max. 5.0. For electrotherapy unit which composes of 2 channels, output characteristics are constant current (CC) or constant voltage (CV), resolution of output signal is in steps of 0.2 mA and timer is limited to 30 minutes during ultrasound and combination therapy are operated."
3289916|NCT01742546|Sham Comparator|Therapeutic ultrasound with sham TENS|Use the same therapeutic ultrasound machine and place the electrode as experimental group but turn-off electrical current during treatment period
3289917|NCT01742559|Experimental|Anterior middle superior alveolar|The AMSA technique was performed in the test group according to Friedman & Hochman (1997). The needle was introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the periodontal procedure.
3289918|NCT01742559|Active Comparator|Supraperiosteal technique|The supraperiosteal technique at the bottom of the vestibule was performed for one minute and 1.8 ml of anesthetic solution was administrated. This amount of anesthetic was divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes were expected for the beginning of the SRP procedure.
3289919|NCT01742572|Experimental|Vegan|A vegan diet is one that does not contain any animal products (no meat, fish, poultry, eggs, or dairy) but emphasizes plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3289920|NCT01742572|Experimental|Vegetarian|A vegetarian diet is one that does not contain meat, fish, or poultry but does contain eggs and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3289921|NCT01742572|Experimental|Pesco-Vegetarian|A pesco-vegetarian diet is one that does not contain meat or poultry but does contain fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. We will also ask you to keep foods low in fat and low in glycemic index.
3289922|NCT01742572|Experimental|Semi-Vegetarian|A semi-vegetarian diet is one that contains all foods, including meat, poultry, fish and shellfish, eggs, and dairy, in addition to plant-based foods, such as fruits, vegetables, whole grains, and legumes/beans. However, red meat is limited to one time per week and poultry is limited to 5 times per week or less. We will also ask you to keep foods low in fat and low in glycemic index.
3289923|NCT01742572|Active Comparator|Omnivorous|An omnivorous diet contains all food groups. However, as part of this study, we will ask participants in this group to keep foods low in fat and low in glycemic index. Participants in this group will not need to attend weekly meetings but will receive information via e-mail each week.
3289924|NCT01742585|Experimental|ASP1585 group|
3289925|NCT01742585|Placebo Comparator|placebo group|
3289926|NCT01742598|Experimental|Portico Implant|
3289927|NCT01742611|Experimental|ASP1585 group|
3289928|NCT01742624|Experimental|Advagraf group|
3289929|NCT01742624|Active Comparator|Prograf group|
3289930|NCT01742637|Experimental|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)
3289931|NCT01742637|Active Comparator|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)
3289932|NCT01742637|Placebo Comparator|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)
3289933|NCT01742650|Active Comparator|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
3289934|NCT01742650|Active Comparator|TightRope|TightRope transfixation of syndesmosis
3289935|NCT01742663|Experimental|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)
3289936|NCT01742663|Active Comparator|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)
3289937|NCT01742663|Placebo Comparator|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.)
3289938|NCT01742676|Experimental|ADVAGRAF group|
3289939|NCT01742676|Active Comparator|PROGRAF group|
3289940|NCT01742689|Experimental|Desmopressin intranasal spray|Patients in this arm will receive 40 microgram desmopressin intranasal spray & 100 milligram indomethacin suppository
3289941|NCT01742689|Placebo Comparator|Placebo intranasal spray|Patients in this group will receive placebo nasal spray & 100 milligram indomethacin suppository
3289942|NCT01742702||DYNAMIC (ongoing)|Subjects with primary or secondary hypertension and normotensive control subjects. In addition haemodynamic recordings to 50 subjects suffering from chronic fatigue syndrome will be performed.
3289943|NCT01742702||AERO-DYNAMIC (recordings completed)|Subjects who had voluntarily decided to participate in a professionally coached marathon school (Varala Sports Institute, Tampere) were given the chance for haemodynamic recordings before, during and after the training protocol.
3289944|NCT01742702||Liquorice (recordings completed)|Normotensive subjects, daily liquorice ingestion (daily glycyrrhizin dose 290-370 mg) for 2 weeks, haemodynamic measurements before and after the intervention.
3289945|NCT01742702||Milk polypeptides (recordings completed)|Daily ingestion of yoghurt containing small milk casein-derived polypeptides for 12 weeks versus placebo yoghurt.
3289946|NCT01742702||Bisoprolol (recordings completed)|Hypertensive subjects, bisoprolol 5 mg once daily versus placebo in a double-blind, cross-over protocol.
3289947|NCT01742702||Aortic stenosis (ongoing)|Subjects with aortic stenosis confirmed by echocardiography
3289948|NCT01742702||Methodological (recordings completed)|35 normotensive subjects who received research drugs (nitroglycerin, salbutamol, placebo resoriblet, placebo inhalation, L-arginine infusion, saline infusion) in a placebo-controlled, double-blinded manner
3289949|NCT01742702||Participants of Ironman Triathlon|Altogether 80 athletes participating in a full length Ironman competition. Non-invasive recordingds are performed under normal conditions during the training period and after completion of a full-length Ironman competition.
3289950|NCT01742715|Experimental|PEEP by Best oxygenation|"Set Positive End Expiratory Pressure (PEEP) at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg Ideal Body Weight (IBW). fraction of inspired oxygen (FiO2) is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with arterial blood gas (ABGs), and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% Partial Oxygen tension (PaO2) PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
3289951|NCT01742715|Experimental|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
3289952|NCT01742715|Experimental|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
3289953|NCT01742728||Nagasaki|Sample collection
3289954|NCT01742728||Tokushima|Oxidative stress, cytokine
3289955|NCT01742728||Kanagawa|oxidative stress
3289956|NCT01742741|Experimental|Experimental Involving Automated CTR|Closed-Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs)system running in Control to Range (CTR) or in Safety Only mode. The subject will interact with the system through its Graphic User Interface (GUI). Subjects will not be allowed to administer correction boluses between meals and snacks as the DiAs will automatically be adjusting insulin to correct the hyperglycemia. The total doses recommended by the DiAs prior to meals and snacks includes the correction dose and Insulin on Board (IOB) calculated by the system.
3289957|NCT01742741|No Intervention|CGM-Augmented Insulin Pump Treatment|Open Loop Control: Insulin delivery will be controlled by the Diabetes Assistant (DiAs) system running in open-loop mode. Subjects will interact with the system through its Graphic User Interface (GUI). Subjects will be permitted to administer correction boluses at any time during the Control Admission, whether or not they are eating a scheduled meal or snack. DiAs will be initialized with the subject's typical insulin pump settings. Subjects will be reminded that all treatment decisions should be based on fingerstick values and not on continuous glucose monitor (CGM) values.
3289958|NCT01742754|Experimental|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation by colonoscopic delivery of stool to the right colon.
3289959|NCT01742767|Active Comparator|Cis (D1) + Pem (D1)|Cisplatinum 75 mg/m2 d 1 Pemetrexed 500 mg/m2 d 1 q d 21
3379202|NCT00084305||Family|Family members of patients with pulmonary fibrosis
3289960|NCT01742767|Experimental|CIS (D1+8) + Pem (D!)|Cisplatinum 40 mg/m2 d 1 + d 8 Pemetrexed 500 mg/m2 d 1 q d 21
3289961|NCT01742780|Active Comparator|Standard Vidacare Site Identification Method|Palpate up the proximal humerus towards the anterior shoulder just above the surgical neck, to the greater tubercle of the proximal humerus. Insert the needle set perpendicular to skin with a slight downward angle at the most prominent aspect of greater tubercle to establish proximal humerus intraosseous vascular access.
3379203|NCT00084305||Healthy Volunteers|Healthy Volunteers
3379204|NCT00084305||Pulmonary Fibrosis|Patients with pulmonary fibrosis
3379206|NCT00081523||Patients|Individuals with known or suspected sickle cell disease
3379213|NCT00073060||NIH Platelepheresis|75, Apheresis Study Group - donation procedures use same devices as leukapheresis donors, also requiring citrate infusion
3379214|NCT00073060||NIH Research Leukapheresis Donors|75, Apheresis Study Group - donation procedures use same devices as plateletpheresis donors, also requiring citrate infusion; citrate administered may be twice as great as during plateletpheresis.
3379215|NCT00073060||NIH Whole Blood Donors|150 age, gender, race-matched donors - CONTROL GROUP
3289962|NCT01742780|Active Comparator|Saussy Site Identification Method|Palpate the proximal humerus to locate the intertubercular groove; rotate the forearm medially and laterally to isolate the groove. Move one finger breadth laterally from the groove to the greater tubercle. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access.
3379216|NCT00071786||Group 1|All study participants fall into one group for this observational family study regardless of diagnosis.
3289963|NCT01742780|Active Comparator|Campbell Site Identification Method|"With the fingers on both hands fully extended similar to a karate chop, place one hand into the anterior joint space (acromioclavicular joint) of the patient. Place the second karate chop hand along the midline of the patient's lateral shoulder; touch the pinkie fingers over the superior aspect of the patient's shoulder. Overlap the thumbs on the patient's shoulder, which will be at the most prominent aspect of the greater tubercle. Insert the needle set perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
3379225|NCT00067054||1|Sample Collection Only
3379233|NCT00055055||Healthy Volunteers|A healthy individual who has not used any NSAIDS, with no infectious disease, or severe trauma within 8 weeks of enrollment, doesn't have a first degree relatives with RA, SLE, SSc or IIM
3379234|NCT00055055||Parent of Proband|Biological mother or father of the proband who is willing to enroll in the study
3379235|NCT00055055||Primary Unaffected Dizygous Twin|Dizygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
3379236|NCT00055055||Primary Unaffected Monozygous Twin|Monozygotic twin pair of the proband who does not meet criteria for one of the rheumatic diseases
3379237|NCT00055055||Primary Unaffected Non-twin Sibling|Sibling of the same biological parents, same gender, within 5 years of age of the proband who does not meet criteria for one of the rheumatic diseases
3379238|NCT00055055||Proband|Proband should have documented evidence that he/she meets criteria for adult and juvenile forms of systemic rheumatic disorders
3379239|NCT00055029||Affected males and family members|Up to 500 participants, including a minimum of 150 males diagnosed with XLRS
3379242|NCT00050752||1 / Patients|Patients with known or suspected Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
3379243|NCT00050752||2 / Family Members|Family members (related by blood) of patients who have or are suspected of having Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome (HLRCC)
3289964|NCT01742780|Active Comparator|Davlantes Site Identification Method|"Using one hand, place the thumb on the acromioclavicular joint in the natural recess or pocket between the distal clavicle and the humeral head, wrapping the rest of the hand around the upper arm. The hand should be oriented such that the index finger and rest of the hand is at a 90-degree angle to the thumb. The webspace between the thumb and index finger will be approximately where the surgical neck of the humerus is; move one finger breadth (approximately 1 cm) superior. Insert perpendicular to skin with a slight downward angle to establish proximal humerus intraosseous vascular access."
3289965|NCT01742793|Experimental|Arm L: subjects with lymphoma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with lymphoma who are eligible to enter Arm L:~Dose Level Arm L Lenalidomide dose Oral Romidepsin Dose Intravenous~2 10mg D1-7, D15-21 6mg D1, 8, 15~1 10mg D1-7, D15-21 8mg D1, 8, 15~10mg D1-21 8mg D1, 8, 15 2 15mg D1-21 8mg D1, 8, 15 3 15mg D1-21 10mg D1, 8, 15 4 15mg D1-21 12mg D1, 8, 15 5 15mg D1-21 14mg D1, 8, 15 6 25mg D1-21 14mg D1, 8, 15~The first patient in arm L will be entered into the study at dosing level one."
3289966|NCT01742793|Experimental|Arm M: subjects with myeloma|"The following dosing steps will be applied to the dose-escalation, phase-I component of the study for patients with myeloma who are eligible to enter Arm M:~Dose Level Arm M Lenalidomide dose Oral Romidepsin Dose Intravenous Dexamethasone~2 15mg D1-7, D15-21 6mg D1, 8, 15 20mg D1,8,15,22~1 15mg D1-7, D15-21 8mg D1, D8, 15 20mg D1,8,15,22~15mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 2 25mg D1-21 8mg D1, 8, 15 20mg D1,8,15,22 3 25mg D1-21 10mg D1, 8, 15 20mg D1,8,15,22 4 25mg D1-21 12mg D1, 8, 15 20mg D1,8,15,22 5 25mg D1-21 14mg D1, 8, 15 20mg D1,8,15,22~The first patient in arm M will be entered into the study at dosing level one."
3289967|NCT01742806|No Intervention|control|not to use bio-absorbable felt(NEOVEIL®)
3289968|NCT01742806|Experimental|NEOVEIL®|To use bio-absorbable felt
3289969|NCT01742819||Advanced glaucoma|Patients with MD < -6 or visual field loss within the central 10 degrees of the visual field.
3289970|NCT01742845|Active Comparator|control group|landmark-based superficial cervical block is used. After insertion of the needle superficially below the skin, 20 to 30 ml of 4.75 mg/ml ropivacaine are injected fan-like in the subcutaneus plane.
3289971|NCT01742845|Experimental|echo group|ultrasound-guided intermediate cervical block was performed. The probe is placed perpendicular to the skin, in the horizontal plane at the C3-C4 level. Needle is inserted in-plane. 10 ml ropivacaine 4.75mg/ml are injected under ultrasound control, 5 ml injected when needle is withdrawn under ultrasound control, 5 ml in the subcutaneous plane.
3289972|NCT01742858||Adolescents|15-18 years old
3289973|NCT01742858||Young adults I|19-24 years old
3289974|NCT01742858||Young adults II|25-30 years old
3289975|NCT01742871||controls|Patient under anti-vitamin K with no haemorrhagic manifestations admitted for another reason to Emergency Adults
3289976|NCT01742871||kaskadil|Patient under anti-vitamin K with a serious bleeding event that required treatment in the emergency Adults. Is considered serious accident requiring the use of a reversion by PPSB (Kaskadil ®).
3289977|NCT01742884|Experimental|Thealoz|Treatment with Thealoz (Trehalose) 3% for 1 month
3289978|NCT01742884|Placebo Comparator|Treatment with Thealoz´s vehicle|Treatment with Thealoz´s vehicle for 1 month
3289979|NCT01742910|Other|Tecnis ZCB00|eyes with implantation of Tecnis ZCB00
3289980|NCT01742910|Other|Acrysof SA60AT|eyes with implantation of Acrysof SA60AT
3289981|NCT01742923|Placebo Comparator|Usual care|Usual care
3289982|NCT01742923|Experimental|Complex tailored intervention|"The interventions consists of 3 elements:~Medication review with recommendations focused on antihypertensives and statins and adherence to guidelines and patient´s adherence to medications~Consultation with a pharmacist using motivational interviewing techniques~Follow-up telephone calls one month and six months after inclusion"
3289983|NCT01742962||Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
3289984|NCT01742975|Experimental|Arm A: Applying Ifabond|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients.
3289985|NCT01742975|No Intervention|Arm B: without Ifabond|The synthetic adhesive solution Ifabond, will not be applied at the end of conventional breast cancer surgery in arm B patients.
3289986|NCT01742988|Experimental|Fimepinostat - Continuous Once Daily|Fimepinostat 30-60 mg/day
3289987|NCT01742988|Experimental|Fimepinostat - 2x/week|Fimepinostat 60-240 mg/day
3289988|NCT01742988|Experimental|Fimepinostat - 3x/week|Fimepinostat 60-180 mg/day
3289989|NCT01742988|Experimental|Fimepinostat - 4x/week|Fimepinosta 60-180 mg/day
3289990|NCT01742988|Experimental|Fimepinostat - 5x/week|Fimepinostat 60-180 mg/day
3289991|NCT01742988|Experimental|Fimepinostat - Expansion 5x/week|Fimepinostat 60 mg on the 5 days on/2 days off
3289992|NCT01742988|Experimental|Fimepinostat - Expansion 3x/week|Fimepinostat 120 mg 3 days on/4 days off
3289993|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ rituximab|Fimepinostat 60 mg 5 days on.2 days off plus rituximab
3289994|NCT01742988|Experimental|Fimepinostat 120 mg - Combination w/ rituximab|Fimepinostat 120 mg 3x/week plus rituximab
3289995|NCT01742988|Experimental|Fimepinostat - Biocomparability Arm|Biocomparability Arm
3289996|NCT01742988|Experimental|Fimepinostat 30 mg - Combination w/ venetoclax|Fimepinostat 30 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
3289997|NCT01742988|Experimental|Fimepinostat 60 mg - Combination w/ venetoclax|Fimepinostat 60 mg 5 days on/2 days off plus venetoclax. Different combinations of dose levels for venetoclax will be explored
3289998|NCT01742988|Experimental|Fimepinostat - Combination w/ venetoclax and rituximab|Fimepinostat and venetoclax dosed at dose levels determined for that combination. Rituximab dosed at 375 mg/m2 IV on Day 1 of each 21 day cycle
3289999|NCT01743014|Active Comparator|ramipril|Ramipril 10 mg tablets. Each dose will be taken orally with water once daily.
3290000|NCT01743014|Active Comparator|clopidogrel and ramipril|clopidogrel 75mg tablet and ramipril 10mg. Each drug will be taken orally with water once daily
3290001|NCT01743053|Other|Control: Standard Care|The control group will receive standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa™ Clear).
3379244|NCT00050752||3 / Non-Biologic Family Members|Spouses enrolled primarily for linkage analysis (Spouses have been removed from the inclusion criteria for this study. This closed cohort is for spouses previously enrolled on study.)
3379245|NCT00050310||Acute Infection|adults and children with acute anthrax infection
3379246|NCT00050310||AVA Recipient/Healthy Volunteer|healthy adults who have received AVA vaccine
3379247|NCT00050310||Recovered|adults and children in recovering phase of anthrax infection
3290002|NCT01743053|Experimental|ReCell|The ReCell group will receive ReCell in addition to standard care (debridement, cleansing) and Profore® multi-layer compression therapy (replacing the wound contact layer with Telfa Clear).
3290003|NCT01743066|Experimental|Arsenicosis patients|Vitamin E (200 IU, caplet) daily orally for 20 weeks
3290004|NCT01743066|Active Comparator|Arsenic exposed controls|vitamin E (200 IU, caplet) daily orally for 20 weeks
3290005|NCT01743066|Active Comparator|Heathy volunteers|Vitamin E (200 IU, caplet) daily orally for 20 weeks
3290006|NCT01743079|Experimental|Telbivudine|Mother receives telbivudine 600mg per day. Infant receives standard immunoprophylaxis
3290007|NCT01743079|Experimental|Lamivudine|Mother receives lamivudine 100mg per day. Infant receives standard immunoprophylaxis.
3290008|NCT01743079|No Intervention|No antiviral treatment|Mother receives no antiviral treatment. Infant receives standard immunoprophylaxis
3290009|NCT01743105|Experimental|Study population|"The study population consists of patients treated for acute respiratory distress in the emergency department at the Nîmes University Hospital. See inclusion and exclusion criteria.~Interventions: Diaphragm excursion measures 1, Diaphragm excursion measures 2"
3290010|NCT01743118|Experimental|Psoriasis Plaque Test|SPS4251 Ointment, 0.01%; SPS4251 Ointment, 0.1%; SPS4251 Ointment, 1%; SPS4251 Placebo, Daivonex® ointment
3290011|NCT01743144|Active Comparator|Magnesium sulphate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
3290012|NCT01743144|Placebo Comparator|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
3290013|NCT01743157|Experimental|Biochemo + Bevacizumab then Ipilimumab|Single arm: Biochemotherapy with 4 cycles at 3 week intervals of Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days each cycle; then ipilimumab 3mg/kg q 21 days x 4, then q 3 months x 8 for total 3 years.
3290014|NCT01743170|No Intervention|Control group|In the control group doctors will receive information on the self-measured blood pressure as recorded at home via a diary card.
3290015|NCT01743170|Experimental|Intervention group|In the intervention group, doctors will receive weekly reports via telemonitoring of self-measured blood pressure.
3290016|NCT01743183|Experimental|threshold|Held inspiratory muscle strengthening for 5 weeks with Threshold, charging 30% of maximal inspiratory pressure, 7 days a week, one supervised and unsupervised 6.
3290017|NCT01743196||Normal weight|Women with BMI 18.5 to 24.9 kg/m2
3290018|NCT01743196||Obese|Women with BMI > 30 kg/m2
3290019|NCT01743222|Experimental|eASC|"eASC~First cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 2.5 millions of eASCs suspended in 0.25 ml of HTS per lymph node, total dose 5 millions of cells.~Second cohort (3 volunteers, first volunteer is not randomized to detect any acute reaction): injection of 5 millions of eASCs suspended in 0.5 ml of HTS per lymph node, total dose 10 millions of cells."
3290020|NCT01743222|Placebo Comparator|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of Hypo Thermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of Hypo Thermosol (HTS) per lymph node"
3290021|NCT01743235|Experimental|Placebo|30 subjects administered a placebo
3290022|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combination drug|30 subjects are given combination drug (0.25 mg Testosterone + 5 mg Buspirone hydrochloride)
3290023|NCT01743235|Experimental|Testosterone + Buspirone hydrochloride combinat|30 subjects are given combination drug (0.25 mg Testosterone + 10 mg Buspirone hydrochloride)
3290024|NCT01743235|Experimental|Testosterone + Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 5 mg Buspirone hydrochloride)
3290025|NCT01743235|Experimental|Testosterone +Buspirone Combination Drug|30 subjects are given combination drug (0.5 mg Testosterone + 10 mg Buspirone hydrochloride)
3290026|NCT01743235|Experimental|Testosterone|30 subjects are given 0.5 mg Testosterone
3290027|NCT01743235|Experimental|Buspirone|30 subjects are given 10 mg Buspirone hydrochloride
3290028|NCT01743261|Active Comparator|usual care|In this arm patients were managed according to the organization of the management model which took on the care of the patient. The organization of these models is characterized by one or two professional figures (physiatrists, neurologist), with hierarchical relationships, in spaces limited to a specific pathology; access is determined by clinical stability; the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas; the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty.
3290029|NCT01743261|Experimental|Graded intensive rehabilitation|"Instruments of governance are the diagnostic-therapeutic rehabilitation. pathways (DTRP), the Quality system and product standards.~Medical care process with result-oriented autonomy. Technology support of vital signs. Multidisciplinary intervention"
3290030|NCT01743274|No Intervention|Control Group|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups. In the Control Group, the angioplasty procedure will be guided by traditional fluoroscopy alone.~In both groups, fractional flow reserve (FFR) will be measured at the end of the procedure, once the operator considers the result of the angioplasty to be optimal. The average of three consecutive FFR measures will be recorded."
3290031|NCT01743274|Experimental|Optical Coherence Tomography|"Randomization will be performed after initial coronary angiography, once the operator has identified the lesion responsible for the ACS. Patients will be randomly allocated to one of two groups.~In the OCT group, OCT will be performed to optimise the results of angioplasty. The procedure will be performed according to usual practice, with or without pre-dilation before implantation of one or more stents (drug-eluting or bare metal). In the OCT group, OCT will be performed after initial coronary angiography and at the end of the procedure and the operator will have the possibility to change procedural strategy according to the data immediately available on the OCT images, with the possibility of additional interventions (additional balloon inflations, addition stent implantation, use of GPIIb/IIIa inhibitors and/or thromboaspiration and/or rotational atherectomy)."
3290032|NCT01743287|Experimental|Imotun capsule|Imotun capsule: 300.03mg/cap, orally, 1 capsule once a day during 24 weeks
3290033|NCT01743287|Placebo Comparator|Imotun capsule placebo|Imotun capsule Placebo: Placebo 1 capsule once a day during 24 weeks
3290034|NCT01743300|Active Comparator|Grapefruit juice arm|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment
3290035|NCT01743300|Active Comparator|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment.
3290036|NCT01743313||Hip and knee replacement recipients|"Hip and knee replacement recipients (with osteoarthritis) enrolled previously into Perioperative Hyperglycaemia in Primary Total Hip and Knee Replacement study (NCT01021826)."
3290037|NCT01743326|Experimental|RFD-group|Radio Frequency Denervation
3290038|NCT01743326|Active Comparator|Local Anesthesia-group|Local Anesthesia-group
3290039|NCT01743339|Active Comparator|Control|Control (brief check-in calls) and Cognitive Processing Therapy (12 individual weekly sessions)
3290040|NCT01743339|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia (4 individual therapy sessions over 5 weeks) and Cognitive Processing Therapy (12 individual weekly sessions)
3290041|NCT01743352||Hypertension patients|Local common carotid artery pulse wave velocity is compared in patients with hypertension and healthy volunteers.
3290042|NCT01743352||Healthy Volunteers|Local common carotid artery pulse wave velocity is compared in hypertension patients and healthy volunteers
3290043|NCT01743365|Experimental|Cisplatin-5FU-Afatinib|"Cisplatin 75mg/m2 iv administered on Day 1, 5FU 750mg/m2 at 24-hour iv infusion on Days 1-4, Afatinib (BIBW-2992) 40mg per os on Days 3-5, 8-12, 15-19 of each cycle. Administration of Afatinib will start on Day 3 of each cycle with an administration interval on each weekend (Weekday on, Weekend off) for 21 days. The administration of the combination Cisplatin-5FU-Afatinib will be continued until disease progression, appearance of significant toxicity, completion of 6 cycles, or withdrawal of consent. At completion of 6 cycles of the combination, in the absence of disease progression, the administration of Afatinib as maintenance monotherapy will be continued until disease progression, appearance of significant toxicity, or withdrawal of consent at the weekday on-weekend off schedule."
3290044|NCT01743378|Experimental|TAP Block Ropivacaine 0,75 %|Bilateral Transversus Abdominis Plane Block with 2 x 20 ml Ropivacaine 0,75 %
3290045|NCT01743378|Placebo Comparator|TAP Block Saline 0,9 %|Bilateral Transversus abdominis plane block with 2 x 20 ml Saline 0,9 %
3290046|NCT01743391|No Intervention|Control|Standard treatment
3290047|NCT01743391|Experimental|Intervention|Office-hysteroscopy with endometrial biopsy before standard treatment
3290048|NCT01743404|Active Comparator|Inflaminat|Inflaminat 500 mg tablet by mouth three times a day
3290049|NCT01743404|Placebo Comparator|Sugar pill|Placebo 500 mg tablet by mouth three times a day
3290050|NCT01743417|Experimental|Cognitive intervention|Children in this arm will receive computerised cognitive rehabilitation training for 24 sessions lasting 45 minutes. The Captain's log brain training software is programmed to increase in difficulty as child progresses through the training levels.
3290051|NCT01743417|Active Comparator|Active control|Children in this arm will receive 24 sessions of computerised cognitive rehabilitation training. Captain's log, the brain training software will not be programmed to increase in difficulty with each successive level in this arm.
3290052|NCT01743417|No Intervention|Passive control|No computer training or games will be provided to this group
3290053|NCT01743430|Experimental|telerehabilitation|telerehabilitation via internet
3290054|NCT01743430|No Intervention|conventional|conventional therapy
3290055|NCT01743443|Experimental|Sensitiviy|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
3290056|NCT01743456|No Intervention|Current practice (BIS and rSO2 blinded)|
3290057|NCT01743456|Experimental|Targeted intra-operative depth of anaesthesia|
3290058|NCT01743482|Experimental|Pazopanib|Patients will receive pazopanib at the dose of 800 mg/day orally until disease progression or evidence of unacceptable toxicity/side effects. The study will be performed according to Simon's two-stage optimal design.
3290059|NCT01743495|Other|Functional Services|The program consists of up to 10 home-based functional services sessions over 4 months.
3290060|NCT01743508|Active Comparator|Misoprostol by physician|Misoprostol treatment by midwife
3290061|NCT01743508|Experimental|Misoprostol by midwife|Misoprostol treatment by midwife
3290062|NCT01743534||Conservation of praxies and form plates|
3290063|NCT01743547|No Intervention|No Intervention; Arm A; Control Group|24 subjects who declined yoga but agreed to data collection
3290064|NCT01743547|Active Comparator|Active Comparator; Arm B; Intervention Group|24 subjects participating in 8 weeks of Yoga and agreed to data collection
3290065|NCT01743573|Experimental|yoga training|Yoga training
3290066|NCT01743573|No Intervention|control|no yoga training
3290067|NCT01743586|No Intervention|Control|
3290068|NCT01743599||Diabetic men|
3290069|NCT01743599||Non-diabetic men|
3290070|NCT01743612|Experimental|Sclerodermic patients|patients with systemic sclerosis according to Leroy's classification
3290071|NCT01743612|Experimental|Primary Raynaud's phenomenon|without secondary disease
3290072|NCT01743612|Experimental|Healthy subjects|18 years old or more
3379248|NCT00050310||Suspected Exposure|adults and children with suspected exposure to anthrax
3290073|NCT01743625|Experimental|COV155|COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
3290074|NCT01743625|Placebo Comparator|Placebo|Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.
3290075|NCT01743638|Experimental|MR-Guided Laser Ablation|
3290076|NCT01743651|Placebo Comparator|Placebo|Placebo
3290077|NCT01743651|Active Comparator|Baclofen|Baclofen
3290078|NCT01743651|Experimental|Arbaclofen|Arbaclofen
3290079|NCT01743664|Experimental|Eye Movement Desesitization Reprocessing|The EMDR protocol follows procedures and phases described by Shapiro (1996). This is a complex treatment that incorporates many different interventions in order to recall trauma-related memories and to subdue them. EMDR processing consists of attending to oscillatory stimulation presented in a visual, auditory or tactile modalities, such as moving the finger from side to side across the patient's visual field or presenting an alternating tapping on the hands alternatively. Eye movements are the most commonly used external stimulus, but if the patient has problems with this kind of stimulation, such as headaches or sensomotor deficits, the therapist chooses tapping as an alternative form of oscillatory stimulation with equivalent therapeutic efficacy.
3290080|NCT01743664|Active Comparator|relaxation|Relaxation sessions will include diaphragmatic breathing, progressive muscle relaxation, visualisation, and rapid relaxation.
3290081|NCT01743690|Active Comparator|fluocinolone, placebo|fluocinolone, placebo
3290082|NCT01743690|Experimental|fluocinolone, probiotic|fluocinolone, Probiotic lactobacilli reuteri
3290083|NCT01743690|Active Comparator|Nystatin, placebo|Nystatin, placebo
3290084|NCT01743690|Experimental|nystatin, probiotic|nystatin, Probiotic lactobacilli reuteri
3290085|NCT01743703|Other|whole body MRI|diagnostic whole body MRI, and skeletal imaging following guidelines (whole body radiographic and scintigraphic screening)
3290086|NCT01743716||MDD Mothers|Adult women with a history of major depressive disorder (MDD) and a healthy adolescent daughter between the ages of 12-14
3290087|NCT01743716||Healthy Control Mothers|Adult women with no history of psychopathology and an adolescent daughter between the ages of 12-14
3290088|NCT01743716||High Risk Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the MDD Mothers cohort
3290089|NCT01743716||Healthy Female Adolescents|Healthy female adolescents aged 12-14 with a mother in the Healthy Control Mothers cohort.
3290090|NCT01743742|Experimental|Oral vitamin E, vitamin C|Single dose of vitamin E drops 200 IU within 6 hours of birth and vitamin C tablet 250 mg in pulverised form (2 doses at 24 hr interval) via infant feeding tube
3290091|NCT01743755|Active Comparator|Dexamethasone|
3290092|NCT01743755|Placebo Comparator|Placebo|Placebo tablet, once daily for four consecutive days
3290093|NCT01743768|Experimental|SB010|"The drug will be administered in phosphate-buffered saline solution, inhaled over 5 - 10 min, using inhalation device.~Administered dose: 10 mg hgd40 in 2 mL solution (5.0 mg/mL).~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
3290094|NCT01743768|Placebo Comparator|Placebo|"The placebo (phosphate-buffered saline) is administered as a solution, inhaled over 5 - 10 min, using inhalation device.~Initial dose on Day 1 (single-dose PK profile); once daily dose for 28 consecutive days (Days 1 to 28); last inhalation on Day 28 (steady state PK profile)."
3290095|NCT01743781|Experimental|intervention group|view a 10-minute informational video about comprehensive eye examination
3290096|NCT01743781|No Intervention|control group|No intervention
3290097|NCT01743794|Experimental|ropivacaine 0.2%, wound infusion|
3290098|NCT01743794|Placebo Comparator|saline solution 0.9%, wound infusion|
3290099|NCT01743807|Experimental|Dose Level 1|GNKG168 0.25 mg/kg/day on days 1 through 5
3290100|NCT01743807|Experimental|Dose Level 2|GNKG168 0.75 mg/kg/day on days 1 through 5
3290101|NCT01743807|Experimental|Dose Level 3|GNKG168 1.5 mg/kg/day on days 1 through 5
3290102|NCT01743807|Experimental|Dose Level 0|If dose level #1 is too toxic the study will back down to dose level 0. GNKG168 0.15 mg/kg/day on days 1 through 5.
3290103|NCT01743820|Active Comparator|dihydroartemisinin-piperaquine only|dihydroartemisinin -piperaquine (DP) only
3290104|NCT01743820|Experimental|DP and 0.125 mg/kg primaquine|DP and single dose oral 0.125 mg/kg primaquine
3290105|NCT01743820|Experimental|DP and 0.5 mg/kg primaquine|DP and single dose oral 0.5 mg/kg primaquine
3290106|NCT01743820|Experimental|DP and 0.25 mg/kg primaquine|DP and a single dose oral 0.25 mg/kg primaquine
3290107|NCT01743820|Experimental|DP and 0.0625 mg/kg primaquine|DP and a single dose oral 0.0625 mg/kg primaquine
3290108|NCT01743833|Active Comparator|Thoracic HVLAMT, Postive Message|Thoracic HVLAMT with a positive message given prior to the intervention.
3290109|NCT01743833|Active Comparator|Thoracic HVLATM, Neutral Message|Thoracic HVLAMT with a neutral message given prior to the intervention.
3290110|NCT01743833|Active Comparator|Scapular HVLATM, Positive Message|Scapular HVLAMT with a positive message given prior to the intervention.
3290111|NCT01743833|Active Comparator|Scapular HVLATM, Neutral Message|Scapular HVLAMT with a neutral message given prior to the intervention.
3290112|NCT01743846||Major Surgery|Patients undergoing major surgery
3290113|NCT01743872|Active Comparator|Contrast Injection|Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
3290114|NCT01743872|Active Comparator|Dextran Injection|Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
3290115|NCT01743872|Active Comparator|CO2 Injection|Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
3290116|NCT01743885|Active Comparator|propanolol|Propanolol (Syprol:oral solution)
3290117|NCT01743885|Active Comparator|Acebutolol|Acebutolol (Sectral:oral solution)
3290118|NCT01743898||Experimental|Patient taking FDA approved dose of rivaroxaban
3290119|NCT01743898||Control Group|Patient not taking any form of anticoagulation
3379254|NCT00046059||ADHD|Children aged 7-17 with ADHD and their families.
3290120|NCT01743911|Placebo Comparator|sugar pill|Intervention: sugar pill
3290121|NCT01743911|Active Comparator|tadalafil|Intervention: tadalafil
3290122|NCT01743924|Experimental|Raw|Broccoli,200 grams
3290123|NCT01743924|Experimental|cooked|Microwaved, 200 grams
3290124|NCT01743937|Active Comparator|Ticagrelor|Coronary occlusion with balloon inflation
3290125|NCT01743937|Active Comparator|Clopidogrel|Coronary occlusion with balloon inflation
3290126|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent glioblastoma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3290127|NCT01743950|Active Comparator|Bevacizumab-exposed with refractory recurrent glioblastoma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3290128|NCT01743950|Active Comparator|Bevacizumab-naïve with recurrent anaplastic glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3290129|NCT01743950|Active Comparator|Bevacizumab-exposed with recurrent anaplastic glioma|27fractions over 5.5weeks of PRDR radiation with bevacizumab followed by adjuvant bevacizumab until time of progression
3290130|NCT01744002|Experimental|Shoulder Treatment with Neck Mobilization|The experiment group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and Unlateral Posterior Anterior Mobilization to the cervical spine; applied as 3 X 30 seconds, to each comparable (stiff or painful) segment.
3290131|NCT01744002|Active Comparator|Control Group|The control group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
3290132|NCT01744015|Experimental|Patient Decision Making Tool|Patients will be given an opportunity to use a decision making tool to assist in decision making of their care
3290133|NCT01744015|Active Comparator|Standard of care|Control group consisting of normal care
3290134|NCT01744028|Experimental|Remote patient monitoring|Remote patient monitoring system including the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) tool can use changes in daily scores over a certain threshold level to alert notification to the clinical site. The site will contact the patient in order to determine the clinical significance associated with the change in score, and to treat the patient based on clinical judgment and clinical practice.
3290135|NCT01744028|Experimental|Usual care|This group of patient will continue on their usual standard care as close to real life situation as possible.
3290136|NCT01744041|Experimental|Dyadic Interpersonal Psychotherapy|Brief Interpersonal Psychotherapy during pregnancy followed by dyadic mother-infant psychotherapy for one year postpartum
3290137|NCT01744041|Active Comparator|Enhanced Treatment as Usual|Personalized referral to community resources for depression treatment
3290138|NCT01744054|Other|PET/MR or PET/CT|"Patients must have had radioembolization, within 72 hours of the PET/MR or PET/CT~Subjects will be asked to lie still within the scanner for up to 1.5 hours while images are acquired for the liver"
3290139|NCT01744067|Active Comparator|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.
3290140|NCT01744067|Placebo Comparator|Placebo|Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.
3290141|NCT01744080|Active Comparator|Early Surgery|
3290142|NCT01744080|Experimental|Regular Wait Time|
3290143|NCT01744106|Experimental|pseudoephedrine hydrochloride 30 mg tablets|Test product
3290144|NCT01744106|Placebo Comparator|placebo tablets|Placebo
3290145|NCT01744119||Abdominal Aortic Aneurysm|
3290146|NCT01744132|Experimental|Aim 3: Contract|Half of patients screened in the pharmacy are selected to a contract group, which encourages patients to review the results of the screen, share the results with their PCP, and schedule and attend a follow-up appointment with an ophthalmologist if the results are abnormal.
3290147|NCT01744132|No Intervention|Aim 3: Control|No contract is signed for half of the patients screened in Aim 3.
3290148|NCT01744145|Active Comparator|Interventional 40-60|Interventional group aged 40-60
3290149|NCT01744145|Placebo Comparator|Control 40-60|Control group aged 40-60
3290150|NCT01744145|Active Comparator|Interventional 60 and above|Interventional group aged 60 and above
3290151|NCT01744145|Placebo Comparator|Control 60 and above|Control group aged 60 and above
3290152|NCT01744158||Children with cerebral palsy|No intervention applicable
3290153|NCT01744171|Experimental|Treatment (recombinant hsp110-gp100 chaperone complex vaccine)|Patients receive recombinant hsp110-gp100 chaperone complex vaccine ID on days 1, 15, and 43 in the absence of unacceptable toxicity.
3290154|NCT01744184|Active Comparator|Midazolam|"midazolam sedation combined with pharyngeal anaesthesia~Participants randomized to receive midazolam will have an intravenous cannula sited and, following the administration of xylocaine throat spray as above, will be put into the left lateral position. They will then be given up to 5mg midazolam as appropriate to achieve conscious sedation as for standard protocol in endoscopy."
3290155|NCT01744184|Experimental|Entonox|"Entonox combined with pharyngeal anaesthesia.~Pharyngeal anaesthesia, given as 8-16 sprays of xylocaine to the pharynx; 3 minutes will be given to allow the pharynx to become anaesthetized.~Participants randomized to receive Entonox will be given the 50:50 nitrous oxide:oxygen mix via a mouthpiece with a demand valve system, once in position for the procedure. Inhalations will be given for 3-5 minutes (or until the participant feels adequately sedated) measured using a stopwatch. Oxygen will be given at 2 litres per minute via nasal cannulae during the procedure, (standard care for sedated procedures). The endoscopist will then proceed to intubate the cricopharynx and perform the procedure in the standard manner."
3290156|NCT01744210||CHF|
3290157|NCT01744223|Experimental|SCT, BPX-501 dose 1, Rimiducid if needed|"2x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
3290158|NCT01744223|Experimental|SCT, BPX-501 dose 2, Rimiducid if needed|"5x10E5 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
3290159|NCT01744223|Experimental|SCT, BPX-501 dose 3, Rimiducid if needed|"1x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant.~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
3290160|NCT01744223|Experimental|SCT, BPX-501 dose 4, Rimiducid if needed|"3x10E6 BPX-501 (rivogenlecleucel) cells per kg infused after TCR alpha beta depleted donor stem cell transplant .~Rimiducid: Dimerizer drug administered by intravenous infusion in those subjects with acute GVHD with no response to steroids and/or other aGVHD medications or worsening in stage or grade of aGVHD after 48 hours. Subjects with chronic GvHD who do not respond to steroids/systemic therapies within 7 days, or there is a worsening in cGVHD, patients may then receive rimiducid."
3290161|NCT01744236|Experimental|Liraglutide (main study, long-term intervention)|This arm (n=20) will receive liraglutide 1.8mg and sitagliptin-placebo during 12 weeks
3290162|NCT01744236|Experimental|Sitagliptin (main study, long-term intervention)|This arm (n=20) will receive sitagliptin 100mg and liraglutide-placebo during 12 weeks
3290163|NCT01744236|Placebo Comparator|Placebo (main study, long-term intervention)|This arm (n=20) will receive liraglutide-placebo and sitagliptin-placebo during 12 weeks
3290164|NCT01744236|Experimental|Exenatide (main study, acute intervention)|Prior to the 12-week intervention study, a GLP-1 receptor agonist (exenatide) will be administered intravenously (n=30).
3290165|NCT01744236|Placebo Comparator|Placebo (main study, acute intervention)|Prior to the 12-week intervention study, placebo will be administered intravenously (n=30).
3290166|NCT01744236|Other|Acute MRI intervention study|In a subset of 12 patients with type 2 diabetes, a crossover trial with acute infusion of exenatide and placebo is performed. This is done prior to the 12-week intervention study.
3290167|NCT01744236|Other|Pilot-study|In 10 healthy obese subjects, a crossover trial with acute infusion of exenatide, placebo and L-NMMA is performed.
3290168|NCT01744249|Experimental|Axitinib + Sandostatin LAR|Axitinib 5 mg BID + Sandostatin LAR 30mg/28 days
3290169|NCT01744249|Placebo Comparator|Placebo + Sandostatin LAR|Placebo BID + Sandostatin LAR 30mg/28 days
3290170|NCT01744262|Active Comparator|Inhalational anesthesia group|
3290171|NCT01744262|Experimental|Total intravenous anesthesia group|
3290172|NCT01744275|Placebo Comparator|Placebo|Placebo
3290173|NCT01744275|Experimental|Omega 3 fatty acids supplementation|Omega 3 fatty acids capsules
3290174|NCT01744288|Experimental|1|Ticagrelor with Platelet transfusion
3290175|NCT01744288|Experimental|2|Ticagrelor without Platelet transfusion
3290176|NCT01744288|Active Comparator|3|Clopidogrel with Platelet transfusion
3290177|NCT01744288|Active Comparator|4|Clopidogrel without Platelet transfusion
3290178|NCT01744301||All patients newly prescribed PPI|All patients newly prescribed PPI
3290179|NCT01744301||All patients newly prescribed H2RA|All patients newly prescribed H2RA
3290180|NCT01744314|Experimental|drug|The treatment arm will receive 21 days of Indomethacin and Pantoprazole (gastrointestinal protective agent). The patients will receive Indomethacin 25mg three times a day and Pantoprozole 40mg once a day.
3290181|NCT01744314|Placebo Comparator|placebo|The placebo group will receive microcrystalline cellulose powder tablets to be taken as a control. The placebo will be dosed at the same intervals and duration as the treatment arm in this study.
3290182|NCT01744327||Chronic Plaque type psoriasis|Patients with plaque type psoriasis
3290183|NCT01744366|Experimental|Degarelix|Degarelix 240/80 mg
3290184|NCT01744366|Active Comparator|Goserelin|Goserelin 3.6 mg
3290185|NCT01744379|Experimental|200 mg lesinurad|200 mg lesinurad or placebo fasted and fed
3290186|NCT01744379|Experimental|400 mg lesinurad|400 mg lesinurad or placebo fasted and fed
3290187|NCT01744379|Experimental|100 mg lesinurad|100 mg lesinurad or placebo fasted and fed
3290188|NCT01744379|Experimental|50 mg lesinurad|50 mg lesinurad or placebo fasted and fed
3290189|NCT01744379|Experimental|600 mg lesinurad|600 mg lesinurad or placebo fasted and fed
3290190|NCT01744405||Lactating Women with Chagas disease|Women with Chagas disease who fulfill clinical criteria for treatment with nifurtimox, and who are also lactating
3290192|NCT01744431||No treatment|
3290193|NCT01744444|Experimental|Memantine first|
3290194|NCT01744444|Experimental|Gabapentin first|
3379255|NCT00044174||Depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as exhibiting depressive symptoms
3379256|NCT00044174||Non-depressed Mothers/Infants|Mothers and their 5 month old infants who have been clinically diagnosed as not exhibiting depressive symptoms
3290195|NCT01744457|Other|20 patients with dry eye syndrome|Patients with dry eye syndrome defined as outlined in the inclusion and exclusion criteria
3290196|NCT01744457|Other|20 healthy control subjects|age- and sex-matched controls
3290197|NCT01744470|Experimental|Group A - tacrolimus half-dose|"Immunosuppressive strategy with 50 % reduction of Advagraf® daily dose at M4 (randomization) and unchanged MMF dose. Targeted tacrolimus trough level are to be higher than 3 ng/mL . If the dose is not in adequation with the dispensable units, the prescribed dose will be the closest higher dose.~Drug: Tacrolimus targeted half-dose"
3290198|NCT01744470|Experimental|Group B - tacrolimus unchanged dose|Immunosuppressive strategy will remain identical after randomization (M4): unchanged Advagraf® and MMF doses. Targeted tacrolimus trough level are to be between 7 and 12 ng/mL Drug: Tacrolimus targeted plain dose
3290199|NCT01744509|Other|Diagnosis of CRC|All the patients enrolled received all the 3 procedures: capsule colonoscopy; CT-colonography and optical colonoscopy.
3290200|NCT01744522||Leech therapy|Patients receiving leech therapy in the outpatient clinic
3290201|NCT01744535|Active Comparator|Paper food diary|
3290202|NCT01744535|Active Comparator|Online food diary|
3290203|NCT01744535|Experimental|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users can select foods from the large Weight Loss Resources food database. Instant nutritional feedback is provided along with weekly feedback by text message."
3290204|NCT01744548|Experimental|tCBT treatment|Participants randomised to the tCBT treatment arm will receive 12 individual, 1-hour tCBT sessions based upon Barlow et al.'s (2011) Unifed Protocol for emotional disorders (UP).
3290205|NCT01744548|No Intervention|7-week delayed tCBT treatment|Participants randomised to the delayed-treatment arm will receive a brief telephone call and complete the Hospital Anxiety and Depression Scale (HADS) in order to monitor risk and symptom deterioration during the 7-week delayed treatment phase. They will also receive TAU (e.g. Community Mental Health Team appointments, case reviews, etc) during this time. At the end of 7 weeks, participants in the delayed-treatment arm will crossover into the treatment arm and receive the tCBT intervention. This arm will serve as a control condition in order to enable between-group comparisons.
3290206|NCT01744561|Experimental|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
3290207|NCT01744561|No Intervention|Control|Keep activity level constant
3290208|NCT01744587|Placebo Comparator|Placebo|Placebo qd (2# bid) for 3 years
3290209|NCT01744587|Experimental|Epigallocatechin Gallate (EGCG)|EGCG 600 mg qd (2# bid) for 3 years
3290210|NCT01744600|Experimental|Music Therapy|Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
3290211|NCT01744600|No Intervention|Control|Participants in the control group will receive normal, standard daily care for the 22 week period.
3290212|NCT01744613||Group A|Will include patients with PRU values above the optimal cut-off value determined by ROC analysis
3290213|NCT01744613||Group B|Will include patients with PRU values below the optimal cut-off value determined by ROC analysis.
3290214|NCT01744626|Experimental|CC-292 with Rituximab|Dose Escalation
3290215|NCT01744639|Experimental|HCC under treatment with radioablation|Assessment of nutritional status by anthropometry, bioelectrical impedance, blood sampling and application of psychometric hepatic encephalopathy score and critical flicker frequency, to assess the presence of hepatic encephalopathy.
3290216|NCT01744652|Experimental|Arm A - Crizotinib + Dasatinib|"Arm A: Patients receive dose of crizotinib plus an increasing dose of dasatinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle.~Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle. Dasatinib Expansion Dose: MTD from dose escalation group."
3290217|NCT01744652|Experimental|Arm B - Dasatinib + Crizotinib|"Arm B: Patients receive dasatinib plus an increasing dose of crizotinib. All participants take dasatinib by mouth 1 time each day. Patients take this drug alone on Day 1 of Cycle 1, before the first day they receive the study drug combination. Final dose level in both arms (dose level number 5) is identical. In the case that both arms define dose level 5 as the MTD, then the expansion cohort for safety will include 10 patients with that dose. If two different MTDs on both arms defined, then both MTDs cohorts expanded with 10 patients and 20 patients included on the safety expansion analysis.~Dasatinib 140 mg by mouth daily in a 28 day cycle. Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle.~Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
3290218|NCT01744678|Experimental|Access to experimental break room|"Subjects will visit the experimental break room 4 times per Orbit 1 shift:~first, prior to the beginning of the work shift~second, during an operationally feasible 20-min break during the 1st half of the work shift~third, once during an operationally feasible 20-min break during the 2nd half of the work shift~fourth, immediately after the end of the work shift~In the break room, subjects will be passively exposed to blue-wavelength enriched ceiling lights during all four visits for each work shift.~Also in the break room, subjects will perform 10-minutes of mild exercise during the first three visits to the break room during each work shift."
3290219|NCT01744717||Critically ill uncommunicative patients|Critically ill non-communicative patients, on mechanical ventilation
3290220|NCT01744743|Active Comparator|preconception|Participants will be included according to their first outpatient visiting time. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3379257|NCT00044122||Adult Relatives|Relatives of patient with mastocytosis
3379258|NCT00044122||Adults with Mastocytosis|Adults with documented mastocytosis
3379259|NCT00044122||Pediatric Patients with Mastocytosis|Pediatric patients with documented mastocytosis
3379260|NCT00044122||Pediatric Relatives|Pediatric relatives of patients with mastocytosis
3379261|NCT00042614||Controls|Matched to patients for age, gender and race
3379262|NCT00042614||Patients|Who have had heart transplants, awaiting, or controls screened.
3379263|NCT00040222||1|Individuals and families with known or suspected syndromes that include breast, ovarian or genetically-related cancers are enrolled in this family study.
3379264|NCT00039689||HIV chronic infection|For example, an individual infected with HIV-1 for an indeterminate amount of time.
3379265|NCT00039689||HIV early infection|For example, a negative HIV antibody immunoassay within 6 months of a positive HIV antibody assay and confirmatory test (as defined by current CDC criteria).
3379267|NCT00034216||Healthy Volunteers|Healthy volunteers 18 years of age and older
3379268|NCT00034216||Participants|Participants with cancer 18 years of age and older
3379269|NCT00033774||1|Eligible healthy volunteers 18 and older
3379273|NCT00032513||CAEBV|Patients with chronic active Epstein-Barr virus.
3379274|NCT00032513||Hydroa vaccineforme|Patients with EBV hydro vaccineforme.
3379275|NCT00029965||Galactosialidosis|Galactosialidosis
3379276|NCT00029965||GM1 gangliosidosis|GM1 gangliosidosis
3379277|NCT00029965||GM2 gangliosidosis|GM2 gangliosidosis
3379278|NCT00029965||Sialidosis|Sialidosis
3379283|NCT00028080||Lyme Disease|Participants who have been diagnosed with or are strongly suspected to have Lyme disease.
3379285|NCT00027274||1|All families with a member who has one of the relevant syndromes.
3379286|NCT00027183||1|Healthy Volunteers
3379287|NCT00027183||2|Cystic Fibrosis subjects
3379290|NCT00026663||1/Patients with Cancer|Cancer patients providing samples for research studies
3379291|NCT00026663||2/Normal Volunteers|Normal Volunteers providing samples for research studies
3379299|NCT00025714||Patients|Patients who have agreed to undergo brain surgery to treat drug resistant epilepsy and are enrolled in protocol 11-N-0051 Epilepsy Surgery.
3379300|NCT00024804||1|Subjects with known or suspected bone disease and disorder of mineral metabolism.
3379306|NCT00023036||1|Patients with known or suspected nonsyndromic SNHL associated with EVA
3379307|NCT00023036||2|Patients with nonsyndromic EVA
3379308|NCT00023036||3|unaffected siblings and parents of affected family members
3379309|NCT00023036||4|Other unaffected relatives; included if there is more than one sibship with affected family
3290221|NCT01744743|Active Comparator|early conception|Participants will be included according to their first outpatient visiting time before 15+6 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3290222|NCT01744743|Placebo Comparator|late conception|Participants will be included according to their first outpatient visiting time after 16 gestational week. Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks. Medical records include: a)maternal thyroid function at enrollment; b) Levothyroxine: length, dose, drug adverse effects; c)Early trimester of pregnancy: Down's screening; d)2nd trimester of pregnancy: fetal echocardiography; e)Whole course of pregnancy: maternal complications, maternal blood pressure at each visit, fetal growth; f)Pregnancy outcome: type of delivery, length of labor, type and timing of analgesia/anesthesia, Apgar scores, postpartum hemorrhage, fetal complications; g)Offspring cognitive assessment at 0-3 years old
3290223|NCT01744756|Experimental|Subconjunctival Bevacizumab|One aplication of subconjunctival Bevacizumab 0,5 ml
3290224|NCT01744769||Hypothyroidism for RAI|The group of patients who experience hypothyroidism after thyroid hormone withdrawal for radioactive iodine(RAI) therapy
3290225|NCT01744795|Experimental|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the CardioQ and thermodilution technique.
3290226|NCT01744808|Active Comparator|EB-1020 SR1|Sustained release formulation
3290227|NCT01744808|Active Comparator|EB-1020 SR2|Sustained Release Formulation
3290228|NCT01744808|Active Comparator|EB-1020 SR3|Sustained Release Formulation
3290229|NCT01744808|Active Comparator|EB-1020 IR|Immediate Release Formulation
3290230|NCT01744808|Placebo Comparator|Placebo|Placebo Formulation
3290231|NCT01744834||18-year-old males|18-year-old males, representative random sample of the Dresden/Berlin (Germany) area, categorized as high and as low-risk drinkers respectively
3290232|NCT01744847|Active Comparator|DGT, Tracer Metro® Direct™ Wire Guide|Double guide wire technique was performed by Tracer Hybrid® Wire Guides and Tracer Metro® Direct™ Wire Guide
3290233|NCT01744847|Active Comparator|TPS, Tracer Hybrid® Wire Guides|trans pancreatic sphincterotomy was performed by Tracer Hybrid® Wire Guides
3290234|NCT01744873|Experimental|Bisoprolol Fumarate Tablet 10 mg|Bisoprolol Fumarate Tablet 10 mg of M/s Ipca Laboratories Limited, India
3290235|NCT01744873|Active Comparator|Zebeta®|Zebeta® (Bisoprolol Fumarate) Tablets 10 mg of Duramed Pharmaceuticals Inc., USA
3290236|NCT01744886|Active Comparator|lung surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
3290237|NCT01744886|Active Comparator|port-access cardiac surgery|"An initial baseline arterial blood gas (ABG) will be taken before anesthesia induction while breathing room air.~A second ABG will be taken on FIO2=0.5 during double lung ventilation. Then 3 ABG's will be consecutively determined each 15 min once OLV is initiated. PaO2/FIO2 is calculated on every ABG's measurement. In the port-access group, FIO2 is maintained on 1 after the stopping of the ECC, so PaO2 will become our only indicator for oxygenation. If necessary, measures are taken to maintain oxygenation during one lung ventilation."
3290238|NCT01744899||Prolonged sitting|Includes individuals who spent an average of at least 6 hours a day sitting over the past year.
3290239|NCT01744899||Control|Includes individuals who spent 4 hours or less/day sitting over the past year.
3290240|NCT01744912|Experimental|Ublituximab + Lenalidomide|"4 cohorts, with 3 - 6 patients per cohort, as follows:~Cohort 1: Ublituximab 450 mg + Lenalidomide 10 mg~Cohort 2: Ublituximab 450 mg + Lenalidomide 15 mg~Cohort 3: Ublituximab 600 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Cohort 4: Ublituximab 900 mg + Lenalidomide 10 mg (escalation to 15 mg permitted after cycle 1)~Ublituximab is an IV infusion on days 1, 8, and 15 of cycles 1 & 2 followed by a planned maintenance with a single infusion on day 1 of cycles 3 thru 6.~Lenalidomide is taken orally on days 9 - 28 of cycle 1 followed by daily administration on Days 1 - 28 for cycles 2 thru 6. Non-hodgkins lymphoma patients may have up to a 7 day rest period (Days 21-28) in any cycle."
3290241|NCT01744925|Active Comparator|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
3290242|NCT01744925|Experimental|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
3290243|NCT01744938|No Intervention|early surgery|only receiving pancreaticoduodenectomy without preoperative biliary drainage
3290244|NCT01744938|Experimental|preoperative biliary drainage|percutaneous preoperative biliary drainage before pancreaticoduodenectomy guided by CT scan
3290245|NCT01744951|Experimental|ADAPT|ADAPT is a manualized intervention with eight treatment modules designed as an early intervention for children, ages 5-14, who are being adopted from foster care and their adoptive parent/s.
3290246|NCT01744951|No Intervention|Care as usual|Children, ages 5-14, and their adoptive parent/s will receive care as usual in the treatment setting.
3290247|NCT01744964|Placebo Comparator|Saline|Assessment of experimental pain models before and after treatment
3290248|NCT01744964|Active Comparator|Apomorphine|Assessment of experimental pain models before and after treatment
3290249|NCT01744990|Other|Interventional single arm|Single group of children undergoing the same investigations and follow up
3290250|NCT01745003|Experimental|Fibromyalgia|Investigate biochemical, functional, and structural neuroimaging changes following non-invasive brain stimulation in patients with chronic widespread pain: fibromyalgia (FM). We will be using tDCS as intervention.
3290251|NCT01745016|Placebo Comparator|Placebo|placebo
3290252|NCT01745016|Experimental|Beta-Alanine|beta-alanine
3290253|NCT01745029||Ulcerative Colitis|
3290254|NCT01745042||android postmenopausal women|Clinical exams
3290255|NCT01745042||gynoid postmenopausal women|Clinical exams
3290256|NCT01745068|No Intervention|Control group|
3290257|NCT01745068|Experimental|Integrated program|Participants will be involved in an integrated interorganisational fragility fracture prevention program, which combines both post-fracture management as well as fall prevention strategies. The intervention will last up to 18 months.
3290258|NCT01745081|Experimental|Mannitol|Bolus mannitol 20% at skin incision
3290259|NCT01745081|Experimental|Hypertonic saline|Hypertonic saline 3% at skin incision
3290260|NCT01745107|No Intervention|surgery alone|No prophylactic postoperative radiation therapy,that is surgery alone is developed in this arm
3290261|NCT01745107|Experimental|surgery plus radiation|Prophylactic postoperative radiation therapy is developed in this arm
3290262|NCT01745159|Experimental|continued tacrolimus treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and continuing to apply tacrolimus ointment during disease control period.
3290263|NCT01745159|No Intervention|no additional treatment|children with moderate/severe atopic dermatitis treated with tacrolimus ointment and with no additional treatment during disease control period.
3290264|NCT01745172|Experimental|Carotid body excision|Patients undergoing the carotid body excision to test the hypothesis that carotid body excision is sufficient to attain target blood pressure.
3290265|NCT01745185||Fabry disease switch group|Subjects will include individuals with Fabry disease who are switching from agalsidase alfa to agalsidase beta
3290266|NCT01745185||Control Group|Controls will include individuals with Fabry disease who have only received agalsidase beta as treatment in their lifetime.
3290267|NCT01745198||Treatment Group|This group consists of patients diagnosed with homocysteinemia who have been treated with Cerefolin®/CerefolinNAC® in the past or are currently being treated with Cerefolin®/CerefolinNAC®.
3290268|NCT01745198||Non-Treatment Group|This group consists of patients not diagnosed with homocysteinemia who have no past or current treatment with Vitamin B12, Folate or Cerefolin®/CerefolinNAC®.
3290269|NCT01745224|Experimental|Revlite Q switched Nd:YAG laser|Revlite Q switched Nd:YAG laser 1064 nm
3290270|NCT01745224|Experimental|TriVantage Q switched Nd:YAG laser|TriVantage Q switched Nd:YAG laser 1064nm
3290271|NCT01745250|Experimental|Emervel Lips|Emervel Lips
3290272|NCT01745250|Experimental|Juvederm Ultra Smile|Juvederm Ultra Smile
3290273|NCT01745263|Active Comparator|VitD-Omega3-StrengthExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
3290274|NCT01745263|Active Comparator|VitD-Omega3-FlexibilityExercise|Vitamin D3 (2000 IU/d); Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
3290275|NCT01745263|Active Comparator|Placebo-Omega3-StrengthExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Strength Home Exercise (3*30 minutes/week)
3290276|NCT01745263|Active Comparator|Placebo-Omega3-FlexibilityExercise|Placebo Vitamin D3; Omega-3 fatty acids (1 g/d); Flexibility Home Exercise (3*30 minutes/week)
3290277|NCT01745263|Active Comparator|VitD-Placebo-StrengthExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
3290278|NCT01745263|Active Comparator|VitD-Placebo-FlexiblityExercise|Vitamin D3 (2000 IU/d); Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
3290279|NCT01745263|Active Comparator|Placebo-Placebo-StrengthExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Strength Home Exercise (3*30 minutes/week)
3290280|NCT01745263|Sham Comparator|Placebo-Placebo-FlexibilityExercise|Placebo Vitamin D3; Placebo Omega-3 fatty acids; Flexibility Home Exercise (3*30 minutes/week)
3290281|NCT01745276|Experimental|External pins coated by biphosfonate.|External pins coated by biphosfonate.
3290282|NCT01745276|Active Comparator|External pins coated by hydroxylapatite.|External pins coated by hydroxylapatite.
3290283|NCT01745302||TCM plus EGFR-TKIs|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day, six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day ，until progression or unacceptable toxicity;
3290284|NCT01745302||Placebo plus EGFR-TKIs|TCM Placebo:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang,four packages,twice a day ,six months; EGFR-TKIs:oral tablet,Gefitinib 250mg daily or Erlotinib 150mg daily or Icotinib 125 mg three times a day until progression or unacceptable toxicity;
3290285|NCT01745315|Active Comparator|LigaSure (advanced bipolar device)|Laparoscopic hysterectomy will be done with LigaSure in 15 patients.
3290286|NCT01745315|Active Comparator|Halo PKSforceps(advanced bipolar device)|Laparoscopic hysterectomy will be done with Halo PKS cutting forceps in 15 patients.
3290287|NCT01745315|Active Comparator|EnSeal (advanced bipolar device)|Laparoscopic hysterectomy will be done with EnSeal in 15 patients.
3290288|NCT01745328|Active Comparator|LVX-AMX|subject is treated with LAV-AMX, then followed by placebo.
3290289|NCT01745328|Active Comparator|TCM treatment|subject is treated with TCM
3290290|NCT01745341||vitreoretinal surgery patients|Patients undergoing vitreoretinal surgery under monitored anesthesia care. They will be observed during surgery and no interventions will be administered.
3290291|NCT01745354|Experimental|SD-101 + Combined with Local Radiation|
3290292|NCT01745406||Doctor and nurse|
3290293|NCT01745406||Doctor without nurse|
3290294|NCT01745419||COPD Frequent Exacerbators|COPD patients having experienced at least two episodes of acute exacerbations in the former 12 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
3290295|NCT01745419||COPD non- exacerbators|COPD patients who have not experienced exacerbations in the former 24 months. (Acute exacerbations are defined as worsening symptoms requiring treatment with systemic steroids (oral or parenteral) or antibiotics, a visit to the emergency room, and/or admission to a hospital. Events separated by at least 21 days are considered as separate events of exacerbation.)
3290296|NCT01745432|Experimental|ADBLOCK +laparoscopic surgery|Adhesion Barrier System is site-specific sprayable adhesion barrier gel administered on the surgical field to reduce risk of adhesion formation.
3290297|NCT01745432|No Intervention|laparoscopic surgery|Laparoscopic surgery only without use of adhesion barrier
3290298|NCT01745445|Experimental|radiotherapy alone arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; All patients will be radiated by external beam radiation, using 3-D conformal radiation technique.
3290299|NCT01745458|Experimental|SB-659032|250 mg non-enteric coated SB-659032
3290300|NCT01745458|Placebo Comparator|Placebo|matched placebo QD for 14 days
3290301|NCT01745471||PCOS group|12 women with Polycystic Ovary Syndrome (PCOS) as defined by NIH criteria
3290302|NCT01745471||Pear shapes|12 with an android pattern as defined by a waist-to-hip greater than 0.85
3290303|NCT01745471||Apple shapes|12 will have a gynoid pattern as defined by a waist-to-hip ratio less than 0.78
3290304|NCT01745484|Experimental|Arm 1|SPECT scan will be performed at baseline. Patients will receive radiotherapy according to standard CT-based plan with conventional dose-volume histogram
3290305|NCT01745497|Experimental|Ferrous Sulfate|3mg/kg divided twice per day, 30 minutes before a meal or 2 hours after a meal
3290306|NCT01745497|Placebo Comparator|Placebo|Equivalent volume of liquid placebo administered twice daily, before a meal or 2 hours after a meal
3290307|NCT01745510|Experimental|DHA Group|"DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.~They will receive one dose, administered by enteral feeding every 24 h during 14 days"
3290308|NCT01745510|Placebo Comparator|Control Group (Placebo)|"Control group will receive sunflower oil which is the excipient of the DHA in this study.~They will receive one dose every 24 h during 14 days."
3290309|NCT01745523|Experimental|Vitrified oocytes using HPC+Trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
3290310|NCT01745523|Active Comparator|Vitrified oocytes using SSS+ Sucrose|Oocytes are vitrified using the SSS containing HSA and sucrose
3290311|NCT01745536|Experimental|Vitrified oocytes using closed Cryotop®|Oocytes are vitrified/stored using a closed device
3290312|NCT01745536|Active Comparator|Vitrified oocytes using open Cryotop®|Oocytes are vitrified/stored using an open device
3290313|NCT01745549|Experimental|needle 4 mm gauge 33|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge (the smaller needle)
3290314|NCT01745549|Active Comparator|needle 4 mm gauge 32|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge
3290315|NCT01745562|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3290316|NCT01745562|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3290317|NCT01745575|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3290318|NCT01745575|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3290319|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone + stem cell|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28, pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28-day cycle. Patients randomized to auto-SCT will proceed within 28 days after completion of the 4th cycle of ClaPD to receive melphalan 140mg/m2 or 200mg/m2 (as per institutional guidelines) followed by hematopoietic cell infusion.
3290320|NCT01745588|Experimental|Clarithromycin + Pomalidomide + Dexamethasone Alone|All patients will receive 4 cycles of clarithromycin 500mg twice daily on days 1-28 pomalidomide 4 mg daily on days 1 through 21 and dexamethasone orally at a dose of 40 mg daily on days 1, 8, 15, and 22 of each 28 day cycle. Patients assigned to ClaPD alone will receive 5 additional cycles of ClaPD.
3290321|NCT01745601|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3290322|NCT01745601|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3290323|NCT01745614|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3290324|NCT01745614|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3290325|NCT01745640|Experimental|POMALIDOMIDE and dexamethasone treatment|All patients will receive pomalidomide (4 mg/day per os) and dexamethasone (40/20 mg/wk per os) during 21 day/28 day cycle
3290326|NCT01745653|Experimental|Low level laser therapy|Low level laser (970nm) will be delivered on the mucous membrane in regard to the first molar teeth on which rings of the quadhelix have been settled.
3290327|NCT01745653|Sham Comparator|sham procedure|Same procedure than experimental arm except that the laser is not activated.
3290328|NCT01745653|No Intervention|no intervention|no intervention : Patient received the quadhelix with nothing else
3290329|NCT01745666|Experimental|patients with KCNQ1 or KCNH2 mutation|
3290330|NCT01745666|Other|patients WITHOUT KCNQ1 or KCNH2 mutation (control group)|
3290331|NCT01745679|Experimental|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
3290332|NCT01745692|Active Comparator|Intravenous rtPA|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms
3290333|NCT01745692|Experimental|Intravenous rtPA and Mechanical Thrombectomy|IV alteplase (rtPA) 0.9mg/kg (10% of dose as bolus followed by 90% as infusion over 1 hour, to a maximum dose of 90mg total) given within 4.5 hours of onset of stroke symptoms + additional mechanical thrombectomy procedure to commence within 90 minutes of start of IV rtPA infusion
3290334|NCT01745705|Experimental|Cervical Spine Manipulation|Subjects will lie supine on a treatment table and receive a high velocity low amplitude thrust joint manipulation to their cervical spine in rotation to each side of the neck.
3290335|NCT01745705|Sham Comparator|Manual Contact|Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
3290336|NCT01745718|Other|MRI and targeted biopsies|All patients receive the same level/number of diagnostic procedures. They all undergo targeted biopsies which are compared to the cytological imprints.
3290337|NCT01745731|Experimental|Experimental|Patients with hepatic space occupying lesion requiring an extended hepatic resection to those who were preoperatively performed a Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
3290338|NCT01745731|No Intervention|Control|Patients with hepatic space occupying lesion that require an extended liver resection that were performed preoperatively portal embolization of the affected segments.
3290339|NCT01745744|Experimental|Low dose|- Infusion of mesenchymal stem cells from adipose tissue: 0.5x106 cells / kg of patient weight.
3290340|NCT01745744|Experimental|High dose|- Infusion of mesenchymal stem cells from adipose tissue: 1x106 cells / kg of patient weight.
3290341|NCT01745744|No Intervention|Control|Conventional treatment
3290342|NCT01745757||Cohort|first line treatment for metastatic breast cancer
3290343|NCT01745770|Experimental|A|
3290344|NCT01745770|Active Comparator|B|
3290345|NCT01745783|Experimental|Experimental|"Receive a single IV administration of cellular product (Bone marrow mesenchymal stem cells autologous) on Day 0 and placebo infusion on day + 180.~Dose: 1-2x10^6 cells/Kg"
3290346|NCT01745783|Placebo Comparator|Placebo Comparator|Receive a placebo infusion on day 0 and a single administration cellular product on day +180. Dose: 1-2x10^6 cells/Kg
3290347|NCT01745796||Intubated ICU patients|
3290348|NCT01745809||Severe Asthmatics|Subjects with a pre-existing physician diagnosis of asthma with reversible airflow obstruction of at least 12%.
3290349|NCT01745809||Healthy non-smokers|Subjects will be never smokers or former smokers for the past year and less than 10 pack years lifetime with no history of asthma or any other lung disease.
3290350|NCT01745835|Active Comparator|2L Coolprep®|
3290351|NCT01745835|Experimental|1L Coolprep® and Bisacodyl|
3290352|NCT01745861|Active Comparator|Lipidem® (BBraun)|Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)
3290353|NCT01745861|Placebo Comparator|Lipofundin® MCT/LCT 20%|Lipid emulsion containing medium and long chain triglycerides
3290354|NCT01745887|Active Comparator|EBI-005-2 5mg/ml|Administration: 3 times per day
3290355|NCT01745887|Active Comparator|EBI-005-2 20 mg/ml|Administration: 3 times per day
3290356|NCT01745887|Placebo Comparator|EBI-005-2 Placebo|Administration: 3 times per day
3290357|NCT01745926||CPR|MECHANICAL CHEST COMPRESSION
3290358|NCT01745939|Active Comparator|Lumbar manipulation|Patients will receive thrust joint manipulation to their lumbar spine in side lying
3290359|NCT01745939|Sham Comparator|Sham manipulation|Patients will receive oscillations into slight rotation, without cavitation, in side lying
3290360|NCT01745965|Experimental|T-DM1|single agent T-DM1 for 12 weeks (3,6 mg/kg q3w)
3290361|NCT01745965|Experimental|T-DM1 + endocrine therapy|Single agent T-DM1 for 12 weeks (3,6 mg/kg q3w) with standard endocrine therapy (tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if no contraindications are present, in a standard daily dosage).
3290362|NCT01745965|Active Comparator|Trastuzumab + endocrine therapy|The control group will receive trastuzumab in 3-weekly schedule (8 mg/kg as loading dose and then 6 mg/kg q3w)with endocrine therapy tamoxifen in premenopausal women and an aromatase inhibitor in postmenopausal women, if not contraindications are present, in a standard daily dosage).
3290363|NCT01745978|Experimental|the knob-tipped knife|the knob-tipped knife using for precut papillotomy in difficult CBD cannulation
3290364|NCT01745978|Active Comparator|the needle knife|the needle knife using for precut papillotomy in difficult CBD cannulation
3290365|NCT01745991||Biliary Atresia undergoing Kasai op|Randomisation for the use of CoSeal at the time of Kasai and assessment at the time of Transplantation.
3290366|NCT01746004|Experimental|[^14C]-LY2157299|Single 150 mg oral dose of LY2157299 monohydrate containing 100 micro curies of [^14C] labeled drug
3290367|NCT01746030||Questionnaires|No treatment
3290368|NCT01746056|Active Comparator|Heat Patch Continuous|applied 2 hrs daily for 12 weeks
3290369|NCT01746056|Active Comparator|Heat Patch Noncontinuous|applied 2 hrs daily 2 weeks on and 2 weeks off for 12 weeks
3290370|NCT01746069|Placebo Comparator|health advice|clinical practice routine
3290371|NCT01746069|Experimental|Quit smoking combined cessation programme|Health advice and support sms messages to patient's mobile phone + clinical routine practice
3290372|NCT01746082|Experimental|Subjects 18 - 64 years|100 (up to 120) subjects 18 - 64 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
3290373|NCT01746082|Experimental|Subjects > /= 65 years|100 (up to 120) subjects greater than or equal to 65 years old receive two doses of monovalent inactivated influenza H3N2 variant (MIV), delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart.
3290374|NCT01746121||Amelogenesis Imperfecta|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
3290375|NCT01746121||healthy family members|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth
3290376|NCT01746134||Cohort|
3290377|NCT01746147||Patients with MDS and AML prior to allogeneic SCT|
3290378|NCT01746160|Experimental|C1 Implant|Patient having C1 implant installed.
3290379|NCT01746186||21-35 years of age|200 Men and 200 women: Ages 21-27 and Ages 28-35, BMI: 20-35,living in the Columbia, SC area.
3290380|NCT01746199|Experimental|cotrimoxazole daily prophylaxis|cotrimoxazole daily prophylaxis
3290381|NCT01746199|Active Comparator|Intermittent Preventive sulphadoxine-pyrimethamine Treatment|Referent treatment given according WHO recommendations
3290382|NCT01746212||Degenerative Disc Disease|Patients diagnosed with degenerative disc disease, meeting all eligibility requirements (please refer to inclusion/exclusion criteria), will be asked to participate in this study. A one-level or two-level anterior lumbar interbody fusion surgery using InQu Bone Graft Extender and Substitute, mixed with BMAC (bone marrow aspirate concentrate) as autograft, with Synthes Spinal Instrumentation will be recommended to the patient. If patients elect to proceed with surgery using the prescribed surgical components, they will be offered enrollment into the study. If the patient opts to use a different bone graft, or other spinal instrumentation, then the patient will not meet all inclusion criteria and will not be offered the opportunity to enroll in this study.
3290383|NCT01746238|Experimental|Treatment Arm|Bevacizumab, metronomic doxorubicin and radiation therapy
3290384|NCT01746251|Active Comparator|Concise Afatinib|Afatinib oral daily dose for 3 months
3290385|NCT01746251|Active Comparator|Prolonged Afatinib|Afatinib oral daily dose for 2 years
3290386|NCT01746277|Other|combined group|combined group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
3290387|NCT01746277|Other|sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
3290388|NCT01746290|Experimental|PulsePoint notification|Conventional Emergency Dispatch PLUS The PulsePoint notification. In the event of a potential cardiac arrest identified by 911call-takers, data will be automatically pushed to PulsePoint smartphone application users within very close proximity to the emergency. This will be done in parallel with normal emergency dispatch of paramedics and fire fighters to the scene of the emergency. The activation radius around the emergency is somewhat variable, depending on phone signal strength, climate conditions and whether the phone is inside or outside, but is approximately 200-500 meters.
3290389|NCT01746290|No Intervention|Usual Care|Patients randomized to the control arm will receive conventional emergency medical dispatching procedures but no PulsePoint notification will be sent to nearby PulsePoint users.
3290390|NCT01746303|Experimental|Omega 3 and Blueberry powder|This group will receive omega-3 fatty acid and blueberry powder supplement for 24 weeks (6 months)
3290391|NCT01746303|Experimental|Omega-3 and placebo powder|This group will receive omega-3 fatty acid and placebo powder for 24 weeks (6 months)
3290392|NCT01746303|Experimental|Placebo oil and blueberry powder|This group will receive placebo oil and blueberry powder for 24 weeks (6 months).
3290393|NCT01746303|Placebo Comparator|Placebo oil and placebo powder|This group will receive placebo oil and placebo powder for 24 weeks (6 months)
3290394|NCT01746329|Experimental|Tea|Oral intake of tea containing 75 grams of glucose
3290395|NCT01746329|Experimental|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
3290396|NCT01746329|Placebo Comparator|Placebo|Oral intake of 75 grams of glucose in water
3290397|NCT01746342|Active Comparator|Effective CPAP|Continuous positive airway pressure: effective fixed level determined by polysomnographic titration
3290398|NCT01746342|Sham Comparator|Sham CPAP|Continuous positive airway pressure device modified by manufacturer to deliver minimal pressure
3290399|NCT01746355|Active Comparator|rTMS-active|patients undergoing of rTMS real
3290400|NCT01746355|Sham Comparator|rTMS-Sham|patients undergoing to placebo rTMS
3290401|NCT01746381|Experimental|IVAPS mode of non-invasive ventilation|Patients with ALS randomized to this arm will be treated with non-invasive home ventilation using the Intelligent Volume-Assured Pressure Support (IVAPS) mode
3290402|NCT01746381|Active Comparator|BIST mode of non-invasive ventilation|Patients with ALS who are randomized to this arm will receive non-invasive home ventilation with the traditional bilevel non-invasive ventilation in spontaneous/timed (BIST) mode
3290403|NCT01746394|Experimental|Parents as Teachers Enhanced|Participants in the Parents as Teachers Enhanced (PaTE) intervention arm will receive the enhanced diet and activity maternal, infant, and early childhood home visiting program
3290404|NCT01746394|Active Comparator|Parents as Teachers|Participants in the Parents as Teachers (PaT) control arm will receive the standard maternal, infant, and early childhood home visiting program
3290405|NCT01746433|Active Comparator|Hanging Triangle Bar|"The patients randomized to this group will use a hanging triangle bar for aid in sitting up exercises.~No particular brand of hanging bar is targeted."
3290406|NCT01746433|Experimental|Ergonome|"The patients randomized to this group will use the l'ERGONOME device for aid in sitting up exercises.~Commercial name of the device: SAM ERGONOM (TM)~Manufacturer: Medicatlantic groupe Winncare, Le Pas du Château, 85680 Saint-Paul-Mont-Penit"
3290407|NCT01746446|Experimental|Care team|Patients are offered the support and services of the care team.
3290408|NCT01746446|No Intervention|Usual Care|Patients receive usual care.
3290409|NCT01746459|Active Comparator|Low Low|Low Intensity, Low Frequency Reminder System
3290410|NCT01746459|Active Comparator|Low, High|Low Intensity, High Frequency Reminder System
3290411|NCT01746459|Active Comparator|High, Low|High Intensity, Low Frequency Reminder System
3290412|NCT01746459|Active Comparator|High, High|High Intensity, High Frequency Reminder System
3290413|NCT01746472|Experimental|2 - B-passive|
3290414|NCT01746472|Experimental|3 - B-active|
3290415|NCT01746472|Experimental|4 - B-active, B-passive|
3290416|NCT01746472|Experimental|6 - z, B-passive|
3290417|NCT01746472|Experimental|7 - z, B-active|
3290418|NCT01746472|Experimental|8 - z, B-active, B-passive|
3290419|NCT01746472|Experimental|10 - t, B-passive|
3290420|NCT01746472|Experimental|11 - t, B-active|
3290421|NCT01746472|Experimental|12 - t, B-active, B-passive|
3290422|NCT01746472|Experimental|14 - t, z|
3290423|NCT01746472|Experimental|15 - t, z, B-active|
3290424|NCT01746472|Experimental|16 - t, z, B-active, B-passive|
3290425|NCT01746485|Experimental|UT-15C|
3290426|NCT01746498|Active Comparator|Group 1|11 patients We Applied real anodal tDCS on the left dorsolateral prefrontal cortex (DLPFC)20 minutes every day for 10 consecutive days.
3290427|NCT01746498|Active Comparator|Group 2|11 patients we applied cathodal tDCS on left DLPFC for 20 minutes every day for 10 consecutive days.
3290428|NCT01746498|Sham Comparator|Group 3|11 patients We applied sham stimulations(anodal tDCS) on the left DLPFC for few seconds the stop stimulations 2 mA every day for 10 days.
3290429|NCT01746524||CR FB|Subjects receiving Cruciate Retaining Fixed Bearing configuration of ATTUNE Primary Knee Implant
3290430|NCT01746524||PS FB|Subjects receiving Posterior Stabilized Fixed Bearing configuration of ATTUNE Primary Knee Implant
3379317|NCT00013559||Family|Parents and/or siblings of patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
3379318|NCT00013559||Patients|Patients with Smith-Magenis Syndrome (SMS) or suspected SMS.
3290431|NCT01746524||CR RP|Subjects receiving Cruciate Retaining Rotating Platform configuration of ATTUNE Primary Knee Implant
3290432|NCT01746524||PS RP|Subjects receiving Posterior Stabilized Rotating Platform configuration of ATTUNE Primary Knee Implant
3290433|NCT01746550|Experimental|MD-12-001 Stent Arm|This study includes a single arm, the MD-12-001 Stent Arm.
3290434|NCT01746563|Experimental|Ranibizumab|Ranibizumab 0,05 mg intravitreal injection
3290435|NCT01746563|Active Comparator|Laser Therapy|Laser Therapy alone
3290436|NCT01746576|Other|All|All subjects will undergo spontaneous ventilation through an impedance threshold device and ScvO2 will be recorded before and after
3290437|NCT01746589|Other|myopic LASIK procedure|All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
3290438|NCT01746602|Experimental|healthy subjects I|20 healthy subjects
3379319|NCT00012545||Healthy Pregnant Volunteers|Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study.
3379322|NCT00009243||Patients|Patients with acute stroke symptoms
3290439|NCT01746602|Experimental|healthy subjects II|20 healthy subjects
3290440|NCT01746602|Experimental|healthy subjects III|20 healthy subjects
3290441|NCT01746602|Experimental|healthy subjects IV|20 healthy subjects
3290442|NCT01746602|Experimental|healthy subjects V|20 healthy subjects
3290443|NCT01746602|No Intervention|healthy subjects VI|20 healthy subjects
3290444|NCT01746615|Experimental|30 Patients with BRVO in one eye|
3290445|NCT01746615|Experimental|30 healthy age and sex matched controls|
3290446|NCT01746628|Placebo Comparator|Hysterectomy without FloSeal|Endometrial curettage Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
3290447|NCT01746628|Active Comparator|Hysterectomy with FloSeal|Endometrial curettage FloSeal placement into uterine cavity Intrauterine foley balloon placement for 5 minutes Removal of intrauterine foley balloon Saline irrigation of uterine cavity Hysterectomy
3379326|NCT00006177||1|Children and adolescents between the ages of 6-17 years old who meet criteria for Bipolar Spectrum Disorders (BSD) (including Substance/Medication induced Bipolar &amp; Related Disorder (SMIBRD)).
3290448|NCT01746641|Active Comparator|Remifentanil|"Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria."
3290449|NCT01746641|Active Comparator|Propofol|"Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria."
3379327|NCT00006177||2|Adults between the ages of 18-58 years old who meet criteria for Bipolar Disorder, including those 18-25 years old previously enrolled as a subject with Bipolar Spectrum Disorders.
3379328|NCT00006177||3a|Control populations of healthy volunteer children and adolescents between the ages of 3-17 years old.
3379329|NCT00006177||3b|Control populations of parents of healthy volunteer children or healthy adults in research
3379330|NCT00006177||3C|Control populations of children 8-17 years old with attention deficit hyperactivity disorder (ADHD), who do not have a mood disorder.
3290450|NCT01746654|Experimental|P128-0.1 mg|Three healthy adult volunteers will be enrolled to P128-0.1 mg single dose-cohort 1 (Part A) Three healthy adult volunteers will be enrolled to P128-0.1 mg multiple doses-Cohort 4 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.1 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.1 mg single dose (Part D)
3290451|NCT01746654|Experimental|P128-0.3 mg|Three healthy adult volunteers will be enrolled to P128-0.3 mg single dose-Cohort 2 (Part A) Three healthy adult volunteers will be enrolled to P128-0.3 mg multiple doses-Cohort 5 (Part B) Ten chronic kidney disease patients will be enrolled to P128-0.3 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-0.3 mg single dose (Part D)
3290452|NCT01746654|Experimental|P128-1.0 mg|Three healthy adult volunteers will be enrolled to P128-1.0 mg single dose-Cohort 3 (Part A) Three healthy adult volunteers will be enrolled to P128-1.0 mg multiple doses-Cohort 6 (Part B) Ten chronic kidney disease patients will be enrolled to P128 1.0 mg multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to P128-1.0 mg single dose (Part D)
3290453|NCT01746654|Placebo Comparator|Placebo|Three healthy adult volunteers will be enrolled to placebo single dose-Cohort 1-3 (Part A) Three healthy adult volunteers will be enrolled to placebo multiple doses-Cohort 4-6 (Part B) Ten chronic kidney disease patients will be enrolled to placebo multiple doses (Part C) Ten patient harboring S.aureus nasally will be enrolled to placebo single dose (Part D)
3290454|NCT01746667|Experimental|Exposure in vivo|This treatment will consist of 10 sessions (twice a week) of exposure therapy based on the protocol used previously in exposure therapy for social anxiety disorder by Scholing & Emmelkamp (1993).
3290455|NCT01746667|Experimental|Virtual Reality Exposure Therapy|"This treatment consists of 10 sessions (twice a week) of exposure therapy by using virtual environments.~The difference between the exposure in vivo and virtual reality exposure therapy is the exposure component, which will be delivered in vivo in one condition and through the Head Mounted Display (HMD) in the other condition."
3379331|NCT00006177||4|First and second-degree biological relatives of those in Group 1 or Group 2, and are between 3-58 years old.
3379332|NCT00006177||5a|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 1.
3379333|NCT00006177||5b|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 2.
3290456|NCT01746667|No Intervention|Wait-list|Participants on the wait-list will be offered either exposure in vivo or in virtual reality after a waiting period of five weeks.
3290457|NCT01746680|Experimental|Tacrolimus with Methotrexate|Subjects have tacrolimus per oral once daily with methotrexate for 24weeks. Tacrolimus increased dosing regimen: 1mg for 0~4 weeks, 2mg for 4 weeks~8 weeks, 3mg for 8 weeks~24 weeks
3290458|NCT01746693|Experimental|amblyopia ex anisometropia|20 male and female volunteers with amblyopia ex anisometropia
3290459|NCT01746693|Experimental|amblyopia ex strabismus|20 male and female volunteers with amblyopia ex strabismus
3290460|NCT01746693|Experimental|control subjects|20 healthy male and female control subjects
3290461|NCT01746706|Experimental|patients|
3290462|NCT01746706|Experimental|volunteers|
3290463|NCT01746719|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
3290464|NCT01746719|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
3290465|NCT01746758|Experimental|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
3290466|NCT01746758|No Intervention|Comparison arm|No intervention will be implemented in intervention arm. Data on reproductive health conditions and treatments and data on referrals from drug stores in this arm will be obtained directly from ministry of health registers filled and filed at the dispensary and health centres, plus a tailor-made form which is filled by the dispensary and health centre clinicians whenever they receive a patient in the eligible categories.
3290467|NCT01746771|Experimental|HM781-36B, Paclitaxel, Trastuzumab|HM781-36B(Poziotinib): QD*2weeks/3weeks Paclitaxel: 175mg/m2 Trastuzumab(Herceptin): 8mg/kg
3290468|NCT01746797||Women currently taking antidepressants|Women who have selected to stay on antidepressant medication while undergoing infertility treatment.
3290469|NCT01746797||Women not on antidepressants|Women who decided to discontinue their antidepressants while undergoing fertility treatments.
3290470|NCT01746810|Experimental|Stereotactic Body RT and IRGA|Patients undergo stereotactic body radiation therapy QD for a total of 5 fractions and then undergo IRGA (either radiofrequency ablation or microwave ablation) 1 week later.
3290471|NCT01746823||Controls, Keratoconus|Sub group of Keratoconus to be treated with anti-inflammatory agents ie Cyclosporine-A
3290472|NCT01746849|Experimental|palifermin with Lupron|All patients undergo total body irradiation (TBI) on days -9 to -6 & receive thiotepa intravenously (IV) over 2-4 hours on days -5 to -4, cyclophosphamide IV over 30-60 minutes on days -3 to -2, & anti-thymocyte globulin infused over 12 hours on days -3 to -2 Pts undergo T-cell depleted allogeneic hematopoietic stem cell transplant on day 0. Pts will receive a three month depot dose of Lupron 3-6 weeks prior to the start date of the pre-transplant conditioning regimen. Pts will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 & no more than 48 hours prior to the start of cytoreduction. Pts will receive three additional daily doses of palifermin the first approximately 6 hours after the stem cell infusion on day 0, followed by two daily doses given at 24 hour intervals on d+1 & d+2. Pts will receive a further 3-month depot injection of Lupron approximately 3 months (+/- one week) post the first dose.
3290473|NCT01746849|Experimental|palifermin with Degarelix|Participants on the degarelix arm will receive a loading dose of degarelix 240 mcg subcutaneous 4-14 days before the start of pre-transplant conditioning. All participants will receive palifermin at 60mcg/kg/day IV on three consecutive days, 24 hours apart with the last dose administered no less than 24 and no more than 48 hours prior to the start of cytoreduction.
3290474|NCT01746875|Experimental|Treatment|aflibercept intravitreal injections, 2.0 mg monthly x 3 doses, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; aflibercept intravitreal injections, 2.0 mg x 3 doses is repeated, then injections as needed based on recurrence of activity on OCT. If no effect of the treatment; verteporfin photo dynamic therapy.
3290475|NCT01746875|No Intervention|Observation|
3290476|NCT01746888||Older Adults|Adults 65 years and older who present to the Emergency Department.
3290477|NCT01746914||Lung transplantated patients|Patients undergone lung transplantation
3290478|NCT01746927||cricoid pressure|
3290479|NCT01746966||Rheumatoid Arthritis|20 patients age of 20-60 with Rheumatoid Arthritis according to ARA 1987 revised criteria and disease activity Disease Activity Score (DAS) 3-5
3290480|NCT01746966||Healthy controls participants|Healthy controls age of 20-60 according to conclusion of preventive medicine department
3290481|NCT01746992|Experimental|pirarubicin|3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate
3290482|NCT01746992|Active Comparator|doxorubicin|8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)
3290483|NCT01747005||Conventional therapy|
3379334|NCT00006177||5c|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 3a.
3379335|NCT00006177||5d|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 3b.
3379336|NCT00006177||5e|A subgroup of these cohorts will be Old Order Amish individuals who fulfill eligibility for Group 4.
3379337|NCT00006150||Affected adults and children|Confirmed or suspected history of a Hyper IgE syndrome
3379338|NCT00006150||Relatives|Family members of subjects with confirmed or suspected history of a Hyper IgE syndrome
3379339|NCT00005927||Hyperaldosteronism and cushing participants|Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
3290484|NCT01747005||ERAS|Oral intake of solid food restriction 6 hours before surgery. Oral intake clear fluids restriction 2 hours before surgery. Intravenous 5% Dextrose-500 ml 1 hour before surgery. Intravenous dexamethasone -4mg before anesthesia. Combined spinal-epidural anesthesia. Intraoperatively 10 ml/kg intravenous of crystalloids. Paracetamol intravenous 1g. Early mobilization of patient. Oral solid food intake 4 hour postoperative. Postoperative continuous epidural analgesia.
3290485|NCT01747018|Experimental|Platelet-rich Plasma|From all the patients who participated in the clinical trial, 27 ml of blood sample was collected with a 20-G needle from an antecubital vein so that the ratio of the blood and the anti-coagulant became 10:1. The collected blood samples were transferred to a prepared separation kit (Prosys PRP, Seoul, Korea) and underwent centrifugation at the speed of 3,000 RPM for three minutes. The buffy coat layer and the plasma of the upper portion of the layer were obtained and were transferred to a concentration kit (Prosys PRP, Seoul, Korea) using a 10-ml syringe. They again underwent centrifugation at the speed of 3,300 RPM for three minutes in order to obtain concentrated PRP. The injection area was sterilized aseptically and 3-4 cc of PRP were percutaneously injected into the knee joints.
3290486|NCT01747031|Experimental|Single arm study|Single arm study.The investigators will conducte computed tomography,angiography and FFR measurement during angiography in this single arm.
3379341|NCT00005909||Alkaptonuria|Patients with confirmed or suspected alkaptonuria
3379342|NCT00005902||1|250 subjects with von Hippel-Lindau (VHL) disease.
3379343|NCT00004850||HBV positive|HBV positive subjects
3379344|NCT00004850||HCV positive partners|HCV positive partner subjects
3379345|NCT00004850||HCV postive|HCV positive subjects
3379346|NCT00004738||Family Members|At least 2 family members of a patient with a confirmed diagnosis of Chiari I malformation.
3379347|NCT00004738||Patients|Patient with a confirmed diagnosis of Chiari I malformation who has a family member with syringomyelia or Chiari I malformation
3290487|NCT01747044|Active Comparator|Milnacipran|Milnacipran is an antidepressant known and used in major depressive disorder according to its marketing authorization but is also part of the molecules used in the treatment of chronic neuropathic pain and fibromyalgia according to the recommendations of the EULAR
3290488|NCT01747044|Placebo Comparator|Capsules of lactose|placebo over a period of 8 weeks to 24 weeks
3290489|NCT01747057|Experimental|Dynamic guide resuscitation|This arm follows a resuscitation protocol based on dynamic-parameters-guided fluid management.
3290490|NCT01747057|Active Comparator|Standard resuscitation|This arm follows a common resuscitation protocol based on Surviving Sepsis Campaign recommendations.
3290491|NCT01747070|Active Comparator|tDCS and EAC sham|Subjects will receive 05 sessions of tDCS. The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline solution. The sham DIMST consist of the use of rubber electrodes placed in the same places that active treatment. Will use the same electrical apparatus, but without pass of current to the electrodes. The unit will be in front of the patient on with their lights blinking.
3379348|NCT00004577||Healthy Volunteer|Any healthy, male or female volunteer 18 years of age and older.
3379349|NCT00004571||Healthy volunteers|Healthy subjects from the community
3379350|NCT00004571||Schizophrenia|Patients with schizophrenia and psychosis
3379351|NCT00004571||Williams Syndrome|Individuals with copy number variation in the Williams Syndrome Region.
3379354|NCT00001979||Patients|Patients with known or suspected immunologically-mediated kidney diseases or immunologically-mediated diseases with potential for kidney disease.
3379355|NCT00001975||Group 1|Patients will be those already diagnosed with TSC (definite or possible)
3379358|NCT00001888||1|Asthmatics
3379359|NCT00001888||2|Research Volunteers
3379364|NCT00001850||Children|with reproductive disorders
3379365|NCT00001850||Men|with reproductive disorders
3379366|NCT00001850||Woman|with reproductive disorders
3379368|NCT00001813||1|Subjects with clinical and/or laboratory documentation of typical features or suggestiveclinical features of XP, CS, TTD, or overlap syndromes
3379369|NCT00001813||2|Family members of patients with XP, CS, TTD, or overlap syndromes
3379370|NCT00001813||3|Healthy Volunteers
3379371|NCT00001778||healthy volunteers|At least 18 years old and have no history of any medical illness that may confound studyresults or make participation in this protocol impossible
3290492|NCT01747070|Placebo Comparator|tDCS sham and EAC sham|The subjects will receive 05 sessions of tDCS sham and EAC sham. The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC sham consists of placement of rubber electrodes in the same areas of active stimulation (beside the spinous processes of L1 to S2, muscles vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus). The electrodes are connected to the same device electro, for 30 minutes, but without passage of electrical stimulation to the patient. The device is kept on and in front of the patient, with the lights blinking.
3290493|NCT01747070|Active Comparator|tDCS sham and EAC|Subjects will receive 05 sessions of tDCS sham and EAC.The sham tDCS be performed in the same way as the active, although the Electro device is turned off 30 seconds after the beginning of treatment, the session will have the same duration of 30 minutes. The EAC consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
3290494|NCT01747070|Experimental|tDCS and EAC|Subjects will receive 05 sessions of transcranial direct current stimulation(tDCS) and electroacupuncture(EAC). The tDCS consist of application of current of 2 mA, the anode being placed in the motor cortex (M1) and the cathode in the supraorbital region, for 30 minutes,using electrodes with saline. The electroacupuncture consist of electrical stimulation with a frequency of 2 Hz for 30 min. The needles are placed beside the spinous processes of L1 to S2, with a depth of 3 cm and in the muscles: vastus lateralis, rectus anterioris, vastus medialis, tibialis anterior, peroneus longus and insertion of the pes anserinus.
3290495|NCT01747083|Experimental|A|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fasting condition
3290496|NCT01747083|Experimental|B|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mgx2tablets))under fed condition
3290497|NCT01747109|Experimental|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
3290498|NCT01747109|Active Comparator|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. No specific trademark is requested by the protocol."
3290499|NCT01747122|Experimental|Wound catheter|Wound catheter
3290500|NCT01747122|Active Comparator|Epidural|Standard epidural, pre-operative insertion, to be run for 48 hours
3290501|NCT01747135|Experimental|Open label|
3290502|NCT01747161|Experimental|botulin toxin|botulin toxin
3290503|NCT01747161|Placebo Comparator|physiological water|physiological water
3290504|NCT01747174|Experimental|Std PCI + Intra-coronary (IC) Adenosine|IC Adenosine in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
3290505|NCT01747174|Experimental|Std PCI + IC Sodium Nitroprusside (SNP)|IC SNP in to IRA (following thrombus aspiration) with further dose via guide catheter following coronary stent deployment.
3290506|NCT01747174|Active Comparator|Std PCI|Standard PCI only
3290507|NCT01747187||Septic shock|
3290508|NCT01747226|Placebo Comparator|Fluoride rinse|A fluoride rinse with alcohol was chosen because its similarity in color and aroma to the active rinses. This anti-cavity rinse does not contain any active components and therefore it is not expected to have any anti-malodour activity.
3290509|NCT01747226|Active Comparator|Halita|Halita is a CHX-containing benchmark product that has proven to be clinically effective against halitosis (Roldan et al, 2003)
3290510|NCT01747226|Active Comparator|Meridol Halitosis|This study aims to confirm the effect of meridol®Halitosis(AmF/SnF2 and zinc) already observed in volunteers with morning bad breath (physiological)(Wigger-Alberti et al, 2010; Wilhelm et al, 2010)in patients with oral malodor (pathological).
3290511|NCT01747226|Sham Comparator|Water|To distinguish the masking effect caused by the formulations and the one caused by the rinsing itself.Only for short term evaluation (15') to not to compromise compliance of patients.
3290512|NCT01747239|Experimental|Cabazitaxel|25 mg/m2 IV every three weeks
3290513|NCT01747252|Experimental|RGC1|RGC containing the equivalent of 50 mg resveratrol
3290514|NCT01747252|Active Comparator|Resveratrol|The equivalent of 150 mg resveratrol
3290515|NCT01747252|Experimental|RGC2|RGC containing the equivalent of 150 mg resveratrol
3290516|NCT01747278|No Intervention|Placebo|Patients were not treated with Trimethoprim/Sulfamethoxazole (TMP/SMX).
3290517|NCT01747278|Experimental|TMP/SMX|Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 80 mg/400 mg p.o. every day as PCP Prophylaxis.
3290518|NCT01747291||Atypical femur fracture cohort|
3290519|NCT01747304||Screening population|Healthy post-menopausal women attending bone mineral density screening clinic with leg/hip/groin pain/discomfort/weakness an has been on anti-resorptive therapy for at least 5 years.
3290520|NCT01747304||Comparator Group|Control group from Toronto CaMOS cohort willing to participate.
3290521|NCT01747304||AFF group|participants in the AFF Cohort study at UHN
3290522|NCT01747317|Experimental|Single arm study|Single arm study.The investigators will conduct computed tomography,angiography and FFR measurement during angiography in this single arm.
3290523|NCT01747356|Experimental|Resolute stent treatment group|"All patients will receive Resolute stent implantation to cure severe coronary atherosclerotic lesions.~RESOLUTE stent system specification (eluted zotarolimus 1.6μg/mm2):~After stent implantation, each patient will be followed up at time point of 30-day, 6-month and 12-month.~Follow-up window:~Duration of hospital stay Follow-up 1: 30days after procedure (±7 days) Follow-up 2: 6-month after procedure (±30 days) Follow-up 3: 12-month after procedure (±30 days)"
3290524|NCT01747395|No Intervention|Control Group|No exercise group (sedentary)
3290525|NCT01747395|Experimental|Aerobic Exercise Training|Group undergoing isolate aerobic exercise training 3 times/week, during 40 minutes, for 04 mouths
3290526|NCT01747395|Experimental|Inspiratory Muscle Training|Group undergoing isolate inspiratory muscle training 7 times/week, during 30 minutes, for 04 mouths
3379372|NCT00001778||individuals seropositive for HTLV|Positive HTLV-1 ELISA followed by a positive Western Blot
3290527|NCT01747395|Experimental|Aerobic+Inspiratory Muscle Training|Group undergoing aerobic exercise training (3 times/week during 40 minutes) associate inspiratory muscle training (7 times/week during 30 minutes) for 04 mounths
3290528|NCT01747408|Experimental|25% human albumin|Subjects will be entered into one of 4 increasing dosages of 25% human albumin sequentially. Once the first 20 subjects have been enrolled and the DSMB reviews data and approves moving to the next dosage tier patients will be entered into the following dosage tier.
3290529|NCT01747512|Active Comparator|C-PERT|45 patients with cancer
3290530|NCT01747512|Active Comparator|G-PERT|65 patients with cancer
3290531|NCT01747525||NIRS/IVUS of coronary artery|All patients will have an epicardial coronary artery stenosis of intermediate severity (>50% to <70% stenosis) (stenosis ≥20% - ≤70%) by invasive angiography in whom IVUS is planned to further clinical evaluation of lesion severity; or a severe epicardial coronary artery stenosis by invasive angiography and percutaneous coronary intervention (PCI) is planned for definitive treatment.
3290532|NCT01747538|Placebo Comparator|Placebo|
3290533|NCT01747538|Experimental|Dose 1 gevokizumab|
3290534|NCT01747538|Experimental|Dose 2 gevokizumab|
3290535|NCT01747564|Experimental|mirabegron group|
3290536|NCT01747577|Experimental|Solifenacin group|
3290537|NCT01747577|Placebo Comparator|Placebo group|
3290538|NCT01747590|Experimental|Zolpidem, Alprazolam, Caffeine, and Placebo|The 4 medications are given in a counterbalanced design.
3290539|NCT01747603|No Intervention|Current management of LPTB|The current pragmatic, but non-systematic, pattern of management of LPTB infants. Growth measurements, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, and basic developmental milestones (as itemized in the Rourke Developmental screening tool) will be recorded by families and primary health care providers as itemized in the Memory Book at the assessments made at the discretion of the health care providers.
3290540|NCT01747603|Experimental|Specialized LPTB Clinic|Additional 6 specialized LPTB follow-up clinic visits attended by pediatricians and neonatologists. Detailed findings from physical examination, feeding histories/methods, illness history including emergent visits to clinicians, walk-in clinics and emergency departments and breast-feeding support clinics, basic developmental milestones (as itemized in the Rourke Developmental screening tool) and physician recommendations will be recorded at each appointment. These will be compared to those obtained from families and primary health care providers as itemized in the Memory Book.
3290541|NCT01747616|Experimental|12 subjects wearing soft contact lenses|The medical test device will be administered with the contact lenses inserted
3290542|NCT01747616|Experimental|12 subjects wearing rigid contact lenses|The medical test device will be administered with the contact lenses inserted
3290543|NCT01747616|Experimental|12 subjects with soft contact lenses|The medical test device will be administered before insertion of the contact lenses
3290544|NCT01747616|Experimental|12 subjects with rigid contact lenses|The medical test device will be administered before insertion of the contact lenses
3290545|NCT01747642|Active Comparator|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
3290546|NCT01747642|Active Comparator|Oncoxin & Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd orally for 180 days
3290547|NCT01747642|No Intervention|Supportive treatment|Only supportive treatment. No chemotherapy, radoiotherapy, ablation or surgical intervention will be carried out.
3290548|NCT01747668|Placebo Comparator|Control Supplement|soft-gel placebo capsules, 2 capsules from the placebo bottle per day
3290549|NCT01747668|Experimental|Experimental Supplement A|soft-gel capsules; 1 capsule from the experimental bottle and 1 capsule from the placebo bottle per day
3290550|NCT01747668|Experimental|Experimental Supplement B|soft-gel capsules; 2 capsules from the experimental bottle per day
3290551|NCT01747681||Microfracture|Microfracture of articular chondral defect
3290552|NCT01747694|Experimental|Multi-respiratory muscle training|Patients will perform multi-repiratory muscle training programe for 12 weeks
3290553|NCT01747694|No Intervention|Diaphragmatic breathing|Patients will be taught diaphragmatic breathing technique routinely. To practice at home lasting 12 weeks
3290554|NCT01747707|Experimental|docetaxel, cisplatin and S-1 (DCS)|All patients receive the combination therapy of docetaxel, cisplatin and S-1 for a maximum of 6 cycles. Docetaxel 60mg/m2 IV infusion over 1 hour on d1; Cisplatin 30mg/m2 IV infusion on d1,2; S-1 40mg orally twice a day for patients with the body surface area (BSA) less than 1.25m2, 50mg twice a day with the BSA between 1.25 and 1.5m2, 60mg twice a day with the BSA over 1.5m2.
3290555|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 1000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 1000 IU daily, for 12 months
3290556|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 2000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 2000 IU daily, for 12 months
3290557|NCT01747720|Experimental|Vitamin D3 (cholecalciferol) 3000 IU|Oral vitamin D3 (cholecalciferol) supplementation, 3000 IU daily, for 12 months
3290558|NCT01747720|Placebo Comparator|Placebo|daily, for 12 months
3290559|NCT01747733||Endoscopy patients|Patients undergoing endoscopy in the endoscopy unit in HUCH (Helsinki University Central Hospital).
3290560|NCT01747746|Active Comparator|Rivaroxaban|Anticoagulation with Rivaroxaban 20 mg daily with dinner for 30 days
3290561|NCT01747746|Other|Warfarin and Enoxaparin|Warfarin: 1-10 mg per Nomogram Enoxaparin weight based 1 mg/kg Q12 or 1.5 mg/kg/day Historic control
3290562|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
3290563|NCT01747759|Other|Fisher exact test|The evaluations will take place at baseline, the day before surgery and 6 weeks post-surgery on knowledge and beliefs scores at each visit and on a satisfaction score on the last one. Quantitative data will be compared between groups by the Kruskal-Wallis and qualitative parameters via Fisher exact test
3290564|NCT01747785||Healthy controls|Individuals without history of cardiovascular disease and at least 18 years of age will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 3 visits over a 12 week period.
3379373|NCT00001778||individuals with indeterminate HTLV sero-status|Positive HTLV ELISA but a Western Blot that only partially fulfills criteria
3290565|NCT01747785||Patients at risk of heart failure|Individuals at risk of heart failure and a preserved ejection fraction of at least 50% will take a baseline (at rest) cardiopulmonary exercise test (CPX) and have a baseline cardiac echocardiogram to measure myocardial deformation. CPX and echocardiograms will be repeated during exercise sessions at 6 visits over a 12 week period. A cardiac rehabilitation exercise program will also occur over 12 weeks.
3290566|NCT01747798|Experimental|Treatment (auranofin)|Patients receive auranofin PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3290567|NCT01747824||Agitation Group|Patients that are evaluated to have an altered mental status score greater than 1 will be enrolled in the Agitation Group.
3290568|NCT01747824||Pain Group|Patients that report severe pain secondary to a long bone fracture or dislocation and report a visual analog scale pain score greater than 7 will be enrolled in the Pain Group.
3290569|NCT01747863||Mild NE|Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia.
3290570|NCT01747889|Experimental|Electronic system|patients managed with an electronic chest drainage system
3290571|NCT01747889|No Intervention|traditional system|patients managed with a traditional analogue chest drainage system
3290572|NCT01747902|Other|Biceps tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
3290573|NCT01747902|Other|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
3290574|NCT01747941|Experimental|Cohort 1|Single ascending oral doses in fasted conditions
3290575|NCT01747941|Experimental|Cohort 2|Single ascending oral doses in fasted conditions
3290576|NCT01747941|Experimental|Cohort 3|Single ascending oral doses in fed conditions
3290577|NCT01747954|Experimental|Bag Squeezing|"20% increase in FiO2~Inflation pressure of 30 cm H2O + 10l O2/min~0.5 ml saline 0.9%~10 Manual Hyperinflation~10 vibrocompression~Aspiration Tracheal"
3290578|NCT01747954|Active Comparator|Thoracic vibrocompression|"20% increase in FiO2~0.5 ml saline~10 vibrocompression toracica on the right and left~Aspiration Tracheal"
3290579|NCT01747967|Experimental|Meal test|Both new-onset T1D children and adults will be recruited and followed up through 4 meal tests at 0, 6, 12 , 18, 24 and 30 months.
3290580|NCT01747980|Experimental|PRX-112|250 mL of resuspended carrot cells administered orally in a vehicle
3290581|NCT01747993|Experimental|tamsulosin|Tamsulosin (0.4 mg/j) (1 tablet / day for 6 days)
3290582|NCT01747993|Placebo Comparator|placebo|1 tablet / day for 6 days
3290583|NCT01748006||Blood and urine samples|
3290584|NCT01748019|Experimental|ST1968|"ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks~--------------------------------------------------------------------------------"
3290585|NCT01748032|Other|Alternative Uses Training|In this task, subjects are asked to produce atypical and alternative uses for common daily objects.
3290586|NCT01748032|Other|Word Association Training|In this task, subjects are asked to generate the first word that comes to their mind, and thus, encourages more general and spontaneous divergent thinking.
3290587|NCT01748058|Experimental|Active video games|Exercise based on active video gaming
3290588|NCT01748058|No Intervention|Routine care|
3290589|NCT01748084|Placebo Comparator|NaCl|NaCl 500 ml IV day 1 and day 15 plus 100 mg methylprednisolone
3290590|NCT01748084|Experimental|Rituximab|Rituximab 1G IV day 1 and day 15 plus 100 mg methylprednisolone
3290591|NCT01748097|Experimental|IV bicarbonate 4.2% 20 cc|injecting 20cc 4.2% to a newly administered IV line
3290592|NCT01748097|Placebo Comparator|IV normal saline|injecting 20 cc normal saline to a newly administered IV line
3290593|NCT01748110|No Intervention|Local Control Group|This arm is for patients in the District of Columbia (DC), (Maryland) MD, (Virginia) VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
3290594|NCT01748110|Experimental|Local TRIMM Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
3290595|NCT01748110|Experimental|Local Intensive Group|This arm is for patients in the DC, MD, VA area that are able to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to undergo intensive in-person fitness interventions according to the Look AHEAD model. This will involve attendance at weekly support group meetings and personal monthly meetings with a health care provider/
3290596|NCT01748110|No Intervention|Distant Control Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to standard recommendations for fitness/health interventions prior to surgery.
3290597|NCT01748110|Experimental|Distant TRIMM Group|This arm is for geographically distant patients that are unable to attend all follow up visits at 3 month, 6 month, 12 month and 18 months post operative periods that have been randomized to receive daily text message reminder and prompts targeted to the patient's dietary, fitness and urologic goals and needs using the Tailored Rapid Interactive Mobile Messaging (TRIMM) method. Patients will receive these text messages from 4 weeks prior to surgery until 8 week after surgery
3290598|NCT01748123|Active Comparator|Chlorthalidone|25mg daily orally for 8 weeks
3290599|NCT01748123|Active Comparator|Hydrochlorothiazide|50mg daily orally for 8 weeks
3290600|NCT01748136||Single Arm|CT Scan Arm
3290602|NCT01748175|Other|Longitudinal follow up|Patients will undergo a characterization phase, which includes a baseline evaluation (1 visit), and a steroid responsiveness evaluation (2 visits). The longitudinal phase will include 3 office visits (annually) over 36 months with bi-annual phone calls. During the study patients will answer questionnaires, perform lung function testing and provide blood, urine, sputum and exhaled breath condensate samples.
3290603|NCT01748188|Active Comparator|Ultrasound + Exercises + Cryotherapy|Ultrasound of 1 Megahertz (MHz), intensity 2 W/cm2, 5 minutes, for 20 sessions.
3290604|NCT01748188|Experimental|Phonophoresis + Exercises + Cryotherapy|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
3290605|NCT01748188|Experimental|Iontophoresis + Exercices + Cryotherapy|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 milliamperes (mA), 20 minutes, for 20 sessions.
3290606|NCT01748201|Experimental|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
3290607|NCT01748214||Nasal CPAP|Infants received nasal CPAP as standard of care.
3290608|NCT01748214||High Flow Nasal Cannual|Infants received high flow nasal cannula as standard of care.
3290609|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (morning)|
3290610|NCT01748253|Active Comparator|Telmisartan-amlodipine tablet administration group (bedtime)|
3290611|NCT01748266||microcirculatory reactivity|Patients were studied during the first 48 postoperative hours. Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
3290612|NCT01748279|Active Comparator|Atorvastatin|40 mg of Atorvastatin once daily as add-on to Formoterol only 12 weeks therapy.
3290613|NCT01748279|Placebo Comparator|Lactose tablet|One tablet taken once a day as add-on treatment to Formoterol baseline 12 weeks therapy.
3290614|NCT01748305|Experimental|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
3290615|NCT01748318|Experimental|NM Regional Honey|15 ml of NM Honey applied directly to wound
3290616|NCT01748318|Active Comparator|Bactrim DS|Standard of Care Oral Antibiotic
3290617|NCT01748331|Other|Strict fluid restriction < 1 L/day|20 patients will be randomized to strict fluid restriction < 1 L/day
3290618|NCT01748331|Other|Moderate fluid restriction < 2.5 L/day|20 patients will be randomized to moderate fluid restriction < 2.5 L/day
3290619|NCT01748344|Experimental|Experimental 1|High dose ONO-4053
3290620|NCT01748344|Active Comparator|Cetirizine|10mg Cetirizine
3290621|NCT01748344|Experimental|Experimental 2|Low dose ONO-4053
3290622|NCT01748344|Placebo Comparator|Placebo|Placebo
3290623|NCT01748357||Tuberculosis group|Patients with confirmed pulmonary infection with M. tuberculosis. At least 50% of the subjects should be tested before therapy is started. Patients with treatment for tuberculosis >1 week are excluded.
3290624|NCT01748357||Inflammation group|Patients with another inflammatory disease of the lower respiratory tract, i.e. pneumonia, sarcoid or bronchial carcinoma. This group is required to detect VOC pattern caused by pulmonary inflammation.
3290625|NCT01748357||Healthy group|Healthy subjects without lung disease. These subjects should be recruited from outside the hospital / study site to avoid confounding VOC pattern caused by continuous exposure to the hospital environment.
3290626|NCT01748370|Experimental|Vitamin D hypogonadal|Vitamin D supplementation in hypogonadal men
3290627|NCT01748370|Experimental|Vitamin D eugonadal|Vitamin D supplementation in eugonadal men
3290628|NCT01748370|Placebo Comparator|Placebo hypogonadal|Vitamin D supplementation in hypogonadal men
3290629|NCT01748370|Placebo Comparator|Placebo eugonadal|Vitamin D supplementation in eugonadal men
3290630|NCT01748383|Experimental|Transplantation of BMMCs|Autologous BMCs aspiration and transplantation of these cells
3290631|NCT01748383|Experimental|Transplantation of CD 133+ cells|Autologous CD 133+ BMCs aspiration and transplantation of CD 133+ cells
3290632|NCT01748383|Active Comparator|stenting of IRA|The only stenting of IRA
3290633|NCT01748396|Experimental|Calcitriol + CaCO3|Calcitriol 0.25mcg 1cap daily for 8 weeks, and Calcium Carbonate 500mg 1tab 3 times daily for 8 weeks
3290634|NCT01748396|Active Comparator|Calcitriol|Calcitriol 0.25mcg 1cap daily for 8 weeks
3290635|NCT01748422||Experimental: Qutenza|Single treatment with Qutenza (topical capsaicin8%) transdermal patch
3290636|NCT01748435||Qutenza|Single treatment with QUTENZA (topical capsaicin 8%) transdermal patch
3290637|NCT01748448|Active Comparator|Vitamin D|Every month 100 000 units of Vitamin D in syringe oral dispenser is taken . Study duration is maximum 3,5 years or until relapse occurs
3290638|NCT01748448|Placebo Comparator|arachides oleum raffinatum|Every month 100 000 units of vitamin D in syringe Oral dispenser is taken. Study duration is maximum of 3.5 years or until relapse occurs
3290639|NCT01748461|Active Comparator|Structured intervention|Supervised cycle ergometer program
3290640|NCT01748461|Active Comparator|Coach intervention|Non-supervised cycle ergometer program
3290641|NCT01748461|No Intervention|Control group|No cycle ergometer program
3290642|NCT01748474|Experimental|Supplemental oxygen|Supplemental oxygen will be applied via a mask during CPET
3290643|NCT01748474|Placebo Comparator|Sham room air|Room air will be applied similarly to oxygen
3290644|NCT01748487|Experimental|OZURDEX|24 patients will receive an intravitreal injection of OZURDEX at the end of cataract surgery.
3290645|NCT01748500|Experimental|Pantoprazole, Docetaxel, Prednisone|
3290646|NCT01748513||preoperative venous return optimizing|Morbidly obese patients scheduled for bariatric surgery
3290647|NCT01748526|Experimental|Treatment A|Each volunteer will receive a single 200 mg dose of canagliflozin (JNJ-28431754) on Day 1.
3290648|NCT01748526|Experimental|Treatment B|Each volunteer will receive a single 300 mg dose of canagliflozin (JNJ-28431754) on Day 1.
3290649|NCT01748539|Experimental|KHK4827 70mg SC|
3290650|NCT01748539|Experimental|KHK4827 140mg SC|
3290651|NCT01748539|Experimental|KHK4827 210mg SC|
3290652|NCT01748539|Placebo Comparator|Placebo SC|
3290653|NCT01748565||premature infants|Infants born prematurely between 23-0/7 and 27-6/7 weeks post-menstrual age with and without bronchopulmonary dysplasia
3290654|NCT01748578|Active Comparator|EBI-005-1 5mg/mL|Healthy subjects will be randomized to EBI-005 5mg/mL vs. EBI-005-1 Placebo 3x/day
3290655|NCT01748578|Active Comparator|EBI-005-1 20 mg/mL|Healthy subjects will be randomized to EBI-005 20 mg/mL vs. EBI-005-1 Placebo 3x/day
3290656|NCT01748591||PICOPREP treatment|PICOPREP powder for oral solution according to standard clinical practice
3290657|NCT01748604|Active Comparator|Standard trimodality therapy with MLD|Manual Lymphatic Drainage (MLD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day.
3290658|NCT01748604|Experimental|Trimodality therapy with LPD|Pneumatic massage with Lymphapress-Plus(TM) device (LPD) followed by intermittent pneumatic compression (IPC) and followed by multilayer, multicomponent bandages (MB) until next day
3290659|NCT01748604|Experimental|Bimodality therapy without MLD|intermittent pneumatic compression (IPC) followed by multilayer, multicomponent bandages (MB) until next day.
3290660|NCT01748617|Experimental|Pomegranate Juice|Acute ingestion of pomegranate juice with high fat meal.
3290661|NCT01748617|Placebo Comparator|Control|Acute ingestion of juice-free sweetened beverage with high fat meal.
3290662|NCT01748630|Active Comparator|Dexmedetomidine, Midazolam|dexmedetomidine (group DEX); starting dose, 0.4 μg•kg-1•h-1,with intermittent fentanyl
3290663|NCT01748630|Active Comparator|Midazolam|midazolam (group MDZ); starting dose, 0.1 mg•kg-1•h-1
3290664|NCT01748656|Active Comparator|AVAPS|AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night
3290665|NCT01748656|Active Comparator|IVAPS|IVAPS mode(STELAR 150-RESMED)1 night
3290666|NCT01748669|Experimental|Patients of palmer arsenical keratosis|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3290667|NCT01748669|Active Comparator|Arsenic exposed controls|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3290668|NCT01748669|Active Comparator|Heathy volunteers|One soft capsule of garlic oil (10 mg) daily for 12 weeks
3290669|NCT01748682|Experimental|Liquid Diet Group|The group followed a very low calorie liquid diet for two weeks
3290670|NCT01748682|Active Comparator|Control Group|The group followed a very low calorie diet of normal consistency for two weeks.
3290671|NCT01748708|Experimental|Magnetic seizure therapy|
3290672|NCT01748708|Active Comparator|Electroconvulsive therapy|
3290673|NCT01748721|Experimental|Treatment (MORAb-004)|Patients receive anti-endosialin/TEM1 monoclonal antibody MORAb-004 IV on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.
3290674|NCT01748734|Experimental|Supportive care (cognitive behavioral therapy)|Cognitive behavioral therapy comprising progressive muscle relaxation training, behavioral activation, seeking information as a coping strategy, enhancing social support, cognitive reappraisal, assertive communication, changing depressive core beliefs, goal setting and planning for maintenance, and maintenance over 1 hour once weekly sessions for 12-20 weeks, biweekly sessions for 4-6 weeks, and monthly sessions for 2-3 months for a total of 16-26 sessions.
3290675|NCT01748747|Experimental|Arm I (MART-1 antigen, Gag:267-274 peptide vaccine)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 1.
3290676|NCT01748747|Experimental|Arm II (MART-1 antigen, resiquimod, Montanide ISA 51 VG)|Patients receive MART-1 antigen emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
3290677|NCT01748747|Experimental|Arm III (MART-1 antigen, Gag:267-274 peptide, resiquimod)|Patients receive MART-1 antigen and Gag:267-274 peptide vaccine peptide vaccine emulsified in Montanide ISA 51 VG SC followed by resiquimod applied topically on day 1.
3290678|NCT01748773|Experimental|Combination Therapy|Participants will receive combination therapy comprising of trastuzumab, oxaliplatin, capecitabine, and radiation.
3290679|NCT01748786|Experimental|Mindfulness Emotion Regulation|12 on-line modules targeting social and emotional regulation through mindfulness training
3290680|NCT01748786|Placebo Comparator|Placebo|12 on-line modules providing information regarding health behaviors
3290681|NCT01748838|Experimental|Part 1: CTX-4430|
3290682|NCT01748838|Placebo Comparator|Part 1: Placebo + Mannitol|
3290683|NCT01748838|Experimental|Part 2: CTX-4430|
3290684|NCT01748838|Placebo Comparator|Part 2: Placebo + Mannitol|
3290685|NCT01748851|Experimental|XELOX|Capecitabine 1000mg/m2 bid D1-D14 Oxaliplatin 130mg/m2 + 5% Dextrose water (5DW) 500ml over 2hour D1 Q 2weeks
3290686|NCT01748851|Active Comparator|FOLFOX|Oxaliplatin 85mg/m2 + 5DW 500ml over 2hr D1 Leucovorin 400mg/m2 + 5DW 500ml over 2hr D1 5-Fluorouracil (5-FU) 400mg/m2 IV PUSH D1 5-FU 1200mg/m2 + 5DW 1 Liter over 22hr D1-D2 Q 2weeks
3290687|NCT01748864|Experimental|Single Arm - Healthy Volunteers|Etarfolatide (EC20)
3290688|NCT01748877|Experimental|NXN-462|capsule, 200 mg, bi.d. 28-days
3290689|NCT01748877|Placebo Comparator|Placebo|capsule, b.i.d. 28-days
3290690|NCT01748903||Target 360°, 2D, Nano Coils|Subjects will undergo embolization using Target 360°, 2D, Nano Coils for the treatment of their intracranial aneurysm.
3290691|NCT01748929|Experimental|Albendazole|single dose 400 mg tablet of albendazole
3290692|NCT01748929|Placebo Comparator|Placebo|Placebo Manufactured by Hersil Laboratories in Lima, Peru
3290693|NCT01748968||Veterans with HIV/AIDS|Veterans with HIV/AIDS
3290694|NCT01748981|Other|Physical training|Exercise intervention.
3290695|NCT01748981|Other|As usual|Controls
3290696|NCT01749007||Veterans with HIV/AIDS|
3290697|NCT01749020|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
3290698|NCT01749020|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
3290699|NCT01749046|Experimental|Remegal|Remegal 1500 mg
3290700|NCT01749046|Placebo Comparator|Placebo|Placebo
3290701|NCT01749059||Congenital Heart Defect|
3290702|NCT01749072|Other|Gefitinib|Gefitinib group Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
3290703|NCT01749072|Other|Vinorelbine-Ifosfamide|VI group Vinorelbine 25mg/m2 d1,d8;Ifosfamide 1.25g/m2 d1-d3(Usually Ifosfamide 2g d1-d3 with Mesna 400mg 0,4,8hours after Ifosfamide administration for 3 days);every 3 weeks;at least for 2-6 cycles depending on the progression disease or the patient's physical condition
3290704|NCT01749085|Experimental|Sequence 1|
3290705|NCT01749085|Experimental|Sequence 2|
3290706|NCT01749098|Experimental|PF-04958242|PF-04958242 and ketamine
3290707|NCT01749098|Placebo Comparator|Placebo|Placebo and ketamine
3290708|NCT01749111|Experimental|Arm A|Graft versus host disease prophylaxis will be done with cyclophosphamide 50 mg/kg on day +3 and day +4
3290709|NCT01749111|Active Comparator|Arm B|In this arm, patients will receive a combination of methotrexate and a calcineurin inhibitor as graft versus host disease prophylaxis
3290710|NCT01749124|Experimental|My Coach Connect|"To evaluate the feasibility and effectiveness of this telephone tool while engaging clients and providers in discussion groups and surveys to better understand how this tool impacts the care provided and their overall experience in healthcare. Clients will use this tool to leave voice messages and survey answers which their providers will have access to by logging in to a secure website. Providers will have access to audio recordings of the voice responses, transcribed text of the responses, as well as word clouds generated from the text. Word clouds are a method of displaying the content of text such that words that are used more frequently are displayed in a larger size than words used less frequently."
3290711|NCT01749137|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1mg/24hrs via subcutaneous infusion for 90 days.
3290712|NCT01749137|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 90 days.
3290713|NCT01749150|Experimental|with cirrhosis|
3290714|NCT01749150|Experimental|without cirrhosis|
3290715|NCT01749163|Experimental|Control|Saline will be coninfused during the pancreatic clamp
3290716|NCT01749163|Experimental|GIP|GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min
3290717|NCT01749163|Experimental|GLP-1|GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min
3290718|NCT01749176|Experimental|SMS texting intervention|Behavioral text messages will be sent at random times throughout the week reagarding Healthy nutrition tips, benefits of physical activity, benefits of medication adherence and requests to check blood sugar and send back results.
3290719|NCT01749176|Placebo Comparator|Control-Usual Care|Participants will continue to receive their usual care in their primary care home. They will return at months 3 and 6 to conduct behavioral and laboratory assessments to compare results with the intervention group.
3290720|NCT01749189|Placebo Comparator|Placebo|Placebo dry blended beverage (carbohydrate)
3290721|NCT01749189|Experimental|Blend|A dry blended beverage containing a protein blend of soy, whey and casein
3290722|NCT01749189|Active Comparator|Whey|A dry blended beverage containing Whey protein
3290723|NCT01749202|Placebo Comparator|Negative Control|
3290724|NCT01749202|Active Comparator|Positive Control|
3290725|NCT01749202|Experimental|Active|
3290726|NCT01749228|Experimental|Etodolac Capsules USP 300 mg|Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India
3290727|NCT01749228|Active Comparator|Etodolac Capsules USP 300mg|Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA
3290728|NCT01749241|Experimental|Loteprednol etabonate ointment|This is the arm which contains loteprednol steroid
3290729|NCT01749241|Other|Vehicle Ointment|This arm contains vehicle only.
3290730|NCT01749254||Acute Coronary Syndrome|40 patients admitted with ACS (NSTEMI/STEMI) will be recruited undergo 18F NaF PET, 18F FDG and CTCA within 1 month of the event.
3290731|NCT01749254||Stable angina cohort|40 patients with previously diagnosed coronary artery disease and listed to undergo elective coronary angiogram will be recruited. VH-IVUS will be attempted in all patients. Selected patients will undergo PET scan after stent implantation.
3290732|NCT01749267|Experimental|partial caries removal|partial caries removal only at enamel dentin junction (EDJ) without carious tissue removal at the pulpal site
3290733|NCT01749280||Abdominal Aortic Aneurysms|Patients will be recruited from the outpatient AAA surveillance population at the vascular unit in the Royal Infirmary of Edinburgh.Potential participation in the study will be completely asymptomatic from their AAA.
3290734|NCT01749306|Other|ABH001|ABH001 application plus wound care dressings.
3290735|NCT01749306|Other|Control|Control wound treatment
3290736|NCT01749319|Active Comparator|Oral Baclofen|
3290737|NCT01749319|Experimental|Intervenous baclofen|Crossover study that eacg subject is given both oral and intervenous baclofen
3290738|NCT01749332|Experimental|Pts having liver or colon surgery|Blood will be obtained from patients at the time of laparotomy for hepatic resection and/or hepatic arterial infusion pump placement, or pancreatic head resection . Blood will be drawn from a peripheral vein or artery (when an arterial catheter is present), the portal vein, and suprahepatic IVC and given to a research assistant and placed on ice followed by immediate processing. Total amount of blood drawn will not exceed fifty milliliters (50ml).
3290739|NCT01749358|Experimental|High Therapy Dose|Sixty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3290740|NCT01749358|Experimental|Moderate Therapy Dose|Thirty total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3290741|NCT01749358|Experimental|Low Therapy Dose|Fifteen total hours of ASAP therapy--challenging, intensive and meaningful practice of tasks of your choice in a collaborative partnership with your personal trainer (therapist).
3290742|NCT01749358|Other|Active Monitoring|This is an observation only group.
3290743|NCT01749371|Experimental|Early Vitamin E|Vitamin E is administered from Days 1-15 after the initial excision surgery after admission.
3290744|NCT01749371|Experimental|Delayed Vitamin E|Vitamin E is administered from Days 16-30 after the initial excision surgery after admission.
3290745|NCT01749384|Experimental|Treatment (bevacizumab, tivantinib)|Patients receive bevacizumab IV over 30-90 minutes on days -15, 1, and 15 (day -15 of course 1 only) and tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3290746|NCT01749397|Experimental|Treatment (veliparib and floxuridine)|Patients receive veliparib PO BID on days 1-10 and floxuridine IP on days 3-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3290747|NCT01749423||All participants|Previous treatment with onabotulinumtoxinA for Chronic Migraine based on retrospective review of medical records.
3290748|NCT01749436||Lung ultrasound imaging|Lung ultrasound imaging examinations performed during the perioperative period for the monitoring of atelectasis associated with laparoscopic surgery
3290749|NCT01749449|Experimental|High protein 3 meals/day|35% protein intake eaten as 3 meals per day
3290750|NCT01749449|Experimental|High carbohydrate consumed 3 meals/day|High carbohydrate 3 meals/day
3290751|NCT01749449|Experimental|High protein consumed 6 meals/day|35% protein 6 meals/day
3290752|NCT01749462||Oxis|
3290753|NCT01749475||midazolam|
3290754|NCT01749475||hypnosis|
3290755|NCT01749488|No Intervention|Control intensive care wards|This is a randomized cluster trial. The centers randomized into this arm will serve as controls. No interventions will be implemented for these centers.
3290756|NCT01749488|Experimental|Experimental intensive care wards|"This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.~Intervention: Designated dietitian for the ward"
3290757|NCT01749514|Experimental|ACE-536|Subjects assigned to 1 of 7 possible dosing groups.
3290758|NCT01749527|Other|24-hour pad test|decreased activity
3290759|NCT01749540|Experimental|ACE 536|ACE-536 - 1 of 7 possible dose levels.
3290760|NCT01749553|Experimental|sleeper stretch|
3290761|NCT01749553|No Intervention|no intervention|
3290762|NCT01749566|Active Comparator|Group A (standard maraviroc dosing)|maraviroc 300mg po bid x 7 days
3290763|NCT01749566|Active Comparator|Group B (reduced maraviroc dosing)|maraviroc 300mg po daily x 7 days
3290764|NCT01749566|No Intervention|Group C (no drug)|No additional drug
3290765|NCT01749579|Experimental|Propofol|The patients will receive propofol for sedation in addition to fentanyl
3290766|NCT01749579|Active Comparator|Midazolam|The patients will receive midazolam for sedation in addition to fentanyl
3290767|NCT01749592|Experimental|Cochlear Implant|Surgical Implantation of a Cochlear Implant
3290768|NCT01749618|No Intervention|No education or feedback|Rheumatologists randomized to this treatment arm receive no additional education or feedback about their systematic assessments of patients
3290769|NCT01749618|Experimental|Education and Feedback|Rheumatologists randomized to receive education and feedback participate in six web conferences designed to improve their systematic assessments of their patients, and are given feedback about their performances
3290770|NCT01749644||CF patients with chronic pseudomonas infection|
3290771|NCT01749657|Active Comparator|Off-the-shelf Device and shoe|subjects will wear an off-the-shelf orthotic device (AirLift PTTD Brace) and standard Edge shoe (Aetrex Co) for 12 weeks
3290772|NCT01749657|Experimental|Custom Device - standard and Shoe|subjects will wear a custom (standard) orthotic device (Arizona Co) and Edge shoes (Aetrex Co.) for 12 weeks.
3290773|NCT01749657|Experimental|Custom Articulated device and Shoe|subjects will wear a custom articulated device (Arizona Co) and Edge shoe (Aetrex Co)for 12 weeks
3290774|NCT01749657|Experimental|Custom Extended Device and Shoe|subjects will wear a custom extended foot plate orthotic device (Arizona Co) and Edge shoe (Aetrex Co) for 12 weeks.
3290775|NCT01749670||Autism|Children ages 4-17 years old with DSM-IV defined autism spectrum disorder
3290776|NCT01749670||Control|Age- and gender-matched controls with typical neuropsychological developmental patterns
3290777|NCT01749696||Patients with pelvic organ prolapse|Patients, who were operated on because of pelvic organ prolapse.
3290778|NCT01749696||Patients without pelvic organ prolapse|Patients, who had hysterectomy due to other reasons than pelvic organ prolapse.
3290779|NCT01749709|Experimental|Instrumental music listening|Daily music listening
3290780|NCT01749709|Experimental|Vocal music listening|Daily music listening
3290781|NCT01749709|No Intervention|control|Standard rehabilitation
3290782|NCT01749722|Experimental|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
3290783|NCT01749748|Other|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy for asymptomatic women breasts.
3290784|NCT01749761|Placebo Comparator|Hemodialysis without biofeedback|Patients will be randomized to receive hemodialysis without biofeedback for a period of 8 weeks.
3290785|NCT01749761|Active Comparator|BioLogic RR biofeedback|Patients will receive 8 weeks of HD with BioLogic RR Blood pressure guided biofeedback.
3290786|NCT01749774|Experimental|Physical activity counseling|
3290787|NCT01749787|Experimental|1.5 mcg/kg|PRTX-100 at 1.5 mcg/kg administered via infusion once per week for 5 weeks
3290788|NCT01749787|Experimental|3.0 mcg/kg|PRTX-100 at 3.0 mcg/kg administered via infusion once per week for 5 weeks
3290789|NCT01749787|Experimental|6.0 mcg/kg|PRTX-100 at 6.0 mcg/kg administered via infusion once per week for 5 weeks
3290790|NCT01749787|Experimental|12.0 mcg/kg|PRTX-100 at 12.0 mcg/kg administered via infusion once per week for 5 weeks
3290791|NCT01749787|Experimental|240 mcg|PRTX-100 at 240 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
3290792|NCT01749787|Placebo Comparator|Placebo|Placebo administered via infusion once per week for 5 weeks
3290793|NCT01749787|Experimental|420 mcg|PRTX-100 at 420 mcg/dose administered via infusion once per week for 5 weeks then once every four weeks for 16 weeks thereafter.
3379374|NCT00001756||Healthy Volunteers|Healthy Volunteers
3379375|NCT00001756||Patients|Patients have mast cell hyperplasia compatible with a diagnosis of systemic mastocytosis (applicable to systemic mastocytosis patients only) or other allergic, hematologic, orimmunologic condition.
3290794|NCT01749852|Experimental|Polyphenol-rich Dark chocolate|Dark chocolate with 500 mg of polyphenols
3290795|NCT01749852|Placebo Comparator|Placebo Dark chocolate|This chocolate contains little or no polyphenols
3290796|NCT01749865|Experimental|A, CIK|Biological/Vaccine: Cytokine-Induced Killer Cells
3379377|NCT00001721||Patients|Patients diagnosed with SLOS
3290797|NCT01749865|No Intervention|B, CONTROL|Regular follow up with no intervention
3290798|NCT01749878|Experimental|Group A: Cohorts 1 through 6|"Group A:~Cohorts 1 through 3 will receive REGN1500 subcutaneous (SC) or placebo Cohorts 4 through 6 will receive REGN1500 intravenous (IV) or placebo"
3290799|NCT01749878|Experimental|Group B|Group B will receive REGN1500 IV or placebo
3290800|NCT01749878|Experimental|Group C: Cohorts 1 and 2|"Group C:~Cohort 1 will receive REGN1500 SC or placebo Cohort 2 will receive REGN1500 IV or placebo"
3290801|NCT01749891|Experimental|Arm 1.5 mg ALG - 1001|Arm 1.5 mg ALG- 1001 per 50ul
3290802|NCT01749891|Experimental|Arm 2.5 mg ALG -1001|Arm 2.5 mg ALG -1001 per 50ul
3290803|NCT01749891|Experimental|Arm 4.0 mg ALG -1001|Arm 3 4.0 mg ALG -1001 per 50ul
3290804|NCT01749917|Active Comparator|Control group|30 people are recruited in order to the inclusion criteria for the study. The study include subjects who can complete the assessment battery of tests at the beginning and end in order to perform the control intervention.
3290805|NCT01749917|Experimental|Exercise program group|30 people are recruited, diagnosed with Parkinson attending to the Parkinson Association of Granada aged between 40 and 65 years. No sex differences. The study include subjects who can complete the assessment battery of tests at the beginning and end.
3290806|NCT01749943||EDSS Score 0-3.5|21 Subjects Total : 7 with normal to mildly limited walking
3290807|NCT01749943||EDSS Score 4.0-5.5|21 Subjects total: 7 subjects with moderately limited walking ability.
3290808|NCT01749943||EDSS Score 6.0-7.5|21 Subjects total: 7 subjects with severely limited walking ability
3290809|NCT01749969|Experimental|SAR650984 (isatuximab)|"SAR650984 (isatuximab) (escalating dose) plus lenalidomide 25 mg on Days 1 to 21 plus dexamethasone 40 mg on Days 1, 8, 15, 22 in 28-day cycles for all cohorts up to disease progression.~For Q2W cohorts: SAR650984 (isatuximab) on Days 1 and 15 of every cycle. For QW/Q2W cohorts: SAR650984 (isatuximab) on Days 1, 8, 15, and 22 of first cycle and Days 1 and 15 of every subsequent cycle."
3290810|NCT01750008|Other|Global Fibroid Ablation|Global Fibroid Ablation
3290811|NCT01750008|Other|Laparoscopic Myomectomy|Myomectomy via laparoscopy
3290812|NCT01750021|Experimental|High fat low carbohydrate diet|High fat low carbohydrate diet
3290813|NCT01750021|Experimental|Low fat high carbohydrate diet|Low fat high carbohydrate diet
3290814|NCT01750034|Active Comparator|Closed method|Burn patients randomized to closed method of burn wound care.
3290815|NCT01750034|Experimental|Open method|Burn patients randomized to the open method of burn wound care.
3290816|NCT01750060|Active Comparator|Fentanyl citrate IV infusion & Naltrexone|Fentanyl citrate (equivalent to 80 mcg fentanyl)administered over 20 minutes by IV infusion every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3290817|NCT01750060|Experimental|Fentanyl Study System (170 mcAmps) & Naltrexone|Two consecutive 40 mcg fentanyl doses each delivered over 10 minutes by the Study System (170 mcAmps) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3290818|NCT01750060|Experimental|Fentanyl, Study System (140 mcAmp) & Naltrexone|Two consecutive 35 mcg fentanyl doses, each delivered over 10 minutes by the Study System (140 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3290819|NCT01750060|Experimental|Fentanyl, Study System (200 mcAmp) & Naltrexone|Two consecutive 50 mcg fentanyl doses, each delivered over 10 minutes by the Study System (200 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3290820|NCT01750060|Experimental|Fentanyl, Study System (230 mcAmp) & Naltrexone|Two consecutive 54 mcg fentanyl doses, each delivered over 10 minutes by the Study System (230 mcAmp) every hour through 23.33 hours. Naltrexone (50 mg) will be administered orally (PO) every 12 hours, beginning 14 hours before the start of fentanyl treatment and ending approximately 11 hours after completion of treatment regimen to antagonize the clinical opioid effects of fentanyl.
3290821|NCT01750073|Experimental|Treatment (chemotherapy, surgery, post-operative therapy)|See Detailed Description
3290822|NCT01750099|Experimental|Combined spinal-epidural|After verification of being in the intrathecal space with free-flow of cerebral spinal fluid, 1 mL of 0.25% bupivicaine along with 20 mcg of fentanyl will be injected into the intrathecal space. Subsequently, a B/Braun Perifix FX closed tip multiorifice flexible epidural catheter will be threaded 4 cm into the epidural space. After obtaining a T6 dermatomal level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a patient controlled epidural analgesia (PCEA) option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
3290823|NCT01750099|Placebo Comparator|Continuous lumbar epidural|After identifying the epidural space with the loss of resistance technique, a standard flexible epidural catheter will be threaded 4 cm into the epidural space. A standard test dose of 3 mL of 1.5% lidocaine with epinephrine 1:200,000 will be given through the catheter. If positive for vascular or intrathecal placement, procedure to be repeated at different interspace. If negative, catheter will be secured and slowly dosed with 5-10 mL of 0.25% bupivicaine through epidural catheter with a goal dermatome level of T6. After obtaining the dermatome level of sensory blockade, a standard solution consisting of 0.125% bupivicaine with 2 mcg of fentanyl/mL of solution will be started at 10 mL/hour with a PCEA option of 8 mL every 45 minutes. If a patient requires redosing, 5-10 mL of 0.25% bupivicaine will be injected slowly through epidural catheter with a goal dermatome level of T6. No systemic opioids will be given.
3290824|NCT01750112|Experimental|Macrolane VRF20|All subjects will receive treatment with Macrolane VRF20 to correct pectus excvatum deformity.
3290825|NCT01750125||Healthy subjects|In these health subjects we will measure ascending aortic blood flow with pulse wave Doppler and also record the raw audio of the Doppler signal
3290826|NCT01750138|Experimental|Glutamine|Glutamine powder given preoperatively for five days
3290827|NCT01750138|Active Comparator|Placebo|dextrose powder for 5 days pre-operatively
3290828|NCT01750151|Experimental|Glucose beverage|Glucose beverage
3290829|NCT01750151|Experimental|Control beverage and video game playing|Control beverage and video game playing
3290830|NCT01750151|Experimental|Glucose beverage and video game playing|Glucose beverage and video game playing
3290831|NCT01750151|Experimental|Control beverage|Control beverage
3290832|NCT01750164||Invasive breast cancer with metastatic disease|
3290833|NCT01750177|Experimental|Television Viewing|Television viewing before mealtime
3290834|NCT01750177|Experimental|Video Game Playing|Video Game Playing before mealtime
3290835|NCT01750177|Experimental|Computer Use|Computer Use before mealtime
3290836|NCT01750177|Experimental|Sitting Quietly|Sitting Quietly before mealtime
3290837|NCT01750203||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
3290838|NCT01750216||Cohort|
3290839|NCT01750307|Experimental|Fatty acid supplementation|4 capsules to be taken daily
3290840|NCT01750307|Placebo Comparator|Medium Chain Triglyceride (MCT) oil softgel|4 capsules to be taken daily
3290841|NCT01750320|Experimental|Koning Breast CT - guided Biopsy|
3290842|NCT01750333||Lean children|
3290843|NCT01750333||Overweight Children (OW)|
3290844|NCT01750333||Obese children (Ob)|
3290845|NCT01750359|Active Comparator|curcumin|
3290846|NCT01750359|Placebo Comparator|placebo|
3290847|NCT01750372||Persons with lower limb amputation|Persons with amputation below the hip and at or above the ankle
3290848|NCT01750385|Active Comparator|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
3290849|NCT01750385|Active Comparator|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
3290850|NCT01750411||Asthma|Severe Asthma Not severe Asthma
3290851|NCT01750424|Experimental|Fat Grafted|The experimental arm of the study will be composed of 15 patients who undergo autologous fat grafting into the site of the facial reconstructive scar at 3 months post-operatively. A small amount of fat will be removed near the umbilicus through a cannula using local anesthetic and a small, 2-3mm incision just barely large enough for the cannula to pass. That fat will be injected directly under the scar site in those patients using a similar cannula, local anesthetic, and small, 2-3mm incision. No sutures will be required at either the donor or injection site. Patients will subsequently return to clinic for 3-D photographic assessment at 3, 6 and 12 months post-fat grafting. The images generated at each session will be provided to a group of assessors for evaluation. They will either use the Manchester Scar Scale or the modified Manchester Scar Scale depending on whether they are within the health care profession.
3290852|NCT01750424|Placebo Comparator|Non-fat grafted|The control arm will be composed of 15 patients who undergo no intervention. These patients will be identified at 3 months post-operatively from their facial reconstruction. They will undergo no fat-grafting but will be followed up with the same frequency as the experimental group, at 3 months, 6 months, and 12 months after their initial 3 month post-surgical follow-up. 3-D images will be taken at each appointment and will be distributed to all assessors. Assessors will use either the Manchester Scar Scale or a modified Manchester Scar Scale to evaluate the appearance of the scar at each time point.
3290853|NCT01750437|Experimental|YH1885L 33.3 mg|TID, Subject takes it for 4 week.
3290854|NCT01750437|Experimental|YH1885L 50mg|BID, Subject takes it for 4 week.
3290855|NCT01750437|Experimental|YH1885L 66.6 mg|TID, Subject takes it for 4 week.
3290856|NCT01750437|Experimental|YH1885L 100mg|BID, Subject takes it for 4 week.
3290857|NCT01750437|Active Comparator|Esomeprazole 20mg|QD, Subject takes it for 4 week.
3290858|NCT01750450||Elective left heart cath|Patients undergoing elective left heart catheterization will be consented for this study
3290859|NCT01750463||Arm A|"Critically ill pediatric patients admitted to PICU requiring hemoglobin monitoring.~Patients admitted to PICU requiring hemoglobin monitoring will have a reading total hemoglobin (SpHb) assessment done with the Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor,prior to standard laboratory blood draw and hemoglobin analysis."
3290860|NCT01750476||Depo-Provera|Women who choose to initiate Depo-Provera
3290861|NCT01750476||Mirena|Women who choose to initiate Mirena (intrauterine device)
3290862|NCT01750476||Oral contraception|Women who choose to initiate oral contraception
3290863|NCT01750489|No Intervention|COPD|
3290864|NCT01750489|Experimental|COPD with non-invasive ventilation (NIV)|Starting non-invasive ventilation with the patient's own device during registration of MSNA.
3290865|NCT01750489|No Intervention|Healthy control subjects|
3290866|NCT01750515|Experimental|Intervention group - acupuncture treatment|
3290867|NCT01750515|No Intervention|Control group|
3290868|NCT01750528||Ankylosing spondylitis|patients aged 18 years or more who meet the 1984 modified New York criteria
3290869|NCT01750528||Control|age- (± 3 years) and gender-matched volunteers who do not have inflammatory arthropathy.
3290870|NCT01750541|Active Comparator|Haloperidol|Haloperidol 5mg intramuscular injection
3290871|NCT01750541|Active Comparator|Valproate|Valproate single Infusion; 400 mg (weigh<60 kg), 500 mg (weight>60 Kg)
3290872|NCT01750554|Experimental|bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
3290873|NCT01750554|No Intervention|No bupivacaine digital nerve block|Patients undergoing spine surgery will have a 50/50 chance of being randomized to not receive a bupivacaine 0.25% (2 milliliters total) intermediate-acting digital nerve block.
3290875|NCT01750580|Experimental|Arm 1: Lirilumab + Ipilimumab|Lirilumab and Ipilimumab on specific days
3290876|NCT01750593|Experimental|radiofrequency ablation of thyroid nodule|Under ultrasonography the thyroid nodules will be ablated by radiofrequency ablation
3290877|NCT01750606||pre-THA|Patients who are planned but have not yet received a total hip arthroplasty. No intervention or treatment - blood draw only to be used as a surrogate baseline for metal ion exposure.
3290878|NCT01750606||Metal-on-Poly|Patients receiving a Biomet metal on poly hip implanted between January 1, 2003 and December 31, 2006.
3290879|NCT01750606||M2a Magnum hip|Patients receiving a Biomet M2a Magnum hip implanted between January 1, 2006 and January 1, 2011.
3290880|NCT01750606||M2a38 hip|Patients receiving a Biomet metal on metal M2a38 hip implanted between January 1, 2004 and December 31, 2006.
3290881|NCT01750606||M2a Ringloc hip|Patients receiving a Biomet M2a Ringloc metal on metal hip implanted between January 1, 2002 and December 31, 2004.
3290882|NCT01750606||M2a Taperloc hip|Patients receiving a Biomet M2a Taperloc metal on metal hip implanted between January 1, 2002 and December 31, 2003.
3290883|NCT01750619||Mucosal tumors of the colon|Patients who received endoscopic treatment for noninvasive mucosal tumors of the colon.
3290884|NCT01750619||Nonampullary tumors of the duodenum|Patients who received endoscopic treatment for noninvasive mucosal tumors of the duodenum.
3290885|NCT01750619||Ampullary tumors|Patients who received endoscopic treatment for noninvasive ampullary tumors.
3290886|NCT01750632|Experimental|Orchiectomy|The patients undergo subcapsular orchiectomy
3290887|NCT01750645||Intervention Group|
3290888|NCT01750645||Control Group|
3290889|NCT01750658||COPD|"COPD patients admitted in any of the participating ECOS hospitals due to a COPD exacerbation.~- External factors. The episodes of COPD exacerbations are associated to exogenous factors (pollution, change of ambient temperature, humidity, infections). The prevalence of environmental contamination and infections is higher than expected.~- Endogenous factors. These factors (hyperinflation, pulmonary embolism, cardiac dysfunction, mucus hypersecretion) are present in a proportion higher than expected~- During exacerbations of COPD serum markers of inflammation and autoimmunity are high relative to baseline in COPD and decrease progressively during the follow-up, after controlling the acute episode"
3290890|NCT01750723|Active Comparator|Acetazolamide|Acetazolamide 1 g in 10 ml saline, i.v. infusion
3290891|NCT01750723|Placebo Comparator|Saline|Saline, 10 ml i.v. infusion
3290892|NCT01750736|Experimental|Augmented Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a specific exercise to augment the specific manual treatment provided.
3290893|NCT01750736|Active Comparator|General Exercise and Manual Therapy|Subjects will receive manual therapy according to clinical guidelines followed by instruction in a general neck range of motion exercise.
3290894|NCT01750749|Experimental|Autologous BMDC implantation at the venous ulcer|Autologous BMDC implantation at the venous ulcer in conjunction with SOC treatment (advanced wound management plus pressure therapy)
3290895|NCT01750762|Experimental|Lenalidomide|Dose escalation. Starting dose is 10 mg/day for 3 weeks followed by 1 week off (1 cycle). Subject will receive a total of 3 cycles.
3290896|NCT01750775|Experimental|Shensong Yangxin capsule|Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
3290897|NCT01750775|Placebo Comparator|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
3290898|NCT01750788||Group 1|
3290899|NCT01750801|Active Comparator|Propolis|alcohol-free mouthwash containing 5% green propolis (MGP 5%) on the control of plaque and gingivitis.
3290900|NCT01750801|Active Comparator|chlorhexidine|chlorhexidine used on the control of plaque and gingivitis.
3290901|NCT01750814|Active Comparator|GC FLU inj.|Influneza vaccine, single-dose vial
3290902|NCT01750814|Experimental|GC3102C|Influneza vaccine, multi-dose vial
3290903|NCT01750827|Experimental|SB-659032|Single dose open label
3290904|NCT01750853|Experimental|Group 1|"Period 1: 0.1 milligrams (mg) LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 1 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 10 mg LY3045697 administered once orally or matching placebo administered once orally."
3290905|NCT01750853|Experimental|Group 2|"Period 1: 0.3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 3 mg LY3045697 administered once orally or matching placebo administered once orally.~Period 3: 30 mg LY3045697 administered once orally or matching placebo administered once orally."
3290906|NCT01750853|Experimental|Group 3|"Period 1: 100 mg of LY3045697 administered once orally or matching placebo administered once orally.~Period 2: 300 mg of LY3045697 administered once orally or matching placebo administered once orally (via split delivery over a 15-minute period)."
3290907|NCT01750866|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. Treatment will continue until disease progression, intolerable side effects, or a maximum of 10 cycles of therapy.
3290908|NCT01750892|Active Comparator|Group 1: Control|Group 1 will be the control group. They will complete questionnaires but will otherwise receive usual care from their Primary Care Provider (PCP). At the end of the study period they will be given the Study Materials for participating.
3290909|NCT01750892|Experimental|Group 3: Group Intervention|Group 3 (Group Intervention) will receive the Study Materials at the beginning of the study and will also be invited to attend two REACH for Independence group sessions.
3290910|NCT01750892|Experimental|Group 4: Full Intervention|Group 4 (Full Intervention) will receive the Study Materials at the beginning of the study, will be invited to attend the REACH for Independence group sessions, and will be invited to a Transition Consult with an MD and social worker.
3290911|NCT01750892|Experimental|Group 2: Basic Intervention|Group 2 (Basic Intervention) will receive the Study Materials at the beginning of the study but will otherwise continue with their usual PCP care.
3290912|NCT01750905|Active Comparator|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
3290913|NCT01750905|Placebo Comparator|Placebo|Placebo: Vehicle (D5W) SQ
3290914|NCT01750944|Experimental|Healthy Volunteers 1|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: ankle first"
3290915|NCT01750944|Experimental|Healthy Volunteers 2|"The study population consists of adult, healthy volunteers randomized into two identical groups.~Intervention: toe first"
3290916|NCT01750957|Placebo Comparator|Placebo|
3290917|NCT01750957|Experimental|RO4917523 Dose A|
3290918|NCT01750957|Experimental|RO4917523 Dose B|
3290919|NCT01750970|Experimental|Resection under blue light|
3290920|NCT01750970|Active Comparator|Resection under white light|
3290921|NCT01750983|Experimental|Ipilimumab + Lenalidomide|"Dose Escalation Group Ipilimumab Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Escalation Group Lenalidomide Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab and Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Groups."
3290922|NCT01750996|No Intervention|Usual Care control (Parenting tips)|Participants randomized to usual care will have access to a brief information website containing brief parenting tips but will not receive Strongest Families Intervention
3290923|NCT01750996|Experimental|Strongest Families|Strongest Families intervention
3290924|NCT01751009|Experimental|Vitamin A supplements|Sprinkles with Vitamin A
3290925|NCT01751009|Active Comparator|Sprinkles without Vitamin A|Made of other micronutrients without Vitamin A
3290926|NCT01751035|Placebo Comparator|Treatment as Usual (TAU)|Treatment as Usual (TAU) will be defined as it already exists within the community child advocacy centers. This could include individual and/or group therapy using a variety of treatment models.
3290927|NCT01751035|Experimental|RRFT|RRFT is an acronym for an experimental intervention named Risk Reduction through Family Therapy. Please see intervention description for more detail about the model.
3290928|NCT01751048|Experimental|Group #1|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE)
3290929|NCT01751048|Experimental|Group #2|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 10 mcg Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE)
3290930|NCT01751048|Experimental|Group #3|N=16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + Stable oil-in-water Emulsion (SE)
3290931|NCT01751074|Experimental|Part A|All subjects will be of Caucasian descent and will receive single dose of Rosuvastatin 10 mg for 1 day (Day 1) during treatment period 1, then will receive Darapladib 160 mg once daily (QD) for 10 days (Day 5 to 14) in treatment period 2. Immediately following this, all subjects will receive the combination of Darapladib 160 mg and Rosuvastatin 10 mg for 1 day (Day 15) and continued Darapladib dosing of 160 mg QD for additional 3 days (Days 16 to 18) in treatment period 2.
3290932|NCT01751074|Experimental|Part B|The decision to initiate Part B will be made by the GSK study team based on an evaluation of data from Part A. Part B will consist of a cohort of healthy subjects of Far-East Asian descent and will be conducted similar to Part A.
3290933|NCT01751100|Active Comparator|HIV Test Offer|Group 1 (Control) is the current standard of care in HIV testing. A trained counselor provides required information to obtain informed consent for HIV testing and provides rapid HIV testing on site.
3290934|NCT01751100|Experimental|General Health Screen Offer|In Group 2 (Intervention), a free general health screening is offered that may include a blood pressure check, blood glucose measurement, a Hepatitis C (HCV) test, and an HIV test.
3290935|NCT01751126|Experimental|Ciclosporin|One drop of ciclosporin (NOVA22007) 1 mg/ml 4 times a day as monotherapy (morning, noon, afternoon and evening).
3290936|NCT01751126|Experimental|Ciclosporin/Placebo|One drop of ciclosporin (NOVA22007) 1 mg/ml twice a day and one drop of placebo twice a day (active study treatment morning and evening and placebo noon and afternoon) as monotherapy.
3290937|NCT01751126|Placebo Comparator|Placebo|One drop of placebo 4 times a day as monotherapy (morning, noon, afternoon and evening).
3290938|NCT01751152|Experimental|NNC0114-0006|
3290939|NCT01751152|Placebo Comparator|Placebo|
3290940|NCT01751191||Training set-chronic response to propranolol|
3290941|NCT01751191||Validation set-chronic response to propranolol|
3290942|NCT01751191||Acute response to propranolol|
3290943|NCT01751204|Active Comparator|Calcium tablet|250 mg calcium/tablet
3290944|NCT01751204|Experimental|Calcium ion water (250mg)|250 mg calcium in 200 ml water
3290945|NCT01751204|Experimental|Calcium ion water (125mg)|125 mg calcium in 200 ml water
3290946|NCT01751217|Experimental|Funct Family Tx/Video Teleconf (FFT-V)|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Adolescents and parents assigned to the FFT-V condition will receive a Verizon netbook laptop computer equipped with the Microsoft Windows 7 operating system, webcam, and VTC software for use in the family home. The VTC software is designed to stream live video between therapists and participants, to record video, and to store recorded videos as digital mpeg files. All family sessions will take place via video teleconference.
3290947|NCT01751217|Experimental|Functional Family Tx|Functional Family Therapy (FFT) is a brief treatment for youth with problem behaviors, including substance abuse that consists of 12 to 14 weekly family sessions. The FFT treatment is applied in five distinct phases: Engagement, Motivation, Relational Assessment, Behavior Change, and Generalization and each phase has specific goals, techniques, and therapist skills. Families in the FFT condition will not be provided with the laptop and internet access described above. Instead, adolescents and parents in this condition will receive the FFT intervention face-to-face from an FFT therapist who will travel to the family home for each session.
3290948|NCT01751217|Active Comparator|Services as Usual|The main CYFD service provider for adjudicated youth in both Sandoval and Valencia counties is Youth Development Incorporated (YDI) which is a private not-for-profit youth service organization serving adolescents in New Mexico . YDI provides an array of services for youth including tutoring, after-school activities, gang intervention, school drop-out prevention, family counseling services, an emergency teen shelter, parenting skills training, youth leadership development, community corrections services, GED studies, substance abuse and AIDS education, etc. The YDI juvenile corrections services include intensive supervision, educational and employment assistance, community service, victim restitution, and institutional transition services.
3290949|NCT01751243|Placebo Comparator|Group 0|Haploidentical transplantation of hematopoietic progenitors
3290950|NCT01751243|Experimental|Group 1|Allo-depleted lymphocyte infusion dose: 1x105 CD3/Kg
3290951|NCT01751243|Experimental|Group 2|Allo-depleted lymphocyte infusion dose: 3x105 CD3/Kg
3290952|NCT01751243|Experimental|Group 3|Allo-depleted lymphocyte infusion dose: 5x105 CD3/Kg
3290953|NCT01751243|Experimental|Group 4|Allo-depleted lymphocyte infusion dose: 1x106 CD3/Kg
3290954|NCT01751243|Experimental|Group 5|Allo-depleted lymphocyte infusion dose: 3x106 CD3/Kg
3290955|NCT01751256|Experimental|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
3290956|NCT01751256|No Intervention|Control|Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
3290957|NCT01751269|Experimental|Ascending Single and Multiple dose of RPX7009|Ascending Single and Multiple dose of RPX7009
3290958|NCT01751269|Placebo Comparator|Normal Saline|Ascending Single and multiple dose of normal saline.
3290959|NCT01751282|Placebo Comparator|Standard therapy and control saline spray|Conventional standard therapy and control saline spray
3290960|NCT01751282|Sham Comparator|standard therapy and fibrin spray|Conventional standard therapy and fibrin spray
3290961|NCT01751282|Experimental|Conventional standard therapy and MSCs|Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
3290962|NCT01751295|Active Comparator|atorvastatin|PCI with atorvastatin pre-treatment group
3290963|NCT01751295|No Intervention|control|PCI without atorvastatin pre-treatment group
3290964|NCT01751321|Other|sitagliptin, metformin, placebo|"group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day~group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day"
3290965|NCT01751334|Experimental|Mobile Bearing|Mobile bearing total knee arthroplasty
3290966|NCT01751334|Active Comparator|Fixed Bearing|Fixed Bearing total knee arthroplasty
3290967|NCT01751347|Active Comparator|Lidocaine|Subjects randomized to this treatment arm will receive lidocaine during their elective hand surgery.
3290968|NCT01751347|Experimental|Bupivacaine|Subjects randomized to this treatment arm will receive bupivacaine during their elective hand surgery.
3290969|NCT01751360|Experimental|SYR-472 100mg|SYR-472 100mg
3290970|NCT01751373|Active Comparator|Standard Therapy|Coupling focal BoNT-A injections with a therapy program comprising of functional tasks.
3290971|NCT01751373|Experimental|Optimal Muscle Activation Therapy|Coupling focal BoNT-A injections with a motor training program that focuses on developing and maintaining activation patterns in the muscle treated with BoNT-A.
3290972|NCT01751425|Experimental|Treatment (TKIs, ruxolitinib)|Participants receive commercially available TKIs (imatinib mesylate, nilotinib, or dasatinib) as they had been receiving during the last 6 months and ruxolitinib PO BID. Courses repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
3290973|NCT01751438|Experimental|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST). Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
3290974|NCT01751438|Experimental|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
3290975|NCT01751464|Experimental|WrapAround Care|
3290976|NCT01751477||Probiotics (Infloran)|Very low birth weight Infants receiving 2 capsules/d Infloran starting in the first week of life
3290977|NCT01751477||Control|Very low birth weight Infants who did not receive Infloran (historical cohort)
3379387|NCT00001582||1|Suspected or known disorder of the immune system or cancer; or, known or potential carrier of autoimmune disorder or immunodeficiency disease.
3379388|NCT00001539||healthy volunteers|healthy individuals who have never had Lyme disease
3379389|NCT00001539||Lyme arthritis|patients with suspected Lyme arthritis
3379390|NCT00001539||multiple sclerosis controls|patients diagnosed with multiple sclerosis who have never been diagnosed with Lyme disease
3379391|NCT00001539||OspA vaccine|patients who received two doses of the OspA vaccine
3379392|NCT00001539||PTLDS|presumed PTLDS
3379393|NCT00001539||PTLDS for screening|patients suspected of PTLDS for screening
3379394|NCT00001539||recovered controls|patients who were diagnosed with Lyme disease, treated, and fully recovered
3379395|NCT00001539||seropositive controls|patients who are seropositive for Lyme disease, but have no manifestations/symptoms and have never been treated for Lyme disease
3379398|NCT00001529||Group 1|Healthy volunteers
3379401|NCT00001503||1/All Patients|Patients who were previously enrolled on a CCR protocol and need follow-up by CCR Investigators.
3290978|NCT01751490|Active Comparator|physiotherapy alone|patients undergoing physiotherapy only
3290979|NCT01751490|Active Comparator|surgery and physiotherpay|patients receiving surgical treatment followed by physiotherapy
3379406|NCT00001471||Healthy Volunteers|Healthy Volunteers
3379407|NCT00001471||HIV-infected|HIV-infected individuals
3379408|NCT00001471||ICL|Idiopathic CD4 lymphopenia
3290980|NCT01751503|Active Comparator|Interosseous route of TPTT|The investigators will have two groups of patients, one who had their tendon transfer using the extra membranous route and other group which had their tendon transfer through the interosseous route. Patients will be randomized to either groups before the surgery and both the patients and the assessors will be blinded to the technique used. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors.
3379420|NCT00001392||Study Cohort|Subjects with known or suspected forms of sclerosing glomerular or chronic, fibrosing tubulointerstitial kidney diseases
3379431|NCT00001355||Healthy Volunteer|Healthy Volunteer to serve as controls
3379432|NCT00001355||Patient|Patients known to have or suspected of having an immune defect significantly or primarily involving the phagocytes
3379433|NCT00001355||Patient Relatives|blood relatives of patients
3379434|NCT00001352||Genetic Relatives|Controls
3379435|NCT00001352||Healthy Volunteers|Controls
3379436|NCT00001352||Patient Population|Adult patients with cryptococcosis no predisposing conditions except ICL
3379437|NCT00001351||Immediate family members of patients|immediate family members of patients with inflammatory conditions may be evaluated under this protocol
3379438|NCT00001351||Patients|Inflammatory conditions associated with, but not limited, to acute and chronic infections or presumed infections, and congenital or acquired immunologic disorders
3379441|NCT00001316||Individuals with HIV|Individuals with HIV
3379442|NCT00001316||Individuals without HIV|Individuals without HIV
3379443|NCT00001281||HIV Infected Individuals|HIV Infected Individuals
3379444|NCT00001281||HIV Uninfected Individuals|HIV Uninfected Individuals
3379445|NCT00001276||Patients with hypoglycemia|Patients with hypoglycemia due to diverse etiologies.
3290981|NCT01751503|Active Comparator|Extra membranous route of TPTT|Extramembranous or circumtibial route of Tibialis Posterior tendon transfer.Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
3290982|NCT01751529|Experimental|Contrast-enhanced Ultrasound|
3290983|NCT01751542|Experimental|Mindfulness + residential treatment|Mindfulness and Acceptance Group Therapy + residential treatment
3290984|NCT01751542|Active Comparator|Residential Treatment|Residential treatment alone
3290985|NCT01751555|Experimental|TDF/3TC/EFV Treatment HIV/HBV Co-infection|TDF+3TC+EFV treatment regimen in Adults with HIV/HBV Coinfection
3290986|NCT01751581|Active Comparator|Habitual Sleep|Women sleep 8 h/night throughout the study phase
3290987|NCT01751581|Experimental|Short Sleep|Women sleep 4 h/night throughout the study phase
3290988|NCT01751594|Active Comparator|H4L Comparison Intervention|
3290989|NCT01751594|Experimental|MOVE Intervention|
3290990|NCT01751607||genetic variants|AFib patients with or without the genetic variants
3290991|NCT01751620|Experimental|Project ACCEPT|Participants randomized to the intervention (Project ACCEPT) arm.
3290992|NCT01751620|Active Comparator|HEALTH|Participants randomized to the comparison (HEALTH) arm.
3290993|NCT01751633||Surgical treatment|"Surgical treatment according to one of the following:~Posterior open approach~Posterior minimally-invasive surgery (MIS) approach The choice of the approach will be left upon the surgeon's discretion"
3290994|NCT01751633||Conservative treatment|Conservative treatment according to hospital's standard of care
3290995|NCT01751659||Phase I|"Semi-structured face-to-face or telephone interviews of 10 ATN-affiliated clinicians.~The total duration of Phase 1 is expected to last approximately nine months, including data analysis."
3290996|NCT01751659||Phase II|"Development of a new theory-based survey instrument and cognitive interview testing of this survey with approximately five clinicians (of those who participated in Phase 1).~The total duration of Phase 2 is expected to last approximately three months, including qualitative analysis of the interviews and modification of the survey."
3290997|NCT01751659||Phase III|"Administration of the newly developed survey to approximately 60 ATN-affiliated clinicians.~The total duration of Phase 3 will last approximately six to nine months."
3290998|NCT01751672|Active Comparator|SBIRT|Screening, Brief Intervention, and Referral to Treatment
3290999|NCT01751672|Experimental|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment
3291000|NCT01751685|Experimental|Kyphosis-specific spinal exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
3291001|NCT01751685|Placebo Comparator|Control|Usual care control group will meet once a month for educational lectures on various topics. At the end of 6 months, each control group participant will get a one-on-one session with the physical therapist who was leading the intervention classes.
3291002|NCT01751698|Active Comparator|JASP-EMT|JASP-EMT (Joint Attention, Symbolic Play and Enhanced Milieu Teaching) focuses on creating a context for joint engagement within naturally occurring child-led play routines. There is evidence of the effects of these interventions with children with ASD, and pilot data showing effects with minimally verbal children.
3291003|NCT01751698|Active Comparator|DTT|CORE-DTT (discrete trial training for core features of ASD) emphasizes didactic adult-led instruction and is considered the current evidenced-based 'standard of care' for children with autism (NRC, 2001).
3291004|NCT01751737|Experimental|Prostate Cancer Imaging|"Subjects will receive multi-sequence Magnetic Resonance Imaging (MRI) of the prostate and pelvis. This scan will take approximately 90 minutes.~In addition, a 18F-Choline PET/CT(Positron emission tomography/computed tomography) scan of the abdomen and pelvis is performed. This scan will take about 30 minutes. Subjects may receive an additional 30 minute scan, if needed.~Patients participating in an active surveillance program at the University of Michigan may receive yearly imaging followed by a prostate biopsy procedure."
3291005|NCT01751750|Other|Grape|
3291006|NCT01751763||Group 1|
3291007|NCT01751776|Experimental|BI 655064 Part 1|3 different doses plus placebo in healthy volunteers
3291008|NCT01751776|Experimental|BI 655064 Part 2|2 different doses plus placebo in rheumatoid arthritis patients
3291009|NCT01751789|Active Comparator|Linkage|Participants will receive Suboxone during their inpatient detoxication and be given outpatient appointments to continue Suboxone treatment after completing inpatient detoxification
3291010|NCT01751789|Placebo Comparator|Detoxification|Participants will receive Suboxone to detoxify from opioids and the standard treatment offered by the inpatient detoxification program
3291011|NCT01751815|Experimental|Acu-TENS|
3291012|NCT01751815|Sham Comparator|Placebo-TENS|
3291013|NCT01751828|Experimental|Sertraline|Open-label sertraline, 8 week trial, dosing from 50mg to 200mg daily.
3291014|NCT01751841||Spinal fusion patients with MIS surgery|Spinal fusion patients for whom Silicate-Substituted Calcium Phosphate Ceramic has been used as the Bone Graft
3291015|NCT01751854|Experimental|SSRI|SSRI alone or with training
3291016|NCT01751854|Placebo Comparator|Placebo|Placebo alone or with training
3291017|NCT01751880|Experimental|Exercise Group|
3291018|NCT01751893|Experimental|Henna arm|Based on the treatment protocol for this study the patients will receive the henna treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna mixture (paste) (40gr natural henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hour and then the mixture will be rinsed with fresh water.
3291019|NCT01751893|Placebo Comparator|Placebo|Based on the treatment protocol for this study the patients in this arm will receive the henna placebo treatment for 4 weeks (supervised treatment for first week and then unsupervised sessions twice a week). The treatment will include the application of the henna placebo mixture (paste) (40gr placebo henna and 40ml of purified water) to the affected areas (feet or/and hands) and wear socks or/and gloves. The treatment session will last for 1 hours and then the mixture will be rinsed with fresh water.
3291020|NCT01751919|Other|Group 1 (RT)|"Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)~Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)"
3291021|NCT01751919|Other|Group 2 (TR)|"Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)~Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)"
3291022|NCT01751932|Experimental|CGM Monitoring|Fitting of Dexcom G4 Platinum CGM monitor and Medtronic Enlite CGM monitor
3291023|NCT01751945|Experimental|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
3291024|NCT01751945|No Intervention|Standard of care|Standard care as per national policy
3291025|NCT01751958|Experimental|Epidural Steroid injection|Group-Epidural Steroid injection (Intermittent)
3291026|NCT01751958|Experimental|Epidural Steroid Injection2|Group-injection under angiography (continuous)
3291027|NCT01751984|Experimental|ETC-1002|ETC-1002 treatment, once daily oral
3291028|NCT01751984|Placebo Comparator|Placebo|Placebo treatment, once daily oral
3291029|NCT01751997|Active Comparator|Transplants from 8/8-matched unrelated|Participants will receive transplants from 8/8-matched unrelated donors using myeloablative or reduced-intensity conditioning according to age or comorbidity.
3291030|NCT01751997|Experimental|Transplants from family-mismatched/haploidentical donors|Participants will receive FMT using a reduced intensity conditioning regimens.
3291031|NCT01752010|Active Comparator|Acupuncture Treatment|Traditional Chinese acupuncture.
3291032|NCT01752010|Active Comparator|Tennant™ Biomodulator Treatment|
3291033|NCT01752010|Active Comparator|Transcutaneous electrical nerve stimulation (TENS) Treatment|
3291034|NCT01752075||REVLIMID|Taiwanese patients treated with REVLIMID
3291035|NCT01752127|Active Comparator|DM arms|comparison of two different stents(Xience prime and Resolute integrity)
3291036|NCT01752127|Active Comparator|Small vessel arms|comparison of two different stents(Xience prime and Resolute integrity)
3291037|NCT01752140|Active Comparator|10-core prostate biopsy protocol group|Ultrasound guided prostate biopsy with extraction of 10 cores
3291038|NCT01752140|Active Comparator|Vienna nomogram prostate biopsy protocol group|Ultrasound guided prostate biopsy performed according to the Vienna nomogram
3291039|NCT01752153|Experimental|Silymarin (Legalon)|Patients who were unable or unwilling to use desferrioxamine or had stopped desferrioxamine treatment for at least 6 months, were received only silymarin.
3291040|NCT01752153|Experimental|Combined therapy (Deaferrioxamine+Silymarin (Legalon)|In combined therapy group, patients continued desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy) was added to desferrioxamine regimen at the dose of 140 mg, taken orally, three times a day, 7 days a week.
3291041|NCT01752166||Blood culture|Subjects have had a blood culture ordered, per routine standard of care
3291042|NCT01752179|Experimental|kinesio tape|kinesio Tape : Width 5cm ,Length 35cm Y shape
3291043|NCT01752179|No Intervention|Control group|without using Kinesio tape
3291044|NCT01752192|Experimental|Telerehabilitation programme|Telerehabilitation programme: Each patient will use a telehealth monitor and measure blood pressure, pulse and weight once or twice a week over a 3 months periods with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital step-counter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with healthcare professionals. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound. The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
3291045|NCT01752192|No Intervention|Control group traditional rehabilitation|The control group of heart patients follow traditional rehabilitation activities for a period of 3 months.The patients are randomised in block of different sizes to follow rehabilitation from hospital, healthcare center or a callcenter.
3291046|NCT01752205|Active Comparator|Chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV ，dosing schedule: 45mg/m2/w.
3291047|NCT01752205|Experimental|Erlotinib and chemoradiotherapy|The patients will receive radiation therapy QD, 5 days a week and receive paclitaxel IV (45mg/m2/w) and erlotinib PO QD.
3291048|NCT01752218|Experimental|Arcuate Incision|Study arm will consist of patients who show cataract and corneal astigmatism.
3291049|NCT01752231||DCE-MRI (dynamic contrast-enhanced MRI)|Patients undergo DCE-MRI over approximately 30-60 minutes consisting of an anatomical scout image to localize the region of interest, a set of pre-injection scans to calibrate the dynamic image set, a dynamic image set during which contrast agent will be injected, and a set of post-injection scans to calibrate the DCE-MRI database.
3291050|NCT01752244|Experimental|Alfacalcidol|Alfacalcidol
3291051|NCT01752244|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram: were given to the intervention group once a day for 8 weeks
3291052|NCT01752257|Other|EF5 Hypoxia|EF5 administered at 21mg/kg
3291053|NCT01752270|Experimental|diane-35|Diane-35 pretreatment from the third day of menstrual cycle
3291054|NCT01752270|No Intervention|blank control|
3291055|NCT01752283|Experimental|Hypnosis and local anesthesia|video-assisted thyroidectomy under hypnosis and local anesthesia.
3291056|NCT01752283|Active Comparator|General anesthesia|Video-assisted thyroidectomy under general anesthesia
3379448|NCT00001258||1|Patients with schizophrenia spectrum disorder
3291057|NCT01752309||Rheumatoid Arthritis, ultrasound, persistence disease activity|Patients diagnosed with early Rheumatoid Arthritis will be assessed three times in one year with ultrasound to evaluate the predictive value of ultrasound.
3291058|NCT01752322|Experimental|Lidocaine plaster|Topical hydrogel plaster
3291059|NCT01752322|Placebo Comparator|Placebo plaster|Topical hydrogel plaster
3291060|NCT01752335|Other|tocilizumab|"All the patients are treated with tocilizumab before inclusion. The doses, frequency and duration are in acordance with the Summary of Characteristics of the Product authorised by EMA.~Usually 8mg/kg (not minor than 480 mg), once each 4 weeks."
3379449|NCT00001258||2|normal volunteers
3379450|NCT00001254||Patients|Patients will Zollinger-Ellison Syndrome
3379451|NCT00001252||healthy volunteer|Normal/healthy volunteers
3379452|NCT00001252||Impaired volunteer|volunteers with impairments of the neuromusculoskeletal system.
3291061|NCT01752348|Placebo Comparator|Placebo (isotonic saline)|Endotoxin + isotonic saline. Reference for model of acute inflammatory illness
3291062|NCT01752348|Experimental|Acipimox + Placebo (isotonic saline)|Endotoxin + Acipimox + Placebo (isotonic saline). Intervention: blockage of endogenous lipolysis.
3291063|NCT01752348|Experimental|Acipimox + free fatty acids|Endotoxin + Acipimox + free fatty acids. Intervention: free fatty acids
3291064|NCT01752348|Experimental|Acipimox + 3-hydroxybutyrate|Endotoxin + Acipimox + 3-hydroxybutyrate. Intervention: 3-hydroxybutyrate
3291065|NCT01752361||Ulcerative Colitis|
3291066|NCT01752374||Palonosetron group|Patient recieving Palonosetron/granisetron and ramosetron
3291067|NCT01752374||Granisetron group|
3291068|NCT01752374||Ramosetron group|
3291069|NCT01752439|Experimental|Anodal transcranial direct current stimulation|Anodal transcranial direct current stimulation
3291070|NCT01752439|Sham Comparator|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation
3291071|NCT01752439|No Intervention|Control group|
3291072|NCT01752465|Active Comparator|Standard Care|Patients in the standard care group will receive standard clinical care from their attending psychiatrist, including pharmacotherapy and education. Study assessments will be done at baseline, and once a month thereafter at Months 1, 2, 3, and 6.
3291073|NCT01752465|Experimental|Health Coaching|Patients in the Health Coaching group will receive both Health Coaching, and standard care. In addition to routine clinical appointments, patients receiving Health Coaching will attend Health Coaching sessions twice a month during Months 1, 2, and 3, and once a month during Months 4, 5, and 6. Study assessments will be conducted at baseline, and once a month thereafter during Health Coaching sessions at Months 1, 2, 3, and 6.
3291074|NCT01752491|Experimental|15g Ascorbate|"During radiation therapy:~Radiation: 61.2 Gray (1.8 Gray / fraction / day), 5 days/week, for approximately 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once daily, every day, until radiation is completed.~Ascorbate: 15 g administered by IV three times a week until 1 month after radiation is completed (approximately 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3291075|NCT01752491|Experimental|25g Ascorbate|"If the 15g arm is tolerated, the study opens the 25g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 25 g administered by IV three times/wk until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3291076|NCT01752491|Experimental|50g arm|"If the 25g arm is tolerated, the study opens the 50g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 50 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3291077|NCT01752491|Experimental|62.5g|"If the 50g arm is tolerated, the study opens the 62.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 62.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3291078|NCT01752491|Experimental|75g Ascorbate|"If the 62.5g arm is tolerated, the study opens the 75g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 75 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3291079|NCT01752491|Experimental|87.5g Ascorbate|"If the 75g arm is tolerated, the study opens the 87.5g arm.~During radiation therapy:~Radiation: 61.2 Gray (1.8 Gy/fraction/day), 5 days/wk, for about 8 weeks.~Temozolomide: 75 mg/m2, taken orally, once every day, until radiation is completed.~Ascorbate: 87.5 g administered by IV three times a week until 1 month after radiation is completed (about 12 weeks).~After radiation therapy:~Temozolomide: Starting 1 month after radiation. 150 mg/m2 and then 200 mg/m2 daily. Starting 28 days after the completion of radiation therapy. Taken for 5 days followed by 23 days of rest for 6 cycles.~Ascorbate: escalating weekly doses of ascorbate (up to 125 grams) to target a serum level of 350 mg/dL (20 mM). Ascorbate is administered twice weekly, each week, for up to 6 months."
3379456|NCT00001246||1|Our studies include data from typically developing youth, and individuals with a range of psychiatric presentations from behaviorally-defined (e.g. Childhood-Onset Schizophrenia, Autism Spectrum Disorder) as well as genetically-defined (e.g. Sex Chromosome Aneuploidy) groups. Participants span a wide age range (from 3 years of age upwards).
3379457|NCT00001244||General Population|MD referred or self-referred
3379458|NCT00001242||Study Cohort|Patients of any age or sex with vitamin D resistance, rickets, osteomalacia, pseudohypoparathyroidism, pseudo- pseudohypoparathyroidism, or suspicion of these or related disorders
3291080|NCT01752504|Experimental|Intervention group|Community members who become engaged in the coalitions and in the broader mobilization effort. A subset of community members..
3291081|NCT01752517||refractory SCLC|NI group vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days; every 3 weeks; up to the maximum cycles (total:6);
3291082|NCT01752530|Experimental|Computer program C8 + treatment as usual|Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
3291083|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
3291084|NCT01752543|Active Comparator|Conivaptan|10 patients will be randomized to conivaptan treatment
3291085|NCT01752543|Placebo Comparator|Dextrose|10 patients will receive placebo treatment (dextrose)
3291086|NCT01752556|Active Comparator|Hospital diagnosis|diagnosis of Sleep Apnea and therapeutic decision will perform according to polysomnography
3379459|NCT00001238||Disease Category I|Patients, biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is known, including VHL and HPRC
3379460|NCT00001238||Disease Category II|Patients and biologic family members with a suspected or an established diagnosis of an inherited urologic malignancy in which the disease gene is not yet known
3379461|NCT00001238||Disease Category III|Patients and biologic family members with a urologic malignant disease of suspected, but not proven genetic etiology
3379462|NCT00001230||1|Patients that have, or are suspected of having, one of the filarial infections affecting humans
3379463|NCT00001223||CF Patients|cystic fibrosis patients
3379464|NCT00001223||CF Relatives|relatives of cystic fibrosis patients
3379465|NCT00001215||Control|healthy volunteers
3379466|NCT00001215||Family Member|a family member of a documented proband
3379467|NCT00001215||Patient|the participant on initial screening must be found to have or be a carrier of a documented lysosomal storage disorder
3379468|NCT00001208||Patients|Patients will be eligible for participation if they have a movement disorder that, in the judgment of the treating physician, might be amenable to treatment with BTX.
3291087|NCT01752556|Experimental|Home diagnosis|diagnosis of Sleep Apnea and therapeutic decision will be perform according to home respiratory polygraphy
3291088|NCT01752569|Experimental|Selumetinib treatment|Phase I is a dose-finding study to discover the maximum tolerated dose of selumetinib in combination with HAART. Phase II will consider the efficacy of selumetinib for treating Kaposi's sarcoma at the recommended phase II dose discovered in phase I.
3291089|NCT01752582|Other|BuMA stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~BuMA stent Arm:About 35 patients will undergoing implantation of BuMA stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
3379471|NCT00001186||Cohort 1|Children 7-17 years of age who are currently being treated for cancer or are up to 5 years post therapy.
3379472|NCT00001186||Cohort 2|Young adults with cancer (YACers) acting as counselors at Camp Fantastic and are enrolled in another NIH protocol.
3379473|NCT00001184||1|Patients between the ages of 0 and 75 years of age with Crohn s disease or ulcerative colitis or symptoms of inflammatory bowel disease may be eligible for this study.
3379474|NCT00001174||Healthy Volunteers|Healthy volunteers
3379475|NCT00001174||Patients|Patients with bipolar disorder
3379478|NCT00001160||thyroid cancer|Patients with thyroid cancer
3379479|NCT00001160||thyroid nodules|Patients with thyroid nodules
3379480|NCT00001159||Thyroid Disorders|Those with thyroid function disorders
3379481|NCT00001154||Patients|Subjects with new and undefined dyslipidemia
3448458|NCT04063722|Experimental|Modified Benelli Procedure|point x refers to the point where the nipple areola complex should be placed at 18 cm from the mid clavicular line. line A is marked above and medial to the areola and a second radial line above it and parallel to it passing in the point (X) was made and named line B. The ends of this line is curved to approximate and connect to both ends of the line A . two incisions were made on the lines A and B . Next, the whole thickness of the excess skin between line A and the line B was excised (Simon classification 2A, 2B and 3) and subcutaneous mastectomy was done and sent to histopathology. Later on, bleeding control was done by good hemostasis and suction drain was put in its proper site. Finally subcuticular suturing was done by approximation of two incisions using Nylon 3/0. Lastly, sterile pressure dressing was placed.
3291090|NCT01752582|Other|EXCEL stent|"This study will enroll a total of 70 patients in Fuwai Hospital.All patients will be randomly assigned two groups(in a 1:1 ratio).~EXCEL stent Arm:About 35 patients will undergoing implantation of EXCEL stent.All of the patients will receive 6 months dual antiplatelet therapy and they will be followed (at the outpatient clinic) for up to 2 years. The follow-up visits will be conducted at 3 months(including angiographic/OCT investigation), 6 months, 1 and 2 years post PCI,in order to observe the Primary Endpoint and Secondary Endpoints."
3291091|NCT01752595|No Intervention|Standard|Subjects randomized to this group will receive standard, usual care with no intervention.
3291092|NCT01752595|Active Comparator|Preference Based Music Intervention|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods.
3291093|NCT01752595|Active Comparator|Preference Based Rhythmic Auditory Stimulation Music|Subjects randomized to this arm will receive an iPod player and an activity monitoring device. The iPod will be loaded with patient indicated music preferences that is synched to the patients pace prescription. Subjects will be asked to use their iPod player during off-site exercise periods. Rhythmic Auditory Stimulation (accentuation of beats, frequencies) will be added to the music subliminally.
3291094|NCT01752608|Experimental|eCBT Mood|Electronic cognitive behavioral therapy application running on the iPhone and iPod Touch.
3291095|NCT01752608|No Intervention|Mood Tracker|Mood monitoring application running on the iPhone and iPod Touch
3291096|NCT01752621||acromegaly|patients with acromegaly
3291097|NCT01752621||comparison population|matched background population
3291098|NCT01752647|Experimental|Low dose computed tomography|Patients will have one baseline LDCT scan.
3291099|NCT01752660|Experimental|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
3291100|NCT01752660|Active Comparator|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center
3291101|NCT01752673|Experimental|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
3291102|NCT01752673|Active Comparator|Didactic review pulmonary embolism lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
3291103|NCT01752686|Experimental|carboplatin chemotherapy|At the time of post neo-adjuvant period, the patients will be assigned to each treatment group in a 1:1 ratio i.e. carboplatin AUC 6 group vs. observation group. Six cycles of carboplatin (AUC=6) on the first day of every 21 days.
3291104|NCT01752686|No Intervention|Observation arm|In this observation arm, patients should be follow up with regular interval without treatment.
3291105|NCT01752699|Experimental|Methadone|in this arm patients will take methadone 5mg.
3291106|NCT01752699|Experimental|Placebo|in this arm patients will take placebo pills.
3291107|NCT01752725|Experimental|BiCision Arm|Coagulation with BiCision
3291108|NCT01752725|Active Comparator|Ultracision Arm|Coagulation with Ultracision
3291109|NCT01752751||Cancer Patients Age 65 or above|Cancer patients age 65 years or above with a diagnosis of head and neck cancer or lung cancer with radiotherapy or chemoradiotherapy planned as part of curative standard treatment.
3291110|NCT01752764|Experimental|Test product|Test product: Salad with high dosage fat
3291111|NCT01752764|Other|Control product|Control product: Salad with low dosage fat
3291112|NCT01752777|Experimental|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
3291113|NCT01752777|Sham Comparator|General Health Improvement|Participants in this condition receive education conducted in one office session followed by 4 cell-phone-based sessions. The education sessions focus on raising awareness of health services and health improvement strategies.
3291114|NCT01752790|Experimental|Top-down|patients randomized on top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus azathioprine (2 mg/Kg per os/day). During maintaining phase, patients will receive subsequent infusions of infliximab (5 mg/kg every 8 weeks), starting 8 weeks after the end of the induction phase (week 14). At 12 motnhs patients will stop azathioprine and continue infliximab (5 mg/kg every 8 weeks)
3291115|NCT01752790|Active Comparator|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day). Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop).
3291116|NCT01752803|Experimental|probiotic|subjects in this arm will receive probiotic supplementation for 12 weeks.
3291117|NCT01752803|Placebo Comparator|placebo|subjects in this arm will receive placebo in identical sachets similar to probiotics which only differs in the codes mentioned on the label of sachets.
3291118|NCT01752816|Active Comparator|endurance training|40 min bicycle or treadmill training at 60% maximal oxygen uptake
3291119|NCT01752816|Experimental|Strength following endurance training|20 minutes bicycle or treadmill training at 60% maximal oxygen uptake followed by 20 minutes stength training increasing from 15RM to 10RM
3291120|NCT01752868|Experimental|supplement|
3291121|NCT01752868|No Intervention|control|
3291122|NCT01752881|Experimental|AdimFlu-S|
3291123|NCT01752894|Active Comparator|Angio guided PCI|
3291124|NCT01752894|Experimental|OCT-guided PCI|
3291125|NCT01752894|Active Comparator|BES|
3291126|NCT01752894|Experimental|EES|
3291127|NCT01752894|Active Comparator|Keep dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
3291128|NCT01752894|Active Comparator|Discontinue Dual antiplatelet therapy (DAPT)|Study subjects will be allocated into this arm with non-randomization method
3291129|NCT01752959|Active Comparator|Remifentanyl|Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva
3291130|NCT01752959|Experimental|esmolol|Grup E 500 micg/kg/min lading dose after 50-500 μcg/kg/dk esmolol infusion
3291131|NCT01752972|Experimental|Palmer arsenical keratosis|Spirulina 10 g/day orally for 12 weeks
3291132|NCT01752972|Active Comparator|Arsenic exposed controls|Spirulina 10 g/day orally for 12 weeks
3291133|NCT01752972|Active Comparator|Heathy volunteers|Spirulina 10 g/day orally for 12 weeks
3291134|NCT01752998|Active Comparator|TOPPS Intervention|Individuals randomized into this arm will receive 7 individual sessions of the Treating Opioid Patients' Pain and Sadness (TOPPS) intervention, designed to reduce symptoms of pain and depression.
3291135|NCT01752998|Placebo Comparator|Health Education|Individuals randomized into this arm will receive 7 individual sessions on general health education.
3291136|NCT01753011||Stress Urinary Incontinence|Stress Urinary Incontinence
3291137|NCT01753024||Sepsis-PEST|septic patients with enteral nutrition and pancreatic enzyme supplementation therapy
3291138|NCT01753024||Sepsis-NPEST|Septic patients with enteral nutrition only
3291139|NCT01753024||DM-PEST|Diabetic patients with enteral nutrition and pancreatic enzyme supplementation therapy
3291140|NCT01753024||DM-NPEST|Diabetic patients with enteral nutrition only
3291141|NCT01753024||PCAS-PEST|Patients suffering from cardiac arrest receive both enteral nutrition and pancreatic enzyme supplementation therapy
3291142|NCT01753024||PCAS-NPEST|Patients suffering from cardiac arrest receive enteral nutrition only
3291143|NCT01753024||ARF-PEST|Patients with acute renal failure receive both enteral nutrition and pancreatic enzyme supplementation therapy
3291144|NCT01753024||ARF-NPEST|Patients with acute renal failure receive enteral nutrition only
3291145|NCT01753037|Active Comparator|DHEA Group|Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.
3291146|NCT01753037|Placebo Comparator|Placebo Group|Oral administration of an identical capsule containing placebo for 5 days.
3291147|NCT01753050|No Intervention|Standard care|No specific hemodynamic optimization measures
3291148|NCT01753050|Experimental|Hemodynamic optimization|Hemodynamic optimization by stroke volume monitoring
3291149|NCT01753063|Experimental|Patient Expectations|At the family's initial visit to the pediatric weight management program/clinic each parent/guardian and adolescent (if age 12 yrs. or older) will complete the survey tool. At 3 months, families will be asked to complete a follow up survey. This will be fielded at a visit for those returning to clinic or by phone/mail for those not returning.
3291150|NCT01753089|Other|WDVAX|Treatment
3291151|NCT01753102|Experimental|Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
3291152|NCT01753102|Active Comparator|Reference: Estradiol|Intravaginal self-administration of study medication once daily for 14 days.
3291153|NCT01753102|Placebo Comparator|Placebo|Intravaginal self-administration of study medication once daily for 14 days.
3291154|NCT01753128|Active Comparator|imipramine|
3291155|NCT01753141|Experimental|Active|Cognitive Behavioral Therapy for smoking cessation plus anxiety sensitivity reduction.
3291156|NCT01753141|Active Comparator|Control|Cognitive Behavioral Therapy for smoking cessation.
3291157|NCT01753154|Experimental|Solution B (balance PD solution)|Treatment 8 weeks with solution B (balance PD solution), next 8 weeks with solution A (conventional PD solution)
3291158|NCT01753154|Active Comparator|Solution A (conventional PD solution)|Treatment 8 weeks with solution A (conventional PD solution), next 8 weeks with solution B (balance PD solution)
3291159|NCT01753167|Experimental|MCMV5322A/MCMV3068A|Participants will receive a total of four doses of study drug administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57. MCMV5322A/MCMV3068A will be tested in this study at 10 milligrams per kilogram (mg/kg) of each component antibody. Thus, at each dose, 10 mg/kg of MCMV5322A and 10 mg/kg of MCMV3068A will be tested (20 mg/kg total).
3291160|NCT01753167|Placebo Comparator|Placebo|Participants will receive a total of four doses of placebo matched with MCMV5322A/MCMV3068A administered by intravenous infusion: at the time of transplantation (Day 1), and at Days 8, 29, and 57.
3291161|NCT01753180|Experimental|collagenase|
3291162|NCT01753180|Placebo Comparator|saline|
3291163|NCT01753219|Experimental|Onstep|Participants in this group will have a inguinal hernia repair ad modum Onstep.
3291164|NCT01753219|Active Comparator|Lichtenstein|Participants in this group will receive a inguinal hernia repair ad modum Lichtenstein.
3291165|NCT01753232||DALI-adsorber, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated at least twice a month with the DALI-system
3291166|NCT01753232||MONET-Filter, hypercholesterolemia|Patients suffering from familial hypercholesterolemia treated with the MONET-Lipoprotein filter
3291167|NCT01753245||Non-Metabolic Syndrome|Patients without Metabolic Syndrome criteria (OMS).
3291168|NCT01753245||Metabolic Syndrome|Patients with Metabolic Syndrome criteria (OMS).
3291169|NCT01753258||Definite diagnosis of dyspareunia|Patients who report dyspareunia, and whose dyspareunia was evaluated prior to delivery by a caregiver experienced with sexual pain disorders, with definite diagnosis.
3291170|NCT01753258||No definite diagnosis of dyspareunia|"Patients who report dyspareunia but were not evaluated prior to delivery or were evaluated inappropriately (i.e. yeast infection without cultures, inflammation and other vague definitions)."
3291171|NCT01753258||Patients without dyspareunia|Patients without dyspareunia- those who report non painful sexual intercourse. This group of patients will be used as a control group.
3291172|NCT01753271|Experimental|Thoracic Mobilization|thoracic mobilization in addition to shoulder mobilization plus exercise
3291173|NCT01753271|Active Comparator|exercise only|shoulder mobilization plus exercise alone
3291174|NCT01753349||Idiopathic cervical dystonia|Adults subjects from Hospitals, Private Practices suffering idiopathic cervical dystonia. BoNT-A injections, 3-4 times yearly.
3291175|NCT01753375|Active Comparator|Vitamin D3|Administered orally on weekly basis
3291176|NCT01753375|Placebo Comparator|Placebo|To be administered orally on weekly basis
3291177|NCT01753388|Experimental|Treatment by the Liberty Stent|
3291178|NCT01753414|Other|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
3291179|NCT01753414|Experimental|Sterotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy (SBRT) given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
3291180|NCT01753440|Other|Stem cells implantation|Patients with severe coronary artery disease and chronic ischemic cardiomyopathy with a LVEF ≤40% who are scheduled for elective CABG according to accepted guidelines. Additional criteria include the following: age <75 years, history of myocardial infarction (not less than 14 days before the procedure), LVEF ≤40 % assessed with echocardiography, and a distinct area of dyskinetic or akinetic left ventricular myocardium corresponding with the infarct localization.
3291181|NCT01753453|Active Comparator|G-CSF alone|Patients will receive G-CSF for 5 consecutive days
3291182|NCT01753453|Experimental|G-CSF plus plerixafor|Patients will receive G-CSF for 4 consecutive days, then receive plerixafor before the 5th dose of G-CSF
3291183|NCT01753466|Experimental|Hydration|Participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 L water per day, depending on sex and weight, in addition to usual consumed beverages, for 6 weeks
3291184|NCT01753466|No Intervention|Control|
3291185|NCT01753479|Experimental|Test subject|
3291186|NCT01753492|Experimental|Ologen implantation (single arm)|Ologen implantation as an adjunctive to trabeculectomy
3291187|NCT01753505|Experimental|MDCTA|
3291188|NCT01753531||Flu Symptoms|
3291189|NCT01753583|Experimental|10 patients with corneal abrasions|
3291190|NCT01753583|Experimental|10 patients with corneal infiltrates|
3291191|NCT01753596|Experimental|30 healthy subjects|Subjects will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
3291192|NCT01753596|Experimental|30 patients with dry eye syndrome|Patients will receive 1 drop of Genteal HA eye drops in one randomly chosen eye, the other eye will receive placebo
3291193|NCT01753609|Experimental|Tulip capsule|swallowing Tulip capsule for up to 29 days
3291194|NCT01753622|No Intervention|Control group|Sedentary Obese and overweight pregnant women
3291195|NCT01753622|Experimental|Exercise group|Physical exercise program
3291196|NCT01753635|Experimental|Baska mask|In this arm the Baska mask will be used as the airway management device
3291197|NCT01753635|Active Comparator|single use laryngeal mask airway device (LMA)|in this arm a single use LMA device will be used for airway management.
3291198|NCT01753648|Experimental|hypertensive retinopathy|30 patients with hypertensive retinopathy stage 2 or 3
3291199|NCT01753648|Experimental|healthy controls|30 healthy age- and sex-matched controls
3291200|NCT01753661|Experimental|Project ASPIRE Treatment Condition|The Project ASPIRE Treatment condition will receive the Project ASPIRE intervention program which includes the linguistic feedback reports and the multimedia education sessions. This group will complete the same assessments as the control group.
3291201|NCT01753661|Active Comparator|EI-As-Usual Condition|As an ethical decision, eligible participants may roll over to the experimental group after satisfactory completion of this treatment.
3291202|NCT01753674|Experimental|TA-65|TA-65 will be provided to volunteers for 12 weeks, two pills per day of 8 mg each
3291203|NCT01753674|Placebo Comparator|Placebo|Placebo will be provided to volunteers for 12 weeks, 2 pills per day of 8 mg each.
3291204|NCT01753687|Other|50 patients with dry eye syndrome|
3291205|NCT01753700|Experimental|UHT treated milk|1,5 L of 1,5% UHT milk pr day for 3 weeks (21days)
3291206|NCT01753700|Placebo Comparator|Paseurised milk|1,5 L 1,5% pasteurised milk pr day for 3 weeks (21 days)
3291207|NCT01753726|Experimental|Experimental group|43 people are recruited in order to the inclusion criteria for the study. They are healthy people. A diaphragm stretching technique was employed in this experimental group.
3291208|NCT01753726|Placebo Comparator|Placebo group|37 healthy people were recruited in order to the inclusion criteria.
3291209|NCT01753752|Experimental|Chitosan-N-acetylcystein|Instillation into the study eye
3291210|NCT01753752|Placebo Comparator|Placebo|Instillation into the fellow eye
3291211|NCT01753765|Experimental|Treatment|Study treatment with Cryo-Touch III device at Day 0.
3291212|NCT01753778|Experimental|Treatment|Treatment with Cryo-Touch III Device at Day 0
3291213|NCT01753791|Experimental|Cohort 1|
3291214|NCT01753791|Experimental|Cohort 2|
3291215|NCT01753791|Experimental|Cohort 3|
3291216|NCT01753791|Experimental|Cohort 4|
3291217|NCT01753804||Study participants|All participants will follow the same protocol, including muscle strength and function testing, and blood and urine collection, for a maximum of 7 visits over 3 years.
3291218|NCT01753817||Study cohort|Cohort of patients who have previously undergone transradial catheterization with the use of a 7F vascular sheath
3291219|NCT01753843|Active Comparator|early cord clamping|cord clamping within 20 sec
3291220|NCT01753843|Experimental|brief delay in cord clamping|cord clamping delayed by 30 to 60 seconds
3291221|NCT01753869|Active Comparator|ACTs after HTS inhalation:|ACTs after HTS inhalation: Patients will take a bronchodilator (Salbutamol, 2 puffs) wait 15 minutes, and then take a single inhalation (4 mls) of 7% HTS (Nebusal™) via updraft nebulizer (Portex) (approximately 20 minutes) immediately followed by an airways clearance session of 10 supervised cycles of Active Cycle of Breathing Technique (ACBT) using the acapella® (approximately 20 minutes).
3291222|NCT01753869|Active Comparator|ACTs during HTS inhalation|ACTs during HTS inhalation: Patients take a bronchodilator (Salbutamol, 2 puffs), wait 15 minutes, and then take a single inhalation (4mls) of 7% HTS (Nebusal™) through the acapella® duet (with portex updraft nebulizer attached) device. During inhalation, an airways clearance session of 10 supervised cycles of ACBT using the acapella® will be carried out (approximately 20 minutes).
3291223|NCT01753882|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training for 4 weeks (3X week) with Lexapro (10 mg SSRI), wash out period of 1 week, gait training for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3291224|NCT01753882|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3291225|NCT01753908|Experimental|Arm I (broccoli sprout extract)|Patients receive broccoli sprout extract PO QD on days 1-14 immediately prior to surgery.
3291226|NCT01753908|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO QD on days 1-14 immediately prior to surgery.
3291227|NCT01753921||DKA Group|Subjects who presented in diabetic ketoacidosis.
3291228|NCT01753921||Healthy control|Control subjects without diabetes.
3291229|NCT01753947|Experimental|Deliberate Practice|Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.
3291230|NCT01753947|No Intervention|Conventional Feedback|Residents in the control group received informal feedback as they performed the initial laparoscopic cholecystectomy in the operating room. This was left up to the discretion of the staff surgeon supervising the operation. This corresponds to the routine teaching and feedback practices that occur during conventional surgical residency training
3291231|NCT01753960||Control group|Anesthesiologists without access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
3291232|NCT01753960||SpHb group|Anesthesiologists with access to data from a continuous noninvasive hemoglobin monitoring device during surgery.
3291233|NCT01753986|Experimental|Brief Alcohol Intervention plus Standard Batterer intervention|Brief Alcohol Intervention plus 40 hours of Standard Batterer intervention
3291234|NCT01753986|Placebo Comparator|General Health Improvement plus Standard batterer intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer intervention
3291235|NCT01754012|Experimental|Dietary Intervention|This group will follow for a year the NU-AGE whole diet approach elderly-specific and will be supplemented with 10micrograms per day of Vitamin D (cholecalciferol) from MCOHealth.
3291236|NCT01754012|No Intervention|Control Group|This group will follow the habitual diet.
3291237|NCT01754025||Cancer patients with T790M|Have a diagnosis of cancer of any type. Have an EGFR T790M mutation identified on either genotyping of their cancer at diagnosis OR on quantitative plasma genotyping with evidence of high level (>40% allelic fraction) EGFR T790M. OR another EGFR mutation previously reported as germline detected on tumor genotyping of their cancer.
3291238|NCT01754025||Relatives of Carriers|Have a relative known to carry a germline EGFR mutation (either T790M or other novel germline EGFR mutation)
3291239|NCT01754025||Individuals known to be carriers|Have a known germline EGFR mutation (either T790M or other novel germline EGFR mutation)
3291240|NCT01754038||Integrative Medicine Clinic Attendees|All patients attending a participating Integrative Medicine clinic for clinical services will be invited to participate in the PRIMIER Registry
3291241|NCT01754051||Treatment by the PC 400 coils|Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use.
3291242|NCT01754064||Cardiac Rhythm Management device|Implanted with implantable defibrillator or pacemaker system
3291243|NCT01754077|Experimental|Thirty Million Words Project|The participants in the intervention group receive the LENA linguistic feedback reports intervention and the home visiting educational session intervention. Participants in this arm complete the same assessments as participants in the control group.
3291244|NCT01754077|Other|Control Group|The control group receives the Childhood Nutrition Education intervention. Participants in this group completed the same assessments as the treatment group. Following participation in the control group, eligible families were offered the opportunity to continue into the experimental group.
3291245|NCT01754090|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
3291246|NCT01754090|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
3291247|NCT01754103|Experimental|Functional Connectivity MRI|Functional Connectivity will be measured by MRI, we will perform one T1WI run as well as three resting state bold based runs. Bold runs parameters: TE 30ms, TR 3000ms, flip angle 90º, gap 0mm, 124 time points, voxel size 3mm, duration 6min18s each, FOV 240x240x141.
3291248|NCT01754116|Experimental|Lead In Period GSK1265744 30 mg + midazolam 3mg|During the lead-in period, a group of 12 subjects will receive a midazolam probe (on Day -29 and Day -14) to examine the potential of GSK265744 to inhibit or induce cytochrome P450 (CYP)3A activity. On Day -28, subjects will begin a 14 day oral dose of GSK265744 30 mg. to be taken once daily from Day-28 to Day -14. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
3291249|NCT01754116|Experimental|Lead in Period GSK1265744 30mg|On Day -28, subjects will begin a 14 day oral dose lead-in period. Subjects will be dispensed a 14 day supply of 30mg oral GSK1265744 to be taken once daily from Day-28 to Day -15. Subjects will begin a wash out period from Day -14 to Day -1 and be randomized to GSK1265744 LAP on Day 1
3291250|NCT01754116|Experimental|Treatment A|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Nanomilled 200 nm) LAP intramuscular suspension injection
3291251|NCT01754116|Experimental|Treatment B|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400mg GSK1265744 (Nanomilled 1 micro m) LAP intramuscular suspension injection
3291252|NCT01754116|Experimental|Treatment C|Approximately 15 subjects will be enrolled and randomized on Day 1 to receive a single dose of 400 mg GSK1265744 (Dry milling and homogenization 5 micro m) LAP intramuscular suspension injection
3291253|NCT01754142||Type 2 diabetes mellitus subjects initiating Kombiglyze XR|Patients with diagnosis of type 2 diabetes mellitus initiating Kombiglyze XR treatment within the approved indications will be enrolled
3291254|NCT01754155|Other|Vitamin E Polyethylene and RSA|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
3291255|NCT01754181|Experimental|Proposed treatment by Diabeloop algorithm|the insulin dose is calculated by the algorithm based on the usual treatment of the patient, the ratio I / C, the intensity of physical activity and blood glucose sensor.
3291256|NCT01754181|No Intervention|usual treatment|
3291257|NCT01754220|Active Comparator|Montelukast|Montelukast tablets: adults - 10 mg, children - 5mg taken daily for two weeks
3291258|NCT01754233|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3291259|NCT01754246|Experimental|Alexandrite Laser for Skin Toning|755 nm Alexandrite Laser for Skin Toning
3291260|NCT01754246|Experimental|Alexandrite Laser for Pigmented Lesions|755nm Alexandrite Laser for Epidermal Pigmented Lesions
3291261|NCT01754272||FOLFIRI + Aflibercept|Non-interventional study. No drugs administered. In this arm 612 patients from the VELOUR trial
3291262|NCT01754272||FOLFIRI + Placebo|Non-interventional study. 614 patients from the FOLFIRI + placebo arm in the VELOUR trial.
3291263|NCT01754285|Experimental|LF-PB 10 mg|2 IM injections = placebo + 10 mg
3291264|NCT01754285|Experimental|LF-PB 20 mg|2 IM injections = placebo + 20 mg
3291265|NCT01754285|Experimental|LF-PB 30 mg|2 IM injections = 10 mg + 20 mg
3291266|NCT01754285|Placebo Comparator|Placebo|2 IM injections of placebo
3291267|NCT01754298|Active Comparator|Retro-articular drilling|Retro-articular drilling goes through the cortical margin of the affected condyle, thereby sparing the articular surface and physes.
3291268|NCT01754298|Active Comparator|Trans-articular drilling|Trans-articular drilling penetrates the articular cartilage through multiple sites to create subchondral penetrations.
3291269|NCT01754311||HTLV-1 infected patients|HAM/TSP patients and HTLV-1 Asymtomatic patients
3291270|NCT01754311||control|Blood donors
3291271|NCT01754324||Methadone|All infants requiring pharmacological treatment of their NAS symptoms are treated with a standardized protocol utilizing oral methadone. This treatment protocol has been the standard of care for infants with NAS at our institution for many years. Infants enrolled in this study will have blood samples drawn at predetermined times in order to obtain information regarding the pharmacokinetics of oral methadone in this population.
3291272|NCT01754337|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels.
3291273|NCT01754337|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels.
3291274|NCT01754337|Active Comparator|Insulin pump therapy|Patient's conventional treatment will be implemented.
3291276|NCT01754415|No Intervention|control|Do exercise at home with video program designed by our team.
3291277|NCT01754415|Experimental|hydraulic resistance circuit training|Intervention:12 weeks resistance training
3291278|NCT01754454|Experimental|Human Umbilical Cord Derived MSC|"Human Umbilical Cord Derived MSC:~Patients who receive standard of care plus treatment with ex vivo cultured adult human Umbilical Cord Derived Mesenchymal Stem Cells"
3291279|NCT01754506|Experimental|EPA+DHA|EPA+DHA (fish oil)
3291280|NCT01754506|Placebo Comparator|Placebo|mineral oil
3291281|NCT01754532||Schizophrenia patients|
3291282|NCT01754545|Experimental|Octaplas infusion and placebo (group 1)|Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.
3291283|NCT01754545|Experimental|Octaplas infusion and placebo (group 2)|Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks
3291284|NCT01754558|Experimental|Ajust sling|The sling a a new device for stress urinary incontinence. The sling is ajustable and is not penetrating the skin, i.e. is only attached to the obturator membrane
3291285|NCT01754558|Experimental|TVT/TVT-O, polypropylne slings|TVT/TVT-O system. These two systems is wellknown and used for treatment of stress urinary incontinence. The sling penetrate the skin in order to secure adjustment.
3291286|NCT01754571|Experimental|CBT treatment|
3291287|NCT01754597|Experimental|Peptide Natriurétique de type B|Peptide Natriurétique de type B
3291288|NCT01754636||Elderly patients|patients aged 65 years old or older : no intervention
3291289|NCT01754636||"Young patients"|patients aged 18-64 years (added by amendment n°3 -02/2014) : no intervention
3291290|NCT01754649|Active Comparator|misoprostol vaginal 200 mcg|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
3291291|NCT01754649|Placebo Comparator|placebo|The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
3291292|NCT01754662|Experimental|Soy protein with isoflavones and cocoa|Soy protein with isoflavones and cocoa bars. 2 bars daily for 8 weeks.
3291293|NCT01754662|Experimental|Soy protein alone with cocoa|Soy protein alone with cocoa with no isoflavones. 2 bars daily for 8 weeks.
3291294|NCT01754662|Experimental|Soy protein with soy isoflavones|Soy protein with isoflavones bar. 2 bars daily for 8 weeks.
3291295|NCT01754662|Experimental|Soy protein alone|Soy protein alone without soy isoflavone or cocoa polyphenol. 2 bars daily for 8 weeks.
3291296|NCT01754662|Placebo Comparator|Placebo|Placebo bar without soy protein, isoflavones or cocoa polyphenols. 2 bars daily for 8 weeks
3291297|NCT01754675|Experimental|Soccer|Watching the soccer match at the time that the favorite team is playing
3291298|NCT01754675|Placebo Comparator|Movie|Watching a movie at the time that the favorite team is playing
3291299|NCT01754701|Experimental|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
3291300|NCT01754701|Experimental|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
3291301|NCT01754740|Experimental|Study Group|19 patients whom received topical medication of urea 10%
3291302|NCT01754740|Placebo Comparator|Control Group|19 patients whom received placebo
3291303|NCT01754792|Experimental|Normal fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3291304|NCT01754792|Experimental|Impaired fasting glucose subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3291305|NCT01754792|Experimental|Diabetic subjects|Before pinitol/placebo administration a four weeks run-in period of a healthy diet will be follow for all subjects. After this adaptation period, each subject will be randomized (1:1) into one of two groups: one that received the pinitol-enriched beverage (4 g/day) (n=20), and the other a placebo beverage (n=20) for 12 weeks.
3291306|NCT01754805|Experimental|ASP015K and methotrexate|Patients receive a single dose of methotrexate on day 1 and day 8 and ASP015K (twice daily) on days 3 through 8 plus the morning of day 9.
3291307|NCT01754818|Placebo Comparator|Placebo|Placebo, oral capsule, no active study drug, single dose
3291308|NCT01754818|Experimental|Bendavia 10mg|Bendavia, oral capsule, 10mg, single dose
3291309|NCT01754818|Experimental|Bendavia 50mg|Bendavia, oral capsule, 50mg, single dose
3291310|NCT01754818|Experimental|Bendavia 100mg|Bendavia, oral capsule, 100mg, single dose
3291311|NCT01754831|Other|Fluoride varnish|Topical fluoride
3291312|NCT01754844|Experimental|Group 1-5, single ascending dose AZD7624|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
3291313|NCT01754844|Placebo Comparator|Placebo|Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo.
3291314|NCT01754857|Experimental|Bendamustine, rituximab, lenalidomide|"INDUCTION: Bendamustine 90mg/m2 IV D1&2 and rituximab IV D1 (up to day 5 of course 1) every 28 days for 6 cycles. Patients with objective response move to maintenance therapy. Patients with objective response after 4 courses are eligible to for maintenance therapy if ongoing induction therapy is associated w/unacceptable toxicity.~MAINTENANCE: At 6-12 wks post induction therapy, patients receive rituximab IV on day 1 of odd-numbered cycles for 24 cycles; lenalidomide 5mg PO daily on days 1-21 of each cycle (28 day cycles). Dose escalation to 10mg daily on days 1-21 allowed at start of cycle 2 or at start of subsequent cycles in subjects w/acceptable toxicities. Lenalidomide dose escalation only allowed at start of a new cycle up to a max dose of 10 mg/day on days 1- 21. Subjects entering maintenance with CrCl ≥40 & <60mL/min will begin dosing at 5mg every other day on days 1-21. Patients with excessive toxicity from lenalidomide may continue maintenance therapy with rituximab alone."
3291315|NCT01754870|Experimental|Bendamustine + Rituximab-->Rituximab and Lenalidomide|"Induction chemoimmunotherapy:~Bendamustine 70 mg/m2 IV days 1 & 2 every 28 days X 6 cycles~Rituximab 500 mg/m2 IV day 1 every 28 days X 6 cycles (375 mg/m2 IV cycle 1 only, day 1 or 2)~Maintenance phase:~Rituximab 375 mg/m2 IV on day 1 of every odd-numbered 28 day cycle for a maximum of 12 doses during the maintenance phase.~Lenalidomide 5 mg orally daily on days 1-28 of each 28-day cycle for 24 cycles (maintenance cycles 1-24); dose escalation to 10 mg orally daily will be allowed at the start of cycle 2 or at the start of any subsequent cycle in subjects with acceptable toxicities needed to escalate the dose of lenalidomide to 10 mg/day."
3291316|NCT01754883|Experimental|Lithium Augmentation|Open-label trial - active treatment
3291317|NCT01754896|Experimental|Mail-out/Mail-back|Mailing of FIT kit directly to patient. Mailing completed kits in for processing.
3291318|NCT01754896|Experimental|Mail-out/Drop-off|Mailing of FIT kit directly to patient. Dropping completed kits at lab for processing.
3291319|NCT01754896|Experimental|Pick-up/Mail-back|Mailed invitation to pick up lab requisition and then kit. Mailing completed kits in for processing.
3291320|NCT01754896|Experimental|Pick-up/Drop-off|Mailed invitation to pick up lab requisition and then kit. Dropping completed kits at lab for processing.
3291321|NCT01754935|Experimental|VX-509 100 mg qd Arm|
3291322|NCT01754935|Experimental|VX-509 200 mg qd Arm|
3291323|NCT01754935|Experimental|VX-509 300 mg qd Arm|
3291324|NCT01754935|Placebo Comparator|Placebo Arm|
3291325|NCT01754961|Placebo Comparator|Placebo|Placebo will be given on Day 1 orally
3291326|NCT01754961|Active Comparator|Vitamin D|Administration of 500,000 IU Vitamin D orally on Day 1
3291327|NCT01754974|Experimental|Peginterferon Lambda-1a + Ribavirin|Peginterferon Lambda-1a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
3291328|NCT01754974|Active Comparator|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 μg solution for subcutaneous (sc) injection once weekly and Ribavirin 1000 or 1200 mg based on weight tablet by mouth twice daily for 48 weeks
3291329|NCT01755000|Other|Aim 1: Hemodynamically Healthy Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will perform the USCOM second scan within five minutes of Nurse 1's scan and record the values of Vpk and SV on the clinical data sheet.~Nurse 1 and 2 will be blinded to each other's scans by using separate clinical data forms"
3291330|NCT01755000|Other|Aim 2: Hemodynamically Unstable Patients|"Nurse 1 will perform an USCOM scan and record values of Vpk and SV on the clinical data sheet.~Nurse 2 will also be notified of the hypotensive event, will then perform the USCOM second scan within five minutes of PI's scan and record the values of Vpk and SV on the clinical data sheet.~The two USCOM scans will be completed within 10 minutes of the hypotensive episode.~Nurse 1 and Nurse 2 will be blinded to each other's scans by using separate clinical data forms."
3448459|NCT04063722|Active Comparator|webester procedure|periareolar incision with excision of the breast tissue
3291331|NCT01755000|Other|Aim 3: Hemodynamically Unstable Patients + Fluid Bolus|"At the time that an enrolled patient meets one of the following criteria; SBP drops below 95 mmHg or MAP drops below 65 mmHg the PI will be notified to PI to perform the USCOM scan and record the Vpk, SV, systolic blood pressure and mean arterial pressure on the clinical data sheet within 10 minutes of the hypotensive episode, prior to the patient receiving a fluid bolus (fluid bolus is part of standard of care).~The USCOM scan will then be repeated within 5 minutes after fluid bolus delivery.~Before the hemodynamically unstable patient receives subsequent fluid boluses (multiple boluses are common standard of care), the PI will perform an USCOM scan. Then within 5 minutes after the delivered fluid bolus, the PI will perform another USCOM scan. This will continue, until no further boluses are prescribed."
3291332|NCT01755013|Experimental|PDT Group|Subjects who receive Photodynamic therapy with plastic optic diffuser.
3291333|NCT01755039||Patients with invasive out-of-hospital ventilation|
3291334|NCT01755065||Teenager laparoscopic patients|
3291335|NCT01755078|Experimental|Sevelamer HCl|Sevelamer HCl regular treatment 1-3 tablets TID
3291336|NCT01755078|Active Comparator|Calcium-based binder|Calcium-based phosphate binder (either CaCO3 or Ca acetate) administered 1-3 tablets TID
3291337|NCT01755104|Experimental|Stablor|dietary supplement Stablor
3291338|NCT01755104|Placebo Comparator|Placebo|dietary supplement Placebo
3291339|NCT01755117|Active Comparator|TKR, sciatic, femoral, obturator|TKR surgery under ultrasound guided sciatic nerve block plus femoral nerve block plus obturator nerve block
3291340|NCT01755117|Active Comparator|TKR sciatic nerve block, posterior lumbar plexus block|TKR surgery under ultrasound guided sciatic nerve block plus posterior lumbar plexus block
3291341|NCT01755130|Experimental|Diagnostic (LOUISA 3D)|Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
3291342|NCT01755182|Active Comparator|Pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy alone
3291343|NCT01755182|Experimental|TAE and pharmacologic therapy|Patients in this arm receive systemic pharmacologic therapy and TAE
3291344|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|"Restech pH probe placement at initial clinic visit; Subject returns 24 hours later for probe removal~Proton pump inhibitor (PPI) therapy; Subject starts PPI medication (omeprazole 40mg once daily) and returns for follow-up visit 8-12 weeks later~Optional second pH probe placement at follow up visit; Subject returns 24 hours later for probe removal; Subject continues PPI medication for 2 more weeks"
3291345|NCT01755247|Placebo Comparator|Topical Gel Vehicle|Once daily application of topical gel vehicle to forehead for 3 days
3291346|NCT01755247|Active Comparator|8% NVN1000 Topical Gel|Once daily application of 8% NVN1000 Topical Gel to the forehead for 3 days
3291347|NCT01755247|Active Comparator|8% NVN1000 Topical Gel and moisturizer|Once daily application of 8% NVN1000 Topical Gel to the forehead, followed 15 minutes later by application of a commercially available moisturizer
3291348|NCT01755260|No Intervention|oral intake|The patients at this arm were allowed to take food through mouth
3291349|NCT01755273|No Intervention|Standard pancreaticoduodenectomy|Cases receiving pancreaticoduodenectomy with standard enteral bypass
3291350|NCT01755286|Experimental|4 mg OTO-201|
3291351|NCT01755286|Experimental|12 mg OTO-201|
3291352|NCT01755286|Placebo Comparator|Vehicle for OTO-201|
3291353|NCT01755286|Sham Comparator|Sham|
3291354|NCT01755299|Active Comparator|Active ingredient|"Regular 5-hour Energy"
3291355|NCT01755299|Active Comparator|Active ingredient-2|"5-hour Energy Decaf"
3291356|NCT01755299|Active Comparator|Active ingredient-3|Compounded caffeine product 135 mg/2 ounces
3291357|NCT01755299|Placebo Comparator|Placebo|Flavored placebo
3291358|NCT01755312|Experimental|medication reminder|medication reminder
3291359|NCT01755312|Placebo Comparator|Placebo|Placebo
3291360|NCT01755325|Experimental|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
3291361|NCT01755325|Placebo Comparator|placebo|"placebo tablet,65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib 0.4g qd"
3291362|NCT01755338|Active Comparator|Methylprednisolone|Methylprednisolone i.v. 15mg/kg x 1 intraoperative Aortic Valve Replacement
3291363|NCT01755338|Placebo Comparator|Placebo (NaCl)|Placebo i.v., x1, intraoperative Aortic Valve Replacement
3291364|NCT01755364|Experimental|AdimFlu-V|
3291365|NCT01755377||No Chagas Disease|Participants with no Chagas Disease will be evaluated as a Control Group
3291366|NCT01755377||Chagas Disease|Participants diagnosed with Chagas Disease will be followed-up as a Case Group
3291367|NCT01755390|Experimental|Cabazitaxel|"IV escalation part:~XRP6258 administered as a 1-hour IV infusion on Days 1, 8, 15 and 22 of each 5-week cycle until evidence of disease progression, unacceptable toxicity or patient's withdrawal.~Oral bioavailability part:~XRP6258 administered at the dose of 8.4 mg/m² as an oral administration on Day 1 Cycle 1 and as a weekly 1-hour i.v. infusion at the subsequent weeks of treatment. Patients receiving oral administration at Day 1, Cycle 1 are to fast for 12 hours before and 4 hours after administration."
3291368|NCT01755403|Other|Benznidazole|
3291369|NCT01755442|Active Comparator|AMG 151|
3291370|NCT01755442|Placebo Comparator|Placebo|
3291371|NCT01755468|Active Comparator|Continuous metformin|After a 3-week course of intensive insulin therapy, participants will be treated with ongoing metformin monotherapy. Metformin will be initiated at 500mg twice a day for the first 2 weeks, before progressing to 1000mg twice a day for the duration of the trial (24 months).
3291372|NCT01755468|Experimental|Intermittent insulin therapy|After a 3-week course of intensive insulin therapy, participants will receive intermittent intensive insulin therapy for 2 weeks every 3 months. The 2-week course of insulin therapy will be repeated at 3-, 6-, 9-, 12-, 15-,18- and 21-months, with final outcome measurement performed at 24-months
3291373|NCT01755481|Experimental|Probiotics F19|F19 in an infant formula
3291374|NCT01755481|Experimental|Whey protein concentrate|Whey protein concentrate in an infant formula
3291375|NCT01755494|Experimental|Lower dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR®) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)
3291376|NCT01755494|Experimental|Higher dose|co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR®) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)
3291377|NCT01755507|Experimental|B|norUDCA
3291378|NCT01755507|Experimental|C|norUDCA
3291379|NCT01755507|Placebo Comparator|placebo|Placebo
3291380|NCT01755507|Experimental|A|norUDCA
3291381|NCT01755520|Experimental|Ticagrelor|Intervention: Drug: Ticagrelor verum + Aspirin placebo
3291382|NCT01755520|Active Comparator|Aspirin|Intervention: Drug: Aspirin verum + Ticagrelor placebo
3291383|NCT01755533|Experimental|Rural curriculum|Receive rural version of curriculum
3291384|NCT01755533|Experimental|Classic curriculum|Receive classic version of curriculum
3291385|NCT01755533|No Intervention|Control|Continue normal prevention activities
3291386|NCT01755559|Other|Artesunate-amodiaquine|Efficacy estimates at 95%
3291387|NCT01755559|Other|Dihydroartemisinin-piperaquine|Efficacy estimates at 95%
3291388|NCT01755559|Other|Artemether-lumefantrine|Efficacy estimates at 95%
3291389|NCT01755572|Experimental|Liraglutide|Liraglutide 0.6mg for 7 days, liraglutide 1.2mg for 7 days, liraglutide 1.8mg for 7 days
3291390|NCT01755572|Placebo Comparator|Placebo|Placebo 0.6mg sc for 3 weeks, Placebo 1.2mg sc for 3 weeks, Placebo 1.8mg for 3 weeks.
3291391|NCT01755585||C/T-RT group|Chemotherapy (C/T) is applied in the morning. After 2-4 hrs, radiotherapy (RT) is delivered (according to the clinical practice)
3291392|NCT01755585||RT-C/T group|Radiotherapy (RT) is delivered in the morning. After 2-4 hrs, chemotherapy (C/T) is applied (according to the clinical practice).
3291393|NCT01755611|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3291394|NCT01755611|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3291395|NCT01755624|Experimental|NovoTTF-100A device|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3291396|NCT01755624|Active Comparator|Best Standard of Care|Patients will be treated as the best known standard of care for Non-Small Cell Lung Cancer metastatic to the brain.
3291397|NCT01755650|Experimental|D-18F FPM|
3291398|NCT01755650|Experimental|L-18F FPM|
3291399|NCT01755663|Experimental|Ivabradine|Patients will recieved ivabradine(5) 1 tab bid pc for 3 day and the day of CT, and recieve placebo of metoprolol
3291400|NCT01755663|Active Comparator|metoprolol|Metoprolol (100) 1/2 tab bid pc for 3 day and the day of CT coronary , and placebo of ivabradine
3291401|NCT01755676|Experimental|Orlistat 60 mg|
3291402|NCT01755676|Placebo Comparator|Placebo|
3291403|NCT01755689|Experimental|Nimenrix+Cervarix (1,2,7-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 1, Month 2 and Month 7. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3291404|NCT01755689|Experimental|Nimenrix+Cervarix (0,1,6-Month) Group|Subjects in this group received 1 dose of Nimenrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3291405|NCT01755689|Experimental|Cervarix Group|Subjects in this group received 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6, administered intramuscularly (IM) in the deltoid region of the arm.
3291406|NCT01755689|Experimental|Nimenrix+Cervarix+Boostrix Group|Subjects in this group received 1 dose each of Nimenrix and Boostrix vaccines at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. All vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3291407|NCT01755689|Experimental|Boostrix+Cervarix Group|Subjects in this group received 1 dose of Boostrix vaccine at Month 0 and 3 doses of Cervarix vaccine at Month 0, Month 1 and Month 6. Both vaccines were administered intramuscularly (IM) in the deltoid region of the arm.
3291408|NCT01755715|No Intervention|Control group|Insertion of IUD at 2-4 weeks after abortion.
3291409|NCT01755715|Experimental|Immediate IUD insertion|Insertion of IUD immediately (at the same day to 3 days) after expulsion of placenta.
3291410|NCT01755728|No Intervention|No known PDA|For all infants, we do echo cardiogram study only if they are suspected of having PDA, due to sings and symptoms. Hence, we do not do echo cardiogram study to most of the infants.
3291411|NCT01755728|Active Comparator|Ibuprofen|If there is a PDA, that should be treated, and the infant is less than 2 weeks of age, we use ibuprofen, as this is the gold standard in literature.
3291412|NCT01755728|Active Comparator|Surgical closure of PDA|Infants with symptomatic PDA, who had to be treated, but could not be treated by ibuprofen, either due to age (> 2 weeks) or due ibuprofen contraindications (thrombocytopenia or renal failure), whose could not be treated by paracetamol (either because of parents' refuse or because they were on nothing per os protocol due to other disease), for whom surgery was the treatment of choice to close the arterial duct.
3291413|NCT01755728|Experimental|Paracetamol|Infants with symptomatic PDA who could not be treated with ibuprofen, and their parents agreed and they could be treated with paracetamol.
3291414|NCT01755728|No Intervention|DA closed spontaneously|Infants with PDA, who did not get any treatment for it, and the duct was closed spontaneously.
3291415|NCT01755741|Experimental|Placebo Vaginal Ring|Placebo vaginal ring with condom use
3291416|NCT01755741|Other|Condom|Male condoms during vaginal intercourse in presence and absence of the vaginal ring.
3291417|NCT01755754|Experimental|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
3291418|NCT01755754|Experimental|Female Condom|This trial will test the performance of female condoms when used concurrently with a placebo vaginal ring
3291419|NCT01755780||Left interscalene block|Left interscalene block on hypotension and bradycardia during beach chair positioning
3379485|NCT05162911|Active Comparator|Ask, Advise, Assist (AAA) and Refer.|Patients will receive Ask, Advise, Assist (AAA) and refer to the quitline as the intervention.
3379486|NCT05162911|Active Comparator|AAA plus referral to onsite counselor (Counsel).|Patients will receive Ask, Advise, Assist plus referral to onsite counselor.
3291420|NCT01755780||Right interscalene block|Right interscalene block on hypotension and bradycardia during beach chair positioning
3291421|NCT01755806||aortic root dimension change|those without aortic valve calcification
3291422|NCT01755806||aortic root dimension change, aortic valve calcium score|those with aortic valve calcification
3291423|NCT01755819|Other|Biocomposite interference screw|Thirty patients treated with ACL reconstruction and graft fixation is performed using Biocomposite interference screw on tibial and femoral side. Patients are randomized to one of the two study arms.
3291424|NCT01755819|Other|Extracortical ACL Tightrope fixation|Thirty patients treated with ACL reconstruction and graft fixation is performed using extracortical ACL Tightrope fixation on tibial and femoral side. Patients are randomized to one of the two study arms.
3291425|NCT01755832||Pool exercise group|Patients with inflammatory rheumatic disease
3291426|NCT01755845|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area. After completion of chemoradiotherapy, patients receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.
3291427|NCT01755845|Active Comparator|Arm 2|Patients receive chemoradiotherapy as in arm 1.
3291428|NCT01755871|Experimental|Fingolimod|Gilenya 0,5mg per day, oral
3291429|NCT01755884|Experimental|Wheat oral immunotherapy|Well-cooked wheat spaghetti is given daily to the patients starting from a minimal dosage (0,0003 g of wheat protein) and increasing the dosing in every 1-2 weeks until a dosage corresponding the size of one meal.
3291430|NCT01755897|Experimental|Adjuvant Chemotherapy (Arm A)|Paclitaxel (T): 135-175 mg/m(2) intravenously (IV) on day 1, administrated intravenously over 3 hours; followed by cisplatin 75-85 mg/m(2) IV on day 2 and 3. Patients received at least 3 cycles at 4-week intervals beginning 2-3 weeks after surgery. 3-6 cycles as necessary.
3291431|NCT01755897|Active Comparator|Concurrent radiochemotherapy, CCRT (Arm B)|Pelvic RT is delivered using IMRT technique, 45～50.4 Gy/4～7 weeks, brachytherapy will been given as necessary. Cisplatin 35 mg/m(2) IV once a week. Total treatment time is 6-7 weeks.
3291432|NCT01755910||Left thoaracic paravertebral block|Surgery in the left breast under left thoracic paravertebral block and HRV
3291433|NCT01755910||Right thoracic paravertebral block and HRV|Surgery in the right breast under right thoracic paravertebral block and HRV
3291434|NCT01755923|Experimental|Gefitinib|Gefitinib (Iressa) 250mg once per day until progression disease or intolerant side effects
3291435|NCT01755923|Active Comparator|Docetaxel|Docetaxel 75mg/m2,d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
3291436|NCT01755936||Controls|Patients will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
3291437|NCT01755936||Aortic Stenosis patients|All patients who agreed to study will undergo cardiac magnetic resonance imaging, echocardiography and 72 hour holter monitoring
3291438|NCT01755962|Experimental|Low Glycemic Load + Resistance Training|12-week intervention diet + resistance training (1 hour, 3 times per week)
3291439|NCT01755962|Experimental|High Glycemic Load + Resistance Training|12-week control diet + resistance training (1 hour, 3 times per week)
3291440|NCT01755962|Experimental|Low Glycemic Load|12-week intervention diet
3291441|NCT01755962|Other|High Glycemic Load|12-week control diet
3291443|NCT01755988|No Intervention|Usual care|
3291444|NCT01755988|Experimental|Educational website.|Educational website (in addition to usual care).
3291445|NCT01755988|Experimental|Website and interactive platform with telemonitoring.|Adjusted care pathway, including both the educational website and an interactive web-based platform with telemonitoring facilities. In this arm all routine consultations with heart failure nurses and general practitioner will be substituted by this combination of telemonitoring facilities connected to an interactive web-based platform plus the Dutch version of the European Society of Cardiology (ESC) website on heart failure.
3291446|NCT01756001||Control Arm|Arm 1 will be the Control arm, in which subjects will be instructed to use the GlowCap for their chronic disease medication but will not be provided with any specific incentive for taking the medication or with any aid in remembering to do so.
3291447|NCT01756001||Reminder Arm|Arm 2 will be the Reminder arm with daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
3291448|NCT01756001||Incentives Arm|Arm 3 will be the financial incentives arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform.
3291449|NCT01756001||Incentives and Reminders Arm|Arm 4 will be the financial incentives and reminders arm, in which subjects will be paid for adherence. Their total earnings will be administered at the end of the experiment through the WTH platform. They will also receive daily email, text message, or phone call reminders for intervention. Subjects will be told that to aid in daily adherence to the medication, they will be provided with reminders for the first three months of the study and possibly again later in the study. At the start of the study, subjects will be given the option to receive daily email reminders, text message reminders, or daily (automated) phone call reminders to take their pill, each at a time of day that they choose. The default setting will be for subjects to receive both text and email reminders at 8AM each day. Subjects will be instructed on how to change their settings if they would like to receive a different set of reminders at different points in time.
3448460|NCT04063761|Experimental|Esophageal Cooling|Single arm study: Patients receive the Attune Medical Esophageal Heat Transfer Device
3291450|NCT01756014||Controls|Age matched healthy subjects
3291451|NCT01756014||Mild DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class II
3291452|NCT01756014||Severe DCM|Heart failure patients with dilated cardiomyopathy (DCM) with NYHA-functional class III/IV
3291453|NCT01756027|Active Comparator|Group A|Ulthera System providing one treatment per cheek
3291454|NCT01756027|Active Comparator|Group B|Ulthera System providing two treatments per cheek
3291455|NCT01756040|Other|Lactulose - rhamnose solution|Preterm Infants age 24-32 weeks gestation
3291456|NCT01756066|Active Comparator|A|Participant has 50% subsidy, i.e. gets a 50% discount off regular price of the program
3291457|NCT01756066|Experimental|B|Participant has 100% subsidy, i.e. program attendance is free
3291458|NCT01756066|Experimental|C|Participant has 80% subsidy; i.e. gets 80% discount off regular price of the program
3291459|NCT01756066|Experimental|D|Participant has 50% subsidy up front (i.e. pays 50%), with possibility for 100% subsidy based on attaining monthly participation goals
3291460|NCT01756092|Experimental|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
3291461|NCT01756105|Experimental|treatment by Metformin plus insulin if needed|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
3291462|NCT01756105|Active Comparator|treatment by insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
3291463|NCT01756118|Experimental|BEZ235|
3291464|NCT01756131|Experimental|Cohort 1|100 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291465|NCT01756131|Experimental|Cohort 2|200 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291466|NCT01756131|Experimental|Cohort 3|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291467|NCT01756131|Experimental|Cohort 4|800 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291468|NCT01756131|Experimental|Cohort 5|100 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3291469|NCT01756131|Experimental|Cohort 6|200 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3291470|NCT01756131|Experimental|Cohort 7|400 mg GSK1265744 injectable suspension or placebo, subcutaneous dosing
3291471|NCT01756131|Experimental|Cohort 8|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291472|NCT01756131|Experimental|Cohort 9|400 mg GSK1265744 injectable suspension or placebo, intramuscular dosing
3291473|NCT01756144|Active Comparator|Autologous bone grafting|autologous bone of the iliac crest
3291474|NCT01756144|Experimental|rhBMP-2|Inductos, recombinant human bone morphogenetic protein
3291475|NCT01756170|Active Comparator|Arm 2|Patients receive radiotherapy alone as in arm 1.
3291476|NCT01756170|Experimental|Arm 1|Patients in this arm will postoperatively receive paclitaxel 135 mg/m2 d1 and cisplatin 25mg/m2 d1-3 intravenously every 4 weeks with radiation. Radiotherapy consisted of 46-50 gray (5 x 2.0 gray/week) on pelvic area.
3291477|NCT01756183|Experimental|S-1 + Paclitaxel Chemotherapy|"S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Paclitaxel: 150 mg/m2, iv, 3h, at D1"
3291478|NCT01756196||Steroid Injection|Reactions associated with spinal steroid injection
3291479|NCT01756222||Bicuspid Aortic Valve Disease Patients|Patients with the diagnosis of BAV disease.
3291480|NCT01756248||Group 1|
3291481|NCT01756261||Group 1|
3291482|NCT01756287|Experimental|Standardized Chinese ocular exercise|The participants are trained with standardized Chinese ocular exercise which contains accurate positions of acupuncture points and appropriate pressure on the points.
3291483|NCT01756287|Sham Comparator|Nonstandardized ocular exercise|The participants are trained with nonstandardized ocular exercise performed on wrong positions where no acupuncture points at all.
3291484|NCT01756287|No Intervention|Eye closure|The participants are told to close eyes and don't do ocular exercise at all.
3291485|NCT01756313|Experimental|Laser+Methylaminolevulinat|It's a single arm. Intervention as described in the detailed description.
3291486|NCT01756326|Experimental|PREOB® Implantation|Each patient will undergo a single administration of PREOB® into the non-union site, under local or loco-regional anesthesia.
3291487|NCT01756326|Active Comparator|Bone Autograft|Each patient will be treated by Bone Autograft according to standard-of-care procedure of the investigating site.
3291488|NCT01756339|Experimental|Solithromycin|Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
3291489|NCT01756339|Active Comparator|Moxifloxacin|Moxifloxacin 400 mg PO daily on Day 1 through Day 7
3291490|NCT01756365|Experimental|CECA|
3291491|NCT01756378|Experimental|Muligan mobilization with movement|"Interventions are:~medial glide mobilization with movement lateral glide mobilization with movement rotation mobilization with movement dorsal glide with active knee flexion"
3291492|NCT01756378|Active Comparator|traditional physical therapy program|Infra-red, stretching exercises, strengthening exercises,
3291493|NCT01756404|Experimental|Cohort 1|Each volunteer will receive a total daily dose of 30 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3291494|NCT01756404|Experimental|Cohort 2|Each volunteer will receive a total daily dose of 100 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3291495|NCT01756404|Experimental|Cohort 3|Each volunteer will receive a total daily dose of 300 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3291496|NCT01756404|Experimental|Cohort 4|Each volunteer will receive a total daily dose of 600 mg of canagliflozin (JNJ-28431754) or placebo (inactive medication) on Days 1 through 14.
3291497|NCT01756404|Experimental|Cohort 5|Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) twice daily (600 mg total daily dose) or placebo (inactive medication) twice daily on Days 1 through 14.
3291498|NCT01756417|Experimental|Metformin + canagliflozin (JNJ-28431754)|Each volunteer will receive a single dose of metformin on Day 1 followed by canagliflozin (JNJ-28431754) once daily on Days 4 to 7. On Day 8, volunteers will receive a single dose of canagliflozin in combination with a single dose of metformin.
3291499|NCT01756430|Experimental|Carvedilol SR 32mg, 64mg|•Carvedilol SR 32mg QD for first 4 weeks and Carvedilol SR 64mg QD for following 4 weeks.
3291500|NCT01756430|Active Comparator|Carvedilol IR 25mg|•Carvedilol IR 25mg QD for first 4 weeks and Carvedilol IR 25mg BID for following 4 weeks.
3291501|NCT01756443|Active Comparator|Premixed group|Patients will receive sciatic nerve block with premixed 7.5 mls of 2% lidocaine/adrenaline and 7.5 mls of 0.5% bupivacaine followed by an interval of 90 seconds with an injection of same amount of both drugs.
3291502|NCT01756443|Experimental|Sequential Group|Patients will receive a sciatic nerve block with 15 mls of 2% lidocaine/adrenaline followed by an interval of 90 seconds with 15 mls of 0.5% bupivacaine.
3291503|NCT01756469|No Intervention|Control|non-alcohol related information about nutrition
3291504|NCT01756469|Active Comparator|Intervention|Behavioral Intervention for Alcohol Use
3291505|NCT01756482|Experimental|GS-5806|GS-5806, powder for oral solution
3291506|NCT01756482|Placebo Comparator|Sugar powder for oral solution in juice|Sugar powder for oral solution
3291507|NCT01756495|Experimental|Losmapimod 7.5 mg|Each subject will receive losmapimod 7.5 mg BID orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3291508|NCT01756495|Experimental|Losmapimod 20 mg|Each subject will receive losmapimod 20 mg QD orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3291509|NCT01756495|Active Comparator|Moxifloxacin 400 mg|Each subject will receive moxifloxacin 400 mg orally on Day 5, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3291510|NCT01756495|Placebo Comparator|Placebo|Each subject will receive losmapimod matched placebo and moxifloxacin placebo orally for 5 days, in one of the 4 study periods (per randomization sequence) separated by a minimum washout period of 5 days
3291511|NCT01756508|Experimental|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
3291512|NCT01756508|No Intervention|control|No intervention will be applied instead eculizumab infusion
3291513|NCT01756521|Experimental|Moxifloxacin 400mg|moxifloxacin 400mg
3291514|NCT01756521|Experimental|Moxifloxacin 800mg|moxifloxacin 800mg
3291515|NCT01756521|Placebo Comparator|Placebo(No treatment)|Only drink water
3291516|NCT01756534|No Intervention|CONVENTIONAL HEMOSTASIS|patients for whom conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone) were used to achieve hemostasis
3291517|NCT01756534|Active Comparator|SURGICEL|patients will receive an oxidized cellulose patch (Surgicel®) in addition to conventional surgical procedures (i. e., ligatures and bipolar electrocautery alone)
3291518|NCT01756547|Experimental|Potassium citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age.
3291519|NCT01756547|Placebo Comparator|Placebo|Oral solution 30ml, that contains distilled water and simple syrup, in the same dose like the active treatment 0,3ml/kg/day.
3291520|NCT01756599|Experimental|leukaemia during childhood or adolescence|
3291521|NCT01756612||Chronic Kidney Disease Participants|Participants for whom the treating physician has decided to initiate treatment with MIRCERA for medical reasons prior to study start, will be observed for 9 months.
3291522|NCT01756625||First line WT KRAS mCRC|
3291523|NCT01756638|Experimental|Abiraterone plus Prednisolone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3291524|NCT01756651|Experimental|Intranasal Fentanyl 100mcg|fentanyl pectin nasal spray 100mcg
3291525|NCT01756651|Experimental|Intranasal Fentanyl 200mcg|fentanyl pectin nasal spray 200mcg
3291526|NCT01756664|Placebo Comparator|Control|Vaseline has been used on the first day after laser treatment
3291527|NCT01756664|Active Comparator|Sunscreen|Sunscreen has been used on the first day after laser treatment
3291528|NCT01756703|Experimental|MT-3995 Low group|
3291529|NCT01756703|Experimental|MT-3995 High group|
3291530|NCT01756703|Placebo Comparator|Placebo group|
3291531|NCT01756716|Experimental|MT-3995 Low group|
3291532|NCT01756716|Experimental|MT-3995 High group|
3291533|NCT01756716|Placebo Comparator|Placebo group|
3291534|NCT01756729|Active Comparator|Best Standard of Care|Patients recruited to the BSC group will be treated according to the BSC practiced at each center.
3291535|NCT01756729|Experimental|NovoTTF-100A (monotherapy)|Patients will be treated continuously with the NovoTTF-100A device. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
3291536|NCT01756742|Experimental|Respiratory physiotherapy|54 people according to the inclusion criteria were recruited to have a respiratory physiotherapy treatment added to their medical intervention.
3291537|NCT01756742|Placebo Comparator|Conservative treatment|49 people were recruited in this group. These participants received conservative medical treatment intervention
3291538|NCT01756755|No Intervention|Control|Treat with severe sepsis / septic shock practice guideline
3291539|NCT01756755|Experimental|PMX HP|Treat with severe sepsis / septic shock practice guideline Treat with PMX-20R Hemoperfusion [Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood].
3291540|NCT01756768|Experimental|Radio-labeled Dose Arm|
3291541|NCT01756781|Experimental|Sequence 1|Subjects randomized to Sequence 1 will receive Treatment A followed by Treatment B. Treatment A is a single 2 mg oral dose of midazolam alone. Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
3291542|NCT01756781|Experimental|Sequence 2|Subjects randomized to Sequence 2 will receive Treatment B followed by Treatment A with a washout of no less than 14 days in between.Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991 and a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose. There will be a minimum washout of 14 days prior to beginning Treatment A. Treatment A is a single 2 mg oral dose of midazolam alone.
3291543|NCT01756794|Other|Transplantation of alcoholic hepatitis|Patients of this arm will be selected for early liver transplantation for severe alcoholic hepatitis not responding to medical therapy. Selection process will be based on a specific algorithm and follow-up time will be 2 years
3291544|NCT01756794|Other|Transplantation for alcoholic cirrhosis|Patients of this arm will be selected for liver transplantation for alcoholic cirrhosis using an abstinence period of 6 months. Outcome of these patients will be compared to that of patients transplanted for severe alcoholic hepatitis.
3291545|NCT01756807|Experimental|The Combo Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
3291546|NCT01756820|Active Comparator|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|Single-portal Endoscopic Carpal Tunnel Release (Microaire®) will be used, according to the endoscopic technique described by Agee at al.
3291547|NCT01756820|Active Comparator|Knifelight®|A mini-open technique will be performed, using the Knifelight® (Stryker).
3291548|NCT01756859||Patients with HVPG measurements|Patients having HVPG measurements for clinical reasons will be recruited to undergo research MRI scan.
3291549|NCT01756872||Ovarian reserve study participants|Measurements of ovarian reserve for women attending the Oxford Fertility Unit having their first IVF/IVF-ICSI cycle.
3291550|NCT01756911|Experimental|Thotaco-abdominal aneurysm|MFM
3291551|NCT01756924|Experimental|CEM-102 plus Rifampin|
3291552|NCT01756924|Active Comparator|Standard of Care|
3291553|NCT01756937|Active Comparator|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
3291554|NCT01756937|Placebo Comparator|Placebo|1 capsule once daily for 24 weeks
3291555|NCT01756950|Experimental|Cohort 1 - CR8020|2 mg/kg CR8020
3291556|NCT01756950|Placebo Comparator|Cohort 1 - Placebo|5% dextrose in water
3291557|NCT01756950|Experimental|Cohort 2 - CR8020|5 mg/kg CR8020
3291558|NCT01756950|Placebo Comparator|Cohort 2 - Placebo|5% dextrose in water
3291559|NCT01756950|Experimental|Cohort 3 - CR8020|15 mg/kg CR8020
3291560|NCT01756950|Placebo Comparator|Cohort 3 - Placebo|5% dextrose in water
3291561|NCT01756950|Experimental|Cohort 4 - CR8020|30 mg/kg CR8020
3291562|NCT01756950|Placebo Comparator|Cohort 4 - Placebo|5% dextrose in water
3291563|NCT01756950|Experimental|Cohort 5 - CR8020|50 mg/kg CR8020
3291564|NCT01756950|Placebo Comparator|Cohort 5 - Placebo|5% dextrose in water
3291565|NCT01756950|Experimental|Cohort 6 - CR8020|30 mg/kg CR8020
3291566|NCT01756950|Placebo Comparator|Cohort 6 - Placebo|5% dextrose in water
3291567|NCT01756963||IBD-SL cohort|
3291568|NCT01756989|Experimental|Thalidomide, etoposide, celecoxib|Single arm study,phase II
3291569|NCT01757002|Experimental|Tailored asthma management program|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.
3291570|NCT01757002|Active Comparator|Control|Teens in the control group will receive generic, web-based asthma education.
3291571|NCT01757015|Placebo Comparator|Placebo|Placebo to NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening
3291572|NCT01757015|Experimental|NVA237|NVA237 (50 μg) o.d. in the morning Patients will also receive open label salmeterol/fluticasone propionate (50/500 µg) b.i.d., in the morning and evening.
3291573|NCT01757054|Experimental|Probiotic group|
3291574|NCT01757054|No Intervention|Control group|This is a non-supplemented control group that will follow the same dietary and medication restrictions. The purpose of this group is to ensure results are due to supplementation and not due to random dietary exposure.
3291575|NCT01757080|Experimental|Diabetic-hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
3291576|NCT01757080|Active Comparator|Hypertensive elderly|Biochemical analysis and Cardiorespiratory performance assessment with ergospirometry test
3291577|NCT01757093|Experimental|Automatic tube compensation plus CPAP|The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
3291578|NCT01757093|Active Comparator|Continuous Positive Airway Pressure|The patients is going to undergo a trial of spontaneous breathing with continuous positive airway pressure and later with automatic tube compensation plus continuous positive airway pressure, during 30 minutes each.
3291579|NCT01757106|Experimental|Drug: Xenon|gaseous anesthetic, dosage: 50-60% (v/v) in oxygen, continuous application during surgery
3291580|NCT01757106|Active Comparator|Drug: Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application during surgery
3291581|NCT01757119|Experimental|Drug|
3291582|NCT01757132|Other|Implantable Miniature Telescope|Post approval study
3291583|NCT01757145|Experimental|Eltrombopag|"Eltrombopag will be given orally as a single daily dose. From day +1 after cord blood transplantation, start eltrombopag 100 mg/d. If primary end point not reached on day +14,then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d (maximal dose). If dose not tolerated, return to last tolerated dose.~Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.~In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks.~After 4 weeks we will re-attempt to hold the drug."
3291584|NCT01757158|Experimental|Cs-131 brachytherapy seeds|sub-lobar resection plus cesium-131 brachytherapy
3291585|NCT01757223|Experimental|Part A, Group 1 - 10^8 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^8 particle units.
3291586|NCT01757223|Experimental|Part A, Group 2 - 10^9 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^9 particle units.
3291587|NCT01757223|Experimental|Part A, Group 3 - 10^10 pu|Part A is a dose-escalation, open-label study, administering 3 doses of AdVEGF-All6A+ to n=9 individuals, with n=3 each at 10^8, 10^9, and 10^10 particle units. The purpose of Part A is to determine the highest tolerable dose. Group 1 will receive 10^10 particle units.
3291588|NCT01757223|Experimental|Part B, Group 1 - AdVEGF-All6A+|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 1 will receive AdVEGF-All6A+ at the highest tolerable dose determined in Part A.
3291589|NCT01757223|Experimental|Part B, Group 2 - AdNull placebo|Part B (n=32 subjects) is a randomized, double blind, placebo-controlled study that will compare the AdVEGF-All6A+ vector (n=24) to a placebo, AdNull (n=8). Group 2 will receive AdNull, the placebo vector.
3291590|NCT01757236|Active Comparator|Treatment A|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive standard of care antibiotic therapy including oral rifampin (10-15mg/kg every 12 hours) combined with either oral clindamycin (600 mg every 8 hours) or oral sulfamethoxazole and trimethoprim (800/160 mg every 8 hours) or oral fluoroquinolone (Ofloxacin 200 mg every 12 hours). The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
3291591|NCT01757236|Experimental|Treatment B|"IV vancomycin (15mg/kg every 12 hours or in a continuous infusion) and IV ceftriaxone (2g daily) until Day 2 to 7 (until the susceptibility test results are obtained).~Patients with only a confirmed Gram-positive infection will continue the study and will receive oral linezolid (600mg every 12 hours) combined with oral rifampin (10-15mg/kg every 12 hours).~The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 6 weeks."
3291592|NCT01757236|Experimental|Treatment C|IV linezolid (600 mg every 12 hours)and IV ceftriaxone (2g daily) until Day 2. Oral or IV rifampin (10-15 mg/kg every 12 hours) will be added 48 hours after initiating the study treatment. Treatment with the study drug will continue until Day 2 to 7 (until the susceptibility test results are obtained). Patients with only a confirmed Gram-positive infection will continue the study. Treatment with ceftriaxone will be discontinued and the patient will switch to oral linezolid and oral rifampin. The total duration of antibiotic therapy from the day of the surgical procedure until the end of treatment (EOT) will be 4 weeks.
3291593|NCT01757249|Experimental|Group 1 OCP|Combined oral contraceptive pill (OCP) (Microgynon 30) containing Levonorgestrel/Ethinylestradiol 150/30mcg. Taken orally on a continuous regime for 8 weeks, once a day.
3291594|NCT01757249|No Intervention|Group 2 Control|Control Group - no intervention
3291595|NCT01757262|Experimental|Ticagrelor|90 mg Ticagrelor
3291596|NCT01757262|Active Comparator|Clopidogrel|75mg Clopidogrel
3291597|NCT01757314||CA 1 and 2 anethesia residents|palpation technique
3291598|NCT01757314||Ca1 and 2 residents|ultrasound guided technique
3291599|NCT01757327|Experimental|Arm I (erismodegib [LDE225])|400 mg daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
3291600|NCT01757327|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO daily and treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
3291601|NCT01757340|No Intervention|Weight maintenance|Weight maintenance with normal protein and leucine intake
3291602|NCT01757340|Active Comparator|Weight loss with normal protein intake|
3291603|NCT01757340|Experimental|Weight loss with leucine supplementation|
3291604|NCT01757353|Active Comparator|Self-directed: Information only|Participants in this arm will complete a baseline assessment, followed by a 50-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students; BASICS) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
3291605|NCT01757353|Active Comparator|BASICS motivational interview|Participants in this arm will complete a baseline assessment, immediately after which they will be administered alcohol-related informational sheets. These participants will participate in follow-up assessment sessions at approximately 3 and 9 months.
3291606|NCT01757353|Experimental|BASICS plus normative enhancement motivational interview|Participants in this arm will complete a baseline assessment, followed by a 60-minute brief motivational interview (the Brief Alcohol Screening and Intervention for College Students, with a normative enhancement module) 10-14 days after the initial assessment. Participants in this arm will complete follow-up assessments at approximately 3 and 9 months.
3291607|NCT01757366|Experimental|experimental|Ginsenoside Rg3 plus First-line Chemotherapy
3291608|NCT01757366|Active Comparator|Active Comparator|First-line Chemotherapy
3291609|NCT01757379|Experimental|13C-labeled acetate|
3291610|NCT01757379|Experimental|13C-labeled propionate|
3291611|NCT01757379|Experimental|13C-labeled butyrate|
3291612|NCT01757379|Experimental|Inulin|
3291613|NCT01757418|Experimental|Immune Globulin Intravenous|IVIG used in the trial is the GAMUNEX brand, at doses up through 800 mg/kg in Phase 1 and at 400mg/kg in Phase 2.
3291614|NCT01757418|Placebo Comparator|Normal saline|An equivalent volume (weight-based)of normal saline
3291615|NCT01757431|Other|ECULIZUMAB|
3291616|NCT01757444|Experimental|BiPAP - A40|BiPAP with AVAPS AE mode
3291617|NCT01757444|Active Comparator|BiPAP- ST|Patients receiving BiPAP- ST at home
3291618|NCT01757457|Experimental|Intracoronary abciximab|Intracoronary administration of an abciximab bolus during primary PCI
3291619|NCT01757457|Active Comparator|Intravenous abciximab|Intravenous standard administration of an abciximab bolus during primary PCI
3291620|NCT01757470||Caprelsa Patient|All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.
3291621|NCT01757470||Caprelsa Prescriber|All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.
3291622|NCT01757483||Prescribers|
3291623|NCT01757496|Experimental|Cough Assist|These children will receive 2 Cough Assist sessions daily.
3291624|NCT01757496|No Intervention|Control group|These children receive standard care but no physiotherapy.
3291625|NCT01757509|Other|Intervention group|Participants in this group will receive a set dancing intervention along with their usual care.
3291626|NCT01757509|No Intervention|Control Group|The control group will continue with their usual medical regime, activities of daily living and exercise habits and at the end of the study participants in this group will be offered the set dancing intervention.
3291627|NCT01757522||ARDS group|Patients under mechanical ventilation since less than 24 hours at inclusion and presenting acute respiratory distress syndrome criteria.
3291628|NCT01757522||ALI group|Patients under mechanical ventilation and presenting acute lung injury criteria.
3291629|NCT01757522||Control Group|Patients under mechanical ventilation for a non-respiratory cause
3291630|NCT01757548|Experimental|open operation|high ligation of spermatic vein by open operation
3291631|NCT01757548|Experimental|microsurgery|high ligation of spermatic vein by microsurgery
3291632|NCT01757574|Experimental|Alemtuzumab|Open label study of alemtuzumab
3291633|NCT01757587|Active Comparator|Vildagliptin|
3291634|NCT01757587|Placebo Comparator|Placebo|
3291635|NCT01757600||Macular Hole|
3291636|NCT01757613|Active Comparator|AK 3012 a for topical use|
3291637|NCT01757613|Active Comparator|AK 3012 b for topical use|
3291638|NCT01757613|Active Comparator|AK 3012 c for topical use|
3291639|NCT01757626|Experimental|Hu3F8 with GM-CSF|The phase I single arm trial assesses escalating doses of iv hu3F8 (days 1, 3, 5) in the presence of sc GM-CSF (day -4 through 5). These 3 doses of hu3F8 and 10 days of GM-CSF constitute a treatment cycle. The expansion phase II single arm trial assesses the anti-NB activity of hu3F8+GM-CSF.in 3 groups of patients: Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123I-MIBG scan. Group 2 patients are in ≥2nd CR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123I-MIBG scan. Ph II: Groups 1 & 3 pts can continue to get cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved.
3291640|NCT01757626|Experimental|expansion phase II single arm trial|Group 1 patients have primary refractory disease (no prior relapse but incomplete response to treatment) in BM as documented by histology and/or 123^I-MIBG scan. Group 2 patients are in >2nd CR/VGPR and at high risk for another relapse. Group 3 patients have secondary refractory disease (prior relapse and incomplete response to retrieval therapy) in BM as documented by histology and/or 123^I-MIBG scan. GM-CSF can be omitted if patients have a history of an allergy to GM-CSF or develop an allergic reaction to GM-CSF after initiating therapy while on the protocol.
3291641|NCT01757639|Experimental|Treatment (ipilimumab)|"INDUCTION: Patients receive ipilimumab IV on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Beginning 12 weeks after last dose of induction ipilimumab, patients receive ipilimumab IV on day 1. Treatment repeats every 12 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity."
3291642|NCT01757730||Altered Stiffness|Tissue stiffness will be evaluated in subjects those with disease conditions where stiffness changes from normal. These studies will be repeated for reproducibility.
3291643|NCT01757730||Healthy Volunteers|Tissue stiffness will be evaluated in normal subjects to determine the normal values. These studies will be repeated for reproducibility.
3291644|NCT01757743||Interventional closure|Interventional catheterization closure
3291645|NCT01757743||Open Heart Surgery|Surgery for Atrial septal defect
3291646|NCT01757756|Experimental|Arm Label Pf-05175157, placebo, midazolam|
3291647|NCT01757769|Experimental|Silodosin|Silodosin capsule 8 mg daily for 24 weeks
3291648|NCT01757782|Active Comparator|Oral Sildenafil|In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
3291649|NCT01757782|Placebo Comparator|Distilled water|In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses.
3291650|NCT01757795|Experimental|SP-8203|Active arm
3291651|NCT01757795|Placebo Comparator|Placebo|Matching Placebo
3291652|NCT01757808|Experimental|Ranolazine|
3291653|NCT01757808|Placebo Comparator|Placebo|
3291654|NCT01757834|Experimental|SWUS Elastography|This is a noninvasive technique using focused ultrasonic beams (pushing beams.) Several pushing beams at increasing depths are transmitted to generate a quasi-plane shear wave frame that propagates throughout the imaging area. After generating the shear wave, an ultrafast imaging sequence is performed to acquire successive raw radiofrequency dots at a very high frame rate (up to 20,000 per second). A tissue elasticity assessment can be derived from shear wave propagation speed. A color-coded image is displayed; softer tissue in blue and stiffer tissue in red. Quantitative information is delivered by drawing regions of interest on the thyroid and surrounding tissues which is the Elasticity Index expressed in kilo-Pascal (kPa). Due to the lack of manual compression and known value of the strength of pushing beam, SWUS gives an objective number to stiffness within the nodule.
3291655|NCT01757860|Experimental|CARD-024|CARD-024 oral administered: 3, 9, 27 or 81 mcg.
3291656|NCT01757860|Placebo Comparator|Drug Carrier|Placebo: 20% ethanol:80% propylene glycol solution oral administered.
3291657|NCT01757873|Experimental|Z160|375 mg BID
3291658|NCT01757873|Placebo Comparator|Placebo|matching placebo control
3291659|NCT01757886||ST-elevation acute coronary syndrome|ARTERY is a prospective, multicenter, which will include patients admitted with the diagnosis of ST-elevation acute coronary syndrome and thrombus aspiration is performed during primary angioplasty
3291660|NCT01757899|Active Comparator|Methylprednisolone Arm|"The patients in this arm will receive methylprednisolone, which is available in vials containing 125 mg/2mL after dilution, as it follows:~Day 0 Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day"
3291661|NCT01757899|Placebo Comparator|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
3291662|NCT01757912|Experimental|Cuff pressure after positioning|The patient will be positioned in 16 distinct body positions. Immediately after correct positioning, the cuff pressure is measured.
3291663|NCT01757925|Experimental|Active Gaming|Participants will receivce a weight management program plus active gaming device
3291664|NCT01757925|Active Comparator|Control Group|Participants will receive a weight management program without active gaming
3291665|NCT01757938|Experimental|Shang Ring Guided Circumcision|The Shang Ring (SR) (Wuhu Santa Medical Devices Technology Co Ltd, China) male circumcision performed by study surgeon (study PI). In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine. The surgeon measured participants in the SR group to determine ring size. Patients for whom a suitable ring size was not available crossed over to the FG group, but remained in the SR group for intention to treat (ITT) analyses.
3291666|NCT01757938|Active Comparator|Forceps Guided Circumcision|Standard forceps guided adult male circumcision was performed. In both study groups, participants were cleaned with povidone iodine solution and draped in a sterile fashion. Local anesthesia was administered to the dorsal penile nerve and penile ring blocks using 3mg/kg of 1% lidocaine.
3291667|NCT01757951|Experimental|Unimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
3291668|NCT01757951|Active Comparator|Bimalleolar Fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
3291669|NCT01757977|Experimental|Vivasight DL|placement and intraoperative use of Vivasight DL double lumen endobronchial tube
3291670|NCT01757977|Active Comparator|standard DLT|placement and intraoperative use of a standard double lumen endotracheal tube.
3291671|NCT01757990|Experimental|Stevioside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Stevioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3291672|NCT01757990|Experimental|Rebauside extract|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the solution containing Rebaudioside extract. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3291673|NCT01757990|Sham Comparator|Saccarosio|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
3291674|NCT01758029||Testosterone Undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
3291675|NCT01758042|Other|Haploidentical Bone Marrow/Kidney|Single Arm Study
3291676|NCT01758055|Experimental|Autologous MSCs transplantation|intra bronchial injection, Autologous MSCs transplantation derived bone marrow, 60millions cells, once
3291677|NCT01758068|Experimental|Coconut Oil Application|The oil (coconut oil) was applied by the trained nurse to the entire body surface of infant except the face two times a day started as early as possible Four ml of coconut oil was applied using both hands of the caregiver in four strokes starting from the level of clavicles over the chest and abdomen till the groin, from the front of thighs, knee, leg and upto the sole, from above the shoulders over the arm and forearm till the palm continuing medially over the forearm and arm till the axilla and the final stroke was used for the back reaching over the back of the thighs till the heel. Just prior to the first application, and thereafter prior to the subsequent applications the TEWL was recorded using the portable closed chamber evaporimeter. The oil application was continued twice daily (every 12 hrs at the same time as the hour of birth e.g. 11 am and 11pm) till the completion of the seventh day (168 hrs of life)..
3291678|NCT01758068|No Intervention|No Oil Application|Babies in this group were not subjected to oil application. TEWL measurement was recorded every 12 hrs for the first week of life, at the same time as the hour of birth.
3291679|NCT01758081|Active Comparator|vitamin D + fish oil|vitamin D3 + Omacor
3291680|NCT01758081|Active Comparator|vitamin D + fish oil placebo|vitamin D3 + fish oil placebo
3291681|NCT01758081|Active Comparator|vitamin D placebo + fish oil|vitamin D placebo + Omacor
3291682|NCT01758081|Placebo Comparator|vitamin D placebo + fish oil placebo|vitamin D placebo + fish oil placebo
3291683|NCT01758094||Hypogonadotropic hypogonadism patients|Treatment naive 25 patients with idiopathic hypogonadotrophic hypogonadism
3291684|NCT01758107|Experimental|Sirolimus with Prednisolone|Sirolimus with Prednisolone, and withdraw cyclosporine
3291685|NCT01758107|No Intervention|Sirolimus with Cyclosporine with Prednisolone|
3291686|NCT01758120|Experimental|prednisone plus cyclophosphamide|prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months)
3291687|NCT01758120|Experimental|prednisone alone|prednisone alone: prednisone(0.5mg/kg/day*6 months)
3291688|NCT01758133||Mothers exposed to medical clowns|Mothers of premature infants who have been exposed to medical clown activities
3291689|NCT01758133||Mothers not exposed to medical clown activity|
3291690|NCT01758146|Experimental|Arm A- Letrozole|Aromatase inhibitor- letrozole 2.5mg once daily for 5 years
3291691|NCT01758146|Active Comparator|Arm B- Tamoxifen|Tamoxifen 20 mg once daily for 5 years
3291692|NCT01758159|Experimental|CFR group|The children in this group will receive complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
3291693|NCT01758159|Experimental|Fe group|The children in this group will receive iron supplementation 2mg/kg/day of ferric Na EDTA (in the form of syrup) daily for 24 weeks duration.
3291694|NCT01758159|Experimental|CFR + Fe group|The children in this group will receive both local food-based complementary feeding according to CFR and Iron supplementation for 24 weeks duration
3291695|NCT01758159|Placebo Comparator|Control group|The children in this group will receive basic health services and placebo syrup.
3291696|NCT01758172|Active Comparator|Albumin|albumin was administered to reach CVP up to 7mmHg
3291697|NCT01758172|Experimental|6% hydroxyethyl starch 130/0.4|6% hydroxyethyl starch 130/0.4 was administered to reach CVP up to 7mmHg
3291698|NCT01758185|Placebo Comparator|recombinant hepatitis b vaccine|0.5ml intramuscular
3291699|NCT01758185|Experimental|Aleph influenza vaccine|0.5ml intramuscular
3291700|NCT01758198|Experimental|Group 1: Abatacept + Methotrexate (MTX)|"Abatacept 10 mg/kg solution intravenous (IV) infusion, once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
3291701|NCT01758198|Placebo Comparator|Group 2: Placebo matching with Abatacept + Methotrexate|"Placebo matching with Abatacept 0 mg/kg solution, intravenous (IV) infusion once monthly for 12 months~Methotrexate ≥6 mg/week for 12 months"
3291702|NCT01758211|Experimental|fMRI guided resection of AVM|fMRI Navigation AVM resection in AVM patients
3291703|NCT01758211|Active Comparator|conventional AVM resection|conventional resection of AVM
3291704|NCT01758224|Experimental|Functional Magnetic Stimulation|This group will receive magnetic stimulation of the respiratory (breathing) muscles that may improve the breathing function in subjects with MS. The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes).
3291705|NCT01758224|Active Comparator|Resistive Expiratory Muscle Training|Participants in this group will perform breathing exercises using a resistive breathing device. The training will take place in the FMS lab. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home.
3291706|NCT01758237|Experimental|Superior Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the superior aspect of the iris in the eye being treated. This will be in the 11 to 1 o'clock position.
3291707|NCT01758237|Experimental|Temporal Laser Peripheral Iridotomy|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser peripheral iridotomy was performed on the temporal aspect of the iris in the eye being treated. The position will be in the 2 to 4 o'clock in the left eye and 8 to 10 o'clock in the right eye.
3291708|NCT01758250||Systemic Sclerosis|Patients with SSc will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
3291709|NCT01758250||GVHD|Patients with GVHD will have imaging studies performed at baseline and at 3, 6, 9, 12, 18 and 24 months.
3291710|NCT01758250||Undergoing HSCT|Patients who are about to undergo HSCT will have imaging studies performed at 1 week pre-transplantation, day 40 and 80 post transplantation and at 3 months, 6 months, 12 months 18 months and 24 months post-transplant.
3291711|NCT01758250||Controls|Healthy Controls and Controls with hematologic and solid organ malignancies and dermatitis will have imaging studies performed at a single point in time.
3291712|NCT01758250||Sickle cell disease|Patients with SCD will have imaging studies performed at baseline and at 3, 6, 9, 12, 15, 18, 21 and 24 months.
3291713|NCT01758250||Cutaneous fibrosing disorder|Patients with active cutaneous fibrosing disorder will have imaging studies performed at a single point in time.
3291714|NCT01758263||Metoprolol to Nebivolol|Patients with high blood pressure (hypertension) who were continuously treated with metoprolol for a minimum of 6 months prior to switching to nebivolol. Patients were then continuously treated with nebivolol for a minimum of 6 months.
3291715|NCT01758276||Non smokers|Women who did not report smoking in pregnancy
3291716|NCT01758276||Smokers in pregnancy|Women who report smoking in pregnancy
3291717|NCT01758302|Active Comparator|No physical task + Taste cookies|Participants in this arm do not engage in a physical activity task. They are asked to taste test chocolate chip cookies.
3291718|NCT01758302|Active Comparator|No physical task + Taste vegetable|Participant does not complete a physical activity. Asked to taste test raw celery or radishes.
3291719|NCT01758302|Active Comparator|Simple physical task + Taste vegetables|Participants are asked to complete a simple physical task and are asked to taste test raw celery or radishes.
3291720|NCT01758302|Active Comparator|Complex physical task + Taste vegetables|Participants complete a more complex physical task that is novel and challenging. They are asked to taste test raw celery or radishes.
3291721|NCT01758315|Experimental|Improvement Sessions|We will implement a context-sensitive collaborative improvement model that will emphasize training and in-office coaching by quality improvement, efficiency and safety experts, as well as shared learning methods to develop, test and implement changes in the following four key risk areas: medication management; test and lab results management; follow-up and referral management; and communication - within and between practices as well as with patients.
3291722|NCT01758315|No Intervention|Control|Control practices will not receive training or in-office coaching.
3291723|NCT01758328|Experimental|Pts with Mutiple myeloma|Patients will undergo a preparative regimen with busulfan, melphalan, fludarabine, and anti-thymocyte globulin (ATG), and a T cell depleted stem cell transplant from a histocompatible related or unrelated donor. Hematopoietic stem cell donors for this trial will include individuals who are 10/10 HLA matched or one antigen or allele mismatched at the HLA-A, B, C, DRB1 or DQB1 locus, as defined by high resolution methods .Donors who are 8/10 HLA matched with an antigen or allele mismatched at HLA-DQB1 and at one other locus will also be eligible for the trial. The administration of WT1-specific cytotoxic T cells (WT1 CTLs) post transplantation is integrated to induce complete remissions in patients with residual disease and to decrease the rate of relapse following the allogeneic transplant.
3291724|NCT01758341|Experimental|Malignant biliary obstruction|All patients who underwent endoscopic radiofrequency ablation with the HabibTM EndoHBP as a treatment for malignant biliary obstruction in Austria between November 2010 and December 2012.
3291725|NCT01758354|Experimental|Pompe disease newborn screening|newborns will be tested if they were affected by Pompe disease
3291726|NCT01758367|Experimental|Decitabine+DLI|Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.
3291727|NCT01758380|Experimental|Vildagliptin + placebo to Gliclazide|Vildagliptin tablets will be given at 50mg twice daily (bid). Placebo to Gliclazide capsules will be given at an equivalent dose to previous sulfonylurea in multiples of 80mg only (80-320 mg/day). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
3291728|NCT01758380|Active Comparator|Gliclazide + placebo to Vildagliptin|Gliclazide capsules will be given in multiples of 80 mg (80-320 mg/day) at a dose equivalent to previous sulfonylurea dose, unless at the investigator's discretion it could be up-titrated to the next available dose (if HbA1c is higher than 7.5%). Placebo to Vildagliptin tablets will be given at 50mg twice daily (bid). Patients will continue their open-label metformin therapy at dosage between 1500-2500 mg daily.
3291729|NCT01758393|Experimental|Medium Dose|Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
3291730|NCT01758393|Experimental|High Dose|Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.
3291731|NCT01758406|Experimental|cardiac stem cell transplantation|The patients with heart failure that underwent cardiac stem cell transplantation.
3291732|NCT01758406|Placebo Comparator|Placebo|The patients with heart failure that underwent placebo injection.
3291733|NCT01758419||Tomotherapy|Breast cancer female s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT. Comparing the clinical follow-up data between different groups (left-sided s/p tomography, left-sided s/p conventional RT, and right-sided RT), respectively.
3291734|NCT01758445|Experimental|Proton Radiotherapy|Proton Radiotherapy
3291735|NCT01758458|Experimental|Treatment (autologous T cells and aldesleukin)|"Patients undergo radiation therapy or recombinant interferon beta intralesional injection within day -3 to day -1.~Patients receive MCPyV TAg-specific polyclonal autologous CD8-positive T cell infusion IV on day 1 and aldesleukin SC every 12 hours on days 1-14. Treatment repeats at least every 28 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~Patients with continued presence of detectable metastatic disease 8 weeks after the first infusion may repeat the treatment regimen including radiation therapy or recombinant interferon beta injection."
3291736|NCT01758471|Experimental|Acarbose|The minimum dosage of acarbose in this study is 100mg tid p.o.(oral) for 3 month. With this dosage, patients should have similar glycemic control with those using glipizide, that is FBG(fasting blood glucose)<7.0,PBG(postprandial blood glucose)<10.0
3291737|NCT01758471|Active Comparator|glipizide|There is no fixed dosage of glipizide to control hyperglycemia for patients in this group. As long as the targeted blood glucose concentration is reached, FBG< 7.0, PBG< 10.0, patients will have the least dosage of glipizide according to their glucose level.
3291738|NCT01758484|Experimental|Supportive care (palliative care support)|Patients undergo palliative care support before transplantation and at least once monthly while they remain at the transplant center.
3291739|NCT01758497|Active Comparator|Ropivacaine|US guided injections of 30 ml 0.5% ropivacaine (Fascia Iliaca Compartment Block)
3291740|NCT01758497|Sham Comparator|Saline|US guided injections of 30 ml 0.9% NaCl (Fascia Iliaca Compartment Block)
3291741|NCT01758510|Experimental|HYNR-CS-Allo|HYNR-CS-Allo inj. 2 times by intrathecal administration with 28 days interval.
3291742|NCT01758536|Placebo Comparator|Placebo Pills|"12 g each time, twice daily.~3 months"
3379487|NCT05162911|Active Comparator|AAA+Counsel+N (Nicotine gum).|Patients will receive Ask, Advise, Assist, plus referral to onsite counselor and nicotine gum.
3291743|NCT01758536|Experimental|Huatuo Zaizao Pills|"12 g each time, twice daily.~3 months."
3291744|NCT01758549|Experimental|Aggressive Intravenous Hydration Group|Patients randomized to the aggressive intravenous hydration group receive lactated ringers (LR) IV at 3 mL kg-1 hr-1 during the procedure, a 20cc/kg LR IV bolus immediately afterward, and LR IV at 3 mL kg-1 hr-1 for 8 hours following the procedure.
3291745|NCT01758549|Active Comparator|Standard Fluids Arm|Those in the control arm receive standard fluids defined as LR at 1.5 mL kg-1 hr-1 during the procedure and for 8 hours afterwards.
3291746|NCT01758562|No Intervention|State-of-the-art mouth care|
3291747|NCT01758562|Active Comparator|Mouth rinse Caphosol|Mouth rinse,aqueous solution. Caphosol is a preparation comprising two separately packaged aqueous solutions, a phosphate solution and a calcium solution, which, when both solutions are combined in equal volumes, forms a solution supersaturated with respect to both calcium and phosphate ions.
3291748|NCT01758575||antiangiogenic tyrosine kinase inhibitors|Sunitinib: 50 mg orally once daily Sorafenib: 400 mg orally twice daily Pazopanib: 800 mg orally once daily
3291749|NCT01758575||EGFR inhibitors|Cetuximab 250 mg/m2 intravenously, weekly Panitumumab 6 mg/Kg intravenously, every 2 weeks
3291750|NCT01758575||mTOR inhibitors|Everolimus 10 mg orally once daily
3291751|NCT01758575||BRAF inhibitor|Vemurafenib 960 mg orally twice daily
3291752|NCT01758575||anti-CTL4 antibody|Ipilimumab 3 mg/kg intravenously, every 3 weeks
3291753|NCT01758601|Experimental|Fish - no fish|The individuals randomized to this arm continued with their previous alimentary habits, avoiding any significant nutritional imbalance, and with an ingestion of 7 serves of hake (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain) per week for a period of 8 weeks. Then switched to previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood.
3291754|NCT01758601|Active Comparator|No fish - fish|Patients were on previous diet except for the avoidance of fish and any other seafood for 8 weeks. Afterwards they were changed to the same diet but with 7 serves of hake per week.
3291755|NCT01758627|No Intervention|Peritoneal dialysis group|
3291756|NCT01758627|Experimental|Conventional treatment group|medical treatment such as diuretics
3291757|NCT01758640|Active Comparator|Pregnant|Group of Pregnant patients who will receive either warfarin or phenindione according to the study design
3291758|NCT01758640|Active Comparator|Non Pregnant|Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design
3291759|NCT01758653||Biorepository|Patients with acute CO poisoning. Blood collection for biorepository only, no study intervention.
3291760|NCT01758666|Experimental|Methotrexate and Calcium folinate|
3291761|NCT01758679|Experimental|Licartin，Licartin and CIK|Intravenous Licartin 27.75 M Bq(0.75 mCi)/kg Licartin and CIK
3291762|NCT01758692||Able-bodied Controls|"10 controls between the ages of 18 and 65 of either gender; free of cardiovascular disease and/or medication.~An addition 40 controls ages 18-89 of either gender, will perform the non-invasive manipulations only."
3291763|NCT01758692||Spinal Cord Injury|"40 subjects to perform the pharmacological and non-invasive manipulations; between the ages of 18 and 65 years old in stable health for the last 6 months, non-smoker, and level of injury from C1 - S4 for over 1 year and an AIS classification of A, B, C. Free of arrhythmia, hypertension, cardiovascular disease, kidney disease, diabetes, neuropathies, neuromuscular disease, and sulfite allergies or hypersensitivity.~60 subjects to perform the non-invasive manipulations only; between 18-89 years of age in stable condition (>6 months), non-smoker. Level of injury from C1-S4 for over a year with a AIS classification of A, B, or C. No history of diabetes, autonomic neuropathy, parkinson's disease, or acute illness or infection. An additional 30 will perform the non-invasive testing before and after completion of an ambulatory training protocol."
3291764|NCT01758705||Cohort 1|Cohort 1
3291765|NCT01758718|Active Comparator|Entropion with Down's syndrome|Eyelash resection surgery was performed for entropion with Down's syndrome
3291766|NCT01758744|Experimental|Treprostinil|Inhaled prostanoid therapy with Treprostinil
3291767|NCT01758757|Active Comparator|Proliferative diabetic retinopathy|
3291768|NCT01758783|Placebo Comparator|placebo group|
3291769|NCT01758783|Experimental|Glutamine group|
3291770|NCT01758809|Active Comparator|Bupivacaine|
3291771|NCT01758809|Other|Intravenous Patient Controlled Analgesia|postoperative pain control with intravenous patient controlled analgesia
3291772|NCT01758822|Experimental|No Endotracheal suction|In the experimental group, endotracheal suction will not be performed during the initial steps of resuscitation of non-vigorous meconium stained neonate
3291773|NCT01758822|No Intervention|Endotracheal suction|In the No intervention group endotracheal suction will be performed during the initial steps of resuscitation of non - vigorous meconium stained neonate
3291774|NCT01758835|Active Comparator|Splint 3 weeks|Removable ankle brace/splint
3291775|NCT01758835|Active Comparator|Cast 3 weeks|Below-the-knee cast (glass fiber)
3291776|NCT01758835|Active Comparator|Cast 6 weeks|Below-the-knee cast (glass fiber)
3291777|NCT01758861|Experimental|EPO group|EPO group received 300 IU/kg of rHuEPO-alpha via intravenous bolus administration after induction of anesthesia.
3291778|NCT01758861|Placebo Comparator|Placebo group|Placebo group received normal saline via intravenous bolus administration after induction of anesthesia.
3291779|NCT01758874|No Intervention|Non phlebotomy group (control group)|"• This control group is the patients who had Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss. They were treated with conventional standard treatment including revascularization operative procedure if feasible, maximum medical treatment with anticoagulation (heparin, low molecular weight heparin, etc), acetylsalicylic acid, cilostazol, and prostaglandin E1, dextran, and pain analgesia with opioid, and finally major amputation.~We records all control arms' amputation, day to amputation, mortality, etc. We will compare amputation and mortality between control and treatment groups.~Non phlebotomy arm has no phlebotomy treatment."
3291780|NCT01758874|Experimental|PH (study group)|"The patients will be pre-amputation and have Rutherford classification Grade 3, Category 5 or 6 (Fontaine stage IV) treatment-resistant chronic critical limb ischemia having tissue loss.~Procedures for therapeutic phlebotomy~Inject heparin 5000 units to prevent blood clot during phlebotomy~Inject volume expander equivalent to 5% of blood volume~Remove 5% of whole blood~Monitor the vital sign of the patient during the phlebotomy~They were treated both phlebotomy and conventional standard management including surgery, medication, amputation, etc.~We will compare amputation and mortality between control and study groups."
3291781|NCT01758887||Controls|Healthy control
3291782|NCT01758887||patients|clinical high risk subjects for psychosis
3291783|NCT01758913|Experimental|Ibuprofen|Infant who was assigned to ibuprofen, an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours respectively as a course was given.
3291784|NCT01758926||Inflammatory bowel disease|Patients previously diagnosed as having IBD
3291785|NCT01758926||Health control|Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
3291786|NCT01758939||Hepatitis C virus infected patients|
3291787|NCT01758952||Beijing Chaoyang Hospital|2000 cases
3291788|NCT01758952||Peking University Hospital|2000 cases
3291789|NCT01758952||Zhongshan Hospital of Fudan University|2000 cases
3291790|NCT01758952||Tongji Hospital, Wuhan|2000 cases
3291791|NCT01758952||Tangdu Hospital, Xi'an|2000 cases
3291792|NCT01758952||The Prince Welsh Hospital|1000 cases
3291793|NCT01758965|Experimental|combination therapy of H2RA and surgicel|H2RA and surgicel
3291794|NCT01758965|Experimental|Monotherapy of PPI|PPI
3291795|NCT01758978|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test)."
3291796|NCT01758978|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 60-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 30-mg hydrocodone bitartrate extended-release tablets (reference)."
3291797|NCT01758991|Active Comparator|real tDCS|"patients will receive non-invasive and painless brain stimulation over the rain areas involved in swallowing.~tDCS will be applied during swallowing therapy, during 20 minutes"
3291798|NCT01758991|Placebo Comparator|sham tDCS|"this will be exactly as for real tDCS unless that the tDCS will be rapidly turned off, unbeknown from patients-therapist-examinator (double-blind trial)"
3291799|NCT01759004|Active Comparator|patient with lipoedema|"Lipedema group:~diagnosed with lipedema following the criteria of Wold~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
3291800|NCT01759004|Active Comparator|patients with obesity|"Obesity group:~BMI ≥ 30~women~age ≥ 18 years~clinimetrics: volume, muscle strength, physical condition, BMI"
3291801|NCT01759017||Infliximab responders|Gastroenterologist's overall assessment (response) Decrease in Harvey-Bradshaw index score of 2 or more points (clinical response) Harvey-Bradshaw index score less than 5 (clinical remission) Maintenance of steroid-free remission No Crohn's-related hospitalizations or surgeries
3291802|NCT01759017||Infliximab non-responders|Gastroenterologist's overall assessment (no response) Decrease in Harvey-Bradshaw index score of 1 or 0 points, or increase in HBI (no response) Harvey-Bradshaw index score greater than or equal to 5 (no remission) Resumption of steroid treatment Crohn's-related hospitalization or surgery
3291803|NCT01759030|Active Comparator|MabThera (F. Hoffmann-La Roche Ltd.)|"Stage 1 (week 1 - week 24) MabThera will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24 - 48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves BCD-020 at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15); if he/she if he/she randomised into group B then he/she continues to recieve MabThera at a dose f 1000 mg, IV, once in 2 weeks, 2 infusions per course (on day 1 and day 15).~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
3291804|NCT01759030|Experimental|BCD-020 (CJSC BIOCAD)|"Stage 1 (week 1-week 24) BCD-020 will be administered at a dose of 1000 mg, IV (on day 1 and day 15).~Stage 2 (week 24-48) If the disease activity remains on Week 24 the patient will undergo the second randomization (1:1 ratio): if he/she randomised into group A then he/she recieves MabThera at a dose f 1000 mg, IV, on day 1 and day 15; if he/she if he/she randomised into group B then he/she continues to recieve BCD-020 at a dose f 1000 mg, IV, on day 1 and day 15.~MabThera/BCD-020 will be used in combination with methotrexate (irrespectively to study stage)."
3291805|NCT01759043|Experimental|guiding catheter|a single transradial guiding catheter for coronary angiography and intervention in patients with STEMI
3291806|NCT01759043|Active Comparator|Diagnostic catheter|Diagnostic catheter followed by guiding catheter selection for transradial primary PCI
3291807|NCT01759056|Active Comparator|AVX 470|AVX 470 0.2 g(Cohort 1), 1.6 g (Cohort 2) and 3.5 g (Cohort 3) will be administered daily for 28 days
3291808|NCT01759056|Placebo Comparator|Placebo|Placebo will be administered daily for 28 days as a comparator with AVX-470 (all dose groups)
3291809|NCT01759069|Experimental|treatment with microscope|treatment with microscope
3291810|NCT01759069|Experimental|treatment without microscope|treatment without microscope
3291811|NCT01759095|No Intervention|Control|At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
3291812|NCT01759095|Experimental|Electronic Multidrug Blister Pack|
3291813|NCT01759108|Experimental|Rebamipide|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of rebamipide for 12 weeks together with their usual therapy
3291814|NCT01759108|Placebo Comparator|Placebo|Patients will be randomized 1:1 to receive 300mg/d (100mg x3/day) of placebo for 12 weeks together with their usual therapy.
3291815|NCT01759121|Active Comparator|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
3291816|NCT01759121|Experimental|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
3291817|NCT01759134|Experimental|Post Discharge Formula|Babies will be given formula for first three months post discharge
3291818|NCT01759147|Experimental|Surgery|Surgical repair of acromioclavicular dislocation.
3291819|NCT01759173||college athletes|
3291820|NCT01759186||None interventional|
3291821|NCT01759199|Experimental|The six minute Stepper Test|Experimental : The six minute Stepper Test with a Conventional respiratory rehabilitation
3291822|NCT01759212|Experimental|Stem cells implantation|Patients with end-stage heart failure due to ischemic cardiomyopathy will undergo combined cellular and mechanical support with implantation of off-the-shelf allogeneic mesenchymal stem cells and left ventricular assist device.
3291823|NCT01759225||Cardiovascular Disease Patients|
3291824|NCT01759238|Experimental|Chemoradiation|Chemoradiation with different radiotherapy regimes (depending on location and size of irradiated lesions; e.g. conventional radiotherapy with a total dose of 35 Gy, delivered in 2.5Gy fractions for 14 days or intensity-modulated and image-guided radiotherapy with a total dose of 40 Gy, delivered in 4.0 Gy fractions for 10 days or 3-8 fractions with 8-15 Gy) combined with bevacizumab (7.5mg/kg day 1) and capecitabine (825mg/m2 bid on day 1-5, 8-12 and 15-19)
3291825|NCT01759303|Experimental|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
3291826|NCT01759316|Active Comparator|heliox|Heliox is use in this group
3291827|NCT01759316|Placebo Comparator|Placebo|Oxygen is used in this group
3291828|NCT01759329|Experimental|test coffee|test coffee
3291829|NCT01759329|Active Comparator|control coffee|control coffee
3291830|NCT01759342|Experimental|Comprehensive exercise program|Moderate to high intensity aerobic, resistance, flexibility, posture and balance exercise program
3291831|NCT01759342|Active Comparator|Usual care exercise|30 minutes/day of self selected mode and intensity of aerobic exercise
3291832|NCT01759355||Surgery|Participants undergoing surgical intervention will receive a PET/MR scan prior and following surgery for a total of two (2) scans.
3291833|NCT01759355||Chemoradiation|Participants undergoing chemoradiation intervention will receive a PET/MR scan prior, during, and following chemoradiation for a total of three (3) scans.
3291834|NCT01759394|Experimental|Avatrombopag maleate 40 mg|
3291835|NCT01759459|Experimental|Lidocaine|1% Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm
3291836|NCT01759459|Experimental|Buffered Lidocaine|"1% Buffered Lidocaine for injection, 0.50 mL administered one time intradermally in peripheral forearm~Buffered lidocaine is compounded by the following process:~2.3 mLs of 8.4% sodium bicarbonate is added to a vial of 1% lidocaine"
3291837|NCT01759459|Experimental|Bacteriostatic Normal Saline|Bacteriostatic Normal Saline for injection, 0.50 mL administered one time intradermally in peripheral forearm
3291838|NCT01759472||montelukast，vitamin C pill|leukotriene receptor antagonist:(montelukast)，montelukast (10 mg, once per night)，56 days vitamin C pill:100mg，once per night，56 days
3291839|NCT01759472||montelukast, vitamin C pill|montelukast:10 mg, once per night，56 days vitamin C pill:100mg，once per night，56 days
3291840|NCT01759485|Active Comparator|Vitamin D|Supplementation of Vitamin D as add-on to the regular anti-psychotic treatment
3291841|NCT01759485|Placebo Comparator|Placebo|Placebo as oral drops once weekly as add-on to the regular anti-psychotic treatment
3291842|NCT01759498|Experimental|HYDRO 2|Subjects in the second experimental group will follow the procedures of first experimental group with additional administration of hydrogen-rick packs 6 times per day for 20 minutes throughout the study.
3291843|NCT01759498|Active Comparator|ACTIVE|During the period of 2 weeks subjects will receive traditional treatment protocol after the soft-tissue injury, consisting of RICE protocol during the first 48 h (e.g. rest, ice packs for 20 minutes every 2 hours, compression with elastic bandage, elevation of the injured area above the level of the heart at all possible times) and sub-acute protocol thereafter (e.g. passive stretching 3 times per day for 90 sec, isometric strength exercise with 3 sets with 15 repetitions, 30 min of pain-free weight-bearing exercise).
3291844|NCT01759498|Experimental|HYDRO|Subjects in the first experimental group will follow the PLA procedures with additional administration of oral hydrogen-rich capsules (4 capsules three times per day) throughout the study.
3291845|NCT01759524|Experimental|Group L|40 mls of 2% lidocaine + 1.5 mcg/kg will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
3291846|NCT01759524|Active Comparator|Group B|40 mls of 0.5% bupivacaine will be drawn up by an attending anaesthetist to blind the operator. Patients in this group will receive an ultra sound guided sciatic nerve block , 3 cm proximal to the nerve bifurcation, with 25 mls of the above mentioned solution and an ultra sound guided saphenous nerve block in the midthigh just lateral to the profunda femoris artery with 15 mls of the above mentioned solution.
3291847|NCT01759537|Experimental|Implants placed at sub-crestal position.|Ankylos dental endosseous implants-sub-crestal
3291848|NCT01759537|Active Comparator|Epi-crestal implants.|Ankylos dental endosseous implants-Epi-crestal
3291849|NCT01759550||LigaSure Device|In this prospective observational study, 60 patients scheduled to undergo a Roux-en-Y or gastric reduction procedure (sleeve gastrectomy or plication) will have hemostasis controlled with LigaSure Advance ™ Pistol Grip or LigaSure™ Blunt Tip, respectively. Both devices are regularly used at Duke in the Bariatric Surgery division. The surgeon will select which device is used. There will be no randomization. The device decision tree will be based upon the procedure. Cases that require enterotomy will utilize the AdvanceTM pistol grip. Cases which don't need enterotomy will utilize the 5 Blunt Tip. The LigaSure AdvanceTM pistol grip and LigaSureTM Blunt Tip are used exclusively with the Force TriadTM Energy platform. There is no simultaneous use.
3291850|NCT01759563|Other|single arm study|
3291851|NCT01759576|Experimental|Group 1 (normal kidney function)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3291852|NCT01759576|Experimental|Group 2 (mild kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3291853|NCT01759576|Experimental|Group 3 (moderate kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3291854|NCT01759576|Experimental|Group 4 (severe kidney impairment)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1
3291855|NCT01759576|Experimental|Group 5 (hemodialysis)|Each volunteer will receive a single dose of canagliflozin (JNJ-28431754) on Day 1 following completion of hemodialysis. Approximately 10 days later, each volunteer will receive another single dose of canagliflozin before hemodialysis begins.
3291856|NCT01759589|Placebo Comparator|propofol (Group P)|The patients in Group P received 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
3291857|NCT01759589|Active Comparator|remifentanil and propofol (Group R)|Patients in Group R received remifentanil 1 µg/kg IV (over 60 sec) and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
3291858|NCT01759589|Active Comparator|sevoflurane (Group S)|In Group S, sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered, at which time it was stopped.
3291859|NCT01759615|Experimental|Early enteral feeding|Early enteral feeding group received minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours followed by regular feeding with feed increments of 20ml/kg/day to reach 150 ml/kg.
3291860|NCT01759615|Active Comparator|Late enteral feeding|Late enteral feeding group was kept NPO for a period of 48 hours followed by minimal enteral feed (MEF) of 8 ml/kg of expressed human milk of the biologic mother for 48 hours and thereafter received regular feeding with feed increments of 20ml/kg/day till full enteral feeds of 150 ml/kg/day were achieved
3291861|NCT01759628|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3291862|NCT01759628|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity
3291863|NCT01759641||Hypotension-prone patients|The study group included all patients treated with standard HD prone to acute intradialytic hypotension.
3291864|NCT01759654|Experimental|AdimFlu-V|
3291865|NCT01759667|Experimental|A standard mixed Meal|The standard mixed meal was composed of a chicken salad sandwich and 200ml of coconut water, totalling 260 kcal, distributed among carbohydrates (62%), proteins (12%) and lipids (26%).
3291866|NCT01759680|Experimental|Whole Body Vibration Group|The whole body vibration group received 3 training sessions every week composed of 5 series of 15 seconds of vibrations at 30 Hz intensity.
3291867|NCT01759680|No Intervention|Control Group|The control group had a normal daily life for the whole study period
3291868|NCT01759693||Skin disease|Patients with urticaria or atopic dermatitis
3291869|NCT01759693||Control|Healthy volunteers
3291870|NCT01759706|Experimental|Enhanced Recovery After Surgery (ERAS)|Patients treated with enhanced recovery after surgery protocol: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia with naropin + sufentanil, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV prophylaxis with ondansetron + dexamethasone, hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, postoperative mobilization program, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
3291871|NCT01759706|Active Comparator|Standard perioperative care (Control)|Patients treated with standard care perioperative protocol: epidural analgesia with naropin + sufentanil, pre-anesthetic medication with diazepam, Preoperative bowel preparation with sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
3291872|NCT01759719||PtCr stent PCI treated patients|patients treated with PCI in whichat least 1 PtCr stent was used
3291873|NCT01759732|Experimental|HAPLO|
3291874|NCT01759745||Blepharospasm|Blepharospasm, patient's group
3291875|NCT01759745||Control|Healthy control subjects
3291876|NCT01759758|Active Comparator|Plaster Ulnar Gutter Splint|Patients will have their hand placed in a conventional Plaster ulnar gutter splint. This immobilizes all joints of the ring and small fingers and the wrist
3291877|NCT01759758|Experimental|Thermoplastic Splint|Patients will be fitted with a custom molded thermoplastic splint that stabilizes the metacarpals of the injured hand but does not immobilize any joints
3291878|NCT01759771|Experimental|Arm 1|4,000 IU of VD3 for one year
3291879|NCT01759771|Placebo Comparator|Arm 2|placebo for one year
3291880|NCT01759784|Experimental|stem cell recipient|The patients who underwent mesenchymal stem cell transplantation.
3291881|NCT01759797|Experimental|stem cell reciepient|the patients with ALS who underwent intravenous injection of mesenchymal stem cell.
3291882|NCT01759810|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3291883|NCT01759810|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3291884|NCT01759823|Experimental|mesenchymal stem cell transplantation|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
3291885|NCT01759823|Sham Comparator|Control|vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1
3291886|NCT01759823|Experimental|MNC's TRANSPLANTATION|Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.
3291887|NCT01759836|Experimental|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
3291888|NCT01759836|Placebo Comparator|Placebo|Placebo daily for 1 year
3291889|NCT01759849||Allergen challenge|Determination of the effects of a β-chain monoclonal antibody (MAb) on the function of cells naturally activated by in vivo allergen exposure, from donors with allergen-induced asthma
3291890|NCT01759875|Active Comparator|Ritonavir-boosted Atazanavir|
3291891|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole|
3291892|NCT01759875|Experimental|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine HCl|
3291893|NCT01759888|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 60 PD patients, including 20 LRRK2 G2385R, 20 PARK6, and 20 idiopathic PD. Subjects will be evaluated sequentially with 18F-DTBZ during a 36 month period. 18F-DTBZ PET scans will be performed twice, at baseline, and 24 (21~27) months following the start of their participation in the study.
3291894|NCT01759901|Experimental|Pringle|Intermittent vascular inflow occlusion applied during liver resection
3291895|NCT01759901|No Intervention|Non-Pringle|No vascular inflow occlusion applied during liver resection
3291896|NCT01759914||Potent topical steroid-treated|Patients treated with potent topical steroids
3291897|NCT01759914||Superpotent topical steroid-treated|Patients treated with superpotent topical steroids
3291898|NCT01759927|No Intervention|Control condition|Physically inactive employees are measured on anthropometrics, fitness and psycho-social variables.
3291899|NCT01759927|Experimental|Physical Activity Coaching|Physically inactive employees receiving a 12-week behavioural support intervention grounded in self-determination theory.
3291900|NCT01759940|Experimental|ropivacaine 0,375%|In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
3291901|NCT01759940|Active Comparator|ropivacaine 0,75%|In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
3291902|NCT01759953|Active Comparator|InsuOnline game|Playing the InsuOnline game, on the web, in the player´s own time and rhythm, until its end, as already described previously.
3291903|NCT01759953|Active Comparator|Traditional CME|Traditional learning session as used for Continuing Medical Education, on insulin therapy, including a short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
3291904|NCT01759966||Heart transplant recipients|Patients receiving orthotopic heart transplant in the enrollment period
3291905|NCT01759966||Healthy controls|Healthy control subjects, having the same age and sex distribution as the heart transplant recipients
3291906|NCT01759979|Experimental|Laser and mechanical lithotripsy|Bile duct stones with be treated with cholangioscopy guided laser therapy in addition to mechanical basket and balloon techniques.
3291907|NCT01759979|Active Comparator|Mechanical lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloon for removal of large stones.
3291908|NCT01759992|No Intervention|Control group|Usual care
3291909|NCT01759992|Experimental|Treatment group|Participants will breathe against a load ≥ 50% of their baseline MIP, after which loads will increase according to the participant's tolerance across the remaining training period, using a Borg scale rating of 4 to 6 on perceived exertion as an indicator of adequate training intensity.
3291910|NCT01760005|Experimental|Gantenerumab|
3291911|NCT01760005|Experimental|Solanezumab|
3291912|NCT01760005|Placebo Comparator|Matching placebo (Gantenerumab)|
3291913|NCT01760005|Placebo Comparator|Matching Placebo (Solanezumab)|
3291914|NCT01760005|No Intervention|Cognitive Run-in|
3291915|NCT01760005|Active Comparator|Gantenerumab Open Label Extension|Subcutaneously every 4 weeks at escalating doses
3291916|NCT01760018|Experimental|Desflurane group|
3291917|NCT01760018|Active Comparator|TIVA(total intravenous anesthesia) group|
3291918|NCT01760031||Subjects with impaired renal function|Subjects with baseline impaired renal function undergoing cardiac catheterization with contrast-medium exposure
3291919|NCT01760044|Experimental|Tissue oxygenation monitoring|Tissue oxygenation monitoring
3291920|NCT01760057|Placebo Comparator|Health promotion message|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites
3291921|NCT01760057|Experimental|Combined Web-based HIV intervention|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging
3291922|NCT01760070|Experimental|Hybrid knife|O-type Hybrid knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
3291923|NCT01760070|Active Comparator|IT knife|IT knife is used the whole ESD process except for minimum use of dual knife in border marking and initial mucosal cutting.
3291924|NCT01760083|Active Comparator|Biolimus-eluting stent implantation|PCI of CTO using a Biomatrix drug-eluting stent system + optimal medical therapy.
3291925|NCT01760083|No Intervention|Medical therapy|Optimal medical therapy. Subsequent PCI only if symptoms of angina persist despite optimal medical therapy. At least 2 anti-anginal agents or the maximum tolerated anti-anginal therapy should be used before crossover. Medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate.
3291926|NCT01760096|Experimental|Levamisole+cyclosporin A+Glucocorticoids|Levamisole+cyclosporin A+Glucocorticoids
3291927|NCT01760096|Active Comparator|cyclosporin A+Glucocorticoids|cyclosporin A+Glucocorticoids
3291928|NCT01760096|Active Comparator|Glucocorticoids|Glucocorticoids
3291929|NCT01760109|Experimental|Piperacillin Sodium and Sulbactam Sodium|"Drug:xintemie 1.5-3.0g,iv,bid 7-14 days~serious infections 6.0-12.0g,iv,tid for 7-14 days"
3291930|NCT01760122|Experimental|Ypeginterferon Alfa-2b|
3291931|NCT01760122|Active Comparator|Pegasys|
3291932|NCT01760135|Experimental|low calory|15kcal/kg caloric supplement
3291933|NCT01760135|Active Comparator|high calory|25kcal/kg
3291934|NCT01760148||Interferon and ribavirin|All the patients followed the standard treatment protocol.
3291935|NCT01760161|Active Comparator|Ropivacain|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
3291936|NCT01760161|Placebo Comparator|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
3291937|NCT01760174|Active Comparator|Bupivacain-infusion in epidural catheter|Bupivacain-infusion in epidural catheter and intermittent isotonic potassium chloride bolus in transversus abdominis plane catheter.
3291938|NCT01760174|Active Comparator|Ropivacaine bolus in transversus abdominis plane catheter|Intermittent ropivacaine bolus in bilateral transversus abdominis plane catheter and isotonic potassium chloride infusion in epidural catheter.
3291939|NCT01760200||Drug eluting balloon angioplasty|Drug eluting balloon angioplasty
3291940|NCT01760200||Drug eluting stent group|Drug eluting stent intervention
3291941|NCT01760213|Experimental|Treatment|intervention delivered via internet
3291942|NCT01760213|No Intervention|Control|
3291943|NCT01760226|Experimental|DA-EPOCH-R for DLBCL, PTLD & PMBCL|"Minimum of 6 cycles (cycle=3 weeks), possibly 8. Dosages of the drugs will be determined by the subject's weight and height for cycle 1. Thereafter, the dosages of some drugs will be adjusted up or down for the next cycle, dependent on the blood tests results.~DA-EPOCH-R for 2 cycles then two more cycles of DA-EPOCH-R. If complete response (CR), then DA-EPOCH-R for more 2 cycles. If no CR, DA-EPOCH-R for 4 more cycles."
3291944|NCT01760252|Experimental|CAPOXIRI Chemotherapy Regimen|"Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)~The proposed chemotherapy regimen CAPOXIRI is:~Capecitabine 1000mg/m2 p.o. bid on days 1-7~Oxaliplatin 85mg/m2 intravenously (IV) on day 1~Irinotecan 150mg/m2 IV on day 1"
3291945|NCT01760278|Experimental|Study Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured by time-lapse imagery technique (embryoscope) and analysis would be done using patients receive rFSH (Gonembryo viewer equipped with latest software.
3291946|NCT01760278|Active Comparator|Control Arm|Subjects would receive recombinant Follicle Stimulating Hormone (rFSH) by S.C. injection 150 - 225 IU/day for 9 days. The embryos of subjects would be cultured in conventional culture environment and analysis would be done using established subjective morphological criteria.
3291947|NCT01760317|Active Comparator|Midline|Midline Lumbar Epidural Steroid Injection
3291948|NCT01760317|Active Comparator|Parasagittal|Parasagittal Lumbar Epidural Steroid Injection
3291949|NCT01760330|Active Comparator|IV acetaminophen|IV acetaminophen administered q 4 hrs. for a total of 24 hrs.
3291950|NCT01760330|Placebo Comparator|Placebo|Normal saline administered IV every 4 hrs. for a total of 24 hrs.
3291951|NCT01760343|Experimental|Berinert, then CSL830|A single intravenous dose of Berinert at 1500 units (1500 IU), followed by a single intravenous dose of CSL830 at 1500 IU.
3291952|NCT01760343|Experimental|CSL830, then Berinert|A single intravenous dose of CSL830 at 1500 IU, followed by a single intravenous dose of Berinert at 1500 IU.
3291953|NCT01760356||Healthy Volunteers No treatment|This is set as reference a cohort of untreated healthy volunteers, over which will be measured the biomarkers to determine the baseline. Implies PBMC ex-vivo exposure to Tacrolimus prior all cell incubations to study ex-vivo PD in stimulated conditions with mitogens to identify potential genetic sources of interindividual variability in physiological conditions Number proposed 30.
3291954|NCT01760356||Liver Transplant Patients on Tacrolimus|"To explore PD/PG/PK relationships of TAC residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 50."
3291955|NCT01760356||Waiting List for Liver Transplantation|"To study the ex-vivo PD response to TAC in stimulated and non-stimulated conditions and the potential genetic sources of PD variability in pathological conditions.~The number proposed is 12."
3291956|NCT01760356||Liver Transplant Patients on Cyclosporine|"To explore PD/PG/PK relationships of CsA residual PD activities ex-vivo in stimulated and non-stimulated conditions in liver recipients.~The number proposed is 10."
3291957|NCT01760356||Longitudinal Cohort|"Patients form the waiting list for liver transplantation will be enrolled and monitored at different times after transplantation to study the relationships between TAC PD and the clinical responses.~The number proposed is 20."
3291958|NCT01760382||STEMI network Primary PCI patients|Patients with STEMI brought to the Hub Hospital by the STEMI network ambulance and treated by primary PCI.
3291959|NCT01760382||STEMI Hospital ED Primary PCI patients|Patients with STEMI who reached by themselves the Hub Hospital, where they were admitted for STEMI and tretated by Primary PCI
3291960|NCT01760408||Home PN - pediatric|Pediatric patients (under 18) on Home PN
3291961|NCT01760408||Adult patients on Home PN|Adult patients on Home PN
3291962|NCT01760421|Experimental|Hydroxychloroquine|Receive treatment with hydroxychloroquine
3291963|NCT01760434|Other|Long-Term Outcomes|Patients will be recruited who were diagnosed with adolescent idiopathic scoliosis prior to age 18 and before 1994 (minimum 20 year outcomes) with available xrays. Patients will be included who were treated with surgery, observation, or bracing. Patients will return for a one-time visit for new xrays, physical exam, health-related quality of life surveys, and pulmonary function testing.
3291964|NCT01760460|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib, orally, once-daily for 24 weeks. Participants will continue on once-daily 100-mg anacetrapib during 28 week open-label extension.
3291965|NCT01760460|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 24 weeks. Participants will be switched to once-daily 100-mg anacetrapib during 28 week open-label extension.
3291966|NCT01760486|Active Comparator|Shape Up Rhode Island|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive periodic newsletters throughout the 12 month trial.
3291967|NCT01760486|Experimental|Shape Up Rhode Island + Professional Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a professional weight loss coach and will be incentivized for submitting information to their coach and meeting weight goals.
3291968|NCT01760486|Experimental|Shape Up Rhode Island + Peer Coach + Incentives|Individuals who join Shape Up Rhode Island 2013, enter our research study, and lose 5% of their initial body weight during the first two months of Shape Up will be randomized to one of the three maintenance interventions. If randomized to this treatment arm, participants will receive a peer coach and will be incentivized for reporting to their coach and meeting weight goals.
3291969|NCT01760499|Experimental|Immunotherapy Followed by Surgery|PV-10 administration, adverse events assessment, surgery to remove melanoma tumors, follow-up visit.
3291970|NCT01760512|Experimental|Robot-assisted surgery|Robot-assisted (da Vinci surgical system) gastric bypass
3291971|NCT01760512|Active Comparator|Conventional laparoscopy|Laparoscopic gastric bypass
3291972|NCT01760525|Experimental|CGM097 - Dose escalation|
3291973|NCT01760525|Experimental|CGM097 - Dose Expansion at MTD or RP2D|
3291974|NCT01760538|Experimental|exercise group|exercise training
3291975|NCT01760538|Active Comparator|Control|usual care
3291976|NCT01760551||Patients assessed with AMA guide fifth edition|
3291977|NCT01760551||Patients assessed with AMA guide sixth edition|
3291978|NCT01760564|Experimental|Miglustat|miglustat 200mg tid
3291979|NCT01760577|Experimental|The Botulinum Toxin A group|The Botulinum Toxin A group received intraarticular injections of 100 units of Botulinum Toxin A (Allergan, Inc, Irvine CA) reconstituted in 2 cc normal saline.
3291980|NCT01760577|Active Comparator|The hyaluronate group (Hyalgan, Italy)|The hyaluronate group received intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, molecular weight 500-730kDa, Fidia Pharmaceutical Corporation, Abano Terme, Italy) and subsequent 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise for 2 weeks .
3291981|NCT01760590|Experimental|Manual Manipulation|Patients will be randomized to receive a thrust manipulation
3291982|NCT01760590|Experimental|Manual Mobilization|Patients will be randomized to receive mobilization
3291983|NCT01760603|Experimental|ISFF|The patients performed ischia spinous fascia fixation surgery.
3291984|NCT01760616|Experimental|Test group|Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
3291985|NCT01760616|No Intervention|Control group: adjuvant therapy|Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.
3291986|NCT01760629|Experimental|Cooling arm|Whole body cooling to 33 to 34 C rectal temperature
3291987|NCT01760642|Experimental|Midazolam|"period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.~period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days."
3291988|NCT01760655|Experimental|Treatment (RIC and stem cell transplant)|"REDUCED INTENSITY CONDITIONING: Patients receive fludarabine phosphate IV on days -15 to -12, thiotepa IV over 2 hours on days -15 to -13, donor lymphocyte infusion (DLI) on day -6, and cyclophosphamide IV on days -3 and -2. Patients also undergo TBI on day -10.~TRANSPLANT: Patients undergo allogeneic PBSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV on days -1 to 42 followed by taper and mycophenolate mofetil IV BID on days -1 to 28."
3291989|NCT01760668||Turner syndrome (TS)|TS verified by genotyping Age > 18 years awaiting operation due to aortic dilation
3291990|NCT01760668||Marfan syndrome (MS)|Females with MS verified clinically or by genotyping Age > 18 years awaiting operation due to aortic dilation
3291991|NCT01760668||Bicuspid aortic valve|females with bicuspid aortic valve Age > 18 years awaiting operation due to aortic dilation
3291992|NCT01760668||Controls|Men/females who died from conditions other than aortic dilation or dissection. Age 20-60 years.
3291993|NCT01760681|Experimental|H coil DTMS|20 daily deep TMS treatments
3291994|NCT01760681|Sham Comparator|inactive stimulation|20 daily sham deep TMS treatments
3291995|NCT01760694|Experimental|Resectable Patients|Surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery
3291996|NCT01760694|Experimental|Marginally Resectable Patients|2-3 cycles of neoadjuvant FOLFIRINOX then restaged, then undergo surgery with Intraoperative Radiation Therapy (IORT) within 2-4 weeks following chemotherapy. Then Radiation Therapy within 6-8 weeks followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles
3291997|NCT01760707|Experimental|Exercise Training|aerobic exercise training
3291998|NCT01760707|Active Comparator|Control|
3291999|NCT01760720|No Intervention|control|Standard care
3292000|NCT01760720|Experimental|intervention|The MMT CARE intervention has 3 session/modules: 1) MMT protocol and procedures, understanding stigma and its impact; 2) effective communication with clients, introducing motivational interviewing; 3) application of motivational interviewing, motivating clients for behavior change. The intervention contents reflect challenges faced by service providers working at MMT clinics and the impact of these challenges on their clients. Sessions will occur once a week for three weeks, with each session featuring a different set of themes and relevant activities. Each session will be 90-100 minutes long and will be conducted with a group of 5 to 7 providers.
3292001|NCT01760746||PDR, Avastin/Lucentis, randomization, humour, inflamation|Patients will be randomized to receive pre-treatment with either bevacizumab or ranibizumab . Sample of aqueous humour will be taken before injection and before surgery.Both the patient and the treating physician will be masked to the identity of the study drug.
3292002|NCT01760759|No Intervention|Usual care|Patients receive usual care from their medical providers.
3292003|NCT01760759|Experimental|Usual care plus cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
3292004|NCT01760759|Experimental|Usual care, reminders & contingency management for adherence|Patients receive reminders and reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
3292005|NCT01760772|Placebo Comparator|Saline|0.9% saline
3292006|NCT01760772|Experimental|Exendin-9 (Ex-9)|Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min
3292007|NCT01760772|Experimental|GLP-1|GLP-1 infusion at 0.3 pmol/kg/min
3292008|NCT01760798|Active Comparator|Daily Teriparatide group|This group will recieve 20µg of teriparatide by subcutaneous route daily at 8 pm for 1 year
3292009|NCT01760798|Experimental|Weekly Teriparatide group|This group will recieve 60µg of teriparatide by subcutaneous route weekly at 8pm on Sunday for 1 year
3292010|NCT01760811|Other|Cetuximab ,neoadjuvant administration|Drug administration ,Cetuximab(merck Serono )given neoadjuvant ,3 courses prior surgery followed by post operatve radiation and Cetuximab
3292011|NCT01760824|Experimental|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
3292012|NCT01760824|Active Comparator|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg aid, bismuth sub citrate 120mg aid and tetracycline 500mg qid, all for 10 days
3292013|NCT01760837|Other|baked milk products, cow's milk allergy|to offer baked milk products to cow's milk allergic patients and to follow them for tolerance and if this intervention may have any impact on the natural history of milk allergy
3292014|NCT01760850|Experimental|Arm I (Esperanza y Vida)|Participants engage in the Esperanza y Vida educational information session for breast and cervical cancer.
3292015|NCT01760850|Active Comparator|Arm II (control)|Participants engage in an educational information session for diabetes.
3292016|NCT01760863|Experimental|Oral Antibiotics|Oral antibiotics for 3 months; recommendation for antibiotics will be made by an infectious disease specialist.
3292017|NCT01760863|No Intervention|No oral antibiotics|No oral antibiotics.
3292018|NCT01760902|Experimental|Diet and Physical Activity|Participants convene weekly for 12 consecutive weeks and then once per month for 9 months. Each sessions is 90 minutes
3292019|NCT01760928||Asthma patients|all
3292020|NCT01760967|Active Comparator|Dexmedetomidine|administer dexmedetomidine (0.1-0.7ug/kg/h) from the beginning of ICU treatment
3292021|NCT01760967|Active Comparator|non-Dexmedetomidine|administer sedatives except Dexmedetomidine
3292022|NCT01760980|Experimental|Test product (B)|B: Subjects receive Exemestane 25 mg tablets under fasting conditions
3292023|NCT01760980|Active Comparator|Reference product (A)|A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions
3292024|NCT01761032||Infrequent tanners|Individuals who tan less than twice a week and do not meet modified DSM-IV criteria for tanning addiction.
3292025|NCT01761032||Compulsive Tanners|Individuals who tan more than 3 times per week in a tanning bed. Tanning must cause disruption in daily functioning. Must meet modified DSM-IV criteria for tanning addiction
3292026|NCT01761045|Active Comparator|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
3292027|NCT01761045|Active Comparator|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
3292028|NCT01761045|Placebo Comparator|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
3292029|NCT01761058||Severe Asthma|Subjects with Severe Asthma (SARP protocol definition)
3292030|NCT01761058||Well controlled asthma|subjects with well controlled asthma
3292031|NCT01761071|Experimental|group KO|(ketorolac 0.5% in one eye, ofloxacin 0.3% in the other eye)
3292032|NCT01761071|Active Comparator|group DO|(diclofenac 0.1% in one eye, ofloxacin 0.3% in the other eye)
3292033|NCT01761097|Active Comparator|Endocuff assisted colonoscopy|Endocuff attachment
3292034|NCT01761097|Placebo Comparator|Control standard colonoscopy|Standard colonoscopy
3292035|NCT01761110|No Intervention|Pre-intervention|Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
3292036|NCT01761110|Experimental|Post-intervention|Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
3292037|NCT01761123|Experimental|VXA-A1.1|Intestinal Delivery
3292038|NCT01761136|Active Comparator|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
3292039|NCT01761136|Experimental|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
3292040|NCT01761149|Active Comparator|Remifentanil (Low dose)|remifentanil(Low):dose of 0.2ug/kg/min. The dose of remifentanil is widely used intraoperatively clinically;
3292041|NCT01761149|Experimental|Remifentanil (High dose)|The high dose of remifentanil is 1.2ug/kg/min. The does is sometimes used in clinical practice.
3292042|NCT01761188|Experimental|STABLE-SR|CPVI plus electrophysiologic substrate ablation in the left atrium during sinus rhythm ( STABLE-SR)
3292043|NCT01761188|Experimental|Control Group|conventional stepwise ablation approach for persistent AF(CPVI + Lines +CFE) .
3292044|NCT01761201|Experimental|levofloxacin|Levofloxacin 500 mg daily for 9 months starting on the waiting list for liver transplant
3292045|NCT01761201|Active Comparator|Isoniazid|"Isoniazid 300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months"
3292046|NCT01761214|Active Comparator|Fluroquinolones|The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.). All medications are administered based on the bronchiectasis guideline issued by British Thoracic Society.
3292047|NCT01761214|Active Comparator|Beta-lactamase inhibitor|In the present study, amoxicillin and amoxicillin clavulanate potassium compound are employed, based on the British Thoracic Society guideline for bronchietasis, as mainly determined by sputum microbiology during steady-state bronchiectasis.
3292048|NCT01761227|Experimental|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
3292049|NCT01761227|Placebo Comparator|Placebo|3 tablets per time, 3 times per day for 24 weeks. The placebo has similar smile and appearance as the Fufangdanshen Tablets
3292050|NCT01761240|Experimental|Study Drug|
3292051|NCT01761253||Assessing costs & cost-variability|Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
3292052|NCT01761305|Experimental|Brace|Hypercorrective night-time brace worn 8 hours per night. A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions regarding physical activity will be delivered during a one hour session.
3292053|NCT01761305|Experimental|Scoliosis specific exercises.|Scoliosis specific exercises. The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. An additional session will be provided every 6 months for the entirety of the study. A prescription of general physical activity will be provided at a dose of 60 minutes per day.
3292054|NCT01761305|Active Comparator|Self-mediated physical activity.|A prescription of general physical activity will be provided at a dose of 60 minutes per day. Instructions will be delivered during a 1 hour session.
3292055|NCT01761318|Active Comparator|Liraglutide|"Liraglutide: Solution for subcutaneous injection 6 mg/ml; Flexpen 3 ml.~Dose: s.c. 0,6 mg (0,1 mL) once daily. After 1 week, the dose will be increased to 1,2 mg (0,2 mL) once daily. If tolerated, after 1 week, dose will be increased to 1.8 mg (0,3 mL) once daily. In case of a hypoglycaemic episode, the dosage of oral blood glucose lowering medicaments will be adjusted first. If hypoglycaemia persists, Liraglutide / Liraglutide placebo will be adjusted on the basis of clinical parameters.~Duration: 26 weeks"
3292056|NCT01761318|Placebo Comparator|Liraglutide-placebo|"Liraglutide placebo: Solution for injection; Flexpen 3 ml.~Dosage: same as Liraglutide~Duration: 26 weeks"
3292057|NCT01761331|Active Comparator|Group A: Standardized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Intervention: Infants in the standardized acupuncture group get minimal acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
3292058|NCT01761331|Active Comparator|Group B: Individualized acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. Infants in the individualized acupuncture group get acupuncture in points chosen by the acupuncturists according to symptoms: maximum 5 needles are inserted about 3 mm in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute.
3292059|NCT01761331|No Intervention|Group C: No acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse, trained in acupuncture, is alone with the infant for five minutes. The nurse hold the infant´s hand and talks to it but no acupuncture is given.
3292060|NCT01761344|Experimental|Intraoperative measurement of cortisol|Intervention: During a routine procedure intraoperative cortisol is measured. Upon unsuccessful sampling, the sampling will be repeated.
3292061|NCT01761370|Active Comparator|Treatment|AHA diet plus exercise with BIB placement
3292062|NCT01761370|Sham Comparator|Sham control|AHA diet plus exercise with sham BIB placement
3292063|NCT01761383|Experimental|Nintendo Wii and Chronic Schizophrenia|Participants enrolled in the study will be provided with the Nintendo Wii console and Nintendo Wii Fit Plus video games to use for the duration of the study (6 months) with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life with the use of self report questionnaires and psychiatric assessment.
3292064|NCT01761396|Experimental|CBT|Cognitive behavioral therapy
3292065|NCT01761396|Active Comparator|UC|Usual care
3292066|NCT01761422||SLE active flare|Patients who are having an active flare of their lupus confirmed by labs
3292067|NCT01761435|Experimental|Influenza vaccine, second administration after 5 weeks|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first one.
3292068|NCT01761435|Active Comparator|Influenza vaccine|Drug: Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
3292069|NCT01761448|Experimental|Device Guided Exercise|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities of patients.
3292070|NCT01761461|Experimental|Arm A|S-1 40-60mg BID (4weeks - 2weeks off) x 8 cycles
3292071|NCT01761461|Active Comparator|Arm B|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 week} x 8 cycles
3292072|NCT01761461|Active Comparator|Arm C|{S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 2 cycles → S-1 40mg BID (2weeks - 1week off - 2weeks)+ RT 45 Gy (5weeks) → Rest for 4 weeks → {S-1 40-60mg BID (2weeks - 1week off) + Oxaliplatin 130mg/m2 q 3 weeks} x 4 cycles
3292073|NCT01761474||1. Carbon dioxide insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
3292074|NCT01761474||2. Carbon dioxide insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
3292075|NCT01761474||3. Air insufflation with BPS|Both midazolam (0.05 mg/kg body weight; 1 mg if age[70 or ASA class III-IV) and fentanyl (50 lg; 25 lg if age[70 or ASA class III-IV) were given intravenously at the initiation of sedation. Thereafter, repeated doses of 10-20 mg propofol were administered to achieve a moderate level of sedation. Maintenance of sedation was also performed with repeated doses of 10-20 mg propofol.
3292076|NCT01761474||4. Air insufflation with Propofol|Sedation was induced by intravenous bolus injection of propofol (0.5 mg/kg body weight; 10 mg if age[70 or ASA class III-IV), followed by repeated doses of 10-20 mg propofol to induce sedation. Repeated doses of 10-20 mg propofol were then administered to maintain adequate sedation, according to the desired sedation depth and patient risk profile.
3292077|NCT01761487|Other|One arm only - Gentamicin and polymyxin E|All subjects will receive:Gentamicin and polymyxin E paste applied on buccal surface four times daily + gentamicin + polymyxin E PO + Strict contact precautions
3292078|NCT01761500|Other|Modified BFM-90 protocol|Using the Modified BFM-90 protocol to treat Chinese children and adolescents with NHL
3292079|NCT01761513|Experimental|Sequence 1|
3292080|NCT01761513|Experimental|Sequence 2|
3292081|NCT01761513|Active Comparator|Sequence 3|
3292082|NCT01761513|Active Comparator|Sequence 4|
3292083|NCT01761526|Experimental|Rotigotine in Healthy Japanese|"Rotigotine transdermal patch~Single dose application of 2 mg / 24 hours Rotigotine in Healthy Japanese subjects~Transdermal patch over 24 hours"
3292084|NCT01761526|Experimental|Rotigotine in Caucasian|"Rotigotine transdermal patch~Single-Dose application of 2 mg / 24 hours Rotigotine in healthy Caucasian subjects~Transdermal patch over 24 hours"
3292085|NCT01761539|Experimental|Aggressive Hydration|Receives Lactated Ringers solution at 3cc/kg/hr following an initial 20cc/kg bolus.
3292086|NCT01761539|Active Comparator|Moderate Hydration|Receives Lactated Ringers solution at 1.5cc/kg/hr following an initial 10cc/kg bolus.
3292087|NCT01761552|Experimental|Sugammadex (tradename Bridion)|
3292088|NCT01761552|Active Comparator|Traditional reversal or spontaneous recovery:|Atropine/Neostigmine: Atropine, 0.02 mg/ kg, and Neostigmine,0.05 mg/kg diluted in 100 ml Normal Saline and given over a 10 min drip. Reversal will be given only recommended if spontaneous recovery has occurred up to the reappearance of T2 (shallow blockade) following rocuronium induced blockade.
3292089|NCT01761578|Experimental|ART18Z Bioresorbable stent|
3292090|NCT01761591|Experimental|Acrobat|Device: PCI with Svelte Acrobat
3292091|NCT01761591|Active Comparator|Control BMS|Device: PCI with other BMS
3292092|NCT01761604|Other|Nasal ganglion block for TN|Sphenopalatine ganglion block using the Tx360™ device
3292093|NCT01761617|Active Comparator|Yoga Class Twice Per Week|Participants attend two hatha yoga classes each week for 12 weeks.
3292094|NCT01761617|Active Comparator|Yoga Class Once per Week|Participants attend one hatha yoga class each week for 12 weeks.
3292095|NCT01761630||Severe Asthma|"We will classify subjects as having severe asthma using the following stages:~Stage 1: Subjects must have asthma which requires treatment with high-dose inhaled corticosteroids plus a 2nd controller, or systemic corticosteroids with or without a 2nd controller to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy~Stage 2: Assess for uncontrolled asthma by any one of the following criteria:~Poor symptom control evidenced by an Asthma Control Questionnaire score consistently > 1.5 or an Asthma Control Test Score < 20 or not well controlled by NAEPP or GINA asthma treatment guidelines~Frequent severe exacerbations as reflected by ≥ 2 bursts of systemic corticosteroids (> 3 days each) in the previous 12 months~Serious exacerbations reflected by at least one hospitalization, ICU stay or mechanical ventilation in the previous 12 months~Presence of airflow limitation evidenced by FEV1 < 80% predicted (in the face of reduced FEV1/FVC)"
3292096|NCT01761630||Non-severe Asthma|Those with mild-to-moderate persistent asthma as defined by the NAEPP EPR-3 guidelines.
3292097|NCT01761630||Healthy Control|"The purpose of the SARP Control Sub-study is to generate reference data for outcomes measured in biospecimens collected from asthmatic subjects enrolled in the SARP Longitudinal Protocol.~Seven healthy subjects between the ages of 18-65 will be enrolled."
3292098|NCT01761656|Experimental|loading dose atorvastatin|For the arm of loading dose atorvastatin, patients will be treated with 80 mg atorvastatin 12 hours before PCI and 40 mg atorvastatin 2 hours before PCI and then 20mg/d after PCI.
3292099|NCT01761656|Active Comparator|conventional dose atorvastatin|For the arm of conventional dose atorvastatin, patients will be treated with 20 mg atorvastatin 12 hours before PCI and then 20mg/d after PCI.
3292100|NCT01761669||healthy voulnters|
3292101|NCT01761682||Ph-ALL|Diagnosed as ALL with Philadelphia-negative
3292102|NCT01761682||Ph+ALL|Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)
3292103|NCT01761682||Other ALL|Diagnosed as ALL of other type, including Burkitt leukemia
3292104|NCT01761695||CML CP|Diagnosed as CML with chronic phase
3292105|NCT01761695||CML AP|Diagnosed as CML with accelerated phase
3292106|NCT01761695||CML BC|Diagnosed as CML with blast crisis
3292107|NCT01761695||CML other|Diagnosed as CML, which is not included in any of other category
3292108|NCT01761708||umbilical, epigastric and trocar-site hernia|
3292109|NCT01761721||RAHL|Women suspected of endometrial cancer planned to be treated by robotic assisted laparoscopy hysterectomy
3292110|NCT01761734|Experimental|text message|receipt of text message
3292111|NCT01761734|No Intervention|usual care|usual care
3292112|NCT01761760|Experimental|Contingent|"Patients will earn game-based incentives contingent on meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
3292113|NCT01761760|Active Comparator|Non-contingent|"Patients will earn game-based incentives independent of meeting carbon monoxide goals.~Behavioral: Videogame-based smoking cessation intervention"
3292114|NCT01761773|Experimental|Group 1|Subjects with normal renal function: healthy normal adult subjects with an eGFR ≥ 90 mL/min/1.73m2.
3292115|NCT01761773|Experimental|Group 2|Subjects with mild renal impairment: adult subjects with a eCFR ≥ 90 mL/min/1.73m2.
3292116|NCT01761773|Experimental|Group 3|Moderate renal impairment: adult subjects with an eGFR between ≥30 - ≤ 59 mL/min/1.73m2.
3292117|NCT01761773|Experimental|Group 4|Severe renal impairment: adult subjects with an eGFR ≤ 29 mL/min/1.73m2, not on dialysis.
3292118|NCT01761786|No Intervention|Control group|CYP2C19 genotyping will be performed after end of study. Patients will be treated with prasugrel or ticagrelor, according to local protocol.
3292119|NCT01761786|Active Comparator|Intervention group|CYP2C19 genotyping will be performed <48h after PCI and antiplatelet treatment will be chosen based on genotyping results.
3292120|NCT01761799|Experimental|P3 Vaccine Promotion Package|The 5 obstetric practices randomized to the intervention arm will receive and implement all components of the evidence-based P3 vaccine promotion package at the beginning of the study.
3292121|NCT01761799|No Intervention|No P3 vaccine promotion package intervention|The 5 obstetric practices randomized to the control arm will not receive the comprehensive vaccine promotion package at the beginning of the study and will instead be instructed to continue their standard of care regarding influenza and Tdap vaccination of pregnant patients.
3292122|NCT01761812|Experimental|Single arm study|
3292123|NCT01761825|Active Comparator|Ivabradine|Ivabradine 10 mg once
3292124|NCT01761825|Placebo Comparator|placebo|
3292125|NCT01761838|Experimental|SMT for low back pain patients|To investigate the effects of high velocity, low amplitude lumbopelvic spinal manipulative therapy on spinal stiffness and back muscle activity.
3292126|NCT01761838|Other|Asymptomatic arm|To investigate the sequential changes in spinal stiffness and back muscle activity of asymptomatic participants over time without any intervention. Participants of this arm can volunteer for an additional experimental pain protocol after their third visit (at 1 week) to investigate the effects of experimental pain on the changes of spinal stiffness and back muscle activity using a randomized crossover design (injecting 5% hypertonic saline or 0.9% isotonic saline to the interspinous ligaments at L3 to L5 levels in random order in two additional visits).
3292127|NCT01761838|Other|Low back pain participants without SMT|To investigate the temporal changes in lumbar disc diffusion within a 1-hour period without SMT
3292128|NCT01761851||Cases|Liver cirrhosis
3292129|NCT01761864|Experimental|intervention group|academic detailing receiver
3292130|NCT01761864|No Intervention|control group|not receiving an academic detailing intervention
3292131|NCT01761877|Experimental|Sulindac (Clinoril)|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will receive 150 mg of sulindac twice daily for 12 months. They will receive up to 4 MRI within 12 months.
3292132|NCT01761877|No Intervention|Observational|Women taking aromatase inhibitors for adjuvant therapy for their breast cancer will continue their treatment, and will be monitored with MRI and standard of care tests every 6 months for up to 12 months.
3292133|NCT01761890||CML patients|
3292134|NCT01761903||Primary Focal Dystonia|Volunteers with primary focal dystonia
3292135|NCT01761903||Healthy Controls|'Healthy' volunteers, consisting of people of the same age as the PFD volunteers, w/o a diagnosis of PFD.
3292136|NCT01761916|Experimental|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
3292137|NCT01761916|Active Comparator|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral CAPTOPRIL (25mg)
3292138|NCT01761929|Experimental|Stereotactic Body Radiation Therapy|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
3292139|NCT01761942|Placebo Comparator|placebo ,anorexia nervosa|2x3 placebo capsules with olive oil
3292140|NCT01761942|Experimental|fatty acids preparation- eye-q|2 x 3 tablets of eye -q preparation daily ( 558 mg of EPA, 175 mg of DHA, 60 mg fo GLA).
3292141|NCT01761955|Experimental|High Dairy|Consuming four or more servings of dairy per day.
3292142|NCT01761955|Placebo Comparator|Control, Low Dairy|Participants consumed less than 2 servings of low fat dairy per day.
3292143|NCT01761968|Experimental|givinostat|"Patients will continue at their last tolerable dose and treatment schedule of givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
3292144|NCT01761994|Active Comparator|M100|heparin free CRRT group
3292145|NCT01761994|Experimental|HF1000|CRRT with nafamostat mesilate anticoagulation group
3292146|NCT01762007||6Mo-2Yr old penile hypospadias patients before operation|
3292147|NCT01762007||6Mo-2Yr old male patients without hypospadias|
3292148|NCT01762007||penile hypospadias patients under the age of 5 Yr|penile hypospadias patients under the age of 5 Yr who got tubularized incised plate operation at out institution at the age between 6Mo and 2Yr old and more than 1 Yr have passed
3292149|NCT01762007||2Yr-5Yr old male patients without hypospadias|
3292150|NCT01762020|Active Comparator|3M Cavilon No Sting Barrier Film|Two of four regions of the breast will be randomly chosen to receive 3M Cavilon No Sting Barrier Film treatment twice per week.
3292151|NCT01762020|Placebo Comparator|Standard preparations|Standard treatment
3292152|NCT01762033|Experimental|ASONEP|ASONEP will be administered by intravenous infusion over 90 minutes at 15 mg/kg once a week every 4 consecutive weeks per cycle
3292153|NCT01762046|Other|Glipizide and Metformin|On day 1, subjects will receive a single oral dose of glipizide 5 mg, and will have blood drawn at various time points for up to 240 minutes. During study days 2-7, the participants will fill out a dietary intake food record, including 3 weekdays and one weekend day. During days 6-8, the subject will receive a short-course metformin treatment of four 500-mg doses. On the morning of study day 8, 60 minutes after taking the fourth metformin dose, the subject will do a 75g Oral Glucose Tolerance Test. Blood draws will again be taken at time points for 120 minutes.
3292154|NCT01762072|Placebo Comparator|vitaminB12|VitB12 group (VitB12, n=10) receives 8 weeks of treatment with daily oral doses of 1000 μg of vitamin B12 (one capsule)
3292155|NCT01762072|Experimental|Fish oil|Fish oil group (FO, n=10)receives 8 weeks of treatment with daily oral doses of 2g of fish oil in the form of two capsules of fish oil) .
3292156|NCT01762072|Experimental|Fish oil+vitaminB12|VitB12+Fish oil group (VitB12+FO, n=10) receives 8 weeks of treatment with daily oral doses of a combination of 1000 μg of vitamin B12 and 2g of fish oil
3292157|NCT01762085|Placebo Comparator|healed DFU control arm|"clinic-specific usual best care"
3292158|NCT01762085|Experimental|healed DFU surgical intervention|"clinic-specific best care plus nerve decompression at 4 known sites of lower leg fibro-osseous entrapment"
3292159|NCT01762098||Recurrent miscarriages|
3292160|NCT01762098||Repeated embryo implantation failures|
3292161|NCT01762124|Experimental|Native Outflow Tract TPV|Implantation of the Native Outflow Tract TPV
3292162|NCT01762137|Active Comparator|Coiling|Coiling
3292163|NCT01762137|Active Comparator|Flow Diversion|Flow Diversion
3292164|NCT01762150|Experimental|sorafenib combined with chemotherapy|this trial is designed single arm. all the subjects enrolled will receive the experimental intervention,ie. sorafenib+gemcitabine+cisplatin.
3292165|NCT01762163|Experimental|Qizhitongluo Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night;the routine recovery training.~intervention treatment:the Capsules were administered orally, four capsules each time, three times a day after each meal（placebo was taken only after lunch, and Qizhitongluo Capsule was taken after breakfast and supper)for 12 weeks."
3292166|NCT01762163|Active Comparator|Naoxintong Capsule|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night; the routine recovery training.~intervention treatment:Naoxintong Capsule was administered orally, four capsules each time, three times a day after each meal for 12 weeks."
3292167|NCT01762163|Placebo Comparator|Placebo|"Basic treatment：Aspirin Enteric-coated Tablets was administered orally at a dosage of 100mg/d once per night and the routine recovery training.~intervention treatment:placebo capsule was administered orally four capsules each time, three times a day after each meal for 12 weeks."
3292168|NCT01762176|Active Comparator|Usual care group|Usual care
3292169|NCT01762176|Active Comparator|Intensive care group|Protocolized intensive treatment
3292170|NCT01762202|Experimental|Study therapy|
3292171|NCT01762215|Experimental|PLM|Upon consenting to the study, participants will be asked to register an account on PatientsLikeMe; no personal identifiers will be required. As part of registration patients create a user name and password for the website and share their email with PatientsLikeMe. Participants will be asked to provide a set of demographic variables and to complete a survey assessing elements of self-management, disease knowledge, social support, and quality of life. Paticipants will then use the PatientsLikeMe website for 6 weeks as much as they wish. After 6 weeks the participants are asked to complete a second survey.
3292172|NCT01762228|Active Comparator|Transcutaneus electrical stimulation|Sensorial transcutaneous electrical stimulation to the pharynx and larynx will be used 1 hour/day during 5 days/week for 2 weeks.
3292173|NCT01762228|Active Comparator|TRPV1 agonist|Sensorial stimulation of TRPV1 receptors into the oropharynx of patients will be used 3 times/day (before meals) during 5 days/week for 2 weeks.
3292174|NCT01762241|Experimental|Intervention group|12 weeks systematically home based training 3 times per week one hour at the time using the Xbox Kinect system.
3292175|NCT01762241|No Intervention|Control group|No systematically training/standard of care
3292176|NCT01762254|Active Comparator|incisionless laparoscopic colectomy|incisionless laparoscopic colectomy: Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
3292177|NCT01762254|Active Comparator|conventional laparoscopic colectomy|conventional laparoscopic colectomy: The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
3292178|NCT01762267|Active Comparator|diet intervention, DASH diet|intervention: nutrition intervention: DASH diet
3292179|NCT01762267|No Intervention|not intervention, control diet|control weight loss diet
3292180|NCT01762280|Experimental|Famitinib Malate|Famitinib either at 4,8,13,20,27,36 mg, p.o. once daily
3292181|NCT01762293|Experimental|Famitinib|Famitinib 25 mg qd p.o. and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3292182|NCT01762293|Placebo Comparator|Placebo|Placebo qd p.o., and the medication continued until disease progression or intolerable toxicity or patients withdrawal of consent
3292183|NCT01762306|Experimental|Diclofenac Potassium|Diclofenac Potassium 50 mg PO 1 hour prior to fractional curettage
3292184|NCT01762306|Placebo Comparator|Folic Acid|Folic acid 5 mg PO 1 hour prior to fractional curettage
3379488|NCT05162885|Active Comparator|implant placement in defective Sockets preserved with alendronic acid sponge|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
3379489|NCT05162885|Active Comparator|Implant placement in Defective sockets preserved with sticky bone|"anesthesia according the site of implant placement were administered using mepivacaine HCl (2%) with levonordefrin 1:20 000 (Scandonest 2%; Septodont, Saint- Maur-des-Fossés, France). Injection to control pain and bleeding for hemostasis. Crestal incision with a full thickness mucoperiosteal flap was reflected .A pilot drill will be used to start the osteotomy preparation, then different drilling sizes will be used to attain the final drill size and the planed implant height and width according to Cone Beam CT. Implants were screwed directly into the osteotomy site, primarily the screwing was done mechanically by Fixture Mount Connection attached to the implant carrier.~The created gap sutured passively to allow tension-free interrupted closure using 3-0 coated undyed braided polyglactin 910 suture material."
3379490|NCT05162872|Experimental|PD-(L)1 naive patients, ≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 naive patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=23 participants, if CR+PR≥3,then go to the second step, continue to enroll N2=39 participants, if CR+PR<3，then do not go to the second step."
3379491|NCT05162872|Experimental|PD-(L)1 previously treated patients，≥1L of platinum-based chemotherapy|"Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma (including recurrence and metastasis after radiotherapy, or a condition not suitable for surgery and radiotherapy judged by investigator)~≥ 1L of platinum-based chemotherapy at least 1 measurable lesion (RECIST 1.1) ECOG 0-1, PD-(L)1 previously treated patients, Niraparib 200 mg QD D1-21,Sintilimab 200 mg IV q3W, first step enroll N1=20 participants, if CR+PR≥1,then go to the second step, continue to enroll N2=17 participants, if CR+PR<1，then do not go to the second step."
3379492|NCT05162859||Former Exercise Training|Patients that were randomized to high-intensity-interval training, moderate continuous training (OptimEx-Clin) or moderate continuous training + resistance training (Ex-DHF)
3379493|NCT05162859||Former Control|Patients that were randomized to guideline control (OptimEx-Clin) or usual care (Ex-DHF)
3379494|NCT05162846|Active Comparator|Arm 1 - Usual care (UC)|Participants are provided with a link to the Michigan Department of Health and Human Services (MDHHS) informational website and are instructed to follow up with their oncology provider about genetic testing.
3379495|NCT05162846|Experimental|Arm 2 - Virtual genetics navigator|Participants receive access to an online genetics tool, the virtual genetics navigator, to help learn why and how to seek out genetic testing for hereditary cancer syndromes.
3292185|NCT01762319|Experimental|Misoprostol|200 mcg Misoprostol SL 1 hour prior to fractional curettage
3292186|NCT01762319|Placebo Comparator|Vitamin B6|100 mg Vitamin B6 SL 1 hr prior to fractional curettage
3292187|NCT01762332|Active Comparator|Low opioid level|Base level of remifentanil effect side concentration: 2ng/ml Stopped recruitment (May 2014)
3292188|NCT01762332|Active Comparator|High opioid level|Base level of remifentanil effect side concentration: 4ng/ml Stopped recruitment (May 2014)
3292189|NCT01762332|Other|chronic beta-blocker treatment|"Patients with chronic beta-blocker treatment prior to surgery and study. Will all be allocated to the high opioid level arm without randomization.~Continue recruitment."
3292190|NCT01762358|Active Comparator|Standard Therapy|Standardized physiotherapy for 12 times (15 patients)
3292191|NCT01762358|Experimental|Standard + Khalifa|Initial one hour Khalifa therapy followed by twelve times standardized Physiotherapy (15 patients)
3292192|NCT01762371|Experimental|K-Pat|Getting one time one hour of Khalifa's therapy for ACL injury treatment.
3292193|NCT01762384|Active Comparator|LSC|procedure: laparoscopic sacral colpopexy.
3292194|NCT01762384|Active Comparator|Modified PFRS|procedure: modified pelvic floor reconstructive surgery with mesh.
3292195|NCT01762397|Experimental|PMK-S005|
3292196|NCT01762410|Experimental|P7170|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
3292197|NCT01762423|Experimental|Active Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with Velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Active Devices The device will be activated at the time of placement. The active devices are programmed to automatically deliver treatment. Each treatment duration is 15 minutes. The active device delivers treatment every 2 hours. A light will flash on the device when the PEMF begins and will continue to flash every second until the end of the treatment. Between treatments the device will be in sleep mode and the light will flash every 5 seconds."
3379496|NCT05162846|Experimental|Arm 3 - Motivational interviewing (MI)|Participants receive up to 2 phone calls from trained genetics health coaches who provide information about genetic testing and use motivational interviewing to encourage participants to seek out clinical genetic testing.
3379497|NCT05162833|Experimental|Maintenance group|"Subjects that completed the clinical study Evaluation of the TheraNova Neuromodulation System for the Treatment of Overactive Bladder Symptoms that were in the active treatment group will be offered to extend treatment for 3 months."
3292198|NCT01762423|Sham Comparator|Sham Device|"Device Placement:~Upon completion of the subjects' standard of care body contouring surgery, the device will be placed directly on the operative dressings within an unobtrusive binder with velcro strips and will be activated before the subject leaves the OR. Subjects will then be educated on the functionality and interpretation of the user interface of the device. They will be educated on the application, removal, and return of the device.~Sham Devices The sham devices mirror the active device with the exception of the delivery of the PEMF. The sham device will be activated at the time of placement. A light will flash on the device when the SHAM PEMF begins and will continue to flash every second until the end each treatment interval. While in sleep mode the device will not deliver treatment and the light will flash every 5 seconds."
3292199|NCT01762436|Experimental|bisoprolol|initially received 5 mg of bisoprolol (Concor®, Merck Serono, Darmstadt, Germany) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 10 mg Qd for bisoprolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
3292200|NCT01762436|Active Comparator|atenolol|initially received 50 mg atenolol (Beijing Double-Crane Pharmaceutical Co., Ltd, Beijing, China) once daily. The heart rate was assessed every two weeks. If the RHR was ≤65 bpm, a 2-week maintenance treatment was added during the final visit. If the target RHR was not achieved, the dose was changed as recommended in the study protocol. The maximal dose was 100 mg Qd for atenolol. The longest treatment period was 8 weeks. If the patient's RHR did not reach below 65 bpm at week 6, the treatment was ended at week 8.
3292201|NCT01762449||Patients who received cyclophosphamide|Patients who received cyclophosphamide on the Scleroderma Lung Study
3292202|NCT01762449||Patients who received placebo|Patients who received placebo on the Scleroderma Lung Study
3292203|NCT01762462|Experimental|SAR302503|single treatment with oral dose up to 300 mg of SAR302503
3292204|NCT01762475|Experimental|Experimental: Group 1--Symptomatic TBI|"Experimental Group, Group 1, will consist of twenty-four male and female adult participants who have persistent TBI symptoms lasting more than six months.~Participants in the experimental group will be randomized in a 1:1 ratio, assigned to group a or b.~Participants randomized into Group 1a will take placebo twice daily for 8 weeks, followed by 8 weeks of sildenafil 25 mg twice daily with a 2-week washout period between the two 8-week periods.~Participants randomized into Group 1b will take sildenafil 25 mg twice daily for 8 weeks, followed by 8 weeks of placebo twice daily with a 2-week washout period between the two treatment periods."
3292205|NCT01762475|Active Comparator|Active Comparator: Group 2--Healthy Controls|Group 2 will be comprised of twenty male and female adult participants who have never experienced a TBI or concussion to serve as age and gender-matched healthy controls. Participants in Group 2 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
3292206|NCT01762475|Active Comparator|Group 3--Recovered TBI|Group 3 will be comprised of twenty male and female adult participants who have experienced a TBI, have recovered, and are asymptomatic at the time of screening, to serve as age and gender-matched asymptomatic TBI controls. Participants in Group 3 will have a single visit to measure cerebrovascular reactivity before and after a single dose of sildenafil (50 mg by mouth).
3292207|NCT01762488|Active Comparator|Renal denervation by ablation of the renal arteries|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to active treatment, renal artery ablation will be carried out straight away.
3292208|NCT01762488|Sham Comparator|Control|By femoral access, renal angiography is performed. The patient will be sedated. In case of acceptable renal artery anatomy allowing renal ablation, the patient will be randomized in the cath. lab. If randomized to sham treatment, the procedure stops.
3292209|NCT01762514|No Intervention|Program I|Patients with American Joint Cancer Committee/Union Internationale Contre le Cancer (UICC/AJCC) 2010 Stage I and II; Radiotherapy applied
3292210|NCT01762514|Experimental|Program II|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine every-other-day regimen
3292211|NCT01762514|Active Comparator|Program III|Patients with UICC/AJCC 2010 Stage I and II; Radiotherapy applied; Amifostine everyday regimen
3292212|NCT01762514|No Intervention|Program IV|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied
3292213|NCT01762514|Experimental|Program V|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine every-other-day regimen
3292214|NCT01762514|Active Comparator|Program VI|Patients with UICC/AJCC 2010 Stage III, IVa and IVb; Concurrent chemoradiotherapy applied; Amifostine everyday regimen
3292215|NCT01762527|Experimental|ART|Online adaptive radiotherapy
3292216|NCT01762540|Placebo Comparator|Calcium supplement|Capsule with tablet of calclium supplement
3292217|NCT01762540|Active Comparator|Glucocorticoids|Capsule with tablet of Prednisolone 37,5mg
3292218|NCT01762553|Experimental|intervention|The TEA intervention program will be implemented for the intervention group. The TEA intervention has three modules (healthy body & healthy mind, family interaction, and quality of life) logically connected to each other and implemented at three levels from individual, family to the community: 1) TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; 2) TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; 3) TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
3292219|NCT01762553|No Intervention|Control|In order to tease out the impact of the proposed intervention from the impact of attention in general, we will add limited activities to the control group condition. The differences between the intervention and control conditions consist in both contents and formats. For the control group, there will only be group sessions once a week for three weeks starting after baseline assessment. The content of the sessions for the control group will focus on basic care, health education and promotion, nutrition, personal and family hygiene. The Essential Care Package (ECP), a set of education materials originally developed by the World Health Organization (WHO) and supported by the Global Fund Project, will be used and explained in these group sessions. Health workers from villages in the control group will also visit participating families once a week for the initial three weeks and once a month for 12 months.
3292220|NCT01762566|Active Comparator|wheat|wheat is administered blindly versus placebo in capsules once
3292221|NCT01762566|Placebo Comparator|xylose|placebo (xylose) will be administered blindly versus wheat in capsules once
3292222|NCT01762579|Active Comparator|wheat flour|wheat flour is administered blindly versus placebo for 15 days
3292223|NCT01762579|Placebo Comparator|Xylose|placebo will be administered blindly versus wheat flour for 15 days
3292224|NCT01762592|Experimental|Iodine (124I) Girentuximab|Single infusion of radio labeled antibody: 30 mL will be infused using an infusion pump at a rate of 2mL/min over 15 minutes on study day 0.
3292225|NCT01762605|Experimental|Supportive Care|No casting or splinting, supportive care only by parents
3292226|NCT01762605|Active Comparator|Cast|Casting for 4 weeks
3292227|NCT01762618|Experimental|Cognitive Behavioral Therapy Group|14 therapy sessions, once a week for one and a half hours.
3292228|NCT01762618|No Intervention|Control Group|Social support for caregiver (through the social worker) as usual. The social worker gives information when they considered that there is a social economic risk or upon request by the caregiver.
3292229|NCT01762644|Experimental|Arm 1|Immune Tolerance and Proton Pump Inhibitor
3292230|NCT01762644|Active Comparator|Arm 2|Proton Pump Inhibitor
3292231|NCT01762657|Experimental|Oral CyclosporineA and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day in two divided dosages given with Lansoprazole dosed at 30 mg per day in two divided dosages for subjects aged 8-15 year and 60 mg per day for those aged 16-60.
3292232|NCT01762657|Placebo Comparator|Placebos|
3292233|NCT01762670|Active Comparator|Metronidazole|Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days
3292234|NCT01762670|Experimental|GoldenCare|GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights.
3292235|NCT01762683|Experimental|pre-conceptional obesity with a scheduled cesarean section|
3292236|NCT01762683|Active Comparator|non-obese women with a scheduled cesarean section|
3292237|NCT01762683|Active Comparator|women entering labour|women entering labour for vaginal delivery and for vaginal delivery
3292238|NCT01762696|Active Comparator|MET only|Motivational Enhancement Therapy only
3292239|NCT01762696|Experimental|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
3292240|NCT01762709|Active Comparator|The VT 4 ml/kg group|Use of tidal volume of 4 ml/kg during one lung ventilation
3292241|NCT01762709|Active Comparator|The VT 6 ml/kg group|Use of tidal volume of 6 ml/kg during one lung ventilation
3292242|NCT01762709|Experimental|The VT 8 ml/kg group|Use of tidal volume of 8 ml/kg during one lung ventilation
3292243|NCT01762735|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3292244|NCT01762735|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
3292245|NCT01762748|Experimental|S. boulardii 200mg (Floratil®)|"The patients received S. boulardii every 8h during 30 days as an oral capsule formulation which contained 200 mg lyophilized S. boulardii-17 (Floratil®).~The patients enrolled in the study were evaluated immediately before the beginning of treatment, after a thirty-day period of treatment with probiotic and at the end of the second study month (after a thirty-day period without treatment with probiotic)."
3292246|NCT01762761|Experimental|Eltrombopag (ETB115)|Thrombopoietin- receptor (TPO-R) agonist
3292247|NCT01762761|Placebo Comparator|Placebo|Placebo
3292248|NCT01762774|Experimental|Cohort 1|Healthy male subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 2 mg GSK2256294 capsules, Treatment B = 6 mg GSK2256294 capsules, Treatment C = 18 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
3292249|NCT01762774|Experimental|Cohort 2|Obese adult male smoker subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive single dose of all four treatments (one per period) in a random order. Treatment A = 15 mg GSK2256294 capsules, Treatment B = 40 mg GSK2256294 capsules, Treatment C = 100 mg GSK2256294 capsules, Treatment P = Matched Placebo capsules.
3292250|NCT01762774|Experimental|Cohort 3|Obese adult male smoker subjects in Cohort 3 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 3 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2.
3292251|NCT01762774|Experimental|Cohort 4|Obese adult male smoker subjects in Cohort 4 will receive single or twice daily dose of GSK2256294 or placebo for 14 days. Dose selection for Cohort 4 will be based on the safety, PK profile and enzyme inhibition obtained in cohorts 1 and 2 as well as safety and PK profile obtained in cohort 3.
3292252|NCT01762787|Active Comparator|Effect of Aspirin|Positive control as previously used in the cantharidin blister experimental model of inflammation
3292253|NCT01762787|Experimental|Effect of steroid - Prednisolone|Prednisolone selected as steroids should provide the most robust positive control anti-inflammatory therapy
3379498|NCT05162820|Experimental|Smoker Solarplast|Smoker's assigned to solarplast
3379499|NCT05162820|Placebo Comparator|Smoker Placebo|Smoker's assigned to placebo
3292254|NCT01762787|Experimental|Cantharidin exposure to optimise blister formation|Cantharidin exposure to optimise blister formation
3292255|NCT01762813||open and laparoscopic surgery|Patients with primary and or metastatic colorectal cancer (CRC) eligible for curative surgery will be included. Subcohorts may be based on either colon cancer, rectal cancer, metastatic cancer, surgery (laparoscopy or open), node negative and node positive disease, and molecular profiling.
3292256|NCT01762826||Placebo control|Diet pills of 400 mcg of acid folic daily
3292257|NCT01762826||D-chiro-inositol / Myo-inositol|Diet sachets 2000 mg myo-inositol and 250 mg d-chiro-inositol and 400 mcg folic acid daily
3292258|NCT01762826||D-chiro-inositol|Diet pills with 500 mg d-chiro-inositol and 400 mcg folic acid daily
3292259|NCT01762826||Myo-inositol|Diet sachets with 2000 mg myo-inositol and 200 mcg folic acid twice daily
3292260|NCT01762839|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3292261|NCT01762839|Placebo Comparator|Placebo|IV placebo
3292262|NCT01762839|Active Comparator|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a moxifloxacin tablet and will not receive a placebo infusion.
3292263|NCT01762852|Experimental|Belimumab Arm|Subjects will receive belimumab 10 mg/kg intravenous infusion [will last for 1 hour (hr)] on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
3292264|NCT01762852|Placebo Comparator|Placebo Arm|Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks with frequency adjusted for subjects with >1000 mg/mmol uPCR (>10 g/24 hrs). All subjects will receive background supportive therapy throughout the study.
3292265|NCT01762878|Experimental|GSK2269557 100 mcg arm|Each subject will receive 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 100 mcg in one of the 4 treatment periods.
3292266|NCT01762878|Experimental|GSK2269557 500 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 500 mcg in one of the 4 treatment periods
3292267|NCT01762878|Experimental|GSK2269557 3000 mcg arm|Each subject will undergo 4 treatments in 4 treatment periods in Part A of the study. Subjects in this arm will be randomized to receive GSK2269557 3000 mcg in one of the 4 treatment periods
3292268|NCT01762878|Placebo Comparator|Placebo arm|The subjects will receive single dose of placebo in each treatment period of part A and repeat doses of placebo in Part B of the study.
3292269|NCT01762878|Experimental|Part B GSK2269557 arm|The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
3292270|NCT01762891|Experimental|Celecoxib|Celecoxib 200mg/day oral rout Intervention: celecoxib 200mg oral rout administered durng 15 days and followed by administration of rofecoxib 25mg/day during 15 days, placebo 15 days and acetaminophen 3g/day during 15 days.
3292271|NCT01762917||Obstruction|Patients suffering from pulmonary obstruction
3292272|NCT01762917||Restriction|Patients suffering from pulmonary restriction
3292273|NCT01762917||Controls|Pulmonary healthy controls
3292274|NCT01762930|Active Comparator|Shanchol stored at 2-8oC|Vaccines will be stored at 2-8oC before administration.
3292275|NCT01762930|Experimental|Shanchol stored at 25oC|Vaccines will be stored at 25oC for 14 days before administration.
3292276|NCT01762930|Experimental|Shanchol stored at 37oC|Vaccines will be stored at 37oC for 14 days before administration.
3292277|NCT01762930|Experimental|Shanchol stored at 42oC|Vaccines will be stored at 42oC for 14 days before administration.
3292278|NCT01762956|Experimental|Training group (TG)|The group of patients undergoing radiotherapy and submitted to pelvic floor muscles training.
3292279|NCT01762956|No Intervention|Control group(CG)|The group of patients undergoing radiotherapy only.
3292280|NCT01762969|Experimental|Modified by molecular response|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
3292281|NCT01762995|Experimental|Cohort 1|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment B = single dose DTG 50 mg + Calcium Carbonate 1200 mg fasted. Treatment C = single dose of DTG 50 mg + Calcium Carbonate 1200 mg fed. Treatment D = single dose DTG 50 mg 2 hours prior to single dose Calcium Carbonate 1200 mg fasted
3292282|NCT01762995|Experimental|Cohort 2|Subjects in this cohort will take part in 4 treatment periods with one of the following treatments in each period. Subjects will receive all four treatments (one per period) in a random order. Treatment A = single dose DTG 50 mg fasted. Treatment E = single dose DTG 50 mg + Ferrous Fumarate 324 mg fasted. Treatment F = single dose of DTG 50 mg + Ferrous Fumarate 324 mg fed. Treatment G = single dose DTG 50 mg 2 hours prior to single dose Ferrous Fumarate 324 mg fasted
3292283|NCT01763008||Doripenem|Patients will be administered doripenem as per the dosing regimen given on product insert approved in Philippines.
3292284|NCT01763021|Experimental|PCI-32765 + Rifampin|Participants will recieve a single oral dose of PCI-32765 560 mg on Day 1 and Day 11 along with rifampin; and rifampin 600 mg from Day 4 to Day 13.
3292285|NCT01763034|Sham Comparator|limb ischemia|
3292286|NCT01763060||ECMO survivors|CT scan of the chest of all ECMO survivors after 2009/2010 pandemics Tests for cognitive function MRI of the brain Lung function
3292287|NCT01763073||Medical Students|Fourth-year students in accredited US medical schools who have applied to, but not yet been matched with, residency programs in obstetrics and gynecology.
3292288|NCT01763086|Experimental|Mesenchymal stem cells|Mesenchymal stem cells 1×10^6 cells/kg, intravenously
3292289|NCT01763099|Experimental|Mesenchymal stem cells|Mesenchymal stem cells group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)
3379500|NCT05162820|Experimental|Non-smoker Solarplast|Non-smoker assigned to solarplast
3292290|NCT01763099|Experimental|Mesenchymal stem cells and cord blood|Mesenchymal stem cells and cord blood group refers to treatment with mesenchymal stem cells (at a dose of 1×10^6 cells/kg) and cord blood
3292291|NCT01763112|Placebo Comparator|Placebo group|This group will not do any specific training baseline and week 4 investigation will be done only
3292292|NCT01763112|Active Comparator|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
3292293|NCT01763125||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions. Blood samples will be taken."
3292294|NCT01763125||Benign controls|"Patients with a benign tumor or an inflammatory disease - to be matched by age and affected organ with a patient with a malignant disease.~Blood samples will be taken."
3292295|NCT01763125||Healthy controls|"People/patients who have no known disease at time of blood sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.~Blood samples will be taken."
3292296|NCT01763138|Other|pamphlet and reminder|pictorial oral health pamphlet comprising of instructions on child's oral hygiene and feeding practices and a oral health education reminder phone call after a period of one month.
3292297|NCT01763138|Other|pamphlet only|oral health education pictorial pamphlet would be provided to mothers however there will be no reminder phone calls.
3292298|NCT01763138|No Intervention|control|no oral health education or reminder phone calls will be provided to mothers.
3292299|NCT01763151|Active Comparator|toric IOL|aspherical, toric acrylic IOL (Lentis L-312T, Oculentis, Germany)
3292300|NCT01763151|Active Comparator|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with OCCI
3292301|NCT01763177|No Intervention|No oxygen|No given oxygen at post-anesthetic care unit
3292302|NCT01763177|Active Comparator|Oxygen|Oxygen nebulizer via face mask, Fraction of inspired oxygen (FiO2) 0.4, flow 8 liter per minute (LPM) for 30 minutes
3292303|NCT01763190|Experimental|SAR302503|single treatment of 300 mg oral dose of SAR302503
3292304|NCT01763216|Experimental|Road Tour|Road Tour was designed to improve the efficiency and accuracy of visual information processing and the ability to perform complex visual attention tasks. It focuses on improving the speed and accuracy with which users identify and locate visual information using a divided attention format. Over time, the difficulty and complexity of each task is systematically increased as users attain specified performance criteria. Difficulty is increased by reducing visual stimuli duration, adding visual distracters, increasing similarity between target and distracter stimuli, and presenting visual targets over a broader spatial expanse.
3292305|NCT01763216|Sham Comparator|Boatload of Crosswords|Boatload of Crosswords offers the user a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also provides optional help features that the user may select, like filling in a letter or word to minimize frustration levels often associated with puzzle completion. Boatload of Crosswords was chosen for this study because it is computerized, it is very popular and easy to use, and many older adults enjoy doing crossword puzzles. Boatload of Crosswords, however, does not improve speed of processing because it does not focus on central discrimination and peripheral target location. Indeed, Boatload of Crosswords is not designed to train on any aspect of cognitive ability associated with visual speed of processing.
3292306|NCT01763229|Experimental|transthoracic echocardiography|
3292307|NCT01763242|Active Comparator|EMAN|Electronic auditing via synchronised blood tests and monthly dosing ESA and Home delivery of ESA from Pharmacy if required
3292308|NCT01763242|No Intervention|Control|Standard Outpatient Care with usual blood tests and follow up, and varied ESA dosing and frequency times. Patients are responsible for collecting their own ESA from Pharmacy
3292309|NCT01763255|Experimental|CD133 transplantation|The patients with cerebral palsy that underwent CD133 transplantation.
3292310|NCT01763255|No Intervention|Control|The patients with cerebral palsy that underwent regular observation.
3292311|NCT01763268|Experimental|Trivivac|Children who receive Trivivac vaccine
3292312|NCT01763281|Active Comparator|CRH|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
3292313|NCT01763281|Placebo Comparator|Normal Saline (0.9%)|"100 microgram bolus of Cortisol Releasing Hormone intravenous injection given at a 20 minutes prior to Fructose drink during one of the two visits.~The placebo comparator will be 0.9% saline (1ml) bolus injection given intravenously at the same time point during one of the two visits"
3292314|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min|Apply 1 session of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3292315|NCT01763294|Active Comparator|Nicolet Endeavor CR: 60min|Apply 1 session of 2 milliampere intensity for 60 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3292316|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 3 days|Apply 3 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3292317|NCT01763294|Active Comparator|Nicolet Endeavor CR: 30min for 5 days|Apply 5 sessions of 2 milliampere intensity for 30 minutes. The stimulation mode will be continuous with frequency of 3 Hz. The site of application depends on the basal EEG findings based on the international 10/20 system.
3292318|NCT01763294|Placebo Comparator|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
3292319|NCT01763307|Experimental|RECONVAL CREAM|half face treated with RECONVAL CREAM
3292320|NCT01763307|Placebo Comparator|PLACEBO|half face treated with PLACEBO cream
3292321|NCT01763385|Experimental|Erlotinib & secondary brain radiotherapy|Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.
3292322|NCT01763385|Other|Erlotinib & concurrent brain radiotherapy|Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons
3292323|NCT01763398||non-Hodgkin's lymphoma|Patients with non-Hodgkin's lymphoma, high risk group for neutropenic fever, treated by CHOP-like regimen and primary G-CSF prophylactic therapy
3292324|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN60D3 IOL)|No Intervention: Multifocal Spheric IOL implantation
3292325|NCT01763411||Monofocal Spheric Intraocular Lens (AcrySof SN60AT IOL)|No Intervention: Monofocal Spheric IOL implantation
3292326|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMA00 IOL)|No intervention Multifocal IOL implantation
3292327|NCT01763411||Monofocal Aspheric Intraocular Lens (AcrySof SN60WF IOL)|No Intervention: Monofocal IOL implantation
3292328|NCT01763411||Multifocal Aspheric Intraocular Lens (Tecnis ZMB00 IOL)|No intervention Multifocal IOL implantation
3292329|NCT01763411||Multifocal Spheric Intraocular Lens (Restor SN6AD1 IOL)|No intervention Multifocal IOL implantation
3292330|NCT01763424|Active Comparator|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
3292331|NCT01763424|Experimental|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
3292332|NCT01763437|No Intervention|Observation|30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
3292333|NCT01763437|Experimental|Tetracycline|30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
3292334|NCT01763450|Experimental|Bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
3292335|NCT01763463||Patients with COPD who develop severe pneumonia|Patients with COPD who develop severe pneumonia
3292336|NCT01763463||Patients with COPD who do not develop severe pneumonia|Patients with COPD who do not develop severe pneumonia
3292337|NCT01763476|Active Comparator|Paclitaxel-coated balloon angioplasty|Target lesion to be treated with paclitaxel-coated balloon
3292338|NCT01763476|Active Comparator|Atherectomy + paclitaxel-balloon|Target lesion to be treated with atherectomy (TurboHawk, ev3) and paclitaxel-coated balloon
3292339|NCT01763489|Experimental|ASSIST tool group|Surgeons will assess the applicability of a trial using the ASSIST
3292340|NCT01763489|Active Comparator|Synopsis Group|Surgeons will assess the applicability of a trial using the synopsis presented in a case vignette
3292341|NCT01763502|Experimental|FOOD|Food transfer linked to preschool enrollment
3292342|NCT01763502|Experimental|CASH|Cash transfer linked to preschool enrollment
3292343|NCT01763502|No Intervention|CTRL|No transfer linked to preschool enrollment
3292344|NCT01763515|Experimental|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
3292345|NCT01763528|Active Comparator|nutrition intervention|high protein diet
3292346|NCT01763528|No Intervention|control group|control diet
3292347|NCT01763541|Other|Testosterone|"To determine the effect of testosterone on the NP responses to acute and chronic salt loading.~One testosterone patch (Androderm 5 mg) applied to each male subject each day for 14 days.~Intervention: Leuprolide acetate and anastrozole"
3292348|NCT01763541|Other|Estradiol|"To determine the effect of estradiol on the NP responses to acute and chronic salt loading.~Two estradiol patches (Vivelle Dot 0.1mg) will be applied to each female subject twice-a-week for 2 weeks.~Intervention: leuprolide acetate"
3292349|NCT01763580|Experimental|Tacrolimus with low-dose corticosteroid|Oral
3292350|NCT01763580|Active Comparator|High-dose corticosteroid alone|Oral
3292351|NCT01763593||Aurosleek blades|Patients having cataract will undergo surgery by using Aurosleek blades
3292352|NCT01763619|Experimental|Freedom Cervical Disc|
3292353|NCT01763658|Experimental|Antioxidant, drug therapy for ITP|interventional arm 1 and will receive antioxidant therapy (Antox tablets ( 1 tablet contains : Vit. A 2000 IU, Vit C 90 mg, Vit E 15 mg and selenium yeast 55 ug ) with the therapy selected for ITP tailored according to patient's presentation.For Antox tablets it will be given daily for 6 months.
3292354|NCT01763658|Active Comparator|drug therapy for ITP|drug therapy for ITP according to ASH, 2011 guidelines.
3292355|NCT01763671|Active Comparator|Docetaxel|
3292356|NCT01763671|Experimental|Paclitaxel - Bevacizumab|
3292357|NCT01763697|Active Comparator|Morhpine/Taste acuity|Taste acuity assessment after 1mg subcutaneous morphine injection
3292358|NCT01763697|Placebo Comparator|Placebo/Taste acuity|Taste acuity assessment after subcutaneous placebo injection
3292359|NCT01763697|Active Comparator|Morphine4/Taste acuity|Taste acuity assessment after 4mg subcutaneous morphine injection
3292360|NCT01763710|Active Comparator|Arm A|Paclitaxel 80 mg/m2 days 1, 8 and 15
3292361|NCT01763710|Experimental|Arm B|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
3292362|NCT01763710|Experimental|Arm C|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
3292363|NCT01763710|Experimental|Arm D|Nab-paclitaxel 150 mg/m2 days 1 and 15
3292364|NCT01763723|Experimental|IPL after UV-exposure|8 UV-exposures followed by 3 weekly IPL exposures
3292365|NCT01763736|Experimental|Music|Everyone enrolled with receive music sessions.
3379501|NCT05162820|Placebo Comparator|Non-smoker Placebo|Non-smoker assigned to placebo
3292366|NCT01763749|Experimental|Closone|75mg/100mg per day, 4weeks, PO
3292367|NCT01763749|Active Comparator|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
3292368|NCT01763762|Experimental|Electrical pudendal nerve stimulation|At a frequency of 2.5 Hz and an intensity (45~55 mA) as high as the patient can tolerate without discomfort; 60 minutes three times a week for a total of four weeks
3292369|NCT01763762|Active Comparator|PFM training with Transvaginal ES|"PFM training: EMG-biofeedback assisted PFMT was performed by specially trained therapists, 20 min three times a week for a total of four weeks. Patients conduct 30 maximal high intensity PFM contractions for 2-6 sec (with 2-6 sec rest), three sessions a day at home for a total of four weeks.~Transvaginal ES: At a current intensity of < 60 mA (as high as possible to get a contraction) and frequencies of 15 Hz and 85 Hz (alternate 3-min periods of stimulation); 20 min three times a week for a total of four weeks."
3292370|NCT01763775|Experimental|Transtek 125X|Which measured by DUT (Transtek 125X): GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B.
3292371|NCT01763775|Experimental|Transtek 950D|Measured by Reference (Transtek 950D): GBF-950-D.
3292372|NCT01763788|Experimental|Necitumumab + Gem and Cis|"Phase 1b Dose Escalation: Necitumumab 800 milligram (mg) on Days 1 and 8 of every 21 day cycle, administered as an intravenous (IV) infusion. Gemcitabine (Gem) dose escalation of 1000 or 1250 milligram per square meter (mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin (Cis) 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles.~Phase 2 Randomized: Necitumumab 800 mg on Days 1 and 8 of every 21 day cycle, administered as an IV infusion. Gemcitabine at fixed dose determined in Phase 1b (1000 or 1250 mg/m^2) on Days 1 and 8 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion for a maximum of 4 cycles."
3292373|NCT01763788|Active Comparator|Gemcitabine + Cisplatin|Phase 2 Randomized: Gemcitabine at fixed dose determined in Phase 1b (1000 to 1250 mg/m^2) on Day 1 and Day 8 of every 21 day cycle,administered as an IV infusion over approximately 30 minutes for a maximum of 4 cycles. Cisplatin 75 mg/m^2 on Day 1 of every 21 day cycle, administered as an IV infusion over approximately 120 minutes for a maximum of 4 cycles .
3292374|NCT01763801|Active Comparator|P-Max group|Includes cases in which the catheter tip was considered correctly positioned when the Maximal P wave was obtained
3292375|NCT01763801|Active Comparator|P-Submax group|Includes cases in which the catheter tip was considered correctly positioned when the Submaximal P wave was obtained
3292376|NCT01763814|Active Comparator|Single shot femoral nerve block|A ultrasound probe will be used to identify the nerve, and correct needle placement.
3292377|NCT01763814|Active Comparator|Femoral nerve block non stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered off.
3292378|NCT01763814|Active Comparator|Femoral nerve block stimulating catheter|A ultrasound probe will be used to identify the nerve, and correct needle placement. The catheter will be placed with the nerve stimulator powered on.
3292379|NCT01763840|Experimental|Contrast enhanced Ultrasound|Presence and grade of solid organ injury on contrast enhanced ultrasound
3292380|NCT01763853|Other|albumin|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
3292381|NCT01763853|Other|crystalloid|The main objective of our prospective double blind, randomized, controlled trial is to compare the rate of alveolar fluid clearance, a marker of alveolar edema fluid resorption, in 2 groups of patients with ARDS and suffering from hypovolemia: those treated with albumin and those treated with crystalloid (fluid challenge of 7 mL/kg over 15 minutes, that can be repeated 3 times if hypovolemia persists).
3292382|NCT01763879|Active Comparator|The PCV-VCV group|The dependent lung will be ventilated with pressure controlled (PCV) followed by the volume-controlled ventilation (VCV)
3292383|NCT01763879|Active Comparator|The VCV-PCV group|The dependent lung will be ventilated with volume-controlled ventilation (VCV) followed by the pressure controlled (PCV)
3292384|NCT01763892||Children admitted to hospital with a TBI|non-intervention study
3292385|NCT01763944|Active Comparator|Low carbohydrate, lifestyle counseling|The Low carbohydrate arm will receive counseling to follow a carbohydrate restriction diet (<20 grams per day) for 6 months.
3292386|NCT01763944|No Intervention|Control|The control arm will receive no dietary intervention.
3292387|NCT01763957|Active Comparator|Pelvic Floor Muscle Training (PFMT)|
3292388|NCT01763957|Active Comparator|Paula Method|
3292389|NCT01763983|Experimental|Aerobic Exercise|12-week structured and monitored aerobic exercise program
3292390|NCT01763983|Experimental|CBT and Aerobic Exercise|Combined 12-week individual Cognitive Behavioural Therapy and Exercise Program
3292391|NCT01763983|No Intervention|Waitlist Condition|12-week waitlist control condition, after which participants will have the chance to receive CBT group treatment.
3292392|NCT01764009|Experimental|Plasmid AMEP electrotransfer in muscle|
3292393|NCT01764035|Active Comparator|Brief Supportive Psychotherapy (SP)|30 people will be randomized to receive Brief Supportive Psychotherapy.
3292394|NCT01764035|Experimental|Body Scan (BS) Meditation Intervention|30 people will be randomized receive the Body Scan Meditation Intervention.
3292395|NCT01764048|Experimental|Fix protocol|"During 48 hours following surgery pain medications will be given as followed (listed in brackets are the generic names of each medication):~At patient arrival to the department: Intravenous Tramadol hydrochloride 100 milligrams + TAB. Paracetamol 500 milligrams + TAB. Diclofenac 100 milligrams~After 6 hours from patient arrival and every 6 hours: TAB. Zaldiar (Paracetamol 650 milligrams + Tramadol 75 milligrams).~After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.~Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.~The total amount of paracetamol is limited to 4 gr per day."
3292396|NCT01764048|Experimental|medications following demand protocol|The same combinations will be given as in the fixed protocol however only after patient request
3379502|NCT05162807|Experimental|Palliative Care Education|The intervention arm will view a psychoeducational video on palliative care.
3292397|NCT01764074|Experimental|Brief Sleep Intervention|Every participant in the study will complete a 3-session sleep intervention with a clinician to improve sleep problems such as insomnia or hypersomnia.
3292398|NCT01764087|Experimental|KX2-391 and Paclitaxel|"The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. 3 or 6 subjects with solid tumor per dose group will likely be necessary to determine the MTD of KX2-391 in combination with weekly paclitaxel. With paclitaxel dose fixed at 80 mg/m2/weekly, KX2-391 treatment will be started at 20 mg dose once daily (QD)~The phase II portion of this trial has a design to determine the efficacy of KX2-391 when administered in combination with paclitaxel in 20 subjects with stomach cancer and 20 subjects with breast cancer"
3292399|NCT01764100|Experimental|Mesenchymal Stromal Cells (MSC)|Intravenous injections for a dose of 1 ± 0.5 x 106 MSC/kg recipient body weight
3292400|NCT01764113|Experimental|Mindful Eating|Subjects and at least one of their parents will receive mindful eating based behavioral modification program
3292401|NCT01764113|Active Comparator|Standard Dietary Couseling|Subjects and their parents will receive standard nutritional counseling provided by a registered dietician
3292402|NCT01764126|Active Comparator|Pneumococcal protein vaccine|Pneumococcal protein vaccine
3292403|NCT01764126|Placebo Comparator|Placebo|Placebo
3292404|NCT01764139||Knee pain patients with minimal knee changes|Male & no pregnant female age between 18-40 yrs.
3292405|NCT01764152|Experimental|Nasopharyngeal sample|one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days.
3292406|NCT01764165|Active Comparator|oxygen|nocturnal oxygen of 2 L/min
3292407|NCT01764165|Experimental|High Flow of room air|Warm and humidified air at a rate of 20 L/min through a small nasal cannula (similar to oxygen cannula)
3292408|NCT01764178|Experimental|Livalo fixed combination drug|Livalo fixed combination drug(Pitavastatin + Valsartan)
3292409|NCT01764178|Active Comparator|Pitavastatin + Valsartan|Pitavastatin, Valsartan
3292410|NCT01764204||Qingkailing Injection|
3292411|NCT01764230|Experimental|case group|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
3292412|NCT01764230|No Intervention|control group|no intervention
3292413|NCT01764243|Experimental|MT-4666 Low Dose|low dose
3292414|NCT01764243|Experimental|MT-4666 High Dose|high dose
3292415|NCT01764243|Placebo Comparator|Placebo|placebo
3292416|NCT01764269|Other|inactivated influenza vaccine (IIV)|Patients whose provider chooses to administer to them inactivated influenza vaccine (IIV)
3292417|NCT01764269|Other|Live attenuated influenza vaccine (LAIV)|Patients whose provider chooses to administer to them Live attenuated influenza vaccine (LAIV)
3292418|NCT01764282|Experimental|Intervention|comprehensive intervention components
3292419|NCT01764282|No Intervention|Usual|According the National HIV Antiretroviral treatment Guideline, provide treatment referrals for those treatment-eligible HIV-positive patients.
3292420|NCT01764295|Experimental|DWJ1276|Once daily, administered orally, 8 week
3292421|NCT01764295|Active Comparator|Olmesartan|Once daily, administered orally, 8 week
3292422|NCT01764295|Active Comparator|Rosuvastatin|Once daily, administered orally, 8 week
3292423|NCT01764295|Placebo Comparator|Placebo|Once daily, administered orally, 8 week
3292424|NCT01764308|Experimental|O3FA|Omega 3 Fatty Acid 1200mg twice a day for 24 weeks
3292425|NCT01764308|Placebo Comparator|Placebo|4 tablets twice a day for 24 weeks
3292426|NCT01764321||Certolizumab Pegol treatment|Certolizumab Pegol in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
3292427|NCT01764321||Other Tumor Necrosis Factor TNF inhibitor treatment|Other subcutaneous (sc) Tumor Necrosis Factor (TNF) inhibitor (Adalimumab, Golimumab, Etanercept) in combination with at least one Disease Modifying Antirheumatic Drug (DMARD)
3292428|NCT01764334|Active Comparator|Fractional flow reserve|"Fractional flow reserve - guided group:~The initial treatment decision and the coronary arteries for fractional flow reserve (FFR) measurement will be established and recorded before randomization. FFR will then be measured by the cardiologist immediately after randomization and the FFR result will used to guide treatment decisions based on a threshold of 0.80. An FFR ≤ 0.80 should result in a treatment decision for revascularization by PCI or CABG combined with optimal medical therapy and an FFR>0.80 should result in treatment with optimal medical therapy alone. Changes in treatment compared to the treatment plan prior to FFR disclosure will be recorded at the time."
3292429|NCT01764334|Placebo Comparator|Angiography-guided|FFR is measured by but not disclosed to the clinical team. Treatment decisions are therefore guided by angiography but not by FFR. The patient and the clinical team, including the cardiologists and nurses, will be blinded to FFR. The RadiAnalyzer Xpress (St Jude Medical) will be turned away from the clinical team who will not see the pressure wire data. FFR will not be displayed on any other monitor. Quality control checks, such as assessments of equalized pressure, will be done in the usual way, by the unblinded clinical research team. These steps will be followed for all FFR measurements. Adherence to the blinding protocol, including any non-protocol FFR disclosure at any time, will be prospectively recorded and blinding procedures will be monitored with site visits.
3292430|NCT01764347|Experimental|Diagnostic (MRI-TRUS fusion image-guided biopsy)|Patients undergo robotic radical prostatectomy, followed by 3 MRI-TRUS fusion image-guided prostate biopsies.
3292431|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will be randomized at different timepoints to receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
3292432|NCT01764373|Experimental|16-Week Exercise Program|Subjects to participate in 16-week3 supervised aerobic exercise 3 times per week. Exercise sessions to last between 30 and 60 minutes.
3292433|NCT01764399|Experimental|Care4U intervention|Care4U intervention with 6 weekly sessions focusing on physical activity, healthy eating, self-management, emotional responses.
3292434|NCT01764399|No Intervention|Information group|The information group receives 6 weekly socialization sessions.
3292435|NCT01764412||Healthy women|Non interventional
3292436|NCT01764425|Active Comparator|P7435|Tablets for once daily oral administration, For SAD part of the study dose would be 10 mg for Cohort 1; Cohorts 2, 3, 4 and 5 will be dosed subsequently at 30 mg, 100 mg, 300 mg, 1000 mg respectively Dose for MAD and food effects part of the study would be based on SAD study results
3292437|NCT01764425|Placebo Comparator|Placebo|Placebo tablets for oral administration
3292438|NCT01764438||very early or early staged patients|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious HCC by liver dynamic CT
3292439|NCT01764451|Experimental|Simvastatin|20-40 mg tablet taken daily by mouth. Month 1: 20 mg; Months 2 and 3: 40 mg.
3379503|NCT05162807|Placebo Comparator|Attention Control|The control arm will view an educational video on nutrition as an attention control.
3379504|NCT05162794|Other|Active Surgery|
3292440|NCT01764451|No Intervention|No Treatment|
3292441|NCT01764477|Experimental|PRI-724 and Gemcitabine|This study will have one arm: all enrolled subjects will be treated with both PRI-724 and Gemcitabine.
3292442|NCT01764516||Zinc level (micro gram per deciliter)|In all cases
3292443|NCT01764516||Selenium level (micro gram per deciliter)|In all cases
3292444|NCT01764516||Zinc level in male (micro gram per deciliter)|
3292445|NCT01764516||Selenium level in male (micro gram per deciliter)|
3292446|NCT01764516||Zinc level in Female (micro gram per decilitre)|
3292447|NCT01764516||Selenium level in Female (micro gram per decilitre)|
3292448|NCT01764542|Other|Endoscopy and biopsy|Endoscopy with biopsy taken Endoscopy and biopsy Blood samples Questionnaire
3292449|NCT01764555|Experimental|normal weight patients|normal weight patients receiving acetaminophen 2 g instead of 1 g
3292450|NCT01764555|Experimental|mobidly obese patients|morbidly obese patients receiving acetaminophen 2 g instead of 1 g
3292451|NCT01764568|Experimental|Metacognitive Training for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Metacognitive Training twice weekly for 8 weeks (16 sessions).
3292452|NCT01764568|Experimental|Cognitive Remediation for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will receive Cognitive Remediation treatment twice weekly for 8 weeks (16 sessions).
3292453|NCT01764568|No Intervention|Treatment as Usual for Psychosis|Individuals with psychosis (Schizophrenia, Schizoaffective, Schizophreniform, etc.) who will continue to receive treatment as usual (TAU) as defined by their health care team (i.e., medication, other therapies) while still taking part in baseline, midpoint, and end-point assessments.
3292454|NCT01764581|Experimental|Tacrolimus dose regulation|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL.
3292455|NCT01764581|No Intervention|Control|immunosuppressive therapy is managed either by standard practice at our center (Control)
3292456|NCT01764594|Experimental|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
3292457|NCT01764594|Placebo Comparator|Placebo|Placebo
3292458|NCT01764620|Other|Control|In this session, the athletes will be evaluated before and after the fatigue protocol, without any taping application.
3292459|NCT01764620|Experimental|Kinesio taping|A kinesio taping technique for facilitating lower trapezius muscle function will be applied just before fatigue protocol and removed after in the end of the evaluation session.
3292460|NCT01764620|Sham Comparator|Sham|A similar technique, using the same tape, will be applied but without any tension (tension is considered to be the therapeutic effect). The tape will be applied just before the fatigue protocol and removed in the end of the session.
3292461|NCT01764646|Experimental|9 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) once a week over 28 days
3292462|NCT01764646|Experimental|28 days|Patients undergo extreme hypofractionated radiation therapy (Intensity modulated radiation therapy, Volumetric modulated arc therapy, Image guided radiation therapy) other 9 days.
3292463|NCT01764672|Experimental|Attention Deficit Hyperactivity Disorder|Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
3292464|NCT01764672|Experimental|Healthy adults|Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days.
3292465|NCT01764698|Experimental|CALM-SUD|Participants receive the adaptation of the Coordinated Anxiety Learning and Management (CALM) protocol that demonstrated effectiveness in a large primary care sample. CALM will be adapted for those with anxiety and substance use disorder comorbidity, and will consist of an orientation session and 6 group treatment sessions. These participants will also receive substance abuse treatment as usual at a community Intensive Outpatient Program.
3292466|NCT01764698|Active Comparator|Treatment as usual|Participants in this arm receive the standard Intensive Outpatient treatment for their substance use disorder at a community addictions treatment facility.
3292467|NCT01764724||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
3292468|NCT01764737|Experimental|VX15/2503|
3292469|NCT01764737|Experimental|Placebo|
3292470|NCT01764750|Experimental|Low Dose Intrasite Vancomycin|10 patients will be enrolled to receive low dose (see protocol) intrasite Vancomycin at the time of surgery. This will be the first group enrolled in the dose-escalation trial.
3292471|NCT01764750|Experimental|Mid-dose Intrasite Vancomycin|10 patients will be enrolled to receive mid-dose intrasite Vancomycin at the time of surgery.
3292472|NCT01764750|Experimental|High-dose Intrasite Vancomycin|10 patients will be enrolled to receive high-dose intrasite Vancomycin at the time of surgery.
3292473|NCT01764750|Active Comparator|Optimally-dosed IV Vancomycin|10 patients will be enrolled to receive optimally-dosed IV Vancomycin at the time of surgery and two doses post-operatively (standard peri-operative IV antibiotics)
3292474|NCT01764763||non epiaortic group|non epiaortic group ( n=1019)
3292475|NCT01764763||epiaortic group|epiaortic group ( n=1273)
3292476|NCT01764776|Experimental|LDE225|LDE225
3292477|NCT01764789|Experimental|Supportive care (psychosocial intervention)|Patients participate in a multi-component intervention based on cognitive and behavioral principles comprising MBSR, an intervention to promote hopefulness, and a problem solving approach which navigates around obstacles or generates alternatives when goals become blocked. Additional topics may be covered as indicated by clinical need and patients goals. Biobehavioral components include addressing social and disease-specific quality of life, and pain education. Intensive treatment sessions continue weekly for 16 weeks followed by 2 biweekly and 2 monthly maintenance sessions.
3292478|NCT01764802|Active Comparator|Arm I (enhanced standard care)|Patients participate in enhanced standard care intervention comprising stress reduction, information delivery regarding cancer treatments and sexuality delivered over two sessions.
3379505|NCT05162794|Other|Diagnostic Surgery|
3379506|NCT05162794|Other|No-surgery control|
3292479|NCT01764802|Experimental|Arm II (psychological intervention)|Patients participate in individual or group therapy over 1.5 hours weekly for 6 weeks, bi-weekly for 8 weeks, and monthly for 2 months and complete assessment interviews.
3292480|NCT01764815|Experimental|Directional lead|
3292481|NCT01764828|Experimental|Refametinib (BAY86-9766)+ Gemcitabine|Single dose of BAY86-9766 on Cycle 1 Day -17; twice daily dosing every day starting on day -14, start dose 50mg bid ( 30mg or 20mg are possible based on adverse events need) in addition with Gemcitabine intravenous on day 1,8 and 15 1000mg/m2
3292482|NCT01764867|Active Comparator|Algorithm Guided Treatment (AGT)|Algorithm Guided Treatment (AGT) strategies include two steps. In the first step, participants will be randomly assigned to escitalopram (10-20mg/d) or mirtazapine (30-45mg/d) group. In the second step those non-remitted will be allocated into a set of different intervention groups including mirtazapine monotherapy (only for those taken escitalopram in the first step), escitalopram monotherapy (only for those taken mirtazapine in the first step), or combination therapies (i.e. escitalopram plus mirtazapine, escitalopram or mirtazapine plus either modified electroconvulsive therapy with 6-10 sessions or repetitive transcranial magnetic stimulation with 20 sessions respectively) according to intent-to-treat principle. Medication dosage in combination therapy has the same range as the first.
3292483|NCT01764867|Active Comparator|Treatment As Usual (TAU)|This control arm refers to routine antidepressant treatment strategies for participants. Any of the new-generation antidepressants including fluoxetine, citalopram, escitalopram, paroxetine, sertraline, fluvoxamine, venlafaxine, duloxetine, mirtazapine, bupropion, or trazodone, which are all available in Chinese psychiatric clinics, may be used for participants who are randomly assigned to this treatment arm based on clinician's expertise and clinical judgement. The dosage range of any of the above antidepressants depends on clinician's judgement. The follow-up period will last up to 6-12 weeks. During follow-ups, clinician can decide to continue current treatment or start a switch or combination strategy based on his/her own clinical judgement.
3292484|NCT01764880|Experimental|SST0001 (Roneparstat)|"SST0001 once daily for 5 or 10 days in a cycle of 28 days. Starting dose 25 mg, to be escalated in subsequent cohorts.~Duration of treatment depending on toxicities observed or until documentation of disease progression or other discontinuation criteria are met."
3292485|NCT01764893|Active Comparator|PTNS and solifenacin|PTNS bladder neuromodulation weekly for 12 treatments; solifenacin 5 mg capsule daily for 15 weeks
3292486|NCT01764893|Placebo Comparator|PTNS and placebo|PTNS bladder neuromodulation weekly for 12 treatments; placebo 1 capsule daily for 15 weeks
3292487|NCT01764906|Experimental|Novosis|Bongros/rhBMP-2
3292488|NCT01764906|Active Comparator|Iliac crest bone graft|Iliac crest bone graft
3292489|NCT01764932|Other|Thoracic epidural catheter insertion|Fluoroscopic imaging. For patients undergoing thoracic epidural analgesia (TEA) with catheter placement for pain associated with thoracic or upper abdominal surgery
3292490|NCT01764958||preterm infants and their mothers|"Inclusion criteria are: preterm infants born between 26-34 weeks of gestation, whose mothers speak and write Hebrew fluently. Exclusion criteria are: preterm infants who suffer from perinatal asphyxia, genetic or metabolic diseases, necrotizing colitis that requires operation, intra uterine growth retardation, deafness, retinopathy of prematurity (ROP) or major congenital defects.~Infants and their mothers will be recruited from child developmental centers and Pediatric Clinics of Maccabi. No intervention is included in the research."
3292491|NCT01764971||chronic itp and cerebral dysfunction|patients with chronic itp and had behavioral and or cognitive dysfunction
3292492|NCT01764971||chronic itp only|chronic ITP patients without cerebral dysfunction
3292493|NCT01764984|Experimental|Trabecular metal|Primary Total Knee Arthroplasty is performed with a non cemented trabecular metal tibial baseplate.
3292494|NCT01764984|Active Comparator|Titanium|Primary total knee arthroplasty is performed with cemented titanium traditional tibial base plate
3292495|NCT01765010|Placebo Comparator|Placebo control|Placebo control
3292496|NCT01765010|Active Comparator|Cholecalciferol 1000IU|Cholecalciferol 1000IU qd for 8 weeks
3292497|NCT01765010|Experimental|alfacalcidol|alfacalcidol 0.5ug qd for 8 weeks
3292498|NCT01765010|Experimental|Calcitriol|Calcitriol 0.25ug qd for 8 weeks
3292499|NCT01765023|Experimental|Part A|single administration : atorvastatin 40mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
3292500|NCT01765023|Experimental|Part B|single administration : metformin XR 1000mg, qd, 7days(oral) combination administration : atorvastatin 40mg and metformin XR 1000mg, qd, 7days(oral)
3292501|NCT01765036|Experimental|SonoVue®|"Non randomised study~Sonovue 4,8 ml intravenous administration, in 1 bolus, during the EUS examination"
3292502|NCT01765062||Before Rapid Maxillary Expansion|T0
3292503|NCT01765062||3 months After Rapid Maxillary Expansion|T1
3292504|NCT01765062||One year After Rapid Maxillary Expansion|T2
3292505|NCT01765075||Patients undergoing cardiac ablation for permanent AF|
3292506|NCT01765088|Active Comparator|temozolomide|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide (150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles)
3292507|NCT01765088|Experimental|temozolomide +α-IFN|Four weeks after radiotherapy, patients will be received 6 cycle of temozolomide plus α-IFN α-IFN：3mIU (3million) Day1,3,5 of each 28 day TMZ：150 mg/m^2 daily on Days 2-6 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles
3292508|NCT01765101|Experimental|customized insoles|"customized full-length lateral wedged shoe insoles~1 month and 3 months study the immediate, short-term and intermediate-term therapeutic effects"
3292509|NCT01765101|Placebo Comparator|ready made insoles|"ready-made full-length lateral wedged shoe insoles at 1 and 3 months~study the immediate, short-term and intermediate-term therapeutic effects"
3292510|NCT01765114|Experimental|PEG-Formulation|PEG-Formulation, applied twice daily during the treatment period (duration: 6 months)
3292511|NCT01765127||Asenapine|Patients prescribed asenapine for any indication by a National Health Service (NHS) general practitioner (GP) in England.
3292512|NCT01765166|Experimental|Control(ChO)|Children receive traditional SSGRIN child treatment with no parent involvement
3292513|NCT01765166|Experimental|Parent attention control(PAC)|Children will participate in traditional SSGRIN treatment, and parents will participate in a weekly support group to meet with other parents regarding their child's peer relations and behavior. The support group will meet for a parallel amount of time (1 hour/week for 10 weeks) and be facilitated by two parents with no SSGRIN or Parent Guide experience. The PAC condition will reflect the social support functions of a parenting group, but no therapeutic skills training or other instructional materials will be provided.
3292514|NCT01765166|Experimental|Parent Guide-Home Study(PG-HS)|Children will receive traditional SSGRIN treatment, and parents will receive the Parent Guide to SSGRIN training by participating in the online Parent Guide Home Study (PG-HS) course. The PG-HS course will include all instructional content and materials for the in-person Parent Guide course, but parent will receive the training online.
3292515|NCT01765166|Experimental|Parent Guide(PG)|Children will receive traditional SSGRIN treatment and parents will receive parallel traditional in-person SSGRIN-Parent Guide treatment.
3292516|NCT01765205||Newborns with Pulse oximetry|Up to 50 healthy newborn participants will receive 15 minutes of pulse oximetry to determine the effectiveness of measuring somatic oxygen saturation.
3292517|NCT01765205||CHD infant with pulse oximetry|Up to 10 infants diagnosed with congenital heart disease will receive 15 minutes of pulse oximetry using the INVOS Cerebral/Somatic Oximeter to determine the effectiveness of measuring somatic oxygen saturation.
3292518|NCT01765218|Placebo Comparator|Placebo|Subjects will receive the standard of care intervention for HIE at our institution (whole body cooling for 72h followed by gradual rewarming)
3292519|NCT01765218|Active Comparator|Topiramate|In addition to whole body cooling, infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
3292520|NCT01765231|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of antitumor therapy, and will be continued until at least 6 months after completion of antitumor therapy.
3292521|NCT01765231|Active Comparator|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
3292522|NCT01765244|Experimental|Anterior lamellar nanostructured artificial human cornea|Anterior lamellar nanostructured artificial human cornea with allogenic from dead donor and cultured in its inside and allogeneic corneal epithelium cultured in its surface
3292523|NCT01765244|Active Comparator|Amniotic membrane transplantation|Amniotic membrane transplantation as conventional treatment of corneal trophic ulcers.
3292524|NCT01765257|Experimental|rasagiline|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
3292525|NCT01765257|Placebo Comparator|placebo|Randomized, double-blind, rasagiline (1 mg) vs placebo study. Parallel group (randomization 1/1). Duration 3 months 16 recruiting centers in France
3292526|NCT01765283|Experimental|Hepastem Low dose|12.5x106cells/kg
3292527|NCT01765283|Experimental|Hepastem Intermediate dose|50x106cells/kg
3292528|NCT01765283|Experimental|Hepastem High dose|200x106cells/kg
3292529|NCT01765296|Active Comparator|Celecoxib|Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
3292530|NCT01765296|Placebo Comparator|Placebo|Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)
3292531|NCT01765296|Experimental|CG100649|CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)
3292532|NCT01765309|Experimental|Bilateral mastectomy with reconstruction|The trial was a comparison between each breast in a single patient undergoing bilateral mastectomy with reconstruction
3292533|NCT01765322|Experimental|Assisted hatching group (AH group)|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).
3292534|NCT01765322|No Intervention|Control group|The subjects are going to undergo the same procedure except for the treatment of assisted hatching.
3292535|NCT01765335|Experimental|NICaS system efficacy in HF patients|NICaS system efficacy in HF patients
3292536|NCT01765348|Experimental|Sentence combining|
3292537|NCT01765348|Active Comparator|Narrative based method|
3292538|NCT01765374|Experimental|rituximab|Only one arm; all patients are treated by rituximab (monotherapy or in combination with conventional DMARD)
3292539|NCT01765387|Experimental|Spa therapy|A cycle of 3 Vichy shower and whirlpool baths are applied during 30-minutes period. Vichy sedative shower is applied for 90-120 sec to the sides of the trunk and the abdomen, avoiding as much as possible the gall bladder area, at a temperature of 36-38ºC. A short, partial jet spray followed the shower. A whirlpool bath is administered where subjects immersed the body until their clavicle level for a 10min period with a water temperature ranging 33.5-35.5 ºC. Aromatherapy application using lavender and chamomile oils is used in all Spa therapy sessions.
3292540|NCT01765387|No Intervention|Control group|"The control group perform a rest session in supine position in a room with neutral temperature condition with a same duration to Spa session. Participants of both groups are encouraged to drink water ad libitum to prevent dehydration."
3292541|NCT01765400|Active Comparator|Prasugrel|Prasugrel 10 mg once daily for 2 weeks
3292542|NCT01765400|Active Comparator|Clopidogrel|Clopidogrel 75 mg once daily for 2 weeks
3292543|NCT01765413|Experimental|Varilrix|Participants receive one dose of 'Varilrix' varicella-zoster vaccine.
3292544|NCT01765413|Experimental|Stamaril|Participants receive one dose of 'Stamaril' yellow fever vaccine.
3292545|NCT01765413|Placebo Comparator|Placebo|Participants receive one injection of placebo.
3292546|NCT01765439|Experimental|CD resected|Patients with Crohn´s disease with the history of single resection (<60 cm) of distal leum.
3292547|NCT01765439|Experimental|UC unoperated|Patients with ulcerative colitis without history of gut resection.
3292548|NCT01765439|Experimental|UC IPAA|Patients with ulcerative colitis after proctocolectomy and ileal pouch-anal anastomosis(IPAA).
3292549|NCT01765439|Experimental|Healthy volunteers|Subjects without any sign of disease of the digestive tract.
3292550|NCT01765452|Experimental|Closone|75mg/100mg per day, 8weeks, PO
3292551|NCT01765452|Active Comparator|Plavix with Astrix|75mg per day, 8weeks, PO 100mg per day, 8weeks, PO
3292552|NCT01765478|Experimental|Treatment A Period 2|40mg HM71224 single dose
3292553|NCT01765478|Experimental|Treatment B Period1|20mg HM71224 single dose
3292554|NCT01765478|Experimental|Treatment A Period1|10mg HM71224 single dose
3292555|NCT01765478|Experimental|Treatment B Period2|80mg HM71224 single dose
3292556|NCT01765478|Experimental|TreatmentA Period3|160mg HM71224 single dose
3292557|NCT01765478|Experimental|TreatmentB Period3|200mg HM71224 single dose
3292558|NCT01765478|Experimental|Food effect period1|active 4subjects + placebo 4subjects
3292559|NCT01765478|Experimental|Food effect period2|active 4subjects + placebo 4subjects
3292560|NCT01765478|Experimental|TreatmentC|HM71224 Xmg multiple dose for 14days
3292561|NCT01765478|Experimental|TreatmentD|HM71224 Ymg 14days multiple dose
3292562|NCT01765478|Experimental|TreatmentE|HM71224 Zmg 14days multiple dose
3292563|NCT01765491|Experimental|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy.
3292564|NCT01765491|Active Comparator|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy.
3292565|NCT01765517|Experimental|Probiotics|Probitoics
3292566|NCT01765517|Placebo Comparator|Placebo|Placebo
3292567|NCT01765556|Experimental|Ketoconazole treatment|
3292568|NCT01765556|Experimental|Vemurafenib treatment|
3292569|NCT01765595|Experimental|DDI+|DDI+ Incorporated in routine ambulatory practice
3292570|NCT01765595|No Intervention|Control|Standard care
3292571|NCT01765608|Experimental|Zonisamide|Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
3292572|NCT01765608|Active Comparator|Placebo|Matched for Zonisamide. Hard white capsule. Manufactured by Eisai Inc. Placebo tablets will be administered according to a forced stepwise weekly titration scheme with weekly 1 tablet escalations from 1 to 3 tablets daily matching the Zonisamide (Zonegran ®) dosing regimen for a total duration of 4 weeks. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
3292573|NCT01765608|Active Comparator|nCPAP|Continuous positive nasal airway pressure (nCPAP) delivers slightly pressurized air throughout the breathing cycle and will be given through a mask that is placed and secured over the person's nose. nCPAP titration will follow clinical routines whereby the patient is equipped with an autotitrating device (Sullivan S8 or S9). The standard setting is a pressure delivery in the pressure range 5-15 mbar and the full treatment is maintained in the patient´s home. The adequate performance of the device is controlled by user time readers and built-in memory cards and control readings are routinely performed within the first 4 weeks of treatment initiation. Patients will be encouraged via telephone calls for maximum use. Total duration of CPAP treatment is 24 weeks.
3292574|NCT01765621|Experimental|DDI+ and Pharmacogenetic data|DDI+ System and Pharmacogenetic data
3292575|NCT01765621|No Intervention|Standard Care|Control
3292576|NCT01765634|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)each week, four times for a cycle
3292577|NCT01765634|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
3292578|NCT01765660|Experimental|Non-mesenchymal stem cells|Non-mesenchymal stem cell group refers to treatment with other second line drugs
3292579|NCT01765660|Experimental|Mesenchymal stem cells|Mesenchymal stem cell group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously)every two weeks, four times for a cycle
3292580|NCT01765686|Active Comparator|Harmonic|Harmonic scalpel uses ultrasound technology to coagulate and to cut tissues.
3292581|NCT01765686|Active Comparator|Small Jaw|Small Jaw device uses bipolar electrical energy and pressure to form a seal and a micro blade to divide the sealed tissues.
3292582|NCT01765699||Primary knee arthroplasty|Patients with osteoarthritis of the knee undergoing primary knee arthroplasty
3292583|NCT01765725|No Intervention|Control group|The control group will be offered to take part in the patient education group as soon as they have completed the last outcome evaluations
3292584|NCT01765725|Experimental|Patient education program|Patient education program
3292585|NCT01765738|Active Comparator|Antibiotic coated PICC|Cook Medical Spectrum Turbo-Ject Minocycline/Rifampin Power-Injectable PICC (5fr double lumen or 6fr triple lumen)
3292586|NCT01765738|Active Comparator|Non-antibiotic coated PICC|Bard Access PowerPICC Power Injection PICCs (6fr double lumen or 6fr. triple lumen)
3292587|NCT01765777|No Intervention|Control Group|Subjects in this arm continue with standard medical care
3292588|NCT01765777|Experimental|Osteopathic Manipulative Medicine Group|Subjects in this arm will receive an OMM intervention.
3379507|NCT05162781|Experimental|CICT with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
3379508|NCT05162781|Experimental|CICT without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) shaping on IADL and (B) the Cognitive Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
3292589|NCT01765777|Experimental|Phototherapy Group|Subjects in this arm will receive a phototherapy intervention.
3292590|NCT01765777|Experimental|OMM and Phototherapy Group|Subjects in this arm will receive both the OMM and phototherapy interventions.
3379509|NCT05162781|Active Comparator|BF-HELP with Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis.
3379510|NCT05162781|Active Comparator|BF-HELP without Follow-up Phone Calls|Participants in this group will receive 35 hours of training. Ten 1-hour sessions of SOPT will be scheduled in the home with training conducted independently by participants. Ten 2.5 hours of in-lab, face-to-face, therapist directed sessions will be scheduled. These sessions will feature a brief period of SOPT; the bulk of the sessions will be committed to (A) training on relaxation, healthy nutrition, and healthy sleep, and (B) the Healthy Lifestyle Transfer Package. Training sessions will be permitted to be scheduled over 2-4 weeks. Family caregivers will receive training on how to best support participants in their therapeutic program. No follow-up phone calls will be made after treatment ends.
3379511|NCT05162768|Experimental|Elamipretide|0.75 mL of 80mg/mL solution of elamipretide for a single daily SC dose of 60mg elamipretide
3379512|NCT05162768|Placebo Comparator|Placebo|0.75 mL of 80mg/mL solution of matching placebo for a single daily SC dose of 60mg
3379513|NCT05162755|Experimental|Dose escalation 1a: S95029|
3379514|NCT05162755|Experimental|Dose escalation 1b: S95029 and Sym021|
3379515|NCT05162755|Experimental|Dose expansion 2a: S095029 and Sym021 and anti-HER2 therapy|
3379516|NCT05162755|Experimental|Dose expansion 2b: S095029 and Sym021 and futuximab/modotuximab|
3292591|NCT01765790|Experimental|Malignant Solid Tumor (Arm 1)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
3379517|NCT05162742|Active Comparator|Colchicine|75 patients will receive colchicine tablets
3379518|NCT05162742|Placebo Comparator|Placebo|75 patients will receive placebo tablets
3379519|NCT05162729|Experimental|Working memory intervention group|Receive game-like working memory online training for 5 weeks, 3 times per week, each lasting for15 minutes.
3379520|NCT05162729|Active Comparator|Social emotional intervention group|Receive game-like social-emotional online training for 5 weeks, 3 times per week, each lasting for 15 minutes.
3379521|NCT05162729|No Intervention|Control group|Receive no training
3379522|NCT05162716||LBBAP|Patients with permanent atrial arrhythmia with an indication of cardiac pacing and atrioventricular junction ablation will undergo the implantation of a single-chamber pacemaker with left bundle branch area pacing, and then atrioventricular junction ablation.
3379523|NCT05162703|Experimental|Intervention group|Participants will be equipped with a spirometer and and the AsthmaTuner mobile phone app to perform an exercise tests in their natural training environment. Feasibility will be evaluated using questionnaires.
3379524|NCT05162690|Active Comparator|The Drug Arm|"Dapagliflozin 10 milligram Once a day~1 year"
3379525|NCT05162690|Placebo Comparator|The Placebo Arm|Metformin 1gram Per Oral Twice a day Glimepiride 2 milligram oral twice a day Dipeptidyl peptidase 4 inhibitors (DPP4 inhibitors)
3379526|NCT05162664|Other|Healthy controls|Healthy controls
3379527|NCT05162664|Other|Patients with migraine|
3379528|NCT05162651|Active Comparator|Contingency management group|Randomized to receive individual motivational interviewing therapy and contingency management
3379529|NCT05162651|Other|Control group|Randomized to receive individual motivational interviewing therapy alone
3379530|NCT05162638|Other|'In-and-out' catheterization|"Safety and immune-cell profile of lymphatic fluid in MS patients with a single time-point sampling of lymphatic fluids and peripheral blood compared to healthy controls.~Two healthy controls and six patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to the 'In-and-out' catheter procedure. MS participants can also consent to OMB treatment with 2-year follow-up."
3292592|NCT01765790|Experimental|Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)|"Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -> 2. Safety data review. If dose escalation permissible -> 3. Next dose group -> 4. Safety data review, etc.~Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s)."
3292593|NCT01765816|Experimental|high intensity interval training|one interval training session with 1 x 4 and 4 x 4 minutes interval training at 90-95% of peak heart rate
3292594|NCT01765816|Active Comparator|moderate intensity training|45 minutes of moderate continuous training at 75% of maximal heart rate
3292595|NCT01765829|Active Comparator|Antipsychotic treatment|"Antipsychotic treatment according to common clinical practice~Drugs: Aripiprazole, Olanzapine, Zuclopenthixol, Clotiapine, Flupentixol, Risperidone, Sulpiride, Trifluoperazine, Haloperidol, Quetiapine, Paliperidone, Chlorpromazine, Pipotiazine, Flufenazine, Periciazine, Clozapine, Pimozide, Perfenazine, Sertindole, Levomepromazine, Amisulpride, Asenapine, Tiapride, Droperidol, Ziprasidone."
3292596|NCT01765829|Experimental|Discontinuation antipsychotic treatment|Dose reduction of antipsychotic treatment (25% every 4 weeks).
3292597|NCT01765842|Active Comparator|Rituximab (1 cycle)|"1 cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2"
3292598|NCT01765842|Experimental|Rituximab (2 cycles)|"A second cycle of Rituximab~First cycle of Rituximab (4 i.v. infusions):~Day 0: 375 mg/m2 Day 7: 375 mg/m2 Day 14: 375 mg/m2 Day 21: 375 mg/m2~Second cycle of Rituximab (4 i.v. infusions, 6 months later)"
3292599|NCT01765855|Experimental|Single Arm Oral Betrixaban|
3292600|NCT01765868|Experimental|Single Arm Oral and IV Betrixaban|
3292601|NCT01765881|Experimental|Misoprostol|one 25 micrograms capsule all 4 hours by intravaginal route
3292602|NCT01765881|Active Comparator|Dinoprostone|one unique intravaginal sustained released of 10 milligrams
3292603|NCT01765894||Normal glucose tolerance subjects|Healthy controls. If any medication then paused 3 days prior to test days. BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description.
3292604|NCT01765894||DM2|"Type 2 diabetics in diet treatment or type 2 diabetics who have paused their oral medication for 3 whole days.~Insulin treatment is an exclusion criteria. If any other medication then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description."
3292605|NCT01765894||DM2 + Metformin|"Type 2 diabetics in metformin treatment. Insulin treatment is an exclusion criteria. If any other medication (besides from metformin) then paused 3 days prior to test days.~BMI: 20-35. VO2max: 20-50. Age: 30-60 years All subjects perform same tests. - See protocol for description"
3292606|NCT01765907|Experimental|HIFU|
3292607|NCT01765933|Experimental|DMAA|Single oral dose 25 mg DMAA
3292608|NCT01765946|Experimental|Metformin|Metformin tablets 500 mg tid for 2 months
3292609|NCT01765946|Placebo Comparator|Placebo|Placebo tables tid for 2 months
3292610|NCT01765959|Active Comparator|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
3292611|NCT01765959|Active Comparator|Cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 How to solve problems, planning for the future"
3292612|NCT01765985|Experimental|Intercurrent PSORIAMED|5 minutes twice a day for 12 weeks
3292613|NCT01765985|Active Comparator|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
3292614|NCT01765998|Experimental|Probiotic|To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.
3292615|NCT01765998|Placebo Comparator|placebo|This will be the comparison group to the experimantal group that recives Probiotic.
3292616|NCT01766011|Experimental|study pre-term formula|Pre-term formula with a modified stabilizer system in 2 oz. ready to feed plastic bottles
3292617|NCT01766063||Group 1|
3292618|NCT01766089|Active Comparator|Dexmedetomidine|dexmedetomidine intravenous infusion rate of 0.4 µg/kg/h
3292619|NCT01766089|Placebo Comparator|Remifentanil|remifentanil intravenous infusion rate of 0.1 µg/kg/min
3292620|NCT01766115|Experimental|Telaprevir|750 mg oral tablet of telaprevir will be given three times per day for 4 weeks within a five (5) day period from health care worker exposure.
3292621|NCT01766128|Active Comparator|Zonisamide|The patients in this arm are treated with zonisamide 50mg/d
3292622|NCT01766128|Placebo Comparator|Placebo|The patients in this arm are treated with placebo
3292623|NCT01766141|No Intervention|Acute versus chronic low back pain|No manipulative intervention. Phlebotomy for inflammatory biomarker determinations to compare acute versus chronic at baseline.
3292624|NCT01766141|Experimental|Spinal manipulation (SMT)|Inflammatory biomarker determinations after a course of 6 SMT interventions over the period of 2 weeks; a single SMT per treatment.
3292625|NCT01766141|No Intervention|No treatment controls|Asymptomatic subjects. Biomarker determinations at time zero and again two weeks later.
3292626|NCT01766154|Experimental|Subjects with normal renal function given tirofiban|Subjects with normal renal function (CrCl >90 mL/min)
3292627|NCT01766154|Experimental|Subjects with moderate renal insufficiency given tirofiban|Subjects with moderate renal insufficiency (CrCl 30-59 mL/min)
3292628|NCT01766154|Experimental|Subjects with severe renal insufficiency given tirofiban|Subjects with severe renal insufficiency (CrCl <30 mL/min).
3292629|NCT01766167|Experimental|MP-424|
3292630|NCT01766180|No Intervention|Placebo / Placebo|In this control group, subjects receives placebo supplement pills without Fruitflow or ResVida ingredients.
3292631|NCT01766180|Active Comparator|Fruitflow-II / Placebo|In this group subjects receive Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for resVida.
3292632|NCT01766180|Active Comparator|Placebo / resVida|In this group subjects receive resVida daily supplied in capsules which contain 150 mg active ingredient. They also receive placebo capsules for Fruitflow-II.
3292633|NCT01766180|Active Comparator|Fruitflow-II / resVida|In this group subjects receive resVida and Fruitflow-II daily supplied in capsules which contain 150 mg active ingredient.
3292634|NCT01766193||vaginal birth|women whose first child was born by spontaneous vaginal delivery
3292635|NCT01766193||cesarean section|women whose first child was born by cesarean section
3292636|NCT01766193||forceps|women whose first child was born by forceps extraction
3292637|NCT01766193||vacuum|women whose first child was born by vacuum extraction
3292638|NCT01766232||Obstructed nasolacrimal drainage group|This group of patients is clinically identified as having epiphora due to an obstruction of the lacrimal drainage system.
3292639|NCT01766232||Ectropion group|This group of patients is clinically determined to have functional epiphora due to ectropion and a patent lacrimal drainage system.
3292640|NCT01766245|Experimental|Formulation A followed by Formulation B|
3292641|NCT01766245|Active Comparator|Formulation B followed by Formulation A|
3292642|NCT01766258|Active Comparator|Stalevo|levodopa/carbidopa/entacapone
3292643|NCT01766258|Experimental|ODM-101 65mg Carbidopa|levodopa/carbidopa/entacapone
3292644|NCT01766258|Experimental|ODM-101 105mg Carbidopa|levodopa/carbidopa/entacapone
3292645|NCT01766271|Experimental|Standard Risk Assessment (SRA) Only|
3292646|NCT01766271|Experimental|SRA plus Health Coaching|
3292647|NCT01766271|Experimental|SRA plus Genetic Testing|
3292648|NCT01766271|Experimental|SRA plus Health Coaching plus Genetic Testing|
3292649|NCT01766284|Experimental|Niris 1300e OCT imaging|OCT imaging of the cervix using Niris 1300e will include computer aided calculations for epithelial brightness.
3292650|NCT01766297|Experimental|Proton Radiotherapy|Proton Radiotherapy 4.0 Gy (RBE) x10 fractions to 40 Gy (RBE) Total Dose
3292651|NCT01766323|Placebo Comparator|Arm Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
3292652|NCT01766323|Active Comparator|Arm-Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
3292653|NCT01766349||esophagus cancer patients|Respiratory muscle performance will be followed in patients with esophagus cancer during CCRT or RT treatments.
3292654|NCT01766362|Experimental|A session|
3292655|NCT01766362|Other|Four sessions|Every session are spaced out of month
3292656|NCT01766375|Experimental|IDBUCY|"Idarubicin: 20mg/m2 a day, d-12 ~d-10, intravenous infusion for 1 hour. Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
3292657|NCT01766375|Active Comparator|BUCY|"Busulfan: 4mg/Kg a day, oral administration, d-7 ~d-4, or 3.2mg/Kg a day, intravenous infusion, d-7~d-4.~Cyclophosphamide: 60mg/Kg a day, intravenous infusion, d-3~d-2."
3292658|NCT01766388||Pregnant women|Pregnant women of 13-22 weeks gestation
3292659|NCT01766414|Active Comparator|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion followed by administration of Endotoxin 2ng/kg
3292660|NCT01766414|Placebo Comparator|Placebo|Placebo (saline 0.9%) infusion followed by administration of Endotoxin 2ng/kg
3292661|NCT01766427||morning electroacupuncture with pills|
3292662|NCT01766427||afternoon EA with pills|
3292663|NCT01766427||no EA group with pills|
3292664|NCT01766453|No Intervention|Non exercise control|Non exercise control will undergo baseline testing and follow up testing but will not participate in an exercise intervention.
3292665|NCT01766453|Experimental|Standard Exercise|The standard exercise group will attend exercise sessions under the supervision of a Certified Personal Trainer. Intensity will increase every four weeks by 10% from 50-80% of maximal heart rate to ensure that exercise is progressive in nature. Participants will be provided with a heart rate monitor during their exercise sessions and have the option to perform the aerobic training on a treadmill, upright bike, elliptical machine or recumbent bike as long as heart rate is kept within the prescribed training intensity. Intensity, duration, resting and exercise heart rates will be recorded for each exercise session for the duration of the intervention to ensure compliance to the exercise program.
3292666|NCT01766453|Experimental|Bhangra Dance Exercise|Bhangra dance classes taught be a certified instructor progressing in difficulty over the 12 week period. Bhangra dance is an Indian folk dance that consists of jumping and kicking of a high intensity. This group will attend exercise sessions under the supervision of a Bhangra Dance Instructor. The intensity of bhangra dance will be tracked through heart rate monitors worn by participants.
3292667|NCT01766479|Experimental|Family Degree-relatives of pts. with CRC|Consecutive patients admitted with CRC diagnosis (index case, IC) were prospectively evaluated. Following the systematic identification of ICs with inherited predispositions to CRC, ICs who agreed to contact their FDRs ≥40 years old were included. Available FDRs were invited to undergo non-cathartic CTC, with OC the following day.
3292668|NCT01766492||male (age > 18 y/o) with prostate cancer|Men received Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer
3292669|NCT01766505|Experimental|Candemore tablet|Candemore tablet: candesartan cilexetil 8mg, 16mg, 32mg/tab, orally, 1 tablet once a day during 16 weeks
3292670|NCT01766505|Active Comparator|Cozzar tablet|Cozzar tablet: Losartan potassium 50mg, 100mg/cap, orally, 1 capsule once a day during 16 weeks
3292671|NCT01766518|Experimental|MY-REPT capsule|MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally
3292672|NCT01766531|Experimental|Body bioelectrical impedance|comparison with four methods for assessing nutritional status. ; compare length of mechanical ventilation, length in ICU and energy expenditure rest between malnourished and non-malnourished patient
3292673|NCT01766544|Active Comparator|Standard practice group (SPG)|Send a copy of the latest Canadian asthma and COPD guidelines to all PCPs.
3292674|NCT01766544|Active Comparator|Targeted Intervention Strategy (TISG)|interactive educational intervention, expert mentorship, practice-based tools. Consisting of 3 interactive sessions, 2 of which would be live meetings of 3h each and the third a one-hour teleconference.
3292675|NCT01766557|Experimental|Semi-controlled intervention with fish protein diet|Women with polycystic ovarian syndrome who are assigned to a 12 weeks experimental diet containing cod as the protein source.
3292676|NCT01766557|Active Comparator|Semi-controlled intervention with other animal proteins|Women with polycystic ovarian syndrome who are assigned to a 12 week experimental diet containing beef, pork, veal, eggs and milk products (BPVEM) as protein sources.
3292677|NCT01766570|Experimental|Phenol|Men and women who are assigned to a 6 weeks experimental period where they consume the rich polyphenol berries extract mix.
3292678|NCT01766570|Placebo Comparator|Control|Men and women who are assigned to a 6 weeks experimental period where they consume a placebo.
3292679|NCT01766583|Experimental|CC-292 + lenalidomide|Combination of CC-292 + lenalidomide
3292680|NCT01766596|Other|3C cohort|
3292681|NCT01766609|Active Comparator|A: Triamcinolone acetonide|Injections will be given within one half of a single vitiligo patch. The concentration of triamcinolone acetonide (TA) that will be used initially is 2.5 mg/ml. Dilution will be done using a bacteriostatic normal saline. Each half will receive injections with either TA 2.5 mg/ml or normal saline as a control. Only one investigator will know the intervention each half has received. If the patient did not show any evidence of repigmentation during the 3rd visit (i.e. after two injection sessions with TA 2.5 mg/ml) , the concentration of TA will be increased to 5 mg/ml. A total of 4 injections will be given over 4 visits. The treatment will be repeated every 3 to 5 weeks for a total of 4 treatment sessions.
3292682|NCT01766609|Placebo Comparator|B: Normal saline|Bacteriostatic normal saline will injected into one half of the vitiligo patch.
3292683|NCT01766648|Experimental|Far Cortical Locking screw fixation|Far Cortical Locking screw fixation
3292684|NCT01766648|Active Comparator|Standard locking screw fixation|Standard locking screw fixation
3292685|NCT01766661|Active Comparator|Coloanal anastomosis with ileostomy|Hand-sewn coloanal anastomosis protected by a loop ileostomy
3292686|NCT01766661|Experimental|Two stage Turnbull-Cutait anastomosis|Two staged coloanal anastomosis without protective ileostomy (Turnbull-Cutait procedure).
3292687|NCT01766674|Experimental|Kyphosis spinal exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
3292688|NCT01766674|No Intervention|Control|Control group will be enrolled in the usual care waitlist group
3292689|NCT01766687|Experimental|Hydration|Participants randomized to the hydration-intervention group will be asked to drink 1.0 to 1.5 L of water per day (depending on sex and weight), in addition to usual consumed beverages, for 12 months.
3292690|NCT01766687|No Intervention|Control|
3292691|NCT01766700|Experimental|No calorie beverages|2 no calorie beverages per day.
3292692|NCT01766700|Active Comparator|Water|2 water beverages per day.
3292693|NCT01766726||Healthy control subjects|Historical healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to arterial inflammation and coronary atherosclerotic plaque. Prospectively recruited healthy control subjects matched to HIV+ patients on traditional cardiovascular risk factors will be studied at baseline with respect to lipid and immune function.
3292694|NCT01766726||ART-naïve HIV+ patients starting QUAD/Stribild|ART-naïve HIV+ patients who are about to be started QUAD/Stribild by their treating clinicians will be studied at baseline and 6 months after initiating QUAD/Stribild therapy.
3292695|NCT01766739|Experimental|GL-ONC1|This is an open-label, dose-escalating, non-randomized, single-center Phase I therapeutic study of GL-ONC1 originally administered intrapleurally as a single dose and now escalating to three consecutive daily doses in patients with a diagnosis (histologically or cytologically documented) of malignant pleural effusions.
3292696|NCT01766752|Experimental|GlucoTab System|Investigational system: GlucoTab system supports the glycaemic management of non-critically ill patients with type two diabetes at the general ward.
3292697|NCT01766752|No Intervention|no intervention|standard care
3292698|NCT01766765|Experimental|Early jejunostomy nutrition|
3292699|NCT01766765|Active Comparator|Early oral nutrition|
3292700|NCT01766791|Experimental|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1 Repetition Maximum (1RM)
3292701|NCT01766791|Experimental|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - <75% 1RM
3292702|NCT01766791|Experimental|HIT-exercise with protein|High Intensity Resistance Exercise Training with protein supplementation
3292703|NCT01766791|Placebo Comparator|Control|No physical exercise intervention
3292704|NCT01766804|Experimental|Bovine colostrum|A daily supplement of bovine colostrum powder.
3292705|NCT01766804|Placebo Comparator|Placebo|A daily placebo supplement consisting of whole milk powder and whey protein.
3292706|NCT01766830|Experimental|Phase 3 Diagnostic|A total of 10 RDTs will be assessed in the patients cohort for the respective target condition
3292707|NCT01766843|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
3292708|NCT01766843|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
3292709|NCT01766843|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
3292710|NCT01766843|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
3292711|NCT01766856||children undergoing myringoplasty/tympanoplasty|child having repair of eardrum because of hole in eardrum after tube extruded or after tube removal
3292712|NCT01766882|Experimental|Treatment|"Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day~Lower dialysate sodium at 137 mmol/L.~Progressive Challenge to Post Dialysis Weight:~The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments."
3292713|NCT01766882|No Intervention|Control|Usual care in addition to Blood pressure monitoring and and Hydration status monitoring
3292714|NCT01766895||uremic patients|blood sampling of viral hepatitis in uremic patients
3292715|NCT01766908|Active Comparator|Cord Clamp 20 Seconds After Delivery|Intervention is cord clamp at 20 seconds following vaginal or cesarean delivery
3292716|NCT01766908|Active Comparator|Cord Clamp 40 seconds After Delivery|Timing of cord clamp at 40 seconds following vaginal or cesarean delivery.
3292717|NCT01766908|Active Comparator|Cord Clamp 60 seconds After Delivery|Intervention is timing of cord clamp at 60 seconds following vaginal or cesarean delivery
3292718|NCT01766947|Experimental|Triggerfish|Device : Sensimed Triggerfish
3292719|NCT01766960|Experimental|Healthy volunteers|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
3292720|NCT01766960|Experimental|Advanced nonalcoholic fatty liver disease patients|Subjects will be asked to fast overnight. Upon presentation, FibroScan procedure with CAP will be conducted and baseline and postprandial bile acid profile will be assessed. Then, intravenous morphine will be administered and the pharmacokinetic profile will be assessed over 8 hours.
3292721|NCT01766973||Chronic back pain|Adults, >6months duration
3292722|NCT01766973||Control|Age and sex matched controls
3292723|NCT01766999||SpMetHb > 8%|hemoximetric MetHb measurements triggered
3292724|NCT01767012|Active Comparator|Polylens EC-Y10-PAL (uncoated)|hydrophobic acrylic IOL (no coating) implantation during cataract surgery
3292725|NCT01767012|Active Comparator|Polylens EC-Y10H-PAL (coated)|hydrophobic acrylic heparin-coated IOL implantation during cataract surgery
3292726|NCT01767025|Experimental|Oxytocin|Oxytocin 24 IU (3 puffs) per nostril
3292727|NCT01767025|Placebo Comparator|Sea water|Sea water 3 puffs per nostril
3292728|NCT01767051||Children born from mothers who are diagnosed with PCOS|Children at the age of 2.5-4 years or at the age of 6-8 years born from mothers who are diagnosed with PCOS at the University Medical Centre in Utrecht (UMCU) in the period 2004-2012 (n=891) will be asked to participate. Children who were born before the diagnosed PCOS of their mothers at the UMCU will be asked to participate too. All mothers have been diagnosed with PCOS according to standardised extensive diagnostic work-up and have given informed consent to be approached for future research purposes.
3292729|NCT01767051||Children who participated in the WHISTLER study|Children who participated in the WHISTLER 3 (11-163) and WHISTLER/Cardio study (10-194) in 2002-2012. The children were born from mothers with a regular cycle prior to conception who conceived naturally. The children were examined at the age of 2.5-4 years or at the age of 7-8 years. The data of the WHISTLER 3 and WHISTLER/Cardio study have already been collected.
3292730|NCT01767077|Placebo Comparator|Butter oil|Daily intake of 40 g butter oil
3292731|NCT01767077|Active Comparator|Cream|Daily intake of 100 g cream (40%)
3292732|NCT01767090|Placebo Comparator|Placebo|Applicable to first 12 week period (Part One); subjects in this arm will be randomized to one of the ASP1707 dose levels for the second 12 week period (Part Two)
3292733|NCT01767090|Experimental|ASP1707 lowest dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
3292734|NCT01767090|Experimental|ASP1707 low dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
3292735|NCT01767090|Experimental|ASP1707 medium dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
3292736|NCT01767090|Experimental|ASP1707 high dose|Subjects in this arm will be dosed with ASP1707 once daily for a total of 12 weeks (Part One) and continue taking the assigned dose for a further 12 weeks during the extension phase of the study (Part Two) for a total of 24 weeks
3292737|NCT01767090|Active Comparator|Leuprorelin acetate|Subjects in this arm will be treated with leuprorelin acetate for a total of 24 weeks
3292738|NCT01767129|Experimental|AVP-923-45|AVP-923-45 twice daily for 14 days
3292739|NCT01767129|Placebo Comparator|Placebo|Placebo twice a day for 14 days
3292740|NCT01767181|No Intervention|A|Control group without intervention
3292741|NCT01767181|Experimental|B|Intensive light therapy during the first half of the night shift
3292742|NCT01767181|Experimental|C|Exercise before the beginning of the night shift
3292743|NCT01767181|Experimental|D|Exercise after the end of the night shift
3292744|NCT01767207||screening for mental disorders|screening for mental disorders
3292745|NCT01767220|Active Comparator|Strategy 1- endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial.
3379531|NCT05162638|Other|"Indwelling catheterization"|"immune-biology in people with MS before and during/after OMB treatment within thoracic duct and peripheral blood via indwelling catheter and multiple time-point sampling compared to healthy controls (without drug treatment).~Twelve patients with early MS (never treated or at least 90 days after discontinued treatment with glatiramer acetate or interferons), who consent to treatment with OMB and to the indwelling catheter procedure with serial sampling and up to four healthy controls (no drug treatment)"
3292746|NCT01767220|Active Comparator|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and ablation are done from endocardial and epicardial.
3292747|NCT01767233|Experimental|Pancreatic stenting|Pancreatic stenting versus observation
3292748|NCT01767246|Experimental|PFS algorithm treatment|The Patellofemoral Syndrome algorithm is designed to determine what deficits a patient may have and addressing these sequentially. This subgrouping first assesses a patient fear avoidance beliefs, flexibility, body mechanics, and then strength and functional ability. The reason for sequential treatment is that there is evidence that without adequate flexibility a patient will be unable to perform exercises with proper body mechanics, and without proper mechanics strengthening and functional activity can cause increased stress on the patellofemoral joint. Progression through each specific subgroup is based on objective goals. Once the patient has met these goals they are progressed to the next treatment subgroup until discharge.
3379532|NCT05162625|Active Comparator|Topical Moxifloxacin|Pre-surgical prophylaxis with the use of topical 0.5% moxifloxacin eye drops every 3 hours until the surgery.
3379533|NCT05162625|Active Comparator|Intravenous Cephazolin and Ciprofloxacin|Pre-surgical prophylaxis with cefazolin 1 gram every 6 hours and ciprofloxacin 400 milligrams intravenously every 12 hours, until the surgery.
3379534|NCT05162599|Experimental|Diagnostic study, experimental evaluative cross-sectional study|Evaluate the performance of the Cardiags Trimod medical device, compared to a reference examination, echocardiography, for the detection of heart murmurs Verification of the performance of the Cardiags Trimod medical device compared to a reference examination (ECG, Cardiologist interpretation) for the detection of rythm abnormalities Verification of the repeatability of measurements Verification of safety and suitability for use Verification of acceptability
3379535|NCT05162586|Placebo Comparator|Cohort A: Placebo|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI-A] greater than or equal to [>=] 8) will be enrolled in Cohort A to receive placebo matched to M5049.
3379536|NCT05162586|Experimental|Cohort A: M5049 low dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive low dose of M5049.
3379537|NCT05162586|Experimental|Cohort A: M5049 medium dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive medium dose of M5049.
3379538|NCT05162586|Experimental|Cohort A: M5049 high dose|Participants with CLE (active SCLE and/or DLE) or SLE with predominantly active lupus rash (CLASI-A >= 8) will be enrolled in Cohort A to receive high dose of M5049.
3379539|NCT05162586|Placebo Comparator|Cohort B (Part 1 + Part 2): Placebo|Participants with active SLE who have moderate to high systemic disease activity (British Isles Lupus Assessment Group [BILAG A/2B]) with 1 or 2 of the following: CLASI-A >= 8 and/or Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) >= 6 will be enrolled in Cohort B to receive placebo matched to M5049.
3379540|NCT05162586|Experimental|Cohort B (Part 1 + Part 2): M5049 high dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive high dose of M5049.
3379541|NCT05162586|Experimental|Cohort B (Part 2): M5049 low dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive low dose of M5049.
3379542|NCT05162586|Experimental|Cohort B (Part 2): M5049 medium dose|Participants with active SLE who have moderate to high systemic disease activity (BILAG A/2B) with 1 or 2 of the following: CLASI-A >= 8 and/or SLEDAI >= 6 will be enrolled in Cohort B to receive medium dose of M5049.
3379543|NCT05162534||Patients needing IoC|"Patients needing IoC can be recognized by the acronym IoCp"
3379544|NCT05162534||30-day deceased patients|"Patient died after a period of observation of 30 days are presented with the acronyms 30-ddp (30-day deceased patients)"
3379545|NCT05162534||did not undergo IoC|"Patients did not undergo IoC, we chose the acronym nIoCp."
3379546|NCT05162534||30-day survived patients|"Patient survived after a period of observation of 30 days are presented with the acronyms 30-dsp (30-day survived patients)"
3379547|NCT05162495|Experimental|Arm A|Requiring a diagnostic or screening RT-PCR test for COVID-19.
3379548|NCT05162495|Experimental|Arm B|Positive to COVID-19 in RT-PCR test performed up to 48 hours before screening.
3379549|NCT05162482|Active Comparator|Heterologous 1|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379550|NCT05162482|Active Comparator|Heterologous 2|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379551|NCT05162482|Active Comparator|Heterologous 3|"CanSinoBIO (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379552|NCT05162482|Active Comparator|Heterologous 4|"CanSinoBIO (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379553|NCT05162482|Active Comparator|Heterologous 5|"AstraZeneca ChAdOx (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV(0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379554|NCT05162482|Active Comparator|Heterologous 6|"AstraZeneca ChAdOx (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2)~(160 participants)"
3379555|NCT05162482|Active Comparator|Homologous 7|"BIBP (CNBG, Sinopharm) WIV (0.5ml) at baseline BIBP (CNBG, Sinopharm) WIV (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
3379556|NCT05162482|Active Comparator|Homologous 8|"CanSinoBIO (0.5ml) at baseline CanSinoBIO (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
3292749|NCT01767246|Active Comparator|Multimodal Treatment|Patients randomized to the this treatment group will be treated in a manner consistent with a Multimodal treatment approach previously described in literature that has been found effective in treating Patellofemoral Syndrome (Lowry, 2008). Treatment consists of strengthening, flexibility and manual treatments aim to improve patients knee pain.
3292750|NCT01767259|Other|Valsartan 160 mg alone|Valsartan alone
3292751|NCT01767259|Other|Hydrochlorothiazide 12.5 mg alone|Hydrochlorothiazide alone
3292752|NCT01767259|Other|Valsartan160 mg + Hydrochlorothiazide12.5 mg|Concomitant administration of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
3292753|NCT01767259|Other|Valsartan / Hydrochlorothiazide 160 mg/12.5mg|Fixed dose combination of valsartan 160 mg + Hydrochlorothiazide 12.5 mg
3292754|NCT01767272|Other|fexofenadine 60 mg|First dose strength
3292755|NCT01767272|Other|fexofenadine 120 mg|Second dose strength
3292756|NCT01767272|Other|fexofenadine 180 mg|Third dose strength
3292757|NCT01767272|Other|fexofenadine 240 mg|Fourth dose strength
3292758|NCT01767272|Other|fexofenadine 360 mg|Fifth dose strength
3292759|NCT01767298|Other|Valsartan 320 mg alone|Valsartan alone
3292760|NCT01767298|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide alone
3292761|NCT01767298|Other|Valsartan 320 mg + Hydrochlorothiazide 25 mg|Concomitant administration of valsartan 320 mg + Hydrochlorothiazide 25 mg
3292762|NCT01767298|Other|Valsartan / Hydrochlorothiazide 320 mg/25mg|Fixed dose combination of valsartan 320 mg + Hydrochlorothiazide 25 mg
3292763|NCT01767311|Experimental|Core Study: Lecanemab 2.5 mg/kg biweekly|2.5 mg/kg biweekly
3292764|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg biweekly|5.0 mg/kg biweekly
3292765|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg biweekly|10 mg/kg biweekly
3292766|NCT01767311|Experimental|Core Study: Lecanemab 5.0 mg/kg monthly|5.0 mg/kg monthly
3292767|NCT01767311|Experimental|Core Study: Lecanemab 10 mg/kg monthly|10 mg/kg monthly
3292768|NCT01767311|Placebo Comparator|Core Study: Lecanemab-matched Placebo|Matching placebo biweekly
3292769|NCT01767311|Experimental|Extension Phase: Lecanemab 10 mg/kg|All participants who fulfill Extension phase inclusion and exclusion criteria will have the option to participate in the Extension phase to receive lecanemab 10 mg/kg biweekly for up to 60 months or until the drug is commercially available in the country where the subject resides, or until the benefit-to-risk ratio from treatment with lecanemab is no longer considered favorable, whichever comes first.
3292770|NCT01767324|Experimental|Injection to deltoid|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3292771|NCT01767324|Experimental|Injection to forearm|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3292772|NCT01767324|Experimental|Injection to thigh|Deliver saline from FLUGEN 101.2 microneedle-based delivery device.
3292773|NCT01767337|Experimental|injection of 0.1 mL saline|deliver from FluGen 101.2 device
3292774|NCT01767337|Experimental|injection of 0.25 mL saline|deliver from FluGen 101.2 device
3292775|NCT01767337|Experimental|Injection of 0.5 mL saline|deliver from FluGen 101.2 device
3292776|NCT01767350||children with organ transplant|Subjects who received an solid organ transplant at our institution at the age of 0-19 yrs and who were subject to pharmacokinetic evaluation during their follow up. Additional blood withdrawal for DNA will be performed
3292777|NCT01767363||5-alpha reductase inhibitors with or without alpha-blockers|Men using 5-alpha reductase inhibitors with or without alpha-blockers over the course of the study period.
3292778|NCT01767363||Alpha-blockers|Men using alpha-blockers over the course of the study period.
3292779|NCT01767389||Type 2 diabetes patients taking antidiabetic agents|Subjects should also have at least 1 claim of T2D diagnosis identified using ICD-9 codes 250.x0 or 250.x2 (excluding 250.x1 and/or 250.x3 - Type 1 diabetes and 648.0x - gestational diabetes).
3292780|NCT01767402|Experimental|PhtD Group 1|Subjects will receive PhtD vaccine formulation 1 without any adjuvant.
3292781|NCT01767402|Experimental|PhtD Group 2|Subjects will receive adjuvanted PhtD vaccine formulation 2.
3292782|NCT01767402|Experimental|PhtD Group 3|Subjects will receive adjuvanted PhtD vaccine formulation 3.
3292783|NCT01767402|Experimental|PhtD Group 4|Subjects will receive adjuvanted PhtD vaccine formulation 4.
3292784|NCT01767402|Experimental|PhtD Group 5|Subjects will receive adjuvanted PhtD vaccine formulation 5.
3292785|NCT01767402|Active Comparator|23 PPV Group|Subjects will receive the Pneumovax 23TM vaccine and NaCl.
3292786|NCT01767428|Experimental|Experimental Paracetamol Tablet|Experimental paracetamol tablet (500 milligrams [mg]) administered with 240 milliliters (mL) of water.
3292787|NCT01767428|Active Comparator|Standard Paracetamol Tablet (500 mg)|Standard paracetamol tablet (500 mg) administered with 240 mL of water.
3292788|NCT01767441||Roux-en-Y-gastric bypass|morbidly obese subjects undergoing gastric bypass surgery
3292789|NCT01767441||gastric banding|morbidly obese subjects undergoing laparoscopic adjustable gastric banding
3292790|NCT01767441||sleeve gastrectomy|morbidly obese subjects undergoing laparoscopic sleeve gastrectomy
3292791|NCT01767441||control group|morbidly obese subjects not undergoing bariatric surgery, on diet treatment
3292792|NCT01767454|Experimental|Doublet arm|Subjects will be started with dabrafenib 150 mg twice daily (BID) orally for 2 weeks (run-in). The doublet arm will comprise 2 cohorts. Cohort A1 (Dabrafenib 150 mg BID + ipilimumab). Cohort A-1 (Dabrafenib 100 mg BID +ipilimumab). Ipilimumab will be administered as 3 mg/kg every 3 weeks (Q3W) for a total of 4 infusions over approximately 12-16 weeks. Dabrafenib will be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
3292793|NCT01767454|Experimental|Triplet arm|This arm will be initiated using dabrafenib and ipilimumab doses established in the doublet dose-finding. Subjects will be started with dabrafenib and trametinib orally for 2 weeks (run-in), followed by ipilimumab 3 mg/kg Q3W for a total of 4 infusions over approximately 12-16 weeks. The triplet arm will comprise 3 planned cohorts. Cohort B-1: Dabrafenib 100 mg BID + trametinib 1 mg once daily + ipilimumab, Cohort B1: Dabrafenib 150 mg BID + trametinib 1 mg once daily+ ipilimumab, Cohort B2: Dabrafenib 150 mg BID + trametinib 2 mg once daily + ipilimumab. Dabrafenib and trametinib wil be continued through combination with ipilimumab and post-ipilimumab until no longer of clinical benefit, in the opinion of the treating physician, or until unacceptable AE or death
3292794|NCT01767480|Experimental|Higher-intensity RT group|All participants received a duration-matched intervention for 90-120 minutes/day, 5 days/week for 4 consecutive weeks. For the RT groups, they will receive RT training together with functional rehabilitation trainings. Within 1 training session, each patient in the higher-intensity RT group will use Bi-Manual-Tract to practice 400-600 repetitions of the mode 1 and 800-1000 repetitions of mode 2, totaling 1200-1600 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 100-200 repetitions in mode 3, if application.
3292795|NCT01767480|Experimental|Lower-intensity RT group|Patients in the lower-intensity RT received half the number of the repetitions per unit of time than patients in the higher-intensity RT group. Within 1 training session, patients in the lower-intensity RT group will practice 200-300 repetitions of the mode 1 and 400-500 repetitions of mode 2, totaling 600-800 repetitions, respectively for the forearm and the wrist movements. In addition, the patients will practice 50-100 repetitions in mode 3, if application.
3292796|NCT01767480|Active Comparator|Conventional rehabilitation (CR) group|The CR group will be designed to control for the duration of therapeutic activities. CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
3292797|NCT01767532|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3292798|NCT01767532|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3292799|NCT01767545|Active Comparator|Dexamethasone-implant (Group 1)|Group 1 included 38 patients (22 with CRVO and 16 with BRVO) and was treated with a dexamethasone-implant injection from the beginning.
3292800|NCT01767545|Active Comparator|Bevacizumab/Dexamethasone-implant (Group 2)|Group 2 included 26 patients (14 CRVO, 12 BRVO) and was treated with three consecutive injections of bevacizumab at a monthly interval, followed by a dexamethasone-implant injection four weeks after the last bevacizumab injection.
3292801|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
3292802|NCT01767571|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3292803|NCT01767571|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3292804|NCT01767584|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3292805|NCT01767584|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3292806|NCT01767610|Experimental|micronized fenofibrate|
3292807|NCT01767610|Experimental|pitavastatin Ca|
3292808|NCT01767610|Experimental|micronized fenofibrate plus pitavastatin Ca|
3292809|NCT01767623|Active Comparator|Cohort 1: Participants with Normal Liver Function|Participants with normal liver function (according to National Cancer Institute [NCI] liver dysfunction criteria) will receive vemurafenib 960 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
3292810|NCT01767623|Experimental|Cohort 2: Participants with Severe Liver Dysfunction|Participants with severe liver dysfunction (according to NCI liver dysfunction criteria) will receive vemurafenib 720 mg BID from Day 1 until the morning dose on Day 20 and then from Day 27 onward until disease progression, safety-related treatment termination, withdrawal of consent, death, or a decision by the Sponsor to terminate the study, whichever occurs first.
3292811|NCT01767649||Caesarean|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
3292812|NCT01767649||Vaginal Delivery|Normal pregnant women at term without complication during pregnancy and without inflammatory disorders
3292813|NCT01767662|Experimental|manipulation|home program for parents manipulation
3292814|NCT01767662|Placebo Comparator|observe|observation
3292815|NCT01767675|Experimental|Secondary Cytoreductive Surgery with HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B). In some patients randomized to HIPEC at MSKCC only , peritoneal fluid and blood samples will be drawn before, during and after the HIPEC procedure.
3292816|NCT01767675|Experimental|Secondary Cytoreductive Surgery without HIPEC|secondary cytoreductive surgery (CRS) with or without carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) followed by systemic combination chemotherapy for recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Patients will be randomized intraoperatively to undergo CRS with HIPEC (arm A) or CRS only (arm B) in a manner 1:1. Both arms will receive a standard platinum-based systemic chemotherapy postoperatively (5 cycles in arm A and 6 cycles in arm B).
3292817|NCT01767714|Experimental|G-CSF + plerixafor|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive plerixafor in the evening up to a maximum of 4 doses.
3292818|NCT01767714|Placebo Comparator|G-CSF + Placebo|Patients will receive G-CSF for 4 mornings for mobilization, followed by another dose each morning before apheresis on days that the patient is to continue apheresis (up to 8 doses total). Patients will also receive placebo in the evening up to a maximum of 4 doses.
3292819|NCT01767727|Other|Surgical flap|Surgical flap is based on the dorsal branch of the digital artery, and is used for soft tissue coverageof multiple finger defects.
3292820|NCT01767740|Experimental|ULTRABRAID PLUS SUTURE|ULTRABRAID Plus Suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
3292821|NCT01767740|Active Comparator|ULTRABRAID SUTURE|ULTRABRAID Suture is a marketed suture manufactured by Smith & Nephew used in subjects undergoing rotator cuff repair.
3292822|NCT01767753|Experimental|Triggerfish|Device: Sensimed Triggerfish
3292823|NCT01767766|Experimental|TGR-1202|TGR-1202 Daily Oral Dose
3292824|NCT01767779||seizure free infants with dx of TSC|infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC
3292825|NCT01767779||Parents or family guardian of cohort 1|Parent or family guardian of infants that are seizure free at the time of the study enrollment and meets genetic or clinical diagnostic criteria for TSC.
3292826|NCT01767805|Other|Type of incubator|Embryos are cultured in a standard incubator or a mini-incubator
3292827|NCT01767805|Other|Oxygen concentration|Embryos are cultured in an incubator with a gas mixture with 20% oxygen or with 5% oxygen
3292828|NCT01767818||Previously treated PD patients|220 subjects with PD treated and responsive to dopaminergic medication
3292829|NCT01767818||Previously untreated PD|20 subjects with de-novo, previously untreated PD confirmed by I-123 Ioflupane SPECT
3292830|NCT01767818||Healthy age-matched controls|46 age-matched healthy controls will be studied.
3292831|NCT01767831||Group A: CGM monitoring (1) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
3292832|NCT01767831||Group B: CGM monitoring (2) vs Intervention|Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention. The 4 week intervention period will be followed by an additional CGM monitoring period (session 2). For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
3292833|NCT01767844|Experimental|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
3292834|NCT01767844|Placebo Comparator|Fruit powder drink|A regular fruit flavoured powder that has no benefits
3292835|NCT01767870|Experimental|FIT-Sigmoidoscopy|This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.
3292836|NCT01767870|Experimental|Colonoscopy|This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.
3292837|NCT01767883|Experimental|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation"
3292838|NCT01767883|Active Comparator|Clinical Decision Support Only|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support System~Academic detailing concerning the rationale for the algorithms"
3292839|NCT01767896|Experimental|ASP7374 group|cell-culture-derived vaccine group
3292840|NCT01767896|Active Comparator|TIV group|approved egg-derived TIV group
3292841|NCT01767922|Experimental|Extramel 10 mg - 140 UI SOD|This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
3292842|NCT01767922|Placebo Comparator|Placebo - exipients only|This arm receives daily one capsule Placebo containing excipients only.
3292843|NCT01767948|Experimental|Patients with mild hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3292844|NCT01767948|Experimental|Patients with moderate hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3292845|NCT01767948|Experimental|Patients with severe hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3292846|NCT01767948|Experimental|Patients with normal hepatic function|Patients will receive PCI-32765 140 mg, orally, as a single dose, on Day 1.
3292847|NCT01767961|Experimental|Diagnostic (modified barium swallow)|Patients undergo the modified barium swallow, comprising swallowing boluses of thin liquid barium, barium honey, barium pudding, and barium crackers while undergoing fluoroscopic imaging.
3292848|NCT01767974||Non-Small Cell Lung Cancer|Locally advanced stage IIIB or IV (metastatic) or Relapsed Non-Small Cell Lung Cancer
3292849|NCT01768026||No treatment|Subjects diagnosed with Dystrophic Epidermolysis Bullosa
3292850|NCT01768039|Active Comparator|Vitamin D|treatment with weekly 50000IU vitamin D
3292851|NCT01768039|Placebo Comparator|Placebo|Treatment with placebo
3292852|NCT01768052||functional Near Infrared Spectroscopy|Noninvasive functional Near Infrared Spectroscopy (fNIRS) monitoring will take place during patients' clinical rTMS treatment sessions.
3292853|NCT01768065|Experimental|Nasal Expiratory Positive Airway Pressure Devices|Nasal Expiratory Positive Airway Pressure Device
3292854|NCT01768065|Sham Comparator|placebo sham|A sham device
3292855|NCT01768078|Experimental|with corticoids|
3292856|NCT01768078|Other|without corticoids|
3292857|NCT01768091|Experimental|POEM|POEM for patients with esophageal achalasia
3379557|NCT05162482|Active Comparator|Homologous 9|"AstraZeneca ChAdOx (0.5ml) at baseline AstraZeneca ChAdOx (0.5ml) after 70±7 days (10 wks±2) Full dose booster: 80 participants (0.5ml) 6 months after second dose Fractional dose booster: 80 participants (dose to be decided) 6 months after second dose No booster: 80 participants~(240 participants)"
3379558|NCT05162469|Experimental|SHR-1909 monotherapy|
3379559|NCT05162456||participants willing to receive a 3-dose vaccination schedule|participants willing to receive a 3-dose vaccination schedule
3379560|NCT05162456||participants unwilling to receive a 3rd dose of vaccination|participants who received a 2-dose vaccination schedule, unwilling to receive a 3rd dose
3292858|NCT01768091|Active Comparator|Pneumatic dilation|Pneumatic dilation for patients with esophageal achalasia
3292859|NCT01768104|Experimental|ESTD|Endoscopic submucosal tunnel dissection (ESTD) for patients with upper gastrointestinal submucosal tumors (SMTs)
3292860|NCT01768104|Active Comparator|VATS|Video-assisted thoracoscopic surgery (VATS) for patients with upper gastrointestinal submucosal tumors (SMTs)
3292861|NCT01768143||Nurse Trainees|unexperienced endoscopy nurses
3292862|NCT01768143||Nurse Experts|Educated endoscopy Nurses
3379561|NCT05162430|Experimental|P1 group|Administration of 0.1 mg/kg of propofol and 5mg dexamethasone phosphate sodium
3379562|NCT05162430|Experimental|P2 group|Administration of 0.2mg/kg of propofol and 5mg dexamethasone phosphate sodium
3379563|NCT05162430|Experimental|P3 group|Administration of 0.3mg/kg of propofol and 5mg dexamethasone phosphate sodium
3379564|NCT05162430|Experimental|P4 group|Administration of 0.4 mg/kg of propofol and 5mg dexamethasone phosphate sodium
3379565|NCT05162430|Experimental|P5 group|Administration of 0.5mg/kg of propofol and 5mg dexamethasone phosphate sodium
3379566|NCT05162430|No Intervention|D1 group|Administration of 5mg dexamethasone phosphate sodium
3379567|NCT05162417|No Intervention|Control group|patient in this arm will receive scaling and root planning treatment only.
3379568|NCT05162417|Experimental|Test group (toluidine Blue O)|patients in this arm will receive Toluidine Blue O as an adjunctive to scaling and root planing.
3292863|NCT01768156|Experimental|Study arm|
3292864|NCT01768169||fish oil capsule|10 capsules per day will provide 2130 mg of EPA (1280 mg) and DHA (850 mg)
3292865|NCT01768182|Experimental|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
3292866|NCT01768182|Placebo Comparator|Placebo|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning.
3292867|NCT01768195|Experimental|Entecavir prophylaxis|Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of immunochemotherapy and/or chemotherapy, and will be continued until 12 months after completion of the immunochemotherapy and/or chemotherapy.
3379569|NCT05162417|Experimental|Methylene blue|Patients will receive Methylene blue as adjunctive to scaling and root planning.
3292868|NCT01768208|Experimental|Saxagliptin|
3292869|NCT01768221|Other|Caregiver intervention|
3379570|NCT05162404|Experimental|Video Intervention|The intervention in this study is a TED-talk style video series designed to provide patient education on cancer, care coordination, and self-advocacy. The content is designed to provide both a background about cancer disease and to address each of the specific domains in care coordination (CCI). The development of video contents was informed by our prior/current research in rural care coordination and components of evidence-based interventions including the patient navigator training by the George Washington University Cancer Institute, Imi Hale (the Native Hawaiian Cancer Network), and a supportive care intervention by Mokuau et al. As the target population of this intervention is rural patients, videos include some rural-specific considerations related to care coordination.
3379571|NCT05162391|Other|Contingency management|All enrolled participants will participate in a Contingency Management intervention where rewards are linked with demonstrated abstinence from methamphetamine use.
3379572|NCT05162365|Experimental|IBI314|a cocktail of two SARS-CoV-2 S protein IgG1 antibodies, IBI314-A and IBI314-B, in a 1:1 [w/w] ratio
3379573|NCT05162365|Placebo Comparator|Placebo|
3292870|NCT01768234|Experimental|Supplemental water|This arm receives up to 2 L of supplemental water during the course of the testing day.
3292871|NCT01768234|No Intervention|Control|No supplemental water provided
3292872|NCT01768247|Experimental|HCG priming|Patients in this arm after 7-9 days of estrogen replacement they will receive a 150 international units (IU) HCG every day for 7 days concomitantly with the estradiol
3292873|NCT01768260|Active Comparator|Enhanced External conterpulsation|Enhanced external counterpulsation (EECP) is a noninvasive modality for the treatment of ischemic cardiovascular disease. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole.
3379574|NCT05162352|Experimental|Donafenib+sintilimab|Donafenib combined with sitilimab.
3379575|NCT05162339||IBD patients|
3292874|NCT01768260|Active Comparator|aspirin|The subjects with Anterior ischemic Optic Neuropathy received aspirin therapy.
3292875|NCT01768273|Experimental|Midazolam and 824|2 mg midazolam (oral syrup) Day 1 and Day 17. 400 mg PA-824 once daily Day 4 - 17.
3292876|NCT01768299|Experimental|Mifepristone at home 24 hours before miso dosing starts|"All women will receive study packet one containing mifepristone to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing a placebo. Simultaneously, they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled."
3379576|NCT05162326|Experimental|BC-101|BC-101 will be injected at the dose of 0.1 mL per linear centimeter along the nasolabial fold, up to 2 mL in total volume for each side of the nasolabial folds.
3292877|NCT01768299|Experimental|Mifepristone and first dose of misoprostol simultaneously.|"Will receive study packet one containing placebo to swallow at home on study day 1. They will be told to return to the hospital for induction and will be scheduled to return to the hospital 24 hours later. Upon their return, they will be hospitalized and receive another study packet containing mifepristone. Simultaneously they will receive one dose of 400 mcg buccal misoprostol. Women will remain hospitalized and receive repeated doses of 400 mcg buccal misoprostol every three hours.~Participants will receive up to eight doses of misoprostol (e.g. 3200 mcg misoprostol) over 24 hours. Misoprostol dosing will stop when both the fetus and placenta are expelled. The procedure will be considered complete once both the fetus and placenta are expelled."
3292878|NCT01768312|Active Comparator|Restasis eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3292879|NCT01768312|Experimental|T-sporin eye drop|Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes
3292880|NCT01768338|Experimental|Ofatumumab combined with SB-485232|Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
3292881|NCT01768351|Active Comparator|Control|Patients receiving treatment for secondary hyperparathyroidism with calcitriol. The calcitriol dosage schedule provided for an initial dose of 0.5 mch every other day and titration was performed on the basis of the serum levels of intact PTH (iPTH) (target 150-300 pg/mL), Ca, P and Ca x P product as suggested by the US National Kidney Foundation Dialysis outcomes Quality Initiative (NKF-DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
3292882|NCT01768351|Experimental|Paricalcitol|Patients treated by Paricalcitol for hyperparathyroidism. The paricalcitol initial dose was 1 mcg/die, and titration was performed on the basis of the serum levels of iPTH, Ca, P and Ca x P product as suggested by the NKF-DOQI and KDIGO guidelines.
3292883|NCT01768364|Active Comparator|Antibiotics|will receive antibiotics
3292884|NCT01768364|Active Comparator|No antibiotics|will not receive antibiotics
3292885|NCT01768377|Active Comparator|Intubation with sedation|Sedation with midazolam and analgesia with fentanyl
3292886|NCT01768377|Experimental|Intubation with Nerve block|Laryngeal plus supraglottic plus intratracheal nerve block plus sedation with midazolam
3292887|NCT01768390|Experimental|5000 Test|Twice daily use of a toothpaste containing 5,000 ppm fluoride
3292888|NCT01768390|Active Comparator|1450 GCP|Twice daily use of a toothpaste containing 1,450 ppm fluoride
3292889|NCT01768429|Experimental|Fatty fish|Four fatty fish meals per week
3292890|NCT01768429|Experimental|Lean Fish|Four lean fish meals per week
3292891|NCT01768429|Experimental|Alpha-linolenic acid|10 g of alpha-linolenic acid daily from camelina sativa oil
3292892|NCT01768429|Experimental|Control diet|Limited fish and alpha-linolenic acid intake
3292893|NCT01768455|Experimental|Gemigliptin and Glimepiride|Multiple administrations of gemigliptin and single concomitant administration of gemigliptin and glimepiride
3292894|NCT01768455|Experimental|Glimepiride|Single administration of glimepiride
3292895|NCT01768468|Experimental|LAYLA|Drug : LAYLA tablet/ bid
3292896|NCT01768468|Active Comparator|JOINS|Drug : JOINS tablet/ tid
3292897|NCT01768481|Experimental|Statin|Atorvastatin 10 mg every day for one year
3292898|NCT01768481|Placebo Comparator|Sugar pill|Same size, taste and size placebo tablet (manufactured by sponsor) given every day for one year.
3292899|NCT01768507|Placebo Comparator|Placebo|no medication
3292900|NCT01768507|Experimental|Resveratrol|Trans-resveratrol (Resveratrol - Terraternal®): 5 g (10 capsules) as single oral dose on day 1 of the investigation period.
3292901|NCT01768533||Survey|A lifestyle survey was administered to primary-care givers or legal guardians who take their children 4-10 y/o to the pediatric well-child visits.
3292902|NCT01768546|Experimental|Video on Demand (VOD)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD arm of the study received access to a paper tracker to track food and activity during the program.
3292903|NCT01768546|Experimental|Video on Demand Plus (VOD+)|Virtual Diabetes Prevention Program: All participants will view the 16 Comcast on Demand episodes, weigh themselves, and track their progress weekly. Participants in the VOD+ arm of the trial received access an interactive tracking and problem solving web portal offered by SparkPeople™ (Cincinnati, Ohio).
3292904|NCT01768585|Active Comparator|Ivabradine|Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor
3292905|NCT01768585|Placebo Comparator|Placebo|Drug: Placebo bid placebo Other Name: Placebo control
3292906|NCT01768598||Fracture - Boys|Boys who have sustained a distal radius fracture
3292907|NCT01768598||Fracture - Girls|Girls who have sustained a distal radius fracture
3292908|NCT01768598||Non Fracture - Boys|Boys who have not sustained a distal radius fracture
3292909|NCT01768598||Non Fracture - Girls|Girls who have not sustained a distal radius fracture
3292910|NCT01768611||Withou Diabetic Nephropathy|Patients who have persistent normoalbuminuria (<30 mg/g creatinine or <20 μg/min).
3292911|NCT01768611||Incipient Nephropathy|Patients who have persistent microalbuminuria (30-300 mg/g creatinine or 20-200 μg/min).
3292912|NCT01768611||Overt Diabetic Nephropathy|Patients who have persistent macroalbuminuria (>300 mg/g creatinine or >200 µg/min), proteinuria (>500 mg/24 h) or renal replacement therapy.
3292913|NCT01768624||Stage 5 chronic kidney disease|Patients receiving home hemodialysis Patients receiving home peritoneal dialysis Patients receiving center-based hemodialysis Patients who had a pre-emptive kidney transplant Patients who planned for renal conservative care
3292914|NCT01768650|Experimental|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
3292915|NCT01768650|Experimental|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
3292916|NCT01768663|Experimental|Treatment Group (Cohort 1)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and ciprofloxacin through Day 21.
3292917|NCT01768663|Experimental|Treatment Group (Cohort 2)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and itraconazole through Day 21.
3292918|NCT01768663|Experimental|Treatment Group (Cohort 3)|Subjects will take lumacaftor in combination with ivacaftor for 14 days. Beginning on Day 15, subjects will take lumacaftor in combination with ivacaftor and rifampin through Day 24.
3292919|NCT01768663|Experimental|Treatment Group (Cohort 4)|Subjects will take a single dose of lumacaftor in combination with ivacaftor on 3 occasions separated by 7 days.
3292920|NCT01768689|No Intervention|Run-in period|First 3 months of study during which adherence will be measured for each consecutively included study subject, but no intervention will be performed. Patient will receive routine treatment for CML according to the physician discretion.
3292921|NCT01768689|Experimental|Adherence-encouraging period|"Months 4 to 9 of study during which adherence will be measured for each consecutively included study subject, while implementing adherence-encouraging interventions:~adherence-encouraging interventions - Group meetings~adherence-encouraging interventions - Individual meetings~adherence-encouraging interventions - Monthly phone calls~Patient will receive routine treatment for CML according to the physician discretion."
3292922|NCT01768702|Sham Comparator|Control|Sham, no injection
3292923|NCT01768702|Experimental|C3BS-CQR-1 Treated|Injection of C3BS-CQR-1
3292924|NCT01768715||Good response|Patients with severe alcoholic hepatitis and good response to therapy.
3292925|NCT01768715||Non transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are not candidates to transplantation, according to the specified criteria.
3292926|NCT01768715||Transplant candidates|Patients with severe alcoholic hepatitis and poor response to therapy, that are candidates to transplantation, according to the specified criteria.
3292927|NCT01768728|Active Comparator|Laparoscopic left hemihepatectomy group|Group of patients that are operated with laparoscopic left hemihepatectomy
3292928|NCT01768728|Active Comparator|Open left hemihepatectomy|Group of patients operated with open left hemihepatectomy
3292929|NCT01768741|Active Comparator|Laparoscopic liver resection group|
3292930|NCT01768741|Active Comparator|Open liver resection|
3292931|NCT01768754||COPD patients|Usual and Fast Walking Speeds
3292932|NCT01768767|Experimental|Ketamine/Lithium|Participant will receive ketamine/lithium
3292933|NCT01768767|Active Comparator|Ketamine|Participant will receive ketamine
3292934|NCT01768767|Placebo Comparator|Placebo|Participant will receive placebo
3292935|NCT01768780|Experimental|sensory nerve block level of spinal anesthesia|This test group and the control group. Because within the group in two ways to check the level after spinal anesthesia will be.
3292936|NCT01768793|Experimental|Parents As Teachers + Lifestyle Int.|Participants assigned to this group will receive Parents As Teachers Plus (PAT+). This will be a diet and physical activity lifestyle intervention integrated within the standard Parents As Teachers home visiting curriculum. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
3292937|NCT01768793|Active Comparator|Standard Parents as Teachers (PAT)|Participants assigned to this group will receive the standard Parents As Teachers (PAT) home visiting curriculum, focusing on parenting and child development. There will be a total of 28 home visits, delivered over 24 months (6 month prenatal phase and 18 month post-partum phase).
3292938|NCT01768806|Experimental|P.L.A.Y. Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
3292939|NCT01768806|Active Comparator|Special Education Pre-school|Special education pre-school services include 10-12 hours per week of special education preschool, occupational therapy, and speech and language therapy. No intensive intervention is provided.
3292940|NCT01768819|Experimental|Intervention Group|Physical Activity
3292941|NCT01768819|No Intervention|Control Group|
3292942|NCT01768884|Experimental|Nitric oxide inhalation + standard treatment|Inhalation of 160 ppm gNO for 30 minutes, 5 times daily, for 5 consecutive days or until discharged, which occurs first.
3292943|NCT01768884|Placebo Comparator|Standard treatment|Standard treatment
3292944|NCT01768897|Experimental|Treatment (CPI-613, cytarabine, mitoxantrone hydrochloride)|"Patients receive CPI-613 IV over 2 hours on days 1-5, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 3, and mitoxantrone hydrochloride IV over 15 minutes after the 1st, 3rd, and 5th doses of cytarabine. Treatment repeats every 14 days for up to 2 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients undergoing a second course of therapy receive CPI-613 IV over 2 hours on days 1-3, cytarabine IV over 3 hours every 12 hours for 5 doses beginning on day 2, and mitoxantrone hydrochloride IV over 15 minutes after the 1st and 3rd doses of cytarabine."
3292945|NCT01768910|Experimental|Healthy controls|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures (e.g. bladder cooling, body warm or room temperature)of the filling liquid.
3292946|NCT01768910|Experimental|MS with OAB|Procedure: 1-2 fMRI measurements within 4 weeks from first exam. Measurements include repetitive retrograde bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
3292947|NCT01768910|Experimental|MS without OAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid.
3292948|NCT01768910|Experimental|NNOAB|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus additional post-treatment fMRI scan 5 to 7 weeks after OAB treatment (such as antimuscarinics, intradetrusor injections of botulinum toxin type A)
3292949|NCT01768910|Experimental|SCI with neurogenic detrusor overactivity|Procedure: 1-2 measurements within 4 weeks from first exam. Measurements include repetitive bladder filling via transurethral catheter at different bladder volumes and temperatures of the filling liquid plus 1 additional post-treatment fMRI scan 5 to 7 weeks after intradetrusor injections of botulinum toxin type A
3292950|NCT01768923|Active Comparator|SDAI remission group|SDAI remission
3292951|NCT01768923|Active Comparator|Minimal disease activity group|Minimal disease activity remission
3292952|NCT01768936||eliminated infectious abdominal focus|
3292953|NCT01768936||persisting/progressing infectious abdominal focus|
3292954|NCT01768949|Other|Echocardiography|An echocardiography will be systematically realised in all the patients included in the study in order to evaluate whether any echocardiographic criterion exploring the right ventricle can predict the efficacy and/or safeness of recruitment maneuvers in patients suffering from acute respiratory distress syndrome.
3292955|NCT01768962|Active Comparator|Sequence A|2 weeks, 6 week washout, 2 weeks
3292956|NCT01768962|Active Comparator|Sequence B|2 weeks, 6 week washout, 2 weeks
3292957|NCT01768975|Experimental|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
3292958|NCT01768975|Placebo Comparator|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
3292959|NCT01768988|Experimental|Group I|Conventional analgesic treatment + pregabalin.
3292960|NCT01768988|Placebo Comparator|Group II|Conventional analgesic treatment + placebo.
3292961|NCT01769027|Active Comparator|SSRI+AB|Intervention: sertraline+antibiotic (penicillin/azithromycin) 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day)and one antibiotic ( benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week ). Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
3292962|NCT01769027|Placebo Comparator|SSRI+placebo|Intervention: Sertraline+placebo 12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and a placebo
3292963|NCT01769040|Experimental|Rifaximin|Rifaximin tablets for oral ingestion, 550 mg twice daily for 28 days.
3292964|NCT01769040|Placebo Comparator|Placebo tablets|Placebo tablets similar in shape and size to intervention treatment, 1 tablet twice daily for 28 days.
3292965|NCT01769053|Active Comparator|Variable Ventilation|Patients are ventilated with variable pressure support mode.
3292966|NCT01769053|No Intervention|Conventional (non-variable) Ventilation|Patients are ventilated with non-variable(conventional) pressure support ventilation mode.
3292967|NCT01769066|Experimental|Sequential Gefitinib With Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1 Gefitinib PO. 250mg DAY3-16
3292968|NCT01769066|Active Comparator|Pemetrexed/Platinum|Pemetrexed IV 500 mg/m2 ，DAY2 DDP IV 75mg/m2 ，DAY1 OR CAP IV AUC 5,DAY1
3292969|NCT01769079|Active Comparator|oral nitrate|In nitrate group will be provided the same prescribed dose for this drug. One group remains on nitrate use and other on placebo (same number of pills) use.
3292970|NCT01769079|Placebo Comparator|Placebo|In the placebo group will be given the same dose and frequency prescribed nitrate.
3292971|NCT01769092|Experimental|Fish Oil|Each capsule contains 625 mg of fish oil (100 mg EPA & 250 mg DHA). Participants will take 12 capsules per day over 6 months.
3292972|NCT01769092|Placebo Comparator|Safflower Oil|Each capsule will contain 625 mg of Safflower oil. Participants will take 12 capsules per day over 6 months.
3292973|NCT01769118||Caffeine|caffeine will be given according to clinical judgment
3292974|NCT01769131||Allis|
3292975|NCT01769131||Tenaculum|
3292976|NCT01769144|Active Comparator|Acticoat Absorbent|Acticoat Absorbent wound dressing
3292977|NCT01769144|Experimental|BCT wound dressing|wound dressing
3292978|NCT01769157|Active Comparator|L-carnitine|L-carnitine 330mg, 3 tablet twice daily
3292979|NCT01769157|Placebo Comparator|Placebo|placebo drug, 3 tablet twice daily
3292980|NCT01769183|Experimental|Squalamine|Study eyes will be assigned to receive Squalamine. The dose will be one drop twice daily. If neovascularization fails to regress at week one or if neovascularization returns within the study, the dose will be increased to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Patients will continue administering study drug until week 20.
3292981|NCT01769235|Experimental|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)
3292982|NCT01769235|Active Comparator|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)
3292983|NCT01769235|Placebo Comparator|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)
3292984|NCT01769261|Experimental|Internet, eligible patients|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
3292985|NCT01769261|Active Comparator|Telephone, eligible patients|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge..
3292986|NCT01769261|Other|" Non eligible patients"|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
3292987|NCT01769287||Surgical operation|The study aims to recruit a total of 20 patients, 10 of whom have AF and 10 who do not.
3292988|NCT01769300|No Intervention|Control practices|Practices that do not use the ADHD clinical decision support
3292989|NCT01769300|Experimental|Clinical decision support|Electronic health record-based clinical decision support for ADHD medication titration.
3292990|NCT01769313|Experimental|Group A|In Group A the anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
3292991|NCT01769313|Active Comparator|Group B|Group B acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually.
3292992|NCT01769417|Placebo Comparator|Placebo|
3292993|NCT01769417|Active Comparator|MEDI4893|
3292994|NCT01769430||Community acquired respiratory infection|Measurement of exhaled breath aerosol
3292995|NCT01769482|Experimental|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
3292996|NCT01769482|Placebo Comparator|Placebo|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg or placebo po q d for 3 months.
3292997|NCT01769495|No Intervention|Control|Standard post ED care
3292998|NCT01769495|Experimental|2-3 day return appointment|Patients will receive further treatment in Geriatric Clinic 2-3 days post ED discharge.
3292999|NCT01769521|Experimental|Triggerfish|Device: Sensimed Triggerfish
3293000|NCT01769547|Experimental|Dovitinib|Dovitinib 500 mg PO OD (5 days on, 2 days off); Each cycle = 28 days
3293001|NCT01769560|No Intervention|Centers for Disease Control and Prevention (CDC) Fact Sheet|Participants will receive the CDC Fact sheet about HPV vaccination while they are taking the survey.
3293002|NCT01769560|Experimental|MeFirst Intervention|Participants will receive a tailored website regarding their own individualized risk for HPV and information about HPV Vaccination while they are taking the survey as opposed to receiving the CDC fact sheet. This tailored website is generated based on answers provided by each subject in the baseline survey.
3293003|NCT01769599||Grid Treatment|30 patients that were treated with laser grid treatment
3293004|NCT01769599||Avastin Treatment|patients that were treated with Avastin injections
3293005|NCT01769625|Placebo Comparator|placebo & cholecalciferol 400 IU|In this arm, the placebo is in place of celecoxib and the current RDA for cholecalciferol is used the control of the cholecalciferol higher dose.
3293006|NCT01769625|Active Comparator|placebo & cholecalciferol 2,000 IU|Placebo & cholecalciferol 2,000 IU
3293007|NCT01769625|Experimental|celecoxib 400mg & cholecalciferol 2,000 IU|celecoxib 400 mg & cholecalciferol2,000 IU
3293008|NCT01769638|Experimental|SPO1101|
3293009|NCT01769638|Experimental|SPO1101D|
3293010|NCT01769651||Drug service users|Those patients who receive Methadone replacement therapy as part of their treatment plan. In addition, those drug user patients who have a first consultation session with their Addiction Nurses.
3293011|NCT01769664|Experimental|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.)
3293012|NCT01769664|Active Comparator|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel)
3293013|NCT01769664|Placebo Comparator|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.)
3293014|NCT01769677|Experimental|Treatment Group AB|"Subjects in this group will receive study drug in the following sequence:~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference).~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test)."
3293015|NCT01769677|Experimental|Treatment Group BA|"Subjects in this group will receive study drug in the following sequence:~Treatment B: one 90-mg hydrocodone bitartrate extended-release tablet (test).~Treatment A: two 45-mg hydrocodone bitartrate extended-release tablets (reference)."
3293016|NCT01769690|Experimental|DBS stimulator setting alteration|
3293017|NCT01769703|Experimental|Dabigatran|
3293018|NCT01769716|Experimental|Umbilical cord blood transplantation|Allogeneic umbilical cord blood will be administered intravenously or intraarterially under non-myeloablative immunosuppression. In case of autologous umbilical cord blood, immunosuppression is not required.
3293019|NCT01769729|Experimental|PEPP + care management|"This 4-month collaborative psychotherapy, entitled Program for Emotional and Physical Pain (PEPP), will include 1 joint meetings with the behavioral health specialist (BHS), primary care provider (PCP), and patient, 10 psychotherapy sessions, and continued collaboration between the BHS and the PCP to assure a shared treatment plan.~Care management will include monthly calls with a depression care manager."
3293020|NCT01769729|Active Comparator|Care management alone|Care management will include monthly calls with a depression care manager.
3293021|NCT01769742|Experimental|Early mobility bundle|Delivery of early targeted physiotherapy to patients on the interventional wards; to comprise assessment and communication of mobility to ward staff and patient, provision of mobility aids, guidance and encouragement to patient and staff to allow patient to dress and mobilise independently if clinically safe to do so
3293022|NCT01769742|No Intervention|Usual care|Usual physiotherapy service only
3293023|NCT01769755|Experimental|Human Placenta-Derived Cells PDA001 Intravenous Infusion|Intravenous infusion of Human Placenta-Derived Cells PDA001 over the course of 2 hours.
3293024|NCT01769755|Placebo Comparator|Vehicle controlled placebo|Intravenous infusion of Vehicle Controlled Placebo over the course of 2 hours
3293025|NCT01769768|Experimental|LDE225+Warfarin|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.
3293026|NCT01769768|Experimental|LDE225+Bupropion|At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group
3293027|NCT01769781|Experimental|anastrazole|women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
3293028|NCT01769781|Active Comparator|GnRH analog alone|women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
3293029|NCT01769794|Active Comparator|Western therapy & Placebo|Western therapy(oral care, skin care and reducing temperature) Placebo for JET(Jinlianqingre Effervescent Tablets )
3293030|NCT01769794|Experimental|Western therapy & JET|Jinlianqingre Effervescent Tablets plus western therapy
3293031|NCT01769807|Experimental|CPAP treatment|67 consecutive male patients with OSA were recruited: 36 with mild-moderate OSA and 31 with severe OSA. Data were collected in all subjects at baseline and after 1 month of CPAP.
3293032|NCT01769820|Active Comparator|Dexamethasone|Study 1, and study2(2 arms); Dexamethasone 1.5mg daily Study 3 (adaptive -7 arms): Dexamethasone of 0.4, 0.8, 1.0, 1.2, 1.5, and 1.8 mg total dose per day
3293033|NCT01769820|Placebo Comparator|Placebo|Placebo
3293034|NCT01769833|Active Comparator|PEG-interferon-alfa 2A|PEG-interferon-alfa 2A
3293035|NCT01769833|Placebo Comparator|Nucleosides|Nucleosides
3293036|NCT01769846|Experimental|Early Mobilization protocol|Early Mobilization protocol: Patients in the treatment group additionally received a progressive cycling exercise session 7 days a week, until the last day of ICU stay, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). Cycling exercise will be realized during 30 consecutive minutes, initially in continuos and passive (classified patients with RASS - 4) exercise, at a fixed pedaling rate of 20 cycles/min and after in actively (classified patients with RASS 0), with an exercise intensity of 3-5 on the Borg rate of perceived exertion scale.
3293037|NCT01769846|No Intervention|Control group|Group will undergo usual mobilization per standard ICU care. Conventional physical and respiratory therapy were provided by the ICU physical therapists twice daily, for approximately 30 min, 7 days per week. The protocol included vibrocompression maneuvers; lung hyperinflation by the mechanical ventilator; and tracheal aspiration, when necessary; as well as passive and active-assisted motor exercises for arms and legs, depending on the clinical course of patients.
3293038|NCT01769872|Experimental|Autologous Adipose Tissue derived MSCs|
3293039|NCT01769885|Experimental|Treatment (tivozanib and surgery)|Patients receive tivozanib PO QD on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy.
3293040|NCT01769898|Placebo Comparator|Placebo+formoterol-budesonide|"Placebo(for Theophylline sustained-release tablet) tablet by mouth 100mg every 12hours for 24weeks.~Inhaled Formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
3293041|NCT01769898|Experimental|Theophylline+formoterol-budesonide|"Theophylline sustained-release tablet by mouth 100mg every 12hours for 24weeks.~Inhaled formoterol-budesonide combined treatment 4.5µg/160µg every 12hours for 24weeks."
3293042|NCT01769911|Experimental|Treatment (gene modified peripheral blood cell transplant)|"CONDITIONING: Patients receive carmustine IV over 3 hours on day -7, cytarabine IV over 2 hours BID and etoposide IV over 2 hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.~TRANSPLANTATION: Patients receive an autologous PBSC infusion and/or infusion of autologous transduced hematopoietic cells on day 0.~Beginning 28-120 days later, patients eligible for in vivo selection after detection of gene-marked cells receive O6-benzylguanine IV over 1 hour and carmustine IV over 3 hours on days 14, 28, and then monthly until completion of therapy. Patients achieving > 10% gene marking and CD4 count of >= 500 cells/uL receive up to 2 courses of structured treatment interruption without undergoing in vivo selection."
3293043|NCT01769924||Live kidney donors|Nephrectomy
3293044|NCT01769924||Healthy controls|Who also meet criteria to donate a kidney
3293045|NCT01769937|Experimental|H.P. Acthar Gel SQ injection|Patients will administer single dose (80 units) of Acthar subcutaneously every day for 10 days (with a possible 5 day dosing rescue).
3293046|NCT01769950|Experimental|Choline-PET arm|Every eligible patient will be scanned with Choline-PET at the time of diagnosis of prostate cancer. MRI will also be obtained as it is the current standard of care. CT scan will be obtained as part of the same procedure while procuring the Choline-PET scan with PET-CT dual imaging hardware.
3293047|NCT01769963|Experimental|Dietary intervention|All participants will be fed a high AGE diet followed by a low AGE diet (single arm study)
3293048|NCT01769976|Experimental|Daily energy restriction|25% reduction in daily energy intake
3293049|NCT01769976|Active Comparator|Energy balance diet|Diet provides 100% of energy requirements and is designed to achieve weight stability
3293050|NCT01769976|Experimental|Periodic fasting with weight loss|Fast 3 days per week, and consume 1.5 times usual amount of food on other days
3293051|NCT01769976|Experimental|Periodic fasting without weight loss|Fast 3 days per week, and consume double usual amount of food on other days
3293052|NCT01769989|Active Comparator|Eletrodermabrasion|The side treated with electrodermabrasion will be burned with an electric cautery machine to remove the outermost layer of skin as well as the lumps and bumps and a small area of surrounding skin.
3293053|NCT01769989|Active Comparator|Dermabrasion|The side treated with dermabrasion will be scraped with a sterile piece of sandpaper until the outermost layer of skin and lumps and bumps have been removed and a small layer of surround skin.
3293054|NCT01770002|Active Comparator|Everted suture technique|Technique that everts the skin; the edges will sit up against each other in a little peak, raised above the surrounding skin.
3293055|NCT01770002|Active Comparator|Non-everted suture technique|Surgical wound will be approximated such that the suture line is flat relative to the surrounding skin.
3293056|NCT01770015|Experimental|ventilated patient|"all patients underwent the same diagnostic test . cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization.~HLA DR antigen, cytokines (IL 6 and 10), B-glucan. fungi and bacteria endotracheal aspiration"
3293057|NCT01770028||Intervention partners|Partners of pregnant women randomized to lifestyle intervention. Note: There is no intervention in partners of pregnant women.
3293058|NCT01770028||Standard care partners|Partners of pregnant women randomized to Standard Care. Note: There is no intervention in partners of pregnant women.
3293059|NCT01770041||Liver resection group|Patients undergoing liver resection and receiving paracetamol (observation of routine administration)
3293060|NCT01770054||obtention of a blood sample|all Atahualpa residents aged 40 years or more
3293061|NCT01770067|Experimental|Infection Prone Patients Prior to CIED|Administration of high-dose antibiotics (CIA-RNPT)
3293062|NCT01770080|Active Comparator|Euminz®|Acute treatment (3 to 5 time topical use of Euminz® = 10%ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
3293063|NCT01770080|Placebo Comparator|Placebo|Acute treatment (3 to 5 time topical use of Placebo= 0,5% ethanolic solution of peppermint oil) will start immediately after assessment of a baseline pain intensity of at least moderate pain (3 on VPRS).
3293064|NCT01770093||Parents of Pediatric Inpatients|
3293065|NCT01770106|Experimental|Denosumab|Patients in this arm will receive subcutaneous injection of denosumab 60mg every 6 months (1 dose for the study period).
3293066|NCT01770106|Active Comparator|Standard treatment|Patients (n=20) in this arm will receive oral alendronate (Fosamax®)70mg once.
3293067|NCT01770119|Experimental|MMR vaccination|MMR vaccine to seronegative pediatric SOT recipients
3293068|NCT01770132|Experimental|porfimer sodium, EUS-PDT, gemcitabine|Patients receive porfimer sodium IV over 3-5 minutes on day 1 and undergo endoscopic ultrasonography-photodynamic therapy (EUS-PDT) on days 1, 3, 8, and 21. After completion of EUS-PDT, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 of courses 1 and 2 and on day 22 of courses 3 and 5. During courses 1-5, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. After course 5, treatment with gemcitabine hydrochloride repeats every 2 months in the absence of disease progression or unacceptable toxicity.
3293069|NCT01770171|Experimental|Carboplatin-paclitaxel-bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg every 3 weeks until disease progression
3293070|NCT01770171|Active Comparator|carboplatin-paclitaxel|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
3293071|NCT01770184|Experimental|Intervention Group|The intervention group will receive the rehabilitation services and support that is recommended and provided in the current health care structure. The intervention group will also receive the Chronic Disease Self-Management Program (CDSMP). The CDSMP is an education program based on the concept of self-management. Self-management refers to the ability of an individual to manage the day-to-day responsibilities of living with a chronic condition. The CDSMP will be delivered in two and a half hour sessions, once a week, for six weeks, in group format.
3293072|NCT01770184|No Intervention|Usual Care Group|The usual care group for this study will receive the rehabilitation services and support that is recommended and provided in the current health care structure. No additional intervention will be provided to the usual care group within this study.
3293073|NCT01770197||recombinant tissue plasminogen activator|Stroke patients with rt-PA treatment in the 3-4.5 hour time window were compared with those within 3h.
3293074|NCT01770197||rt-PA|One group of was treated with standard recombinant tissue plasminogen activator therapy in 3h and the other group of stroke patients was treated within 3-4.5h.
3293075|NCT01770210||Cardiovascular events|Patients on atorvastatin treatment hospitalised due to cardiovascular events
3293076|NCT01770223|Experimental|Boceprevir + PegIFN-2b + RBV|All participants will start treatment with 4 weeks of PegIFN-2b subcutaneously, 1.5μg/kg per week + RBV capsules orally, at a weight-based dose between 800-1400 mg/day divided into two daily doses (double therapy). Participants without cirrhosis will then continue on the PegIFN-2b and RBV with the addition of boceprevir capsules orally, 800 mg three times per day for 32 weeks (triple therapy), and will transition back to double therapy for the final 12 weeks of treatment (48 total weeks of therapy). Participants with cirrhosis or documented as null responders will receive triple therapy for 44 weeks (48 total weeks of therapy).
3293077|NCT01770236|Experimental|IV acetaminophen|Patients in this group will receive intraoperative intercostal block + IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)
3293078|NCT01770236|No Intervention|On-Q Pain Pump catheter|Patients in this group will receive the current standard care which includes an intraoperative intercostal block + On-Q Pain Pump catheter (continuous dosing).
3293079|NCT01770249|Other|Per-oral Endoscopic Esophagomyotomy (POEM)|An endoscopic surgical procedure for achalasia; Per-oral Endoscopic Esophagomyotomy (POEM)will be performed. The POEM procedure will be performed in the operating room under general anesthesia and a scope will then be inserted into your mouth and down your throat and measurements will be taken. With the use of this lighted flexible scope the surgeon will make a small incision in the inner lining of your esophagus (throat), create a tunnel and then cut the muscle between the esophagus (throat) and the stomach. The initial little opening will be closed with a small clip. This procedure will allow easier passage of food into the stomach.
3293080|NCT01770262||Osteoporosis|Hospitalized subjects diagnosed with osteoporosis
3293081|NCT01770262||Healthy|
3293082|NCT01770275||patients with esophageal cancer|Patients with esophageal cancer who underwent esophagectomy
3293083|NCT01770288|Experimental|Anaerobic Performance|
3293084|NCT01770301|Active Comparator|A - Paclitaxel|patients will receive paclitaxel alone at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks for 6 cycles. Thereafter, patients will be followed-up with imaging exams every 12 weeks. At the time of confirmed progression, patients could receive bevacizumab 15 mg/kg every 3 weeks for 12 months following investigator's decision. In some cases, longer therapy may be allowed after discussion with the Principal Investigator/Sponsor
3293085|NCT01770301|Experimental|B - Paclitaxel + Bevacizumab followed by Bevacizumab|patients will receive paclitaxel at the dose 80 mg/m² administered by intravenous injection at D1, D8 and D15 every 4 weeks + Bevacizumab at the dose 10 mg/kg administered by intravenous injection every 2 weeks (D1 and D15) for 6 cycles. Thereafter, patients will receive IV injection of bevacizumab 15 mg/kg every 3 weeks for up to 1 year
3293086|NCT01770327|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
3293087|NCT01770327|Experimental|Group 2 (Intervention) - Milk|This group will drink Non-Fat Milk in 1st trial
3293088|NCT01770327|Experimental|Group 3 (Intervention) - Orange Juice|This group will drink Orange Juice in 1st trial
3293089|NCT01770327|Experimental|Group 4 (Intervention) - Iced Tea|This group will drink Iced Tea in 1st study
3293090|NCT01770340|Sham Comparator|Control group|Radical prostatectomy without implantation of allograft
3293091|NCT01770340|Experimental|Treatment group|Radical prostatectomy with implantation of allograft
3293092|NCT01770405||pancreatic cysts|Patient indicated for a first endoscopic ultrasound fine needle aspiration (EUS-FNA) for a pancreatic cyst,
3293093|NCT01770418|Experimental|Proton Radiotherapy with Chemotherapy|
3293094|NCT01770444|Experimental|Low-dose cardiac CT|Patients randomized to this group will be assessed by low-dose cardiac CT protocol.
3293095|NCT01770444|Other|Conventional cardiac CT|Patients randomized to this group will be assessed by conventional cardiac CT protocol.
3293096|NCT01770470||Patients receiving chronic hemodialysis|Dialysis patients chewing chitosan-containing gum
3293097|NCT01770496|No Intervention|No reminder / recall notice|No childhood vaccination reminder / recall notification sent. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
3293098|NCT01770496|Experimental|mailed reminder / recall notice|Childhood vaccination reminder / recall notification sent by postal mail. Stratified by age cohort of subjects: 7 month recall; 12 month reminder; 19 month recall
3293099|NCT01770548|Experimental|Autism|Analysis of the glutamate synapse in autism
3293100|NCT01770548|Other|Relative|Analysis of the glutamate synapse in autism
3293101|NCT01770548|Other|Major control|DNA collection
3293102|NCT01770548|Other|Minor control|auditory evoked potentials
3293103|NCT01770561|Experimental|Integrated sensor and infusion set.|All subjects must have been previously diagnosed Type 1 Diabetics and being used to sensor augumented pumps
3293104|NCT01770574|Experimental|ReproBone|calcaneal lengthening
3293105|NCT01770574|Active Comparator|Autologous bone graft|calcaneal lengthening
3293106|NCT01770587|Experimental|Behavioral Insomnia Treatment|Brief Behavioral Insomnia Treatment
3293107|NCT01770600|Active Comparator|Risperidone|Administer pill of risperidone 1 mg once a day by mouth for 5 days.
3293108|NCT01770600|Placebo Comparator|Placebo|Administer pill of placebo once a day by mouth for 5 days.
3293109|NCT01770613|Experimental|Stem Cells|ALLOGENEIC MESENCHYMAL BONE MARROW CELLS
3293110|NCT01770613|Placebo Comparator|Control|Lactated Ringer's Solution
3293111|NCT01770626|No Intervention|Single arm|evaluate the composition of a participant's body, diagnosed with a brain tumor (glioblastoma multiforme) as determined by bioelectrical impedance analysis
3293112|NCT01770639||MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
3293113|NCT01770665||Mesothelioma|
3293114|NCT01770665||all cancer types|
3293115|NCT01770678|Experimental|Constraint induced movement therapy (prolonged restraint)|Constraint induced movement therapy(prolonged restraint)consists of a combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
3293116|NCT01770678|Active Comparator|Constraint induced movement therapy(manual restraint)|Constraint induced movement therapy(manual restraint)consists of a combination of manual restraint of the unaffected upper limb and massed practice of the affected upper limb over a forty-two day period.
3293117|NCT01770704||Patients diagnosed with bipolar disorder I or II|
3293118|NCT01770717||Pressure Ulcer Formation|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
3293119|NCT01770730|Experimental|LAM plus standard care|Patients allocated to this study arm will receive urine LAM strip testing in addition to the standard TB diagnostic tools WHO approved and available at each site
3293120|NCT01770730|No Intervention|Standard care|Patients allocated to this study arm will receive standard TB diagnostics currently WHO approved and available at the study site
3293121|NCT01770756|Experimental|Enhancing willpower using active skills|This group will use active tasks such as learning skills using hands to enhance willpower.
3293122|NCT01770756|Experimental|Enhancing willpower using passive tasks|This group will use passive tasks such as taking still postures to enhance willpower.
3293123|NCT01770769|Active Comparator|Internal fixation - standard treatment|Internal fixation with two parallel cancellous screws (Hip Pins(R)) Current standard treatment
3293124|NCT01770769|Experimental|Hemi - arthroplasty|cemented Hemi - arthroplasty (Exeter(R)) modular system V40 by Stryker. Refobacin cement.
3293125|NCT01770782|Other|Laser Scanner|Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
3293126|NCT01770782|Other|SARME|Surgically Assisted rapid Maxillary Expansion -SARME was used for the treatment of transverse maxillary deficiency.This procedure is a combination of a surgical procedure and orthopedic expansion of the maxilla.
3293127|NCT01770795|Experimental|Genexol-PM/Gemcitabine|
3293128|NCT01770808|Experimental|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).
3293129|NCT01770808|Experimental|AquaPT|AquaPT are produced by Marigot Ltd. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.
3293130|NCT01770808|Placebo Comparator|Placebo|Produced by Marigot Ltd
3293131|NCT01770821|Active Comparator|Standard physical training & standard nutrition|Standard of care
3293132|NCT01770821|Experimental|Tailored physical training and sipdrink|Tailored physical training and sipdrink (Protein nutridrink, 200 ml x 2)
3293133|NCT01770821|Experimental|Tailored physical training and standard nutrition.|Standard physical training provided by the hospital and standard hospital nutrition
3293134|NCT01770821|Experimental|Standard physical training and sip drink|Standard physical training provided by the hospital and sipdrink (Nutridrink protein, 200 ml x2)
3293135|NCT01770834||Cohort|
3293136|NCT01770847||Healthy controls|Healthy age matched controls
3293137|NCT01770847||Chronic kidney diease|Chronic kidney disease patients stage 2-4
3293138|NCT01770873|Experimental|Take Charge 2|Receipt of BBBS mentoring plus youth and parent violence prevention curriculum
3293139|NCT01770873|No Intervention|Control|Standard emergency room protocol followed
3293140|NCT01770886|Active Comparator|UE2343|Oral capsule
3293141|NCT01770886|Placebo Comparator|Placebo|Oral capsule
3293142|NCT01770899|Experimental|Montelukast|Montelukast 5mg capsules for 2-5 year old every 24h and 8mg capsules for 6-14 year olds every 24h.
3293143|NCT01770899|Placebo Comparator|Placebo|One placebo capsule given every 24h
3293144|NCT01770925|Active Comparator|n-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
3293145|NCT01770925|Active Comparator|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
3293146|NCT01770925|Active Comparator|NIPPV|o The NIPPV group will receive at extubation a positive end expiratory pressure of 5 cm water, peak inspiratory pressure of 15cm of water, RRof35 and Ti of 0.32
3293147|NCT01770938|Active Comparator|Effective light-emitting diode therapy and training|Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
3293148|NCT01770938|Placebo Comparator|Placebo light-emitting diode therapy and training|Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
3293149|NCT01770964|Other|Training Type A, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type A
3293150|NCT01770964|Other|Training Type B, pregabalin|Subjects randomized to receive pregabalin at a site that received training Type B
3293151|NCT01770964|Other|Training Type A, placebo|Subjects randomized to receive placebo at a site that received training Type A
3293152|NCT01770964|Other|Training Type B, placebo|Subjects randomized to receive placebo at a site that received training Type B
3293153|NCT01770977|Active Comparator|Effective Light-emitting diode therapy|Effects of light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
3293154|NCT01770977|Placebo Comparator|Placebo light-emitting diode therapy|Effect of placebo light-emitting diode therapy on clinical, biochemical and biomechanical of muscle performance in athletes
3293155|NCT01770990|Active Comparator|Tel-PT without mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) without additional motivating letters.
3293156|NCT01770990|Experimental|Tel-PT including mail|Telephone-based psychotherapy (1 personal session, 8-10 telephone sessions, educational materials and monitoring questionnaires) with an additional motivating letter after every telephone session.
3293157|NCT01771003|Placebo Comparator|Without CellAegis' autoRIC™ Device|patients will have a blood pressure cuff attached to their arm that will not inflate/deflate as in the active group
3293158|NCT01771003|Active Comparator|With CellAegis' autoRIC™ Device|Patients will have the CellAegis' autoRIC™ Device attached and it will inflate to 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles (while under general anesthetic)
3293159|NCT01771042|Experimental|Normal glucose tolerant|"Weight loss attained by 25% caloric restriction.~This arm will be both a glycemic and time control. Initially they will undergo a 4-month weight maintenance phase (acting as time control), followed by 4 month weight loss."
3293160|NCT01771042|Experimental|Impaired glucose tolerant|"Weight loss using 25% caloric restriction.~Impaired glucose tolerant subjects will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3293161|NCT01771042|Experimental|Type 2 diabetic hyperinsulinemic|"Weight loss using 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3293162|NCT01771042|Experimental|Type 2 diabetic hypoinsulinemic|"Weight loss via 25% caloric restriction.~This group will undergo 4 months weight loss (25% caloric deficit) followed by 3 months weight loss maintenance"
3293163|NCT01771068|No Intervention|Waiting list|
3293164|NCT01771068|Experimental|Parenting Discussion Group|Two-hour discussion group on child noncompliance. Groups were composed by a maximum of 10 parents and were facilitated by the principal researcher, who is an accredited practitioner. The groups were interactive and discussion based, and a power point presentation with embedded-video clips was used to aid the facilitator. The key points covered in the discussion group included reasons for disobedience, parenting traps, encouraging good behaviour, and managing disobedience. Parents also received a workbook that included the content covered in the discussion group and 2 follow up telephone calls to check how they were doing after the discussion groups.
3293165|NCT01771081||Group1|
3293166|NCT01771094|Placebo Comparator|Group 1 (placebo) - Water|This group will drink water in 1st trial
3293167|NCT01771094|Experimental|"Group 3 (Intervention) - Low Sucralose"|This group will drink Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage in 1st trial
3293168|NCT01771094|Experimental|"Group 2(Intervention)-High Sucralose"|This group will drink Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage in 1st trial
3293169|NCT01771107|Experimental|Treatment (brentuximab and combination chemotherapy)|Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3293170|NCT01771120||Asthma Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3293171|NCT01771120||Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3293172|NCT01771120||Asthma and Rhinitis Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3293173|NCT01771120||Healthy Group|Subjects will undergo diagnostic tests, medical interview and questionnaires
3293174|NCT01771133|No Intervention|Lifestyle and nutrition control group|The control arm will receive routine prenatal care in the prenatal clinic. They will receive regular phone calls and mailings, token gifts and some useful information from data collected in the study, such as physical activity, feedback on behavior throughout the study. To additionally promote adherence (since they will have less contact with study staff), we will include 2 pre-partum and 1 post-partum group sessions meant to increase bonding between participants and retention of control participants. These sessions will include general pregnancy information not related to our interventions.
3293175|NCT01771133|Active Comparator|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
3293176|NCT01771146|Other|Neoadjuvant FOLFIRINOX Regimen|Single arm, treated with neoadjuvant FOLFIRINOX prior to surgical resection
3293177|NCT01771159|Experimental|Population|All subjects will undergo the implantation of the TBC.
3293178|NCT01771185|Active Comparator|Best medical treatment|Metformin 2 g/day; gliclazide 30 mg
3293179|NCT01771185|Active Comparator|Duodenal jejunal bypass plus sleeve gastrectomy|Duodenal jejunal bypass plus sleeve gastrectomy is a metabolic surgical procedure
3293180|NCT01771198|Experimental|SIMVASTATIN 40mg|SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment
3293181|NCT01771211|Experimental|anodal tDCS|anodal tDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left inferior frontal gyrus
3293182|NCT01771211|Sham Comparator|sham tDCS|sham tDCS will be administered to the left inferior frontal gyrus
3293183|NCT01771224|Experimental|palmitoleic acid|Palmitoleic acid: 720 mg/day for 56 days
3293184|NCT01771224|Placebo Comparator|Sugar pill|Sugar pill: 720 mg/day for 56 days
3293185|NCT01771237|Experimental|MyPeeps Manualized Group Intervention|Highly interactive, HIV prevention skills-based group intervention in 6 sessions. Tailored to YMSM.
3293186|NCT01771237|Active Comparator|Standard Sexual Health Education|Educational group intervention focused on HIV and STI knowledge using a lecture-based format in 6 sessions. Non-tailored to YMSM.
3293187|NCT01771263|Other|iControl-RP|iControl-RP is a system which performs controlled delivery of both remifentanil and propofol infusions.
3293188|NCT01771276|Experimental|Ultimate Anchor|Use of the g-Cath Suture Anchor Delivery Catheter and accessories in placing the ultimate number of anchors for weight loss.
3293189|NCT01771289|Experimental|chemoradiation|
3293190|NCT01771302|Active Comparator|Bio-Oss|the xenograft is of bovine origin where the organic phase has been eliminated.
3293191|NCT01771302|Experimental|calcium phosphate ceramic|is a calcium phosphate biomaterial
3293192|NCT01771315|Experimental|telephone follow-up|Nurse led follow-up in form of consultation by telephone 4 days and 2weeks after discharge, respectively as a supplement to conventional admission course.
3293193|NCT01771315|No Intervention|Usual treatment|All patients follow conventional admission course which implies preoperative seminar and a discharge planning consultation on the day of discharge. The patients are discharged to home, referred to physiotherapy in the community and a scheduled follow-up by the surgeon after 3 month in the orthopedic outpatient clinic.
3293194|NCT01771328|Active Comparator|hydrocortisone|Treatment B ( Solu-Cortef) the initial standard dose of 10mg/m2/24hrs. Hydrocortisone infusate will be given as Solu-Cortef Act-o-Vial 50mg/ml, produced by Pfizer. Treatment will take 4 months.
3293195|NCT01771328|Active Comparator|cortisone acetate|Treatment A (Cortisone tbl.) is current treatment, i.e. glucocorticoid and mineralocorticoid replacement according to best clinical judgement. This treatment period will take 6 months.
3293196|NCT01771341|Placebo Comparator|Pressure support|
3293197|NCT01771341|Experimental|NAVA|
3293198|NCT01771354|Placebo Comparator|Placebo|Placebo
3293199|NCT01771354|Active Comparator|Vaccine|Engerix B vaccine
3293200|NCT01771367|Active Comparator|Fluad|Participants receive one dose of Fluad vaccine.
3293201|NCT01771367|Active Comparator|Agrippal|Participants receive one dose of Agrippal vaccine.
3293202|NCT01771367|Placebo Comparator|Placebo|Participants receive one dose of saline placebo.
3293203|NCT01771380||Subjects with impaired glucose tolerance|
3293204|NCT01771393|Experimental|CBCT prior to MDCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the CBCT performed prior to the MDCT.
3293205|NCT01771393|Experimental|MDCT prior to CBCT|To avoid systematic bias in performance or image quality due to dilution of the contrast enhancement within the joint, the order of the CBCT and the MDCT will be randomized. This arm is composed of patients who will have the MDCT performed prior to the CBCT.
3293206|NCT01771406|Experimental|Nebivolol then CPAP|8 weeks of Nebivolol treatment (5m/day), 6 weeks of washout, 8 weeks of CPAP and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
3293207|NCT01771406|Experimental|CPAP then Nebivolol|8 weeks of CPAP treatment, 6 weeks of washout, 8 weeks of Nebivolol and if the patient is still hypertensive 8 weeks of Nebivolol plus CPAP treatment
3293208|NCT01771419|Experimental|loop-tip arm|The cannulation of CBD will be obtained using the loop-tip wire (Cook Medical inc.)
3293209|NCT01771419|Active Comparator|Control arm|The cannulation of CBD will be obtained with a Cook Medical sphincterotome CT-25 mm (tradictional technique)
3293210|NCT01771432|Active Comparator|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.
3293211|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
3293212|NCT01771445|Active Comparator|IL-1Ra|
3293213|NCT01771445|Placebo Comparator|Placebo|
3293214|NCT01771458|Active Comparator|Standard chemotherapy|Treatment choice is based on Investigator decision.
3293215|NCT01771458|Experimental|Personalized treatment|"Targeted therapy based on the patient molecular profil (if there is at least one abnormality that could be targeted)~Elligible therapies in this trial are :~Imatinib Everolimus Vemurafenib Sorafenib Erlotinib Lapatinib Trastuzumab Dasatinib Tamoxifen (or letrozole if contra-indication) Abiraterone"
3293216|NCT01771471|Experimental|NuQu treatment|single administration
3293217|NCT01771471|Other|Saline|single administration
3293218|NCT01771484|Experimental|Low Sodium Diet|participants will consume a diet (10 milliequivalent Na+/day)for 4-5 days prior to study day.
3293219|NCT01771484|Experimental|High sodium diet|Participants will consume a diet high in sodium (300 milliequivalent Na+/day) for 4-5 days prior to study intervention.
3293220|NCT01771497||Women undergoing neoadjuvant therapy|
3293221|NCT01771523|Active Comparator|Group 1|thyroidectomy
3293222|NCT01771523|Active Comparator|Group 2|thyroidectomy use of drain
3293223|NCT01771536|Active Comparator|PCI Choice decision|Decision Aid intervention is provided to clinician to share with patient
3293224|NCT01771536|No Intervention|Usual Care|
3293225|NCT01771549||Group 1|Patients with breast cancer beginning chemotherapy with a dose-dense regimen including adriamycin without concurrent trastuzumab.
3293226|NCT01771549||Group 2|Patients receiving trastuzumab in the adjuvant, neo-adjuvant, or metastatic setting in a regimen not containing simultaneous adriamycin therapy.
3293227|NCT01771575|Experimental|Treatment Arm|PoNS™ device
3293228|NCT01771575|Placebo Comparator|Placebo Arm|placebo device
3293229|NCT01771588|Experimental|New human milk fortifier|New human milk fortifier
3293230|NCT01771588|Active Comparator|Currently marketed fortifier|Currently marketed fortifier
3293231|NCT01771588|Experimental|New human milk fortifier with new Ca source|a subgroup of patients will receive the new milk fortifier containing a new source of calcium.
3293232|NCT01771601||Near-infrared spectroscopy sensors|Term infants born by elective Caesarean section
3293233|NCT01771614|Experimental|Normoglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3293234|NCT01771614|Experimental|Steady-State Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3293235|NCT01771614|Experimental|Fluctuating Hyperglycemia + exercise|At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, fluctuating hyperglycemia (~8-15 mM) will be induced by intravenously injecting 0.15 g/kg boluses of 20% dextrose every 30 minutes. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
3293236|NCT01771640|Experimental|stem cell reciepient|The patients with ALS that underwent mesenchymal stem cell transplantation
3293237|NCT01771653||Previously treated|Data from patients who were previously treated with Peg, interferon (IFN), alfa, and ribavirin
3293238|NCT01771653||Previously untreated|Records of patients who have never received anti-HCV treatment.
3293239|NCT01771679|Experimental|Allogeneic Mesenchymal Bone Marrow Cells|1550 nm Fraxel laser treatment (6-8 mJ, Level 2) to full face followed by IV infusion of Allogeneic Mesenchymal Bone Marrow Cells (0.5, 1.0, or 1.5 million cells/kg, up to 150 million cells)
3293240|NCT01771692|Active Comparator|Conventional ligation|Modules ligated in a conventional manner (figure of 0)
3293241|NCT01771692|Active Comparator|Figure of 8 ligation|Modules ligated in a figure of 8 configuration
3293242|NCT01771705|Experimental|Dose adjust group (NFAT)|Within 4 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is <20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
3293243|NCT01771705|No Intervention|Standard of care group|A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.
3293244|NCT01771718||Human skin|Multiphoton microscopy imaging to collect information about changes in skin cells and fibrilar structure.
3293245|NCT01771744||Morbidly obese patients|48 morbidly obese patients with revisional gastric bypass
3293246|NCT01771744||48 morbidly obese patients|with primary gastric bypass
3293247|NCT01771783|Experimental|ACEI-ARB-RI|angiotensin converting enzyme inhibitor (ACEI) angiotensin receptor antagonist (ARB) renin inhibitor (RI)
3293248|NCT01771783|Experimental|ARB-RI-ACEI|ARB-RI-ACEI
3293249|NCT01771783|Experimental|RI-ACEI-ARB|RI-ACEI-ARB
3293250|NCT01771796|Experimental|Aerobic and muscle resistance training|
3293251|NCT01771796|No Intervention|Usual care group|All patients (intervention and usual care group) are patients with lung cancer who underwent a resection surgery.
3293252|NCT01771822|Experimental|Ibuprofen 5% topical gel|
3293253|NCT01771822|Experimental|Topical gel vehicle|
3293254|NCT01771822|Active Comparator|Sodium lauryl sulfate 0.2%|
3293255|NCT01771822|Sham Comparator|Sodium chloride solution 0.9% (saline)|
3293256|NCT01771835||Diabetes patients|Patients with diabetes mellitus type I + II, without diabetic retinopathy
3293257|NCT01771848|Experimental|Grp 1-10ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 1 (n=6): 2,500 PfSPZ administered IM in a volume of 10 µL in 2 sites (one injection of 10µL containing 1,250 PfSPZ in each deltoid)."
3293258|NCT01771848|Experimental|Grp 2-50ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 2 (n=6): 2,500 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50µL containing 1,250 PfSPZ in each deltoid)."
3293259|NCT01771848|Experimental|Grp 3-250ul x 2; 2,500 PfSPZ Challenge-Part A|"PART A:~Group 3 (n=6): 2,500 PfSPZ administered IM in a volume of 250 µL in 2 sites (one injection of 250 µL containing 1,250 PfSPZ in each deltoid)."
3293260|NCT01771848|Experimental|Grp 4-50ul x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 4 (n=6) (control group) 25,000 PfSPZ administered IM in a volume of 50 µL in 2 sites (one injection of 50 µL containing 12,500 PfSPZ in each deltoid)."
3293261|NCT01771848|Experimental|Grp 5-Optimal vol Part A x 2; 25,000 PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 5 (n=6) 25,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 12,500 PfSPZ in each deltoid).~If the optimal volume in Part A is 50µL, then Group 5 will be modified to avoid duplication of regimens between groups 4 and 5. In this case, volunteers in group 5 will be administered a dose of 25,000 PfSPZ administered intradermally in four 10 µL injections. (Every volunteer will receive 4 ID injections of 6,250 PfSPZ in a volume of 10 µL each, with 2 injections in each arm respectively)."
3293262|NCT01771848|Experimental|Grp 6-Optimal vol Part A x 2; 125,000* PfSPZ Challenge, Part B|"PART B: BEGINS AFTER COMPLETION OF PART A~Group 6 (n=6) 125,000 PfSPZ administered IM in the optimum volume determined in Part A in 2 sites (one injection of the optimum volume containing 62,500 PfSPZ in each deltoid) if the volume is 50 µL or 250 µL.~*If the optimal volume in Part A is 10 µL, then Group 6 will receive 100,000 PfSPZ (2 inoculations of 50,000 PfSPZ) instead of 125,000 PfSPZ."
3293263|NCT01771861||Seriously injured or potentially seriously injured patients|
3293264|NCT01771874|Experimental|MDMA, bupropion, placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two (actually 4) treatment conditions in the same subject. The four treatment conditions are placebo-placebo, bupropion-placebo, placebo-MDMA, and bupropion-MDMA.
3293265|NCT01771887|Experimental|education program|education program in 6 hours for groups of 10 people. The content will be divided into 2 sessions with an interval of 2 weeks, the duration of each session is 3 hours. Means active learning, teaching materials in Arabic accompany the content masterful discussions on flipcharts, situation analysis, computer-assisted presentation, demonstration, 150 photos of Lebanese dishes. After, patients receive a 10-page illustrated book, a logbook of diabetes control. 2 weeks after the second education session, each participant will receive 5 calls every 15 days in 2 months. During each call, the research assistant will ask the patient about diet, exercise and self-monitoring, medication and foot care and this according to a checklist.
3293266|NCT01771900|Experimental|Heart Camp Group|
3293267|NCT01771900|Experimental|Attention Control Group|
3293268|NCT01771926|Experimental|High Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3293269|NCT01771926|Experimental|Low Resistant Starch Potatoes|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3293270|NCT01771926|Placebo Comparator|Other Carbohydrate Source|Subjects will receive 1 serving daily for 8 weeks during the weight loss group sessions.
3293271|NCT01771939|Experimental|idiopathic epiretinal membranes|Patients in first arm, with worse visual condition, treated with 25-G Vitrectomy and phacoemulsification (cataract intervention)
3293272|NCT01771939|Active Comparator|idiopathic epiretinal membrane|Patient in second arm, with better pre-operative condition, treated with phacoemulsification (cataract intervention) only
3293273|NCT01771978|Placebo Comparator|Arm1: control group|Received 250 ml of a 5% dextrose solution as placebo drug
3293274|NCT01771978|Experimental|Arm 2: diltiazem group|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
3293275|NCT01771978|Experimental|Arm 3: acetylcystein group|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
3293276|NCT01771978|Experimental|Arm 4: diltiazem and acetylcystein group|"Received a combination of drug :~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution and 150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
3293278|NCT01772017|Experimental|Device Treatment|Tongue Advancement Retainer Device
3293279|NCT01772030|Other|Recurrent Atrial Fibrillation|
3293280|NCT01772043||Duchenne muscular dystrophy|
3293281|NCT01772056|Experimental|Fluticasone, cream|fluticasone propionate (FP) cream of 0.05%. The vehicle is:Base PFCO/W, Propyleneglycol and Water conservant.
3293282|NCT01772056|Placebo Comparator|Placebo, cream|Vehicle cream is composed by Base PFCO/W, Propyleneglycol and Water conservant.
3293283|NCT01772082|Active Comparator|Pedometer alone|pedometer
3293284|NCT01772082|Experimental|Pedometer plus website|pedometer and website
3293285|NCT01772095||Patients with Dementia|Patients diagnosed with dementia and evaluated by specific Alzheimer disease scales
3293286|NCT01772108|Experimental|MitraClip Device|Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
3293287|NCT01772108|No Intervention|Control|Subjects randomized to the Control group will receive optimal standard of care therapy alone.
3293288|NCT01772121||HCV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HCV infection
3293289|NCT01772121||HBV Cohort|A total of 1000 subjects were enrolled in the study and of that 500 subjects had a diagnosis of chronic HBV infection
3293290|NCT01772173||subjects with diabetes developing hypertension|subjects with diabetes not developing hypertension
3293291|NCT01772186|No Intervention|Without real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system but not receive the real-time somatosensory cue during freezing-of-gait episodes.
3293292|NCT01772186|Experimental|With real-time somatosensory cue|Parkinson patients wear the somatosensory stimulation system and receive the real-time somatosensory cue during freezing-of-gait episodes.
3293293|NCT01772199|Experimental|GSK239512 Arm|GSK239512 once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
3293294|NCT01772199|Placebo Comparator|Placebo Arm|Placebo once daily orally
3293295|NCT01772212|Experimental|A(test)/B(reference)|Initial administration of test and crossover to reference
3293296|NCT01772212|Experimental|B(reference)/A(test)|Initial administration of reference and crossover to test
3293297|NCT01772225||Deceased Group|Subjects in this group will include the deceased patients from each of the three countries.
3293298|NCT01772225||Living Group|Subjects in this group will include living patients aged 18 years or older from each of the three countries.
3293299|NCT01772238|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3293300|NCT01772238|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3293301|NCT01772251|Experimental|Oshadi Icp & placebo|
3293302|NCT01772264|Experimental|Arm A - active treatment|
3293303|NCT01772264|Placebo Comparator|Arm B - placebo|
3293304|NCT01772277||MMC group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy with intraoperative MMC
3293305|NCT01772277||Control group|patients were scheduled to undergo Endoscopic dacryocystorhinostomy without intraoperative MMC
3293306|NCT01772290|Active Comparator|A: Vismodegib|
3293307|NCT01772290|Experimental|B: Rabeprazole + Vismodegib|
3293308|NCT01772290|Experimental|C: Itraconazole + Vismodegib|
3293309|NCT01772290|Experimental|D: Fluconazole + Vismodegib|
3293310|NCT01772303|Experimental|HO/03/03 10-40 micro gram|Topically treatment with HO/03/03 10-40µg once daily for up to 24 weeks. Subjects will receive treatment with HO/03/03 10µg at a dose of 1-4 vials (i.e. 10-40 µg/administration) daily depending on their wound size.
3293311|NCT01772329|Experimental|4 weekly CT sessions - in person|4 weekly CT sessions; all will be 1-hr individual cognitive therapy sessions with the psychology staff (under the supervision of John Burns, PhD).
3293312|NCT01772329|Experimental|8 weekly CT sessions|"8 weekly CT sessions; 1st and 8th will be 1-hr individual cognitive therapy session with the psychology staff (under the supervision of John Burns, PhD). The intermediate CT sessions will be by telephone call or video/Skype. Our group will purchase and setup a web camera and headphone/microphone for the subjects in the CT groups that use Skype. The 1-hr CT protocol was adapted from Dr. Beverly E. Thorn's CT manual (Cognitive Therapy for Chronic Pain: A Step-by-Step Guide; Thorn, 2004; with the Client and Therapy Workbooks."
3293313|NCT01772329|Experimental|4 weekly CT sessions - Tele-video|"4 weekly CT sessions; 1st and 4th will be 1-hr individual cognitive therapy session with the psychology staff. The intermediate CT sessions will be by telephone call or video/Skype."
3293314|NCT01772329|Placebo Comparator|Routine care|Routine care; no CT sessions
3293315|NCT01772342|Experimental|Nocturnal Air Purification|"Hepa Filtration with PureNight~SHAM with PureNight"
3293316|NCT01772355|Other|tissue core|semi automated core needle biopsy of the orbital tumors
3293317|NCT01772381|Experimental|Dexamethasone|Dexamethasone, im , 12 mg twice, 12 hrs apart, 48 hrs before elective cesarean section
3293318|NCT01772394|Active Comparator|Cognitive Remediation Therapy (CRT)|Active : CRT
3293319|NCT01772394|Sham Comparator|Sham Therapy (ST)|Sham : ST
3293320|NCT01772407||1|laparoscopic surgery in right colon cancer operations
3293321|NCT01772407||2|open surgery in right colon cancer operations
3293322|NCT01772420|Experimental|Arm A (lenalidomide, eltrombopag olamine)|"Patients with baseline platelet counts >= 50,000 receive lenalidomide PO daily or QOD on days 1-21. If platelet counts fall below 50,000, patients discontinue lenalidomide and receive eltrombopag olamine PO daily or QOD until platelet count is maintained above 50,000 for 2 weeks. Patients then resume lenalidomide PO daily or QOD. If platelets fall below 50,000 again, patients receive eltrombopag olamine as before. When platelet counts are maintained above 50,000 for 2 weeks, patients resume lenalidomide concurrently with eltrombopag for all subsequent courses.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3293323|NCT01772420|Experimental|Arm B (eltrombopag olamine, lenalidomide)|"Patients with baseline platelet counts < 50,000 receive eltrombopag olamine PO daily or QOD on days 1-28 until platelet count is maintained above 50,000 for 2 weeks. Patients then receive treatment as in Arm A.~Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity."
3293324|NCT01772433|Placebo Comparator|Phonophoresis Gel|The Phonophoresis gel will be used as placebo
3293325|NCT01772433|Experimental|Olive Oil|Olive oil will be used as a replacement to phonophoresis gel in this arm
3293326|NCT01772446|No Intervention|CONTROL GROUP|ROUTINE CLINICAL PRACTICE
3293327|NCT01772446|Experimental|SMS MESSAGING|SMS MESSAGES TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED HEMOGLOBIN
3293328|NCT01772459||Paper/Paper|This group will complete paper questionnaires at baseline and two week follow up.
3293329|NCT01772459||Paper/Internet|This group will complete paper questionnaires at baseline and internet questionnaires at two week follow up.
3293330|NCT01772459||Internet/Paper|This group will complete internet questionnaires at baseline and paper questionnaires at two week follow up.
3293331|NCT01772459||Internet/Internet|This group will complete internet questionnaires at baseline and two week follow up.
3293332|NCT01772485|Experimental|Cognitive Training|Training group participants will engage in 30 hours of at-home online training on the novel neuroplasticity-based cognitive training program ('Rewired') in 30 minute sessions completed approximately 3-5 days per week, for a total training period lasting 12-20 weeks. Both visual and auditory exercise forms will be practiced daily. Level progression criteria will be flexibly set to assure that almost all individuals can reach them in a reasonable time. Training compliance and performance data (accuracies and reaction times) will be continuously monitored remotely, and analyzed over secure online servers to assure that subjects are completing their training as scheduled and to deal with any unexpected road-blocks in training.
3293333|NCT01772485|Active Comparator|Active Control|The active control group shall engage in an at-home computer game suite, as used in a prior cognitive training trial in a psychiatric population (Fisher et al., 2009), for the same number of hours as the training group to control for the effects of computer exposure and interaction, contact with clinical research personnel and monetary rewards. Compliance will be monitored via an online data portal.
3293334|NCT01772498|Experimental|Heart rate variability biofeedback|Heart rate variability biofeedback training administered in eight, individual, weekly, one hour sessions. There will also be 20 minutes a day of resonant frequency breathing to be conducted at home. This intervention involves teaching subjects how to breath at their resonant frequency in a relaxed, diaphramatic manner.
3293335|NCT01772511||Questionnaire|Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
3293336|NCT01772524|Experimental|ALD403|Single IV Dose on Day 0
3293337|NCT01772524|Placebo Comparator|Saline|Single IV infusion on Day 0
3293338|NCT01772563|Experimental|volasertib + itraconazole|administration of volasertib alone and in combination with itraconazole
3293339|NCT01772589|Active Comparator|New saw blade|New saw blade
3293340|NCT01772589|Active Comparator|Reprocessed saw blade|Reprocessed saw blade
3293341|NCT01772615|Experimental|ciprofloxacin-EcN|
3293342|NCT01772615|Experimental|ciprofloxacin-placebo|
3293343|NCT01772615|Experimental|placebo-EcN|
3293344|NCT01772615|Placebo Comparator|placebo-placebo|
3293345|NCT01772628|Experimental|Promoting parent-child communication|This is the arm in which all interventions of Promoting parent-child communication on selected sexual and reproductive health issues among young secondary school adolescents in Kampala and Wakiso Districts were implemented. The interventions included; classroom-based component, STI/HIV prevention education, parenting component and homework assignment component.
3293346|NCT01772628|No Intervention|Comparison|The 11 comparison schools did not receive any form of intervention. Instead the students continued with the official standard school curriculum and regular parent/guardian involvement in school activities. No homework assignments were given to the senior one students.
3293347|NCT01772641|Experimental|Scheduled Gradual Reduction + Varenicline|Participants will be given the behavioral intervention of Scheduled Gradual Reduction along with the smoking cessation drug, Varenicline.
3293348|NCT01772641|Experimental|Scheduled Gradual Reduction + Placebo Drug|Participants will be given the behavioral intervention, SGR, along with a placebo drug matching the schedule of the VN group.
3293349|NCT01772641|Experimental|Basic Advice + Varenicline|Participants will be given basic advice about quitting smoking along with the smoking cessation drug Varenicline
3293350|NCT01772641|Placebo Comparator|Basic Advice + Placebo Drug|Participants will be given basic advice along with a placebo drug matching the schedule of the VN group.
3293351|NCT01772667|No Intervention|Usual care|Usual care during the whole study period without pulmonary rehabilitation. The patients will perform their normal daily life.
3293352|NCT01772667|Active Comparator|Inpatient Rehabilitation|3-week inpatient multimodal pulmonary rehabilitation program, including daily exercise training, breathing therapy, medical treatment and psychological support. In the following 3 month, the patients will perform their normal daily life.
3293353|NCT01772680|Experimental|Zinc Supplementation|25 mg elemental Zinc as Zn sulfate in capsule form taken daily for 3 months
3293354|NCT01772706|Experimental|laser low-level energy functional|The material used will be a diode laser of 100 mW, with a wavelength of 658 nm. Application will be made after each radiotherapy session in an adapted room (low light intensity, possibility of ENT examination) on all grade superior or equal to 2 stomatitis injuries. The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be determined by an abacus.
3293355|NCT01772706|Placebo Comparator|laser low-level energy nonfunctional|The procedure is identical to the one used in arm A but the laser will not be functional. The period of application will be around one minute.
3293356|NCT01772732|Experimental|Simotinib Treatment|"3+3 design, ascending multiple doses. Simotinib Hydrochloride: 100mg, 200mg, 300mg, 400mg, 500mg, bid, for 28 days"
3293357|NCT01772745|Active Comparator|Group 1|SILS cholecystectomy
3293358|NCT01772745|Active Comparator|Group 2|TPCL cholecystectomy
3293359|NCT01772771||Ancillary-correlative (biospecimen collection, chart review)|Patients' previously collected tissue samples are analyzed. Patients may also undergo collection of blood, saliva or buccal samples for analysis. Patients' medical records are reviewed.
3293360|NCT01772784|Experimental|phenolic acids|Maltodextrine + Phenolic acids
3293361|NCT01772784|Placebo Comparator|placebo|Maltodextrine
3293362|NCT01772784|Experimental|phenolic acid|Maltodextrine + Phenolic acids
3293363|NCT01772784|Active Comparator|polyphenol|
3293364|NCT01772797|Experimental|LDK378 and AUY922|
3293365|NCT01772810|Experimental|Surgical implantation of human spinal cord stem cells|Surgical implantation of human spinal cord derived neural stem cells.
3293366|NCT01772836|Placebo Comparator|Normal saline|Single and multiple dose of normal saline
3293367|NCT01772836|Experimental|Single dose IV of biapenem or RPX7009|Single dose IV infusion of biapenem or RPX7009
3293368|NCT01772836|Experimental|Single dose of biapenem or RPX7009|Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
3293369|NCT01772836|Experimental|Biapenem and RPX7009 in combination|Single dose followed by a multiple dose of biapenem and RPX7009 in combination
3293370|NCT01772849|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
3293371|NCT01772849|No Intervention|Standard educational programme|The children receive the standard of care with respect to education this include education in the hospitals school or at home without a class mate and no specific activity to secure continuous linkage with community school and class mates
3293372|NCT01772862|No Intervention|Only conventional supportive care|The children receive conventional supportive care with respect to physical training
3293373|NCT01772862|Experimental|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
3293374|NCT01772875|Active Comparator|lavage Isobetadine Dermicum solution|Patient will receive 1 bladder lavage daily with a solution of 5ml Isobetadine Dermicum in 100cc saline
3293375|NCT01772875|Active Comparator|lavage Acetic Acid solution|Patients will receive a daily bladder lavage during 5 consecutive days with a solution of 0.5% acetic acid in 100cc of saline
3293376|NCT01772875|Sham Comparator|lavage with saline|patients will receive during 5 consecutive days a bladder lavage with 100cc saline
3293377|NCT01772875|Active Comparator|lavage Urotainer Suby G|patients will receive during 5 consecutive days a bladder lavage with 100cc of Urotainer Suby G
3293378|NCT01772888||Patients with ALS|All subjects aged > 18 years, diagnosed with an ALS and included in the multidisciplinary follow-up of the HUG at time of diagnosis will be considered and included, if possible, at their first visit.
3293379|NCT01772888||Healthy age and gender-matched subjects|Controls matched for age and gender and dental status and without a medical history for neurological or otolaryngologic disease (1 control for 1 patient). They will be recruited among hospital staff and patients of the dental school.
3293380|NCT01772901|No Intervention|Control|Usual outpatient antenatal care consists of routine checking of the maternal and foetal health by either clinic midwives or obstetricians along with health education to promote a healthy pregnancy.
3293381|NCT01772901|Experimental|Influenza Vaccine Intervention|The intervention group will receive a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions.
3293382|NCT01772927||Very low birth weight infants,|Parenteral nutrition
3293383|NCT01772940|Active Comparator|nevirapine and tenofovir/emtricitabine|nevirapine 200 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
3293384|NCT01772940|Experimental|lopinavir/r and tenofovir/emtricitabine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks
3293385|NCT01772940|Active Comparator|Nevirapine and zidovudine/lamivudine|nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks
3293386|NCT01772940|Experimental|Lopinavir/r and zidovudine/lamivudine|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks
3293387|NCT01772953|Experimental|treosulfan, fludarabine and low-dose TBI prep regimen|"Treosulfan: 10-14 g/m2/day IV over 120 minutes on days -6, -5 and -4. Treosulfan will be administered prior to fludarabine on days -6 to -4 to facilitate PK testing.~Fludarabine: 30 mg/m2 IV for patients > 10 kg (or 1 mg/kg IV for patients < 10 kg) once daily per institutional infusion standards on days -6 through -2 for a total dose of 150 mg/m2 (or 5 mg/kg).~A single fraction of 200 cGy TBI will be administered on day -1. Stem cell infusion on day 0"
3293388|NCT01772966|Experimental|Spinal manipulation|Participants will receive spinal manipulation delivered as segmental thrust to a specific site in the neck. They will receive three intervention sessions over 7-10 days.
3293389|NCT01772966|Sham Comparator|Control manipulation|Participants will receive spinal manipulation delivered as non-segmental thrust to the neck. They will receive three intervention sessions over 7-10 days.
3293390|NCT01772979|Experimental|Trabectedin|"Trabectedin 1.3 mg/m2 q 21 days~Patients will receive trabectedin until disease progression or unacceptable toxicity"
3293391|NCT01772992|No Intervention|Control group (iVCT)|Male couples randomized to the control group (iVCT) will each receive individual HIV counseling and testing, separately.These couples in the control group (iVCT) will return every 6 months, up to 18 months, for individual visits, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted separately.
3293392|NCT01772992|Experimental|Experimental group (CVCTPLUS)|Male couples randomized to the experimental group (CVCTPLUS) will each receive HIV counseling and testing as a couple. These couple will return for two additional visits that members of the control arm do not get, for two one-hour sessions of the Partner-STEPS. Couples in the experimental group (CVCTPLUS) at 8 and 10 weeks after the initial enrollment. They will also return every 6 months, up to 18 months, for visits in which they will be seen as a couple, in which they will have STI testing and repeat HIV testing. All follow-up visits will be conducted for the couples together.
3293393|NCT01773005|Sham Comparator|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
3293394|NCT01773005|Active Comparator|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
3293395|NCT01773018|Experimental|Volitinib(HMPL-504)|"There are six dose cohorts,including 100, 200, 400, 600,800 and 1000 mg/day, HMPL-504 will be administered orally to patients once daily for each dose cohort.~An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of Volitinib(HMPL-504)."
3293396|NCT01773031||Autoimmune pancreatitis|Patients with autoimmune pancreatitis based on clinical and CT findings
3293397|NCT01773044|Active Comparator|alkalinized lidocaine & lidocaine|
3293398|NCT01773044|Active Comparator|alkalinized lidocaine &Placebo|
3293399|NCT01773057|Experimental|Active decision support|Regular NHGDoc domains plus NHGDoc domain heart failure
3293400|NCT01773057|No Intervention|Passive decision support|Regular NHGDoc domains
3293401|NCT01773083|Experimental|unfractionated heparin|25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
3293402|NCT01773083|Placebo Comparator|placebo|Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)
3293403|NCT01773096|Experimental|Study group|Weight-based dose (0.15 mg/kg for patients less than 38 kg, 8 mg for patients weighing 38-62 kg, or 12 mg for patients weighing greater than 62 kg) of methylnaltrexone will be administered on post-operative day 3 and again, if indicated, on post-operative day 4. This group will also receive the standard bowel protocol beginning on postoperative day one as per protocol.
3293404|NCT01773096|Active Comparator|Institutional bowel protocol|Patient will receive institutional standard bowel protocol. Beginning on post-operative day one either miralx,docusate sodium or senna, on a weight-based dose. If no bowel movement in 72 hours, either oral bisacodyl or magnesium hydroxide, on a weight-based dosing, will be added.
3293405|NCT01773148|Experimental|Arstasis Access System (AXERA) placement|Placement of AXERA device in subjects undergoing common femoral artery access for PCI and/or PVI through a 5F or 6F introducer sheath.
3293406|NCT01773161||Cerebral palsy, post hip surgery|Children between the ages of 4-18 undergoing surgical treatment for hip subluxation or dislocation secondary to cerebral palsy.
3293407|NCT01773174|Experimental|dabigatran etexilate|single dose treatment with dabigatran oral solution
3293408|NCT01773200||Aneurysmal Subarachnoid Hemorrhage|Each consecutive patient suffering from aneurysmal subarachnoid hemorrhage
3293409|NCT01773213|Other|Bladder dysfunction, ice-water-test|
3293410|NCT01773213|Other|Bladder dysfunction, warm water-test|
3293411|NCT01773239|Experimental|TARA computer-based exercises|"TARA is a computerized social cognitive (SC) remediation program consisting of a set of specific SC exercises. The program creates a game-like experience where the participant is encouraged to earn points and in-game rewards to further advance in each 'game'. Participants perform tens to hundred of trials over the course of their session, with each trial providing auditory and visual feedback and rewards to indicate if the trial was performed correctly or incorrectly. After each trial, the difficulty of the next trial is updated to ensure that within each session, the participant gets ~85% of trials correct. Summary screens including game metrics (points, levels) and exercise metrics (usage, progress) are shown to the participant at the end of each session.~Participants in the TARA computer-based exercises arm will complete baseline- assessments, 24 hours of TARA computer based-exercises, and repeat post-assessments."
3293412|NCT01773252|Experimental|TEE|Within patient comparison of TEE, FDS and a TCD from select study sites
3293413|NCT01773278|Experimental|antioxidant effects on retinal function|Patients with SLOS will be treated with both cholesterol supplementation and antioxidants. Retinal function will be followed by serial electroretinogram (ERG) testing and pigmentary retinopathy will be followed by Serial Ophthalmologic exams under anesthesia
3293414|NCT01773278|Experimental|antioxidant effects on hearing|Patients with SLOS will be treated with cholesterol and antioxidant medication and their hearing will be followed by serial brainstem audiometry (ABR)
3293415|NCT01773278|Experimental|Antioxidant effect on Oxysterols|Patients with SLOS will be treated with antioxidants and cholesterol. Blood oxysterol levels will be measured. Future focus will be on being able to use oxysterol levels to regulate antioxidant doses, and to determine which particular antioxidants might have the most benefit in lowering oxysterols
3293416|NCT01773304|Experimental|Meal rich in dairy protein|
3293417|NCT01773304|Experimental|Meal rich in meat protein|
3293418|NCT01773317|Experimental|Perturbation|Subjects complete the training protocol and peturbation training exercises
3293419|NCT01773317|Experimental|Control|Subjects will complete the training protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
3293420|NCT01773330|Experimental|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
3293421|NCT01773343|Active Comparator|CO2 laser at 1 month interval|CO2 laser treatment of mild to severe acne scars at 1 month interval
3293422|NCT01773343|Active Comparator|CO2 laser at 3 monrths interval|CO2 laser treatment of mild to severe acne scars at 3 month intervals
3293423|NCT01773356|Placebo Comparator|Placebo 0 mg/d|0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
3293424|NCT01773356|Active Comparator|Dihydrocapsiate 9 mg/d|9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
3293425|NCT01773369|Experimental|Early treatment group|These children will undergo the intervention (i.e., early leg training) shortly after recruitment. Measures will be taken before, during and after the intervention.
3293426|NCT01773369|Experimental|Delayed treatment group|These children will undergo the intervention (delayed leg training) after a delay of ~3 months, during which outcome measures will be taken so that they can serve as a control for the early treatment group. Their intervention is identical to the Immediate treatment group.
3293427|NCT01773369|No Intervention|Control group|These children will be recruited close to the age of 4 years old, and will only undergo gait analysis and GMFM-66 scoring.
3293428|NCT01773369|Experimental|Parent training group|These children will undergo the intervention (i.e., parent leg training) shortly after recruitment. Parents will be trained to provide the intervention instead of a physical therapist. Measures will be taken before, during and after the intervention.
3293429|NCT01773382|No Intervention|control|standard treatment of IgA nephropathy including ACEI/ARB for blood pressure control (target BP <130/80 mmHg)
3293430|NCT01773382|Experimental|weight reduction|target weight reduction is 3-5% from baseline
3293431|NCT01773395|Active Comparator|GVAX|"GVAX vaccine~Participants in the GVAX vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. GVAX arm participants meeting criteria to begin vaccinations will be administered the GVAX vaccine at established study time points."
3293432|NCT01773395|Placebo Comparator|Placebo|"Placebo vaccine~Participants in the Placebo vaccine arm will undergo a conditioning regimen with busulfan and fludarabine prior to allogeneic hematopoietic stem cell transplant. Immediately after allogeneic hematopoietic stem cell transplant participants will start tacrolimus and methotrexate to prevent GVHD. Placebo vaccine arm participants meeting criteria to begin vaccinations will be administered the placebo vaccine at established study time points."
3293433|NCT01773408|Experimental|Part 1: RO5503781|Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
3293434|NCT01773408|Experimental|Part 2: RO5503781 + Cytarabine|Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
3293435|NCT01773408|Experimental|Part3:RO5503781+Cytarabine+Anthracycline|Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
3293436|NCT01773408|Experimental|Part 4: Optimized RO5503781 + Cytarabine|Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
3293437|NCT01773434|Experimental|MORAb-004|
3293438|NCT01773447|Active Comparator|Set-back suture|Wound to be close by set-back suture technique.
3293439|NCT01773447|Active Comparator|Vertical mattress suture technique|Wound to be closed by vertical mattress technique.
3293440|NCT01773460|Experimental|Everolimus|Everolimus is given beyond progress
3293441|NCT01773460|Placebo Comparator|Everolimus-placebo|Everolimus-placebo is given beyond progress
3293442|NCT01773486|Active Comparator|Hesperidin|Subjects will receive oral hesperidin 500 mg/day
3293443|NCT01773486|Placebo Comparator|Placebo|subjects will receive matching placebo to hesperidin daily for 1 month
3293444|NCT01773499||Patient with Cellulitis|Patients with uncomplicated cellulitis treated as outpatients
3293445|NCT01773512|Experimental|Rosuvastatin|All patients will be using rosuvastatin 40 mg
3293446|NCT01773538|Active Comparator|Anti cHE treatment arm|Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
3293447|NCT01773538|Placebo Comparator|Placebo arm|The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
3293448|NCT01773551||Optical Index of Breast Density|Breast Density
3293449|NCT01773564|Active Comparator|Available current hospital dressing|Control group: depending on the type of dressing available at the hospital, either 3M™ HP Dressing or Smith & Nephew IV3000 ™
3293450|NCT01773564|Experimental|3M™ IV Advanced Securement dressing|New generation transparent dressing
3293451|NCT01773577||Physician Pract. Employee and Off. Staff|The office staff and providers and physician practices enrolled in the RHIO
3293452|NCT01773590|Other|Asthmatics|Rhinovirus Infection
3293453|NCT01773590|Other|Healthy Volunteers|Rhinovirus Infection
3293454|NCT01773603|No Intervention|Conventional incubation|Five-day embryo culture in conventional incubators
3293455|NCT01773603|Active Comparator|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
3293456|NCT01773616|Experimental|Rituximab|Rituximab, methyl prednisolone and mycophenolate mofetil
3293457|NCT01773616|Active Comparator|Oral prednisolone|Oral prednisolone, methyl prednisolone and mycophenolate mofetil
3293458|NCT01773629|Experimental|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
3293459|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
3293460|NCT01773642|Experimental|Cognitive-behavioral intervention|A cognitive-behavioural intervention aimed at supporting caregivers through paediatric HIV diagnosis disclosure to the child in their care.
3293461|NCT01773642|No Intervention|Standard of Care|
3293462|NCT01773655||tissue|This is a protocol to obtain and/or analyze tumor and germline DNA specimens of patients with MPM, choroidal nevus, and UM.
3293463|NCT01773668|Experimental|Integrated sensor and infusion set|
3293464|NCT01773694|Active Comparator|Early Water Exposure|The Intervention group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
3293465|NCT01773694|No Intervention|Standard Care|The Standard Care group will receive standard wound care instructions and verbal education by the staff to keep the dressing dry and intact for 48 hours.
3293466|NCT01773707|Experimental|abatacept IV infusion|CTLA4-Ig (Abatacept) will be administered as 14 (30 minute) infusions over one year (3 infusions every other week the first month; monthly for the following 11 months)
3293467|NCT01773707|Placebo Comparator|Placebo|The placebo arm will receive 14 (30 minute) IV infusions (containing saline) given 3 times (every other week) the first month and monthly for the following 11 months.
3293468|NCT01773733||BMI ≥ 30|
3293469|NCT01773733||BMI ≥27 kg/m2 associated with DM2|
3293470|NCT01773746|Active Comparator|Room Air|Neonatal Resuscitation using continuous positive airway pressure(CPAP) or positive pressure ventilation (PPV) will be provided with 21% oxygen. Infants will remain on 21% oxygen until they have a functioning oximeter when SpO2 will be managed as below. FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
3293471|NCT01773746|Active Comparator|60% Group|Neonatal Resuscitation using CPAP or PPV will be provided with 60% oxygen. Infants will remain on 60% oxygen until they have a functioning oximeter at which time their SpO2 will be managed as described below FiO2 will be increased by 10% increments when the infant's SpO2 is below the lower sat limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 seconds as often as is necessary to bring the SpO2 within the pre-specified range. The FiO2 will be decreased by 10% increments when the SpO2 is above the upper limit for 30 seconds and repeated if the SpO2 remains outside the limit for a subsequent interval of 30 second as often as is necessary to bring the SpO2 within the pre-specified range.
3293472|NCT01773759|Experimental|Intervention child care programs|Intervention child care programs will receive immunization outreach and education.
3293473|NCT01773759|No Intervention|Control child care programs|Control programs will receive no more than usual training regarding childhood immunization requirements.
3293474|NCT01773772|Experimental|Progesterone|Subjects will take 25-50 mg oral micronized P or placebo at 1600 h and again at 2000 h. P dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those > or = 42 kg.
3293475|NCT01773772|Placebo Comparator|Placebo|Subjects will take placebo at 1600 h and again at 2000 h.
3293476|NCT01773785|Experimental|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
3293477|NCT01773798|Experimental|IDegAsp 15|
3293478|NCT01773798|Experimental|IDegAsp|
3293479|NCT01773798|Experimental|IDeg|
3293480|NCT01773798|Active Comparator|IAsp|
3293481|NCT01773798|Experimental|IDeg + IAsp|
3293482|NCT01773811|No Intervention|Control|Individuals will write objectively about the events of their day.
3293483|NCT01773811|Experimental|Narrative Writing: Trauma-Assigned|Trauma-assigned: Individuals will write about their most traumatic life experience and be instructed to continue to think about their writing topic in the weeks following writing.
3293484|NCT01773811|Active Comparator|Narrative Writing: Trauma-Spontaneous|Individuals will write about their most traumatic life experience but will not be given further instructions for processing. Any additional processing about their writing topic in the weeks following writing will be considered spontaneous.
3293485|NCT01773824|Other|No feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial).
3293486|NCT01773824|Experimental|Antibiotic prescription feedback|Physicians receive quarterly electronic feedback on their antibiotic prescriptions
3293487|NCT01773837|Experimental|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
3293488|NCT01773837|Placebo Comparator|placebo|the same number of pills (p.o.) than methylphenidate for six days
3293489|NCT01773850||Patients|Patients with a breast lesion undergoing surgical biopsy. All patients will undergo stationary Carbon Nanotube x-ray digital breast tomosynthesis imaging in addition to routine conventional digital mammography.
3293490|NCT01773876|Active Comparator|Micafungin|MYCAMINE 100 mg intravenous an injection of 24 hours
3293491|NCT01773876|Placebo Comparator|PLACEBO|0.9% sodium chlorides 100ml infusion
3293492|NCT01773902|Experimental|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
3293493|NCT01773902|Experimental|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
3293494|NCT01773902|Active Comparator|Standard protein supplementation|Protein supplementation independent of individual breast milk content using a standard dose of a standard breast milk fortifier until 1 week before discharge
3293495|NCT01773915||AD patients|Subject fulfilling the McKhann criteria for clinical probable AD
3293496|NCT01773915||Healthy elder persons|Healthy controls with abscence of any cognitive disorder
3293497|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
3293498|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
3293499|NCT01773928|Experimental|VCIV - Modified manufacturing process (18-49 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
3293500|NCT01773928|Active Comparator|VCIV manufactured with current process (18-49 Years Old)|Vero cell-derived trivalent influenza vaccine (VCIV)
3293501|NCT01773928|Active Comparator|Fluzone® (18-49 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
3293502|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 1|Vero cell-derived trivalent influenza vaccine (VCIV)
3293503|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 2|Vero cell-derived trivalent influenza vaccine (VCIV)
3293504|NCT01773928|Experimental|VCIV - Modified manufacturing process (≥50 Years Old) Lot 3|Vero cell-derived trivalent influenza vaccine (VCIV)
3293505|NCT01773928|Active Comparator|Fluzone® (≥50 Years Old)|Fluzone®, licensed trivalent influenza vaccine (TIV)
3293506|NCT01773980||Patient and Clinic Intervention|"The patient intervention consists of a single 90-minute interactive in-person session.~The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff."
3293507|NCT01773980||Patient Intervention Only|The patient intervention consists of a single 90-minute interactive in-person session.
3293508|NCT01773980||Clinic Intervention Only|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
3293509|NCT01773980||Neither Clinic nor Patient Intervention|Consists of no intervention
3293510|NCT01774006||Group culture|Embryos cultured in groups of 2-10
3293511|NCT01774006||Individual culture|Embryos cultured individually
3293514|NCT01774032|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection into the musculus deltoideus in the upper arm on Day 1 and 22.
3293515|NCT01774058|Experimental|Ilomedin, bloodflow volume, measurement,|Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
3293516|NCT01774071|Experimental|89Zr DFOMSTP2109A tracer Group 1|The first group of participants will include 6 participants whom will receive 10mg of 89Zr-DFO-MSTP2109A. A second group of 6 participants may receive twice the amount of antibody to determine if this results in better pictures of your tumors. Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2.
3293517|NCT01774071|Experimental|89Zr-DFO-MSTP2109A tracer Group 2|Once we determine whether 10 mg or the larger 20 mg dose of 89Zr-DFOMSTP2109A is best and well tolerated we will use that amount for future participants in Group 2. Group 2 will include up to 15 participants whom may receive a dose of up to 20mg.
3293518|NCT01774123||Healthy|Healthy controls
3293519|NCT01774123||MS-ON|Multiple sclerosis with optic neuritis
3293520|NCT01774123||MS-NON|Multiple sclerosis without optic neuritis
3293521|NCT01774136|Experimental|Enhanced HIV and MCH training for CHW|The intervention includes two components: (1) a 2-week HIV/C-IMCI training for CCGs and their associated facilitators and supervisors, and (2) continuous support and supervision following the continuous quality improvement (CQI) framework, a low-technology approach to management and supervision of health programs.
3293522|NCT01774136|No Intervention|Standard of Care|
3293523|NCT01774162|Active Comparator|FNA for cytology|Fine needle aspiration using conventional FNA for cytology
3293524|NCT01774162|Experimental|FNB core biopsy for histology|Fine needle biopsy using ProCore needle for histology.
3293525|NCT01774175||Coolprep|A total of 2L A : NaCl 5.382g KCl 2.03g Sodium sulfate 15g Polyethylene glycol 3350 200.0g B : Ascorbic acid 9.4g Sodium ascorbate 11.8g
3293526|NCT01774175||Picolyte|Sodium picosulfate 30.0mg Magnesium citrate 10.5g + 36.0g
3293527|NCT01774188||Intraocular pressure, EECP, no glaucoma|To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks
3293528|NCT01774188||intraocular pressure, EECP, glaucoma|To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks.
3293529|NCT01774201|Experimental|Breathing exercises|Daily deep breathing exercises during two month
3293530|NCT01774201|No Intervention|Control|Control group
3293531|NCT01774214|Experimental|A|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm A, subjects will perform the Push-Pull Technique of manual fluid resuscitation first, followed by the Disconnect-Reconnect Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
3293532|NCT01774214|Experimental|B|"As this is a crossover trial, the study arms denote the order in which the two interventions are performed by the subject. In Arm B, subjects will perform the Disconnect-Reconnect Technique of manual fluid resuscitation first, followed by the Push-Pull Technique second. A washout period of at least 30 minutes between each of the two interventions will be observed."
3293533|NCT01774227|Experimental|The pops-titration group|"The titration method uses power that is titrated according to the audible pop."
3293534|NCT01774227|Experimental|The slow-coagulation group|The slow-coagulation group utilize the low-energy using the Gaasterland's slow-coagulation technique
3293535|NCT01774240|No Intervention|before|no systematic approach
3293536|NCT01774240|Experimental|after|systematic screening and treatment of delirium
3293537|NCT01774266||Molina - Chile|Molina is one of the counties with the highest mortality rate of gastric cancer in Chile. Molina has a population of 40.000 hab mostly rural. Half of the population lives in Molina city and the other half in the suburbs. Molina is located near the Mountain Andes.
3293538|NCT01774279||anaplastic thyroid cancer|
3293539|NCT01774292|Active Comparator|Alkalized lidocaine|160 mg of 4% lidocaine (4 ml) in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
3293540|NCT01774292|Placebo Comparator|Sterile saline|4 mL of sterile saline in the endotracheal cuff and add bicarbonate 8,4% until appropriate seal.
3293541|NCT01774318|Other|preterm cohort|preterm infants born at medical university of vienna and born at gestational age 23+0 - 28+6 weeks of gestation intervention: aEEG and conventional EEG measurements will be performed every two weeks untill 36 weeks of gestation
3293542|NCT01774331||Immunoglobulin Therapy|Immunoglobulin Therapy
3293543|NCT01774370||Pradaxa group|
3293544|NCT01774396|Other|group 2|The intervention will be the injection of Emervel® Volume Lidocaine alone in the dorsa of one hand and Emervel® Deep Lidocaine alone in the dorsa of the contralateral hand.
3293545|NCT01774396|Experimental|group 1|EThe intervention will be the injection of mervel® Volume Lidocaine plus Emervel® Touch in the dorsa of one hand and Emervel® Deep Lidocaine plus Emervel® Touch in the dorsa of the contralateral hand
3293546|NCT01774409|Experimental|Blood and tumor samples|
3293547|NCT01774422|Experimental|noninvasive ventilation alone|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
3293548|NCT01774422|Other|noninvasive ventilation associated with the DECAP CO2 device|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~Noninvasive ventilation alone~Noninvasive ventilation associated with the DECAP CO2 device"
3293549|NCT01774435|Experimental|EN3342|EN3342 (risperidone) subcutaneous implant
3293550|NCT01774448|No Intervention|Waitlist Control|Participants in the control group will undergo a non-intervention 8-week period while on the 'waitlist control' then will be crossed-over to the Mindfulness-Based Cognitive Therapy intervention.
3293551|NCT01774448|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy is an 8-week intervention, one session per week for 2 hours, where participants will learn and practice formal and informal mindfulness meditation, and participate in group discussion and inquiry.
3293552|NCT01774461|No Intervention|Sham RIC|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
3293553|NCT01774461|Active Comparator|Remote ischemic conditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
3293554|NCT01774474|Active Comparator|Non diabetics: bromfenac|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperatively
3293555|NCT01774474|Active Comparator|Non diabetics: dexamethasone|dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3293556|NCT01774474|Active Comparator|Non diabetics: bromfenac & dexamethasone|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3293557|NCT01774474|Active Comparator|Diabetics: eye drops|bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week
3293558|NCT01774474|Active Comparator|Diabetics: eye drops & TA|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA, Triesence/Vistrec)"
3293559|NCT01774474|Active Comparator|Diabetics: eye drops & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative & dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative intravitreal injection of 1.25 mg bevacizumab (Avastin)"
3293560|NCT01774474|Active Comparator|Diabetics: eye drops, TA & bevacizumab|"bromfenac 0.09% eye drops twice daily starting two days before surgery and continuing 2 weeks postoperative, dexamethasone 0.1% eye drops four times daily starting two days before surgery and continuing four times daily during the first postoperative week and one drop less per day every following week~& a peroperative subconjunctival injection of 40 mg triamcinolone acetonide (TA)~& a peroperative intravitreal injection of 1.25 mg bevacizumab"
3293561|NCT01774487|Experimental|Pentoxifylline|"All newly-diagnosed biliary atresia patients fulfilling the study's inclusion criteria will receive oral pentoxifylline, 20 mg/kg/day divided in three doses for a total of 90 days.~The hospital pharmacy will create a 20 mg/ml oral pentoxifylline solution using 400 mg pentoxifylline tablets and established compounding recipes."
3293562|NCT01774513|Experimental|Procore Needle|
3293563|NCT01774539||Physeal Injury - Distal Radius|Patients who suffer a physeal fracture of the distal radius will be scanned and compared to their healthy contralateral limb.
3293564|NCT01774552||Port-wine stain|Photo Acoustic Microscopy and Optical Coherence tomography
3293565|NCT01774565|Experimental|Fully Automated Closed-Loop Insulin Delivery (phase 1-4)|The control algorithm will automatically direct between meals and meal-related subcutaneous insulin delivery utilizing real-time continuous glucose monitoring (RT-CGM) data. The subcutaneous insulin pump will deliver insulin Aspart or similar. In phase 1, a once daily basal insulin analogue will also be given subcutaneously at 20% the patient's usual total daily dose. In phase 3 and 4 faster-acting insulin aspart (Fiasp) is applied.
3293566|NCT01774565|Active Comparator|Usual care/ fully-automated closed-loop using Iasp|"Phase 1-3: During usual care (conventional therapy), subject's s.c. insulin dose and regimen on admission will be adjusted as necessary by the clinical team according to local centres' usual clinical practice. Subjects will have masked CGM sensors inserted during the study (CGM readings will be masked throughout the study).~Phase 4: subjects will receive fully-automated insulin delivery using standard insulin aspart (Iasp)"
3293567|NCT01774578|Active Comparator|Arm 1: Docetaxel|"Arm 1: Docetaxel 75 mg/m^2 IV given every 3 weeks x 4 doses. If response or stable: Observe until disease progression.~First Progression: Gemcitabine 1250 mg/m^2/week for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity."
3293568|NCT01774578|Experimental|Arm 2a: HyperAcute®-Lung Immunotherapy (weekly)|"Arm 2a: 300 Million HAL cells given by intradermal injection weekly for 11 weeks and then every 2 months for 5 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
3293569|NCT01774578|Experimental|Arm 2b: HyperAcute®-Lung Immunotherapy (biweekly)|"Arm 2b: 300 Million HAL cells given by intradermal injection biweekly for 6 doses and then every month for 10 additional doses.~Up to 16 total immunizations of 300 million immunotherapy cells until disease progression or toxicity.~First Progression: Docetaxel 75 mg/m^2 IV given every 3 weeks or Gemcitabine 1250 mg/m^2 for 2 weeks with 1 week rest or Pemetrexed 500 mg/m^2 every 3 weeks until disease progression or significant toxicity and continue with HAL administration given every 2 weeks (not to exceed 16 total immunizations)."
3293570|NCT01774617||Patients with advanced liver disease|Inclusion criteria are diagnosis of cirrhosis with portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Exclusion criteria were age 18 or older, previous contrast allergy, hepatocellular carcinoma or any malignancy except basocellular carcinoma, renal failure (creatinine level >1.5 mg/dL), severe bleeding disorder (prothrombin activity test < 30% or platelets count <35,000/mcL) or decompensated cirrhosis characterized by severe ascites or grade II or higher encephalopathy. Patients with alcoholic cirrhosis should be abstinent for at least six months.
3293571|NCT01774630|Experimental|Nilotinib|300 mg/twice a day
3293572|NCT01774643||Pancreatic cancer with liver metastases|Tumor tissue biopsy, blood samples
3293573|NCT01774656|Experimental|HeartMate II plus Pharmacological Treat|"The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.~The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily."
3293574|NCT01774669|Experimental|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each.
3293575|NCT01774669|Active Comparator|Conventional therapy|Patients in the control group (CG) will receive 16 therapy sessions (physiotherapy or occupational therapy) lasting for 45 minutes each.
3293576|NCT01774682|Other|6-minute walk test|the 6-minute walk test is performed for each patient prior to the surgery and 6 months after by a specialist.
3293577|NCT01774695|Other|Control and intervention|In the first study half of the subjects first served as controls for 12 weeks and then they went through the intervention. The other half only went through the intervention.
3293578|NCT01774708||Bed Exit|"Participants will be up to 60 ambulatory Budd Terrace residents.~Inclusion/Exclusion:~Inclusion:~Ambulatory patient able to leave the bed.~Willingness to consent and participate in a 30-night study~Exclusion:~Lack of capacity to consent, without an identifiable surrogate.~Terminal Prognosis~Unstable health, as determined by the principal investigator, medical doctor, or registered nurse."
3293579|NCT01774734|Experimental|neck strength exerciser (NSE) group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based NSE training 20 minutes daily
3293580|NCT01774734|Placebo Comparator|Physical therapy group|Traditional physiotherapy 30 minutes per session for three times weekly + home-based general neck exercise 20 minutes daily
3293581|NCT01774747|Experimental|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
3293582|NCT01774747|Placebo Comparator|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
3293583|NCT01774773|Experimental|Group A|E5501 5mg, then 20mg, then 40 mg, then 5mg
3293584|NCT01774773|Experimental|Group B|E5501 20mg, then 40mg, then 5 mg, then 5mg
3293585|NCT01774773|Experimental|Group C|E5501 40mg, then 5mg, then 20 mg, then 5mg
3293586|NCT01774812|Active Comparator|Vitamin D Sequence 1|6 weeks - alfacalcidol 0.25mcg + placebo 3x per week, 12 week washout, 6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days)
3293587|NCT01774812|Active Comparator|Vitamin D Treatment Sequence 2|6 weeks - alfacalcidol 0.25mcg 3x per week + 50,000IU ergocalciferol 1x per week (placebo the 2 remaining days), 12 week washout, 6 weeks - alfacalcidol 0.25mcg + placebo 3x per week
3293588|NCT01774825|Active Comparator|IQP-CL-101|2 softgels twice a day
3293589|NCT01774825|Placebo Comparator|Placebo|2 softgels twice a day
3293590|NCT01774838|Experimental|Prasugrel|3 months treatment with 10 mg prasugrel
3293591|NCT01774838|Active Comparator|Clopidogrel|3 months treatment with clopidogrel 75 mg
3293592|NCT01774864|Experimental|DA-8159 dose 1|Udenafil
3293593|NCT01774864|Experimental|DA-8159 dose 2|Udenafil
3293594|NCT01774864|Placebo Comparator|Placebo|
3293595|NCT01774877|Experimental|Xinfeng capsule & placebo|"Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months~placebo(for leflunomide): 10 mg each time, 1 time a day, Oral,for3 months"
3293596|NCT01774877|Active Comparator|leflunomide & placebo|"leflunomide :10mg each time, one time a day, by mouth,for 3 months~placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for3 months"
3293597|NCT01774916|Other|patients|
3293598|NCT01774916|Other|volunter|
3293599|NCT01774942|Experimental|Procedure/Surgery (Impants/Overdentures)|One-arm clinical intervention study: All teeth out, full dentures, dental implants, blood draw. The interventions are not experimental in nature, they are standard procedures, namely extraction of all natural teeth followed by suturing to hold soft tissue in place during initial healing; surgical insertion of commercially available dental implants; and fabrication and re-lining (filling in with acrylic the base of the denture as needed during healing and shrinking of underlying tissue) of full dentures, that is full plates in upper and lower jaw to replace all teeth.
3293600|NCT01774994|Experimental|stable isotopes|stable isotope infusion for measurement of metabolism
3293601|NCT01775007|Experimental|Normal Healthy Subjects|Brillouin Ocular Analyser
3293602|NCT01775020|Experimental|L-arginine|L-arginine
3293603|NCT01775033|Experimental|Multicomponent intervention|Hospitals in the experimental arm will receive a four-component intervention that integrates local education, community outreach, telemedicine and protocolized triage and transport
3293604|NCT01775033|No Intervention|Control|Hospitals in the control arm will receive usual care.
3293605|NCT01775046||DTA patients|160 patients presenting with a disease of descending thoracic aorta(DTA)with an indication for endovascular treatment with Valiant Thoracic Stent Graft with the Captivia Delivery System and who meet the inclusion/exclusion criteria are intended to participate in this non-interventional.
3293606|NCT01775059|Experimental|Integrated sensor and infusion set.|
3293608|NCT01775085|Experimental|Meaning-Centered Group for Breast Cancer Survivors (MCG-BCS)|
3293609|NCT01775085|Active Comparator|Discussion Group (DG)|
3293610|NCT01775098|Experimental|Allopurinol|treatment with allopurinol
3293611|NCT01775098|Placebo Comparator|placebo|placebo comparator
3293612|NCT01775111|Sham Comparator|Cognitive Training|Cognitive Training (riddles, skill games, ...) is performed twice a week in small groups
3293613|NCT01775111|Experimental|Strength Training|Progressive strength training is applied, meaning that the intensity is adjusted continuously in order to obtain a sufficient training stimulus. Exercises are chosen to involve the major muscle groups and are performed by using the own body weight or elastic bands.
3293614|NCT01775111|Experimental|Strength Training and Supplement|In addition to strength training as described above, participants receive a water-soluble dietary supplement 9x/week (FortiFit, Nutricia) consisting of 20.7 g of protein (56 En%, 19.7 g whey protein, 3 g leucine,> 10 g essential amino acids), 9.3 g carbohydrates (25 En%, 0.8 BE), 3.0 g fat (18 En%), 1.2 g fiber (2 En%), 800 IU (20μg) of vitamin D, 250mg calcium, vitamins B6 and B12, folic acid and magnesium.
3293615|NCT01775150|Experimental|health education|health education via text messaging
3293616|NCT01775150|No Intervention|no health education|no health education via text messaging
3293617|NCT01775163||Self Directed Exercise|Participants randomized to the self-directed group will receive information on physical activity recommendations and guidelines on nutrition aimed at promoting weight loss. Participants will not be given a specific exercise recommendation in terms of weekly energy expenditure.
3293618|NCT01775163||Low Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 8 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
3293619|NCT01775163||High Intensity Exercise|Individuals assigned to the low dose exercise group will be required to expend 20 calories per kg of body weight per week in structured aerobic exercise on a treadmill or stationary bicycle. The exercise intensity will be maintained at 65% of VO2peak. The caloric goal of each session will be calculated by dividing the weekly caloric expenditure goal by participant selected exercise frequency (i.e., 3, 4 or 5 times per week). The training program consists of a 3-min warm-up at a progressively increasing intensity until the prescribed training intensity is reached. All exercise sessions are conducted at the PBRC Fitness Center and will be supervised by staff trained on the aspects of the study protocol.
3293620|NCT01775176||Polycystic Ovary Syndrome|Overweight women with polycystic ovary syndrome. 20 - 40 years, inclusiveBody mass index ≥ 25kg/m2History of irregular menstrual cycles (fewer than 8 regular cycles in the past year)Clinical and/or biochemical androgen excess (Free androgen index>3.85 and/or hirsuitism rating ≥8)Anovulatory menstrual cycles (determined during screening)
3293621|NCT01775215||A - Symptomatic severe AS|Patients with symptomatic severe aortic stenosis (AS) as per ESC guidelines, requiring aortic valve replacement.
3293622|NCT01775215||B - Asymptomatic moderate to severe AS|Asymptomatic patients with moderate to severe aortic stenosis (AS) as per ESC guidelines ,with Left Ventricular ejection fraction >50%, not yet requiring aortic valve replacement.
3293623|NCT01775228|No Intervention|Regular follow up care|No intervention group - received routine follow up care following discharge from hospital after cardiac surgery (no peer support intervention).
3293624|NCT01775228|Active Comparator|Peer Support intervention|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
3293625|NCT01775254||Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancers followed by adjuvant chemotherapy.
3293626|NCT01775254||No Chemotherapy Group|Colon cancer survivors who undergo open or laparoscopic resection of their colon cancer and who do not receive chemotherapy.
3293627|NCT01775267|Experimental|ALPPS|Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
3293628|NCT01775267|Active Comparator|PVO|Patient undergo portal vein embolization or ligation
3293629|NCT01775280|Experimental|Radioembolization|Radioembolization using Yttrium-90 microspheres using a transarterial approach
3293630|NCT01775293|Experimental|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
3293631|NCT01775319|Active Comparator|Biofortified wheat|Biofortified wheat
3293632|NCT01775319|Placebo Comparator|Control wheat|Control wheat with low level of Zn
3293633|NCT01775319|Active Comparator|Fortified wheat|Wheat fortified before consumption
3293634|NCT01775332|Experimental|Educational Intervention|Educational Intervention - Access to educational materials provided (i.e. website, videos, brochure)
3293635|NCT01775332|No Intervention|No Intervention/Use of Own Resources|No educational materials are provided to participants, but they can use their own resources
3293636|NCT01775345|Experimental|Isotonic exercises + ST|"This group will realize 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a maximum repetition (MR)(MR is the maximum resistance that a muscle can conquer).~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
3293637|NCT01775345|Experimental|Isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
3293638|NCT01775345|Experimental|Isotonic and isokinetic exercises + ST|This group will realize 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
3293639|NCT01775358|Experimental|ALRN-5281 0.015 mg/kg|Dosage-0.015 mg/kg
3293640|NCT01775358|Experimental|ALRN-5281 0.05 mg/kg|Dosage- 0.05 mg/kg
3293641|NCT01775358|Experimental|ALRN-5281 0.15 mg/kg|Dosage- 0.15 mg/kg
3293642|NCT01775358|Placebo Comparator|Placebo 0.015 mg/kg|Dosage- 0.015 mg/kg
3293643|NCT01775358|Placebo Comparator|Placebo 0.05 mg/kg|Dosage- 0.05 mg/kg
3293644|NCT01775358|Placebo Comparator|Placebo 0.15 mg/kg|Dosage - 0.15 mg/kg
3293645|NCT01775384|Experimental|Nutrasorb|Soy protein powder sorbed with polyphenols from blueberries and green tea extract
3293646|NCT01775384|Placebo Comparator|Placebo|Soy protein isolate powder without polyphenols (with food coloring)
3293647|NCT01775397|Experimental|Fidaxomicin|Fidaxomicin with alternating matching placebo
3293648|NCT01775397|Active Comparator|Vancomycin|Participants received 4 doses (1 dose every 6 hours) of oral vancomycin hydrochloride each day for the duration of the 10-day treatment period
3293649|NCT01775423|Experimental|BBI608|
3293650|NCT01775436|Active Comparator|Healthy Living Control|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Developmental History: Goal: To take a non-medical developmental history. The Research Assistant (RA)-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
3293651|NCT01775436|Experimental|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
3293652|NCT01775449|Experimental|polyamines depleted diet|• in the group with a polyamines depleted diet : 2-4 cans per day of Polydol® (oral alimentation without polyamines), associated to predefined menus low in polyamines, according to the chemotherapy cycle and for 107 days
3293653|NCT01775449|Other|normal polyamines containing diet|• in the control group with a normal polyamines containing diet: 1 can per day of Polydol® associated with predefined menus with normal average in polyamines and for 107 days.
3293654|NCT01775462|Experimental|EDI200, 3mg/kg|Five doses of EDI200 given at 3 mg/kg twice weekly
3293655|NCT01775462|Experimental|EDI200, 10 mg/kg|Five doses of EDI200 given at 10 mg/kg twice weekly
3293656|NCT01775475|Active Comparator|Arm I (CHOP)|Patients receive CHOP chemotherapy comprising cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3293657|NCT01775475|Experimental|Arm II (oral chemotherapy)|Patients receive lomustine PO QD on day 1 (courses 1 and 3 only), etoposide PO QD on days 1-3, cyclophosphamide PO QD on days 22-26, and procarbazine hydrochloride PO QD on days 22-26. Treatment repeats every 6 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3293658|NCT01775488|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx, is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
3293659|NCT01775514||Participants With Cancer|Participants from Turkey with non-small cell lung, colon cancer, breast cancer, gastric cancer and malignant melanoma will be included.
3293660|NCT01775527|Other|blood test|
3293661|NCT01775540|Experimental|Systane Ultra|Artificial tear Eyedrop, 1 drop used four times a day (QID) for 4 weeks
3293662|NCT01775540|Placebo Comparator|Saline solution|Saline solution Eyedrop, 1 drop used QID for 4 weeks
3293663|NCT01775540|Active Comparator|Maxidex|Steroid eyedrop, 1 drop QID for 4 weeks
3293664|NCT01775566||Eperisone SR tablet 75mg, Myonal 50mg|Eperisone SR tablet 75mg Myonal 50mg
3293665|NCT01775579|Experimental|Crestor tablet 20 mg|Crestor tablet 20 mg single--->wash out---->Glucophage SR tablet 750 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
3293666|NCT01775579|Experimental|Glucophage SR tablet 750 mg and Crestor tablet 20 mg both|Glucophage SR tablet 750 mg, Crestor tablet 20 mg both--->wash out---->Glucophage SR tablet 750 mg single------>washout--->Crestor tablet 20 mg single
3293667|NCT01775579|Experimental|Glucophage SR tablet 750 mg|Glucophage SR tablet 750 mg single --->wash out---->Crestor tablet 20 mg single---->washout--->Glucophage SR tablet 750 mg, Crestor tablet 20 mg both
3293668|NCT01775592|Other|Arterakin|"Number of DHA- PPQ (Arterakin™) tablets per day at 0hour, 8hours, 24hours, 48hours (according to age): 2 - 3 years:0.5, 0.5, 0.5, 0.5 3 - < 8 years: 1.0, 1.0, 1.0, 1.0 8 - < 15 years:1.5, 1.5, 1.5, 1.5~≥ 15 years:2.0, 2.0, 2.0, 2.0"
3293669|NCT01775605|Active Comparator|Synera|Synera Pain Patch
3293670|NCT01775605|No Intervention|No patch control|No intervention group
3293671|NCT01775605|Sham Comparator|Control|Sham
3293672|NCT01775618|Experimental|Main study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25-60 international units/kilogram (IU/kg) twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an intravenous (IV) infusion as per clinical needs of each subject up to at least 50 exposure days (EDs) and a minimum of at least 6 months.
3293673|NCT01775618|Experimental|Part 2 (Expansion group)|Participants were administered with BAY94-9027 at a dose of 25-60 IU/kg twice per week for prophylaxis for 12 weeks.
3293674|NCT01775618|Experimental|Extension study|Participants were treated and prophylaxis administered with BAY94-9027 at a dose of 25- 60 IU/kg twice per week or 45-60 IU/kg every 5 days or 60 IU/kg every 7 days as an IV infusion as per clinical needs of each subject for at least 50 EDs or until marketing authorization of the drug.
3293675|NCT01775631|Experimental|Arm -1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
3293676|NCT01775631|Experimental|Arm 1 - Urelumab + Rituximab|"Urelumab (BMS-663513) flat dose intravenous infusion on specified days~Rituximab intravenous flat dose infusion on specified days"
3293677|NCT01775657|Experimental|Air leak present - Analogue|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, air leak present.
3293678|NCT01775657|Active Comparator|Air leak absent - Analogue (Pleur Evac)|Patients randomized to Pleur Evac (Analogue drainage) monitoring system, no air leak present
3293679|NCT01775657|Experimental|Air leak present - Digital (Thopaz)|Patients with an air leak present, randomized to Thopaz (digital drainage) monitoring system.
3293680|NCT01775657|Active Comparator|Air leak absent - Digital (Thopaz)|Patients randomized to digital system, no air leak present.
3293681|NCT01775683||Group A - chronically homeless|Men and women, greater than or equal to age 18 years, English-speaking, who are currently homeless and/or housed in an emergency shelter or housing facility for chronically homeless individuals ≥ 6 months.
3293682|NCT01775683||Group B - control/formerly homeless|Men and women, greater than or equal to 18 years, English-speaking who are not homeless ≥4 times in the last 3 years and currently living in stable housing ≥ 6 months and in the last 3 years, has been homeless ≤ 1 month
3293683|NCT01775696||sporadic AD|80 sporadic AD patients (40 at the stage of MCI, 40 at the stage of mild or moderate dementia)
3293684|NCT01775696||familial forms of AD|15 familial forms of AD caused by APP, PSEN1 or PSEN2 mutations
3293685|NCT01775696||asymptomatic relatives|30 asymptomatic relatives to familial AD patients
3293686|NCT01775696||controls|40 controls
3293687|NCT01775696||genetic FTD|5 genetic forms of FTD
3293688|NCT01775709|Experimental|PE tube with Duckbill Valve|PE tube with Duckbill Valve
3293689|NCT01775748|Other|Active First|Active Concord Grape Juice 12 oz per day Placebo Grape Juice 12 oz per day
3293690|NCT01775748|Other|Placebo First|Placebo Grape Juice 12 oz per day Active Concord Grape Juice 12 oz per day
3293691|NCT01775761|Experimental|Period 1: 960 mg tafamidis (Vyndaqel)|
3293692|NCT01775761|Experimental|Period 2: 400 mg moxifloxacin|400 mg moxifloxacin
3293693|NCT01775761|Experimental|Period 3: Placebo|
3293694|NCT01775813|Experimental|Metformin|Dosage form: Metformin 1000 mg tablets Dosage: 1000 mg by mouth twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
3293695|NCT01775813|Placebo Comparator|Sugar pill|Dosage form: Stamped placebo pill to look like the 1000 mg metformin pill Dosage: 1 pill taken orally twice daily Duration: From early puberty (Tanner 3-4) until puberty completion (Tanner 5), approximately 3 years
3293696|NCT01775826|Other|All Purposes|All participants.
3293697|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(oral)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
3293698|NCT01775839|Experimental|Aspirin+Clopidogrel/Digoxin(IV)|Aspirin: Day 1 ~ Day 59(~65; till the EGC) Clopidogrel: Day -3, 26, 54 Digoxin: Day -2, 27, 55
3293699|NCT01775878|No Intervention|Usual Care|This arm received usual care from the diabetes care managers
3293700|NCT01775878|Experimental|Telemonitoring Device|Patients in this arm received a telemonitoring device installed in their homes
3293701|NCT01775891|Active Comparator|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
3293702|NCT01775891|Placebo Comparator|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
3293703|NCT01775969|No Intervention|Standard of Care|Written discharge instructions only
3293704|NCT01775969|Experimental|Text Message|Written discharge instructions plus a text message with antibiotic prescription instructions
3293705|NCT01775969|Experimental|Voicemail|Written discharge instructions plus a voicemail with antibiotic prescription instructions
3293706|NCT01775982||Study population|"See inclusion and exclusion criteria.~Intervention: Psychiatric evaluation Intervention: Geriatric evaluation~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
3293707|NCT01776021|Active Comparator|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
3293708|NCT01776021|Placebo Comparator|Placebo|placebo beverage at a dose of one 8 oz. beverage per day for six months
3293709|NCT01776034|Experimental|SystemCHANGE Group Lifestyle counseling|"The SystemCHANGE™ intervention will be delivered over a six-month period involving 12 face-to-face group sessions (1.5 hours each) held weekly for three months, followed by three monthly booster calls. Intervention groups include up to 10 patients, and family is encouraged to attend. Intervention sessions consist of 30-min of behavior change activities and 60-min focused on healthy behaviors."
3293710|NCT01776034|Active Comparator|Phone Lifestyle Counseling|Participants will receive pamphlets that contain information on healthy eating, physical activity, sleep, and symptom management, and will be followed-up with telephone calls.
3293711|NCT01776047|Active Comparator|Exforge® 10/160 (Amlodipine besylate 10mg / Valsartan 160mg)|Exforge® 10/160
3293712|NCT01776047|Experimental|G-0081 (Amlodipine orotate 10mg / Valsratan 160mg)|G-0081
3293713|NCT01776073|Experimental|Patient navigation|In addition to receiving the standard of care, these patients will be connected with a patient navigator who will provide personalized assistance with regard to completion of the pre-waitlisting process
3293714|NCT01776073|No Intervention|Standard of Care|These patients will receive the standard of care, which includes assistance from the current Emory Transplant Center team of social workers, physicians, and other support staff with regard to completion of the pre-waitlisting process
3293715|NCT01776086|Other|Normal patients|for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task
3293716|NCT01776099|Active Comparator|pure galactose|5 grams of galactose, three times a day with the main meals, duration: 4 weeks
3293717|NCT01776099|Placebo Comparator|pure palatinose|5 grams of palatinose, three times a day with the main meals, duration: 4 weeks
3293718|NCT01776099|Placebo Comparator|soluble non-fermentable fibers|5 grams of soluble non-fermentable fibers, three times a day with the main meals, duration: 4 weeks
3293719|NCT01776099|Active Comparator|non-soluble non-fermentable fibers|5 grams of non-soluble non-fermentable fibers, three times a day with each main meal, duration: 4 weeks
3293720|NCT01776112|Experimental|SZ-Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3293721|NCT01776112|Placebo Comparator|SZ-TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3293722|NCT01776112|Experimental|HC-Exercise|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
3293723|NCT01776125||Dystrophic Scolisis and NF1|Patients with NF1 diagnosed with dystrophic scoliosis that have been clinically treated will be asked for a cheek swab for genetic testing
3293724|NCT01776125||Non-dystrophic scoliosis and NF1|NF1 patients with non-dystrophic scoliosis that have been treated clinically. will be asked for a cheek swab for genetic testing
3293725|NCT01776138||Bladder Cancer Patients|Patients diagnoses with bladder cancer who are eligible to undergo treatment.
3293726|NCT01776164||Patient with FRDA|Patients affected by Friedreich's ataxia
3293727|NCT01776164||Healthy controls|Healthy volunteers age- and gender-matched with no neurological disease identified.
3293728|NCT01776177||Continue Therapy Group|Patients who continued to recieve Omalizumab therapy beyond 6 month period
3293729|NCT01776177||Discontinued Therapy group|Patients who discontinued Omalizumab therapy prior to 6 month period from the start of therapy
3293730|NCT01776190|Experimental|UVA1 treatment|Low-dose UVA1 will be applied to active cutaneous lupus lesions three times a week for 10 weeks.
3293731|NCT01776203|Active Comparator|medroxyprogesterone acetate|
3293732|NCT01776203|No Intervention|control|
3293733|NCT01776216|Experimental|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy into their everyday diet.
3293734|NCT01776216|Placebo Comparator|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products into their everyday diet.
3293735|NCT01776229|Experimental|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child utilizes behavioral and cognitive therapy techniques of exposure therapy and cognitive restructuring.
3293736|NCT01776229|No Intervention|Waitlist Control|All potential participants will be evaluated and some will be randomly placed in the control group, following the five-week treatment phase, participants in the control group will be re-evaluated and offered the treatment
3293737|NCT01776255|Experimental|Healthy Children, Strong Families (first)|Healthy Children, Strong Families intervention (first). This is a series of monthly educational tool kits mailed to primary caregivers for use with the participating child. This arm crosses over to receive the Child Safety in Year 2.
3293738|NCT01776255|Active Comparator|Child Safety (first)|A series of 12 monthly newsletters and providing education on child safety mailed to primary caregivers. This Arm crosses over to receive the Healthy Children, Strong Families intervention in Year 2.
3293739|NCT01776281|Experimental|Kangaroo Mother Care|Other than routine clinical care per hospital policy. Infants will receive skin-to-skin contact for minimum one hour daily during hospital stay and at home till one month.
3293740|NCT01776281|Active Comparator|Standard Care|Routine incubator or cot care with breastfeeding support from nurses as per policy.
3293741|NCT01776294||prehypertensives|students will be classified as prehypertensives as per the JNC-7 (Joint National Commission) guidelines based on their Blood Pressure measurement
3293742|NCT01776294||normotensives|students will be classed as normotensives based on their BP measurement as per JNC-7 guidelines (systolic <120 AND diastolic <80)
3293743|NCT01776320|Experimental|VITAROS|VITAROS (Alprostadil) 330 ug PRN (as needed) transdermal topical 4-8 weeks
3293744|NCT01776333|No Intervention|usual care|
3293745|NCT01776333|Experimental|video arm|video decision aid intervention
3293746|NCT01776346||Barrett's Esophagus/Esophageal Adenocarcinoma|Patients who have Barrett's esophagus or esophageal adenocarcinoma.
3293747|NCT01776346||Healthy control|
3293748|NCT01776359|Active Comparator|High Protein|High Protein
3293749|NCT01776359|Placebo Comparator|Low Protein|Low Protein
3293750|NCT01776372|Active Comparator|Digital thoracic drainage system|Medela Thopaz Thoracic Drainage System
3293751|NCT01776372|Active Comparator|Non-digital thoracic drainage system|Atrium Express Dry Seal Chest Drain
3293752|NCT01776385|Experimental|Group patients|Patients with Malignant Pleural Mesothelioma (all stages)
3293753|NCT01776385|Placebo Comparator|Control group|Patients with pneumothorax or of benign tumor of the thyroid
3293754|NCT01776398||1.1 HEALTHY SUBJECTS|Healthy as defined by those not having lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population.
3293755|NCT01776398||1.2 SUBJECTS WITH LUNG DISEASE|Defined by those having lung disease or symptoms of lung disease and inclusive of: all races, ethnicities, sex, HIV status, smoking status and multiple birth status, etc., within the general population)
3293756|NCT01776398||2. WCMC/NYPH CLINICAL PATIENTS|"Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit.~WCMC/NYPH clinical patients will not undergo any additional procedures listed in this protocol as part of this research study."
3293757|NCT01776398||3. PCNY CLINICAL PATIENTS|Subjects may be recruited if subjects fit inclusion/exclusion criteria and are deemed eligible to participate as long as informed consent is given. Sample collection will occur during a separate study visit. Clinical patients seen at the Pulmonary Consultants of New York will only undergo the nasal sample collection and may be asked to have a blood draw of about 2 teaspoons (9ml).
3293758|NCT01776411|Experimental|Single Arm|Drug: forodesine hydrochloride 600 mg / body/day (3 x 100 mg capsules twice daily)
3293759|NCT01776437|Experimental|Treatment A|Period 1: fasted control → Period 2: fed control
3293760|NCT01776437|Experimental|Treatment B|Period 1: fed control → Period 2: fasted control
3293761|NCT01776463|Experimental|Z-360|1)Single dose study (60, 120, 240, 480, 720mg), 2)Food effect study(120mg), 3)Multiple doses study(120, 240mg (BID))
3293762|NCT01776463|Placebo Comparator|Placebo|1)Single dose study, 2)Multiple doses study
3293763|NCT01776489||food allergic|positive reaction during DBPCFC
3293764|NCT01776489||Non-food allergic|no reaction during DBPCFC
3293765|NCT01776502||Patients with Hyperparathyroidism|The cohort of patients is made of patients with primary mild hyperparathyroidism and who have received a surgery at Nantes, Angers, Limoges or Marseille University Hospitals
3293766|NCT01776515|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|
3293767|NCT01776515|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|
3293768|NCT01776528|Experimental|Cohort 1 SAD|NGM282 Dose 1 vs Placebo
3293769|NCT01776528|Experimental|Cohort 2 SAD|NGM282 Dose 2 vs Placebo
3293770|NCT01776528|Experimental|Cohort 3 SAD|NGM282 Dose 3 vs Placebo
3293771|NCT01776528|Experimental|Cohort 4 SAD|NGM282 Dose 4 vs Placebo
3293772|NCT01776528|Experimental|Cohort 5 SAD|NGM282 Dose 5 vs Placebo
3293773|NCT01776528|Experimental|Cohort 6 SAD|NGM282 Dose 6 vs Placebo
3293774|NCT01776528|Experimental|Cohort 7 MAD|NGM282 Dose 1 vs Placebo
3293775|NCT01776528|Experimental|Cohort 8 MAD|NGM282 Dose 2 vs Placebo
3293776|NCT01776528|Experimental|Cohort 9 MAD|NGM282 Dose 3 vs Placebo
3293777|NCT01776528|Experimental|Cohort 10 MAD|NGM282 Dose 4 vs Placebo
3293778|NCT01776528|Experimental|Cohort 11 MAD|NGM282 Dose 5 vs Placebo
3293779|NCT01776528|Experimental|Cohort 12 MAD|NGM282 Dose 6 vs Placebo
3293780|NCT01776567|Active Comparator|Cobalt Chromium Everolimus-eluting stent (Xience Prime)|Cobalt Chromium Everolimus-eluting stent (Xience Prime)
3293781|NCT01776567|Active Comparator|Platinum Chromium Everolimus-eluting stent (Promus Element)|Platinum Chromium Everolimus-eluting stent (Promus Element)
3293782|NCT01776580||Lower urinary tract symptoms|Women with lower urinary tract symptoms
3293783|NCT01776593||Lower urinary tract symptoms|
3293784|NCT01776606|Active Comparator|Dose A|Dose A: Botulinum toxin type A
3293785|NCT01776606|Placebo Comparator|Dose B|Dose B: Placebo
3293786|NCT01776619|Experimental|Multiple Dose: Cohort 1|
3293787|NCT01776619|Experimental|Multiple Dose: Cohort 2|
3293788|NCT01776619|Experimental|Multiple Dose: Cohort 3|
3293789|NCT01776619|Experimental|Multiple Dose: Cohort 4|
3293790|NCT01776619|Experimental|Relative Bioavilability: Cohort 1|
3293791|NCT01776658|Experimental|SYL1001 eye drops dose A|Ocular topical administration of SYL1001 eye drops dose A
3293792|NCT01776658|Placebo Comparator|Placebo|Ocular topical administration of placebo eye drops
3293793|NCT01776671|Other|Gralise|Efficacy of Gralise
3293794|NCT01776684|Experimental|EGFR positive arm|Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)
3293795|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fasting|
3293796|NCT01776697|Active Comparator|pelubiprofen (30mg) tablet IR TID, fed|
3293797|NCT01776697|Experimental|pelubiprofen SR (as a pelubiprofen 90 mg) tablet QD|
3293798|NCT01776710|Experimental|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
3293799|NCT01776710|No Intervention|Standard care control|Standard care will consist of general advice to increase walking and an information sheet on peripheral arterial disease, plus a consultation with a Consultant Vascular Surgeon.
3293800|NCT01776736|Experimental|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
3293801|NCT01776749|No Intervention|no SubQ|No subcutaneous leads due to adequate low back stimulation by only SCS. Patient not randomised
3293802|NCT01776749|Active Comparator|SubQ ON|Subcutaneous stimulation on
3293803|NCT01776749|Sham Comparator|SubQ OFF|subcutaneous leads implanted, but no stimulation
3293804|NCT01776762|Experimental|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
3293805|NCT01776762|No Intervention|Standard Follow-home programme|Standard Follow-home programme without individual nutritional therapy
3293806|NCT01776775|Active Comparator|abdominal binder|use of postoperative abdominal binder 30 days after the hernia repair
3293807|NCT01776775|No Intervention|No abdominal binder|No intervention
3293808|NCT01776788|Experimental|insulin lispro injection, exenatide injection|
3293809|NCT01776788|Active Comparator|insulin lispro injection|
3293810|NCT01776801|Experimental|Hydrocephalus|Patients suffering of hydrocephalus (cognitive impairment, gait disturbance, urinary incontinence and enlargement of the ventricles) require for clinical purpose infusion studies i.e. injection of mock cerebrospinal fluid (CSF) in the sub arachnoid space to artificially increase ICP. We aim at using infusion studies as a indirect tool to assess whether a moderate increase in ICP has any influence on haemodynamics.
3293813|NCT01776853|Placebo Comparator|Glucose|40g glucose in 500ml water flavoured with lime juice
3293814|NCT01776853|Experimental|Fructose|40g fructose in 500ml water flavoured with lime juice
3293815|NCT01776853|Experimental|Fructans|40g fructans in 500ml water flavoured with lime juice
3293816|NCT01776866|Other|Coronary Angiography|"Patient first undergo standard coronary angiography(SA) of either left or right coronary system followed by dual-axis rotational coronary angiography(DARCA). The SA protocol consist of six different projections (right anterior oblique (RAO)-caudal, RAO-cranial (CRA), left anterior oblique (LAO)-CRA, LAO-caudal (CAU), antero-posterior (AP)-CRA and AP-CAU) for left coronary artery (LCA) and two projections (LAO and AP-cranial) for right coronary artery (RCA).~The DARCA protocol consist of two coronary acquisitions specified by the protocol: one for LCA (Swing LCA CRA 35 5.8s), another for RCA (Swing RCA AP 4.0s)."
3293817|NCT01776879||early & advanced PD 1st degree relatives|no intervention is performed in the study
3293818|NCT01776879||recording speech and voice|no intervention(s) will be administered
3293819|NCT01776879||speech intelligibility|no intervention(s) will be administered
3293820|NCT01776892|Experimental|Collagenase and needle aponeurotomy|"Participants in this arm of the study will be treated once with needle aponeurotomy and up to 3 times at 4 week intervals with collagenase injection.~Affected Dupuytren's cords will be treated with 1-3 collagenase clostridium histolyticum injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained."
3293821|NCT01776892|Active Comparator|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained. Participant feedback is obtained throughout the procedure to prevent digital nerve or flexor tendon injury. Participants are asked to report Tinel's sign which indicates that the needle is in close proximity to the digital nerve and to report pain with needle advancement which indicates proximity to the flexor tendon.
3293822|NCT01776892|Active Comparator|Collagenase injection|Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
3293823|NCT01776905||Healthy control subjects|Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.
3293824|NCT01776905||Advanced-Stage Melanoma|To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.
3293825|NCT01776905||Early-Stage Melanoma|To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.
3293826|NCT01776918||Metabolic Disease- Phenylketonuria|
3293827|NCT01776918||Mitochondrial disorder|
3293828|NCT01776931|Experimental|Lysine intake|Dietary supplement:lysine intake
3293829|NCT01776944||Obese children|
3293830|NCT01776957||IUD|Repeat abortion rate in women receiving IUDs immediately post-abortion
3293831|NCT01776970|Experimental|Sativex|Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml)
3293832|NCT01776970|Placebo Comparator|Placebo|Placebo oromucosal spray
3293833|NCT01777009|Experimental|Patellar Eversion|Patients randomized to the Patellar Eversion arm of the study were surgically exposed by everting the patella during their Primary Total Knee Replacement Surgery.
3293834|NCT01777009|Active Comparator|Patellar Lateral Retraction|Patients randomized to the Patellar Lateral Retraction arm of the study were surgically exposed by laterally retracting the patella during their Primary Total Knee Replacement Surgery.
3293835|NCT01777022|No Intervention|Current treatment|Current education and management protocols will be followed
3293836|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
3293837|NCT01777035|Experimental|Early physical therapy(PT) occupational therapy (OT)|Early PT OT assessments begin on first day of study. Therapy delivered by a team consisting of physical and occupational therapists and coordinated with daily sedative interruption
3293838|NCT01777035|No Intervention|standard care|PT OT delivered as ordered by the primary ICU team
3293839|NCT01777048|Experimental|Omega-3 Fatty Acids|1g of Omega-3 per day [400mg DHA & 600mg EPA] for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
3293840|NCT01777048|Placebo Comparator|Omega-3 Placebo|1g of Omega-3 Placebo per day for 12 weeks: 2 capsules after breakfast and 2 capsules after dinner
3293841|NCT01777074||Generalist physicians Cohort|
3293842|NCT01777074||Paediatricians Cohort|
3293843|NCT01777087|Experimental|Healthy normal volunteers|Healthy normal volunteers
3293844|NCT01777100|Experimental|sufentanil|Anesthetic induction with IV sufentanil at 0.5 mcg.kg-1 and analgesic maintenance with IV remifentanil at 0.1 to 0.3 mcg.kg-1.min-1 on demand target-controlled infusion
3293845|NCT01777100|No Intervention|remifentanil|Anesthetic induction with target-controlled infusion IV remifentanil at 0.5 mcg.kg-1.min-1 in 5 minutes followed by analgesic maintenance on demand of IV target-controlled infusion remifentanil at 0.1 to 0.3 mcg.kg-1.min-1.
3293846|NCT01777113|Experimental|High Intensity Aerobic training|The subjects will perform a high intensity treadmill training
3293847|NCT01777113|Experimental|High Intensity Strength Training|The subjects will perform and high intensity training on the same leg horizontal press.
3293848|NCT01777113|Active Comparator|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises.
3293849|NCT01777165|Experimental|Arm 1 ABT-719 lower dose|
3293850|NCT01777165|Experimental|Arm 2 ABT-719 intermediate dose|
3293851|NCT01777165|Experimental|Arm 3 ABT-719 higher dose|
3293852|NCT01777165|Placebo Comparator|Arm 4 placebo|
3293853|NCT01777178|Experimental|Low bicarbonate dialysis|
3293854|NCT01777204||Tacrolimus|Influence of tacrolimus on gastrointestinal transit and motility in renal transplant recipients.
3293855|NCT01777204||Cyclosporine|Influence of cyclosporine on gastrointestinal transit and motility in renal transplant recipients.
3293856|NCT01777204||Mycophenolate mofetil|Influence of mycophenolate mofetil on gastrointestinal transit and motility in renal transplant recipients.
3293857|NCT01777204||Mycophenolate sodium|Influence of mycophenolate sodium on gastrointestinal transit and motility in renal transplant recipients.
3293858|NCT01777204||Everolimus|Influence of everolimus on gastrointestinal transit and motility in renal transplant recipients.
3293859|NCT01777204||Sirolimus|influence of sirolimus on gastrointestinal transit and motility in renal transplant recipients.
3293860|NCT01777204||Without immunosuppression|Gastrointestinal transit and motility in healthy volunteers.
3293861|NCT01777230||All patients|Alle subjects included retain in one cohort.
3293862|NCT01777243|Experimental|Part A Arm|Two subjects in Part A will receive starting dose level of GSK2398852 as 5 milligram (mg) [approximately equivalent to 0.1 mg/kilogram (kg)]. The next escalation dose levels in two subjects each are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg. GSK2315698 will be administered at variable dosed until the concentration of the SAP mAb has fallen below 100 ng/mL.
3293863|NCT01777243|Experimental|Part B Arm|The precise selection of numbers of subjects and dose levels in Part B will be informed by the results from Part A.
3293864|NCT01777256|Experimental|GSK2586184 50 mg Arm|Subjects in the GSK2586184 50 mg Arm will receive twice daily dose of GSK2586184 50 mg 1 x 50 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal
3293865|NCT01777256|Experimental|GSK2586184 100 mg Arm|Subjects in the GSK2586184 100 mg Arm will receive twice daily dose of GSK2586184 100 mg (2 x 50 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3293866|NCT01777256|Experimental|GSK2586184 200 mg Arm|Subjects in the GSK2586184 200 mg Arm will receive twice daily dose of GSK2586184 200 mg (1 x 200 mg tablet + 1x placebo tablet) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3293867|NCT01777256|Experimental|GSK2586184 400 mg Arm|Subjects in the GSK2586184 400 mg Arm will receive twice daily dose of GSK2586184 400 mg (2 x 200 mg tablets) orally up to 12 weeks. Study medication should be taken with food, immediately following a meal.
3293868|NCT01777256|Placebo Comparator|Placebo|Subjects in the placebo arm will receive twice daily dose of 2 matching placebo tablets orally up to 12 weeks; taken with food, immediately following a meal.
3293869|NCT01777295|Experimental|HBsAg/AS Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 2 doses of HBsAg/AS, at Day 0 and Day 30.
3293870|NCT01777295|Active Comparator|Engerix-B Group|Subjects in this group received 1 dose of Placebo at Day -30 followed by 3 doses of Engerix-B at Day 0, Day 30 and Day 180.
3293871|NCT01777347|Experimental|3% Saline|Nebulized 3% Saline
3293872|NCT01777347|Placebo Comparator|0.9% Normal Saline|Nebulized 0.9% normal saline
3293873|NCT01777360|Experimental|THERMOPLASTY|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
3293874|NCT01777373||Idiopathic pulmonary fibrosis (IPF)|Idiopathic pulmonary fibrosis (IPF)
3293875|NCT01777373||Control|Control
3293876|NCT01777373||Non-IPF interstitial lung disease (ILD)|Non-IPF interstitial lung disease (ILD)
3293877|NCT01777373||Uncharacterized ILD|Uncharacterized ILD
3293878|NCT01777386|Active Comparator|preexpanded flap|Fourteen patients were treated with fifteen '' preexpanded perforator flap surgery '' interventions. The last six cases were evaluated in terms of perforator artery diameter before and after expansion process. The preexpanded flap donor sites' perforator artery diameters were also compared with their anatomic equivalents located in the symmetric side of the body.
3293879|NCT01777386|No Intervention|control side|In six of the 14 patients, perforator artery diameter of the nonexpanded symmetric anatomical side of the body (equivalent to the expanded site)were measured.
3293880|NCT01777451||Neurofibromatosis 1|"All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )~GROUP 2:~No suspicious lesions at MRI. Follow-up within 2 years(Study MRI)."
3293881|NCT01777464|Experimental|patients|patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
3293882|NCT01777464|Sham Comparator|healthy controls|healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit
3293883|NCT01777477|Experimental|Chloroquin in addition to Gemcitabine|Gemcitabine 1000 mg/m2 i.v. at days 1, 8, 15 of every 28-day cycle. Chloroquine 100 mg, 200 mg or 300 mg (according to dose level) p.o. at days 2, 9, 16 of every 28-day cycle.
3293884|NCT01777503|Experimental|prasugrel|prasugrel 60 mg loading dose, followed by 5 mg once daily until the end of follow-up
3293885|NCT01777503|Active Comparator|clopidogrel|Clopidogrel 300 mg loading dose followed by 75 mg once day until the end of follow-up
3293886|NCT01777516||healthy volunteers|1 group with no treatment : They provide the blank plasma to be used at in vitro study.
3293887|NCT01777529|Experimental|Multidose|Multidose from MMR Vaccine produced by Bio-Manguinhos/Fiocruz
3293888|NCT01777529|Active Comparator|Singledose|Singledose from MMR (GSK-TV), produced by GlaxoSmithKline
3293889|NCT01777555|Experimental|CVT-301|CVT-301 at Dose Level 1 for 1st 14 days of treatment then increased to Dose level 2 for last 14 days of treatment.
3293890|NCT01777555|Placebo Comparator|Inhaled Placebo|Subjects randomized to receive placebo in a 1:1 randomization scheme
3293891|NCT01777594|Experimental|G-202 (Mipsagargin)|G-202 (mipsagargin) administered by intravenous infusion on 3 consecutive days of a 28-day cycle
3293892|NCT01777607|Experimental|Intervention|
3293893|NCT01777633|Experimental|re-irradiation|re-irradiation for progressive DIPG in children
3293894|NCT01777646|Experimental|MSC-NTF|
3293895|NCT01777659|Experimental|TENS CABG|Eligible patients will be randomized to a transcutaneous electrical nerve stimulation program (TENS; n = 20) or to placebo-TENS (P-TENS; n = 18). All patients were followed by their own physicians, received routine nursing assistance, and were visited daily by one of the investigators, but P-TENS group will be not exposed to any specific electrical stimulation or motor physical intervention.
3293896|NCT01777659|Placebo Comparator|P-TENS CABG|Patients will be treated with placebo-TENS (P-TENS) condition for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). P-TENS device underwent modifications in its internal programming: the control capacitor of the time constant was changed and the active time between pulses was modified from 330 milliseconds to 33 seconds, in order to prevent an analgesic effect (33).
3293897|NCT01777672|Active Comparator|Dietary and oral hygiene recommendations|Patients in this group will receive recommendations from their healthcare providers about bolus volume and viscosity adaptation for fluids, dietary and nutritional adjustments (liquids and solids) of bolus volume and viscosity/texture. Before leaving each hospital they will also learn basic rehabilitation strategies for OD including swallow postures, compensatory manoeuvres and oropharyngeal rehabilitation exercises and oral hygiene to follow at home.
3293898|NCT01777672|Experimental|oral TRPV1 agonist|Patients will receive the same recommendations as the control group and also recommendation for the administration of a TRPV1 agonist (natural capsaicin) supplement (5 mL bolus before each meal), 3 meals/day, 5 days/week for 2 consecutive weeks.
3293899|NCT01777672|Experimental|pharyngeal electrical stimulation|Treatment in this group will also include the same measures as in the control group, plus neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during one week, done at the same center.
3293900|NCT01777672|Experimental|transcutaneous electrical stimulation|Treatment in this group will be the same as the control group plus trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
3293901|NCT01777685|Other|sulpiride 50 mg|
3293902|NCT01777711|Active Comparator|Couple condition|Couples randomized to the couple condition will undergo the experimental manipulations and both partners will complete all study measures. Both members of the couple will be given body mass index (BMI) based on measurements taken during the intervention. Both will complete three surveys on paper and do some prompted planning and goal-setting together regarding weight loss through healthier eating and physical activity.
3293903|NCT01777711|Active Comparator|Individual Condition|Couples randomized to the individual condition will be stratified on gender and one partner, chosen at random, will undergo the experimental manipulations and complete all study surveys while the other will not (heretofore called the active partner vs. the passive partner). The active partner will receive BMI feedback based on measurements taken during the intervention appointment, complete three surveys, and verbally state some goals and plans for weight loss to the passive partner. The passive partner will not complete any study materials or participate in the intervention during the session.
3293904|NCT01777724|Experimental|Intervention|The intervention is a combination of Triple P Discussion Groups and Stress Control
3293905|NCT01777724|No Intervention|Control|Waitlist control. Participants allocated to the waitlist control will be able to access the intervention after post-intervention equivalent measures have been completed.
3293906|NCT01777737|Experimental|Cotrimoxazole|Sulfamethoxazole 400 mg. + trimethoprim 80 mg. weight-adjusted
3293907|NCT01777737|Placebo Comparator|Placebo|Identical capsules to cotrimoxazole
3293908|NCT01777750|Active Comparator|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
3293909|NCT01777750|No Intervention|Standard treatment|Standard treatment
3293910|NCT01777802||Prostate Cancer|Patients with prostate cancer will be treated with SBRT, IMRT or brachytherapy
3293911|NCT01777802||Breast Cancer|Patients with breast cancer will be treated with SBRT, IMRT or brachytherapy
3293912|NCT01777802||Lung Cancer|Patients with lung cancer will be treated with SBRT, IMRT or brachytherapy
3293913|NCT01777802||Melanoma Cancer|Patients with melanoma cancer will be treated with SBRT, IMRT or brachytherapy
3293914|NCT01777815|Experimental|Implanting ePTFE sutures|Implanting ePTFE sutures as artificial neochordae using the NeoChord DS1000 Artificial Chordae Delivery System
3293915|NCT01777828||Transcatheter Aortic Valve Implantation|FRANCE TAVI registry aims to identify all patients with a change of valves implanted catheter meets the selection criteria of the technical accepting the scheduled evaluations in the context of this disease and who have agreed to participate in the study .
3293916|NCT01777841|Other|Electronic Care plan delivery|
3293917|NCT01777867||Healthy Volunteers|Subjects in this arm were healthy volunteers. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3293918|NCT01777867||Non-erosive reflux disease with reflux|Subjects enrolled in this arm had non-erosive reflux disease with reflux (heartburn) for at least 6 of the preceding 12 months. Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3293919|NCT01777867||Non-erosive reflux disease without reflux|Subjects enrolled in this arm had non-erosive reflux disease with normal levels of reflux (heartburn). Subjects underwent both Cough Reflex Sensitivity and the Methacholine Challenge procedures.
3293920|NCT01777893|Experimental|HP-HI|High protein/ high intensity physical activity
3293921|NCT01777893|Experimental|HP-MI|High protein/ moderate intensity physical activity
3293922|NCT01777893|Experimental|MP-HI|Moderate protein/ high intensity physical activity
3293923|NCT01777893|Experimental|MP-MI|Moderate protein/ moderate intensity physical activity
3293924|NCT01777906||Fluticasone|Fluticasone nasal spray will be given 2 sprays twice a day for 6 weeks.
3293925|NCT01777906||Dexamethasone sodium phosphate 0.032%|Dexamethasone 0.032% nasal spray will be given at a dose of 2 sprays twice a day for 6 weeks.
3293926|NCT01777919|Experimental|Temozolomide+Disulfiram/copper|"Disulfiram/copper combination will be started on the 5th postoperative day and before the initiation of the standard radiochemotherapy (fractionated irradiation with a total dose of 60 Gy with concomitant 75 mg/m2 body surface temozolomide each day, including weekends, during irradiation). After completion of the radiation therapy patients will receive maintenance temozolomide 150-200 mg/m2 body surface on Days 1-5 every 28 days for 6 months. Daily administration of disulfiram and copper will take place for the whole study period.~NOTE: Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3293927|NCT01777958||Cohort|
3293928|NCT01777971||Patients with cirrhosis|Male and female subjects who have cirrhosis of the liver and diuretic-resistant ascites (based on International Ascites Clib criteria) and have been evaluated and approved to have a large-volume paracentesis as part of standard of care treatment.
3293929|NCT01778036||Neck pain patients following physiotherapy treatment|Neck pain patients will follow physiotherapy treatment in primary health care.
3293930|NCT01778075|Experimental|Treatment sequence AB|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
3293931|NCT01778075|Experimental|Treatment sequence BA|Treatment A: Newly developed Ultracet ER; Treatment B: Marketed Ultracet ER
3293932|NCT01778088|Other|Single Group|I-131-CLR1404 Injection
3293933|NCT01778101|Experimental|lansoprazole|lansoprazole 1mg/kg twice a day for 14days
3293934|NCT01778114|Placebo Comparator|Placebo + orange juice without vitamin D|Placebo + orange juice without vitamin D
3293935|NCT01778114|Experimental|Placebo + 1000 IU vitamin D3 in OJ|Vitamin D3 in orange juice
3293936|NCT01778114|Experimental|Placebo + 1000 IU vitamin D2 in OJ|Vitamin D2 in orange juice
3293937|NCT01778114|Active Comparator|1000 IU vitamin D3 + placebo OJ|1000 IU vitamin D3 + placebo OJ
3293938|NCT01778114|Active Comparator|1000 IU vitamin D2 + placebo OJ|1000 IU vitamin D2 + placebo OJ
3293939|NCT01778140|Experimental|Patient-specific reminder|Intervention: Patient-specific computerized reminder. The physicians assigned to this arm will use the patient-specific CDSS on CPOE. The patient-specific reminder is designed as a real-time CDSS implemented on CPOE to monitor physician's contrast-enhanced image study orders. Computerized pop-up reminders provide the patient-specific CIN risk profile and optimal decision options which are generated when patients with high risk or with unknown risk of CIN are encountered.
3293940|NCT01778140|Active Comparator|Non-patient-specific reminder|Intervention: Non-patient-specific Computerized reminder. The physicians assigned to this arm will use the Non-patient-specific reminders through CPOE. Non-patient-specific reminders always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
3293941|NCT01778140|No Intervention|Control Arm|The physicians assigned to this arm will not use and any computerized reminder.
3293942|NCT01778153|Experimental|Equinox Personal Coaching|Participants assigned the Coached group will receive up to 36 sessions about three times a week, consisting of both strength and aerobic exercises, through a program designed by Equinox Fitness Centers.
3293943|NCT01778153|No Intervention|Self-directed exercise training|Participants in the Self-directed group will receive general exercise training advice as any member of the fitness club would, and will record the details of their exercise in log sheets. They will be asked to continue their usual exercise routine.
3293944|NCT01778166|Active Comparator|Standard early enteral nutrition|There would be 100 patients in this group
3293945|NCT01778166|Experimental|Immuno-enhanced early enteral nutrition|There would 100 patients in this group
3293946|NCT01778192|Active Comparator|Same day PEG|group 1 (same day PEG, N=50) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
3293947|NCT01778192|Active Comparator|split PEG|group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
3293948|NCT01778192|Active Comparator|SPMC 2|group 3 (SPMC 2, N=50) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
3293949|NCT01778192|Active Comparator|SPMC 3|group 4 (SPMC 3, N=50) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
3293950|NCT01778205||Pregnant women|Pregnant women with confirmed viable fetus at first prenatal check-up at <12 gestational weeks
3293951|NCT01778218|Experimental|99mTc-EC-DG|99mTc-EC-DG injection followed by SPECT imaging during a cardiac rest study (Visit 1) and an exercise/regadenoson study (Visit 2)
3293952|NCT01778231|Experimental|Vitamin Supplement|1 capsule of Nutrof Total made by Laboratories Thea for 16 weeks
3293953|NCT01778231|Placebo Comparator|Inert oil capsule|1 capsule daily for 16 weeks
3293954|NCT01778244|Experimental|metformin|metformin
3293955|NCT01778244|Placebo Comparator|placebo|placebo
3293956|NCT01778257|Experimental|Mate extracts group|Mate extract(3150 mg/day)for 12 weeks
3293957|NCT01778257|Placebo Comparator|Placebo group|Placebo (3150 mg/day) for 12 weeks
3293958|NCT01778270|Other|non invasive sensor pleural drainage|feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor in Ohm before and after pleura drainage, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume before and after pleura drainage. Additionally heart sound analysis via electronic stethoscope will be compared to standard methods.
3293959|NCT01778270|Other|non invasive sensor healthy control|"the same measurements as in arm 1: feasibility data will be collected with thorax impedance measurements via body bioimpedance sensor before and after pleura drainage in Ohm, via impedance cardiography stroke volume and cardiac output will be calculated and also respiratory parameters determined via capnograph as carbon dioxide (CO2) in %/ml exhaled volume once in 25 healthy controls.~Additionally heart sound analysis via electronic stethoscope will be compared to standard methods."
3293960|NCT01778283|Experimental|Acetate-free solution first|Acetate-free solution first : hemodialysis 4 hours with Acetate-free solution (Acetate 0 mEq/L Citrate 2 mEq/L) at the first session after enrollment, and then switch to Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the next 4-hr hemodialysis session
3293961|NCT01778283|Active Comparator|Acetate-based solution first|Acetate-based solution first : hemodialysis 4 hours with Acetate-based solution (Acetate 3 mEq/L Citrate 0 mEq/L) at the first session after enrollment, and then switch to Acetate-free solution (Acetate 2 mEq/L Citrate 2 mEq/L) at the next 4-hr hemodialysis session
3293962|NCT01778309|Experimental|n-acetylcysteine/placebo supplementation|n-acetylcysteine supplementation, orally in three daily dosages, at 20 mg/kg/day, daily for eight days after exercise placebo, orally in three daily dosages, content: 500 mL drink that contained water (375 mL), sugar-free cordial (125 ml), and 2 g of low-calorie glucose/dextrose powder.
3293963|NCT01778322||Index Embolization Cohort|WEB Aneurysm Embolization System
3293964|NCT01778335|No Intervention|Control|Control arm subjects will receive best medical care.
3293965|NCT01778335|Experimental|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
3293966|NCT01778348|Experimental|Overnight closed-loop combined with CGM|Glucose level is controlled by the automated closed loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system overnight at home for a total duration of 12 weeks.
3293967|NCT01778348|Active Comparator|Real-time CGM alone|The subjects will use the study CGM alone at home for the period of 12 weeks. Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
3293968|NCT01778361||HIV positive|
3293969|NCT01778361||HIV negative|
3293970|NCT01778374|Experimental|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
3293971|NCT01778374|Experimental|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
3293972|NCT01778387|Active Comparator|Laparoscopic ventral hernia repair|Laparoscopic repair: Pneumoperitoneum was performed to 12 mmHg. Herniary contents and sac are reduced releasing adhesions with diathermy or harmonic scalpel. Defects are repaired with a polytetrafluoroethylene (PTFE) patch (Dual Mesh; W.L Gore and Associates, FlagstaV, AZ USA) with double crown fixation as technique of Carbajo et al, ensuring exceed 3 cm edge of defect, using 5mm tackers (Protack, Autosuture; Tyco Healthcare, USA), reducing intrabdominal pressure to 8 mmHg. All operations were performed by experienced surgeons, over than 40 laparoscopic ventral hernia repairs.
3293973|NCT01778387|Placebo Comparator|Open ventral hernia repair|Open repair: Incision was made over hernia defect, reducing herniary contents by opening sac if it is necessary. We made 4 cm soft tissue flaps around edge of defect depending on available healthy fascial tissue. Chevrel technique with fascial closure using anterior rectus sheath with continuous and absorbable suture and placement of polypropylene mesh (Parietene standart polypropylene mesh, Covidien, Norwalk, CT) in an onlay position fixed with polypropylene suture.
3293974|NCT01778400|Experimental|Radiofrequency ablation|Treatment with radiofrequency ablation for the thyroid lesions and compare the results with ethanol ablation in terms of volume reduction at 6-month follow-up (primary end point).
3293975|NCT01778400|Active Comparator|Ethanol|Treatment of predominantly cystic nodule with ethanol ablation and compare these results to radiofrequency ablation in terms of volume reduction at 6-month follow-up.
3293976|NCT01778413|Experimental|ATRIPLA three times a week.|Atripla (600 mg/200 mg/245 mg) three times a week.
3293977|NCT01778413|Active Comparator|ATRIPLA one time a day.|Atripla (600 mg/200 mg/245 mg) one time a day.
3293978|NCT01778439|Experimental|OMP-52M51|
3293979|NCT01778452|Active Comparator|Natural cycle|Natural cycle endometrial biopsy, lh+7
3293980|NCT01778452|Experimental|Antagonist cycle + endometrial priming.|Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5
3293981|NCT01778452|Experimental|Agonist cycle + endometrial priming.|Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5
3293985|NCT01778621|Experimental|Acupuncture (Hwato®)|30-40 minutes acupuncture at certain acupoints that chosen according to traditional Chinese medicine and included LIV3,SP6,SP8,ST36,SP10,ST29,LI14,Ren 04;starting at follicular phase of the cycle till 2 days before oocyte picked up.
3293986|NCT01778621|No Intervention|No acupuncture|No intervention was done for this group of patients.
3293987|NCT01778647|Experimental|Stimulants plus Lovaza|Usual dose of stimulant plus Lovaza (prescription Omega-3 fatty acids) at a dose of 1800 mg daily.
3293988|NCT01778647|Placebo Comparator|Stimulants plus placebo|Usual dose of stimulants plus placebo(corn oil), which will be given to the patients by MMC's pharmacy.
3293989|NCT01778660|Active Comparator|Standard Counselling|Patients in this arm are randomised to standard counselling.
3293990|NCT01778660|Experimental|Mnemonic Counselling|Patients in this arm are randomised to counselling with the aid of a mnemonic.
3293991|NCT01778673||Distal radius fractures Sundsvall Hospital|
3293992|NCT01778673||Distal radius fractures Östersund Hospital.|
3293993|NCT01778686|Experimental|Citalopram and Pindolol|"Citalopram intravenous infusion starting 30 min before scanning, 40 mg/h for 1 hour.~Pindolol peroral administration starting 3 days before scanning:~Day 1: 2.5 mg 3 times daily, day 2: 5 mg 3 times daily, day 3: 7.5 mg 3 times daily, Day 4 (scan day) 7.5 mg morning and noon."
3293994|NCT01778686|Placebo Comparator|Placebo|"Placebo for pindolol: sugar tablets that resembles pindolol~Placebo for ATD: amino acid drink balanced formula (containing tryptophan)~Placebo for Seropram: NaCl infusion"
3293995|NCT01778686|Experimental|Acute tryptophan depletion|Amino acid drink without tryptophan. Ingested 4-5 hours prior to PET scanning.
3293996|NCT01778699|Experimental|Lozenges with Lactobacillus brevis CD2|During the treatment phases subjects will use 2 lozenges a day.
3293997|NCT01778699|Placebo Comparator|Lozenges|During the treatment phases subjects will use 2 lozenges a day.
3293998|NCT01778712|Experimental|Intervention|Multi-level intervention
3293999|NCT01778738|Experimental|Sleeve gastrectomy|Sleeve gastrectomy.
3294000|NCT01778738|Experimental|Gastric bypass|Gastric bypass surgery.
3294001|NCT01778738|No Intervention|Control group|This is an extra control group without diabetes. All subjects are morbidly obese patients recruited from the Morbid Obesity Centre.
3294002|NCT01778764||retrospective cohort|retrospective follow-up of patients treated since 2006
3294003|NCT01778764||prospective cohort|patients treated over a 5-year period from January 15, 2013 to December 31, 2017 and followed for at least one year thereafter
3294004|NCT01778777|Experimental|UniverseReverse|Cohort get an universe reverse prosthesis
3294005|NCT01778790|Sham Comparator|Sham Stimulation for 8 weeks|Implantation of internal pulse generator (IPG), Sham Stimulation
3294006|NCT01778790|Active Comparator|Stimulation for 8 weeks|Implantation of IPG and active stimulation
3294007|NCT01778803|Experimental|defactinib (VS-6063) plus paclitaxel|Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
3294008|NCT01778829|Active Comparator|CPAP ventilation mode|Once the patient is extubated, CPAP ventilation mode is inmediately administered in order to prevent reintubation
3294009|NCT01778829|Experimental|NIPPV ventilation mode|NIPPV: Non Invasive Ventilation mode is administered inmediately after extubation to prevent reintubation
3294010|NCT01778842|Experimental|Prasugrel low dose|Patient will be randomized to this intervention will receive prasugrel 5 mg and after 15 days and 30 days we will control the responsivness of the study drug.
3294011|NCT01778842|Experimental|Clopidogrel standard dose|Patient will be randomized to this intervention will receive clopidogrel 75 mg and after 15 days and 30 days we will control the responsivness of the study drug.
3294012|NCT01778868||Overweight and obese individuals|
3294013|NCT01778868||Normal weight individuals|
3294014|NCT01778881|Experimental|Massage + Exercise|Massage and stretching exercises
3294015|NCT01778881|Experimental|Relaxation +Imagination|Relaxation and Imagination therapies
3294016|NCT01778881|Experimental|Dental treatment|Reconstruction with composite resin
3294017|NCT01778881|Experimental|Massage + Exercise + Relaxation + Imagination|Massage, stretching exercises, relaxation and imagination
3294018|NCT01778894||Healthy Control|Healthy controls with no history of heart disease or heart failure. Subjects will undergo a medical history review and 1 echocardiograph procedure.
3294019|NCT01778894||>Grade 2 Diastolic Dysfunction|Diastolic Heart Failure, > Grade II (NYHA functional class) and/or > Grade II Diastolic Dysfunction as evaluated by echocardiography
3294020|NCT01778907|No Intervention|Normal genotype- control (NG-C)|In the external control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice. Allocation to this arm is not based on randomization.
3294021|NCT01778907|No Intervention|Deviating genotype -control (DG-C)|In the internal control group, an advice for dose adaptation based on patients serum drug levels will be given to the physician according to current daily practice
3294022|NCT01778907|Experimental|Deviating genotype (DG-I)|In the intervention group, genotype information accompanied by a drug dosing advice will be given to the treating physician. Blood level of the drug will be communicated by a dedicated research team to the treating physician according to daily practice.
3294023|NCT01778920|Experimental|IV Injection of EC17|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3294024|NCT01778933|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3294025|NCT01778946|Experimental|Nicotine|"Low Dose Nicotine (7mg) Moderate Dose Nicotine (14mg)~All participants in study will begin with the 7mg patch, titrating from 2 hours/day to a full 16 hours/day over the course of the first 7 days (based on individual tolerance).~Day 7 - Day 28 of the study, participants will apply a new nicotine patch daily. Depending on tolerance, some participants may increase to the moderate dose (14mg) patch.~All participants will apply a new patch daily for a total of 28 days (1 month)"
3294026|NCT01778959|Active Comparator|standard OVD|
3294027|NCT01778959|Active Comparator|Iris hooks|
3294028|NCT01778959|Active Comparator|Malyugin Ring|
3294029|NCT01778959|Active Comparator|OVD|
3294030|NCT01778972|Experimental|Otago home training programme|"Otago home exercise programme was designed specifically to prevent fall. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
3294031|NCT01778972|Experimental|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
3294032|NCT01778972|No Intervention|Control grop|Participants are instructed to live their ordinary lives.
3294033|NCT01778998|Active Comparator|MICS-group|
3294034|NCT01778998|Active Comparator|SICS-group|
3294035|NCT01778998|Active Comparator|SICS pre-cut|
3294036|NCT01778998|Active Comparator|SICS stab-incision|
3294037|NCT01779011||A cohort post amputation|Those patients undergoing either traumatic amputation or surgical amputation of limb
3294038|NCT01779011||A cohort post limb conserving surgery|Patients whose surgical management involved conservation of their injured limb
3294039|NCT01779037||Inpatient Rehabilitation Patients|
3294040|NCT01779050|Active Comparator|Arm I (definitive therapy)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel"
3294041|NCT01779050|Experimental|Arm II (definitive therapy, trastuzumab)|"Patients receive definitive surgery and best practice standard chemotherapy according to NCCN guidelines. The 5 chemo backbone options are:~doxorubicin or epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~docetaxel plus cyclophosphamide~single-agent paclitaxel~docetaxel plus carboplatin~fluorouracil plus epirubicin plus cyclophosphamide followed by paclitaxel or docetaxel~Patients will also receive trastuzumab IV over 30-90 minutes for 52 weeks starting such that there is a minimum of 8 weeks of overlap with the standard of care chemotherapy. Trastuzumab may be given weekly, every 2 weeks, or every 3 weeks while overlapping with standard of care chemotherapy. Trastuzumab will be given every 3 weeks after all standard of care chemotherapy has concluded. Treatment continues in the absence of disease progression or unacceptable toxicity."
3294042|NCT01779063|Experimental|web based multimedia intervention|interactive,web based multimedia intervention
3294043|NCT01779063|Active Comparator|education booklet|printed educational booklet
3294044|NCT01779076|Experimental|100% oxygen during extubation|In this arm the intervention will consist of 100 % oxygen.
3294045|NCT01779076|Experimental|30% oxygen during extubation|In this arm the intervention will consist of 30 % oxygen.
3294046|NCT01779089|Experimental|Minocycline|Minocycline 100 mg po bid for 6 months
3294047|NCT01779089|Placebo Comparator|Placebo|Placebo one tablet po bid
3294048|NCT01779102|Experimental|0.1 µg C-Tb|The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
3294049|NCT01779102|Active Comparator|2 T.U Tuberculin PPD RT 23 SSI|The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme
3294050|NCT01779102|Experimental|0.1 µg C-Tb / 2 T.U Tuberculin PPD|The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme
3294051|NCT01779128|Experimental|Experimental Arm|PET/CT Scan MR-PET Scan
3294052|NCT01779154||eosinophilic gastrointestinal disorders|Individuals with a diagnosis of EGID including: eosinophilic esophagitis, eosinophilic gastritis, eosinophilic enteritis, eosinophilic colitis
3294053|NCT01779193|Experimental|latic acid bacteria and cranberry|oral latic acid bacteria and cranberry capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
3294054|NCT01779193|Active Comparator|cranberry|oral cranberry capsule without lactic acid bacteria, one pill daily
3294055|NCT01779193|Placebo Comparator|placebo|placebo without lactic acid bacteria and cranberry, one pill daily
3294056|NCT01779206|Active Comparator|Anthracycline - Taxane|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
3294057|NCT01779206|Experimental|Taxane - Anthracycline|Study sites can choose between either Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q3w OR Epirubicin (90mg/m²) Cyclophosphamide (600mg/m²) q2w for anthracycline treatment and between either 4 x Docetaxel (100mg/m²) q3w OR 12 x Paclitaxel (80mg/m²) q1w for taxane treatment.
3294058|NCT01779232|Placebo Comparator|control|patients treated with placebo for at least 4 months before IVF attempt
3294059|NCT01779232|Active Comparator|danazol|patients treated with danazol (100mg/day)for at least 4 months before IVF attempt
3294060|NCT01779245|Placebo Comparator|Control|A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
3294061|NCT01779245|Experimental|High-Calcium|A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
3294062|NCT01779258|Other|Group 2|Active control arm, Locatop@, Locapred@
3294063|NCT01779258|Other|Group 3|Absence of emollient treatment, Locatop@, Locapred@
3294064|NCT01779258|Experimental|Group 1|"glycerol, paraffin (liquid and white soft), Locatop@~, Locapred@"
3294065|NCT01779271|Experimental|Pelubiprofen|
3294066|NCT01779271|Active Comparator|Loxoprofen|
3294067|NCT01779284|Active Comparator|Travoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
3294068|NCT01779284|Active Comparator|Latanoprost/Timolol therapy|Enrolled patients will be treated for 3 months with travoprost/timolol drops administered once in the evening. 24-hour pressure monitoring will be carried out for this drug after 3 months of chronic dosing. All patients will be crossed over to therapy for 3 months with latanoprost/timolol fixed combination drops administered once in the evening. Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
3294069|NCT01779310||Alzheimer's disease|Outpatients with clinically significant cognitive impairment per judgment of the participating physicians are enrolled.
3294070|NCT01779323||Pre and Post Sling Pelvic MRI|Cohort: Measure change in hypermobility of urethra after transobturator sling surgery via pelvic MRI.
3294071|NCT01779336|Experimental|PL225B|Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design.
3294072|NCT01779349|Experimental|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
3294073|NCT01779362|Active Comparator|Metformin alone|Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day). Participants randomized to the metformin-alone arm will be blinded to treatment.
3294074|NCT01779362|Active Comparator|Glargine followed by Metformin|Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 80-90 mg/dl, followed by open-label metformin (titrated up to 2000 mg/day) for 9 months.
3294075|NCT01779362|Placebo Comparator|Placebo|Placebo - masked to metformin-alone. Placebo will be titrated to the maximum number of tablets equivalent to maximum dose of metformin.
3294076|NCT01779362|Active Comparator|Liraglutide + Metformin|Liraglutide + open-label Metformin. Liraglutide will be titrated to the maximum dose tolerated (up to 1.8 mg/day) after which metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
3294077|NCT01779388|Other|Bronchoscopy guided by fluoroscopy|Bronchoscopy guided by fluoroscopy followed by ENG
3294078|NCT01779388|Experimental|Bronchoscopy guided by electromagnetic navigation|Bronchoscopy guided by ENG followed by fluoroscopy
3294079|NCT01779401|Active Comparator|Clopidogrel + Aspirit|A Standard antiplatelet therapy control group： Clopidogrel 75mg Qd + Aspirin 100mg Qd
3294080|NCT01779401|Active Comparator|Clopidogrel + Aspirin|B Double-dosage Clopidogrel group： Clopidogrel 150mg Qd + Aspirin 100mg Qd
3294081|NCT01779401|Active Comparator|Clopidogrel + Aspirin + Cilostazol|C triple antiplatelet therapy group： Cilostazol 100mg Bid + Aspirin 100mg Qd + Clopidogrel 75mg Qd
3294082|NCT01779414|No Intervention|Enhanced Usual Care|Participants in this arm of the study will receive a standard, usual care psychological risk assessment by a social worker and then recommended to a mental health referral.
3294083|NCT01779414|Experimental|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
3294084|NCT01779427|Experimental|AIM Intervention|
3294085|NCT01779427|Experimental|Wait List Control|Participants are in the Wait List Control group for 10 weeks and then they will participate in the AIM Intervention
3294086|NCT01779453|Experimental|ETC-1002|ETC-1002 treatment group, oral once daily
3294087|NCT01779453|Placebo Comparator|Placebo|Placebo treatment group, oral once daily
3294088|NCT01779466|Experimental|Experimental A|
3294089|NCT01779466|Experimental|Experimental B|
3294090|NCT01779466|Placebo Comparator|Placebo|
3294091|NCT01779479|Experimental|Cabacitaxel|
3294092|NCT01779479|Active Comparator|Paclitaxel|
3294093|NCT01779492|Experimental|GL2907|Oxycodone HCl 20mg
3294094|NCT01779492|Active Comparator|Oxycontine CR 10mg|Oxycodone HCl 10mg
3294095|NCT01779505|Experimental|GS-4774 at 10 yeast units (YU)|10 YU of GS-4774 given either weekly or monthly
3294096|NCT01779505|Experimental|GS-4774 at 40 YU|40 YU of GS-4774 given either weekly or monthly
3294097|NCT01779505|Experimental|GS-4774 at 80YU|80 YU of GS-4774 given either weekly or monthly
3294098|NCT01779531||pCR，XT|
3294099|NCT01779544|Active Comparator|Brief intervention only|Brief intervention, an educational model, consists of information
3294100|NCT01779544|Active Comparator|Exercise group|Brief educational intervention combined with exercise therapy
3294101|NCT01779557|Experimental|Huaren peritoneal dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
3294102|NCT01779557|Active Comparator|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
3294103|NCT01779570|Experimental|Macrolide treatment|Azithromycin 500 mg daily for 5 days
3294104|NCT01779570|No Intervention|No macrolide treatment|No azithromycin
3294105|NCT01779583||Advanced gastric cancer patients|Treatment näive advanced gastric cancer patients candidates to first-line chemotherapy
3294106|NCT01779583||Control group|Healthy adult volunteers without a cancer diagnosis
3294107|NCT01779596|Experimental|Bosentan|Single dose of Bosentan (125 mg)
3294108|NCT01779596|Placebo Comparator|Placebo|Single dose of placebo (125 mg)
3294109|NCT01779609|Experimental|Bosentan + Exercise|2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise
3294110|NCT01779609|Placebo Comparator|Placebo + Exercise|2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise
3294111|NCT01779609|Other|Exercise|3x/week supervised exercise for 8 weeks
3294112|NCT01779622|Experimental|1|Healthy volunteers are ingesting a mixed meal either rapidly or slowly
3294113|NCT01779635|Active Comparator|oXiris as first filter|Start off the first CRRT circuit with oXiris, then cross-over to M150, then oXiris, then back to M150
3294114|NCT01779635|Other|M150 as first filter|Patients in M150 arm will start off with M150 as first filter for CRRT, then cross-over to oXiris after the former clots, then back to M150, then to oXiris.
3294115|NCT01779661|Active Comparator|Infant Aquatics|
3294116|NCT01779661|Active Comparator|Infant Massage|Infant Massage
3294117|NCT01779687|Active Comparator|raltegravir alone|Raltegravir 400 mg BID for 7 days
3294118|NCT01779687|Active Comparator|Atorvastatin alone|Atorvastatin 20 mg QD for 7 days
3294119|NCT01779687|Experimental|Raltegravir + atorvastatin|Raltegravir 400 mg BID + Atorvastatin 20 mg QD for 7 days
3294120|NCT01779713||Vasospastic patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) and developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
3294121|NCT01779713||Control patients|Any patient send to the neuro-anesthesia intensive care unit in the 48 hours following an aneurismal sub-arachnoid hemorrhage and treated in the 96 first hours (embolization or surgery) not developing a vasospasm during the first 12 days after the bleeding; aged more than 18; of Caucasian origin; affiliated to a social care service; having (or one of is related if he is comatose) given its informed consent
3294122|NCT01779726|Experimental|CT scan before chest physician|CT scan before chest physician
3294123|NCT01779726|Active Comparator|Usual diagnostic workup|Usual diagnostic workup
3294124|NCT01779739|No Intervention|No perineorrhaphy|Subjects will not have a perineorrhaphy procedure added to the vaginal prolapse repair
3294125|NCT01779739|Active Comparator|Perineorrhaphy|Subjects will have a perineorrhaphy added to the vaginal repair of prolapse
3294126|NCT01779765|Experimental|PHGG|2.5gr per day for the first week and then 5gr per day for 11 weeks.
3294127|NCT01779765|Placebo Comparator|Maltodextrin|2.5gr per day for the first week and then 5gr per day for 11 weeks.
3294128|NCT01779791|Experimental|PCI-32765 (Ibrutinib)|
3294129|NCT01779804||Patients with foot and ankle injury|After baseline data is obtained a cohort of patients with acute foot and ankle injuries will have OFAR applied
3294130|NCT01779817|Other|child born to hyperthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
3294131|NCT01779817|Other|child born to euthyroid mother during pregnancy|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.
3294132|NCT01779830|Experimental|0.3 mg LY2624803|Single dose of 0.3 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3294133|NCT01779830|Experimental|3.0 mg LY2624803|Single dose of 3.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3294134|NCT01779830|Experimental|6.0 mg LY2624803|Single dose of 6.0 mg LY2624803 administered orally in up to 2 of 4 treatment periods.
3294135|NCT01779830|Active Comparator|10 mg Zolpidem|Single dose of 10 mg zolpidem administered orally in up to 1 of 4 treatment periods.
3294136|NCT01779830|Placebo Comparator|Placebo|Single dose of placebo administered orally in up to 1 of 4 treatment periods.
3294137|NCT01779843|Experimental|Treatment|"Induction: 100 mg/m2/day Cytarabine intravenous, days 1-7 of induction cycle. 12 mg/m2/day Idarubicin intravenous, days 1-3. Alisertib orally, twice a day for one week starting on day 8, dose escalation-starting dose 10 mg PO BID.~Consolidation: Cytarabine 3 g/m2 by IV infusion over 3 hours given every 12 hours on Days 1, 3 and 5 (subjects younger than age 60) or Cytarabine 2 g/m2 per day by IV infusion over 3 hours on days 1-5 (subjects at or older than age 60)"
3294138|NCT01779882|Active Comparator|BU-CY|Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)
3294139|NCT01779882|Experimental|CY-BU|Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)
3294140|NCT01779895|Active Comparator|NCC2461|probiotic blended in maltodextrin powder to be taken daily
3294141|NCT01779895|Placebo Comparator|Placebo|maltodextrin
3294142|NCT01779908|Experimental|Vitamin D supplementation|5000 IU of vitamin D3 for 6 months
3294143|NCT01779908|Placebo Comparator|Placebo|Placebo pill for 6 months
3294144|NCT01779921||FVII|
3294145|NCT01779947|Experimental|Estradiol Vaginal Insert 10 mcg|Estradiol Vaginal Insert 10 mcg - Test Product
3294146|NCT01779947|Active Comparator|Vagifem Tablets 10 mcg|Vagifem® (Estradiol Vaginal Tablets) 10 mcg - Reference Listed Drug
3294147|NCT01779947|Placebo Comparator|Placebo|Placebo for the test product Estradiol Vaginal Tablets 10 mcg
3294148|NCT01779960||Londrina|20 patients with moderate-severe COPD from State University of Londrina, Brazi
3294149|NCT01779960||Leuven|20 patients with moderate-severe COPD from Catholic University of Leuven, Belgium
3294150|NCT01779973|Experimental|Remote Observed Dosing|Compliance with dosage observations of suboxone doses using remote observed dosing 4 days per week and 1 weekly in-office visit.
3294151|NCT01779999||PICC-carrying patients|All patients carrying a peripherally inserted central catheter in our service
3294152|NCT01780012|Experimental|Intervention|Osteoporosis prevention program: Women will receive oral and written information and advices on osteoporosis, a letter and a leaflet on osteoporosis management to give to their family physician, and phone call reminders.
3294153|NCT01780012|No Intervention|Control|Control women will receive usual post-fracture care without information
3294154|NCT01780025||Mixed hearing loss|
3294155|NCT01780038|Experimental|Receipt of Genetic Results|Receipt of Genetic Results indicates that participants have received the results of genotyping for RS1051730
3294156|NCT01780038|Active Comparator|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
3294157|NCT01780051|Experimental|Sequence A|
3294158|NCT01780051|Experimental|Sequence B|
3294159|NCT01780064|Placebo Comparator|Standard group|routine monitoring with questionnaires
3294160|NCT01780064|Active Comparator|Interviews with psychologist|Patients have interviews with a psychologist (at cure one of chemotherapy treatment,at cure six of chemotherapy treatment, at last radiotherapy session, and three months after the end of radiotherapy) and questionnaires
3294161|NCT01780077|Experimental|RXI-109|
3294162|NCT01780077|Placebo Comparator|Placebo|
3294163|NCT01780090|Experimental|iPad software|Student participants will use specialized, iPad software under the direction of the SLP, 1 time a week over the course of 2 months.
3294164|NCT01780116|Experimental|Medicaiton adherence therapy|"Adherence therapy, consisting of six, 2-hour sessions over 3 months, in three phases:~Engaging patients: assessing needs and concerns in medication adherence;~Reviewing strengths and barriers and developing coping strategies; and~Rationalizing beliefs and concerns and preventing relapse."
3294165|NCT01780116|No Intervention|Routine community care|Routine Community psychiatric nursing services provided by the Community Psychiatric Nurses in the practice field
3294166|NCT01780129|Experimental|Polydatin Injectable (HW6)|10ml(2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
3294167|NCT01780129|Placebo Comparator|HW6 blank dummy (0.9%NaCl)|10ml (2 ampoules) diluted in 500ml of 0.9% NaCl solution for i.v. infusion over 2 hours; once daily for 5 consecutive days
3294170|NCT01780155||1|Parents and premature newborns with a birth weight less than or equal to1250 g from member institutions of the hospital network will be invited to participate in this study.
3294172|NCT01780181||TCM plus chemotherapy|TCM:oral granules,YangYinFang or YiQiFang or YiQiYangYinFang, four packages,twice a day, three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
3294173|NCT01780181||Placebo plus chemotherapy|TCM Placebo: oral granules,YangYinFang orYiQiFang or YiQiYangYinFang, 10% of the original dose,four packages,twice a day ,three months; Chemotherapy : Intravenous drug use, treated with single-agent chemotherapy :DOC、NVB、GEM.Each cycle was 21-days. Cycles were repeated until disease progression, unacceptable toxicity, or chemotherapy taboo;
3294174|NCT01780194||Lumbar fusion group|
3294175|NCT01780194||Conservative treatment group|
3294176|NCT01780207|No Intervention|OSA without PFO|
3294177|NCT01780207|Other|OSA with PFO|PFO closure
3294178|NCT01780220|Experimental|abiraterone|Abiraterone acetate (three dose levels in phase I) + prednisone (10mg/day)+LHRH + Radiotherapy
3294179|NCT01780233|Experimental|Fentanyl 400 µg sublingual spray + naltrexone 50 mg|Patients received a single administration of 400 µg of fentanyl spray sublingually + naltrexone hydrochloride 50 mg orally.
3294180|NCT01780233|Active Comparator|Actiq® 400 µg transmucosally + naltrexone 50 mg|Patients received a single administration of 400 µg of Actiq® transmucosally + naltrexone hydrochloride 50 mg orally.
3294181|NCT01780233|Active Comparator|Fentanyl citrate injection 100 µg iv + naltrexone 50 mg|Patients received a single administration of 100 µg of fentanyl citrate intravenously + naltrexone hydrochloride 50 mg orally.
3294182|NCT01780246|Experimental|nusinersen|
3294183|NCT01780259|Experimental|Cohort 1: Treatment A|Participants will receive 1 spray of esketamine solution in each nostril once (total dose: 28 mg).
3294184|NCT01780259|Experimental|Cohort 1: Treatment B|Participants will receive 1 spray of esketamine solution in each nostril twice, with 5 minutes interval (total dose: 56 mg).
3294185|NCT01780259|Experimental|Cohort 1: Treatment C|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 5 minutes interval between each repeated sprays (total dose 84 mg).
3294186|NCT01780259|Experimental|Cohort 1: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
3294187|NCT01780259|Experimental|Cohort 2: Treatment D|Participants will receive 1 spray of esketamine solution in each nostril thrice, with 10 minutes interval between each repeated sprays (total dose 84 mg).
3294188|NCT01780259|Experimental|Cohort 3: Treatment E|Participants will receive 1 spray of esketamine solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution.
3294189|NCT01780259|Experimental|Cohort 3: Treatment F|Participants will receive 1 spray of placebo solution in each nostril, 4 times with 10 minutes interval between each repeated sprays (total dose: 112 mg). Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution.
3294190|NCT01780272|Other|Normoglycaemia followed by hypoglycaemia|
3294191|NCT01780272|Other|Hypoglycaemia followed by normoglycaemia|
3294192|NCT01780285|Active Comparator|Nitinol-framed PTFE mesh hiatal repair|Nitinol-framed lightweight PTFE mesh for hiatal repair
3294193|NCT01780285|Active Comparator|Lightweight mesh hiatal repair|Partially absorbable lightweight mesh for hiatal repair
3294194|NCT01780298||Group 1: COPD GOLD Stage 1-2|Sixty subjects with a clinical diagnosis of COPD, according to the GOLD guidelines (Stages 1-2), who are current smokers with at least a 10 pack-year smoking history.
3294195|NCT01780298||Group 2: Current Cigarette Smokers|Sixty subjects who are current smokers with at least a 10 pack-year smoking history and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3294196|NCT01780298||Group 3: Ex-Smokers|Sixty subjects who are ex-smokers with at least a 10 pack-year smoking history who have not smoked for at least one year and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3294197|NCT01780298||Group 4: Never Smokers|Sixty subjects who have never smoked (non-smokers) and matched to the COPD cases by ethnicity, gender and age (within 5 years).
3294198|NCT01780311|Active Comparator|Antiarrhythmic drugs|Flecainide or Propafenone or Sotalol (oral, standard dosage)
3294199|NCT01780311|Experimental|ABLATION|Catheter Ablation
3294200|NCT01780363||controls|frequency of mevalonate kinase gene frequency
3294201|NCT01780363||Behçet patients|frequency of mevalonate kinase gene mutations
3294202|NCT01780376|Experimental|WBV group|whole-body vibration (WBV) group
3294203|NCT01780402|Experimental|Hand feeding intervention delivery|Trained Research Feeding Assistants (TRFA), blind to the study outcomes, will assist enrolled PWDs with all three meals for two days using a pre-specified hand feeding technique. Videotaping will occur for two enrolled PWD during the six day time frame to promote efficiency. Coding of the video will be done by a trained Data Technician after meals have been recorded to determine frequency of aversive feeding behaviors, calculate meal intake, and time spent assisting with the meal.
3294204|NCT01780415||Bastovit|all the patients that have supernumerary embryos to vitrify at blastocyst stage
3294205|NCT01780428|Experimental|CL-108|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, Promethazine 12.5 mg)
3294206|NCT01780428|Active Comparator|Norco|Commercial product containing hydrocodone 7.5 mg. acetaminophen 325 mg
3294207|NCT01780428|Placebo Comparator|Placebo|CL-108 formulation without API
3294208|NCT01780441||Tuberous Sclerosis Complex (TSC)|Tuberous Sclerosis Complex
3294209|NCT01780467|Experimental|patients with and without treatment by L dopa)|to study the role of dopamine in the loss aversion phenomenon by comparing brain activity in parkinsonian patient with and without treatment with L Dopa, when they are exposed to mixed (gain/loss) gambles using money.
3294210|NCT01780467|Other|healthy paired control|to highlight the role of a dopamine depletion by comparing patient without treatment vs healthy paired control.
3294211|NCT01780480|Experimental|Dynamic Chinese herbal granule formula|Based on standard medical care, after evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a combination therapy of a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules, including 3 gram of Huangqi(Astragalus root), 2 gram of Renshen(ginseng), 2.5 gram of Danggui(Angelica sinensis), 2 gram of Danshen(Salvia miltiorrhiza), 2 gram of Dilong(Geosaurus), 3 gram of Chishao(Radix Paeoniae Rubra), 2 gram of Honghua(Safflower), 2 gram of Chuanxiong(Rhizoma Chuanxiong), 2 gram of Sanqi(Radix Notoginseng), 3 gram of Shudihuang(Radix Rehmanniae Preparata). The Chinese herbal granule formula could be weekly changed according to differentiation of Zhenghou.
3294212|NCT01780480|Placebo Comparator|Placebo|The process is the same as the experimental arm, except that the matched placebo granules should be in turn of Chinese herbal granules.
3294213|NCT01780493|Other|Direct Nipple Ureteroneocystostomy|
3294214|NCT01780519|Other|L/VL APOE e3/e4 carrier|long and very long poly - T variants of TOMM40 and APOE e3/e4 carrier
3294215|NCT01780519|Other|L/S APOE e3/e4 carrier|long and short poly - T variants of TOMM40 and APOE e3/e4 carrier
3294216|NCT01780519|Other|S/VL APOE e3/e3 carrier|short and Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
3294217|NCT01780519|Other|VL/VL APOE e3/e3 carrier|Very long poly - T variants of TOMM40 and APOE e3/e3 carrier
3294218|NCT01780519|Other|S/S APOE e3/e3 carrier|short poly - T variants of TOMM40 and APOE e3/e3 carrier
3294219|NCT01780532|Experimental|Photo Acoustic Imaging|An exploratory, single armed, pilot study designed to evaluate the feasibility of Photo Acoustic Imaging (PAI) in a clinical setting.
3294220|NCT01780558|Other|group NC-A|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the natural cycles.
3294221|NCT01780558|Other|group HRT-B|Patients with regular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospitalwill be recruited , who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
3294222|NCT01780571|No Intervention|Control group|Neutral pressure breathing after 2 min preoxygenation
3294223|NCT01780571|Active Comparator|Active group|CPAP 5cm H2O + PSV 5cm H2O breathing after 2 min preoxygenation
3294224|NCT01780597||Organ Donors (declared Brainstem-Dead)|This group of subjects is defined as those who have previously expressed their future wish to organ donation and who have suffered events leading to declaration of brainstem-death. Furthermore these subjects will have had their hearts declined for heart transplantation on the basis of poor function.
3294225|NCT01780610|Other|group OI-A|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited , who should not be elder than 40 and had more than 3 frozen embryos.They will be randomized to receive the Letrozole and human chorionic gonadotrophin ovulation induced cycles.
3294226|NCT01780610|Other|group HRT-B|Patients with irregular cycles undergoing FET in reproductive medicine renter of Sun Yat-sen Memorial Hospital will be recruited, who should not be elder than 40 and had more than 3 frozen embryos will be randomized to receive the estradiol and progesterone replacement therapy cycles.
3294227|NCT01780623|Experimental|Bright White Light|Bright white light exposure every morning for 30 minutes for 28 consecutive days
3294228|NCT01780623|Active Comparator|Dim Red Light|Dim red light exposure every morning for 30 minutes for 28 consecutive days
3294229|NCT01780649|Experimental|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI)
3294230|NCT01780649|Active Comparator|ICSI|Intracytoplasmic sperm injection (ICSI)
3294231|NCT01780675|Active Comparator|Prophylactic Cranial Irradiation|Radiation. Prophylactic Cranial Irradiation: 10 times 2.5 Gy (total 25 Gy)
3294232|NCT01780675|Experimental|Hippocampal Avoidance PCI|Radiation. Hippocampal Avoidance PCI. 10 times 2.5 Gy (total 25 Gy).
3294233|NCT01780688|Active Comparator|smoking conventional cigarettes (CC)|After a 1-day nicotine deprivation, subjects are smoking one single cigarette (usual own brand) on one day and then smoking ad libitum on the subsequent day
3294234|NCT01780688|Experimental|using the Tobacco Heating System 2.1 (THS 2.1)|After a 1-day nicotine deprivation, subjects are puffing one single tobacco stick using the THS 2.1 on one day and then puffing ad libitum on the subsequent day
3294235|NCT01780701||High risk prostate cancer patients|Men who have been recently diagnosed with high risk prostate cancer (Gleason score 7 and above) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
3294236|NCT01780701||Low risk prostate cancer patients|Men who have been recently diagnosed with low risk prostate cancer (Gleason score 7 [3+4] and below) and who choose prostate removal for their cancer treatment will undergo Magnetic Resonance Spectroscopy Imaging (MRSI) with rectal probe at the Oregon Health & Science University's Advanced Imaging Research Center.
3294237|NCT01780714|Active Comparator|Conventional cigarettes (CC)|Smokers are continuing to smoke exclusively their usual own brand of CC, for 5 days, ad libitum, under highly controlled conditions
3294238|NCT01780714|Experimental|Tobacco Heating System 2.1 (THS 2.1)|Smokers are switching to the exclusive and ad-libitum use of THS 2.1 for 5 days, under highly controlled conditions
3294239|NCT01780727|No Intervention|Standard Hemodynamic Management (SHEM)|use of standard hemodynamic management
3294240|NCT01780727|Experimental|EGHEM|use of echocardiography guided hemodynamic management to control fluid and drug therapy.
3294241|NCT01780740|Experimental|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
3294242|NCT01780740|Placebo Comparator|Sugar pill|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included.
3294243|NCT01780753|Experimental|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
3294244|NCT01780766||Indolent myeloma patient|
3294245|NCT01780766||Symptomatic Myeloma patient|
3294246|NCT01780779||Osteosarcoma|"All patients with Osteosarcoma), proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURAMOS protocol)~An MRI will be performed before, during and post-treatment"
3294247|NCT01780779||Ewing Sarcoma|"All patients with proven diagnosis of Ewing sarcoma, proven by surgical biopsy and histopathology.~All included patients will be treated by chemotherapy (EURO-EWING protocol)~An MRI will be performed in all included patients before, during and after the chemotherapy"
3294248|NCT01780792|Experimental|Dance Dance Revolution game play|Dance Dance Revolution video game play
3294249|NCT01780792|No Intervention|control|individuals continue usual care for 8 weeks
3294250|NCT01780805||Young adult alcohol drinkers|Young adults between the ages of 21-25 who regularly drink alcohol
3294251|NCT01780818|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3294252|NCT01780818|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
3294253|NCT01780818|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
3294254|NCT01780844|Active Comparator|Standard of Care|Basiliximab induction + Tacrolimus + MMF + Corticosteroids
3294255|NCT01780844|Experimental|CNI avoidance|Basiliximab induction + ASKP1240 + MMF + Corticosteroids
3294256|NCT01780844|Experimental|CNI minimization-MMF avoidance|Basiliximab induction + ASKP1240 + Tacrolimus + Corticosteroids
3294257|NCT01780857||PPP patients|Patients with palmoplantar pustulosis who have had blood and tissue samples taken.
3379577|NCT05162313|Other|all patients undergoing tracheal intubation procedure|"In current practice, the endotracheal intubation procedure includes the systematic use of the capnometer, which is immediately connected to the tube after its insertion by direct laringoscopy. Confirmation of the correct tube positioning is established by color change of the capnometer from violet to yellow. Then, the colorimetric capnometer is usually removed before connecting the endotracheal tube to the flow-sensor of the ventilator.~For the purpose of our study, after the tube insertion the care provider will connect in line both the capnometer and the ventilator flow-sensor to the tracheal tube."
3379578|NCT05162300|Experimental|Group A|"Subjects will be given the same-day combination of VI Peel (Procedure) and Botox Cosmetic (Botulinum Toxin) (Drug). Botox will be administered via intramuscular injection via package insert to Glabella, Forehead and Crows Feet. Dosage will follow package insert guidelines.~The two interventions will be administered once at the start of the study, subsequent study visits will focus on assessment and evaluation."
3379579|NCT05162287||Patients who are treated in the acute ward of the child and adolescent psychiatry|All children and adolescents aged 12 to 18 years who are treated in the acute ward of the Department of Child and Adolescent Psychiatry, Psychotherapy and Psychosomatics at the University Medical Center Hamburg-Eppendorf are recruited.
3379580|NCT05162274|Experimental|Group 1|Participants first received lazertinib(G001) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G002) 240mg in a fasting state morning for 1 day.
3379581|NCT05162274|Experimental|Group 2|Participants first received lazertinib(G002) 240mg tablet morning in a fasting state for 1 day. After a washout period of 14~21days, they then received lazertinib(G001) 240mg in a fasting state morning for 1 day.
3379582|NCT05162261|Experimental|Tixel Group|Screening and baseline visits, Treatment- 3 treatment sessions, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
3294258|NCT01780857||Healthy controls|Patients without palmoplantar pustulosis or any inflammatory skin condition who have had blood and tissue samples taken.
3294259|NCT01780883|Placebo Comparator|Placebo|5 tablets of placebo once a day, an hour before falling asleep, for 6 weeks.
3379583|NCT05162261|Active Comparator|LipiFlow|LipiFlow: Screening and baseline visits,Treatment session, followed by 2 Follow up sessions, 1and 3 months after the last treatment visit. Subject will be questioned about Discomfort and Pain Questionnaires (self-assessed) and OSDI questionnaire.
3379584|NCT05162248||Microsatellite instability|Immunohistochemical analysis was performed for Microsatellite Instability (MSI) status of colorectal tumors tissue.
3294260|NCT01780883|Experimental|2 mg melatonin|1 tablet of 2mg melatonin and 4 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
3294261|NCT01780883|Experimental|4 mg melatonin|2 tablets of 2mg melatonin and 3 tablets of its placebo once a day, an hour before falling asleep, for 6 weeks.
3379585|NCT05162235|Experimental|AR-localization|
3379586|NCT05162222|Experimental|Danicamtiv, followed by itraconazole + danicamtiv|
3379587|NCT05162222|Experimental|Danicamtiv, followed by diltiazem + danicamtiv|
3379588|NCT05162209|Experimental|Synbiotic|Multisspecies synbiotic mixture including Lactobacillus acidophilus), Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Enterococcus faecium (total 2.5 x10 9CFU/sachet), fructooligosaccharydes (FOS) 625 mg, oral sachet daily, for 12 weeks
3379589|NCT05162209|Placebo Comparator|Placebo|Oral sachet dailyi for 12 weeks
3379590|NCT05162196|Experimental|SBRT combined with Niraparib and Toripalimab|"Induction therapy (cyc1: D1-D28): Niraparib 200mg QD + SBRT 8Gy✖️3 QD, D4-D6 + Toripalimab 240mg iv drip D7~Maintenance (cyc2+): Niraparib 200mg QD, D1-D21 + Toripalimab 240mg iv drip D1, until disease progression or intolerable toxicity"
3379591|NCT05162183||Glimepiride|Reference Group
3379592|NCT05162183||Liraglutide|Exposure group
3379593|NCT05162170||Primary Mediastinal large B-Cell Lymphoma (PMBCL)|The present study consists of a retrospective multicenter collection of series of consecutive patients diagnosed with PMBCL over the relevant time period (13 years, from 2007 to 2019 included).
3379594|NCT05162157||at-home spirometry|This group performs spirometry at home with the Nuvoair spirometer
3294262|NCT01780883|Experimental|10 mg melatonin|5 tablets of 2mg melatonin once a day, an hour before falling asleep, for 6 weeks.
3294263|NCT01780896||Study Group|
3294264|NCT01780909|Experimental|Paromomycin Sulfate Fasted State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state. Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. • After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3294265|NCT01780909|Experimental|Paromomycin Sulfate Fed State|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fed state. Fed state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. When you arrive at the hospital for the clinical trial, you will receive an Ensure Plus Shake, after the gastrointestinal catheters are placed. 20 minutes after the intake of the shake, you will receive the a glass of water, where Gabbroral is in dissolved. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3294266|NCT01780909|Experimental|Paromomycin Sulfate w/ Domperidone|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Motilium® (API: domperidone 10 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Motilium®, which stimulates the gastric emptying. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3294267|NCT01780909|Experimental|Paromomycin Sulfate w/ Loperamide HCl|Intake of Gabbroral® oral tablet formulation, which will be dissolved in a glas of 240mL water, in fasted state, in addition of the intake of Imodium® (API: loperamide HCl 2 mg). Fasted state means that you have eaten nothing for 12 hours for the investigation and only have been drinking water. 20 minutes for the intake of the medicine, you will take 2 tablets of Imodium®, which has an inhibited effect on the intestine. After intake of the medicine at regular intervals, gastrointestinal fluids will be aspirated over 4 hours. You sit in a comfortable position in bed; eating and sleeping is not permitted (after 2 hours you have the possibility to drink some water). After 4 hours, the gastrointestinal catheters will be removed and you may eat and roam freely.
3294268|NCT01780948|Placebo Comparator|everolimus|Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL
3294269|NCT01780948|Experimental|everolimus with atorvastatin 20 mg|"Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.~Atorvastatin 20 mg/day (fixed dose)"
3294270|NCT01781000|Experimental|Auditiory verbal discrimination training|Brain Fitness & Brain Training- Posit Science
3294271|NCT01781000|Experimental|Facial affect discrimination training|Behavioral: Facial Affect Training- FAT
3294272|NCT01781000|Active Comparator|Treatment as usual|standard treatment/rehabilitation protocol of schizophrenia ward
3294273|NCT01781013|Experimental|Technology-supported care|This arm consists of Clinic Resource Management (CRM) clinics and serves as our intervention arm where the tested technology is implemented. Our overarching aim in these comparisons is to assess the potential effects of technology-facilitated depression symptom monitoring, relapse prevention, and medication adjustments and to examine depression care receipt and symptom improvement, patient/provider acceptance, and cost.
3294274|NCT01781013|No Intervention|Supported-Care|This arm consists of CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
3294275|NCT01781013|No Intervention|Usual Care|This arm consists of non-CRM (Clinic Resource Management) clinics and serves as one of the two control arms in the study.
3294276|NCT01781039||low HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
3294277|NCT01781039||high HIN difficulty- anesthetized|Subjects with normal OHC function and who will be undergoing an previously scheduled anesthetized procedure will be assigned into 2 groups based on their self-perceived HIN difficulty (high and low difficulty), and then undergo a test battery consisting of auditory threshold tests, objective HIN assays, OHC measurements, cognitive processing, and central auditory processing evaluations. Immediately after anesthetization, electrocochleography (ECochG) will be used to measure CAP amplitudes, which will be correlated with measurements obtained from unanesthetized subjects as described below. This aim will determine the optimal CAP recording method with the strongest correlation with HIN performance in humans
3294278|NCT01781039||Hearing Aid fitting: MAD|Microphone adaptive directionality (MAD) feature will be activated, the WDC set to linear, and the DNR minimized
3294279|NCT01781039||Hearing Aid fitting: WDC|Wide dynamic compression (WDC) feature will be set to target levels, the MAD feature set to omnidirectional, and the DNR minimized.
3294280|NCT01781039||Hearing Aid fitting: DNR|Digital noise reduction (DNR) set to maximum, MAD set to omnidirectional, and WDC set to linear
3294281|NCT01781039||Hearing Aid fitting: Positive control|All hearing aid features enables
3294282|NCT01781039||Hearing Aid fitting: Negative control|All hearing aid features disabled
3294283|NCT01781052||Group 1|
3294284|NCT01781065|Experimental|transcranial direct current stimulation|Anodal stimulation on motor cortex
3294285|NCT01781065|Sham Comparator|Sham transcranial direct current stimulation|Turn off after 10 s of stimulation
3294286|NCT01781091|Experimental|FULLY CLOSED-LOOP VENTILATION|IntelliVent-ASV automatic mode
3294287|NCT01781091|Active Comparator|Conventional modes ventilation|Conventional modes
3294288|NCT01781104|Active Comparator|RM-131|
3294289|NCT01781104|Placebo Comparator|Placebo|
3294290|NCT01781117|Experimental|HoLEP group|Holmium Laser Enucleation of the Prostate (HoLEP)
3294291|NCT01781130|Placebo Comparator|Percutaneous release alone|The patients who perform percutaneous release of trigger finger only
3294292|NCT01781130|Experimental|Percutaneous release + Steroid injection|Steroid local injection after percutaneous release of trigger finger
3294293|NCT01781143|Experimental|Perform echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
3294294|NCT01781195||Advagraf-based immunosuppression|50 patients after liver transplantation (25 with a MELD-score ≤20 and 25 patients with a MELD-score >20) under CNI-based immunosuppression with Advagraf
3294295|NCT01781221|Active Comparator|Alpha-Bio's GRAFT Natural Bovine Bone|two different bone substitutes commonly used in dental procedures.
3294296|NCT01781221|Active Comparator|Bio-Oss xenograft|two different bone substitutes commonly used in dental procedures.
3294297|NCT01781247|Experimental|Intervention group|Patients in the intervention group will participate in one single counseling session of 45 minutes (the minimal behavioral intervention) that targets specific MI-triggered traumatic reactions.
3294298|NCT01781247|Active Comparator|Control group|Patients in the control group will participate in one single counseling session of 45 minutes (the control intervention) that targets more general information about the role of psychological stress in coronary heart disease.
3294299|NCT01781260||Young. Fit. Minor neurosurgical operation. Prone position.|18-65 year old patients, without serious medical co-morbidities (assessed as ASA I/II status) who are having minor to moderate severity neurosurgical operations in the prone position.
3294300|NCT01781273|Placebo Comparator|Cranberry juice alone|500 mL of cranberry juice
3294301|NCT01781273|Experimental|BAC 0.5 g/L|Cranberry juice with ethanol to rise BAC to 0.5 g/L
3294302|NCT01781273|Experimental|BAC 0.65 g/L|Cranberry juice with ethanol to rise BAC to 0.65 g/L
3294303|NCT01781273|Experimental|BAC 0.8 g/L|Cranberry juice with ethanol to rise BAC to 0.8 g/L
3294304|NCT01781312|Experimental|ProTectis|
3294305|NCT01781312|Experimental|Gastrus|
3294306|NCT01781325|Active Comparator|IBEHR|IBEHR
3294307|NCT01781325|No Intervention|Standard therapy|written instructions
3294308|NCT01781338|Experimental|Induction Therapy|The kind of induction therapy is dependent on the respective sub-protocol.
3294309|NCT01781351|Experimental|taping the ankle|
3294310|NCT01781364|Experimental|Cognitive Training|Brain Fitness Training, Posit Science SF
3294311|NCT01781377|Experimental|PROPOFOL|PROPOFOL SINGLE BOLUS 10 mg + 1mg/kg/hr INFUSION AT UMBILICAL CORD RESECTION
3294312|NCT01781377|Experimental|METOCLOPRAMIDE|METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
3294313|NCT01781377|Experimental|PROPOFOL & METOCLOPRAMIDE|PROPOFOL SINGLE BOLUS of 10 mg + 1mg/kg/hr INFUSION AND METOCLOPRAMIDE 10 mg I.V. AT UMBILICAL CORD RESECTION
3294314|NCT01781377|Placebo Comparator|PLACEBO|SALINE INFUSION
3294315|NCT01781390|Experimental|12.5M Mesenchymal Precursor Cells (MPC)|12.5M Mesenchymal Precursor Cell (MPC) administered via IC infusion
3294316|NCT01781390|Experimental|25M Mesenchymal Precursor Cells (MPC)|25M Mesenchymal Precursor Cell (MPC) administered via IC infusion
3294317|NCT01781390|Placebo Comparator|Placebo|Placebo via IC infusion
3294318|NCT01781416||1|
3294319|NCT01781442||Patient Arm- temsirolimus|
3294320|NCT01781455|Experimental|BBI503|
3294321|NCT01781494|Active Comparator|Immobilization|Immobilization followed by protected range of motion
3294322|NCT01781494|Experimental|Immediate range of motion|Immediate motion after anterior submuscular ulnar nerve transposition
3294323|NCT01781507|Experimental|Cetirizine|Cetirizine 10 mg orally once a day
3294324|NCT01781507|Placebo Comparator|Sugar pill|This will be the placebo arm
3294325|NCT01781520|Experimental|S-1 plus DC-CIK|"Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles."
3294326|NCT01781520|Active Comparator|DC-CIK alone|DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis, and then cultured DC-CIK cells were infused back to the patients on days 15, 17, and 19 of 21-day cycles.
3294327|NCT01781520|Active Comparator|S-1 alone|Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
3294328|NCT01781520|Active Comparator|Best supportive care|
3294329|NCT01781533|Experimental|algorithm|
3294330|NCT01781546|Experimental|drug-eluting balloon (DEB)|Patients treated with drug-eluting balloon (DEB). Provisional stenting with BMS is permitted in case of a flow-limiting dissection or significant recoil (>30% in main branch and >50% side-branch), Includes both stable CAD and ACS patients.
3294331|NCT01781546|Active Comparator|bare-metal stent (BMS)|Patients treated with bare-metal stent (BMS). Includes both stable CAD and ACS patients.
3294332|NCT01781559|Experimental|phenolic acid + maltodextrin|phenolic acid + maltodextrin;
3294333|NCT01781559|Placebo Comparator|Maltodextrin|Maltodextrin
3294334|NCT01781559|Active Comparator|flavanol + maltodextrin|flavanol + maltodextrin
3294335|NCT01781585||sustained low-efficiency dialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
3294336|NCT01781585||continuous veno-venous hemofiltration|Patients were randomized to receive CVVH or SLED and the next day on the other.
3294337|NCT01781598||Patients treated with Patient specific instruments in TKA|
3294338|NCT01781624|Experimental|Study Oral Nutritional Supplement|2 containers a day of a high calorie, complete, balanced, ready-to-drink oral nutritional supplement with a new protein blend.
3294339|NCT01781650|Active Comparator|Air insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3294340|NCT01781650|Experimental|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
3294341|NCT01781650|Experimental|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
3294342|NCT01781663|Experimental|KAM2904 Face Cream and KAM3008 Body Lotion|A group treated with KAM2904 Face Cream and KAM3008 Body Lotion
3294343|NCT01781663|Sham Comparator|petrolatum-based moisturizer|control group
3294344|NCT01781689|Experimental|Functional Electric Stimulation|perform arm cranking with functional electrical stimulation
3294345|NCT01781689|Sham Comparator|traditional rehabilitation program|Receive traditional rehabilitation programs
3294346|NCT01781689|No Intervention|Health|with no motor function impairment
3294347|NCT01781702|Experimental|Pelubiprofen 30 mg|Pelubiprofen 30 mg, tid
3379595|NCT05162144|Experimental|Proximal Medial Gastrocnemius Recession Surgery|All patients included in the Cohort Study will recieve this PMGR-surgery
3294348|NCT01781702|Active Comparator|Celebrex 200 mg|Celebrex 200 mg, tid
3294349|NCT01781715|Experimental|Multivessel stenting|This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
3294350|NCT01781715|Active Comparator|Staged revascularization|This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
3379603|NCT05162118|Experimental|Single Arm|"Intratumoral injection of VG161 - 1.5*10^8 on D1 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2 + Nivolumab on D8, D22~Intratumoral injection of VG161 - 1.0*10^8 on D1, D2, D3 + Nivolumab on D8, D22"
3379604|NCT05162105|Experimental|Evening shift followed by day shift (Quick Return)|Participants work a simulated evening shift, from 03:00PM to 11:00PM, followed by a simulated day shift, 07:00AM to 03:00PM, the following day.
3294351|NCT01781741|Experimental|Treatment (TEMLA and SBRT)|Patients undergo TEMLA to remove the mediastinal lymph nodes followed by a single fraction of SBRT to the primary tumor (unless VATS procedure done) and mediastinal lymph node beds (if positive on TEMLA), with or without minimally invasive surgery.
3294352|NCT01781754||Diabetic patients|Un balanced diabetic patients
3379605|NCT05162105|Active Comparator|Day shift followed by day shift|Participants work a simulated day shift, from 07:00AM to 03:00PM, followed by another simulated day shift, from 07:00AM to 03:00PM, the following day.
3379606|NCT05162092|Experimental|Group A|training duration for each session is 30 mints with 5 mints rest and it includes passive soft tissue elogation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing
3379607|NCT05162092|Experimental|Group B|It included passive soft tissue elongation of tight muscles,lower limb resistance exercises,movement transition,balance board standing ,walking and stair climbing and Vestibular Stimulation exercises such as Swinging in standing in all directions, trampoline jumps, rocking movement in rocking chair, gaze stabilization exercises and visual pursuit exercises under supervision.
3379608|NCT05162066|Other|C3G cohort|Approximately 14 eligible participants with C3G will be enrolled.
3294353|NCT01781780|Active Comparator|General Nutrition Recommendations|Participants will be provided with a free USDA nutrition pamphlet describing general good nutrition habits. They will also receive an instruction handout to emphasize some of the points in the dietary guidelines in the handout. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the suggestions as best they can into their daily life.
3294354|NCT01781780|Experimental|Breakfast Recommendation|Participants randomized to the breakfast group will be instructed to consume breakfast before 10:00 a.m. every day, and will be asked to not eat again until after 11:00 a.m. Participants will be counseled on what a healthy breakfast is using an instruction handout. No specific restrictions will be given on types of foods that can be consumed for the breakfast meal. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also be provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
3379609|NCT05162066|Other|IgAN cohort|Approximately 14 eligible participants with IgAN will be enrolled.
3379610|NCT05162066|Other|PMN cohort|Approximately 14 eligible participants with PMN will be enrolled.
3379611|NCT05162053|Experimental|Ultra extensive metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
3379612|NCT05162053|Experimental|Extensive metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
3379613|NCT05162053|Experimental|Normal metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
3379614|NCT05162053|Experimental|Intermediate metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
3379615|NCT05162053|Experimental|Poor metabolizers group|A 7-day cross-dosing of vicagrel and clopidogrel between two cycles
3379616|NCT05162040||Experimental Group|Twenty participants joined the experimental group (15 males and 5 females, mean aged=61.10; SD=12.62) and provided written informed consent to be enrolled onto the study. Participants with neurological pathologies were diagnosed with (6) ischemic strokes, (1) hemorrhagic stroke, (1) thalamic stroke, (1) internal capsule stroke (3) traumatic brain injury (TBI), (1) Parkinson syndrome, (1) mixed axonal neuropathy with sensory demyelination, (1) progressive multifocal leukoencephalopathy, (1) secondary obstructive hydrocephalus, (1) angioma avernosus hemorrhage, (1) hemiprotuberancial hemorrhage - cavernoma, (1) ataxia and (1) cerebral artery aneurysm.
3379617|NCT05162027|Active Comparator|Erenumab-aooe|"Erenumab-aooe 70 mg/ml. Subcutaneous injection. Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other Name: Aimovig®"
3379618|NCT05162027|Placebo Comparator|Placebo|"Placebo. Subcutaneous injection.Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.~Other name: Placebo"
3294355|NCT01781780|Experimental|No Breakfast Recommendation|Participants randomized to the no breakfast group will receive a detailed handout with instructions to not consume any calories before 11:00 a.m. every day. Only water or 0 calorie beverages may be consumed from the time of waking until 11:00 a.m. They will be instructed to keep track of their breakfast consumption (yes/no) using a calendar diary that will be provided to them. Participants will also provided with a free USDA nutrition pamphlet describing general good nutrition habits. The clinician will go through both documents with participants in detail by reading them aloud and answering any questions, and it will be recommended that they incorporate the recommendations into their daily life as much as they can.
3294356|NCT01781793|Placebo Comparator|Fibrotic ILD Patients, Room Air|Fibrotic ILD patients will breathe room air (21% oxygen) during a constant work rate exercise test
3294357|NCT01781793|Active Comparator|Fibrotic ILD Patients, Hyperoxia|Fibrotic ILD patients will breathe hyperoxia (60% oxygen) during a constant work rate exercise test
3294358|NCT01781819|Experimental|ARFI SVI ultrasound imaging|Acoustic Radiation Force Impulse (ARFI) Shear Wave Velocity Imaging (SVI) ultrasound imaging
3294359|NCT01781845|Experimental|ARFI-SVI Ultrasound|Ultrasound scan using acoustic radiation force impulse-shear wave velocity imaging in the characterization of pediatric hydronephrosis. This is a non-invasive scan that uses sound waves to create the images.
3294360|NCT01781858||pulmonary embolism|Consecutive outpatients and inpatients with first episode of acute pulmonary embolism
3294361|NCT01781871|Experimental|Prevenar13|68 kidney transplant patients vaccinated with Prevenar13 as they enter the transplant waiting list. Pre- and postvaccination serotype specific ELISA and OPA measured. Revaccination at 6 months after the transplantation with Prevenar13, again pre- and postvaccination serotype specific ELISA and OPA measured
3294362|NCT01781871|Active Comparator|Pneumovax|68 kidney transplant patients vaccinated with Pneumovax as they enter the transplant waiting list, serotype specific ELISA and OPA measured before and after the vaccination. At six and seven months after transplantation ELISA and OPA measured parallel to the experimental group
3294363|NCT01781871|Experimental|liver Prevenar13|30 liver transplant patients vaccinated with Prevenar13 once they enter the transplant waiting list. Serotype specific ELISA and OPA measured before and after the vaccination. Revaccinated with Prevenar13 at 6 months after the transplantation. ELISa and OPA measured pre- and postvaccination.
3294364|NCT01781871|Active Comparator|liver Pneumovax|30 liver transplant patients vaccinated with Pneumovax once they enter the transplant waiting list. Serotype specific ELISA and OPA measured pre- and postvaccination. At 6 and 7 months posttransplant ELISA and OPA measured parallel to the experimental group.
3294365|NCT01781884|Active Comparator|Gamma Aminobutyric Acid (GABA)|GABA will be given 50mg/kg/Day, thrice daily for 52 weeks
3294366|NCT01781884|Active Comparator|Gamma Aminobutyric Acid GABA)|GABA will be given 100mg/kg/Day, thrice daily for 52 weeks.
3294367|NCT01781884|Placebo Comparator|placebo|placebo will be given thrice daily for 52 weeks
3294368|NCT01781897|Active Comparator|mosapride|mosapride
3294369|NCT01781897|Experimental|Electro-acupuncture|Electro-acupuncture
3294370|NCT01781897|Sham Comparator|mosapride + sham acupuncture|mosapride + sham acupuncture
3294371|NCT01781910|Experimental|Branch Chain Amino Acid supplement|A drink supplement containing 1.22 grams of branched chain amino acids, plus glucose.
3294372|NCT01781910|Placebo Comparator|Placebo supplement|The placebo was formulated to match both the taste and color of the test supplement. Crystal Light Lemonade powder (Kraft Foods, Northfield, IL, USA) was mixed with 5.6g of powdered dextrose (Now Foods, Bloomingdale, IL, USA) to match the amount of dextrose present in the BCAA supplement.
3294373|NCT01781923|Experimental|Cognitive Remediation|"12 week computer-based cognitive remediation program aimed to improve working memory, processing speed, and verbal learning/memory.~40 week small group social skills training sessions aimed to improve social skills and cognition."
3294374|NCT01781923|No Intervention|Control|No intervention
3294375|NCT01781936|Experimental|Low dose FA-i (Fluocinolone Acetonide insert)|Each FA-i contains 180 µg FA (Fluocinolone Acetonide) designed to be released over 15 - 30 months.
3294376|NCT01781949|Other|A: Nontargeted rapid HIV screening|Eligible patients randomized to this arm will be offered rapid HIV screening without assessment of risk. HIV testing will occur on a 24-hour basis as part of routine ED care.
3294377|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions regarding HIV risk using the Denver HIV Risk Score (DHRS), an empirically-developed clinical prediction instrument for assessing HIV risk, to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
3294378|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Eligible patients randomized to this arm will be asked to answer questions related to HIV risk using a traditional behavioral risk screening tool to identify patients at increased risk for HIV infection. Patients identified as being at increased risk for HIV infection will be offered rapid HIV testing. HIV testing will occur on a 24-hour basis as part of routine ED care.
3294379|NCT01781988|Experimental|A.individual therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
3294380|NCT01781988|Experimental|B. non-individualized therapy|Carboplatin was administrated at an area under the plasma concentration time curve (AUC) of 5 on day 1 every 21 days, while gemcitabine was administrated at a dose of 1250 mg/m2 on day 1 and 8 and pemetrexed was administrated at a dose of 500 mg/m2 on day 1.
3294381|NCT01782001|Experimental|Vitamin A and zinc|combination of vitamin A and zinc supplements
3294382|NCT01782001|Active Comparator|Vitamin A and placebo|vitamin A with placebo
3294383|NCT01782014|Experimental|Water Insufflation|Colonoscopy using water insufflation
3294384|NCT01782014|Active Comparator|Carbon dioxide insufflation|Colonoscopy using carbon dioxide insufflation
3294385|NCT01782014|Active Comparator|Air insufflation|Colonoscopy using air insufflation
3294386|NCT01782027|Experimental|3H-cholesterol|
3294387|NCT01782040|No Intervention|Control Group|Control Group didn't receive any treatment and it was evaluated at the same time and the same way of interventions group
3294388|NCT01782040|Experimental|Auriculotherapy group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.It was used 6 points: Kidney, Liver, Stomach, Brain Stem, Ovary and Uterus point with semi-permanent needles one time per week for 8 sessions
3294389|NCT01782053|Experimental|Control condition|Current packaging with warning on side replaced with one of 9 mandated warning statements
3294390|NCT01782053|Experimental|Text plus picture|Revised packaging with half of front and back of pack showing FDA proposed warning including image.
3294391|NCT01782053|Experimental|Picture plus additional warning text|Same as text plus picture but containing additional text elaborating on the basis for the warning.
3379621|NCT05162001|Experimental|Disulfiram|A group of adults with a body mass index bigger than 22, treated with disulfiram
3294392|NCT01782066|Experimental|Menveo, dose escalating|
3294393|NCT01782066|Experimental|Nimenrix, dose escalating|
3294394|NCT01782079|Experimental|L. brevis|
3294395|NCT01782092||Chiropractic & Diabetes|All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.
3379622|NCT05161975|Placebo Comparator|Placebo|Food supplement tablets do not contain vitamin K2
3379623|NCT05161975|Experimental|Vitamin K2|Food supplement tablets contain vitamin K2
3379624|NCT05161962|Experimental|One group received standard oral care.|
3379625|NCT05161962|Placebo Comparator|It was applied to the other group by aspiration.|
3379626|NCT05161949||group 1|200 patients with suspected ovarian cancer
3379627|NCT05161949||group 2|40 non oncological patients of witch 20 with endometriosis
3379628|NCT05161936|Experimental|Lumasiran Dose 1|Participants will be administered lumasiran by subcutaneous (SC) injection.
3379629|NCT05161936|Experimental|Lumasiran Dose 2|Participants will be administered lumasiran by SC injection.
3379630|NCT05161936|Placebo Comparator|Placebo|Participants will be administered placebo by SC injection.
3379632|NCT05161897|No Intervention|Control Group|"This arm will receive generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carbohydrate choices. Participants will also be provided with a CGM device; however, participants will be blind to the CGM recordings until the end of the study."
3379633|NCT05161897|Experimental|Intervention Group|"This arm will receive both individualized nutrition therapy and generalized nutrition therapy throughout the study.~Participants will receive dietary recommendations based on their needs and will be educated about the recommended amount of carbohydrates for each meal and the carb choices. Participants will also be provided with a CGM device and will be educated to review their blood glucose measurements and record above range measures along with time, types and amount of food items consumed, cooking method, and any type of physical activity within one hour before or after the meal. This information will be reviewed by one of the research staff at each visit and will be used to set individualized goals for modifying diet and controlling blood glucose. Participants will visit every 10 days for 30 days to conduct measurements, replace their CGM, set new goals based on their food diary and CGM recordings, and receive further dietary recommendations."
3379634|NCT05161884||Preclinical Study group|n=10 Landrace pigs The aim of the pre-clinical study was to assess the accuracy of BOLD-T2 MRI in acute systemic hyper- and hypoxemia in a porcine model in contrast to cardiac catheterization.
3379635|NCT05161884||Validation Study group|"n=25 The patients have an indication for a right heart catheter examination. This is a routine diagnostic examination that is performed on these patients.~Compared to the clinical routine, an additional MRI measurement will be performed. The measurement will be performed before the cardiac catheterization.~For the MRI examination, the patient/subject is placed in a magnetic resonance imaging machine. The MRI examination initially includes approximately 15 minutes of standard images for orientation and determination of function, morphology, and tissue characteristics. This is followed by images to determine oxygen saturation in the ventricles (approximately 5 minutes).~If a CMR examination is already planned for a patient for other reasons, this will only be extended by the recordings for the determination of oxygen saturation (approx. 5 minutes) at the time of study inclusion.~During the MRI measurements, patients will also perform a stepper stress test."
3294396|NCT01782105|Active Comparator|Control group|In addition to the usual monitoring of pregnancy, this group will receive information about the recommended weight gain during pregnancy and an evaluation about of their nutritional and physical activity habits.
3379636|NCT05161884||Pulmonary Hypertension group|n=25 patients with pulmonary hypertension (definition: pulmonary arterial pressure (PAP) above 25 mmHg)
3379637|NCT05161884||Valvular heart disease group|n=25 patients with valvular heart disease (at least moderate)
3379638|NCT05161884||Ischemic cardiomyopathy group|n=25 patients with ischemic cardiomyopathy
3379639|NCT05161884||HFpEF group|n=25 patients with HFpEF (heart failure with preserved ejection fraction, definition: EF over 50%, heart failure symptoms, elevated NT-proBNP over 400pg/ml)
3379640|NCT05161871|Active Comparator|Cathodal transcranial direct current stimulation|
3294397|NCT01782105|Experimental|Intervention group|"This group will receive a regular monitoring by health professionals (nutritionist and kinesiologist) who will ensure nutritional changes and physical activity necessary to secure the adoption of a healthy lifestyle and could participate to a physical activity group session once a week until week 36 of gestation.~The intervention include:~A nutritional counseling every 2 weeks by a nutritionist until week 36 of gestation; a physical activity group session once a week lead by a kinesiologist until week 36 of gestation; 2 sessions of physical activity counseling (weeks 12 and 24)."
3294398|NCT01782118|Experimental|Lactobacillus GG|Lactobacillus GG given for six weeks two times per day.
3294399|NCT01782118|Placebo Comparator|Placebo|Placebo two times per day for six weeks
3294400|NCT01782144|Active Comparator|NutriSystem|weekly behavior group weight loss education
3294401|NCT01782144|Placebo Comparator|Education|monthly behavior group weight loss education
3294402|NCT01782157||Prompt intervention|The prompt intervention group will receive context-aware text, audio, and video prompts to initiate specified activities of daily living.
3294403|NCT01782157||No prompt intervention|The no prompt intervention will not receive any prompts to initiate activities of daily living.
3294404|NCT01782170|Active Comparator|Iocide Oral Rinse|Iocide Oral Rinse once daily 30 second rinse for 24 weeks
3294405|NCT01782170|Placebo Comparator|Placebo Control|Once daily 30 second rinse for 24 weeks
3294406|NCT01782183|Experimental|Thermal camera by Flir HM series|all patients in both study and control groups will undergo thermal camera photo of the tonsils by Flir HM series
3294407|NCT01782196|Experimental|Type A Pouch followed by Type B pouch|Enhanced one piece drainable pouch with Type A mouldable adhesive for Stage 1 and 2 followed by pouch with Type B mouldable adhesive for Stage 3
3294408|NCT01782196|Experimental|Type B Pouch followed by Type A pouch|Enhanced one piece drainable pouch with Type B mouldable adhesive for Stage 1 and 2 followed by pouch with Type A mouldable adhesive for Stage 3
3294409|NCT01782235|Experimental|Tocilizumab arm|Tocilizumab arm will receive tocilizumab.
3294410|NCT01782235|Placebo Comparator|Placebo arm|Placebo arm will receive placebo.
3294411|NCT01782248|Other|Alzheimer disease|Patients with Alzheimer disease
3294412|NCT01782248|Other|Fronto-temporal lobar dementia|Patients with Fronto-temporal lobar dementia
3294413|NCT01782248|Other|Control|Control group
3294414|NCT01782261|Experimental|Liraglutide|Liraglutide subcutaneous injection every day. first week 0.6mg, week 2-4 1.2mg.
3294415|NCT01782261|Active Comparator|Saxagliptin|Saxagliptin 5mg tablet by mouth every day for 4 weeks
3294416|NCT01782274|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3294417|NCT01782274|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3294418|NCT01782287|Experimental|allogeneic stem cells|3 ml suspension of allogeneic hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3294419|NCT01782287|Active Comparator|autologous stem cells|3 ml suspension of proteome-modified autologous hematopoietic stem cells in 0.9%NaCl solution is administered in L3-L4 vertebrae interspace with 16-18G needle. The preparation is administered every 2 weeks for the first 2 months (at day 1, 14, 28, 42, 56). 2 ml of individual dendritic vaccine are administered subcutaneously in 4 points (shoulders and abdomen) 3 times every 14 days from the therapy beginning (at day 14, 28 and 42). Meloxicam, 7.5mcg once a day is started from day 7 till day 42. Preparation of cytotoxic lymphocytes is administered intrathecally once in 2 weeks during the first 3 months, and then once in a month for three months.
3294420|NCT01782300|Experimental|TV003 Vaccine|Participants will receive an injection of the TV003 vaccine at study entry and Day 360.
3294421|NCT01782300|Placebo Comparator|Placebo Vaccine|Participants will receive an injection of the placebo vaccine at study entry and Day 360.
3294422|NCT01782339|Experimental|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
3294423|NCT01782352|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3294424|NCT01782352|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3294425|NCT01782352|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
3379641|NCT05161871|Sham Comparator|Sham transcranial direct current stimulation|
3294426|NCT01782352|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3294427|NCT01782365|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
3294428|NCT01782365|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of SWS
3294429|NCT01782391|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3294430|NCT01782391|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3294431|NCT01782404|Experimental|Chlorhexidine|
3294432|NCT01782417|Other|Patient and provider intervention|participants will receive a patient and provider intervention
3294433|NCT01782430|Experimental|Standard oxygenation|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3294434|NCT01782430|Experimental|High flow nasal oxygen therapy|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3294435|NCT01782430|Other|invasive ventilation (VNI)|Prospective randomized clinical multicentric study in ICU, comparing standard oxygenation, high flow nasal oxygen therapy and non invasive ventilation (NIV) , with pulse oxymetry values (SpO2), during preoxygenation for hypoxemic patients
3294436|NCT01782443|Experimental|Experimental Treatment Arm|Ziv-aflibercept IV every 2 weeks, 4 mg/kg
3294437|NCT01782456|Experimental|Study Oral Nutritional Supplement|2 servings per day of a complete and balanced, ready-to-drink oral nutritional supplement with a new protein blend.
3294438|NCT01782508|Experimental|imatinib|Participants will take 400mg tablets once daily for one year
3294439|NCT01782508|Active Comparator|inteferon|Participants will receive Interferon 1500wiu/m2 d1-5for 4 weeks followed by 900wiu IH TIW for 11 months
3294440|NCT01782521|No Intervention|Primer|Metal brackets bonded with primer
3294441|NCT01782521|Experimental|No primer|Metal brackets bonded without primer
3294442|NCT01782534||aortic dissection|aortic dissection
3294443|NCT01782547|Experimental|Telehealth Intervention|Telehealth intervention - 6 months
3294444|NCT01782547|Active Comparator|Usual care|Usual care control with comparable frequency of contact
3294445|NCT01782560|Placebo Comparator|Placebo|Two different placebo formulations will be created which will designed to be identical in appearance, taste, and consistency to the two study medications.
3294446|NCT01782560|Active Comparator|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. 2 mg/kg/day omeprazole.
3294447|NCT01782573|Active Comparator|Chlorhexidine gluconate ( CHG )|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
3294448|NCT01782573|Active Comparator|0.9% Sodium Chloride ( N/S )|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
3294449|NCT01782599|Experimental|Dual nicotine patch and electronic cigarette|Nicotine patch and the electronic cigarette will be administered.
3294450|NCT01782612|Active Comparator|General Ansethesia|Subjects undergoing Total uni-Hip Replacement will receive standard General Anesthesia with Laryngeal Mask Airway and Multimodal analgesic techniques
3294451|NCT01782612|Experimental|Peripheral Nerve Blocks|Subjects undergoing Total uni-Hip Replacement will receive Lumbar plexus block and Sciatic nerve block with 0.4% Ropivacaine and Multimodal analgesic techniques
3294452|NCT01782625|Experimental|dive to 122 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with no exercise at depth
3294453|NCT01782625|Experimental|dive to 158 feet, no exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with no exercise at depth
3294454|NCT01782625|Experimental|dive to 122 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 122 feet of seawater with exercise at depth
3294455|NCT01782625|Experimental|dive to 158 feet, exercise|Subjects will undergo a simulated dive to a maximum depth of 154 feet of seawater with exercise at depth.
3294456|NCT01782638|Experimental|deep brain stimulation with high frequency|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
3294457|NCT01782638|Other|low frequency on gait of patients|The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency vs low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
3294458|NCT01782651||HER2+ metastatic breast cancer patients treated with lapatinib|HER2+ metastatic breast cancer patients treated with lapatinib plus capecitabine
3294459|NCT01782677|Experimental|Bilateral Surgical Resection of Carotid Bodies|Patients undergoing Bilateral Surgical Resection of Carotid Bodies.
3294460|NCT01782703||Control|Healthy subjects with no history of atopy (atopic dermatitis, asthma, or allergic rhinitis) from 0 months to 17 years of age that are age and sex matched to our atopic dermatitis subjects.
3294461|NCT01782703||Atopic Dermatitis|Children with atopic dermatitis from 0 months to 17 years of age.
3379642|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Well State|Subjects with confirmed PCD in Well State
3379643|NCT05161858||Primary Ciliary Dyskinesia (PCD) - Sick State|Subjects with confirmed PCD in Sick State
3379645|NCT05161832|Experimental|nocebo|Ultrasound with fake results of rotator cuff injury.
3379646|NCT05161832|Active Comparator|placebo|Ultrasound with fake results of the healthy rotator cuff.
3379647|NCT05161819|Experimental|High-frequency rTMS at left DLPFC|Receive an rTMS course with high-frequency stimulation at left DLPFC
3379648|NCT05161819|Sham Comparator|High-frequency sham stimulation at left DLPFC|Receive an sham rTMS course with high-frequency stimulation at left DLPFC with the sham coil
3379649|NCT05161806|Experimental|SOK583A1 (40 mg/mL)|SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration
3379650|NCT05161793||CGM-Tele-monitoring Type 1|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
3379651|NCT05161793||CGM-Tele-monitoring Type 2|Tele-CGM-monitoring: Subjects are remotely monitored daily through a continuous glucose monitoring (CGM) system (Libre 2) that communicates via smart phone to a Libreview designed dashboard. Alerts set for: ≥4 hours without CGM signal, ≥2 hours 54-70 mg/dl, and 15 minutes <54 mg/dl. Libreview dashboard automatically emails daily alerts to the Certified Diabetes Care and Education Specialist (CDCES). If alerts occurred, the CDCES performed telemedicine outreach based on type of alert.
3379652|NCT05161780|Active Comparator|Normal Saline|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the normal saline group using a random number generator.
3379653|NCT05161780|Experimental|Lactated Ringer's Irrigation|This study will be a prospective double blinded randomized controlled trial. Fifteen patients will be randomly assigned to the lactated reinger group using a random number generator.
3379654|NCT05161767||Recovered group|This will group will consists of people who have a remission of their symptoms at 6-months follow-up after whiplash injury.
3379655|NCT05161767||non-recovered group|This will group will consists of people who develop persistent symptoms at 6-months follow-up after whiplash injury.
3379656|NCT05161754|Experimental|Treatment 1|Participants left tonsil: cold dissection and hot hemostasis. Participants right tonsil: cold dissection and cold hemostasis.
3379657|NCT05161754|Experimental|Treatment 2|Participants right tonsil: cold dissection and hot hemostasis. Participants left tonsil: cold dissection and cold hemostasis.
3379659|NCT05161728|Experimental|PSMA response evaluation arm|PSMA-PET/CT response evaluation, 2 months after starting hormonal therapy, 2 months after starting upfront therapy
3379660|NCT05161715|Experimental|10mg obicetrapib tablets|10mg obicetrapib (5mg tablets) administered orally daily for 24 weeks
3379661|NCT05161689|Experimental|Mpowerment-based intervention|YMSM in this arm may be exposed to a multicomponent, multi-level, community mobilization, combination intervention to address the entire HIV Continuum of Prevention and Care.
3379662|NCT05161689|No Intervention|Standard of care|YMSM in this arm will not be exposed to the intervention.
3379663|NCT05161676|Experimental|Ketone monoester (3-OHB)|
3379664|NCT05161676|Experimental|Placebo Treatment|
3379665|NCT05161663|Experimental|PDI group|
3379666|NCT05161663|No Intervention|Control group|
3379667|NCT05161650|Experimental|Ketone monoester (3-OHB)|
3379668|NCT05161650|Experimental|Isocaloric placebo|
3379673|NCT05161624||Path planning model|
3379674|NCT05161624||Junior ablation specialists|
3379675|NCT05161624||Senior ablation specialists|
3379678|NCT05161585|Experimental|ctDNA dynamic monitoring + routine postoperative follow-up|"ctDNA is detected before operation, before chemotherapy, and then every three months for 2 years, 10 times in total. At the same time, routine postoperative follow-up is given.~To be pointed out, after the completion of the adjuvant chemotherapy, if the ctDNA test indicates positive, patients will immediately perform chest, abdominal and pelvic CT and other imaging tests to determine whether there is recurrence /metastasis. If it is not confirmed, repeat the imaging review every two months, and continue to perform ctDNA test every three months. If the following ctDNA test is negative for two consecutive times, the above imaging reexamination will return to the routine follow-up frequency. In addition, during the follow-up, the following situations may occur: the imaging examination has found recurrence/metastasis, but the ctDNA test is still negative. At this time, the patient will be informed and treated in time of the recurrence/metastasis."
3379679|NCT05161585|No Intervention|routine postoperative follow-up|Only routine postoperative follow-up is given as follows: Physical examination and CEA were performed every 3-6 months for the first 2 years, every 6 months within the third to fifth year, and then annually. Chest/abdominal/pelvis computed tomography was performed annually for up to 5 years, and colonoscopy was performed for proper patients the first year after treatment and repeated in the third year if no advanced adenoma was found and then every 5 years.
3379680|NCT05161572|Experimental|Perioperative chemotherapy plus PD-1 antibody plus preoperative chemoradiotherapy|In this arm, patients will receive preoperative chemoradiotherapy (45Gy/25Fractions), two cycles of SOX and three cycles of PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
3294462|NCT01782703||Control with Atopy history|Healthy subjects from 0 months to 17 years of age with history of asthma, food allergies, or allergic rhinitis, but no atopic dermatitis or with positive family history of atopy
3294463|NCT01782716||ASA|
3294464|NCT01782716||ASA+Euroscore|
3294465|NCT01782729|Experimental|Tacrolimus ointment (pediatric)|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
3294466|NCT01782755|Active Comparator|Lactobacillus rhamnosus GG|Patients allocated to the intervention group will receive 1x1010 colony forming units (CFU) of Lactobacillus rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule suspended in sterile water, administered through a nasogastric, nasoduodenal, percutaneous gastrostomy or percutaneous jejunal tube twice daily while patients are mechanically ventilated until 24 hours of spontaneous breathing. The first dose will be within 48 hours of intubation.
3294467|NCT01782755|Placebo Comparator|Placebo|Patients allocated to the placebo group will receive a capsule identical in appearance to the L. rhamnosus GG capsule, but containing microcrystalline cellulose. The placebo will also be suspended in sterile water and similarly administered twice a day. When suspended in water, the placebo has identical appearance and consistency as the probiotic. The placebo will be prepared by the manufacturer of L. rhamnosus GG, Culturelle, and has been used successfully in a recent RCT in the ICU population
3294468|NCT01782768|Experimental|Effect of different NPPV mode on NRD|13 hypercapnic recovering AECOPD patients were placed on different mode of noninvasive positive pressure ventilation(NPPV,such as the PAV or PSV mode) randomly.For each mode, three levels (PA-, PA, PA+or PS-, PS, PS+), ) of support were applied.PS and PA are set for the patient's comfort . On the basis of these two levels, 25% increase and reduction assisted level of pressure were set both for PS and PA (PA-, PA+or PS-, PS+). At each level, the patients were ventilated at least 20 minutes until the breathing was stable.
3294469|NCT01782781|Placebo Comparator|Group P|"Group P (Placebo) receives a local infiltration of saline in the operating field and ketorolac iv.~In Group P the injectant consists of saline, total volume 156 mL. This is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. Ketorolac 30 mg (1 mL) is also injected iv."
3294470|NCT01782781|Active Comparator|Group A|"Group A (Active) receives a local infiltration of ropivacaine, ketorolac and epinephrine in the operating field and saline iv.~Drug: ropivacaine, ketorelac and epinephrine~In Group A the injectant mixture consists of ropivacaine 300 mg mixed with 30 mg ketorolac and 0.5 mg epinephrine, total volume 156 mL. This mixture is infiltrated by the surgeon into the soft tissue of the vagina, tubosacral and rotundum ligaments, in the abdominal fascia and subcutaneous at the end of surgery. One mL saline is also injected iv."
3294471|NCT01782794||Cohort A|Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
3294472|NCT01782794||Cohort B|Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
3294473|NCT01782807|No Intervention|Hysterectomy|Hysterectomy without oophorectomy or salpingectomy
3294474|NCT01782807|Experimental|Hysterctomy with salpingectomy or fimbriectomy|Salpingectomy or Fimbriectomy
3294475|NCT01782820||dexamethasone late|dexamethasone during induction of anesthesia
3294476|NCT01782820||no dexamethasone|no dexamethasone during measurements
3294477|NCT01782820||dexamethasone early|dexamethasone before induction of anesthesia
3294478|NCT01782846|Active Comparator|Ixprim®|2 capsules of Ixprim® given orally (1000 mg Paracetamol + 75 mg Tramadol)
3294479|NCT01782846|Active Comparator|Dafalgan Codeine®|Two capsules of Dafalgan Codeine® given orally (1000 mg Paracetamol + 46.8 mg Codeine)
3294480|NCT01782911|Experimental|Resveratrol|Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.
3294481|NCT01782911|Placebo Comparator|Control|Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.
3294482|NCT01782924|Experimental|KHK4827 140mg SC|
3294483|NCT01782924|Experimental|KHK4827 210mg SC|
3294484|NCT01782937|Experimental|KHK4827|
3294485|NCT01782950|Other|anti-tuberculosis drugs|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide tablets 3 to 5 tablets once daily for 2 months followed by Rifampicin, Isoniazid 3 to 5 tablets once daily for 4 months
3294486|NCT01782976|Experimental|Cilengitide + Bevacizumab|Cilengitide administered intravenously at 2000 mg twice weekly, while Bevacizumab administered intravenously at 10 mg/kg every other week. Each cycle of therapy will be 4 weeks long.
3294487|NCT01782989|Experimental|ORACEA®|40mg doxycycline
3294488|NCT01782989|Placebo Comparator|Placebo|
3294489|NCT01783002|Experimental|Primary hyperparathyroidism|Subjects with biochemical evidence, including elevated serum calcium and PTH levels, of primary hyperparathyroidism. All patients will undergo 11C-methionine PET/CT, SPECT-CT and 18F-FDG PET/CT scanning.
3294490|NCT01783028|Experimental|Community Health Worker support|home visits from community health workers providing education and support for self-management of asthma, assessment of the home for environmental triggers, resources for asthma control, and assistance in effective communication with medical providers
3294491|NCT01783028|No Intervention|the usual care control group|Usual care is defined as services received by participants in the absence of the intervention plus information about community resources that support asthma self-management (such as classes and support groups) and educational pamphlets
3294492|NCT01783041|Placebo Comparator|5% dextrose|Infants randomized to the placebo group will receive 5% dextrose intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of placebo (5% Dextrose) will be given to the study patients.
3294493|NCT01783041|Experimental|L-carnitine|Infants randomized to the study group will receive L-carnitine intravenously. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
3294494|NCT01783067|Experimental|Iron and zinc biofortified pearl millet|Participants in the experimental arm consume pearl millet which has been biofortified with iron and zinc.
3294495|NCT01783067|Active Comparator|Pearl millet|Participants in the control arm consume non-biofortified pearl millet.
3294496|NCT01783093||Sickle cell and pulmonary hypertension|
3294497|NCT01783106|Active Comparator|budesonide|Oral Budesonide 9mg per day for 8 weeks followed by 6mg per day for 2 weeks and subsequent 3mg per day over a further 2 weeks
3294498|NCT01783106|Experimental|Ciprofloxacine, doxycycline and hydroxychloroquine|Oral Ciprofloxacin 500mg bd plus Doxycycline 100mg bd and Hydroxychloroquine 200mg tds followed by a further 20 weeks continued therapy with Doxycycline 100mg bd and Hydroxychloroquine 200mg tds
3294499|NCT01783119|Experimental|Aloe Vera|Consume 200 ml of aloe vera gel per day over a period of three months
3294500|NCT01783119|Placebo Comparator|water|Consume 200 ml of placebo per day over a period of three months
3294501|NCT01783132|Other|Budesonide|Asthma treated patient with Budesonide for 1 year, 4 different dosage according to measurement of exhaled NO done with NIOX MINO.
3294502|NCT01783132|No Intervention|Standard of care|Asthma treated patient with standard of care during 1 year. Exhaled NO measurement will be done 4 times/year, and compared afterwards with the Budesonide group.
3294503|NCT01783145||Patients|Patients with disseminated TC who have finished their chemotherapy, if needed followed by surgery, and who are in complete remission and currently in active follow-up.
3294504|NCT01783158||Diagnostic group|A total of 132 patients with HNSCC were enrolled in this study. The patients underwent esophagoscopy and chromoendoscopy. The most frequent primary tumors were oropharyngeal (49/132), tumors of the oral cavity (36/132) and larynx (35/132). The majority of subjects (107/132 patients, 81.1%) had advanced HNSCC carcinomas (stages III and IV). Multiple LVLs were discovered in 24 subjects (18.2%), and no LVLs in 108 (81.8%) subjects. Fifty-five LVL biopsy specimens were obtained and assessed. Squamous cell carcinomas were detected in two patients, peptic esophagitis in 11 patients, gastric heterotopic mucosa in two patients, hyperplasia in two patients, and low- and high-grade dysplasia in three patients.
3294505|NCT01783171|Experimental|Arm A (dinaciclib, Akt inhibitor MK2206)|"Patients receive dinaciclib IV over 2 hours on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3294506|NCT01783171|Experimental|Arm B (Akt inhibitor MK2206, dinaciclib)|"Patients receive Akt inhibitor MK2206 PO on day 1 of course 1.~After day 1, all patients receive Akt inhibitor MK2206 PO on days 1, 8, and 15 and dinaciclib IV over 2 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3294507|NCT01783197|Experimental|Paclitaxel and carboplain plus selumetinib|"Cohort 1: Standard Chemotherapy (paclitaxel and carboplatin) plus selumetinib~If you are registered to Cohort 1, you will receive two commonly-used chemotherapy drugs called paclitaxel and carboplatin, plus you will be given the experimental drug selumetinib."
3294508|NCT01783197|Experimental|pemetrexed and cisplain plus selumetinib|"Cohort 2: Standard Chemotherapy (pemetrexed and cisplatin) plus selumetinib (cohort closed)~If you are registered to Cohort 2, you will receive two commonly-used chemotherapy drugs called pemetrexed and cisplatin, plus you will be given the experimental drug selumetinib."
3294509|NCT01783197|Experimental|pemetrexed plus selumetinib|"Cohort 3: Standard Chemotherapy (pemetrexed) plus selumetinib (cohort closed)~If you are registered to Cohort 3, you will receive one commonly-used chemotherapy drug called pemetrexed, plus you will be given the experimental drug selumetinib."
3294510|NCT01783210|Experimental|TLC(Therapeutic Lifestyle Changes) group|"Intervention: Specific Therapeutic Lifestyle Changes program in pregnancy. TLC Program includes a diet (with a specific amount of calories and macronutrients) and a mild physical activity."
3294511|NCT01783210|Other|Control group|"Intervention: Dietary and behavioral counselling in pregnancy. The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake."
3294512|NCT01783223||Intoxicated patients|patients in the Emergency Department who appear to be intoxicated with ethanol.
3294513|NCT01783249|No Intervention|Control|Usual care monitoring
3294514|NCT01783249|Other|Exercise using stationary cycling|Stationary cycling exercise program
3294515|NCT01783262|Active Comparator|Extracorporeal shock wave therapy|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
3294516|NCT01783262|Placebo Comparator|sham extracorporeal shock wave therapy|The second grouop of patients received 0.04 mJ/mm2, 2400 pulses once a week for 4 weeks.
3294517|NCT01783275|Experimental|Aerobic Exercise|12 weeks of aerobic exercise
3294518|NCT01783275|No Intervention|Control|12 weeks with no change in diet or exercise habits (weight maintenance).
3294519|NCT01783301|Active Comparator|Antral follicle count|"Start dose of recombinant Follicle-Stimulating Hormone (rFSH) based on AFC guide~AFC < 6 on both ovary: 375 IU FSH~6<AFC <=15 on both ovary: 225 IU FSH~AFC> 15 on both ovary: 150 IU FSH"
3294520|NCT01783301|Active Comparator|Anti-Mullerian Hormone|"Start dose of FSH based on AMH guide~AMH < 5 pmol/L or < 0.7ng/ml: 375 IU FSH~AMH 5 to < 15 pmol/L or 0.7 to 2.1ng/ml: 225 IU FSH~AMH ≥ 15 pmol/L or > 2.1ng/ml: 150 IU FSH"
3294521|NCT01783314|Active Comparator|Normal liver function|Control group. Subjects will obtain MRI of liver.
3294522|NCT01783314|Experimental|Hepatitis C|Subjects with hepatitis C. Subjects will obtain both MRI of liver and limited CT of liver.
3294523|NCT01783327|Experimental|Teens-Connect|The Teens-Connect Program is an internet-based program that combines Managing Diabetes and TEENCOPE.
3294524|NCT01783327|Active Comparator|Planet D|Planet D is an internet program developed by the American Diabetes Association for children and adolescents with diabetes.
3294525|NCT01783340|Active Comparator|CQ and falciparum immunization|"This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Placebo capsules daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3379681|NCT05161572|Experimental|Perioperative chemotherapy plus PD-1 antibody|In this arm, patients will receive three cycles of SOX and PD-1 antibody, followed by D2 surgery and three more cycles of SOX and PD-1 antibody. Then PD-1 antibody will be given until one year after surgery.
3379682|NCT05161559|Experimental|Fuji Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Fuji Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
3379683|NCT05161559|Experimental|Riva Bond LC (Glass ionomer based adhesive)|Patients received in Class V cavity preparation Riva Bond LC (Glass ionomer based adhesive) on one tooth of the mouth
3379684|NCT05161559|Experimental|Single Bond Universal (self-etch adhesive)|Patients received in Class V cavity preparation Single Bond Universal (self-etch adhesive) on one tooth of the mouth
3379685|NCT05161559|Experimental|Clearfill S3 Bond (self-etch adhesive)|Patients received in Class V cavity preparation Clearfill S3 Bond (self-etch adhesive) on one tooth of the mouth
3379686|NCT05161559|Experimental|OptiBond FL (three step etch & rinse adhesive)|Patients received in Class V cavity preparation OptiBond FL (three step etch & rinse adhesive) on one tooth of the mouth
3379687|NCT05161546|Experimental|patients with bipolar disorder (BD)|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit.~Between day 23 and day 28 (after the second visit), patients will be offered to assess the retinal structure and microvascularization using Spectral Domain Optical Coherence Tomography (SD-OCT) and OCT-Angiography (OCT-A)."
3379688|NCT05161546|Active Comparator|healthy volunteers|"Electrophysiological recordings with ERG and EEG will be performed with a virtual reality headset after a standardized clinical evaluation (first visit).~Then, an actigraphic monitoring of 21 consecutive days will be carried out. At the end of this period a neuropsychological evaluation will be performed during a second visit."
3379689|NCT05161533|Experimental|Treatment (durvalumab, chemotherapy, radiation therapy)|"INDUCTION: Patients receive standard of care chemotherapy consisting of carboplatin or cisplatin and etoposide. Patients also receive durvalumab IV on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity.~MAINTENANCE: Patients receive durvalumab IV on day 1. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Beginning cycle 5 or 6 of durvalumab, patients undergo hypofractionated radiation therapy."
3379690|NCT05161520|Active Comparator|IOL plus CTR Patients will undergo phacoemulsification combined with IOL and CTR implantation.|
3379691|NCT05161520|Placebo Comparator|single IOL Patients will undergo phacoemulsification combined with IOL implantation.|
3379692|NCT05161507||Non-palpable breast cancer lesion|Patients with the non-palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - the tumor lesion will be labeled with Magseed.
3379693|NCT05161507||Palpable breast cancer lesion|Patients with the palpable histologically confirmed breast cancer lesion that will undergo breast-conserving surgery and sentinel lymph node detection - The Magtrace will be injected preoperatively into the tumor and detected by Sentimag.
3379694|NCT05161507||Axillary lymph node metastasis|Patients with the histologically confirmed breast cancer lesion with Axillary lymph node metastasis with pathologic confirmation by needle biopsy - the positive axillary lymph node lesion will be labeled with Magseed before the neoadjuvant systemic therapy.
3379695|NCT05161481|Experimental|BI 685509, dose group 1|
3379696|NCT05161481|Experimental|BI 685509, dose group 2|
3379697|NCT05161481|Placebo Comparator|Placebo|Placebo
3379698|NCT05161468|Active Comparator|Lidocaine|50 Subjects will be randomized to this group and will receive a lidocaine injection in their ACJ.
3379699|NCT05161468|Active Comparator|Corticosteroid|50 Subjects will be randomized to this group and will receive a corticosteroid injection in their ACJ.
3294526|NCT01783340|Experimental|CQ/AZM and falciparum immunization|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).~Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3379700|NCT05161468|Active Comparator|Platelet Rich Plasma (PRP)|50 Subjects will be randomized to this group and will receive a PRP injection in their ACJ.
3379701|NCT05161455|Experimental|L-PRF|
3379702|NCT05161455|Experimental|L-PRF+ allograft bone|
3379703|NCT05161455|Active Comparator|allograft bone|
3379704|NCT05161455|Sham Comparator|collagen plug|
3379710|NCT05161416|Experimental|Bubble Group|The children started to blow bubbles 3 minutes before the procedure. The procedure and the bubble blowing intervention were terminated simultaneously.
3379711|NCT05161416|Experimental|Cartoon Group|The children started to watch the cartoon 3 minutes before the procedure. The children were supported by their parents in holding the tablet. The procedure and the cartoon watching intervention were terminated simultaneously.
3379712|NCT05161403|Active Comparator|Hyaluronic acid.|1mm layer of hyaluronic acid on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
3379713|NCT05161403|Active Comparator|Honey|1mm layer of Honey on a piece of gauze will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
3294527|NCT01783340|Placebo Comparator|CQ and AZM control|"This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.~Azithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.~Challenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.~When thick smear positive, of at day 21 after challenge, a standard 3 day treatment of Malarone will be given."
3294528|NCT01783353|Placebo Comparator|Corn starch pill|Two (2) corn starch pills will be taken three (3) times a day for 60 days.
3294529|NCT01783353|Experimental|Zinc gluconate|Two (2) zinc gluconate 50 mg capsules will be taken three (3) times a day for 60 days.
3294530|NCT01783366|No Intervention|CONTROL|In the control group (Group A) inserting the lubricated NG tube through the nostril, at that time head maintained in the neutral position.
3294531|NCT01783366|Active Comparator|tube-exchanger|The tube-exchanger group (Group B) made use of tube-exchanger G36402 (CAEC, [cook medical, Bloomington, IN]) as a stylet that was lubricated and inserted within 20-F NGT until the tip of the tube-exchanger was at the tip of the NGT
3294532|NCT01783379||ICU patient on micafungin|ICU patients with an invasive fungal infection on micafungin treatment
3294533|NCT01783392|Active Comparator|Unilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve and sets the stimulation intensity to a comfortable level.
3294534|NCT01783392|Active Comparator|Bilateral Posterior Tibial Nerve Stimulation|Transcutaneous posterior tibial nerve stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode electrode above, and the anode electrode behind, the medial malleolus, over the posterior tibial nerve on both legs and sets the stimulation intensity to a comfortable level.
3294535|NCT01783392|Active Comparator|Shoulder stimulation|Stimulation applied 40 minutes every day for a duration of 4 weeks. The patient places the cathode and the anode electrodes on the lateral side of the left shoulder.
3294536|NCT01783405||Cases|FH heterozygous
3294537|NCT01783405||Controls|Parents of FH heterozygotes with FH
3294538|NCT01783431|Experimental|Leukapheresis and Poly-ICLC|Screening tests will be conducted to determine whether or not subjects can participate in this study. If subjects are eligible and choose to participate, they will have a procedure called leukapheresis. The leukapheresis product that is collected from you will be taken to a special lab at MUSC where it will undergo a process that will grow additional dendritic cells under controlled conditions in the lab. These cells will be given together with Poly-ICLC therapy when you begin study treatment. Some days you will receive both Poly-ICLC and dendritic cells, but on other days you will receive the Poly-ICLC by itself. After study treatment, subjects may be asked to return to MUSC approximately every 3 months for the first 2 years, then every 6 months thereafter for follow up procedures.
3294539|NCT01783457|Experimental|Individual psychoeducation|Usual treatment + individual psychoeducational intervention (14 sessions). The psychoeducational programme consists of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
3294540|NCT01783457|Active Comparator|Control|Usual treatment
3294541|NCT01783509||LGMD|Patients with GENETICALLY CONFIRMED limb girdle muscular dystrophy
3294546|NCT01783587|Experimental|High Risk Group|Dose escalation of afatinib + docetaxel + radiation therapy
3294547|NCT01783587|Experimental|Intermediate Risk Group|Dose escalation of afatinib + radiation therapy
3294548|NCT01783600|Other|NanoCross .014 balloon catheter|NanoCross .014 balloon catheter
3294549|NCT01783613|Experimental|Docosahexaenoic acid administration|50 patients will receive docosahexaenoic acid
3294550|NCT01783613|Placebo Comparator|placebo|50 patients will receive placebo
3294551|NCT01783626|Sham Comparator|Evodial|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3294552|NCT01783626|Experimental|Evodial+ Condition B1|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3294553|NCT01783626|Experimental|Evodial+ Condition B2|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3294554|NCT01783626|Experimental|Evodial+ Condition C|Period I: HDF post dilution Total Volume 8 liters : 1 HD session (2nd HD of the week) Period II: HDF post dilution Total Volume 20 liters : 1 HD session (2nd HD of the week)
3294555|NCT01783652|Experimental|Intervention group|Study participants in the intervention group will be given access to an anti-depression website and have four telephone follow-up within the 1-year study period.
3294556|NCT01783652|No Intervention|Control group|Study participants in the control group will not received any depression-related service other than an interactive anti-smoking website provided by the University of Hong Kong.
3294557|NCT01783665|Experimental|Aerobic Exercise|3x/week supervised moderate intensity aerobic exercise on recumbent stepper
3294558|NCT01783665|Active Comparator|Home exercise program|Walking and stretching exercises performed 3x/week for 30 minutes at intensity considered non-aerobic
3294559|NCT01783691|Experimental|NKTT120|
3294560|NCT01783704|Experimental|PUSH and Nutrition|PUSH is a specific multi-component intervention based on improving specific precursors to community ambulation. The intervention addresses endurance with continuous upright exercise for 20 min.; function by improving fast walking, standing from a chair, and stair negotiation; muscle performance by exercising to enhance lower extremity strength; and balance by performing unilateral activities and activities with decreased base of support. Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits take place in the participant's place of residence. Participants also receive the nutritional intervention for the duration of the 16-week study.
3294561|NCT01783704|Experimental|PULSE and Nutrition|PULSE is a non-specific multi-component intervention in which participants will receive flexibility exercises, active range of motion (AROM) for the upper and lower extremities, breathing exercises, and transcutaneous electrical nerve stimulation (TENS). Participants receive 32 visits of approximately 60 minutes in duration from a study PT. Participants will receive up to three visits a week, on non-consecutive days, for 16 weeks. Visits will take place in the participant's place of residence. Participants will also receive the nutritional intervention for the duration of the 16-week study.
3294562|NCT01783717|Experimental|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
3294563|NCT01783756|Experimental|Treatment (lapatinib ditosylate, everolimus, capecitabine)|Patients receive lapatinib ditosylate PO QD and everolimus PO QD on days 1-21, and capecitabine PO BID on days 1-14. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity.
3294564|NCT01783769|No Intervention|Normal O.R. Traffic|"This Normal O.R. Traffic protocol follows the national standards of care."
3294565|NCT01783769|Active Comparator|"Low O.R. Traffic"|"This protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
3294566|NCT01783782|Experimental|DIET|Group A followed the standard regime consisting of a clear liquid diet for 12 hours on the day before CE, followed by an overnight fast.
3294567|NCT01783782|Experimental|HIGH PEG|Group B received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed always by an overnight fast.
3294568|NCT01783782|Experimental|LOW PEG|Group C, defined as a low volume regime, received 25 mL/Kg (up to 1Lt/die) of polyethylene glycol 4000 solution with simethicon solution the evening before the examination, followed by an overnight fast.
3294569|NCT01783782|Experimental|SIMETHICONE|Group D received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion.
3294570|NCT01783782|Experimental|SIMETH+PEG|Group E received 25 mL/Kg (up to 1 Lt/die) of polyethylene glycol 4000 solution with simethicon solution followed by an overnight fast plus 20mL oral simethicone and 200mL water 30 minutes before capsule ingestion.
3294571|NCT01783795|Other|Genetic Analysis|Genetic Analysis
3294572|NCT01783808|Experimental|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
3294573|NCT01783808|No Intervention|Control group|The control group will not get supplemental oxygen during physical activity but they will get the same physical activity intervention as the intervention group.
3294574|NCT01783834|Active Comparator|pemetrexed|pemetrexed
3294575|NCT01783834|Active Comparator|gefitinib|gefitinib
3294576|NCT01783873|Placebo Comparator|Placebo|
3294577|NCT01783873|Active Comparator|flour allergen extract or quaternary ammonium compound|
3294578|NCT01783899|Experimental|Hemospray Group|"Hemospray device consists of a syringe containing the Hemospray powder (21 g per syringe), a delivery catheter that will be inserted into the working channel of the endoscope, and an introducer handle with a built-in carbon dioxide canister to propel the Hemospray powder out of the catheter.~In addition to Hemospray device any other required endoscopic accessories can be used during the procedure."
3294579|NCT01783925||Group 1|
3294580|NCT01783951|Experimental|DC-CIK plus S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone. Meanwhile those patients will receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
3294581|NCT01783951|Active Comparator|S-1 based chemotherapy|Patients will be receive S-1 based chemotherapy, including S-1 plus cisplatin or S-1 alone.Cycles were repeated every 21 days. Treatment was continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
3294582|NCT01783964|Experimental|[14C]-Elacytarabine Microdose|intravenous (IV) administration of one dose of elacytarabine
3294583|NCT01783977|Experimental|Part A: Group 1: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) in the same deltoid at Days 0, 14, and 28.
3294584|NCT01783977|Experimental|Part B: Group 2: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
3294585|NCT01783977|Placebo Comparator|Part B: Group 2: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 14, and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
3294586|NCT01783977|Experimental|Part B: Group 3: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 84.
3294587|NCT01783977|Placebo Comparator|Part B: Group 3: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0 and 28. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 84.
3294588|NCT01783977|Experimental|Part B: Group 4: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the DNA-HIV-PT123 injection was given) at Day 140.
3294589|NCT01783977|Placebo Comparator|Part B: Group 4: Placebo|Participants will receive the placebo vaccine for DNA-HIV-PT123 administered as 1 mL IM in the same deltoid at Days 0, 28, and 56. They will then receive the placebo vaccine for NYVAC-HIV-PT1 and the placebo vaccine for NYVAC-HIV-PT4; each will be administered as 1 mL IM in the same deltoid (opposite deltoid to where the placebo for DNA-HIV-PT123 injection was given) at Day 140.
3294590|NCT01784003||Non-amputee|People without an amputation will be recruited to participate in the study.
3294591|NCT01784003||Below the knee amputee|People with a unilateral transtibial amputation will be recruited to participate in the study.
3294592|NCT01784016|Experimental|Healthy Smokers|Healthy smokers aged 18-50 years reporting average cigarette consumption of 15 or more cigarettes/day for the past year, providing an expired breath carbon monoxide reading exceeding 10 ppm at screening.
3294593|NCT01784016|Experimental|Healthy Nonsmokers|Healthy nonsmoking controls aged 18-50 reporting consumption of <100 cigarettes in their lifetime, none in the last 6 months, providing an exhaled breath carbon monoxide reading of < 9 ppm at screening.
3294594|NCT01784042|Placebo Comparator|No dietary energy restriction plus Placebo|No dietary energy restriction plus Placebo
3294595|NCT01784042|Placebo Comparator|Dietary energy restriction plus placebo|Dietary energy restriction plus placebo
3294596|NCT01784042|Experimental|Lovaza|Lovaza only
3294597|NCT01784042|Experimental|Dietary energy restriction plus Lovaza|Dietary energy restriction plus Lovaza
3294598|NCT01784081||palliative care with iPC3|Palliative care with decision aids will be administered at each palliative care visit.
3294599|NCT01784094||Low back pain subjects|Subjects with chronic or recurrent low back pain
3294600|NCT01784094||No low back pain subjects|Subjects who are generally healthy with no low back pain
3294601|NCT01784107|Experimental|Belotecan and Ifosfamide|
3294602|NCT01784120|Experimental|doxotubicin/Genexol-PM|
3294603|NCT01784133|Active Comparator|omiganan mid dose|omiganan mid dose once daily application for 12 weeks
3294604|NCT01784133|Active Comparator|omiganan high dose|omiganan high dose once daily application for 12 weeks
3294605|NCT01784133|Placebo Comparator|Vehicle group|Vehicle once daily application for 12 weeks
3294606|NCT01784133|Active Comparator|omiganan low dose|omiganan low dose once daily application for 12 weeks
3294607|NCT01784146|Placebo Comparator|Oxygen|
3294608|NCT01784146|Experimental|PEEP + Heliox|
3294609|NCT01784146|Experimental|Oxygen + PEEP|
3294610|NCT01784146|Active Comparator|Heliox|
3294611|NCT01784159|Placebo Comparator|Placebo|Placebo 1tb / day/ 7days
3294612|NCT01784159|Active Comparator|Aspirin|Intervention aspirin 200 mg/day for 7 days
3294613|NCT01784172|Experimental|electroacupuncture group|"Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward. Bilateral B L35 are given acupuncture of 50～60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
3294614|NCT01784172|Experimental|sham electroacupuncture group|"Bilateral sham BL33 and sham BL35 are given sham electroacupuncture with no current output.~Every session lasts for 30 min per day. The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all."
3294615|NCT01784185|Experimental|virtual bronchoscopy guided transbronchial needle aspiration|virtual bronchoscopy guided transbronchial needle aspiration (VB-TBNA)(experimental method) and EBUS-TBNA (reference method) are performed in the same diagnostic session
3294616|NCT01784198|Experimental|Protein Intake|Dietary supplement:Protein intake
3294617|NCT01784224|Experimental|Speaking Valves|"All participants will either have a Blom tracheotomy tube in place or have their current tracheotomy tube changed to a Blom tracheotomy tube to allow for use of both the Blom low profile voice inner cannula and the Passy-Muir one-way speaking valves.~The Blom low profile voice inner cannula and Passy-Muir speaking valves will be provided to participants in a random order. All valves will be placed by the PI. Duration of data collection trials will range from 10 to 30 minutes."
3294618|NCT01784237|Experimental|Anterior meatuscopy|All patients in the study group receive anterior meatoscopy whereas patients in the control group perform a sniff test to select the most patent nostril for nasal anesthesia and transnasal endoscopic insertion.
3294619|NCT01784237|Active Comparator|Nasal sniff test|A sniff test for nasal patency is a common method before ultrathin transnasal esophago-gastro-duodenoscopy (UT-EGD) to select the right or left nostril for insertion.
3294620|NCT01784250|Experimental|Propanolol|Propranolol 40mg tablets, one tablet administered 1 hour before surgery
3294621|NCT01784250|Placebo Comparator|Placebo|Placebo tablets, one tablet administered 1 hour before surgery
3294622|NCT01784250|Experimental|Clonidine|clonidine 150mcg tablets, one tablet administered 1 hour before surgery
3294623|NCT01784263|Experimental|Individual Cognitive Behavioral Therapy|
3294624|NCT01784263|Active Comparator|Standard Community Treatment|
3294625|NCT01784276|No Intervention|Control|Children assigned to Group A (control group) received usual care and therefore had no intervention before or during the return visit.
3294626|NCT01784276|Experimental|Video peer modeling|Video peer modeling (at home, the child watched a DVD recording of a typically developing child undergoing a dental visit);
3294627|NCT01784276|Experimental|Video goggles or portable DVD only|Video goggles/DVD (during the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player);
3294628|NCT01784276|Experimental|Video peer modeling plus video goggles|Video peer modeling plus video goggles/DVD. At home, the child watched a DVD recording of a typically developing child undergoing a dental visit; During the dental visit, the child watched their favorite movie using sunglass style video eyewear, or portable DVD player.
3294629|NCT01784289||normal|Patients with no overweight and no type 2 diabetes
3294630|NCT01784289||lipodystrophy|patients with a lipodystrophy, most are diabetics
3294631|NCT01784289||obese non diabetics|Patients with obesity (BMI <30kg/m2), without diabetes
3294632|NCT01784289||obese diabetics|Patients with obesity (BMI <30 kg/m2), with diabetes
3294633|NCT01784302|Active Comparator|Maalox Plus extra|Subjects will receive doses of raltegravir 400 mg and maalox plus extra
3294634|NCT01784302|Active Comparator|Multivitamin|Subjects will receive doses of raltegravir 400 mg along with a multivitamin tablet
3294635|NCT01784302|Active Comparator|Sodium bicarbonate|Subjects will receive doses of raltegravir 400 mg along with sodium bicarbonate
3294636|NCT01784315||Chloroquine, primaquine and ACT|"Standard dose of Chloroquine( 10mg/kg on day 0 and 5mg/kg on day1 and day2) and Primaquine(0.25mg/kg for 14 days).~Artemisinin combination therapies (ACT) of 4 tablets on 0,8,24,36,48 and 60 hours will be used for Chloroquine resistant P.vivax infection"
3294637|NCT01784328|Other|Use of a bowel irrigation system|Open label. No placebo use in this study. All volunteers will trial the bowel irrigation system. Eligible volunteers will be those patients who have failed conventional supportive bowel care.
3294638|NCT01784354|Placebo Comparator|Education|target education toward Raynaud's
3294639|NCT01784354|Active Comparator|Acupressure|acupressure- dilatation
3294640|NCT01784354|Active Comparator|Acupressure relaxation|acupressure relaxation protocol
3294641|NCT01784367|Experimental|ECLA-group|Treatment with a pump driven, venovenous extracorporeal lung assist
3294642|NCT01784380||the case group|
3294643|NCT01784380||the control group|
3294644|NCT01784380||the treatment group|Patients of the treatment group recieved drugs,then we observed drugs' treatment effect.
3294645|NCT01784406|Experimental|Autonomy-supportive counselling|"2-4 autonomy-supportive conversations with an experienced nurse, educated both theoretically and practically in the method Guided Self-Determination that includes specific reflection sheets and use of advanced communication; in addition to standard care."
3294646|NCT01784406|No Intervention|Control|Standard of care.
3294647|NCT01784432|Active Comparator|Low-level laser therapy and training|Effects of low-level laser therapy on muscle performance during physical strength training and gene expression of muscle tissue.
3294648|NCT01784432|Active Comparator|Training without low-level laser therapy|Effects of physical strength training without low-level laser therapy on muscle performance and gene expression of muscle tissue
3294649|NCT01784445|Experimental|Ceftazidime plus placebo|Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo
3294650|NCT01784445|Active Comparator|Diclophenac sodium plus placebo|Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo
3294651|NCT01784458||intra-abdominal hypertension(IAH)|IAH group : patients developing IAH non-IAH group : patients without IAH
3294652|NCT01784471|Experimental|Magic foot shoe|Magic Foot™ will be dispensed to all subjects. Shoes will be activated at the clinic for 30 minutes. Subjects will self-use and activate the shoes at home daily for 30 days.
3294653|NCT01784484||patients with abnormal liver enzymnes|
3294654|NCT01784497||Recipients of Living Donor Liver Transplantation|Patients who will undergo Living Donor Liver Transplantation (LDLT) In Ain Shams Center For Organ Transplantation (ASCOT) .
3294655|NCT01784510|Active Comparator|2 cm|
3294656|NCT01784510|Experimental|6 cm|
3294657|NCT01784536|Experimental|Oritavancin|Single-Dose IV Oritavancin Diphosphate
3294658|NCT01784549|Active Comparator|Cisplatin Docetaxel|- Cisplatin + Docetaxel day 1 q 21 days for 3 cycles
3294659|NCT01784549|Experimental|Gefitinib Pemetrexed Vinorelbine Gemcitabine|"Gefitinib day for 8 wks;~Pemetrexed day 1 q 21 days for 3 cycles;~Docetaxel day 1 + Vinorelbine days 1,8 q 21 days for 3 cycles;~Docetaxel days 1,8 + Gemcitabine days 1,8 q 21 days for 3 cycles;~Cisplatin + Docetaxel day 1 q 21 days for 3 cycles;~Cisplatin day 1+ Gemcitabine days 1,8 q 21 days for 3 cycles;"
3294660|NCT01784575|Experimental|Patient Navigator Intervention|The Patient Navigator Intervention arm will have two 20 minute interactive sessions with a patient navigator in which they will learn about quality measures and view scores on the Massachusetts Health Quality Partner's website.
3294661|NCT01784575|Active Comparator|Control|The control arm will receive an information pamphlet about health care quality.
3294662|NCT01784601||Control Group|We will be including all patients undergoing shoulder surgery not scheduled for a nerve block.
3294663|NCT01784601||Study Group|We will be including all patients undergoing shoulder surgery scheduled for a nerve block.
3294664|NCT01784627|No Intervention|Treatment at Usual|Participants in this group will receive treatment as usual (TAU) from their provider, which may or may not include screening and brief advice regarding alcohol use.
3379714|NCT05161403|Placebo Comparator|Saline|a piece of gauze moistened with normal saline will be applied directly to the sockets wound for 45 minutes at baseline and on the third & seventh day after extraction of teeth.
3379717|NCT05161377|Active Comparator|Surgical management|
3379718|NCT05161377|Active Comparator|Endovascular management|
3294665|NCT01784627|Experimental|c-ASBI|Participants in this group will receive the computerized alcohol screening and brief intervention (c-ASBI).
3294666|NCT01784640|Experimental|Treatment (Hsp90 inhibitor AUY922, pemetrexed disodium)|Patients receive Hsp90 inhibitor AUY922 IV over 60 minutes weekly and pemetrexed disodium IV over 15 minutes every 3 weeks. Courses repeat every 21 days for 6 months in the absence of disease progression or unacceptable toxicity.
3379719|NCT05161364||A: PFA|partial foot amputation
3379720|NCT05161364||B: PN|peripheral neuropathy
3379721|NCT05161351|Experimental|Baclofen|Participants will receive a single dose of either 10mg, 30mg, 60mg or 90mg of Baclofen administered as oral tablets.
3379722|NCT05161351|Placebo Comparator|Vitamin D3|Participants will receive a single dose of either 20μg, 60μg or 120μg of Vitamin D3 administered as oral tablets.
3379723|NCT05161338|Experimental|FROZEN EMBRYO TRANSFER|Women who undergo an artificial cycle for frozen embryo transfer and receive luteal phase support.
3379724|NCT05161325||Cohort 1|Participants with untreated advanced or recurrent non-small cell lung cancer (NSCLC) receiving first-line nivolumab plus ipilimumab with or without chemotherapy
3294667|NCT01784653|No Intervention|Treatment as Usual|Patients will receive the usual care from the treatment program
3294668|NCT01784653|Experimental|iMET|Participants will complete a self-guided computerized Motivational Enhancement Therapy
3294669|NCT01784653|Experimental|MET|Clinician-delivered Motivational Enhancement Therapy
3294670|NCT01784679||Natural History Prospective Observational Group|
3294671|NCT01784679||Online Registry Patient Reported Group|
3294672|NCT01784692|Placebo Comparator|Placebo|10 participants will be randomized to take 1 capsule of placebo daily.
3294673|NCT01784692|Experimental|Immulina 200 mg/day|10 participants will be randomized to take 200 mg/day of Immulina.
3294674|NCT01784692|Experimental|Immulina 400 mg/day|10 participants will be randomized to take 400 mg/day of Immulina.
3379725|NCT05161312|Experimental|iACT-BC: Oncovox experimental|A guided internet-delivered ACT intervention to improve psychosocial outcomes in BCP diagnosed in the past two years.
3379726|NCT05161312|No Intervention|Wait list control group|Wait list, treatment as usual
3379727|NCT05161299||Control (normal practice)|Patients that underwent surgery (across all specialities), performed by a surgeon in an operating theatre, AND had a positive SARS-CoV-2 PCR swab or rapid antigen test (if PCR swab is not available) within 7 days before or 30 days after surgery. Patients can be included regardless of whether a specific variant is suspected or unknown
3379728|NCT05161286||Healthy pain-free cohort|Healthy pain-free Dutch-speaking men and women between the age of 18 and 65 years
3379729|NCT05161260|Experimental|Yoga Breathing (YB)|A first production version of a mobile application that guides users through proscribed yoga breathing exercises.
3379730|NCT05161260|Experimental|Attention Control|A first production version of a mobile application that guides users through an attention control activity, presented as methods for mindfulness.
3379731|NCT05161247|Experimental|Zona pellucida sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up.~Zona pellucida sperm selection: Spermatozoa are selected according to their ability to adhere to zona pellucida proteins obtained from their partners native zona pellucida.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
3379732|NCT05161247|Active Comparator|Conventional sperm selection|"Semen processing: liquefaction followed by centrifugation and swim-up. Samples are incubated until time of injection.~Conventional sperm selection: Spermatozoa are selected according to their morphology.~Intracytoplasmic sperm injection (ICSI): Each oocyte is injected with a single morphologically normal spermatozoa. The injection procedure is carried out in a sterilized dish using holding pipette and injection needle."
3294675|NCT01784692|Experimental|Immulina 800 mg/day|10 participants will be randomized to take 800 mg/day of Immulina.
3379733|NCT05161221|Active Comparator|Pre-operative femoral nerve catheter|participants undergoing ACL reconstruction surgery will receive a femoral prior to their surgery
3294676|NCT01784705|Experimental|Transcranial bright light therapy|
3294677|NCT01784705|Placebo Comparator|Transcranial placebo treatment|
3294678|NCT01784731||Patients|
3294679|NCT01784744||ASD Control|Patients aged 5 to 17 diagnosed with ASD.
3294680|NCT01784744||ASD Case|Patients diagnosed with ASD aged 5 to 17 with a history of amelioration of symptoms during febrile episodes.
3294681|NCT01784757|Experimental|ODM-201 Tablet A|ODM-201 tablet A in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
3294682|NCT01784757|Experimental|ODM-201 Tablet B|ODM-201 Tablet B in fed and fasted states plus ODM-201 capsule in fed state in randomised order.
3294683|NCT01784783|Experimental|HOPE Intervention|"Pregnant women and their male partners will receive home-based couple HIV testing and counseling and partner education 1-2 weeks after enrollment. The intervention will include educational messages concerning socio-behavioral, condom-based, and treatment-oriented approaches to prevention of horizontal and vertical HIV transmission, based on the status of each of the partners. The couple will also be educated about the importance of facility delivery, exclusive breastfeeding, family planning, and post-partum contraception.~During the HOPE Intervention, the purpose and design of the study will be explained to male partners. Men will be asked to provide written informed consent for study participation. Provided they consent, men will complete a questionnaire asking for sociodemographic characteristics, medical and sexual history, behavioral data and information on prior HIV testing and counseling."
3379734|NCT05161221|Active Comparator|Pre-operative adductor canal block with liposomal bupivacaine|participants undergoing ACL reconstruction surgery will receive a nerve block using liposomal Bupivacaine (Exparel)
3379735|NCT05161208|Experimental|OC-01 (varenicline 0.6mg/ml) nasal spray|Intranasal delivery of OC-01 nasal spray twice daily (BID)
3379736|NCT05161208|Placebo Comparator|Placebo (vehicle) nasal spray|Intranasal delivery of placebo vehicle nasal spray twice daily (BID)
3379737|NCT05161195|Other|Ribociclib|All participants will receive ribociclib in combination with other drugs at the same dose/schedule as in the parent study.
3379738|NCT05161182|Experimental|High fat, low carbohydrate diet|
3379739|NCT05161182|Experimental|Low fat, high carbohydrate diet|
3379740|NCT05161169|Experimental|Sequencing cohort|Infants receive genome sequencing with analysis of approximately 1000 genes associated with childhood-onset and highly actionable adult-onset disease risks. Pathogenic and likely pathogenic variants are reported to the child's parents and pediatrician. Participants also receive a detailed family history report and standard well-child care.
3379741|NCT05161169|No Intervention|Control cohort|Infants receive a detailed family history report plus standard well-child care.
3379742|NCT05161156|Experimental|Treatment A: 18 mcg of Test Product (tiotropium bromide inhalation powder)|2 inhalations of test product, followed by 2 inhalations of reference placebo product
3379743|NCT05161156|Active Comparator|Treatment B: 18 mcg of Reference Product (Spiriva)|2 inhalations of reference product, followed by 2 inhalations of test placebo product
3379744|NCT05161156|Placebo Comparator|Treatment C: Zero-dose (Placebo)|2 inhalations of reference placebo powder, followed by 2 inhalations of test placebo product
3379745|NCT05161143|Experimental|Experimental: Donafenib plus TACE|"Donafenib: 4-8 weeks after radical surgery,patients will take donafenib, 200mg Bid,at least 6 months.~TACE:4-8 weeks after radical surgery,Patients will receive TACE once."
3379746|NCT05159700|Experimental|Monotherapy Escalation|3+3 Dose escalation arm with PRJ1-3024 which will begin with 2 subjects treated at the lowest planned dose level PRJ1-3024 is administered orally once daily. The starting dose is 80mg/day.
3379747|NCT05156281|Experimental|Remibrutinib - Core|Remibrutinib tablet and matching placebo of teriflunomide capsule
3379748|NCT05156281|Active Comparator|Teriflunomide - Core|Teriflunomide capsule and matching placebo remibrutinib tablet
3379749|NCT05156281|Experimental|Remibrutinib - Extension|Participants on remibrutinib in Core will continue on remibrutinib tablet
3379750|NCT05156281|Experimental|Remibrutinib - Extension (on teriflunomide in Core)|Participants on teriflunomide in Core will switch to remibrutinib tablet
3379755|NCT05154994|Experimental|Treatment (durvalumab, tremelimumab, belinostat)|Patients receive durvalumab IV over 30 minutes on day 1. Patients also receive tremelimumab IV over 60 minutes on day 1 of cycle 1. Beginning cycle 2, patients receive belinostat IV over 30 minutes on days 1-5. Treatment repeats every 21 days for 7 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 30 minutes on day 1. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3379756|NCT05152147|Active Comparator|Arm A|Trastuzumab (Herceptin®) plus physician's choice of capecitabine plus oxaliplatin (CAPOX) or 5-fluorouracil (5-FU) plus cisplatin (FP)
3379757|NCT05152147|Experimental|Arm B|Zanidatamab plus physician's choice of CAPOX or FP
3379758|NCT05152147|Experimental|Arm C|Zanidatamab and tislelizumab plus physician's choice of CAPOX or FP
3379767|NCT05144841|Experimental|MK-2140 (zilovertamab vedotin)|Participants will receive treatment with zilovertamab vedotin 2.5 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) up to 16 cycles.
3379768|NCT05144659|Active Comparator|Double faced transverse preputial onlay island flap (group A)|Thirty-four patients undergo double faced transverse preputial onlay island flap are categorized as (group A)
3379769|NCT05144659|Active Comparator|transverse inner preputial onlay island flap (control group) (group B)|Another thirty-four patients undergo transverse inner preputial onlay island flap are categorized as the control group = (group B)
3379770|NCT05144542|Active Comparator|Group A (usual brand cigarettes)|Participants smoke their usual brand of cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 1, 6, 12, and 26 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
3294684|NCT01784783|Experimental|INVITE Intervention|Pregnant women will be tested and encouraged to bring their male partners to the antenatal clinic for testing. Women will receive a clinic invitation to give to their male partners to attend the next visit for couple HIV counseling and testing. The couples will also be offered the relevant components of the intervention at the final study visit, 6 months postpartum.
3294685|NCT01784809|Experimental|Multimedia HIV/STI prevention|Multimedia WORTH is a 4-session group based gender specific HIV and drug abuse prevention intervention.
3294686|NCT01784809|Active Comparator|Traditional HIV/STI prevention|Traditional WORTH is a 4-session group-based HIV/STI and drug abuse prevention intervention that covers the same content as Multimedia WORTH without the use of interactive videos, computerized assessments, and other audiovisual tools.
3294687|NCT01784809|Placebo Comparator|Wellness Promotion|Wellness Promotion is a 4-session group based intervention that aims to improve diet, physical fitness and well-being which is designed as an attentional control condition.
3294688|NCT01784822||Zenapro™ Hybrid Hernia Repair Device|Device to be used to reinforce or bridge the abdominal wall for the repair of ventral hernias.
3294689|NCT01784835|Other|control|patients under standard medical care
3294690|NCT01784835|Experimental|OMT|patients under usual medical care plus osteopathic treatment
3294691|NCT01784874|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg) Serum Free
3294692|NCT01784874|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies
3294693|NCT01784887|Active Comparator|Bioelectric Dressing|SOC + Bioelectric Dressing
3294694|NCT01784887|No Intervention|SOC|Standard of Care
3294695|NCT01784900|Experimental|Schema B (140µg)|"D0 : 20 μg of catumaxomab~D2 : 40 μg~D4 : 80 μg"
3294696|NCT01784900|Experimental|Schema A (100µg)|"D0 : 10 μg of catumaxomab~D2 : 30 μg~D4 : 60 μg"
3294697|NCT01784913|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally at the same injection in the lower abdomen.
3294698|NCT01784939||HEPFER cohort|"male, aged 18 and over, hereditary hemochromatosis C282Y homozygous diagnosed and followed in the service of Liver Diseases, University Hospital of Rennes~- Maintenance therapy with phlebotomy for at least 1 year with stable iron stock on the basis of at least four previous plasma ferritin < 50μg / L"
3294699|NCT01784952|Experimental|Whole grains and lequmes|
3294700|NCT01784952|Placebo Comparator|refined rice|
3294701|NCT01784978|Experimental|Rotational arm|Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.
3294702|NCT01784978|Active Comparator|Sequential arm|The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.
3294703|NCT01785004|Active Comparator|Vitamin D + fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3294704|NCT01785004|Active Comparator|Vitamin D + fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
3294705|NCT01785004|Active Comparator|Vitamin D placebo + fish oil|Vitamin D placebo and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
3294706|NCT01785004|Placebo Comparator|Vitamin D placebo + fish oil placebo|Vitamin D placebo and fish oil placebo
3294707|NCT01785017||Chidren with critical asthma|Pre- and post-SCAMP
3294708|NCT01785030|Experimental|50% Nitrous oxide|
3294709|NCT01785043|Experimental|Liraglutide|Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day. The starting dose will be 0.6 mg. After one week, the dose will be increased to 1.2 mg, and then it will be increased to 1.8 mg one week later to achieve better control of blood glucose. When Liraglutide is added to existing treatment containing metformin, as it is our scenario, the dose of metformin does not have to be changed.
3294710|NCT01785043|Active Comparator|Sitagliptin|"Sitagliptin will be administered once daily at a 100 mg dose. When Sitagliptin is used in combination with metformin, as it is our scenario, the dose of metformin should be maintained. If a dose of Sitagliptin is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.~Sitagliptin will be used daily during the study period of 12 weeks."
3294711|NCT01785056|Experimental|Privigen|Privigen is a ready-to-use, sterile, 10% protein liquid preparation of polyvalent human immunoglobulin G (IgG) for intravenous administration. Subjects will be given 2 g/kg/month of IVIGfor 6 months. Each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
3294712|NCT01785056|Placebo Comparator|Placebo (Albuminar-5)|Albuminar-5 is a sterile solution of albumin obtained from large pools of adult human venous plasma and used as the placebo in this study. Albuminar-5 will be administered by the intravenous route and each dose will be split into 2 to 4 infusions on consecutive days to achieve the total monthly dose.
3294713|NCT01785082|Experimental|LiMAx-group|Intravenous pre- and post-surgical injection of 0.4% 13-C-Methacetin solution. Dosage is adapted due to body weight (2 mg/kg). A LiMAx-test of >150 µg/kg/h would correspond to a general ward indication.
3294714|NCT01785082|No Intervention|control group|Control group without intervention. Post-surgical management as defined prior to surgery following well-established clinical standards.
3294715|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg, Vitamin D and Ibuprofen|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450~Ibuprofen, 400 mg/day, from Day 1 to Day 90"
3294716|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20µg and Vitamin D|"GAD-Alum (Diamyd) 20 µg given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
3294717|NCT01785108|Active Comparator|GAD-Alum (Diamyd) 20 µg x 2 and Vitamin D|"GAD-Alum (Diamyd) 20 µg X 2 given twice with one month interval~Vitamin D oral drops, 2000 IU/day, from Day 1 to Day 450"
3294718|NCT01785108|Placebo Comparator|Placebo|
3294719|NCT01785121|Active Comparator|Control Group|Patients who are randomized to the MSO group will get a protocoled exercise advice from a member of the HF team (nurse, cardiologist or physiotherapist). During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their current activity.
3294720|NCT01785121|Experimental|Wii Group|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
3294721|NCT01785147|Experimental|BP1.4979 3mg|BP1.4979 3mg during 3 months
3294722|NCT01785147|Experimental|BP1.4979 10mg|BP1.4979 10mg during 3 months
3294723|NCT01785147|Experimental|BP1.4979 15mg|BP1.4979 15mg during 3 months
3294724|NCT01785147|Placebo Comparator|Placebo|Placebo during 3 months
3294725|NCT01785173|Experimental|Endoscopic-guided gauze pledgetting|All patients in the study group receive endoscopic-guided gauze pledgetting (EGGP) nasal anesthesia. Each patient will receive an anterior rhinoscopy to select the most patent meatus for gauze pledegetting by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up the acute angle between the shorter leg and hypotenuse of a right-angled gauze strip (already soaked with anesthesia/decongestant) and retract back just into the biopsy channel. When the transnasal endoscope tip is set in the nasal vestibule, the preloaded biopsy forceps is protruded slowly into the desired meatus under endoscope monitoring. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3294726|NCT01785173|Active Comparator|Cotton-tipped applicator pledgetting|"Another randomized group of patients will receive cotton-tipped applicator gauze pledgetting (CTGP) method of nasal anesthesia. Two cotton-tippled applicators help determine the following: (a) right or left side, (b) inferior or middle nasal meatus (INM or MNM) and (c) the need of local epinephrine. The investigators apply gently in parallel two sterile 3 x 1/10, double-ended, plastic shaft cotton-tipped applicators, pretreated with minimal amount of 2% viscous lidocaine plus 4% liquid lidocaine, to lubricate and anesthetize the more patent meatus One cotton-tipped applicator is re-used to deliver a triangular gauze strip to the selected meatus during the gauze pledgetting procedure."
3294727|NCT01785199|Placebo Comparator|normal (AHI < 5)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3294728|NCT01785199|Active Comparator|mild OSA (AHI between 5 and 15)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3294729|NCT01785199|Active Comparator|moderate OSA (AHI between 15 and 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3294730|NCT01785199|Active Comparator|severe OSA (AHI > 30)|Patients who are eligible for this study will sleep on an automatic adjustable bed with a second PSG performed within the next one month.
3294731|NCT01785212|Other|Stapler-hepatectomy|The liver parenchyma is crushed with a Pean clamp and subsequently divided using Covidien Endo-Gia™ Ultra Handle Short Staplers and Endo Gia™ TRI staple 60 mm or 45 mm AVM/AMT loading units (Covidien). Hepatic veins and portal pedicles clamped and suture ligated.
3294732|NCT01785212|Other|CUSA-hepatectomy|The liver parenchyma is divided along the transection line by CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO) and bipolar forceps in a two surgeon technique. Vessels of less than 2 mm in diameter are coagulated with bipolar forceps. The remaining vessels are clipped or ligated. Hepatic veins and portal pedicles clamped and suture ligated.
3294733|NCT01785225|Experimental|modified commercial drape Tegaderm (R)|
3294734|NCT01785238|Experimental|cases with neonatal acute renal failure in preterm|
3294735|NCT01785238|Other|controls without neonatal acute renal failure in preterm|
3294736|NCT01785251|Experimental|NMES|Application of neuromuscular electrical stimulation to the calf muscles of the patient in order to elicit contraction of the calf muscle pump and thus, eject venous blood proximally.
3294737|NCT01785264|Active Comparator|Open surgery|Treatment is divided into three arms, and patients between 18 and 60 years of age sustaining first time achilles tendon ruptures will be invited to participate. All three groups will have identical rehabilitation protocol. Open surgical repair is done through a 10 cm longitudinal incision, through the fascia curries and the paratenon. After necessary revision of the injure site, the tendons ends is sutured with a double layer, three knot, Krakow whip suture technique. 5 to 10 degrees of overcorrection compared to the uninjured side is endeavored. The paratenon is sewn as much as possible back over the injure site and suture material. The fascia is sutured and then continuous lying mattress skin suture.
3294738|NCT01785264|Active Comparator|Non-operative treatment|Non-operative treatment starts with casting the ankle in equinus position. The rest of the treatment from there on will be identical to the two other arms: Minimal invasive and open surgery. Casting lasts for 2 weeks for all three arms.
3294739|NCT01785264|Active Comparator|Mini-invasive surgery|Patients allocated to mini-invasive treatment will (as patients treated with open surgery) be operated within 7 days from injury with the technique developed by Dr Amlang and Prof Zwipp in Dresden. Patients in all three arms will have an active, early weight bearing rehabilitation protocol.
3294740|NCT01785277||SCIM scores for patients with SCI|All patients with SCI included in the study
3294741|NCT01785290|Experimental|Haloperidol 1mg/q8h|Prophylactic haloperidol of 1 mg/q8h i.v.
3294742|NCT01785290|Experimental|Haloperidol 2mg/q8h|Prophylactic haloperidol 2mg/q8h i.v.
3294743|NCT01785290|Placebo Comparator|Sodium chloride 0.9%|Placebo (Sodium chloride 0.9%) three times a day
3294744|NCT01785303|Active Comparator|Model A|Model A consists of a 4 session CBT-I in phase I and CPAP for OSA in Phase II.
3294745|NCT01785303|Active Comparator|Model B|Model B consists of 4 weeks of monitoring using sleep diaries in Phase I. Phase II consists of concurrent initiation of CBT-I and CPAP for OSA.
3294746|NCT01785303|Other|Model C|Model C consists of 4 weeks of monitoring with sleep diaries in Phase I. Phase II consists of CPAP for OSA.
3294747|NCT01785316|Experimental|IHP|Isolated Hepatic Perfusion
3294748|NCT01785316|No Intervention|BAC|Best alternative care
3294749|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose A|"alirocumab SAR236553 (REGN727) - Dose A - Injection in healthy subjects through subcutaneous administration in the abdomen.~alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)"
3294750|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose B|alirocumab SAR236553 (REGN727) - Dose B - Injection in healthy subjects through subcutaneous administration in the upper arm.
3294751|NCT01785329|Experimental|alirocumab SAR236553 (REGN727) - Dose C|alirocumab SAR236553 (REGN727) - Dose C - Injection in healthy subjects through subcutaneous administration in the thigh.
3294752|NCT01785342||Indeterminate Pulmonary Nodule|The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
3294753|NCT01785355||Dental treatment|Assessment of the clinical state of the patient. Professional prophylaxis and removal of calculus. Extraction of hopeless teeth.Education of patient for oral hygiene. Periodic reevaluation.
3294754|NCT01785368|Other|Before guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period BEFORE the implementation of the referral guidelines.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Baseline observation"
3294755|NCT01785368|Other|After guideline implementation|"This study population consists of all patients for whom a participating ER doctor requests an imaging exam during the observation period AFTER the implementation of the referral guideline.~[This study is composed of (1) a period of observation for 1 month BEFORE the implementation of the referral guidelines, followed by (2) the implementation of the referral guidelines, then (3) a 5-6 month washout period, and finally (4) a 1 month observational period AFTER the implementation of the referral guidelines.]~Intervention: Implementation of guidelines"
3294756|NCT01785381|No Intervention|usual care|usual care
3379771|NCT05144542|Experimental|Group B (e-cigarettes)|Participants vape e-cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood, and log daily smoking activity every day for up to 182 days. Participants complete questionnaires over 50 minutes and undergo collection of urine sample at 1, 6, 12, and 26 weeks, and collection of blood samples at 6, 12, and 26 weeks. Participants may also undergo measurement of CO levels at 1, 6, 12, and 26 weeks.
3379772|NCT05144035|Experimental|GH treatment group|GH treatment group (n = 68): the subjects were given PEG-rhGH injection 0.2 mg / kg / week (initial dose), once a week, subcutaneously before going to bed for 104 weeks. Each follow-up, the researchers adjusted the dosage according to the IGF-1 results of the center and other individual conditions.
3294757|NCT01785381|Other|Added value of coordinator|Added value of coordinator
3294758|NCT01785394|Active Comparator|5 grass allergen extract|30 patients will receive the active component 5 grass allergen extract daily during the active pollen season (February-July)
3294759|NCT01785394|Placebo Comparator|Placebo|30 patients will receive placebo
3294760|NCT01785407|Active Comparator|80 mg FeSO4|
3379773|NCT05144035|No Intervention|Control group|Control group (n = 68): no treatment, only follow-up examination and growth and development related evaluation, and the follow-up time was 104 weeks.
3379774|NCT05143450|Experimental|Experimental Group|Before the procedure, manual pressure will be applied to the injection site with the thumb for 10 seconds to the infants by the researcher.
3294761|NCT01785407|Active Comparator|40 mg FeSO4|40 mg FeSO4
3294762|NCT01785407|Active Comparator|160 mg FeSO4|
3379775|NCT05143450|No Intervention|Control Group|No intervention will perform to reduce pain in the control group.
3379776|NCT05143073|No Intervention|No educational materials|No educational materials will be provided.
3379777|NCT05143073|Active Comparator|Alcohol use disorder and strategies to reduce risk|The information provided to participants will be related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies. The content is based on information from National Institute of Alcohol Abuse and Alcoholism websites, Mayo Clinic websites, and the National Survey on Drug Use and Health.
3379778|NCT05143073|Active Comparator|Complex polygenic risk scores, alcohol use disorder, and strategies to reduce risk|The information provided to participants will explain polygenic risk scores by discussing genetic variation, risk variants, how polygenic scores are created, and how they can be interpreted. The participants will also receive the same information related to alcohol use disorder, including a definition, prevalence, consequences, risk factors, and risk-reducing strategies.
3379779|NCT05143021||Pregnant Women with Sickle Cell Disease|Pregnant women with sickle cell disease from the 3 centers in Ghana
3294763|NCT01785407|Active Comparator|240 mg FeSO4|
3294764|NCT01785420|Experimental|Drug Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
3294765|NCT01785420|Placebo Comparator|Control|A 90 minute intravenous infusion of saline as placebo
3294766|NCT01785433|Experimental|Treatment ABCD|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day"
3294767|NCT01785433|Experimental|Treatment BDAC|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day"
3294768|NCT01785433|Experimental|Treatment CADB|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day"
3294769|NCT01785433|Experimental|Treatment DCBA|"The following treatments are to be studied in a 4-period, crossover design with once daily (QD) dosing for 7 days and at least 21 day washout period between treatments:~Treatment D: Spiriva® Respimat® 5 mcg/day~Treatment C: SPIRIVA® HandiHaler® 18 mcg/day~Treatment B: Tiotropium HFA BAI 9.0 mcg/day~Treatment A: Tiotropium HFA BAI 4.5 mcg/day"
3294770|NCT01785446|Active Comparator|P 1|"In this group patients were aged from 20 to 45. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3294771|NCT01785446|Active Comparator|P 2|"In this group patients were aged from 46 to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3294772|NCT01785446|Active Comparator|P 3|"In this group patients were aged from 66 to 85. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3294773|NCT01785446|Active Comparator|D|"In this group patients were aged from 46to 65. Propofol infusion was used to maintain Bispectral Index (BIS) between 45 and 55.~Dexmedetomidine infusion is started at induction,a bolus dose of 0.5 µg/kg is given over the first hour which is followed by infusion of 0.4 µg/kg/hr.~Intermittent doses of sufentanil 10-20 microgram were given intra-operatively on a required basis."
3294774|NCT01785485||Primary care patients|Primary care patients who are members of UAIHC.
3294775|NCT01785498|No Intervention|Control Group|Receive standard clinical care and supports.
3294776|NCT01785498|Experimental|Supplementary resources|Receive standard care and supports plus supplementary resources developed for the intervention.
3294777|NCT01785511|Sham Comparator|Sham UVA|sham exposure will be provided by covering the UVA lamps with space blanket.
3294778|NCT01785511|Experimental|UVA Radiation|Patients will be exposed to UVA radiation for 20 minutes
3294779|NCT01785537||E-cigarettes only|Smokers of e-cigarettes containing nicotine only (non smoking traditional cigarettes and inhaling at least 50 puffs per week since six or more months). This group will be further split in the secondary analyses: never or former smokers of traditional cigarettes
3294780|NCT01785537||Traditional cigarettes only|Smokers of traditional cigarettes only (smokers of at least one traditional cigarette per day since six or more months). This group will be further split in the secondary analyses: recent and older smokers.
3294781|NCT01785537||Mixed group|Smokers of both electronic and traditional cigarettes (at least one per day since six or more months). This group will be further split in the secondary analyses: mixed smokers who quit and who did not quit traditional cigarette smoking during follow-up
3294782|NCT01785550||Control Group|No intervention to be performed.
3294783|NCT01785550||Ultrasound Group|All will receive nerve and muscle ultrasound.
3294784|NCT01785563|Experimental|Nasal NIV-NAVA|Infants will be transitioned from their current mode of ventilation to nasal NIV-NAVA. If patients are currently on nasal NIV-NAVA an increase in the NAVA level will be utilized for the intervention.
3294785|NCT01785576|Experimental|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
3294786|NCT01785576|No Intervention|Treatment as Usual|The treatment as usual group will complete all assessements and will not receive the psychosocial couple based intervention.
3294787|NCT01785589|Other|coronary angiography-FFR-CZT|Patients who were referred to our cardiology department for stress-rest CZT SPECT for known or suspected CAD and submitted for a clinical reason to invasive coronary angiography within 2 month of the SPECT studies. for these patients, A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
3294788|NCT01785641|Experimental|ceftazidime+ciprofloxacin|2 synergistic antibiotics(ceftazidime IP and ciprofloxacin po for gram negative bacterial peritonitis)
3294789|NCT01785641|Active Comparator|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
3294790|NCT01785641|Experimental|cefazolin+gentamicin|cefazolin IP and gentamicin IP for gram positive bacterial peritonitis
3294791|NCT01785641|Active Comparator|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
3294792|NCT01785654||reventilation collapse|
3294793|NCT01785667||Young Danish adults with type 1 diabetes|This is an observational study with no interventions.
3294794|NCT01785693|Other|NaC1|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
3294795|NCT01785693|Other|Levobupivacaine + clonidine|The aim of this study is to assess, in patients scheduled for femoropopliteal bypass, the benefit of a double peripheral nerve block (femoral + sciatic) with levobupivacaine and clonidine in a single dose, performed before induction of general anaesthesia, on analgesia postoperatively assessed by morphine consumption.
3294796|NCT01785719|Experimental|Overweight Women|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
3294797|NCT01785732|Active Comparator|Renal denervation|Patients are randomized to renal denervation
3294798|NCT01785732|No Intervention|Optimization of medical therapy|Antihypertensive treatment is optimized
3294799|NCT01785745|Active Comparator|Traditional therapeutic exercise|The traditional exercise protocol contains mainly strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance.
3294800|NCT01785745|Experimental|Neurocognitive therapeutic exercise|The neurocognitive exercise protocol contains ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture).
3294801|NCT01785758|Experimental|Renal Group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
3294802|NCT01785758|Active Comparator|Control group|Sugammadex (4mg/Kg) single dose to reverse profound neuromuscular blockade
3294803|NCT01785771|Experimental|ITCA 650|
3294804|NCT01785784|Experimental|burn patients|
3294805|NCT01785797|No Intervention|Control: burr hole drainage only|Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
3294806|NCT01785797|Experimental|Intervention: silicon subdural drain|Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.
3294807|NCT01785823|Experimental|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr
3294808|NCT01785823|Active Comparator|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the decremental rates of 6.0 ml/hr (D6-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
3294809|NCT01785823|Active Comparator|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at at the decremental rates of 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr,
3294810|NCT01785836|Experimental|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3294811|NCT01785836|Experimental|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3294812|NCT01785836|Experimental|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3294813|NCT01785836|Active Comparator|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
3294814|NCT01785862|Experimental|Drug|V0498, Ibuprofen 25 mg
3294815|NCT01785862|Placebo Comparator|Placebo|Placebo
3294816|NCT01785888||Locally advanced/metastatic NSCLC pts.|Patients(pts.) with locally advanced (stage IIIA/B) or metastatic NSCLC who have not received any local or systemic chemotherapy, and are not eligible for curative treatment (including surgery and chemoradiotherapy)
3294817|NCT01785901||Target subject population 1500|Asthma patients who have already received the treatment of budesonide/formoterol by physicians' determination and whose medications are aligned with the package insert of budesonide/formoterol approved in China
3294818|NCT01785914||1|
3294819|NCT01785927|Other|ABCD|ABCD A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3294820|NCT01785927|Other|BCDA|BCDA A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3294821|NCT01785927|Other|CDAB|CDAB A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3294822|NCT01785927|Other|DABC|DABC A = rifampicin, B = isoniazid, C= pyrazinamide, D = levofloxacin
3294823|NCT01785940|Experimental|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
3294824|NCT01785953||1|
3294825|NCT01785966|Experimental|Daily checklist and clinician prompting|Checklist during multidisciplinary daily visits + clinician prompting + audit & feedback
3294826|NCT01785966|No Intervention|Usual care|Usual care
3294827|NCT01785979|Experimental|Prednisone induction - chloroquine|0.5 mg/Kg daily of prednisone for 4 weeks after randomization, 0.25 mg daily for weeks 5-6, 0.15 mg daily for week 7 and 2.5 mg daily for week 8 and chloroquine at a fixed dose (300 mg base per week) for months 1-12
3294828|NCT01785979|Active Comparator|chloroquine|chloroquine at a fixed dose (300 mg base per week) for months 1-12
3294829|NCT01785992|Other|Irosustat (Single arm study)|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or the development of unacceptable toxicities.
3294830|NCT01786005|Sham Comparator|Sham|Imitation of stimulation.
3294831|NCT01786005|Experimental|High-frequency stimulation|High-frequency stimulation
3294832|NCT01786005|Experimental|TBS Theta burst stimulation|TBS Theta burst stimulation
3294833|NCT01786005|Experimental|Low-frequency stimulation|Low-frequency stimulation
3294834|NCT01786018|Experimental|1|"Thiotepa 5 mg/kg/day on days -7, -6 (Total Dose 10 mg/kg)~Busulfan (i.v.) 3.2 mg/kg on days -5,-4,-3 (Total Dose 9.6 mg/kg)~Fludarabin: 50 mg/m2/day on days -5,-4,-3 (Total Dose 150 mg/m2)"
3294835|NCT01786031|Experimental|experimental|metastasis biopsy
3294836|NCT01786044|Experimental|MasterMed|MasterMed, an online interactive educational program
3294837|NCT01786044|Placebo Comparator|Usual care|Access to an online patient portal
3294838|NCT01786057|Active Comparator|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
3294839|NCT01786057|Placebo Comparator|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
3294840|NCT01786070|Active Comparator|Budesonide|Budesonide : 1 mg/4ml every 12 hrs for 48 hrs
3379780|NCT05142696|Experimental|Dose Level 1 (DL1)|Dose Level 1 (DL1): [177Lu]Lu-DOTA-TATE 100 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 100 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3294841|NCT01786070|Placebo Comparator|Placebo|Normal saline at an equivalent volume (4 ml every 12 hrs for 48 hrs)
3294842|NCT01786083|Experimental|Lifestyle counseling|Application of Problem Solving Technique
3294843|NCT01786083|No Intervention|No counseling|Usual care by caregiver
3379781|NCT05142696|Experimental|Dose Level 2a (DL2a)|Dose Level 2a (DL2a): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 150 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3294844|NCT01786096|Experimental|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
3294845|NCT01786122|Experimental|Exercise group|supervised exercise program education program on healthy habits Pharmacological treatment and selfcare encouragement
3294846|NCT01786122|No Intervention|control group|Pharmacological treatment and selfcare encouragement.
3379782|NCT05142696|Experimental|Dose Level 2b (DL2b)|Dose Level 2b (DL2b): [177Lu]Lu-DOTA-TATE 150 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3379783|NCT05142696|Experimental|Dose Level 3a (DL3a)|Dose Level 3a (DL3a): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 200 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3379784|NCT05142696|Experimental|Dose Level 3b (DL3b)|Dose Level 3b (DL3b): [177Lu]Lu-DOTA-TATE 200 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3379785|NCT05142696|Experimental|Dose Level 4 (DL4)|Dose Level 4 (DL4): [177Lu]Lu-DOTA-TATE 250 mCi Q6W with carboplatin AUC 5 D1, etoposide 100 mg/m2 D1-3 Q3W, and tislelizumab 200 mg Q3W in induction period, then [177Lu]Lu-DOTA-TATE 250 mCi Q3W plus Tislelizumab 200 mg Q3W in the maintenance period.
3379786|NCT05142254|Experimental|Tadalafil and Hydroxyurea|Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day
3379787|NCT05142254|Placebo Comparator|Placebo and Hydroxyurea|Placebo and Hydroxyurea 20 mg/kg/day
3379788|NCT05141903||Arm 1|Antibiotic conditioning
3379789|NCT05141903||Arm 2|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
3379790|NCT05141903||Arm 3|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
3379791|NCT05141903||Arm 4|Antibiotic conditioning, Dose ranging of dietary supplement with and probiotic.
3379792|NCT05141903||Arm 5|Antibiotic conditioning and probiotic treatment.
3379793|NCT05141838|Experimental|Group 1 - Vitamin D|Patients receiving vitamin D supplements in therapy
3294847|NCT01786135|Experimental|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
3294848|NCT01786200|Active Comparator|Aspirin|20 patients randomised to aspirin 75mg PO once daily
3379794|NCT05141838|Experimental|Group 2 - Oral nutritional supplement|Patients receiving oral nutritional supplement
3379795|NCT05141838|Experimental|Group 3 - Vitamin D+Oral nutritional supplement|Patients receiving vitamin D supplements and oral nutritional supplement in therapy
3294849|NCT01786200|Active Comparator|Ibuprofen|20 patients randomised to ibuprofen 400mg PO three times daily
3294850|NCT01786200|No Intervention|Control|20 patients randomised to receive no treatment
3294851|NCT01786213||Colonoscopist A|
3294852|NCT01786213||Colonoscopist B|
3294853|NCT01786213||Colonoscopist C|
3379796|NCT05141838|No Intervention|Group 4 - No intervention|Patients with dystrophic form of congenital epidermolysis bullosa who have not taken vitamin D supplements and/or oral nutritional supplement
3294854|NCT01786213||Colonoscopist D|
3294855|NCT01786213||Colonoscopist E|
3294856|NCT01786213||Colonoscopist F|
3294857|NCT01786213||Colonoscopist G|
3294858|NCT01786213||Colonoscopist H|
3294859|NCT01786213||Colonoscopist I|
3294860|NCT01786213||Colonoscopist J|
3294861|NCT01786226|Experimental|Mifepristone 2.5 mg daily for three months|Experimental: 1
3294862|NCT01786226|Experimental|Mifepristone 5 mg daily for three months|Experimental: 2
3294863|NCT01786278|Experimental|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
3294864|NCT01786278|Other|Endoscopic Stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
3294865|NCT01786291||CPAP compliant|CPAP (continuous positive airway pressure) compliant patients
3294866|NCT01786291||CPAP non-compliant|patients who did not use CPAP therapy
3294867|NCT01786304||Fecal incontinence|Patient with fecal incontinence and referred for a treatment with sacral nerve stimulation
3294868|NCT01786317||Fecal incontience|Patient with fecal incotinence who will be explored using high resoltuion manometry
3294869|NCT01786317||Healthy controls|Healthy volunteers who will be explored using high resoltuion manometry
3294870|NCT01786356|Other|HOYA iMics Y-60H|eyes with implanted intraocular lens HOYA iMics Y-60H
3294871|NCT01786356|Other|B&L MI60|eyes with implanted intraocular lens B&L MI60
3294872|NCT01786369||Admitted Patients with Acute Psychosis|Patients 18 years of age or older with a documented diagnosis of schizophrenia, schizoaffective disorder, or bipolar 1 disorder who are admitted to an inpatient psychiatric unit at Zucker Hillside Hospital for a psychotic compensations. Patients must have been in the outpatient setting for at least one month prior to admission on a regimen including risperidone, olanzapine, quetiapine, paliperidone or aripiprazole.
3294873|NCT01786382|Experimental|midazolam|potential effects of PPI-668 on midazolam pharmacokinetics
3294874|NCT01786382|Experimental|omeprazole|potential effects of PPI-668 on omeprazole pharmacokinetics
3294875|NCT01786382|Experimental|telaprevir|potential effects of PPI-668 on telaprevir pharmacokinetics
3294876|NCT01786395|Experimental|- UF-021|UF-021 is experimental code for isopropyl unoprostone
3294877|NCT01786395|Placebo Comparator|- Placebo|
3294878|NCT01786408|Experimental|TAP20-C|Single Use Integrated Capillary Blood Collection System
3294879|NCT01786408|Active Comparator|SAFE-T-FILL CAPILLARY SYSTEM|Single Use Capillary Blood Collection System
3294880|NCT01786421||General population|Healthy volunteers,patients with hyperlipidemia,a known medical history of cardiovascular diseases or type 2 diabetes mellitus.
3294881|NCT01786434|Experimental|Routine medication arm|Fentanyl is given routinely to all patients before the procedure
3294882|NCT01786434|Active Comparator|Fentanyl on-demand arm|Fentanyl is given during the procedure if the patient experiences pain
3294883|NCT01786447||Traumatic Brain Injury|Patients who present to the health care facility with mild or moderate traumatic brain injury (Glasgow Coma Scale 9-15) within 4 hours of injury
3294884|NCT01786447||Orthopedic Control|Patients who present to the health care facility with isolated extracranial orthopedic injury within 4 hours of injury
3294885|NCT01786460||Healthy Volunteers|
3294886|NCT01786473|Experimental|Testogel 1% 5g QD|
3294887|NCT01786473|Placebo Comparator|Placebo gel 5g QD|
3294888|NCT01786486||Delivery system entry|
3294889|NCT01786499|Other|Relaxation Response Training|
3294890|NCT01786525|Experimental|House Calls only|60-minute educational intervention in patient's home which will be delivered by a health educator.
3294891|NCT01786525|Active Comparator|House Calls + Web-Based Decision Support|Home based intervention plus web-based patient-centered decision support program that will be offered to participants following the home based intervention.
3294892|NCT01786525|No Intervention|Control|100 patients on the Organ Transplant Tracking Record who are not receiving the study intervention
3294893|NCT01786538|Experimental|Regorafenib/FOLFOX|
3294894|NCT01786538|Active Comparator|Placebo/FOLFOX|
3294895|NCT01786577||Surgery|80 patients will undergo total knee replacement surgery; two Magnetic Resonance Imaging scans; cognitive assessment testing.
3294896|NCT01786577||Non-Surgery|80 non-surgery participants will be included as part of the control group; two Magnetic Resonance Imaging scans; cognitive assessment testing.
3294897|NCT01786590|Experimental|EBUS-TBNA|
3294898|NCT01786616||Formoterol|12 mcg BID for four weeks
3294899|NCT01786642||conscious|bronchoscopy without sedative drugs
3294900|NCT01786642||conscious sedation|bronchoscopy under midazolam
3294901|NCT01786655|Experimental|Neosaxitoxin in saline|Subjects receive only one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5mcg, 10mcg, 15mcg, 20mcg, 30mcg, and 40mcg NeoSTX.
3294902|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2%|Subjects receive only one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg NeoSTX.
3294903|NCT01786655|Experimental|Neosaxitoxin + bupivacaine 0.2% + epinephrine 5mcg/ml|Subjects receive one injection of NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml on the back of one calf (test side). Subjects receive NeoSTX in bupivacaine 0.2% with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
3294904|NCT01786655|Placebo Comparator|Saline placebo|Subjects receive one injection of saline on the back of one calf (test side).
3294905|NCT01786681|Experimental|Positive pressure before surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour before bariatric surgery.
3294906|NCT01786681|Experimental|Positive pressure during the surgery|Individuals treated with 10 cm H2O of PEEP (Positive End Expiratory Pressure) during the surgical procedure.
3294907|NCT01786681|Experimental|Positive pressure after surgery|Subjects treated with positive pressure in the BiPAP mode (Bi-Level Positive Airway Pressure) for one hour after bariatric surgery.
3294908|NCT01786681|No Intervention|Control|Individuals treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3294909|NCT01786694|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
3294910|NCT01786720||Prior Triple Therapy|Patients prescribed triple therapy prior to initial date of COPD diagnosis
3294911|NCT01786720||Triple therapy at COPD diagnosis|Patients prescribed triple therapy on date of initial COPD diagnosis
3294912|NCT01786720||Triple therapy after COPD diagnosis|Patients prescribed triple therapy after initial date of COPD diagnosis
3294913|NCT01786733|Experimental|Behavioral Activation|Behavioral Activation + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at increased activation towards goals and personal values and decreased avoidance behaviors.
3294914|NCT01786733|Active Comparator|Supportive Therapy|Supportive Therapy + Treatment as Usual. 12 sessions twice weekly (i.e. 6 weeks). Individual therapy. Therapy is initiated during inpatient admission and continue after discharge. Protocol aimed at providing psychological non-directive support.
3294915|NCT01786746|Experimental|Psychotherapy|Psychotherapy arm that consists of a randomization into 12 session manualized cognitive behavioral therapy or culturally adapted cognitive behavioral therapy for Chinese Americans.
3294916|NCT01786759|Active Comparator|LCT lipid emulsion|the LCT lipid emulsion is Intralipid
3294917|NCT01786759|Experimental|Olive oil lipid emulsion|the olive oil lipid emulsion is ClinOleic
3294918|NCT01786772|Experimental|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
3294919|NCT01786772|Active Comparator|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
3294920|NCT01786785||Stroke Patients|Subjects between 2 and 17 years of age with a confirmed arterial ischemic stroke.
3294921|NCT01786785||Controls|Age and Gender Matched Controls
3294922|NCT01786798|Other|Transvaginal sonography|
3379797|NCT05141695|Experimental|therapeutic group|therapeutic repetitive peripheral magnetic stimulation
3294923|NCT01786811|Experimental|Trained Clinicians|Clinicians randomized into this group will receive training in using the Serious Illness Conversation Guide with their patients. Patients of these clinicians will also be in the intervention arm.
3294924|NCT01786811|No Intervention|Non-trained Clinicians|Clinicians randomized into this group will not receive training in using the Serious Illness Conversation Guide with their patients. They will provide usual care. Patients of these clinicians will also be in the control arm.
3294925|NCT01786811|No Intervention|Non-volunteer Clinicians|These clinicians do not agree to participate in the study. They will continue to provide usual care. Their patients will be invited to participate and be followed.
3294926|NCT01786824|Experimental|Bicarbonate|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate.~Intervention: Hydration strategy using sodium bicarbonate Intervention: Coronarography"
3294927|NCT01786824|Active Comparator|Saline|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution.~Intervention: Hydration strategy using saline Intervention: Coronarography"
3294928|NCT01786824|Experimental|Bicar + L-Carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy containing sodium bicarbonate. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using sodium bicarbonate Intervention: L-carnitine Intervention: Coronarography"
3294929|NCT01786824|Experimental|Saline + L-carnitine|"The patients included in this arm will be administered a hydration regime for the prevention of contrast-induced nephropathy using sodium chloride solution. They will also receive an oral L-carnitine solution on days -1, 0, 1 to 7.~Intervention: Hydration strategy using saline Intervention: L-carnitine Intervention: Coronarography"
3294930|NCT01786837|Experimental|Treatment|FMS will be administered for 5 weeks
3294931|NCT01786837|Sham Comparator|Sham|FMS at 5% intensity for 5 weeks
3294932|NCT01786863||Neuromuscular blockade|
3294933|NCT01786889|Experimental|Patient with angiosarcoma of the liver|Blood and urine collections, questionnaire and telephone interview
3294934|NCT01786915|Experimental|Bendavia 10mg|Bendavia capsule, 10mg, once daily for 7 days
3294935|NCT01786915|Placebo Comparator|Placebo|Placebo (matching), once daily for 7 days
3294936|NCT01786915|Experimental|Bendavia 50mg|Bendavia capsule, 50mg, once daily for 7 days
3294937|NCT01786928|Experimental|resistance training|resistance training of the upper and lower limbs, two series of 80% of repetition maximum test
3294938|NCT01786928|No Intervention|Control|Traditional Respiratory Therapy for bronchial hygiene
3294939|NCT01786941|No Intervention|Lean Group|Healthy Controls - no intervention
3294940|NCT01786941|Other|Pre-Diabetes Group|Pre-Diabetes Group will undergo a 6-mo Aerobic and Resistance combined exercise training intervention
3294941|NCT01786941|Other|Gastric Bypass Group|Non-diabetic patients intending to undergo Gastric Bypass surgery
3294942|NCT01786980||liver cancer, Radical hepatic resection|
3294943|NCT01787019|Experimental|30 weeks|initiation of oral feedings at 30 weeks
3294944|NCT01787019|Active Comparator|33 weeks|initiation of oral feedings at 33 weeks
3294945|NCT01787045|Experimental|Intervention Group|"Early and Active Physical Therapy will be performed by physiotherapist twice a day. During first week patients will be positioned in chair or bed and performed cycle-ergometer exercise during 30 min.~Our physiotherapy protocol will be continued until Intensive Care Unit (ICU) discharge."
3294946|NCT01787045|Other|Control Group|Routinary Passive Range of Motion will be performed by physiotherapist 20 min and twice a day until ICU discharge.
3294947|NCT01787058||Dubai Cares beneficiary|Pupils who attend a school that has benefitted from a water, sanitation and hygiene intervention as part of the Dubai Cares program.
3294948|NCT01787058||Control|Pupils who attend a school of the same size and location as a school that benefitted from a water, sanitation and hygiene (WASH) intervention through the Dubai Cares program, but which has not benefitted from that program or any other WASH program since 2009.
3294949|NCT01787071||one group|Patients receiving fluid challebnge
3294950|NCT01787084||Inoperable Patients Alternative Access|Non-femoral delivery (or alternative access) in patients iwht severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis
3294951|NCT01787110|No Intervention|No oxygen|"For patients randomised to withholding oxygen treatment~no oxygen is administered at any time as long as the oxygen saturation is ≥90% on pulse oximeter (repetitive checks are performed)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies~observation duration 12 hours"
3294952|NCT01787110|Active Comparator|Oxygen|"For patients randomised to oxygen therapy:~6 L/min of oxygen delivered by oxymask® started immediately after inclusion of the ambulance service or in the emergency department given continuously for 6-12 hours (at least 6 hours)~all patients receive standard acute coronary syndrome treatment including reperfusion strategies"
3294953|NCT01787123|Placebo Comparator|Control: standard management|Standard management for patient suffering from aneurysmal subarachnoid haemorrhage
3294954|NCT01787123|Active Comparator|Intervention: standard management AND Cerebrolysin|Standard management for aneurysmal subarachnoid hemorrhage and a 14-day administration of intravenous Cerebrolysin
3294955|NCT01787149|Placebo Comparator|Placebo|DMARDs alone
3294956|NCT01787149|Experimental|ENIA11|ENIA11 25 mg
3294957|NCT01787162||myeloproliferative disorders|Echocardiography, spiroergometry, cardiac catheterization
3294958|NCT01787214|Active Comparator|Full dose|full dose of walnuts (20% energy needs)
3294959|NCT01787214|Active Comparator|Half-dose|Half dose of walnuts (10% of energy needs)
3294960|NCT01787214|Other|Control|Walnut free meals
3379798|NCT05141695|Sham Comparator|sham group|sham repetitive peripheral magnetic stimulation
3294961|NCT01787227||Blinded, Pre-selected Arm|For targets that exhibit lower prevalence rates in the intended use population, banked, pre-selected, positive clinical specimens will be tested.
3294962|NCT01787227||Blinded, Prospective Arm|Diagnostic accuracy for the more prevalent targets will be evaluated in prospectively collected, de-identified, left-over, clinical specimens accrued during the 2012/2013 flu season.
3294963|NCT01787253||Irritable bowel syndrome (IBS)|
3294964|NCT01787253||Healthy controls|
3294965|NCT01787253||Microscopic Colitis (MC)|
3294966|NCT01787253||Irritable bowel disease (IBD)|
3294967|NCT01787266||1|pregnant women
3294968|NCT01787318|Experimental|ePID closed loop system using Insupatch|Insupatch activated at mealtimes
3294969|NCT01787318|Active Comparator|ePID closed loop system without InsuPatch|InsuPatch will not be activated at mealtimes
3294970|NCT01787344|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A (Botulax®)
3294971|NCT01787344|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
3294972|NCT01787357|Experimental|Sequence 1 (ADBC)|Each volunteer will receive Treatment A on Day 1 of Treatment Period 1, followed by Treatment D on Day 1 of Treatment Period 2, followed by Teatment B on Day 1 of Treatment Period 3, and followed by Treatment C on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3294973|NCT01787357|Experimental|Sequence 2 (BACD)|Each volunteer will receive Treatment B on Day 1 of Treatment Period 1, followed by Treatment A on Day 1 of Treatment Period 2, followed by Treatment C on Day 1 of Treatment Period 3, and followed by Treatment D on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3294974|NCT01787357|Experimental|Sequence 3 (CBDA)|Each volunteer will receive Treatment C on Day 1 of Treatment Period 1, followed by Treatment B on Day 1 of Treatment Period 2, followed by Treatment D on Day 1 of Treatment Period 3, and followed by Treatment A on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3294975|NCT01787357|Experimental|Sequence 4 (DCAB)|Each volunteer will receive Treatment D on Day 1 of Treatment Period 1, followed by Treatment C on Day 1 of Treatment Period 2, followed by Treatment A on Day 1 of Treatment Period 3, and followed by Treatment B on Day 1 of Treatment Period 4. Each treatment period will be 2 days in duration and there will be a washout period (with no medication) of 10 to 14 days between each treatment period.
3294976|NCT01787370||Patients undergoing coronary angiography|Consecutive patients referred for coronary angiography for the suspect of coronary artery disease
3294977|NCT01787396|Experimental|Arm1|Gemigliptin 50mg + Metformin Once daily with dinner
3294978|NCT01787396|Experimental|Arm 2|Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner
3294979|NCT01787396|Experimental|Arm3|Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner
3294980|NCT01787409|Experimental|Treatment (cholecalciferol)|Vitamin D sufficient patients receive no intervention. Vitamin D insufficient patients receive cholecalciferol PO once weekly for 12 weeks and then once monthly for a total of 36 months.
3294981|NCT01787422|Experimental|Telemedicine Visit|Patients who are seen by use of an off-site telemedicine physician.
3294982|NCT01787422|Active Comparator|Traditional Visit|Patients who are seen in followup with a traditional in-office visit.
3294983|NCT01787435||All women exposed to PPI at any time during pregnancy|Exposure to PPI defined as presence of at least one prescription of a PPI any time between last menstrual period and delievry date
3294984|NCT01787435||All women exposed to H2RA at any time during pregnancy|Exposure to H2RA defined as presence of at least one prescription of H2RA any time between last menstrual period and delivery date
3294985|NCT01787435||Pregnant women with no recorded use of acid suppressing drugs|Pregnant women with no recorded use of acid suppressing drugs at any time during pregnancy
3294986|NCT01787448|Experimental|Ibuprofen 5% topical gel|
3294987|NCT01787448|Experimental|Topical gel vehicle|
3294988|NCT01787448|Active Comparator|Sodium lauryl sulfate 0.1%|
3294989|NCT01787448|Sham Comparator|Sodium chloride solution 0.9% (saline)|
3294990|NCT01787474|Experimental|Treatment (NK cells)|Patients receive filgrastim-sndz SC QD beginning on day -7 and continuing until ANC are equal or over 1000. Patients also receive fludarabine phosphate IV over 30 minutes and approximately 4 hours later followed by cytarabine IV over 1 hour on days -6 to -2 (days -6 to -3 for patients over age 60). Beginning 2-7 days after the last dose of fludarabine phosphate and cytarabine, patients receive membrane-bound interleukin-21-expanded haploidentical natural killer cells IV over 30 minutes thrice weekly for 3 doses over 4 days (Monday-Thursday only).
3294991|NCT01787487|Experimental|Arm I (MF patients)|Patients with MF receive ruxolitinib phosphate PO BID on days 1-28. Beginning course 4, patients also receive azacytidine SC or IV for 5 days. Treatment repeats every 28 days for 15 courses in the absence of disease progression or unacceptable toxicity.
3294992|NCT01787487|Experimental|Arm II (MDS/MPN patients)|Patients with MDS/MPN receive ruxolitinib phosphate and azacytidine as in Arm I.
3294993|NCT01787500|Experimental|Treatment (vemurafenib, cetuximab, irinotecan hydrochloride)|Patients receive vemurafenib PO BID on days 1-14, cetuximab IV over 90 minutes, and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3294994|NCT01787513|Experimental|CBM Version A + iCBT|CBM Version A is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
3294995|NCT01787513|Placebo Comparator|CBM Version B (Control) + iCBT|CBM Version B (Control) is an Internet-based intervention taking place over 1 week (identical to CBM Version A without the putative active components) followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
3294996|NCT01787526|Active Comparator|Oral Iron|oral iron in a corresponding dose of 10g (assuming an absorption of 10%, 100 capsules a 100mg iron each) taken over 8-12 weeks
3294997|NCT01787526|Experimental|Intravenous high dose iron|high dose intravenous iron (ferric carboxymaltose, 1000mg)
3294998|NCT01787539|Experimental|Complete Perioperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery with the same regimen as in the preoperative part."
3294999|NCT01787539|No Intervention|Preoperative Chemotherapy|"Preoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Surgery: total or subtotal gastrectomy with D2 lymph node dissection. The surgical resection will be conducted 4-6 weeks after preoperative chemotherapy.~Patients with tumor regression grade 0, 1, 2 randomized to preoperative chemotherapy will not undergo postoperative chemotherapy and will be followed-up."
3295000|NCT01787552|Experimental|LDE225 + INC424|LDE225 and INC424 in combination
3295001|NCT01787565||painPREMIER cohort|
3295002|NCT01787565||Control cohort|
3295003|NCT01787578|Experimental|Sobetirome|Subjects will receive oral doses of sobetirome. All subjects will start with a 50 mcg dose, once-daily for 14 days. If this dose proves safe and well tolerated, subjects will receive a 100 mcg dose once-daily for an additional 14 days.
3295004|NCT01787617|Placebo Comparator|Control Group|We will randomly assign 52 individuals to a no exercise healthy living group.
3295005|NCT01787617|Experimental|Aerobic Plus Resistance Training Group|We will randomly assign 52 individuals to an aerobic plus resistance training group.
3295006|NCT01787630|Experimental|Hyaluronic acid|Hyaluronic acid will be injected in the space between the prostate and rectum prior to radiotherapy to perform a dorsal movement of rectum.
3295007|NCT01787643|Experimental|Standing desk|Installation of standing desk
3295008|NCT01787669|Active Comparator|Avastin (bevacizumab)|Intravitreal Avastin loading doses followed by as prn for remainder of 6 months according to defined retreatment criteria
3295009|NCT01787669|Active Comparator|Ozurdex (dexamethasone)|single dose at baseline and repeat dose when required according to defined re-treatment criteria
3295010|NCT01787682|Experimental|Boost High Protein|Boost high protein with added spirulina
3295011|NCT01787695|No Intervention|No treatment (covered)|
3295012|NCT01787695|Active Comparator|UVA1|
3295013|NCT01787708|Active Comparator|Low intensity red laser|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3295014|NCT01787708|Active Comparator|High intensity red light|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3295015|NCT01787708|No Intervention|No treatment1 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3295016|NCT01787708|No Intervention|No treatment2 (covered)|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into four quadrants. Two opposite quadrants will be shielded by foil and served as control, the third quadrant will be exposed to low intensity red laser (at 3 J/cm¬2), and the fourth quadrant will be exposed to high intensity red light (at 37 J/cm¬2).~Treatments will be given twice weekly for 10 weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
3295017|NCT01787721|Experimental|Ankle manipulation|Treatment will consist of manipulation of the tibiotalar joint intended to produce anterior to posterior glide of the tibia on the talus
3295018|NCT01787721|Sham Comparator|Sham manipulation|Sham manipulative procedure of the tibiotalar joint.
3295019|NCT01787747|Experimental|Cohorts A and C|Single dose (D1) followed by twice daily dosing for 7 days
3295020|NCT01787747|Experimental|Cohorts B and D|Single dose (D1) followed by twice daily dosing for 7 days
3295021|NCT01787747|Experimental|Cohorts E and F|Single dose (D1) followed by twice daily dosing for 7 days
3295022|NCT01787747|Experimental|Cohorts G and I|Single dose (D1) followed by twice daily dosing for 7 days
3295023|NCT01787747|Experimental|Cohorts H and J|Single dose (D1) followed by twice daily dosing for 7 days
3295024|NCT01787773|Experimental|Veniti Inferior Vena Cava Filter|
3295025|NCT01787786||Irritable Bowel Disease|Infliximab administered according to current FDA and EMS approved doses and intervals.
3295026|NCT01787851|Active Comparator|Triheptanoin oil|The standard dose of triheptanoin oil for adults is 1-2gm/kg/24 hours. For purposes of this study, we will administer 0.25mg/kg four-times per day. The liquid study drug will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake, depending on patient preference.
3295027|NCT01787851|Placebo Comparator|Simple sugar|0.25mg/kg of sugar syrup will be mixed into sugar-free, low fat yogurt, pudding or nutritional supplement shake four-times per day before meals.
3295028|NCT01787864||Cross-Sectional Post-Ablation|"The cross-sectional arm will consist of patients who have undergone ablative therapy for Barrett's Esophagus (BE) and have had at least one clear pathology report with no evidence of Barrett's Esophagus (BE) since their first ablation.~Cross-sectional participants will receive one-time study biopsies during a routine care follow-up endoscopy."
3379801|NCT05141149|Experimental|Cohort 1M|1 mg/kg of PBP1510 as monotherapy will be administered
3379802|NCT05141149|Experimental|Cohort 1C|1 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
3379803|NCT05141149|Experimental|Cohort 2M|3 mg/kg of PBP1510 as monotherapy will be administered
3379804|NCT05141149|Experimental|Cohort 2C|3 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
3379805|NCT05141149|Experimental|Cohort 3M|6 mg/kg of PBP1510 as monotherapy will be administered
3379806|NCT05141149|Experimental|Cohort 3C|6 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
3379807|NCT05141149|Experimental|Cohort 4M|10 mg/kg of PBP1510 as monotherapy will be administered
3379808|NCT05141149|Experimental|Cohort 4C|10 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
3379809|NCT05141149|Experimental|Cohort 5M|15 mg/kg of PBP1510 as monotherapy will be administered
3379810|NCT05141149|Experimental|Cohort 5C|15 mg/kg of PBP1510 and 1000 mg/m^2 of gemcitabine as combination therapy will be administered
3379811|NCT05141123||Preloaded Fenestrated Stent-graft Designs for Endovascular Aortic Procedures|Patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type B dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone)
3379812|NCT05139992||Observational Cohort|Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.
3379813|NCT05139901|Active Comparator|4% saline|4% Saline inhalations twice daily
3379814|NCT05139901|Experimental|Pulmosyme|DNAse alpha inhalations twice daily
3379815|NCT05139836||Participants Receiving Upadacitinib|Participants receiving upadacitinib for moderate to severe atopic dermatitis.
3295029|NCT01787864||Prospective Longitudinal Pre-Ablation|"Concurrently enrolled will be a prospective longitudinal arm which will consist of patients prior to their first ablation procedure. The prospective cohort will be followed for 12 months or longer if Barrett's Esophagus (BE) is not yet clear 6 months after the initial treatment.~Prospective longitudinal participants will receive biopsies prior to ablation therapy and 6 and 12 months after the initial treatment. If Barrett's Esophagus (BE) is not yet clear at 6 months, biopsies will be taken at the first endoscopy after Barrett's Esophagus (BE) clearance and again at the next clinically scheduled follow-up visit."
3295030|NCT01787877||Stroke patients reporting to the ER|
3379816|NCT05138497|Experimental|HILIT group|An experimental group (EG) that after an initial evaluation and with their consent, will be subjected to a directed physical training program, based on Beat Fit exercises for 12 weeks with 3 weekly sessions (Monday, Wednesday and Friday), with a duration of 50 min per session. The exercises to be carried out will be divided into three different phases: warm-up during the first 10 minutes; the main part with a duration of 30 minutes (where each exercise should be performed for 20 to 30 seconds as intense or fast as possible without generating joint impact, and then take a break for 10 to 15 seconds, before repeating it); and the return to calm, based mainly on stretching exercises with a total duration of 10 minutes.
3379817|NCT05138497|No Intervention|Control group|A control group (CG) that will not undergo treatment, which will be evaluated in the pre and post phase of the study. The participants assigned to this group will receive general advice on the positive effects of the regular practice of physical activity, and they will be given the guide of recommendations for the promotion of physical activity.
3379818|NCT05137886|Experimental|PD-1 inhibitor combined with decitabine followed by ASCT|Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles, If PR or CR was obtained after salvage treatment, patients will receive GBM (gemcitabine, bulsufan and melphalan) conditioning regimen followed by ASCT. High-risk patients will receive PD-1 inhibitor for 1 year after ASCT as maintenance therapy.
3379819|NCT05137600|Experimental|ATI-2173 50 mg|ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth
3379820|NCT05137600|Experimental|Midazolam|Midazolam is a sensitive CYP3A index substrate
3379821|NCT05137600|Experimental|Clarithromycin|Clarithromycin is a sensitive P-gp index inhibitor to evaluate potential effect of P-gp inhibition on ATI-2173 and its metabolites
3379822|NCT05137548|Experimental|ATI-2173.|ATI-2173
3379823|NCT05137548|Experimental|Tenofovir Disoproxil Fumarate|Tenofovir disoproxil fumarate
3379824|NCT05137132|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides
3379825|NCT05137132|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
3379826|NCT05136651|Experimental|Immediate Treatment|Couples assigned to the Immediate Treatment condition will begin the OurRelationship program immediately following random assignment.
3379827|NCT05136651|Other|Waitlist Control|Couples assigned to the Waitlist Control condition will begin the OurRelationship program following a 2-month delay after random assignment.
3379828|NCT05135624|Experimental|Cohort dose 1 of SP16|Patients in cohort 1 (low dose SP16) will receive a single dose of SP16 (0.1 mg/kg or 6 mg) by subcutaneous injection
3379829|NCT05135624|Experimental|Cohort dose 2 of SP16|Patients in cohort 2 (high dose SP16) will receive a single dose of SP16 (0.2 mg/kg or 12 mg) by subcutaneous injection
3379830|NCT05135624|Placebo Comparator|Placebo|Patients in placebo arm will receive sterile water by subcutaneous injection.
3379831|NCT05134649|Experimental|BOTOX|BOTOX will be injected into the platysma muscle for up to 3 administrations.
3379832|NCT05133596|Experimental|Study population|Adult subjects up to 55 years of age with persistent olfaction disorder after a symptomatic episode of COVID-19.
3295031|NCT01787903|Active Comparator|Real-time continuous glucose monitor|16 weeks use of a real-time continuous glucose monitor
3295032|NCT01787903|Placebo Comparator|Continuous glucose monitor|16 weeks use of a (blinded, retrospective) continuous glucose monitor
3295033|NCT01787929|Other|Cemented hemiarthroplasty|hemiarthroplasty surgery with cement for displaced femoral neck fractures
3295034|NCT01787929|Other|Uncemented hemiarthroplasty|hemiarthroplasty surgery without cement is a surgery for displaced femoral neck fractures
3295035|NCT01787942|Active Comparator|Blepharoplasty|"Participants under this group will undergo blepharoplasty from the oculoplastic clinic. These patients will form the case group of the cross-sectional study, and will be on follow-up for the prospective study."
3295036|NCT01787942|Placebo Comparator|Control|"Participants under this group will be recruited from the general ophthalmology clinic. These patients are cleared to have no lid disturbances in terms of function or anatomy, and will serve as the control group of the cross-sectional study."
3295037|NCT01787955|Experimental|Braun anastomosis group|
3295038|NCT01787955|Active Comparator|conventional group|conventional Pylorus preserving pancreaticoduodenectomy
3295039|NCT01787968||TcI, TcII|TcI: T. cruzi seropositive mothers from countries where TcI predominates, or/and with TcI genotyping TcII: T. cruzi seropositive mothers from countries where TcII (non-TcI) predominates, or/and with TcII (non-TcI) genotyping
3295040|NCT01787994|Experimental|Cohort 1|"Cohort 1: HIV-1-positive women and men ≥18 years with a CD4 count > 350 cells/mm3, HIV-1-RNA levels undetectable by ultrasensitive HIV PCR Abbott assay. Subjects with HIV-1 RNA < 400 copies/mL are also eligible; however, the HIV-1 RNA must be < 50 copies/mL within 60 days prior to study entry based on the Abbott assay. Subjects with intermittent isolated episodes of detectable low level viremia (> 50 but <1,000 copies RNA/mL; blips) will be eligible.~There should be at least 2 documented HIV-1 RNA assays, one drawn >3 months before study entry, one drawn <3 months before study entry. Subjects should be on HAART (no changes to treatment within 4 weeks of study entry) for at least 3 months.~Cohort 1 subjects will receive a single dose of MazF-T cells."
3295041|NCT01787994|Experimental|Cohort 2|"Cohort 2: HIV-1-positive men and women ≥18 years with a CD4 count > 450 cells/mm3, having well controlled HIV replication on HAART. The subjects should have a CD4 nadir ≥200 cells/mm3. Subjects in Cohort 2 will participate in a 16 week analytical treatment interruption beginning 2 weeks after T cell infusion.~Cohort 2 subjects will receive a single dose of MazF-T cells."
3295042|NCT01788007|Experimental|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.)
3295043|NCT01788007|Placebo Comparator|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.)
3295044|NCT01788007|Active Comparator|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.)
3295045|NCT01788020|Experimental|DRC+Bortezomib|"Induction experimental arm (Arm B):~Cycle 1:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5~Cycle 2-6:~Bortezomib 1.6 mg/m2 s.c. Day 1,8,15; Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
3295046|NCT01788020|Active Comparator|DRC|"Induction standard arm (Arm A)~Cycle 1:~Dexamethasone 20 mg p.o. Day 1; Rituximab 375 mg/m2 i.v. Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5;~Cycle 2-6:~Dexamethasone 20 mg p.o. Day 1; Rituximab 1400 mg absolute sc Day 1; Cyclophosphamide 100 mg/m2 x 2 p.o. Day 1-5; Repeat day 29."
3295047|NCT01788033|Active Comparator|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
3295048|NCT01788033|Placebo Comparator|Placebo|0.3 mg/kg placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
3295049|NCT01788059|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then inject to non union site 2-3 ml with approximately 40 X 10E6 Mesenchymal Stem Cells (MSC) will be injected in the nonunion site of the bone fracture under fluoroscopic gide and general or spinal anesthesia as deemed appropriate by the anesthetist.
3295050|NCT01788072|Active Comparator|Intranasal Oxytocin|
3295051|NCT01788072|Placebo Comparator|Placebo|
3295052|NCT01788085|Experimental|pH monitoring procedure|Bravo pH monitoring procedure
3295053|NCT01788098||Rheumatoid Arthritis|Patients with rheumatoid arthritis
3295054|NCT01788098||Healthy controls|Healthy control subjects
3295055|NCT01788111|Experimental|Low back exercises 1|Specific low back extensor exercises in special training bench
3295056|NCT01788111|Active Comparator|Low back exercise 2|Traditional low back exercises.
3295057|NCT01788124||Metal Speculum|exam with metal speculum
3295058|NCT01788124||Plastic Speculum|exam with plastic speculum
3295059|NCT01788137|Active Comparator|CHOP|CHOP regimen Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles.
3295060|NCT01788137|Active Comparator|c-ATT regimen|c-ATT regimen Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
3295061|NCT01788176|Placebo Comparator|Saline|One single intravenous infusion of 100ml of saline (placebo control group).
3295062|NCT01788176|Active Comparator|Zoledronic acid|one single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
3295063|NCT01788189|Experimental|Lenalidomide|"The LeMLAR protocol:~Lenalidomide 25 mg p.o., days 1 - 21; Methotrexate 30 - 60 - 90 - 120 - 150 mg/m² i.v. bolus, days 1, 8, 15; Leucovorin 4 x 45 mg p.o. (every 6 hrs), days 2, 9, 16; Cytarabine (Ara-C) 75 - 150 - 225 - 300 - 375 mg/m² i.v. bolus, days 1, 8, 15; Rituximab 375 mg/m² i.v. infusion, day 1.~28-day cycles, maximum 6 cycles, definition of dose-limiting toxicity in cycles 1 and 2, intra-patient dose escalation after cycles 2 and 4 in case of absence of dose-limiting toxicity in previous cycles"
3295064|NCT01788241||CAG and CT group|CAG group = patients included based on coronary angiography screening; CT group = patients included based on computed tomography screening
3295065|NCT01788254|Experimental|Drug cocktail|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
3295066|NCT01788267|Experimental|Healthy volunteers|Volunteers realize a HR-pQCT scanner
3295067|NCT01788267|Experimental|Cystic Fibrosis patient|Patients realize a HR-pQCT scanner
3295068|NCT01788280|Experimental|All participants|All enrolled participants
3295069|NCT01788293|Active Comparator|Intervention group|Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
3295070|NCT01788293|No Intervention|Control group|Control group will receive fluid at the discretion of the anesthetist
3295071|NCT01788306|Active Comparator|Intervention (OOPEN+BBCC)|Study intervention, overdose prevention, education, intervention, brief behavioral change counseling, take-home naloxone, referral to local available resources.
3295072|NCT01788306|No Intervention|Control|Standard of care, referral to local available resources.
3295073|NCT01788319|Experimental|lasertrabeculoplasty|
3295074|NCT01788332|Active Comparator|Olaparib|3 100mg tablets to be administered twice a day with approximately 240ml of water.
3295075|NCT01788332|Placebo Comparator|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water.
3295076|NCT01788345|Experimental|non-invasive ventilation|
3295077|NCT01788371|No Intervention|No antiviral arm|provide standard of care to mothers and standard immunoprophylaxis to their infants
3295078|NCT01788371|Experimental|Lamivudine|lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
3295079|NCT01788371|Experimental|Telbivudine|Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants
3295080|NCT01788384|Active Comparator|Acanya|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% gel (Valeant Pharmaceuticals, North America)
3295081|NCT01788384|Experimental|Clindamycin Phosphate / Benzoyl Peroxide|Clindamycin Phosphate / Benzoyl Peroxide Gel, 1.2%/2.5%
3295082|NCT01788384|Placebo Comparator|Vehicle Gel|Placebo (Vehicle Gel)of the test product (Watson Laboratories, Inc.)
3295083|NCT01788397|Experimental|Physical activity|Physical activity 2-4 times pr. day
3295084|NCT01788397|No Intervention|Control group|No intervention in the control group
3295085|NCT01788410||Cryoablation under image guidance|Patients with facet joint disease, or compressed or damaged nerve roots causing pain in the head, neck or spine. Procedures performed with MRI Seednet Cryotherapy System (Galil Medical).
3295086|NCT01788436|Experimental|Group 1: Patients with schizophrenia|
3295087|NCT01788436|Active Comparator|Group 2: Young healthy volunteers|
3295088|NCT01788436|Experimental|Group 3: Elderly healthy volunteers|
3295089|NCT01788462||HIV and Lipodystrophy|The study population will consist of HIV patients with lipodystrophy who receive Tesamorelin (Egrifta).
3295090|NCT01788488|No Intervention|Standard Therapy|
3295091|NCT01788488|Experimental|Procalcitonin-guided therapy|Procalcitonin levels will be measured to determine when it is appropriate to discontinue antibiotic therapy.
3295092|NCT01788501|Experimental|Tacrolimus/Methotrexate|"Tacrolimus D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to therapeutic drug monitoring(TDM) (10-20ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
3295093|NCT01788501|Active Comparator|Cyclosporine/Methotrexate|"Cyclosporine D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)~Methotrexate D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push"
3295094|NCT01788514|Other|Videogame|Subject will play educational videogame
3295095|NCT01788527|Experimental|CGM|Continuous Glucose Monitoring
3295096|NCT01788527|No Intervention|HGM|Standard of care, Home Glucose Monitoring
3295097|NCT01788540|Experimental|Intralipid|"IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.~the intralipid infusion is then repeated within the one week of positive pregnancy test and every 2 weeks till end of first trimester"
3295098|NCT01788540|No Intervention|Control|No intervention
3295099|NCT01788553||patients with generalized anxiety disorder|
3295100|NCT01788579|Experimental|Multimedia WINGS|A one-hour session of a self-paced multimedia IPV screening, brief intervention and referral service delivered on a computer.
3295101|NCT01788579|Active Comparator|Caseworker Delivered WINGS|A one-hour session of IPV screening, brief intervention and referral service delivered by a case manager.
3295102|NCT01788592||Drug eluting stent|Patients who receiving drug eluting stents
3295103|NCT01788605|Experimental|ramosetron|
3295104|NCT01788618|Other|Experimental group|Cognitive exams at T0 and T3. Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
3295105|NCT01788618|Other|The control group 1 (Homework)|Cognitive exams at T0 and T3. These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
3295106|NCT01788618|Other|Control group 2 ( telephone follow)|Cognitive exams at T0 and T3. These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
3295107|NCT01788644||No treatment (observational study)|
3295108|NCT01788657|Experimental|Standard internet-based cognitive behavior therapy|Standard internet-based cognitive behavior therapy for depression with a written treatment material consisting of 60000 words (textmaterial only).
3295109|NCT01788657|Experimental|Condensed internet-based cognitive behavior therapy|Condensed internet-based cognitive behavior therapy for depression with a written treatment material consisting of 30000 words (available as text or audio).
3295110|NCT01788670|Placebo Comparator|Water|Lemon-flavoured water (150 ml)
3295111|NCT01788670|Active Comparator|Ethanol high dose|The high dose corresponds to 30 g of ethanol in pilot cohort 1, to 12 g of ethanol in pilot cohort 2 and to 42 g of ethanol in pilot cohort 3. For the definitive study the high dose corresponds to 30 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
3295112|NCT01788670|Active Comparator|Ethanol low dose|The low dose corresponds to 18 g of ethanol in pilot cohort 1, to 6 g of ethanol in pilot cohort 2 and to 24 g of ethanol in pilot cohort 3. For the definitive study the low dose corresponds to 18 g of ethanol. Ethanol was administered as a single dose of pure ethanol diluted in lemon-flavoured water (150 ml each beverage).
3295113|NCT01788683|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged tendon.
3295114|NCT01788683|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate rotator cuff strengthening exercises and given an instructional hand-out to take home.
3295115|NCT01788696|Active Comparator|Group A - Early Imaging|Group A will receive SPECT imaging 3 times during the study. The first scan will take place prior to the initiation of any treatment, followed by scans at week 26 and week 52.
3295116|NCT01788696|Active Comparator|Group B - Delayed Imaging|Group B will receive SPECT imaging 2 times during the study. Group B will not have the first scan (prior to the initiation of any treatment). Scan will take place at week 26 and week 52.
3295117|NCT01788709|Active Comparator|A|Fortrans (split dose) + Mentholyptus drops
3295118|NCT01788709|Active Comparator|B|MoviPrep (split dose)
3295119|NCT01788722||Group 1|
3295120|NCT01788748|Active Comparator|bipolar radiofrequency and infrared|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only bipolar radiofrequency potentiated by infrared, 3 treatments one month apart.
3295121|NCT01788748|Active Comparator|fractional bipolar radiofrequency|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive only fractional bipolar radiofrequency , 3 treatments one month apart.
3295122|NCT01788748|Active Comparator|combined treatment|The abdomen of each patient will be divided in four quadrants around the navel. One quadrant, selected randomly at the subject enrollment, will receive first bipolar radiofrequency potentiated by infrared, followed in the same session by fractional bipolar radiofrequency, 3 treatments one month apart.
3295123|NCT01788761|Experimental|Probiotic Supplemented Group|500,000,0000 cells of Lactobacillus GG (utilizing either Culturelle for Kids or Kids Culturelle preparation) and 500,000,000 cells of Bifidobacterium Infantis (utilizing Align capsule) diluted in 3 ml breastmilk/formula and administered enterally from first day of enteral feeds until term gestation/discharge/transfer/death (whichever occurs first) every day infant is receives enteral feedings
3295124|NCT01788761|Sham Comparator|Control Group|3 ml enteral feeding of breastmilk/formula administered once daily in addition to regularly prescribed enteral feedings from day of first feeding until term gestation/discharge/transfer/death (which ever occurs first) and administered every day that infant receives enteral feedings
3295125|NCT01788774|Other|Risperidone ISM 50mg|Three different single doses will be evaluated
3295126|NCT01788774|Other|Risperidone ISM 75mg|Three different single doses will be evaluated
3295127|NCT01788774|Other|Risperidone ISM 100mg|Three different single doses will be evaluated
3295128|NCT01788787||Texas Quitline|Patients interested in smoking cessation treatment by calling the Texas Quitline.
3295129|NCT01788787||Training Providers|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians).
3295130|NCT01788800|Experimental|Exercise training|"Cognitive Behavioural Therapy (CBT)~+ Exercise training 3 times/week, 30 minutes on a treadmill, 70% maximal oxygen uptake (VO2max), 8 weeks"
3295131|NCT01788800|Active Comparator|Movements|"Cognitive Behavioural Therapy (CBT)~+ Low intensity physical activity without cardiovascular activation, 3 times/week, 30 minutes, 8 weeks"
3295132|NCT01788813|Experimental|GSK2245035 Arm|Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).
3295133|NCT01788813|Placebo Comparator|Placebo Arm|Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)
3295134|NCT01788826|Experimental|Prophylactic Mesh|Use of a prefascial polypropylene mesh when closing midline laparotomy
3295135|NCT01788826|Experimental|No prophylactic mesh closure|In this arm the laparotomy of the patients are closed with a running absorbable suture without a mesh
3295136|NCT01788839||women with breast cancer|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with breast cancer. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Breast cancer patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
3295137|NCT01788839||women with lymphoma|"This study is a prospective, observational, longitudinal study assessing the prevalence of sexual dysfunction and distress in premenopausal and postmenopausal women with Diffuse Large B-cell Lymphoma or Hodgkin's Lymphoma. This study will also evaluate the severity, time course, and predictors of sexual dysfunction. Lymphoma patients and survivors will be administered surveys of comprehensive questionnaires related to sexual function. In the case that participants miss the follow up questionnaires, study staff may contact the patient by phone to request and record the patients responses. The study staff may also mail the missed questionnaires to each patient."
3295138|NCT01788852||Perinatally HIV-infected adolescents|Perinatally HIV-infected adolescents
3295139|NCT01788852||behaviorally HIV-infected adolescents|behaviorally HIV-infected adolescents
3295140|NCT01788852||HIV negative adolescents|HIV negative adolescents
3295141|NCT01788865|Experimental|cSEMS|Patients with malignant ureteral obstruction have cSEMS(Covered self-expandable dual-layered metal stent) implant
3295142|NCT01788878|Experimental|Questionnaires|completion of questionnaires
3295143|NCT01788891||second-line pediatric cohort|Asian HIV-positive children <18 years old who are receiving HIV care at one of the participating TREAT Asia Pediatric HIV Observational Database (TApHOD) sites that have been identified for TASER-P participation will be monitored for treatment failure of second-line ART
3295144|NCT01788904||Patients with acute mesenteric ischemia|Patients with acute mesenteric ischemia meeting the in-/exclusion criteria
3295145|NCT01788917|Active Comparator|linseed oil|
3295146|NCT01788930|Active Comparator|CPAP|"This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.~Other Name: positive airway pressure"
3295147|NCT01788930|Placebo Comparator|Sham-CPAP|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
3295148|NCT01788956||ICU Patients|80 subjects (male and female)
3295149|NCT01788969|Experimental|Gait Training with Lexapro|Gait training 2 weeks, gait training 4 weeks (3 X week) with Lexapro (10mg SSRI), wash out period of 1 week, gait training, for 4 weeks with placebo (10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3295150|NCT01788969|Active Comparator|Gait Training with Placebo|Gait training 2 weeks, gait training for 4 weeks (3X week) with Placebo (10 mg), wash out period of 1 week, gait training for 4 weeks with Lexapro(10 mg). Patients will also be provided prescribed TIZ by their physician to help control of spastic motor behaviors.
3295151|NCT01788982|Experimental|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
3295152|NCT01788982|Placebo Comparator|Placebo|Placebo should be administered orally at a dose of 200 mg twice daily. Cross-over to nintedanib is allowed after progression.
3295153|NCT01788995||Cohort|
3295154|NCT01789008|Other|Transient elastography|evaluation of fibrosis stage by transient elastography
3295155|NCT01789008|Active Comparator|liver biopsie|evaluation of fibrosis stage by liver biopsie
3295156|NCT01789060||p-AKT|p-AKT immunohistochemical staining,high p-AKT expression (upper quartile), low p-AKT expression (lower 3 quartiles)
3295157|NCT01789073|Experimental|Oral Impact, Nestlé Health Science|Oral Impact-arm receives the intervention the last 7 days prior to surgery
3295158|NCT01789073|No Intervention|Control|The control-arm receives no intervention but is treated according to the standard procedures
3295159|NCT01789086|Experimental|Liraglutide|
3295160|NCT01789086|Placebo Comparator|Placebo|
3295161|NCT01789099|Experimental|UV1 synthetic peptide vaccine and GM-CSF|GM-CSF (Leukine) followed by UV1 peptide vaccine with escalating concentrations (100, 300 and 700 microgram) will be injected intradermally in the lower abdomen.
3295162|NCT01789112|Experimental|CCM aggregate|Taking of 10 blood samples
3295163|NCT01789125|Active Comparator|Smoking Termination and Anxiety Reduction Treatment|Cognitive-behavioral treatment program that blends smoking cessation and anxiety reduction treatment strategies
3295164|NCT01789125|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
3295165|NCT01789164||Healthy group|Healthy group with no history of TBI or concussion. Gender matched non-TBI volunteers
3295166|NCT01789164||TBI group|Males and females between 18 and 60 years who have a diagnosis of TBI and are symptomatic with DSM-IV Research Criteria for Post-Concussional Disorder (see below), gender matched non-TBI volunteers
3295167|NCT01789177|Experimental|Modified incentive spirometry|Patients will be given a disposable incentive spirometer postoperatively and instructed to use the spirometer every hour while awake.
3295168|NCT01789177|Active Comparator|Postoperative chest physiotherapy|Patients will be given standard postoperative chest physiotherapy, according to hospital protocol, but will not receive incentive spirometers.
3295169|NCT01789190||Group S (sedentary)|Group S included patients that did not perform any physical activity at the moment of onset, continuing with the same habits during the subsequent observational period.
3295170|NCT01789190||Group A (active)|The inclusion criteria for group distribution took in account the principles of the American College of Sports Medicine, considering as active physical activity to practice a moderate-vigorous exercise during 1h, 5 days or more/week. In this context, a sedentary or less active person should be a person that practices any or less than 5h weekly
3295171|NCT01789216|Placebo Comparator|Placebo|"Standard pain management + perioperative intravenous placebo & oral placebo.~Control group will receive an oral dose of placebo up to two hours prior to surgery and twice daily for up to 48 hours following any surgery, in addition to an intravenous dose of placebo up to two hours prior to surgery and every 6 hours for up to 48 hours following surgery. All study medications will be in addition to standard of care pain medication.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
3295172|NCT01789216|Active Comparator|NSAID|"Standard pain management + perioperative intravenous ketorolac & oral placebo.~The NSAID group will receive 30 mg of intravenous (IV) ketorolac (Ketorolac 30 mg/ml dose vial, NDC 00409-3795-01; manufacturer: Hospira) administered up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an oral dose of placebo up to two hours prior to the procedure and every 12 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
3295173|NCT01789216|Active Comparator|Gabapentinoid|"Standard pain management + perioperative intravenous placebo & oral pregabalin.~The Pregabalin group will receive an oral bolus dose of 300 mg of pregabalin up to two hours prior to the procedure and a 75 mg dose every 12 hours for up to 48 hours following the procedure. In addition, as part of the perioperative protocol, patients will receive an IV dose of placebo up to two hours prior to the procedure and every 6 hours for up to 48 hours following the procedure.~*Previous preoperative protocol was removed due to difficulty of medication adherence and limited importance of preoperative regimen to the intervention overall."
3295174|NCT01789229||Malignant tumors|"Patients who have one of the Neoplasms stated above under conditions."
3295175|NCT01789229||Benign controls|Patients with a benign tumor or an inflammatory disease - to be matched by age.
3295176|NCT01789229||Healthy controls|People/patients who have no known disease at time of sampling or are admitted to the hospital for minor interventions and have no inflammatory disease.
3295177|NCT01789242|Experimental|Carfilzomib|All eligible subjects will receive the study intervention of Carfilzomib. Patients with suboptimal hematologic responses (<VGPR after 4 cycles) will have Dexamethasone added to their treatment.
3295178|NCT01789268||Full-Term Healthy Infants (> /=37 weeks gestational age)|130 male and female term infants born at a gestational age of 37 0/7 to 41 6/7 weeks (Healthy comparator) will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
3295179|NCT01789268||Preterm Infants (<36 weeks gestational age)|150 male and female preterm infants born at gestational age 23 0/7 to 35 6/7 weeks will be observed for sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity
3295180|NCT01789294|Experimental|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects
3295181|NCT01789294|No Intervention|Observation|A close clinical observation without therapy was taken in control patients, whom parents were alerted to refer immediately if symptoms persisted or get worse.
3295182|NCT01789294|Experimental|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists
3295183|NCT01789307|Active Comparator|corn syrup solids|corn syrup solids oral ingestion
3295184|NCT01789307|Experimental|sucrose|sucrose oral ingestion
3295185|NCT01789333|Experimental|9 mw/cm2 at 10 minutes group|30 patients will be treated with UVA light source at 9 mw/cm2 at 10 minutes. Drug: Riboflavin Dose:1 drop every 2 to 3 minutes for 15 to 20 minutes
3295186|NCT01789346|Other|532nm KTP laser|Cutera ExcelV 532nm KTP laser
3295187|NCT01789346|Active Comparator|595nm PDL|Cynosure Cynergy 595nm pulsed-dye laser
3295188|NCT01789359|Other|anthocyanin-free diet|Maintain anthocyanin-free diet throughout study. Day 1 to day 30, consume daily 250 ml single strength blueberry juice containing 229 mg anthocyanins, taken either as 1 morning dose or 1/3 dose morning, 1/3 mid-day and 1/3 evening. At d 31-38 continue anthocyanin-free diet. On d 39 consume daily dose.
3295189|NCT01789385|Other|dexmedetomidine|Precedex 200 mcg 2ml
3295190|NCT01789398|Experimental|BF2.649 (pitolisant)|BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
3295191|NCT01789398|Placebo Comparator|placebo|Placebo of BF2.649 (5mg, 10mg, 20mg or 40mg) in capsules
3295192|NCT01789411||ATHEROREMO-IVUS cohort|Drawing blood samples. Coronary intravascular ultrasound imaging. Coronary near-infrared spectroscopy.
3295193|NCT01789437|Active Comparator|Dexamethasone Intravitreal Implant|
3295194|NCT01789450|Experimental|Section of Periareolar Dermis|Section of Periareolar Dermis
3295195|NCT01789463|Active Comparator|Self rehabilitation|Self rehabilitation
3295196|NCT01789463|Experimental|Self rehabilitation plus physiotherapy|Self rehabilitation plus physiotherapy
3295197|NCT01789489|Active Comparator|3 dimensional sonohysterography|3 dimensional sonohysterography
3295198|NCT01789489|Active Comparator|Standard hysteroscopy|Standard hysteroscopy
3295199|NCT01789502|Active Comparator|Plastic stents|Plastic stents are inserted by ERCP
3295200|NCT01789502|Experimental|Fully covered metal stents|Fully covered metal stents are inserted by ERCP
3295201|NCT01789515||rectal cancer|Low Anterior Resection for Rectal Cancer
3295202|NCT01789528|Experimental|CAZ-AVI or CXL|"Cohort 1: CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) by intravenous infusion given over 2 hours, every 8 hours~Cohort 2: CXL (600 mg ceftaroline fosamil and 600 mg avibactam)"
3295203|NCT01789541||Atrial fibrillation|Patients with atrial fibrillation undergoing ablation
3295204|NCT01789541||AV-nodal reentry tachycardia|Patients with AV-Nodal Reentry Tachycardia undergoing ablation
3295205|NCT01789554|Experimental|MLS dispatch for bystander CPR|When an alarm call of a suspected OHCA suspected is received by the EMS dispatch operator a Mobile positioning system (MPS) is activated. The MPS uses the mobile phone network to geographically locate all lay volunteers connected to a tailored mobile phone service called mobile life saver (MLS). The MPS then locates all lay volunteers within a pre defined radius from the suspected OHACA an alerts them with a computer generated voice call and an sms containing data about were about were the suspected OHCA is located. A map is also sent in order to make route finding easy.
3295206|NCT01789554|No Intervention|NO MLS dispatch for bystander CPR|No activation of mobile positioning system to locate and recruit lay responders to nearby OHCAs
3295207|NCT01789580|No Intervention|Control group|The participants play on their preferred online gambling site (experimental gambling session) without gambling moderator.
3295208|NCT01789580|Experimental|Bonus group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : bonus (with different modalities of the moderator).
3295209|NCT01789580|Experimental|Auto-exclusion group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto-exclusion.
3295210|NCT01789580|Experimental|Auto- limitation group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : auto- limitation(with different modalities of the moderator).
3295211|NCT01789580|Experimental|Information group|The participants play on their preferred online gambling site (experimental gambling session) with the first gambling moderator sudied : information (with different modalities of the moderator).
3295212|NCT01789593|Other|Hypoglycaemia / euglycaemia clamp|
3295213|NCT01789593|Other|Euglycaemia clamp / hypoglycaemia|
3295214|NCT01789619||Extended release tacrolimus (Advagraf®)|
3295215|NCT01789645|Experimental|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
3379833|NCT05132231||Brodalumab initiator|Eligible adult participants who are enrolling into the SILIQ (brodalumab) Patient Support Program (PSP) and initiating brodalumab as per routine care.
3295216|NCT01789645|Active Comparator|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
3295217|NCT01789658|Experimental|Cryotherapy|Cryotherapy during conditioning treatment with chemotherapy prior to HSCT
3295218|NCT01789658|No Intervention|Control|Standard oral Care. No Cryotherapy during conditioning treatment prior to HSCT
3295219|NCT01789671|Experimental|Peer Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by parents who previously received this treatment (PEER). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
3295220|NCT01789671|Active Comparator|Professional Interventionist|Families randomized to this family-based behavioral intervention arm will receive 20 weeks of family-based behavioral pediatric overweight intervention delivered by behavioral specialists(PROFESSIONAL). This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
3295221|NCT01789684|Experimental|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve 1) appropriate referral of breast cancer patients at risk for HBOC to genetic counseling in the community cancer center setting and 2) pre-surgical referral among newly diagnosed patients. They will also receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
3295222|NCT01789684|No Intervention|Passive Provider Intervention|Participating Sites assigned to the passive intervention cluster will only receive the National Comprehensive Cancer Network (NCCN) guidelines and Commission on Cancer definition of qualified genetics professional.
3295223|NCT01789697|Experimental|Receives text messages/emails|Will receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
3295224|NCT01789697|No Intervention|Does not receive text messages/emails|Will not receive text messages and emails periodically from the surgeon from Day 1 (day after discharge) through day 21.
3295225|NCT01789710|Experimental|Active Contingency Management|All participants are assigned to a single arm, active contingency management. In this arm, participants are provided monetary rewards for remaining abstinent from smoking.
3295226|NCT01789723|Experimental|Cohort 1: Fusilev - 10 doses|"Fusilev: 5 mg/m2 QID, starting on Day 2 (24 ± 3 hours after Folotyn dose) for a total of 10 doses Day 2: 4 doses Day 3: 4 doses Day 4: 2 doses.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3295227|NCT01789723|Experimental|Cohort 2: Fusilev - 6 doses|"Fusilev: 5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose), 3, and 4.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3295228|NCT01789723|Experimental|Cohort 3: Fusilev - 4 doses|"5 mg/m2 BID, on Days 2 (24 ± 3 hours after Folotyn dose) and 3.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3295229|NCT01789723|Experimental|Cohort 4: Fusilev - 2 doses|"5 mg/m2 BID, on Day 2 (24 ± 3 hours after Folotyn dose.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3295230|NCT01789723|Experimental|Cohort 5: Fusilev - 1 dose|"Fusilev: 5 mg/m2 once on Day 2.~Folotyn: 30 mg/m2 once weekly for 6 weeks"
3295231|NCT01789736|Experimental|PG286|PG286 Ophthalmic Solution q.d. O.U.
3295232|NCT01789736|Experimental|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
3295233|NCT01789736|Active Comparator|Travoprost 0.004%|Travoprost 0.004% q.d. O.U.
3295234|NCT01789749|Active Comparator|No Coagulation Arm|Patients do not receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
3295235|NCT01789749|Experimental|Coagulation Arm|Patients to receive Snare Tip Soft Coagulation to the edge of the endoscopic resection defect
3295236|NCT01789762|Active Comparator|Historical control arm|Patients transfused with platelet concentrates re-suspended in autologous plasma
3295237|NCT01789762|Active Comparator|Control arm|Patients transfused with platelets prepared in additive solution
3295238|NCT01789762|Experimental|Experimental arm|Patients transfused with platelets treated by pathogen reduction process
3295239|NCT01789788|Placebo Comparator|Placebo|
3295240|NCT01789788|Experimental|RO6811135|
3295241|NCT01789801|Active Comparator|Palpation only|"Patients randomized to this arm will have radial artery puncture via palpation of arteries.~Intervention: RAP palpation only"
3295242|NCT01789801|Experimental|Ultrasound guidance|"Patients randomized to this arm will have radial artery puncture with ultrasound guidance for artery localisation.~Intervention: RAP with ultrasound guidance"
3295243|NCT01789827|Experimental|Cohort I (scintigraphy prior to immunotherapy and 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab and at 12 weeks.
3295244|NCT01789827|Experimental|Cohort II (scintograpy prior to immunotherapy, 3-4, 12 weeks)|Patients undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy prior to receiving ipilimumab or pembrolizumab, at 3-4 weeks, and at 12 weeks.
3295245|NCT01789853|Experimental|Intensive Walking|High intensity walking training in variable context for 8 weeks
3295246|NCT01789853|Active Comparator|Conventional Physical Therapy|Regular physical therapy for 8 weeks
3295247|NCT01789879|Active Comparator|Control group (no current ART)|Levonorgestrel subdermal implant in subjects not yet receiving ART (control group)
3295248|NCT01789879|Active Comparator|NVP-based ART group|Levonorgestrel subdermal implant in subjects receiving nevirapine-based ART
3295249|NCT01789879|Active Comparator|EFV-based ART group|Levonorgestrel subdermal implant in subjects receiving efavirenz-based ART
3295250|NCT01789892|Experimental|Diagnostic (methylprednisolone and FDG PET/CT scan)|Within 1-14 days of undergoing standard FDG PET/CT scan, patients receive methylprednisolone IV and then undergo a second FDG PET/CT scan.
3295251|NCT01789918|Experimental|Percutaneous renal denervation|PARADISE percutaneous renal denervation
3295252|NCT01789931|Experimental|Research arm|"The participants will undergo an examination day in which they will complete VO2max test to evaluate their aerobic fitness. Afterwards they'll undergo 3 heat tolerance test (HTT) days: without CB protective clothing, with CB protective clothing, and with work clothes. During the tests, a Lifebeam sensor will be attached to their skin."
3295253|NCT01789944|Experimental|Provide Treatment|Peers provide treatment to 2nd generation following receipt of the intervention.
3295254|NCT01789944|Experimental|Treatment Only|Peers receive treatment and return for a 6-month follow-up
3295255|NCT01789957|Experimental|Open-label AC2993|
3295259|NCT01789996|Active Comparator|Alternative six minute walk test|"Subjects will be given the following instructions~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
3295260|NCT01789996|Placebo Comparator|Standard six minute walk test|"Subjects will be given the following instruction~1. walk as far as they can in 6 minutes"
3295261|NCT01790009|Active Comparator|Flavanol Rich drink|Flavanol-rich drink containing 800 mg/75 Kg of Body Weight (BW)
3295262|NCT01790009|Active Comparator|Flavanol rich drink|Flavanol Intervention drink 400 mg/75 Kg BW
3295263|NCT01790009|Active Comparator|Acetaminophen|2 tabletsx500 mg
3295264|NCT01790022|Experimental|Methylprednisolone 500 mg|Methylprednisolone 500 mg administered intravenously at baseline
3295268|NCT01790061|Experimental|Standardized FMT|endoscopy Tubing Once or repeat
3295269|NCT01790061|Experimental|Traditional treatments|Oral Tubing
3295270|NCT01790074|Experimental|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
3295271|NCT01790074|Placebo Comparator|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
3295272|NCT01790087|Experimental|ANX-188 Therapeutic dose level|IV administration. 100 mg/kg for one hour followed by 30 mg/kg/hour for five hours
3295273|NCT01790087|Experimental|ANX-188 Supratherapeutic dose|IV administration. 300 mg/kg for one hour followed by 200 mg/kg/hr for five hours
3295274|NCT01790087|Placebo Comparator|Saline|IV administration. Six hour infusion.
3295275|NCT01790087|Active Comparator|Moxifloxacin|Oral tablet. 400 mg.
3295276|NCT01790100|Experimental|VX-135 low dose in combination with ribavirin|12 weeks of VX-135 in combination with ribavirin
3295277|NCT01790100|Experimental|VX-135 high dose in combination with ribavirin|
3295278|NCT01790139|No Intervention|Control|Control group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte and fecal/fluid tagging. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte.
3295279|NCT01790139|Experimental|Intervention-Oral Simethicone|Intervention group undergoes CT colonography after usual cathartic bowel cleansing using Colonlyte, fecal/fluid tagging, and oral administration of simethicone. The tagging is done by administering orally 50 mL of iohexol (Omnipaque 350, GE Healthcare) 10 minutes after the completion of Colonlyte. As the interventional procedure in this intervention group, 10 mL of simethicone is administered orally immediately following the administration of iohexol.
3295280|NCT01790152||Ancillary-Correlative (laboratory biomarker analysis)|Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.
3295281|NCT01790165|Experimental|TDT067|Active treatment
3295282|NCT01790165|Placebo Comparator|Placebo|Placebo
3295283|NCT01790191|Experimental|RE group|Repeated consumption of artichoke purée. This group was exposed to basic artichoke puree from Exposure 1 to 10 (E1 to E10)
3295284|NCT01790191|Active Comparator|FFL group|Repeated consumption of artichoke purée. This group (Flavor-flavor learning group) was exposed to sweet artichoke puree from Exposure 1 to 10 (E1 to E10).
3295285|NCT01790191|Active Comparator|FNL group|Repeated consumption of artichoke purée. This group (Flavor-nutrient learning group) was exposed to fat, energy-dense artichoke puree from Exposure 1 to 10 (E1 to E10).
3295286|NCT01790204|Experimental|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
3295287|NCT01790217||Cohort|
3295288|NCT01790230|No Intervention|Standard of Care|Standard of Care Arm - subjects treated by routine manner
3295289|NCT01790230|Experimental|LifeSeal™ Kit|LifeSeal™ Kit Arm - subjects treated with the LifeSeal™ Kit device + Standard of Care treatment
3295290|NCT01790256|Active Comparator|Cereve Sleep System at 14-16 degrees C.|Active
3295291|NCT01790256|Active Comparator|Cereve Sleep System at 30 degrees C|Active
3295292|NCT01790269||fingolimod treated patients|Indication for on-label treatment with fingolimod (Gilenya®) according to the current approval
3295293|NCT01790282|Experimental|estradiole - progesterone arm|Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer
3295294|NCT01790282|Active Comparator|Progesterone only arm|Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer
3295295|NCT01790308|Active Comparator|CSII|continuous subcutaneous insulin infusion for 2-4 weeks
3295296|NCT01790308|Active Comparator|Liraglutide|continuous subcutaneous insulin infusion for 2-4 weeks combined with combined with Liraglutide 0.6mg/d for 2-4 weeks and 1.2mg/d for next 9 weeks
3295297|NCT01790321|No Intervention|Pump water|Untreated pump water (pump water recognised as improved water source by WHO)
3295298|NCT01790321|Placebo Comparator|Filtered water|Pump water purified by the LSF-filtering device
3295299|NCT01790321|Experimental|Zinc water|Pump water purified and zinc-fortified by the LSF-filtering device
3295300|NCT01790334||Spontenous Ventilation (Group S)|ultrasonography of Right internal jugular vein
3295301|NCT01790334||Pressure control Ventilation (Group P)|ultrasonography of Right internal jugular vein
3295302|NCT01790334||Volume control ventilation (Group V)|ultrasonography of Right internal jugular vein
3295303|NCT01790347|Experimental|Exercise group|
3295304|NCT01790347|No Intervention|Control group|Sedentary pregnant women
3295305|NCT01790360|Active Comparator|Patient Navigation (PN)|Behavioral Intervention: 'Patient Navigation (PN) Intervention' participants will receive support from navigators in choosing a provider and remembering to attend appointments
3295306|NCT01790360|Experimental|Financial Incentives (FI)|Behavioral Intervention: 'Financial Incentives (FI) Intervention' participants will receive gift cards and money for attending clinic visits
3295309|NCT01790386||Surgical Patients Group|Patients undergoing cardiovascular surgery and cardiology procedures
3295310|NCT01790386||Reference Ranges Group|Healthy volunteer subjects for determination of normal hemostasis parameter results
3295311|NCT01790399|Experimental|Identification of sentinel node(s)|
3295312|NCT01790412|Experimental|Exercise group|"Three sessions per week:~Supervised exercise program"
3295313|NCT01790412|No Intervention|Control|Sedentary pregnant women
3295314|NCT01790425|Experimental|water colonoscopy|The water (study) method: Warm water (body temperature) will be infused into colon to open the lumen for water infusion colonoscopy. Higher rate of complete colonoscopy will be achieved.
3295315|NCT01790425|Active Comparator|Air Colonoscopy|The air (conventional) method: Air is pumped gently (insufflation) into the colon will be used to open the inside space of the colon and aid in colonoscope insertion
3295316|NCT01790451|Active Comparator|peripheral ablation|an ablation of the peripheral area of the prostate
3295317|NCT01790451|Active Comparator|More central ablation|an ablation, more centrally, in proximity of the urethra
3295318|NCT01790464|Placebo Comparator|NS gauze|Standard airway anesthesia with 20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked in normal saline (Control Group)
3295319|NCT01790464|Active Comparator|Lidocaine gauze|20 ml of aerosolized 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
3295320|NCT01790477|Experimental|Auricular Acupuncture|Use of auricular acupuncture in bilateral ears
3295321|NCT01790477|No Intervention|Control|
3295322|NCT01790529|Experimental|Early Prophylaxis|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)
3295323|NCT01790529|Active Comparator|Late Prophylaxis|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)
3295324|NCT01790542|Other|A|Iron fortified cereal
3295325|NCT01790542|Other|B|Iron fortified cereal with fruit
3295326|NCT01790542|Other|C|Meat
3295327|NCT01790555|Experimental|Namisol|The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).
3295328|NCT01790555|Other|Diazepam/Placebo|"The study medication is given from the day before surgery (day -1: 5 mg in the afternoon and in the evening) up to the fifth day after surgery (day 0 to +5: 5 mg four times daily).~Before surgery, diazepam is used as an active comparator, to aid in blinding. After surgery, an inactive placebo is used as an inactive comparator."
3295329|NCT01790607|Experimental|Subjects with moderate chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3295330|NCT01790607|Experimental|Healthy subjects matched to moderate hepatic impaired subjects|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3295331|NCT01790607|Experimental|Subjects with mild chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3295332|NCT01790607|Experimental|Healthy subjects matched to mild hepatic impaired subjects|Single IV bolus of NO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3295333|NCT01790607|Experimental|Subjects with severe chronic hepatic impairment|Single IV bolus of ONO-2745/CNS 7056 over 1 minute at 0.1 mg/kg body weight
3295334|NCT01790620|Experimental|CVVHD-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVHD with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVHD. No citrate anticoagulation will be used.
3295335|NCT01790620|Active Comparator|CVVH-ST150|Patients with sepsis whom present AKI meeting CRRT initiation criteria will be started on CVVH with PrismafleX eXeed™ II (Hospal) using an ST150SET copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface. Anticoagulation of the ST150 set with unfractioned heparin will only be initiated if there´s no clinical contraindication. ST150 set will be changed when clotted and every 24 hours during the first 72 hours of CVVH. No citrate anticoagulation will be used.
3295336|NCT01790646||patients undergoing general anesthesia|every elective patient undergoing general anesthesia for neurosurgical procedures with endotracheal intubation
3295337|NCT01790672|Placebo Comparator|Water|Lemon-flavored water. 293 ml in pilot A, 147 ml in pilot B, 235 ml in pilot C, 147 ml in the definitive study.
3295338|NCT01790672|Active Comparator|Alcoholized wine|"Wine 13º in pilot A (293 ml), B (147 ml) and the definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and 15 g of ethanol in the definitive study.~Wine 8º in pilot C (235 ml). Corresponding to 15 g of ethanol."
3295339|NCT01790672|Placebo Comparator|De-alcoholized wine|Wine 0º. Pilot A: 293ml; pilot B: 147 ml; pilot C: 235 ml; definitive study: 147 ml. Corresponding to 0 g of ethanol.
3295340|NCT01790672|Active Comparator|Ethanol|"Ethanol 13º in pilot A (293 ml), B (147 ml) and definitive study (147 ml). Corresponding to 30 g of ethanol in pilot A, 15 g of ethanol in pilot B and in the definitive study.~Ethanol 8º in pilot C (235 ml). Corresponding to 15 g of ethanol.~Ethanol was administered as a single dose of Vodka Absolut (40º) diluted in lemon-flavored water."
3295341|NCT01790711|Experimental|FMT by endoscopy|Once, fresh or frozen bacteria
3295342|NCT01790724|Experimental|Walking exercise|Participants will be instructed in safe walking exercise. They will participate in an eight week, tapered, on-site program. Participants will also attend group workshops where they will learn self-regulatory skills such as goal-setting, self-monitoring, barrier trouble-shooting, rewarding, and relapse prevention and recovery.
3295343|NCT01790724|Active Comparator|Metabolic health education|Participants will complete an eight-week online metabolic health education course. Topics will include glucose control, insulin, weight management, nutrition, physical activity, eye/kidney/foot health, stress reduction, and doctor-patient communication.
3295344|NCT01790737|Active Comparator|A|Cyclophosphamide plus filgrastim
3295345|NCT01790737|Active Comparator|B|Filgrastim
3295346|NCT01790763|Active Comparator|Keramatrix|Keramatrix
3295347|NCT01790763|Active Comparator|Mepilex|Mepilex
3295348|NCT01790776|Active Comparator|Conventional urethrography|Current golden standard.
3295349|NCT01790776|Experimental|Sono-urethrography|Experimental urethrography, which could be followed by conventional urethrography if the results are inconclusive.
3295350|NCT01790789|Experimental|Stress reduction program|
3295351|NCT01790789|Other|Attention control|
3295352|NCT01790802|Experimental|Active laser|Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
3295353|NCT01790802|Sham Comparator|Sham laser procedure|The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied. The laser remains in standby mode preventing accidental laser firing.
3295354|NCT01790841||ICD system with DF4 connection|Iforia/Ilesto ICD with DF4 connection and Linox smart DF4 lead/ Protego
3295355|NCT01790841||ICD system with DF-1 connection|Ilesto/Iforia ICD with DF-1 connection
3295356|NCT01790854|Experimental|Prasugrel dose 5 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months
3295357|NCT01790854|Active Comparator|Prasugrel dose 10 mg/day|225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of 100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months
3295358|NCT01790880|Active Comparator|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system, for 90 minutes per day, 6 days per week for 6 weeks.
3295359|NCT01790880|Experimental|ORLA + Writing|"Practice on ORLA + writing computer program, 90 minutes per day, 6 days per week, for 6 weeks."
3295360|NCT01790893|Experimental|intravitreal aflibercept injection|"Group A -Monthly intravitreal aflibercept injection for 3 months (Baseline, Months 1 and 2), then mandatory every 2 months intravitreal aflibercept injection (Months 4,6, 8 and 10)for 12 months. Monthly visits with evaluations for as needed intravitreal aflibercept injection.~."
3295361|NCT01790893|Experimental|intravitreal aflibercept|Group B- One intravitreal aflibercept injection at Baseline, then monthly visits with evaluations for as needed dosing of intravitreal aflibercept injection for 12 months.
3295362|NCT01790906|Active Comparator|RSD+Conventional therapy|We will recruit 100 randomised CHF patients who meet the inclusion criteria.First undergo renal artery angiography procedure to confirm anatomy.If renal artery meet the inclusion criteria,give the renal sympathetic denervation.At the same time, we will use conventional therapy to protect cardiac function.then we will conduct a clinic follow-up and a telephone follow-up.
3295363|NCT01790906|Placebo Comparator|Conventional therapy|We also will recruit 100 randomised CHF patients who meet the inclusion criteria.there are no significant differences in age,gender,race,past medical history,personal history and so on between the two groups.In this group we will use therapy just like the RSD+Conventional therapy group.we will conduct a clinic and a telephone follow-up.
3295364|NCT01790919|Experimental|Cognitive Therapy plus Cognitive Support|Cognitive therapy for depression with cognitive support added
3295365|NCT01790919|Active Comparator|Cognitive therapy|Cognitive therapy for depression
3295366|NCT01790945||No treatment Study|Population of subjects will have been diagnosed with mild NPDR, Moderate NPDR, Severe NPDR, PDR and DME
3295367|NCT01790971|Active Comparator|Intrathecal morphine|100μg of morphine will be added to the intrathecal mixture.
3295368|NCT01790971|Active Comparator|No Intrathecal morphine|Morphine will not be added to the intrathecal mixture.
3295369|NCT01790997|Experimental|Treatment I|1 tablet of DLBS1033 490 mg thrice daily, after meal
3295370|NCT01790997|Active Comparator|Treatment II|1 tablet of aspirin 80 mg once daily, after meal
3295371|NCT01790997|Active Comparator|Treatment III|1 tablet of clopidogrel 75 mg once daily, after meal
3295372|NCT01791010|Experimental|Inspiratory muscle training|Inspiratory muscle training for 8 weeks using a device that provides a linear resistance in the inspiratory phase. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was at 40% of Maximal Inspiratory Pressure.
3295373|NCT01791010|Sham Comparator|Training sham|Training sham for 8 weeks using a device without provides resistance. 7 days a week. 8 sets of 2 minutes twice a day. Intensity was canceled.
3295374|NCT01791023|Experimental|Physical exercise|Physical exercise
3295375|NCT01791036|Experimental|Adductor Canal Block Group|Adductor Canal Block
3295376|NCT01791036|Active Comparator|Femoral Nerve Block Group|Femoral Nerve Block
3295377|NCT01791049|Experimental|Active|Single escalating doses of TD-1607, administered intravenously
3295378|NCT01791049|Placebo Comparator|Placebo|Placebo
3295379|NCT01791062|Experimental|HYTOP®|
3295380|NCT01791075|Active Comparator|Tan Endoglide|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide.
3295381|NCT01791075|Active Comparator|Endosaver/serter|Patients assigned to this arm will have their endothelial donor graft injected into the anterior chamber using the Endosaver/serter injector.
3295382|NCT01791088|Experimental|Treatment (sirolimus)|Patients receive sirolimus PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3295383|NCT01791101|Experimental|Eltrombopag|Eltrombopag 50 mg/daily.
3295384|NCT01791114|Experimental|Cold water consumption|Subjects will participate in two trials as part of this protocol: a) cold water (4 °C) consumption and b) tepid (36 °C) water consumption
3295385|NCT01791114|Experimental|Meal consumption|Subjects will participate in two trials as part of this protocol: a) High calorie meal consumption and two weeks later b) no meal consumption.
3295386|NCT01791114|Experimental|Cold exposure|Participants will complete three studies: a) cold exposure study (above their individually determined shivering threshold ~ 16°C); b) Cold exposure plus 0.5mg/kg up to 40mg propranolol at the beginning of the metabolic study and again after 4-6 hrs; c) thermoneutral conditions (26 - 28°C).
3295387|NCT01791114|Experimental|Exercise|Subjects between 18 and 35 years old will be asked to participate in two trials: a) Exercise, i.e. four times for 10 min- at 85% VO2max (maximal oxygen consumption). with 15-min breaks between each bout b) and two weeks later rest.
3295388|NCT01791140||Cohort|
3295389|NCT01791166|Experimental|Pulmonary transplant|
3295390|NCT01791179|Experimental|Substance Abuse Treatment Group|
3295391|NCT01791192|Experimental|FTY720|Fingolimod
3295392|NCT01791192|Active Comparator|Oral Corticosteroid|Oral Corticosteroid
3295393|NCT01791218|Experimental|CABG, AVR or CABG+AVR and PVI|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis (AVR) or combination (CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation (PVI) in CBP prior to occlusion and CABG
3295394|NCT01791218|Active Comparator|CABG, AVR or CABG+AVR|Coronary artery bypass (CABG), aortic valve replacement for aortic stenosis(AVR) or combination(CABG+AVR) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation
3295395|NCT01791231|Experimental|Radiolabeled 14C-canagliflozin|Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1.
3295396|NCT01791257||SAH with DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3295397|NCT01791257||SAH without DCI|After 21 days from ictus the patients with subarachnoid hemorrhage are stratified to group 1 or 2 depending on their development of delayed cerebral ischemia.
3295398|NCT01791257||Neurological healthy controls|12 patients (ASA 1) undergoing spinal anesthesia for orthopedic surgery have 2 ml of cerebrospinal fluid drawn preceding injection of local analgetic.
3295399|NCT01791270||OSA versus Control subjects.|sleep apnea-hypopnea syndrome and control
3295400|NCT01791270||OSA patients before and after treatment, CPAP|Continuous positive pressure CPAP
3295401|NCT01791283||Healthy volunteers|Healthy volounteers with no previous medical history, age between 20-40. Both male and female. Subjects are provided extensive information about the study and the obligations and expectations included. All subjects sign a witnessed informed consent before inclusion.
3295402|NCT01791296|Experimental|Dexmedetomidine|Dexmedetomidine 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
3295403|NCT01791296|Placebo Comparator|Placebo|Normal Saline 0.2-0.7 mcg/kg/hr from 21:30 to 6:00
3295404|NCT01791309|Experimental|combination panitumumab and vemurafenib|This will be a pilot study of the combination panitumumab and vemurafenib in patients with metastatic colorectal cancer with a BRAF V600E mutation. Patients participating in this study must have BRAF V600E mutated metastatic colorectal cancer and not previously received treatment with an anti-EGFR targeting antibody (cetuximab or panitumumab).
3295405|NCT01791335||COPD patients receiving NIV|
3295406|NCT01791348|Other|d2 test of attention|
3295407|NCT01791361||Round 1|50 oncologists participate in Round 1. At least 3 medical records will be reviewed per oncologist
3295408|NCT01791361||Round 2|50 oncologists will participate in Round 2. At least 3 medical records will be reviewed per oncologist. Round 2 will occur approximately 12 months after Round 1
3295409|NCT01791361||Round 3|50 oncologists will participate in Round 3. At least 3 medical records will be reviewed per oncologist. Round 3 will occur approximately 24 months after Round 1
3295410|NCT01791374|Experimental|Rilotumumab Monotherapy|Cohort 1A: Rilotumumab 10 mg/kg IV Q2W Cohort 1B: Rilotumumab 20 mg/kg IV Q2W Cohort 1C (if needed): Rilotumumab 15 mg/kg IV Q2W
3295411|NCT01791374|Experimental|Rilotumumab plus CX|Cohort 2A: Rilotumumab 15 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W Cohort 2B (if needed): Rilotumumab 10 mg/kg IV Day 1 Q3W Cisplatin 80 mg/m2 IV (max of 6 cycles) Day 1 Q3W Capecitabine 1000 mg/m2 PO BID, Days 2-14 Q3W
3295412|NCT01791387|Experimental|Dovitinib|Dovitinib 500 mg taken orally once daily 5 days on / 2 days off, until disease progression
3295413|NCT01791400|Other|sumatriptan|Patients who underwent 6 mg sumatriptan subcutaneous one time
3295414|NCT01791400|Other|Metoclopramide|Patients who underwent 20 mg Metoclopramide intravenous one time
3295415|NCT01791426|Experimental|Artelac Rebalance|Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL.
3295416|NCT01791426|Active Comparator|Vismed|Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL.
3295417|NCT01791439|Experimental|Lidocaine|Patients in this arm will have gauze soaked with lidocaine applied to the peritonsillar pillars.
3295418|NCT01791439|Placebo Comparator|Saline|Application of saline to the glossopharyngeal nerve.
3295419|NCT01791452||NAFLD|
3295420|NCT01791478|Experimental|Treatment (PI3K inhibitor BYL719, letrozole)|Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3295421|NCT01791504|Experimental|TissuGlu Surgical Adhesive|Standard wound closure techniques plus TissuGlu and no drains.
3295422|NCT01791504|No Intervention|Control - Standard of Care|Standard wound closure techniques with drains.
3295423|NCT01791530||MV>48h|10-20 consecutive admissions with a predictive duration of intubation and mechanical ventilation > 48h.
3295424|NCT01791543|Experimental|Intramural Needle Catheter Ablation|Ablation of Ventricular Tachycardia with Intramural Needle Ablation Catheter
3295425|NCT01791556|No Intervention|Standard of Care|clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months with confirmatory or targeted viral load monitoring based upon Kenya Ministry of Health and World Health Organization guidelines
3295426|NCT01791556|Experimental|HIV-1 viral load testing|viral load in addition to clinical (World Health Organization staging) and immunological (CD4 count) monitoring every 6 months
3295427|NCT01791608|Active Comparator|Zinc sulphate|Preschool children healthy enrolled in FAN Foundation of Medellin, which will be supplied with zinc sulphate
3295428|NCT01791608|Experimental|Zinc Amino Acid Chelate|Preschool children healthy enrolled in FAN Foundation of Medellin , which will be supplied with zinc amino acid chelate
3295429|NCT01791608|Placebo Comparator|Milk without fortification|Milk without zinc
3295430|NCT01791621|Experimental|Elimination/Challenge Diet|Once non-IgE mediated food allergy testing has been administered, study participants will follow food choices according to a pre-specified elimination diet for three weeks (Elimination phase). After the Elimination phase, study participants will introduce one food every three days (Challenge phase)and monitor their symptoms. Eight different foods will be introduced in the Challenge phase of the study.
3295431|NCT01791634|Experimental|proximal open wedge osteotomy with LPS system|Proximal open wedge osteotomy with Low profile plate and screws
3295432|NCT01791634|Active Comparator|proximal wedge osteotomy|Proximal wedge osteotomy procedure
3295433|NCT01791647|Active Comparator|myo-inositol|1500 mg/day myoinositol
3295434|NCT01791647|Active Comparator|metformin|1500 mg/day of metformin
3295435|NCT01791660|Experimental|Zeltiq Coolsculpting System|non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
3295436|NCT01791673|Experimental|Ultrasound Glaucoma treatment|Cyclocoagulation using High Intensity Focused Ultrasound (HIFU)
3295437|NCT01791686|Experimental|Dense Deposit Disease|"► Induction Period~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri). There will be two doses of 5 mg/kg, with intrapatient dose-escalation in 5 mg/kg increments up to a maximum dose of 30 mg/kg. This period may last up to 8 weeks.~► Maintenance Period~The starting dose for CDX-1135 Maintenance will be the same dose level as the last dose during the Induction Period; however, the Maintenance Period allows for dose decrease to 2 mg/kg, which is lower than the starting dose in the Induction Period.~Patients will receive CDX-1135 as an IV infusion twice weekly (Mon-Thur or Tues-Fri) for up to a total of 26 weeks."
3295438|NCT01791699|Placebo Comparator|Control group|"The patients of the control group will undergo standard ablation procedure (pulmonary vein isolation) and will receive placebo, starting one week before scheduled ablation.~Optimal antihypertensive treatment will be prescribed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
3295439|NCT01791699|Active Comparator|Moxonidine group|"Patients of the active treatment group will receive moxonidine in a starting dose of 0.2 mg daily. The first dose will be administered 1 week before scheduled ablation. 3 weeks after the first dose the daily dose will be increased to 0.4 mg, if the lower dose is well tolerated.~Optimal antihypertensive treatment, in addition to moxonidine, will be prescribed, if needed, with adequate follow-up to ensure good control of hypertension (goal <= 140/90)."
3379834|NCT05132231||Matched cohort|Participants treated with other therapies, with similar characteristics as the subgroup (participants who can be linked to an administrative health services database) of brodalumab treated participants such as age, gender/sex, comorbidities, and prior biologic experience.
3295440|NCT01791712|Experimental|On-line hemodiafiltration|On-line hemodiafiltration is a type of renal replacement therapy that was assigned as the intervention to compare with the control arm
3295441|NCT01791712|Active Comparator|High-flux hemodialysis (control)|The standard high-flux hemodialysis is the routine renal replacement therapy in sepsis-related acute kidney injury patients and is assigned as the intervention for the control group.
3295442|NCT01791738|Experimental|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
3295443|NCT01791738|No Intervention|Standard total hip arthroplasty|Each surgeon will use their standard methods of pre-operative planning using pre-operative x-rays, and complete the procedure using standard surgical instruments for total hip arthroplasty.
3295444|NCT01791751|Experimental|Clomifene Citrate|Clomifene Citrate 50 mg
3295445|NCT01791751|No Intervention|Control|No intervention
3295446|NCT01791777|Experimental|Purveyor|"The purveyor arm will include SafeCare Coaching that is conducted by a Training Specialists from the National SafeCare Training and Research Center (NSTRC), a GSU (Georgia State University)-Center that conducts training and research on the SafeCare model."
3295447|NCT01791777|Experimental|Local|"The the local are will receive SafeCare Coaching that is provided by a staff member who works for the local social service agency."
3295448|NCT01791790|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3295449|NCT01791790|Sham Comparator|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3295450|NCT01791816|Experimental|Phenylephrine and L-Ng-monomethyl Arginine (L-NMMA)|
3295451|NCT01791829||Luminal A with other Clinical Criteria|BCS postulated to be at low risk for IBTR following Endocrine Therapy
3295452|NCT01791842|Experimental|Tocilizumab first, then placebo|one IV infusion per month of Tocilizumab for 6 months followed by 1 infusion per month of placebo, for 6 months.
3295453|NCT01791842|Experimental|Placebo first, then Tocilizumab|one IV infusion per month of Placebo for 6 months followed by 1 infusion per month of Tocilizumab, for 6 months.
3295454|NCT01791855|Experimental|Healthy Volunteers|
3295455|NCT01791855|Experimental|Mild Renal Impairment|
3295456|NCT01791855|Experimental|Moderate renal impairment|
3295457|NCT01791855|Experimental|Severe renal impairment|
3295458|NCT01791868|Experimental|Intravenous sodium valproate|"Intravenous sodium valproate:~30 mg/kg during 15 min then 1 mg/kg/h during 12 h"
3295459|NCT01791868|Placebo Comparator|Intravenous Placebo|"Intravenous Placebo:~NaCl 0,9 % during 15 min at first then during 12 h."
3295460|NCT01791881|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A(Botox®)
3295461|NCT01791881|Experimental|Botulinum toxin type A(Hugeltox)|Botulinum toxin type A(Hugeltox)
3295462|NCT01791907|Experimental|Structured education in carbohydrate counting|A structured education in carbohydrate counting, a course inspired by the DAFNE program (Dose Adjustment For Normal Eating)
3295463|NCT01791907|Experimental|Structured education in healthy food choices and low GI|"A new, structured education for heart healthy food choices and low glycemic index in type 1 diabetes. The education is called My Wellness-LADDER (Lifelong Adult Diet & Diabetes Education Resource) and it is specifically designed to provide high long-term adherence through improved empowerment and transformative life style change."
3295464|NCT01791907|No Intervention|Regular routine|
3295465|NCT01791920|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
3295466|NCT01791920|Experimental|Botulinum toxin type A (Botulax®)|Botulinum toxin type A
3295467|NCT01791933||CAM treatment|
3295468|NCT01791946|Experimental|Treatment Group A (Post-Surgery)|Subjects enrolled in this arm will first have eye alignment corrective surgery and then complete six weeks of the investigational binocular treatment training.
3295469|NCT01791946|Experimental|Treatment Group B (Pre-Surgery)|Subjects enrolled in this arm will first complete six weeks of the investigational binocular treatment training and then have eye alignment corrective surgery.
3295470|NCT01791946|Sham Comparator|Sham Treatment|Subjects enrolled in this arm will first complete six weeks of the sham binocular treatment and then undergo eye alignment corrective surgery.
3295471|NCT01791959|Active Comparator|Synbiotic|2 synbiotic capsules for 28 weeks
3295472|NCT01791959|Placebo Comparator|maltodexterin|two capsules per day for 28 weeks
3295473|NCT01791985|Experimental|Single arm study|"NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off."
3295474|NCT01791998|Experimental|Treatment (MR-thermal image guided LITT)|Patients undergo MR-thermal image guided LITT over 1 hour.
3295475|NCT01792011|Experimental|PVI|A new non-invasive device (Radical-7 pulse oximeter monitor, Masimo Corp.) has been introduced that continuously detects changes in the plethysmograph waveform and computes a Plethysmography Variability Index (PVI) reflecting alteration in preload and fluid management.
3295476|NCT01792037|Active Comparator|Etomidate|After taking of the blood samples, patients in Group I will be intubated with 0.3 mg/kg etomidate iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
3295477|NCT01792037|Active Comparator|etomidate, steroid|After taking of the blood samples, patients in Group II will be intubated with 0.3 mg/kg etomidate iv following a 2mg/kg methylprednisolone iv Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired.
3379835|NCT05130970|Experimental|CSL312|Administered IV and SC
3295478|NCT01792037|Active Comparator|midazolam|"After taking of the blood samples, patients in Group III will be intubated with 0.01 mg/kg midazolam iv. Blood samples will be repeated in the 4th and 24th hour of the intubation.systolic, diastolic and mean arterial pressures, heart rates will be recorded with 15 minutes intervals in the first hour and after that hourly during surgery.~Cortisol Levels in the 0,4th and 24th hour will be compared from the blood samples acquired."
3295479|NCT01792050|Placebo Comparator|Arm 1A: Docetaxel + Placebo|Arm 1A: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus placebo PO BID (days 1-14 of 21 day cycle).
3295480|NCT01792050|Experimental|Arm 1B: Docetaxel + Indoximod|Arm 1B: Docetaxel 75 mg/m^2 IV given every 3 weeks (on day 8 of 21 day cycle), plus Indoximod 1200 mg PO BID (days 1-14 of 21 day cycle).
3295481|NCT01792050|Placebo Comparator|Arm 2A: Paclitaxel + Placebo|Arm 2A: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus placebo PO BID (days 1-21 of 28 day cycle).
3295482|NCT01792050|Experimental|Arm 2B: Paclitaxel + Indoximod|Arm 2B: Paclitaxel 80 mg/m^2 IV given weekly x3 followed by a week of rest (28 day cycle), plus Indoximod 1200 mg PO BID (days 1-21 of 28 day cycle).
3295483|NCT01792063|Active Comparator|Sevoflurane A|Generic sevoflurane
3295484|NCT01792063|Active Comparator|Sevoflurane B|Orginal sevoflurane
3295485|NCT01792089||non-obese healthy subjects|subjects with BMI<25 and no known disease
3295486|NCT01792089||post-gastric bypass|post-obese subjects 12-48 months after Roux-en-Y gastric bypass
3295487|NCT01792089||matched control subjects|Nonobese, healthy subjects of similar age, weight, and gender ratio, than post-bypass subjects
3295488|NCT01792102|Experimental|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose with dexamethasone administered at 8mg.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: Carfilzomib and dexamethasone will be administered in the same fashion as the previous treatment cycles, but only on days 1, 2, 15, and 16."
3295489|NCT01792167|Experimental|Second Step|Second Step Curriculum
3295490|NCT01792167|No Intervention|Stories of Us|Stories of Us was provided to schools
3295491|NCT01792180|No Intervention|Control group|No intervention besides weekly telephone calls from the computerized falls telephone system
3295492|NCT01792180|Experimental|Intervention group|Weekly use of the mobility feedback device, use of instruction book with every day exercises, use of activity diary in intervention group.
3295493|NCT01792193||Parkinson's disease|Patients with Parkinson's disease
3295494|NCT01792193||Control|Healthy controls
3295495|NCT01792206|Active Comparator|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
3295496|NCT01792206|Placebo Comparator|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
3295497|NCT01792219|Experimental|interprofessioal education module|an interprofessional education module will be given to learn to collaborate interprofessionally.
3295498|NCT01792232|Active Comparator|Filtered air|Exposure for 2 hours to filtered air followed by subject specific allergen placed in lung
3295499|NCT01792232|Experimental|Diesel exhaust|Exposure for 2 hours to diesel exhaust followed by subject specific allergen placed in lung
3295500|NCT01792232|Active Comparator|Filtered air control|Exposure for 2 hours to filtered air followed by subject saline placed in lung
3295501|NCT01792232|Active Comparator|Diesel exhaust control|Exposure for 2 hours to diesel exhaust followed by saline placed in lung
3295502|NCT01792245|Active Comparator|NB-UVB|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
3295503|NCT01792245|Active Comparator|Topical PUVA|This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA. For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB. Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly. Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
3295504|NCT01792258||critical ill patients|The investigator will enroll all the critical ill patients undergoing percutaneous tracheostomy performed in ICU
3295505|NCT01792271|Placebo Comparator|AB: 7% HS home tx, then 0.12% NaCl|"Inhaled Inhaled 7% HS (hypertonic saline) home treatment' , then 0.12% sodium chloride solution home treatment.~The intervention consists of the subject receiving both concentrations of inhaled sodium chloride solution, each during a different home treatment periods. Subjects randomized to order AB will receive inhaled 7% NaCl (sodium chloride solution) mist during the first home treatment period, then 0.12% NaCL during the second home treatment period."
3295506|NCT01792271|Placebo Comparator|BA: 0.12% NaCl home tx, then 7% HS|Subjects randomized to order BA will receive inhaled 0.12% NaCl mist during the first home treatment period, then Inhaled 7% HS home treatment during the second home treatment period.
3295507|NCT01792297|Experimental|Bovine Colostrum|60 g/d bovine colostrum in powder form to be mixed with drinks. The dose will be spread out 3 times per day (20 g per dose)
3295508|NCT01792297|Active Comparator|Whey protein|60 g/d whey protein powder mixed into drinks. It is to be divided into 3 daily doses (20 g per dose)
3295509|NCT01792310|Experimental|Dose Cohort 1|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 7 dose cohorts of up to 6 patients have been performed in the dose escalation phase. The starting dose cohort received 250 mg twice daily.
3295510|NCT01792310|Experimental|Dose Cohort 2|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 500 mg twice daily
3295511|NCT01792310|Experimental|Dose Cohort 3|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 1g twice daily
3295512|NCT01792310|Experimental|2-OHOA Dose Cohort 4|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 2g twice daily
3295513|NCT01792310|Experimental|2-OHOA Dose Cohort 5|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g twice daily
3295514|NCT01792310|Experimental|2-OHOA Dose Cohort 6|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 4g three times daily
3295515|NCT01792310|Experimental|2-OHOA Dose Cohort 7|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA). 8g twice daily
3295516|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with malignant glioma.
3295517|NCT01792310|Experimental|2-OHOA Dose Expansion cohort. Non-glioma|Intervention: 2-hydroxyoleic acid (2-OHOA/2OHOA) at the MTD: 4g three times daily. Up to 10 patients with other advanced solid tumours that are suitable for biopsy.
3295518|NCT01792323|Experimental|1 bolus of insulin lispro with short bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 30 seconds
3295519|NCT01792323|Experimental|1 bolus of insulin lispro with long bolus duration|Subcutaneous administration of insulin lispro as a bolus of 15 IU over a period of 10 minutes
3295520|NCT01792349|Experimental|STARFISH intervention|STARFISH is a smartphone-based programme designed as a behavioural intervention to encourage the user to become more physically active
3295521|NCT01792349|No Intervention|Control group|A smartphone application will record levels of physical activity, but subjects will not have access to daily step count or to the STARFISH application.
3295522|NCT01792362|Experimental|AMH|obese PCOS patients who underwent weight loss diet
3295523|NCT01792375|Active Comparator|Concurrent membrane sweeping with Dinoprostone|
3295524|NCT01792375|Active Comparator|Dinoprostone|
3295525|NCT01792388|Placebo Comparator|Soya Bean oil|
3295526|NCT01792388|Active Comparator|Vitamin D|
3295527|NCT01792401|Placebo Comparator|Placebo|Patients on enteral feeding in intensive care units are administered a placebo
3295528|NCT01792401|Active Comparator|Probiotics|Patients on enteral feeding in intensive care unit are given a probiotic
3295529|NCT01792414|Active Comparator|Active TES|Active TES
3295530|NCT01792414|Sham Comparator|Sham TES|Sham TES
3295531|NCT01792440||non-cystic fibrosis bronchiectasis|patients with non-cystic fibrosis bronchiectasis will be evaluated cross-sectionally
3295532|NCT01792440||healthy control subjects|healthy control subjects will be evaluated cross-sectionally
3295533|NCT01792453|Experimental|240 mL water drink|Volunteers will be asked to drink 240 mL water drink
3295534|NCT01792466|Experimental|Transpacnreatic sphincterotomy|In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
3295535|NCT01792466|No Intervention|Double wire without sphincterotomy|In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation
3295536|NCT01792479|Experimental|Arm A: BIND-014 every 3 weeks|
3295537|NCT01792479|Experimental|Arm B: BIND-014 weekly|
3295538|NCT01792505|Experimental|Biological/Vaccine|
3295539|NCT01792531|Experimental|Treatment focus - Parenting vs lifestyle|To determine the effectiveness of two obesity treatment interventions: 1) parent training group (n=90) and 2) standard treatment with focus on lifestyle (n=90). The two treatment conditions will be evaluated with respect to child weight status (BMI SDS; primary outcome), psychosocial and metabolic health, lifestyle choices, and family functioning (secondary outcomes). This design will allow us to assess whether a program targeting only parents and focusing on parenting practices will result in better outcomes than treatment as usual emphasizing lifestyle changes.
3295540|NCT01792531|Experimental|Length of treatment|To understand the influence of treatment duration by comparing the effectiveness of two obesity treatment interventions: the parent training group administered for 12 wks only (n=45) and the parent training group with booster sessions which include additional booster sessions at 8-week intervals for the following year (n=45). Thus we will randomize families to either a group with booster sessions or without. This design will allow us to evaluate if prolonged care is necessary to maintain intervention effects, or if a 12-week program is equally effective.
3295541|NCT01792544|Experimental|Statement|A statement is added to the echocardiography report describing if and when a follow-up echocardiogram is recommended. The statement may be positive (e.g. follow-up recommended in 6 months) or negative (e.g. no follow-up recommended).
3295542|NCT01792544|Experimental|No Statement|No statement is added to the echocardiography report
3295543|NCT01792557|Active Comparator|Phenol|Crystallized Phenol Group
3295544|NCT01792557|Active Comparator|Limberg|Limberg Flap Group
3295545|NCT01792557|Active Comparator|Modified Limberg|Modified Limberg Flap Group
3295546|NCT01792557|Active Comparator|Karydakis|Karydakis Flap Group
3295547|NCT01792570|Experimental|RPV + DRV/r|switch to RPV + DRV/r
3295548|NCT01792570|Active Comparator|continue the PI/r-containing HAART.|continue the PI/r-containing HAART
3295551|NCT01792596|Other|pasta|1. Plain pasta
3295552|NCT01792596|Other|pasta with protein|Pasta with protein
3295553|NCT01792596|Other|pasta with fiber|Pasta with Fiber
3295554|NCT01792609|Active Comparator|Maximum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
3295555|NCT01792609|Active Comparator|Minimum Number of Screws|Once enrolled and consented, patients with Lenke 1A curves will be randomized to a high- or low-density screw cohort. The high-density pattern will be designated as ≥ 1.8 implants per level fused. The low density pattern will be ≤ 1.4 screws per level fused. At least 75% of the implants must be pedicle screws for both cohorts.
3379836|NCT05130970|Placebo Comparator|Placebo|Administered IV and SC
3295556|NCT01792622||Phase I Patient Interviews|Indepth interviews will be completed with approximately 15 patients.
3295557|NCT01792622||Phase II Patient Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I
3295558|NCT01792648|Active Comparator|Standard Reference Diet|
3295559|NCT01792648|Experimental|Almond Supplemented Diet|
3295560|NCT01792648|Active Comparator|Low Carbohydrate Reference Diet|
3295561|NCT01792661|Active Comparator|MyChart|The control group receives standard Cleveland Clinic care and has access to MyChart which is the standard Cleveland Clinic electronic PHR.
3295562|NCT01792661|Active Comparator|Enhanced MyChart|The enhanced PHR functionality adds the ability to securely receive and review CKD-education related messages to the existing features available to all PHR users. The CKD-educational related messages can be automatically delivered at pre-defined intervals and customized for each individual patient at their discretion and convenience.
3295563|NCT01792661|Active Comparator|Patient Navigator|A tracking log is kept by the Patient Navigator of each interaction regarding type of encounter, length of encounter, barriers addressed, and actions that occurred, adapting what is in use for the NIH-funded Patient Navigator program.
3295564|NCT01792661|Active Comparator|Patient Navigator and Enhanced MyChart|Combines patient self empowerment, regarding their CKD, with the Enhanced MyChart along with the aid and direction of a Patient Navigator.
3295565|NCT01792674|Experimental|In situ simulation|'In situ simulation' which is training in the actual patient care unit, in this situation the labour suite and operation theatre
3295566|NCT01792674|Active Comparator|Off site simulation|The control group will receive the same training 'off site simulation', i.e., in training rooms away from the actual patient care unit.
3295567|NCT01792687|Experimental|Treatment|ARN-509 when combined with the approved dose of abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily).
3295568|NCT01792700|Active Comparator|MEA|MEA: moxifloxacin (400 mg q.d.), esomeprazole (20 mg b.i.d), and amoxicillin (1000 mg b.i.d.)
3295569|NCT01792700|Active Comparator|EBMT|EBMT: esomeprazole (20 mg b.i.d), tripotassium dicitrate bismuthate (300 mg q.i.d), metronidazole (500 mg t.i.d), and tetracycline (500 mg q.i.d)
3295570|NCT01792713|Active Comparator|Sertaconazole 2% cream|2x daily treatment with Sertaconazole 2% cream for 4 weeks, 2 weeks follow-up
3295571|NCT01792713|Placebo Comparator|Placebo Arm|2x daily treatment with Placebo cream for 4 weeks, 2 weeks follow-up
3295572|NCT01792726|Experimental|TARGIT|The experimental policy is to give targeted intra-operative radiotherapy (TARGIT-Boost) in a single dose to substitute for the usual boost dose, in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
3295573|NCT01792726|Active Comparator|External beam radiotherapy boost|The conventional policy is to receive radiation boost to the tumour bed delivered by external beam radiotherapy (EBRT) in addition to whole breast external beam radiotherapy delivered according to local treatment guidelines.
3295574|NCT01792739|Experimental|Kadit B|Probiotic Lactobacillus casei variety rhamnosus granules
3295575|NCT01792739|Placebo Comparator|Kadit A|Placebo
3295576|NCT01792752|Experimental|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. The neighborhoods will receive the intervention at different times throughout the study period, but once the intervention is initiated in a neighborhood it will continue being implemented in that neighborhood until the end of the study period.
3295577|NCT01792752|No Intervention|Control / Neighborhood(s) not receiving the intervention|The neighborhood(s) not receiving the intervention will act as a control while the intervention is initiated and implemented in other neighborhoods. All neighborhoods will receive the intervention but at different times throughout the study period. Once the intervention is initiated in a neighborhood, that neighborhood will continue receiving the intervention until the end of the study period.
3295578|NCT01792765|No Intervention|Control Arm|This arm will undergo ureteroscopy using conventional fluoroscopy to guide the procedure and visualize scope position, safety wire status, etc.
3295579|NCT01792765|Experimental|Ultrasound guidance|This arm will have intraoperative ultrasound guidance to determine safety wire position and for scope guidance.
3295580|NCT01792778|Active Comparator|ViaValve Safety IV Catheter|Catheter insertion using the ViaValve Safety IV Catheter.
3295581|NCT01792778|Active Comparator|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|Catheter insertion using the Insyte Autoguard BC Shielded IV Catheter
3295582|NCT01792791||Single Arm|
3295583|NCT01792804|Experimental|Orally administered antibiotic|First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days
3295584|NCT01792804|Experimental|Intravenously administered antibiotic|First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days
3295585|NCT01792843||Parkinson's disease|Patients with Parkinson's disease according to international criteria
3295586|NCT01792856|Experimental|intervention group|Subjects are scheduled to receive a 6-month group-based recovery-oriented coaching program. This is a structured, manualised treatment program based on life coaching principles with cognitive-behavioural and solution-focused elements incorporated. It guides subjects to undergo an active, yet stepwise change process by stimulating motivation, setting achievable goals, generation of action plans via collaborative exploration, fostering self-regulatory capacity, and provision of autonomy-supportive treatment environment and peer support. Subjects' perceived competence, sense of control, self-management skills and hence functioning will be improved via successful experiences and positive feelings generated after attainment of self-initiated goals. Cognitive-behavioural techniques such as self-monitoring, activity scheduling and behavioural modification will be employed.
3295587|NCT01792856|Experimental|control group|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
3295588|NCT01792882||Cancer Subjects|
3295589|NCT01792895|Active Comparator|Manipulation group|This Technique will be applied over four sessions, during two weeks
3295590|NCT01792895|Active Comparator|Mobilisation|This treatment will be applied on cervical spine during four sessions, over two weeks
3295591|NCT01792895|Active Comparator|Mobilization with movement|This Technique will be applied over four sessions, during two weeks
3295592|NCT01792908|Experimental|KT group|The KT group received ankle KT on the lateral ligament in the non-dominant leg and a recommendation guide. The Kinesio tape procedure was carried out by the same certified athletic therapist to ensure consistency throughout the study.
3295593|NCT01792908|No Intervention|Control group|Any intervention has been applied. Using another kind of tape or a different KT application for control group may increase cutaneous information, undermining our goal.
3295594|NCT01792921||control waitlist|
3295595|NCT01792934|Active Comparator|XELOX or FOLFOX regimen|XELOX or FOLFOX regimen
3295596|NCT01792934|Experimental|XELOX or FOLFOX regimen and maximal tumor debulking|XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).
3295597|NCT01792947|Active Comparator|Diet|Diet 1200 Kcal during 3 months
3295598|NCT01792947|Experimental|PENS associated to diet|Percutaneous electroneurostimulation of dermatome T6 associated to diet 1200 Kcal
3295599|NCT01792960||familial hypertrophic cardiomyopathy|familial hypertrophic cardiomyopathy patients and their relatives
3295600|NCT01792999|No Intervention|Non-contrast KBCT|About 187 subjects, who had diagnostic imaging of the breast including mammography and were categorized as Breast Imaging-Reporting and Data System(BIRADS) scores 1, 2, 3, 4, or 5, received KBCT imaging without contrast injection.
3295601|NCT01792999|Experimental|Contrast-enhanced KBCT|About 231 subjects, who had diagnostic imaging of the breast including mammography and were scheduled for biopsy or surgery, received contrast-enhanced KBCT imaging of the affected breast before biopsy or surgery.
3295602|NCT01793012||critically ill intensive care patients|Treatment with one or more of the following antibiotics: piperacillin/tazobactam, cefepime, meropenem, ciprofloxacin, linezolid, colistin
3295603|NCT01793025|Experimental|ATAC Therapy|
3295604|NCT01793038|Active Comparator|CC-plus uFSH|clomiphene citrate 50 mg tablets twice/day for cycle days 3-7 plus daily IM injection of 37.5 IU HP uFSH for days 3-12
3295605|NCT01793038|Experimental|Aromataze inhibitor plus uFSH|Aromataze inhibitor (litrezole )2.5 mg twice daily for cycle days 3-7 plus daily IM injection of uFSH 37.5 IU for cycle days 3-12
3295606|NCT01793064|Experimental|Adaptive Intervention Group (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
3295607|NCT01793064|Active Comparator|Static Intervention group (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
3295608|NCT01793077||Prostate Cancer patients|
3295609|NCT01793090|Active Comparator|EPI-743|"EPI- 743 in capsule or formulation comprised of USP/NF (United States Pharmacopeia and The National Formulary)Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.~Dose: 100mg or 200 mg tid for 12 months, to be continued if clinically effective"
3295610|NCT01793090|Placebo Comparator|Placebo supplementation|placebo in the same formulation as the active comparator will be administered to patients, assigned to this arm in a randomized design
3295611|NCT01793155|Experimental|Inspiratory muscle training|Inspiratory muscle training for two weeks following surgery
3295612|NCT01793155|Placebo Comparator|Standard physiotherapy|Breathing exercises, cough/hugh, advice on early and active mobilization
3295613|NCT01793181||CRVO patients|Patients with a newly diagnosed CRVO. Maximum duration 3 months.
3295614|NCT01793181||Control patients|Controls matched for age,gender, month of onset from the Central Bureau of Statistics Sweden
3295615|NCT01793194|No Intervention|No Stocking Use|For pregnant women randomized to the no stocking use group, no compression stockings will be worn.
3295616|NCT01793194|Experimental|Compression Stocking Use|Patients who are randomized to the stocking use group (Treatment Subgroup A) will be formally measured for their stockings by a certified stocking fitter, given (at no charge) two pair of 20-30mmg Hg maternity pantyhose compression stockings, and will undergo a brief tutorial regarding how to put the stockings on. Each patient will be instructed to wear the stockings on a daily basis, during the day.
3295617|NCT01793207||Normal|Subjects who had a normal colonoscopic examination (No polyps, masses or any evidence of colorectal neoplasia)
3295618|NCT01793207||colorectal cancer|Patients with endoscopic and histopathological evidence of colorectal cancer
3295619|NCT01793207||Adenoma|Patients with colorectal adenomas only detected on colonoscopy
3295620|NCT01793207||Hyperplastic polyps|Patients with hyperplastic polyps detected on colonoscopy.
3295621|NCT01793220|Experimental|SMS Reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
3295622|NCT01793220|No Intervention|No SMS Reminders|The service user will not be sent text message reminders prior to each appointment at their Psychosis Community Service
3295623|NCT01793233||Ancillary-Correlative (menstrual diary, biomarker analysis)|Patients complete a menstrual diary to document vaginal bleeding and undergo blood sample collections at baseline, the 3rd course of chemotherapy, at the end of chemotherapy, and at 6 and 12 months post-treatment.
3295624|NCT01793246||pCLE for Discrete lung lesions|Patients undergoing bronchoscopy for the diagnosis of a lesion with probe based laser endomicroscopy (pCLE) imaging before biopsy
3295625|NCT01793246||pCLE for acute lung transplant rejection|Patients undergoing bronchoscopy for the detection of acute rejection of lung transplant with probe based laser endomicroscopy (pCLE) imaging before biopsy
3295626|NCT01793259|Other|prefilled pen then prefilled syringe|weekly methotrexate injection with a prefilled pen during 3 weeks and subsequently with the prefilled syringe the last 3 weeks
3295627|NCT01793259|Other|prefilled syringe then prefilled pen|weekly methotrexate injection with a prefilled syringe during 3 weeks and subsequently with the prefilled pen the last 3 weeks
3295628|NCT01793272|Other|Pentoxifylline|effect of pentoxifylline on ICSI outcome
3295629|NCT01793298|Experimental|Healthy Subjects - ASM-024 Single Administration|Single administration of ascending doses of ASM-024
3295630|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo|Single administration of placebo
3295631|NCT01793298|Experimental|Healthy Subjects - ASM-024 Repeat Administration|Repeat administration of ascending doses of ASM-024
3295632|NCT01793298|Placebo Comparator|Healthy Subjects - Placebo Repeat Administration|Repeat administration of ascending doses of placebo
3295633|NCT01793298|Experimental|Subjects with Asthma|Repeat administration of ascending doses of ASM-024 or placebo in a crossover fashion
3295634|NCT01793311|Sham Comparator|Group1: Decaffeinated coffee|contains 0.5-2 mg of caffeine
3295635|NCT01793311|Active Comparator|Group2: regular dose coffee|contains 91.8 mg of caffeine
3295636|NCT01793311|Active Comparator|Group3: high dose coffee|contains 144 mg of caffeine
3295637|NCT01793324||GER|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners and psychiatrists in Germany based upon patient encounters recorded in IMS Disease Analyzer during the calendar period 13 February 2012 - 31 August 2012
3295638|NCT01793324||UK|All patients with a diagnosis of schizophrenia, bipolar disorder or major depressive disorder treated with Seroquel® or Seroquel® XR seen by general practitioners in the United Kingdom based upon patient encounters recorded in IMS Disease Analyzer during the calendar period from 11 January 2012 - 31 July 2012
3295639|NCT01793337|Other|Cold first|temperature is measured in cold (-20°C) environment first, and warm (23°C) environment afterwards
3295640|NCT01793337|Other|Warm first|temperature is measured in warm (23°C) environment first, and cold (-20°C) environment afterwards
3295641|NCT01793350|Active Comparator|BC-DN-01 topically applied cream, DPN|4g topically applied BC-DN-01 cream applied twice daily to each leg and foot, for 12 weeks
3295642|NCT01793350|Placebo Comparator|Placebo topically applied cream, DPN|4g topically applied cream applied twice daily to each leg and foot, for 12 weeks
3295643|NCT01793363|Experimental|tracheotomized patients|
3295644|NCT01793389|Active Comparator|Subepithelial connective tissue graft|Soft tissue harvested from palatum of the subjects.
3295645|NCT01793389|Experimental|Platelet Rich Fibrin|Autogenous platelet and leukocyte fibrin material was obtained from blood.
3295646|NCT01793402||Preterm infants born at or less than 32 weeks gestation|
3295647|NCT01793415|Active Comparator|IodoCarb (r)|3 g iodinated activated charcoal, IodoCarb(r), daily for 28 +-2 days.
3295648|NCT01793415|Placebo Comparator|Placebo|3 g of non-iodinated activated charcoal daily for 28+-2 days.
3295649|NCT01793428||Injured patient admitted in vital emergency unit|
3295650|NCT01793441|Placebo Comparator|Placebo|Participants will receive placebo matching to RG7314 in each stage (Stage I, II, III and IV) for 12 weeks.
3295651|NCT01793441|Experimental|RG7314|Participants will receive RG7314 orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
3295652|NCT01793454|Active Comparator|40% oxygen|Patients in this group will be ventilated with fraction of inspired oxygen 40% during the surgery.
3295653|NCT01793454|Active Comparator|80% oxygen|Patients in this group will be ventilated with a fraction of inspired oxygen 80% during the surgery.
3295654|NCT01793480|Experimental|patient-controlled dose of methadone|The titration will be done on the patient's request (patient-controlled dose of methadone), with no overlapping with the previous opioid treatment, under the investigator's supervision.
3295655|NCT01793480|Experimental|fixed-dose of methadone|The titration will be done with fixed-dose of methadone, on a progressive switch with overlapping with the previous opioid treatment, to avoid withdrawal syndrome when the opioid is discontinued.
3295656|NCT01793493|Experimental|Cognitive stimulation|
3295657|NCT01793493|Active Comparator|Sanitary education|
3295658|NCT01793506||PID|Any subject having testing done to evaluate the immune system is eligible for this study. This will include patients with known PIDs as well as patients evaluated for a suspected immunodeficiency.
3295659|NCT01793519|Active Comparator|Anti-tumor necrosis factor agent|Anti-TNF agent - etanercept, infliximab, adalimumab - administered parentally at standard dosage and frequencies
3295660|NCT01793519|Placebo Comparator|Placebo|Administered appropriately to active comparator
3295661|NCT01793545||Endometrial Cancer Cohort|Women with abnormal bleeding or other conditions associated with increased risk ofendometrial cancer.
3295662|NCT01793558|No Intervention|Control; passive insulation|The mothers will receive passive temperature insulation by a cotton blanket (standard procedure) after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the cotton blanket (also passive insulation without active warming) for 20 min after birth (bonding period).
3295663|NCT01793558|Experimental|Active Warming|The mothers will receive active warming by a forced-air warming blanket after start of the spinal anaesthesia for cesarean section. The newborn will be bonded on the mothers chest under the warming blanket for 20 min after birth (bonding period).
3295664|NCT01793571|Experimental|TAP block|20 ml Levobupivacaine 0,5%
3295665|NCT01793571|Active Comparator|Local wound infiltration|20 ml levobupivacaine 0,5%
3295666|NCT01793584|Active Comparator|Laparoscopic hysterectomy|Total laparoscopic hysterectomy, laparoscopic assisted vaginal hysterectomy
3295667|NCT01793584|Active Comparator|Abdominal hysterectomy|Total Abdominal Hysterectomy
3295668|NCT01793597||clopidogrel|previous treatment with clopidogrel
3295669|NCT01793597||ticagrelor|previous treatment with ticagrelor
3295670|NCT01793623||nonemergent heart surgery, atrial tissue|patients undergoing non-emergent heart surgery
3295671|NCT01793636|Experimental|AZD2014|AZD2014- tablets, starting dose 50mg BD everyday, until disease progression or untolerable toxicity
3295672|NCT01793636|Active Comparator|Everolimus|Everolimus- tablets, starting dose 10mg OD everyday until disease progression or untolerable toxicity
3295673|NCT01793649|Experimental|Cross-Over Sequence 1|85 μg GS-5737 in 2.8% saline or 2.8% saline alone (blinded)
3295674|NCT01793649|Experimental|Cross-Over Sequence 2|2.8% saline alone or 85 μg GS-5737 in 2.8% saline (blinded)
3295677|NCT01793675||haploidentical transplant|transplant with haploidentical donor
3295678|NCT01793727|Experimental|Glidescope intubation|Comparison of direct laryngoscopy and Glidescope videolaryngoscopy
3295679|NCT01793740|Experimental|Cogmed|These children are enrolled in the Cogmed intervention.
3295680|NCT01793740|No Intervention|Waitlist|These children are enrolled in a waitlist condition, after which they will be offered the opportunity to complete the intervention.
3295681|NCT01793753||Propofol|Chronically constipated children ages 2-6 years who will receive anesthesia for anorectal manometry including propofol per standard of care
3295682|NCT01793766|Experimental|Brain modulation|10 sessions of brain modulation with Eldith/Neuroconn transcranial Direct Current Stimulation device
3295683|NCT01793766|Placebo Comparator|Placebo (sham modulation)|10 placebo sessions where no brain modulation takes place
3295684|NCT01793779|Placebo Comparator|Control|Placebo supplement given prior to exercise and two times per day following exercise
3295685|NCT01793779|Experimental|cold water immersion|Placebo supplement to be give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
3295686|NCT01793779|Experimental|HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement to be give prior to exercise and two times per day following exercise
3295687|NCT01793779|Experimental|cold water immersion group + HMB-FA|beta-hydroxy-beta-methylbutyrate free acid supplement give prior to exercise and two times per day following exercise in combination with cold water immersion therapy following exercise
3295688|NCT01793805||Metastatic Colorectal Cancer Patients|
3295689|NCT01793818|Placebo Comparator|Group 1 Phase I/II|Three injections with no active principle
3295690|NCT01793818|Active Comparator|Group 2 Phase I/II|Three injections of Tat Oyi vaccine containing 11 µg of active principle
3295691|NCT01793818|Active Comparator|Group 3 Phase I/II|Three injections Tat Oyi vaccine containing 33 µg of active principle
3295692|NCT01793818|Active Comparator|Group 4 Phase I/II|Three injections Tat Oyi vaccine containing 99 µg of active principle
3295693|NCT01793831|Experimental|Fecal microbiota transplantation|Standard fecal microbiota transplantation, once.
3295694|NCT01793844||A (R-CHOP21)|"CHOP combined with Rituximab regimen（R-CHOP21）~Treatment Arm A(R-CHOP21): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P) 60mg/m2 orally on days 2 to 6. The therapy was repeated every 21 days for a total of 6 cycles."
3295695|NCT01793844||B (CHOP14)|Biweekly CHOP regimen （CHOP14） Treatment Arm B (CHOP14): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50mg/m2 for injection on day1; and Vincristine(O), 1.4 mg/m2 for injection on day1, prednisone(P) 60mg/m2 orally on days 1 to 5. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 6 for a total use of 6-8 days.
3295696|NCT01793844||C （R-CHOP14)|Biweekly CHOP combined with Rituximab regimen（R-CHOP14） Treatment Arm C (R-CHOP14): Rituximab 375mg/m2 for injection on day1; cyclophosphamide(C), 750mg/m2 for injection on day2; doxorubicin(H), 50mg/m2 for injection on day2; and Vincristine(O), 1.4mg/m2 for injection on day2, prednisone(P),60mg/m2 orally on days 2 to 6. The therapy was repeated every 14 days for a total of 6 cycles.PS: G-CSF 1.0-2ug/kg/ d for subcutaneous injections will be administered on day 7 for a total use of 6-8 days patients with bulky disease or extranodal lesion wil be received radiotherapy after finishing the chemotherapy.
3295697|NCT01793857||Study Group|Approximately 1300 primary caregivers of at least one child aged 6 months to less than 30 months who were interviewed during a clinic visit in Panama.
3295698|NCT01793870|Experimental|Treatment A (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 milligram [mg]) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3295699|NCT01793870|Experimental|Treatment B (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3295700|NCT01793870|Experimental|Treatment C (33.75 mg total maximum dose)|Single oral dose of carvedilol (31.25 mg) as a 1 x 25 mg immediate release tablet, a 1 x 6.25 mg immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fasted conditions.
3295701|NCT01793870|Experimental|Treatment D (27.5 mg total maximum dose)|Single oral dose of carvedilol (25 mg) as a 1 x 25 mg x immediate release tablet and up to 2.5 mg of enriched carvedilol drug substance under fed conditions.
3295702|NCT01793896|Sham Comparator|control period|control period with no intervention. Comparison of parameters at entrance and one month later without any intervention
3295703|NCT01793896|Experimental|Diet group|Mediterranean diet prescription during 3 months
3295704|NCT01793896|Experimental|Exercise group|Subjects will be trained 3 times a week during 3 months
3295705|NCT01793896|Experimental|Diet + Exercise|Both a dietary prescription plus exercise training during 3 months
3295706|NCT01793922|Active Comparator|PD|pneumodilation
3295707|NCT01793922|Active Comparator|POEM|peroral endoscopic myotomy
3295708|NCT01793948|Experimental|Arm I (metformin hydrochloride)|Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3295709|NCT01793948|Placebo Comparator|Arm II (placebo)|Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
3295710|NCT01793961|Other|"Cannabis Arm"|patient addicted to cannabis
3295711|NCT01793961|Other|"Tobacco Arm"|patient addicted to tobacco
3295712|NCT01793961|Other|"Healthy volunteers"|no smokers
3295713|NCT01793974||Latent Autoimmune Diabetes in Adult|Individuals who meet criteria for Latent Autoimmune Diabetes in Adult
3295714|NCT01793974||Without Latent Autoimmune Diabetes in Adult|Individuals who do not meet criteria for Latent Autoimmune Diabetes in Adult
3295715|NCT01793987|No Intervention|control: shaver|
3295716|NCT01793987|Experimental|Coblation polypectomy|
3295717|NCT01794013|Active Comparator|Parent trianing|The parent training group will learn about DIR/ Floortime™ model approach through one on one coaching for 1 hour at the beginning of the study, the end of 1st and 3th month and through 2 hours DVD lecture and a pocket book.
3295718|NCT01794013|Active Comparator|Routine care|The children in the control group will continue their standard routine care.
3295719|NCT01794026|Experimental|diffusion MRI|histopathology of lymph nodes diagnosed by diffusion weighted magnetic resonance imaging
3295720|NCT01794052|Experimental|DSS enabled health care delivery model|Evidence based, DSS enabled, health care delivery model
3295721|NCT01794065||Cypher|100 patients who have received a Cypher stent during their coronary intervention
3295722|NCT01794065||Taxus Express|100 patients who have received a Taxus Express stent during their coronary intervention
3295723|NCT01794065||Endeavor|100 patients who have received an Endeavor stent during their coronary intervention
3295724|NCT01794065||Promus/Xience V|100 patients who have received a Promus/Xience V stent during their coronary intervention
3295725|NCT01794065||Promus Element|100 patients who have received a Taxus Element stent during their coronary intervention
3295726|NCT01794078|Placebo Comparator|Control|Oral placebo, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3295727|NCT01794078|Experimental|Aminophylline 400 mg|Oral aminophylline 400 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3295728|NCT01794078|Experimental|ambrisentan 5 mg|Oral ambrisentan 5 mg, administered as single dose during simulated altitude episodes Cycle 1 and Cycle 2
3295729|NCT01794078|Experimental|Combined aminophylline 400 mg and ambrisentan 5 mg|Oral combined aminophylline 400 mg and ambrisentan 5 mg, administered as single doses during simulated altitude episodes Cycle 1 and Cycle 2
3295730|NCT01794091|Experimental|Eplerenone|In a subgroup of 50 patients, 25 will be randomized to eplerenone to assess effects on fibrotic index pre- and post-6 months of therapy.
3295731|NCT01794091|Placebo Comparator|Sugar pill|
3295732|NCT01794104|Experimental|1|Open-label Phase I trial evaluating weekly administration of LMP400, on days 1, 8, and 15, in 28-day cycles.
3295733|NCT01794143|Active Comparator|Sulfonylurea (glimepiride)|Sulfonylurea
3295734|NCT01794143|Active Comparator|DPP-4 inhibitor|DPP-4 inhibitor (sitagliptin)
3295735|NCT01794143|Active Comparator|GLP-1 receptor agonist|GLP-1 receptor agonist (liraglutide)
3295736|NCT01794143|Active Comparator|Insulin (glargine)|Insulin (glargine), Lantus
3295737|NCT01794156|Active Comparator|Cognitive behavior therapy|"The cognitive-behavioral model is presented and individualized.~Cognitive correction: beliefs are addressed by explaining their roles in maintaining cognitive biases. Next, clients are trained to identify and to challenge their key beliefs~Exposure and response prevention (ERP) using imaginal and in vivo exposure and to both over and covert neutralization is implemented according to hierarchies developed following the individual assessment. Extended periods of exposure permits emotional discomfort to dissipate.~Combined phase: continues ERP while making explicit links to the cognitive targets.~Relapse prevention included a written individualized guide to encourage the maintenance of treatment gains. Self-directed ERP continues."
3295738|NCT01794156|Active Comparator|Mindfulness-based stress reduction (MBSR)|The entire intervention is based on systematic and intensive training in MBSR following Santorelli and Kabat-Zinn and their applications to everyday life. The program is divided in 8 consecutive blocks with daily homework in mindfulness-based stress reduction skills. The main activity of MBSR is a cognitive and intervention-based process characterized by self-regulation of attention to the present moment and an open and accepting orientation towards one's experience.
3295739|NCT01794156|Experimental|Inference-based therapy|"The inference-based therapy will be delivered in 10-step~The client will:~learn that the compulsions, anxiety and discomfort are driven by an initial obsessional doubt~learn why this doubt is 100% irrelevant here and now~learn the inferential confusion process~have to recognize that the doubt originates from him/her~have to identify/describe the narrative leading him/her to the doubt~have to identify the cross-over point when he/she leaves reality~learn to be aware of the reasoning devices~learn how personal themes dictate the idiosyncratic nature of the person's obsession~explore and reinforced an alternative self-view~be trained to use properly his/her senses in the face of obsessional triggers situations"
3295740|NCT01794169|Experimental|Azacitidine|Azacitidine 75mg/m2/d subcutaneously once daily for 5 days given every 5:th week for 8 cycles.
3295741|NCT01794169|Active Comparator|DA|"Two courses of DA in accordance with the Swedish National treatment program (reduced doses):~In case one induction course was given:~First consolidation course: daunorubicin 45 mg/m2 x 1 (iv infusion) day 1-3 and cytarabine 1000 mg/m2 x 2 (iv infusion) day 1-4.~Second consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~In case two induction courses were given:~First consolidation course: daunorubicin 45 mg/m2 x 1( iv infusion) day 1-2 and cytarabine 200 mg x 2 (fixed dose sc injection) day 1- 5.~Second consolidation course: cytarabine 200mg x 2 (fixed dose sc injection) day 1-5."
3295742|NCT01794182|Placebo Comparator|Matching Placebo|Participants received a bolus dose of matching placebo over 2 minutes, followed by a continuous matching placebo infusion for 72 hours.
3295743|NCT01794182|Experimental|Glyburide for Injection|Participants received a 0.13 mg bolus dose of glyburide over 2 minutes, followed by a 0.16 mg/hr continuous infusion for 6 hours and than a 0.11 mg/hr for 66 hours for a total dosing period of 72 hours.
3295744|NCT01794195|Experimental|apathetic patients with Parkinson's disease|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3295745|NCT01794195|Experimental|non apathetic paired patients|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3295746|NCT01794195|Experimental|healthy paired control|The objective of this study is to explore, using diffusion weighted MRI, the regions of the brain which are proposed to play a role in motivation in apathetic Parkinson's disease patients and to define more precisely the relation between dopaminergic fibres and the meso-cortico-limbic system with the help of tractography methods
3295747|NCT01794208|Experimental|treatment 1|Follitropin Epsilon 52.5 IU quaque die (QD) s.c.
3295748|NCT01794208|Experimental|treatment 2|Follitropin Epsilon 75 IU QD s.c.
3295749|NCT01794208|Experimental|treatment 3|Follitropin Epsilon 112.5 IU QD s.c.
3295750|NCT01794208|Experimental|treatment 4|Follitropin Epsilon 150 IU QD s.c.
3295751|NCT01794208|Experimental|treatment 5|Follitropin Epsilon 150 IU quaque altera die (QAD) s.c.
3295752|NCT01794208|Active Comparator|treatment 6|Follitropin alfa 150 IU QD s.c.
3295753|NCT01794221|Active Comparator|Stitches only|Stitches only closing circumcision wound
3295754|NCT01794221|Experimental|Stitches and skin adhesive|application of 2-octyl cyanoacrylate skin adhesive.
3295755|NCT01794234||Cohort|
3295756|NCT01794247|Experimental|Intrathecal magnesium|Intrathecal magnesium sulfate 15% 0,5 mL (75 mg) is added to lidocaine 5% 1 mL (50 mg)as anesthetic adjuvant
3295757|NCT01794247|Active Comparator|Intrathecal fentanyl|Intrathecal fentanyl 0.5 mL (25 micrograms)is added to lidocaine 5% 1 ML (50 mg) as anesthetic adjuvant
3295758|NCT01794260|Placebo Comparator|Placebo cream|Placebo cream
3295759|NCT01794260|Experimental|Plai cream|Cream from Zingiber cassumunar Roxb. extract
3295760|NCT01794273|Experimental|ephedrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
3295761|NCT01794273|Experimental|phenylephrine|This is a randomised trial comparing ephedrine and phenylephrine as used for accidental hypotension occurring during carotid surgery, on cerebral perfusion, assessed by near-infrared spectroscopy (NIRS).
3295762|NCT01794286|Active Comparator|Control Group|Trigger alerts only
3295763|NCT01794286|Experimental|Intervention Group|Trigger alerts + provider bulletins
3295764|NCT01794325|Active Comparator|Trans-radial access|Coronary angiography performed through trans-radial access
3295765|NCT01794325|Active Comparator|Trans-femoral access|Coronary angiography performed through trans-femoral access
3295766|NCT01794338|Experimental|Bio-A Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected."
3295767|NCT01794338|Active Comparator|Strattice Arm|"Patients will receive underlay mesh tissue reinforcement followed by standard fascial closure with #1 PDS. As described by Dr. Stoppa10-12, the mesh will be secured via abdominal wall sutures. Additional full thickness sutures will be placed every 8 cm circumferentially. After securing the mesh in place, #1 PDS sutures will be used to close the fascia in a running fashion with 1.5-2 cm bites from the fascial edge and a 1cm walk between stitches. Skin will be closed with staples or monofilament suture according to surgeon preference. Drains will be placed on the mesh in each case, and one or two drains will be placed in the subcutaneous tissues at the discretion of the surgeon depending on the amount of subcutaneous tissue dissected.."
3295768|NCT01794351|Experimental|Placebo then resveratrol|Participants in this arm (decided according to Latin square) first received placebo and then resveratrol, on seperate days, with a 7-14 day wash-out period between visits.
3295769|NCT01794351|Experimental|Resveratrol then placebo|Participants in this arm (decided according to Latin square) first received resveratrol and then placebo, on seperate days, with a 7-14 day wash-out period between visits
3295770|NCT01794364|Experimental|Experimental: Cohort A|Each subjects in Cohort A will receive 2 single doses of PF-06291874 and 1 placebo dose in random order in Periods 1-3; in addition, 1 dose of PF-06291874 will be administered in Period 4 in the fed state.
3295771|NCT01794377|Active Comparator|40 of an endurance training|Endurance training at 50% of VO2 peak measured by indirect calorimetry. Dietary Supplement: supplementation in fruits and vegetables.
3295772|NCT01794377|Experimental|30 minutes of a high intensity training|"This arm consist of an interval strength training for 30 min on bicycle ergometer (which include strengthening exercises in an high intensity interval training).~Dietary Supplement: supplementation in fruits and vegetables."
3295773|NCT01794390||Turbuhaler and MDI patients (Arm 1)|Patients (Diskus naive) will be randomised to receive training on the PulmoJet© device followed by Diskus, or vice versa
3295774|NCT01794390||Diskus patients (Arm 2)|Patients (Turbuhaler naive) will be randomised to receive training on the PulmoJet© device followed by Turbohaler, or vice versa
3295777|NCT01794416|Active Comparator|Thoracoscopic epicardial ablation|"Patients were treated with video-assisted thoracoscopy under general anesthesia. PVI was performed from the epicardial side with a bipolar RF ablation clamp (AtriCure). At least 2 overlapping applications around each of the ipsilateral veins were made, and isolation was confirmed by the absence of PV potentials and exit block during pacing. An additional application was made in the interatrial Waterston groove in the right side to isolate the ganglionic plexi from the atria. On the left side, the ligament of Marshal was cut, but no additional ablation of ganglionic plexi was pursued.~The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
3295778|NCT01794416|Active Comparator|Endocardial catheter ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster). The RevealXT (implantable loop recorder) was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
3379837|NCT05130294|Active Comparator|Best Standard of Care + CARDIO®|6 gram/day ( 1000 mg per capsule) of unrefined salmon oil, duration of 20 weeks. CARDIO® capsule contains 1000 mg of full spectrum of omega fatty acids, including 21 different fatty acids, with a minimum of 270 mg polyunsaturated fatty acids (PUFA) and10 mg lipopeptides.
3379838|NCT05130294|Placebo Comparator|Best Standard of Care + Placebo|6 gram/day (1000 mg per capsule) of natural oil, duration of 20 weeks. The placebo is a medium-chain triglyceride (MCT), with triglyceride from natural fatty acid, mainly caprylic- and capric acid.
3379839|NCT05130034|Experimental|Home-based pulmonary rehab for fibrotic interstitial lung disease|Subjects diagnosed with fibrotic interstitial lung disease will participate in a home-rehab program that promotes more physical activity in daily life.
3295779|NCT01794429|Placebo Comparator|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
3295780|NCT01794429|Active Comparator|exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
3295781|NCT01794442||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3295782|NCT01794442||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3295783|NCT01794442||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3379840|NCT05129423|Experimental|Part 1: MTPS9579A Dose A|In Part 1, participants will receive MTPS9579A dose A every 4 weeks from randomization to Week 12.
3379841|NCT05129423|Placebo Comparator|Part 1: Placebo|In Part 1, participants will receive placebo matched with MTPS9579A, every 4 weeks from randomization through Week 12.
3295784|NCT01794468|Experimental|study group-Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor
3295785|NCT01794481|No Intervention|Usual Care|Participants allocated to usual care will receive their usual treatment program which will include dietician counseling as needed. As part of standardized care, participants will not be encouraged to begin a new exercise program(patients needing physical therapy at time of enrollment will be excluded.
3379842|NCT05129423|Experimental|Part 2: MTPS9579A Dose A|In Part 2, participants will receive MTPS9579A dose A, every 4 weeks from randomization to Week 12.
3379843|NCT05129423|Experimental|Part 2: MTPS9579A Dose B|In Part 2, participants will receive MTPS9579A dose B, every 4 weeks from randomization to Week 12.
3379844|NCT05129423|Experimental|Part 2: MTPS9579A Dose C|In Part 2, participants will receive MTPS9579A dose C, every 4 weeks from randomization to Week 12.
3379845|NCT05129423|Experimental|Part 2: MTPS9579A Dose D|In Part 2, participants will receive MTPS9579A dose D, every 4 weeks from randomization to Week 12.
3379846|NCT05129423|Placebo Comparator|Part 2: Placebo Dose A|In Part 2, participants will receive placebo matched with MTPS9579A dose A and B, every 4 weeks from randomization through Week 12.
3379847|NCT05129423|Placebo Comparator|Part 2: Placebo Dose B|In Part 2, participants will receive placebo matched with MTPS9579A dose C and D, every 4 weeks from randomization through Week 12.
3379848|NCT05128474|Experimental|Group 1|Neuromuscular Control-Based Exercise Training Group
3379849|NCT05128474|Active Comparator|Group 2|Conventional Exercise Training Group
3379850|NCT05127486|Experimental|Galcanezumab|"Galcanezumab administered subcutaneously (SC).~Placebo for rimegepant will be used for blinding."
3379851|NCT05127486|Active Comparator|Rimegepant|"Rimegepant administered oral disintegrating tablets (ODT).~Placebo for galcanezumab will be used for blinding."
3379852|NCT05126966|Experimental|Ranibizumab|Subjects will have the implant (filled intra-operatively prior to implantation with approximately 20 µL of the 100-mg/mL formulation of ranibizumab [approximately 2-mg dose of ranibizumab]) surgically inserted in the study eye at the Day 1 visit following their randomization visit. Subjects will have their implant refilled with ranibizumab at weeks 36 and 72.
3379853|NCT05126966|Active Comparator|Aflibercept|Subjects will receive intravitreal injections of aflibercept (2mg) administered in the study eye per treat-and-extend. The decision to extend, maintain, or reduce the interval until next treatment will be per investigator judgment.
3379854|NCT05125367||multivessel coronary artery disease|From BEST trial study population_NCT00997828
3379855|NCT05121103|Experimental|Open-label EZM0414|
3379856|NCT05120869|Experimental|Treatment|A tailored HPV education and professional skills intervention.
3379857|NCT05120869|Active Comparator|Control|General/publicly available educational materials on HPV and communication skills.
3379858|NCT05119569|Experimental|fenebrutinib|Participants will receive oral fenebrutinib.
3379859|NCT05119569|Placebo Comparator|placebo|Participants will receive oral placebo.
3295786|NCT01794481|Experimental|Resistance Exercise Training|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
3295787|NCT01794494||Open surgical group|Bypass surgery for critical limb ischemia
3295788|NCT01794494||Endovascular treatment|Endovascular recanalization for critical limb ischemia
3295789|NCT01794507|Experimental|ABT-199 + BTZ/Dex Dose Escalation Cohorts|Evaluate the safety and pharmacokinetics profile of ABT-199 administered with standard therapy bortezomib and dexamethasone in a dose escalation scheme in approximately 54 subjects.
3295790|NCT01794507|Experimental|ABT-199 + BTZ/Dex Safety Expansion Cohort|Safety expansion cohort to further evaluate recommended phase two dose (RPTD) of ABT-199 administered with standard therapy bortezomib and dexamethasone in approximately 12 subjects.
3295791|NCT01794533|Placebo Comparator|Lidocaine with Epinephrine+ Normal saline|
3295792|NCT01794533|Active Comparator|Lidocaine with Epinephrine + fentanyl|
3295793|NCT01794546|Experimental|Immediate Telehealth|"The immediate intervention group will receive the telehealth intervention during the first 6 months of the study timeline."
3295794|NCT01794546|Active Comparator|Wait List Control|"The wait list control group will receive the telehealth intervention during months 6 through 12 of the study timeline."
3295795|NCT01794559|Experimental|Informed by PEER Interactive Report|"The PEER Interactive Report -This study is prospective in nature. For subjects in the experimental group, the treating physician will follow the guidance of the subject's PEER Interactive Report as regards sensitivity to on-label medications and classes of medication.~The subjects will be washed out of all current medications prior to having an EEG, which is necessary to generate the PEER Interactive Report. The wash out period for outpatients is no longer than 14 days.~The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health."
3295796|NCT01794559|No Intervention|No Report|This study is prospective in nature. Subjects in the control group will be treated according to treatment as usual and best judgment of the treating physician. PEER Interactive Report is not provided to the investigator. The subjects will be followed for 6 months after the initial treatment, or until the patient has achieved maximum medical improvement (MMI). The patient will be seen on a routine basis and assessments will be made at each interaction to evaluate the patient's improvement in mental health.
3295797|NCT01794572|Experimental|Total BM irradiation dose|"Total Bone Marrow Irradiation (TBMI) is delivered by the Tomotherapy HI-ART machine, in 2 fractions per day during 4 consecutive days from d -6 to d -3. The escalated dose levels are determined according to a 3x3 modified Fibonacci method and five dose levels will be explored. The doses per fraction are: 1gy, 1.25gy, 1.5gy, 1.75gy and 2gy, and consequently the cumulative TBMI doses are: 8gy, 10gy, 12gy, 14gy and 16gy.~For Every patients:~Drug : Melphalan is infused intravenously in 30 minutes on day -2 after IV anti-emetics.~Autologous Peripheral Stem Cell Rescue : are re-infused in the central line on day 0 after adequate premedication."
3295798|NCT01794585|Experimental|Virtual Reality Based Exercise|
3295799|NCT01794585|Active Comparator|Standard Exercise|
3295800|NCT01794598|Experimental|Educational materials|Receiving educational materials of depression care
3295801|NCT01794598|Sham Comparator|No educational materials|Receiving an envelope but no inclusion of educational materials of depression care
3295802|NCT01794611|Experimental|Laryngoscopy|Patients will be intubated by an experienced anesthesiologists. Anesthesiologist first uses Macintosh laryngoscope then KingsVision videolaryngoscope and lastly C-MAC videolaryngoscope to intubate patients. Cormack-Lehane scores, the time from the start of laryngoscopy to visualization of the vocal cords and the time from the visualization of the vocals from the successful intubation will be recorded. The success of the intubation will be assessed with bilateral chest auscultation. If visualization of the vocal cords or placing of the endotracheal tube was not successful after 60 seconds with a particular laryngoscope, it will be left out and patient will be ventilated for 1 minutes and then pass to other laryngoscopes.
3295803|NCT01794624|Active Comparator|Cognitive Therapy|Cognitive Therapy for Catastrophizing
3295804|NCT01794624|Active Comparator|Behavioral Therapy|Behavioral Therapy for Sleep Continuity Disturbance
3295805|NCT01794624|No Intervention|TMJD Education|6-sessions of TMJD disease education/support control
3295806|NCT01794637||the end-stage liver disease patients|the end-stage liver disease scheduled for liver transplantation
3295807|NCT01794650|Other|Meal composition|Changing the glycaemic index of the meals consumed after exercise and before sleep. (High GI - High GI, Low GI - Low GI, High GI - Low GI, Low GI - High GI).
3295808|NCT01794663|Experimental|OPN-305|
3295809|NCT01794663|Placebo Comparator|Matching placebo|
3295810|NCT01794676||Family 1|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3295811|NCT01794676||Family 2|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3295812|NCT01794676||Family 3|Approximately a 10 ml of blood draw will be taken from each participant for genetic testing.
3295813|NCT01794728||Elderly inpatients with heart failure|A single cohort group of elderly patients hospitalized for heart failure.
3295814|NCT01794754|Other|Control|Care as usual
3295815|NCT01794754|Experimental|Occupational therapy|Occupational therapy
3295816|NCT01794767|Active Comparator|0,9% NaCl flush|for children enrolled in this group, the nurse will perform the flushing of peripheral venous catheter using flush-solution as a bolus with saline 0.9% NaCl in the amount (ml) needed to fill the entire circuit of the catheter. The flushing will be performed routinely at the end of each fleboclisis
3295817|NCT01794767|Experimental|Heparin 50U/ml|for children enrolled in this group, the nurse will perform the washing of peripheral venous catheter using flush-solution as a bolus with heparin 50U/ml in the amount (ml) needed to fill the entire circuit of the catheter. The washing will be performed routinely at the end of each fleboclis
3295818|NCT01794793|Experimental|Pasireotide subcutaneous|0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines. Cabergoline may be combined in this arm for Cushing's Disease and Acromegaly patients.
3295819|NCT01794793|Experimental|Pasireotide Long Acting Release (LAR)|10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
3295820|NCT01794819|Experimental|C-reactive protein test|"The C-reactive protein test was performed in the intervention group at both the first and second consultations.~The Afinion test system (Axis Shield) was used, which provides results within 5 minutes and before treatment was determined. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L."
3295821|NCT01794832||Elderly with severe aortic stenosis|Patients with severe symptomatic aortic stenosis referred for consideration of surgical aortic valve replacement
3295822|NCT01794858|Experimental|Therapeutic Hypothermia|"Primary - Organ specific outcome at 28 days Logistic Organ Dysfunction Score (LOD) will be compared before and after TH. Change in LOD will reflect LOD day 4 minus LOD day 1 (Ehrmann, Can J Anesth 2006).~Secondary~Lab values: D-Dimer, IL-6, CRP~APACHE II Scores Day 1 and after TH (day 4)~Length of stay in the ICU and hospital~Prevalence of infections~28-day mortality~Hypothermia-related side effects: cardiac arrhythmia, electrolyte balance, hyperglycemia, bleeding, acute pancreatitis"
3295823|NCT01794884|Experimental|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg)(volume ratio=1:5).Intravenous injection twice (24 hours、1 hour before operation).
3295824|NCT01794884|Placebo Comparator|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation).
3295825|NCT01794897|Experimental|Valacyclovir treatment|Drug: Experimental: Valacyclovir treatment. Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either Valacyclovir (VAV) or placebo (PLA) group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
3295826|NCT01794897|Placebo Comparator|Placebo|Placebo comparator: Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
3295827|NCT01794910|Experimental|Plevic floor muscle therapy|The pelvic floor muscle therapy to women with vaginal or cesarean deliveries involved perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions.
3295828|NCT01794910|No Intervention|Controll group|Women with vaginal or cesarean deliveries did not did not undergo muscle training
3295829|NCT01794962|Experimental|Manual therapy and exercises|Manual therapy treatment: spinal manipulation, Soft tissue treatment, muscle energy techniques. Exercises: stabilisation exercises, Mckenzie exercises and general muscle exercises.
3295830|NCT01794962|Experimental|Cognitive Functional Therapy|An in depth interview, including investigating the patients beliefs on back pain, fear towards movement, anxiety and distress, using reflecting questions. The physical part consists of specific and functional exercises related to the patients functional complaints.And general physical activity for 30 mins 3-4 times weekly.
3295831|NCT01794975|Active Comparator|Ketamine|Ketamine will be administered intravenously using a pseudo steady state infusion approach with a target plasma concentration of 300 ng/ml starting 15 minutes before the PET scan and continued throughout the scan.
3295832|NCT01794975|Active Comparator|Atomoxetine and the cold pressor test|An oral dose of approximately 1.2 mg/kg (range, 1.12-1.26 mg/kg) of atomoxetine is administered 1 h before the PET scans. A cold pressor test is employed as a physiological noradrenergic stimulus. The subject's foot is placed in a 8 °C water basin for the duration of the PET scan.
3295833|NCT01794975|Placebo Comparator|Placebo|Placebo capsules are given to mimic the atomoxetine treatment at each treatment visit except the atomoxetine visit. A baseline PET scan with [11C]ORM-13070 will be performed for all subjects with the placebo treatment only.
3295834|NCT01794988|Experimental|Group Cognitive Behavioral Therapy|Participants will undergo 11 weeks of group cognitive behavioral therapy (CBT) and a pre- and post-intervention MRI brain scan.
3295835|NCT01794988|Active Comparator|Pain Education|Participants will receive 11 weeks of pain education and a pre- and post-intervention MRI brain scan.
3295836|NCT01794988|Experimental|Therapeutic Interactive Voice Response|Four months of therapeutic interactive voice response (TIVR).
3295837|NCT01794988|Active Comparator|No TIVR|Control - no intervention
3295838|NCT01795001||late-onset FECD|tissue samples from patients with late-onset Fuchs' endothelial corneal dystrophy (FECD)
3295839|NCT01795001||normal control|tissue samples from patients with normal corneas
3295840|NCT01795001||non-FECD edematous control|tissue samples from patients with corneal edema but without FECD
3295841|NCT01795014||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an IOP above 21 mmHg that could suggest possible glaucoma suspects.
3295842|NCT01795014||Primary open-angle Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3295843|NCT01795014||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3295844|NCT01795027|Experimental|S-1 plus Oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
3295845|NCT01795027|Active Comparator|S-1 single|S-1 40~60mg twice daily for 14 days in 3 weeks for totally 16 courses after D2 resection
3295846|NCT01795040|Experimental|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
3295847|NCT01795040|Placebo Comparator|placebo without PUFAs|Placebo without PUFAs
3295848|NCT01795053|Experimental|playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and intensity and thereby reduce ADHD symptoms
3295849|NCT01795053|Placebo Comparator|open play session|the open play sessions are conducted in the same rooms, by the same staff and in the same time frame as the experimental sessions. The therapist plays with the child without structuring the sitauation through behavioral tecniques. The play situation is designed to be ineresting and comfortable for the child.
3295850|NCT01795066|Experimental|EUS-FNB with 25-gauge|
3295851|NCT01795092|No Intervention|Control|Those in the control group do not obtain a dermatology evaluation and will be assessed and treated by their primary care provider. We will perform a chart review two weeks after presentation to assess for admission versus discharge home from clinic and outcome.
3295852|NCT01795092|Experimental|Dermatology consultation|Patients randomized to the treatment group will obtain a dermatology evaluation at the primary care physician's office and will be sent to the Emergency Department (ED) or discharged home with outpatient dermatology follow-up in 2-3 days to assess their condition. Patients who are evaluated by a dermatologist and require hospitalization will have their transition to the ED managed by the dermatologist. Patients who are admitted after the initial outpatient discharge or at the follow-up visit will be considered treatment failures. A medical record review will be performed for patients in the treatment group two weeks after initial evaluation at the internal medicine clinic.
3295853|NCT01795131|Active Comparator|Vitamin B12|Supplementation group (N=60) that will receive 250 µg of vitamin B12 in addition to 60 mg of Fe and 400µg of folate.
3295854|NCT01795131|Placebo Comparator|Placebo|Placebo group (N=60) that will receive placebo tablets and 60 mg of Fe and 400µg of folate daily.
3295855|NCT01795144|Active Comparator|Healthy controls|"Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
3295856|NCT01795144|Experimental|Monogenic diabetes|"Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:~OGTT~IGI~IGI with GLP-1 infusion~OGTT with Exendin 9-39 infusion"
3295857|NCT01795157|Experimental|CCADSS|questionnaire completed using i-Pad
3295858|NCT01795157|Active Comparator|pen-paper|Questionnaire completed using pen and paper
3295859|NCT01795170||Test Group|Patients receiving a lysine restricted diet adjunct to pyridoxine therapy will be considered as participants in the 'exposure'/test group
3295860|NCT01795170||Control Group|Patients on pyridoxine mono-therapy will be participants in the 'control' group
3295861|NCT01795183|Experimental|Amisulpride|Patients are treated with Amisulpride referring to the dosage and usage section in Chinese Solian® PI. Amisulpride dosage is adjusted based on individual response and reaches the sufficiency within 1 week
3295862|NCT01795209|Experimental|Ranibizumab group|Patients will receive three monthly injections of 0.5 mg of Lucentis (0.05 ml), followed by retreatment/rescue laser as needed.
3295863|NCT01795209|Sham Comparator|Standard of care group|Patients will receive three monthly sham injections, followed by retreatment/rescue laser as needed.
3295864|NCT01795222|Active Comparator|Oral Midazolam|Midazolam oral syrup 1mg/Kg twenty minutes before starting the procedure
3295865|NCT01795222|Placebo Comparator|placebo|placebo oral syrup twenty minutes before starting the procedure
3295866|NCT01795235|Other|Saline s.c. injection and placebo tablet|Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
3295867|NCT01795235|Other|glucagon s.c. injection and placebo tablet|1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
3295868|NCT01795235|Other|Saline s.c. injection and atenolol tablet|Saline s.c. injection and 100 mg atenolol tablet
3295869|NCT01795235|Other|glucagon s.c. injection and atenolol tablet|1 mg glucagon s.c. injection and 100 mg atenolol tablet
3295870|NCT01795248|Experimental|Liraglutide|1.8 mg liraglutide, subcutaneous, once-daily for five years
3295871|NCT01795248|Placebo Comparator|Placebo|Placebo, subcutaneous, once-daily for one year
3295872|NCT01795248|No Intervention|Control|Control without previous GDM.
3295873|NCT01795261||Lifestyle counseling|Prevention of mother to child transmission of HIV
3295874|NCT01795261||Lifestyle counseling Male|male partners and PMTCT completion rate among HIV-infected pregnant women.
3295875|NCT01795274|Experimental|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
3295876|NCT01795287|Active Comparator|Spinal anesthesia|Spinal anesthesia
3295877|NCT01795287|Active Comparator|General anesthesia|General anesthesia with fentanyl, propofol and rocuronium and sevoflurane
3295878|NCT01795300|Experimental|Carbon Ion Radiotherapy|Treatment Schedule Carbon Ion Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3295879|NCT01795300|Experimental|Proton Therapy|Treatment Schedule Proton Radiation Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3295880|NCT01795300|Experimental|Hypofractionated Photon Therapy|Treatment Schedule Photon Radiation 3 Gy E Total Dose 45 Gy E, 15 fractions, 3 Gy E single dose
3295881|NCT01795300|Active Comparator|Conventional Photon Radiotherapy|Treatment Schedule Photon Radiation 1.8 Gy E Total Dose 57.6 Gy Gy E, 32 fractions, 1.8 Gy E single dose
3295882|NCT01795313|Experimental|HLA-A2 restricted tumor antigen vaccine|This is a single-arm study of a HLA-A2 restricted tumor antigen peptide vaccine, administered in conjunction with imiquimod
3295883|NCT01795326||Germany|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295884|NCT01795326||United Kingdom|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295885|NCT01795326||Spain|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295886|NCT01795326||Hungary|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295887|NCT01795326||Netherlands|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295888|NCT01795326||Sweden|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295889|NCT01795326||Romania|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295890|NCT01795326||Italy|A sample of physicians who were targeted to receive the metabolic educational materials and either currently prescribe or have the potential to prescribe SEROQUEL® or SEROQUEL® XR.
3295891|NCT01795339|Experimental|AZD3293|Part 1: Up to 6 sequential cohorts of healthy elderly subjects are planned, with multiple ascending doses, starting with 5 mg (subject to confirmation by the Safety Review Committee) Part 2: Up to 16 mild-to-moderate AD patients administered one to up to 3 dosage levels of AZD3293
3295892|NCT01795339|Placebo Comparator|Placebo|Part 1: Placebo given (2 subjects in each cohort) Part 2: Placebo given (up to 4 subjects)
3295893|NCT01795365|Active Comparator|Epstein + (group I)|"Epstein + (Group I) PSA <10 ng/ml; Gleason 3+3=6; Number of positive biopsies ≤3/12;~% of tumor biopsy invasion <50% or ≤3mm; mp MRI negative; c-rTNM T1-T2a N0 M0"
3295894|NCT01795365|Experimental|Epstein - (group II)|"Epstein - (Group II) PSA <15 ng/ml; Gleason score max 3+4; Number of positive biopsies ≤5/12~% of tumor biopsy invasion <50% and ≤8mm; mp MRI positive; T1-T2c N0 M0"
3295895|NCT01795391||Tegaderm HP|Patients whose intravasculare devices dressings are made exclusevely with Tegaderm HP dressings.
3295896|NCT01795391||Advanced|Patients whose intravasculare devices dressings are made exclusevely with Advanced dressings
3295897|NCT01795404|Experimental|Inquiry Based Stress Reduction (IBSR) Program|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts. Through the use of self-inquiry practices participants are taught to increase awareness of their thoughts and feelings, to observe their emotional and physical responses during situations perceived by them as stressful, and allow their mind to return to its true, peaceful, creative nature. Through the process of self-inquiry, participants take an active role in investigating their stressful thoughts, and by this regulating their stress and managing symptoms and emotions, thus enabling them to cope better with the distress related to the possibility of cancer.
3295898|NCT01795404|No Intervention|Control group|Waited-list control
3295899|NCT01795417|Experimental|XP200 device RF treatments|Every subject in the study will undergo 4 treatments and will be followed up for 6 months with photoraphic 3 evaluations: before treatment, 3 and 6 months follow-up. Photographs will be scored on a Fitzpatrick scale by 3 blinded evaluators.
3295900|NCT01795430|Experimental|Treatment (radiation therapy/chemotherapy, stem cell infusion)|"BLOCK I: Patients receive etoposide IV over 1-2 hours and ifosfamide IV over 1 hour on days 1-5. Patients also undergo WB-MRI-guided intensity-modulated radiation therapy BID, 5 days a week, for approximately 4 weeks. Patients may also undergo 4 fractions of SRT QOD, 3-8 fractions of SBRT QOD, or 10 fractions of 3D RT daily to sites of metastatic disease.~BLOCK II: Patients receive high-dose chemotherapy comprising topotecan hydrochloride IV continuously over 24 hours on days -8 to -4, busulfan IV over 2 hours every 6 hours on days -8 to -4, and melphalan IV over 30 minutes on days -3 and -2. Patients undergo autologous peripheral blood or bone marrow stem cell infusion on day 0."
3295901|NCT01795443|Active Comparator|Healthy volunteers 1|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
3295902|NCT01795443|Active Comparator|Healthy volunteers 2|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
3295903|NCT01795443|Active Comparator|Healthy volunteers 3|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
3295904|NCT01795443|Active Comparator|Healthy volunteers 4|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
3295905|NCT01795443|Active Comparator|Healthy volunteers 5|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
3295906|NCT01795443|Active Comparator|Healthy volunteers 6|"The patients in this arm of the study are healthy volunteers with no history of back pain in the last five years (see inclusion/exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
3295907|NCT01795443|Experimental|Back pain patients 1|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - high vibration; Intervention: Measures - low vibration;"
3295908|NCT01795443|Experimental|Back pain patients 2|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - no vibration; Intervention: Measures - low vibration; Intervention: Measures - high vibration;"
3295909|NCT01795443|Experimental|Back pain patients 3|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - no vibration; Intervention: Measures - low vibration;"
3295910|NCT01795443|Experimental|Back pain patients 4|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - high vibration; Intervention: Measures - low vibration; Intervention: Measures - no vibration;"
3295911|NCT01795443|Experimental|Back pain patients 5|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - no vibration; Intervention: Measures - high vibration;"
3295912|NCT01795443|Experimental|Back pain patients 6|"The patients included in this arm have had back pain for at least 6 months; the origin of this back pain can not be from a previous surgery (see inclusion and exclusion criteria).~Propioception measures will be carried out in the following order:~Intervention: Calibration; Intervention: Practice; Intervention: Measures - low vibration; Intervention: Measures - high vibration; Intervention: Measures - no vibration;"
3295913|NCT01795469|Experimental|Abdominal and LE compression|Zoex compression garment during tilt testing (all straps)
3295914|NCT01795469|Experimental|abdominal compression only|Zoex compression garment use during tilt table testing (straps 4 and 5 fastened around thighs and abdomen)
3295915|NCT01795469|Experimental|Lower extremity compression only|Zoex compression garment use during tilt table testing (straps 1-4, lower extremity and thighs, fastened)
3295916|NCT01795482|Experimental|Group 2, Prewarming only before general anaesthesia|Active forced-air warming for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3295917|NCT01795482|Experimental|Group 3, Prewarming before epidural and general anaesthesia|Active forced-air warming for 15 min before start of epidural anaesthesia and for 15 min after completion of epidural anaesthesia / before start of general anaesthesia. Continued active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3295918|NCT01795482|No Intervention|Group 1, control group|No active warming before start of epidural or general anaesthesia, active forced-air warming after induction of general anaesthesia until operation is finished (intraoperatively). Application of warmed infusions (41 °C).
3295919|NCT01795508|Experimental|PMTO|Parent Management Training Oregon
3295920|NCT01795508|Active Comparator|TAU|Other kinds of family treatment
3295921|NCT01795521|Experimental|Stereotactic Body Radiotherapy (SBRT)|All eligible patients will be offered Stereotactic Body Radiotherapy using Four-dimensional computed tomography (4D-CT) planning (as a minimum), delivering a dose of 60 Gy in 8 fractions of 7.5 Gy on alternate days over a planned treatment time of 2.5 weeks
3295924|NCT01795599|Experimental|mifepristone/misoprostol|
3295925|NCT01795599|Active Comparator|misoprostol|
3295926|NCT01795599|Active Comparator|mifepristone|
3295927|NCT01795612|Other|Arm A|6-month ETP, during adjuvant or neoadjuvant therapy
3295928|NCT01795612|Other|Arm B|6-month ETP, after adjuvant or neoadjuvant therapy
3295929|NCT01795612|Other|Arm C|12-monthETP, during and after adjuvant or neoadjuvant treatment
3295930|NCT01795651||Take-Home message|
3295931|NCT01795664|Active Comparator|Seretide Evohaler|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Seretide Evohaler, Allen & Hanburys, UK)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
3295932|NCT01795664|Experimental|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Salmeterol xinafoate and Fluticasone propionate combination HFA pMDI (Cipla Ltd., India)~Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; a total dose of 50/500 mcg"
3295933|NCT01795677|Experimental|RUXOLOTINIB|Ruxolotinib : patient with donor HSCT 4 months later patients without donor: ruxolotinib alone
3295934|NCT01795703|Experimental|Abiraterone|Abiraterone 1000 milligram (mg) oral tablets will be administered once daily along with 5 mg oral prednisolone tablet administered twice daily for 28-daily dosing cycles and will be continued until disease progression or unacceptable toxicity.
3295935|NCT01795729|Experimental|1: Coronary stent+optimal medical therapy|Coronary stent on top of optimal medical therapy
3295936|NCT01795729|Active Comparator|2: Optimal medical therapy|Optimal medical therapy
3295937|NCT01795742|Active Comparator|Electric Nebulizer|Pulmo-Aide Model 5650D
3295938|NCT01795742|Experimental|Human-Powered Nebulizer|Human-Powered
3295939|NCT01795755|Experimental|Treat as usual + Horse assisted therapy ( HAT)|Treatment as usual means mentalization based inpatient treatment. Horse assisted therapy(HAT) is a structured program of 12 X 90 minute sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists.
3295940|NCT01795755|Active Comparator|Treatment as usual|Treatment as usual means mentalization based inpatient treatment.
3295941|NCT01795768|Experimental|Single Treatment Arm|16-24 patients per tumour group will be treated with AZD4547 administered 80mg twice daily, 2 weeks on, 1 week off in 21 days cycles.
3295942|NCT01795781||Patients receiving a new anticoagulant|Patients are receiving dabigatran for atrial fibrillation or rivaroxaban for osteoarthritis of hip or knee undergoing total hip or knee replacement respectively
3295943|NCT01795794|Experimental|LOSEC|"LOSEC will be given 20 mg X 1/day for 6 months and then for the next 6 months the same group will be the control group of herself."
3295944|NCT01795820|Other|Group 1 (no loading)|Patients allocated to this group will not receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start), while ticagrelor 90 mg bis in die will be administered from the day of the pharmacological shift on.
3295945|NCT01795820|Other|Group 2 (loading)|Patients allocated to this group will receive a loading dose of ticagrelor. In other words, clopidogrel 75 mg/die will be administered until the day before the pharmacological shift (study start). On the very day of the pharmacological shift, patients allocated in Group 2 will receive Ticagrelor 180 mg (loading dose) on the morning and Ticagrelor 90 mg on the evening, while ticagrelor 90 mg bis in die will be administered from the day after the pharmacological shift on.
3295946|NCT01795846||monosensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites
3295947|NCT01795846||polysensitized allergic rhinitis, asthma|adult patients with moderate/severe perennial allergic rhinitis and mild/moderate asthma who were monosensitized to house dust mites or sensitized to at least 2 different allergens including house dust mites.
3295948|NCT01795872|Other|Several diagnostic procedures|
3295949|NCT01795885|Experimental|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the show 16 and Pregnant once a week for 4 weeks."
3295950|NCT01795911|Experimental|Substudy C: Pegylated Interferon Lambda+Ribasphere+Daclatasvir|"Pegylated Interferon Lambda 180 μg Solution, Subcutaneous Once weekly for 12 weeks;~Ribasphere 1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg oral tablets per day [subjects should take either 400 mg for subjects < 75 kg or 600 mg ≥ 75 kg in the morning with food and 600 mg in the evening with food] for 12 weeks;~Daclatasvir 60 mg oral tablet Once daily for 12 weeks"
3295951|NCT01795924|Experimental|PD-616 plus low-dose Cytarabine|Patients will receive low-dose cytarabine (20 mg/m2) subcutaneously (SC) once daily (QD), followed by a 1-hour intravenous (IV) infusion of PD-616 for 5 consecutive days during Week 1 (D1 to D5) and Week 2 (D8 to D12) of a 28-day treatment cycle. Cytarabine is to be administered approximately 30 minutes before PD-616. In Phase 1 part, the starting dose of PD-616 is 0.0875 mg/m2, with sequential increments of 0.0375 mg/m2, to 0.125, and 0.1625 mg/m2. The dose of PD-616 to be administered in Phase 2 part will be the maximum tolerated dose (MTD)determined from Phase 1 part of the study.
3295952|NCT01795950|Experimental|0.5 M PLX-PAD|0.5 million (M) PLX-PAD cells per kg body weight
3295953|NCT01795950|Experimental|1 M PLX-PAD|1.0 million (M) PLX-PAD cells per kg body weight
3295954|NCT01795950|Experimental|2 M PLX-PAD|2.0 million (M) PLX-PAD cells per kg body weight
3295955|NCT01795963|Placebo Comparator|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
3295956|NCT01795963|Active Comparator|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress.
3295957|NCT01795976|Experimental|NY-ESO-1 T cells|"NY-ESO-1 T cells are T cells engineered to target the tumour antigen NY-ESO-1. Autologous T cells are obtained from eligible patients who have NY-ESO-1 positive tumours and who are Human Leukocyte Antigen serotype A serotype group (HLA2) positive. The T cells undergo lentiviral transduction with NY-ESO-1 specific nucleic acid under Good Manufacturing Practice (GMP) conditions. The patient will then undergo preconditioning chemotherapy with a regime of cyclophosphamide 60mg/kg/day day -7 and -6 followed by fludarabine 25mg/m2 day -5 to -1. They will receive autologous NY-ESO-1 T cells on day 0 and following on from that they will receive up to 14 doses of intravenous IL-2 at a dose of 100000 units per kg.."
3295958|NCT01795989||Healthy Volunteers|Research only musculoskeletal (MSK) MRI for healthy volunteers.
3295959|NCT01795989||Clinical Efficacy|Clinically indicated musculoskeletal (MSK) MRI with sequences obtained using this pediatric elbow coil.
3295960|NCT01796002|Experimental|Experimental: Romidepsin plus CHOP|"Patients in experimental arm receive romidepsin plus CHOP (Ro-CHOP) administered in 3 week cycles for 6 cycles.~Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks."
3295961|NCT01796002|Active Comparator|Standard: CHOP|Patients in control Arm receive cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered in 3 week cycles for 6 cycles.
3295962|NCT01796015|Other|For the 97 patients|"day 0: ultrasound of ONSD (= 4 measurements: 1 transverse and 1 sagittal for each eye) + transcranial Doppler at T-15 (15 minutes before ICP measurement), within 1h following ICP measurement, and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~day 1: ONSD ultrasound + transcranial Doppler in the morning and one more measurement is to be done if significant ICP variations are noticed (variation over 15 mmHg during at least 5 minutes)~days 2 and 3 : same as day 1~when leaving the intensive care unit: Pediatric Overall Performance Category (POPC) scale"
3295963|NCT01796015|Other|For the control group|one single ONSD in addition to their usual care (4 measurements: 1 transverse and 1 sagittal for each eye) in the morning in absence of painful sensation
3295964|NCT01796015|Other|For the learning curve|minimum 15 ONSD ultrasounds will be performed by each of the 15 intensive care doctor or interns expected. One ONSD ultrasound corresponds to 2 measurements: 1 transverse and 1 sagittal. Each volunteer will have maximum 30 ONSD ultrasound measures over a 1 month period.
3295965|NCT01796028|Placebo Comparator|Arm A : TAXOTERE® + Metformin placebo|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin (or placebo) is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
3295966|NCT01796028|Experimental|Arm B : TAXOTERE® + Metformin|Docetaxel (TAXOTERE®) will be administered at 75 mg/m2. Metformin is formulated into 850 mg tablets for oral administration and is to be dispensed twice a day on a continuous daily dosing schedule
3295967|NCT01796041|Experimental|IV Injection of ICG|
3295968|NCT01796054|Experimental|Stress Free Now with group support|Randomized participants have access to online stress reduction program, Stress Free Now. Participants will log in to online program, read daily lessons and practice therapeutic exercises. They will also attend weekly group support session during 6-week program
3295969|NCT01796054|Experimental|Stress Free Now|Randomized participants have access to online stress reduction program, Stress Free Now, for 6 weeks. Participants will log into online program, read daily lessons and practice therapeutic exercises.
3295970|NCT01796054|No Intervention|Control|Randomized participants do not have access to online stress reduction program, Stress Free Now, nor do they attend weekly group support sessions.
3295971|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Interv.|Participants are randomized to motivational and family weight loss program plus the online intervention.
3295972|NCT01796067|Experimental|Mot. & Fam. Weight Loss + Online Control|Participants are randomized to motivational and family weight loss intervention and then the online control program.
3295973|NCT01796067|Experimental|Basic Health Educ. & Online Interv.|Participants are randomized to the basic health education program and then the online intervention program.
3295974|NCT01796067|Active Comparator|Basic Health Educ. & Online Control|Participants are randomized to the basic health education program and then to the online control program.
3295975|NCT01796080|Active Comparator|Mueller manoeuvre|Mueller manoeuvre lasting for 20 seconds
3295976|NCT01796080|Active Comparator|Inspiratory threshold|One continuous inspiration through an inspiratory threshold load for 20 seconds
3295977|NCT01796080|Active Comparator|Expiratory apnoea|Expiratory apnoea (without respiratory effort) lasting for 20 seconds
3295978|NCT01796080|Sham Comparator|Steady state normal breathing|Steady state normal breathing for 20 seconds
3295979|NCT01796093||Digoxin cross-over ivabradine|Digoxin 0,125 mg once a day 5 days per week during 3 months. Ivabradine, 7,5 mg b.id. during 3 months.
3295980|NCT01796106|Experimental|Icon|The study clinician will provide Icon treatment to all study participants randomized to study arm 1 after the radiograph and visual exam.
3295981|NCT01796106|Active Comparator|control|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish) to all study participants randomized to study arm 2 after the radiograph and visual exam.
3295982|NCT01796119|Experimental|Ridge Splitting|"Dental implants placed using ridge splitting technique. To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
3295983|NCT01796119|Active Comparator|Implants placed using drilling technique|"Dental implants placed in the ridge with sufficient thickness using drilling technique.~To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
3295984|NCT01796132|No Intervention|Control|Pregnant and/or nursing mothers not taking a SSRI or SNRI antidepressant are recruited in a non-exposed group (Control or no SSRI/SNRI). Control group participates only in the sub-studies related to neonatal adaptation, neurodevelopment, growth and early mother-infant relationship.
3295985|NCT01796132|Experimental|SSRI/SNRI exposure|Pregnant and/or nursing mothers under SSRI or SNRI treatment are recruited in an exposed group (SSRI/SNRI exposure). Drug regimen including dosage, frequency and duration is not modified by the study.
3295986|NCT01796145|Experimental|TACE|
3295987|NCT01796145|Experimental|Systemic Therapy|
3295988|NCT01796145|Experimental|Surgery|
3295989|NCT01796158|Experimental|cASBI+cMET|Participants will complete the computerized alcohol screening and brief intervention (cASBI)protocol at the time of an office visit and also complete the 2-session computerized Motivational Enhancement Therapy intervention (cMET).
3295990|NCT01796158|Active Comparator|cASBI|Participants will complete the computerized screening and brief intervention protocol at the time of a primary care office visit.
3295991|NCT01796171|Experimental|Part A, Arm 1: with lilotomab pre-dosing|"Betalutin, 10 MBq/kg b.w. in escalated doses with lilotomab pre-dosing.~COMPLETED enrolment into this arm"
3295992|NCT01796171|Experimental|Part A, Arm 2: without pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing.~COMPLETED enrolment into this arm"
3295993|NCT01796171|Experimental|Part A, Arm 3: with rituximab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing.~COMPLETED enrolment into this arm"
3295994|NCT01796171|Experimental|Part A, Arm 4: with higher dose lilotomab pre-dosing|"Betalutin, 15 MBq/kg b.w. in escalated doses with a higher dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
3295995|NCT01796171|Experimental|Part A, Arm 5: with intermediate dose lilotomab pre-dosing|"Betalutin, 20 MBq/kg b.w. with an intermediate dose lilotomab pre-dosing regimen.~COMPLETED enrolment into this arm"
3295996|NCT01796171|Experimental|Part B|"Available dosing arm - '40/15'~Open to Enrolment"
3295997|NCT01796223|Experimental|Feedback|Feedback system included in psychotherapy
3295998|NCT01796223|Active Comparator|control|Psychotherapy as usual
3295999|NCT01796262|Placebo Comparator|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
3296000|NCT01796262|Active Comparator|docosahexaenoic acid|DHA Richoil 250 mg pearl (DMF srl): b.i.d. for six months
3296001|NCT01796275|Experimental|Group A|Subjects will have a core session intervention and booster intervention; questionnaire evaluation is conducted at baseline, post-session, pre-booster and 3 month after core session.
3296002|NCT01796275|Experimental|Group B|Subjects will only have a core session intervention; Questionnaire evaluation are conducted at baseline (T1-baseline), post-session (T2), 4 weeks after core session (T3) and 3 month after core session (T4).
3296003|NCT01796275|Other|Group C|Group C is a waiting list control, only questionnaire evaluations can be conducted at T1-baseline, T3- tea gathering and T4- 3 month after baseline evaluation; when finish T4 evaluation, the core session and booster can be optionally conducted subsequently.
3296004|NCT01796288|Experimental|Erlotinib & simultaneous radiotherapy|patients started simultaneously radiotherapy for all gross tumors
3296005|NCT01796288|Other|Erlotinib & no radiotherapy|patients received no radiotherapy for all gross tumors
3296006|NCT01796314|Experimental|Group A : intervention|"85 dyads patient/caregiver in witch the patient suffers from mild to moderately severe Alzheimer's disease patients (MMSE 11 to 26), and lives at home with a caregiver"
3296007|NCT01796314|No Intervention|Group B : Control|There si no associated intervention
3296008|NCT01796327|Experimental|Treatment|Dacomitinib will be administered as a single oral dose and as an intravenous infusion
3296009|NCT01796340|Experimental|Food cue exposure|
3296010|NCT01796340|Active Comparator|Psycho-education|
3296011|NCT01796353|Experimental|sexual rehabilitation|exercise plus psycho-education
3296012|NCT01796353|Active Comparator|usual care|usual care
3296013|NCT01796366|Experimental|Insulin 338 + placebo|
3296014|NCT01796366|Active Comparator|Insulin glargine + placebo|
3296015|NCT01796379|Experimental|High Intensity Interval Training|
3296016|NCT01796379|Other|Moderate Training|Regular exercise training offered as usual care to all heart transplant recipients.
3296017|NCT01796405|Experimental|Low-Risk|Multifocal or Low-Risk Multi System Clofarabine, Low Dose, Two Cycles
3296018|NCT01796405|Experimental|High-Risk|High-risk Multi System Clofarabine, Standard Dose, Two Cycles
3296019|NCT01796418|Experimental|Beraprost sodium|Beraprost sodium 0.02 mg capsule by mouth every 12 hours for 12 weeks
3296020|NCT01796418|Placebo Comparator|Placebo|Placebo capsule by mouth every 12 hours for 12 weeks
3296021|NCT01796431|Experimental|Eviplera®|Participants will take Eviplera every day for 14 days. Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in order to understand how long these drugs persist in the blood.
3296022|NCT01796444|Active Comparator|Axillary Lymph Node Dissection|After sentinel lymph node biopsy, surgery for standard axillary lymph node dissection. Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
3296023|NCT01796444|Experimental|Non-Axillary Lymph Node Dissection|After sentinel lymph node biopsy, no surgery of axillary lymph node In this study, the absence of surgery is the experimental arm (non-inferiority trial). Pathological evaluation (include intraoperative pathological examination) is performed routinely. All women were to receive whole-breast opposing tangential-field radiation therapy. Adjuvant systemic therapy was determined by the treating physician.
3296024|NCT01796483|Active Comparator|healthy Volunteers|
3296025|NCT01796483|Experimental|Patients|
3296026|NCT01796496|Experimental|Manipulative Therapy Techniques|Manipulative Therapy Techniques involve three techniques on lumbar and sacral areas. This protocol will be administered one a week for 3 weeks.
3296027|NCT01796496|Active Comparator|Functional Technique|Manipulative Therapy Technique involves one technique on lumbar area. This protocol will be administered one a week for 3 weeks.
3296028|NCT01796509|Experimental|multidisciplinary follow-up|
3296029|NCT01796509|No Intervention|no follow-up|
3296030|NCT01796522|Active Comparator|Nifedipine (60 mg / day orally)|The name of this arm is Nifedipine. These Prolonged release tablets(Oros) presents a release system for 24h, acting as an osmotic pump releasing the nifedipine through an orifice in the tablet produced by laser technology.The Nifedipine tablet 60mg administered once daily to week 34 of gestation.
3296031|NCT01796522|Active Comparator|Progesterone 200 mg / day vaginally|The name of this arm is Progesterone. Soft gelatin capsule vaginal use, used in clinical practice as maintenance tocolytic therapy after episode of threatened preterm labor. The 200mg capsule administered once daily to week 34 of gestation. The patients assigned to this arm will begin treatment while the patient assigned to the arm of nifedipine.
3296032|NCT01796535||PerX360º System™|Patients treated with PerX360º System™
3296033|NCT01796561|Active Comparator|Olive leaf extract liquid|20ml of polyphenol-rich olive leaf extract liquid to be consumed daily for 6 weeks
3296034|NCT01796561|Placebo Comparator|Placebo liquid|20ml of polyphenol-free placebo liquid (containing water, glycerin, flavours, colours and aromas) to be consumed daily for 6 weeks
3296035|NCT01796574|Experimental|Ketogenic diet|Patients will receive the ketogenic diet as a formula delivered via feeding tube. Once able to tolerate food by mouth, patients will be switched to a modified Atkins diet.
3296036|NCT01796587||LoFric Origo|
3296037|NCT01796600|Experimental|Conventional and a cone-beam scanner 5G|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner
3296038|NCT01796613|Active Comparator|Vaginal Ring - intermittent regimen|3 weeks ring use followed by one week of no ring use to allow menstruation
3296039|NCT01796613|Active Comparator|Vaginal Ring - continuous regimen|3 weeks of ring use with no off period. The next ring is immediately inserted after the previous one
3379861|NCT05117515||Uni-Graft KDV Patch|
3296040|NCT01796626|Experimental|Wrinkle treatment|Wrinkle treatment with ResurFX 1565nm module
3296041|NCT01796626|Experimental|Striae treatment|Striae treatment with the REsurFX 1565nm module
3296042|NCT01796639||kidney transplantation patients with living-donor grafts|
3296043|NCT01796652||Home and hospital treatment groups|Patients were randomized into either home or hospital groups after a brief hospitalization(≤24 hours. Hospital patients were followed 5 days in hospital.Home patients were visited on 2nd,3rd and 5th days by a staff nurse and the vital signs, symptoms, and general condition were recorded and transmitted back to the attending physician. On the 7th, 14th and 30th days, the home and hospital group patients were requested to return for a follow-up clinic visit at Bezmialem, at which time an assessment of their symptoms, physical examination, and laboratory evaluation was conducted.
3296044|NCT01796678|Experimental|Arginine|100 mg/kg T.I.D 3x a day IV or PO
3296045|NCT01796678|Placebo Comparator|Placebo|Saline or sugar pill
3296046|NCT01796691||Standard therapy|Antiplatelet therapy following coronary stenting without platelet function testing
3296047|NCT01796691||Optimized antiplatelet therapy|"Platelet function testing and according to a test and treat strategy improve the antiplatelet therapy in low-responder.~Treatment adjustments were done as published before - see BOCLA-Plan manuscript. (Reference: Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011 Jan 12;9:3.)"
3296048|NCT01796704||healthy and mild heart failure|diversity of patients
3379865|NCT05109702|Experimental|0.25% HL036 Ophthalmic Solution|Participants self-administered HL036 0.25 percent (%) ophthalmic solution as topical ophthalmic drops, twice daily (BID) for 8 weeks.
3379866|NCT05109702|Placebo Comparator|Placebo|Participants self-administered HL036 placebo matching vehicle solution as topical ophthalmic drops, BID for 8 weeks.
3379867|NCT05109676|Experimental|Patients having embryo transfert|Patients benefit from the usual treatment for frozen embryo transfer with a preparatory cycle of the artificial endometrium: 150 µg of percutaneous estradiol for approximately 11 days and 200 mg of progesterone morning and evening to be taken vaginally for 2 days in case of embryo transfer at day 2 stage, 3 days in case of embryo transfer at day 3 stage, 5 days in case of day 5 embryo transfer or 6 days in case of day 6 embryo transfer.
3379868|NCT05109104|Experimental|CAP UnScented|Single topical application: 80 +/- 2 milligrams (mg) (2.0 +/- 0.05 mg per square centimeter [mg/cm^2]) of CAP UnScented will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3379869|NCT05109104|Experimental|CAP Herbal Mint Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Herbal Mint Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3379870|NCT05109104|Experimental|CAP Mountain Berry Flavour|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of CAP Mountain Berry Flavour will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3379871|NCT05109104|Active Comparator|SPF Standard|Single topical application: 80 +/- 2 mg (2.0 +/- 0.05 mg/cm^2) of SPF Standard will be applied to the assigned test site using a fingercot. Test material will be evenly spread over the test site using light pressure for 35 +/- 15 seconds.
3379872|NCT05108922|Experimental|Donanemab|Donanemab is administered intravenously (IV) every 4 weeks (Q4W)
3379873|NCT05108922|Active Comparator|Aducanumab|Aducanumab administered IV per label
3379874|NCT05108831|Experimental|ePOCT+|Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.
3379875|NCT05108831|No Intervention|Routine care|In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.
3379876|NCT05107518||children with physical disabilities|his study was designed to examine the validity and reliability of the Turkish version of the Children Participation Assessment Scale. While examining the validity of the scale in children, it was planned to use the Child Health Questionnaire-(CSA) scale, which had previously been shown to be reliable and valid in healthy children with different disability levels.
3296049|NCT01796717|Active Comparator|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
3296050|NCT01796717|Experimental|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
3296051|NCT01796730|Experimental|sequence I|10mg (21 days) -washout (7 days) - bambuterol 5mg (21 days) -washout (7 days) -placebo (21 days)
3296052|NCT01796730|Experimental|sequence II|bambuterol 5mg (21 days) -washout (7 days) - placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days)
3296053|NCT01796730|Experimental|sequence III|placebo (21 days) -washout (7 days) - bambuterol 10mg (21 days) - washout (7 days) - bambuterol 5mg (21 days)
3379881|NCT05104099|Experimental|Metvixia application for Photodynamic diagnosis|Patients who benefit Metvixia application to the vulva to realize fluorescence guided biopsies (Photodynamic diagnosis).
3296054|NCT01796743||Controls|Age and gender matched controls ('control' group) with acute MI with similar degree of troponin elevation who are managed based solely on the basis of clinical or angiographic data alone.
3296055|NCT01796743||Cardiac MRI|Hospitalized patients with acute MI with a clinically-indicated CMR ordered will be enrolled. Data for T2 mapping will be added to the clinically prescribed cardiac MRI scan.
3296056|NCT01796756|Experimental|Handover program|Standardized handover program Dedicated place and time Template Face-to-face communication Evidence-based education session Feedback and audit
3296057|NCT01796756|No Intervention|Usual handover practice|
3296058|NCT01796769|Experimental|Conventional|
3296059|NCT01796769|Active Comparator|Telemedicine|
3296060|NCT01796782|Active Comparator|Xeloda|Subjects will receive Xeloda until progression
3296061|NCT01796782|Experimental|QYHJ Granules|patients will receive QYHJ Granules until progression
3296062|NCT01796795|Placebo Comparator|vehicle gel|The vehicle gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3296063|NCT01796795|Active Comparator|SR-T100 gel with 1.0% of SM|SR-T100 contains 1.0% SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3296064|NCT01796795|Active Comparator|SR-T100 gel with 2.3% of SM|SR-T100 contains 2.3%SM. The gel will be applied in appropriate amount evenly and gently in a thin-layer of gel by finger, not to exceed 0.2 g per administration (approximately 2 cm gel squeezed in length). Each dose of study drug is applied on the target lesion(s) and covered with an occlusive dressing for the entire day.
3296065|NCT01796808|Other|Pathway A|"Screening visit followed by pedal fat grafting procedure with local anesthetic and visits at:~1 week~Post op study visit 2 (1 month)~Post op study visit 3 (2 month)~Post op study visit 4 (6 month)~Post op study visit 5 (12 month)~Crossover to standard podiatry visits~Study visit 6 (18 months)~Study visit 7 (24 months)"
3296066|NCT01796808|Other|Pathway B|"Screening visit followed by:~Study visit 1 (6months)~Study Visit 2 (12 months)~Crossover to Pathway A~pedal fat grafting procedure and local anesthetic and visits at:~1 week~Post op study visit 2 (1 month post procedure)~Post op study visit 3 (2 month post procedure)~Post op study visit 4 (6 month post procedure)~Post op study visit 5 (12 month post procedure)"
3296067|NCT01796821|Placebo Comparator|Vehicle gel|vehicle gel is used as a control group. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3296068|NCT01796821|Active Comparator|SR-T100 gel with 1.0 % SM|SR-T100 contains 1.0% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3296069|NCT01796821|Active Comparator|SR-T100 gel with 2.3% SM|SR-T100 contains 2.3% SM. The maximum daily dosage is 3 times of 400+/-100 mg of gel, meaning no more than 1,500 mg of gel. Patients should wash thoroughly their hands, then squeeze until 4 cm of gel is out from the aluminum tube. Apply gel on the lesion warts and on the clinical normal skin on the treated area.
3296070|NCT01796834|Experimental|Mindfulness-Based Stress Reduction|Subjects attend a community based Mindfulness-Based Stress Reduction course.
3296071|NCT01796847||PTEN, hyperglycemia|
3296072|NCT01796886|Experimental|patient's neurological status|
3296073|NCT01796899|Other|Brivaracetam 10 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 10 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 10 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3296074|NCT01796899|Other|Brivaracetam 50 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 50 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 50 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3296075|NCT01796899|Other|Brivaracetam 75 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 75 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 75 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3296076|NCT01796899|Other|Brivaracetam 100 mg oral tablet|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of BRV 100 mg oral tablet will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg~Form: Oral tablet~Frequency: Once daily~Duration: 1 day"
3379882|NCT05099003|Experimental|Treatment (selinexor and radiation therapy)|"CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance.~MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity."
3379883|NCT05096728||Once daily Nifedipine XL 60mg|Participants will receive Nifedipine XL once daily 60 mg for 48 hours.
3379884|NCT05096728||Twice daily Nifedipine XL 30mg|Participants will receive Nifedipine XL twice daily 30 mg for 48 hours.
3379885|NCT05095818|No Intervention|Standard of Care with EMR Enhancements|Participants in this arm will receive Standard of Care with EMR Enhancements.
3296077|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|"Subjects check into the clinic the afternoon prior to the day of Brivaracetam (BRV) administration. The next day, a single dose of 10 mL of BRV intravenous bolus injection (10 mg/mL) will be administered in the morning. Following BRV administration, subjects will be observed for up to 48 hours. A Wash-Out Period of at least 7 days will separate the subsequent drug administrations.~Strength: 100 mg (10 mg/mL)~Form: Intravenous bolus injection~Frequency: Once daily~Duration: 1 day"
3296078|NCT01796925|Experimental|aura6000 THN Therapy|The aura6000 THN system will be implanted and activated for nightly therapy during sleep.
3379886|NCT05095818|Experimental|Standard of Care with EMR Enhancements and PrEP-RN|Participants in this arm will receive Standard of Care with EMR Enhancements and PrEP-RN.
3379888|NCT05093699|Active Comparator|Control Group|Arterial line placement via standard mechanism; utilization of a single-plane ultrasound probe
3296079|NCT01796938|Experimental|Group 1: Healthy subjects|Single dose of 100 mg Lacosamide
3296080|NCT01796938|Experimental|Group 2: Subjects with mild renal insufficiency|Single dose of 100 mg Lacosamide
3296081|NCT01796938|Experimental|Group 3: Subjects with moderate renal insufficiency|Single dose of 100 mg Lacosamide
3379889|NCT05093699|Experimental|Butterfly iQ+ ultrasound probe|Arterial line placement utilizing dual-plane, Butterfly iQ+ ultrasound probe
3379890|NCT05093348|Active Comparator|Click2Print digital Artificial Eye|Supply and fit a digitally designed and manufactured ocular prosthesis for four months in comparison to the current hand-made ocular prosthesis in a cross over trial
3379891|NCT05093348|Active Comparator|Current hand made artificial eye|Wear the hand-made artificial eye for four months and compare to the digitally design ed and manufactured artificial eye
3379894|NCT05091918|Other|Motionsense Wearable Group|Using Motionsense from pre-op to 90 days post-op during the recovery after primary TKA
3379895|NCT05089019|Experimental|Selpercatinib (Test)|Selpercatinib given orally on days 1 and 15.
3379896|NCT05089019|Active Comparator|Selpercatinib (Reference)|Selpercatinib given orally on days 1 and 15.
3379898|NCT05086445|Experimental|LY3502970 (Part A)|Single doses of LY3502970 administered orally.
3379899|NCT05086445|Experimental|LY3502970 (Part B)|Multiple doses of LY3502970 administered orally.
3379900|NCT05086445|Placebo Comparator|Placebo (Part A)|Placebo administered orally.
3379901|NCT05086445|Placebo Comparator|Placebo (Part B)|Placebo administered orally.
3379902|NCT05086289|Experimental|LY3526318|LY3526318 administered orally
3379903|NCT05086289|Placebo Comparator|Placebo|Placebo administered orally
3379904|NCT05085366|Experimental|mRNA-1647|Participants will receive mRNA-1647 vaccine by intramuscular (IM) injection on Day 1, Day 57, and Day 169.
3379905|NCT05085366|Placebo Comparator|Placebo|Participants will receive mRNA-1647 vaccine matching placebo by IM injection on Day 1, Day 57, and Day 169.
3379906|NCT05082051|Active Comparator|CDX-7108|CDX-7108, an oral recombinant lipase. It is a modified version of a triacylglycerol lipase enzyme derived from the bacteria Bacillus thermoamylovans (btLIP) and produced by fermentation of recombinant Escherichia coli.7
3379907|NCT05082051|Placebo Comparator|Placebo|Excipients only
3296082|NCT01796938|Experimental|Group 4: Subjects with severe renal insufficiency|Single dose of 100 mg Lacosamide
3296083|NCT01796938|Experimental|Group 5: Subjects with end stage renal insufficiency|Single dose of 100 mg Lacosamide
3296084|NCT01796951|Experimental|Celecoxib, aspirin, followed by aspirin/celecoxib|Celecoxib 200 mg twice daily x3 days, aspirin 325 mg daily x10 days, celecoxib 200 mb twice daily + aspirin 325 mg daily x 3 days
3296085|NCT01796990|Active Comparator|REF group|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
3379908|NCT05081232|Experimental|Umbilical Cord Allograft Recipients|Male patients undergoing Robot Assisted Radical Prostectomy with bilateral nerve sparing technique will remain eligible to receive allograft during the surgery.
3379909|NCT05080660|Experimental|LY3526318|LY3526318 administered orally.
3379910|NCT05080660|Placebo Comparator|Placebo|Placebo administered orally.
3379911|NCT05079698|Experimental|Stereotactic Body Radiotherapy and 177Lu-PSMA-617|
3296086|NCT01796990|Other|ACT group|"The ACT group gets the same procedure as the REF group. In addition, they will participate the ACT based program. The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
3296087|NCT01797003|Active Comparator|Opening wedge HTO|Opening wedge high tibial osteotomy using Puddu plate
3296088|NCT01797003|Active Comparator|Closing wedge HTO|Closing wedge high tibial osteotomy using cramp fixation
3296089|NCT01797042|Active Comparator|Fructose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3296090|NCT01797042|Active Comparator|Glucose 9%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3296091|NCT01797042|Active Comparator|High fructose corn syrup 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3296092|NCT01797042|Active Comparator|Sucrose 18%|Sugar sweetened milk consumed in an amount that added sugar provides 9% of calories required for weight maintenance
3296093|NCT01797068|Experimental|Patient Navigator|Patients in the experimental group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH).
3296094|NCT01797068|Active Comparator|Standard of Care|Patients in the active comparator group will experience the usual intake process in the ED setting.
3296095|NCT01797107|Experimental|Treatment eye|Azasite (azithromycin ophthalmic 1%) twice a day for 2 days followed by nightly for 4 weeks
3296096|NCT01797107|Placebo Comparator|Durasite|Vehicle of Azasite used as placebo
3296097|NCT01797133|Active Comparator|Fellow arm|Patients in this arm will receive the ID fellow-based antibiotic pre-authorization intervention.
3296098|NCT01797133|Active Comparator|Pharmacist arm|Patients in this arm will receive the pharmacist-based antibiotic pre-authorization intervention.
3296099|NCT01797146|Active Comparator|CARE|All patients in the intervention wards will receive the Catheter Reminder and Evaluation (CARE) intervention.
3296100|NCT01797146|No Intervention|Control|All patients in the control wards will receive usual care without the CARE intervention.
3296101|NCT01797172|Experimental|Percutaneous Cervical Nucleoplasty|Percutaneous Cervical Nucleoplasty
3296102|NCT01797172|Active Comparator|Pulsed Radio Frequency|Pulsed Radio Frequency treatment
3296103|NCT01797198|Experimental|gemfibrozil + ASP3652|Multiple doses of gemfibrozil and single dose of ASP3652
3296104|NCT01797198|Experimental|ASP3652 + repaglinide|Multiple doses of ASP3652 and the single dose of repaglinide
3296105|NCT01797211|Experimental|diet group A|Mediterranean diet+olive oil
3296106|NCT01797211|Experimental|Diet Group B|Mediterranean diet+not-fried fish
3296107|NCT01797211|Experimental|Diet Group C|Mediterranean diet+nuts
3296108|NCT01797224||Cohort 1 - Exposed Cohort|Pregnant women with a current diagnosis of an approved indication who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception.
3296109|NCT01797224||Cohort 2 - Diseased Comparison Cohort|Pregnant women with a current diagnosis of a Cimzia approved indication who have not used Cimzia (certolizumab pegol) during the current pregnancy.
3296110|NCT01797224||Cohort 3 - Non-Diseased Comparison Cohort|Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy.
3296111|NCT01797224||Group 4 -Cimzia Registry, Not Qualified for the Cohort Study|Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study.
3296112|NCT01797237|Experimental|Stable intertrochanteric fracture|The type of intertrochanteric fracture was below A2.1 (with A2.1) according to the AO/ATO classification.
3296113|NCT01797237|Experimental|Unstable intertrochanteric fracture|The type of intertrochanteric fracture was above A2.1 (without A2.1) according to the AO/ATO classification.
3296114|NCT01797289|Experimental|First episode of loss of consciousness|
3296115|NCT01797315|Active Comparator|Sirolimus|Patients who meet all inclusion criteria will be included into the study and randomised. If converted to Sirolimus (SRL), patients will take SRL according to the investigator's instructions and medication label, once daily preferably 4 hours after calcineurin-inhibitor medication or in case without calcineurin-inhibitor co-medication in the morning. The dose of SRL will be correlated to the former immunosuppressive therapy according to the study's conversion protocol.
3296116|NCT01797315|No Intervention|Standard therapy|Patients who will not receive SRL stay on their previous immunosuppressive therapy including one or more of the following drugs: azathioprine, cyclosporine, tacrolimus, mycophenolate-sodium and steroids.
3296117|NCT01797341|Experimental|Prograf arm|"patients will self-administer tacrolimus in the form of Prograf (twice daily administration.~Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day."
3296118|NCT01797341|Experimental|Advagraf Arm|patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
3296119|NCT01797354|Experimental|Cognitive-behavioral therapy and hypnosis group|Patients will receive (in groups of 6) fifteen 120-min sessions of group therapy including cognitive-behavioral techniques and hypnosis.
3296120|NCT01797354|Active Comparator|Support group|Patients will receive (in groups of 6) fifteen 120-min support group session.
3296121|NCT01797393|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3296122|NCT01797393|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .The mucosa was observed by inflating the bowel with air while withdrawing the colonoscope.All the patients were examined without sedation during the whole procedure.
3296123|NCT01797393|Experimental|" Air assisted water colonoscopy"|" Air assisted water injection colonoscopy: Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.All the patients were examined without sedation during the whole procedure."
3296124|NCT01797406|Active Comparator|Air insufflation colonoscopy|Air insufflation colonoscopy is the conventional colonoscopy,which is inflating air to help searching the bowel cavity while advancing the colonoscope until reaching the cecum.All the patients were examined without sedation during the whole procedure.
3296125|NCT01797406|Experimental|Water injection colonoscopy|Water injection colonoscopy : Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the caecum .All the patients were examined without sedation during the whole procedure.
3296126|NCT01797419|Experimental|GS-5806|Single dose, oral liquid, .5 mL/kg
3296127|NCT01797419|Placebo Comparator|Placebo|Single dose, oral liquid, .5 mL/kg
3296128|NCT01797497|Experimental|Care plan and coaching group|In the intervention group, parents complete a referral care plan with their children's physicians and receive a brief coaching session about how to exchange information with specialists. Outcome data are collected from parents before and after the specialist visit.
3296129|NCT01797497|No Intervention|Preintervention group|In the preintervention group, no care plan is used and no coaching takes place. Outcome data are collected from parents before and after the specialist visit.
3296130|NCT01797510|Experimental|Coaching|Interventional web based coaching study
3296131|NCT01797510|No Intervention|Usual Care|
3296132|NCT01797523|Experimental|Letrozole + Metformin + RAD001|"Patients have a 7-10 day lead in period where they take Metformin alone. The starting dose of Metformin 500 mg by mouth daily for 4 days and then increased to 500 mg by mouth twice a day. Everolimus and Letrozole added and considered the start of Cycle #1.~Everolimus administered by mouth as once daily dose of 10 mg. Letrozole 2.5 mg tablet by mouth once daily. The oral dose of Everolimus should be taken together with the daily dose of Letrozole 2.5mg."
3296133|NCT01797549||History of having sustained TBI|Males and females between 18 and 60 years who have a diagnosis of TBI
3296134|NCT01797549||Control group|Control group with no history of TBI or concussion. Gender and age matched non-TBI volunteers
3296135|NCT01797588|Active Comparator|adductor-canal block and periarticular infiltration|Adductor-canal block,performed prior to surgery using ultra sound guidance by an anesthetist, with a total of 30mL of 0.33% ropivacaine injected into the area surrounding the saphenous nerve. Periarticular infiltration, performed intra-operatively by the surgeon, involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee.
3296136|NCT01797588|Active Comparator|adductor-canal block|The adductor-canal block only group will receive an adductor-canal block prior to surgery in the block room using ultra sound guidance by an anesthetist. After the adductor-canal is located a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve. Participants will also receive 110mL of normal saline administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
3296137|NCT01797588|Active Comparator|periarticular infusion group|Periarticular infiltration,performed intra-operatively,involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. It will be administered as follows: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
3296138|NCT01797601|Active Comparator|Human Insulin|Nasal spray
3296139|NCT01797601|Placebo Comparator|Placebo solution|Nasal spray
3296140|NCT01797653|Placebo Comparator|Placebo CPAP|patients established on CPAP therapy, who are randomized to the placebo comparator, will use a CPAP device with subtherapeutic pressure during two weeks.
3296141|NCT01797653|Active Comparator|therapeutic CPAP|patients who are randomized to the active comparator, will continue with CPAP treatment with therapeutic pressure during two weeks
3296142|NCT01797679|Other|Strength Training|"The strength group include progressive strength training and neuromuscular exercises. The inclusion will be performed 2-3 times a week for 12 weeks.~Intervention: Other: Strength training"
3296143|NCT01797679|Experimental|Aerobic exercise|The aerobic exercise group will cycle on an ergometer bicycle 2-3 times a week for 12 weeks on moderate loading. The loading will be controlled by a heart rate monitor and is defined as 85% of maximal heart rate.
3296144|NCT01797679|No Intervention|Control Group|The control group will do as usual.
3296145|NCT01797692|Other|geriatric assessment|geriatric assessment
3296146|NCT01797718|Active Comparator|Testosterone|~1mg/kg every 4 weeks for 6 months
3296147|NCT01797718|Active Comparator|Letrozole|2.5mg daily for 6 months
3296148|NCT01797744|Experimental|Vestibular rehabiliation|Vestibular rehabiliation
3296149|NCT01797744|No Intervention|Control group|Usual rehabilitation whitout additional vestibular exercises
3296150|NCT01797757|Active Comparator|Fish oil enriched with EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
3296151|NCT01797757|Active Comparator|MAG-EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
3296152|NCT01797757|Active Comparator|MAG-EPA + ORLISTAT|"The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.~The Orlistat capsules of 120mg (except for groups 1 and 2). 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days."
3296153|NCT01797757|Active Comparator|Fish oil enriched with EPA|The oil will be liquid form of 1g /capsule. 3 capsules will be administrated per day: one capsule to be swallowed with a glass of water before every major meal, 3 times a day for 21 days.
3296154|NCT01797770||Mechanical bowel preperation|mechanical bowel preparation with polyethylene glycol one day prior to surgery
3296155|NCT01797796|Experimental|PF-06305591|
3296156|NCT01797796|Placebo Comparator|Placebo|
3296157|NCT01797809||Group 1|
3296158|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Placebo|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 48 weeks~Ribavirin 200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 48 weeks~Placebo 0 mg Tablets, by mouth, Once daily, 24 weeks"
3296159|NCT01797848|Experimental|pegIFNα 2a + Ribavirin + Daclatasvir|"pegIFNα 2a 180 µg, Solution for injection, Subcutaneous, Once weekly, 24 or 48 weeks depending on response~Ribavirin 1000-1200 mg Tablets, by mouth, 400-600mg AM, 600 mg PM, 24 or 48 weeks depending on response~Daclatasvir 60 mg Tablets, by mouth, Once daily, 24 weeks"
3296160|NCT01797861|Active Comparator|Half-dose photodynamic therapy (PDT)|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne ®) is administered, with an infusion time of 10 minutes. At 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first treatment with half-dose PDT), a second treatment with half-dose PDT will be performed (Treatment Visit 2)."
3296161|NCT01797861|Active Comparator|Micropulse laser (ML) treatment|"ML treatment with an 810 nm diode laser will be performed of the areas identified on mid-phase ICG angiography. Multiple laser spots will be applied, covering the leakage area on mid-phase ICG angiography. The area(s) that has to be treated is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (3 minutes) fluorescein angiogram.~If there still is subretinal fluid on OCT scan at Evaluation Visit 1 (6-8 weeks after Treatment Visit 1 / the first ML treatment), a second ML treatment will be performed (Treatment Visit 2)."
3296162|NCT01797874|Experimental|Pazopanib|pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
3296163|NCT01797874|Placebo Comparator|placebo|placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
3296164|NCT01797887|Experimental|Ayurveda|Ayurveda Diet and Lifestyle Counseling
3296165|NCT01797887|Active Comparator|Conventional|Standard Conventional Diet and Lifestyle Counseling
3296166|NCT01797900|Experimental|Inductive + concurrent chemotherapy|Inductive chemotherapy :paclitaxel 175mg/m2 d1+ cisplatin 80mg/m2d1, every 21 days for two cycles concurrent chemotherapy:cisplatin 80mg/m2 on week 1, 4, 7 radiotherapy: IMRT
3296167|NCT01797900|Active Comparator|concurrent + adjuvant chemotherapy|concurrent chemotherapy: cisplatin 80 mg/m2, on week 1, 4, 7 adjuvant chemotherapy: paclitaxel 175mg/m2 + cisplatin 75mg/m2, every 21 days for 4 cycles radiotherapy: IMRT
3296168|NCT01797913|Experimental|gemcitabine|
3296169|NCT01797926|Experimental|Group 1 (5 mg amlodipine and 50 mg losartan)|Subjects in Group 1 will be randomized to receive a single dose FDC 5/50 mg tablet and also separate single tablets each of reference treatment 5 mg amlodipine and 50 mg losartan. The reference treatment will be replicated in a three sequence, three period design
3296170|NCT01797926|Experimental|Group 2 (5 mg amlodipine and 100 mg losartan)|Subjects in Group 2 will be randomized to receive a single dose FDC 5/100 mg; and also separate single tablets each of reference treatment 5 mg amlodipine and 100 mg losartan. The reference treatment will be replicated in a three sequence, three period design
3296171|NCT01797939||Erosive reflux disease (ERD)|
3296172|NCT01797939||Non-erovise reflux disease (NERD)|
3296173|NCT01797939||Functional heartburn (FH)|
3296174|NCT01797952|Active Comparator|Lactobacillus CD 2 lozenges|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
3296175|NCT01797952|Placebo Comparator|Placebo lozenges|The placebo is a mix of sugars and salts used as excipients in the active formulation
3296176|NCT01797978|Experimental|Intravenous methylene blue administration|2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion for 6hrs
3296177|NCT01797978|Placebo Comparator|Placebo|Normal saline administration instead of methylene blue
3296178|NCT01797991|Active Comparator|Group A (dexamethasone per os)|"Dexamethasone 20 mg per os 12 hours and 6 hours before paclitaxel (form: opaque white capsules)~Matching placebo for dexamethasone IV (NaCl 0,9%) 30 minutes before paclitaxel"
3296179|NCT01797991|Experimental|Group B (dexamethasone IV)|"Dexamethasone 20 mg IV 30 minutes before paclitaxel~Matching placebo for dexamethasone per os (lactose capsule) 12 hours and 6 hours before paclitaxel (form: opaque white capsules)"
3296180|NCT01798017|Experimental|Mifepristone-misoprostol|Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol
3296181|NCT01798030||Vitamin D|Specimen analysis
3296182|NCT01798043|Experimental|Septal RV lead with >50% pacing (B1)|Cardiac MRI with pacemaker stimulation
3296183|NCT01798043|Experimental|Septal RV lead with <50% pacing (B2)|Cardiac MRI with and without pacemaker stimulation
3296184|NCT01798043|Experimental|Apical RV lead with >50% pacing (A1)|Cardiac MRI with pacemaker stimulation
3296185|NCT01798043|Experimental|Apical RV lead with <50% pacing (A2)|Cardiac MRI with and without pacemaker stimulation
3296186|NCT01798069|Experimental|Behavioral intervention|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
3296187|NCT01798069|Active Comparator|behavoral intervention|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading medical publication workshops. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3296188|NCT01798082|No Intervention|Standard counseling|
3296189|NCT01798082|Experimental|Standard counseling, pelvic organ prolapse decision aid|In addition to standard counseling at the time of the initial new patient visit, the patients randomized to the experimental arm will recieve a pelvic organ prolapse decision aid prior to their initial visit.
3296190|NCT01798095|Experimental|Aplisol|To confirm the response of PPD materials
3296191|NCT01798095|Active Comparator|PPD Standard|Determine equivalent specificity for new material compared to standard material.
3296192|NCT01798108|Experimental|Radium-223 dichloride|The study had 2 parts. Part 1a was designed with single injections of Radium-223 given to cohorts of 5 patients for each of 5 pre-defined dose levels. Part 1b was designed to retreat and fractionate the dose of Radium-223 in multiple injections.Based on the revised correction factor by calibration, recalculations verified that the single injection doses administered in the part 1a were : 46, 93, 163, 213 and 250 kBq/kg b.w. Two re-treated patients (dose group 6) received a second dose that resulted in a total dose of 250 kBq/kg b.w. The fractionated doses were 1/5 and ½ of the highest dose in part1b (i.e. 250kBq so 5 x 50 and 2 x 125 kBq/kg b.w. respectively).
3296193|NCT01798121|Experimental|Aplisol|To compare new PPD to reference standard material
3296194|NCT01798121|Placebo Comparator|Reference standard|Response of standard material
3296195|NCT01798147|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
3296196|NCT01798147|Experimental|SIRT|Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)
3296197|NCT01798160|Active Comparator|DEB TACE|Drug eluting Beads (DC Beads) loaded with Doxorubicin
3296198|NCT01798160|Experimental|SIRT|Selective Internal Radiation Therapy using Yttrium 90 loaded resin beads (Sir Spheres)
3296199|NCT01798173|Experimental|Cases: cirrhotic patients with hepatocellular carcinoma|
3296200|NCT01798173|Active Comparator|Controls: cirrhotic patients without hepatocellular carcinoma|
3296201|NCT01798199|Experimental|Alzheimer disease|
3296202|NCT01798212|Other|full thickness gastroplication|
3296203|NCT01798238|Placebo Comparator|Placebo group|
3296204|NCT01798238|Experimental|MP-513 group|
3296205|NCT01798251|Experimental|XELOX-X|"XELOX: Oxaliplatin: 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine: 850mg/m^2 bid, days 1-14, every 3 weeks and maximum 4 cycles, or progression/intolerance.~X Maintenance: Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks after 4 cycles XELOX regimen, until progression/intolerance."
3296206|NCT01798251|Active Comparator|XELOX|XELOX: Oxaliplatin 100mg/m2 d1 Intravenous infusion, every 3 weeks. Capecitabine 850mg/m^2 bid, days 1-14, every 3 weeks, until progression/intolerance.
3296207|NCT01798277|Active Comparator|Catheter Ablation|Radiofrequency ablation procedure
3296208|NCT01798277|Active Comparator|Medical therapy|Antiarrhythmic drug therapy will include amiodarone or sotalol. Which antiarrhythmic drug will prescribed per patient depends on the observing physician.
3296209|NCT01798290|Experimental|Behavioral: narrative medicine: reading workshop|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading patients' diaries or nurses'diaries. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3296210|NCT01798290|Active Comparator|Behavioral: critical reading|Students allocated to the active comparator arm will follow 5 sessions in Class-led instruction of reading literature. They will be divided into eight subgroups of 12 students. The first and fifth sessions will be presential, and 2nd 3rd and 4th sessions will be homework to do on internet.
3296211|NCT01798303|Experimental|LY2940094|40 mg LY2940094 oral tablet, QD for 8 weeks
3296212|NCT01798303|Placebo Comparator|Placebo|Identically matched placebo oral tablet, QD for 8 weeks
3296213|NCT01798329|Active Comparator|Probiotic|Probiotic VSL#3 for 15 weeks, dosage variations according to the weight
3296214|NCT01798329|Placebo Comparator|Placebo|subjects treated with placebo for 15 weeks
3296215|NCT01798342|Active Comparator|Maltodextrin|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin
3296216|NCT01798342|Experimental|Glutamine|The same volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of glutamine
3296217|NCT01798355|Experimental|Cognitive Behavioral Therapy|
3296218|NCT01798355|Active Comparator|Treatment as usual|
3296219|NCT01798368|Experimental|PBASE system 2.0|
3296220|NCT01798381|Active Comparator|Essential fatty acids|Omega-3
3296221|NCT01798381|Placebo Comparator|Placebo|Placebo tablet
3296222|NCT01798407|Experimental|Activa Tremor Control Sys (DBS Implant)|all subjects will receive bilateral surgical implantation of DBS system. Those who respond at 12 months will enter a randomized, staggered withdrawal phase.
3296223|NCT01798407|Experimental|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
3296224|NCT01798420||Corticosteroid|
3296225|NCT01798420||non-corticosteroid group|
3296226|NCT01798433|Experimental|One stent technique alone|One stent technique alone for non-true LM bifurcation
3296227|NCT01798433|Experimental|One stent technique + Elective FKB|One stent technique + Elective FKB for non-true LM bifurcation
3296228|NCT01798433|Experimental|Provisional approach|Provisional approach for true LM bifurcation
3296229|NCT01798433|Experimental|Elective 2-stent|Elective 2-stent for true LM bifurcation
3296230|NCT01798446|Experimental|Axitinib|This is a single arm study. Axitinib arm is the only arm who receive axitinib.
3296231|NCT01798459|Active Comparator|Methylphenidate|Methylphenidate 0.3 mg/kg per os is given before performing a continuous performance test.
3296232|NCT01798459|Placebo Comparator|Placebo|Placebo is given before performing a continuous performance test.
3296233|NCT01798472|Experimental|uncemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an uncemented hemiarthroplasty
3296234|NCT01798472|Experimental|reverse hybrid total hip arthroplasty|Patients aged between 65 and 79 years treated with an reverse hybrid arthroplasty.
3296235|NCT01798472|Active Comparator|cemented hemiarthroplasty|Patients aged 80 or older with displaced femoral neck fracture treated with an cemented hemiarthroplasty
3296236|NCT01798472|Active Comparator|cemented total hip arthroplasty|Patients aged between 65 and 79 years treated with an cemented total hip arthroplasty.
3296237|NCT01798498|Experimental|Princess® VOLUME|"Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.~A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.~The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds"
3296238|NCT01798511|Experimental|Nasogastric Tube Feeding|Patients who are to have NTF will receive enteral nutrition within 6 hours after randomisation via a nasogastric tube placed into the stomach. A commercially available low fat semi-elemental feed (Peptisorb®, Nutricia Clinical NZ) will be used. The caloric target will be 2000 kcal per day. Enteral tube feeding will be commenced at a rate of 30 mL/h and increased gradually until 100 mL/h over 24-48 h.
3296239|NCT01798511|Active Comparator|Conventional Nutritional Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case enteral tube feeding will be introduced) or the signs of AP mitigate,in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced.
3296240|NCT01798524||Kidney allograft recipients|
3296241|NCT01798537|Experimental|Neomycin Colistin Nystatin Vancomycin|"All participating study arm patients will receive SDD from admission to discharge according to the following plan:~ENTERAL MEDICATION (via feeding tube) x 4 times daily:~375 mg Neomycin 100 mg Colistin Sulphate~1 million units Nystatin * 250 mg Vancomycin *~Nystatin will be prescribed only if there is a positive sputum or urine culture for yeast or candida Vancomycin will be prescribed only in case of a positive screen or culture for MRSA"
3296242|NCT01798537|No Intervention|Control|No SDD given for 1 year Screening performed as in intervention arm
3296243|NCT01798563||Tremor Dominant PD|Volunteers with predominantly tremor-related motor symptoms of PD
3296244|NCT01798563||Postural Instability & Gait Difficulty PD|Volunteers with primarily walking & balance-related motor symptoms of PD.
3296245|NCT01798563||Healthy Controls|Healthy volunteers consisting of people of same age as PD volunteers, w/o a diagnosis of PD.
3296246|NCT01798576||Pegylated interferon alfa-2a|Participants with chronic hepatitis C with previous treatment failure received combination therapy with pegylated interferon alfa-2a plus ribavirin or treatment regimens containing direct-acting anti-viral (DAAs)
3296247|NCT01798602|Experimental|Rosuvastatin|"Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug~Both are crushed for administration"
3296248|NCT01798602|Placebo Comparator|Placebo|Identical drug vehicle with no active agent
3296249|NCT01798628|Experimental|Sequence ABC|
3296250|NCT01798628|Experimental|Sequence ACB|
3296251|NCT01798628|Experimental|Sequence BAC|
3296252|NCT01798628|Experimental|Sequence BCA|
3296253|NCT01798628|Experimental|Sequence CAB|
3296254|NCT01798628|Experimental|Sequence CBA|
3296255|NCT01798654||Antithrombotic agents|
3296256|NCT01798667|Placebo Comparator|Placebo|PO administration
3296257|NCT01798667|Experimental|DA-8031 dose 1|PO administration
3296258|NCT01798667|Experimental|DA-8031 dose 2|PO administration
3296259|NCT01798667|Experimental|DA-8031 dose 3|PO administration
3296260|NCT01798680|Experimental|Vitamin D3 (cholecalciferol)|
3296261|NCT01798680|Placebo Comparator|Placebo|
3296262|NCT01798693|Placebo Comparator|Placebo (maltodextrin)|Maltodextrin
3296263|NCT01798693|Active Comparator|Multi-Nutrient Blend|Blend of vitamins, minerals, and amino acids, given twice daily
3296264|NCT01798719|Placebo Comparator|Diet: Dietary Advice|Some general dietary advice about healthy dietary components, servings size and frequency of servings
3296265|NCT01798719|Experimental|Low glycemic index Mediterranean Diet|Low glycemic index Mediterranean Diet prescription with indication about type of foods than can be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
3296266|NCT01798732|Experimental|Selective laser trabeculoplasty (Tango Laser, Ellex)|Patients treated with selective laser trabeculoplasty (Tango Laser, Ellex, Minneapolis, USA)
3296267|NCT01798745|Experimental|Cohort A: JNJ-54452840 20 mg|Each patient will receive 20 mg of JNJ-54452840 as a single dose.
3296268|NCT01798745|Experimental|Cohort A: JNJ-54452840 80 mg|Each patient will receive 80 mg of JNJ-54452840 as a single dose.
3296269|NCT01798745|Experimental|Cohort A: JNJ-54452840 160 mg|Each patient will receive 160 mg of JNJ-54452840 as a single dose.
3296270|NCT01798745|Placebo Comparator|Cohort A: Placebo|Each patient will receive matching placebo as a single dose.
3296271|NCT01798745|Experimental|Cohort B: JNJ-54452840 <= 240 mg|Each patient will receive JNJ-54452840 at a dose of less than or equal to 240 mg as a single dose (dose determined by the Data Monitoring Committee).
3296272|NCT01798745|Placebo Comparator|Cohort B: Placebo|Each patient will receive matching placebo as a single dose.
3296273|NCT01798745|Experimental|Cohort C: JNJ-54452840 for 3 days|Each patient will receive JNJ-54452840 once daily for 3 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3379915|NCT05077397|Active Comparator|Group 1|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 1 will be monitored by the InSpectra Tissue Spectrometer, StO2, added to standard ASA monitorisation."
3296274|NCT01798745|Placebo Comparator|Cohort C: Placebo|Each patient will receive matching placebo once daily for 3 days.
3296275|NCT01798745|Experimental|Cohort D: JNJ-54452840 for 5 days|Each patient will receive JNJ-54452840 once daily for 5 days at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3379916|NCT05077397|Active Comparator|Group 2|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by O3TM Regional Oximeter System, added to standard ASA monitorisation."
3379917|NCT05077397|No Intervention|Group 3|"After the approval of the local ethics committee and written informed consent, 60 ASA I-III patients aged 18-75 years who will undergo liver resection will be included in the study.~Patients of Group 2 will be monitored by standard ASA monitorisation."
3379918|NCT05076149|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
3379919|NCT05076149|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
3379920|NCT05074420|Experimental|Baricitinib|Baricitinib given orally to participants daily
3379921|NCT05074056|Experimental|Ketorolac|A double-blinded number of children will get one dose of intravenous 0.5 mg/kg (max dose 30mg) ketorolac intraoperatively.
3379922|NCT05074056|Placebo Comparator|Placebo|A double-blinded number of children will get one dose of intravenous placebo intraoperatively.
3296276|NCT01798745|Placebo Comparator|Cohort D: Placebo|Each patient will receive matching placebo once daily for 5 days.
3296277|NCT01798745|Experimental|Cohort E: JNJ-54452840 weekly|Each patient will receive JNJ-54452840 once weekly on Days 1, 8, 15, and 22 at a dose determined by the Data Monitoring Committee (daily dose not exceeding 240 mg).
3296278|NCT01798745|Placebo Comparator|Cohort E: Placebo|Each patient will receive matching placebo once weekly on Days 1, 8, 15, and 22.
3296279|NCT01798745|Experimental|Cohort F: JNJ-54452840 multiple dose|Each patient will receive JNJ-54452840 once daily (for 3 or 5 days) or once weekly (up to Day 22) as determined by the Data Monitoring Committee and as explored in Cohorts C, D, and E (daily dose not exceeding 240 mg).
3296280|NCT01798745|Placebo Comparator|Cohort F: Placebo|Each patient will receive matching placebo once daily (for 3 or 5 days) or once weekly (up to Day 22).
3379923|NCT05072886|Experimental|AT193|Topical applied daily
3379924|NCT05072886|Placebo Comparator|Placebo|Topical applied daily
3296281|NCT01798771|Other|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
3296282|NCT01798771|Other|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
3296283|NCT01798784|No Intervention|Control Arm|Arm 1 will be the Control arm, in which participants receive an electronic pill container and are provided with daily reminders to take their medication but are not enrolled in the sweepstakes.
3296284|NCT01798784|Experimental|Sweepstakes Incentive 1|Arm 2 will be a sweepstakes incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which participants may win money if they remember to take their medication.
3296285|NCT01798784|Experimental|Sweepstake Incentive 2|Arm 3 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which monetary prizes may be awarded if participants take their medication prior to receiving a reminder.
3379927|NCT05068102|Experimental|Tumor patients|
3379928|NCT05067933|Experimental|Part 1 Cohort 1a (Naïve, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
3379929|NCT05067933|Experimental|Part 1 Cohort 1b (Naïve, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who are vaccine naïve
3379930|NCT05067933|Experimental|Part 1 Cohort 1c (Naïve, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
3379931|NCT05067933|Experimental|Part 1 Cohort 1d (Naïve, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who are vaccine naïve
3379932|NCT05067933|Experimental|Part 1 Cohort 2a (Prior vaccinated, low dose, young adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
3379933|NCT05067933|Experimental|Part 1 Cohort 2b (Prior vaccinated, high dose, young adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in young adults (18-55 yrs) who have received prior vaccinations with an mRNA vaccine
3379934|NCT05067933|Experimental|Part 1 Cohort 2c (Prior vaccinated, low dose, older adult)|1E10 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
3379935|NCT05067933|Experimental|Part 1 Cohort 2d (Prior vaccinated, high dose, older adult)|1E11 repeat-dose vaccinations with VXA-CoV2-1.1-S at Days 1 and 29 in older adults (56-75 yrs) who have received prior vaccinations with an mRNA vaccine
3379936|NCT05067933|Experimental|Part 2 Healthy Adults: Active vaccine|Repeat dose vaccinations with VXA-CoV2-1.1-S at dose selected from Part 1 in healthy male and female adult volunteers 18 to 75 years old
3379937|NCT05067933|Placebo Comparator|Part 2 Healthy Adults: Placebo control|Repeat dose administration with matching placebo tablets in healthy male and female adult volunteers 18 to 75 years old
3296286|NCT01798784|Experimental|Sweepstake Incentive 3|Arm 4 will be a sweepstake incentive arm where participants receive an electronic pill container and daily reminders to take their medication. In addition, this group is enrolled in a sweepstakes, in which each participant maintains an account that will accumulate money based on their medication adherence throughout the study.
3296287|NCT01798797||no treatment|non-randomized, all subjects who have been implanted with an ICD or CRT-D for at least 3 months
3296288|NCT01798810|Experimental|Supplemental Perioperative Oxygen (80% FiO2)|After intubation, patients in the Treatment Group will receive intraoperative inspired oxygen set at 80 percent (FiO2 of 0.80). Post-extubation, patients in the treatment arm will be placed on high flow non-re-breather mask at 15L/min for up to 2 hours postoperatively and then transitioned to nasal cannula, which will be weaned as tolerated.
3296289|NCT01798810|No Intervention|Control (30% FiO2)|After intubation, patients in the control arm will receive typical standard of care intraoperative inspired oxygen of 30 percent (FiO2 of 0.30). Post-extubation, patients in the control arm of the study will be placed on a nasal cannula at 4L/min to maintain SaO2≥92% as determined by pulse oximetry. This will be maintained for up to 2 hours and then weaned as tolerated.
3296290|NCT01798823||EIB+A+|"children with EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3296291|NCT01798823||EIB+A-|"children with EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3296292|NCT01798823||EIB-A+|"children without EIB and asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3296293|NCT01798823||EIB-A-|"children without EIB without asthma~History, physical, LF, SPT, blood sample, FeNO, EBC"
3296294|NCT01798836|Experimental|Oestradiol and ultrashort GnRH agonist/antagonist protocol|Women will begin pretreatment with 4 mg/day of 17 β-estradiol before the combination of GnRH ultashort agonist and antagonist protocol
3296295|NCT01798836|Active Comparator|GnRH agonist or antagonist protocol.|Women will undergo either a conventional short or long GnRH agonist or an antagonist protocol during COH for IVF
3296296|NCT01798862|Experimental|Endometrial injury by hysteroscopy or pipelle sapling|Endometrial Sampling by pipelle or hysteroscopy performed once between 6th to 10th day in the cycle prior to the fresh IVF/ ICSI cycle.
3296297|NCT01798862|Active Comparator|COH for IVF without hysteroscopy or pipelle sampling|Procedure: COH for IVF Both GnRH agonists (long, starting at day 2 or 21) with triptorelin acetate 0.1 mg (Gonapeptyl daily) and antagonists with ganirelix 0.25mg (Orgalutran) or cetrorelix 0.25mg (Cetrotide) protocols will be used; for ovarian stimulation both recombinant FSH ( Puregon) and human menopausal gonadotrophin ( Menopur) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the Hcg triggering and for luteal phase support 600 mg progesterone tablets ( Utrogestan) will be applied.
3296298|NCT01798875|Active Comparator|Metformin|oral metformin at a dose of 850mg twice daily
3296299|NCT01798875|Active Comparator|Oral contraceptive|oral contraceptive containing 35ug of ethynylestradiol and 2mg of cyproterone acetate (21 day regimen)
3296300|NCT01798901|Experimental|Treatment (HDAC inhibitor AR-42, decitabine)|"INDUCTION THERAPY: Patients receive HDAC inhibitor AR-42 PO daily on days 1, 3, and 5 or 1, 3, 4, 5 and decitabine IV over 1 hour on days 6-15. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients achieving CR or CRi receive HDAC inhibitor AR-42 as in Induction Therapy and decitabine IV over 1 hour on days 6-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3296301|NCT01798953||UC/PSC with IPAA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileal pouch-anal anastomosis
3296302|NCT01798953||UC with IPAA|Patients with ulcerative colitis reconstructed with ileal pouch-anal anastomosis.
3296303|NCT01798953||UC/PSC with IRA|Patients with ulcerative colitis and primary sclerosing cholangitis reconstructed with ileorectal anastomosis.
3296304|NCT01798953||UC with IRA|Patients with ulcerative colitis reconstructed with ileorectal anastomosis.
3296305|NCT01798979|Experimental|Midazolam and GLPG0634|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8) and multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
3296306|NCT01799005|Active Comparator|flavanol rich intervention|Ingestion of 410mg flavanols twice a day for 30 days
3296307|NCT01799005|Placebo Comparator|flavanol free intervention|Ingestion of a macro and micro nutrients matched flavanol free drink
3296308|NCT01799018||SAH Patients|Patients admitted with the diagnosis of aneurismal subarachnoid hemorrhage (SAH) and cerebral angiogram negative SAH who would need to have the external ventricular drain (EVD) placed for the management of hydrocephalus.
3296309|NCT01799018||Control Patients|Patients with non-hemorrhagic brain pathology such as posterior fossa tumor or stroke who will have the CSF sampling for diagnostic or therapeutic purposes.
3296310|NCT01799031|Experimental|Arm I (WISE)|Patients receive access to the WISE web-based educational intervention to help BCS manage their symptoms, identify ergonomic workplace problems and risks, and implement ergonomic modifications. Patients also receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
3296311|NCT01799031|Active Comparator|Arm II (control)|Patients receive standard of care comprising symptom management therapies and a pamphlet on employment rights.
3296312|NCT01799044|Experimental|Irreversible electroporation|Single arm study: Irreversible electroporation of colorectal liver metastasis
3296313|NCT01799057|Experimental|Metformin|Metformin at a maximum dose of 1000mg twice daily for 16-18 weeks (i.e. maximum of 2000mg per day).
3296314|NCT01799057|Placebo Comparator|Placebo|Matching placebo twice daily for 16-18 weeks.
3296315|NCT01799070||CHS|
3296316|NCT01799083|Experimental|Decitabine|A continuous 5-day treatment of lower dose decitabine within 4-6 weeks is regarded as a treatment cycle, transfusion of auto-CIK cells or chemotherapy regimen may be used for patients.
3296317|NCT01799096|Experimental|Sucrose|Receives sucrose
3296318|NCT01799096|Placebo Comparator|Aspartame|Receives Aspartame sweetened drinks
3296319|NCT01799109|Experimental|nebulization ms and albuterol|magnesium sulfate 150mg & albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3296320|NCT01799109|Active Comparator|nebulized albuterol|albuterol 2.5mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3296321|NCT01799109|Experimental|nebulized ms|magnesium sulfate 150mg nebulized with 5-6L/min of oxygen and consisted about 5 min,which used only once
3296322|NCT01799122|Active Comparator|Precise sling vs TVT-O sling|
3296323|NCT01799148||Particulate air pollutants|Cohort of consecutive patients admitted with diagnosis of acute coronary syndrome in the cardiology unit of a tertiary hospital, which will quantify the exposure of particulate air pollutants 24 hours a day 7 days earlier prior to admission.
3296324|NCT01799161|Active Comparator|DS-1|6 week course of gp96 Vaccine: >= 4 x 10^7 cells twice monthly on Day 1. Up to 3 courses, 9 vaccinations.
3296325|NCT01799161|Active Comparator|DS-2|6 week course of gp96 Vaccine: >= 2 x 10^7 cells weekly on Day 1. Up to 3 courses, 18 vaccinations.
3296326|NCT01799161|Active Comparator|DS-3|6 week course of gp96 Vaccine: >= 1 x 10^7 cells twice weekly on Days 1 and 4. Up to 3 courses, 36 vaccinations.
3296327|NCT01799174|Active Comparator|UVA-1 Phototherapy|Receive medium dose UVA-1 (70 J/cm2) 3x/week for 10 weeks
3296328|NCT01799174|Sham Comparator|Placebo|"Receive sham UVA1 phototherapy (0 J/cm2) 3x/week for 10 weeks"
3296329|NCT01799187|Experimental|revascularization|revascularization is is an alternative new treatment of immature permanent teeth with necrotic pulp. The use of triple antibiotic paste is followed by Induction of bleeding from the apical root during this intervention.
3296330|NCT01799187|Active Comparator|apexification|apexification is a traditional therapy of immature permanent teeth with necrotic pulp.calcium hydroxide is served as medication to induce the developing of root .
3296331|NCT01799252||Doxy|Women who are prescribed a seven-day regimen of doxycycline following medical abortion
3296332|NCT01799252||No Doxy|Women who are not prescribed antibiotics following medical abortion
3296333|NCT01799291|Other|Treatment: Decision Making Tutorial|A brief presentation on mood disorders (i.e., Control condition) combined with the intervention (i.e., Treatment condition): a 20-minute training on decision-making errors and cognitive de-biasing strategies.
3296334|NCT01799291|No Intervention|Control|A brief presentation about mood disorders.
3296335|NCT01799304|Experimental|no distractor control group|postural control and locomotion of CP children without attentional distractor and without additional cognitive task (control condition)
3296336|NCT01799304|Experimental|visual and sound attentional distractors|postural control and locomotion of CP children with visual and sound attentional distractors (video film).
3296337|NCT01799304|Experimental|sound attentional distractor alone|postural control and locomotion of CP children with sound attentional distractor alone (sound track of the video film).
3296338|NCT01799304|Experimental|additional cognitive task|postural control and locomotion of CP children with an additional cognitive task (adapted Stroop task with animals)
3296339|NCT01799317|Active Comparator|Treatment with vitamin D2|Vitamin D2 50,000u titrated to serum 25(OH)D values given orally once a month in addition to standard of care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
3296340|NCT01799317|No Intervention|Standard of Care|Standard of Care: Doxercalciferol escalating doses beginning at 2.5 mcg given orally thrice weekly. Sevelamer Carbonate 800 mg (1600- 4800 mg) given orally with each meal
3296341|NCT01799330|Experimental|Group 1:Active TCEMS|Transcutaneous Electrical Muscle Stimulation (TCEMS): Group 1 will undergo TCEMS using an Omnistim FX-2 with two surface patch electrodes (8 x 6 cm) applied to each quadriceps, hamstring and calf muscles. The knee angle will remain at 90 degrees during simultaneous muscle stimulation to prevent joint movement. Electrical stimulation will be performed for 20 minutes on each limb, 3 days/week for 8 continuous weeks on an outpatient basis. The stimulator will be set to generate brief bursts of electrical impulses at 50Hz lasting 200 ms every 1500 ms. Muscles will be stimulated with an asymmetrical square wave pulse with an initial intensity set to create a visible contraction ranging from 55 mA to 120 mA.
3296342|NCT01799330|Placebo Comparator|Group 2: Sham TCEMS|Patients randomized to Group 2 (Sham TCEMS) will receive the identical set-up for active TCEMS except they will receive a minimal electrical stimulus that does not produce a motor response.
3296343|NCT01799343|Experimental|Immersion into water|Normal healthy singleton pregnant women. The case serves as its own control. Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion (Baseline), during immersion (Immersion) and after immersion (Post-immersion).
3296344|NCT01799356|Active Comparator|moxifloxacin Group|Treatment at uPID with moxifloxacin
3296345|NCT01799356|Placebo Comparator|Ofloxacin Group|Treatment at uPID with Ofloxacin plus metronidazole
3296346|NCT01799369|No Intervention|Control|Routine post-operative care
3296347|NCT01799369|Experimental|Intervention|Post-operative care influenced by the Surgical Apgar Score
3296348|NCT01799382|Experimental|EBUS-TBNA + Rapid on-site evaluation|Patients in this arm will undergo rapid-on site evaluation of samples obtained with EBUS-TBNA
3296349|NCT01799382|Active Comparator|EBUS-TBNA|Patients in this arm will undergo EBUS-TBNA without rapid on-site evaluation
3296350|NCT01799395||Lung Cancer|All patients with advanced lung cancer candidate for chemotherapy or chemotherapy + radiation therapy will be enrolled and followed-up for 1 year clinically and radiologically (Chest CT) to verify whether or not central airway obstruction is present at the time of diagnosis or occurs in the year following diagnosis (or in the life span from diagnosis and death in patients who die before 1 year of diagnosis). Furthermore, predictor variables possibly associated with central airway obstruction will be studied.
3296351|NCT01799408||betamethasone|Patients who had intra-articular injection of betamethasone
3296352|NCT01799408||Hyaluronic acid|Patients who had intra-articular injection of hyaluronic acid
3296353|NCT01799421||Non-haematologic cancer|
3296354|NCT01799434|Experimental|Exercise|All participants had to run 20min on their individual anaerobic threshold
3296355|NCT01799447|Other|Early intervention|Early intervention. Quasiexperimental study. Inclusion of 150 first times families in intervention and matched with 150 families from control group.
3296356|NCT01799460||CR/CTR group|The complete remission group treated by the Comprehensive Treatment Regimen
3296357|NCT01799460||NR/CTR group|The non-remission group treated by the Comprehensive Treatment Regimen
3379938|NCT05067270|Experimental|Sodium citrate and Treprostinil (Part A)|Participants receive sodium citrate and treprostinil in Humalog diluent with magnesium chloride (without insulin) as subcutaneous (SC) infusion using Medtronic™ MiniMed™ 770G pump
3296358|NCT01799460||CR/IA group|The complete remission group treated by Immunosuppressive Agents
3296359|NCT01799460||NR/IA group|The non-remission group treated by Immunosuppressive Agents.
3296360|NCT01799486|Experimental|Telbivudine|Telbivudine,600mg/d,oral,100patients,2 years.
3296361|NCT01799486|Experimental|Adefovir|Adefovir,10mg/d,oral,100 patients,2years.
3296362|NCT01799486|Experimental|Enecavir|Enecavir,0.5mg/d,oral,100 patients,2 year
3296363|NCT01799499|Experimental|Group A: 20 mg MMC mixed with 60cc TC-3|Group A: 20 mg MMC mixed with 60cc TC-3 hydrogel. (n=8)
3296364|NCT01799499|Experimental|• Group B: 40 mg MMC mixed with 60cc TC-3|• Group B: 40 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
3296365|NCT01799499|Experimental|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)|• Group C: 80 mg MMC mixed with 60cc TC-3 hydrogel (n=8)
3296366|NCT01799512|Experimental|real-time continuous glucose monitoring|"real-time continuous glucose monitoring: Use will be made of the online real-time (RT) monitoring facility of the GlucoDay® (a continuous glucose monitoring (CGM)system). This will allow immediate adaptation of the insulin dose in order to maintain values within an optimal range.~The same IV insulin infusion protocol will be used in the experimental and the active comparator group (adapted Yale protocol).~When glycaemic changes of >25 mg/dl per 30 minutes are observed from the RT-CGM - GlucoDay data, this will be checked by measuring arterial blood glucose and the insulin infusion rate will be adapted according to the adapted Yale protocol."
3296367|NCT01799512|Active Comparator|blinded continuous glucose monitoring|"In the active comparator group the same continuous glucose monitoring device (GlucoDay) will be used in a blinded fashion. Glucose data will be analysed retrospectively.~IV insulin infusion will be adapted according to arterial blood glucose values, using the adapted Yale protocol."
3296368|NCT01799525|Experimental|Hypercapnia|Intervention: SAH patients are subjected to gradual hypercapnia by reduction of respiratory volume in one trial session every day. PaCO2 is raised from normocapnia to 50 mmHg for 10 - 15 minutes and 60 mmHg for 10 - 15 minutes.
3296369|NCT01799551|Active Comparator|Ca CBT|Experimental arm will receive brief version of Culturally adapted CBT for depression. This is based on our previous work in which we adapted CBT for depression in Pakistan
3296370|NCT01799551|No Intervention|Treatment As Usual|Patients in this arm will get only Treatment As Usual, which normally includes regular follow up and medicines.
3296371|NCT01799564|Experimental|Micropulse|Micropulse laser will be applied to the inferior hemiretina next to the area of atrophy in a randomly selected eye in 1, 2 or 3 occasions
3296372|NCT01799564|No Intervention|Control|The fellow eye does not receive any treatment
3296373|NCT01799577||Gynecologist|Gynecologist can use laparoscopic surgery.
3296374|NCT01799603|Experimental|TMC435 in fasted then fed condition|Participants under fasting condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fed condition of second treatment period (after washout period of 9 days, between the two treatment periods).
3296375|NCT01799603|Experimental|TMC435 in fed then fasted condition|Participants under fed condition will be administered with TMC435, 100 milligram (mg) as oral capsule on Day 1 of first treatment period and then will be administered with TMC435, 100 mg oral capsule on Day 1 under fasting condition of second treatment period (after washout period of 9 days, between the two treatment periods).
3296376|NCT01799616|Experimental|Pamidronate|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
3296377|NCT01799616|Other|Placebo|In total, 48 patients will need to be recruited. These patients will be randomly assigned to one of the two groups, with each group comprising 24 patients: one group will be given pamidronate and the other placebo
3296378|NCT01799629|Experimental|Intervention|Intervention group will receive the glycerin suppository
3296379|NCT01799629|No Intervention|Control|Normal care
3296380|NCT01799642||Cystic Fibrosis Patients|Participants with Cystic Fibrosis
3296381|NCT01799642||Healthy Controls|Participants who do not have cystic fibrosis and are otherwise healthy.
3296382|NCT01799681|Experimental|EXPERIMENTAL|a 4-week indoor and 4-week outdoor balance training with stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
3296383|NCT01799681|Active Comparator|CONTROL|an eight-week training on upper limb stretching and strengthening, hand agility exercise, knot tying and Chinese calligraphy
3296384|NCT01799694|Experimental|Autologous Expanded Stem Cells|Inject of Autologous Adipose-derived expanded stem cells
3296385|NCT01799707|Active Comparator|vision restoration training|Vision restoration training (VRT): visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
3296386|NCT01799707|Placebo Comparator|Discrimination training|Discrimination training. Here, the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
3296387|NCT01799733|Active Comparator|LWT+AM BWL|Late-wake therapy in combination with morning bright white light
3296388|NCT01799733|Placebo Comparator|EWT+PM BWL|Early-wake therapy in combination with evening bright white light
3296389|NCT01799759|Experimental|Online intervention for parent and child|Children complete 8 online modules of Project FUN Parents complete 6 modules of Project FUN for Parents
3296390|NCT01799759|Other|Instruments only|The waiting list control group only completes instruments and body composition, fitness measures
3296391|NCT01799772|Experimental|Comprehensive behavioral intervention|"It will involve regular contacts over 6 month period. It will include 2 weekly contacts for weeks 1-6, weekly contacts for weeks 7-8, bi-weekly contact for months 3-4, and monthly contact for months 5-6. There is a combination of 20 individual and group-based sessions.~It is a combination of 4 components: a) Evidence-based exercise program, b) Physical activity promotion, c) Healthy nutrition guidance, and d) Self-management."
3296392|NCT01799772|Active Comparator|Standard of Care Exercise Program (SCE)|The SCE will be delivered by a physical therapist. It represents the typical rehabilitation after TKA surgery. It is expected to provide small and short-lived functional improvement. Subjects will participate in 12 supervised sessions (2 x/week, for 6 weeks). The SCE consists of: a) lower extremity range of motion and stretching exercises, b) lower extremity strengthening exercises of moderate intensity, and d) endurance exercises using treadmill.
3296393|NCT01799785|Experimental|Aerobic exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
3296394|NCT01799785|Placebo Comparator|Usual care group|These patients will continue with their normal daily activity and will not be provided with supervised aerobic exercise training during the study period.
3296395|NCT01799798|Experimental|Denosumab subcutaneously|
3296396|NCT01799811||CLI patient's needing open bypass|Patients presenting with Rutherford Class 5 or 6 CLI that are being evaluated for open peripheral arterial revascularization.
3296397|NCT01799824|Experimental|Active|ANT-1403
3296398|NCT01799824|Placebo Comparator|Vehicle|Vehicle
3296399|NCT01799837|Other|Healthy Controls|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
3296400|NCT01799837|Other|Veterans with PTSD|Posttraumatic stress disorder (PTSD) is a potentially debilitating anxiety disorder triggered when a person is exposed to a traumatic event that is beyond what is experienced in everyday life. A traumatic event may include an interpersonal event like physical or sexual assault, exposure to a disaster or accidents, combat or witnessing a traumatic event. Some symptoms of PTSD include not being able to sleep, nightmares, flashbacks of the event and having problems with memory or not being able to focus. You are being asked to volunteer because you are either 1) a normal healthy volunteer or 2) a deployed veteran or non-deployed veteran who is diagnosed with PTSD. We anticipate enrolling 16 subjects; 8 veterans with PTSD and 8 healthy volunteers without PTSD.
3296401|NCT01799850|Active Comparator|Actos|Actos 30 mg daily
3296402|NCT01799850|Placebo Comparator|placebo|double blind placebo controlled
3296403|NCT01799863|Experimental|Ketorolac trometamol 0.45%|Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.
3296404|NCT01799863|Placebo Comparator|Artificial tears|Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.
3296405|NCT01799876|Experimental|Autologous Cell|Regenerative cells obtained from autologous fat are administered in the knee at microfracture site.
3296406|NCT01799876|Sham Comparator|Control|Standard arthroscopy with sham lipoplasty procedure (no fat cells harvested).
3296407|NCT01799902||Male subjects with LUT predominant storage symptoms (OAB)|male subjects with Overactive Bladder Syndrome (OAB) being treated with solifenacin in monotherapy or combination
3296413|NCT01799954|Other|NYVAC Prime / NYVAC + AIDSVAX® B/E Boost vs. Placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a NYVAC vaccine prime and NYVAC + AIDSVAX® B/E boost. Twenty participants will get vaccines and 4 will get only placebos.
3296414|NCT01799954|Other|NYVAC + AIDSVAX® B/E Prime / Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of priming and boosting with the vaccines NYVAC + AIDSVAX® B/E. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 1 to see if the priming makes a difference in the body's immune response.
3296415|NCT01799954|Other|DNA prime + NYVAC + AIDSVAX® B/E Boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 4 to see if the priming makes a difference in the body's immune response.
3296416|NCT01799954|Other|DNA+AIDSVAX® B/E prime / NYVAC+AIDSVAX® B/E boost vs. placebo|This arm will evaluate the safety of and the body's immune response to a vaccine regimen consisting of a DNA vaccine + AIDSVAX® B/E priming and NYVAC + AIDSVAX® B/E boosting. Twenty participants will receive the vaccines and 4 will receive placebos. This arm will also be compared to arm 3 to see if the priming makes a difference in the body's immune response.
3296417|NCT01799980||Cervical mediastinoscopy|This group will undergo cervical mediastinoscopy before surgery to stage their lung cancer (procedure decided by the surgeon).
3296418|NCT01799980||Endo-bronchial ultrasound|This group will undergo endobronchial ultrasound before surgery to stage their lung cancer (procedure decided by the surgeon).
3296419|NCT01800006||Group 1|
3379939|NCT05067270|Experimental|Sodium citrate (Part B - Test 1)|Participants receive sodium citrate in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump
3379940|NCT05067270|Experimental|Treprostinil (Part B - Test 2)|Participants receive treprostinil in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump
3379941|NCT05067270|Experimental|Sodium citrate and Treprostinil (Part B - Test 3)|Participants receive sodium citrate and treprostinil in Humalog diluent with magnesium chloride (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump
3379942|NCT05067270|Experimental|Humalog diluent (Part B - Test 4)|Participants receive Humalog diluent (without insulin) as SC infusion using Medtronic™ MiniMed™ 770G pump
3296420|NCT01800019|Active Comparator|NRT arm|"Drug: Nicotine Replacement Therapy (Nico-Derm® and Nicorette®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study baseline, and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~Additionally, participants will be provided with a supply of short-acting nicotine gum in order to supplement their long acting NRT patch regimen.~Individuals who smoke their first cigarette more than 30 minutes after waking are advised to use the 2 mg NRT gum. Participants who smoke their first cigarette within 30 minutes of waking will be advised to use the 4 mg NRT gum. Both NRT gum dosages will be recommended for use on an ad lib basis to address cravings and/or withdrawal symptoms, up to a maximum of 12 pieces of NRT gum per day."
3379943|NCT05064722|Experimental|SNAP-S|Creation of a D-I diversion in participants undergoing primary sleeve gastrectomy (SNAP-S cohort)
3379944|NCT05064722|Experimental|SNAP-PS|Creation of a D-I diversion in participants who have experienced inadequate weight loss following sleeve gastrectomy (SNAP-PS cohort)
3379945|NCT05064332|Experimental|OC only|Subjects will receive a single dose of an oral contraceptive during the first period of the study
3379946|NCT05064332|Experimental|PF-06650833 + OC|Subjects will receive PF-06650833 every day for 11 days and a single dose of an oral contraceptive on day 10.
3379947|NCT05063851|Experimental|Memantine hydrochloride|
3379948|NCT05063851|Placebo Comparator|Placebo|
3379949|NCT05063539|Experimental|LY3372689 High Dose|LY3372689 given orally
3379950|NCT05063539|Experimental|LY3372689 Low Dose|LY3372689 given orally
3379951|NCT05063539|Placebo Comparator|Placebo|Placebo given orally
3379953|NCT05060237|Experimental|BF-200 ALA|"Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).~One single photodynamic therapy (PDT)."
3379954|NCT05058651|Experimental|Arm I (atezolizumab, platinum, etoposide)|During induction phase, patients receive atezolizumab IV over 60 minutes on day 1 of each cycle, carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
3379955|NCT05058651|Experimental|Arm II (atezolizumab, platinum drug, etoposide, observation)|During induction phase, patients receive atezolizumab IV over 60 minutes on day 1 of each cycle, carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year
3379956|NCT05058651|Active Comparator|Arm III (platinum drug, etoposide, observation)|During induction phase, patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.
3379957|NCT05057858|Experimental|Perfect Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC once daily (7 doses per week).
3379958|NCT05057858|Experimental|Moderate Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet 4 times per week (Monday, Tuesday, Thursday, Friday)
3379959|NCT05057858|Experimental|Poor Adherence|Cisgender women will receive a single tablet of co-formulated 300 mg TDF/ 200mg FTC tablet twice per week(Monday and Tuesday)
3379960|NCT05056987|Other|TOTAL30, then AOHP|Lehfilcon A contact lenses worn first, with senofilcon A contact lenses worn second, as randomized. The lehfilcon A contact lenses will be worn for approximately 28 days. The senofilcon A contact lenses will be worn for approximately 14 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
3379961|NCT05056987|Other|AOHP, then TOTAL30|Senofilcon A contact lenses worn first, with lehfilcon A contact lenses worn second, as randomized. The senofilcon A contact lenses will be worn for approximately 14 days. The lehfilcon A contact lenses will be worn for approximately 28 days. Each product will be worn bilaterally (in both eyes) in a daily wear modality, with AOSEPT PLUS with HydraGlyde used for nightly cleaning and disinfection.
3379962|NCT05056870|Experimental|Test/Control|Eligible subjects will be randomized to the sequence, Test/Control
3379963|NCT05056870|Experimental|Control/Test|Eligible subjects will be randomized to the sequence, Control/Test
3379964|NCT05054790|Experimental|"Autologous Neo-Bladder Construct"|All subjects enrolled will have non-neurogenic, fibrotic contracted bladder that is refractory to medical treatment and require augmentation cystoplasty for preventing long-term sequelae (i.e., kidney failure) that result from persistently high intravesical pressure.
3379965|NCT05054725|Experimental|RMC-4630 and sotorasib, Safety Run-in|"Safety Run-In:~RMC-4630 and sotorasib"
3379966|NCT05054725|Experimental|RMC-4630 and sotorasib, Expansion|"Dose Expansion:~RMC-4630 and sotorasib"
3379969|NCT05051579|Experimental|LY3502970 Dose 1|Participants will receive LY3502970 administered orally
3379970|NCT05051579|Experimental|LY3502970 Dose 2|Participants will receive LY3502970 administered orally
3379971|NCT05051579|Experimental|LY3502970 Dose 3|Participants will receive LY3502970 administered orally
3379972|NCT05051579|Experimental|LY3502970 Dose 4|Participants will receive LY3502970 administered orally
3379973|NCT05051579|Placebo Comparator|Placebo|Placebo administered orally
3296421|NCT01800019|Active Comparator|NRT and HIV Tailored Quit Smoking Counseling|"Drug: Nicotine Replacement Therapy (Nico-Derm®)~Dose: 7mg - 42mg depending on # of cigarettes smoked per day at study randomization and withdrawal symptoms.~Mode of Administration: Transdermal Patch~Duration of Treatment: up to 24 Weeks~HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
3296422|NCT01800019|Active Comparator|Varenicline (VR) Arm|"Drug: Varenicline (Champix®)~Doses: 0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)"
3296423|NCT01800019|Active Comparator|Varenicline (VR) and HIV Tailored Quit Smoking Counseling|"Drug: Varenicline (Champix®)~0.5 mg once daily for 3 days(i.e.day 1-3 of the week prior to quit date) 0.5 mg twice daily for 4 days i.e. day 4-7) and 1 mg twice daily for the remainder of the treatment period~Mode of Administration: Oral~Duration of Treatment: 24 Weeks (+ 1 Week of Dose Escalation, total of 25 weeks)~Intervention: HIV tailored Smoking Cessation Counseling: The counseling consists of face-to-face sessions with a trained smoking cessation counselor at the start of the study, on your chosen quit date, and then at weeks 4, 8, 12 and 24; supportive telephone calls if needed."
3296424|NCT01800032||Plexiform Neurofibroma|NF1 associated plexiform neurofibroma
3296425|NCT01800032||Optic Glioma|NF1 associated optic glioma
3296426|NCT01800045|Experimental|Pitolisant|Pitolisant at 5, 10, 20 or 40mg
3296427|NCT01800045|Placebo Comparator|Placebo|Capsules of placebo containing lactose
3296428|NCT01800084|Experimental|Patients undergoing SPECT-CT|"The patients in this study are scheduled for a SPECT-CT at the Nîmes University Hospital as part of their normal care regimen.~Intervention: Device: Asir Image Acquisition"
3296429|NCT01800097|Placebo Comparator|placebo|placebo
3296430|NCT01800097|Active Comparator|Modafinil|Modafinil
3296431|NCT01800110|Experimental|2|label I- 200 cc pomegranate juice once daily for 6 weeks post partum. label II- control group, no placebo is givening.
3296432|NCT01800123||Acute poisoning|Consecutive acute drug self poisoned patients admitted in the ED.
3296433|NCT01800136|Experimental|rTMS; tDCS|
3296434|NCT01800149|Active Comparator|BBM+collagen|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with BioOss Collagen and covered with Bio-Gide
3296435|NCT01800149|Active Comparator|BBM granules|Ridge Augmentation After tooth extraction, edentulous sockets will be filled with Bio-Oss Granules, 0-25-1 mm, and covered with Bio-Gide
3296436|NCT01800175|Experimental|Formulation C|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
3296437|NCT01800175|Experimental|Formulation D|Two formulations of the OTX Punctum Plug will be evaluated in this trial. The difference in formulations is the time required for degradation of the PEG hydrogel. The persistence of OTX Punctum Plug (Formulation C) is anticipated to be slightly shorter than the persistence of OTX Punctum Plug (Formulation D).
3296438|NCT01800188||Dialysis|Patients with dialysis dependent ESRD and normal fasting glucose will undergo a meal test during a hemodialysis and hemodiafiltration session. A meal test without dialysis is optional.
3296439|NCT01800214||Alzheimer's disease (AD)|
3296440|NCT01800214||Vascular Cognitive Disorders (VCD)|
3296441|NCT01800214||Lewy Body Disease (LBD)|
3296442|NCT01800214||Frontotemporal Dementia (FTD)|Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)
3296443|NCT01800214||Mild Cognitive Impairment (MCI)|
3296444|NCT01800214||Cognitively Normal (CN)|
3296445|NCT01800214||Small Vessel Disease -Neurodegenerative (SVD)|
3296446|NCT01800214||Subjective Cognitive Complaints (SCC)|
3296447|NCT01800253|Experimental|Total sleep deprivation|Participants will be required to stay up for the entire night before 'Blood Samples' and 'Tissue samples' will be taken and the 'Portion Size Task' and 'Inhibitory task' will be performed. This will then be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
3296448|NCT01800253|Experimental|Sleep|Participants will have an 8-h sleep opportunity before 'Blood Samples' and 'Tissue samples' will be taken and 'Portion Size Task' and 'Inhibitory task' will be performed. This will be followed by the 'Oral glucose tolerance test' with additional 'Blood Samples' to be taken as described for that test.
3296449|NCT01800266|Experimental|Symptom and Fidelity Monitoring (SFM)|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
3296450|NCT01800266|Experimental|SFM + Behavioral Rehearsal|Half of the study clinicians will be randomized to this supervision condition of TF-CBT.
3296451|NCT01800279|Active Comparator|Deontology Therapy|The patients in the control group will port a deprogramming occlusal splint to sleep every night, an average of 8 hours per day, for 12 weeks of the treatment.
3296452|NCT01800279|Experimental|Physiotherapy Protocol|The physiotherapy protocol involves the application of kinesitherapy techniques and a myofascial therapy protocol. This protocol will be administered twice a week for 12 weeks.
3296453|NCT01800292|Experimental|sildenafil therapy|Subjects will have 2D-Echocardiogram measuring left ventricular strain and strain rate using speckle tracking techniques, have 6 minute walk test, World Health Organization functional class (I-IV)assignment, and BNP lab result at baseline and at 3 months. Subjects will be started on sildenafil at 20 mg by mouth three times per day at the baseline visit. Each individual will serve as his/her own control.
3296454|NCT01800305|Experimental|Pegylated rhEPO|Subcutaneous single-dose administration of 0.5mcg/kg, 1.0mcg/kg, 1.6 mcg/kg, 2.4 mcg/kg, 3.2 mcg/kg，3.2mcg/kg, 4.2mcg/kg, 5.5 mcg/kg, 7.2 mcg/kg, 9.3 mcg/kg (in dose-escalation, if the previous dose is confirmed to be safe.started with the second 3.2mcg/kg dose,Every subject takes Niferex 150mg every day, from day 1 to day 20. ) of the test drug (Pegylated rhEPO)
3296455|NCT01800305|Active Comparator|EPIAO®|Subcutaneous six-dose administration of 50IU/kg or 150IU/kg, as randomization, of the comparator drug(EPIAO®) at day 1, 3, 5, 8, 10, 12.
3296456|NCT01800331|Experimental|Text2bHealthy|The intervention arm receives the Text2bHealthy program on a PDA
3296457|NCT01800331|No Intervention|Control group|The control group will complete a paper dairy to keep track of their lifestyle behaviours
3296458|NCT01800344|Active Comparator|The laryngeal mask airway-ClassicTM (LMA)|The LMA is a large foreign body that exerts pressure on the pharyngeal mucosa. High LMA intracuff pressures may reduce pharyngeal mucosal perfusion and lead to throat discomfort.
3296459|NCT01800344|Active Comparator|The AES Ultra CPVTM LMA (Ultra)|Ultra is a new supraglottic airway with anatomical features and insertion technique virtually identical to the LMA-ClassicTM. The cuff and the shaft are made of silicone with a built-in CPV pilot balloon valve which provides continuous monitoring of the intracuff pressure. The CPV cuff pressure indicator has 3 zones indicated by color: yellow corresponds to pressure < 50 cm H2O; green 60 cm H2O; and red >70 cm H2O
3296460|NCT01800357|Experimental|mildronate|infusion of mildronate
3296461|NCT01800357|Placebo Comparator|placebo|infusion of placebo mildronate
3296462|NCT01800370|Experimental|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
3296463|NCT01800370|Placebo Comparator|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine. Includes blood draws and fasting requirements.
3296464|NCT01800370|Experimental|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds.~Includes blood draws and fasting requirements."
3296465|NCT01800383||Control|No Axis I psychiatric disorder and no trauma exposure
3296466|NCT01800383||Trauma-Exposed Normal Control|History of trauma exposure and subthreshold PTSD symptoms.
3296467|NCT01800383||PTSD|Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of PTSD as determined by the Structured Clinical Interview for DSM-IV-Text Revised
3296468|NCT01800396|Placebo Comparator|Milk protein|Milk powder, twice daily at breakfast and dinner.
3296469|NCT01800396|Experimental|Milk protein rich in phospholipids|Milk powder, twice daily at breakfast and dinner.
3296470|NCT01800409|Experimental|AFES training|Participants will take part in AFES training sessions five times per week (Mon-Fri) for a total of 8 weeks During these sessions participants will receive AFES for 40 minutes. Training sessions are designed to strengthen the participants abdominal muscles in order to improve respiratory function
3296471|NCT01800409|No Intervention|Control period|Four week control period. The order of the control and training periods will be randomised for each participant.
3296472|NCT01800422|Experimental|Arm I (telapristone acetate)|Patients receive telapristone acetate orally once daily for 2-10 weeks and then undergo surgical resection.
3296473|NCT01800422|Placebo Comparator|Arm II (placebo)|Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.
3296474|NCT01800435|Active Comparator|aPCC, aPCC + TXA|aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
3296475|NCT01800435|Active Comparator|rFVIIa, rFVIIa + TXA|rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
3296476|NCT01800461|Experimental|OPC-Stroke, Usual care|OPC-Stroke - 10 weekly sessions of goal setting followed by problem solving process
3296477|NCT01800461|Other|Usual care|Usual care - Follow-up by physician and possible receipt of home care services
3296478|NCT01800487|Active Comparator|silymarin|Silymarin 140 mg three times a day for 4 weeks
3296479|NCT01800487|Placebo Comparator|placebo|"Placeo~1 tab three times a day for 4 weeks"
3296480|NCT01800500|Experimental|Arm I (fixed rate ST product prices)|Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
3296481|NCT01800500|Experimental|Arm II (escalating ST product prices)|Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.
3296482|NCT01800513|Experimental|Endometrial Biopsy|Subjects will have a vaginal speculum placed and visualization of the cervix will be obtained. The cervix will be cleaned with betadine (or hibiclens for those with an iodine allergy). Those randomized to the treatment arm (endometrial biopsy) will have an endometrial pipelle (Endocell, Wallach, Orange, Connecticut) inserted gently through the cervix into the uterus. Two passes will be performed with the pipelle catheter. For each pass the catheter will be rotated and scraped 4 times, once in each quadrant.
3296483|NCT01800513|Sham Comparator|Control|Those randomized to the control group will have a small cotton swab placed gently into the cervix. No tissue will be obtained with this method. The randomization to a placebo control is necessary to prove that any positive effects seen are due to the biopsy and not just random chance.
3296484|NCT01800526|Experimental|Oral N-acetylcysteine (NAC)|Eligible subjects who did not participate in Intravenous NAC or subjects who are at least 4 weeks after participation in Intravenous NAC, will be given Oral NAC at a dose of 2400mg daily, in two equally divided doses, for 4 weeks. Subjects will have blood drawn prior to beginning the phase and weekly for 4 weeks. At each visit interim medical events and adverse events will be collected.
3296485|NCT01800526|Experimental|Intravenous N-acetylcysteine (NAC)|"For part 1, Eligible subjects who did not participate in Oral NAC or subjects at least 4 weeks after oral NAC will receive IV NAC 150 mg/kg over 8 hours. At least four weeks after the first infusion, the subject will receive IV NAC 300 mg/kg over 8 hours.~For part 2, Eligible subjects with sickle cell disease and hospitalization for VOC within the past 2 years, who now present in VOC will be enrolled. Subjects will receive IV NAC 75 mg/kg over 1 hour every 6 hours for 5 days or discharge, whichever occurs earlier."
3296486|NCT01800539|Experimental|Provider Education Model (PEM)|condition wherein providers will receive specially structured training during their typical home visits based by Kennedy Krieger Institute (KKI) staff
3296487|NCT01800539|No Intervention|Treatment-as-Usual (TAU)|condition wherein providers continue with their existing practices
3296488|NCT01800565|Other|pubertal progression|A collection of first voided urine sample for the measurement of LH.
3296489|NCT01800578||Bispectral Index Group|
3296490|NCT01800591|No Intervention|Control Arm|No other financial incentive other than for enrollment, 6-month weigh in, and completion.
3296491|NCT01800591|Experimental|Delayed gratification|In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
3296492|NCT01800591|Experimental|Immediate gratification|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be told that they can weigh in again any time before the study ends when they think they have lost 5% of their initial body weight. If they did meet their 5% goal, they will begin receiving a bi-weekly premium discount during the next pay period for a total duration of 12 months. Subjects that do not meet the 5% cut off during a weigh in are allowed to re-weigh themselves as many times as they like although they are encouraged to do so when they think they have met their target weight. Their premium goes back to normal price after this 12-month discount ends.
3296493|NCT01800591|Experimental|Financial incentive with frequent feedback|In addition to the standard enrollment, 6-month, and completion incentives, the subject will be asked to weigh in on the IncentaHEALTH scales everyday they are at work. These subjects will participate in a daily lottery with the possibility of winning the same amount as the discount in Arms 2 and 3 over the course of the study. The subject can choose to select or be designated a two digit number that ranges from 00 to 99. Each day a lottery will be held and the subject will be given a 1% chance of matching both digits or an 18% chance of matching one digit. In order to get the lottery winnings, the subject must meet a weight goal that consistently decreases to accumulate to a 5% weight loss by the 6 month mark. After 6 months, the subject will receive the lottery winnings if they maintain that target weight (initial weight minus 5%) until the end of the 12-month study.
3296494|NCT01800604|Experimental|Pain Self-Management Arm #1|Pain Self-Management Intervention #1
3296495|NCT01800604|Experimental|Pain Self-Management Arm #2|Pain Self-Management Intervention #2
3296496|NCT01800604|Experimental|Pain Self-Management Arm #3|Pain Self-Management Intervention #3
3296497|NCT01800604|Experimental|Pain Self-Management Arm #4|Pain Self-Management Intervention #4
3296498|NCT01800617|Experimental|Liothyronine, Sodium|
3296499|NCT01800630|Experimental|Gemcitabine HCl Oral Formulation (D07001-F4)|Subjects will receive a single 5-mg (nontherapeutic) dose of gemcitabine (Gemzar®) via an IV push and then treated with Gemcitabine HCl Oral Formulation (D07001-F4)according to assigned cohort (2 mg to 80 mg) on Day 1, 3, 5, 8, 10, and 12 of 4 21-day cycles study treatment period.
3296500|NCT01800643|Other|Orally Busulfan PK|Evaluate the Pharmacokinetics of orally busulfan
3296501|NCT01800643|Other|Intravenously Busulfan PK|Evaluate the Pharmacokinetics of intravenously busulfan
3296502|NCT01800656|Experimental|Ligate and let go|"Subjects are submitted to endoloop-assisted ligate and let go colorectal polypectomy."
3296503|NCT01800656|Active Comparator|Snare polypectomy|Subjects are submitted to endoloop-assisted snare colorectal polypectomy
3296504|NCT01800669|Experimental|Intervention|Use of the complete CHICA MLP module in routine clinical care. The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
3296505|NCT01800669|Active Comparator|Control|CHICA without the MLP module. This version includes a module that screens families for medical-legal issue but does not provide additional guidance or referrals to resolve them.
3296506|NCT01800682|Experimental|Tramodol Extended-release (ER), 25 milligram (mg)|Tramodol ER, 25 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3296507|NCT01800682|Experimental|Tramodol ER, 50 mg|Tramodol ER, 50 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3296508|NCT01800682|Experimental|Tramodol ER, 100 mg|Tramodol ER, 100 mg tablets will be administered orally once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
3296509|NCT01800695|Experimental|Arm A|ABT-414 in combination with radiation and temozolomide
3296510|NCT01800695|Experimental|Arm B|ABT-414 in combination with temozolomide
3296511|NCT01800695|Experimental|Arm C|ABT-414 monotherapy
3296512|NCT01800708|Active Comparator|Triamcinolone acetonide|The study group will receive an intraoperative intracameral injection of triamcinolone acetonide
3296513|NCT01800708|Active Comparator|Prednisolone syrup|The control group will receive prednisolone syrup postoperatively
3296514|NCT01800721|Experimental|Experimental Condition SNAP|"Behavioral Intervention SNAP HIV training and peer outreach~Participants learn skills for sexual health and peer outreach which includes talking with network members about HIV testing and prevention."
3296515|NCT01800721|Active Comparator|SNAP Control Condition|"SNAP Control~Participants receive information on HIV/STDs as well as healthy eating and nutrition instruction."
3296516|NCT01800734|Other|Clamp-Mixed Meal Arm|Twenty adults patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
3296517|NCT01800747|Active Comparator|Direct antibiotic treatment|The doctor gives to parents an antibiotic prescription for their son's respiratory infection which he should start immediately.
3296518|NCT01800747|No Intervention|No antibiotic treatment|The doctor does not give to parents an antibiotic prescription for their son's respiratory infection.
3296519|NCT01800747|Experimental|Delayed antibiotic prescription|The doctor gives to parents an antibiotic prescription for their son's respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improve.
3296520|NCT01800760|Experimental|No groups|
3296521|NCT01800773|Experimental|Written Exposure Therapy|Written exposure treatment is a 5 session treatment in which participants write about their trauma event in a specified manner.
3296522|NCT01800773|Active Comparator|Cognitive Processing Therapy|cognitive processing therapy will be included as the evidence-based treatment for PTSD in this study.
3296523|NCT01800799|Experimental|UTI (WBC>10 per high power field)|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
3296524|NCT01800799|Experimental|Recurrent UTI|"Antimicrobial agent (Baktar 800mg h.s.)~Anti-inflammatory agent (Celecoxib 200mg QD)"
3296525|NCT01800799|No Intervention|Normal control|Normal control
3296526|NCT01800825|Active Comparator|Clindamycin|Clindamycin 300mg orally twice daily for five days
3296527|NCT01800825|Placebo Comparator|placebo|This will be an identical placebot
3296528|NCT01800851|Experimental|no weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3296529|NCT01800851|Experimental|weight gain|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3296530|NCT01800851|Other|lean body mass|The characteristics of the renal transplant patients are compared with those of 10 healthy volunteers matched for age and lean body mass
3296531|NCT01800864|Other|Normal|Normal weight subjects
3296532|NCT01800864|Other|Over weight /obese subjects|Overweight and obese subjects
3296533|NCT01800929|Experimental|N6|The N6 system comprises an investigational sound processor, remote assistant and fitting software
3296534|NCT01800929|Active Comparator|N5|The current commercially-available cochlear implant system Performance of N5 will be compared to performance with N6 using a within-subject design.
3296535|NCT01800942|Placebo Comparator|Placebo|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
3296536|NCT01800942|Experimental|Azithromycin|"830 women will be recruited into the study and randomised in a ratio of 1:1 per study arm to receive either Azithromycin or placebo.~A single dose of Azithromycin 2g or Placebo will be given orally to pregnant women in labour."
3296537|NCT01800955|Experimental|resistive capacitive diathermy|in the resistive capacitive diathermy protocol patients are administered the resistive capacitive diathermy treatment for a thirty minutes session, three times per week for a total of ten sessions
3296538|NCT01800955|Sham Comparator|sham placebo group|"The sham treatment is administered with the resistive capacitive diathermy device set on on but not active (not supplying energy) with the same type of application, the same frequency and duration of experimental diathermy group"
3296539|NCT01800981||Debrase|Patients previously treated with Debrase for burn debridement
3296540|NCT01800981||Standard of Care|Patients previously treated with local Standard of Care for burn debridement
3296541|NCT01800994||asthma, COPD|patients with asthma and COPD treated with inhalation devices
3296542|NCT01801020|Experimental|temperature measuremts|A temporal artery measurement will be taken from two points a strait line across the forehead and an additional measurement behind the earlobe. In addition tympanic temperature will be measured.
3296543|NCT01801046|Experimental|Treatment (chemotherapy, G-PBSC)|INDUCTION CHEMOTHERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-3 and cytarabine IV on days 1-7. HMMACT: Patients receive G-PBSC on day 9.
3296544|NCT01801059|Active Comparator|Arm I education CRC and CRC screening|Educational intervention: Patients receive CRC and CRC screening information from an educational video and received a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
3296545|NCT01801059|Experimental|Arm II education and patient activation intervention|Educational intervention administered: Patients receive patient activation intervention comprising CRC and CRC screening information and communication skills training intervention by educational video and brochure, and they also receive a brochure focused on healthy hints to prevent CRC. Questionnaire administration prior to and after the intervention.
3296546|NCT01801072|Active Comparator|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days.
3296547|NCT01801072|No Intervention|No levetiracetam|No levetiracetam
3296548|NCT01801085||FOLFOX4|Leucovorin 200 mg/m2 iv over 2 hrs before 5-FU, d1 and 2 5-FU 400 mg/m2 iv bolus and then 600 mg/m2 iv over 22 hrs, d 1 and d2 Oxaliplatin (Eloxatin) 85 mg/m2 iv d1 Q2w x 12 cycles
3296549|NCT01801085||XELOX|Capecitabine (Xeloda) 1000 mg/m2 po bid x 14 days Oxaliplatin (Eloxatin) 130 mg/m2 iv over 2 hrs d1 Q3w x 8 cycles
3296550|NCT01801137|Experimental|Afinitor|Treatment by Afinitor 10 mg per day
3296551|NCT01801150|No Intervention|lifestyle and diabetes treatment|Counseil about lifestyle and current diabetes treatment
3296552|NCT01801150|Experimental|CPAP nasal treatment|Continuous positive airway pressure (CPAP) nasal during the night and current diabetes treatment. Device
3296553|NCT01801163|Experimental|Sorafenib plus Stereotactic Radiotherapy|Single agent Sorafenib x 2 weeks followed by Stereotactic Radiotherapy, then Sorafenib until disease progression.
3296554|NCT01801176|Experimental|Initial monitoring group|
3296555|NCT01801189|Experimental|Pregabalin|Single, 300 mg pre-operative oral dose of Pregabalin.
3296556|NCT01801189|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose.
3296557|NCT01801202|Experimental|Hair removal|hair removal treatment using 805nm LightSheer Duet HS handpiece
3296558|NCT01801228|Experimental|Eplerenone|oral daily treatment with doses 100 to 400 mg
3296559|NCT01801228|Active Comparator|Spironolactone|oral daily treatment with doses 100 to 400 mg
3296560|NCT01801254|Experimental|STRIDES|Brain-computer interface training protocol designed to up-regulate specific types of neural activity in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
3296561|NCT01801254|Sham Comparator|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior. Stimuli used and durations of training sessions for this protocol are identical to those used in the treatment condition.
3296562|NCT01801267|Experimental|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV).
3296563|NCT01801267|Active Comparator|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision.
3296564|NCT01801293|Experimental|Intervention Arm|One-time single dose of 50 mg radiolabeled GS-5806 administered orally in 3 capsules in the morning.
3296565|NCT01801306|Other|NeMoProbe|The NeMo System is used for intracranial pressure (ICP) and brain temperature monitoring, as well as the determination of the brain tissue oxygenation saturation (SbtO2) and cerebral blood flow. The sensors for NIRS are implemented into a conventional brain tissue probe for ICP monitoring (NeMo Probe).
3296566|NCT01801319|Active Comparator|Stimulation|Libra Deep Brain Stimulation System is implanted and activated post implantation
3296567|NCT01801319|Sham Comparator|No Stimulation|The Libra DBS System is implanted and not activated
3296568|NCT01801332|Experimental|intensive arm|Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days + intensive enteral nutrition by feeding tube for 14 days
3296569|NCT01801332|Active Comparator|control arm|"Corticosteroïds (Methylprednisolone 32 mg/d) for 28 days +  classical  oral alimentation for 14 days"
3296570|NCT01801345|Other|Rested|Subjects will perform the scenario, once during a normal workday (rested)
3296571|NCT01801345|Active Comparator|Fatigued|Subjects will perform the scenario after working a 12-24 hour overnight shift (fatigued).
3296572|NCT01801371|Experimental|68Ga-BNOTA-PRGD2|In patients in suspicion of glioma, single bolus of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be intravenously injected 30 minutes before brain PET/CT to determine 68Ga-BNOTA-PRGD2 uptake in tumor and brain.
3296573|NCT01801384|Experimental|Original contingent vouchers schedule|Women will receive an abstinence-contingent voucher-based incentives intervention (Contingency Management) for smoking cessation and relapse prevention.
3296574|NCT01801384|Experimental|Revised contingent vouchers schedule|Women receive abstinence-contingent voucher-based incentives (Contingency Management) intervention designed to further increase cessation and relapse prevention rates.
3296575|NCT01801384|Sham Comparator|Non-contingent vouchers schedule|This serves as a control condition wherein women earn incentives independent of smoking status.
3296576|NCT01801397|Other|Teriparatide|one arm study. All patients receive teriparatide
3296577|NCT01801410|Active Comparator|Misoprostol|Group 2 will be induced using oral misoprostol tablets (25 mcg) every 2 hours for a maximum of 12 doses or until active labour commences. In primigravid women, if contractions have not commenced after 2 doses, the dosage may be increased to 50mcg every 2 hours. Once in labour (regular painful contractions with a cervical dilatation of at least 4cm) no more misoprostol will be used and artificial membrane rupture and/or oxytocin infusion will be used as clinically indicated. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of repeat misoprostol, Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
3296578|NCT01801410|Active Comparator|Foley Catheter|Group 1 will undergo induction using a transcervical Foley catheter (silicone, size 18F with 30ml balloon) which will remain until active labour starts, the Foley catheter falls out, or 12 hours have elapsed. If the Foley catheter falls out within 12h, membranes will be ruptured and/or oxytocin infusion started. If the Foley catheter does not fall out within 12h, it will be removed at 12h and oxytocin commenced with an artificial rupture of membrane when possible. If labour has still not commenced after 24 hours, they will be deemed to have a 'failed induction' and the decision on further management will be made by the clinical team (their choice could include the use of misoprostol, repeat Foley catheter, dinoprostone, caesarean section or delay as deemed appropriate).
3296579|NCT01801423|Experimental|Hydroxyurea|Study investigators propose to enroll 60 children with SCA and an elevated TCD measurement between 5 and 12 years of age in this one arm feasibility study of hydroxyurea therapy, with follow-up of at least 12 months per subject. The study intervention will include HU to begin at ~ 20 mg/kg/day(range 17.5 - 26 mg/kg/day). No dose escalation will occur. Given the success of the first year of enrollment and the favorable response of TCD measurement after 3 months on HU therapy, the study investigators have participants as an internal pilot. The definitive phase III trial will now compare low dose HU therapy to the result of no treatment arm from the STOP Trial.
3296580|NCT01801462|Experimental|Simulation-based ultrasound training|The initial training is provided on a high-fidelity Virtual-Reality (VR) simulator (Scantrainer, Medaphor). The VR simulator provides images obtained from real patients and haptic feedback from the ultrasound probe. The basic gynecologic and advanced gynecologic modules are selected for training purposes. When all modules are passed on the VR simulator, the participants receive 30 minutes of training on the low-fidelity simulator (BluePhantom) to allow participants to review the functions, they just trained, using real ultrasound equipment.
3296581|NCT01801462|No Intervention|Control|Participants randomized to the control group receive traditional clinical introduction locally in the departments. This may include observation and supervised practice and the different types of clinical training provided by each department are gathered through the department's head of education and registered.
3296582|NCT01801488||AVM Patients|Patients receiving surgical intervention for an intracranial arterial-venous malformation.
3296583|NCT01801488||Ruptured Aneurysm|Patients receiving surgical intervention for a ruptured intracranial aneurysm.
3296584|NCT01801488||Unruptured Aneurysm|Patients receiving surgical intervention for an unruptured intracranial aneurysm.
3296585|NCT01801501||Critical Care Patients|Patients admitted in Critical Care Unit with diagnosis of severe sepsis/septic shock
3296586|NCT01801527|Experimental|Telerehabilitation group|
3296587|NCT01801527|No Intervention|Control group|Information about usual care
3296588|NCT01801540|Experimental|0% arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3296589|NCT01801540|Other|5 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3296590|NCT01801540|Other|10 % arabinose meal sucrose/starch|A meal containing a bon with butter and marmalade, a cup cake, The and water
3296591|NCT01801540|Other|0 % arabinose meal Starch|A meal containing two bons with butter and cheese, The and water
3296592|NCT01801540|Other|5 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
3296593|NCT01801540|Other|10 % arabinose meal starch|A meal containing two bons with butter and cheese, The and water
3296594|NCT01801553|Active Comparator|spinal manipulation intervention group|Spinal manipulation: 3 sessions within one week of true lumbopelvic manipulation
3296595|NCT01801553|Sham Comparator|Spinal manipulation control group|Sham spinal manipulation: 3 sessions within one week of sham lumbopelvic manipulation
3296596|NCT01801566|Active Comparator|Conventional implant loading protocol|Single implant-retained mandibular overdenture
3296597|NCT01801566|Experimental|Immediate loading implant protocol|Single implant-retained mandibular overdenture
3296598|NCT01801605|Active Comparator|on|active session
3296599|NCT01801605|Placebo Comparator|off|fictive session
3296600|NCT01801631|Experimental|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
3296601|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
3296602|NCT01801644|Experimental|gemcitabine plus cisplatin|gemcitabine plus cisplatin: 3 cycles of gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion and cisplatin 70 mg/m2 on day 1 as an 2 hour infusion will be applied
3296603|NCT01801657||Bronchiectasis,stable|A patient was defined as stable if there was no exacerbation for the previous 4 wk
3296604|NCT01801657||Bronchiectasis,exacerbations|Bronchiectasis exacerbations were defined by subjective and persistent(>24 h) deterioration in at least three respiratory symptoms, including cough, dyspnea, hemoptysis, increased sputum purulence or volume, chest pain (with or without fever), radiographic deterioration, systemic disturbances, or changes in chest auscultation
3296605|NCT01801670||MF patients for blood & biopsy|Participants who are cared for at Boston Medical Center will first be assessed by physicians of the CTCL multi-specialty clinic if vorinostat, administered per standard of care, is an appropriate therapy for their CTCL. The decision to invite patients to participate in this study is (1) separate from the above described clinical decision to utilize vorinostat, and (2) will be offered subsequent to the clinical decision to utilize vorinostat. Vorinostat (Zolinza) will be administered as follows: each subject will receive each month for the first 3 months (cycle 1 to 3) 3 capsules of vorinostat 100 mg po daily. For months 4-6 (cycles 4 to 6), subjects will receive each month for 4 capsules of vorinostat 100 mg po daily.
3296606|NCT01801683|Other|Intervention: PEARLS (evidence based reports)|Intervention was modified academic detailing method, performed by sixth-year medical students/academic detailers.Each mentor chose two patients from real life who represented diagnostic, therapeutic or prognostic challenge. The students formed an answerable question, using PICO, and wrote report according to PEARLS.
3296607|NCT01801683|No Intervention|Control group of GPs|GPs not mentors who do not receive academic detailing intervention using PICO/PEARLS.
3296608|NCT01801696|Experimental|Parent massage tx group|Children in this group receive the parent-delivered massage intervention right after randomization.
3296609|NCT01801696|Experimental|Parent massage wait-list control group|Children in this group receive the parent-delivered massage intervention 5 months after randomization.
3296610|NCT01801709|Experimental|AAVrh.10cuARSA|intracerebral administration of AAVrh.10cuARSA at 12 sites in the white matter of both brain hemispheres.
3296611|NCT01801722||NT-proBNP,ejection fraction ,COPD stage.|The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.
3296612|NCT01801748|Experimental|oral wheat challenge|
3296613|NCT01801761||develop group|previous COPD study
3296614|NCT01801761||validation group|consecutive COPD patients from outpatient clinics
3296615|NCT01801774|Placebo Comparator|Dexamethasone|Dexamethasone 0.1%/Tobramycin 0.3% eye drop 4 times per day for 28 days
3296616|NCT01801774|Active Comparator|Triamcinolone|Subtenon 20-mg Triamcinolone injection
3296617|NCT01801787|Experimental|verum tDCS|left-hemispheric tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
3296618|NCT01801787|Sham Comparator|sham tDCS|left-hemispheric sham tDCS: anode placed midway between F3 and FP1, cathode placed midway between T3 and P3
3296619|NCT01801800||Aneurysmal subarachnoid haemorrhage|Speckle-tracking images in Echocardiography
3296620|NCT01801813||Neurosurgery for brain tumor patients|Collecting pre-operative and per-operative data, neuro-radiological data and post-operative complications
3296621|NCT01801826||Treatment|Treatment with CryoTouch IV device
3296622|NCT01801839||SIRS,sepsis,normal|"SIRS~(1) temperature > 38 centigrade or < 36 centigrade; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000/μL or < 4000/μL , or > 10% immature cells.~sepsis~SIRS + infection.~normal~not SIRS and have no infection."
3296623|NCT01801852|Experimental|NKT cells|NKT cells treatment plus regular treatment
3296624|NCT01801878|Experimental|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
3296625|NCT01801878|Active Comparator|Normal saline|Normal saline inject to the half of irradiated breast
3296626|NCT01801891|Active Comparator|Control group|Patients randomised to the control group will, in addition to their routine compression bandaging, be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The stimulators given to the control group will be set to provide minimal stimulation resulting in no visible muscular contraction.
3296627|NCT01801891|Experimental|VASGARD stimulator|Patients randomised to this group, in addition to their routine treatment with compression bandaging, will be given muscle stimulators for home use and instructed to apply 3x 30 minute sessions of comfortable electrical stimulation daily for 12 weeks. The intervention group stimulators will be capable of causing muscular contraction with a maximum force ranging from 30-40% of voluntary contractions.
3296628|NCT01801904|Experimental|Panitumumab|
3296629|NCT01801943|Experimental|Cognitive Remediation Therapy Group|30 minute Cognitive Remediation Therapy and 60 minute Healthy Living Class three time per week
3296630|NCT01801943|Experimental|Walking Intervention Group|60 minutes of walking and 30 minutes of reading stimulation three times a week
3296631|NCT01801943|Experimental|Combination Group|30 minutes of Cognitive Remediation therapy and 60 minutes of walking three times a week
3296632|NCT01801943|Experimental|Healthy Living Group|60 minute Healthy Living Class and 30 minutes of reading stimulation three times a week.
3296633|NCT01801956|Active Comparator|Motivational interviewing|A one hour motivational interview
3296634|NCT01801956|Experimental|Physical activity|Four motivational interviews, free membership of a sport club, virtual arena to upload training data from a GPS-watch
3296635|NCT01801969||Rehabilitation service|"Centralized or Decentralized rehabilitation~Size of municipality"
3296636|NCT01802008|Active Comparator|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
3296637|NCT01802008|Active Comparator|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
3296638|NCT01802021|Experimental|Qingshu-Yiqi-Tang+standard therapy|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy, maximal for 6 months.~1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD."
3296639|NCT01802021|No Intervention|1st line doublet chemotherapy|1st line doublet chemotherapy: Cisplatin 70 mg/m2+Taxotere 60 mg/m2 D1/Q3W x 6 cycles, and then 2nd line target therapy: Erlotinib 150mg QD.
3296640|NCT01802034||Native, Renal Tissue Preservation Group|Subjects who have a renal biopsy and the tissue is possessed and maintained by the RENAL AID repository.
3296641|NCT01802034||Native, Non-tissue Preservation Group|"Subjects who have had a renal biopsy but the tissue is not held by RENAL AID repository; and/or~Subjects with diabetes and renal disease who have not had a renal biopsy."
3296642|NCT01802034||Transplant Nephropathy Group|"Subjects who have had a renal transplant and require a transplant biopsy for either surveillance or for-cause indications."
3296643|NCT01802047|Experimental|Electric Pump Modality|Each mother follows all 3 electric pump modalities in a randomized order.
3296646|NCT01802099|Other|Parenteral nutrition|Patients will receive parenteral nutrition during the first week of mechanical ventilation. After Day 3, the parenteral route may be switched to the enteral route if shock resolve (vasoactive drug stopped since 24 hours and serum lactate level < 2 mmol/l). After Day 7, all patients will be fed via the enteral route.
3296647|NCT01802099|Other|Enteral nutrition|Patients will receive nutrition only via the enteral route during the firs week of invasive mechanical ventilation.
3296648|NCT01802112|Placebo Comparator|Maltodextrins|15 grams of maltodextrins per day dissolved in water during 21 days
3296649|NCT01802112|Experimental|Resistant maltodextrins|15 grams of resistant maltodextrins per day, dissolved in water during 21 days
3296650|NCT01802125||Basic science (SNP array analysis)|Tissue samples are analyzed using laboratory biomarker analysis for LOH and SNP array profiling using microarray and immunohistochemistry.
3296651|NCT01802138|Experimental|Activated T-lymphocyte|"This was designed as a single-center, single group clinical trial, and subjects include patients with refractory refractory/relapsed neuroblastoma.~If subjects agree to participate in the clinical trial by signing a written consent, only appropriate subjects, who meet the criteria on the examinations and tests, will undergo this clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml should be withdrawn to make a study drug at least 3 weeks before administration. Subjects should visit to hospital according to the protocol and receive a study drug. Therapeutic response rate, overall survival rate, time to progression should be investigated."
3296652|NCT01802164|Experimental|1|Conventional abdominal wall closure with mesh implantation
3296653|NCT01802164|No Intervention|2|Conventional abdominal wall closure without mesh implantation
3296654|NCT01802177|Experimental|UVB excimer light|Patches of alopecia will be treated twice weekly with UVB excimer light. Only one half of a single alopecia areata patch will be treated. In order to treat the same half during each visit, a transparent sheet will be marked, using a marking pen, to delineate the borders of the treatment area with a central dividing line. The other half will be covered and used as a control. Treatments will be given randomly (by sealed envelope randomization method) into one of the two halves in different patients but will be given into the same half in each patient in all treatment sessions. Only one investigator will know the intervention each half has received. A total of 23 treatments will be given over 12 weeks.
3296655|NCT01802177|No Intervention|No treatment (covered)|
3296656|NCT01802190||Deafness patients|Deafness patients
3296658|NCT01802229|Active Comparator|Suture|Umbilical port-site closure with simple suture of the fascia.
3296659|NCT01802229|Experimental|Prophylactic mesh|Umbilical port-site closure with mesh placement
3296660|NCT01802242|Experimental|Active Radiation Treatment (Cohort 2)|
3296661|NCT01802242|Other|Prior Radiation Treatment (Control Cohort)|Patients who received 78Gy RT to the prostate gland 3-4.5 years prior to enrollment. This group will not be receiving any active treatment
3296662|NCT01802255|Experimental|Inhalatory sedation|Sevoflurane given via AnaConDa for sedation minimum 48 hours
3296663|NCT01802255|Active Comparator|Intravenous sedation|Midazolam given intravenously for sedation minimum 48 hours
3296664|NCT01802268|Active Comparator|Sirolimus|Conversion from Tacrolimus to Sirolimus
3296665|NCT01802268|Active Comparator|Tacrolimus|Maintenance on tacrolimus
3296666|NCT01802294|Experimental|Parenting Program|12-week group-based parenting program (Sinovuyo Caring Family Programme) delivered in weekly sessions. Program is manualized.
3296667|NCT01802294|No Intervention|Wait-list control|Wait-list control group. Program delivered 3 months after posttest.
3296668|NCT01802307|Experimental|Focal Therapy|
3296669|NCT01802359||Mirodenafil|
3296670|NCT01802372|Active Comparator|WHO CVD Risk Assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health Insurance and the WHO CVD Risk Assessment package for 12 months.
3296671|NCT01802372|Sham Comparator|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline,and usual care.
3296672|NCT01802398||No treatment|Observational cohort study of older (age≥60 years) adults who present to an emergency department with syncope (otherwise known as fainting)
3296673|NCT01802424|Experimental|The Friends program|Youth with increased levels of anxiety are thought to regulate their fear by recognizing bodily cues, learning relaxation, regulating thoughts and feelings and expose themselves to situations and objects that activate their anxiety.
3296674|NCT01802450|Experimental|Dasatinib (Sprycel)|Dasatinib (Sprycel): 100 mg QD administered orally as continuous daily dosing (CDD)until disease progression or adverse events that, by protocol definition or Investigator judgment, would preclude further treatment with dasatinib
3296675|NCT01802463||Controls|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3296676|NCT01802463||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3296677|NCT01802463||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3296678|NCT01802476|Other|Fixed Sequence Crossover Arm|This study arm consists of a fixed sequence crossover where study subjects will receive Treatment A and following a washout of no less than 10 days will then receive Treatment B. The drug class is a CDK4/6 inhibitor.
3296679|NCT01802489|Active Comparator|Amiloride|Amiloride capsules 10mg once per day for 5 months
3296680|NCT01802489|Placebo Comparator|Placebo|Placebo capsules one per day for 5 months
3296681|NCT01802502|Active Comparator|Rifampicin 600 mg|Subjects in this arm receive 600 mg rifampicin intravenously
3296682|NCT01802502|Experimental|rifampicin 750 mg|Subjects in this arm receive 750 mg rifampicin orally
3296683|NCT01802502|Experimental|rifampicin 900 mg|Subjects in this arm receive rifampicin 900 mg orally
3296684|NCT01802528||Obturator externus muscle injection|patients were treated with obturator externus injection
3296685|NCT01802541|Experimental|DAG oil|
3296686|NCT01802541|Placebo Comparator|TAG oil|
3296687|NCT01802567|Experimental|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
3296688|NCT01802593|Experimental|Immunomodulator therapy 26 weeks|IFX 5mg/kg for 76 weeks, continuing immunomodulator for 6 months from first infusion
3296689|NCT01802593|Experimental|Immunomodulator therapy 2 weeks|IFX 5mg/kg induction for 76 weeks, discontinuing immunomodulator on day of second infusion( after 14 days).
3296690|NCT01802619|Placebo Comparator|inhaled nitrogen|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, pure nitrogen (placebo) is mixed with pure O2 or air. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the NO is delivered through the inspiratory limb of the anesthetic or ventilator circuit.
3296691|NCT01802619|Experimental|inhaled nitric oxide|Using an Inovent (Ikaria Inc, N.J., USA) or volumetrically-calibrated flowmeters, 800 ppm NO gas is mixed with pure O2 or air to obtain a final concentration of 80 ppm NO. During CPB the gas mixture is delivered through the extracorporeal oxygenator, after CPB the gas is delivered through the inspiratory limb of the anesthetic or ventilator circuit. NO, NO2 and O2 and methemoglobin levels are monitored by an unblinded observer.
3296692|NCT01802645|Active Comparator|Cetuximab/FOLFIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 180 mg/m² (1 h)*, d-l Folinic acid 400 mg/m² (2 h), 5-FU 400 mg/m² (Bolus), 5-FU 2400 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3296693|NCT01802645|Experimental|Cetuximab/FOLFOXIRI|"Cetuximab 250 mg/m² (1 h) weekly Irinotecan 125 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3296694|NCT01802645|Active Comparator|FOLFOXIRI|"Irinotecan 165 mg/m² (1 h)*, Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3296695|NCT01802645|Experimental|Bevacizumab/FOLFOXIRI|"Bevacizumab 5 mg/kg (30-90 min i.v.), Irinotecan 165 mg/m² (1 h),* Oxaliplatin 85 mg/m² (2 h), d-l Folinic acid 400 mg/m² (2 h), 5-FU 3200 mg/m² (46 h) every 2 weeks~*reduced in UGT1A1 7/7 patients"
3296696|NCT01802658|Active Comparator|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times over two years.
3296697|NCT01802658|Placebo Comparator|NACL|NACl 100 ml IV. 3 infusions. Administration 3 times over two years.
3296698|NCT01802671|Experimental|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways: a web tool named TEO (Emotional Therapy Online) and SMS that will send to the patients' mobile phone with reminders and reinforcements.
3296699|NCT01802671|Active Comparator|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment and information
3296700|NCT01802671|Experimental|cognitive behavioural therapy (CBT)|Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT.
3296701|NCT01802684|Experimental|OPTIMOX-aflibercept|"Induction therapy (sequence #1)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after induction (sequence #2) First phase (sequence #2A)~Regimen : aflibercept + fluoropyrimidine (simplifed LV5FU2 or capecitabine)~Duration : 6 cycles (3 months) Second phase (sequence #2B)~Regimen : aflibercept +/- fluoropyrimidine (simplifed LV5FU2 or capecitabine) according to eligibility criteria for chemotherapy-free interval)~Duration : until PD or limiting toxicity Reintroduction (sequence #3)~Regimen : aflibercept + modified FOLFOX7~Duration : 6 cycles (3 months) Maintenance after reintroduction (sequence #4)~Regimen : aflibercept + fluoropyrimidine~Duration : until PD or limiting toxicity"
3296702|NCT01802697|Experimental|IdeS|Intravenous infusion
3296703|NCT01802697|Placebo Comparator|PBS Buffer|Intravenous infusion
3296704|NCT01802723|Experimental|LIPO-202, Low|Drug: salmeterol xinafoate
3296705|NCT01802723|Experimental|LIPO-202, Mid|Drug: salmeterol xinafoate
3296706|NCT01802723|Experimental|LIPO-202, High|Drug: salmeterol xinafoate
3296707|NCT01802723|Experimental|LIPO-202, Placebo|Drug: Placebo
3296708|NCT01802736|Active Comparator|Standard Positive Prevention Counselling|"Standard positive prevention counseling which includes alcohol reduction and sexual risk behavior counseling provided in the clinic by the clinic medical counselors on the day of enrollment and at month 3 visit.~Although there is awareness of the need to engage and include PLWHA in HIV prevention, there are little practical efforts devoted towards this engagement even in developed countries. One of the major reasons is the lack of a well-defined standard positive prevention package that needs to be delivered to PLWHA. The approach proposed by Kennedy et al modified to suit the local setting and involves a simpler understandable classification of the goals, interventions and expected outcomes of the treatment."
3296709|NCT01802736|Experimental|Alcohol Motivational intervention counselling plus SPP|
3296710|NCT01802749|Active Comparator|chemotherapy|"Combination chemotherapy with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC (area under curve) 5 on day 1 every 4 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days;~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days."
3296711|NCT01802749|Experimental|Chemotherapy and bevacizumab|"Combination chemotherapy AND bevacizumab with ONE of the following regimens:~PLD-C: Pegylated liposomal doxorubicin 30 mg/m2 + Carboplatin AUC 5 on day 1 every 4 weeks and Bevacizumab 10 mg/kg i.v. on Day 1 every 2 weeks;~GEM-C: Gemcitabine 1000 mg/m2 on day 1, 8 every 21 + Carboplatin AUC of 4 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks;L~PAC-C: Paclitaxel 175 mg/m2 on day 1, every 21 + Carboplatin AUC of 5 on day 1 every 21 days AND Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks.~Patients whose disease has not progressed after the initial six cycles of combination treatment will continue bevacizumab, at 15 mg/kg every 3 weeks until disease progression,unacceptable toxicity or patient withdrawn."
3296712|NCT01802762|Other|NeMo Patch and NeMo Probe|TBI and SAH patients, one arm
3296713|NCT01802788||Cohort A|"Patients implanted with a Portico valve bearing the CE mark (implanted after St Jude Medical declared the device compliant with all applicable essential requirements within the European union and marketed the device bearing the CE mark.)"
3296714|NCT01802788||Cohort B|Patients implanted with a Portico valve as part of an Investigational Device study.
3296715|NCT01802801||1|
3296716|NCT01802814|No Intervention|SR-A|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized not to receive epratuzumab.This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
3296717|NCT01802814|Active Comparator|SR-A + Epratuzumab|Patients randomized to the SR-A Arm receive induction, consolidation and maintenance therapy according to a modified protocol ALL-REZ BFM 2002 with Protocol II-IDA as 1st consolidation element. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
3296718|NCT01802814|No Intervention|SR-B|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized not to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
3296719|NCT01802814|Active Comparator|SR-B + Epratuzumab|Patients randomized to the SR-B Arm receive induction, post-induction and maintenance therapy according to the protocol ALL-R3. In this arm patients are randomized to receive epratuzumab. This randomizaton has been stopped pre-term on 1.2.2019 since the investigational product is not provided anymore by the manufacturer.
3296720|NCT01802827||VAT patients|Patients developing Ventilator Associated Tracheobronchitis
3296721|NCT01802827||VAP|Patients presenting ventilator associated pneumonia
3296722|NCT01802827||No ventilator associated infection|patients who do not present ventilator associated infection during their stay in ICU
3296723|NCT01802840|Placebo Comparator|biscuits without soy fiber|biscuits without soy fiber
3296724|NCT01802840|Experimental|biscuits supplemented with soy fiber|biscuits supplemented with soy fiber
3296725|NCT01802853|Experimental|A: RO6811135 s.c.|
3296726|NCT01802853|Active Comparator|B: RO6811135 i.v.|
3296727|NCT01802866|Experimental|ACU-4429 2.5 mg|2.5 mg tablet
3296728|NCT01802866|Experimental|ACU-4429 5 mg|5 mg tablet
3296729|NCT01802866|Experimental|ACU-4429 10 mg|10 mg tablet
3296730|NCT01802866|Placebo Comparator|Placebo|Includes identical tablets with only inactive ingredients (0 mg).
3296731|NCT01802892|Experimental|Ronacaleret 100 mg|Subjects will receive ronacaleret (100 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
3296732|NCT01802892|Experimental|Ronacaleret 400 mg|Subjects will receive ronacaleret (400 mg once daily) for 5 consecutive days, given in conjunction with a single dose of plerixafor (0.24 mg/kg) SC on the evening of Day 5.
3296733|NCT01802905|Experimental|Sequenced patients|Patients enrolled on the study who have successful sequencing of their cancers will be closely monitored for: what chemotherapy agents are next used, what response and toxicity do they have, is there any early sign of response detected on PET-CT, overall did the genomic information change treatment decision-making.
3296734|NCT01802918|Experimental|Cohort 1|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): ABCD, BACD, BCAD, or BCDA. Where A=Placebo, B= GSK2838232 5mg, C=GSK2838232 10mg, and D=GSK2838232 20mg
3296735|NCT01802918|Experimental|Cohort 2|Subject in this cohort will be randomized to one of the four following treatment sequences (1 treatment per visit): EGHJ, FEHJ, FGIJ, or FGHK. Where E=Placebo, F= GSK2838232 50mg, G= GSK2838232 100mg, H= GSK2838232 50mg + food, I= Placebo + food, J= GSK2838232 10mg + RTV, K= placebo + RTV.
3296736|NCT01802931|Active Comparator|Session 1 or Session 2|Single dose sessions without ketoconazole co-administration
3296737|NCT01802931|Active Comparator|Co-dose Session|Single dose session with ketoconazole co-administration
3296738|NCT01802944|Experimental|10 IU BID|10 IU BID Intranasal Insulin
3296739|NCT01802944|Experimental|20 IU BID|20 IU BID Intranasal Insulin
3296740|NCT01802944|Experimental|PLACEBOS|Saline nasal solution used as placebo
3296741|NCT01802957|Other|St. Paul and Networked Health Centers|An uncontrolled before and after design with baseline and follow-up cross sectional measurements will be used at the overall site level (St. Paul Hospital and the 8 associated HCs). There will be no control unit.
3296742|NCT01802970|Experimental|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
3296743|NCT01802996|Experimental|Arm I|Magnesium Isoglycyrrhizinate Injection 200mg IV on days 1-5
3296744|NCT01802996|No Intervention|Arm II|Only chemotherapy
3296745|NCT01803009|Experimental|One arm|View CRC RAT and view presentation regarding risk of advanced adenoma
3296746|NCT01803022||Low Molecular Weight Heparin|
3296747|NCT01803035|Experimental|1 % LTX-109|LTX-109 topical gel in 1 % strength
3296748|NCT01803035|Experimental|2 % LTX-109|LTX-109 topical gel in 2 % strength
3296749|NCT01803035|Placebo Comparator|Placebo|Placebo gel, containing all ingredients except LTX-109
3296750|NCT01803048||TBI|30 individuals who will be tested at two weeks post-TBI; 30 individuals who will be tested at one month post-TBI; 30 individuals who will be tested at three months post-TBI; 30 individuals who will be tested at six months post-TBI; 30 individuals who will be tested at 12 months post-TBI.
3296751|NCT01803048||Healthy Control|30 healthy individuals with no history of TBI
3296752|NCT01803061|Experimental|WebCan|Provides computerized PRO to the treating physician at the point of care
3296753|NCT01803061|No Intervention|Usual care|
3296754|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) TEST 1|Adolescents CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
3296755|NCT01803087|Active Comparator|CHF 1535 100/6 pMDI (Foster®) AeroChamber Plus™ (TEST 2).|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ spacer device in adolescents (TEST 2)
3296756|NCT01803087|Active Comparator|(Qvar®: BDP 400 µg)+(Atimos®: formoterol 24 µg)|BDP 100 µg pMDI, 4 puffs (Qvar®, total dose: BDP 400 µg) + formoterol fumarate 6 µg pMDI, 4 puffs (Atimos®, total dose: formoterol 24 µg)
3296757|NCT01803087|Active Comparator|CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI|Adults CHF 1535 100/6, 4 puffs (total dose: BDP 400 µg/FF 24 µg) pMDI
3296758|NCT01803100||Hospitalized inpatients|Inpatients newly admitted into freshly-cleaned rooms.
3296759|NCT01803126||atherosclerosis|No treatment.
3296760|NCT01803139|Active Comparator|Standard breast radiotherapy|The treatment is planned using 2D wedges optimisation on the central CT-planning slice.
3296761|NCT01803139|Experimental|Breast IMRT|The treatment is planned 3D IMRT optimisation using all CT-planning slices.
3296762|NCT01803152|Experimental|Part 1-DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3296763|NCT01803152|Active Comparator|Part 2-Gemcitabine/DC Vaccine/Lysate|"Leukapheresis: Baseline, post-surgery;~Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks;~Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks;~Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3296764|NCT01803165||Single shot femoral and sciatic nerve block|Prospective patient study group who present for infrainguinal bypass grafting and will receive single shot femoral and sub gluteal sciatic nerve blocks.
3296765|NCT01803165||Retrospective study group|Retrospective chart review will be performed and data collected on patients who have undergone infrainguinal bypass grafting under general anesthesia and without the use of regional or neuraxial anesthesia.
3296766|NCT01803178|Active Comparator|Plant Sterols|Plant Sterols
3296767|NCT01803178|Placebo Comparator|Placebo Product|Placebo Product
3296768|NCT01803191|Experimental|Fosfomycin 3 g|Unique oral dosis of 3 g of fosfomycin 1hour before of biopsy
3296769|NCT01803191|Active Comparator|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg before biopsy
3296770|NCT01803217|Experimental|mode switch to atrial pacing|
3296771|NCT01803217|Active Comparator|atrioventricular hysteresis function|
3296772|NCT01803230|Placebo Comparator|placebo|placebo (dextrose)
3296773|NCT01803230|Experimental|creatine|creatine supplementation
3296774|NCT01803243|Experimental|Leg length correction|The shorter leg in a sample of 15 patients with structural leg length inequality will be corrected by either a shoe insole or a modified shoe with sole lift.
3296775|NCT01803243|Experimental|Control of foot position 1|The foot position in in a sample of 15 patients with hemiplegic cerebral palsy will be controlled by an ankle foot orthosis.
3296776|NCT01803243|Experimental|Control of foot position 2|The foot position in in a sample of 15 patients with diplegic cerebral palsy will be controlled by an ankle foot orthosis.
3296777|NCT01803243|No Intervention|Control|A sample of 15 healthy controls from a simultaneously conducted study (UKBB-Spine-1315-1) will be used for comparative purposes.
3296778|NCT01803256||Scoliosis patients:|15 patients with adolescent idiopathic scoliosis.
3296779|NCT01803256||Control subjects:|15 adolescent healthy control subjects
3296780|NCT01803295|Experimental|40 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
3296781|NCT01803295|Active Comparator|Standard of care MMC mixed with water|40 mg MMC mixed with 40cc water. Six weekly intravesical instillations of 40 mg of MMC mixed with 40 cc of water will be instilled using catheter
3296782|NCT01803295|Experimental|80 mg MMC gel|"Device: TC-3 gel mixed with Mitomycin C (MMC) Six weekly intravesical instillations of 60 cc of TC-3 gel mixed with 80 mg MMC will be instilled using catheter.~Other Name: MMC Gel"
3296783|NCT01803308|Experimental|Experimental Part A|"Experimental: Part A: Part A will use a single ascending dose protocol in small, open-label cohorts to determine the starting dose for Part B in the potentially therapeutic range.~Intervention: SB9200"
3296784|NCT01803308|Experimental|Experimental Part B|"Experimental: Part B: Part B will use a multiple ascending dose protocol to further explore the safety, tolerability, pharmacokinetics and pharmacodynamics of SB9200 over 7-14 days of dosing.~Intervention: SB9200 and Placebo"
3296785|NCT01803321|Experimental|Cohort 1|Dose 1
3296786|NCT01803321|Experimental|Cohort 2|Dose 2
3296787|NCT01803334|Experimental|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
3296788|NCT01803334|No Intervention|Control|If she is randomized to the control group, then she will undergo traditional preoperative counseling by the same team without marking the abdomen.
3296789|NCT01803347|Experimental|ASC + fibrin glue|Intervention: drug: ASC + fibrin glue Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 100 million ASCs plus fibrin glue plus a deep curettage and closure of the internal orifice and evaluated after 16 weeks. If needed a second dose of 100 million ASCs plus fibrin glue will be applied then.
3296790|NCT01803347|Active Comparator|Fibrin glue|Intervention: fibrin glue Fibrin glue: Subjects will be treated with a dose fibrin glue plus a deep curettage and closure of the internal orifice, and evaluated after 16 weeks. If needed a second dose of fibrin glue will be applied then.
3296791|NCT01803360|Experimental|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
3296792|NCT01803360|Placebo Comparator|Placebo|Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment
3296793|NCT01803373|Experimental|Treatment Sequence ABC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296794|NCT01803373|Experimental|Treatment Sequence ACB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296795|NCT01803373|Experimental|Treatment Sequence BAC|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296796|NCT01803373|Experimental|Treatment Sequence BCA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296797|NCT01803373|Experimental|Treatment Sequence CBA|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296798|NCT01803373|Experimental|Treatment Sequence CAB|Participants in Panel 1 will take the sequence of 3 treatments with a standardized breakfast, participants in Panel 2 will take the sequence of 3 treatments with yogurt, and participants in Panel 3 will take the sequence of 3 treatments after a 10-hour overnight fast (without food). Each treatment in each treatment sequence to be separated by 4 weeks.
3296799|NCT01803386||ALS Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. The ALSFRS-R will also be administered. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
3296800|NCT01803386||Healthy Subjects|EIM measurements will be taken on two upper and two lower extremity muscles with several different electrode arrays. Subcutaneous fat measurement will also be performed on all four muscles using skinfold calipers.
3296801|NCT01803399|Experimental|GSK1322322 1200 mg Arm|Each subject will receive a single dose of GSK1322322 1200 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
3296802|NCT01803399|Experimental|GSK1322322 3000 mg Arm|Each subject will receive a single dose of GSK1322322 3000 mg IV over 60 minutes on Day 1 of one of the 4 treatment periods
3296803|NCT01803399|Placebo Comparator|Placebo Arm|Each subject will receive a single dose of GSK1322322 Placebo IV over 60 minutes on Day 1 of one of the 4 treatment periods
3296804|NCT01803399|Active Comparator|Moxifloxacin 400 mg Arm|Each subject will receive a single dose of moxifloxacin 400 mg administered orally on Day 1 of one of the 4 treatment periods
3296805|NCT01803412|Experimental|Alternate Intravenous Dosing Arm|Subjects will receive drisapersen as a regimen of 3 mg/kg over 1 hr IV weekly throughout the duration of participation.
3296806|NCT01803412|Experimental|Primary continuous Dosing Arm|Subjects will receive drisapersen 6 mg/kg as SC injection(s) once a week, continuously throughout their duration of participation.
3296807|NCT01803412|Experimental|Alternate Intermittent Dosing Arm|Subjects will receive drisapersen intermittently, as a regimen of 6 mg/kg as SC injection(s) once a week for 8 weeks followed by 4 weeks of no dosing, throughout their duration of participation.
3296808|NCT01803425||Synflorix™ cohort|Only those subjects to whom Synflorix™ will be administered as per normal clinical practice, according to the locally approved PI, will be included in the study.
3296809|NCT01803438|Active Comparator|AADs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
3296810|NCT01803438|Experimental|Cryoablation procedure|electrical pulmonary veins isolation performed with cryoballoon ablation system
3296811|NCT01803451|Experimental|hyperglycemic clamp-Meal tolerance test|these studies are to evaluate the effect of exendin-9 on insulin secretion before and after meal ingestion in patients after bariatric surgeries compared to non-surgical controls
3296812|NCT01803451|Experimental|Labeled meal tolerance test|The effect of GLP-1 receptor blockade on glucose tolerance and glucose kinetics are evaluated in the group patients with bariatric surgery vs. nonsurgical using exendin-9-39 infusion during one of the the 2-day dual tracer studies of meal tolerance test
3296813|NCT01803477|Active Comparator|Picato® 0.05% gel|once daily for two consecutive days
3296814|NCT01803477|Experimental|ingenol mebutate vehicle formulation 1|once daily for two consecutive days
3296815|NCT01803477|Experimental|ingenol mebutate vehicle formulation 2|once daily for two consecutive days
3296816|NCT01803477|Experimental|ingenol mebutate vehicle formulation 3|once daily for two consecutive days
3296817|NCT01803503|Active Comparator|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks. Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities.
3296818|NCT01803503|Experimental|Docetaxel + Sunitinib|"Docetaxel 75mg/m2 day 1, every 3 weeks, preceded by 7 days of sunitinib 12.5mg orally daily during each cycle.~Patients will be treated for a maximum of 6 cycles of chemotherapy in the absence of tumor progression or unacceptable toxicities."
3296819|NCT01803516||Breast cancer survivors with radiation-induced Telangiectasias|A quality of life assessment will also be completed by the patient using the Skindex-16 and a subscale of the BREAST-Q Breast Conserving Module questionnaire.
3296820|NCT01803529|Experimental|heat-pack with massage|deep friction massage and standard heat-pack given a maximum of 8 treatments
3296821|NCT01803529|Active Comparator|heatpack only|standard heat-pack given a maximum of 8 treatments
3296822|NCT01803542|Experimental|SBRT|High dose of radiation will be used to treat tumours.
3296823|NCT01803555|Experimental|Budesonide/Formoterol SPIROMAX®|2 inhalations of BF Spiromax at a dosage of 160/4.5 mcg and 2 inhalations of SYMBICORT placebo administered twice daily (AM and PM) during the 12-week treatment period.
3296824|NCT01803555|Active Comparator|SYMBICORT® TURBOHALER®|2 inhalations of SYMBICORT TURBOHALER at a dosage of 200/6 mcg and 2 inhalations of placebo SPIROMAX administered twice daily (AM and PM) during the 12-week treatment period.
3296825|NCT01803568|Experimental|Exercise in normoglycaemic individuals|
3296826|NCT01803568|Experimental|Exercise in hyperglycaemic individuals|
3296827|NCT01803581|Experimental|X92001327|the X92001327 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
3296828|NCT01803581|Active Comparator|RID shampoo|The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
3296829|NCT01803594|Placebo Comparator|Control Shake|Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder.
3296830|NCT01803594|Active Comparator|PC700, Krill Oil, and Lutein|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 = dairy lipids (Fonterra brand)"
3296831|NCT01803594|Active Comparator|PC700, Krill Oil, Lutein, and Niacin|"Each shake delivers 30% of each participant's calculated energy expenditure and provides 45% energy as fat, 40% energy as carbohydrate and 15% energy as protein. The shake contains whipping cream, frozen fruit, glucose polymer, and protein powder. Fifty percent of the fat is made up of PC700. Additionally, 3.0g Krill oil and 40mg of lutein capsules are swallowed with water. Nicotinic acid was added to each shake prior to consumption at a doses 5mg/kg of body weight.~Neptune Krill Oil capsules (Nutrigold); Lutein capsules (Jarrow Formulas); PC700 (Fonterra); Nicotinic acid (Natures Way)"
3296832|NCT01803633|Experimental|Cheese|Cheese sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain medium cheddar cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, high oleic sunflower oil, high polyunsaturated fatty acids (PUFA) sunflower oil, and canola oil.
3296833|NCT01803633|Active Comparator|Vegan cheese|Non-dairy cheese alternative sandwich plus supplemental beverage will deliver 40% of each participants' energy expenditure and will be made up of 50% of energy as fat, 35% of energy as carbohydrate and 15% of energy as protein. The sandwich will contain vegan cheese and whole wheat bread. The supplemental beverage will contain fruit sorbet, glucose polymer, protein powder, cream of tartar, high oleic sunflower oil, high PUFA sunflower oil, and palm oil.
3379977|NCT05049824|Experimental|SFM Treatment Arm|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion
3296834|NCT01803659|Experimental|b-carotene|600 ug RAE/d as b-carotene, 6 d/wk for 3 weeks
3296835|NCT01803659|Active Comparator|retinyl palmitate|600 ug retinol equivalent/d, 6 d/wk for 3 weeks
3296836|NCT01803659|Placebo Comparator|placebo (corn oil)|0 ug RAE/d as corn oil
3296837|NCT01803672|Experimental|health talk and adventure-based training|Participate will join a four-day integrated health education and adventure-based training programme, which contains education talks, workshop and adventure-based training activities. The programme will be implemented on four different days within six months in a day camp training centre. The integrated programme will be implemented in small group with maximum 15 participants in one group. Health education talks and workshop will be implemented in between adventure-based training activities in day camp centre, which will be conducted by healthcare professionals working in a local university.
3379978|NCT05049720|Experimental|Experimental|Patients will be implanted with an Extravascular ICD and undergo requisite electrical testing.
3379979|NCT05048719|Experimental|LY3502970 Dose 1|Participants will receive escalated doses of LY3502970 administered orally
3379980|NCT05048719|Experimental|LY3502970 Dose 2|Participants will receive escalated doses of LY3502970 administered orally
3379981|NCT05048719|Experimental|LY3502970 Dose 3|Participants will receive escalated doses of LY3502970 administered orally
3296838|NCT01803672|Placebo Comparator|Placebo Control|Participants will receive an amount of time and attention that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
3296839|NCT01803685||Surgical treatment|Surgical resection of intracranial arteriovenous malformations.
3379982|NCT05048719|Experimental|LY3502970 Dose 4|Participants will receive escalated doses of LY3502970 administered orally
3379983|NCT05048719|Experimental|LY3502970 Dose 5|Participants will receive escalated doses of LY3502970 administered orally
3379984|NCT05048719|Active Comparator|Dulaglutide|Participants will receive Dulaglutide subcutaneously (SC)
3379985|NCT05048719|Placebo Comparator|Placebo Matching LY3502970|Participants will receive placebo matching LY3502970 orally
3379986|NCT05048719|Placebo Comparator|Placebo Matching Dulaglutide|Participants will receive placebo matching Dulaglutide subcutaneously
3379987|NCT05046730|Experimental|Prospective Evaluation of the SFM Device|This is a multicenter, single-arm study in which clinical outcomes prospectively evaluated for a minimum of 100 subjects undergoing ileostomy reversal using the SFM Anastomosis Device
3379988|NCT05046730|Active Comparator|Retrospective Chart Review of Historical Controls|In order to have a sufficient pool of retrospective patients for matching, retrospective data will be collected for a minimum of 300 patients. The historical control cohort will be accrued from the same pool of institutions participating in the prospective study.
3379989|NCT05046522|Experimental|Palmitoylethanolamide sold as Levagen +|Palmitoylethanolamide in capsule form - taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
3379990|NCT05046522|Placebo Comparator|A comparator placebo capsule - Maltodextrin and microcrystalline cellulose mix|A comparator capsule taken as a 700mg (2 x 350mg) dosage at onset of migraine and if unresolved at 2 hours post onset a second dose of 700mg (2 x 350mg)
3379991|NCT05045612|Experimental|Intervention|Stop antibiotic therapy as instituted by admitting physician
3379992|NCT05045612|No Intervention|Control|Continue antibiotic therapy at the discretion of the treating physician (no change in ongoing treatment)
3296840|NCT01803685||Stereotaxic radiosurgery|Deliver a relatively high dose of focused radiation precisely to the arteriovenous malformations.
3296841|NCT01803685||Endovascular treatment|Deliver embolic materials to the feeding arteries or the nidus by microcatheters
3296842|NCT01803685||Comprehensive treatment|Use two or three methods ( Surgical treatment stereotaxic radiosurgery endovascular treatment ) to cure the intracranial arteriovenous malformations
3296843|NCT01803685||Conservative treatment|Patients refused to any of the treatment above
3379995|NCT05043298|Experimental|IBI360|
3379996|NCT05043090|Experimental|Arm A|savolitinib 600mg plus durvalumab 1500mg
3379997|NCT05043090|Active Comparator|Arm B|sunitinib 50mg
3379998|NCT05043090|Experimental|Arm C|durvalumab 1500mg
3379999|NCT05042076|Experimental|BK with VST|Adult patients with BKV infection and nephropathy (BKN) following kidney transplantation. Consented patients who lack a donor or have a cell manufacturing failure will be entered into an observational group and will be replaced, if they do not become eligible during the study period
3380000|NCT05041946|Experimental|Methylphenidate|treatment of attention deficit disorder and narcolepsy (sleep disorder)
3380001|NCT05041946|Experimental|Placebo|Sugar pill
3380004|NCT05039515|Experimental|IPN60130 high dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
3380005|NCT05039515|Experimental|IPN60130 low dosage|Oral capsule, swallowed whole or sprinkled onto food, once daily
3380006|NCT05039515|Placebo Comparator|Placebo|Oral capsule, swallowed whole or sprinkled onto food, once daily
3380007|NCT05039424|Active Comparator|Endoscopic per-oral pyloromyotomy (POP)|Participants will undergo Endoscopic per-oral pyloromyotomy (POP).
3296844|NCT01803698|Experimental|Training in the use of IOM charts|"Training family physicians to regularly refer to the Institute of Medicine guideline trajectories and provide feedback about GWG (training in the use of IOM charts) during routine prenatal visits."
3296845|NCT01803698|No Intervention|Usual care|Family physicians providing usual prenatal care.
3380008|NCT05039424|Sham Comparator|Sham / Control Arm|Participants will undergo a diagnostic esophagogastroduodenoscopy (EGD) without pyloric disruption. Following the 12-week blinded trial period, these participants will be unblinded and offered Endoscopic per-oral pyloromyotomy (POP) if they remain symptomatic.
3380009|NCT05037734|Active Comparator|Robotic-Assisted UKA|Randomized participant will receive UKA via the ROSA Partial Knee System.
3380010|NCT05037734|Active Comparator|Traditional/Conventional UKA|Randomized participant will receive the UKA via Conventional/Traditional UKA Methods.
3296846|NCT01803750||Primary Care Providers|Conduct and analyze in-depth, semi-structured interviews with community-based primary care providers serving large Latino populations and Form a community-based participatory committee.
3296847|NCT01803763|Active Comparator|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
3296848|NCT01803763|Placebo Comparator|Placebo|Fixed dose of Placebo is subcutaneously administered in total 4 monthly doses
3296849|NCT01803776|Experimental|lifestyle counseling|Physical activity and dietary counseling
3296850|NCT01803776|No Intervention|Control|No active intervention
3296851|NCT01803789|Active Comparator|Single Kirschner Wire|Antegrade intramedullary fixation of with a single Kirschner wire.
3380011|NCT05036850||Incident and Prevalent Patients|Incident and prevalent patients diagnosed with a kidney disease at participating centres
3380016|NCT05034952|Experimental|VX-548|Participants will be randomized to receive different dose levels of VX-548.
3380017|NCT05034952|Active Comparator|Hydrocodone bitartrate/ acetaminophen (HB/APAP)|Participants will receive HB/APAP.
3380018|NCT05034952|Placebo Comparator|Placebo|Participants will receive placebos matched to VX-548 and HB/APAP.
3380019|NCT05033080|Experimental|VX-121/TEZ/D-IVA|Participants will receive VX-121/TEZ/D-IVA in the morning.
3380020|NCT05033080|Active Comparator|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA in the morning and IVA in the evening.
3380022|NCT05030792|Experimental|ART VR 3 times/week|ART VR practice for 30 minutes, at home, 3 times per week
3380023|NCT05030792|Experimental|ART VR 4 times/week|ART VR practice for 30 minutes, at home, 4 times per week
3380024|NCT05027971||Lithotripsy Cohort|Subjects in this cohort will undergo lithotripsy procedure for the treatment of urinary calculi.
3380025|NCT05027971||Benign Prostatic Hyperplasia (BPH) Cohort|Subjects in this cohort will undergo Holmium Laser Enucleation of the Prostate (HoLEP) procedure for the treatment of BPH.
3296852|NCT01803789|Active Comparator|Double Kirschner Wire|Antegrade intramedullary fixation with double Kirschner wire.
3296853|NCT01803802|Placebo Comparator|Time management|Writing prompts oriented towards objective recounting of previous day
3380033|NCT05026866|Experimental|Donanemab|Donanemab administered intravenously (IV)
3296854|NCT01803802|Experimental|Sexual schema writing|Expressive writing prompts oriented towards beliefs about sexuality
3296855|NCT01803802|Active Comparator|Trauma writing|Expressive writing prompts oriented towards processing traumatic experiences
3296856|NCT01803828|Active Comparator|Drug Group (Tadalafil)|Tadalafil 20 mg
3380034|NCT05026866|Placebo Comparator|Placebo|Placebo is administered intravenously
3296857|NCT01803828|Placebo Comparator|Placebo Group (PLC)|Placebo 20 mg
3296858|NCT01803841|Active Comparator|Transradial access|Coronary angiography and intervention via radial artery approach
3296859|NCT01803841|Active Comparator|Transfemoral access|Coronary angiography and intervention via femoral artery approach
3296860|NCT01803867|Placebo Comparator|rHIgM22|"Cohorts 1-5: In each dosing cohort, the first 2 eligible patients will be enrolled and randomized 1:1 to receive rHIgM22 or placebo, and monitored for safety for a minimum of 7 days before the remaining 8 patients in the cohort are randomized (7 active: 1 placebo) and dosed.~Expanded Cohort: Upon establishment of a Maximally Tolerated Dose (MTD), a new group of 21 patients will be enrolled in an Expansion Cohort. Randomly assigned in a 1:1:1 ratio to 1 of 3 treatment groups: placebo, Investigational Product (IP) at MTD, or IP at one full dose level lower than MTD."
3296861|NCT01803893||Embryo culture media|measurement using immunoassay
3296862|NCT01803893||maternal serum|measurement by immunoassay
3296863|NCT01803906||Mitochondrial disease|Patients with known or suspected DNA mutations that affect mitochondrial function. Patients with suspected mitochondrial disorders
3296864|NCT01803919|Experimental|Silver Alloy-Coated Urinary Catheters|Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
3296865|NCT01803919|Other|Conventional Urinary Catheter|Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
3296866|NCT01803932|Experimental|Behavioral intervention|Male-focused group violence prevention intervention
3296867|NCT01803932|No Intervention|Control communities|Communities in which male-focused group prevention activities will not be conducted
3296868|NCT01803945|Placebo Comparator|Placebo Group|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
3296869|NCT01803945|Active Comparator|AVE8112|Sequential cohorts of eight patients with PD will be administered ascending oral doses of AVE8112 (n=6) or placebo (n=2) once a day for 14 days. Dosing for subsequent cohorts will only proceed, and the dose level selected, after the safety and tolerability of the previous cohort has been reviewed. Doses are planned to be 1.0, 2.0, 3.0, and 4.0 mg once a day for 14 days. These are planned treatments, but doses may be modified based on safety review of previous cohort(s). In addition, cohorts may be added to reconfirm a previously administered dose, and/or a titration strategy may be employed to reach a desired dose. Patients will be assessed in clinic for 30 hours following the initial oral dose of AVE8112 or placebo
3296870|NCT01803958|Experimental|partial breast irradiation|38.5 Gy total in 10 fractions (3.85 Gy per fraction), twice a day with an interval of at least 6 hours between the two fractions, for five consecutive working days
3296871|NCT01803958|Active Comparator|whole breast irradiation|50.0 Gy in 25 fractions (2 Gy per fraction), once a day for 5 days in the week, or other biologically equivalent schedule
3296872|NCT01803971|Experimental|vascular access in out-of-hospital cardiac arrest patients|Obtention of vascular access according to the current strategy, ie after one unsuccessful attempt to obtain a peripheral venous access, use of an intra osseous device
3296873|NCT01803984||Patient with migraine with aura|Patients with a clearly defined migraine (as per IHS criteria) with aura, who are aged 30 and older and are able to fluently speak French.
3296874|NCT01803984||Patient with migraine without aura|patients with a clearly defined migraine (as per IHS criteria) without aura who are aged 30 and older, are able to fluently speak French, and who are willing to participate
3296875|NCT01803997|Other|STRIDE|12 cooking classes offered over 6 weeks (approximately 2 classes/week)
3296876|NCT01803997|Other|SPARK|12 physical activity classes offered over 6 weeks (approximately 2 classes/week)
3296877|NCT01804010|Active Comparator|Ivabradine|Single and repeated oral administrations of 3 doses of ivabradine
3296878|NCT01804010|Placebo Comparator|Placebo|Placebo administration
3296879|NCT01804023||Healthy women|
3296880|NCT01804088|Experimental|Stent|
3296881|NCT01804127|Experimental|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
3296882|NCT01804153|Experimental|Autologous expanded stem cells|Adipose-derived expanded stem cells
3296883|NCT01804179|Active Comparator|Standard Intervention (SI)|"At Baseline Visit, Participants in the standard intervention (SI) condition will get: I-FOBT kit and Screen for Life brochure, a mailed reminder card at two weeks post-intervention to remind them about FOBT testing and follow up assessments at 12 months."
3296884|NCT01804179|Experimental|CARES Intervention|Colorectal Cancer Awareness, Research, Education and Screening (CARES). At Baseline Visit, Participants in the CARES intervention will receive: I-FOBT kit, a newly developed DVD and booklet, and a mailed reminder card at two weeks post-intervention to remind them about FOBT testing, and follow-up assessments at 12 months.
3296885|NCT01804192|Experimental|Acu-TENS to LI4 and LI11|"Acu-TENS Group (Experimental Group), subjects received TENS over right L14 and LI11.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
3296886|NCT01804192|Active Comparator|Control group|"Control Acu-TENS Group (Control Group), subjects received TENS over tips of bilateral knee caps.~Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV."
3296887|NCT01804192|Placebo Comparator|Placebo group|Placebo Acu-TENS Group (Placebo Group), subjects received the same protocol as the Acu-TENS group and TENS was applied over right LI4 and LI11 that covered with non-conducting plastics (with the same dimension as the TENS electrodes) Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor. The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device. The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 for data acquisition and analysis of the HRV.
3296888|NCT01804205|Experimental|Magnesium sulfate group|In the magnesium group, patients received MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h.
3296889|NCT01804205|Placebo Comparator|Control group|Controls received 100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h.
3296890|NCT01804218|Placebo Comparator|Placebo|Placebo
3296891|NCT01804218|Experimental|Active, nadolol|Active
3296892|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients eligible for the study will have an 18F-FCH PET/MRI in addition to standard of care clinical assessment and imaging (CT and bone scan)
3296893|NCT01804244|Experimental|TMC278|All participants will receive a single-dose of TMC278 (1 25-mg tablet [27.5 mg as the hydrochloride salt]) after an overnight fast (going without food) of at least 10 hours before eating a standard breakfast. Study drug will be taken within 10 minutes after completion of a standardized breakfast.
3296894|NCT01804270|Active Comparator|Part 1 Active|Blinded, active repetitive transcranial magnetic stimulation
3296895|NCT01804270|Sham Comparator|Part 1 Sham|Blinded, sham repetitive transcranial magnetic stimulation
3296896|NCT01804283|Sham Comparator|CON|Patients undergoing double valve replacement (aortic and mitral).
3296897|NCT01804283|Experimental|IPO|Patients undergoing double valve replacement (aortic and mitral) with ischemic postconditioning.
3296898|NCT01804296|Experimental|Part 2 Acute|Open-label, active repetitive transcranial magnetic stimulation
3296899|NCT01804296|Experimental|Part 2 Maintenance|Open-label, active repetitive transcranial magnetic stimulation
3296900|NCT01804309||Early breast cancer patients|Clinical stage T1-2 N0M0 primary unilateral invasive breast cancer patients
3296901|NCT01804322|Active Comparator|Usual care|usual care according to the practice of participating Epilepsy Centers
3296902|NCT01804322|Experimental|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
3296903|NCT01804335|Experimental|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
3296904|NCT01804348|Experimental|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
3296905|NCT01804361|Experimental|Haporine-S|Moderate to severe dry patients administered with with Haporine-S
3296906|NCT01804361|Active Comparator|Restasis, Cyclosporine 0.05%|Moderate to severe dry eye patients with Restasis(cyclosporine 0.05%)
3296907|NCT01804374|Experimental|sorafenib and everolimus|This is an open label study: all patients will be treated with sorafenib 400 mg twice a day in combination with everolimus 5mg per day
3296908|NCT01804387|Active Comparator|Telbivudine plus adefovir|study drugs
3296909|NCT01804387|Active Comparator|Lamivudine plus adefovir|standard drugs
3296910|NCT01804400|Experimental|QAW039 + Montelukast|
3296911|NCT01804400|Experimental|QAW039 Once a day (q.d.)|
3296912|NCT01804400|Experimental|QAW039 Twice a day (b.i.d.)|
3296913|NCT01804400|Active Comparator|Montelukast|
3296914|NCT01804400|Placebo Comparator|Placebo|
3296915|NCT01804413|Active Comparator|Pegvisomant-glucagon test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
3296916|NCT01804413|Active Comparator|Insulin tolerance test|To compare the combined pegvisomant with the glucagon test to the insulin tolerance test and the glucagon test in diagnosing adult growth hormone and cortisol insufficiency.
3296917|NCT01804426||Trauma Exposed participants|18-50 years old men and women who have been brought to the ER after being involved or witnessing a life threatening event (or an event which was perceived as such).
3296918|NCT01804439||CALIBER Healthy Cohort|We will report findings from the CALIBER (CArdiovascular disease research using Linked BEspoke studies and Electronic Records) collaboration where we linked primary care data (from the General Practice Research Database [GPRD]) to three further sources of electronic health records: the Myocardial Ischemia National Audit Project registry (MINAP),cause specific discharge data from Hospital Episodes Statistics (HES) and cause specific mortality from the Office for National Statistics (ONS).
3296919|NCT01804452||Subjects with a diagnosis of PSP or CBD|
3296920|NCT01804478|Experimental|Pneumatic Compression|Both diabetic and control subjects will undergo mild pneumatic compression while tissue oxygenation and blood flow are recorded with a non-invasive NIRS and PPG device
3296921|NCT01804491||Control group|Healthy age matched control subjects
3296922|NCT01804491||Cheilectomy prospective group|"Patients with hallux rigidus treated by the surgery type cheilectomy"
3296923|NCT01804491||Arthrodesis prospective group|"Patients with hallux rigidus treated by the type of surgery arthrodesis"
3296924|NCT01804491||Mixed prospective group|"Patients with hallux rigidus treated by other type of surgery: Arthoplasty, joint resection (Keller-Brandes technique)"
3296925|NCT01804491||Cheilectomy retrospective group|Patients after cheilectomy due to hallux rigidus
3296926|NCT01804491||Arthrodesis retrospective group|Patients after arthrodesis of the metatarsophalageal joint due to hallux rigidus
3296927|NCT01804491||Mixed retrospective group|Patients after other types of surgery due to hallux rigidus: arthroplasty or resection of the first metatarso-phalangeal joint
3296928|NCT01804504|No Intervention|Control|"Food Frequency Questionnaire(FFQ) and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial."
3380037|NCT05024032|Experimental|Tirzepatide Dose 1|tirzepatide administered subcutaneously (SC) once a week.
3380038|NCT05024032|Experimental|Tirzepatide Dose 2|tirzepatide administered SC once a week.
3380039|NCT05024032|Placebo Comparator|Placebo|placebo administered SC once a week.
3380040|NCT05019976|Experimental|Dose-Finding Group 0 - Dose Level 0|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
3380041|NCT05019976|Experimental|Dose-Finding Group 1 - Dose Level 1|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
3380042|NCT05019976|Experimental|Dose-Finding Group 2 - Dose Level 2|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
3380043|NCT05019976|Experimental|Dose-Finding Group 3 - Dose Level 3|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
3380044|NCT05019976|Experimental|Dose-Finding Group 4 - Dose Level 4|"High-energy radiation will be delivered to a focused area of your body using a treatment machine called a linear accelerator. Radiation will be delivered through an IV. A mold will also be customized to fit your body, so you don't move during the radiation process. The actual time on the radiation treatment machine will be 30-60 minutes. The mold will be removed after the treatment.~The longest possible treatment will be 14 radiation treatments over a course of 3 weeks. The shortest possible treatment will be 3 treatments in duration or less than 1 week. The amount of time required for radiation treatment depends on the dose group your are assigned.~Participants will receive radiation to at least 1 but no more than 5 lesions (areas of body with cancer)."
3380045|NCT05019261|Experimental|Intervention|Multi-component Family Support Intervention
3296929|NCT01804504|Experimental|Nutrition education|"FFQ and KAP Questionnaire will be carried out before and after the trial to evaluate changes in calorie and nutrients intake, dietary structure, and KAP scores.~Physical examination and biochemical examination before and after the trial.~Do nutrition education"
3296930|NCT01804517||Physician based approach|Patients will be managed as usual at the clinic without the intervention of the nurse.
3296931|NCT01804517||Physician and nurse|Patients will be managed with the help of the nurse for education and follow-up.
3296932|NCT01804530|Experimental|PLX7486-TsOH, Dose escalation and RP2D|Part 1: Open-label, sequential PLX7486-TsOH single-agent dose escalation in approximately 60 patients with solid tumors.
3296933|NCT01804543||Angina, Heart Disease|ranolazine 500 mg twice daily for 1 week, then 1000 mg twice daily for 3 weeks
3296934|NCT01804556|Other|Myofascial trigger point injection|Myofascial trigger point injection on gastrocnemius muscle
3296935|NCT01804569|Experimental|moxa|moxibustion treatment 3 times a week for 3 weeks
3380046|NCT05019261|No Intervention|Control|Usual ICU care
3380047|NCT05016622|Experimental|Booster dose|
3380048|NCT05015998||Non-dialysis dependent patients with CKD stage 3-5|A cohort of patients will be created from the Stockholm CREAtinine Measurement (SCREAM) cohort based on the eligibility criteria.
3296936|NCT01804595|Experimental|Sunscreen|To reduce barriers to obtaining sunscreen and serve as cues to action, this group will be mailed during the months of May through September, a supply of SPF30 sunscreen lotion (known to prevent sun burning and skin cancer). The mailing will consist of large bottles of sunscreen and a small bottle that can be refilled and attached to their huge key rings that hang off of their belts.
3296937|NCT01804595|Experimental|Text Message Reminders|"As cues to action, this group will receive 60 cellular telephone text-messages on three random mornings per week during the month of May, June, July, August, and September when UV rays are the highest. Using an internet text-messaging service, the messages will be computer generated and sent to Operating Engineers and contain information about weather conditions and various reminders (e.g., Put on sunscreen today or Wow, it's a hot one, you know what to do!)."
3296938|NCT01804595|Experimental|Sunscreen and Text Message Reminders|Just as multimodal interventions such as surgery and radiation can be used to treat skin cancer, multimodal behavioral interventions may reduce sun burning and prevent skin cancer. To determine if the combination of these interventional components results in improvements above and beyond the individual parts, both sunscreen and text messaging interventions will be provided in addition to education.
3296939|NCT01804595|Active Comparator|Education|A 30-minute, picture enhanced power point presentation will be offered to all Operating Engineers during their annual safety trainings. The content of the power point presentation will include information on incidence and prevalence of skin cancer especially among outdoor workers, types of skin cancers and skin cancer risk, sunburn, Sun Protection Factor (SPF), sun protection behaviors including sunscreen use, correct application of sunscreen, types of products, and the new Food and Drug Administration (FDA) labeling of sunscreen products. In addition, other sun protection behaviors such as wearing hats, sunglasses, using shade, etc., will be discussed.
3296940|NCT01804608|Experimental|Sensorimotor|Sensorimotor, this arm will receive sensorimotor and hip muscle strengthening.
3296941|NCT01804608|Active Comparator|Strength|Strength, this arm will receive only hip muscle strengthening.
3380049|NCT05012176|Experimental|Arm I (EFT)|Patients participate in EFT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in EFT in their daily lives. Patients are asked to recall future positive experiences to create text cues which vividly describes these experiences.
3296942|NCT01804621|Experimental|Exercise|Participant received health newsletter with targeted articles about exercise behavior.
3296943|NCT01804621|Experimental|Fruit & Vegetable|Participant received health newsletter with targeted articles about fruit & vegetable consumption.
3296944|NCT01804621|Experimental|Colorectal Cancer Screening|Participant received health newsletter with targeted articles about colorectal cancer screening.
3296945|NCT01804621|Experimental|Mammography|Participant received health newsletter with targeted articles about mammography screening.
3296946|NCT01804634|Experimental|Reduced intensity conditioning|Fludarabine IV infusion over 30 minutes on D-7 to D-3. The dose will be 30 mg/m2/dose (adjusted for renal function). Melphalan: IV infusion over 30-60 minutes, depending on volume, on D-2. The dose will be 100mg/m2.Total body irradiation: 200 cGy AP/PA with 4MV or 6MV photons at 8 12 cGy/min at the point of prescription (average separation of measurements at mediastinum, abdomen, and hips) will be administered in a single fraction on day -1. Bone Marrow will be harvested and infused on day 0. Post-transplantation Cyclophosphamide 50mg/kg will be given on D+3 post-transplant (within 60-72 hr of marrow infusion) and on D+4 post-transplant. Tacrolimus begins on Day 5, at least 24 hours after completion of posttransplantation Cy at 0.015mg/kg IBW/dose IV over 3 hours every 12 hours. Mycophenolic acid mofetil (MMF) F will be given at a dose of 15 mg/kg PO TID (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1 g PO TID).
3296947|NCT01804647||33 RRMS patients|No study treatments administered
3296948|NCT01804647||9 PPMS patients|No study treatments administered
3296949|NCT01804647||12 SPMS patients|No study treatments administered
3296950|NCT01804647||4 CIS patients|No study treatments administered
3296951|NCT01804660||25 healthy volunteers|No study treatments administered
3296953|NCT01804699||Proband|Probands - Participants diagnosed with ARVC according to the 2010 Task Force Criteria
3296954|NCT01804699||Family|First Degree Family member (blood related mother, father, sister, brother, child) of the proband
3296955|NCT01804712|Experimental|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
3296956|NCT01804738|No Intervention|Glucose|Glucose anhydrous 50g dissolved in 250ml water
3296957|NCT01804738|Active Comparator|Jasmine rice|50g available carbohydrate portion
3296958|NCT01804738|Active Comparator|Parboiled basmati rice|50g available carbohydrate portion
3296959|NCT01804777|Experimental|Amiloride 10 mg, 20 mg, and diet|Amiloride 10 mg for 14 days and diet. Then dose titrated up at day 14 to 20 mg, and diet.
3296960|NCT01804777|Active Comparator|HCTZ 12.5 mg, 25 mg and diet|HCTZ 12.5 mg for 14 days and diet. Then dose titrated up at day 14 to 25 mg, and diet
3296961|NCT01804790|Active Comparator|Arm A : Radiotherapy + capecitabine|Chemoradiotherapy 5 weeks (50 Grays (Gy), 2 Gy/session ; 25 fractions) + capecitabine 800 mg/m² twice daily 5 days/7, excluding weekends), then 6-8 weeks after chemoradiation, surgery with total mesorectal excision (TME), followed by adjuvant chemotherapy for 6 months, either mFolfox6 or capecitabine, depending on the center's choice.
3296962|NCT01804790|Experimental|Arm B : Chemotherapy then radiochemotherapy|"Drug: Chemotherapy mFolfirinox~Investigational arm: Neoadjuvant CT mFolfirinox, 6 cycles (ca. 3 months; each cycle = 2 weeks):~oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-fluorouracil (5-FU): 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles).~Then followed by 5 weeks of chemoradiotherapy 50 Gy (2 Gy/session, 5 sessions per week) + capecitabine 800 mg/m² twice daily 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, followed by 3 months of adjuvant chemotherapy, either mFolfox6 or capecitabine depending on the center's choice."
3296963|NCT01804803|Experimental|T-SMBG|This group will perform SMBG using a smartphone-connected glucometer implemented with a software for real-time collection and transmission of measured glucose values to the remote server. SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS). A specific algorithm incorporated into the DSS will allow the patients to self-calculate the dose of basal insulin to be administered according to the measured fasting blood glucose levels for consecutive periods of three days. Glucose data and analyses will be made accessible to the patients and medical staff anytime and anywhere via the web. Patients will be also assisted by the diabetes medical team located at or connected with a call center 24-hours/day, 7 days/week.
3296964|NCT01804803|Active Comparator|SMBG|This group will perform SMBG using a regular glucometer and will report glucose data on paper charts (or download data from the glucometer onto the PC) at the planned study visits. Patients will not receive feed-back on their glucose levels nor instructions on how to potentially modify their drug therapy except when undergoing medical visits at the planned intervals. Patients, finally, will not be assisted by the diabetes team/call center.
3296965|NCT01804829|No Intervention|Observational Control|Subjects who attain HCV RNA <100 IU/ml and are randomized to the control arm will receive standard post-transplant immunosuppressant therapy and be followed for a 34 week period.
3296966|NCT01804829|Experimental|Civacir® 10% at 200 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir 200 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
3296967|NCT01804829|Experimental|Civacir® 10% at 300 mg/kg dose|Subjects who attain HCV RNA <100 IU/ml and are randomized to the Civacir® 300 mg/kg treatment arm will receive Civacir® before liver transplant, followed by 15 infusions over a 10 week regimen, with standard post-transplant immunosuppressant therapy. Civacir® treated subjects will be followed up to 34 weeks post-transplant.
3296968|NCT01804855|Active Comparator|W82GO|Usual face-to-face care as per the W82GO multidisciplinary treatment intervention (phase 1 for 6 weeks and phase 2 for 46 weeks).
3296969|NCT01804855|Experimental|Smartphone|Usual care for Phase 1 of treatment. Treatment during Phase 2 of intervention using the Reactivate smartphone application only.
3296970|NCT01804868|Experimental|case vignette tutorial|The web tutorial composed of 4 case vignettes.
3296971|NCT01804868|Active Comparator|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation.
3296972|NCT01804894||athletes with lower extremity injury|athletes who were injured during one season of play
3296973|NCT01804907|Experimental|CBT|Cognitive Behavioral Therapy
3296974|NCT01804907|Sham Comparator|Behavioral Modification|Standard sleep hygiene education/desensitization therapy
3296975|NCT01804920|Experimental|D-serine adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
3296976|NCT01804920|Placebo Comparator|Placebo adjuvant treatment|"Random assignment, parallel group, double blind, placebo controlled 8 weeks trial.~First arm: D-serine adjuvant treatment, up to 4 g/day Second arm: Placebo adjuvant treatment"
3296977|NCT01804933|No Intervention|conventional neuromuscular blockade|No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement
3296978|NCT01804933|Active Comparator|optimal neuromuscular blockade|Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively
3296979|NCT01804933|Experimental|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
3296980|NCT01804959|Placebo Comparator|Active vs Placebo|In phase I, subjects will be randomized into either the Vivomixx probiotics or placebo arm of the study at a 1:1 ratio. All randomized subjects will receive probiotics (4 sachets/ day or 1800 billion bacteria/day) or placebo (4 placebo sachets/day) for the first 60 days.
3296981|NCT01804959|Active Comparator|60 days of Active vs 120 days of Active|In phase II, subjects from both arms in phase I will receive Vivomixx probiotics 4 sachets/ day for another 60 days. Comparison will be made between the arm receiving 60 days of Vivomixx probiotics vs 120 days of Vivomixx probiotics
3296982|NCT01804972|Active Comparator|Verbal and written infomation|Verbal and written information:Patients will receive both verbal information and written patient information leaflets
3296983|NCT01804972|Experimental|Verbal and electronic information|Patient will receive both verbal information and a web address to access patient information electronically
3296984|NCT01804985|Experimental|De-escalated Treatment|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months
3296985|NCT01804998|Experimental|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in this arm
3296986|NCT01804998|Active Comparator|Laparoscopy Assisted Gastrectomy|Conventional procedure is laparoscopy assisted gastrectomy in early gastric cancer patient.
3296987|NCT01805011||50 healthy mothers|
3296988|NCT01805050||New Technique|All patients who underwent surgical repair of the anterior instability due an HAGL lesion.
3296989|NCT01805063||Fire suppression|Firefighters will attend for vascular assessments following a night shift where they have performed fire suppression
3296990|NCT01805063||Non-fire emergency duty|Firefighters will attend for vascular assessments following a night shift where they have had an emergency response without fire suppression eg. road traffic collision.
3296991|NCT01805063||Sedentary shift|Firefighters will attend for vascular assessments following a night shift where they have remained sedentary throughout the shift.
3296992|NCT01805076|Other|Arm 1 (control)|Patients undergo a clinical breast examination and mammography with ultrasound of the breast and regional nodes followed by breast conserving surgery.
3296993|NCT01805076|Experimental|Arm 2 (experimental)|Patients undergo a clinical breast examination, mammography with ultrasound of breast and regional nodes and breast MRI followed by breast conserving surgery or mastectomy.
3296994|NCT01805102||maternal serum|measurement by immunoassay
3296995|NCT01805115|Experimental|Oral misoprostol|The oral group (misoprostol 400 ug) self-administered the medications orally 8-10 h before surgery.
3296996|NCT01805115|Experimental|Sublingual misoprostol|The sublingual group (misoprostol 400 ug) self-administered the medications sublingually 8-10 h before surgery.
3296997|NCT01805115|Experimental|Vaginal misoprostol|The vaginal group (misoprostol 400 ug) self-administered the medications vaginally 8-10 h before surgery.
3296998|NCT01805115|Experimental|Control|The no-misoprostol group did not administer the medication of misoprostol before the procedure
3296999|NCT01805128|Experimental|schizophrenia|child with a DSM-IV diagnosis of schizophrenia
3297000|NCT01805128|Experimental|autism spectrum disorder|child with a DSM-IV diagnosis of autism spectrum disorder
3297001|NCT01805128|Experimental|Healthy|child having no DSM-IV diagnosis of schizophrenia spectrum disorder or autism
3297002|NCT01805167|Other|subjects with a cochlear implant|
3297003|NCT01805193||Suspected coronary heart disease|
3297004|NCT01805206|Experimental|iFABP Monitored|Subjects monitored for urinary iFABP content during the first 4-12 days of life. Enteral feedings administered when iFABP levels are normal during the first four days of life or, if elevated during the first four days of life, have normalized for five days.
3297005|NCT01805219||healthy subjects|
3297006|NCT01805232|Experimental|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
3297007|NCT01805232|Active Comparator|quinine|quinine infusion 80 mg/kg every 8 hours
3297008|NCT01805245|Experimental|Mindfulness Based Stress Reduction|
3297009|NCT01805245|Active Comparator|Health Education Control|
3297010|NCT01805258|Experimental|Intervention 2: Nevirapine|HIV and Tuberculosis co-infected patients on standard dose nevirapine (Intervention) based ART and Rifampicin based ATT.
3297011|NCT01805258|Active Comparator|Intervention 2: Efavirenz|HIV and Tuberculosis co-infected patients on standard dose Efavirenz(Intervention)based ART and Rifampicin based ATT.
3297012|NCT01805271|Experimental|Everolimus|1 or 2 tablets/day (i.e.5 or 10mg/day )
3297013|NCT01805271|Placebo Comparator|Placebo|1 or 2 tablets/day
3297014|NCT01805310|Other|Bowel Preparation|Women randomized to the bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one. They will also be placed on a clear liquid diet on preoperative day number one.
3297015|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
3297016|NCT01805336|Other|Arm A|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by traditional tests + executive function by virtual reality tests.~One week later, Assessment 2 : attentional function by virtual reality tests + executive function by traditional tests."
3297017|NCT01805336|Other|Arm B|"Inclusion : cognitive complaint,fatigue, anxiety an depression questionnaires.~Assessment 1 : attentional function by virtual reality tests + executive function by traditional tests.~One week later, Assessment 2 : attentional function by traditional tests + executive function by virtual reality tests."
3297018|NCT01805349|Other|X-Rays|patients with digital arthrosis and hip/knee arthrosis will practice hand X-rays
3297019|NCT01805362|Active Comparator|MORNING|patients continue to take their treatments (RAS blockers and diuretics) on awaking
3297020|NCT01805362|Experimental|EVENING|Patients take their treatments(RAS blockers and diurectics)at bedtime
3297021|NCT01805388|Experimental|Regeneration Treatment Group|RTC with Triple Antibiotic Study Drug
3297022|NCT01805388|No Intervention|Control Non-study Drug Group|RTC on contralateral tooth with no study drug
3297023|NCT01805401|Experimental|Left OFC Group|Anode applied to the left OFC and cathode applied to the right OFC
3297024|NCT01805401|Experimental|Right OFC Group|Anode applied to the right OFC and cathode applied to the left OFC
3297025|NCT01805401|Sham Comparator|Sham tDCS|
3297026|NCT01805414|Experimental|Intervention Breakfast|40-45g carbs (300-350 kcal)
3297027|NCT01805414|Active Comparator|Control Breakfast|These patients received the usual hospital breakfast which contained 40-45 g carbs.
3297028|NCT01805427||patients treated with efavirenz|HIV-infected on stable HAART regimen with efavirenz
3297029|NCT01805427||patients treated with atazanavir|HIV-infected patients on stable HAART regimen with atazanavir
3297030|NCT01805427||patients treated with darunavir|HIV-infected patients on stable HAART regimen with darunavir
3297031|NCT01805453|Active Comparator|Arm A: Losartan|Arm A: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan 50mg*2/day until the halting for any reason
3297032|NCT01805453|Placebo Comparator|Arm B: Placebo|Arm B: Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
3297033|NCT01805466|Experimental|EVADO|"The E.V.A.D.O. system is made of the following components:~The ADMIRAL oxygenator, that requires low priming volumes (, has a limited contact surface and contains an accessory independent cardiotomy reservoir, allowing separation of pericardial suction blood.~The HARMONY Smart Suction System, which allows automatic regulation of a pumpless extracavity blood sucker, whose rates and pressures depend on whether suction is required for blood/air surfaces (skimming), or for fluids (pooled).~Paediatric circuits with 3/8 tubing for both arterial and venous lines."
3297034|NCT01805466|Active Comparator|Conventional CPB|conventional cardiopulmonary by-pass (CPB) system
3297035|NCT01805479|Placebo Comparator|stretching-flexibility|This group will use a stretching and flexibility program designed to utilize minimal levels of aerobic capacity. It was chosen in place of a education-based control group due to the high level of personal interaction that is found in the active arm.
3297036|NCT01805479|Active Comparator|aerobic exercise group|aerobic activity targeting 60% peak heart rate for 12 weeks is the active group.
3297037|NCT01805492|Experimental|Intervention|Dr. Dean Ornish Program for Reversing Heart Disease
3297038|NCT01805492|No Intervention|Control|Non-intervention controls retrospectively matched to intervention participants
3297039|NCT01805505|Experimental|Transvaginal ultrasound-guided embryo transfer|Transvaginal ultrasound-guided transfer of two day-3 embryos
3297040|NCT01805505|Active Comparator|Transabdominal ultrasound-guided embryo transfer|Transabdominal ultrasound-guided transfer of two day-3 embryos
3297041|NCT01805518|Active Comparator|Scelectium Tortuosum|S Tortuosum
3297042|NCT01805518|Placebo Comparator|Sugar pill/placebo|Sugar pill/placebo
3297043|NCT01805531||Rivaroxaban|
3297044|NCT01805544||Rivaroxaban|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
3297045|NCT01805570|Active Comparator|Prasugrel loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI.
3297046|NCT01805570|Active Comparator|Ticagrelor loading dose|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI.
3297047|NCT01805583|Experimental|ACT|The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action.
3297048|NCT01805583|Experimental|WPI|"This interventions aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
3297049|NCT01805583|Experimental|ACT and WPI|"The study participants receive both ACT and WPI. The ACT intervention consists of 6 manual-based face-to-face sessions and internet-based homework modules. The manual is based on the six core processes in the ACT-model: acceptance, mindfulness, defusion, self as context, values and committed action. WPI aims at the facilitation of dialogue between the participant and the workplace through a series of steps consisting of individual interviews with the participant and his/her nearest supervisor and a so called convergence dialogue meeting in order to agree upon short- and long-term solutions."
3297050|NCT01805583|No Intervention|Control group|Treatment as usual (TAU) which means that the participant continues in ordinary health care and does not receive interventions other than the initial assessment.
3297051|NCT01805596|Experimental|clopidogrel-ticagrelor|21 days clopidogrel followed by 21 days ticagrelor
3297052|NCT01805596|Experimental|ticagrelor-clopidogrel|ticagrelor for 21 days followed by clopidogrel for 21 days
3297053|NCT01805609|Experimental|Working with the Caregiving Family (WCF) training|This is a new training curriculum for inpatient oncology providers called Working with the Caregiving Family (WCF) training, a program designed to teach MSKCC inpatient staff to address family-level concerns during acute hospitalization. The WCF training will teach staff to recognize and inquire about areas of family distress that are likely to impact the caregiving process; to provide brief, supportive interventions, and/or to transition families to specialized support services when needed. We will provide staff with skills to address especially challenging family situations (e.g., noncompliance with medical care, conflict, poor communication) in collaborative and compassionate ways. We will teach clinicians to intervene and respond more effectively when problematic relationships develop within families or between families and larger systems (e.g., medical team, institutional programs).
3297054|NCT01805622|Experimental|Passive Arm #1|Active Arm #1, 2; Passive Arm #1, 2 Community coalitions randomized to the Passive Arm #1-Web Access Without Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will not participate in monthly technical assistance teleconferences.
3297055|NCT01805622|Experimental|Passive Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to the Passive Arm #2-Web Access With Technical Assistance will receive access to EPICS facilitator training materials and toolkits via the Research-Tested Intervention Programs (RTIPs) website and will participate in monthly technical assistance teleconferences.
3297056|NCT01805622|Active Comparator|Active Arm #1|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #1-In-Person Access Without Technical Assistance will receive training from intervention developers with access to facilitator training materials but will not participate in monthly technical assistance teleconferences.
3297057|NCT01805622|Active Comparator|Active Arm #2|Active Arm #1, #2; Passive Arm #1, #2 Community coalitions randomized to Active Arm #2-In-Person Access with Technical Assistance will receive training from intervention developers with access to facilitator training materials and will participate in monthly technical assistance teleconferences.
3297058|NCT01805635||Children suspected of allergic diseases|Children suspected of allergic diseases No intervention
3297059|NCT01805648|Experimental|rhTPO|Active investigational product
3297060|NCT01805661|Active Comparator|Femoral With Tibial Nerve Block|Continuous femoral nerve block with catheter and selective tibial nerve block in the popliteal fossa
3297061|NCT01805661|Experimental|Canal Block and Capsular Injection|Adductor canal block with a continuous catheter and ultrasound guided posterior capsular injection with local anesthetic solution.
3297062|NCT01805674||isoflavones combined with magnolia|A food supplement containing soy isoflavones, lactobacillus sporogenous, Ca,vitamin D3, magnesium and magnolia extract will be administered once a day during 12 weeks.
3297063|NCT01805700|Experimental|Regular caffeine enhanced energy drink|Regular caffeine enhanced energy drink (containing 240mg caffeine & 84g glucose) e.g. regular red bull cans (x3)
3297064|NCT01805700|Experimental|Diet Caffeine enhanced energy drink|Diet Caffeine enhanced energy drink ( containing 240mg of caffeine alone) e.g. Red Bull light)
3297065|NCT01805700|Active Comparator|Glucose drink|Glucose drink (containing 84g glucose alone)
3297066|NCT01805713||CF Infant Cohort|Infants with CF followed for the first two years of life.
3297067|NCT01805713||CF Child/Adult Cohort|CF patients > 8 years of age followed during hospitalization for pulmonary exacerbation and when well for two years.
3297068|NCT01805726|Placebo Comparator|Xylocain (C)|(C): Local anesthesia
3297069|NCT01805726|Active Comparator|Alfentanil Group + Xylocain (A)|Local anesthesia and Alfentanil
3297070|NCT01805726|Active Comparator|Dexmedetomidine Group + Xylocain (D)|Local anesthesia and dexmedetomidine
3297071|NCT01805752|Experimental|Integrated family-focused PMTCT arm|"Intervention package includes: 1) task-shifting to lower-cadre providers at PMTCT sites; 2) POC CD4+ cell count testing; (3) integrated mother-infant care; and (4) a prominent role for influential family members (male partners), working in close partnership with community-based health workers/volunteers.~Patients attending sites randomized to this arm will also receive group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired."
3297072|NCT01805752|No Intervention|Standard of care|Arm will receive standard of care activities, namely: group health education; opt-out HIV testing, same-day HIV test results; infant feeding counseling; HBC services; infant prophylaxis, early infant diagnosis, linkage to family spacing services, if desired.
3297073|NCT01805765|Active Comparator|Qing'E pills|9 g pills,twice a day for 12 weeks
3297074|NCT01805765|Placebo Comparator|Placebo|9 g pills,twice a day for 12 weeks
3297075|NCT01805778||Acute Cohort|Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy
3297076|NCT01805778||Survivor Cohort|Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy.
3297077|NCT01805804|Placebo Comparator|Placebo|Placebo pills to match valsartan tablets administered once daily
3297078|NCT01805804|Experimental|valsartan 80mg daily|Valsartan 80mg tablet once daily
3297079|NCT01805804|Experimental|valsartan 160mg daily|Valsartan 160mg tablet once daily
3297080|NCT01805817|Experimental|Levonorgestrel releasing intrauterine device, contraception|LNG-IUS - Mirena ®,20μgr, once intrauterine insertion per 5 year, 1 year
3297081|NCT01805817|Experimental|YASMIN® (Drospirenone/Ethinyl Estradiol), contraception|oral, once a day, 1 year
3297082|NCT01805817|Experimental|Copper T 380 A , contraception|intrauterine device, once per 10 year, 1 year period
3297083|NCT01805830|Experimental|MP513 group|
3297084|NCT01805830|Placebo Comparator|Placebo group|
3297085|NCT01805843||chronic meloid leukemia|echo, exercise echo, and if indicated, right heart catheter
3297086|NCT01805856|Experimental|Group A (intervention PIPC)|Patients in group A (intervention PIPC) were given AMP of 2g PIPC intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose PIPC was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
3297087|NCT01805856|Experimental|Group B (intervention CEZ)|Patients in Group B (intervention CEZ) were given AMP of 1g CEZ intravenously just after intubation. If the operation time was longer than 3 hours, additional infusion of same dose CEZ was done. After coming back to the patients' own room, one more infusion of same dose of same drug was done.
3297088|NCT01805856|No Intervention|Group C (without AMP)|Patients in Group C underwent surgery without any AMP.
3297089|NCT01805908|Experimental|111In-Pertuzumab + SPECT-CT|Radiopharmaceutical 111In-labeled Pertuzumab given intravenously prior to SPECT-CT imaging.
3297090|NCT01805921|Experimental|Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|"Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3297091|NCT01805921|Experimental|Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|"Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.~Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks."
3297092|NCT01805921|Experimental|Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|"Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3297093|NCT01805921|Experimental|Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)|"Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.~Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks."
3297094|NCT01805921|No Intervention|Arm 5. No vaccine|Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.
3297095|NCT01805921|Experimental|Arm 6. MVA-RSV (IM)|Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.
3297096|NCT01805921|Experimental|Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)|Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.
3297097|NCT01805921|Experimental|Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)|Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
3297098|NCT01805921|Experimental|Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)|Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.
3297099|NCT01805934|Active Comparator|Group RBLF|receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
3297100|NCT01805934|Active Comparator|Group RA|receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
3297101|NCT01805947||Lifestyle Modification|"All patients with chronic pain conditions participate in a 8-weeks structured group program. Detailed information on the mindfulness based program can be found in the publication by Paul, A. et al. An Integrative Day Care Clinic for chronically ill patients: Concept and case presentation in the European Journal of Integrative Medicine, 2012, 4(4):e455-e459."
3297102|NCT01805960|Experimental|Canakinumab|1 s.c. injection of canakinumab 150mg directly after cardioversion
3297103|NCT01805960|Placebo Comparator|Placebo|1 s.c. injection directly after cardioversion
3297104|NCT01805973|No Intervention|Control|Standard pre-operative care, no active intervention
3297105|NCT01805973|Experimental|Exercise Training|"Supervised Exercise Training Programme Patients will be required to attend three 50 minute exercise sessions per week for 18 weeks. They will exercise in groups of 8-12 and will be supervised by an experienced exercise physiologist. Each session will comprise a 15 minute warm up, 30 minutes of moderate intensity aerobic exercise followed by a 10 minute cool down period.~The patients will have the option to choose from three different exercise programmes tailored to individuals of mixed abilities (and co-morbidities)."
3297106|NCT01805986||MS patient|
3297107|NCT01805999|Experimental|7 g Ispaghula|Volunteer will take 7 g of ispaghula 3 times daily for one week
3297108|NCT01805999|Placebo Comparator|7 g placebo|Volunteer will take 7 g of a placebo 3 times a day for one week
3297109|NCT01805999|Active Comparator|3.5g ispaghula + 3.5 g placebo|Volunteers will take 3.5 g of ispaghula with 3.5 g placebo 3 times daily for one week
3297110|NCT01806012|Experimental|Enseal|Tissue sealing with Enseal device
3297111|NCT01806012|Active Comparator|Supracervical hysterectomy using conventional instruments|Supracervical hysterectomy using conventional instruments
3297112|NCT01806025||Cystic Fibrosis Patients|Patients with Cystic Fibrosis with two known severe (class I and class II) mutations
3297113|NCT01806038|Experimental|RPh Counseling + Outpatient Dispensing|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist.
3297114|NCT01806038|Active Comparator|Routine Med Dispensing + Counseling|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
3297115|NCT01806077|Experimental|PZ-128|
3297116|NCT01806090|Active Comparator|Clopidogrel|Continue clopidogrel for 7 days prior to the endoscopic procedure
3297117|NCT01806090|Placebo Comparator|Placebo|Placebo daily for 7 days prior to the endoscopic procedure
3297118|NCT01806103|Experimental|Antimicrobial Stewardship Bundle|"An intervention bundle to reduce outpatient antibiotic use in children will include education, creation of and access to guidelines, and audit of and feedback on individual prescribing within the context of achievable benchmarks."
3297119|NCT01806103|No Intervention|Control|Control sites will be within strata to maintain balance of treatment arm within strata
3297120|NCT01806116|Experimental|decitabine + transplantation|
3297121|NCT01806129|No Intervention|Arm A (no intervention)|Patients undergo usual standard practice related to reproductive health.
3297122|NCT01806129|Experimental|Arm B (reproductive health program)|Patients undergo reproductive health program comprising didactics, reproductive health assessment and navigating algorithm, and network development.
3297123|NCT01806142|Experimental|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
3297124|NCT01806142|Active Comparator|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
3297125|NCT01806155||Craniotomy|Patient undergoing major craniotomy
3297126|NCT01806181|Other|Cancer Treatment|
3297127|NCT01806194|Active Comparator|Educational control arm|Control group receives 16 mailings of diabetes educational materials but no regular contact with community health workers
3297128|NCT01806194|Experimental|Lifestyle counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers.
3297129|NCT01806207|Active Comparator|Durolane injection|Intraarticular injection of 3 ml Durolane.
3297130|NCT01806207|Placebo Comparator|Saline injection|Intraarticular injection of physiological sodium chloride (0.9% NaCl) solution pH 7.
3297131|NCT01806220|Active Comparator|biopsy of retrocrycoid laryngeal mucosa|"During upper digestive endoscopy a biopsy specimen of the retrocrycoid laryngeal mucosa was obtained with a forceps introduced by the working channel of the scope.~Intervention: biopsy of retrocrycoid laryngeal mucosa"
3297132|NCT01806220|Active Comparator|biopsy of distal esophagus mucosa|"during upper digestive endoscopy a biopsy specimen of the distal esophageal mucosa was obtained~Intervention:biopsy of distal esophagus mucosa"
3297133|NCT01806233|Experimental|Acupuncture|acupuncture
3297134|NCT01806233|Experimental|Rehabilitation|rehabilitation exercise
3297135|NCT01806246|Experimental|integrative rehabilitation program|28 sessions during 12 months with focus on psychoeducation, activity planning, and thoughts and feelings connected to having a serious chronic disease. From week 13 to week 32 a training programme aiming at balancing heart rate variability.
3297136|NCT01806272|Experimental|Arm A|"Local use of rhGM-CSF + Compound Vitamin B12 solution: The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.~Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
3297137|NCT01806272|Active Comparator|Arm B|"Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily~Radiotherapy: Intensity modulated radiation therapy(IMRT)~Chemotherapy:Docetaxel or cisplatin weekly or cisplatin once every three weeks during radiotherapy."
3297138|NCT01806285||Patients with Respiratory Symptoms|
3297139|NCT01806311|Active Comparator|PartA: Candesartan, Candesartan + Amolodipine|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
3297140|NCT01806311|Active Comparator|PartB: Amlodipine, Amlodipine+Candesartan|Candesartan : multiple dose 32mg administered orally Amlodipine : multiple dose 10mg administered orally
3297141|NCT01806324|Experimental|HL040XC(Atorvastatin+Losartan)|HL040XC lag time released combination drug
3297142|NCT01806324|Active Comparator|Losartan + Atorvastatin|Coadministration group
3297143|NCT01806337|Experimental|Alemtuzumab, antibody|alemtuzumab - anti CD 52 antibody administered as consolidation, total dose 133 mg
3297144|NCT01806350|Experimental|Arm I (PFMT)|Patients receive a handout describing behavioral management tips for urinary incontinence, including information and suggestions about optimal volume fluid intake, constipation management, measures to reduce urgency by spreading fluid intake, and avoiding caffeine and other bladder irritants that have proved effective in other intervention trials. Patients undergo PFMT over 20-30 minutes teaching them to contract the pelvic floor muscles correctly and receive feedback to avoid the contraction of abdominal, gluteal or adductor muscles. Patients are asked to perform 3 sets of 10 pelvic muscle contractions with a goal of holding the contraction for 5 seconds daily for 12 weeks and also receive a reminder phone call to address concerns and review the instructions at 4 weeks.
3297145|NCT01806350|Active Comparator|Arm II (usual care)|Patients receive usual care for urinary incontinence, with an option to join the training program after completion of study.
3297146|NCT01806363|Active Comparator|Part A: Telmisartan, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
3297147|NCT01806363|Active Comparator|Part B: Chlorthalidone, Chlorthalidone + Telmisartan|telmisartan 80mg : multiple dose administered orally chlorthalidone 25mg : multiple dose administered orally
3297148|NCT01806376|Experimental|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
3297149|NCT01806402||Retina|Having clinical diagnosis of retina pathology
3297150|NCT01806402||Glaucoma|Having clinical diagnosis of glaucoma
3297151|NCT01806415|Experimental|Fenobam 50 mg|Treatment regimen 1: Fenobam [1-(3-chlorophenyl)-3-(1-methyl-4-oxo-2-imidazolidinylidine) urea hydrate], oral administration of one 50 mg gelatin capsule.
3297152|NCT01806415|Experimental|Fenobam 100 mg|Treatment regimen 2: Fenobam, oral administration of one 100 mg gelatin capsule.
3297153|NCT01806415|Experimental|Fenobam 150 mg|Treatment regimen 3: Fenobam, oral administration of one 150 mg gelatin capsule.
3380050|NCT05012176|Active Comparator|Arm II (ERT)|Patients participate in ERT over 12 weeks, in which they will receive prompts via a guided smartphone application to engage in ERT in their daily lives. Patients are asked to recall past positive experiences to create text cues which vividly describes these experiences.
3297154|NCT01806415|Placebo Comparator|Placebo arm|Treatment regimen 4: Placebo (lactose), oral administration of one 150 mg gelatin capsule.
3297155|NCT01806428||aPC treatment group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis treated with activated protein C at 24 mcg/Kg/h for 96 hours
3380055|NCT05005052|Experimental|Sulodexide arm|Name: Vessel (medicinal product registered in Italy) Dosage form: soft capsules Active substance: sulodexidum 250 LSU Dosage: 2 x 2 soft capsules daily (oral use), in line with the labelled posology (500 LSU twice a day) Duration: 24 ± 4 weeks
3380056|NCT05005052|Placebo Comparator|Placebo arm|Dosage form: soft capsules Appearance: undistinguishable from the active Dosage regimen: 2 x 2 soft capsules daily Duration of placebo intake: a total of 24 ± 4 weeks
3380057|NCT05002959||TESS Anatomic|Subjects who received the Anatomic T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
3380058|NCT05002959||TESS Reverse|Subjects who received the Reverse T.E.S.S.® V3 Modular Total Shoulder System to relieve pain and restore the joint function and who met the inclusion/exclusion criteria.
3380059|NCT05001945|Placebo Comparator|Placebo|Placebo tablet(s) by mouth once or twice daily.
3380060|NCT05001945|Experimental|Dose 1|MLS-101 tablet(s) by mouth once or twice daily.
3380061|NCT05001945|Experimental|Dose 2|MLS-101 tablet(s) by mouth once or twice daily.
3380062|NCT05001945|Experimental|Dose 3|MLS-101 tablet(s) by mouth once or twice daily.
3297156|NCT01806428||Control group|Septic patients with at least two sepsis-induced organ failures occurring within 48 hours of the onset of sepsis not treated with activated protein C because of contraindications
3297157|NCT01806441|Experimental|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
3297158|NCT01806441|Active Comparator|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
3297159|NCT01806454|Active Comparator|calcium A|tablets, 600mg per day,till birth
3297160|NCT01806454|Active Comparator|calcium B|tablets,1200mg per day,till birth
3380063|NCT05001945|Experimental|Dose 4|MLS-101 tablet(s) by mouth once or twice daily.
3380064|NCT05001945|Experimental|Dose 5|MLS-101 tablet(s) by mouth once or twice daily.
3380065|NCT04998851|Experimental|Women with CIS or MS|Lactating women with CIS or MS (in line with the locally approved indications) who decided together with their treating physician to continue on, or start treatment with, OCREVUS (ocrelizumab) post-partum. Women resuming treatment with ocrelizumab post-partum will be included only if the last exposure to ocrelizumab occurred more than 3 months before the last menstrual period to exclude any interference between fetal exposure and exposure via lactation.
3380066|NCT04998786|Experimental|assessment of treatment Ixazomib, dexamethasone, iberdomide|Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression
3380067|NCT04995419|Experimental|Enfortumab vedotin|Participants will receive enfortumab vedotin on Days 1, 8 and 15 of every 4-week (28 days) cycle.
3297161|NCT01806467||critically ill patients|patients admitted to the medical-surgical ICU
3297162|NCT01806467||post-cardiac surgical patients|patients admitted to the post-cardiac surgical ICU
3380068|NCT04992312|Experimental|Glucagon Nasal Powder|A single dose of glucagon nasal powder administered intranasally.
3380069|NCT04991974|No Intervention|Usual Care (UC)|The UC Arm will include standard services from the sexual health clinic / city health department [at the time of the study, no standardized intervention for opioid use disorder treatment linkage].
3297163|NCT01806480|Experimental|Person-centred proactive breastfeeding telephone support|Proactive breastfeeding telephone support initiated by the Breastfeeding Support Team (BST) at the NICU from which the infant is discharged. Daily phone calls from one member in the BST to the mother will be performed from day 1 until day 14 after discharge. In addition to this, the mother has the option to call someone in the BST during the same period (reactive). The telephone support will be conducted with a person-centered approach. Thus, the mother is enabled to talk about whatever feels important to her including the situation with the new infant at home and her breastfeeding. The feeding support team member should during the telephone support session: have an authentic presence, characterized by being there for the mother, having an empathic approach, taking time touching base, providing affirmation, being responsive, sharing the mother's experience and enabling a relationship.
3380070|NCT04991974|Active Comparator|Patient Navigation (PN)|The PN Arm will include all UC Arm services, with the addition of a Patient Navigator who will assist the participant in selecting a community OUD treatment program, facilitate an intake appointment, help to resolve barriers and coordinate OUD treatment entry, and support early retention in OUD treatment.
3297164|NCT01806480|No Intervention|Person-centred reactive breastfeeding telephone support|The control group (and the intervention group) will be offered the possibility to person-centred reactive telephone support initiated by the mother who can phone the feeding support team from day 1 after discharge until day 14 after discharge, between 08.00-16.00 every day. Each NICU will set up a specific telephone number for their telephone support, and schedule the members in the BST for availability. The same level of person-centeredness will be provided in both reactive and proactive telephone support.
3297165|NCT01806493||obese subjects|One hundred and three overweight or obese subjects were included in the study: 74 women (aged 41.5±10 years) and 29 men (aged 43.8±8 years);
3297166|NCT01806532||18F-FDG PET-CT|A total of 10 patients with acute respiratory distress syndrome (ARDS) will be imaged with 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) and PET-CT scan.
3297167|NCT01806558|Experimental|Women with lesion on MBI|Women with lesion on MBI
3297168|NCT01806610|Experimental|BPS804|Single dose BPS804 administration.
3297169|NCT01806610|Placebo Comparator|Placebo|Single dose placebo administration.
3297170|NCT01806636||Treatment|Patients treated with PneumRx Coil System
3297171|NCT01806649|Experimental|BKM120|BKM120, starting at 100 mg oral once daily
3297172|NCT01806701|Experimental|Psychotherapy|Trauma-focused Cognitive Behavioral Therapy
3297173|NCT01806727|Active Comparator|Diabetes Self Management (DSM)|Diabetes Self Management education, delivered in the clinics, using group-based visits and targeting improved control of hemoglobin A1c and related risk factors.
3297174|NCT01806727|Experimental|Community Lifestyle Weight Loss (LWL)|Participants with type 2 diabetes will be enrolled in a 12 month lifestyle intervention designed to achieve a mean >7% weight loss induced through caloric restriction and increased physical activity. The intervention will be delivered via supervised Community Health Workers (CHWs). Most meetings will be at a community location.
3297175|NCT01806753|Experimental|midazolam/propofol injection|Intermittent midazolam/propofol injection controlled by endoscopist
3297176|NCT01806753|Active Comparator|propofol infusion|Continuous propofol infusion with opioid administration
3297177|NCT01806766|Active Comparator|Ceramic on Ceramic|Ceramic on Ceramic bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
3297178|NCT01806766|Active Comparator|Ceramic on HXPE|Ceramic on HIghly crosslinked polyethylene bearing coupled side of a single patient undergoing bilateral total hip arthroplasty
3297179|NCT01806792|Experimental|Risendronate and Cholecalciferol combination|risedronate 150mg and cholecalciferol 30,000 IU 1 tablet + Placebo(for risedronate 150mg) 1 tablet by once a month.
3297180|NCT01806792|Active Comparator|Risedronate|risedronate 150mg 1 tablet + Placebo(for risedronate 150mg and cholecalciferol 30,000 IU) 1 tablet by once a month.
3297181|NCT01806805|Experimental|Zonegran|Zonegran / Placebo Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
3297182|NCT01806805|Placebo Comparator|placebo|Placebo /Experimental Zonisamide (Zonegran ®) and its placebo appear under the shape of virgin capsules of size 1. Each drug will be dispensed successively in a box containing blister packs of 14 capsules. For every period (A and B), box will contain 26 blister packs. A phase of progressive increase of doses by stages of 50 mg / week is planned before reaching the fixed dose of 300 in the daytime during 4 weeks. Then, a progressive diminution over two weeks is planned before the stop.
3297183|NCT01806818|Experimental|Eperisone 50mg BID|Administrate Eperisone 50mg tablet after the breakfast and dinner, and pacebo tablet after the lunch for 7 days
3297184|NCT01806818|Experimental|Epirisone 50mg TID|
3297185|NCT01806818|Placebo Comparator|Placebo comparator|
3297186|NCT01806870|Experimental|Nutritional Supplements Zinc and SAMe|Each subject will receive 1600mg of SAMe per day Men subjects will receive 30mg Zinc Women subjects will receive 25mg Zinc
3297187|NCT01806883|Experimental|Rehabilitation using Nintendo-Wii|30 patients will receive rehabilitation using Nintendo-Wii.
3297188|NCT01806883|Active Comparator|Traditional physiotherapy|30 patients will receive traditional physiotherapy.
3297189|NCT01806909|Other|Intranasal|Ad4-H5-VTN intranasal vaccine administered in cohorts of 3 at increasing dosages
3297190|NCT01806922|Experimental|Yoga training, Tradiational physiotherapy|Experimental Group(20 people) receive tradiational physiotherapy(4 times in a week, every time 1 hour), and 8-weeks yoga training(2 time in a week, every time 1 hour)
3297191|NCT01806922|No Intervention|Tradiational physiotherapy|Control Group(20 people)only receive tradiational rehabiliation( 4 times in a week, every time 1 hour ) for 8 weeks.
3297192|NCT01806935|Experimental|DC086|cream
3297193|NCT01806935|Placebo Comparator|placebo|
3297194|NCT01806948|Placebo Comparator|Control|Single dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, placebo will be intravenously injected at 4 hours after surgery.
3297195|NCT01806948|Experimental|Experimental|Double dose of antiemetics. Specifically, Ramosetron 0.3 mg will be intravenously injected when surgery is ended. Additionally, Ramosetron 0.3 mg will be intravenously injected at 4 hours after surgery.
3297196|NCT01806974|Other|patient with parodontitis|Patient with rheumatoid arthritis and pparodontitis.
3297197|NCT01806974|Other|Patient without parodontitis|Patient with rheumatoid arthritis but periodontally healthy
3297198|NCT01806987|Experimental|KITS Program|The KITS Program consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
3297199|NCT01806987|No Intervention|Services as usual|These include any services that the child and family might already be receiving in the community.
3297200|NCT01807039||patients after surgery with isolated proximal femur fracture|Patients between 18-110 years admitted to Faculty Hospital Brno with isolated injury of proximal femur (ICD dg. S72.0 a S72.1)who underwent surgery between 1.1. 2011 00:00 - 31.12. 2012 23:59 in Faculty hospital Brno (tertiary care university hospital).
3297201|NCT01807052||Observational|Tissue samples are analyzed for tumor factor expression levels by immunohistochemistry.
3297202|NCT01807078|Active Comparator|Ezetimibe|Patients will receive for 6 months ezetimibe (10 mg/day)
3297203|NCT01807078|Active Comparator|Nutraceuticals|Patients will receive for 6 months a commercially available nutraceutical combined pill (1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
3297204|NCT01807117|Experimental|Diagnostic (PET-CT and PET-MRI)|Patients undergo fludeoxyglucose F 18 PET-CT and PET-MRI.
3297205|NCT01807130|Placebo Comparator|Registry|Patients randomized to the registry arm will be followed per usual standard of care by their primary providers. Those providers may refer to subspecialty HF or electrophysiology care as they see fit.
3297206|NCT01807130|Experimental|Intervention|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology with recommendations to consider those therapies that are not in compliance with guidelines.
3297207|NCT01807143||Correlative studies|Tissue samples are analyzed for translocations and deletions and analyzed using PCR or FISH.
3297208|NCT01807169|Experimental|Colonic polypectomy or endoscopic mucosal resection|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
3297209|NCT01807182|Experimental|Treatment (TIL, combination chemotherapy, aldesleukin)|Patients receive cyclophosphamide IV on days -7 to -6 and fludarabine phosphate IV on days -5 to -1. Patients undergo TIL infusion over 30-60 minutes on day 0 and receive aldesleukin IV every 8 hours on days 1-5 for up to a maximum of 14 doses.
3297210|NCT01807195||the medical records of those in whom a contrast medium|
3297211|NCT01807208|Experimental|Educational tool|Patients randomized to the educational tool arm of the study will receive mailed educational materials at 1 week post hospital discharge and again at 3 months after discharge.
3297212|NCT01807208|No Intervention|Usual care|Patients in this arm of the study will receive usual care.
3297213|NCT01807247||Hemiparetic|Intensive lower limbs muscles strengthening
3297214|NCT01807247||Spinal cord injury|Intensive lower limbs muscles strengthening
3297215|NCT01807247||Multiple sclerosis|Intensive lower limbs muscles strengthening
3297216|NCT01807260|Active Comparator|conventional Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
3297217|NCT01807260|Active Comparator|stepwise Shock wave lithotripsy group|All procedures were performed under continu¬ous intravenous sedo-analgesia (using a combi-nation of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave number was limited to a maximum of 3000 waves/session. In the stepwise group, the voltage was started at 10 kV and increased stepwise (every 250 shock waves) to 13 kV. The stone burden was defined as the stone area that was calculated by multiply¬ing the largest length and width of the individual stones measured from the abdominal plain X-ray.
3297218|NCT01807273||Hemiplegic subjects|60 hemiplegic outpatients walking test
3297219|NCT01807286|Experimental|Pomalidomide + Melphalan + Dexamethasone|Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21. Melphalan 9 mg/m2 by mouth on days 1-4 of every 28-day cycle. Dexamethasone 40 mg/day by mouth on days 1-4. Questionnaires completed at different time points during study.
3297220|NCT01807312|Experimental|CO2 insufflation|CO2 insufflations was applicated in routine colonoscopy examination with Endoscopic CO2 regulation unit and accessories
3297221|NCT01807312|Placebo Comparator|Air insufflation|Air insufflations is applicated in Routine Colonoscopy Examination
3297222|NCT01807325||pancreas cysts and solid masses|patents referred for solid and cystic lesions of the pancreas who will have a biopsy for usual medical care.
3297223|NCT01807338||saline|Saline administration to patients with idiopathic Parkinson's disease (PD) of moderate severity, who have previously been treated with sNN0031
3297224|NCT01807364||Congenital adrenal hyperplasia|Patients > 18 yrs with classical or non classical CAH diagnosed during childhood
3297225|NCT01807364||controls|control patients
3297226|NCT01807377|Experimental|PF-05175157, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: 200 mg PF-05175157 administered BID Day 11: Midazolam and PF-05175157
3297227|NCT01807377|Experimental|Placebo, Midazolam|Day 0: Midazolam 2 mg administered alone Days 1-14: Placebo administered BID Day 11: Midazolam and Placebo
3297228|NCT01807403|Experimental|Deep brain stimulation of subthalamic nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Stimulation of subthalamic nucleus
3297229|NCT01807403|Experimental|Deep brain stimulation of caudate nucleus|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker. Caudate nucleus stimulation
3297230|NCT01807403|Experimental|Deep brain stimulation of nucleus accumbens|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.Nucleus accumbens stimulation.
3297231|NCT01807416|Active Comparator|standard platform , standard abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to standard designed prosthetic abutments
3297232|NCT01807416|Active Comparator|standard platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with regular collar connected to flat designed prosthetic abutments
3297233|NCT01807416|Active Comparator|switching platform, standard abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to standard designed prosthetic abutments
3297234|NCT01807416|Active Comparator|switching platform, flat abutment|implant insertion and abutment connection Osseointegrated implants with switched platform collar connected to flat designed prosthetic abutments
3297235|NCT01807429|Experimental|Ketamine-midazolam|300 to 500 mcg/kg ketamine plus 0.03 mg/kg midazolam
3297236|NCT01807429|Active Comparator|Morphine|0.05 to 0.1 mg/kg morphine
3297237|NCT01807442|Other|Optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of greater than or equal to 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of greater than or equal to 15 suggests optimal adherence to health behaviors."
3297238|NCT01807442|Other|Sub-optimal adherence|"Participants receive the qualitative interview and adherence intervention.~This arm includes participants with scores of less than 15 on the Medical Outcomes Study Specific Adherence Scale. This scale ranges from a score of 3 (extremely low adherence to health behaviors) to a score of 18 (extremely high adherence to health behaviors). A score of less than 15 suggests sub-optimal adherence to health behaviors."
3297239|NCT01807468|Experimental|HaploSC+NK|
3297240|NCT01807481|Experimental|Mircera Arm|Once Monthly Mircera
3297241|NCT01807494|Active Comparator|Posterior approach|Subjects in this group will total hip replacement performed with a posterior surgical approach and total hip replacement components.
3297242|NCT01807494|Active Comparator|Anterior Approach|Subjects in this group will have total hip replacement performed with a direct anterior surgical approach and total hip replacement components.
3297243|NCT01807507||Healthy Volunteers|
3297244|NCT01807533|Experimental|Family-centered intervention program|FCIP: family members were encouraged to present in all intervention sessions included 5 in-hospital intervention, 7 after-discharge interventions (0, 1, 2, 4, 6, 9, and 12 months of corrected age), and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
3297245|NCT01807533|Other|Usual care intervention program|UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
3297246|NCT01807546|Experimental|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
3297247|NCT01807572||obesity risk status|Lean adolescents at high-risk for obesity, by virtue of parental obesity, and lean adolescents at low-risk for obesity, by virtue of lean parents.
3297248|NCT01807611|Experimental|Transplant Recipients|"Participants undergo a preparative regimen of total lymphoid irradiation, fludarabine, cyclophosphamide, fludarabine, thiotepa, melphalan, and mycophenolate mofetil, followed by HPC,A infusion and TC-NK infusion. They also receive G-CSF and mesna.~Cells for infusion are prepared using the CliniMACS System."
3297249|NCT01807663|Experimental|healthy volunteers|Free breath monitoring. Correlation between two device for recording parameters of ventilation.
3297250|NCT01807663|Experimental|Chronic patient|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
3297251|NCT01807663|Experimental|ACUTE PATIENT|Free breath monitoring. Number of pathological respiratory events (apneas, hypopneas, paradoxical breath) compared with the recording of the PtCO2 and the SpO2)
3297252|NCT01807676|Active Comparator|ET View Double Lumen Tube|Patients assigned to the thisgroup will be intubated using the VivaSight-DL.
3297253|NCT01807676|Active Comparator|conventional Double Lumen Tube|Patients assigned to the first group will be intubated using conventional DLT (Bronchocath, left sided; Rüsch, Kernen, Germany).
3297254|NCT01807702|Experimental|13C-pyruvate,13C-Lactate and dichloroacetate|During the first day of the subjects participation pyruvate will be given and blood, breath and buccal cell samples will be collected over a two hour period. On the last day DCA will be given.
3297255|NCT01807715||Study group|Women seeking first trimester surgical abortion
3297256|NCT01807728|Experimental|Group 1 Training Program|
3297257|NCT01807728|Experimental|Group 2 Training Program|
3297258|NCT01807741|Experimental|Asenapine Group|Asenapine will be given beginning on day 0 at 5 mg bid. Dose will be increased to 10 mg bid if there is less than 50% decrease in MADRS score by week 2. Dose increases may be held if clinically indicated. Doses may be decreased at any time, if clinically indicated, by increments of 5 mg/day to a minimum of 5 mg qHS. Daily treatment with asenapine will be for 8 weeks.
3297259|NCT01807741|Active Comparator|Placebo Group|Sublingual tablets similar to the asenapine tablets.
3297260|NCT01807754||Imaging scans for breast cancer screening|"To simulate the performance of the combination of three new breast imaging systems to digital mammography and hand-held ultrasound that are currently used to find and evaluate breast masses.~These three different systems make images of the breast in several ways to find breast masses and to distinguish normal and abnormal masses. This may result in less unnecessary call-backs from mammography."
3297261|NCT01807767|Experimental|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
3297262|NCT01807767|Other|Myfortic and Tacrolimus|Normal Care: Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
3297263|NCT01807780|Other|single arm :vaccinated|military personnel vaccinated with multiple vaccines and monitored about safety, immunogenicity and efficacy
3297264|NCT01807793|Active Comparator|Psychoeducation|Psychoeducation will include attending individual and group sessions.
3297265|NCT01807793|No Intervention|Care as usual|Receive care as usual
3297266|NCT01807806|Experimental|Role-playing game|All eligible participants were invited to play the role playing game
3297267|NCT01807819||Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
3297268|NCT01807832|Other|chronic cough|Capsaicine challenge in chronic cough patients
3297269|NCT01807845|Active Comparator|Skimmilk VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80;
3297270|NCT01807845|Placebo Comparator|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk.
3297271|NCT01807845|Active Comparator|enriched skimmilk with VD|enriched skimmilk with VD
3297272|NCT01807858|Active Comparator|Bifidobacterium lactis|5 billion Bifidobacterium lactis
3297273|NCT01807858|Active Comparator|İnulin|900 mg İnulin per day will be given
3297274|NCT01807858|Placebo Comparator|Maltodextrin|Maltodextrin
3297275|NCT01807858|Active Comparator|Bifidobacterium lactis plus İnülin|5 billion active Bifidobacterium lactis plus 900 mg İnülin per day
3297276|NCT01807884|Experimental|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
3297277|NCT01807884|Placebo Comparator|Routine oral care|Oral suction followed by mouth care and tracheal suction
3297278|NCT01807897|Experimental|CPAP|Nocturnal continuous positive airway pressure
3297279|NCT01807897|Experimental|NSO|Nocturnal supplemental oxygen
3297280|NCT01807897|Other|HLSE|Healthy lifestyle and sleep education control
3297281|NCT01807910|Experimental|Fructose|Participants will receive fructose (3g/kg/day) for 2 weeks.
3297282|NCT01807910|Active Comparator|Glucose|Participants will receive glucose (3g/kg/day) for 2 weeks.
3297283|NCT01807936|Experimental|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field lymphadenectomy
3297284|NCT01807936|No Intervention|Two -field lymphadenectomy|Thoracic-upper abdominal two -field lymphadenectomy
3297285|NCT01807962|Active Comparator|rapidocain and bethametsaone|"Rapidocain and Bethametsaone :~Lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine Bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de bétaméthasone and 2mg/ml phosphate disodique de bétaméthasone)"
3297286|NCT01807962|Placebo Comparator|sterile saline|Placebo arm with 5ml of sterile saline (NaCl) solution
3297287|NCT01807975|Experimental|post allogreffe patients|Functional evaluation of distal airway by forced oscillation technique : relevance earlier diagnostic of pulmonary syndrom of oblitérant bronchiolit in post allogreffe patients
3297288|NCT01807988|Experimental|iCBT|Internetbased cognitive behavior therapy (iCBT) aimed att preventing relapse into major depression.
3297289|NCT01807988|No Intervention|Control group|The control group in the study will fill out questionnaires every month and will be interviewed every month to detect any relapses. They will also receive feedback on there self-reported symptoms.
3297290|NCT01808014|Experimental|The addition of Nefopam|The addition of Nefopam for intravenous patient-controlled analgesia in patients with lumbar spinal surgery would reduce the side effects seen in monotherapy with opioid analgesia and result in effective pain management.
3297291|NCT01808027||Acute myocardial infarction|patient with suspected acute coronary syndrome (ACS).
3297292|NCT01808040|Experimental|1|"Tak700 (orteronel) dose escalation schedule:~1a 200 mg PO BID TAK700~1b 200mg PO BID TAK + glucocorticoid~1a 300mg PO BID TAK700 starting dose~1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid"
3297293|NCT01808053||Healthy older and independently living adults|The BodyGuardian remote health monitoring system will used by healthy older and independently living adults
3297294|NCT01808079||Ancillary-correlative (genetic markers of Wilms tumor)|Samples are analyzed for SNP profiling using real-time PCR and MLPA.
3297295|NCT01808105|Other|Human Milk|Reference group, breast feeding ad libitum
3297296|NCT01808105|Active Comparator|Control Formula|Ready to feed infant formula, feed ad libitum
3297297|NCT01808105|Experimental|Experimental Formula 1|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
3297298|NCT01808105|Experimental|Experimental Formula 2|Ready to feed infant formula with human milk oligosaccharides, feed ad libitum
3297299|NCT01808131|Experimental|lesinurad 200 mg + allopurinol|
3297300|NCT01808131|Experimental|lesinurad 400 mg + allopurinol|Patients on lesinurad 400 mg had their dose changed to lesinurad 200 mg after implementation of protocol amendment 4, dated 07 October 2015.
3297301|NCT01808157|Experimental|0.05% w/w CT327 ointment|Active
3297302|NCT01808157|Experimental|0.5% w/w CT327 ointment|Active
3297303|NCT01808157|Placebo Comparator|vehicle|Placebo
3297304|NCT01808170|Active Comparator|laparoscopic ovarian cystectomy|laparoscopic ovarian cystectomy will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
3297305|NCT01808170|Active Comparator|laparoscopic cyst deroofing|laparoscopic cyst deroofing will be performed on proliferative phase of menstrual cycle.Anti-mullerian hormone level measurement and estimation of antral follicle count will be done before surgery and will be repeated one month after surgery.
3297306|NCT01808183||supracondylar humerus fractures|All members of the study will have near Infrared spectroscopy pads placed on their injured and uninjured arms as a part of this study.
3297307|NCT01808235|Experimental|Oral health intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
3297308|NCT01808261|Placebo Comparator|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
3297309|NCT01808261|Active Comparator|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
3297310|NCT01808274|Experimental|TAVR|with CENTERA self-expanding valve
3297311|NCT01808287|Experimental|High risk population|SAPIEN 3 transcatheter heart valve was implanted in high risk patients
3297312|NCT01808287|Experimental|Intermediate risk population|SAPIEN 3 transcatheter heart valve was implanted in intermediate risk patients
3297313|NCT01808300|Experimental|A-B-C|Drug will be administered to according to A-B-C sequence for 3 period.
3297314|NCT01808300|Experimental|A-C-B|Drug will be administered to according to A-C-B sequence for 3 period.
3297315|NCT01808300|Experimental|B-C-A|Drug will be administered to according to B-C-A sequence for 3 period.
3297316|NCT01808300|Experimental|B-A-C|Drug will be administered to according to B-A-C sequence for 3 period.
3297317|NCT01808300|Experimental|C-A-B|Drug will be administered to according to C-A-B sequence for 3 period.
3297318|NCT01808300|Experimental|C-B-A|Drug will be administered to according to C-B-A sequence for 3 period.
3297319|NCT01808352|Other|Daily PrEP + coordination of client centered svs|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
3297320|NCT01808365||Study cohort|
3297321|NCT01808378|Experimental|Autologous Stem Cells|Autologous expanded adipose-derived stem cells
3297322|NCT01808391||Clinical Follow-up Cohort|The clinical FU cohort comprises among patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who arbitrarily underwent angiographic FU at 22 months (±60 days) after index PCI and those who did not undergo angiographic follow-up at all during the entire study period.
3297323|NCT01808391||Routine Angiographic Follow-up Cohort|The routine angiographic FU cohort comprises patients who underwent clinical FU at 9, 12, and 24 months after index PCI those who undergo angiographic FU at 10 months (±60 days) after index PCI.
3297324|NCT01808404|Experimental|Web-Based Guided Self-Help|The study is an open trial and all participants will be assigned to the same intervention arm.
3297325|NCT01808417|Experimental|Near Infrared Imaging|The intervention to be administered is the indocyanine green for NIR Lymphatic Mapping. All study subjects will receive this same intervention; there is only one arm.
3297326|NCT01808430||VATS for NSCLC patients|VATS for confirmed non-small cell lung cancer (NSCLC)
3297327|NCT01808443|Active Comparator|Cryotherapy|Cryotherapy, at most 4 times
3297328|NCT01808443|Experimental|laser|laser, at most 4 times
3297329|NCT01808456|Experimental|High Dose Flu Vaccine|influenza trivalent inactive vaccine high dose. IM (intramuscular) injection one time administration
3297330|NCT01808456|Active Comparator|Flu Vaccine|influenza trivalent inactive vaccine IM injection one time administration
3297331|NCT01808469|Experimental|NI-0101|NI-0101 is an anti-Toll-like receptor monoclonal antibody.
3297332|NCT01808469|Placebo Comparator|Placebo|The placebo to be used for the proposed clinical trial is a sterile solution for intravenous infusion. The placebo is identical to the NI-0101 drug product but does not include the active substance.
3297333|NCT01808482|Experimental|Part A: GSK2618960|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session.
3297334|NCT01808482|Placebo Comparator|Part A: Placebo|Subjects will receive ascending single dose in 3:1 ratio of active:placebo respectively in each dosing session
3297335|NCT01808482|Experimental|Part B: GSK2618960|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
3297336|NCT01808482|Placebo Comparator|Part B: Placebo|Subjects will receive ascending repeat dose (dose decided from Part A) in 3:1 ratio of active:placebo respectively in each cohort.
3297337|NCT01808482|Experimental|Part C: GSK2618960|Subjects will receive active treatments for 2 to 4 repeated doses (dose decided from Part A& B)
3297338|NCT01808521|Experimental|N-acetylcysteine|IV administration of N-acetylcysteine (Acetadote) at 150mg/Kg loading bolus over 60 minutes followed by 150mg/Kg over 17 hours if loading dose was well tolerated.
3297339|NCT01808586|Experimental|Dexamethasone|Intra-articular corticosteroid number 2.
3297340|NCT01808586|Experimental|Betamethasone|Subjects will receive either betamethasone or dexamethasone injected into the cervical facet joints (levels determined by experienced physician).
3297341|NCT01808586|Active Comparator|Intramuscular injection|Subjects in this group will receive lidocaine injection directly into tender myofascial trigger points.
3297342|NCT01808586|Active Comparator|Home exercise|Subjects in this group will receive education and a pamphlet on a set of standardized home exercises for neck pain
3297343|NCT01808599|Experimental|Chlorambucil, Rituximab i.v., Rituximab s.c.|"Chlorambucil 6 mg/m2 daily p.o for 42 consecutive days (weeks 1-6) in combination with intravenous Rituximab 375mg/m2 on days 1, 8, 15 and 22 (day 1 of weeks 1, 2, 3 and 4).~Starting from d56, (month 3) patients will receive Chlorambucil 6 mg/m2 daily p.o for 14 consecutive days (d1-14) every 28 days for 4 cycles in combination with subcutaneous Rituximab 1400mg on day 1 of each 28-day cycle. Therefore subcutaneous Rituximab 1400mg every two months for 2 years (in total 12 injections)."
3297344|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 atmospheres absolute(ATA).
3297345|NCT01808638|Other|Lead in safety period|Cohort of three subjects with non-pancreatic cancer for whom conventional treatment options have failed, will be treated. If one of the subjects in the safety cohort experiences an unacceptable toxicity, the safety cohort is expanded to six subjects.
3297346|NCT01808638|Experimental|Treatment arm 1|Subjects with advanced pancreatic cancer will be treated.
3297347|NCT01808638|Experimental|Treatment arm 2|Subjects with advanced pancreatic cancer will be treated.
3297348|NCT01808664|Experimental|Standardized Patient Instructor Intervention|"Primary care physicians (PCPs) randomized to intervention will receive over a three month run-in period two visits by standardized patient instructors portraying: 1) a 48 year-old patient with low back pain for less than six-weeks and no red flags for immediate spinal imaging; and 2) a 50 year-old recently menopausal woman establishing care with concerns about osteoporosis risk."
3297349|NCT01808664|Active Comparator|Control|"In the latter half of visits with control PCPs, standardized patient instructors (SPIs) will share information regarding low back pain or bone health that are unrelated to diagnostic testing, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
3297350|NCT01808677||Thoracic Reirradiation Registry|Data collection on patients being treated with thoracic reirradiation with PBT or IMRT for NSCLC, with or without chemotherapy.
3297351|NCT01808703|Experimental|Scaling and root planing plus PerioPatch|"All subjects in this group will receive scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam). Thereafter, PeriZone PerioPatch will be dispensed to subjects per randomization for administration over the trial period. Subjects will apply study patches (i.e., BID on Days 1, 28 and 42; QD on Days 2-6; Days 14-20, 29-30 and 43-44) to designated treatment sites (i.e., measuring 6 mm or more in pocket depth at Baseline)."
3297352|NCT01808703|Active Comparator|Scaling and root planing alone|Subjects in this group will receive only scaling and root planing (full mouth during no more than 2 sessions within two weeks following the Baseline exam).
3297353|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) on muscle damage|Effects of low-level laser therapy (LLLT)on muscle damage
3297354|NCT01808716|Active Comparator|Low-level laser therapy (LLLT) placebo on muscle damage|Effects of low-level laser therapy (LLLT) placebo on muscle damage
3297355|NCT01808729||FMD or CAD (as appropriate)|The study group will either have FMD, early onset CAD, or other rare/unusual vascular disorder. These differing disorders will be sub-groups within the overall study
3297356|NCT01808729||Healthy control subjects without vascular disease|Healthy controls will not exhibit signs, symptoms or other evidence of vascular disease.
3297357|NCT01808742||Treatment|Treatment with CryoTouch III device
3297358|NCT01808768|Experimental|Alcaftadine|subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks
3297359|NCT01808781|Experimental|Intervention group|Home exercise program plus walking program during 8-week period
3297360|NCT01808781|Active Comparator|Comparison group|Walking only program throughout the 8-week period.
3297361|NCT01808807||cesarean section rate after audit|cesarean section rate after audit
3297364|NCT01808833||Frail patients|
3297365|NCT01808833||Non-frail patients|
3297366|NCT01808846||Lean Adolescents|Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results
3297367|NCT01808846||Obese Insulin Sensitive|Obese Insulin Sensitive Adolescents aged 12-17 with BMI>95th% and whole body insulin sensitivity index > 3.
3297368|NCT01808846||Obese Insulin Resistant Adolscent|Obese Insulin Resistant Adolescents 12-17 with BMI> 95th% and WBISI<1.2.
3297369|NCT01808859|Experimental|Tourniquet|The Torniquet will be inflated to 100 mmHg over systolic pressure just before skin incision. The tourniquet will be deflated when the last stich/agraf is fixed
3297370|NCT01808859|No Intervention|No tourniquet|"The patients operated on in the non-tourniquet group will have the same surgery and surgical technique but without tourniquet~hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks."
3297371|NCT01808872||Heart Failure|
3297372|NCT01808885|Experimental|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
3297373|NCT01808885|Placebo Comparator|placebo|placebo (3 soft capsules, od) will be administered orally for 6 months
3297374|NCT01808898|Experimental|Local anaesthetic|2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
3297375|NCT01808898|Placebo Comparator|Saline|2mls of Normal Saline solution in a 5ml syringe
3297376|NCT01808911|Active Comparator|Bras A|Steroid 1mg/kg/d and Cyclophosphamide 2mg/kg/d
3297377|NCT01808911|Experimental|Bras B|Steroid 1mg/kg/d and Rituximab 375 mg/m2 every week during four weeks
3297378|NCT01808937||Morphea|Those having the condition morphea or other synonymous diagnosis (such as localized scleroderma, linear scleroderma, Parry-Romberg syndrome, en coup de sabre)
3297379|NCT01808976|Active Comparator|Evolution|This app is designed to be a cognitive training game that conditions the CCN. This is done by having participants play a multitasking game that targets their perceptual discrimination abilities, selective attention, and visuomotor tracking skills. At the first session, participants will be directed to an initial assessment of each of these cognitive control skills in a single task and dual-task setting (a total of 3 different diagnostics, described below). Each week, this diagnostic phase will reflect the training paradigm they will encounter for that week, as each week the perceptual and tracking challenges will increase.
3297380|NCT01808976|Experimental|Problem Solving Therapy|This app is based on the social problem solving protocol developed by Nezu and D'Zurilla . The app begins with explaining the PST steps. Participants are informed that they can learn each step one session at a time, or they can chose to learn all the steps at once. After each step completed, participants are asked if they want to continue onto the next step or save it for the next session, thus the app tailors itself to the users ability to absorb new information.
3297381|NCT01808976|Active Comparator|Basic health push app|This app provides daily suggestions for overcoming depressed mood and allows users to track their mood, using the 0-9 scale available for all three apps. In the first app session, participants are given a general education about depression and its known causes and consequences. Participants are told that to overcome mood problems, they must engage in one mood improvement strategy a day and that the app will suggest one to try each day.
3297382|NCT01809002|Experimental|Processed Nerve Allograft|Processed Nerve Allograft
3297383|NCT01809002|Active Comparator|Collagen Nerve Cuff|
3297384|NCT01809015||Cohort A: Regular medical care|Patients treated with vitamin K antagonists in regular medical care system
3297385|NCT01809015||Cohort B: Coagulation service|Patients with oral anticoagulation therapy in a telemedicine-based coagulation service
3297386|NCT01809028|Active Comparator|EUS FNA with 2 passes|biopsy with 2 passes of the needle
3297387|NCT01809028|Active Comparator|EUS FNA with 4 passes|biopsy with 4 passes of the needle
3297388|NCT01809041|Experimental|Sevoflurane & remifentanil|sevoflurane at 0.5 to 1.5 minimum alveolar concentrations plus remifentanil (0.1 - 0.5 µg/kg/min) during the surgery.
3297389|NCT01809041|Active Comparator|propofol & remifentanil|propofol (50 - 150 µg/kg/min) and remifentanil (0.1 - 0.5 µg/kg/min)
3297390|NCT01809067|Active Comparator|Lavender Aromatherapy Inhalers|Lavender Aromatherapy Inhalers
3297391|NCT01809067|No Intervention|No aromatherapy|No aromatherapy
3297392|NCT01809080||2020|
3297393|NCT01809080||2019|
3297394|NCT01809080||2018|
3297395|NCT01809080||2017|
3297396|NCT01809080||2016|
3297397|NCT01809080||2015|
3297398|NCT01809080||2014|
3297399|NCT01809080||2013|
3297400|NCT01809080||2012|
3297401|NCT01809080||2011|
3297402|NCT01809080||2010|
3297403|NCT01809080||2009|
3297404|NCT01809080||2008|
3297405|NCT01809080||2007|
3297406|NCT01809080||2021|
3297407|NCT01809093||Blood draw|Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.
3297408|NCT01809119|Experimental|Laparoscopic Partial Nephrectomy|Patients with kidney neoplasms submitted to laparoscopic partial nephrectomy
3297409|NCT01809119|Active Comparator|Open Partial Nephrectomy|Patients with kidney neoplasms submitted to open partial nephrectomy
3297410|NCT01809145|Other|metal hypersensitivity|peripheral blood test for metal hypersensitivity (MELISA test)
3297411|NCT01809158|Active Comparator|minocycline|Subjects randomized to the minocycline group will take 2 tablets per day, each 100mg of minocycline, for a total daily dose of 200mg of minocycline.
3297412|NCT01809158|Placebo Comparator|placebo|Subjects randomized to the placebo group will take 2 tablets of placebo (matched for minocycline) per day.
3297413|NCT01809171|Experimental|vitamin D3|1000 mg Ca2+/800IU vitamin D3 daily + 25 000IU vitamin D3 weekly during 6 months
3297414|NCT01809171|Placebo Comparator|Placebo|1000 mg Ca2+/ 800IU vitamin D3 daily + 25000IU placebo every week during 6 months
3297415|NCT01809184|Experimental|Dose level 1|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297416|NCT01809184|Experimental|Dose level 2|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297417|NCT01809184|Experimental|Dose level 3|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297418|NCT01809184|Experimental|Dose level 4|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297419|NCT01809184|Experimental|Dose level 5|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297420|NCT01809184|Experimental|Dose level 6|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297421|NCT01809184|Experimental|Dose level 7|Each subject will be randomly assigned to receive either insulin 287, placebo or insulin glargine within the dose group.
3297422|NCT01809223|Experimental|conbercept treatment group|Subjects will receive conbercept injections at a dose of 0.5 mg/eye, once a month for first 3 months. In the next 6 months, the investigator will decide whether repeat injections are needed base on the monthly assessment results.
3297423|NCT01809223|Sham Comparator|sham injection group|Subjects will receive sham injections monthly for 3 months and will receive 0.5 mg/eye conbercept at month 4. The investigator will decide whether repeat injections are needed base on the monthly assessment results from month 5 to month 9.
3297424|NCT01809236|Experimental|0.5 mg Conbercept|patients will receive monthly intravitreal injections of Conbercept to month 3 (total 3 times) and then on an as needed (PRN) dosing schedule based on the pre-specified retreatment criteria till to month 9.
3297425|NCT01809275|Experimental|QBECO|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
3297426|NCT01809275|Placebo Comparator|Placebo|Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
3297428|NCT01809301|Active Comparator|Niaspan|Single dose of one NIASPAN® 1000 mg Extended-Release Tablet following dinner
3297429|NCT01809301|Experimental|TRIA-662|Single dose of two TRIA-662, 500 mg Immediate-Release Tablets following dinner
3297430|NCT01809340|Experimental|Minocycline|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive oral minocycline twice daily for up to 6 weeks in a blinded manner. In addition, non-responders may receive oral minocycline twice daily for up to 6 weeks in an open-label manner.
3297431|NCT01809340|Placebo Comparator|Placebo|Following a 12-day open-label treatment phase (involving ketamine and minocycline), responders may receive placebo twice daily for up to 6 weeks in a blinded manner
3297432|NCT01809340|Experimental|Ketamine and Minocycline|All patients will receive 6 IV infusions of ketamine and oral minocycline twice daily during a 12-day open-label treatment phase
3297433|NCT01809353|Experimental|Group A: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
3297434|NCT01809353|Experimental|Group A: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
3297435|NCT01809353|Experimental|Group A: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
3297436|NCT01809353|Placebo Comparator|Group A: Placebo|Each participant will receive matching placebo as a single intravenous dose.
3297437|NCT01809353|Experimental|Group B: JNJ-54452840 20 mg|Each participant will receive 20 mg of JNJ-54452840 as a single intravenous dose.
3297438|NCT01809353|Experimental|Group B: JNJ-54452840 80 mg|Each participant will receive 80 mg of JNJ-54452840 as a single intravenous dose.
3297439|NCT01809353|Experimental|Group B: JNJ-54452840 240 mg|Each participant will receive 240 mg of JNJ-54452840 as a single intravenous dose.
3297440|NCT01809353|Placebo Comparator|Group B: Placebo|Each participant will receive matching placebo as a single intravenous dose.
3297441|NCT01809366|Experimental|seminal plasma insemination|seminal plasma insemination
3297442|NCT01809366|Placebo Comparator|culture medium insemination|culture medium insemination
3297443|NCT01809379|Experimental|intraperitoneal chemotherapy|Intraperitoneal chemotherapy with cisplatin at a dose of 7.5 mg/m2 body surface in a 150 ml NaCl 0.9% and doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution with a flow of 30 ml/min and a max upstream pressure of 200 psi.
3297444|NCT01809392|Experimental|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
3297445|NCT01809392|No Intervention|no decitabine|
3297446|NCT01809418|Experimental|keePAP|
3297447|NCT01809431|Experimental|intervention|Breastfeeding, progression to type 2 diabetes, nutrition, and exercise education, coping skills training, exercise training, a home-based exercise program and educational and motivational text messaging.
3297448|NCT01809431|No Intervention|Wait-listed control group|Wait-listed control group receive usual care delivered by their health care provider and after completion of their time in the study they are offered the intervention
3297449|NCT01809444|Active Comparator|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks.
3297450|NCT01809444|Experimental|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg/d for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
3297451|NCT01809457|Experimental|educational poster|poster display for 2 weeks in classrooms,
3297452|NCT01809457|No Intervention|control|no intervention, waiting for two weeks
3297453|NCT01809470|Experimental|Watching TV|Watching TV (comedy, 'Friends') for 1 hour
3297454|NCT01809470|Experimental|FIFA2013|Playing the video game 'FIFA2013' for 1 hour
3297455|NCT01809470|Experimental|Call of Duty|Playing the video game 'Call of duty' for 1 hour
3297456|NCT01809483|Experimental|Bandage contact lens group|subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and bandage contact lens. Bandage contact lenses maintained for 24 hours. Antibiotic eye drops were instilled without removing the contact lenses
3297457|NCT01809483|Active Comparator|Pressure patching group|Subject received antibiotic eye drops (combination of Polymyxin B, neomycin and gramicidin, q.i.d), and cycloplegic eye drops (tropicamide 0,5 %, q.d) and pressure patching. Pressure patching maintained for 24 hours and only opened for drug application. Subject and their families were educated on how to perform a good pressure patching
3297458|NCT01809496|Active Comparator|Informational counseling, patient only|The purpose of this experimental group is to evaluate the effectiveness of informational counseling alone. This type of counseling is considered the standard of care in audiologic practice. Patients in this will review this material in detail with a member of the study team for approximately 30 minutes at the second visit. Spouses in this experimental group will be will review material regarding VA services with a member of the study team for about 30 minutes.
3297459|NCT01809496|Experimental|Informational Counseling, couples|The purpose of this experimental group is to evaluate the influence of spousal involvement when receiving informational counseling. In this manner, both patients and spouses are presented with the same information regarding hearing loss and hearing aids. Couples in this experimental group will be given the same information that the patients in the first group were given. At the second visit, couples in this group will review this information together with a member of the research team for approximately 30 minutes.
3297460|NCT01809496|Experimental|Patient Centered Counseling,patient only|In order to assess the effects of enhanced patient-centered counseling (PCC), the patients assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. In addition to the PCC techniques used in audiology, this counseling also will involve the core components of motivational interviewing. These principles and methods will be used to allow the patient to clearly express his/her expectations of, concerns about, and motivations for hearing-aid use. The spouses in this experimental group will be given information regarding VA services. This material will be reviewed with a member of the research team for about 30 minutes at the second visit.
3297461|NCT01809496|Experimental|Patient Centered Counseling, couples|In order to assess the influence of the spouse on the enhanced PCC process, the couples assigned to this group will meet together with either Dr. Lewis or the Research Audiologist for approximately 30 minutes of counseling. This counseling will be conducted with both the patient and the spouse together, giving both partners time to express their thoughts.
3297462|NCT01809522|Experimental|Posterior reconstruction of the musculofascial plate|These patients will receive reconstruction of the muscolofascial plate after radical prostatectomy. The reconstruction will be performed using two 3-0 Poliglecaprone sutures (on RB-1 needles) tied together, with each individual length being 12-15 cm. seven - Ten knots will be placed when tying the sutures to provide a bolster. The free edge of the remaining Denonvillier's fascia will be identified after the prostatectomy and approximated to the posterior aspect of the rhabdosphincter and the posterior median raphe using one arm of the continuous suture. As a rule, four passes will be taken from the right to the left and the suture is locked. The second layer of the reconstruction will be then performed with the other arm of the suture approximating the posterior lip of the bladder neck (full thickness) and the vesicoprostatic muscle to the posterior urethral edge and to the already reconstructed median raphe .This suture will be then tied to the end of the first suture arm.
3297463|NCT01809522|No Intervention|Standard radical prostectomy|
3297464|NCT01809535|Experimental|The Monthly EVL|Patients in the Monthly group were received EVL at 28-day treatment intervals.
3297465|NCT01809535|Active Comparator|The Biweekly EVL|Patients in the Biweekly group received repeating EVL every 2 weeks.
3297466|NCT01809548|Experimental|Early complementary feeding group|"Early intervention group:~Introduction of early complementary feedings between the 10th -12th week of gestation corrected for prematurity"
3297467|NCT01809548|Experimental|Late complementary feeding group:|"Late intervention group:~Introduction of late complementary feedings between the 16th and 18th week of life corrected for prematurity"
3297468|NCT01809561||endometriosis|The study group will consist of women with suspected endometriosis facing surgical treatment
3297469|NCT01809561||no endometriosis|The control group will consist of healthy women facing gynecologic surgery for different indication
3297470|NCT01809587|Experimental|IQP-PO-101|Day 1 to Day 7 - 1 sachet to be mixed in 250ml of water and consumed twice a day Day 8 to Day 28 - 1 sachet to be mixed in 250ml of water and consumed once a day Day 28 to Day 42 - no investigational product intake (post treatment observation only)
3297471|NCT01809600||Patients with Burkitt's Lymphoma|should be diagnosed pathologically by WHO 2008 criteria
3297472|NCT01809613||Deep Brain Stimulation|Functional Magnetic Resonance Imaging (fMRI) will be performed to determine the areas of BOLD signal modulation with DBS.
3297473|NCT01809626|Experimental|Zolpidem (10 mg)|Oral administration of the drug zolpidem (Ambien)
3297474|NCT01809626|Placebo Comparator|Gelatin capsule|Oral administration of a placebo pill that is packaged identically to the active condition.
3297475|NCT01809652|Experimental|Remote Implant Support|Implant supported through remote implant support capability
3297476|NCT01809665||ICD/CRT-P therapy|Standard indication for ICD or triple-chamber pacemaker therapy
3297477|NCT01809678|Experimental|Smoking Cessation plus Yoga|Twice weekly, 1-hour yoga classes delivered for 8 weeks combined with once-weekly, 1-hour cognitive-behavioral smoking cessation classes.
3297478|NCT01809678|Active Comparator|Smoking Cessation plus Wellness|Twice-weekly, 1-hour Wellness classes given on a variety of health topics twice weekly to match schedule of the yoga classes, plus 1-hour per week of cognitive-behavioral smoking cessation
3297479|NCT01809691|Experimental|ADT + TAK-700|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~TAK-700, 300 mg, PO, twice daily"
3297480|NCT01809691|Active Comparator|ADT + Bicalutamide|"LHRH agonist - given as approved for androgen deprivation at a dose necessary to maintain castrate levels and equivalent to 22.5 mg of Leuprolide IM every 3 months.~Bicalutamide, 50 mg, PO, q daily"
3297484|NCT01809717|Experimental|Weight Lifting Exercises|
3297485|NCT01809730||Cardiovascular risk|patients with CV disease
3297486|NCT01809743|Active Comparator|Regadenoson central - peripheral|First bolus regadenoson administered central, second bolus administered peripheral
3297487|NCT01809743|Active Comparator|Regadenoson peripheral - central|First bolus regadenoson administered peripheral, second bolus administered central
3297488|NCT01809743|Active Comparator|Regadenoson central - central|First bolus regadenoson administered central, second bolus administered central
3297489|NCT01809743|Active Comparator|Regadenoson peripheral - peripheral|First bolus regadenoson administered peripheral, second bolus administered peripheral
3297490|NCT01809756|Active Comparator|Caphosol|
3297491|NCT01809756|No Intervention|No intervention|
3297492|NCT01809769|Experimental|Mesenchymal stem cells low-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 1 x 10 E7 cells (3 ml), Frequency: 0,3 weeks.
3297493|NCT01809769|Experimental|Mesenchymal stem cells mid-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage: 2 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
3297494|NCT01809769|Experimental|Mesenchymal stem cells high-dose group|Biological: Mesenchymal progenitor cells. Administrated for intra-articular use. Dosage:5 x 10 E7 cells (3 ml). Frequency: 0,3 weeks.
3297495|NCT01809782||Study group:20 patients undergoing two stage liver-operation|Patients undergo two liver operations.First surgery: insitu-split for induction of proliferation in the remaining liver tissue; Second surgery: resection of the liver Tumor (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
3297496|NCT01809782||Control group: 20 patients (ASA class II/III)|Relatives from study personel or patients from outpatient clinics from Charité in Berlin and surrounding area (4 cognitive measurements: Baseline, 7 days, 3 months and 1 year)
3297497|NCT01809795|Experimental|Blueberry Smoothie|Participants in this group will receive a smoothie containing 1 1/2 cups of freeze-dried whole blueberries crushed into a powder.
3297498|NCT01809795|Sham Comparator|Sham Smoothie|Participants in this group will receive a smoothie that contains no blueberries.
3297499|NCT01809808||Acromegaly Subjects|People who have a biochemical diagnosis of acromegaly, and will or have already undergone surgery for acromegaly and will be taking medications for acromegaly . Subjects will undergo blood sampling, metabolic rate measurement, adipose tissue biopsy and total body magnetic resonance imaging before and over time after either surgery or medical therapy for acromegaly.
3297500|NCT01809808||Healthy Subjects|People who are not diagnosed with acromegaly, responding to flyer or by word of mouth for participation, without medical problems, not taking medications, and with a stable weight for 3 months prior to study. Subjects will undergo blood sampling, total body MRI and adipose tissue biopsy once.
3297501|NCT01809821|Experimental|Online Sleep Education|The sleep intervention is a multi-component online intervention consisting of sleep information and sleep hygiene education, along with behavioural and cognitive components.
3297502|NCT01809821|No Intervention|Usual CV care|Specialist nurses will administer the CV risk factor education intervention to participants in small groups over one hour.
3297503|NCT01809847|Experimental|Ofatumumab|First dose of 300 mg Ofatumumab followed by seven weekly infusions of 2000 mg. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
3297504|NCT01809860|Experimental|isavuconazole and sirolimus|Single dose of sirolimus on Days 1 and 26, isavuconazole 3 times a day (TID) for 2 days (Days 22 to 23) followed by once a day (QD) for 11 days
3297505|NCT01809873|Experimental|Performance based incentives|Performance based incentives: The Incentive arm will receive monthly visits and external quality assurance of malaria diagnostic accuracy, identical to the comparison. Incentive arm will also receive quarterly incentives linked to performance of the facility around six indicators of appropriate malaria case management
3297506|NCT01809873|No Intervention|Comparison|The comparison arm will receive monthly visits and monthly external quality assurance of malaria diagnostic accuracy.
3297507|NCT01809886|Experimental|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
3297508|NCT01809886|Active Comparator|Neostigmina|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
3297509|NCT01809912|Experimental|Greenstatin|"Cohort 1 : 6 mg/m2 Cohort 2 : 12 mg/m2 Cohort 3 : 24 mg/m2 Cohort 4 : 48 mg/m2 Cohort 5 : 96 mg/m2 Cohort 6 : 192 mg/m2 28 Day Course Subjects will receive MG1102 (Recombinant human apolipoprotein(a) Kringle V ) by IV administration on Day 0. If no DLTs are observed during the 6 days following the initial infusion, the same dose will be administered once daily for 5 consecutive days followed by a 2-day rest period three times (over 21 days), completing the course on Day 27.~Additional 21 Day Courses In the absence of a DLT, and in the case of stable disease or better, a subject may continue to receive MG1102 (Recombinant human apolipoprotein(a) Kringle V~) on a compassionate use basis at the same dose and regimen ."
3297510|NCT01809925|Experimental|psyllium fiber 6.8g|Two (2) packets Metamucil Orange Sugar Free Fiber Singles (psyllium 6.8 g) thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
3297511|NCT01809925|Placebo Comparator|placebo|One (1) level teaspoon of placebo product thoroughly mixed in Ten (10) ounces of water. Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
3297512|NCT01809951||Isomil Advance with LCP|4 spoonful of Isomil Advance with LCP in 240 mL of water, 4 times a day
3297513|NCT01809964|Experimental|Dose 1|ANT-1401
3297514|NCT01809964|Experimental|Dose 2|ANT-1401
3297515|NCT01809964|Placebo Comparator|Vehicle|Placebo Vehicle
3297516|NCT01809977|Other|total removal|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
3297517|NCT01809977|Other|partial removal|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
3297518|NCT01809990|Experimental|internet-delivered cognitive behavior therapy|Participants will be assigned to a 12 weeks internet-delivered cognitive behavior therapy program including therapist contact via an internet platform and telephone.
3297519|NCT01810003|Experimental|High DHA|High DHA supplementation (3g/day)
3297520|NCT01810003|Experimental|High EPA|EPA supplementation (3g/day)
3297521|NCT01810003|Placebo Comparator|Placebo|Placebo (3g corn oil/day)
3297522|NCT01810029|Experimental|Cardiac Rehabilitation plus Transcendental Meditation|a standard validated cardiac rehabilitation program plus a standard validated stress reduction component, the Transcendental Meditation program
3297523|NCT01810029|Active Comparator|Cardiac Rehabilitation|This control is a standard Cardiac Rehabilitation without a stress reduction technique
3297524|NCT01810068|Sham Comparator|Placebo|patients who are undergoing diagnostic cystoscopy
3297525|NCT01810068|Active Comparator|HOLEP|Holmium laser enucleation of the prostate
3297526|NCT01810068|Active Comparator|monopolar TURP|Monopolar transurethral resection of the prostate
3297527|NCT01810068|Active Comparator|Bipolar TURP|Bipolar transurethral resection of the prostate
3297528|NCT01810081||cholecystectomy|cholecystectomy group: H.Pylori infection in gall bladder
3297529|NCT01810094||Minimally invasive Approach|Patients with a thoracolumbar Fracture A3.1 to A 3.3 treated by fracture fixation by a minimally invasive approach
3297530|NCT01810107||Children Examined with the OCT Probe|Children undergoing surgery will also have the Optical Coherence Tomography probe.
3297531|NCT01810107||Adults|Adults undergoing surgery will also have the Optical Coherence Tomography probe.
3297532|NCT01810120|Experimental|TCR alfa beta depleted graft, infusion|The leukapheresis product will undergo TCR alfa beta negative selection following the standardized protocol.
3297533|NCT01810133||Anesthesia patients|All patients undergoing general anesthesia between January 2006 and December 2011 in Charité - University Berlin
3297534|NCT01810146|No Intervention|Digestive functions investigations|Results from digestive functions investigations will be compared between patients eligible for bariatric surgery (BMI>40kg/m2) and volunteers (BMI between 20 and 25kg/m2).
3297535|NCT01810159|Experimental|ICC|Integrated collaborative care
3297536|NCT01810159|Active Comparator|E&R|Education and Resources--enhanced usual care
3297537|NCT01810172|Active Comparator|Dry suction pleural drainage system|The control group will have their chest tube connected to a dry suction pleural drainage system The intervention will be the dry suction pleural drainage system
3297538|NCT01810172|Experimental|Digital pleural drainage system|The experimental group will have their chest tube connected to a digital pleural drainage. The intervention will be the digital pleural drainage system.
3297539|NCT01810185|Experimental|Low dose naltrexone|Subjects in this arm will recieve low dose naltrexone (4.5 mg) daily for 12 weeks.
3297540|NCT01810185|Placebo Comparator|Placebo|Subjects in this arm will recieve a placebo daily for 12 weeks.
3297541|NCT01810198|Active Comparator|Cardiac CT|Patients who undergo Cardiac CT (instead of Invasive Coronary Angiography)
3297542|NCT01810198|Active Comparator|Invasive Coronary Angiography|Patients did not undergo Cardiac CT, went straight to Invasive Coronary Angiography
3297543|NCT01810211|Experimental|Horizontal Adduction Stretch and Pendulums|"Horizontal Adduction Stretch- Individual standing with their operative scapula against a wall and rotating toward the side to be stretched to stabilize scapula and the operative arm is relaxed. The opposite hand is placed under the elbow of the involved extremity and assists the operative shoulder into horizontal adduction attempting to bring the hand to the opposite shoulder.~Pendulum -Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
3297544|NCT01810211|Experimental|Modified Sleeper Stretch and Pendulum|"Modified Sleeper Stretch: Individual in supine with operative shoulder abducted to approximately 45 degrees and elbow at 90 degrees of flexion with neutral rotation of the glenohumeral joint. The individual then places other hand on the wrist of the involved extremity and passively moves the glenohumeral joint into internal rotation.~Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction."
3297545|NCT01810211|No Intervention|Pendulum Exercise|Pendulum Exercise: Individual leans over with support from uninvolved extremity placed on an immovable object while involved extremity is relaxed. The individual than rotates their hips in order to allow the involved extremity to create small circles passively in a clockwise direction.
3297546|NCT01810224|Active Comparator|Angio-guided arm|In this arm will be included the patient randomized to a Angiography-guided surgical revascularization strategy.
3297547|NCT01810224|Experimental|FFR-guided arm|In this arm will be included the patient randomized to a FFR-guided surgical revascularization strategy.
3297548|NCT01810237|Experimental|Dabigtran instead of LMWH for perioperative bridging.|
3297549|NCT01810250||Abdominal Aortic Aneurysm (Challenging anatomy)|Endovascular aneurysm repair
3297550|NCT01810276|Placebo Comparator|Saline|400 mL of Saline will be given intravenously over 2 hours once.
3297551|NCT01810276|Active Comparator|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
3297552|NCT01810315|No Intervention|Baseline|Premenopausal women will undergo baseline sampling in each the follicular and luteal phase. Postmenopausal women will undergo baseline sampling one time.
3297553|NCT01810315|Experimental|TFV 1% Gel|"Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel.~Premenopausal women will undergo sampling after TFV gel use in each the follicular and luteal phase. Postmenopausal women will undergo sampling after TFV gel use one time."
3297554|NCT01810315|Experimental|Estradiol Vaginal Cream|Post menopausal women only: Participants will insert 2 grams of estradiol cream into the vagina every night for 14 days and then one gram of estradiol cream into the vagina every other night
3297555|NCT01810315|Experimental|TFV 1% gel and estradiol cream|Postmenopausal women only: Participants will vaginally insert 1 applicator of TFV gel followed by a 2nd applicator 2 hours later. Each applicator contains 4.4 gm of TFV 1% gel. In addition, participants will one gram of estradiol cream into the vagina every other night.
3297556|NCT01810328|Active Comparator|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
3297557|NCT01810328|Active Comparator|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
3297558|NCT01810341||Development Group|In the Development Phase, analyses will be performed until the classification algorithm is finalized.
3297559|NCT01810341||Validation Group|The Validation Phase will assess the performance of the finalized classification algorithm in 300 subjects.
3297560|NCT01810354|Experimental|Two grams cefazolin|Two grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
3297561|NCT01810354|Active Comparator|Three grams cefazolin|Three grams of cefazolin will be given by intravenous bolus zero to 60 minutes prior to the start of the cesarean section.
3297562|NCT01810367|Experimental|ABX Combined With Cisplatin|ABX，100mg/m2，d1、8、15，ivgtt,in 30 min，28day one cycle； cisplin 75mg/m2 d1 ivgtt
3297563|NCT01810367|Active Comparator|Gemcitabine Combined With Cisplatin|gemcitabine 1000mg/m2，d1、8；cisplatin 75mg/m2 d1 ivgtt,3 weeks one cycle.
3380071|NCT04991974|Experimental|Patient Navigation + Buprenorphine Initiation (PN+BUP)|The PN+BUP Arm will include all PN Arm services, with the addition of meeting with the sexual health clinic's buprenorphine-waivered provider (typically a nurse practitioner) to initiate buprenorphine treatment, as a bridge until successful transfer to OUD treatment in the community. The standard buprenorphine bridge prescription will be for buprenorphine/naloxone film: 8/2mg, up to 16mg per day, 7 day supply.
3297564|NCT01810393|Experimental|Trastuzumab IV Then Trastuzumab SC|Participants will receive treatment with Trastuzumab IV for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab SC for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
3297565|NCT01810393|Experimental|Trastuzumab SC Then Trastuzumab IV|Participants will receive treatment with Trastuzumab SC for the first 3 cycles (cycle length = 21 days) followed by Trastuzumab IV for the next 3 cycles. Participants will continue receiving treatment with trastuzumab SC for another 12 cycles (if SC treatment is well tolerated, otherwise participants will continue IV treatment) for a total of 18 cycles of treatment during the study.
3297566|NCT01810406|Experimental|Epidural Volume Extension|CSE with 10 ml EVE
3297567|NCT01810406|Active Comparator|No Epidural Volume Extension|CSE without EVE
3297568|NCT01810419|Experimental|normal and various degrees splenomegaly|"Vscan Ultrasound (GE Healthcare, USA) Conventional Ultrasound (Ultrasonix) used to determine spleen size Crossover design, all subjects will be measured with both devices. half will have the handheld done first, then conventional half the Conventional done first, then handheld~Will complete questionaire for both:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
3297569|NCT01810445||1|Patients undergoing a surgical bladder procedure in the main O.R.
3297570|NCT01810458||AATD ZZ and Rare Alleles Group|Participants will get a history and physical (H&P) and have an intravenous catheter (IV) placed, for blood draws, at the screening and years 1-3 visits. An IV will also be placed at the liver biopsy visit(s) for the administration of medication. An abdominal ultrasound will be done at the screening and year 3 visits along with the completion of a liver questionnaire. Finally, participants will have a liver biopsy done, with the use of lidocaine, lorazepam, or midazolam and fentanyl, after the screening visit and potentially at the year 3 study visit, depending on the results of the first liver biopsy. Participants who experience pain after the liver biopsy may receive acetaminophen or oxycodone/acetaminophen. Any subject experiencing nausea may receive ondansetron.
3297571|NCT01810471|Experimental|ankle supports|
3297572|NCT01810484|Active Comparator|Group 1|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment only; Treatment Area B will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area C will be treated with CO2 laser treatment only"
3297573|NCT01810484|Active Comparator|Group 2|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with Ultherapy® treatment and CO2 laser treatment; Treatment Area B will be treated with CO2 laser treatment only; Treatment Area C will be treated with Ultherapy® treatment only"
3297574|NCT01810484|Active Comparator|Group 3|"The abdominal region will be divided into 3 treatment areas: Treatment Area A, B and C.~Treatment Area A will be treated with CO2 laser treatment only; Treatment Area B will be treated with Ultherapy® treatment only; Treatment Area C will be treated with Ultherapy® treatment and CO2 laser treatment"
3297575|NCT01810497|Active Comparator|Seven-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for seven days after otoplasty
3297576|NCT01810497|Active Comparator|Thirty-day bandage use|Patients randomized and instructed to use of ear bandage 24h/day for thirty days after otoplasty
3297577|NCT01810510|Experimental|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
3297578|NCT01810510|Experimental|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
3297579|NCT01810523|Experimental|Narrative|This arm will receive information regarding leg injuries and X-ray usage in narrative form in addition to standard of care discharge information.
3297580|NCT01810523|Placebo Comparator|Control|This arm will receive a blank piece of paper in addition to the standard of care discharge information.
3297581|NCT01810536|Experimental|Hi-flow nasal cannula|This group will receive supplemental oxygen by nasal cannula using the Optiflow system, with high flows of 100% humidified oxygen
3297582|NCT01810536|Active Comparator|Venturi mask|This group will receive supplemental oxygen by the current standard in our Institution: Venturi masks
3297583|NCT01810549|Active Comparator|Anakinra|Anakinra 100mg. Every subject will receive one subcutaneous injection of study drug once during the study, a total of one injection.
3297584|NCT01810549|Placebo Comparator|Placebo|Every study participant will receive a single subcutaneous injection of Placebo once during the study, a total of one injection.
3297585|NCT01810562|Experimental|Specific treatment + std stroke care|Specific treatment in addition to standard stroke care
3297586|NCT01810562|No Intervention|Std stroke care|Patients receive only standard stroke treatment and no specific treatment.
3297587|NCT01810575|Active Comparator|WC3036-11F/Alprostadil in Vehicle 2.5%|Treatment A
3297588|NCT01810575|Experimental|WC3036-12F/Alprostadil in Vehicle 0.5%|Treatment B
3297589|NCT01810575|Placebo Comparator|WC3036-13P/Vehicle Only 0.5%|Treatment C
3297590|NCT01810588|Experimental|All Patients|"Haplo-cord transplantation:~All subjects will receive a conditioning regimen of chemotherapy prior to stem cell transplantation. No experimental drugs are used in this study, and the combinations of drugs that will be used in the conditioning regimen are combinations that have been used in the past.~For the transplant component of treatment, subject will receive umbilical cord blood. The study involves transplantation of unlicensed units of cord blood. Therefore, these are considered investigational products.~In addition to the umbilical cord blood unit, recipients will receive stem cells from a family member ( a haplo-identical donor). After collection and prior to infusion, these cells will be purified using a device called a CliniMACS CD34 selection device."
3297591|NCT01810601|Experimental|Ultrasound guided embryo transfer|GnRh, HMG, HCG, Progesterone 45 patients had ultrasound guided embryo transfer during ICSI
3297592|NCT01810601|Placebo Comparator|clinical touch technique|GnRh, HMG, HCG, Progesterone 45 patients had embryo transfer using clinical touch technique during ICSI
3297593|NCT01810614|Experimental|ADPKD Diet|All study participants will follow their regular diet for 8 days. After that, they will be asked to follow the ADPKD diet for a total of 4 weeks.
3297594|NCT01810627||MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
3297595|NCT01810640|No Intervention|Control|In this group a liver biopsy will not be performed. All management would be as per standard of practice
3297596|NCT01810640|Active Comparator|Percutaneous liver biopsy|In this group a percutaneous biopsy of the liver will be performed prior to organ recovery
3297597|NCT01810653|Experimental|Macrogol (Transipeg)|
3297598|NCT01810653|Active Comparator|Macrogol (Forlax)|
3297599|NCT01810679|Experimental|Perceval S Aortic Heart Valve|Treatment with the Perceval S Aortic Heart Valve
3297600|NCT01810705|Experimental|GRASPA|"patients will receive one injection of GRASPA (100 IU/kg) after each course of low-dose cytarabine (see Arm Control)"
3297601|NCT01810705|No Intervention|Control|patients will receive successive courses of low intensive chemotherapy, as subcutaneous low-dose cytarabine 20mg twice daily for 10 days per course (from day 1 to day 10), each course occurring every 28 days, for a duration up to 24 months
3297602|NCT01810718|Experimental|Nilotinib|"3 patients (pts) will receive Nilotinib 200 mg daily dose. If no dose-limiting toxicity, the next 3 pts will be treated with next dose of Nilotinib 300 mg daily dose.~Doses will not be escalated beyond 600 or below 200 mg/die. The dose estimated as the MTD in phase I will be used for phase II."
3297603|NCT01810731|Experimental|Quadrivalent Influenza Vaccine (QIV)|"15µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 0.5mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
3297604|NCT01810731|Active Comparator|Inactivated Polio Vaccine|A sterile suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF1) and Type 3 (Saukett). This vaccine is prepared from types 1, 2 and 3 of poliomyelitis virus cultured on Vero cells, purified and then inactivated by formaldehyde and administered as a 0.5ml intramuscular or subcutaneous injection. A single dose of vaccine will be administered upon enrollment.
3297605|NCT01810731|Experimental|Double Dose QIV|"30µg of each of 2 influenza A strains (H1N1 and H3N2) and 2 influenza B strains in a buffer solution totaling 1.0mL which is administered intramuscularly.~Administered as a single dose on the day of enrollment."
3297606|NCT01810744|Other|metastatic colorectal cancer|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
3297607|NCT01810744|Other|glioblastoma|Patients treated by bevacizumab will be follow up by capillaroscopy and blood pressure measurements.
3297608|NCT01810757|Active Comparator|Standard planning|Standard planning radiotherapy
3297609|NCT01810757|Experimental|Adaptive planning|Adaptive planning radiotherapy
3297610|NCT01810770|Experimental|Radium-223 dichloride|
3297611|NCT01810796|Experimental|Ranolazine treatment|Ranolazine 500-1000mg bid
3297612|NCT01810796|Placebo Comparator|Placebo|Placebo
3297613|NCT01810809|Active Comparator|Articular Lavage|Patients from Group Zero will receive articular lavage with saline injection
3297614|NCT01810809|Experimental|Group 1|Patients from Group 1 will receive articular lavage with saline injection and viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
3297615|NCT01810809|Experimental|Group 2|Patients from Group 2 will receive articular lavage with saline injection and viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
3297616|NCT01810809|Experimental|Group 3|Patients from Group 3 will receive articular lavage with saline injection and viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
3297617|NCT01810822||Genesis French-Belgium Study|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 501 patients, including 279 individuals (55.7%) with diagnosis of diabetic nephropathy.
3297618|NCT01810822||GENEDIAB|Cross-sectional, multi-center, binational (Belgian and France) study designed to evaluate the genetic components of diabetic nephropathy. It is a cohort with 444 patients, including 310 individuals (69.8%) with diagnosis of diabetic nephropathy.
3297619|NCT01810822||Brazilian cohort|The cohort comprised 451 patients with type 1 diabetes for more than 10 years (56% women; aged 36 ± 11 years, mean ± SD) recruited in diabetes/endocrinology departments of three university hospitals in the cities of São Paulo (SP), Campinas (SP) and Porto Alegre (RS), Brazil.
3297620|NCT01810848|Active Comparator|Hylan G-F 20|Patients will receive a single injection of hylan G-F 20 6ml into affected knee. Injections will be performed under fluoroscopic guidance.
3297621|NCT01810848|Sham Comparator|Control|Patients will receive a single sham puncture into the affected knee. Sham punctures will be identical to the treatment injections in all other respects, including duration, use of sterile drapes, sterile preparation, and dimming of the lights. This procedure will include a 22g needle stick through the skin without violating the joint capsule or performing arthrocentesis.
3297622|NCT01810861||Serotype distribution (this is a non-interventional study)|Serotype distribution both in pediatrics and adults (this is a non interventional study)
3297623|NCT01810874|Active Comparator|Transperitoneal|Patients who where randomized to transperitoneal laparoscopic aortic lymphadenectomy.
3297624|NCT01810874|Experimental|Extraperitoneal|Patients who where randomized to extraperitoneal laparoscopic aortic lymphadenectomy.
3297625|NCT01810887|Experimental|Ritonavir and darunavir|Ritonavir will be administered orally twice daily at a dose of 100 milligram (mg) from Day 1-5. Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 mg on Day 3.
3297626|NCT01810900|Experimental|Protescal|Protescal is applied to this arm.
3297627|NCT01810900|No Intervention|non-treatment|
3380072|NCT04990739|Experimental|Part A Dose-Escalation and Part B RP2D Dose-Expansion|"Study has two parts:~Part A Dose-Escalation will evaluate MTB-9655 monotherapy administered in 21 days cycle,and will be conducted in 2 stages (accelerated titration and dose-escalation).~The first stage will consist of accelerated titration in single-patient cohorts for the initial two dose levels.~In the second stage, a conventional 3+3 schema using a modified Fibonacci dose titration strategy will be implemented. The first dose at every dose level and in every patient will be administered under close medical supervision, and the patients will be hospitalized for approximately 24 hours.~Up to 30 participants will participate in this dose escalation arm.~Part B dose-expansion will further explore the safety, PK and preliminary efficacy of MTB-9655 at the RP2D. The RP2D level will be no higher than the MTD identified in Part A."
3297628|NCT01810926|Experimental|MRD-Regimen&Polyclonal antibody|Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 & ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
3297629|NCT01810926|Sham Comparator|MRD-Regimen|Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
3297630|NCT01810926|Experimental|MUD-Regimen & Rituximab|Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 & Rituximab in a single infusion of 200 mg/m2 on day -1
3380077|NCT04985058||Patients with advanced breast cancer|Patients with advanced breast cancer treated with abemaciclib in combination wih endocrine treatment
3380078|NCT04984902|Experimental|Treatment|Treatment with Microbind® Affinity Blood Filter
3380079|NCT04984902|No Intervention|Control|Antibiotics
3380080|NCT04983589|Experimental|AGN-190584|One drop bilaterally twice daily for 14 days.
3380081|NCT04983589|Placebo Comparator|Vehicle|One drop bilaterally twice daily for 14 days.
3297631|NCT01810926|Sham Comparator|MUD-Regimen|Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2
3297632|NCT01810965|Experimental|Cohort|
3297633|NCT01810978|Active Comparator|Bifidobacterium lactis plus inulin|Bifidobacterium lactis plus inulin
3297634|NCT01810978|Placebo Comparator|maltodextrin|maltodextrin
3297635|NCT01811017|Experimental|755nm Alexandrite Laser|755nm Alexandrite Laser
3297636|NCT01811017|Experimental|Nanosecond 755nm Alexandrite Laser|Nanosecond 755nm Alexandrite Laser
3297637|NCT01811043|Experimental|Guided Meditation|Guided meditation is played via headphones during biopsy
3297638|NCT01811043|Active Comparator|Music|Music is played via headphones during biopsy
3297639|NCT01811043|Placebo Comparator|Supportive Dialogue|Supportive dialogue is provided during biopsy by the radiologist performing the procedure
3297640|NCT01811056|No Intervention|In-Center Use of Mifepristone|Participants who choose to take mifepristone in the center
3297641|NCT01811056|Experimental|Out-of-Center Use of Mifepristone|Participants who choose to take the mifepristone outside of the center
3297642|NCT01811082|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3297643|NCT01811082|Active Comparator|Pantethine 600mg|Pantethine 600mg per day.
3297644|NCT01811095|Experimental|Training arm|"The training arm participates in the robotic suturing simulation curriculum, a proficiency curriculum that it is focused on the goal of achieving proficiency targets for five simulator tasks. Those six tasks are : Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2, and Suture sponge 3. The curriculum also includes a sixth task, Suturing Skills (Symbionix): Horizontal suturing defect. Participants are encouraged to complete this task ten times rather than to attain a certain score. Participants set their own hours about when and how much to train during the 5 week intervention period. They are instructed that approximately one hour per week over 5 weeks will be required to achieve the targets, on average."
3297645|NCT01811095|Placebo Comparator|Control|Participants in this group carry on with regular training (residents) or regular clinical work (attending surgeons) without robotic simulator training during the five week period when they are in the control group.
3297646|NCT01811108||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
3297647|NCT01811121|Experimental|5-aminolévulinique acid (5-ALA)|5-aminolévulinique acid :microsurgical resection guided by fluorescence (CGF) in addition to the usual techniques of neuronavigation, after oral administration of 20mg/kg of 5-ALA 3-5 hours prior to surgical incision
3297648|NCT01811121|Placebo Comparator|Placebo|Laroscorbine :microsurgical excision guided solely by neuronavigation, after oral administration of a placebo 3 to 5 hours before the surgical incision
3297649|NCT01811134|Experimental|PIPELINE flow diverter stent|flow diverter stent
3297650|NCT01811134|Active Comparator|Coils, with or without expendable stent|Coils
3297651|NCT01811160|Experimental|Melatonin 5mg (extended release capsules)|Subjects received melatonin (extended release) 5mg nightly during the follow up period
3297652|NCT01811160|Placebo Comparator|Placebo|Subjects received a placebo capsule nightly during the eight week follow up period.
3297653|NCT01811173|Experimental|Nurse-physician comprehensive care|Comprehensive self management support and care coordination by a nurse-primary care physician team
3297654|NCT01811173|No Intervention|Usual care survey control group|Patients will receive usual primary care and asked to complete questionnaires on four time points throughout the study
3297655|NCT01811173|No Intervention|Usual care blinded control group|Patients will receive usual primary care.
3297656|NCT01811251|Experimental|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
3297657|NCT01811251|Placebo Comparator|Lactose (150mg), NaC1 0.9% (50ml)|The aim of the study is to show a decrease in postoperative pain during the first postoperative mobilization surgery lumbar disc herniation through a co-analgesia with a single dose of dexamethasone, pregabalin, or a combination of these two products
3297658|NCT01811264|Experimental|Intervention|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. Then they will be helped through the Patient-Participation Aid (PPA) by the research assistant (RA). Then they will meet with their doctor while the visit is video-recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication. Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
3297659|NCT01811264|No Intervention|Usual Care|Participants will begin with a pre-visit structured interview to determine emotional and physical well-being, anxiety, depression, and self-efficacy. They will have their doctor's visit video recorded. After they will complete a post-visit interview to see if there were any health decisions made, patients level of involvement, and doctor communication.Follow up phone interviews will be conducted at 1 week and 3 months to assess patients self-reported changes in well-being, anxiety, depression, and decision regret.
3297660|NCT01811277|Experimental|SOX sequential S-1|4-6 cycles of SOX followed by S-1 monotherapy until disease progression
3297661|NCT01811290||Gilenya Subjects|Gilenya therapy group subjects must have been treated with Gilenya a minimum of 3 months uninterrupted prior to screening visit, and approved by the principal investigator to continue on this agent.
3297662|NCT01811290||Controlled Therapy Group|Control therapy group subjects must have been consistently on an FDA approved disease modifying therapy other than Gilenya or off such therapy a minimum of 6 months prior to screening visit.
3297663|NCT01811329|Active Comparator|Palm fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and protein powder.
3297664|NCT01811329|Experimental|Palm fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain palm fat, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
3297665|NCT01811329|Active Comparator|Dairy fat|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and protein powder.
3297666|NCT01811329|Experimental|Dairy fat + MFGM|The amount of calories in the shake will be equivalent to 30% of each participant's calculated energy expenditure. The macronutrient composition of the shake as a percent of energy will be: 45% fat, 40% carbohydrate and 15% protein. The shake will contain whipping cream, frozen fruit, glucose polymer, and BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids. Fifty percent of the shake's fat will be derived from BPC50.
3297667|NCT01811342||Hemoglobin Measurement|Patients requiring intra-operative hemoglobin measurement.
3297668|NCT01811381|Experimental|Curcumin and aerobic exercise|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six to 12 months after the beginning of the study, subjects will take curcumin (4 capsules BID before meals, total 800 mg/day) and also participate in an aerobic yoga exercise program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3380089|NCT04976257|Experimental|Ga-PSMA-11, PET/CT, Angiogram, and Prostatic Arterial Catheterization|Patients receive 68Ga-PSMA-11 IV over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after on day 1. One to 14 days later, patients undergo pelvic angiogram and prostatic arterial catheterization. Patients then receive 68Ga-PSMA-11 IA over 30 minutes and undergo dynamic PET imaging over infusion period and for 15 minutes after.
3380090|NCT04976192|Experimental|TEV-45779-300 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
3297669|NCT01811381|Placebo Comparator|Placebo vs non-aerobic yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3380091|NCT04976192|Active Comparator|Xolair-300 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8
3380092|NCT04976192|Experimental|TEV-45779-150 mg Main Treatment period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
3380093|NCT04976192|Active Comparator|Xolair-150 mg Main Treatment Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8
3380094|NCT04976192|Experimental|TEV-45779-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to TEV-45779-300 mg in the Main Treatment period.
3380095|NCT04976192|Experimental|Xolair-300 mg Main / TEV45779-300 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
3380096|NCT04976192|Active Comparator|Xolair-300 mg Main / Xolair-300 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.
3380097|NCT04976192|Experimental|TEV-45779-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to TEV-45779-150 mg in the main treatment period.
3380098|NCT04976192|Experimental|Xolair-150 mg Main / TEV-45779-150 mg Transition Period|TEV-45779 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.
3380099|NCT04976192|Active Comparator|Xolair-150 mg Main / Xolair-150 mg Transition Period|XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.
3380100|NCT04974047|Experimental|Cohort A (Responder)|Participants with a decrease in positron emission tomography (PET) Standardized Uptake Value (SUV)max ≥ 35% will receive 3 cycles of tislelizumab (200 milligrams [mg]/cycle) plus 2 cycles of chemotherapy doublet (cisplatin + paclitaxel)
3380101|NCT04974047|Experimental|Cohort B (Non-responder)|Participants with a decrease in PET SUVmax < 35% will receive 3 cycles of tislelizumab (200 mg/cycle) plus 2 cycles of investigator-chosen chemotherapy doublet (paclitaxel + cisplatin or 5-fluorouracil + cisplatin) plus concurrent radiotherapy (40 grays/20 fractions).
3297670|NCT01811381|Active Comparator|Placebo vs Aerobic Yoga|For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3297671|NCT01811381|Active Comparator|Curcumin vs non aerobic yoga|For the first 6 months of the study, subjects will take 800 mg of curcumin (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Curcumin (4 capsules x BID, total 800 mg/day) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration [or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient] and 2 home practices of 30 minute duration per week).
3297672|NCT01811394|Experimental|protons|16x4GyE protons
3297673|NCT01811394|Experimental|Carbon ions|16x4GyE carbon ions
3297674|NCT01811407|Other|Private/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Participants will be required to set a forward-looking commitment each week as to how many days during the following week they will meet their step count target. Commitment and results will be private.
3297675|NCT01811407|Experimental|Public/private|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments are made as in the Private/Private condition. In addition, one Facebook announcement will be posted at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week. An email will also be sent directly to 3 friends the participant chose with the same announcements.
3297676|NCT01811407|Experimental|Public/public|Participants will wear a pedometer for 14-15 weeks and receive a weekly step count target each week. Commitments will be made as in the Private/Private condition. In addition, one message will be posted to Facebook at the beginning of the week that says how many days the participant thinks they will meet their walking target the following week, and how they did on their previous weekly commitment. An email will also be sent directly to 3 friends the participant chose with the same announcements.
3297677|NCT01811420|Experimental|CHEMOMECHANICAL CARIES REMOVAL|Dental caries removal using papain based gel
3297678|NCT01811420|Active Comparator|conventional method|Dental caries removal using rotatory instrument
3297679|NCT01811446|Experimental|Obese|Subjects with BMI > 30
3297680|NCT01811446|Experimental|COPD|Non-hospitalized COPD patients
3297681|NCT01811459|Experimental|Quetiapine|Drug: Quetiapine 50-250 mg PO BID (5 levels of treatment) + IV Placebo Rescue IV haloperidol available.
3297682|NCT01811459|Experimental|Haloperidol|Drug: Haloperidol 1-5 mg BID (5 levels of treatment) + PO placebo Rescue IV haloperidol available.
3297683|NCT01811459|Placebo Comparator|Placebo|IV placebo + PO placebo Rescue IV haloperidol available.
3297684|NCT01811498|Experimental|SIACI of Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab
3297685|NCT01811511|Experimental|Chungkookjang|Chungkookjang(35g/day)
3297686|NCT01811511|Placebo Comparator|Placebo|Placebo(35g/day)
3297687|NCT01811524||Glioma and meningioma patientsl|Glioma and meningioma patients of Tampere University Hospital during the study period
3297688|NCT01811537|Experimental|Experimental: premeasured Neochordae|Transthoracic echocardiography(TTE) is done for all patients. The new device will be setup using the TTE measurements.The artificial Chordae loops will be made at the operation room before starting the surgery. These loops will be attached to the respective papillary muscle's head and the free edge of respective prolapsed scallop.
3297689|NCT01811550||SHINE study subjects|Subjects enrolled in the SHINE trial who are not receiving intra-arterial therapy nor systemic anticoagulation; have no known moderate/severe hepatic insufficiency; have no known history of hypercoaguable or thrombotic condition; have INR =<1.5 (if known) at baseline and provide informed consent (self or LAR) will be enrolled in the I-SPOT study.
3297692|NCT01811589|Experimental|Thomale-Guide|Positioning of ventricular catheter with the Thomale-Guide instrument
3297693|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
3297694|NCT01811602|Other|Training|Pelvic floor muscle training delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction
3297695|NCT01811602|Other|Usual Care Control|Participants randomized to this arm will receive a 1-page educational pamphlet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
3297696|NCT01811615|Active Comparator|toothbrushing plus rinsing|0.06% CHX + 0.025% NaF plus toothbrushing and alcohol-containing mouth rinsing
3297697|NCT01811615|Experimental|alcohol-free experimental mouth rinse|0.06% CHX + 0.025% NaF plus toothbrushing
3297698|NCT01811615|Experimental|toothbrushing and rinsing|0.06% CHX + 0.03% CPC + 0.025% NaF, alcohol-free, mouth rinsing
3297699|NCT01811615|No Intervention|toothbrushing alone|negative control
3297700|NCT01811628||Questionnaire + Interview|Latinos and Hispanics who are smokers and recent quitters.
3297701|NCT01811641||maternal methyl-donors, infant epigenetics|women of reproductive age in rural Gambia, infants born to these women
3297702|NCT01811667|Experimental|Sirolimus|Seric level between 10 to 15 ng/ml Pills for the adults and liquid for the children. Twice a day.
3297703|NCT01811719|Experimental|Enhanced NFP (NFP+)|"Enhanced NFP(NFP+)provides for the usual NFP services plus a three-prong experimental preventive intervention:~Structured and regularly occuring assessments for intimate partner violence (IPV);~McFarlane and Parker Brochure Driven Intervention for women experiencing IPV, including safety planning, referrals, and advocacy; and~Markman and Stanley Within My Reach Training which is a skills-based curriculum delivered to all participants focusing on improving relationship deicsions and outcomes."
3297704|NCT01811719|Active Comparator|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
3297705|NCT01811745|Experimental|Jaques-Dalcroze eurhythmics training|Once-weekly 60-min Jaques-Dalcroze eurhythmics class, for 12 months.
3297706|NCT01811745|Active Comparator|Multicomponent exercise training|Once-weekly 60-min multicomponent exercise class supplemented by one 30-min home-based exercise session, for 12 months.
3297707|NCT01811758|Experimental|Culturally Specific CBT|Culturally specific cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes. Up to 8-weeks of transdermal nicotine patches. Focused on African Americans: smoking patterns, health outcomes, discrimination, stress, weight concerns, cultural beliefs and practices.
3297708|NCT01811758|Active Comparator|Standard CBT (control)|Standard cognitive behavioral therapy. Group format, 8 sessions, approximately 90 minutes each. Up to 8-weeks of transdermal nicotine patches. Traditional CBT, with no focus on race: smoking and health, benefits of quitting, weight control, relapse prevention, coping skills.
3297709|NCT01811771|Active Comparator|Shanchol vaccine|Around 30,000 individuals will be vaccinated with two doses of oral cholera vaccine at least 14 days apart.All male and non-pregnant female residents above one year age will be targeted for vaccination.
3297710|NCT01811771|No Intervention|Non-intervention|No intervention will be given. Health education will be provided to the study participants.
3297711|NCT01811784|Experimental|Use skirt on raw sap consumption|"Phase one: Test the effectiveness of a single message of do not drink raw sap."
3297712|NCT01811784|Experimental|Ask people not to drink sap|Test the effectiveness of a risk reduction approach, encouraging people to avoid drinking sap, if they do, they should only drink sap from skirt protected trees.
3297713|NCT01811784|No Intervention|Phase 1: Routine raw sap consumption among household members.|"Test the effectiveness of a single message of do not drink raw sap"
3297714|NCT01811784|No Intervention|Phase 2:|Raw sap consumption from skirt protected trees
3297715|NCT01811797|Experimental|Low Intensity Shockwave treatment|4 weekly sessions of Low Intensity Shockwave treatment.
3297716|NCT01811797|Sham Comparator|Control group|
3297717|NCT01811810|Other|xrt and long term ADT|Radiation therapy (XRT) and long term androgen deprivation therapy
3297718|NCT01811810|Other|xrt, chemotherapy and short term ADT|radiation therapy (XRT), chemotherapy and short term ADT
3297719|NCT01811823|Other|TIV|"Trivalent Inactivated Influenza Vaccine The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
3297720|NCT01811836|Experimental|Resistant Starch|"Oral and intravenous zinc stable isotopes. Zinc: 67Zn (>97% enrichment),68Zn (>99% enrichment) and 70Zn (>95% enrichment) Days 1 and 38: children will be administered 40-75 μg of 67Zn through consumed food. At the end of these days, children will be given an intravenous injection of an accurately measured quantity of ~800 μg of 68Zn.~Days 3-35: resistant starch feeding -- which will be given to mothers and integrated into the food."
3297721|NCT01811849|Experimental|BIOD-238|Subcutaneous injection
3297722|NCT01811849|Experimental|BIOD-250|Subcutaneous injection
3297723|NCT01811849|Active Comparator|Humalog|Subcutaneous injection
3297726|NCT01811888||Patients with knee osteoarthritis|
3297727|NCT01811901|Active Comparator|Intervention group (SITS-WATCH centers)|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
3297728|NCT01811901|No Intervention|Control group (non SITS-WATCH centers in SITS registry)|Centres that do not use 15-item list of suggested interventions aiming to reduce DNT.
3297729|NCT01811914|Experimental|intraoperative TTE|TTE if a hemodynamic instability occurs
3297730|NCT01811927|Experimental|PRO-Kinetic Energy Stent|PRO-Kinetic Energy Stent
3297731|NCT01811966|Sham Comparator|Control|preoperative none substitution of i.v. fluids.
3297732|NCT01811966|Active Comparator|Volume|preoperative substitution of a defined amount of i.v. fluids (8 ml/kg RingerAcetate solution for 15 min prior to introduction of anesthesia).
3297733|NCT01811979|Active Comparator|oral sucrose solution|local anesthetic eye drops (Alcaine 0.5% drop) and a pacifier, plus 0.5 cc/kg of 24% sucrose, to relieve pain associated with eye examinations for retinopathy of prematurity will be given
3297734|NCT01811979|Placebo Comparator|steril water|steril water 0,5 cc/kg plus topical anesthetics (Alcaine %0.5 damla) before eye examination will be given
3297735|NCT01811992|Experimental|Dose escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"This protocol is a dose escalation study of Ad-hCMV-TK and Ad-hCMV-Flt3L infused at the time of surgical resection followed by systemic oral administration of valacyclovir in addition to current standard of care with temozolomide and radiotherapy. Eligible subjects will be enrolled in six sequential dosing cohorts:~A= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^9 vp~B= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^9 vp~C= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^10 vp~D= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^10 vp~E= Ad-hCMV-TK: 1x10^10 vp and Ad-hCMV-Flt3L: 1x10^11 vp~F= Ad-hCMV-TK: 1x10^11 vp and Ad-hCMV-Flt3L: 1x10^11 vp~Subjects will be treated sequentially with a minimum of 21 days before treatment of new subjects within a cohort or before dose escalation."
3297736|NCT01812018|Experimental|Endostar|Endostar, Gemcitabine, Docetaxel
3297737|NCT01812031|Experimental|Lung nodules|"Medical imaging intervention applied on patients included in the trial"
3297738|NCT01812070|Experimental|ACT|Acceptance & Commitment Therapy
3297739|NCT01812070|Active Comparator|CBT|Cognitive Behavioral Therapy
3297740|NCT01812096|Experimental|the pharmacokinetic of bortezomib|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of subcutaneous administration of bortezomib
3297741|NCT01812096|Active Comparator|Intravenous|the pharmacokinetic and pharmacodynamic, and assessed safety and efficacy of intravenous administration of bortezomib
3297742|NCT01812122|Experimental|Glimepiride|Starting with Glimepiride. After 3 month, switching to vildagliptin.
3297743|NCT01812122|Experimental|Vildagliptin|Starting with vildagliptin. After 3 month, switching to Glimepiride.
3297744|NCT01812135|Experimental|Group 1: 400U EV71 vaccine without adjuvant|60 infants received 2 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant 28 days apart
3297745|NCT01812135|Experimental|Group 2: 400U EV71 vaccine without adjuvant|60 infants received 1 doses of 400U EV71 vaccine without aluminium hydroxide adjuvant
3297746|NCT01812135|Experimental|Group 3: 400U EV71 vaccine with adjuvant|60 infants received 1 doses of 400U EV71 vaccine with aluminium hydroxide adjuvant
3297747|NCT01812148||Peritoneal Mesotheliomas|Cytoreductive surgery and HIPEC
3297748|NCT01812161|Active Comparator|Acupuncture protocol 1|Acupuncture protocol 1：participants will receive treatment (acupuncture protocol 1, real acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
3297749|NCT01812161|Sham Comparator|Acupuncture protocol 2|Acupuncture protocol 2：participants will receive treatment (acupuncture protocol 2, sham acupuncture) twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
3297750|NCT01812174|Experimental|17mm On-X Aortic Heart Valve|Patients receiving the 17mm On-X aortic heart valve as a replacement for diseased native or prosthetic aortic heart valve.
3297751|NCT01812174|Experimental|23mm On-X Mitral Heart Valve|"Patients receiving the 23mm On-X mitral heart valve as a replacement for diseased native or prosthetic mitral heart valve.~Enrollment into the 23mm On-X mitral arm has been terminated."
3297752|NCT01812187|Experimental|SHIFT Cognitive Behavioral Therapy|Service to Home for Individually-Focused Therapy (SHIFT), a Cognitive Behavioral Treatment for Substance Use Disorders
3297753|NCT01812200|Active Comparator|Dabigatran, Ticagrelor, ASA|Dabigatran 150mg td Ticagrelor 90 mg td ASA 100 mg od for 5 days
3297754|NCT01812200|Active Comparator|Rivaroxaban, Ticagrelor, ASA|Rivaroxaban 20 mg od Ticagrelor 90 mg td ASA 100 mg od for 5 days
3297755|NCT01812200|Active Comparator|Phenprocoumon, Ticagrelor, ASA|Phenprocoumon X mg to reach an INR of 2-3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days
3297756|NCT01812213|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 (8.1 mCi) administered once every 18 months
3297757|NCT01812226||experimental group|This group will consist of men and women who received a liver transplant for alcohol-related liver disease.
3297758|NCT01812226||control group|This group will consist of men and women who had a liver transplant for reasons that are not alcohol-related.
3297759|NCT01812239|Active Comparator|Vaginal Progesterone|Daily administration of Vaginal Progesterone (200mg) Gel between 20 weeks of pregnancy and 34 weeks of pregnancy.
3297760|NCT01812239|Placebo Comparator|Placebo|Daily vaginal administration of Placebo gel (Vanicream)between 20 weeks of pregnancy and 34 weeks of pregnancy.
3297761|NCT01812252|Other|Arm A (decitabine or azacitidine)|Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.
3297762|NCT01812252|Other|Arm B (induction-like chemotherapy regimen)|Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.
3297763|NCT01812265|Experimental|PF-06305591 Dose 1|
3297764|NCT01812265|Experimental|PF-06305591 Dose 2|
3297765|NCT01812265|Placebo Comparator|Placebo|
3297766|NCT01812278|Experimental|ACT|Acceptance & Commitment Therapy
3297767|NCT01812278|Active Comparator|CBT|Cognitive Behavioral Therapy
3297768|NCT01812291|Experimental|Stepped Care Approach for Depression|"Step 1: Diabetes-Specific CBT (5 group sessions)~Step 2: Depression-Specific CBT (6 single sessions)~Step 3: Referral to Psychotherapist and/or Psychiatrist"
3297769|NCT01812291|Active Comparator|Treatment-as-usual|Standard Diabetes Education
3297770|NCT01812304|Experimental|hands-on training|probands perform predefined maneuvers to manage a vaginal breech hands-on after one instruction
3297771|NCT01812304|Active Comparator|frontal teaching|Probands perform predefined maneuvers to resolve a vaginal breech after forntal teaching
3297772|NCT01812317|Active Comparator|Real-fire training exercise|Subjects will undergo a 20 minute standardised training exercise in a fire simulation facility.
3297773|NCT01812317|Sham Comparator|Sedentary training session|Subjects will undergo a training exercise where they will remain sedentary for 20 mins in an ambient temperature.
3297774|NCT01812330|Experimental|group 1|Group 1 will be administered with Clopidogrel 75mg daily until the end of the trial
3297775|NCT01812330|Experimental|group 2|Group 2 will be administered with Clopidogrel 150mg daily until the end of trial
3297776|NCT01812330|Experimental|group 3|Group 3 will be administered with Ticagrelor 90mg twice daily until the end of the trial
3297777|NCT01812343|Other|Exercise test|Ankle pressure Index measure before and after Maximal Exercise Tests
3297778|NCT01812356|Experimental|Argon gas probe|Cryomaze procedure using Argon gas probe
3297779|NCT01812356|Active Comparator|Nitrous oxide probe|Cryomaze procedure using Nitrous oxide probe
3297780|NCT01812369|Experimental|GC|gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles
3297781|NCT01812369|Active Comparator|MVAC-HD|Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles
3380102|NCT04971681|Experimental|Low frequency repetitive transcranial magnetic stimulation (rTMS)|Low frequency repetitive transcranial magnetic stimulation (rTMS)
3380103|NCT04971681|Sham Comparator|Sham rTMS Stimulation|Sham rTMS Stimulation
3297782|NCT01812382|Experimental|Microdialysis arm|Three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure/infusion using a microdialysis device. All subjects will receive Sodium Chloride solution perfused for 30 minutes followed by Retapamulin perfusion for 90 minutes and then Saline perfusion will occur during the washout period.
3297783|NCT01812395|Active Comparator|Ultrasonic Dissector Thyroidectomy|Thyroidectomy using harmonic focus (r) device
3297784|NCT01812395|Active Comparator|Classic thyroidectomy|Patients having conventional thyroidectomy
3297785|NCT01812421|Experimental|Ischemic Stroke or TIA (ISTIA) patients|
3297786|NCT01812434|Experimental|Sildenafil|Patients will be randomized to sildenafil arm taken three times a day for 28 days and then crossed over to the alternate arm.
3297787|NCT01812434|Experimental|Placebo|Subject randomized to either Sildenafil or placebo arm
3297788|NCT01812447|Experimental|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
3297789|NCT01812447|Experimental|Spiration Valve System, α-1|α-1 antitrypsin deficiency subjects will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management. There is no randomization for this group.
3297790|NCT01812447|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
3297791|NCT01812460|Experimental|Intervention-training-group|"The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times) The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every session of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoe as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.~The weight cuffs are handed over to the patients for self guided exercise during weekends"
3297792|NCT01812460|No Intervention|Control group|The patients randomized to the control group receive lung physiotherapy from day two of admittance. Lung physiotherapy consists of help to bring up sputum from the bronchi and lungs. The patients are instructed in breath exercises, use of Positiv Ekspiratory Pressure, breathing exercises, cough and pursed lip breathing. The patients are encouraged to spend as little time in bed as possible.
3297793|NCT01812486|Active Comparator|control arm|NID2Gy = 50 Gy Swallowing apparatus: standard dose
3297794|NCT01812486|Experimental|Experimental de escalated arm|NID2Gy = 40 Gy Swallowing apparatus: Dmax ≤ 60 Gy at 1 cm Dmax ≤ 50 Gy at 1.5 cm from the GTV or PSTB edge
3297795|NCT01812512|Other|TIPS for HF Intervention HT Training-Charleston-Pre/Post|Group 1 (Charleston): In the proposed intervention, called Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF) , the observations from the previous RRP are used along with best practices from other studies of patient-centered communication in the VA , telephone coaching for chronic disease , problem-solving and counseling skills for telehealth nurse care managers , difficulties identified by patients working with the Health Buddy for telemonitoring , participation in provider-patient communication , essentials of patient education in heart failure process and content, and teach to goal theory to improve HF self-management for patients with low health literacy . Rather than an experimental trial, this implementation quasi-experimental pilot study examines pre- and post-training nurse practices and Veteran outcomes before and after communication skills training. The same intervention will then be delivered to Group 2 HT nurse care coordinators.
3297796|NCT01812512|Other|TIPS for HF Intervention HT Training-Columbia-Pre/Post|Group 2 (Columbia VAMC): To test the TIPS for HF educational intervention sufficiently in a sample not previously exposed to the information, the HT program at Dorn VA Medical Center in Columbia, South Carolina has volunteered to participate as a second study site. There are six nurse care coordinators who will be recruited; the larger number supports recruitment of a comparable number with 25 Veterans with HF to be recruited in the second site for a total of 50 Veterans. Both groups will use a purposeful sampling plan, beginning with an IRB-approved flyer for recruitment. The demographic make-up of the Charleston VAMC group is comparable Columbia HT group in age, race, and NYHA HF class. Also, consistent with an implementation quasi-experimental pilot study, the second site will examine pre-training and post-training nurse care coordinator communication practices and Veteran outcomes before and after communication skills training.
3297797|NCT01812525|Active Comparator|NaCl 3% inhalations + standard therapy|"In this group, patients receive NaCl 3% inhalations ( 4ml QID) together with standard therapy.~Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed."
3297798|NCT01812525|Placebo Comparator|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
3297799|NCT01812538|Placebo Comparator|Placebo|Placebo
3297800|NCT01812538|Experimental|Experimental 1|DIC075V 37.5 mg
3297801|NCT01812538|Experimental|Experimental 2|DIC075V 75 mg
3297802|NCT01812538|Active Comparator|Active control|Moxifloxacin hydrochloride 400 mg
3297803|NCT01812551|Active Comparator|Alendronate|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~65 subjects were randomized to this arm. Oral alendronate dose: 5 mg/day, if body weight ≤25 kg; 10 mg/day, if body weight >25 kg."
3297804|NCT01812551|Placebo Comparator|Placebo|"128 subjects participated in the study's Phase 2 (1-year double-blind, randomized, placebo-controlled, parallel group study).~63 subjects were randomized to this arm. Oral placebo (inactive pills)."
3297805|NCT01812564|Placebo Comparator|PPP|"Placebo: Platelet Poor Plasma~Under sterile conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PPP each, administered by a sports medicine physician (total 3 cc PPP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3297806|NCT01812564|Active Comparator|PRP|"Biological: Platelet Rich Plasma~Under sterile ultrasound conditions, patients will receive under ultrasound guidance 3 times, 1 cc injection of PRP each, administered by a sports medicine physician (total 3 cc PRP).~Following the completion of the injections (treatment or control) physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3297807|NCT01812564|No Intervention|Physiotherapy|"These patients will not receive an injection.~Following the inclusion physiotherapy will commence. Physiotherapy protocols will be based on current ASPETAR best practice models (usual care)"
3297808|NCT01812577||Thoracic paravertebral block (TPVB)|Twenty patients receiving thoracic paravertebral block at level of T7, before the interventistic procedure.
3297809|NCT01812577||Deep Sedation (DS)|Twenty patients receiving local and intravenous anesthesia during the procedure.
3297810|NCT01812590|No Intervention|Resting Trial|Pancreatic endocrine function will be determined the morning following a day where no exercise is performed
3297811|NCT01812590|Experimental|Exercise Trial|Pancreatic endocrine function will be determined the morning following a day where a 1-hour aerobic exercise is performed at 65% of pre-determined HRmax (maximal heart rate measured during an incremental work-load exercise test to volitional exhaustion)
3297812|NCT01812603|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide and in open-label manner
3297813|NCT01812616|Experimental|Sativex and Dose-Intense Temozolomide|Patients will received Sativex and Dose-Intense Temozolomide in a double-blind manner
3297814|NCT01812616|Placebo Comparator|Placebo and Dose-Intense Temozolomide|Patients will received placebo and Dose-Intense Temozolomide and in double-blind manner
3297815|NCT01812629|Experimental|Experimental Infant Formula|Complete peptide amino acid-based infant formula
3297816|NCT01812642|Experimental|JNJ-37822681 10 milligram|JNJ-37822681 oral capsule will be administered at a starting dose of 10 milligram (mg) twice daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14.
3297817|NCT01812642|Experimental|JNJ-37822681 20 milligram and placebo|JNJ-37822681 oral capsule will be administered at a starting dose of 20 mg once daily for the first 3 days and thereafter dose will be titrated from Day 3 to Day 10 up to 80 mg per day and will be continued at same dose up to Day 14. Matching Placebo will be administered orally in the evening for 14 days (12 hour post JNJ-37822681 administration).
3297818|NCT01812720|Experimental|Treatment (carfilzomib, dexamethasone)|Patients receive carfilzomib IV over 30 minutes and dexamethasone PO on days 1, 2, 15, and 16. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
3297819|NCT01812746|Experimental|BIND-014|
3297820|NCT01812772|Experimental|Double J-stent with a long tether|Following ureteroscopy patients will have placed a double J-stent with a long tether.
3297821|NCT01812772|Active Comparator|Double J-stent without a long tether|Following ureteroscopy patients will have a double J-stent placed without a long tether
3297822|NCT01812798|Active Comparator|Peanut|"Double Blind Placebo Controlled Food Challenge 5 gram peanut challenge~17 doses of peanut will be administered. Dose will be increased every 20-30 minutes. All doses listed are in g of peanut flour.~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000"
3297823|NCT01812798|Placebo Comparator|Placebo|Double Blind Placebo Controlled Food Challenge (No peanut - placebo only)
3297824|NCT01812824|Experimental|Intervention (Virtual Patient Advocate)|Participants assigned to the Intervention (Virtual Patient Advocate) arm will have access to the Virtual Patient Advocate system on-line for 6 months; they will be encouraged, but not required, to log on once a week.
3297825|NCT01812824|No Intervention|Control (Letter)|Participants in the Control (Letter) arm will take the online Preconception Risk Assessment at baseline, but not have access to the Virtual Patient Advocate system during the 6 month study period. They will be sent a list of the Preconception Risks identified through their answers to the Risk Assessment, which they can choose to share with their healthcare provider(s).
3297826|NCT01812850||Invisalign®|All subjects in the study (estimation of 40 subjects) will be treated using the Invisalign® appliance.
3297827|NCT01812863|Experimental|Supraclavicular Nerve Block|Maximum dose of 5 mL of 0.25% bupivacaine, and we base the dose on a ml/ kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. Bupivacaine is given with 1:200,000 epinephrine
3297828|NCT01812863|Placebo Comparator|No Nerve Block|A band-aid will be placed on all patients where a supraclavicular nerve block would have been inserted, and parents will be asked to leave the band-aid on for 3 days to maintain the blindness to the treatment type by the patient.
3297829|NCT01812889|Active Comparator|Part 2|10 women diagnosed with BV, 10 diagnosed with VVC will be randomized to receive either TOL-463 gel or TOL-463 ovules administered intravaginally once daily for 7 consecutive days
3297830|NCT01812889|Active Comparator|Part 1|20 Healthy women randomized, two-way crossover design will receive a single dose of TOL-463 gel and ovule intravaginally, separated by a minimum of 7 day washout period between administrations
3297831|NCT01812902|Experimental|Extended LND|Radical Prostatectomy with extended lymphadenectomy
3297832|NCT01812902|Active Comparator|Limited LND|Radical Prostatectomy with Limited lymphadenectomy
3297833|NCT01812915|Experimental|Cylindrical-shape cuff ETT (Group C)|Control group: Mallinckrodt HiLo(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt Hi-Lo(TM) tube.
3297834|NCT01812915|Experimental|Tapered-shape cuff ETT (Group T)|Experimental group: Mallinckrodt TaperGuard(TM) endotracheal tube. Intracuff pressures of the tubes every 10 minutes, Adult patients under general anesthesia with Mallinckrodt TaperGuard(TM) tube.
3297835|NCT01812928|No Intervention|Gel only|This group will be given only intraurethral gel during flexible cystoscopy.
3297836|NCT01812928|Experimental|Diclofenac and Gel|This group will also receive intraurethral gel during cystoscopy but additionally diclofenac suppository will be given per rectally one hour before procedure as preemptive analgesia.
3297837|NCT01812941|Other|Burn: blood collection|Procedure: Blood draws as the intervention.
3297838|NCT01812941|Other|trauma: blood collection|blood to be collected at different time intervals. Blood draw as the intervention
3297839|NCT01812941|Other|healthy volunteers: blood collection|Blood draws as the intervention
3297840|NCT01812980|Experimental|Trivalent Inactivated Influenza Vaccine|"Single dose, intramuscular injection from a pre-filled syringe~WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
3297841|NCT01812993|No Intervention|Control|No ventilatory treatment; standard stroke care
3297842|NCT01812993|Experimental|Active|Non-invasive ventilatory treatment with auto-BPAP plus standard stroke care
3297843|NCT01813006|Active Comparator|Omega-3|Omega-3 fatty acids
3297844|NCT01813006|Placebo Comparator|Placebo|Placebo/olive oil
3297845|NCT01813032||Firefighters|20 firefighters will attend for vascular assessments following a minimum of 48 hours off-duty.
3297846|NCT01813032||Police Officers|20 police officers will attend for vascular assessments following a minimum of 48 hours off-duty.
3297847|NCT01813045||Chronic Coronary Occlusion group|"We will also recruit 10 patients with an angiographically documented chronic (>6 months) proximal coronary artery occlusion that has not been revascularised but has extensive collateral coronary blood flow.~We will perform CT-coronary angiogram, cardiac MRI scan and CT-PET scan."
3297848|NCT01813045||MI (non-revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
3297849|NCT01813045||MI (revascularised)|"These patients (n=15) will undergo Cardiac MRI, CT-PET scan and CT-coronary angiogram scan 2 weeks following their myocardial infarction.~They will undergo a second CT-PET scan 9 weeks following their myocardial infarction.~They will undergo a second cardiac MRI scan 6 - 12 months following their myocardial infarction."
3297850|NCT01813084|Experimental|Part A: single dose escalation|
3297851|NCT01813084|Experimental|Part B: 14 day repeat dose escalation (healthy volunteers)|
3297852|NCT01813084|Experimental|Part C: 14 day repeat dose (asthma patients)|
3297853|NCT01813097||combination iodine 125 seed implants|30 cases should be treated with iodine 125 seed implants 0.5 mc transperineal prostate implant +Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
3297854|NCT01813097||LHRH agonists|30 cases should be treated with Zoladex 3.6mg im 1/28d (LHRH agonist, 3.6mg subcutaneous injection 1/4weeks).
3297855|NCT01813123|No Intervention|Control|
3297856|NCT01813123|Experimental|Intervention|RealTeen
3297857|NCT01813136|Active Comparator|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
3297858|NCT01813136|Experimental|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
3297859|NCT01813162|Active Comparator|Tenofovir 1% gel|Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.
3297860|NCT01813162|Active Comparator|Vaginal product alone|"Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen)."
3297861|NCT01813162|Experimental|Vaginal product and Tenofovir 1% gel|"Tenofovir gel: Participants will vaginally insert 1 applicator of TFV gel twice a day for 7 days, with each dose inserted approximately 12 hours after the previous dose (for a total of 13 doses). Each applicator contains 4.4 gm of TFV 1% gel.~In addition, Participants will use their assigned vaginal product for 5 to 21 days depending on the dosing instructions for the particular product:~Terconazole 0.4% vaginal cream: once a day for seven days. 1 applicator (5 gm) of terconazole cream contains 20 mg terconazole.~Metronidazole gel: once a day for 5 days. 1 applicator (5 gm)of metronidazole gel contains 37.5 mg metronidazole.~Contraceptive IVR: insert ring and leave in place for 21 days; return to clinic for removal on day 21. The IVR contains two active components, etonogestrel (progestin) and ethinyl estradiol (estrogen). Use of TFV gel will begin on day 15 of IVR use."
3297862|NCT01813175|Active Comparator|Intervention Group I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
3297863|NCT01813175|Active Comparator|Interventional Group II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
3297864|NCT01813175|Placebo Comparator|Control Group|Regular non-hydrolysed cow's milk based infant formula
3297865|NCT01813175|No Intervention|Reference Group|Exclusively breast-fed infants
3297866|NCT01813188|Experimental|ABM seeded onto a porous TCP and DBM|ABM seeded onto a porous TCP and DBM
3297867|NCT01813188|Active Comparator|autologous bone graft|autologous bone graft
3297868|NCT01813201|Active Comparator|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose)
3297869|NCT01813201|Placebo Comparator|Saline isotonic solution (Placebo)|Placebo (saline isotonic solution)administered at inclusion and every 12 weeks for 9 months (4 dose) (control group).
3297870|NCT01813227|Experimental|Carfilzomib|Carfilzomib 20 mg/m2 on day 1, 2 then 56 mg/m2 days 8, 9 and 15, 16 over 30 minutes every 28 days. Dexamethasone 4 mg (8 mg if > 45 mg/m2) orally each day of carfilzomib therapy. If less than a partial remission (PR) after 4 cycles, add rituximab 375 mg/m2 on day 16 of each cycle. Patients who meet the criteria for progression prior to 4 cycles of therapy will have rituximab added to their treatment. For patients receiving rituximab, the carfilzomib dose will be decreased to 27 mg/m2. Patients will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
3297871|NCT01813240|Experimental|Minocycline, Spinal Tumor patients, quality of life|
3297872|NCT01813240|Experimental|Minocycline, Trauma patuents, quality of life|
3297873|NCT01813240|Placebo Comparator|Placebo, Trauma patients, quality of life|
3297874|NCT01813240|Placebo Comparator|Placebo, Spinal cord tumors, quality of life|
3297875|NCT01813253|Experimental|Irinotecan and nimotuzumab|Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly
3297876|NCT01813253|Active Comparator|Irinotecan|Administration of irinotecan 150 mg/m2 IV once every 2 weeks
3297877|NCT01813266||Usual practice in screening for Hepatitis C virus.|Three clinics in this group will use this approach.
3297878|NCT01813266||USPTF risk factors to screen for chronic HCV infection.|3 internal medicine clinics will use this screening strategy.
3297879|NCT01813266||USPTF/CDC recommendations to screen for chronic HCV infection.|3 internal medicine clinics.
3297880|NCT01813279|Experimental|patients|
3297881|NCT01813305|Active Comparator|CSTC1|CSTC1 (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof), topical, two times daily
3297882|NCT01813305|Placebo Comparator|CSTC1 Matched vehicle|Matched vehicle, topical, two times daily
3297883|NCT01813318|Placebo Comparator|Placebo/sugar pill|Placebo will be dosed similar to acamprosate, in terms of dosage form, frequency and duration.
3297884|NCT01813318|Active Comparator|Acamprosate|"Acamprosate: The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.~Other Name: Campral"
3297885|NCT01813331||Chronic Heart Failure Patients|Chronic Heart Failure patients older than 65 years, which accept to participate to the study and give their informed written consent and consecutively refer to the A.R.C.A Campania Cardiologists in the pertaining healthcare districts.
3297886|NCT01813370||Pts with prostate cancer|Patients who have progressed or hit their 36 month post treatment date between the closure of TAX3503 and the activation of this TAX3503 Registry protocol will be permitted on the study to capture their date of progression or their 36 month post treatment progression free date.
3297887|NCT01813383||HLA-DR3-DQ2 patients|Patients with HLA-DR3-DQ2 haplotype
3297888|NCT01813383||HLA-DR7-DQ2 patients|Patients with HLA-DR7-DQ2 haplotype
3297889|NCT01813396|Experimental|joint mobilization/massage|"joint mobilization: End-range joint mobilization~massage: massage twice a week on the identified muscle(s) of the involved shoulder about 6 minutes for each muscle for 3 months. The techniques of massage include petrissage for 3 minutes and rolling for 3 minutes of soft tissues"
3297890|NCT01813396|Experimental|joint mobilization/shoulder physical activity guide|joint mobilization: End-range joint mobilization shoulder physical activity guide: shoulder physical activity guide is based on the appropriate cut off activity level identified in the predication rule
3297891|NCT01813448|Experimental|Cohort 1: Fidaxomicin low dose in Japanese males|
3297892|NCT01813448|Experimental|Cohort 2: Fidaxomicin high dose in Japanese males|
3297893|NCT01813448|Experimental|Cohort 3: Fidaxomicin high dose in Caucasian males|
3297894|NCT01813448|Placebo Comparator|Matching Placebo in Caucasian males|
3297895|NCT01813448|Placebo Comparator|Matching Placebo in Japanese males|
3297896|NCT01813461|Experimental|14C-labeled prodrug isavuconazonium sulfate|single dose
3297897|NCT01813487|Other|HBsAg vaccine with Entecavir|
3297898|NCT01813500||IBD Patients|Subjects with Crohn's Disease or Ulcerative colitis. IBD patients will be asked to provide a blood and stool sample.
3297899|NCT01813500||Control Subjects|Subjects without Crohn's Disease or Ulcerative Colitis. Controls will also be asked to provide a blood and stool sample.
3297900|NCT01813513|Experimental|Group A: IDX719 then IDX719/Simeprevir|Healthy participants take IDX719 150 mg once daily (QD) on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
3297901|NCT01813513|Experimental|Group B: Simeprevir then IDX719/Simeprevir|Healthy participants take simeprevir 150 mg QD on Days 1-7 and IDX719 150 mg QD + simeprevir 150 mg QD on Days 8-14.
3297902|NCT01813513|Experimental|Group C: IDX719|Healthy participants take IDX719 150 mg QD on Days 1-14.
3297903|NCT01813513|Experimental|Group D: IDX719/Simeprevir|Participants from Groups A and B will be asked to return for Group D. Participants take IDX719 and simeprevir QD on Days 1-7 to determine the impact of food on single-dose (on Day 1) and steady state (Day 7) PK.
3297904|NCT01813513|Experimental|Group E: High-Fat then Low-Fat PK|Participants from Group C will return to determine the PK of IDX719 after high-fat (Day 1) and low-fat (Day 7) meals (Days 2-6 are drug-free washout).
3297905|NCT01813513|Experimental|Group F: Low-Fat then High-Fat PK|Participants from Group C will return to determine the PK of IDX719 after low-fat (Day 1) and high-fat (Day 7) meals (Days 2-6 are drug-free washout).
3297906|NCT01813526|Experimental|Experimental Infant Formula|Experimental formula to be fed ad libitum.
3297907|NCT01813539|Experimental|Dose Escalation: Cohort 1|Participants will receive ARGX-110 as an intravenous infusion (IV) at dose level 1.
3297908|NCT01813539|Experimental|Dose Escalation: Cohort 2|Participants will receive ARGX-110 as an IV infusion at dose level 2.
3297909|NCT01813539|Experimental|Dose Escalation: Cohort 3|Participants will receive ARGX-110 as an IV infusion at dose level 3.
3297910|NCT01813539|Experimental|Dose Escalation: Cohort 4|Participants will receive ARGX-110 as an IV infusion at dose level 4.
3297911|NCT01813539|Experimental|Dose Escalation: Cohort 5|Participants will receive ARGX-110 as an IV infusion at intermediate dose level at the conclusion of Cohort 4 prior to opening the safety expansion cohorts to participants enrolment.
3297912|NCT01813539|Experimental|Safety Expansion: Cohort 1|Participants with solid tumors will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
3297913|NCT01813539|Experimental|Safety Expansion: Cohort 2|Participants with hematological malignancies (all etiologies) will receive ARGX-110 as an IV infusion at a dose based on the safety, PD, and PK profiles of ARGX-110 as per the dose escalation part of the trial.
3297914|NCT01813539|Experimental|Safety Expansion: Cohort 3|Participants with cutaneous T-cell lymphoma (CTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
3297915|NCT01813539|Experimental|Safety Expansion: Cohort 4|Participants with peripheral T-cell lymphoma (PTCL) will receive ARGX-110 as an IV infusion at dose level 2 followed by a maintenance therapy at dose level 2 or 3.
3297916|NCT01813539|Experimental|Exploratory Efficacy: Cohort 5|Participants with relapsed/refractory CTCL will receive ARGX-110 as an IV infusion followed by a maintenance therapy at dose level 3.
3297917|NCT01813552|Experimental|Samatasvir + Ritonavir|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fed or fasted conditions with water. Days 5-16: Healthy Volunteers will take ritonavir in the mornings under fasted or fed conditions with water.
3297918|NCT01813552|Experimental|Samatasvir + Omeprazole|Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
3297919|NCT01813565|Experimental|Additional instillation of hyaluronic acid/chondroitin sulfate|Transurethral resection of bladder ulcer + instillation of hyaluronic acid/chondroitin sulfate
3297920|NCT01813565|Active Comparator|Transurethral resection of bladder ulcer|Transurethral resection of bladder ulcer
3297921|NCT01813578|Experimental|Intervention|An SSED study is an open-label design where the individual is his or her own control. All patients included received the same exercise intervention.
3297922|NCT01813591|Experimental|H.P. Acthar Gel 80IU|H.P. Acthar Gel of 80IU (1.0 ml)
3297923|NCT01813591|Experimental|H.P. Acthar Gel 40IU|H.P. Acthar Gel of 40IU (0.5 mL)
3297924|NCT01813604|Active Comparator|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
3297925|NCT01813604|Active Comparator|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
3297926|NCT01813604|Active Comparator|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
3297927|NCT01813604|Active Comparator|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
3297928|NCT01813604|Active Comparator|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
3297929|NCT01813617||Recent onset polymyositis and dermatomyositis|Patients in this cohort was diagnosed with polymyositis or dermatomyositis during 2003-2010 and was treated with corticosteroids and other immunosuppressive agents according to standard care. They were all diagnosed and treated at the Rheumatology Clinic, Karolinska University Hospital.
3297930|NCT01813630|Experimental|DA-3002|0.14 IU (0.045-0.050mg)/kg/day of DA-3002 is injected for 52 weeks by changing injecting areas
3297931|NCT01813630|Active Comparator|Genotropin®|0.14 IU (0.045-0.050mg)/kg/day of Genotropin is injected for 52 weeks by changing injecting areas
3297932|NCT01813643|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,20-30mg/day,non-forced titration method.last2-4weeks.
3297933|NCT01813643|Active Comparator|Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks.
3297934|NCT01813656|Experimental|Aripiprazole|Aripiprazole arm,5mg/pill,10mg/day.last12weeks.
3297935|NCT01813656|Placebo Comparator|Sugar pill|placebo arm,5mg/pill,10mg/day,last12weeks
3297936|NCT01813669|Experimental|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
3297937|NCT01813669|No Intervention|Waitlist Control|Participants in the waitlist condition will not receive any experimental intervention. They can continue any treatments as usual. The waitlist will be approximately 10-14 weeks in duration. At the end they will be offered the opportunity to participate in the intervention. If they elect to participate in the intervention, post-study data will also be collected from this group, approximately 13-weeks following the first group session.
3297938|NCT01813682|No Intervention|control group|preterm infants of this group with iron-free TPN for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3297939|NCT01813682|Experimental|treatment group1|preterm infants of this group with iron supplementation of 200μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3297940|NCT01813682|Experimental|treatment group2|preterm infants of this group with iron supplementation of 400μg/kg/d for more than ten days, compare serum iron, iron protein, total iron binding force, MDA, 8-iso-PGF2α on baseline and after intervention.
3297941|NCT01813695||Preemptive|Patients with genotype testing entered into electronic medical record for consideration and opioid administration postoperatively.
3297942|NCT01813695||Control|Genetic sample taken but withheld from electronic medical record.
3297943|NCT01813708|Experimental|Intensive Life-Style Counseling|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
3297944|NCT01813708|Active Comparator|Collaborative Educational|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
3297945|NCT01813747|Experimental|1440 nm wavelength laser with hand piece|To assess the effectiveness of the 1440 nm wavelength laser with handpiece for skin tightening and laser lipolysis for the mandibular and sub-mandibular areas
3297946|NCT01813760|Experimental|Diode laser|Diode laser to treat peri-orbital and peri-oral wrinkles
3297947|NCT01813773|Experimental|Group A - IAI every 4 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will continue to receive IAI every 4 weeks, beginning week 20, through week 48.
3297948|NCT01813773|Experimental|Group B - IAI every 8 weeks|Receives 5 injections of Intravitreal Aflibercept Injection (IAI) beginning Day 1, and then at weeks 4, 8, 12, and 16. Following the 5 initial injections, this group will receive IAI every 8 weeks, beginning week 24, through week 48.
3297949|NCT01813786|Experimental|755nm Alexandrite Laser with Handpiece 2|Focusing energy on skin
3297950|NCT01813786|Experimental|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
3297951|NCT01813786|Experimental|755nm Alexandrite laser with handpiece 1|Focusing energy on skin
3297952|NCT01813799|Experimental|DA-9801 300mg|
3297953|NCT01813799|Experimental|DA-9801 600mg|
3297954|NCT01813799|Experimental|DA-9801 900mg|
3297955|NCT01813799|Placebo Comparator|Placebo|
3297956|NCT01813812|Experimental|DA-6034 45mg|two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
3297957|NCT01813812|Experimental|DA-6034 90mg|two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
3297958|NCT01813812|Active Comparator|Rebamipide 300mg|two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
3297959|NCT01813825||Female >=45 years, negative margins, DCIS|
3297960|NCT01813838|Experimental|ACADESINE 140mg/kg/d|3 patients will be included at the initial dose of Acadesine 140mg/kg/d
3297961|NCT01813838|Experimental|ACADESINE 210mg/kg/d|In absence of toxicity at the dose of 140mg/kg/d. There is a dose escalation of acadesine at the dose of 210mg/kg/d for 3 additionnal patients
3297962|NCT01813838|Experimental|ACADESINE 315mg/kg/d|In absence of toxicity at the dose of 210mg/kg/d. There is a dose escalation of acadesine at the dose of 315mg/kg/d for 3 additionnal patients
3297963|NCT01813851|No Intervention|control group|"Patients in the control group will receive:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day"
3297964|NCT01813851|Experimental|activity group|"Patients in the group exercise will:~Dietary counseling by a dietician and if necessary modification of the prescription of oral nutritional supplements or intradialytic parenteral nutrition to reach recommended targets according to the European Best Practice Guidelines on Nutrition (energy intake 30-40 kcal/kg of ideal weight/day, protein intake 1.1 g/kg of ideal weight/day A program of physical activity consisting of progressive endurance and resistance training on a cycle ergometer, performed during the dialysis session under supervision and counseling by a qualified trainer"
3297965|NCT01813864|Experimental|CASPAR Resource Guide|Treatment Enhanced/CASPAR-- All counselors in this study will receive a training and take part in the experimental arm of the study in Phase 2.
3297966|NCT01813877|No Intervention|Standard Diagnostics without PET|
3297967|NCT01813877|Experimental|Diagnostics with PET|All 18F-DOPA PET/CT studies will be interpreted qualitatively during a clinical readout session. Based on a previous study scans will be classified as positive if tumor regions defined on CT exhibited tracer uptake above the level of the contra-lateral caudate nucleus. Scans will be classified as negative if tumor 18F-FDOPA uptake is lower than that of the contra lateral caudate nucleus. Uptake at the level of the contra-lateral caudate will be considered equivocal for malignancy.
3297968|NCT01813903|Experimental|Nutrition|Intensified dietary counseling and use of web application.
3297969|NCT01813903|Experimental|Flexible mind|Use of mobile applications.
3297970|NCT01813903|No Intervention|Normal maternity clinic visits|In control maternity clinics, nurses continue their usual counseling.
3297971|NCT01813916|No Intervention|proteomic analysis|
3297972|NCT01813929|Experimental|Metformin|
3297973|NCT01813929|Placebo Comparator|Placebo|
3297974|NCT01813955|Experimental|Papaverine|Patients will receive either Papaverine or placebo added to their current medical treatment. Then after one week, they will receive the other treatment (if it was placebo first, then it will be papaverine; if it was papaverine first, then it will be placebo)
3297975|NCT01813968|Experimental|Ischemic postconditioning|"Ischemic postconditioning via the cardioplegia line starting with 2 min of reperfusion followed by 2 min of ischemia x 3"
3297976|NCT01813968|No Intervention|Control|Standard operating technique
3297977|NCT01813981|Placebo Comparator|High roast coffee|110mg caffeine with 108 mg chlorogenic acid at start of study
3297978|NCT01813981|Active Comparator|Low roast coffee|110 mg caffeine with 235 mg chlorogenic acid at start of the study
3297979|NCT01813981|Placebo Comparator|Control|110 mg caffeine at start of study
3297980|NCT01813994|Placebo Comparator|Control group|Without simvastatin
3297981|NCT01813994|Experimental|Statin group|With simvastatin
3297982|NCT01814033|Experimental|LRU Pillow|Experimental: LRU Pillow
3297983|NCT01814033|Active Comparator|Control Group|Other: Control Group
3297984|NCT01814085|Experimental|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
3297985|NCT01814098|Experimental|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
3297986|NCT01814111|Experimental|renal sympathetic denervation|Perform renal angiogram immediately prior to renal sympathetic denervation procedure to confirm anatomic eligibility，The treatment catheter was introduced into each renal artery using a guiding catheter. Up to six ablations at 10 W for 1 min each were performed in both renal arteries. Treatments were delivered from the first distal main renal artery bifurcation to the ostium proximally and were spaced longitudinally and rotationally under fluoroscopic guidance. Catheter tip impedance and temperature were constantly monitored, and radio frequency energy delivery was regulated according to a predetermined algorithm. Visceral pain at the time of energy delivery was managed with intravenous analgetics and sedatives.
3297987|NCT01814111|No Intervention|Drug Treatment Group|All the patients in this group will take their baseline antihypertensive medication at the original doses, without any changes except when medically required. AAD treatment is consistent in both arms.
3297988|NCT01814124|Active Comparator|Advice and home exercise|All participants will be given a handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week
3297989|NCT01814124|Experimental|Manual Therapy Plus Exercise|"Participants in this group will be given the same handout consisting of education about avoidance of certain activities as well as 3 stretches and 3 strengthening exercises to be performed as a home exercise program 2-3x/week.~Participants in this group will also receive 12 individualized physical therapy treatment sessions (2x/week for 6 weeks) consisting of both manual therapy and exercise directed at the hip and surrounding areas based upon findings from the initial examination. Participants will also be given additional exercises to be performed at home as directed by the treating physical therapist"
3297990|NCT01814150||Oncology Institute, Meir Medical Center|Metastatic cancer patients treated with docetaxel at the Oncology Institute, Meir Medical Center
3297991|NCT01814163||Paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
3297992|NCT01814176|Active Comparator|Macintosh Direct Laryngoscope|2 main forces - a 'lifting' force to elevate the structures not in the line of sight and a force exerted by the user's wrist to counterbalance the torque effect of the tongue tissues on the blade
3297993|NCT01814176|Active Comparator|GlideScope Video Laryngoscope|The GlideScope has a 60º angulation anteriorly at the distal portion of the blade, allowing an anterior view of the larynx.
3297994|NCT01814189|Active Comparator|sumatriptan+promethazine (SPr)|The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg).
3297995|NCT01814189|Placebo Comparator|Sumatriptan+placebo (SP)|The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine.
3297996|NCT01814202|Experimental|PTM202|PTM202 is a medical nutrition product
3297997|NCT01814202|Placebo Comparator|Placebo|The placebo is a placebo for PTM202, a food product that can not be distinguished from PTM202 by appearance, taste or odor
3297998|NCT01814215|Experimental|Healthy Lifestyles Group|The Experimental Arm will receive the Keys to Healthy Family Child Care Homes intervention to be delivered over 9 months in 3 modules (3 months/module). The intervention group will be asked to participate in 3 workshops on 3 content areas. Participants will be asked to meet with a coach 3 times in-person, as well 3-9 times by phone/email, over the course of the 9-months. Three content areas are designed to help providers:(1) modify their own weight-related behaviors so they can role model healthy behaviors for children in their care (Healthy You module), (2) create environments that support children's physical activity and healthy dietary intakes (Healthy Home module), and (3) adopt sound business practices that will help them sustain the changes introduced (Healthy Business module).
3297999|NCT01814215|Placebo Comparator|Healthy Business Group|The Control Arm will receive the Healthy Business Education and Coaching program to be delivered over 9 months in 3 modules (3 months/module). The control group will be asked to participate in 3 workshops and a similar number of coaching contacts about their business practices. The focus on business topics is relevant, but not directly related to physical activity or nutrition.
3298000|NCT01814228|Experimental|right atrium ganglionated plexi transcatheter ablation|right atrium ganglionated plexi transcatheter ablation
3298001|NCT01814254||Receiving hemodialysis|
3298002|NCT01814267|Experimental|Telemedicine|care and follow-up through telemedicine.
3298003|NCT01814267|Active Comparator|Conventional care|care and follow-up through iterative diabetes physician consultations (conventional care and follow-up)
3298004|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
3298005|NCT01814293|Active Comparator|Handheld humidifier|Study design is a nonblinded randomized controlled comparison study of pediatric patients presenting to the UCSF Emergency Department (ED) with upper respiratory infection (URI) symptoms for which the ED physician has recommended supportive care only (ie. non-prescription symptom relief). Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
3298006|NCT01814293|No Intervention|Control group|Subjects will manage cold symptoms with any desired supportive over the counter treatment, and complete surveys related to symptom scores and modalities used.
3298007|NCT01814306|Active Comparator|Supreme|Supreme LMA
3298008|NCT01814306|Active Comparator|Proseal|Proseal LMA
3298009|NCT01814319|Experimental|Probenecid|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate therapy.
3298010|NCT01814319|Placebo Comparator|placebo|Probenecid 1 gr oral twice daily or placebo will be given to the subject for 1 week (randomly assigned). A subsequent 1 week washout period will occur followed by the alternate (placebo) therapy.
3298011|NCT01814358|Experimental|Whey protein|Subjects on this arm will receive whey protein
3298012|NCT01814358|Active Comparator|Gelatin protein|Subjects on this arm will consume gelatin protein
3298013|NCT01814358|No Intervention|Control arm|Subjects on this arm will receive no intervention
3298014|NCT01814384|Other|Control group|Control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
3298015|NCT01814384|Other|Matched patient|Treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
3298016|NCT01814410|Placebo Comparator|intravenous ethanol placebo and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3298017|NCT01814410|Active Comparator|intravenous ethanol 40% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3298018|NCT01814410|Active Comparator|intravenous ethanol 100% and nicotine infusions|Each subject will participate in three separate interventions. Each intervention will include three nicotine infusions (placebo and 2 active conditions). The interventions will differ on the ethanol infusion: placebo or one of two ethanol concentrations.
3298019|NCT01814423|Experimental|Chloroquine-base 50 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another day.
3298020|NCT01814423|Active Comparator|Chloroquine-base 70 mg|Chloroquine-base 10 mg/kg twice a day for 2 days and 5 mg/kg twice a day for another 3 days.
3298021|NCT01814436|Experimental|scaffold-free SHED-derived pellet|
3298022|NCT01814449||Hypoxic Group|Higher 18FMISO uptake (Target to background Ratio, TBR>1.2) in Primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy Letrozole was given to the patients.
3298023|NCT01814449||Non-Hypoxic Group|Lower 18FMISO uptake (TBR<1.2)in primary breast cancer by 18FMISO PET/CT scan.Primary endocrine therapy letrozole was given to the patients.
3298024|NCT01814462|Experimental|6 months CPAP|Application of continuous positive airway pressure (CPAP) therapy as established per routine clinical treatment. Home use of therapy for a period of 6 months.
3298025|NCT01814475|Active Comparator|A: Fludarabine + Busulphan|Conventional conditioning regimen with Fludarabine and Busulphan (Busilvex)for allogeneic stem cell transplantation in myelofibrosis
3298026|NCT01814475|Experimental|B: Fludarabine + Thiotepa|Reduced-intensity conditioning with Fludarabine and Thiotepa for allogeneic stem cell transplantation in myelofibrosis
3298027|NCT01814488|Experimental|allogenic transplant|The experimental treatment consists in the application of a therapeutic strategy of allogeneic transplantation as a potential curative procedure in a population of patients with chemoresistant acute leukemias. Therapeutic intervention, namely the conditioning regimen as well as GVHD prophylaxis, are based on regimens currently in standard use in the context of allogeneic transplantation.
3298028|NCT01814501|Experimental|Treatment (panitumumab, combination chemotherapy)|5-Fluorouracil, irinotecan, and panitumumab
3298029|NCT01814514|Active Comparator|Timolol-trusopt|Dosage:One drop/12hours,duration:3 months
3298030|NCT01814514|Placebo Comparator|placebo,Artificial tear|dosage:one drop/12 hours,duration:3 months
3298031|NCT01814527|Active Comparator|Docosahexaenoic acid|The experimental group will be given a standardized dose of omega-3 fatty acid containing 2200mg of DHA for 30 days after onset of concussion or longer for those with continued symptomatology. Brain Armor an over the counter DHA supplements that is independently tested and certified by the National Science Foundation Athletic Banned Substance Certified for Sport Program. The Docosahexaenoic acid supplement has 440mg of DHA per capsule and each subject will be given 5 capsules of Brain Armor once daily for a DHA dose of 2200mg/day.
3298032|NCT01814527|Placebo Comparator|Placebo|The placebo group will be given an equal amount of capsules.
3298033|NCT01814540|Placebo Comparator|Placebo Control, Glucose polymer|Treatment 1: Polycose Glucose Polymer Module powder (Abbott Nutrition, Abbott Park, Illinois 60064), fed as 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days.
3298034|NCT01814540|Experimental|Treatment 2: Low-Dose BMO|"Treatment 2: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 25% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 25% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
3298035|NCT01814540|Experimental|Treatment 3: High-Dose BMO|"Treatment 3: Bovine Milk Oligosaccharide (BMO) powder (Hilmar Ingredients, Hilmar, California 95324) Dosage: 35% of individual daily fiber intake, split into two daily servings Frequency: Two servings per day (for total of 25% dosage per day) Duration: 11 days, followed by a 2-week wash-out period~Fiber intake was 35% of each individual's daily fiber intake based on calculated energy expenditure (14 grams of fiber for every 1000 kcal consumed) for eleven consecutive days."
3298036|NCT01814579|Experimental|V-Loc Vaginal Cuff Closure|Patients in this arm will receive vaginal cuff closure with unidirectional barbed suture at time of their robotic hysterectomy.
3298037|NCT01814579|Active Comparator|Vicryl Vaginal Cuff Closure|Patients enrolled in this arm will have their vaginal cuff closed with polyglactin 910 (Vicryl) at the time of their robotic hysterectomy.
3298038|NCT01814592|Experimental|coronally mucosal thickness flap|coronally mucosal thickness flap plus connective tissue graft for root coverage (subepithelial connective tissue graft)
3298039|NCT01814592|Active Comparator|coronally partial thickness flap|coronally partial thickness flap plus connective tissue for root coverage (subepithelial connective tissue graft)
3298040|NCT01814605|Experimental|Subgluteal space group|"The patients in Subgluteal space group will receive sciatic block according to the approach described by Karmakar et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint will be designated with a marker and will be the site of needle entry.~A 50 to 90 mm 22 G insulated needle will be inserted at the midpoint previously designated and advanced under real time guidance in an out-of-plane approach until the needle reaches the subgluteal space."
3298041|NCT01814605|Active Comparator|Infragluteal space group|The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. After skin and transducer preparation, a curved 5 MHz(megahertz) transducer will be placed over the subgluteal region in a transverse plane to scan the sciatic nerve. A 50 to 90 mm 22 G needle is used and advanced under real time guidance in an out-of-plane approach until the needle tip is adjacent o the nerve.
3298042|NCT01814618|No Intervention|Observation|These subjects did not have improved sense of smell after surgery and were randomized to this observation group or treatment group. These patients will be observed post-operatively but will not receive the trial medication.
3298043|NCT01814618|Experimental|Treatment|"These subjects did not have improved sense of smell after surgery and were randomized to this treatment group or the observation. These patients will be observed post-operatively and will receive a 3-month course of topical nasal steroids(budesonide respules).~Drug: Budesonide Respules~Other Names:~Pulmicort respules~Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months."
3298044|NCT01814631||Aloka|image quality and resolution
3298045|NCT01814644|Active Comparator|Standard Care|Individual assessment Lifestyle counseling
3298046|NCT01814644|Experimental|TRIMM Intervention|Individual assessment Lifestyle counseling Text messages
3298047|NCT01814657|Placebo Comparator|Normal Saline|Conscious sedation and sterile normal saline (placebo) paracervical block
3298048|NCT01814657|Active Comparator|Lidocaine|Conscious sedation and Lidocaine hydrochloride 1% solution paracervical block
3298049|NCT01814683|Experimental|Primaquine 7 day|Standard blood schizontocidal therapy plus 7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
3298050|NCT01814683|Placebo Comparator|Placebo controlled arm|Standard blood schizontocidal therapy plus 14 days placebo.
3298051|NCT01814683|Active Comparator|Primaquine 14 day|Standard blood schizontocidal therapy plus 14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
3298052|NCT01814709|Experimental|Itraconazole Arm|
3298053|NCT01814709|Experimental|Rifampin Arm|
3298054|NCT01814735|Experimental|Brown rice|Brown Rice
3298055|NCT01814735|Active Comparator|White rice|White rice
3298056|NCT01814826|Experimental|MLN4924 and Azacitidine|
3298057|NCT01814839|Active Comparator|ALN-TTRSC (revusiran)|
3298058|NCT01814839|Placebo Comparator|Sterile Normal Saline (0.9% NaCl)|
3298059|NCT01814852|Experimental|Shockwaves|4 weekly sessions of low-intensity shockwave therapy
3298060|NCT01814852|Sham Comparator|Control Group|
3298061|NCT01814865|Experimental|Abiraterone Acetate + Prednisone|Abiraterone 1000mg PO OD + Prednisone 5mg PO OD x 2 weeks
3298062|NCT01814865|Active Comparator|Aromatase Inhibitor|Anastrozole 1mg PO OD x 2 weeks
3298063|NCT01814891|Experimental|Orange maize|"Children were fed orange maize and the intervention name was orange"
3298064|NCT01814891|Active Comparator|Blue vitamin A group|Received vitamin A in the form of retinyl palmitate in oil at the estimated average requirment.
3298065|NCT01814891|Placebo Comparator|White|Received oil only at the same volume as the vitamin A group
3298066|NCT01814904|Experimental|MCI-196-L|MCI-196 BSA eq 3g
3298067|NCT01814904|Experimental|MCI-196-M|MCI-196 BSA eq 6g
3298068|NCT01814904|Experimental|MCI-196-H|MCI-196 BSA eq 9g
3298069|NCT01814904|Active Comparator|CBPB|Calcium-based P binder
3298070|NCT01814917|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
3298071|NCT01814917|Active Comparator|CBPB|Calcium-based P binder
3298072|NCT01814930|No Intervention|Routine Care|Routine postpartum contraceptive counseling
3298073|NCT01814930|Experimental|Individual counseling|Brief standardized contraceptive counseling intervention
3298074|NCT01814943||Patients with prescription for low dose ASA (75-300 mg/day)|
3298075|NCT01814956|Experimental|1|i.v. lipid emulsion for parenteral nutrition
3298076|NCT01814956|Active Comparator|2|i.v. lipid emulsion for parenteral nutrition
3298077|NCT01814969|Experimental|Hyperfractionated Radiochemotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks with simultaneous two cycles of chemotherapy according to the scheme: 5FU-325mg/m2 (bolus) on 1-3 and 16-18 (last 3 days of radiotherapy).~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiochemotherapy (HRTCT)."
3298078|NCT01814969|Active Comparator|Hyperfractionated Radiotherapy|"radiotherapy in rectal tumor area due to the placing of pelvic nodal groups to a total dose of 42 Gy, 1.5 Gy d fx 2 times a day; (gap between the factions min. 6-8h) - duration of treatment 2.5 weeks.~Surgical resection has to be done within 14 days or 5-6 weeks after the completion of hyperfractionated radiotherapy (HRT)."
3298079|NCT01814982|Experimental|Part 1: JNJ-17299425|JNJ-1729425 will be administered once as 1 milligram (10 milliliter of a 0.1 milligram/milliliter (mg/ml) solution) intravenous bolus injection over 2 minutes in central vein. In case of no toxicity or Intra cranial pressure response, dose will be increased to a maximum of 200 milligram (mg).
3298080|NCT01814982|Experimental|Part 2: JNJ-17299425|JNJ-1729425 will be repeated once at a dose (which is, determined by Investigator in Part 1) as intravenous bolus injection over 2 minutes in central vein.
3298081|NCT01814995|Experimental|Nutrition/Physical Activity Intervention|There will be four in-person group sessions (1/month), two including the participants' partners, and all with on-site child care. Sessions will include preparation of a healthy meal (hands-on) and discussions of mindful eating, balanced meals, portion sizes, and preparing food at home, under a dietitian's supervision. Sessions will also include a one-hour physical activity information/practice session with a kinesiologist. Participants will track daily step counts with a pedometer and aim to eventually reach more than 10,000 steps/day. They will also receive instruction and demonstration from a kinesiologist of some simple resistance exercises they may perform at home. Between sessions, participants will receive advice and support through a study-specific website and telephone calls.
3298082|NCT01815021|Experimental|amorphous calcium carbonate|50, 100 and 200 mg elemental calcium tablets, according to the doctor's decision
3298083|NCT01815021|Active Comparator|crystalline calcium supplements|Tablets, according to the doctor's decision
3298084|NCT01815047|Experimental|200 IU Vitamin D3|A singular daily dose of 200 IU vitamin D3
3298085|NCT01815047|Experimental|2000 IU Vitamin D3|A singular daily dose of 2000 IU vitamin D3
3298086|NCT01815073|Experimental|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3298087|NCT01815073|Experimental|Live Attenuated Varicella Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3298088|NCT01815073|Experimental|Live Attenuated JE Vaccine|use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3298089|NCT01815086|Experimental|124I-labeled anti-amyloid mAb 11-1F4|124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.
3298090|NCT01815112|Experimental|Alzheimer|Alzheimer patients detected via conventional clinical and neuropsychological tests. They will undergo Magnetic resonance imaging and positron emission tomography examinations.
3298091|NCT01815112|Experimental|Vascular dementia|Vascular dementia patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
3298092|NCT01815112|Experimental|Mild cognitive impairment (MCI)|Mild cognitive impairment (MCI) patients detected via conventional clinical and neuropsychological tests. They will undergo magnetic resonance imaging and positron emission tomography examinations.
3298093|NCT01815112|Experimental|Healthy subjects (MRI)|Healthy subjects agreeing to undergo magnetic resonance imaging examination.
3298094|NCT01815112|Experimental|Healthy subjects (PET)|Cognitively healthy subjects. These subjects are people addressed in the nuclear medicine department for cancer-related positron emission tomography examination. If they agree, an extended neuropsychological test will assess that they do not suffer any cognitive disorder.
3298095|NCT01815125|Experimental|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
3298096|NCT01815125|Placebo Comparator|Placebo|The control group will receive a similar looking/ tasting pill of placebo.
3298097|NCT01815164|Active Comparator|Hypnotherapy|Hypnotherapy
3298098|NCT01815164|Active Comparator|Educational intervention|Educational intervention
3298099|NCT01815177|Experimental|Arthroscopic transosseous fixation|Patients with torn rotator cuff randomized to experimental treatment receive a complete arthroscopic transosseous cuff repair
3298100|NCT01815177|Other|Repair using suture anchors|Patients randomized to this arm receive an arthroscopic rotator cuff repair using suture anchors.
3298101|NCT01815190||IgA-positive vasculitis|Patients with immune complex vasculitis who show perivascular deposits of IgA
3298102|NCT01815190||IgA-negative vasculitis|Patients with immune complex vasculitis who show no perivascular deposits of IgA
3298103|NCT01815203|Experimental|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
3298104|NCT01815203|Placebo Comparator|Placebo|Administration of placebo (one gelatin capsule containing starch) with subsequent cognitive tasks and food test.
3298105|NCT01815216|Experimental|Bariatric surgery|patients participating in the intervention group , i.e. assessing effects of bariatric surgery on: Brain activity in resting state Memory performance
3298106|NCT01815216|Active Comparator|Control|"Patients in the control group will not undergo surgery during study.~These patients will be examined twice:~9 weeks before the operation (i.e. clinical intervention to reduce body weight has not started).~after 4 weeks of low-calorie diet (which will be a week before their surgery, when patients are in a catabolic metabolism because they eat much less energy than is needed) to assess effect of acute weight loss on: Brain activity in resting state Memory performance"
3298107|NCT01815242|Experimental|Arm A|nab-Paclitaxel + gemcitabine
3298108|NCT01815242|Experimental|Arm B|nab-Paclitaxel + carboplatin
3298109|NCT01815255||tenofovir (TDF)|HIV-infected children who are currently on TDF-based regimen or are changing to TDF based on their clinical indication
3298110|NCT01815268|Experimental|HD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and provided free SD vaccine (Fluzone) for the staff.
3298111|NCT01815268|Experimental|HD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive high-dose trivalent influenza vaccine (Fluzone High-Dose) for the residents and not provided free vaccine for the staff.
3298112|NCT01815268|Active Comparator|SD Vaccine (Residents) + Free Vaccine (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and provided free standard dose vaccine (Fluzone) for the staff.
3298113|NCT01815268|Active Comparator|SD Vaccine (Residents) + Usual Care (Staff)|NH facilities randomized to receive standard dose influenza vaccine (Fluzone) for the residents and not provided free vaccine for the staff.
3298114|NCT01815281|Experimental|Foot Mechanical Stimulation|The FMS stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
3298115|NCT01815281|Sham Comparator|Footh Mechanical Stimulation|The sham stimulation will be given to all participants using GONDOLA equipment (Ecker Technologies Sagl, Switzerland).
3380104|NCT04971226|Experimental|Asciminib|Patients will take asciminib 80 mg QD under fasting conditions on ongoing basis; Patients will be randomized 1:1 asciminib versus Investigator selected TKIs
3380105|NCT04971226|Active Comparator|Investigator selected TKIs|"Patients will take on ongoing basis the Investigator selected TKIs that will include one of the below treatments:~Imatinib 400 mg QD administered with food Nilotinib 300 mg BID administered under fasting conditions Dasatinib 100 mg QD administered with or without a meal Bosotunib 400 mg QD administered with food"
3298116|NCT01815294|Experimental|Treatment A: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the current site of manufacturing administered by IV infusion over 90 minutes on Day 1
3380110|NCT04969224|Experimental|ELX/TEZ/IVA|Participants will receive ELX/TEZ/IVA fixed-dose combination (FDC) in the morning and IVA in the evening.
3380111|NCT04968236|Experimental|Deep dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a deep dry needling technique to the latent trigger point and make 10-12 incisions.
3380112|NCT04968236|Experimental|Superficial dry needling|With the subject lying supine, we will first locate a latent myofascial trigger point in the rectus femoris muscle.Subsequently, we will apply a superficial dry needling technique to the latent trigger point. Once the needle is placed in the subcutaneous cellular tissue, we manipulate the needle by twisting it until an unpleasant response is provoked. We keep the needle for 5 minutes
3380113|NCT04968236|Experimental|Passive muscle stretching|With the patient positioned in the supine position, the pelvis stabilized with a strap and the lower extremity where we are going to apply the rectus femoris muscle stretch placed outside the table, we perform a passive stretching technique, increasing hip extension and knee flexion until the patient feels the tension. The position is held for 60 seconds.
3380114|NCT04965597|Experimental|treosulfan, fludarabine and Thymoglobulin, tacrolimus and methotrexate|Patients will be treated with a preparative regimen of treosulfan (total dose 30-42 g/m2), fludarabine (total dose 150 mg/m2), and Thymoglobulin (total dose 6 mg/kg). GVHD prophylaxis will be with tacrolimus and methotrexate.
3380115|NCT04963270|Experimental|Satralizumab|Participants will receive Satralizumab at Weeks 0, 2, 4, and Q4W thereafter
3380116|NCT04963270|Placebo Comparator|Placebo|Participants will receive placebo at Weeks 0, 2, 4, and Q4W thereafter
3298117|NCT01815294|Experimental|Treatment B: DOXIL/CAELYX (doxorubicin)|50 mg/m2 of doxorubicin manufactured at the new site of manufacturing (test product) administered by IV infusion over 90 minutes on Day 1
3298118|NCT01815307|Experimental|Gemcitabine group|1000mg/m2, day 1 every 2 weeks
3298119|NCT01815307|Experimental|S-1 group|80mg/m2/day, day 1-28, every 6 weeks
3298120|NCT01815320|Experimental|Contrast-enhanced ultrasound (CE-US)|Ce-US is performed by contrast agent infusion SonoVue. The acquisition protocol will consist of two different administrations of SonoVue, performed 10 minutes apart. In the first session, SonoVue microbubbles will be administered as a fast 1.5 ml bolus immediately followed by 5 ml saline solution. In the second session, max 2 vials (9.6 ml) of SonoVue will be infused at an infusion rate between 0.5 and 1.0 ml/min.
3298121|NCT01815346|Experimental|Acupuncture Group - Twice a Week|Acupuncture 2 times a week for 6 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
3298122|NCT01815346|Experimental|Acupuncture Group - Three Times a Week|Acupuncture 3 times a week for 4 weeks. Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes.
3298123|NCT01815359|Experimental|Appendiceal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3298124|NCT01815359|Experimental|Appendiceal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3380120|NCT04961619||dabrafenib and trametinib|patients on adjuvant treatment with dabrafenib + trametinib
3380121|NCT04961567|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC), every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
3380122|NCT04961567|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
3380123|NCT04961567|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
3298125|NCT01815359|Experimental|Colorectal, no chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3298126|NCT01815359|Experimental|Colorectal, chemotherapy within 6 months prior to surgery|"First, patients will be stratified by previous systemic chemotherapy and by the organ of origin as determined by the PI or Co-PI.~Exposure to chemotherapy in the prior 6 months vs. no such exposure~Appendix vs. Colon or Rectum • Then, patients will be randomly assigned in the operating room, by envelope, to either HIPEC (Group A) or EPIC (Group B) after the operating surgeon determines that the patient is optimally cytoreduced to nodules no greater than 2.5mm."
3298127|NCT01815372|Experimental|SPEDI|These are the patients that will be randomized to receive a SPEDI block of the sciatic and saphenous nerve with at single needle penetration of the skin
3298128|NCT01815372|Active Comparator|Popliteal sciatic and mid-femoral saphenous|These are the patients that will be randomized to the administration of a popliteal sciatic nerve block combined with a mid-femoral saphenous nerve block with two separate injections
3298129|NCT01815398|Active Comparator|Computer skills training|26 sessions conducted 2-3 times a week to train in computer skills related to the workforce.
3298130|NCT01815398|Experimental|Cognitive Remediation|26 sessions conducted 2-3 times a week of cognitive remediation
3298131|NCT01815411|Experimental|Mushroom extract|The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
3298132|NCT01815411|No Intervention|Control group|The control group is selected by randomisation.
3298133|NCT01815437|Active Comparator|2000 IU Vitamin D3- Cholecalciferol|Take 2000 IU crystalline vitamin D3 once/day for 12 weeks.
3298134|NCT01815437|Active Comparator|2000 IU Vitamin D2- Ergocalciferol|Take 2000 IU crystalline vitamin D2 supplement once/day for 12 weeks.
3298135|NCT01815437|Experimental|2000 IU Mushroom Vitamin D2|Take 2000 IU vitamin D2 in a mushroom supplement once/day for 12 weeks
3298136|NCT01815437|Placebo Comparator|Mushroom Extract|Capsules with mushroom extract and no vitamin D. The intervention is mushroom extract.
3298137|NCT01815450|Experimental|BLI1100|BLI1100 topical cream
3298138|NCT01815450|Experimental|BLI1100 - modified formulation|BLI1100 topical cream
3298139|NCT01815450|Placebo Comparator|Placebo|Topical cream
3298140|NCT01815463||colorectal neoplasia|No interventions Record colorectal neoplasia
3298141|NCT01815476|Other|RT Positioning Intervention: Supine|Patient will be treated in a supine position as per standard of care/control.
3298142|NCT01815476|Experimental|RT Positioning Intervention: Prone|Patient will be treated in the prone position.
3298143|NCT01815528|Experimental|Catumaxomab|Catumaxomab treatment followed by an established chemotherapy regimen
3298144|NCT01815541|Experimental|teicoplanin|this group receive the teicoplanin
3298145|NCT01815554||DPS Cohort|All patients implanted with a DPS within the past 5 years at one of 6 collaborating sites will be included. Patients will be interviewed as they cross their 1st, 3rd, 5th or 7th anniversary with the DPS.
3298146|NCT01815567||controlled hypertension|hypertension with medication controlled
3298147|NCT01815567||uncontrolled hypertension|non-controlled hypertension
3298148|NCT01815567||hypertensive urgency|hypertensive urgency no previous history or antihypertensives
3298149|NCT01815567||asymptomatic normotensive|asymptomatic normotensive control group
3298150|NCT01815580|Active Comparator|Immediate ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at enrollment.
3298151|NCT01815580|Placebo Comparator|Deferred ART (Atripla or Stribild)|Daily Atripla or Stribild will be provided to these patients for the duration of the study beginning at 24 weeks.
3298152|NCT01815593|Experimental|Enhanced External Counterpulsation|Men with erectile dysfunction receive Enhanced External Counterpulsation treatment
3298153|NCT01815593|No Intervention|Control|Men with erectile dysfunction without Enhanced External Counterpulsation treatment
3298154|NCT01815606|Active Comparator|19 Gauge needle biopsy|biopsy with 19 gauge needle
3298155|NCT01815606|Active Comparator|25 gauge needle biopsy|biopsy with 25 gauge needle
3298156|NCT01815619|Experimental|on-site evaluation of specimens by cytopathologist|The specimen will be evaluated onsite by a cytopathologist during the procedure to render a diagnosis
3298157|NCT01815619|Active Comparator|off-site specimen evaluation|The specimen will be evaluated offsite by a cytopathologist during the procedure and render a diagnosis
3298158|NCT01815632|Experimental|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow (without myeloablation) on the day of bone marrow harvest. Infusion of autologous blood at one year post-harvest
3298159|NCT01815632|Experimental|Late infusion of autologous marrow|Intravenous infusion of autologous blood on the day of bone marrow harvest. Infusion of autologous bone marrow (without myeloablation) at one year post-harvest
3298160|NCT01815658||Broken humerus shaft|Patients presenting with broken humerus shaft
3298161|NCT01815684|Experimental|ASP3652 Group 1|Dosed according to the following scheme: placebo, low dose, medium dose, high dose
3298162|NCT01815684|Experimental|ASP3652 Group 2|Dosed according to the following scheme: low dose, placebo, medium dose, high dose
3298163|NCT01815684|Experimental|ASP3652 Group 3|Dosed according to the following scheme: low dose, medium dose, placebo, high dose
3298164|NCT01815684|Experimental|ASP3652 Group 4|Dosed according to the following scheme: low dose, medium dose, high dose, placebo
3298165|NCT01815697|Experimental|Enhanced External Counterpulsation|Men with benign prostatic hyperplasia receive 35- 36 hours Enhanced External Counterpulsation treatment
3298166|NCT01815697|No Intervention|Control|Men with benign prostatic hyperplasia without Enhanced External Counterpulsation treatment as control
3298167|NCT01815710||Vomiting & Diarrhea|Alberta Health Services Acute Childhood Vomiting & Diarrhea Pathway
3298168|NCT01815710||Pediatric Asthma Clinical Pathway|Pediatric Asthma Clinical Pathway
3298169|NCT01815723|Experimental|FP187|500 mg FP187 daily (250 mg twice daily)
3298170|NCT01815723|Active Comparator|Dimethyl fumarate|720 mg Fumaderm® daily (240 mg three times daily)
3298171|NCT01815723|Placebo Comparator|Placebo|Matching FP187 and Fumaderm® placebo
3298172|NCT01815749|Experimental|Treatment (genetically modified T cell infusion)|Patients undergo mobilization for autologous stem cell collection with cytoreductive chemotherapy and filgrastim and/or plerixafor per current standard operating policies. Patients undergo myeloablative conditioning regimen per institutional standards beginning day -7 followed by hematopoietic stem cell transplantation on day 0. Patients receive CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells IV on day 2 or 3 (may be delayed up to day 45 if the patient is not yet eligible). Patients who experience disease progression and have not experienced DLTs at greater than or equal to 100 days post HSCT will be allowed to receive an optional second T cell infusion.
3298173|NCT01815762|Active Comparator|active arm of the study|The number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. The US B-line score (BLS) will be measured before dialysis. In patients presenting moderate to severe lung congestion (≥15 BLS pre-dialysis) LUS measurements will be repeated once a week until the treatment goal was achieved (<15 BLS pre-dialysis) and once a month thereafter. monthly monitoring frequency will be adopted also in patients without pulmonary congestion (BLS <15). Patients without evidence of lung congestion at baseline who developed pulmonary congestion (≥ 15 BLS) during the trial will received the same treatment contemplated for those with lung congestion at baseline during the trial.
3298174|NCT01815762|No Intervention|Standard care arm|In the control arm of the study, the dry weight will be assessed only clinically.Patients in the control arm of the study will be followed up and managed strictly with standard criteria according to current recommendations (implying optimization of fluids volume control on the basis of clinical criteria and the use of carvedilol, ACE inhibitors/sartans whenever deemed necessary); the use of lung US / bioimpedance assistance was not allowed in these patients.
3298175|NCT01815775|Experimental|Normal pressure hydrocephalus|Hydrocephalus patients planned for shunting surgery. They will undergo clinical and imaging examinations at day 1, 3 months and 1 year after their surgery.
3298176|NCT01815788|Experimental|Teo first|"Mild and moderate presbycusis (20 to 50 dB average hearing loss at 500, 1000, 2000 Hz and 4000 Hz)~Patient 60 years of age and older,~No previous hearing aid"
3298177|NCT01815801|Experimental|Ventilated group|Lungs were mechanically ventilated during subclavian vein catheterization.
3298178|NCT01815801|Active Comparator|Control group|Lungs were not mechanically ventilated during subclavian vein catheterization.
3298179|NCT01815814|Experimental|Rolfing After 3-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 3 months after they start the study.
3298180|NCT01815814|Other|Rolfing After 6-Month Wait|The children in this arm receive the therapy (rolfing / myofascial structural integration) 6 months after they start the study.
3298181|NCT01815827|Active Comparator|Caucasian Healthy volunteers|
3298182|NCT01815827|Experimental|Japanese Healthy volunteers|
3298183|NCT01815853|Experimental|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
3298184|NCT01815853|Active Comparator|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 D1; 21-days/cycle) following with D2 Gastrectomy and 3 cycles of Adjuvant XELOX Chemotherapy
3298185|NCT01815866||CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
3298186|NCT01815879||Control Group|Retrospective review of clinical data on at least 1,000 evaluable US patients with 12+weeks follow up that were treated with 90Y resin microsphere radioembolization for metastatic colorectal liver metastases
3298187|NCT01815892|Active Comparator|Withdrawal of Furosemide|The patient's Furosemide will be withdrawn
3298188|NCT01815892|Experimental|Administration of furosemide|The patient will receive furosemide 120 mgms daily
3298189|NCT01815905|Active Comparator|Traditional therapy|Traditional rehabilitation therapy
3298190|NCT01815905|Experimental|Mobile program|Mobile program for occupational and speech therapy
3298191|NCT01815931||ED patients|
3298192|NCT01815944|Active Comparator|0.75% Ropivacaine and normal saline|Ultrasound-guided supraclavicular block using 0.75% ropivacaine diluted with normal saline
3298193|NCT01815944|Experimental|0.75% ropivacaine and dextrose 5%|Ultrasound guided supraclavicular block using 0.75% ropivacaine diluted with dextrose 5%
3298194|NCT01815957|Experimental|Ranalozine|After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
3298195|NCT01815970|Experimental|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation
3298196|NCT01815983|Experimental|Videolaryngoscopy review.|Video review.
3298197|NCT01815996||Pregnant Women|"Females between the age of 18-80 who are pregnant~One time blood draw to look at patient's DNA"
3298198|NCT01815996||Pulmonary Embolism Patients|"Male and Female patients that have suffered a pulmonary embolism within the past 48 hours~One time blood draw to look at patient's DNA"
3298199|NCT01815996||Myocardial Patients|"Male and Female patients who have myocardial infarction in the past 48 hours.~One time blood draw to look at patient's DNA"
3298200|NCT01815996||Autoimmune Patients|"Male and Female patients that have been diagnosed with an Autoimmune disease~One time blood draw to look at patient's DNA"
3298201|NCT01815996||Healthy Controls|"Self-declared healthy adults (men and women).~One time blood draw to look at patient's DNA"
3298202|NCT01816009|Experimental|6 weeks|the duration of antibiotic treatment will be six weeks.
3298203|NCT01816009|Active Comparator|12 weeks|the duration of antibiotic treatment will be 12 weeks.
3298204|NCT01816035|Experimental|Treatment (trastuzumab emtansine)|Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients achieving response may continue treatment.
3298205|NCT01816087|Experimental|brief assessment tool (BAT)|all participants will have a brief assessment tool (BAT) for the identification of geriatric syndromes performed by their general practitioner. Afterwards, all participants will have a full geriatric assessment performed by geriatricians
3298206|NCT01816100|Experimental|exercise session|"6 months weight resistance session, with before/after evaluations by MEG and DTI. Fifty minute exercise sessions, twice weekly will be done. Each session will rotate between 3 separate exercise protocols: Static weights, free weights and balance. Exercises will be done with each extremity independently. For consistency and convenience, the resistance training will be performed at Fast Forward Gym, Omaha, NE.~The primary outcome exercise data include strength and endurance"
3298207|NCT01816113|Experimental|Group 1|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
3298208|NCT01816113|Experimental|Group 2A|4 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
3298209|NCT01816113|Experimental|Group 2B|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 1 x 10^8 pfu 8 weeks later intramuscularly
3298210|NCT01816113|Experimental|Group 2C|8 volunteers; 1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly and 1 dose MVA PvDBP 2 x 10^8 pfu 8 weeks later intramuscularly
3298211|NCT01816126||one-operator technique|
3298212|NCT01816126||two-operator technique|
3298213|NCT01816139|Experimental|WC3011|Vaginal Cream, 0.015 mg estradiol/0.5 g vehicle administered daily for initial 14 days followed by twice weekly for 10 weeks
3298214|NCT01816139|Placebo Comparator|Vehicle|0.5 g Vehicle vaginal cream administered daily for initial 14 days followed by twice weekly for 10 weeks
3298215|NCT01816152|Active Comparator|Active Intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where active lighting is experienced by patients.
3298216|NCT01816152|Placebo Comparator|Inactive intervention|Light levels, primary and secondary measurements are obtained after a 4-week intervention period where an inactive lighting is experienced by patients
3298217|NCT01816165|Experimental|Acipimox|Drug: acipimox
3298218|NCT01816165|Placebo Comparator|Placebo|Drug: Placebo
3298219|NCT01816178|Experimental|communication training|Participants were instructed in the use of a voices output communication aid.
3298220|NCT01816191|Experimental|Diltiazem Hydrochloride|Topical cream and oral pill
3298221|NCT01816204|Experimental|Therapist assisted online treatment (TAO)|Students assigned to treatment with weekly online modules and weekly 10-15 minute video conference with counselor.
3298222|NCT01816204|Active Comparator|face-to-face individual therapy|weekly individual 50 minute psychotherapy sessions.
3298223|NCT01816217|Experimental|Intubated patient|Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)
3298224|NCT01816256|Other|Screening tests|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
3298225|NCT01816269||Patients with scaling and patients without scaling|No drug
3298226|NCT01816269||Helicobacter eradicated or non-eradicated|
3298227|NCT01816282|Experimental|Evicel|
3298228|NCT01816282|No Intervention|Control|
3298229|NCT01816321|Experimental|Corifollitropin alfa followed by hpHMG|
3298230|NCT01816321|Active Comparator|recombinant FSH|
3298231|NCT01816334|Active Comparator|methylprednisolone|administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm
3298232|NCT01816334|Active Comparator|Ketoprofen|administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm
3298233|NCT01816334|Placebo Comparator|sodium chloride|administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm
3298234|NCT01816347||Routine PCI patients|
3298235|NCT01816360|Experimental|Aromatherapy group|20 sessions of olfactory aromatherapy using protocol.
3298236|NCT01816360|Experimental|Yogatherapy group|20 sessions of yogatherapy with aroma-placebo using protocol.
3298237|NCT01816360|Experimental|Aromatherapy-Yogatherapy group|20 sessions of yogatherapy with olfactory aromatherapy, using protocol.
3298238|NCT01816360|No Intervention|Control group|Control group in the waiting-list model (all volunteers were offered the treatment after the completion of data collection).
3298239|NCT01816373|Other|Vacuum Bell|Patients with pectus excavatum will be treated with the Vacuum Bell device
3298240|NCT01816386|Active Comparator|Acupuncture Regimen|Standard anaesthetic procedure plus press needle acupuncture
3298241|NCT01816386|No Intervention|Standard Treatment Control|"Standard anaesthetic procedure plus No treatment.~All standardized medication according to the perioperative anaesthetic guideline, Department of Anaesthesiology, University of Munich, will be allowed. In special:~According to the guidelines, anxiolysis will be performed intravenously according to the standard guidelines with opioid immediately prior to the induction of anaesthesia.~Intraoperative anaesthesia will be performed according to our in-house guidelines: on general recommendations and guidelines of the German society for anaesthesiology (DGAI). Opioids and propofol will be administered via TCI pumps according to the standard protocol.~It is allowed to treat the subject for pain with metamizol (4*1.25 g/day) and additional piritramide (PCA; 2 mg each 10 minutes; maximum dosage 30 mg/4 hours) .~Variation of this guideline based regimen are allowed if medically indicated."
3298242|NCT01816386|Active Comparator|Acupressure Regimen|Standard anaesthetic procedure plus press plaster acupressure
3298243|NCT01816399||Routine coronary angiography patients|
3298244|NCT01816412|Experimental|LDCB|Paclitaxel Coated Balloon
3298245|NCT01816412|Active Comparator|PTA|Standard Uncoated Balloon Angioplasty Catheter PTA Catheter
3298246|NCT01816425|Experimental|thermoplastic partial denture|The patients that need oral rehabilitation with partial denture will receive a thermoplastic partial denture as treatment
3298247|NCT01816425|Active Comparator|CoCr partial denture|The patients that need oral rehabilitation with partial denture will receive a CoCr partial denture as treatment
3298248|NCT01816438||dysplasia or colorectal lesion|300 patients
3298249|NCT01816464|Experimental|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus.~Dose: Single Dose 0.5 mL of TIV from pre-filled syringe."
3298250|NCT01816503||Fentanyl matrix|
3298251|NCT01816516|Experimental|Healthy Babies|Participants receive the Healthy Babies curriculum via 6 in home lessons and 3 follow up telephone calls delivered by Extension paraprofessionals.
3298252|NCT01816516|Active Comparator|EFNEP|Participants receive the Expanded Food and Nutrition Education Program (EFNEP) curriculum via 6 in home lessons delivered by Extension paraprofessionals.
3298253|NCT01816529|Experimental|Topical Diltiazem Hydrochloride 2% Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3298254|NCT01816529|Placebo Comparator|Vehicle Cream|0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3298255|NCT01816529|Active Comparator|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3298256|NCT01816529|Placebo Comparator|0.9% Saline|0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.
3298257|NCT01816542|Other|patch tests on healthy skin|
3298258|NCT01816555|Experimental|Vitamin D- Normal Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects have a normal level of Vitamin D(25-hydroxyVit D 30-100ng/mL), they will be assigned to this group.
3298259|NCT01816555|Experimental|Vitamin D- Insufficient or Deficient Level at Screening|Subjects will have surgery as their initial breast therapy. If subjects are insufficient (25-hydroxy Vit D 21-29 ng/mL)or deficient (25-hydroxyVit D <20ng/mL) Vitamin D levels, they will be assigned to this group.
3298260|NCT01816568|Active Comparator|Group 1|SILS appendectomy
3298261|NCT01816568|Active Comparator|Group 2|Three port laparoscopic appendectomy
3298262|NCT01816581|Active Comparator|Targin/OxyNorm|Patients randomized to this study arm will receive Targin as basis pain medication and additional OxyNorm (Oxycodone), if requested by the patients.
3298263|NCT01816581|Active Comparator|PCA|Patients randomized to this group will receive a PCA pump with morphine. The basic rate is 0.3 mg/h. Patients will be allowed to administer 1 mg each five minutes after a vesting period of five minutes, if subjectively needed.
3298264|NCT01816607||Rectal cancer|
3298265|NCT01816620|Experimental|Lenalidomide, dexamethasone|Lenalidomide 10mg qd d1-21 & dexamethasone 40mg qw d1,8,15,22
3298266|NCT01816633|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive AutoloGel treatment.
3298267|NCT01816646|Experimental|Cidofovir|Patients receive a single dose of 2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours. Probenecid 2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
3298268|NCT01816659|Experimental|Metformin + Colon Surgery|Patients randomized to Metformin-ER 500 mg once daily for one week and then escalation to 1000 mg/day for the duration of the trial. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
3298269|NCT01816659|No Intervention|Colon Surgery Alone|Patients will not receive any study drug from the time of colonoscopy until surgery.
3298270|NCT01816672|Active Comparator|AutoloGel|AutoloGel treatment
3298271|NCT01816672|Other|Usual and Customary Care|Standard of care
3298272|NCT01816698|Active Comparator|Taurine|Interventions Drug: Taurine granule Arms: Group 1
3298273|NCT01816698|Placebo Comparator|Placebo|Interventions Drug: Placebo Arms: Group 2
3298274|NCT01816724||Men with nocturia|Men older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
3298275|NCT01816724||Women with nocturia|Women older than 60 years old suffering from nocturia (one or more voidings overnight) without exclusion criteria
3298276|NCT01816750|Experimental|Anatomical accuracy Cardiac GSI vs ICA|The identification and quantification of coronary artery stenoses using Cardiac in comparison to ICA.
3298277|NCT01816750|Experimental|Stress perfusion Cardiac GSI vs MPI-SPECT|Assessment of the functional impact of coronary stenoses using Cardiac GSI in comparison to MPI-SPECT
3298278|NCT01816750|Experimental|Delayed enhancement Cardiac GSI vs CMR|Assessment of abnormal myocardial tissue characteristics representing ischaemic or scarred tissue using Cardiac GSI in comparison to CMR.
3298279|NCT01816789|Active Comparator|"Group A: age"|Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.
3298280|NCT01816789|Experimental|"Group B: nomogram"|Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.
3298281|NCT01816802||In-vitro fertilization using Eeva|Patients undergoing in-vitro fertilization treatment who provide informed consent and use Eeva in their treatment cycle.
3298282|NCT01816815|Experimental|BAY1002670 [0.1mg]|0.1 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298283|NCT01816815|Experimental|BAY1002670 [0.5mg]|0.5 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298284|NCT01816815|Experimental|BAY1002670 [1.0mg]|1.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298285|NCT01816815|Experimental|BAY1002670 [2.0mg]|2.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298286|NCT01816815|Experimental|BAY1002670 [5.0mg]|5.0 mg BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298287|NCT01816815|Placebo Comparator|Placebo|Placebo for BAY1002670, oral administration, four tablets to be taken daily, 84 consecutive days
3298288|NCT01816828|Experimental|Immediate|In the immediate arm, participants will begin the 8 session group motivational interviewing intervention, Gay Poz Sex, within 2 weeks of randomization.
3298289|NCT01816828|Active Comparator|Wait List/Standard of Care|Participants in the wait list/standard of care group will be given active referrals to existing community resources available to HIV+ MSM. For ethical reasons, participants randomized to the control group will have the option to attend the Gay Poz Sex program after a 6-month wait period.
3298290|NCT01816841|Experimental|Diagnostic (COE and DVFE)- Arm I|Arm I - Patients undergo COE followed by DVFE. Patients with tissue abnormalities found by COE or DVFE undergo biopsy within 2 weeks.
3298291|NCT01816841|Experimental|Arm II - Comparison of surgical margins using COE vs. DVFE|Comparison of surgical margins using COE vs. DVFE
3298292|NCT01816854||Patients with PAD|
3298293|NCT01816867||Patients with a ventral hernia|
3298294|NCT01816880||Healthy Elderly|Age 90 and over Gender: Male and Female Enrolled in the Healthy Elderly (HEAL) study prior to enrollment in this sub-study Blood sample of approximately 20mL is drawn.
3298295|NCT01816919|Experimental|eNose breath samples|
3298296|NCT01816932|Experimental|Home Visit|20 participants will be randomized to receive a home visit for the insertion of their implantable birth control rather than the standard office visit.
3298297|NCT01816932|Placebo Comparator|Office Visit|20 participants will be randomized to receive an office visit (standard of care).
3298298|NCT01816958||chronic depression and/or pain|co-administration of TMS and infused ketamine for patients with chronic pain of psyche and/or soma
3298299|NCT01816971|Experimental|Treatment (dexamethasone, carfilzomib, lenalidomide)|"INDUCTION THERAPY: Patients receive dexamethasone IV or PO QD on days 1, 8, 15 and 22; carfilzomib IV over 10-30 minutes on days 1, 2, 8, 9, 15, and 16; and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity..~TRANSPLANT: Patients undergo autologous stem cell transplant.~CONSOLIDATION THERAPY: Patients receive dexamethasone, carfilzomib, and lenalidomide as in induction. Treatment repeats every 28 days for 4 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive dexamethasone and lenalidomide as in induction therapy and carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Treatment repeats every 28 days for 10 courses in the absence of disease progression or unacceptable toxicity."
3298300|NCT01816997|Placebo Comparator|Control|IFG subjects with total cholesterol less than 200 mg/dL will be served as controls.
3298301|NCT01816997|Active Comparator|Pravastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
3298302|NCT01816997|Experimental|Rosuvastatin|The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL will be randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
3298303|NCT01817010|Experimental|Multi-Component Rehabilitation (CMC)|The CMC group will receive a multi-component program focused on rehabilitation of the abdominal and core musculature, neuromuscular re-education through therapeutic exercise as well as hip and knee muscle strengthening beginning 2 weeks after THA.
3298304|NCT01817010|Active Comparator|Control (CON)|The CON group will participate in physical therapist recommended activities based on their home rehabilitation and then will complete the same CMC rehabilitation intervention beginning 10 weeks after THA.
3298305|NCT01817023|Experimental|RT alone|SIB-IMRT was given to the patients with a regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
3298306|NCT01817023|Active Comparator|CCRT group|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume and cisplatin 100mg/m2 was given at d1, d22,d43 during radiotherapy.
3298307|NCT01817036|Placebo Comparator|Placebo|5 placebo pills per day, 16 weeks
3298308|NCT01817036|Experimental|400 IU|(4 placebo pills + 1 vitamin D pill) per day, 16 weeks
3298309|NCT01817036|Experimental|800 IU|(3 placebo pills + 2 vitamin D pills) per day, 16 weeks
3298310|NCT01817036|Experimental|1200 IU|(2 placebo pills + 3 vitamin D pills) per day, 16 weeks
3298311|NCT01817036|Experimental|2000 IU|5 vitamin D pills per day, 16 weeks
3298312|NCT01817049|Experimental|HAPA intervention|Coaches will receive a 3.5 hour HAPA-based coach education workshop prior to the start of the first study season.
3298313|NCT01817049|Placebo Comparator|Attention control|Coaches will receive a 3.5 hour workshop prior to the start of the first study season, consisting of innocuous sport nutrition and sport psychology information as an attention control.
3298314|NCT01817062||Neonates|Neonates with very low birth weight and surgery therapy of acute abdomen
3298315|NCT01817088|Experimental|New targeting procedure without electrophysiology|Patients with the high precision procedure under general anesthesia alone without electrophysiological stimulation
3298316|NCT01817088|Active Comparator|Classical neurosurgical procedure|patients with a first step of electrode implantation under awake surgery with electrophysiological control followed by a second step under general anesthesia
3298317|NCT01817101|Active Comparator|Dietary Supplement capsule|One capsule at meals (3 each day) during 1 year with Omega-3 fatty acid supplementation
3298318|NCT01817101|Placebo Comparator|Empty gelatine capsule|One capsule at meals (3 each day during 1 year)
3298319|NCT01817114|Experimental|Chronic Remote Ischemic Conditioning|Remote ischemic conditioning will be induced using an AutoRIC device (occluding arm bloodflow exactly like manual bloodpressure cuff). With the participant in a supine or seated upright position, the AutoRIC device will be placed on the right arm and will inflate to a pressure of 200mmHg for 5 minutes (ischemia). The device will then auto-deflate (reperfusion), completing one cycle of ischemia-reperfusion. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
3298320|NCT01817114|Sham Comparator|SHAM Remote Ischemic Conditioning|Sham conditioning will involve the AutoRIC device being placed on the right arm and will inflate to a pressure of 10mmHg for 5 minutes (ie. no limb ischemia will occur). The device will then auto-deflate, completing one cycle. A total of 4 inflation and deflation cycles will occur. This will be initiated at first medical contact just prior to the performance of primary PCI in eligible subjects (RIPerC), and then repeated daily for 28 days following MI.
3298321|NCT01817127||Main Study|Women enrolled in this cohort of the study will collect their breast milk, infant urine and stool, and their urine and stool samples. Blood and saliva will be collected from these participants by study personnel.
3298322|NCT01817127||Gestational Diabetes Mellitus Cohort|Women who have been diagnosed with gestational diabetes mellitus, type 2 diabetes mellitus or impaired glucose tolerance will be enrolled in this cohort. Participants will be asked to report their fasting and postprandial blood glucose levels if they are monitoring these outcomes at home with a glucometer.
3298323|NCT01817127||Fresh Milk Cohort|Women enrolled in this cohort will provide fresh milk samples (stored in the refrigerator and picked up by study personnel within 1 hour of collection) for analysis of glycan composition and gene expression of glycan metabolizing enzymes of somatic cells in milk.
3298324|NCT01817127||RNA Milk Fat Cohort|Women enrolled in this cohort must have given birth to sons and will collect a fresh milk sample for transcriptomic analysis compared against non-human primate milk.
3298325|NCT01817127||Skin Study|This cohort includes mothers and their infants who will provide milk and infant stratum corneum cells to act as the control group for a different study designed to investigate skin function in premature infants.
3298326|NCT01817127||BMMI Project|Subjects enrolled in this cohort will be part of the control group for the BMMI Project.
3298327|NCT01817140||Patient MRI|Adult patients with possible maxillofacial and/or mandibular bone invasion with oral cancer or osteoradionecrosis who are scheduled for surgery. All eligible and consented participants will have MRI scans obtained using 3T and 4T magnets prior to their surgery.
3298328|NCT01817140||Normal MRI|Healthy adult volunteers recruited to test the comfort of the coil apparatus and to determine configurations which lead to satisfactory image acquisition.
3298329|NCT01817153|Placebo Comparator|placebo|10 mL normal saline iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H8, H14 and H20
3298330|NCT01817153|Active Comparator|hydrocortison|50 mg hydrocortison iv at H0 and H6 (2 first injections blinded), followed by hydrocortison (open label) 50 mg iv at H12, H18 and H24
3298331|NCT01817166|Placebo Comparator|Placebo|"Patients in this arm will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Placebo Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
3298332|NCT01817166|Experimental|Vit D|"Patients in this arm will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.~Intervention: Vitamin D Intervention: Imaging Intervention: Lumbar puncture Intervention: Blood sampling Intervention: Urine samples"
3298333|NCT01817179|Experimental|FES neuroprosthesis to dorsiflexors on affected side|Participants will use FES neuroprosthesis to dorsiflexors on affected leg for 3 months at home.
3298334|NCT01817205|Other|TACE with Hyperthermia treatment|Interventions: TACE to all liver lesions and two sessions of systemic hyperthermia performed at 24 hours and 48 hours respectively after TACE.
3298335|NCT01817218|Experimental|PRP (Platelet Rich Plasma)|PRP treatment of vascular ulcers one a week PRP: a volume of 9-30 ml of blood will be collected from the patient (depending of the size of their ulcer) in sterile 4.5-ml tubes containing 3.8% sodium citrate, which will bind to the calcium ions, preventing clot formation we will add 50 μl of CaCl2 per ml liquid plasma. The extraction of the PRP fraction by sticking with a syringe and the adding of CaCl2 should be performed under sterile conditions.
3298336|NCT01817218|Active Comparator|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
3298337|NCT01817231||breast cancer cases|breast cancer cases versus controls
3298338|NCT01817244|Experimental|care management type 1|2-month care management
3298339|NCT01817244|Active Comparator|care management type 2|6-month care management
3298340|NCT01817257|Experimental|A: Continue treatment|Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
3298341|NCT01817257|No Intervention|B: Discontinue treatment|Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.
3298342|NCT01817270|Experimental|Live Attenuated Varicella Vaccine|use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3298343|NCT01817283|Placebo Comparator|placebo + cART|combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months
3298344|NCT01817283|Experimental|Triptolide + cART|combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.
3298345|NCT01817296|Experimental|Single arm|
3298346|NCT01817309|Experimental|Study group|endotoxin assay in peritoneal dialysis effluent
3298347|NCT01817322|Experimental|Myfortic® (Enteric-coated Mycophenolate Sodium)|reduced cyclosporine+steroids+standard dose of myfortic
3298348|NCT01817322|Active Comparator|Myfortic|Conventional Dose+cyclosporine+steroid+Reduced Dose of Myfortic
3380137|NCT04950764|Experimental|Seladelpar 10 mg|Part A: Single oral dose 10 mg
3380138|NCT04950764|Experimental|Seladelpar 10 mg or less|Part B: Multiple oral dose of 10 mg or less
3380139|NCT04950504|Experimental|CNP-201 250 mg|200 mL intravenous infusion on Day 1 and Day 8: 250 mg CNP-201
3380140|NCT04950504|Experimental|CNP-201 450 mg|200 mL intravenous infusion on Day 1 and Day 8: 450 mg CNP-201
3380141|NCT04950504|Experimental|CNP-201 650 mg|200 mL intravenous infusion on Day 1 and Day 8: 650 mg CNP-201
3380142|NCT04950504|Placebo Comparator|Placebo|200 ml intravenous infusion on Day 1 and Day 8: CNP-201 Placebo
3380144|NCT04947137|Experimental|Subjects Free of Inflammatory Disease|The first arm will be comprised of HCs who are deemed to be clinically free of inflammatory diseases, arthropathies, and/or arthroplasties and clinically free of joint pain for at least 28 days prior to the consent date.
3380145|NCT04947137|Experimental|Healthy Controls and RA Subjects on Stable Therapy|The second arm is comprised of [1] disease-free HCs and [2] clinically diagnosed RA subjects on stable treatment.
3380146|NCT04943861|Active Comparator|weCare/Secure|The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth
3298349|NCT01817335|Experimental|Supportive care (psycho-educational program)|Patients participate in a psycho-educational program focused on medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks.
3298350|NCT01817348|Experimental|Lidocaine group|"1% lidocaine 5ml intra-articular injection to shoulder joint + physiotherapy three times weekly~Injection is performed if pain during intervention equals to or greater than 7cm in a 10-cm VAS scale.~Injection frequency is not greater than twice per week and total injection time is limited to 10 times in the whole course~In each week, patient will receive 3 times of PT with or without intra-articular lidocaine injection."
3380147|NCT04943861|Other|Usual Care|There is no peer navigation within usual care.
3380148|NCT04943497||ribociclib + AI/fulvestrant|Patients administered ribociclib + AI/fulvestrant by prescription AI: Aromatase inhibitor
3380149|NCT04943497||aplelicib + fulvestrant|Patients administered aplelicib + fulvestrant by prescription
3380150|NCT04943497||mono endocrine therapy|Patients administered mono endocrine therapy by prescription
3298351|NCT01817348|Placebo Comparator|PT group|- Apply to every patient, each by the same physical therapist, 3 times weekly for 3 months or till the patients gain satisfactory results.
3298352|NCT01817387|Experimental|PRIME + CT|4 months use of PRIME mobile application on mobile device and 30 hours of cognitive training
3298353|NCT01817387|Experimental|Daily Goals + CT|4 months use of Daily Goals mobile application on mobile device and 30 hours of cognitive training
3298354|NCT01817400|Experimental|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
3298355|NCT01817400|Experimental|Anti-inflammatory treatment|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa - Fish Oil 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
3298356|NCT01817400|Experimental|Insulin-lowering therapy|We will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
3298357|NCT01817413|Active Comparator|Apexification with MTA|"The control group will receive:~Visit 1: root canal dressing with calcium hydroxide Visit 2: apexification with mineral trioxide aggregate (MTA), followed by obturation of the root canal with gutta percha.~Treatment will be carried out over two visits, two weeks apart."
3298358|NCT01817413|Experimental|Pulp revascularisation|"The experimental group will receive:~Visit 1: root canal dressing with triple antibiotic paste Visit 2: pulp revascularisation procedure Treatment will be carried out over two visits, two weeks apart."
3298359|NCT01817426|Active Comparator|infliximab|Patients in this arm are randomized to continue IFX therapy at an unchanged dosage and frequency.
3298360|NCT01817426|Placebo Comparator|Placebo|Patients in this arm are randomized to receive matching placebo.
3298361|NCT01817439|Experimental|oral amiodarone, group A|oral amiodarone 400 mg three times a day for 2 days
3298362|NCT01817439|Experimental|IV amiodarone, Group B|"Amiodarone:~IV loading of 300 mg for 30 min in 100cc glucose 5% IV infusion with 900 mg/24h in 1000cc glucose 5%"
3298363|NCT01817452|Experimental|Arm A|Trastuzumab + Pertuzumab
3298364|NCT01817452|Active Comparator|Arm B|Trastuzumab + Pertuzumab + Paclitaxel
3298365|NCT01817465|Experimental|Motilione®|30 mg is administered with a tablet of placebo (Pantoline®)
3298366|NCT01817465|Active Comparator|Pantoline®|40mg is administered with a tablet of Motilitone®
3298367|NCT01817465|Active Comparator|Motilitone® and Pantoline®|Both drugs are administered at once
3298368|NCT01817478|Experimental|medical staff|
3298369|NCT01817504|Active Comparator|Study group|The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,
3298370|NCT01817504|Other|Control group|The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis
3298371|NCT01817517|Experimental|Deep Brain Stimulation implant|Unblinded treatment arm, thalamic DBS for Tourette syndrome.
3298372|NCT01817543|Experimental|AutoloGel|Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
3298373|NCT01817556|Experimental|Stillen Tab.|administered three times daily for four weeks
3298374|NCT01817556|Active Comparator|Mucosta Tab.|administered three times daily for four weeks
3298375|NCT01817569||Byetta|
3298376|NCT01817595|Active Comparator|BG Star (Conventional Meter)|25 patients will use the (conventional) BG star meter in which patients will upload their readings onto a computer and send in their readings via email.
3298377|NCT01817595|Active Comparator|IBG Star Group (iPhone)|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
3298378|NCT01817621|Experimental|Experimental Intervention|
3298379|NCT01817621|Active Comparator|TAU Condition|
3298380|NCT01817634|Experimental|Food supplement Intervention - Capsule Intervention|Omega 3 food supplement + Omega 3 capsule.
3298381|NCT01817634|Experimental|Food Supplement Intervention - Capsule Control|Omega 3 food supplement + Control Capsule.
3298382|NCT01817634|Experimental|Food Supplement Control - Capusle Intervention|Food supplement control + Omega 3 Capsule.
3298383|NCT01817634|Active Comparator|Food Supplement Control - Capsule Control|Food supplement control + Control Capsule.
3298384|NCT01817647||PCT|Patients undergoing colorectal surgery with an anastomosis performed
3298385|NCT01817660|Active Comparator|Open Surgery|In this arm, patients randomized to open surgical repair of popliteal artery aneurysm (OPAR).
3298386|NCT01817660|Active Comparator|Endovascular Surgical repair (EPAR)|In this arm, patients randomized to endovascular repair of popliteal artery aneurysm (EPAR).
3298387|NCT01817673|Experimental|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
3298388|NCT01817673|Placebo Comparator|placebo (dextrose)|20 g/d for 5 d followed by 5 g/d throughout the trial
3298389|NCT01817686|Experimental|Comfort Default|ADs with pre-selected defaults that focus on providing comfort at end-of-life.
3298390|NCT01817686|Experimental|Life Extension Default|ADs with pre-selected defaults that focus on extending life.
3298391|NCT01817686|Experimental|Standard Default|ADs without pre-selected defaults.
3298392|NCT01817699|No Intervention|Low Hb target without cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL
3298393|NCT01817699|Active Comparator|Low Hb target with cholecalciferol|Target Hemoglobin level: ≥9.5 and <10.5 g/dL Cholecalciferol: 1,000 IU/day
3298394|NCT01817699|Active Comparator|High Hb target without cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL
3298395|NCT01817699|Experimental|High Hb target with cholecalciferol|Target Hemoglobin level: ≥12.5 and <13.5 g/dL Cholecalciferol: 1,000 IU/day
3298396|NCT01817738|Active Comparator|CV9104|CV9104 intradermal injection
3298397|NCT01817738|Placebo Comparator|Placebo|Placebo intradermal injection
3298398|NCT01817803|Active Comparator|1) Add furosemide/no spironolactone|
3298399|NCT01817803|Active Comparator|2) Add metolazone/no spironolactone|
3298400|NCT01817803|Active Comparator|3) Add furosemide/spironolactone|
3298401|NCT01817803|Active Comparator|4) Add metolazone/spironolactone|
3298402|NCT01817816|Experimental|Botox_A|receiving Botulinum Toxin Type-A (Botox-A, Allergan) at both affected lower extremity (aLE) and upper extremity (aUE)
3298403|NCT01817816|Placebo Comparator|placebo_A|receiving placebo injection at both aLE & aUE ; receiving Botox-A at both aLE & aUE at 6-month.
3298404|NCT01817816|Experimental|Botox_B|receiving Botox-A injection at aLE and placebo injection (sterile normal saline) at aUE.
3298405|NCT01817816|Placebo Comparator|placebo_B|receiving placebo injection at both aLE & aUE ; receiving Botox-A only at aLE at 6-month.
3298406|NCT01817829|Active Comparator|paracetamol|paracetamol 2 tablets1000mg PO.
3298407|NCT01817829|Placebo Comparator|placebo|placebo 2 tablets containing Starch PO
3298408|NCT01817842|Experimental|mEX support|Participants in this arm receive both standard DC Quitline Support and Mobile EX cessation support. Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
3298409|NCT01817842|Active Comparator|Device Control|Participants randomized to this arm receive standard DC Quitline Support plus the device control. Device control includes an identical device (i.e., mobile phone) to that provided to the intervention group, but participants do not receive any of the phone-based mEX support features. Those in the device control group receive their device at the 1-month time point - a design feature that allows a direct comparison of the mEX intervention to standard quitline services over the first month.
3298410|NCT01817868||Group 1|
3298411|NCT01817894|Other|split-face eflornithin vs. no treatment|Eflornithine cream 11.5 W/W% applied twice daily to one side of the face for six months
3298412|NCT01817920|Experimental|integrated multidisciplinary fall prevention program|
3298413|NCT01817933|Experimental|Physical therapy|
3298414|NCT01817946||Genetic testing|All participants determined eligible for the study will be placed into genetic testing arm.
3298415|NCT01817972|Placebo Comparator|Certolizumab pegol-Placebo Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine placebo tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets. This is not active Azathioprine.
3298416|NCT01817972|Active Comparator|Certolizumab pegol plus Azathioprine|Certolizumab pegol (Cimzia) 400mg Subcutaneous injection (per standard induction protocol) - which is at week 0, week 2, week4, week 6, then every 4 weeks until week 26. You will also be receiving Azathioprine tablets at a dosage of 1.5mg per kilogram of body weight once a day for 26 weeks. They will be 50mg tablets.
3298417|NCT01817985|Experimental|Cohort 1|(N = 20 Moderately Impaired / Normal Hepatic Function) 100 mg GS-5816.
3298418|NCT01817985|Experimental|Cohort 2|(N = 20 Severely Impaired / Normal Hepatic Function) up to 100 mg GS-5816.
3298419|NCT01817998|Experimental|High Intensity Endurance Physical Exercise|High Intensity endurance physical exercise, intensity measured on Borg Scale with progression from Borg 10-13 (50% of maximum) to 17-18 (80 % of maximum). One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
3298420|NCT01817998|Active Comparator|Low Intensity Endurance Physical Exercise|Low Intensity endurance physical exercise, intensity measured on Borg Scale, Borg 10-13 (50% of maximum) with no progression in intensity. One hour of exercise twice weekly for 12 weeks supervised by physiotherapists.
3298421|NCT01818011|Experimental|Part A GSK1322322 single dose Arm|Subjects will receive single dose of one of the following 4 GSK1322322 treatments in 4 treatment periods (one per period) with an aqueous suspension of a low dose of GSK1322322F (stable isotope labeled drug substance) PO in a fed condition: 1500 mg (fit for purpose formulation), 1500 mg (intended commercial formulation), 1500 mg (over granulated formulation), and 2000 mg (intended commercial formulation)
3298422|NCT01818011|Experimental|Part B Cohort 1- GSK1322322 Oral Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Cohort 1 will receive following GSK1322322 (intended commercial formulation) doses po in fed state: 1000 mg, 1500 mg and 2000 mg
3298423|NCT01818011|Experimental|Part B Cohort 2 -GSK1322322 IV Arm|Subjects in this part will receive single dose of GSK1322322 on Day 1 of each of the three treatment periods. Subjects in Part B Cohort 2 will receive following GSK1322322 IV fasted doses (one per period): 600 mg, 900 mg and 1200 mg
3298424|NCT01818011|Experimental|Part C GSK1322322 Arm|Subjects in this arm will receive repeat doses of GSK1322322 as following: GSK1322322 1200 mg IV fasted for 4 days twice a day (BID), followed by GSK1322322 2000 mg orally fed for 6 days BID
3298425|NCT01818011|Placebo Comparator|Part C Placebo Arm|Subjects in this arm will receive repeat doses of Placebo IV fasted for 4 days BID, followed by placebo po fed for 6 days BID
3298426|NCT01818024|Experimental|Part 1: Cohort 1a|Single IV dose of GSK2862277 as a continuous infusion over 2 hours.
3298427|NCT01818024|Experimental|Part 1: Cohort 1b|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
3298428|NCT01818024|Experimental|Part 1: Cohort 1c|Single IV dose of GSK2862277 as a continuous infusion over 3 hours.
3298429|NCT01818024|Experimental|Part 2: Cohort 2a GSK2862277|Single IV dose of GSK2862277 as a continuous infusion over 1 hour.
3298430|NCT01818024|Experimental|Part 2: Cohort 2a Placebo|Matching placebo will be administered as a continuous IV infusion over 1 hour.
3298431|NCT01818024|Experimental|Part 2: Cohort 2b GSK2862277|Single IH dose of GSK2862277.
3298432|NCT01818024|Experimental|Part 2: Cohort 2b Placebo|Matching placebo will be administered.
3298433|NCT01818024|Experimental|Part 3: Cohort 3a GSK2862277|IV dose of GSK2862277 (decided from Part 2) as a continuous infusion over 1 hour for daily 5 days.
3298434|NCT01818024|Experimental|Part 3: Cohort 3a Placebo|Matching placebo will be administered as IV infusion over 1 hour daily for 5 days.
3298435|NCT01818024|Experimental|Part 3: Cohort 3b GSK2862277|Repeat IH dose of GSK2862277 (decided from Part 2) daily for 5 days.
3298436|NCT01818024|Experimental|Part 3: Cohort 3b Placebo|Matching placebo will be administered as IH daily for 5 days.
3380151|NCT04943497||chemotherapy|Patients administered chemotherapy by prescription
3298437|NCT01818037||Microphthalmos with congenital cataract|72 eyes of 36 patients with microphthalmos who underwent bilateral congenital cataract surgery between January 2003 and June 2008.
3298438|NCT01818050|Other|Wing stent arm|There is only one arm in this study. Intervention: checking liver function tests to evaluate stent patency
3298439|NCT01818076|Experimental|Dose A|Dose A: Botulinum toxin type A
3298440|NCT01818089||Lung Sound Analyzer|Patient with pneumonia admitted to hospital will receive additional auscultation with lung sound analyzing stethoscope
3298441|NCT01818102|Experimental|Width 1000 HU/Level -450 HU|
3298442|NCT01818102|Active Comparator|Width 400 HU/Level 25 HU|
3298443|NCT01818115|Experimental|IOL placement with Hydrus Implant|Cataract extraction with intraocular lens (IOL) placement and Hydrus Implant
3298444|NCT01818115|Active Comparator|IOL placement only.|Cataract Extraction with IOL placement only.
3298445|NCT01818128|Active Comparator|Neutral shape of bronchial tip|
3298446|NCT01818128|Experimental|Bent shape of bronchial tip|
3298447|NCT01818154|Experimental|Minimal Erythema Dose LED|A 2 x 2 cm section of skin will be exposed to LED light.
3298448|NCT01818154|Placebo Comparator|Minimal Erythema Dose narrow band UVB|A 2 x 2 cm section of skin will be exposed to narrow band UVB light.
3298449|NCT01818167|Active Comparator|10% Benzoyl Peroxide Topical Body Wash|Subjects will use 10% benzoyl peroxide twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
3298450|NCT01818167|Active Comparator|Provodine Topical Cream|Subjects will use Provodine Topical Cream twice daily. The product will be applied to the affected areas, left on for 45 seconds, then rinsed off.
3298451|NCT01818180|Experimental|Urell|
3298452|NCT01818180|Placebo Comparator|Placebo|
3298453|NCT01818206|Experimental|Cystic fibrosis (CF) patients|Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
3298454|NCT01818219|Experimental|Study|
3298455|NCT01818232|Experimental|[14C]-LX4211|400 mg LX4211 administered orally
3298456|NCT01818271|Active Comparator|conventional physical Therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
3298457|NCT01818271|Experimental|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
3298458|NCT01818310|Experimental|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
3298459|NCT01818310|Experimental|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
3298460|NCT01818310|Experimental|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
3298461|NCT01818310|Other|Group D: Control-standard treatment|Group D: Control Group Study subjects in Group D will receive a standard treatment for NO-option CLI.
3298462|NCT01818323|Experimental|Intra-tumoral T4 immunotherapy|Treatment arms comprise escalating doses of T4 immunotherapy, administered alone or in combination with lymph-depleting chemotherapy
3298463|NCT01818349|Active Comparator|isokinetic lower-limb training|3 times/week for 6 weeks
3298464|NCT01818349|Placebo Comparator|isokinetic uppe-limb training|3 times/week for 6 weeks
3298465|NCT01818362|Experimental|Group 2|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 52 weeks later.
3298466|NCT01818362|Experimental|Group 3|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 8 weeks later.
3298467|NCT01818362|Experimental|Group 4|MVA NP+M1 1.5 x 10⁸pfu followed by ChAdOx1 NP+M1 2.5 x 10¹⁰vp 52 weeks later.
3298468|NCT01818362|Experimental|Group 1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
3298469|NCT01818362|Experimental|Group 5|ChAdOx1 NP+M1 2.5 x 10¹⁰vp
3298470|NCT01818362|Experimental|Group 6|ChAdOx1 NP+M1 2.5 x 10¹⁰vp followed by MVA NP+M1 1.5 x 10⁸pfu 8 weeks later.
3298471|NCT01818375|Experimental|Goal Directed Fluid Therapy (GDFT)|"During surgery, patients in the Goal Directed Fluid Therapy (GDFT) will receive:~maintenance infusion of intravenous infusion of ringer lactate at a rate of 1.5 ml/Kg/hr to compensate insensible blood loss and fluid shift during surgery as recommended by perioperative fluid management guidelines for patients undergoing surgery with an enhanced recovery program and receiving a GDFT approach;~intraoperative intravenous boluses of colloids (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride-Voluven) guided by an algorithm based on Esophageal Doppler (ED) estimation of the stroke volume (SV) provided by the manufacture, and also used in other clinical trials."
3298472|NCT01818375|Active Comparator|Standard Fluid Therapy|During surgery, patients will receive a maintenance infusion of intravenous infusion of ringer lactate as recommended by international guidelines and anesthesia text-books (Standard Fluid Therapy). In the Standard Fluid Therapy arm, the Esophageal Doppler (ED) monitor will be turned away from the anesthesia care provider, and the screen will be covered with an opaque card. The ED variables will be collected by an independent research personnel. Hemodynamic variables triggering extra fluid administration (Ringer Lactate or Voluven) will be decided based on the clinical judgment of the anesthetist in charge and will include: urinary output less than 0.5/ml/kg/hr, an increase in heart rate more than 20% above baseline or more than 110 beats/min, a decrease in mean systolic blood pressure less than 20% below baseline or less than 90 mmHg and intraoperative blood loss. Boluses of 200 ml of intravenous fluid will be administered until the above targets will be restored
3298473|NCT01818388||IVTM system, therapeutic hypothermia|Induced therapeutic hypothermia post cardiac arrest
3298474|NCT01818401|Other|Control group|The control group will be constituted of patients with the prosthesis GMK ® without the ancillary MyKnee ® LBS.
3298475|NCT01818401|Other|Matched patient|The treated group will consist of patients which the GMK ® prosthesis with ancillary ® MyKnee LBS.
3298476|NCT01818440|Active Comparator|A|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method
3298477|NCT01818440|Experimental|B|Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy
3298478|NCT01818453|Active Comparator|Computerized self-help program for depression|Participants will have access to a computerized self-help program for depression, called deprexis, for 8 weeks.
3298479|NCT01818453|No Intervention|Wait List Control|"Participants randomly assigned to a wait list control condition will wait 8 weeks after assignment before they can access the deprexis program."
3298480|NCT01818479|Experimental|All participants|
3298481|NCT01818505||Gouty arthritis|Patient with gouty arthritis
3298482|NCT01818505||Asymptomatic hyperuricemia|Patient with asymptomatic hyperuricemia
3298483|NCT01818505||OA without hyperuricemia|Patient of osteoarthritis but without hyperuricemia and gout
3298484|NCT01818544|Experimental|BAY85-8501|
3298485|NCT01818544|Placebo Comparator|Placebo|
3298486|NCT01818557|No Intervention|Every day blood glucose testing|Patients will test their blood glucose values 4 times every day
3298487|NCT01818557|Experimental|Every other day blood glucose testing|Patients will test their blood glucose 4 times every other day
3298488|NCT01818570|Placebo Comparator|Placebo solution|A 100 ml placebo solution will be administered through an esophageal probe. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with placebo in one out of three visit days.
3298489|NCT01818570|Active Comparator|PPC-5650|"PPC-5650 is a asic-sensing ion channel-1a antagonist that can block the acid-sensing ion channels, leading to a reduction in the pain signal under up-regulated conditions. A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered through an esophageal probe to assess local effects. 100 ml will be administered as an infusion with a rate of 7ml/min. Healthy volunteers will be treated with PPC-5650 in one out of three visit days."
3298490|NCT01818583|Experimental|Potassium|Potassium chloride infusion at a rate of 15 mmol/h (60 mmol KCl in 1000 ml of 5% glucose with a concentration of 0.05 mmol/mL, flow rate 265 mL/h). If the serum Mg ≤0.8 mmol/L, MgSO4 infusion (0.5 mmol/kg/24 hours in 1000 mL NaCl 0.9% corresponding to an infusion rate of approximately 42 mL/hour) will also be administered.
3298491|NCT01818583|Placebo Comparator|Placebo|5% glucose (flow rate 265 ml/h) as placebo infusion.
3298492|NCT01818609|Experimental|Step Reduction|"Step reduction:~Take less than 1500 steps/d~No disease"
3298493|NCT01818622|Experimental|Patient-group blue-blockers|N= 21 Blue-blocking goggles/screens from 6 p.m. to 08 a.m. in addition to treatment as usual (TAU). The goggles may be taken of when going to bed and turning of the light. For consenting patients who are unable to use goggles according to the protocol blue-blocking screens covering light-sources will be used.
3298494|NCT01818622|Placebo Comparator|Patient group clear-lensed goggles|N= 21 (Patient group) clear-lensed goggles from 06 p.m. to 08 a.m. in addition to TAU.
3298495|NCT01818622|Experimental|Non-bipolar control-group blue-blockers|N= 42 For baseline day 1-7: Actiwatch Spectrum worn at the wrist of dominant hand, day 8-14 continued wearing of Actiwatch spectrum + blue-blocking goggles from 6 p.m. to 08 a.m. In addition to selfreport forms described in the outcome section self report forms Horne-Ostberg Morningness-Eveningness Questionaire (HOMEQ)and Seasonal Pattern Assessment Questionaire (SPAQ).
3298496|NCT01818648|Experimental|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
3298497|NCT01818648|Placebo Comparator|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
3298498|NCT01818661|Experimental|Tau positron emission tomography (PET)|All subjects will receive Tau PET scan on approximately day 1 or day 2 of study to assess Tau burden in the brain.
3298499|NCT01818674|Experimental|Group A - Microclinic Behavioral Health Enhanced Program|Group A received the Microclinic Behavioral Health Full Program (structured social interactions + fully interactive classroom education curriculum; parallel clinical screenings)
3298500|NCT01818674|Experimental|Group B - Microclinic Behavioral Health Basic Program|Group B received the Microclinic Behavioral Health Basic Program (no social structured interactions; basic classroom education; parallel clinical screenings)
3298501|NCT01818674|No Intervention|Group C - Controls with Parallel Monitoring|Group C only received standard care, and only received parallel risk factor screening measurements; not participation in classroom or any social activities.
3298502|NCT01818687|Experimental|MCI-196 (Flexible dose)|MCI-196 BSA eq 3g, 6g, 9g, 12g or 15g
3298503|NCT01818713|Experimental|2B3-101|A single dose of 2B3-101 (a glutathione (GSH) pegylated liposomal doxorubicin hydrochloride formulation) will be administrated intravenously once per cycle. To minimize the risk of infusion reactions, 5% of the total dose of 2B3-101 (in mg) will be administrated over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes
3298504|NCT01818778|Experimental|Stimulation Group|Cognitive Stimulation Group: One-on-one (one volunteer visiting one resident at a time), stimulation-group residents and stimulation-group volunteers met 3 times each week, for 8 weeks, to work through a variety of memory, reasoning, and selective attention exercises. Each visit was 20 minutes in length.
3298505|NCT01818778|Active Comparator|Control Group|"Standard Friendly Visit: Control-group residents and control-group volunteers, one-on-one, met for 8 weeks, 3 times each week, for friendly visits. Each visit was 20 minutes in length."
3298506|NCT01818791|Active Comparator|Making Proud Choices alone|These sites will be trained in Making Proud Choices.
3298507|NCT01818791|Experimental|Making Proud Choices+Getting To Outcomes|These sites will receive training in Making Proud Choices and receive the Getting To Outcomes intervention.
3298508|NCT01818817||TPVB group|In this group of patients thoracic paravertebral block is performed.
3298509|NCT01818817||GA group|In this group of patients general anesthesia is performed.
3298510|NCT01818830||SIRS group|(1) temperature > 38oC or < 36oC; (2) pulse rate > 90 beats/min; (3) ventilation rate > 20 breaths/min or hyperventilation with a partial pressure of arterial carbon dioxide (PaCO2) < 32 mmHg; (4) white blood cell (WBC) count >1 2,000μL-1 or < 4000 μL-1 , or > 10% immature cells.
3298511|NCT01818830||sepsis|SIRS+infection
3298512|NCT01818830||normal control|For the healthy control outpatients, possibilities of acute or past chronic diseases were excluded. Moreover, we made sure that the healthy control subjects had not been hospitalized or taken vitamin-based substitutive drugs in the last 12 months, and proved normal in physical checkups and lab examinations.
3298513|NCT01818843|Experimental|Safety and Adverse Reaction in CO|Inhaled Carbon Monoxide
3298514|NCT01818856|Experimental|Telaprevir interactions|"Telaprevir 750 mg/8h or 1125 mg/12h (+ pegIFN alfa and ribavirin) plus Atazanavir/ritonavir 300/100 mg/24. Pharmacokinetic profile on day 0.~Intervention: Ritonavir will be withdrawn and the atazanavir dose increased to 200 mg/12h for days 1 to 7. On day 8: a morning dose of Telaprevir (750 mg or 1125 mg) plus Atazanavir 200 mg. Pharmacokinetic profile for 12 hours"
3298515|NCT01818869|Experimental|AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
3298516|NCT01818869|Placebo Comparator|Placebo to match AZD8848|Subjects will participate in 1 of 3 groups and receive multiple doses of AZD8848 or matching placebo. In each group 6 subjects will receive AZD8848 and 2 subjects will receive matching placebo.
3298517|NCT01818882|Active Comparator|Standard care|"Patients randomized to this arm will receive standard care.~Intervention: Standard care."
3298518|NCT01818882|Experimental|Standard care + ultrasound|"Patients randomized to this arm will receive standard care + pleuropulmonary ultrasound.~Intervention: Standard care + ultrasound"
3298519|NCT01818895||Withdrawal of mechanical ventilation|
3298520|NCT01818908|Experimental|DA-EPOCH|"Infused agents:~Etoposide 50 mg/m2/day CI24h d1-d4; Doxorubicin 10 mg/m2/day CI24h d1-d4; Vincristine 0.4mg/m2/day CI24h d1-d4;~Bolus agents:~Rituximab(B-NHL) 375 mg/m2/day IV d0; Cyclophosphamide 750 mg/m2/day IV d5 ; Prednisone 60 mg/m2/bid oral or IV d1-d5;~The details of dose adjustment are described in ref 1.~If enrolled patient was histologically confirmed CD20+ B cell lymphoma, standard dose of rituximab will be recommend to combined with DA-EPOCH regimen."
3298521|NCT01818921|Placebo Comparator|ZGN-440 sterile diluent|Subjects will receive placebo twice weekly subcutaneous injections for up to 6 weeks.
3298522|NCT01818921|Experimental|1.2 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3298523|NCT01818921|Experimental|1.8 mg ZGN-440 for injectable suspension|Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.
3298524|NCT01818934|Active Comparator|expert clinical exam only|all babies assigned to this group had expert clinical examination only, no hip ultrasound
3298525|NCT01818934|Active Comparator|selective hip ultrasound screening|all children classified at increased risk, based on clinical findings and/or risk factors (breech presentation, family history, foot deformity)received a hip ultrasound at birth, in addition to expert clinical screening
3298526|NCT01818934|Active Comparator|universal hip ultrasound screening|All newborns assigned to this arm received hip ultrasound at birth in addition to expert clinical examination
3298527|NCT01818947||Gefitinib|
3298528|NCT01818960|Active Comparator|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
3298529|NCT01818960|Active Comparator|IRA-PCI|IRA only PCI with planned staging for non-IRA lesions
3298530|NCT01818973|Experimental|Single Arm|"Neoadjuvant chemotherapy with XELOX: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 130mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1, during the first cycle (each cycle has 3 weeks).~Followed by chemoradiotherapy, 50 Gy/25 fractions during 5 weeks plus 2 cycles XELOX and Bevacizumab: Xeloda, po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning; Oxaliplatin, iv, 100mg/m2, day 1; and Bevacizumab, iv, 7.5 mg/kg, day 1.~6-7 weeks from the last radiation therapy, Total Mesorectal Excision (TME) surgery will be performed.~3-4 weeks after operation, 3 cycles XELOX (the same as the neoadjuvant chemotherapy) and 2 cycles Xeloda (po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning) will be administered."
3298531|NCT01818986|Experimental|arm one|Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR)
3298532|NCT01818999|Experimental|arm one|IXABEPILONE and STEREOTACTIC BODY RADIATION THERAPY (SBRT)
3298533|NCT01819012|Experimental|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
3298534|NCT01819012|Experimental|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
3298535|NCT01819012|Experimental|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
3298536|NCT01819025|Experimental|4 face-to-face and smartphone-app|Four face-to-face therapy sessions and smartphone app as a complement and support to the four sessions.
3298537|NCT01819025|Active Comparator|TAU|10 sessions of face-to-face therapy, full behavioral activation
3298538|NCT01819038|Experimental|High NGAL and early RRT|NGAL level > 400 ng/ml and start continuous renal replacement therapy early
3298539|NCT01819038|Experimental|High NGAL and late RRT|NGAL > 400 ng/ml and start continuous renal replacement therapy late
3298540|NCT01819038|Active Comparator|Low NGAL|NGAL < 400 ng/ml and starting continuous renal replacement therapy follow with absolute indication
3298541|NCT01819051|Experimental|Plasma|Apply plasma to great toenail for up to 20 minutes, 1X/week for 3 weeks
3298542|NCT01819064||Children less than 5Kg.|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh less than 5Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
3298543|NCT01819064||Children weighing 5Kg to 15Kg|This group consists of children who are ASA physical status I and II, less than 2 years of age and scheduled for elective surgical procedure and weigh between 5Kg and 15Kg will receive atropine 5 mcg/kg IV during sevoflurane anesthesia.
3298544|NCT01819077||TMMR|Patients with cervical cancer Stages IB - IIA treated with TMMR and tLNE
3298545|NCT01819090|Active Comparator|No ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an usual (with no ventilation switch control) Elysee 150 ventilator while speaking
3298546|NCT01819090|Active Comparator|Ventilation switch control|Neuromuscular patients non invasively ventilated in a stable state at the time of the study testing an Elysee 150 ventilator with a ventilation switch control allowing them to control ventilation while speaking
3298547|NCT01819103||Acute myocardial infarction|Drug Adherence
3298548|NCT01819142|Experimental|AutoloGel|Subjects will be treated with AutoloGel on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All patients will receive Autologel treatment
3298549|NCT01819155|Experimental|adjTIV|Children randomized to receive adjTIV
3298550|NCT01819155|Experimental|TIV|Children randomized to receive TIV
3298551|NCT01819155|Placebo Comparator|Placebo|Children randomized to receive Placebo
3298552|NCT01819207|Experimental|TEG group|
3298553|NCT01819220|Active Comparator|amlodipine/valsartan|
3298554|NCT01819220|Experimental|hydrochlorothiazide/telmisartan|
3298555|NCT01819246|Active Comparator|Pheresis Treatment Arm|
3298556|NCT01819246|Sham Comparator|Control Arm|
3298557|NCT01819259|Active Comparator|ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3298558|NCT01819259|Active Comparator|Non-ADHD Nonsmokers|All participants will be non-smokers defined as never having smoked an entire cigarette and no tobacco use in the past 3 years. The group will then be split into those diagnosed with ADHD/ADD and controls for comparison.
3298559|NCT01819285|Active Comparator|Immediate Endocrine Therapy|Immediate Endocrine Therapy. Orchiectomy or LHRH Agonist Therapy plus (initially) Antiandrogen Therapy. Buserelin (BSRL); Cyproterone acetate (Androcur) (CPTR), Cyproterone acetate (Androcur)(NSC-81430). Treatment initiated within 1 month of randomization.
3298560|NCT01819285|Experimental|Delayed Endocrine Therapy|Orchiectomy or LHRH Therapy plus (initially) Antiandrogen Therapy. BSRL; CPTR. Treatment delayed until onset of symptoms.
3298561|NCT01819298||bacteria colonization in CAT less 20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores less than 20
3298562|NCT01819298||the PPM in change of CAT >2|the change of potential pathogenic microorganism in CAT difference more than 2 while follow-up
3298563|NCT01819298||the change of CAT<=2|the change of potential pathogenic microorganism in CAT difference less than or equal to 2 while follow-up
3298564|NCT01819298||PPM in CAT>=20|the incidence of sputum potential pathogenic microoragnism in patients with CAT scores more than or equal to 20
3298565|NCT01819324|Experimental|Targeting the Teachable Moment|Receiving Targeting the Teachable Moment Intervention materials (focusing on health behaviors and issues specific to breast cancer survivors) every other week for 4 months
3298566|NCT01819324|Active Comparator|Standardized Lifestyle Management|Receiving Standardized Lifestyle Management materials (focusing mostly on health behaviors) every other week for 4 months
3298567|NCT01819324|No Intervention|Usual Care|Receiving SLM materials at the end of the 7 months
3298568|NCT01819350|Experimental|G4 and G5|Application of antibiotic group of pediatric medicines and control group (sucrose 10 %)on dental biofilm.
3298569|NCT01819350|Experimental|G1, G2 and G3|Application of Nutritional, Respiratory and Endocrine groups medicines pediatric on dental biofilm
3298570|NCT01819363||Study group|Patients with Malignant pleural effusion according to inclusion and exclusion criteria.
3298571|NCT01819376|Experimental|Intervention: Facebook updates|The experimental group will be encouraged to update their Facebook status regarding healthy lifestyle decisions at least once a day.
3298572|NCT01819376|No Intervention|Control: No Facebook|This group will be encouraged not to share their healthy lifestyle decisions on Facebook.
3298573|NCT01819389|Experimental|Imatinib and nilotinib combination|All patients will receive treatment as follows: imatinib 100 mg tablets, 200 mg daily for 6 months; and nilotinib 150 mg capsule, 300 mg daily for 6 months.
3298574|NCT01819402|Active Comparator|Active Comparator: 1|up to 30 mg pioglitazone, tablet, orally, once daily
3298575|NCT01819402|Sham Comparator|Sham Comparator: 1|up to 4 mg/day glimepiride, tablet, orally, once daily
3298576|NCT01819428|Experimental|NOV120101 (Poziotinib)|Single arm study with NOV120101(poziotinib)12mg PO daily administration
3298577|NCT01819441|Sham Comparator|Normal Azelnidipine/Perindopril|Systole blood pressure controlled between 130 mmHg~140 mmHg(with or without hydrochlorothiazide).
3298578|NCT01819441|Experimental|Intensive Azelnidipine/Perindopril|Systole blood pressure controlled below 130 mmHg(with or without hydrochlorothiazide).
3298579|NCT01819454|Experimental|pH monitoring sinusitis no polyps|30 patients with chronic rhinosinusitis without nasal polyposis, without asthma bronchiale or ASA syndrome
3298580|NCT01819454|Experimental|pH monitoring sinusitis with polyp|30 patients with chronic rhinosinusitis with nasal polyposis, without asthma bronchiale or ASA syndrome
3298581|NCT01819454|Experimental|pH monitoring sinusitis, polyps, asthma|30 patients with chronic rhinosinusitis with nasal polyposis and with asthma bronchiale and/or ASA syndrome
3298582|NCT01819467|Active Comparator|Treatment Group|Patients in this group will receive Seprafilm onto the uterine incision and the anterior midline of the uterus.
3298583|NCT01819467|No Intervention|Control Group|This arm will be known as the control/no intervention group. This group will not receive Seprafilm or any other adhesion barrier method
3298584|NCT01819480|Experimental|Transoral robotic surgery|Transoral robotic surgery
3298585|NCT01819493|Active Comparator|Standard Family-Based intervention|"Families randomized to the Standard Family-based Intervention will receive three-month family YMCA memberships, one orientation training session, access to available equipment and programming at the YMCA, and receive diabetes educational materials from the Power to Prevent curriculum via email. Based on our previous experience with AA adults, the investigators anticipate that all families will have access to email either at home or at work. Educational materials will be mailed to families without access to email. The study will also maintain contact with participants by sending holiday and birthday cards, as well as postcard reminders of scheduled data collection visits."
3298586|NCT01819493|Experimental|Lifestyle Intervention|"The lifestyle intervention for adults will involve a dietary weight loss program and an increase in caloric expenditure through moderate PA. Parents will be encouraged to decrease caloric intake in a sound manner to produce a total weight loss of 5%. The PA component will be to promote an increase in family home-based activity.~Children. The study will promote healthy eating behaviors, rather than restrictive eating plans with caloric restrictions."
3298587|NCT01819519|No Intervention|Standard Prenatal Care|Participants will receive standard prenatal care from the time they are screened for CMV to delivery. This includes a CMV brochure.
3298588|NCT01819519|Experimental|Educational Intervention|This group will be approached during a routine prenatal visit and will receive a 5-10 minute educational intervention (CMV prevention video, preventive information, weekly text messages/emails as reminders for hygiene behaviors, developmental calendar with hygiene reminders).
3298589|NCT01819532|Active Comparator|Immediate umbilical cord clamping|The umbilical cord will be clamped immediately after delivery.
3298590|NCT01819532|Experimental|Cord milking group|"The umbilical cord will be milked in direction towards neonate 4 times over the course of 10 minutes."
3298591|NCT01819545||Alzheimer's disease|no intervention
3298592|NCT01819545||Mild cognitive impairment|no intervention
3298593|NCT01819545||Normal aging|no intervention
3298594|NCT01819558|Experimental|immune therapy|6 administration every 2 weeks of intra-muscular 200 micrograms of protein recwt1-A10+AS01B at week 1, 3, 5, 7, 9 and 11.
3298595|NCT01819571|Experimental|Normal diastolic function group|
3298596|NCT01819571|Active Comparator|Diastolic dysfunction group|
3298597|NCT01819584||Patients below 15 years old|
3298598|NCT01819584||Patients above 15 years old|
3298599|NCT01819610|Experimental|SPRIX|Subjects will be administered open label SPRIX according to subject weight.
3298600|NCT01819623|Experimental|Non-pharmacological therapy|This group will be supervised nonpharmacologic therapy
3298601|NCT01819623|No Intervention|Control|This group will receive the standard treatment for mild cognitive impairment
3298602|NCT01819636|Experimental|Sparkling highly mineral bicarbonated sodium water|1.25 liter a day of sparkling highly mineral bicarbonated sodium water
3298603|NCT01819636|Placebo Comparator|Sparkling low mineralized water|1.25 liter a day of sparkling low mineralized water
3298604|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 100 mcg/d|
3298605|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 200 mcg/d|
3298606|NCT01819649|Experimental|Selenium enriched-yeast tablet; SelenoPRECISE 300 mcg/d|
3298607|NCT01819649|Placebo Comparator|Yeast tablet|
3298608|NCT01819662|Placebo Comparator|Standard management|No echocardiogram
3298609|NCT01819662|Active Comparator|Enhanced standard management|Echocardiogram performed, with results to GP
3298610|NCT01819662|Active Comparator|Optimised heart failure management|Echocardiogram, followed by referral to comprehensive heart failure program for those with left ventricular dysfunction
3298611|NCT01819675|Experimental|High frequency (10Hz) rTMS|<high frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 10Hz; Number of total stimuli: 750; Coil orientation: tangential to scalp
3298612|NCT01819675|Experimental|Low frequency (1Hz) rTMS|<low frequency rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: tangential to the scalp
3298613|NCT01819675|Sham Comparator|Sham rTMS|<Sham rTMS parameters> Intensity: 120% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1200; Coil orientation: perpendicular to scalp
3298614|NCT01819701|Placebo Comparator|Placebo|starch
3298615|NCT01819701|Experimental|LC and Coenzyme Q10|L-carnitine: 1000 mg/d and 2000 mg/d Coenzyme Q10: 150 mg/d and 300 mg/d
3298616|NCT01819714|Experimental|Study population|Patients hospitalized at the Serre-Cavalier centre and who have Alzheimer's-type neurodegenerative disease (see inclusion criteria).
3298617|NCT01819740||patients with suspected prostate cancer|
3298618|NCT01819753|Active Comparator|Single access|It was performed only single access standard PCNL in this group.
3298619|NCT01819753|Active Comparator|Multiple access|It was performed multiple access standard PCNL in this group
3298620|NCT01819766||IBD or PSC|Subjects will be men and women, 18 to 84 years of age, inclusive, who are at increased risk of developing colorectal cancer.
3298621|NCT01819779|Active Comparator|Exforge tab. 10/160mg|"amlodipine besylate (10mg as amlodipine)~valsartan 160mg"
3298622|NCT01819779|Experimental|Lodivixx tab. 5/160mg|"S-amlodipine nicotinate (5mg as S-amlodipine)~valsartan 160mg"
3298623|NCT01819792|Other|patient with Acute Myeloïd Leukemia|
3298624|NCT01819805||Patients taking tramadol hydrochloride and acetaminophen|
3298625|NCT01819818||Paliperidone palmitate|
3298626|NCT01819831|Experimental|Preoperative proton radiation|Patients will receive 50 Gray equivalents (GyE) in 25 fractions with proton therapy, followed by surgery 4-8 weeks after completion of radiation.
3298627|NCT01819857|Active Comparator|Droperidol 0.625 mg intravenously|
3298628|NCT01819857|Active Comparator|Droperidol 1.25 mg intravenously|
3298629|NCT01819857|Active Comparator|Ondansetron 8 mg intravenously|
3298630|NCT01819870|Experimental|Dilatrend SR capsule 32mg|
3298631|NCT01819870|Active Comparator|Dilatrend IR tablet 25mg|
3298632|NCT01819896||pacemakers and defibrillators|
3298633|NCT01819909|Experimental|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
3298634|NCT01819909|Experimental|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
3298635|NCT01819948|Experimental|single-arm|Two capsules in the morning, one at night, every day for a month, taken with a glass of water.
3298636|NCT01819961|Experimental|MCT/LCT|Structural Fat Emulsion Injection 250ml per day, for 7 days
3298637|NCT01819961|Experimental|MCT/LCT and fish oil|Structural Fat Emulsion Injection 250ml and fish oil 100ml for 7 days.
3298638|NCT01819974|No Intervention|Control|The normal procedure at the ward
3298639|NCT01819974|Active Comparator|Stratified medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist in patients with highest medication error risk
3298640|NCT01819987|Active Comparator|Mailing information|Participants in the mailing information group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
3298641|NCT01819987|Experimental|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
3298642|NCT01820000|Experimental|Diffusion Weighted Imaging with MRI scans|Subjects will undergo a MRI (magnetic resonance imaging) scan where DWI (diffusion weighted imaging) will be performed. Subjects will not receive contrast during this sequence, but will receive contrast as standard MRI protocol.
3298643|NCT01820013|Experimental|Customised Orthoses|Customised Dynamic Elastomeric Fabric Orthoses (DEFO)
3298644|NCT01820013|Active Comparator|Rigid 'off the shelf' pelvic support|Serola Sacroiliac Belt.
3298645|NCT01820026|Experimental|Imipenem & Vancomycin & Azithromycin|"Tienam combined with vancomycin (1g/12 h) for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of a source of infections.~Tienam combined with vancomycin (1g/12 h)and azythromycin (500 mg/24 h)for pneumonia"
3298646|NCT01820026|Active Comparator|Cefotaxime & Amoxicillin & Azithromycin|Cefotaxime IV(2g/12 h): for Spontaneous bacterial peritonitis, cholangitis, sepsis without evidence of specific site of infection Amoxicillin/clavulanic acid (2,2 g/8 h)or Ciprofloxacin (500 mg/12 h: urinary tract infections Amoxicillin/clavulanic acid (2,2 g/8 h)and azithromycin (500 mg/24 h): pneumonia Amoxicillin/clavulanic acid (2,2 g/8 h)for skin or soft tissue infection
3298647|NCT01820039|Experimental|FertiScreen|all patients between 18 and 38 years, consulting their general practitioner for infertility will be asked to use FertiScreen.
3298648|NCT01820052|Active Comparator|Oral Iron|Patient will receive 230 mg of oral elemental iron daily for 3 months
3298649|NCT01820052|Placebo Comparator|Oral Placebo|Oral Placebo tablets will be administered daily for 3 months
3298650|NCT01820065||Patients undergoing phacoemulsification|Patients undergoing phacoemulsification for age-related cataract with implantation of a single-piece Acrysof IOL (SN60AT)
3298651|NCT01820078|Experimental|Paricalcitol, Daily treatment, CKD|Experimental Arm
3298652|NCT01820078|Other|Daily treatment for CKD|Comparator Arm
3298653|NCT01820091|Experimental|Cohort 1 - Fusilev - 20 doses|"5 mg/m2 QID (6 hours apart) starting on Days 2 and 16 (24 hours after Folotyn dose) for a total of 20 doses in a 28-day cycle~Days 2 and 16: 4 doses/day~Days 3 and 17: 4 doses/day~Days 4 and 18: 2 doses/day~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3298654|NCT01820091|Experimental|Cohort 2 - Fusilev - 12 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 4, 16, 17, and 18 for a total of 12 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3298655|NCT01820091|Experimental|Cohort 3 - Fusilev - 8 doses|"5 mg/m2 BID 8 hours apart on Days 2, 3, 16, and 17 for a total of 8 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3298656|NCT01820091|Experimental|Cohort 4 - Fusilev - 4 doses|"5 mg/m2 BID 8 hours apart on Days 2 and 16 for a total of 4 doses in a 28-day cycle.~Fusilev dose to start 24 hours after Folotyn dose.~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3298657|NCT01820091|Experimental|Cohort 5 - Fusilev - 2 doses|"5 mg/m2 once on Days 2 and 16 for a total of 2 doses in a 28-day cycle~Folotyn: 190 mg/m2 on Days 1 and 15 in a 28-day cycle"
3298658|NCT01820104|Placebo Comparator|Placebo|oral sitagliptin 100 mg on day 6 after administration of placebo (30 mg per day) for 6 days
3298659|NCT01820104|Experimental|Combination of lansoprazole and sitagliptin|oral sitagliptin 100 mg on day 6 after administration of lansoprazole (30 mg per day) for 6 days
3298660|NCT01820117||Hodgkin lymphoma|"Participants previously treated at St. Jude Children's Research Hospital with thoracic radiation therapy for Hodgkin lymphoma.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
3380157|NCT04938141||Acalabrutinib|CLL patients initiating acalabrutinib alone or in combination with an anti-CD20 mAb
3380158|NCT04938141||Ibrutinib|CLL patients receiving ibrutinib alone or in combination with an anti-CD20 mAb
3380159|NCT04936815|Experimental|Echocardiographic screening|Echocardiographic screening for the detection of latent structural heart disease
3380160|NCT04936815|No Intervention|Control arm|Routine antenatal care
3298661|NCT01820117||Normal control|"A group of healthy individuals matched for age, sex and race.~Interventions: Neurocognitive Evaluation, Quantitative Brain Imaging, Neurologic Evaluation, Comprehensive Health Questionnaire, Vascular Testing, Cardiopulmonary Exercise Testing, Echocardiography, Pulmonary Function Testing, Serum Biomarkers, and Ophthalmology Examination."
3298662|NCT01820130|Experimental|Spinal Cord Stimulation system therapy|St Jude Medical EON mini rechargeable system
3380164|NCT04931654|Experimental|Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) acquired resistance|AZD7789 monotherapy
3298663|NCT01820143|Experimental|Treatment sequence ADBC|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3380165|NCT04931654|Experimental|Dose Expansion Part B1: NSCLC IO acquired resistance|AZD7789 Monotherapy
3380166|NCT04931654|Experimental|Dose Expansion Part B2: NSCLC IO naive|AZD7789 Monotherapy
3380171|NCT04923269|Experimental|LY3532226|Single ascending doses of LY3532226 administered subcutaneously (SC).
3380172|NCT04923269|Placebo Comparator|Placebo|Placebo administered SC.
3298664|NCT01820143|Experimental|Treatment sequence BACD|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3380179|NCT04922697|Experimental|Prevention (educational videos, questionnaires)|Participants watch 2 educational videos during week 3 regarding air pollution, health effects, and personal preventive health behaviors to reduce air pollution exposure. Participants will use wearable air pollution sensors. Participants will complete questionnaires at weeks 1 and 5.
3380180|NCT04922554|Experimental|Omadacycline 300 mg PO|omadacycline 150 mg tablets (x 2) administered orally, once daily, q24h
3380181|NCT04922554|Placebo Comparator|Placebo PO|Placebo tablets resembling omadacycline (x 2) administered once daily, q24h
3380184|NCT04914546|Experimental|LY3819469 (Part A)|Single ascending doses of LY3819469 administered subcutaneously (SC).
3380185|NCT04914546|Experimental|LY3819469 (Part B)|Single doses of LY3819469 administered SC in Japanese Participants.
3380186|NCT04914546|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
3380187|NCT04914546|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
3380188|NCT04911777|Experimental|Pentarlandir™ UPPTA - High Dose|High dose of Pentarlandir™ UPPTA, q8h (over 3 hours postprandially)
3380189|NCT04911777|Experimental|Pentarlandir™ UPPTA - Low Dose|Low dose of Pentarlandir™ UPPTA and placebo, q8h (over 3 hours postprandially)
3298665|NCT01820143|Experimental|Treatment sequence CBDA|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3298666|NCT01820143|Experimental|Treatment sequence DCAB|Regimen A: 10 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen B: 20 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen C: 40 mg of ilaprazole administered QD for 5 days with 240 mL of water. Regimen D: 40 mg of esomeprazole administered QD for 5 days with 240 mL of water.
3298667|NCT01820156|Experimental|HRP-PSG|First performance three nights of HRP and following one night of laboratory PSG
3298668|NCT01820156|Experimental|PSG-HRP|First perform laboratory PSG and following three nights of HRP
3298669|NCT01820169|Experimental|Single arm|
3298670|NCT01820182|Experimental|capsocam capsula|capsocam capsula readings
3298671|NCT01820195|Active Comparator|Intravenous N Acetyl Cystein|1200 mg IV N- Acetyl Cystein half an hour before contrast administration. This group will also take oral placebo
3298672|NCT01820195|Placebo Comparator|Placebo|Patients on both oral placebo and IV placebo just like patients on oral and IV N-acetyl cystein groups in regard of dose and timing.
3298673|NCT01820195|Active Comparator|Oral N Acetyl Cystein|Patients on 600 mg oral N-Acetyl Cystein bid started at the day before contrast exposure and continue until the next day of contrast exposure.These patients will also take IV placebo
3298674|NCT01820208|Placebo Comparator|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
3298675|NCT01820208|Experimental|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
3298676|NCT01820221|Active Comparator|Arm 1: Skin closure with suture|Subjects in this group will be randomized to suture for skin closure with computer generated random card draw.
3298677|NCT01820221|Active Comparator|Arm 2: Skin closure with staples|Subjects randomized to skin closure with staples with computer generated random card draw.
3298678|NCT01820234|Other|In-person dermatology evaluation|Health care modality
3298679|NCT01820234|Other|Store-and-forward teledermatology evaluation|Health care modality
3298680|NCT01820247|Experimental|enteral nutrition|The patients receive treatment of enteral nutrition only.
3298681|NCT01820247|Experimental|tripterygium glycosides|The patients receive treatment of tripterygium glycosides only.
3298682|NCT01820247|Experimental|tripterygium glycosides and enteral nutrition|The patients receive treatment of tripterygium glycosides and enteral nutrition.
3298683|NCT01820286|Experimental|Positive psychology intervention|4-week positive psychology intervention of 1 positive psychology exercise per week. Exercises will include 1) recalling 3 good events, 2) writing a letter of thankfulness, 3) using a personal strength, 4) envisioning a best possible future.
3298684|NCT01820286|Active Comparator|Recollection intervention|4-week recollection intervention of 1 recollection exercise per week. Exercises will include recalling events related to 1) daily activities, 2) health, 3) social life, 4) morning and evening.
3298685|NCT01820299|Experimental|Grape Seed Extract and Vitamin D|All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64. For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU.
3298686|NCT01820325|Experimental|Buparlisib + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib for up to 6 cycles, followed by blinded buparlisib maintenance
3298687|NCT01820325|Placebo Comparator|Placebo + Carboplatin + Paclitaxel|Carboplatin and paclitaxel plus buparlisib-matching placebo for up to 6 cycles, followed by blinded placebo maintenance
3298688|NCT01820338|Experimental|Behavioral Family Intervention|Child and Parent attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
3298689|NCT01820338|Experimental|Behavioral Parent-Only Intervention|Only parents attend intervention including nutrition and physical activity education, plus behavioral strategies to facilitate behavior and weight status change
3298690|NCT01820338|Active Comparator|Education Control|Child and parent attend intervention that includes only nutrition and physical activity education; no instruction or assistance in the use of behavioral strategies are included in this condition
3298691|NCT01820377|Experimental|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4 students, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s act as the intervention group.
3298692|NCT01820377|No Intervention|Control Group|This group acts as a control, and are not apart of the Aboriginal Youth Mentorship Program
3298693|NCT01820403|Experimental|portion size small|400 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3298694|NCT01820403|Experimental|portion size medium|800 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3298695|NCT01820403|Experimental|portion size large|1600 kcal box lunch was delivered each weekday to each participant at the worksite for a six month period.
3298696|NCT01820403|No Intervention|control|no box lunch provided to participants.
3298697|NCT01820429||First 48 hours|Patients in the first 48 hours of non ST-elevation acute coronary syndromes.
3298698|NCT01820429||3 months after discharge|Patients with 3 months after hospital discharge for non ST-elevation acute coronary syndromes.
3298699|NCT01820442|Active Comparator|Lofexidine Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on lofexidine up to the target therapeutic dose of 0.8 mg QID (4 tablets QID) or to the highest level tolerated. Following this initial titration attempt, all subjects will have their buprenorphine dose reduced by 50% and lofexidine titration efforts will resume.
3380190|NCT04911777|Placebo Comparator|Placebo|Pacebo, q8h (over 3 hours postprandially)
3298700|NCT01820442|Placebo Comparator|Placebo Titration in Buprenorphine Maintained Subjects|Buprenorphine maintained subjects will be titrated on placebo tablets in ascending doses of 1 tablet starting with 2 tablets (e.g., Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) to mimic titration for subjects randomized to lofexidine.
3298701|NCT01820455|Active Comparator|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal Mupirocin ointment daily for 5 days
3298702|NCT01820455|Placebo Comparator|Soap baths, Lubricating jelly|Soap and water baths with lubricating jelly to each nare daily for 5 days
3298703|NCT01820468|Experimental|Adapted critical time intervention team|Community-based team will help facilitate early inpatient discharge and re-entry into the community.
3298704|NCT01820468|No Intervention|Regular inpatient care|
3298705|NCT01820481|Experimental|Treatment 1|
3298706|NCT01820481|Experimental|Treatment 2|
3298707|NCT01820481|Experimental|Treatment 3|
3298708|NCT01820481|Placebo Comparator|Placebo|
3298709|NCT01820494|Experimental|Experimental Infant Formula|Complete amino acid-based infant formula
3298710|NCT01820507|Experimental|High Flow Conditioned Oxygen Therapy|Intervention: The Optiflow(R) device supplies oxygen in controlled concentrations and at high flow (from 10 to 70 liters/min) through special nasal cannulae. The device also humidifies the gases mixtures up to 100% relative humidity.
3298711|NCT01820507|Active Comparator|Standard Oxygen Therapy|The standard way of oxygen supply after extubation is either by nasal cannulae at flow between 1 and 5 liters/min or by mask with controlled oxygen concentration from 24% to 50%.
3298712|NCT01820520|Experimental|Double staining with brilliant blue G during vitrectomy|
3298713|NCT01820533||smokers|
3298714|NCT01820598|Other|m-NMES first|Multisite electrostimulator first (Visit 1) and conventional electrostimulator then (Visit 2)
3298715|NCT01820598|Other|c-NMES first|Conventional electrostimulator first (Visit 1) and multisite electrostimulator then (Visit 2)
3298716|NCT01820611||With Bonemaster HA|100 patients using Arcos Revision Stem System with BoneMaster Hydroxyapatite
3298717|NCT01820611||Without BoneMaster HA|100 patients using Arcos Revision Stem System without BoneMaster Hydroxyapatite
3298718|NCT01820624|Experimental|Treatment (tretinoin, lithium carbonate)|Patients receive tretinoin PO every 12 hours on days 1-7 and 15-21 and lithium carbonate PO TID on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3298719|NCT01820663|Experimental|Modified Atkins Diet|Patients will receive a 14 day menu consisting of the Modified Atkins diet, a low-carbohydrate, high protein, high fat diet.
3298720|NCT01820663|Placebo Comparator|Control Diet|Patients will receive a diet (e.g. regular, low cholesterol, diabetic) determined by the attending physician.
3298721|NCT01820676||iUni G2+|iUni G2+ in all patients
3298722|NCT01820689|Experimental|Tympanometry measurement|
3298723|NCT01820702|Active Comparator|defined training programme|
3298724|NCT01820702|No Intervention|Control|
3298725|NCT01820715|Experimental|600㎍ of DA-3030 Injection|600㎍ of DA-3030 is injected once a day, for 5 continuous days.
3298726|NCT01820715|Placebo Comparator|Placebo|Placebo(a salin drip) is injected once a day, for 5 continuous days.
3298727|NCT01820728|Experimental|DA-3801 injection|Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days
3298728|NCT01820728|Active Comparator|Gonal-F®|75 IU/day is injected for 14 days
3298729|NCT01820767|Experimental|Paricalcitol|SUBGROUP 1 (G1): Paricalcitol oral dosis triphosphoinositide mgc/100, 3 days a week.
3298730|NCT01820767|Active Comparator|Paricalcitol, Atorvastatin|SUBGROUP 2 (G2): Paricalcitol (same dosis than G1) + Atorvastatin (1 daily dosis 20 mg)
3298731|NCT01820767|Active Comparator|Atorvastatin|SUBGROUP 3 (G3): Atorvastatin (same G2 dosis)
3298732|NCT01820780|Experimental|intensive disease management|Planned consultations with HF specialist including biological test at weeks 1, 2 and 4; in addition to usual care.
3298733|NCT01820780|Active Comparator|usual disease management|usual care according to guidelines; including first medical consultation and biological test within the 4-week time following discharge.
3298734|NCT01820793|Experimental|cefoxitin|this study is centered on women with pyelonephritis without severity symptoms due to ESBL-producing E. coli.
3298735|NCT01820806|Experimental|[14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
3298736|NCT01820819||Registered or not on the transplantation national waiting list|
3298737|NCT01820832|Experimental|Calcitriol|General treatments (such as blood pressure control, lipid lowering, and so on) plus Calcitriol 0.5 ug/BIW for 24 weeks.
3298738|NCT01820832|No Intervention|Control|General treatments.
3298739|NCT01820845||Cohort of children with scoliosis surgery|
3298740|NCT01820858|Experimental|Adjuvant Chemotherapy|Paclitaxel: 175 mg/m(2) intravenously (IV); followed by Paraplatin (Carboplatin Injection) AUC=5 IV. 3-6 cycles as necessary.
3298741|NCT01820858|Active Comparator|Adjuvant Radiotherapy|"Histopathological grade G3 and <50% myometrial invasion: Vaginal brachytherapy 5Gy, 3 times;~Histopathological grade G3 and vascular space involvement: Pelvic radiation 45-50 Gy;~≥50% myometrial invasion: Pelvic radiation 50 Gy + Vaginal brachytherapy 5Gy, 2-4 times."
3298742|NCT01820871|Experimental|application arm|"The patients of application arm have the smartphone application (android) for management of type 2 DM.~The application contains action plans and alarm system for each situation of serum fasting glucose, blood pressure, body weight, exercise amount, calori intake, medication, etc."
3298743|NCT01820871|Active Comparator|conventional arm|The patients of conventional arm have the booklet for management of type 2 DM. The application contains general medical guideline and knowledge for management of type 2 DM such as,exercise amount, calori intake, medication, etc.
3298744|NCT01820884|Experimental|Total Hysterectomy (TH)|Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).
3298745|NCT01820884|Active Comparator|TH and bilateral salpingo-oophorectomy (TH/BSO)|Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.
3298746|NCT01820897|Experimental|Fosfomycin-Trometamol, Sulfamethoxazole trimethoprim, placebo|Fosfomycin-Trometamol 3 grams every 10 days for 6 months Plus Sulfamethoxazole trimethoprim 800/160 mg monday, wednesday and friday for 6 months Plus Placebo of Sulfamethoxazole trimethoprim Tuesday,thursday, saturday and sunday for 6 months.
3298747|NCT01820897|Active Comparator|Sulfamethoxazole trimethoprim, placebo|Sulfamethoxazole trimethoprim 800/160 mg every day for 6 months plus Placebo of Fosfomicyn-trometamol every 10 days for 6 months
3298748|NCT01820910|Experimental|Doxycycline|
3298749|NCT01820923|Experimental|Brain stimulation|"Brain stimulation will consist of 4 types of intervention:~real transcranial direct current stimulation (two weeks, five days a week)~a week of wash-out~Sham transcranial direct current stimulation (two weeks, five days a week)~two weeks of wash-out~real repetitive transcranial magnetic stimulation (two weeks, four days a week)~a week of wash-out~Sham repetitive transcranial magnetic stimulation (two weeks, three days a week)~Stimulations will be counterbalanced between patients."
3298750|NCT01820936|Experimental|Treatment A: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 30 minutes after completing a high-fat breakfast
3298751|NCT01820936|Experimental|Treatment B: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water after fasting for at least 10 hours and 30 minutes before starting a high-fat breakfast
3298752|NCT01820936|Experimental|Treatment C: PCI-32765|420 mg capsules administered by mouth with 240 mL noncarbonated water 2 hours after completing a high-fat breakfast
3298753|NCT01820936|Experimental|Treatment D: PCI-32765|420 mg capsules administered with 240 mL noncarbonated water after fasting at least 10 hours
3298754|NCT01820936|Experimental|Treatment E: PCI-32765|840 mg capsules administered with 240mL noncarbonated water 30 minutes after completing a high-fat breakfast
3298755|NCT01820949||Control cohort|Standard care before implementation (pre-implementation)
3298756|NCT01820949||PBM cohort|After implementation of PBM program (post-implementation)
3298757|NCT01820962|Active Comparator|A: heparin (Heparin LEO)|After each use, the central venous catheter lumen will be flushed with 10 ml 0.9% NaCl and then locked with heparin 5000 IU/ml(standard treatment)using a volume exactly equivalent to the internal volume noted on each catheter.
3298758|NCT01820962|Experimental|B: concentrated citrate (Citralock)|locking the central venous catheter with concentrated citrate after each use
3298759|NCT01820975|Experimental|High protein intake|High protein intake: large bolus of protein in teh diet the day before testing
3298760|NCT01820975|Placebo Comparator|No protein intake|No protein in the diet the day before testing
3298761|NCT01820988||Sarcopenic vs. non-sarcopenic|Participants are classified as sarcopenic/non-sarcopenic according to the criteria of the European Working Group of Sarcopenia in Older People (EWGSOP).
3298762|NCT01821001|Experimental|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
3298763|NCT01821014|Experimental|Telemedicine First|Patients whose first physician visit during the clinic was using videoconference, a form of telemedicine, and whose second physician visit during the clinic was with a physician in-person.
3298764|NCT01821014|Experimental|Telemedicine Second|"Patients whose first physician visit during the clinic was with a physician in-person, and whose second physician visit during the clinic was using videoconference, a form of telemedicine. This is the reverse order of visits of the Telemedicine fist arm."
3298765|NCT01821014|Active Comparator|Two physician visits|Patients who had two sequential visits with different in-person physicians.
3298766|NCT01821027|Experimental|Canagliflozin + simvastatin|Each volunteer will receive a single dose of simvastatin on Day 1, followed by canagliflozin (JNJ-28431754) once daily on Days 2 through 6. On Day 7 volunteers will receive a single dose of simvastatin in combination with a single dose of canagliflozin.
3298767|NCT01821040|Experimental|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
3298768|NCT01821040|Active Comparator|Prednisone IR|Prednisone IR 15mg daily start dose (immediate release) administered in the morning
3298769|NCT01821053||pregestational type 1 diabetes|It is an observational study. No intervention is made.
3298770|NCT01821066|Experimental|Two-Period Fixed-Sequence Arm|This arm is comprised of two treatment periods in fixed sequence. Period 1 is 7 days long, while Period 2 is 28 days long. In Period 1 the subjects receive a single 125 mg oral dose of PD-0332991 on Day 1. In Period 2 the subjects receive 4 daily 60 mg oral doses of tamoxifen (Days 1-4), followed by 23 daily 20 mg oral doses of tamoxifen (Days 5-27). On Day 22 of Period 2 the subjects receive a second 125 mg oral dose of PD-0332991.
3298771|NCT01821079|Experimental|PF-05175157 PIC in fed state|200 mg single dose of PF-05175157 administered as PIC in the fed state (following a standard high fat meal).
3298772|NCT01821079|Experimental|PF-05175157 tablet in fed state|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
3298773|NCT01821079|Experimental|PF-05175157 tablet in fed state (repeat)|200 mg single dose of PF-05175157 administered as tablet formulation in the fed state (following a standard high fat meal).
3298774|NCT01821079|Experimental|PF-05175157 tablet in fasted state|200 mg single dose of PF-05175157 administered as tablet formulation in the fasted state (following at least a 10 hour fast).
3298775|NCT01821092|Active Comparator|standard implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in healed ridge, prosthetic connection with switching platform
3298776|NCT01821092|Active Comparator|immediate implant, switching platform|osseointegrated implant insertion and abutment connection Implants inserted in immediate post-extraction sites, prosthetic connection with switching platform
3298777|NCT01821131|Experimental|30g ground flaxseed per day|consume 1 muffin containing 30g ground flaxseed every day for 4 weeks
3298778|NCT01821131|Experimental|20g ground flaxseed per day|consume 1 muffin containing 20g ground flaxseed every day for 4 weeks
3298779|NCT01821131|Placebo Comparator|0g ground flaxseed per day|consume 1 muffin containing 0g ground flaxseed every day for 4 weeks
3298780|NCT01821144|Other|Control|No salt awareness education
3298781|NCT01821144|Experimental|Salt reduction|Salt reduction
3298782|NCT01821157|Active Comparator|Flapless|Flapless: Gingivectomy and osteoplasty, as necessary, will be performed without flap elevation.
3298783|NCT01821157|Active Comparator|Open-flap|Gingivectomy and osteoplasty, as necessary, will be performed with flap elevation
3298784|NCT01821170|Experimental|Cognitive remediation|
3298785|NCT01821170|Active Comparator|Supportive psychotherapy|
3298786|NCT01821170|Active Comparator|Methylphenidate|
3298787|NCT01821183||hip rotators muscle strength|
3298788|NCT01821183||control group|no intervention
3298789|NCT01821196|Experimental|biopsy|Additional biopsies by means endoscopy, 5 from tumor tissue, 5 from adjacent normal mucosa per patient.
3298790|NCT01821209|No Intervention|Control|Standard robot assisted radical prostatectomy
3298791|NCT01821209|Experimental|Sling|Placement of sling at time of robot assisted radical prostatectomy
3298792|NCT01821222|Experimental|Wired mothers intervention|The wired mothers' intervention consisted of two components: an automated short messaging service (SMS) system providing wired mothers with unidirectional text messaging and a mobile phone voucher system providing the possibility of direct two-way communication between wired mothers and their primary health care providers. While only women with registered phone numbers received text messages, all women in the intervention group were given mobile phone vouchers to contact their local primary health care provider.
3298793|NCT01821222|No Intervention|Control|The control group received standard care
3298794|NCT01821235|Experimental|Neurontin® (gabapentin) batch A|
3298795|NCT01821235|Experimental|Neurontin® (gabapentin) batch B|
3298796|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch A|
3298797|NCT01821235|Experimental|Gabasandoz® (gabapentin) batch B|
3298798|NCT01821248|Experimental|Gemcitabine, Cisplatin, S-1|1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7
3298799|NCT01821261|Experimental|Mouth Rinse 19668-012|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 20 ml of mouth rinse 19668-012 for 30 seconds and spit it out - do not swallow.
3298800|NCT01821261|Active Comparator|Mouth Rinse 500347078842|"Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner, rinse mouth with water, and then rinse with 10 ml of mouth rinse 500347078842 for 60 seconds and spit it out - do not swallow.~Attention: Toothpastes can stop mouth rinse from working. Rinse your mouth thoroughly with water and wait 5 minutes after brushing your teeth before using the mouth rinse. You can also use the mouthwash at a different time of day."
3298801|NCT01821261|Other|Toothpaste 035000513007|Twice each day, brush with about one inch of toothpaste 035000513007 in the usual manner. Subjects in this arm will not use any mouth rinse.
3298802|NCT01821274|Experimental|topical Diltiazem Hydrochloride 2% Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
3298803|NCT01821274|Placebo Comparator|Vehicle Cream|0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.
3298804|NCT01821274|Active Comparator|0.2% sodium lauryl sulfate (SLS)|0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.
3298805|NCT01821274|Placebo Comparator|0.9% saline|0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.
3298806|NCT01821287||CHD Infants|Infants with a single ventricle (Congenital Heart Disease) CHD admitted to Cincinnati Children's Hospital Medical Center (CCHMC) for neonatal medical management or surgical palliation
3298807|NCT01821287||Normal Controls|Healthy newborns (full-term infants with no known medical problems) recruited from Cincinnati Children's Hospital Medical Center (CCHMC) and private practices
3298808|NCT01821313|Experimental|Moderate exercise|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The moderate exercise group will begin with a five-minute warm-up, cycling at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the moderate group will cycle for 30 minutes at 65-70% of maximal heart rate. The subject will then complete a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
3298809|NCT01821313|Active Comparator|High Intensity Interval Exercise (HIIE)|The subject will participate in a 6-week exercise intervention, 3 days per week on a cycle ergometer. The subjects in the HIIE group will begin with a five-minute warm-up at 50-55% of the subject's maximal heart rate as determined by the initial fitness assessment. Following the warm-up, the HIIE group will perform 10, two-minute exercise bouts at 90-95% of maximal heart rate, with one minute of active recovery at 55% of maximal heart rate between each interval for a total of 30 minutes. They will complete the test with a 5-minute cool-down at 50-55% of maximal heart rate. Heart rate will be measured via individual heart rate monitors.
3298810|NCT01821404|Placebo Comparator|Placebo|Similar capsules as in the atorvastatin arm, but including no active ingredient. Used daily for 3-5 weeks before prostatectomy
3298811|NCT01821404|Experimental|Atorvastatin|Atorvastatin capsules orally, 80 mg daily for 3-5 weeks before prostatectomy
3298812|NCT01821430|Experimental|Pregabalin|Pregabalin 400mg / Day
3298813|NCT01821430|Placebo Comparator|Placebo Control|Placebo Tablet
3298814|NCT01821443|Experimental|Stereotactic Radiosurgery (SRS)|Stereotactic radiosurgery technique via Gamma Knife® Perfexion™ radiosurgical system
3298815|NCT01821456||Antiinfectives|To analyze the efficacy of antiinfectives at high risk patients
3298816|NCT01821469|Experimental|psychoeducation|psychoeducation (12 weeks)
3298817|NCT01821482|Experimental|A|After complete resection or TACE, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) (every 4 weeks)
3298818|NCT01821482|No Intervention|B|After complete resection or TACE, Patient only regularly follow up
3298819|NCT01821495|No Intervention|B|After accepting concurrent radiotherapy and chemotherapy, patients will just regularly follow up.
3298820|NCT01821495|Experimental|A|After accepting concurrent radiotherapy and chemotherapy, patients will receive 3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK)treatment.
3298821|NCT01821508|Active Comparator|Clinical treatment|Best and most modern clinical treatment of type 2 diabetes mellitus.
3298822|NCT01821508|Active Comparator|Roux-En-Y gastric bypass surgery|"A metabolic surgery consists of any surgical procedure in which there is any anatomical alteration in the gastrointestinal tract by means of a diversion of food passage, resulting in improved metabolic control in patients with type 2 diabetes mellitus [SCHULMAN, 2009]."
3298823|NCT01821521|Experimental|AGSPT_L20|tablet, q.d.
3298824|NCT01821521|Active Comparator|Pantoloc 40mg|tablet, q.d.
3298825|NCT01821573|Experimental|Botox Injection|Patients treated by botulinum toxin.
3298826|NCT01821573|Placebo Comparator|Saline Solution|Patients treated with saline solution.
3298827|NCT01821586|Experimental|Modified ORS-1|Modified ORS -1 will be assigned to the enrolled particfipants according to the randomization schedule.
3298828|NCT01821586|Experimental|Modified ORS-2 (ReSoMal)|Modified ORS -2 (ReSoMal) will be assigned to the enrolled particfipants according to the randomization schedule.
3298829|NCT01821586|Experimental|Modified ORS-3 (Benefibre)|Modified ORS -3 (Benefibre) will be assigned to the enrolled particfipants according to the randomization schedule.
3298830|NCT01821599|Active Comparator|Conventional group|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
3298831|NCT01821599|Experimental|Accelerated group|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction
3298832|NCT01821612|Other|mFOLFIRINOX, chemoradiation, surgery and gemcitabine|"Each patient will receive mFOLFIRINOX therapy administered every other week for a total of 4 cycles. Each treatment cycle is a total of 14 days. This treatment program consists of four drugs (oxaliplatin 85 mg/m^2 IV over 2 hours on day 1 followed by irinotecan 180 mg/m^2 IV over 90 minutes on day 1 followed by, leucovorin 400 mg/m^2 IV over 2 hours on day 1 followed by 5-FU 2400 mg/m^2 IV over 46-48 hours).~Two to six weeks following treatment with the mFOLFIRINOX, if the tumor has not spread to other parts of the body then the patient will receive capecitabine 825 mg/m^2, twice daily for 28 days along with radiation therapy. Patients will have surgery within 4-10 weeks of the last dose of chemoradiation if the tumor has gotten smaller or stayed the same.~Within 6-8 weeks following surgery, patients will receive gemcitabine for 2 cycles (1 cycle is 28 days). Gemcitabine will be given IV on days 1, 8 and 15 of every 28 day cycle."
3298833|NCT01821638||Older adults with heart failure|Older adults with heart failure
3298834|NCT01821651|Experimental|HeartNavigator|Group with HeartNavigator-Software
3298835|NCT01821651|Active Comparator|Control|Control-group without HeartNavigator-Software
3298836|NCT01821651|Experimental|EchoNav|Group with EchoNav-Software
3298837|NCT01821651|Active Comparator|Conrol|Control-group without EchoNav-Software
3298838|NCT01821664||Prosthetic vascular graft implantation, follow up|
3298839|NCT01821677|Experimental|Low Dose Danazol|Low Dose Danazol
3298840|NCT01821677|Placebo Comparator|Placebo|Placebo
3298841|NCT01821690|Experimental|Buspirone Treatment|starting at 15 mg/day and ending at 60 mg/day as prescribed
3298842|NCT01821690|Placebo Comparator|Buspirone Placebo|placebo tablets as prescribed
3298843|NCT01821703|Experimental|LY3045697|Escalating dose (0.1 milligrams [mg] up to 100 mg) of LY3045697 administered once daily, orally, for 8 days in 2 of 3 dosing periods
3298844|NCT01821703|Active Comparator|Spironolactone|25 mg spironolactone administered once daily, orally, for 8 days in up to 1 of 3 dosing periods
3298845|NCT01821703|Placebo Comparator|Placebo|Placebo matching LY3045697 administered once daily, orally for 8 days in up to 1 of 3 dosing periods
3298846|NCT01821716|Experimental|1|"Three concentrations of Dermatophagoides pteronyssinus allergen extract (10, 1, 0.1 mg/ml)~Positive control (10 mg/ml histamine dihydrochloride)~Negative control (glycerinated phenol saline solution)"
3298847|NCT01821742||Children requiring fluid bolus on PICU|
3298848|NCT01821755|Experimental|Behavioral: Foster parent intervention|Foster parents receive a foster parent intervention consisting of 10 individual home visits and three group sessions. Duration of the intervention is four months
3298849|NCT01821755|No Intervention|Control|waiting-list control group who receive care-as-usual
3298850|NCT01821768|No Intervention|Arm 1: No sentinal lymph node biopsy|Patients will receive no additional axillary surgery which is experimental.
3298851|NCT01821768|Active Comparator|Arm 2: Sentinel lymph node biopsy|Patients will receive standard of care sentinel lymph node biopsy
3298852|NCT01821781|Experimental|Preparative|
3298853|NCT01821820|Experimental|Pistachios|Pistachio treatment (3 oz/d) for two weeks; 3 oz pistachio nuts and water (1.5 oz. before, and 1.5 oz during) cycling 75 km.
3298854|NCT01821820|No Intervention|No pistachios|No pistachios for two weeks, or before and during 75 km cycling.
3298855|NCT01821833|Experimental|Arm I (Omega-3 fatty acid)|"Four Omega-3 fatty acid capsules (at 1 gram/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
3298856|NCT01821833|Placebo Comparator|Arm II (placebo)|"Four placebo capsules (at 1 gram microcrystalline cellulose/capsule) are administered orally daily.~The capsules may be administered either once daily or as 2 capsules two times daily."
3298857|NCT01821846||Liraglutide|
3298858|NCT01821872|Active Comparator|Sampling at approx 15 minutes|Plasma and CSF samples to be taken at 15 minutes post administration of intravenous paracetamol
3298859|NCT01821872|Active Comparator|Sampling at approx 30 minutes|Plasma and CSF samples to be taken at 30 minutes post administration of intravenous paracetamol
3298860|NCT01821872|Active Comparator|Sampling at approx 120minutes|Plasma and CSF samples to be taken at 120 minutes post administration of intravenous paracetamol
3298861|NCT01821885|Experimental|Spirometry and a brief advice to quit smoking|"Intervention group:~The intervention consists of completing a questionnaire and undergo spirometry with bronchodilator test by a trained nurse. Later, the patients receives a brief advice to quit smoking and a report of the spirometry results by their family doctor."
3298862|NCT01821885|Active Comparator|Brief advice to quit smoking|"Control group:~Patients in the control group complete a questionnaire by a nurse and then receive a brief advice to quit smoking by their family doctor."
3298863|NCT01821911|Experimental|Zagreb2-1-1|Injection on day 0、7、21
3298864|NCT01821911|Active Comparator|Essen|Injection on day 0、3、7、14、28
3298865|NCT01821950|No Intervention|Physical education as usual|Physical education curriculum established by the school, including competitive sports, aerobic and anaerobic activities, balance and coordination skills. Yoga is not a component of the curriculum.
3298866|NCT01821950|Experimental|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
3298867|NCT01821976|Active Comparator|Ertl Procedure|Patients randomized to the Ertl Procedure Arm will receive an amputation very similar to the Burgess Procedure, except the surgeon will perform an additional step to make the cut end of the tibia bone heal to the cut end of the fibula bone with a bone bridge. This bone bridge connects the two bones together.
3298868|NCT01821976|Active Comparator|Burgess Procedure|Patients randomized to the Burgess Procedure Arm will receive a below the knee amputation where the bone is cut and skin and muscle from the back of the leg are rotated to cover the cut end of your bone. This provides good soft tissue padding to the bone and a good shape to the leg for later fitting of your prosthesis.
3298869|NCT01821989|Active Comparator|Low Dose|Lactoferrin,dose of 100 mg/day.
3298870|NCT01821989|Experimental|High Dose|Lactoferrin, dose of 150 mg/kg/ twice daily.
3298871|NCT01821989|Placebo Comparator|Control|Receive placebo in form of distilled water.
3298872|NCT01822002|Active Comparator|Canalith repositionig maneuver; Epley maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver.
3298873|NCT01822002|Active Comparator|Canalith repositioning maneuver : Semont maneuver group|Patients with PC-BPPV will be randomly assigned to Epley maneuver or Semont maneuver group.
3298874|NCT01822015|Experimental|Treatment (sirolimus, idarubicin, cytarabine)|Patients receive sirolimus PO QD on days 1-10, idarubicin IV over 3-5 minutes on days 4-6, and cytarabine IV continuously over 24 hours on days 4-10.
3298875|NCT01822028|Placebo Comparator|Treatment A|"Treatment A: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
3298876|NCT01822028|Experimental|Treatment B|"Treatment B: Florastor® 500 mg twice per day from Day 1 to Day 16 of the treatment period, and Zavesca® 100 mg three times per day from Day 3 to Day 16.~For Period 2, subjects will receive the alternate dosing regimen."
3298877|NCT01822041|Active Comparator|Part A - 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an intravenous (i.v.) microdose of 100 μg (9.25 kBq, 250 nCi) 14C-ARN-509
3298878|NCT01822041|Active Comparator|Part B: 14C labeled ARN-509|Single oral dose of 240 mg ARN-509, followed after 2 hours (at the average tmax of ARN-509) by an oral dose of 240 mg ARN-509 with 37 kBq (1000 nCi) of 14C-ARN-509
3298879|NCT01822054||Normal weight|
3298880|NCT01822054||Obese|
3298881|NCT01822067||Normal weight- Non Maternal obesity|Full-term neonates at 2 weeks of age born to normal weight mothers
3298882|NCT01822067||Obese- Obese Mothers|Full-term neonates at two weeks of age born of obese mothers
3298883|NCT01822080|Experimental|Dienogest|50% of the participants will be randomized to this arm and will receive 2 mg dienogest (DNG) once daily by mouth from 0-52 weeks
3298884|NCT01822080|Placebo Comparator|Placebo|50% of the participants will be randomized to this arm and will receive placebo once daily by mouth from 0-24 weeks then switch to 2 mg dienogest (DNG) once daily by mouth from 25-52 weeks
3298885|NCT01822093|Experimental|Cytovir-ADV|Adenovirus-specific T-cells
3298886|NCT01822106|Active Comparator|Omeprazole|Omeprazole at a rate of 20mg once per day
3298887|NCT01822106|Experimental|Wu-Chu-Yu Tang|Wu-Chu-Yu Tang at a rate of 3.0 g three times per day
3298888|NCT01822145||ICD recipients|ICD recipients with documented cardiac arrest or ventricular arrhythmias
3298889|NCT01822158|Other|vaginal delivery debrief checklist|Utilization of a Vaginal Delivery Debrief Checklist after vaginal deliveries for a period of three months, by team members who have consented to be a part of this study and who are present at vaginal deliveries. The Vaginal Delivery Debrief checklist consists of 2 levels. The first level includes a list of 6 key elements, such as APGAR scores,estimated blood loss, perineal repair, etc. The second level,or extended debrief, occurs whenever unanticipated outcomes, such as low APGAR scores, postpartum hemorrhage or a difficult delivery occurs. Team members complete the checklist after each delivery they attend.
3298890|NCT01822171|Experimental|Discharge counseling and MTM follow-up|"At the time of hospital discharge the subject will receive:~Discharge medication counseling from a pharmacist~Home medication if needed~Approximately 7 days after hospital discharge the subject have a Follow-up visit at Medication Therapy Management clinic."
3298891|NCT01822184||No treatment|Observational non-treatment study
3298892|NCT01822210|Experimental|Botox|Injection of Botox in the tumor and surrounding stomach wall.
3298893|NCT01822236|Experimental|Craniosacral Therapy Program|A program of 10 craniosacral therapy techniques
3298894|NCT01822236|Active Comparator|One technique of craniosacral therapy|Decompression L5-S1.
3298895|NCT01822249|Active Comparator|EPI-743 15 mg/kg|Subjects in this arm will receive EPI-743 at a dose of 15 mg/kg three times daily
3298896|NCT01822249|Placebo Comparator|Placebo|Subjects in this arm will receive placebo at a volume equivalent to the volume of EPI-743 they would receive if in active group based on their weight
3298897|NCT01822262|Experimental|gallbladder reservation|Patients in trial group all took minimally invasive cholecystolithotomy with gallbladder reservation
3298898|NCT01822262|Experimental|laparoscopiccholecystectomy|Patients in control group all received LC.
3298899|NCT01822275|Other|Low Dose WBRT|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by either 6 or a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
3298900|NCT01822288|Experimental|Tibolone group|Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.
3298901|NCT01822288|Active Comparator|Conventional hormone therapy group|Estradiol valerate (E2V) 1mg & medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.
3298902|NCT01822314|Active Comparator|Paclitaxel|"Paclitaxel will be given on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
3298903|NCT01822314|Experimental|Abraxane|"Abraxane will be given at the dosage of 125 mg/m2 on week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles.~AC or EC or FEC will then be given on day 1 every 3 weeks for 4 cycles"
3298904|NCT01822327|Experimental|Contingent Vouchers Unmatched|CRA therapy plus Voucher incentives contingent on cocaine abstinence with monetary values set at usual monetary values across all patients.
3298905|NCT01822327|Experimental|Contingent Vouchers, Matched|CRA therapy plus Vouchers contingent on cocaine abstinence, with more severe patients receiving twice the usual voucher monetary values.
3298906|NCT01822327|Active Comparator|Non-Contingent Vouchers control|CRA therapy plus Vouchers earned independent of drug use
3298907|NCT01822340|Experimental|Cohort 1|Once weekly HM10560A
3298908|NCT01822340|Experimental|Cohort 2|Once weekly HM10560A
3298909|NCT01822340|Experimental|Cohort 3|Once weekly HM10560A
3298910|NCT01822340|Experimental|Cohort 4|Biweekly HM10560A
3298911|NCT01822340|Active Comparator|Cohort 5|Once daily Genotropin
3298912|NCT01822379|Experimental|Cell transplantation|All patients will undergo transplantation of two distinct vitiligo lesions. One lesion will receive cells prepared with trypsin. The other lesion will receive cells prepared with dispase.
3298913|NCT01822392|Active Comparator|Online treatment, High therapist contact|Participants receive online Parent Management Training (interactive).
3298914|NCT01822392|Experimental|Online treatment, Low therapist contact|Participants receive online Parent Management Training (recorded).
3298915|NCT01822405|Active Comparator|Pentoxifylline + Tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Tocopherol 1000 mg/day oral during 6 months
3298916|NCT01822405|Experimental|pentoxifylline + tocopherol + Hyperbaric Oxygen Therapy|
3298917|NCT01822418|Experimental|Treatment|Open-label treatment with agomelatine 25 mg/day (or 50 mg/day after week 3).
3298918|NCT01822431||Patients with type 1 diabetes mellitus|Metaiodobenzylguanidine scintigraphy, Autonomic function tests, Pupillometry, Holter monitoring
3298919|NCT01822431||Healthy controls|Autonomic function tests, Pupillometry, Holter monitoring
3298920|NCT01822444||Intent-to-treat population with aCRC or mCRC|Advanced Colorectal Cancer with planned treatment with a aCRC or mCRC and who fulfil all inclusion and exclusion criteria
3298921|NCT01822470||Study group|a. Study Subjects will be recruited from patients who are already undergoing upper enteroscopy and aspiration for diagnosis of SIBO.
3298922|NCT01822470||Control group|b. Control Subjects will be recruited from patients who are already undergoing a double balloon enteroscopy or upper enteroscopy for another medical reason
3298923|NCT01822483|Experimental|Mycophenolate sodium|Arm1(Conversion):MPA AUC below 30mcg*h ml-1 - MPS+Calcineurin inhibitor+prednisone
3298924|NCT01822483|Active Comparator|Mycophenolate mofetil|Arm2(Maintained):MPA AUC between 30 to 60 mg*h ml-1 or above 60 mg - MMF+Calcineurin inhibitor+prednisone
3298925|NCT01822509|Experimental|Treatment (ipilimumab, nivolumab)|See Detailed Description.
3298926|NCT01822522|Experimental|Treatment (cabozantinib s-malate)|Patients receive cabozantinib s-malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3298927|NCT01822600|Experimental|Normal albumin group|"Based on the serum albumin level at enrollment, the patients were assigned into the normal albumin group if their serum albumin ≥ 30 g/L.~Patients in this group receive intravenous omeprazole treatment."
3298928|NCT01822600|Experimental|Intervention group|"Based on the serum albumin level at enrollment, the patients were assigned into an intervention group if their serum albumin < 30 g/L.~Patients in this group receive both Human albumin and intravenous omeprazole."
3298929|NCT01822600|Experimental|Cohort control group|"The study also included 29 patients with peptic ulcer bleeding and with hypoalbuminemia (serum albumin level < 30 g/L), but without receiving albumin supply from our previous study to serve as the cohort control group.~Patients in this group receive intravenous omeprazole treatment."
3298930|NCT01822613|Experimental|LJM716-BYL719 arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the LJM716-BYL719 combination arm to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
3298931|NCT01822613|Active Comparator|Paclitaxel, Docetaxel or Irinotecan arm|approximately 42 previously treated esophageal squamous cell carcinoma (ESCC) patients will be enrolled to the Paclitaxel, Docetaxel or Irinotecan arm (physician's choice arm) to evaluate the anti-tumor activity and further assess the safety, tolerability and anti-tumor activity of the LJM716-BYL719 combination versus current therapies (physician's choice of paclitaxel, docetaxel or irinotecan).
3298932|NCT01822626|Experimental|motivational counseling|
3298933|NCT01822626|No Intervention|Usual Care|
3298934|NCT01822639|Experimental|Sequence 1|Subjects in this arm will receive Treatment A in period 1 and Treatment B in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
3298935|NCT01822639|Experimental|Sequence 2|Subjects in this arm will receive Treatment B in period 1 and Treatment A in period 2. Treatment A is co-administration of 5mg amlodipine tablet and 20 mg enalapril maleate tablet. Treatment B (GSK2944404) is fixed dose combination tablet of 5 mg amlodipine and 20 mg enalapril.
3298936|NCT01822652|Experimental|iC9-GD2 T Cells - fresh - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
3298937|NCT01822652|Experimental|iC9-GD2 T Cells - frozen - CLOSED|The cells will be given IV over 5-10 minutes. There is a possibility for additional doses of iC9-GD2 T cells.
3298938|NCT01822652|Experimental|iC9-GD2 T cells,Cytoxan,Fludara,Keytruda|Fresh T cells will be given IV over 5-10 mins. There is a possibility for additional doses of iC9-GD2 T cells.
3298939|NCT01822704|Active Comparator|Control|This group will undergo three 45-minute exercise sessions per week for 10 weeks. No whole body vibration will be given.
3298940|NCT01822704|Experimental|Low intensity vibration|This group will receive three 45-minute whole body vibration training sessions for 10 consecutive weeks. The vibration will be of low intensity (frequency: 20 Hertz, amplitude: 1mm).
3298941|NCT01822704|Experimental|High intensity vibration|This group will receive three 45-minute whole body vibration training sessions per week for 10 consecutive weeks.The vibration will be of higher intensity than the low intensity vibration group (frequency: 30 Hertz, amplitude: 1mm).
3298942|NCT01822717|Experimental|Nonvisual foot inspection|Instruction for nonvisual foot inspection included in comprehensive diabetes self-management education
3298943|NCT01822717|Active Comparator|Usual Care for foot inspection|Usual instruction for foot care included in comprehensive diabetes self-management education
3298944|NCT01822730|Experimental|paliperidone|paliperidone arm,6mg/pill,6-12mg/day,non-forced titration method.last2-4weeks.
3298945|NCT01822730|Active Comparator|.Risperidone|Risperidone arm and placebo tables,1mg/pill,2mg-6mg/day,non-forced titration method.last2-4weeks
3298946|NCT01822743|Experimental|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
3298947|NCT01822743|Sham Comparator|Sham comparator|sham Osteopathic pterygopalatine node compression
3298948|NCT01822769|Experimental|Cardiopulmonary rehabilitation|The subjects will attend 2 sessions each week for 12 weeks. Each session will be approximately 2 hours in duration, consisting of both exercise (aerobic and strength,~60 minutes) and education. In addition, subjects will be directed to participate in 3 weekly ~40 minute home exercise training sessions, personalized to their level of aerobic conditioning.
3298949|NCT01822769|Other|Standard of care|Subjects randomized to standard of care will not be enrolled in a rehabilitation program, but may receive any other clinically indicated exercise training or other intervention (e.g., an exercise prescription).
3298950|NCT01822782||Cases|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Cases are classified as those with a vaginal lesion due to delivery."
3298951|NCT01822782||Controls|"The study population consists of all consecutive women meeting inclusion/exclusion criteria and delivering at the Nîmes University Hospital, France during an inclusion period of 6 months. Controls are classified as those without a vaginal lesion due to delivery."
3298952|NCT01822795|Experimental|Lung volume reduction coïl treatment|Lung volume reduction coïl treatment,added to usual medical treatment and follow up after the intervention
3298953|NCT01822795|Other|Regular Medical Treatment|No intervention, just a follow up under usual medical treatment
3298954|NCT01822808|Active Comparator|Hydralazine|24 week course of Hydralazine 25mg 3 times daily for 4 weeks, thereafter uptitrating to 50mg hydralazine 3 times daily up to week 24. Those assigned to the Hydralazine control arm will receive the same number of identical placebo tablets.
3298955|NCT01822808|Active Comparator|Isosorbide dinitrate|24 week course of Isosorbide dinitrate 10mg 3 times daily for 4 weeks, thereafter uptitrating to 20mg isosorbide dinitrate 3 times daily up to week 24. Those assigned to the Isosorbide dinitrate control arm will receive the same number of identical placebo tablets.
3298956|NCT01822834||Non-CF Bronchiectasis Patients with or without NTM|Patients over the age of 18 with non-CF Bronchiectasis with or without Nontuberculosis Mycobacteria (NTM).
3298957|NCT01822834||Nontuberculosis Mycobacteria (NTM)|Patients over the age of 18 with Nontuberculosis Mycobacteria (NTM)
3298958|NCT01822847||catheterization|patients undergoing elective heart catheterization
3298959|NCT01822860|Placebo Comparator|Placebo|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3298960|NCT01822860|Experimental|Chlorthalidone 12.5 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3298961|NCT01822860|Active Comparator|Hydrochlorothiazide 25 mg|Subjects will receive chlorthalidone, hydrochlorothiazide, and placebo each for 4 weeks in a randomized sequence.
3298962|NCT01822873||Normal|
3298963|NCT01822873||Age-related macular degeneration|
3298964|NCT01822912|Active Comparator|Heart Failure Disease Management Program|Patients will receive personalized care to include medication titration, daily weights, symptom and activity assessment, documentation of ejection fraction, patient and caregiver education,dietary surveillance, discharge instructions and follow up visit within 7 days of SNF discharge
3298965|NCT01822912|Placebo Comparator|Heart Failure Usual Care|SNF patients with HF will receive usual care
3298966|NCT01822938|Experimental|effects of a incentive program for physical activity|The aim of the study is the assessment of the effects of a incentive program for physical activity on people following/with stroke
3298967|NCT01822938|No Intervention|control group|No intervention
3298968|NCT01822951|Experimental|Cerebrolysin Verum|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). For the infusion 2x10 ml Cerebrolysin (215.2 mg/ml) is diluted with 80 ml 0.9% NaCl (saline) to a total volume of 100 ml, i.v.~Placebo for donepezil: 1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
3298969|NCT01822951|Active Comparator|Donepezil Verum|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Placebo for Cerebrolysin: 100 ml 0.9% NaCl (saline), i.v. infusion. Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly)."
3298970|NCT01822964|Active Comparator|targeted brain cooling|In these 15 pts, targeted brain cooling (tympanic temperature of 33°C) will be applied during the TAVI intervention by the use of the RhinoChill device (Benechill Inc, San Diego cA)
3298971|NCT01822964|Placebo Comparator|no use of targeted brain cooling|In these 15 pts, no cooling techniques will be applied and current clinical practice as to maintenance of normothermia will be followed during these TAVI interventions
3298972|NCT01822977|No Intervention|Proton pump inhibitor|"We will recruit 10 healthy adult individuals and 5 adult patients with an initial episode of CDI cared for at Mayo Clinic in Arizona. A baseline stool sample will be collected from the healthy individuals. They will then be given a PPI, omeprazole 20 mg, to be taken once (n=5) or twice (n=5) daily for 1 month. Stool samples will be collected after 1 week and again after 1 month. A final stool sample will be collected 1 month after stopping the omeprazole.~A stool sample will be collected from the CDI subjects before treatment of the infection and again 2 months after treatment to avoid enrolling those at risk for relapse (which most commonly occurs during the first 2 months after treatment)."
3298973|NCT01822990||Atherosclerotic patients|Male patients with intermittent claudication.
3298974|NCT01822990||Control subjects|healthy male subjects with normal results on vascular examination and no cardiovascular risk factors, who are not in receipt of any pharmacological treatment, matched by age within two years with peripheral arterial disease patients
3298975|NCT01823003|Experimental|A. 34 Gy in a single fraction|34 Gy by single fraction Risk-adapted radiation dose.
3298976|NCT01823003|Experimental|B. 54Gy (18Gy/fr. x 3 fractions)|54Gy administered in 3 fraction of 18 Gy, risk adapted radiation dose
3298977|NCT01823003|Experimental|C. 50Gy (12 x 5 fr.s)|54Gy administered in 5 fraction of 12 Gy, risk adapted radiation dose
3298978|NCT01823003|Experimental|D. 60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fraction of 7.5 Gy, risk adapted radiation dose
3298979|NCT01823016|Placebo Comparator|Placebo|
3298980|NCT01823016|Experimental|JNJ-38518168|
3298981|NCT01823029|Experimental|erythropoietin,injection of iron and enteral nutrition|The patients receive treatment of erythropoietin,injection of iron and enteral nutrition.
3298982|NCT01823029|Experimental|erythropoietin and enteral nutrition.|The patients receive treatment of erythropoietin and enteral nutrition.
3298983|NCT01823042|Experimental|enteral nutrition+azathioprine|Patients is fasting and receive enteral nutrition and azathioprine treatment.
3298984|NCT01823042|Experimental|azathioprine|Patients have regular diet and receive only azathioprine treatment.
3298985|NCT01823055|Experimental|Surgery|Transvaginal suture capturing mesh device
3298986|NCT01823068|Experimental|Vandetanib treatment arm|Vandetanib 300 mg once daily orally
3298987|NCT01823081|Active Comparator|Intravitreal bevacizumab (Avastin)|Dosage: 1.25 mg/0.05 ml Frequency: 3 consecutive injections every 4 weeks
3298988|NCT01823081|Active Comparator|Combined intravitreal fasudil and bevacizumab (Avastin)|Dosage: bevacizumab 1.25 mg/0.05 ml + fasudil 0.025mg/0.05ml Frequency: 3 consecutive injections every 4 weeks
3298989|NCT01823094||Variability of measurements|variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates
3298990|NCT01823094||Treatment induced effects|The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment
3298991|NCT01823120|No Intervention|No text messages|Patients in the non-intervention group will not receive any text messages. However, they will also receive the routine outpatient follow-up arrangements associated with attendance at an ED with self-harm including the provision of a contact phone number for the Samaritans.
3298992|NCT01823120|Experimental|Supportive and interactive text messages|We will deliver daily supportive and informative text messages for one month followed by one supportive and informative text message every other day the second month and then one weekly text message the third month to patients in the intervention group after they have been discharged from the ED following an episode of self-harm. Supportive text messages will mainly target relieving the patients of mood symptoms and providing them with strategies for dealing with suicidal thoughts while the informative ones will provide patients with a dedicated mobile phone number through which they can receive interactive support from the Samaritans. The text messages will encourage participants to text the Samaritans in times of crisis. Please see appendix I for examples of the relevant text messages.
3298993|NCT01823133|Experimental|gemigliptin only|Multiple administrations of gemigliptin
3298994|NCT01823133|Experimental|rosuvastatin only|Multiple administrations of rosuvastatin
3298995|NCT01823133|Experimental|gemigliptin and rosuvastatin|Multiple administrations of gemigliptin and rosuvastatin
3298996|NCT01823159|Active Comparator|Retigabine|Administration of a single dose of 400 mg retigabine, two hours before the measures
3298997|NCT01823159|Placebo Comparator|placebo|Randomized administration of a single dose of placebo, two hours before the measures.
3298998|NCT01823172|Experimental|Methylene Blue|1% Methylene Blue - 1 ml. Methylene blue dye injection of sentinel lymph node
3298999|NCT01823185|Active Comparator|Clopidogrel|CYP2C19 genotyping will be carried out at the end of the study period. Clopidogrel will be used for treatment for one year according to local protocol. Patients will receive clopidogrel 75 mg per day.
3299000|NCT01823185|Experimental|Ticagrelor or prasugrel|Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
3299001|NCT01823198|Experimental|Treatment (NK cells, PBSC transplant)|Patients receive fludarabine phosphate IV over 1 hour and busulfan IV over 3 hours on days -13 to -10. Patients then receive allogeneic CD56-positive CD3-negative natural killer cells IV over 1 hour on day -8. Patients also receive aldesleukin SC QD on days -8 to -4. Patients then undergo allogeneic PBSC transplant on day 0.
3299002|NCT01823211||ischaemic cardiomyopathy|EP (Electrophysiology) study,magnetic resonance with LGE (Late gadolinium enhancement), ICD implantation
3299003|NCT01823211||non-ischaemic cardiomyopathy|EP study,magnetic resonance imaging with LGE, ICD implantation
3299004|NCT01823237|Active Comparator|rTMS|rTMS condition, rTMS will be applied at 0.1-0.5 Hz frequency at a subthreshold intensity
3299005|NCT01823237|Placebo Comparator|rTMS sham|Placebo condition will use a sham coil and apply a very small magnetic stimulus
3299006|NCT01823250|Experimental|CIFFTA|Culturally Informed and Flexible Family-Based Treatment for Adolescents (CIFFTA)involves four months of intervention. Adolescents and families receive one family therapy session per week and an additional session which is either a psycho-educational session for the adolescent and/or parents, or an individual therapy session with the adolescent. There is a total of 2 sessions per week.
3299007|NCT01823250|Active Comparator|Traditional Family Therapy (TFT)|The Traditional Family Therapy condition consists of once per week family therapy based on Structural Family Theory and a didactic group intervention once per week in which HIV/STI risk is discussed.
3299008|NCT01823263|Experimental|Partial sleep deprivation|Partial sleep deprivation: participants will have a 4-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed by repeated blood sampling and an 'Intake task'.
3299009|NCT01823263|Experimental|Normal sleep|Normal sleep: participants will have an 8-h sleep opportunity before a 'Blood Sample' will be taken, and the 'Memory tasks', 'Working memory function task' and 'Portion size task' will be performed. This will be followed by an 'Interference task', followed with repeated blood sampling and an 'Intake task'.
3299010|NCT01823276|Active Comparator|Tyrosine-Containing Bar|150 mg/kg dose of tyrosine per administration, administered twice
3299011|NCT01823276|Placebo Comparator|Placebo Bar|0 mg/kg dose of tyrosine per administration, administered twice
3299012|NCT01823302|Other|nutritional counseling|nutritional counseling
3299013|NCT01823302|Other|nutritional counseling and milk-based supplement|nutritional counseling plus oral milk-based nutrition supplement
3299014|NCT01823315|Experimental|Methotrexate Single-coure chemotherapy|Regimen: Methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5. If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen.
3299015|NCT01823315|Experimental|Methotrexate+dactinomycin Single-dose chemotherapy|"Regimen: dactinomycin d 0.6mg/m2, IV, on day1, 2; methotrexate 100mg/m2, IV, on day1 (after Act-d); methotrexate 200mg/m2, IVgtt, on day1 (after methotrexate, 500ml NS, >4h).~If 10-fold fall of hCG achieved 18 days after treatment completion, success of primary single-course chemotherapy was defined and further treatment was withheld; otherwise, failure was defined and the patient was referred to multi-course chemotherapy. During the period of observation for those with success, if the level of hCG became stationary for at least 3 weeks or rose again, the patient was also referred to multi-course chemotherapy. Additional consolidation chemotherapy with 1-3 courses was given for those who achieved CR by multi-course chemotherapy, but not by single-course regimen."
3299016|NCT01823315|Active Comparator|MTX multiple courses chemotherapy|"Regimen: methotrexate 0.4mg/(kg·d) intramuscularly (IM) on days 1-5, 2-week intervals. Patients continue on treatment until 1 beta HCG titer is below the institutional normal. Patients then receive at least 1 additional consolidation treatment.~After treatment, all the patients were asked for contraception with condom or oral contraception. Regular hCG surveillance, once a month for 3 consecutive months and once every 3 months for 2 years, was performed. During follow-up period, pelvic ultrasound and pulmonary X ray or CT scan were conducted if needed."
3299017|NCT01823354|Other|Patients|Polysomnography, Assessment of executive functions, Clinical scales, Medical consultation
3299018|NCT01823354|Other|Controls|Polysomnography, Assessment of executive functions, Clinical scales Medical consultation
3299019|NCT01823367|Experimental|Lifestyle counseling mom only|This intervention, delivered to groups of mothers only, builds upon the evidence-based curriculum used in the Diabetes Prevention Program (DPP) and incorporates into the curriculum detailed education regarding ways to help their children adopt healthier lifestyle behaviors.
3299020|NCT01823367|Experimental|Lifestyle counseling mom and child|The second intervention is delivered to both mothers and children in separate groups using the same parent Diabetes Prevention Program (DPP) curriculum, but adds a group program for children that directly teach these children strategies for eating better and increasing physical activity.
3299021|NCT01823380|Other|Amyotrophic lateral sclerosis|Blood test
3299022|NCT01823393|Experimental|Heparin|injection of unfractionated heparin (50 IU / kg)
3299023|NCT01823393|Placebo Comparator|NaCl|without heparin
3299024|NCT01823406|Experimental|Type 1 Diabetes no complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3299025|NCT01823406|Experimental|Type 1 Diabetes with microalbuminuria|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3299026|NCT01823406|Experimental|Type 1 Diabetes with advanced complications.|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3299027|NCT01823406|Experimental|Aged and sex matched healthy control volunteers|Each cohort group will be admitted to the Michigan Clinical Research Unit for Blood glucose Clamp studies. Each subject will have a Euglycemic clamp (normal blood sugar clamp) for 4 hours and a hyperglycemic clamp (elevated blood sugar to 300) for 4 hours. Once the subject is clamped, bloods and urine will be collected to assay for specific metabolomics and proteomic biomarkers. We will perform the same clamps for each cohort.
3299028|NCT01823419||7-9 year olds|Typically developing 7- to 9-year-olds will be enrolled and tested.
3299029|NCT01823432||BAV Cohort|Patients with bicuspid or unicuspid aortic valves, regardless of surgical status.
3299030|NCT01823445|Experimental|Xylitol disk|Daily use of 8 disks containing 0.5 grams xylitol each for two weeks. The disks adhere to gum tissue with a food grade adhesive backing and slowly dissolve. The disks are applied one on each side of the mouth in the morning after breakfast, again at midday, and four are applied, two on each side, at bedtime.
3299031|NCT01823458|Experimental|Lottery Insurance|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Participants in the 'Lottery Insurance' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They have the option to insure their lottery ticket by attending a second exercise class during the week on either Wednesday or Thursday. If they do not attend the second class, they have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
3299032|NCT01823458|Experimental|Standard Lottery|All participants receive a one time, $10 payment for attending the first exercise class of the 12 week session. Subjects in the 'Standard Lottery' arm receive a lottery ticket valued at $20 for attending either a Monday or Tuesday exercise class. They also receive the expected value of the insurance ($2) for attending a second exercise class during the week on either Wednesday or Thursday. They have a 90% chance of winning the weekly lottery. This sequence is repeated each week over the 12 week exercise session.
3299033|NCT01823471|Experimental|I-scan first group|After the caecum is reached patients will be first examined with high definition i-scan endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass white light will be used.
3299034|NCT01823471|Active Comparator|White light first group|After the caecum is reached patients will be first examined with high definition white light endoscopy. Each colonic segment will be investigated in a back to back fashion, during the second pass i-scan will be used.
3299035|NCT01823484|Experimental|AN 69 ST hemofilter|Use AN 69 ST hemofilter during CRRT
3299036|NCT01823484|Active Comparator|AN 69 hemofilter|Use AN 69 hemofilter during CRRT
3299037|NCT01823523|Active Comparator|Cefazolin, Cephalexin, Clindamycin|"Group will be receiving 1 day of IV cefazolin or clindamycin followed by 2 days of oral cephalexin or clindamycin~Clindamycin will be used in patients with allergy"
3299038|NCT01823523|Placebo Comparator|cefazolin, clindamycin, placebo|"Group will receive 1 day IV cefazolin, or clindamycin followed by 2 days of oral placebo~clindamycin will be used if patient has allergy"
3299039|NCT01823562|Active Comparator|Arm I (regular diet)|Patients follow a regular diet for 4-6 weeks and then undergo prostatectomy.
3299040|NCT01823562|Active Comparator|Arm II (low polyphenol diet)|Patients follow a low polyphenol diet for 4-6 weeks and then undergo prostatectomy.
3299041|NCT01823562|Active Comparator|Arm III (low ellagitannin diet)|Patients follow a low ellagitannin diet for 4-6 weeks and then undergo prostatectomy.
3299042|NCT01823562|Experimental|Arm IV (lower-dose lyophilized black raspberry gummy)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
3299043|NCT01823562|Experimental|Arm V (higher-dose black raspberry gummy)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry gummy PO daily for 4-6 weeks and then undergo prostatectomy.
3299044|NCT01823562|Experimental|Arm VI (lower-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive lower-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
3299045|NCT01823562|Experimental|Arm VII (higher-dose black raspberry confection)|Patients follow a low ellagitannin diet and receive higher-dose black raspberry confection PO daily for 4-6 weeks and then undergo prostatectomy.
3299046|NCT01823575|Experimental|Silicone-covered metallic ureteral stent|Deployment of a silicone-covered metallic ureteral stent for malignant ureteral obstruction and compare the results with placement of a double-J stent in terms of primary patency rate at 3 month follow-up (primary end point)
3299047|NCT01823575|Active Comparator|Double-J stent|Placement of a double-J stent for malignant ureteral obstruction and compare these results to deployment of a silicone-covered metallic stent in terms of primary patency rate at 3 month follow-up.
3299048|NCT01823588|No Intervention|Usual care|Educational program and usual cardiovascular prevention.
3299049|NCT01823588|Experimental|Nurse-led reminder through email|In addition to usual care and educational program, the intervention group will also receive email alerts and phone calls from the nurse-care manager (NCM)
3299050|NCT01823601|Active Comparator|Seminars in Health|This group of volunteers will attend to seminars in health. Each seminar will last about 120 minutes, a similar period of time used for training experimental group.
3299051|NCT01823601|Experimental|Behavioral Management Program|"Behavioral Management Program consists in to teach to the volunteers procedures which involve autogenic muscle relaxation, progressive self-focus meditation and cognitive-behavioral training to change thoughts, beliefs and behavior in order to control emotions. This program will consist in 10 weekly sessions of about 120 minutes each."
3299052|NCT01823627|Other|Spirometry with reversibility test|Spirometry with reversibility test
3299053|NCT01823640|Experimental|Placebo-HRV|inoculation with placebo followed by inoculation with HRV
3299054|NCT01823640|Experimental|HRV-HRV|inoculation with HRV followed by a second inoculation with HRV
3299055|NCT01823666||Mild cognitive impairment|People with cognitive complaint will be recruited. Who can be diagnosed as mild cognitive impairment will be enrolled according to the MCI criteria.
3299056|NCT01823666||Control|Normal cognition.
3299057|NCT01823692|Other|Distal Radius Fracture|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
3299058|NCT01823705|Experimental|Gastric Electrical Stimulation (GES)|Gastric Electrical Stimulation (GES) therapy for the treatment of obesity.
3299059|NCT01823744|Experimental|micronutrient supplementation|"All the enrolled subjects will recieve orally, onca a day, during school days a chocolate bar including vitamins and minerals.~The micronitrient supplementation will be consumed over 6 weeks, 5 days/week."
3299060|NCT01823757||Non-pharmaceutical care|Veterans do not receiving pharmaceutical care
3299061|NCT01823757||Pharmaceutical care|Veterans receiving pharmaceutical care
3299062|NCT01823770|Active Comparator|Rotigotine|Patients randomized to rotigotine who will be treated with rotigotine patchs
3299063|NCT01823770|Placebo Comparator|Placebo|Patients randomized on the placebo group who will be treated with placebo patchs
3299064|NCT01823770|No Intervention|Control group|Volunteers matched on sex, age and BMI with RLS patients who will not receive treatment(no treatment)
3299065|NCT01823783|Other|DMD infant|Muscle biopsy
3299066|NCT01823783|Other|Control infant|Muscle biopsy (during lower limb operation surgery for pure orthopedic causes)
3299067|NCT01823796||Healthy women.|35 healthy women. Control group.
3299068|NCT01823796||Fibromyalgia women group|35 women with fibromyalgia were measured at baseline of the observational study.
3299069|NCT01823809|Other|Imaging arm|There is one study arm only. The imaging modalities will be performed in all patients.
3299070|NCT01823822|Experimental|Oral protein supplement (Tested product)|
3299071|NCT01823822|Active Comparator|Iso-caloric supplement (Control product)|
3299072|NCT01823848|Active Comparator|Sodium phosphate enema|Administration of sodium phosphate (fleets) enema for functional constipation in children ages 4-12 years Age 4-5: 33ml per rectum Age 5-12: 66ml per rectum
3299073|NCT01823848|Active Comparator|Normal saline enema|Administration of normal saline enema for functional constipation in children ages 4-12 years Admininstered as 10ml/kg with maximum of 700ml
3299074|NCT01823848|Experimental|Mineral oil enema|Administration of mineral oil enema for functional constipation in children ages 4-12 years Administered as 66ml per rectum
3299075|NCT01823874|Experimental|ID virtual reality distraction|virtual reality distraction
3299076|NCT01823874|Experimental|HMD virtual reality distraction|virtual reality distraction
3299077|NCT01823887|Experimental|Left Sided Stimulation|Left cervical Vagus Nerve Stimulation (VNS)
3299078|NCT01823887|Experimental|Right Sided Stimulation|Right Cervical Vagus Nerve Stimulation (VNS)
3299079|NCT01823900|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 7 days apart in a fasted state
3299080|NCT01823913|Experimental|Test and reference formulations|Test formulation and reference formulation given orally 14 days apart in a fasted state
3299081|NCT01823926|Active Comparator|Control Group|Noninvasive ventilation + jet nebulizer
3299082|NCT01823926|Experimental|Experimental Group|Noninvasive ventilation + vibrating mesh nebulizer
3299083|NCT01823939|Other|Males / Females (Healthy)|Part A: This initial part of the study will be conducted in adult Bangladeshi healthy volunteers (4 males, 4 females) to assess the pharmacokinetics, safety, and tolerability of single doses of iOWH032. Participants will be admitted to the Clinical Trial Unit (CTU) of icddr,b (located at a 10 minute drive from the icddr,b main campus) the day prior to dosing and remain for 48 hours after dosing, unless treatment and/or follow-up of an adverse event (AE) require longer in-unit observation or treatment.
3299084|NCT01823939|Other|Males (Patient)|Part B: Patients will be eligible for the study if they have clinically severe dehydration and meet all other inclusion and exclusion criteria. Upon signing consent, they will be admitted to the Research Ward of the Dhaka Hospital of icddr,b.
3299085|NCT01823952||Males|Adult 18-65
3299086|NCT01823965|Experimental|ranibizumab|
3299087|NCT01823978|Experimental|BPX-201|BPX-201 vaccine plus AP1903
3299088|NCT01824004|Experimental|S-1,chemoradiotherapy, adjuvant treatment|Pts with radically D2 resected adenocarcinoma of the stomach or GEJ in AJCC stage Ib-IV (M0) were eligible for this study. Pts were treated with S-1 (40-60 mg depending on BSA) b.i.d. for 3 wks, and cisplatin (60 mg/m²) iv on day 1, followed by a 2-wk rest period, within a 5-wk cycle. Subsequently, radiotherapy (RT) started which consisted of 25 fractions of 1.8 Gy to a total dose of 45 Gy in 5 wks (5 fractions/wk). On RT days, S-1 (40-60 mg depending on BSA ) b.i.d., 5 days/wk was given. One month after the completion of RT, two 5-wk cycles of S-1/ciplatin chemotherapy were given.
3299089|NCT01824017|Other|Blood Draw|Data will be collected at patients' usual follow-up intervals for monitoring their metabolic conditions (i.e., T2D, hyperlipidemia, hypertriglyceridemia, etc.), which will be at 3 or 6 month intervals with a +/- 30 day window. Standard treatment surveillance measures such as hemoglobin A1c, LDL, and triglyceride levels will be performed as the standard of care for patients with MsY. Blood samples for these tests will be drawn while subjects are fasting
3299090|NCT01824030|Active Comparator|FFR guided PCI arm|Patients with angiographic intermediate coronary artery stenosis randomized to FFR assessment. PCI performed only if FFR ≤ 0.80
3299091|NCT01824030|Active Comparator|OCT guided PCI arm|"Patients with angiographic intermediate coronary artery stenosis randomized to OCT. PCI will be performed if:~percentage area stenosis ≥75 %~percentage area stenosis between 50 and 75% and minimal lumen area <2.5 mm2~percentage area stenosis between 50 and 75% and major plaque ulceration"
3299092|NCT01824043|Experimental|vitreous hemorrhage group|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
3299093|NCT01824056|Experimental|18F-DTBZ for Parkinson's Disease|This study will compare the brain uptake of 18F- DTBZ in 40 patients with PD, 40 patients with MSA, 20 patients with CBD, and 20 patients with PSP . Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping, each subject will have 3 visits in this study. Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.
3299094|NCT01824069|Experimental|Autologous mesenchymal stem cells|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight in a dosis
3299095|NCT01824095|Placebo Comparator|placebo|Acute phase (1st treatment through Week 4): Placebo. 2 capsules 3 x day. Chronic phase (Weeks 5-16): Placebo. 1 capsule 3 x day.
3299096|NCT01824095|Experimental|dietary supplement|"Acute phase (1st treatment through Week 4): Ligaplex 1. Ligaplex 1 supplies nutrients to support connective tissue and reduce inflammation. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 2 capsules 3 x day.~Chronic phase (Weeks 5-16): Glucosamine Synergy. This supplement maintains connective tissue and joint health. The protocol is commonly used in chiropractic practice and suggested by Standard Process: 1 capsule 3 x day."
3299097|NCT01824108|Active Comparator|control group: Lumbar discectomy|Lumbar discectomy alone
3299098|NCT01824108|Experimental|Treatment group: lumbar discectomy + Wallis implant|lumbar discectomy combined with Wallis interspinous dynamic stability system
3299099|NCT01824121|Active Comparator|immediate stem cell therapy|patients will undergo active intervention i.e. they will be given stem cell therapy immediately. After 6 months they will undergo a sham procedure.
3299100|NCT01824121|Sham Comparator|delayed stem cell therapy|patients allocated to delayed stem cell therapy will undergo a sham procedure (incannulation of the femoral vein and infusion of saline solution). They will receive stem cell therapy after 6 months
3299101|NCT01824134|Active Comparator|Klean & Klear|aloe vera gel
3299102|NCT01824134|Active Comparator|The Skin Gel|aloe vera gel
3299103|NCT01824147||CABG Patients|Patients undergoing surgery for coronary revascularization.
3299104|NCT01824173|Experimental|Amino Acid Infusion in Lean|Amino Acid Infusion in Lean
3299105|NCT01824173|Experimental|Amino acid Infusion in Obese|Amino acid Infusion in Obese
3299106|NCT01824173|Experimental|Exercise in lean|Exercise in lean
3299107|NCT01824173|Experimental|Exercise in Obese|Exercise in Obese
3299108|NCT01824186|Experimental|SILC|Subjects in this arm were randomized to undergo single-incision laparoscopic cholecystectomy, through a transumbilical incision
3299109|NCT01824186|Active Comparator|LC|Subjects in this arm were randomized to undergo conventional 4-port laparoscopic cholecystectomy. Wound sites at umbilicus, right hypocondrium, epigastrium and right flank
3299110|NCT01824199|Experimental|Omeprazole|Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire 30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
3299111|NCT01824212||ICD-patients|Patients to whom cardiac fibrillation will be induced during the implantation of an implantable cardioverter defibrillator (ICD) or patients with an already implanted ICD, which function needs to be revised and during the revision cardiac defibrillation will be induced.
3299112|NCT01824225|Active Comparator|PRN injection of aflibercept|Intravitreal aflibercept
3299113|NCT01824225|Active Comparator|Two months injection of aflibercept|Intravitreal afilibercept
3299114|NCT01824238|Experimental|Anacetrapib|Participants will receive 100-mg anacetrapib tablet, orally, once-daily for 12 weeks.
3299115|NCT01824238|Placebo Comparator|Placebo|Participants will receive placebo tablet, orally, once daily for 12 weeks.
3299116|NCT01824251|Experimental|NPB-01|Intravenous immunoglobulin
3299117|NCT01824264|Experimental|LIK066 2.5 mg|Patients receive 2.5 mg of LIK066 once daily for 12 weeks
3299118|NCT01824264|Experimental|LIK066 5 mg|Patients receive 5 mg of LIK066 once daily for 12 weeks
3299119|NCT01824264|Experimental|LIK066 10 mg|Patients receive 10 mg of LIK066 once daily for 12 weeks
3299120|NCT01824264|Experimental|LIK066 25 mg|Patients receive 25 mg of LIK066 once daily for 12 weeks
3299121|NCT01824264|Experimental|LIK066 50 mg|Patients receive 50 mg of LIK066 once daily for 12 weeks
3299122|NCT01824264|Experimental|LIK066 100 mg|Patients receive 100 mg of LIK066 once daily for 12 weeks
3299123|NCT01824264|Experimental|LIK066 150 mg|Patients receive 150 mg of LIK066 once daily for 12 weeks
3299124|NCT01824264|Active Comparator|Sitagliptin 100 mg|Patients receive 100 mg sitagliptin once daily for 12 weeks
3299125|NCT01824264|Placebo Comparator|Placebo|Patients receive placebo for 12 weeks
3299126|NCT01824277|No Intervention|Group 1|Group 1 - Standard Pre-operative Diabetes Care
3299127|NCT01824277|Experimental|Group 2|Group 2 - Structured Pre-operative Diabetes Optimization
3299128|NCT01824329|Active Comparator|Prostate capsule sparing cystectomy Group|Prostate capsule sparing cystectomy involves removing the entire bladder.
3299129|NCT01824329|Active Comparator|Nerve sparing cystectomy Group|Nerve sparing cystectomy involves removal of the whole bladder and the entire prostate.
3299130|NCT01824368|Experimental|People with liver transplantation|People with liver transplantation over 2 years following treatment with immunosuppression including cyclosporine or tacrolimus.
3299131|NCT01824381|Experimental|Amniotic membrane in large wounds|
3299132|NCT01824407|Active Comparator|Active device plus standard of care|Active device plus standard of care
3299133|NCT01824407|Sham Comparator|Sham device plus standard of care|dermaPACE device that uses a dummy applicator that does not emit shock waves
3299134|NCT01824420|Experimental|Study group|Tolterodine (Detrusitol) 4mg QD and Oxybutynin (Ditropan) ER 5mg QD
3299135|NCT01824420|Experimental|Control group|Tolterodine (Detrusitol) 4mg QD
3299136|NCT01824433|Active Comparator|venlafaxine|venlafaxine 75-225mg qd
3299137|NCT01824433|Active Comparator|fluoxetine|fluoxetine 20-60mg qd
3299138|NCT01824459|Active Comparator|S-1 + cisplatin(SP)|S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
3299139|NCT01824459|Experimental|S-1+Oxaliplatin（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
3299140|NCT01824485|Experimental|Group 2|Patients from Group 2 will receive an intra-articular injection of 1 ampoule (2ml) of OSTEONIL®, on a weekly basis, for 3 weeks (total of 3 injections)
3299141|NCT01824485|Experimental|Group 1|Patients from Group 1 will receive a single intra-articular injection of 3 ampoule (6ml) of OSTEONIL®
3299142|NCT01824511|Experimental|Smokers Cease Smoking|Participants are paid to quit smoking without using any medications.
3299143|NCT01824524|Experimental|OROS Hydromorphone|
3299144|NCT01824537|Active Comparator|HPV vaccine, Gardasil 9|HPV vaccine intervention: The intervention vaccine will be Gardasil 9, a 9-valent vaccine by Merck. This vaccine was chosen because it allows for the observation of 9 HPV outcomes (HPV 6, 11, 16 and 18) (the other available vaccine, Cervarix, protects against HPVs 16 and 18, only).
3299145|NCT01824537|Placebo Comparator|Hepatitis A vaccine|"The placebo comparator will be Avaxim, by Sanofi Pasteur. This control vaccine was chosen because hepatitis A immunization provides a similar health prevention incentive as HPV vaccination to study participants while preserving the scientific cogency of a placebo comparator. Gardasil 9 requires administration of 3 doses, while Avaxim only requires 2 doses. For this reason, a placebo injection (saline solution) will be added in between the Avaxim vaccination regimen. Consequently, both treatment and control vaccines will have similar regimens, i.e., study entry, 2 months, and 6 months."
3299146|NCT01824550|Experimental|home-based exercise training condition|Home based endurance exercise training
3299147|NCT01824550|No Intervention|attention control condition|Attention control condition - home based flexibility training
3299148|NCT01824563||study population|Subjects will need to be standard CI patients acording to national implant criteria and the study criteria.
3299149|NCT01824615|Experimental|Sunitinib|Use Sutent for treatment of recurrent / persisted OCCA
3299150|NCT01824628||• HIV positive subjects receiving antiretroviral regimen|
3299151|NCT01824628||• HIV negative subjects from the pre-admission surgical clinic|
3299152|NCT01824641|Experimental|Eliminate|Eliminate aspiration catheter
3299153|NCT01824641|Active Comparator|Conventional primary angioplasty|Patients treated with conventional primary angioplasty
3299154|NCT01824654|Experimental|Rigid and Elastic registration softwares|
3299155|NCT01824667|Experimental|B-GOS|2.75g daily for 4 weeks
3299156|NCT01824667|Placebo Comparator|Maltodextrin|2.75g daily for 4 weeks
3299157|NCT01824680|Experimental|obesity|
3299158|NCT01824706||craniectomy|craniectomy
3299159|NCT01824719||Allergic group|All patients who used Reduning Injection have anaphylaxis.
3299160|NCT01824719||Control group|All patients who used Reduning Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
3299161|NCT01824732||Allergic group|All patients who used Tanreqing Injection have anaphylaxis.
3299162|NCT01824732||Control group|All patients who used Tanreqing Injection don't have anaphylaxis.One allergic group patient should matched four control group patients.
3299163|NCT01824745|Experimental|Arm I (SCP-BCS template booklet and counseling)|Participants receive SCP-BCS template booklet and receive counseling sessions with a patient navigator for 40 minutes twice weekly for 4 sessions.
3299164|NCT01824745|Active Comparator|Arm II (SCP-BCS template booklet)|Participants receive SCP-BCS template booklet and receive standard follow-up care.
3299165|NCT01824758|Experimental|brevibloc (esmolol)|Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL)
3299166|NCT01824758|Active Comparator|Aritmal (Lidocaine)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
3299167|NCT01824758|Placebo Comparator|Placebo (NaCl 0.9%, 5 ml)|Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL)
3299168|NCT01824797||Roux-en-Y Gastric Bypass|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
3299169|NCT01824797||Sleeve Gastrectomy|Changes in bone mineral density will be determined by comparing a peroperative DEXA scan with a one year postoperative DEXA scan on postmenopausal subjects who have already planned to undergo Roux-en-Y gastric bypass or sleeve gastrectomy. Serum will be collected from subjects preoperatively and 12 months postoperatively. The serum will be used at the completion of the study to run enzyme-linked immunosorbent assay (ELISA) to determine biochemical changes in bone metabolism.
3299170|NCT01824810|Experimental|Intramuscular Stimulation|Participants in this group will receive up to 12 sessions of Intramuscular Stimulation (IMS). Each session may last from 30 to 60 minutes. Primary and secondary outcome measures will be assessed prior to the first treatment, after completion of the last treatment, and 6 months after treatment is complete.
3299171|NCT01824810|Experimental|myoActivation|Participants in this group will receive up to 12 sessions of myoActivation treatment. Each treatment is approximately 15 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3299172|NCT01824810|Experimental|Neural Prolotherapy|Participants in this group will receive up to 12 sessions of neural prolotherapy. treatment. Each treatment is approximately 30 to 60 minutes minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3299173|NCT01824810|Sham Comparator|Sham Needling Control|Participants in this group will receive up to 12 sessions of sham needle treatment. Each treatment is approximately 15 to 60 minutes. Primary and Secondary outcome measures will be assessed prior to treatment, one week after all treatments have been completed, and again 6 months after treatment is complete.
3299174|NCT01824836|Experimental|Supportive care (anastrozole)|Patients receive anastrozole PO QD for 12 months.
3299175|NCT01824849|Experimental|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients.
3299176|NCT01824849|Experimental|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients.
3299177|NCT01824862||eyes without diabetic retinopathy|eyes of patients with diabetes mellitus type 2 that does not have retinopathy
3299178|NCT01824862||CSME without centre involvement|eyes with CSME without thickening in the 500 µm adjacent to the centre of the macula
3299179|NCT01824862||CSME with centre involvement|eyes with CSME with thickening in the 500 µm adjacent to the centre of the macula
3299182|NCT01824888|Active Comparator|Control|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by using 60% propan-2-ol into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
3299183|NCT01824888|Experimental|JUC solution|Following standard one-minute handwashing, both hands were immersed up to the mid-metacarpals for 5 seconds into a contamination fluid containing E. coli. Handrubs were performed by pouring 1.5 ml of JUC into the cupped hands and rub vigorously for 30 seconds, the procedure was completed by a 5 seconds rinse of the fingers under running tap water and excess water was shaken off.
3299184|NCT01824914|Experimental|McGrath Videolaryngoscope|to compare the Cormack-Lehane grade in sedation and anesthesia by McGrath videolaryngoscope
3299185|NCT01824927|Active Comparator|First eye (FE)|Phacoemulsification cataract extraction surgery of first eye
3299186|NCT01824927|Active Comparator|Second eye (SE)|Phacoemulsification cataract extraction surgery of second eye
3299187|NCT01824927|Experimental|Steroids eye drops|Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery
3299188|NCT01824940|Placebo Comparator|Standard of Care|The Standard of Care interventions are the blanket interventions.
3299189|NCT01824940|Active Comparator|WASH|"One of two active interventions to be studied in this 2X2 (two by two) Factorial trial:~Intervention 1: a package of interventions to improve household sanitation and hygiene (WASH)"
3299190|NCT01824940|Active Comparator|Nutrition|"One of two active interventions to be studied in this 2X2 Factorial trial:~Intervention 2: a package of interventions to improve infant and young child feeding (IYCF)"
3299191|NCT01824940|Active Comparator|WASH and Nutrition|This arm receives a combination of all standard care interventions, all WASH and all IYCF interventions.
3299192|NCT01824953||atrophy-/Hp- group|Subjects without Helicobacter pylori infection and without atrophy
3299193|NCT01824953||atrophy-/Hp+|Subjects with Helicobacter pylori infection and without atrophy
3299194|NCT01824953||atrophy+/Hp+|Subjects with Helicobacter pylori infection and with atrophy
3299195|NCT01824953||atrophy+/Hp-|Subjects without Helicobacter pylori infection and with atrophy
3299196|NCT01824966||SRC<50%|Adenocarcinoma containing < 50% of signet ring cells
3299197|NCT01824966||SRC>50%|Adenocarcinoma containing > 50% of signet ring cells
3299198|NCT01824992|No Intervention|Observation|subject only got observation
3299199|NCT01824992|Experimental|Drug|subject were treated with Yallaferon®， the recombinant human interferon α-2b gel
3299200|NCT01825005||group 1:surgery|treatment = surgery only
3299201|NCT01825005||group 2: radiotherapy|treatment = radiotherapy only
3299202|NCT01825005||group 3: RT and CT, and/or hyperthermia|treatment= radiotherapy combined with chemotherapy and/or hyperthermia
3299203|NCT01825005||group 4: stage IVb , any treatment|cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care
3299204|NCT01825018|Experimental|Social Network Leader Endorsement|Leaders of social networks randomized to this arm will be taught to endorse compliance with medical guidelines, safer behaviors, and effective ways to communicate these concepts to social network members.
3299205|NCT01825018|Active Comparator|Comparison Group|Members of social networks assigned to this group will receive only HIV counseling at the baseline session.
3299206|NCT01825031|Experimental|Antiretroviral Therapy|Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs
3299207|NCT01825031|Experimental|Opportunistic Infection (OI) Prophylaxis|Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.
3299208|NCT01825031|Experimental|Nutritional Support|Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.
3299209|NCT01825044|Active Comparator|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
3299210|NCT01825044|Active Comparator|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
3299211|NCT01825070|Experimental|low dose|Montmorency cherry concentrate, 30 mls
3299212|NCT01825070|Experimental|higher dose|Montmorency cherry concentrate, 60 mls
3299213|NCT01825083|Active Comparator|Ketamine|Ketamine administered 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
3299214|NCT01825083|Placebo Comparator|Placebo|Saline group will received the same volume in saline as the ketamine dose
3299215|NCT01825096||baseline|No intervention. Participants are scanned at baseline.
3299216|NCT01825109|Experimental|6 weeks RV & normal breast feeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
3299217|NCT01825109|Experimental|6 weeks RV & delayed breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
3299218|NCT01825109|Experimental|14 weeks RV & Normal breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
3299219|NCT01825109|Experimental|14 weeks RV & delayed breastfeedin|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
3299220|NCT01825135|Experimental|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be applied to the quadriceps muscles for 30 minutes
3299221|NCT01825135|Sham Comparator|Sham stimulation|Sham stimulation will be applied to the quadriceps for 30 minutes
3299222|NCT01825148||Type 1 Diabetes|patients with long standing T1D
3299223|NCT01825148||Healthy volunteer|healthy volunteers with normal glucose tolerance
3299224|NCT01825174|Active Comparator|Non-overweight children in ball games program|twice a week different ball games 90min
3299225|NCT01825174|Experimental|Overweight children in nutrition counseling program|9 units of 90min each of nutrition counseling
3299226|NCT01825174|Placebo Comparator|Control group overweight children|No intervention during six months
3299227|NCT01825174|Experimental|Overweight children in ball games program|twice a week different ball games 90min
3299228|NCT01825174|Experimental|Overweight children in ball games and nutrition counseling|twice a week different ball games 90min and 9 units of 90min each of nutrition counseling
3299229|NCT01825174|Placebo Comparator|Non-overweight control (no intervention)|
3299230|NCT01825187|Active Comparator|Treatment Group 1|Patients in this group will be randomized to receive the ULTRAPRO mesh
3299231|NCT01825187|Active Comparator|Treatment Group 2|Patients in this group will be randomized to receive the 3DMAX Mesh
3299232|NCT01825187|Other|Evaluation of Surgical Residents|Surgical residents will be evaluated on the ease of use and the amount of time it takes for them to perform the surgery using these two different meshes.
3299233|NCT01825213||Multispectral CT of the liver|Images of lesions and liver will be compared to histology.
3299234|NCT01825226|Experimental|Program participation|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
3299235|NCT01825226|No Intervention|Control|
3299236|NCT01825239|Other|Electrophysiology Study|This is a single arm study, all study participants will be referred for an Electrophysiology Study
3299237|NCT01825252|Experimental|Social Network Intervention|Approximately 20% of people in this condition will be trained to have discussions endorsing less risky behaviors with their social network members.
3299238|NCT01825252|Active Comparator|Counsel, Test, and Treat|People in this arm will only receive standard-of-care counseling, testing, and treatment for HIV and STDs.
3299239|NCT01825278||Single group, obese surgical patients with monitoring strip|All eligible patients will have a monitoring strip prospectively applied to their right chest
3299240|NCT01825291||sleep apnea|
3299241|NCT01825304|Active Comparator|esophageal pressure ,titrated setting|
3299242|NCT01825304|Other|ARDSNet recommendations,peep|
3299243|NCT01825317|Active Comparator|NeuroAD|Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
3299244|NCT01825317|Sham Comparator|Sham NeuroAD|Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
3299245|NCT01825330|Active Comparator|NeuroAD|NeuroAD treatment, synchronized TMS and cognitive training stimulation
3299246|NCT01825330|Sham Comparator|Sham TMS+Cog|Sham device, has the same appearance and sound as the real device, combined with sham cognitive exercises. Patients come for the same number of sessions, delivers no real stimulation or cognitive training.
3299247|NCT01825356|Active Comparator|Dorsal Cheilectomy no Amniotic Membrane Tissue Implantation|Dorsal cheilectomy is a surgery for hallux rigidus(degenerative arthritis and stiffness due to bone spurs that affect the joint at the base of the big toe). No amniotic membrane will be used for this group.
3299248|NCT01825356|Experimental|Dorsal Cheilectomy-Amniotic Membrane Tissue Implantation|Dorsal cheilectomy procedure with the addition of the amniotic membrane. Amniotic membrane represents a biologic therapy that has the ability to actively regulate myrofibroblast formation and activity within the joint space and surgical site
3299249|NCT01825369|Experimental|IV L-carnitine|L-carnitine (25, 50, or 100mg/kg IV) will be given, 30-60 minutes prior to the initiation of CPB, and a second dose ~2 hr. following separation from CPB (with a minimum of 4 hrs from initial dose). The first 5 subjects will receive 25 mg/kg, with an escalation of dose after each 5 subjects enrolled. The study drug will be brought to the operating room and administered over 5 minutes by the anesthesiologist after an IV has been placed. Prior to the administration of the study drug, and again 24 and 48 hrs after CPB, 3.0 ml of blood will be collected for determinations of carnitine levels (free, total, and acylcarnitine), mitochondrial function, ROS and bioavailable NO as described in Aim 3A. Additional blood (0.5-1.0 ml) will be obtained to determine carnitine levels before CPB, and then before and 0.5, 1.5, 3, 5, 9, 12, and 24h after the second dose.
3299250|NCT01825382|No Intervention|Accu-chek Meter|Patients receiving the Accu-chek nano meter for use during the study.
3299251|NCT01825382|Experimental|iBGStar meter interventional Arm|Subjects are given iBGstar meter along with iPhone to use as interventional meter.
3299252|NCT01825421|No Intervention|Control (continue antibiotics) group|The antibiotics will be continued for at least another 24h i.e. for 48h, pending blood culture results at 48h, as per standard practice in the NICU.
3299253|NCT01825421|Active Comparator|Study (discontinue antibiotics) group|The intervention is to discontinue antibiotics at 24h, and he/she will be kept under observation in the NICU for at least an additional 24h, pending blood culture results at 48h.
3299254|NCT01825434|Active Comparator|Treatment Group|yogurt containing polydextrose, L. acidophilus NCFM® (ATCC 700396) and B. lactis HN019 (AGAL NM97/09513) 1 time per day, for 30 days.
3299255|NCT01825434|Placebo Comparator|Placebol group|regular yogurt, 1 time per day for 30 days.
3299256|NCT01825447|Placebo Comparator|Treatment A|
3299257|NCT01825447|Experimental|Treatment B|
3299258|NCT01825447|Active Comparator|Treatment C|
3299259|NCT01825460|Experimental|Manual Therapy Protocol|A protocol with five techniques on thoracic area applied twice a week.
3299260|NCT01825460|Active Comparator|Two manual techniques|Two manual therapies on thoracic area applied twice a week.
3299261|NCT01825473|Experimental|Erythromycin|50 mg/kg/day divided every 6 hours oral for 7 days
3299262|NCT01825473|Placebo Comparator|Placebo|Dextrose 5 Water (D5W) equal amount as experimental every 6 hours oral for 7 days
3299263|NCT01825486||accidental falls|
3299264|NCT01825499||Very low birth weight infants|Infants 401 to 1500 g or 22 to 29 weeks gestational age admitted to Vermont Oxford Network member centers within 28 days of birth
3299265|NCT01825525|Experimental|Cardiac device patients.|Exposure to ScopeGuide - patients with cardiac devices exposed to ScopeGuide as per study protocol
3299266|NCT01825538||COPD, pulmonary fibrosis|observational study, no interventions to be administered
3299267|NCT01825551|Active Comparator|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor 10 microgram/ kg/ day for 5 days subcutaneously
3299268|NCT01825551|Placebo Comparator|Placebo|normal saline 0.01 ml/kg/day for 5 days subcutaneously
3299269|NCT01825590||Subjects undergoing sodium alignment|Dialysate and serum sodium concentration aligned
3299270|NCT01825590||Subjects not undergoing sodium alignment|Dialysate and serum sodium concentration not aligned
3299271|NCT01825603|Experimental|Treatment (ADH-1, cisplatin, gemcitabine hydrochloride)|Patients receive ADH-1 IV over 20-80 minutes on days 1, 4, 8, 11, 15, and 18, cisplatin IV and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease may receive maintenance therapy with cisplatin and gemcitabine hydrochloride.
3299272|NCT01825616|Experimental|Vitamin D2 mushroom powder|4000 IU/day vitamin D2 mushroom powder
3299273|NCT01825616|Placebo Comparator|Placebo|Mushroom powder without vitamin D2 (not exposed to UV radiation)
3299274|NCT01825629|Experimental|Multidisplinary Therapy|The multidisciplinary therapy involves the application of physical therapy, manual therapy and deontology therapy. This multidisciplinary therapy will be administered twice a week for 15 weeks.
3299275|NCT01825629|Placebo Comparator|One technique of myofascial release|"A physiotherapist administered 15 sessions of induction occipital once a week."
3299276|NCT01825642|Active Comparator|Control Group|nerve-sparing radical prostatectomy
3299277|NCT01825642|Active Comparator|Treatment Group|seminal vesicle-sparing radical prostatectomy
3299278|NCT01825668|Experimental|High cholesterol|600 mg cholesterol/day in 240 ml milk shake
3299279|NCT01825668|Experimental|Plant sterols|2.0 g of plant sterols/day in 240 ml milk shake containing 50 mg cholesterol
3299280|NCT01825668|Placebo Comparator|Placebo|50 mg cholesterol/day in 240 ml of milk shake
3299281|NCT01825681|Experimental|positive affect intervention|positive affect intervention
3299282|NCT01825681|No Intervention|wait list control|wait list control
3299283|NCT01825694|No Intervention|Standard of Care|The Standard of Care condition includes: 1) an individual session with the counselor, once per week; 2) a treatment group with the counselor, twice per week; and 3) parents of youth are invited to attend parent-only educational sessions weekly.
3299284|NCT01825694|Experimental|Trauma-focused Substance Abuse Intervention|See Intervention Arm description.
3299285|NCT01825707|Experimental|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg
3299286|NCT01825720|Experimental|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
3299287|NCT01825720|Active Comparator|normal saline group|same rate of normal saline
3299288|NCT01825733|Experimental|ramosetron|
3299289|NCT01825733|Active Comparator|palonosetron|
3299290|NCT01825746|Active Comparator|Early implementation practices|"9 practices that will initially field the MOHR assessment for up to 6 months. These practices will serve as intervention sites for the effectiveness outcomes measured by the patient experience survey."
3299291|NCT01825746|Other|Delayed implementation practices|"9 practices that will field the MOHR assessment for up to 6 months but starting 4 months after the early implementation practices. These practices will serve as control sites for the effectiveness outcomes measured by the patient experience survey. However, they will provide intervention data with respect to Reach and cost during the delayed phase."
3299292|NCT01825759|Experimental|danshen dripping pill|danshen dripping pill 27mg ten pills by mouth every 8 hours for one year
3299293|NCT01825811|Experimental|TissueGene-C (Low dose)|TissueGene-C (1.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
3299294|NCT01825811|Experimental|Experimental: TissueGene-C (High dose)|TissueGene-C (3.0 x 10^6 cells per cm^2 of the cartilage defect) combined with fibrin-glue
3299295|NCT01825824|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for unresectable hepatocellular carcinoma with size ≤ 5 cm and 3cm apart from gastrointestinal tract after incomplete trans-arterial chemo-embolization
3299296|NCT01825850|Experimental|Gemigliptin|Gemigliptin 50mg q.d. during 7 days
3299297|NCT01825850|Experimental|Irbesartan|Irbesartan 300mg q.d. during 7 days
3299298|NCT01825850|Experimental|Gemiglitin + Irbesartan|Gemigliptin 50mg + Irbesartan 300mg q.d. during 7 days
3299299|NCT01825863|Active Comparator|Active abdominal wall block|60ml ropivacaine 0.375% single shot
3299300|NCT01825863|Placebo Comparator|Placebo abdominal wall block|60ml saline 9% single shot
3299301|NCT01825902|Experimental|Diagnostic (18F-FLT PET, 18F-FDG PET, DW-MRI)|Patients undergo 18F-FLT PET, 18F-FDGPET, and DW-MRI the week prior to induction therapy, within one week after the completion of induction therapy, the week prior to RT (for patients that received surgery), and within 1 week of completion of RT.
3299302|NCT01825915|Active Comparator|Laparoscopic Hysterectomy|Laparoscopic hysterectomy involving removal of both uterine corpus and cervix
3299303|NCT01825915|Active Comparator|Laparoscopic Supracervical Hysterectomy|Laparoscopic hysterectomy involving removal of the uterine corpus alone with conservation of the cervix.
3299304|NCT01825928|Experimental|paliperidone|paliperidone arm,3mg/pill,3mg/day.last84 days.
3299305|NCT01825928|Placebo Comparator|placebo|placebo group,3mg/pill,3mg/day non-forced titration method,last84 days.
3299306|NCT01825954|Active Comparator|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from NeuroPoint device
3299307|NCT01825954|Active Comparator|8-week RINCE|RINCE - active RINCE therapy involving 16 total treatment applications from NeuroPoint device, followed by 8 sham applications from the NeuroPoint device
3299308|NCT01825954|Sham Comparator|Sham RINCE|Sham RINCE - sham RINCE therapy involving 24 total sham applications from NeuroPoint device
3299309|NCT01825967||Acute Diverticulitis|We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
3299310|NCT01825980|Experimental|BZF961|
3299311|NCT01825980|Placebo Comparator|Placebo|
3299312|NCT01825993|Experimental|PCA endovenous|1mg/10 min Morphine
3299313|NCT01825993|Active Comparator|PERIDURAL CATHETER|Peridural L-bupivacaine 0.25%
3299314|NCT01825993|Active Comparator|TANSABDOMINAL BLOCK (TAP)|L-BUPIVACAINE im
3299315|NCT01826006|Active Comparator|Excimer laser|After wire crossing, Excimer Laser will be performed. Consequently, intracoronary adenosine will be selectively administered through the guiding catheter.
3299316|NCT01826006|Active Comparator|Manual Thrombus Aspiration|After wire crossing, thrombus aspiration will be performed. The device will removed outside the body, flushed with saline and subsequently reintroduced in the culprit vessel beyond the occlusion site and intracoronary adenosine will be selectively administered.
3299317|NCT01826019|Experimental|Intervention|Intensive CV risk detection, counselling and follow-up program by NPHW; recommended CV medications will include combinations of anti-hypertensive medications (both low and high doses) and a lipid lowering agent (e.g. statin) in accordance with treatment algorithm [precise formulations used may differ in each country]; use of treatment supporters to reinforce adherence.
3299318|NCT01826019|Other|Control - Usual Care|Participants in control communities will be referred to usual care.
3299319|NCT01826032|Experimental|CPAP|"Patients with CPAP treatment. Titration will be performed by polysomnography or automatic CPAP to determine the optimal treatment pressure.~This group will also be instructed in hygienic-dietary measures and sleep hygiene counselling."
3299320|NCT01826032|Active Comparator|Standard care for OSA|Sleep hygiene ( regular sleep schedule, avoid sedative drugs, alcohol and tobacco, physical exercise) and dietary counselling
3299321|NCT01826045|Experimental|Poly-gamma Glutamic Acid|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered Poly-gamma Glutamic Acid for 4 weeks.
3299322|NCT01826045|Placebo Comparator|Placebo|Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered placebo for 4 weeks.
3299323|NCT01826058|Experimental|Stereotactic body radiation therapy|"SBRT in one to four fractions~Irradiated total RT dose to gross tumor volume (GTV) according to fraction size~1 fx: 16 to 24 Gy~2 fx's: 20 to 26 Gy~3 fx's: 21 to 30 Gy~4 fx's: 24 to 36 Gy"
3299324|NCT01826071|No Intervention|Symptomatic Treatment|
3299325|NCT01826071|Experimental|Static Stretch|Home exercise program with static stretching
3299326|NCT01826071|Experimental|Active Elongation|Home exercise program with active elongation exercises
3299327|NCT01826097|Experimental|Vibration|Whole body vibration applied to a group of 20 bladder cancer patients.
3299328|NCT01826110|Experimental|[11C]PIB|[11C]PIB
3299329|NCT01826123|Active Comparator|Conventional laboratory testing|"After being randomized to the group conventional coagulating testing, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
3299330|NCT01826123|Active Comparator|POC testing (ROTEM and Multiplate)|"After being randomized to the group POC testing, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests."
3299331|NCT01826136|Experimental|Acapella|use of the Acapella device postoperatively
3299332|NCT01826136|No Intervention|Control|
3299333|NCT01826149|Experimental|Propofol 1.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 1.0mcg/ml using target controlled infusion.
3299334|NCT01826149|Experimental|Propofol 2.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 2.0mcg/ml using target controlled infusion.
3299335|NCT01826149|Experimental|Propofol 3.0mcg|Propofol dosage titration, comparison of the effect of different concentration of propofol to the myocardial performances, namely at 3.0mcg/ml using target controlled infusion.
3299336|NCT01826162|Experimental|sigmoidoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the proximal colon (sigmoidoscopy)
3299337|NCT01826162|Experimental|colonoscopy|2 actetate concentrations and 1 placebo are administered in randomized order after clipping a catheter in the distal colon (colonoscopy)
3299338|NCT01826175|Experimental|Ticagrelor|Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
3299339|NCT01826175|Active Comparator|Clopidogrel|Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
3299340|NCT01826188|Active Comparator|THC 5 mg/ml and CBD 50 mg/ml.|olive oil containing THC 5 mg/ml and CBD 50 mg/ml. which will be taken twice daily.
3299341|NCT01826188|Placebo Comparator|Placebo|olive oil but without any active ingredients.
3299342|NCT01826240|Experimental|MBCT+SPI|Note: There is only one condition in this study. Mindfulness-Based Cognitive Therapy (MBCT) is combined with Safety Planning Intervention (SPI). All individuals who choose to participate will receive MBCT+SPI.
3299343|NCT01826253||Hypovolemia|Fluid expansion
3299344|NCT01826266|Placebo Comparator|PER977-Dose 1|Dose titration
3299345|NCT01826266|Placebo Comparator|PER977-Dose 2|Dose Titration
3299346|NCT01826266|Placebo Comparator|PER977-Dose 3|Dose Titration
3299347|NCT01826266|Placebo Comparator|PER977-Dose 4|Dose Titration
3299348|NCT01826266|Placebo Comparator|PER977-Dose 5|Dose Titration
3299349|NCT01826266|Placebo Comparator|PER977-Dose 6|Dose Titration
3299350|NCT01826266|Placebo Comparator|PER977-Dose 7|Dose Titration
3299351|NCT01826279|Experimental|Resveratrol|Resveratrol 500mg 3 times daily for 1 month
3299352|NCT01826279|Placebo Comparator|Placebo|Placebo 1 tablet 3 times daily for 1 month
3299353|NCT01826305|Active Comparator|Formal Rehabilitation Therapy|Patients randomized to the formal rehabilitation therapy cohort will receive a prescription for therapy for twelve weeks following their primary knee replacement.
3299354|NCT01826305|Experimental|Independent Exercise Cohort|Patients randomized to the independent exercise cohort will receive online access to a twelve-week protocol of exercises to perform at home to strengthen and improve function of the replaced knee.
3299355|NCT01826318|Experimental|intervention|"Participants received a 10 minute instruction to cope with stress by loudly posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention group)"
3299356|NCT01826318|No Intervention|Control|Students in the control group did not receive any further instructions.
3299357|NCT01826331|No Intervention|Control Group|Participants will be incentivized for assessments only
3299358|NCT01826331|Experimental|Incentives for Participation|Participants will be incentivized for each assessment and for each smoking cessation session they complete
3299359|NCT01826331|Experimental|Incentives for Cessation|Participants will be incentivized for each assessment and biochemically confirmed abstinence at 12 and 24 months
3299360|NCT01826383|Experimental|Active Video|This is a five-minute video that coaches parents about how to soothe their infant post-immunization.
3299361|NCT01826383|Placebo Comparator|Placebo Video|This is a video identical to that of the active video, except no specific instructions regarding how to soothe an infant post-immunization are given.
3299362|NCT01826396|Experimental|high dose irinotecan|high dose irinotecan based on UGT1A1 genotype, 5-fluorouracil, and leucovorin (FOLFIRI) for first-line treatment of locally advanced colon cancer
3299363|NCT01826409|Experimental|Fermented red ginseng|
3299364|NCT01826409|Placebo Comparator|Placebo|
3299365|NCT01826435|Experimental|Electronic Intervention|Over the three months, participants will receive a technology intervention. This will include text or email encounter notifications associated with appropriate mobile or online self-management information for medication adherence and behavior change.
3299366|NCT01826461|Experimental|PDI-192 Foam, 0.1%|topical foam, 0.1% concentration, twice daily
3299367|NCT01826461|Experimental|PDI-192 Foam, 0.15%|topical foam, 0.15% concentration, twice daily
3299368|NCT01826461|Placebo Comparator|Vehicle Foam|topical foam, 0% concentration, twice daily
3299369|NCT01826474|Experimental|PRO045, cohort 1|0.15 mg/kg until dose-titration
3299370|NCT01826474|Experimental|PRO045, cohort 2|1.0 mg/kg until dose-titration
3299371|NCT01826474|Experimental|PRO045, cohort 3|3.0 mg/kg until dose-titration
3299372|NCT01826474|Experimental|PRO045, cohort 4|6.0 mg/kg until dose-titration
3299373|NCT01826474|Experimental|PRO045, cohort 5|9.0 mg/kg until move to 48 week treatment phase
3299374|NCT01826474|Experimental|PRO045, cohort 6|48 week treatment phase
3299375|NCT01826500||Patients|"Patients having any of the following criteria:~Patients with embryo transfer fresh or frozen~Patients from an IVF cycle,~Patients supported surgically for endometriosis"
3299376|NCT01826500||Controls|Controls
3299377|NCT01826526|Active Comparator|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
3299378|NCT01826526|Placebo Comparator|Saline solution 0.9%|"5 ml of saline will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of saline administration in this trial will be 12 months."
3299379|NCT01826539|Other|Innervated finger flap|donor nerve attached with the flap for finger pulp reconstruction
3299380|NCT01826552|Experimental|Orsiro|The Patient group who are treated with Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
3299381|NCT01826552|Active Comparator|Resolute Integrity|The Patient group who are treated with ② Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
3299382|NCT01826565|No Intervention|Control|i-gel will be inserted without rotation
3299383|NCT01826565|Experimental|Rotation|Rotational technique applied
3299384|NCT01826578|Experimental|single port arm|
3299385|NCT01826578|No Intervention|Conventional arm|Using 3-4 port for laparosocpic surgery
3299386|NCT01826591|Experimental|Experimental: Low-Carbohydrate Diet|Healthy, Low-Carbohydrate Diet
3299387|NCT01826591|Experimental|Experimental: Low-Fat Diet|Healthy, Low-Fat Diet
3299388|NCT01826617||Prostate Cancer- Indolent type|Patients diagnosed with Indolent type will be classified according to Epstein Criteria on histopathology results and National Comprehensive Cancer Network (NCCN) guideline recommended classification
3299389|NCT01826617||Prostate cancer- aggressive type|Patients diagnosed with aggressive type will be classified according to Epstein criteria on final histopathology findings and NCCN guideline recommended classification
3299390|NCT01826617||Acute Prostatitis|Patient diagnosed with Acute prostatitis- according to histopathology description of Biopsy result
3299391|NCT01826617||Chronic Prostatitis|Patient diagnosed with Chronic prostatitis- according to histopathology description of Biopsy result
3299392|NCT01826617||Benign Prostatic Nodular Hyperplasia|Patient diagnosed with Benign Prostatic Nodular Hyperplasia- according to histopathology description of Biopsy result
3299393|NCT01826630|Active Comparator|CLn BodyWash|CLn BodyWash will be used to wash hands of patients with Hand Atopic Dermatitis
3299394|NCT01826630|Active Comparator|Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser will be used to wash hands of patients with Hand Atopic Dermatitis
3299395|NCT01826656|Other|post-menopausal osteoporotic women|Subjects of test group will follow a tooth extraction and they will perform a CBCT scan within 10 days from the extraction and after 3 months (+/-15 days)
3299396|NCT01826656|Active Comparator|non-osteoporotic post-menopausal women|Subjects of the control group will follow a tooth extraction and will perform a CBCT scan within 2 days from the extraction and after 3 months (+/- 2 days)
3299397|NCT01826669|Active Comparator|Stretching|"The respiratory muscle stretching were developed bilaterally as follows:~Upper trapezius: head lateral flexion with a hand therapist supports the the occipital region and his shoulder, promotes the stretching;~Sternocleidomastoid: was stretched with flexion lateral and rotation of the head to the side which hands on the occipital region and in the sternal region;~Scalene: with one hand on the occipital region and the other in the sternum, the two points was stretched;~Pectoralis major: the arm was abducted, flexed the forearm and hand was in the occipital region the therapist hands in the arm and in the side of the upper chest, which was stretched craniocaudal direction;~Intercostal: therapist performs with both hands to mobilize and stretch the ribs in cranial-caudal directions."
3380191|NCT04910568|Experimental|Single-Agent Cevostamab (Arm A)|"Cohort A1S is a safety run-in arm evaluating Cevostamab administered in 28-day cycles on a modified weekly schedule.~Upon completion, Cohort A1E, an expansion cohort may be opened. Participants will be treated with single-agent cevostamab administered in 28-day cycles on a modified weekly schedule."
3299398|NCT01826669|No Intervention|Rest|COPD patients were not submitted to any intervention, remaining at rest in the same place, position and time period to the treatment group.
3299399|NCT01826682|Placebo Comparator|Medical treatment|29 people are being recruited in order to the inclusion criteria for the study. Placebo controlled.
3299400|NCT01826682|Active Comparator|Physiotherapy program+medical treatment|29 people are recruited in order to the inclusion criteria for the study. Experimental group
3299401|NCT01826695|Placebo Comparator|Placebo group|35 women are recruited in order to the inclusion criteria for the study. Placebo controlled. They received only standard treatment without neurodynamic intervention. They are diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and end.
3299402|NCT01826695|Active Comparator|Neurodynamic technique group|35 women are recruited, diagnosed with Fibromyalgia attending to the Fibromyalgia Association of Granada. The study include subjects who can complete the assessment battery of tests at the beginning and at the end.
3299403|NCT01826708|No Intervention|Psychomotor retardation syndromic|Psychomotor retardation syndromic by Identification of breakpoints
3299404|NCT01826721|No Intervention|Standard of Care|Patients in the Standard of Care arm receive the usual in-hospital post-transplant medication teaching class led by a transplant pharmacist.
3299405|NCT01826721|Active Comparator|TMITT|Patients in this arm receive the standard of care plus the TMITT educational intervention.
3299406|NCT01826734||Patients with dacryolits|The study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.
3299407|NCT01826747|Experimental|experimental|Luteal Phase support
3299408|NCT01826747|No Intervention|control|No luteal Phase support
3299409|NCT01826760||acute-on-chronic hepatitis B liver failure, training group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. ACHBLF patients were assigned to a training cohort and a validation cohort randomly. One of the major limitations of ANN is over-training, which can lead to good performance on training sets but poor performance on relatively independent validation sets. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
3299410|NCT01826760||acute-on-chronic hepatitis B liver failure, testing group|ACHBLF was defined as an acute hepatic insult manifesting as jaundice and coagulopathy, complicated within 4 weeks by ascites and/or encephalopathy in a patient with chronic HBV infection according to consensus recommendations of the Asian Pacific Association for the Study of the Liver in 2009. To avoid over-training during building ANN, a part of ACHBLF patients were again randomly selected from the training group to train the network and the remaining were used for cross-validation.
3299411|NCT01826773|Experimental|Stress only CardioPET™|"Group I will consist of 15-20 patients and will have CardioPET™ imaging performed with a repeat identical stress component at ≥ 48 hours and ≤ 10 days after the initial stress MPI study. There should be no intervention or change in symptoms between the tests, and the patient must have an angiography scheduled to be performed within 30 days.~The analysis of the acquired imaging data will determine if CardioPET™ is suitable for identifying myocardial flow defects that were observed in exercise or pharmacologic stress Tc-99m MPI imaging. The goal for this CardioPET™ imaging group is to measure blood flow at near maximal stress."
3299412|NCT01826773|Experimental|Rest only CardioPET™|"Group II will consist of 15-20 subjects will have undergone either, stress, Tc-99m MPI study or stress-echocardiography indicating ≥2 segments of ischemia. These patients must have been referred and scheduled for coronary angiography. If initial evaluation was performed with stress echocardiography, subjects will have either exercise or pharmacologic stress MPI.~CardioPET™ imaging in these subjects must be performed ≥ 48 hours and ≤ 10 days from the initial stress (stress MPI or echocardiography) at rest only. An angiography must be scheduled to be performed within 30 days."
3299413|NCT01826786|Experimental|JNJ-42165279 (100 mg)|
3299414|NCT01826786|Placebo Comparator|Placebo|
3299415|NCT01826799||adult ICU patients|All adult patients without hearing disabilities and admitted to the ICU more than 48 hours ago, with a Richmond Agitation-Sedation Scale (RASS) of -2 or higher and the capability to understand Dutch are eligible.
3299416|NCT01826838|Experimental|Dasatinib|Three dasatinib dose levels will be evaluated, 50 mg/day, 70 mg/day and 100 mg/day. Dasatinib will begin with day #1 of radiation and will be discontinued once radiation is completed.
3299417|NCT01826864|Experimental|Arm I (sargramostim and sentinel lymph node biopsy)|Patients receive sargramostim SC 3-5 days prior to undergoing sentinel lymph node biopsy.
3299418|NCT01826864|Active Comparator|Arm II (hypertonic saline and sentinel lymph node biopsy)|Patients receive hypertonic saline SC 3-5 days prior to undergoing sentinel lymph node biopsy.
3299419|NCT01826877|Experimental|Treatment (autologous dendritic cells)|Patients receive AdGMCAIX-transduced autologous dendritic cells ID on days 1, 15, and 29.
3299420|NCT01826890|Experimental|NAVA technology|Following randomisation, a NAVA catheter will be introduced. The Electrical Activity of the Diaphragm (EAdi) will be viewed primarily to ensure a minimum level of diaphragm activation during the weaning phase. NAVA mode suitability/safety assessments will be conducted in all patients prior to the first initiation of the NAVA mode. The NAVA preview function on the Maquet Servo-i ventilators will be used to transfer from the previous mode to the NAVA mode, and the assessment will last for a maximum of 30 minutes. We are recommending the use of the NAVA ventilation mode during the weaning period. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
3299421|NCT01826890|No Intervention|Standard Care|A NAVA catheter will be inserted following randomisation. The NAVA capabilities of the ventilator will be disabled. Patients will be ventilated according to local weaning protocol as per current standard care with either Pressure Support, Synchronised Intermittent Mandatory Ventilation, Volume Controlled Ventilation, Pressure Controlled Ventilation or Pressure Regulated Volume Controlled Ventilation. Following the commencement of weaning, sedation holds and spontaneous breathing trials will be conducted according to local protocols.
3299422|NCT01826903||depressed mother/child dyad - intervention|
3299423|NCT01826903||depressed mother/child dyad - no intervention|
3299424|NCT01826903||non-depressed mother/child dyad|
3299425|NCT01826916|Experimental|5mg/m2 DX-88 IV|5mg/m2 DX-88 (ecallantide)administered intravenously
3299426|NCT01826916|Experimental|10mg/m2 DX-88 IV|10mg/m2 DX-88(ecallantide)administered intravenously
3299427|NCT01826916|Experimental|20mg/m2 DX-88 IV|20mg/m2 DX-88 (ecallantide) administered intravenously
3299428|NCT01826916|Experimental|30 mg DX-88 SC|30mg DX-88(ecallantide)administered subcutaneously
3299429|NCT01826929|Experimental|Therapeutic education|Organized intervention strategy:Informed active patient, shared decision making, appointment planning, primary care doctor-nurse teamwork, actions based on scientific evidence.
3299430|NCT01826929|No Intervention|Usual care model|
3299431|NCT01826942|Experimental|Thin skin|Single fractional CO2 treatment at surgical area closure procedure on thin skin
3299432|NCT01826942|Experimental|Thick skin|Single fractional CO2 treatment at surgical area closure procedure on thick skin
3299433|NCT01826955||Open gastrectomy|patient who undergoing open gastrectomy
3299434|NCT01826955||laparoscopic gastrectomy|patient who undergoing laparoscopic gastrectomy
3299435|NCT01826968|Experimental|Recruitment Group|The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. In this group PEEP was set to 8 cmH2O, after the recruitment maneuver, and was left until the end of the operation.
3299436|NCT01826968|No Intervention|Control Group|We did not used alveolar recruitment maneuver
3299437|NCT01826994|Other|patients|heart type fatty acid binding protein testing
3299438|NCT01827007|Experimental|Study arm, elevation of PEEP|
3299439|NCT01827020|Active Comparator|Group L (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL lidocaine 2%, 1mg/kg into nasal cavity.
3299440|NCT01827020|Active Comparator|Group K (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of 12 mL ketamine 0.5 mg/kg plus lidocaine 2% 1 mg/kg of the intranasal cavity.
3299441|NCT01827020|Placebo Comparator|Group S (number of participants=30)|After standard anesthesia induction and before surgery, patients will receive submucosal infiltration of saline 12 mL into intranasal cavity.
3299442|NCT01827033|Other|meditation training|
3299443|NCT01827059|Active Comparator|Bosentan|Tracleer, 125-mg orange-white, round, biconvex, film-coated tablets
3299444|NCT01827059|Placebo Comparator|Placebo|Placebo tablet
3299445|NCT01827072|Experimental|NPB-01|Intravenous immunoglobulin
3299446|NCT01827085||Macintosh laryngoscope|Patients will be intubated with a conventional Machintosh laryngoscope
3299447|NCT01827085||Videolaryngoscope|Intubation with Stortz video laryngoscope
3299448|NCT01827098|Experimental|Delayed induction|The root canal is disinfected and calcium hydroxide is placed in the canal. Blood clot is induced in the canal 4 weeks later. Endodontic Regeneration is performed.
3299449|NCT01827098|Experimental|Immediate Induction|Blood clot is induced after disinfection of the canal during the same visit. Endodontic regeneration is performed.
3299450|NCT01827111|Experimental|ABI-007 + Ipilimumab|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. Ipilimumab 3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses. Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
3299451|NCT01827124|Experimental|carbetocin and placebo|100microgram carbetocin IV and 1cc normal saline(placebo)infusion
3299452|NCT01827124|Experimental|oxytocin and placebo|20Interntional unit oxytocin infusion and 1cc normal saline IV
3299453|NCT01827137|Experimental|vaccine|Galinpepimut-S (GPS) inoculations are started 12-22 d following autologous stem cell transplantation (ASCT). GPS (1.0 ml of emulsion) is given s.c. on weeks 0, 2, 4, 6, 8, & 10 (i.e., x 6). Injection sites are pre-stimulated with Sargramostim (GM-CSF; 70 μg) s.c. on d -2 (± 1 d ) & d 0 of each GPS inoculation. N.B.: during each GPS inoculation, the Sargramostim & GPS are administered to the same anatomical site. Subjects are observed for >/= 30 minutes after vaccination. Non-progressing subjects who are clinically stable (no active infection with fevers & no cardiovascular/respiratory compromise) may receive up to 6 more vaccinations q-month. The use of post-ASCT maintenance therapy with either lenalidomide or bortezomib is allowed starting >/= 3 months after ASCT.
3299454|NCT01827150|Experimental|Redbull, optic nerve|"15 subjects will each be drinking a can of Redbull (250 ml) and an equal amount of water (250 ml) in two different sessions. The order in which they will do so, is determined by randomization.~Intervention: Drug: Redbull, energy drink"
3299455|NCT01827176||Recurrent Acute Rhinosinusitis|Recurrent Acute Rhinosinusitis is defined as acute rhinosinusitis more than 3 times/6 months or more than 4 times/year
3299456|NCT01827189||Comprehensive primary care practices|Comprehensive primary care practices are the intervention group.
3299457|NCT01827189||Comparison practices|Comparison practices are the case-control group--the matched set of practices in a comparison area--whose patients' outcomes will be compared to those of intervention practices.
3299458|NCT01827202|Active Comparator|Aliskiren|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking aliskiren 150 mg once daily for 4 weeks. Thereafter, the dose will be increased to 300 mg once daily for another 4 weeks.
3299459|NCT01827202|Active Comparator|Candesartan|After a two-week phase where all RAS blockade is eliminated, patients in this arm will commence taking candesartan 8 mg once daily for 4 weeks. Thereafter, the dose will be increased to 16 mg once daily for another 4 weeks.
3299460|NCT01827215|Experimental|Intervention (Virtual Patient Advocate)|The Intervention Virtual Patient Advocate (VPA) Group participants will be given a username and secure password to log on to the Gabby site for the 12 months of the intervention. They will be encouraged to log on every two weeks or twice a month, but using the system is voluntary. They will be given the contact information of the Program Manager in the event that they have any issues or questions about the system. The research team will call each intervention participant after 6 and 12 months to conduct a follow-up phone call to collect outcome data. At the end of the intervention period, intervention participants will be invited to participate a focus group session.
3299461|NCT01827215|No Intervention|Control (Letter)|The control group will receive a letter listing the preconception risks identified in the risk assessment and they will be encouraged to see their clinician to discuss them.
3299462|NCT01827228|Experimental|Primary Recent infection network tracing|"Subjects: LAg+ recent HIV infection testees & referrals with recent/acute infection; those in social/risk networks of index subjects; people who go to their venues. We'll network trace direct contacts of Index Cases & network/venue members of contacts; and maybe 3rd ring as exploratory part of project. We'll test network/venue members for recent & acute HIV. If they have recent/acute HIV infection, their network/venue contacts will be traced. We'll refer HIV+ Primary arm participants for medical/social evaluation and treatment; those with recent/acute infection on expedited scheduling and case management. We will distribute community alerts to warn people in the social environments of recent/acute infectees to be super-careful in their behaviors for the next 6 months; to tell them how to be safer; and to repeat the importance of assisting rather than stigmatizing anyone they suspect has recently become infected."
3299463|NCT01827228|Active Comparator|Contact tracing of long-term HIV+ people|We will start with 50 subjects in each city who test HIV+ but LAg negative-and who report they have just learned they are HIV+. We will recruit their sexual and injection partners, and other risk environment contacts, for two steps, as in Primary Arm. HIV+ will be referred for treatment; recent/acutes on expedited and assisted basis.
3299464|NCT01827228|Active Comparator|HIV negative comparison arm|This comparison arm will consist of 150 uninfected people in each city whom we screen in the course of testing. The key comparisons here are on two of the central variables: adverse/supportive events and behavior change. This comparison arm will help mitigate social desirability effects that can lead to inaccurate reporting and/or Hawthorne effects and related processes that can lead to behavior changes simply based on the interview. Participants in this arm will be matched on age (within five years), risk group, and gender with an Arm 1 member.
3299465|NCT01827241||Colonoscopy Outcomes|Data collected from endoscopy reports to complete a descriptive analysis of demographics, colonoscopy procedure performance, and assess type of benign colon polyps detected during screening and surveillance from 02/01/2009 - 12/31/2020.
3299466|NCT01827280|Experimental|Metformin|Metformin 850mg/pill will be administered at lunch time and dinner time for 30 days
3299467|NCT01827280|Experimental|Vildagliptina|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
3299468|NCT01827293|Active Comparator|Promethazine|IV promethazine (25 mg)
3299469|NCT01827293|Active Comparator|lorazepam|IV lorazepam (2 mg)
3299470|NCT01827345|Experimental|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
3299471|NCT01827384|Experimental|Regimen I (veliparib, temozolomide)|Patients receive veliparib PO BID on days 1-7 and temozolomide PO QD on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3299472|NCT01827384|Experimental|Regimen II (adavosertib, carboplatin)|Patients receive adavosertib PO BID for 5 doses starting on day 1 and carboplatin IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3299473|NCT01827384|Experimental|Regimen III (everolimus)|Patients receive everolimus PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3299474|NCT01827384|Experimental|Regimen IV (trametinib)|Patients receive trametinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3299475|NCT01827397|Experimental|EN41-UGR7C HIV vaccine|Group 1: IM injection of 210 µg UGR7-C in 560 µg of Alum at month 0, 1 and 4
3299476|NCT01827397|Placebo Comparator|NaCl|Group 2: IM injection of 700 µL of 0.9% sodium chloride (NaCl) at month 0, 1 and 4
3299477|NCT01827410||patients with a ventral hernia repair|All patients with a ventral hernia repair performed in Region Zealand and registered in The Danish Ventral Hernia Database during October 1st 2010 to October 1st 2011
3299478|NCT01827423|Experimental|Surgical removal of sinonasal papiloma|The study group consisted of patients following a surgical removal of sinonasal papiloma, in which the SCCA blood levels were assessed in pre-defined intervals.
3299479|NCT01827436|Active Comparator|Conventional physical therapy|Includes traditional physical treatment, such as gait and balance training and muscle strengthening.
3299480|NCT01827436|Active Comparator|Asymmetrical gait training|Includes walking on a split-belt treadmill with the belts moving at different speeds under each leg, alternated with overground walking training.
3299481|NCT01827501|Experimental|Group GDT|Goal-directed Management according to pulse contour analysis (PulsioflexTM Monitoring)
3299482|NCT01827501|No Intervention|Group Co|Conventional fluid management
3299483|NCT01827514||People with diagnosed cancer|People wich were diagnosed with one of specific type of cancer: breast, lung, colon, head, neck and lymphoma
3299484|NCT01827527||Healthy Adult|This is a protocol development study, with no interventions or treatments.
3299485|NCT01827540|Experimental|Cenicriviroc + Midazolam, and CVC + DTG|Grp 1: CVC 150mg qd alone from Days 1-10; CVC 150mg qd + DTG 50mg qd from Days 11-20. A single dose of midazolam 5mg administered alone on Day -1 & w/ CVC 150mg on Day 9.
3299486|NCT01827540|Experimental|Dolutegravir , and DTG + CVC|Grp 2: DTG 50 mg qd alone from Days 1-10, DTG 50 mg qd + CVC 150 mg qd from Days 11-20.
3299487|NCT01827553|Experimental|Induction CT, chemoradiotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Radiotherapy, 28 x 1.8 Gy; Chemotherapy, gemcitabine;
3299488|NCT01827553|Active Comparator|Induction CT, chemotherapy|Induction chemotherapy with gemcitabine or FOLFIRINOX; Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
3299489|NCT01827566|Active Comparator|gluten|10 grams of gluten in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
3299490|NCT01827566|Placebo Comparator|gluten free flour|10 grams of gluten free flour in each sachet to be dispersed daily on food for ten days, while maintaining a gluten free diet
3299491|NCT01827579|Experimental|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
3299492|NCT01827579|No Intervention|Control (normal HSCT)|Patients randomised to the control arm with undergo stem cell transplantation according to site local practice.
3299493|NCT01827618|Experimental|Rapamycin|Rapamycin 3mg orally daily x 4weeks prior to radical cystectomy
3299494|NCT01827618|No Intervention|Control|
3299495|NCT01827631|Experimental|GSK1605786 500 mg once daily|GSK1605786 500 mg is given once daily in the morning
3299496|NCT01827631|Experimental|GSK1605786 500 mg twice daily|GSK1605786 500 mg is given twice daily in the morning and in the evening
3299497|NCT01827644|Experimental|Sequence 1|Subjects will receive single doses of AFU HPMC capsule administered in a fasted state, AFU ECT administered in a fasted state, AFU HPMC capsule administered in a fed state and AFU GC administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3299498|NCT01827644|Experimental|Sequence 2|Subjects will receive single doses of AFU ECT administered in a fasted state, AFU ECT administered in a fed state, AFU GC administered in a fasted state and AFU GC administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
3299499|NCT01827644|Experimental|Sequence 3|Subjects will receive single doses of AFU GC administered in a fasted state, AFU GC administered in a fed state, AFU ECT administered in a fed state and AFU HPMC capsule administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period.
3299500|NCT01827644|Experimental|Sequence 4|Subjects will receive single doses of AFU GC administered in a fed state, AFU HPMC capsule administered in a fed state, AFU HPMC capsule administered in a fasted state and AFU ECT administered in a fasted state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3299501|NCT01827644|Experimental|Sequence 5|Subjects will receive single doses of AFU ECT administered in a fed state, AFU HPMC capsule administered in a fasted state, AFU GC administered in a fed state and AFU HPMC capsule administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3299502|NCT01827644|Experimental|Sequence 6|Subjects will receive single doses of AFU HPMC capsule administered in a fed state, AFU GC administered in a fasted state, AFU ECT administered in a fasted state and AFU ECT administered in a fed state (sequentially), on Day 1 of Dosing Period 1, 2, 3 and 4 (one treatment per period) respectively, with a minimum 10 Day washout between the doses in each Dosing Period
3299503|NCT01827657|Experimental|Part 1 Cohort 1 - Mild hepatic impairment|Subjects with mild hepatic impairment will be enrolled in Cohort 1 and will receive a single dose of 60 mg GSK2336805
3299504|NCT01827657|Experimental|Part 1 Cohort 2 - Moderate hepatic impairment|Subjects with moderate hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805
3299505|NCT01827657|Experimental|Part 1 Cohort 3 - Matched healthy volunteers to Cohort 2|Control subjects will be matched for gender, age (+/- 10 years), body mass index (BMI) (+/- 20%), and smoking status to the subjects in the moderate hepatic impairment arm. These healthy volunteers will receive a single dose of 60 mg GSK2336805
3299506|NCT01827657|Experimental|Part 2 Cohort 4 - Severe hepatic impairment|Subjects with severe hepatic impairment will be enrolled in Cohort 2 and will receive a single dose of 60 mg GSK2336805. The decision to move forward into Part 2 (severe hepatic impairment) will be based on a review of the preliminary safety and pharmacokinetic data from subjects with moderate hepatic impairment
3299507|NCT01827657|Experimental|Part 2 Cohort 5 - Matched healthy volunteers to Cohort 4|Based on emerging data from Part 1, the sponsor may decide to enroll matched controls to the severe hepatic group (i.e. in case of a change in dose or the demographics of the severe hepatic group are not well matched with the moderate control data). The subjects in this optional control cohort will be matched for gender, age (+/- 10 years), BMI (+/- 20%), and smoking status to the subjects in the severe hepatic impairment category
3299508|NCT01827683|Active Comparator|Hyperbaric oxygen therapy group|hyperbaric oxygen therapy during the first 2 months
3299509|NCT01827683|Other|Crossed group|no active intervention during the first 2 months.After 2 months will be crossed to HBOT
3299510|NCT01827696|Experimental|Treatment|American Ginseng ingestion
3299511|NCT01827696|Placebo Comparator|Placeobo|non-active ingredient
3299512|NCT01827722|Experimental|Ozurdex Arm|Ozurdex intravitreal injection (combination with monthly sham injection) administered at a 16 week interval beginning on Day 1 and ending at Week 16.
3299513|NCT01827722|Experimental|Ranibizumab Arm|Ranibizumab injection (combination with sham injections beginning on Day 1 and Week 16) administered at monthly intervals beginning Day 1 and ending at Week 20.
3380192|NCT04910568|Experimental|Cevostamab plus Pomalidomide and Dexamethasone (Pd) (Arm B)|"Participants will be treated with cevostamab monotherapy during a 21-day period prior to the start of pomalidomide treatment (cevostamab pre-phase).~Cohort B1S is a safety run-in arm evaluating cevostamab and Pd administered in 28-day cycles every 2 weeks (Q2W) followed by every 4 weeks (Q4W) schedule.~Upon completion, Cohort B1E, an expansion corhort may be opened. It will follow the same Q2W/Q4W dosing schedule as Cohort B1S."
3299514|NCT01827722|Experimental|Combination Ozurdex with Ranibizumab PRN|"Ozurdex intravitreal injection administered at 16 week intervals beginning on Day 1 and ending at Week 16 with an initial IV Ranibizumab injection administered at Day 1, then treated with Ranibizumab according to reinjection parameters assessed monthly (in combination with sham if reinjection parameters are not met).~Reinjection Parameters:~10 letter drop from best corrected visual acuity or a 100 µm increase in central retinal thickness according to optical coherence tomography (Spectralis HRA + OCT)."
3299515|NCT01827748|Experimental|Intraoperative Autorefractor IAR-1|This is a auto refractor mounted on an operating microscope.
3380193|NCT04910568|Experimental|Cevostamab plus Daratumumab and Dexamethasone (Dd) (Arm C)|"Cohort C1S is a safety run-in arm evaluating cevostamab and Dd administered in 21 day cycles from Cycle(C)1 - C8 every 3 weeks (Q3W) and 28-day cycles from C9 onwards Q4W.~Upon completion, Cohort C1E, an expansion corhort may be opened. It will follow the same Q3W/Q4W dosing schedule as Cohort C1S."
3380197|NCT04906759|Experimental|Meals plus exercise|
3380198|NCT04906759|Experimental|Meals only|
3380199|NCT04903574|Experimental|Sedentary behavior smartphone app|This arm will be assigned to download and use a smartphone app that prompts you to stand up when your smartphone detects 30 minutes of sitting.
3380200|NCT04903574|Active Comparator|Pregnancy smartphone app|This arm will download and use a commercially available pregnancy smartphone app that does not attempt to change activity behavior.
3380201|NCT04903119|Experimental|Level 1|Patients in this group will receive 100mg Nilotinib PO BID.
3380202|NCT04903119|Experimental|Level 2|Patients in this group will receive 200mg Nilotinib PO BID.
3299516|NCT01827748|Active Comparator|Hartmann-Shack Auto Refractor|The Hartmann-Shack type auto refractor used with the subject sitting upright in front of the instrument.
3299517|NCT01827761||Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
3299518|NCT01827774|Experimental|Surgisis® Soft Tissue Graft|
3299519|NCT01827800|Experimental|eHealth weight loss intervention|The 12-month eHealth behavioral intervention includes interactive self-monitoring and feedback, tailored skills training materials, telephone counseling calls from a study coach, and primary care provider counseling.
3299520|NCT01827800|No Intervention|Usual care|Participants in the usual care arm will receive the usual primary care services offered by their community health center primary care providers.
3380203|NCT04903119|Experimental|Level 3|Patients in this group will receive 300mg Nilotinib PO BID.
3380204|NCT04903119|Experimental|Level 4|Patients in this group will receive 400mg Nilotinib PO BID.
3380205|NCT04901351|Experimental|Patients chronically infected with HPV|The study will be offered to patients with chronic HPV infection as part of an annual consultation scheduled in the gynecology care package.
3380208|NCT04897074|Experimental|AKL-T01|Digital Treatment
3380213|NCT04895839|Experimental|Intervention Arm|
3380214|NCT04895241|Experimental|BIIB059 High Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive high dose of BIIB059, subcutaneously (SC) every 4 weeks (Q4W), up to Week 48 with an additional dose at Week 2.
3380215|NCT04895241|Experimental|BIIB059 Low Dose|Participants who are receiving background nonbiologic lupus SOC therapy will receive low dose of BIIB059, SC Q4W, up to Week 48 with an additional dose at Week 2.
3380216|NCT04895241|Placebo Comparator|Placebo|Participants who are receiving background nonbiologic lupus SOC therapy will receive BIIB059 matching placebo, SC Q4W, up to Week 48 with an additional dose at Week 2.
3380217|NCT04890548|Experimental|Patients with HFpEF or HFrEF|Patients will be enrolled in 2 cohorts in parallel: 1 cohort of patients with HFpEF and 1 cohort of patients with HFrEF. Patients will receive a sequence of 5 IA infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
3299521|NCT01827813|Active Comparator|Saturation biopsy|Saturation biopsy was performed in left lateral decubitus position after application of sedo-analgesia by the anesthesiologists on an outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen. As a total,24,26 or 28 biopsies were taken depending on prostate volume.
3299522|NCT01827813|Active Comparator|10-12 core biopsy|10-12 core biopsy was performed in left lateral decubitus position without sedo-analgesia on an outpatient basis. After preparation of the probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. After injecting 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region, prostatic size was measured and changes in the zonal anatomy and ultrasonographic view of the tissue were defined. Next, biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. As a total 10 or 12 core biopsies were taken depending on prostate volume. The biopsies were taken form right base, right mid, right apex, right far-lateral base, right far-lateral mid and left base, left apex, left far-lateral base, and left far-lateral mid in 10 core biopsy, also two additional transitional zone biopsies were taken in 12 core biopsies.
3299523|NCT01827826|Active Comparator|Intervention|Participants assigned to the intervention group worked with the study interventionist over the phone to reduce their risk for developing Diabetes Mellitus, Type 2. The intervention lasted for 24 weeks, with weekly phone calls for the first 12 weeks and 4 maintenance calls over the second 12 weeks. Study measurements were taken at baseline, 12 weeks, 24 weeks, and 52 weeks. After 24 weeks, the investigators randomly divided the intervention group in half. The first group did not receive any more phone calls from the interventionist. The second group continued to receive monthly 20-minute phone calls from the interventionist. At 52 weeks post-baseline participants from both groups had their labs drawn, wore a pedometer for 3 days, and called in with a self-reported weight.
3380220|NCT04889898||ALS Patients|All ALS patients will be enrolled in this arm, which involves a combination of clinical and home-based assessments of speech and swallowing.
3380221|NCT04889898||Listeners|Healthy listeners will be recruited to listen to the audio recordings of patients in the study in order to judge the intelligibility of their speech.
3380222|NCT04889209|Experimental|Cohort 1 Group 10E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
3380223|NCT04889209|Experimental|Cohort 1 Group 11E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273.211 (delayed boost dose). N = 50
3380224|NCT04889209|Experimental|Cohort 1 Group 12E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA- 1273 N = 50
3380225|NCT04889209|Experimental|Cohort 1 Group 13E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna-mRNA-1273 at 100mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
3380226|NCT04889209|Experimental|Cohort 1 Group 14E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 50-mcg dose of mRNA-1273. N = 50
3380227|NCT04889209|Experimental|Cohort 1 Group 1E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
3380228|NCT04889209|Experimental|Cohort 1 Group 2E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
3380229|NCT04889209|Experimental|Cohort 1 Group 3E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA) -dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n ˜ 25) randomized to receive a single intramuscular (IM) injection of a 100-mcg dose of mRNA-1273 (delayed boost dose). N = 50
3380230|NCT04889209|Experimental|Cohort 1 Group 4E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV2-S at 5x10^10 vp stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
3299524|NCT01827826|No Intervention|Control|Participants randomized into this group did not receive any intervention, although they were encouraged to follow-up with their doctor and follow through with usual clinical care.
3299525|NCT01827852||Cohort|
3299526|NCT01827865|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
3299527|NCT01827865|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
3299528|NCT01827878|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
3299529|NCT01827878|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
3299530|NCT01827891|Placebo Comparator|control group|Control participants did not experience the procedure of transient upper-limb ischemia.
3299531|NCT01827891|Active Comparator|remote ischemic preconditioning (RIPC) group|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
3299532|NCT01827904|Experimental|Transcranial ExAblate|Transcranial ExAblate
3299533|NCT01827904|Sham Comparator|Sham Transcranial ExAblate|Sham Treatment with Transcranial ExAblate
3299534|NCT01827917|Experimental|rabies vaccine|When injured by the animal who carries the rabies virus, the patient after standard treatment would survive or die
3299535|NCT01827956||Blood sample|Blood sample for identifying the polymorphism
3299536|NCT01827969|Experimental|ablathermy focused ultrasound|ablathermy focused ultrasound
3299537|NCT01827982|Experimental|Part 1 - Cohort 1: JNJ-54861911 1 mg|Following each dose level the observed safety and tolerability profile will be evaluated. The dose will be escalated only if the observed safety and tolerability profile is acceptable.
3299538|NCT01827982|Experimental|Part 1 - Cohort 2: JNJ-54861911 3 mg|
3299539|NCT01827982|Experimental|Part 1 - Cohort 3: JNJ-54861911 9 mg|
3299540|NCT01827982|Experimental|Part 2 - Cohort 4: JNJ-54861911 9 mg|
3299541|NCT01827982|Experimental|Part 2 - Cohort 5: JNJ-54861911 27 mg|
3299542|NCT01827982|Experimental|Part 2 - Cohort 6: JNJ-54861911 81 mg|
3299543|NCT01827982|Experimental|Part 2 - Cohort 7: JNJ-54861911 160 mg|
3299544|NCT01827982|Experimental|Part 3 - Cohort 8: JNJ-54861911 (dose to be determined [tbd])|
3299545|NCT01827982|Placebo Comparator|Parts 1 through 3 - Placebo|Participants in each cohort will receive matching placebo.
3299546|NCT01827995|Other|Duo test|Self assessment
3299547|NCT01827995|Other|Routine follow up|Follow up in the clinic
3299548|NCT01828047||Elective colorectal surgeries|Patients undergoing elective colorectal procedures with an Enhanced Recovery Program. Orthogonal polarization spectral (OPS) imaging will be used to measure sublingual microcirculation
3299549|NCT01828060|Experimental|Jobelyn™|Dietary supplement Jobelyn™, 500mg daily for 8 weeks Jobelyn is a sorghum bicolor extract marketed as dietary supplement Other Name: Sorghum bicolor extract
3299550|NCT01828060|Placebo Comparator|Placebo|Placebo capsules
3299551|NCT01828086|Experimental|CJM112|CJM112 in different doses; single ascending and multiple ascending
3299552|NCT01828086|Placebo Comparator|Placebo|Placebo to match
3299553|NCT01828086|Active Comparator|Secukinumab|Active investigational drug.
3299554|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 1mg glucagon|A 1.0mg glucagon dose will be given during the hyperinsulinemic hypoglycaemic clamp
3299555|NCT01828125|Active Comparator|Hyperinsulinemic hypoglycaemic clamp 0.1 or 0.2mg glucagon|A dose of 0.1mg or 0.2mg will be given during the hyperinsulinemic hypoglycaemic clamp.
3299556|NCT01828138|Other|Preeclampsia|"patients with preeclampsia are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement."
3299557|NCT01828138|Other|Controls|"Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
3299558|NCT01828138|Other|not-pregnant women|"This arm is also a control- group. Controls are given a diet with a fixed content of sodium chloride ( 50-60 mmol/day ) plus a supplement of sodium chloride tablets ( 150-200 mmol/day) OR they are given placebo tablets.~After 5 days they switch their supplement"
3299559|NCT01828151||Developed skin lesions|Patients treated with noninvasive ventilation for an episode of acute respiratory failure
3299560|NCT01828177|Experimental|PDI-320|Foam, twice daily for up to 12 weeks
3299561|NCT01828177|Experimental|PDI-320 Monad #1|Foam, twice daily for up to 12 weeks
3299562|NCT01828177|Experimental|PDI-320 Monad #2|Foam, twice daily for up to 12 weeks
3299563|NCT01828177|Placebo Comparator|Vehicle|Foam, twice daily for up to 12 weeks
3299564|NCT01828190|Experimental|Hyperbaric oxygen|hyperbaric oxygen therapy will be given for 2 months. TNF alpha blocker therapy will remain the treatment received before recruitment.
3299565|NCT01828203|Experimental|Minocycline|Minocycline twice daily infused over 30 minutes through central venous access as follows 800 mg + 700 mg on Day 1, 600 mg + 500 mg on Day 2, and 400 mg thereafter from Day 3 thru Day 7
3299566|NCT01828203|Placebo Comparator|Placebo|250 ml normal saline and infused over 30 minutes through central venous access twice daily for 7 days
3299567|NCT01828229|Experimental|female inactivity and hypercaloric diet|inactivity and hypercaloric diet in women for two weeks
3299568|NCT01828229|Experimental|inactivity|Inactivity for two weeks
3299569|NCT01828229|Experimental|inactivity and hypercaloric diet|inactivity and hypercaloric diet for two weeks
3299570|NCT01828229|Experimental|normal activity and hypercaloric diet|Normal activity and hypercaloric diet for two weeks
3299571|NCT01828229|Active Comparator|inactivity and iso-caloric diet|inactivity and iso-caloric diet for two weeks
3299572|NCT01828242|Experimental|Empowerment model to Diabetes|Empowerment model to improve dietary intake
3299573|NCT01828242|Active Comparator|Control group following conventional approach|Control group following conventional approach
3299574|NCT01828268||HIV infectors|100 confirmed HIV-1 infected patients who meet inclusion criteria.
3299575|NCT01828294|Other|Study Population|Study population will include patients (18-80 years old) with non-thymomatous myasthenia gravis MGFA Class II-IV receiving a minimum of 30mg of Prednisone daily and no other immunosuppression and no more 240 mgs per day of Cholinesterase inhibitor. Patients will receive Subcutaneous immunoglobulins weekly for 6 months.
3299576|NCT01828307|Active Comparator|Standard Aftercare Treatment|Standard aftercare treatment consists of once per week group counseling for six months. Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
3299577|NCT01828307|Experimental|Standard Aftercare Treatment + Exercise Intervention|In addition to attending standard aftercare treatment, participants will receive three 50-minute motivational enhancement therapy sessions focused on exercise, plus 24 weekly contingency management sessions for exercise.
3299578|NCT01828320|Experimental|Treatment 1|Integrates evidence-based treatments derived from basic research on the circadian system
3299579|NCT01828320|Active Comparator|Treatment 2|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
3299580|NCT01828333||Intravenous artesunate - new routine in DRC|"350 patients to be enrolled~A first study group with the currently used standard for treatment of severe malaria in the DRC, i.v. quinine, was enrolled from 21 October 2012 to 15 January 2013. This study was initially planned as limited scope implementation study with pure observational character (routine diagnosis and treatment, time and motion study, feasibility assessment and costing) and thus not registered. Due to additional publications on i.v. artesunate, non-routine testing for hemoglobin levels before and after treatment plus non-routine follow up was added: Registration of study at this point."
3299581|NCT01828346|Experimental|Treatment|5-Azacitidine plus birinapant
3299582|NCT01828359|Experimental|Amosartan® tab|Amlodipine 5mg /Losartan 100mg
3299583|NCT01828359|Active Comparator|Cozaar® plus pro tab|Losartan 100mg/ HCTZ 12.5mg
3299584|NCT01828372|Other|additional blood withdrawals|"Theoretical anyone with taking a drug of interest (see list of substances and metabolites of interest) can join this trial. But we turn mainly our attention to patient groups who are excluded in modern drug approval studies."
3299585|NCT01828385|Experimental|Group Mg|Magnesium sulfate 40 mg.kg-1 + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
3299586|NCT01828385|Active Comparator|Group C|Saline 100 ml + rocuronium 0.6 mg.kg-1 + sugammadex 2 mg.kg-1
3299587|NCT01828398|Sham Comparator|sham-tDCS + UE robot-assisted therapy|This group will receive the same robot-assisted therapy of the intervention group, in association of sham-tDCS. This consists in a 30 seconds stimulation, with the same instrumentation and electrodes placement. This method of sham stimulation was previously validated.
3299588|NCT01828398|Experimental|real-tDCS + UE robot-assisted therapy|"This group will receive continuous stimulation lasting 30 minutes during the session of robot-assisted therapy. The training session, which includes multiplanar, repetitive and target reaching movements, will be given 5 times a week for 2 weeks(REO Therapy System; Motorika, Medical LTD, Israel). Each session will last about 30 minutes.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the affected hemisphere and the cathode on the contralateral M1 area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries (Brainstim, EMS, Italy). This continuous stimulation lasted 30 minutes, with an intensity of 1mA."
3299589|NCT01828411||Cardiopulmonary bypass group|Patients requiring normothermic (or mild hypothermic) cardiopulmonary bypass.
3299590|NCT01828411||Hypothermic Cardiopulmonary Bypass Group|Patients requiring (deep) hypothermic cardiopulmonary bypass.
3299591|NCT01828437|Experimental|Pyridoxine plus prednisolone|allocated patients receive pyridoxine (30 mg/kg/day) in addition to prednisolone
3299592|NCT01828437|Active Comparator|Prednisolone|allocated patients receive prednisolone alone
3299593|NCT01828463|No Intervention|no treatment|comparrator
3299594|NCT01828463|Experimental|Nitisinone 1mg|interventional
3299595|NCT01828463|Experimental|Nitisinone 2mg|interventional
3299596|NCT01828463|Experimental|Nitisinone 4mg|interventional
3299597|NCT01828463|Experimental|Nitisinone 8mg|interventional
3299598|NCT01828489|Active Comparator|Standard arm MEC and ADxE|Standard protocol arm with mitoxantrone in first course (MEC) and standard ADxE treatment in course two
3299599|NCT01828489|Experimental|Experimental DxEC and standard ADxE|Experimental arm with DaunoXome in course one (DxEC) and standard ADxE treatment in course two
3299600|NCT01828489|Experimental|Standard arm MEC and experimental FLADx|Experimental arm with standard MEC in the first course (MEC) and experimental treatment with FLADx in course two
3299601|NCT01828489|Experimental|Experimental DxEC and experimental FLADx|Experimental treatment with DaunoXome in course one (DxEC) and experimental treatment with FLADx in course two
3299602|NCT01828502|Experimental|Active Intervention|Those randomized to the active intervention will receive education about secondhand smoke exposure and feedback using the cotinine test strip.
3299603|NCT01828502|Other|Education only|Those randomized to the education only group will receive only the education about secondhand smoke exposure.
3299604|NCT01828528||NAFLD after SG|26 patients with NAFLD undergoing sleeve gastrectomy (SG).
3299605|NCT01828541|Other|Standard Care|Subjects in this condition will receive our standard care for itch, which includes a stepped based algorithm of medications.
3299606|NCT01828541|Experimental|Hypnosis Condition|Subjects in this condition will receive standard care plus the addition of 4 sessions of hypnosis delivered over a two month period.
3299607|NCT01828580|Experimental|AutoLap|
3299608|NCT01828606|Experimental|Coban 2 system|The two layer system is more stiff and the material is different designed
3299609|NCT01828606|Experimental|coban lite systems|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
3299610|NCT01828619||modified BuFlu, HSCT, elder/intolerable|The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
3299611|NCT01828632|Experimental|Respiratory Physical Therapy|Patients assigned to interventional group (Respiratory Physical Therapy) were undergone a program of inspiratory muscular training (IMT) and incentive spirometer for a period of 30 days before the actual date of surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values)
3299612|NCT01828632|No Intervention|Control|Usual care for the four weeks before surgery. PiMAX, PeMAX and spirometry parameters were measured at the randomization day (baseline values).
3299613|NCT01828645|No Intervention|Control|Patients will be submitted to upper digestive endoscopy in the morning bearing traditional NPO (nil per oral)fast after 11:00PM
3299614|NCT01828645|Experimental|Intervention|The patients belonging to the intervention group will fast from 11:00 PM the night before but will drink 200 mL of a Carbohydrate plus whey protein enriched drink 2h before the exam.
3380231|NCT04889209|Experimental|Cohort 1 Group 5E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
3380232|NCT04889209|Experimental|Cohort 1 Group 6E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of Ad26.COV2.S 5x10^10 vp (delayed boost dose). N = 50
3299615|NCT01828658|No Intervention|Clinical (control)|In the clinical arm, dry weight and ultrafiltration prescription were done exclusively using traditional clinical methods of volume assessment.
3299616|NCT01828658|Active Comparator|Bioimpedance arm|Strict bioimpedance guided dry weight prescription arm. All patients dry weights were permanently maintained in the dry weight interval recommended by the BCM device (+/- 1,1 kg); BCM measurements were performed every 3 months.
3299617|NCT01828671|Active Comparator|Oral Glucose Solution 296 ml|Study Participants will consume oral glucose solution 296 mls. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer. Per standard glycemic index testing protocols, this will be repeated at another visit.
3299618|NCT01828671|Active Comparator|Corn Tortilla|Study Participants will consume 2 to 3.5 corn tortillas (12-15 cm in diameter each) with a total serving of 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3380233|NCT04889209|Experimental|Cohort 1 Group 7E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Janssen - Ad26.COV.2.S 5x10^10 vp stratified with two age ranges of 18-55 years (n=˜ 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
3380234|NCT04889209|Experimental|Cohort 1 Group 8E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Moderna - mRNA-1273 at 100 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
3299619|NCT01828671|Active Comparator|Low Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a low amount of soy flour that is 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3380235|NCT04889209|Experimental|Cohort 1 Group 9E|Adaptive design cohort with participants that previously (>/=12 weeks) received Emergency Use Authorization (EUA)-dosed vaccination with Pfizer/BioNTech - BNT162b2 at 30 mcg for two doses stratified with two age ranges of 18-55 years (n = 25) and 56 or older (n = 25) randomized to receive a single intramuscular (IM) injection of a 30-mcg dose of BNT162b2 (delayed boost dose). N = 50
3380236|NCT04889209|Experimental|Cohort 2|A prospective design cohort with naïve to COVID-19 vaccine and infection participants of > / = 18 years of age to receive COVID-19 vaccine intramuscularly under Emergency Use Authorization dosing (EUA) (two vaccinations of mRNA-1273 at the 100mcg dose at a 28 days of interval) followed by a delayed booster vaccination (50 mcg mRNA-1273) after a minimum of 12 weeks. Additional pools of subjects can be included as additional COVID-19 vaccines are awarded EUA (e.g., Janssen - Ad26.COV2.S or Novavax- NVX-CoV2373). N=250
3380239|NCT04886596|Experimental|RSVPreF3_L1 Group|Participants in this group receive lot 1 of the RSVPreF3 OA vaccine
3380240|NCT04886596|Experimental|RSVPreF3_L2 Group|Participants in this group receive lot 2 of the RSVPreF3 OA vaccine
3380241|NCT04886596|Experimental|RSVPreF3_L3 Group|Participants in this group receive lot 3 of the RSVPreF3 OA vaccine
3380242|NCT04886596|Experimental|RSVPreF3_L4 Group|Participants in this group receive lot 4 of the RSVPreF3 OA vaccine
3380243|NCT04886596|Placebo Comparator|Placebo Group|Participants in this group receive 1 dose of placebo
3380244|NCT04886518|Active Comparator|High dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning."
3380245|NCT04886518|Active Comparator|Low dose pitolisant|"Double-Blind Treatment Phase:~Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning"
3299620|NCT01828671|Active Comparator|Moderate Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with moderate amount of soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3299621|NCT01828671|Active Comparator|High Soy Flour Corn Tortilla|Study Participants will consume 2 to 3.5 tortillas (12-15 cm in diameter each) with a high amount soy flour that has 25 grams of available carbohydrate. Blood will be sampled via capillary at time-point 0 (before the product is consumed), and 15, 30, 45, 60, 90 and 120 minutes after consumption to determine blood glucose concentrations using a glucometer.
3299622|NCT01828684|Experimental|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks
3299623|NCT01828684|Sham Comparator|Sham Lens Coating|Subjects will wear a sham lens coating for 2 weeks
3299624|NCT01828697|Active Comparator|Low dose LMWH|"Fixed low dose low-molecular-weight heparin:~Fixed low dose nadroparin, or;~Fixed low dose enoxaparin, or;~Fixed low dose dalteparin, or;~Fixed low dose tinzaparin."
3299625|NCT01828697|Active Comparator|Intermediate dose LMWH|"Intermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol.~Intermediate dose nadroparin, or;~Intermediate dose enoxaparin, or;~Intermediate dose dalteparin, or;~Intermediate dose tinzaparin."
3299626|NCT01828710|Sham Comparator|Myo-inositol normospermic|29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid
3299627|NCT01828710|Active Comparator|Myo-inositol OAT|13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid
3299628|NCT01828710|Placebo Comparator|Folic acid normospermic|20 normospermic patients treated with 400 µg of folic acid
3299629|NCT01828723|Experimental|SVF-Enriched Lipoinjection|
3299630|NCT01828736|Active Comparator|Arm A: Platinum + Gemcitabine|"Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
3299631|NCT01828736|Experimental|Arm B: Platinum+Gemcitabine+Trastuzumab|"Trastuzumab: Charging dose = 8mg/kg on day 1; then 6mg/kg every 21 days given IV + Gemcitabine = 1 000 mg/m2 Day1 and Day8 given every 21 days IV~+ If Creatinin Clearance > 60 ml/min : Cisplatin = Day 1: 70 mg/m² given every 21 days If Creatinin Clearance < 60 ml/min : Carboplatin = Day 1: AUC 5 given every 21 days"
3299632|NCT01828749||CT abdomen and pelvis|blunt trauma patients without suspected fractures of the pelvis, hip or lumbar spine in two age groups: ages 3-17 years and 18-60 years
3299633|NCT01828762|Experimental|DC-TC+GM-CSF|
3299634|NCT01828775|Experimental|Arm I (early PCI)|Patients receive part I of the PCI comprising quantitative surveys, comprehensive palliative care assessment by the Research Nurses, and goals of care discussions beginning prior to administration of the first dose of phase I treatment. Patients then receive part II of the PCI comprising recommendations from the interdisciplinary team, patient educational sessions, and supportive care referrals following the first dose of phase I treatment and is completed within one month of the first treatment.
3299635|NCT01828775|Experimental|Arm II (delayed PCI)|Patients receive usual care until 12 weeks post-treatment initiation. Patients then receive both part I and II of the PCI.
3299636|NCT01828788|Experimental|Ropivacaïne|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
3299637|NCT01828788|Placebo Comparator|Placebo|Prospective, controlled, randomised, parallel, single-centre, single-blinded trial, comparing to a control (conventional care with no locoregional anaesthesia) an infusion of ropivacaine through two multihole catheters placed lateral to the sternum. In both groups, postoperative analgesia will be achieved by paracetamol plus titrated then self-administered intravenous morphine.
3299638|NCT01828801||Pre-Op|Pre-operative patients who will undergo a total hip replacement.
3299639|NCT01828801||1 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 1 year post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299640|NCT01828801||2 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 2 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299641|NCT01828801||3 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 3 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299642|NCT01828801||4 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 4 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299643|NCT01828801||5 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 5 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299644|NCT01828801||6 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 6 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299645|NCT01828801||7 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 7 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299646|NCT01828801||8 year post-op|Patients that underwent a Pinnacle Metal-on-Metal (MoM) total hip replacement (THR) and at the time of enrollment, based on their date of surgery, were 8 years post-operative . Alternatively these are patients who have had their Pinnacle Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3299647|NCT01828814||RUSF (500kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 500kcal/day for 10 months
3299648|NCT01828814||Super Cereal Plus (SC+)|Monthly distributions of SC+ 800kcal per day during hunger gaps (5 months twice) and SC+ 400kcal per day in-between (5 months)
3299649|NCT01828814||RUSF|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 500kcal per day during hunger gaps (5 months twice) and RUSF 250kcal per day in-between (5 months)
3299650|NCT01828814||RUSF (250kcal/day) and cash transfer|Monthly distributions of Ready-to-use Supplementary Food (RUSF) 250kcal per day associated with cash transfer during hunger gap (5 months) then RUSF 250kcal/day for 10 months
3299651|NCT01828814||SC+ and cash transfer|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with cash transfer during hunger gap (5 months)
3299652|NCT01828814||SC+ and household ration|Monthly distributions of Super Cereal Plus (SC+) 800 kcal per day associated with food ration for household support during hunger gap (5 months)
3299653|NCT01828814||Cash transfer|Monthly distributions of cash transfer only during hunger gap (5 months)
3299654|NCT01828827|Experimental|Fed 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water approximately 30 minutes after a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast.
3299655|NCT01828827|Experimental|Fasting 1000 mg PA-824|Each dose will be 1000 mg PA-824 (5 x 200 mg tablets), and will be administered with 240 mL tap water after a minimum 10-hour overnight fast.
3299656|NCT01828840|Active Comparator|morphine, epidural|Epidurally administrated morphine
3299657|NCT01828840|Active Comparator|fentanyl, epidural|epidurally administrated fentanyl
3299658|NCT01828840|Active Comparator|methadone, epidural|epidurally administrated methadone
3299659|NCT01828840|Active Comparator|morphine, intervenous|intravenously administrated morphine
3299660|NCT01828866|Active Comparator|Community Reinforcement Approach|Treatment as usual, provided in out-patient setting
3299661|NCT01828866|Experimental|Community Reinforcement Approach + EMDR|Treatment as usual + additional sessions of EMDR
3299662|NCT01828879|Experimental|Tacrolimus ointment|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
3299663|NCT01828892|Experimental|PRFG treatment|As described in our previous study, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage. Prior to application, frozen cryoprecipitate and thrombin stored were thawed in a 37°C water bath. Aminomethylbenzoic Acid (1ml: 1mg, Sigma-Aldrich, St Louis, MO) was added into the cryoprecipitate in the volume ratio of 1:10.
3299664|NCT01828892|Sham Comparator|Control|Patients in this group only received standard of care when their fistula output < 200ml/24h.
3299665|NCT01828892|Experimental|Commercial FG|Commercial FG (Zhejiang Puji Porcine fibrin sealant) was applied to close fistulas.
3299666|NCT01828905|Experimental|Cerament|"CERAMENT™|BONE VOID FILLER as bone graft substitute"
3299667|NCT01828905|Active Comparator|Bone graft|Autologous cancellous bone graft (iliac crest)
3299668|NCT01828918|Other|early recurrence|find the postoperative early relapse out
3299669|NCT01828931|Active Comparator|Usual Care|Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
3299670|NCT01828931|Experimental|Lifestyle Intervention|A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
3299671|NCT01828944|Active Comparator|Extra virgin olive oil|Extra virgin olive oil
3299672|NCT01828944|Experimental|Enriched extra virgin olive oil|Enriched extra virgin olive oil
3299673|NCT01828944|Placebo Comparator|refined olive oil|refined olive oil
3299674|NCT01828957|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
3299675|NCT01828957|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
3299676|NCT01828970|Experimental|Basal-bolus specific insulin regimen|Basal-bolus detemir-aspart insulin regimen in hemodialyzed diabetic patients
3299677|NCT01828996|Active Comparator|Shock wave therapy|This group of patient will be treated with the shock wave head in the first 4 sessions then crossover to have the stand-off placebo for another 4 sessions.
3299678|NCT01828996|Placebo Comparator|Placebo|This group of patient will be treated with the stand-off placebo for the first 4 sessions then crossover to have the shock wave head in the other 4 sessions .
3299679|NCT01829009|No Intervention|General Recommendations Group|General information about sarcopenia will be provided to the participants, as well as general recommendations of healthy habits. We will contact the participants weekly by phone to answer questions about sarcopenia, and remind them of their next appointment and about adverse events occured during this period of time. The frequent contact with the participants has also the purpose to prevent losses or rejections for future evaluations
3299680|NCT01829009|Experimental|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
3299681|NCT01829022||E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
3299682|NCT01829035|No Intervention|Arm S|sorafenib 400mg bid daily po until progression
3299683|NCT01829035|Experimental|Arm C|after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression
3299684|NCT01829061||No Treatment|
3299685|NCT01829087|Experimental|Botox injection|
3299686|NCT01829087|Placebo Comparator|Control|
3299687|NCT01829100|Experimental|Group Behavioral Activation Therapy|Group Behavioral Activation Therapy (GBAT)
3299688|NCT01829100|No Intervention|waitlist|15-week waitlist
3299689|NCT01829126||CCB|Patients receiving calcium channel blockers (CCB)
3299690|NCT01829126||ACEi|Patients receiving angiotensin converting enzyme inhibitors (ACEi)
3299691|NCT01829126||CCB and ACEi|Patients receiving calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEi)
3299692|NCT01829126||No treatment|Patients not receiving calcium channel blockers (CCB) and/or angiotensin converting enzyme inhibitors (ACEi)
3299693|NCT01829139||Wait-and-see group|After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
3299694|NCT01829139||Choleretics group|After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
3299695|NCT01829152|No Intervention|Control|Subjects in the Control Group will receive Heart Failure care as routinely delivered by the SMH HF clinicians according to their standards of care.
3299696|NCT01829152|Experimental|CHM Intervention Group|The Intervention Group subjects will receive Converged Health Management (CHM) in addition to continuing to receive care as routinely delivered by the SMH HF clinicians.
3299697|NCT01829178|Placebo Comparator|Control arm|Placebo 420 mg daily in three divided doses for 65 days as control along with [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2]
3299698|NCT01829178|Active Comparator|Exprimental: Silymarin and chemotherapy|silymarin 420 mg daily in three divided doses for 65 days along with standard chemotherapy [cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 +docetaxel 60-80 mg/m2 control
3299699|NCT01829204||Non pregnant asymptomatic|Asymptomatic, non-pregnant, healthy women ages 21 to 75 years with no previous history of any chronic or recurrent vulvovaginal condition who attend our clinical offices for their annual well-woman physical examination
3299700|NCT01829204||Non pregnant symptomatic|Non-pregnant women ages 12 to 75 years being evaluated for any gynecological vulvovaginal condition.
3299701|NCT01829204||Pregnant asymptomatic|Pregnant women ages 12 to 75 years who are both asymptomatic and healthy
3299702|NCT01829204||Pregnant symptomatic|Pregnant women ages 12 to 75 who have any gynecological vulvovaginal condition
3299703|NCT01829256|Experimental|Pharmacist Telehealth Intervention|Will receive a tailored multi-factorial clinical pharmacist-administered telehealth intervention, which includes medication management and behavioral-educational components. The intervention will occur monthly over 3 years.
3299704|NCT01829256|No Intervention|Education Control|Will receive educational material about management of kidney disease
3299705|NCT01829269||Patients with a defibrillator|The study population is that of patients with a defibrillator to have a change of probe.
3299706|NCT01829282|Experimental|Risk Reduction|"The Risk Reduction group will receive the Eban II Intervention upon enrollment. This group will do the following:~Provide HIV and STI test results~First Interview~Attend 8 sessions - 1 session per week~Second interview occurs immediately following the 8th session with HIV and STI tests~Third interview occurs 3 months after the 8th session with HIV and STI tests"
3299707|NCT01829282|Active Comparator|Waitlist|"The Waitlist group will receive the same intervention after waiting for the Risk Reduction group to complete the entire intervention.~Provide HIV and STI test results~First Interview~No sessions for 8 weeks~Second interview and proof of HIV and STI status occurs after the 8 weeks from when you were enrolled~Third interview occurs 3 months after the 8th session with HIV and STI tests The Waitlist Group will then be invited to participate in the Risk Reduction group activities.~Attend 8 sessions - 1 session per week~Fourth interview occurs immediately after the 8th session with HIV and STI tests~Fifth interview occurs 3 months after the 8th session with HIV and STI tests"
3299708|NCT01829308|Experimental|Specialist|The brief interventions are delivered by behavioral health counselors.
3299709|NCT01829308|Active Comparator|Generalist|The brief interventions are delivered by the primary care provider.
3299710|NCT01829321|Experimental|GLPG0974|1 capsule of 200 mg GLPG0974 twice daily
3299711|NCT01829321|Placebo Comparator|Placebo|1 capsule placebo twice daily
3299712|NCT01829334|Active Comparator|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
3299713|NCT01829334|Experimental|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
3299714|NCT01829334|Experimental|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
3299715|NCT01829334|Experimental|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
3299716|NCT01829373|Experimental|Vaccine plus oral beta glucan|Vaccine plus oral beta glucan
3299717|NCT01829412|Experimental|DW- MRI|"The patients will perform the DW-MRI, WB-MRI and MRI of the spine in the same session with the following timing:~Patients at first-line treatment for MM:~Within 15 days before the start of the treatment~Within one month after the end of the first-line treatment~Six (6) months after the end of the first-line treatment~Patients at relapse after disease response (CR or PR) lasting at least 6 months~At relapse~Within 15 days after the end of the treatment of relapse~Six (6) months after the end of the treatment of relapse Each DW-MRI, WB-MRI, MRI of the spine and skeletal X-Ray will be independently read and interpreted by two radiologists with proven experience in MM. ."
3299718|NCT01829438|No Intervention|Without music|6MWT without music
3299719|NCT01829438|Experimental|With fast music|6MWT with a fast music
3299720|NCT01829438|Experimental|With slow music|6MWT with a slow music
3299721|NCT01829438|Experimental|With preferred music|6MWT with the preferred music of the child
3299722|NCT01829451|Experimental|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
3299723|NCT01829451|Placebo Comparator|No hyaluronic acid gel|An empty Pipelle device is taken into the uterus after endometrial ablation as an placebo procedure
3299724|NCT01829490|Experimental|Starter Group|The first six volunteers will receive one dose of 5x10^9vp of ChAdOx1 85A intramuscular injection.
3299725|NCT01829490|Experimental|Group A|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A intramuscular injection.
3299726|NCT01829490|Experimental|Group B|12 subjects will receive one dose of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection 56 days later.
3299727|NCT01829490|Experimental|Group C|12 subjects will receive two doses of 2.5x10^10vp of ChAdOx1 85A by intramuscular injection at day 0 and day 28, followed by a boost dose of 1x10^8pfu of MVA85A by intramuscular injection at day 119.
3299728|NCT01829529|Experimental|Amoxicillin|All subjects receive one dose of 2 g Amoxicillin
3299729|NCT01829542|Active Comparator|319 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3299730|NCT01829542|Active Comparator|639 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3299731|NCT01829542|Active Comparator|766 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3299732|NCT01829542|Active Comparator|1466 mg blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3299733|NCT01829542|Active Comparator|1791 mg total blueberry polyphenols|Freeze-dried blueberry powder dissolved in water
3299734|NCT01829542|Placebo Comparator|O mg blueberry polyphenols|Macro- and micronutrient matched control drink
3299735|NCT01829555|Experimental|contingency management|The intervention will provide escalating financial reinforcement for self-monitored blood glucose testing.
3299737|NCT01829581||oral anticoagulation associated intracerebral hemorrhage|
3299738|NCT01829594|Experimental|Case Management|
3299739|NCT01829607|Active Comparator|Functional electrical stimulation|Functional electrical stimulation of lower limbs
3299740|NCT01829607|Placebo Comparator|Placebo|
3299741|NCT01829620|Active Comparator|Treatment as Usual (TAU)|The Treatment as Usual (TAU) control group will reflect current clinical practices for treating suicidal Soldiers and Marines.
3299742|NCT01829620|Experimental|Continuing Contacts via Text (CCVT)+TAU|The intervention group will receive Continuing Contacts via Text (CCVT) in addition to Treatment as Usual (TAU).
3299743|NCT01829633||Rotator cuff tears|Patients who were diagnosed with a symptomatic full-thickness tear of the rotator cuff. Tear examination by sonography and MRI showed a repairable tear. All patients were initially treated conservatively by physiotherapy.
3299744|NCT01829659||AA Ticagrelor|African Americans who present with acute coronary syndrome (ACS) to the cath lab, and receive ticagrelor during their hospital stay.
3299745|NCT01829672|Experimental|Other: pulmonary vascular disease|Dual-energy computed tomography investigation
3299746|NCT01829685|Active Comparator|Group I|oral entecavir 1mg daily and adefovir 10mg daily for 144 weeks
3299747|NCT01829685|Active Comparator|Group II|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks
3299748|NCT01829698|Experimental|tauroursodeoxycholic|tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
3299749|NCT01829698|Active Comparator|ursodeoxycholic|control arm: ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
3299750|NCT01829711|Experimental|Moxetumomab pasudotox 40 µg/kg|Patients will receive Moxetumomab Pasudotox intravenously (IV) over 30 minutes on days 1, 3, 5 of each 28 day cycle for a maximum of 6 cycles or until disease progression, unacceptable toxivity, initiation of alternate therapy or documented CR.
3299755|NCT01829763|Experimental|botox|
3299756|NCT01829776|Experimental|education|Educational intervention
3299757|NCT01829789|Experimental|G-CRT|Group Community Reinforcement Training for parents
3299758|NCT01829789|Active Comparator|I-CRT|Individual Community Reinforcement Training for parents
3299759|NCT01829802|Experimental|RAL+ATA/r|Raltegravir 400 mg BID plus Ritonavir Boosted Atazanavir 300/100 mg QD
3299760|NCT01829802|Active Comparator|TDF/FTC (or 3TC) +ATA/r|TDF/FTC (or 3TC)- Fixed dose combination of Tenofovir 300 mg plus Emtricitabine 200 mg (or Lamivudine 300 mg) QD plus Ritonavir Boosted Atazanavir 300/100 mg QD
3299761|NCT01829815|Experimental|"Parents Make the Difference"|Caregivers are enrolled in the 10-session Parents Make the Difference intervention.
3299762|NCT01829815|Other|Waitlist Control|Caregivers assigned to the control group received the 10-session Parents Make the Difference intervention after the study was completed.
3299763|NCT01829828||Inpatients with cancer pain|Inpatients admitted for cancer pain management
3299764|NCT01829841|Experimental|Famitinib|Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3299765|NCT01829841|Active Comparator|Sunitinib|Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3299766|NCT01829867|Experimental|sNN0031|
3380246|NCT04886518|Placebo Comparator|Placebo|"Double-Blind Treatment Phase:~Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets"
3380247|NCT04886284|Experimental|Ertapenem|Ertapenem 1g IV daily infused over 2 hours x 5 days
3380248|NCT04886284|Placebo Comparator|Placebo|Saline placebo infused daily over 2 hours x 5 days
3380249|NCT04884815|Experimental|Stage 1: UX701 Dose Level 1|Participants randomized to receive a single, peripheral intravenous (IV) infusion of UX701 at dose level 1 plus prophylactic oral corticosteroids.
3299767|NCT01829880||Chronic heart failure patients|Patients with chronic heart failure who attend to internal medicine outpatient clinic.
3299768|NCT01829893|Active Comparator|Reference arm|Treated with Reference (in combination of 0.2mg tamsulosin and 5mg finasteride) Intervetion: In combination of 0.2mg finasteride and 5mg tamsulosin simultaneously
3299769|NCT01829893|Experimental|Test arm|Treated with Test formulation (single pill combination of 0.2mg finasteride and 5mg tamsulosin) Intervention : GL2701 capsule
3380250|NCT04884815|Placebo Comparator|Stage 1: Placebo for Dose Level 1|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
3380251|NCT04884815|Experimental|Stage 1: UX701 Dose Level 2|Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 2 plus prophylactic oral corticosteroids.
3380252|NCT04884815|Placebo Comparator|Stage 1: Placebo Dose Level 2|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
3380253|NCT04884815|Experimental|Stage 1: UX701 Dose Level 3|Participants randomized to receive a single, peripheral IV infusion of UX701 at dose level 3 plus prophylactic oral corticosteroids.
3380254|NCT04884815|Placebo Comparator|Stage 1: Placebo Dose Level 3|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
3380255|NCT04884815|Experimental|Stage 2: UX701|Participants randomized to receive a single, peripheral IV infusion of UX701 at a dose selected in Stage 1 plus prophylactic oral corticosteroids.
3380256|NCT04884815|Placebo Comparator|Stage 2: Placebo|Participants randomized to receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
3380257|NCT04884815|Experimental|Stage 3: UX701|Participants originally randomized in Stage 1 or Stage 2 to placebo will be eligible for a single, peripheral IV infusion of UX701 at the selected dose plus prophylactic oral corticosteroids.
3299770|NCT01829906|Experimental|Outpatient group|Multidisciplinary outpatient programme including both individual and group-based therapy. During the first visit, every patient will have an individual consultation with the dietician, physiotherapist and psychiatric nurse. After this, the patients will be followed up in groups every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
3299771|NCT01829906|Experimental|Inpatient group|"Inpatient lifestyle programme offered at a rehabilitation center consisting of a continuous care weight loss program, with three intermittent stays (each with three-week duration) over a one year period."
3299772|NCT01829932|Active Comparator|High Factor Diet|Patients will be on a factor altered diet to see effects on their lactulose breath test and symptoms.
3299773|NCT01829932|Active Comparator|Low Factor Diet|Patients will be on a factor altered diet to assess its effects on symptoms and lactulose breath test.
3380258|NCT04884815|Placebo Comparator|Stage 3: Placebo|Participants originally randomized in Stage 2 to UX701 will receive a single, peripheral IV infusion of matching placebo plus placebo oral corticosteroids.
3380259|NCT04881630|Active Comparator|Standard Care (SC)|Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.
3380260|NCT04881630|Experimental|Contingency Management (CM)|CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.
3380261|NCT04879862|Experimental|Locomotion|Participants will receive 160 locomotor training sessions with epidural stimulation. These sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
3380262|NCT04879862|Experimental|Bladder+Locomotion|Participants will receive 80 sessions of bladder training alone followed by 80 sessions of locomotor training sessions with epidural stimulation. They will be asked to continue with your bladder training once you start locomotor training. Locomotor Training sessions may occur once a day (stand and step will alternate days) or twice a day (stand and step on the same day) as recommended by the study physician. Participants will train 5 days per week and each session will last between 1 to 1.5 hours.
3380265|NCT04877730|Experimental|FCL (Fully Closed Loop)|Closed-loop control without meal anticipation module without meal bolus
3380266|NCT04877730|Experimental|FCL+ (Fully Closed Loop with meal anticipation)|Closed-loop control with meal anticipation module without meal bolus
3380267|NCT04877730|Experimental|HCL (Hybrid Closed Loop)|Closed-loop control without meal anticipation module with meal bolus
3380268|NCT04875429|Experimental|Aortic abdominal aneurysm|
3380269|NCT04874636|Experimental|LY3556050|LY3556050 administered orally
3380270|NCT04874636|Placebo Comparator|Placebo|Placebo administered orally
3380271|NCT04869943|Experimental|Enobosarm Treatment Group|Subjects in the Enobosarm Treatment Group will receive enobosarm 9mg each day by mouth until disease progression or an unacceptable adverse event is observed. The total duration of the study for a subject in the study from screening to follow-up visit is not standardized and will be different for each subject.
3380272|NCT04869943|Active Comparator|Control Treatment Group|Subjects in the Control Treatment Group will receive a ER targeted therapy limited to exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM) approved for the treatment of breast cancer and is part of the standard of care at the clinical study site. The decision of which comparator treatment will be used will be made prior to randomization
3380273|NCT04869488|Experimental|Fluzoparib|
3299774|NCT01829958|Experimental|Pre-Phase Arm|They will be treated with a single dose of rituximab 375mg/m2, once, by intravenous infusion 3-10 days prior to initiation of planned R-CHOP-like chemoimmunotherapy, and prednisone 50mg to 100 mg (preferred dose is 100mg) PO daily for 5-7 days (preferred duration is 7 days) of the 14 days prior to initiation of planned R-CHOP, R-EPOCH or R-CEPP chemoimmunotherapy. Pre-phase therapy may be given in either the inpatient or outpatient setting. After completion of a single course of pre-phase rituximab and prednisone as described above, further treatment will be according to the choice of the attending physician, in accordance with appropriate medical practice. It is expected, based on the inclusion criteria, that patients enrolled on the pre-phase arm will most often receive initial therapy consisting of R-CHOP, R-EPOCH or RCEPP chemoimmunotherapy for ≥ 2 cycles, but alternative therapies as deemed appropriate by the treating physician will not be considered violations of this protocol.
3299775|NCT01829958|Experimental|Geriatric Assessment (GA) only arm|Patients enrolled on the GA only arm of the study will be treated according to the choice of the attending physician. This arm of the study is non-therapeutic.
3299776|NCT01829971|Experimental|MRX34|Single agent MRX34
3299777|NCT01829984||control injection teaching|The first 25 subjects recruited into the study will be that control group. Subjects accrued during the control phase will receive the control injection teaching, which at MSKCC is verbal instruction. To minimize practice variation, the teaching will be provided by the office-practice nurse guided by a verbal script. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
3299778|NCT01829984||intervention group|The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
3299779|NCT01830010|Experimental|Study Part 1: KRP203|All patients to receive KRP203 for 111days
3299780|NCT01830010|Experimental|Study Part 2: lower KRP203 dose|in this treatment arm patients will receive the lower KRP203 dose for 111 days on top of the standard treatment with cyclosporine A and methotrexte for GVHD prophylaxis
3299781|NCT01830010|Experimental|Study Part 2: higher KRP203 dose|in this treatment arm patients will recieve the higher KRP203 dose for 111 days on top of standard treatment with tacrolimus and methotrexate for GVHD prophylaxis
3299782|NCT01830023||cardiac ultrasound examination|
3299783|NCT01830036||Quality of Life (SF12), 2-channel Polygraphy|cardiological treatment
3299784|NCT01830049||Group I|Older males with ED
3299785|NCT01830049||Group II|Older males with normal erectile function
3299786|NCT01830049||Gourp III|Young males with normal rectile function
3299787|NCT01830062|Experimental|CACS and NIRS|All patients will undergo NIRS to at least 2 major epicardial vessels as a research related intervention. Patients will be considered to be enrolled in the trial upon completion NIRS evaluation. Patients who had a clinically indicated CT with CACS evaluation within 3 months prior to the cardiac catheterization with NIRS evaluation will not have any other research related interventions. Patients who have not had a clinically indicated CT with CACS within 3 months prior to the cardiac catheterization with NIRS evaluation will have the CACS after NIRS imaging prior to discharge from the hospital.
3299788|NCT01830075|No Intervention|Control group|The control group receives care as usual.
3299789|NCT01830075|Experimental|Consultations|An intervention of two consultations with a spiritual counselor supported by an e-application.
3299790|NCT01830088|Experimental|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
3299791|NCT01830088|Active Comparator|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
3299792|NCT01830101|Experimental|TMZ plus concurrent re-irradiation|TMZ plus concurrent re-irradiation
3299793|NCT01830101|Experimental|TMZ alone|TMZ alone
3299794|NCT01830114|Experimental|Web app evaluation group|
3299795|NCT01830153|Experimental|RAD001|RAD001 was given as 10 mg orally once daily, and one cycle was defined as 28 days.
3299796|NCT01830166|Experimental|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
3299797|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
3299798|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
3299799|NCT01830218||Obstetric anesthesia and analgesia|Women in labor undergoing anesthesia care
3299800|NCT01830231|Experimental|Cabazitaxel|Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
3299801|NCT01830231|Active Comparator|Vinflunine|"• Vinflunine will be given intravenously once every 21 days, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation~280 mg/m2 in patients aged >75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
3299802|NCT01830244|Experimental|Nab-Paclitaxel 125mg/m2|"Epirubicin 90 mg/m2 and cyclophosphamide 600mg/m2 IV every 3 weeks for 4 cycles.~Nab paclitaxel 125mg/m2 IV days 1, 8 and 15 for 12 weeks In case of HER2 positive tumour patients will receive trastuzumab in combination with nab-Paclitaxel"
3299803|NCT01830257|Experimental|sending message|The investigators would send the tip to the children's guardian
3299804|NCT01830270|Experimental|PET regimen|
3299805|NCT01830283|Active Comparator|1 dose varicella vaccine|The providers would get the 2nd dose since they had one dose varicella vaccine
3299806|NCT01830283|Experimental|2 dose varicella vaccine|The provider never get the varicella vaccine
3299807|NCT01830296|Active Comparator|Remifentanil+Morphine|Morphine(M) Remifentanil+Morphine(MR)
3299808|NCT01830296|Active Comparator|IV morphine PCA|IV remifentanil+morphine PCA
3299809|NCT01830309|Experimental|Sequence 1|Drug: CJ-12420 200mg Period1: CJ-12420 under fed condition Period2: CJ-12420 under fasting condition
3299810|NCT01830309|Experimental|Sequence 2|Drug: CJ-12420 200mg Period1: CJ-12420 under fasting condition Period2: CJ-12420 under fed condition
3299811|NCT01830322|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
3299812|NCT01830322|Active Comparator|Any non-gemcitabine chemotherapies or best supportive care|This arm is for patients that have failed, or are not eligible for, all available therapies INCLUDING gemcitabine-based therapies. This arm includes any best-practice standard-of-care chemotherapies deemed appropriate by the clinical investigators, including the option for supportive care, following good clinical practice.
3299813|NCT01830322|Experimental|Gemcitabine + CPI-613 in combination|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. When gemcitabine and CPI-613 are administered in combination, gemcitabine will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. CPI-613 will be infused twice a week, administered on Days 1 and 4 for 3 consecutive weeks, followed by a week-of-rest, the same as gemcitabine. The dose of CPI-613 will be 710 mg/m2 infused IV over 2-hours (this is approximate maximum tolerated dosing [MTD] found from Phase I studies in combination with gemcitabine). To note, the dose of CPI-613 may be increased from 710 mg/m2 if ongoing Phase I trial data shows that the MTD of CPI-613 is higher than 710 mg/m2 CPI-613, diluted with D5W.
3299814|NCT01830322|Experimental|Gemcitabine alone or in combination with therapeutic agent(s)|This arm is for patients who have failed, or are not eligible for, all available therapies EXCEPT gemcitabine-based therapies. Gemcitabine, or Gemcitabine-based, chemotherapy will be administered via 30-minute intravenous (IV) infusion at a concentration of 1,000 mg/m2 once-a-week on Day 1 for 3 consecutive weeks, followed by a week-of-rest. This arm includes any best-practice standard-of-care Gemcitabine-based chemotherapies deemed appropriate by the clinical investigators following good clinical practice.
3299815|NCT01830335|Experimental|Drug|Indomethacin 1.2 mg kg 1 dose
3299816|NCT01830335|Placebo Comparator|Placebo|flour capsule
3299817|NCT01830348|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
3299818|NCT01830348|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
3299819|NCT01830361|Experimental|midostaurin (PKC412), capsules|midostaurin 50 mg (two 25 mg capsules) is given in combination with the second of two induction cycles and in combination with three cycles of high-dose cytarabine (HiDAC) consolidation chemotherapies and maintenance treatment in patients with c-kit or FLT3-ITD positive t(8;21) AML in an open-label one-arm design. The first cycle of induction is not part of the study.
3299820|NCT01830374||Women with bulimia nervosa|This is not a treatment study. All participants will go through the same steps.
3299821|NCT01830387||Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump. All subjects enrolled in the study will have their medical chart reviewed from consent to 30 days post operatively.
3299822|NCT01830387||Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy during a one year time span by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
3299823|NCT01830400||Eslicarbazepine Acetate tablets|
3299824|NCT01830413||Stenting|cerebral artery stenting for systematic Intracranial artery stenosis
3299825|NCT01830439|Experimental|Fed PA-824 200mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3299826|NCT01830439|Experimental|Fasted PA-824 200 mg|200 mg PA-824 (4 x 50 mg tablets) in Phase A was administered 30 minutes after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3299827|NCT01830439|Experimental|Fed PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered 30 minutes after the start of a high-calorie, high-fat breakfast provided after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3299828|NCT01830439|Experimental|Fasted PA-824 50mg|50 mg PA-824 (1 x 50 mg tablets) in Phase B was administered after a minimum 10-hour overnight fast and was administered with 240 mL tap water.
3299829|NCT01830452|Experimental|Parietex Progrip mesh|Ventral hernioplasty using a (self gripping / self adhering / self fixating) Progrip mesh not needing fixation devices
3299830|NCT01830452|Active Comparator|Parietex Mesh|Ventral hernioplasty using a polyester mesh fixed with non absorbable sutures as described by Lichtenstein/Amid
3299831|NCT01830465|Experimental|Bortezomib + Rituximab|Single arm. Patients will be treated with Bortezomib, 1,3 mg/m2 intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of 21 day cycle for 6 cycles and Rituximab 375 mg/m2 intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
3299832|NCT01830478|Experimental|Lenalidomide and Rituximab|Lenalidomide 20 mg once daily on days 1-21 of 28 days cycle for up to 6 courses and Rituximab 375 mg/m2 at day 14 of every course.
3299833|NCT01830491|Experimental|Clopidogrel napadisilate|aspirin 100mg
3299834|NCT01830491|Active Comparator|clopidogrel bisulfate|aspirin 100mg
3299835|NCT01830504|Experimental|NVP-BKM120 (BKM120) PI3K inhibitor|
3299836|NCT01830517|Experimental|amlodipine camsylate|amlodipine camsylate 5mg
3380274|NCT04869488|Active Comparator|Enzalutamide OR abiraterone acetate With Prednisone Acetate Tablets|
3299837|NCT01830517|Active Comparator|losartan potassium|losartan potassium 50mg
3299838|NCT01830530|Experimental|Telmisartan/nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
3299839|NCT01830530|Placebo Comparator|Placebo|Two tablets containing placebo daily in the morning
3299840|NCT01830556|Active Comparator|Arm A: cetuximab with 5FU and carboplatin or cisplatin|Arm A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h maintenance treatment thereafter with cetuximab 500 mg/m2 every second week until PD or toxicity
3299841|NCT01830556|Experimental|Arm B: cetuximab paclitaxel and carboplatin|Arm B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter maintenance treatment day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
3299842|NCT01830569|Experimental|EBMeDS group|The regular Evidence Linker and the EBMeDS system will be available in this group.
3299843|NCT01830569|Other|Control group|The regular Evidence Linker will be available in this group.
3299844|NCT01830582|Experimental|1 A|The patients will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 24 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3299845|NCT01830582|Experimental|1 B|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 48 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the third week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3299846|NCT01830582|Experimental|1 C|The patient will undergo the standard pre chemoradiation MRI scan, followed by a repeat research scan 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3299847|NCT01830582|Experimental|2|The last patient patients that will undergo a standard pre-chemoradiation MRI scan, followed by a repeat research scan either 24, 48 or 72 hours (+/- 6 hours) after their first radiation treatment. Then they will get another research MRI scan during the second, third or fourth week (+/- 5 days) of radiation. Finally they will get a standard post chemoradiation MRI scan prior to surgery.
3299848|NCT01830608||300 patients with AMD|
3299849|NCT01830634|Experimental|Theraband with strengthening and stretching exercise|All subjects were received theraband exercises (strengthening and stretching), and then compare the measured outcomes between groups.
3299850|NCT01830647||Cohort|
3299851|NCT01830660|Experimental|hetrombopag|hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily
3299852|NCT01830660|Placebo Comparator|placebo|Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.
3299853|NCT01830673||under SIT|patients completed second or third year of SIT. We include the patients directly after last SIT vaccination.
3299854|NCT01830673||after SIT|Patients completed three years of SIT for at least three years. We included them as a follow up.
3299855|NCT01830673||no SIT|These patients were determined randomly. They have a clinically relevant grass pollen allergy. They never had a SIT.
3299856|NCT01830686|Experimental|Sugarcane bagasse|10 subjects will consume food (brownies and cookies) made with 13 g of sugarcane bagasse everyday for 4 weeks
3299857|NCT01830686|Active Comparator|Non-caloric, non-fermentable fiber|10 subjects will consume food (brownies and cookies) made with 13 g of non caloric, non-fermentable fiber everyday for 4 weeks
3299858|NCT01830686|Placebo Comparator|Minimal fiber|10 subjects will consume food (brownies and cookies) made with 4 g of dietary fiber everyday for 4 weeks
3299859|NCT01830712||Chart review|
3299860|NCT01830725||Gout/Hyperuricemia|Subjects with a diagnosis of hyperuricemia (defined as a uric acid of > 7.2 mg/dl) and/or gout.
3299861|NCT01830725||Control|Approximate age and gender matched controls without hyperuricemia or gout
3299862|NCT01830738|Experimental|Peri-umbilical single-port|"Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.~Intervention: Single-port, peri-umbilical hysterectomy"
3299863|NCT01830738|Active Comparator|Multi-port|"Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.~Intervention: Multi-port hysterectomy"
3299864|NCT01830751|Experimental|Limit trunk flexion upon rising|Immediately upon rising particpants perform the Restrained Sitting Treatment intervention for one hour.
3299865|NCT01830751|Sham Comparator|Limit trunk flexion before going to bed|Immediately prior to going to bed, particpants perform the Restrained Sitting Treatment intervention for one hour.
3299866|NCT01830764|Other|Red light dose (PDT) 75 J/cm2|Subjects in Cohort 1 will receive active and vehicle solution followed by a red light dose of 75 J/cm2 at 25 mW/cm2
3299867|NCT01830764|Other|Red Light (PDT) 150 J/cm2|Subjects in Cohort 2 will receive active and vehicle solution followed by a red light dose of 150 J/cm2 at 40 mW/cm2
3299868|NCT01830777|Experimental|Experimental Arm|Brentuximab Vedotin + MEC
3299869|NCT01830803||HowRU/HowRwe|All participants will fill out the HowRwe and HowRU questionnaires. Although this questionnaire may be considered an intervention, it is not the goal of this study to investigate the questionnaires as an intervention but to investigate whether they are reliable questionnaires.
3299870|NCT01830829|Experimental|Jaylyn|Jalyn: dutasteride 0.5 mg/day and tamsulosin 0.4 mg/day combination tablet
3299871|NCT01830829|Placebo Comparator|Placebo|Placebo
3299872|NCT01830868||Zonisamide tablets|
3299873|NCT01830894|Experimental|spontaneous ICH bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
3299874|NCT01830894|Experimental|chronic sub dural bleeding|An initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
3380275|NCT04869488|Experimental|Fluzoparib Combined With Apatinib|
3380276|NCT04869488|Experimental|Fluzoparib Combined With Apatinib or Fluzoparib|
3380277|NCT04869189|Experimental|High Sphere-Game/Video/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively.
3380278|NCT04869189|Experimental|High Sphere-VA/Video/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
3380279|NCT04869189|Experimental|High Sphere-VA/Game/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
3299875|NCT01830894|Experimental|acute sub-dural bleeding|An initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
3299876|NCT01830907|Active Comparator|Enteral|Enteral nutrition composed of carbohydrates and vitamins
3380280|NCT04869189|Experimental|High Sphere-Game/VA/Video|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
3380281|NCT04869189|Experimental|High Sphere-Video/VA/Game|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
3380282|NCT04869189|Experimental|High Sphere-Video/Game/VA|Subjects in the high-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test). Subjects will also be randomized to a Humidity sequence (low/high or high/low) for visit 2 and 3 respectively
3380283|NCT04869189|Experimental|Low Sphere-Game/Video/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, video, or continuous VA test).
3380284|NCT04869189|Experimental|Low Sphere-VA/Video/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, video, or order permutation of game).
3380285|NCT04869189|Experimental|Low Sphere-VA/Game/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (continuous VA test, order permutation of game, or video).
3380286|NCT04869189|Experimental|Low Sphere-Game/VA/Video|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (order permutation of game, continuous VA test, or video).
3380287|NCT04869189|Experimental|Low Sphere-Video/VA/Game|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, continuous VA test, or order permutation of game).
3380288|NCT04869189|Experimental|Low Sphere-Video/Game/VA|Subjects in the low-sphere group will be randomly assigned to one of the 6 sequences (video, order permutation of game, or continuous VA test).
3380289|NCT04867785|Experimental|LY3437943 Maintenance Dose 1|LY3437943 administered by subcutaneous (SC) injection
3380290|NCT04867785|Experimental|LY3437943 Maintenance Dose 2|LY3437943 administered by SC injection
3380291|NCT04867785|Experimental|LY3437943 Maintenance Dose 3|LY3437943 administered by SC injection
3380292|NCT04867785|Experimental|LY3437943 Dose 4|LY3437943 administered by SC injection
3380293|NCT04867785|Active Comparator|Dulaglutide|Dulaglutide will be given SC
3380294|NCT04867785|Placebo Comparator|Placebo|Placebo will be given SC
3380297|NCT04861350|Experimental|motor imagery with action observation|The subjects will perform the exercises mentally for 3 sets with video, 10 reps for 1 set.
3380298|NCT04861350|Experimental|physical training|The subjects will perform the exercise physically for 3 sets with supervision of investigator, 10 reps for 1 set.
3299877|NCT01830907|Active Comparator|Parenteral|
3299878|NCT01830946|Experimental|Whey Protein and Exercise Training|This arm involves 4 weeks of consuming a whey protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3380299|NCT04861350|Experimental|combine physical training and motor imagery with action observation|The subjects will perform the exercise mentally with video for 1 set and physically with supervision of investigator for 2 sets, 3 sets totally, 10 reps for 1 set.
3299879|NCT01830946|Placebo Comparator|Carbohydrate and Exercise Training|This arm involves 4 weeks of consuming a carbohydrate placebo late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3380302|NCT04858009|Experimental|Treatment (HIPEC)|Patients undergo HIPEC with mitomycin and cisplatin over 60 minutes in the absence of disease progression or unacceptable toxicity. Patients may undergo additional HIPEC with mitomycin and cisplatin up to 5 times.
3380303|NCT04857411|Experimental|Participant 'Buddies'|Participants will have an 8-week program initiation phase followed by a maintenance phase through 6-months, supported by Ambassadors.
3380304|NCT04856982|No Intervention|Part A: Natural History Run-in|Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.
3299880|NCT01830946|Experimental|Casein Protein and Exercise Training|This arm involves 4 weeks of consuming a casein protein supplement late in the evening before bed along with combined resistance and high-intensity interval training 3 days per week for 4 weeks (two days of resistance training and one day of high-intensity interval training).
3299881|NCT01830959|Experimental|Roflumilast|Roflumilast
3299882|NCT01830959|Placebo Comparator|Placebo|Placebo
3299883|NCT01830985|Experimental|Single Arm VX-509|
3299884|NCT01830998||control,MCI, Olfactory dsfunction|There are different groups:control,MCI, Olfactory dsfunction.
3299885|NCT01830998||control, MCI|control and MCI group.Glycaemic control
3299886|NCT01830998||control and MCI|treatment and without treatment
3299887|NCT01830998||MCI and Olfactory function|observation between MCI and Olfactory function groups.
3299888|NCT01831011|Experimental|mildronate|infusion of mildronate
3299889|NCT01831011|Active Comparator|cinepazide maleate|infusion of cinepazide maleate
3299890|NCT01831024|Experimental|Treatment Group|Dignicap System
3299891|NCT01831024|No Intervention|Control Group|Concurrent age and chemotherapy matched control
3299892|NCT01831037||Regression of fibrosis|Group conformed by patients experiencing improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
3299893|NCT01831037||No regression of fibrosis|Group conformed by patients not showing the predefined improvement in the noninvasive markers of fibrosis, Fibrotest/Fibrosure and transient elastography, while enrolled in the study.
3299894|NCT01831050|Experimental|G1: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3299895|NCT01831050|Experimental|G2: Sanofi bOPV Control|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3299896|NCT01831050|Experimental|G3: Trivalent OPV Control|100 infants receiving Trivalent Oral Polio Vaccine (tOPV)' at 6, 10 and 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3299897|NCT01831050|Experimental|G4: Sanofi bOPV, Sanofi IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3299898|NCT01831050|Experimental|G5: Sanofi bOPV, Sanofi 2 IPV|210 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 dose of Sanofi-Pasteur IPV (Sanofi IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3299899|NCT01831050|Experimental|G6: Sanofi bOPV, GSK IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Glaxo SmithKline IPV (GSK IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3299900|NCT01831050|Experimental|G7: Sanofi bOPV, GSK 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Glaxo SmithKline IPV (GSK IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3299901|NCT01831050|Experimental|G8: Sanofi bOPV, SII IPV|50 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 1 dose of Serum Institute of India IPV (SII IPV) at 14 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 18 weeks
3299902|NCT01831050|Experimental|G9: Sanofi bOPV, SII 2 IPV|190 infants receiving Bivalent Oral Polio Vaccine (bOPV) at 6, 10 and 14 weeks and 2 doses of Serum Institute of India IPV (SII IPV) at 14 and 36 weeks with Monovalent Oral Polio Vaccine Type 2 (mOPV2) challenge at 40 weeks
3299903|NCT01831063|No Intervention|1|This group received the traditional seizure teaching. This consisted of verbal instruction from health care professionals on acute seizure management and administration of the rescue medication.
3299904|NCT01831063|Experimental|2|This group received the traditional seizure teaching as well as the supplemental simulation based seizure management teaching. The simulation based seizure teaching consisted of numerous opportunities to manage a simulated seizure with instructor guidance and feedback. This session was deemed complete when caregivers verbalized confidence with seizure management.
3299905|NCT01831102||non-Latino white|no Latino ancestry, Caucasian
3299906|NCT01831102||Mexican American|Mexican American ancestry
3299907|NCT01831128||ASV Treatment|AutoSet CS, PaceWave
3299908|NCT01831128||Control|No ASV treatment
3299909|NCT01831167|Experimental|dynamic light|dynamic light
3299910|NCT01831167|No Intervention|reference|normal light
3299911|NCT01831180||Premenopausal women 19-25 yrs|
3299912|NCT01831180||Postmenopausal 60 yrs +|
3299913|NCT01831193|Active Comparator|Diabetic|
3299914|NCT01831193|Active Comparator|Non-diabetic|
3299915|NCT01831206|Experimental|Collagen cross-linking|Collagen cross-linking with standard treatment
3299916|NCT01831206|No Intervention|standard treatment|Standard treatment alone
3299917|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
3299918|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
3299919|NCT01831284||heroin injecting drug users|Sigmoidoscopy with biopsy, in medically stable active injecting drug users
3299920|NCT01831284||healthy controls|Sigmoidoscopy with biopsy, in non-injecting controls-
3299921|NCT01831284||Former heroin injection drug users|Sigmoidoscopy with biopsy, in former injectors of heroin with or without other agents
3299922|NCT01831297||syncope|
3299923|NCT01831310|Active Comparator|Control (standard) (Kabiven)|an isocaloric and iso-nitrogenous standard parenteral nutrition (Kabiven)
3299924|NCT01831310|Experimental|Standard parenteral-glutamine (S-D)|alanine-glutamine (aln-gln) (Dipeptiven) supplemented parenteral nutrition (S-D group, n=8),
3299925|NCT01831310|Experimental|Standard-Omega-3 fatty acid (S-O)|Omega-3 fatty acid (Omegaven) supplemented parenteral nutrition (S-O group, n=8)
3299926|NCT01831310|Experimental|Standard-glutamine-omega 3 (S-D-O)|ala-gln and omega 3 fatty ascid supplemented parenteral nutrition (S-D-O group, n=10).
3299927|NCT01831323||mesalazine|10 female patients with first diagnosis of SUDD will take mesalazine 1,6g per day for 14 days (1 tablet 800mg twice daily)
3299928|NCT01831323||VSL#3|10 female patients with first diagnosis of SUDD will take VSL#3 2 sachets a day for 14 days (1 sachet twice a day, for a total of 900 billion bacteria per day)
3299929|NCT01831323||Rifaximin|10 female patients with first diagnosis of SUDD will take 800mg/day of rifaximin (2 tablets of 200mg twice a day)
3299930|NCT01831323||fiber|10 female patients with first diagnosis of SUDD will take fibers for 14 days (psyllium 10grams per day)
3299931|NCT01831336||Orsiro DES|
3299932|NCT01831362|Experimental|Focused Attention (FA)|This 8 week program consists solely of focused attention practices, i.e. selected attention to an object (breath etc) and deselection of other stimuli
3299933|NCT01831362|Experimental|Open-Monitoring (OM)|This 8-week program consists solely of open monitoring practices, or noticing and/or labeling the contents of ongoing experience ( thoughts, body sensations, emotions, seeing, hearing etc) without focusing on or deselecting any stimuli
3299934|NCT01831362|Experimental|Mindfulness-Based Cognitive Therapy (MBCT)|The 8 week MBCT program follows the 2nd Edition (2012) manual (Segal, Williams, Teasdale) and includes both focused attention and open- monitoring practices
3299935|NCT01831375|Experimental|Speak Up|Participants will learn how to speak up to their medical doctors for improving their medical care.
3299936|NCT01831375|Other|Get Connected|Attention control group
3299937|NCT01831388|Experimental|The breath training program|Approximately 30-minutes of group instruction session on breathing techniques delivered at a Main Campus outpatient clinic, followed by approximately 15 minutes twice daily home practice for six weeks with weekly telephone coaching. The intervention will conclude at about week 6. Patients will be encouraged to continue the practice, but there will be no further phone calls to remind patients or to confirm their continuing practice.
3299938|NCT01831401|Experimental|0° Head Down (horizontal) & Standard Introducer.|Operating table position 0° head down (horizontal) & standard straight acetabular component introducer without alignment guide.
3299939|NCT01831401|Experimental|0° Head Down (horizontal) & Modified 35° Introducer.|Operating table position 0°head down (horizontal) & modified 35° acetabular component introducer.
3299940|NCT01831401|Experimental|0°Head Down (horizontal) & Inclinometer-assisted Introducer.|Operating table position 0°head down (horizontal) & standard straight acetabular component introducer without alignment guide.
3299941|NCT01831401|Experimental|7° Head Down & Standard Introducer.|Operating table position 7° head down & standard straight acetabular component introducer without alignment guide.
3299942|NCT01831401|Experimental|7° Head Down & Modified 35° Introducer.|Operating table position 7° head down & modified 35° acetabular component introducer.
3299943|NCT01831401|Experimental|7° Head Down & Inclinometer-assisted Introducer.|Operating table position 7° head down & inclinometer-assisted acetabular component introducer.
3299944|NCT01831401|Experimental|Y° Head Down & Standard Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & standard straight acetabular component introducer without alignment guide.
3299945|NCT01831401|Experimental|Y° Head Down & Modified 35° Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & modified 35°acetabular component introducer.
3299946|NCT01831401|Experimental|Y° Head Down & Inclinometer-assisted Introducer.|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines) & inclinometer-assisted acetabular component introducer.
3299947|NCT01831414|Experimental|Water immersion at cervical level|Lung function of spinal cord injury patients will be studied with a water immersion at cervical level
3299948|NCT01831414|Experimental|Water immersion at xyphoid level|Lung volumes of spinal cord injury patients will be studied with a Water immersion at xyphoid level
3299949|NCT01831440|Other|medicine combined CBT|Besides clinical routine antidepressant treatment,participants receive CBT weekly for 8 weeks and monthly until the end of the study.
3299950|NCT01831440|Other|medicine (SSRI antidepressants)|clinical routine antidepressant treatment--Selective serotonin reuptake inhibitors（SSRIs）.
3299951|NCT01831453|Placebo Comparator|isopropylmyristate oil|placebo Soft gelatinous capsules filled with isopropylmyristate oil
3299952|NCT01831453|Active Comparator|experimental|omega-3 1 gram three times daily for 6 months
3299953|NCT01831479|Experimental|Rosuvastatin and Olmesartan|A multiple-dose administration of rosuvastatin, a multiple-dose administration of olmesartan, and a multiple-dose administration of rosuvastatin and olmesartan, given orally with a washout period of 8 days between each administrations
3299954|NCT01831492|Active Comparator|zeolite + dolomite|28 trained subjects receive encapsulated zeolite + dolomite
3299955|NCT01831492|Placebo Comparator|cellulose|28 trained subjects receive encapsulated micro-crystalline cellulose
3299956|NCT01831505|Experimental|Multiple drug microinjection|Multiple drug microinjection with locally injected rituximab, vincristine, doxorubicin, bendamustine, prednisolone, or a combination of them
3299957|NCT01831518|Experimental|CRT Eligible|ACC/AHA/HRS/ESC guidelines for device-based therapy
3299958|NCT01831531|Experimental|S-1|"Patients will receive chemoradiation with S-1.~Interventions:~Drug: S-1 Radiation: Radiation therapy"
3299959|NCT01831557||Childrens' Milk Intake|The milk intake of children will be reconciled with body measurement index and blood samples will be taken for gene sequencing
3299960|NCT01831583|Experimental|Measurement of PPG waveforms|Collection of photoplethysmograph(PPG)waveform data from patients with obstructive sleep apnea for 4-8 hours
3299961|NCT01831583|Experimental|Measurement of Pulse Arrival Time (PAT)|Collection of PAT waveform data from patients with obstructive sleep apnea for 4-8 hours
3299962|NCT01831622|Experimental|Behavioral|"Cognitive testing of participants. Asterisk applies for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before computer-testing.*~Case Report Form (CRF), ASRS and Wechsler Adult Intelligence Scale (WAIS) subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*~Day 2:~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention (opposite of Day 1), and wait 60 minutes before computer-testing.*~CRF 3, ASRS and Edinburgh Handedness Inventory (EHI).~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
3299963|NCT01831622|Experimental|fMRI-arm|"Asterisk applies only for patient group.~Day 1:~Patient arrives having abstained medication for minimum 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before MRI testing.*~CRF 2, Adult ASRS and WAIS subtests.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment to ensure the patients have not been withheld from medication for too long while keeping blind.*~Day 2 (after 14 - 40 days):~Patient arrives having abstained medication for a minimum of 20 hours.*~Administer either Ritalin or placebo intervention, and wait 60 minutes before testing (opposite of Day 1).*~CRF 3, ASRS and EHI.~Blood sample, if consented.*~Computerized testing.~Administer opposite treatment.*"
3299964|NCT01831635||Myeloproliferative neoplasm case|"Patients with Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) will be recruited based on the WHO diagnostic criteria.~Exclusion Criteria~younger than 18 years old.~where the clinician/General Practitioner (GP) does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate."
3299965|NCT01831635||General Practice Control|"For each MPN case one GP control will be randomly selected and frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender.~The following patient groups will be excluded. Those:~younger than 18 years old.~where the clinician/GP does not provide consent.~incapable of giving informed consent.~physically or cognitively incapable of completing the questionnaire.~too ill to participate. The WHO performance evaluation scale will be used at the stage of participant identification. Only those scoring 0-3 will be considered eligible for inclusion in the study. Those scoring 3 are described as Symptomatic >50% in bed but not bedbound."
3299966|NCT01831635||Non-blood relative or family control|Recruitment of 100 non-blood relative/friend controls will be undertaken by asking cases to pass on a flyer to up to 2 or 3 non-blood relatives/friends aged 18 years or older.
3299967|NCT01831648|Experimental|Volonteers|Blood sample
3299968|NCT01831661|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA
3299969|NCT01831661|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
3299970|NCT01831674|Experimental|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India
3299971|NCT01831674|Active Comparator|GLUCOPHAGE®XR|GLUCOPHAGE®XR tablet 750 mg of Bristol-Myers Squibb Company, USA
3299972|NCT01831687|Active Comparator|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA
3299973|NCT01831687|Experimental|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India
3299974|NCT01831700|Experimental|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India
3299975|NCT01831700|Active Comparator|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA
3299976|NCT01831713||CHF patients and Controls|CHF patients refer to Decompensated patients and Compensated patients
3299977|NCT01831739||Multi-organ|Non-acute presentation, any Scadding stage, evidence of 5 or more organ systems involved, chronic or uncertain clinical course.
3299978|NCT01831739||Non-acute, Stage I, untreated|Non-acute presentation, Scadding stage I, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3299979|NCT01831739||Stage II-III, treated|Non-acute presentation, Scadding stages II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treated for at least 3 months.
3299980|NCT01831739||Stage II-III, untreated|Non-acute presentation, Scadding stage II or III, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3299981|NCT01831739||Stage IV treated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, treatment current and for at least 3 months.
3299982|NCT01831739||Stage IV untreated|Non-acute presentation, Scadding stage IV, no multi-organ involvement, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3299983|NCT01831739||Acute Sarcoidosis, untreated|Acute presentation, Scadding stages I, II, or III, chronic or uncertain clinical course, no cardiac manifestations, untreated for at least 3 months.
3299984|NCT01831739||Remitting, untreated|Remitting clinical course, no treatment for at least 3 months.
3299985|NCT01831739||Cardiac defining therapy|Chronic or uncertain clinical course, no multi-organ involvement, cardiac manifestations defining need for systemic corticosteroid and/or immunomodulatory therapy.
3299986|NCT01831752||Type 1 Diabetes Melitus|Subjects aged 12 through 75, previously diagnosed with type 1 diabetes mellitus, currently using insulin to treat their diabetes.
3299987|NCT01831778||all women|women receiving mammography at one of 6 mammography registries across the country.
3299988|NCT01831830|No Intervention|control condition|The control group receives two attention-control calls.
3299989|NCT01831830|Experimental|The Veterans' in-home program|The VIP intervention consists of 8 sessions (up to 6 in the home and 2 phone calls) from an occupational therapist. This is delivered to Veterans and their family members.
3299990|NCT01831843|Placebo Comparator|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
3299991|NCT01831843|Experimental|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
3299992|NCT01831843|Experimental|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
3299993|NCT01831869|Active Comparator|L-thyroxine|Oral administration, starting dose 25 or 50 micrograms once daily.
3299994|NCT01831869|No Intervention|blank|no intervention
3299995|NCT01831882||Major Depressive Disorder|
3299996|NCT01831882||Healthy Control|
3299997|NCT01831895|Experimental|MobiusHD™|MobiusHD™
3299998|NCT01831908|Sham Comparator|Lifestyle counseling|These persons will be advised on their cardiovascular status and will receive information on how to improve it.
3299999|NCT01831908|No Intervention|People not seeking attention|Evaluation of cardiovascular health status will be performed in these persons as part of yearly door-to-door survey that will perform in Atahualpa up to the end of the study
3300000|NCT01831947|Experimental|Ranibizumab fixed dose|Injection of 0.5 mg Ranibizumab every 2 months for one year, following a monthly injection during the first 3 months.
3300001|NCT01831947|Experimental|Ranibizumab on demand|Injection of 0.5 mg Ranibizumab on demand for one year, following a monthly injection during the first 3 months.
3300002|NCT01831973|Experimental|Lipotecan, injection for chemotherapy|Patients receive TLC388 (50 mg/m2) given as a 30-minute IV infusion, on Days 1, 8, and 15 of a 28-day cycle.
3300003|NCT01831986|Experimental|Pregnenolone + L-Theanine|The 60 participating subjects will be randomized into 2 groups: 30 patients will receive PREG (50 mg/day) with L-theanine (400 mg/day) and 30 patients will receive a placebo, each for 8 weeks in a double-blind manner.
3300004|NCT01831986|Placebo Comparator|Sugar caps.|Placebo (4 caps/day)
3300005|NCT01831999|Experimental|RecoveryTrack - Extended Care (RT-E)|Counselors will conduct monitoring and feedback sessions using the RecoveryTrack-Extended Care (RT-E) web-based monitoring system for clients newly admitted to Intensive Outpatient (IOP) treatment. Counselors will be instructed to document their reminders, contact attempts, and scheduling of RT-E appointments within a Contact Log incorporated into RT-E. All RT-E sessions will be audio recorded.
3300006|NCT01831999|No Intervention|Treatment as Usual (TAU)|Counselors will conduct standard treatment during IOP/OP in this condition. Exceptions to this condition are that counselors will: audio record their first 3 biweekly and subsequent 7 monthly individual in-person sessions; document on a Contact Log outreach attempts; and complete a Counselor Activity Log for client participants. There are several steps that counselors typically take when a client misses a session. Clients are called to reschedule for the same week, if the client doesn't return for their next scheduled session, the counselor sends a letter asking the client to return, etc.
3300007|NCT01832012|Active Comparator|Video refresher|Group 3, received 7 minute video refresher prior to examination.
3300008|NCT01832012|Experimental|Video refresher and hands-on practice|Group 4, received same 7 minute video refresher, along with hands-on practice along with the video on a Laerdal BLS manikin.
3300009|NCT01832012|No Intervention|No intervention|Group 2
3300010|NCT01832025|Active Comparator|Internal|internal maxillary sinus floor elevation technique with simultaneous implant placement
3300011|NCT01832025|Active Comparator|External|external maxillary sinus floor elevation technique with simultaneous implant placement
3300012|NCT01832051|Experimental|HER2-PET|Injection of 89Zr-trastuzumab followed by PET scan
3300013|NCT01832064|Experimental|Mailed Chronic Disease Self-Management|Mailed Chronic Disease Self-Management Program: self management information and self assessment
3300014|NCT01832077||rural doctor|examine patient's fundus by 90D fundus pre-set lens
3300015|NCT01832077||grader|grade fundus pictures in ZOC
3300016|NCT01832103|Experimental|MK-7145|MK-7145 2 mg IR administered as a single oral dose.
3300017|NCT01832116|Experimental|Tracerinjection|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
3300018|NCT01832129|Active Comparator|i.m. injection of Vitamin B12|Weekly i.m. injections of 1 mg Cyanocobolamin after 1, 2, and 3 weeks.
3300019|NCT01832129|Experimental|Oral administration of vitamin B12|High dose (1 mg/day) oral Cyanocobolamin will be adminstrated with electronic adherence monitoring.
3300020|NCT01832168|Other|Control|Robotic Assisted Laparoscopic Prostatectomy with application of absorbable hemostat.
3300021|NCT01832168|Experimental|AmnioFix|Robotic Assisted Laparoscopic Prostatectomy with application of dehydrated human amniotic membrane.
3300022|NCT01832194|Experimental|Botox|"Botox:~A concentrated dose of Onabotulinum Toxin A of 100 units dissolved in 2 cc of 2% xylocaine for a one-time injection."
3300023|NCT01832207|Active Comparator|MTS|Motor threshold of stimulation
3300024|NCT01832207|Active Comparator|STS|Sensorial threshold of stimulation
3300025|NCT01832207|Sham Comparator|Placebo|
3300026|NCT01832220||PiZZ not on therapy|Individuals with the PiZZ genotype not on augmentation therapy.
3300027|NCT01832220||PiZZ on therapy|Individuals with the PiZZ genotype on augmentation therapy.
3300028|NCT01832220||PiMZ not on therapy|Individuals with the PiMZ genotype not on augmentation therapy.
3300029|NCT01832220||PiMM with COPD|Individuals with the PiMM genotype and COPD.
3300030|NCT01832233|Experimental|Renal Denervation|Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
3300031|NCT01832272|Experimental|Reinflation after early deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled (Reinflation after early tourniquet deflation).
3300032|NCT01832272|No Intervention|No reinflation after early deflation|The tourniquet is released after cement implant fixation, and remained deflated without reinflation, even after hemostasis.
3300033|NCT01832285|Experimental|Fluvoxamine|Tablets of Fluvoxamine in dosage 100mg/day will be added to the treatment regimen and continued for 6 weeks
3300034|NCT01832298|Experimental|Simmitecan Hydrochloride for Injection|Dissolving in 2ml water for injection, then transfering to 500 mL of 5% dextrose for i.v.90 minutes
3300035|NCT01832311|Experimental|senile cataract with NSAID|"15 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
3300036|NCT01832311|Experimental|diabetic cataract with NSAID|"17 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac."
3300037|NCT01832311|No Intervention|senile cataract without NSAID|"17 non-diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
3300038|NCT01832311|No Intervention|diabetic cataract without NSAID|"12 diabetic patients undergoing phacoemulsification combined with IOL implantation.~Subgroup not receiving topical ketorolac."
3300039|NCT01832337|Experimental|precondition|
3300040|NCT01832350|Experimental|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
3300041|NCT01832363|Experimental|HXe MRI guided treatment sequence for BT|Patients in this arm will undergo bronchial thermoplasty treatment where the first session of the procedure will target the six most problematic airways as determined with HXe imaging. Patients will have the remaining of the airways treated in the two subsequent sessions.
3300042|NCT01832363|Active Comparator|Standard treatment sequence for BT (control)|Patients in this arm will undergo standard treatment sequence of bronchial thermoplasty. To preserve the blind of the procedure to the subjects, the same timeline and clinical measures will be followed as for HXe guided patients.
3300043|NCT01832376|Experimental|Ultrasound guided needle lavage|Ultrasound guided needle lavage
3300044|NCT01832389|Active Comparator|Group P|PiCCO-controlled group
3300045|NCT01832389|No Intervention|Group C|control group
3300046|NCT01832415||Use of bevacizumab (Avastin ®) - First-line ovarian cancer|Patient receiving bevacizumab in ovarian cancer first line treatment
3300047|NCT01832428|Other|Transfer of autologous MNC intrathecally|Intra thecal transplantation of autologous stem cells 100 Millions per dose in 3 divided doses at interval of 7days.
3300048|NCT01832441|Other|Transfer of autologous MNC intrathecally|single arm Intra thecal transplantation of autologous MNC
3300049|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
3300050|NCT01832467|Experimental|cetuximab-containing chemotherapy|"Cetuximab may be given at either one of the following schedules at the investigator's discretion:~2-weekly: Cetuximab is started on day 1 of each cycle of chemotherapy, at 500mg/m2 every 2 weeks over 120/90/60minutes.~Weekly: Cetuximab may be given at a loading dose of 400mg/m2 on day 1over 120 minutes, followed by weekly dosing at 250mg/m2 on day 1, over 60 minutes of each cycle of chemotherapy.~Chemotherapy: Only one of the following regimens may be combined with cetuximab at the investigator's discretion according to institutional standard. Some recommended regimens used in Hong Kong.~Regimens to be combined with biweekly cetuximab:~Irinotecan at 2-weekly schedule.~FOLFIRI (as inpatient or via ambulatory pump).~FOLFOX (as inpatient or via ambulatory pump)."
3300051|NCT01832519||CF group|Infants with Cystic Fibrosis will receive 2 chest MRIs with contrast, 2 HRCTs and blood for proteomics and metabolomics at 12 month interval.
3300052|NCT01832519||Non-CF Control|1 chest MRI with contrast and blood for proteomics and metabolomics
3300053|NCT01832545|Active Comparator|Educational Program|The communitarian PESO program is based on appropriate clinical guidelines and on validated behavior change principles. Implemented by an intervention team with expertise gained from current scientific research in weight control determinants, this program as well PICO, is free of charge for all interested adults who wish to manage their weight and health. It operates since 2005 with the aims to prevent obesity or reduce excess weight, as well as, some of the risks associated with obesity in adults through a change to steady healthy habits, attitudes and behaviors. PESO has 3 months duration and it is structured in 12 sessions of one and a half hour, once a week.
3300054|NCT01832545|Experimental|Aquatic Exetcise|Aquatic Exercise program is organized in 24 sessions distributed over 12 consecutive weeks, with a frequency of twice a week. The duration of each session will be 60 minutes, being that 10 minutes are for patient reception, blood pressure control, pain register or others and the effective time inside the water is 45 minutes. The indoor pool works with an air temperature around 27±1ºC and water temperature is controlled for 30.5±5ºC. Workout is organized in order to have a progressive overload every week or every two sessions, when occurs an introduction of a new stimulus. Water is the main instrument to create resistance and only in the last weeks, according with participants progression and if the self-reported pain controlled, drag equipment will be added.
3300055|NCT01832558|Experimental|Eplerenone|Eplerenone 25-50mg daily additionally to standard ACE-inhibition with enalapril 20mg daily
3300056|NCT01832558|Placebo Comparator|Placebo|Placebo additionally to standard ACE-inhibition with enalapril 20mg daily
3300057|NCT01832571|Experimental|Once daily Truvada®|One tablet of Truvada (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) daily
3300058|NCT01832584|Experimental|RGC1|200 mg of Red Grape Cell (RGC) powder; daily oral dose
3300059|NCT01832584|Experimental|RGC2|1000 mg of Red Grape Cell (RGC) powder; daily oral dose
3300060|NCT01832584|Placebo Comparator|Placebo|1000 mg placebo to Red Grape Cell (RGC) powder; daily oral dose
3300061|NCT01832623|Experimental|Exploration of Vitamin D roles|Various exams will be performed during two visits (the same day or within three months) in order to answer the objectives of the study.
3300062|NCT01832636|Active Comparator|Alanyl-Glutamine 3g/d|Alanyl-Glutamine orally 3g/day for 10 days
3300063|NCT01832636|Active Comparator|Alanyl-Glutamine 6g/d|Alanyl-Glutamine orally 6g/day for 10 days
3300064|NCT01832636|Active Comparator|Alanyl-Glutamine 12g/d|Alanyl-Glutamine orally 12g/d for 10 days
3300065|NCT01832636|Placebo Comparator|Glycine 12.5g/d|Glycine orally 12.5 g/d for 10 days. This dose is calculated to be isonitrogenous to 12g of Alanyl-Glutamine.
3300066|NCT01832649|Experimental|Exercise|Moderate-vigorous intensity strength exercise. 50 minutes per session, 2 times per week, 8 weeks.
3300067|NCT01832649|Active Comparator|Health education|Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
3300068|NCT01832662|Experimental|Coffee|4 cups/day of 2.5g of coffee each
3300069|NCT01832662|Active Comparator|coffee polyphenols mixed with placebo|4 cups/day of 2.5g of product each
3300070|NCT01832662|Placebo Comparator|maltodextrin enriched with caffeine|4 cups/day of 2.5g of product each
3300071|NCT01832675|Active Comparator|Bupivacaine lozenge|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
3300072|NCT01832675|Active Comparator|Xylocain, cutaneous spray, solution|The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
3300073|NCT01832688||Baseline cohort|The baseline survey will be implemented among pregnant women in randomly selected villages using a continuous enrollment schedule over the period of 18 months
3300074|NCT01832688||Optimization cohort|The programmatic impact of optimized prenatal care services on women's health and behavior will be assessed among pregnant women in randomly selected villages (Programmatic prenatal care optimization)
3300075|NCT01832701|Experimental|coffee|4 cups of soluble coffee per day (2.5g per cup)
3300076|NCT01832701|Placebo Comparator|Maltodextrine with caffeine|4 cups per day containing 2.5 g of product each
3300077|NCT01832714||mTBI|Subjects who undergo an mTBI event
3300078|NCT01832714||Control|Subjects who do not undergo an mTBI
3300079|NCT01832740|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3300080|NCT01832740|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3300081|NCT01832779||Achalasia subjects|Information about teh subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after the subject's medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
3300082|NCT01832792|Experimental|Self-help|In this condition, participants complete a self-help intervention with the support of a therapist. This lasts 12 weeks.
3300083|NCT01832792|Other|Waiting List|One third of participants will be allocated to a treatment waiting list, after which they will be randomised to one of the other two arms.
3300084|NCT01832805|Experimental|Theta burst stimulation|Specific developed sham coil.
3300085|NCT01832831||Continent Men|
3300086|NCT01832831||Incontinent Men|
3300087|NCT01832844|Active Comparator|"Group  with scan prior to infiltration "|
3300088|NCT01832844|Placebo Comparator|"Group  without scan "|"Patients will have a dummy lumber spine evaluation in order to put patients in blind conditions"
3300089|NCT01832857|Experimental|CPI-613 Alone|This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
3300090|NCT01832870|Experimental|Treatment|Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab.
3300091|NCT01832883||Normal Controls|Structurally normal eye with equal visual acuity and normal stereopsis.
3300092|NCT01832883||Referral required|"Diagnosed with amblyopia or constant strabismus, categorized based on the GSE.~Amblyopia:~VA <20/40 and 2 logMAR lines difference in normal eye~Mild amblyopia (>20/40)~Moderate amblyopia (20/40 and <20/100)~Severe amblyopia (≥20/100 or worse)~Bilateral amblyopia: >4 years age VA<20/40 OU including high hyperopia or high astigmatism.~Strabismus:~Constant: >2 PD at near and or distance.~Intermittent: strabismus that could be controlled intermittently either through fusional mechanisms or a compensatory head position.~Amblyogenic factor categorization:~'Anisometropia'- (1.5 Diopters (D) or more difference in refractive error between the two eyes.~'hypermetropia' (≥3.5 D),~'myopia' (≥-4.0 D),~'astigmatism' (≥1.5 D).~'structural abnormalities' of the eye will not be excluded, but will be considered to have vision loss if visual acuity is 20/40 or worse."
3300093|NCT01832883||Borderline|(no long-term harm to patient if referral is delayed, however the patient does have conditions that might benefit from monitoring): Equal visual acuity and no structural abnormality with any of the following: Amblyogenic factor, intermittent strabismus, structural abnormalities, refractive error, reduced stereopsis.
3300094|NCT01832896|Experimental|Ecallantide|"Study Medication, Dose, and Mode of Administration:~Single dose of ecallantide subcutaneous dosing:~Age less than 10: Weight <25 Kg: 10mg subcutaneously at one site; 25-50kg: 20mg subcutaneously, 10mg per site for 2 separate sites; >50 kg 30mg subcutaneously, 10mg per site for 3 separate sites. Dosing will not exceed 30mg.~Age greater than 10: 10mg per site for 3 separate sites. Dosing will not exceed 30mg."
3300095|NCT01832909|Experimental|Walnut Diet first, then Control Diet|Controlled diet with 1.5 oz/d of walnuts, followed by controlled diet without walnuts.
3300096|NCT01832909|Experimental|Control Diet first, then Walnut Diet|Controlled diet without almonds first (control), then controlled diet with 1.5 oz/d of almonds.
3300097|NCT01832922|Experimental|Significant Comorbidiities|Significant comorbidities as defined by Cumulative Illness Rating Score (CIRS) of ≥7.
3300098|NCT01832922|Active Comparator|Significant renal dysfunction|Significant renal dysfunction defined as CrCL 15-40 mL/min, but not receiving dialysis.
3300099|NCT01832935|Active Comparator|insulin glargine|patients receiving variable doses of Insulin glargine.start with 0.2 to 0.6unit per kg
3300100|NCT01832935|Active Comparator|Insulin NPH|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
3300101|NCT01832948|Experimental|Treatment|Endostar d1-d7 15mg/d Oxaliplatin 85 mg/m2 d6 Folinic acid 400 mg/m2 d6 5-FU 400 mg/m2 d6, and then 5-FU 2,400 mg/m2 INTRAVENOUS over 46 h
3300102|NCT01832974|Other|Part 1- 1 μg/kg|Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3300103|NCT01832974|Other|Part 1 - 2 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 2 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3300104|NCT01832974|Other|Part 1 - 3 μg/kg|If lower dose was tolerated, 3-6 participants receiving IL-13-PE 3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
3300105|NCT01832974|Experimental|Part 2 - All Participants|All participants in Part 2, receiving maximum tolerated dose of IL-13-PE 1-3 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), 3 times per monthly cycle for up to 4 cycles (or longer for participants receiving clinical benefit)
3300106|NCT01832987|Experimental|co-trimoxazole|On 4, 5 or 6 consecutive days, 960 mg co-trimoxazole (oral) will be added to the normal treatment of tuberculosis.
3300107|NCT01833000|Other|newborn suspected to suffer from necrotizing enterolitis|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler
3300108|NCT01833013|Other|endometriosis cohort|females suffer from endometriosis
3300109|NCT01833052|Other|Cerebral Protection Filter|Patient is treated with Cerebral protection Filter.
3300110|NCT01833052|Other|No Cerebral Protection Filter|Patient is not treated with Cerebral protection Filter.
3300111|NCT01833091|Experimental|intervention|creat light period 12 hours with cover on incubator
3300112|NCT01833091|No Intervention|control|
3300113|NCT01833104|Experimental|Training Cohort 1 (TC1)|"(N = 80) in the order Presence - Affect - Perspective"
3300114|NCT01833104|Experimental|Training Cohort 2 (TC2)|"(N = 81) in the order Presence - Perspective - Affect"
3300115|NCT01833104|No Intervention|Retest Control Cohort 1 (RCC1)|(up to N = 30) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
3300116|NCT01833104|Active Comparator|Training Cohort 3 (TC3)|"(N = 81) here, the Affect Module only intervention is administered."
3300117|NCT01833104|No Intervention|Retest Control Cohort 2 (RCC2)|(up to N = 60) this is a non-intervention control group to access measurement effects and will be tested at each timepoint.
3300118|NCT01833156|Experimental|patient with local edema by histamin|Measuring at 3 locations (on the histmin spot, at 5 cm and 10 cm border (is the control) at 7 times: T0 - T10 minutes - T20 - T30 - T45 - T60 - T75
3300119|NCT01833182|Placebo Comparator|Sham intervention|"Those randomized to the sham or placebo treatment group will receive an ADL kit treatment designed only to address fine motor upper extremity function.A series of six 90-minute sessions will be provided to each participant in the sham condition using a standardized protocol."
3300120|NCT01833182|Experimental|Tailored home intervention|Those randomized to the study treatment group will receive a tailored home modification intervention delivered in a series of six 90-minute sessions via a standardized protocol. The tailored treatment may include medical equipment and modifications to the home.
3300121|NCT01833195||Heart transplant recipients|Heart transplant rejection surveillance including AlloMap testing
3300122|NCT01833208|Experimental|Treatment (radiation therapy)|Patients undergo single-fraction radiation therapy to at least 1 bone lesion 2 days after the first sipuleucel-T dose.
3300123|NCT01833221|Experimental|Neurotized facial muscle patients|injection of 1% lidocaine, 2mL for facial nerve block
3300124|NCT01833234||People with epilepsy|People with epilepsy who have have had at least one seizure in the prior year.
3300125|NCT01833260|Experimental|With music|Pulmonary rehabilitation with music in the room
3300126|NCT01833260|No Intervention|Without music|
3300127|NCT01833273|Experimental|PolyMVA|This arm will be taking 8 tsp/day of the study compound (PolyMVA) in addition to receiving normal care as determined by his/her neuro-oncologist.
3300128|NCT01833286|Experimental|TACE+RFA|TACE was performed according to the following protocol: All patients underwent a distal super-selective catheterization of the hepatic arteries using a coaxial technique and micro-catheters (2.9 Fr, Terumo Corporation, Tokyo, Japan). Then, the same three chemotherapeutic agents at the same dosages were used throughout this study, regardless of tumor number and size. Hepatic artery infusion chemotherapy was performed using carboplatin 300 mg. After that, chemolipiodolization was performed using epirubicin 50 mg, and mitomycin C 8 mg mixed with 5 mL of lipiodol. If the territory of the chemolipiodolized artery did not show stagnant flow, pure lipiodol was then injected. RFA was performed after TACE in 2 months by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).
3300129|NCT01833286|Active Comparator|re-resection|Re-resection was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant and the possibility of a negative resection margin. We performed anatomical resection aiming at a resection margin of at least 1 cm. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 minutes and 5 minutes, respectively. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
3300130|NCT01833299|Active Comparator|TACE group|Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
3300131|NCT01833299|Experimental|TACE+sorafinib|TACE+sorafinib
3300132|NCT01833312|Experimental|Hypothermia|Best medical treatment + hypothermia 34-35°C for 24h
3300133|NCT01833312|No Intervention|Control|Best medical treatment
3300134|NCT01833325|Experimental|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
3300135|NCT01833338|Other|Single arm|There is only one arm in this study. All patients undergo MSCT, IVUS and OCT.
3300136|NCT01833351|Experimental|Phase I, IV Vitamin C Healthy Normals|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
3300137|NCT01833351|Experimental|Phase 1 IV Vitamin C- Cancer Patients|Safety and pharmacokinetics of intravenous ascorbate,IV Vitamin C.
3300138|NCT01833364|Experimental|Implantation of Perpherial Nerve Graft|Subjects own peripheral nerve tissue that will be used to create the graft for implantation. The autologous peripheral nerve graft will then be implanted unilaterally into the substantia nigra of the subject after the placement of DBS electrodes.
3300139|NCT01833377|Experimental|caraway sample|caraway sample
3300140|NCT01833377|Active Comparator|Placebo|
3300141|NCT01833390|Experimental|HXe MRI lung ventilation|Each subject will inhale a dose of HXe gas (up to one liter HXe) while lying inside an MRI scanner. A high-resolution 3D map of the lung spaces filled with HXe gas will be acquired during a short breath-hold. Additionally, proton MRI of the chest cavity will be recorded during the same breath-hold for registering the lung boundaries. All subjects will undergo Pulmonary Function Tests. Subjects suffering from obstructive lung disease will have Tc-99m DTPA lung scintigraphy performed for comparing with HXe images.
3300142|NCT01833429||Resistant Hypertension|The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
3300143|NCT01833442|Active Comparator|Kundalini Yoga Meditation|Kundalini Yoga Meditation is going to be use as therapy for OCD, and it will be compare with Relaxation Response Meditation.
3300144|NCT01833442|Active Comparator|Relaxation Response Meditation|Relaxation Response Meditation is going to be use as therapy for OCD, and it will be compare with Kundalini Yoga Meditation.
3300145|NCT01833507|Active Comparator|self-exercise|Intervention will include a video(DVD) on exercise, and 2 self-help manuals on exercise and nutrition, in addition to a journal and pedometer.
3300146|NCT01833507|Placebo Comparator|usual care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics.
3300147|NCT01833559|Other|Incidence of GDM|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3300148|NCT01833559|Other|Gestational outcomes|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3300149|NCT01833559|Other|Metabolic disorder|Dietary control will be suggested to patients if their fasting blood glucose is between 5.1 mmol/L and 7.0 mmol/L. If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized.
3300150|NCT01833572|Experimental|Gefitinib|A total of 42 cases of resectable stage II-IIIA NSCLCs patients with EGFR activating mutations will be enrolled in this arm.Gefitinib 250 mg/day oral daily is given to patients after enrolment for 42 days or until disease progression or unacceptable toxicity.
3300151|NCT01833585|Experimental|peripheral blood mononuclear cells|peripheral blood mononuclear cells will be injected to calf muscle of critical limb ischemia
3300152|NCT01833598|Active Comparator|PNT + PRP|percutaneous needle tenotomy with peritendinous platelet-rich plasma injection
3300153|NCT01833598|Active Comparator|PNT alone|percutaneous needle tenotomy alone
3300154|NCT01833611|Experimental|ETV group|Entecavir 0.5mg at first year; then open with entecavir 0.5mg qd for 2nd, 3rd year
3300155|NCT01833611|Placebo Comparator|Placebo group|Placebo at first year, then opne with entecavir 0.5mg qd for 2nd, 3rd year
3300156|NCT01833624|Active Comparator|Sondalis® HP|The Control Group that will receive Sondalis ® HP (a whole-peptide formula).
3300157|NCT01833624|Experimental|Peptamen® AF|In this arm, patients have enteral nutrition with Peptamen® AF
3300158|NCT01833637|No Intervention|Arm A: Control Group|Patients randomized to the control group will be asked to fill out a patient symptom questionnaire using an iPad at the time of registration and then every 24 hours until released from the hospital. It should take about 10 minutes to complete the questions each time. The survey will not interfere with the care the healthcare team will be providing. Patients will be asked to fill our a Patient Satisfaction Questionnaire at the time of discharge.
3300159|NCT01833637|Active Comparator|Arm B: APN Intervention Group|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
3300160|NCT01833650|No Intervention|Standard care|This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
3300161|NCT01833650|Experimental|Candy plus thymus honey mouthwash 12|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
3300162|NCT01833650|Experimental|Candy plus thymus honey mouthwash 24|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
3300163|NCT01833650|Experimental|Candy plus thymus honey mouthwash 1|This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
3300164|NCT01833663|Experimental|Solifenacin Succinate Tablets and Estrogen capsules|Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks
3300165|NCT01833663|Active Comparator|Solifenacin Succinate Tablets|Solifenacin Succinate Tablets (5mg/d) for 12 weeks
3300166|NCT01833676|Active Comparator|Desflurane|Patient receiving Desflurane for maintenance of general anaesthesia
3300167|NCT01833676|Active Comparator|Sevoflurane|Patient receiving Sevoflurane for maintenance of general anaesthesia
3300168|NCT01833689|Placebo Comparator|food consumption: control|The control product will be 50g glucose powder dissolved in 250ml of water
3300169|NCT01833689|Active Comparator|food consumption: product|The test food will provide 50g of available carbohydrate
3380305|NCT04856982|Experimental|Part B: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive BIIB067 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
3380306|NCT04856982|Experimental|Part C: Open-Label Extension|Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years. Participants who received BIIB067 during Part B will receive BIIB067 100 mg on Days 1, 29, and every 28 days thereafter for up to 2 years, with a dose of placebo on Day 15 to maintain the study blind.
3300170|NCT01833702||Automated response|Canned responses are provided at the end of daily entries
3300171|NCT01833702||No automated feedback|Canned responses are not provided at the end of daily entries
3300172|NCT01833715|Active Comparator|Morphine|morphine group 0.08 mg / kg, to start surgery
3300173|NCT01833715|Experimental|Methadone|methadone group 0.08 mg / kg, to start surgery
3300174|NCT01833728|Experimental|nefopam-propacetamol combination group|
3300175|NCT01833728|Active Comparator|propacetamol alone group|
3300176|NCT01833767|Experimental|Cyclophosphamide and Interleukin-2|Cytoxan IV on day 1, IL2 IV on days 1-5
3300177|NCT01833780||GBS carriage status|
3300178|NCT01833780||GBS status during labor|
3300179|NCT01833793||Group 1|
3300180|NCT01833806|Experimental|ExAblate Test Arm|Focused Ultrasound Surgery delivered by ExAblate MRgFUS
3300181|NCT01833819|Other|Opiod-free group|Opioid-free anesthesia (Group DL) with dexmedetomidine (0.6 mg/kg loading, 0.3 mg/kg/h infusion), lidocaine (1.5 mg/kg loading, 2 mg/kg/h infusion), and propofol infusions (3-12 mg/kg/h).
3300182|NCT01833819|Other|Opioid-based group|Opioid-based anesthesia (Group RF) with single dose fentanyl (2μg/kg), remifentanil (0.25μg/kg/min), and propofol infusions (3-12 mg/kg/h).
3300183|NCT01833858|Placebo Comparator|Placebo +rFSH|Patients received rFSH injections with a placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
3300184|NCT01833858|Active Comparator|Low dose HCG with rFSH|Low dose hCG (200 IU per day) will be given daily with rFSH when at least six follicles of 12 mm will be observed and E2 levels are higher than 600 ng/l, until the day of the hCG trigger administration
3300185|NCT01833871|Experimental|myometrial fibroid/adenomyoma|Patients scheduled for myomectomy or hysterectomy with preoperative diagnosis of uterine myoma, adenomyosis or both by ultrasound .Trans-vaginal 3D power Doppler and uterine artery doppler will be done for all participants prior to surgery.
3300186|NCT01833884|Other|Single arm|Collection of blood specimen for Cytokines dosing scheduled before, during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
3300187|NCT01833910|Experimental|Video-only - DVD|CPR Training with AHA CPR Anytime DVD presented on a TV with DVD player and no psychomotor skill practice.
3300188|NCT01833910|Experimental|Video-only - iPad|CPR Training with AHA CPR Anytime DVD presented on a portable video player and no psychomotor skill practice.
3300189|NCT01833910|Experimental|Video-only with Household Object|CPR Training with AHA CPR Anytime DVD and practice on a household item
3300190|NCT01833910|Experimental|Video Self Instruction Kit|CPR Training with AHA CPR Anytime Video Self-Instruction kit including manikin
3300191|NCT01833923|Experimental|anlotinib|dosage form:capsule dosage:5mg,10mg,16mg,12mg frequency:once one day duration:Continuous two weeks then stop a week
3300192|NCT01833949|Active Comparator|ULOD arm (N=49)|"Unilateral laparoscopic drilling~In the ULOD group, we treated the right ovary.The thermal dose of 60 J applied per one cubic centimeter of ovarian volume was calculated from the mean total energy applied on a 10 cm3 ovary (627 J) from three earlier ULOD reports. Ovarian volume had been measured by ultrasound at baseline to determine the total thermal dose to apply on the right ovary. The number of punctures (Np) was also calculated for each patient according to the following formula:~Np = 627 J / 30 W / 4 s Therefore, patients in the ULOD group differed in the number of punctures and energy received by the right ovary, depending on its volume."
3300193|NCT01833949|Active Comparator|BLOD arm (N=47)|"Bilateral laparoscopic drilling~In the comparator, BLOD group, all patients received 600 J per ovary (totaling 1200 J) through five punctures at 30 W for 4 s each (5 punctures x 4 s x 30 W = 600 J).~The ovaries in both groups were cooled after the drilling by irrigating the abdominal cavity with 200-300 mL of physiological saline."
3300194|NCT01833962||Actifuse|Patients who recieved Actifuse synthetic bone brafting material
3300195|NCT01833975|Other|stem cell [ MNCs ]|transplantation of autologous stem cell [MNCs ]
3300198|NCT01834014|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
3300199|NCT01834014|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
3300200|NCT01834040|Other|intralesional and Intravenous|Intralesional/ Intravenous of Autologous Stem cells.
3300201|NCT01834053|Other|STEM CELL|Transfer of autologous Stem cell( MNCs) intrathecally
3300202|NCT01834066|Other|STEM CELL|Intra thecal transplantation of autologous Stem Cell MNCs
3300203|NCT01834079|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
3300204|NCT01834092|Active Comparator|Fresh frozen plasma|2 portions of FFP will be transfused prior to reperfusion
3300205|NCT01834092|Experimental|Fresh non-frozen plasma|2 portions of non-frozen plasma will be transfused prior to reperfusion
3300206|NCT01834105|Experimental|Liuwei Dihuang Pills|
3300207|NCT01834131|No Intervention|Usual Care|Clinics assigned to usual care will not receive any of the intervention components. Physicians in these clinics will continue to treat patients using their usual methods. Participants from these clinics will not receive community health worker visits or the mobile health intervention
3300208|NCT01834131|Experimental|Comprehensive Intervention|"Physicians will receive training in the use of treatment algorithms based on hypertension guidelines.~Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change.~Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly."
3300209|NCT01834157||methotrexate|methotrexate with or without low-dose corticosteroids
3300210|NCT01834157||other DMARDs|other DMARDs (leflunomide, azathioprine, mycophenolate mofetil) with or without low-dose corticosteroids
3300211|NCT01834157||low-dose corticosteroids|low-dose corticosteroids without DMARDs
3300212|NCT01834157||No DMARD or corticosteroids|No DMARD or corticosteroid treatment
3300213|NCT01834157||CPH/CSA - Exploratory cohort|cyclophosphamide or cyclosporine-A with or without other DMARDs or low-dose corticosteroids
3300214|NCT01834157||Biologics - Exploratory cohort|Biologic therapy with or without other DMARDs or low-dose corticosteroids
3300215|NCT01834157||Combinations - Exploratory cohort|Combination of two or more DMARDs with or without low-dose corticosteroids
3300216|NCT01834170|Experimental|Intratumoral gemcitabine injection|Intratumoral injection of gemcitabine by means of endoscopic ultrasound.
3300217|NCT01834183|Experimental|Tivozanib/Gemcitabine|Segment 1: Tivozanib, taken orally days 1-21 of each 28 day cycle. Segment 2: Tivozanib, taken orally days 1-21 of each 28 day cycle. Gemcitabine, taken intravenously, Days 1 and 8 of each 28 day cycle.
3300218|NCT01834196|Other|retinal vascular occlusion arm|Patients with existing retinal microvascular disease will undergo imaging.
3300219|NCT01834235|Active Comparator|Abraxane, gemcitabine|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.
3300220|NCT01834235|Experimental|Abraxane, gemcitabine, NPC-1C|"Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30 minute infusion for 3 consecutive weeks followed by a week of rest.~Patients on arm B will receive NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 4-week cycle. This will be administered 30minutes after completion of the gemcitabine infusion."
3300221|NCT01834248|Experimental|Treatment (CDX-1401, Poly ICLC, decitabine)|Patients receive DEC-205/NY-ESO-1 fusion protein CDX-1401 SC and ID and poly-ICLC SC on days -14 and 15 of course 1 and on day 15 for courses 2-4. Patients also receive decitabine IV over 1 hour on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3300222|NCT01834287|Experimental|Physical Activity Intervention|Motivationally-tailored, Spanish Language, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
3300223|NCT01834287|Active Comparator|Wellness Control|Internet-based, Spanish language, Wellness Contact control intervention addressing relevant health topics other than Physical Activity.
3300224|NCT01834300|Experimental|Control|Unsupervised exercise training This group will be given 1 hour lifestyle counseling by the exercise trainer after which they will have no contact with the exercise trainer to the end of the intervention period. The exercise intervention will be offered to the subjects once the post studies are completed.
3300225|NCT01834300|Experimental|lifestyle counseling and exercise|Supervised exercise training Four months exercise training intervention will be either gym-based or patients will choose the mode of exercise that suits their lifestyle. Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
3300226|NCT01834339|Active Comparator|AlloDerm|The subject will be treated with the standard of care, AlloDerm, to cover the defect in the mouth.
3300227|NCT01834339|Experimental|EVPOME|An ex-vivo produced oral mucose equivalent (EVPOME) will be used to cover the defect in the top of the mouth.
3300228|NCT01834352|Active Comparator|Walnut protein flour|Walnut protein flour that is ingested in gradually increasing amounts up to a maintenance dose.
3300229|NCT01834352|Placebo Comparator|Oat flour|Oat flour administered in identical increasing amounts as the active walnut protein flour.
3300230|NCT01834365|Experimental|Structured education & checklist|Formatted education and checklist every month for 3 months
3300231|NCT01834365|Active Comparator|Structured education|Formatted education every month for 3 months
3300232|NCT01834365|Active Comparator|Without Structured Education with checklist|No structured education with checklist
3300233|NCT01834378|No Intervention|No intervention|
3300234|NCT01834378|Experimental|Low intensity intervention|
3300235|NCT01834378|Experimental|High intensity intervention|
3300236|NCT01834391||Geriatric Traumatic Injury|Geriatric trauma pateints being admitted to Saint Marys Hosptial.
3300237|NCT01834430|Experimental|EN group|The EN group gradually restored enteral nutrition, while the PN group continued to receive parenteral nutrition treatment. Both groups received between 20 to 25 kcal/kg/day and 1.5 g/kg/day of protein. Because of the low volume, concentration, and calorie amount, on the first day, tube feeding utilized 500 ml with the speed of 30 ~ 50 ml/h. On the second day, tube feeding utilized 1000 ml with the speed of 60 ~ 80 ml/h. On the third day, tube feeding utilized 1500 ~ 2000 ml with the speed of 100 ~ 120 ml/h. If enteral nutrition could not meet a patient's caloric requirements, PN supplement was started on the fourth day. The required calories and protein for each individual in the two groups was assumed to be achieved after three days of therapy. The PN group continued to receive parenteral nutrition.
3300238|NCT01834430|No Intervention|parenteral nutrient group|
3300239|NCT01834443|Experimental|GVS CL|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the left mastoid
3300240|NCT01834443|Experimental|GVS CR|Transmastoid galvanic vestibular stimulation is applied, with the cathode placed on the right mastoid
3300241|NCT01834443|Sham Comparator|GVS Sham|Transmastoid galvanic stimulation set-up is applied, with only 30s of stimulation
3300242|NCT01834456|Experimental|Med Complex Children Intervention|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~Medically Complex Children in the Intervention group will be treated at an innovative primary care facility designed for their care. This includes actively addressing QOL, care coordination, and behavioral needs of the child, and addressing contextual and support needs for the child's family."
3300243|NCT01834456|No Intervention|Med Complex Children Control|"Children with Medical Complexity, previously defined in research as, children with complex chronic conditions, children with life-limiting conditions, fragile children, complex chronic illness, or a subset of children with special healthcare needs. Meeting criteria for complexity is a combination of high utilization, multiple chronic diagnoses, use of medical technology (g-tube, tracheostomy, shunt, etc.), functional impairment, and contextual needs.~The control group will continue to receive usual care as they did before they enrolled in this study"
3300244|NCT01834469|Other|ICG NIR imaging|see Summary and description iv injection of ICG
3300245|NCT01834482|Active Comparator|Modified Atkins diet plus KetoCal|Patients will receive the modified Atkins diet in combination with a KetoCal tetrapak daily for the first month. The second month, no tetrapaks will be given.
3300246|NCT01834482|Active Comparator|Modified Atkins diet|Patients will receive the modified Atkins diet for the first month. The second month, they will be given the choice to also use KetoCal in addition to the modified Atkins diet if they choose to do so.
3300247|NCT01834495|Experimental|Balloon expandable stent|study design is 1:1 randomization design. Patients will be randomized in a 1:1 manner according to different two (balloon expandable versus Self expandable)stents. Randomization procedure will be performed using a web-based program
3300248|NCT01834495|Active Comparator|Self expandable stent|same to Balloon expandable stent
3300249|NCT01834508|Other|Treatment group|
3300250|NCT01834521|Experimental|Web-based screening and tailored support|A personalized website (username/password) will become available to patients assigned to the intervention arm for 12 subsequent weeks. Key features of the website are self-screening, tailored patient education and self-referral. Self-screening will be performed by an online version of the Dutch Distress thermometer (DT) and Problem List (PL). Patients will receive digital feedback on their DT score immediately after test completion together with information regarding problems reported on the PL, (self)help options and possibilities for referral to professional care. Contact information of one of the investigators will also be available to discuss questions, problems and/or referral needs. Patients may also request a telephone call.
3300251|NCT01834521|No Intervention|Standard care|Patients assigned to standard convalescent care will receive the usual follow-up care delivered by their treating oncologists. Patients will be referred to psychosocial or allied care by their oncologist and/or oncology nurse if certain physical and/or psychosocial problems require more in-depth professional care
3300252|NCT01834534|Experimental|CarePartners for depression|For one year, patients receive weekly automated telemonitoring of mood and self-management, while their CarePartners receive weekly reports of the patient's assessment results with tailored instructions on supporting the patient's depression self-management.
3300253|NCT01834534|No Intervention|Usual care|Usual medical care.
3300254|NCT01834547|Experimental|Methylphenidate|Methylphenidate
3300255|NCT01834547|Experimental|modafinil|modafinil
3300256|NCT01834547|Experimental|caffeine|caffeine
3300257|NCT01834547|Placebo Comparator|placebo|placebo
3300258|NCT01834573|Active Comparator|Intervention|Patients of the intervention arm receive a 10 week exercise program
3300259|NCT01834573|No Intervention|Control|Patients of the control arm do not participate in exercise
3300260|NCT01834599||anterior placenta|"Cerebral oximetry device used to obtain:~Saturation value of the placenta probe with no oxygen, saturation value of the placenta probe with oxygen, saturation value of the myometrium probe with no oxygen saturation value of the myometrium probe with oxygen saturation value of the forearm probe with no oxygen, saturation value of the forearm probe with oxygen saturation value of the leg probe with no oxygen saturation value of the leg probe with oxygen Timing between the contractions measure by cardiotocography"
3300261|NCT01834612|Active Comparator|Blood draw|CM1500 with blood draw
3300262|NCT01834612|Sham Comparator|No blood draw|CM 1500 with no blood draw
3300263|NCT01834625||Florbetapir +ve NPH patients|Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
3300264|NCT01834625||Florbetapir -ve patients|Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
3300265|NCT01834638|Experimental|ABT-126 low dose|ABT-126 low dose
3300266|NCT01834638|Experimental|ABT-126 middle dose|ABT-126 middle dose
3300267|NCT01834638|Experimental|ABT-126 high dose|ABT-126 high dose
3300268|NCT01834664|Other|STEM CELL|Transfer of autologous stem cell [MNCs ]intrathecally
3300269|NCT01834677||Healthy Human|
3300270|NCT01834677||Depressed Human|
3300271|NCT01834677||Depressed Human, Undergoing Electroconvulsive Therapy|Electroconvulsive Therapy is being received as standard of care, not as a study intervention.
3300272|NCT01834677||Human Diagnosed with Parkinson's Disease|
3300273|NCT01834690||liver transplantation recipients|adult liver transplantation recipients (>=20 years at the date of surgery)
3300274|NCT01834703|Active Comparator|UAE treatment|After randomization, patient recruited will be arranged to receive UAE treatment. 100 patients will be recruited for UAE treatment
3300275|NCT01834703|Active Comparator|HIFU|After randomization, patient recruited will be arranged to receive HIFU treatment. 100 patients will be recruited for HIFU treatment
3300276|NCT01834742|Experimental|Part A, arm 1|Evening dose 1 plus fixed morning dose
3300277|NCT01834742|Experimental|Part A, arm 2|Evening dose 2 plus fixed morninf does
3300278|NCT01834742|Experimental|Part A, arm 3|Evening dose 3 plus fixed morning dose
3300279|NCT01834742|Active Comparator|Part A, arm 4|Moviprep
3300280|NCT01834742|Experimental|Part B, arm 1|Fixed evening dose plus morning dose 1
3300281|NCT01834742|Experimental|Part B, arm 2|Fixed evening dose plus morning dose 2
3300282|NCT01834742|Experimental|Part B, arm 3|Fixed evening dose plus morning dose 3
3300283|NCT01834742|Experimental|Part B, arm 4|Fixed evening dose plus alternative morning dose
3300284|NCT01834755|Other|single arm|Evaluation of psychological phenotype with several questionnaire (Big Five, EPADV-16), physical activity with a self-administered questionnaire (Baecke) and several test ( SPPB, Handgrip Strengh test, MicroFET 2 Digital Dynamometer)
3300285|NCT01834768|Experimental|A|Eplerenone
3300286|NCT01834781|Active Comparator|Pulsed electromagnetic fields|Pulsed electromagnetic fields is applied transcranially 30 minutes twice a day for 7 days a week over 6 consecutive weeks
3300287|NCT01834781|Placebo Comparator|Wearing the inactive device|The inactive device is worn on the head for 30 minutes twice a day for 7 days a week over 6 consecutive weeks
3300288|NCT01834794|Experimental|MET/CBT/CM plus NRT|"Motivational Enhancement Therapy, Cognitive Behavior Therapy, Contingency Management plus Nicotine Replacement Therapy (MET/CBT/CM) + NRT~Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT."
3300289|NCT01834807||Cohort|
3300290|NCT01834820|Experimental|Epinephrine and Dexamethasone|First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes. And one treatment of nebulized dexamethasone every 24h for three days.
3300291|NCT01834820|Experimental|Hypertonic Saline 3%|3 treatments of nebulized HS 3% 4ml in first day of treatment with interval 20 minutes And one treatment of nebulized HS 3% 4ml every 24 hours for 3 days
3300292|NCT01834820|Active Comparator|Normal Saline 0.9%|3 treatments of nebulized Normal Saline 0.9% 4ml in first day of treatment with interval 20 minutes. And one treatment of nebulized Normal Saline 0.9% 4ml every 24 hours for 3 days
3300293|NCT01834833|No Intervention|Control|usual care without systematic cardiology evaluation between 1 and 2 weeks
3300294|NCT01834833|Experimental|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
3300295|NCT01834846|Experimental|no-touch|no-touch technique of harvesting the saphenous vein graft for coronary artery bypass grafting
3300296|NCT01834846|Active Comparator|conventional|conventional technique of harvesting the saphenous vein graft for coronary artery bypass grafting
3300297|NCT01834859|Experimental|Outpatient|Multidisciplinary outpatient program including both individual and group-based therapy. During the first visit, there will be offered an individual consultation with the dietician, physiotherapist and psychiatric nurse. Follow-up will be in groups meeting every month for the first four months and every two months afterwards up to one year. The intervention will focus on nutritional education, healthy eating, increased physical activity levels (aiming initially at 10 minutes/day, then increasing to 30 minutes/day) and cognitive therapy.
3300298|NCT01834859|Experimental|Inpatient|"Inpatient lifestyle program consisting of a continuous care weight loss program offered at a rehabilitation center, with three intermittent stays (each with 3-week duration) over a one year period."
3300299|NCT01834872|Experimental|Amigo|Ablation completed with Amigo
3300300|NCT01834872|Active Comparator|Manual|Ablation completed with manual catheter
3300301|NCT01834885|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3300302|NCT01834885|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3300303|NCT01834898||Controlled-release oxycodone|Controlled-released oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
3300304|NCT01834911|Experimental|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication.
3300305|NCT01834950|Experimental|Trastuzumab|The study is a single arm prospective study, aiming at identifying biomarkers of early response to trastuzumab
3300306|NCT01834963|Experimental|Interferon Alfa、Fluorouracil|"Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
3300307|NCT01834963|Experimental|Cisplatin、Fluorouracil|"Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
3300308|NCT01834989|Active Comparator|Insulin-like growth factor I|3 injection (1 mg), once a week the first 3 weeks of the 12 weeks of intervention
3300309|NCT01834989|Placebo Comparator|Placebo injections|3 Injections of saline into the patellar tendon 3 times during the first 3 weeks of the 12 weeks interventions period
3300310|NCT01835002|Experimental|OkuStim|Electrostimulation Standard Treatment with OkuStim
3300311|NCT01835028||Classical Low-Flow, Low-Gradient AS|"Observational study in patients with Classical Low-Flow, Low-Gradient Aortic Stenosis and Low LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
3300312|NCT01835028||Paradoxical Low-Flow, Low-Gradient AS|"Observational study in patients with Paradoxical Low-Flow, Low-Gradient Aortic Stenosis and Preserved LV Ejection Fraction undergoing surgical aortic valve replacement, transcatheter aortic valve replacement, or conservative management:~I- Baseline visit: Medical history, physical / functional evaluation, blood biomarkers, resting echocardiography, stress echocardiography, aortic valve calcium scoring by computed tomography, myocardial fibrosis by magnetic resonance imaging II- Follow-up: clinical outcomes, physical / functional evaluation, echocardiography, blood biomarkers"
3300314|NCT01835054||Patients with mitral regurgitation|"At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.~At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.)."
3300315|NCT01835067|Sham Comparator|Control Group (A)|Ranibizumab only (active control). Participants will receive a 'sham injection' to simulate C3F8 and/or tPA administration.
3300316|NCT01835067|Experimental|C3F8 Only Group (B)|C3F8 given. Ranibizumab given as standard.
3300317|NCT01835067|Experimental|tPA and C3F8 Group (C)|Both C3F8 gas and tPA given. Ranibizumab given as standard.
3300318|NCT01835067|Experimental|tPA Only Group (D)|tPA given. Ranibizumab given as standard.
3300319|NCT01835093|Experimental|A single-arm study|
3300320|NCT01835106|Active Comparator|Epidural|Epidural catheter is used postoperatively
3300321|NCT01835106|Experimental|Fascia Iliaca Compartment|Fascia iliaca compartment catheter is used postoperatively
3300322|NCT01835119|Experimental|chewing gum|"Gum type was standardized with all subjects receiving sugar-free peppermint-flavored gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (one stick) 3 times daily in the morning, afternoon, and evening at least 5 min. The administration of the therapy was implemented by ward nursing staff and recorded in the patients file. All gum-chewing patients completed their course of gum chewing until bowel function."
3300323|NCT01835119|No Intervention|control group|no gum
3300324|NCT01835184|Experimental|Treatment (cabozantinib-s-malate, vemurafenib)|Patients receive cabozantinib-s-malate PO QD and vemurafenib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3300325|NCT01835197|Experimental|SAD Cohorts 1-8 Experimental Arm|
3300326|NCT01835197|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3300327|NCT01835197|Experimental|MAD Cohorts 3 through 5 Experimental Arm|
3300328|NCT01835197|Placebo Comparator|MAD Cohorts 3 through 5 Placebo Arm|
3300329|NCT01835197|Experimental|MAD Cohorts 6 and 7 Experimental Arm|
3300330|NCT01835197|Placebo Comparator|MAD Cohorts 6 and 7 Placebo Arm|
3300331|NCT01835197|Experimental|MAD Cohort 8 Experimental Arm|
3300332|NCT01835197|Placebo Comparator|MAD Cohort 8 Placebo Arm|
3300333|NCT01835197|Experimental|MAD Cohort 9 Experimental Arm|
3300334|NCT01835197|Placebo Comparator|MAD Cohort 9 Placebo Arm|
3300335|NCT01835210||Quality of life|Teenager with acne vulgaris This is an observational study, in which the disease of interest is acne vulgaris.
3300336|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, T-DM1|First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
3300337|NCT01835236|Active Comparator|Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine plus T-DM1|First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
3300338|NCT01835249|Experimental|Intensive BP Arm|"Participants randomized into the Intensive BP arm will have a goal of SBP <120mmHg. Drugs will be added and/or titrated at each visit (monthly) to achieve SBP <120 mmHg. At periodic milepost visits, addition of another drug will be required if not at goal."
3300339|NCT01835249|Active Comparator|Standard BP Arm|Participants randomized into the Standard arm will have a goal of SBP <140 mm Hg. Intensify therapy if SBP ≥160 mmHg @ 1 visit; ≥140 mmHg @ 2 consecutive visits; Down-titration if SBP <130 mmHg @ 1 visit; <135 mmHg @ 2 consecutive visits.
3300340|NCT01835275|Experimental|Music conditioning|Subjects are tested with music, sound, and silence, after conditioning to enhance music induced analgesia
3300341|NCT01835275|Active Comparator|Sound|Subjects are tested with music, sound, and silence, after conditioning to enhance sound induced analgesia
3300342|NCT01835275|No Intervention|Calibration|Subjects are tested with music, sound, and silence, with no enhanced audio received
3300343|NCT01835288|Experimental|Treatment (arsenic trioxide)|Patients receive arsenic trioxide IV over 1-2 hours daily for up to 45 days. Patients achieving complete remission, receive arsenic trioxide IV over 1-2 hours daily 5 days a week for 4 weeks. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
3300344|NCT01835301||DES|Patients who received a DES stent > 3 years ago.
3300345|NCT01835301||BMS|Patients who received BMS stents > 3 years ago.
3300346|NCT01835327||Exposed|Cerebral oximetry desaturation below 65% for a minimum of 3 minutes
3300347|NCT01835327||Not Exposed|Those patients who do not experience a cerebral oxygen desaturation below 65% for a minimum of 3 minutes
3300348|NCT01835340|Experimental|propofol|Propofol Patients will receive propofol anesthesia on the study day
3300349|NCT01835353|Experimental|Prasugrel 100mg loading dose|Prasugrel 100mg loading dose
3300350|NCT01835353|Active Comparator|Prasugrel 60mg loading dose|
3300351|NCT01835392|Experimental|Remote Ischemic Preconditioning|Four 5-minute cycles of leg ischemia interspersed with 5-minute cycles of reperfusion using a blood pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure.
3300352|NCT01835392|Sham Comparator|Control|Placement of blood pressure cuff around leg without inflation for 40 minutes
3300353|NCT01835405|Active Comparator|LiquiBand Flex|LiquiBand® Flex skin adhesive is indicated for topical application only, to hold closed easily approximated skin edges from surgical incisions, including punctures from minimally invasive surgery, and simple, thoroughly cleansed trauma-induced lacerations. It may be used in conjunction with, but not in place of deep dermal sutures.
3300354|NCT01835405|Active Comparator|Dermabond Advanced|Dermabond Advanced™ adhesive is intended for topical application only, to hold closed easily approximated skin edges of wounds from surgical incisions, including incisions from minimally invasive surgery, and simple, thoroughly cleansed, trauma-induced lacerations. Dermabond Advanced ™ adhesive may be used in conjunction with, but not in place of, deep dermal stitches.
3300355|NCT01835405|Active Comparator|Sutures (Prolene)|Prolene™ Suture is indicated for use in general soft tissue approximation and/or ligation, including use in cardiovascular, ophthalmic and neurological procedures.
3300356|NCT01835418|Experimental|Lisinopril|bedtime administration of lisinopril 20mg
3300357|NCT01835418|Experimental|Amlodipine|Bedtime administration of amlodipine 5mg
3300358|NCT01835444||MD model|Hospital wards at which ward care is provided only by Medical Doctors (MDs)
3300359|NCT01835444||PA/MD model|Hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
3300360|NCT01835457|Experimental|Concentration/meditation group|Subjects in this arm will be performing the concentration/meditation technique of Wim Hof (The Iceman) prior to, during and after intravenously injected 2 ng/kg Lipopolysaccharide
3300361|NCT01835457|Active Comparator|Control group|Subjects in this group will be intravenously injected with 2 ng/kg Lipopolysaccharide
3300362|NCT01835509|Experimental|Intervention, Camp + Reunions|5 day , day camp plus 5 monthly reunions
3300363|NCT01835509|No Intervention|Control, Newsletters|
3300364|NCT01835535|Experimental|Severe Resistant HTN|Patients presenting with resistant hypertension and office systolic blood pressure of 160 mmHg (150 mmHg for DM) or greater
3300365|NCT01835561|Experimental|Part 1: Severe liver disease and healthy volunteer match|Subjects with severe liver disease (Group 2) and healthy volunteer subjects (Group 1) matched to the subjects with liver disease
3300366|NCT01835561|Experimental|Part 2: Mild and moderate Liver disease|Subjects with moderate (Group 3) and/or mild (Group 4) liver disease
3300367|NCT01835574|Other|Conditional Cash Transfer and Cognitive-behavioral aftercare|Pre- and post- CCT+AC intervention comparison
3300368|NCT01835600|Active Comparator|with PEEP|10 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
3300369|NCT01835600|Placebo Comparator|without PEEP|0 cmH2O PEEP added to the respiratory curcuit during suspension of mechanical ventilation
3300370|NCT01835613|Other|Tocilizumab|"Biomarkers Measures~At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers."
3300371|NCT01835639|Experimental|Vitamin D Supplementation|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
3300372|NCT01835652|Active Comparator|Active Exercise|Aerobic Exercise Intervention (stationary cycling)
3300373|NCT01835652|Other|Passive Exercise|Passive Exercise (stretching and balance based exercise)
3300374|NCT01835665|Experimental|Nimodipine|
3300375|NCT01835678|Active Comparator|Linagliptin|Linagliptin
3300376|NCT01835678|Placebo Comparator|Placebo|Placebo
3300377|NCT01835691|Experimental|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
3300378|NCT01835691|Experimental|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
3300379|NCT01835704||Chronic pain associated to facet-joints|Patients where the pain can be localized to the facet joints.
3300380|NCT01835704||Chronic pain of other origin|Patients with pain that can not be localized to facet joints.
3300381|NCT01835717||Cognitively normal individuals|
3300382|NCT01835730|Experimental|PE0139 Injection|Single subcutaneous injection of PE0139, 40 mg/mL
3300383|NCT01835730|Placebo Comparator|Placebo|Single subcutaneous injection of 0.9% Sodium Chloride (NaCl) (Placebo)
3300384|NCT01835782|Active Comparator|2.5 grams BID|5 Patients will be evenly randomized into this group
3300385|NCT01835782|Active Comparator|.5 grams BID|5 Patients will be evenly randomized into this group
3300386|NCT01835782|Active Comparator|7.5 grams BID|5 Patients will be evenly randomized into this group
3300387|NCT01835782|Active Comparator|15 grams BID|5 Patients will be evenly randomized into this group
3300388|NCT01835795|Active Comparator|Radial Extracorporeal Shock Wave|Swiss DolorClast® CLASSIC applicator
3300389|NCT01835795|Placebo Comparator|Placebo|Swiss DolorClast® CLASSIC placebo applicator
3300390|NCT01835808||Fractional Flow Reserve|Coronary artery disease patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation).
3300391|NCT01835821|Experimental|prosthesis|"NobelProcera™ Crown shaded zirconia:~The device is an individual, ceramic core (figure a) made of shaded zirconium with an anatomic contour providing homogenous veneering material thickness and a minimum core thickness of 0.4 or 0.7mm. The core is veneered with dental porcelain (IPS e.max Ceram) at the dental laboratory"
3300392|NCT01835834|Experimental|zirconia bridge restoration|"The device is a ceramic core made of shaded zirconium with an anatomic contour core with a minimum of 0.6 mm** thickness and minimal connector size of 4.0 x 3.0 / 9.4 (height x width [mm] / area [mm2])** of high strength zirconia framework providing homogenous veneering material thickness as an external coating with 1.0 - 2.0 mm* wall thickness. The core is veneered with dental porcelain at the dental laboratory.~Intended use and indications:~NobelProceraTM Bridge Shaded Zirconia consists of an individualized, supporting substructure in a ceramic bridge construction for tooth/teeth replacement.~NobelProceraTM Bridge Zirconia is intended for patients in need of prosthetic oral reconstruction in order to restore chewing function. Zirconia bridges for natural tooth restorations are customized, designed, and milled from pre-sintered blanks of zirconia. The multi-unit restorations can be placed in all positions in the mouth."
3300393|NCT01835847|Experimental|A single-arm study|
3300394|NCT01835860|Other|Embolization|Prostate artery embolization
3300395|NCT01835873|Active Comparator|Lactated Ringer's|Crystalloid solution - 1000 ml preload
3300396|NCT01835873|Active Comparator|HES 130/0.42|Hydroxyethyl starch (HES 130/0.42) - 500 ml preload
3300397|NCT01835886|Experimental|Performs stair-climbing|Performs stair climbing
3300398|NCT01835925||Tissue specmien|
3300399|NCT01835938|Experimental|1- Erlotinib|"Erlotinib is a first class HCV entry inhibitor. In this study, Erlotinib will be administered in escalating doses in sequential patient cohorts for 14 days as follows:~Dose level (DL) 1 = 50 mg / day,~Dose level (DL) 2 = 100 mg / day, and~Dose level (DL) 3 = 150 mg / day .~Each Dose Level (DL) includes 4 patients (3 patients treated with Erlotinib and one patient treated with the Placebo). Dose escalation will proceed to the subsequent DL in the absence of DLT (dose-limiting toxicity) in 2 patients receiving Erlotinib."
3300400|NCT01835938|Placebo Comparator|placebo|
3300401|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
3300402|NCT01835951|Other|Grouped Debriefing|Grouped debriefing consists in the analysis of the management of the anaesthesia crisis simulated in the presence of all the subject included in the Grouped Debriefing group.
3300403|NCT01835964|Experimental|Glucose Variability Observation|The study procedures will start after CGM device training & practice using the blinded CGM for 2 days and will continue over the course of ~33 days. The study team will collect data about diabetes management including blood glucose data from fingerstick and CGM values along with insulin pump records throughout the 4 week observation period. Insulin sensitivity will be evaluated at home with predetermined meals' carbohydrate count. At the mid-study point glucose variability will be simulated in clinic with a metabolic challenge (liquid mixed meal) followed 4 hours later by the induction of hypoglycemia with an intravenous insulin injection. Insulin sensitivity, as well as glucagon and epinephrine counterregulatory responses will be evaluated to be related to overall Glucose Variability.
3300404|NCT01835977|Active Comparator|Focal ablation|Focal ablation of unilateral histopathologically confirmed, organ confined prostate cancer using IRE
3300405|NCT01835977|Active Comparator|Extended ablation|Extended ablation unilateral histopathologically confirmed, organ confined prostate cancer using IRE
3300406|NCT01835990|Experimental|geko|For subjects randomized to the experimental treatment arm, one gekoTM device will be applied to each leg according to the manufacturer's instructions by the subject's primary care nurse. All nurses applying the devices must be trained on proper application technique. The old devices will be removed and new devices applied daily. The subject will continue to use the devices until he or she exits the study.
3300407|NCT01835990|Active Comparator|IPCs|The control treatment will consist of the hospital's standard IPC devices. The IPCs will be applied to each leg by the subject's primary care nurse according to the manufacturer's instructions. They will continue to be applied until exit from the study. At the time of withdrawal from the study, the decision regarding continued use of IPCs will be made by the treating physician.
3300408|NCT01836003|Experimental|Tokafatso programmatic intervention|Antenatal clinic receives the Tokafatso programmatic intervention, including educational session, SMS-based facilitation of CD4 result delivery, and patient tracing support.
3300409|NCT01836003|No Intervention|Usual Care|Has not yet received Tokafatso combination programmatic intervention
3300410|NCT01836016|Experimental|conventional medicine|According to the individualized assessment of symptoms and exacerbation risk recommended by revised 2011 GOLD, patients in this group will be given conventional medicine treatment including three drugs, which are Salbutamol (Ventolin®), Formoterol (Oxis Turbuhaler®), Salmeterol / fluticasone (Seretide®).
3300411|NCT01836016|Experimental|traditional Chinese medicine|Patients in this group will receive four types of TCM treatment according to traditional Chinese syndrome differentiation and treatment, which are Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule.
3300412|NCT01836016|Experimental|conventional medicine + TCM|Patients in this group will receive conventional medicine and traditional Chinese medicine.
3300413|NCT01836055||Clinically Isolated Syndrome|Patients diagnosed with Clinically Isolated Multiple Sclerosis
3300414|NCT01836055||Relapsing Remitting MS|Patients diagnosed with Relapsing Remitting Multiple Sclerosis
3300415|NCT01836055||Control Subjects|Aged Matched Healthy volunteers
3300416|NCT01836081|Experimental|fluid responsiveness|
3300417|NCT01836094|Experimental|Methylene Blue|Methylene Blue, 280mg, oral, one time
3300418|NCT01836094|Placebo Comparator|Placebo|FD&C Blue No. 2 (food dye), oral, one time
3300419|NCT01836120|Experimental|Raltitrexed plus Docetaxel|
3300420|NCT01836120|Active Comparator|Docetaxel|
3300421|NCT01836146|Experimental|Renal Artery Ablation|
3300422|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual/standard care. No experimental intervention will be given to this group.
3300423|NCT01836159|Experimental|iPad Intervention|Patients randomized to the iPad arm will be instructed to self-administer 20 minutes of game sessions per day for 10 days over a 2 week (14 day) period.
3300424|NCT01836172|Placebo Comparator|Placebo t.i.d.|Placebo t.i.d.
3300425|NCT01836172|Placebo Comparator|YJP-14 25 mg t.i.d.|YJP-14 25 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
3300426|NCT01836172|Placebo Comparator|YJP-14 50 mg t.i.d.|YJP-14 50 mg t.i.d. YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems.
3300427|NCT01836172|Placebo Comparator|YJP-14 100 mg t.i.d.|YJP-14 is a 50% ethanolic extract of Lindera obtusiloba stems. YJP-14 100 mg t.i.d.
3300428|NCT01836211|Experimental|Fast strategy|High sensitivity cardiac troponin T followed by computed coronary tomography angiography
3300429|NCT01836211|Active Comparator|Standard of care strategy|Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
3300430|NCT01836224|Active Comparator|Noradrenaline|Noradrenaline: Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65.
3380307|NCT04856982|Experimental|Part D: Randomized, Double-Blind, Placebo-Controlled|Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will be randomized to receive BIIB067 100 mg or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.
3300431|NCT01836224|Experimental|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
3300432|NCT01836237|Experimental|Alexis group|In experimental group patients, the surgeon will use Alexis - a wound protector during surgery.
3300433|NCT01836237|No Intervention|Control group|In no intervention group patients, the surgeon will not use any wound protector during surgery.
3300434|NCT01836263||Prevention arm: CCB & i.v. iloprost|prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
3300435|NCT01836263||Prevention arm: bosentan & sildenafil|prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
3300436|NCT01836263||Healing arm: CCB & i.v. iloprost|healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)
3300437|NCT01836263||Healing arm: bosentan & sildenafil|healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil
3300438|NCT01836289|Experimental|High-dose Cyclophosphamide|High-dose Cyclophosphamide
3300439|NCT01836302||Patients with Cerebral Desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
3300440|NCT01836302||Patients without cerebral desaturation|We will compare the primary and secondary outcomes between the patients who experience cerebral desaturations and those that do not.
3300441|NCT01836315||Obese|Defined by a BMI >35 kg/M2
3300442|NCT01836315||Non-Obese|Defined by a BMI <35 kg/M2
3300443|NCT01836328|Active Comparator|Parenteral /oral methadone ratio 1:2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the double of OPTIMISED DOSE of parenteral METHADONE, orally every 24h in 3 administrations during the following 3 days."
3300444|NCT01836328|Experimental|Parenteral /oral methadone ratio 1:1.2|"Far advanced cancer patients with cancer pain hospitalized, and treated with PMTD undergo a preliminary 48 hours observation phase.~Blinded evaluators assess pain management and treatment toxicity and determine an OPTIMISED DOSE of parenteral METHADONE (pain control without toxicity) for each patient.~Only patients with a correct control of pain and without significant toxicity throughout this period are eligible for randomization.~INTERVENTION: Patients randomized to this arm will receive the following Oral Methadone dose: 20% increase of optimised parenteral methadone dose every 24h in 3 administrations during the following 3 days."
3300445|NCT01836341|Experimental|Afatinib w Cisplatin Pemetrexed Chemoradiation|"induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*~*afatinib dose levels: 20mg daily, 30mg daily & 40mg daily (3+3 design) Then adjuvant afatinib x 2 years"
3300446|NCT01836354|Active Comparator|DESERVE education|Intervention group will receive education on stroke preparedness plus risk factor reduction education, and help accessing follow up care with health workers.
3300447|NCT01836354|No Intervention|Usual Care|The usual care group will only receive written preparedness education, which is the standard care for the hospital.
3300448|NCT01836367|Experimental|Ingenol Mebutate 0.015%|two cycles of ingenol mebutate 0.015%
3300449|NCT01836380|Experimental|Swimming Training|The swimming training will be performed at two swimming pools on the campus of The University of Texas at Austin (University Aquatic Center or Gregory Gym pool). In the first 2-3 weeks a swimming instructor will provide personalized skill feedback to the subjects in the swim training group. Subjects will swim 15-20 minutes/day at a relatively low intensity of exercise while they receive swimming skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
3300450|NCT01836380|Experimental|Cycling Training|The cycling training will be conducted in the newly-constructed Exercise Training Intervention Core-Laboratory in the Department of Kinesiology and Health Education on the University of Texas campus. In the first 2-3 weeks a cycling instructor will provide personalized skill feedback to the subjects in the cycle training group. Subjects will cycle 15-20 minutes/day at a relatively low intensity of exercise while they receive cycling skill instructions. As their overall level of fitness and exercise skill improve, the intensity and duration of exercise will increase to 40-45 minutes/day at a moderate intensity of 70-75% of maximal heart rate. Exercise training will be performed three days per week.
3300451|NCT01836393|Experimental|placebo and plai|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
3300452|NCT01836406|Experimental|Keromin Group|
3300453|NCT01836406|Placebo Comparator|Placebo Group|
3300454|NCT01836419|Experimental|young adult group|young adult patients undergoing minor urologic surgery or lower extremity surgery
3300455|NCT01836419|Active Comparator|elderly group|elderly patients undergoing minor urologic surgery or lower extremity surgery
3300456|NCT01836432|Experimental|FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy|"Arm 1A: SOC FOLFIRINOX + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation+ HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue FOLFIRINOX bi-weekly + HAPa bi-weekly 7 days offset from FOLFIRINOX up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage Gem/Nab-Paclitaxel (6 cycles) + HAPa given days 8 and 22 for up to 18 doses total."
3380308|NCT04856891|Experimental|3.0 mg/kg of Lirentelimab (AK002)|Subjects in this arm will receive 6 monthly doses of lirentelimab (AK002) at 3 mg/kg.
3380309|NCT04856891|Placebo Comparator|Placebo|Subjects in this arm will receive 6 monthly doses of placebo at 3 mg/kg.
3380310|NCT04853355|Experimental|Spironolactone Treatment|Patients with non-responsive Diabetic Macular Edema will be treated with Spironolactone in addition to the regular course of monthly aflibercept (Eylea).
3380311|NCT04853017|Experimental|ELI-002 2P Cohort 1|ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)
3380312|NCT04853017|Experimental|ELI-002 2P Cohort 2|ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)
3380313|NCT04853017|Experimental|ELI-002 2P Cohort 3|ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosiing)
3380314|NCT04852419|Experimental|ZN-c5 50mg QD dose cohort|Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily. Safety lead in phase will be applied.
3380315|NCT04852419|Experimental|Zn-c5 150mg QD dose cohort|Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
3380320|NCT04850105||TEGSEDI-exposed cohort|This cohort consist of patients diagnosed with hATTR-PN who are receiving any dose of commercial TEGSEDI and who have provided written informed consent to be included into the study.
3380321|NCT04850105||TEGSEDI-unexposed cohort|This cohort which will consist of patients diagnosed with hATTR-PN who have not taken any dose of TEGSEDI within 25 weeks prior to enrollment and are eligible for TEGSEDI treatment per applicable product label and who have provided written informed consent to be included into the study.
3380322|NCT04848402|Experimental|On-Body Delivery System (OBDS)/Multiple Bolus Injector|On-Body Delivery System (OBDS)/Multiple bolus injector used to administer placebo subcutaneously (SC).
3380323|NCT04848402|Experimental|Single Auto Injector|Single auto injector used to administer placebo SC.
3380324|NCT04847557|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC)
3380325|NCT04847557|Placebo Comparator|Placebo|Placebo administered SC
3380326|NCT04847531||Stage 3 chronic kidney disease patients|Patients with two consecutive eGFR measurements indicating stage 3 CKD (≥30 and <60 mL/min/1.73m2) during the observation period
3380327|NCT04846270|Experimental|Investigational Device|TENA SmartCare Change Indicator
3380328|NCT04845828|Experimental|Sentinel lymph node mapping|The group composed of patients who undergo sentinel lymph node mapping
3380329|NCT04845828|Active Comparator|Routine lymph node dissection|The group composed of patients who undergo routine pelvic lymph node dissection
3380330|NCT04844892|Experimental|PROTECT Diaphragm Pacing Therapy|
3380331|NCT04844606|Experimental|Mirikizumab Dose 1 for UC|"Dose 1 of Mirikizumab is administered subcutaneously (SC)~Dosing is based on the assessments of the participant's weight."
3380332|NCT04844606|Experimental|Mirikizumab Dose 2 for UC|"Dose 2 of Mirikizumab is administered SC~Dosing is based on the assessments of the participant's weight."
3380333|NCT04844606|Experimental|Mirikizumab Dose 3 for UC|"Dose 3 of Mirikizumab is administered SC~Dosing is based on the assessments of the participant's weight."
3380336|NCT04840888|Experimental|LY3484356 (Cohort 1)|LY3484356 administered as single doses orally with (fed) or without food (fasted).
3380337|NCT04840888|Experimental|LY3484356 + Omeprazole (Cohort 2)|LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.
3380338|NCT04840888|Experimental|LY3484356 + Itraconazole (Cohort 3)|LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.
3380339|NCT04840888|Experimental|LY3484356 + Carbamazepine (Cohort 4)|LY3484356 administered as single dose orally on Day 1 and carbamazepine administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of carbamazepine on Day 12 orally followed by single dose of carbamazepine administered orally on Days 13 to 15.
3380342|NCT04838769|Active Comparator|REZŪM|"Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use (IFU). The REZŪM System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with benign prostatic hyperplasia (BPH). It is indicated for men with a prostate volume ≥ 30 ml. The REZŪM System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.~1:1 randomization will occur via the electronic data capture (EDC) system."
3380343|NCT04838769|Active Comparator|Dual Drug Therapy|Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
3380344|NCT04838626|Experimental|PET/CT imaging with [18F]CTT1057|All eligible participants will be enrolled to receive [18F]CTT1057 imaging agent on Day 1 and have PET/CT scan
3300457|NCT01836432|Active Comparator|FOLFIRINOX (SOC) ALONE|"Arm 2A: FOLFIRINOX (Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours) given days 1, 15, 29, 43 & 57~Day 71-80 Disease eval: New disease = salvage Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest~Day 71-80 Disease eval: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue FOLFIRINOX~Ineligible for surgical resection & progressive disease = salvage Gem/Nab-Paclitaxel"
3380345|NCT04836832|Experimental|Treatment (acalabrutinib, duvelisib)|Patients receive acalabrutinib PO BID, and duvelisib PO BID on days 1-28. Treatment repeats every 28 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Beginning cycle 19, patients receive acalabrutinib PO BID for up to 60 months in absence of disease progression or unacceptable toxicity.
3380347|NCT04829448|Experimental|Protein Intervention Group|Patients who receive the protein nutritional supplement as part of their prescribed exercise-based rehabilitation program.
3380348|NCT04829448|No Intervention|Control Group|Patients who receive the prescribed exercise-based rehabilitation program, without protein supplement.
3380351|NCT04828707|Active Comparator|Migraine prevention treatment with active Nerivio|Participants will treat with an active Nerivio device every other day for migraine prevention.
3380352|NCT04828707|Sham Comparator|Migraine prevention treatment with sham Nerivio|Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
3380353|NCT04826003|Experimental|Part I: Dose-escalation of RO7122290|The dose-escalation of RO7122290 will use a QW dosing schedule of RO7122290 in combination with a Q3W dosing interval for cibisatamab with obinutuzumab pre-treatment. The starting dose for RO7122290 will be 35 mg, which represents the human equivalent dose for the minimal pharmacologically active dose (1 mg/kg) in mice.
3380354|NCT04826003|Experimental|Part II: Dose-expansion of RO7122290|Part II of this study will evaluate selected dose levels of RO7122290 from Part I (a QW RO712290 administration in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment) in a Q3W regimen in combination with a Q3W cibisatamab administration with obinutuzumab pre-treatment.
3380357|NCT04821284|Experimental|Arm I (sonazoid, ultrasound, chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity. Patients also receive sonazoid IV over 20 minutes and undergo CEUS.
3380358|NCT04821284|Active Comparator|Arm II (chemotherapy)|Patients receive standard of care chemotherapy consisting of gemcitabine hydrochloride and nab-paclitaxel IV over 60 minutes on days 1, 8 and 15 OR FOLFIRINOX IV on days 1 and 2. Treatments repeat every 28 days for up to 3 cycles for gemcitabine and nab-paclitaxel, and every 14 days for up to 7 cycles for FOLFIRINOX in the absence of disease progression or unacceptable toxicity.
3300458|NCT01836432|Experimental|Gemcitabine/Nab-Paclitaxel+Algenpantucel-L HAPa Immunotherapy|"Arm 1B: Gemcitabine/Nab-Paclitaxel + Algenpantucel-L (HAPa) Immunotherapy~Day 71-80 Disease evaluated: New distant disease = salvage regimen FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total.~Day 71-80 Disease evaluated: No distant disease = 5-FU or capecitabine plus Radiation + HAPa on days 1 and 15 of Chemoradiotherapy.~Post-Chemoradiation Disease evaluation: surgically resectable = surgery + adjuvant SOC Gemcitabine + HAPa given days 1 and 15 for up to 18 doses total.~Post-Chemoradiation Disease evaluation: not eligible for surgical resection (Stable) = continue Gem/Nab-Paclitaxel + HAPa given on days 8 and 22 for up to18 doses of algenpantucel-L Immunotherapy.~Post-Chemoradiation Disease evaluation: non-eligible for surgical resection (Progression) = salvage FOLFIRINOX + HAPa given every 14 days (alternate weeks of FOLFIRINOX) for up to 18 doses total."
3300459|NCT01836432|Active Comparator|Gemcitabine/Nab-Paclitaxel (SOC) Alone|"Arm 2B: Gemcitabine/Nab-Paclitaxel (SOC) Alone~SOC Gem/Nab-Paclitaxel: nab-paclitaxel 125mg/m^2 IV over 30-40 minutes followed by gemcitabine 1000 mg/m^2 IV over 30-60 minutes for 3 weeks with 1 week rest. Given on days 1, 8, 15, 29, 36, 43, 57, 64 and 71~Day 71-80 Disease evaluated: New distant disease = salvage FOLFIRINOX given every 14 days~Day 71-80 Disease evaluation: No disease = 5-FU or capecitabine plus Radiation (5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks or Capecitabine 825 mg/m^2 PO BID M-F) concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions total dose of 50.4 Gy~Post-XRT Disease eval: surgically resectable = surgery + adjuvant SOC Gemcitabine~Ineligible for surgical resection & stable disease = continue gem/nab-paclitaxel given for 3 weeks (days 1, 8 and 15) with 1 week rest~Ineligible for surgical resection & progressive disease = salvage FOLFIRINOX given every 14 days"
3300460|NCT01836484||Surgically staged endometrial and cervical carcinoma|
3300461|NCT01836536|Other|BEVACIZUMAB|BEVACIZUMAB standard of care
3300462|NCT01836562|Other|STEM CELL|intra thecal injection of MNC stem cell therapy
3300463|NCT01836575|Experimental|Arm B|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle] + Antiemetic therapy at investigator's discretion.
3300464|NCT01836575|Active Comparator|Arm A:|Pemetrexed, 500mg/m2 + appropriate vitamin supplementation + Antiemetic therapy at investigator's discretion.
3300465|NCT01836588|Active Comparator|gentle tissue extraction (curettage)|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
3380386|NCT04812925|Experimental|efgartigimod PH20 SC|Patients receiving efgartigimod PH20 SC treatment
3380387|NCT04812795|Experimental|Culturally tailored|The anti-smoking and anti-industry messages will be culturally tailored to specifically reach out to young adult SMW. They will receive only messages that are culturally tailored at baseline and weeks 1, 2, and 3.
3380388|NCT04812795|Active Comparator|Non-culturally tailored|The anti-smoking and anti-industry messages will not be culturally tailored. They will receive only messages that are not culturally tailored at baseline and weeks 1, 2 and 3.
3380389|NCT04811040|Experimental|Lenacapavir (LEN), GS-5423, GS-2872 Dose C|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + GS-5423 + GS-2872 Dose C followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + GS-5423 + GS-2872 Dose C.
3380390|NCT04811040|Experimental|LEN, GS-5423, GS-2872 Dose D|Participants will begin treatment by receiving LEN Dose A + LEN Dose B + GS-5423 + GS-2872 Dose D followed by LEN Dose A on the next day. The last treatment regimen will include LEN Dose B + GS-5423 + GS-2872 Dose D.
3380391|NCT04809766|Experimental|Cohorts I, II, and III (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days 39-41.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
3380392|NCT04809766|Experimental|Cohort IV (FH-TCR Tᴍsʟɴ)|"LYMPHODEPLETION CHEMOTHERAPY: Patients receive cyclophosphamide IV and fludarabine IV on days -3 to -1.~T-CELL THERAPY: Patients receive FH-TCR-Tᴍsʟɴ IV over 60-120 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity."
3300466|NCT01836588|Active Comparator|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
3300467|NCT01836601|No Intervention|Pre-nighttime communication intervention arm|This arm is the pre-intervention arm of parents, nurses, and residents before the nighttime communication bundle has been enacted.
3300468|NCT01836601|Experimental|Post-nighttime communication intervention arm|This arm is the post-intervention arm of parents, nurses, and residents after the nighttime communication bundle has been enacted.
3300469|NCT01836614|Active Comparator|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes. The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
3300470|NCT01836614|Placebo Comparator|Saline|The saline will be administered over an infusion pump over 10 minutes and followed by a bolus. The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
3300471|NCT01836627|Experimental|Treatment Hyperinsufflation Therapy|Treatment group will have 15 minute hyperinsufflation treatments twice a day for one year.
3300472|NCT01836627|No Intervention|Control|The control group will continue with their current daily care
3300473|NCT01836653|Experimental|mFOLFOX + Bmab|mFOLFOX plus bevacizumab
3300474|NCT01836653|Active Comparator|mFOLFOX + Cmab|mFOLFOX plus cetuximab
3380393|NCT04809090|Active Comparator|SMT Group|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews
3300475|NCT01836679|Experimental|Arm 1|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive Chidamide 20mg orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
3300476|NCT01836679|Placebo Comparator|Arm 2|Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1.The chemotherapy cycles are repeated every 3 weeks to a maximum of 4 cycles. Patients also receive placebo orally twice a week until disease progression,or unacceptable toxicities,or withdrawal of consent occurred.
3300477|NCT01836692|Experimental|Thoracic radiotherapy|Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
3300478|NCT01836705|Experimental|Single-sequence|SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)
3300479|NCT01836718||HCV RNA (-) on anti-viral therapy|Patients undergoing liver transplantation who are documented HCV viral load undetectable while on antiviral therapy
3300480|NCT01836718||HCV RNA (+) on anti-viral therapy|Patients undergoing liver transplantation who are receiving anti-viral therapy and who have a documented detectable HCV viral load
3300481|NCT01836718||HCV RNA (+) not on anti-viral therapy|Patients undergoing liver transplantation who are not currently receiving anti-viral therapy and are documented viral load positive will be included and serve as a comparison group
3300482|NCT01836731|Experimental|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
3300483|NCT01836731|Experimental|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
3300484|NCT01836731|No Intervention|Control|"The control group is not enrolled in the CBEHPP.~Because of the government's commitment for the national roll out to the CBEHPP, the control population will receive the intervention as soon as possible following the conclusion of the trial phase. Nevertheless, we will continue to evaluate the sustained impact of the intervention for two additional years by monitoring various behavioural outcomes and indicators and their impact on exposure outcomes (drinking water, hand hygiene, consumption, schooling and labour market participation etc.). We will use data from the RCT phase and clinical records to estimate the effect of any sustained impact on health. Long term impacts can be inferred by using data from the trial as well as data on long term behavioural outcomes."
3300485|NCT01836744|Active Comparator|survival rate autologous bone|dental implant placement in the previous sinus lift side with autologous bone; dental implant placement in the previous sinus lift side with xenograft material side;
3300486|NCT01836744|Active Comparator|survival rate axenograft material|dental implant placement in the previous sinus lift side with xenograft material side;
3300487|NCT01836757|Experimental|MSM group|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
3300488|NCT01836757|Placebo Comparator|Placebo Group|Placebo 3 gr twice a day for 26 weeks (6 gr/day total)
3300489|NCT01836770||Transforaminal Epidural Steroid Injection|Patients with a history of lumbosacral radiculopathy or lumbar herniated nucleus pulposus, scheduled for Transforaminal Epidural Steroid Injection.
3300490|NCT01836783|Experimental|Amnion Allograft|Atraumatic tooth extractions and amnion allograft procedures
3300491|NCT01836783|Active Comparator|Allograft|Atraumatic tooth extractions and allograft procedures
3300492|NCT01836796|Active Comparator|Lactobacillus Reuteri low|100 million Lactobacillus Reuteri once daily
3300493|NCT01836796|Active Comparator|Lactobacillus Reuteri High|10 billion Lactobacillus Reuteri once daily
3300494|NCT01836796|Placebo Comparator|Placebo|
3380394|NCT04809090|Experimental|SMT+CA|This group will receive a standard 8 SMT (Stress Management Training) psychological interviews and subjects will use an APP together a CA (Conversational Agent) an Artificial Intelligence.
3380395|NCT04809090|Experimental|Only CA|This group will receive only an APP together a CA (Conversational Agent) an Artificial Intelligence.
3380396|NCT04809090|No Intervention|Waiting-List|This group will not receive any intervention
3380398|NCT04807972|Experimental|Phase 1b Dose Escalation|Participants will receive escalating doses of ABBV-927 in combination with modified FOLFIRINOX (mFFX) and Budigalimab.
3300495|NCT01836822|Experimental|Bronchoscopic lymph node sampling|Several different sampling techniques will be used in each patient. They include: EBUS guided transbronchial needle aspiration (EBUS-TBNA), EBUS guided transbronchial forceps biopsy (EBUS-TBFB), large bore (19G) histologic needle biopsy of the mediastinal lymph nodes, forceps biopsy of bronchial mucosa in central and peripheral bronchi
3300496|NCT01836835||Hyperemesis gravidarum|Women diagnosed with hyperemesis gravidarum admitted to hospital Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
3380399|NCT04807972|Experimental|Phase 2 Cohort A|Participants will receive modified FOLFIRINOX on Day 1 and Day 15 of each 28 day cycle.
3380400|NCT04807972|Experimental|Phase 2 Cohort B|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV-927 in each 28 day cycle.
3380401|NCT04807972|Experimental|Phase 2 Cohort C Expansion|Participants will receive modified FOLFIRINOX (Day 1 and Day 15) + ABBV 927 and Budigalimab as Intravenous (IV) Infusion in each 28 day cycle.
3380402|NCT04802681|Other|Wirecath - PressureWire X|Patients will undergo simultaneous FFR measurements with the Wirecath and PressureWire X simultaneously.
3380403|NCT04799964|Experimental|Group A|Flow diverter(Ton-bridgeMT, China)
3380404|NCT04799964|Active Comparator|Group B|Tubridge(Microport, China)
3300497|NCT01836835||Healthy pregnant women|Women with presumed normal pregnancy Pregnancy Unique Questionnaire of Emesis (PUQE) and 24 hours self-reported nutritional intake form administered
3300498|NCT01836848|Experimental|indocyanine green|in this arm we do the Intervention 'measuring cerebral perfusion by NIRS with ICG', the pat. gets before a CT-Scan with perfusion measurement a indocyanine green bolus i.v. and a measurement of cerebral perfusion with near-infrared-spectroscopy
3300499|NCT01836861|Experimental|IPI-145 and [14C] IPI-145|
3300500|NCT01836874||Topiramate|
3380408|NCT04797260|Experimental|Gene therapy|In this arm, 10 patients will be included for gene therarpy
3380409|NCT04795544|Experimental|cuff inflation by the residual volume|"LMA will be inserted with the initial inflating volume correspondent to residual volume group (RV group):~volume result of equilibrating pressure between intracuff pressure and atmospheric pressure. A 20 mL syringe without plunger is connected to the laryngeal cuff for 5 minutes"
3380410|NCT04795544|Experimental|cuff inflation by half of the maximum volume|LMA will be inserted with the initial inflating volume correspondent to half of the maximum volume recommended by manufacturers (MV group)
3380411|NCT04795544|Placebo Comparator|unchanged cuff inflation volume|LMA will be inserted unchanged (NV group): LMA is unpacked and used without inflating or deflating the cuff.
3380412|NCT04784533|Experimental|Part A, Period 1 - Low dose|8 mg BID CTP-543 for 24 weeks
3300501|NCT01836887|Placebo Comparator|Intervention 1|Very low polyphenol fruit based drink (control)
3300502|NCT01836887|Active Comparator|Intervention 2|Polyphenol-enriched fruit-based drink - low
3300503|NCT01836887|Active Comparator|Invervention 3|Polyphenol-enriched fruit-based drink - high
3380413|NCT04784533|Experimental|Part A, Period 1 - High dose|12 mg BID CTP-543 for 24 weeks
3380414|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from low dose|Dose reduction for a maximum of 24 weeks for those previously receiving 8 mg BID
3380415|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from low dose|Placebo for a maximum of 24 weeks for those previously receiving 8 mg BID
3300504|NCT01836900|Active Comparator|Standard Therapy|Endoscopic therapy with Standard Clip + injection of epinephrine solution or thermal therapy + injection of epinephrin-solution
3300505|NCT01836900|Experimental|OTSC (Over The Scope Clip)|Endoscopic therapy with Application of OTSC Clip and Injection of epinephrin-solution
3300506|NCT01836913||Radiotherapy for esophageal cancer|Patients with histology proven esophageal cancer who are planned for high dose radiotherapy with or without chemotherapy with or without surgery.
3380416|NCT04784533|Experimental|Part A, Period 2 - Dose reduction from high dose|Dose reduction for a maximum of 24 weeks for those previously receiving 12 mg BID
3380417|NCT04784533|Placebo Comparator|Part A, Period 2 - Drug discontinuation from high dose|Placebo for a maximum of 24 weeks for those previously receiving 12 mg BID
3380418|NCT04784533|Experimental|Part B - Low dose|8 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
3380419|NCT04784533|Experimental|Part B - High dose|12 mg BID CTP-543 for a maximum of 24 weeks for those meeting loss of maintenance criteria
3300507|NCT01836926|Active Comparator|Open intersphincteric resection|surgical Instruments for open approach intervention: Open laparotomy through abdominal incision and mobilization of the colon and rectum up to the splenic flexure with high ligation of the inferior mesenteric vessels and mesorectal excision till the levator ani then the peranal approach to resect the distal margin of the rectum through high or low intersphincteric resection in the plane between internal and external anal sphincters.
3380421|NCT04778722|Experimental|Probiotic group|pilot study with one interventional group
3300508|NCT01836926|Active Comparator|laparoscopic intersphincteric resection .|"instruments used: 4 or 5 laparoscopic trocars (two or three (10-mm) trocar, Two 5-mm trocars and a 12-mm trocar with reducers),Three 5-mm fenestrated grasping forceps, Five-millimetre coagulating shears, a 5-mm straight grasping forceps, Harmonic scalpel, 5 or 10 mm, a 10-mm fenestrated forceps, a 10-mm dissector,5 mm Bipolar grasper, a 5-mm needle holder, Twelve-millimetre linear staplers~intervention:~Trocar Placement and Exposure~Rectosigmoid Mobilization and Control of Inferior Mesenteric Vessels~Taking Down the Splenic Flexure~rectal dissection till the levator ani muscle and resection of thye lateral ligaments~then the peranal phase as in the laparotomy approach."
3300509|NCT01836939|Active Comparator|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
3300510|NCT01836939|Active Comparator|TSO 7500|TSO 7500: 7500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
3300511|NCT01836952||Infants|Infant born via vaginal delivery
3300512|NCT01836965|Experimental|Social Skills Intervention|The intervention is a 12-week social skills training program that will consist of a 90 minute group therapy session followed by a 90 minute peer generalization session (in the form of a photography class with typically developing peers) meeting once per week. Each cohort will consist of 6 adolescents with Aspergers or high-functioning autism, who will be joined by 6 typically-developing peers for the photography class. During the group therapy session adolescents will discuss and watch video clips addressing social skills topics relevant to their age group. They will have a chance to practice these skills when paired with a typically developing peer for the photography class.
3300513|NCT01836978|No Intervention|Control|Patients in this group will follow standard MUHC clinical guidelines. This group will receive general instructions, by the preoperative clinic nurse, on exercises (breathing, ankle rotation) to be done before and after surgery. They will also be seen by a nutritionist who will provide general counseling for healthy eating.
3300514|NCT01836978|Experimental|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program, and stress reduction strategies.
3300515|NCT01836991|Other|D2 surgery|D2 surgery(No.1、No.3、No.4sb、No.4d、No.5、No.6、No.7 and No.8a、No.9、No.11p、No.12a lymph node)
3300516|NCT01836991|Experimental|D2+ surgery|D2+ surgery(D2+8p、12b、13、14v lymph node)
3300517|NCT01837004|Experimental|CORTEX|The CORTEX group will attend 10, 2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
3300518|NCT01837017|Experimental|Home-based Exercise|The home-based exercise group attends 4 exercise instructional sessions lead by a train exercise specialist. The exercise protocol focuses on improving balance, walking, lower limb and core muscle strength, and spasticity. The instructional session teaches participants a standardized series of exercises that focus on balance, muscle strength, and stretching. The exercises target lower limb & core muscle function. Once taught, participants will perform the exercises 3 times a week in their home as outlined in a manual. Subjects return in the first month and second month to ensure that exercises are being executed with correct form and appropriate intensity level. Compliance of at-home exercise will be assessed with diaries that participants complete every other week.
3300519|NCT01837017|No Intervention|Control|Wait-list control.
3300520|NCT01837030|Other|Oral Iron|
3300521|NCT01837030|Other|Oral Iron and Capsule Endoscopy|
3300522|NCT01837043|Experimental|Belatacept|Subjects will be converted from standard of care CNI therapy to Belatacept 10 mg/kg IV on post renal transplant Day 7 (+/- 3 days). As suggested in the package insert for de novo dosing, further dosing of belatacept will be given as 10 mg/kg IV at weeks 2, 4, 8 and 12 then 5 mg/kg at week 16 and then every 4 weeks (+/- 5 days) through week 52. CNI will be stopped during the first belatacept infusion.
3300523|NCT01837043|Active Comparator|Calcineurin Inhibitor|Patients randomized to this arm will remain on the current CNI as prescribed by post-transplant standard of care therapy.
3300524|NCT01837082|Active Comparator|Iron|ferric carboxymaltose
3300525|NCT01837082|Placebo Comparator|Placebo|Sodium chloride 0.9%
3300526|NCT01837095|Experimental|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
3300527|NCT01837108|Placebo Comparator|Placebo|fully mimicking placebo 50 mg bid during 8 days
3300528|NCT01837108|Experimental|eplerenone|eplerenone 50 mg bid during 8 days
3300529|NCT01837121|Other|the SMS group|the diabetic retinopathy patient in the SMS group will receive a SMS reminder message about the revisit time,address 1 week and 3 day before the appointment.
3300530|NCT01837121|No Intervention|the control group|the diabetic retinopathy patient in the control group won't get any reminder message before the appointment.
3300531|NCT01837134|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks. After 12 weeks they will also be given a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. During the next 12 weeks they will get care calls from the study centre aiming to discuss measured data and to fix target agreements.
3300532|NCT01837134|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
3300533|NCT01837134|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements. After 12 weeks the care calls be be given once per month for further 9 months.
3300534|NCT01837147|Experimental|Web-based Tracking Group|Technology-Based Physical Activity Promotion
3300535|NCT01837147|Active Comparator|Pedometer Group|Participants assigned to this group will receive a pedometer.
3380423|NCT04766723|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units) into muscles of the upper limbs."
3380424|NCT04766723|Placebo Comparator|Placebo|"Unilateral Treatment Period (1 treatment cycle): subjects to receive unilateral intramuscular placebo injection into muscles of the upper limb.~Open Label Bilateral Treatment Period (1 treatment cycle): subjects to receive bilateral intramuscular injection of NT 201 (130-165 units per arm) into muscles of the upper limbs."
3380425|NCT04765449|Experimental|ARM A: Covid-19 Patients Receiving CTLs|Patients who have an HLA antigen in common with COVID-19 fighting T cells will be admitted to the hospital and receive the COVID-19 T cells. They will be premedicated with diphenhydramine and acetaminophen before the cells are infused intravenously. The patients will be monitored for side effects for at least 4 days prior to discharge. Close monitoring will continue in the patients' homes for 14 days. Three to six patients will receive a specific dose of T cells, and then if there are no serious side effects, the dose will be increased for the next group of patients. There are 4 doses of T cells to be tested, and each patient will complete a 14 day monitoring period before the next patient can be treated.
3380426|NCT04765449|No Intervention|ARM B: Covid-19 Patients Not Receiving CTLs|Patients in the observation arm will not have inherited an HLA antigen in common with the COVID-19 T cells and so cannot receive the T cells. They will be monitored by the study staff for the 14 day monitoring period in their homes. They will be taught to record their own blood pressure, temperature, and oxygen level (pulse oximetry) at home and report this information, as well as their progress in getting over the COVID-19 infection, to the study staff every day by phone. The outcomes of patients on arm B will be compared to the outcomes of patients treated on Arm A to see if the T cells made a difference in how patients recovered from COVID-19. Patients in Arm B are not prevented from being treated with any available COVID-19 therapy.
3380433|NCT04755816|Sham Comparator|Control Group|Standard heart failure educational information.
3380434|NCT04755816|Experimental|Dietary Sodium Intervention|The dietary sodium intervention facilitates lower sodium choices using tailored push notifications.
3380435|NCT04755816|Experimental|Clinical Worsening Intervention|The clinical worsening intervention promotes self-monitoring and self-management and is linked tailored push notifications.
3300536|NCT01837160||Healthy Volunteers|"10 patients with normal echocardiogram studies and no history of ischaemic heart disease.~Patients to recieve CT-PET with fluciclatide, cardiac MRI scan, CT-coronary angiogram and echocardiogram."
3300537|NCT01837160||Moderate Aortic Stenosis (n=10)|"Patients with moderate aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3300538|NCT01837160||Mild Aortic Stenosis (n=10)|"Patients with mild aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3380436|NCT04755816|Experimental|Dietary Sodium and Clinical Worsening|Full access to all content in the control, dietary sodium, and clinical worsening interventions.
3380438|NCT04754191|Experimental|Treatment: all patients|Enfortumab will be administered in monotherapy on days 1, 8, and 15 as part of a 28-day cycle at 1.25 mg/kg up to 125 mg.
3380439|NCT04752332|Experimental|Abemaciclib Plus (+) Endocrine Therapy (ET)|Abemaciclib administered orally and standard adjuvant ET (physician's choice) administered according to package label.
3380440|NCT04752332|Active Comparator|Placebo + ET|Placebo administered orally and standard adjuvant ET (physician's choice) administered according to package label.
3380441|NCT04747977|Experimental|OTX-DED 0.2mg|Approximately 50 subjects
3380442|NCT04747977|Experimental|OTX-DED 0.3mg|Approximately 50 subjects
3300539|NCT01837160||Severe aortic Stenosis (n=10)|"Patients with severe aortic stenosis. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 - 24 months."
3380443|NCT04747977|Placebo Comparator|Hydrogel Vehicle (HV)|Approximately 50 subjects
3300540|NCT01837160||Severe Aortic Stenosis for AVR (n=10)|"Patients with severe aortic stenosis proceeding to aortic valve replacement. Patients are to recieve Cardiac MRI, CT-PET scan, echocardiography and CT-coronary angiogram scan at baseline.~They will undergo a repeat CT-PET scan 3 months after the operation.~They will undergo repeat cardiac MRI scan and echocardiogram at 12 months after the operation."
3300541|NCT01837173||Extracapsular LNI|Patients with positive lymph nodes that show extracapsular lymph node involvement
3380449|NCT04738123|Experimental|KarXT|
3380450|NCT04738123|Placebo Comparator|Placebo|
3380451|NCT04737772|Active Comparator|Standard Quitline Treatment As Usual (TAU)|State quitline treatment as usual
3300542|NCT01837173||Intracapsular LNI|Patients with positive lymph nodes that show NO extracapsular lymph node involvement
3300543|NCT01837186||EFP|Empyema following pneumonectomy
3300544|NCT01837186||nEFP|No empyema following pneumonectomy
3380452|NCT04737772|Experimental|QL Marijuana Check-Up intervention (QL-MJCU).|Newly developed intervention for co-users of marijuana and tobacco.
3300545|NCT01837199|Experimental|Smoking|Metronidazole plus Amoxicillin
3300546|NCT01837199|Experimental|Non-Smoking|Metronidazole plus Amoxicillin
3300547|NCT01837225||Control|Patients in the control arm will not receive the fluorescent contrast agent (5-ALA); however, intraoperative fluorescence imaging will still be performed. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3300548|NCT01837225||Low Dose Contrast Agent|Patients in the low dose arm will receive 15 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3380453|NCT04734106|Experimental|Desert Harvest Super-Concentrated, Freeze-Dried Aloe Vera Capsules|Participants will self-administer Desert Harvest super-concentrated, freeze-dried aloe vera capsules orally over a sixteen week period. The dosing regimen includes administering 3 capsules twice daily for the first month, 3 capsules three times daily for the second month, and 4 capsules three times daily for the third month. During the fourth month, participants will administer 10 capsules per day the first week (4 in the morning, 2 in the afternoon, and 4 in the evening), 8 capsules per day the second week (4 in the morning, 4 in the evening), 6 capsules per day the third week (3 in the morning, 3 in the evening), and 4 capsules per day the fourth week (2 in the morning, 2 in the evening). A participant must stay on a minimum of 6 capsules per day for the first three months in order to remain in the study.
3380454|NCT04734106|Placebo Comparator|Placebo|Participants will self-administer placebo capsules orally, matching the dosing regimen of the experimental treatment, over a sixteen week period. Placebo capsules will be identical in appearance and packaging to the experimental capsules.
3380455|NCT04732429|Experimental|Active Drug|Part B is the 6-month, randomized, double-blind (Subject/Investigator/Sponsor), placebo-controlled, 2-period crossover study consisting of 2 intervention periods of 12 weeks each to evaluate the safety and efficacy of the optimal dose of HST5040 in PA and MMA subjects ≥ 2 years old (N = minimum 12) in addition to SoC determined in Part A (within-subject dose escalation).
3380456|NCT04732429|Experimental|Placebo|Placebo in addition to standard of care.
3380457|NCT04729621|Experimental|TVB-009 main treatment period|TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26
3380458|NCT04729621|Active Comparator|PROLIA main treatment period|Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26
3380459|NCT04729621|Experimental|TVB-009 main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period
3380460|NCT04729621|Active Comparator|PROLIA main / PROLIA transition period|Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
3300549|NCT01837225||High Dose Contrast Agent|Patients in the high dose arm will receive 30 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3300550|NCT01837225||Intermediate Dose Contrast Agent|Patients in the intermediate dose arm will receive 20 mg/kg 5-ALA fluorescent contrast agent administered orally 3 hours prior to intraoperative fluorescence imaging. Patients will receive conventional breast conservation surgery and care independent of the contrast agent dose they receive.
3300551|NCT01837238|Experimental|beta-hydroxy beta-methylbutyrate|Calcium-HMB (3g) will be consumed daily for 6 months by all participants assigned to the HMB group.
3300552|NCT01837238|Placebo Comparator|Placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
3300553|NCT01837251|No Intervention|Control Arm|Patients receive bevacizumab 15 mg/kg iv on day 1 followed by gemcitabine 1000mg/m² iv on day 1 & 8 and carboplatin AUC4 iv on day 1 every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
3300554|NCT01837251|Experimental|Research Arm|Patients receive bevacizumab 10 mg/kg iv on day 1 & 15 followed by PLD 30mg/m² iv on day 1 carboplatin AUC4 iv on day 1 every 4 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities. Patients then continue to receive bevacizumab 15 mg/kg iv every 3 weeks until progression disease or unacceptable toxicities.
3300555|NCT01837264|Experimental|Bone Marrow Cell Concentrate|
3300556|NCT01837277|Experimental|Dolutegravir|Intervention: Patients will receive ART regimen based on investigational drug Dolutegravir 50 mg QD + TDF 300 mg QD+ 3TC 150 mg BID
3300557|NCT01837277|Active Comparator|Efavirenz|Intervention: Patients who received ART regimen based efavirenz (EFV 600 mg QD +TDF 300 mg QD+ 3TC 300 mg QD) for one year, befor the use of DTG as SOC for first-line therapy (historic controls)
3300558|NCT01837290|Active Comparator|Group Dexmedetomidine (Group D)|Midazolam 0.02 mg/kg intravenously + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication + Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
3300559|NCT01837290|Placebo Comparator|Group Control (Group C)|Midazolam 0.02 mg/kg + saline infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5mg) (n=30)
3300560|NCT01837303||Liquid based cytology|All participants will undergo both manual and conventional automated liquid based cytology (pap smear, cervical cytology).
3300561|NCT01837316|Experimental|FF/VI|A single dose inhalation of FF/VI 100/25 mcg in the morning
3300562|NCT01837316|Placebo Comparator|Placebo|A single dose inhalation of matching placebo in the morning
3300563|NCT01837329|Experimental|Tetrathiomolybdate|"Dose Escalation - It is aimed at determining the maximum tolerated dose of TM in combination with carboplatin and pemetrexed.~Dose Expansion - The dose expansion portion of the study will begin after completion of the dose escalation phase."
3300564|NCT01837342|Other|Sigmoidectomy arm|Standard of care arm : sigmoid reserction after randomisation
3300565|NCT01837342|Experimental|Control arm|laproscopic drainage and washing
3300566|NCT01837355|Placebo Comparator|Placebo|placebo once daily for 12 weeks
3300567|NCT01837355|Experimental|Lactobacillus rhamnosus|lactobacillus rhamnosus once daily for 12 weeks
3300568|NCT01837381|Other|Transarterial Ethanol Ablation (TEA)|Two treatment sessions at 2 months apart were given and started within 4 weeks after randomization.
3300569|NCT01837394|Active Comparator|Block arm|Ultrasound guided block of the SN and ONP with 7.5 ml of Ropivacaine 7.5 mg/ml injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
3300570|NCT01837394|Placebo Comparator|Placebo arm|Ultrasound guided placebo block of the SN and ONP with 7.5 ml of isotonic saline solution injected at each site, respectively, immediately prior to induction of general anesthesia. Standard postoperative analgesia with paracetamol 1 g every 6 hours and Morphine 5 mg as needed. Ondansetron or Metoclopramide as needed for nausea.
3300571|NCT01837407|Other|Surgical flap|The flap includes the nerve for repair of the soft tissue and nerve defects
3300572|NCT01837420|Other|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 16.
3300573|NCT01837420|Experimental|VB-201 80mg|Subjects will receive VB-201 80mg/day for 24 weeks
3300574|NCT01837420|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks
3300575|NCT01837433|Experimental|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
3300576|NCT01837433|Active Comparator|Prednisone 6 weeks|Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.
3300577|NCT01837446|Experimental|Morphine mouthwash|The morphine group uses the mouthwash of 2% morphine solution (20 mg morphine sulfate diluted in 100 mL of water), 10 mL every three hours; six times a day. The morphine solution is prepared by the faculty of pharmacy under supervision of the Food and Drug Organization of the local Medical University.
3300578|NCT01837446|Active Comparator|Magic mouthwash|The magic group uses a mouthwash contained a mixture of 240 mL magnesium aluminum hydroxide (Alborz Co., Iran), 25 mL 2% viscous lidocaine (SinaDaru Co., Iran), and 60 mL diphenhydramine (Emad Co., Iran), 10 mL every three hours; six times a day.
3300579|NCT01837459||Obese-Normal|Obese with Apnea Hypopnea index (AHI) <1
3300580|NCT01837459||Obese-SDB|Obese and with AHI>1
3300581|NCT01837459||Lean-Normal|Non-obese with AHI<1
3300582|NCT01837459||Lean-SDB|Non-obese with AHI>1
3300583|NCT01837472|Experimental|Probiotic|
3300584|NCT01837472|Placebo Comparator|Placebo|
3300585|NCT01837485|Experimental|Lactol|
3300586|NCT01837485|Placebo Comparator|Placebo|
3300587|NCT01837498||Neostigmine group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
3300588|NCT01837498||Sugammadex group|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
3300589|NCT01837511||Cancer Group|Patients with pathologically proven stage I, II and III NSCLC.
3300590|NCT01837576|Experimental|Calcipotriol plus BDP gel in different doses|A-E: calcipotriol, BDP gel in different concentrations
3300591|NCT01837589|Other|QCT and DXA|All the patients will have both QCT and DXA
3300592|NCT01837602|Experimental|cMet positive breast cancer patients|Metastatic breast cancer patients with an accessible tumor (cutaneous, subcutaneous, or superficial) and/or a palpable adenopathy/mass, with ≥ 30% tumor cells expressing cMet as demonstrated on immunohistochemical analysis . The intensity for cMet IHC should be greater than or equal to 1+. The targeted tumor must be accessible (i.e. is not near a great vessel or the spinal cord) and can be surgically excised or biopsied.
3300593|NCT01837615|Experimental|Photopill treatment|
3300594|NCT01837628|Active Comparator|Lidocaine gel|Intraurethral Lidocaine gel 2%
3300595|NCT01837628|Experimental|Paraffin Oil|Intraurethral injection
3300596|NCT01837641|Experimental|LY3002813-Single 0.1 mg/kg then multiple 0.3 mg/kg|0.1 milligram per kilogram (mg/kg) single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks intravenously (IV)
3300597|NCT01837641|Experimental|LY3002813-Single then multiple 0.3 mg/kg|0.3 mg/kg single dose then 0.3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3300598|NCT01837641|Experimental|LY3002813-Single then multiple 1 mg/kg|1 mg/kg single dose then 1 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3300599|NCT01837641|Experimental|LY3002813-Single then multiple 3 mg/kg|3 mg/kg single dose then 3 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3300600|NCT01837641|Experimental|LY3002813-Single then multiple 10 mg/kg|10 mg/kg single dose then 10 mg/kg LY3002813 given every 4 weeks for up to 16 weeks IV
3300601|NCT01837641|Placebo Comparator|Placebo-Single then multiple|Placebo given once, then every 4 weeks for up to 16 weeks IV
3300602|NCT01837641|Experimental|LY3002813-SC|Up to 3 mg/kg LY3002813 given once subcutaneously (SC)
3300603|NCT01837641|Experimental|LY3002813-IV|Up to 3mg/kg LY3002813 given once intravenously (IV)
3300604|NCT01837667|Experimental|LB-100 for Injection and Docetaxel|Part 1: LB-100 infusion. Part 2: LB-100 infusion and docetaxel infusion.
3300605|NCT01837693|No Intervention|one year follow up|A random sample of HPV positive women with negative cytology will be invited to repeat HPV DNA test and biomarkers after a year, as recommended by the current screening protocols based on HPV DNA
3300606|NCT01837693|Experimental|direct sending in colposcopy|Experimental: immediate colposcopy. A random sample of HPV positive women with negative cytology will be sent to immediate colposcopy
3300607|NCT01837706||Emergency Room Patients|
3300608|NCT01837732|Experimental|A: relational touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
3300609|NCT01837732|Active Comparator|B: relational|Relational: 10 mn verbal patient's centered exchanges
3300612|NCT01837758||Dialysis|Platelet function will be documented during the first 48 hours of veno-venous hemofiltration using the Multiplate system.
3300613|NCT01837771|Active Comparator|Diaphragmatic stimulation|Diaphragmatic stimulation via electrode for 4 weeks
3300614|NCT01837771|No Intervention|No intervention|
3300615|NCT01837784||Elderly patients|
3300616|NCT01837784||Patients with diabetes mellitus|
3300617|NCT01837784||Patients with heart failure|
3300618|NCT01837784||Patients with resistant hypertension|
3300619|NCT01837810|Experimental|Ibuprofen|800mg ibuprofen every 8 hours prn pain.
3300620|NCT01837810|Placebo Comparator|Methylcellulose Powder|Subjects receive inert methylcellulose powder as placebo
3300621|NCT01837836|Experimental|Health education|The arm includes all the villages under study. Health education will be provided targeting following groups: 1. Home makers 2. School children 3. Water tank operators.
3300622|NCT01837862|Experimental|Low-grade Glioma|Patients on the low-grade arm will receive treatment with seven 10-week cycles of carboplatin, vincristine, temozolomide, and mebendazole.
3300623|NCT01837862|Experimental|High-grade Glioma/Pontine Glioma|Patients on the high-grade glioma/pontine glioma arm will receive treatment with twelve 28-day cycles of bevacizumab, irinotecan, and mebendazole.
3300624|NCT01837875|No Intervention|Control|Mailed informational literature
3300625|NCT01837875|Active Comparator|Set Menu|Intervention: Enrollment in a local Chronic Disease Self-Management program (CDSMP) and monthly follow up calls to gauge progress and comfort
3300626|NCT01837875|Experimental|Intervention|Intervention: Each individualized intervention plan (IIP) will include 1-4 options, including a mail-delivered arthritis kit, addition and access to a listserv, participation in a support group, and enrollment in local self-management program(s).
3300627|NCT01837888|No Intervention|Standard training provided by clinician|Participants in the control group will receive the current standard of care. (i.e., any training provided by the clinician or vendor who prescribes/provides the wheelchair). Participants will receive one follow up phone call to remind them of followup testing.
3300628|NCT01837888|Experimental|WheelSee Training Program|Participants allocated to the intervention group will take part in WheelSee in groups of 2-4. The WheelSee intervention consists of 6 (twice weekly, minimum 3 days apart) x 1.5 hour sessions. Participants will be encouraged to bring a family member to each session, who may act as a spotter during the practice of wheelchair skills. If no family member is available, a student volunteer spotter will be available to ensure a 1:1 spotter: wheelchair user ratio. All spotters will be trained in appropriate spotting techniques.
3300629|NCT01837914|Experimental|Maxillary expansion as First treatment|Orthodontic expansion of upper jaw, then cross-over to adenotonsillectomy
3300630|NCT01837914|Active Comparator|Adenotonsillectomy as First treatment|surgical removal of tonsils and adenoids, then cross-over to maxillary expansion
3300631|NCT01837927|Experimental|NVA237|NVA237 inhaled via the Breezhaler® device once daily
3300632|NCT01837927|Active Comparator|Tiotropium|Tiotropium 5μg inhaled via the Respimat® device once daily
3300633|NCT01837940|Placebo Comparator|Placebo|
3300634|NCT01837940|Active Comparator|dietary supplement|Lactobacillus reuteri DSM 17938
3300635|NCT01837953|Other|Unguided Self-Help, No Further Treatment for 16 Weeks|All participants will first receive 10 weeks of unguided self-help (USH), followed by no further treatment for 16 weeks. Participants will be offered a follow up referral to the eating disorders program at The Ottawa Hospital after the 16 week no-treatment period.
3300636|NCT01837953|Experimental|Unguided Self-Help, GPIP|All participants will first receive 10 weeks of unguided self-help (USH). For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy condition, this second step will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy.
3300637|NCT01837979||DBS screening test|cell-free fetal DNA for Dried blood spots samples in high risk pregnant women.
3300638|NCT01837979||maternal serum screening test|cell-free fetal DNA for maternal serum screening test samples in high risk pregnant women.
3300639|NCT01837992|Active Comparator|Standard dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered the standard recommended primaquine dose of 0.25mg/kg for 14 consecutive days.
3300640|NCT01837992|Active Comparator|High dose|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, and will be administered a primaquine dose of 0.5mg/kg/day for 14 consecutive days.
3300641|NCT01837992|Other|Control|Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent parasitaemia or completion of 3 months follow up.
3300642|NCT01838005|No Intervention|Standard of Care|"Routine implementation of the national PMTCT guidelines which are an adaptation of the WHO's Option A"
3300643|NCT01838005|Experimental|Conditional Cash Transfer|Financial incentive to attend regular clinic visits and receive PMTCT care
3300644|NCT01838018||PKAN|This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
3300645|NCT01838018||Healthy volunteers|This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
3300646|NCT01838031|No Intervention|the control group|The serum will be stored and the measurements will be obtained after the delivery
3300647|NCT01838031|Active Comparator|the thyroid screening group|The thyroid function and antibody will be measured during pregnancy. The subclinical hypothyroidism will be treated individually.
3300648|NCT01838057||painPREMIER cohort|
3300649|NCT01838057||Control cohort|
3300650|NCT01838070||Study Group|Participants that has received AVAXIM 160U vaccine administered under the routine practice according to Summary of Product Characteristics
3300651|NCT01838083|Experimental|Insulin glargine new formulation (test T formulation)|Once daily for 6 days
3300652|NCT01838083|Experimental|Insulin glargine new formulation (reference R formulation)|Once daily for 6 days
3300653|NCT01838096|Experimental|THA|
3300654|NCT01838109|Experimental|ONS group|oral administration of Encover 2 package for day starting at the time of discharge (200ml/package x 2, total 400Kcal/day) total 87 patients
3300655|NCT01838109|No Intervention|Control group|no intervention total 87 patients
3300656|NCT01838122||Study Arm|This group/cohort will have subjects having infertility due to PCOS (as per Rotterdam criteria)
3300657|NCT01838122||Control arm|This group/cohort will have subjects without PCOS but with any other diagnosis of infertility or any other complain.
3300658|NCT01838135|No Intervention|Group-based information sessions|Control group subjects will take part in 6 x 1.5 hour sessions of group-based information sessions facilitated by a trained instructor, consisting of topics on general wheelchair use, transportation, pain and fatigue management, nutrition, and internet resources. The instructor will be trained to not provide any training on wheelchair skills, and will be instructed to divert any wheelchair skills related questions.
3300659|NCT01838135|Experimental|WheelSeeU Training Program|Experimental group subjects will attend 6 x 1.5 hour training sessions (1-2 sessions/week) with a peer-Trainer. The peer-Trainer will facilitate WheelSeeU sessions and will lead participants through practice of wheelchair use goals.
3300660|NCT01838161|Active Comparator|Part I|Interview questions will focus on reticence to vaccinate children.
3300661|NCT01838161|Experimental|Part II|"We will pilot the vaccination vignettes in a health department (clinical) setting with eligible parents of adolescents.~a pretest survey~the video vignette~and a post-test survey measuring intention to receive appropriate adolescent vaccines"
3300662|NCT01838161|Experimental|Part III|"enhanced video educational intervention (video vignettes + standard of care vaccine event)~standard of care vaccination event"
3300663|NCT01838174|Experimental|Acthar Gel (ACTH)|15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
3300664|NCT01838174|Active Comparator|IV methylprednisolone (steroids)|3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
3300665|NCT01838239|Experimental|Fish oil|
3300666|NCT01838252|Experimental|Hyaluronic acid|Patients in this arm will receive hyaluronic acid fillers to the lower lid.
3300667|NCT01838252|Sham Comparator|Saline|
3300668|NCT01838265||AS: Active Surveillance Alone|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
3300669|NCT01838265||MRI-AS: MRI+ Active Surveillance|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
3300670|NCT01838278|Experimental|Vojta physiotherapy Method|Children in the experimental group or Vojta group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
3300671|NCT01838291||Patients on Ferriprox therapy <1 month|
3300672|NCT01838330|Experimental|Chronic Kidney Disease Stage 3-4|Study participants with stage 3 or 4 CKD will receive 15 grams/day of soluble fiber psyllium for the first week, followed by 30 grams/day of a soluble fiber psyllium for 4 months.
3300673|NCT01838330|No Intervention|Chronic Kidney Disease Stage 1-2|Study participants with stage 1 or 2 CKD will not receive study treatment
3300674|NCT01838343|No Intervention|No Ultrasound|Patients randomized to no ultrasound will get standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
3300675|NCT01838343|Experimental|Ultrasound|Patients randomized to ultrasound will get a goal-directed ultrasound performed by a critical care fellow along with standard diagnostic and therapeutic interventions that are clinically indicated during the rapid response event.
3300676|NCT01838356||No treatment.|
3300677|NCT01838369|Experimental|BI-505|
3300678|NCT01838382|Experimental|laparoscopic hysterectomy group|female patients undergoing total laparoscopic hysterectomy.
3300679|NCT01838395|Experimental|BL-8040 + Ara-C|"Eligible subjects will receive subcutaneous (SC) injections of BL-8040 (monotherapy period) over two days (one injection per day) followed by concurrent administration of BL-8040 with standard salvage chemotherapy (combined period) over 5 days. During the combined period, BL-8040 will be administered 4 hours prior to chemotherapy. The chemotherapy will consist of cytarabine (Ara-C) 1.5 or 3 g/m2/d per dose (based on age), administered intravenously (IV) over 3 hours, for 5 days and will not be escalated."
3300680|NCT01838408|Experimental|EZ2go Complete|EZ2go complete: Peg 3350, Magnesium Citrate and Simethicone
3300681|NCT01838408|Active Comparator|LoSo Prep ™|LoSo Prep ™: Magnesium citrate and Bisacodyl
3380461|NCT04729621|Experimental|PROLIA main / TVB-009 transition period|TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period
3300682|NCT01838421||Children under 12 years of age|Children under 12 years of age who underwent surgery in the Charité - University Medicine Berlin, Campus Virchow - Klinikum in the years 2011/12
3300683|NCT01838434|Active Comparator|lenalidomide (Phase II)|Lenalidomide will be administered orally at 20 mg daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). (Phase II)
3300684|NCT01838434|Experimental|lenalidomide and idelalisib (Phase II)|Lenalidomide will be administered orally and daily on days 1-21, repeated every 28 days for a maximum of 12 cycles (48 weeks). Idelalisib will be orally administered for continuous 28-day cycles until progression, intolerance, or patient/physician discretion. Dosing will be determined by the Phase I portion of the study. (Phase II)
3300685|NCT01838460|Experimental|6 mg dose of sublingual nicotine tablets|6 mg dose of sublingual nicotine tablets, single dose.
3300686|NCT01838460|Active Comparator|PSWM 0.5 g (16 mg nicotine/g)|Swedish portion snus, smokeless tobacco, PSWM 0.5 g (16 mg nicotine/g), single dose
3300687|NCT01838460|Active Comparator|PSWL 1.0 g (8 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (8 mg nicotine /g), single dose
3300688|NCT01838460|Active Comparator|PSWL 1.0 g (16 mg nicotine /g)|Swedish portion snus, smokeless tobacco, PSWL 1.0 g (16 mg nicotine /g), single dose
3300689|NCT01838460|Active Comparator|PSWL (8 mg nicotine /g) 2x1.0 g|Swedish portion snus, smokeless tobacco, PSWL (8 mg nicotine /g) 2x1.0 g, single dose
3300690|NCT01838473|Active Comparator|General 1 g pouch|Oral pouch 0.3-1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3300691|NCT01838473|Active Comparator|Catch Licoice 1 g pouch|Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3300692|NCT01838473|Active Comparator|Catch Licorice Mini 0.5 g pouch|Oral pouch 0.5g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3300693|NCT01838473|Active Comparator|Catch Licorice dry mini 0.3 g pouch|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
3300694|NCT01838486|Experimental|Bladder Thermal Distention (BTD)|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using the PelvixTT system
3300695|NCT01838512||IMiDs|"Diagnosed relapsed/refractory multiple myeloma patients who receive IMiD treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3300696|NCT01838512||Proteasome inhibitors|"Diagnosed relapsed/refractory multiple myeloma patients who receive Proteasome inhibitor treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3300697|NCT01838512||Combination novel therapies|"Diagnosed relapsed/refractory multiple myeloma patients who received combinations novel therapies (an IMiD plus a proteasome inhibitor) treatment~Note: Additional use of corticosteroids and/or cytotoxic agents (eg, alkylating agents) is permitted for all 3 cohorts."
3300698|NCT01838512||New Agents|New Agents (regimens including any approved new agent classes with new MOAs, such as mAbs, HDACIs, AKT inhibitors and any novel
3300699|NCT01838525||SIRS, SEPSIS|
3300700|NCT01838525||sepsis, severe sepsis, septic shock|
3300701|NCT01838525||health, SIRS, Sepsis|
3300702|NCT01838538|Experimental|Bevacizumab+TC|The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.
3300703|NCT01838538|Active Comparator|TC|patients were treated with TC chemotherapy (paclitaxel 135mg/m2 ,iv d1+ carboplatin AUC=5, iv d1), 1 time/3 weeks for 6 weeks, and with intraperitoneal hyperthermic perfusion chemotherapy combined with intraperitoneal cisplatin 40mg/m2，1 time/2 weeks for 6 weeks
3300704|NCT01838564|Active Comparator|Routine data collection|Routine collection of patient-reported symptom and Quality of life data using PediQUEST surveys
3300705|NCT01838564|Experimental|Feedback of patient-reported outcomes|Routine collection of QOL and symptom data + feedback
3300706|NCT01838577||Case cohort|"Patients with proven EGFR mutation in exons 18-21 from tumor material. Patients with unknown or failed tumor EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR mutation will become eligible for the case cohort.~No known somatic KRAS, HER2, LKB1, BRAF, or PI3K, mutation or ALK gene rearrangement (or ALK3+ immunohistochemistry). If these mutations are known to be present the patient will be ineligible. However, patients will not be tested specifically for these mutations for this study and patients with unknown status are acceptable. If patients are subsequently tested after enrollment and found to harbor any of these mutations they will be considered ineligible and will be replaced.~No known Li Fraumeni, Li Fraumeni-like, or Peutz Jeghers syndrome family, or known germline carriers of mutant LKB1 or TP53. Patients will not have to be tested specifically for these syndromes to be eligible for this study."
3300707|NCT01838577||Control cohort|"Patients known to be somatic EGFR wild-type, i.e. no mutation detected in exons 18-21 from tumor material.~Patients with unknown or failed EGFR genotyping will be ineligible. Patients subsequently undergoing re-genotyping which demonstrates an EGFR wild-type will become eligible for the control cohort.~Never smoker (<100 cigarettes in lifetime) or ex-light smoker (stopped ≥1 year ago and smoked ≤10 pack-years)."
3300708|NCT01838603||Interventional pain management patients|Patients passed through interventional pain management program
3300709|NCT01838629||thyroid nodule|
3300710|NCT01838668|Placebo Comparator|Part I Placebo|"Placebo orally twice a day. In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID~Participants will begin the study by taking 1 capsule orally BID for first 7 days and escalate their dosing from day 8 to 2 matching capsules orally BID."
3300711|NCT01838668|Experimental|Part I BG00012|BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg BG00012 twice daily (BID) for the first 7 days and 240 mg BG00012 BID thereafter.) In Part I: participants will be randomized into one of 2 groups: BG00012, 240 mg twice daily (BID) or matching placebo BID
3300712|NCT01838668|Experimental|Part II BG00012|Part II: All participants will receive BG00012 240 mg orally twice a day (participants will begin dosing at 120 mg (1 capsule) BG00012 twice daily (BID) for the first 7 days and 240 mg (2 capsules) BG00012 BID thereafter.
3300713|NCT01838707|Active Comparator|Bupivacaine|0.125% Bupivacaine HCL @ 4-5 ml/h
3300714|NCT01838707|Active Comparator|Bupivacaine, Morphine|0.125% Bupivacaine HCL , Morphine sulphate 3 mg @ 3-5 ml/h
3300715|NCT01838707|Active Comparator|Bupivacaine, Fentanyl|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h
3300716|NCT01838720|Experimental|zero ischemia laparoscopic RFA assisted TE|RFA will be performed for 1 to 4 cycles for 4 to 12 minutes each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping.
3300717|NCT01838720|Active Comparator|conventional laparoscopic partial nephrectomy|Renal hilum will be accurately isolated and then the artery only will be clamped during surgery.
3300718|NCT01838733||Cerebral Desaturation|Patients who suffer an intra-operative cerebral desaturation
3300719|NCT01838746||PCI|Patients undergoing PCI
3300720|NCT01838746||CABG|Patients undergoing CABG
3300721|NCT01838759||Hypovolemic hyponatremia|"Negative values of Overhydration measured by Bioimpedance spectroscopy"
3300722|NCT01838759||Hypervolemic hyponatremia|"Positive values of Overhydration measured by Bioimpedance spectroscopy"
3300723|NCT01838772|Other|Pegylated-Interferon and Ribavirin|"Pegylated-interferon 1.5 microgr/kg, subcutaneously, once weekly for 48 weeks*. Ribavirin, weight-based dosage, divided in two daily doses for 48 weeks*.~*patients with genotype 2 and 3, moderate liver fibrosis, and rapid virologic response will receive therapy for 24 weeks."
3300724|NCT01838798||Study population|"See in inclusion/exclusion criteria.~Interventions: Baseline activities; Clinical interview with a psychologist; Telephone interview 2 months after ICU discharge; Clinical interview with a psychologist ."
3300725|NCT01838824|Experimental|Speed of Processing Training - Group 1|Group 1 will receive speed of processing training immediately following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
3300726|NCT01838824|Experimental|Speed of Processing Training - Group 2|Group 2 will receive speed of processing training 6 weeks following baseline testing. They will have an evaluation immediately following treatment and a long-term follow-up 6 weeks after finishing treatment.
3300727|NCT01838850|Experimental|CS8635 20/5/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this triple fixed dose combination therapy (CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5mg) + placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 40/5/12.5mg (OM/AML/HCTZ 40/5/12.5 mg).
3300728|NCT01838850|Active Comparator|Olmetec® Plus 20/12.5mg and placebo|Participants receiving Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5 mg) for the 4-week, Run-in Period but who do not meet their blood pressure goals(Non-responders) could start receiving this dual fixed dose combination therapy (Olmetec® Plus 20/12.5mg (OM/HCTZ 20/12.5mg) + Placebo) in randomized, 8-week, double-blind Period. The non-responders finishing double-blind treatment could continue the 8-week Open-label Period with CS8635 20/5/12.5mg (OM/AML/HCTZ 20/5/12.5 mg).
3300729|NCT01838889|Experimental|Culturally adapted psychological intervention (PHP)|Depressed Mothers randomized to experimental arm will undergo a 12 week group psychological intervention on the 'positive health programme'.
3300730|NCT01838889|No Intervention|Treatment as usual (TAU)|Depressed mothers randomized to TAU arm will receive treatment as usual.
3300731|NCT01838902|Other|Eurartesim (control)|All participants will receive a complete course of DHA-PPQ (Eurartesim)
3300732|NCT01838902|Experimental|Primaquine 0.75mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
3300733|NCT01838902|Experimental|Primaquine 0.4mg base /kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
3300734|NCT01838902|Experimental|Primaquine 0.2mg base/kg|Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight
3300735|NCT01838915|Experimental|Dietary Supplement: Prebiotics+Glutamine|
3300736|NCT01838915|Placebo Comparator|Placebo|
3300737|NCT01838928|Experimental|Bupivacaine|
3300738|NCT01838954|Active Comparator|Short-wave diathermy|Short-wave diathermy device turned on
3300739|NCT01838954|Placebo Comparator|control|Short-wave diathermy device turned off
3300740|NCT01838967|Experimental|C - V - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300741|NCT01838967|Experimental|V - C - C+V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300742|NCT01838967|Experimental|V - C+V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300743|NCT01838967|Experimental|C+V - V - C|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300744|NCT01838967|Experimental|C+V - C - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300745|NCT01838967|Experimental|C - C+V - V|C - Cilnidipine 10mg will be administered orally only one time. V - Valsartan 160mg will be administered orally only one time. C+V - Cilnidipine 10mg plus Valsartan 160mg will be administered orally only one time
3300746|NCT01838993|Active Comparator|Lidocaine|Inhalation of lidocaine before intubation
3300747|NCT01838993|Placebo Comparator|Control|Normal saline inhalation before intubation
3300748|NCT01839006||patients with supranormal renal function|Patients with preoperative HN and supranormal renal function in DTPA renography
3300749|NCT01839019|Placebo Comparator|Placebo|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
3300750|NCT01839019|Experimental|ODM-102|Each subject will receive 2 single doses of study drug, either both of them active doses or the other placebo.
3300751|NCT01839032|Experimental|Vinorelbine cisplatin radiotherapy|Induction period + radio chemotherapy
3300752|NCT01839045||Breast Cancer|ACR BI-RAD Category 3 or 4 result
3300753|NCT01839071|Other|biopsy of fat tissue|
3300754|NCT01839084|Experimental|Xenon|Gaseous anesthetic, dosage: 60% (v/v) in 40% oxygen, continuous application during surgery
3300755|NCT01839084|Active Comparator|Isoflurane|Inhalative anesthetic, dosage: 1.2% (v/v) in 40% oxygen/medical air , continuous application during surgery
3300756|NCT01839097|Experimental|Dose Finding Phase|"This is a Phase 1 dose finding study using the traditional escalation rule of 3+3 design to evaluate the Maximum Tolerated Dose of Belinostat when administered in combination with CHOP. In Part A of the study, up to three sequential dose cohorts will enroll a maximum of 6 patients each.~Enrollment will begin with the enrollment of patients into Cohort 3.~On Day 1 of each 21-day treatment cycle, the study treatment will start with belinostat followed by CHOP regimen."
3300757|NCT01839123|Active Comparator|Non-Vacuum Socket|Prosthetic suction or pin socket
3300758|NCT01839123|Experimental|Vacuum Socket|Prosthetic LimbLogic vacuum socket
3300759|NCT01839136|Experimental|Intrauterine transfer of gametes|After the oocyte retrieval, the oocytes will be selected depending on the morphology of the granular cells. The transfer will be conducted in up to 2 hours after the oocytes collection, when the semen and up to 3 oocytes will be transferred. Surplus oocytes will be cryopreserved for future use. We will use a Sydney catheter (Cook Medical Inc., Bloomington, IN, USA) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with oocytes and semen prepared in the following sequence: 10 µL of the prepared semen, a small space of air, 20 µL of the medium containing the oocytes, another small space of air and more 10 µL of prepared semen. The catheter will be placed through the endocervical canal up to the endometrial cavity guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
3300760|NCT01839136|Active Comparator|intrauterine transfer of embryos|The oocytes will be denuded and those considered to be mature will be selected for fertilization up to the number of seven. In vitro fertilization will be performed and up to two embryos will be transferred 2-3 days after the oocyte retrieval. The other embryos will be cryopreserved for future use. We will use Sidney catheter (Cook Medical Inc.) coupled to a 1 mL syringe to perform the transfer. The catheter will be loaded with embryos in the following sequence: 10 µL of culture medium, a small space of air, 20 µL of the medium containing embryos, another small space of air, and more 10 µL of culture medium. The catheter will be placed through the endocervical canal up to the endometrial cavity, guided by transabdominal ultrasound, where the liquid will be released. We will try to place the point of the catheter 1.0-1.5cm before touching the fundus of the endometrial cavity and release the liquid slowly, in approximately 30 seconds.
3300761|NCT01839149|Experimental|TI-001 (intranasal oxytocin)|TI-001 is intranasal oxytocin
3300762|NCT01839149|Placebo Comparator|Placebo|Placebo for TI-001 is the same intranasal formulation without oxytocin
3300763|NCT01839162|Experimental|Pelvic drape|Pelvic shield drape over the patient
3300764|NCT01839162|Experimental|Arm drape|Right radial arm drape over the patient
3300765|NCT01839162|Experimental|Pelvic and arm drape|Pelvic and arm drpaes placed over the patient
3300766|NCT01839162|Sham Comparator|No drapes|Standard radioprotection devices
3300767|NCT01839175|Experimental|Group 1|
3300768|NCT01839175|Active Comparator|Group 2|
3300769|NCT01839201|Active Comparator|etomidate/sevoflurane|Anesthesia induction: etomidate, maintenance: sevoflurane
3300770|NCT01839201|Active Comparator|propofol/sevoflurane|2.induction: etomidate, maintenance: sevoflurane
3300771|NCT01839201|Active Comparator|propofol/propofol|Anesthesia induction:propofol, maintenance:propofol
3300772|NCT01839214|Experimental|VB-201 160mg|Subjects will received 80mg twice daily for 24 weeks.
3300773|NCT01839214|Placebo Comparator|Placebo with crossover to VB-201 160mg|Subjects on placebo will crossover to VB-201 160 at week 12.
3300774|NCT01839227|Experimental|regional cerebral oxygen saturation|
3300775|NCT01839240|Experimental|Treatment (azacitidine, cytarabine, and mitoxantrone)|"INDUCTION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5, cytarabine IV over 4 hours on days 6 and 10, and mitoxantrone hydrochloride IV over 60 minutes on days 6 and 10.~CONSOLIDATION: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Treatment repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients ineligible for allogeneic stem cell transplantation continue on to maintenance.~MAINTENANCE: Patients receive azacitidine IV over 10-40 minutes or SC QD on days 1-5. Courses repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity."
3300776|NCT01839253|Experimental|Atenolol|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
3300777|NCT01839253|Active Comparator|Enalapril|In each group, premedication with either b-blocker (Atenolol) or ACE inhibitor (enalapril) or nothing (control group) in the preparation room.
3300778|NCT01839253|Placebo Comparator|control|none of antihypertensive agents
3300779|NCT01839266||acute PE survivor, acute PE nonsurvivor|acute PE survivor, acute PE nonsurvivor (in-hospital death)
3300780|NCT01839292|Active Comparator|uncovered D-type stent|uncovered D-type stent, which effectively reduces stent migration, especially in malignant colorectal obstruction
3300781|NCT01839292|Active Comparator|double-layered ComVi stent|double-layered ComVi stent, which is a modified covered stent with an additional outer bare wire mesh to overcome both tumor ingrowth and stent migration
3300782|NCT01839305|Experimental|Hidrotherapy|Patients performed hydrotherapy 2 twice a week, for 16 weeks, to check if there was any effect on the outcome measures for women with fibromyalgia
3300783|NCT01839331|Experimental|Low Dose Ampion|4 mL Ampion
3300784|NCT01839331|Placebo Comparator|Placebo|4 mL placebo
3300785|NCT01839331|Experimental|High Dose Ampion|10 mL Ampion
3300786|NCT01839331|Placebo Comparator|10 mL Placebo|10 ml Placebo
3300787|NCT01839344|Experimental|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
3300788|NCT01839344|Active Comparator|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
3300789|NCT01839344|Placebo Comparator|Placebo|An oral single dose of a solid, colored empty capsule.
3300790|NCT01839357|Experimental|Rivaroxaban|
3300791|NCT01839370|Experimental|Closed Loop with Pramlintide|The experimental condition consists of closed loop admission with the Adaptive Insulin Meal Supervisor system (AIMS) system with pramlintide 30 mcg at meal time. During this admission, the Diabetes Assistant (DiAs), a Cell Phone Medical Platform and the central component of the system, will provide basal insulin to maintain glucose levels within a prescribed range.
3300792|NCT01839370|Placebo Comparator|Open Loop with Pramlintide|Insulin delivery will be controlled by the DiAs system running in Open Loop mode. Subjects will be permitted to administer correction boluses and set temporary temporary basal levels at any time during the admission, whether or not they are eating a scheduled meal. Subjects will inject Pramlintide 30 mcg prior to meal time.
3300793|NCT01839383|Active Comparator|DCa1.25|using dialysate calcium concentration 1.25 mmol/L(DCa1.25)
3300794|NCT01839383|Active Comparator|DCa1.5|using dialysate calcium concentration 1.5mmol/L
3300795|NCT01839383|Active Comparator|DCa1.75|using dialysate calcium concentration 1.75mmol/L
3300796|NCT01839409|No Intervention|control|Control without vestibular stimulation
3300797|NCT01839409|No Intervention|Bilateral areflexia|Patient with vestibular bilateral areflexia
3300798|NCT01839409|No Intervention|Areflexia controls|Controls for patients with vestibular bilateral areflexia, matched in sex and age
3300799|NCT01839409|Experimental|vestibular stimulation|Subjects submitted to vestibular stimulation in order to improve circadian rhythms
3300800|NCT01839422|Experimental|Controls|Memory assessment. Brain imaging examination MRI.
3300801|NCT01839422|Experimental|Beginner Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
3300802|NCT01839422|Experimental|Severe Alzheimer's Disease patients|Memory assessment. Brain imaging examination MRI.
3300803|NCT01839435|Experimental|outpatient patients|Outpatient surgery will be proposed to all patients
3300804|NCT01839448||GD diagnosis before 24 weeks|"Patients in this group are diagnosed with gestational diabetes (GD) before 24 weeks of amenorrhea by means of a fasting blood glucose test >= 0.92 g/l.~Intervention: Post-partum oral glucose tolerance test"
3300805|NCT01839448||GD diagnosed at 24 to 28 weeks|"Patients in this group are diagnosed with gestational diabetes between 24 and 28 weeks of amenorrhea based on a normal fasting blood glucose level before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test between 24 and 28 weeks of amenorrhea.~Intervention: Post-partum oral glucose tolerance test"
3300806|NCT01839474|Experimental|CPAP|Children will be placed on nasal CPAP until they have an age appropriate respiratory rate and receive standard medical therapy.
3300807|NCT01839474|No Intervention|Control|Children will receive standard medical therapy.
3300808|NCT01839500||Cohort I: HER2-Positive mGC Treated With Trastuzumab|HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
3300809|NCT01839500||Cohort II: HER2-Positive mGC not Treated With Trastuzumab|HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
3300810|NCT01839500||Cohort III: HER2-Positive non-mGC|HER2-positive non-mGC participants will be included in this cohort.
3300811|NCT01839500||Cohort IV: HER2-Negative mGC|HER2-negative mGC participants will be included in this cohort.
3300812|NCT01839500||Cohort V: HER2-Negative non-mGC|HER2-negative non-mGC participants will be included in this cohort.
3300813|NCT01839526|Other|Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR)|Evaluations of renal and cardiac function
3300814|NCT01839539|No Intervention|B|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will only regularly follow up.
3300815|NCT01839539|Experimental|A|After neoadjuvant and (or) adjuvant chemotherapy or (and) radiotherapy according to NCCN guidelines, patients will receive 2-3 cycles of Dendritic and Cytokine-induced Killer Cells (DC-CIK) treatment (every 4 weeks).
3300816|NCT01839552|Experimental|Fentanyl Citrate Nasal Spray (FCNS)|Treatment for breakthrough pain with Fentanyl Citrate Nasal Spray (FCNS)
3300817|NCT01839565||Patients|Patients undergoing osteosynthesis of acetabular fractures by using the Quadrilateral Surface Plate
3300818|NCT01839578|Experimental|RCA Group|SHF-CVVHD with regional citrate anticoagulation
3300819|NCT01839578|Experimental|Heparin group|SHF-CVVHD with systemic heparin anticoagulation
3300820|NCT01839591|Experimental|Bronchial Thermoplasty|bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
3380462|NCT04727710|Experimental|Part 2: Couples-based mindfulness intervention|Mindfulness-based intervention + Usual care
3380463|NCT04727710|Active Comparator|Part 2: Usual care|Usual care
3380464|NCT04723251|Experimental|Taking Photographs|Participants will be asked to take photos with their cell phone.
3380465|NCT04721002||Participants With Multiple Myeloma|Participants with newly diagnosed and relapsed/refractory multiple myeloma will receive standard of care. Bone marrow and blood samples will be collected.
3300821|NCT01839617|Active Comparator|Early parenteral nutrition|Parenteral nutrition starts at 2nd postoperative day.
3300822|NCT01839617|Active Comparator|Late parenteral nutrition|Parenteral nutrition starts at 7th postoperative day.
3300823|NCT01839630||Group 1|
3300824|NCT01839643|Experimental|2.4 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
3300825|NCT01839643|Experimental|3.0 g Meloxicam Vaginal Ring|Continuous wearing during one menstrual cycle (6 participants)
3300826|NCT01839669|Active Comparator|Foot Orthoses Only|including Patient Education; Abbreviation: FOO
3300827|NCT01839669|Experimental|Foot Orthoses and Eccentric Exercise|including Patient Education; Abbreviation: FOE
3300828|NCT01839669|Sham Comparator|Sham Foot Orthoses|including Patient Education; Abbreviation: FOS
3300829|NCT01839721|Active Comparator|Bifilact® probiotics standard dose|concentration of 1.3 billion of Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. one pill twice a day. Each capsule contained maltodextrin and magnesium stearate as excipient
3300830|NCT01839721|Active Comparator|Bifilact® probiotics high dose|containing 10 billion Lactobacillus acidophilus LAC-361 and Bifidobacterium longum BB-536. One pill three times a day. Each capsule contained maltodextrin and magnesium stearate as excipient
3300831|NCT01839721|Placebo Comparator|placebo|Each capsule contained maltodextrin and magnesium stearate as excipient. One pill twice a day
3300832|NCT01839734|Experimental|Arm A|4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)
3300833|NCT01839734|No Intervention|Arm B|No intervention
3300834|NCT01839747|Experimental|Imaging|PET-MRI PET-CT
3300835|NCT01839760||Inpatient cohort|Patients admitted to general wards
3300836|NCT01839760||ICU cohort|Patients admitted to ICU
3300837|NCT01839773|Experimental|DHP107 (oral paclitaxel)|DHP107 (oral paclitaxel) will be administered weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
3300838|NCT01839773|Active Comparator|Taxol® (IV paclitaxel)|Taxol® (IV paclitaxel) will be administered 3-weekly as second line chemotherapy in patients with metastatic or recurrent gastric cancer after failure of first line chemotherapy with fluoropyrimidine +/- platinum.
3300839|NCT01839786||PHTN patients|2. Patients who underwent RHC in the past and were diagnosed with PHTN (retrospective arm)
3300840|NCT01839812|Other|cosyntropin stimulation test|All patients enrolled in the study are administered cosyntropin stimulation tests to assess their adrenal response.
3300841|NCT01839825|Experimental|QuietCare|QuieCare system installed
3300842|NCT01839825|No Intervention|control|no system installed
3300843|NCT01839838|Experimental|APBI with protons|
3300844|NCT01839851||Asthma|Treatment with any inhaled corticosteroid
3300845|NCT01839851||Allergic rhinitis|Treatment with any intranasal glucocorticoid
3300846|NCT01839851||Asthma and allergic rhinitis|Inhaled corticosteroid + intranasal glucocorticoid
3300847|NCT01839864|Experimental|Promotora plus standard care model|Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count
3300848|NCT01839877|Experimental|HIA DEBIRI + systemic FOLFOX|Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX
3300849|NCT01839890|Experimental|Bare metal Stent plus Paclitaxel Balloon|Conventional bare metal Stent plus Paclitaxel Eluting Balloon(Pantera Lux)®
3300850|NCT01839890|Active Comparator|Bare metal Stent|Conventional Bare Stent
3300851|NCT01839903|Active Comparator|RIH EDIS|Data will be collected in two steps at the RIH site: step one will be care as usual. Step 2 will involve changes to the EDIS system
3300852|NCT01839903|Active Comparator|Care as usual|Care as usual in the ED will be tracked
3300853|NCT01839929|Experimental|Prograf/Advagraf|conversion from Prograf to Advagraf
3300854|NCT01839942||no gap closure|no hernia gap closure
3300855|NCT01839942||extracorporal gap closure|"extracorporal hernia gap closure~extracorporal suturing of gap"
3300856|NCT01839942||intracorporal gap closure|intracorporal hernia gap closure
3300857|NCT01839955|Experimental|Arm I (Dose Escalation Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The first three or six patients will be entered in this part of the study. Then this part will end.
3300858|NCT01839955|Experimental|Arm II (Extension Group)|Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
3300859|NCT01839968||Study patients|Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)
3300860|NCT01839981|Experimental|Treatment (6,8-bis(benzylthio)octanoic acid)|Patients receive 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1-5 of week 1 (pre-course 1 only), days 1 and 4 of weeks 2 and 3 (course 1 only), and days 1 and 4 of weeks 1-3 (courses 2-6). Treatment repeats every 4 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3300861|NCT01839994|Experimental|CF-CRT combined with BT or SBRT boost|"Conventionally fractionated CRT (IMRT or Rapid Arc) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND two 10 Gy fractions of real- time HDR brachytherapy OR CRT combined with two stereotactic body radiotherapy boosts of 10 Gy per fraction delivered with dynamic SBRT technique (IMRT or Rapid Arc).~The choice between two ways of delivering radiation dose to the boost volume will be based solely on clinical criteria, decision made by interdisciplinary team, according to the institutional protocol (in non-randomized fashion).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
3300862|NCT01839994|Active Comparator|CF-CRT alone|"Conventionally fractionated external beam conformal radiotherapy (IMRT or Rapid Arc) to the prostate and seminal vesicles (intermediate risk group) or to the prostate, SV and pelvic lymph nodes (high risk group) to the total dose of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).~Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients."
3300863|NCT01840007|Experimental|Metformin|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
3300864|NCT01840020||Gastric bypass|patients recruited from Central Norway
3300865|NCT01840020||Gastric sleeve|patients recruited from Central Norway
3300866|NCT01840033|Active Comparator|Group B|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
3300867|NCT01840033|Experimental|Group A|PICC Line (group A) : patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications.
3300868|NCT01840046|Experimental|Interleukin 2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit (MIU) / day D1 to D5, S3, S6 and S9: 3 mille-International unit /Jour D1 to D5."
3300869|NCT01840059|Experimental|Renal sympathetic denervation|Renal denervation using the Medtronic Symplicity catheter.
3300870|NCT01840059|No Intervention|Control|HF-PEF patients who will serve as control.
3300871|NCT01840085|Experimental|0.03% DSC127 topical gel|
3300872|NCT01840098|Active Comparator|control|Isocaloric carbohydrate drink
3300873|NCT01840098|Active Comparator|low leucine content drink|A soy protein drink
3300874|NCT01840098|Active Comparator|high content of leucine drink|A whey protein drink
3300875|NCT01840098|Active Comparator|low leucine content + HMB drink|Soy protein drink added HMB
3300876|NCT01840124|Experimental|Acessa|All women in the trial will be in this group who receive treatment using the Acessa device.
3300877|NCT01840137|Experimental|Prehabilitation|The progressive, pre-operative exercise training program includes 3 supervised exercise sessions per week for 4 weeks. The first week of training will include an acclimation period accomplished via a ramping protocol. Subjects will warm-up on a treadmill for 5-minutes. Subjects will then complete 1 set of 15 repetitions exercising 8 major muscle groups during week one; during week #2 they will complete 2 sets with a goal of at least 12 repetitions; if subjects reach 15 repetitions on the second set, the resistance will be increased by 10% at the next training session to ensure progression. After completion of the resistance training portion of each session, subjects will walk on a treadmill for 30 minutes at a low/moderate intensity followed by a 5 minutes cool-down period.
3300878|NCT01840150|Experimental|Treatment (NA-NOSE breath test)|Patients undergo breath sample collection for the NA-NOSE breath test at baseline (2 pre-treatment samples), and post-treatment samples at regularly scheduled follow up visits, for 2 years in the absence of disease progression.
3300879|NCT01840176|No Intervention|Routine|These women are randomized to receive no McCall culdoplasty at the time of their total laparoscopic hysterectomy.
3300880|NCT01840176|Other|McCall culdoplasty|The women in this arm are those randomized to undergo a McCall culdoplasty at the time of their total laparoscopic hysterectomy.
3300881|NCT01840189|Active Comparator|Cortef|Treatment A is oral hydrocortisone replacement( Cortef 5 mg)with weight-adjusted doses as suggested by Mah et al , will take 2 months
3300882|NCT01840189|Active Comparator|Solu-cortef|This is the treatment B by continuous subcutaneous hydrocortisone infusion. Solu-cortef infusion will be given as Solu-Cortef Act-o-Vial 50mg/ml, , produced by Pfizer. Pump designed for subcutaneous insulin infusion can be used for subcutaneous administration.
3300883|NCT01840202||Control|Healthy volunteers with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3300884|NCT01840202||Primary open-angle glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3300885|NCT01840202||Normal Tension Glaucoma|Patients with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg
3300886|NCT01840215||Controls|Patients scheduled for elective ophthalmic surgery with no family history of glaucoma, an increased or asymmetrical cup/disc ratio or any other optic disc structural change (notching, disc hemorrhage) or an intraocular pressure (IOP) above 21 mmHg that could suggest possible glaucoma suspects.
3300887|NCT01840215||Primary open-angle Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at least one measurement of IOP of >21 mmHg required
3300888|NCT01840215||Normal Tension Glaucoma|Patients scheduled for an elective glaucoma surgery that present with a characteristic optic disc damage (based on cup/disc ratio, thinning of neuroretinal rim, notching, disk hemorrhages, etc.) and visual field defects, with at maximum recorded IOP of < 21 mmHg.
3300889|NCT01840241|Experimental|BIVON group|
3300890|NCT01840241|Placebo Comparator|Placebo group|normal saline infusion
3300891|NCT01840254|Experimental|dexmedetomidine|addition of dexmedetomidine to fentanyl-based intravenous patient controlled analgesia (PCA)
3300892|NCT01840254|Placebo Comparator|normal saline|normal saline as a placebo
3300893|NCT01840267||laparoscopic surgery under general anesthesia|pediatric patients undergoing laparoscopic surgery under general anesthesia
3300894|NCT01840280||Carcinoma, Irinotecan onkovis (Irinotecan)|Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma.
3300895|NCT01840293||Primary Breast Cancer|
3300896|NCT01840293||Recurrent/Metastatic Breast Cancer|
3300897|NCT01840306||Cohort 1: HER2 positive breast cancer|Female patients with newly diagnosed (including metastatic) HER2 positive breast cancer.
3300898|NCT01840306||Cohort 2: HER2 negative breast cancer|Female patients with newly diagnosed HER2 negative breast cancer
3300899|NCT01840332|Experimental|L-thyroxin|this is one arm study
3300900|NCT01840358|Other|Patients starting pump therapy|
3300901|NCT01840371|Experimental|Propofol based group|
3300902|NCT01840371|Active Comparator|Fentanyl based group|
3300903|NCT01840384|Experimental|Multi-micronutrients|Multi-micronutrients
3300904|NCT01840384|Placebo Comparator|Maltodextrin and Lactose|Placebo contained maltodextrin and lactose
3300905|NCT01840397||Spine surgery|Patients undergoing spine surgery
3300906|NCT01840397||Bone surgery|Patients undergoing bone surgery for fracture treatment other than spine fractures
3300907|NCT01840423|Experimental|ODM-104|Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days
3300908|NCT01840423|Placebo Comparator|Placebo|Oral capsules given once daily for one day or three times daily for 7 days
3300909|NCT01840423|Active Comparator|entacapone + levodopa/carbidopa|entacapone: oral tablet 200mg given four times daily for one day; levodopa/carbidopa: oral tablet 100/25mg given four times daily for one day
3300910|NCT01840436|Placebo Comparator|Placebo|This arm receives a placebo (saline solution) mouthwash treatment twice a day.
3300911|NCT01840436|Experimental|MUCIPLIQ 0.05 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.05 mg/mL twice a day.
3300912|NCT01840436|Experimental|MUCIPLIQ 0.015 mg/mL|This arm receives MUCIPLIQ mouthwash treatment at a final concentration of 0.015 mg/mL twice a day.
3300913|NCT01840449||Neuroendocrine Tumours|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
3300914|NCT01840449||Acromegaly|The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
3300915|NCT01840462||Subjects naïve to botulinum toxin A (BoNT-A) treatment|Patients naïve to botulinum toxin A treatment
3300916|NCT01840462||Subjects pre-treated with botulinum toxin A (BoNT-A) injection|"Patients pre-treated with botulinum toxin A for at least 2 years.~4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
3300917|NCT01840475||Botulinum toxin type A (BoNT-A) injection (Dysport®) Naïve|Subjects naïve to BoNT-A treatment.
3300918|NCT01840475||Botulinum toxin type A (BoNT-A) Pre-treated|"Subjects pre-treated with BoNT-A.~Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics [SmPC])."
3300919|NCT01840488|Experimental|Irosustat (BN83495)|Single oral administration of irosustat
3300920|NCT01840501|Experimental|Part 1: Panel 1 (0.1 mg JNJ-42721458)|6 participants will receive a single dose of 0.1 mg of JNJ-42721458.
3300921|NCT01840501|Experimental|Part 1: Panel 2 (0.3 mg JNJ-42721458)|6 participants will receive a single dose of 0.3 mg of JNJ-42721458.
3300922|NCT01840501|Experimental|Part 1: Panel 3 (1.0 mg JNJ-42721458)|6 participants will receive a single dose of 1.0 mg of JNJ-42721458.
3300923|NCT01840501|Experimental|Part 1: Panel 4 (2.5 mg JNJ-42721458)|6 participants will receive a single dose of 2.5 mg of JNJ-42721458.
3300924|NCT01840501|Experimental|Part 1: Panel 5 (5.0 mg JNJ-42721458)|6 participants will receive a single dose of 5.0 mg of JNJ-42721458.
3300925|NCT01840501|Experimental|Part 1: Panel 6 (10.0 mg JNJ-42721458)|6 participants will receive a single dose of 10.0 mg of JNJ-42721458.
3300926|NCT01840501|Experimental|Part 1: Panel 7 (20.0 mg JNJ-42721458)|6 participants will receive a single dose of 20.0 mg of JNJ-42721458.
3300927|NCT01840501|Experimental|Part 1: Panel 8|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-7 in Part 1.
3300928|NCT01840501|Experimental|Part 1: Panel 9|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-8 in Part 1.
3300929|NCT01840501|Experimental|Part 1: Panel 10|6 participants will receive a single dose JNJ-42721458, the dose will be determined after completion of panels 1-9 in Part 1.
3300930|NCT01840501|Placebo Comparator|Part 1: Placebo|2 participants from each panel will receive a single dose of placebo.
3300931|NCT01840501|Experimental|Part 2: Panel 1 (5.0 mg JNJ-42721458)|6 participants will receive multiple doses of 5.0 mg of JNJ-42721458.
3300932|NCT01840501|Experimental|Part 2: Panel 2 (10.0 mg JNJ-42721458)|6 participants will receive multiple doses of 10.0 mg of JNJ-42721458.
3300933|NCT01840501|Experimental|Part 2: Panel 3|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-2 in Part 2.
3300934|NCT01840501|Experimental|Part 2: Panel 4|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-3 in Part 2.
3380468|NCT04712903|Experimental|Durvalumab in Combination with Platinum-Etoposide|Durvalumab 1500 mg via IV infusion will be concurrently administered with first-line chemotherapy (EP) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (PD) or unacceptable toxicity.
3380471|NCT04707157|Experimental|LY3556050|LY3556050 given orally
3380472|NCT04707157|Placebo Comparator|Placebo|Placebo given orally
3380473|NCT04697550|Experimental|Fecal moicrobiome transplant|intervention arm
3380474|NCT04697550|Placebo Comparator|Placebo|placebo capsules administration
3300935|NCT01840501|Experimental|Part 2: Panel 5|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-4 in Part 2.
3300936|NCT01840501|Experimental|Part 2: Panel 6|6 participants will receive multiple doses of JNJ-42721458, the dose will be determined after completion of panels 1-5 in Part 2.
3300937|NCT01840501|Placebo Comparator|Part 2: Placebo|2 participants from each panel will receive multiple doses of placebo.
3300938|NCT01840527||Group 1|Advanced Melanoma
3300939|NCT01840527||Group 2|Stage II/III Melanoma
3380475|NCT04696159|Experimental|Endoscopic Per-Oral Pyloromyotomy (POP)|The study cohort will include 40 patients with a HbA1c >7.5% with medically refractory gastroparesis who are scheduled to undergo POP. Each patient will undergo two 10-day periods of CGM at an interval of approximately seven months, one month prior to the procedure and six months after. Symptoms and diabetes management improvement will be measured by the Gastroparesis Cardinal Symptom Index (GCSI) scores and the Diabetes Self-Management Questionnaire (DSMQ).
3380477|NCT04691622|Experimental|Norovirus -specific T-cell (NST) therapy for chronic norovirus infection|"This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or with primary immunodeficiency disorders (PID) who have not undergone HSCT. There are two arms in this study:~Arm A: Participants who receive donor-derived NST therapy after HSCT~Arm B: Participants who receive partially HLA matched NSTs. The following participants apply:~Participants with PID who have not undergone HSCT~Participants who undergo HSCT but do not have available donor derived NSTs~Participants who have donors from whom NSTs cannot be generated due to norovirus seronegativity"
3380481|NCT04690348|Active Comparator|Resection without brachytherapy|Patients will undergo craniotomy.
3380482|NCT04690348|Experimental|Resection plus brachytherapy|Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist.
3380485|NCT04686305|Experimental|Arm 1A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
3380486|NCT04686305|Experimental|Arm 1B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
3380487|NCT04686305|Experimental|Arm 1C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
3380488|NCT04686305|Experimental|Arm 1D: T-DXd|T-DXd
3380489|NCT04686305|Experimental|Arm 2A: T-DXd, Durvalumab and Cisplatin|T-DXd, Durvalumab and Cisplatin
3380490|NCT04686305|Experimental|Arm 2B: T-DXd, Durvalumab and Carboplatin|T-DXd, Durvalumab and Carboplatin
3380491|NCT04686305|Experimental|Arm 2C: T-DXd, Durvalumab and Pemetrexed|T-DXd, Durvalumab and Pemetrexed
3380492|NCT04686305|Experimental|Arm 2D: T-DXd, Durvalumab|T-DXd, Durvalumab
3380495|NCT04682704|Experimental|Frequency 20Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
3380496|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 1mA below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 1mA below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
3380497|NCT04682704|Active Comparator|Frequency 20Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 20Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
3380498|NCT04682704|Active Comparator|Frequency 5Hz; amplitude 50% below discomfort threshold|Patients will receive tragus stimulation for 15 minutes using the following settings: Frequency 5Hz; amplitude 50% below discomfort threshold. Continuous ECG will be recorded to assess heart rate variability.
3380499|NCT04681066|Active Comparator|2.0 mg/kg (1.25 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
3300940|NCT01840540|Experimental|infusion of autologous mesenchymal stem cells|Patients will undergo a subcutaneous fat biopsy for expansion of mesenchymal stromal (stem) cells (MSC) in the Human Cell Therapy Laboratory. Patients will be admitted to the inpatient Clinical Research Unit of the Mayo Clinic Center for 3 days prior to treatment, for pre-infusion tests. Renal angiography will be performed to deliver a single intra-arterial dose of MSC's into one affected kidney. Patients will be observed for 24 hours for acute adverse events. Patients will have remote visits at 1 week, 4 weeks,8 weeks, and 6 months. At 3 months, patients will return for repeat evaluation of kidney function, blood flow and structural alterations within the clinical research unit at St. Mary's Hospital, Rochester, Minnesota. Thereafter, health assessment and blood draws will be repeated at 12 and 24 months with urinary cytology and MRI.
3300941|NCT01840553|Active Comparator|polyethylene glycol|4 Liters of PEG administered split in 2 doses
3300942|NCT01840553|Experimental|oral sodium phosphate tablets|oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid
3300943|NCT01840566|Experimental|HIGH DOSE CHEMOTHERAPY AND ASCT|This is a phase 1 dose escalation study designed to determine the maximum tolerated dose (MTD) of CAR modified T cells in patients with relapsed and refractory aggressive B-NHL. Three dose levels (5 x 106 19-28z T cells/kg, 1 x 107 19-28z T cells/kg, and 2 x 107 19-28z T cells/kg) are considered for the MTD.
3300944|NCT01840592|Experimental|Sorafenib plus Doxorubicin|Doxorubicin 60 mg/m2 IV on Day 1 of each 3 weeks cycle until unacceptable toxicity Sorafenib 400 mg PO BID or last dose patient from previous sorafenib based therapy, until unacceptable toxicity or disease progression, after which sorafenib can be continued as a single agent.
3300945|NCT01840618||Obese PCOS and sleep apnea|"BMI >95%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
3300946|NCT01840618||Obese PCOS without sleep apnea|BMI >95%ile AND Polysomnography with AHI <2.5
3300947|NCT01840618||Normal weight Controls|BMI <85%ile AND regular menses
3300948|NCT01840618||Lean PCOS and sleep apnea|"BMI <85%ile AND Polysomnography with AHI >2.5~Will initiate Nasal Continuous positive airway pressure (CPAP)"
3300949|NCT01840618||Lean PCOS without sleep apnea|BMI <85%ile AND Polysomnography with AHI <2.5
3300950|NCT01840631|Active Comparator|Group nutritional counseling|In this arm, the Nutritionist will conduct the nutritional counseling with numerous patient families as a group
3300951|NCT01840631|Active Comparator|Individual nutritional counseling|In this arm the nutritionist conducts the nutritional counseling with one patient family at a time
3300952|NCT01840644||all participants|Walking on treadmill, different velocities and incline
3300953|NCT01840683|Experimental|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|A total of 8 apheresis therapies with the H.E.L.P. Plasmat Futura System will be performed over a period of 12 weeks.
3300954|NCT01840696|Experimental|Regadenoson|
3300955|NCT01840709|Experimental|Psychotherapy treatment|The experimental group will be treated with Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks.
3300956|NCT01840709|No Intervention|control group|the patients in this group will be just assessed with the same questionnaires at baseline and after 20 weeks, without psychotherapy.
3300957|NCT01840735|Active Comparator|GS-5737|The GS-5737 85 μg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline.
3300958|NCT01840735|Placebo Comparator|Placebo|The vehicle (placebo) control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL.
3300959|NCT01840748||no vasodilator|patients receiving no vasodilator
3300960|NCT01840748||CCB|patients receiving a calcium channel blocker (CCB) for digital vasculopathy
3300961|NCT01840748||i.v. prostanoids or PDE5i or ETRAs|patients treated with i.v. prostanoids or phosphodiesterase-5 inhibitors (PDE5i) or endothelin receptor antagonists (ETRA), regardless of whether a calcium channel blocker is given in addition
3300962|NCT01840761|Experimental|herbal drug|Traditional Chinese herbal drug
3300963|NCT01840761|Placebo Comparator|Placebo|
3300964|NCT01840774|Active Comparator|Low-dose pain medication|80min IV infusion of a low-dose pain medication
3300965|NCT01840774|Placebo Comparator|saline placebo|80min IV infusion of a saline placebo
3300966|NCT01840787|Experimental|Contralateral lens comfort comparisons|Subjects will be randomized into receiving balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in one eye, and balafilcon A (8.3), or balafilcon A (8.6), or senofilcon A in the other eye.
3300967|NCT01840800|Active Comparator|Active FEM+ONP|Nerveblock of n. femoralis (FEM) with 10 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerveposterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml.
3300968|NCT01840800|Active Comparator|Active SAPH+ONP|Nerveblock of n.saphenous (SAPH) with 5 ml Ropivacaine 7.5 mg/ml and nerveblock of obturator nerve, posterior branch (ONP) with 10 ml Ropivacaine 7.5 mg/ml
3300969|NCT01840800|Placebo Comparator|Placebo|Saline 9 mg/ml
3300970|NCT01840813|Active Comparator|Misoprostol|4 misoprostol tablets (Misotac® 200 micrograms tablet) dissolved in 20 ml of normal saline injected to umbilical vein
3300971|NCT01840813|Placebo Comparator|Normal saline|Normal saline 0.9%, 20 ml was injected in the umbilical vein in cases of retained placenta
3300972|NCT01840826|Experimental|RED-D Care Management|Patients randomized to receive the Intervention work with a RED-D Care Manager post-discharge. The Care Manager meets with the patient in the hospital, prior to discharge, and post-discharge via weekly phone calls. Patients have access to a range of treatment options, overseen by the Care Manager, including: (1) medication; (2) cognitive behavioral therapy (CBT); (3) complementary and alternative medicine (CAM) information and referral; (4) Self-help, such as reading a book, making a change in diet and/or exercise in order to improve mood; (5) active surveillance; and (6) any combination of 1, 2, 3, 4 & 5.
3300973|NCT01840826|No Intervention|RED and Behavioral Health Referral|"Patients randomized to the control group will receive the regular RED intervention, including a follow-up phone call two days post-discharge from the hospital to review and confirm medications, and a referral to behavioral health."
3300974|NCT01840839|Experimental|0,75 Hz stimulation|transcranial slow oscilliating stimulation (tSOS)during periods of SWS
3300975|NCT01840839|Sham Comparator|no stimulation|Sham stimulation during periods of SWS
3300976|NCT01840852||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3300977|NCT01840865|Experimental|SHAM stimulation|SHAM stimulation during periods of Slow Wave Sleep
3300978|NCT01840865|Experimental|0,75 Hz stimulation|slow transcranial oscillating stimulation (~0,75Hz) during periods of Slow Wave Sleep
3300979|NCT01840878||Acute Diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3300980|NCT01840891|Experimental|Noro virus shedder|Lactose H2 breath test (LH2BT)
3300981|NCT01840891|Active Comparator|No norovirus shedding|Lactose H2 breath test (LH2BT)
3300982|NCT01840904||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3300983|NCT01840917||acute uncomplicated diverticulitis|CT-verified acute uncomplicated diverticulitis managed by antibiotics
3300985|NCT01840969||CAOD group|Single arm study group
3300986|NCT01840982|Experimental|Giant embryonic brown rice|
3300987|NCT01840982|Experimental|Giant embryonic rice|
3300988|NCT01840982|Active Comparator|White rice|
3300989|NCT01840982|Active Comparator|Glucose solution|
3300990|NCT01840995||stellate ganglion block|Patients receiving stellate ganglion block at our pain management clinic
3300991|NCT01841008|Experimental|Tacrolimus ointment 0.1%|
3300992|NCT01841008|Placebo Comparator|Group Placebo|
3300993|NCT01841034||Conceptio|Any patient receipt within the framework of the coverage(care) of an infertility in the pole ORG, whatever is the étiologie and the type of treatment proposing and presenting during at least two spermogrammes an oligospermie and\or an asthénospermie. The necessity of realizing 2 spermogrammes different to determine the pathological character of the values of a spermogramme takes into account the personal variability of the results.
3300994|NCT01841086|Active Comparator|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
3300995|NCT01841086|Experimental|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
3300996|NCT01841099|Experimental|Mesalamine|Mesalamine. Mesalamine granules. 30 mg/kg/day oral for 7 days followed by 50 mg/kg/day oral for 21 days if tolerated.
3300997|NCT01841099|Placebo Comparator|Placebo granules|Placebo granules
3300998|NCT01841112|Placebo Comparator|Placebo (Multiple dose part)|Placebo tablet
3300999|NCT01841112|Experimental|Dose 2, EM, single dose|Extensive Metaboliser (EM), single dose part, medium dose
3301000|NCT01841112|Experimental|Dose 3, EM, single dose|Extensive Metaboliser (EM), single dose part, high dose
3301001|NCT01841112|Experimental|Dose 3, PM, single dose|Poor Metaboliser (PM), single dose part, high dose
3301002|NCT01841112|Experimental|Dose 3, PM, multiple dose|Poor Metaboliser (PM), multiple dose part, high dose
3301003|NCT01841112|Placebo Comparator|Placebo (Single dose part)|Placebo tablet
3301004|NCT01841112|Experimental|Dose 1, EM, single dose|Extensive Metaboliser (EM), single dose part, low dose
3301005|NCT01841125|Experimental|escitalopram|escitalopram 15mg
3301006|NCT01841125|Placebo Comparator|Placebo|placebo 15mg
3301007|NCT01841151|Active Comparator|SCP training|Neurofeedback 1 (NF1) Slow Cortical Potential (SCP) training
3301008|NCT01841151|Active Comparator|Live Z-score training|Neurofeedback 2 (NF2) Live Z-score training
3301009|NCT01841151|Active Comparator|WM training|Working Memory training (WMt)
3301010|NCT01841151|No Intervention|Waiting-list|Treatment as usual only
3301011|NCT01841164|Experimental|Montelukast|5 to 7 days of treatment with montelukast 10 mg 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
3301012|NCT01841164|Placebo Comparator|Sugar pill|Placebo for montelukast 5-7 days 2 tablets bid. Efficacy of treatment is evaluated on airway responsiveness to inhaled leukotriene E4.
3301013|NCT01841177|Experimental|Therapeutic Drug Monitoring|The intervention is [1] regular measurement of milrinone levels; [2]physician feedback of plasma levels in experimental arm by the ICU pharmacist ( this process currently occurs for other drugs such as vancomycin).
3301014|NCT01841177|Active Comparator|Standard Care|Standard care involves titration of milrinone infusion based on clinical examination by the treating team. The control group will receive standard care: with milrinone dose modification on clinical assessment. Control patients will have milrinone plasma levels drawn but not analysed until the end of the study.
3301015|NCT01841190||PROCALCITONIN|
3301016|NCT01841190||DELTA SOFA|
3301017|NCT01841203||DPP/RPR-TPHA comparison|The evaluation of T1 (treponemal line) will be conducted by using the T1 positivity identified by naked eye or automated reader to compare with that of TPHA; while the evaluation of T2 (non-treponemal line) will be conducted by using the T2 positivity identified by naked eye, or automatic reader at cut-off value of 20, to compare with the result of RPR.
3301018|NCT01841242|Active Comparator|alcoholic povidone iodine|Betadine Alcoolique 5% One cutaneous application before implant procedure
3301019|NCT01841242|Experimental|alcoholic chlorhexidine|ChloraPrep 2% One cutaneous application before implant procedure
3301020|NCT01841255|Sham Comparator|Tidal breathing using the facemask|Control
3301021|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, no instruction|First experimental measure
3301022|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM device, instructions|Second experimental measure
3301023|NCT01841255|Experimental|Tidal volume breathing with the UMOXTM, device, nose clip|Third experimental measure
3301024|NCT01841268||Preterm Infants|Infants born prematurely will have their skin, sebum, microbiota, blood, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
3301025|NCT01841268||Term Infants, Control|Term infants enrolled in the UC Davis Lactation Study (protocol # 216198) will serve as the control group for this study; they will have their skin, sebum, microbiota, and mother's breast milk analyzed for changes between 0, 2, and 4 weeks of life.
3301026|NCT01841294|Experimental|Intravenous Lidocaine|Patients undergoing laparoscopic surgery for resection of colorectal cancer will benefit of an infusion of intravenous lidocaine from the induction of anesthesia untill one hour after PACU admission
3301027|NCT01841294|Placebo Comparator|Placebo|Infusion of normal saline form the induction of anaesthesia untill one hour after PACU admission
3301028|NCT01841307|Experimental|Gastrocrom|4 ingestions (at 2h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (inpatient) OR 2 ingestions (at 4h intervals) of a 200 mL of a 1mg/mL solution of cromolyn sodium (outpatient)
3301029|NCT01841320|Experimental|Intervention|Participants who are assigned to intervention arm will receive ART and methadone maintenance at an integrated methadone and antiretroviral therapy (iMART) clinic and ART adherence support through the use of mobile phone technologies.
3301030|NCT01841320|No Intervention|Standard of Care|Participants will be referred to standard HIV outpatient clinics and methadone maintenance clinics.
3301031|NCT01841333|Experimental|PF-04449913|Beginning 80 days after allogeneic stem cell transplant, patients receive PF-04449913 (100mg) orally once daily on days 1-28. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.
3301032|NCT01841346||PCI patients|Patients undergoing PCI for elective or ACS will be enrolled.
3301033|NCT01841359|Other|Pramlintide (Symlin)|"Participants in this study will be asked to complete 4 study visits. Study visit 1 will be for screening. Eligible individuals who provide informed consent will be asked to keep a 3-day log of food intake, blood glucose (8 per day), as well as any hypoglycemic symptoms. At study visit 2, a baseline mixed meal tolerance test will be performed. Glucose, hormonal responses, and satiety will be assessed. Glucose and symptom log will be reviewed. Pramlintide will be prescribed, with instructions for titration from minimal to maximal dose (15 to 120 µg). During treatment, the participants will keep a record of all hypoglycemic symptoms and blood glucose measurements at those times.~Study visit 3 will occur at week 4 of treatment and focus on evaluation of symptoms and side effects. Participants will again complete a food and glucose diary for 3 days. During study visit 4 (week 8 of treatment), participants will undergo a repeat mixed meal tolerance test."
3301034|NCT01841372|Active Comparator|Group Phone Conference Call|Group phone clinic will be conducted weekly during the first 9 months and twice/month during the final 9 months (3 to 12 months).
3301035|NCT01841372|Experimental|Second Life (2L)|2L group meeting will be conducted weekly during the first 9 months and twice/month during the final 9 months
3301036|NCT01841385|Experimental|Pilates Group|"Sedentary volunteers, but that would begin activities with the Pilates method and evaluated in three months.~Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions.~For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load."
3301037|NCT01841385|No Intervention|Control Group|Sedentary volunteers and remain sedentary and evaluated in three months. The volunteers comprised the control group did not perform any physical activity during the study period.
3301038|NCT01841398|Active Comparator|Multimedia Lifestyle Improvement|Includes goal setting, self monitoring and participants will receive regular health messaging using electronic media regarding smoking, dietary habits & physical activity
3301039|NCT01841398|Placebo Comparator|Usual Care|Includes usual advice and no regular health messaging.
3301040|NCT01841411|Experimental|Metronidazole + N-Acetyl cysteine|the second patient group will use NAC sachets containing 200 mg as a vaginal douche once daily plus oral metronidazole 500 mg twice daily for 7 days
3301041|NCT01841411|Experimental|N- Acetyl cysteine|the third patient group will use NAC sachets containing 200 mg as a vaginal douche only without taking metronidazole
3301042|NCT01841411|Active Comparator|Metronidazole|the first group of patients will take oral metronidazole 500 mg twice daily for a week
3301043|NCT01841424|No Intervention|Control|Subjects receive usual care for pregnancy and postpartum.
3301044|NCT01841424|Experimental|Dietary Counseling and Food Diary|Dietary counseling before 16 weeks of pregnancy Maintain food diary during pregnancy
3301045|NCT01841437||iStent|
3301046|NCT01841450|Experimental|iStent|Implantation of one iStent in conjunction with cataract surgery
3301047|NCT01841450|Active Comparator|Cataract surgery|Cataract surgery alone
3301048|NCT01841463|Experimental|P1446A-05|"The study will be conducted in two phases- Phase I ('Dose escalation' phase), and Extension phase:-~In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of three to six patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~In the 'Extension' phase, sixty patients with BRAF V600E/K mutations (forty patients naïve to selective BRAF inhibitor therapy, and twenty progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity"
3301049|NCT01841476|Experimental|POL6326|2-hour single intravenous infusion doses of POL6326
3301050|NCT01841489|Experimental|Sequence 1|
3301051|NCT01841489|Experimental|Sequence 2|
3301052|NCT01841489|Experimental|Sequence 3|
3301053|NCT01841489|Experimental|Sequence 4|
3301054|NCT01841502|Active Comparator|paroxetine alone|paroxetine 20 mg tablet once daily oral
3301055|NCT01841502|Experimental|paroxetine + telaprevir|paroxetine 20 mg tablet once daily + telaprevir 1125 mg (3 tablets 375mg) twice daily oral
3301056|NCT01841515|Experimental|Desmopressin|Twenty five patients with chronic kidney disease and who were taking antiplatelet agents and needed an emergent catheter insertion for hemodialysis
3301057|NCT01841528|Experimental|fresh embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
3301058|NCT01841528|Experimental|frozen-thawed embryo transfer group|rFSH/GnRH antagonist will be administered for ovarian stimulation. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with hormone replacement therapy (HRT) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum human chorionic gonadotropin (HCG) will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
3301059|NCT01841541|Experimental|Ombda Locality: informal providers|"Ombda locality is located in Western Khartoum and populated with population size of 988,163.~Intervention: 380 unpaid Informal providers trained to recognise TB symptoms and to refer presumptive TB cases to formal health care facilities within the area."
3301060|NCT01841541|No Intervention|Jabal Awlia Locality|The control arm: A locality in south eastern site of Khartoum state populated with 942,429. No intervention took place
3301061|NCT01841645|Other|CLA depletion-repletion|
3301062|NCT01841658|Experimental|Folic Acid Normal Weight|Folic acid, tablet, 800 mcg, daily, eight weeks. Normal Weight individuals, each will serve as her own control.
3301063|NCT01841658|Experimental|Folic acid Obese|Folic acid, tablet, 800 mcg, daily, eight weeks. Obese individuals, each will serve as her own control.
3301064|NCT01841671|Experimental|IPV/IPV/IPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, IPV at 8, 16 and 24 weeks of age respectively, Rotarix at 8 and 16 weeks if parents accept (optional), and mOPV type 2 at 28 weeks of age
3301065|NCT01841671|Active Comparator|IPV/IPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, IPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks f age (optional) and mOPV type 2 at 28 weeks of age
3301066|NCT01841671|Active Comparator|IPV/bOPV/bOPV/Rotarix/mOPV type 2|190 healthy infants due for their first dose of polio vaccines will be receive IPV, bOPV, bOPV at 8, 16 and 24 weeks of age respectively and Rotarix at 8 and 16 weeks of age (optional)and mOPV type 2 at 28 weeks of age
3301067|NCT01841684|Experimental|Anacetrapib|Participants receive anacetrapib 100 mg orally once daily for 12 weeks.
3301068|NCT01841684|Placebo Comparator|Placebo|Participants receive placebo orally once daily for 12 weeks.
3301069|NCT01841710||Women|
3301070|NCT01841723|Experimental|Treatment (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3301071|NCT01841749|Other|Surgery|sentinel node biopsy and mastectomy
3301072|NCT01841788|Experimental|Thermal Adhesion Patch|Group of subjects wearing the experimental patch for 8 hour study duration
3301073|NCT01841788|Active Comparator|Marketed Thermal Adhesion Patch|Group of subjects wearing comparative predicate device for 8 hour study duration.
3301074|NCT01841788|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hour study duration
3301075|NCT01841801|Active Comparator|Marketed Thermal Adhesive Patch|Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.
3301076|NCT01841801|Experimental|Thermal Adhesive Patch|Group of subjects wearing the experimental patch for 8 hours daily for 7 days.
3301077|NCT01841801|Placebo Comparator|Placebo Patch|Group of subjects wearing the placebo patch for 8 hours daily for 7 days.
3301078|NCT01841814|Experimental|lymphoma|
3301079|NCT01841827|Active Comparator|Cilostazol|Capsule of Cilostazol 200 mg are taken orally on each study day
3301080|NCT01841827|Placebo Comparator|Placebo|A capsule of placebo containing starch are taken orally on each study day.
3301081|NCT01841840|No Intervention|Control|This arm involves not implementing any form of intervention (passive vibration)on the subject during this visit.
3301082|NCT01841840|Experimental|Low-Frequency Pasive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude.
3301083|NCT01841840|Experimental|High-Frequency Passive Vibration|This arm involves exposing the subject to a 10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude.
3301084|NCT01841853|Experimental|Senior meetings|The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting.The main purpose of the senior meetings is to give information and facilitate discussion of the ageing process and provide tools and suggest strategies to enable the clients to solve the various problems that may arise at home in order to remain living at home in a safe and secure way. The information will also include what the municipality provides in the form of local meeting places, activities run by local associations, physical training for seniors, walking groups, possibilities of offering or accepting help on a voluntary basis. Furthermore, they will be informed about help and support available in their city district. Identification of risks for, and advice on, how to prevent falls will also be included.
3301085|NCT01841853|No Intervention|Control group|The control group will receive conventional care on their own initiative.
3301086|NCT01841866|Active Comparator|deep anesthetic state|LMA removal
3301087|NCT01841866|Placebo Comparator|awake|LMA removal
3301088|NCT01841879|Experimental|Intervention Program|Receives the full Healthy, Safe, and Tobacco-Free Worksites intervention
3301089|NCT01841879|Other|Delayed Intervention Control|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
3301090|NCT01841892|No Intervention|Usual Care Control|
3301091|NCT01841892|Experimental|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
3301092|NCT01841905||Observational Study|Pre-Symptomatic Alzheimers' Disease
3301093|NCT01841918|Experimental|A/17/turkey/Turkey/05/133 (H5N2)|100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
3301094|NCT01841918|Placebo Comparator|Placebo|50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.
3301095|NCT01841944|Active Comparator|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
3301096|NCT01841944|Placebo Comparator|Corn oil|3x capsules of corn oil pr day
3301097|NCT01841957|Experimental|ISBCS|Immediate Simultaneous Bilateral Cataract Surgery
3301098|NCT01841957|Active Comparator|DSBCS|Delayed Sequential Bilateral Cataract Surgery
3301099|NCT01841983|Experimental|Intervention|Be Well Work Well
3301100|NCT01841983|No Intervention|Control|No intervention
3301101|NCT01841996|Experimental|ME1111 solution|
3301102|NCT01841996|Placebo Comparator|Vehicle Solution|
3301103|NCT01842009|Experimental|Active anodal HD-tDCS|Subjects will undergo 20 minutes active HD-tDCS.
3301104|NCT01842022|Other|Better glucose tolerance|Take meals with isomaltulose, sucrose or glucose
3301105|NCT01842022|Other|Better glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
3301106|NCT01842022|Other|Poorer tolerance levels remain high|Take meals with isomaltulose, sucrose or glucose
3301107|NCT01842022|Other|Poorer glucose tolerance / Levels fall|Take meals with isomaltulose, sucrose or glucose
3301108|NCT01842035|Experimental|Regadenoson|"Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.~--------------------------------------------------------------------------------"
3301109|NCT01842048|Experimental|External-beam radiotherapy combine hyperthermia|Hyperthermia 42℃ ± 0.5℃ for 40min, 2 times/week within 2hr after irradiation. Radiation protocol are 3Gy 5 times a week for a total of 30Gy/10fx/2 weeks
3301110|NCT01842048|Active Comparator|External-beam radiotherapy alone|External-beam radiotherapy alone comprising 30Gy/10 fractions, 5 times a week, administered with 2 weeks.
3301111|NCT01842074|Experimental|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
3301112|NCT01842087|Placebo Comparator|Control Foods|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
3301113|NCT01842087|Experimental|Fiber Fortified Foods|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
3301114|NCT01842100|Active Comparator|Universal antibiotic prophylaxis|In the universal prophylaxis group, all women received doxycycline 100 mg twice daily for 7 days starting on the day of induced abortion. Screening for sexually transmitted diseases was done as baseline but the results were not revealed to the patients.
3301115|NCT01842100|Active Comparator|Screen-and-treat|In the screen-and-treat group, the results of screening for sexually transmitted infections (STI) were revealed to the patients. They would only receive appropriate specific antibiotics treatment only if they were screened positive for any of the STIs. If they were found to have STI, their sexual partners would also be referred to the local social hygiene clinics for contact tracing and treatment. Contraception by barrier methods would also be advised.
3301116|NCT01842113|Active Comparator|Lactulose and Rifaximin Placebo|Standard portal hypertension care, standard nutritional advice, Lactulose 30ml three times a day and Rifaximin (Xifaxan) Placebo twice a day.
3301117|NCT01842113|Active Comparator|Rifaximin and Lactulose Placebo|Rifaximin (Xifaxan) twice a day and Lactulose Placebo three times a day.
3301118|NCT01842126|Experimental|Single Ascending Dose (SAD): BG00010|Up to five cohorts of healthy volunteers will receive a single dose of intravenous (IV) BG00010 followed by a single SC dose of BG00010 2 weeks apart.
3301119|NCT01842126|Experimental|SAD: Placebo|Up to five cohorts of healthy volunteers will receive a single IV dose of placebo followed by a single SC dose of placebo 2 weeks apart.
3301120|NCT01842126|Experimental|Multiple Ascending Dose (MAD): BG00010|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of BG00010.
3301121|NCT01842126|Experimental|Multiple Ascending Dose (MAD): Placebo|Up to 6 cohorts of participants with painful lumbar radiculopathy will receive 3 SC doses of placebo.
3301122|NCT01842139|Experimental|Arm A (vaccine with Montanide)|Patients receive WT1 126-134 peptide vaccine emulsified in Montanide ISA 51 VG SC on day 0 and then once every 2 weeks.
3301123|NCT01842139|Experimental|Arm B (vaccine with poly-ICLC)|Patients receive WT1 126-134 peptide vaccine in poly-ICLC SC on day 0 and then once every 2 weeks.
3301124|NCT01842139|Experimental|Arm C (vaccine therapy, monoclonal antibody)|Patients assigned to Arm C receive basiliximab IV over 30 minutes on day -7 and WT1 126-134 peptide vaccine as in Arm A or Arm B, whichever had a superior cellular immune response.
3301125|NCT01842165|Other|177Lu-octreotate therapy|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
3301126|NCT01842178|Experimental|scratching|"Patients will have an endometrial injury done on purpose, between 18-24 days prior to IVF cycle with a transfer catheter on the surgery outpatient department.~Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control"
3301127|NCT01842178|Placebo Comparator|scratching simulation|Patients will come to control visit between day 18-24. A scratching simulation will be done.
3301128|NCT01842191|Experimental|Fish oil|
3301129|NCT01842191|Placebo Comparator|Placebo|
3301130|NCT01842204|Experimental|active kit|Patient receives an active kit with pulsed electromagnetic field over wound surface area.
3301131|NCT01842204|Placebo Comparator|non-active kit|Patient receives a non-active kit.
3301132|NCT01842217|Other|Premenopausal women|healthy female subjects: premenopausal
3301133|NCT01842217|Other|Postmenopausal women|healthy female subjects: postmenopausal
3301134|NCT01842230|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
3301135|NCT01842230|Active Comparator|Telmisartan 80mg and S-amlodipine 5mg|
3301136|NCT01842243|Active Comparator|Apical Pacing|Pacemaker programmed to pacing the heart at apex for 9 months.
3301137|NCT01842243|Active Comparator|Septal Pacing|Pacemaker programmed to pacing the heart at the septum for 9 months.
3301138|NCT01842256|Experimental|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|
3301139|NCT01842256|Active Comparator|Atorvastatin 40mg|
3301140|NCT01842269|Experimental|My-Rept® Tablet|My-Rept® Tablet, Mycophenolate Mofetil 500mg, orally
3301141|NCT01842269|Active Comparator|My-Rept® Capsule|My-Rept® Capsule, Mycophenolate Mofetil 250mg, orally
3301142|NCT01842282|Experimental|Amlexanox|
3301143|NCT01842295|No Intervention|Bariatric surgery|Obese men with associated co-morbidities selected for bariatric surgery by multidisciplinary team
3301144|NCT01842321|Experimental|Abiraterone Acetate|
3301145|NCT01842347|Experimental|Pediatrics, C. Diff.|Fecal Microbiota Transplantation in children with c. difficile infection
3301146|NCT01842360|Experimental|MV130|The subjects will receive daily dose of MV130 during 12 months
3301147|NCT01842360|Placebo Comparator|Placebo|The subjects will receive daily dose of placebo during 12 months
3301148|NCT01842373|Experimental|LMX4|3 g of LMX4 will be applied to one half of the face for 60 minutes
3301149|NCT01842373|Active Comparator|BLT|3 g of BLT will be applied to half of face for 60 minutes
3301151|NCT01842399|Placebo Comparator|Experimental 1|2x/day orally
3301152|NCT01842399|Experimental|Experimental 2|75 mg, 2x/day, orally
3301153|NCT01842399|Experimental|Experimental 3|150 mg, 2x/day, orally
3301154|NCT01842412||claudication|
3301155|NCT01842412||healthy|
3301156|NCT01842451|Experimental|VX-135 High Dose with Daclatasvir|12 weeks of a high dose of VX-135 in combination with Daclatasvir
3301157|NCT01842451|Experimental|VX-135 Low Dose with Daclatasvir|12 weeks of a low dose of VX-135 in combination with Daclatasvir
3301158|NCT01842477|Experimental|Implantation surgery|All the patients will have the implantation surgery. This trial is a one-arm study.
3301159|NCT01842503|Active Comparator|GET 73|300 mg (3 capsules) tid for 3 days
3301160|NCT01842503|Placebo Comparator|inactive ingredients capsule|3 capsules tid for 3 days
3301161|NCT01842516|Experimental|LCB01-0371 800mg|LCB01-0371 800mg
3301162|NCT01842516|Experimental|LCB01-0371 1200mg|LCB01-0371 1200mg
3301163|NCT01842516|Placebo Comparator|Placebo|Placebo
3301164|NCT01842529|Active Comparator|CABG+ Botulinum toxin|All patients underwent conventional CABG. After the main stage of the surgery botulinum toxin (Xeomin, incobotulinumtoxin A, Merz Pharma GmbH & Co KGaA, Germany; 50 U/1 mL at each fat pad; botulinum toxin group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
3301165|NCT01842529|Active Comparator|Control|All patients underwent conventional CABG. After the main stage of the surgery 0.9% normal saline (1 mL at each fat pad; placebo group) was injected into the entire four visible area of the major epicardial fat pads. First epicardial left atrial fat pad is located anterior to the right superior pulmonary vein and corresponding to the anterior right GP; second epicardial fat pad is located inferoposterior to the right inferior pulmonary vein and corresponding to the inferior right GP; third fat pad is located anterior to the left superior PV and left inferior PV (between the PVs and LAA), corresponding to the Marshall tract GP and superior left GP; forth fat pad located inferiorly to the left inferior PV and extends posteriorly and corresponding to the inferior left GP.
3301166|NCT01842542|Experimental|Transcranial Magnetic Stimulation (TMS)|"Patients will receive NeuroStar Transcranial Magnetic Stimulation (TMS) therapy treatments 5 times a week for up to 8 weeks during the acute phase, 3 times during the first week, 2 times during the second week and 1 time during the third week of the taper phase.~Efficacy Assessments will be conducted throughout the acute and taper phase at protocol specific timepoints."
3301167|NCT01842555||PDT registry patients|Any newly diagnosed lung or esophageal cancer that is being being treated with PDT at a participating institution.
3301168|NCT01842659|Experimental|Pregnant women requiring amniocentesis|Pregnant women requiring amniocentesis
3301169|NCT01842672|Experimental|Mitoxantrone/Clofarabine|Clofarabine Dose escalation starting 20 mg/m2/d days 1-5 Mitoxantrone 12 mg/m2/d days 3-6. Rituximab in patient with CD20+ disease only 375 mg/m2 day 1, 8, 15. IT Depocyt 35 or 50 mg/dose day 1 per cycle. IT ARA-C in children < 3 years age based dosing.
3301170|NCT01842685|Experimental|Bladder Thermal Distention|Continuous irrigation of the bladder with warm saline (up to 45 Celsius) using a specific 3 ways catheter. The procedure will last 1 hour. Saline will be irrigated by the PelvixTT system.
3301171|NCT01842698|Experimental|ultrasoundguided paravertebral catheter|ultrasoundguided paravertebral catheter
3301172|NCT01842724|Active Comparator|Motec total wrist arthroplasty|
3301173|NCT01842724|Active Comparator|Remotion total wrist arthroplasty|
3301174|NCT01842737|Experimental|Spinal Treatment|Participant receives High Velocity Low Amplitude Spinal Manipulation (HVLA) to the low back only from a doctor of chiropractic. Also receives focused palpation procedures to the low back paired with visual input of these procedures using a tablet computer. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. The doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
3301175|NCT01842737|Active Comparator|Foot Massage|The doctor of chiropractic will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
3301176|NCT01842750|Experimental|Endorectal Balloon insertion|A cone Beam scan will be performed prior to balloon insertion and then again with balloon in situ. The scans will be compared to see if the organs are stabilised. Questionnaires will be completed by the radiographer and the patient.
3301177|NCT01842802|Experimental|Diode Laser Treatment Before Abdominoplasty|Patient will be treated with Diode Laser prior to abdominoplasty.
3301178|NCT01842802|Experimental|YAG Laser Treatment Before Abdominoplasty|Patients will be treated with YAG prior to abdominoplasty
3301179|NCT01842828|Active Comparator|Standard care plus electronic cigarettes|Standard care for smoking cessation plus electronic cigarettes
3301180|NCT01842828|Other|Standard care|Standard care for smoking cessation
3301181|NCT01842854||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3301182|NCT01842867||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3301183|NCT01842880||Patients with Chagas disease diagnosis|Diagnosis of Chagas disease in both forms: indeterminate and cardiac ones, with and without ventricular dysfunction.
3301184|NCT01842893|Experimental|Fentanyl / Placebo|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
3301185|NCT01842919|Other|Huntington patient|This group will perform Magnetic Resonance Imaging (MRI), kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
3301186|NCT01842919|Other|Assisting Person|This group will perform MRI, kinesthetic test and psychological questionnaires before and after 8 months of dance lessons
3301187|NCT01842919|Other|Pilot subject|Healthy volunteers to set up the kinesthetic test
3301188|NCT01842932|Experimental|Phloroglucin & Placebo|Phloroglucin 20ml before examination & Placebo 1ml before examination
3301189|NCT01842932|Experimental|Cimetropium bromide & Placebo|Cimetropium bromide 1ml before examination & Placebo 20ml before examination
3301190|NCT01842945|No Intervention|Wait-list control|
3301191|NCT01842945|Experimental|Treatment with therapist contact|
3301192|NCT01842945|Experimental|Treatment without therapist contact|
3301193|NCT01842971|Experimental|two stage hepatectomy|the two stage hepatectomy is defined as a two step procedure: first step: hepatotomy with ligature of the right branch of the portal vein second step (one week after the first step): right hepatectomy
3301194|NCT01842984|Experimental|I-SOCIAL intervention|Participants in this group will have up to 10 personal meetings with activities counselors and several group meetings.
3301195|NCT01842984|No Intervention|Control group|Participants in this group will not have meetings with the activities counselors, and will not take part in the group meetings.
3301196|NCT01842997|Experimental|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|split-virion, non-adjuvanted H1N1 vaccine of 15 μg made by Shanghai Institute of Biological Products lot number: 200909008
3301197|NCT01843010|Active Comparator|Parecoxib|Intravenously Parecoxib 40mg at 30min before intubation, 8h and 20h after surgery.
3301198|NCT01843010|Placebo Comparator|Placebo|Normal saline 5ml will be intravenously infused at the same time points., respectively.
3301199|NCT01843036|Experimental|Durham Connects Eligible|From January 1, 2014 - June 30, 2014, all odd-birth-date residential births in Durham County, North Carolina will be randomly assigned to receive the Durham Connects nurse home visiting program.
3301200|NCT01843036|No Intervention|Control|From January 1, 2014 - June 30, 2014, all even-birth-date residential births in Durham County, North Carolina will be randomly assigned to a control group condition. These families will be assigned to receive services as usual and serve as the randomized comparison group for evaluating Durham Connects program impact.
3301201|NCT01843049|Experimental|radiotherapy+chemotherapy|"Radiotherapy:~LEVEL 1: dose given at PTV-G and PTV-C will be 64Gy/32 fractions and 50Gy/25 fractions.~LEVEL 2: dose given at PTV-G and PTV-C will be 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 3: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/28 fractions, 63Gy/28 fractions and 50.4Gy/28 fractions.~LEVEL 4: dose given at PTV-GR (with an integrated boost to the 50% SUVmax area of the primary tumor of the pre-treatment 18FDG-PET/CT scan), PTV-G and PTV-C will be 70Gy/25 fractions, 62.5Gy/25 fractions and 50Gy/25 fractions.~Chemotherapy:~Concurrent chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24 hours daily on Days 1-4 and 29-32.~Consolidation chemotherapy: Cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks for 2 cycles."
3301202|NCT01843075|Experimental|Liraglutide|Daily administration of 1.8 mg liraglutide by subcutaneous injection
3301203|NCT01843075|Placebo Comparator|Placebo|Daily administration of matched placebo by subcutaneous injection
3301204|NCT01843088|Experimental|Mannitol cream|cream containing 25% mannitol, applied as often and as much as needed to one leg ( chosen at random), on the day of a 10 km run, following the run and for five days afterwards
3301205|NCT01843088|Placebo Comparator|Placebo cream|Same carrier cream as that containing the active ingredient, mannitol, but without the active ingredient. Placebo cream to be applied to the painful areas of the other leg, chosen at random, on the day of a 10 km or more race, following the race, and as needed for the five days after the race. It is to be noted that, as almost no mannitol is absorbed through the skin, it is highly unlikely that this would involve the pain levels in the placebo leg.
3301206|NCT01843101|Other|Healthy volunteers|10 healthy volunteers
3301207|NCT01843101|Other|Corneal Neovascularisation|5 patients with corneal neovascularisation
3301208|NCT01843101|Other|Keratoconus|5 patients with keratoconus
3301209|NCT01843114|Other|Patients with Type I Diabetes|24 patients with type I diabetes with no or mild non-proliferative retinopathy
3301210|NCT01843114|Other|Healthy subjects|24 healthy age-and sex- matched control subjects
3301211|NCT01843127|Active Comparator|Placebo, Ranolazine, Exenatide|
3301212|NCT01843127|Active Comparator|Ranolazine, Placebo, Exenatide|
3301213|NCT01843140||Young female cancer survivors|
3301214|NCT01843153|Other|intermittent|injection of ropivacaine on demand
3301215|NCT01843153|Other|continuous|continuous ropivacaine infusion
3301216|NCT01843166|Active Comparator|Treatment group|These patients will utilize a pessary and be given instructions for use and prescription for Premarin vaginal cream 2g at bedtime twice weekly.
3301217|NCT01843166|Placebo Comparator|Control group|These patients will utilize a pessary with an inactive placebo cream.
3301218|NCT01843179|Experimental|Sulindac Treatment Arm|Induction Chemotherapy followed by treatment with sulindac
3301219|NCT01843218|Other|Register R|Evaluation of erectile dysfunction in the management of localized rectal cancer
3301220|NCT01843231|Experimental|g-Cath EZ Treatment Group|Evaluate the safety and effectiveness of the g-CathTM EZ Suture Anchor Delivery Catheter as an early weight loss intervention
3301221|NCT01843231|Active Comparator|Diet and exercise Control Group|Diet and Exercise only control group
3301222|NCT01843257||Gastric Bypass longitudinal|Morbidly obese subjects undergoing gastric bypass surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3380500|NCT04681066|Active Comparator|1.0 mg/kg (0.625 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
3380501|NCT04681066|Active Comparator|0.5 mg/kg (0.3125 mL/kg)|administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
3380502|NCT04681066|Placebo Comparator|Placebo (1.25, 0.625, or 0.3125 mL/kg)|patients randomized to placebo will receive one of three following volumes (1.25 mL/kg, 0.625 mL/kg, and 0.3125 mL/kg. although three volumes - all patients randomized to placebo will be analyzed together as one arm. administered intravenously over 4 hours at a constant rate of infusion. They will be administered every 24 hours (±1 hours) for three consecutive days for a total of 3 doses.
3380503|NCT04678440|Experimental|Healthy Volunteers|Study participants will undergo a single dynamic [18F]F-AraG PET/CT scan (of duration up to 90-minutes) on the uEXPLORER PET/CT scanner. There will be a follow-up visit or call 7 days after the scan to assess any adverse events that could be attributed to either the scan or the administration of [18F]F-AraG.
3380504|NCT04678440|Experimental|Non-Small Cell Lung Cancer Patients (NSCLC)|Study participants with NSCLC who are planned to receive PD-1/PD-L1 immunotherapy will undergo a pre-therapy dynamic [18F]F-AraG PET/CT scan, and an optional post-therapy (first dose only) dynamic [18F]F-AraG PET/CT scan on the uEXPLORER total-body scanner.
3380505|NCT04677179|Experimental|LY3471851 (High Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
3380506|NCT04677179|Experimental|LY3471851 (Low Dose)|"Stage 1 LY3471851 given subcutaneously (SC)~Stage 2 LY3471851 multiple doses to be confirmed"
3380507|NCT04677179|Placebo Comparator|Placebo|"Stage 1 Placebo given SC~Stage 2 Placebo given SC"
3301223|NCT01843257||Gastric Banding longitudinal|Morbidly obese subjects undergoing laparoscopic gastric banding surgery. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3380511|NCT04672876|Experimental|Telotristat Ethyl (Xermelo®)|After the surgery is performed, study participants will stop taking telotristat ethyl (Xermelo®) as part of this study and there will be no follow-up visits or calls required outside of the usual postoperative care. The research team will collect clinical data on the participants' outcomes up to 30 days after surgery by accessing medical records.
3380512|NCT04672434|Experimental|Sym024 Dose Level 1|Part I, Sym024 monotherapy dose level 1
3380513|NCT04672434|Experimental|Sym024 Dose Level 2|Part I, Sym024 monotherapy dose level 2
3380514|NCT04672434|Experimental|Sym024 Dose Level 3|Part I, Sym024 monotherapy dose level 3
3380515|NCT04672434|Experimental|Sym024 Dose Level 4|Part I, Sym024 monotherapy dose level 4
3380516|NCT04672434|Experimental|Sym024 Dose Level -1|Part I, Sym024 monotherapy dose level -1. Evaluate only if needed based on tolerability
3380517|NCT04672434|Experimental|Sym021+Sym024 Dose Level 2|Part II, Sym021 in combination with dose level 2 of Sym024
3380518|NCT04672434|Experimental|Sym021+Sym024 Dose Level 3|Part II, Sym021 in combination with dose level 3 of Sym024
3380519|NCT04672434|Experimental|Sym021+Sym024 Dose Level 4|Part II, Sym021 in combination with dose level 4 of Sym024
3301224|NCT01843257||Gastric Bypass (cross-sectional)|Subjects who underwent gastric bypass surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3301225|NCT01843257||Gastric Banding (cross-sectional)|Subjects who underwent gastric banding surgery 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3301226|NCT01843257||Sleeve gastrectomy (longitudinal)|Morbidly obese subjects who will undergo sleeve gastrectomy. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery. The two testing sessions will be repeated ~ 9 months after surgery.
3301227|NCT01843257||Sleeve gastrectomy (cross-sectional)|Subjects who underwent sleeve gastrectomy 1-5 years ago. Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery.
3380520|NCT04672434|Experimental|Sym021+Sym024 Dose Level 1|Part II, Sym021 in combination with dose level 1 of Sym024. Evaluate only if needed based on tolerability
3380521|NCT04672434|Experimental|Dose Expansion Sym021 (+Sym024)|Part III, dose expansion Sym024 and/or Sym021+Sym024
3380522|NCT04670640|Experimental|Breath Focus|Participants receiving the breath focus study intervention.
3380523|NCT04670640|Experimental|Vibration|Participants receiving the vibration study intervention.
3380524|NCT04670640|Experimental|Vibration With Breath Focus|Participants receiving the vibration with breath focus study intervention.
3301228|NCT01843257||No bariatric surgery control|"Control group of women with age and BMI similar to those in the cross-sectional arm of the study who have not undergone bariatric surgery.~Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion before surgery."
3301229|NCT01843270|Experimental|ideal body weight|LMA size based on ideal body weight
3301230|NCT01843270|Experimental|actual body weight|LMA size according to actual body weight
3301231|NCT01843283|Experimental|Daily Enhancement Meaningful Activity (DEMA)|The group member will receive Self-management Toolkit and 6 bi-weekly individualized sessions, 2 face-to-face and 4 via telephone delivered by a trained intervener. DEMA will provide autonomy support by helping patients to identify and prioritize activities, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed.
3301232|NCT01843283|Active Comparator|Information Support (IS)|The IS group will receive 2 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer Association, educational brochure. Then they will receive 4 biweekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials.
3301233|NCT01843296|Active Comparator|Magnesium|Patients in group C received a premixed solution of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc) and 50 mg of magnesium sulfate 50% (0.1 ml) (Pasteur Institute Co, Tehran, Iran) for spinal anesthesia
3301234|NCT01843296|Active Comparator|Fentanyl|Patients in Fentanyl group received a premixed solution of of 15 mg hyperbaric bupivacaine 0.5% (3 ml) and 25 µg fentanyl (0.5cc),plus 0.1 cc preservative free 0.9% normal saline for spinal anesthesia
3301235|NCT01843296|Active Comparator|Bupivacaine|Patients in Bupivacaine group(control) received a premixed solution of 15 mg of hyperbaric bupivacaine 0.5% (3 ml), plus 0.6 cc preservative free 0.9% normal saline for spinal anesthesia
3301236|NCT01843309|Experimental|Spironolactone 200mg|Spironolactone 100 mg twice a day orally
3301237|NCT01843309|Placebo Comparator|Placebo|Placebo twice a day orally
3301238|NCT01843309|Experimental|Spironolactone 100mg|Spironolactone 100mg once a day
3301239|NCT01843322|Experimental|navigation technology|custom made navigation technology integrated in a Siemens angiography suite for feasibility evaluation in endoleak repair procedure
3301240|NCT01843361||acute ischemic stroke|Determing cardiovascular risk factors or medication on clopidogrel response rates after an acute ischemic stroke
3301241|NCT01843387|Experimental|Cohort 1|Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo
3301242|NCT01843387|Experimental|Cohort 2|Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo
3301243|NCT01843400||Group 1|
3301244|NCT01843426|Experimental|Low-volume, Low-concentration contrast (Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
3301245|NCT01843439|Experimental|Intervention|"We designed a intervention study to correct additional risk factors in elderly asthma patients.~We offer following specific interventions simultaneously to intervention arm and will measure the effects of interventions after 1 years.~popularize and educate the asthma action plan~run a emergency call system for acute exacerbation~educate the proper techniques using inhalers~correct the deficiency of magnesium (magnesium 500mg per day)"
3301246|NCT01843452|Experimental|Capecitabine, mitomycin, panitumumab and radiotherapy|"RADIOTHERAPY: daily fraction dose of 1.8Gy , 5 days a week between day 1 and 45 Intensity modulated radiotherapy (IMRT), using a linac based facility or helical tomotherapy, is obligatory.~The first treatment sequence consists of a total dose of 36 Gy in 20 daily fractions of 1.8 Gy on five days a week.~The second treatment sequence consists of a total dose of 23.4 Gy in 13 daily fractions of 1.8 Gy on five days a week.~PANITUMUMAB: 6 mg/kg IV over 60 min infusion on days 1, 15 and 29~MITOMYCIN: 10 mg/m2 IV over 15 min infusion on days 1 and 29~CAPECITABINE: 825 mg/m2 oral twice daily on days 1 to 45"
3301247|NCT01843478|Experimental|HPV Self-Collection|The intervention is a self-collected HPV test, followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
3301248|NCT01843478|Placebo Comparator|Usual Care|In the usual care arm, women do not receive the HPV test. They are encouraged to have Pap testing. In addition, there is a phone call as an attention control, where women are reminded to make a Pap test appointment about 2-3 weeks after the baseline visit.
3301249|NCT01843491|Experimental|Ad-PfCA|Single injection of Ad-PfCA containing 2 x 10^10 pu total dose in 1 ml of Final Formulation Buffer by intramuscular injection
3301250|NCT01843504|Active Comparator|Platelet Rich Plasma|Subjects in Group 1 (PRP) will receive a single US-guided injection of 5 mL autologous platelet-rich plasma at week 0 (baseline).
3301251|NCT01843504|Placebo Comparator|Group 2|Subjects in Group 2 (saline control) will receive a single injection of 5 mL 0.9% normal saline at week 0.
3301252|NCT01843517||endogenous pain facilitation|Pain facilitation is studied by a simple test of applying over the counter capsaicin cream to the skin for only 30 min, then removing it and heating the skin to a non-noxious temperature.
3301253|NCT01843517||endogenous pain inhibition|Pain inhibition is studied by a simple test of mild pain on one area of the body reducing response to a pain stimulus in another area.
3301254|NCT01843530|Experimental|Group 1|Cortisone, Clemastin + BERINERT
3301255|NCT01843530|Placebo Comparator|Group 2|Cortinsone, Clemastin + NaCl
3301256|NCT01843543|Experimental|MBSR participants|Subjects in this arm will participate in an 8 week Mindfulness Based Stress Reduction Course
3301257|NCT01843543|No Intervention|No MBSR Participants|Subjects in this arm will not participate in the Mindfulness Based Stress Reduction Course.
3301258|NCT01843556|Experimental|E2022 Tape Formulation|
3380525|NCT04670640|Experimental|Screens Free|Participants receiving the screens free study intervention.
3301259|NCT01843569|Experimental|IVM|All patients registered in this study will undergo natural cycle IVF with In Vitro maturation (IVM) performed on all immature retrieved oocytes.
3301260|NCT01843595|Experimental|REFIT Intervention|This arm will receive the REFIT intervention immediately after randomization.
3301261|NCT01843595|No Intervention|Wait-list control|This arm will receive a modified version of the REFIT program after the 6-month assessment.
3301262|NCT01843608|No Intervention|Control Group|"Patients in this group will be asked to maintain the same activity level until the baseline assessments.~They cannot change physical activity and nutritional habits."
3301263|NCT01843608|Experimental|Physical Intervention Group|"They have to perform two days per week of guide and planned exercise during three months. All classes are composed by different parts: aerobic exercise, to improve cardiovascular capacity, strength, to work muscle mass and flexibility to increase joint movements.~They have to present an attendance above or equal to 80%."
3301264|NCT01843647|Experimental|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.
3301265|NCT01843647|Active Comparator|Chemotherapy|Patients receive 8-week icotinib induction treatment before surgery and 4-cycle adjuvant chemotherapy with vinorelbine/cisplatin regimen after surgery.
3301266|NCT01843686|Experimental|Autologous Platelet Rich Plasma (PRP)|Magellan Autologous Platelet Separator used to extract Platelet Rich Plasma from autologous whole blood. PRP is mixed with calcified thrombin to create a gel, which is place on the excised wound bed prior to application of split thickness autograft.
3301267|NCT01843686|Placebo Comparator|Saline Gel, Standard of Care|Normlgel Saline is placed on the excised wound bed prior to application of split thickness autograft.
3301268|NCT01843699|Experimental|Topiramate|A 12-week topiramate flexible dose administration plus 4 sessions of a manualized cognitive restructuring intervention.
3301269|NCT01843699|Placebo Comparator|Placebo|A 12-week placebo matching tablets plus 4 sessions of a manualized cognitive restructuring intervention.
3301270|NCT01843725|Experimental|Metronomic arm|capecitabine 1100 to 1600 mg/m2/day orally in association with aflibercept 6mg/kg intravenous every 3 weeks
3301271|NCT01843725|Experimental|Intermittent arm|capecitabine 1700 to 2500 mg/m2/day orally 2 weeks out of 3 and aflibercept 6mg/kg intravenous every 3 weeks
3301272|NCT01843738|Experimental|All participants|
3301273|NCT01843764||children with malaria|Tanzanian children between 6-59 months with an uncomplicated P.falciparum monoinfection, followed after arthemeter-lumefantrine treatment according to national treatment guidelines
3301274|NCT01843790|Placebo Comparator|Placebo, saline|Saline, dosed weekly for 8 weeks
3301275|NCT01843790|Experimental|GCS-100 low dose|Low dose of GCS-100 given IV once per week for 8 weeks
3301276|NCT01843790|Experimental|GCS-100 high dose|High dose of GCS-100 given IV once per week for 8 weeks
3301277|NCT01843816||healthy subjects|18-65 aged healthy subjects who have no disorder that may disturb posture or erect position (inflammatory diseases, kyphosis, scoliosis, joint deformities)
3301278|NCT01843829|Experimental|Carboplatin and Paclitaxel Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Paclitaxel 50mg/m2 Days 1,8,15,22,29 (IV infusion); Carboplatin AUC 2 Days 1,8,15,22,29 (IV infusion) XRT: 45 Gy in 25 fractions~then surgery.~All drugs will be sourced from local stock"
3301279|NCT01843829|Experimental|Oxaliplatin and Capecitabine Arm|"2 cycles OxCap: Oxaliplatin 130mg/m2 Day 1 (IV infusion) Capecitabine 625mg/m2 bd Day 1- 21 (oral)~then CRT: Oxaliplatin 85mg/m2 Days 1, 15, 29 (IV infusion); Capecitabine 625mg/m2 bd (oral) only on days when receiving RT XRT: 45 Gy in 25 fractions*~then surgery.~All drugs will be sourced from local stock"
3301280|NCT01843855|Experimental|Exendin 9,39|Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes.
3301281|NCT01843855|Placebo Comparator|Placebo|Subjects randomized to this arm will receive a saline infusion for 360 minutes.
3301282|NCT01843868|Other|R-CHOP and standard anti-emetics|"This is a single arm study.~All patients receive R-CHOP every 14 or 21 days for a minimum of 3 cycles. Standard anti-emetics will be used as follows:~5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential use of ondansetron or granisetron will be encouraged.~Dexamethasone will not to be used as patients receive hydrocortisone and oral prednisolone in R-CHOP. In this study, the use of oral prednisolone on day 1 will be regarded as equivalent to dexamethasone. Prednisolone will be given PRIOR to the chemotherapy with the 5HT3 antagonist.~Anti-emetics (metoclopramide, prochlorperazine and lorazepam) may be prescribed to be used 'as needed' for breakthrough emesis.~Patients 'failing' the standard Chemotherapy Induced Nausea and Vomiting prophylactic regimen will be eligible to receive aprepitant (Days 1 to 3) for subsequent cycles."
3301283|NCT01843881|Experimental|Exendin 9, 39|Exendin 9, 39 will be infused at 300pmol/kg/min in either first intervention period or second intervention period.
3301284|NCT01843881|Placebo Comparator|Placebo|A saline infusion will be administered in either first intervention period or second intervention period.
3301285|NCT01843894|Placebo Comparator|placebo|In Stage I, each patient will instill 1 drop of placebo into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
3301286|NCT01843894|Experimental|RU-101|In Stage I, each patient will instill 1 drop of RU-101 ophthalmic solution (5%, 10%, or 15%) into each eye, 6 times a day with at least 2 hours between each dose, for 28 days (4 weeks; a total of 168 doses to each eye). In Stage II, each patient will instill 1 drop of RU-101 ophthalmic solution (selected dose from Stage I) into each eye, 6 times a day with at least 2 hours between each dose, for 84 days (12 weeks; a total of 504 doses to each eye).
3301287|NCT01843907|Other|Empowerment|Patients in the intervention group 1 receive a communication report which will also be sent to the physician and home care. In communication report includes the results and interpretation and explanation of the measurements in layman's terms. The report also includes relevant and targeted information on pain management, depression among the elderly, dementia and disability in old age and ways to maintain and improve functional capacity. Links and addresses of relevant, local organizations, and networks are also included. The information material is also included in the report sent to the General Practitioner (GP) and home care.
3301288|NCT01843907|Other|Conversation with Nurse|"Patients in the intervention group 2 gets clarification and follow-up conversation with a nurse anchored in both medical department and municipalities. The nurse is blinded in relation to the patient's screening results. Problems identified in connection therewith are communicated to the GP and home care."
3301289|NCT01843907|No Intervention|Controle Group|Patients in the control group are undergoing the same measurements and records at discharge, as the intervention group, but are otherwise receiving treatment and care as usual without further intervention.
3301290|NCT01843959||Emirati Population|"The individuals enrolled in this study will be divided into children (5-16 years of age) and adults (above 18). The groups will be further divided into BMI categories and glucose tolerance groups.~* Group 1: Underweight (adjusted BMI <10th percentile) and no diabetes~Group 2:~Normal weight (adjusted BMI 10th to 84.9th percentile) and no diabetes~Group 3:~Overweight or obese children (adjusted BMI >= 85th percentile) and no diabetes~Group 4:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T1DM~Group 5:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T1DM~Group 6:~Normal weight (adjusted BMI 10th to 84.9th percentile) and T2DM~Group 7:~Overweight or obese children (adjusted BMI ≥ 85th percentile) and T2DM"
3301291|NCT01843985||1. Eligible RCT/Elect RCT|Eligible for regular chemotherapy, elects and receives regular chemotherapy
3301292|NCT01843985||2. Eligible RCT/Elect LDC|Eligible for regular chemotherapy, elects and receives low-dose chemotherapy
3301293|NCT01843985||3. Eligible RCT/Elect PCO|Eligible for regular chemotherapy, elects and receives palliative care only
3301294|NCT01843985||4. Ineligible RCT/Elect LDC|Ineligible for regular chemotherapy, elects and receives low-dose chemotherapy
3301295|NCT01843985||5. Ineligible RCT/Elect PCO|Ineligible for regular chemotherapy, elects and receives palliative care only
3301296|NCT01843998|Experimental|Sirolimus 0.1% ointment|Sirolimus 0.1% ointment
3301297|NCT01844011|Experimental|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart.
3301298|NCT01844011|No Intervention|Education only|All women enrolled in the trial will receive a paper-based kick count chart, will be educated in the use of the kick count chart, and will be instructed to keep track of their fetal movements on a daily basis.
3301299|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
3301300|NCT01844024|No Intervention|Misoprostol by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
3301301|NCT01844037|Other|Renal denervation|Patients will be treated with the OneShot ablation system
3301302|NCT01844050|Experimental|Chinese herbal medicine|Individualized Treatment with Chinese herbal
3301303|NCT01844050|Placebo Comparator|Placebo|Individualized Treatment with placebo Chinese herbal which Containing 2% of Chinese herbal medicine.
3301304|NCT01844063|Experimental|Conventional treatment|Participants will receive conventional treatment and then be followed until the week 72 study visit.
3301305|NCT01844063|Experimental|Conventional plus BM-MSC treatment|Participants will receive conventional treatment plus a dose of BM-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
3301306|NCT01844063|Experimental|Conventional plus UC-MSC treatment|Participants will receive conventional treatment plus a dose of UC-MSC(each subgroups with a different dose ) and then be followed until the week 72 study visit.
3301307|NCT01844102|Experimental|PrePex|PrePex circumcision procedures will be offered as part of the minimum package of HIV prevention services recommended by the Zambian Ministry of Health (MOH)
3301308|NCT01844128||overweight women with infertility|
3301309|NCT01844141|Experimental|alcohol - clorhexidine|Ingrown toenail irrigated using 70% alcohol - 0.5% clorhexidine
3301310|NCT01844141|Active Comparator|70% alcohol|Ingrown toenail irrigated using 70% alcohol
3301311|NCT01844167|Active Comparator|Physical therapy arm (PT)|"The TENS device used: FDA K071951~Patients will be treated with standard physical therapy, including the electrical stimulation. Manual therapy, cold/heat therapy or exercise will be applied at the discretion of the physical therapist for about 60 minutes in each session. Patient education and self-care instructions will be provided. TENS will also be performed in each session for about 30 minutes based on the typical PT guidelines, which will serve both as a part of the standard of care and as a placebo equivalent. It will typically be set at Normal/Modulate mode and 120 Hertz rate."
3301312|NCT01844167|Experimental|Noxipoint Therapy arm (NT)|"Patients will be treated with TENS following Noxipoint Therapy guidelines as highlighted below:~The TENS device used: FDA K071951~TENS is calibrated to allow for maximum range in the specifications.~A pair of electrode pads is placed at the corresponding pair of Noxipoints of the injured muscle/soft tissue, for about 2- 5 minutes during each application.~The electrical stimulation is set to induce the C-fiber response based on the feedback of the patient.~If the corresponding pain is not eliminated or reduced after a couple of applications on correct Noxipoints, apply an ice pack for about 10-15 minutes on site before and during the next Noxipoint stimulation."
3301313|NCT01844180|Experimental|Experimental Arm 1|ONO-2952 low dose every day for 4 weeks
3301314|NCT01844180|Experimental|Experimental Arm 2|ONO-2952 high dose every day for 4 weeks
3301315|NCT01844180|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 4 weeks
3301316|NCT01844219||Patients who underwent aortic surgery|Patients who underwent aortic surgery in Samsung Medical Center during the period between 2004 and 2010
3301317|NCT01844232|Experimental|Arbaclofen Extended Release (ER) Tablets|Arbaclofen Extended Release Tablets, 20 mg/day, 30 mg/day or 40 mg/day
3301318|NCT01844245|Experimental|Endobiliary RFA group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive endobiliary radiofrequency ablation (Endobiliary RFA) followed by plastic stent(s) placement.~Three months later, subjects will receive the second RFA therapy followed by biliary stents (plastic or SEMS) placement.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
3301319|NCT01844245|No Intervention|Control group|"Endoscopic retrograde cholangiopancreatography (ERCP) would be performed under standard operating conditions to confirm the biliary malignancy. Subjects will receive plastic biliary stent(s) placement only.~Three months later, subjects will receive the second endoscopic intervention for stents (plastic or SEMS) exchange.~During follow-up, if stent occlusion occurs, the patient will undergo endoscopic re-intervention for stent exchange without endobiliary RFA"
3301320|NCT01844258|Experimental|Modified technique for I/A group|"In the modified cataract surgery procedure, the size of the capsulorhexis opening will be decreased to 1.0-1.5 mm in diameter.~The capsulorhexis will be located in the peripheral area of the lens instead of the central area.~A 0.9 mm phacoemulsification probe will be used to remove the cataractous lens.~One drop of 0.5% or 1% atropine and an antibiotic/steroid ointment will be placed in the eye, which will then be patched."
3301321|NCT01844258|Active Comparator|Traditional technique for I/A group|• In traditional technique group, the cataractous lens will be removed through an anterior continuous curvilinear capsulorhexis (ACCC) that is about 5-6 mm in diameter.
3301322|NCT01844271|Placebo Comparator|Placebo Low Level Laser|Application of low level laser without any dose (0 Joule) before strenuous exercise. A laser device with a cluster of 5 diodes (810 nm, 200 mW) each diode was used for this study.
3301323|NCT01844271|Experimental|2 Joules Low Level Laser|Application of 2 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3301324|NCT01844271|Experimental|6 Joules Low Level Laser Therapy|Application of 6 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3301325|NCT01844271|Experimental|10 Joules Low Level Therapy|Application of 10 Joules of Low Level Laser Therapy before strenuous exercise with a cluster of 5 diode (810 nm, 200 mW each diode).
3301326|NCT01844271|Experimental|Power of 100mW|After assigning ideal dose of application it was delimited two experimental groups which was irradiated with the dose established by the first part of the study and power of 100mW.
3301327|NCT01844271|Experimental|Power of 400mW|After assigning ideal dose of application it was delimited two experimental groups which were irradiated with the dose established by the first part of the study and power of 400mW.
3301328|NCT01844297|Other|TDF+3TC+EFV|
3301329|NCT01844310|Active Comparator|RAL +TDF+ LPV/r|Arm A: RAL +TDF+ KELETRA(LPV/r) Group A will be assigned with RAL+TDF+LPV/r.
3301330|NCT01844310|Active Comparator|3TC+ TDF+LPV/r|Arm B: 3TC+ TDF+KELETRA(LPV/r) Group B will be assigned with 3TC+TDF+LPV/r
3301331|NCT01844323|Active Comparator|Treatment A|treatment A, reference, 20 micron palbociclib and lubrication level 1
3301332|NCT01844323|Active Comparator|Treatment B|treatment B, test, 50 micron palbociclib and lubrication level 1
3301333|NCT01844323|Active Comparator|Treatment C|treatment C, test, 20 micron palbociclib and lubrication level 2
3301334|NCT01844323|Active Comparator|Treatment D|treatment D, test, 20 micron palbociclib and lubrication level 3
3301335|NCT01844336|Experimental|PBASE system 1.1 + CT100 (active treatment)|
3301336|NCT01844336|Placebo Comparator|PBASE system 1.1 + CT100 (placebo treatment)|
3301338|NCT01844401|Experimental|Spiromax/ProAir|Single dose of Albuterol Spiromax® 180 mcg followed by a 4 to 14 day washout period then a single dose of ProAir® HFA 180 mcg
3301339|NCT01844401|Experimental|ProAir/Spiromax|Single dose of ProAir® HFA 180 mcg followed by a 4 to 14 day washout period then a single dose of Albuterol Spiromax® 180 mcg
3301340|NCT01844414|Experimental|Parolee Comprehensive Care + Phone Coach|PCPC Intervention: Eight specialized nurse case managed hepatitis education sessions, the Hepatitis A/B vaccine series and coach-facilitated mentoring.
3301341|NCT01844414|Experimental|Parolee Brief HBV program + Phone Coach|PBPC Intervention: Eight twenty minute hepatitis education sessions, coach facilitated mentoring and the Hepatitis A/B vaccine series.
3301342|NCT01844414|Active Comparator|Usual Care Group|UC Control Group: One brief general health information program, one-on-one coaching and the Hepatitis A/B vaccine.
3301343|NCT01844427|Active Comparator|Memantine HCl|Memantine administered in capsule form twice daily for 12 weeks and titrated up to a maximum daily dose of 20mg.
3301344|NCT01844427|Placebo Comparator|Placebo|Masked placebo administered in capsule form twice daily for 12 weeks. Placebo titration will be titrated according to the same procedure as active memantine.
3301345|NCT01844440|Experimental|HRM|
3301346|NCT01844453|Experimental|Luteal Phase Arm|Local Endometrial Injury in mid-luteal phase (cycle day 21-26) prior to the treatment cycle.
3301347|NCT01844453|Experimental|Proliferative Phase Arm|Local Endometrial Injury in early proliferative phase of current treatment cycle (cycle day 2-3).
3301348|NCT01844453|No Intervention|Control Arm|No Local Endometrial Injury will be performed. Patients will undergo a routine fresh IVF treatment cycle.
3301349|NCT01844466|Experimental|stroke patients|
3301350|NCT01844492|Active Comparator|ICU Usual Care Control|described below
3301351|NCT01844492|Experimental|The PARTNER Intervention|described below
3301352|NCT01844544||patients after femur neck fracture|
3301353|NCT01844557||Group 1(High Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participant to tell whether they did as many repetitions as possible and if not, why they were not able to do as many as possible. This portion of the experiment will be videotaped. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3301354|NCT01844557||Group 2(Low Accountability-Human Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3380534|NCT04666272||dabrafenib in combination with trametinib as adjuvant treatment|Patients will be treated according to the China package insert for dabrafenib and trametinib. The approved starting doses of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) will be used.
3380535|NCT04662008|Active Comparator|High resource tailored intervention|Tele-coaching arm
3380536|NCT04662008|Active Comparator|Low-resource web-only intervention|Website arm
3380537|NCT04661150|Experimental|Arm A: Atezolizumab plus Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive atezolizumab + trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, patrticipants will receive 5 further cycles of this regimen.
3380538|NCT04661150|Active Comparator|Arm B: Trastuzumab with XELOX (Capecitabine + Oxaliplatin)|Participants will receive trastuzumab + XELOX (Capecitabine + Oxaliplatin) for 3 treatment cycles prior to surgery, each cycle is 3 weeks. Following surgery, participants will receive 5 further cycles of this regimen.
3380539|NCT04660799|Active Comparator|Rituximab IV+CHOP|Participants will receive 8 cycles of IV rituximab in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
3380540|NCT04660799|Experimental|Rituximab SC+CHOP|Participants will receive 1 cycle of IV plus 7 cycles of SC in combination with six or eight cycles of CHOP chemotherapy administered every 3 weeks
3380541|NCT04660344|Experimental|Arm A: Atezolizumab|Atezolizumab will be administered intravenously at a dose of 1680 milligrams (mg) on Day 1 of each 28-day cycle for 12 cycles or up to 1 year (whichever occurs first). Atezolizumab will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
3380542|NCT04660344|Placebo Comparator|Arm B: Placebo|Placebo will be administered intravenously on Day 1 of each 28-day cycle. Placebo will be discontinued in the event of IRF-assessed disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination by the Sponsor.
3380545|NCT04659161|Experimental|KarXT|
3380546|NCT04659161|Placebo Comparator|Placebo|
3380547|NCT04658186|Experimental|UCB0599 High Dose Arm|Participants will be randomized to receive a predefined high dosage of UCB0599 during the Treatment Period.
3380548|NCT04658186|Experimental|UCB0599 Low Dose Arm|Participants will be randomized to receive a predefined low dosage of UCB0599 during the Treatment Period.
3380549|NCT04658186|Placebo Comparator|Placebo Arm|Participants will be randomized to receive a predefined dosage of Placebo during the Treatment Period.
3380550|NCT04657003|Experimental|10 mg Tirzepatide|10 mg Tirzepatide administered subcutaneously (SC)
3380551|NCT04657003|Experimental|15 mg Tirzepatide|15 mg Tirzepatide administered SC
3380552|NCT04657003|Placebo Comparator|Placebo|Placebo administered SC
3380553|NCT04655547|No Intervention|Control|The participants will follow the usual offered course on the outpatient clinic of Hammel Neurocenter. They wil anticipate in data collection three times in line with the intervention group.
3301355|NCT01844557||Group 3(Low Accountability-Technological Monitoring)|Participants randomly assigned to receive one of three sets of instructions before starting. Instructions for three swallowing exercises as well as an introductory script explaining the purpose of the exercises will be videotaped and shown to participants. Participants perform 3 swallowing exercises while researcher leaves the room. At the end of the testing period, researcher will come back into the room and record the number on participant's tracking device. The videocamera will tape participant's session so evaluation can be made as to exercise accuracy. Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before procedure as well as a brief 3-page post-session questionnaire.
3380554|NCT04655547|Experimental|Intervention|The participants will receive dietary guidance from an dietician, with focus on energy intake and food texture. This guidance will include two sessions on site and three phone meetings. The last on site meeting, will be concluding.
3380555|NCT04653714|Experimental|Full mouth debridement|Supragingival plaque/calculus removal and scaling and root planing
3380556|NCT04653714|Sham Comparator|Supragingival plaque/calculus removal|Supragingival plaque and calculus removal
3380557|NCT04653714|Experimental|Probiotic lozenges|Daily usage of probiotic lozenges
3380558|NCT04653714|Active Comparator|Placebo lozenges|Daily usage of placebo lozenges
3380559|NCT04650854|Experimental|Rozanolixizumab dosage regimen 1|Study participants randomized/assigned to dosage regimen 1 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
3380560|NCT04650854|Experimental|Rozanolixizumab dosage regimen 2|Study participants randomized/assigned to dosage regimen 2 will receive assigned dosage of rozanolixizumab for the initial cycle. The dose regimen may be switched before the start of each subsequent treatment cycle based on investigator discretion.
3380561|NCT04648826|Experimental|1/ Phase I Dose Escalation|Azacytidine (aerosolized) at escalating doses (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 [+/- 3 days] of every 3-week cycle starting with Cycle 2)
3380562|NCT04648826|Experimental|2/ Phase II Dose Expansion|Azacytidine (aerosolized) at the RP2D established in Phase I (given on 3 consecutive days in the first week of every 3-week cycle) with a flat dose of Bintrafusp alfa 2400 mg (given on day 13 [+/- 3 days] of every 3-week cycle)
3380563|NCT04647487|Experimental|LY3484356 Dose Level 1|Administered orally.
3380564|NCT04647487|Experimental|LY3484356 Dose Level 2|Administered orally.
3301356|NCT01844570||Levamlodipine Maleate (Xuanning)|Primary hypertensive patients who take Levamlodipine Maleate (Xuanning) as the only anti-hypertensive medication or one of their medications
3301357|NCT01844570||Amlodipine Besylate (Norvasc)|Primary hypertensive patients who take Amlodipine Besylate (Norvasc) as the only anti-hypertensive medication or one of their medications
3380568|NCT04644809|Experimental|LY3561774 (Part A)|Single ascending doses of LY3561774 administered subcutaneously (SC).
3380569|NCT04644809|Experimental|LY3561774 (Part B)|Repeat doses of LY3561774 administered SC.
3380570|NCT04644809|Experimental|LY3561774 (Part C)|Single doses of LY3561774 administered SC in Japanese Participants.
3380571|NCT04644809|Placebo Comparator|Placebo (Part A, B & C)|Placebo administered SC.
3380572|NCT04644003|Experimental|STP1 Low Dose|1 capsule and 1 tablet per intake
3380573|NCT04644003|Experimental|STP1 High Dose|1 capsule and 1 tablet per intake
3380574|NCT04644003|Placebo Comparator|Placebo|1 placebo capsule and 1 placebo tablet per intake
3380575|NCT04641975|Experimental|Mirabegron Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily pediatric equivalent dose (PED) low dose of IP (Investigational Product) orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
3301358|NCT01844596|No Intervention|Usual Care|Usual Care: Community Health Workers (CHW) with standard training on recruitment of individuals.
3380576|NCT04641975|Placebo Comparator|Placebo Children (5 to <12 Years)|Participants aged 5 to < 12 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
3380577|NCT04641975|Experimental|Mirabegron Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
3301359|NCT01844596|Experimental|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
3301360|NCT01844596|Experimental|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
3301361|NCT01844609|Experimental|Self Study Journal Club|25 Chinese Medical Professionals that will be participating in Self Study Journal Club Meetings three times a week for one hour for 8 weeks with interactive questions and answers and discussion of the journal articles.
3301362|NCT01844609|Experimental|Intensive Journal Club|25 Chinese Medical Professionals that will be participating Face to Face Journal Club Meetings three times a week for one hour for 8 weeks along with a native English speaking mentor.
3301363|NCT01844622|Other|Domperidone|Domperidone will be given at 10 mg before each meal and at bedtime. At completion of the study, patients will receive standard medical therapy
3301364|NCT01844635|Experimental|2.5 mg/kg/day of Thymoglobulin for 5 days|2.5 mg/kg/day of Thymoglobulin for 5 days
3301365|NCT01844635|Active Comparator|3.5 mg/kg/day of Thymoglobulin for 5 days|3.5 mg/kg/day of Thymoglobulin for 5 days
3301366|NCT01844648|Experimental|NH004 tropicamide|tropicamide 1 mg thin film, twice daily for 7 days
3301367|NCT01844648|Placebo Comparator|NH004 placebo|placebo thin film, twice daily for 7 days
3301368|NCT01844661|Experimental|CELYVIR|Patients will received weekly (n=6) IV infusion of Celyvir.
3301369|NCT01844674|Experimental|Pharmacokinetic Population|All participants will receive a 3-period treatment including single-dose tizanidine on Day 1, twice-daily vemurafenib on Days 2 to 21, and both agents together on Day 22.
3301370|NCT01844713|Experimental|Experimental: Workbook|Distribution of the sun protection educational workbook
3301371|NCT01844713|No Intervention|Control|Distribution of general skin care information
3301372|NCT01844726|Experimental|GLYX-13|Single IV infusion of GLYX-13, 5mg/kg,
3301373|NCT01844726|Placebo Comparator|Placebo|Single IV administration of placebo
3301374|NCT01844739|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily to the face for 2 weeks
3301375|NCT01844739|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily to the face for 2 weeks
3301376|NCT01844752|Experimental|NVN1000 1% Gel|NVN1000 1% Gel twice daily
3301377|NCT01844752|Experimental|NVN1000 4% Gel|NVN1000 4% Gel twice daily
3301378|NCT01844752|Placebo Comparator|Vehicle Gel|Vehicle Gel twice daily
3301379|NCT01844791|Experimental|OCZ103-OS, Platinum, Gemcitabine|OCZ103-OS in combination with Platinum-Gemcitabine as standard of care
3301380|NCT01844804|Experimental|A = PF-06438179|
3301381|NCT01844804|Active Comparator|B = Infliximab-EU|
3301382|NCT01844804|Active Comparator|C = Infliximab-US|
3301383|NCT01844843|Experimental|TCD-10023 drug eluting stent|All patients will be treated with the new Drug eluting stent TCD-10023
3301384|NCT01844869|Experimental|omacetaxine mepesuccinate|"Period A: 7-day pharmacokinetic assessment period in which all patients will be administered a single subcutaneous radiolabeled dose of 1.25-mg/m2 omacetaxine.~Period B: omacetaxine will be administered as an sc injection at a dosage of 1.25 mg/m2 twice daily for 7 days (patients with solid tumors) or 14 days (patients with hematologic malignancies) of every 28-day cycle for up to 6 cycles."
3301385|NCT01844882||Chronic Kidney Disease|
3301386|NCT01844908|Experimental|Electroacupuncture|
3301387|NCT01844934|No Intervention|Standard treatment|The no intervention group will receive standard treatment that includes a four hour class pre-surgery consisting of a description of the surgery, what to expect in the hospital and during recovery and some exercises to be done in preparation for surgery.
3301388|NCT01844934|Experimental|Prehabilitation|Prehabilitation:The experimental group will receive a three week prehabilitation program prior to surgery in addition to standard treatment.
3301389|NCT01844947|Experimental|vinflunine + sorafenib|Single arm study.
3301390|NCT01844960|Active Comparator|Multiple Incision Gastric Band Insertion|Current standard surgical approach for laparoscopic gastric band insertion
3301391|NCT01844960|Experimental|Single Incision Gastric Band Insertion|New surgical approach for gastric band insertion
3301392|NCT01844973|Placebo Comparator|Vehicle|
3301393|NCT01844973|Active Comparator|M518101|
3301394|NCT01844999|Other|Usual patient education + standard educational websites|
3301395|NCT01844999|Experimental|Usual patient education + P3P decision support website|
3301396|NCT01845012|Experimental|Daily hemodialysis at low dialysate flow|
3301397|NCT01845038|Experimental|OTX-TPa|OTX-TPa is a hydrogel punctum plug eluting travoprost in sustained release of ~4µg/day over approximately 2 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
3301398|NCT01845038|Experimental|OTX-TPb|OTX-TPb is a hydrogel punctum plug eluting travoprost in sustained release of ~3µg/day over approximately 3 months. For study masking purposes, subjects in this arm will also have natural tears drops administered.
3301399|NCT01845038|Active Comparator|Timolol|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily (BID). For study masking purposes, subjects in this arm will also have a hydrogel punctum plug with no drug placed for approximately 3 months.
3301400|NCT01845051||Migraine group|Patients diagnosed with migraine
3301401|NCT01845051||Healthy group|Healthy subjects with no migraine as control
3301402|NCT01845064|Experimental|Part A - SAD in healthy subjects|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive DM199 subcutaneously (sc).
3301403|NCT01845064|Experimental|Part B - SAD in type 2 diabetic patients|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive DM199 subcutaneously (sc).
3301404|NCT01845064|Experimental|Part C - MAD in healthy subjects|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive sequential doses of DM199 sc for 14 days.
3301405|NCT01845064|Experimental|Part D - POC in type 2 diabetes patients|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive doses of DM199 sc for 28 days.
3301406|NCT01845064|Placebo Comparator|Part A - Healthy subjects SAD placebo|A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and/or female subjects. Subjects will receive placebo subcutaneously (sc).
3301407|NCT01845064|Placebo Comparator|Part B - Type 2 diabetic patients SAD placebo|A randomized, partially double-blinded, placebo-controlled, sequential SAD study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo subcutaneously (sc).
3301408|NCT01845064|Placebo Comparator|Part C - Healthy subjects MAD placebo|A randomized, double-blinded, placebo-controlled, 14-day multiple ascending dose (MAD) study in healthy male and/or female subjects each. Subjects will receive placebo sc for 14 days.
3301409|NCT01845064|Placebo Comparator|Part D - Type 2 diabetic patients POC placebo|A randomized, double-blinded, placebo-controlled, 28-day multiple-dose proof of concept (POC) study in male and/or female type 2 diabetes mellitus patients. Subjects will receive placebo sc for 28 days.
3301410|NCT01845090|Active Comparator|Lanthanum carbonate|Lanthanum carbonate 375mg~750 mg tid for 6 months
3301411|NCT01845090|Active Comparator|Calcium carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
3301412|NCT01845116|Other|Single Arm|Single Omegaven® Intervention Arm
3301413|NCT01845129|Experimental|anodal tDCS|atDCS will be administered for 20 minutes with 1 milliampere (1 mA) to the left primary hand motor cortex
3301414|NCT01845129|Sham Comparator|sham tDCS|sham tDCS will be administered to the left primary hand motor cortex
3301415|NCT01845142|Active Comparator|intramuscular 100.000 I.U. vitamin D3|intramuscular 100.000 I.U. vitamin D3
3301416|NCT01845142|Placebo Comparator|intramuscular placebo|intramuscular 0.9% sodium chloride
3301417|NCT01845142|Active Comparator|subcutaneous 100.000 I.U. vitamin D3|subcutaneous 100.000 I.U. vitamin D3
3301418|NCT01845142|Placebo Comparator|subcutaneous placebo|subcutaneous 0.9% sodium chloride
3301419|NCT01845168|Active Comparator|Computer-alert|2 arm study active group: 'A computer alert which pops up when the GP prescribes NSAID/ASA to a patient with risk-factors
3301420|NCT01845168|No Intervention|controlgroup, normal procedures|The control-group: GP working in normal procedures
3301421|NCT01845181|Placebo Comparator|Dose Level I - Group A - Placebo|2 capsules of placebo
3301422|NCT01845181|Experimental|Dose Level II - Group B - Active|20 mg: 1 capsule of 20 mg PBF-680
3301423|NCT01845181|Placebo Comparator|Dose Level II - Group B - Placebo|1 capsule of placebo
3301424|NCT01845181|Experimental|Dose Level I - Group A - Active|10 mg: 2 capsules of 5 mg PBF-680
3301425|NCT01845181|Experimental|Dose Level III - Group C - Active|40 mg: 2 capsules of 20 mg PBF-680
3301426|NCT01845181|Placebo Comparator|Dose Level III - Group C - Placebo|2 capsules of placebo
3301427|NCT01845181|Experimental|Dose Level IV - Group D - Active|60 mg: 3 capsules of 20 mg PBF-680
3301428|NCT01845181|Placebo Comparator|Dose Level IV - Group D - Palcebo|3 capsules of placebo
3301429|NCT01845194|Experimental|Drug application|"Two treatment periods:~Treatment period 1:~three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application~Treatment period 2:~combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.~Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week"
3301430|NCT01845207||Aortic valve replacement|Patients aged ≥70 years referred for surgical or transcatheter aortic valve replacement.
3301431|NCT01845233||Non invasive ventilation|
3301432|NCT01845246|No Intervention|Standard doses of colistin will be used.|Patients will receive the standard doses of colistin without TDM (Therapeutic drug monitoring).
3301433|NCT01845246|Experimental|Prospective TDM (Therapeutic drug monitoring)of colistin arm|CMS dose will be adjusted based on protocol obtained TDM levels.
3301434|NCT01845259|Experimental|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
3301435|NCT01845259|Placebo Comparator|Liraglutide placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
3301436|NCT01845272|Experimental|Part 1|"single administration : candesartan cilexetil 32mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
3301437|NCT01845272|Experimental|Part 2|"single administration : amlodipine 10mg, qd, 10days(oral).~combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd, 10days(oral)."
3301438|NCT01845285||aortic valve disease|aortic valve replacement
3301439|NCT01845298|Experimental|HIV-infected subjects|HIV-infected subjects who have not yet initiated highly active antiretroviral therapy (HAART). All enrolled subjects will receive a single dose of rifampicin 600 mg.
3301440|NCT01845311|Experimental|ReZolve2 Treatment Group|
3301441|NCT01845324||Diabetes Mellitus in pregnancy|Our cohort will include all consequtive women with Diabetes Mellitus atending our clinic
3301442|NCT01845337|Active Comparator|Capecitabine single agent|Capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days
3301443|NCT01845337|Active Comparator|Capecitabine /Oxaliplatin|Capecitabine 1000 mg/m2 twice daily, days 1-14 every 21 days (in frail or elderly patients, a CAP dose of 750 mg/m2 BD should be considered). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
3301444|NCT01845337|Active Comparator|Teysuno single agent|Teysuno will be administered at a dose of 30 mg/m2 twice daily, for 14 days, with a subsequent 7-day rest period. Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 40mg (BSA < 1.5 m2), 45 mg (BSA 1. 5 to < 1.7 m2), 55mg (BSA 1.7 - 1.9 m2),
3301445|NCT01845337|Active Comparator|Teysuno/ Oxaliplatin|Teysuno will be administered orally at a dose of 25mg/m2 twice daily, days 1-14 every 21 days Patients will be assigned a dose on the basis of body surface area (BSA) and will receive one of the following doses twice daily: 35mg (BSA < 1.5 m2), 40mg (BSA 1.5 to < 1.7 m2), 45mg (BSA 1.7 - 1.9 m2), 50mg (BSA >1.9 m2). Oxaliplatin will be given as an iv infusion at a dose of 130 mg/m2 over 2-6 hours on day 1.
3301446|NCT01845350|Other|M2 macrophages|M2 macrophage introduction
3301447|NCT01845363|Other|Cefazolin|"Cefazolin used in antimicrobial prophylaxis~Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by High Pressure Liquid Chromatography (HPLC)."
3301448|NCT01845376|Experimental|local anesthesia group|In the local anesthesia group, patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine. Surgeons will be taught to do the local anesthetic technique in a standardized manner.
3301449|NCT01845376|Experimental|spinal anesthesia group|In the spinal anesthesia group, patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected. Sensory block (T4 and below dermatomes) to cold and pinprick will be tested before starting operation. An incremental dose containing 1 mg of midazolam and 25 mcg of fentanyl will be intravenously given if patients in the LA and SA group require.
3301450|NCT01845376|Experimental|general anesthesia group|In the general anesthesia group, patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
3301451|NCT01845389|Experimental|Epidural|epidural anesthesia was administered via a 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air. Bupivacaine 0.5% 5 ml every 5 minutes for T10 sensory level
3301452|NCT01845389|Active Comparator|Spinal|An18-gauge Tuohy peel-away epidural sheath was introduced into the epidural space by using loss of resistance technique to air. Epidural introducer was removed leaving epidural sheath to be a pathway for Wiley spinal catheter. A flexible, convenience curve 27-gauge atraumatic pencil point tip spinal needle was introduced through the epidural sheath. After CSF flow was confirmed, a 23-gauge flexible cannula was threaded over the spinal needle. Peel-away epidural sheath was removed and flexible cannula was continually advanced over the spinal needle into the intrathecal space cephaled. Bupivacaine 0.5% 0.5 ml every 5 minutes for T10 sensory level.
3301453|NCT01845402||congenital cardiac diseases|blood sample and urine sample.
3301454|NCT01845415|Active Comparator|Social Marketting Only|Two communities receive a social marketing campaign to reduce child falls in the home.
3301455|NCT01845415|No Intervention|No treatment Control|two communities receive no intervention
3301456|NCT01845415|Active Comparator|Social Marketing plus Intervention|Two communities receive the social marketing campaign and additional intervention components
3301457|NCT01845428|Other|pravastatin|All participants will receive pravastatin 20mg daily
3301458|NCT01845441|Experimental|Dexmedetomidine arm|Precedex will be started after randomization/prior to catheterization and will be stopped at the end of the procedure. It will be used for an average of 90 minutes and will be used as a continuous intravenous infusion started at 0.3 mcg/kg/hour. If HR > 80 and BP > 120/70, a full loading dose (1.0 mcg/kg/hour) will be administered over 10 minutes. If HR is 60 - 80 or systolic BP is 90 - 120, or age > 65 years, a reduced loading dose of 0.5 mcg/kg will be given over 10 minutes. If no volume overload history, 500mL of colloid (hespan or albumin) will be bolused with 0.2mg of glycopyrrolate. Every 10 minutes, Precedex will be titrated by 0.1 mcg/kg/hour to achieve and maintain RASS of 0 to -1.
3301459|NCT01845441|Active Comparator|Control arm|Our usual standard of care is to attempt the intervention without sedation. As per attending physician discretion, Fentanyl (50mcg) and/or Midazolam (0.5 mg) intravenous boluses will be used to control aggressive patient movement that adversely affects the technical capacity of the procedure. The boluses will be repeated at interval of 10 minutes, as necessary. Control arm patients will receive a normal saline placebo drip for the purposes of ensuring patient assessor blindness.
3301460|NCT01845454|Active Comparator|Dose 1|The first 15 patients enrolled will receive a dose of 1 application of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3301461|NCT01845454|Active Comparator|Dose 2|If a second cohort of 15 participants is necessary, the next dose will include 1 application of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3301462|NCT01845454|Active Comparator|Dose 3|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 20 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3301463|NCT01845454|Active Comparator|Dose 4|If an additional cohort of 15 participants is necessary, the next dose will include 2 applications of 30 seconds each of spray cryotherapy using the trūFreeze™ spray cryotherapy device throughout the affected tissue.
3301464|NCT01845467||Auto-immune pancreatitis, suspected|Patients suspected with auto-immune pancreatitis (AIP) and undergoing secretin assisted MRCP as per the standard of care at our institute.
3301465|NCT01845480|Experimental|Healthful eating phys activity coaching|The healthful eating and physical activity skills coaching intervention is designed to help children set goals and self-monitor healthful eating and physical activity; teach kitchen skills for fruit and vegetable snack preparation; teach children enjoyable physical activities to do at home (e.g., dancing); and provide modeling and social support for physical activity and healthful eating.
3301466|NCT01845480|Active Comparator|Health education coaching|Health education coaching is designed to help children set goals and self-monitor behavior; educate children on a range of relevant health promotion behaviors (e.g., tooth brushing, not smoking, physical activity, etc.); and provide modeling and social support for practicing healthful behavior.
3301467|NCT01845493|Active Comparator|Sulforaphane-rich supplement|Intervention: broccosprout homogenate (rich in Sulforaphane) taken orally daily x 3 days
3301468|NCT01845493|Placebo Comparator|Alfalfa Sprout Homogenate|Placebo: Alfalfa sprout homogenate taken daily x 3 days (poor in sulforaphane)
3301469|NCT01845506|Experimental|Wireless pressure transducer|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
3301470|NCT01845506|Active Comparator|Cardiorespiratory Monitor|Following informed consent, each subject will be also be fitted with ECG leads (five), and an oxygen saturation monitor. This information as well as blood pressure and temperature will be recorded at 5-minute intervals by a nurse.
3301471|NCT01845519|Experimental|Tailored Group|
3301472|NCT01845519|Active Comparator|Targeted Group|
3301473|NCT01845532|Experimental|TPI group|
3301474|NCT01845532|Active Comparator|ELMA group|
3301475|NCT01845532|No Intervention|None group|
3301476|NCT01845545|No Intervention|Late intervention|CPSL will support the establishment of self-help groups after 18 months of start of the study.
3301477|NCT01845545|Experimental|Early intervention|CPSL will support the establishment of Women's self-help group. Microfinance will be provided to this group from the first 18 months of the study. The women in these groups will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help groups.
3301478|NCT01845558|Experimental|Wobenzym® plus|Treatment with the licenced drug Wobenzym® plus (3x4 Capsules/ day)
3301479|NCT01845558|Placebo Comparator|Placebo equates Wobenzym® plus but without active ingredients|3x4 capsules/ day
3301480|NCT01845571||Retinal detachment group|400 patients patients, who received surgery due to retinal detachment exclusion: if patients had prior vitrectomy or scleral buckel if patients have no adequate follow-up
3301481|NCT01845584|Experimental|NPB-01|Intravenous immunoglobulin
3301482|NCT01845597||MAKOplasty® medial UKA|Patients who have received a MAKOplasty® robotically guided unilateral knee arthroplasty (UKA) and received a medial MCK onlay implant.
3301483|NCT01845610|Experimental|Fortified fat-based paste with EFAs, DHA, ARA and phytase|Complementary food supplement providing micronutrients and both essential fatty acids, DHA, ARA, phytase and L-lysine, potassium, phosphorous, magnesium and manganese
3301484|NCT01845610|Experimental|Fortified fat-based paste with essential fatty acids|Complementary food supplement providing micronutrients and essential fatty acids (EFAs)
3301485|NCT01845610|No Intervention|Control group|The control group will receive a delayed intervention
3301486|NCT01845623|Experimental|Treatment A|
3301487|NCT01845623|Experimental|Treatment B|
3301488|NCT01845623|Placebo Comparator|Treatment C|
3301489|NCT01845649|Active Comparator|Active|Estradiol Vaginal Gel (0.03 mg estradiol / g )
3301490|NCT01845649|Sham Comparator|Vehicle|Vehicle Vaginal Gel
3301491|NCT01845662||surgical or non-surgical management|Patients with non traumatic cause of splenic rupture such as infectious disease (e.g. malaria)and myeloproliferative that have been treated conservatively in one group and operatively in another group.
3301492|NCT01845675|Experimental|temozolomide or dacarbazine-based chemotherapy, endostatin|Endostatin 15mg/d，IV infusion, d1-d14 Temozolomide 150-200mg/m2/d，p.o., d1-d7 or dacarbazine 250mg/m2/d, IV infusion, d1-5, 5-FU 500mg/m2/d, IV infusion d1-5 Repeat every 3 weeks.
3301493|NCT01845688|Experimental|Losartan Tablets & QingReMoShen Granule|Losartan Tablets: 50mg, qd, po. QingReMoShen Granule: 12g, tid, po.
3301494|NCT01845688|Placebo Comparator|Losartan Tablets & Placebo Granule|Losartan Tablets: 50mg, qd, po. Placebo Granule: 12g, tid, po.
3301495|NCT01845701|Experimental|Artesunate-Amodiaquine|As a fixed-dose combination of artesunate-amodiaquine developed by Sanofi-Aventis (France). It has the advantage of being a 3-day regimen usable by all age groups and potentially low cost. tablets are administered per every day at dose of 25mg/67.5mg for those between 4,5kg and 9kg for 48H
3301496|NCT01845701|Experimental|Dihydroartemisinine_Piperaquine|As a fixed-dose combination of dihydroartemisinin-piperaquine which is produced by Fouley (China). It is a potentially low cost 2-day regimen that has been used in children between 5-10kg as half a tablet of 40mg/320mg every day for 48H
3301497|NCT01845701|Active Comparator|Artemeter-Lumefantrine|This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
3301498|NCT01845714|Active Comparator|Cross Linking Group (CxL group)|Patients that received CXL
3301499|NCT01845714|Active Comparator|Cross Linking with topo-guided PRK (tCxL)|Patients that received tCxL
3301500|NCT01845727|Experimental|Topical Amphotericin B three times per day|Anfoleish applied 3 times per day for 4 weeks (TID group)
3301501|NCT01845727|Experimental|Topical Amphotericin B two times per day|Anfoleish applied 2 times per day for 4 weeks (BID group)
3301502|NCT01845740|Experimental|Milatuzumab SC 250 mg|Milatuzumab 250 mg will be administered subcutaneously once weekly for 4 weeks.
3301503|NCT01845740|Experimental|Milatuzumab 150 mg SC|Milatuzumab 150 mg will be administered subcutaneously once weekly for 4 weeks.
3301504|NCT01845740|Placebo Comparator|Placebo SC|Placebo will be administered subcutaneously once weekly for 4 weeks.
3301505|NCT01845753||All colorectal cancer patients|
3301506|NCT01845766|Experimental|rehabilitation arm|daily standardized exercise rehabilitation during the admission period, and daily standardized self exercise after discharge
3301507|NCT01845766|No Intervention|control arm|
3301508|NCT01845779|Experimental|patients in complete response|
3301509|NCT01845805|Experimental|Arm A: CC-486|"CC-486 (oral azacitidine), 300 mg total (three 100mg tablets), taken daily on days 1-21 (of a 28 day cycle); indefinite cycles until visible tumor recurrence, then first line chemotherapy"
3301510|NCT01845805|Active Comparator|Arm B: observation|"Observation, indefinite until visible tumor recurrence, then first line chemotherapy"
3301511|NCT01845844|Experimental|Ranibizumab 0.3mg (12 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
3301512|NCT01845844|Active Comparator|Ranibizumab 0.3mg (6 months)|Intravitreal injection of ranibizumab 0.3mg/0.05cc
3301513|NCT01845857|Experimental|Chronic Disease Self-Management Workshop|Longitudinal study of participants who take the CDSMP workshop
3301514|NCT01845870||urinary albumin >300mg/24h|none extra intervention was given by the investigator
3301515|NCT01845870||urinary albumin <30mg/24h|none extra intervention was given by the investigator
3301516|NCT01845870||urinary albumin 30 to 300mg/24h|none extra intervention was given by the investigator
3301517|NCT01845883|Other|Deep Brain Stimulator|Some of our subjects that participate to the study have Deep Brain Stimulation implanted. They will perform the behavioral task twice, with the stimulation ON or OFF.
3301518|NCT01845896|Experimental|Combined exercise|12 weeks combined exercise programme (supervised)
3301519|NCT01845896|Experimental|High intensity interval training|12 weeks high intensity interval exercise programme (supervised)
3301520|NCT01845896|No Intervention|Control|sedentary/habitual lifestyle
3301521|NCT01845909||young adults - Central region of Portugal|
3301522|NCT01845922|Experimental|Low sodium diet|Low sodium diet
3301523|NCT01845922|No Intervention|Control|Standard diet regime
3301524|NCT01845935|Experimental|only one treatment group|Patients presenting inoperable venous vascular malformations in soft tissues with indication of cryoablation.
3301525|NCT01845948|Placebo Comparator|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
3301526|NCT01845948|Experimental|parental training programme|The parental training programme was run in small groups of 8 to 12 parents over four consecutive weeks. They consisted of four group sessions, each lasting about two hours. The major focus of the parental intervention included teaching parents: (1) to use more active listening skills, (2) to engage less in harsh parenting practices, (3) to use more praise and encouragement and (4) to set reasonable expectations in the rearing of their children. Each session was started with revision of skills or concepts discussed in previous sessions, therefore, each session built on the previous session.
3301527|NCT01845987|Placebo Comparator|Placebo|
3301528|NCT01845987|Experimental|CNTO 1959|
3301529|NCT01846000|Experimental|Muscles of mastication|This group with TMD will receive low-level laser treatment at masseter and temporal muscles - three points on the masseter (upper, middle and lower) and one point on the anterior temporal
3301530|NCT01846000|Experimental|TMJ and muscles|This group with TMD will receive a mixed application of low-level laser treatment- TMJ and muscles of mastication.
3301531|NCT01846000|Placebo Comparator|Placebo|This group with TMD will receive a low-level laser placebo treatment at TMJ and muscles of mastication. The same equipment will be used with a pen that emits a red guide light and a warning sound, but without the emission of laser
3301532|NCT01846000|Experimental|Tempormandibular Joint|This group with TMD will receive low-level laser treatment in TMJ region - five points around the TMJ.
3301533|NCT01846000|No Intervention|Withou TMD|This will be a follow up group, with volunteers without TMD.
3301534|NCT01846013|Experimental|Stand|
3301535|NCT01846013|Experimental|Move|
3301536|NCT01846013|Experimental|Stand and Move|
3301537|NCT01846013|No Intervention|General Wellness|
3301538|NCT01846026|Experimental|Vitamin D|"Decristol (cholecalciferol) 20000 IU per capsule~1 capsule per week"
3301539|NCT01846026|Placebo Comparator|Placebo|capsule with peanut oil
3301540|NCT01846078|Experimental|Mean absolute errors, median absolute errors|
3301541|NCT01846091|Experimental|Treatment (MV-NIS)|Patients receive oncolytic measles virus encoding thyroidal sodium iodide symporter IT on day 1.
3301542|NCT01846117|Active Comparator|secoisolariciresinol diglucoside|Secoisolariciresinol diglucoside (SDG) supplementation as 1.6g/day of BeneFlax containing 600 mg SDG. 1000 IU vitamin D as standard of care.
3301543|NCT01846117|Placebo Comparator|Whey powder|Natural Factors Whey Factors whey protein (unflavored). An equal volume of measured whey protein (unflavored) to the Beneflax and 1000 IU vitamin D as standard of care.
3301544|NCT01846130|No Intervention|Control|Control bed rest group
3301545|NCT01846130|Experimental|Leucine|Leucine will be administered in mixed meal 3 times a day at 0.06g/kg lean body mass/meal
3301546|NCT01846130|Experimental|Exercise|Daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
3301547|NCT01846130|Experimental|Leucine + Exercise|Leucine (0.06 g/kg lean body mass/meal, 3 meal/day) and exercise daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate.
3301548|NCT01846130|Experimental|Whey protein|22 g of whey isolate 3x a day (with meals)
3301549|NCT01846130|Experimental|Whey protein + exercise|22 g whey isolate 3x day (with meals) and daily bouts of low intensity, bed-based exercise for 30 min/day @ 70% of stress test determined maximal heart rate
3301550|NCT01846130|No Intervention|Skewed|Protein intake is distributed similar to typical American diet with low protein intake at breakfast, intermediate at lunch and high at dinner.
3301551|NCT01846143|Experimental|Arm A: pBCAR3-phosphopeptide + tet vaccine plus polyICLC|"pBCAR3-phosphopeptide + tet vaccine plus polyICLC~The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3301552|NCT01846143|Experimental|Arm B: pIRS2-phosphopeptide + tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3301553|NCT01846143|Experimental|Arm C: 2-MpP+ tet vaccine plus polyICLC|"The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants will be vaccinated with 100 mcg each of the phosphopeptides and 200 mcg of the tetanus peptide (Peptide-tet). The peptides will be administered subcutaneously (0.5 ml) and intradermally (0.5 ml) in Montanide ISA-51 VG adjuvant at six separate vaccine sites in a minimum of two separate extremities.~Poly ICLC: PolyICLC will be administered by a separate 0.5 ml injection (0.25 ml subcutaneously and 0.25 ml intradermally), immediately after, and directly into the precise site where the peptide emulsion was given. We will administer 1 mg per vaccine."
3301554|NCT01846156|Experimental|Abrreviated MgSO4 protocol|- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.
3301555|NCT01846156|Experimental|No maintenance protocol|- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate
3301556|NCT01846156|Active Comparator|standard MgSO4 protocol|- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.
3301557|NCT01846169|Experimental|food deliveries|After baseline screening, participants receive weekly or bi-weekly food deliveries and brief nutrition education.
3301558|NCT01846195|Sham Comparator|no blood draw|CM 1500 with no blood draw
3301559|NCT01846195|Active Comparator|blood draw|CM 1500 with blood draw
3301560|NCT01846234||MS patients|MS patients
3301561|NCT01846247|Placebo Comparator|Standard Care|Standard stroke unit rehabilitation care
3301562|NCT01846247|Experimental|Standard Care + VEM|Standard stroke unit rehabilitation care in addition to a very early rehabilitation protocol
3301563|NCT01846273|Experimental|Ranibizumab + vPDT|Treatment initiation with Ranibizumab and verteporfin PDT (vPDT), with re-treatment need (either Ranibizumab alone or combined with vPDT) determined at monthly visits based on defined retreatment criteria
3301564|NCT01846273|Active Comparator|Ranibizumab monotherapy|Treatment initiation with Ranibizumab and Sham PDT, with re-treatment need (either Ranibizumab alone or combined with Sham PDT) determined at monthly visits based on defined retreatment criteria
3301565|NCT01846286||Newly Diagnosed HNC|For AIM 2 and AIM3, Newly diagnosed and previously untreated patients with locoregional squamous cell carcinoma of the head and neck recruited at MD Anderson: Pain assessed at baseline, weekly during treatment, and during clinic visits (every 6-8 weeks) for a period of 3 months after treatment. Quantitative sensory testing performed at baseline and at 3 months from completion of treatment to determine nociceptive versus neuropathic component.
3301566|NCT01846312||All participants|
3301567|NCT01846325|Experimental|DHA plus vitamin E|Cap DHA 460mg plus vitamin E 600mg per day
3301568|NCT01846325|Active Comparator|VitaminE plus placebo|vitamin E 600 mg plus placebo
3301569|NCT01846325|Placebo Comparator|placebo plus placebo|DHA shaped placebo plus vitamin E shaped placebo
3301570|NCT01846325|Active Comparator|DHA plus placebo|460 mg DHA plus placebo
3301571|NCT01846338|Experimental|green tea extract EGCG|experimental: green tea extract EGCG, 500mg , tid, 4 weeks
3301572|NCT01846338|Placebo Comparator|cellulose|Placebo Comparator: cellulose, 500 mg tid, 4 weeks
3301573|NCT01846364|Experimental|A|Subjects with proliferative thyroid disease
3301574|NCT01846377|Experimental|G4H-Diab-Nano|Intervention - play two videogames Diab and Nanoswarm (9 sessions each, 18 total sessions) over a 12-week time period.
3301575|NCT01846377|No Intervention|Wait List Control|5-months after baseline assessment they will receive the two video games: 1) Diab and 2) Nanoswarm.
3301576|NCT01846390|Experimental|romidepsin, gemcitabine, dexamethasone and cisplatin|A traditional phase I dose escalation design is proposed to assess the feasibility and tolerability of romidepsin in combination with GDP, where treatment will be escalated. Treatment will be given for 6 cycles unless there is evidence of progression prior to completion of the 6 cycles or tolerability to the regimen is not sustained.
3301577|NCT01846403|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (dBest One Step hCG Panel Test Kit)
3301578|NCT01846429|Experimental|Sodium Bicarbonate Treatment|A 3+3 design for Phase I component and a two staged design for Phase II were to be used. Treatment: Sodium Bicarbonate Capsules (900 mg).
3301579|NCT01846468|Experimental|Stage 1 : LHW090, Healthy Volunteers|Healthy Volunteers will receive single dose of LHW090 on Day 1.
3301580|NCT01846468|Experimental|Stage 2: LHW090, Healthy Volunteer|Healthy Volunteers across 7 single ascending dose cohorts will be administered LHW090 or matching placebo day 1
3301581|NCT01846468|Experimental|Stage 3: LHW090, Healthy Volunteer|Healthy Volunteers across 6 multiple ascending dose cohorts will be administered LHW090 or matching placebo for 14 days.
3301582|NCT01846468|Experimental|Stage 4: LHW090, Patients|Subjects with Chronic Renal Insufficiency across 3 cohorts will be administered a single dose of LHW090 in Day 1.
3301583|NCT01846481|Experimental|RBP-8000 100mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
3301584|NCT01846481|Experimental|Placebo/RBP-8000 100mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 100mg intravenous infusion of RBP-8000"
3301585|NCT01846481|Experimental|RBP-8000 200mg/Placebo|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000~Day 6: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo"
3301586|NCT01846481|Experimental|Placebo/RBP-8000 200mg|"Day 1: 50mg intravenous infusion of cocaine~Day 3: 50mg intravenous infusion of cocaine followed by an intravenous infusion of placebo~Day 6: 50mg intravenous infusion of cocaine followed by a 200mg intravenous infusion of RBP-8000"
3301587|NCT01846520|Experimental|Arm I (FCPCI)|Participants receive FCPCI with an APN, comprising 4 home education sessions once weekly followed by 4 telephone support sessions for 30 minutes once monthly and 24 hour telephone support available for 6 months.
3301588|NCT01846520|No Intervention|Arm II (usual care)|Participants receive usual care.
3301589|NCT01846546||Severe Traumatic Brain Injury|Patients with severe TBI (Glasgow Coma Scale GCS score of 8 or less) requiring continuous lumbar drainage of CSF
3301590|NCT01846559|Experimental|Clopidogrel & Endotoxin|"Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily~E.coli Endotoxin Day 7 - 2 ng/kg"
3301591|NCT01846559|Placebo Comparator|No antiplatelet medication & Endotoxin|"No antiplatelet medication~E.coli Endotoxin Day 7 - 2 ng/kg"
3301592|NCT01846559|Experimental|Ticagrelor & Endotoxin|"Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily~E.coli Endotoxin Day 7 - 2 ng/kg"
3301593|NCT01846585|Other|ABTI|Arousal Based Therapy for Insomnia
3301594|NCT01846585|Other|CBTI|Cognitive Behavioral Therapy for Insomnia
3301595|NCT01846637|Experimental|2 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 2 cm from the pylorus.
3301596|NCT01846637|Active Comparator|6 cm from pylorus|at laparoscopic sleeve gastrectomy the distal point of gastric division is 6 cm from the pylorus
3301597|NCT01846650|Experimental|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
3301598|NCT01846650|Active Comparator|XELODA|Single oral XELODA 2000mg qd
3301601|NCT01846676|Active Comparator|Program counseling|Active branch, subject to the rehabilitation program
3301602|NCT01846676|Placebo Comparator|No counseling|Passive branch, which was control, with usual management (no intervention).
3301603|NCT01846689|Experimental|ESS|Prescription medical food erythropoietin stimulating system
3301604|NCT01846715|Experimental|NKA Treatment|Patients will receive an implantation of autologous selected renal cells (SRC).
3301605|NCT01846754||Hemodialysis patients|
3301606|NCT01846767|Experimental|Type 2 diabetes|Diabetic patients Oral glucose breath test
3301607|NCT01846767|Experimental|Healthy controls|non-diabetic Oral glucose breath test
3301608|NCT01846780||Venous outflow obstruction lower limb|Patients with unilateral post-thrombotic iliac vein/common femoral vein obstruction undergoing PTA & stenting (possibly with additional endophlebectomy and AV-fistula)
3301609|NCT01846793|Experimental|Open Label Injection of NX-1207|Intraprostatic injection of 2.5 mg NX-1207
3301610|NCT01846806|Experimental|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
3301611|NCT01846819||Ambulatory cirrhotic patients|"Severity of liver disease will be assessed through a detailed clinical examination of ascites grade, history of complications from cirrhosis (hepatic coma, spontaneous bacterial peritonitis, gastrointestinal bleeding), laboratory tests (TBili, Albumin, INR, hemoglobin).~Depression will be assessed with the following questionnaires: Beck Depression Inventory (BDI), EQ-5D, Psychological General Well-Being Index (PGWBI), LDQOL.~Fatigue will be assessed with the FIS and 6 Minute Walk Test.~Hepatic Encephalopathy will be assessed with the number connection, digit-symbol coding and inhibitory control test."
3301612|NCT01846832|Experimental|TMC435 + PegIFNα-2a + RBV|TMC435 will be administered as triple therapy with pegylated interferon alfa-2a (PegIFNα-2a) and ribavirin (RBV).
3301613|NCT01846845|Active Comparator|Conventional TF Socket System|Conventional Prosthetic Transfemoral Socket System
3301614|NCT01846845|Experimental|Novel TF Socket System|Novel Prosthetic Transfemoral Socket System
3301615|NCT01846858||CO2 Laser|
3301616|NCT01846858||Monopolar energy|
3301617|NCT01846910|Active Comparator|Motivational Counseling|The extended counseling group will receive one to three, 45-minute individual motivational counseling sessions using a motivational interviewing approach to Express empathy, Develop discrepancy, Roll with resistance, and Support self-efficacy.
3301618|NCT01846910|Experimental|Tooth Whitening Incentive|The tooth whitening group will receive all of the interventions previously described for the Motivational Counseling Group, and as an extra incentive against relapse, will also be offered complimentary tooth whitening procedures if biochemically verified as tobacco-free by Carbon Monoxide monitor (bleaching at 3-weeks, whitening strips at 3-months, and whitening touch-up at 1 year).
3301619|NCT01846923|Experimental|PCV13|
3301620|NCT01846936|Experimental|DLT with conventional technique|"The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.~One lung ventilation is initiated after the lumen of operative lung is clamped and opened."
3301621|NCT01846936|Active Comparator|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under fiberoptic bronchoscopy (FOB) vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation. And then, dependent lung is ventilated."
3301622|NCT01846936|Active Comparator|Disconnection technique|Disconnection technique; 1) before initiating OLV, we turned-off the ventilator and fully opened the adjustable pressure limiting valve allowing both lungs to collapse, and 2) after loss of the carbon dioxide trace on the capnograph, 3) inflated the BB cuff with air, and 4) turned-on the ventilator allowing only dependent-lung reventilation.
3301623|NCT01846962|Experimental|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
3301624|NCT01846962|Experimental|fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3301625|NCT01846962|Experimental|Budesonide|The administered dose of topical steroid was 400mcg/day or 800 mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3301626|NCT01846962|Experimental|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1 or mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
3301627|NCT01846975|Experimental|Switch from SC to IV Abatacept and back|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
3301628|NCT01847040||TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who were screened positive for Mild TBI
3301629|NCT01847040||No TBI while Deployed|Active duty service members returning from Afghanistan or Iraq who screened negative for mild TBI.
3301630|NCT01847053|Placebo Comparator|Oatmeal control|Oatmeal control, around 70g; without cinnamon
3301631|NCT01847053|Active Comparator|Ground cinnamon, 3g|3 g ground cinnamon in Oatmeal (~70 g)
3301632|NCT01847053|Active Comparator|Cinnamon extract, 3 g|3 g cinnamon extract in Oatmeal (~70 g)
3301633|NCT01847053|Active Comparator|Cinnamon extract, 6 g|6 g cinnamon extract in Oatmeal (~70 g)
3301634|NCT01847066|Active Comparator|Erbium plus cosmetics plus Impact|Erbium 2940 plus cosmetics plus Impact Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
3301635|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics|Erbium 2940 plus cosmetics Patient shall be treated with erbium 2940nm laser, cosmetics
3301636|NCT01847066|Active Comparator|Erbium 2940 plus cosmetics plus Impact|Patient shall be treated with erbium 2940nm laser, cosmetics and the Impact.
3301637|NCT01847066|Active Comparator|Erbium 2940nm plus cosmetics|Patients shall be treated with Erbium 2940nm laser plus cosmetics only.
3301638|NCT01847079|Other|Intervention group, procalcitonin|procalcitonin to guid obtaining bloodcultures in the ICU
3301639|NCT01847079|No Intervention|Control group, ICIS, procalcitonin|Measurement of PCT and ICIS.
3301640|NCT01847105|Experimental|RevitaLens|AMO's RevitaLens contact lens solution
3301641|NCT01847118|Experimental|Sevacizumab|2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57
3301642|NCT01847144|Active Comparator|Gliclazide - Sitagliptin|Gliclazide 80mg OD and Sitagliptin 100mg OD
3301643|NCT01847144|Active Comparator|Sitagliptin - Gliclazide|Gliclazide 80mg OD and Sitagliptin 100mg OD
3301644|NCT01847157|Experimental|tDCS & epidermis anesthesia & repeated passive movement|"The patients in the experiment group will receive multi-strategy combination treatment mode- combined tDCS and sensory input regulation treatment mode, including bilateral tDCS , epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side , and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
3301645|NCT01847157|Sham Comparator|Shame tDCS & sham anesthesia & repeated passive movement|"the control group is repeated passive movement stimulation, including sham bilateral tDCS, sham epidermis anesthesia in the proximal hand of affected side and in the distal hand of unaffected side, and repeated passive movement training for the hand of affected side.~Treatment modes are 3 times a week, 30 minutes each time, lasting for 8 weeks, and totally 24 trainings. The treatment content of each strategy is separately described in the following."
3301646|NCT01847170|Experimental|Fecal Microbial Transplantation|
3301647|NCT01847183|Experimental|Click City®: Alcohol|Receive the Click City®: Alcohol program as part of their school curriculum.
3301648|NCT01847183|No Intervention|Usual Curriculum|Students receive their usual alcohol curriculum
3301649|NCT01847222|Experimental|SANGUINATE™|PEG-bHb-CO
3301650|NCT01847222|Placebo Comparator|Normal Saline Solution|Saline Solution
3301651|NCT01847235|Experimental|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days
3301652|NCT01847248||sepsis|Patients with sepsis but not severe sepsis
3301653|NCT01847248||Severe sepsis|Patients with severe sepsis
3301654|NCT01847248||SIRS|Patients with SIRS after major orthopedics surgery
3301655|NCT01847248||Control|Healthy volunteers
3301656|NCT01847261|Experimental|Soy Dairy Protein Blend|30 grams of Soy Dairy Protein Blend given as a single beverage following leg resistance exercise
3301657|NCT01847261|Active Comparator|Positive Control (Dairy Whey Protein)|30 grams of Dairy Whey Protein will be given as a single beverage following leg resistance exercise
3301658|NCT01847287||Tysabri|All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted.
3301659|NCT01847300|Experimental|cSBI-M|Participants in this group will complete the cSBI-M screening and brief intervention program
3301660|NCT01847300|No Intervention|Treatment as Usual|Participants in this group will receive treatment as usual.
3301661|NCT01847326|Experimental|Treatment (induction therapy and AFHX or AXX)|See Detailed Description
3301662|NCT01847339|Experimental|bupivacaine soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure
3301663|NCT01847339|Placebo Comparator|saline soaked sponges|Patients will be randomized using a reproducible set of computer-generated random numbers. In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in saline solution and then will be placed by the surgeon in the epidural space before final closure.
3301664|NCT01847352|Other|Iron-deficient|Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
3301665|NCT01847352|Other|Iron-replete|Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
3301666|NCT01847365|Experimental|Retinitis Pigmentosa|Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.
3301667|NCT01847378||Catheter ablation|Patients with chronic chagasic disease and documented monomorphic ventricular tachycardia
3301668|NCT01847391|Experimental|Cohort 1|Randomized to 6 mg once daily (Days 1-7) followed by 3 mg once daily (Days 8-21) of GS-6615 or matching placebo
3301669|NCT01847391|Experimental|Cohort 2|Randomized to 12 mg once daily (Days 1-7) followed by 6 mg once daily (Days 8-21) of GS-6615 or matching placebo
3301670|NCT01847391|Experimental|Cohort 3|Randomized to 20 mg once daily (Days 1-7) followed by 9 mg once daily (Days 8-21) of GS-6615 or matching placebo
3301671|NCT01847404|Experimental|Overall Study Arm|All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order after an overnight fasting of at least 10 hours fast in each period. Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet
3301672|NCT01847417|Experimental|Overall Study Arm|"All the subjects in this study will take part in 3 treatment periods with one of the following treatments in each period. Subjects will receive all three treatments (one per period) in a random order in fed condition.~Test 1= Fixed dose combination (FDC) formulation one of a capsule containing ASA 100 mg and pantoprazole 20 mg. Test 2= FDC formulation two of a capsule containing ASA 100 mg and pantoprazole 20 mg. Reference= ASA 100 mg tablet + pantoprazole 20 mg gastro-resistant tablet"
3301673|NCT01847456|Experimental|insulin nasal spray|160 Units of human insulin as nasal spray
3301674|NCT01847456|Placebo Comparator|Placebo nasal spray|Nasalspray containing placebo solution
3301675|NCT01847482|Experimental|Therapeutic Hypothermia|
3301676|NCT01847495|Experimental|Low-Dose Irinotecan & CyberKnife SBRT|Irinotecan 40mg/m2 x 3-5 days + CyberKnife SBRT 45-60Gy x 3-5 fractions
3301677|NCT01847508|Active Comparator|PHILOS +|Proximal Humeral Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
3301678|NCT01847508|Active Comparator|PHILOS|Proximal Humeral Internal Locking System (PHILOS)
3301679|NCT01847521|Experimental|Capsule containing Luteolin, Quercetin, and Rutin|One capsule containing Luteolin (100 mg/capsule), Quercetin (70 mg/capsule), and Rutin (30 mg/capsule). 1 capsule per 10 kg weight per day with food
3301680|NCT01847534|Other|Standard Care|Standard care: Nutrition will be managed as per best practice and local policy including the use of small bowel feeding tubes, prokinetics and PN if required to meet nutrition needs.
3301681|NCT01847534|Experimental|Supplemental PN|"Supplemental PN to complete inadequate EN provision~Patients allocated to the supplemental PN (intervention) group will have PN commenced within 2 hours of randomisation. The starting dose of PN will be determined by the amount of energy received in the 24 hours prior to randomisation.~EN will be managed as per local protocol however EN must not be reduced based on the supplemental PN being administered.~The adequacy of nutrition provision from both PN and EN will be assessed at midday each day for 7 days or until ICU discharge. The dose of PN will be adjusted according to a prespecified schedule."
3301682|NCT01847573|Experimental|Cohort 1: HT-100 tablet, Dose 1|"Single dose administration: Dose 1~Multiple dose administration: Dose 1"
3301683|NCT01847573|Experimental|Cohort 2: HT-100 tablet, Dose 2|"Single dose administration: Dose 2~Multiple dose administration: Dose 2"
3301684|NCT01847573|Experimental|Cohort 3: HT-100 tablet, Dose 3|"Single dose administration: Dose 3~Multiple dose administration: Dose 3"
3301685|NCT01847573|Experimental|Cohort 4a: HT-100 tablet, Dose 4|"Single dose administration: Dose 4~Multiple dose administration: Dose 4"
3301686|NCT01847573|Experimental|Cohort 4b: HT-100 tablet, Dose 5|* Multiple dose administration: Dose 5
3301687|NCT01847573|Experimental|Cohort 5: HT-100 tablet, Dose 6|* Multiple dose administration: Dose 5
3301688|NCT01847586|Experimental|Alzheimer's disease-rPAS|The intervention procedure will done in this group is r-Paired Associative Stimulation. This involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC
3301689|NCT01847586|Placebo Comparator|Alzheimer's disease-rPAS-C|The intervention procedure being done with this group is PAS-C. This is a control Paired Associative Stimulation paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
3301690|NCT01847586|Other|Control|Controls will have a one time Paired Associative Stimulation-Control (PAS-C) paradigm intervention in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
3301691|NCT01847599|Other|capecitabine|patients treated by capecitabine alone (n=100)
3301692|NCT01847599|Other|capecitabine + lapatinib|patients treated by capecitabine and lapatinib (n=100)
3301693|NCT01847612|Experimental|indocyanine green fluorescent cholangiography|use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
3301694|NCT01847612|Active Comparator|methylene blue|injection of methylene blue during the surgery
3301695|NCT01847625||Physicians experienced in lead extraction|Physicians experienced in lead extraction
3301696|NCT01847651|Active Comparator|LOLA|"Other Names:~Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA~Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)"
3301697|NCT01847651|Placebo Comparator|Placebo|
3301698|NCT01847664|Experimental|Rifamycin SV-MMX® 400 mg b.i.d.|Rifamycin SV-MMX® 800 mg
3301699|NCT01847664|Experimental|Rifamycin SV-MMX® 600 mg t.i.d.|Rifamycin SV-MMX® 1800 mg
3301700|NCT01847664|Placebo Comparator|Rifamycin SV-MMX® Placebo|Rifamycin SV-MMX® placebo
3301701|NCT01847677|Active Comparator|Paclitaxel & Carboplatin|"Preoperative treatment Cycle 1 to 4 (4 cycles every 3 weeks of chemotherapy pre-surgery)~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Surgery~Post-Operative treatment~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day~Paclitaxel 175 mg/m2 i.v. first day~Bevacizumab 15 mg/Kg i.v. first day1~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
3301702|NCT01847677|Experimental|Paclitaxel & Carboplatin & Bevacizumab|"4 cycles every 3 weeks (at least 3 Bevacizumab neoadjuvant cycles): Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~b) Surgery Ovarian cancer surgery should be performed according to FIGO guidelines.~c) Postoperative treatment~Both arms:~Cycle 5 to 7 (3 cycles every 3 weeks of chemotherapy post-surgery):~Carboplatin AUC 6 i.v. first day Paclitaxel 175 mg/m2 i.v. first day Bevacizumab 15 mg/Kg i.v. first day.~When the chemotherapy treatment is completed, the patient will continue with maintenance bevacizumab until 15 months length treatment."
3301703|NCT01847690|Placebo Comparator|Placebo|Treatment B is placebo (2 placebo tablets).
3380578|NCT04641975|Placebo Comparator|Placebo Adolescents (12 to <18 Years)|Participants aged 12 to < 18 years will receive a daily placebo to match PED low dose of IP orally on day 1/week 0 and will continue on this dose until day 28/week 4. At day 28/week 4, participants will receive a dose up-titration to placebo to match PED high dose of IP unless the investigator determines that the participant is adequately treated for OAB at the PED low dose or if there are safety concerns identified and considered associated with the use of PED low dose. Participants that receive a dose up-titration may remain on the PED high dose until day 84/week 12, however, down-titration from PED high dose to PED low dose can be done at any time for safety reasons.
3380581|NCT04634253|Experimental|LY3462817 Low Dose|LY3462817 given intravenously (IV).
3380582|NCT04634253|Experimental|LY3462817 High Dose|LY3462817 given IV.
3380583|NCT04634253|Placebo Comparator|Placebo|Placebo given IV.
3380586|NCT04631016|Experimental|MEDI3506|Approximatley 161 participants will be randomzed to recieve MEDI3506
3380587|NCT04631016|Placebo Comparator|Placebo|Approximatley 161 participants will be randomzed to recieve placebo
3380588|NCT04630652|Experimental|Psoriasis treatment with risankizumab|Moderate-to-severe psoriasis treatment with risankizumab for 16 weeks
3380589|NCT04628754|Experimental|Intervention|Resistance exercise and dietary protein guidance
3301704|NCT01847690|Active Comparator|Hydrocortisone|Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise. Cortef tablets 5 mg produced by Pharmacia and Upjohn . One day.
3301705|NCT01847703|Experimental|Robotic surgery|Experimental method, to be compared with standard care
3380590|NCT04628754|No Intervention|Control|Usual care
3380591|NCT04627103|Experimental|Device Placement|The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.
3380592|NCT04626297|Experimental|Lebrikizumab|Lebrikizumab given by subcutaneous (SC) injection.
3301706|NCT01847703|Active Comparator|Abdominal surgery|Conventional open surgery (laparotomy)
3301707|NCT01847716||PH with wasting|This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
3301708|NCT01847716||PH no wasting|This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
3380593|NCT04626297|Placebo Comparator|Placebo|Placebo given by SC injection.
3380594|NCT04619693||The study population|The study population corresponds to patients hospitalized for proven SARS-COV-2 pneumonia with an indication (hypoxemia) for dexamethasone (see eligibility criteria)
3380595|NCT04616365|Experimental|Semi-Elective Lung Transplantation|Planned Semi-Elective Lung Transplantation Using 10°C Cold Static Preservation
3380596|NCT04616326|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
3301709|NCT01847716||Controls|This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting
3301710|NCT01847729||Patients on OST prescribed to treat opiate dependence|Collecting socio-demographic data, data concerning opiate dependence, data about other substance use disorder, data regarding gambling practice, psychopathological data.
3301711|NCT01847742|Experimental|EMDR intervention|40 participants with trauma symptoms will be randomly assigned to treatment group and receive EMDR intervention for trauma symptoms.EMDR is a trauma focused therapy starts with resource development and continue with bilateral stimulation while working on the most troubling traumatic memory.
3380597|NCT04616326|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
3380598|NCT04613505||Phase 1: Instrument Development|Parents will be asked to participate in a semi-structured interview with one of the researchers that will explore their attitudes toward day of surgery consent. Particular attention will be given to a) study designs, b) previous research experience, and c) previous medical experiences.
3301712|NCT01847742|No Intervention|Waiting List|40 participants with trauma symptoms will be randomly assigned to waiting list as the control group.
3380599|NCT04613505||Phase 2: Questionnaire Adaptation|Parents will be given approximately 5 minutes to review a questionnaire we developed using participant responses in Phase 1. After reviewing the questionnaire, participants will be asked to participate in a semi-structured interview with one of the investigators.
3380600|NCT04613505||Phase 3: Questionnaire Application & Development of Day of surgery consent Table of Guidelines|Participants will be asked to complete the questionnaire developed in Phase 2.
3301713|NCT01847768|Experimental|Asthmatic Group|"Subjects with well-controlled, mild-moderate allergic asthma.Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
3380601|NCT04613505||Phase 4: Table of Guidelines Refinement|Participants will be given approximately 5 minutes to review the table of guidelines developed in Phase 3. After reviewing the guidelines, participants will be asked to participate in a semi-structured interview with one of the investigators.
3380602|NCT04613492|Experimental|Single dose MEDI9253, sequential Durvalumab|Various dose level cohorts for single dose MEDI9253 with sequential Durvalumab dosing
3301714|NCT01847768|Active Comparator|Healthy Non-Asthmatic Control Group|"Healthy volunteers. Subjects will be inoculated with a total dose of 1000 TCID50 of HRV- 39.~The inoculum is diluted, as appropriate, in lactated Ringer's solution and delivered via the following procedure: 0.5 ml per nostril is administered by pipette while the subject tilts their head back."
3380603|NCT04613492|Experimental|Multiple dose MEDI9253, sequential Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with sequential Durvalumab dosing;
3380604|NCT04613492|Experimental|Multiple dose MEDI9253, concurrent Durvalumab|Various dose level cohorts for multiple dose MEDI9253 with concurrent Durvalumab dosing.
3380606|NCT04606498||1- Retrospective|Retrospective Seraph® 100 - this group will be composed of subjects that were treated with Seraph® 100 after the date of the EUA approval (17 April 2020), but before the date that the study is approved at the study site. A waiver of informed consent will be requested from the Institutional Review Board (IRB) to allow the collection of these retrospective data
3380607|NCT04606498||2 - Prospective|Prospective Seraph® 100 - To identify prospective Seraph® 100 patients, the individual site investigators will review currently admitted ICU patients for inclusion criteria and exclusion criteria. The study team will then ask the physician caring for the patient to contact the study team should the patient require therapy with Seraph® 100. Additionally, the study team will review the medical records of admitted patients to see if they have recently been started on Seraph. Patients found to meet eligibility will be offered the opportunity to consent and participate in the study. Note that patients that were started on Seraph® 100 before the date of approval but are still admitted, will not be eligible to give biospecimens.
3380608|NCT04606498||3 - Historical Control|The historical control group will be a sample of convenience, composed of patients admitted to the ICU at participating sites with severe COVID-19 infection, meeting the EUA treatment criteria, but not treated with Seraph® 100 up to the time the PURIFY-OBS protocol is approved at the site. A waiver of informed consent will be requested from the IRB to allow the collection of these retrospective data
3380609|NCT04606394|Other|Open label treatment|All subjects receive Trelegy and Ventolin for 2 weeks
3380610|NCT04605991|Experimental|LY900014|LY900014 given via subcutaneous (SC) injection
3380611|NCT04604808||Non hypocalcemic group|Patients that don't develop post-thyroidectomy hypocalcemia
3380612|NCT04604808||Hypocalcemic group|Patients that develop post-thyroidectomy hypocalcemia
3301715|NCT01847781|Active Comparator|IgG-deficient patients|Prevenar13
3301716|NCT01847781|Active Comparator|Healthy controls|Prevenar13
3301717|NCT01847794|Experimental|chemotheropy|
3301718|NCT01847807|Active Comparator|High-dose Astragalus group|treatment with 10 gram astragalus
3301719|NCT01847807|Active Comparator|Low-dose Astragalus group|treatment with 5 gram astragalus
3301720|NCT01847807|No Intervention|MS control|
3301721|NCT01847820||Symptomatic|Individuals with signs, symptoms or suspicion of membrane rupture at 11 to 42 weeks gestation that will receive the AmniSure ROM test.
3301722|NCT01847833||Patients with brain tumors|
3301723|NCT01847846|Experimental|Prototype mask|Participants will be randomised to trial the new prototype mask for 4 and 8 weeks. The prototype mask will be used in conjunction with the participant's home CPAP machine. The participant's will be instructed to use the prototype mask every night until the completion of the trial. No changes will be made to the participant's prescribed CPAP settings.
3301724|NCT01847872|Experimental|IPV IM (Visit 1)|IM IPV vaccine using syringe and needle pair is given at visit 1 followed by MR vaccine at visit 2 and YF vaccine at visit 3
3301725|NCT01847872|Experimental|IPV IM (Visit 2)|MR vaccine at visit 1 followed by IM IPV vaccine using syringe and needle pair at visit 2, then YF vaccine at visit 3
3301726|NCT01847872|Experimental|IPV IM (Device - Visit 2)|YF vaccine at visit 1 followed by IPV given IM using a Jet injector device at visit 2 and MR vaccine at visit 3
3301727|NCT01847872|Experimental|IPV IM and MR (Visit1)|IM IPV using syringe and needle pair is given alongside MR at visit 1 followed by YF vaccine at visit 2
3301728|NCT01847872|Experimental|IPV IM and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine at visit 1 followed by MR at visit 2
3301729|NCT01847872|Experimental|IPV ID (Visit 2)|MR and YF vaccines are co-administered at visit 1 followed by ID IPV using syringe and needle pair is given at visit 2
3301730|NCT01847872|Experimental|IPV IM and MR and YF (Visit 1)|IM IPV using syringe and needle pair is given alongside YF vaccine and MR vaccine at visit 1
3301731|NCT01847872|Experimental|IPV (ID Device Visit 2)|MR vaccine is given at visit 1 followed by IPV vaccine by ID Jet injector device at visit 2 and YF vaccine at visit 3
3301732|NCT01847898|Experimental|Vertebral Body Stenting (VBS)|
3301733|NCT01847898|Experimental|Balloon Kyphoplasty|
3301734|NCT01847911|Experimental|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
3301735|NCT01847911|Active Comparator|instructor training|A standard hands-on training with a face-to-face instructor following a pre-validated OSCE program guidelines.
3301736|NCT01847924|Active Comparator|MLC901|Brand: Neuroaid II. Dosage: 2 capsules 3 times a a day
3301737|NCT01847924|Placebo Comparator|placebo|MLC901 matching placebo made by the same manufacturer for this study dosage: 2 capsules 3 times a day.
3301738|NCT01847937||Diabetics Type I non-neuropathic|Diabetics with type 1 diabetes and without neuropathy
3301739|NCT01847937||Diabetics Type II non-neuropathic|Diabetics with type 2 diabetes without neuropathy
3301740|NCT01847937||Diabetics Type I neuropathic|Diabetics with type 1 diabetes and neuropathy
3301741|NCT01847937||Diabetics Type II neuropathic|Diabetics with type 2 diabetes and neuropathy
3301742|NCT01847937||Hereditary axonal neuropathic|
3301743|NCT01847937||Hereditary demyelinated neuropathic|This will mainly be patients with Chronic inflammatory demyelinating polyneuropathy (CIDP).
3301744|NCT01847950|Experimental|short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
3301745|NCT01847950|Placebo Comparator|Maltodextrin|maltodextrins are consummed at 5g/day for 6 weeks
3301746|NCT01847963|Experimental|Sindhuvallathy mezhugu|Sindhuvallathy mezhugu (SVM) 500 mg Twice daily per Oral 45 days duration
3301747|NCT01847963|Experimental|Kalladaippu Kudineer|Kalladaippu Kudineer (KK) 130 ml decoction Twice daily Per oral 45 days Duration
3301748|NCT01847963|Experimental|Sindhuvallathy + Kalladaippu Kudineer|Sindhuvallathy mezhu -500 mg capsules twice daily + Kalladaippu kudineer -130 ml decoction twice daily-per oral for 45 days.
3301749|NCT01847976|Experimental|Doxycycline|100 mg of Doxycycline orally twice a day for 12 weeks.
3301750|NCT01847989|Experimental|rFXIII|
3301751|NCT01847989|Placebo Comparator|Placebo|
3301752|NCT01848002|Experimental|rFXIII|
3301753|NCT01848002|Placebo Comparator|Placebo|
3301754|NCT01848015||CTCs positive|
3301755|NCT01848028||Fumaric acid ester|Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed
3301756|NCT01848028||Methotrexate|Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
3301757|NCT01848028||Cyclosporine A|Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
3301758|NCT01848028||Efalizumab (withdrawn)|Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed
3301759|NCT01848028||Etanercept|Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
3301760|NCT01848028||Infliximab|Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
3301761|NCT01848028||Adalimumab|Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
3301762|NCT01848028||Ustekinumab|Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
3301763|NCT01848028||Golimumab|Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed
3301764|NCT01848028||Secukinumab|Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed
3301765|NCT01848028||Apremilast|Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed
3301766|NCT01848028||Certolizumab|Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed
3301767|NCT01848028||Retinoids|Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed
3301768|NCT01848028||Leflunomids|Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed
3301769|NCT01848028||systemic PUVA|Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed
3301770|NCT01848080|Experimental|Tai chi program via Telerehabilitation|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via telerehabilitation.
3301771|NCT01848080|Active Comparator|Tai chi program via home visits|An individualized exercise program, based on Tai Chi, was developed by our team for previous studies aiming to improve balance in elderly, diabetic individuals and in frail, elderly individuals with balance problems. The exercise program consists of movements based on a combination of alignments and body-specific orientations, weight transfers and changes in direction inspired by Tai Chi. This group will receive this program via home visits.
3301772|NCT01848093||COPD exacerbation|"COPD Stadium 2 and 3 during pulmonary exacerbation~sputum collection"
3301773|NCT01848106|Active Comparator|Bivalirudin|Bivalirudin bolus and infusion
3301774|NCT01848106|Experimental|Reg 1 (pegnivacogin/anivamersen)|Bolus pegnivacogin plus anivamersen active control agent
3301775|NCT01848119|Active Comparator|Gabapentin|Gabapentin 600mg, 1 dose preoperatively, followed by Gabapentin 200mg tid for 5 doses.
3301776|NCT01848119|Placebo Comparator|Placebo|lactose capsules
3301777|NCT01848132|Active Comparator|R-CHOP|"6 cycles every 21 days.~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Vincristine: intravenous, 1,4 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
3301778|NCT01848132|Experimental|B-R-CAP|"6 cycles every 21 days~Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15~Rituximab: intravenous, 375 mg/m2, day 1~Cyclophosphamide: intravenous, 750 mg/m2, day 1~Doxorubicin: intravenous, 50 mg/m2, day 1~Prednisone: oral, 100 mg, days 1-5"
3301779|NCT01848171|Active Comparator|L-thyroxine|Oral administration, tablets, starting dose 25 or 50 micrograms once daily, during the follow-up period
3301780|NCT01848171|No Intervention|blank|No intervention
3301781|NCT01848197|Experimental|EC-P2|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 2-week intervals for 4 cycles.
3301782|NCT01848197|Active Comparator|EC-P1|all patients first received 4 cycles of intravenous epirubicin and cyclophosphamide at 3-week intervals and were then intravenous paclitaxel 1-week intervals for 12 cycles.
3301783|NCT01848223||late menopause|
3301784|NCT01848236|Experimental|Vitamin D2|Total of 500,000 IU vitamin D2 (50,000 IU twice weekly for 5 weeks)
3301785|NCT01848236|Experimental|Vitamin D3|Total of 500,000 IU vitamin D3 (50,000 IU twice weekly for 5 weeks)
3301786|NCT01848249||Deceased-Donor Cohort|We will collect urine samples from approximately 1600 deceased donors and approximately 600 perfusate samples from machine-pumped kidneys from participating organ procurement organizations (OPOs).
3301787|NCT01848249||Recipient Cohort (Overall and Detailed)|No samples will be collected from the recipients. Only clinical data and outcomes will be collected from the recipients.
3301788|NCT01848262|Active Comparator|ECALMIST|ECALMIST will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
3301789|NCT01848262|Experimental|InSurE|InSurE will be used in preterm infants between 24 weeks to 31 weeks in the 1st day of life with RDS and spontaneously breathing with decision to give surfactant
3301790|NCT01848275|Active Comparator|Group 1|Group 1 received ablation from distal to ostial of bilateral renal arteries
3301791|NCT01848275|Experimental|Group 2|group 2 received ablation at proximal of bilateral renal arteries
3301792|NCT01848301|Experimental|Single arm|All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
3301793|NCT01848314|Experimental|Patients undergoing renal denervation|patients diagnosed with resistant hypertension, eligible to undergo renal denervation
3301794|NCT01848327|Experimental|Caprylic Triglyceride|Caprylic Triglyceride (40 gram packet orally once a day for 90 days)
3301795|NCT01848327|Placebo Comparator|Placebo|Placebo (40 gram packet orally once a day for 90 days)
3301796|NCT01848340|Experimental|Part A: 14C-GSK1265744 Arm|Each subject will receive a single 30 mg oral solution dose of GSK1265744 containing 14C-GSK1265744 of approximately 70 mcgCi (0.96 MSv) of radioactivity.
3301797|NCT01848340|Experimental|Part B: GSK1265744 Arm|In Part B - 8 subjects will be randomised to receive a single dose of GSK1265744 150 mg
3301798|NCT01848340|Placebo Comparator|Part B: Placebo Arm|In Part B - 2 subjects will be randomised to receive a single dose of placebo
3301799|NCT01848379|Experimental|Antidiabetic Therapy(ADT)+Full Mouth Decontamination(FD)|"ADT:~(Par-)enteral, anti-diabetic medication, diet and dietetic supervision, physiotherapy and physical exercises~FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
3301800|NCT01848379|Active Comparator|Full Mouth Deconatamination(FD)|"FD:~The oral use of topical antiseptics prior and after mechanical tooth debridement, tooth as well as root surface planing and soft tissue decontamination in combination with systemic antibiotics (a combination of amoxicillin and metronidazole - if no microbial resistances were detected)"
3301801|NCT01848379|No Intervention|No Treatment|Healthy individuals to be monitored cross-sectional
3301802|NCT01848392||physical activity CF cohort|adult patients with CF at time of their yearly assessment at Cochin adult CF centre
3301803|NCT01848431||anaemia group|no blood transfusions will be given until hct falls under 25%
3301804|NCT01848431||normal hct group|patients in group 2 will receive transfusions as is currently standard protocol outside the study
3301805|NCT01848444||Lactating women who give her breastmilk to a milkbank|180 women will be included in 6 milk banks in France during 18 months
3301806|NCT01848470|Experimental|E1. CG400549 640mg|CG400549 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
3301807|NCT01848470|Experimental|E2: CG400549 320mg|CG400549 320mg QD on Day 1-5 in the fed-state.
3301808|NCT01848470|Experimental|E3: CG400549 640mg|CG400549 640mg QD on Day 1-5 in the fed-state.
3301809|NCT01848470|Experimental|E4: CG400549 960mg|CG400549 960mg QD on Day 1-5 in the fed-state.
3301810|NCT01848470|Placebo Comparator|P1 Placebo|Placebo 640mg BID on Day 1-5 and QD on Day 6 in the fed-state
3301811|NCT01848470|Placebo Comparator|P2: Placebo 320mg|Placebo 320mg QD on Day 1-5 in the fed-state
3301812|NCT01848470|Placebo Comparator|P3 Placebo 640mg|Placebo 640mg QD on Day 1-5 in the fed-state.
3301813|NCT01848470|Placebo Comparator|P4: Placebo 960mg|Placebo 960mg QD on Day 1-5 in the fed-state.
3301814|NCT01848496|Experimental|Cordless technique|This technique does not employ a gingival cord to obtain gingival displacement.
3301815|NCT01848496|Active Comparator|Conventional technique|This technique employ a gingival cord to obtain gingival displacement.
3301816|NCT01848509|No Intervention|Without telemonitoring|Without teletransmission of alerts
3301817|NCT01848509|Experimental|With telemonitoring|With teletransmission of alerts
3301818|NCT01848535|Placebo Comparator|GOS addition|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 1 receives a drink with GOS (2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
3301819|NCT01848535|Placebo Comparator|placebo (maltodextrine)|All subjects will receive amoxicillin (375 mg 3x per day) for 5 days. Group 2 receives a drink with placebo, maltodextrin(2,5 g 3x per day) simultaneously to the antibiotic for 5 days and after the antibiotic treatment for another 7 days. The intervention products should be consumed at breakfast/lunch/dinner.
3301820|NCT01848548||Assessment of Superior Laryngeal Nerve Block Technique|
3301821|NCT01848561||Immunomodulatory Therapy|Patients who are being prescribed and treated with Immunomodulatory Therapy
3301822|NCT01848561||Adalimumab (Humira) Treatment|Patients who are prescribed and treated with Adalimumab
3301823|NCT01848574|No Intervention|Usual procedure|Investigators will give medical information to their patients as usual.
3301824|NCT01848574|Experimental|Experimental procedure|"You must use the standardized patient information. The final Information of the patient before the final output should be clear and concise in the presence of trustworthy people if the patient wishes.~Deliver the following information in the orde of the items below:~Decline your identity and function Provide a final diagnosis, indicating the affected organ and Inform prognosis (any severity), and the potential duration of affection~Briefly additional tests:~Radio show~Explain the main abnormalities Explain treatment modalities and setpoint monitoring Finish with an open question: Do you have questions? If you think the state anxiety or depression alters the patient's understanding, still deliver all the information listed above."
3301825|NCT01848587|Experimental|acupuncture|5 acupuncture sessions over a 4 week period plus standard treatment
3301826|NCT01848587|Active Comparator|usual care|standard treatment (pregnancy belt, behavioral recommendations, exercises, pain killers as prescribed by usual health care professional)
3301827|NCT01848600|Experimental|abstract without limitation section|the experimental arm is abstract without the limitation section
3301828|NCT01848600|Other|abstract with limitation section|the control arm is abstract with the original limitation section
3301829|NCT01848613|Experimental|Arm A|•Arm A: first cycle of IV vinorelbine (30 mg/m2) and second cycle of PO vinorelbine (60mg/m2)
3301830|NCT01848613|Experimental|Arm B|• Arm B: first cycle with PO vinorelbine (60mg/m2) followed by a second cycle of IV vinorelbine (30mg/m2)
3301831|NCT01848639|Active Comparator|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
3301832|NCT01848639|Placebo Comparator|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
3301833|NCT01848652|Experimental|MYOCET|
3301834|NCT01848665|Experimental|Drug|Indomethacin, 1.2 mg kg 1 dose
3301835|NCT01848665|Placebo Comparator|Placebo|generic flour placebo capsule
3301836|NCT01848691|Experimental|Sickle Cell|This arm will include 20 children with sickle cell anemia
3301837|NCT01848691|Active Comparator|Control|This arm will include 20 children without sickle cell anemia
3301838|NCT01848704|Active Comparator|abstract with spin|30 abstracts of 2 parallel arms negative RCTs (ie, non-statistically significant primary outcome) evaluating treatment in the field of cancer and having spin in the abstract conclusion according to a classification developed previously
3301839|NCT01848704|Experimental|abstract without spin|The abstracts with spin were systematically rewritten without spin
3301840|NCT01848717|Experimental|Lift thread|
3301841|NCT01848730|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
3301842|NCT01848730|Placebo Comparator|Placebo|Placebo tid 21 days
3301843|NCT01848743|Active Comparator|Tenofovir|All enrolled patients are randomized to tenofovir arm who receives tenofovir 300 mg qd for 36 months
3301844|NCT01848743|Placebo Comparator|lamivudine|All enrolled patients are randomized to lamivudine arm who received lamivudine 100 mg qd for 6 months, followed by tenofovir for another 30 months.
3301845|NCT01848769|Experimental|CHF1535 pMDI + AC Plus|Fixed combination of Beclomethasone Dipropionate and Formoterol 50/6 mcg with Aerochamber Plus spacer device
3301846|NCT01848769|Active Comparator|BDP and Formoterol + AC Plus|Beclomethasone Dipropionate 50 mcg and Formoterol 6 mcg with Aerochamber Plus spacer device
3301847|NCT01848782|Experimental|abstract with limitation section added|we add a limitation section in each selected abstract, the limitation section will focus on the quality of included studies.
3301848|NCT01848782|Active Comparator|abstract without limitation section|We selected 30 abstracts with a conclusion in favour the experimental treatment from a sample of systematic reviews that evaluate the effect of health care intervention.
3301849|NCT01848795|Experimental|EndoBarrier Gastrointestinal Liner|The treatment in this arm is the endoscopic positioning of the EndoBarrier Gastrointestinal Liner and follow up.
3301850|NCT01848795|Active Comparator|Intragastric Balloon|The treatment in this arm is the endoscopic positioning of the intragastric balloon (Easy life balloon) as a comparator and follow up.
3301851|NCT01848808|Experimental|Wobenzym PS|During the 4-week of the Wobenzym supplementation, participants will take 6 tablets of Wobenzym: 2 tablets 3 times daily at least 45 minutes before meal.
3301852|NCT01848808|Placebo Comparator|Placebo|During the 4-week of placebo phase, participants will take 6 tablets of placebo: 2 tablets 3 times daily at least 45 minutes before meal.
3301853|NCT01848860|Sham Comparator|Control group|In this group, only thoracoscopic bullectomy and pleural abrasion will be done.
3301854|NCT01848860|Experimental|Mesh group|In this group, absorbable mesh coverage of the staple line will be performed after thoracoscopic bullectomy and pleural abrasion.
3301855|NCT01848873|Experimental|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid (FA),once daily for 8 weeks.
3301856|NCT01848873|Experimental|amlodipine-FA tablet ,high dose group|5mg amlodipine combined with 0.8 mg of folic acid (FA), once daily for 8 weeks.
3301857|NCT01848873|Active Comparator|amolodipine|5 mg amlodipine, once daily for 8 weeks.
3301858|NCT01848886|Other|Grp 1: ERAH, Mammarioradial (Y-graft)|Endoscopic radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an composite graft (Y-graft).
3301859|NCT01848886|Other|Grp 2: ERAH, Aortoradial (Free RA)|Endoscopic radial artery harvest Aortooradial (free RA) In this group the radial artery is harvested as an endoscopic procedure and positioned on the heart as an free RA graft.
3301860|NCT01848886|Other|Grp 3: ORAH, Mammarioradial (Y-graft)|Open radial artery harvest Mammarioradial graft (Y-graft) In this group the radial artery is harvested as an open procedure and positioned on the heart as an composite graft (Y-graft).
3301861|NCT01848886|Other|Grp 4: ORAH, Aortoradial graft (Free RA)|Aortooradial graft (free RA) Open radial artery harvest In this group the radial artery is harvested as an open procedure and positioned on the heart as an free RA graft.
3301862|NCT01848912||Bone Marrow Transplant Patients|
3301863|NCT01848925|Experimental|SANGUINATE™|PEG-bHb-CO
3301864|NCT01848925|Active Comparator|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
3301865|NCT01848951||Epidural|The skin will be disinfected with 2% chlorhexidine. Under sterile technique, the epidural will be placed.Epidural catheter will be placed at thoracic vertebral levels T5 to T10. Level chosen as clinically indicated. The epidural solution should contain UNMCs standard solution of Bupivicaine 0.05% and hydromorphone 10 mcg/cc. However, solution type should be clinically indicated.
3301866|NCT01848951||TAP Block|The skin will be disinfected with 2% chlorhexidine. The bilateral dual TAP infiltrative blocks will be placed using high-frequency ultrasound.2.The TAP blocks will be performed using lipospheric bupivacaine (Exparel) with the following dosing regimen.A 266mg (20cc) vial of lipospheric bupivacaine will be equally into 2 30 ml syringes using strict sterile technique. The solution will be diluted in each syringe with 20cc preservative free sterile 0.9% normal saline to a total volume of 30 ml in each syringe. Once the transversus abdominal plane is identified then a 5-10 ml of plain 0.9% normal saline will be injected to open the fascial plane. Once the plane is opened then the 15cc of diluted lipospheric bupivacaine will be administered under direct ultrasound visualization in all 4 TAP quadrants ( subcostal position x2 and lateral position x2)
3301867|NCT01848964|Experimental|Evaluation|"First, the assessment will be performed to evaluate the relationship between pressure repartition pattern, clinical evaluation and motor capabilities. All the patients and volunteers will be concerned by this first part.~A second part will be conducted in 15 amputees within the 40 patients. Assessments of pressure pattern during gait and standing will be repeated two times: by the same investigator and by a different investigator, in order to test intra- and inter-evaluator reproducibility.~After the first assessment, the prosthesis may be modified in order to solve clinical problems. In that case, a new assessment will be proposed 2 to 8 weeks after in order to test the effect of the prosthesis modification on pressure pattern, gait, posture and clinical parameters."
3301868|NCT01849003|Experimental|Cohort 1|Participants will receive a single 10 mg dose of GS-6615.
3301869|NCT01849003|Experimental|Cohort 2|Participants will receive a single 20 mg dose of GS-6615.
3301870|NCT01849003|Experimental|Cohort 3|Participants will receive a single 30 mg dose of GS-6615.
3301871|NCT01849003|Experimental|Cohort 4|Participants will receive a single 60 mg dose of GS-6615.
3301872|NCT01849003|Experimental|Cohort 5|"Participants will receive single doses of GS-6615 as follows:~Day 1: 20 mg (loading dose)~Day 2: 40 mg (loading dose)~Days 3-7: 6 mg (maintenance dose) once daily~If a participant has a QTcF value of ≤ 420 msec on 2 consecutive time points after the 20 mg dose on Day 1, the participant will receive the maintenance dose of 6 mg on Day 2."
3301873|NCT01849003|Experimental|Cohort 6|"Participants will receive single doses of GS-6615 as follows:~Day 1: 50 mg (loading dose)~Day 2-3: 10 mg once daily~Days 4-7: 20 mg once daily"
3301874|NCT01849016|Experimental|N-Acetylcysteine|N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
3301875|NCT01849016|Placebo Comparator|Placebo|Placebo 1 oral tablet twice daily during 6 months
3301876|NCT01849029|Experimental|Cognitive Processing Theapy-Cognitive|Immediate group receives Cognitive Processing Therapy-Cognitive CPT-C intervention within one week of being consented into the study
3301877|NCT01849029|Other|Cognitive Processing Threapy-Cognitive|Wait list group: waits 6 weeks before receiving the Cognitive Processing Therapy-Cognitive (CPT-C) intervention. During this period no intervention is received
3301878|NCT01849042|Other|donepezil maintain group|continue already taking same dose (5mg or 10mg per day) of donepezil who assigned donepezil group
3301879|NCT01849042|Active Comparator|add-on Ebixa oral pump group|Ebixa dosage titration (5mg per day for 1week, then 10mg per day for 1week, then 15mg per day for 1week, then up to 20mg per day) add-on already taking donepezil (5mg or 10mg per day)
3301880|NCT01849081|Experimental|CPAP|Subjects in this arm with receive treatment with CPAP for fatty liver disease.
3301881|NCT01849081|Active Comparator|Lifestyle Intervention|Subjects in the lifestyle arm will undergo 12 weeks of dietary counseling.
3301882|NCT01849094|Experimental|Milrinone 6mg|"single oral dose of 6mg ER milrinone tablet (Part A).~1. single intravenous infusion of milrinone (per Alfred Hospital protocol. 50ug/kg loading dose over 15 mins followed by infusion at 0.375 ug/kg/min for 6 hrs) - Part B."
3301883|NCT01849094|Active Comparator|Milrinone 10mg ER|single oral dose of 10 mg ER milrinone tablet (Part A) single oral dose of 10 mg ER milrinone tablet (Part B)
3301884|NCT01849094|Active Comparator|Milrinone 14mg|single oral dose of 14 mg ER milrinone tablet (Part A) single dose of 14 mg ER milrinone tablet 4. single oral dose of 18 mg ER milrinone tablet (if the group average plasma milrinone levels is less than 150 ug/L with 15 mg dose) - (Part B)
3301885|NCT01849107|Experimental|Plasma citrulline|
3301886|NCT01849120||Near-infrared spectroscopy (NIRS)|After cardiac surgery, all subjects will have EQUANOX Advance 8004CB sensors applied to peripheral sites (left and right calf and side of abdomen).
3301887|NCT01849133|Experimental|ELIOT|intraoperative radiotherapy
3301888|NCT01849133|Active Comparator|EXTERNAL RT|external fractionated radiotherapy
3301889|NCT01849146|Experimental|Arm I (adavosertib, temozolomide, radiation)|"INITIATION CYCLE: Patients receive adavosertib PO on days 1, 3, and 5 or 1-5 weekly and temozolomide PO QD for 6 weeks. Patients also undergo concurrent radiation therapy 5 days per week for 6 weeks.~MAINTENANCE CYCLES: Beginning in week 10, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity."
3301890|NCT01849146|Experimental|Arm II (adavosertib, temozolomide)|Patients receive adavosertib PO QD on days 1, 3, and 5 or 1-5 weekly, and temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3301891|NCT01849159|Active Comparator|MSC group|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution. Infusions will be performed every 2 months for 1 year
3301892|NCT01849159|Placebo Comparator|Control Group|400 mL of 0.9% NaCl solution. Infusions will be performed every 2 months for 1 year
3301893|NCT01849185|Active Comparator|BIO 25 (food supplements)twice a day for 8 weeks|BIO 25 - Innovative Formula contains 11 different strains of probiotic bacteria patents and more than 25 billion active bacteria in each capsule.
3301894|NCT01849185|Placebo Comparator|Placebo twice a day for 8 weeks|Placebo twice a day for 8 weeks
3301895|NCT01849198|Other|Group trapezius|Assessment of intubation conditions after onset of the neuromuscular block at the m. trapezius
3301896|NCT01849198|Other|group adductor pollicis|assessment of intubation conditions after onset of the neuromuscular block at the m. adductor pollicis
3301897|NCT01849211|Other|neuromuscular block|
3301898|NCT01849224|Experimental|Pelvic and lower extremity exercise|Experimental arm will be educated the guidelines for prevention and early detection of lower extremity edema. Additionally, pelvic and lower extremity exercise will be educated and participants will continue exercise for 1 year at home.
3301899|NCT01849224|No Intervention|Control|Control group will be educated the guidelines for prevention and early detection of lower extremity edema
3380619|NCT04592913|Placebo Comparator|Arm B|placebo product and FLOT chemotherapy
3380620|NCT04592913|Experimental|Arm A|Durvalumab and FLOT chemotherapy
3380622|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Lower Trapezius group|Rotator cuff tears excluding the subscapularis muscle repaired using Lower Trapezius tendon
3380623|NCT04588506|Active Comparator|Cuff tear without subscapularis tear-Latissimus Dorsi group|Rotator cuff tears excluding the subscapularis muscle repaired using Latissimus Dorsi tendon
3301900|NCT01849237|Active Comparator|Standard therapy of septic shock|according to Surviving Sepsis Campaign 2012 Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
3301901|NCT01849237|Experimental|Mesenchymal stromal cells+ standard therapy of septic shock|"MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).~according to Surviving Sepsis Campaign 2012: Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids"
3301904|NCT01849302|Experimental|High protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 42 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301905|NCT01849302|Experimental|High protein/ Normal CHO beverage|"Beverage based on milk protein: 1.8 MJ, 40 E% Protein, 47 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301906|NCT01849302|Experimental|Low protein/ High fat beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 63 E% fat~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301907|NCT01849302|Experimental|Low protein/ High CHO beverage|"Beverage based on milk protein: 1.8 MJ, 9 E% Protein, 71 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301908|NCT01849302|Experimental|Normal protein/ Normal CHO beverage 1|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301909|NCT01849302|Experimental|Normal protein/Normal CHO beverage 2|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301910|NCT01849302|Experimental|Normal protein/Normal CHO beverage 3|"Beverage based on milk protein: 1.8 MJ, 24 E% Protein, 50 E% CHO~Acute effect of beverages varying in macronutrient content on appetite and energy intake"
3301911|NCT01849315|Placebo Comparator|Control|Sedentary intervention
3301912|NCT01849315|Active Comparator|AKIDS II|Physically active group
3301913|NCT01849328||Breast Cancer|
3301914|NCT01849328||Healthy|
3301915|NCT01849341|Experimental|Roflumilast alternated days|Intervention: 500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
3301916|NCT01849341|Active Comparator|Roflumilast 500 mcg per day|Roflumilast 500μg standard dosage
3301917|NCT01849354||Endometriosis patients|Endometriosis patients to be operated in Turku university hospital 2013-2015
3301918|NCT01849354||Control patients|Patients who will be operated because of an adnexal finding other than endometriosis, for example ovarian cyst. Also patients with laparoscopic sterilization will be recruited to the control group.
3301919|NCT01849367|Experimental|Active tDCS (1)|
3301920|NCT01849367|Active Comparator|Active tDCS (2)|
3301921|NCT01849380|Experimental|Epirubicin-cyclophosphamide-S-1( ECS)|S-1(SuLi,QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration followed by a 14-day rest, combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
3301922|NCT01849380|Active Comparator|Epirubicin-cyclophosphamide-5-FU (ECF)|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively), combined with by epirubicin(80mg/m2, d1 and d8 respectively) and cyclophosphamide(500mg/m2, d1, infusion). The chemotherapy was applicated 4 cycles 4-weekly.
3301923|NCT01849393||Study Population|Participants must meet the eligibility requirements will complete a questionnaire on the computer.
3301924|NCT01849406|Active Comparator|Nasal spray Budesonide|one week therapy of nasal budesonide (twice per day)
3301925|NCT01849406|Placebo Comparator|Nasal spray Normal Saline|one week therapy of nasal normal saline (twice per day)
3301926|NCT01849432||Control|Healthy Controls
3301927|NCT01849432||Posttraumatic Stress Disorder|Participants with Posttraumatic Stress Disorder
3301928|NCT01849432||Panic Disorder|Participants with Panic Disorder
3301929|NCT01849432||Specific Phobia|Participants who have specific phobias
3301930|NCT01849445|Active Comparator|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
3301931|NCT01849445|Active Comparator|Home physiotherapy excercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
3301932|NCT01849471||patients with prostate cancer|questionnaires
3301933|NCT01849484|Experimental|hippocampal sparing radiotherapy|Radiation according to indication with hippocampal sparing
3301934|NCT01849484|Active Comparator|Control|Radiation according to indication without hippocampal sparing
3301935|NCT01849510|Experimental|dose intensified|hypofractionated 12x3 Gy + integrated boost 12x4 Gy
3301936|NCT01849510|Active Comparator|standard|hypofractionated 10x3 Gy
3301937|NCT01849523|Experimental|Web-based information and support|Web-based tailored information and support
3301938|NCT01849523|No Intervention|Standard care|Standard care
3301939|NCT01849536|Experimental|SENSIMED Triggerfish®|SENSIMED Triggerfish®
3301940|NCT01849549|Experimental|brain damaged subjects|patients with circumscribed brain injury, selective disorders of cognitive development or degenerative disorders responsible for focal troubles
3301941|NCT01849549|Sham Comparator|healthy volunteers|healthy controls
3301942|NCT01849601|Experimental|PTA catheter|
3301943|NCT01849614||Patient group|Women with left-sided breast cancer
3301944|NCT01849627|Experimental|Low-ED|This condition will focus lowering on the energy density of the diet of the diet. This prescription does not include goals for any other nutrients, thus there are no energy goals.
3301945|NCT01849627|Experimental|Energy Balance|This condition will focus have an energy balance prescription. Participants will be asked to consume a daily energy intake at estimated energy needs for weight loss maintenance.
3301946|NCT01849640|Active Comparator|DHA-piperaquine with Primaquine|3-day treatment course of DHA-piperaquine with 45mg single dose primaquine
3301947|NCT01849640|Active Comparator|DHA-piperaquine without Primaquine|3-day treatment course of DHA-piperaquine
3301948|NCT01849653||Women - Upcoming routine clinic visit|This group of women will self-obtain vaginal swabs at home on the day of their medical appointment and bring the specimens to the clinic. Subjects will then self-obtain another set of vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic.
3301949|NCT01849653||Women - Recruited while at the clinic|This group of women will self-obtain vaginal swabs at the clinic. Clinician/nurse will obtain another set of vaginal swabs from the subject at the clinic. Within 24 hours of their clinic visit, subjects will self-obtain another set of vaginal swabs at their home and mail them to the laboratory.
3301950|NCT01849666|Active Comparator|A: phenprocoumon single dose|
3301951|NCT01849666|Experimental|B: vemurafenib + phenprocoumon single dose|
3301952|NCT01849679||Post-Extubation Subjects|
3301953|NCT01849705||All subjects|No intervention
3301954|NCT01849718||CBT - Cognitive Behavioural Therapy|"40 participants will receive cognitive behavioural therapy in a clinical setting.~The duration of the individual sessions are one hour, and there are 1-2 sessions per. week, totaling 20 hours, incl. 4 hours of transition conversations.~The conversations will be exclusively CBT-based. Number of hours for conversational therapy: 20 hours of individual psychotherapy"
3301955|NCT01849718||Nacadia Therapy|"40 participants will receive garden therapy in a designed, natural environment.~The individual sessions last three hours with two sessions per week the first and last week and three sessions per week in week 2-9. This gives a total of 96 hours, including 4 x 3 hours transition conversation and 10 x ½ hour individual interviews.~Experiences and activities related to the garden environment are integrated with mindfulness exercises. The individual conversations in the Nacadia-therapy will be mindfulness-based CBT.~10 x ½ an hour of individual psychotherapy."
3301956|NCT01849731|Experimental|Intervention A|Face-to face intervention
3301957|NCT01849731|Experimental|Intervention B|Face-to-face intervention plus telephone reinforcement
3301958|NCT01849731|No Intervention|Control Group|
3301959|NCT01849744|Experimental|VS-4718|Oral VS-4718 administered BID (QD during first cohort) during a 28 day cycle.
3301960|NCT01849757|Active Comparator|Human Albumin|Human albumin solution used as part of the priming volume for the cardiopulmonary bypass circuit.
3301961|NCT01849757|Active Comparator|Voluven or hydroethylstarch HES 130/0.4|Hydroethylstarch HES 130/0.4 used as part of the priming volume for the cardiopulmonary bypass circuit.
3301962|NCT01849757|Placebo Comparator|Crystalloid|Crystalloid will be used to prime the cardiopulmonary bypass circuit
3301963|NCT01849783|Experimental|autologous stem cell transplant|"Induction : DPACE(dexamethasone,cisplatin,doxorubicin,cyclophosphamide,etoposide) chemotherapy plus stem cell collection. Additional stem cell collection and/or chemotherapy may be required.~After collection, participants will receive dexamethasone x 4 days every 14 days.~Transplant: The transplant preparative regimen will be bortezomib/thalidomide/dexamethasone/melphalan.~Once recovered, participants start thalidomide daily and dexamethasone x 4 days every 21 days.~Consolidation (if administered): VDT-PACE(bortezomib,dexamethasone,thalidomide,cisplatin,doxorubicin,cyclophosphamide, etoposide)~Maintenance: Year 1 - VTD (bortezomib, thalidomide, dexamethasone) cycles. Year 2 - VCD (bortezomib, cyclophosphamide, dexamethasone)cycles."
3301964|NCT01849796|Active Comparator|Group A: Anodal tDCS|Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.
3301965|NCT01849796|Sham Comparator|Arm B: Cathodal tDCS|Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.
3301966|NCT01849809|Experimental|Gamma Ventral Capsulotomy|
3301967|NCT01849835|Experimental|trans-rectal|trans-rectal to perform the prostate biopsy
3301968|NCT01849835|Experimental|trans-perineal|trans-perineal to perform the prostate biopsy
3301969|NCT01849861|Experimental|Methimazole,|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
3301970|NCT01849887|Active Comparator|mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
3301971|NCT01849887|Placebo Comparator|Placebo|Placebo
3301972|NCT01849900|Other|Healthy Lifestyle|60 women randomly assigned to the control group
3301973|NCT01849900|Other|Knowing your body|60 women randomly assigned to intervention group
3301974|NCT01849913|Experimental|Group B & Group C|Group B equal to low-level laser therapy dosis 5,9 j per point Group C equal to Placebo group
3301975|NCT01849913|No Intervention|Group A & Group C|Group A equal to Control (no intervention) Group C equal to Placebo group
3301976|NCT01849926|Active Comparator|Ibuprofen|Tablet, over capsulated, 600mg three times a day for three days.
3301977|NCT01849926|Active Comparator|Mecillinam|Tablet, over capsulated, 200mg three times a day for three days.
3301978|NCT01849939|Experimental|Fludarabin|
3301979|NCT01849965|Active Comparator|DSC127|DSC127 0.03% in a vehicle gel (hydroxyethyl cellulose (HEC) with parabens)
3301980|NCT01849965|Placebo Comparator|Vehicle gel|Vehicle gel comprising HEC with parabens
3301981|NCT01849965|Placebo Comparator|Standard of Care gel|Aquasite gel, as standard of care gel
3301982|NCT01849978|Active Comparator|Control arm|"Participants in this arm will receive the newsletter about their reported minutes of physical activity and the benefits of physical activity specific to breast cancer survivors, and the brochure Changing your habits, developed by the NIH."
3301983|NCT01849978|Active Comparator|Habit Formation Arm|Participants in this arm will receive all of the intervention materials.
3301984|NCT01849991|Active Comparator|Lactobacillus reuteri|The first arm of the cohort will include 30 patients on LR (5x10^8 cfu's orally once daily.)
3301985|NCT01849991|Placebo Comparator|Sunflower Oil|The second arm includes 15 subjects on placebo (sunflower oil.)
3301986|NCT01850017|Experimental|Methadone and dexmedetomidine|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and dexmedetomidine 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure."
3301987|NCT01850017|No Intervention|Methadone and placebo|"Standard American Society of Anesthesiology monitors. Midazolam 1-2 mg for pre-operative sedation. Lidocaine 0.5-1 mg/kg with induction. Propofol 1-2 mg/kg with induction. Fentanyl 0.5-1 mcg/kg with induction. Rocuronium 0.5 -1 mg/kg with induction. Total intravenous anesthesia with propofol for maintainence of anesthesia. Titrated to maintain BIS (bispectral index) between 30-60.~Methadone 0.2 mg/kg ideal body weight and placebo (normal saline) 1 mcg/kg load over 20 minutes followed by a continuous infusion of 0.5 mcg/kg/h for the duration of the procedure"
3301988|NCT01850043||Military Conscripts|A term of whole military conscripts per year in one Reserve Force Battalion. Military conscripts gather from all around area in Korea randomly
3301989|NCT01850056|Experimental|drug eluting balloon catheter|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
3301990|NCT01850056|Active Comparator|common balloon catheter(uncoated drug)|use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery
3301991|NCT01850069||Intracranial hypertension|Patients with raised intracranial pressure
3301992|NCT01850095|Active Comparator|treatment 1|topical acid azelaic, used 2 times a day for 6 months
3301993|NCT01850095|Active Comparator|treatment 2|contraceptive with drospirenone/ethinyl estradiol used for 6 months
3301994|NCT01850095|No Intervention|control|control group ( only take biopsies and blood samples )
3301996|NCT01850121||Infliximab|Patients with active AS defined as BASDAI score above 4 and no exclusion criteria were consecutively included in this single-armed unblinded trial.
3301997|NCT01850134|Placebo Comparator|Control Study Product|1 serving of control beverage.
3301998|NCT01850134|Experimental|Experimental Study Product|1 serving of a nutritional supplement for people with diabetes.
3301999|NCT01850147|Experimental|Sunitinib|
3302000|NCT01850160|Experimental|GROUP A: Valsartan plus Chlorthalidone|GROUP A: Combination therapy of Valsartan plus Chlorthalidone. Valsartan 80 mg/Chlorthalidone 12,5 mg. Once daily during 12 weeks.
3302001|NCT01850160|Experimental|GROUP B: Valsartan|GROUP B: Treatment with Monotherapy. Valsartan 80 mg. Once daily during 12 weeks.
3302002|NCT01850160|Experimental|GROUP C: Chlorthalidone|GROUP C: Treatment with Monotherapy. Chlorthalidone 12,5 mg. Once daily during 12 weeks.
3302003|NCT01850173|Experimental|static work with a vertical vibration platform|The training was designed to perform static work of the lower limbs. Patients worked in a squatting position, with 30º of hip flexion and 55º of knee flexion, holding onto the bars of the WBV platform.
3302004|NCT01850173|No Intervention|Control group|general recommendations about physical activity and lifestyle
3302005|NCT01850186|Experimental|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
3302006|NCT01850186|Placebo Comparator|Stabilized kilnman trio|Patients will receive treatment by stabilized kilnman trio for four weeks on all the face (one application per day). At the beginning of week 5, Patient will receive stabilized kilnman trio on the hemi-face during three months (side not treated by dual yellow laser, split body study). The stabilized kilnman trio will be prescribed for one month at inclusion (applied all over the face), and on the half of the face not treated by laser at weeks 4, 8 and 12.
3302007|NCT01850199|Active Comparator|Usual management (presential visits)|Patient will follow the usual care program, which includes in-person appointment (weekly/biweekly)
3302008|NCT01850199|Experimental|Smart telemedicine remote monitoring for gestational diabetes|After receiving an structured education on the matter, patients will be followed remotely by analysing glucose and diet/physical activity/other events data with a periodicity no longer than 48 hours
3302009|NCT01850212||Male (≥ 50 years), TDF|Male (≥ 50 years of age) on regimens containing tenofovir disoproxil fumarate (TDF)
3302010|NCT01850212||Male (≥ 50 years of age), Non-TDF|Male (≥ 50 years of age) on non-TDF (tenofovir disoproxil fumarate) based nucleoside reverse transcriptase inhibitors (NRTIs)
3302011|NCT01850212||Female (Postmenopausal), TDF|Female (postmenopausal) on regimens containing tenofovir disoproxil fumarate (TDF)
3302012|NCT01850212||Female (Postmenopausal), Non-TDF|Female (postmenopausal) on non-TDF (tenofovir disoproxil fumarate) based NRTIs
3302013|NCT01850225|Experimental|Device implantation|Implantation of device
3302014|NCT01850238|Placebo Comparator|Placebo (adjuvant in saline solution)|"Placebo patients will receive 1 dose of placebo per month over 3 months, for a total of 3 administrations.~Placebo consists of vaccine adjuvant in saline solution. Placebo is administered subcutaneously."
3302015|NCT01850238|Experimental|AADvac1|"AADvac1 patients will receive 1 dose of AADvac1 per month over 3 months, for a total of 3 administrations.~AADvac1 is a vaccine (single-use vials with solution ready for injection) AADvac1 is administered subcutaneously."
3302016|NCT01850251|Experimental|Supplement with HMB and vitamin D|Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
3302017|NCT01850251|Active Comparator|Standard nutritional supplement|Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.
3302018|NCT01850264|Active Comparator|Quadripolar LV electrode|Application of a quadripolar LV electrode
3302019|NCT01850264|Active Comparator|Bipolar LV electrode|Application of a bipolar LV electrode
3302020|NCT01850277|Experimental|Rhythm control|"In this group a strategy to restore and maintain SR, including amiodarone and an external electrical cardioversion (EEC), is implemented. A procedure of AF ablation is possible but not obligatory.~At baseline, patients assigned to the group undergo a standard 12-lead ECG, a 6-minute walk test (6MWT), a cardiopulmonary exercise test(CPX), an echocardiography(ECHO), a standard device control; a serum thyroid -stimulating hormone (TSH) level is assessed and patients fill the Minnesota Living With Heart Failure Questionnaire (MLHFQ). Control visits are performed every 3 months including a 12-lead ECG measurement and a device control. On the visits in the 3rd and 12th month an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled; control TSH levels are assessed every 6 months."
3302021|NCT01850277|Active Comparator|Rate control|"In the latter group a pharmacotherapy to slow and control ventricular rate by means of pharmacotherapy and an atrio-ventricular junction ablation (AVJA) is implemented.~At baseline, each patient assigned to the rate control group undergoes a standard 12-lead ECG, a 6MWT, a CPX, an ECHO, a standard device control and a serum TSH level assessed. Moreover, the patient fills the Minnesota Living With Heart Failure Questionaire (MLHFQ). The control visits are performed for one year, every 3 months including a standard 12-lead ECG measurement and standard control of the device. On the visits in the 3rd and 12th month additionally an ECHO, a CPX, a 6MWT are performed and a MLHFQ is filled. The control TSH levels are assessed every 6 months."
3302022|NCT01850290||Dopamine Imaging|
3302023|NCT01850303|Other|Surveillance|
3302024|NCT01850303|Experimental|Maintenance|Pemetrexed for non squamous NSCLC Gemcitabine for squamous NSCLC
3302025|NCT01850316|Experimental|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
3302026|NCT01850329|No Intervention|control|No computed-assisted information program will be administered.
3302027|NCT01850329|Experimental|intervention|computed-assisted information program will be administered.
3302028|NCT01850342|Experimental|Fat micrograft enhanced with ADRC|
3302029|NCT01850355|Experimental|Buspirone|Buspirone administered in tablets twice daily titrated to a maximum daily dose of 60mg for 8 weeks.
3302030|NCT01850368|Experimental|Stereotactic ablative radiotherapy|Stereotactic ablative radiotherapy for HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein)
3302031|NCT01850381|Experimental|GM608|4 subjects will receive 320 mg of GM608. 6.4 mL of GM608 (50 mg/mL) will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
3302032|NCT01850381|Placebo Comparator|Placebo comparator|2 subjects will receive matching placebo (bacteriostatic saline). 6.4 mL Bacteriostatic saline will be administered intravenously as a slow bolus, once a day for 3 times a week for 2 weeks.
3302033|NCT01850407|No Intervention|Education Counseling|Education of caregivers to counter lack of Preparedness for Children Undergoing Sexual Abuse Medical Examination
3302034|NCT01850420|Experimental|IMC-1|Experimental intervention
3302035|NCT01850420|Placebo Comparator|Matching placebo|
3302036|NCT01850433|Experimental|Internet CBT|
3302037|NCT01850459||Autism Spectrum Disorder group|Diagnosis of autistic disorder as confirmed by a clinical interview, utilizing the DSM-V
3302038|NCT01850459||IQ-Matched Control Subjects|
3302039|NCT01850459||Age-Matched Neurotypical Controls|
3302040|NCT01850459||Shipped Biomarker Control Group Subjects|These subjects provide a blood sample only that serves as a shipping control that is shipped along with all blood samples from Autistic Disorder Subjects, IQ-Matched Control Subjects or Age-Matched Neurotypical Control Subjects. For these shipping control samples, blood samples will also be drawn from the subjects.
3302041|NCT01850472||Healthy controls|Individuals with no psychiatric diagnosis as determined by structured clinical interview for DSM-IV (SCID) at time of enrollment. There is no intervention administered in this study.
3302042|NCT01850498||Partial seizures|Partial seizures with secondary generalization which results in visible clonic or tonic-clonic motor behavior
3302043|NCT01850498||Generalized seizures|Primarily generalized seizures (in patients with either primary [idiopathic] or secondary [symptomatic] generalized epilepsy), which may involve the following depending on the motor manifestation observed: myoclonic seizures, clonic seizures, tonic-clonic seizures, or atonic seizures.
3302044|NCT01850511|Experimental|Vibrissae trimming|Patients will serve as their own control, with assessment of primary outcomes pre- and post-trimming of vibrissae.
3302045|NCT01850537|Experimental|single arm study|treatment of degenerative disc disease using the PROW LIF
3302046|NCT01850576|Experimental|Intervention|Those randomized to the intervention group will be invited to attend the risk reduction intervention.
3302047|NCT01850576|No Intervention|Control|The control group will receive usual care. Both treatment and control groups will have received the video-based risk reduction intervention.
3302048|NCT01850628||Paclitaxel plus trastuzumab or trastuzumab/pertuzumab|Patient received paclitaxel plus trastuzumab or a trastuzumab/pertuzumab-based combination administered per investigators discretion
3302049|NCT01850654|Other|Probands|Participants with colorectal or endometrial cancer.
3302050|NCT01850654|Other|First-degree relatives of the participants with CRC|The first-degree relatives of the CRC probands (participants with colorectal cancer).
3302051|NCT01850654|Other|At-risk relatives|The relatives of the participants found to have Lynch syndrome.
3302052|NCT01850667|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy for unresectable hepatocellular carcinoma after incomplete trans-arterial chemo-embolization
3302053|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 1|First dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3302054|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 2|Second dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3302055|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 3|Third dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3302056|NCT01850680|Experimental|Sarilumab (SAR153191, REGN88) Dose 4|Fourth dose of Sarilumab in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3302057|NCT01850680|Placebo Comparator|Placebo Dose 5|Placebo to match Sarilumab (SAR153191, REGN88) in a single SC injection. Methotrexate (stable dose) and folic acid are continued as background therapy
3302058|NCT01850693||Coronary artery disease, Stroke|Coronary artery disease, stroke, coronary CT angiography
3302059|NCT01850719|Experimental|Arthroscopic Partial Meniscectomy|
3302060|NCT01850719|Active Comparator|Physical Therapy|
3302061|NCT01850732|Other|ultrasound of aorta|
3302062|NCT01850758|Active Comparator|Regenexx SD|Bone Marrow Aspirate Concentrate injected under imaging guidance into the area of the damaged ligament.
3302063|NCT01850758|Active Comparator|Exercise Therapy|Subjects will be instructed in a set of appropriate knee strengthening exercises and given an instructional hand-out to take home.
3302064|NCT01850771|Active Comparator|Regenexx PL-Disc|Injection of Regenexx PL-Disc into the epidural space once a week for two weeks.
3302065|NCT01850771|Active Comparator|Steroid Epidural|Injection of steroid into the epidural space once a week for two weeks
3302066|NCT01850784|Active Comparator|High energy formula|High energy formula (Similac)
3302067|NCT01850784|Active Comparator|Standard formula|Standard formula
3302068|NCT01850797||NOAC|Patients receiving NOAC and suffering from ischemic stroke or intracranial bleeding.
3302069|NCT01850810|Experimental|Experimental Study Product|1 serving of a nutritional product for people with diabetes.
3302070|NCT01850810|Placebo Comparator|Control Study Product|1 serving of control beverage.
3302071|NCT01850836|Active Comparator|Real rTMS|19 subacute stroke pts with aphasia received 10 rTMS (5sessions/week) for 2 successive weeks
3302072|NCT01850836|Sham Comparator|Sham rTMS|10 patients received sham rTMS stimulation (5 sessions/week) for 2 successive weeks
3302073|NCT01850849|Experimental|LEO 39652 cream|Active drug
3302074|NCT01850849|Placebo Comparator|LEO 39652 cream vehicle|Placebo drug
3302075|NCT01850862|Experimental|Collective group exercise program in patients with KOA|Collective exercises program for patients with osteoarthritis and orientation about this disease
3302076|NCT01850862|Active Comparator|Control group (without exercise)|Orientation about osteoarthritis disease but without any exercise program
3302077|NCT01850875|Experimental|Eye-Movement-Desensitization-Reprocessing|Eye-Movement-Desensitization-Reprocessing
3302078|NCT01850875|No Intervention|Treatment as usual (control group)|treatment as usual
3302079|NCT01850888|Experimental|131 I-MIBG Treatment Arm|Therapeutic 131 I-Metaiodobenzylguanidine (131I-MIBG) will be infused intravenously, intravenous fluids will be administered to help maintain urine flow and isotope excretion. Potassium iodide solution will be administered to protect thyroid function. G-CSF will be used if necessary for neutrophil recovery. Hematopoietic stem cell infusion if meets the criteria.
3302080|NCT01850901|Experimental|Renal sympathetic denervation|Catheter-based renal nerve ablation
3302081|NCT01850901|No Intervention|Usual care|Antihypertensive treatment according to guidelines
3302082|NCT01850914||Shunted patients with INPH|Cases: Patients with normal pressure hydrocephalus who have underwent surgery. Controls: Sex- and age-matched community based controls.
3302083|NCT01850914||Populationbased elderly.|A group of populationbased elderly, matched according to age and sex to the patients with INPH. Vascular risk factors studied.
3302084|NCT01850927|Active Comparator|Intervention|Patients will receive remote ischaemic preconditioning prior to surgery. After the induction of anaesthesia, a blood pressure cuff will be placed on an upper arm and inflated to 200mmHg for 5 minutes, then deflated for 5 minutes, repeated for a total of 3 inflation-deflation cycles.
3302085|NCT01850927|Sham Comparator|Control|Patients will have the same procedure as for the intervention group, however the blood pressure cuff valve will be left open throughout the 30 minute treatment. Patients will be kept under anaesthesia for this additional time.
3302086|NCT01850940||Tolvaptan Group|Tolvaptan,qd, po
3302087|NCT01850940||Conventional therapy|control group:Conventional therapy without tolvaptan
3302088|NCT01850953|Placebo Comparator|Sugar Pill|This is a sugar pill that will be used as a placebo comparator.
3302089|NCT01850953|Active Comparator|Varenicline|Varenicline will be titrated to steady-state levels of 2mg/day over 4 days (0.5mg BID for day 1 and 1.0mg BID for days 2-4) before testing at 2mg/day on days 5 and 6.
3302090|NCT01850966||Iguratimod|
3302091|NCT01850979|Active Comparator|tacrolimus|tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
3302092|NCT01850979|Placebo Comparator|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
3302093|NCT01850992|Active Comparator|ACtive CPAP|Continuous positive airway pressure (CPAP) to treat obstructive Sleep Apnea
3302094|NCT01850992|Placebo Comparator|Sham CPAP|This is placebo CPAP
3302095|NCT01851005|Placebo Comparator|Group 1|General anesthesia with sevoflurane. Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
3302096|NCT01851005|Placebo Comparator|Group 2|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of normal saline during surgery. Administer rocuronium 0.8 mg/kg for induction.
3302097|NCT01851005|Experimental|Group 3|General anesthesia with sevoflurane. Infusion of dexmedetomidine (0.4 ug/kg/hr) during anesthesia. Administer rocuronium 0.8 mg/kg for induction.
3302098|NCT01851005|Experimental|Group 4|General anesthesia with propofol and remifentanil. (Total intravenous anesthesia) Infusion of dexmedetomidine (0.4 ug/kg/hr) during surgery. Administer rocuronium 0.8 mg/kg for induction.
3302099|NCT01851018|Experimental|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
3302100|NCT01851018|Active Comparator|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists.
3302101|NCT01851031|Experimental|the minor approach group|Thirty-six patients (the minor parotid anterior approach group) were treated with minor parotid anterior approach
3302102|NCT01851031|Other|control group|24 patients (control group) were treated with the retromandibular approach
3302103|NCT01851044|Placebo Comparator|Vehicle (Saline)|2 ml of saline is injected to the proximal insertion of extensor carpi radialis brevis (ECRB) muscle.
3302104|NCT01851044|Active Comparator|Whole Blood|2 ml of patient own venous blood is injected to the proximal insertion of ECRB.
3302105|NCT01851044|Experimental|Platelet Rich Plasma|9 ml of patient own venous blood is centrifuged using The Arthrex ACP® Double Syringe System and 2 ml of platelet rich plasma is injected to the proximal insertion of ECRB.
3302106|NCT01851057|Active Comparator|Education Only|Education only arm (8 total sessions)
3302107|NCT01851057|Experimental|STAR: Education and Problem Solving|Problem-solving and education intervention (8 total sessions)
3302108|NCT01851070|Placebo Comparator|Normal Saline Placebo|Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
3302109|NCT01851070|Active Comparator|Allogeneic Mesenchymal Precursor Cells|Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.
3302110|NCT01851083|Experimental|autologous bone marrow mononuclear cells|a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
3302111|NCT01851083|Placebo Comparator|placebo infusion|a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
3302112|NCT01851096|Experimental|SNX-5422|Open label administration of SNX-5422 tablets every other day for 21 days on a 28 day cycle. Dose escalation of SNX-5422 based on safety outcomes
3302113|NCT01851109|No Intervention|Control|
3302114|NCT01851109|Experimental|Genetic counseling|After randomization the participant is offered a referral to a genetic counselor.
3302115|NCT01851122|Placebo Comparator|Placebo|
3302116|NCT01851122|Experimental|l-theanine|
3302117|NCT01851135|Experimental|Patients with NF1|
3302118|NCT01851135|Other|Healthy controls|
3302119|NCT01851148|Sham Comparator|sham therapy|subtracting serial sevel (McPartland 2003)
3302120|NCT01851148|Other|usual care|triptans treatment only
3302121|NCT01851148|Experimental|OMT|8 sessions of osteopathic manipulative treatment
3302122|NCT01851161||Diagnostic (CT and 4D CT in supine and prone positioning)|Patients undergo conventional CT scan and 4D CT scan in both supine and prone positioning before undergoing radiation therapy.
3302123|NCT01851187|Experimental|emotional management (EM) group|emotional management (EM) group received antenatal psychological intervention
3302124|NCT01851187|Active Comparator|the usual care (UC) group|the usual care (UC) group was given routine prenatal care only
3302125|NCT01851200|Experimental|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
3302126|NCT01851213||FoundationOne™ Test Ordered|Patients for whom a FoundationOne™ test was ordered and a report is delivered.
3302127|NCT01851226|Experimental|5 minutes group|The time limit of attempt selective cannulation by trainees is limited to 5 minutes. If the trainees failed to enter the targeted duct within 5 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3302128|NCT01851226|Experimental|10 minutes group|The time limit of attempt selective cannulation by trainees is limited to 10 minutes. If the trainees failed to enter the targeted duct within 10 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3302129|NCT01851226|Experimental|15 minutes group|The time limit of attempt selective cannulation by trainees is limited to 15 minutes. If the trainees failed to enter the targeted duct within 15 minutes, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
3302130|NCT01851239||medical ICU inpatients|
3302131|NCT01851239||surgical ICU inpatients|
3302132|NCT01851252|Experimental|Methacetin (for BT) before / after Propanolol treatment.|The methacetin breath test (MBT) will be performed before and after (within 2 hours) injection of Propanolol (BB) dose and once again after 60 days of oral administration of Propanolol.
3302133|NCT01851265|Other|Fasted|Olaparib capsules following no breakfast
3302134|NCT01851265|Other|Standard meal|Olaparib capsules after standard breakfast
3302135|NCT01851265|Other|High Fat|Olaparib capsules after high fat breakfast
3302136|NCT01851278|Active Comparator|high dose|intraarticular wrist injection of 40mg, 2ml
3302137|NCT01851278|Active Comparator|low dose|intraarticular wrist injection of 20mg, 1ml.
3302138|NCT01851304|Placebo Comparator|Control Bread|A 100 g portion of Control Bread with no extra fiber added. The control bread will be consumed in the intervention Satiety of breads
3302139|NCT01851304|Experimental|Bread Crust Bread|A 100 g portion of Bread Crust Bread with 3 g bread crust per 100 g portion of control bread. The bread crust bread will be consumed in the intervention Satiety of breads.
3302140|NCT01851304|Experimental|Coffee Melanoidins Bread|A 100 g portion of Coffee Melanoidins Bread with 3 g of isolated coffee melanoidins per 100 g portion of control bread. The coffee melanoidins bread will be consumed in the intervention Satiety of breads.
3302141|NCT01851304|Experimental|beta-Glucans Bread|A 100 g portion of beta-Glucans Bread with 3 g of barley beta-glucans per 100 g portion of control bread. The beta-glucans bread will be consumed in the intervention Satiety of breads.
3302142|NCT01851304|Placebo Comparator|Control Pudding|A 150 g portion of Control Pudding without the addition of any extracts. The control pudding will be consumed in the intervention Satiety of puddings.
3302143|NCT01851304|Experimental|Gentian extract pudding|A 150 g portion of Gentian Pudding with the addition of 1 g Gentian extract per 100 g pudding. The Gentian extract pudding will be consumed in the intervention Satiety of puddings.
3302144|NCT01851304|Experimental|Encapsulated Gentian Extract Pudding|A 150 g portion of Microencapsulated Gentian extract pudding with the addition of 1 g of a microencapsulated Gentian extract per 100 g pudding. The Microencapsulated Gentian extract pudding will be consumed in the intervention Satiety of puddings.
3302145|NCT01851317||Intracuff pressure|Procedure/Surgery: Cuffed endotracheal tube
3302146|NCT01851343|Experimental|1|All patients will receive the same treatment
3302153|NCT01851408|Experimental|Temsirolimus + Sorafenib|Temsirolimus intravenous (IV) over 30 minutes on days 1, 8,15, and 22 and oral sorafenib once or twice daily on days 1-28.
3302154|NCT01851421||Double-Variant MC3R|Volunteers with homozygous polymorphisms causing protein changes to T6K and V81I.
3302155|NCT01851421||Wild Type MC3R|Volunteers with no polymorphisms in MC3R gene.
3380624|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Pectoralis group|Rotator cuff tears involving the subscapularis muscle repaired using Pectoralis tendon
3380625|NCT04588506|Active Comparator|Cuff tear involving subscapularis tear-Latissimus Dorsi group|Rotator cuff tears involving the subscapularis muscle repaired using Latissimus Dorsi tendon
3380626|NCT04586985|Experimental|Single Ascending Dose (SAD) cohorts in Healthy Subjects (Part A)|Subjects will be randomized to receive a single dose of FTX-6058 or placebo. Cohorts 1 and 2 will enroll 5 subjects per cohort randomized 3:2. Cohorts 3-8 will enroll 7 subjects per cohort randomized 5:2. Planned doses are 2 mg (Cohort 1), 4 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), 40 mg (Cohort 6), 60 mg (Cohort 7), and 90 mg (Cohort 8).
3302158|NCT01851460|Experimental|RFA|All subjects enrolled onto this study will receive treatment of their liver abscess (es) by RFA ablation
3302159|NCT01851486|Active Comparator|Clonidine+ Saline|Clonidine 0.15 mg and saline 0.15 mg/kg
3302160|NCT01851486|Active Comparator|Clonidine + Naloxone|Clonidine 0.15 mg and Naloxone 0.15 mg/kg
3302161|NCT01851486|Active Comparator|Placebo +Naloxone|Placebo 0.15 mg+ naloxone 0.15 mg/kg
3302162|NCT01851486|Placebo Comparator|Placebo +saline|Placebo 0.15 mg+ saline 0.15 mg/kg
3302163|NCT01851499|Experimental|Ultramicronized PEA (Normast)|"Normast is ultramicronized Palmitoylethanolamide (PEA) classified as Dietary foods for special medical purposes."
3302164|NCT01851499|Placebo Comparator|Microgranules|Same as Normast, without active component.
3302165|NCT01851512|Experimental|T-R (Test-Reference drug)|DA-3803 Injection is injected first and Ovidrel liquid injection is injected after 3-week period
3302166|NCT01851512|Experimental|R-T (Reference-Test drug)|Ovidrel liquid injection is injected first and DA-3803 Injection is injected after 3-week period
3302167|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Blinded|Contact Force Sensing (CFS) Blinded: Operator will be blinded to data provided by the integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
3302168|NCT01851525|Active Comparator|Contact Force Sensing (CFS) Guided|Contact Force Sensing (CFS) Guided: Operator will be guided by integrated force sensor in the ablation catheter (ThermoCoolSmartTouch ablation catheter)
3302169|NCT01851538||Chronic heart failure patients visiting the outpatient clinic|
3302170|NCT01851551|Experimental|VSLI plus rituximab|VSLI (vincristine sulfate liposome injection) plus rituximab
3302171|NCT01851564|Experimental|SEMS for primary variceal haemorrhage|Use of the Self-expanding mesh-metal oesophageal stent (SEMS) as primary therapy for Acute Variceal Haemorrhage.
3302172|NCT01851564|Active Comparator|Standard Therapy - Primary Haemorrhage|Use of standard medical and endoscopic therapy for the treatment of primary variceal haemorrhage.
3302173|NCT01851564|Experimental|SEMS for Failure to Control Bleeding|Use of the self expanding mesh-metal stent for failure of standard therapy in oesophageal variceal haemorrhage.
3302174|NCT01851564|Active Comparator|Standard Therapy - Failure of Control|Use of standard medical and endoscopic therapy for failure of standard therapy in oesophageal variceal haemorrhage.
3302175|NCT01851577|Experimental|Family Foundations coparenting program|Family Foundations is a coparenting prevention program that will be administered concurrently with ongoing home visiting.
3302176|NCT01851577|Active Comparator|Home visiting|"Home visiting as usual will be provided without the added Family Foundations coparenting prevention program."
3302177|NCT01851603|Experimental|AVL-3288|Oral administration of AVL-3288
3302178|NCT01851603|Placebo Comparator|Sugar pill|Placebo
3302179|NCT01851616|Active Comparator|Glucose 25g|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)
3302180|NCT01851616|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)
3302181|NCT01851629|Experimental|ADAPT Locomotor Training|Individuals receive 15 sessions of ADAPT-locomotor training for 3 weeks. During ADAPT-locomotor training, stepping in response to obstacles and walking challenges are practiced on a treadmill and overground.
3302182|NCT01851629|Active Comparator|Basic Locomotor Training|Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
3302183|NCT01851629|Other|Cross-Sectional Testing|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
3302184|NCT01851642||AAT Deficiency|Those diagnosed with Alpha-1 Antitrypsin (AAT) Deficiency. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3302185|NCT01851642||Cystic Fibrosis|Those diagnosed with Cystic Fibrosis (CF) with mutation Delta F508. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3302186|NCT01851642||Without Lung Disease Diagnosis|Those without the diagnosis of AAT Deficiency or CF. At every study visit, a history and physical exam (H&P), blood draw, and pulmonary function testing (PFTs) with the use of an albuterol inhaler will be done.
3302187|NCT01851668||Preterm inter-hospital transfers|preterm infants <31 weeks gestation and <=day 3 of life
3302188|NCT01851668||Preterm infants inborn|Preterm infants <31 weeks gestation and <=3 days old born and remaining at same hospital.
3302189|NCT01851668||Ex-preterm infants back transfered|Mature ex-preterm infants transferred back to referring hospital
3302190|NCT01851681|Active Comparator|Amoxicillin taken 2 g preoperatively|2 g amoxicillin 1h preop then placebo tid x 7 days
3302191|NCT01851681|Active Comparator|Amoxicillin 2g taken preoperatively and 500mg tid x 7 days|2g amoxicillin 1h preop then tid x 7 days
3302192|NCT01851707|Experimental|IPI-145, low dose BID|
3302193|NCT01851707|Experimental|IPI-145, medium dose BID|
3302194|NCT01851707|Experimental|IPI-145, high dose BID|
3302195|NCT01851707|Placebo Comparator|Placebo BID|
3380627|NCT04586985|Experimental|Multiple Ascending Dose (MAD) cohorts in Healthy Subjects (Part B)|Subjects will be randomized 3:1 to receive once daily FTX-6058 or placebo by mouth for 14 days. Up to 6 cohorts of 8 subjects per cohort will be enrolled. Planned doses are 2 mg (Cohort 1), 6 mg (Cohort 2), 10 mg (Cohort 3), 20 mg (Cohort 4), 30 mg (Cohort 5), and 40 mg (Cohort 6).
3380628|NCT04586985|Experimental|Pilot Food Effect Cohort in Healthy Subjects (Part C)|Ten subjects will be randomized to receive a single 20 mg dose of FTX-6058 with and without a high-fat meal with a washout period of 4 days.
3380629|NCT04586985|Experimental|Potential for CYP3A Induction in Healthy Subjects (Part D)|Sixteen subjects will receive 3 mg Midazolam once by mouth on Day 1. On Days 3-12, subjects will receive FTX-6058 by mouth once daily. On Day 12, a second dose of 3 mg Midazolam will be given once by mouth. The dose of FTX-6058 will be the highest tolerated dose from Part B.
3380630|NCT04586985|Experimental|Multiple Dose Cohort in Sickle Cell Disease Subjects (Part E)|Subjects will be randomized 3:1 to receive FTX-6058 or placebo once daily by mouth for 14 days. Up to 8 subjects will be enrolled. The planned dose is 6mg.
3380631|NCT04586907|Experimental|LY3537021 (Part A/Healthy)|LY3537021 administered subcutaneously (SC) to healthy participants.
3380632|NCT04586907|Experimental|LY3537021 (Part A/Type 2 Diabetes)|LY3537021 administered SC to participants with type 2 diabetes mellitus (T2DM).
3380633|NCT04586907|Placebo Comparator|Placebo (Part A)|Placebo administered SC.
3380634|NCT04586907|Experimental|LY3537021 (Part B/Healthy)|LY3537021 administered SC to healthy participants.
3380635|NCT04586907|Experimental|LY3537021 (Part B/Type 2 Diabetes)|LY3537021 administered SC to participants with T2DM.
3302196|NCT01851733|Experimental|Arm B: (MLA, doxorubicin hydrochloride at 6-8 weeks)|"Patients undergo MLA (MRI-guided laser heat ablation). A subset of patients will have a biopsy at time of MLA.~Beginning 6-8 weeks later, patients receive doxorubicin hydrochloride 20 mg/m2 intravenously (IV) over 5 minutes once weekly for 6 weeks.~Biomarker blood draws will be drawn at different time points.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
3302197|NCT01851733|Experimental|Arm C: (MLA, doxorubicin hydrochloride at 72 hours)|"Patients undergo MLA (MRI-guided laser heat ablation).~Beginning within 72 hours later, patients receive doxorubicin hydrochloride 20 mg/m2 IV over 5 minutes once weekly for 6 weeks.~DSC-MRI: no more than 2 weeks prior to MLA, within approximately 3 days after MLA, 2/4/6 weeks after MLA, 10 weeks after MLA only if 6-week scan shows prolonged disruption of the blood brain barrier, 14 weeks after MLA only if week 10 MRI shows contined blood brain barrier disruption, and every 8 weeks until disease progression (these scans do not have to be DSC-MRI)"
3380636|NCT04586907|Placebo Comparator|Placebo (Part B)|Placebo administered SC.
3380637|NCT04586387|Experimental|Active brain stimulation|
3380638|NCT04586387|Sham Comparator|Inactive brain stimulation|inactive TMS
3380639|NCT04584502|Experimental|Intervention as adjunct to Treatment as Usual|Participants will attend an 8-session group-based yoga-mindfulness intervention offered over the course of approximately 10 consecutive weeks. Participants will also be asked to use a mobile companion app once a week during the intervention period. All intervention participants also receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
3380640|NCT04584502|No Intervention|Treatment as Usual|Participants receive treatment as usual for OUD at the partner practice, which includes medication for OUD, individual and/or group counseling, and case management.
3380643|NCT04581317|Experimental|Phase 1 (meals only)|Participants will receive meals delivered to them by the Meals oN wheels(MOW) program for 6 weeks.MOW will once a week deliver in-person enough frozen meals to cover lunch for 5 days and breakfast for 7 days. Study staff will call the participants twice a week to ask 5 questions about their health, mood, and meal consumption.At the end of the 6 weeks, a study team member will make an in-person visit to the participants' homes to measure Fried Frailty Phenotype(FFP), MHS, CES-D, MOCA, Activities of Daily Living (ADL)/Instrumental activities of daily living(IADL)s, NSI, and ZCBI. Caregivers will not receive meals during this first phase as the focus is on the nutritional status of the cognitively impaired older adult.
3380644|NCT04581317|Experimental|Phase 2 (Meals + Amazon Echo Show 8 (AES 8) basic usage)|Participants will have meals delivered and the AES device installed for basic usage
3380645|NCT04581317|Experimental|Phase 3 (meals + AES 8 advanced )|Participants will have meals delivered and the AES device installed for advanced usage
3302198|NCT01851759|Experimental|Cinepazide, Stroke, Injection|Test drug：Methanesulfonic acid cinepazide injection（5ml/125mg）
3302199|NCT01851759|Placebo Comparator|palcebo,Stroke,Injection|Placebo：simulation agent of Methanesulfonic acid cinepazide injection（5ml sterile water for injection）
3302200|NCT01851785|No Intervention|Attention control|Subjects randomized to the attention control arm will receive an educational program (an NIH-developed booklet) that summarizes how to live with knee OA but does not specifically mention joint replacement. This booklet provides information about OA, examples of exercises one could do to improve pain and reduce stiffness, types of non-drug pain relief such as massage, and information about various medications. The interventionist will give the participant the booklet and describe what can be found inside. They are also encouraged to ask their doctor any questions they may have about the information in the booklet or questions they may have about their OA. The purpose of this educational program is to provide a tangible clinical incentive to the control group for participating in this additional component of the study.
3302201|NCT01851785|Experimental|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
3302202|NCT01851798||ambulatory orthopedic surgery patients with OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI => 5
3302203|NCT01851798||ambulatory orthopedic surgery patients without OSA|ambulatory orthopedic surgery patients with home sleep test preoperative AHI < 5
3302204|NCT01851824|Experimental|Acenocoumarol + Vemurafenib|
3302205|NCT01851837|Active Comparator|Group I|Study group I (57 participants) received the continuous training of exercise time.
3302206|NCT01851837|Active Comparator|Group II|Study group II (58 participants) received the interval training of exercise time.
3302207|NCT01851850|Experimental|Drug|
3302208|NCT01851889||CF-LVAD pump speed.|
3302209|NCT01851902||CHA2DS2-VASc Score 2 - 4|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a low risk cohort.
3302210|NCT01851902||CHA2DS2-VASc Score 5 - 6|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a medium risk cohort.
3302211|NCT01851902||CHA2DS2-VASc Score 7 - 9|Physicians estimate the risk of stroke in AF patients using either the CHADS2 or CHA2DS2-VASc scoring; this is a high risk cohort.
3302212|NCT01851915|Active Comparator|Cognitive Behavioral therapy (CBT)|Short term therapy for treatment of depression
3302213|NCT01851915|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal short term therapy for treatment of depression
3302214|NCT01851941|Experimental|mFOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
3302215|NCT01851954|Experimental|clarithromycin|Population PK
3302216|NCT01851967|Experimental|MoodGYM|This study is a single-arm intervnetion. All subjects will be assigned to receive six weeks of online CBT through MoodGYM.
3302217|NCT01851980|Experimental|CWS+Furosemide (40 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (40 mg)
3302218|NCT01851980|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
3302219|NCT01851980|Experimental|CWS+Furosemide (120 mg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of furosemide (120 mg)
3302220|NCT01851993|Experimental|Inhaled Ondansetron (8 mg)|Single-dose inhalation of nebulized ondansetron (8 mg)
3302221|NCT01851993|Placebo Comparator|Inhaled 0.9% saline placebo|Single-dose inhalation of 0.9% saline placebo
3302222|NCT01852006|Experimental|COPD AB ON|"Abdominal Binder ON"
3302223|NCT01852006|No Intervention|COPD AB OFF|"Abdominal Binder OFF (control)"
3302224|NCT01852097|Experimental|CBT based online intervention|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.
3302225|NCT01852097|No Intervention|Control group|Care as Usual. Participants in the control group will be able to access the online intervention after they complete their last follow-up questionnaire.
3302226|NCT01852123|Other|Early implementation|The high-sensitivity troponin I assay will be implemented after a 6 month validation phase
3302227|NCT01852123|Other|Late implementation|The high-sensitivity troponin I assay will be implemented after a 12 month validation phase
3302228|NCT01852136||NEXT 31G x 5mm|Subjects will use their current pen needle or the BD NEXT 31G x 5mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3302229|NCT01852136||NEXT 31G x 8mm|Subjects will use their current pen needle or the BD NEXT 31G x 8mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3302230|NCT01852136||NEXT 32G x 4mm|Subjects will use their current pen needle or the BD NEXT 32G x 4mm pen needle for approximately one week (Period 1). The alternate pen needle will be used for one week in Period 2.
3302231|NCT01852149|Experimental|MPAS Implant|MPAS Implant
3302232|NCT01852188|Other|Nonsterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
3302233|NCT01852188|Other|Sterile|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
3302234|NCT01852240||erectile dysfunction|"Inclusion criteria:~male patients with ED defined by an IIEF-5 score of ≤ 21~age between 18-45a~Exclusion criteria:~systemic diseases (e.g. diabetes mellitus, heart disease, hypertension, neurological disorders etc.)~pure psychogenic (non-organic) ED with good spontaneous / nightly erections~periodontal treatment within the last 3 months~antibiotic intake within the last 3 months"
3302235|NCT01852253|Active Comparator|2% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 2 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
3302236|NCT01852253|Sham Comparator|0.12% chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline and 1 minute of local application of a 0.12 % chlorhexidine solution. After 1 minute of saline rinsing the gingival flap will be returned slightly apical (in order to reduce pockets) and will be firmly sutured. The surgery is followed by 2 weeks of rinsing with 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol twice daily during 30 seconds.
3302237|NCT01852266|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
3302238|NCT01852266|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
3302239|NCT01852279|Experimental|Active muscle stimulation|Muscle stimulation delivered by Brain Computer Interface
3302240|NCT01852279|Active Comparator|Passive muscle stimulation|FES will be delivered by therapist
3302241|NCT01852305|Experimental|Lab Sleep Study (group 1)|The patients in the Sleep Study group will be referred to a sleep medicine specialist who is part of the Bariatric Surgery Psychosocial Program. In the Sleep Study group, patients will undergo sleep studies overnight in a sleep laboratory. At the same time, they will also wear the oximeter wristwatch to measure overnight oximetry.
3302242|NCT01852305|Active Comparator|Oximetry group (group 2)|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night polysomnography(PSG) will be employed to confirm obstructive sleep apnea OSA) diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night.
3302243|NCT01852318|Experimental|Pregabalin|pregabalin 75mg daily for 12 weeks
3302244|NCT01852318|Active Comparator|fexofenadine|fexofenadine 60 mg daily for 12 weeks
3302245|NCT01852318|Placebo Comparator|Placebo|placebo 75 mg for 12 weeks
3302246|NCT01852331|Active Comparator|PGD granules|While continuing current antipsychotic medications, subjects will receive adjunctive Peony-Glycyrrhiza Decoction (PGD) granules (equivalent to 45 g raw materials in total per day). They need to take the granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
3302247|NCT01852331|Placebo Comparator|Placebo|While continuing current antipsychotic medications, subjects will receive adjunctive treatment with placebo granules. They need to take the placebo granules two times a day, each time one sachet (aluminum foil pack of 9g, tear open and empty contents into a cup, add 200ml hot water, stir until dissolute completely, and drink the preparation when warm), for a consecutive of 16 weeks.
3302248|NCT01852357|Sham Comparator|Sham control|This group will receive 12 sham neurofeedback sessions in which the feedback is based on pre-recorded data.
3302249|NCT01852357|Experimental|Neurofeedback|The intervention will be 24 sessions of beta/SMR neurofeedback.
3302251|NCT01852396|Experimental|Regional anesthesia|Recruit 50 patient having elbow, forearm, wrist or hand surgery and block brachial plexus using the novel retroclavicular approach
3302252|NCT01852409|Experimental|bevacizumab|The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;
3302253|NCT01852422||Pelvic prolapse|
3302254|NCT01852435|Active Comparator|R-CHOP-50|R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3302255|NCT01852435|Experimental|R-CEOP-70|R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3302256|NCT01852435|Experimental|R-CEOP-90|R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
3302257|NCT01852448||Patients with Cystic Fibrosis|Blood or Saliva Sample Collection and Glucose -potentiated arginine (GPA) stimulation tests will be completed for all enrolled patients.
3302258|NCT01852461|Active Comparator|Beractant|Beractant;bovine lung extract; both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
3302259|NCT01852461|Active Comparator|Poractant alfa|Poractant alfa; porcine lung extract; initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
3302260|NCT01852474|Experimental|Active tDCS|Subjects will receive active tDCS stimulation for 5 sessions (20m/each) over one week.
3302261|NCT01852487|Active Comparator|Pumpkin Seed Oil|400mg/ day during 6 months
3302262|NCT01852487|Placebo Comparator|sweet potato starch|400mg/day during 6months
3302263|NCT01852500|Experimental|Sham OMT|patients under standard medical care plus sham OMT
3302264|NCT01852500|Other|Control|patients under standard medical care plus only osteopathic evaluation
3302265|NCT01852526|Experimental|hybrid system|hybrid system (PLIF + flexible pedicle screw system above the fusion) (Dynamic Rod®: AESCULAP AG, Tuttlingen: Germany
3302266|NCT01852526|Active Comparator|Plif posterior lumbar intervertebral fusion|Conventional monosegmental posterior lumbar intervertebral fusion (PLIF) (Fixateur: S4®: AESCULAP AG, Cage: Wave® Cage, Fa. AMT®)
3302267|NCT01852539|Experimental|dexmedetomidine|After intravenous infusion of dexmedetomidine for 2 min, propofol 2.0 mg/kg was administrated. And laryngeal mask airway device was inserted(LMA # 3,4).
3302268|NCT01852552||Transcatheter aortic valve implantation|All consecutive patients undergoing TAVI at participating centres during study period
3302269|NCT01852552||Aortic Valve Replacement|All consecutive patients aged ≥ 80 years or with Logistic Euroscore≥ 15% undergoing AVR for AS at participating centers during the period of enrollment
3302270|NCT01852565|Experimental|Darapladib+Diltizem Arm|Each subject will receive darapladib EC tablet 160 mg once daily for 10 days followed by darapladib EC tablet 160 mg once daily + diltiazem 240mg once daily for 14 days and then diltiazem 240mg once daily alone for three days
3302271|NCT01852578|Experimental|1|
3302272|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 50/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 50 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302273|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 100 mg and samatasvir matching placebo once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302274|NCT01852604|Experimental|Part A: GT 1b, 4 - samatasvir 150/simeprevir/RBV|Part A: Participants with genotype 1b or 4 received samatasvir 150 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302275|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 25/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 25 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302276|NCT01852604|Experimental|Part B: GT 1b, 4 - samatasvir 100/simeprevir/RBV|Part B: Participants with genotype 1b or 4 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302277|NCT01852604|Experimental|Part B: GT 6 - samatasvir 100/simeprevir/RBV|Part B: Participants with Genotype 6 received samatasvir 100 mg once daily, plus simeprevir 150 mg capsule once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302278|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprevir/TCM647055/RTV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily plus RTV 30 mg once daily for 12 weeks
3302279|NCT01852604|Experimental|Part C: GT 1a, 1b - samatasvir 50/simeprivir/TCM647055/RTV/RBV|Part C: Participants with Genotype 1a or 1b received samatasvir 50 mg once daily, plus simeprevir 75 mg capsule once daily, plus TMC647055 450 mg once daily, plus RTV 30 mg once daily, plus RBV (dosing weight-based, according to product label) twice daily for 12 weeks
3302280|NCT01852617|Experimental|Implementation of intervention|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
3302281|NCT01852617|No Intervention|No implementation of the intervention|Standard in-service activities
3302282|NCT01852630|Experimental|cefepime + Albumin|cefepime 1g iv 8 hourly + Albumin will be given for 2 days.
3302283|NCT01852630|Active Comparator|Imipenem + Albumin|Imipenem 1g iv 8 hourly + Albumin will be given for 2 days.
3302284|NCT01852643|Active Comparator|Spreader graft|
3302285|NCT01852643|Active Comparator|Lateral crural overlay|
3302286|NCT01852656|Active Comparator|Postcard Only Reminder Group|In the postcard reminder intervention, the member will receive a single postcard, addressed to the member with asthma or COPD.
3302287|NCT01852656|Active Comparator|IVR Only Reminder Group|In the IVR reminder intervention, targeted members will be contacted by the interactive voice response system
3302288|NCT01852656|Active Comparator|Postcard and IVR Reminder Group|In this group, individuals will receive both a postcard reminder and an IVR reminder.
3302289|NCT01852682|Experimental|PA21|
3302290|NCT01852695|Experimental|Family Integrated Care Arm|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
3302291|NCT01852695|No Intervention|Control Arm|Regular care by nurse will be provided to patients admitted to control sites.
3302292|NCT01852708||Pregnant Women|Women and their partners (presumed biological father of the fetus) who are currently pregnant and carrying a fetus that has been diagnosed with a microdeletion/duplication syndrome, aneuploidy or another genetic disorder (positive karyotype result or positive result on microarray test).
3302293|NCT01852721|Experimental|Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
3302294|NCT01852721|Experimental|Women and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group, 3 individual counseling sessions, and 4 telephone interviews. The registered dietitian will encourage participants to make their own decision about dietary changes while promoting their autonomy and competence, and will accept participants' choices, avoiding pressuring them to perform a specific change.
3302295|NCT01852734|Other|embolizations, uterine fibroid|embolization interventions with microspheres
3302296|NCT01852747|Experimental|Multilevel Spinal Fusion w/ Actifuse ABX®|An osteostimulatory,phase pure,porous,silicate substituted calcium phosphate bone graft substitute used during multilevel spinal fusion.
3302297|NCT01852747|No Intervention|Multilevel Spinal Fusion|Multilevel spinal fusion without Actifuse ABX.
3302298|NCT01852760||UC in Remission|Patients with UC in remission
3302299|NCT01852760||UC Mild Disease|Patients with mild UC disease activity based on partial Mayo Score
3302300|NCT01852760||UC Moderate to severe|Patients with ulcerative colitis with moderate to severe disease activity based on partial Mayo score
3302301|NCT01852773||Blunt Aortic Injury Patients|Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.
3302302|NCT01852786||Contraceptives, Oral, Combined|The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy.
3302303|NCT01852786||Controls|The women, presenting for non- hormonal contraception- barrier contraception methods -BCM- or natural family planning methods- NFPM.
3380652|NCT04577690|Experimental|PECS block|A PECS block of 0.25 % bupivacaine with epinephrine 1:200000 (below the toxic dose limit of 3 mg/kg) in divided doses to cover the fascial planes identified in PECS I and PECS II. At the completion of surgery, the wound will be infiltrated with up to 0.2 ml/kg of 0.25 % bupivacaine into the wound.
3380653|NCT04577690|Active Comparator|Infiltration|At the completion of surgery, the EP cardiologist will infiltrate the wound with up to 0.8 ml/kg of 0.25 % bupivacaine with epinephrine 1:200000.
3380654|NCT04577352|Experimental|Vatiquinone|Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if ˂12 years of age and weighing ˂25 kilograms (kg) or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 72 weeks during the placebo-controlled phase and for 24 weeks during the open-label extension phase.
3380655|NCT04577352|Placebo Comparator|Placebo|Participants will receive placebo matching to vatiquinone (per age and weight) orally TID for 72 weeks during the placebo-controlled phase and vatiquinone at a dose of either 200 mg orally TID if ˂12 years of age and weighing ˂25 kg or 400 mg orally TID if ≥12 years of age and/or weighing ≥25 kg for 24 weeks during the open-label extension phase.
3380656|NCT04574856|Experimental|Patients with Newly Diagnosed Glioblastoma|Patients will receive dose-intensified, adaptive photon radiation therapy
3380657|NCT04571736|Active Comparator|access to the internet information platform|usual preoperative information and access to the internet information platform
3380658|NCT04571736|No Intervention|usual preoperative information|medical information delivered to the patient before any surgery
3380659|NCT04570501|Experimental|Angiotensin (1-7)|Participants receive treatment for 7 days.
3302304|NCT01852838||Lung cancer patients, pre treatment|Patients who have diagnosed with lung cancer before treatment
3302305|NCT01852838||High risk patients for lung cancer|high risk patients who are age and co-morbidity matched controls without proof of lung cancer.
3302306|NCT01852851|Active Comparator|Intervention Group|The intervention group will participate in the on-line eLearning program, an ergonomic assessment by an Occupational Therapist and job retention vocational counselling by a Vocational Rehabilitation Counsellor
3302307|NCT01852851|No Intervention|Control Group|"The control group will receive usual care and receive printed educational materials about work and arthritis."
3302308|NCT01852864|Experimental|Degarelix treated group|240mg degarelix s.c. injection to be administered 7 days prior to radical prostatectomy for high/intermediate risk prostate cancer.
3302309|NCT01852877||Jail: HIV testing, corrections case mgt|For all jail detainees regardless of HIV status, we observed the uptake of opt-out and opt-in HIV testing. For HIV-positive jail detainees leaving jail, we observed 1) health outcomes for corrections case management versus other than corrections case management, 2) the impact of an incentive to visit an HIV service organization after release from jail
3302310|NCT01852877||Prison: telemed, corrections case mgt|We compared outcomes for for HIV-positive prisoners before and after the implementation of telemedicine to deliver HIV medical care. For HIV-positive prisoners released from prison and returning to Chicago, we observed health outcomes for those enrolled in corrections case management those not enrolled in corrections case management.
3302311|NCT01852890|Experimental|50g Ascorbate|"This arm is the initial starting dose. The first study participant will be assigned the 50g ascorbate arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 50 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3302312|NCT01852890|Experimental|75g Ascorbate|"If the 50g arm is tolerated, the study opens the 75g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 75 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3302313|NCT01852890|Experimental|100g Ascorbate|"If the 75g arm is tolerated, the study opens the 100g arm.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 100 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3380660|NCT04570501|Placebo Comparator|Placebo|Participants receive treatment for 7 days.
3302314|NCT01852890|Experimental|25g Ascorbate|"This study arm will only be used if participants cannot tolerate the 50g arm. If participants cannot tolerate 50 grams of Ascorbate, the 25g arm is opened.~Radiation: Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.~Gemcitabine: 600 mg/m2, once weekly for 6 weeks.~Ascorbate: 25 grams administered intravenously (by IV) during radiation therapy, for approximately 5 to 6 weeks."
3302315|NCT01852903|Experimental|calcium ascorbate|
3302316|NCT01852903|Active Comparator|ascorbic acid|
3302317|NCT01852903|Placebo Comparator|placebo|
3302318|NCT01852916|Active Comparator|Nasal CPAP|Nasal CPAP using Infant flow
3302319|NCT01852916|Experimental|NHFOV|Nasal High Frequency Oscillatory Ventilation using Dräger Babylog® VN500 ventilator machine
3302320|NCT01852929|Other|Apnea patients on and off PAP in order A|Subject using usual positive airway pressure therapy while sleeping for one night, then crossing over to not using usual apnea therapy while sleeping for another night.
3302321|NCT01852929|Other|Apnea patients on and off PAP in order B|Subject not using apnea therapy while sleeping for one night, then crossing over and subject using usual positive airway pressure therapy while sleeping for one night.
3302324|NCT01852981|Experimental|Lifestyle counseling|Physical activity promotion using methods based on health education.
3302325|NCT01852981|Experimental|Supervised exercise|Supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations.
3302326|NCT01852981|No Intervention|Control|Control group.
3302327|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
3302328|NCT01852994|Other|Testosterone replacement|Testosterone replacement will be done quarterly
3302329|NCT01852994|Other|Testosterone replacement+Exercise|Both Testosterone replacement and Exercise will done
3302330|NCT01853007|No Intervention|Usual care|Patients in this arm will receive only the education offered by the transplant center, as required by Medicaid. Upon completion of all data collection activities, patients in this arm will be offered the program.
3302331|NCT01853007|Experimental|COACH Program|Participants randomized to the intervention condition will attend a COACH session held in a small group format. The session provides information on living and deceased donor transplantation (i.e., the processes, risks and benefits) and on the key communication skills needed to effectively initiate and maintain conversations about transplantation.
3302332|NCT01853020|Active Comparator|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
3302333|NCT01853020|Placebo Comparator|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
3302334|NCT01853033|Experimental|Group 1|Randomized 6 drug/2 placebo by group
3302335|NCT01853033|Experimental|Group 2|Randomized 6 drug/2 placebo by group
3302336|NCT01853033|Experimental|Group 3|Randomized 6 drug/2 placebo by group
3302337|NCT01853059||IMRT|Prospective longitudinal assessment of patients receiving intensity-modulated radiation therapy for anal cancer
3302338|NCT01853059||Conventional|Cross-sectional analysis of patients receiving conventional radiotherapy
3302339|NCT01853098|Experimental|Positive Affect Training (PAT)|The intervention will be conducted in groups with 6-8 participants and 2 facilitators/therapists per group. The groups will meet once a week for 12 successive weeks and each session will be approximately 60 minutes long.
3302340|NCT01853111|Experimental|Interleukin 2|Subjects who receive a tolerogenic drug protocol
3302341|NCT01853124|Experimental|Lacidofil|Lacidofil sachet containing active ingredients
3302342|NCT01853124|Placebo Comparator|Placebo|Placebo sachet containing inactive ingredients
3302343|NCT01853150|Experimental|rTMS Motor cortex|rTMS will be applied over the motor cortex
3302344|NCT01853150|Active Comparator|rTMS Supplementary motor area|rTMS will be applied over the supplementary motor area
3302345|NCT01853163|Other|Gadolinium contrast agent|Patients who have received Gadolinium contrast agents in the past
3302346|NCT01853189|Other|OMT + Usual Care|
3302347|NCT01853189|Other|Usual Care|
3302348|NCT01853202|Experimental|Group 1 - Supervised aerobic exercise training|This group will participate in 3 supervised exercise sessions/week at an intensity of 50%-70% of the individually determined VO2max between 30-45 min/session for 12 weeks. The aerobic training intervention will closely mimic the standard exercise-based guidelines adopted in cardiac rehabilitation. All intervention sessions will be performed in a supervised setting with one-on-one supervision by an American College of Sports Medicine-certified exercise physiologist. Aerobic exercise training will be prescribed based on the guiding ACSM principles with the aim of improving VO2max. Walking was chosen because it is the preferred mode of exercise training in cancer patients.
3302349|NCT01853202|No Intervention|Group 2|The 12-week program will consist of monthly phone contacts to check in with patient and review their exercise log entries for that month in order to capture physical activity done outside of the intervention setting.
3302350|NCT01853241||Single balloon|Single Balloon Enteroscopy
3302351|NCT01853241||Spirus|Spirus Enteroscopy
3302352|NCT01853267|Active Comparator|Control group (Packing)|The perianal abscess cavity will continue to be packed after discharge until healing is complete
3302353|NCT01853267|Experimental|Intervention Group (Non-Packing)|The cavity will be allowed to heal by secondary intention without packing.
3302354|NCT01853293|Active Comparator|Kudzu extract|Participants will take two 500-mg capsules of Kudzu extract, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
3302355|NCT01853293|Placebo Comparator|Placebo|Placebo capsule contains sugar beet filler. Participants will take two 500-mg capsules, t.i.d. (morning, 6:00 to 8:30 a.m.; afternoon, 2:00 to 4:30 p.m.; evening, 9:00 to 11:30 p.m.).
3302356|NCT01853306|Experimental|Veliparib formulation A|veliparib formulation A
3302357|NCT01853306|Experimental|Veliparib formulation B|Veliparib formulation B
3302358|NCT01853306|Experimental|Veliparib formulation C|veliparib formulation C
3302359|NCT01853319|Experimental|Regorafenib|Regorafenib, 40 mg tablets
3302360|NCT01853345||Refractory/Recurrent/High Risk Solid Tumors|
3302361|NCT01853358|Experimental|NK Cell infusion|"Cell collection~o Lymphocytes will be harvest from the original and consenting donor as soon as possible around day 60 post transplantation~NK Cell selection~o Cells will be obtained after double selection: CD3+ depletion followed by CD56+ selection using an european approved device (Miltenyi corporation)~NK Cell ex-vivo activation~o ex-vivo activation: interleukin-2 according to a classical procedure (7 days at 37°C with RPMI clinical grade medium supplemented with 10% of foetal calf serum, 0.5 x 106 cellules / ml, 1000 U/ml d'IL-2 (interleukin, proleukin)~NK Cell infusion (60 to 90 days after transplantation)"
3302362|NCT01853410|Experimental|gekoTM device application|Single arm study. Application of gekoTM device as described above with assessment of effect on coronary flow and endothelial function.
3302363|NCT01853423|Experimental|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
3302364|NCT01853436|Experimental|Single stage reconstructions|as defined for use in the Experimental arm
3302365|NCT01853436|Other|Two stage breast reconstructions|CONTROL: standard two stage breast reconstructions without Acellular dermal matrices (ADM), in patients who are clinically suitable candidates for reconstruction with Acellular dermal matrices(ADM)based single stage reconstruction technique. Reconstructions with Strattice™ Reconstructive Tissue Matrix
3302366|NCT01853449|Experimental|CWS+Fentanyl Citrate (250 mcg)|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
3302367|NCT01853449|Placebo Comparator|CWS+0.9% saline placebo|Chest wall strapping to reduce vital capacity by 20% of its baseline value + single-dose inhalation of 0.9% saline placebo
3302368|NCT01853449|Active Comparator|No CWS+Fentanyl Citrate (250 mcg)|No chest wall strapping (unloaded control) + single-dose inhalation of nebulized fentanyl citrate (250 mcg)
3302369|NCT01853449|Placebo Comparator|No CWS+0.9% saline placebo|No chest wall strapping (unloaded control) + single-dose inhalation of 0.9% saline placebo
3302370|NCT01853488||Spinal Cord Injury|Persons with spinal cord injury Osteodensitometry DXA pQCT
3302371|NCT01853488||Reference|Reference population (able-bodied) Osteodensitometry DXA pQCT
3302372|NCT01853501|Experimental|POF,treatment,ADSC|Fat from POF patients undergo Autologous fat grafting operation were separated, from which Adipose Derived Stem Cell were then purified and injected into the both ovaries of patients.
3302373|NCT01853514||Low income|Income level equal or less than 250% above the poverty level
3302374|NCT01853527||Angina pectoris, non-obstructive CAD|Contrast stress echocardiography will be performed in patients with angina pectoris and non-obstructive CAD on CT-angiography to detect presence of myocardial ischemia
3302375|NCT01853566|Experimental|growth hormone|GH group received an initial dose of 0.5 units (UI)/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study (6 months).
3302376|NCT01853579|Experimental|1|Experimental: Drug: Levothyroxine The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
3302377|NCT01853579|Placebo Comparator|2|"Placebo Comparator: Drug: Placebo Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
3302378|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell ALL|"3 daily doses of cyclophosphamide together with fludarabine with be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
3302379|NCT01853631|Experimental|CD19 CAR T Cells for Bcell ALL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
3302380|NCT01853631|Experimental|CD19 CAR T Cells and Lymphodepletion for Bcell NHL/CLL|"3 daily doses of cyclophosphamide together with fludarabine will be administered finishing at least 24 hours before T cell infusion.~CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0."
3302381|NCT01853631|Experimental|CD19 CAR T Cells for Bcell NHL/CLL|CD19.CAR/28 and CD19.CAR/28.137 T cells will be administered on Day 0.
3302382|NCT01853657|Active Comparator|Virological monitoring|In addition to routine clinical and immunological monitoring with CD4 counts
3302383|NCT01853657|No Intervention|Routine monitoring|Immunological and clinical monitoring
3302384|NCT01853670|Experimental|definitive radiation + concomitant chemo|"Concurrent chemo + IGRT:~These patients will have chemotherapy during the time of radiation treatment"
3302385|NCT01853670|Experimental|neoadjuvant chemo|"Neoadjuvant chemo + IGRT:~These patients will have chemotherapy prior to other radiation treatment."
3380663|NCT04568538|Experimental|İntervention group|"Randomization with a sealed envelope will be applied to mothers who have 2-4 months old babies who apply to Akdeniz University Hospital Pediatric Outpatient Clinic for health control and who accept the study. A pre-test application will be made in the intervention group. The Researcher will fill in the Personal Information Form and the Shaken baby syndrome assessment survey at this stage.~The training prepared to prevent shaken baby syndrome, which was prepared immediately after the end of the pre-test application, will be given to the mothers in the intervention group. The training will be given with mothers using one-to-one face-to-face interview method. Necessary equipment will be provided for training. At the end of the training, the questions of the mothers will be answered and a booklet prepared to prevent shaken baby syndrome will be given and tele-consultancy will be provided for 2 months."
3380664|NCT04568538|No Intervention|Control group|No application will be made to the mothers in the control group after the pre-test application. After 2 months, the final test application will be made. After the last test, the mothers in the control group will be given a training and a booklet prepared to prevent shaken baby syndrome.
3302386|NCT01853683|Experimental|Conservative Management|Children randomized to conservative management will be seen in the clinic 6-10 weeks after discharge and phoned to follow up every 3 month for a total follow-up of a year. Family will be instructed to come back to the hospital or call the treating physician if the child develops any abdominal pain or fever.
3380666|NCT04561362|Experimental|Cohort A-1 BT8009 Monotherapy Dose Escalation|Participants will receive increasing doses of BT8009. It is expected that approximately 34 participants will participate in this dose escalation arm.
3302387|NCT01853683|Active Comparator|Operative Management|Children randomized to IA will be scheduled for an interval appendectomy 6-10 weeks after discharge, and will be seen in the clinic 6-8 weeks following the interval appendectomy and phoned for follow-up every 3 month for a total of one year.
3380667|NCT04561362|Experimental|Cohort A-2 BT8009 and Nivolumab Dose Escalation|Participants will receive increasing doses of BT8009 and a standard dose of nivolumab. It is expected that approximately 20 participants will participate in this dose escalation arm
3380668|NCT04561362|Experimental|Cohort B-1 - Dose expansion (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 40 participants will participate in this dose expansion arm
3302388|NCT01853709|Experimental|Multidisciplinary approach|"The multidisciplinary approach will include:~Education Fiber free diet Bisacodyl: 10 mg 2 days before the procedure, 20 mg the day before the procedure and 10 mg 3 hours before the procedure Adjuvants: Olive Oil:60 mL/Apple Juice: 200 mL PEG: 1 L the night before the procedure and 1 L 3 hours before the procedure"
3302389|NCT01853709|Active Comparator|Conventional approach|"The conventional approach will include:~Education Fiber free diet Polyethylene glycol (PEG): 2 L the night before the procedure, 2 L 3 hours before the procedure"
3302390|NCT01853722|Experimental|DCN01|
3302391|NCT01853722|Placebo Comparator|Unisol|
3302392|NCT01853735||bowel injury, NPO|Patients with bowel injury who remain nil-per-os (fed nothing)
3302393|NCT01853735||bowel injury, EN|Patients with bowel injury who are fed by enteral nutrition (EN)
3302394|NCT01853735||no bowel injury, NPO|Patients without bowl injury who remain nil-per-os (fed nothing)
3302395|NCT01853735||no bowel injury, EN|Patient without bowl injury who are fed by enteral nutrition (EN)
3302396|NCT01853748|Active Comparator|Study Drug|T-DM1 every three weeks by IV for 17 treatments (total of 51 weeks)
3380669|NCT04561362|Experimental|Cohort B-2 - Dose expansion (BT8009 and nivolumab)|Participants will receive a selected dose of BT8009 and a standard dose of nivolumab. It is expected that approximately 40 participants will participate in this dose expansion arm.
3380670|NCT04561362|Experimental|Cohort C - Renal Insufficiency (BT8009 alone)|Participants will receive a selected dose of BT8009. It is expected that approximately 12 participants will participate in this arm.
3380671|NCT04551482|Experimental|Oxytocin|Oxytocin nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
3380672|NCT04551482|Placebo Comparator|Placebo|Placebo nasal spray (24 IU nasal spray, 4 times per day for 12 weeks)
3302397|NCT01853748|Active Comparator|Standard of Care|Paclitaxel and Trastuzumab once per week by IV for 12 weeks. Beginning week 13, Trastuzumab only by IV injection every three weeks for 13 treatments
3302398|NCT01853761|Experimental|Exercise after, Transcutaneos, 25-10Hz|Experimental group 1 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3302399|NCT01853761|Experimental|25-50Hz microcurrent|Experimental group 2 performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50Hz.
3380674|NCT04540887|Experimental|Treatment|Treatment will be provided via self-administration of pulsed electromagnetic field (PEMF) therapy using the B. Body (whole body mat), B. Pad (targeted pelvic mat), and Control Unit. The participant will lay the B. Body mat on any flat surface (i.e. floor, bed, reclining chair, etc.) and lie down on the mat with the smaller B. Pad placed directly over their pelvic area. Then, the participant will turn the PEMF device on using the attached control unit, which has been pre-programmed to deliver the same level of energy every time. Participants will be instructed to administer this home treatment twice a day (morning and evening) for 8-minute sessions over a four-week period. As this is a single-group assignment, all participants will be given the PEMF device.
3302400|NCT01853761|Experimental|percutaneous microcurrent|Experimental group 3 performed aerobic exercise just after microcurrent in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3302401|NCT01853761|Experimental|Exercise at same time|Experimental group 4 performed aerobic exercise at the same time microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
3302402|NCT01853761|Placebo Comparator|Control Group|Control group performed aerobic exercise just after microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, but microcurrent device was switched off.
3302403|NCT01853787|Experimental|Formoterol Fumarate|At study day n°1 the patients will be randomized to take either Salmeterol or Formoterol in a double blind way.
3302404|NCT01853787|Active Comparator|Salmeterol|The second study arm represents the crossing over arm. Every patient, at study day number 2 will take a different medication (Salmeterol 50 mcg or Formoterol 12 mcg) from that taken at the study day n° 1.
3302405|NCT01853800|Experimental|Rivaroxaban (Treatment A) suspension (BN03501), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment A, Batch number BN03501) under fasting conditions in any intervention period.
3302406|NCT01853800|Experimental|Rivaroxaban (Treatment B) suspension (BN03501), fed|Subjects received single oral dose of Rivaroxaban suspension 20 mg (Treatment B, Batch number BN03501) under fed conditions in any intervention period.
3302407|NCT01853800|Experimental|Rivaroxaban (Treatment C) suspension (BR05701), fasted|Subjects received single oral dose of Rivaroxaban suspension 10 mg (Treatment C, Batch number BR05701) under fasting conditions in any intervention period.
3302408|NCT01853800|Experimental|Rivaroxaban (Treatment D) IR tablet, fasted|Subjects received single oral dose of Rivaroxaban IR tablet 10 mg (Treatment D) under fasting conditions in any intervention period.
3302409|NCT01853813|Other|Bevacizumab and FOLFIRI|Bevacizumab 5 mg/kg d1 q14 in combination with FOLFIRI (Irinotecan, leucovorin, 5FU I.V.bolus and 5FU I.V. c.i.)
3302410|NCT01853852|Experimental|50 mg|GR181413A/AT1001
3302411|NCT01853852|Experimental|150 mg|GR181413A/AT1001
3302412|NCT01853852|Experimental|450 mg|GR181413A/AT1001
3302413|NCT01853852|Placebo Comparator|Placebo|placebo
3302414|NCT01853865|No Intervention|Follow-up|Patients in this arm attend regular follow-up examinations, as is the current standard, at the department of gynecology following surgery.
3302415|NCT01853865|Experimental|Self-referral|Instead of regular follow-up examinations, this group is carefully instructed in alarm symptoms that require contact with a physician.
3302416|NCT01853891|No Intervention|usual condition|sleep in usual room light condition for 5 nights
3302417|NCT01853891|Experimental|dLAN|sleep with dim light at night for 5 nights
3302418|NCT01853904|Other|Channel Suction first|This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
3302419|NCT01853904|Other|Syringe Suction first|This arm is for patients who will receive syringe suction first to obtain the specimen then channel suction to obtain the specimen.
3302420|NCT01853917||questionaires and structured interview|HIV infected women who are pregnant and receiving care in Harris County Hospital District single arm study Single arm study
3302421|NCT01853943||Patent radial artery|Patient with patent radial artery after the percutaneous coronary procedure
3302422|NCT01853943||Occluded radial artery|Patients with occluded radial artery after the procedure
3302423|NCT01853956|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3302424|NCT01853956|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3302425|NCT01853969||Patients who have carpal tunnel release surgery|
3302426|NCT01853995|Experimental|FLMGM Treatment Group|Cl II/1 patients treated with Fixed Lingual Mandibular Growth Modificator (FLMGM)
3302427|NCT01853995|No Intervention|Untreated Class II Control Group|control group
3302428|NCT01854008|Experimental|rehabilitation program more the urban circuit|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG).These circuits can be obtained on the website http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index
3302429|NCT01854008|Experimental|rehabilitation program non circuit group .|One group, the urban circuit group (UCG), received a triptych that included urban walking circuits,the remaining patients formed the non circuit group (NCG)
3302430|NCT01854021|Experimental|inhalational anesthesia|inhalational anesthesia
3302431|NCT01854021|Experimental|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
3302432|NCT01854021|Experimental|intravenous anesthesia|intravenous anesthesia
3302433|NCT01854060||irritable bowel syndrome|All new cases of clinical diagnosis of irritable bowel syndrome
3302434|NCT01854073|Active Comparator|Group A|Group A, will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose 2 hours after.
3302435|NCT01854073|Placebo Comparator|Group B|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose 2 hours after.
3302436|NCT01854086||Postmenopausal women|Postmenopausal women treated with bisphosphonates
3302437|NCT01854099|Active Comparator|5 Day TMZ with PEP-CMV on Day 6-8|Standard TMZ (200 mg/m2/day x 5 days) with PEP-CMV vaccination on Day 6-8 of each monthly TMZ cycle
3302438|NCT01854099|Active Comparator|5 day TMZ with vaccine on day 22-24|Standard TMZ (200 mg/m2/day x 5 days) with vaccination on Day 22-24 of each monthly TMZ cycle
3302439|NCT01854099|Active Comparator|21 day TMZ wtih vaccine on day 22-24|Dose-intensified TMZ (100 mg/m2/day x 21 days) with vaccination on day 22-24 of each monthly TMZ cycle
3302440|NCT01854112||T-cell lymphoma|
3302441|NCT01854125|Active Comparator|autologous bone marrow mesenchymal stem cells transplantation|Every patient is given 1x106 MSCs per kg infused via liver artery
3302442|NCT01854125|Active Comparator|mesenchymal stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
3302443|NCT01854125|Experimental|stem cells transplantation|autologous bone marrow mesenchymal stem cells transplantation
3302444|NCT01854151|No Intervention|Standard Practice|Parents whose children are prescribed medication and meet inclusion/exclusion criteria will fill their medication at their regular pharmacy and receive medication with labeling and dosing instruments as per routine
3302445|NCT01854151|Experimental|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication and meet inclusion/exclusion criteria will receive medications with health literacy informed labels and dosing instruments
3302446|NCT01854164|Experimental|HGE(hydrolyzed ginseng extract)|HGE capsules(2cap/d, 960mg/d) for 8 weeks.
3302447|NCT01854164|Placebo Comparator|Placebo|Placebo for 8 weeks
3302448|NCT01854190||Resistant hypertension|"Patients with uncontrolled blood pressure despite 3 medications, including diuretic.~Endothelial function assessed by peripheral arterial tonometry (PAT) by EndoPAT and the OSA diagnosis also through PAT, using the portable device WatchPAT."
3302449|NCT01854190||Controlled hypertension|Patients with controlled blood pressure by medications. These drugs are the same used in both groups.
3302450|NCT01854203|Experimental|IInductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30 mg/m2，on day 1) repeated every weeks for 6 cycles during radiotherapy.
3302451|NCT01854203|Experimental|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
3302452|NCT01854216|Experimental|Rotigotine in Japanese subjects|Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours
3302453|NCT01854216|Experimental|Rotigotine in Caucasian subjects|Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours
3302454|NCT01854229|Active Comparator|Prospective pump candidates|New candidates who will receive the Prometra Programmable Intrathecal Infusion Pump
3302455|NCT01854229|Active Comparator|Previous IDE study subjects continuing with the therapy|Patients who were part of the previous IDE study, still have an active Prometra Programmable Intrathecal Infusion Pump, and are willing to continue in a study protocol.
3302456|NCT01854255|Experimental|Intraperitoneal Chemotherapy|Patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4-6 weeks, applied intraperitoneally as pressurized aerosol chemotherapy. Duration of treatment will be 3 single doses in 6 weeks intervals, thus the duration of treatment is 18 weeks.
3302457|NCT01854294|Experimental|GM604 treated|8 subjects will receive GM604. Each GM604 treated subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
3302458|NCT01854294|Placebo Comparator|Placebo comparator|4 subjects will receive placebo. 6.4 mL Bacteriostatic saline will be used for the Placebo group. Injections will be given to the subject in the same manner as in GM604 treated group. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
3302459|NCT01854307|Experimental|Pneumoperitoneum and SVV/PPV|
3302460|NCT01854320|Experimental|Acceptance-based treatment|Behavioral therapy for weight loss focusing on acceptance-based cognitive strategies and techniques.
3302461|NCT01854320|Active Comparator|Standard behavioral treatment|"Standard behavioral therapy for weight loss, the gold standard treatment."
3302462|NCT01854333|Other|ADOS module 1-4, ADI-R|Individuals recruited within clinical services in child psychiatry and child medicine in Stockholm county and Lund for whom assessments with ADOS module 1-4 or ADI-R are appropriate.
3302463|NCT01854346|Experimental|Social skills group training KONTAKT|N= 144 participants are offered group training KONTAKT. The intervention includes 12 (brief intervention) and 24 (long intervention) sessions.
3302464|NCT01854346|No Intervention|Control group (TAU), the usual intervention / treatment|N = 144 participants are received treatment as usual (pharmacological therapy, family therapy, Cognitive behavioral therapy etc).
3302465|NCT01854372|Experimental|R-HCVAD and R-MC Chemotherapy|"R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).~R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg)."
3302466|NCT01854398|Experimental|CPAP group|
3302467|NCT01854398|Sham Comparator|sham-CPAP group|
3302468|NCT01854411||analgesic dose measure|breastfeeding mother who will take analgesics
3302469|NCT01854424||ARDS|Ventilated patients with ARDS criteria (Berlin criteria) will be recruited in 3 ICU (2 from Bichat Hospital and 1 from Tenon Hospital, Paris) during the first 48 hours of their evolution. The patients will considered in 2 groups during analysis by taking into account their vital status at day-28 of inclusion.
3302470|NCT01854437||Mg Oxide|Mg Oxide (Mg®, 21st Century®) 250 mg orally for 4 weeks
3302471|NCT01854437||placebo|placebo 1 tab TDS
3302472|NCT01854450|Experimental|Asymmetrical Lateral Decubitus|Women in labor are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion
3302473|NCT01854450|Other|control|usual obstetrical care
3302474|NCT01854463|Experimental|Vitamin D3|25-hydroxy vitamin d 2000 IU and elemeental calcium 200mg daily for 24 weeks
3302475|NCT01854463|Placebo Comparator|placebo|administered elemental calcium 200mg daily for 24 weeks
3302476|NCT01854476|Experimental|Tranexamic acid|pad-gauze with tranexamic acid (Hemostopan™)
3302477|NCT01854476|Placebo Comparator|Pad gauze|Pad gauze with no tranexamic acid
3302478|NCT01854489|Active Comparator|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
3302479|NCT01854489|Placebo Comparator|Placebo|The volunteers will be given oral placebo at 20.00 for 7 days
3302480|NCT01854489|Active Comparator|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
3302481|NCT01854502|Experimental|Oral hygiene and fluoride use|Parents of young children were given counseling of their own oral hygiene and the use of fluoride on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
3302482|NCT01854502|No Intervention|Control|"Control, The parents were not given any intervention on their child's visit to public dental service.~The child was given multi-faceted counseling for good oral health habits."
3380675|NCT04539964|Experimental|Treatment|Active stimulation for 1 min once per day
3302483|NCT01854502|Experimental|Diet and use of xylitol|Parents of young children were given counseling of their own diet and the use of xylitol on their child's visit to public dental service. The child was given multi-faceted counseling for good oral health habits.
3302484|NCT01854515|Active Comparator|Budesonide|1 mg diluted in 4 cc of sterile water for 20 minutes, one hour preceding extubation. After extubation patients received nebulizing Budesonide via oxygen mask at the same dose every 12 h. for 48 h.
3302485|NCT01854515|Experimental|Dexamethasone|0.15 mg/kg before extubation. After extubation, the administration of intravenous Dexamethasone continued at the same dose every 12 h. for 48 h.
3302486|NCT01854541||Radiotherapy|All patients receiving radiotherapy
3302487|NCT01854554|Experimental|Intensity Modulated Proton Radiotherapy (IMPT)|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
3302488|NCT01854554|Experimental|Intensity Modulated Radiotherapy (IMRT)|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
3302489|NCT01854567|Experimental|Active|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
3302490|NCT01854567|Active Comparator|Control|Infusion of two unexpanded cord blood units.
3302491|NCT01854580||Integrated care|Insured people in the Techniker Krankenkasse that are registered in the integrated care project.
3302492|NCT01854580||Control group|Insured people in the Techniker Krankenkasse that are not registered in the integrated care project.
3302493|NCT01854606|Experimental|AEB071 and EVEROLIMUS|AEB071 and EVEROLIMUS will be taken together in this open-label non-randomized study
3302494|NCT01854619|Active Comparator|Saline irrigation|Saline irrigation via syringe will be administered using a sinus irrigation catheter under endoscopic control.
3302495|NCT01854619|Active Comparator|Double photodisinfection treatment|Patients in the double treatment arm will receive a second photodisinfection treatment 4 weeks following the first treatment with regular follow-up visits
3302496|NCT01854619|Active Comparator|Single photodisinfection treatment|The single-treatment group will receive a single photodisinfection treatment of all involved paranasal sinuses with multiple follow-up visits.
3302497|NCT01854671|No Intervention|standard care|
3302498|NCT01854671|Experimental|family planning counseling led by community health worker|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
3302499|NCT01854684|Experimental|Treatment (surgery and intraoperative PDT)|Patients receive temoporfin IV over no less than 6 minutes and then undergo standard surgical resection with intraoperative PDT.
3302500|NCT01854723|Experimental|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
3302501|NCT01854723|Active Comparator|Continuation of insulin glargine|Patients in this arm will continue on insulin glargine and serve as a control group.
3302502|NCT01854736|Active Comparator|GRAZAX|Tablet 75.000SQ-T once daily
3302503|NCT01854736|Placebo Comparator|Placebo|Tablet with no active grass component
3302504|NCT01854749|Experimental|S1 combined with cisplatin|
3302505|NCT01854762|Experimental|Raltegravir|Use of Raltegravir plus backbone treatment for pregnant women
3302506|NCT01854762|Active Comparator|Lopinavir/Ritonavir|Use of standard PI treatment (Lopinavir/r) plus backbone treatment for pregnant women
3302507|NCT01854788|Active Comparator|Autogenic drainage|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3302508|NCT01854788|Active Comparator|Slow expiration with glottis opened in lateral posture|All patients performed all interventions in a randomized order.Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3302509|NCT01854788|Active Comparator|Temporary-Positive Expiratory Pressure|All patients performed all interventions in a randomized order. Each technique was applied in 3 non consecutively sessions during one week. The time spent during the session was 40 minutes
3302510|NCT01854801|Experimental|Experimental|Patients who declare themselves to be intolerant to electromagnetic fields benefit from medical care in occupational and environmental diseases centers and from a measurement of individual electromagnetic exposures and symptoms episodes. Each patient is his own control.
3302511|NCT01854814|Experimental|mycophenolate mofetil|mycophenolate mofetil 1.5g/day and maximum tolerated labeled dose of losartan
3302512|NCT01854814|Active Comparator|losartan|maximus tolerated labeled dose of losartan
3302513|NCT01854840||Celesten in prevention of hyaline membrane disease.|Pregnant women that received at least a first injection of Celesten in the prevention of hyaline membrane disease.
3302514|NCT01854853|Experimental|STYLE Brazil|STYLE-BRazil Multifamily Group HIV/STI Prevention intervention
3302515|NCT01854853|Active Comparator|Health Promotion|Health Promotion Intervention - Adolescents only
3302516|NCT01854866|Experimental|Drug-packaging Microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
3302517|NCT01854892|Experimental|Manipulation|Spinal manipulation
3302518|NCT01854892|Experimental|Mobilization|Spinal mobilization
3302519|NCT01854892|Experimental|Laser Therapy|Cold laser therapy
3302520|NCT01854931|Other|Tai Ji Quan|Single aim intervention - 2 twice per week for 48 weeks
3302521|NCT01854957|Experimental|Autologous Mesenchymal Stem Cells|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3302522|NCT01854957|Placebo Comparator|Suspension media|At week 0 a single infusion of either ex-vivo expanded autologous MSC or suspension media will be administered intravenously at a dose of 1-2 x 1000000 MSC/Kg body weight. At week 24, another infusion will be performed for cross-over re-treatment: at week 24 treatments will be reversed compared to week 0
3302523|NCT01854970|Experimental|Patient|
3302524|NCT01854996|Experimental|Oral disperion fasted|A single dose of 450 mg PF-05089771 TS oral dispersion in fasted conditions.
3302525|NCT01854996|Experimental|Capsule fasted|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fasted conditions
3302526|NCT01854996|Experimental|Capsule fed|single dose of 450 mg PF-05089771 TS as 3 x 150 mg capsules in fed conditions
3302527|NCT01855009|Active Comparator|MannaBears|Subjects will take 4 MannaBears daily
3302528|NCT01855009|Active Comparator|MannaBears, AlgaeCal Calcium, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
3302529|NCT01855009|Active Comparator|MannaBears, Calcium Carbonate, Vitamin D3|Subjects will take 4 MannaBears daily and 3 Calcium/Vit D capsules (2 with breakfast and 1 with dinner or vice-versa) daily
3302530|NCT01855022|Experimental|MI + IVR|90 days of motivational interviewing and 30 days of interactive voice response monitoring
3302531|NCT01855022|No Intervention|Usual Care|Usual care that a patient would receive absent the intervention
3302532|NCT01855035|Experimental|prolonged ECG monitoring|Prolonged ECG monitoring: 10-day Holter ECG at months 0, 3 and 6
3302533|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
3302534|NCT01855061||Irinotecan|"Patients will be subjected to a their metastatic solid tumor. Radiological response will be evaluated after each 2 cycles: 1. percentage change in radiological volume of the index lesion (radiological measurable lesion that underwent biopsy) after the first two cycles of irinotecan; 2. radiological response according to RECIST 1.1 after each 2 cycles. Patients are intended to receive irinotecan until progressive disease or unacceptable toxicity. Patients will be subjected to another biopsy of the index lesion at definitive discontinuation of irinotecan. Patients will also be subjected to blood draws for determining patient's genetic background variation.~Side studies include:~pharmacogenetics~pharmacokinetics of SN-38~carboxylesterase activity in the index lesion~midazolam clearance test (only in Rotterdam patients)"
3302535|NCT01855100||Rivaroxaban|
3302536|NCT01855113||INVISALIGN®|those with an Invisalign® Treatment for orthodontic correction
3302537|NCT01855113||braces|those with braces for orthodontic correction.
3302538|NCT01855139||Rivaroxaban|
3302539|NCT01855152|Experimental|Optimised WHELD intervention|The optimised WHELD intervention combining person centred care, promoting person centred activities and interactions and provide care home staff and general practitioners with updated knowledge regarding the optimal use of psychotropic medications for persons with dementia in care homes, is more effective in improving the quality of life and mental health, than usual care for people with dementia living in nursing homes.
3302540|NCT01855152|Experimental|Treatment as usual|Treatments delivered as usual
3302541|NCT01855165|Experimental|Advice on DDIs|Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.
3302542|NCT01855165|No Intervention|General advice|
3302543|NCT01855191||Standard|
3302544|NCT01855191||Standard + saliva collection|
3302545|NCT01855204|Active Comparator|Conventional|Computed tomographic urography was done with conventional protocols.
3302546|NCT01855204|Experimental|Reduced|Computed tomographic urography was done with the protocols of low voltage and low iodine concentration.
3302547|NCT01855217|Active Comparator|Sugammadex total body weight|1 mg/kg total body weight
3302548|NCT01855217|Active Comparator|Sugammadex ideal body weight|1 mg /kg ideal body weight
3302549|NCT01855217|Placebo Comparator|placebo|placebo 0,9% NaCl
3302550|NCT01855230|Experimental|ASM-024|Dry Powder for Inhalation, b.i.d., 14 days
3302551|NCT01855230|Placebo Comparator|Placebo|Dry Powder for Inhalation, b.i.d., 14 days
3302552|NCT01855256|Experimental|oxybutynin|Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
3302553|NCT01855256|Placebo Comparator|Placebo|Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks.
3302554|NCT01855269|Active Comparator|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
3302555|NCT01855269|Active Comparator|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil, foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
3302556|NCT01855269|Placebo Comparator|Sterile water|Sterile water: 5 drops, 30 minutes after feeding, once per day for 3 weeks
3302557|NCT01855282|Experimental|Behavioral intervention|Behavioral intervention consisting of 10 educational sessions promoting healthy diet and increased physical activity.
3302558|NCT01855282|Active Comparator|Control|Control arm received no behavioral intervention
3302559|NCT01855295|Experimental|Protein Supplementation|Hemodialysis patients with inflammation and low body mas index to receive protein dietary advice and protein supplements while on dialysis
3302560|NCT01855308||Single site robotic chole|Cholecystectomy performed through a single incision with the robot.
3302561|NCT01855321|Active Comparator|Vitamin D|the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
3302562|NCT01855321|Placebo Comparator|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
3302563|NCT01855334|Experimental|Spironolactone + Placebo|Spironolactone 25 mg by mouth daily + Placebo L-arginine-liquid formulation by mouth 3 times daily
3302564|NCT01855334|Placebo Comparator|Double Placebo|Placebo spironolactone-1 tablet by mouth daily + Placebo L-arginine liquid formulation by mouth 3 times daily
3302565|NCT01855334|Experimental|Spironolactone + L-arginine|Spironolactone 25 mg daily + L-arginine 3 grams orally 3 times daily
3302566|NCT01855334|Experimental|L-arginine + Placebo|L-arginine 3 grams by mouth 3 times daily + Placebo spironolactone 1 tablet by mouth daily
3302567|NCT01855347||Preterm infants|Preterm infants (32 to 36 weeks of postmenstrual age) will be evaluated with a Near infrared Spectroscopy monitor device.
3302568|NCT01855373|Other|Placebo|No active ingredient
3302569|NCT01855373|Active Comparator|PEAK ATP® with GlycoCarn®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)and Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
3302570|NCT01855373|Active Comparator|PEAK ATP®|Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)
3302571|NCT01855373|Active Comparator|GlycoCarn®|Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule)
3302572|NCT01855386||Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
3302573|NCT01855386||Controls without Gestational Diabetes|Matched control subjects without Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
3302574|NCT01855438|No Intervention|Usual Care|Kidney transplant candidates randomized to this arm will receive only the education provided by the transplant center. After data collection activities have concluded, transplant candidates in this arm will be offered the opportunity to attend a program session.
3302575|NCT01855438|Experimental|Living Donor Transplant Education 1|Participants randomized to Living Donor Transplant Education 1 will receive education on living donor kidney transplantation and its discussion.
3302576|NCT01855438|Experimental|Living Donor Transplant Education 2|Participants randomized to Living Donor Transplant Education 2 will receive education on living donor kidney transplantation and its discussion; they will also have the opportunity to practice discussing living kidney transplantation with simulated patients portraying participants' conversational partners.
3302577|NCT01855451|Active Comparator|Radiation Therapy + Cetuximab|RT (70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cetuximab (400 mg/m2 loading dose IV prior to radiation, followed by weekly cetuximab 250 mg/m2 for the duration of the radiotherapy)
3302578|NCT01855451|Active Comparator|Radiation Therapy + Cisplatin|RT(70 Gy in 35 fractions, 5 days a week over 7 weeks) with weekly Cisplatin (40 mg/m2 IV for the duration of the radiotherapy)
3302579|NCT01855464|Experimental|wedge resection+parietal pleurectomy|Surgical treatment includes parietal pleurectomy and wedge resection of the tip of the lung.
3302580|NCT01855464|Active Comparator|parietal pleurectomy|Surgical therapy is limited to parietal pleurectomy.
3302581|NCT01855477|Other|Histological biopsy procedure|This is a multicenter study combining histological biopsy of tumor material with DNA sequencing using Next Generation Sequencing (NGS) platform. The study aims to obtain a more accurate pre-treatment stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing to obtain a mutational profile.
3302582|NCT01855490|Experimental|Single-arm treatment with Exenatide|Exenatide 5 mcg sc. injection 15 minutes prior to a MMTT and IVGTT
3302583|NCT01855503||Metastatic Breast Cancer|
3302584|NCT01855516|Active Comparator|UFH 5000 U three times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
3302585|NCT01855516|Active Comparator|UFH 5000 U two times a day|Study subjects will be randomized to receive heparin 5000 U subcutaneous two times a day.
3302586|NCT01855529|Experimental|Ropivacaine arm|Ropivacaïne 2 mg/ml 10ml/h
3302587|NCT01855529|Placebo Comparator|NaCl arm|NaCl 0,9% 250ml 10 ml/h
3302588|NCT01855542|Experimental|0.9% saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
3302589|NCT01855542|Active Comparator|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
3302590|NCT01855555||sedation group|Children requiring sedation for MRI/CT
3302591|NCT01855568|Experimental|Single-dose methotrexate protocol|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
3302592|NCT01855568|Experimental|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
3302593|NCT01855581||sedation group|Children requiring sedation for MRI/CT
3302594|NCT01855594|Experimental|Lithium treatment group|Lithium carbonate, 250mg/tablet. The dose starts with three times a day and one tablet each time for a week. The daily dose will then be adjusted according to serum lithium level and clinical finding. Target serum lithium level is 0.6 - 1.2mmol/L.
3302595|NCT01855594|Placebo Comparator|Control group|The dose of the placebo will be adjusted according to the dummy serum level report.
3302596|NCT01855607|Experimental|topical menthol|topical menthol cream to hands and feet
3302597|NCT01855607|Placebo Comparator|placebo cream|topical cream without menthol
3302598|NCT01855620||Normal weight women|Women with implant for more than twelve months who have BMI <25.
3380676|NCT04539964|Sham Comparator|Control|Non-active stimulation for 1 min once per day
3380677|NCT04535999|Experimental|Open Label|Secukinumab
3302599|NCT01855620||Overweight women|Women with implant for more than twelve months who have BMI > or = 25 and <30.
3302600|NCT01855620||Obese women|Women with implant for more than twelve months who have BMI > or = 30.
3302601|NCT01855633|Experimental|Tradtional Theta burst stimulation (TBS) rTMS|Participants will receive continuous theta burst stimulation (cTBS) rTMS to contralesional hemisphere based on a previous study (Huang et al., 2005)
3302602|NCT01855633|Active Comparator|Modified TBS rTMS|Participants will receive modified cTBS rTMS to contralesional hemisphere based on a previous study (Nyffeler et al., 2006)
3302603|NCT01855633|Sham Comparator|Sham rTMS|Participants will receive sham cTBS rTMS to contralesional hemisphere.
3302604|NCT01855659||COPD patients|Patients who are stratified in the subgroups of COPD based on the severity: stages II, III, IV
3302605|NCT01855672|Active Comparator|Perceivable Stimulation|Stimulation of the occipital nerves.
3302606|NCT01855672|Active Comparator|Non-Perceivable|Stimulation of the occipital nerves.
3302607|NCT01855685|Experimental|Open label|X vivo gene therapy
3302608|NCT01855698||All patients registered|
3302609|NCT01855711|Experimental|GR68755 (Alosetron hydrochrolide) group|GR68755 1 mg tablets QD in the morning every day for 28 days
3302610|NCT01855724|Experimental|Gemcitabine-Pazopanib|"Gemcitabine 1000 mg/m2 administered intravenously on days 1 and 8 and Pazopanib 800 mg administered per os on days 1 to 21 every 21 days.~Treatment with gemcitabine/pazopanib combination will continue until disease progression, appearance of significant toxicity, completion of 8 cycles or informed consent withdrawal.~Upon completion of 8 treatment cycles with the combination, and in the absence of disease progression, administration of pazopanib monotherapy as maintenance treatment will be continued until disease progression, appearance of significant toxicity or informed consent withdrawal."
3302611|NCT01855737||Warfarin Using Group|
3302612|NCT01855763|Experimental|metformin|group A1:Consists of patients with GDM who were given drug metformin as treatment group B1:Consists of patients with type 2 diabetes in pregnancy were given the drug metformin as treatment intervention with drug metformin is given for control of diabetes in esclation dose of 500mg /day upto 2.5 grams per day in two to three divided doses till delivery
3302613|NCT01855763|Active Comparator|insulin|GroupA2:gestational diabetes on insulin treatment Group B2:type 2 diabetes on insulin treatment intervention:insulin treatment till delivery
3302614|NCT01855776|Other|Control Group|"The control group will receive a usual care educational programme at baseline created by the Singapore Health Promotion Board. This guide describes the importance of physical activity and illustrates one possible physical activity programme. It also discusses strategies for adopting a healthy lifestyle. They will not receive the Fitbit Zip wireless pedometer from the study team. However, they will receive $4 per week, regardless of physical activity levels."
3302615|NCT01855776|Experimental|Programme Only Group|This group receives the Fitbit Zip, and access to the Fitbit website. Fitbit Zip counts the number of steps walked, calories burned, and distance travelled. Participants can set goals for their physical activity levels, and will have access to personalised feedback from Fitbit. This group will also receive $4 per week, regardless of physical activity levels.
3302616|NCT01855776|Experimental|Cash Incentive Group|"This group receives the Fitbit Zip and the opportunity to earn money each week based on the number of steps logged on the pedometer during that week. We will offer the following incentive schedule:~$0 SGD for less than 50,000 steps during the week~$15 SGD for 50,000 - 69,999 steps during the week (max of 20,000 steps per day)~$30 SGD for 70,000 or more steps during the week (max of 20,000 steps per day) Participants will receive monthly payments in cash after their physical activity is confirmed. The incentive will be calculated separately for each week of the 6-month incentive programme."
3302617|NCT01855776|Experimental|Charitable Incentive Group|This group is identical to the cash incentive group except that incentive payments will be donated directly to a tax-exempt nonprofit charity of the participant's choice. The charity will be selected at the start of the programme but will be limited to the most common tax-exempt nonprofit charities operating in Singapore. As a motivational feedback component of the programme, participants will receive a thank-you email or letter from the charity.
3302618|NCT01855841|Active Comparator|Hemin|A peripheral perfusion of 4mg/kg of hemin (Normosang) diluted in 100mL NaCL (sodium chloride) 0.9% will be administered in 30-60minutes as soon as possible after the end of the ERCP, followed by 100mL of NacL 0.9% to flush the vein
3302619|NCT01855841|Placebo Comparator|Placebo|The same amount of NaCl 0.9% (100 ML followed by a flushing perfusion of 100mL) will be perfused to the patient as soon as possible after the end of the ERCP
3302620|NCT01855854|Experimental|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.
3302621|NCT01855867|Other|Stribild|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg) taken for 28 days, within 72 hours of a possible sexual exposure to HIV
3302622|NCT01855880|Experimental|AbGn-168H Low Dose|Subject to receive low dose of AbGn-168H intravenously
3302623|NCT01855880|Experimental|AbGn-168H: High Dose|Subject to receive high dose of AbGn-168H intravenously
3302624|NCT01855880|Placebo Comparator|Placebo AbGn-168H|Subject to receive placebo
3302625|NCT01855893|Experimental|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
3302626|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
3302627|NCT01855906|Active Comparator|Gap balanced surgical technique|Study patients in this arm of the study will have their knee replacement done using the gap balanced technique. Gap balancing adjusts the bony cuts for femoral rotation to balance the soft tissues of the knee in flexion.
3302628|NCT01855906|Active Comparator|Measured resection surgical technique|Study patients in this arm of the study will have their knee replacement done using the measured resection surgical technique. Pre-determined bony cuts are made and appropriate balance is obtained by judicious soft tissue releases as required.
3302629|NCT01855932|Experimental|Technology Supported|
3302630|NCT01855971|Active Comparator|Fragile X syndrome experimental group|"Administration of 400 mg/day of epigallocatechin-3-gallate (EGCG). Life Extension, Mega Green Tea Extract Decaffeinated, a dietary supplement containing EGCG extract (45% EGCGC).~Dosage form: capsules of 200mg Route of administration: orally Dosage: 2 capsules per day (400 mg EGCG/day) Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Treatment period: 3 months (from month 1 to month 4)~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
3302631|NCT01855971|Placebo Comparator|Fragile X syndrome control group|"Placebo administration. Placebo consists in capsules containing rice flour. Dosage form: capsules Route of administration: orally Dosage: 2 capsules per day Frequency: one capsule in the morning (fasting state) and a second capsule in the afternoon (before dinner).~Cognitive training: non-pharmacological cognitive training 3 sessions per week (1 hour per session) by using the Feskits program."
3302632|NCT01855984|Experimental|Oral mixed tocotrienols|2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months
3302633|NCT01855984|Placebo Comparator|Placebo|2 capsules containing soya bean oil taken orally once a day for 6 months
3302634|NCT01856010||ECT Treatment|Those who were referred for ECT treatment for behavior refractory to standard care and who opted to undergo ECT treatment
3302635|NCT01856010||Standard Care (Non-ECT Group)|Those who were referred for ECT treatment for behavior refractory to standard care, but who opted to not undergo ECT treatment and continue with standard care.
3302636|NCT01856023|Active Comparator|Treatment Arm 1|Patients will receive two courses (four cycles) of High Dose Interleukin-2 (HD IL-2) followed by one course (four doses) of ipilimumab.
3302637|NCT01856023|Active Comparator|Treatment Arm 2|Patients will receive one course (four doses) of ipilimumab followed by two courses (four cycles) of HD IL-2.
3302638|NCT01856036|Experimental|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
3302639|NCT01856049|Other|Umbilical Cord Blood Collection|Umbilical Cord Blood is drawn from the umbilical cord of newborn babies diagnosed with Hypoplastic Left Heart Syndrome, before placental detachment. Cord blood is packaged in a Credo Cube, and sent at a temperate state to the manufacturer immediately after draw. At least 65 mL of cord blood is needed to produce a stem cell product during manufacturing. Once processed, the patient's autologous cord blood stem cells will be frozen for their potential future use in a clinical trial.
3302640|NCT01856062|Experimental|Clomiphene plus dexamethasone|Oral dexamethasone will be added to clomiphene citrate
3302641|NCT01856062|Placebo Comparator|Clomiphene plus placebo|A placebo of dexamethasone will be given with clomiphene citrate
3302642|NCT01856075||Patients treated with dronedarone|Patients treated with dronedarone at inclusion
3302643|NCT01856075||Patients treated with other antiarrhythmic drugs of interest|"The antiarrhythmic drugs of interest to which dronedarone will be compared are:~Class 1a/1c antiarrhythmics~Sotalol~Amiodarone"
3302644|NCT01856088|Experimental|Inspiron Stent|Stent Inspiron with Sirolimus
3302645|NCT01856088|Active Comparator|Biomatrix Flex Stent|Stent Biomatrix Flex with biolimus
3302646|NCT01856101|Experimental|BEZ235, powder|"Group 1: patients without PI3K pathway activation; no loss of PTEN and no activating PIK3CA mutation.~Group 2: patients with PI3K pathway activation as defined by PIK3CA mutation and/or PTEN loss"
3302647|NCT01856127|Experimental|Vilazodone|Vilazodone
3302648|NCT01856127|Active Comparator|Sertraline|Sertraline
3302649|NCT01856140|Experimental|1 million cells/ml of ALLO-ASC|1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
3302650|NCT01856140|Active Comparator|10 million cells/ml of ALLO-ASC|10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.
3302651|NCT01856153|Other|Before meal|Strawberry-Placebo-Placebo
3302652|NCT01856153|Other|With Meal|Placebo-Strawberry-Placebo
3302653|NCT01856153|Other|After Meal|Placebo-Placebo-Strawberry
3302654|NCT01856166|Active Comparator|CEI-PCEA|Continuous Epidural Infusion coupled with Patient Controlled Epidural Analgesia
3302655|NCT01856166|Experimental|PIEB-PCEA|Programmed Intermittent Epidural Bolus coupled with Patient Controlled Epidural Analgesia
3302656|NCT01856179|Experimental|Echium oil young|"BMI<25,~age 20-30"
3302657|NCT01856179|Experimental|Echium oil older|age 40-70 BMI <25
3302658|NCT01856179|Experimental|Echium oil older, overweight|age 40-70 BMI >25
3302659|NCT01856205|Placebo Comparator|IVIG in JE (JE-positive)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
3302660|NCT01856205|Placebo Comparator|IVIG in Non-JE(JE-negative)|We randomly allocated patients to treatment with IVIG or placebo. Children received either saline or intravenous immunoglobulin (IVIG) [ImmunoRel™ (batch 20081217)] at a dose of 400mg/kg/day for 5 days or an equivalent volume of 0.9% normal saline given intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute. All investigators, care providers and participants were blinded of the study drug. A second sealed envelope was kept with the patient's notes in case a physician urgently needed to know which drug a patient had received.
3302661|NCT01856231|Experimental|8 week group|Lifestyle physical activity self-efficacy
3302662|NCT01856244|Experimental|sensorimotor treadmill training|specific treadmill control using oscillating platform
3302663|NCT01856244|Active Comparator|conventional treadmill training|conventional treadmill control
3302664|NCT01856283|Experimental|Nilotinib|study of nilotinib 300 mg BID
3380680|NCT04534283|Experimental|Abemaciclib + LY3214996|Subjects will receive Abemaciclib 150 mg orally twice daily with LY3214996 200 mg orally daily until disease progression, unacceptable toxicity, or patient preference to withdraw from study.
3380681|NCT04533763|Experimental|Mindful Living (ML)|Mindful Living Intervention A 10-week group-based and web-delivered psychosocial intervention targeting key concerns of ovarian cancer survivors.
3380682|NCT04533763|Active Comparator|Healthy Lifestyles (HL)|Healthy Lifestyle Intervention A 10-week group-based and web-delivered intervention providing information on health promotion for ovarian cancer survivors.
3380683|NCT04527523||Endothelial Dysfunction Cohort|All patients enrolled in the study will receive a baseline Optical Coherence Tomography scan (OCT) within 4 weeks prior to surgery. Two additional OCT scan will be performed 6 weeks and 3 months after surgery.
3380684|NCT04526912|Experimental|VIB7734 Dose|Participants will receive a single subcutaneous dose of VIB7734.
3380685|NCT04526912|Placebo Comparator|Placebo|Participants will receive a single subcutaneous dose of placebo (saline) matched to single dose of VIB7734.
3302665|NCT01856296|Experimental|Arm A|ARM A patients with an identified oncogenic driver mutations/amplifications/translocations), who will potentially benefit from targeted therapies, either on the market or in clinical trials according to existing knowledge of matching oncogenic events with actionable drugs. This will be detected through Next Generation Sequencing (NGS) performed by Foundation Medicine, CLIA certified.
3302666|NCT01856296|Experimental|Arm B|patients negative for oncogene events (which remains the majority), for whom genome based relevant information will be obtained through functional genomics (micro arrays and gene expression profiling) performed by Institut Gustave Roussy, and innovative computational methods enabling a rational choice of therapies. For such patients we will apply a new prediction model of efficacy of existing and under clinical trial drugs, based on differences in gene expression profiling between tumor and normal biopsies to be matched with relevant genes that are related to drug activities.
3302667|NCT01856348|Experimental|1, 25 dihydroxyvitamin D3 intake|This is a single arm study.
3302668|NCT01856374|Active Comparator|Cypher group|
3380692|NCT04523922|Experimental|Oxytocin Treatment Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.~40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session."
3380693|NCT04523922|Active Comparator|Placebo Group|"Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).~Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session."
3302669|NCT01856374|Experimental|Xience group|
3302670|NCT01856374|Active Comparator|Pravastatin group|
3302671|NCT01856374|Experimental|Atorvastatin group|
3302672|NCT01856387||normal pregnancy outcomes|do not expect poor pregnancy outcomes on normal patients
3302673|NCT01856387||adverse pregnancy outcome|high ratio of Neutrophil / lymphocyte ratio may predict preeclampsia eclampsia
3380694|NCT04518748|Experimental|Y-90 SIRT followed by SBRT|Y-90 SIRT followed by SBRT
3380695|NCT04518410|Experimental|Bamlanivimab|Administered by IV infusion.
3380696|NCT04518410|Experimental|BRII-196/BRII-198|Administered by IV infusion.
3380697|NCT04518410|Experimental|AZD7442 (IV)|Administered by IV infusion.
3380698|NCT04518410|Experimental|Placebo (IV)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and use the same method of administration. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3380699|NCT04518410|Experimental|SNG001|Administered by inhalation.
3302674|NCT01856413|Experimental|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
3302675|NCT01856426|Experimental|1- EDP239|EDP239 given once a day.
3302676|NCT01856426|Placebo Comparator|Placebo|1 treatment arm will be placebo, dose given once a day.
3302677|NCT01856426|Experimental|2- EDP239|EDP239 given once a day.
3302678|NCT01856426|Experimental|3-EDP239|EDP239 given once a day.
3302679|NCT01856426|Experimental|4-EDP239|EDP239 given once a day.
3302680|NCT01856439|Other|Long term follow up|Long term follow up of patient's who received ProSavin in previous study
3302681|NCT01856452|Active Comparator|radioisotope|sentinel lymph node operation using radioisotope in the breast cancer patients
3302682|NCT01856452|Experimental|the mixture including indocyanine green|sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients
3302683|NCT01856465||Bariatric surgery of morbid obese|Morbid obese patient who undergo Bariatric surgery with NAFLD (NASH or SS) status
3302684|NCT01856504||CCTA Patient|"Consenting adult patients ≥18 years of age;~Suspected but without known prior history of CAD~Not actively taking heart rate lowering agents at least 48 hours prior to study (e.g., AV nodal blockers such as beta blockers, calcium channel blockers or digoxin)~Glomerular filtration rate >60 ml/min~CCTA and ICA within 1 week of each other with no interscan event (e.g., myocardial infarction or coronary revascularization)"
3302685|NCT01856517|Placebo Comparator|placebo|saline administration over 24 h following full optimization of patient according to current guidelines
3302686|NCT01856517|Active Comparator|clonidine|clonidine 1 mcg.kg-1.h-1 over 24 h following full optimization of the patient according to current guidelines
3302687|NCT01856556|Experimental|NRX-1074, 1 mg|1 mg IV
3302688|NCT01856556|Placebo Comparator|Placebo|Saline
3302689|NCT01856556|Experimental|NRX-1074, 5 mg|5 mg IV
3302690|NCT01856556|Experimental|NRX-1074, 10 mg IV|10 mg
3302691|NCT01856556|Experimental|NRX-1074, 50 mg IV|50 mg
3302692|NCT01856556|Experimental|NRX-1074, 25 mg PO|25 mg
3302693|NCT01856556|Experimental|NRX-1074, 125 mg PO|125 mg
3302694|NCT01856621|Active Comparator|Seretide Diskus and charcoal|Single-dose of Seretide Diskus (50/500 mcg/inhalation) and charcoal
3302695|NCT01856621|Active Comparator|Seretide Diskus|Single-dose of Seretide Diskus (50/500 mcg/inhalation)
3302696|NCT01856621|Experimental|SF Easyhaler and charcoal|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation) with charcoal
3302697|NCT01856621|Experimental|SF Easyhaler|Salmeterol/fluticasone Easyhaler (50/500 mcg/inhalation)
3302698|NCT01856634|Experimental|Group 1: 12 to 17 years of age|Group 1: 100 mg Delamanid BID for 10 days + OBR
3302699|NCT01856634|Experimental|Group 2: 6 to 11 years of age|50 mg Delamanid BID for 10 days + OBR
3302700|NCT01856634|Experimental|Group 3: 3 to 5 years of age|25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
3302701|NCT01856634|Experimental|Group 4: Birth to 2 years of age|"Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~Patient's > 10 kg will receive DPF 10 mg BID + OBR~Patient's > 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~Patients ≤ 8 kg will receive DPF 5 mg QD + OBR"
3302702|NCT01856647||lean (BMI≤ 24.9 Kg/m2)|Adipose tissue biopsy (fat biopsy) in 9 lean (BMI≤ 24.9 Kg/m2)
3302703|NCT01856647||obese (BMI= 30-40 Kg/m2)|9 obese (BMI= 30-40 Kg/m2)
3302704|NCT01856647||psoriatic lean|9 psoriatic lean
3302705|NCT01856647||psoriatic obese|9 psoriatic obese
3302706|NCT01856660|Experimental|Low-Fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
3302707|NCT01856660|Experimental|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow a low-carbohydrate diet where the daily carbohydrate target is 50g/d. There is no energy restriction. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
3302708|NCT01856699||Study Group|Patients with cortical superficial siderosis and possible or probable cerebral amyloid angiopathy meeting the modified Boston criteria.
3302709|NCT01856699||Control Group|Patients with possible or probable cerebral amyloid angiopathy meeting the classic Boston criteria but without any cortical superficial siderosis.
3302710|NCT01856725|Active Comparator|MultiPoint Pacing programming based on hemodynamics|"CRT device implant with MultiPoint Pacing~Hemodynamic measurements for CRT device programming"
3302711|NCT01856725|Experimental|MultiPoint Pacing programming without hemodynamics|"CRT device implant with MultiPoint Pacing~CRT device programming without hemodynamics"
3302712|NCT01856738|Placebo Comparator|Placebo|placebo capsule for oral use 6,0 mg BID during 24 months of follow-up
3302713|NCT01856738|Experimental|Rivastigmine|rivastigmine capsule for oral use 6,0 mg BID during 24 months of follow-up
3302714|NCT01856751||haemophilia|Patients with acquired haemophilia. Patients with haemophilia A with inhibitor.
3302715|NCT01856777|Other|High sensitivity urine pregnancy test|Standard medical care and high sensitivity urine pregnancy test
3302716|NCT01856777|Other|Semi-quantitative panel test|Standard medical care and semi-quantitative panel test
3302717|NCT01856803|Active Comparator|routine prophylaxis|In this group, CSA plus MMF and MTX adopted as prevention of GVHD.
3302718|NCT01856803|Experimental|ATG prophylaxis|In this group,ATG+MMF+CsA+MTX was adopted as prevention of GVHD
3302719|NCT01856816|Experimental|Meal Pattern Treatment A|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group A.
3302720|NCT01856816|Experimental|Meal Pattern Treatment B|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group B.
3302721|NCT01856816|Other|Treatment Group C|A large vegetable salad (262g) and with a moderate amount of canola oil (8g) was consumed over a two meal period as designated by treatment group C.
3302722|NCT01856829|Placebo Comparator|Control|Control participants will take placebo capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
3302723|NCT01856829|Experimental|Omega-3|Omega-3 participants will take capsules daily for 4 weeks before and for the duration of the test. At week 4, participants will undergo a training protocol consists of a series of five sessions consecutively performed at intervals of 3 to 7 days. Taking products will be made more specifically 30 minutes before the start of the sessions.
3302724|NCT01856842|Active Comparator|Interlock fibered IDC Occlusion System|Pulmonary angiography and embolotherapy technique using Interlock (TM) fibered IDC Occlusion System(TM)
3302725|NCT01856842|Active Comparator|Nestor Coil|Pulmonary angiography and embolotherapy technique using Nestor coils
3302726|NCT01856855|Experimental|Stereotactic Body Radiation Therapy with Integrated Boost|
3302728|NCT01856881|Active Comparator|AMG 876|
3302729|NCT01856881|Placebo Comparator|Placebo|
3302730|NCT01856920|Experimental|A|GI-6207 for 1 year
3302731|NCT01856920|Experimental|B|6 months of surveillance followed by GI-6207 for 1 year
3302732|NCT01856946|Experimental|4,000 IU Vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
3302733|NCT01856959|Experimental|nebulized magnesium sulfate|nebulized magnesium sulfate 150mg and consisted about 5 min,which used only once
3302734|NCT01856959|Experimental|nebulized magnesium sulfate & albuterol|nebulized magnesium sulfate 150mg & albuterol 2.5mg and consisted about 5 min,which used only once
3302735|NCT01856959|Active Comparator|nebulized albuterol|nebulized albuterol 2.5mg and consisted about 5 min,which used only once
3302736|NCT01856972|Experimental|Instrument Assisted Soft Tissue Mobilization|Subjects randomized into this treatment arm will receive Instrument Assisted Soft Tissue Mobilization to the Gastrocnemius/Soleus complex, as well as a standard stretching/ROM protocol
3302737|NCT01856972|Experimental|Rearfoot joint mobilization|Subjects randomized into this treatment arm will receive a rear-foot joint mobilization as well as a standard stretching/ROM protocol
3302738|NCT01856972|Active Comparator|Static stretching/ROM exercises|This is the control group consisting of Static stretching/ROM exercises. No manual intervention is performed with the group. The subjects will perform the standard stretching and ROM protocol
3302739|NCT01856985|Experimental|Misoprostol at clinic|"Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 µg misoprostol buccally (study 1) or 800 µg misoprostol sublingually (study 2) to self administer at home.~Participants will be asked to return to the hospital 14 days later for a follow-up visit."
3302740|NCT01856998|Active Comparator|Diprivan® 20 mg/mL (AstraZeneca)|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
3302741|NCT01856998|Experimental|Propofol 2% (20 mg/mL) MCT Fresenius|"Dosage form: lipid emulsion~Dosage: Initial effect-site target concentration: 5 μg/mL, if necessary increased by 1 μg/mL every 60 seconds until LOER~Frequency: continuously (will be adjusted to keep Bispectral Index (BIS) between 40 and 60, however maintenance target concentration can be increased if a patient needs a BIS <40 with regard to individual condition and the respective surgery)~Duration: Until end of surgery"
3302742|NCT01857011|Experimental|IV Iron|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
3302743|NCT01857011|Active Comparator|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
3302744|NCT01857037|Other|Single arm|Single arm
3302745|NCT01857076|Active Comparator|Clinical|Subject submitted to clinical obesity treatment
3302746|NCT01857076|Active Comparator|Gastric bypass surgery|Subjects submitted to Gastric Bypass Surgery
3302747|NCT01857076|Active Comparator|Surgical ileal transposition with sleeve|Subjects submitted to surgical ileal transposition with sleeve
3302748|NCT01857089|Experimental|Pressure Measurement|
3302749|NCT01857115|Experimental|CCyd|"Treatment schedule for 9 cycles of induction:~Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.~Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.~Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).~Treatment schedule for maintenance until progression or intolerance:~Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15."
3302750|NCT01857128|Experimental|Drawtex Hydroconductive Dressing|Gauze-like dressing placed onto wound
3302751|NCT01857128|Active Comparator|Negative Pressure Wound Therapy|Usual care including vacuum and canister
3302752|NCT01857141|Experimental|dexmedetomidine|
3302753|NCT01857141|Placebo Comparator|normal saline|
3302754|NCT01857154|Active Comparator|Bisphosphonates/Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
3302755|NCT01857154|Active Comparator|Bisphosphonates/Non-Micronized Calcium Carbonate/Vitamin D3|Subjects currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total amount of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
3302756|NCT01857154|Active Comparator|Non-Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 1000 mg of Non-Micronized Calcium Carbonate and 800 IU Vitamin D3.
3302757|NCT01857154|Active Comparator|Micronized Calcium Carbonate/Vitamin D3|Subjects who are not currently being treated with Bisphosphonates will replace any calcium they are currently taking with four Capsules/Day containing a total of 500 mg of Micronized Calcium Carbonate and 800 IU Vitamin D3
3302758|NCT01857167|Experimental|Fish Oil Supplementation|Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.
3302759|NCT01857167|Experimental|Flaxseed Oil Supplementation|Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA
3302760|NCT01857167|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.
3302761|NCT01857180|Experimental|Curriculum|Participants in the curriculum group took part in a structured, comprehensive curriculum consisting of a 1 hour didactic cognitive component, a 1 hour didactic non-technical (team-based skills) component, and 6 hours of structured technical skills practice in peg transfer, intracorporeal suture, and VR simulator tasks. Participants had the opportunity to ask questions and engage in discussion with experts after the didactic sessions, and received subjective feedback from circulating residents in addition to objective feedback in the technical skills tasks.
3302762|NCT01857180|No Intervention|Self-directed|Participants in the control (self-directed) group took part in 8 hours of self-directed learning with written materials for cognitive and non-technical skills components and unstructured surgical simulation practice of technical skills with only objective feedback from the simulator for the VR tasks or time for the peg transfer and intracorporeal suture tasks.
3302763|NCT01857193|Experimental|L-R-E arm|Participants who took ribociclib (LEE011), everolimus (RAD001) and exemestane triple combination
3302764|NCT01857193|Experimental|L-E arm|Participants who ribociclib (LEE011) and exemestane double combination
3302765|NCT01857219|Experimental|Role of Tai Chi in Fibromyalgia|"Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM.~In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. For the remaining sessions, the subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm-up and self-massage and a review of Tai Chi principles; (2) Tai Chi movement; (3) breathing techniques; (4) relaxation. Each component of the program derives from classical Yang style Tai Chi 108 posture.30"
3302766|NCT01857245|Experimental|Modified Directly Observed Therapy (mDOT)|In our mDOT model, pegylated interferon is administered once weekly, and one daily dose of oral medication is administered at the methadone window.
3302767|NCT01857245|Experimental|Concurrent Group Treatment (CGT)|In our CGT model, patients initiate HCV treatment within a once weekly treatment group which provides social support to mitigate fears of side effects, promote efficient education, and deliver weekly injections.
3302768|NCT01857245|Active Comparator|Treatment as Usual|In the TAU arm, subjects will receive all medications monthly (or more often as needed) at the clinic.
3302769|NCT01857284|Experimental|Group 1|Tauroursodeoxycholic Acid Capsules,250mg,tid.
3302770|NCT01857284|Active Comparator|Group 2|Ursodeoxycholate acid capsules, 250mg,tid,
3302771|NCT01857336|Experimental|infusion group|Patients with PGF were planed to infusion peripheral harvest. The peripheral cell harvest was aphaeresis on the fourth or fifth day after mobilization with recombinant human granulocyte colony stimulating factor.
3302772|NCT01857349|Active Comparator|Chlora Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol; Enturia, El Paso, Texas)
3302773|NCT01857349|Active Comparator|Dura Prep|Food and Drug Administration (FDA)-approved, surgical skin preparation solution:DuraPrep (0.7% available iodine and 74% isopropyl alcohol; 3MHealthcare, St. Paul, Minnesota).
3302774|NCT01857375||Group receiving insulin via vial/syringe|This group will receive their insulin via vial/syringe
3302775|NCT01857375||Insulin Pen|Patients receiving insulin via insulin pen
3302776|NCT01857388|Experimental|ParentCorps|Teachers from Intervention schools will receive ParentCorps training and support.
3302777|NCT01857388|No Intervention|Wait List Control|Teachers from control schools will not receive training and support in Year 1, but will receive training and support in Year 2.
3302778|NCT01857401||Observational study|Blood draw only, observational study
3302779|NCT01857440||Subjects with glaucoma (Cases)|This group will consist of patients with glaucoma who are under care at the Ohio State University Havener Eye Institute.
3302780|NCT01857440||Subjects without glaucoma (Controls)|This group will consist of matched controls who are free of glaucoma and other complications, and who received a comprehensive eye examination at the Ohio State University College of Optometry.
3302781|NCT01857453|Experimental|teatment arm|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
3302782|NCT01857466|Experimental|Floseal|In the Floseal group, the sites of bleeding were covered with Floseal under direct vision with a laparoscopic applicator and ovarian cortex was closed on itself and waited for 2 minutes for Floseal to act. Then, subsequently bleeding sites were reexamined with irrigation.
3302783|NCT01857466|Active Comparator|Bipolar coagulation|In the bipolar group, hemostasis of the ovarian parenchyma was achieved with selective minimal (20-30 watt current) bipolar coagulation without excessive coagulation of surgical defect to avoid damaging the ovary.
3302784|NCT01857479|Active Comparator|Inhaled budesonide|Nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]
3302785|NCT01857479|Experimental|Inhaled budesonide plus amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
3302786|NCT01857492|Sham Comparator|SHAM|We will apply sham tDCS on the primary motor cortex. We will use the same montage and parameters of active tDCS. However the current will be applied for 30 seconds in the beginning of the procedure and after that the current is turned off. This parameter for sham stimulation was chosen based on previous studies that have shown that perceived sensations on the scalp such as tingling usually fade out in the first 30 seconds of tDCS. It should be noted that less than 3 minutes of tDCS induces no effects on cortical excitability [29] and also using 30 seconds of sham is a reliable method of blinding as shown by a randomized controlled study [30]. Subjects will also meditate while receiving stimulation
3302787|NCT01857492|Active Comparator|ACTIVE|"A 1x1 Low-intensity DC Stimulator such as the Soterix Medical Inc. (Model 1224-B New York, NY, USA) or an equivalent device will be used to deliver direct current through 35cm² saline-soaked electrodes. The anodal electrode will be placed over the left primary motor cortex (M1) while the cathodal electrode will be placed over the contralateral supra-orbital area. Primary motor cortex will be localized using the 10/20 EEG system (C3 or C4) and this is a reliable method for the technique of tDCS [5]. During active tDCS, a 2mA constant current will be delivered for 20 minutes while the subject meditates. The primary motor cortex is a reliable entry port to modulate dysfunctional activity in pain-related neural networks."
3302788|NCT01857505||Direct Anterior Approach hip replacement|Single surgeon series of 105 consecutive patients who underwent hip replacement via the direct anterior approach on a fracture table
3302789|NCT01857505||Posterior Approach Hip Replacement|105 consecutive patients previously operated on by a less invasive posterior approach at the same institution. These surgeries occurred prior to March, 2010.
3302790|NCT01857518|Other|Depressed adolescents Group|Adolescents with a major depressive episode diagnosis
3302791|NCT01857518|Other|Healthy adolescent control Group|Healthy adolescents recruited from general population
3302792|NCT01857544|Experimental|Aflibercept 2.0mg|Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
3302793|NCT01857557|Experimental|Aerobic Exercise|Fitness program for migraine patients in addition to usual headache care.
3302794|NCT01857557|No Intervention|Control Group|Patients receiving usual headache care but no exercise program
3302795|NCT01857570||Adult, clinical suspicion fractures wrist or carpus|- Patients (18 years and older) who are referred to our hospital for conventional radiography of the wrist and carpus
3302796|NCT01857596|Experimental|Bupropion -> Lorexys LO -> Lorexys HI|Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys
3302797|NCT01857609|Experimental|Metformin only|metformin 750mg(D-1), metformin 500mg (D1)
3302798|NCT01857609|Experimental|Metformin and Pantoprazole|pantoprazole 40mg(D-2)/ metformin 750mg + pantoprazole 40mg(D-1)/metformin 500mg + pantoprazole 40mg(D1)
3302799|NCT01857609|Experimental|Metformin and Rabeprazole|rabeprazole 20mg(D-2)/metformin 750mg+rabeprazole 20mg(D-1)/metformin 500mg+rabeprazole 20mg(D1)
3302800|NCT01857648|Experimental|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
3302801|NCT01857648|No Intervention|Control|Control group.
3302802|NCT01857661|Other|control|hearing aid without an integrated sound generator
3302803|NCT01857661|Experimental|sound generator|hearing aid with an integrated sound generator
3302804|NCT01857687||patients with coronary artery stenosis|
3302805|NCT01857700|Experimental|Conditional economic compensation|A scratch off card will be used to randomly determine which of the compensations will be offered: compensation for transport cost, compensation for lost wages, or compensation for transport cost and lost wages
3302806|NCT01857700|Placebo Comparator|Standard of Care|
3302807|NCT01857726|Experimental|The TACE/TACI combination group|Transarterial chemoembolization with doxorubicin/transarterial chemoinfusion with cisplatin combination
3302808|NCT01857726|Active Comparator|The TACE-only group|Transarterial chemoembolization with doxorubicin
3302809|NCT01857752|Experimental|temozolomide|
3302810|NCT01857765|Active Comparator|Standard of Care|
3302811|NCT01857765|Experimental|Rehabilitation|
3302812|NCT01857778||Lactating Women|
3302813|NCT01857791|Experimental|multidisciplinary, behavior modification|
3302814|NCT01857804|Experimental|antibiotics and local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with chlorhexidine gluconate 0,2%
3302815|NCT01857804|Experimental|antibiotics without local antiseptics|systemic antibiotics (2 x 750mg amoxicillin/day) + implant surface decontamination with saline
3302816|NCT01857804|Experimental|local antiseptics no antibiotics|no systemic antibiotics + implant surface decontamination with chlorhexidine gluconate 0,2%
3302817|NCT01857804|Placebo Comparator|no antibiotics and no local antiseptics|no systemic antibiotics + implant surface decontamination with saline
3302818|NCT01857817|Experimental|VT-122 with physician's choice therapy|Participants will receive oral doses of 66 mg propranolol and 680 mg etodolac daily. Propranolol will be administered 44 mg with breakfast and 22 mg in the mid-afternoon (3PM). Etodolac will be administered 340 mg with breakfast and 340 mg with dinner.
3302819|NCT01857817|Placebo Comparator|Placebo with physician's choice therapy|Participants will receive physician's choice therapy as the standard of care as well as the placebo capsules that are of the same weight as propranolol and etodolac.
3302820|NCT01857830|Experimental|Meditation Retreat Group|Participants in this group will participate in a 6 day meditation retreat at the La Costa Resort and Spa in Carlsbad, CA. They will be self-selected to participate in the retreat or are novice meditators randomized into this retreat.
3302821|NCT01857830|Active Comparator|Relaxation/Control Group|Participants in this group will stay at La Costa Resort and spa for a 6 day period and will participate in the Active Comparator Relaxation Group activities (i.e. series of lectures on longevity and health, shared meals, and other leisure activities).
3302822|NCT01857843|Experimental|ZES group|
3302823|NCT01857843|Active Comparator|EES group|
3302824|NCT01857843|Experimental|Vytorin group|
3302825|NCT01857843|Active Comparator|Mevalotin group|
3302826|NCT01857856|No Intervention|No treatment|no medical treatment
3302827|NCT01857856|Active Comparator|Eplerenone|Eplerenone (Inspra, 50 mg for 3 years once daily) oral, film-coated tablet 50 mg for 3 years once daily
3302828|NCT01857895|Experimental|Exenatide infusion in Part A|Subjects in Part A will receive exenatide as a subcutaneous infusion at a constant rate for 24 hours.
3302829|NCT01857895|Experimental|Exenatide infusion in Part B|Subjects in Part B will receive exenatide with daily increases in the infusion rate.
3302830|NCT01857908||Abiraterone acetate|All patients will be receiving abiraterone acetate as per standard of care
3302831|NCT01857921|Active Comparator|Pravastatin group|
3302832|NCT01857921|Experimental|Combination of Atorvastatin and trimetazidine group|
3302833|NCT01857934|Experimental|Treatment|"Participants receive IV hu14.18K322A with each course of chemotherapy (cyclophosphamide, topotecan, cyclophosphamide, doxorubicin, vincristine, cisplatin, and etoposide). Mesna will be given prior to and after cyclophosphamide infusion. Peripheral blood stem cell harvest (PBSC) and surgical resection of primary tumor will be performed, if feasible. Intensification therapy includes busulfan, melphalan, and levetiracetam with peripheral blood stem cell transplantation. A course of hu14.18K322A with natural killer cell infusion will be given to consenting participants. Radiation therapy will follow PBSC transplant with the exception of any patient requiring emergent radiotherapy. MRD treatment includes hu14.18K322A, G-CSF, GM-CSF, interleukin-2 and isotretinoin.~Cells for infusion are prepared using the CliniMACS System."
3302834|NCT01857947|No Intervention|AECOPD Mr proADM|Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study
3302835|NCT01857960||Adolescents|Acne survey among Mexican adolescents
3302836|NCT01857999|Experimental|Losartan|Losartan 50 mg bid orally
3302837|NCT01857999|Placebo Comparator|Placebo|Placebo 1 pill bid orally
3302838|NCT01858012||HCV infection|patients with hepatitis C infection
3302839|NCT01858012||non-HCV infection|healthy controls
3302840|NCT01858025|Experimental|Pencil Beam Scanning Radiation|Pencil Beam Radiation daily, Monday-Friday, for 5-6 weeks Mitomycin-C via IV on Days 1 and 29 5-Fluorouracil via infusion pump over 4 days, starting Day 1 and 29 of chemotherapy
3302841|NCT01858038|No Intervention|Control|The scar will be randomized and demarcated as the following: (1) treatment site and (2) control site (no treatment, no intervention) The treatment condition assigned for each site will be kept the same for all following treatment sessions
3302842|NCT01858038|Experimental|Intervention Fractional Laser treatment|Intervention: An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
3302843|NCT01858051|Active Comparator|Cholecalciferol Bolus Dose|70 patients will receive a bolus pre-operative oral dose of 150,000 IU cholecalciferol 3-7 days before surgery
3302844|NCT01858051|Active Comparator|Cholecalciferol Divided Dose|70 patients will receive an oral 100,000 IU cholecalciferol dose 3-7 days before surgery and an additional oral 50,000 IU cholecalciferol dose on post-operative day 1
3302845|NCT01858051|Placebo Comparator|Sugar Pill|35 patients will receive a placebo pill orally 3-7 days before surgery
3302846|NCT01858064|Experimental|OROS-MPH|OROS-MPH is administered in capsule form daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90mg/day.
3302847|NCT01858077|Active Comparator|ABSORB BVS™|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
3302848|NCT01858077|Active Comparator|XIENCE™|XIENCE PRIME everolimus eluting coronary stent system and the XIENCE Xpedition everolimus eluting coronary stent system
3302849|NCT01858090|Placebo Comparator|Control Group|Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
3302850|NCT01858090|Active Comparator|Group Fentanyl|Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
3302851|NCT01858090|Active Comparator|Group sufentanil|Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)
3302852|NCT01858116|Experimental|[68Ga]ABY-025|
3302853|NCT01858129|Experimental|Inhaled steroids (Budicort)|Inhaled Budicort
3302854|NCT01858129|Placebo Comparator|Control|Inhaled NS 0.9%
3302855|NCT01858142|Experimental|Preparation intervention|The parental presence decision tool will be delivered as an App shown to families using an iPAD and a set of headphones. This App will include information on what to expect in the operating room as well as the role of the parents. The App incorporates the basic principles of other effective perioperative preparation interventions (e.g., providing both sensory and procedural information) and is tailored to the local context. In addition to preparatory information, the App will also inform parents of the role of parent anxiety on children's outcomes in the operating room.
3302856|NCT01858142|Placebo Comparator|Standard preparation|In standard preparation condition, treating nurses and anesthesiologists will provide information to parents as they standardly do when parents are present at induction; this includes information on logistical issues and safety in the operating room (e.g., where to stand, how to put on gown) and risks of anesthesia induction. Additionally, parents in the standard preparation condition will view a summary of this standard information as text on an iPAD.
3302857|NCT01858155|Experimental|Melatonin|
3302858|NCT01858168|Experimental|One|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Ewing sarcoma
3302859|NCT01858168|Experimental|Two|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle Irinotecan, given by IV once per day on days 1-7 of each cycle
3302860|NCT01858168|Experimental|Three|Olaparib, taken orally twice per day on days 1-7 (week 1) of each cycle Temozolomide, taken orally once per day on days 1-7 (week 1) of each cycle for patients with Rhabdomyosarcoma
3302861|NCT01858181|Experimental|Cohort 1|SC ocaratuzumab 40 mg weekly x 4 doses
3302862|NCT01858181|Experimental|Cohort 2|SC ocaratuzumab 80 mg weekly x 4 doses
3302863|NCT01858181|Experimental|Cohort 3|SC ocaratuzumab 80 mg weekly x 8 doses
3302864|NCT01858207|Active Comparator|TACE+ RFA|"This arm will be conventional TACE(Transcatheter Arterial Chemoembolization) plus RFA(radiofrequency ablation.~use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor."
3302865|NCT01858207|Active Comparator|RFA|Recent advances in local ablation are aimed to expand the ablation size (> 3cm in diameter) in a minimal session by utilizing the switching RF controller and simultaneous 2 or 3 RF electrodes placement. The procedure of RFA was according to manufacture algorithm. RFA was performed within 7 days after TACE because the embolization effect in reducing blood flow will be not evident afterwards.
3302866|NCT01858220||Video capsule examinee|Every subject having capsule endoscopy for any indication
3302867|NCT01858233|Experimental|Intensive Behavioral Modification|intensive dietary counseling, increased activity, lactation consult
3302868|NCT01858233|No Intervention|Routine care|standard dietary counseling
3302869|NCT01858246|Active Comparator|Bonebridge|Implantation with a Bonebridge
3302870|NCT01858246|Active Comparator|Bone Anchored Hearing Aid|Implantation with a Bone Anchored Hearing Aid
3302871|NCT01858259||cyclophosphamide|Patients receiving cyclophosphamide
3302872|NCT01858259||azathioprine|Patients receiving azathioprine
3302873|NCT01858259||mycophenolate mofetil|Patients receiving mycophenolate mofetil
3302874|NCT01858259||methotrexate|Patients receiving methotrexate
3302875|NCT01858259||no therapy|Patients receiving no immunosuppressive therapy
3302876|NCT01858272|Experimental|H5.020CMV.PDGF-b and limb compression bandage|This study will use a standard, three-six Phase I dose escalation scheme. Three subjects will be treated at the lowest dose. If zero of three experience dose limiting toxicity (DLT), three new subjects will be treated at the next higher dose. If one of three of the subjects at the lowest dose had experienced DLT, then three more for a total of six will receive the lowest dose. Of the six subjects who received the lowest dose, if only one of six experience DLT, then the dose will be escalated to the next higher dose. However, if more than one of six experiences DLT (i.e., any of the additional subjects), then the MTD will be declared and the next lower dose will be the recommended dose for future trials.
3302877|NCT01858285||Epilepsy, genetics|
3302878|NCT01858298|Experimental|pulpectomy|The technique of pulpectomy will be performed in one appointment according to clinical guidelines and followed by a composite resin crown.
3302879|NCT01858298|Experimental|tooth extraction|The technique of tooth extraction of primary teeth will be performed according to clinical guidelines
3302880|NCT01858311||Placebo vehicle|(2) placebo capsules following AM meal and (2) placebo capsules following PM meal.
3302881|NCT01858311||Tocotrienol capsules (400 mg)|(2) 100mg TCT capsules following AM meal and (2) 100mg TCT capsules following PM meal.
3302882|NCT01858311||Tocotrienol Capsules (800 mg)|(2) 200mg TCT capsules following AM meal and (2) 200mg TCT capsules following PM meal.
3302883|NCT01858324|Experimental|educational tools|Subjects will receive at time 0 the educational tools (pamphlet-including a graphic-based summary, a magnet and a 12 minutes video). They will then have to answer a questionnaire 1 month later about knowledge, anxiety and satisfaction.
3302884|NCT01858324|No Intervention|Usual antenatal care|Subjects in this group will not receive any more educational tools that what is generally offered in routine antenatal care.
3302885|NCT01858337|Experimental|green beans group,|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With green beans every other day and another vegetable on the days in between.
3302886|NCT01858337|Experimental|Artichoke group|1 of the 2 vegetable groups. The infants were weaned only with vegetables. With Artichoke every other day and another vegetable on the days in between
3302887|NCT01858337|Active Comparator|Apple group|1 of the 2 fruit groups. The infants were weaned only with fruits. With Apple every other day and other fruits on the days in between
3302888|NCT01858337|Active Comparator|Plums group|1 of the 2 fruit groups. The infants were weaned only with vegetables. With Plums every other day and other fruits on the days in between
3302889|NCT01858350|Other|Active Music Therapy|Active Music Therapy: A music therapist plays music to patients for 15 minutes
3302890|NCT01858350|Other|Passive Music Therapy|Passive Music Therapy: A music therapist plays a compact disc (CD) to patients for 15 minutes
3302891|NCT01858350|No Intervention|No intervention|
3302892|NCT01858350|Other|Distraction Therapy|Distraction Therapy: A child life specialist plays with patients for 15 minutes
3302893|NCT01858402|Active Comparator|Paracetamol|15 mg/kg paracetamol, IV (in the vein)(premixed with 0.9% sodium chloride to a total of 50 ml)single dose
3302894|NCT01858402|Active Comparator|Dipyrone|15 mg/kg IV (in the vein)dipyrone received (premixed with 0.9% sodium chloride to a total of 50 ml), single dose
3302895|NCT01858415|Experimental|Single arm|
3302896|NCT01858441|Other|Abiraterone Acetate|
3302897|NCT01858454|Experimental|HALS for myomectomy|Hand-assisted laparoscopic surgery for myomectomy
3302898|NCT01858454|Active Comparator|Open myomectomy|Open surgery for myomectomy
3302899|NCT01858467|Experimental|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway (Airway Device) with gastric tube. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
3302900|NCT01858467|Active Comparator|Endotracheal Intubation|Endotracheal intubation (Airway Device) using Macintosh Laryngoscope with tracheal tube with gastric tube insertion after placement. Preoxygenation, rapid sequence induction and cricoid pressure. Propofol 2 to 3mg/kg with 100mg succinylcholine. General anaesthesia with sevoflurane.
3302901|NCT01858480|Active Comparator|D-ribose|D-ribose administered via peripheral intravenous for 24 hours followed by oral D ribose dosing for 3 months versus placebo in subjects with CHF who have been stabilized following hospitalization for acute decompensation.
3302902|NCT01858480|Placebo Comparator|Placebo|Placebo dosage form designed to mock active.
3302903|NCT01858493|Experimental|Continence promotion group education|A single 1-hour continence promotion group education workshop, facilitated by the research coordinator, aimed at changing knowledge and beliefs about urinary incontinence and different treatment options. An evidence-based self-management tool will be distributed at the end of the workshop.
3302904|NCT01858493|Sham Comparator|Sham health lecture|A single 1-hour group education workshop on other health topics of concern to older women such as memory, hearing, insomnia
3302905|NCT01858506|Experimental|I-ACE intervention arm|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
3302906|NCT01858506|Active Comparator|Standard lifestyle advice arm|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
3302907|NCT01858519||CF patients receiving PERT|Cystic fibrosis (CF) patients receiving pancreatic enzyme replacement therapy (PERT)
3302908|NCT01858519||Matched control patients unexposed to PERT|Patients unexposed to pancreatic enzyme replacement therapy (PERT); matched on age and location of residence to PERT-exposed CF patients with chronic disease.
3302909|NCT01858571|Experimental|Low dose chemotherapy|"Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
3302910|NCT01858571|Placebo Comparator|Best supportive care|"Placebo: Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration)~Capsules of same size and color as used in metronomic therapy Best supportive care~Management of pain as per WHO standard for pain management"
3302911|NCT01858584|Experimental|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
3302912|NCT01858584|Active Comparator|Thickened Formula|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
3302913|NCT01858584|No Intervention|control group|
3302914|NCT01858597||gestational diabetes mellitus|Those women (subjects) with gestational diabetes mellitus
3302915|NCT01858597||control|Those healthy pregnant women
3302916|NCT01858610|Other|Irbesartan alone|Irbesartan 300 mg alone
3302917|NCT01858610|Other|Hydrochlorothiazide 25 mg alone|Hydrochlorothiazide 25 mg alone
3302918|NCT01858610|Other|Irbesartan 300 mg + Hydrochlorothiazide 25 mg|Irbesartan 300 mg + Hydrochlorothiazide 25 fixed dose combination
3302919|NCT01858623|Other|Losartan / Hydrochlorothiazide100 mg/25mg|Losartan / Hydrochlorothiazide100 mg/25mg fixed dose combination
3302920|NCT01858623|Other|Losartan 100 mg|Losartan 100 mg alone
3302921|NCT01858623|Other|hydrochlorothiazide 25 mg|hydrochlorothiazide 25 mg alone
3302922|NCT01858649|Active Comparator|Folfox: oxaliplatin +leucovorin+ 5FU|FOLFOX (oxaliplatin +leucovorin+ 5FU) +bevacizumab+ metastases resection
3302923|NCT01858649|Active Comparator|FOLFIRI: irinotecan+leucovorin+5FU|FOLFIRI (irinotecan+leucovorin+5FU) +bevacizumab +metastases resection
3302924|NCT01858662|Active Comparator|oxaliplatin +leucovorin L+5FU+ cetuximab|oxaliplatin +leucovorinL+5-Fluorouracile +cetuximab+'Metastases Resection ( multiple steep surgery possible)
3302925|NCT01858662|Active Comparator|Irinotecan+ + leucovorinL +5-Fluorouracil +cetuximab|Irinotecan+ + leucovorinL +5-Fluorouracile + cetuximab +'Metastases Resection ( multiple steep surgery possible)
3302926|NCT01858675|Experimental|Biomarkers, total blood volume|
3302927|NCT01858688|Experimental|Accuracy of multi-parametric MRI relative to prostate biopsy|Determine the sensitivity and specificity of MP-erMRI relative to repeat 12 core TRUS biopsy for classifying upgrading of disease extent or Gleason grade in men considering AS.
3302928|NCT01858714|Active Comparator|Behavior Therapy (BT)|"Active Comparator: Behavior Therapy~Behavioral treatment strategies will be utilized to facilitate adherence to the treatment goals in all three treatments. Participants in the BT condition will receive only the BT intervention. Strategies that will be emphasized are listed below:~Self monitoring Stimulus control Changing eating behaviors Goal setting Problem solving Social support Cognitive restructuring Relapse prevention"
3302929|NCT01858714|Experimental|Behavior Therapy + Environment|Participants will receive standard behavioral therapy with an emphasis on environmental strategies.
3302930|NCT01858714|Experimental|Acceptance-based BT + Environment|Participants will receive acceptance-based behavioral therapy with an emphasis on environmental strategies.
3302931|NCT01858727|Active Comparator|forced air warming group|30 minutes before the preoperative will use forced air warming.
3302932|NCT01858727|No Intervention|control group|do not active heating group
3302934|NCT01858779||Study-cohort|"Patients after ischemic stroke without a history of atrial fibrillation will perform measurements of peripheral pulse three times daily and in case of symptomatic arrhythmic episodes. Results will be entered into a diary which will be send to the center every month. In parallel to the measurements, patients will transmit ECGs via a mobile ECG recorder to the study center.~At 3 and 6 months after inclusion patients will be evaluated using 72h holter ECG. During the whole study period AEs as well as SAEs and changes in medications are recorded."
3302935|NCT01858792||Baseline Health-Related Quality of Life (HRQOL)|Quality of life assessment tools were similar across the treatment groups and indicated that there was impairment in quality of life of subjects in the Low C+anti-dsDNA Population
3302936|NCT01858792||SLE Medication Usage at Baseline|All subjects in the Low C+anti-dsDNA Population
3302937|NCT01858805||detection of circulating tumors cells|This prospective, single-institution study conducted at the University Hospital Hamburg-Eppendorf (Hamburg, Germany) enrolled 123 patients with ECs that were initially considered resectable. Only patients with histologically proven EC were included. Peripheral blood samples for CTC analysis were collected immediately before surgery.
3302938|NCT01858818||healthy 18 year old males|
3302939|NCT01858831|Experimental|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
3302940|NCT01858831|Active Comparator|Atovaquone 750 mg|Atovaquone 750 mg
3302941|NCT01858831|Active Comparator|Atovaquone 1500 mg|Atovaquone 1500 mg
3302942|NCT01858844|Active Comparator|CHEST COMPRESSION TECHNIQUE 2|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR(respiratory rate)(timer for 1 minute); HR (heart rate) and SpO2(oxygen saturation) through pulse oximetry in infants without atelectasis.
3302943|NCT01858844|Experimental|CHEST COMPRESSION TECHNIQUE|The CCT was held only once. Prior to the start of data collection the patients were placed in supine position, with the slope of the headboard of the bed in 30 degrees for collection of signs of respiratory distress (runs), RR (timer for 1 minute); HR and SpO2 through pulse oximetry in infants with atelectasis.
3302944|NCT01858857||Geriatric psychiatric in patients|
3302945|NCT01858870||Lacosamide|patients with Partial Crisis of epilepsy treated with Lacosamide for at least 12 months
3302946|NCT01858883|Experimental|itacitinib, gemcitabine, nab-paclitaxel, filgrastim|
3302947|NCT01858896|Active Comparator|Glucagon-Like Peptide -1 (GLP-1) infusion|Infusion of GLP-1 during experimental period
3302948|NCT01858896|Placebo Comparator|Saline Infusion|Saline infusion during experimental period
3302949|NCT01858909|Placebo Comparator|Control|saline every 12 hours for 28 days
3302950|NCT01858909|Experimental|Melatonin|Oral 30mg/12hours melatonin 28 days
3302951|NCT01858922|Experimental|Rapid Early Responders|All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients with rapid early response (RER) determined by FDG-PET/CT scan after two cycles of ABVE-PC will receive two more cycles of ABVE-PC. If subsequent PET/CT scan indicates a complete response (CR), therapy will stop and regular follow-up will begin. If the subsequent PET/CT for RER patients indicates a partial response, those patients will undergo IFRT.
3302952|NCT01858922|Experimental|Slow Early Responders|"All patients will have initial treatment utilizing ABVE-PC x2 cycles. Those patients determined to have a slow early response (SER) determined by PET/CT scan after two cycles of ABVE-PC will receive 2 courses of DECA. If after PET/CT, the patient has a partial or complete response, then 2 additional courses of ABVE-PC will be given. If subsequent PET/CT scan indicates PR or CR, those patients will then undergo IFRT.~If stable or progressive disease is found at either PET/CT scan, the patient will be taken off-study and follow up will begin."
3302953|NCT01858935|Experimental|ND-L02-s0201 Injection 0.03 mg/kg|
3302954|NCT01858935|Experimental|ND-L02-s0201 Injection 0.1 mg/kg|
3302955|NCT01858935|Experimental|ND-L02-s0201 Injection 0.2 mg/kg|
3302956|NCT01858935|Experimental|ND-L02-s0201 Injection 0.4 mg/kg|
3302957|NCT01858935|Experimental|ND-L02-s0201 Injection 0.5 mg/kg|
3302958|NCT01858935|Experimental|ND-L02-s0201 Injection 0.6 mg/kg|
3302959|NCT01858935|Experimental|ND-L02-s0201 Injection 0.8 mg/kg|
3302960|NCT01858935|Placebo Comparator|Placebo|
3302961|NCT01858948|Experimental|Quitiapine plus Omega|Patients will be randomized to EPA+DHA supplements (OmegaRx) for 24 weeks
3302962|NCT01858948|Placebo Comparator|Quetiapine plus Placebo|Patients will be randomized to similar in shape an color placebo supplements (corn oil)
3302963|NCT01858961|Experimental|Group 1|BI 201335 in combination with BI 207127 and ribavirin for 24 weeks
3302964|NCT01858961|Experimental|Group 2|Telaprevir in combination with PegIFN and ribavirin for 24 weeks or 48 weeks
3302965|NCT01858987|Active Comparator|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
3302966|NCT01858987|Experimental|LigaSure Hepatectomy|Liver resection using LigaSure for transection of the parenchyma
3302967|NCT01859000|Experimental|Multidimensional Family Therapy|MDFT is a multi-systems family-based approach (Liddle, 2002a) designed to address the multiple developmental disruptions and symptoms that result from interacting individual, family, peer, and community risk factors (Liddle, 2002a). MDFT assesses and intervenes at multiple levels and in multiple domains of the adolescent's life -- individual, familial and extrafamilial.
3302968|NCT01859000|Other|Group CBT|The group treatment employed in the proposed study is a state-of-the-art peer group-based CBT model. The treatment will be based on established guidelines for CBT therapy for teen substance abuse (CSAT, 1999; Waldron & Kaminer, 2004) as well as trauma (La Greca & Silverman, in press). The treatment adopts a risk and protective factor framework, seeking to reduce substance use both by targeting cognitions about use directly and by focusing on accompanying problem behaviors such as poor academic performance and limited social skills (Hawkins et al, 1992).
3302969|NCT01859026|Experimental|Phase I - Dose Escalation|"For the Phase I portion, patients will start MEK162 by mouth (p.o.) on cycle 1, day 1 and erlotinib on cycle 1, day 2. The MEK162 will be dosed once daily (QD) or twice (b.i.d.), and erlotinib will be dosed daily (QD) on a 28-day cycle.~Phase I will be followed by an expansion Phase Ib."
3302970|NCT01859026|Experimental|Arm A: Dose Expansion|"Phase Ib Arm A: EGFR Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
3302971|NCT01859026|Experimental|Arm B: Dose Expansion|"Phase Ib Arm B: KRAS Mutant Tumor Status. In the phase IB expansion cohort study there are 2 arms based on the presence of the EGFR (Arm A) or KRAS (Arm B) mutation.~The treatments for each arm are the same: MEK162 (2 time a day) and erlotinib (once) daily on 28 day cycles."
3302972|NCT01859039||Egg allergic children|Administration of Live attenuated influenza vaccine
3302973|NCT01859052|Other|Obese migraineurs|Low carbohydrate diet
3302974|NCT01859052|Other|low-fat diet|Obese Migraineurs
3302975|NCT01859052|Other|Controls|Controls receiving AHA diet recommendations
3302976|NCT01859065|Placebo Comparator|Control|Mothers receive routine anticipatory guidance
3302977|NCT01859065|Experimental|Intervention|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
3302978|NCT01859091|Experimental|Fat Reduction|
3302979|NCT01859104|Other|Smartphone Arm|This is a feasibility trial and thus all participants in the study will be provided a smartphone app to assist them in making lifestyle modifications
3302980|NCT01859117|Experimental|3 x 10^6 cells|3 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3302981|NCT01859117|Experimental|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3302982|NCT01859117|Experimental|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3302983|NCT01859117|Experimental|100 x 10^6 cells|100 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
3302984|NCT01859130|Other|Persona TKA|Primary total knee arthroplasty subjects that receive the Zimmer Persona Total Knee System
3302985|NCT01859156||Carbon Monoxide Exposure|
3302986|NCT01859169||Control Group|Group that be administrated biliary drainage only
3302987|NCT01859169||PDT Group|Group that be administrated photodynamic therapy and biliary drainage
3302988|NCT01859182|Experimental|Treatment (selumetinib, Akt inhibitor MK2206)|Patients receive Akt inhibitor MK-2206 PO on days 1, 8, 15, and 22 (days 8, 15, and 22 of course 1) and selumetinib PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3302989|NCT01859221|Experimental|Castration Resistant|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
3302990|NCT01859221|Experimental|Hormone Receptive|There are two different prognostic categories, hormones receptive and castration resistant, that have differing historical disease progression rates. We have therefore stratified the trial so that we can independently monitor the hypothesized improvement provided by radiation therapy in these two groups. Both groups will receive the same radiation modality which is interventional stereotactic radiation with two possible schedules of SBRT and SHRT.
3302991|NCT01859234|Experimental|89Zr-bevacizumab PET scan|all patients included in the study will have a 89Zr-bevacizumab PET scan
3302992|NCT01859260|No Intervention|Control|
3302993|NCT01859260|Experimental|Intervention|CPAP/autopap
3302994|NCT01859273|No Intervention|Standard Care|Standard Care after kidney transplantation
3302995|NCT01859273|Experimental|mHealth|subjects provided with electronic medication tray, electronic blood pressure cuff, and a smart phone.
3302996|NCT01859286||regular sign out process|
3302999|NCT01859338||MRI, CBCT, FBCT|Patients undergo MRI and fan beam CT (FBCT) at baseline, within the first 3 weeks of radiotherapy and between week 4 and 6 of radiotherapy. Patients with lung cancer may undergo 4D cone beam x-ray CT (CBCT) on the same day as the second and third MRI and FBCT.
3303000|NCT01859351|Experimental|WX-037|PI3K inhibitor
3303001|NCT01859351|Experimental|WX-037 in combination with WX-554|PI3K inhibitor in combination with MEK inhibitor
3303002|NCT01859377|Other|Sequence 1|Test Drug (V0498 - A mg) - Reference (Ibuprofen)
3303003|NCT01859377|Other|Sequence 2|Reference (Ibuprofen) - Test drug(V0498 - A mg)
3303004|NCT01859416|Experimental|Oral nutritional supplement|2 * 125 mL low volume, energy and nutrient dense ONS per day (2 * 300 kcal) in addition to usual nutritional care
3303005|NCT01859416|No Intervention|Control|Usual nutritional care
3303006|NCT01859429|Experimental|Stepped Care|Structured stepped requirement of psychosocial support
3303007|NCT01859429|No Intervention|Care as usual|Unstructured requirement of psychosocial support
3303008|NCT01859442|Active Comparator|Exercise group|6 week structured responsive interval exercise training programme
3303009|NCT01859442|Sham Comparator|Control group|Negative, unsupervised, out of hospital control group
3303010|NCT01859455|Experimental|Patient: LGT209 50 mg|50 mg LGT209 subcutaneous (SC) (1 mL injection x 1 site) in statin patients
3303011|NCT01859455|Experimental|Patient: LGT209 300 mg|300 mg LGT209 subcutaneous (SC) (1 mL injection x 2 sites) in statin patients
3303012|NCT01859455|Experimental|Healthy Volunteers: LGT209 300 mg|300 mg LGT209 or placebo subcutaneous (SC) (1 mL injection x 2 sites) in healthy volunteers
3303013|NCT01859455|Placebo Comparator|Patient: Placebo|matching placebo subcutaneous (SC) of LGT209 50 mg or 300 mg in statin patients
3303014|NCT01859455|Placebo Comparator|Healthy volunteers: Placebo|matching placebo subcutaneous (SC) of LGT209 300 mg in healthy volunteers
3303015|NCT01859468|Experimental|Amorphous calcium carbonate|200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
3303016|NCT01859468|Placebo Comparator|StarLac|Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.
3303017|NCT01859481|Placebo Comparator|Placebo|
3303018|NCT01859481|Experimental|Eletriptan HBr 40 mg|
3303019|NCT01859481|Experimental|Eletriptan HBr 80 mg|
3303020|NCT01859520|Experimental|Swim up, density gradient|swim-up and density gradient sperm preparation techniques in male factor infertility and unexplained infertility groups
3303021|NCT01859533|Experimental|Neopuff group|includes 34 newborns showing signs of TTN who received CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
3303022|NCT01859533|No Intervention|Control group|includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010).
3303023|NCT01859546|No Intervention|One time standard verbal counseling|The control group will receive one time standard verbal counseling at the time of initial visit related to EPI vaccination
3303024|NCT01859546|Experimental|SMS Reminders|Short message service (SMS) - SMS reminders for EPI vaccination at 6, 10 and 14 weeks of life sent in the week that these vaccines are due
3303025|NCT01859559|Experimental|Easy Access|This arm will included emergency department patients that are judged to have easy intravenous access in at least one of the upper extremities by the ED technician.
3303026|NCT01859559|Experimental|Difficult Access By Clinician Judgment|This arm will include patients that at least one vein is visible or palpable in one of the upper extremities but either the ED technician and/or ED nurse judges the patient to have difficult intravenous access.
3303027|NCT01859559|Experimental|Non visible and Non palpable|This arm will include patients for whom neither the ED technician nor an ED nurse can identify a visible or palpable vein that is suitable for an intravenous access line in either upper extremity.
3303028|NCT01859585|Experimental|Parecoxib|Parecoxib
3303029|NCT01859585|Experimental|Ketorolac|Ketorolac
3303030|NCT01859585|No Intervention|No medication|No medication
3380700|NCT04518410|Placebo Comparator|Placebo (Inhaled solution)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3303031|NCT01859624|Experimental|Albuterol|This study includes the off-label administration of oral albuterol (4 mg pill) and tracking the effect of motor function at two additional visits, 6 and 12 weeks following the initiation of the study drug. The initial dose of albuterol will be a 4 mg daily for the first 6 weeks. If the 4 mg is well tolerated, the dose will be increased to 8 mg at the 6 week visit.
3303032|NCT01859650||NSCLC patients undergoing RT|
3303033|NCT01859663||Women with a past diagnosis of PCOS|We aim to recruit 120 women with a past diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
3303034|NCT01859663||Women with a history of regular menstrual cycles|We aim to recruit 120 women with a history of regular menstrual cycles. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
3303035|NCT01859663||Women with a history of irregular menstrual cycles|We aim to recruit 120 women with a history of irregular menstrual cycles, and no previous diagnosis of PCOS. An equal number of lean and overweight/obese women will be recruited within this group based on body mass index (BMI; Lean = 18 - 24 kg/m2 and overweight/obese ≥ 25 kg/m2).
3303036|NCT01859689|Experimental|Treatment (image-guided HDR brachytherapy)|Patients undergo 3 fractions of image-guided HDR brachytherapy over 2 days.
3303037|NCT01859728|Experimental|IP (irinotecan and cisplatin)|Irinotecan 65mg/m² D1 and D8 q21 days plus Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
3303038|NCT01859728|Active Comparator|GC (gemcitabine and cisplatin)|Gemcitabine 1000mg/m² D1 and D8 every 21 days plus cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity, with standard hydration and antiemetics.
3303039|NCT01859754||Octagam 5%|Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.
3303040|NCT01859754||Other marketed IVIG product|Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.
3303041|NCT01859767|Experimental|[123I]MNI-672 SPECT|[123I]MNI-672 single photon emission tomography (SPECT)imaging
3303042|NCT01859780|Experimental|Prescription packages (vials and blisters)|"Stage I Prescription vials and wallets (packaging) with three levels of distractor placement (hidden, absent and obvious) will be tested for an effect of placement on selection behavior and time to package selection.~Stage II Prescription vials and wallets (packaging) with and without distractors will be tested for an effect on time to open and number of successful openings."
3303043|NCT01859806|Active Comparator|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
3303044|NCT01859806|Active Comparator|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
3303045|NCT01859819|Experimental|Group B|"De-novo Mature CD 20 + B-NHL excluding PMBL histology. Good Risk FAB Group B includes patients with St. Jude Stages I /II (unresected) and stage III/IV with diagnostic LDH <2 X ULN.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate INDUCTION:Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin CONSOLIDATION: Rituximab, Methotrexate, Leukovorin, Cytarabine"
3303046|NCT01859819|Experimental|Group C, CNS negative|"De-novo Mature CD 20 + B-ALL (> 25% Bone marrow blasts) without CNS involvement.~REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Vincristine, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Prednisone, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, Etoposide, Cytarabine"
3303047|NCT01859819|Experimental|Group C, CNS Positive|"De-novo Mature CD 20 + B-NHL with CNS involvement:~Any L3 blasts in CSF~Cranial nerve palsy (if not explained by extracranial tumor)~Clinical spinal cord compression~Isolated intracerebral mass~Parameningeal extension: cranial and/or spinal REDUCTION: Cyclophosphamide, Vincristine, Prednisone, IT Methotrexate, IT Cytarabine INDUCTION: Rituximab, Methotrexate, Leukovorin, Cyclophosphamide, Doxorubicin, IT Methotrexate, IT Cytarabine, IT Liposomal ARA-C, Vincristine CONSOLIDATION: Rituximab, Cytarabine, Etoposide MAINTENANCE: Vincristine, Cyclophosphamide, Methotrexate, Leukovorin, Doxorubicin, IT Liposomal ARA-C,"
3303048|NCT01859832||Enrolled participants|"All participants enrolled in this study will have been previously consented to the study entitled, A Comparison of Effects of Standard Dose vs Low Dose Advagraf with Il-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB-based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response. This is an observational study with only one group/cohort in which all participants have bloodwork collected pre-transplant and at various time points post-transplant and these samples are analyzed using the Cylex ImmuKnow Assay."
3303049|NCT01859845|No Intervention|Control Study Arm|The control participants will first interact with the simulated melanoma back model to learn clinical unaided visual inspection skills and then view a passive image projected onto a screen for dermoscopy learning. Remediation of inappropriate clinical decisions will be carried out by the research coordinator and is based on predefined feedback consistent across both arms of the study. Along with the projected images, the coordinator will provide each control participant with worksheets for the clinical Asymmetry, Border, Color, Diameter (ABCD) and Dermoscopy 3-point check list. A copy of the completed worksheet will be made at the end of the workshop.
3303050|NCT01859845|Experimental|smartphone|Each participant in the educational intervention arm will have access to a smartphone with a preloaded android software package. The smartphone software allows the participant to visualize a dermoscopic image of the pigmented lesion at the surface of the simulated melanoma model. Participants are given the freedom to navigate through the program via the smartphone to learn at their own pace with reinforcement of correct clinical management decisions and correction of weaknesses. The software content is limited to the dermoscopy information available to the positive control arm through the coordinator and the dermoscopic images projected onto the screen, thus a comparison of retention rates across both arms is possible.
3303051|NCT01859858|Experimental|curcumin + irinotecan (part 1)|Oral Curcumin (1, 2, 3,or 4 grams per day) for 4 days prior to irinotecan + 200 mg/m2 irinotecan IV, days 1 and 15
3303052|NCT01859858|Experimental|curcumin + irinotecan (part 2)|MTD oral Curcumin as determined in part 1 + 200 mg/m2 irinotecan IV, days 1 and 15
3303053|NCT01859871|No Intervention|Control Arm|Study participants will take the self-administered pre-test and receive the standard of care. After taking the pre-test, control arm participants will be done with study participation for that day and will attend the transplant center's education sessions. All participants will receive a letter and follow-up call at about two weeks later to schedule the final survey. They will take a final survey via telephone about 3 weeks later. The final survey includes the same topics as the pre-test. They will receive a thank you letter and gift card by mail after completing the final survey.
3303054|NCT01859871|Experimental|Website Intervention|Navigate website plus standard of care
3303055|NCT01859884|Experimental|Inform Me: web-based education tool|Intervention will receive the standard of care, the Inform Me intervention, a post-test evaluation, and 1 week recall test.
3303056|NCT01859884|No Intervention|Control Standard of Care|This group receives standard of care with a post test.
3303057|NCT01859897||Optimal therapy|All subjects will be treated by optimal medical therapy and lifestyle modification.
3303058|NCT01859910|Experimental|compression|compression and scrub of lid margin for 5 circles before cataract surgery
3303059|NCT01859910|Active Comparator|control|no compression or scrub of lid margin
3303060|NCT01859936|Experimental|preoperative breast MRI|The intervention is that preoperative MRI breast will be performed in women under 56 years with newly diagnosed breast cancer
3303061|NCT01859936|No Intervention|no MRI breast|The arm type description implies that no MRI breast will be performed to women under 56 years with newly diagnosed breast cancer
3303062|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 1, Faldaprevir, and Ribavirin dosed in combination
3303063|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 2, Faldaprevir, and Ribavirin|PPI-668, BI 207127 Dose 2, BI 207127 Placebo, Faldaprevir, and Ribavirin dosed in combination
3303064|NCT01859962|Active Comparator|PPI-668, BI 207127 Dose 1, and Faldaprevir|PPI-668, BI 207127 Dose 1, and Faldaprevir dosed in combination
3303065|NCT01860014|Active Comparator|Beractant|Beractant (Survanta): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
3303066|NCT01860014|Active Comparator|Poractant alfa|Poractant alfa (Curosurf): 100 mg/kg-intratracheal, just after pulmonary hemorrhage
3303067|NCT01860027||Children with reading disabilities|Children diagnosed with reading disabilities (age 7 to 13).
3303068|NCT01860027||Children with eye movement disorders|Children diagnosed with eye movement disorders (age 7 to 13).
3303069|NCT01860027||Control Group|Children with normal reading ability and normal eye movements (age 7 to 13.
3303070|NCT01860053|Experimental|behavioral intervention|
3303071|NCT01860053|No Intervention|no treatment control|
3303072|NCT01860066|Experimental|QVA149|QVA149 study medication kit will contain blister strips and a unique inhaler. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3303073|NCT01860066|Active Comparator|fluticasone/salmeterol|Fluticasone/salmeterol study medication kit will contain an inhaler in the manufacturer's device. Patients will be instructed to inhale their medication twice a day for 12 weeks.
3303075|NCT01860105|Active Comparator|75mg MDCO-157|iv
3303076|NCT01860105|Active Comparator|150mg MDCO-157|iv
3303077|NCT01860105|Active Comparator|300mg MDCO-157|iv
3303078|NCT01860105|Active Comparator|300mg PLAVIX|oral
3303079|NCT01860118||Parkinson's Disease|1) the presence of bradykinesia and either rest tremor or rigidity; 2) asymmetric onset; 3) progressive motor symptoms 4) age at onset 21-99 years.
3303080|NCT01860118||Healthy Control|Healthy controls between ages of 21-99 years and a lack of PD in first-degree blood relatives
3303081|NCT01860131|Active Comparator|Weight Wise Community Modules: Workshops|Groups workshops (10 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
3303082|NCT01860131|Active Comparator|Weight Wise Community Modules: Online|Online modules (13 in total) designed to improve weight management skills and enhance self-efficacy, delivered over 3 months, prior to entering a multidisciplinary bariatric care.
3303083|NCT01860131|No Intervention|Educational Written Materials|"Educational pamphlets about healthy living and tips on self-management strategies.~Delivered by mail 3 months prior to entering a multidisciplinary bariatric care.~This is minimal intervention and considered the control arm."
3303084|NCT01860144||bevacizumab|Patients with metastatic colorectal cancer who accept treatment with chemotherapy and bevacizumab
3303085|NCT01860157|Sham Comparator|Sham H1 Coil|deep rTMS sham treatment
3303086|NCT01860157|Active Comparator|Active H1|deep rTMS active treatment
3303087|NCT01860183|Experimental|MMF 3g daily|
3303088|NCT01860183|Active Comparator|MMF 2 g daily|
3303089|NCT01860196|Active Comparator|Treatment-Placebo Group|Treatment on 0 day Placebo at 5th week
3303090|NCT01860196|Active Comparator|Placebo-Treatment Group|Placebo on 0 day Treatment at 5th week
3303091|NCT01860209|Experimental|Group A|the first polysomnography (PSG) is performed before hemodialysis (HD), followed by a post-HD PSG on the subsequent night
3303092|NCT01860209|Experimental|Group B|the first PSG is performed after hemodialysis (HD), followed by a pre-HD PSG, on the subsequent night
3303093|NCT01860222|Active Comparator|SR|
3380701|NCT04518410|Experimental|AZD7442 (IM)|Administered by IM injection.
3303094|NCT01860222|Experimental|PLAT|
3303095|NCT01860235|Experimental|sextant 1|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (EMLA)
3303096|NCT01860235|Active Comparator|sextant 2|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Injectable anesthesia)
3303097|NCT01860235|Active Comparator|sextant 3|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (2% Benzocaine)
3303098|NCT01860235|Placebo Comparator|sextant 4|Treatment with subgingival scaling and root planing was done in 6 weekly sessions, being the sextant 1 in the randomization for experimental procedures (Placebo)
3303099|NCT01860248|Experimental|Vapocoolant spray|Vapocoolant is administered in 20 centimeters distance for 20 seconds to the patients as anesthetic before ABG.
3303100|NCT01860248|Placebo Comparator|Water spray|The Patients in this arm will receive water spray as anesthetic before ABG.
3303101|NCT01860261|Experimental|Aerobic and Strength Training|Participants in the Aerobic and Strength Training intervention group will receive a standardized aerobic and strength training exercise program for 12 weeks, including paid gym membership, personal training, and 3 workshops in ChiWalkRun technique.
3303102|NCT01860261|No Intervention|Control (delayed onset of intervention)|After 12 weeks of active observation, this group will receive a modified version of the exercise intervention consisting of a free gym membership for 12 weeks, with limited personal training.
3303103|NCT01860274|Experimental|External Mesh|
3303104|NCT01860300|Experimental|Antibiotic|Amoxicillin-Potassium Clavulanate Combination
3303105|NCT01860300|Placebo Comparator|Placebo|Placebo
3303106|NCT01860313|Experimental|Web-based interactive educational group|This group was submited to the web-based interactive education created for train teachers in child mental health, how to identify mental health problems in children and to know how to deal with problematic children in class.
3303107|NCT01860313|Experimental|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
3303108|NCT01860313|No Intervention|Waiting List group|This group was used as control group and did not receive any intervention.
3303109|NCT01860326|Experimental|Alisporivir|Single 200 mg oral dose
3303110|NCT01860339||Gene-expanded (GE)|Children at risk for HD who have a CAG repeat length of 40 and above.
3303111|NCT01860339||Gene Non-Expanded (GNE)|Children at risk for HD who have a CAG repeat length of 39 or less
3303112|NCT01860352|Other|Fish Oil|
3303113|NCT01860365|Experimental|Complementary medicine counseling|Patients receiving chemotherapy who are referred by their oncology provider to complementary medicine consultation and treatment provided in addition to conventional supportive care
3303114|NCT01860365|Active Comparator|Conventional supportive care|Patients receiving conventional supportive care
3303115|NCT01860378|Active Comparator|No Video: Full price & $5 off|Participants will not view the pertussis video
3303116|NCT01860378|Experimental|Video: Full price & $5 off|Participants will watch a brief (~ 1 minute) video about Tdap vaccination
3303117|NCT01860391|Experimental|Application of Diammine SIlver Fluoride|"GROUP A (6 TEETH): 18 mcL will be expressed from a Hamilton syringe into a dappen dish, and then a single preweighed microbrush will be used to apply the material to the tooth surface after drying with cotton gauze. The 6 teeth will be treated consecutively until all the material in the dappen dish will be used. Then the brush will be reweighed to establish the non-applied amount.~GROUP B (28 TEETH) Measure out 3 mcL X number of teeth present into dappen dish. Procedure is the same."
3303118|NCT01860404|Placebo Comparator|Placebo|Placebo will be administered orally twice daily for 21 days
3303119|NCT01860404|Experimental|Branched Chain Amino Acids (27g BID)|27 grams of BCAA's will be administered twice-daily for 21 days
3303120|NCT01860404|Experimental|Branched Chain Amino Acids (22.5g BID)|22.5 grams of BCAA's will be administered twice-daily for 21 days
3303121|NCT01860404|Experimental|Branched Chain Amino Acids (15g BID)|15 grams of BCAA's will be administered twice-daily for 21 days
3303122|NCT01860404|Experimental|Branched Chain Amino Acids (7.5g BID)|7.5 grams of BCAA's will be administered twice-daily for 21 days
3303123|NCT01860417|Experimental|Allogenic Mesenchymal Stromal Cells|Mesenchymal stem cells (MSC) prepared from bone marrow from healthy donor expanded ex vivo for 3-4 weeks. Intradiscal injection of 25 millions MSC in 2 ml of saline
3303124|NCT01860417|Active Comparator|Mepivacaine|Infiltration of paravertebral musculature close to the affected disc(s) with 2 ml of 1% Mepivacaine
3303125|NCT01860443|Experimental|Telepsychiatry collaborative program|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care clinics participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL).~Supervision of primary care professionals through an internet site run by a team of specialists.~Telephone monitoring of patients by personnel trained on clinical progress, treatment adherence, and side effects (applicable for patients taking drugs)."
3303126|NCT01860443|Active Comparator|Usual care|"Online training on the diagnosis and management of adolescent depression for health professionals from primary care centers participating in active branch.~Clinical management of depression by primary care professionals, according to algorithms based on the Clinical Guidelines of the Chilean Ministry of Health (MINSAL)."
3303127|NCT01860456||CML Imatinib/Nilotinib|Patients affected by chronic myeloid leukemia and treated with imatinib or nilotinib
3303128|NCT01860469|Active Comparator|plain mesh|standard practice of using plain mesh (non vancomycin-soaked) for open hernia repair
3303129|NCT01860469|Experimental|vancomycin-soaked mesh|use of vancomycin-soaked mesh for open hernia repair
3303130|NCT01860482|Experimental|Newrabell single arm|Newrabell® Tablet 10mg b.i.d PO during 8 weeks
3303131|NCT01860495||perforated membrane group|perforated membrane group (G1- 15 sites)
3303132|NCT01860495||occlusive membrane group|occlusive collagen membrane that are tradetionally used in guided tissue regeneration , control occlusive group (G2-15 sites)
3303133|NCT01860508|Experimental|pemetrexed|
3303134|NCT01860547|Experimental|bilberry|
3303135|NCT01860547|Experimental|sea buckthorn berry|
3303136|NCT01860547|Experimental|sea buckthorn phenolic extract|
3303137|NCT01860547|Experimental|sea buckthorn oil|
3303138|NCT01860560|Experimental|CPAP First / HFT Second|Subjects to receive both therapies, order-randomized to receive Continuous Positive Airway Pressure (CPAP) therapy study first, followed by a washout period, and a follow-on High-Flow Therapy (HFT) therapy study
3303139|NCT01860560|Experimental|HFT First / CPAP Second|Subjects to receive both therapies, order-randomized to receive High-Flow Therapy (HFT) therapy study first, followed by a washout period, and a follow-on Continuous Positive Airway Pressure (CPAP) therapy study.
3303140|NCT01860599|Other|Prediabetes with exercise|150 minutes of moderate exercise per week
3303141|NCT01860599|Other|Prediabetes without exercise|Pre-study activity level (i.e. no exercise)
3303142|NCT01860612|Experimental|PMA Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
3303143|NCT01860612|Experimental|Compassionate Use Cohort|Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.
3303144|NCT01860612|Experimental|Continued Access Cohort|Study participants that meet the inclusion/exclusion criteria for the study may be enrolled in the Continued Access cohort, after enrollment in the PMA cohort is complete.The fellow eye can be treated 1 month after the primary eye.
3303145|NCT01860625|Experimental|1(12.5㎠)|"drug : 9 people, 43.75mg/12.5㎠~placebo : 3 people, 12.5㎠"
3303146|NCT01860625|Experimental|2(25㎠)|"drug : 9 people, 87.5mg/25㎠~placebo : 3 people, 25㎠"
3303147|NCT01860625|Experimental|3(50㎠)|"drug : 9 people, 175mg/50㎠~placebo : 3 people, 50㎠"
3303148|NCT01860638|Experimental|First-Line Bevacizumab followed by Bevacizumab + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to bevacizumab will receive bevacizumab plus lomustine until PD2. Following PD2, participants will continue with blinded bevacizumab with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
3303149|NCT01860638|Placebo Comparator|First-Line Bevacizumab followed by Placebo + Lomustine/SOC|Participants will receive first-line treatment with radiotherapy, temozolomide, and bevacizumab. All three treatments will be given concurrently for the first 6 weeks, followed by 6 cycles (28 days each) of temozolomide plus bevacizumab, followed by bevacizumab monotherapy until PD1 or unacceptable toxicity. At PD1, participants randomized to placebo will receive placebo plus lomustine until PD2. Following PD2, participants will continue with blinded placebo with the addition of appropriate SOC. Following PD3, for subsequent treatment lines blinded bevacizumab may continue or open-label bevacizumab may be given at the discretion of the investigator and the participant.
3303150|NCT01860664|Experimental|hydrocortisone ophthalmic ointment 0.5%|Topical ophthalmic corticosteroid ointment, is produced in a concentration of 0.5% of hydrocortisone Acetate in a vehicle composed of mineral oil and white petrolatum
3303151|NCT01860664|Placebo Comparator|Placebo|mineral oil and white petrolatum
3303152|NCT01860690|Experimental|MTX , treatment outcome|patient receiving MTX. in a dosage of 50 mg/m^2 , IM , in single dose
3303153|NCT01860716|Placebo Comparator|Solution for infusion|Solution for infusion administrated via nasogastric tube
3303154|NCT01860716|Experimental|Melatonin|30 mg melatonin administrated via nasogastric tube in the Intensive Care Unit when included in the study and 30 mg melatonin 60 minutes before transfer to the operating room.
3303155|NCT01860729|Experimental|Anacetrapib|100 mg tablet, oral, once daily for 24 weeks
3303156|NCT01860729|Placebo Comparator|Placebo|Matching tablet to Anacetrapib 100 mg, oral, once daily for 24 weeks
3303157|NCT01860742|Active Comparator|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day until progression or unacceptable adverse event from a clinical or a patient point of view.
3303158|NCT01860742|Active Comparator|177Lu-DOTATATE|intravenous injection of 177Lu-octreotate with simultaneous infusion of an aminoacid solution
3303159|NCT01860755|Experimental|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport. This group also received the control intervention.
3303160|NCT01860755|Active Comparator|Control|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
3303161|NCT01860768||acute aortic dissectin patients|definite diagnosis by computed tomography arteriography (CTA).
3303162|NCT01860768||acute chest pain patients|aortic dissection is exclude by aorta CTA
3303163|NCT01860781|Experimental|paliperidone palmitate|paliperidone palmitate
3303164|NCT01860794|Other|Mesencephalic Neuronal Precursor Cells|
3303165|NCT01860820|No Intervention|Best Medical Therapy|Participants will follow standard post-transplant protocols with IPC
3303166|NCT01860820|Active Comparator|Geko device|Participants will be fitted with the device to ensure that it functions according to the manufacturer's instructions by a trained technician. This device will be changed every 24 hours. The device is worn on both legs and is worn for 24 hours a day. The device will first be put on the first day following the day of surgery and will then be changed the following day at the same time for a total of 7 days after surgery.
3303167|NCT01860833|Active Comparator|diclofenac 75 mg/day|diclofenac 75 mg once day slow release
3303168|NCT01860833|Active Comparator|diclofenac 150 mg/day|diclofenac 75 mg bid
3303169|NCT01860833|Active Comparator|ibuprofen 1200 mg/day|ibuprofen 600 mg bid
3303170|NCT01860833|Active Comparator|ibuprofen 1800 mg/day|ibuprofen 600 mg tid
3303171|NCT01860833|Active Comparator|celecoxib 200 mg/day|celecoxib 200 mg once day
3303172|NCT01860833|Active Comparator|celecoxib 400 mg/day|celecoxib 200 mg bid
3303173|NCT01860859|Other|Unlocked double layer|Double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium.
3303174|NCT01860859|Other|Locked single layer closure|As reported in Williams Obstetrics textbook
3303175|NCT01860859|Other|Locked double layer|Double layer closure with a first continuous locked suture and a second imbricating continuous suture.
3303176|NCT01860872||CF Group|Cystic Fibrosis group with MRI and CT of chest
3380702|NCT04518410|Placebo Comparator|Placebo (IM)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3380703|NCT04518410|Experimental|Camostat|Administered as oral tablets.
3380704|NCT04518410|Placebo Comparator|Placebo (oral tablets)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3380705|NCT04518410|Experimental|BMS 986414 + BMS 986413|Administered as subcutaneous (SC) injections.
3380706|NCT04518410|Placebo Comparator|Placebo (SC injections)|The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3380707|NCT04518410|Experimental|SAB-185 (Lower dose)|Administered by IV infusion.
3380708|NCT04518410|Experimental|SAB-185 (Higher dose)|Administered by IV infusion.
3380709|NCT04518410|Active Comparator|Casirivimab + Imdevimab (Phase III only)|Administered by IV infusion
3380710|NCT04514497|Experimental|Cohort I (elimusertib, irinotecan)|Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3303177|NCT01860872||Control group|Non-CF controls will have MRI and no CT of chest
3303178|NCT01860872||Combined Group|MRI Quality & Image Relatedness
3303179|NCT01860885||Patients requiring naloxone for respiratory depression|
3303180|NCT01860898|Other|Skin Biopsy|
3303181|NCT01860911|Experimental|Insulin-Sensitive|One group consists of insulin sensitive volunteers.
3380711|NCT04514497|Experimental|Cohort II (elimusertib, topotecan)|Patients receive topotecan IV over 30 minutes on days 1-5 and elimusertib PO BID on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3380712|NCT04510311|Experimental|PET/CT scan with radiotracer [18F]3F-PHPG|Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.
3380713|NCT04510311|Active Comparator|Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG|FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).
3303182|NCT01860911|Experimental|Insulin-Resistant|One group consists of insulin resistant volunteers.
3303183|NCT01860924|Active Comparator|health education|health education control
3380714|NCT04507204|Experimental|Adhansia XR|Adhansia XR capsules taken orally once daily with or without food.
3380715|NCT04507204|Active Comparator|Concerta|Concerta tablets taken orally once daily in the morning and swallowed whole with the aid of liquids, with or without food.
3380716|NCT04498910|Experimental|LY3451838|LY3451838 given intravenously (IV)
3380717|NCT04498910|Placebo Comparator|Placebo|Placebo given IV
3380718|NCT04497038|Experimental|Cabozantinib|Cabozantinib 20-60 mg by mouth once daily.
3380719|NCT04496596|Experimental|Suramin|
3380720|NCT04496596|Placebo Comparator|Placebo|
3380721|NCT04493502|Experimental|LY3041658|LY3041658 given intravenously (IV).
3380722|NCT04493502|Placebo Comparator|Placebo|Placebo given IV. Participants will switch to LY3041658 given IV after week 16.
3303184|NCT01860924|Experimental|exercise|vigorous supervised exercise
3380723|NCT04489537|Experimental|MarzAA|Coagulation Factor VIIa variant, 60 µg/kg by subcutaneous route, administered on-demand during bleeding episodes for a maximum of 3 doses as needed for hemostasis
3380724|NCT04489537|Active Comparator|Standard of Care|Standard of care administered on-demand during bleeding episodes
3380725|NCT04487067|Experimental|Atezolizumab + Bevacizumab|Participants will receive atezolizumab 1200 mg intravenous (IV) infusions Q3W (dosed in 3-week cycles) + bevacizumab 15 mg/kg IV Q3W (dosed in 3-week cycles)
3380726|NCT04485013|Experimental|Phase 1a, Monotherapy Dose Escalation|
3380727|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
3303185|NCT01860937|Experimental|Cohort 1 (MRD)|Patients with no morphologic evidence of disease at the time of T cell infusion, (<5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Cohort 1 patients will receive conditioning chemotherapy followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of End of Production (EOP) T cells, under or over estimation of CAR modified T-cells may occur. Patients may receive an altered fractionation of the total doses (e.g. ½ on Day 0 and ½ on Day +1) or up to 35% over total cell dose with approval by the participating site PI. In both cohorts, patients will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion and did not experience any non-hematologic grade 4 toxicities.
3303186|NCT01860937|Experimental|Cohort 2 (Morphologic Disease)|Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion & did not experience any non-hematologic grade 4 toxicities.
3303187|NCT01860963|Active Comparator|IBD patients on immunosuppression|Patients on azathioprine/6-mercaptopurine (6MP), prednisone, methotrexate, infliximab, adalimumab, certolizumab, natalizumab, and etanercept are included.
3303188|NCT01860963|Active Comparator|IBD patients off immunosuppressants|Patients off immunosuppressants, on 5-aminosalicylic acid (5-ASA) agents, antibiotics, or no treatment for IBD are included.
3303189|NCT01860963|Active Comparator|Healthy controls|Age-matched healthy controls enrolled from the hospital, outpatient clinics, and from the general public via flyers and online advertisements.
3303190|NCT01861015|Experimental|Epinephrine|In the epinephrine group, we used a dilute epinephrine, 0.5 mg of epinephrine ([1/2] vial of 1mg/mL) in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject.
3303191|NCT01861015|Active Comparator|Vasopressin|In the vasopressin group, a dilute vasopressin, 5 units in 50 mL of saline solution, taking care to use no more than 20 mL of solution per a subject was injected.
3303192|NCT01861041|Experimental|Heavy Bupivacain, Local anesthetic, Amp|Heavy bupivacaine 7.5 mg (1.5 ml), 20 microgram fentanyl(0.4 ml), 1.1 ml saline , Total 3 ml
3303193|NCT01861041|Active Comparator|Isobaric spinal, Local anesthetic, Amp|7,5 mg isobaric bupivacaine, 20 microgram (0.4 ml)fentanyl, 1.1 ml saline, Total 3 ml
3303194|NCT01861067|Experimental|LESS-TLH|laparoendoscopic single-site (LESS) total laparoscopic hysterectomy (TLH)
3303195|NCT01861067|Active Comparator|LESS-LAVH|laparoendoscopic single-site (LESS) laparoscopically-assisted vaginal hysterectomy (LAVH)
3303196|NCT01861080||incident hypertensives|"Inclusion Criteria:~age≧30years~primary incident hypertension~signed informed consent"
3303202|NCT01861119|Experimental|Silicone gel|Silicone gel (Kelo-cort™; Advanced Bio-Technologies, Silverdale, WA, USA) From the day of suture removal, the treatment was applied three times daily for 3 months.
3303203|NCT01861119|Active Comparator|Onion extract gel|Onion extract gel (Contractubex™; Merz Pharma, Frankfurt, Germany) From the day of suture removal, the treatment was applied three times daily for 3 months.
3303204|NCT01861119|No Intervention|No treatment|Subjects who assigned In the no treatment group did not receive any topical scar emollients.
3303205|NCT01861132||Healthy pregnant women|Healthy pregnant women for C-section under spinal anesthesia
3303206|NCT01861145|Active Comparator|Bed Alarm|Patients in the control arm will use only the bed alarm for treatment of their enuresis
3303207|NCT01861145|Experimental|Bed alarm + intranasal steroids|"Intervention: Nasonex (Mometasone furoate aqueous nasal spray) Children 5-11: 50 mcg/metered spray, 1 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm.~Children ≥ 12: 50 mcg/metered spray, 2 sprays in each nostril daily for 3 months in conjunction with nightly use of the bed alarm."
3303208|NCT01861158|Experimental|Parenting Wisely|Immediate access to the online Parenting Wisely program
3303209|NCT01861158|Active Comparator|Parenting Wisely + Community Forum|Immediate access to the online Parenting Wisely program, as well as access to a community form where parents can receive social support from other online users of the program and a moderator
3303210|NCT01861158|No Intervention|Delayed Parenting Wisely|Delayed (6-month) access to the Parenting Wisely program. Parents will receive access to PW after the final, 6-month, follow-up assessment.
3303211|NCT01861171|Placebo Comparator|Placebo|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
3303212|NCT01861171|Active Comparator|Green Tea|Crossover randomized controlled double-blinded trial. Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
3303213|NCT01861184||LRTI group|Non-pneumonic LRTI (no radiological consolidation but the presence of clinical signs) or community acquired pneumonia (radiological consolidation) Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
3303214|NCT01861184||Control group|Able to give fully informed consent (mental capacity assessed using trust guidelines) Age>18yrs old Fluent English speaker
3303215|NCT01861197|Experimental|Dovitinib monotherapy|
3303216|NCT01861210|Experimental|Couples Counseling and Testing|Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.
3303217|NCT01861210|Active Comparator|Individudal Counseling and Testing|"Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention's Fundamentals of HIV Prevention Counseling training."
3303218|NCT01861223|Experimental|afatinib + nimotuzumab|
3303219|NCT01861236||Advanced Prostate Cancer|Advanced Prostate Cancer that receive Firmagon therapy in the context of usual clinical practice
3303220|NCT01861249|Experimental|SAR339658|SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial
3303221|NCT01861262|Experimental|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
3303222|NCT01861275||Nasal CPAP|We want to study the nasal-cpap treatment and it's compliance in sleep apnea patients with ischaemic stroke.
3380728|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (HNSCC)|Cohorts will enroll subjects with advanced/metastatic PD-1/PD-L1 experienced Head and Neck Squamous Cell Carcinoma (HNSCC)
3380729|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (CRC)|Cohorts will enroll subjects with advanced/metastatic colorectal cancer (CRC)
3380730|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR colorectal cancer (CRC)
3380731|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with cetuximab (CRC)|Cohorts will enroll subjects with advanced/metastatic MSI-H/dMMR (KRAS wild type) colorectal cancer (CRC)
3303223|NCT01861275||no Nasal CPAP|No nasal-cpap in sleep apnea patients with ischaemic stroke.
3303224|NCT01861288||Adults and children with and without IBD|"The study includes adult and pediatric patients with and without IBD who, as part of an ongoing investigation or treatment, have to undergo a sigmoidoscopy (for children: colonoscopy).~Inclusion of adult patients, age 15-67 years: 50 patients with UC in remission, 50 patients with active UC, 50 patients without IBD~Inclusion of pediatric patients, <15 years: We expect to include: 10 UC / CD patients in remission,10 UC / CD patients in relapse,10 non-IBD patients."
3380732|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 monotherapy (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
3303226|NCT01861327|Experimental|lower limb angioplasty with CO2|lower limb angioplasty made with carbon dioxide as contrast media
3303227|NCT01861327|Active Comparator|lower limb angioplasty with Iodine|lower limb angioplasty made with Iodine as contrast media
3303228|NCT01861327|Experimental|aorto-iliac angioplasty with CO2|aorto-iliac angioplasty made with carbon dioxide as contrast media
3303229|NCT01861327|Active Comparator|aorto-iliac angioplasty with Iodine|aorto-iliac angioplasty made with Iodine as contrast media
3303230|NCT01861327|Experimental|endovascular AAA correction with CO2|endovascular abdominal aortic aneurysm (AAA) correction made with carbon dioxide as contrast media
3303231|NCT01861327|Active Comparator|endovascular AAA correction with Iodine|endovascular abdominal aortic aneurysm (AAA) correction made with Iodine as contrast media
3303232|NCT01861340|Experimental|Lenalidomide, Dexamethasone, and MEDI-551|Eligible patients will receive Lenalidomide and dexamethasone as per standard of care guidelines for 2 cycles. Patients with a clinical response to lenalidomide and dexamethasone after 2 cycles will proceed to get MEDI-551 for 2 cycles. MEDI-551 will be dosed at 4mg/kg IV on days 1 and 8 of cycle 3 and 4mg/kg IV on day 1 of cycle 4.
3303233|NCT01861353|Experimental|Cranberry-lingonberry juice|"Cranberry-lingonberry juice. Cranberry 12.8%, Lingonberry 12.4%, together 38g/l, contains added sugars 10g/dL.~Dose is 5 mL/kg/day, max. 300 ml/day per day. Juice was manufactured and donated by Eckes-Granini, Finland"
3303234|NCT01861353|Placebo Comparator|Placebo juice|"Contains no cranberry or lingonberry extracts. Added sugars 10g/dL (same as in the active juice group). Contains natural cranberry flavour and red anthocyanin colour. Contains 5.5 g/L citric acid. Has been tested by chemists and does not contains PAC-compounds which are thought to be the main active compound in cranberry juice.~Placebo juice was manufactured by Eckes-Granini. Dose is 5 mL/kg/day, max. 300 mL/day."
3303235|NCT01861366|Experimental|External facilitator|The external facilitation is a one year multifaceted intervention, including support, guidance, practice audit and feedback, training targeted to a team of practitioners involving the unit manager, the nurses and diet aides at the nursing home. The facilitator is a researcher and dietician.
3303236|NCT01861366|Active Comparator|Educational outreach visit|The outreach visit is a three hour lecture about the nutritional guidelines targeted to a team of practitioners including the unit manager, the nurses and diet aides at the nursing home. The trained person giving the lecture is a researcher and dietician.
3303237|NCT01861379|Experimental|Ghost Ileostomy|The patients were subjected to laparoscopic anterior rectal resection with performance of ghost ileostomy
3303238|NCT01861379|Placebo Comparator|No protective stoma|The patients were subjected to laparoscopic anterior rectal resection without simultaneous construction of any protective stoma.
3303239|NCT01861392|Active Comparator|sensory-motor training|Guidelines + sensory-motor training.Evaluation Biomechanical data will be collected (balance, baropodometry, electromyography strength and joint position sense), as well as questionnaires ADDQoL and BESTest. The intervention will be twice a week for 45 minutes for 12 weeks, divided into three phases: heating, sensory-motor training and cool-down, with monitoring of blood pressure and blood glucose.
3303240|NCT01861392|Active Comparator|guidelines|receive the same guidelines and reviews that group orientation and training sensorineural engine and will be guided home exercises for postural twice a week 45 minutes for 12 weeks.
3303241|NCT01861405||Cerebral metastases subjects|Prior to each subject's radiation treatment (either whole brain radiation therapy or stereotactic radiosurgery), he/she will have fMRI scanning and neuropsychological testing and conduct a quality of life assessment. Each subject will then have standard of care WBRT or SRS treatment. Following WBRT or SRS treatment, subjects will have 4 month follow up fMRI scanning, and have neuropsychological testing and a quality of life assessment 4 months and 12 months post treatment.
3303242|NCT01861405||Healthy participants|Healthy control subjects will be matched by age, gender, education, ect. to cerebral metastases subjects. Each will have fMRI scannings (3 total), neuropsychological testings (3 total), and quality of life assessments (3 total) at the same time points as their matched cerebral metastases subject.
3303243|NCT01861418|Placebo Comparator|Sham manipulation|Each participant will lie in a supine position. The treating investigator (TI) will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The TI will side bend the participant's spine towards the non-painful side, reach through the participant's hands and perform a spinal rotation away from the painful side. The TIs other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. Lastly, the TI will take up the slack and maintain the pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If the participant can tolerate the pressure for at least 5 seconds. Then, the subjects will be re-positioned to the starting position.
3303244|NCT01861418|Experimental|Lumbopelvic Manipulation, Chicago|Each participant will lie in supine position. The treating investigator (TI) will stand opposite of the low back pain. Participant will clasp his/her hand behind the neck. TI will side bend the participant's spine toward non-painful side, reach through participant's hands and perform a spinal rotation away from the painful side. TI's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side. The TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from the participant and the TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
3303245|NCT01861431|Active Comparator|HIVSRR|4 sessions of HIV sexual risk reduction
3303246|NCT01861431|Experimental|HIVSRR + Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
3303247|NCT01861444||Cohort|
3303248|NCT01861470||Preterm infants|all <32 weeks
3303249|NCT01861496|Experimental|LiPlaCis|Dose escalation of LiPlaCis - a liposomal formulation of cisplatin will be administered intravenously in cycles every 3 weeks on day 1, day 8. Upon the investigator's judgement the patient may continue treatment for more than 3 cycles when benefiting from the study drug.
3303250|NCT01861509|Experimental|BP-C1 IM Injections|BP-C1 given in daily intramuscular doses of 0.035 mg/kg bodyweight in one syringe per day during a total treatment of 32 days.
3303251|NCT01861535|Experimental|Primary Imiquimod|Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
3303252|NCT01861535|Active Comparator|Primary surgery|The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.
3303253|NCT01861548||Children (up to 24 months after birth)|Investigators include into the study children delivered from women observed starting from between 8-12 weeks of single pregnancy, not assisted with reproductive technology, and not expected to be finished as spontaneous abor-tion. All women with the serious chronic diseases specified in study protocol such as diabetes, hypertension, nephrop-athy, epilepsy and cancer are excluded from the study. The same refers to suspicion of serious child malformations known to exist at the inclusion into the study.
3303254|NCT01861561|Experimental|Low-dose intravenous cyclophosphamide|Low-dose intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months for 7 doses. Total duration is 6 months for the induction treatment.
3303255|NCT01861561|Active Comparator|High-dose intravenous cyclophosphamide|High-dose intravenous cyclophosphamide 1,000 mg/m2/dose, the first dose will be started with 500 mg/m2/dose and steped up to 750 mg/m2/dose for the second dose. Then the dosage will be increased to 1,000 mg/m2/dose for the third dose and continued the dosage through the seventh dose. Total duration is 6 months for the induction treatment.
3303256|NCT01861600|Experimental|Experimental (EF) 1|For 8 weeks, infants will consume ad libitum per day S-26 Gold EF1
3303257|NCT01861600|Active Comparator|Standard Formula|For 8 weeks, infants will consume ad libitum per day. S-26 Gold
3303258|NCT01861600|Experimental|Experimental 2 (EF2) S-26 Gold|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF2
3303259|NCT01861600|Other|Human milk (HM)|For 8 weeks, infants will consume ad libitum per day. Human Milk
3303260|NCT01861600|Experimental|Experimental formula (EF) 3|For 8 weeks, infants will consume ad libitum per day. S-26 Gold EF3
3303261|NCT01861613|Experimental|HBV vaccine|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)
3303262|NCT01861626|Other|sequence 1 : Test drug - Reference|
3303263|NCT01861626|Other|Sequence 2 : Reference - Test drug|
3303264|NCT01861639|Experimental|ineffective rTMS - Active TBS - fMRI|
3303265|NCT01861639|Experimental|Effective rTMS - Active TBS - fMRI|
3303266|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - fMRI|
3303267|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - fMRI|
3303268|NCT01861639|Experimental|ineffective rTMS - Active TBS - EEG|
3303269|NCT01861639|Experimental|Effective rTMS - Active TBS - EEG|
3303270|NCT01861639|Sham Comparator|ineffective rTMS - Sham TBS - EEG|
3303271|NCT01861639|Sham Comparator|Effective rTMS - Sham TBS - EEG|
3303272|NCT01861652|Experimental|Venous health systems Vasculaire leg compression device|Vasculaire leg compression device
3303273|NCT01861678|Active Comparator|High tie of IMA|In High tie group, IMA was transected at its origin from the abdominal aorta.
3303274|NCT01861678|Experimental|Low tie of IMA|In the low tie of the IMA, IMA was separated after branching to the left colic artery. The lymph node dissection around the IMA at its origin was performed.
3303275|NCT01861691|Active Comparator|Open surgery|Open colectomy
3303276|NCT01861691|Experimental|Laparoscopic surgery|Laparoscopic colectomy
3303277|NCT01861730|Experimental|Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
3303278|NCT01861730|Experimental|Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo|1 Dose; Subject ≥ 168 to ≤ 196 days of age
3303279|NCT01861730|Experimental|Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
3303280|NCT01861730|Experimental|Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo|2 Doses; Subject ≥ 168 to ≤ 189 days of age
3303281|NCT01861730|Experimental|Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
3303282|NCT01861730|Experimental|Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo|3 Doses; Subject ≥ 84 to ≤ 98 days of age
3303283|NCT01861730|Experimental|Cohort 6 AERAS-404 (dose level pending) or Placebo|3 Doses; Subject ≥ 64 to ≤ 83 days of age
3303284|NCT01861743|Experimental|Multimodal analgesia|multiple analgesic medications utilized in a synergistic manner to control pain while minimizing side-effects of individual drugs due to decreased doses. This includes pre-operative patient education, intra-operative pain management and post-operative pain protocols.
3303285|NCT01861743|Active Comparator|Patient Controlled analgesia|Pain management using patient controlled narcotic analgesia.
3303286|NCT01861769|Experimental|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
3303287|NCT01861769|Experimental|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
3303288|NCT01861769|No Intervention|No consultation|No Consultation/Fidelity Monitoring Only. Participants assigned to this condition will receive no post-workshop expert consultation, but will be subject to the same audiorecorded session-uploading and client-outcome reporting as the other conditions. This condition allows us to assess the effect of clinicians knowing that their sessions are subject to fidelity assessment.
3303289|NCT01861782|Experimental|Dead Sea Solar and Water Treatment|Dead Sea Solar and Water Treatment
3303290|NCT01861782|Experimental|Sulfur Pool & Medicinal Mud|Sulfur Pool & Medicinal Mud
3303291|NCT01861795||Preterm Neonates|Preterm neonates born at or above 27+0 weeks of gestational age sufficiently stable on nasal continuous positive airway pressure (CPAP) will be treated by standard of care.
3303292|NCT01861808|Other|lumbar puncture|That's not really an arm label because the only intervention on the patients is the lumbar puncture
3303293|NCT01861821|Active Comparator|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication for labor analgesia
3303294|NCT01861821|Active Comparator|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication for labor analgesia
3303295|NCT01861847|Placebo Comparator|Placebo Group|Placebo Comparator
3303296|NCT01861847|Active Comparator|Drug group|7 Keto-DHEA
3303297|NCT01861860|Experimental|New OPERA Criteria|TAXUS™ Element long stent
3303298|NCT01861873|Other|liver metastases|measuring liver function by PET/CT at patients where SBRT is planned for liver metastases
3303299|NCT01861886|Experimental|ESS505|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
3303300|NCT01861899||SI-Joint Dysfunction|Device- SI-LOK
3303301|NCT01861912|Active Comparator|Arsenic trioxide TACE|Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
3303302|NCT01861912|Experimental|Arsenic trioxide TACE+IV|"Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.~Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE."
3303303|NCT01861938|Experimental|Melanoma vaccine|
3303304|NCT01861951|Experimental|Pazopanib|"Pazopanib 800 mg, p.o., daily~Duration of treatment:~Until disease progression, treatment failure, or death due to any cause, whichever occurs first"
3303305|NCT01861951|Active Comparator|Doxorubicin|"Doxorubicin 75 mg/m² BSA, d1, q3wk, i.v.~Duration of treatment:~Six cycles (approximately 18 weeks) or until disease progression, treatment failure, or death due to any cause, whichever occurs first"
3303306|NCT01861964|Placebo Comparator|Sugar Pill|
3303307|NCT01861964|Active Comparator|Xylooligosarcharide 2.8g|Xylooligosarcharide 2.8grams
3303308|NCT01861964|Active Comparator|Xylooligosarcharide 1.4g|
3303309|NCT01861977|Experimental|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
3303310|NCT01861977|Active Comparator|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
3380733|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (NSCLC)|Cohorts will enroll subjects with advanced/metastatic non-small cell lung cancer (NSCLC)
3380734|NCT04485013|Experimental|Phase 1b, Dose Expansion: TTX-080 in combination with pembrolizumab (TNBC)|Cohorts will enroll subjects with advanced/metastatic triple negative breast cancer (TNBC)
3380735|NCT04480541|Experimental|Roadmap 2.0 + Fitbit Charge 3|"Caregivers and patients download the Roadmap 2.0 mobile app on their own mobile phones or tablet to use freely throughout the 120 day study period.~Caregivers and patients receive a Fitbit wearable activitiy sensor to track activity and sleep."
3303311|NCT01861990|Experimental|Treatment arm|All participants will be enrolled on to one, open-label arm. Participants will be treated with valproic acid in addition to standard of care therapy.
3303312|NCT01862003|Experimental|Arm 1|AZD8931 160 mg bd, on days 1-4, + FOLFIRI in a 2 weekly schedule
3380736|NCT04475393|Experimental|Carmat TAH|Subjects implanted with Carmat TAH
3380737|NCT04472377|Experimental|study population|"We enroll a total of 1,200 women, as follows,~120 cases with no history or current cervical intraepithelial lesion or malignancy.~180 cases with a history of abnormal Pap test including ASCUS, CIN1, or atypical glandular cell.~240 cases with a history of atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma.~240 cases with current ASCUS, CIN1, or atypical glandular cell.~420 cases with current abnormal Pap test as atypical squamous cells favor HSIL, dysplasia cannot exclude HSIL, CIN2, CIN3, cervical carcinoma in situ, squamous cell carcinoma, atypical glandular cells favor neoplasm, adenocarcinoma in situ, or cervical adenocarcinoma."
3380738|NCT04464317||Patient who has had cardiovascular surgery|Undergone an elective, urgent, and/or emergent cardiovascular surgery via endovascular or open (sternotomy and/or extended thoracotomy) technique at the University of Florida Health.
3380739|NCT04461327|Experimental|Major Depressive patients|"3 groups:~Women having recently attempted suicide (less than 72 hours).~Women having a past suicide attempt (more than 72 hours).~Women without lifetime history of suicidal behaviour."
3380740|NCT04458922|Experimental|Treatment (atezolizumab)|Patients receive atezolizumab IV over 30-60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3303313|NCT01862016|Active Comparator|VAC mode, Controlled ventilation|From randomization, patients are put under controlled ventilation with specific settings
3303314|NCT01862016|Experimental|APRV mode, Spontaneous breathing|During 1 to 3 hours after randomization, patients are put under controlled ventilation with specific settings for baseline data. After that, they are placed under APRV mode with specific settings
3380741|NCT04452591|Experimental|Single Arm|"Patients with carcinoma in situ with or without concomitant high-grade Ta or T1 papillary disease.~CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline. CG0070 will be administered weekly x 6 on Weeks 1, 2, 3, 4, 5, and 6. If the patient has persistent high-grade disease at Week 13, the patient will receive another cycle of 6 weekly treatments. If there is no disease present at Week 13 (e.g. complete response) then the patient will receive 3 weekly treatments.~Beginning at Week 25, patients will receive weekly x 3 treatments every 12 weeks through week 49then every 24 weeks thereafter."
3380742|NCT04447846|Experimental|Cannabidiol/ Epidiolex|All subjects will receive the experimental Epidiolex (cannabidiol) oral solution to be taken at home twice a day, and will be treated on an outpatient basis. The drug will be taken for 24 weeks unless the subject chooses to participate in the extension phase of the study, in which case the subject will continue to receive the drug for one additional year or until the drug is approved for clinical use for the treatment of cognitive impairments in patients with Sturge-Weber syndrome.
3303315|NCT01862042|Other|Supportive and Palliative care|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
3303316|NCT01862055||SAS cohort|Consecutive patients undergoing planned cesarean section under spinal anesthesia
3380743|NCT04447053|Experimental|Belimumab + SOC|Patients will be administered Belimumab, 10mg/kg, intravenously (IV) (together with SOC) in 1 hour on days 0, 14, and 28, and then every 28 days (4 weeks) until week 48.
3380744|NCT04447053|No Intervention|SOC only|Patients will receive SOC based on the discretion of attending physicians in accordance with the clinical disease manifestations of SLE and NUH practice of the treatment of SLE.
3303317|NCT01862068||GPA patients|GPA patients with an active disease at inclusion
3303318|NCT01862068||MPA patients|
3303319|NCT01862068||Healthy Blood Donors|
3303320|NCT01862068||Atherosclerotic patients|
3303321|NCT01862068||EGPA (Eosinophilic Granulomatosis With Polyangiitis)|
3303322|NCT01862081|Experimental|Arm A: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily for 21 consecutive days (beginning from Day 1) in each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3303323|NCT01862081|Experimental|Arm B: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily for 28 consecutive days (beginning from Day 1) in each 28-day cycle along with Paclitaxel on Days 1, 8, 15 and 22 of each 28-day cycle.
3303324|NCT01862081|Experimental|Arm C: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Day 1 and Days 8-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3303325|NCT01862081|Experimental|Arm D: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 2-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3303326|NCT01862081|Experimental|Arm E: GDC-0032 + Docetaxel|Participants will receive GDC-0032 once daily on Days 1-14 of each 21-day cycle along with Docetaxel on Day 1 of each 21-day cycle.
3303327|NCT01862081|Experimental|Arm F: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 5-days on, 2-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
3303328|NCT01862081|Experimental|Arm G: GDC-0032 + Paclitaxel|Participants will receive GDC-0032 once daily on a 3-days on, 4-days off schedule in each 28-day cycle along with Paclitaxel on Days 1, 8, 5 and 22 of each 28-day cycle.
3303331|NCT01862120|Experimental|interleukin-2|Dose D1 of interleukin-2
3303332|NCT01862120|Experimental|Dose D2 of interleukin-2|Dose D2 of interleukin-2
3303333|NCT01862120|Experimental|Dose D3 of interleukin-2|Dose D3 of interleukin-2
3303334|NCT01862120|Placebo Comparator|placebo|placebo
3303335|NCT01862146||Current Smoker underwent TCA|subjects who smokes daily
3303336|NCT01862146||Former Smokers underwent TCA|subjects who do not smoke since 7 years
3303337|NCT01862172|Other|additional MRI|
3303338|NCT01862185|Experimental|semi-quantitative procalcitonin|patients whom checked semi-quantitative procalcitonin examination
3303339|NCT01862185|No Intervention|control|patients whom do not checked semi-quantitative procalcitonin examination
3303340|NCT01862198|Experimental|hybrid metallic stent|Patients group who were inserted a hybrid metallic stent
3303341|NCT01862211|Experimental|members of family of children with a DA1AT|
3303342|NCT01862211|Experimental|children with a DA1AT|
3303343|NCT01862224|Experimental|JNJ-38518168|JNJ-38518168 30 mg once daily for 52 weeks.
3303344|NCT01862224|Placebo Comparator|Placebo/JNJ-38518168|Matching placebo once daily for 12 weeks followed by JNJ-38518168 30 mg once daily for 40 weeks.
3303345|NCT01862237|Experimental|Patients with type II diabetes|Type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
3303346|NCT01862237|Experimental|Patients without type II diabetes|No type II diabetes patients with aortic valve stenosis referred for aortic valve replacement.
3303347|NCT01862263|Experimental|Vildagliptin|Vildagliptin 50 mg twice daily (bid) + Insulin 20 to 40 IU/day
3303348|NCT01862263|Placebo Comparator|Placebo|Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)
3303349|NCT01862289|Experimental|Severe uncontrolled asthma|Asthmatics patients with uncontrolled symptoms despite a daily treatment by high doses of inhaled steroids and LABA. Diagnostic of chronic hyperventilation syndrome.
3303350|NCT01862302|Active Comparator|Haloperidol|Haloperidol 1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
3303351|NCT01862302|Placebo Comparator|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
3303352|NCT01862315|Experimental|No prior chemo or responded/stable with prior chemo|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day30} pump flow rate) on Day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
3303353|NCT01862315|Experimental|patients who have failed systemic therapy|All patients receive HAI FUDR ([0.12 mg/kg/day kg 30] / pump flow rate)& dexamethasone ({1 mg/m2/day 30}/ pump flow rate) on day 1 of each cycle. Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. All patients receive Gemcitabine (800 mg/m2 IV over 30 minutes) & Oxaliplatin (85 mg/m2 IV over 120 minutes) on Days 1 & 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, & then every 2 weeks thereafter. Clinical MRI examinations of the abdomen & pelvis are obtained at baseline following surgery, prior to treatment initiation & 4 weeks after initiation of HAI FUDR. Subsequently, the patient will undergo MRI approximately at months 3, 6 & 9 thereafter A non-contrast CT of chest, abdomen & pelvis will also be obtained as part of routine clinical care.
3303354|NCT01862315|Experimental|pts who have had prior oxaliplatin & have existing neuropathy|All patients receive will receive gemcitabine alone with HAI FUDR/Dex Gemcitabine (800 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first doses of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.
3303355|NCT01862341|Experimental|Milk powder|ANMUM In-Shape Nutritional Milk Powder for Active Mothers. The dose of the milk powder is 40g added to 200ml of drinkable water and will be taken twice a day.
3303356|NCT01862354|Active Comparator|Group TAP block|Patients in this group received a transverse abdominal plan block with local anesthetics and clonidine as postoperative analgesia.
3303357|NCT01862354|Active Comparator|Group : Continuous wound infusion|Patients in this group received continuous wound infusion with local anesthetics and clonidine as postoperative analgesia.
3303358|NCT01862367||rFXIII|
3303359|NCT01862380|Experimental|Cases|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in female patients with non classical 21-hydroxylase deficiency.
3303360|NCT01862380|Experimental|Control|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively in healthy female controls.
3303361|NCT01862393|Experimental|400 microseconds|Electrically-induced torque generated with stimulus phase duration set at 400 microseconds.
3303362|NCT01862393|Experimental|700 microseconds|Electrically-induced torque generated with stimulus phase duration set at 700 microseconds.
3303363|NCT01862393|Experimental|1000 microseconds|Electrically-induced torque generated with stimulus phase duration set at 1000 microseconds.
3303364|NCT01862406|Experimental|Generic Label|Purportedly generic version of the analgesic presented
3303365|NCT01862406|Active Comparator|Brand-name Label|actual brand-name analgesic presented
3303366|NCT01862432|Experimental|immediate skin-to-skin|
3303367|NCT01862432|No Intervention|control|
3303368|NCT01862445||Study group|Patients receiving Chlorambucil plus Rituximab
3303369|NCT01862458|Active Comparator|tPA alone|tPA alone used to treat empyema
3303370|NCT01862458|Experimental|tPA plus dornase|tPA plus dornase used to treat empyema
3303371|NCT01862471|Experimental|DVT prophylaxis|"Neuromuscular electrical stimulation using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation was applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
3303372|NCT01862497||Carvedilol (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Carvedilol x 8 weeks (titrated up to 50 mg po bid), washout x 1 week, Prazosin x 8 weeks (titrated up to 16 mg daily)"
3303373|NCT01862497||Prazosin (for Aim 3 only)|"Eligible case subjects from aims 1-2 will participate in a randomized crossover study where each subject will receive carvedilol and prazosin for 8 weeks each(under randomized treatment sequence) with a 1 week washout period included in between treatments.~The first arm will include subjects that are assigned to the randomization sequence: Prazosin x 8 weeks, washout x 1 week, Carvedilol x 8 weeks"
3303374|NCT01862523|Placebo Comparator|diluent|diluent
3303375|NCT01862523|Experimental|capsaicin|capsaicin
3303376|NCT01862523|No Intervention|control healthy volunteers|control healthy volunteers
3303377|NCT01862549|Experimental|DBT for children|Dialectical Behavior Therapy for children is a 32 session intervention (it consists of 2 pre-treatment sessions and 30 treatment sessions; treatment sessions are to be delivered in 32 weeks total) with once per week meetings, including 30 min. individual child therapy, 20 min. meeting with a caregiver and 40 min. of skills training with both.
3303378|NCT01862549|Active Comparator|Treatment as Usual|Children in active comparison conditions will receive Treatment as Usual (TAU) that primarily consists of 32 weekly sessions of supportive individual psychotherapy and adjunctive family interventions. Individual therapy included cognitive behavioral skills training (e.g., psychoeducation, cognitive modifications, thought blocking) and non-directive supportive therapy. Family therapy includes parenting skills training (e.g., limit setting, reinforcement techniques), structuring household environment, and safety planning.
3303379|NCT01862562|Active Comparator|Open surgery|Conventional procedure
3303380|NCT01862562|Experimental|Laparoscopic surgery|Minimum invasive procedure
3303381|NCT01862601|Experimental|JetTouch injections|
3303382|NCT01862627||Macular retinoschisis and detachment|
3303383|NCT01862653|Experimental|Auricular Acupuncture|An insomnia auricular acupuncture protocol will be administered for 30 minutes, three times per week, for three weeks in the intervention group.
3303384|NCT01862653|No Intervention|Control|The control group is a wait-list control group and will be offered the auricular acupuncture intervention after the study is complete. No intervention will be performed on control group.
3303385|NCT01862679|Experimental|8 weeks HF haemodialysis / 8 weeks HD-filtration|8 weeks high-flux haemodialysis followed by 8 weeks haemodiafiltration
3303386|NCT01862679|Experimental|8 weeks HD-filtration /8 weeks HF haemodialysis|8 weeks haemodiafiltration followed by 8 weeks high-flux haemodialysis
3303387|NCT01862692|Active Comparator|Developmental Awareness Skils|
3303388|NCT01862692|Experimental|Baby-Net condition|
3303389|NCT01862705|Experimental|Thoracic spine manipulation thrust|Thoracic spine manipulation thrust
3303390|NCT01862705|Sham Comparator|Thoracic spine manipulation non-thrust|Thoracic spine manipulation non-thrust
3303391|NCT01862718|Experimental|1|Ablation plus radiation
3303394|NCT01862809||cases|smokers
3303395|NCT01862809||controls|non-smokers
3303396|NCT01862822|Experimental|upright position|Upright position during urine bag collection
3303397|NCT01862822|No Intervention|usual position|
3303398|NCT01862835|Experimental|Degarelix/Te/placebo/ placebo|Degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3303399|NCT01862835|Experimental|degarelix/Te/anastrozole/ placebo|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3303400|NCT01862835|Experimental|degarelix/Te/ anastrozole/E2 patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; Te enanthate 100 mg i.m. given on day 1, 8 and 15; Oral anastrozole 2.0 mg once daily x 22 days; and an E2 patch calibrated to deliver 0.05 mg/day E2 beginning on day 1 and changed every 3 days through day 22.
3303401|NCT01862835|Experimental|degarelix/ placebo/placebo/no patch|degarelix 80 mg (given as two s.c. injections of 60 mg) once [called day 1]; placebo i.m. given on day 1, 8 and 15; Oral placebo once daily x 22 days; and no patch beginning on day 1 and changed every 3 days through day 22.
3303402|NCT01862861||Peri or post-menopausal women.|Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age.
3303403|NCT01862887|Experimental|PH-797804|Subjects will receive a single 24 mg dose in the fed state
3303404|NCT01862887|Experimental|Moxifloxacin|Subjects will receive a single 400 mg dose in the fed state
3303405|NCT01862887|Experimental|Placebo|Subjects will receive a single placebo dose
3303406|NCT01862900|Experimental|15 Gy|Patients receive a radiation dose of 15 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3303407|NCT01862900|Experimental|20 Gy|Patients receive a radiation dose of 20 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3303408|NCT01862900|Experimental|25 Gy|Patients receive a radiation dose of 25 Gy to their liver or lung metastases. Patients receive a dose of MEDI6469 following radiation and on Days 3, and 5.
3303409|NCT01862913|Experimental|Computer-assisted CBT|"Usual medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile.~Eight sessions of a computer-assisted cognitive-behavioral therapy. Trained psychologists administer this program in face to face meetings."
3303410|NCT01862913|Active Comparator|Usual care treatment|"- Usual psychological and medical treatment in accordance with a decision algorithm based on the Clinical Guidelines for the Treatment of Depression of the Ministry of Health of Chile."
3303411|NCT01862926|Experimental|Rituximab|1g given at baseline and two weeks.
3303412|NCT01862926|Active Comparator|Cyclophosphamide|Intravenous dose of 600 mg/m2 body surface area. 6 doses given 4 weekly.
3303413|NCT01862939|Experimental|part 1 DS-7309 ascending dose|1, 2.5, 5, 10, 20 mg blinded DS-7309 powder in bottle.
3303414|NCT01862939|Experimental|part 2 DS-7309|1, 2.5, 5, and 15mg DS-7309 powder in bottle for oral solution.
3303415|NCT01862939|Placebo Comparator|part 2 placebo|placebo to match part 2 DS-7309
3303416|NCT01862952|Active Comparator|antiepileptic treatment as used in daily clinical practice|Antiepileptic treatment as used in daily clinical practice.
3303417|NCT01862952|No Intervention|No medication|
3303418|NCT01862965|Experimental|PredEver|Prednisone and Everolimus
3303419|NCT01862978|Experimental|Heparin|Patient receiving Heparin
3303420|NCT01862978|Experimental|Nadroparin|Patient receiving nadroparin
3303421|NCT01862978|Placebo Comparator|Placebo|Patients receiving placebo
3303422|NCT01863004|Experimental|Bortezomib (Velcade®)|"This study tests whether salvage of mis-sense mutated dysferlin through proteasomal inhibition seen in cultured muscle cells can be translated into patients harboring dysferlin mis-sense mutations. The proteasomal inhibitor Bortezomib (Velcade®) is already approved as a medication for the treatment of multiple myeloma in Switzerland and in other countries.~Following an administration of a single dose of Bortezomib repeated needle muscle biopsies and blood draws will be performed to assess dysferlin levels in skeletal muscle and blood monocytes over a five day period."
3303423|NCT01863043|Active Comparator|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
3303424|NCT01863043|Experimental|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
3303425|NCT01863056|Experimental|Sit-Stand Desk|Cross-over trial: so one group got the intervention in period 1 and didn't get the intervention in period 2 (serving as control for self in period 2) and the other group got the intervention in period 2 and didn't get the intervention in period 1 (serving as control for self in period 1).
3303426|NCT01863056|No Intervention|Control|Used normal work desk which only allows working sitting down
3303427|NCT01863082|Experimental|exercise|the patients will be submitted to an exercise protocol
3303428|NCT01863095|Experimental|Lifestyle counseling|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will receive personalized feedback on their MJ use and will be provided a smart phone app on which they report their MJ use episodes, which also is designed to promote the use of exercise/physical activity as an alternative to MJ use. Level of Physical activity will be measured using accelerometers.
3303429|NCT01863095|Active Comparator|Personalized Feedback only|MJ users assigned to this condition will participate in 4 individualized intervention sessions that are based on Motivational Interviewing principles. They will only receive personalized feedback on their MJ use.
3303430|NCT01863108|Experimental|GeniusVac-Mel4|Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
3303431|NCT01863121||Cirrhotic Patients|Patients of cirrhosis
3303432|NCT01863147|Experimental|Sitagliptin|Sitagliptin 0.1 daily for 1 year
3303433|NCT01863147|Active Comparator|acarbose|acarbose 150mg daily for 1 year
3303434|NCT01863160|Other|0.1% ZEP-3 cream|250 mg of ZEP-3 Cream 0.1% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
3303435|NCT01863160|Other|placebo|250 mg of ZEP-3 Cream 1.0% is applied on the right ventral forearm and 250 mg placebo is applied on the left ventral forearm 4 times daily
3303436|NCT01863173|Active Comparator|metoprolol|patient or intervention group
3303437|NCT01863173|Active Comparator|placebo group|control group
3303438|NCT01863199|Active Comparator|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
3303439|NCT01863199|Active Comparator|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every 12 weeks
3303440|NCT01863199|Experimental|Treat and extend|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
3303441|NCT01863212|Experimental|Risk allele carriers|Individuals homozygous for the risk allele (A/A) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
3303442|NCT01863212|Experimental|Non risk allele carriers|Individuals homozygous for the non-risk allele (T/T) The interventions administrated to this group: 'Blood sampling for genetic analyse', 'Stroop test', 'fMRI'
3303443|NCT01863225|Experimental|Group A|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 40 mg
3303444|NCT01863225|Experimental|Group B|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 20 mg
3303445|NCT01863225|Experimental|Group C|RVX000222 200 mg (100 mg b.i.d.) + Atorvastatin 80 mg
3303446|NCT01863225|Experimental|Group D|RVX000222 200 mg (100 mg b.i.d.) + Rosuvastatin 40 mg
3303447|NCT01863238||Ivacaftor Treated|
3303448|NCT01863251|Experimental|Atomoxetine|Patients assigned to atomoxetine will receive atomoxetine 40 mg daily, beginning on Day 5. Atomoxetine dose will be increased to 80 mg daily for all patients beginning on Day 12. Atomoxetine will be increased to 120 mg daily for patients with persistent ATS use after 4 weeks of treatment.
3303449|NCT01863251|Placebo Comparator|Placebo|Placebo inactive medication
3303450|NCT01863264|Experimental|Cold Thin Liquid Barium|"Poland Spring Natural Spring Water will be placed in a refrigerator set to 36 °F, this will allow the water to cool to approximately 4-9 °C. As described by several authors, these waters will be used to mix the barium powder (Varibar® Thin Liquid Barium Sulfate for Suspension) to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula.~the infant will be required to swallow 5 boluses of this cold liquid barium while bottle feeding."
3303451|NCT01863277|Active Comparator|Melatonin|Melatonin 14mg/daily given over 14 days
3303452|NCT01863277|Placebo Comparator|sugar pill|sugar pill given over 14 days
3303453|NCT01863290||Former inmates|Former inmates with a chronic disease condition or aged 50 years and above engaged into primary care through an innovative primary care redesign model of the Transitions Clinic Network.
3303454|NCT01863316|Experimental|1) I gel group|using supraglottic airway I gel
3303455|NCT01863316|Active Comparator|2) LMA Supreme group|using supraglottic airway LMA Supreme
3303456|NCT01863329||both optic nerve sheath diameter|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
3303457|NCT01863342||CSI score < 40|CSI cutoff value<40
3303458|NCT01863342||Group 2: CSI score ≥ 40|CSI cutoff value≥40
3303459|NCT01863355|Experimental|B0|(basal rate 0cc/hr, bolus 3cc, lockout time 10min)
3303460|NCT01863355|Active Comparator|BL|(basal rate 1cc/hr, bolus 2cc, lockout time 10min)
3303461|NCT01863355|Active Comparator|BH|(basal rate 2cc/hr, bolus 1cc, lockout time 10min)
3303462|NCT01863381|Experimental|Hydrocephalus/Pseudotumor|Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.
3303463|NCT01863394|Active Comparator|Screening by community health workers|"One Community Health Worker (CHW) will be trained per village in the comparator arm. The training the CHWs receive will be identical to that delivered in the Community Management of Acute Malnutrition program run by ALIMA/BEFEN (Bien Être de la Femme et l'Enfant Niger) over the last 3 years. This involves 6 hours theoretical training and a practical session in the health centre.~CHWs will screen children 06-59 months in their village once a month"
3303464|NCT01863394|Experimental|Screening by mothers|"Mothers in the intervention health district will be trained in small womens' groups in their village. Training will have a theoretical component and a practical demonstration component on children in the village~During the first baseline door to door mass screening campaign, mothers will also receive individual training on conducting a Mid Upper Arm Circumference (MUAC) classification and looking for pedal oedema. they will receive a brief recap during the three monthly door-to-door mass screening campaigns~Mothers will be asked to check their child's MUAC and look for pedal oedema~whenever the child does not seem to be in 'good health' to the mother~whenever the mother feels that the child is 'unwell' or 'sick'~whenever it seems to the mother that her child has lost weight~whenever the mother thinks that it is necessary to do so"
3303465|NCT01863407|Experimental|DAM Solution|Preheated to a temperature level, mixed the DAM Solution 2ml and Normal Saline 250ml, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
3303466|NCT01863407|Placebo Comparator|Normal Saline|Preheated the Normal Saline 250ml to a temperature level, poured into abdominal cavity and infiltrate the operative field before the abdominal closure
3303467|NCT01863420||Rectal cancer patients|For rectal cancer patients before surgery, IMRT is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.The dose constraints for active bone marrow are V5<95%, V10<88%,V20<80%,V30<65%, V40<45%.
3303468|NCT01863420||Gastric cancer patients|For gastric cancer patients after surgery and chemotherapy,the 4500 cGy of radiation was delivered in 25 fractions, five days per week. Concurrent chemotherapy regimen is monotherapy with capecitabine 1600mg∙m2 twice a day (b.i.d.).The dose constraints for active bone marrow are V5<90%, V10<80%,V20<70%,V30<55%, V40<35%.
3303469|NCT01863446|Experimental|Lighting1|Ocular light exposure of a red wavelength light for one or two nights
3303470|NCT01863446|Experimental|Lighting2|Ocular light exposure of a blue-green wavelength light for one night
3303471|NCT01863446|Experimental|Lighting3|Ocular light exposure to a red wavelength light on night 1 and to a blue-green wavelength light on night 2
3303472|NCT01863446|Experimental|Lighting4|Ocular light exposure to a red wavelength light on day1 and to a blue-green wavelength light on day 2
3303473|NCT01863459|Experimental|Lidexamfetamine Dimesylate|"Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.~Duration of treatment in this arm is 8 weeks; tablet is taken once per day"
3303474|NCT01863459|Placebo Comparator|Placebo|"Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.~Placebo is taken once per day for 8 weeks"
3303475|NCT01863472|Active Comparator|HeartLight(TM) Laser Balloon|Safety and efficacy of pulmonary vein isolation using the HeartLight(TM) Laser Balloon (endoscopically guided ablation)
3303476|NCT01863472|Active Comparator|irrigated radiofrequency current ablation|Safety and efficacy of pulmonary vein isolation using the irrigated radiofrequency current ablation
3303477|NCT01863485|Experimental|CM082|CM082 tablet
3303478|NCT01863511|Active Comparator|usual care|IV loop diuretics
3303479|NCT01863511|Active Comparator|Usual care plus tolvaptan|IV loop diuretic plus Tolvaptan 30 mg orally once daily
3303480|NCT01863511|Active Comparator|ultrafiltration|Volume removal through a brachial line extended length catheter or a quad lumen catheter via the internal jugular vein
3303481|NCT01863537|Experimental|Intervention|Multimedia Connect and the Multimedia facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultations with CBO staff to provide technical assistance at 2 and 4 months following the training workshop;
3303482|NCT01863537|Active Comparator|Traditional Connect|The original, manualized version of Connect (CDC DEBI)and manualized facilitator training curriculum with a 4-day, face-to-face structured orientation and training for implementation, and planned, investigative team initiated telephone consultation with CBO staff to provide technical assistance at 2 and 4 months following the training workshop.
3303487|NCT01863576|Active Comparator|Omega-3|This group is receiving omega-3 supplement.
3303488|NCT01863576|Placebo Comparator|Oil Corn|This group is receiving the placebo comparator.
3303489|NCT01863589||Subjects prescribed adefovir tablets|Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
3303490|NCT01863602||Subjects prescribed lamotrigine tablets|Subjects with epilepsy with partial seizures, tonic-clonic seizuresm or generalized seizures of Lennox-Gastaut syndrome to whom lamotrigine tablets are administered.
3303491|NCT01863615|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3303492|NCT01863615|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3303493|NCT01863628|Placebo Comparator|psychoeducation|including delivering knowledge on symptoms, discussion of suffering mental difficulties, and general coping techniques
3303494|NCT01863628|Experimental|aerobic exercise|The aerobic exercise would include cycling, jogging, table tennis,and playing badminton for 40 mins at least 3 times per week for 3 months. In each exercise, participants are supposed to exercise to the extent of getting sweaty
3303495|NCT01863641|Experimental|treatment group|Patients will receive calcitriol at a fixed dose daily.
3303496|NCT01863641|Active Comparator|control group|Patients will receive placebo daily.
3303497|NCT01863654|Experimental|A(reference)/B(test)|initial administration of reference and cross-over to test
3303498|NCT01863654|Experimental|B(test)/A(reference)|initial administration of test and cross-over to reference
3303499|NCT01863693||Cohort|
3303500|NCT01863706|Experimental|Misoprostol|400µg oral misoprostol
3303501|NCT01863706|Active Comparator|Oxytocin|20 IU oxytocin
3303502|NCT01863719|Experimental|Cohort 1|9 Subjects
3303503|NCT01863719|Experimental|Cohort 2|9 Subjects
3303504|NCT01863719|Experimental|Cohort 3|9 Subjects
3303505|NCT01863719|Experimental|Cohort 4|12 Subjects
3303506|NCT01863745|Experimental|nilotinib|16 patients who are currently enrolled in a Novartis- sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study receiving nilotinib and has fulfilled all their requirements in the parent study will be enrolled.
3303507|NCT01863784|Experimental|JNJ-38518168|
3303508|NCT01863797|Active Comparator|Early induction|"Induction was performed if membranes were still intact and cervical dilation was less than four centimetres five hours after medication for therapeutic rest. For participants with an unripe cervix intravaginal prostaglandin E2 (PgE2, dinoproston) was used. A transcervical catheter (BARD) was inserted if this procedure was possible 19 and if cervical dilatation permitted, amniotomy was performed. The physician in charge performed all assessments and procedures except amniotomy.~When the participants reached the active phase they were monitored according to the clinical guidelines."
3303509|NCT01863797|Experimental|expectant management|The participants in the control group awaited spontaneous onset of labour as long as possible (expectant management). If contractions had ceased or subsided after the therapeutic rest women could be discharged from hospital, but were still included in the study. When reaching the active phase of labour women were monitored according to the clinical guidelines.
3303510|NCT01863810|Experimental|KW21052|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with KW21052 300mg and Placebo of Lyrica for intervention period of 8 weeks.
3303511|NCT01863810|Active Comparator|LYRICA|This arm will be pre-treated with Lyrica 150mg (75mg bid) for titration period of 1 week and then be treated with Lyrica 300mg (150mg bid) and Placebo of KW21052 300mg for intervention period of 8 weeks.
3303512|NCT01863823|Other|Amoxicillin and Tetracyclines|drug treatment
3303513|NCT01863823|Other|Mouth washing|Mouth washing
3303514|NCT01863836|Experimental|Fluoroscopy|Patients will undergo bronchoscopy and radial endobronchial ultrasound-guided biopsy of a peripheral lung lesion like patients in the other group. However, single-plane fluoroscopy will be used to help locate the lesion (with the help of a steerable curette) in case of failure to locate the lesion, and it will also be used to guide tissue sampling and ensure appropriate sampling tool function. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
3303515|NCT01863836|Active Comparator|No fluoroscopy|Patients will undergo biopsy of peripheral lung lesions using radial endobronchial ultrasound guidance only, without the use of fluoroscopy. Transbronchial biopsies, transbronchial needle aspiration, brushings, and bronchoalveolar lavage will be performed for each lesion.
3303516|NCT01863862|Experimental|Clinical complete responders.|Patients with complete clinical response obtained 8 weeks after chemoradiation or 10 weeks after short-course radiation.
3303517|NCT01863875||Childhood cochlear implant recipients|The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
3303518|NCT01863875||Normal hearing people|Reference group: A group of normal hearing people matching the target group on gender and age.
3303519|NCT01863888|Experimental|teriflunomide (HMR1726)|Participants administered 14mg Teriflunomide once daily, oral. For participants who permanently discontinue Teriflunomide, an accelerated elimination procedure with either cholestyramine or charcoal will be administered.
3303520|NCT01863888|No Intervention|Reference population|Untreated healthy subjects
3303521|NCT01863901|Experimental|Treatment with the Cryo-Touch III Device|
3303522|NCT01863914|Placebo Comparator|Placebo|Placebo tablet contains only inactive ingredient. The placebo tablets will be taken once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
3303523|NCT01863914|Active Comparator|Rosuvastatin|Rosuvastatin (CrestorÒ, Astrazeneca) 5mg once daily for 4 weeks (1 week before operation and 3 weeks after creation of AV fistula)
3303524|NCT01863927|Experimental|Research arm|Each of the participants will be randomly exposed to 4 conditions during four separate consecutive days.
3303525|NCT01863940|Experimental|Wound catheter|Wound catheters will be placed subcutaneously in the skin graft donor site in the lateral thigh while the patient remain intra-operative. The patients will receive a continuous infusion of procaine 0.5% at 4-5mL/hr using an elastomeric infusion device for 48 hours. Patients will be asked to asses pain on a 0-10 scale immediately prior to dressing changes, during dressing changes and 1 hour post dressing changes.
3303526|NCT01863940|No Intervention|Control|Patients will receive the standard of care pain medication regimen of Analgin/Metamizole 1 g IM and Ketorolac 3%- 30 mg IM for post-operative pain treatment. The patients will be asked to rate pain on a scale of 0-10 immediately prior to dressing changes, during dressing changes and 1 hour after dressing changes.
3303527|NCT01863966|Experimental|Hot water drinking therapy|Hot water drinking before,after meal and before sleep
3303528|NCT01863966|Active Comparator|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation
3303529|NCT01863979||Acute Atrial Fibrillation|
3303530|NCT01864018|Experimental|Treatment (ixazomib citrate, cyclophosphamide, dexamethasone)|"INDUCTION THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15 and cyclophosphamide PO and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.~MAINTENANCE THERAPY: Patients receive ixazomib citrate PO on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3303531|NCT01864057|Active Comparator|Cambodian mothers|thiamine hydrochloride 100 mg orally daily for 5 days
3303532|NCT01864057|No Intervention|American mothers|Baseline blood and breast milk sample collection
3303533|NCT01864070|Experimental|TheraSphere + Everolimus|"Each cycle is 28 days. Target dose of TheraSphere is fixed at 120 Gy to entire tumor bearing portion of liver given at a single session on Cycle 1 Day 15. The dose of everolimus will be escalated in 2 sequential cohorts of 6 TheraSphere-treated patients each. Starting dose of everolimus is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg PO daily starting cycle 3 day 1.~Once DLT is defined or dose level 2 has been completed, a dose expansion cohort of 10 patients with advanced low to intermediate grade neuroendocrine tumor will be enrolled.~At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had."
3303534|NCT01864083|Experimental|Local staging patients|Breast MR and FACBC PET/PEM will be scheduled within one week of each other. Breast MR is a standard clinical examination and will be performed as standard.
3303535|NCT01864083|Experimental|Neoadjuvant chemotherapy patients|Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
3303536|NCT01864096|Experimental|Metformin|
3303537|NCT01864096|Placebo Comparator|Placebo|
3303538|NCT01864109|Experimental|Patients with localized disease|"Patients with localized disease will receive six cycles of the combination as maintenance therapy following standard chemotherapy.~Cycles 4-6 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 7 will include :~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)~Cycles 8-13 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously"
3303539|NCT01864109|Experimental|Patients with metastatic disease|"Patients will get 10 cycles of the combination intercalated between the final 4 cycles of standard chemotherapy.~Cycles 4, 5, 7, 8, 10, 11, 13, 14, 16, and 17 will include:~Irinotecan will be given on 10 days over weeks 1 and 2 of a cycle at a dose of 20 mg/m2/day intravenously~Temozolomide will be given daily on the first 5 days of irinotecan administration at a dose of 100 mg/m2/day orally or intravenously~Cycles 6, 9, and 12 will include:~Ifosfamide 2,800 mg/m2/day on days 1-5~Etoposide 100 mg/m2/day on days 1-5~Cycle 15 will include:~Cyclophosphamide will be given on days 1 and 2 at a dose of 2,100 mg/m2/day, or for patients < 10 years of age at a dose of 70 mg/kg/day~Doxorubicin will be given on days 1 and 2 at a dose of 37.5 mg/m2/day~Vincristine will be given on day 1 at a dose of 2 mg/m2 or 0.067 mg/kg (whichever is lower, to a max dose of 2 mg)"
3303540|NCT01864135|Experimental|MRI|Comparison of targeted transrectal ultrasound guided prostate biopsies based on 3T multiparametric MRI findings to systematic non-targeted transrectal ultrasound guided prostate biopsies
3303541|NCT01864161|Experimental|oral liposomal iron|patients receive a dose of liposomal 30 mg/die iron (equivalent to 1 cp Sideral forte).
3303542|NCT01864161|Active Comparator|endovenous iron|patients receive a total dose 1000 mg of intravenous iron gluconate divided into administrations of 125 mg diluted in 250 mL normal saline infused weekly for 3 months
3303543|NCT01864187|Experimental|Dexmedetomidine|Each team will be administered for 1μg/kg of dexmedetomidine eace one.
3303544|NCT01864213|Experimental|Ametop cream|
3303545|NCT01864226|Placebo Comparator|Placebo|
3303546|NCT01864226|Experimental|RO5545965|
3303547|NCT01864239|Experimental|Patient-centred tailored intervention|Medicines Advice Service
3303548|NCT01864239|No Intervention|Control|Usual care
3303549|NCT01864252|Sham Comparator|Group 1 Control (65 patients)|Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.
3303550|NCT01864252|Active Comparator|Group 2 (65 patients)|Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.
3303551|NCT01864252|Experimental|Group 3 GTN (65 patients):|Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.
3303552|NCT01864252|Experimental|• Group 4 RIPC+GTN (65 patients):|Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery
3303553|NCT01864265|Active Comparator|Certolizumab Pegol|
3303554|NCT01864265|Placebo Comparator|Placebo|
3303555|NCT01864278||Lutonix Drug Coated Balloon|Paclitaxel coated ballooncatheter
3303556|NCT01864304||Williams Syndrome|Children and adults with Williams Syndrome
3303557|NCT01864304||Control Group|Controls will be recruited in 2 ways: 1) a gender matched and age- and BMI-similar control for each WS patient, and, 2) sibling controls when available
3303558|NCT01864317|Experimental|Primary Open Angle Glaucoma|30 patients with primary open angle glaucoma
3303559|NCT01864317|Experimental|Normal Tension Glaucoma|30 patients with normal tension glaucoma
3303560|NCT01864317|Experimental|Ocular Hypertension|30 patients with ocular hypertension
3303561|NCT01864317|Other|Healthy subjects|30 healthy control subjects
3303562|NCT01864330|Experimental|Dry Eye Syndrome I|20 patients with moderate dry eye syndrome
3303563|NCT01864330|Active Comparator|Dry Eye Syndrome II|20 patients with moderate dry eye syndrome
3303564|NCT01864330|Active Comparator|Dry Eye Syndrome III|20 patients with moderate dry eye syndrome
3303565|NCT01864343|Experimental|Pre- and perinterventional hypothermia|Cooling will be initiated by the application of cooling pads in the out-of-hospital setting followed by an infusion of 1000-2000ml of cold saline. In the cath lab a endovascular cooling catheter will be placed into the inferior vena cava via a femoral vein to achieve a core temperature of <35°C prior to revascularization.
3303566|NCT01864356|Experimental|NT100 Dose 1|NT100 Dose 1
3303567|NCT01864356|Experimental|NT100 Dose 2|NT100 Dose 2
3303568|NCT01864356|Placebo Comparator|Placebo|Placebo
3303569|NCT01864369|Active Comparator|Control: eInfo + Usual Care|Usual Care + eInfo on general guidelines for heart healthy living
3303570|NCT01864369|Experimental|Behavioral: eCounseling + Usual Care|Behavioral:eCounseling + Usual Care: interactive web pages utilized to provide e-counseling messages and e-tools.
3303571|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises 5 days a week during 5 weeks
3303572|NCT01864382|Experimental|Core stability|Core stability.5 days a week during 5 weeks
3303573|NCT01864395|Experimental|Control (CF)|Centrifugation Method (CF): currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
3303574|NCT01864395|Experimental|Online MUF|Online MUF: hemofilter is used online while the heart-lung machine is connected to the patient.
3303575|NCT01864395|Experimental|Offline MUF|Offline MUF: hemofilter is used offline when the heart-lung machine is not connected to the patient.
3303576|NCT01864408|Other|Group 1|"Group 1: subjects will receive usual practice counseling regarding pelvic organ prolapse after new patient history and physical exam."
3303577|NCT01864408|Experimental|Group 2|"Group 2: subjects will receive usual practice counseling in addition to interactive patient/provider counseling using the pelvic organ prolapse web-based tool (iPad) after new patient history and physical exam."
3303578|NCT01864421||Deferred Clamping|Infants undergoing a deferring of umbilical cord clamping for 30 seconds or more
3303579|NCT01864421||Immeadiate Cord Clamping|Infants undergoing immediate umbilical cord clamping in the first 20 seconds of life.
3303580|NCT01864447|Experimental|VTE REHABILITATION|"The exercise prescription emphasizes gradual progression to longer duration (45-60 minutes per session), lower intensity (60-70% peak heart rate (PHR) exercise. Subjects have an exercise expenditure goal of >3000 kcal/wk, attained after 2 to 4 weeks of gradually lengthening exercise bouts. All exercise sessions will be performed onsite for the first two weeks, after which subjects will perform 2 additional sessions a week in the home environment. Exercise logs will be reviewed weekly.~The Dietary Behavioral Weight Loss Intervention(BWL) intervention consists primarily of 12 small group sessions led by a dietician emphasizing dietary records, itemization of food, and caloric content. Subjects will be given individualized daily caloric goals 500 kcal less than predicted maintenance calories based on their baseline body weight."
3303581|NCT01864447|No Intervention|CONTROL|The 12-week program will consist of monthly phone contacts to check-in to capture physical activity done outside of the intervention setting.
3303582|NCT01864460|Experimental|Diet, Physical Activity and Balance Enhancement Program (DPAE|Subjects in the DPAEP group will undergo a structured weight loss for approximately 6 months, followed by approximately 6 months of weight maintenance, as well as 12 months of aerobic exercise. This intervention stresses a personalized program emphasizing activities that are meaningful to and are tailored to individual participants; provides consistent contact between the participants and research staff; and allows monitoring of activity levels using questionnaires, actigraphy, monitoring of heart rate, direct and telephone contact. Participants dietary and physical activity goals as assessed by the dietician and trainer will be discussed at face-to face meetings to re-establish these goals. These programs will be tailored to meet the realistic goals of the individual participant. The program stresses aerobic exercise, rather than other types of exercise interventions, as aerobic exercise appears to correlate best with improved autonomic function.
3303583|NCT01864460|Active Comparator|Standard Care (SC)|The SC group will be assigned an interventionist assessor. This assessor will meet with the subjects during their orientation meeting and will be provided guidelines and a weight loss and physical activity target to achieve by the end of the program at their orientation meeting. Participants will contacted approximately weekly during the approximate 12 month period.
3303584|NCT01864473|Other|Kshar Sutra|
3303585|NCT01864486|Experimental|Intelligent Retinal Implant System|
3303586|NCT01864499|Experimental|Tumor Resection|
3303587|NCT01864499|Active Comparator|Biopsy Brain Tumor|
3303588|NCT01864512||ITP patients receiving eltrombopag therapy|
3303589|NCT01864551|Active Comparator|lamotrigine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
3303590|NCT01864551|Active Comparator|olanzapine|maintenance treatment of the patients with bipolar disorder with olanzapine or lamotrigine
3303591|NCT01864577|Experimental|With negative pleural suction|Patients are put on negative pleural suction at - 20 cm H2O
3303592|NCT01864577|Active Comparator|With water seal|Patients al left on water seal only
3303593|NCT01864590|Experimental|Open Abdomen - Vacuum Pack|Patients that Require open abdomen
3303594|NCT01864590|Active Comparator|Double Sylo Bag - Mesh Protocol|Open Abdomen
3303595|NCT01864603|Experimental|1st: universal test and treat; 2nd: targeted PrEP and cascade|"Intervention arm first phase: annual universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery~Intervention arm second phase: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery + targeted PrEP, and targeted HIV testing interventions"
3303596|NCT01864603|Active Comparator|1st: baseline community testing; 2nd: universal test & treat|"Intervention arm first phase: baseline community-based HIV and multi-disease testing~Intervention arm second: baseline universal community-based HIV and multi-disease testing; ART for all HIV+ using streamlined care delivery"
3303597|NCT01864616|Experimental|Group 3|Vitamin D3, 10,000 IU daily
3303598|NCT01864616|Experimental|Group 2|Vitamin D3 2,000 IU daily
3303599|NCT01864616|Experimental|Group 1|Vitamin D3 600 IU daily (Control group, RDA level)
3303600|NCT01864629|Other|Contraception after preterm birth|Intervention name: Focused contraception counseling This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
3303601|NCT01864629|No Intervention|Control Group|Participants will receive the standard postpartum contraception counseling that is received by all patients who deliver at our institution.
3303602|NCT01864642|Experimental|osteopathic manipulative treatment|osteopathic manipulative treatment (OMT)
3303603|NCT01864655|Experimental|Saracatinib group 1|This group will receive AZD0530 (saracatinib) experimental oral drug , once daily, for a duration of 4 weeks. Dosage is 50mg per day.
3303604|NCT01864655|Experimental|Saracatinib group 2|Group 2 will receive saracatinib at a daily oral dose determined by the response to 50mg P.O. daily. Duration is 4 weeks.
3303605|NCT01864655|Experimental|Saracatinib group 3|Group 3 will receive saracatinib at a dose determined by the response to 50mg P.O. daily, as well as dose given to group 2. Duration is 4 weeks.
3303606|NCT01864655|Placebo Comparator|Placebo group 1-3|Subjects receiving saracatinib in groups 1-3 will be compared to subjects receiving daily, oral, placebo drug.
3303607|NCT01864681|Experimental|Arm A|Gefitinib and metformin. Metformin starting at a dose of 500 mg twice a day, orally with meals. After one week, increase the dose of metformin to 1000 mg as the first dose of the day and 500 mg as the second dose. After another week, increase to 1000 mg of metformin two times a day. Metformin treatment will be initiated one week before beginning TKI therapy, if possible, but TKI therapy will not be delayed for metformin loading.
3303608|NCT01864681|Placebo Comparator|Arm B|Gefitinib and placebo. Placebo was given to patients in the same way as that of metformin in Arm A.
3303609|NCT01864694|Experimental|TLC-Diet|Participants receive diet intervention through automated telephone system: TLC-Diet
3303610|NCT01864694|Experimental|WEB-Diet|Participants receive diet intervention through web-based system: WEB-Diet
3303611|NCT01864694|Experimental|Control|Assessment-only control group
3303612|NCT01864707|Experimental|usual care + acupuncture|standardized acupuncture treatment in addition to usual care
3303613|NCT01864707|Experimental|usual care+mbsr|mindfulness based stress reduction in addition to usual care not recruiting anymore
3303614|NCT01864707|Active Comparator|usual care|usual care without additional treatment
3303615|NCT01864720|Active Comparator|Professionally Administered CBT-I (Standard Care)|Patients assigned to this group will receive 6 weekly sessions of cognitive-behavioral therapy for insomnia (CBT-I) of approximately 50 minutes, offered individually by a licensed psychologist with significant experience (at least 2 years) in the administration of CBT-I with cancer patients.
3303616|NCT01864720|Experimental|Stepped Care CBT-I|Patients having an ISI score > 7 but < 15 (approximately 100 patients), will all receive first a web-based CBT-I for six weeks. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). Patients with an ISI score > 14 (approximately 100 patients) will receive six weekly sessions of CBT-I administered individually by a professional.
3303617|NCT01864733|Experimental|intervention group|"1) The 'intervention' group: 3-month multimodal approach associating exercise rehabilitation, ONS, n-3 PUFAs and androgen substitution:~Physical rehabilitation including endurance and resistance exercises two to three times a week.~Oral nutritional supplements: Fortimel max® (Nutricia®) (300 ml, 720 kcal, 29 g de proteins), once per day.~n-3 polyunsaturated fatty acids : DHA phospholipids (GPL-DHA®), 240 mg/day.~Testosterone: Testopatch® 2.4 mg in men and 1.2 mg in women; 2 patches renewed every two days."
3303618|NCT01864733|Other|control group|2) The 'control' group: no multimodal approach but the treatment currently recommended: heart rehabilitation and dietary counseling during 3 months.
3303619|NCT01864746|Experimental|Palbociclib|Palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
3303620|NCT01864746|Placebo Comparator|Placebo|Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a28-day cycle for thirteen cycles
3303621|NCT01864759|Experimental|ICOVIR5|ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp.
3303622|NCT01864772|Experimental|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
3303623|NCT01864785|Other|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
3303624|NCT01864785|Other|Fixation Combined With Fusion|Posterior Fixation Combined With Articular Process Fusion in thoracolumbar Fracture.
3303625|NCT01864798|Experimental|Denosumab|
3303626|NCT01864811|Experimental|Baby-CIMT|The infants will be prevented from using the preferred hand while the other hand will be trained using amusing and easily handled toys.
3303627|NCT01864811|Experimental|baby-massage|The infants will receive baby massage
3303628|NCT01864824|Experimental|methyl donor|"Methyl donor is made up of:~2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure."
3303629|NCT01864824|Placebo Comparator|placebo|placebo: The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
3303630|NCT01864837||Functional dyspepsia|They should meet the Rome III criteria for functional dyspepsia.
3303631|NCT01864850|Active Comparator|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
3303632|NCT01864850|Experimental|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
3303633|NCT01864863|Experimental|Test→Reference|HGP1206 125 mg 1 tablet → Traclear 62.5 mg 2 tablets
3303634|NCT01864863|Experimental|Reference→Test|Traclear 62.5 mg 2 tablets → HGP1206 125 mg 1 tablet
3303635|NCT01864876|Experimental|GLA-AF|5 mcg GLA-AF given as one subcutaneous injection.
3303636|NCT01864876|Experimental|GLA-SE|5 mcg GLA-SE given as one intramuscular injection.
3303637|NCT01864876|Experimental|EM060G (SE)|EM060G (SE) given as one intramuscular injection.
3303638|NCT01864889|Experimental|anti-CD19 CAR T cells|Patients receive anti-CD19-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3303639|NCT01864902|Experimental|anti-CD33 CAR T cells|Patients receive anti-CD33-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3303640|NCT01864915|Experimental|No Booster-low dose prucalopride booster|low dose prucalopride booster arm
3303641|NCT01864915|Experimental|Prucalopride Booster-high dose prucalopride booster|additional 2mg prucalopride at time of capsule ingestion
3303642|NCT01864915|Experimental|Picosalax Booster Arm|One sachet of Picosalax 2hrs after capsule ingestion and 1/2 sachet at 4 hrs after swallowing colon capsule.
3303643|NCT01864928||Stroke population|Adults with ischemic stroke.
3303644|NCT01864941|Active Comparator|Catheter Venography & Balloon Venoplasty|Patients will undergo catheter venography with balloon venoplasty procedure.
3303645|NCT01864941|Sham Comparator|Catheter Venography Only|Patients will undergo catheter venography only.
3303646|NCT01864954|Experimental|Enhanced Web+phone|Engaging and interactive website access plus phone calls from personal coach.
3303647|NCT01864954|Active Comparator|Basic Static Web|Static website access only, only introductory call.
3303648|NCT01864967||carbon dioxide infusion|Group I: receive carbon dioxide infusion
3303649|NCT01864967||control|did not receive carbon dioxide
3303650|NCT01864980||Hb group:15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
3303651|NCT01864980||SpHb group: 15 patients|scheduled for elective surgery associated with undetected, i.e., difficult to reliably monitor intraoperative blood loss.
3303652|NCT01864993|Experimental|suspected NC gluten sensitive subjects|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
3303653|NCT01864993|Experimental|suspected NC gluten sensitive|Patients referring gastrointestinal functional disorders will be selected and they will follow a gluten free diet
3303654|NCT01865006||Ligasure LF1212|
3303655|NCT01865006||Ultracision|
3303656|NCT01865006||Conventional|
3303657|NCT01865019||volume controlled|volume ontrolled ventilation
3303658|NCT01865019||pressure controlled|pressure controlled ventilation
3303659|NCT01865032||Skin Ulcers|Skin ulcers. No intervention. Subjects will be followed up by their respective primary providers.
3303660|NCT01865045||no treatment|no treatment
3303661|NCT01865058||DLBCL|Patients with newly diagnosis of diffuse large B-cell lymphoma is offered enrollment in this protocol.
3303662|NCT01865071|Experimental|loop ileostomi|Compare early vs. late closer of the protecting ileostoma in patients requiring rectal resection for rectal cancer
3303663|NCT01865097|Experimental|Relaxation guided imagery|
3303664|NCT01865097|Active Comparator|Relaxing music|
3303665|NCT01865110|Experimental|Induction experimental arm|R-CHOP / R-HAD : Alternating 3 cycles of R-CHOP administered in 3 week cycles + 3 cycles of R-HAD administered in 4 week cycles.
3303666|NCT01865110|Active Comparator|Standart induction arm|8 cycles of R-CHOP administered in 3 week cycles
3303667|NCT01865110|Experimental|Maintenance experimental arm|lenalidomide + rituximab : 13 cycles of rituximab SC 1400 mg administered in 8 week cycles + 26 cycles Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
3303668|NCT01865110|Active Comparator|Maintenance standart arm|13 cycles of rituximab SC 1400 mg administered in 8 week cycles for 24 months
3303669|NCT01865123|Experimental|Transcendental Meditation|TM is a simple, natural, effortless mental technique practiced with eyes closed sitting for 20 minutes twice a day. This allows the practitioner to experience lesser excited levels of the mind and correspondingly greater degrees of physical relaxation. TM is a traditional meditation technique that has its origin in the ancient Vedic tradition of India.
3303670|NCT01865123|Active Comparator|Prolonged Exposure|Prolonged Exposure (PE) is a specialized type of Cognitive Behavorial Therapy employing a manualized, trauma-focused behavioral treatment for PTSD and is based on exposure principles and emotional processing theory.
3303671|NCT01865123|Placebo Comparator|Educational Control|Didactic based instructional classes will provide health education which will include the benefits of proper diet, exercise, and reducing smoking and alcohol. No stress management techniques will be taught.
3303672|NCT01865136|Other|Medical Post Abortion Care by Midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
3303673|NCT01865136|No Intervention|Medical Post Abortion Care by physician|Women with incomplete abortion is diagnosed and treated with misoprostol by physician
3303674|NCT01865149||both optic nerve sheath diameter|
3303675|NCT01865162|Experimental|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
3303676|NCT01865175|Active Comparator|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine folloowed by 7 days of heme iron.
3303677|NCT01865175|Experimental|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
3303678|NCT01865188|Experimental|LCZ696 200 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg once daily for 8 weeks.
3303679|NCT01865188|Experimental|LCZ696 400 mg|Patients randomized to this treatment arm will receive LCZ696 400 mg once daily for 8 weeks.
3303680|NCT01865188|Active Comparator|Amlodipine 5 mg|Patients randomized to this treatment arm will receive amlodipine 5 mg once daily for 8 weeks.
3303681|NCT01865188|Active Comparator|Amlodipine 10 mg|Patients randomized to this treatment arm will receive amlodipine 10 mg once daily for 8 weeks.
3303682|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 8 weeks.
3303683|NCT01865188|Experimental|LCZ696 200 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 200 mg and amlodipine 10 mg once daily for 7 weeks.
3303684|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 5 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 5 mg once daily for 7 weeks.
3303685|NCT01865188|Experimental|LCZ696 400 mg and amlodipine 10 mg|Patients randomized to this treatment arm will receive LCZ696 200 mg and amlodipine 5 mg once daily for 1 week followed by LCZ696 400 mg and amlodipine 10 mg once daily for 7 weeks.
3303686|NCT01865188|Placebo Comparator|Placebo|Patients randomized to this treatment arm will receive placebo once daily for 8 weeks.
3303687|NCT01865201|Experimental|Edaravone group|Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
3303688|NCT01865201|Experimental|Control group|All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
3303689|NCT01865227|Active Comparator|Group Counseling|The major aim of the post-operative counseling groups is to engage patients in discussing and exchanging their thoughts on issues of concern related to their surgery and overall well-being. The selected patients will be informed about the purpose of these support groups and will be made aware that their attendance is entirely voluntary.
3303690|NCT01865227|No Intervention|Standard treatment|
3303691|NCT01865240|Experimental|Renal Denervation Group|participants randomised to undergo the renal denervation procedure
3303692|NCT01865240|No Intervention|Usual care|participants randomised to the usual care group will receive additional antihypertensive medication in an attempt to achieve blood pressure targets
3303693|NCT01865253|Experimental|Renal Denervation|Renal Denervation treatment
3303694|NCT01865266|Experimental|NUTIG|"The normal dose of ulinastatin for injection group(NUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 100,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3303695|NCT01865266|Experimental|HUTIG|"The high dose of ulinastatin for injection group(HUTIG):~Ulinastatin(Techpool inc,Guangdong,China) was administered to the group as a bolus of 200,000 U diluted in 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3303696|NCT01865266|Placebo Comparator|CG|"The compare group(CG):~The group was given 100 mL of normal saline every 8 hour.A course of treatment consisted of 7 days after the patients were diagnosed as VAP."
3303697|NCT01865279|Experimental|Trial part 1|
3303698|NCT01865279|Active Comparator|Trial part 2|
3303699|NCT01865292|Experimental|Insulin degludec|
3303700|NCT01865292|Active Comparator|Insulin glargine|
3303701|NCT01865305|Experimental|Trial part 1|
3303702|NCT01865305|Experimental|Trial part 2|
3303703|NCT01865318|Experimental|Part 1 (Once-daily dosing regimen, high concentration)|
3303704|NCT01865318|Experimental|Part 2 (Twice-daily dosing regimen, high concentration)|
3303705|NCT01865318|Experimental|Part 3 (Once-daily dosing regimen, low concentration)|
3303706|NCT01865331|Experimental|Low dose, insulin degludec|
3303707|NCT01865331|Experimental|Medium dose, insulin degludec|
3303708|NCT01865331|Experimental|High dose, insulin degludec|
3303709|NCT01865331|Experimental|IDegAsp 50|
3303710|NCT01865344||Heart surgery|Pain monitoring at different time periods
3303711|NCT01865357|Experimental|Patient|Clinically isolated neurological syndrome (CIS) compatible with a demyelinating inflammatory episode within the central nervous system, potentially beginning multiple sclerosis (MS) whatever the mode of presentation
3303712|NCT01865357|Experimental|Control|healthy subject
3303713|NCT01865370|Experimental|Kochujang Pills|
3303714|NCT01865370|Placebo Comparator|Placebo|
3303715|NCT01865383|Experimental|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
3303716|NCT01865383|No Intervention|Control|Control: Participants will receive delayed HIV prevention training at the conclusion of the intervention involving participants in the other condition.
3303717|NCT01865409|Active Comparator|Kangoroo care|"While performing Kangaroo care the infant should be held skin-to-skin contact with her mother for 30-60 minutes. The baby, who is naked except for a diaper and a piece of cloth covering his or her back (either a receiving blanket or the parent's clothing), is placed in an upright position against a parent's bare chest. The values of heart rate variability will be measured during and also without Kangaroo Care in the same infants but different times."
3303718|NCT01865422|Experimental|chronic cough|
3303719|NCT01865435|Experimental|new borns|
3303720|NCT01865474|Experimental|Treatment I|DLBS1033 bioactive fraction tablet 490 mg thrice daily
3303721|NCT01865474|Experimental|Treatment II|Placebo tablet of DLBS1033, thrice daily
3303722|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 4mg|
3303723|NCT01865500|Active Comparator|Metil prednisolone & Budesonide 8 mg|
3303724|NCT01865500|Active Comparator|Budesonide 4 mg & Budesonide 8 mg|
3303725|NCT01865526|Active Comparator|Low protein diet|The patients of this group received a classical low protein diet (LPD),according to their desired body weight (DBW), obtained by multiplying the squared value of the height times a reference body mass index (BMI) value of 23. LPD were individually prepared and explained to the patients by a dedicated dietician and contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
3303726|NCT01865526|Experimental|Six point diet|These patients were assigned to receive the 6-points-diet, and were given by the Nephrologist the list of six items indicating how to modify their dietary habits; all the items were thoroughly explained and discussed with the patients
3303727|NCT01865539|Active Comparator|Custom Foot Orthotic|Custom foot orthotic
3303728|NCT01865539|Sham Comparator|Sham Orthotic|Will be a sham orthotic that will be the same as the actual orthotic without the custom support pads.
3303729|NCT01865565||Imatinib treat|"• Locally advanced unresectable GIST without metastasis at~EC junction requiring total gastrectomy,~Duodenum requiring Whipple operation;~Large GIST requiring multiviceral resection;~Rectum: requiring APR."
3303730|NCT01865578|Experimental|tDCS|Transcranial direct current stimulation
3303731|NCT01865578|Sham Comparator|sham stimulation|sham stimulation
3303732|NCT01865591|Experimental|Renal denervation|Subjects are treated with unfocussed ultrasound-based renal denervation and are maintained on baseline anti-hypertensive medications.
3303733|NCT01865604|Experimental|Anodal tDCS|anaodal transcranial direct current stimulation
3303734|NCT01865604|Active Comparator|Cathodal tDCS|cathodal transcranial direct current stimulation
3303735|NCT01865604|Sham Comparator|Sham tDCS|no stimulation
3303736|NCT01865617|Experimental|Treatment (anti-CD19-CAR autologous T cells)|"Patients receive anti-CD19-CAR lentiviral vector-transduced autologous T cells IV over 20-30 minutes on day 0. Treatment may be repeated in no less than 21 days with or without additional lymphodepleting chemotherapy if there is persistent disease in the absence of unacceptable toxicity.~DOSE DENSE EXPANSION COHORT: An additional cohort will receive a second anti-CD19-CAR lentiviral vector-transduced autologous T cell infusion without additional lymphodepleting chemotherapy 10-21 days after the first infusion if adequate CD19 CAR-T cells can be produced and appropriate criteria are met."
3303737|NCT01865630|Experimental|Etanercept|Patients with aneurysmal subarachnoid hemorrhage will be treated with etanercept, 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
3303738|NCT01865643|Other|Standard GlideScope intubation|This standard GlideScope (GS) technique involves a midline larygoscopy followed by insertion of a styleted endotracheal tube, once an adequate view of the vocal cords is achieved.
3303739|NCT01865643|Experimental|Alternative GlideScope intubation|"Alternative GlideScope (GS) intubation involves the insertion of the endotracheal tube under direct vision as a fish hook at the side of the mouth before the GS blade is introduced into the oropharynx."
3380747|NCT04443660||Group A|without medical history or risk factors, with a normal pregnancy
3380748|NCT04443660||Group B|without medical history or risk factors, developing a pregnancy complication
3380749|NCT04443660||Group C|with risk of complication, having a normal pregnancy
3380750|NCT04443660||Group D|with a risk of complication, developing a pregnancy complication
3380756|NCT04437511|Experimental|Donanemab|Donanemab given intravenously (IV).
3380757|NCT04437511|Placebo Comparator|Placebo|Placebo given IV.
3380759|NCT04435249|Experimental|Treatment Arm|Patients will have a patch of expanded somatic mesenchymal stromal cells (MSCs) seeded onto a decellularised human tracheal-scaffold surgically implanted to repair bronchial fistula.
3380761|NCT04433585|Experimental|LY3471851 High Dose|LY3471851 administered subcutaneously (SC).
3380762|NCT04433585|Experimental|LY3471851 Mid Dose|LY3471851 administered SC.
3380763|NCT04433585|Experimental|LY3471851 Low Dose|LY3471851 administered SC
3380764|NCT04433585|Placebo Comparator|Placebo|Placebo administered SC.
3380776|NCT04425096|Experimental|Skin to skin contact|The mothers and their babies in the experimental group received a 30-minute skin to skin contact immediately after birth (n:34)
3380777|NCT04425096|No Intervention|Routine care|The babies in the control group received routine care (n:34)
3380778|NCT04424316|Experimental|RSVpreF vaccine|RSVpreF
3380779|NCT04424316|Placebo Comparator|Placebo dose|Placebo
3380780|NCT04421196|No Intervention|Standard multimodal analgesic pathway with opioids|"This is the control group, who will receive the current standard multimodal analgesic regimen, which includes opioids following total hip arthroplasty at Johns Hopkins Bayview Hospital.~The current standard multimodal analgesic regimen utilizes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Opioid (fentanyl) & Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: 0.25 % bupivacaine with epinephrine and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Oxycodone 5-10 mg PO, IV opioids (Morphine, hydromorphone), Acetaminophen 1000 mg PO q6hr"
3380781|NCT04421196|Experimental|Modified multimodal analgesic pathway without opioids|"This is the experimental group, who will receive a modified multimodal analgesic regimen, which excludes the use of any opioids.~The modified multimodal analgesic regimen utilizes the following medications:~includes the following medications: Gabapentin 300 mg, Celecoxib 200 mg (Meloxicam if sulfa), Non-opioid anesthetics (fluranes, propofol, ketamine, etc.); Periarticular injection: Liposomal bupivacaine, 0.25 % bupivacaine with epinephrine, Betamethasone sodium phosphate, betamethasone acetate and Ketorolac IV; high volume cryotherapy, Ketorolac 30 mg IV, Ketamine IV, Ketorolac 15 mg PO, Acetaminophen 1000 mg PO q6hr"
3380782|NCT04416906|Experimental|Biktarvy|This is a fixed dose combination regimen containing 50 mg of Bictegravir + 200 mg of Emtricitabine + 25 mg of Tenofovir alafenamide.
3380783|NCT04413851||Dementia|Subjects with a diagnosis of dementia who are experiencing agitation severe enough that it interferes with activities of daily living or social interaction.
3303740|NCT01865656|Other|4 intervention first referral units|"A Quasi-experimental intervention/control trial will be implemented to assess the impact of the following interventions on the outcome measures in a cluster of 4 intervention sites relative to a matched cluster of 4 control sites:~Refresher/simulation training to improve provider skills/knowledge Implementation of Emergency Obstetric Drills Revised Case sheets(for data collection and therefore part of both control and intervention sites), Mentoring and Supportive supervision, and Referral Strengthening"
3303741|NCT01865656|No Intervention|Control Arm|
3303742|NCT01865669|No Intervention|Control|A control sample from each patient (no oxytocin applied) will be measured concurrently with samples treated with varying concentrations of oxytocin.
3303743|NCT01865669|Experimental|Oxytocin|Samples from each patient will be bathed in a solution containing varying concentrations of oxytocin.
3303744|NCT01865695|Placebo Comparator|Placebo|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
3303745|NCT01865695|Active Comparator|Creon|Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
3303746|NCT01865721|Active Comparator|Continuous administration of Entonox|Patients randomized to this arm will be asked to inhale Entonox throughout the insertion phase of colonoscopy
3303747|NCT01865721|Active Comparator|As required administration of Entonox|Patients randomised to this arm will be asked to use Entonox if and when they have pain
3303748|NCT01865734|Experimental|Early Physical Therapy|Physical therapy after initial podiatry visit
3303749|NCT01865734|Active Comparator|Usual Podiatric Care|Usual care provided by podiatry
3303750|NCT01865760|Experimental|Gastric bypass surgery, hypoglycemia|Subjects with previous gastric bypass surgery (more then 1 year ago) and symptomatic hypoglycemia according to Whipples triade. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal. They will furthermore undergo two additional liquid mixed meal; one with concomitant treatment with synthetic Exendin 9-39 and another with treatment with Octreotide. All tests will be separated by at least one week.
3303751|NCT01865760|Active Comparator|Gastric bypass surgery, asymptomatic|Subjects with previous gastric bypass surgery (more then 1 year ago) without any signs of hypoglycemia. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
3303752|NCT01865760|Other|Controls|Healthy non-operated control subjects, matched on BMI, age and sex. These subjects will undergo an oral glucose tolerance test (OGGT), an isoglycemic intravenous glucose infusion (IIGI) and a 300 kcal liquid mixed meal.
3303753|NCT01865773|Experimental|HFR|We selected 8 inflamed chronic HD patients, which underwent a single 240 minutes HFR session
3303754|NCT01865786||FTC/TDF for PrEP|The study has one target prospective cohort defined as HIV-1 negative women who had been prescribed FTC/TDF for pre-exposure prophylaxis (PrEP); with two strata: a) those who continue to take FTC/TDF for PrEP during their pregnancy, and b) those who decide to stop FTC/TDF for PrEP during pregnancy.
3303755|NCT01865786||ARV population|The study has one comparison cohort defined as HIV-positive women who were on any antiretroviral (ARV) medication at the time the pregnancy was detected. This is a propensity score matched retrospective cohort selected from the prospective arm of the APR. This cohort is assembled retrospectively in order to appropriately match the subjects by calendar time and the correlates of exposure, with exposure being defined as being on FTC/TDF for PrEP vs being exposed to other ARVs.
3303756|NCT01865799||FTC/TDF for PrEP|This prospective case series is composed of every subject in a database containing de-identified patient-level data from all healthcare channels in the US, of individuals that are exposed to FTC/TDF or its components for any indication.
3303757|NCT01865825||Esophageal barium xray|"We will recruit 20 patients with GERD without dysphagia for an esophageal barium xray for esophageal diameter measurements.~The 20 Gastroesophageal Reflux Disease (GERD) patients will complete the Mayo Dysphagia Questionnaire 30-day and the Eosinophilic Esophagitis Actitivy Index (EEsAI) questionnaires"
3303758|NCT01865838|Active Comparator|Seprafilm (Sanofi, USA)|Patients in this arm received Seprafilm during surgery.
3303759|NCT01865838|No Intervention|Control|Patients in this arm does NOT receive Seprafilm during surgery.
3303760|NCT01865851|Active Comparator|Start with Classic Face Mask Group|The volunteers will be asked to breathe normally (Tidal Volume Breathing) through face mask for 5 minutes. After 5 minutes, the volunteers will be asked to breathe room air for 5 minutes and then breathe through a NuMask for 5 minutes. This will be followed by room air breathing for 5 minutes. At the end of the 5 minutes of room air breathing, the same volunteers will be asked to breathe through the face mask for 5 minutes.
3303761|NCT01865851|Active Comparator|Start with NuMask Group|The volunteers will be asked to breathe through the NuMask for 5 minutes, followed by room air breathing for 5 minutes, then 5 minutes of breathing through the face mask. This will be followed by room air breathing for 5 minutes and then 5 minutes of NuMask breathing.
3303762|NCT01865864||1|Compliant with CPAP
3303763|NCT01865864||2|noncompliant with CPAP
3303764|NCT01865877||PD Cohort|Subjects diagnosed with Parkinson's disease
3303765|NCT01865890||patient on hemodialysis taking plavix|patient on hemodialysis taking plavix
3303766|NCT01865903||Cohort 1|All with diagnose of NSCLC in Oslo during 6 months
3303767|NCT01865903||Cohort 2|All NSCLC in Ulleval university hospital whom are in need of palliative chemotherapy
3303768|NCT01865916|Active Comparator|2 Liters Bi-Peglyte|Subjects will be asked to take split dose of 2 Liters PEG + 15mg bisacodyl for bowel preparation the day before colonoscopy.
3303769|NCT01865916|Experimental|2 Liters Moviprep|Subject will be asked to take split dose of 2 Liters PEG + ascorbic acid for bowel preparation the day before colonoscopy
3303770|NCT01865929|Active Comparator|Robotic hysterectomy|Minimally invasive hysterectomy by robotic surgery
3303771|NCT01865929|Active Comparator|Vaginal or laparoscopic hysterectomy|Minimal invasive hysterectomy by vaginal or traditional laparoscopic surgery.
3303772|NCT01865942|Active Comparator|open surgery|One arm receives open surgery. In our department open surgery is considered as the standard procedure since all spine surgeons are preforming this operation.
3303773|NCT01865942|Active Comparator|Minimal access surgery|We compare to well-known types of surgery for metastatic spinal cord compression. The other arm receive open surgery. In our department minimal access surgery is considered as a standard procedure but it is not preformed by all spine surgeons.
3303774|NCT01865955|No Intervention|Palpation|Palpation will be used to determine placement of the spinal needle.
3303775|NCT01865955|Experimental|Ultrasound|Ultrasound will be used prior to placement of the spinal needle.
3303776|NCT01865968|Experimental|Inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with one-dose regimen.
3303777|NCT01865968|Active Comparator|Live attenuated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received live attenuated HAV vaccine containing 6.50 lgCCID50/vial with one-dose regimen.
3303778|NCT01865968|Experimental|Two-dose inactivated HAV vaccine|Healthy undergraduate students aged 16 to 25 years with anti-HAV negative received inactivated HAV vaccine containing 500u/vial with two-dose regimen.
3303779|NCT01865981||Hereditary VF|Patients with hereditary ventricular fibrillation, negative for known mutations
3303780|NCT01865981||Brugada|Patients suffering from Brugada syndrome
3303781|NCT01865994||Pediatric cardiac surgery|Children scheduled for elective cardiac surgery
3303782|NCT01866007|Experimental|Group 1|40 participants will receive a single subcutaneous (SC) injection of 100 mg guselkumab prepared from lyophilized formulation.
3303783|NCT01866007|Experimental|Group 2|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with UltraSafe Passive Delivery System (PFS-U).
3303784|NCT01866007|Experimental|Group 3|40 participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with a prefilled syringe facilitated injection device (PFS FID).
3303785|NCT01866007|Experimental|Group 4|20 participants will receive a single intravenous (IV) infusion of 100 mg guselkumab prepared from liquid formulation.
3303786|NCT01866033|Experimental|PCI-32765|During Period 1, all patients will receive PCI-32765 560 mg administered by mouth (Treatment A). In Periods 2 and 3, patients will receive PCI-32765 560 mg administered by mouth without grapefruit juice (Treatment B) and PCI-32765 140 mg administered by mouth with grapefruit juice (Treatment C) according to a randomization schedule. An intravenous dose of 13C6 PCI-32765 will be administered 2 hours after each oral dose for reference purposes.
3303787|NCT01866046|Experimental|RESPECT-IPV|Rapid HIV testing and risk prevention intervention for victims of intimate partner violence
3303788|NCT01866059|Experimental|Calcium silicate cement|Biodentine
3303789|NCT01866059|Active Comparator|Glass Ionomer Cement|Fuji IX
3303790|NCT01866059|Active Comparator|Resin Modified Glass Ionomer Cement|Fuji II LC
3303791|NCT01866072||AVH|AVH: Patients with Acute Viral Hepatitis
3303792|NCT01866072||ACLF|ACLF: Patients with Acute on Chronic Liver Failure
3303793|NCT01866085|Active Comparator|AdVance|sling procedure
3303794|NCT01866085|Active Comparator|ARGUS|sling procedure
3303795|NCT01866111|Placebo Comparator|Placebo|Placebo
3303796|NCT01866111|Experimental|YKP3089 Low Dose|YKP3089 Low Dose
3303797|NCT01866111|Experimental|YKP3089 Medium Dose|YKP3089 Medium Dose
3303798|NCT01866111|Experimental|YKP3089 High Dose|YKP3089 High Dose
3303799|NCT01866124|Experimental|Cash transfer|"Mothers are the primary recipient of the CT. The proposed approach will be based on monthly seasonal CTs during 5 months, from May to September, for two years (2013 and 2014). A monthly 10 000 FCFA will be transferred to the selected households.~These CTs will be done via mobile phones, in collaboration with the mobile phone company Airtel."
3303800|NCT01866124|No Intervention|Comparison group|
3303801|NCT01866137||no treatment|no treatment
3303802|NCT01866176|Experimental|Knee osteoarthritis patients|Knee osteoarthritis patients with Kellgren & Lawrence grade I, II or III Stabilizing Knee Brace Valgus Knee Brace New Knee Brace
3303803|NCT01866189|Experimental|PET and MRI|Included patients will have F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF) as soon as possible after stroke onset (less than 36 hours). A second brain MRI (MRI-2) will be performed on day 7.
3303804|NCT01866215|Experimental|Study1a|exercice performed 90 min before 13C fructose meal ingestion
3303805|NCT01866215|Experimental|study 1b|exercise performed 90 min after 13C fructose meal ingestion
3303806|NCT01866215|No Intervention|study 1c|no exercise
3303807|NCT01866215|Experimental|study 2a|meals containing fructose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
3303808|NCT01866215|Active Comparator|study 2b|meals containing glucose, cream and whey proteins over 24 hours after a glycogen/intramyocellular lipid depleting exercise
3303809|NCT01866228|No Intervention|No Consultation Recording|Participant does not receive consultation recording
3303810|NCT01866228|Experimental|Consultation Recording|Participant receives consultation recording
3303811|NCT01866241|Experimental|Arm A: sublingual misoprostol 600µg|Misoprostol is a uteretonic drug
3303812|NCT01866241|Placebo Comparator|Arm B: 10 IU Oxytocin|Oytocin is a standard of care treatment for PPH
3303813|NCT01866254|Experimental|Hydromorphone|100 mg, intrathecal administration
3303814|NCT01866254|Active Comparator|Morphine|200 mg, intrathecal administration
3303815|NCT01866267|Other|Maraviroc|Patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
3303816|NCT01866280|Experimental|Normal sleep Normal meals|Normal sleep/Normal meal times
3303817|NCT01866280|Experimental|Normal sleep Late meals|Normal sleep/Late meal times
3303818|NCT01866280|Experimental|Late sleep Late meals|Late sleep/Late meal times
3303819|NCT01866280|Experimental|Late sleep Normal meals|Late sleep/Normal meal times
3303820|NCT01866332|Active Comparator|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
3303821|NCT01866332|Experimental|Conventional Physical Therapy plus Kinesiotaping|"Patients will receive conventional physical therapy plus an application of Kinesiotaping in their lumbar spine.~Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)."
3303822|NCT01866345|Active Comparator|Conventional orthodontic treatment|conventional orthodontic treatment in the mandibular anterior region
3303823|NCT01866345|Experimental|Surgically facilitated Orthodontics|Surgically facilitated Orthodontic treatment in the mandibular anterior region
3303824|NCT01866358|Placebo Comparator|Umbilical vein infusion|using umbilical vein infusion for resucitation
3303825|NCT01866358|Experimental|Intraosseous infusion|using intraosseous infusion for resucitation
3303826|NCT01866371||Retinal degeneration|This group will include patients with retinal degeneration and vision abnormalities. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
3303827|NCT01866371||Normal control|This group will include individuals without retinal degeneration. The group will participate in retinal imaging procedures including adaptive optics imaging, optical coherence tomography and fundus photography. Vision may be assessed using microperimetry, visual fields, and visual acuity.
3303828|NCT01866384|Other|Normal Temperature|72 hours of Normal Temperature (36-37 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
3303829|NCT01866384|Experimental|Mild Induced Hypothermia|72 hours of mild induced hypothermia (32-34 degrees Celcius). Subjects in all arms will otherwise receive identical therapeutic interventions pre-defined by our local IPH management protocol.
3303830|NCT01866397|Experimental|Cidofovir pharmacokinetics|Patient received cidofovir due to clinical necessity (therapy resistant HCMV retinitis) while being on continuous hemofiltration. Pre- and postfilter plasma samples were taken at multiple timepoints during 24 hours.
3303831|NCT01866436|Experimental|Multimedia group|The multimedia group is the interventional arm of the study
3303832|NCT01866436|Experimental|Study Day Group|The study day group are the control arm of the study
3303833|NCT01866449|Experimental|Cabazitaxel|Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
3303834|NCT01866462|Experimental|Metformin, NM504|metformin 500mg b.i.d. with NM504 b.i.d. for 1 week followed by metformin 500mg t.i.d. with NM504 b.i.d. for 1 week.
3303835|NCT01866462|Placebo Comparator|Metformin, Placebo|metformin 500mg b.i.d. with Placebo b.i.d. for 1 week followed by metformin 500mg t.i.d. with Placebo b.i.d. for 1 week.
3303836|NCT01866475|Active Comparator|Renal Disease|Those with mild to moderate renal disease and had an EZ-IO for 48 hours
3303837|NCT01866475|Active Comparator|Diabetes|Those with controlled diabetes and had an EZ-IO for 48 hours
3303838|NCT01866475|Active Comparator|Renal disease and diabetes|Those with both mild to moderate renal disease and controlled diabetes and had an EZ-IO for 48 hours
3303839|NCT01866475|Active Comparator|Healthy adults|Those who are healthy, defined as lacking co-morbidities that are a study exclusion, and had an EZ-IO for 48 hours
3303840|NCT01866488|Experimental|Cook Catheter, Oral Misoprostol|Cook Catheter is placed and a 50mcg misoprostol tablet is given orally. A repeat dose is administered in 3 hours.
3303841|NCT01866488|Placebo Comparator|Cook Catheter, Oral Placebo|Cook Catheter is placed and a placebo tablet is given orally. A repeat dose is administered in 3 hours.
3303842|NCT01866501|Experimental|Blended Technique|Using the blended technique device operators will establish proximal humerus intraosseous vascular access.
3303843|NCT01866514|Experimental|Anesthesia Arm|proximal humerus intraosseous vascular access will be established bilaterally in the proximal humerus using the anesthesia approach in which the arm is abducted from the body.
3303844|NCT01866527||all newborns born 1991-2006|all newborns born 1991-2006
3303845|NCT01866540|Experimental|Fluenz vaccine|LAIV vaccine
3303846|NCT01866553|Experimental|Nilotinib, Pegylated interferon α2b|"Patients will be treated with nilotinib 300 mg BID during the first 3 months. Then the combination phase ensues with continued daily nilotinib 300 mg BID combined with PegIFN 25 ug/week for 3 months up to the Month 6 time point. If the patient has no more than grade 1 non-hematological toxicity or grade 2 hematological toxicity, the dose will be increased to 40 μg/w until Month 12. The follow-up phase with daily nilotinib 300 mg BID covers the next 12 months period (Month 12 to 24). until Month 12, which is followed by monotherapy phase of nilotinib 300 mg BID. Overall study duration for the individual patient is 24 months."
3303847|NCT01866566|Placebo Comparator|HBV-3|one dose HBV
3303848|NCT01866566|Placebo Comparator|HBV-6|one dose HBV
3303849|NCT01866566|Experimental|varicella-3|2 doses varicella vaccine either BCHT or Kengen and 3 month of the interval time
3303850|NCT01866566|Experimental|varicella-6|2 doses varicella vaccine either BCHT or Kengen and 6 month of the interval time
3303851|NCT01866579||ethambutol optic neuropathy|
3303852|NCT01866605|Placebo Comparator|1|Single un-warmed cotton blanket over body and limbs, and reassurance, during preoperative period in anaesthetic room
3303853|NCT01866605|Active Comparator|2|Single un-warmed cotton blanket over body and limbs, reassurance and intravenous midazolam 30 µg/kg i.v, during preoperative period in anaesthetic room
3303854|NCT01866605|Active Comparator|3|Single un-warmed cotton blanket, reassurance and forced-air warming with a Bair Hugger, during preoperative period in anaesthetic room
3303855|NCT01866618||Natural IVF Cycle|All patients will undergo a natural IVF cycle using trigger shots of Leuprolide Acetate(Lupron) and human chorionic gonadotropin (hCG) to ensure the patient surges.
3303856|NCT01866631||No treatment|
3303857|NCT01866644|Experimental|N-acetylcysteine|At portal level, a cannula is inserted with the usual technique of infusion of 3000 ml of preservation fluid to free fall as containing or not scrambling inserted by the NAC scrub nurse then (400 mg of N-acetylcysteine at 10%, 4 ml ).
3303858|NCT01866644|Placebo Comparator|Saline|With usual technique
3303859|NCT01866657|Experimental|Intervention cohort|Open cerebral oximetry monitoring; observed desaturations will be treated with an intervention algorithm including increase FiO2, head/neck repositioning,vasoconstrictor agents, IV fluid bolus, increase ETCO2, additional anesthesia, RBC transfusion.
3303860|NCT01866657|No Intervention|Blinded cerebral oximetry monitoring|These subjects will have continous cerebral oximetry monitoring like the experimental cohort but the values will be blinded to all clinicians and research staff. There will be no cerebral desaturation interventions in this group because the clinicians will not be aware of a desaturation as the monitor's output is blinded in this group.
3303861|NCT01866670|Experimental|spiritual support|"-Spiritual Support: deep breathing + guided image + meditation~Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the experimental group, it will be developed the support spiritual intervention in all three meetings.~In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
3303862|NCT01866670|Active Comparator|relaxation therapy|"Relaxation Therapy Each patient will participate individually in three sequential meetings (A1, A2 and A3).~In the control group, it will be performed just relaxing in all three meetings. In all meetings, namely A1, A2 and A3 the physiological parameters will be recorded (PA, SpO2, HR) through the monitor BM5."
3303863|NCT01866683|Experimental|Group 1|1 month respiratory training
3303864|NCT01866683|Experimental|Group 2|1 month waiting period
3303865|NCT01866696|Experimental|guided implant insertion and immediate loading|This work was designed as a prospective case series clinical study. Twenty patients have been consecutively rehabilitated with an immediately loaded oral implant supported fixed full prosthesis. A total of 120 oral implants (Nobel Replace Tapered Groovy; Nobel Biocare AB, Goteborg, Sweden) supporting 23 bridges (8 mandible, 15 maxilla) were placed , 22 of which in fresh post extraction sockets. 117 out of 120 oral implants were immediately loaded.
3303866|NCT01866722|Active Comparator|Usual Care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
3303867|NCT01866722|Active Comparator|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
3303868|NCT01866722|Active Comparator|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
3303869|NCT01866735|No Intervention|Usual Care|
3303870|NCT01866735|Experimental|Standardized Rehabilitation Therapy|"Standardized Rehabilitation Therapy (SRT):~Participants randomized to the Standardized Rehabilitation Therapy arm will receive three types of interventions - Passive Range of Motion (PROM), Physical Therapy (PT) and Progressive Resistance Exercise (PRE). The SRT protocol will be administered by the BICU Mobility Team within 80 hours of ventilation and contains four levels of activity therapy. This Protocol will be delivered 7 days a week. Patients will be assessed daily and if appropriate will receive 3 separate sessions of activity each day."
3303871|NCT01866748|Experimental|Part A (single dose)|
3303872|NCT01866748|Experimental|Part B (multiple dose)|
3303873|NCT01866761||Periodontitis, Lifestyle-related disease|
3303874|NCT01866774|Experimental|Fecal calprotectin level|Fecal calprotectin level
3303875|NCT01866774|No Intervention|Symptom questionnaire|
3303876|NCT01866787||Study cohort|
3303877|NCT01866800|Active Comparator|Renal Guard|Renal Guard in addition to Saline and N-Acetylcysteine
3303878|NCT01866800|Placebo Comparator|Conventional Treatment|Saline and N-Acetylcysteine
3303879|NCT01866813|No Intervention|Waiting list control group|Waiting list control group who is offered cognitive training at the end of the data collection period.
3303880|NCT01866813|Experimental|Cognitive training intervention group|"Cognitive training intervention group: 6 weeks of intervention with the online cognitive training scientific brain training pro for 40-60 minutes a day/ 5 days a week. Reminders and motivational phone-calls throughout the intervention period. Phone and Internet-based technical support is available."
3303881|NCT01866878|Experimental|A group enjoying a corrective touch|"At first, the patient is asked to gradually define the different types of touch that is applied to the hyposensitive area (fixed or mobile touches) with different textures and then compare them with the healthy side. In a second step, the patient is asked to associate multiple items sensation shape and texture, shape and weight. In a third step is used everyday objects.~Desensitisation techniques find their interest mainly when symptoms or dysesthetic hyperesthésique. The objective is to increase the threshold of sensitivity to textures and particles eventually reduce dysaesthetic sensations.~The patient class in order of increasing tolerance 10 textures. Dysesthetic area is stimulated 5 to 10 minutes by the first texture to numb the area by saturation of the action potential. This helps promote functional work and recognition of objects. As soon as the texture causes more trouble we go to the next texture by applying the same job."
3303882|NCT01866878|Experimental|A group receiving TENS (TENS)|Well known in the management of neuropathic pain based on the gate control theory, the application of TENS in the rehabilitation of touch remains to be demonstrated. A recent study applied to the September highlighted the long-term interest of the transcutaneous electrical nerve stimulation (TENS) to improve sensitivity tact arguing possible action on brain plasticity.
3303883|NCT01866878|No Intervention|A control group|
3303884|NCT01866891|Experimental|single arm|
3303885|NCT01866904||Stable CAD patients aged 50 years or older|Stable CAD patients aged 50 years or older with documented history of presumed spontaneous MI with their most recent MI occurring 1 to 3 years prior to enrollment and have at least 1 additional risk factor
3303886|NCT01866930|Experimental|Cohort A: GT-2 or -3 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 weeks~Ribasphere 200 mg tablets (800 mg per day: two 200 mg tablets in the morning and two 200 mg tablets in the evening) by mouth twice daily for 24 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
3303887|NCT01866930|Experimental|Cohort B: GT-1 or -4 HCV Treatment Naïve Subjects|"Pegylated Interferon Lambda 180 µg solution, injection subcutaneously once weekly for 24 or 48 weeks~Ribasphere 200 mg tablets, (1000 mg per day: two 200 mg tablets in the morning and three 200 mg tablets in the evening for subjects weighing <75 kg and 1200 mg per day: three 200 mg tablets in morning and three 200 mg tablets in evening for subjects weighing ≥75 kg) by mouth twice daily for 24 or 48 weeks~Daclatasvir 30 mg, 60 mg, or 90 mg tablets (depending on concomitant HIV regimen) once daily for 12 weeks"
3303888|NCT01866969|Experimental|Supportive care (quality of life questionnaire)|Caregivers complete a self-administered questionnaire about factors associated with increased caregiver burden and decreased quality of life.
3303889|NCT01866982|Active Comparator|Umbilical Cord Milking|Milking the umbilical cord 4 times towards the infants at a speed of 20cm/2 seconds
3303890|NCT01866982|Active Comparator|Delayed Cord Clamping|Delayed clamping of the umbilical cord for 45-60 seconds
3303891|NCT01866995|Experimental|Raylis|"This arm (10 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months"
3303892|NCT01866995|Active Comparator|standard prostatostasis therapy|This arm (20 men with symptoms of prostatostasis) will get the standard (pathogenetic) therapy of prostatostasis
3303893|NCT01866995|Experimental|Raylis plus standard prostatostasis therapy|"This arm (20 men with symptoms of prostatostasis) will get Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg) 2 kapsules a day per 3 months together with standard prostatostasis therapy"
3303894|NCT01867034|Active Comparator|Bare Metal stent|Stent that has not been impregnated with an anti-restenotic drug
3303895|NCT01867034|Active Comparator|Drug Eluting Stent|Stent that has been impregnated with an anti-restenotic drug
3303896|NCT01867060|Other|Personal Heart Rhythm Monitor|Automated Cardiac Event Recorder in parallel with Personal Heart Rhythm Monitor.
3303897|NCT01867073||Advanced solid tumours|
3303898|NCT01867099||Post-successful ablation|Patients who had undergone PVI ablation for AF and were free of AF for at least one year
3303899|NCT01867112|Active Comparator|Individualized Program|Based on personal fitness an individualized physical activity program will be built and followed by each individual in the arm
3303900|NCT01867112|Active Comparator|General Physical Activity Guidelines|The entire group of individuals in this arm will follow a physical activity program according to the General Physical Activity Guidelines
3303901|NCT01867125|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 milligrams [mg]) every 4 weeks for 104 weeks.
3303902|NCT01867125|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
3303903|NCT01867125|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
3303904|NCT01867138|Experimental|Cefazolin group|Initial empirical treatment with cefazolin and amikacin
3303905|NCT01867138|Active Comparator|Vancomycin|Initial empirical treatment with vancomycin and amikacin
3303906|NCT01867151|Experimental|Gluten free diet|BMS patients following a GFD
3303907|NCT01867151|Sham Comparator|Normal Diet|Patients with BMS maintaing a normal diet
3303908|NCT01867177|Other|HIV testing|Identification of HIV infection among recently infected adults
3303909|NCT01867177|Experimental|HIV care utilization|Improved access to HIV care and HIV care utilization, particularly among newly diagnosed adults
3303910|NCT01867177|Active Comparator|standard of care|Standard of HIV care; standard of linkage to HIV care
3303911|NCT01867190|Other|ASCT01|ASCT01 (Autologous Stem Cell Transplantation)
3303912|NCT01867203||Statin users|
3303913|NCT01867229||FEC- TC|Fluorouracil- Epiadriamycine- Cyclophosphamide Taxotère-Cyclophosphamide
3303914|NCT01867242|Experimental|Usual Brand Cigarette|Smoking usual brand cigarette controls, who after 8-weeks will be offered Camel Snus and instructed for partial or complete substitution of cigarettes (subject's choice);
3303915|NCT01867242|Experimental|Complete Substitution|Use snus in place of cigarettes
3303916|NCT01867242|Experimental|Partial Substitution (Snus and Cigarettes)|Use snus and cigarettes how ever you like
3303917|NCT01867255|Other|venlafaxine ER|venlafaxine ER (extended-release) 75 mg once
3303918|NCT01867268|Experimental|Acetazolamide|administration of Acetazolamide for 10 days following the surgery
3303919|NCT01867268|No Intervention|Control|control group without any intervention
3303920|NCT01867268|Experimental|Prone positioning|Positioning the patient following surgery for 10 days
3303921|NCT01867268|Experimental|Acetazolamide and Prone positioning|applying both Acetazolamide and prone positioning
3303922|NCT01867281|Active Comparator|Intervention: Aspirin|Participants will undergo aspirin desensitization over a 2-day period with increasing doses of aspirin (60, 125, 325 and 625 mg). Thereafter,they will be followed with 625 mg aspirin bid.
3303923|NCT01867281|Placebo Comparator|Control: placebo|Participants will receive placebo
3303924|NCT01867320|Experimental|Raltegravir|Raltegravir at 400mg by mouth twice daily in an initial 6 months treatment phase, followed by an additional 9 months post treatment phase.
3303925|NCT01867333|Experimental|1|Enzaluatmide alone
3303926|NCT01867333|Experimental|2|Enzaluatmide with PSA-TRICOM
3303931|NCT01867437|Active Comparator|RM-493|Double blind RM-493 will be administered at a dose of 1 mg/24 hrs via subcutaneous infusion for 3 days
3303932|NCT01867437|Placebo Comparator|Placebo|Double blind placebo will be administered via subcutaneous infusion for 3 days
3303933|NCT01867450||Biomarker Cross-section|Cross-sectional biomarker study in Chinese diesel workers
3303934|NCT01867463|Experimental|Group 1|Group 1: n=20, randomized to receive 16 g Pfs25-EPA/Alhydrogel (n=10) or the comparator (EuvaxB, n=10) on D0, D56
3303935|NCT01867463|Experimental|Group 2|Group 2: n=30, randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=15) or the comparator (EuvaxB and Menactra , n=15) on D0, D56, D112, D480
3303936|NCT01867463|Experimental|Group 3|Group 3: n=70 randomized to receive 47 g Pfs25-EPA/Alhydrogel (n=35) or the comparator (EuvaxB and Menactra , n=35) on D0, D56, D112, D480
3303937|NCT01867476||Healthy Normals|
3303938|NCT01867489||Chemotherapy, Cancer|Adult cancer patients (with any type of cancer) being treated with chemotherapy
3303939|NCT01867502|Other|MET + Glibenclamide Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). When the adjustments will be done, the dose may reaching the maximum dose allowed, which is 20 mg / day."
3303940|NCT01867502|Other|MET + Vildagliptin Group|"Usual Metformin stipulated: 500 or 850mg 3 times a day, if tolerated by patients.~Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks."
3303941|NCT01867528|Experimental|Laparoscopic adhesiolysis|
3303942|NCT01867528|Active Comparator|Open adhesiolysis|
3303943|NCT01867554||Intellectual disability|patients with intellectual disability or psycho-motor retardation and their parents and sibs (affected or not)
3303944|NCT01867567|Experimental|6 Hours|Removal of bandage after 6 hours
3303945|NCT01867567|Active Comparator|24 hours|removal of bandage after 24 hours
3303946|NCT01867593|Experimental|C-11 methionine PET|C-11 methionine PET pre and post radiation
3303947|NCT01867645|Active Comparator|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
3303948|NCT01867645|Placebo Comparator|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
3303949|NCT01867684|No Intervention|Treatment as usual|Standard NHS care for the patient group (NHS care will vary as participants will be recruited from a variety of NHS clinics).
3303950|NCT01867684|Experimental|Psychotherapy|Brief psychotherapy intervention delivered over 8 weeks in addition to standard care.
3303951|NCT01867697|Active Comparator|Biweekly cetuximab with continuously FOLFIRI|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI (irinotecan 180 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
3303952|NCT01867697|Experimental|Biweekly cetuximab with alternating FOLFIRI and mFOLFOX6|Biweekly cetuximab 500 mg/m2 in combination with FOLFIRI alternating with FOLFOX6 (Oxaliplatin: 85 mg/m2 IV, leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 46 hours 5FU infusion of 2400 mg/m2 every 2 weeks)
3303953|NCT01867723|Experimental|Internet communication application|Experiment 1 Effect of internet support program on cancer patients and their caregivers
3303954|NCT01867723|No Intervention|Control group|Control group get usual care
3303955|NCT01867736|Experimental|Passeo-18 Lux DRB|Passeo-18 Lux Drug Releasing Balloon catheter
3303956|NCT01867736|Active Comparator|Standard PTA (POBA)|Uncoated Passeo-18 PTA balloon catheter
3303957|NCT01867749|Experimental|Group Interpersonal Psychotherapy (IPT-G)|Participants in the IPT-G condition will receive 12 group therapy sessions over 2 weeks as well as 2 individual (pre-group and 1-month booster sessions). In addition, 3 of the 12 group sessions will invite women to include their partners or other support people to bolster the woman's social support system and to reduce conflicts over how to react to the loss. This study adapted IPT for treatment of depression after perinatal loss.
3303958|NCT01867749|Active Comparator|Coping with Depression (CWD)|The Coping with Depression (CWD) course is a highly structured, manualized psycho-educational group treatment for MDD. The course content is cognitive-behavioral in nature and is designed to train skills that can be used in the alleviation of depression. The skill modules focus on relaxation, cognitive skills, and behavioral activation. CWD will consist of an individual pre-group interview, 12 group therapy sessions over 12 weeks and a 1-month individual booster session to provide an identical treatment dose as the experimental condition.
3303959|NCT01867762|Experimental|JNJ 49095397|
3303960|NCT01867762|Placebo Comparator|Placebo|
3303961|NCT01867775|Active Comparator|Mirtazapine|Mirtazapine, 15 mg once a day, at night for 14 days
3303962|NCT01867775|Placebo Comparator|Placebo|Placebo 15 mg, once a day at night for 14 days
3303963|NCT01867788||Parkinson's disease subjects|
3303964|NCT01867788||Healthy Control subjects|
3303965|NCT01867814|Experimental|Pneumoperitoneum|Patients undergoing laparoscopic surgery
3303966|NCT01867827|Experimental|Neurofeedback and Physical Exercise|This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
3303967|NCT01867827|Active Comparator|Physical Exercise|This group will undergo Physical Exercise intervention on the WiiFit device 3 times a week in the first month and once a week after the first month till the end of the study at 12 weeks.
3303968|NCT01867840||arthritis|
3303969|NCT01867853||successful weaning|the SUCCESS of SBT or not need for reintubation or noninvasive ventilation within 48 h following extubation
3303970|NCT01867853||failed weaning|the failure of SBT or the need for reintubation or noninvasive ventilation within 48 h following extubation
3303971|NCT01867866|Experimental|TAS-102|
3303972|NCT01867866|Experimental|FTD (Trifluridine)|
3303973|NCT01867879|Experimental|TAS-102|
3303974|NCT01867879|Placebo Comparator|Placebo|
3303975|NCT01867892|Experimental|ICT of oxaliplatin,irinotecan,5-FU and leucovorinon and CCRT|Arm1:oxaliplatin,irinotecan,5-FU and leucovorinon D1,15 every 28days for 3 cycles,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
3303976|NCT01867892|Active Comparator|ICT of gemcitabine,oxaliplatin,5-FU,leucovorin and CCRT|Arm 2:gemcitabine,oxaliplatin,5-FU,leucovorin on D1,15 every 28 days for 3 cycles,Evaluation of Tumor Response,CR/PR/SD or localized disease RT 5,040cGy in 28 fractions/ 5.5 wks Arm 2: Gem 400mg/m2 iv 40min weekly
3303977|NCT01867905||Severe sepsis and septic shock|Patients who present in severe sepsis or septic shock will have blood cultures taken before and after antibiotic administration. The antibiotic choice will be determined by the emergency physician and the patients will be treated as per routine hospital protocol. No therapeutic interventions will be administered.
3303978|NCT01867918|Experimental|Cheomotherapy and local treatment|Standard chemotherapy + local treatment
3303979|NCT01867918|Placebo Comparator|Cheomotherapy|Standard chemotherapy
3303980|NCT01867931||Erosive Esophagitis|
3303981|NCT01867931||Non-erosive Reflux Disease|
3303982|NCT01867931||Heatlhy volunteers|
3303983|NCT01867944|Experimental|Perineal Self-Acupressure|Participants in this group (intervention group) will receive education in perineal self-acupressure in addition to education in conventional treatment options for constipation.
3303984|NCT01867944|Active Comparator|Educational Control|Participants in this group (the control group) will receive education in conventional treatment options for chronic constipation.
3303985|NCT01867957|Experimental|Low-dose GC1109|
3303986|NCT01867957|Placebo Comparator|Low-dose Placebo|
3303987|NCT01867957|Experimental|High-dose GC1109|
3303988|NCT01867957|Placebo Comparator|High-dose Placebo|
3303989|NCT01867970|Experimental|Tool + Self-management Support Program|"The system consists of three elements: a 3D accelerometer worn on the hip together with; an application (app) on a smartphone; a server and a website. The patient receives three types of feedback on the mobile phone concerning the amount of activity, the amount of activity in relation to an activity goal, and the response of a nurse based on the measured activity. Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
3303990|NCT01867970|Experimental|Self- management Support Program|"Practice nurses will use a consultation approach to coach patients in their self-management regarding physical activity based on a five A's cycle counselling technique (assess-advise-agree-assist-arrange). Motivational interviewing, risk assessment, and goal setting are specific aspects of this approach.The patient comes to the practice four times: in the first week, after 2 weeks, after 8-12 weeks and after 16-24 weeks."
3303991|NCT01867970|No Intervention|Care as usual|Patients attend the practice regularly: at least once a year for a consultation with the GP. In addition, COPD patients have consultations (15-30 minutes) with the practice nurse once or twice a year. Most patients with diabetes type 2 see the GP ones per year and the practice nurse three times per year for a health check.Normally, physical activity is not high on the agenda during consultations with the practice nurse. Barriers for paying attention are the competition with other topics that should also be covered during consultations, co-morbidity and limitations of patients, and the assumption of most practice nurses that nowadays the patient decides on the topics of the consultation. All interviewees agreed that many patients do not perceive physical activity as an important issue.
3303992|NCT01867983|Active Comparator|Control|Behavioral: Smoking cessation
3303993|NCT01867983|Experimental|Simultaneous|Behavioral: Weight gain prevention and smoking cessation
3303994|NCT01867983|Experimental|Sequential|Behavioral: Weight gain prevention and smoking cessation
3303995|NCT01867996|Experimental|Retosiban and EFZ|All subjects will receive on Day 1, a 6 mg bolus of retosiban for 5 min, followed by a 6 mg/hr infusion for 12 hrs. On Day 2 a washout day will occur. On Days 3-17, subjects will receive EFZ 600 mg OD dose of in the evening. On Day 18, subjects will receive a 6 mg bolus of retosiban for 5 mins, followed by a 6 mg/hr infusion for 12 hrs plus a 600 mg dose of EFZ.
3303996|NCT01868048|Experimental|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects received study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
3303997|NCT01868048|Placebo Comparator|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
3303998|NCT01868061|Experimental|Lebrikizumab (125 mg)|Participants will receive SC injection of lebrikizumab (125 mg) every 4 weeks for 104 weeks.
3303999|NCT01868061|Experimental|Lebrikizumab (37.5 mg)|Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
3304000|NCT01868061|Placebo Comparator|Placebo|Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
3304001|NCT01868087|Experimental|Impact Advanced Recovery®|3 briks daily (240 mL per brik) of Impact Advanced Recovery® to be take for 5 days before and after RC surgery
3304002|NCT01868087|Placebo Comparator|Boost Plus®|3 briks daily (240 mL per brik) of Boost Plus® to be take for 5 days before and after RC surgery
3304003|NCT01868100|No Intervention|self-completion questionnaire|
3304004|NCT01868113|Active Comparator|Inhaled fluticasone propionate|Inhaled corticosteroid
3304005|NCT01868113|Placebo Comparator|Inhaler propellant|Placebo
3304006|NCT01868126|Experimental|Group 1: DE-117 ophthalmic solution|One drop DE-117 Low Dose in each eye daily for 28 days
3304007|NCT01868126|Experimental|Group 2: DE-117 ophthalmic solution|One drop DE-117 Low Middle Dose in each eye daily for 28 days
3304008|NCT01868126|Experimental|Group 3: DE-117 ophthalmic solution|One drop DE-117 High Middle Dose in each eye daily for 28 days
3304009|NCT01868126|Experimental|Group 4: DE-117 ophthalmic solution|One drop DE-117 High Dose in each eye daily for 28 days
3304010|NCT01868126|Active Comparator|latanoprost ophthalmic solution|One drop latanoprost 0.005% in each eye daily for 28 days
3304011|NCT01868126|Placebo Comparator|placebo (vehicle of DE-117) ophthalmic solution|One drop DE-117 vehicle in each eye once daily for 28 days
3304012|NCT01868178||BIS Spectral Entropy Group|intraoperative monitoring with BIS and Spectral Entropy
3304013|NCT01868191|Placebo Comparator|Placebo for benfotiamine|Placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
3304014|NCT01868191|Experimental|Benfotiamine|Treatment with benfotiamine 600 mg/day for 3 months followed by 300 mg/day for 9 months
3304015|NCT01868230|Experimental|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
3304016|NCT01868230|No Intervention|Standard of Care|
3304017|NCT01868256|Experimental|Early discharge (< 72 h)|Patients randomized the early discharge group will be discharged from the hospital in < 72 hours
3304018|NCT01868256|Active Comparator|Conventional discharge|Patients randomized to the conventional discharge group will be discharged according to the local hospital protocol and/or treating physician criterion
3304019|NCT01868269|Other|Dexamethasone Cyclophosphamide Rituximab|
3304020|NCT01868282|Experimental|Group 1|Hamstrings block
3304021|NCT01868282|Active Comparator|Group 2|Obturator block
3304022|NCT01868282|Sham Comparator|Group 3|Control group
3304023|NCT01868295|Experimental|Sleeping with denture|Sleeping with denture at night
3304024|NCT01868295|No Intervention|Sleeping without denture|Sleeping without denture at night
3304025|NCT01868308||Preterm Labor|"Symptomatic women with singleton pregnancy at high risk for preterm birth between 22 - 33 6/7 weeks gestational age. We define high risk for preterm birth as women who present to our triage unit with complaints of preterm labor, including but not limited to preterm contractions, abdominal cramping, back pain, vaginal pressure, and vaginal bleeding."
3304026|NCT01868321||Mechanical Ventilation|Patients under mechanical ventilation in the ICU
3304027|NCT01868347|Active Comparator|control|PEEP after pneumoperitoneum and trendelenburg
3304028|NCT01868347|Experimental|Treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
3304029|NCT01868360|Experimental|Group A subconjunctival aflibercept|"Patients will receive 2mg (0.05mL) subconjunctival aflibercept injection in addition to standard of care treatment (steroids and cyclosporine). Patients will receive one injection four weeks (+/- 1 week) prior to transplantation. They will receive a second injection at the conclusion of corneal transplantation.~Patients may receive as-needed repeat injections (minimum of 30 days in between treatments) for recurrence of corneal neovascularization (defined as >1.0 mm crossing onto the cornea, past the limbus, or extension of vessels beyond previously documented extent) during the follow-up period."
3304030|NCT01868360|Placebo Comparator|Group B: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
3304031|NCT01868373|Other|microbiota transplantation|Two hundred mL of the bacterial suspension (microbiota transplantation) will be instilled into the small intestine via a catheter introduced through the biopsy channel of the endoscope and the flushed with 25 mL of sterile pre-reduced 0.9% saline. After removal of the endoscope, after recovery, patients will be allowed to resume a normal diet and physical activities.
3304032|NCT01868386|Experimental|Dose Level 1|Hypofractionated therapy, 26 treatments at 2.5 Gy
3304033|NCT01868386|Experimental|Dose Level 2|Hypofractionated therapy, 20 treatments at 2.83Gy
3304034|NCT01868386|Experimental|Dose Level 3|Hypofractionated therapy,15 treatments at 3.36 Gy
3304035|NCT01868386|Experimental|Dose Level 4|Hypofractionated therapy, 10 treatments at 4.26 Gy
3304036|NCT01868399||Suspected dengue fever subjects|No any intervention
3304037|NCT01868399||Community Healty Residents|No intervention
3304038|NCT01868412|Experimental|Resin & honey|Abilar 10% resin salve
3304039|NCT01868412|Active Comparator|Resin vs. honey|Activon Tube 25 g
3304040|NCT01868438|Active Comparator|Pyronaridine-artesunate granules (Period 1)|"In first dosing period, single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate."
3304041|NCT01868438|Active Comparator|Pyronaridine-artesunate tablets (Period1)|"In first dosing period, single administration of pyronaridine-artesunate tablets: total dose 540mg pyronaridine + 180mg artesunate.~In second dosing period, cross-over to single administration of pyronaridine-artesunate granules: total dose 540mg pyronaridine + 180mg artesunate."
3304042|NCT01868451|Experimental|Cohort 1 (completed accrual)|Patients received 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30 Gy involved site radiotherapy. Involved site radiotherapy should be initiated from 12 days to 42 days after completion of chemotherapy. It is mandatory to administer prophylactic growth factor support starting with cycle 1. Choice of growth factor and dosing can be determined at the discretion of the treating physican.
3304043|NCT01868451|Experimental|Cohort 2|Patients with early stage, unfavorable risk Hodgkin lymphoma. The definition of disease bulk, one of the unfavorable risk features, has been updated, and is defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm OR coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin & AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. This may be followed by 20 Gy involved site radiotherapy.
3304044|NCT01868451|Experimental|Cohort 3|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. Patients will receive 4 cycles of brentuximab vedotin and AVD chemotherapy. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 and 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, and Dacarbazine 375 mg/m2 will be administered on days 1 and 15 of each 28 day cycle. This may be followed by 30.6 Gy CVRT.
3304045|NCT01868451|Experimental|Cohort 4|Patients will have early stage, unfavorable risk classical Hodgkin lymphoma with disease bulk defined as the presence of any lymph node mass with transverse maximal diameter > 7.0 cm or coronal maximal diameter > 7.0 cm. In this cohort. Pts will receive 4 cycles of brentuximab vedotin & AVD chemo. Brentuximab vedotin, 1.2 mg/kg, will be administered on days 1 & 15 of each 28 day cycle. Doxorubicin 25 mg/m2, Vinblastine 6 mg/m2, & Dacarbazine 375 mg/m2 will be administered on days 1 & 15 of each 28 day cycle. Pts whose PET scan is negative after 4 cycles of brentuximab vedotin & AVD chemotherapy will not receive RT. Pts whose PET scan is positive after 4 cycles of brentuximab vedotin & AVD chemo, but subsequent biopsy is neg, will also receive no RT. Upon MSK PI approval, if the simulation can't be covered by the institution or the pts insurance, a diagnostic IV contrast CT neck & diagnostic IV contrast CT CAP scan will be done in addition to the FDG-PET done after 4 cycles of chemo.
3304046|NCT01868464|Experimental|BCG 16x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 16x10^6 cfu
3304047|NCT01868464|Experimental|BCG 2x10^6 CFU|30 subjects, one dose of Tice Bacillus Calmette-Guerin vaccine (BCG) intradermally, 2x10^6 colony forming units (cfu)
3304048|NCT01868464|Experimental|BCG 4x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 4x10^6 cfu
3304049|NCT01868464|Experimental|BCG 8x10^6 CFU|30 subjects, one dose of Tice BCG intradermally, 8x10^6 cfu
3304050|NCT01868490|Experimental|drug|single-group studies
3304051|NCT01868516|Placebo Comparator|Placebo|One tablet of placebo to be administered orally twice a day.
3304052|NCT01868516|Experimental|0.5 mg dexmecamylamine (TC-5214)|One tablet of 0.5 mg dexmecamylamine to be administered orally twice a day.
3304053|NCT01868516|Experimental|1 mg dexmecamylamine (TC-5214)|One tablet of 1 mg dexmecamylamine to be administered orally twice a day.
3304054|NCT01868516|Experimental|2 mg dexmecamylamine (TC-5214)|One tablet of 2 mg dexmecamylamine to be administered orally twice a day.
3304055|NCT01868529|Experimental|Low dose|
3304056|NCT01868529|Experimental|Medium dose|
3304057|NCT01868529|Experimental|High dose|
3304058|NCT01868555|Experimental|IDegAsp 30|
3304059|NCT01868555|Experimental|IDegAsp 45|
3304060|NCT01868555|Experimental|insulin degludec (B)|
3304061|NCT01868555|Experimental|insulin degludec (E)|
3304062|NCT01868568|Experimental|IDegAsp 30 + placebo|
3304063|NCT01868568|Experimental|Insulin aspart + insulin degludec - low concentration 1|
3304064|NCT01868568|Experimental|IDegAsp 40 + placebo|
3304065|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration 1|
3304066|NCT01868568|Experimental|IDegAsp 45 + placebo|
3304067|NCT01868568|Experimental|Insulin aspart + insulin degludec|
3304068|NCT01868568|Experimental|IDegAsp 55 + placebo|
3304069|NCT01868568|Experimental|Insulin aspart + insulin degludec - high concentration|
3304070|NCT01868568|Active Comparator|BIAsp 30 + placebo|
3304071|NCT01868581|Experimental|insulin degludec|
3304072|NCT01868581|Experimental|IDegAsp|
3304073|NCT01868607||Adult lung function|
3304074|NCT01868620|Experimental|Iontophoretic CXL|The iontophoretic CXL involves a constant current source and two electrodes. The main electrode is a circular cup, with a surrounding annular suction ring to affix the device on the cornea during the procedure. The electrode itself is a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with riboflavin solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated by a UVA light for 3mW/cm2 during 30 minutes.
3304075|NCT01868620|Active Comparator|Standard CXL|In the standard CXL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes.
3304076|NCT01868659|Experimental|Diagnostic checklist|Diagnostic checklist used before patient discharged
3304077|NCT01868659|Placebo Comparator|Usual care|No diagnostic checklist used during patient encounter
3304078|NCT01868672|No Intervention|Control|Participant receives usual care.
3304079|NCT01868672|Experimental|Intervention|Educational print materials and coaching call: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
3304080|NCT01868685|Placebo Comparator|Placebo|
3304081|NCT01868685|Experimental|BYM338|
3304082|NCT01868698|Experimental|Kinesiotherapy|Will be made active and resisted exercises of the lower limbs.
3304083|NCT01868698|Experimental|shortwave diathermy|Will be applied for 20 minutes on the lower limbs.
3304084|NCT01868698|Experimental|high-voltage electrical stimulation|The therapeutic current will be applied for 20 minutes on lower limbs.
3304087|NCT01868737|Experimental|HIV exposed infants|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
3304088|NCT01868737|Placebo Comparator|HIV- exposed infants|MCT oil
3304089|NCT01868737|Placebo Comparator|HIV-unexposed infants|MCT oil
3304090|NCT01868737|Experimental|HIV-unexposed|Probiotic: L. rhamnosus GG (0.35 x 109 colony-forming units [CFU]) and B. infantis (0.35 x 109 CFU) daily
3304091|NCT01868750|Active Comparator|Vitamin D (Calcitriol)|Calcitriol, 1.0ug twice daily for 7 days prior to surgery
3304092|NCT01868750|Placebo Comparator|Control|Placebo pill taken twice daily for 7 days prior to surgery
3304093|NCT01868763|No Intervention|control (C) group|The control group will remain in routine care for 12 weeks.
3380789|NCT04410042|Experimental|Tranexamic Acid|At initiation of surgical preparation, participants randomized to the active treatment arm will receive tranexamic acid 10 mg/kg (max 1 g), given via syringe pump programmed to infuse over 15 minutes. If no unacceptable toxicities occur, a second dose of tranexamic acid IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
3304094|NCT01868763|Experimental|telemedical (TM) group|Participants in the telemedical (TM) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre.
3304095|NCT01868763|Experimental|telemedical coaching (TMC) group|Participants in the telemedical coaching (TMC) group will get a weighing machine and a step counter, with automatic transfer into a personalized online portal, which can be monitored from both, the participant and the study centre. Additionally, they will be called once per week for 12 weeks from the study centre aiming to discuss measured data and to fix target agreements.
3304096|NCT01868802|Experimental|Ketamine treated|
3304097|NCT01868802|Placebo Comparator|Control, placebo treated|
3304098|NCT01868828|Experimental|PAD Followed by ASCT|"Drug: Bortezomib(1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Epidoxorubicin(15 mg/m2, iv, on days 1-4)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
3304099|NCT01868828|Experimental|VCD Followed by ASCT|"Drug: Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11)~Drug: Cyclophosphamide (200mg/m2, orally, on days 1-5)~Drug: Dexamethasone(40mg, orally, on days 1-4)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.~Not suitable for transplant patients will continue accept treatment for 8 cycles."
3304100|NCT01868841|Active Comparator|Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging|SPECT imaging of 10 millicurie of Adreview
3304101|NCT01868841|Active Comparator|AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging|SPECT imaging of 10 millicurie of Adreview
3304102|NCT01868854||Radiographic Plane 1|the tip of peritoneal dialysis catheter is located at the bottom of the pelvis, below a line connecting the head of the femur
3304103|NCT01868854||Radiographic Plane 2|the tip of the peritoneal dialysis catheter is located above the plane 1 and below a line connecting the two iliac spines
3304104|NCT01868854||Radiographic plane 3|The location of the catheter tip is on the line connecting iliac spines and below a line connecting the iliac crests
3304105|NCT01868854||Radiographic plane 4|The location of the catheter tip is on the line connecting the iliac crests
3304106|NCT01868867|Experimental|Intervention|Receives on line training and text messaging for treatment
3304107|NCT01868867|No Intervention|Treatment as Usual|Treatment as usual (TAU) for similar duration as intervention group. Intervention provided following TAU period.
3304108|NCT01868880|Experimental|ivabradine plus beta-blocker(bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
3304109|NCT01868880|Active Comparator|beta-blocker (bisoprolol) titration|Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
3304110|NCT01868906|Other|Arm-A: 18F-FMISO-PET without SCS|One 18F-FMISO-PET study for assessment of tumor hypoxia before radiotherapy and Temozolomide, without spinal cord stimulation.
3304111|NCT01868906|Other|Arm-B: 18F-FMISO-PET without/with SCS|"Two 18F-FMISO-PET studies for assessment of tumor hypoxia before radiotherapy and Temozolomide: one without and one with spinal cord stimulation"
3304112|NCT01868919|Experimental|Positive Parenting Program|Level 3 or 4 of Triple P
3304113|NCT01868932|Experimental|hypertonic saline|inhalation of 4 ml nebulized study solution containing 3% hypertonic saline (HS, study group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
3304114|NCT01868932|Active Comparator|saline|inhalation of 4 ml nebulized study solution containing saline 0.9% saline (NS, control group). Each dose of study solution will also contain a standard dose of bronchodilator (salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution) 1,2 added by the ED staff. Initial therapy will consist of 3 consecutive nebulizations given in rapid succession (back-to-back, approximately every 20 minutes).
3304115|NCT01868945|Experimental|5 µg/day Hy.D Calcifediol|
3304116|NCT01868945|Experimental|10 µg/day Hy.D Calcifediol|
3304117|NCT01868945|Experimental|15 µg/day Hy.D Calcifediol|
3304118|NCT01868945|Active Comparator|20 µg/day vitamin D3|
3304119|NCT01868958||CSM subjects|Subjects with clinical indications of cervical spondylotic myelopathy (CSM).
3304120|NCT01868958||Control group|Aged matched to the CSM group but with no signs of CSM
3304121|NCT01868971|Other|Colonoscopy procedure with the EndoRings|Colonoscopy procedure using an add-on device (EndoRings) that is attached to the distal tip of the endoscope
3304122|NCT01868984|Sham Comparator|Standard Therapy Alone|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique."
3304123|NCT01868984|Active Comparator|Standard Therapy Plus Paclitaxel|"Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met."
3304124|NCT01869010||HIV Tenofovir|
3304125|NCT01869010||HIV No tenofovir|
3304126|NCT01869010||Seronegative controls|
3304127|NCT01869023|Other|6 h infusion Gemcitabine and Cisplatin|Gemcitabine 250 mg/m2 Cisplatin 30 mg/m2
3304128|NCT01869036|Active Comparator|caudal anesthesia|
3304129|NCT01869036|Active Comparator|caudal anesthesia supplemented with morphine|
3304130|NCT01869049||ITP patients accepted splenectomy|
3304131|NCT01869049||Trauma with spleen rupture underwent splenectomy|
3304132|NCT01869062|Other|SonR CRT Optimization 'On'|CRT-D device with the SonR optimization algorithm programmed being 'on'.
3304133|NCT01869062|Other|SonR CRT Optimization 'Off'|CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
3304134|NCT01869088|Active Comparator|TACE Only|TACE with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
3304135|NCT01869088|Experimental|TACE Plus Adenovirus|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery of HCC patient and followed with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg) and lipiodol emulsion or/and polyvinyl alcohol particles(dependent on the tumor size) Procedure: TACE (Transcatheter arterial chemoembolization)
3304136|NCT01869127|No Intervention|Control|Standard care
3304137|NCT01869127|Experimental|Shoes|Shoes
3304138|NCT01869140|Sham Comparator|sham spinal manual therapy|activator set to zero
3304139|NCT01869140|Experimental|percussive spinal manual therapy|activator set to the maximum force
3304140|NCT01869140|Experimental|Firm thoracic spinal manual therapy|Firm thoracic manipulation
3304141|NCT01869153||Preterm infants|Preterm infants born at either <32 weeks gestation or < 1750g birth weight
3304142|NCT01869166|Experimental|anti-tumor response of CART-EGFR|
3304143|NCT01869179|Experimental|Community of Voices choir program|Participants will receive the 12 month choir program as soon as possible after study enrollment.
3304144|NCT01869179|Experimental|Wait-list control group|Waits six months, and at the end of the six months is offered the option of participating in the 12 month choir program.
3304145|NCT01869205|Experimental|Endobronchial valve:|Endobronchial valve (size 4.0 - 7.0 mm or 5.5 - 8.5 mm) insertion for target bronchi
3304146|NCT01869218||Pre-treatment tumor biopsies|Patients who meet eligibility criteria will undergo a fresh tumor biopsy and collection of research blood samples. Archived tumor specimens will also be obtained and analyzed. At the time of disease progression, fresh tumor biopsies and blood samples will be collected in patients who have evaluable pre-biopsy specimens and who are eligible to be screened for another study.
3304147|NCT01869231|Experimental|major surgery|colic surgery
3304148|NCT01869231|Experimental|minor surgery|appendectomy; cholecystectomy
3304149|NCT01869231|Experimental|ileostomy and colostomy|ileostomy colostomy
3304150|NCT01869231|Experimental|other surgery|all of others abdominal surgical intervention
3304151|NCT01869244||hand resting splint|Patients with hand resting splint treatment
3304152|NCT01869257|Active Comparator|control|regular suture not coated with triclosan
3304153|NCT01869257|Experimental|triclosan|Experimental group will receive abdominal wound closure with suture matherial that is coated with triclosan
3304154|NCT01869283|Experimental|Kinesiotherapy group|The volunteer will be subjected to the following protocol: cervical traction, 3 sets of 1 minute, 30-second rest between sets; mobilization grade III postero-anterior on the spines processes of vertebrae C2 to C7, 10 oscillations for each vertebrae; myofascial release of the upper trapezius muscle, 3 sets of 1 minute for each side; static stretching of the upper trapezius muscle, 3 sets of 30 seconds, with an interval of 10 seconds between sets.
3304155|NCT01869283|Experimental|kinesiotherapy + static ultrasound group|Same protocol group kinesiotherapy + ultrasound on the trigger points of the upper trapezius muscle in a static way, with 1 MHz, continuous dose of 1.5 W/cm2, for 1.5 minutes.
3304156|NCT01869283|Experimental|kinesiotherapy + diadynamic currents group|Same protocol group kinesiotherapy + diadynamic currents, with negative electrode (7.0 x 7.0 cm) placed on the myofascial trigger point, while the positive electrode (7.0 x 7.0 cm) is placed between the shoulder blades. Will apply 4 minutes from the biphasic mode (DF) and 6-minute short period (CP), the first of which intesidade the sensory threshold and the second threshold motor, both bearable for the patient.
3304157|NCT01869283|No Intervention|Control group|The volunteers of this group will not be subjected to any form of treatment, was evaluated in three stages, as the other groups. It is noteworthy that, after the volunteer's participation, will be offered at the same physical therapy for myofascial pain.
3304158|NCT01869296|Active Comparator|higher flow rates endoscope pump|higher flow rates endoscope water pump : 10.4 ml/sec
3304159|NCT01869296|Experimental|lower flow rates endoscope water pump|lower flow rates endoscope water pump : 1.7 ml/sec
3304160|NCT01869309|No Intervention|Non-HPR group|The non-HPR group will have PD and genetic testing, with no change in medication.
3304161|NCT01869309|Active Comparator|HPR Group|This arm will be split into Group A and Group B which will receive Ticagrelor/Prasugrel in a crossover manner.
3304162|NCT01869322|Experimental|Sling and Swathe|In this arm, study subjects will receive sling and swathe immobilization for humeral shaft fracture.
3304163|NCT01869322|Active Comparator|Coaptation Splint|In this arm participants receive a coaptation splint for humeral shaft fracture.
3304164|NCT01869335|Active Comparator|radiography|Arm1: patients undergo mammographic localizations and radiography of the specimen after surgical resection.
3304165|NCT01869335|Active Comparator|MRI (magnetic resonance imaging)|Arm2: patients undergo MRI localization and ex vivo MRI after surgical resection.
3304168|NCT01869387|No Intervention|Standard treatment|Standard treatment consists in bronchodilator and parenteral corticosteroids and oxygen therapy.
3304169|NCT01869387|Experimental|Standard treatment plus non-invasive ventilation|This arm consists in bronchodilator and parenteral corticosteroids and oxygen therapy plus non-invasive ventilation.
3380790|NCT04410042|Placebo Comparator|Placebo|At initiation of surgical preparation, participants randomized to the placebo treatment arm will receive 0.9% sodium chloride (salt water). It will be matched in appearance, volume, and administration to the active treatment arm with tranexamic acid. If no unacceptable toxicities occur, a second dose of placebo IV push over 5 to 15 minutes will be given 6 hours (with a window of +/- 30 minutes) after the first dose (either intra- or post-operatively).
3304170|NCT01869400||Yondelis-Pegylated liposomal Doxorubicin|30 mg/m² PLD i.v. followed by 1.1 mg/m² Yondelis® i.v. 3 h, q3weeks
3304171|NCT01869413|Experimental|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours). For example, an 80 kg patient would receive 800 mg prior to incision and a 400 mg/hr infusion for the duration of surgery. For a 6 hour procedure, the total dose administered would be 3200 mg.
3380793|NCT04402944|Experimental|Study Drug|Study drug
3380794|NCT04402944|Placebo Comparator|Placebo|Placebo
3304172|NCT01869413|Placebo Comparator|Placebo control|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
3304173|NCT01869426|Active Comparator|VSL#3 drops|31 infants will receive 10 drops active product that should be taken daily (preferably in the morning before feeding) for 21 days.
3380795|NCT04402632|Active Comparator|Interventional Cohort: Control Arm|Control
3380796|NCT04402632|Experimental|Interventional Cohort: Treatment Arm|Treatment
3380797|NCT04402632|Active Comparator|Observational Cohort: Control Arm|Control
3380798|NCT04402632|Experimental|Observational Cohort: Treatment Arm|Treatment
3304174|NCT01869426|Placebo Comparator|VSL#3 drops placebo|31 infants will receive 10 drops of placebo product that should be taken daily (preferably in the morning before feeding) for 21 days.
3304175|NCT01869452|Other|therapeutic education class 1|patients in class 1 will have a follow up call with therapeutic education every 3 months. this is the light follow up.
3304176|NCT01869452|Other|therapeutic education class 2|patients in class 2 will have a follow up call with therapeutic education every month. this is the moderate follow up
3304177|NCT01869452|Other|therapeutic education class 3|patients in class 3 will have a follow up call with therapeutic education twice a month. this is the heavy follow up.
3304178|NCT01869465|Active Comparator|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration. A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above ,basic principles of health education and in communication skills through a 2 days training workshop. The trained head teachers and heath teachers will in turn, deliver the messages to the children through face to face interactions during school assemblies, twice a week.
3380799|NCT04402593|Experimental|Modified Heidelberg Model of Neuro-Music Therapy (mHNMT)|The mHNMT for Tinnitus program was modified based on participant feedback of the original HNMT. This study will include 6 sessions, 2 sessions a week including the following interventions: resonance training, music relaxation, Intonation Training and session review/homework.
3380802|NCT04396574|Experimental|Lasmiditan Dose 1|Lasmiditan administered orally.
3380803|NCT04396574|Experimental|Lasmiditan Dose 2|Lasmiditan administered orally.
3380804|NCT04396236|Experimental|Lasmiditan High Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
3380805|NCT04396236|Experimental|Lasmiditan Mid Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
3380806|NCT04396236|Experimental|Lasmiditan Low Dose|Lasmiditan administered orally with matching placebo to maintain the blind.
3380807|NCT04396236|Placebo Comparator|Placebo|Placebo administered orally.
3380808|NCT04393974||Cancer patients with COVID-19|All cancer patients can be recruited onto this research following a positive test for Sars-Cov2. The research will follow what treatments they are given for the infection, but also look at their past medical history including prior and any current anti-cancer therapy.
3380809|NCT04393311|Experimental|Ulinastatin|Patients will receive ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
3380810|NCT04393311|Placebo Comparator|Placebo|Patients will receive placebo to match ulinastatin via IV infusion every 8 hours for up to 5 days or until hospital discharge (whichever is earlier).
3304179|NCT01869465|Experimental|Snack arm|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers. The snack is estimated to cost about 1 US $ per child.
3304180|NCT01869491|Active Comparator|Sodium Alginate Double Action Tablets|Compound Sodium Alginate Double Action Chewable Tablets, 2 tablets four times daily
3380811|NCT04393298|Experimental|Part A|Study participants assigned this arm will receive UCB6114 as monotherapy in escalating cohorts at pre-specified dose levels.
3304181|NCT01869491|Placebo Comparator|Matching placebo tablets|Matching placebo tablets, 2 tablets four times daily
3304182|NCT01869504|Experimental|Balloon-tipped intercostal drain|Subjects who have given written informed consent and who fulfill the inclusion and exclusion criteria will proceed to have the study drain inserted at the earliest opportunity as per standard hospital protocols using local anaesthetic, and conscious sedation where appropriate. All other aspects of their treatment will be identical to usual clinical care, including chest drain checks and fluid drainage strategies.
3304183|NCT01869517|Active Comparator|Intrastromal corneal continuous ring (Myoring)|
3304184|NCT01869517|Active Comparator|Intrastromal corneal ring segments (Keraring)|
3304185|NCT01869543|Experimental|Stand Alone Air Cleaner-True/Sham|The participant will have stand alone air cleaners placed in their home. They will have true filtration followed by sham filtration.
3304186|NCT01869543|Experimental|Stand Alone Air Cleaner-Sham/True|Participants will have stand alone air cleaners placed in their homes. They will begin with sham filtration.
3304187|NCT01869543|Experimental|HVAC modification-True/Sham|Participants will have their HVAC system modified to include high efficiency filtration. They will begin true filtration followed by sham filtration.
3304188|NCT01869543|Experimental|HVAC Modification-Sham/True|Participants will have their HVAC system modified to include high efficiency filtration. They will begin sham filtration.
3304189|NCT01869556|Active Comparator|Oxytocin only|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3304190|NCT01869556|Active Comparator|Oxytocin + Ergot|Oxytocin 5IU IV bolus + Ergot 0.25mg IV, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3304191|NCT01869556|Active Comparator|Oxytocin + Carboprost|Oxytocin 5IU IV bolus + Carboprost 0.25mg IM, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
3304192|NCT01869569|Active Comparator|Pregabalin|Arm I:At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
3304193|NCT01869569|Placebo Comparator|Placebo|Arm II:At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
3304194|NCT01869582|Experimental|Doppler, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a wind-up, hand-held Doppler
3304195|NCT01869582|Experimental|Fetoscope, Fetal heart rate|Eligible women in labour randomized to intermittent fetal heart rate assessments using a Pinard fetoscope, which is the current standard management
3304196|NCT01869582|Experimental|Upright Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to an Upright Resuscitator
3304197|NCT01869582|Experimental|Standard Resuscitator, Resuscitation|Non-breathing newborn infants in need of positive pressure ventilation randomized to a standard horizontal Resuscitator, which is the current standard management
3304198|NCT01869608|Experimental|postpartum screening|Oral glucose tolerance test 2 days post-partum
3304199|NCT01869621|Experimental|Metformin|6 days treatment with metformin
3304200|NCT01869660|Experimental|Shared Decision Making|The present SDM intervention is based on principles derived from previous randomized controlled trials of SDMs. SDM meetings comprise at least 4 weekly 20 minutes sessions. Meetings have at least three professionals: a case manager (psychiatrists or nurses), a primary doctor, and a nurse/social worker. The focus of the meeting is to empower patients to discuss their attitudes and preferences toward treatments.
3304201|NCT01869660|No Intervention|Usual Care|Patients with no special program about decision making.
3304202|NCT01869673|Active Comparator|Face Mask|Patients will be ventilated with a face mask first and with a oral mask thereafter
3304203|NCT01869673|Experimental|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
3304204|NCT01869712|Experimental|Cupping therapy (randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
3304205|NCT01869712|Experimental|Cupping therapy (non-randomized)|Use retained cupping as the main cupping method, supplemented with flash cupping and/or moving cupping. First use empty cupping, which means the cups are removed after suction without delay, then practitioners should control the suction by gently moving the cup toward direction of DU and/or BL, repeat this moving for several times, finally cupping practitioners utilize the flaming heating power to achieve suction (minus pressure) inside the cups to make them apply on the desired part of the body. Cups should retain for 10 minutes daily, patients accept the treatment three times weekly for totally 15 times.
3304206|NCT01869712|Active Comparator|Acupuncture (non-randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes. Patients accept the treatment three times weekly for totally 15 times.
3304207|NCT01869712|Active Comparator|Acupuncture (randomized)|Sterilize the selected points with alcohol, and then select the specific size of needles to do the acupuncture. Do the manual stimulation for seconds after needles' insertion, including twist, pull up and deeper insert. Needles should be withdrawn after 30 minutes.
3304208|NCT01869738|Experimental|MGuard Prime|MGuard Prime stent
3304209|NCT01869738|Active Comparator|Control|(BMS/DES) Includes FDA approved bare metal or drug eluting stents, including ENDEAVOR, TAXUS Liberte, XIENCE Prime, PROMUS Element, ION, RESOLUTE, Driver, Vision, VeriFlex and Integrity.
3304210|NCT01869751||Prucalopride|Slow-transit constipation with treatment with prucalopride
3304211|NCT01869790|Experimental|Meal challenge|Different fat types
3304212|NCT01869816||Acute coronary syndrome (ACS)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Acute myocardial infarction or unstable angina.
3304213|NCT01869816||Stable angina pectoris (SAP)|Who were admitted to the coronary care units of the division of cardiology at Guro hospital in Korea University Medical Center. They have Stable angina.
3304214|NCT01869816||Control|Who were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.
3304215|NCT01869829||Pediatric Invasive Candidiasis|Pediatric patients (age > 120 days and < 18 years) with documented proven or probable invasive candidiasis
3304216|NCT01869842|Active Comparator|DM, angio group|
3304217|NCT01869842|Experimental|DM, OCT group|
3304218|NCT01869842|Active Comparator|non DM, angio group|
3304219|NCT01869842|Experimental|non DM, OCT group|
3304220|NCT01869855|Active Comparator|110 patients with cSDH assigned to subdural drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
3304221|NCT01869855|Active Comparator|110 patients with cSDH assigned to subperiosteal drainage|Randomization of 110 patients with cSDH to one treatment group (subdural or subperiosteal drainage) out of the 220 patients included in the study.
3304222|NCT01869868||Depression, ECT|
3304223|NCT01869881|Active Comparator|Sarpogrelate|
3304224|NCT01869881|Placebo Comparator|Placebo|
3304225|NCT01869894|Active Comparator|uncovered double bare metallic stent (S&G Biotech.)|uncovered double bare metallic stent
3304226|NCT01869894|Active Comparator|uncovered single bare metallic stent (S&G Biotech.)|uncovered single bare metallic stent
3304227|NCT01869894|Active Comparator|uncovered single bare metallic stent (Taewoong Medical.)|uncovered single bare metallic stent
3304228|NCT01869907|Placebo Comparator|Placebo|Placebo, once daily
3304229|NCT01869907|Active Comparator|Amitriptyline|Amitriptyline 25mg, once daily
3304230|NCT01869907|Active Comparator|Minocycline|Minocycline 100mg, once daily
3304231|NCT01869920|Experimental|intervention group|Intervention group receive a training education on breastfeeding. Education training is provided by an expert group from General Direction of Primary Care
3304232|NCT01869920|Other|Controll group|Usual care
3304233|NCT01869933|Experimental|1% OC-10X|Subjects selected to Cohort I will receive active 1% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
3304234|NCT01869933|Experimental|2% OC-10X|Subjects selected to Cohort II will receive active 2% OC-10X in OD (Oculus Dexter - right eye) and placebo (vehicle) in OS (Oculus Sinister - left eye) in the Period 1 dosing. On Study Day 1 the subjects will have a drop instilled in each eye by personnel at study hours 0, 3, 6 and 9, and be evaluated frequently throughout the day. Subjects will be examined on Study Day 2 (24 hours after first dose). On Study Day 3 (48 hours after the first dose), these subjects will commence Period 2 dosing, with the active (OD) or placebo (OS). Dosing will continue q.i.d. for an additional 13 days.
3304235|NCT01869946||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the hip joint following hip arthroplasty. Total dose 180mls of 0.2% ropivacaine or 360mg at the time of surgery.
3304236|NCT01869972||Wide PHE group|Subjects prescribed diet alone to treat their PKU who have >1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
3304237|NCT01869972||Target PHE group|Subjects prescribed diet alone to treat their PKU who have ≤ 1/3 of monitoring phenylalanine levels (with at least 3 levels measured) outside the target treatment range in the 6 months preceding enrolment. Target therapeutic range is 120 - 360 umol/L for age <12 years and 120 - 600 umol/L for age ≥ 12 years.
3304238|NCT01869972||Kuvan(TM) group|Subjects on Kuvan(TM) (any dose for at least 3 months with no dosage change for most recent 1 month) ± diet therapy
3304239|NCT01869972||Control group|Subjects with non-PKU hyperphenylalaninemia (maximum phenylalanine level 120 - 599 umol/L on no therapy).
3304240|NCT01869985|Experimental|HCP1104|HCP1104
3304241|NCT01869985|Active Comparator|Mulex Tab. and Airtal Tab.|Eperisone Hydrochloride and Aceclofenac
3304242|NCT01869998||Low risk group (A)|(A)Vortex depth≥0.45
3304243|NCT01869998||High risk group 1 (B)|(B)Vortex depth<0.45 with anticoagulation
3304244|NCT01869998||High risk group 2 (C)|(C)Vortex depth <0.45 without anticoagulation
3304245|NCT01870011|Experimental|Desflurane balanced anesthesia group|
3304246|NCT01870011|Active Comparator|Propofol total intravenous anesthesia group|
3304247|NCT01870024|Active Comparator|1: Lorazepam + Placebo|[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
3304248|NCT01870024|Active Comparator|2: Clonazepam + Placebo|[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes
3304249|NCT01870024|Active Comparator|3: Clonazepam + Fosphenytoin|[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
3304250|NCT01870037|Placebo Comparator|Placebo (PBS-20% sucrose)|PBS-20% sucrose administered during two single-treatment dose levels (16000 micrograms [µg] and 24000 µg) by direct bladder wall intramuscular injections, 20 to 30 injections depending on active dose comparator.
3304251|NCT01870037|Experimental|hMaxi-K 16000 µg|Single treatment (16000 µg by 20 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
3304252|NCT01870037|Experimental|hMaxi-K 24000 µg|Single treatment (24000 µg by 30 intramuscular injections). A total of 6 participants will receive hMaxi-K, and 3 will receive placebo.
3304253|NCT01870050|Active Comparator|dapsone gel - verum|dapsone gel - verum
3304254|NCT01870050|Placebo Comparator|dapsone gel - vehicle only|
3304255|NCT01870063||open heart surgery|
3304256|NCT01870089|Experimental|Study group|
3304257|NCT01870102|Active Comparator|Pelubiprofen IR (Pelubiprofen 30 mg)|
3304258|NCT01870102|Experimental|Pelubiprofen SR (Pelubiprofen 45 mg)|
3304259|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fasting condition|
3304260|NCT01870102|Other|Pelubiprofen SR (Pelubiprofen 45 mg) fed condition|
3304261|NCT01870115|Placebo Comparator|Fiber pill|2 plant fiber pills taken p.o. (by mouth) nightly for one year
3304262|NCT01870115|Active Comparator|strontium/melatonin/Vitamins K2 and D3|2 pills taken p.o. (by mouth) nightly for one year. Each pill contains strontium citrate (225 mg), melatonin (2.5 mg), Vitamin K2 (MK7) (30 mcg) and Vitamin D3 (1000 IU)
3304263|NCT01870128|Active Comparator|Methotrexate|Single agent Methotrexate 15 to 25 mg PO per week
3304264|NCT01870128|Active Comparator|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
3304265|NCT01870128|Experimental|Combination Steroid|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day Methylprednisolone 1000 mg intravenous per day for 3 days
3304266|NCT01870141|Experimental|Psychological Intervention|Cognitive Behavioural Intervention
3304267|NCT01870141|No Intervention|Current standard of care|
3304268|NCT01870154|Experimental|Intervention group|The intervention consists of 16 hours of training, to be held at the subject's health center. The workshop involves mixed learning, comprising 4 sessions, each 2 hours long, in addition to personal work previous to and after each session of reading relevant bibliography and performing exercises, self-evaluation, and case studies (8 hours of individual work).
3304269|NCT01870154|Active Comparator|Control group|Usual care
3304270|NCT01870167|Placebo Comparator|placebo|Placebo
3304271|NCT01870167|Experimental|co-amoxiclav|co-amoxiclav is a combination antibiotic consisting of amoxicillin trihydrate, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor
3304272|NCT01870180|Experimental|EyeBag|Eye self-treated with heated eyebag in the morning and evening each day as per manufacturer's instructions (see http://www.eyebagcompany.com/how)
3304273|NCT01870180|Placebo Comparator|Placebo|Non-heated EyeBAG: As with eyebag arm but second eyebag applied on other eye at same time BUT not heated
3304274|NCT01870206|Experimental|Trivalent OPV Birmex|Newborns receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine. A second dose four weeks after the first application.
3304275|NCT01870206|Active Comparator|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine. A second dose four weeks after the first application.
3304276|NCT01870219|Active Comparator|Group S|In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.
3304277|NCT01870219|Active Comparator|Group K|In group K, ketamine was given to 1mg/kg ıv bolus.
3304278|NCT01870232|Experimental|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
3304279|NCT01870245|Experimental|ACHN-975|
3304280|NCT01870245|Placebo Comparator|Placebo|
3304281|NCT01870258|Placebo Comparator|those without MI in 2 weeks|patient without MI in 2 weeks
3304282|NCT01870258|Active Comparator|patient with MI|group with MI in 2 weeks
3304283|NCT01870271|Experimental|DCPT|Treatment with developmentally adapted D-CPT. 30 to 36 individual treatment sessions. Treatment sections comprise a commitment phase (5 sessions), emotion regulation phase (6 sessions), CPT (15 sessions) and a final phase targeting developmentally-related challenges (4 sessions).
3304284|NCT01870284|Experimental|Ixekizumab Dosing Regimen 1|Administered by 80 milligram (mg) subcutaneous (SC) injection
3304285|NCT01870284|Experimental|Ixekizumab Dosing Regimen 2|Administered by 80 mg SC Injection
3304286|NCT01870284|Placebo Comparator|Placebo|Placebo for ixekizumab and placebo for adalimumab administered by SC injection
3304287|NCT01870284|Active Comparator|Adalimumab|Administered by 40 mg SC injection
3304288|NCT01870310|No Intervention|Standard medical therapy|
3304289|NCT01870310|Experimental|Renal denervation + standard medical therapy|Patients in this arm will undergo catheterised renal denervation in addition to having optimization of medical therapy for heart failure.
3304290|NCT01870323|Experimental|SMART Behavioral Group|Intervention condition which has access to SMART Group Wall on Facebook and receives privately-delivered weekly behavioral modules. (SMART Facebook Group + video-based behavioral modules)
3304291|NCT01870323|Active Comparator|SMART Informational Group|Comparison condition (i.e., attentional control) has access to SMART Group Wall on Facebook, and receives privately-delivered weekly text-based messages with generic content. (SMART Facebook Group + NO video-based behavioral modules)
3304292|NCT01870336|Experimental|Lateral customized foot orthoses|Foot orthoses with arch support and lateral inclination set at 7° (alone)
3304293|NCT01870336|Experimental|Knee brace|OdrA Knee brace (alone)
3304294|NCT01870336|Experimental|Combination of the two treatments|Combination of Lateral customized foot orthoses and knee brace
3304295|NCT01870349||Titanium Implant Abutments|Gingival Crevicular Fluid Sampling
3304296|NCT01870349||Zirconium Implant Abutments|Gingival Crevicular Fluid Sampling
3304297|NCT01870362|Experimental|Probiotic (Inersan) Arm|Inersan Lozenges (2 Lozenges bid). Each probiotic lozenge contains not less than 1 billion CFU of L. brevis CD2
3304298|NCT01870362|Placebo Comparator|Placebo Arm|Placebo Lozenges (2 lozenges bid). Placebo lozenge contains only excipients (without probiotic).
3304299|NCT01870375||MPS IH, MPS IHS, MPS IS|MPS IH (Hurler syndrome) patients; MPS IHS (Hurler-Scheie syndrome) patients; and MPS IS (Scheie syndrome) patients
3304300|NCT01870375||MPS II|Hunter syndrome patients
3304301|NCT01870375||MPS IV|Morquio syndrome patients who will be considered for enrollment in the study on an individual basis
3304302|NCT01870375||MPS VI|Maroteaux-Lamy syndrome patients
3304303|NCT01870375||MPS VII|Sly syndrome patients who will be considered for enrollment in the study on an individual basis
3304304|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm.
3304305|NCT01870427|Experimental|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
3304306|NCT01870440|Experimental|Ozurdex Injection|Ozurdex Intravitreal Injection (0.7 mg)
3304307|NCT01870453||Isoflurane Anesthesia|Recruited subjects that were anesthetized with isoflurane for their surgery.
3304308|NCT01870453||Sevoflurane Anesthesia|Recruited subjects that were anesthetized with sevoflurane for their surgery.
3304309|NCT01870453||Desflurane Anesthesia|Recruited subjects that were anesthetized with desflurane for their surgery.
3304310|NCT01870453||Propofol Anesthesia|Recruited subjects that were anesthetized with propofol for their surgery.
3304311|NCT01870466|Experimental|C -> C + S|cilostazol (C) in period 1, cilostazol + simvastatin (C+S) in period 2
3304312|NCT01870466|Experimental|C + S -> C|cilostazol + simvastatin (C+S) in period 1, cilostazol (C) in period 2
3304313|NCT01870466|Experimental|S -> S + C|simvastatin (S) in period 1, simvastatin + cilostazol (S+C) in period 2
3304314|NCT01870466|Experimental|C + S -> S|cilostazol + simvastatin (C+S) in period 1, simvastatin (S) in period 2
3304315|NCT01870466|Experimental|R -> C + R|rosuvastatin (R) in period 1, cilostazol + rosuvastatin (C+R) in period 2
3304316|NCT01870466|Experimental|C + R -> R|cilostazol + rosuvastatin (C+R) in period 1, rosuvastatin (R) in period 2
3304317|NCT01870479|Experimental|Live music|Patient preferred live music during chemotherapy session.
3304318|NCT01870479|Active Comparator|Taped music|Patient preferred taped music during chemotherapy
3304319|NCT01870479|No Intervention|Control|Usual care during chemotherapy
3304320|NCT01870492||Acute ischemic stroke or TIA|Patients presenting with acute ischemic stroke or transient ischemic attack and underwent treatment using Activase and/or endovascular therapy.
3304321|NCT01870505|Experimental|Arm A: BYL719 plus Letrozole|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on letrozole, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
3304322|NCT01870505|Experimental|Arm B: BYL719 plus Exemestane|For both the dose-finding phase and the expansion phase, patients may have stable or progressive disease on Exemestane, and BYL719 will be added. A treatment cycle will consist of 28 days. Treatment doses for each AI will be fixed at the established dose. Patients will continue on treatment until progression of disease or unacceptable toxicity. The initial scan interval to assess disease status will be every two cycles (8 weeks) for the first four cycles (16 weeks), and then every 3rd cycle (12 weeks) thereafter.
3304323|NCT01870505|Experimental|Arm C: BYL719 plus Letrozole|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added.Letrozole 2.5mg orally once daily with BYL719 given on days 1-7 and 15-21 of a 28 day cycle. The starting dose of BYL719 in Arms C will be 250mg daily. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
3304324|NCT01870505|Experimental|Arm D: BYL719 plus Exemestane|For both the dose-finding and expansion phases of Arms C and D, patients may have stable or progressive disease on letrozole or exemestane, and BYL719 will be added. Exemestane 25mg orally once daily BYL719 Days 1-5, 8-12, 15-19, 22-26 of 28 day cycle. For Arm D, the established dose is 350mg for BYL719 we are currently enrolling 10 patients to the corresponding arm in the expansion phase of the study. Patients who are on study under Amendment 13, the scan interval will become every 4th cycle (16 weeks ±4 weeks) from their last scan.
3304325|NCT01870518|Active Comparator|Parkinson's patients with MCI|Procedure: deep brain stimulation surgery
3304326|NCT01870518|Active Comparator|Parkinson's patients without MCI|Procedure: deep brain stimulation surgery
3304327|NCT01870544|Experimental|LGG Administration|Lactobacillus Rhamnosus GG (LGG) will be taken orally for 44 days. The daily dose is 2*10^10 organisms. The LGG is contained in capsules (1*10^10 organisms per capsule), and two capsules will be taken per day.
3304328|NCT01870544|Placebo Comparator|Placebo|Placebo to be taken orally for 44 days.
3304329|NCT01870557||Diabetes Mellitus type 1|n=100
3304330|NCT01870557||Diabetes Mellitus type 2|n=100
3304331|NCT01870570|Other|Reference Glucose|Glucose Standard (50g of Glucose)
3304332|NCT01870570|Experimental|Food Product A: Corn Flakes|Corn Flakes
3304333|NCT01870570|Experimental|Food Product B: Ginger Bread|Ginger Bread
3304334|NCT01870570|Experimental|Food Product C:Sandwiched Breakfast Biscuit|Sandwiched Breakfast Biscuit
3304335|NCT01870570|Experimental|Food Product D: Crackers Nature|Crackers Nature
3304336|NCT01870570|Experimental|Food Product E: Breakfast Biscuit|Breakfast Biscuit
3304337|NCT01870570|Experimental|Food Product F: White Bread|White Bread
3304338|NCT01870609|Active Comparator|defactinib (VS-6063)|2 x 200 mg defactinib (VS-6063) tablets, administered orally, twice daily
3304339|NCT01870609|Placebo Comparator|Placebo|2 placebo tablets, administered orally, twice daily
3304340|NCT01870622|Active Comparator|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
3304341|NCT01870622|Experimental|Flow waves|Flow waves will be used to confirm correct tube placement
3304342|NCT01870635|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
3304343|NCT01870635|Placebo Comparator|Placebo (sugar pill)|
3304344|NCT01870648|Experimental|Ondansetron|"4 mg oral disintegrating tablet of ondansetron~Participant weight 8-15 kg = half dose (2mg) Participant weight greater than 15 kg = full dose (4mg)"
3304345|NCT01870648|Placebo Comparator|Placebo (sugar pill)|
3304346|NCT01870661|Experimental|Long axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
3304347|NCT01870661|Active Comparator|Short axis ultrasound placement of IV|Long axis ultrasound placement of IV catheter
3304348|NCT01870674|Experimental|YH12852|"<SAD cohort>~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~Experimental: YH12852 10mg/single dose, qd~<FSD cohort>~Experimental: YH12852 0.5mg/single dose, qd~Experimental: YH12852 1mg/single dose, qd~Experimental: YH12852 2mg/single dose, qd~Experimental: YH12852 3mg/single dose, qd~<MAD cohort>~Experimental: YH12852 0.5mg/repeat dose, qd~Experimental: YH12852 1mg/repeat dose, qd~Experimental: YH12852 2mg/repeat dose, qd~Experimental: YH12852 3mg/repeat dose, qd~Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)"
3304349|NCT01870674|Active Comparator|Prucalopride|<each cohort> Prucalopride succinate 1.321mg
3304350|NCT01870674|Placebo Comparator|Placebo|<each cohort> Matching Placebo
3304351|NCT01870687|Experimental|VAC BNO 1095 2x10 mg FCT|VAC BNO 1095 2x10 mg FCT 2 tablets of verum in the morning, oral, 3 months treatment
3304352|NCT01870687|Placebo Comparator|Placebo|2 tablets in the morning, oral, 3 months treatment
3304353|NCT01870700|Experimental|lactobacillus reuteri|Intervention: supplementation with the probiotic Lactobacillus reuteri (DSM 17938),Reuflor, was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks.
3304354|NCT01870700|Placebo Comparator|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
3304355|NCT01870713||type 2 diabetes patients with gastric bypass surgery.|Participants who have type 2 diabetes and with decreased glucose after gastric bypass surgery.
3304356|NCT01870713||Weight matched non-operated controls|Participants who are overweight to moderately obese, and have no personal of family history of Type 1, Type 2, or Gestational Diabetes.
3304357|NCT01870752|Other|Transplantation of previously cryopreserved ovarian tissue|Surgical transplantation of previously collected cryopreserved ovarian cortical tissue.
3304358|NCT01870765|Active Comparator|non-invasive ventilation|Performance of bronchoscopy during non-invasive ventilation.
3304359|NCT01870765|Experimental|high-flow oxygen|Performance of bronchoscopy during high-flow oxygen therapy.
3304360|NCT01870791|Experimental|Omegaven|Omegaven in combination with EOX chemotherapy
3304361|NCT01870804|Active Comparator|Rosuvastatin|Rosuvastatin (40 mg on-admission followed by 20 mg/day) until discharge; then 20 mg/day (10 mg/day if creatinine clearance < 30 ml/min)
3304362|NCT01870804|Active Comparator|Atorvastatin|atorvastatin (80 mg on-admission followed by 40 mg/day before and after discharge)
3304363|NCT01870817|Active Comparator|Home jejunostomy feeding|Six weeks of post hospital discharge home enteral feeding
3304364|NCT01870817|No Intervention|Control|Standard care
3304365|NCT01870830|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1650-2590m
3304366|NCT01870830|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1650m
3304367|NCT01870830|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1650-2590-490m
3304368|NCT01870830|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1650-490m
3304369|NCT01870882|Active Comparator|Retraining|Using the PED, participants repeatedly complete a version of attentional bias task that orients their attention away from drug-related cues.
3304370|NCT01870882|Sham Comparator|Control|Using the PED, participants repeatedly complete versions of the attentional bias task in which their attention is oriented toward and away from drug-related cues on an equal number of trials.
3304371|NCT01870895|Experimental|YM060 group|
3304372|NCT01870895|Placebo Comparator|Placebo group|
3304373|NCT01870908||tacrolimus + biological agents|
3304374|NCT01870934||Telemedicine, Diabetes, foot ulcer|
3304375|NCT01870947|Experimental|'Assisted-Rate' Exercise Intervention|Subjects in the assisted exercise group will cycle on the same stationary exercise bike; however, a motor will provide assistance to the patient in order to maintain a pedaling rate 35% greater than their voluntary rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
3304376|NCT01870947|Experimental|'Voluntary-Rate' Exercise Intervention|Subjects in the voluntary group will exercise on a stationary recumbent exercise cycle and pedal at their preferred rate. Subjects in the exercise groups will complete 45 minute to 1-hour sessions, three times per week for eight weeks.
3304377|NCT01870960|Other|right control|the patient is his own control The right side will be treated as normal while the left side will also receive the emdogaim
3304378|NCT01870960|Other|left control|the patient is his own control The left side will be treated as normal while the right side will also receive the emdogaim
3304379|NCT01870986|Experimental|A|PF-06410293
3304380|NCT01870986|Active Comparator|B|Adalimumab-EU
3304381|NCT01870986|Active Comparator|C|Adalimumab-US
3304382|NCT01871012||non-diabetes mellitus group|Subjects undergoing Total Knee Replacement are not diagnosed with diabetes mellitus.
3304383|NCT01871012||diabetes mellitus group|subjects have been diagnosed diabetes mellitus mora than three years without serious nerve system complications.
3304384|NCT01871025|Experimental|Hospital and home exercise training|Usual care plus hospital exercise training (aerobic and strength) followed by exercise training at home until 30 days to discharge.
3380812|NCT04393298|Experimental|Part B|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with trifluridine/tipiracil (TFD/TPI).
3304385|NCT01871025|Other|Usual care|Usual care in COPD
3304386|NCT01871038||Rotavirus Positive Cases|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested positive for rotavirus.
3304387|NCT01871038||Rotavirus Negative Controls|Children <6 years of age born on or after 8/10/2008 enrolled in active surveillance for AGE who tested negative for rotavirus
3304388|NCT01871103|Other|Surgical flap|The dorsal homodigital island flap is a perforator type flap based on the DB, which uses the dorsal skin of the injured finger to provide soft tissue coverage for a volar defect.
3304389|NCT01871116|Experimental|POWER-remote|Participants will start a weight loss program called POWER-remote for Breast Cancer Survivors. This program involves two main components: an online portion accessed on a computer through the internet and a telephone portion to help monitor progress.
3304390|NCT01871116|Active Comparator|Self-directed|"Participants will receive a pamphlet entitled Aim for a Healthy Weight, to help guide weight loss goals without access to the web-based POWER-remote system and coach support."
3304391|NCT01871129|Placebo Comparator|Saline group|Difference from the normal protocol actualizes at the point when propofol infusion is cut off. From there on the patient in this group receives saline infusion up to the point where 15 minutes have passed after the extubation procedure.
3304392|NCT01871129|Active Comparator|Dexmedetomidine group|Difference from the normal protocol happens when normally the propofol infusion is cut off. From there on the patient in this group receives dexmedetomidine infusion up to the point where 15 minutes have passed after the extubation procedure.
3304393|NCT01871155|Experimental|Nutri-jelly along with radiotherapy|Continuous intake: orally take 1-3 boxes / day for at least 3 days/ week during radiotherapy
3304394|NCT01871155|No Intervention|Radiotherapy only|Receive either definitive (total of 30-35 fractions) or palliative ( total of 10 fractions) radiotherapy with no continuous intake of Nutri-Jelly
3304395|NCT01871168|Sham Comparator|Sham TAP block|Patients receive TAP catheters but saline infusion instead of local anesthetic
3304396|NCT01871168|Experimental|TAP block|Patients receive a continuous TAP block
3304397|NCT01871181|Experimental|Ilioinguinal block|Patients in this group will receive an ultrasound-guided ilioinguinal nerve block.
3304398|NCT01871181|Active Comparator|Local infiltration|Patients in this group will receive the standard method of local infiltration of local anesthetic around the surgical site.
3304399|NCT01871194||Rivaroxaban|This is a non-interventional study
3304400|NCT01871194||Alternative anticoagulant therapy|This is a non-interventional study
3304401|NCT01871207||Diabetic patients|Diabetic patients who underwent vitrectomy for Proliferative Diabetic Retinopathy
3304402|NCT01871207||Non-diabetic patients|Non-diabetic patients who underwent vitrectomy for macular hole or pucker
3304403|NCT01871220|Active Comparator|Divergent Abutment|Divergent Transition Profile
3304404|NCT01871220|Experimental|Concave Abutment|Concave Transition Profile
3304405|NCT01871246||People with COPD & recent exacerbation|The group consists of people with COPD who have had an exacerbation in the last year.
3304406|NCT01871272||Meniscus Injury Patients|Patients having surgery for a meniscal tear.
3304407|NCT01871298|Other|Website access|While this pilot intervention is not a randomized trial, study participants who report internet use at least once a month will told of a Pilot Website Evaluation Component that they will be able to access for a 4-week study period. This website will contain a educational information tailored to the health needs of drug users. Web content will be similar to materials and public health messages released by the NYC Department of Health and therefore, harm is not likely to arise from viewing such content.
3304408|NCT01871298|No Intervention|No website access|Participants who report internet use less than once a month will not receive access to the Pilot Website Evaluation Component.
3304409|NCT01871311|Experimental|Nilotinib + Cetuximab|All patients with receive Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
3304410|NCT01871324|Experimental|Lifestyle counseling|
3304411|NCT01871337|Experimental|Paula method|"the Paula method, a circular muscle exercise, invented in Israel by Paula Garbourg.The method is based on the principle that all sphincters in the body are synchronized, with the movement of one affecting the other.One can rehabilitate damaged muscles by contracting and relaxing specific circular muscles in other parts of the body."
3304412|NCT01871350|Experimental|Protein and Fish Oil|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g fish oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g fish oil"
3304413|NCT01871350|Experimental|Protein|"Low Dose (FFM <49kg): 30.00g milk protein + 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 40.00g milk protein + 17.00g maltodextrin and 8g olive oil"
3304414|NCT01871350|Placebo Comparator|Placebo|"Low Dose (FFM <49kg): 12.75g maltodextrin and 6g olive oil~High dose (FFM >49kg): 17.00g maltodextrin and 8g olive oil"
3304415|NCT01871363|Experimental|preoperative chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15,31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
3304416|NCT01871376|Active Comparator|Previously Treated|"Patients that have previously received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for previously treated arm."
3304417|NCT01871376|Active Comparator|Treatment-Naive|"Patients that have not received treatment for polypoidal choroidal vasculopathy.~Intervention: Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for treatment-naive arm."
3304418|NCT01871389||cholecalciferol|
3304419|NCT01871389||usual treatment|
3304420|NCT01871415|Experimental|Aleglitazar + metformin|
3304421|NCT01871415|Active Comparator|Placebo + metformin|
3304422|NCT01871428|Experimental|Aleglitazar|
3304423|NCT01871428|Placebo Comparator|Placebo|
3304424|NCT01871454|Experimental|radiotherapy (SABR) plus pentoxifylline|standard of care radiotherapy (SABR) plus pentoxifylline and Vitamin E
3304425|NCT01871467|Experimental|Sargramostim administration|Subjects will receive sargramostim.
3304426|NCT01871480|Experimental|Group A|Gefitinib combination with CIK cell immunotherapy
3304427|NCT01871480|Active Comparator|Group B|Gefitinib alone
3304428|NCT01871493|Experimental|LY2605541-Part A|1.42 units per kilogram (U/kg) of LY2605541 given once daily (QD) for 1 day, subcutaneously (SQ) in 1 of 4 treatment periods.
3304429|NCT01871493|Active Comparator|Insulin Lispro-Part A|Single dose 0.36 U/kg of insulin lispro given QD for 1 day, SQ in 1 of 4 treatment periods.
3304430|NCT01871493|Experimental|LY2605541/Lispro Mix 1-Part A|Single dose 0.54 U/kg of LY2605541 and 0.36 U/kg insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
3304431|NCT01871493|Experimental|LY2605541/Lispro Mix 2-Part A|Single dose 1.42 U/kg of LY2605541 and 0.36 insulin lispro mixture given QD for 1 day, SQ in 1 of 4 treatment periods.
3304432|NCT01871493|Active Comparator|Insulin Lispro-Part B|0.18 U/kg insulin lispro given twice daily (BID) for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3304433|NCT01871493|Experimental|LY2605541/Lispro Mix-Part B|0.71 U/kg LY2605541 and 0.18 U/kg insulin lispro mixture given BID for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3304434|NCT01871493|Experimental|LY2605541 QD-Part B|0.54 U/kg of LY2605541 given QD for 1 day, SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3304435|NCT01871493|Experimental|LY2605541 BID-Part B|0.71 U/kg of LY2605541 given BID for 1 day SQ in 1 of 4 treatment periods. Part B is contingent on data from Part A.
3304436|NCT01871571|Experimental|Treatment (bevacizumab, mFOLFOX7)|Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.
3304437|NCT01871584|Experimental|Hydrocolonic cleansing|Subjects undergo colon cleansing by hydrotherapy with the study device
3304438|NCT01871584|Active Comparator|Standard preparation solution|Subjects undergo colon cleansing by standard preparation solution
3304439|NCT01871597|Experimental|Intervention Group|Intervention - Pulmonary Artery Energy Seal
3304440|NCT01871610|Experimental|Alzheimer disease after mild traumatic brain injury|Based on the TBI registry databank, to recruit patients 1, 5, 10, 15 years after mTBI for cognitive evaluatio
3304441|NCT01871610|Experimental|mild traumatic brain injury without Alzheimer disease|To recruit patients 1, 5, 10, 15 years after mTBI with or without cognitive impairment and age-gender-matched controls (a total of 3 groups) for amyloid- positron emission tomography (A-PET)
3304442|NCT01871610|Experimental|Normal control|People aged 30 or older without mTBI or AD
3304443|NCT01871623|Experimental|Segmental Le Fort I Osteotomy|For some cases that bone filling over cleft site is not good enough for tooth movement, it is possible that we put them into this group which means by using Segmental Le Fort I Osteotomy to approximate two dental alveolar segments.
3304444|NCT01871623|Active Comparator|One-piece Le Fort I Osteotomy|For patients having ideal bone graft result over cleft site, traditional One-piece Le Fort I Osteotomy will be performed.
3304445|NCT01871636|Active Comparator|endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
3304446|NCT01871636|Active Comparator|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
3304447|NCT01871649|Active Comparator|methotrexate|methotrexate is the active comparator, it will be compared to golimumab + methotrexate
3304448|NCT01871649|Experimental|golimumab and methotrexate|The combination of golimumab en methotrexate will be compared to methotrexate alone.
3304449|NCT01871662|Active Comparator|Group C: RIB + Peg-IFN|Ribavirin(800-1400 mg/day,divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC)for 25 weeks if RVR has been achieved or 49 weeks if EVR has been achieved
3304450|NCT01871662|Experimental|Group B:Legalon® SIL + RIB + Peg-IFN|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) + Peg-IFN alfa2b (1.5 μg/kg/week SC) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
3304451|NCT01871662|Experimental|Group A: Legalon® SIL + RIB|Silibinin (20 mg/Kg/day) for 6 days, followed by Silibinin + ribavirin (800-1400 mg/day, divided BID PO) for 15 days, followed by ribavirin (800-1400 mg/day, divided BID PO) + 2 days of Silibinin per week for 9 weeks, followed by ribavirin (800-1400 mg/day, divided BID PO) for 13 weeks if RVR has been achieved (for a total of 25 weeks of treatment) or 37 weeks if EVR has been achieved (for a total of 49 weeks of treatment)
3304452|NCT01871675|Experimental|Arm 1: IPI-145 plus Rituximab|"IPI-145 will be administered orally, twice daily, in 28-day (4-week) cycles, on a continuous basis at the maximum tolerated dose of 25 mg twice-daily (BID), as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly during a 28 day cycle; 2 cycles of rituximab will be administered."
3380813|NCT04393298|Experimental|Part C|Study participants assigned to this arm will receive UCB6114 in escalating cohorts at pre-specified dose levels in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) regimen.
3380814|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label) from Parent Study|Participants assigned to lebrikizumab Q2W (once every 2 weeks) arm will receive investigational product Q2W by subcutaneous (SC) injection.
3380815|NCT04392154|Experimental|Lebrikizumab Q2W (Blinded) from Parent Study|Participants assigned to lebrikizumab Q2W arm will receive investigational product Q2W by SC injection. Some participants will receive loading doses.
3380816|NCT04392154|Experimental|Lebrikizumab Q2W (Open-Label Addendum)|Participants enrolling in Open-Label Addendum will receive lebrikizumab Q2W by SC injection after loading doses.
3380817|NCT04392154|Experimental|Lebrikizumab Q4W|"Participants assigned to lebrikizumab Q4W (once every 4 weeks) arm will receive investigational product Q4W by SC injection.~Intervention assigned: Lebrikizumab balanced with Placebo to maintain the blind between treatment arms."
3380819|NCT04384484|Experimental|Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)|"Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.~Participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles."
3380820|NCT04384484|Experimental|Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)|Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 every Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles.
3380821|NCT04384484|Active Comparator|Part 2: Standard Immunochemotherapy (R-GemOx)|Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2 every 2 weeks (Q2W) for up to 8 cycles.
3380824|NCT04376593|Experimental|18F-αvβ6-BP|Following a 10 mCi (±20%) intravenous injection (IV) of 18F-αvβ6-BP, PET/CT images will be acquired at 60 minutes. Baseline blood samples will be drawn and banked. Vital sign (VS) measurements (heart rate, respiratory rate, blood pressure and temperature) monitored throughout. Region-of-interest analysis (ROI) will be performed in the lung. Each participant will undergo up to 3 18F- αvβ6-BP PET/CT scans over a 6-month timeframe.
3380825|NCT04373343|Other|16-week Food Addiction Clinical Treatment (FACT) Program|16-week Food Addiction Clinical Treatment (FACT) Program, first session will be 120 mins, all subsequent sessions will be 90 mins. Treatment will be led, at a minimum, by a full licensed psychologist
3380848|NCT04361799|Experimental|Closed-loop insulin therapy|
3380849|NCT04361799|Active Comparator|Standard insulin therapy|
3380850|NCT04359784|Experimental|Prevention (anakinra, axicabtagene ciloleucel)|Patients receive anakinra SC daily on days 0-13 and axicabtagene ciloleucel via infusion on day 0.
3304453|NCT01871675|Experimental|Arm 2: IPI-145 plus Rituximab/Bendamustine|"IPI-145 will be administered orally, twice daily, in 28 day cycles, on a continuous basis, until disease progression, unacceptable toxicity or patient refusal. The maximum tolerated dose of IPI-145 will be 25 mg twice-daily (BID) as determined in the dose escalation phase. Twelve (12) cycles of IPI-145 will be administered. Patients who benefit from treatment may continue on study for additional cycles until toxicity or progressive disease.~Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Day 1 once weekly of each 28 day cycle. A maximum of 6 cycles of rituximab will be given. Bendamustine 90 mg/m2 IV will be administered on Days 1 and 2, of each 28 day cycle. Rituximab should be administered prior to bendamustine."
3304454|NCT01871688|Other|pelvic floor exercise|pelvic floor rehabilitation program with neuromodulation
3304455|NCT01871701|Experimental|Quetiapine|Quetiapine 100 mg (Seroquel, Tablet)
3304456|NCT01871701|Experimental|Moxifloxacin|Moxifloxacin 400 mg (Avelox, Tablet)
3304457|NCT01871701|Experimental|Escitalopram|Escitalopram 20 mg (Lexapro, Tablet)
3304458|NCT01871701|Placebo Comparator|Placebo|Water intake
3304459|NCT01871714||XLHED affected Males|All males ages 4 and up affected by XLHED
3304460|NCT01871714||Females affected by XLHED|Adult females (ages 18-45) affected by XLHED
3304461|NCT01871714||Unaffected females|Unaffected adult female controls (ages 18-45)
3304462|NCT01871727|Experimental|E7777|
3304463|NCT01871740|Experimental|Enalapril maleate and folic acid tablets|A fixed combination drug is given. The dose is fixed in enalapril 10 mg / folic acid 0.8 mg per day.
3304464|NCT01871740|Active Comparator|Enalapril maleate|Enalapril maleate 10 mg per day is given
3304465|NCT01871753|Experimental|Antibiotics|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up).
3304466|NCT01871753|No Intervention|No treatment|no antibiotics delivered in case of asymptomatic bacteriuria, independently of the number of asymptomatic episodes.
3304467|NCT01871766|Experimental|Low-Risk, Subset 1|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3304468|NCT01871766|Experimental|Low-Risk, Subset 2|"Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3304469|NCT01871766|Experimental|Intermediate-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3304470|NCT01871766|Experimental|High-Risk|"Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy [vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed.~Participants also receive ^1^1C-methionine as described in the intervention section."
3304471|NCT01871779|Experimental|Standard Treadmill Exercise|The first group would undergo standard treadmill exercise to the point of pain and repeat these cycles for a total period of 35-45 minutes twice weekly for 12 weeks
3304472|NCT01871779|Experimental|Intermittent Treadmill & Resistance Training|The second group would have a combination of intermittent treadmill and some resistance training with weights. They will undergo repeated cycles to a maximum of 35-45 minutes twice weekly for 12 weeks
3304473|NCT01871792|Experimental|Pitavastatin|Pitavastatin 4 mg/day for 7 days before coronary angiography/intervention
3304474|NCT01871792|Placebo Comparator|Placebo|Placebo tablet for 7 days before coronary angiography/intervention
3304475|NCT01871818|Experimental|Combined program|"Combined program with physiotherapy, endurance training and resistance training.~120 patients will receive this combined program"
3304476|NCT01871818|Active Comparator|Physiotherapy|Active comparator: physiotherapy in private practice 120 patients will receive this usual rehabilitation
3304477|NCT01871844|Experimental|ITF2984 500 mcg/Placebo sc bid for 7 days|TF2984 500 mcg/Placebo sc bid for 7 days
3304478|NCT01871844|Experimental|ITF2984 1000 mcg/Placebo sc bid for 7 days|ITF2984 1000 mcg/Placebo sc bid for 7 days
3304479|NCT01871844|Experimental|ITF2984 2000 mcg/Placebo sc bid for 7 days|ITF2984 2000 mcg/Placebo sc bid for 7 days
3304480|NCT01871844|Active Comparator|octreotide 50 mcg tid|octreotide 50 mcg tid
3304481|NCT01871857|Active Comparator|Normal saline and epinephrine|0.9 % saline with 0.5 ml of 1:1000 epinephrine inhalation
3304482|NCT01871857|Experimental|Hypertonic saline and epinephrine|3 ml 7% saline with 0.5 ml of 1:1000 epinephrine inhalation
3304483|NCT01871883|Experimental|Sensitive Skin|Subjects with sensitive skin, diagnosed by the lactic acid stinging test. Skin biopsy Oral mucosa specimen
3304484|NCT01871883|Active Comparator|Non-sensitive skin|Subjects without sensitive skin, determined by a negative lactic acid stinging test Skin biopsy Oral mucosa specimen
3304485|NCT01871896|Experimental|Weight Gain|Patients who previously underwent bariatric surgery who failed to lose the expected weight or regained weight.
3304486|NCT01871909||Physical trauma|Patients with report of physical trauma within 24 hours of presentation to the hospital.
3304487|NCT01871922|Placebo Comparator|General anesthesia + placebo|Propofol/remifentanil anesthesia + saline
3304488|NCT01871922|Active Comparator|General anesthesia + atropine|Propofol/remifentanil anesthesia + atropine
3304489|NCT01871935|Active Comparator|Remifentanil|Anaesthesia with remifentanil/propofol
3304490|NCT01871935|Active Comparator|Sufentanil|Anaesthesia with sufentanil/propofol
3304491|NCT01871948|No Intervention|Patient survey at 2 points in time|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later.
3304492|NCT01871948|Experimental|"WeWant to Know campaign, patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
3304493|NCT01871961|Experimental|Methotrexate|
3304494|NCT01871974|Experimental|low-dose group FK949E|oral
3304495|NCT01871974|Experimental|high-dose group FK949E|oral
3304496|NCT01871987|Experimental|fasted group|receiving FK949E in fasted condition
3304497|NCT01871987|Experimental|low fat group|receiving FK949E after low fat meal
3304498|NCT01871987|Experimental|high fat group|receiving FK949E after high fat meal
3304499|NCT01872000|Experimental|Multifocal IOL|Phacoemulsification and IOL inserted following cataract surgery
3304500|NCT01872000|Active Comparator|Standard IOL|Phacoemulsification and IOL inserted following cataract surgery
3304501|NCT01872013|Experimental|low dose ASP7991|
3304502|NCT01872013|Experimental|middle dose ASP7991|
3304503|NCT01872013|Experimental|high dose ASP7991|
3304504|NCT01872013|Placebo Comparator|Placebo|
3304505|NCT01872026|Experimental|Part 1- single administration|The lowest, middle and the highest dose ASP7991 as a single oral administration on non-dialysis day in step 1 to 3 and the highest dose on day of dialysis in step 4.
3304506|NCT01872026|Experimental|Part 2- repeated administration|The lowest, middle and the highest dose ASP7991 as repeated oral administration in step 1 to 3.
3304507|NCT01872039|Active Comparator|Weight-based adjustment group|Dosage regimen according to the current Package Insert approved by SFDA
3304508|NCT01872039|Experimental|Non-weight-based adjustment group|Dosage regimen according to the Package Insert approved by FDA
3304509|NCT01872052|Experimental|Acutus Medical System|
3304510|NCT01872065|Experimental|ARC-520|Single dose, intravenous administration of ARC-520.
3304511|NCT01872065|Placebo Comparator|Normal Saline|Single dose, intravenous administration of Normal Saline
3304512|NCT01872091|Experimental|cryotherapy by immersion|Cryotherapy group immersion (GI) composed of 20 volunteers, which will be subjected to immersion cryotherapy upper limb dominant in cold water (6°C ± 2°C), at the level of the elbow joint.
3304513|NCT01872091|Experimental|Control group|(CG) consisted of 20 volunteers, which will be submitted to immersion of the dominant upper limb in water at room temperature indifferent to the level of the elbow joint;
3304514|NCT01872104|No Intervention|Chemotherapy alone|Group that be scheduled to undergo chemothrapy only using FOLFOX4 protocol.
3304515|NCT01872104|Experimental|PDT and Chemotherapy|Group that not only be scheduled to undergo chemothrapy using FOLFOX4 protocol,but also receive colonscopy-assisted PDT.
3304516|NCT01872117|Experimental|Applications of shortwave diathermy|
3304517|NCT01872117|Experimental|Applications of microwave diathermy|
3304518|NCT01872143|Experimental|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation
3304519|NCT01872156|Experimental|Intervention GESTABAC|"Intervention based on the Clinician's Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
3304520|NCT01872156|Other|Control Group|The group control will act according to usual management.
3304521|NCT01872169|Other|Disordered eating screening questionnaire|
3304522|NCT01872182|Experimental|Test arm|ALS-L1023 300mg in two tablets
3304523|NCT01872182|Placebo Comparator|Comparator arm|placebo in two tablets
3304524|NCT01872195|Experimental|* Before checklists|The comprehensive patient safety checklist system
3304525|NCT01872195|Experimental|* After checklists|Without the comprehensive patient safety checklist system
3304527|NCT01872221|Experimental|Surgery and radio-chemotherapy|Surgery (on the basis of all preoperative multimodal MRI) followed by standard radio-chemotherapy stupp protocol
3304528|NCT01872234|Experimental|Device Arm: Two Lead CRT-P|Intervention: Device: Two-lead CRT-P. Patients will be implanted with a two lead CRT-P system: right atrial lead, left ventricular lead and a dual chamber pacemaker. Patients in this group will also be under optimal pharmacologic therapy.
3304529|NCT01872234|No Intervention|Control: Optimal Pharmacologic Therapy|The control group will be managed on optimal pharmacologic therapy only. They will not be implanted with a device.
3304530|NCT01872286|Experimental|Pillcam SB2 first|patients were assigned to swallow PSB first, followed by the AKE
3304531|NCT01872286|Experimental|AKE-1 first|patients were assigned to swallow AKE first, followed by the PSB
3304532|NCT01872299||Control|Healthy control subjects
3304533|NCT01872299||Heart failure without co-morbidities|Patients with a clinical diagnosis of chronic heart failure without co-morbidities
3304534|NCT01872299||Heart failure with co-morbidities|Patients with a clinical diagnosis of chronic heart failure with co-morbidities
3304535|NCT01872299||Type 2 diabetes mellitus|Patients with type 2 diabetes mellitus and without heart failure
3304536|NCT01872312|Other|treatment|Loading IBV® Valve System
3304537|NCT01872351||pre and 12 months post ENT|"Compare the clinical status of CFS patients after at least 12 months of ENT to their status before ENT.~ENT consists of:~Daily conditioning exercise: 35-40 minutes~Nutraceutical supplements: acetyl-L-carnitine 500 mg bid, alpha-lipoic acid (Alpha Lipoic Sustain 300) 300 mg qd, CoQ10 (Ubiquinol QH-absorb) 100 mg qd, docosahexanoic acid (maxDHA) 300 mg qd, plus a multivitamin (Centrum Silver) ½ tab bid.~Diet: 25% protein, 35- 40% carbohydrate, 35-40% fat"
3304538|NCT01872364||Dominican Republic patients at NPO Outpatient Surgery Center|
3304539|NCT01872377|Experimental|Radiotherapy Boost|All participants will receive the CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost treatment however, there are 5 dose levels that could be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Participants will be assigned to either receiving 6, 7, 8, 9 or 10 Gy X 3Fr.
3304540|NCT01872390|Experimental|CIP Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
3304541|NCT01872390|Other|SOC Participants|Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
3304542|NCT01872403|Experimental|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung
3304543|NCT01872416|Experimental|Refractory and relapsed SCLC|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
3304544|NCT01872429||Short-term group|Patients with postoperative 6-month laboratory data were included in the short-term group
3304545|NCT01872429||Long-term group|Patients with postoperative more than 6-month laboratory data were included in the long-term group
3304546|NCT01872442|Experimental|Dasatinib|Dasatinib,Bristol Myers Squibb
3304547|NCT01872442|Experimental|Peg-Interferon alpha2b|Peg-Interferon alpha2b (Peg-IFN α2b), Merck
3304548|NCT01872455|Active Comparator|Group CON|patients who refused to assume the n-3 rich diet and continued their usual diet
3304549|NCT01872455|Experimental|Group DIET|the patients assumed n-3 rich diet: Patients of the DIET group were requested to follow a diet specifically designed to increase the intake of n-3 PUFAs and to decrease the ratio n-6/n-3 by using natural foods.
3304550|NCT01872468|No Intervention|Control|There is not intervention in this group.
3304551|NCT01872468|Active Comparator|Structured intervention|Initial training session based on significant learning and follow up visits every four months at physicians and nurses´ offices over a two-year period
3304552|NCT01872481|Placebo Comparator|Sham stimulation|"rTMS with sham coil. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks."
3304553|NCT01872481|Experimental|Active stimulation|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
3304554|NCT01872494|Experimental|Local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
3304555|NCT01872494|Active Comparator|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
3304556|NCT01872507|Active Comparator|biofeedback training|usual treatment+12 treatment of biofeedback training
3304557|NCT01872507|No Intervention|control|usual treatment
3304558|NCT01872520||the Injection of DanShenDuoFenSuanYan|Patient who use the Injection of DanShenDuoFenSuanYan
3304559|NCT01872533|Experimental|Hypoxia Exposure|There was only one study arm: All participants slept in moderate hypoxia (see description below).
3304560|NCT01872546|Experimental|Adalimumab|
3304561|NCT01872559||3D sonographic analysis|The study is designed to evaluate a new imaging modality, 3D sonographic volumetric analysis, and compare it to the conventional 2-dimmensional analysis that is currently in place. Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do no require any additional sonograms, tests, or interventions.
3304562|NCT01872572|Other|Cohort 1|Cohort 1: 6 subjects received Subcutaneous RB006 0.5 mg/kg and 2 subjects received SC placebo
3304563|NCT01872572|Other|Cohort 1-A|Cohort 1-A: 4 subjects received open-label Subcutaneous RB006 0.5 mg/kg
3304564|NCT01872572|Other|Cohort 2|Cohort 2: 6 subjects received Subcutaneous RB006 1.0 mg/kg and 2 subjects received SC placebo
3304565|NCT01872572|Other|Cohort 3|Cohort 3: 6 subjects received Subcutaneous RB006 3.0 mg/kg and 2 subjects received SC placebo
3304566|NCT01872572|Other|Cohort 4|"8 subjects received subcutaneous RB006 2.0 mg/kg as well as the following:~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration"
3304567|NCT01872585|Experimental|Mentalization based therapy|Women who are the primary caregivers of a child between the ages of 0-7 years and are involved with mental health services for themselves or a child.
3304568|NCT01872598|Experimental|Masitinib escalating dose|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily, with a dose escalation to 6 mg/kg/day after 3 months of treatment
3304569|NCT01872598|Experimental|Masitinib fixed dose (4.5 mg/kg/day)|Participants receive masitinib at 4.5 mg/kg/day, given orally twice daily.
3304570|NCT01872598|Experimental|Masitinib fixed dose (3.0 mg/kg/day)|Participants receive masitinib at 3.0 mg/kg/day, given orally twice daily.
3304571|NCT01872598|Placebo Comparator|Placebo (escalating dose)|Participants receive placebo, given orally twice daily, with a matched dose escalation after 3 months of treatment
3304572|NCT01872598|Placebo Comparator|Placebo (fixed dose)|Participants receive fixed dose placebo, given orally twice daily
3304573|NCT01872624|Active Comparator|Valves plus cells|Bronchoscopy Five patients will be selected to receive bone-marrow derived mesenchymal stromal cells delivered bronchoscopically right before insertion of one-way endobronchial valves.
3304574|NCT01872624|Placebo Comparator|Valves plus saline|Bronchoscopy Five patients will be selected for treatment with one-way endobronchial valves only, with saline injected prior to valve insertion.
3304575|NCT01872637|Experimental|Progressive Multi-Component Intervention|Patients in this exercise group will receive 10-18, 45-60 minute, physical therapy visits in their home. This group will consist of progressive resistance exercises for the upper and lower extremity with a portable training device, a motor control-based program of gait/balance training, Activities of Daily Living (ADL) training, and mobility training.
3304576|NCT01872637|Active Comparator|Usual Care Group|"The patients in this group will receive approximately five visits of usual home care but the total number of visits will be determined by the therapist as part of usual care. These visits will likely occur at 1-2 times per week for 3-4 weeks. This group will receive intervention as determined by the physical therapist's initial examination. Interventions may include patient education, home exercises, low intensity strengthening exercise, training in gait, balance and transfers; home safety and assistive device assessment."
3304577|NCT01872650|No Intervention|Control|No placement of an adhesion barrier
3304578|NCT01872650|Experimental|C-Qur|C-Qur film placement beneath the incision. Possibly placement of C-Qur film at other sites considered to be adhesiogenic (but not around the anastomosis)
3304579|NCT01872663|Experimental|Incentive spirometry (Voldyne®)|Individuals will be treated with incentive spirometry, Voldyne Model 5000® in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3304580|NCT01872663|Experimental|Continuous positive airway pressure|Individuals will be treated with flow generator(Whisperflow, Caradyne, Ireland)and valve PEEP type spring-loaded which remain 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
3304581|NCT01872663|Experimental|Expiratory Positive Airway Pressure|Subjects will be treated with oronasal mask affixed to the face, with the PEEP valve set at 10 cmH2O, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3304582|NCT01872663|Experimental|Intermittent positive pressure breathing|Subjects will be treated with application of Müller Resuscitator (Engesp®) through a nozzle, using a pressure endotracheal 20-30 cmH2O, refering to 2-3 kgf/cm², adjusted throttle valve oxygen, according to the patient's comfort and the micronebulizer coupled only saline as the diluent. The procedure will be performed in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3304583|NCT01872663|Experimental|Bi-level positive airway pressure|Individuals will be treated with positive pressure in the BiPAP mode (Bi-level positive airway pressure) in the immediate and the first postoperative day, twice a day, in sessions 30 minutes each, with an interval of four hours between them.
3304584|NCT01872663|Experimental|Breath Stacking|Subjects will be treated with a siliconized mask connected to a unidirectional valve and adapted to the patient's face, allowing only the inspiration and the expiratory limb remains occluded, while the volunteer is instructed to perform successives inspiratory efforts, in the immediate and the first postoperative day, twice a day, in sessions of 6 sets of 15 repetitions each, with an interval of four hours between them.
3304585|NCT01872663|No Intervention|Control|Individuals will be treated with conventional physiotherapy according to the routine service of physiotherapy of the hospital.
3304586|NCT01872676|Experimental|Manipulation|The experimental group received upper thoracic manipulation of the T3 vertebra. The volunteer was instructed to lie in the supine position, interlace her fingers and position her hands in the posterior region of the base of the neck. The therapist than positioned a stabilizing hand in a pistol grip immediately caudal to the T3 vertebra, pushing the volunteer's arms downward to generate flexion of the upper thoracic spine.
3304587|NCT01872676|Sham Comparator|Sham|The placebo group was placed precisely as the experimental group, with the exception of the positioning of the therapist's hand, which remained with the palm open and not in a pistol grip. Once positioned, the volunteers were instructed to breathe deeply. The maneuver was terminated after one cycle of deep breathing.
3304588|NCT01872702|Experimental|malaria elimination using DP and low-dose primaquine|Two villages randomly allocated to intervention (chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages the entire population will be invited to receive three, monthly rounds of treatment with dihydroartemisinin-piperaquine and primaqunine to kill malaria parasites. The micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.
3304589|NCT01872702|No Intervention|Control villages|"Two villages randomly allocated to control (no chemo-elimination) at each of the 4 sites (population approximately 500 people in each village). In these villages only the micro-epidemiology of malaria will be studied and prevalence and patterns of transmission used for comparison. NB, in Cambodia there will be no intervention villages and all four villages will be used to study the micro-epidemiology of malaria transmission in the absence of malaria elimination.~From June 2013 to June 2014 Cambodia site conducted surveys with no medical intervention (treatment arm). In July 2015 Cambodia implemented the TCE protocol with two intervention and two control villages. Primaquine is not used in the TCE treatment regimen in Cambodia. Both studies were approved under OxTREC reference no. 1017-13 and 1015-13."
3304590|NCT01872728|Placebo Comparator|Control|placebo for the realization of the facial block and morphine for intraoperative analgesia
3304591|NCT01872728|Active Comparator|Levobupivacaine|Levobupivacaine for the realization of the facial block and placebo for intraoperative analgesia
3304592|NCT01872741|Active Comparator|Ruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
3304593|NCT01872741|Active Comparator|Unruptured intracranial aneurysms|Pterional craniotomy Minipterional craniotomy
3304594|NCT01872754|Active Comparator|2: Propofol|Control arm: the use of TCI of hypnotic (Propofol) during realization bronchial fibroscopy.
3304595|NCT01872754|Experimental|1: Remifentanil|Interventional arm: the use of TCI of morphinomimetic (Remifentanil) during realization bronchial fibroscopy.
3304596|NCT01872767||Cirrhotics/ Acute on chronic liver failure admitted to ICU|
3304597|NCT01872780|Active Comparator|rosiglitazone|avandia
3304598|NCT01872780|Active Comparator|genetic polymorphism|avandia CYP2C8 genotype
3304599|NCT01872806|Experimental|Experimental: Mobile phone radiation|Dialing mobile phone placed against the ear/chest for a duration of 15 minutes, before and after 15 minutes sham phone will be placed against the ear/chest.
3304600|NCT01872832|Experimental|5 mg RDEA3170|RDEA3170 5 mg or placebo fasted and fed
3304601|NCT01872832|Experimental|10 mg RDEA3170|RDEA3170 10 mg or placebo fasted and fed
3304602|NCT01872832|Experimental|15 mg RDEA3170|RDEA3170 15 mg or placebo fasted and fed
3304603|NCT01872832|Experimental|2.5 mg RDEA3170|RDEA3170 2.5 mg or placebo fasted and fed
3304604|NCT01872845|Active Comparator|Rosuvastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
3304605|NCT01872845|Experimental|Pravastatin|All study subjects will be received percutaneous coronary intervention (PCI) with Biolimus-eluting stent as index procedure at the time of enrollment After index procedure, patients will be randomly assigned to receive pravastatin 40mg or rosuvastatin 20mg in a 1:1 ratio. a> Test group: Pravastatin 40mg PO daily for 1year from the day of BES implantation b> Control group: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
3304606|NCT01872858|Active Comparator|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
3304607|NCT01872858|Experimental|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
3304608|NCT01872871|Placebo Comparator|local anasthetic drops|topical anaesthetic drop with placebo
3304609|NCT01872871|Active Comparator|Paracetamol|Topical anaesthetic drop with Paracetamol
3304610|NCT01872884|Experimental|General anaesthesia|General anaesthesia with mechanical ventilation. Sevorane Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg.
3304611|NCT01872884|Placebo Comparator|Sedation|Sedation with spontaneous breathing. Remifentanil. Bloodpressure control, systolic pressure 140-180 mmHg
3304612|NCT01872897|Active Comparator|Sodium Alginate Double Action Tablets|Four Compound Sodium Alginate Double Action Chewable Tablets administered as a single dose
3304613|NCT01872897|Placebo Comparator|Placebo tablets|Single dose of 4 Placebo tablets
3304614|NCT01872923|Experimental|Amphinex based PCI of bleomycin|The photosensitiser Amphinex is activated by Laser to enhance the effect of Bleomycin
3304615|NCT01872936|Other|Miravirsen every other week dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 6 every other week doses at 5 mg/kg in combination with telaprevir and ribavirin.
3304616|NCT01872936|Other|Miravirsen monthly dosing|Miravirsen will be dosed as single subcutaneous injections. Subjects will receive 5 weekly doses at 7 mg/kg, then 3 monthly doses at 7 mg/kg in combination with telaprevir and ribavirin.
3304617|NCT01872962|Experimental|Induction chemotherapy+IMRT and concurrent cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy, and then receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
3304618|NCT01872962|Active Comparator|IMRT and concurrent cisplatin|Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
3304619|NCT01872975|Active Comparator|Group 1A Lumpectomy: no regional nodal XRT with WBI|Lumpectomy patients undergo whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
3304620|NCT01872975|No Intervention|Group 1B Mastectomy: No regional nodal or chestwall XRT|Mastectomy patients do not undergo radiation therapy.
3304621|NCT01872975|Experimental|Group 2A lumpectomy: Regional nodal XRT with WBI|Lumpectomy patients undergo regional nodal radiation therapy with whole breast radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks followed by a radiation therapy boost to the lumpectomy cavity once daily 5 days a week for 1-1/2 weeks.
3304622|NCT01872975|Experimental|Group 2B Mastectomy: Regional nodal XRT and chestwall XRT|Mastectomy patients undergo regional nodal radiation therapy using IMRT or 3D-CRT once daily 5 days a week for 5 weeks.
3304623|NCT01872988|Active Comparator|Tenofovir treatment|Start to administer Tenofovir treatment 300mg PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
3304624|NCT01872988|Placebo Comparator|Placebo|Start to administer placebo 1 Tab PO QD within 2 weeks after the 1st TACE. Maximum duration of tenofovir treatment: 3 years.
3304625|NCT01873001|Experimental|Abiraterone acetate + pioglitazone HCl|Participants will receive 15 mg pioglitazone on Day 1 (Period 1). On Day 8 (Period 2), participants will receive 1000 mg abiraterone acetate followed by 15 mg of pioglitazone one hour later.
3304626|NCT01873014|Experimental|high Iodine intake|
3304627|NCT01873014|Active Comparator|low Iodine intake|
3304628|NCT01873027|Experimental|OFDI-guided PCI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
3304629|NCT01873027|Active Comparator|IVUS-guided PCI|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12 months after PCI."
3304630|NCT01873040|Experimental|Social media plus information pages|Participants will have access to the vaccine social media website with information pages and social media features including discussion forums, blogs, chat with an expert, and ask an expert.
3304631|NCT01873040|Experimental|Information Pages|Participants will have website access to vaccine information pages.
3304632|NCT01873040|No Intervention|Usual Care|Participants will not have access to the vaccine website. They will receive pediatric care as usual.
3304633|NCT01873053|Experimental|1st group : WIN-34B 900mg|Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks
3304634|NCT01873053|Experimental|2nd group : WIN-34B 1800mg|Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks
3304635|NCT01873053|Placebo Comparator|3rd group : Placebo|Patients assigned to 3rd group take Placebo BID for 12weeks
3304636|NCT01873066|Experimental|Closed-loop insulin delivery|Glucose level is controlled by the automated closed-loop glucose control system. After initial training with the closed-loop system devices, subjects will use the closed-loop system day and night at home for a total duration of 7 days (phase 1) and 21 days (phase 2).
3304637|NCT01873066|Active Comparator|real-time CGM alone|Glucose level will be controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM) during the day and night over 7 days (phase 1) and 21 days (phase 2).
3304638|NCT01873079|Active Comparator|Esomeprazole|esomeprazole 40mg bd for 10 days
3304639|NCT01873079|Sham Comparator|Standard care|No other study drug or placebo will be given
3304640|NCT01873092||Patients with COPD|Patients who meet criteria for chronic obstructive pulmonary disease
3304641|NCT01873105|Experimental|Health team educational intervention|Agency for Healthcare Research and Quality (AHRQ) TeamSTEPPS approach will be used to redesign health team communication processes regarding preparation for discharge. This redesign will be followed by education for all health team members.
3304642|NCT01873105|No Intervention|Control pre-intervention|Usual care control before implementation of the health team communication intervention
3304643|NCT01873118|No Intervention|Usual Care Control hospital unit|This study involves implementation of interventions across entire hospital units. This arm is a usual care control unit paired to the intervention unit.
3304644|NCT01873118|Experimental|implementation unit|"3 implementation protocols implemented sequentially:~RN-RHDS: implementation of discharge readiness assessment by the discharging nurse~RN-RHDS+PT-RHDS: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness~RN-RHDS+PT-RHDS+NIAF: implementation of discharge readiness assessment by the discharging nurse which is informed by patient self-assessment of discharge readiness followed by documentation of nurse actions initiated in response to the assessment. Nurse are instructed that action must be taken if any assessment item scores less than 7 ( on a 10 point scale)."
3304645|NCT01873131|Experimental|Topical Timolol|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the timolol arm will receive twice daily topical application of a physician-specified amount of timolol maleate 0.5% ophthalmic solution (hereby referred to as topical timolol) for up to six months.
3304646|NCT01873131|No Intervention|Observation|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the observation arm will be followed at study visits according to protocol.
3304647|NCT01873131|Experimental|Pulsed Dye Laser|After verification of eligibility criteria and obtaining informed consent of parent/guardian, infants randomized to the pulsed dye laser arm will receive a series of six weekly to semi-weekly laser treatments treatments for up to 6 treatments with potential for reduced number of treatments if the hemangioma completely resolves. A 595-nm pulsed-dye laser (PDL, V-beam Perfecta, Candela Corp, Wayland, MA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions.
3304648|NCT01873144|Active Comparator|HSS (3%) + epinephrine|Nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of HSS(3%) every 4h for three times and afterwards at physician in charge criteria.
3304649|NCT01873144|Experimental|HHHFNC+epinephrine+Normal Saline(0.9%)|Flow depending on weight (Tidal volume x respiratory rate x 9) and nebulized solution containing 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 plus 2 mL of Normal Saline (NS) (0.9%) every 4h and afterwards at physician in charge criteria.
3304650|NCT01873157|Placebo Comparator|Placebo (NaCl solution)|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
3304651|NCT01873157|Active Comparator|Bortezomib (Velcade®)|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
3304652|NCT01873183|Experimental|The IGDT group|"30 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will be consecutively enrolled for the study.~The individualized goal-directed therapy (IGDT) with focus on level of venous return will be implemented in two steps in the intervention group. First, preoperative optimizing of venous return will be performed 45 minutes before surgery in a preoperative room with TTE. Second, after induction of anaesthesia perioperative fluid therapy will be implemented by utilizing the FloTrac-device."
3304653|NCT01873183|No Intervention|The control group|20 morbidly obese subjects scheduled for bariatric surgery by laparoscopic Roux-en-Y gastric bypass (RYGB) will consecutively be enrolled for the study. Conventional monitoring will be conducted perioperatively.
3304654|NCT01873196|Experimental|Receive extra oil|This arm will receive enough oil to prepare the CSB they receive in the newly recommended proportion of 100g CSB: 30g oil. They will receive education and instructions on the new method of preparation.
3304655|NCT01873196|No Intervention|Control-No extra oil received|This group will continue to receive only 1L of oil with their CSB has they already have been. They also will not receive any new education.
3304656|NCT01873196|Experimental|Receives behavior changed messages on CSB package|Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
3304657|NCT01873196|No Intervention|Control-No repackaged CSB|
3304658|NCT01873222|Experimental|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
3304659|NCT01873222|Active Comparator|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
3304660|NCT01873235||Main Cohort|This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
3304661|NCT01873248|Experimental|Diagnostics with PET|68Ga-DOTATATE PET scans will be performed on subjects
3304662|NCT01873274|Active Comparator|basic yogurt enriched with MK-7|one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)
3304663|NCT01873274|Active Comparator|MK-7 containing capsule|one study group will receive daily a softgel capsule consisting of 50 μg MK-7
3304664|NCT01873274|Active Comparator|nutrient enriched yogurt with MK-7|one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)
3304665|NCT01873300|Experimental|treatment group|Patients undergoing POEM procedure
3304666|NCT01873313||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following knee arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery plus up to 5 top-up boluses (40mls of 0.2% ropivacaine or 80mg) postoperatively.
3304667|NCT01873326|Experimental|Paclitaxel, Ifosfamide and Cisplatin (TIP)|"Paclitaxel 120 mg/m2 IV over 120-180 min Days 1 and 2 (+/- 4 days)* Mesna 120 mg/m2 IV (duration of infusion per institutional guidelines) approximately 30 minutes prior to initiation of ifosfamide Days 1-5 (+/- 4 days)* Ifosfamide 1200 mg/m2 IV over approximately 60 to 120 min Days 1-5 or per institutional guidelines (mixed 1:1 with mesna) (+/- 4 days)* Mesna** 1200 mg/m2 IV over approximately 60-120 min or per institutional guidelines (mixed 1:1 with ifosfamide)(+/- 4 days)* Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)*~**Additional mesna may be given at the discretion of the investigator~*Paclitaxel or Ifosfamide or Mesna or Cisplatin or any combination of these agents can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
3304668|NCT01873326|Active Comparator|Bleomycin, Etoposide and Cisplatin (BEP)|"Cisplatin 20 mg/m2 IV over approximately 30 min Days 1-5 (+/- 4 days)* Etoposide 100 mg/m2 IV over approximately 1 hour Days 1-5 (+/- 4 days)* Bleomycin 30 U flat dose IV push Days 2, 8 and 15 (all +/- 4 days)~*Etoposide or Cisplatin or both can be held as needed for patient safety on a given day between days 1-5 but must be made up within 4 days to avoid a protocol violation."
3304669|NCT01873339|Experimental|Darapladib|The subjects will receive a single oral dose of midazolam 5 mg on Day 1. The subjects will receive darapladib 160 mg once daily on Days 3-14. The subjects will also receive a single dose of midazolam 5 mg on Day3 and 14.
3304670|NCT01873352|Active Comparator|CA+RD|Catheter ablation of atrial fibrillation plus renal sympathetic denervation
3304671|NCT01873352|Active Comparator|CA (control)|Catheter ablation of atrial fibrillation (control group)
3304672|NCT01873365||Prospective Group|Japanese adults, aged greater than or equal to sixty years, diagnosed with HZ.
3304673|NCT01873378|Experimental|GnRH agonist pretreatment|triptorelin 3.75 mg, im, monthly, three times
3304674|NCT01873378|No Intervention|No pharmacological treatment|
3304675|NCT01873391|Active Comparator|Normal saline|Normal saline is a distension media of uterine cavity in diagnostic hysteroscopy.
3304676|NCT01873391|Active Comparator|Carbon dioxide|Carbon dioxide is a distension media of uterine cavity in diagnostic hysteroscopy.
3304677|NCT01873404|Experimental|BG00010|Administered as an IV injection at various dose levels 3 times per week for 1 week
3304678|NCT01873404|Placebo Comparator|Placebo|Matched placebo IV injection 3 times per week for 1 week
3304679|NCT01873430|Active Comparator|Melatonin: Melatonin cream 2,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied
3304680|NCT01873430|Active Comparator|Melatonin: Melatonin cream 0,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
3304681|NCT01873430|Active Comparator|Melatonin: Melatonin cream 12,5%|One square on the back of each volunteers will be randomized to have the above mentioned dose of melatonin cream applied.
3304682|NCT01873430|Placebo Comparator|placebo cream|One square on the back of each volunteers will be randomized to have placebo cream (vehicle) applied.
3304683|NCT01873430|No Intervention|No treatment|One square on the back of each volunteers will be randomized to receive no treatment.
3304684|NCT01873443|Experimental|Rituximab, MTX, folic acid|
3304685|NCT01873456|Experimental|Multifactorial nutritional intervention|dietician, resistance type exercise, dysphagia assessment and treatment
3304686|NCT01873456|No Intervention|usual care|usual care
3304687|NCT01873469||Radiochemotherapy|glioblastoma patients with indication to radiochemotherapy
3304688|NCT01873482|Experimental|Movement with rhythm|Subjects will move for 1 hour in time to the Congolese rhythm called Zebola.
3304689|NCT01873508|Experimental|Fast release MR capsule|
3304690|NCT01873508|Experimental|Slow release MR capsule|
3304691|NCT01873508|Experimental|Target release MR capsule|
3304692|NCT01873521|Active Comparator|NIV PS|The patients in this arms will received non invasive ventilation in PS mode.
3304693|NCT01873521|Active Comparator|NIV NAVA|The patients in this arm will received non invasive ventilation in NAVA mode.
3304694|NCT01873534|Experimental|FMX-8 (0.5 mg/kg)|0.5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3304695|NCT01873534|Experimental|FMX-8 (5 mg/kg)|5 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3304696|NCT01873534|Experimental|FMX-8 (15 mg/kg)|15 mg/kg FMX-8 IV twice per week for 29 days (9 doses)
3304697|NCT01873547|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
3304698|NCT01873547|Experimental|cell therapy|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
3304699|NCT01873547|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
3304700|NCT01873560||FFRpost|High FFRpost group and low FFRpost group were defined according to the optimal cut-off value for predicting clinical outcome.
3304701|NCT01873573|Active Comparator|EGD with Dilation|Standard of Care: Esophagogastroduodenoscopy (EGD) with dilation alone. If participants are assigned to Arm A and are not showing any clinical improvements as determined by their physician after the first three endoscopic dilation sessions, then they will be crossed over into Arm B.
3304702|NCT01873573|Active Comparator|EGD with Dilation, plus Triamcinolone|Standard of Care: EGD with dilation and Triamcinolone injection.
3304703|NCT01873599|Experimental|Intervention|Participants in the intervention condition will be asked to write for 15 minutes on three days each week to one of the seven positive affect writing prompts on www.stressvax.com. Subjects who do not complete a journal entry within 7 days will receive an email reminder, in case they have lost their password or have some technical problem accessing the site.
3304704|NCT01873599|No Intervention|Control|As there is no clinical standard of care treatment for psychological distress, patients randomized into this condition will receive their usual care. At the end of three months, subjects in this condition will be given access to the positive affect journaling intervention.
3304705|NCT01873612|Experimental|Sedation with dexmedetomidine|Sedation with dexmedetomidine
3304706|NCT01873612|Experimental|Sedation with propofol|Sedation with propofol
3304707|NCT01873625|Placebo Comparator|placebo|Normal salin injection in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
3304708|NCT01873625|Active Comparator|mesencymal stem cell|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
3304709|NCT01873638|Other|Minilaparotomy|Minilaparotomy cholecystectomy as a day surgery
3304710|NCT01873638|Other|Laparoscopy|Laparoscopic cholecystectomy as a day surgery
3304711|NCT01873651|Experimental|Delta III|Implantation of a Delta III Prosthesis
3304712|NCT01873664|Experimental|Jaw tapping|All subjects performed the jaw-tapping for 4 weeks at home.
3304713|NCT01873677|Placebo Comparator|Vehicle|Proper quantity twice a day
3304714|NCT01873677|Experimental|M518101|Proper quantity twice a day
3304715|NCT01873690|Placebo Comparator|Placebo|Placebo
3304716|NCT01873690|Active Comparator|Ciprofloxacin|Ciprofloxacin
3304717|NCT01873703|Experimental|pracinostat plus azacitadine|"60 mg of pracinostat by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
3304718|NCT01873703|Placebo Comparator|Placebo with Azacitadine|"Placebo by mouth 3 times a week for 3 weeks followed by 1 week of rest repeated every 28 days.~75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable"
3304719|NCT01873716|Experimental|Injection of Indocyanine Green|Injection of Indocyanine Green prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
3304720|NCT01873716|No Intervention|No injection|No injection prior to carotid endarterectomy surgery. Collection of specimen during surgery with subsequent carotid tissue analysis.
3304721|NCT01873755|Experimental|asthma physical activity intervention|two schools will receive intervention
3304722|NCT01873768|Active Comparator|Tranexamic acid (TXA)|1g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 50ml of saline will be infused over 30 minutes beginning at the time of wound closure.
3304723|NCT01873768|Active Comparator|ε-Aminocaproic Acid (EACA)|7g in 50ml of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 50ml saline will be infused over 30 minutes beginning at the time of wound closure.
3304724|NCT01873781||30 healthy male and female subjects|30 healthy male and female subjects aged 18-35
3304725|NCT01873794|Active Comparator|Bright white light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
3304726|NCT01873794|Active Comparator|Dim red light|using systematic light exposure (SLE), consisting of a daily 30-minute exposure to as much as 10,000 lux of light from a commercially available light box
3304727|NCT01873807|Experimental|IDA-Etoposide Intensified Conditioning|
3304728|NCT01873807|Active Comparator|Non-IDA Conditioning|
3304729|NCT01873820|Experimental|Calcium ascorbate -> ascorbic acid|
3304730|NCT01873820|Experimental|Ascorbic acid -> calcium ascorbate|
3304731|NCT01873833|Experimental|Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)|Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3304732|NCT01873872|Active Comparator|Theralac probiotic|
3304733|NCT01873872|Active Comparator|Culturelle probiotic|
3304734|NCT01873872|Placebo Comparator|Placebo|
3304735|NCT01873885|Experimental|Cohort 1: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 1 - Single 30 minute infusion Vasomera (PB1046) at 0.01 mg/kg diluted in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3304736|NCT01873885|Experimental|Cohort 2: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 2 - Single 30 minute infusion Vasomera (PB1046) at 0.005mg/kg in 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3304737|NCT01873885|Experimental|Cohort 3: Single IV Infusion Vasomera (PB1046) or Placebo|Cohort 3 - Single 30 minute infusion Vasomera (PB1046) at 0.02mg/kg 0.9% Sodium Chloride or Placebo (0.9% Sodium Chloride)
3304738|NCT01873898|Experimental|Single Arm|This is a single arm, prospective study to collect data on the safety and effectiveness of the Rex Medical Closer™ Vascular Closure System. Only subjects who are scheduled to undergo an interventional diagnostic procedure that requires closure of the femoral access site are eligible for study participation.
3304739|NCT01873924||Batten disease|Individuals with any form of Batten disease (Neuronal Ceroid Lipofuscinosis)
3304740|NCT01873937|Experimental|Red LED|Irradiation parameters: 630 nm, 60 sec and 18 J/cm² per point.
3304741|NCT01873937|Experimental|infrared LED|Irradiation parameters: 850 nm, 60 sec and 18J/cm² per point
3304742|NCT01873937|Active Comparator|LASER|Irradiation parameters: 780 nm, 60 sec and 105 J/cm²
3304743|NCT01873963||Pediatric cardiomyopathy|Diagnosis of primary or idiopathic dilated, hypertrophic or restrictive cardiomyopathy. Diagnosis must have been made before the age of 18 and must be confirmed by established echocardiographic criteria or cardiac MRI (cMRI) at the time of diagnosis.
3304744|NCT01873976||Incident DCM|A case of dilated cardiomyopathy that presents to the study site for the first time.
3304745|NCT01873976||Incident/Recent HCM|A new or existing diagnosis of idiopathic or familial hypertrophic cardiomyopathy, diagnosed within the past 2 months and with a cMRI within 2 months of diagnosis.
3304746|NCT01873976||Prevalent HCM or DCM|Any child with a diagnosis of dilated cardiomyopathy or idiopathic or familial hypertrophic cardiomyopathy who has survived transplant-free at least 24 months from the date of cardiomyopathy diagnosis.
3304747|NCT01874002||Combo stent|Consecutive patients in whom a treatment with a Combo stent in the setting of routine clinical care is attempted are entered into the registry.
3304748|NCT01874015|Active Comparator|mesenchymal cell and fibroblast transplantaion|The patients with crohn's disease who underwent mesenchymal cell and fibroblast injection.
3304749|NCT01874015|Active Comparator|mesenchymal cell transplantaion|The patients with Crohn's disease who underwent mesenchymal cell transplantation.
3304750|NCT01874028|Experimental|Trientine dihydrochloride|
3304751|NCT01874041|Experimental|Massage group|The massage group was submitted to three weekly 30-minute sessions of massage of the muscles of mastication over four consecutive weeks.
3304752|NCT01874041|Experimental|The occlusal splint group|The occlusal splint group was submitted to treatment with an occlusal splint for four weeks.
3304753|NCT01874041|No Intervention|Control group|The control group was not submitted to any form of intervention and was evaluated on two occasions, with a four-week interval between evaluations.
3304754|NCT01874067||Arthritis glove|Early inflammatory, rheumatoid or hand osteoarthritis with hand/wrist swelling and pain
3304755|NCT01874080|Experimental|Arm A: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg /Metformin 1000 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day 1 of Periods 1 and 2
3304756|NCT01874080|Experimental|Arm B: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 1000 mg (Mt. Vernon) tablet by mouth once daily on Day 1 of Periods 1 and 2
3304757|NCT01874080|Experimental|Arm C: Saxagliptin/Metformin XR FDC (Mt. Vernon/Humacao)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon/Humacao) tablet by mouth once daily on Day1 of Periods 1 and 2
3304758|NCT01874080|Experimental|Arm D: Saxagliptin/Metformin XR FDC (Mt. Vernon)|Saxagliptin 5 mg/Metformin 500 mg (Mt. Vernon) tablet by mouth once daily Day 1 of Periods 1 and 2
3304759|NCT01874093|Experimental|Active Stimulation|INS implantation, 5 Days of Ischemic Stroke System (ISS) Stimulation + Standard of Care
3304760|NCT01874093|Sham Comparator|Sham Stimulation|Sham implantation, 5 Days of Sham Stimulation + Standard of Care
3304761|NCT01874106|Experimental|Diet therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
3304762|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
3304763|NCT01874158||TV postive women|All women who are TV positive by wet prep or in-pouch and meet the inclusion exclusion requirements.
3304764|NCT01874171|Active Comparator|Cisplatin|Three doses of cisplatin 100mg/m2 given at days 1, 22 and 43 from start of radiotherapy.
3304765|NCT01874171|Experimental|Cetuximab|Initial dose of 400mg/m2 one week before start of radiotherapy followed by seven weekly doses of 250 mg/m2 during radiotherapy.
3304766|NCT01874184|Experimental|Arm I (DEEM intervention)|Participants take part in weekly 2-hour group counseling sessions for 6 months with taper beginning at 3 months. Group sessions include education, group process, and experiential learning on the benefits of physical activity, balanced nutrition, and mindfulness techniques. Participants set goals for changing their dietary habits with the help of a mental health counselor and are also encouraged to exercise 3-4 times per week, including experiential group activities such as brisk walking, yoga, Zumba, and group fitness.
3304767|NCT01874184|No Intervention|Arm II (usual care)|Participants receive their usual care and are provided with study materials on healthy diet and exercise at the end of the study.
3304768|NCT01874197|Other|B -TEVAR|Implantation of the B-TEVAR device
3304769|NCT01874210||Hemodialysis|Hemodialysis patients
3304770|NCT01874210||Control|"Household contacts on the same diet~Healthy unrelated controls"
3304771|NCT01874223||IPF-diagnosed patients|A group of up to 40 patients with a diagnosis of mild to severe IPF per American Thoracic Society (ATS) guidelines, either with no cough at baseline to severe cough at baseline, will be followed for at least a one-time assessment and every six months for up to 18 months to establish validity, responsiveness, and reliability of cough, dyspnea, and QOL instruments in patients with IPF.
3304772|NCT01874236|Active Comparator|1st sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3304773|NCT01874236|Active Comparator|2nd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3304774|NCT01874236|Active Comparator|3rd sequence|Blinded 3 blocks (2 bupivacaine, 1 sham block)
3304775|NCT01874249|Experimental|Electronic detailed information|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease.
3304776|NCT01874249|Experimental|NAFLD Score|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score.
3304777|NCT01874249|Experimental|NAFLD Score plus Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by NAFLD score and transient elastography.
3304778|NCT01874249|Experimental|Transient elastography|Standard of care for patients with diagnosis of fatty liver by ultrasound, plus electronic detailed information about non alcoholic fatty liver disease, plus diagnosis of advanced fibrosis by transient elastography.
3304779|NCT01874249|No Intervention|Standard of care|Standard of care for patients with diagnosis of fatty liver by ultrasound.
3304780|NCT01874301|Experimental|High quantity probiotic food product|
3304781|NCT01874301|Experimental|Low quantity probiotic food product|
3304782|NCT01874301|Placebo Comparator|Placebo|
3304783|NCT01874314|Experimental|SQ109 450 mg|Single daily dose of oral 450mg SQ109 for 7 days.
3304784|NCT01874314|Active Comparator|Moxifloxacin|Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
3304785|NCT01874314|Placebo Comparator|SQ109 Placebo|Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
3304786|NCT01874314|Experimental|SQ109 300 mg|Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
3304787|NCT01874327|Active Comparator|Baby JASPER|This classroom will spend the majority of the time focusing on social-communication goals
3304788|NCT01874327|Active Comparator|Standard Baby Classroom|This classroom will focus more heavily on developing motor and cognitive skills
3304789|NCT01874366|Experimental|P11187|"Part I: Step wise dose escalation in subsequent cohorts and will be based upon the review of safety and tolerability results of the preceding cohort~Part II: Step wise dose escalation in the multiple dosing for 14 consecutive days after review of the safety and tolerability of the preceding cohorts~Part III: Study drug will be administered under the fasted or fed conditions in two different periods separated by a wash-out interval of 7-10 days"
3304790|NCT01874366|Placebo Comparator|Placebo|Placebo capsules will be matching in appearance with the active drug capsules of P11187.
3304791|NCT01874379|Experimental|Guided Imagery|The therapist will instruct the patient on the Guided Imagery protocol and will provide the patient with headphones and an MP-3 player to use for the guided imagery intervention. The patient will listen to the Guided Imagery for 18min 30 sec.
3304792|NCT01874379|Active Comparator|Standard of Care|This group will serve as the control arm
3304793|NCT01874379|Experimental|'M'-Technique®|The 'M'-Technique will be administered to the patient's hands and feet for a total of 18-20 minutes, to be equally divided between extremities used according to limitations as outlined. Any hand or foot that is accessed by an IV will be avoided.
3304794|NCT01874418|Other|Biomarker study|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
3304795|NCT01874444|Experimental|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex .
3304796|NCT01874444|Experimental|Active rTMS2|Temporal low frequency rTMS of left primary auditory cortex.
3304797|NCT01874444|Experimental|Active rTMS3|Frontal low frequency rTMS of left dorsolateral prefrontal cortex .
3304798|NCT01874444|Sham Comparator|Sham rTMS4|sham treatment Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
3304799|NCT01874470|Placebo Comparator|standard medication|Standard Medication: Continued usage of 3 or more antihypertensive medications of different classes, including a diuretic
3304800|NCT01874470|Experimental|renal denervation|Allegro Renal Denervation System (AngioCare)
3304801|NCT01874483|Experimental|BI 187004 dose 1|multiple dose given over 14 days
3304802|NCT01874483|Experimental|BI 187004 dose 2|multiple dose given over 14 days
3304803|NCT01874483|Experimental|BI 187004 dose 3|multiple dose given over 14 days
3304804|NCT01874483|Experimental|BI 187004 dose 4|multiple dose given over 14 days
3304805|NCT01874483|Experimental|BI 187004 dose 5|multiple dose given over 14 days
3304806|NCT01874483|Experimental|BI 187004 dose 6|multiple dose given over 14 days
3304807|NCT01874483|Placebo Comparator|Placebo|placebo
3304808|NCT01874483|Experimental|BI 187004 dose 7|multiple dose given over 14 days
3304809|NCT01874496|Experimental|GDS, meal|GDS, meal
3304810|NCT01874496|Experimental|GDS, no meal|GDS, no meal
3304811|NCT01874496|Active Comparator|control, no meal|control, no meal
3304812|NCT01874496|Active Comparator|control, meal|control, meal
3304813|NCT01874509|Active Comparator|Check Your Drinking screener|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
3304814|NCT01874509|Experimental|Alcohol Help Centre|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
3304815|NCT01874522|Experimental|TAS-102 tablets|
3304816|NCT01874522|Experimental|TAS-102 oral solution|
3304817|NCT01874548||Normal cervix|Control group (n=30) comprising surgical candidates with normal cervical tissue will be collected for comparison.
3304818|NCT01874548||Cervical cancer|"1st year: 30 surgical candidates with cervical cancer tissue collected during operation.~2nd year: Enroll another 30 surgical candidates and complete the data regarding clinical MRS/DWI and tissue high resolution MRS. Together with the 30 cancer subjects in part one there will be in total 60 cancer subjects for analysis.~3rd year: enroll 60 patients primarily treated with CCRT and collect the data using clinical MR and tissue high resolution MRS."
3304819|NCT01874561|Experimental|Group 1|"Group 1: investigational product (custirsen) will receive:~320 mg of custirsen + 5 mg of dexamethasone on day 1~480 mg of custirsen + 5 mg of dexamethasone on day 3~640 mg of custirsen + 3 mg of dexamethasone on day 5~640 mg of custirsen on day 7 under fasting conditions"
3304820|NCT01874561|Placebo Comparator|Group 2|"Group 2: placebo (normal saline) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~placebo on day 7 under fasting conditions"
3304821|NCT01874561|Active Comparator|Group 3|"Group 3: positive control (moxifloxacin) will receive:~placebo + 5 mg of dexamethasone on day 1~placebo + 5 mg of dexamethasone on day 3~placebo + 3 mg of dexamethasone on day 5~400 mg of moxifloxacin + placebo (immediately after moxifloxacin administration) on day 7 under fasting conditions"
3304822|NCT01874574|Experimental|Single shot Hylan G-F 20 (Synvisc)|Intra-articular injection of the Single shot 6 mL of Hylan G-F 20 (Synvisc)
3304823|NCT01874574|Active Comparator|Corticosteroid (Triamcinolone acetonide)|Intra-articular injection of 1 mL of 40 mg Triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline injected at the knee by single shot
3304824|NCT01874587|No Intervention|standard radiotherapy|single pre-treatment planning before radiotherapy
3304825|NCT01874587|Experimental|adaptative radiotherapy|adaptive Radiotherapy based on a weekly replanning
3304826|NCT01874600||Epilepsy Patients|This study will compare accuracy of seizure detection by the study device to simultaneously collected data of seizure detection by video EEG.
3304827|NCT01874613|Experimental|Skull bone reconstruction|Patients with skull bone defect
3304828|NCT01874613|Experimental|Orbital floor defect|Patients with orbital floor defect
3304829|NCT01874626|Active Comparator|Active|SST-0225 Topical Ibuprofen Cream (investigational product) Dose: 2.7 grams of cream containing 200 mg ibuprofen
3304830|NCT01874626|Placebo Comparator|Placebo|Placebo topical formulation (Reference product)
3304831|NCT01874639|Experimental|hepatectomy ( conventional hemostasis )|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Control group: hepatectomy with conventional hemostasis using standard bipolar coagulation"
3304832|NCT01874639|Other|hepatectomy with Aquamantys|"After validation of the inclusion and exclusion criteria, the patients include in this clinical trial will be randomized between the two arms of the study:~- Test group: hepatectomy with Aquamantys®"
3304833|NCT01874652|Experimental|Light Weight Breast Implants|Assessment of Safety and Efficacy of Light Weight Breast Implant
3304834|NCT01874678|Experimental|TS-1/Cisplatin|single arm
3304835|NCT01874691||acute myocardial infarction|acute myocardial infarction including ST-elevation and non ST-elevation myocardial infarction
3304836|NCT01874704|Other|biomarkers of stress|Comparison of biomarkers of stress in emergency physicians working a 24-hour shift or a 14-hour night shift
3304837|NCT01874717|Experimental|oral midazolam|oral administration of midazolam : the dose administered is twice the individual dose determined in session 1.
3304838|NCT01874717|Other|intravenous midazolam|intravenous administration of midazolam at the individual dose determined in session 1
3304839|NCT01874730|Other|Standard of Care (SOC)|Intraoperative fluid management includes Volulyte® (6% hydroxyethyl starch {HES} 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg. Intraoperative anesthesia and postoperative analgesia will follow the established practice of the individual institution.
3304840|NCT01874730|Active Comparator|Enhanced Recovery Strategy (ERS) group|GDFT regimen using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg. Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
3304841|NCT01874743|Experimental|Rosuvastatine 20 mg|Rosuvastatin 20 mg/day, once a day during 3 months
3304842|NCT01874769||Blood collection and skin biopsies|
3304843|NCT01874782|Experimental|Transcranial electrical stimulation|Subject will be determined as autonomically complete or incomplete injury with measuring of the sympathetic skin responses (SSR+), an established protocol for measuring integrity of sympathetic spinal pathways, versus complete autonomic injury (SSR-).
3304844|NCT01874795|Experimental|Ganglionar Electrical Stimulation|TENS intervention consisted of continuous flow, symmetrical and rectangular TENS biphasic pulses. The frequency ofstimulation was 80 Hz and the pulse duration was 150 μs, with the intensity in adjusted to the point of muscle contraction.
3304845|NCT01874795|Sham Comparator|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
3304846|NCT01874808||Healthy|Healthy
3304847|NCT01874808||ALS with postural instability|ALS with postural instability
3304848|NCT01874808||ALS without postural instability|ALS without postural instability
3304849|NCT01874821|Experimental|Dynasplint|Along with standard manual physical therapy, patients will have a stretching device (Dynasplint) used in rehabilitation to regain ROM in stiff joints. Patients will use this device 20-30 minutes 2 times per day at home.
3304850|NCT01874821|Other|Control|Patient's in the Physical Therapy Group will have the standard manual treatments during their usual physical therapy visits with no additional intervention
3304851|NCT01874834|Placebo Comparator|Filtered air exposure|2 hr exposure to clean, filtered air with intermittent exercise
3304852|NCT01874834|Experimental|Ozone|2 hr exposure to 300 ppb ozone with intermittent exercise
3304853|NCT01874834|Experimental|Diesel Exhaust, No ozone|2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
3304854|NCT01874834|Experimental|Ozone + Diesel Exhaust|2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
3304855|NCT01874847|Experimental|Melatonin 10mg|Melatonin 10mg capsule(high dose arm), oral, once at night, given for 28 days
3304856|NCT01874847|Placebo Comparator|Sugar Pill|Sugar Pill, one capsule, once at night, 28 days
3304857|NCT01874847|Experimental|Melatonin 3mg|Melatonin 3mg capsule (low dose arm), once, at night, 28 days
3304858|NCT01874860|Experimental|Extensive treatment group|"Doxycycline capsule, 100 mg, taken twice daily; sunscreen SPF 30 or higher applied to exposed skin areas at least 30 minutes before going outdoors each morning; moisturizer applied to the face, hands, feet, neck, back, and chest each morning after sunscreen; Hydrocortisone 1% topical cream applied to the face, hands, feet, neck, back, and chest each evening.~For patients with grade 1 rash, hydrocortisone 1% cream and clindamycin 1% gel (tetracycline antibiotic) are recommended for daily use.~For patients with grade 2 rash, hydrocortisone cream and doxycycline 100mg twice daily or minocycline (tetracycline antibiotic) 100mg once daily is recommended.~For patients with grade 3 rash, systemic steroid therapy (a Medrol dose-pack) will be added to the grade 2 treatment."
3304859|NCT01874860|Experimental|Standard care group|Patient will not receive preventive treatment but will be allowed to use sunscreen and moisturizer if desired.
3304860|NCT01874873|Experimental|Anlotinib|
3304861|NCT01874886||Cannabis users|⋄Heavy Marijuana Users : 60-80 years old; Marijuana use initiated in adolescence with marijuana use of no more than 1-2 x/month after 30 years of age; Used marijuana more than 20 times/month for at least 1 year during this period. Cigarette smoking (tobacco) and alcohol will be allowed in both groups, which will be matched on number of smokers and nicotine dependence, measured according to the Fagerstrőm Test for Nicotine Dependence. Light alcohol use will also be allowed in and matched across both groups (< 14 drinks/week for men; < 7 drinks/week for women; may not meet DSM-IV criteria for alcohol dependence).
3304862|NCT01874886||Clean or Non-Users|⋄No marijuana use, may smoke cigarettes, fewer than 7 drinks/week (women) or 14 drinks/week (men). 60-80 years old.
3304863|NCT01874899||Manual, then Automatic Stimulation|The RestoreSensor neurostimulator will be programed for manual stimulation adjustments and the patients will crossover to automatic stimulation group after 1.5 months
3304864|NCT01874899||Automatic, then Manual Stimulation|The RestoreSensor neurostimulator will be programed for automatic stimulation adjustments and the patients will crossover to manual stimulation group after 1.5 months.
3304865|NCT01874938|Experimental|LY2875358|LY2875358 will be administered intravenously (IV) at 2000 milligram (mg) bi-weekly in 28 day Cycle.
3304866|NCT01874964|Experimental|Methadone Maintenance|Participants assigned to Arm 1 will be maintained on ther pre-incarceration methadone dosage during short term incarceration (6 months or less) and will be actively transferred back to their community methadone clinic upon release from incarceration. Additionally, the study will pay for the cost of methadone maintenance treatment for 10 weeks after re-enrollment post release.
3304867|NCT01874964|Active Comparator|Methadone Detoxification|Individuals assigned to Arm 2 will undergo methadone detoxification as is standard procedure at the Rhode Island Department of Corrections. They will receive active assistance with returning to their home methadone clinic upon release from incarceration and 10 weeks financial assistance to pay for treatment.
3304868|NCT01874977|Experimental|Pedometer only|This group will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer. Participants will be shown how to wear the pedometer, and instructed to wear it from the time they get out of bed in the morning until they go to bed at night, except while showering or bathing. (If any subjects begin a swimming- or cycling-based activity program, we will ask them to remove the pedometer at that time but track the time they are in the water. Step counts will be adjusted to account for this time by adding 150 steps for every minute engaged in swimming and/or cycling.)
3304869|NCT01874977|Experimental|Pedometer + step count goals|Pedometer + step goals. This group will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
3304870|NCT01874977|Other|Education materials|"Educational materials. This group will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment. They will receive follow-up contact at the same time points as the intervention groups, although the Week 0 and Week 1 contacts will be by phone instead of in-person and the content of contacts will be different."
3304871|NCT01874990|Experimental|women with a history of severe preeclampsia|women with a history of severe preeclampsia(< 34 weeks gestation) between 5 and 10 years ago
3304872|NCT01874990|Experimental|control|women with no history of pregnancy-related hypertensive complications
3304873|NCT01875003|Experimental|Lebrikizumab High|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms [mcg] of fluticasone propionate dry powder inhaler [DPI] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
3304874|NCT01875003|Experimental|Lebrikizumab Low|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.
3304875|NCT01875003|Placebo Comparator|Placebo|Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.
3304876|NCT01875029|Sham Comparator|sham-tDCS + Back School|"This group will receive sham-tDCS for 5 days before back school beginning. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.~The back school session, a behavioural intervention,will be given 10 times for 4 weeks."
3304877|NCT01875029|Experimental|real-tDCS + Back School|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days before back school beginning. The back school session, a behavioural intervention,will be given 10 times for 4 weeks.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
3304878|NCT01875042|Experimental|TENS|Transcutaneous Electrical Nerve Stimulation
3304879|NCT01875042|Sham Comparator|Sham TENS|Sham Transcutaneous Electrical Nerve Stimulation
3304880|NCT01875055|Experimental|NIRS derived cerebral oximetry|NIRS derived cerebral oximetry device used but data not visable to ICU caregivers
3304881|NCT01875055|Active Comparator|NIRS and Algorithm|NIRS derived cerebral oximetry device used and the caregiver in the ICU will see the data in order to guide the use of the interventional algorithm to treat the cerebral desaturation
3304882|NCT01875068|Experimental|NPs & PAs referral discussions with a supervising physician|required consultations between NPs and PAs and their supervising physicians
3304883|NCT01875068|Other|NPs and PAs - no consultations with supervising physisians|NPs and PAs who are not required to discuss patient referrals
3304884|NCT01875081|No Intervention|Control group|Best Supportive care
3304885|NCT01875081|Experimental|1-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery.
3304886|NCT01875081|Experimental|2-time injection group: Livercellgram|Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells.
3304887|NCT01875094|Experimental|Self-Management / MTM via Health IT|Stroke survivors are trained to measure and enter BP into an online health management tool
3304888|NCT01875094|No Intervention|Usual Care|
3304889|NCT01875107|Experimental|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
3304890|NCT01875120||Female patients with increased risk to experience PONV.|
3304891|NCT01875133|Other|A: low-intermediate-high altitude|Altitude exposure sequence A, 490-1630-2590m
3304892|NCT01875133|Other|B: low-high-intermediate altitude|Altitude exposure sequence B, 490-2590-1630 m
3304893|NCT01875133|Other|C: intermediate-high-low altitude|Altitude exposure sequence C, 1630-2590-490 m
3304894|NCT01875133|Other|D: high-intermediate-low altitude|Altitude exposure sequence D, 2590-1630-490 m
3304895|NCT01875146|Active Comparator|4x4 min HIT|Conventional 4x4 min high-intensity interval training
3304896|NCT01875146|Experimental|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
3304897|NCT01875146|Experimental|4x4 min HIT + WBV (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
3304898|NCT01875146|Active Comparator|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
3304899|NCT01875172|Experimental|Bupropion SR|Study medication (150 mg bupropion SR) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day (150 mg bid). Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
3304900|NCT01875172|Placebo Comparator|Placebo|Study medication (placebo) daily for 14 days. Women still smoking at 2-weeks & 4-weeks were encouraged to increase their medication to two times per day. Women received smoking cessation counseling at baseline, 2, 4, 6, and 8 weeks.
3304901|NCT01875185|Experimental|Aspirin|The patients are given aspirin 81 mg orally for 7 days.
3304902|NCT01875198|Experimental|RAMPS|Radical Antegrade Modular Pancreatectomy with Splenectomy
3304903|NCT01875198|Active Comparator|RAMP|Radical Antegrade Modular Pancreatectomy without splenectomy
3304904|NCT01875224|Experimental|Belatacept and CellCept|Belatacept administered based on patient's weight once a month after initial period, Cellcept taken twice daily.
3304905|NCT01875224|Active Comparator|Tacrolimus and CellCept|Tacrolimus and CellCept taken twice daily based on patient response.
3304906|NCT01875263|Experimental|Experimental|Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.
3304907|NCT01875263|Active Comparator|Control|Cloxacillin 2g / 4 hrs iv 14 days
3304908|NCT01875276||Persistent Patients|Defined as those with ≥1 treatment for allergic rhinitis in the six months preceding the IPD (defined as the first script of the hay fever season - May to August)
3304909|NCT01875276||Seasonal Rhinitis|No treatment for allergic rhinitis in the six months preceding the IPD
3304910|NCT01875289|Experimental|Ropivacain|Local anaesthesia
3304911|NCT01875289|Placebo Comparator|NaCl 0.9%|Saline
3304912|NCT01875328|Experimental|Telemedicine|Telemedicine group
3304913|NCT01875328|Active Comparator|Clinic|Clinic group
3304914|NCT01875341|Active Comparator|Active treatment with NCPAP|This group will receive treatment with NCPAP, Nasal Continuous Positive Airway Pressure for 6 weeks. Nasal Continuous Positive Airway Pressures will be increased until apneas & hypopneas are prevented during all sleep stages.
3304915|NCT01875341|Sham Comparator|Sub- active treatment with NCPAP|This group will receive treatment with Nasal Continuous Positive Airway Pressure at sub-therapeutic levels for 6 weeks. Patients will be taught how to use NCPAP in the sleep lab. Pressures will be left unchanged at the lowest possible value for the NCPAP device. After completion of treatment patients will be provided usual NCPAP therapy.
3304916|NCT01875354|Placebo Comparator|Placebo and Low Fat Eating Plan|"Placebo Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Placebo Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Placebo Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~The placebo group will be instructed to consume every day, a low fat standard of care eating plan delivering approximately 1200-1500 Kcals."
3304917|NCT01875354|Experimental|Dietary Supplements and TR90 Eating Plan|"Supplement A Powder Mix Days 1 - 15, (1 packet mixed in water or favorite beverage once a day) Supplement B Days 1 - 90, (1 capsule taken three times a day with a meal) Supplement C Days 1 - 90, (2 capsules taken with morning and evening meal)~Experimental group will be instructed to consume every day, dietary supplements and a moderate protein eating plan delivering approximately 1200-1500 Kcals."
3304918|NCT01875380|Experimental|Regorafenib|Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen.
3304919|NCT01875393|Experimental|TOOKAD® Soluble|TOOKAD® Soluble, lyophilized formulation,given at a dose of 4 mg/kg.
3380855|NCT04341623|Other|Control Group|All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis
3380856|NCT04341623|Other|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence.
3380857|NCT04341623|Other|GPSkin group|The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily.
3304920|NCT01875406|Experimental|diagnostic exercises|The three diagnostic exercises will be administered in random order to minimize effects of order and period on the results. Enrollment logs and study randomization will be administered electronically via a respective REDCap data modules. The enrollment, randomization and diagnostic tests will be administered by research coordinator or PI. The patients will be independently evaluated and scheduled for SIJ injection by Cleveland Clinic pain clinic staff and fellow pain physicians.
3304921|NCT01875419|Experimental|Patients tDCS|A group of 30 patients will receive active tDCS stimulation once a week for 8 weeks, immediately prior to CBT.
3304922|NCT01875419|Sham Comparator|Patients - Sham|Another group of 30 patients will receive sham stimulation once a week during 8 weeks, immediately prior to CBT.
3380859|NCT04339738|Experimental|Arm I (nivolumab, paclitaxel)|Patients receive nivolumab IV over 30 minutes on day 1 and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3304923|NCT01875458||CASES|Adults with current or past history of bisphosphonate treatment (exposed) with Bisphosphonate related Osteonecrosis of the Jaws (BRONJ), or, Adults with current or past history of bisphosphonate treatment (exposed) with atypical fracture
3304924|NCT01875458||COUNTER MATCHED CONTROLS|Adults with current or past history of bisphosphonate treatment (exposed) without bisphosphonate related osteonecrosis of the jaws (BRONJ, or, Adults with current or past history of bisphosphonate treatment (exposed) with typical fracture or joint replacement or osteoporosis
3304925|NCT01875458||MATCHED CONTROLS|Adults without current bisphosphonate treatment (unexposed) with Typical fracture (healthy fracture patients) Adults without current bisphosphonate treatment (unexposed) without BRONJ (healthy oral surgery subjects or adults with radionecrosis of the jaws)
3380860|NCT04339738|Experimental|Arm II (paclitaxel)|Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3380861|NCT04339738|Experimental|Arm III (nivolumab, cabozantinib S-malate)|Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3380862|NCT04338269|Experimental|Atezo+Cabo|Participants will receive atezolizumab every 3 weeks on Day 1 of each 21-day cycle (1 cycle=21 days) plus oral tablets of cabozantinib every day.
3380863|NCT04338269|Active Comparator|Cabozantinib|Participants will receive cabozantinib every day.
3380864|NCT04336826|Experimental|Ataluren|Participants will receive ataluren oral suspension 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening each day for 24 weeks.
3380868|NCT04321330|Experimental|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
3380873|NCT04311411|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC).
3380874|NCT04311411|Placebo Comparator|Placebo|Placebo administered SC.
3380875|NCT04311411|Active Comparator|Liraglutide|Liraglutide administered SC.
3380876|NCT04310735|Experimental|Experimental: Expect-Yes|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will perceive an opportunity to smoke during the experimental session.
3380877|NCT04310735|Experimental|Experimental: Expect-No|Participants assigned to this condition will undergo a verbal smoking expectancy manipulation such that they will not perceive an opportunity to smoke during the experimental session.
3304926|NCT01875458||Healthy Adult Volunteers|Healthy volunteers with or without current bisphosphonate treatment without jaw or extremity pathologies or injuries to contribute blood and saliva samples only.
3304927|NCT01875484||High miR-126 group|
3304928|NCT01875484||Moderate miR-126 group|
3304929|NCT01875484||Low miR-126 group|
3304930|NCT01875497|Experimental|Dietary Supplement|Before the exercise, the individuals intake only one capsule with 205 mg of the grape fruit extract in capsule with 205 mg.
3304931|NCT01875523|Experimental|Group 1 Treatment with serelaxin|Patients with severe renal impairment will receive a single 4 hour i.v. infusion of serelaxin
3304932|NCT01875523|Experimental|Group 2 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
3304933|NCT01875523|Experimental|Group 3 Treatment with serelaxin|Patients with end stage renal disease will receive a single 4 hour i.v. infusion of serelaxin and treatment and PK will be done in dialysis-free interval
3304934|NCT01875523|Experimental|Group 4 Treatment with serelaxin|Healthy volunteers will receive a single 4 hour i.v. infusion of serelaxin and dialysis will be done on the day of treatment
3304935|NCT01875536|Experimental|rTMS|The experimental group received rTMS to the primary motor cortex of the unaffected side in 10 sessions, 3 days per week, and conventional physical therapy
3304936|NCT01875536|Sham Comparator|control|The control group received sham stimulation (same area as the experimental group) in 10 sessions, 3 days per week, and conventional physical therapy
3304937|NCT01875549|Active Comparator|Unilateral stent insertion group|the use of unilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
3304938|NCT01875549|Active Comparator|Bilateral stent insertion group|the use of bilateral stent insertion in malignant hilar obstruction for using endoscopic retrograde cholangiopancreatography(ERCP)
3304939|NCT01875562|Experimental|Qishe Pill|
3304940|NCT01875575|Active Comparator|Glucose 10g|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
3304941|NCT01875575|Active Comparator|Glucose 25g|25g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)via nasogastric tube
3304942|NCT01875575|Placebo Comparator|Placebo|intragastric tap water
3304946|NCT01875601|Experimental|A|NK cell infusion (dose escalation)
3304947|NCT01875601|Experimental|B|NK cell infusion + escalating doses of rhIL15
3304948|NCT01875627|Placebo Comparator|Carbohydrate Noodles|0g Konjac Noodles
3304949|NCT01875627|Experimental|Carbohydrate and Konjac Noodles|Half Carbohydrate and Half Non-Caloric Konjac Noodles - 122.5g Konjac
3304950|NCT01875627|Experimental|Konjac Noodles|Non-Caloric Konjac Noodles (viscous gel meal) - 240g Konjac
3304951|NCT01875640||Usual Care|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will not utilize the Decision Support Tool. A qualitative analysis of these recordings will assess quality assurance and provide guidance for the development of the Decision Support Tool.
3304952|NCT01875640||Use of Decision Support Tool|After obtaining consent, we will audio-record standard clinical consultations with specialists represented on the DSD team. These appointments will utilize the Decision Support Tool (DST). A qualitative analysis of these recordings will assess the practicality of use and possible benefits of the DST's implementation.
3304953|NCT01875653|Active Comparator|Autologous PBMCs in GM-CSF (MC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of MC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of MC contains approximately 10 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
3304954|NCT01875653|Experimental|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|"DOSE/ROUTE/REGIMEN:~Treatment Duration: Doses of DC-TC will be administered subcutaneously weekly for 3 consecutive weeks, then monthly for the next 5 months.~Dosage: Each dose of DC-TC contains approximately 10-20 million cells. Each dose is suspended in 500 mcg GM-CSF prior to administration.~Mode of Administration: Subcutaneous (SC) injections."
3304955|NCT01875666|Active Comparator|Trastuzumab|single dose intravenous infusion administration of trastuzumab (8 mg/kg)
3304956|NCT01875666|Active Comparator|pertuzumab|single dose infusion of pertuzumab (840 mg)
3304957|NCT01875666|Active Comparator|trastuzumab plus pertuzumab|single dose infusion of combination trastuzumab (8 mg/kg) plus pertuzumab (840 mg)
3304958|NCT01875666|Active Comparator|trastuzumab plus lapatinib|combination of single dose infusion of trastuzumab (8 mg/kg) plus oral lapatinib (1000 mg daily for 7 days)
3304959|NCT01875679|Active Comparator|Conventional residency training|This group will continue their regular surgical training without any specific intervention.
3304960|NCT01875679|Experimental|Comprehensive Surgical Coaching (SCS)|The participants will receive an analysis of the technical performance as observed on baseline recordings of the index procedure. Training needs will be identified and a personalized coaching concept will be designed. Coaching sessions will include video debriefing of the participant's performance (sample recordings will be submitted by the participant during the sessions) and video assisted behavioral modeling using examples of good and poor technical performance. Coaching will also target increasing awareness of weaknesses and potential pitfalls in surgical technical task execution (error recognition).
3304961|NCT01875705|Experimental|Stage I-Dose Escalation|
3304962|NCT01875705|Experimental|Stage II-Cohort-Expansion|
3304963|NCT01875718|Active Comparator|UC1010 low dose|
3304964|NCT01875718|Active Comparator|UC1010 high dose|
3304965|NCT01875718|Placebo Comparator|Vehicle|
3304966|NCT01875744|Experimental|Polyethylene glycol small dose|Polyethylene glycol 4000: 0.3 g/kg/day for 6 weeks
3304967|NCT01875744|Active Comparator|Polyethylene glycol high dose|Polyethylene glycol 4000: 0.7g/kg for 6 weeks
3304968|NCT01875757|Experimental|Vitamin D3 1000 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 1.000 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
3304969|NCT01875757|Active Comparator|Vitamin D3 400 IU/day|Infants will be supplemented with vitamin D and/or placebo to receive a total amount of vitamin D3 of 400 IU/day during the first year of life, taking into account the vitamin D received with artificial milk
3304970|NCT01875770||Treated with Ranibizumab in previous trial|Treated with Ranibizumab in previous trial
3304971|NCT01875796|Experimental|Cannabis & Anxiety Reduction Treatment|Cognitive-behavioral treatment program that integrates strategies to manage both cannabis use and anxiety with techniques to address motivation to change cannabis use.
3304972|NCT01875796|Active Comparator|Motivation/cognitive-behavioral therapy|Motivational Enhancement Therapy (MET) and cognitive-behavioral therapy (CBT) that includes techniques to address motivation to change cannabis use with strategies to manage use.
3304973|NCT01875809||Renal denervation (RDN)|Change of catecholamine spill-over during RDN
3304974|NCT01875809||Electrophysiology (EP) Ablation|Change of catecholamine spill-over during EP ablation
3304975|NCT01875822|Experimental|Supercurcumin|The study protocol stipulates that subjects diagnosed as DSM IV-TR (Diagnostic Statistical Manual IV-Transitional Revised) would be receiving either 1 gm Super-Curcumin@ capsule once daily or 4 gm Super-Curcumin@ once daily for a total of 16 weeks. Super-Curcumin@ in capsule form is a patented formulation of curcumin certified by Sabinsa Corp.NJ USA and produced by America's Finest Inc. 1 gm-capsule Super-Curcumin@ consist of 1 gm Curcumin C-3 complex and 5 mg of Bioperine.
3304976|NCT01875835|Active Comparator|DES|Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
3304977|NCT01875835|Active Comparator|BMS|Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
3304978|NCT01875887||treat bilateral maxillofacial deformties|treatment of bilateral maxillofacial post-traumatic deformities
3304979|NCT01875900|Active Comparator|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) digital video disc (DVD) will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
3304980|NCT01875900|Experimental|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
3304981|NCT01875913|Experimental|Standard Message|Participants will receive email messages that encourage them to complete their VHR.
3304982|NCT01875913|Experimental|Curiosity Message|"Participants receive email messages containing curiosity-inducing questions. The messages tell the participants that they will receive the answer to the question after they complete their VHR."
3304983|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Single Dose (SD)|
3304984|NCT01875926|Experimental|ALX-0171 Oral Inhalation - Multiple Dose (MD)|
3304985|NCT01875926|Experimental|ALX-0171 Intravenous (IV)|
3304986|NCT01875939|Other|Oral WCK 2349 fed/fasting|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
3304987|NCT01875939|Other|IV WCK771|This is a single center, randomized, open label, 2X2 oral IV cross over, food-effect and absolute bioavailability study. The study will be conducted in three parts i.e., Period 1 and Period 2 (foodeffect study) and Period 3 (absolute bioavailability study).
3304988|NCT01875952|Other|one arm|All patients with response to positive purified protein derivative (PPD) test are treated
3304989|NCT01876004|Experimental|Methotrexate|Administered a single intramuscular dose of 50 mg/m2 of Methotrexate.
3304990|NCT01876004|Placebo Comparator|Placebo|Prescribed Placebo intramuscularly.
3304991|NCT01876017|Other|BMMNC|Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
3304992|NCT01876030|Experimental|FES|All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
3304993|NCT01876030|No Intervention|Conventional|Treated with regular gait re-education with or without AFO fitting. All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the AFO will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
3304994|NCT01876056|Experimental|Brief CaCBTp|The experimental group will receive brief for of Culturally adapted CBT for psychossis
3304995|NCT01876056|No Intervention|Treatment As Usual|Treatment as usual means seeing a mental health professional and taking the prescribed anti psychotics and being cared by family members
3304996|NCT01876069|Active Comparator|22 gauge ProCore needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge ProCore needle
3304997|NCT01876069|Active Comparator|22 gauge Fine needle aspiration|EUS-guided pancreatic mass aspiration with 22 gauge Fine needle
3304998|NCT01876095|Experimental|Multidisciplinary medication review|"The multidisciplinary medication review consists of 5 steps:~Step #1: Assessing patients' experiences and preferences regarding medicine use en assessing their medical history, allergies and lab results Step #2: Drug reviewing to assess contra-indicated medication and duplicate medication using consensus criteria e.g. START STOPP Beers criteria Step #3: Reflecting on results of drug reviewing Step #4: Setting up a pharmacotherapeutical action plan Step #5: Execution of pharmacotherapeutical action plan"
3304999|NCT01876095|No Intervention|usual care|Includes medication safety monitoring and ad hoc medication reviews on clinical indication that differ in quality and frequency, but no standardized multidisciplinary multistep medication reviews in the way as described for the intervention arm
3305000|NCT01876108|Experimental|H.pylori eradication|H.pylori eradication by quadruple antibiotic therapy for two weeks plus obtaining ideal body weight by calorie restriction diet and programmed physical activity.
3305001|NCT01876108|No Intervention|Lifestyle modification|Obtaining ideal body weight by calorie restriction diet and programmed physical activity
3305002|NCT01876121||Celecox group|
3305003|NCT01876134||Elective cardiac surgery|
3305004|NCT01876147||Order of vision tests 1|Undergo testing with BRVT first, FrACT second.
3305005|NCT01876147||Order of vision tests 2|Undergo testing with FrACT first, BRVT second.
3305006|NCT01876160|Experimental|threshold of sensory perception|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of sensory perception was identified as the first sensation of increased current intensity and the threshold of motor response as the minimum muscle contraction detected.
3305007|NCT01876160|Experimental|threshold of motor response|Eighty healthy volunteers were evaluated; 40 women and 40 men divided into two equal groups of young and elderly subjects. Half of the individuals in each group were stimulated with 5 and 50Hz frequency, with pulse duration of 20, 100, 400, 1000 and 3000µs applied on the flexor muscle bellies of the wrist and fingers. The threshold of motor response as the minimum muscle contraction detected.
3305008|NCT01876173|Experimental|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
3305009|NCT01876173|No Intervention|Usual care|The control group will not receive the patient decision aid prior to consultation with the physician.
3305010|NCT01876186|Experimental|Solifenacin for 12 weeks group|Solifenacin (5 mg qd) for 12 weeks
3305011|NCT01876186|Active Comparator|Solifenacin for 24 weeks group|Solifenacin (5 mg qd) for 24 weeks
3305012|NCT01876199|Experimental|Intense follow up|2-week follow up appointment with addition of a reminder mobile phone call or short text message (SMS) if possible, plus a home visit by a community counselor if the participant fails to present on the appointed date.
3305013|NCT01876199|No Intervention|standard follow-up|2-week follow-up appointment with no reminders
3305014|NCT01876225|No Intervention|No coughing|Cervical punch biopsy without forced coughing intervention
3305015|NCT01876225|Experimental|coughing|Forced coughing during cervical punch biopsy
3305016|NCT01876238|Experimental|T-PAT Intervention|Prognosis discussion intervention with study team.
3305017|NCT01876238|Active Comparator|Control: Standard Care|Usual care appointment
3305018|NCT01876264|Experimental|Extended resection|Patients undergoing an extended resection are subjected to a traditional ileocolic resection with a 2cm macroscopically normal proximal margin. A further 8cm of ileum is then resected from the proximal margin prior to formation of the ileocolic anastomosis
3305019|NCT01876264|Active Comparator|Conventional resection|Patients undergoing a traditional ileocolic resection for Crohn's disease with a 2cm proximal macroscopically disease-free margin
3305020|NCT01876277||Adolescent males with cancer|Males aged 13-21 who have been treated at the Royal Marsden Hospital for cancer.
3305021|NCT01876290|Experimental|Dexamethasone and Ondansetron|Each patient will receive Dexamethasone and Ondansetron
3305022|NCT01876290|Placebo Comparator|Placebo|Each patient will receive placebo instead of Dexamethasone and Ondansetron
3305023|NCT01876303||Ancillary-Correlative (genetic epidemiology of Ewing sarcoma)|Genomic DNA is extracted from participants' saliva samples and analyzed for expression of EWS-FLI1 and other ES-target genes.
3305024|NCT01876316|Active Comparator|Moxifloxacin|single oral administration of 400mg of moxifloxacin
3305025|NCT01876316|Placebo Comparator|Placebo|single oral administration of 400mg of placebo
3305026|NCT01876342|Experimental|Open repair|Open minimal repair (OMR) of Sportsman's hernia using 2-0 continuous sutures
3305027|NCT01876342|Active Comparator|Endoscopic TEP repair|Totally Endoscopic extraperitoneal repair (TEP)using lightweight mesh
3305028|NCT01876355|Experimental|Clonidine|
3305029|NCT01876355|Placebo Comparator|Sodium chloride|
3305030|NCT01876394|Experimental|Coconut oil|
3305031|NCT01876394|Experimental|Canola oil|
3305032|NCT01876394|Experimental|Grapeseed oil|
3305033|NCT01876394|Experimental|Chia oil|
3305034|NCT01876394|Placebo Comparator|Butter|
3305035|NCT01876407|Experimental|Low energy laser|Administration of a low energy laser for oral mucositis.
3305036|NCT01876407|Placebo Comparator|Placebo|
3305037|NCT01876433|Active Comparator|Beta-3-agonist|Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
3305038|NCT01876433|Placebo Comparator|Placebo|Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.
3305039|NCT01876459|Other|"Alzheimer's Disease arm"|Patient with Alzheimer's disease
3305040|NCT01876459|Other|"Lewy Body Disease arm"|Patient with Lewy Body Disease
3305041|NCT01876472||Children aged 3 - 10 years|Assessment of music perception skills with cochlear implant recipients aged 3 - 10 years
3305042|NCT01876472||Teenagers aged 11 - 15 years|Assessment of music perception skills with cochlear implant recipients aged 11 - 15 years
3305043|NCT01876472||Adults aged 16 - 70 years|Assessment of music perception skills with cochlear implant recipients aged 16 - 70 years
3305044|NCT01876498||Patient with M. Dupuytren|Xiaflex Surgery
3305045|NCT01876524|Experimental|tRNS over Anterior Cingulate|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the disease-specific Anterior Cingulate Cortex (ACC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
3305046|NCT01876524|Experimental|tRNS applied over DLPFC|Dual Pathology (Substance Use Disorder plus another psychiatric trait) 75 patients with diagnosed SUDs plus another psychiatric disorder will be receive tRNS in the dorso-lateral-prefrontal-cortex (DLPFC), be studied blindly to evaluate the craving reduction after 35 tRNS sessions.
3305047|NCT01876524|Sham Comparator|Sham Group|75 patients will be receive tRNS sham 35 sessions.
3305048|NCT01876537|Active Comparator|Usual surgery|
3305049|NCT01876537|Active Comparator|Hardware wound healing|
3305050|NCT01876550|Experimental|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.)
3305051|NCT01876550|Active Comparator|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline)
3305052|NCT01876550|Placebo Comparator|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.)
3305053|NCT01876563|Active Comparator|diabetes, vitamin D|patients with type 2 diabetes who receive 4000 IU/day vitamin D
3305054|NCT01876563|Placebo Comparator|placebo, diabetes|patients with type 2 diabetes who receive one tab placebo
3305055|NCT01876576|Active Comparator|clear liquids|Clear liquids the day of bowel preparation up to 2.5 hrs before colonoscopy
3305056|NCT01876576|Active Comparator|low residue diet|Low residue breakfast and lunch up to 1pm; clear liquids thereafter up to 2.5 hrs before colonoscopy
3305057|NCT01876589|Active Comparator|Bioresorbable vascular scaffold|Paritcipants will receive a bioresorbable vascular scaffols (BVS)
3305058|NCT01876589|Active Comparator|Xience Prime|Participant will receive a Xience Prime stent
3305059|NCT01876602|Experimental|Exercise prescription|"Participants are given an exercise prescription in the form of a target heart rate range for exercising. The range is determined based on their personal preferences so that it is an intensity that feels good."
3305060|NCT01876602|Active Comparator|traditional exercise|participants are given an exercise prescription based on percent of vo2 peak
3305061|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac(arm 1)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305062|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 2)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305063|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 3)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305064|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm 4)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305065|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm5)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305066|NCT01876615|Experimental|YH4808 or Diclofenac or YH4808+Diclofenac (arm6)|"6 arm, 3 Sequence design~YH4808 or Diclofenac or YH4808+Diclofenac~3 week wash out period is between each period."
3305067|NCT01876628|Placebo Comparator|Flucloxacillin and placebo|Intravenous or oral Flucloxacillin with an oral placebo
3305068|NCT01876628|Active Comparator|Flucloxacillin and Clindamycin|Intravenous or oral Flucloxacillin with oral Clindamycin
3305069|NCT01876641|Experimental|Study Treatment|In Cohorts 1-4, a subcutaneous dose of decitabine will be administered three times/week over a 2 week period. Cohorts 5 and 6 will receive decitabine two times a week for 8 weeks and Cohorts 7 and 8 will receive decitabine three times a week for 8 weeks. Patients will start treatment with decitabine initially at the cohort in which they enter the study. Patients will remain in the cohort in which they were initially enrolled for the entire treatment course. Vemurafenib + Cobimetinib will be given continuously for subjects in Cohorts 5, 6, 7 and 8. Vemurafenib will be given on a 28-day cycle at the standard dose of 960 mg p.o. BID. Cobimetinib will be given on a 21-day cycle with a 7-day rest between cycles. Decitabine will be given for 2 cycles only. Each cycle will be 28 days long. Vemurafenib + Cobimetinib will be continued indefinitely until disease progression.
3305070|NCT01876654|Experimental|TruMatch® patient specific cutting guide|In patients randomized to experimental arm, TKR components will be implanted using TruMatch® patient specific cutting guides.
3305071|NCT01876654|No Intervention|Conventional cutting guide|In patients randomized to control arm, TKR components will be implanted using Attune® instrumentation (femoral intra-medullary guide, tibial extra-medullary guide), without TruMatch® patient specific cutting guides.
3305072|NCT01876667|Active Comparator|Intervention (CPCRS) Group|CPCRS will ensure patients have regular laboratory monitoring and blood pressure measures, appropriate lipid-lowering and antihypertensive medications, and receive follow-up in a timely manner.
3305073|NCT01876667|Placebo Comparator|Usual Care|Usual Care: Patients randomized to Usual Care will continue to receive interventions/procedures they normally receive according to standard/usual care practices
3305074|NCT01876680|Experimental|Group 1: Stretching and aerobic exercise|Group 1 undertook a stretching programme for neck/shoulder muscles three times weekly and performed aerobic exercise för 30 minutes three times weekly.
3305075|NCT01876680|Experimental|Group 2: Strength training|Group 2 undertook a stretching programme for neck/shoulder muscles three times weekly, performed aerobic exercise three times weekly and performed weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
3305076|NCT01876693|No Intervention|control|nutrition counselling with nasogastric tube insertion in the cases of weight loss more than 10% or severe mucositis developed during chemoradiotherapy
3305077|NCT01876693|Experimental|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
3305078|NCT01876719|Experimental|0.5 mg AR08|0.5 mg AR08, QD for 7 weeks
3305079|NCT01876719|Experimental|1.0 mg AR08|1.0 mg AR08, QD for 7 weeks
3305080|NCT01876719|Experimental|2.0 mg AR08|2.0 mg AR08, QD for 7 weeks
3305081|NCT01876719|Placebo Comparator|Placebo|Placebo, QD for 7 weeks
3305082|NCT01876745||NovoSeven® (activated recombinant factor VII)|
3305083|NCT01876758|Experimental|Cognitive Intervention: Memory Training|Memory training before and after ECT
3305084|NCT01876758|Active Comparator|Comparable general mental stimulation|Puzzle games before and after ECT
3305085|NCT01876758|No Intervention|Treatment as Usual|No memory training or puzzle games, just the study evaluations
3305086|NCT01876771|Experimental|[177]Lu-DOTA-TATE Therapy|"Nominal, induction stage dose of 150 mCi (5.55 GBq) [177]Lu-DOTA-TATE every 10 - 14 weeks for 4 treatments.~Nominal maintenance stage dose of 75 mCi (2.78 GBq) [177]Lu-DOTA-TATE every 22 - 40 weeks, up to a maximum of 8 treatments."
3305087|NCT01876797|Other|ticagrelor-prasugrel|in period 1, 180 mg of ticagrelor will be administrated at a single oral dose. in period 2, 60 mg of prasugrel will be administrated at a single oral dose.
3305088|NCT01876836|Experimental|i-gel|i-gel placed after induction
3305089|NCT01876836|Active Comparator|C-LMA|C-LMA placed after induction
3305090|NCT01876849|Experimental|Group A|Exenatide injection 5mcg or 10 mcg, twice daily
3305091|NCT01876862|Experimental|STOP ART|"Antiretroviral treatment interruption in 3 successive groups of 5 patients.~Zero-risk strategy If after 8 weeks of treatment interruption, at least 1 patient from group 1 does not present any of the failure criteria, patients from group 2 will be included and their treatment interrupted. If after 8 weeks of treatment interruption, at least 2 patients from groups 1 and 2 do not present any failure criteria, patients from group 3 will be included and their treatment interrupted."
3305092|NCT01876875|Experimental|Intervention group|The patients of this group were randomized to receive an energy-restricted diet (20 kcal/kg/ideal body weight/day) enriched of n-3 PUFAs (average 2.6 g/d).
3305093|NCT01876875|Active Comparator|Control group|The participants of this group are randomized to receive drug therapy alone, continuing their usual diet
3305094|NCT01876914||DME patients|Patients suspected to have a problem with at least one eye called diabetic macular edema or DME
3305095|NCT01876927|Experimental|Arm A|"DOX 4 cycles - Surgery - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 4 cycles before surgery. Each cycle will be repeated every 3 weeks."
3305096|NCT01876927|Experimental|Arm B|"DOX 2 cycles - Surgery - DOX 2 cycles - Follow-up~DOX:~Docetaxel 35 mg/m2 day 1 and 8 by one hour infusion; Oxaliplatin 80 mg/m2 day 1 by two hours infusion; Capecitabine 750 mg/m2 x 2 daily for 2 weeks, per OS.~Treatment should be administered for 2 cycles before surgery and for further 2 cycles after surgery, unless progression of disease or unacceptable toxicity occurs, or patient refusal. In these cases patients will go off treatment.~Each cycle will be repeated every 3 weeks."
3305097|NCT01876940|Active Comparator|Fiberoptic Intubation performed by an expert|Tracheal intubation will be performed by an expert anesthesia attending with and without use of the air-Q
3305098|NCT01876940|Experimental|Fiberoptic Intubation performed by a novice|Tracheal intubation will be performed by an anesthesia trainee with and without use of the air-Q
3305099|NCT01876966|Experimental|ETR, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with etravirine for 22 days and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
3305100|NCT01876966|Experimental|DRV/rtv, artemether/lumefantrine|treatment with artemether/lumefantrine 80/480 mg during 3 days (treatment A) and treatment during 22 days with darunavir/ritonavir and artemether/lumefantrine 80/480 mg from day 8 to day 11 (treatment B) with a washout of at least 4 weeks between the 2 treatment periods
3305101|NCT01877005|Experimental|Ruxolitinib|"Induction period: Ruxolitinib will be given twice daily during 6 cycles of 28 days.~Maintenance period: patients who achieve at least a stable disease (according Cheson 2007) at the end of cycle 6 and for whose a clinical benefit is observed according to the Investigator's opinion will be eligible for maintenance treatment by ruxolitinib twice daily every day of 28-day cycles."
3305102|NCT01877018|Experimental|electronic reminder|Electronic reminder introduced into primary care medical health record.
3305103|NCT01877018|No Intervention|Usual care|Usual care control group
3305104|NCT01877031|Active Comparator|Ultrasound|Ultrasound only guidance of central line insertion - current standard of care.
3305105|NCT01877031|Experimental|Virtual Reality|Use of ultrasound plus virtual reality guidance to insert central line
3305106|NCT01877044|Placebo Comparator|Placebo|Maltodextrin
3305107|NCT01877044|Experimental|NAXUS 7.5 grams|Arabinoxylan
3305108|NCT01877044|Experimental|NAXUS 15.0 grams|Arabinoxylan
3305109|NCT01877057|Experimental|Saturn|For the different prototypes of pea protein extract used in this study pea protein NUTRALYS F85M or F85G, Acacia Gum 381A or 396I and water will be used.
3305110|NCT01877070||early stage prostate patients & their partners/close allies|
3305111|NCT01877096|Experimental|Motivational Interviewing|Participants will undergo a brief (20-30 minutes) motivational interviewing session after their primary care appointment
3305112|NCT01877096|Active Comparator|Attention Control|Participants will undergo a brief (20-30 minutes) attention control session after their primary care appointment
3305113|NCT01877109||Lymphoma|Lymphoma patients
3305114|NCT01877122|Experimental|Proflex® Mesh|Device: Partially absorbable lightweight mesh Intervention: Mesh implantation
3305115|NCT01877122|Active Comparator|Marlex® Mesh|Device: Non-absorbable Heavyweight mesh Intervention: Mesh implantation
3305116|NCT01877135||Anal AIN3|patients > 18 years, with anal AIN3, without history of anal carcinoma
3305117|NCT01877174||MICHI(TM) NPS+f|Patients routinely treated with the CE marked MICHI(TM) NPS+f System
3305118|NCT01877200||Subjects with diabetes (type 2)|
3305119|NCT01877213|Experimental|Coaching with coordinate care|After discharge from hospital, patients randomized in the coaching group will be coached by a coordinator nurse.
3305120|NCT01877213|No Intervention|Usual care|After discharge from hospital, patients randomized in the no intervention group will be managed as usually.
3305121|NCT01877226|Experimental|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
3305122|NCT01877252||Endovascular treatment|Angioplasty +/- stent
3305123|NCT01877252||Open treatment|Bypass (vein or prosthetic)
3305124|NCT01877252||Patchplasty/Hybrid treatment|Femoral artery patchplasty +/- profundoplasty +/- endovascular treatment
3305125|NCT01877252||Conservative treatment|no vascular intervention
3305126|NCT01877291||Nonsmokers|Young healthy nonsmokers
3305127|NCT01877291||Smokers<2.5 pack years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history <2.5 pack years"
3305128|NCT01877291||Smokers≥ 2.5 pack-years|"Young healthy or asymptomatic smokers (aged < 35 y.o.) with smoking history ≥ 2.5 pack-years"
3305129|NCT01877304|Experimental|AKITA with program central deposition|Nebulization for central deposition
3305130|NCT01877304|Active Comparator|AKITA with program for peripheral deposition|Nebulization for peripheral deposition
3305131|NCT01877317|Experimental|SelfFit adjusted hearing device|Hearing impaired people with mild to moderate sensorineural hearing loss (PTA124<50 dB) in the test ear compare the performance of their hearing aids adjusted through SelfFit mobile medical App (I-Pad) with the performance of their hearing aids adjusted through conventional audiogram-based fitting.
3305132|NCT01877330|Active Comparator|Injection in interscalene groove|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove anterior and posterior to the brachial plexus nerves.
3305133|NCT01877330|Active Comparator|Injection between nerve roots|Patients undergoing shoulder arthroscopy will have an interscalene nerve block by injection of ropivacaine in the interscalene groove inbetween the C5 and C6 nerve roots.
3305134|NCT01877356|Experimental|bilateral spinal anesthesia|bilateral spinal anesthesia prilocaine plain 20% 50 mg ambulatory surgery
3305135|NCT01877356|Experimental|unilateral spinal anesthesia|unilateral spinal anesthesia prilocaine hyperbaar 2% 30 mg ambulatory surgery
3305136|NCT01877382|Experimental|Part 1, Milademetan Alone|Participants receive milademetan alone with different dose schedules.
3305137|NCT01877382|Experimental|Part 2, Milademetan Alone|Participants with advanced melanoma and diffuse large B cell lymphoma (DLBCL) receive milademetan alone with different dose schedules.
3305138|NCT01877395|Experimental|Purified Vero Rabies Vaccine Group|Participants will receive the Purified Vero Rabies Vaccine (VRVg)
3305139|NCT01877395|Experimental|Imovax® Rabies Vaccine Group|Participants will receive the Imovax® Rabies vaccine
3305140|NCT01877434||Reversed TESS|Patient undergone reversed shoulder arthroplasty
3305141|NCT01877447|Experimental|cathodal F4|"Transcranial Direct Current Stimulation~Cathodal tDCS over F4 (right dorsolateral prefrontal cortex) Anodal tDCS over the left deltoid (extra-cephalic) n=15"
3305142|NCT01877447|Experimental|Anodal F3|"Transcranial Direct Current Stimulation'~Anodal tDCS over F3 (right dorsolateral prefrontal cortex) Cathodal tDCS over the right deltoid (extra-cephalic) n=15"
3305143|NCT01877460|Experimental|Sodium alginate-free chocolate milk|Sodium alginate-free chocolate milk (1% fat) (Beatrice Ltd., Toronto, Ontario)
3305144|NCT01877460|Experimental|1.25% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 1.25% sodium alginate
3305145|NCT01877460|Experimental|2.5% sodium alginate chocolate milk|Chocolate milk (Beatrice Ltd., Toronto, Ontario) with 2.5% sodium alginate
3305146|NCT01877460|Experimental|2.5% sodium alginate milk-free water-based solution|Water solution with 2.5% sodium alginate
3305147|NCT01877473|Active Comparator|Reverse remodeling|Pretreatment with dofetilide or sotalol and restoration of sinus rhythm followed by PVI only ablation
3305148|NCT01877473|Active Comparator|Standard ablation|PVI ablation with additional CFAE and/or linear LA ablation
3305149|NCT01877486||Cryoballoon ablation|After pre-treatment with dofetilide and conversion of persistent AF to sinus rhythm, performance of PVI using cryoballoon
3305150|NCT01877499||optimization of HDF key parameters|The cohort is composed of patients with end-stage renal disease receiving dialysis for at least 6 weeks, either as standard hemodialysis (low- or high-flux) or hemodiafiltration (HDF).
3305151|NCT01877512|Active Comparator|Low dose Growth Hormone|Halve of the group of men and group of women will receive a decrease of their regular dose of Growth Hormone treatment, with the IGF-I target level of -2 - -1 SD score (low dose=LD).
3305152|NCT01877512|Active Comparator|High dose Growth Hormone|Halve of the group of men and group of women will receive an increase of their regular dose of Growth Hormone treatment, with the IGF-I target level of 1 - 2 SD score (high dose=HD).
3305153|NCT01877525||All patients in one cohort|Consecutive adult patients undergoing colonoscopy for colorectal cancer screening or routine surveillance indications were prospectively enrolled between October 2011 and October 2012.
3305154|NCT01877577|Active Comparator|2000 I/U Vitamin D3|2000 I/U Vitamin D3 Daily
3305155|NCT01877577|Active Comparator|4000 I/U Vitamin D3|4000 I/U Vitamin D3 Daily
3305156|NCT01877590|Placebo Comparator|placebo group|An identical placebo daily
3305157|NCT01877590|Experimental|alpha-lipoic acid group|alpha-lipoic acid 600 mg daily for one year.
3305158|NCT01877603||type 2 diabetes|We select 200 newly diagnosed type 2 diabetic patients. Plasma irisin levels will be measured, and endothelial function will be determined.
3305159|NCT01877616|Other|diagnostic test|all persons with a definitive diagnosis of a major sleep disorder (insomnia, hypersomnia, sleep-disordered breathing) will be followed annually for at least five years
3305160|NCT01877629|Experimental|ACT-129968 tablet/capsules|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
3305161|NCT01877629|Experimental|ACT-129968 capsules/tablet|Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period.
3305162|NCT01877681|Experimental|Assisted Care|Assisted care (Tele=assistance) provided by an expert nurse through a informatic online application
3305163|NCT01877681|Active Comparator|Active comparator|Usual care as stated by the Clinical Practice Guidelines for Pressure Ulcers treatment
3305164|NCT01877694|Experimental|Auriclosene Solution 0.3%|Dosed QID for 4 Days
3305165|NCT01877694|Placebo Comparator|Auriclosene Vehicle|Dosed QID for 4 days
3305166|NCT01877707|Other|Cystic Fibrosis patients|Patients with a diagnosis of cystic fibrosis, who are able to produce daily sputum samples. With a history of at least two pulmonary infective exacerbations within the past 12 months.
3305167|NCT01877733|Experimental|Maximal strenght training|Training maximal strength training 3 times a week/1 physiotherapy session for 8 weeks
3305168|NCT01877733|No Intervention|Standard rehabilitation|2-3 physiotherapy sessions a week for 8 weeks/telephone contact by project leader once a week/writing training diary
3305169|NCT01877746|Experimental|R1 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the first dosing regimen
3305170|NCT01877746|Experimental|R2 - combined immunosuppressive therapy|application of the combined immunosuppressive therapy in the second dosing regimen
3305171|NCT01877746|Other|S - standard therapy|only standard medical therapy of chronic heart failure without application of the combined immunosuppressive therapy
3305172|NCT01877759|Other|Mesenchymal stem cell|hUMAN MESENCHYMAL STEM CELLS
3305173|NCT01877772|Active Comparator|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
3305174|NCT01877772|Active Comparator|Control|The control group will undergo standard rotator cuff repair.
3305175|NCT01877785|Experimental|MHAA4549A Arm|
3305176|NCT01877785|Placebo Comparator|Placebo Arm|
3305177|NCT01877798|Experimental|△PCO2/Ca-vO2|△PCO2/Ca-vO2 directed group
3305178|NCT01877798|Experimental|ScvO2|ScvO2 directed group
3305179|NCT01877811|Experimental|RXDX-105|
3305180|NCT01877824|Experimental|Fast-track training|A skills-lap course (1 day) followed by opportunity to perform 20 planned surgical procedures of each type (open groin hernia repair and laparoscopic cholecystectomy) under supervision and within 4-8 weeks. Videorecording at start, mid and end and at follow-up before ending first year of training.
3305181|NCT01877824|No Intervention|Control|Follows the existing training program without intervention. Video recording of the trainee performing a open groin hernia repair and a laparoscopic cholecystectomy procedure at start end end of first training year.
3305182|NCT01877837|Experimental|Related donor|"Matched sibling donors (9-10/10 marrow/PBSC or 5-6/6 UCB (single) with a total TNC dose of greater than 5 x 107/kg recipient weight), age 2-30 years after conditioning regimen Alemtuzumab , Fludarabine, and Melphalan.~1) Patients will receive a conditioning regimen composed of Alemtuzumab, Fludarabine, and Melphalan as detailed in the table below.~Day Treatment~-22 Alemtuzumab 3mg IV (test dose)~-21 Alemtuzumab 10mg IV~-20 Alemtuzumab 15mg IV~-19 Alemtuzumab 20mg IV~-8 Fludarabine 30mg/m2 IV~-7 Fludarabine 30mg/m2 IV~-6 Fludarabine 30mg/m2 IV~-5 Fludarabine 30mg/m2 IV~-4 Fludarabine 30mg/m2 IV~-3 Melphalan 140mg/m2 IV~-2 Rest Day~-1 Rest Day~0 Stem Cell Infusion"
3305183|NCT01877850||case|patients with BPAW-M more than 15 or between 10 and 15, but with Tobin <100 will be weaned with the weaning protocol by nurses
3305184|NCT01877850||control|patients with any BWAP-M will be weaned by clinical judgment of physicians
3305185|NCT01877863|Experimental|intradialytic exercise|baseline data prior to starting exercise program will be obtained and then compared to the data after 12 weeks of an intradialtyic biking program
3305186|NCT01877876||Patient undergoing spine surgery|
3305187|NCT01877889|Experimental|Part 1: Cana|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days.
3305188|NCT01877889|Experimental|Part 2: Sequence 1 (Dapa/Cana)|Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
3305189|NCT01877889|Experimental|Part 2: Sequence 2 (Cana/Dapa)|Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
3305190|NCT01877902||Pemetrexed 500 mg/m 2|
3305191|NCT01877928|Experimental|Boussignac CPAP device|Patients previously diagnosed with obstructive sleep apnea and who are undergoing abdominal or peripheral surgery will have the Boussignac CPAP mask applied for 1 hour starting immediately post-extubation
3305192|NCT01877928|Active Comparator|standard CPAP|Patients previously diagnosed with obstructive sleep apnea who are undergoing peripheral or abdominal surgical procedures will receive the standard-of-care for obstructive sleep apnea. This typically involves CPAP application only at night
3305193|NCT01877954||IPDI Qvar|ICS initiation as Extra-fine hydrofluoroalkane beclometasone dipropionate
3305194|NCT01877954||IPDI FP|ICS initiation as fluticasone propionate
3305195|NCT01877967|Experimental|Intervention|This group will intake the recommended daily amount of the food supplement VSL#3 (two sachets of the supplement in powder form) every day for twelve weeks. The two sachets will either be taken together or one in the morning and one in the evening.
3305196|NCT01877967|Placebo Comparator|Placebo|This group will intake two sachets (2x4.4g) of a placebo each day for 12 weeks. The placebo is in the same powdered form as the food supplement taken by the intervention group. The two sachets will either be taken together or one in the morning and one in the evening.
3305198|NCT01878058|Other|MRI Scan|Patients will receive an extra MRI scan in addition to their routine scan.
3305199|NCT01878071||Single group cross sectional|
3305200|NCT01878110|Experimental|COMB|
3305201|NCT01878123|Experimental|AMP-110|Escalating doses of AMP-110
3305202|NCT01878123|Placebo Comparator|Placebo|
3305203|NCT01878136|Active Comparator|Intraventricular tPA|"Tissue Plasminogen Activator (tPA)~Dose: 1 mg Q8 hr x 12 doses, or until blood is cleared from the ventricles and cisterns Adminstration: Intraventricular; via previously placed external ventricular drain"
3305204|NCT01878136|Placebo Comparator|Placebo|"Placebo~Dose 1 mL sterile saline"
3305205|NCT01878162|Experimental|Exercise|Exercise will occur 3 times weekly for 6 months in 20-minute exercise sessions. Sessions will take place independently. Follow-up and progression of the home program will be completed in person or by video teleconferencing at regular intervals throughout the intervention phase.
3305206|NCT01878188|Experimental|BC-819/PEI and BCG alternating|4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG
3305207|NCT01878188|Experimental|BC-819/PEI and BCG Vaccine sequential|4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG
3305208|NCT01878188|Experimental|twice-weekly treatments of BC-819 and BCG|6 twice-weekly treatments of BC-819/PEI and BCG
3305209|NCT01878201|Experimental|Fimasartan 30 mg|Take one capsule filled with a Fimasartan 30 mg in the every morning
3305210|NCT01878201|Active Comparator|Valsartan 80 mg|Take one capsule filled with a Valsartan 80 mg in the every morning
3305211|NCT01878227|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3305212|NCT01878227|Active Comparator|Fenofibrate 200mg|Fenofibrate 200mg per day
3305213|NCT01878240|Active Comparator|EVAR|Endovascular repair of an Abdominal Aortic Aneurysm
3305214|NCT01878240|Experimental|Coil embolization during EVAR|coil embolization during Endovascular repair
3305215|NCT01878266|Experimental|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week , by conformal radiotherapy sparing of the supratentorial brain. The planning target volume included the tumor as defined by the T2-weighted MRI images with a margin of 1.5-2.0 cm. Margins were adjusted for bony structures and tentorium. With exception of steroids, no neoadjuvant, concomitant, or adjuvant systemic treatment was allowed
3305216|NCT01878266|Experimental|Hypofractionated Arm (2)|The same planning and treatment procedures will be performed. The total dose will be 4500 cGy in 15 fractions in 3 weeks; giving 300 cGy per fraction.
3305217|NCT01878266|Other|Conventional Arm (3)|The same planning and treatment procedures will be performed with 54.0 Gy in 30 fractions giving 1.8 Gy per fraction.
3305218|NCT01878279||HIV negative|
3305219|NCT01878279||HIV positive|HIV positive children in care
3305220|NCT01878305||MARS|Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
3305221|NCT01878318|Experimental|RoActemra/Actemra|
3305222|NCT01878331||Roxolid|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
3305223|NCT01878331||SLActive|Patient do not receive an intervention in the extension study. Rather they are followed on the implant treatment from the core study which included a split-mouth design where all patients received both a Roxolid and SLActive implant.
3305224|NCT01878344|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3305225|NCT01878344|Placebo Comparator|Saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3305226|NCT01878357|Experimental|DHP monthly|Three mass screening and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1), month 2 (MST2), and month 3 (MST3) with an interval of 6 weeks between each MST
3305227|NCT01878357|Experimental|DHP bi-monthly|Two mass screenings and selective treatment using dihydroartemisinin-piperaquine and primaquine i.e. on month 1 (MST1) and month 3 (MST3) with an interval of 3 months.
3305228|NCT01878357|No Intervention|Arm 3|Without MST
3305229|NCT01878370|Experimental|High risk|Feedback reports focusing on the identification and management of patients who appear to have poorly managed diseases and who may require recall into clinic.
3305230|NCT01878370|Experimental|Best Practice|Feedback reports focusing on the achievement of optimal care targets for patients with chronic disease.
3305231|NCT01878396||Mutated Anti-B-RAF|Fourth stage Melanoma patients with both measurable and not measurable lesions undergoing treatment with selective B-RAF inhibitors.
3305232|NCT01878409||Parkinson Disease|Patients with Parkinson Disease
3305233|NCT01878409||Healthy Subjects|Healthy Subjects
3305234|NCT01878422|Experimental|Arm A: FOLFIRI or FOLFOX + Bevacizumab|"BEVACIZUMAB: Day 1,1st cycle 5 mg/kg IV infusion of 90 min Day 1, 2nd cycle if well tolerated, 5 mg/kg IV infusion of 60 min Day 1, 3rd cycle and subsequent cycles if well tolerated, 5 mg/kg IV infusion of 30 min after 5-FU bolus~FOLFIRI Day 1: Irinotecan 180 mg/m2 IV infusion 30-90 min~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours~- FOLFOX Day 1: Oxaliplatin 85 mg/m2 IV infusion of 2hours~Day 1,2:~L-Folinic acid 100 mg/m2 IV infusion of 2 hours 5-Fluorouracil 400 mg/m2 as a bolus 5-Fluorouracil 600 mg/m2 continuous IV infusion of 22 hours"
3305235|NCT01878422|Experimental|Arm B: FOLFIRI or FOLFOX|If FOLFIRI: FOLFIRI as specified in arm A without Bevacizumab If FOLFOX: FOLFOX as specified in arm A without Bevacizumab
3305236|NCT01878422|Experimental|Arm C: FOLFIRI or FOLFOX|Arm C: FOLFIRI or FOLFOX: for patients from arm A: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as defined in arm B)
3305237|NCT01878422|Experimental|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB: for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in 1st line trial, as described in arm B) plus CETUXIMAB
3305238|NCT01878422|Experimental|Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the 1st line trial, as defined in arm B) plus BEVACIZUMAB
3305239|NCT01878422|Experimental|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB;|for patients from arm B: FOLFIRI or FOLFOX (the CT schedule not received in the first-line trial, as defined in arm B) plus BEVACIZUMAB and CETUXIMAB; cycle to be repeated every 2 weeks, whilst cetuximab will be administered weekly.
3305240|NCT01878435|Experimental|SMS reminder|
3305241|NCT01878435|Experimental|SMS reminder and Travel subsidy|
3305242|NCT01878435|No Intervention|Control|
3305243|NCT01878435|Experimental|SMS reminder and Travel subsidy 2|
3305244|NCT01878448|Experimental|Anlotinib|
3305245|NCT01878461|Placebo Comparator|Vehicle|Proper quantity twice a day
3305246|NCT01878461|Experimental|M518101|Proper quantity twice a day
3305247|NCT01878474|Experimental|Single ascending dose in Caucasian men|
3305248|NCT01878474|Experimental|Age-effect in Caucasian men|
3305249|NCT01878474|Experimental|Gender-effect in Caucasian women|
3305250|NCT01878474|Experimental|Single ascending dose in Japanese men|
3305251|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Caucasian men|
3305252|NCT01878474|Placebo Comparator|Placebo: Age-effect in Caucasian men|
3305253|NCT01878474|Placebo Comparator|Placeo: Gender-effect in Caucasian women|
3305254|NCT01878474|Placebo Comparator|Placebo: Single ascending dose in Japanese men|
3305255|NCT01878487|Other|Only one arm|All patients will receive the same treatment, i.e. there is no randomization. There is therefore only one arm, all patients will by treated as per standard practice with thrombus aspiration and stenting as required, the lumen size of the vessel will be assessed with intravascular ultrasound at baseline, after thrombus aspiration and after stenting.
3305257|NCT01878513|Experimental|Low-dose-titration condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the low-dose-titration condition, patients will be treated with risperidone 0.5mg bid for 5 days, then 1mg bid for 5 days, which may be increased to 1.5mg bid for another 5 days.
3305258|NCT01878513|Experimental|Treatment-as-usual condition|Poor and intermediate CYP2D6 metabolizers will be randomized to either low-dose-titration condition or treatment-as-usual condition. In the treatment-as-usual condition, patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
3305259|NCT01878513|Experimental|Open-label treatment-as-usual condition|Extensive and ultrarapid CYP2D6 metabolizers will be treated open-label in the treatment-as-usual condition. Patients will be treated with risperidone 1mg bid for 5 days, then 2mg bid for 5 days, which may be increased to 3mg bid for another 5 days.
3305260|NCT01878539|Experimental|Health Center training|The intervention will consist of a patient training programme involving the provision of information and practical training concerning their condition and its treatment, as well as how to use a portable blood coagulation monitoring device and adjust their anticoagulant dose.
3305261|NCT01878552||ARDS|Mechanically ventilated patients with Acute Respiratory Distress Syndrome
3305262|NCT01878565|Experimental|Drug treatment|Drug: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20μg of HBV vaccine subcutaneously at day 6.
3305263|NCT01878565|Other|GM-CSF control|GM-CSF was given four times as control in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with GM-CSF intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
3305264|NCT01878578|Experimental|Eslicarbazepine acetate|ESL 600 mg tablets
3305265|NCT01878578|Active Comparator|phenytoin|Hidantina® 100 mg tablets
3305266|NCT01878578|Placebo Comparator|Placebo|Placebo tablets
3305267|NCT01878591||Women in active second stage of labour|Ultrasound examinations
3305276|NCT01878630|Experimental|Remote Patient Management|intervention group
3305277|NCT01878630|Active Comparator|Usual Care|control group
3305278|NCT01878643|Placebo Comparator|Drug: Placebo|normal saline 2 mL nebulized Q 8 hours placebo for gentamicin or vancomycin
3305279|NCT01878643|Experimental|Drug: vancomycin or gentamicin|vancomycin 120 mg every 8 hours or gentamicin 80 mg every 8 hours
3305280|NCT01878669|Placebo Comparator|saline|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3305281|NCT01878669|Experimental|n-acetyl cysteine|30 mg/kg/15 min intravenous bolus preprocedural and 50 mg/kg/8 h intravenous infusion during and after the procedure
3305282|NCT01878695|Experimental|IV and oral n-acetylcysteine|"50-150mg/kg of n-acetylcysteine intravenously once a week for at least two weeks.~600mg n-acetylcysteine orally twice daily except on day of infusion"
3305283|NCT01878708|Experimental|PEG-L-asparaginase/Dexamethasone|Patients will receive Oncaspar® (PEG-asparaginase) at a dose of 2,000 IU/m2 administered intramuscularly on day 3 of each 3 week cycle, with dexamethasone 40mg given orally on days 1-4.
3305284|NCT01878721||Staphylococcus aureus bacteremia|PET/CT in patients with Staphylococcus aureus bacteremia
3305285|NCT01878721||Salmonella spp. bacteremia|PET/CT in patients with Salmonella spp. bacteremia
3305286|NCT01878721||Endocarditis|PET/CT in patients with infective endocarditis
3305287|NCT01878721||Pacemaker infection|PET/CT in patients with pacemaker infection
3305288|NCT01878721||Vasculitis|PET/CT in patients with vasculitis
3305289|NCT01878734|No Intervention|Control|This arm will act as a control and will not receive Micronutrient Powders
3305290|NCT01878734|Experimental|Micronutrient Powders|This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
3305291|NCT01878747|Experimental|P-TIPS group|Provider Tailored Intervention for Perioperative Stress (P-TIPS) aims at reducing preoperative anxiety in children via modifying adults' behavior.P-TIPS program is developed from the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors.
3305292|NCT01878747|No Intervention|Control Group|Subjects in this group will not be trained with the P-TIPS method. They will receive a 2-hour seminar on the management of preoperative anxiety and postoperative pain and otherwise will provide standard care to patients.
3305293|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI Scan.
3305294|NCT01878838|Active Comparator|Catalys Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser
3305295|NCT01878838|Active Comparator|LenSx Treated Eyes|Patient's aged 22 and older with visually significant cataracts undergoing Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser.
3305296|NCT01878851||pulpotomy|
3305297|NCT01878864|Experimental|Bupivacaine lozenge|Single dose administration of a 25 mg bupivacaine lozenge before the scaling and root planning was performed.
3305298|NCT01878864|Active Comparator|Lidocaine-adrenalin injection|Xyloplyin Dental Adrenalin (20 mg/ml lidocaine, 12.5 microgram/ml adrenaline). Frequency and duration of injections was decided by the dentist preforming the scaling and root planning.
3305299|NCT01878903||i-pad VAS|All patients will be in one arm and they will be asked for post-operative pain using verbal NRS and visual VAS with i-pad
3305300|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Held|"Allergen(Tree, Grass, Weeds)-Held~Weekly administration of Greer manufactured allergen extract at same dose and concentration patient was on prior to allergen season for the duration of patients allergen season."
3305301|NCT01878929|Active Comparator|Allergen(Tree, Grass, Weeds) -Build-up|"Allergen(Tree, Grass, Weeds) -Build-up~Weekly administration of Greer manufactured allergen extract at escalating dose and concentration patient for the duration of patients allergen season."
3305302|NCT01878942|Other|Placebo, LSD|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but two treatment conditions in the same subject.
3305303|NCT01878955||->6 4-9 mm follicles in bilateral ovaries|Between the ages of 18-35 patients diagnosed with PCOS according to the Roterdam criteria
3305304|NCT01878968|Experimental|Script and Video|Patients in the Script and CPR/Mechanical ventilation video arm will receive information on CPR and mechanical ventilation via a script and a video.
3305305|NCT01878968|Experimental|Script only|Patients in the Script only arm will receive information on CPR and mechanical ventilation via a script only.
3305306|NCT01878994|Placebo Comparator|Counselling Group|Each family will receive a single monthly meeting, a total of 8 with 10 minutes duration each one. The sessions will take place in the consultation of the paediatrician and it will be delivered by the child's nurse or/and paediatrician. The sessions' contents are about promotion of healthy eating and physical activity habits.
3305307|NCT01878994|Experimental|Nereu Group|The Nereu treatment program is an intensive family-based behavioural multi-component lifestyle intervention. Consist in an intensive treatment of 8 months duration (from October to May, that is, an academic year). The intervention is a multidisciplinary intervention consisting in 4 structured components: (a) physical activity training for children, (b) family theoretical and practical sessions for parents, (c) behaviour strategies, that involves both parental and child participation (d) weekend extra activities.
3305308|NCT01879007|Experimental|group 1|received one intravenous administration and one oral medication with interval of 1 week,
3305309|NCT01879007|Experimental|group 2|received one oral administration and one intravenous medication with interval of 1 week
3305310|NCT01879020|Experimental|TA-8995 1 mg|
3305311|NCT01879020|Experimental|TA-8995 2.5 mg|
3305312|NCT01879020|Experimental|TA-8995 5 mg|
3305313|NCT01879020|Experimental|TA-8995 10 mg|
3305314|NCT01879020|Experimental|TA-8995 25 mg|
3305315|NCT01879020|Placebo Comparator|Placebo (TA-8995 1mg)|
3305316|NCT01879020|Placebo Comparator|Placebo (TA-8995 2.5mg)|
3305317|NCT01879020|Placebo Comparator|Placebo (TA-8995 5mg)|
3305318|NCT01879020|Placebo Comparator|Placebo (TA-8995 10mg)|
3305319|NCT01879020|Placebo Comparator|Placebo (TA-8995 25mg)|
3305320|NCT01879033|Active Comparator|Obese adolescents|Those with BMI more than or equal to 95th percentile. This group was further divided into two subgroups on the basis of Oral Glucose Tolerance Test (OGTT) into normal and impaired glucose tolerance groups. Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels for glucose, insulin, lipids and adipocytokines will be measured in the study.
3305321|NCT01879033|Placebo Comparator|Lean adolescents|BMI between 5th-85th percentile.Reactive hyperemia peripheral artery tonometry (Rh-PAT)score and blood levels of glucose, insulin, lipids and adipocytokines will be measured in the study.
3305322|NCT01879046|Experimental|Surgical intervention|Blood, bone marrow and Hoffa's fat pad samplings during surgical intervention
3305323|NCT01879085|Experimental|Combination therapy|Dose Level\Docetaxel IV\ Gemcitabine IV\Vorinostat PO\Pegfilgrastim 1\75 mg/m2\900 mg/m2\300 mg once daily\6 mg on day 9 2\75 mg/m2\900 mg/m2\200 mg twice daily\6 mg on day 9 3\75 mg/m2\900 mg/m2\300 mg twice daily\6 mg on day 9 4\75 mg/m2\900 mg/m2\400 mg twice daily\6 mg on day 9
3305324|NCT01879098|Placebo Comparator|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
3305325|NCT01879098|Experimental|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3305326|NCT01879098|Experimental|Probiotic: Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3305327|NCT01879098|Experimental|Probiotic: Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
3305328|NCT01879111|Experimental|state-of-art depression screening + patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
3305329|NCT01879111|No Intervention|state-of-art depression screening|
3305330|NCT01879124||Kidney transplant recipients|All de novo renal allograft recipients transplanted at the University Hospitals Leuven between March 2004 and October 2007
3305331|NCT01879137||healthy adults|
3305332|NCT01879137||Patients with a polyuria-polydipsia syndrome|
3305333|NCT01879150|Experimental|CYCLAPLEX bone anchors|"Following a 28-day screening period, eligible subjects requiring surgical correction for HV deformity (1st IMA >12degree, =<20 degree) will be enrolled to undergo HV deformity correction procedure with CYCLAPLEX under local or spinal anesthesia.~The device is implanted via small holes drilled in 1st and 2nd metatarsals. Complementary normal medical procedures such as bunionectomy, soft tissue release and HV angle correction will be performed as required.~Subjects will be followed-up for 50 weeks post-procedure."
3305334|NCT01879163|Experimental|Group A|The first six volunteers will receive an intradermal injection of 1x10^7 pfu MVA85A-IMX313 (non-randomised).
3305335|NCT01879163|Active Comparator|Group B|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A-IMX313 (following completion of group A, subjects will be randomised to either group B or group C).
3305336|NCT01879163|Active Comparator|Group C|12 subjects receiving intradermal injection of 5x10^7 pfu MVA85A (following completion of group A, subjects will be randomised to either group B or group C).
3305337|NCT01879189|Experimental|Decision Aid|Those in the decision aid arm of the study will be given access to the breast cancer screening decision aid.
3305338|NCT01879189|No Intervention|Standard of Care|Those in the standard of care arm will not be given access to the decision aid.
3305339|NCT01879202|Active Comparator|Methylphenidate modified release|The active agents is racemic methylphenidate hydrochloride, modified release, a mild central nervous system stimulant (pharmacotherapeutic group: psychostimulants). Study medication will be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
3305340|NCT01879202|Placebo Comparator|Maltodextrin|Study medication has to be taken once daily. Initially patients will be provided with 20mg and 30mg capsules of study medication. They are instructed to take 20mg within the first week and within the second week 30mg capsules. Visit 2 is scheduled two weeks after baseline and at Visit 2 patients will be provided with 40mg capsules and instructed to take them for the rest of the study.
3305341|NCT01879215|Active Comparator|Suprapatellar Approach|Suprapatellar Approach to Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an suprapatellar incision and splitting the quadriceps tendon.
3305342|NCT01879215|Active Comparator|Infrapatellar Approach|Infrapatellar Approach Intramedullary Nailing. Surgeons will be allowed to use any size intramedullary tibial nail through an infrapatellar incision using either a medial parapatellar approach or a transpatellar approach. The knee will then be scanned using T1Rho MRI at 2 weeks postoperatively and 6 months postoperatively.
3305343|NCT01879228|Experimental|Sitagliptin|The dose of sitagliptin (Januvia®) 100 mg tablet will be taken orally each morning for 6 months.
3305344|NCT01879228|Placebo Comparator|Placebo|Placebo tablet will be taken orally each morning for 6 months.
3305345|NCT01879241|Experimental|Rasagiline|"Rasagiline~1 mg/day; 18 months"
3380881|NCT04309916|Experimental|Tegoprazan 50mg|Tegoprazan 50mg tablet, once daily, oral administration
3380882|NCT04309916|Active Comparator|Esomeprazole 40mg|Esomeprazole 40mg tablet, once daily, oral administration
3380883|NCT04307277|Other|Control arm|
3380884|NCT04307277|Experimental|Experimental arm|
3380885|NCT04306510|Other|Group 1|TEGSEDI
3305346|NCT01879241|Placebo Comparator|Placebo|once daily, 18 months
3305347|NCT01879254||DBS for OCD|
3305348|NCT01879267|Other|Exercise Training: HD subjects|Endurance exercise for 6 months (30 min per week) starting one week after a 6-months natural course observation
3305349|NCT01879267|Other|Exercise Training: healthy subjects|6 months of exercise training (2 times 30 min per week)
3305350|NCT01879280|Experimental|osteoplastic craniotomy|Half of the study population will be randomized to traditional pterional craniotomy as the method of exposure. The other half will be randomized to osteoplastic craniotomy as the method of exposure. All other aspects of medical care will remain the same.
3305351|NCT01879280|Active Comparator|traditional pterional craniotomy|traditional pterional craniotomy
3305352|NCT01879293|Experimental|Metformin group|In this group, metformin 0.5 three times daily for one year.
3305353|NCT01879293|Placebo Comparator|Placebo group|In this group, placebo will be given twice daily for one year.
3305354|NCT01879358|Active Comparator|ORSIRO stent|ORSIRO stent group
3305355|NCT01879358|Active Comparator|NOBORI stent|NOBORI stent group
3305356|NCT01879384|Experimental|Microdialysis with CMA 70 catheter|CMA 70 catheter directly positioned in bone tissue
3305357|NCT01879397||CEA Group|Subjects with atherosclerotic stenosis of the carotid artery and are scheduled for a clinically indicated Carotid Endarterectomy (CEA) procedure to remove the atherosclerotic plaque. Prior to CEA procedure, a research ultrasound exam will be performed. The plaque tissue removed during the CEA will be collected and processed into histological slides.
3305358|NCT01879397||Normal Group|Subjects who are not scheduled for a Carotid Endarterectomy (CEA) procedure and have had no prior carotid artery interventions. Subjects will have a Research Ultrasound Exam performed.
3305359|NCT01879423|Experimental|Lamotrigine (Lamictal) D/C 5mg*5, Crossover|Single dose of lamotrigine dispersible/chewable (D/C)5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
3305360|NCT01879423|Experimental|Lamotrigine (Lamictal) Compressed 25mg, Crossover|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
3305361|NCT01879436||Pregnant women|"Women during first trimester of pregnancy (age: 18-45)~Group contain 50 healthy pregnant women, age 18-45. Sera will be taken from: 1. the same branula that will be introduced into the pregnant women as a routine during pregnancy termination procedure.2. from the vein of volunteered pregnant women which do not terminate pregnancy. First trimester placenta will be collected after pregnancy termination.~The measure of outcome is composite and includes several changes:~Changes in:~cell death (% from tested cells)~cell cycle (% cells in G1, G2 and S phases)~cell migration (% closure in Scratch test)~cell invasion (% cells passing through membrane in Transwell assay)~RNA repertoire (Fold change)~miRNA repertoire (Fold change) Investigators will not treat the women with any drug."
3305362|NCT01879436||Non pregnant women|Group contain 50 healthy women, age 18-45. Sera will be taken from the vein of the volunteered women. Investigators will not treat the women with any drug.
3305363|NCT01879462|Experimental|Cohort A|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 5 mg, GSK2878175 50 mg, and GSK2878175 200 mg in treatment period 1, 2, and 3 respectively in fasted state (with 1:3 ratio of placebo to active treatment at each treatment period).
3305364|NCT01879462|Experimental|Cohort B|Subjects in this cohort will receive 3 treatments (either active drug or placebo for each dose level) in 3 treatment periods (one per period). Subjects will receive GSK2878175 15 mg in fasted state, GSK2878175 100 mg in fasted state, and GSK2878175 100 mg in fed state in treatment period 1, 2, and 3 respectively (with 1:3 ratio of placebo to active treatment at each treatment period).
3305365|NCT01879462|Experimental|Cohort C|Subjects in this cohort will receive GSK2878175 15 mg single dose or placebo for 7 days in fasted state (with 1:4 ratio of placebo to active treatment).
3305366|NCT01879462|Experimental|Cohort D|Subjects in this cohort will receive placebo and GSK2878175 50 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3305367|NCT01879462|Experimental|Cohort E|Subjects in this cohort will receive placebo and GSK2878175 100 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3305368|NCT01879462|Experimental|Cohort F|Subjects in this cohort will receive placebo and GSK2878175 200 mg single dose or placebo for 7 days in fasted state, (with 1:4 ratio of placebo to active treatment).
3305369|NCT01879475|Experimental|032-11|032-11 topical haemostat.
3305370|NCT01879475|Active Comparator|Floseal (R)|Floseal(R) topical haemostat
3305371|NCT01879488|Active Comparator|Nebulization during pressure support ventilation|Patients ventilated in pressure support mode during nebulization
3305372|NCT01879488|Active Comparator|Nebulization during volume assist control mode|Patients ventilated in volume assist control mode during nebulization
3305373|NCT01879501|Experimental|Low Vision Self-Management Program|Intervention: The program will work with participants to choose a specific and achievable goal they wish to achieve, involve participants in the learning process, provide information, explore experiences with low vision, and solutions to develop problem solving skills to enhance self efficacy. Participants will learn new techniques to cope with their activities of daily living. In addition to this, local guest experts in the field will be sourced and invited to provide training in aspects of low vision care.
3305374|NCT01879501|No Intervention|Usual Care|Usual care delivered at the Singapore National Eye Centre
3305375|NCT01879514|Experimental|Combination Group|Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg·d, po. 48weeks
3305376|NCT01879514|Placebo Comparator|Placebo|Placebo of Chinese Herb Prescription Granule, 6g, Bid, po. 48weeks plus prednisone, 0.5mg-1mg/kg•d, po. 48weeks
3305377|NCT01879527|Active Comparator|Amiloride hydrochlorothiazide|5,68 mg Amiloridhydrochloride 2H20 (analogue 4,32 mg Amilorid) und 50 mg Hydrochlorothiazid. Trade name of the agent: Amilostad HCT 5/50mg tablets Manufacturer: Stada initial dose: 1 x 5/50mg once daily target dose: 2 x 5/50mg once daily Patients will be provided with capsules (size 00) containing one tablet of study medication and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication
3305378|NCT01879527|Placebo Comparator|Sugar pill|Patients will be provided with capsules (size 00) containing sugar and instructed to take these capsules once daily in the morning together with breakfast.
3305379|NCT01879592||Asthma + sickle cell disease|African American children affected with both sickle cell disease and asthma
3305380|NCT01879592||Sickle cell disease|African American children affected with sickle cell disease but who do not have asthma
3305381|NCT01879592||Asthma|African American children affected with asthma but without sickle cell disease
3305382|NCT01879592||Healthy control|African American children who are healthy with no chronic disease
3305383|NCT01879605|Experimental|Enema|Docusate natrium and sorbitol, 240 ml enema, the evening before surgery
3305384|NCT01879605|Active Comparator|Suppository|Bisacodyl, suppository 10 mg, the evening before surgery.
3305385|NCT01879605|No Intervention|Control grup|No intervention
3305386|NCT01879631||mild to moderate keratoconus cases|keratoconus with a central corneal thickness (CCT) over 400µm, poor corrected visual acuity (≤0.4 at Snellen visual acuity charts), contact lens intolerance, no apical scarring, no ocular or systemic problem other than keratoconus
3305387|NCT01879644|Active Comparator|Neurofeedback with Psychoeducation (NF + PE)|Neurofeedback plus Parental Psychoeducation
3305388|NCT01879644|Active Comparator|Self-Management with Psychoeducation (SM + PE)|Self-management + parental psychoeducation
3305389|NCT01879644|Active Comparator|NF+PE and additional Social Support (SU)|Neurofeedback + parental psychoeducation enhanced with social support
3305390|NCT01879644|Active Comparator|SM+PE and additional Social Support (SU)|Self-management + parental psychoeducation enhanced with social support
3305391|NCT01879657|Experimental|68Ga-DOTATATE PET scans|"Will perform 68Ga-DOTATATE PET scans on subjects. The same anatomic areas will be imaged with 68Ga-DOTATATE PET and 111In-penteoctreotide Scintigraphy to ensure relevant comparison of lesion detection.~The images from 68Ga-DOTATATE PET/CT will be reported by an experienced nuclear medicine physician who will be unaware of the results of the previous 111Inpenteoctreotide study. Areas of abnormal focal uptake will be documented. These areas of abnormal uptake will be compared with cross-sectional imaging (CT or MRI)to confirm the presence of lesions. The images from 111In- penteoctreotide Scintigraphy will be reported independently by another experienced nuclear medicine physician."
3305392|NCT01879670||Synergy|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
3305393|NCT01879670||Control|Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.
3305394|NCT01879696|Experimental|Treatment|Treatment are subjects will have catheter vacuum active for the removal of fluid from the muscle compartment.
3305395|NCT01879696|No Intervention|Control|Treatment are subjects will have catheter vacuum in-active for the removal of fluid from the muscle compartment.
3305396|NCT01879709|Experimental|Yoga Training Group|Yoga Training: Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols).
3305397|NCT01879709|Placebo Comparator|Treatment as Usual Group|Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided
3305398|NCT01879709|Active Comparator|Physical Exercise Group|Physical Exercise: This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises.
3305399|NCT01879748|Experimental|Rasagiline|Rasagiline mesylate oral tablets (AZILECT®) are provided at dose strengths of 0.5 and 1 mg (based on rasagiline base). Rasagiline oral tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
3305400|NCT01879748|Placebo Comparator|Placebo|Placebo tablets match in size and appearance to rasagiline tablets for each dose strength. Placebo tablets will be dispensed for 10 consecutive days of treatment. The oral dose will be administered each day with 240 mL water at room temperature after an overnight fast of at least 10 hours.
3305401|NCT01879761||Immunosuppressed|"Immunosuppressed includes patients with any one of the following:~a diagnosis of a hematological malignancy~a diagnosis of HIV~myelosuppressive chemotherapy in the previous 90 days~immune-modulating medications in the previous 90 days"
3305402|NCT01879761||Non-Immunosuppressed|Subject does not fit immunosuppressed criteria
3305403|NCT01879774|Other|Patients with hyponatremia|Neuropsychological and motoric tests are conducted in patients with hyponatremia.
3305404|NCT01879774|Other|Patients with normal serum sodium|Neuropsychological and motoric tests are conducted in patients with normal serum sodium.
3305405|NCT01879787|Experimental|physiotherapy + anodal tDCS + mCIMT|Before a anodal tDCS with duration of 13 minutes and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3305406|NCT01879787|Experimental|Physiotherapy + cathodal tDCS + mCIMT|Before a cathodal tDCS with duration of 9 minutes and intensity of 1mA applied at the healthy motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3305407|NCT01879787|Experimental|Physiotherapy+bi-hemispheric tDCS+mCIMT|Before a bi-hemispheric tDCS with duration of 13 minutes and intensity of 1mA applied at the healthy (cathode) and injured (anode) motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3380886|NCT04304872|Experimental|Gamification Intervention|"Participants sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day, they are told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who receives a weekly email with the participant's progress. The study group will hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. At 6 weeks, the study group will have a follow up call if the participant is stuck in a lower level and restart them back at the middle level."
3380887|NCT04304872|Experimental|Loss-Framed Financial Incentive Intervention|Participants are informed that each week that $14 is placed in a virtual account for them. Each day, the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that $2 was taken away.
3380888|NCT04304872|Experimental|Gamification and Loss-Framed Financial Incentive Intervention|Participants receive both of the interventions described in the Gamification Intervention arm and the Financial Incentive Intervention arm.
3380889|NCT04297124|Experimental|[14C]-CC-90009|A single IV dose of 0.6 mg [14C]-CC-90009 containing approximately 2 µCi of radioactivity will be administered on Day 1 under fasted conditions.
3305408|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mCIMT|Before a sham tDCS with duration of 30 seconds and intensity of 1mA applied at the injured motor cortex, the patient will be submitted to a 30 minutes physiotherapy protocol. Lastly the individual will realized a 45 minutes mCIMT protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions. At home the patient will spend 6 hours per day with the restraint for the paretic upper limb.
3380890|NCT04294459|Experimental|Phase 1|Isatuximab dose level 1 or dose level minus 1 depending on predefined unacceptable toxicities observed.
3380891|NCT04294459|Experimental|Phase 2: Cohort A|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with living donor.
3380892|NCT04294459|Experimental|Phase 2: Cohort B|Isatuximab dose determined in Phase 1 part of study; active candidates on the kidney waitlist with no living donor cleared for donation.
3380893|NCT04294420|Experimental|Patient education program|Patient education program
3380895|NCT04286776|Experimental|Direct Electrical Stimulation|Stimulation will be applied concurrently with the task, if applicable, and stimulation trials will be interleaved with sham trials, where no stimulation is delivered.
3380898|NCT04283864||Group A|
3380899|NCT04283864||Group B|
3380900|NCT04283864||Group C|
3380901|NCT04282967|Experimental|Exercise|For the first 12 weeks on study (Part 1), participants will train with an exercise physiologist (EP) for 150 minutes/week. This training will be delivered by web-based video conferencing. For the next 12 weeks (Part 2), participants will be instructed to do patient-directed exercise.
3380902|NCT04281485|Other|Cohort 1|Approximately two thirds of participants will be randomized to Cohort 1.
3380903|NCT04281485|Other|Cohort 2|Approximately one third of participants will be randomized to Cohort 2.
3380904|NCT04280848|Experimental|UCPVax vaccine|UCPVax is a therapeutic vaccine derived from telomerase combined with Montanide ISA51 VG as adjuvant.
3380905|NCT04279236||Single-arm|In this single-arm study, the only interventions compared to routine clinical practice are the completion of two patient questionnaires (APHAB and GBI) and an additional follow-up visit after surgery.
3380906|NCT04277637|Experimental|BGB-11417 Monotherapy Dose Finding: Part 1|Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until the maximum tolerated dose (MTD) (or maximum ascending dose (MAD)) and recommended phase 2 dose can be determined
3380907|NCT04277637|Experimental|BGB-11417 Monotherapy Expansion Cohorts: Part 2|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile
3380908|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Finding: Part 3|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 until RP2D can be determined in combination with zanubrutinib
3380909|NCT04277637|Experimental|BGB-11417 + Zanubrutinib Combination Therapy Dose Expansion: Part 4|Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral BGB-11417 at the RP2D dose to further define the safety profile in combination with zanubrutinib
3305409|NCT01879787|Experimental|Physiotherapy+tDCS+mental practice|Before a tDCS protocol applied during de mental practice training , the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3305410|NCT01879787|Sham Comparator|Physiotherapy+sham tDCS+mental practice|Before a sham tDCS protocol applied during the mental practice training, the patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3305411|NCT01879787|No Intervention|Physiotherapy|The patient will be submitted to a 30 minutes physiotherapy protocol. The experimental sessions will be repeated three times per week, will be realized 10 sessions.
3305412|NCT01879813|Active Comparator|Phospholipid drink|Participants will consume a phospholipid drink daily for 6 weeks
3305413|NCT01879813|Placebo Comparator|Placebo milk drink|Participants will consume a placebo drink (no added phospholipids) daily for 6 weeks
3305414|NCT01879839|No Intervention|Control Group|Patients who don't follow a special diet.
3305415|NCT01879839|Other|Diet Group|Patients who subsist on a special diet.
3305416|NCT01879865|Other|Non-stimulation|No auditory stimulation during dexmedetomidine infusion and recovery.
3305417|NCT01879865|Other|Stimulation|Auditory stimulation during dexmedetomidine infusion and recovery.
3305418|NCT01879878|Experimental|Verum, broccoli sprout grain|Active sulforaphane distributed in capsules each containing broccoli sprout grain
3305419|NCT01879878|Placebo Comparator|Placebo|Inactive substances (methylcellulose) with identical capsule and portion distribution
3305420|NCT01879891|Other|Non-Biopsy|"The Non-Biopsy group will complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. This group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups.~Those who select the Non-Biopsy group, in lieu of the biopsy test, will complete an Activities of Daily Living (ADL) test that involves sub-maximal VO2 assessment. The participants will also be asked to where an accelerometer home for 4 consecutive days after the ADL test."
3305421|NCT01879891|Other|Biopsy|The Biopsy group will also complete a VO2 maximum test, are provided food 2 days prior to assessments, exercise in the metabolic chamber, have a Resting Energy Expenditure test, complete a DEXA and have blood drawn. As with the Non-Biopsy group, this group will stay overnight in the metabolic chamber and have the clamp procedure. Exercise training is exactly the same for both groups. One week following the overnight metabolic chamber visit, participants in this group will undergo a muscle biopsy. This group will not complete the Activities of Daily Living (ADL) test nor will they be asked to wear an accelerometer.
3305422|NCT01879904|Experimental|Endoscopic submucosal dissection (ESD)|Endoscopic submucosal dissection (ESD)
3305423|NCT01879917|Active Comparator|Liraglutide|1.8 mg
3305424|NCT01879917|Placebo Comparator|Saline|
3305425|NCT01879930|Active Comparator|doxycycline|Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
3305426|NCT01879930|Placebo Comparator|placebo|Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
3305427|NCT01879943|Experimental|PillCam COLON 2 and Standard Colonoscopy|"Patients will have videocapsule colonoscopy after bowel preparation, followed by standard colonoscopy the next day.~Interventions:~Device: PillCam COLON 2 on D0~Procedure: Standard colonoscopy on D1"
3305428|NCT01879956|Active Comparator|OGI Method|- experimental group: use the OGI method to improve the executive functioning of patients with refractory schizophrenia.
3305429|NCT01879956|Placebo Comparator|craft activities|- control group: use of craft activities, attend the same-number of sessions, but without the intervention of therapists.
3305430|NCT01879969|Experimental|asymmetric patients, classic procedure|random selected
3305431|NCT01879969|Experimental|asymmetric patients, computer assisted|random selected
3305432|NCT01879982||Wellness Wearable System & Smartphone|
3305433|NCT01880008||Treatment|All patients included in this study were treated with temozolomide and radiotherapy after subtotal resection of a WHO grade III or IV glioma.
3305434|NCT01880034||Regional Anesthesia Section Heads|This group will consist of Regional Anesthesia Section Heads at anesthesia residency training programs.
3305435|NCT01880060|Experimental|INCENT weight loss program|INCENT: The INCENT intervention is an internet-delivered weight loss program with periodic financial incentives for weight loss. INCENT participants receive daily e-mail support with nutritional and physical activity suggestions to enhance weight loss. Monetary incentives are earned on a quarterly basis for weight loss and participants receive monthly checks that reflect the percent weight loss. A regularly calibrated scale with a built in digital camera captures an image of the participant during a weigh-in, and is used to objectively obtain weight data from participants at each quarterly weigh-in.
3305436|NCT01880060|Experimental|Livin My Weigh|Livin My Weigh: The Livin My Weigh (LMW) intervention is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
3305437|NCT01880112|Experimental|4 gram dose|Pre-operative prophylactic dose of 4 grams of cefazolin
3305438|NCT01880112|Active Comparator|2 gram dose|Pre-operative prophylactic dose of 2 grams of cefazolin
3305439|NCT01880125|Other|Group A|Period 1: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state
3305440|NCT01880125|Other|Group B|Period 1: Tramadol HCI/Acetaminophen 75/650mg PO once once with water 240ml at fasted state Period 2: Tramadol HCI/Acetaminophen 37.5/325mg PO once with water 240ml at fasted state
3305441|NCT01880138|Experimental|watching animated cartoon|
3305442|NCT01880138|Placebo Comparator|not watching animated cartoon|
3305443|NCT01880151|Experimental|Prodromal AD|Presence of memory impairment Absence of impairment in activities of daily life EEG
3305444|NCT01880151|Experimental|Mild AD dementia|Presence of memory impairment Presence of impairment in activities of daily life EEG
3305445|NCT01880151|Experimental|Healthy control group|Absence of memory impairment Absence of impairment in activities of daily life Absence of known neurological conditions EEG
3380910|NCT04275999|Other|Control Group|In the control group, all subjects will receive ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea. Subjects will not receive any follow-up intervention from the study team.
3380911|NCT04275999|Experimental|Digital Interaction Group|The digital interaction group will receive a survey by email each week asking about their use ivermectin generated by Causa Research; in addition to receiving ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
3380912|NCT04275999|Experimental|GPSkin group|The GPSkin group will receive the GPSkin Barrier® to measure their moisture level of their face daily. Subjects will be instructed to use the ivermectin once daily. Subjects also are receiving the ivermectin equipped with an electronic monitor to measure adherence for daily treatment of rosacea.
3380913|NCT04270058||Cohort 1|Cohort 1 will be pregnant patients who have been exposed to at least 1 dose of TEGSEDI within 25 weeks prior to conception or during pregnancy.
3380914|NCT04270058||Cohort 2|Cohort 2 will be pregnant patients who have hATTR-PN, who were not exposed to TEGSEDI or have not received TEGSEDI within the previous 25 weeks prior to conception.
3305446|NCT01880164||Nonoperative|Adult spinal deformity (degenerative or idiopathic) with an ODI of 30 or greater
3305447|NCT01880177||Current smokers|Current smokers (>10 pk yrs.)
3380917|NCT04266301|Experimental|MBG453 + Azacitidine|Participants will receive MBG453 plus Azacitidine
3380918|NCT04266301|Placebo Comparator|Placebo + Azacitidine|Participants will receive Placebo plus Azacitidine
3380919|NCT04265651|Experimental|Infigratinib 0.016 mg/kg|"Dose Escalation:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
3305448|NCT01880177||Ex-smokers|Ex-smokers with a history of >10 pk yrs
3380920|NCT04265651|Experimental|Infigratinib 0.032 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
3380921|NCT04265651|Experimental|Infigratinib 0.064 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months."
3380922|NCT04265651|Experimental|Infigratinib 0.128 mg/kg|"Dose Escalation and PK substudy:~Infigratinib is provided as minitablets in 2 strengths: 0.1 mg and 1 mg for daily oral administration. The dose and number of minitablets/day will be calculated based on individual participant weight. Doses will be adjusted based on weight changes approximately every 3 months.~Dose Expansion:~Upon identification of the recommended dose from all cohorts analyzed, an expansion cohort of 20 subjects may begin enrollment to further determine safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of the selected dose."
3380923|NCT04260789|Other|Treatment|Treatment with Seraph Filter
3305449|NCT01880177||Never-smokers|Never-smokers, defined as ≤100 cigarettes/pipes/cigars over life
3305450|NCT01880190|Active Comparator|Ringer's Lactate|Crystalloid solution
3305451|NCT01880190|Active Comparator|HES 130/0.4 and Ringer's Lactate|Colloid solution
3305452|NCT01880203|Experimental|aspiration for Molecular Cytogenetic Analysis.|
3305453|NCT01880216|Active Comparator|Enoxaparin sodium|subcutaneous for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
3305454|NCT01880216|Experimental|Bemiprin sodium|Bemiparin sodium (LMWH) s.c. for 7±2 days and starting on Day 2 additionally the oral anticoagulant warfarin
3305455|NCT01880229||non-frail|Categorized as non-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3305456|NCT01880229||pre-frail|Categorized as pre-frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3305457|NCT01880229||frial|Categorized as frail based on Fried's five phenotypic criteria (Fried L.P., et al. Frailty in Older Adults: Evidence for a Phenotype. Journal of Gerontology: 2001, Vol. 56A, No. 3, M146-M156)
3305458|NCT01880242||Orsiro DES|"Subjects requiring coronary revascularization with Drug Eluting Stents (DES). subgroups: Subjects presenting with~Diabetes (all types)~Small vessels (≤2.75 mm)~Chronic total occlusion (CTO)~Acute Myocardial Infarction (incl. STEMI and NSTEMI)"
3305459|NCT01880255|Active Comparator|Active rTMS|"Active treatment will be delivered at an intensity that is 90% of the resting motor threshold (RMT). Stimulation will be delivered at 20 Hz with 25 stimulation trains of 30 stimuli each (i.e., 750 stimuli) and an intertrain interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right dorsolateral prefrontal cortex (DLPFC). The order of bilateral stimulation (i.e. right then left or left then right) will be held constant for all 20 treatments.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3305460|NCT01880255|Sham Comparator|Sham rTMS|"Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.~Intervention: Device: Repetitive Transcranial Magnetic Stimulation"
3305461|NCT01880268|Experimental|BCI-then-Standard Rehab Group (Group A)|Participants will take 8 weeks of BCI rehabilitation first (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session. After finishing 8 weeks of BCI rehabilitation, participants will take 3 standard rehabilitation therapy sessions (for 2 hours) each week for 8 weeks (a total of 24 sessions)
3305462|NCT01880268|Experimental|Standard-then-BCI Rehab Group (Group B)|Participants will take 8 weeks of standard rehabilitation therapy first (3 sessions per week, 2 hours for each session, a total of 24 sessions). After that, participants will take 8 weeks of BCI rehabilitation (3 rehabilitation sessions each week, a total of 24 sessions); participants receive 100 minutes of standard rehabilitation and 20 minutes BCI rehabilitation training using BCI-controlled neurorehabilitation device during each session.
3305463|NCT01880281|Active Comparator|Meat diet without any vegetables or fruits|"The volunteers will follow a diet of 3 days with at least 400g of meat per day. The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 50meq of ammonium chlorid over a period of one hour in order to avoid the effect of nausea."
3305464|NCT01880281|Active Comparator|Vegetarian diet without any sources of protein|"The volunteers will follow a diet of 3 days with at least 600g of fruits and vegetables per day without any proteins (animal or vegetal like soybean). The 3rd day, the volunteers will do a collect of 24-hour urine.~The investigational's day, they will receive 1g of bicarbonate."
3305465|NCT01880294||Asian participants with chronic constipation|Asian participants diagnosed with chronic constipation using Asian Neurogastro-enterology and Motility Association (ANMA) diagnostic questionnaire.
3305466|NCT01880307|Experimental|Top-down|Infliximab and azathioprine; patients will receive 5 infliximab infusions of 5 mg/kg (IFX induction at week 0, 2 and 6, followed by 2 maintenance infusions every 8 weeks). IFX will be discontinued after 5 IFX infusions. Patients will also receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
3380924|NCT04260789|No Intervention|Control|
3305467|NCT01880307|Active Comparator|Step-up|Prednisolon and azathioprine; Patients will receive induction treatment with oral prednisolone 1 mg/kg (maximum 40 mg) once daily for 4 weeks, then tapering of prednisolone in 6 weeks until stop, and receive oral azathioprine 2-3 mg/kg, once daily as maintenance treatment.
3305468|NCT01880333|Experimental|Children on Modified Atkin Diet|
3305469|NCT01880346|Active Comparator|100,000 IU D-50 powder|Vitamin D oil vs powder. 100,000 IU powder form of vitamin D, assessment of D3 absorption. One Dose of vitamin D powder format administered. Absorption rate monitored over 72 hour period
3305470|NCT01880346|Active Comparator|100,000 IU Maximum D3 in oil|Vitamin D oil vs powder. One Dose of 100,000 IU vitamin D oil format administered. Absorption rate monitored over 72 hour period
3380925|NCT04260048||Normal weight|Group defined based on BMI percentile for age and sex.
3380926|NCT04260048||Overweight|Group defined based on BMI percentile for age and sex.
3305471|NCT01880359|Placebo Comparator|Radiotherapy+ Cisplatin+ Placebo|Accelerated radiotherapy (Therapeutic Planning Target Volume (PTV): 70 Gray (Gy), 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) Patients will receive placebo (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only).
3305472|NCT01880359|Experimental|Radiotherapy+ Cisplatin+ Nimorazole|"Accelerated radiotherapy (Therapeutic PTV: 70 Gy, 6 fractions/week, 35 fractions of 2 Gy, prophylactic PTV: 54.25 Gy, 6 fractions/week, 35 fractions of 1.55 Gy) + concomitant cisplatin (weekly schedule of 40mg/m2 (delivered on day 1, 8, 15, 22, 29) .~Patients will receive nimorazole (1.2 g/m2) 90 min (+/- 30 min) prior to each radiotherapy fraction but no more than 5 times a week (If the 6th radiotherapy fraction in a week is given on a separate day from the 5th fraction of radiotherapy, no nimorazole/placebo dose is received that day. If the 6th fraction of radiotherapy is given on the same day as the 5th fraction, nimorazole/placebo is given 90 minutes before the 5th radiotherapy fraction, only)."
3305473|NCT01880372|Experimental|Alpha Lipoic Acid Assignment Group|Alpha lipoic acid assignment group will follow routine care and receive 600 mg oral administration of lipoic acid daily.
3305474|NCT01880372|No Intervention|Alpha Lipoic Acid Control Group|The control group will follow routine care alone.
3305475|NCT01880385|Experimental|bevacizumab, inflammatory breast cancer|Neoadjuvant therapy associating bevacizumab, cyclophosphamide, fluorouracil and epirubicin hydrochloride q3w, 4 cycles Adjuvant therapy by docetaxel q3w, 4 cycles +/- trastuzumab q3w, 18 cycles if tumors overexpress HER2
3305476|NCT01880398||Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
3305477|NCT01880411|Experimental|PEK Fusion Protein Vaccine|PEK Fusion Protein Vaccine Injection 0.1mg, 0.3mg and 1.2mg One injection at one week intervals
3305478|NCT01880450|Experimental|Project Prepared|
3305479|NCT01880450|Active Comparator|TEEN-Teen Education & Employment Network|
3305480|NCT01880463|Active Comparator|Vitamin D + fish oil placebo|"Vitamin D3 (cholecalciferol), 2000 IU per day~Fish oil placebo"
3305481|NCT01880463|Active Comparator|Vitamin D placebo + fish oil|"Vitamin D placebo~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3305482|NCT01880463|Placebo Comparator|Vitamin D placebo + fish oil placebo|"Vitamin D placebo~fish oil placebo"
3305483|NCT01880463|Active Comparator|Vitamin D + fish oil|"Vitamin D (cholecalciferol), 2000 IU per day~Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg. of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])"
3305484|NCT01880476|Experimental|Home visits and group program|
3305485|NCT01880489|Experimental|MI + CBST Intervention|Seven sessions of Motivational Interviewing and Cognitive Behavioral Skills Training
3305486|NCT01880489|No Intervention|Wait List Control Condition|
3305487|NCT01880502|Experimental|Belviq 10mg|
3305488|NCT01880502|Experimental|Belviq 20mg|
3305489|NCT01880502|Placebo Comparator|Placebo|
3305490|NCT01880541|Experimental|hypnosedation|hypnosedation
3305491|NCT01880541|Other|general anesthesia|general anesthesia
3305492|NCT01880567|Experimental|Treatment (ibrutinib, rituximab)|Patients receive ibrutinib PO daily on days 1-28 and rituximab IV over 4-8 hours on days 1, 8, 15, and 22 of course 1; on day 1 of courses 3-8; and on day 1 of every other course for all subsequent courses. Treatment with rituximab repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Courses with ibrutinib repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3380927|NCT04260048||With obesity|Group defined based on BMI percentile for age and sex.
3305493|NCT01880580||Normal Group|In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
3305494|NCT01880580||Diagnostic Group|The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.
3380928|NCT04258826|Experimental|LY3154207|LY3154207 administered orally in one of two study periods.
3380929|NCT04258826|Placebo Comparator|Placebo|Placebo administered orally in one of two study periods.
3305495|NCT01880606||patients with PSC-IBD|Only patients, colonoscopy with endomicroscopy
3305496|NCT01880619|Placebo Comparator|Group A|Patients in this group will receive placebo
3305497|NCT01880619|Active Comparator|Group B|Patients in this group will receive Tamsulosin
3305498|NCT01880619|Active Comparator|Group C|Patients in this group will receive Solifenacin
3305499|NCT01880632|Experimental|XELOX|Clinically diagnosed stage T2-3/N+M0,orT4aN+M0 according to CT/MRI scan, and resectable
3305500|NCT01880645|Other|Ultrasound + Breast Surgery + Lymph Node Removal|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s). If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected. Standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction) performed.
3305501|NCT01880658|Experimental|Capecitabine|Patients undergo R0-R1 resection and receive adjuvant chemotherapy FOLFOX or Capox for no less than 4 months. Radiotherapy may be applied for patients with rectal cancer if clinicians suspect that is necessary. Then patients receive oral capecitabine for 12 months maintenance.
3305502|NCT01880671|Experimental|Migraine Medical Device|
3305503|NCT01880671|Placebo Comparator|Inactive Migraine Medical Device|
3305504|NCT01880684||Passive Leg Rising|
3305505|NCT01880710|Active Comparator|Total hysterectomy|removal of the entire uterus including the cervix. open abdominal surgery. No specific procedures were asked of the surgeon. They were free to do the procedure the way they were used to doing it.
3305506|NCT01880710|Experimental|Subtotal Hysterectomy|removal of the uterine body only leaving the cervix in situ. The surgeon was free to do the procedure as he was used to. The only direction was that the cervical canal should be electrocoagulated.
3305507|NCT01880749|Experimental|RAD001|RAD001 taken by mouth 10mg daily for 10 days before surgery
3305508|NCT01880775|Experimental|prilocaine heavy 2%& fentanyl|prilocaine heavy 2% 30 mg and fentanyl 20 micgr ampoule intrathecal
3305509|NCT01880775|Active Comparator|bupivacaine heavy 0.5% & fentanyl|bupivacaine heavy 0.5% 7.5 mg and fentanyl 20 micg ampoule intrathecal
3305510|NCT01880788||CNV secondary to CSC|
3305511|NCT01880788||CSC without CNV|
3305512|NCT01880788||CNV secondary to advanced AMD|
3305513|NCT01880814|Experimental|Cognitive Behavioral Therapy (CBT)|Type of talk therapy that focuses on individual behavioral and cognitive skills.
3305514|NCT01880814|Experimental|Caregiver-Child Treatment|Type of talk therapy that involves the child and the caregiver and focuses on behavioral and cognitive skills.
3305515|NCT01880827|Active Comparator|Royx-en-Y surgery|Mixed meal test (MMS) with flow studies before and 2 months after the operation
3305516|NCT01880827|Active Comparator|Control|Healthy volunteer group, GIP, GLP-1 and MMS studies
3305517|NCT01880827|Experimental|Sleeve gastrectomy|Mixed meal test (MMS) with flow studies before and 2 months after the operation
3305518|NCT01880853|Experimental|group 1|screening with mammography alone
3305519|NCT01880853|Experimental|group 2|screening with ultrasonography alone
3305520|NCT01880853|Experimental|group 3|screening with both mammography and ultrasound
3305521|NCT01880866|Experimental|(-)-Epicatechin|A single dose of 100mg or 200mg (-)-Epicatechin to be administered orally
3305522|NCT01880879|Experimental|helios stent|the group with helios stent implanted
3305523|NCT01880905|Experimental|female undergoing gynecological surgery|
3305524|NCT01880918||ColonRing|The ColonRing device is intended to be used for the creation of intestinal anastomoses in colorectal surgery in both open and laparoscopic surgeries. This indication is within the currently cleared indication of the ColonRing device, which has been cleared by the US FDA and carries the CE Mark for use throughout the alimentary trct for the creation of circular end-to-end, side-to-end or side-to-side anastomosis.
3305525|NCT01880931|Experimental|Normotensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3305526|NCT01880931|Experimental|Hypertensive patients|To find out the effect site concentration of remifentanil for preventing QTc prolongation < 15 sec during intubation : Dixon's up-and-down method
3305527|NCT01880944||ER-spine trauma|patients with spinal trauma, who initially visits in emergency room
3305528|NCT01880944||OUT-spine trauma|patients with spinal trauma, who initially visits in outpatient clinic
3380931|NCT04255433|Experimental|Tirzepatide|Tirzepatide administered subcutaneously (SC) once a week.
3305529|NCT01880957|Other|Lithium|Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs. Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2 mEq/l. Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
3305530|NCT01880957|Other|Lamotrigine|Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine. Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
3305531|NCT01880970|Active Comparator|Starter infant formula with pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
3305532|NCT01880970|Placebo Comparator|starter infant formula without pro and prebiotics|starter infant formula from enrollment till 6 months of age, followed by a commercially available Nestlé follow-up formula from 6 to 12 months of age
3305533|NCT01880970|No Intervention|Breastfeeding group|exclusively breastfeeding during the first 3 months of age, followed by a commercially available Nestlé starter infant formula from 4 to 6 months of age (if applicable) and the follow-up infant formula from 6 to 12 months of age
3305534|NCT01880996|Experimental|Tai-chi/Qi-gong|30 gynecological cancer patients scheduled for the first or second line of chemotherapy treatment will be recruited for this study to receive Tai-chi/qigong treatment initiated at the beginning of chemotherapy therapy, once a week (45 min each), for 10 weeks.
3305535|NCT01880996|No Intervention|Usual Care|30 gynecological cancer patients scheduled for primary or secondary chemotherapy treatment, will be evaluated by the same measures as the intervention group.
3305536|NCT01881022|Experimental|Psychosexual Intervention|The intervention will consist of 6 weekly sessions of couples psychosexual counseling delivered via videoconferencing.
3305537|NCT01881035|Experimental|Renal nerve denervation|Renal nerve denervation
3305538|NCT01881074||Triclosan containing toothpaste|Patients with type II diabetes will receive triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
3305539|NCT01881074||Non-triclosan containing toothpaste|Patients with type II diabetes will receive non-triclosan containing toothpaste and will be asked to brush their teeth using only this toothpaste for the duration of the study (12 months). Patients will be asked to return for an oral exam, dental cleaning and sample collection for up to 12 months following their baseline appointment.
3305540|NCT01881100|Experimental|resin infiltration|The test group (41 children) had caries lesions treated with the infiltration technique using Icon (DMG, Hamburg, Germany) and fluoride varnish (Duraphat, Colgate Palmolive, Hamburg, Germany)at baseline evaluation. Fluoride varnish was applied every control visit every three months during 1 year.
3305541|NCT01881100|Active Comparator|fluoride varnish|The control group (40 children) had all tooth surfaces including WSL treated with fluoride varnish (Duraphat Colgate Palmolive, Hamburg, Germany)only at baseline evaluation and every control visit every three months during 1 year.
3305542|NCT01881139|Experimental|experimental 1|men with exercise training for 3 months
3305543|NCT01881152|Experimental|Intervention|Educational campaign
3305544|NCT01881152|Other|Control|Usual care
3305545|NCT01881165|Experimental|Cranberry|Each capsule contains 500 mg of cranberry powder at a concentration ratio of 36:1 (36 grams of cranberries equals 1 gram of concentrate).
3305546|NCT01881165|Placebo Comparator|Placebo|A capsule containing control formulation
3305547|NCT01881178|Active Comparator|Apricot|Supplement: Apricot Juice
3305548|NCT01881178|Experimental|Nopalea|Supplement: Nopalea
3305549|NCT01881191||Aubagio MRI|Patients with relapsing-remitting multiple sclerosis who take Aubagio will have an MRI, eye test, blood drawn, and complete a questionnaire.
3305550|NCT01881191||Healthy controls|Subjects who are otherwise healthy, without neurological disorders will have an MRI, eye test, blood drawn, and complete a questionnaire.
3305551|NCT01881204|Experimental|Hesperidin and Calcilock|Subjects will consume 4 cookies containing Hesperidin and Calcilock.
3305552|NCT01881204|Experimental|Hesperidin|Subjects will consume 4 cookies containing Hesperidin, 552mg, daily
3305553|NCT01881204|Placebo Comparator|Control|Subjects will consume 4 cookies daily without Hesperidin or Calcilock.
3305554|NCT01881217|Experimental|BAY1179470 (Dose escalation)|BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3305555|NCT01881217|Experimental|BAY1179470 (additional)|Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3305556|NCT01881217|Experimental|BAY1179470 (expansion)|Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days.
3305557|NCT01881243||Adult patients resuscitated from cardiac arrest|
3305558|NCT01881269||No treatment|No treatment, prospective observational
3305559|NCT01881282|Experimental|Carraghenates Cream|
3305560|NCT01881282|Active Comparator|Mayinglong Musk Hemorrhoid Ointment|
3305561|NCT01881295|Placebo Comparator|Placebo control|Subjects will consume tablets containing no potassium in addition to a basal diet containing 2336 mg potassium
3305562|NCT01881295|Experimental|Low dose potassium gluconate|Subjects will consume 720 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3305563|NCT01881295|Experimental|Medium dose potassium gluconate|Subjects will consume 1440 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3305564|NCT01881295|Experimental|High dose potassium gluconate|Subjects will consume 2160 mg potassium in the form of potassium gluconate tablets daily in addition to a basal diet containing 2336 mg potassium
3305565|NCT01881295|Experimental|Low dose potato|Subjects will consume 720 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3305566|NCT01881295|Experimental|Medium dose potato|Subjects will consume 1440 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3305567|NCT01881295|Experimental|High dose potato|Subjects will consume 2160 mg potassium in the form of potato daily in addition to a basal diet containing 2336 mg potassium
3305568|NCT01881295|Experimental|High dose French fries|Subjects will consume 2160 mg potassium in the form of french fries daily in addition to a basal diet containing 2336 mg potassium
3305569|NCT01881295|Experimental|Basal diet control|Subjects will consume a basal diet containing 2336 mg potassium daily
3305570|NCT01881308|Active Comparator|Stable dose TNF inhibitor|Stable dose TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
3305571|NCT01881308|Experimental|Stepdown and withdrawal of TNF inhibitor|Half-dose of TNF inhibitor for the first four months, thereafter withdrawal of TNF inhibitor. Any co-medication with synthetic DMARDs kept stable.
3305572|NCT01881308|Active Comparator|Stable dose synthetic DMARD|Stable dose of synthetic DMARDs, either monotherapy or combination therapy.
3305573|NCT01881308|Experimental|Synthetic DMARD dose reduction|Half-dose synthetic DMARDs (monotherapy or combination therapy) for the first 12 months of the study. Patients classified as non-failures are re-randomized at 12 months to either continue half-dose synthetic DMARD(s) or withdraw all DMARD(s).
3305574|NCT01881308|Other|ARCTIC follow-up|Patients are treated according to the ARCTIC treatment schedule based on disease activity.
3305575|NCT01881321|Experimental|Group 1: Counseling Intervention|Contraceptive counseling session based on the principles of motivational interviewing
3305576|NCT01881321|No Intervention|Group 2: Usual Care|The standard clinic-based contraceptive counseling with no additional or theory-based contraceptive counseling session
3305577|NCT01881347|Experimental|Active First|Active resveratrol first, placebo second
3305578|NCT01881347|Experimental|Placebo first|Placebo first, active resveratrol second
3305579|NCT01881360|Experimental|Gluten-free diet|
3305580|NCT01881360|Active Comparator|Hypocaloric diet|
3305581|NCT01881386||Lymphoma|Lymphoma patients before and after receiving standard CHOP therapy
3305582|NCT01881386||Metastatic Colorectal|Patients with metastatic colorectal cancer
3305583|NCT01881386||Phase 1|Patients enrolled in Phase 1 clinical trials of new agents, whose mechanism of action is expected to lead to changes in lactate concentration
3305584|NCT01881386||Brain|Patients with primary brain tumours and patients with cerebral lymphoma
3305585|NCT01881399|Experimental|Fluorescence/Virtual cholangiography/IOC|"Prior to cholecystectomy, patients will undergo:~Fluorescence cholangiography (visualization following up to a maximum of 0.5 mg/kg ICG - usually 10 ml of 0,5 mg/ml solution)~Virtual cholangiography (enhanced-reality) superimposed on fluorescence images~Conventional IOC (intraoperative cholangiography)"
3305586|NCT01881425|Experimental|InnFocus MicroShunt|InnFocus MicroShunt
3305587|NCT01881425|Active Comparator|Trabeculectomy|glaucoma surgery to reduce IOP
3305588|NCT01881438||Participants exposed to oral fluoroquinolones|Oral fluoroquinolones in this study are ciprofloxacin, levofloxacin, gatifloxacin, gemifloxacin, moxifloxacin, norfloxacin, and ofloxacin.
3305589|NCT01881464||endothelial dysfunction assessment|This study is a one arm study . In this arm we will assess endothelial function (with Endopath device) in patients with Crohn's disease, before and after treatment of anti TNF α and other medication, and evaluate the possible role of tumor necrosis factor (TNF)-α in the pathophysiology of this abnormality.
3305590|NCT01881477|Experimental|kinetics modalities|passive movements active movements assisted movements resisted movements
3305591|NCT01881490|Active Comparator|Group 1|120 Children with Crohn's disease undergoing MRE & colonoscopy will be enrolled and followed for 18 months. MRE exam will be repeated at 18 months.
3305592|NCT01881490|Active Comparator|Group 2|120 children with Crohn's disease undergoing colonoscopy will be recruited and will have an MRE/pelvic MRI performed. The two or three contending versions of each index (PICMI and pMEDIC) developed based on Group 1, will be then subjected to head-to-head evaluation of Group 2.
3305593|NCT01881503|Other|All subjects|all qualifying subjects will receive HBOC-201 (Hemopure) to treat their life-threatening anemia
3305594|NCT01881516|Active Comparator|Acupuncture|Participants will receive 30-min sessions of true acupuncture per week after randomization for 6 weeks
3305595|NCT01881516|Sham Comparator|sham acupuncture|Participants will receive 30-min sessions of sham acupuncture per week after randomization for 6 weeks.
3305596|NCT01881529||Limited Scleroderma|
3305597|NCT01881529||Diffuse Scleroderma|
3305598|NCT01881555|Other|FRACTIONAL FLOW RESERVE|"Patients will have FFR measured in each diseased vessel identified by the coronary angiographic evaluation. Intra-coronary adenosine (at least 100 micrograms performed 2 times) OR intravenous adenosine (at a dose of 140µg/kg/min during at least 4 minutes) will be administered prior to FFR assessment.~Revascularization strategy will be based upon FFR findings and revascularization either by coronary stenting or CABG will only be performed on target lesions with FFR≤0.8."
3305599|NCT01881555|Other|ANGIOGRAPHY|Patients undergo an angiography. Based on angiographic evaluation, the physicians define the revascularization strategy.
3305600|NCT01881568|Experimental|Experimental|"Topical administration of 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure.~Intravenous administration of Normal saline (0.9% sodium chloride) as follow:~100mL before tourniquet realised~100mL 3 hours after surgery"
3305601|NCT01881568|Active Comparator|Comparator|"Topical administration of Normal saline (0.9% sodium chloride) as follow:~50mL by irrigation before wound closure~50mL by intraarticular administration (Drenofast) after wound closure~Intravenous administration of two dosis of Tranexamic Acid as follow:~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), before tourniquet realised~15mg/kg of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride), 3 hours after surgery"
3305602|NCT01881581|Experimental|Lower dose DNA or Placebo|2.0 mL lower dose D-GPEi (0.5mg) or Saline solution at weeks 0
3305603|NCT01881581|Experimental|Medium dose DNA or Placebo|2.0 mL medium dose D-GPEi (2mg) or Saline solution at weeks 0
3305604|NCT01881581|Experimental|High dose DNA or Placebo|2.0 mL high dose D-GPEi (4mg) or Saline solution at weeks 0
3305605|NCT01881581|Experimental|Lower dose MVA or Placebo|100μL lower dose M-GPE (3×10^7pfu) or Saline solution at weeks 0
3305606|NCT01881581|Experimental|Medium dose MVA or Placebo|100μL medium dose M-GPE (1×10^8pfu) or Saline solution at weeks 0
3305607|NCT01881581|Experimental|High dose MVA or Placebo|300μL high dose M-GPE (3×10^8pfu) or Saline solution at weeks 0
3305608|NCT01881581|Experimental|Low dose DNA+MVA or Placebo control|The dose below the maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1; The dose below the maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
3305609|NCT01881581|Experimental|High dose DNA+MVA or Placebo control|The maximum tolerated dose of D-GPEi or 2.0 mL Saline solution at week 0,1;The maximum tolerated dose of M-GPE or 100/300μL Saline solution at week 2,3
3305610|NCT01881594|Active Comparator|No stimulation|unstimulated patients prior to surgery,ileostomy closure surgery without prior stimulation of efferent limb.
3305611|NCT01881594|Experimental|Stimulation|stimulation of the efferent limb of the ileostomy prior to ileostomy closure.
3305612|NCT01881607|No Intervention|Control|Schoolchildren aged 12-13 years in the first year of Compulsory Secondary Education (Enseñanza Secundaria Obligatoria in the Spanish educational system) in the city of Terrassa. The CONTROL arm is formed by schoolchildren in schools that willnot receive the intervention and will continue with ongoing (usual) health education sessions.
3305613|NCT01881607|Experimental|Intervention|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
3305614|NCT01881633|Experimental|ISU302|15 U/kg I.V. injection
3305615|NCT01881633|Experimental|ISU302 30 U/kg|Drug ISU302 I.V. injection
3305616|NCT01881633|Experimental|ISU302 60 U/kg|Drug ISU302 I.V. injection
3305617|NCT01881633|Placebo Comparator|Placebo|ISU302 Placebo I.V. injection
3305618|NCT01881646|Experimental|Positron emission tomography (PET)|Positron emission tomography (PET) using [11C]PBR28
3305619|NCT01881659||Women attending cervical screening|Women aged 30-64 years who signed informed consent and comply with inclusion and exclusion criteria.
3305620|NCT01881672||Coma patients in ICU under mechanical ventilation|
3305621|NCT01881711|Experimental|SCMP plus Imaging|SCMP plus Imaging will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
3305622|NCT01881711|Active Comparator|Imaging Alone|Imaging alone will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery.
3305623|NCT01881711|Experimental|SCMP Rule Out for Low Risk Cases|"SCMP results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
3305624|NCT01881711|Active Comparator|Imaging Rule for Low Risk Cases|"Imaging results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Negative Predictive Value in ruling out shunt malfunction"
3305625|NCT01881711|Experimental|SCMP plus Imaging in Uncertain Cases|"SCMP plus imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
3305626|NCT01881711|Active Comparator|Imaging alone in Uncertain Cases|"Imaging results in patients who are admitted for observation results in patients judged by the physician to be Unlikely to require shunt surgery will be compared to clinical outcomes within 7 days of ED/NC visit - either shunt obstruction confirmed during shunt revision surgery or shunt patency confirmed by no surgery or patency confirmed in surgery - to determine Positive and Negative Predictive Value"
3305627|NCT01881724|No Intervention|Usual Care|
3305628|NCT01881724|Experimental|sleep education program|
3305629|NCT01881763|Experimental|Ketamine|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
3305630|NCT01881763|Active Comparator|Methohexital|Participants will be randomized 1:1 to either Ketamine (experimental condition) or Methohexital anesthesia (active comparator)
3305631|NCT01881802||morphine or heroin dependence patients|
3305632|NCT01881802||normal control group|
3305633|NCT01881815||No treatment|No cohort as this study is not using a treatment or intervention only swabs are being collected.
3305634|NCT01881841|No Intervention|Treatment As Usual|Those randomized to Treatment as Usual (TAU) will not complete cMET but will receive standard treatment from the doctor.
3305635|NCT01881841|Experimental|cMET|Those randomized to cMET will complete a 2-session computerized Motivational Enhancement Therapy (cMET) intervention.
3305636|NCT01881854||craniopharyngioma|Patients treated for craniopharyngioma, most of them on pituitary substitution therapy
3305637|NCT01881854||Healthy controls|matched for gender, age and BMI to the patients
3305638|NCT01881880|Other|Tomosynthesis|Bilateral mammography with 4 views Tomosynthesis
3305639|NCT01881893|No Intervention|Usual Care|Patients in this arm of the study will continue to receive their regular level of care.
3380932|NCT04255433|Active Comparator|Dulaglutide|Dulaglutide administered SC once a week.
3380933|NCT04251221|Experimental|Social Drinkers|Subjects will drink an alcohol dose designed to achieve a BAL of 0.08.
3380934|NCT04249895||Main Cohort|All patients are undergoing radiotherapy in Tata Medical Center
3380935|NCT04249401||Reduced dose NOAC|Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)
3305640|NCT01881893|Experimental|ACHD-CARE Program|"Group based psychosocial intervention.~Educational: congenital heart disease information~Behavioral: cognitive behavioral therapy~Behavioral: social interactions and communication skills"
3305641|NCT01881906|Other|Control - usual care|"The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment (switch maintenance) will be offered training after 12 weeks, although they have not completed chemotherapy."
3305642|NCT01881906|Other|Exercise + usual care|The supervised exercise training is carried out in groups of 12-16 patients and each session has a duration of 1.5 hours. The training comprised warm up exercises, strength and fitness training as well as stretching. Warm up exercises consisted of 10 minutes of light, stationery cycling, adjusted to 60-90% of the patient's maximum HR. The practical aim of strength training was to complete 3 series of 5-8 sets, with 70-90% of 1RM. Cardiovascular training was carried out as interval training on stationery bikes. Intensity was equivalent to 85-95% of each patient's maximum HR and lasted approximately 10-15 minutes. After the training session, 5-10 minutes were dedicated to stretching the large muscle groups in order to increase agility. Following each training session, progressive relaxation of 15-20 minutes was performed.
3305643|NCT01881919|Experimental|Treatment|Daily intake of Quercetin supplement 500mg tablet for 28 days with meal (breakfast preferred.)
3305644|NCT01881919|Placebo Comparator|Placebo|Daily intake of Placebo (lactose) tablet for 28 days with meal (breakfast preferred)
3305645|NCT01881945|Experimental|Physiological measurments|
3305646|NCT01881958|Experimental|DiaPep277®|
3305647|NCT01881971|Placebo Comparator|Placebo|manufactured sugar pill to mimic rouvastatin once a day for 24 weeks
3305648|NCT01881971|Experimental|Rouvastatin calcium|Rouvastatin calcium once a day by mouth for 24 weeks.
3305649|NCT01881997|Placebo Comparator|Normal Saline|IM normal saline
3305650|NCT01881997|Experimental|Fentanyl|IM Fentanyl
3305651|NCT01882010|Sham Comparator|Controls|Caregivers, spouse, friends, relatives of PD patients, have blood draws, MEG.
3305652|NCT01882010|Placebo Comparator|PD Patients placebo|PD patients that receive placebo, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
3305653|NCT01882010|Experimental|PD Patients sargramostim|PD patients that receive Leukine, have blood draw, physical exam and UPDRS part III assessment, MEG, Motion analysis.
3305654|NCT01882023||Eating disorder|Patients currently in treatment for eating disorders.
3305655|NCT01882023||Healthy Controls|Age- and gender matched healthy controls.
3305656|NCT01882036|Active Comparator|Gastric Bypass w/ matched hypocaloric diet|
3305657|NCT01882036|Active Comparator|Hypocaloric Diet|
3305658|NCT01882049|Experimental|Treatment|Use of Realize gastric band (Ethicon) in adolescents for weight reduction
3305659|NCT01882075|Active Comparator|Open loop|fluid replacement (hydroxyethyl starch 130/0.4) is decided by the physicians according to continuous cardiac output measured by LidCO rapid device
3305660|NCT01882075|Experimental|Closed-loop|Fluid replacement is automated. An algorithm has been developed ; the input value is continuous cardiac output measured by LidCO rapid device; the computer steers iv infusion of hydroxyethyl starch 130/0.4.
3305661|NCT01882101|Experimental|Posterior tibial nerve stimulation|
3305662|NCT01882101|Experimental|Biofeedback|
3305663|NCT01882127|Active Comparator|High dose-DEX|40 patients are enrolled to take dexamethasone orally at a dose of 40 mg daily for 4 days
3305664|NCT01882127|Experimental|ATRA & High dose-DEX|40 patients are enrolled to take Dexamethasone orally at 40mg a day for 4 days and all-trans retinoic acid at 10mg tablet every 8 hours a day for 12 consecutive weeks.
3305665|NCT01882140|Experimental|Study Group|Patients in the Study Group will receive daily treatment for 60 minutes. The treatment is initiated within 24 hours following surgery to achieve graft. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP. These Electrical Stimulation by Capacitive Field devices do not produce heat or cause any sensation in tissue. The equipment will produce an electrical stimulation of low intensity pulsed output (1.5 MHz, 1:4 duty cycles, 30mW). The electrodes consist of two metal plates (20x20cm) separated by an insulating material.
3305666|NCT01882140|Placebo Comparator|Control Group (Sham devices)|Patients in the control group (Sham group) will receive the same treatment but the device remains off. Use of Electrical Stimulation by Capacitive Field was the only addition to the current standard of care of the Emergency Unit of HC-FMRP/USP.
3305667|NCT01882153|Experimental|Developmentally Based Intervention|
3305668|NCT01882153|Experimental|Behaviorally Based Intervention|
3305669|NCT01882166|Experimental|fostimon|subcutaneous 150 IE Fostimon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
3305670|NCT01882166|Experimental|puregon|subcutaneous 150 IE Puregon®. When leading follicles are > 17 mm ovulation will be induced by Ovitrelle® 500μg sc(hCG-injection). Ovum pick up (OPU) will be performed 32-36 hours later.
3305671|NCT01882179|Placebo Comparator|Placebo|Intravenous saline bolus prior to PPCI followed by oral placebo for 3 months
3305672|NCT01882179|Active Comparator|Mineralocorticoid receptor antagonist|"1st dose (day 0) given i.v. (potassium-canrenoate), before primary PCI day 1 - 12 weeks: spironolactone 25mg daily, which is uptitrated to 50mg daily after 2 weeks, if possible~In case the LVEF <40% on baseline MRI and the patient shows signs of heart failure or is diabetic, the patient will receive open label eplerenone instead of the study drug, according to current guidelines."
3305673|NCT01882192|Experimental|Family physical activity planning|The intervention condition will receive the same guidelines as the comparison condition but will also be provided with family physical activity planning material.
3305674|NCT01882192|No Intervention|Control|The standard (comparison group) package will consist of Canada's family guide to physical activity guidelines recommending 60 minutes of activity a day in bouts as short as five to ten minutes for children and a breakdown of ways for the family to achieve this physical activity (structured, unstructured, endurance, strength, activities, less than 60 minutes of sustained sedentary activity, reduce screen viewing by 30 min per day) commensurate with this guide. This will include the new insert by CSEP. The guide also contains arguments and information about the benefits of physical activity.
3305675|NCT01882205|Active Comparator|OLYMPUS CHROMO|Group A: HDTV Olympus colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3305676|NCT01882205|Experimental|OLYMPUS NBI|Group B: Virtual chromoendoscopy: HDTV Olympus colonoscopes and Narrow band Imaging (NBI)
3305677|NCT01882205|Active Comparator|FUJINON CHROMO|Group C: CCD Fujinon colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3305678|NCT01882205|Experimental|FUJINON FICE|Group D: Virtual chromoendoscopy: CCD Fujinon colonoscopes and Fujinon Intelligent Color Enhancement n° 4
3305679|NCT01882205|Active Comparator|PENTAX CHROMO|Group E: HD-Pentax colonoscopes and Chromo-endoscopy, methylene blue 0.1%
3305680|NCT01882205|Experimental|PENTX i-scan|Group F: Virtual chromoendoscopy: HD Pentax colonoscopes and I-scan 2 settings
3305681|NCT01882218|Active Comparator|Standard treatment|Standard liver surgery and post-operative treatment
3305682|NCT01882218|Experimental|Galactose|Standard liver surgery with direct peritoneal resuscitation with galactose after surgery.
3305683|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Patients will have dynamic contrast-enhanced (DCE), diffusion-weighted (DW), magnetization transfer (MT), and chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI) performed before and after 1 cycle of chemotherapy.
3305684|NCT01882244|Experimental|Neural Pathfinder Training|Neural Pathfinder training (PATH) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the PATH intervention.
3305685|NCT01882244|Active Comparator|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of training sessions with a trainer (1-2 hour sessions, average of 1 session per week), up to 3 hours of telephone contact with the trainer (about 15 minutes per week), and approximately 20 hours of home practice). Some subjects will only receive the EDU intervention. Some subjects will receive both the PATH and EDU interventions.
3305686|NCT01882270||Mild Pericoronitis|Those with mild signs/symptoms of pericoronitis affecting at least one lower 3rd molar with adjacent 2nd molar will be monitored for 12 months following study entry or 3 months for those electing to have 3rd molar extraction.
3305687|NCT01882283|Experimental|Tea Treatment Group|5 cups brewed tea beverage per day for 28 days, brewed from 700 mg of black tea solids per cup
3305688|NCT01882283|Placebo Comparator|Placebo Group|5 cups tea-like placebo per day for 28 days. Placebo was exactly matched to tea except for flavonoid composition. Placebo was flavonoid-free.
3305689|NCT01882296|Experimental|AGSPT_10|tablet, 10mg, QD, 7days
3305690|NCT01882296|Experimental|AGSPT_20|tablet, 20mg, QD, 7days
3305691|NCT01882296|Experimental|AGSPT_40|tablet, 20mg x 2, QD, 7days
3305692|NCT01882296|Active Comparator|Pantoprazole_20|tablet, 20mg, QD, 7days
3305693|NCT01882296|Active Comparator|Pantoprazole_40|tablet, 40mg, QD, 7days
3305694|NCT01882322|Experimental|Advagraf conversion group|Oral
3305695|NCT01882322|Active Comparator|Prograf maintenance group|Oral
3305696|NCT01882335|Experimental|Behavioral|Peer support for mothers to encourage them to exclusively breastfeed their babies for 6 months
3305697|NCT01882335|No Intervention|Control|No peer support for exclusive breastfeeding
3305698|NCT01882348|No Intervention|Usual Care Control|"Control groups will receive equal number of contacts for training in preparation for enrollment and data collection for the study.~Clinicians will be given the option to receive a standard American Academy of Pediatrics tobacco control pamphlet to distribute.~Control groups have the option to receive access to the CEASE online module intervention at the conclusion of the research study which allows practitioners in this group to receive 26 continuing education credit hours."
3305699|NCT01882348|Experimental|Intervention|The Intervention Group will receive the CEASE Intervention
3305700|NCT01882361|Active Comparator|injectable naltrexone|One dose of injectable extended release naltrexone (Vivitrol), 380mg dosage, given every four weeks in a 48-week trial.
3305701|NCT01882361|Placebo Comparator|placebo injection for naltrexone|placebo comparator injection starting at week 24 in a 48-week trial.
3305702|NCT01882374|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of hematologic malignancies. Treatment dose is 300 mcg/kg/day TXA127.
3305703|NCT01882387|Experimental|TXA127, blood draws, physical exams|Single-arm safety/efficacy trial of TXA127 (Angiotensin 1-7) in subjects undergoing allogeneic peripheral blood stem cell transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect. Treatment dose is 300 mcg/kg/day TXA127.
3305704|NCT01882400|Experimental|Bisphosphonate treatment|Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements
3305705|NCT01882426|Active Comparator|Enhanced treatment algorithm|Treatment algorithm featuring the early use of combination therapy, treatment intensification guided by objective assessments of inflammation and the use of remission as a therapeutic goal
3305706|NCT01882426|Placebo Comparator|Usual Care|These subjects will be managed according to local treatment guidelines for the treatment of UC.
3305707|NCT01882452|Experimental|Memory Specificity Training|Five weekly one-hour sessions of memory specificity training administered in groups of 5-8 participants.
3305708|NCT01882452|Active Comparator|Education and Support|Five weekly one-hour sessions of an education-and-discussion supportive intervention, administered in groups of 5-8 participants.
3305709|NCT01882478||failure to respond to RF ablation|patients undergoing endoscopic RF ablation therapy with persistent BE with HGD or IMCA despite 2 or more serial RF ablation treatment sessions
3305710|NCT01882491|Placebo Comparator|Placebo|
3305711|NCT01882491|Experimental|gevokizumab|
3305712|NCT01882504|Experimental|gevokizumab|Solution for subcutaneous injection
3305713|NCT01882517|Active Comparator|Yogurt that contains plant stanol esters|Dietary Supplement: Yogurt that contains plant stanol esters
3305714|NCT01882517|Placebo Comparator|Placebo yogurt|Dietary Supplement: Placebo yogurt
3305715|NCT01882530|Placebo Comparator|Control group C: Placebo|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305716|NCT01882530|Experimental|Group P: Paracetamol|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305717|NCT01882530|Experimental|Group N: Nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305718|NCT01882530|Experimental|Group K: Ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305719|NCT01882530|Experimental|Group PN: paracetamol and nefopam|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305720|NCT01882530|Experimental|Group PK: paracetamol and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305721|NCT01882530|Experimental|Group NK: nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305722|NCT01882530|Experimental|Group PNK: paracetamol, nefopam and ketoprofen|All patients will receive treatment intraoperatively (IV) in 30 minutes, 60 minutes before the end of the intervention, then postoperatively every 6 hours for 48 hours.
3305723|NCT01882556|Experimental|Botulinum Toxin - Type A (onabotulinumtoxinA)|Botulinum Toxin - Type A. One set of injections of up to 200 Units of Botox (Allergan). Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
3305724|NCT01882556|Placebo Comparator|0.9% NaCl Saline Injection|Saline - Injected to Biceps, Brachialis, Flexor Dig Superficialis, Flexor Dig Profundus, Flexor Carpi Radialis and Flexor Carpi Ulnaris.
3305725|NCT01882569||Back surgery|
3305726|NCT01882595|Experimental|Nebulization through the tracheostomy|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
3305727|NCT01882595|Active Comparator|Nebulization through the mouth|Each subjects received two nebulization sessions. The first session was performed prior the tracheostomy removal (through the tracheostomy) and the second one when the when the tracheostome was totally scared (through the mouth)
3305728|NCT01882608|No Intervention|Treatment-as-usual|Treatment-as-usual, with no active intervention or follow-up. TAU patients will have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
3305729|NCT01882608|Experimental|Mental Health Telemetry (MHT)|Patients in the MHT group will be encouraged to provide daily symptom self-reports using MHT. MHT patients will also have readmission events monitored over the six-month interval by the study RA via periodic chart reviews and updates from their clinicians
3305730|NCT01882621|Active Comparator|Monosialoganglioside(GM1)|Monosialoganglioside(GM1)80mg + N.S 250ml,qd,D0-D3
3305731|NCT01882621|Placebo Comparator|normal saline|placebo 80mg + N.S 250ml,qd,D0-D3
3305732|NCT01882634|Experimental|Ultrasound arm|
3305733|NCT01882660|Experimental|Decitabine treatment|Treatment with decitabine
3305734|NCT01882673|Experimental|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivate tobacco quitline use
3305735|NCT01882673|Active Comparator|Nutrition Control|Computer delivered nutrition education
3305736|NCT01882686|Experimental|Classification Based Cognitive Functional Therapy|
3305737|NCT01882699|Experimental|Cereve sleep system|Cereve sleep system
3305738|NCT01882712|Experimental|CD07805/47 Gel 0.5%|active arm
3305739|NCT01882712|Placebo Comparator|CD07805/47 Gel Placebo|Comparator arm
3305740|NCT01882751||ConforMIS|Patients with ConforMIS implants
3305741|NCT01882751||Standard Total Knee Implant|Patients implanted with standard total knee implant
3305742|NCT01882777|No Intervention|Existing water management and cooking practices|Households in the control arm continue following their existing drinking water management and cooking practices
3305743|NCT01882777|Active Comparator|Provision of water filters and improved cookstoves|Households in intervention arm are provided with drinking water filters and improved cook stoves
3305744|NCT01882842|Experimental|Endometrial biopsy arm|Participants randomised to this arm arm will undergo an endometrial biopsy procedure using Pipelle endometrial sampler (Pipelle de Cornier, Laboratoire CCD, Paris, France) or Wallace/ Wallach endometrial sampler as an alternative device on cycle day LH+7 to LH+9 of the cycle directly preceding commencement of down-regulation prior to IVF or ICSI treatment. A transvaginal ultrasound scan will be performed prior to the biopsy.
3305745|NCT01882842|No Intervention|Control group|Participants randomised to control group will undergo a transvaginal ultrasound scan on day LH+7 to LH+9 of the cycle directly preceding commencement of IVF/ICSI treatment.
3305746|NCT01882881|Active Comparator|Healthy American Control Diet|
3305747|NCT01882881|Experimental|Dark Chocolate/Cocoa Diet|
3305748|NCT01882881|Experimental|Almond Diet|
3305749|NCT01882881|Experimental|Dark Chocolate/Cocoa + Almond Diet|
3305750|NCT01882894|Experimental|Custom PFO orthosis|This is a custom made orthosis
3305751|NCT01882894|Placebo Comparator|Faux foot orthosis|Foam insert without arch support
3305752|NCT01882920|Experimental|Goal directed therapy intravenous restricitve fluid protocol|
3305753|NCT01882920|Active Comparator|Control arm|
3305754|NCT01882933|Experimental|Curative Gastrectomy + HIPEC|Curative gastrectomy with D1-D2 lymph node dissection + HIPEC with oxaliplatin
3380936|NCT04249401||Vitamin K antagonists (VKA)|Participants with NVAF initiating treatment with vitamin K antagonists (VKA)
3305755|NCT01882933|Other|Curative Gastrectomy|Curative gastrectomy with D1-D2 lymph node dissection
3305756|NCT01882946|Experimental|DCVax-Direct|DCVax-Direct: autologous, activated dendritic cells for intratumoral injection
3305757|NCT01882959||Placebo|
3305758|NCT01882959||Intervention|Radiofrequncy Denervation
3305759|NCT01882972|Experimental|Exercise|Exercise 12 week home-based resistance exercise training intervention. Participants will be coached to engage in resistance training 3 days per week and aerobic exercise for 30 minutes at least 5 days per week for 12 weeks.
3305760|NCT01882972|Placebo Comparator|control|Participants in the attention control arm will not be asked to cease activity they already participate in but will be instructed not to begin a new exercise program for 12 weeks. Participants will receive a meditation CD to use daily to account for the time intervention arm participants are engaged in exercise.
3305761|NCT01882998|Experimental|Women-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled individually and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
3305762|NCT01882998|Experimental|Couples-Extended Repeat Testing and Enhanced Counseling|Pregnant/breastfeeding women enrolled in couples with their male partners and randomized to the intervention arm will receive extended repeat HIV testing and enhanced counseling at the time of labor and delivery and throughout the lactation period at 3, 6, 12, 18 and 24 months postpartum or until cessation of breastfeeding, whichever occurs first.
3305763|NCT01883011|Experimental|Piracetam|"IV infusion 12 g piracetam in 60 ml~IV Ampoules 3 g piracetam in 15 ml~Oral solution 33 % piracetam (bottle of 125 ml)~Oral tablets 1200 mg piracetam (blisters of 10 tablets)"
3305764|NCT01883011|Placebo Comparator|Placebo|"IV infusion 12 g placebo in 60 ml~IV Ampoules 3 g placebo in 15 ml~Oral solution 33% placebo (bottle of 125 ml)~Oral tablets 1200 mg placebo (blisters of 10 tablets)~All IV forms were identical in presentation, size and color to allow a double blind design.~All oral forms were identical in shape, size, color and taste to allow a double blind design."
3305765|NCT01883024|Other|Type 1 diabetes|
3305766|NCT01883037||Laboratory blood glucose|Blood glucose value from Lab
3305767|NCT01883037||HemoCue Glucose 201 RT|Blood glucose value from HemoCue Glucose 201 RT
3305768|NCT01883050|Other|Self Monitoring of Software Application|log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
3305769|NCT01883050|No Intervention|No Intervention|No Intervention
3305770|NCT01883063|Experimental|WRx™ Intramedullary Nail|Patients in this arm of the study will be treated with a minimally invasive WRx™ Intramedullary Nail for their wrist fracture.
3305771|NCT01883063|Active Comparator|Non surgical treatment (Cast)|Patients in this arm of the study will be treated with a cast for their wrist fracture.
3305772|NCT01883076|Experimental|autologous cell-based delivery|autologous cell-based delivery a target dose of 3 million cells / kg of body weight will be delivered into the right heart muscle at the time of surgery. Cells are derived from autologous (self) umbilical cord blood.
3305773|NCT01883089|Other|Other|Participants will be recruited to complete a 90 day daily monitoring study during which time will be invited to participate in a 4 week brief alcohol intervention during days 31-60 (i.e., second month).
3305774|NCT01883102|Experimental|Capsaicin 0.1%|Capsaicin cream 0.1% will be applied to site A or B on the subject's abdomen daily for 7 days.
3305775|NCT01883102|Placebo Comparator|Placebo/cream without 0.1% capsaicin|The placebo cream will be applied to site A or B on the subject's abdomen daily for 7 days.
3305776|NCT01883115||Telescopic group|All eligible patients referred with inguinal/femoral hernias will be enrolled into the study from February 2013
3305777|NCT01883128|Experimental|Whole body MRI|Comparing the detection rate of metastases of whole body MRI compared to current standard of care tests - Choline PET and Bone scan.
3305778|NCT01883128|Experimental|MRI Targeted Biopsies|Transperineal MRI-targeted biopsies and whole-gland transperineal prostate mapping biopsies
3305779|NCT01883128|Experimental|Focal Salvage Therapy|Focal salvage HIFU and cryotherapy of recurrent prostate cancer tumors only
3305780|NCT01883154||IUGR pregnancies|Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile
3305781|NCT01883154||pregnancies with Gestational Diabetes|Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test
3305782|NCT01883154||Pre Gestational Diabetes|A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.
3305783|NCT01883154||IVF pregnancies|
3305784|NCT01883167|Experimental|Febuxostat|"Days 1-7: febuxostat 40 mg qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: RDEA3170 10 mg or placebo qd."
3305785|NCT01883167|Experimental|RDEA3170|"Days 1-7: RDEA3170 10 mg or placebo qd. Days 8-14: RDEA3170 10 mg or placebo qd in combination with febuxostat 40 mg qd.~Days 15-21: febuxostat 40 mg qd."
3305786|NCT01883180|Experimental|ATG 7.5mg/kg|ATG 7.5mg/kg group refers to treatment with ATG in the total dose of 7.5mg/kg.
3305787|NCT01883180|Experimental|ATG 10mg/kg|ATG 10mg/kg group refers to treatment with ATG in the total dose of 10mg/kg.
3305788|NCT01883193|Experimental|Arm 1: Preconception|Arm 1 will commence the comprehensive maternal nutrition intervention at 3-7 months postpartum. Delivery of the intervention will be monitored biweekly by collection of empty and unused sachets of the lipid-based supplement (LNS), maternal report, and casual observation of household behavior. Arm 1 participants will be weighed monthly and Body Mass Index (BMI) calculated. If BMI <20 an additional energy supplement will be provided. Menstrual history will be obtained at each visit and a urine pregnancy test will be performed if menses is delayed.
3305789|NCT01883193|Experimental|Arm 2: Pregnancy|Participants in Arm 2 will commence the same comprehensive maternal nutrition intervention at 12 weeks gestation.
3305790|NCT01883193|No Intervention|Arm 3: Control|Participants in Arm 3 will receive biweekly visits to monitor pregnancy status. No health advice will be given other than information about prenatal care, location of delivery, and breastfeeding education in the third trimester.
3305791|NCT01883219|Experimental|TKI therapy|Treatment with TKI will be initiated if the level of BCR-ABL transcript in the bone marrow is detectable and transcript levels increased for two consecutive tests. TKIs will be given for patients without BCR/ABL mutations and sensitive TKIs will be given for those with mutations.
3305792|NCT01883232|Active Comparator|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine
3305793|NCT01883232|Experimental|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4% mixed with the onset mixing pen
3305794|NCT01883245|Active Comparator|sham tDCS|This group will receive sham-tDCS for 5 days. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 30 seconds, with an intensity of 1 milliampere.
3305795|NCT01883245|Experimental|real tDCS|"This group will receive continuous stimulation lasting 20 minutes daily, for 5 days.~Transcranial direct current stimulation (tDCS) will be administered as follows. The anode will be placed on the primary motor cortex (M1) of the dominant hemisphere and the cathode on the contralateral supraorbital area. The direct current is transmitted through a pair of sponge electrodes, with a surface of 35 cm2 (7x5), soaked in saline solution and, it is generated by a constant current stimulator, with rechargeable batteries. This continuous stimulation lasted 20 minutes, with an intensity of 1 milliampere."
3305796|NCT01883258|Experimental|High intensity aerobic interval training|Type 2 diabetes subjects will complete 8 weeks of high intensity aerobic interval exercise training.
3305797|NCT01883258|Experimental|Continuous moderate intensity exercise|Type 2 diabetes subjects will complete 8 weeks of continuous moderate intensity exercise training.
3305798|NCT01883258|No Intervention|Non-exercise control group|Type 2 diabetes subjects assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
3305799|NCT01883258|No Intervention|Healthy control group|Healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
3305800|NCT01883271|Experimental|High intensity aerobic interval training|Older adults will complete 8 weeks of high intensity aerobic interval exercise training.
3305801|NCT01883271|Experimental|Continuous moderate intensity exercise|Older adults will complete 8 weeks of continuous moderate intensity exercise training.
3305802|NCT01883271|No Intervention|Non-exercise control group|Older adults assigned to the non-exercise control group will maintain their normal lifestyle for 8 weeks.
3305803|NCT01883271|No Intervention|Young Healthy controls|Young healthy subjects will be assigned to the healthy control group and will undergo baseline measures only.
3305804|NCT01883284|Experimental|Cystic Fibrosis patients (CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
3305805|NCT01883284|Other|Control subjects (non CF)|Tests in vitro after sampling nasal cells of CF patients or controls are the intervention done on these subjects
3305806|NCT01883297|Experimental|Re-Stimulated Tumor-Infiltrating Lymphocytes and interleukin-2|Cyclophosphamide will be given prior to Re-Stimulated Tumor-Infiltrating Lymphocytes, and interleukin-2.
3305807|NCT01883310|Active Comparator|sham tDCS + TOCT|The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
3305808|NCT01883310|Experimental|real tDCS + TOCT|the real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
3305809|NCT01883323|Experimental|Cyclophosphamide and Fludarabine followed by TILs and IL-2|Cyclophosphamide, i.v., 60mg/kg per day for 2 days and Fludarabine, i.v., 25mg/m2 per day for 5 days; then Tumor-Infiltrating Lymphocytes, i.v., 1x10^10 - 1.6x10^11 cells and Low-Dose Interleukin, i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
3305810|NCT01883349||ESRD patients|ESRD patients awaiting renal transplantation
3305811|NCT01883349||Control Arm|Subjects without kidney disease
3305812|NCT01883375|Experimental|Dignity Talk dyad completers|Those dyads where both patient and family member co-participant complete the protocol using the Dignity Talk Communication Topics
3305813|NCT01883375|Experimental|Dignity Talk non-completers|Those dyads where patient and family member co-participant either do not complete the protocol or do not use the Dignity Talk Communication Topics (November 2016 - the investigators have not as yet enrolled any participants who have not completed the study without using the Dignity Talk Topics. However some participants have withdrawn from the study without completing.
3305814|NCT01883401|Experimental|High dose strawberry|50g freeze-dried strawberries/day
3305815|NCT01883401|Experimental|Low-dose strawberry|25g freeze-dried strawberries/day
3305816|NCT01883401|Other|Fiber/calorie control (high dose)|Dietary fiber (8g)
3305817|NCT01883401|Other|Fiber/calorie control (low dose)|Dietary fiber (4g)
3305818|NCT01883414|Active Comparator|Group A|Subjects randomized to Group A will receive Ultherapy™ treatment on the superior or lateral half of the scar.
3305819|NCT01883414|Active Comparator|Group B|Subjects randomized to Group B will receive Ultherapy™ treatment on the inferior or medial half of the scar.
3305820|NCT01883466|Experimental|Diesel exhaust exposure|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise
3305821|NCT01883466|Experimental|Biodiesel exhaust exposure|1 hour exposure to dilute biodiesel exhaust (generated at same running conditions as diesel exhaust) during intermittent exercise
3305822|NCT01883479|Experimental|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
3305823|NCT01883479|Experimental|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
3305824|NCT01883479|No Intervention|Usual care|Participants receive usual care and will receive their choice of the interventions at 9 months.
3305825|NCT01883505|Experimental|ND0612|levodopa and carbidopa solution
3305826|NCT01883505|Placebo Comparator|Placebo|Saline
3305827|NCT01883518|Experimental|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
3305828|NCT01883531|Placebo Comparator|Inhaled Placebo|Eight-week treatment period with inhaled placebo b.d.
3305829|NCT01883531|Active Comparator|Inhaled Mannitol|Eight-week treatment period Inhaled Mannitol 400 mg b.d.
3305830|NCT01883544|Experimental|ALXN1007|Infusion of ALXN1007
3305831|NCT01883544|Placebo Comparator|placebo|Infusion placebo
3305832|NCT01883570|Experimental|trained visual search strategy|An expert's visual search strategy for reading the chest x-ray was recorded using a gaze tracking device. This strategy was reproduced using a dynamic cursor and will be made available to participants in the experimental group using an interactive website.
3305833|NCT01883570|Active Comparator|not trained in visual search strategy|Participants will learn to read chest x-rays by having access to a library of chest x-rays identical to the one used by the experimental arm, but without the search strategy.
3305834|NCT01883583|Experimental|Pilot group|Contrast-enhanced Ultrasound And Sonoelastography of transplanted kidney will be performed for acquisition of a number of parameters and time-intensity curves, before ultrasound guided biopsy of transplanted kidney.
3305835|NCT01883596|Experimental|0.12% Chlorhexidine|Bexident® (0.12% chlorhexidine) solution, applied topically, every 8 hrs.
3305836|NCT01883596|Placebo Comparator|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
3305837|NCT01883609|Active Comparator|Group 1|Group 1 receive combination vaccination strategy: RTS,S/AS01B at weeks 0, ChAd63 ME-TRAP at week 2, RTS,S/AS01B at weeks 4 and 8, then MVA ME-TRAP at week 10 followed by sporozoite challenge (mosquito bite) at week 12.
3305838|NCT01883609|Active Comparator|Group 2|Group 2 receive three vaccinations (RTS,S/AS01B) at weeks 0, 4 and 8 followed by sporozoite challenge (mosquito bite) at week 12.
3305839|NCT01883609|No Intervention|Group 3|Groups 3 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 3 will undergo sporozoite challenge at the same time as Group 1 and 2 volunteers (week 12).
3305840|NCT01883609|No Intervention|Group 4|Group 4 is an infectivity-control group for the sporozoite challenge procedures: these volunteers will not be vaccinated. Group 4 volunteers will be used as infectivity controls if any volunteers from groups 1 and 2 are rechallenged 5 - 7 months after the initial CHMI. CHMI may be administered in two separate cohorts if necessary due to limitations on volunteer availability.
3305841|NCT01883622||Type 1 diabetes|Pregnant women affected by type 1 diabetes mellitus
3305842|NCT01883622||GDM|Pregnant women affected by gestational diabetes mellitus
3305843|NCT01883622||Healthy|Healthy pregnant women
3305844|NCT01883648|Experimental|Coconut Oil Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects. This treatment arm will last 3 months.
3305845|NCT01883648|Placebo Comparator|Placebo Beverage|The treatment will consist of a 1.25 oz serving size taken orally, two times daily by subjects.This will similar in look and taste but not have the same ingredients of the actual coconut oil beverage. This treatment arm will last 3 months.
3305846|NCT01883661|Other|BMMNC|Administration of of Bone Marrow derived Mono Nuclear Stem Cell (MNCs)
3305847|NCT01883674|Experimental|Milk proteins|This group will do a resistance training + milk proteins (milk beverage)
3305848|NCT01883674|Experimental|Essential amino acids (add to soya bvg)|This group will do a resistance training + essential amino acids (added to soya beverage)
3305849|NCT01883674|Placebo Comparator|No protein (control)|This group will do a resistance training + ingestion of the control beverage (no protein, rice beverage)
3305850|NCT01883687|Experimental|Septoplasty|patients will receive septoplasty together with Le Fort I osteotomy
3305851|NCT01883687|No Intervention|No septoplasty|patient will only receive Le Fort I osteotomy
3305852|NCT01883700|Experimental|Low-GI, High-GL Meal|Boiled Pasta
3305853|NCT01883700|Experimental|Low-GI, High GL Meal|Boiled Chickpeas with Oil
3305854|NCT01883700|Experimental|High-GI, High-GL Meal|Instant Mashed Potatoes
3305855|NCT01883700|Experimental|High-GI, Low-GL Meal|Instant Mashed Potatoes with Egg Whites
3305856|NCT01883713||Heart surgery during CPB|All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
3305857|NCT01883726|Experimental|Grayson NAM|Intervention: Grayson nasoalveolar molding This technique uses an acrylic plate to mold the alveolar segments and uses an extension to mold the alar cartilage of the nasal component. The construction is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. When the alveolar gap is reduced to 5 mm, nasal component are added to gradually mold the nasal cartilage and other nasal structures.
3305858|NCT01883726|Experimental|Figueroa NAM|Intervention: Figueroa's nasoalveolar molding Figueroa technique uses labial tapes and acrylic relief to the palatal plate to approximate alveolar gap [3]. The nasal component is added in the beginning of the treatment to mold the nasal cartilage.
3305859|NCT01883739|Experimental|Parental Presence at Handover Rounds|"Subjects will receive an educational document prior to transfer rounds introducing the concept of Patient and Family Centered Care and the role of a parent in transfer rounds. These parents will have the option of meeting with a parental peer support person for a coaching or training session prior to their participation in transfer rounds. During the transfer rounds parents will be actively included in discussion of their child's medical management plan upon discharge to the wards."
3305860|NCT01883752|No Intervention|Control|Baseline crystalloid infusion of 5 mL/kg/hr of body weight.
3305861|NCT01883752|Experimental|Goal-directed Therapy group|Goal-direct therapy
3305862|NCT01883765|Experimental|Neurofeedback active|Active neurofeedback training, theta/beta-protocol
3305863|NCT01883765|Sham Comparator|Neurofeedback sham|Neurofeedback training is simulated to subjects in this condition
3305864|NCT01883765|Active Comparator|Metacognitive Training|Metacognitive training, cognitive behavioral therapy
3305865|NCT01883778||Emergency Department Patients|
3305866|NCT01883778||Emergency Medicine Physicians|
3305867|NCT01883791|Experimental|SBIRT|The SBIRT condition will include the WHO's Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) and its accompanying brief intervention that uses motivational interviewing techniques to provide feedback, emphasize personal responsibility, give advice, provide a menu of options, convey empathy, and promote self-efficacy.
3305868|NCT01883791|Other|Health Education|The control group will receive a Health Education (HE) session, informational brochures and a contact information for addiction treatment sites that we will develop with Ventura County. The session will be administered in an individual format for 30-minutes and will address general health, wellness and lifestyle topics.
3305869|NCT01883817|Placebo Comparator|Placebo|Corn/soy oil placebo capsules that are similar in shape and color to the DHA capsules given over 10 weeks
3305870|NCT01883817|Experimental|DHA Omega-3|Long-chain omega-3 fatty acid docosahexaenoic acid (DHA) at 1,200 mg/day, 600 mg twice daily for 10 weeks
3305871|NCT01883830|Experimental|gaming therapy (Xbox)|Subjects belonging to the first group will receive a gaming therapy protocol using the Xbox console. They will receive 24 sessions of treatment within 8 weeks (3 sessions per week). Patients will be required to concentrate in games whose major purposes are increasing balance, selective attention and attention shifting. During sessions the patient will be carefully controlled by a researcher who will prevent the risk of falling and impulsiveness reactions.
3305872|NCT01883830|Active Comparator|Dynamic balance platform training|Control group will receive the same amount of therapy (24 sessions) using a dynamic balance platform (Biodex).
3305873|NCT01883843|Experimental|real tDCS + TOCT|"Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode.~The current reaches 0.5mA and decreases with a ramp of 10 seconds."
3305874|NCT01883843|Active Comparator|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
3305875|NCT01883869|Experimental|ticagrelor|180 mg orally once and then 90 mg orally daily for 7 days or until hospital discharge if sooner
3305876|NCT01883869|Placebo Comparator|placebo|One loading dose and then daily for 7 days or until hospital discharge if sooner
3305877|NCT01883882|Experimental|taper support|Weekly visits with pharmacological and psychological support for opioid taper at 10% of original dose per week
3305878|NCT01883882|No Intervention|Usual care|Usual care for chronic pain. All care allowed except buprenorphine.
3305879|NCT01883921||Immunoglobulin Therapy|
3305880|NCT01883934|Experimental|Enhanced clinic-based support/counseling|Scheduling a consult with a licensed social worker to discuss embryo disposition options. Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
3305881|NCT01883934|Active Comparator|Patients receiving standard of care|Patients who receive standard of care regarding embryo disposition options
3305882|NCT01883947|Experimental|Touch massage|Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
3305883|NCT01883947|Sham Comparator|non-TENS|The sham treatment will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
3305884|NCT01883960||healthy adults|Inclusion criteria for healthy adults were as follows: 40-70 y/o; good cognition and cooperation; and healthy adults.
3305885|NCT01883960||stroke subjects|Inclusion criteria for subjects with brain damage by stroke were as follows: a diagnosis of first-time-onset stroke and aged 40-70 years old.
3305886|NCT01883960||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 16-18 years old.
3305887|NCT01883960||healthy children|Inclusion criteria for healthy children were as follows: ages of 6-18 y/o ; good cognition and cooperation; and healthy children.
3305888|NCT01883973||MER guidance|Will undergo DBS implantation in the awake state using a frame based stereotactic technique and intraoperative microelectrode recording to guide final lead placement.
3305889|NCT01883973||MRI Guidance|Will undergo DBS implantation under general anesthesia using anatomical targeting in an operating room equipped with an intraoperative MRI to guide electrode placement
3305890|NCT01884012|Experimental|Supplemental oxygen|Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day
3305891|NCT01884012|Sham Comparator|Sham room air|Room air given at a flow rate of 3 liters per minute for 16 hours a day
3305892|NCT01884038|Experimental|1|
3305893|NCT01884038|Placebo Comparator|2|
3305894|NCT01884051||PAH patients|Patients diagnosed with WHO Group 1 PAH
3305895|NCT01884051||Healthy subjects|Subjects who have been evaluated for heart and lung disease and found to be healthy
3305896|NCT01884090|Experimental|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
3305897|NCT01884090|Active Comparator|Standard After School Programming|Youth in the comparison arm of the study will participate in standard after-school programming administered by Flint Community Schools and Genesee Intermediate School District. The standard program is the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009)
3380939|NCT04242498|Experimental|Bimekizumab dosing regimen 1|Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the Treatment Period.
3380940|NCT04242498|Experimental|Bimekizumab dosing regimen 2|Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the Treatment Period.
3305898|NCT01884103||EMS Providers|Field Triage Decision-making for older adult patients with potential TBI.
3305899|NCT01884116|Active Comparator|NSAID patch group|administer the NSAID patch
3305900|NCT01884116|Experimental|NSAID patch + transcutaneous electric nerve stimulation group|
3305901|NCT01884116|Experimental|NSAID patch + heating pad group|
3305902|NCT01884116|Experimental|NSAID patch + topical capsaicin group|
3305903|NCT01884142|No Intervention|Heart Failure Untrained Group|Control Group
3305904|NCT01884142|Experimental|Heart Failure Exercise-trained Group|Aerobic Exercise Training
3305905|NCT01884155|Experimental|Allogeneic umbilical cord blood therapy|Allogeneic umbilical cord blood therapy
3305906|NCT01884168||gene expression profile|T-Cell Receptor/B-Cell Receptor gene expression in cavity effusion is detected by micro-array to explore the mechanism that DC-CIK immunotherapy controls the malignant cavity effusion.
3305907|NCT01884181||Huntington Disease Group|Established diagnosis by a neurological examination and genetic assessment of CAG expansion in the Htt gene.
3305908|NCT01884181||Healthy Controls|"The healthy control subjects without a clinically significant neuropsychiatric disorders.~Able to understand and provide signed informed consent.~Age range and gender matched with Patients with Huntington Disease Group."
3305909|NCT01884194||Retinoblastoma patients|patients with diagnosed retinoblastoma
3305910|NCT01884194||non-retinoblastoma patients|aged matched control cohort without the diagnosis of ocular or brain tumor
3305911|NCT01884207||orbital tumors|
3305912|NCT01884220||Patients with Disease|Patients with Wolman disease (WD), Cholesteryl Ester Storage Disease (CESD), or Lysosomal acid lipase (LAL) deficiency.
3305913|NCT01884233|Experimental|Text Messaging CBT|This condition will receive CBT based text messaging (TXT-CBT). Those assigned to TXT-CBT will also be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have an initial meeting with a CBT clinician to review the Life-Steps concepts. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
3305914|NCT01884233|Active Comparator|Standard Care|Those assigned to the Standard Care condition will receive the standard monthly medical management physician visit typically associated with HIV care. In addition, a pamphlet with information about HIV, the importance of ART adherence, and relapse prevention will be provided to participants in this condition.
3305915|NCT01884246|Experimental|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
3305916|NCT01884246|Active Comparator|Referral to primary care provider|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
3305917|NCT01884259|Active Comparator|A|"Patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) and 5-fluorouracil (750mg/m²) followed by Cetuximab (weekly, starting with 400mg/m² then continuing with 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Active comparator is 5-fluorouracil for first three cycles."
3305918|NCT01884259|Experimental|B|"All patients receive 3 cycles (cycle duration 21 days) of docetaxel (75mg/m²), cisplatin (75mg/m²) Cetuximab (weekly, starting with 400mg/m² and continuing with 250 mg/m²), followed by Cetuximab (weekly 250 mg/m²) with radiotherapy (concomitant boost for 6 weeks).~Experimental: cetuximab for the first three cycles."
3305919|NCT01884272|Experimental|Lesinurad 400 mg and naproxen 250 mg|Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14.
3305920|NCT01884272|Active Comparator|Lesinurad 400 mg and indomethacin 25 mg|Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14.
3305921|NCT01884285|Experimental|Part A: AZD8186 monotherapy|Patients will receive a single dose on Day 1 followed by ongoing multiple dosing. The initial schedule will use intermittent dosing of AZD8186.
3305922|NCT01884285|Experimental|Part C2: AZD8186/abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186.
3305923|NCT01884285|Experimental|Part D1: AZD8186 and AZD2014|Combination dosing with AZD8186 and AZD2014 both given on an intermittent schedule at escalating dose levels of each IMP for combination dose finding
3305924|NCT01884285|Experimental|Part B: AZD8186 monotherapy|Part B - multiple dosing of intermittent dose schedule
3305925|NCT01884285|Experimental|Part D2: AZD8186/ AZD2014|Expanded cohort of patients will be treated at a tolerated combination dose level established in Part D1
3305926|NCT01884285|Experimental|Part C1: AZD8186 & abiraterone|Patients will receive a week of abiraterone acetate with prednisone followed by combination dosing with AZD8186 at escalating doses of AZD8186 for the purpose of dose finding
3305927|NCT01884298|Experimental|patients with isolated systolic hypertension|patients combined with isolated systolic hypertension undergoing abdominal surgery
3305928|NCT01884324|No Intervention|Late delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
3305929|NCT01884324|Experimental|Early delivery|The early group will undergo induction of labor at 34 weeks with cesarean delivery reserved for obstetrical indications.
3305930|NCT01884363|Experimental|Walnuts|This group will receive one ounce of walnuts per day
3305931|NCT01884363|No Intervention|Usual diet (no walnuts)|Control group (does not receive walnuts in the diet)
3305932|NCT01884376|Experimental|Neuromaix implantation|Implantation of Neuromaix during an diagnostic nerve biopsy
3305933|NCT01884389|Experimental|Patient Navigation|"Patients are admitted to the navigation program, provided through a local community partner agency. Each of these subjects will be assigned an advanced practice nurse (APN) and licensed social worker (LSW) as co-case managers, with their relative contributions depending on the nature of the subject's needs. Level of need (1, 2 or 3) will be confirmed for each patient, and the level will inform the amount of in-person and phone call contacts made to provide on-going support and monitoring of patients. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
3305934|NCT01884389|No Intervention|Usual Care|"The control group will receive usual care - medical care and support provided by their primary care provider. They will not receive any of the navigation program services. To provide control for the effects of attention, we will contact these subjects at baseline and every other month thereafter by phone. During these contacts, we will ask a scripted social query (e.g. How are things going for you?). A subject who raises any health issues or need for specific information will be referred to the primary care provider. Additionally, this group will meet with the research team for data collection at enrollment and at four 9-month intervals for a total of 5 time points."
3305935|NCT01884402||Pegasys, injection subcutaneous|HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin
3305936|NCT01884415|Experimental|Second HBV vaccination cycle|Second cycle of HBV vaccination (0, 1 and 2 months)will be administered. Three intramuscular doses of 40 µg.
3305937|NCT01884415|Active Comparator|Single dose of HBV vaccine|Single dose (40µg) of HBV vaccine will be administered at 6 months after 1 cycle of HBV vaccination
3305938|NCT01884428|Experimental|Panobinostat + IGEV|Panobinostat + IGEV regimen (Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone)
3305939|NCT01884441|Experimental|BeGEV|Bendamustine, Gemcitabine and Vinorelbine (BeGEV)
3305940|NCT01884454||Total sleep deprivation|Healthy volunteers will be submitted to total sleep deprivation (TSD) for 48 hours.
3305941|NCT01884454||moderate to severe OSA|Patients diagnosed with moderate to severe obstructive sleep apnea syndrome (OSA) with normal or overweight body mass index (BMI), will be recruited.
3305942|NCT01884454||REM sleep deprivation|Healthy volunteers will be submitted to selective REM sleep deprivation (REMSD) for 48 hours.
3305943|NCT01884454||Control|The control group will be subjects with an apnea hypopnea index <5/h.
3305944|NCT01884467|Experimental|Gentamicin|Intervention: Gentamicin; Dosage form: 120mg reconstituted in 250cc of normal saline; Dosage: 30mL; Frequency: nightly instillation into bladder (to remain overnight until draining it out in morning); Duration: 1 year
3305945|NCT01884467|Placebo Comparator|Placebo|Drug: Normal saline; Dosage form: N/A; Dosage: 30 mL; Frequency: nightly bladder instillation; Duration: 1 year
3305946|NCT01884480||500 Stable renal transplant recipients|cohort of 500 stable RTRS. A subset of this group who required dose adjustment after conversion will be compared to a matched cohort not requiring dose adjustment. Genotyping for Cyp3A5 will be done for both cohorts
3305947|NCT01884480||500 renal transplant recipients|500 Stable renal transplant recipients converted from prograf to advagraf
3305948|NCT01884493|Experimental|real iTBS|The paradigm will use a theta burst stimulation pattern (TBS) in which 3 pulses of stimulation will be given at 50Hz, repeated every 200 ms. In the iTBS, a 2-second train of TBS is repeated every 10 seconds for a total of 190 seconds (600 pulses). Subjects will be 8 courses of iTBS stimulation in 10 business days.
3305949|NCT01884493|Sham Comparator|sham iTBS|Subjects will be 8 courses of sham iTBS stimulation in 10 business days.
3305950|NCT01884506|Experimental|labeled iron meal|Test meal (bread with honey) with a labeled iron solution
3305951|NCT01884506|Experimental|labeled iron and ascorbic acid meal|Test meal (bread with honey) with a labeled iron solution and ascorbic acid
3305952|NCT01884532||2 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 2 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3305953|NCT01884532||3 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 3 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3305954|NCT01884532||4 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 4 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3305955|NCT01884532||5 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 5 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3305956|NCT01884532||6 year post-op|Patients that underwent an ASR-XL Metal-on-Metal (MoM) total hip replacement (THR)and at the time of enrollment, based on their date of surgery, were 6 years post-operative. Alternatively, these are patients who have had their ASR-XL Metal-on-Metal hip revised but if they were not revised, would have fallen into this time point.
3305957|NCT01884558|Experimental|isavuconazole and metformin|Metformin single dose on days 1 and 8. Isavuconazole three times a day (TID) on Days 4 and 5 followed by isavuconazole once daily (QD) on Days 6-9.
3305958|NCT01884584|Experimental|Indocyanine green (ICG)|ICG will be administered by intravenous infusion over a 20 second period in a 2-8 hour time window before the time of completion of the surgical procedure.
3305959|NCT01884623|Experimental|Cetuximab|Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV
3305960|NCT01884623|Active Comparator|Methotrexate|Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV
3305961|NCT01884636|Experimental|isavuconazole and methotrexate|Methotrexate single dose on days 1 and 8. Isavuconazole three times a day (TID) on days 4 and 5 followed by isavuconazole once daily (QD) on days 6 - 9
3305962|NCT01884649||Group of Hashimoto thyroiditis patients|
3305963|NCT01884649||Healty control group|
3305964|NCT01884662|Experimental|Virtual walking|A 3D video of legs walking from a first person perspective have been developed in consultation with persons with SCI and virtual reality experts. Participants are provided with a 3D monitor and Blue Ray player for daily viewing of the tape for two weeks.
3305965|NCT01884662|Active Comparator|Wheeling tape|A 3D video was produced of legs in a wheelchair covering the identical conditions of the walking experimental video.
3305966|NCT01884701|Experimental|Intervention|Intervention
3305967|NCT01884714|Experimental|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
3305968|NCT01884727|Active Comparator|ASEA water|Subjects to consume 4-ounces of ASEA water at 9:00 am before breakfast and 4-ounces of ASEA water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
3305969|NCT01884727|Placebo Comparator|Salt water|Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
3305970|NCT01884740|Experimental|SIACI of Erbitux and Bevacizumab|Superselective Intraarterial Cerebral Infusion (SIACI) of Erbitux (200 m/m2) and Bevacizumab (15 mg/kg)
3305971|NCT01884753||Adult women with lower urinary tract symptoms|Adult women (not less than 20 year-old) with lower urinary tract symptoms
3305972|NCT01884766||Epilepsy|All kind of epilepsy, including febrile seizures
3305973|NCT01884766||Control|children without seizures at presentation in the emergency but fever due to banal infections
3305974|NCT01884792|Placebo Comparator|Sitting Oral Glucose Tolerance Test|An OGTT is performed while the subject sits at their desk for the entire 2-hour period. 5 blood sugar measurements are taken and a 75g dextrose beverage is consumed following the first, baseline blood sugar reading. The blood sugar is then measured every 30 minutes up to 120 min.
3305975|NCT01884792|Experimental|Standing Oral Glucose Tolerance Test|The participant stands at their desk for the duration of the 2-hour blood sugar test. The same procedure is performed as in the sitting condition.
3305976|NCT01884792|Placebo Comparator|Sitting Continuous Glucose Monitor|A continuous blood glucose monitor is worn for 5 days while at work. In the sitting condition the participant only sits at their desk for the duration of the week. Blood sugar is monitored 4 times per day to calibrate the CGM and an accelerometer is worn to track physical activity.
3305977|NCT01884792|Experimental|Standing Continuous Glucose Monitor|Participants are instructed to stand intermittently for at least half of their work day during this 5 day period. Blood sugar is monitored and physical activity is tracked with an accelerometer.
3305978|NCT01884805|Other|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|
3305979|NCT01884818|Experimental|Manipulation|Subjects will receive 6 manipulation treatments within 3 weeks period. The manipulated segments are determined individually in baseline assessment.
3305980|NCT01884818|Sham Comparator|TNS for thoracic spine|6 TNS treatments at home for 20min in limited power of devices in three weeks period.
3305981|NCT01884831|Experimental|cell therapy|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions
3305982|NCT01884857|Active Comparator|'TOPROL-XL®' ER Tablets 50 mg|'TOPROL-XL®' ER Tablets 50 mg of Astrazeneca LP, USA
3305983|NCT01884857|Experimental|Metoprolol Succinate ER Tablets 50 mg|Metoprolol Succinate ER Tablets 50 mg of Ipca Laboratories Limited, India
3305984|NCT01884870|Other|Surgical Treatment|Silent Ureteral Stone - Surgical Treatment
3305985|NCT01884883|Other|Internal unicompartmental knee brace|
3305986|NCT01884896|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
3305987|NCT01884896|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
3305988|NCT01884909|Active Comparator|'TOPROL-XL®' ER Tablets 200 mg|'TOPROL-XL®' ER Tablets 200 mg of Astrazeneca LP, USA
3305989|NCT01884909|Experimental|Metoprolol Succinate ER Tablet 200 mg|Metoprolol Succinate ER Tablet 200 mg of Ipca Laboratories Limited, India
3305990|NCT01884922|Experimental|Dose escalation|"Nilotinib (Tasigna®): 115 to 350 mg/m2 twice daily (BID) orally given continuously (115 mg/m2 once daily if de-escalation requested~Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle."
3305991|NCT01884935|Experimental|Natalizumab|300 mg intravenously (IV) every 4 weeks
3305992|NCT01884948|Active Comparator|Omegaven™|Omegaven™ (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven™ or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven™/kg/hour).
3305993|NCT01884948|Placebo Comparator|NaCl 0.9%|100ml of saline is used as a placebo comparator and administered as described above.
3305994|NCT01884961|Experimental|arm A|"Boost of radiotherapy + high dose IL-2 treatment: Three daily doses boost radiotherapy at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of IL-2 (Interleukin 2). The first day of administration of IL-2 of each cycle is the day +1.~Treatment with IL-2 (dose 18 MIU/m2/day in 500cc by continuous IV (intravenous) infusion for 72 hours) will start on day +1 and will be administered every 3 weeks up to 4 cycles, than every 3-4 weeks for a further 2 cycles.~Patients will be evaluated every 8 weeks with computed tomography to determine the response, and every 3 months after completion of treatment until death."
3305995|NCT01884974||myeloproliferative disease|Patients with Myeloproliferative Diseases as specified under inclusion and exclusion criteria
3305996|NCT01884987||group one will receive non-GM1 conservative therapy|"Group one will receive conservative therapy such as hyperbaric therapy or corticosteroids therapy or wait and see policy"
3305997|NCT01885013|Experimental|Metformin + Myocet + Cyclophosphamide|"arm A : Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
3305998|NCT01885013|Active Comparator|Myocet + Cyclophosphamide|arm B : Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days
3305999|NCT01885026|Experimental|eScreen|Web based self-monitoring of problematic alcohol and drug use, and Internet-based treatment for depression or anxiety
3306000|NCT01885026|Experimental|Control|Assessment only of alcohol and drug use and Internet-based treatment for depression or anxiety
3306001|NCT01885052|Placebo Comparator|1|Receives weekly assessment messages ONLY
3306002|NCT01885052|Active Comparator|2|Receives two week countdown messaging to quit date, and weekly assessment messages post quit date
3306003|NCT01885052|Active Comparator|3|Receives two week countdown messages to quit date, receives mulitiple messages per day post quit date with tips, encouragement and supportive messaging
3306004|NCT01885065|Experimental|Gel-based artificial saliva|Continuous oral intake of edible gel-based artificial saliva (30-50 ml/day) for four weeks
3306005|NCT01885078|Experimental|Baricitinib 4 mg|"Baricitinib 4 milligrams (mg) administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.~Participants may continue to receive the background non-investigational, open-label conventional disease-modifying antirheumatic drugs (cDMARD), nonsteroidal anti-inflammatory drug (NSAID), corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
3306006|NCT01885078|Experimental|Baricitinib 2 mg|"Baricitinib 2 mg administered orally once daily throughout the 84 month treatment period. Placebo administered orally to maintain blind.~Participants may continue to receive the background non-investigational, open-label cDMARD, NSAID, corticosteroid, and other analgesic therapies they were receiving at completion of the originating study."
3306007|NCT01885091|Experimental|Kinerase|
3306008|NCT01885130|Experimental|Cetaphil Daily Advance Ultra Hydrating Lotion|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
3306009|NCT01885143||Artifact Correction|A minimum of 6 subjects will be recruited for the purpose of evaluating artifact correction
3306010|NCT01885143||Lossy Compression|A minimum of 6 subjects will be recruited for the purpose of evaluating lossy compression
3306011|NCT01885156|Placebo Comparator|Placebo Cream|Topically applied once daily
3306012|NCT01885156|Experimental|Naftin 1% Cream|Topically applied once daily
3306013|NCT01885169||Cohort A|Participants with CF; Flumist®-naïve
3306014|NCT01885169||Cohort B|Siblings of Cohort A without CF; Flumist®-naïve
3306015|NCT01885169||Cohort C|Participants with CF; Flumist®-experienced
3306016|NCT01885221|Experimental|Multimedia Support Intervention|(a) access to a website providing the content of our supporter guidebook, supplemented with interactive components, video elements, and a supporters' forum, and (b) a mailed copy of our supporter guidebook
3306017|NCT01885221|No Intervention|Delayed Treatment Control|Access to the Multimedia Intervention after participant completes the final follow-up assessment
3306018|NCT01885234|Experimental|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
3306019|NCT01885234|Placebo Comparator|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
3306020|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 1|ISIS-GCGRRx Dose Level 1
3306021|NCT01885260|Experimental|ISIS-GCGRRx Dose Level 2|ISIS-GCGRRx Dose Level 2
3306022|NCT01885260|Placebo Comparator|Placebo|Placebo
3306023|NCT01885273|Experimental|Pressurized irrigation method|Cleansing wound with pressurized irrigation technique using a pressurized irrigation device.
3306024|NCT01885273|Active Comparator|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack), and received the 'standardized usual care'. Frequency of dressing change depended on the amount of exudates.
3306025|NCT01885299||Patients being treated by SRS/SBRT|Patients with a condition being considered for treatment by SRS/SBRT
3306026|NCT01885312|Active Comparator|Tailored not adaptive based Intervention|Tailored Text Messaging - not adaptive in the moment and once a day intervention to reduce problem drinking
3306027|NCT01885312|Other|Ecological Momentary Assessment|Mobile Assessment only
3306028|NCT01885312|Experimental|Tailored Adaptive Text Messaging|Tailored Adaptive Text Messaging intervention to reduce problem drinking
3306029|NCT01885312|Active Comparator|Consequence based text messaging|Consequence based Text Messaging intervention to reduce problem drinking
3306030|NCT01885325|Experimental|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components: Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical Activity in classroom, academic lessons), and enhancing the social environment to promote Physical Activity.
3306031|NCT01885325|No Intervention|Control|The preschools in the control group did not receive the intervention
3306032|NCT01885338|Experimental|N-acetylcysteine (NAC)|Capsules containing N-acetylcysteine 600mg, with inactive ingredients of cellulose, L-leucine, and silica used as filler. Dosage is 2 capsules by mouth twice daily for 8 weeks.
3306033|NCT01885338|Placebo Comparator|Inactive placebo capsule|A placebo capsule is used that is identical to the active treatment but lacks NAC. The inactive ingredients in the placebo capsule are cellulose, L-leucine, and silica. Dose is 2 capsules by mouth twice daily for 8 weeks.
3306034|NCT01885351|Experimental|Phase II: MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
3306035|NCT01885351|Experimental|Phase II: MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers"
3306036|NCT01885351|No Intervention|Phase II: Usual Care|The IPHR will be programmed so that where the IPHR-CRCS would normally present patients, who based on their demographics and health conditions, with content advising them to seek CRCS and links to third-party sites, they would instead be randomized to receive the usual care (IPHR-CRCS).
3306037|NCT01885364|Placebo Comparator|Placebo & propofol|Pretreatment with normal saline before injection of propofol
3306038|NCT01885364|Experimental|esmolol 0.05 mg/kg & propofol|Pretreatment with esmolol 0.05 mg/kg before injection of propofol
3306039|NCT01885364|Experimental|esmolol 1 mg/kg & propofol|Pretreatment with esmolol 1 mg/kg before injection of propofol
3306040|NCT01885364|Active Comparator|remifentanil 0.35 ug/kg & propofol|Pretreatment with remifentanil 0.35 ug/kg before injection of propofol
3306041|NCT01885377|Experimental|Specific exercise group|A progressive program of strength-endurance exercises for the rotator cuff and scapula stabilizing muscles combined with mobilization of the joint capsule when needed
3306042|NCT01885377|Active Comparator|Control exercise group|General movements for the neck and shoulder and self-stretching. No progression some addition of exercises during the three month period.
3306043|NCT01885390|Experimental|Experimental: Group A|ROX Coupler + continuing standard antihypertensive medications
3306044|NCT01885403|Experimental|Respiratory Parameters Measurements|
3306045|NCT01885416|Active Comparator|high fat meal without dairy products|high fat meal without dairy products
3306046|NCT01885416|Experimental|high fat meal with additional milk|high fat meal with additional milk
3306047|NCT01885416|Experimental|dairy product meal|dairy product meal
3306048|NCT01885429|Experimental|Positive Control|Group 1 (Positive(+) Control) will receive: 25g of whey protein. Positive Control
3306049|NCT01885429|Experimental|Negative Control|Group 2 (Negative(-) Control) will receive: 6.25g whey. Negative Control
3306050|NCT01885429|Experimental|Low Protein + Low Leucine Spike|Group 3 (Low Protein + Low Leucine Spike) will receive: 6.25g whey + low added leucine. Low Protein Low Leucine Spike
3306051|NCT01885429|Experimental|Low Protein + High Leucine Spike|Group 4 (Low Protein + High Leucine Spike) will receive: 6.25g whey + high added leucine. Low Protein High Leucine Spike
3306052|NCT01885429|Experimental|Low Protein + High Leucine + BCAA Spike|Group 5 (Low Protein + High Leucine + BCAA Spike) will receive: 6.25g whey + added branched-chain amino acids. Low Protein + High Leucine + BCAA Spike
3306053|NCT01885442|Experimental|In-bed leg cycle ergometry|
3306054|NCT01885455|Active Comparator|Usual Care Arm|Participants who are assigned to the usual care arm may receive the following services: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
3306055|NCT01885455|Experimental|Intervention Arm|"The PN will provide each patient with a copy of the NCI's What You Need to Know About Lung Cancer booklet and encourage them to re-contact his/her primary care physician (or the physician who diagnosed their probable/proven NSCLC) to discuss treatment options.~The PNs will provide patients with their contact information and brief patients on their role. The PNs will navigate study participants for up to 4 months (16 weeks, 112 days) after NSCLC diagnosis, until the patient is deemed ineligible for LDTCI (i.e., lung resection or SBRT) by their physician(s), until receipt of LDTCI, or death (whichever comes first).~During the EPDPN intervention period, PNs will contact each intervention group participant by telephone (or in-person) on weekly basis (at minimum)."
3306056|NCT01885481|Active Comparator|ESI-1|epidural steroid injection using dexamethasone
3306057|NCT01885481|Experimental|ESI-2|epidural steroid injection using betamethasone
3306058|NCT01885494||15µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 15µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
3306059|NCT01885494||75µg AFFITOPE® PD01A|Patients With Parkinson's Disease vaccinated with 4 injections of 75µg AFFITOPE® PD01A adsorbed to adjuvant during AFF008
3306060|NCT01885494||Control group|Untreated control group
3306061|NCT01885507||Control phase (before)|Process of care and outcomes before the educational program
3306062|NCT01885507||Training phase (after)|"Process of care and outcomes after the educational program which recommends:~the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
3306063|NCT01885520|Experimental|fasting condition|eperisone SR administrated under fasting condition
3306064|NCT01885520|Active Comparator|Fed condition|eperisone SR administrated under fed condition
3306065|NCT01885533||Post-radioiodine medication|Anti-thyroid drugs
3306066|NCT01885533||Post-radioiodine medications|anti-thyroid drugs and thyroxine
3306067|NCT01885533||Post-radiodione medication|watchful monitoring
3306068|NCT01885546|Other|Enhanced meter feature usability|Home diabetes monitoring by patient using provided blood glucose monitoring system.
3306069|NCT01885572|Other|TiLOOP Bra|Treatment with TiLOOP Bra
3306070|NCT01885585||Patients with risk of VTE|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
3306071|NCT01885598||Nonvalvular Atrial Fibrillation patients with risk of Stroke|Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release
3306072|NCT01885611|Active Comparator|Multi-Drug Therapy (Novartis Ⓡ)|"Multi-Drug Therapy PB pack consists of 600 milligrams (mg) of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for six months (PB patients)~Multi-Drug Therapy MB pack consists of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily for six months (MB patients)"
3306073|NCT01885611|Experimental|Virgin Coconut Oil (VCO) with MDT|"VCO 10 milliliters (mL) three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ) single dose once a month and 100mg of dapsone (NovartisⓇ) daily for a period of six months (PB patients)~VCO 10mL three times a day in addition to MDT of 600mg of rifampicin (NovartisⓇ), 300mg of clofazimine (NovartisⓇ) as a single dose monthly and 50mg of clofazimine (NovartisⓇ) and 100mg of dapsone (NovartisⓇ) daily or a period of six months (MB patients)"
3306074|NCT01885624|Experimental|TAB08|Single TAB08 i.v. infusion
3306075|NCT01885637|No Intervention|Control group|In the control group, the patients continue to be attached to the health care system in line with current practice. This means that the patient typically remains in hospital or ambulatory and may have contact with one or more hospitals, GP and possibly homecare later in the process. Caregivers in the control group may receive psychological counseling through referral from a GP.
3380941|NCT04242498|Experimental|Bimekizumab dosing regimen 3|Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the Treatment Period.
3380942|NCT04242498|Placebo Comparator|Placebo Group|Subjects randomized to this arm will receive placebo during the Initial Treatment Period and bimekizumab during the Maintenance Treatment Period.
3306076|NCT01885637|Other|Intervention Group|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
3306077|NCT01885650|Experimental|Normal airway clearance|The patients usual airway clearance technique
3306078|NCT01885650|Experimental|Non-Invasive Ventilation|The addition of positive pressure via a non-invasive ventilator to the participants usual airway clearance technique
3306079|NCT01885663|Experimental|Umbilical cord blood therapy|Umbilical cord blood therapy
3306080|NCT01885676|Experimental|PRGF-Endoret|
3306081|NCT01885676|Placebo Comparator|Saline Solution|
3380946|NCT04239703||Kidney transplant biopsies for cause|The study population includes patients with a functioning kidney transplant undergoing a biopsy for clinical indications as standard of care.
3306082|NCT01885689|Experimental|Treatment (clofarabine, melphalan, transplant)|"CONDITIONING REGIMEN: Patients receive clofarabine IV over 2 hours on days -9 to -5 and melphalan IV over 30 minutes on day -4.~TRANSPLANT: Patients undergo allogeneic hematopoietic stem cell transplant on day 0.~GVHD PROPHYLAXIS: Beginning on day -3, patients receive tacrolimus IV or PO and sirolimus PO once daily with taper per City of Hope standard operating procedure."
3306083|NCT01885702|Experimental|MSI-positive CRC patients|I) Adjuvant DC vaccinations for MSI-positive CRC patients (n=5)
3306084|NCT01885702|Experimental|Carriers of germline MMR-gene mutation|II) Preventive DC vaccinations for carriers of germline MMR-gene mutation (n=20) withhout manifestation of CRC
3306085|NCT01885715|Placebo Comparator|Rocuronium-placebo|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306086|NCT01885715|Active Comparator|Rocuronium-neostigmine 10 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0."
3306087|NCT01885715|Active Comparator|Rocuronium-neostigmine 20 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306088|NCT01885715|Active Comparator|Rocuronium-neostigmine 40 ㎍|"At anesthetic induction, rocuronium 0.6 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306089|NCT01885715|Placebo Comparator|Cisatracurium-placebo|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306090|NCT01885715|Active Comparator|Cisatracurium-neostigmine 10 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 10 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306091|NCT01885715|Active Comparator|Cisatracurium-neostigmine 20 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 20 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306092|NCT01885715|Active Comparator|Cisatracurium-neostigmine 40 ㎍|"At anesthetic induction, cisatracurium 0.15 mg/kg will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, neostigmine 40 ㎍/kg will be injected. And we will measure time to take from TOF ratio 0.5 to 1.0"
3306093|NCT01885728|Active Comparator|Arginine rich nutritional supplement|237 ml of an arginine rich nutritional supplement 4 times a day for the five days preceding surgery.
3306094|NCT01885728|No Intervention|No nutritional supplement|No specific nutritional requirements have to be met in this group.
3306095|NCT01885741|Experimental|IPBS|
3306096|NCT01885754||Lung cancer patient with cachexia|Muscle lumbar area < 55cm2/m2 for men and < 39 cm2/m2 for women
3306097|NCT01885754||Lung cancer patients without cachexia|Muscle lumbar area over 55cm2/m2 for men and 39 cm2/m2 for women
3306098|NCT01885767||NF1|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 1
3306099|NCT01885767||NF2|Patients meeting clinical and/or genetic criteria for Neurofibromatosis 2
3306100|NCT01885767||SchW|Patients meeting clinical and/or genetic criteria for Schwannomatosis
3306101|NCT01885780|Experimental|Astigmatic keratotomy|
3306102|NCT01885793||Cuffed endotracheal tube|Surgical patients who require endotracheal intubation with a cuffed endotracheal tube (ETT).
3306103|NCT01885806|Experimental|Repetitive TMS|"Patients will receive 10 consecutive sessions of repetitive transcranial magnetic stimulation with the following protocol:~Frequency: 10 Hz Intensity: 90% motor limiar Session duration: 16 minutes (20 sequencies of 6 seconds of stimulation followed by intervals of 30 seconds); Localization: Left pre-frontal dorsolateral cortex;"
3306104|NCT01885806|Sham Comparator|Sham TMS|Patients will receive 10 consecutive sessions of sham transcranial magnetic stimulation following the same protocol as the intervention arm, but with no magnetic stimulation of the brain.
3306105|NCT01885819|Experimental|Treatment|Autologous stromal vascular fraction cells
3306106|NCT01885832|Experimental|Treatment|In the treatment arm, autologous stromal vascular fraction (SVF) will be injected into joints of 20 patients with grade 2, 3, or 4 radiographic OA severity.
3306107|NCT01885845|Experimental|BRASSS-V drape|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
3306108|NCT01885845|Experimental|Indirect weight method|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
3306109|NCT01885858|Other|Sequence 1|Clinics receive first the indigenous and then the mestizo profile.
3306110|NCT01885858|Other|Sequence 2|Clinics receive first the mestizo and then the indigenous profile.
3306111|NCT01885884|Experimental|Supportive Care Intervention|Monthly (minimum) patient & caregiver visits with a Supportive Care physician, embedded within their standard oncological care (through collaboration with oncology providers).
3306112|NCT01885884|No Intervention|Usual Care|Participants will receive standard oncology care from their oncology providers.
3306113|NCT01885923|Active Comparator|20% antisychotic dose increase in prodromes|Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.
3306114|NCT01885923|No Intervention|Treatment as usual|In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.
3306115|NCT01885949|Experimental|Experimental Treatment Arm|Tivozanib, taken daily for 21 days followed by a 7 day break Enzalutamide taken daily for 28 days
3306116|NCT01885962|No Intervention|Treatment as Usual (TAU)|Participants in this group engage in typical rehabilitation and perform usual skin care routine.
3306117|NCT01885962|Experimental|TAU + iSHIFTup|Participants in this group engage in typical rehabilitation and use iSHIFTup, Internet Skin Health Intervention for Targeted Ulcer Prevention. Participants are instructed to perform program recommendations to engage in preventive skin care behaviors.
3306118|NCT01885988|Active Comparator|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
3306119|NCT01885988|Placebo Comparator|Sugar pill|Sugar pill 5, 10 or 20 mg tablet, orally, daily. Sugar pill dosage will be titrated per blood pressure results.
3306120|NCT01886001|Experimental|Povidone-Iodine (Betadine)|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
3306121|NCT01886001|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
3306122|NCT01886001|Experimental|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied once a day to cord stump while umbilical line(s) are in place
3306123|NCT01886001|Sham Comparator|Control (no application)|Control arm, no product is applied, which is standard of care.
3306124|NCT01886014|Experimental|oxytocin|application of intranasal oxytocin 40IE
3306125|NCT01886014|Placebo Comparator|placebo|"application of intranasal saline~Both sprays (saline/oxytocin) are delivered in identical containers manufactured by the University pharmacy to assure blinding."
3306126|NCT01886027|Experimental|Emotional Awareness and Expression|Emotional awareness and expression training (EAET) is an emotional processing intervention.
3306127|NCT01886027|Active Comparator|Relaxation|Relaxation training will teach patients different relaxation training skills.
3306128|NCT01886027|No Intervention|Wait-list control|Standard medical care until the 3-month follow-up is completed
3306129|NCT01886040||cases with endometrial cancer|
3306130|NCT01886053|Active Comparator|Ertapenem|
3306131|NCT01886053|Experimental|Faropenem（low-dose group)|
3306132|NCT01886053|Experimental|Faropenem（high dose group）|
3306133|NCT01886066|Experimental|Indocyanine Green|All patients on study will have ICG injection for SLN mapping
3306134|NCT01886079|Experimental|Dexmedetomidine group|
3306135|NCT01886079|Placebo Comparator|Saline group|
3306136|NCT01886092|Active Comparator|Active rTMS1|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
3306137|NCT01886092|Active Comparator|Active rTMS2|Temporal low frequency repetitive transcranial magnetic stimulation of left primary auditory cortex
3306138|NCT01886092|Active Comparator|Active rTMS3|Frontal low frequency repetitive transcranial magnetic stimulation of left dorsolateral prefrontal cortex
3306139|NCT01886092|Sham Comparator|Sham Condition|Combined low frequency frontal and temporal repetitive transcranial magnetic stimulation of left primary auditory cortex and left dorsolateral prefrontal cortex
3306140|NCT01886118|Experimental|Autologous Endometrial Co-Culture|The embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5.
3306141|NCT01886118|Active Comparator|Conventional media culture|Patients in this arm will have their embryos cultured in conventional media
3306142|NCT01886131|Experimental|Synchronised video-polysomnography|
3306143|NCT01886144||Knee OA|People with knee OA of one knee
3306144|NCT01886157|Active Comparator|Corticosteroid injection|Standard corticosteroid injection.
3306145|NCT01886157|Experimental|Corticosteroid Injection and Trigger Splint|Corticosteroid Injection + Trigger Splint + Education + Home Exercises
3306146|NCT01886170|No Intervention|Hemoglobin A1C|The arms apply to the second phase of the study. This is the control arm. Participants will receive information regarding their diabetes control using the hemoglobin A1C value (standard medical information)
3306147|NCT01886170|Experimental|Experimental Format #1|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #1. The experimental formats will be determined based on the results from Phase I of the study.
3306148|NCT01886170|Experimental|Experimental Format #2|In phase II of the study, participants in this arm will receive information about their current diabetes control conveyed using experimental format #2. The experimental formats will be determined based on the results from Phase I of the study.
3306149|NCT01886183|Experimental|Virtual Reality Training|The virtual reality training will be done by experimental group with ten games of Nintendo Wii Fit.
3306150|NCT01886183|Active Comparator|Control group: Physical Therapy|The Control Group will be trained by conventional Physical Therapy exercises.
3306151|NCT01886196|Experimental|Non-steroidal anti-inflammatory drug|ibuprofen after exercise training sessions (400 mg, 3 times per week for 9 months)
3306152|NCT01886196|Placebo Comparator|placebo|placebo after exercise training sessions(3 times per week for 9 months)
3306153|NCT01886196|Experimental|resistance exercise|3 sets of 8-12 repetitions of resistance exercises focused on distal radius to be performed 3 times/week for 9 months
3306154|NCT01886196|Sham Comparator|flexibility training|flexibility training to be performed 3 days/week for 1 hour for 9 months
3306155|NCT01886209|Experimental|Cohort 1|Prednisone 10 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
3306156|NCT01886209|Experimental|Cohort 2|Methylprednisolone 8 mg tablet on Day 1 and 7; VX-509 200 mg tablets on Days 2 thru 7
3306157|NCT01886222|Experimental|Long-term mild hypothermia|Focused intervention
3306158|NCT01886222|Other|Normothermia|Standard management
3306159|NCT01886248|Experimental|Antithrombin-III Human 500IU|"Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU~Units required (IU)/kg = 50 + [(desired-baseline AT-III level) x weight (kg) / 1.4]"
3306160|NCT01886274|Experimental|tDCS|The experimental group received tDCS to the occipital cortex in 12 sessions, 3 days per week.
3306161|NCT01886274|Sham Comparator|control|The control group received sham stimulation to the occipital cortex in 12 sessions, 3 days per week.
3306162|NCT01886274|No Intervention|healthy subjects|This group was submitted to one evaluation session of cortical excitability.
3306163|NCT01886326|Experimental|Consumption of 42 g of salted peanuts|Consumption of 42 grams of peanuts daily
3306164|NCT01886326|Experimental|Consumption of 42 g of unsalted peanuts|Consumption of 42 grams of peanuts daily
3306165|NCT01886326|Experimental|Consumption of 42 g of spicy peanuts|Consumption of 42 grams of peanuts daily
3306166|NCT01886326|Experimental|Consumption of 42 g of honey peanuts|Consumption of 42 grams of peanuts daily
3306167|NCT01886326|Experimental|Consumption of 42 g of 3 diff. varieties|Consumption of 42 grams of peanuts daily
3306168|NCT01886326|Experimental|Consumption of 42 g of var. of types|Consumption of 42 grams of peanuts daily
3306169|NCT01886339||Healthy population|
3306170|NCT01886352|Active Comparator|Infiltration of portal sites with 0,5% levobupivacaine.|The first group of patients will receive the standard treatment (paracetamol, diclofenac and an opioid if necessary) with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine).
3306171|NCT01886352|Experimental|Additional injection of 0.5% levobupivacaine via a trocar|The second group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional injection of the local anesthetic ( 0.5% levobupivacaine, non -diluted) in the peritoneal cavity via a trocar both at the beginning and the end of the surgery.
3306172|NCT01886352|Experimental|Additional intraperitoneal atomization of levobupivacaine.|The third group of patients will receive the standard of care, with infiltration of the portal sites with the local anesthetic ( 0.5% levobupivacaine) and additional intraperitoneal atomization of the local anesthetic.
3306173|NCT01886365|Active Comparator|Group A|With start of the cardiopulmonary bypass, computerized algorithmic application of insulin was performed with a dedicated computerized syringe pump system (Space GlucoseControl System, B. Braun, Germany). The targeted corridor for blood glucose was determined with 80 - 150 mg/dl. During surgery, blood glucose was measured every 30 min, and on the ICU every 2 hours. TGC management was continued until ICU discharge.
3306174|NCT01886365|Active Comparator|Group B|Corresponding computerized algorithmic application of insulin management was used as for group A. However, only the interval of blood glucose measurement during surgery was adjusted to 15 minutes.
3306175|NCT01886365|Other|Group C|With start of the cardiopulmonary bypass conventional therapy with a fixed insulin dosing scheme was initiated. If blood glucose was > 150 mg/dl, manual insulin therapy was started following a fixed insulin dosing scheme. Measurements of blood glucose were performed during surgery every 30 minutes, and on the ICU every 2 hours until discharge (Routine Care).
3306176|NCT01886391|Experimental|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
3306177|NCT01886404||Efavirenz Group|Participants will be taking efavirenz as part of their antiretroviral regimen.
3306178|NCT01886430|Experimental|Functional Electrical Stimulation|Functional Electrical Stimulation for 10 days
3306179|NCT01886430|Placebo Comparator|Control Electrical Stimulation|Control Electrical Stimulation for 10 days
3306180|NCT01886443|Experimental|Combined drug approach, safety study|
3306181|NCT01886456|Experimental|PLT|patients treated with patterned laser trabeculoplasty
3306182|NCT01886456|Active Comparator|SLT|patients treated with selective laser trabeculoplasty
3306183|NCT01886469|Experimental|Adolescents (12-17yrs)|
3306184|NCT01886469|Experimental|Children (6-11 yrs)|
3306185|NCT01886482|Active Comparator|nutrition intervention|high protein diet
3306186|NCT01886482|No Intervention|no intervention|control diet
3306187|NCT01886495|Active Comparator|nutrition intervention|high protein diet
3306188|NCT01886495|No Intervention|control diet|
3306189|NCT01886508|Experimental|NSRH|patients in Arm NSRH undergo nerve-spring radical hysterectomy (NSRH)
3306190|NCT01886508|Active Comparator|RH|patients in Arm RH undergo radical hysterectomy (RH)
3306191|NCT01886521|Experimental|Lumbar drain group|Lumbar drain
3306192|NCT01886521|Active Comparator|Ventricular drain|Ventricular drain
3306193|NCT01886534|Experimental|Enhanced Caregiver Support with Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
3306194|NCT01886534|Other|Usual Care with Caregiver|Usual care
3306195|NCT01886534|Experimental|Enhanced Support without Caregiver|"Standardized Heart Failure Discharge Summary to Primary Care Physicians©~Standardized education sessions~Heart Failure Diuretic Decision Support Tool for Patient Self Management©~Digital talking scale"
3306196|NCT01886534|Other|Usual Care without Caregiver|Usual Care
3306197|NCT01886547||New patient presented with prostate disease|prostate disease identified
3306198|NCT01886560|Placebo Comparator|Placebo|Adding eatable flour into the pills
3306199|NCT01886560|Experimental|Doxycycline treatment|Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks
3306200|NCT01886573|Experimental|Treatment (azacitidine, entinostat)|Patients receive azacitidine SC on days 1-6 and 8-10 and entinostat PO on days 3 and 10. Patients undergo surgery between days 11-20 (this period can be extended 10 more days if adverse events from therapy impose a surgical risk).
3306201|NCT01886586|Active Comparator|Problem Solving Therapy|8-12 sessions of Problem Solving Therapy (both members of dyad)
3306202|NCT01886586|Active Comparator|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
3306203|NCT01886586|Active Comparator|Enhanced Usual Care|Staff will will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
3306204|NCT01886599|Experimental|Arm A: Subjects with normal renal function|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3306205|NCT01886599|Experimental|Arm B: Subjects with end stage renal disease|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3306206|NCT01886599|Experimental|Arm C: Subjects with mild renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3306207|NCT01886599|Experimental|Arm D: Subjects with moderate renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3306208|NCT01886599|Experimental|Arm E: Subjects with severe renal impairment|Asunaprevir 100 mg tablet by mouth twice daily for 7 days
3306209|NCT01886612|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Duo-STIM (stimulator), Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 1 second duration over a period of 5 minutes."
3306210|NCT01886625|Experimental|Sympathicotomy|unilateral single-port VATS sympathicotomy
3306211|NCT01886638|Experimental|Abacavir|Abacavir 600mg (as two 300mg tablets) once daily for 15 days
3306212|NCT01886664|Active Comparator|Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
3306213|NCT01886664|Experimental|Desflurane|Performing liver transplantation under general anesthesia using desflurane
3306214|NCT01886677|Experimental|Immediate diet and exercise intervention|A healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week
3380947|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given intravenously (IV) and temozolomide given orally.
3306215|NCT01886677|Other|Delayed diet and exercise intervention|This arm will receive the same diet and exercise intervention as the experimental arm once recovery from prostatectomy is achieved.
3306216|NCT01886703|Experimental|Walking Intervention|Pedometer Walking Program
3306217|NCT01886729|Active Comparator|tDCS simultaneously with hyperbaric oxygen therapy|
3306218|NCT01886729|Active Comparator|tDCS 3 weeks after start tinnitus|
3306219|NCT01886742|Active Comparator|Control group|Standard dose group (2 g intravenous (IV) cefazolin dose for patients <120 kg, and 3 g IV cefazolin for patients >120 kg)
3306220|NCT01886742|Experimental|Treatment group|Weight-based dose group (30 mg/kg cefazolin IV)
3306221|NCT01886755|Experimental|ORS with probiotic and zinc|ORS with probiotic and zinc Oral rehydration solution with freeze-dried Lactobacillus reuteri DSM 17938 and zinc sulphate
3306222|NCT01886755|Placebo Comparator|Placebo Comparator|Standard oral rehydration solution
3306223|NCT01886768|Experimental|Double pledget nasal anesthesia|All patients in the double pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to both the inferior nasal meatus and middle nasal meatus. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A preloaded biopsy forceps is protruded slowly into the middle meatus first under endoscope monitoring. The second gauze pledgetting procedure is performed two minutes after the first gauze pledgetting which serves to induce turbinate size reduction to both the INT and MNT. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3306224|NCT01886768|Active Comparator|Single pledget nasal anesthesia|All patients in the single pledget nasal anesthesia group receive endoscopic-guided gauze nasal pledgetting to either the inferior nasal meatus or middle nasal meatus determined by anterior rhinoscopy. Each patient will receive an anterior rhinoscopy to select the most patent meatus by a validated meatus scoring scale. The endoscope is preloaded with a 1.8 mm biopsy forceps to pick up a right-angled gauze strip. A gauze strip is at least brought onto the posterior end of the inferior or middle turbinate.
3306225|NCT01886794|Experimental|Postmenopausal, topical vaginal cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to estrogen cream.
3306226|NCT01886794|No Intervention|Pre-menopausal, no topical vaginal cream|Pre-menopausal, no topical vaginal cream. These women will be examined at different stages in their menstrual cycle in order to compare characteristics of the cycle at high and lower estrogen timepoints.
3306227|NCT01886794|Placebo Comparator|Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal cream containing estrogen or placebo for about one month's use prior to scheduled surgery. These will include those women randomized to placebo.
3306228|NCT01886820|Experimental|[18F]NAV4694|Intravenous [18F]NAV4694 radioactive dose 8.1 mCi(300 MBq) given once
3306229|NCT01886859|Experimental|Treatment (ibrutinib and lenalidomide)|Patients receive a run-up cycle of ibrutinib PO daily on days 1-28. Patients then receive ibrutinib PO and lenalidomide PO daily on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 12 cycles, patients who have achieved CR/CRi, nodular PR, partial remission with persistent lymphocytosis, partial remission, or who have stable disease discontinue lenalidomide and continue ibrutinib.
3306230|NCT01886885||MBCPM|There is just one group of participants of no more than 20 people.
3306231|NCT01886898|Placebo Comparator|Standard starter infant formula|starter infant formula from enrollment till 16 weeks of age
3306232|NCT01886898|Experimental|starter infant formula with prebiotics|starter infant formula from enrollment till 16 weeks of age
3306233|NCT01886898|Experimental|starter infant formula with pro and prebiotics|starter infant formula from enrollment till 16 weeks of age
3306234|NCT01886898|Other|breastfeeding group|exclusively breastfeeding during the first 16 weeks of age
3306235|NCT01886911|Active Comparator|Control for Attention Intervention|Attentional Control Game is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
3306236|NCT01886911|Experimental|Prosocial Training Intervention Game|The prosocial intervention group, which we expect will be play the experimental prosocial training game for 2 weeks (plus or minus 7 days).
3306237|NCT01886911|Experimental|Attention Training Intervention Game|The attention intervention group, which we expect will be play the experimental attention training game for 2 weeks (plus or minus 7 days).
3306238|NCT01886911|Active Comparator|Control for Prosocial Intervention|This is an active control group. We expect subjects in this group to play a control game for 2 weeks (plus or minus 7 days).
3306239|NCT01886924|Experimental|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
3306240|NCT01886924|Active Comparator|Nutrition Control|Computer delivered nutrition education
3306241|NCT01886976|Experimental|anti-CD138 CAR T cells|Patients receive anti-CD138-CAR retroviral vector-transduced autologous or donor-derived T cells on days 0,1, 2 in the absence of disease progression or unacceptable toxicity.
3306242|NCT01886989|Experimental|Cocoa|Cocoa polyphenols (960mg)
3306243|NCT01886989|Placebo Comparator|Placebo|Placebo powder (109mg polyphenols) in water
3306244|NCT01887002|Experimental|Experimental Arm 1|ONO-2952 Active tablets, every day for 2 weeks
3306245|NCT01887002|Placebo Comparator|Placebo Arm|ONO-2952 Matching Placebo every day for 2 weeks
3306246|NCT01887015|Experimental|Standard oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
3306247|NCT01887015|Other|nasal high flow oxygen therapy|Our hypothesis is that, compared with standard oxygen therapy, early application of nasal high flow oxygen therapy can reduce the need for postoperative NPPV for postoperative hypoxemia (defined as PaO2/FiO2 ratio <300).
3306248|NCT01887028|Experimental|12mmHg intraperitoneal pressure (cool, dry CO2 gas )(n=20)|
3306249|NCT01887028|Other|12mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
3306250|NCT01887028|Other|8mmHg intraperitoneal pressure with cool, dry CO2 gas (n=20)|
3306251|NCT01887028|Other|8mmHg intraperitoneal pressure (warmed, humidified CO2 gas)|
3306252|NCT01887041|Active Comparator|Stent|Arm B, after randomisation the biliary tract stents shall remain. The patients in study arm B will also receive chemotherapy and gemcitabine, according to the recommended palliative therapy for a pancreas carcinoma.
3306253|NCT01887041|Active Comparator|Biliodigestive anastomosis|"Study arm A will, after randomisation, have a biliodigestive anastomosis inserted. After the healing of the wound (al least 14 days postoperative) the treatment using gemcitabine, according to the plan mentioned below.~Gemcitabine shall be administered on days 1, 8 and 15 of each 4 week cycle. The cycle is defined as a weekly, over a period of 3 consecutive weeks, applied infusions, followed by 1 week pause. On the day of therapy a dosage of 1000 mg/ml body surface shall be administered, intravenous, over a period of 30 minutes."
3306254|NCT01887054|Active Comparator|Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Taught how to complete a visual problem-solving task (Tower of Hanoi)~Given a diary to record training at home.~In-home~•For 6 weeks at home, complete the in-home visual problem-solving tasks as instructed at Visit 1~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
3306255|NCT01887054|Placebo Comparator|Non Training Group|"There are 2 study visits. Subjects in this group will complete the following:~Visit 1~Gait evaluation~Neuropsychological testing~Questionnaires and assessments~Visit 2~Gait evaluation~Neuropsychological testing~Questionnaires and assessments"
3306256|NCT01887067|Experimental|Renal denervation therapy|
3306257|NCT01887080|Experimental|Exercise|Experimental group 1 performed cardiovascular rehabilitation home-based program
3306258|NCT01887080|Experimental|Exercise afther Microcurrent|Experimental group 2 performed cardiovascular rehabilitation home-based program just after microcurrent.
3306259|NCT01887080|Other|Cardiovascular Risk Factors|Education about risk factors
3306260|NCT01887093|Experimental|Morning walking|Participants were requested to walk in the morning at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
3306261|NCT01887093|Experimental|Evening walking|Participants were requested to walk in the evening at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks. We demanded everyone to record the situation of walking including duration, distance and time daily in a log book. Each participant was telephoned at least once a week to ensure the adherence to the exercise program. Patients were called back every month to hand in the log book and to understand the information about medication use. Furthermore, at the beginning and end of the 12-week program, both the walking groups were supervised by researchers to walk for continuous three days and the duration and distance of walking were recorded.
3306262|NCT01887093|No Intervention|No walking|The control group was requested to maintain their usual level of physical activity.
3306263|NCT01887106|Experimental|GLPG1205 single dose|Single oral dose of GLPG1205 suspension - ascending doses
3306264|NCT01887106|Placebo Comparator|Placebo single dose|Single oral dose of placebo suspension
3306265|NCT01887106|Experimental|GLPG1205 multiple doses|Multiple oral doses of GLPG1205 suspension - ascending doses
3306266|NCT01887106|Placebo Comparator|Placebo multiple doses|Multiple oral doses of placebo suspension
3306267|NCT01887119|Active Comparator|Eplerenone|Eplerenone 50 mg 1dd during four weeks
3306268|NCT01887119|Placebo Comparator|Placebo|Eplerenone-matched placebo
3306269|NCT01887145|Active Comparator|Open surgery|Open surgery is Open carpal tunnel release
3306270|NCT01887145|Experimental|Endoscopic surgery|Endoscopic surgery is 2-portal endoscopic carpal tunnel release
3306271|NCT01887158|Active Comparator|bisacodyl plus 2-Liter Polyethylene glycol|Patients randomized to the low-volume arm, will be invited to consume 2 sachets of Lovol-esse (Polyethylene glycol) in one liter of water at 8:00 PM the evening before the colonoscopy and 2 sachets in one liter of water 4 hours before their scheduled colonoscopy appointment; furthermore, the patients will be instructed to take three 5-mg tablets of bisacodyl the day before the procedure, at 5:00 PM.
3306272|NCT01887158|Active Comparator|4-Liter Polyethylene glycol|Patients assigned to the high-volume arm will be invited to consume 2 envelopes of Selg-esse 1000 (polyethylene glycol) in 2 litres of water and drink the resulting solution in about 2-3 hours starting at 6:00 PM the evening before the colonoscopy; the day of the procedure, starting 5 hours before the procedure, the patients will be invited to complete the preparation with 2 others envelopes of Selg-esse 1000 (polyethylene glycol) dissolved in 2 litres of water.
3306273|NCT01887184|Placebo Comparator|Normal Saline|Normal saline was given intranasally
3306274|NCT01887184|Active Comparator|Dexmedetomidine|1.5mcg dexmedetomidine was given intranasally before procedure
3306275|NCT01887197|Experimental|Repeatability|Subjects perform two sequential absorptive clearance scans (within 30 days) to determine the repeatability of the technique. Subjects also perform a third scan two years later so that longitudinal change can be measured.
3306276|NCT01887197|Experimental|Response|Subjects perform three different absorptive clearance scans. One is a baseline measurement while the other two measure absorptive clearance after an intervention (inhaled hypertonic saline, mannitol inhalation powder).
3306277|NCT01887223|Experimental|Transconjunctival needling revision|Eyes with primary glaucoma surgery failure with encapsulated bleb submitted to surgical revision
3306278|NCT01887223|Active Comparator|Medical treatment|Eyes with primary glaucoma surgery failure with encapsulated blebs were treated with medical treatment (hypotensive eye drops)
3306279|NCT01887236|Active Comparator|Step Physical Activity|A physical activity program that is based on the Step Apparatus Training Program
3306280|NCT01887236|Active Comparator|Stability Ball|A physical activity program that is based on the Stability Ball
3306281|NCT01887249|Experimental|15 day sequential eradication therapy|the 15-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for 10 days.
3306282|NCT01887249|Active Comparator|10-day sequential eradication therapy|the 10-day sequential therapy regimen, which consisted of esomeprazole (40 mg) plus amoxicillin (1000 mg) twice a day for 5 days, then esomeprazole (40 mg) with clarithromycin (500 mg) and metronidazole (500 mg) twice a day for another five days
3306283|NCT01887249|No Intervention|7-day PPI triple eradication therapy|7-day PPI triple therapy regimen, which consisted of esomeprazole (40mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
3306284|NCT01887262|Experimental|Intervention|Incident peritoneal dialysis (PD) patients who are randomly allocated to BCM-guided fluid management will receive BCM measurement every two months over 1-year period. The BCM results will be notified to the physicians and the participating subjects. Based on the BCM results along with the clinical information such as blood pressure, edema and weight, the physicians will prescribe PD fluid and diuretics, targeting within 1L of overhydration status. They will prescribe dietary education to the patient, if necessary.
3306285|NCT01887262|Active Comparator|Control|BCM will be measured at the beginning and end of the study, respectively. However, the BCM results will be blinded to the physicians and the control group. The physician will prescribe drugs, PD fluids, and dietary education to the patients based on the clinical information alone - such as blood pressure, edema and body weight.
3306286|NCT01887275|Experimental|medical ozone therapy with humares|
3306287|NCT01887275|Active Comparator|conventional interferon-α|
3306288|NCT01887301|Active Comparator|Group 1: mild hepatic impairment|Mild hepatic impairment: eight patients of Child-Pugh Grade A (Score 5-6). All patients received Sativex treatment.
3306289|NCT01887301|Active Comparator|Group 2: Moderate hepatic impairment|Moderate hepatic impairment: eight patients of Child-Pugh Grade B (Score 7-9). All patients received Sativex treatment.
3306290|NCT01887301|Experimental|Group 3: Pugh Grade B (Score 7-9).|Severe hepatic impairment: eight patients of Child-Pugh Grade C (Score 10-15). All patients received Sativex treatment.
3306291|NCT01887301|Active Comparator|Group 4: Control group|Control Group: eight healthy subjects matched with respect to age (±10 years), weight (±10% body mass index [BMI]) and sex to the severe or most severe evaluable patients. All patients received Sativex treatment.
3306292|NCT01887314|Experimental|Standardized Ginger extract soft gel capsules|Patients receive 2 soft gel capsules of Ginger extract, twice a day
3306293|NCT01887314|Placebo Comparator|Placebo soft gel capsules|Patients receive 2 soft gel capsules of Placebo, twice a day
3306294|NCT01887340|Experimental|Cohort 1|"PET-TDM~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
3306295|NCT01887340|Experimental|Cohort 2|"PET-TDM~ETOPOSIDE (100 mg/m2 D1 to D5) and CISPLATINE (20 mg/m2 de D1 to D5)~carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
3306296|NCT01887366|Experimental|TV-1380 150 mg|
3306297|NCT01887366|Experimental|TV-1380 300 mg|
3306298|NCT01887366|Placebo Comparator|Placebo|
3306299|NCT01887379|Experimental|GRDF furosemide fasting conditions|Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
3306300|NCT01887379|Experimental|GRDF furosemide fed conditions|Subjects will be tested under fed conditions after administration of GRDF Furosemide.
3306301|NCT01887392|Experimental|Wave A|LTC Homes randomized into Wave A will receive the intervention first. The intervention includes Knowledge Translation Education Sessions.
3306302|NCT01887392|Experimental|Wave B|LTC Homes randomized into Wave B will receive the intervention after Wave A. The intervention includes Knowledge Translation Education Sessions.
3306303|NCT01887405|Active Comparator|Adrenaline: Session 1 Jext, 2 Epipen|Subjects will be randomised 1:1 to use Jext in session 1 and EpiPen in session 2.
3306304|NCT01887405|Active Comparator|Adrenaline: Session 1 Epipen, 2 Jext|Subjects will be randomised 1:1 to use EpiPen in session 1 and Jext in session 2.
3306305|NCT01887431|Experimental|Telecare|Each patient will transmit glucometer and pump data electronically via a web site to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control.
3306306|NCT01887431|Active Comparator|Conventional therapy|3-month routine clinic visits
3306307|NCT01887444|Experimental|Lactobacillus reteuri|Dietary Supplement: Lactobacillus reuteri DSM17938 probiotic 2 x 10(8) CFU/day 21 days
3306308|NCT01887444|Placebo Comparator|Placebo|Other: Placebo
3306309|NCT01887457|Experimental|Voriconazole|Standard adult Voriconazole (VFEND) Loading (1 hr infusion): 6mg/kg at 1 hour and 12 hours on day 1. Followed by standard maintenance dose 4mg/kg at 1 hour and 12 hours on day 2 (1 hour infusion). Day 3 follows the same schedule, expect the dose is adjusted, this dose is used on Day 4 and a further dose adjustment is made that is administered as above on Day 5.
3306310|NCT01887483|Active Comparator|Vetal Laban active|Vetal Laban with L. acidophilus
3306311|NCT01887483|Placebo Comparator|Placebo|Vetal Laban -like product without L. acidophilus
3306312|NCT01887496||Chickenpox complications|Cases were identified by International Classification of Disease of the Tenth Revision (ICD-10) diagnostic codes for chickenpox infection or chickenpox-associated complications, if available.
3306313|NCT01887522|Experimental|VINILO|"VINILO-arm: Vinblastine and nilotinib given in combination at the RD defined in the Phase I part:~Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28 Recommended doses of the drug combination will be reconsidered at an interim stage of the phase II trial after the analysis of the delayed toxicity encountered in the first 20 patients treated at the initial RD (adaptive design)."
3306314|NCT01887522|Active Comparator|Control Vinblastine only|"Control Vinblastine only arm:~· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Each 28-day cycle is repeated on Day 29/Day 1.~In both treatment groups, dose reductions and/or administration delays will be performed in case of severe hematological and/or non hematological toxicities while on treatment.~Vinblastine will be temporarily stopped in case of neutropenia <1 x109/L or thrombopenia <75 x 109/L. It could be re-started at a reduced dose after complete recovery.~Patients benefiting from study treatment may continue up to 12 cycles as long as the toxicity-benefit ratio is adequate."
3306315|NCT01887535|Experimental|Cohort 1: JNJ-54861911 3 mg|Participants will be administered single doses of JNJ-54861911 on Days 1 to 14. Initially the doses will be once per day, but the frequency of daily dosing (eg, once-daily, twice-daily, three times daily) may change prior to or during study conduct depending on the pharmacokinetic data from the ongoing single-ascending dose study (54861911ALZ1001) or ongoing cohorts in this current study. Actual dose levels as well as the magnitude of dose escalation will depend on the results of the ongoing single-ascending dose study, the observed safety and tolerability profile as well as the observed exposures.
3306316|NCT01887535|Experimental|Cohort 2: JNJ-54861911 10 mg|
3306317|NCT01887535|Experimental|Cohort 3: JNJ-54861911 30 mg|
3306318|NCT01887535|Experimental|Cohort 4: JNJ-54861911 80 mg|
3306319|NCT01887535|Experimental|Cohort 5: JNJ-54861911 25 mg|
3306320|NCT01887535|Placebo Comparator|Cohorts 1-4: Placebo|Participants in Cohorts 1-4 will receive matching placebo.
3306321|NCT01887548|Experimental|Active CD|Patients whose CDAI score >150 points would be enrolled in this group.
3306322|NCT01887548|Active Comparator|Quiescent CD|Patients whose CDAI score ≤150 points would be enrolled in this group.
3306323|NCT01887561|No Intervention|treatment|
3306324|NCT01887574|Experimental|Open|
3306325|NCT01887613||Regnite group|Patients who receive Regnite
3306326|NCT01887626|Experimental|A|Ticagrelor 90 mg as a whole tablet
3306327|NCT01887626|Experimental|B|Ticagrelor 90 mg tablet crushed and suspended in water
3306328|NCT01887626|Experimental|C|Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach
3306329|NCT01887639||Unipolar major depression|Outpatients Individuals between 18 and 75 years old with a current episode of non-psychotic unipolar major depression that are treated with an antidepressant drug according to physician´s current and usual practice.
3306330|NCT01887652|Active Comparator|conventional ovarian stimulation|women whose protocol of ovarian stimulation was based on age, ovarian size and previous treatment
3306331|NCT01887652|Active Comparator|individualized ovarian stimulation|women whose protocol of ovarian stimulation was based on anti-mullerian hormone
3306332|NCT01887665|Experimental|Incentives|Prize-based financial incentives, informed by contingency management principles, are offered to patients who attend treatment visits.
3306333|NCT01887691|Experimental|eszopiclone|We will evaluate the impact of pharmacologic enhancement of effective sleep with nightly eszopiclone (taken before bedtime for 1 week, home environment) on glycemic profiles (continuous glucose monitoring, 72 hrs) in prediabetics and diabetics compared to pretreatment baseline. The dose of eszopiclone will be the lowest tolerated dose (1-3 mg) via dose escalation and side effect profile assessment.
3306334|NCT01887704|Experimental|Rotablator|"Rotablator plus conventional angioplasty and/or stenting was performed in 120 patients in the R group.~Rotablator using 140, -160, 000 rpm, small rota burr (burr-to-artery ratio, 0.6:1), avoid drop of >5000 rpm for 5s.~Conventional intervention will be performed in the rotablator group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
3306335|NCT01887704|Active Comparator|Conventional|"Conventional angioplasty and/or stenting was performed in 120 patients in the C group.~Conventional intervention without rotablator was performed in the C group. All subjects were given 100 mg/day aspirin and clopidogrel (300 mg loading dose and 75 mg/day maintenance dosage) at least 24 h before the procedure. A cutting balloon, buddy wire balloon, buddy wire, or DES (including sirolimus-eluting stent, paclitaxel-eluting stent, everolimus-eluting stent,zotarolimus-eluting stent) was implemented at the discretion of the operator in both groups."
3306336|NCT01887730|Active Comparator|arm 2|Hand washing with soap and water according to instructions. The effect of intervention is assessed by following occurrence of infections.
3306337|NCT01887730|Placebo Comparator|arm 0|No specific advice on hand hygiene. The effect of intervention is assessed by following occurrence of infections.
3306338|NCT01887730|Active Comparator|Arm 3|Hand cleaning with alcohol-containing hand rub
3306339|NCT01887743|Experimental|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
3306340|NCT01887756|Experimental|Single arm study|The clients will receive tele-rehabilitation treatment via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback is given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software generates a report which includes the duration and type of exercises performed by the subject.
3306341|NCT01887769||Lung cancer patient at diagnosis|
3306342|NCT01887782|Experimental|HFL rTMS|High Frequency Left repetitive transcranial magnetic stimulation five days per week for 4 weeks
3306343|NCT01887782|Active Comparator|iTBS|intermittent Theta Burst Stimulation (iTBS) five days per week for 4 weeks
3306344|NCT01887795|Experimental|1. WBRT alone|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
3306345|NCT01887795|Experimental|2. Erlotinib concurrent WBRT|Selected 224 patients with multiple brain metastases from NSCLC, they will be randomized to WBRT or Erotinib concurrent WBRT. It was enough to compare the efficacy of Erotinib concurrent WBRT vs. WBRT
3306346|NCT01887808|Experimental|Cetaphil DermaControl Oil Control Moisturizer SPF 30|All subjects receive Cetaphil DermaControl Oil Control Moisturizer SPF 30
3306347|NCT01887821|Active Comparator|Chloroquine|25mg base/kg for 3 days
3306348|NCT01887821|Active Comparator|Dihydroartemisinin/Piperaquine|Dihydroartemisinin 40 mg + piperaquine phosphate 320 mg per tablet; once daily for three days, doses depend on weight
3306349|NCT01887834|Placebo Comparator|Kyodophilus matching placebo capsules|"Kyodophilus Matching Placebo Capsules~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
3306350|NCT01887834|Active Comparator|Kyodophilus multi strain probiotic capsules|"Kyodophilus multi-strain probiotic capsules~The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
3306351|NCT01887847|Experimental|sublingual nicotine tablet|investigational 2 mg sublingual nicotine tablet
3306352|NCT01887847|Active Comparator|COMMIT nicotine lozenge|COMMIT 2 mg nicotine lozenge
3306353|NCT01887860|Experimental|Cetaphil Daily Facial Moisturizer SPF50|All subjects receive Cetaphil Daily Facial Moisturizer SPF 50
3306354|NCT01887873|Other|Hyaluronan Thiomer i.o. implantable device|active treatment
3306355|NCT01887886|Experimental|Onartuzumab + Erlotinib|
3306356|NCT01887886|Active Comparator|Placebo + Erlotinib|
3306357|NCT01887899|Experimental|transcranial direct current stimulation|
3306358|NCT01887899|Placebo Comparator|sham stimulation|
3306359|NCT01887925||breast cancer|breast cancer patients receiving chemotherapy
3306360|NCT01887938|Experimental|Cohort 1|Participants will receive 10 milligram (mg) of HGT-1110 (Recombinant human arylsulfatase A) intrathecal (IT) injection every-other-week (EOW).
3306361|NCT01887938|Experimental|Cohort 2|Participants will receive 30 mg of HGT-1110 IT injection EOW.
3306362|NCT01887938|Experimental|Cohort 3|Participants will receive 100 mg of HGT-1110 IT injection EOW.
3306363|NCT01887938|Experimental|Cohort 4|Participants will receive 100 mg of HGT-1110 IT injection once weekly for 12 weeks followed by 150 mg EOW.
3306364|NCT01887951|Active Comparator|Tramadol|Tramadol HCL. Dosage form: Injection Strength: 50mg/ampoule Frequency: 1 time
3306365|NCT01887951|Experimental|Penthrox|Dosage form: Inhalation; Strength: 3ml/bottle; Frequency: Up to 6ml per day. Total weekly dose should not exceed 15ml.
3306366|NCT01887964|Other|Community-1|Received control flour first and then Resistant starch type 4 (RS4) flour
3306367|NCT01887964|Other|Community-2|Received RS4 flour first and then control flour
3306368|NCT01887977|Experimental|Computational modeling|
3306369|NCT01888016|Experimental|fascial manipulation|
3306370|NCT01888016|Active Comparator|standard treatment|
3306371|NCT01888029|Experimental|transcranial direct current stimulation|
3306372|NCT01888029|Placebo Comparator|sham stimulation|
3306373|NCT01888042|Experimental|Everolimus|Everolimus will be administered per os every day at the same hour immediately after a meal with a glass of water 10 mg (1 tablet of 10 mg)
3306374|NCT01888055|Experimental|transcranial direct current stimulation|
3306375|NCT01888055|Placebo Comparator|sham stimulation|
3306376|NCT01888068||No treatment|
3306377|NCT01888081|Experimental|A-dmDT390-bisFv(UCHT1) with Ionizing Radiation|A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation
3306378|NCT01888094|Experimental|ultrasound guided for cannulation and examination|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
3306379|NCT01888094|Other|landmark method and examination with chest radiography|Prospective, randomized controlled clinical unicentric study, in ICU, Cannulation of the subclavian venous and examination guided with ultrasound
3306380|NCT01888107|Experimental|Risperidone Long-acting Injectable (LAI)|Risperidone LAI will be administered in dosages of 25, 37.5, and 50 mg.
3306381|NCT01888120||Severe Chronic Pain|
3306382|NCT01888133|Experimental|Group Walk First|Participants attend a weekly walking group session from weeks 1-6 and are not required to attend from weeks 7-12.
3306383|NCT01888133|Experimental|Individual Walk First|Participants are not required to attend a weekly group walking sessions from weeks 1-6 and attend a weekly walking group session from weeks 7-12.
3306384|NCT01888146|Experimental|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
3306385|NCT01888146|No Intervention|Treatment as usual|Patients in this arm will receive care as usual and utilize services as they currently exist in the health plan system.
3306386|NCT01888159|Active Comparator|Tubal Sterilization with bipolar|Salpingectomy vs Tubal Sterilisation
3306387|NCT01888159|Active Comparator|Bilateral Salpingectomy|Salpingectomy vs Tubal Sterilisation
3306388|NCT01888172|Experimental|Weight Watchers Online|
3306389|NCT01888172|Experimental|Weight Watchers Online + ActiveLink|
3306390|NCT01888172|Active Comparator|Internet Delivered Eating and Activity Program|
3306391|NCT01888185||Parkinson's Disease (PD)|Patients with a clinical diagnosis of PD (in various stages)
3306392|NCT01888185||Progressive supranuclear palsy (PSP)|Patients with a clinical diagnosis of PSP (in various stages)
3306393|NCT01888185||Multiple system atrophy (MSA)|Patients with a clinical diagnosis of MSA (in various stages)
3306394|NCT01888185||Controls|Age and gender-matched adults free from neurological disease
3306395|NCT01888198||renal mass ablation candidates|Standard of care interventions for the treatment of renal masses using energy ablation will be studied. Data collection can be divided into five basic categories: 1) Patient demographics and relevant history, 2) Renal mass characteristics, 3) Ablation procedure details, 4) Imaging studies, and 5) Patient-reported quality of life.
3306396|NCT01888211|Experimental|Omega 3 fatty acid supplementation|Omacor 2 grams daily
3306397|NCT01888211|Placebo Comparator|Olive Oil|Olive Oil capsule 2 grams daily
3306398|NCT01888224|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3306399|NCT01888224|Active Comparator|AMNESTEEM|AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
3306400|NCT01888237|Active Comparator|Sequential therapy (ST)|10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
3306401|NCT01888237|Experimental|High dose PPI triple therapy(TT)|10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days
3306402|NCT01888250|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3306403|NCT01888250|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
3306404|NCT01888263|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3306405|NCT01888263|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 200mg of GlaxoSmithKline Research Triangle Park, NC
3306406|NCT01888276|Other|healthy volunteers|evaluation of word generation and of motivation
3306407|NCT01888276|Other|compulsive gamblers|evaluation of word generation and of motivation
3306408|NCT01888289|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3306409|NCT01888289|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
3306410|NCT01888302|Experimental|Treatment (cisplatin, gemcitabine hydrochloride, sirolimus)|Patients receive cisplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and sirolimus PO daily or three times weekly. Treatment repeats every 3 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3306411|NCT01888315|Experimental|Catheter-based renal denervation|"One procedure will be performed using one of the CE-marked devices for renal denervation:~Device: Renal denervation with Symplicity Flex Medtronic/Ardian Device: Renal denervation with EnligHTN St. Jude Medical Device: Renal denervation with Paradise Recor Device: Renal denervation with V2 Vessix"
3306412|NCT01888315|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
3306413|NCT01888328|Experimental|Isotretinoin capsules, 40 mg|Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
3306414|NCT01888328|Active Comparator|ACCUTANE|ACCUTANE 40 mg of Roche Laboratories Inc
3306415|NCT01888341|Experimental|Isotretinoin capsules, 20 mg|Isotretinoin Capsules, 20 mg of Dr.Reddy's Laboratories Ltd
3306416|NCT01888341|Active Comparator|ACCUTANE|ACCUTANE 20 mg of Roche Laboratories Inc
3306417|NCT01888354|Experimental|Acthar Gel 80 IU x 14 days|Acthar Gel 80 IU SQ x 14 days
3306418|NCT01888354|Experimental|Acthar Gel 80 IU x 5 days|Acthar Gel 80 IU SQ x 5 days
3306419|NCT01888380|Experimental|Foetuses|"still birth and termination of pregnancies~intervention: minimally invasive, virtual autopsy"
3306420|NCT01888380|Experimental|Newborns|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
3306421|NCT01888380|Experimental|Children and adolescents|"who died of natural- and non-natural cause~intervention: minimally invasive, virtual autopsy"
3306422|NCT01888393|Experimental|Group A|Approximately 12 subjects (male and female) with moderate hepatic impairment
3306423|NCT01888393|Experimental|Group B|Approximately 12 healthy subjects (male and female)
3306424|NCT01888406|Experimental|Guided Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources. In addition, participants receive 8 individual sessions with a peer coach who supports participants in working the self-help program.
3306425|NCT01888406|Other|Pure Self-Help|Participants receive self-help materials, including a book (Overcoming Binge Eating by C. Fairburn, handouts, and online resources.
3306426|NCT01888419|No Intervention|No active treatment|Clinical follow-up, no active intervention.
3306427|NCT01888419|Experimental|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site.
3306428|NCT01888445|Experimental|ASP1517 Low dose group|Participants received an oral dose of ASP1517 three times a week.
3306429|NCT01888445|Experimental|ASP1517 Middle dose group|Participants received an oral dose of ASP1517 three times a week.
3306430|NCT01888445|Experimental|ASP1517 High dose group|Participants received an oral dose of ASP1517 three times a week.
3306431|NCT01888445|Active Comparator|Darbepoetin group|Participants received Darbepoetin alfa intravenously once a week.
3306432|NCT01888458|Experimental|Micafungine|
3306433|NCT01888471|Other|Cases Group|"Cases Group will be defined as:~Maternal subjects identified with invasive GBS disease from the enrolled maternal-newborn dyad Study cohort: Cases will be classified as follows:~EOD (Early onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 0-6 days of birth.~LOD (Late onset disease): isolation of GBS from the blood or cerebrospinal fluid (CSF) within 7-90 days of birth."
3306434|NCT01888471|Other|Controls Group|Controls will be defined as newborns to mothers, enrolled into the study and identified as colonized by a serotype which is homologous to that of cases, but who do not develop invasive GBS disease.
3306435|NCT01888510|Experimental|Diagnostic (imaging studies)|Patients undergo conventional free breathing CT, 4D CT, ABC CT, ABC CBCT, and free breathing CBCT before undergoing radiation therapy.
3306436|NCT01888523|Experimental|Everyday experiences writing|Involves logging in to an online survey and writing in the survey about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
3306437|NCT01888523|Experimental|Expressive writing|Involves logging in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
3306438|NCT01888536|Experimental|Limaprost & Placebo|Limaprost 5㎍ tablet and a capsule of Pegabalin-Placebo thrice a day for 8 weeks.
3306439|NCT01888536|Active Comparator|Pregabalin & Placebo|Pregabalin 75mg capsule and a tablet of Limaprost-Placebo thrice a day for 8 weeks.
3306440|NCT01888536|Active Comparator|Limaprost+Pregabalin|Limaprost 5㎍ tablet and Pregabalin 75mg capsule thrice a day for 8 weeks.
3306441|NCT01888549|Experimental|arm1-High dose PPI|
3306442|NCT01888549|Active Comparator|arm2-standard dose PPI|
3306443|NCT01888549|Placebo Comparator|arm3-placebo|Esomeprazole placebo
3306444|NCT01888562|Experimental|Ponatinib|Ponatinib 45mg po daily for 4 weeks (4 weeks equal 1 cycle).
3306445|NCT01888575||Aspirin discontinuers; Aspirin non-discontinuers|Patients on low dose ASA for secondary prevention that discontinue aspirin and those not discontinuing aspirin
3306446|NCT01888575||Drug|PPI continuous use; No PPI use
3306447|NCT01888588||Cases|Patients with symptomatic peptic ulcer (UPU)
3306448|NCT01888588||Control group|Control group without symptomatic peptic ulcer (UPU).
3306449|NCT01888601||NSCLC eligible for primary surgery|NSCLC eligible for primary surgery
3306450|NCT01888614||Sickle Cell Patients|Patients with Sickle Cell, over 18 years of age
3306451|NCT01888627|Experimental|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
3306452|NCT01888653|Placebo Comparator|Comparison-Training-Program|Placebo-training program: attention control training (ACT), is identical to the ABM protocol except that during the presentation of the trials where a threat word is presented, the probe will appear with equal frequency in the position of the threat and neutral word. Thus, neither threat nor neutral words provide information regarding the position of the target probe, and there is no contingency between the position of either threat or neutral words, and the position of the probes
3306453|NCT01888653|Active Comparator|Attention Biased Modification|Attention-bias-modification treatment (ABM) is designed to implicitly modify patients' biased threat attendance via computerized training protocols. During each session, 240 trials (80 neutral-neutral pairs, 160 threat-neutral pairs) will be presented. On trials where participants see one neutral word and one threat word, the probe will always follow the neutral word location. Thus, although there is no specific instruction to direct attention away from threat words, on 66% of all trials (and 100% of the threat-neutral trials) the position of the neutral word will indicate the position of the target probe.
3306454|NCT01888666||rapid palatal expansion (RPE) using the Haas appliance|
3306455|NCT01888666||slow palatal expansion (SPE)|
3306456|NCT01888679|Experimental|head movement|head movement in extension, flexion, right and left rotation
3306457|NCT01888705||Control group|Group of nonsmokers individuals without respiratory disease.
3306458|NCT01888705||NE|Smokers wiht normal spirometry.
3306459|NCT01888705||LV|Patients with COPD level I, mild.
3306460|NCT01888705||MOD|Patients with COPD level II, moderate.
3306461|NCT01888705||GV|Patients with COPD level III, severe.
3306462|NCT01888705||MGV|Patients with COPD level IV, very severe.
3306463|NCT01888718|Experimental|Fexofenadine Hydrochloride Orally Disintegrating|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr.Reddy's Laboratories Ltd
3306464|NCT01888718|Active Comparator|ALLEGRA|ALLEGRA orally disintegrating tablets 30 mg of Sanofi Aventis
3306465|NCT01888731|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3306466|NCT01888731|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
3306467|NCT01888744|Active Comparator|Group 1 (GnRH agonist group)|The long GnRH agonist protocol starts on day 21 of the preceding cycle with the administration of GnRH agonist, Decapeptyl® 0,1 mg subcutaneously daily or buserelin acetate, Suprefact® 600 μg daily intranasal. The administration of highly purified human menopausal gonadotropin (hp-HMG), Menopur® 225 IU subcutaneously is started after three weeks of desensitization. The desensitization is checked by ultrasound (absence of cysts) and hormonal measurement (Estradiol levels < 80 pg/ml, FSH ≤ 10 IU/l and progesterone < 1,5ng/ml)
3306468|NCT01888744|Active Comparator|Group 2 (GnRH antagonist group)|Ovarian stimulation is started at day 2 of the menstrual cycle with 225 IU of HMG (Menopur ®) subcutaneously. At day 6 of the stimulation GnRH antagonist (Orgalutran®) 0,25 mg subcutaneously is added. Basal hormonal status will be confirmed in the antagonist group before starting.
3306469|NCT01888757|Experimental|Lamotrigine Extended Release Tablets|Lamotrigine Extended Release Tablets, 25 mg, 50 mg, 100 mg, 200 mg and 300 mgof Dr. Reddy's Laboratories Limited
3306470|NCT01888757|Active Comparator|LAMICTAL XR|(containing Lamotrigine)Extended Release tablets 50 mg of GlaxoSmithKline Research Triangle Park, NC
3306471|NCT01888770||Normotensive Term|Infants born at term (>37 weeks) to Normotensive pregnancies
3306472|NCT01888770||Term Preeclampsia|Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
3306473|NCT01888770||Preterm Normotensive|Infants born to Normotensive pregnancies at <37 weeks gestation
3306474|NCT01888770||Preterm Hypertensive|Infants born to hypertensive pregnancies at <37 weeks completed gestation
3306475|NCT01888770||Term Pregnancy-induced Hypertension|Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
3306476|NCT01888783|Experimental|CRPS Type I|Patients diagnosed with complex regional pain syndrome type I of the upper limb
3306477|NCT01888783|Active Comparator|Median Nerve Neuropathy|Patients diagnosed with a neuropathy of the median nerve of the upper limb.
3306478|NCT01888783|Active Comparator|Healthy Controls|Healthy adult persons.
3306479|NCT01888796|Active Comparator|Linagliptin|Linagliptin 5 mg (tablets) once daily for 6 month
3306480|NCT01888796|Placebo Comparator|Placebo|Placebo (tablets) once daily for 6 month
3306481|NCT01888809|Experimental|Comprehensive preventive services|Combined comprehensive services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
3306482|NCT01888809|Active Comparator|Screening and referral|Annual screening and referral for services as needed
3306483|NCT01888822|Placebo Comparator|Placebo|Intravenous infusion of 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3306484|NCT01888822|Active Comparator|Ampicillin-sulbactam|Intravenous infusion of 3gr ampicillin-sulbactam in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3306485|NCT01888822|Active Comparator|Ciprofloxacin|Intravenous infusion of 400 mg ciprofloxacin in 0.9% Sodium Chloride 250 ml during induction of anesthesia and before laparoscopic cholecystectomy.
3306486|NCT01888835|Active Comparator|Mirtazapine|mirtazapine 30 mg orally per day
3306487|NCT01888835|Placebo Comparator|Placebo|placebo (30 mg) orally per day
3306488|NCT01888848|Experimental|blueberry|Participants randomized into this arm of the study consume freeze-dried blueberry.
3306489|NCT01888848|Placebo Comparator|placebo|Participants randomized into this arm of the study consume a blueberry placebo.
3306490|NCT01888861|Experimental|alpha-lipoic acid|the patients in this arm were received 900mg alpha-lipoic acid for 10 days through nasogastric(NG) tube.
3306491|NCT01888861|Placebo Comparator|placebo|the patients in this arm were received 900mg placebo through NG tube.
3306492|NCT01888887|Experimental|Cetaphil Daily Facial Cleanser|All subjects receive Cetaphil Daily Facial Cleanser
3306493|NCT01888978|Experimental|Modified FOLFOX-6|Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3306494|NCT01888978|Experimental|Ox-Tax|Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed
3306495|NCT01888978|Experimental|FOLFIRI|Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed
3306496|NCT01888978|Experimental|Tax-Iri|2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed
3306497|NCT01888978|Experimental|Gem-Ox|Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3306498|NCT01888978|Experimental|Gem-5FU|Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed
3306499|NCT01888978|Experimental|Gem-Tax|Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle
3306500|NCT01888991|No Intervention|water with resting condition|
3306501|NCT01888991|Experimental|glucose with resting condition|
3306502|NCT01888991|Experimental|water with exercise condition|
3306503|NCT01888991|Experimental|glucose with exercise condition|
3306504|NCT01889004|Experimental|Dexmedetomidine|Intravenous dexmedetomidine using target controlled infusion
3306505|NCT01889004|Experimental|Propofol|Intravenous propofol using target controlled infusion
3306506|NCT01889030||Target population|This observational, cross-sectional, national multicenter designed study will describe the frequency of use of different evaluation methods (risk scores or subjective assessment) employed to determine the cardiovascular risk of patients in a primary care setting, at both General Practitioners (GPs) or Cardiologists offices.
3306507|NCT01889056|Experimental|Erythropoietin (Epoetin beta)|Short infusion of 60.000 IU Epoetin beta in 0.9% sodium chloride solution (250 ml)
3306508|NCT01889056|Placebo Comparator|0.9% sodium chloride solution|Short infusion of 0.9% sodium chloride solution (250 ml)
3306509|NCT01889082|Active Comparator|Face to Face Behavioral Weight Loss|12-week treatment program consisting of weekly, in-person group meetings and brief, bi-weekly individual check-ins
3306510|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching
3306511|NCT01889082|Active Comparator|Web Based Behavioral Weight Loss Plus Optional Group Sessions|12-week treatment program consisting of an initial in-person group session (weight loss 101 and intro to website), followed by weekly web-based program and e-coaching. Participants in this arm will also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training). *New material / content is not provided in these optional sessions, rather they are meant to serve as a place to practice applying the core content from the lessons.
3306512|NCT01889095|Experimental|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
3306513|NCT01889095|Active Comparator|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
3306514|NCT01889108|No Intervention|Control|Usual care
3306515|NCT01889108|Experimental|Intervention group|Intervention with SPEEDI
3306516|NCT01889121||Methadone maintenance program|Mothers on methadone treatment at time of delivery who delivered at Good Samaritan Hospital but were not enrolled in psychosocial intervention offered through the HOPE (Helping Opiate-addicted Pregnant women Evolve) program.
3306517|NCT01889121||Psychosocial intervention|Pregnant women who were in methadone maintenance program PLUS structured psychosocial intervention at the time of delivery (HOPE Program).
3306518|NCT01889134|Experimental|Alendronate|Sedron (alendronate) 70 mg taken orally once a week for 12 months
3306519|NCT01889134|Active Comparator|Parathyroidectomy|Selective parathyroidectomy
3306520|NCT01889134|No Intervention|Control group|No intervention
3306521|NCT01889147|Active Comparator|14C-hRESCAP|Peak plasma concentration response of a dose hRESCAP will be examined and compared with the saline condition
3306522|NCT01889147|Placebo Comparator|saline|Peak plasma concentration response of different dosages of hRESCAP will be examined and controlled with the saline condition
3306523|NCT01889147|Active Comparator|Microdose|Peak plasma concentration of a very low dose of hRESCAP as a first test in humans (first starting dose, before the other arms).
3306524|NCT01889160|Experimental|Part A Active|AZD4721 Solution
3306525|NCT01889160|Placebo Comparator|Part A Placebo|Placebo for AZD4721
3380948|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Irinotecan + Temozolomide|Abemaciclib given orally, irinotecan given IV and temozolomide given orally.
3380949|NCT04238819|Experimental|Dose Escalation: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
3380950|NCT04238819|Experimental|Dose Expansion: Abemaciclib + Temozolomide|Abemaciclib and temozolomide given orally.
3380951|NCT04236804|Experimental|TMC-CP01 Intervention|Ten patients will be randomly assigned to receive the TMC-CP01 intervention every day for 8 weeks in addition to their current opioid prescription and tapering guidelines.
3380952|NCT04236804|No Intervention|Standard of Care|Ten patients will be randomly assigned to receive their current opioid prescription and tapering guidelines, as standard of care.
3380953|NCT04232553|Experimental|Mirikizumab SC|Mirikizumab given subcutaneously (SC).
3380954|NCT04232553|Experimental|Mirikizumab IV and SC|Mirikizumab given intravenously (IV) and SC.
3380955|NCT04230928|Placebo Comparator|Standard GLB Control|Individuals will receive the standard Diabetes Prevention Program-Group Lifestyle Balance (GLB) program as outlined by the American Diabetes Association. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
3306526|NCT01889160|Experimental|Part B solution|AZD4721 Solution
3306527|NCT01889160|Active Comparator|Part B Suspension|AZD4721 Suspension
3306528|NCT01889173|Experimental|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablets (with potassium phosphate) at 2.8 mg
3306529|NCT01889173|Experimental|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablets (with sodium phosphate) at 2.8 mg
3306530|NCT01889173|Experimental|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablets (with trisodium citrate) at 2.8 mg
3306531|NCT01889173|Active Comparator|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine oral tablet
3306533|NCT01889212|Experimental|NSCLC, erlotinib treatment, 11C-erlotinib PET/CT|
3306534|NCT01889225||Multiple Risk Factor Intervention Trial - Usual Group|
3306535|NCT01889225||Multiple Risk Factor Intervention Trial - Referred Group|
3306536|NCT01889225||Framingham Heart study|
3306537|NCT01889225||Framingham Offspring cohort|
3306538|NCT01889225||Atherosclerosis Risk In Communities|
3306539|NCT01889225||Charleston Heart study|
3306540|NCT01889225||Cardiovascular Health study|
3306541|NCT01889225||Rancho Bernardo study|
3306542|NCT01889225||Nurses' Health I study|
3306543|NCT01889225||Panel Study Income Dynamics|
3306544|NCT01889225||MRFIT Referred Care|
3306545|NCT01889225||HDFP Referral Care|
3306546|NCT01889225||Alameda County Health and Ways of Living Study|
3306547|NCT01889225||Nurses' Health II study|
3306548|NCT01889225||Tecumseh County Health study|
3306549|NCT01889225||EPESE-East Boston|Established Populations for Epidemiologic Studies of the Elderly-East Boston
3306550|NCT01889225||EPESE-Duke|Established Populations for Epidemiologic Studies of the Elderly-Duke
3306551|NCT01889225||EPESE-Iowa|Established Populations for Epidemiologic Studies of the Elderly-Iowa
3306552|NCT01889225||EPESE-New Haven|Established Populations for Epidemiologic Studies of the Elderly-New Haven
3306553|NCT01889264||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
3306554|NCT01889277|Experimental|MT-3995-Low|MT-3995-Low Dose
3306555|NCT01889277|Experimental|MT-3995-High|MT-3995-High Dose
3306556|NCT01889277|Placebo Comparator|Placebo|Placebo
3306557|NCT01889290|Experimental|Methylnaltrexone|Pharmacokinetics of methylnaltrexone administered once daily
3306558|NCT01889303|Active Comparator|Arm A|"chemotherapy regimen:Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles → 5-FU 400 mg/m2 IV and Leucovorin 20 mg/m2 IV on the first four and the last three days of radiotherapy + RT 45Gy (5weeks)→ Rest for 4 weeks →Oxaliplatin 85mg/m2 IV d1,Leucovorin 400mg/m2 IV d1,5-FU 400mg/m2 IV bolus d1 ,then 2400mg/m2 over 46h continuous infusion Q2W for 3 cycles.~Radiation: concurrent chemoradiotherapy with 5-FU/CF.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
3306559|NCT01889303|Experimental|Arm B|"chemotherapy regimen:Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles → Docetaxel 35mg iv D1,Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy (5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W x 2 cycles~Radiation: concurrent chemoradiotherapy with DC.Radiotherapy consisted of 45Gy of radiation at 1.8Gy per day, five days per week for five weeks."
3306560|NCT01889316|Other|AN24 in addition to new device (Novii)|"FDA-cleared device (The AN24 device) used in conjunction with the new device (Novii).~Both devices will be placed on the patient's abdomen. Hence the patient acts as their own control."
3306561|NCT01889329|Experimental|RUTF-1|Made from local food ingredients
3306562|NCT01889329|Experimental|RUTF-2|Made from local food ingredients
3306563|NCT01889329|Active Comparator|Plumpynut|Made from peanut
3306564|NCT01889342|Experimental|Metacognitive therapy|The treatment is based on the generic manual by Wells (2009).
3306565|NCT01889342|Active Comparator|Cognitive behavorial therapy|CBT includes the diagnose specific manuals for panic disorder (Clark, 1986), Social Phobia (Clark & Wells, 1995) and PTSD (Foa, 2007).
3306566|NCT01889368|Active Comparator|Grape Seed Extract|This is a 30 day arm. At the baseline study visit, subjects will consume one 300 mg capsule of MegaNatural Gold followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
3306567|NCT01889368|Placebo Comparator|Placebo|This is a 30 day arm. At the baseline study visit, subjects will consume one placebo (maltodextrin) capsule followed by 3 high fat meals: breakfast, lunch, and dinner. Blood will be drawn at specified intervals throughout the day. Flow mediated dialysis will be performed before breakfast and again 1.5 hours later, after capsule consumption and breakfast. A minimum 14 day washout period will be between arms if this is the first arm in the randomized cross-over.
3306568|NCT01889381|Experimental|Treatment (Transplantation)|Face transplantation in combination with a novel donor bone marrow cell-based therapy followed by single-drug immunosuppression with potential weaning.
3306569|NCT01889394|Active Comparator|limberg flap|primary wound closure using a limberg flap
3306570|NCT01889394|Active Comparator|secondary wound healing|secondary wound healing
3306571|NCT01889407||IA regimen|IA regimen: Patients receive idarubicin (8mg/m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
3306572|NCT01889407||DA regimen|Patients receive daunomycin (45mg/ m2.d) iv drip on days 1-3 and cytarabine (100-200mg/ m2.d) iv drip on days 1-7.
3306573|NCT01889433|Experimental|Algeron|Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).
3306574|NCT01889433|Active Comparator|Pegasys|Pegasys in a dose of 180 µg subcutaneously, once a week, in combination with Rebetol, orally, at a daily dose of 800 mg for patients with genotype 2 or 3, and for genotypes 1 or 4 at a daily dose of 1000 mg (for body weight <75 kg) or 1200 mg (for body weight ≥75 kg)
3306575|NCT01889446|Placebo Comparator|Calcium propionate|Addition of calcium propionate (PA arm) in a capsule (1000 mg) consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to a placebo capsule (following identical protocol). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm'.
3306576|NCT01889446|Placebo Comparator|Placebo|Addition of placebo (PA arm) in a capsule consumed together with a mixed meal of 500 kCal in the morning following an overnight fast. Blood is taken at baseline and every 30 minutes for 4 hours. This arm is compared to the PA arm (PA, 1000 mg in a capsule). Following a washout period of a week, the arms will be crossed over and the PA arm participants will repeat the same protocol in the 'placebo arm', and vice versa.
3306577|NCT01889459||PCI for CTO|
3306578|NCT01889472|Active Comparator|oro-nasal mask|Oro-nasal mask during 1 month of auto CPAP
3306579|NCT01889472|Experimental|Nasal mask and oral appliance|Nasal mask and oral appliance during 1 month of auto CPAP
3306580|NCT01889498|No Intervention|control group with no acetazolamide|Treatment as usual without acetazolamide treatment
3306581|NCT01889498|Active Comparator|Acetazolamide|Treatment arm
3306582|NCT01889511|Experimental|Intervention group - texts|The intervention group will receive text messages for 21 days that are tailored to their oral agent regimen.
3306583|NCT01889511|No Intervention|Control group|The control group will receive usual care, which consists of standard care and materials provided by the oncology office or pharmacy. In general, this includes instructions and information on the oral agent regimen (i.e., amount and timing), common side effects, how to manage symptoms, general ways to remember to take your pill (e.g., calendar or pill box), medication safety (i.e., storage), and how to contact a clinician for problems that arise.
3306584|NCT01889524|Active Comparator|NIV plus jet|Noninvasive ventilation-NIV plus jet nebulizer
3306585|NCT01889524|Experimental|NIV plus Mesh|Noninvasive ventilation- NIV plus Mesh nebulizer
3306586|NCT01889537|Experimental|VR during burn care with Ketamine|Comparing Virtual Reality during burn care with Ketamine
3306587|NCT01889537|Experimental|VR durin burn care without Ketamine|Comparing virtual reality during burn care without Ketamine.
3306588|NCT01889550|Active Comparator|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
3306589|NCT01889550|Placebo Comparator|Access to the website www.ouh.dk|Access to the usual information from the hospital website
3306590|NCT01889576|Experimental|Supplementation of Magnesium oxide.|Supplementation of magnesium oxide (450 mg up to 3 times daily maximum), aiming at a serum magnesium concentration of >= 1,9 mg/dL).
3306591|NCT01889576|No Intervention|No supplementation or minimal dose.|No supplementation (or a minimal dose to keep serum magnesium concentration ≥ 1.2mg/dL depending on the treating physician).
3306592|NCT01889589||NYC adults|
3306593|NCT01889615||Suspected ovarian cancer|dual time PET/CT
3306594|NCT01889628|Other|Chinese ethnicity|Three nutritional formulae (Isocal, Protinex and Diasip) and liquid glucose
3306595|NCT01889628|Other|Malay ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
3306596|NCT01889628|Other|Indian Ethnicity|Three liquid nutritional formulae (Isocal, Diasip and Protinex) and liquid glucose
3306597|NCT01889641||Patients with lupus|Patients with lupus (four levels of activity disease)
3306598|NCT01889641||healthy volunteers|Subjects controls
3306599|NCT01889654||patient|
3306600|NCT01889654||healthy volunteers|
3306601|NCT01889680|Active Comparator|Arm 1: 5-FU + LV|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV every 14 days until disease progression (continuation regimen)
3306602|NCT01889680|Experimental|Arm 2: 5-FU + LV + ziv-aflibercept|Patients receive mFOLFOX6 plus ziv-aflibercept every 14 days for 6 cycles (induction regimen), followed by 5-FU/LV plus ziv-aflibercept every 14 days until disease progression (continuation regimen)
3306603|NCT01889693||acute coronary syndrome|patients with acute myocardial infarction and unstable angina
3306604|NCT01889693||chronic stable angina|patients with chronic stable angina
3306605|NCT01889693||control|control subjects without coronary artery disease
3306606|NCT01889719|Experimental|Vaccination with MVA-CMDR Group 1|Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
3306607|NCT01889719|Active Comparator|Vaccination with MVA-CMDR Group 2|Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
3306608|NCT01889732||ROTEM|
3306609|NCT01889758|Active Comparator|Sequence 1|Tacrolimus Hi for 1 week with full PK on Day 7, then tacrolimus Lo for 1 week with full PK on Day 14, then Prograf for 1 week with full PK on Day 21, then tacrolimus Hi with full PK on Day 28, then Prograf for 1 week with full PK on Day 35, and then tacrolimus Lo for 1 week with full PK on Day 42
3306610|NCT01889758|Active Comparator|Sequence 2|Tacrolimus Lo for 1 week with full PK on Day 7, then Prograf for 1 week with full PK on Day 14, then tacrolimus Hi for 1 week with full PK on Day 21, then tacrolimus Lo with full PK on Day 28, then tacrolimus Hi for 1 week with full PK on Day 35, and then Prograf for 1 week with full PK on Day 42
3306611|NCT01889758|Active Comparator|Sequence 3|Prograf for 1 week with full PK on Day 7, then tacrolimus Hi for 1 week with full PK on Day 14, then tacrolimus Lo for 1 week with full PK on Day 21, then Prograf with full PK on Day 28, then tacrolimus Lo for 1 week with full PK on Day 35, and then tacrolimus Hi for 1 week with full PK on Day 42
3306612|NCT01889771|Experimental|Nicotine Patch (4 weeks)|participants receive one 4-weeks supply of nicotine patches
3306613|NCT01889771|Experimental|Nicotine Patch (8 weeks)|participants receive up to 8 weeks of nicotine patches in up to two 4-week supplies
3306614|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3306615|NCT01889784|Other|Health individuals - 150J (phototherapy 150J)|The intervention of this study is phototherapy through light emitting diode (LED) and dose of 150J each muscle. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3306616|NCT01889784|Other|Individuals with diabetes mellitus (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED) with 300J. The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surale muscles bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3306617|NCT01889784|Other|Health individuals (phototherapy 300J)|The intervention of this study is phototherapy through light emitting diode (LED). The Effective-LED or Placebo-LED will be applied in femoral quadriceps and triceps surae muscle bilaterally before constant-load exercise tests in bike. Each individual will perform two tests with Effective-LED and two tests with Placebo-LED randomly allocated. Evaluations will be completed in 4 days in total, respecting 14 days of rest to ensure the long washout phototherapy.
3306618|NCT01889810|Active Comparator|Vitamin D3 supplementation|Patients will take 3000IU (75 µg) Vitamin D3 supplementation per day for a period of 26 weeks.
3306619|NCT01889810|Placebo Comparator|Placebo|Placebo group
3306620|NCT01889823|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
3306621|NCT01889823|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
3306622|NCT01889836|Experimental|MenCC-Bio|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
3306623|NCT01889836|Active Comparator|MENJUGATE®|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE®.
3306624|NCT01889849|Experimental|BIP48|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
3306625|NCT01889849|Active Comparator|Pegasys|Will be recruited for the study 32 volunteers, all of whom will receive two products in two stages separated by at least 4 weeks. Volunteers will be randomized into 2 groups of 16 and at the time of the intervention, the volunteer will receive product application labeled with its corresponding number. The second step in the product administered will necessarily be one that contains the number and it was not administered in the first step.
3306626|NCT01889875|No Intervention|Control group|
3306627|NCT01889875|Active Comparator|Subcutaneous Immunotherapy (SCIT)|"Treatment using ALK AluTard 225 Phleum pratense"
3306628|NCT01889875|Active Comparator|Sublingual Allergen Immunotherapy Tablets (AIT)|"Treatment using ALK Grazax 75,000 SQ-T Phleum pratense"
3306629|NCT01889888|Experimental|ADRC injection|
3306630|NCT01889914|Experimental|continuous infusion of insulin by pump|"in this arm called continuous infusion of insulin with a pump the patient receive continuous rapid insulin (APIDRA ®)with an external pump.~An hepatic IRM and a botnia test will be practice before and six months after the beginning of this treatment(continuous insulin)"
3306631|NCT01889914|Experimental|discontinuous insulin multiple injections|"An arm called  intensification of the multiple daily injections : the patient will receive an additional injection of basal insulin LEVEMIR® : five injections per day (2 injections of Levemir® and 3 injections of Apidra®) instead of four previously (1 injection of Levemir® and 3 injections of Apidra®).~An hepatic IRM and a botnia test will be practice before and six months after the beginning of the treatment"
3306632|NCT01889927|No Intervention|Group 1: Control|Control Group (Arm 1): Children randomised to the control group will receive 24-months of current model of specialist CF care.
3306633|NCT01889927|Active Comparator|Group 2: Exercise Intervention|Intervention group (Arm 2): Children randomised to the intervention group will receive 24-months of current model of specialist CF care PLUS a weekly structured, individually prescribed and personally supervised exercise intervention at a local fitness facility or at school.
3380956|NCT04230928|Experimental|VLC-GLB Intervention|Individuals will receive a version of the DPP-GLB program in which 4 of the 12 modules will teach a very low carbohydrate diet instead of the standard. All other components of the DPP-GLB will follow the standard. This program will be taught at the Baylor Scott & White Health and Wellness Center by trained research staff.
3306634|NCT01889940|No Intervention|Pre-intervention group.|"The initial assessment includes pre-intervention measures (baseline) for the patient, his/her relative (or main caregiver) and the rehabilitation staff.~Patients are assessed during the first week (or ≥ 10 days of SCI Unit admission) and at discharge (an expected average of 8 weeks). At the time of each patient's discharge, their family or main caregiver is also surveyed.~Lastly, rehabilitation team members are also assessed across the pre-intervention phase."
3380959|NCT04209465|Experimental|Phase 1 - Dose escalation|In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations will receive increasing doses of BDTX-189. It is expected that up to approximately 70 patients will be enrolled in this dose escalation arm. If an alternative schedule is explored, up to 24 additional patients may be enrolled.
3380960|NCT04209465|Experimental|Phase 2 - Dose expansion|In Part B, patients with a solid tumor harboring specific allosteric HER2 mutations or an HER2 or EGFR exon 20 insertion mutation will receive the recommended Phase 2 dose of BDTX-189. It is expected that approximately 100 participants will be enrolled in this phase 2 portion.
3306635|NCT01889940|Other|Post-intervention group.|Once intervention and coaching period for professionals has ended, post-intervention sample (patients, family and professionals) is assessed with the same time criteria than the pre-intervention sample.
3306636|NCT01889953|Other|EUS-guided biliary drainage|Patients in this arm will receive EUS-guided biliary drainage.
3306637|NCT01889966|Experimental|Sildenafil|oral Sildenafil 20 mg three times a day for 90 days
3306638|NCT01889979|Experimental|Tramadol|100 mg of tramadol SC (single dose) = 2 mL
3306639|NCT01889979|Placebo Comparator|Placebo|2 mL of a sterile solution SC
3306640|NCT01889992|Active Comparator|Cardiac biopsy C4D stain|A procedure that removes a very small sample of your heart muscle so that it can be evaluated in the lab. This procedure may be done to determine the cause of cardiac myopathy (a weakened heart muscle) or to check for rejection after a heart transplant.
3306641|NCT01889992|Experimental|Genetic Mechanism of M-TOR|"To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.~Sirolimus dosage is based on blood levels."
3306642|NCT01889992|Active Comparator|Cardiac MRI|Cardiac Magnetic Resonance Imaging (MRI) produces no side effects from the magnetic fields and radio waves and doesn't carry a risk of cancer or birth defects. Serious reactions to the special contrast dyes used for MRI are very rare. The MRI examination poses almost no risk to the average patient when appropriate safety guidelines are followed, however side effects are possible and include headache, nausea, dizziness, change in taste and allergic reaction. Such reactions usually are mild and easily controlled by medication.
3306643|NCT01889992|Active Comparator|Coronary Angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
3306644|NCT01889992|Active Comparator|Cardiopulmonary Exercise Test (CPET)|Is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
3380967|NCT04207476|Experimental|Treatment arm|Active magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
3380968|NCT04207476|Placebo Comparator|Placebo|Placebo magnetic field exposure will be performed by use of a EMF resonator. Stimulator will be applied continuously for 1 hour.
3380970|NCT04203199|Experimental|Real rTMS to the mPFC using H7 Coil|One session of low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
3306645|NCT01889992|Experimental|MTor Immunosuppression|"Sirolimus~Sirolimus dosage is based on blood levels.~To assess the potential of mTOR immunosuppressant Sirolimus in attenuation of CAR in HTx recipients and therefore, improve pre-existing cardiac allograft function, vasculopathy, and exercise capacity."
3306646|NCT01889992|Experimental|Cardiac Allograft Remodeling|A surgical procedure in wich a diseased heart is replaced with a healthy heart from a deceased person.
3306647|NCT01890005|Experimental|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
3306648|NCT01890005|Placebo Comparator|Placebo|Placebo (identical to low dose aspirin (100 mg)) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
3306649|NCT01890018|Active Comparator|Control|"This arm will use GlowCaps to have their adherence tracked with no additional modifications:~Arm 1. Control group no modifications~Electronic Pill Bottle tracking"
3306650|NCT01890018|Experimental|Feedback group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 2. Feedback group participants will receive an adherence message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging"
3306651|NCT01890018|Experimental|Adherence partner group|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 3. Adherence partner group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient~Electronic Pill Bottle tracking; Social Influence"
3306652|NCT01890018|Experimental|Adherence partner along with feedback|"This arm will use GlowCaps to have their adherence tracked with the following modifications:~Arm 4. Adherence partner along with feedback group participants will designate a family member or friend who will serve as an adherence partner, encouraging adherence of the patient, both the patient and partner will receive a message after 48 hours of not using the GlowCaps~Electronic Pill Bottle tracking; Adherence Messaging; Social Influence"
3306653|NCT01890044||Moderate to highest risk for VTE|Patients admitted to the hospital for care of traumatic injuries who have from a moderate to highest level of VTE risk. These risk levels are assessed within the first 24 hours following hospital admission as mandated by the Surgical Quality Improvement Project (SCIP) Guidelines. Individual risk level will be assessed and determined according to each individual reporting institution's risk assessment protocol. This will be a prospective registry of trauma patients without any study based interventions.
3306654|NCT01890057|Experimental|Young adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
3306655|NCT01890057|Experimental|Elderly adults|To find out the the dose of sugammadex for recovery of the TOF ratio to 0.9 within 2 minutes from profound neuromuscular block : Dixon's up-and-down method
3306656|NCT01890070|Placebo Comparator|STANDARD DIET|"each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fiber)~Three weeks of washout to avoid additive effects on treatments to follow."
3306657|NCT01890070|Experimental|STANDARD DIET WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
3306658|NCT01890070|Experimental|STANDARD DIET WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 ml of Italian organic Red Wine.~Three weeks of washout to avoid additive effects on treatments to follow."
3306659|NCT01890070|Experimental|STANDARD DIET WITH CHESTNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
3306660|NCT01890070|Experimental|STANDARD DIET WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3306661|NCT01890070|Experimental|STANDARD DIET WITH WILD MIXED GREEN|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3306662|NCT01890070|Experimental|STANDARD DIET WITH OLIVE OIL|"Intervention type: each patient is administered a food plan for four weeks. Every patient patient is required to consume per day :~Standard diet (Mediterrean reference: carbohydrates 55%-60%; protein 15% - 20% of which 50% are of vegetable derivation; total fats < 30% e 30 g of fibers) with 100g of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
3306663|NCT01890070|Placebo Comparator|HIGH FAT DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)~Three weeks of washout to avoid additive effects on treatments to follow."
3306664|NCT01890070|Experimental|HIGH FAT WITH HAZELNUTS|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 40g of Italian hazelnuts from Piedmont with Protected Geographical Indication Certification.~Three weeks of washout to avoid additive effects on treatments to follow."
3380971|NCT04203199|Sham Comparator|Sham rTMS to the mPFC using H7 Coil|One session of sham low frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left medial prefrontal cortex (mPFC) using the H7-coil (sham rTMS - 20 min total, 1200 pulses delivered at 1 Hz continuously, 1 train, 120% resting motor threshold (rMT)).
3380972|NCT04203199|Experimental|Real rTMS to the dlPFC using H1 Coil|One session of high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
3380973|NCT04203199|Sham Comparator|Sham rTMS to the dlPFC using H1 Coil|One session of sham high frequency repetitive transcranial magnetic stimulation (rTMS) will be delivered to the left dorsolateral prefrontal cortex (dlPFC) using the H1-coil (sham rTMS- 20 min total, 3000 pulses delivered at 10 Hz, 60 trains, 50 pulses/train, 5 sec on/15 sec off, 120% resting motor threshold (rMT)).
3380974|NCT04201444|Experimental|Patient group|
3380975|NCT04201444|Active Comparator|Remission control group|
3380976|NCT04201444|Active Comparator|Bilateral surrenalectomy control group|
3306665|NCT01890070|Experimental|HIGH FAT WITH RED WINE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%)with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3380977|NCT04197986|Experimental|Infigratinib 125 mg|Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
3380978|NCT04197986|Placebo Comparator|Placebo|Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks
3380980|NCT04195217|Active Comparator|With art therapy|Art therapy as supportive care in 6 consecutive sessions of cancer treatments with or without additional supportive care
3306666|NCT01890070|Experimental|HIGH FAT WITH CHESTNUT|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Italian organic chestnuts.~Three weeks of washout to avoid additive effects on treatments to follow."
3380981|NCT04195217|No Intervention|Without art therapy|6 consecutive sessions of cancer treatments without art therapy with other supportive care added.
3380982|NCT04194944|Experimental|Selpercatinib|Selpercatinib administered orally.
3380983|NCT04194944|Active Comparator|Pemetrexed with or without Pembrolizumab|Pemetrexed administered intravenously (IV) plus the investigator's discretion of carboplatin IV or cisplatin IV with or without pembrolizumab IV.
3380984|NCT04194944|Active Comparator|Pemetrexed with Pembrolizumab|Pemetrexed administered IV plus the investigator's discretion of carboplatin IV or cisplatin IV with pembrolizumab IV.
3380985|NCT04190914|Active Comparator|necrotic primary molar treated with pulpectomy followed by SSC|control group treated by pulpectomy under rubber dam isolation access cavity will be prepared by a round bur then filling and irrigation will be performed and the tooth will be restored with a temporary filling. After one week all signs and symptoms will be assessed in case of absence of signs and symptoms the tooth will be restored with zin oxide and eugenol and SSC
3306667|NCT01890070|Experimental|HIGH FAT WITH CHOCOLATE|"Intervention type: each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3306668|NCT01890070|Experimental|HIGH FAT WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3380986|NCT04190914|Experimental|necrotic primary molar treated with regeneration using triple|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then triple antibiotic paste will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
3380987|NCT04190914|Experimental|necrotic primary molar treated with regeneration using metape|under rubber dam isolation access cavity will be prepared by a round bur then minimal filling and irrigation will be performed then calcium hydroxide with iodoform (metapex) will be inserted into the canals and the tooth will be restored by a glass ionomer (GI) as a temporary filling. After 2-4 weeks all signs and symptoms will be assessed in case of absence of signs and symptoms an endodontic file will be used to induce bleeding from the periapical area after hemostasis mineral trioxide aggregate will be applied followed by SSC
3380988|NCT04171895||Enhanced Usual Care (EUC)|
3380989|NCT04171895||Communication Training|
3380990|NCT04167514|Experimental|AAT|Alpha-1 antitrypsin (AAT) is a lyophilized powder for intravenous administration
3380991|NCT04167514|Placebo Comparator|Placebo|Albumin solution administered intravenously
3380992|NCT04166773|Experimental|5 mg Tirzepatide|5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.
3306669|NCT01890070|Experimental|HIGH FAT WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High fat diet (carbohydrates 35%; protein 15%; total fats 50%) with 100 of Italian organic Olive oil~Three weeks of washout to avoid additive effects on treatment following."
3380993|NCT04166773|Experimental|10 mg Tirzepatide|10 mg tirzepatide administered SC once a week.
3380994|NCT04166773|Experimental|15 mg Tirzepatide|15 mg tirzepatide administered SC once a week.
3380995|NCT04166773|Placebo Comparator|Placebo|Placebo administered SC once a week.
3380996|NCT04164732|Experimental|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d|randomized in a 1:1 ratio: LCZ696 to placebo
3380997|NCT04164732|Placebo Comparator|Placebo to LCZ696|randomized in a 1:1 ratio: LCZ696 to placebo
3380999|NCT04158687|Experimental|1 g CTP-692|Powder for oral solution, taken once daily
3381000|NCT04158687|Experimental|2 g CTP-692|Powder for oral solution, taken once daily
3381001|NCT04158687|Experimental|4 g CTP-692|Powder for oral solution, taken once daily
3381002|NCT04158687|Placebo Comparator|Placebo|Powder for oral solution, taken once daily
3381003|NCT04158583|Experimental|Part A|Dose-Escalation: Mixed solid tumors participants will receive ascending doses of RO7296682. RO7296682 will be administered by intravenous (IV) infusion in a three-weekly schedule (Q3W) until either the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) is defined.
3381004|NCT04158583|Experimental|Part B|Dose-Expansion: Will start once MTD/RP2D dose is defined in Part A. Participants will receive a fixed dose of RO7296682 at the dosing regimen established in part A (Q3W schedule).
3381005|NCT04156802|Experimental|Real iTBS to the mPFC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
3381006|NCT04156802|Sham Comparator|Sham iTBS to the mPFC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the medial prefrontal cortex (mPFC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real cTBS total) (1 train of stimulation over the mPFC (AFZ); (20 trains of stimulation over dlPFC (middle frontal gyrus) (F3); each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
3381007|NCT04156802|Experimental|Real iTBS to the MC|Two sessions of real intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
3381008|NCT04156802|Sham Comparator|Sham iTBS to the MC|Two sessions of sham intermittent Theta Burst Stimulation (iTBS) will be delivered to the somatomotor cortex (MC) over the course of the treatment and maintenance phase of the study (16 visits, 32 sessions of real iTBS total) (20 trains of stimulation over MC; each train: 3 pulse bursts presented at 5Hz, 15 pulses/ sec for 2 sec, 8 sec rest, 200 pulses/train; 110% RMT, MagPro; 600 pulses per session, 1200 pulses total per visit).
3381009|NCT04156191|Experimental|ARQ-151 cream 0.15% or 0.05%|Open-label study of 0.15% or 0.05% active concentration
3381010|NCT04149535|Experimental|TAVR with Sentinel|Patients assigned to this group will undergo TAVR with the Sentinel® Cerebral Protection System.
3381011|NCT04149535|No Intervention|TAVR without Sentinel|Patients assigned to this group will undergo TAVR without the Sentinel® Cerebral Protection System.
3381012|NCT04148911|Experimental|Atezolizumab plus Nab-Paclitaxel|Participants will receive Atezolizumab via intravenous (IV) infusion on Days 1 and 15 of every 28-day cycle in combination with Nab-Paclitaxel on Days 1, 8, and 15 (individually selected by the investigator) until disease progression, or unacceptable toxicity, additionally until loss of clinical benefit as determined by the investigator or participant decision to discontinue treatment.
3381013|NCT04147884|Experimental|Mitral Valve Repair|All subjects will receive mitral valve repair using the Millipede System
3381014|NCT04146935|Experimental|Patients with XLH|Patients will receive Burosumab monthly at visits 1,2 and 3 subcutaneously at a dose of 1.0 mg/kg. Dose may be adjusted as needed.
3381015|NCT04145700|Experimental|Ramucirumab + Gemcitabine + Docetaxel|Ramucirumab, Gemcitabine and Docetaxel given intravenously (IV).
3306670|NCT01890070|Placebo Comparator|LOW CARBOHYDRATE DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%)~Three weeks of washout to avoid additive effects on treatments to follow."
3306671|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification~Three weeks of washout to avoid additive effects on treatments to follow."
3306672|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3306673|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
3306674|NCT01890070|Experimental|LOW CARBOHYDRATE DIET CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3381016|NCT04145700|Active Comparator|Gemcitabine + Docetaxel|Gemcitabine and Docetaxel given IV.
3381017|NCT04145349|Experimental|Ramucirumab + Cyclophosphamide + Vinorelbine|Ramucirumab given intravenously (IV), Cyclophosphamide given orally and vinorelbine given IV.
3381018|NCT04145349|Active Comparator|Cyclophosphamide + Vinorelbine|Cyclophosphamide given orally and vinorelbine given IV.
3381020|NCT04136353|Experimental|Darolutamide|"Darolutamide 600mg (2 x 300mg tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
3381021|NCT04136353|Placebo Comparator|Placebo|"Placebo (2 tablets) twice daily by mouth for 96 weeks, adherence monitored by participant report.~All participants are treated with an LHRHA for 96 weeks from randomisation and external beam radiation therapy started within 8-24 weeks after randomisation."
3381022|NCT04132817|Experimental|Group A Target class A-1: Nivolumab+nab-paclitaxel|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
3381023|NCT04132817|Experimental|Group A Target Class A-2: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
3381024|NCT04132817|Experimental|Group A Target Class A-3: Nivolumab+nab-paclitaxel+ipilimumab|The CA048-001 clinical study will utilize a master protocol and subprotocols representing distinct mechanisms of actions. Each subprotocol will contain 1 Group, representing a particular mechanism of action, and will consist of 3 treatment arms that will be simultaneously evaluated. One treatment within a group will be selected to move forward to the next sub-protocol based on safety and tolerability, pharmacodynamic and efficacy data. Thus, the number of treatments within each group is increased by one for each subsequent group, with the intent to simultaneously impact a wide range of mechanisms thought to be important for generating anti-tumor immune responses.
3381025|NCT04126031|Experimental|Part A, Cohorts 1-3|Single dose pharmacokinetics. This arm will include three age cohorts.
3381026|NCT04126031|Experimental|Part B, Cohorts 1-3|Multi-dose pharmacokinetics. This arm will include three age cohorts.
3306675|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3306676|NCT01890070|Experimental|LOW CARBOHYDRATE DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~Low carbohydrate diet (carbohydrates 35%; protein 30%; total fats 35%) with 100 of Italian organic Olive Oil~Three weeks of washout to avoid additive effects on treatments to follow."
3306677|NCT01890070|Placebo Comparator|HIGH PROTEIN DIET|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%)~Three weeks of washout to avoid additive effects on treatments to follow."
3306678|NCT01890070|Experimental|HIGH PROTEIN DIET WITH HAZELNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 40g Italian hazelnuts from Piedmont with Protected Geographical Indication Certification"
3306679|NCT01890070|Experimental|HIGH PROTEIN DIET WITH RED WINE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 ml of Italian organic Red Wine~Three weeks of washout to avoid additive effects on treatments to follow."
3381027|NCT04119687|Experimental|Low Dose FX201|Single low dose FX201 injection
3381028|NCT04119687|Experimental|Mid Dose FX201|Single mid dose FX201 injection
3381029|NCT04119687|Experimental|High Dose FX201|Single high dose FX201 injection
3381030|NCT04115293|Experimental|0.3 mg/kg zilucoplan (RA101495)|
3381031|NCT04115293|Placebo Comparator|Placebo|
3381032|NCT04113252|Experimental|Group 1--Diary and Possible Opioid Return Incentive|Participants in this arm will be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
3381033|NCT04113252|Experimental|Group 2--Diary, Coaching, Possible Opioid Return Incentive|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary and will have the possibility to earn incentives for returning any leftover tablets to the study team.
3381034|NCT04113252|Experimental|Group 3--Diary and coaching|Participants in this arm will be given coaching. They will also be given incentives upon return of completed diary.
3381035|NCT04106219|Experimental|LY3295668 Erbumine Escalation|LY3295668 Erbumine given orally.
3381036|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Escalation|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given intravenously (IV).
3381037|NCT04106219|Experimental|LY3295668 Erbumine Expansion|LY3295668 Erbumine given orally.
3306680|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHESTNUT|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Italian organic chestnuts~Three weeks of washout to avoid additive effects on treatments to follow."
3306681|NCT01890070|Experimental|HIGH PROTEIN DIET WITH CHOCOLATE|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 g of Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)~Three weeks of washout to avoid additive effects on treatments to follow."
3306682|NCT01890070|Experimental|HIGH PROTEIN DIET WITH ITALIAN ORGANIC WILD MIXED GREEN|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 200 g of Italian organic wild mixed green~Three weeks of washout to avoid additive effects on treatments to follow."
3306683|NCT01890070|Experimental|HIGH PROTEIN DIET WITH OLIVE OIL|"Intervention type: Each patient is administered a food plan for four weeks. Every patient is required to consume per day:~High protein diet (carbohydrates 30%; protein 40%; total fats 30%) with 100 of Italian organic Olive Oil~This is followed by a 3 week wash out period, to neutralize any additive effects."
3306684|NCT01890083|Active Comparator|Health Education|Participants will three attend heath education sessions per week for 26 weeks.
3306685|NCT01890083|Experimental|Exercise|Participants will engage in a public health dose of moderate-to-vigorous aerobic exercise for 26 weeks.
3306686|NCT01890096|Experimental|HDR 2 fractions|HDR brachytherapy of 27 Gy delivered in 2 fractions one week apart
3306687|NCT01890096|Experimental|HDR 1 fraction|HDR brachytherapy of 19 Gy delivered in a single fraction
3306688|NCT01890135|Active Comparator|endothelin receptor antogonist|10 mg of zibotentan
3306689|NCT01890135|Placebo Comparator|placebo|matched placebo
3306690|NCT01890161|Experimental|AXP1275|AXP1275 50 mg (2 × 25-mg capsules) once daily for 14 days
3306691|NCT01890161|Placebo Comparator|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules) once daily for 14 days
3306692|NCT01890174||AMD with macular drusen|Patients diagnosed with dry AMD with macular drusen
3306693|NCT01890187||Advanced dry AMD with geographic atrophy|Patients diagnosed with advanced dry AMD with geographic atrophy
3306694|NCT01890200|Experimental|TCM-700C (low dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3306695|NCT01890200|Experimental|TCM-700C (high dose)|an add-on drug (t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3306696|NCT01890200|Placebo Comparator|Placebo|placebo add on(t.i.d) to conventional treatment(Peginterferon alfa-2a + ribavirin) of Hepatitis C
3306697|NCT01890213|Experimental|Vaccine|AVX701 Vaccine:4 x 10EE8 IU intramuscularly every 3 weeks for 4 total immunizations
3306698|NCT01890239|Experimental|Care Programme for the Last Days of Life|The Care Programme for the Last Days of Life will be implemented in the acute geriatric hospital wards randomized to the experimental group. Subsequently, older patients hospitalized in one of these experimental wards and for who the multidisciplinary team has decided that he or she has entered the dying phase, will benefit from this Care Programme.
3306699|NCT01890239|No Intervention|Usual care|Care will be provided as usual, also for patients who have entered the dying phase.
3306700|NCT01890278|Active Comparator|Whole Brain IMRT|Whole brain radiation therapy delivered via IMRT (37.5 Gy to brain tumor, 30 Gy to the uninvolved brain in 15 fractions), mean dose of less than 18 Gy to scalp.
3306701|NCT01890278|Active Comparator|Conventional whole brain RT|Conventional whole brain radiation therapy (37.5 Gy to the brain tumors and uninvolved brain in 15 fractions).
3306702|NCT01890291||Non-treatment Group|Patients who were in non-treatment group in phase 3 clinical trial IIC-I01(NCT00699816).
3306703|NCT01890291||Immuncell-LC Group|Patients who were in Immuncell-LC group in phase 3 clinical trial IIC-I01(NCT00699816).
3306704|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|Athletes at risk for mild traumatic brain injury during the course of competitive play or practice. An MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
3306705|NCT01890317|Experimental|Mild hypothermia|Induction of mild hypothermia for 24 hr with invasive cooling in addition to primary percutaneous coronary intervention and optimal medical therapy
3306706|NCT01890317|No Intervention|Control|Percutaneous coronary intervention and optimal medical therapy according to current guidelines
3306707|NCT01890330|Experimental|Canola Oil 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with traditional canola oil to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of Canola oil.
3306708|NCT01890330|Active Comparator|Non-Canola Oil Mixture 25 g/d|Participants randomized to this arm will be provided with food items including entrées, side dishes, salad dressing, baked goods, and desserts prepared with an oil mixture representing the typical Western diet to incorporate into their usual eating pattern. They will consume one or two food items per day containing a total of 25 g/d of the non-canola oil mixture.
3306709|NCT01890356|Experimental|Transcranial electrical stimulation|
3306710|NCT01890369|Experimental|Early leucine refeed|15g Mixed Essential Amino Acids. 90 min delay. 3g Leucine
3306711|NCT01890369|Experimental|Early EAA refeed|15g Mixed Essential Amino Acids. 90 min delay. 15g Mixed Essential Amino Acid REFEED
3306712|NCT01890369|Experimental|Mid latency EAA refeed|15g Mixed Essential Amino Acids. 150 min delay. 15g Mixed Essential Amino Acid REFEED
3306713|NCT01890369|Experimental|Late latency EAA refeed|15g Mixed Essential Amino Acids. 210 min delay. 15g Mixed Essential Amino Acid REFEED
3306714|NCT01890382|Placebo Comparator|Control|alanine as placebo to leucine (same dosage); corn starch as placebo to protein and/or creatine (same dosage)
3306715|NCT01890382|Experimental|whey protein|
3306716|NCT01890382|Experimental|soy protein|
3306717|NCT01890382|Experimental|leucine supplementation|
3306718|NCT01890382|Experimental|whey plus creatine|
3306719|NCT01890382|Experimental|creatine|
3306720|NCT01890395|Other|blood collection|procedure: Blood draws as the intervention
3381038|NCT04106219|Experimental|LY3295668 Erbumine + Topotecan + Cyclophosphamide Expansion|LY3295668 Erbumine given orally and topotecan and cyclophosphamide given IV.
3381039|NCT04106063||deaf children|All Children between 7 and 17 years old attending medical appointment for temporary or persistent deafness in our Ear, Nose and Throat (ENT) department
3306721|NCT01890408|Experimental|ropivacaine|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
3306722|NCT01890408|Placebo Comparator|placebo|patients scheduled to undergo open liver resection Age > 18 years Free from pain in preoperative period
3306723|NCT01890447||Questionnaire design group|A focus group (group of experts) such as physicians, nurses, or other professionals invited by the investigator.
3306724|NCT01890447||Adaptive questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the adaptive choice based conjoint (ACBC) technique.
3306725|NCT01890447||Standard questionnaire group|Adults who are contacts of newborns or expecting mothers in their last trimester of pregnancy or their partners. The data of the subjects in this group will be analysed using the standard discrete choice experiment (DCE) technique.
3306726|NCT01890499|Experimental|Low residue diet arm|"Two arm randomized controlled trial. First arm is the Clear feeds on postoperative day one arm.~The second arm (interventional arm) is the Low Residue diet on postoperative day one arm."
3306727|NCT01890499|Active Comparator|Clear feeds arm|Standard of care is to start clear feeds on postoperative day one for elective colorectal surgery patients.
3306728|NCT01890525||PROMISE study patients|
3306729|NCT01890538|Active Comparator|Piracetam|2 g intravenous piracetam
3306730|NCT01890538|Active Comparator|Dimenhydrinate|Dimenhydrinate 100 mg intravenous
3306731|NCT01890551|Other|affected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
3306732|NCT01890551|Other|unaffected knee|Interest was to evaluate the patellofemoral joint biomechanics with KINE-MRI in adolescents with affected and unaffected knees in a case-control study
3306733|NCT01890564||Bariatric surgery|Patients undergoing bariatric surgery.
3306734|NCT01890590|Experimental|Cyberknife|You will receive a series of Cyberknife Radiosurgery treatments, with the amount of radiation dosing adjusted for the size of your tumor. The treatment will ideally take place over the course of 3-4 days, but not more than 14 days overall. (3 or 4 fractions of radiation therapy delivered by cyberknife)
3306735|NCT01890603|Experimental|Care Coordination Arm|
3306736|NCT01890603|Active Comparator|Quality Measure Improvement|
3306737|NCT01890616||Motility|This arm will ingest the SmartPill.
3306738|NCT01890629|Experimental|Gemigliptin + Metformin|Gemigliptin 50 mg + Metformin 500 mg to 1000mg for 12 weeks
3306739|NCT01890629|Active Comparator|Sitagliptin + Metformin|Sitagliptin 100 mg + Metformin 500 mg to 1000mg for 12 weeks
3306740|NCT01890629|Active Comparator|Glimepiride + Metformin|Glimepiride 2 mg + Metformin 500 mg to 1000mg for 12 weeks
3306741|NCT01890655|Experimental|MT-1303-Low|MT-1303-Low Dose
3306742|NCT01890655|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3306743|NCT01890655|Experimental|MT-1303-High|MT-1303-High Dose
3306744|NCT01890668|Experimental|Osteopathic Manipulative Treatment|Randomization and first OMT will take place at discharge (Day 3); second osteopathic therapy will be performed by the same osteopath practitioner at Day10.
3306745|NCT01890668|Placebo Comparator|Control group|Control group consists in classical medical and paramedical breastfeeding support. OMT on the newborn will be realized by osteopath dissimulated behind a screen. Placebo OMT consists to mimic, without the knowledge of parents, osteopathic techniques on a dolly.
3306746|NCT01890681|Active Comparator|Back to Sleep|"The Back to Sleep arm will encourage safe sleep practices to reduce the risk of Sudden Infant Death Syndrome (SIDS) in child care and at home. This include:~center and family self-assessment,~center intervention materials delivered several times over the 6-month period, and;~parent handouts~After the intervention period, comparator centers will receive an abbreviated version of the Baby NAP SACC intervention."
3306747|NCT01890681|Experimental|Baby NAP SACC|"The intervention will include four complementary and mutually reinforcing components:~center and family self-assessment;~targeted technical assistance by Baby NAP SACC consultant for providers and parents;~training workshops for child care providers; and~parent outreach and support."
3306748|NCT01890720|Experimental|iNPWT|Negative Pressure Wound Therapy (NPWT) is a mechanical wound care treatment using controlled sub-atmospheric pressure to assist and accelerate wound healing. Incisional Negative Pressure Wound Therapy (iNPWT) is a new NPWT devices, which can be used over clean closed surgical incisions. The device behaves in a similar fashion to existing conventional NPWT devices, i.e. transmission of negative pressure levels at the wound bed, tissue contraction and establishing a characteristic pattern of peri-wound blood flow and that it reduces and normalises tissue stresses at the incision
3306749|NCT01890720|Active Comparator|Standard wound dressing|The standard postoperative wound dressing is a normal wound dressing, used over clean closed incisions.
3306750|NCT01890733|Sham Comparator|Best Repair of torn Rotator Cuff|Subjects will undergo surgical intervention (usually arthroscopy) to perform debridment, acromioplasty if deemed necessary, long head of biceps tenotomy, and at least partial repair.
3306751|NCT01890733|Active Comparator|InSpace™ system|Subjects will undergo surgical intervention (usually arthroscopy or mini invasive) of debridment, acromioplasty if deemed necessary with or without long head of biceps tenotomy, and placement of the InSpace™ system.
3306752|NCT01890772|Active Comparator|VitD+telaprevir+peginterferon+ribavirin|Participants randomized to the treatment group will receive 5,000IU/day of vitamin D3 during the lead-in phase. When the serum 25(OH)D level is ≥35ng/ml the participant will begin telaprevir + vitamin D3 (15,000IU/week) + peginterferon alfa-2a (180ug/week) + weight based ribavirin treatment.
3306753|NCT01890772|Active Comparator|Telaprevir + Peginterferon + Ribavirin|Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.
3381040|NCT04101890|Experimental|Diaper care with Theraworx|Participants will be given a 4 week supply of Theraworx Spray Foam, an FDA-registered OTC drug (NDC 61594-000), to apply a thin layer to their infant's entire diaper area with every diaper change (2-4 foam pumps or 4-6 sprays depending on the infant's size) for 4 weeks.
3306754|NCT01890798|Experimental|Drisapersen (DMD117402)|The protocol is open only to the subjects who completed GSK protocol DMD114876 and participated in protocol DMD115501, United States citizens who have completed protocol DMD114044, or United States citizens who are participating in protocol DMD114349 outside the United States and want to end their participation in the DMD114349 study. Eligible subjects will receive drisapersen 6 milligram (mg)/kilograms (kg) once a week via subcutaneous (SC) injection.
3306755|NCT01890811|Experimental|Boost High Protein|Boost high protein with added spirulina
3306756|NCT01890824||Breast Cancer Patients|Breast cancer patients to be studied before and after chemotherapy
3306757|NCT01890824||Healthy Female Controls|Healthy female controls will be compared to breast cancer patients before and after chemotherapy and to healthy male controls
3306758|NCT01890824||Healthy Male Controls|Healthy male controls will be compared to healthy female controls to determine gender differences
3306759|NCT01890837|Experimental|Daikenchuto (TU-100) 15g/day|Daikenchuto (TU-100) 5g TID/3 times per day (15g/day)
3381041|NCT04101890|No Intervention|Routine diaper care|Participants continue their typical diaper care.
3306760|NCT01890837|Placebo Comparator|Placebo|Placebo TID
3306761|NCT01890850||Pertussis Group|Infants less than one year of age diagnosed with pertussis/whooping cough infection within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
3306762|NCT01890850||Control Group|Infants with no evidence of pertussis/whooping cough during within 12 months from birth (first year of life, between July 1, 2005 and September 30, 2010).
3306763|NCT01890863|Experimental|Sequence 1|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): ABBA, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
3306764|NCT01890863|Experimental|Sequence 2|Subjects will receive treatment A and B in following sequence in four treatment periods (one treatment per period): BAAB, where treatment A is 7 doses of FSC (100/50 mcg) delivered via the Ddpi and treatment B is 7 doses of FSC (100/50mcg) delivered via the Rdpi. Subjects will be dosed twice daily for 3 days and once on the fourth day in the morning (a single inhalation of 100/50mcg per dose).
3306765|NCT01890876|Active Comparator|Low altitude|Walking uphill Walking downhill
3306766|NCT01890876|Active Comparator|High altitude|Walking uphill Walking downhill
3306767|NCT01890889|Active Comparator|Ad-Chol-Pre|A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
3306768|NCT01890889|Active Comparator|Half-dose Ad-Chol-Pre|A half-dose of the active comparator in arm one is administered. A functional food ingredient designed to inhibit cholesterol absorption. ACP is a freeze dried defatted egg powder containing specific Anti-NPCIL1 (Niemann-Pick C1-like 1) IgY. NPC1L1 is known as a biological target of the cholesterol-uptake inhibitor, Ezetimibe.
3306769|NCT01890889|Placebo Comparator|Capsule containing inactive component of defatted egg yolk|Placebo capsule is filled with defat egg yolk only without specific IgY which is anti-NPC1L1 IgY, designed to look and taste the same as the active product capsule, but does not contain the active component.
3306770|NCT01890902|Experimental|Impracor (Ketoprofen 10% Cream)|Topical Cream over a period of 14 days
3306771|NCT01890902|Placebo Comparator|Placebo Cream:|Topical Cream over a period of 14 days
3306772|NCT01890928||Critically Ill Septic Pediatric Patients|Age 5-12 years; weight ≥ 17kg and Age 13-19 years, males and females
3306773|NCT01890928||Healthy Adolescents|Age 13-19 years, males and females
3306774|NCT01890941|Experimental|KCT-0809 Lower Dose|
3306775|NCT01890941|Experimental|KCT-0809 Higher Dose|
3306776|NCT01890941|Placebo Comparator|Placebo|
3306777|NCT01890993||Liraglutide|
3306778|NCT01890993||DPP-4|
3306779|NCT01891006|Experimental|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy (NPWT) is an alternative method of conservative wound management, which uses negative pressure to promote wound healing in both chronic and acute wounds. The rationale for using NPWT is that it mechanically stimulates the formation of new tissue and removes wound fluid and infectious material
3306780|NCT01891006|Other|A standard wound dressing|The standard wound dressing is a hydrofiber or alginate dressing, used for open wound
3306781|NCT01891032||the patients with open partial nephrectomy|the adult patients with open partial nephrectomy
3306782|NCT01891032||laparoscopic|the adult patients with laparoscopic partial nephrectomy
3306783|NCT01891032||VAMS|the adult patients with VAMS partial nephrectomy
3306784|NCT01891032||robotic|the adult patients with robotic partial nephrectomy
3306785|NCT01891045|No Intervention|Control|Patients merely monitored on background variables to function as a baseline of comparison
3306786|NCT01891045|Active Comparator|Prediction|Patients randomized to this condition completes the OQ-45.2 weekly, but the reports are withheld from therapists and patients.
3306787|NCT01891045|Experimental|Intervention|Patients and therapists uses the feedback-system as intended, with real-time feedback to the therapist and full use of the suggested interventions
3306788|NCT01891058|Active Comparator|drug-shock vs shock only|For ED patients with RAFF, Investigators will compare conversion to normal sinus rhythm between the two strategies of i) attempted pharmacological cardioversion with intravenous procainamide followed by DC cardioversion if necessary (Drug-Shock), and ii) DC cardioversion alone (Shock Only).
3306789|NCT01891058|No Intervention|pad positions|For ED RAFF patients undergoing DC cardioversion, Investigators will compare conversion to normal sinus rhythm between the i) antero-posterior and ii) antero-lateral pad positions.
3306790|NCT01891071|Experimental|Lung volume recruitment|Lung volume recruitment twice daily for 9 months
3306791|NCT01891071|No Intervention|Standard care|Standard care
3306792|NCT01891084|Active Comparator|Paracetamol|"Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable."
3381042|NCT04099264|Experimental|Intervention group: Personalized music|This arm will receive an intervention which will be personalized music. It will be provided by Music Care application (https://www.music-care.com/fr).
3381043|NCT04099264|Active Comparator|Control: Audio Books|Control will consist of audio books.
3381044|NCT04094311|Other|Tisagenlecleucel|"All patients eligible for treatment with tisagenlecleucel per the Health Authority-approved tisagenlecleucel product information in the respective country/region are considered eligible for this study . Patients will be divided into 2 groups:~Group A: Pediatric and young adult patients with B-cell ALL (pALL) who meet the indication in Health Authority-approved tisagenlecleucel product information in the respective country/region whose final manufactured product is OOS for commercial release.~Group B: Adult patients with r/r LBCL including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, that is consistent with the Health Authority-approved indication in the product information for tisagenlecleucel in respective country/region but whose final manufactured product is OOS for commercial release/acceptance."
3381045|NCT04093739||G7 Freedom Constrained Liners|Patients that have been implanted with a G7 Freedom Constrained liner to repair hip malfunction or disease.
3381046|NCT04092946|Experimental|Patients with musculoskeletal disorders|Tailored digital programs for individuals working for organizations that enter into a commercial agreement with SWORD Health, which acts as a service provider.
3381047|NCT04091386||Hemophilia A patients|Patients with hemophilia A who are being treated with Damoctocog alfa pegol (Jivi, BAY94-9027) in routine medical practice and are enrolled in Bayer-sponsored study NCT03932201
3381048|NCT04089566|Experimental|28/28 Milligram (mg) Safety Group|Part A: Participants with later-onset SMA will receive loading doses of 28 mg of nusinersen intrathecally on Days 1, 15 and 29 followed by maintenance doses of 28 mg on Days 149 and 269.
3381049|NCT04089566|Active Comparator|12/12 mg Randomized Control Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 12 mg of nusinersen intrathecally on Days 1, 15, 29, and 64 followed by maintenance doses of 12 mg on Days 183 and 279. Sham procedure will be administered on Day 135.
3381050|NCT04089566|Experimental|50/28 mg Randomized Treatment Group|Part B: Participants with infantile- or later-onset SMA will receive loading doses of 50 mg of nusinersen intrathecally on Days 1 and 15 followed by maintenance doses of 28 mg on Days 135 and 279. Sham procedure will be administered on Days 29, 64 and 183.
3381051|NCT04089566|Experimental|12/50/28 mg Titration Group|Part C: Participants who have been receiving the approved dose of 12 mg for at least 1 year prior to entry, will receive a single bolus dose of 50 mg of nusinersen intrathecally on Day 1 (4 months after their most recent maintenance dose of 12 mg) followed by maintenance doses of 28 mg on Days 121 and 241.
3381052|NCT04088409|Experimental|Baricitinib|Baricitinib given orally.
3381053|NCT04088409|Active Comparator|Adalimumab|Adalimumab given subcutaneously (SC).
3381054|NCT04088396|Experimental|Baricitinib|Baricitinib given orally.
3381055|NCT04088396|Placebo Comparator|Placebo|Placebo given orally.
3381056|NCT04088331||AMS 800 Artificial Urinary Sphincter Recipients|Adult males with moderate to severe primary stress urinary incontinence (as assessed by a baseline pad weight test) due to ISD who meet the indications for surgical correction of urinary incontinence.
3381057|NCT04086745|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
3381058|NCT04086745|Experimental|Baricitinib High Dose|Baricitinib administered orally.
3381059|NCT04086745|Active Comparator|TNF Inhibitor|Adalimumab or etanercept administered subcutaneously (SC) per standard of care.
3381062|NCT04080791|Experimental|Experimental Group- Virtual Reality (VR) Treatment|The participants in the experimental group will complete the educational/training session on how to use the VR equipment and programs (30 minutes). The following day, participants will begin the VR intervention attending a daily 30-minute sessions for 8 days or until a discharge date has been set, whichever comes first.
3381063|NCT04080791|Active Comparator|Standard of care group|The control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol. Prior to discharge, control group participants will meet with a licensed clinical therapist to complete the cognitive and physical assessments for the posttest evaluation.
3381070|NCT04069156|Placebo Comparator|Placebo Arm|LVAD Patients on the placebo arm will be given placebo medication
3381071|NCT04069156|Active Comparator|Active Arm|LVAD Patients on the active arm will be given 100mg Aspirin
3381072|NCT04066400|Placebo Comparator|wheat-based diet|The patients continue a wheat-based diet aiming at a reduction in bodyweight.
3381073|NCT04066400|Experimental|ATI reduced diet|Patients are counselled to reduce dietary gluten uptake.
3381074|NCT04065334|Experimental|low dose training|
3381075|NCT04065334|Active Comparator|high dose training|
3381076|NCT04063878|Experimental|Single tooth restorations using Acuris conometric concept|
3381080|NCT04039204|Experimental|Elagolix|Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.
3381081|NCT04039204|Active Comparator|Oral contraceptives (Ortho Cyclen)|Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.
3306793|NCT01891084|Placebo Comparator|Placebo|"(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose. Precautionary statement (Do not exceed 8 tablets daily) will be printed on the dispensary label to avoid overdose.~Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable"
3306794|NCT01891097|Active Comparator|Acupuncture|"Patients will be treated at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, Neiguan PC6, Shenmen HT7, Sanyinjiao SP6, and unilateral Yintang EX-HN3 and Baihui GV20. Acupuncture treatment will be performed by a registered Chinese medicine practitioner. De qi(an irradiating feeling considered to be indicative of effective needling) is achieved if possible. An electric-stimulator (ITO ES160, Japan) is connected to these needles to give an electric-stimulation in continuous wave, frequency of 4 Hz, 0.4 ms square wave pulses and constant current. Surgical tape or hair pin will be adhered to the needles.The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks."
3381082|NCT04034264||Afebrile close contact|Lived in the same household or worked in the same enclosed workspace daily with a febrile enrollee at the time they got sick with a known red or yellow flag transmissible pathogen.
3381083|NCT04034264||Febrile patient|Patients between 2 months and 65 years old who present with fever.
3381084|NCT04030585|Experimental|robot-assisted exercise|Robot-assisted exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
3381085|NCT04030585|Active Comparator|Home exercise|Home exercise program will applied by patients with upper limb amputation using myoelectric prosthesis
3381086|NCT04028050|Experimental|Atezolizumab + Carboplatin + Etoposide|Participants will receive intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min), followed by intravenous infusion of etoposide 100 milligrams per square meter (mg/m^2) on days 1 through 3 of each cycle during the induction phase (21-day cycle for four/six cycles). On Days 2 and 3, participants will receive etoposide alone. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks until PD, unacceptable toxicity, loss of clinical benefit or study termination by the Sponsor.
3381087|NCT04024514|Experimental|Low dose|Low CT contrast media dose
3381088|NCT04024514|Active Comparator|Standard dose|Standard CT contrast media dose
3381093|NCT04017442|Experimental|Morphine|2mg preservative free morphine
3381094|NCT04017442|Placebo Comparator|Saline|4 mL preservative free saline
3381095|NCT04015050|Experimental|Test product|Cow's milk based infant formula containing prebiotics and postbiotics
3381096|NCT04015050|Active Comparator|Control product|Cow's milk based infant formula without prebiotics and postbiotics
3381097|NCT04014270|Experimental|Self modulated functional electrical stimulation (SM-FES)|Patients will receive self-modulated functional electrical stimulation SM-FES
3381098|NCT04014270|Active Comparator|Standard care (SC)|Patients will receive standard care, dose matched to the experimental group therapy
3381099|NCT04009499|Experimental|Bimekzumab dosage regimen|Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.
3381100|NCT04004611|Experimental|Mirikizumab Dose 1|Mirikizumab administered intravenously (IV) and Subcutaneously (SC). Participants >40 kilograms (kg)
3381101|NCT04004611|Experimental|Mirikizumab Dose 2|Mirikizumab administered IV and SC. Participants ≤40 kg
3381102|NCT04004611|Experimental|Mirikizumab Dose 3|Mirikizumab administered IV and SC. Participants ≤40 kg
3381103|NCT04000399|Experimental|BRITEPath|"Participants will receive the components in BRITEPath from a mental health (MH) clinician trained by the study staff/PI's on how to implement BRITE safety planning with fidelity.~First, the MH clinician will review possible barriers to implementation of the safety plan and problem-solve appropriately with patient and parent(s); (2) BRITE is the emotion regulation/safety planning app loaded on the patient's smartphone that populated with support from Guide2BRITE.; and (3) BRITEBoard, a clinician dashboard that shows app use, change in distress and symptoms ratings, and can be used for shared decision making with parents, patients, and PCPs. Clinicians will review adolescent's skill development and app content with parents. Prior to discharge or following acute increases in suicide risk."
3381104|NCT04000282|Experimental|Part A: SAR442085 dose escalation|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
3306795|NCT01891097|Experimental|Acupuncture plus auricular acupuncture|Subjects will be treated with electroacupuncture plus auricular acupuncture for 3 weeks. The acupuncture regimen, is the same as in electroacupuncture group. In additional to electroacupuncture, subjects will receive auricular acupuncture using borneol. The following 6 ear acupoints points will be selected: Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex. In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours. We will check for skin irritation at each treatment visit.
3306796|NCT01891097|No Intervention|Waiting-list control|This group will receive no treatment. Subjects will be assessed at baseline and the 4th and 7th week; afterwards, they will be randomized to one of the other two groups in the ratio of 1:1.
3306797|NCT01891110|Experimental|ES of the abdominal muscles|ES with surface electrodes, fixed stimulation parameters and individual mA
3306798|NCT01891110|Experimental|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
3306799|NCT01891110|Experimental|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
3306800|NCT01891123|Placebo Comparator|body surface area|patients receive fixed dose of PTX or DOC based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2. Patients should finish up to 6 cycles chemotherapy
3306801|NCT01891123|Active Comparator|Detection Kit|PTX 175mg/m2, DOC 75mg/m2 at first cycle. the dose of PTX or DOC will adjust based on the pharmacokinetic results of previous cycle. A optimal target of PTX(TC>0.05) and DOC(AUC) have been set from published PK model with an established limited sampling strategy
3306802|NCT01891136|Experimental|Peanut protein|Subjects to receive varying amounts of peanut protein as peanut oral immunotherapy.
3306803|NCT01891149||Malawian women|Malawian women who present for care at the Fistula Care Centre
3306804|NCT01891162||Control|Assessment will be carried out general quality of life beyond the functional evaluation of the pelvic floor through the PERFECT
3306805|NCT01891162||Study|Will be held evaluate the quality of life for general and specific pelvic floor dysfunction beyond the functional assessment of the pelvic floor through the PERFECT.
3306806|NCT01891175|Experimental|Intermittent pneumatic compression|With intermittent pneumatic compression of the lower extremities (Covidien / Kendall SCD ™ sequential compression systems) plus phenylephrine perfusion (usual treatment)in elective caesarean section under spinal anaesthesia.
3306807|NCT01891175|Active Comparator|Only pheniyephrine perfussion|No intermittent pneumatic compression of the lower extremities in elective caesarean section under spinal anaesthesia.
3306808|NCT01891188||Cardiac Cath|All pediatric patients requiring cardiac catheterization who consent
3306809|NCT01891201||Not exposed to oxytocin|Mother-child dyads in which Oxt had not been administered during the birth process
3306810|NCT01891214||Ulcerative Colitis and Crohn's Disease|
3306811|NCT01891227|Experimental|Capecitabine and Bendamustine|"Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).~Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).~Eligible patients will receive capecitabine in combination with bendamustine for a maximum of eight cycles and afterwards capecitabine mono will be continued until disease progression or unacceptable toxic effects. Safety assessments will be conducted in 3-weekly intervals; efficacy assessments will be conducted every 9 weeks."
3306812|NCT01891240||First time, low risk mothers|The study population will consist of first time, low risk mothers attending for antenatal care in one of the participating clinical centres.
3306813|NCT01891253||ventilated patients|ventilated patients in an internal medicine ICU with existing PiCCO invasive hemodynamic monitoring
3306814|NCT01891266|Experimental|Non-tourniquet assisted TKA|
3306815|NCT01891266|Other|Tourniquet assisted TKA|
3306816|NCT01891279|Experimental|elemental formula, Elecare®|Babies will receive elemental formula, Elecare®, if breast milk is not available.
3306817|NCT01891279|Experimental|part hydrolyzed formula, Pregestimil®|Babies will receive partially hydrolyzed formula, Pregestimil®, if breast milk is not available.
3306818|NCT01891292|No Intervention|Control|
3306819|NCT01891292|Active Comparator|Enalapril|
3306820|NCT01891292|Active Comparator|N-Acetylcysteine|
3306821|NCT01891318|Experimental|Treatment (radiosurgery, surgery)|Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
3306822|NCT01891383||History of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
3306823|NCT01891383||No history of TBI|The history of TBI will be assessed by the subject's answers to the Ohio State University Traumatic Brain Injury Identification Method Short Form (OSU TBI-ID SF).
3306824|NCT01891396|Placebo Comparator|Saline|Single injection of 0.9% saline supplied as a 4 mL unit dose in a 5mL glass syringe
3306825|NCT01891396|Experimental|Hyaluronic Acid and TH|Single injection of sodium hyaluronate with triamcinolone hexacetonide (TH) supplied as a 4 mL unit dose in a 5 mL glass syringe
3306826|NCT01891396|Active Comparator|Hyaluronic Acid|Single injection of sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe
3306827|NCT01891409|Other|Single arm|Single arm study study for use of Shang Ring device for male circumcision in children
3306828|NCT01891435|Active Comparator|oral paracetamol|patients in this arm will receive 1000mg of oral paracetamol
3306829|NCT01891435|Active Comparator|Intravenous paracetamol|patients in this arm will receive 1000 mg of intravenous paracetamol
3306830|NCT01891435|Active Comparator|Intramuscular Diclofenac|patients in this arm will receive 75 mg of intramuscular diclofenac sodium
3306831|NCT01891448|Experimental|WebCONSORT tool|This WebCONSORT tool allows authors to combine different extensions relevant to their trial and generate a list of items and a flowchart specific to their trial design and the type of intervention tested.
3306832|NCT01891448|Other|Modified WebCONSORT tool|This tool will include the flowchart part of the WEBCONSORT tool but not the main checklist or elements relating to CONSORT extensions.
3306833|NCT01891461|Experimental|Floseal|"Floseal will be administered during the procedure and prior to release of the tourniquet (if used PRN during the cementing procedure (±10 minutes)) and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissue by the use of a delivery syringe. Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.~Preparation of Floseal requires mixing 5,000 US units of package thrombin (bovine-derived) made up to 5 milliliters of saline solution, to the Gelatin Matrix solution. In this study, 2-4 vials (15-20 mls total) will be used."
3306834|NCT01891461|No Intervention|standard of care|For patients randomized to the control arm, the surgery will proceed in an otherwise identical fashion (with release of the tourniquet if used PRN during cementing procedure (±10 minutes)) and hemostasis followed by drain insertion and wound closure.
3306835|NCT01891474|Experimental|U-health care|voice inception technique based U-healthcare service
3306836|NCT01891474|No Intervention|control|conventional treatment
3306837|NCT01891487|Active Comparator|Track A|Those on active study medication
3306838|NCT01891487|Placebo Comparator|Track B|Those on placebo.
3306839|NCT01891500|Experimental|Early inhaled nitric oxide|Patients randomized to receive iNO at OI 10-15.
3306840|NCT01891500|Placebo Comparator|Bioinert inhaled gas (nitrogen gas)|Patients randomized to bioinert inhaled gas at OI 10-15.
3306841|NCT01891500|Active Comparator|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
3306842|NCT01891513||ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 4 mg/day which will be titrated to 8 mg/day.
3306843|NCT01891513||Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
3306844|NCT01891513||Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
3306845|NCT01891526||Hepatic patients|patients with hepatic insufficiency
3306846|NCT01891526||Healthy Controls|Healthy adults
3306847|NCT01891539||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of drug-eluting microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of drug eluting microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
3306848|NCT01891552||Tacetux|DEBIRI+ CETUXIMAB ADMINISTRATION
3306849|NCT01891552||DEBIRI|only DEBIRI treatment
3306850|NCT01891565|Experimental|Activity Feedback|Feedback
3306851|NCT01891565|No Intervention|No Feedback|
3306852|NCT01891591||obese female subjects|16 obese female subjects with BMI > 40 kg/m2 on a waiting list for bariatric surgery
3306853|NCT01891617|Experimental|Exercise-high-fat diet|Two bouts of exercise followed by a high-fat meal
3306854|NCT01891617|Experimental|Exercise-high-carbohydrate diet|Two bouts of exercise followed by a high-carbohydrate meal
3306855|NCT01891617|Experimental|Sedentary-high-fat diet|Sedentary trial with two high-fat meals
3306856|NCT01891617|Experimental|Sedentary-high-carbohydrate diet|Sedentary trial with two high-carbohydrate meals
3306857|NCT01891630||AA children|African-American children with moderate-to-severe asthma living in a defined geographical area whose asthma is poorly controlled, and up to 30 moderate-to-severe African-American asthmatic children living in the same defined geographical area whose asthma is well controlled.
3306858|NCT01891643|Experimental|Arm 1: Lenalidomide + Dexamethasone|"Lenalidomide 25 mg capsules by mouth once daily (on Days 1-21), repeat every 28 days until subject meets criteria for discontinuation of study drug~Dexamethasone 40 mg tablets by mouth weekly (on Days 1, 8, 15, 22), repeat every 28 days until subject meets criteria for discontinuation of study drug"
3306859|NCT01891643|Experimental|Arm 2: Lenalidomide + Dexamethasone + Elotuzumab|"Lenalidomide 25 mg capsules by mouth once daily (Days 1-21)~Dexamethasone 28 mg tablets by mouth once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15(cycles 3-18); Day 1 (cycle 19 & beyond)]~Dexamethasone 40 mg tablets by mouth once daily [Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 & beyond)]~Dexamethasone 8 mg IV (intravenous) solution once daily [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18); Day 1 (cycle 19 & beyond)]~Elotuzumab 10 mg/kg IV solution weekly [Days 1, 8, 15, 22 (cycles 1 & 2); Days 1 & 15 (cycles 3-18)]~Elotuzumab 20 mg/kg IV solution on Day 1 (cycle 19 & beyond)~Repeat above-mentioned dose cycles every 28 days until subject meets criteria for discontinuation of study drug"
3306860|NCT01891656|Experimental|Motivational Interviewing|"Participants randomized to the MI group will receive a single 60-minute MI session focused on motivation to initiate and engage in treatment. The MI session will be organized around the Check-Up format, with additional planning components as desired by the client."
3306861|NCT01891656|No Intervention|Supervision As Usual|Participants randomized to the SAU group will receive the standard agency intake process as well as baseline and follow-up research interviews, but will not receive any additional intervention as part of the study. They will be referred to a treatment program as per the normal routine.
3306862|NCT01891656|Experimental|Motivational Computer|Participants randomized to the MC group will complete a 60 minute computer intervention focused on motivation to initiate and engage in treatment. The program will be self-guided, interactive, and to the extent possible, will mirror the features of MI session. The MC program will have two main components: a motivation component and a planning component.
3306863|NCT01891682||Critically Ill Pediatric Patients|Critically ill septic pediatric patients, Age 1 month-3 years, Age 4-12 years and Age 13-19 years, males and females
3306864|NCT01891695|Experimental|Reduced Intensity Radiation|39.6 Gy radiation to clinically uninvolved cervical lymphatics
3306865|NCT01891747|Experimental|L-methylfolate with Bevacizumab & Temozolomide|28-day cycle, dose levels L-methylfolate: Phase I 15 mg (once a day) 30 mg (15 mg twice a day) 60 mg (30 mg twice a day) 90 mg (45 mg twice a day) Phase II will use the MTD of L-methylfolate daily with bevacizumab & temozolomide.
3306866|NCT01891760|Experimental|Treatment|Dermagraft - Allogenic Neonatal Dermal Fibroblasts Seeded on poly(glycolide-co-L-lactide)(PGLLA)Scaffold
3306867|NCT01891760|Active Comparator|Reference Therapy|Profore - Four-layer compression bandaging therapy
3306868|NCT01891773|Experimental|School-based therapy|Daily dose of medication to be provided in the school setting.
3306869|NCT01891773|No Intervention|Usual Care|Daily medication to be taken at home.
3306870|NCT01891786|No Intervention|Usual Care|The participant's General practitioner (GP) practice and/or practice nurse will provide care as normal for their patient.
3306871|NCT01891786|Active Comparator|Group Self-Management Intervention (SMI)|Participants will be asked to attend a total of 4 SMI sessions delivered on a weekly basis.
3306872|NCT01891786|Active Comparator|SMI + Risk Results|The participant will provide a saliva sample for analysis. They will attend an appointment with their nurse to receive personalised results on their combined genetic and lifestyle risk for developing CHD in the next 10 years. They will then be asked to attend the 4 week SMI programme.
3306873|NCT01891799||PMTCT Options Evaluation|All HIV positive pregnant women not on ART engaging in PMTCT services at the study sites will be included. This will include HIV+ women not on ART enrolling in PMTCT services and pregnant women newly testing HIV+ in the ANC. All women will eventually receive the intervention of Option B+ as each clinic transitions from Option A to B+.
3306874|NCT01891812|Experimental|Nitrous oxide 50%|Nitrous oxide 50% administered for 15 minutes.
3306875|NCT01891825|Active Comparator|Pecutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
3306876|NCT01891825|Active Comparator|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
3306877|NCT01891838|Active Comparator|Volume controlled ventilation|Volume controlled ventilation: tidal volume of 7 mL/kg ideal body weight, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Ventilatory frequency is changed if necessary to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg.
3306878|NCT01891838|Experimental|Pressure-controlled ventilation|initial pressure of 15 cm H2O, frequency of 12 cycles/minute, I/E ratio of 1:2, no positive end expiratory pressure. Pressure is modified to maintain a tidal volume of 7 mL/kg of ideal body weight and frequency ventilation is modified to maintain end-expiratory pressure of CO2 between 35 and 40 mmHg
3306879|NCT01891851|Experimental|TMC435350 / Ritonavir|TMC435350 2 capsules of 100-mg twice daily / Ritonavir one 100-mg capsule twice daily
3306880|NCT01891877||Current or Former Football Players|Any former or current high school or college football players who carries sickle cell trait.
3306881|NCT01891916|No Intervention|extensively hydrolysed casein formula|extensively hydrolysed casein formula
3306882|NCT01891916|Active Comparator|Extensively hydrolyzed casein formula + LGG|Extensively hydrolized formula plus LGG
3306883|NCT01891929|Experimental|RECOS|The RECOS program (COgnitive REmediation for Schizophrenia) was designed by SBT Company and adapted by Vianin et al (2007) for specific use in schizophrenia. It includes computer based and paper and pencil exercises that target 6 main cognitive functions (selective attention; verbal memory; visuo-spatiale attention and memory, working memory, reasoning, and speed of execution) which have been recommended by the MATRICS consensus. Each exercise has 10 difficulty levels. Allocation of the training modules in RECOS is determined according to the standard scores obtained in the comprehensive neuropsychological assessment. Each patient participates in the module corresponding to his/her most altered cognitive area.
3306884|NCT01891929|Active Comparator|TAU (Treatment as Usual)|The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
3306885|NCT01891942|Experimental|COPD patients|All of the COPD patients included in this study were stable with no episodes of exacerbation within the previous 2 months. Patients with COPD were not currently being treated with oral corticosteroids.
3306886|NCT01891942|Experimental|normal subjects|Fifteen healthy men with normal lung function
3306887|NCT01891955|Active Comparator|Diet A|Healthy diet with grains and dairy
3306888|NCT01891955|Active Comparator|Diet B|Healthy diet without grains and dairy
3306889|NCT01891981|Experimental|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
3306890|NCT01892033|Experimental|Aerobic Exercise|The aerobic exercise intervention is a 12-week program consisting of four 30- to 40-minute exercise sessions of brisk walking per week.
3306891|NCT01892046|Experimental|SNX-5422|Open label administration of SNX-5422 capsules every other day (QOD) for 21 days of a 28 day cycle. Dose escalation will be based on safety outcomes defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level. During the dose escalation phase, subjects will receive carboplatin and paclitaxel once every 21 days for a total of 4 courses. During the maintenance phase, SNX-5422 at the MTD will be dosed every other day (QOD) for 21 days of a 28 day cycle.
3306892|NCT01892059|Experimental|Segmental artery clamping|Patients with Renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of segmental renal artery clamping will performed.
3306893|NCT01892059|Active Comparator|Main renal artery clamping|Patients with renal tumor are randomized into this group,they will received laparoscopic partial nephrectomy. During operation, the technique of traditional main renal artery clamping will be performed.
3306894|NCT01892072||HCC patients|Hepatocellular carcinoma patients treated by surgical treatment
3306895|NCT01892085|Experimental|Early initiation|Initiation of breast milk expression <1 hour following delivery.
3306896|NCT01892085|Experimental|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
3306897|NCT01892085|Other|Late initiation|Initiation of milk expression >3-6 hours following delivery.
3306898|NCT01892098|Active Comparator|Zinc Sulfate|Subjects enrolled in this arm will receive 9mg elemental zinc (23mg zn sulfate)/day for 4 weeks.
3306899|NCT01892098|Placebo Comparator|Cellulose Pill|Subject enrolled in this arm will receive a placebo.
3306900|NCT01892111|Experimental|structured exercise program (SET)|SET one month before and during ARTs. IVF/ICSI procedure.
3306901|NCT01892111|No Intervention|no intervention|IVF/ICSI procedure.
3306902|NCT01892124|Experimental|Motivational Interviewing/Cognitive Behavioral-based Therapy|Receives an immediate weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol.
3306903|NCT01892124|Experimental|Wait-List Control|Receives a weekly 10 session intervention based on a culturally-adapted, motivational interviewing and Cognitive Behavioral Therapy grounded protocol after a three month, no-intervention waiting period.
3306904|NCT01892137|Other|Open label active|
3306905|NCT01892150|Experimental|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
3306906|NCT01892176|Experimental|Coenzyme Q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
3306907|NCT01892215|Experimental|Cephalad-caudad|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
3306908|NCT01892215|Experimental|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
3306909|NCT01892228|Experimental|Two counties: Zhongshan and Pubei|"Immediate post-screening treatment education for HIV-positive participants residing in the Zhongshan and Pubei pilot sites in the Treat-All HIV Pilot Program"
3306910|NCT01892241|Experimental|180µg of peginterferon alfa-2a|Cases in group A receive 180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
3306911|NCT01892241|Active Comparator|Entecavir|cases in group B received an continual entecavir therapy(0.5 mg orally once daily)
3306912|NCT01892241|No Intervention|Control group|Those in group C didn't accept any antiviral regiment .
3306913|NCT01892254|Experimental|Metformin-Placebo|Metformin, 2x 2 tablets a day, 500 mg tablets for 12 weeks, 6 weeks wash-out, 12 weeks placebo
3306914|NCT01892254|Placebo Comparator|Placebo-metformin|Placebo tablets, 2x 2 tablets per day for 12 weeks, 6 weeks wash-out, 12 weeks metformin, 2x 2 tablets per day, 500 mg per tablet
3306915|NCT01892280|Experimental|Teenwork Group|Teen/family will receive the Teenwork intervention at each quarterly study visit.
3306916|NCT01892280|Experimental|Teenwork/Text Message Group|Teen/family will receive the Teenwork intervention at each quarterly study visit. Teen will receive text message reminders to check blood glucose levels at self-selected times.
3306917|NCT01892280|Experimental|Text Message Group|Teen will receive text message reminders to check blood glucose levels at self-selected times.
3306918|NCT01892280|No Intervention|Usual Care Group|Teen/family will receive routine clinical care for the first year of the study (the time period for assessment of primary outcomes). After year 1, teen/family will receive the Teenwork intervention at each remaining study visit and teen will receive text message reminders to check blood glucose levels at self-selected times.
3306919|NCT01892319||All patients|
3306920|NCT01892332|Other|lidocaine with fentanyl 75ug|
3306921|NCT01892358|Active Comparator|SKIN Intervention|Participants will receive the SKIN intervention at Baseline and 1-mo interviews.
3306922|NCT01892358|Placebo Comparator|Assessment-Only|Participants in this arm will receive treatment-as-usual
3306923|NCT01892371|Experimental|Arm I (quizartinib, azacitidine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3306924|NCT01892371|Experimental|Arm II (quizartinib, cytarabine)|Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3306925|NCT01892384|Experimental|BI 409306 dose 1|low dose, once daily
3306926|NCT01892384|Experimental|BI 409306 dose 2|medium dose, once daily
3306927|NCT01892384|Experimental|BI 409306 dose 3|high dose, once daily
3306928|NCT01892384|Placebo Comparator|Placebo|placebo, once daily
3306929|NCT01892397|Experimental|Optune (NovoTTF-100A)|The treatment plan is to have patients use the Optune device in monotherapy for ≥ 18 hours per day as per the treatment standard established from prior studies. A medical professional will see each patient at least once per month while on the device for toxicity assessment, compliance evaluation via downloading of the log-file on the device by the Novocure technician (which involves the technician simply attaching the device to a computer via USB where software reads how many hours per day on each day the device was used), and physical examination. Extent of disease evaluations will occur at baseline, 8 weeks, and then every 8 weeks thereafter. These evaluations will include MRI of the brain with and without contrast and perfusion (or CT head if a patient cannot undergo MRI).
3306930|NCT01892410|Experimental|Cetaphil Restoraderm Skin Restoring Body Wash|All subjects receive Cetaphil Daily Advance Ultra Hydrating Lotion
3306931|NCT01892423|Experimental|Cetaphil Moisturizing Lotion Daily Advance|Each subject had Cetaphil Moisturizing Lotion Daily Advance applied
3306932|NCT01892449|Experimental|prolonged I:E ratio (1:1) group|
3306933|NCT01892449|Active Comparator|conventional I:E ratio (1:2) group|
3306934|NCT01892475|Experimental|Cash Only (CO)|As part of the Incentive-based physical activity program, drivers assigned to the Cash Only (CO) arm will earn incentives in the form of cash for meeting specified monthly step goals from Months 1 to 4.
3306935|NCT01892475|Experimental|Mental-Accounting (MA) based|As part of the Incentive-based physical activity program, drivers assigned to the Mental-Accounting (MA) based arm will receive incentives in the form of taxi rental credits for meeting specified monthly step goals from Months 1 to 4.
3306936|NCT01892488|Placebo Comparator|lactose pill|Placebo for 5 days as supplement to standard of care for patients with AE-COPD
3306937|NCT01892488|Experimental|Sultamicillin|Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD
3306938|NCT01892514|Experimental|Demineralized Bone Marrow (DBM)|core decompression of necrotic area and graft with a biological product based on Demineralized Bone Matrix (DBM), Platelet-Rich-Fibrin (PRF) and Concentrated Bone Marrow (CBM)
3306939|NCT01892514|Experimental|Lyophilized Bone Chips (LBC)|core decompression of the necrotic area and graft with a biological product based on homologous Lyophilized Bone Chips (LBC), Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
3306940|NCT01892527|Experimental|Tivantinib plus Cetuximab|Single arm
3306941|NCT01892553|Experimental|motor/premotor cortex stimulation|Active and sham tDCS applied over the motor/premotor cortex
3306942|NCT01892553|Experimental|insular cortex stimulation|Active and sham tDCS applied over the insular cortex
3381105|NCT04000282|Experimental|Part B: SAR442085 dose expansion|SAR442085 will be given intravenously weekly for 4 weeks (Cycle 1) and on Day 1 and Day 15 of each subsequent cycle until the patient has progressive disease, unacceptable toxicity or other reasons to terminate study treatment. Each cycle will be approximately 28 days in duration.
3381106|NCT03998878|Experimental|Low-Carbohydrate Diet|Participants will be instructed to consume less than 30 grams of carbohydrates per day.
3381107|NCT03998878|Experimental|Intermittent Energy Restriction|Participants choose 2 non-consecutive days per week in which they will consume 500-650 calories.
3381108|NCT03998878|Experimental|Hunger Training|Participants monitor their hunger symptoms and blood glucose, and eat only when blood glucose is below a certain threshold level.
3381109|NCT03996200|Experimental|MINIject CS627 implant|MINIject 627 implant is used to reduce intra-ocular pressure in the eye. It is implanted through a minimally-invasive glaucoma surgical intervention in a stand alone procedure.
3381110|NCT03994367|No Intervention|Standard protein (control)|
3306943|NCT01892566|No Intervention|Usual care for COPD|Usual care for AECOPD in the JHHCC consists of patient-initiated contact with the clinic for change in respiratory symptoms. Participants will be asked to complete a weekly symptom diary assessment which will be returned to the study staff at every 3-month visits. Participants contacting research staff with a worsening in respiratory symptoms will be referred to their assigned clinical providers.
3306944|NCT01892566|Experimental|mHealth Intervention|For the mHealth intervention, investigators will use of the eResearch Technology, Inc system (ERT®; Philadelphia, PA) for home-based monitoring of spirometry and respiratory symptoms. In conjunction, wireless sensor-based inhalers will monitor the frequency of rescue inhaler use (Asthmapolis®; Madison, WI). As well, on a daily basis, participants in the early identification group will complete eight respiratory symptom questions from the COPD Assessment Test (CAT). Participants' short acting beta-agonist inhaler use will be monitored by an Asthmapolis Spiroscout Inhaler Tracker. Based on participant responses, flags or electronic notifications can be generated. Based on severity of symptoms and guidelines for recommended care, participants will be instructed to self-manage by optimizing inhaler use (if symptoms are mild) or present for an acute care visit at JHHCC if necessary.
3381111|NCT03994367|Experimental|High animal protein isolate|
3381112|NCT03994367|Experimental|High animal protein whole food|
3381113|NCT03994367|Experimental|High plant protein isolate|
3381114|NCT03994367|Experimental|High plant protein whole food|
3381115|NCT03993314|Active Comparator|Bupivacaine|1 ml 0.5% isobaric bupivacaine (5 mg) + 15 mcg fentanyl intrathecal plus epidural volume extension (EVE)
3381116|NCT03993314|Experimental|Chloroprocaine|5 ml 1% spinal chloroprocaine (50 mg) intrathecal plus epidural volume extension (EVE)
3381117|NCT03992404|Experimental|NT 201 (IncobotulinumtoxinA, Xeomin)|"Main Period (1 treatment cycle): subjects to receive intramuscular injection of NT 201 (400 units) into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
3381118|NCT03992404|Placebo Comparator|Placebo|"Main Period (1 treatment cycle): subjects to receive intramuscular placebo injection into muscles of the lower limb.~Open Label Extension Period (4-5 treatment cycles): subjects to receive intramuscular injection of NT 201 (up to 800 units) into muscles of the lower limb and upper limb, if indicated."
3381119|NCT03986424|Experimental|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg once daily
3381120|NCT03986424|Active Comparator|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg twice daily
3381121|NCT03973996|Experimental|Green Tea|Participants consuming gummy confections with catechin-rich green tea extract daily for 4 weeks
3381122|NCT03973996|Placebo Comparator|Placebo|Participants consuming matched gummy confections formulated without green tea extract daily for 4 weeks
3381123|NCT03972488|Experimental|Lutathera plus long-acting octreotide|
3381124|NCT03972488|Active Comparator|high dose long-acting octreotide|
3381125|NCT03969953|Experimental|Rivaroxaban|Rivaroxaban 2.5mg, twice daily.
3381126|NCT03969953|Placebo Comparator|Placebo|Matched placebo, twice daily.
3381127|NCT03966872|Experimental|Integrated Illness Management and Recovery (I-IMR):|Participants assigned to I-IMR will receive 2 individual sessions to discuss principles of recovery and set personally meaningful goals, with the remainder of the 14 I-IMR sessions delivered in groups of 8-10 (to enable individual tailoring)
3381128|NCT03966872|Experimental|Stanford Chronic Disease Self-Management Program (CDSMP):|Participants randomly assigned get a 6-session group-based educational program co-delivered by two peers (lay people who have successfully managed a chronic illness) or a peer and a professional
3381130|NCT03958409|Experimental|Rigorous evaluation|Participants will be evaluated for the rigorous evaluation received.
3381131|NCT03958409|Active Comparator|Standard care|The participants will be evaluated for the standard of care received.
3306945|NCT01892579|Experimental|Tailored Activity Program|"The Tailored Activity Program unfolds over 3 phases: Phase I (sessions 1-2) involves assessment of Person with Dementia (PwD)capacity and interests, caregiver (CG) interactions and the physical environment and CG education. Phase II (sessions 3-6) involves identifying and implementing 3 Activity Prescriptions tailored to PwD's cognitive and interest profile using an algorithmic guide. The prescription summarizes PwD capabilities in lay language, identifies the activity and a specific activity goal, and provides specific instructions for introducing the activity. CGs are trained to integrate activities in daily care. Also provided are simple deep breathing stress reduction techniques to address CG upset. Phase III (sessions 7-8) involves instructing CGs in simplifying activities for future cognitive declines and applying simplification principles to other care challenges."
3306946|NCT01892579|Active Comparator|Home Safety and Education Program|This arm receives 6 in-home and 2 brief telephone education sessions. Each contact is structured to provide helpful education. Sessions include information on home safety, fall risk assessment, talking to your doctor, advanced planning, identifying resources, and caring for the caregiver (CG). Each session is prescriptive and designed to maximize attention; yet, sessions will not involve any component of the intervention group. To engage the person with dementia (PwD), the interventionist will socially engage the person briefly in select sessions. Time spent with CG and PwD in the control group is comparable to that for intervention dyads.
3306947|NCT01892592|No Intervention|Usual Care|No Interventions
3306948|NCT01892592|No Intervention|Medication enhancement|Pharmacist will optimize current Kaiser medication protocol for treatment of hypertension.
3306949|NCT01892592|Experimental|Diet and Lifestyle Arm|Patients will receive up to 16 wellness coaching sessions focusing on DASH doest and lifestyle changes - Behavioral Intervention
3306950|NCT01892605|Experimental|music listening, no music|The clinical application and mechanism of music therapy The clinical application and mechanism of music therapy (Mozart's effect) on epilepsy (Mozart's effect) on epilepsy
3306951|NCT01892618|Active Comparator|Pneumovax|Pneumovax, 1x 0.5 ml injection
3306952|NCT01892618|Experimental|Prevenar 13|Prevenar 13, 1x 0.5 ml injection
3306953|NCT01892631|Other|Standard care|Practices in the standard care arm will proceed with their seasonal influenza campaign as planned.
3306954|NCT01892631|Experimental|Text messaging intervention|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
3306955|NCT01892644|Active Comparator|Deferasirox HC|10 patients with hemochromatosis treated with Deferasirox
3306956|NCT01892644|Active Comparator|Venesection HC|10 patients with hemochromatosis treated with venesection
3306957|NCT01892644|Active Comparator|Deferasirox MDS|20 patients with myelodysplastic syndrome treated with Deferasirox
3306958|NCT01892644|No Intervention|Controls|10 healthy control persons to assess the normal level of investigational blood tests.
3306959|NCT01892670|Experimental|Filtered whole blood|"Leukocyte-reduced whole blood, 2 hours holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB(Whole blood)-SP(saving platelets) collection bag system"
3306960|NCT01892670|Experimental|Unfiltered whole blood|"Non-leukocyte-reduced whole blood, 2 hours holding-time after collection.~Device: Terumo IMUFLEX WB-SP collection bag system"
3306961|NCT01892670|Experimental|Warm-filtered whole blood|"Leukocyte-reduced whole blood, no holding-time after collection. Gravitational filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
3306962|NCT01892670|Experimental|Forced warm-filtration of whole bood|"Leukocyte-reduced whole blood, no holding-time after collection. Forced filtration.~Device: Terumo IMUFLEX WB-SP collection bag system"
3306963|NCT01892670|Experimental|RCC produced from cold-stored whole blood|"RCC production from 7 days old, cold-stored, leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP collection bag systems."
3306964|NCT01892670|Experimental|RCC produced from cold-stored non-filtered whole blood|"RCC production from 7 days old, cold-stored, non-leukocyte-reduced whole blood. Units stored for another 35 days. (42 days of storage in total).~Devices: Terumo IMUFLEX WB-SP/WB-RP(removing platelets) collection bag systems."
3306965|NCT01892683||Propofol|This study will investigate patients that undergo routine anesthesia for elective surgical procedure at the hospital of the University of Munich(Klinikum der Universität München. Patients will receive intravenous anesthesia with propofol.
3306966|NCT01892696|Other|mechanically ventilated patients|"patients admitted to a 18-bed medical surgical intensive care unit of the military hospital of Tunisia and were mechanically ventilated fully adapted to their ventilator and in sinus rhythm.~intervention:varying inspiratory flow waveforms"
3306967|NCT01892748|Active Comparator|Cholecalciferol 50.000IU/week|patients will receive vitamin D3 (50.000 IU/week) for 24weeks
3306968|NCT01892748|Placebo Comparator|Placebo|patients receive placebo in similar capsules of cholecalciferol for 24weeks
3306969|NCT01892761||TCL/MMF Group|
3306970|NCT01892761||CyA/MMF Group|
3306971|NCT01892787|Experimental|Formoterol (Atimos Modulite)|Atimos Modulite 1 puff (12 micrograms) twice a day
3306972|NCT01892787|Active Comparator|Salmeterol (Serevent Accuhaler)|Serevent Accuhaler 1 puff (50 micrograms) of twice a day
3306973|NCT01892800||Study population - lung resection|Patients with suspected lung cancer undergoing lung resection by anatomic lobectomy
3306974|NCT01892813|Experimental|Tailored intervention|Participants will receive a combined behavioral and pharmacological intervention. The behavioral component will consist of a six-session cognitive behavioral telephone intervention combined with supplemental treatment modules to address common issues (symptoms of depression, weight gain, risky alcohol use) associated with cigarette smoking based on eligibility and preference.
3306975|NCT01892813|Active Comparator|Enhanced standard of care|Participants assigned to the enhanced standard of care condition will receive referral to their state tobacco quitline along with pharmacotherapy to assist with smoking cessation.
3306976|NCT01892826|Experimental|hCG group|
3306977|NCT01892826|No Intervention|LH pic|
3306978|NCT01892839|Experimental|high dialysate flow, larger dialyzer|high dialysate flow, larger dialyzer
3306979|NCT01892839|Active Comparator|low dialysate flow, smaller dialyzer|low dialysate flow, smaller dialyzer
3306980|NCT01892852|Experimental|Acupuncture|Acupuncture treatment
3306981|NCT01892852|No Intervention|Control|No other active treatment or sham acupuncture for this symptoms
3306982|NCT01892878|Other|Single Arm Study|All patients will receive treatment
3306983|NCT01892891|Experimental|VBY-036|VBY-036 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
3306984|NCT01892891|Placebo Comparator|Placebo comparator|Placebo
3306985|NCT01892904|Experimental|EE20/DRSP(BAY86-5300)-flexibel extended regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with flexible extended regimen (24-day to 120-day active tablet intake followed by 4-day tablet free interval)
3306986|NCT01892904|Active Comparator|EE20/DRSP(BAY86-5300)-28 days cyclic regimen|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day with 28-day cyclic regimen (24-day active tablet intake followed by 4-day placebo tablet intake)
3306987|NCT01892930|Experimental|Treatment (SBRT, nephrectomy)|Patients undergo SBRT on day 1 and undergo partial or radical nephrectomy on day 29.
3306988|NCT01892943||Patients with LHON|
3306989|NCT01892956||Healthy volunteers|
3306990|NCT01892956||Newly diagnosed T2DM|Newly diagnosed T2DM, who have not started yet medical treatment with glucose lowering medications
3306991|NCT01892969||HEART AND LUNG FAILURE|Patients with Heart failure or Respiratory Failure with Hyperglycemia
3306992|NCT01892982|Experimental|Problem Solving Education tailored to NICU|NICU-PSE integrates motivational interviewing and problem solving, with ongoing monitoring and linkage to mental health services for mothers with worsening depressive symptoms over time. The intervention is provided over six sessions, including three tailored, post-discharge sessions, which address issues common to families of preterm infants: caregiver burden, complexity of medical follow-up, and social reintegration following hospitalization.
3306993|NCT01892982|No Intervention|Control|Both study groups receive standard NICU medical, social work, and nursing services. At each study site, attending neonatologists and pediatrics residents constitute the medical team, and all families are assigned a social worker.
3306994|NCT01892995|Experimental|Ketamine|active arm
3306995|NCT01892995|Sham Comparator|Diphenhydramine|sham arm
3306996|NCT01892995|Placebo Comparator|Saline|placebo
3306997|NCT01893008|Experimental|Usual care + Inspiratory Muscle Training (IMT)|
3306998|NCT01893008|No Intervention|Usual care (no IMT)|
3306999|NCT01893021||Postpartum Malawian women|
3307000|NCT01893034|Active Comparator|Conservative treatment|Physiotherapy and activity modification
3307001|NCT01893034|Active Comparator|Surgical treatment|Arthroscopic treatment of femoroacetabular impingement
3307002|NCT01893047|No Intervention|no music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3307003|NCT01893047|Experimental|live music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3307004|NCT01893047|Experimental|recorded music|The mother will be randomized to receive each od three experimental conditions: live music, recorded music, no music in random order over the course of three pumping sessions. She will then experience all three conditions again in random order
3307005|NCT01893060|Experimental|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
3307006|NCT01893060|Experimental|Chlorhexidine|Umbilical stump care. ChloraPrep® Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
3307007|NCT01893060|Experimental|Pluronic Cream|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin), applied twice a day to cord stump while umbilical line(s) are in place
3307008|NCT01893060|Sham Comparator|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
3307009|NCT01893073|Active Comparator|Mindful walking|A weekly 60 minutes walking group exercise program consisting of a combination of walking and mindfulness over 8 weeks.
3307010|NCT01893073|No Intervention|Waiting group|
3307011|NCT01893086|Active Comparator|LH alone|LH, laparoscopic hysterectomy
3307012|NCT01893086|Experimental|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
3307013|NCT01893099|Experimental|Sorafenib- Cohort 1|Sorafenib 400 mg BID will be started 14 days after the administration of SIRT with SIR-Sphere®.
3307014|NCT01893099|Experimental|Sorafenib- Cohort 2|Sorafenib 400 mg BID will be started 11 days after the administration of SIRT with SIR-Sphere®.
3307015|NCT01893099|Experimental|Sorafenib- Cohort 3|Sorafenib 400 mg BID will be started 3 days after the administration of radioembolization with SIR-Sphere®.
3307016|NCT01893099|Experimental|Sorafenib- Cohort 4|Sorafenib 400 mg BID will be started 7 days prior to the administration of radioembolization with SIR-Spheres® and be given continuously, without drug holidays.
3307017|NCT01893112|Experimental|Unity Workshop|The intervention is a workshop facilitated by a peer advocate (an African American woman who is also HIV positive) and a social worker. It has exercises, videos and group discussions intended to equip participants with coping skills to overcome HIV related stigma and the negative outcomes related to stigma. The workshop will last about 8 hours total across 2 two days (4 hours per day). The researcher in the current study has done a lot of work in adapting this intervention for African American women. The workshop has been piloted in Seattle and had promising results. Based on results in the pilot study, a 2 hour booster session has been added 6 months after the initial workshop
3307018|NCT01893112|Other|Breast Cancer Screening|The time and attention control group workshop will be facilitated by a research coordinator. The control group program is based on another program that is designed explore issues related to breast cancer screening among African American women. The program has the same format as the Unity Workshop, with video and group discussion. Although breast cancer may be associated with stigma, we anticipated that breast cancer stigmas would not be related to HIV-associated stigma, which is our primary outcome of interest. The control groups will be held during the same week as the Unity Workshops, and control group participants will complete assessments on the same schedule as the Unity Workshop participants.
3307019|NCT01893125|Experimental|CNV2197944|CNV2197944 75mg tid 21 days
3307020|NCT01893125|Placebo Comparator|Placebo|Placebo 1 cap tid 21 days
3307021|NCT01893138|Experimental|Roll-in: AMDC for USR|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
3307022|NCT01893138|Placebo Comparator|Placebo|Placebo control is the vehicle solution used for the study product.
3307023|NCT01893138|Experimental|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
3381132|NCT03955471|Experimental|Niraparib+Dostarlimab (TSR-042)|Participants will receive both Niraparib and TSR-042 to evaluate the efficacy and safety of the combination of both drugs. Niraparib will be administered once daily (QD) continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) will be administered via a 30-minute intravenous (IV) infusion on Day 1 every 3 weeks (Q3W) during Cycles 1 through 4. Beginning at Cycle 5, dostarlimab (TSR-042) will be administered via a 30-minute IV infusion on Day 1 of each 6-week cycle until PD or toxicity, for a maximum of 3 years.
3381136|NCT03952559|Experimental|Baricitinib Open Label High Dose|Baricitinib administered orally.
3381137|NCT03952559|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3381138|NCT03952559|Experimental|Baricitinib Mid Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3381139|NCT03952559|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3381140|NCT03952559|Placebo Comparator|Placebo|Placebo administered orally. Matching placebo administered orally to maintain the blind.
3307024|NCT01893138|Placebo Comparator|Roll in: Placebo|Roll-in patients are allowed in the study (up to 12 per site) and are randomized and treated exactly the same as standard study patients.
3307025|NCT01893151|Experimental|Iguratimod|Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
3381141|NCT03949894|Experimental|tolvaptan|
3381143|NCT03949140|Experimental|Laser hair removal treatment|Patients who choose to enroll will plan to undergo a total of up to 8 laser hair removal sessions every 4-6 weeks. If patients develop abscess or infection during this time, they will undergo I&D and/or antibiotics, consistent with standard therapy for infection or abscess. If patients have 2 or more infections in 1 year, pain or drainage for more than 1 month, or miss more than 1 week of school or work due to ineffective treatment of pilonidal disease, these patients will undergo surgical excision and subsequent follow-up at surgeon's discretion. Patients will follow up at 2-4-week intervals for 3 months, then at 6, 9, and 18 months after conclusion of the laser therapy sessions. At all follow-up sessions, patients will be given the DQLI, CDQLI, and Promis 3A Pain survey. Unscheduled visits such as unplanned clinic visits, emergency department encounters, and hospitalizations, will be included in data collected for analysis of primary and secondary outcomes.
3381144|NCT03942224|Experimental|Arm I (DId)|"INDUCTION: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1, 8, 15, and 22 of cycles 1-2 and on days 1 and 15 of cycles 3-8, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3307026|NCT01893151|Placebo Comparator|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week;Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week
3307027|NCT01893164|Experimental|moderate cubital tunnel syndrome|Sensory,Intermittent paresthesias; vibratory perception normal or decreasedMotor,Measurable weakness in pinch or grip strengthTests,Elbow flexion test or Tinel's sign is positive; finger crossing may be abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
3307028|NCT01893164|Experimental|severe cubital tunnel syndrome|Sensory,Persistent paresthesias; vibratory perception decreased; abnormal two-point discrimination(static >6 mm, moving >4 mm)Motor,Measurable weakness in pinch and grip plus muscle atrophyTests,Positive elbow flexion test or positive Tinel's sign may be present; finger crossing usually abnormal.Treated by simple decompression,anterior subcutaneous transposition and anterior intramuscular transposition of the ulnar nerve.
3307029|NCT01893177|Experimental|Elderly subjects aged over 60 years|
3307030|NCT01893177|Experimental|Adults from 18 to 60 years old inclusive|
3307031|NCT01893190|Active Comparator|Nimodipine|Nimodipine 60mg q4h for 21 days - oral
3307032|NCT01893190|Experimental|Nimodipine Microparticles|Single intraventricular injection
3307033|NCT01893216||with depression or anxiety|Hospital Anxiety and Depression Scale score over 9 points
3307034|NCT01893216||without depression or anxiety|Hospital Anxiety and Depression Scale score less than 8 points
3307035|NCT01893229|Experimental|Valproate|Name: Valproate; dosage form: tablet, 250mg; dosage and frequency: 800mg-- 1200mg/d; duration: 6 weeks.
3307036|NCT01893229|Experimental|Oxcarbazepine|Name: Oxcarbazepine, dosage form: 300mg, tablet; dosage and frequency: 600-1200mg/d; duration: 6 weeks
3307037|NCT01893229|Experimental|Quetiapine|name: Quetiapine, dosage form: 200mg,tablet; dosage and frequency: 600mg-- 800mg/d; duration: 6 weeks
3307038|NCT01893229|Experimental|Olanzapine|Name: Olanzapine, dosage form: 5mg tablet; dosage and frequency: 10mg--20mg/d; duration: 6 weeks
3381145|NCT03942224|Experimental|Arm II (DVd, DId)|"INDUCTION CYCLES 1-3: Patients receive dexamethasone IV and PO on days 1, 8, and 15, daratumumab IV on days 1, 8, and 15, and bortezomib subcutaneously (SC) on days 1, 4, 8, and 11. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.~INDUCTION CYCLES 4-8: Patients receive dexamethasone IV and PO on days 1, 8, 15, and 22, daratumumab IV on days 1 and 15, and ixazomib PO on days 1, 8, and 15. Treatment repeats every 28 days for 5 cycles in the absence of disease progression or unacceptable toxicity. Eligible patients then undergo stem cell transplant per standard of care. Patients who have at least stable disease after induction and patients who have undergone transplant continue to Maintenance.~MAINTENANCE: Patients receive dexamethasone IV on day 1, daratumumab IV on day 1, and ixazomib PO on days 1, 8, and 15. Cycles repeat every 28 days for up to 24 months in the absence of disease progression or unacceptable toxicity."
3381146|NCT03936413|Experimental|Bay Labs EchoGPS group|In this arm, medical residents will use the Bay Labs EchoGPS system to perform an echocardiogram.
3381147|NCT03936413|Active Comparator|Native Terason group|In this arm, medical residents will use the native Terason machine to perform an echocardiogram.
3381150|NCT03929315||Non-spaced learning|Learning/testing sessions will take place within 30 minutes of one another
3381151|NCT03929315||Spaced learning|Learning/testing sessions will take place 1 week after one another
3381152|NCT03928847|Experimental|EGCG treatment|"Healthy volunteers: 450 mg, 600 mg, or 750 mg Epigallocatechin-3-gallate (EGCG) capsules administered once daily by mouth~Patients: 600 mg EGCG capsules once daily by mouth for two weeks"
3381153|NCT03928704|Experimental|Bimekizumab|Subjects randomized to this arm will receive bimekizumab during the Double-Blind Treatment Period and the Maintenance Period.
3381154|NCT03928704|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and receive bimekizumab during the Maintenance Period.
3307039|NCT01893229|Experimental|Ziprasidone|Name: Ziprasidone, dosage form: 10mg tablet; dosage and frequency: 80mg-160mmg/d; duration: 6 weeks
3307040|NCT01893229|Experimental|Lithium|name: lithium; dosage form: 250mg Tablet; dosage and frequency: 750mg-2000mg/d;serum Li level: 0.6mmol-1.2mmol/L; duration: 6 weeks
3307041|NCT01893242|Experimental|Aleglitazar Arm|
3307042|NCT01893242|Placebo Comparator|Placebo Arm|
3381156|NCT03927157|Experimental|Tezepelumab|Tezepelumab: Tezepelumab subcutaneous injection
3381157|NCT03927157|Placebo Comparator|Placebo|Placebo: Placebo subcutaneous injection
3307043|NCT01893255||Cohort|
3307044|NCT01893268||Cohort|
3381158|NCT03926130|Experimental|Mirikizumab|"Mirikizumab given intravenously (IV) and subcutaneously (SC).~Participants in the open-label adolescent addendum will be given mirikizumab IV and SC."
3381159|NCT03926130|Active Comparator|Ustekinumab|Ustekinumab given IV and SC.
3381160|NCT03926130|Placebo Comparator|Placebo|Placebo given IV and SC.
3307045|NCT01893294|Experimental|Treatment (gemcitabine hydrochloride)|Patients receive gemcitabine hydrochloride IT on day 1. Within 33 hours, patients receive standard chemotherapy comprising fluorouracil IV on days 1, 8, 15, 22, 29, and 36 and undergo standard radiation therapy 5 days a week for 6 weeks.
3307046|NCT01893320|Experimental|Vosaroxin + Decitabine|"The first 6 patients on study (first cohort) receive 1 or 2 induction cycles of therapy according to the following starting schedule: Vosaroxin administered intravenously on days 1 and 4 at a dose of 90 mg/m2 in the first cycle (induction 1) for a total dose of 180 mg/m2/cycle in combination with Decitabine at a dose of 20 mg/m2 intravenously daily for 5 consecutive days (Days 1 to 5).~Following the phase I portion, patients in phase II receive the following induction:~Vosaroxin intravenously on days 1 and 4 at a dose of 70 mg/m2 for a total dose of 140 mg/m2/cycle (days 1 and 4), or the final induction dose (MTD) determined in phase I.~Decitabine intravenously at a dose of 20 mg/m2 for 5 consecutive days (days 1 to 5), or the final induction dose (MTD) determined in phase I."
3307047|NCT01893333|Experimental|Nerve sparing radical hysterectomy group|"sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
3307048|NCT01893333|Active Comparator|Radical hysterectomy group|Conventional radical hysterectomy
3381161|NCT03924414|Active Comparator|Zoledronic acid (ZA)|A single intravenous infusion of Zoledronic acid (5 mg) infused over 45 minutes
3381162|NCT03924414|Placebo Comparator|Placebo|A single intravenous infusion of placebo infused over 45 minutes
3381163|NCT03922997|Experimental|Atezolizumab|Participants will receive atezolizumab intravenously on the first day of each cycle. Atezolizumab treatment will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or patient decision to withdraw from therapy, or death (whichever occurs first).
3307049|NCT01893385|Experimental|vitamin D|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
3307050|NCT01893385|Other|INTANZA 15|The entire project will collect new information on the merits of the use of vitamin D in aging. A better knowledge of mechanisms involved and the impact of aging on them is a necessary prerequisite the definition of a new strategy using this drug in the elderly particularly fragile in order to improve its autonomy. This definition seems a sociological interest obvious economic knowing the current aging population and its impact future of our health system
3307051|NCT01893398|Experimental|rehabilitation (MST) program|The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
3307052|NCT01893398|No Intervention|Usual care program|Usual care PWA program
3307053|NCT01893424|Active Comparator|Sativex buccal spray|volunteers will receive a single dose of 8 actuations of Sativex® which will be administrated within 1-2 min by the study physician. The dose of THC and CBD to be administered is the following: THC 21.6 mg and CBD 20 mg. Sativex® actuations will be directed sublingually and at the buccal mucosa.
3307054|NCT01893424|Experimental|CBD-THC-Piperine-PNL capsule|12 volunteers will receive a single oral dose of THC:CBD P-PNL capsule with 200 mL of water. The dose of THC and CBD to be administered is the same as in the Sativex arm: THC 21.6 mg and CBD 20 mg.
3307055|NCT01893437|Experimental|Single oral dose group|
3307056|NCT01893450|Active Comparator|methimazole|methimazole 30 mg daily during one year
3307057|NCT01893450|Active Comparator|methimazole, bromocriptine|methimazole 30 mg daily during one year, bromocriptine 5 mg twice a day during one year
3307058|NCT01893450|Active Comparator|pentoxifylline|methimazol 30 mg daily and pentoxifylline 400 mg twice a day during one year
3307059|NCT01893463||Patients which received the iTClamp as treatment|Use of the iTClamp50 will be determined by the EMS and ER physicians. Patients who have received treatment will be tracked from pre-hospital to patient discharge (chart review). EMS care providers and physicians will answer a survey about their experience with the iTClamp50.
3307060|NCT01893476|No Intervention|control|In this arm, practitioners will provide usual care for COPD patients.
3307061|NCT01893476|Other|adherence to guideline|Implementation educational programme: guideline adherences. The results of this trial will be directly applicable to primary care settings. Should the interventions delivered at the level of the GP practice be found to be effective in improving patients' quality of life then the findings would have a wider application.
3307062|NCT01893489|Active Comparator|Atherosclerosis|coronary artery disease patients with carotid plaques confirmed by a ultrasound study
3307063|NCT01893489|Sham Comparator|control|no coronary artery disease patients without carotid plaques confirmed by a ultrasound study
3307064|NCT01893502|Active Comparator|Group 1|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for one month
3307065|NCT01893502|Active Comparator|Group 2|Participants will receive weekly proactive and live telephone counselling from Quitline (run by the Health Promotion Board) for six months
3307066|NCT01893515|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
3307067|NCT01893515|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
3307068|NCT01893528|Experimental|REGN2009 dose level 1|Cohort A - REGN2009 or placebo; Cohort B - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3307069|NCT01893528|Experimental|REGN2009 dose level 2|Cohort C - REGN2009 or placebo; Cohort D - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3307070|NCT01893528|Experimental|REGN2009 dose level 3|Cohort E - REGN2009 or placebo; Cohort F - Patients on existing (non-exclusionary) medications + (REGN2009 or placebo)
3307071|NCT01893541|Active Comparator|EBL PLUS PROPRANOLOL|The EBL procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices were obliterated. The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
3307072|NCT01893541|Active Comparator|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
3307073|NCT01893554|Experimental|Group 1: RSV vaccine|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3307074|NCT01893554|Placebo Comparator|Group 1: Placebo|Healthy RSV-seropositive children ages 12 to 59 months will receive one dose of the placebo administered as nose drops at study entry.
3307075|NCT01893554|Experimental|Group 2: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3307076|NCT01893554|Placebo Comparator|Group 2: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
3307077|NCT01893554|Experimental|Group 3: RSV vaccine|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3307078|NCT01893554|Placebo Comparator|Group 3: Placebo|Healthy RSV-seronegative infants and children ages 6 to 24 months will receive one dose of the placebo administered as nose drops at study entry.
3307079|NCT01893554|Experimental|Group 4: RSV vaccine|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the RSV ΔNS2 Δ1313 I1314L vaccine administered as nose drops at study entry.
3307080|NCT01893554|Placebo Comparator|Group 4: Placebo|Healthy infants between the ages 4 to 6 months who have not been screened for RSV serostatus will receive one dose of the placebo administered as nose drops at study entry.
3307081|NCT01893580|Experimental|1. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery.
3307082|NCT01893580|Experimental|2. Experimental|Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery.
3307083|NCT01893580|Experimental|3. Experimental|Exercise in a team initiated two weeks after surgery.
3307084|NCT01893580|Other|4. Usual care|Exercise in a team initiated six weeks after surgery.
3307085|NCT01893593|Other|Control|Usual care
3307086|NCT01893593|Active Comparator|Intervention|Multifaceted intervention to improve clinical systems
3307087|NCT01893606|Placebo Comparator|Starch capsule|During the two weeks screening phase of the study, the daily dose of 3 tablets will be taken before breakfast, lunch and supper.
3307088|NCT01893606|Experimental|N-acetyl-D-glucosamine|During the 8-week treatment phase of the study,the dose of 100mg(3 tablets)per day will be taken.
3307089|NCT01893645||Pregnant women|Pregnant women admitted to the British Columbia Women's Hospital for vaginal or cesarean delivery will get their Hb values spot-checked using the Pronto-7 device.
3307090|NCT01893658|Active Comparator|Omalizumab and Prednisone|"Omalizumab in addition to prednisone. Omalizumab will be given once subcutaneously at a dose of 375 mg within 24 hours after receiving prednisone~Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
3307091|NCT01893658|Active Comparator|Prednisone|"Standard clinical therapy with prednisone.~Day 1-14: 60 mg/day 14 days (2 weeks)~Day 15-28: 40 mg/day (2 weeks)~Day 29-35: 30 mg/day (1 week)~Day 36-42: 20 mg/day (1 week)~Day 43-49: 10 mg/day (1 week)~Day 50-56: 5 mg/day (1 week)~Subjects will stop taking prednisone on day 57~If patients weigh less than 60 Kg, the dose will be adjusted accordingly (to equal 1mg/kg/day of prednisone as the starting dose)."
3307092|NCT01893671||LASIK|Subjects undergoing routine LASIK for the correction of myopia or hyperopia.
3307093|NCT01893684|Experimental|Protein + Exercise|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
3307094|NCT01893684|Experimental|Protein|PRO diet recommendations will include high quality proteins with an emphasis on lean meats, with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams.
3307095|NCT01893684|Experimental|Carbohydrate + Exercise|Diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~30% energy intake. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. The exercise program will require attendance of 3 nonconsecutive days per week. A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period.
3307096|NCT01893697||Healthy Participants|HRCT scan in a specific postural position
3307097|NCT01893710||Control|'Biopsy sampling': Peritoneal biopsies without kidney disease, i.e. diseases not related to the kidney and not affecting the peritoneum. This group is accomplished.
3307098|NCT01893710||chronic kidney disease|Samples will obtained from patients with chronic kidney disease stage 5 (at time of catheter Insertion)
3307099|NCT01893710||Peritoneal dialysis|Patients on PD with different PD fluids and intercurrent abdominal surgery and at time of renal transplantation.
3307100|NCT01893710||Post PD and with functioning graft|Samples will also be collected and analysed from patients with renal transplantation after PD at time of and tenckhoff catheter removal several weeks after Tx or other intercurrent abdominal surgery.
3307101|NCT01893723|Experimental|ANI guided remifentanil arm|remifentanil targets are increased or decreased depending on ANI readings. In case of high blood pressure associated with elevated ANI, nicardipine is administered.
3307102|NCT01893723|Other|ANI blind arm|remifentanil target is adapted as is usual during general anesthesia, depending on hemodynamic reactions to nociceptive surgical stimulations. In case of elevated blood pressure despite a maximum target of 10 ng/ml (Minto Pk/pD model), then nicardipine is administered.
3307103|NCT01893736|No Intervention|Control|In-hospital usual care consists of routine intrapartum and postnatal obstetric care. No extra intervention will be provided by research team.
3307104|NCT01893736|Experimental|In-hospital professional support|"The participants in in-hospital professional support arm will receive three 30-minute one-to-one hands-on breastfeeding counseling sessions during postpartum hospitalization."
3307105|NCT01893736|Experimental|Postpartum telephone follow-up support|"Participants in postpartum telephone follow-up support arm will receive telephone support in the first 4 weeks postpartum."
3307106|NCT01893749|Experimental|CATCH-IT|"200 randomized teens 13-18 year old (inclusive) will be enrolled into the online program that contains 14 modules focused various therapeutic techniques, a booster session of 6 modules at the end of the online program and three 15 minute visits with their primary care doctor to discuss the benefits and disadvantages of the program.~Parents will also be invited to participant in a partnering online program involving 4 modules online and 1 optional module. They will be asked to then participate in three 15 minute interviews with a member of the study team to discuss the benefits and disadvantages of the program."
3307107|NCT01893749|No Intervention|Health Education|"200 randomized teens, ages 13-18 year old (inclusive) receiving an online program with 14 modules that focus on general health education, depression, diet, exercise, hygiene and safety.~Parents will also be invited to participate in an online program with 4 modules that also focus on general health education."
3307108|NCT01893762|Experimental|16 rowers|Adult rowers, aged between 18 and 25, training >6 times a week are subjected to both an aerobic and a an anaerobic exercise challenge. Between the two challenges there must a pause of at least a week.
3307109|NCT01893775|Experimental|1|Hu-Mik-Beta-1 every 3 weeks
3307110|NCT01893788|Active Comparator|Aliskiren|Aliskiren group treated with 150-300mg daily aliskiren without diuretics or ACE inhibitors or angiotensin receptor blockers.
3307111|NCT01893788|Active Comparator|Eplerenone|Eplerenone group treated with 50-100mg daily eplerenone without diuretics or ACE inhibitors or angiotensin receptor blockers
3307112|NCT01893814|Active Comparator|Probiotics|
3307113|NCT01893814|Placebo Comparator|Control|
3307114|NCT01893840|Experimental|FlowOx|5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg
3307115|NCT01893853|Other|Water|Electrolyte- and mineral-free water with exercise intervention
3307116|NCT01893853|Placebo Comparator|Placebo|Calorie- and electrolyte-free, sweetened flavored water with exercise intervention
3307117|NCT01893853|Experimental|Carbohydrate-electrolyte beverage|Commercially-available flavored beverage carbohydrate-electrolyte beverage with Exercise Intervention
3307118|NCT01893866|Experimental|A|
3307119|NCT01893866|Experimental|B|
3307120|NCT01893892|Experimental|Arm I (levocarnitine start)|Patients receive levocarnitine PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to placebo for weeks 9-12.
3307121|NCT01893892|Placebo Comparator|Arm II (placebo start)|Patients receive placebo PO BID during weeks 1-4. Washout is weeks 5-8. Patients then cross-over to levocarnitine for weeks 9-12.
3307122|NCT01893918||COPD patients|COPD patients, males and females, older than 65 years, with smoking history > 20 pack/years
3307123|NCT01893931|Placebo Comparator|Satisfaction Survey|Within 1-3 days after ED discharge, patients will be called by a nurse to complete a brief satisfaction survey.
3307124|NCT01893931|Active Comparator|ED Discharge and Medication Call|Within 1-3 days after ED discharge, patients will receive a follow up phone call from a nurse to review discharge instructions, review medication instructions, and provide any necessary patient navigation.
3307125|NCT01893944|Experimental|Virtual Reality|- Participate in this group 20 women to be treated by means of games Xbox 360 ®, attributed to this, custom applications using virtual and augmented reality to be developed.
3307126|NCT01893944|Experimental|Vibration therapy|- participate in this group 20 women who will undergo 15 minutes of continuous vibration by vibration of the upper mantle, with a frequency of 40 Hz, 3 function and intensity tolerable, keeping the limb supported and raised to 120 °.
3307127|NCT01893944|Active Comparator|control group|- participate in this group 20 women who are treated with conventional cinesioterapia through muscle stretching exercises, dissociation girdle, active and active-assisted exercises for groups flexors, extensors, abductors and adductors of the upper limbs, which will be three series 10 repetitions for each exercise.
3307128|NCT01893957|Experimental|Healthy|Healthy women undergoing high voltage electrical stimulation
3307129|NCT01893957|Experimental|Axillary lymphadenectomy|Axillary lymphadenectomy volunteers undergoing to high voltage electrical stimulation
3307130|NCT01893970|Experimental|SWIFT: Acute Social Work Intervention in the ED and Follow Up|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
3307131|NCT01893970|Active Comparator|SWIFT-Acute Only: Acute social work intervention in the ED|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
3307132|NCT01893996|Experimental|Adalimumab|Active Study Drug is Adalimumab (Humira) which is FDA approved to treat rheumatoid arthritis since 2003.
3307133|NCT01893996|Placebo Comparator|Placebo|Placebo is inert and matches study drug, including the pre-filled syringe, and is supplied by Abbvie, the study drug manufacturer.
3307134|NCT01894009|Active Comparator|Foot manipulation|"Asymmetry of the feet was treated by thrusting of the cuboid bone and the subtalar joint was treated with gapping thrust. Mobilisation of the distal tibia-fibula was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given with morning exercises. Four types of exercises were recommended: 1) Foot training with pro-and supination of the feet from dorsal to plantar flexion. 2)Caterpillar walk. 3) Training the take off of the great toes along a normal walking line and 4) Mobility of lateral malleoli and the talo-crural joint by dorsal flexion of feet while bending the knees."
3307135|NCT01894009|Sham Comparator|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones with the patient in the supine position on a psoas pillow. Further, light pressure on the Achilles tendon, with the patient standing against a wall with the feet 40 cm off the wall with bent knees on order to simulate the tibio-fibular mobilisation. Home exercises in the mornings to be repeated 8 times.
3307136|NCT01894035||Group 1|
3307137|NCT01894048|Experimental|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
3307138|NCT01894061|Experimental|Bevacizumab and NovoTTF-100A|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle.The dose of bevacizumab will be 10 mg/kg of actual body weight.
3307139|NCT01894074|Placebo Comparator|Placebo|Lifestyle counseling:standard dietary education and counseling with a goal of reducing calories to 1500-1800 kcal/day
3307140|NCT01894074|Active Comparator|Intensive Dietary Intervention|Intensive Dietary Intervention employing very low energy diet (800 kcal/day) x 12 weeks followed by transition to regular foodstuffs over 4-6 weeks.
3307141|NCT01894113|Active Comparator|transbronchial forceps lung biopsy|transbronchial lung biopsy forceps
3307142|NCT01894113|Active Comparator|transbronchail cryo lung biopsy|transbronchial lungbiopsy with cryoprobe
3307143|NCT01894126|Experimental|Two-way SMS dialogue|Women will receive SMS messages with prompts to reply. They will have the ability to text back to the system and both respond to and initiate SMS dialogue
3307144|NCT01894126|Experimental|One-way SMS Messaging|Women will receive scheduled one-way SMS messages
3307145|NCT01894126|No Intervention|Control|
3307146|NCT01894139|Experimental|High-protein/Low-GI Diet|High-protein (25-28 E%), especially marine- and dairy-protein (8-10 E%) and low-GI (GI<55) ad libitum Diet in accordance with the principles of palatability and sustainability of the New Nordic Diet.
3307147|NCT01894139|Active Comparator|Low-protein/High-GI Diet|Ad libitum diet based on the Danish National Guidelines (NNR) (protein 10-20 E%; no information on restricting glycaemic load (GI ~ 60)) and in accordance with the principles of palatability and sustainability of the New Nordic Diet.
3307148|NCT01894165|Experimental|ALXN1101|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
3307149|NCT01894165|Placebo Comparator|Placebo|Four cohorts planned. Within each cohort, healthy volunteers are randomized to ALXN1101 IV single dose or placebo IV single dose. Each subsequent cohort is testing an increased dose of ALXN1101 IV or placebo IV.
3307150|NCT01894191|Active Comparator|air insufflation|Air insufflation will be used throughout whole procedure of colonoscopy
3307151|NCT01894191|Active Comparator|water immersion|Water will be infused during the insertion phase and removed during withdrawal phase of colonoscopy.
3307152|NCT01894191|Active Comparator|water exchange|Water will be infused and removed during insertion phase of colonoscopy
3307153|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. For all the patients who participated at the study PADIS-EP, somme exams must be performed.
3307154|NCT01894217|Experimental|Genetic testing|Genetic testing and reporting for SLCO1B1*5 allele
3307155|NCT01894269|Experimental|Anti-viral treatment|Oral antiviral drugs will be commenced after TACE. That is: Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
3307156|NCT01894269|No Intervention|Control|No anti-viral therapy after TACE.
3307157|NCT01894282|Active Comparator|Manual Therapy|Spinal Manipulative therapy (SMT) for the purpose of this study we will allow the use of other types of MT, including non-thrust spinal mobilization and flexion-distraction technique.
3307158|NCT01894282|Experimental|Mind Body Intervention (MBI)|"Mind Body Intervention will consist of a combination of the previously described manual therapy and Cognitive Behavioral Therapy for pain (CBT-p). Cognitive Behavioral Therapy for pain management has three basic components. The treatment rationale, coping skills training and application and maintenance of learned coping skills."
3307159|NCT01894295|Experimental|Vitamin D analogue|1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.
3307160|NCT01894295|Placebo Comparator|Placebo|Corn oil pearl Capsules 1 gram
3307161|NCT01894308|Active Comparator|Forearm dose|Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms.
3307162|NCT01894308|Active Comparator|Chest Dose|Half of Ss will receive their dose of Testosterone on the chest.
3307163|NCT01894334|No Intervention|Control group|no intervention
3307164|NCT01894334|Experimental|Tranexamic acid group|tranexamic acid ，intravenous 30mg/kg/d，Preoperative
3307165|NCT01894334|Experimental|Edaravone group|edaravone, iv, 1mg/kg/d,Preoperative
3307166|NCT01894334|Experimental|Ulinastatin group|Ulinastatin ,iv，20,000 U /kg/d，Preoperative
3307167|NCT01894347||Colistin inhalative|"Adult ICU patients with~invasive ventilation with assumed or assured bacteria with an elevated resistance pattern found in a tracheal or bronchial secretion with or without clinical signs of infection~indicated colistin co-therapy or eradication-attempt with inhalative colistin (β-Lactam) therapy according to the standard operation procedure (SOP) of the hospital~Patients included into the study group receive additional TDM, Monitoring of Neuro-and Nephropathology"
3307168|NCT01894360|Experimental|Belimumab 200 mg/mL, prefilled syringe|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe on Day 0.
3307169|NCT01894360|Experimental|Belimumab 200 mg/mL, Autoinjector|Subjects will be randomly assigned in a 1 to 1 ratio to receive a single dose of 200 mg belimumab SC (1.0 mL injection) via prefilled syringe contained within an autoinjector device on Day 0.
3307170|NCT01894373|Experimental|CIK, psoriasis|
3307171|NCT01894386|Experimental|Sequence 1|Subjects will receive treatment A, B, C, D in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3307172|NCT01894386|Experimental|Sequence 2|Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3307173|NCT01894386|Experimental|Sequence 3|Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3307174|NCT01894386|Experimental|Sequence 4|Subjects will receive treatment D, C, B, A in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment C, A, D, B in each dosing periods 1, 2, 3, and 4 respectively (one per period). Subjects will receive treatment B, D, A, C in each dosing periods 1, 2, 3, and 4 respectively (one per period). A - FF/UMEC/VI 400/500/100; B - FF/UMEC/VI 400/250/100; C - FF/VI 400/100; D - UMEC/VI 250/100
3307175|NCT01894399|Experimental|Cohort 1|100 mg HM61713 single dose in Korean
3307176|NCT01894399|Experimental|Cohort 2|200 mg HM61713 single dose in Korean
3307177|NCT01894399|Experimental|Cohort 3|300 mg HM61713 single dose in Korean
3307178|NCT01894399|Experimental|Cohort 4|200 mg HM61713 single dose in Japanese
3307179|NCT01894399|Experimental|Cohort 5|300 mg HM61713 single dose in Japanese
3307180|NCT01894399|Experimental|Cohort 6|200 mg HM61713 single dose in Caucasian
3307181|NCT01894399|Experimental|Cohort 7|300 mg HM61713 single dose in Caucasian
3307182|NCT01894412|Experimental|HD 203|prefilled syringe
3307183|NCT01894412|Active Comparator|Enbrel|prefilled syringe
3307184|NCT01894425||Study population|"The study population consists of couples under care for infertility in the participating centers. Gamete donations are not included. Please see inclusion and exclusion criteria.~Intervention: HPV screening for women Intervention: HPV screening for men"
3307185|NCT01894438|No Intervention|Control Group|This arm will receive written general advice for a healthy lifestyle.
3307186|NCT01894438|Experimental|Mediterranean Diet Group|Mediterranean Diet Group participants will attend a comprehensive program,focusing on Mediterranean diet, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
3307187|NCT01894438|Experimental|Mediterranean Lifestyle Group|Mediterranean Lifestyle Group participants will attend a comprehensive program,focusing on Mediterranean lifestyle, comprising of seven 60-min group counseling sessions, conducted every two weeks for the first 2 months and every month for the following 4 months, until the 6-month evaluation.
3307188|NCT01894451|Experimental|89Zr-bevacizumab-PET/CT Scan|"89Zr-bevacizumab-PET/CT will be performed at baseline, after 2 cycles of preoperative chemotherapy, and at the completion of preoperative chemotherapy.~The 89Zr-bevacizumab-PET/CT imaging procedure is detailed in Appendix A and is briefly described below.~Participants will be injected with 1 mCi of 89Zr-bevacizumab intravenously and PET/CT images will be obtained at 3-4 days after 89Zr-bevacizumab administration to allow time for antibody accumulation in the tumor. Imaging will be performed on a Centers for Quantitative Imaging Excellence (CQIE) qualified PET/CT scanner at the Dana-Farber Cancer Institute. After the baseline scan, subsequent scans will be obtained on the same PET/CT scanner for an individual participant."
3307189|NCT01894464|Experimental|Teacher led intervention|Teachers will conduct teacher-led interventions that are individualized for each student to prevent emerging truancy among elementary students.
3307190|NCT01894464|No Intervention|Control Group|
3307191|NCT01894490||Jejunostomy|Patients who received a jejunostomy
3307192|NCT01894490||Nasojejunal catheter|Patients who received a nasojejunal catheter
3307193|NCT01894529||Ischemic stroke|Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis
3307194|NCT01894529||Healthy subjects|Age-matched individuals free of acute neurological injury
3307195|NCT01894542|Experimental|Cod protein from presscake|
3307196|NCT01894542|Experimental|Cod protein from presscake + stickwater|
3307197|NCT01894542|Placebo Comparator|Control|Control group will receive tablet containing only tablet fillers (the same as in the cod protein tablets).
3307198|NCT01894594|Experimental|Sodium Bicarbonate|Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:
3307199|NCT01894633|Experimental|Chloroquine, radiosensitizer|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the CLQ plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days.
3307200|NCT01894633|Placebo Comparator|Placebo|30 Gy of whole-brain radiotherapy in 10 daily fractions and an oral matching placebo for 28 days
3307201|NCT01894646|Experimental|Young healthy individuals (ages 18-50)|Positron Emission Tomography (PET) Imaging
3307202|NCT01894646|Experimental|Elderly healthy individuals (ages 60-85)|Positron Emission Tomography (PET) Imaging
3307203|NCT01894646|Other|Patients with Alzheimer's disease or mild cognitive impairment|Positron Emission Tomography (PET) Imaging
3307204|NCT01894659|No Intervention|Control|Neonates randomized to this arm will receive the standard of practice at Loma Linda University NICU.
3307205|NCT01894659|Experimental|24% oral sucrose with pacifier|Neonates randomized to this arm will receive 24% sucrose before every painful procedure on days of life 3-7 in the NICU.
3307206|NCT01894659|Experimental|30% oral glucose with pacifier|Neonates randomized to this arm will receive 30% oral glucose before every painful procedure on days of life 3-7.
3307207|NCT01894685|Experimental|Mesalazine|Mesalazine, 3 grams once daily for six months
3307208|NCT01894685|Placebo Comparator|Placebo|Placebo, 3 grams, once daily for six months
3307209|NCT01894711||Patients with HER2 positive tumors|Patients with HER2 positive tumors treated with trastuzumab or not treated with trastuzumab
3307210|NCT01894724|Experimental|NeuroSave Device|Targeted Hypothermia with NeuroSave Device
3307211|NCT01894737|Placebo Comparator|immobilisation and placebo|Seven days of one-legged knee immobilisation with placebo supplementation
3307212|NCT01894737|Experimental|immobilisation and creatine|Seven days of one-legged knee immobilisation with creatine supplementation
3307213|NCT01894750|Experimental|skill bulding Intevention|group-based skill building self-care program
3307214|NCT01894750|No Intervention|usual care|
3307215|NCT01894763|Active Comparator|Small-diameter stent|Placement of a 23 mm self-expandable metal stent
3307216|NCT01894763|Active Comparator|Large-diameter stent|Placement of a 28-mm self-expandable metal stent
3307217|NCT01894789|Experimental|stable CAD management|Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
3307218|NCT01894789|Active Comparator|CAD comparison group|Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.
3307219|NCT01894802|Experimental|Brain-Machine Interface Users|All participants enrolled in the study who meet eligibility criteria will be individuals implanted with microelectrodes in their brain to record neural activity. There is no control group.
3307220|NCT01894815|Experimental|Active tDCS / placebo pill|transcranial direct current stimulation, using the parameters specified in Interventions.
3307221|NCT01894815|Active Comparator|Sham tDCS / escitalopram|Escitalopram oxalate (Reconter), 10mg/day (first 3 weeks) and 20mg/day (week 3 to week 10).
3307222|NCT01894815|Placebo Comparator|Sham tDCS / placebo pill|"For sham tDCS, the device is automatically turned off after 30 second of stimulation and remains turned off during the 30-min session.~For placebo pill, the pill has the same size, taste and color than escitalopram, and placebo and escitalopram will be provided in identical bottles, differing only according to a random-generated number placed in the label."
3307223|NCT01894828|Active Comparator|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily
3307224|NCT01894828|No Intervention|Control|Patients are asked to keep on to their normal diet. No supplementation is introduced
3307225|NCT01894854|No Intervention|Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems with a collar. The classical Furlong HAC had a collar.
3307226|NCT01894854|Active Comparator|No Stem collar|The stem has two versions, one with and one without a collar. This arm will have stems without a collar. The classical Furlong HAC had a collar.
3307227|NCT01894867|Experimental|magnesium|will get magnesium for 6 weeks
3307228|NCT01894867|Placebo Comparator|placebo|will get placebo for 6 weeks
3307229|NCT01894880|Active Comparator|early SSC|Early SSC: bonding straight after birth
3307230|NCT01894880|Other|late SSC|late SSC: bonding after termination of operation
3307231|NCT01894893||Breastfeeding mothers|
3307232|NCT01894932|Experimental|MBCT Group for stress patient|Mindfulness-based cognitive Group therapy will be administered on stress patient.
3307233|NCT01894932|Experimental|MBCT Group for depression patient|Mindfulness-based cognitive Group therapy will be administered on depression patient.
3307234|NCT01894932|Experimental|SR group for stress patient|psycho-physiological stress regulation group will be administered on stress patient.
3307235|NCT01894932|Experimental|SR group for depression patient|psycho-physiological stress regulation group will be administered on depression patients.
3307236|NCT01894932|No Intervention|normal|normal, no intervention.
3307237|NCT01894932|No Intervention|Drug treatment remission patient|Drug treatment remission patient
3307238|NCT01894945||Patients with suspected lymphoma.|
3307239|NCT01894958|Experimental|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid
3307240|NCT01894958|Placebo Comparator|Placebo (strawberry flavored solution)|Strawberry flavored solution and Water
3307241|NCT01894971|Experimental|twice coagulated side of fallopian tube|twice coagulated side of fallopian tube once coagulated sied of fallopian tube
3307242|NCT01894997|Experimental|DVT Prophylaxis|"Neuromuscular electrical stimulation is to be applied using a custom-built, two-channel stimulator (Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 5 minutes.~Intermittent pneumatic compression is to be applied using the Novamedix A-V Impulse System Model 6000 (Novamedix distribution Limited, England), programmed to deliver compression every 20 seconds at a pressure of 130 mmHg for a 3 second duration over a period of 5 minutes."
3307243|NCT01895010|Experimental|Acupoint and tropisetron|acupoint electric stimulation combined with tropisetron 6mg before TACE
3307244|NCT01895010|Active Comparator|tropisetron|treated with tropisetron 6mg before TACE
3307245|NCT01895023|Experimental|Dexmedetomidine group|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min and oral saline 30 min before induction of anaesthesia
3307246|NCT01895023|Active Comparator|Midazolam group|The midazolam group received intranasal saline 45 min and oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
3307247|NCT01895023|Placebo Comparator|Placebo Group|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
3307248|NCT01895049|Active Comparator|Mycophenolate sodium|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus
3307249|NCT01895049|Experimental|Everolimus|Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.
3307250|NCT01895075|Experimental|Inhaled budesonide|Inhaled budesonide 1mg/dose (2ml) three tid
3307251|NCT01895075|Placebo Comparator|Normal saline|Normal saline inhalation 2ml tid
3307252|NCT01895140|Experimental|Early renal denervation|Renal denervation takes place immediately after patient is randomized.
3307253|NCT01895140|Other|Delayed renal denervation|Renal denervation takes place 6 months after the patient is randomized.
3307254|NCT01895153||pentosan polysulfate cohort|pentosan polysulfate monotherapy
3307255|NCT01895153||hydrodistension(HD) cohort|hydrodistension(HD) monotherapy
3307256|NCT01895153||combination cohort|combination therapy of pentosan polysulfate and hydrodistension.
3307257|NCT01895166|Experimental|EBUS-GS group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images alone, cytologic and pathologic specimens are obtained without fluoroscopic guidance.
3307258|NCT01895166|Active Comparator|EBUS-GS-X-ray group|The EBUS probe and GS are confirmed to reach the lesion by EBUS images and radiograph fluoroscopy, cytologic and pathologic specimens are obtained under fluoroscopic guidance.
3307259|NCT01895179|Experimental|Time-Restricted Feeding (early in the day eating)|Participants will consume all meals early in the day and within a 6-hour window.
3307260|NCT01895179|Placebo Comparator|Grazing|Participants will eat meals spread out over the course of the day.
3307261|NCT01895192|Other|Fertile men|Assessment of sperm morphology by high magnification with interference contrast microscopy.
3307262|NCT01895205|Experimental|Iron isomaltoside 1000|A single dose of 1500 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9% sodium chloride and given over approximately 15 min.
3307263|NCT01895205|Active Comparator|Red blood cell transfusion|"Allogenic RBC transfusion is dosed to trigger Hb:~Women with Hb 5.5 - 6.4 g/dL (3.5-3.9 mmol/L) will receive 2 units of RBC~Women with Hb 6.5 - 8.0 g/dL (4.0-5.0 mmol/L) will receive 1 unit of RBC"
3307264|NCT01895218|Experimental|Iron isomaltoside 1000 (Monofer®)|
3307265|NCT01895218|Active Comparator|Standard medical Care|
3307266|NCT01895231|Experimental|Iron isomaltoside 1000|Monofer® 1000 mg IV infusion over 15 minutes
3307267|NCT01895231|Placebo Comparator|Placebo|0.9 % saline Infusion over 15 min
3307268|NCT01895244|Experimental|Conditioning with CYC/ antithymocyte globulin (ATG)|Each patient receives stem cell transplantation open label with cluster of differentiation (CD)34 selected stem cells mobilisation and conditioning depending on manifestation If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
3307269|NCT01895244|Experimental|Conditioning with CYC/Thiotepa/ATG|In patients with cardiac manifestations as defined in the protocol the conditioning for stem cell transplantation is changed to Cyclophosphamide (CYC), thiotepa and ATG
3307270|NCT01895257|Active Comparator|A: systemic chemotherapy LV5FU2 alone|Modified LV5FU2 as described in protocol (6.2.1) D1-2 +/- bevacizumab or cetuximab or panitumumab (according its previous use) every 2 weeks
3307271|NCT01895257|Active Comparator|B:SIR-spheres+systemic chemotherapy LV5FU2|ARM B: (Hepatic Arterial Infusion) HAI-90Y radioembolization (SIR-spheres injection) + modified LV5FU2 +/- bevacizumab or cetuximab or panitumumab according its previous use (refer to protocol).
3307272|NCT01895283|Experimental|Moderate-intensity training|Regular supervised moderate-intensity training on a bike ergometer, three times per week, for 30 minutes a total of 10 weeks.
3307273|NCT01895296|Experimental|Pasireotide|pasireotide 300 microgram s.c. t.i.d.
3307274|NCT01895296|Placebo Comparator|Placebo|saline s.c. t.i.d.
3307275|NCT01895348|Active Comparator|propofol only|
3307276|NCT01895348|Active Comparator|propofol-remifentanil|
3307277|NCT01895348|Active Comparator|dexmedetomidine-remifentanil|
3307278|NCT01895374|Experimental|amniotic membrane dressing|We compare the efficacy of amniotic membrane and hydrocolloid in same subjects to avoid confounders.
3307279|NCT01895374|Active Comparator|Hydrocolloid dressing|Same subjects received amniotic membrane and hydrocolloid dressing at the same time in different wound.
3307280|NCT01895387|Experimental|Whole grains and legumes|
3307281|NCT01895387|Placebo Comparator|Refined rice|
3307282|NCT01895400|Active Comparator|Renexin|Renexin 1T bid for 12 weeks
3307283|NCT01895400|Placebo Comparator|Placebo|Placebo 1T bid for 12 weeks
3307284|NCT01895413|Experimental|Mesenchymal stem cells|Bone marrow aspiration, Autologous bone marrow-derived mesenchymal stem cells
3307285|NCT01895439|Experimental|MSCs injection|Autologous bone marrow derived stem cells injected intrathecally to enrolled MS patients
3307286|NCT01895465|Experimental|A slitted diaper|An ordinary pediatric urine collection bag used in the ED that will be used together with the slitted diaper
3307287|NCT01895478|Experimental|PACCI-ED|PACCI-ED attendings were given the PACCI-ED use intervention.
3307288|NCT01895478|No Intervention|Control|Control attendings were not given the PACCI-ED use intervention.
3307289|NCT01895491|Experimental|CohortⅠ|VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle
3307290|NCT01895491|Experimental|CohortⅡ|VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle
3307291|NCT01895491|Experimental|CohortⅢ|VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle
3307292|NCT01895504|Experimental|ColoAssist|Screening colonoscopy with a new colonoscope with gradual stiffness
3307293|NCT01895504|Active Comparator|MEI|Screening colonoscopy with colonoscopes compatible with and guided by MEI
3307294|NCT01895517|Active Comparator|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
3307295|NCT01895517|Experimental|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
3307296|NCT01895530|No Intervention|Control group|Conventional treatment with no probiotic supplementation
3307297|NCT01895530|Experimental|Probiotic group|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
3307298|NCT01895556|Experimental|Information|Information about male circumcision and HIV risk
3307299|NCT01895556|Placebo Comparator|Control|Control
3307300|NCT01895569|Experimental|Type 2 diabetic patients|Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin.
3307301|NCT01895582||Active TB-infected patients|TB-infected patients with bacteriological and histological evidences
3307302|NCT01895582||Non active TB-infected patients (already met TB)|some of elders have already met M tuberculosis before active antibiotherapy exists
3307303|NCT01895582||Non active TB-infected patients (other diagnosis)|same symptoms than two others groups but an other diagnosis
3307304|NCT01895595|Experimental|Guided Imagery|The guided imagery program curriculum, added to the lifestyle education curriculum, consists of 12 weekly, 45-minute modules, delivered one-on-one immediately following the lifestyle education class each week. Guided imagery was based on 2 major underlying theoretical principles: 1) relaxation/stress reduction imagery; and 2) imagery designed to improve eating and physical activity behaviors.
3307305|NCT01895595|Active Comparator|"Digital storytelling (Control)"|The digital storytelling program curriculum, to control for contact time with research staff, consists of 12 weekly 45-minute modules delivered one-on-one immediately following the lifestyle education class each week.
3307306|NCT01895621|Experimental|Lipoic|Median nerve decompression at the wrist, followed by Alpha lipoic acid post median nerve decompression: lipoic acid, 800 mg daily for 40 days from the day of the operation, tablets.
3307307|NCT01895621|Placebo Comparator|placebo|Median nerve decompression at the wrist, followed by placebo in the same form frequency and duration as alpha lipoic acid
3307308|NCT01895660|Experimental|Group with continuous constraint and daily therapy|
3307309|NCT01895660|Experimental|Group with continuous constrainit and 3 days a week therapy|
3307310|NCT01895660|Experimental|Group with part-time constraint and daily therapy|
3307311|NCT01895660|Experimental|Group with part-time constraint and 3 days a week therapy|
3307312|NCT01895660|Active Comparator|Usual and customary treatment group|
3307313|NCT01895673||PET-MRI|Twenty patients with RFA/MWA for CRLM or RFA/MWA of recurrent liver lesions after prior local treatment of CRLM and are eligible to undergo MRI-scanning are included when they have adequate renal function. Patients that do not meet inclusion criteria for undergoing an MRI scan are excluded.
3307314|NCT01895686||Open angle glaucoma|patients diagnosed with open angle glaucoma
3307315|NCT01895686||Narrow angle|patients diagnosed with narrow angles
3307316|NCT01895686||Angle Closure Glaucoma|patients diagnosed with angle closure glaucoma
3307317|NCT01895699|Experimental|contrast group (Ioversol)|Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes
3307318|NCT01895699|Placebo Comparator|Placebo group|
3307319|NCT01895699|Other|alpha-lipoic acid group|Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups.
3307320|NCT01895712||Orsiro|
3307321|NCT01895738|Experimental|WrapAround Care|Participants randomized to the intervention arm will be met in the emergency department by a support worker who has lived experience. They will start to build a relationship with the participant at that time (i.e. during the teachable moment) and will work with the participant for approximately one year, delivering WrapAround Care. Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
3307322|NCT01895738|No Intervention|Standard of Care|Standard of Care is typically a sheet of community resources potentially handed out by the emergency physician, nurse or social worker.
3307323|NCT01895751|No Intervention|Conservative therapy|"Conservative therapy group involves optimal medical therapy according to local hospital protocols with selective invasive management as clinically appropriate. Patients assigned to the conservative group may be referred for invasive management if the patient meets one of the following pre-specified criteria:~Recurrent or refractory (class III or IV) angina with documented ischaemic ECG changes while on optimal medical therapy.~New ST segment elevation in two contiguous leads without Q waves or T wave inversion greater than 3 mm or development of hemodynamic instability Deterioration in heart failure status (defined as Killip class 3 or 4)."
3307324|NCT01895751|Active Comparator|Invasive management|Invasive management is timed as appropriate according to local NHS protocols. Usually, invasive management is expected to be performed in line with contemporary guidelines.
3307325|NCT01895764|Active Comparator|Adalimumab|adalimumab 40mg every 2 weeks
3307326|NCT01895764|Experimental|Adalimumab + Methotrexate|adalimumab 40mg every 2 weeks and methotrexate 10mg per week
3307327|NCT01895790|Experimental|Pancreatic Duct|Consecutive adult patients (18-80 years of age) with cytopathologic diagnosis of unresectable pancreatic cancer complaining of pain due to pancreatic duct obstruction will receive a pancreatic duct stent.
3307328|NCT01895803||smoking woman 18-60 years old|
3307329|NCT01895816|Experimental|fertility coated tablet|700 mg fertility coated tablet containing 8 herbal powders by mouth every 12 hours for 180 days
3307330|NCT01895829|Experimental|Ferumoxytol + Magnetic Resonance Imaging (MRI)|"On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. The study MRI performed in the same way that a standard MRI is performed.~On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed."
3307331|NCT01895842|Experimental|Ruxolitinib|"Part 1: Dose of ruxolitinib received will depend when patient joined study. The first group of patients receive the lowest dose of ruxolitinib. Starting dose level for Part 1, 5 mg by mouth twice a day for a 28 day cycle. The second group of patients receive the lowest dose of ruxolitinib for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond. The third group of patients receive the higher dose taken by the second group for 1 cycle and if no intolerable side effects are seen, the dose will be increased for Cycles 2 and beyond. The fourth group of patients take the higher dose taken by the third group for 1 cycle and if no intolerable side effects are seen, the dose will increase to the next higher dose for Cycles 2 and beyond.~If patients enrolled in Part 2, they will receive ruxolitinib at the highest dose that was tolerated in Part 1."
3307332|NCT01895868|Active Comparator|Simulation-based training|Participants in the intervention group receive simulation training using two types of ultrasound simulators: The Scantrainer (Medaphor) and the BluePhantom (CAE). All participants are training to pre-established proficiency-criteria.
3307333|NCT01895868|No Intervention|Control|Clinical training alone.
3307334|NCT01895881|Experimental|Estradiol Daily|1 mg Estradiol daily for 180 days.
3307335|NCT01895881|Placebo Comparator|Placebo|Placebo for 180 days.
3307336|NCT01895894|Experimental|Mycophenolate mofetil|
3307337|NCT01895894|No Intervention|Control|
3307338|NCT01895907||Special Olympic athletes|
3307339|NCT01895920|Experimental|HIV infection|20 HIV infected subjects
3307340|NCT01895933|Active Comparator|Active / control|One side has been treated with SurgiShield
3307341|NCT01895933|No Intervention|No intervention|One side has no intervention
3307342|NCT01895985|Experimental|Latanoprostene Bunod|Participants will instill 1 drop of latanoprostene bunod 0.024% topically into each eye QD in the evening for 14 days.
3307343|NCT01896011|Active Comparator|Teriparatide 20 mcg daily|Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
3307344|NCT01896011|Placebo Comparator|Placebo|Placebo injection pen identical to active drug injection pen
3307345|NCT01896024|Active Comparator|General Psychiatric Management (GPM; Gunderson & Links, 2008)|psychodynamic-psychiatric treatment for borderline personality disorder
3307346|NCT01896024|Experimental|GPM plus Motive-Oriented Therapeutic Relationship|use of Plan Analysis and Motive-oriented therapeutic relationship, as add-on variable to GPM
3307347|NCT01896037|Experimental|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
3307348|NCT01896063|Experimental|Electroacupuncture preconditioning|
3307349|NCT01896076||Pediatric patients in urologic surgery|Pediatric patients undergoing caudal block for urologic surgery were included in this study.
3307350|NCT01896102|Experimental|Lenti-D Drug Product|
3307351|NCT01896154|Experimental|NPS from yeast|Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination.
3307352|NCT01896154|Experimental|NPS from shiitake|Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3307353|NCT01896154|Experimental|NPS from oat|Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3307354|NCT01896154|Experimental|NPS from wheat|Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3307355|NCT01896154|Experimental|NPS from Lactobacillus mucosae|Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination.
3307356|NCT01896154|Placebo Comparator|Maltodextrin|12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS.
3307357|NCT01896167|Active Comparator|Hypoxia|Inhalation of air with 8-12% oxygen content
3307358|NCT01896167|Placebo Comparator|Atmospheric air|Inhalation of atmospheric air, with oxygen content at 21%
3307359|NCT01896180|Experimental|ALZ-1101|ALZ-1101 ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular adminstration
3307360|NCT01896180|Active Comparator|Latanoprost|Latanoprost 0.005% ophthalmic solution dosed as 1 drop, once daily in the evening via topical ocular administration
3307361|NCT01896219|Active Comparator|Gesture performed under control tomodensitometric (CT)|Conventional
3307362|NCT01896219|Experimental|Gesture performed under Navigation-assisted procedure (NAV)|Use of the IMACTIS-CT® Navigation System
3307363|NCT01896245|Active Comparator|sevoflurane 1,0|sevoflurane 1,0: sevoflurane is administered with a concentration of 1,0 MAC
3307364|NCT01896245|Active Comparator|sevoflurane 1,2|sevoflurane 1,2: sevoflurane is administered with a concentration of 1,2 MAC
3307365|NCT01896245|Active Comparator|sevoflurane 1,4|sevoflurane 1,4: sevoflurane is administered with a concentration of 1,4 MAC
3307366|NCT01896258||Regional emergency centers|
3307367|NCT01896258||Local emergency centers|
3307368|NCT01896284|Experimental|0.5mg AFLIBERCEPT injection|Patients will receive intravitreal injection of aflibercept 0.5mg at baseline, week 4,8,16,24 and 32. Optionally, if intra or subretinal fluid persists at week 12, patients will receive an additional injection.
3307369|NCT01896310||pCLE examination|patients will be prospectively recruited and examined first with high-definition endoscopy (EG-2990i, Pentax, Japan) followed by probe-based confocal laser endomicroscopy
3307370|NCT01896323|Experimental|CC-223|CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2
3307371|NCT01896323|Active Comparator|Ketokonazole|Ketoconazole administration on study days 1 through 8 of Period 2
3307372|NCT01896336|Experimental|5mg sublingual Zolpidem hemitartrate|1 QD
3307373|NCT01896336|Active Comparator|10 mg oral Zolpidem hemitartrate|1 QD.
3307374|NCT01896349|Experimental|IPT+antidepressant drugs|"Interpersonal Psychotherapy protocol (IPT) consist of 16 sessions of manualized interpersonal psychotherapy for depression. Patients are allowed to reschedule 3 sessions if they miss their appointments.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetin, citalopram, escitalopram, fluvoxamine, venlafaxin, duloxetin, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
3307375|NCT01896349|Active Comparator|Antidepressant Drugs|"Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice.~Antidepressant Drugs protocol consist of pharmacological management of depression, oriented by international guidelines, clinician´s free choice. Monotherapy or combinations are allowed. Antidepressant and drugs are: fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine, venlafaxine, duloxetine, bupropion, lithium, risperidone, tranylcypromine, Imipramine, amitriptyline, clomipramine, nortriptyline, trazodone, mirtazapine, sulpiride."
3307376|NCT01896388|Active Comparator|Ifenprodil Tartrate|Oral Administration of Ifenprodil Tartrate 40mg/day (20mg After breakfast, 20mg After supper)
3307377|NCT01896388|Placebo Comparator|Placebo|Oral Administration of Placebo (After breakfast, After supper)
3307378|NCT01896401|Experimental|InSeal's Vascular Closure Device|Use of the experimental VCD to close the access site of the artery
3307379|NCT01896414|Experimental|EPA (marine fatty acids)|Subjects will receive EPA , four 1 gram capsules daily.
3307380|NCT01896414|Placebo Comparator|Placebo|Subjects will be randomized to receive placebo, four 1 gram capsules daily.
3307381|NCT01896427|Active Comparator|Dexamethazone IO|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
3307382|NCT01896427|Active Comparator|Dexamethasone IM|For the case group, after the inferior alveolar block injection and before starting the surgery, single dose of dexamethasone (8mg) will injected into medial pterygoid and pterygomandibular space
3307383|NCT01896440|Active Comparator|Group A - standard ondansetron dose first|Group A will receive the standard dose of ondansetron (0.15 mg/kg) with the first cycle of chemotherapy and the high dose (0.3 mg/kg) with second cycle.
3307384|NCT01896440|Active Comparator|Group B - high dose ondansetron first|Group B patients will receive the higher dose of ondansetron (0.3 mg/kg) with the first cycle of chemotherapy and the standard dose (0.15 mg/kg) with the second.
3307385|NCT01896453|Active Comparator|tDCS real + TENS real|"Real transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3307386|NCT01896453|Experimental|tDCS real + TENS sham|"Real transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3307387|NCT01896453|Experimental|tDCS sham + TENS real|"Sham transcranial direct current stimulation associated with real transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes, 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3307388|NCT01896453|Sham Comparator|Sham tDCS + Sham TENS|"Sham transcranial direct current stimulation associated with sham transcutaneous electrical nerve stimulation (TENS).~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).~TENS: 40 minutes (30 seconds ON), 100Hz, 200µs, 2 channels with electrodes over the low back area of pain."
3307389|NCT01896466|Active Comparator|Young Adults - Intervention|Healthy subjects between the ages of 18-39 will participate in Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3307390|NCT01896466|Active Comparator|Healthy Older Adults - Control|Healthy subjects between age 65+ will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3307391|NCT01896466|Active Comparator|Healthy Older Adults - Intervention|Healthy subjects age 65+ will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
3307392|NCT01896466|Sham Comparator|Older Fallers - Control|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3307393|NCT01896466|Experimental|Older Fallers - Intervention|Subjects who are age 65+ with a history of 1-3 falls in the previous six months will participate in Cranial Nerve Non-Invasive Neuromodulation enhanced gait and balance training.
3307394|NCT01896466|Active Comparator|Young Adult - Control|Healthy subjects between the ages of 18-39 will participate in Sham Cranial Nerve Non-Invasive Neuromodulation gait and balance training.
3307395|NCT01896479|Experimental|Cabozantinib (XL184) 140 mg|Cabozantinib (XL184) 140 mg as capsules and placebo tablets administered orally once a day.
3307396|NCT01896479|Experimental|Cabozantinib (XL184) 60 mg|Cabozantinib (XL184) 60 mg as tablets and placebo capsules administered orally once a day.
3307397|NCT01896492|Active Comparator|N-acetyl cystien and clomiphen citrate|N-acetyl cystien and clomiphen citrate,in induction of ovulation in newly diagnosed PCOS,1-2gm schats of NAC PLUS 100 mg of cc in the therd day of the cycle till day 8,with monitoring of follicular growth usin ultrasonography.HCG is giving to trigger of ovulation fo follicular size 18mm or more.
3307398|NCT01896492|Placebo Comparator|Clomiphen citrate and placebo|CC plus placebo compared to cc and NAC in induction of ovulation in PCOS new cases.
3307399|NCT01896492|No Intervention|N-acetyl cystien|In addition to the CC, each patient was selected randomly to receive either NAC (Sedico, Cairo, ARE), in a dose of 1.2 g/d orally, or a placebo (sugar) of the same volume twice daily from day 3 until day 7
3307400|NCT01896505|Experimental|Arm 1 - Treatment A, B, C, D|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 1, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C Week 4, day 1: Treatment D~(Note that recruitment has been completed for this arm)"
3307401|NCT01896505|Experimental|Arm 2 - Treatment B, A, D, C|"There are 4 treatment formulations of KCP-330:~A: fasted, tablet formulation B: high-fat meal, tablet formulation C: low-fat meal, tablet formulation D: low-fat meal, capsule formulation~In Arm 2, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment A Week 3, day 1: Treatment D Week 4, day 1: Treatment C~(Note that recruitment has been completed for this arm)"
3307402|NCT01896505|Experimental|Arm 3|"To evaluate tumor response in sarcoma patients (RECIST v1.1 criteria) on KCP-330.~(Note that recruitment has been completed for this arm)"
3307403|NCT01896505|Experimental|Arm 4 - Treatment A, B, C|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 4, the following order will be utilized:~Week 1, day 1: Treatment A Week 2, day 1: Treatment B Week 3, day 1: Treatment C"
3307404|NCT01896505|Experimental|Arm 5 - Treatment C, A, B|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 5, the following order will be utilized:~Week 1, day 1: Treatment C Week 2, day 1: Treatment A Week 3, day 1: Treatment B"
3307405|NCT01896505|Experimental|Arm 6 - Treatment B, C, A|"There are 3 treatment formulations of KCP-330:~A: Current (1st generation) tablets, 60 mg B: New (2nd generation) tablets, 60 mg C: Suspension dose of current (1st generation) tablets, 60 mg~In Arm 6, the following order will be utilized:~Week 1, day 1: Treatment B Week 2, day 1: Treatment C Week 3, day 1: Treatment A"
3307406|NCT01896518|No Intervention|Counseling|
3307407|NCT01896518|Experimental|Nicotine lozenge|Participants will receive nicotine lozenge to use as needed for 12 weeks.
3307408|NCT01896518|Experimental|Tobacco lozenge|Participants will receive tobacco lozenge to use as needed for 12 weeks.
3307409|NCT01896531|Experimental|Ipatasertib + mFOLFOX6|Participants will receive oral ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
3307410|NCT01896531|Placebo Comparator|Placebo + mFOLFOX6|Participants will receive the placebo equivalent to ipatasertib on Days 1 to 7 of each 14-day cycle in combination with mFOLFOX6, administered on Day 1 of each cycle.
3307411|NCT01896570||Group A: cardioversion at AT|after achievement of AT, pts were cardioverted
3307412|NCT01896570||Group B: ablation to SR|After AT has been achieved, all subsequent AT were ablated with the endpoint of procedural SR termination
3307413|NCT01896583|Experimental|ASP7147|ASP7147, 300 mg, tablet, twice per day for 4 weeks oral
3307414|NCT01896583|Placebo Comparator|Placebo|oral
3307415|NCT01896596|Active Comparator|Menjugate|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menjugate (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3307416|NCT01896596|Active Comparator|Menitorix|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with Menitorix (at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3307417|NCT01896596|Active Comparator|NeisVac-C|Infants will receive intramuscular Infanrix Hexa (at 2-3-4 months) with NeisVac-C(at 3 months), Prevenar13 (at 2-4 months) and oral rotarix (at 2 and 3 months) vaccines
3307418|NCT01896609|Experimental|Arm 1 (Standard therpy)|"Arm 1 : subject randomized to this arm will be receiving the standard care therapy for 48 weeks:~Reiferon Retard® 160 µg /week subcutaneous injection.~Ribavirin in a dose of 13 mg/kg/day orally"
3307419|NCT01896609|Experimental|Arm 2 ( Xerovirinc)|"Arm 2 : Subjects randomized to this arm will be receiving the following medications for 48 weeks;~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
3307420|NCT01896609|Experimental|Arm 3 ( Bon one )|"Arm 3: Subjects randomized to this arm will be receiving the following medications for 48 weeks:~Bon-One ® 0.5 µg daily orally~Reiferon Retard® 160 µg /week subcutaneous injection~Ribavirin in a dose of 13 mg/kg/day orally~Xerovirinc® 500mg twice daily orally."
3307421|NCT01896622|Experimental|A|Ritonavir
3307422|NCT01896622|Experimental|B|Cobicistat
3307423|NCT01896635|Active Comparator|FMT infusions|FMT infusions constituted from stool provided by healthy, screened donors
3307424|NCT01896635|Placebo Comparator|Placebo arm|Placebo infusions
3307425|NCT01896648||Type 2 diabetic women|
3307426|NCT01896661|Experimental|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
3307427|NCT01896661|Active Comparator|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
3307428|NCT01896713|Other|Diagnostic: Single Arm|Imaging (MS3TMRI)
3307429|NCT01896739|Experimental|Experimental group with 0-2-4-6 schedule|HB at 0, Eutravac at 2-4-6
3307430|NCT01896739|Active Comparator|Active comparator group with 0-2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
3307431|NCT01896739|Experimental|Experimental group with 2-4-6 schedule|Eutravac at 2-4-6
3307432|NCT01896739|Active Comparator|Active comparator group with 2-4-6 schedule|Separate injection of DTaP and HB at 2-4-6 (for DTaP) and 0-1-6 (HB)
3307433|NCT01896765|Experimental|Intensive prevention program|"Standard care with respect to medical and interventional therapy plus intensive prevention program with study nurse-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
3307434|NCT01896765|Other|Usual care|Standard care with respect to medical and interventional therapy.
3307435|NCT01896778|Experimental|Arm I (B-WARM for 30 minutes)|Patients undergo B-WARM at 39 degrees C for 30 minutes.
3307436|NCT01896778|Experimental|Arm II (B-WARM for 2 hours)|Patients undergo B-WARM at 39 degrees C for 2 hours.
3307437|NCT01896791|Active Comparator|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation: the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2mili Ampere, 20min, 10 days.
3307438|NCT01896791|Placebo Comparator|Sham Stimulation|Sham Stimulation: appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
3307439|NCT01896830|Experimental|Vaccine Group|Participants will receive the candidate C. difficile toxoid vaccine
3307440|NCT01896830|Placebo Comparator|Placebo Group|Participants will receive a placebo vaccine
3307441|NCT01896882|Experimental|Intervention|Nutritional education on sodium restriction diet.
3307442|NCT01896882|No Intervention|Control|Standard treatment.
3307443|NCT01896908|Experimental|Intervention|Sodium restriction (1.6g sodium daily - 4g salt) combined with 800 ml of fluid intake
3307444|NCT01896908|No Intervention|Control|Normal sodium diet (4g sodium daily - 10g salt) and free fluid intake
3307445|NCT01896947||MRI and MRA group|All patients will receive 3T MRI and MR arthrogram
3307446|NCT01896960|Active Comparator|2 ml Bupivacaine|2 ml Bupivacaine with 15 micrograms of fentanyl
3307447|NCT01896960|Active Comparator|1.5 ml Bupivacaine|1.5 ml Bupivacaine with 15 micrograms of fentanyl
3307448|NCT01896973|Experimental|Vortx Rx - Histotripsy BPH Device|The Vortx Rx is a portable ultrasound therapy device system that is intended for the treatment of BPH by using very intense, low duty-cycle ultrasound pulses to debulk prostatic tissue.
3307449|NCT01897012|Experimental|Treatment (alisertib, romidepsin)|Patients receive alisertib PO BID on days 1-7 (dose levels 1-4) or days 1-3, 8-10, and 15-17 (dose levels 5-8). Patients also receive romidepsin IV over 4 hours on days 1 and 8 (dose levels 1-4) or 2, 9, and 16 (dose levels 5-8). Treatment repeats every 21 days (dose levels 1-4) or 28 days (dose levels 5-8) for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3307450|NCT01897038|Experimental|Cohort 1 (Onartuzumab)|
3307451|NCT01897038|Experimental|Cohorts 2/3 (Onartuzumab + Sorafenib)|
3307452|NCT01897051|Experimental|Combination therapy|Rifaximin(normix®)+nonselective beta-blocker(Propranolol)
3307453|NCT01897051|Placebo Comparator|Monotherapy|nonselective beta-blocker(Propranolol) + Placebo(of Rifaximin)
3307454|NCT01897064|Experimental|Aerobic Exercise|Up to 36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric treatment.
3307455|NCT01897064|Active Comparator|Standard Psychiatric Treatment|12 weeks of standard psychiatric treatment.
3307456|NCT01897090|Experimental|Elimination Diet|"thirty (30) patients will be on the Crohn's Disease Diet (primarily an anti-inflammatory diet that is an elimination diet - gluten-free, casein-free based with limited carbohydrate)"
3307457|NCT01897090|Active Comparator|Dietary Guidelines for Americans|The DASH eating plan is based on 1,600, 2,000, 2,600 and 3,100 calories.
3307458|NCT01897129||Early pregnancy|Women in early pregnancy at around the time of the nuchal translucency scan. The prevalence of HPV will be determined
3307459|NCT01897129||Chorionic villous sampling|Women undergoing chorionic villous sampling for the purpose of prenatal diagnostics.
3307460|NCT01897129||Spontaneous abortion|Women with miscarriage at a gestational age up to 22 weeks
3307461|NCT01897129||Preterm birth|Women with spontaneous preterm birth/premature primary rupture of membranes at a gestational age week 22-32
3307462|NCT01897129||Vaginal delivery at term|Women with spontaneous vaginal delivery at term (week 37+0-)
3307463|NCT01897129||Elective ceaserean section at term|Women undergoing elective cesarean section at term (week 37+0-)
3307464|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 1|
3307465|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 2|
3307466|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 3|
3307467|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 4|
3307468|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 5|
3307469|NCT01897142|Experimental|PF-05230907 and Placebo Cohort 6|
3307470|NCT01897155|Other|SBP 20-30% under baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index (40-60). Patients received a phenylephrine infusion to maintain systolic blood pressure (SBP) 20% to 30% under baseline. The lower limit of SBP was 75 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
3307471|NCT01897155|Other|SBP 20-30% over baseline|Induction of anesthesia was performed with remifentanil, pentothal 3 mg/kg and atracurium 0.5 mg/Kg. Anaesthesia was maintained with remifentanil (0.4 ug/Kg/min) and isoflurane adjusted to bispectral index(40-60). Patients received a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over baseline. The upper limit of SBP was 165 mmHg. In the recovery room, morphine was administered routinely at doses of 3 mg IV every 15 minutes until pain was less than 4 estimated by visual analog scale (VAS). VAS and pain threshold with von Frey filaments were assessed at 2, 6, 12 and 24 postoperative hours. All patients, received ketorolac 30 mg IV every 8 hours and intravenous morphine administered by patient controlled analgesia system (PCA) during the first 24 hours.
3307472|NCT01897168||No grouping|
3307473|NCT01897181|Active Comparator|Hearing aids|Patients who agree to use hearing aids
3307474|NCT01897181|No Intervention|No hearing aids|Patients who did not agree to use hearing aids
3307475|NCT01897194||Coma Patients|Observation of EEG patterns in coma patients.
3307476|NCT01897207|Experimental|Dendritic cell application|
3307477|NCT01897220||University Hospital Patients|Consecutive patients with cardiovascular disease(s) undergoing non-cardiac surgery
3307478|NCT01897246|Active Comparator|Computer-assisted pre-operative planning|Patients enrolled in this arm will undergo corrective surgery of the distal radius, with pre-operative computer-assisted planning and virtual osteotomy.
3307479|NCT01897246|Active Comparator|Conventional pre-operative planning|Patients in this group will undergo corrective osteotomy of the distal radius wit conventional pre-operative planning.
3307480|NCT01897259|Active Comparator|Corticosteroid Injections|Patients will receive 1 cc Kenalong 10 mg injection to the site every 6 weeks until clinical symptoms have resolved. They will also receive an anesthetic of 1cc 1% lidocaine in conjunction with the corticosteroid injection.
3307481|NCT01897259|Active Comparator|Prolotherapy|Participants receive 1cc 50% Dextrose and 1 cc Sodium Morrhuate to the site every 6 weeks until symptoms resolve. These participants will also receive an anesthetic of 1cc 1% lidocaine.
3307482|NCT01897259|Placebo Comparator|Placebo|Participants will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
3307483|NCT01897259|Active Comparator|Physical Therapy|Participants will be prescribed NSAIDS (Diclofenac 75 mg BID) for 2 weeks. Participants will attend therapy for muscle stretches, soft tissue mobilization, and gradual strengthening.
3307484|NCT01897272||Splinting After Surgery|This group will be fitted for a splint and given instructions on wearing their splint after their short-incision Carpal Tunnel Release
3307485|NCT01897272||No Splinting After Surgery|This group will not be splinted after the short-incision carpal tunnel release
3307486|NCT01897298|Experimental|Urban training Intervention|Patients will be advised to walk in the defined urban trails.
3307487|NCT01897298|No Intervention|Usual care|Patients will continue their usual care
3307488|NCT01897311|Experimental|grupo TENS com frequência de 100 Hz|TENS application of high frequency (100 Hz, 100 μs)
3448461|NCT04063787|Experimental|Fist Assist device (all subjects)|"All study subjects will have Stage 4 or 5 Chronic Kidney Disease (CKD) that requires them to start hemodialysis. In preparation for hemodialysis, they will have an arteriovenous fistula (AVF) procedure which provides access to the veins for dialysis.~This study is testing a device called the Fist Assist to dilate the vein in preparation for dialysis. The device is similar to a blood pressure cuff (worn around the arm and applies pressure). All study participants will wear the Fist Assist twice a day up to three months before their AVF procedure."
3307489|NCT01897311|Experimental|grupo TENS com frequência de 4 Hz|Application of low-frequency TENS (4 Hz, 100 μs)
3307490|NCT01897311|Placebo Comparator|Placebo with TENS off|TENS application when off
3307491|NCT01897324|Experimental|The Long protocol|Patients in the group A received a long protocol of pituitary down-regulation with triptorelin (Decapeptyl; Ferring, Switzerland) which started on day 21 of preceding cycle at a dose of 0.1 mg/day. On the second day of menstruation HMG was started and this was associated with reduction of triptorelin to 0.05 mg/day. This reduced daily dose was administered until the day hCG was given. Growth hormone co-treatment was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3307492|NCT01897324|Experimental|The Short protocol|The short agonist protocol was started on cycle day 1 with triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. Human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) were also administered starting from days 2 to 3 of cycle. The dose was adjusted for each patient according to the diameter of the follicles detected in their follow up ultrasound. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3307493|NCT01897324|Experimental|The Antagonist protocol|Gonadotrophins IM daily (HMG 75 IU, Merional, IBSA)was administrated from day 2 of the cycle. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration. The GnRH antagonist (Cetrotide) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
3307494|NCT01897324|Experimental|The Microflare protocol|the patients in this group were given oral contraceptive pills (OCPs) for 28 days, this was followed by 2 days free. Triptorelin (Decapeptyl Ferring Pharmaceuticals, Germany) 0.05 mg/day S.C. was then started daily followed by human menopausal gonadotropin IM daily (HMG 75 IU, Merional, IBSA) 3 days later. Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
3307495|NCT01897337|Experimental|Aprepitant group|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room (Before patient get in the operating room)
3307496|NCT01897337|Placebo Comparator|placebo group|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
3307497|NCT01897350||CMR following ST segment myocardial infarction|
3307498|NCT01897363||Infants with Prader-Willi Syndrome|Infants between ages 2 to 12 months of age with Prader-Willi Syndrome.
3307499|NCT01897376|Other|Pfannenstiel incision|
3307500|NCT01897376|Other|vertical skin incision|
3307501|NCT01897389|Experimental|Sequence 1: abiraterone acetate|Treatment sequence 1 is defined as: AEBD
3307502|NCT01897389|Experimental|Sequence 2: abiraterone acetate|Treatment sequence 2 is defined as: BACE
3307503|NCT01897389|Experimental|Sequence 3: abiraterone acetate|Treatment sequence 3 is defined as: CBDA
3307504|NCT01897389|Experimental|Sequence 4: abiraterone acetate|Treatment sequence 4 is defined as: EDAC
3307505|NCT01897389|Experimental|Sequence 5: abiraterone acetate|Treatment sequence 5 is defined as: DECA
3307506|NCT01897389|Experimental|Sequence 6: abiraterone acetate|Treatment sequence 6 is defined as: EADB
3307507|NCT01897389|Experimental|Sequence 7: abiraterone acetate|Treatment sequence 7 is defined as: ABEC
3307508|NCT01897389|Experimental|Sequence 8: abiraterone acetate|Treatment sequence 8 is defined as: BCAD
3307509|NCT01897415|Experimental|Autologous T cells|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1
3307510|NCT01897428|Active Comparator|Reference arm|Treated with Reference (bepotastine besilate 10 mg)
3307511|NCT01897428|Experimental|Test arm|Treated with Test (bepotastine salicylate 9.64 mg)
3307512|NCT01897441|Experimental|Stratum A (HER2-positive disease)|Patients receive paclitaxel IV over 1 hour and trastuzumab IV over 30-90 minutes weekly for 12 weeks. Beginning 2-3 weeks after the last dose of paclitaxel, patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks
3307513|NCT01897441|Experimental|Stratum B (paclitaxel followed by AC)|Patients receive paclitaxel, doxorubicin hydrochloride, and cyclophosphamide as in Stratum A.
3307514|NCT01897441|Experimental|Stratum C (AC followed by paclitaxel)|Patients receive doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 30-60 minutes every 2 weeks for 8 weeks. Patients then receive paclitaxel IV over 1 hour weekly for 12 weeks.
3307515|NCT01897454|Experimental|Treatment (FOLFIRINOX, IMRT, and gemcitabine hydrochloride)|"CHEMOTHERAPY REGIMEN: Patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and irinotecan hydrochloride IV over 90 minutes on day 1, and fluorouracil IV over 46 hours on days 1-3. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients not achieving disease progression proceed to chemoradiotherapy.~CHEMORADIOTHERAPY REGIMEN: Beginning 4-6 weeks after completion of chemotherapy, patients undergo IMRT on 5 consecutive days per week for a total of 28 fractions and receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Treatment continues in the absence of disease progression or unacceptable toxicity."
3307516|NCT01897467|Placebo Comparator|Control|"The control is a wait-list control, and will have the option to participate in the intervention at the end of the initial 12-week study period. The control group will be asked to not change any of their dietary or exercise habits over the course of the 12 weeks."
3307517|NCT01897467|Experimental|Wii Fit|"Participants in the intervention group will be assigned a Wii console and a Wii Fit balance board. The intervention group will be asked to play for 30 minutes a day, 3 times per week, using only the participant profile pre-programmed for them. They will complete yoga poses and strength training exercises for the first 10 minutes and balance coordination games for the remaining 20 minutes. They will be asked to complete each exercise at least twice, preferably by cycling through all exercises. Participants will be asked to do all of the exercises in one 30-minute session, rather than breaking them up throughout the day.~All participants will be asked to keep a record of which games they play and for how long. The Wii Fit software also keeps a digital record of which exercises were completed and how long they were performed. At the end of the intervention the investigator will use the information stored in the Wii, as well as activity logs, to assess compliance."
3307518|NCT01897480|Experimental|LY2875358 plus Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 milligram (mg) given orally per day.~Randomization: Erlotinib 150 mg given orally per day plus 750 mg LY2875358 given as 1.5 hours intravenous (IV) infusions on Days 1 and 15 of 28-day cycles."
3307519|NCT01897480|Active Comparator|Erlotinib|"Lead In: Approximately 8 weeks of erlotinib 150 mg given orally per day.~Randomization: Continue Erlotinib 150 mg given orally per day, in 28-day cycles."
3307520|NCT01897519|Experimental|Arm 1 lower dose ABT-719|
3307521|NCT01897519|Experimental|Arm 2 intermediate dose ABT-719|
3307522|NCT01897519|Experimental|Arm 3 high dose ABT-719|
3307523|NCT01897519|Placebo Comparator|Arm 4 Placebo|
3307524|NCT01897545|Active Comparator|PV isolation|
3307525|NCT01897545|Active Comparator|PV isolation+renal denervation|
3307526|NCT01897558|Active Comparator|Ventricular pacemaker electrode|receives an active fixation ventricular pacemaker electrode
3307527|NCT01897558|Active Comparator|Passive fixation ventricular pacemaker electrode|receives a passive fixation ventricular pacemaker electrode
3307528|NCT01897584|Experimental|Inverse IE|in only one group, inspiration to expiration ratio 1:2 to 1:1 will be applied during pneumoperitoneum
3307529|NCT01897597|Experimental|BI 144807 PfoS Treatment A|intermediate dose of BI 144807
3307530|NCT01897597|Experimental|BI 144807 PfoS Treatment C|high dose of BI 144807
3307531|NCT01897597|Experimental|BI 144807 Tab Treatment B|intermediate dose of BI 144807
3307532|NCT01897597|Experimental|BI 144807 Tab Treatment D|high dose of BI 144807
3307533|NCT01897597|Experimental|BI 144807 Tab Treatment E|intermediate dose of BI 144807, fasted
3307534|NCT01897597|Experimental|BI 144807 Tab Treatment F|intermediate dose of BI 144807, fed
3307535|NCT01897597|Experimental|BI 144807 Tab Treatment G|intermediate dose of BI 144807, fasted
3307536|NCT01897610|No Intervention|control group|The study subjects randomly assigned to the control group is given Nexavar chemotherapy according to the clinical test plans.
3307537|NCT01897610|Experimental|Immuncell-LC group|The study subjects assigned to the test group blood is drawn before minimum 2 weeks in order to manufacture the test drug. Test group is compared its progression free survival rate after baseline by administering Nexavar chemotherapy same as control group with Immuncell-LC (10 times).
3307538|NCT01897623|Other|ultrasound of aorta|
3307539|NCT01897636|Experimental|EUS-guided fine-needle injection of DCs vaccinations|
3307540|NCT01897649|Experimental|NUTRIOSE|group of volunteers fed with NUTRIOSE
3307541|NCT01897649|Active Comparator|GLUCIDEX|gruop of volunteers fed with GLUCIDEX
3307542|NCT01897662|Experimental|NUTRIOSE|Group of volunteers fed with NUTRIOSE
3307543|NCT01897662|Active Comparator|GLUCIDEX|Group of volunteers fed with GLUCIDEX
3307544|NCT01897675|Active Comparator|Incision and Drainage with Packing|Abscess is cared for in the standard fashion, using an incision and drainage with packing (wick) placement. Packing to be changed every 2-3 days, at the discretion of the treating clinician, until abscess is considered resolved
3307545|NCT01897675|Experimental|Loop Drainage|Abscess is cared for using a minimally invasive abscess drainage with loop placement technique. Two (or more) stab incisions are made in the abscess, the cavity is probed and pus is drained, and a vessel loop is inserted and tied off. The patient manipulates the loop 3 times per day, and removes the loop when all redness is gone and no more pus is present
3307546|NCT01897688|Experimental|Islet Cell Transplant|All qualified subjects will be put on United Network for Organ Sharing (UNOS) Islet Transplant wait list for potential islet cell transplant.
3307547|NCT01897701|Experimental|Group A|High dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
3307548|NCT01897701|Experimental|Group B|Intermediate dose Monovalent Avian Influenza VLP (H7N9); IM; Day 0 & 21
3307549|NCT01897701|Experimental|Group C|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & 21
3307550|NCT01897701|Experimental|Group D|Low dose Monovalent Avian Influenza VLP (H7N9) and Low dose Adjuvant 1; IM; Day 0 & Day 21
3307551|NCT01897701|Experimental|Group E|Intermediate dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
3307552|NCT01897701|Experimental|Group F|Low dose Monovalent Avian Influenza VLP (H7N9) and High dose Adjuvant 1; IM; Day 0 & 21
3307553|NCT01897701|Experimental|Group G|Placebo; IM; Day 0 & 21
3307554|NCT01897753||Small For Gestational Age (SGA) Children|SGA children under growth hormone treatment for more than 36 months.
3307555|NCT01897779|Experimental|Single and multiple dose of RPX7009|Single and multiple dose of RPX7009
3307556|NCT01897779|Experimental|Single and multiple dose of RPX2014|Single and multiple dose of RPX2014
3307557|NCT01897779|Placebo Comparator|Normal Saline|Single and multiple dose of normal saline
3307558|NCT01897779|Experimental|Combination RPX7009 and RPX2014|Single and Multiple dose of Combination RPX7009 and RPX2014
3307559|NCT01897805|Experimental|Heart-protecting Musk Pill|Patients will get standard treatment for coronary artery disease plus 2 Heart-protecting Musk Pills each time, three times a day by mouth for 24 months
3307560|NCT01897805|Placebo Comparator|Placebo|Patients will get standard treatment for coronary artery disease plus 2 placebo pills each time, three times a day by mouth for 24 months
3307561|NCT01897818|Experimental|ALS patients|
3307562|NCT01897831|Experimental|xin te mie|1.5-3.0g,iv,bid or tid for 7-14 days
3307563|NCT01897844|Experimental|ITF2984/Placebo 2000 mcg sc bid|ITF2984/Placebo 2000mcg s.c. b.i.d. for 14 days
3381179|NCT03899792|Experimental|LOXO-292|Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The MTD/recommended dose from Phase 1
3381180|NCT03898479|Experimental|CTP-543|Patients who previously completed a qualifying CTP-543 clinical trial
3307564|NCT01897844|Experimental|ITF2984/Placebo 3000 mcg sc bid|ITF2984/Placebo 3000mcg s.c. b.i.d. for 14 days
3381181|NCT03896581|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen.
3381182|NCT03896581|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo.
3381189|NCT03895203|Experimental|Bimekzumab dosage regimen|Subjects randomized to this arm will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
3381190|NCT03895203|Active Comparator|Adalimumab dosage regimen|Subjects randomized to this arm will receive the assigned adalimumab dosage regimen during the Treatment Period.
3381191|NCT03895203|Placebo Comparator|Placebo|Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be reallocated to receive bimekizumab dosage regimen during the Maintenance Period.
3381192|NCT03894917||Group 1|Participants 65 years or older
3381193|NCT03894917||Group 2|Participants less than 65 years
3381194|NCT03889340||Phase 1 cohort|Subjects resuscitated from cardiac arrest will undergo cooling per standard of care with the IQool device.
3381195|NCT03879434||Ostenil® Mini|1-3 injections of sodium hyaluronate 1.0 % (10 milligrams (mg) / 1,0 millilitres (ml)) in weekly interval.
3448462|NCT04063748|Experimental|Experimental|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
3448463|NCT04063748|Placebo Comparator|Placebo|Participants are asked to train (at least) 5 times a week during 15 - 20 mins. The first 4 sessions are training sessions, the fifth session is an in-training test session (DTT and phoneme discrimination).
3448464|NCT04063709|Experimental|Symptomatic with 50-69% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
3448465|NCT04063709|Experimental|Symptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
3448466|NCT04063709|Experimental|Asymptomatic with 70-99% stenosis|Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
3448467|NCT04063709|Experimental|Asymptomatic with 50-69% stenosis|Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
3448468|NCT04063735|Experimental|Experimental group|supplement was given for 3 months.
3448469|NCT04063735|Placebo Comparator|Placebo group|Placebo was given for 3 months.
3448470|NCT04063813|Experimental|40 minute up trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree incline and at 75% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
3448471|NCT04063813|Experimental|40 minute down trial|Subjects were subjected to 40 minutes of treadmill exercise at a 6 degree decline and at 45% of maximal effort between 8:00 and 8:40 am. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
3307565|NCT01897844|Experimental|ITF2984/Placebo 100 mcg sc bid|ITF2984/Placebo 100mcg s.c. b.i.d. for 14 days
3448472|NCT04063813|Experimental|Two 20 minute up trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 75% of maximal effort, the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h..Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
3448473|NCT04063813|Experimental|Two 20 min down trials|Subjects were subjected to two 20 minutes of treadmill exercise separated by 7 h at a 6 degree incline and at 45% of maximal effort , the first one between 8:00 and 8:40 am and the second one between 15:00 and 15:20 h. Isocaloric meals were provided at 7:00, 13:00. and 19:00 h.
3307566|NCT01897857|Experimental|DM kidney transplantation|patient with DM undergoing undergoing kidney transplantation
3307567|NCT01897857|Active Comparator|without DM undergoing kidney transplantation|patient without DM undergoing undergoing kidney transplantation
3448474|NCT04063813|Active Comparator|Sedentary trial|No exercise day with isocaloric meals provided at 7:00, 13:00. and 19:00 h.
3307568|NCT01897870|Experimental|HomeCoMe-program group|the arm receiving the pharmacist home visit
3448475|NCT04063930|Active Comparator|Lokelma|"Sodium zirconium cyclosilicate Lokelma® 5 g, powder (Astra Zeneca)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
3448476|NCT04063930|Placebo Comparator|Placebo|"Matching placebo (indistinguishable from the active comparator)~After initial dosing subjects will be instructed to take the study drug once daily in the morning, by oral administration after the powder has been dissolved in a glass of drinking water.~Duration: 12 weeks"
3307569|NCT01897883||One Group|Full Analysis Set (FAS) will be the primary analysis set. All post ischemic stroke patients within 6-12 months from attack (i.e., with inclusion criterion No.2 fulfilled) except the screening failure patients, i.e., those who withdraw from the study once the informed consent is given, will be included in the FAS.
3307570|NCT01897909||HIV positive with H. pylori infection|HIV positive patients with H. pylori infection
3307571|NCT01897909||HIV positive without H. pylori infection|HIV positive patients without H. pylori infection
3307572|NCT01897909||HIV negative|HIV negative blood donors
3307573|NCT01897922|Active Comparator|Marketed routine infant formula|
3307574|NCT01897922|Experimental|Infant formula containing a probiotic source|
3307575|NCT01897948|Experimental|Milk-based beverage with DHA at mid-level|
3307576|NCT01897948|Experimental|Milk-based beverage with DHA at high level|
3307577|NCT01897948|Active Comparator|Milk-based beverage without DHA|
3307578|NCT01897961|Other|Patients whose renal disease of origin is a GEM|Patients whose renal disease of origin is a GEM
3307579|NCT01897961|Other|Transplanted Patients of origin is a GEM having done it again|Transplanted Patients of origin is a GEM having done it again
3307580|NCT01897961|Other|Transplanted patients, and having developed a GEM of novo|Transplanted patients, and having developed a GEM of novo
3307581|NCT01897974||Seizure disorder|Patients that are on medications for seizure disorder.
3307582|NCT01897987|Experimental|Pneumostem®|A single intratracheal administration of Pneumostem® (1.0 x 10^7 cells/kg)
3307583|NCT01897987|Placebo Comparator|normal saline|A single intratracheal administration of normal saline
3307584|NCT01898026|Experimental|PGX|samples of white bread, mashed potatoes, muffin, hot breakfast cereal with the addition of soluble fibre blend
3307585|NCT01898026|Other|Control|samples of white bread, mashed potatoes, muffin, hot breakfast cereal without the addition of soluble fibre blend
3307586|NCT01898039|Experimental|A2/4-1BBL melanoma vaccine|"On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm.~On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered at the day care unit. On day 14 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed. Four additional doses of the vaccine will be administered at intervals of 21 days."
3307587|NCT01898052|Experimental|multimodal drug injection|Multimodal drug injection Levobupivacaine 150 mg, epinephrine(1:1000) 0.6 mL(0.6 mg), morphine sulfate 5 mL(5 mg), ketorolac 1 mL (30 mg) and mixed with normal saline up to 100 mL
3307588|NCT01898052|Active Comparator|Single anaesthetic drug|Single anaesthetic drug levobupivacaine 150 mg and epinephrine (1:1000) 0.6 ml (0.6 mg)
3307589|NCT01898065|Experimental|PET imaging, 18 F-miso|Single Arm study
3307590|NCT01898104|Active Comparator|SCRT|short course radiotherapy (SCRT) alone 25 Gy in 5 fractions over one week.
3307591|NCT01898104|Active Comparator|V-SCRT|Valproic acid (V) + short course radiotherapy
3307592|NCT01898104|Active Comparator|C-SCRT|capecitabine (C) + short course radiotherapy
3307593|NCT01898104|Active Comparator|VC-SCRT|valproic acid + capecitabine + short course radiotherapy
3307594|NCT01898117|Active Comparator|Carbo/cyclo|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 Q 4 weeks
3307595|NCT01898117|Active Comparator|Carbo/cyclo + Atezolizumab|Carboplatin AUC=5 Cyclophosphamide 600 mg/m2 atezolizumab 840 mg d1,15 Q 4 weeks
3307596|NCT01898117|Active Comparator|Paclitaxel|Paclitaxel 90 mg/m2 d1, 8, 15 Q 4 weeks
3307597|NCT01898117|Active Comparator|Paclitaxel + atezolizumab|Paclitaxel 90 mg/m2 d1, 8, 15 atezolizumab 840 mg d1,15 Q 4 weeks
3307598|NCT01898143|Other|Whole body vibration in COPD|Patients with COPD GOLD III or IV
3307599|NCT01898143|Other|Whole body vibration in ILD|PAtients with interstitial lung disease
3307600|NCT01898156|Experimental|BIW-8962|"Phase 1 - Dose escalation based on the BIW-8962 tolerability and safety data obtained from three subjects enrolled in a cohort (first cycle of treatment), enrollment at the next dose level or additional subjects into the ongoing cohort will occur~Phase 2 - Recommended dose determined in Phase 1"
3307601|NCT01898169|Experimental|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|
3307602|NCT01898182|Experimental|Kinerase|Kinetin (N6-furfuryladenine) is an essential bio growth factor that regulates cell growth and is proven to delay and reverse the signs of aging. Kinerase has been found out to significantly improve the appearance of skin texture, mottled hyperpigmentation and fine wrinkles. It does not cause the cutaneous side effects that result from other commonly used anti-aging products. The Kinerase cream contains: Water, glyceryl stearate, propylene glycol, butylenes glycol, glycerin, cetyl alcohol, stearic acid, isopropyl palmitate, squalene, stearyl alcohol, glycene soja sterols, dimethicone, laureth-23, aloe barbadensis leaf juice, phenoxyethanol, carbomer, ethylhexyglycerin, sodium hydroxide, soluble collagen, kinetin, panthenol, tocopherol, citric acid, sodium citrate, hydrolysed elastin.
3307603|NCT01898221|Active Comparator|Standard Catheter Ablation Patient Group|Patients will have a standard procedure ablation
3307604|NCT01898221|Active Comparator|Vein of Marshall and Standar procedure|The doctor will inject Ethanol through a balloon catheter into the VOM
3307605|NCT01898234|Experimental|Revaclear|
3307606|NCT01898234|Experimental|Helixone high flux|
3307607|NCT01898234|Experimental|Xevonta|
3307608|NCT01898234|Experimental|Helixone low flux|
3307609|NCT01898247|No Intervention|Traditionally-trained Procedures|Patients who undergo thoracentesis procedures by traditionally-trained residents who have not undergone simulation-based mastery learning.
3307610|NCT01898247|Experimental|Simulator-trained Procedures|Patients who undergo thoracentesis procedures by residents who have undergone simulation-based mastery learning.
3307611|NCT01898260|Other|BYO Daily, then MyDay|Ultrafilcon B contact lenses, followed by stenfilcon A contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
3307612|NCT01898260|Other|MyDay, then BYO Daily|Stenfilcon A contact lenses, followed by ultrafilcon B contact lenses. Each product worn bilaterally for 1 week in a daily wear, daily disposable modality.
3307613|NCT01898273|Experimental|Single|I-124-CLR1404, open-label
3307614|NCT01898312|Experimental|Mifepristone|treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
3307615|NCT01898312|Placebo Comparator|TrioBe|treatment with a quarter of a tablet of TrioBe every second day for 12 weeks
3307616|NCT01898325|Other|Naïve GD patients|"Naïve GD patients~Intervention: device - Fibroscan"
3307617|NCT01898325|Other|GD treated with ERT|GD treated with ERT Intervention: device - Fibroscan
3307618|NCT01898325|Other|Healthy control|Healthy control Intervention: device - Fibroscan
3307619|NCT01898325|Other|NonAlcoholic Steatohepatitis Patients|Patients with NonAlcoholic Steatohepatitis( NASH) Intervention: device - Fibroscan
3307620|NCT01898338|Experimental|Fosfomycin and Daptomycin|fosfomycin 2gr/6h + 10mg/kg/24h iv during 14 or 28 days
3307621|NCT01898338|Active Comparator|Daptomycin|daptomycin 10mg/kg/cada 24h iv during 14 or 28 days
3307622|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
3307623|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 5 mg|Intravenous infusion of 5mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks
3307624|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 10 mg|Intravenous infusion of 10mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
3307625|NCT01898364|Experimental|GZ402666 (neoGAA) Group 1 - 20 mg|Intravenous infusion of 20mg neoGAA to treatment naïve late onset Pompe disease patients once every other week for a total of 24 weeks.
3307626|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 5 mg|Intravenous infusion of 5mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3307627|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 10 mg|Intravenous infusion of 10mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3307628|NCT01898364|Experimental|GZ402666 (neoGAA) Group 2 - 20 mg|Intravenous infusion of 20mg neoGAA once every other week for a total of 24 weeks to late onset Pompe disease patients previously treated with alglucoside alfa.
3307629|NCT01898377|Experimental|Imatinib mesylate, Mycophenolate mofetil|"MMF 15-20mg/kg (Max 1 g) bid + Imatinib mesylate qd~Dose of imatinib : starting dose 260 mg/m2/d (Max. 400 mg)~Imatinib dose adjustment : Dose is adjusted according to the guidelines if there is serious adverse event, toxicity, or intolerance."
3307630|NCT01898390|Experimental|Transplant|Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
3307631|NCT01898390|No Intervention|Control|comparison group of controls, will receive the same observational and scanning assessments but will not receive any surgical procedures
3307632|NCT01898416|Experimental|5-AminoLevulinicc Acid|consists of 60mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia and surgical tumor resection. Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In the case of positive margins (for tumor presence), a second surgical intervention followed by second 60mg/kg 5-ALA administration will be performed.
3307633|NCT01898455|Experimental|Intranasal Cooling|RhinoChill Intranasal cooling, administered for 20 minutes. 10 treatment sessions per participant.
3307634|NCT01898468|Active Comparator|Intracostal Closure Technique|Closure involves drilling four evenly spaced holes using a 5-mm bit attached to the end of a Stryker drill into the bed of the sixth rib.
3307635|NCT01898468|Active Comparator|Pericostal Closure Technique|Closure involves placing sutures around the ribs in the standard pericostal fashion
3307636|NCT01898481||Health Care Triads|This is an exploratory pilot study of 25 health care triads. Triads will include: (1) a patient diagnosed with advanced cancer, (2) a loved one, and (3) an oncology provider.
3307637|NCT01898494|Experimental|Arm A (TOS)|Patients undergo transoral surgical resection of the oropharyngeal tumor.
3307638|NCT01898494|Experimental|Arm B (TOS, low-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.
3307639|NCT01898494|Experimental|Arm C (TOS, standard-dose IMRT)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.
3307640|NCT01898494|Experimental|Arm D (TOS, standard-dose IMRT, chemotherapy)|Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.
3307641|NCT01898507|Experimental|Low nicotine cigarettes|"Participants will smoke their own brand cigarettes during a baseline 5 day period, followed by a 15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.~Other: Low nicotine cigarettes"
3307642|NCT01898520|Active Comparator|Sativex|Oromucosal spray containing delta-9-tetrahydrocannabinol (THC) (27 mg/mL):cannabidiol (CBD) (25 mg/mL). Each 100 μL spray to the sub-lingual or oral mucosa delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
3307643|NCT01898520|Placebo Comparator|Placebo|Oromucosal spray containing ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum number of daily sprays was 12.
3307644|NCT01898546|Experimental|Primary angioplasty and postconditioning|Primary angioplasty followed by postconditioning
3307645|NCT01898546|Active Comparator|Primary angioplasty|Primary angioplasty alone
3307646|NCT01898559|Experimental|Black & Mild little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking Black & Mild little cigars.~Other: Switch to smoking only little cigars"
3307647|NCT01898559|Experimental|King Edward little cigars|"Participants switch from smoking their own brand of cigarettes to only smoking King Edward little cigars.~Other: Switch to smoking only little cigars"
3307648|NCT01898572||Newly diagnosed T2DM|Newly diagnosed T2DM with no CVD. Standard care.
3307649|NCT01898572||Control individuals|Control individuals matched by age, gender, dyslipidemia, hypertension and smoking habit. Standard care.
3307650|NCT01898585|Experimental|Zelboraf Arm|
3307651|NCT01898624||Betanis group|mirabegron treated group
3307652|NCT01898637|Active Comparator|Proven pulmonary embolism.|Augmented pulse oximetry using incentive spirometer. Emergency Department patients with pulmonary embolism.
3307653|NCT01898637|Other|Control patients|Augmented pulse oximetry using incentive spirometer. Emergency Department patients who do not have pulmonary embolism.
3307654|NCT01898650|Experimental|craniofacial abnormalities|Subjects with craniosynostosis or other craniofacial abnormalities associated with ICP who will undergo an MR scan.
3307655|NCT01898663|Experimental|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DCs + CIK cells
3307656|NCT01898676|Active Comparator|Divalproex Sodium Extended Release 250mg|Treatment A: A single 2-tablet dose of divalproex sodium extended-release tablet, 250mg. Each subject will have 2 treatments with this medication and two treatments with a single 2-tablet dose of DEPAKOTE 250mg tablet.
3307657|NCT01898676|Active Comparator|DEPAKOTE 250mg|Treatment B: A single 2-tablet dose of DEPAKOTE ER tablet, 250mg. Each subject will have 2 treament period with this medication and 2 treatment periods with a single 2-tablet dose of Divalproex Sodium Extended-Release 250mg tablet.
3307658|NCT01898702|Experimental|Diabetes expert patients programme|Diabetes expert patients programme: Participate in a scheduled and standardized expert patients programme course
3307659|NCT01898702|Placebo Comparator|No intervention|Don't participate in a scheduled and standardized expert patients programme course
3307660|NCT01898715|Experimental|ATR-101|ATR-101 will be administered as capsules or tablets by mouth once or twice per day to ascending dose cohorts
3307661|NCT01898728|Active Comparator|Liquid preoperative medications|Liquid preoperative medications
3307662|NCT01898728|Active Comparator|Gel preoperative medications|Gel preoperative medications
3307663|NCT01898741|Experimental|irradiation|24 Gy in 3 fractions
3307664|NCT01898767||Mild asthma|Diagnosis of mild asthma as defined by pre-albuterol forced expiratory volume in the first second (FEV1) of >70% predicted.
3307665|NCT01898780|Experimental|horizontal mattress|pancreaticojejunostomy with horizontal mattress suture
3307666|NCT01898780|Experimental|interrupted suture|pancreaticojejunostomy with interrupted suture
3307667|NCT01898793|Experimental|Phase I: 0.5 x 10^6/kg CIML NK cells (Dose Levels 1-3)|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors over 5 hours on day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion over 15-60 minutes on day 0.~Interleukin-2: Patients receive aldesleukin SC every other day for 2 weeks starting on day 1 (total of 7 doses)"
3307668|NCT01898793|Experimental|Lead-in Cohort & Phase II (ALT-803): Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1.~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0.~Subcutaneous ALT-803 will begin approximately 4 hours after the infusion and will continue for a total of 2 doses (Days 0 and 5)."
3307669|NCT01898793|Experimental|Pediatric Cohort: Maximum NK cell/number kg|"Lymphodepleting Preparative Regimen: Patients receive fludarabine phosphate IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 2 hours on days -5 and -4.~Donor Leukapheresis: Peripheral blood cells are collected from haploidentical related donors on Day -1~CIML NK Cells: Patients undergo CIML NK cell infusion on Day 0~Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses"
3307670|NCT01898793|Experimental|Phase II (IL-2): Maximum NK cell/number kg|The recipient will begin a lymphodepleting preparative regimen of fludarabine and cyclophosphamide on Day -6. The haploidentical donor identified by HLA matching of the immediate family members will undergo non-mobilized large volume (20-L) leukapheresis on Day -1, and the NK cell product will be infused into the recipient on Day 0. Subcutaneous IL-2 will begin approximately 2-4 hours after infusion and will continue every other day through Day 12 for a total of 7 doses.
3307671|NCT01898819|Experimental|dexmedetomidine|dexmedetomidine infusion from beginning of the anesthesia to just before returning to horizontal position
3307672|NCT01898819|Placebo Comparator|saline|Saline infusion from same time period.
3307673|NCT01898845|Experimental|LEE011|LEE011
3307674|NCT01898858||HYPOXIA|
3307675|NCT01898858||HYPERCAPNIA|
3307676|NCT01898858||HYPOXIA + HYPERCAPNIA|
3307677|NCT01898871|Experimental|Ready to Use Suplementary Food (RUSF)|A daily ration of 40 kcal/kg of body weight during 56 days
3307678|NCT01898871|Active Comparator|Corn Soya Blend (CSB+)|A daily ration of 40 kcal/kg of body weight during 56 days
3307679|NCT01898897|Active Comparator|robot general anesthesia|"General anesthesia for robot assisted laparoscopic urogenital surgery includes premedication with alprazolam (0.5 mg per os), induction with sufentanil, propofol (1-2 mg/kg), neuromuscular blocking agents (rocuronium 0.5 mg/kg) to facilitate tracheal intubation. Anesthesia is maintained with volatile agents (sevoflurane, desflurane) and reinjection of rocuronium and sufentanil as needed.~Robotic assisted laparoscopic interventions are realised with Da Vinci surgical robot, known to assure a minimally invasive approach with good results in urologic surgery. The system consists of an ergonomic surgeon console, a patient cart with four interactive robotic arms, a 3D high resolution visualization interface and specific EndoWrist articulated tools."
3307680|NCT01898897|Experimental|robot combined anesthesia|Combined anesthesia is defined as association of epidural analgesia to general anesthesia. Epidural catheter is inserted at low thoracic level in the operation theatre before the induction of anesthesia. Correct position is verified with 15 mg bupivacaine plain 0.5%. Infusion is started after the incision at a rate of 6-8 ml/ hour.Epidural continuous infusion of local anesthetic is maintained 12 hours postoperative in the postoperative anesthesia care unit.
3307681|NCT01898910|Active Comparator|PVI+renal denervation+OMT|
3307682|NCT01898910|Active Comparator|PVI+GP ablation+OMT|
3307683|NCT01898936|Experimental|Pretreatment CO2 laser|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluato"
3307684|NCT01898936|Sham Comparator|Only photodynamic therapy|This group will not get pretreatment with CO2 laser
3307685|NCT01898949|Experimental|Cold Exposure|
3307686|NCT01898962|Experimental|Definitive locoregional treatment|All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
3307687|NCT01898975||500ml fluid loading|All enrolled patients
3307688|NCT01899001|Experimental|CBT and Nutrition Counseling|8 weeks of Cognitive Behavioral Therapy (CBT) and 16 weeks of Nutrition Counseling
3307689|NCT01899001|Other|Nutrition Counseling|16 weeks of Nutrition Counseling alone
3307690|NCT01899027|Active Comparator|Rosuvastatin Group|Patients will be randomized to receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
3307691|NCT01899027|Placebo Comparator|Placebo group|Patients will be randomized to receive two overnight high doses of Placebo before RNA and another placebo dose 2 h before the procedure
3307692|NCT01899040|Active Comparator|active device|A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.
3307693|NCT01899040|Placebo Comparator|placebo device|A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.
3307694|NCT01899066|Experimental|Lucentis; chemotherapy|"Lucentis: 0.5mg/0.05 ml;Other Name: Ranibizumab;monthly for the first six months.~Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months."
3307695|NCT01899066|Active Comparator|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
3307696|NCT01899092|Experimental|Escalating Dose of TT-034|The study contains one dose escalation arm with active drug.
3307697|NCT01899105|Experimental|Part A|A single dose of 2 fixed-dose combination tablets of 200mg lumacaftor/125mg ivacaftor (total of 400mg lumacaftor/250mg ivacaftor) in the fed state and fasted state with a 14 day washout period in between each dosing occasion
3307698|NCT01899105|Experimental|Part B|A single dose of 3 fixed-dose combination tablets of 200mg lumacaftor/83mg ivacaftor (total of 600mg lumacaftor and 250mg ivacaftor) in the fed with a 14 day washout period in between dosing occasions
3307699|NCT01899118|Experimental|Nimotuzumab plus chemoradiotherapy|
3307700|NCT01899131|Other|platform-switch tapered internal implants|2 platform-switch tapered internal implants placed in 10 participants.clinical and radiographic assessment in 6,12,24, month post implant insertion
3307701|NCT01899157||Survey|"Thai naive HIV-infected patients~Thai HIV-infected patient reciering highly active antiretroviral therapy"
3307702|NCT01899170|Sham Comparator|Sham-DBS|Only patients. Inactive deep brain stimulation for the initial three months following implantation.
3307703|NCT01899170|Active Comparator|Active DBS|Only patients. Active deep brain stimulation for the initial three months following surgery.
3307704|NCT01899170|Experimental|TMS and PET imaging|This experiment includes all participants (cases and controls). Each subject will undergo both active and sham stimulation (cross-over) with Cervel Neurotech Multi-coil TMS and related test/re-test PET imaging with 11C-Carfentanil. Only patients will proceed into deep brain stimulation experiments.
3307705|NCT01899196|Other|no Arm|
3307706|NCT01899209|Experimental|Group A|STARR
3307707|NCT01899209|Experimental|Group B|Laparoscopic ventral Rectopexy
3307708|NCT01899222||fundus imaging|retinal photograph obtained at visit
3307709|NCT01899235|Active Comparator|Stent|drug eluting stent (Resolute)
3307710|NCT01899235|Experimental|drug eluting balloon|drug eluting balloon (Elutax)
3307711|NCT01899248||Sevoflurane|Performing liver transplantation under general anesthesia using sevoflurane
3307712|NCT01899248||Desflurane|Performing liver transplantation under general anesthesia using desflurane
3307713|NCT01899274|Experimental|bant Group|Subjects in the bant Group will receive care as usual, as well as an iPhone loaded with the bant iPhone application and a bluetooth enabled glucometer. Participants will have their A1C levels measured every 3 months (for 1 year), and also complete questionnaires/interviews relating to their diabetes management and lifestyle.
3307714|NCT01899274|No Intervention|Control Group|Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.
3307715|NCT01899287|Experimental|education in skin care|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
3307716|NCT01899287|No Intervention|no intervention|The control group will not have access to the group education, the profession specific information and the social guidance or the telephone hotline.
3307717|NCT01899313|Experimental|CBT- based SMS text messaging intervention|cognitive behavioral therapy- (CBT-) based short message service (SMS) text messaging intervention
3307718|NCT01899313|Placebo Comparator|Placebo Texts|Placebo texts will be given instead of interventional texts
3307719|NCT01899326|Experimental|Treatment (desipramine, filgrastim)|Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6.
3307720|NCT01899339||pulmonary embolism|patients with submassive pulmonary embolism
3307721|NCT01899352|Other|Tracheostomy|The investigators will enroll all the critical ill patients undergoing tracheostomy performed in intensive care units
3307722|NCT01899365||Multifaceted|"brief structured interview with the physician about pneumococcal risk and vaccination,~information sheet delivered to patients with explanation about risk and benefit of APV,~letter given to patient for his/her general practitioner stating that the patient is at-risk for pneumococcal infection and could benefit of APV,~3 SMS every 2 weeks to remind patients talking of pneumococcal risk with general practitioner."
3307723|NCT01899365||Control|"information sheet delivered to patients with explanation about the aim of the study,~brief interview with the physician about study."
3307724|NCT01899378|Experimental|daily probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis daily for one month
3307725|NCT01899378|Experimental|weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis weekly for one month
3307726|NCT01899378|Experimental|bi-weekly probiotic|10^8 CFU Lactobacillus reuteri DSM 17938 and 10^9 Bifidobacterium longum infantis bi-weekly for one month
3307727|NCT01899378|No Intervention|control|
3307728|NCT01899404|Experimental|18-FDG PET/CT, DWI, DCE-MRI|
3307729|NCT01899417||ConforMIS iTotal® Knee Replacement|knee joint replacement
3307730|NCT01899417||Standard Knee Replacements|knee joint replacement
3307731|NCT01899430|Active Comparator|metformin|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3307732|NCT01899430|Experimental|liraglutide|In the LIRA group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3307733|NCT01899443||Total hip and knee replacement patients|This study will select up to 20 high volume (>275 cases annually) public and private hospitals across Australia. A random sample of c.2200 patients with diagnosis of osteoarthritis undergoing primary total hip or knee replacement surgery will be recruited.
3307734|NCT01899456|No Intervention|Medical therapy|Best medical therapy using guideline recommended drugs in each disease state.
3307735|NCT01899456|Experimental|Catheter-based renal denervation|Renal denervation will be performed in the native renal arteries of patients after renal transplantation. Access side is the contralateral femoral artery.
3307736|NCT01899469|Experimental|Electromagnetic therapy (EM)|The group had performed 20 sessions of EM therapy for 20 minutes and after had a 25 minutes from Back School intervention.
3307737|NCT01899469|Experimental|Transcutaneous Electrical Neurological Stimulation (TENS)|The group had performed 20 sessions of TENS therapy for 20 minutes and after had a 25 minutes from Back School intervention.
3307738|NCT01899469|Experimental|Back School (BS)|The group had performed 20 sessions of Back School therapy for 25 minutes.
3307739|NCT01899482|Experimental|Manual Lymphatic Drainage|One educational session in group, and 10 individual sessions of manual lymphatic drainage in lower extremity, during approximately one month.
3307740|NCT01899482|Active Comparator|Control|One educational session in group.
3307741|NCT01899495|Experimental|High sodium diet and low sodium diet|Each subject experiences both a high sodium and a low sodium diet.
3307742|NCT01899508|Experimental|Pain Coping Training with 3D viewer|All participants will receive a 1 and a half hour pain coping training while using the virtual reality viewer. We are testing the feasability of using the 3D viewer in collaboration with Pain Coping training to see if people who suffer from Osteoarthritis of the knee experience some pain relief.
3307743|NCT01899521|Placebo Comparator|Placebo zinc and placebo SAMe|Placebo tablet of zinc sulfate once daily and placebo tablet of s-adenosylmethionine twice daily
3307744|NCT01899521|Active Comparator|Active zinc and placebo SAMe|Zinc sulfate 220 mg once daily and placebo tablet of s-adenosylmethionine twice daily
3307745|NCT01899521|Active Comparator|Placebo zinc and active SAMe|Placebo tablet of zinc sulfate once daily and s-adenosylmethionine 400 mg twice daily
3307746|NCT01899521|Active Comparator|Active zinc and active SAMe|Zinc sulfate 220 mg once daily and s-adenosylmethionine 400 mg twice daily
3307747|NCT01899534|No Intervention|Paper-based screening|Paper-based screening. Women will complete a mental health screening tool on paper (usual care).
3307748|NCT01899534|Experimental|E-screening|Women will complete mental health screening on a tablet
3307749|NCT01899547|Experimental|Arm I|Patients undergo laparoscopic-assisted rectal resection.
3307750|NCT01899547|Active Comparator|Arm II|Patients undergo conventional open rectal resection.
3307751|NCT01899560|Other|Unique arm|Experimental and comparator
3307752|NCT01899573|Experimental|Treatment|
3307753|NCT01899586|Experimental|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
3307754|NCT01899586|Experimental|Aerobic Exercise (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
3307755|NCT01899599|Experimental|PankoMab-GEX|1700mg, i.v., q3w
3307756|NCT01899599|Placebo Comparator|Placebo|matching placebo
3307757|NCT01899612||Symptomatic postmenopausal women|Postmenopausal women with vulvovaginal symptoms
3307758|NCT01899612||Asymptomatic postmenopausal women|Postmenopausal women without vulvovaginal symptoms
3307759|NCT01899625|Active Comparator|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
3307760|NCT01899625|Active Comparator|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
3307761|NCT01899638|Experimental|UMEC/VI 125/25 mcg|Combination in high dose
3307762|NCT01899638|Experimental|UMEC/VI 62.5/25 mcg|Combination in low dose
3307763|NCT01899638|Experimental|UMEC 125 mcg|LAMA mono in high dose
3307764|NCT01899638|Experimental|UMEC 62.5 mcg|LAMA mono in low dose
3307765|NCT01899638|Experimental|VI 25 mcg|LABA mono
3307766|NCT01899651||Infants of 30-34 weeks gestation.|Inclusion criteria will be infants 30-34 weeks gestation. Exclusion criteria will be any infants with evidence of pre-existing skin condition, breakdown, rashes, or problems with skin integrity. Infants with a known neurological condition (hydrocephalus, Dandy Walker malformation, craniosynostosis, arteriovenous malformation) will be excluded as well. Also, secondary to the nature of the device and the surface area it takes up, infants on continuous positive airway pressure will be excluded as well.
3307767|NCT01899664|Other|Primary Study Population|Study participants (primary study population) will include patients with spinal cord injury at the mid cervical level who are undergoing evaluation for possible surgical treatment with nerve transfers and or tendon transfer/tenodesis to improve their upper extremity function. All enrolled participants will receive the same standard of care surgical procedures.
3307768|NCT01899690|Experimental|antibiotic|7 days of preventive antibiotics after surgery
3307769|NCT01899690|No Intervention|No antibiotic|No preventive postoperative antibiotics
3307770|NCT01899703|Experimental|GSK2330672|Subject will receive GSK2330672 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either (i) GSK2330672 followed by placebo; OR (ii) placebo followed by GSK2330672.
3307771|NCT01899703|Experimental|Placebo|Subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. Patients were randomized to one of two sequences receiving either GSK2330672 followed by placebo; OR placebo followed by GSK2330672.
3307772|NCT01899716|Experimental|Exercise|Aerobic Exercise, 3 times peer week, A dose of 16.5 kcal/kg weight peer week.
3307773|NCT01899716|No Intervention|Control|
3307774|NCT01899755|Experimental|GSK2800528 Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
3307775|NCT01899755|Placebo Comparator|Placebo Arm|Subjects will be assigned to treatments in accordance with the randomization schedule in Cohorts 1 to 3. Treatments will be randomized with placebo in a 3:1 ratio. The final randomization code will also pre-define the sentinel subjects to ensure that of the first two subjects in each cohort, one will receive GSK2800528 and the other will receive placebo.
3307776|NCT01899755|Active Comparator|Adalimumab Arm|In Cohort 4, all subjects will receive adalimumab 40 mg (0.8 mL solution) as subcutaneous injection
3307777|NCT01899781|Experimental|with antibiotic and without antibiotic|
3307778|NCT01899794|Active Comparator|TVT-O|mid-urethral sling
3307779|NCT01899794|Active Comparator|Oxytrol|medication
3307780|NCT01899807|Other|Single Arm|
3307781|NCT01899820|Active Comparator|Artemether lumefantrine|Tablets, 1-4 tablets (weight calculated dose), BD, at hr 0, 8, 24, 36, 48 and 60.
3307782|NCT01899820|Experimental|Dihydroartemisinin piperaquine|Tablets, 2 paediatric tablets/1 adult tablet, OD, every 24 hours for 48 hours
3307783|NCT01899833|Experimental|99mTc-EC-DG, Diagnostic|99mTc-EC-DG (25 ± 5 mCi, up to 250 µg EC-DG) will be administered by intravenous (IV) bolus injection. Other Name:Technetium-99m-labeled Ethylenedicysteine-Deoxyglucose
3307784|NCT01899846|Experimental|Cohort 1|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation following first dose
3307785|NCT01899846|Experimental|Cohort 2|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 24 - 28 weeks gestation
3307786|NCT01899846|Experimental|Cohort 3|Hydroxyprogesterone caproate 250 mg/ml. Detailed pharmacokinetic evaluation 32 - 36 weeks gestation
3307787|NCT01899859|Active Comparator|Cohort 1|Patient receives dose of GR-MD-02 or placebo
3307788|NCT01899859|Active Comparator|Cohort 2|Patient receives dose of GR-MD-02 or Placebo
3307789|NCT01899859|Active Comparator|Cohort 3|Patient receives dose of GR-MD-02 or placebo
3307790|NCT01899872|Experimental|Patients with type 1 diabetes|Patients with type 1 diabetes
3307791|NCT01899885|No Intervention|historic control group|Standard treatment in the historic control group
3307792|NCT01899885|Active Comparator|Intervention group|"AHA (Acute Highrisk Abdominalsurgery): Optimized Course:~Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
3307793|NCT01899898|Experimental|Simplified Modified Atkins Diet|
3307794|NCT01899898|Active Comparator|Antiepileptic drugs alone|
3307795|NCT01899924|Experimental|Event Related Potentials|
3307796|NCT01899963||Tele-ophthalmology Referral Group|This group includes patients referred to a retinal specialist via a teleophthalmology referral system.
3307797|NCT01899963||Conventional Referral Group|This group includes patients referred to a retinal specialist via a conventional fax system.
3307798|NCT01899976|Other|X-Suit NIR Covered Biliary Stent|Stent implantation in the biliary tree
3307800|NCT01900015|Active Comparator|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
3307801|NCT01900015|Active Comparator|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
3307802|NCT01900028|Experimental|Olaparib alone, olaparib+itraconozole|Sequential treatments of olaparib alone followed by olaparib+itraconazole, with a washout period in between.
3307803|NCT01900041|Experimental|Pantovigar + Minoxidil 2%|Minoxidil 2% is given as background therapy in both arms
3307804|NCT01900041|Other|Minoxidil 2% only|Minoxidil 2% is given as background therapy in both arms
3307805|NCT01900080|Experimental|Same-Day ART Group|"Same-Day HIV testing and ART initiation:~All participants in the same-day ART group will receive rapid HIV antibody testing, CD4 cell testing, clinically relevant testing for OIs, WHO staging, counseling and social support, and ART initiation on the day of presentation for HIV testing."
3307806|NCT01900080|Active Comparator|Standard ART Group|"Standard ART Initiation:~The standard group will receive the same services as the same-day ART group (including same-day HIV and CD4 cell testing) except that instead of same-day ART, they will receive the standard GHESKIO protocol of 3 sequential visits for ART readiness counseling and testing for OIs prior to ART initiation."
3307807|NCT01900080|Experimental|Sub-Study - Same-Day ART, CD4>500|Sub-Study - Same-Day CD4 Count and ART Initiation for Patients with CD4 Count >500 cells/mm3: Participants will receive counseling and start ART on the day of study enrollment. They will have follow-up visits with the physician on Days 3, 10, 17, and 24, and with the social worker on Days 3, 10, and 17. They will have also have physician visits at weeks 8 and 12. Participants who are clinically stable, asymptomatic, and adherent at week 12 will then qualify for expedited care at future visits, which includes dispensing of ART directly by nurses in the clinic every four weeks, to reduce waiting time for patients. Participants who are symptomatic or non-adherent will be referred to a physician for evaluation.
3307808|NCT01900080|Active Comparator|Sub-Study - Pre-ART Care, CD4>500|Participants will receive standard GHESKIO pre-ART care, which includes a monthly visit with a physician for 3 months, and then every other month physician visits.
3307809|NCT01900093|Experimental|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
3307810|NCT01900106|Experimental|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
3307811|NCT01900106|Active Comparator|ABC/3TC + DRV/r|abacavir/lamivudine + darunavir/ritonavir
3307812|NCT01900158|Experimental|Phase I|Experimental PCI treatment in dose escalation cohorts consist of Amphinex injection (at different doses) plus a single standard dose of Gemcitabine (1000 mg/m2) plus intraluminal light at the tumour area (at different doses). In addition up to 8 cycles of standard chemotherapy doses of Gemcitabine (1000 mg/m2) and Cisplatin (25 mg/m2) was provided. In the Extended part of the study (last cohort) an additional PCI treatment was introduced at Cycle 5 in the treatment Schedule.
3307813|NCT01900171|Experimental|10 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307814|NCT01900171|Experimental|50 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307815|NCT01900171|Experimental|125 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307816|NCT01900171|Experimental|250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307817|NCT01900171|Experimental|500 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307818|NCT01900171|Experimental|750 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307819|NCT01900171|Experimental|1,000 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307820|NCT01900171|Experimental|1,250 mg of QGC001|Each dose of QGC001 was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307821|NCT01900171|Placebo Comparator|Placebo|The placebo was administered orally with 100 mL of sterile water for irrigation at 08:00 in the morning of Day 1.
3307822|NCT01900184|Experimental|500 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3307823|NCT01900184|Experimental|750 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3307824|NCT01900184|Experimental|1,000 mg bid of QGC001|Each dose of QGC001 will be administered in solution with 200 mL of purified water.
3307825|NCT01900184|Placebo Comparator|Placebo|The placebo will be administered in solution with 200 mL of purified water.
3307826|NCT01900197||Iron deficiency anemia|Patients with iron deficiency anemia treated on the doctor's discretion with 10% Iron Isomaltoside 1000 (Monofer®) as standard treatment according to current practice
3307827|NCT01900210|Experimental|WaySafe|WaySafe -- Participants in this arm received a curriculum titled WaySafe that focused on identifying, planning for, and avoiding HIV risk behaviors after release from prison. WaySafe included 6 hour-long, group-based, highly interactive sessions normally held weekly with homework assignments given between sessions.
3307828|NCT01900210|No Intervention|Treatment as usual|Participants in this arm completed pre- and post-surveys and attended normal substance abuse programming.
3307829|NCT01900223||Shoulder prosthesis bearer|
3307830|NCT01900236|No Intervention|Control|Control arm participants will receive standard clinical care (i.e. receive usual clinic treatment)
3307831|NCT01900236|Experimental|Motivation Behavioral Technique|Behavioral: 4 sessions of tailored, interactive agenda based on behavioral motivational interviewing (MI) techniques. Each iENGAGE intervention session includes: interventionist-delivered educational content for managing HIV medical care appointment-keeping and information sessions for learning to manage HIV medications. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order in order to achieve viral suppression and improve overall health.
3307832|NCT01900262|Experimental|Strengthening|Novice recreational runners from the Calgary area.
3307833|NCT01900262|Experimental|Balance Training|Novice recreational runners from the Calgary area.
3307834|NCT01900262|Experimental|Stretching|Novice recreational runners from the Calgary area.
3307835|NCT01900275||Septic shock or major trauma|Patients admitted within 24 hours to ICU for septic shock or major trauma (ISS > 15). Septic shock is defined by sepsis with hypotension requiring >4 hours of vasopressor support over previous 24 hours.
3307836|NCT01900288|Experimental|HPN Group Clinic Appointments (Group 1)|"A mobile device (iPad mini) is loaned to Group 1 subjects providing a connection to HPN Internet information for the 6 to 12 months of the study. Two scheduled times during the study period, visual connections to geographically distant professionals and peers over the iPad mini (HPN Group Clinic Appointment) will be held for approximately 1 ½ to 2 hours each time (called Healthy Living Connections).~On the iPad mini screen during the HPN Group Clinic Appointments, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive electronic prompts about healthy activities."
3307837|NCT01900288|Placebo Comparator|Mobile Device Access (Group 2)|"A mobile device (iPad mini) is loaned to Group 2 subjects providing a connection to Internet information for the 6 to12 months of the study. At the end of the study period, Group 2 subjects will have 1 scheduled time during the study to connect to professionals and peers over the iPad mini for approximately 1 ½ to 2 hours (called Healthy Living Connections) before the study concludes.~On the iPad mini screen during the placebo control group clinics, subjects will be able to see professionals and peers all at the same time and they will be able to see them in their home. This group will also receive one electronic prompt about healthy activities as a comparison control to the intervention group."
3307838|NCT01900301|Experimental|Scopolamine .4mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3307839|NCT01900301|Placebo Comparator|Intranasal placebo|Participants will be randomized to a placebo, administered via nasal drops, prior to each session of exposure therapy
3307840|NCT01900301|Experimental|Scopolamine .5mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3307841|NCT01900301|Experimental|Scopolamine .6mg|Participants will be randomized to either .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
3307842|NCT01900327|Experimental|neoadj. Treatment|Neoadjuvant CRT with weekly Gemcitabine neoadjuvant 300mg/m2 for 6 weeks combined with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions will be followed by classical or pylorus-preserving partial pancreato-duodenectomy (PD) and adjuvant chemotherapy (CTx), preferentially using Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
3307843|NCT01900327|Active Comparator|Upfront Surgery|Upfront PD followed by adjuvant CTx, preferentially with Gemcitabine adjuvant (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle).
3307844|NCT01900340|Placebo Comparator|iv saline, intraduodenal saline|intravenous infusion of saline plus intraduodenal administration of saline
3307845|NCT01900340|Active Comparator|IV exendin(9-39) plus intraduodenal (ID) saline|intravenous infusion of exendin(9-39) plus intraduodenal administration of saline
3307846|NCT01900340|Placebo Comparator|IV saline, intraduodenal nutrient|intravenous infusion of saline plus intraduodenal administration of nutrient
3307847|NCT01900340|Active Comparator|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
3307848|NCT01900353|Active Comparator|horizontal brushing method|brushing methods
3307849|NCT01900353|Active Comparator|Vertical brushing method|brushing methods
3307850|NCT01900366||Obese subjects for fat biopsy|10 patients recruited during fat biopsies for sample collection
3307851|NCT01900366||Lean controls for fat biopsy|5 Lean controls will be recruited
3307852|NCT01900379|Experimental|OSA/CPAP|OSA patients intervention : CPAP treatment
3307853|NCT01900379|Sham Comparator|OSA/sham CPAP|OSA patients intervention : Sham CPAP treatment
3307854|NCT01900379|No Intervention|control group|Patients without any apnea syndrome
3307855|NCT01900405||Dexmedetomidine|All children undergoing
3307856|NCT01900418|Active Comparator|Walking|Walk with Ease
3307857|NCT01900418|No Intervention|Wait list control|Wait list control receiving the active intervention 6 weeks later.
3307858|NCT01900457|Active Comparator|Volunteer healthy|healthy volunteers
3307859|NCT01900457|Experimental|patients|vestibular defective patients
3307860|NCT01900470|Experimental|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT CHWs conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
3307861|NCT01900470|No Intervention|Usual Primary Care|Patients will be encouraged to make follow-up appointments as needed with their primary care clinic for support towards their health goals. During these appointments, clinicians will help patients determine progress made on existing proximal goals, adjust goals based on self-efficacy, and help patients to create new proximal goals as needed. They will also work with PCPs to adjust medications when appropriate, provide health behavior education and make referrals to community-based services based on patient need.
3307862|NCT01900483||pre bariatric surgery|
3307863|NCT01900483||post bariatric surgery|
3307864|NCT01900496|Experimental|Brentuximab vedotin & Rituximab|"Brentuximab vedotin:~Will be administered at 1.8 mg/kg IV over 30 minutes is given for up to 10 doses (cycles), with a cycle length of 21 days. Brentuximab vedotin is first given on day 1 of cycles 1, 2, 3, and 4 as a single agent (weeks 0, 3, 6, and 9, respectively). Four cycles are chosen because of the 12-week median time to CR in the pivotal phase 2 trial of brentuximab vedotin after autologous BMT for HL.~Brentuximab vedotin will be administered with Rituximab at 375 mg/m2 IV is given for up to 8 induction doses: day 1 of week 6, 7, 8, and 9; day 1 of week 12, 15, 18 and 21. This is followed by rituximab maintenance (375 mg/m2 IV once every 3 months x 2 doses) to complete a ~ 1 year total course of therapy."
3307865|NCT01900509|Experimental|Treatment|"All participants who meet eligibility for this study will follow the same treatment regimen.~INTERVENTIONS: bendamustine, clofarabine, etoposide (or etoposide phosphate), dexamethasone."
3307866|NCT01900522|Experimental|Multiple Rising Dose (MRD) Phase: Ascending ITI-214 Doses|ITI-214 Doses (A, B, C, D, matching placebo), solution, orally, once daily for 14 days.
3307867|NCT01900522|Experimental|Neuroimaging Phase: ITI-214 Doses|ITI-214 (E,F, G, H, matching Placebo) Oral solution, once daily for 7 days in 3 periods with placebo and two of the ITI-214 Doses (E, F, G and H) in a cross-over fashion with minimum 7 days washout between periods
3307868|NCT01900548|Experimental|Whey protein (HPHL)|Whey protein supplementation and resistance training for four month.
3307869|NCT01900548|Experimental|Soy protein (HPLL)|Soy protein supplementation and resistance training for four month.
3307870|NCT01900548|Placebo Comparator|Placebo (P)|Maltodextrin supplementation and resistance training for four month.
3307871|NCT01900587|Experimental|Tapentadol Extended release (ER) TRF then tapentadol ER PR2|Single dose of tapentadol ER 50 milligram (mg), tamper-resistant formulation (TRF) tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, prolonged released (PR2) tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
3307872|NCT01900587|Experimental|Tapentadol ER PR2 then tapentadol ER TRF|Single dose of tapentadol ER 50 milligram (mg), PR2 tablet will be administered under fasted condition in first treatment period; after that in second treatment period, single-dose of tapentadol ER 50 mg, TRF tablet will be administered under fasted condition. A washout period of 7 to 14 days will be maintained between each treatment period.
3307873|NCT01900600|Placebo Comparator|Placebo|Placebo
3307874|NCT01900600|Active Comparator|Canakinumab 50 mg quarterly|Canakinumab 50 mg quarterly
3307875|NCT01900600|Active Comparator|Canakinumab 150 mg quarterly|Canakinumab 150 mg quarterly
3307876|NCT01900600|Active Comparator|Canakinumab 300 mg quarterly|Canakinumab 300 mg quarterly
3307877|NCT01900613|Experimental|Intervention|Niños Sanos Familia Sana consists of CBPR developed nutrition education and economic vouchers for fruit and vegetable purchase in Firebaugh supermarket
3307878|NCT01900613|Active Comparator|Comparison|Comparison community of San Joaquin
3307879|NCT01900639|Active Comparator|aspirin on awakening|intake of 80 acetylsalicylic acid on awakening for 2 weeks
3307880|NCT01900639|Experimental|aspirin at bedtime|intake of 80mg acetylsalicylic acis at bedtime
3307881|NCT01900678|Experimental|VytronUS Ablation System|Treatment with the VytronUS Ablation System.
3307882|NCT01900691|Experimental|Evolution® Esophageal Stent|
3307883|NCT01900717|Active Comparator|chimiotherapy alone|"LV5FU2 simplified,~5-fluorouracil/leucovorin with oxaliplatin 4 (FOLFOX) simplified,~fluorouracil, leucovorin, and irinotecan(FOLFIRI) modified."
3307884|NCT01900717|Experimental|chemiotherapy + bevacizumab 5 mg/kg/ 2 weeks|"LV5FU2 simplified,~FOLFOX 4 simplified,~FOLFIRI modified.~Bevacizumab 5 mg/kg/ 2 weeks"
3307885|NCT01900743|Experimental|Arm A|Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.
3307886|NCT01900743|Placebo Comparator|Arm B|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
3307887|NCT01900756|Active Comparator|Behavioral|"Pre-appointment phone text~In-clinic educational video~Patient report card~Post-clinic phone text~Outpatient stroke registry"
3307888|NCT01900756|No Intervention|Standard care|Routine and customary management.
3307889|NCT01900769|Experimental|Blood Volume Dilution|
3307890|NCT01900782|Experimental|Dosing Regimen 1|Subcutaneous injection
3307891|NCT01900782|Active Comparator|Active Comparator|Subcutaneous injection
3307892|NCT01900782|Placebo Comparator|Placebo|Subcutaneous injection
3307893|NCT01900782|Experimental|Dosing Regimen 2|Subcutaneous injection
3307894|NCT01900795|Experimental|V117957|
3307895|NCT01900795|Active Comparator|Ibuprofen|
3307896|NCT01900795|Placebo Comparator|Placebo|
3307897|NCT01900808||Patients with chronic liver disease|
3307898|NCT01900821||Women|All women having mammograms
3307899|NCT01900834||All participants|
3307900|NCT01900847|Active Comparator|Morphine and placebo|Patient's will receive morphine during the usual course of their emergency department care and will receive a saline in a volume equivalent to the ketamine administered in the experimental arm of the stuy
3307901|NCT01900847|Experimental|Morphine and Ketamine|Patient's will receive a 0.3mg/kg dose of ketamine in addition to morphine given in the usual course of emergency department care
3307902|NCT01900860|Active Comparator|vitamin D 10,000 IU|Subjects in this arm receive 10,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3307903|NCT01900860|Active Comparator|Vitamin D 4000 IU|Subjects in this arm receive 4,000 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3307904|NCT01900860|Active Comparator|Vitamin D 400 IU|Subjects in this arm receive 400 IU Vitamin D p.o. (as 5 drops of a blinded vitamin D solution) per day. Duration: 3 years
3307905|NCT01900873|Experimental|Inspiratory Muscle Strength Training|High intensity inspiratory muscle training
3307906|NCT01900873|Sham Comparator|Inspiratory Muscle Endurance Training|Sham inspiratory muscle training at low intensity
3307907|NCT01900886||Pegasys, injection subcutaneous|Hepatitis C Virus (HCV) patients monoinfected or coinfected, all genotypes, treatment naive to Peginterferon alfa-2a and Ribavirin (RBV)
3307908|NCT01900912|Experimental|CLTS communities|Assigned to a community led total sanitation (CLTS) intervention, carried out by the government with support from Unicef (n=60 communities). The CLTS intervention includes a triggering session facilitated by the government to encourage community members to build their own latrines and stop open defecation. Regular monitoring is conducted by government program staff until the community is declared open defecation free.
3307909|NCT01900912|No Intervention|Rural communities|No intervention will be delivered (n=61 communities)
3307910|NCT01900925|Active Comparator|Low back treatment only (pragmatic)|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
3307911|NCT01900925|Experimental|LBP treatment and Hip treatment|Group two will receive the same pragmatically applied, guideline-oriented treatment that is recommended from group 1. In addition, group 2 will receive prescriptive hip exercises that include 1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge, and the manual therapy treatment techniques of; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone.26 (See Appendix A for photos of the techniques and descriptions)
3307912|NCT01900938|Active Comparator|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
3307913|NCT01900938|Active Comparator|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
3307914|NCT01900951|Experimental|Temozolomide|"Patients in the study will receive the following for the duration of the study:First-line chemotherapy according to the NCCN guidelines. The study will consist of 21-day cycles, to a maximum of 6 cycles of therapy for the first-line chemotherapy. After first-line treatment, temozolomide will be given alone as maintenance therapy in all patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.~Re-staging will be performed every 2 cycles (every 8 weeks) during the study"
3307915|NCT01900964|Active Comparator|PTFE membrane|A non-resorbable PTFE (polytetrafluoroethylene) membrane will be used as a positive control treatment.
3307916|NCT01900964|Experimental|Collagen membrane|A resorbable collagen membrane will be used in the test group.
3307917|NCT01900977|Active Comparator|Arm A Universal Testing w/Immediate ART|
3307918|NCT01900977|Active Comparator|Arm B ART according to National Guidelines|
3307919|NCT01900977|Other|Standard of Care|"Includes:~Strengthening of HIV testing and ART services according to national guidelines at health facilities and other venues; Strengthening of male circumcision and PMTCT services available at health facilities and other venues in the community; and Treatment of STIs and provision of condoms at health facilities and other venues in the community."
3307920|NCT01900990|Experimental|Noninvasive ventilation weaning|Patients in this group were weaned by noninvasive ventilation
3307921|NCT01900990|No Intervention|Conventional weaning|Patients in this group were weaned by conventional stratiges.
3307922|NCT01901003|Placebo Comparator|placebo group|placebo
3307923|NCT01901003|Active Comparator|no premedication group|no premedication
3307924|NCT01901003|Experimental|Lorazepam group|lorazepam
3307925|NCT01901016|Experimental|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
3307926|NCT01901016|Experimental|Schultz's autogenic training|Schultz's autogenic training
3307927|NCT01901016|No Intervention|control|The CG continued to receive their standard care. After data collection at the six-month follow-up, the CG participants were invited to attend one of two relaxation interventions.
3307928|NCT01901029||men of floating population|males who live in Dongguan more than 6 months and without residence cards
3307929|NCT01901029||men of non-floating population|males who live in Dongguan more than 6 months and with residence cards
3307930|NCT01901042|Experimental|Symbiotic|Patients in this group received sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
3307931|NCT01901042|Placebo Comparator|Maltodextrin|patients in this group received sachets five grams of maltodextrin per sachet with identical casing and identical aspect to the product of the other arm group, and were instructed to proceed in the same way as those of the symbiotic group
3307932|NCT01901068||MonoMax|Elective primary laparotomy
3307933|NCT01901081|Experimental|Prosthetic Training with IMES prosthesis|
3307934|NCT01901107||Kiklin group|
3307935|NCT01901120||Betanis|the usual adult dosage of mirabegron once daily after a meal
3307936|NCT01901133|Experimental|A: Mild hepatic impairment subjects + control|
3307937|NCT01901133|Experimental|B: Moderate hepatic impairment subjects + control|
3307938|NCT01901159|Experimental|RO4995819 capsule|
3307939|NCT01901159|Experimental|RO4995819 tablet|
3307940|NCT01901172|Experimental|Extension|
3307941|NCT01901172|Experimental|Part 1: Drug-drug interaction|
3307942|NCT01901172|Experimental|Part 2: Relative bioavailability|
3307943|NCT01901172|Experimental|Part 3: Food effect|
3307944|NCT01901198|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
3307945|NCT01901198|Active Comparator|Pegasys|Peginterferon 180 mcg single dose S.C.
3307946|NCT01901237|Other|Hatha Yoga Program|Single-arm pilot study of a 7-week home/hospice-based Hatha yoga program for adolescent and young adults with non-curative cancer.
3307947|NCT01901263||patient with alzheimer's disease|"Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)~Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate"
3307948|NCT01901276|Experimental|Omeprazole 40 mg bid x 4-8 weeks|See study description for further details.
3307949|NCT01901315|Experimental|Online consultation|Monthly video consultations with psychiatrist
3307950|NCT01901315|Experimental|Face-to-face consultation|Monthly face-to-face consultations with psychiatrist
3307951|NCT01901354|Active Comparator|Low-tidal-volume ventilation|Subjects will be ventilated with a goal tidal volume of 6 cc/kg predicted body weight (PBW), a goal plateau pressure of <30 cm H2O, and a goal respiratory rate of 6-35 bpm to achieve a goal arterial pH of 7.30 to 7.45. Positive end-expiratory pressure is set as per the ARDSNet Positive end-expiratory pressure table
3307952|NCT01901354|Active Comparator|Airway pressure release ventilation (APRV)|"Airway Pressure Release Ventilation (APRV) is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing throughout the respiratory cycle.~Initial settings: Pressure high will be set initially to equal the plateau pressure on baseline ARDSNet settings. Time low will be set to 0.5-0.8 seconds to achieve an end expiratory flow 25-50% of peak expiratory flow, and Time high will be set to obtain a set respiratory rate 60%-70% that of baseline settings. Time high will be adjusted to achieve similar continuous exhaled carbon dioxide levels as baseline ARDSNet settings. Low pressure will be set at <5 cm H20."
3307953|NCT01901367|Experimental|Arm I (intervention)|Patients receive standard of care individualized diet and exercise plan and monthly booster follow-up sessions from the nutritionist and exercise physiologist and weekly phone counseling with a trained health coach to address barriers to improve plan adherence.
3307954|NCT01901367|No Intervention|Arm II (control)|Patients receive standard of care individualized diet and exercise plan
3307955|NCT01901380||extensively hydrolysed casein formula + LGG|children receiving extensively hydrolysed casein formula plus Lactobacillus GG
3307956|NCT01901380||other formulas|children receiving formulas without supplementation of Lactobacillus GG
3307957|NCT01901406||ERM|idiopathic epiretinal membrane patients
3307958|NCT01901432|Experimental|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A.~The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
3307959|NCT01901445|Experimental|Educational action group|
3307960|NCT01901445|No Intervention|Control group|
3307961|NCT01901458|Experimental|IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® IDL-Set in combination with the Spectra Optia® cell separator and the WBC-D program
3307962|NCT01901458|Active Comparator|MNC-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® Collection Set in combination with the Spectra Optia® cell separator and the MNC program
3307963|NCT01901471|Experimental|CsA Group|
3307964|NCT01901471|Placebo Comparator|Placebo group|
3307965|NCT01901484|Active Comparator|Drug: Praziquantel|Praziquantel 40mg/Kg - single dose
3307966|NCT01901484|Active Comparator|Praziquantel|double dose
3307967|NCT01901497|Experimental|Solo nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Solo nebulizer associated with a bilevel ventilator
3307968|NCT01901497|Experimental|Pro nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb Pro nebulizer associated with a bilevel ventilator
3307969|NCT01901497|Experimental|NIVO nebulizer|Amikacin (500 mg/4 mL) administered with an Aerogen AeroNeb NIVO nebulizer associated with a bilevel ventilator
3307970|NCT01901510|Active Comparator|chromoendoscopy|The intervention arm will have Indigo carmine added to the colonic preperation to perform chromoendoscopy
3307971|NCT01901510|Other|Control|The control arm will have minimal Indigo carmine added to the colonic prep in a concentration which will not be enough to perform chromoendoscopy
3307972|NCT01901523|Experimental|Provision of information|Reporting of discrepancy to journal
3307973|NCT01901536|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
3307974|NCT01901536|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
3307975|NCT01901549|Active Comparator|PCI+Renal denervation|
3307976|NCT01901549|Active Comparator|PCI alone|
3307977|NCT01901562|Experimental|Ductoscopic papillomectomy|Ductoscopic papillomectomy to treat pathological nipple discharge
3307978|NCT01901601|Experimental|LALAK|laser-assisted lamellar anterior keratoplasty. Optical Coherence Tomography, femtosecond laser, topical anesthesia, and Retrobulbar Block or General Anesthesia will be used.
3307979|NCT01901601|Active Comparator|IEK|Intralase-enabled keratoplasty. Femtosecond laser and Retrobulbar Block or General Anesthesia will be used.
3307980|NCT01901627||Adalimumab|Chinese adult patients with a diagnosis of AS who meet the requirements per the local label for treatment with adalimumab.
3307981|NCT01901640|Experimental|DA-8159|Udenafil(The study had one arm.)
3307982|NCT01901666|Experimental|Growth hormone deficient group|0.3mg/kg/week GH in seven divided doses will be given subcutaneously for one year.
3307983|NCT01901692|Experimental|TACE+External beam RT|Transarterial chemoembolization plus external beam radiation therapy
3307984|NCT01901692|Active Comparator|Sorafenib|Sorafenib 800 mg/day orally
3307985|NCT01901705|Active Comparator|Indigo|The Indigo naturalis ointment will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
3307986|NCT01901705|Placebo Comparator|Placebo|The Placebo will be provided and patients are instructed to use it twice daily for 8 weeks or achieve completely skin clearing whichever comes first.
3307987|NCT01901718||Subsys|Cancer patients experiencing breakthrough pain.
3307988|NCT01901731|Experimental|Embolisation of pelvic veins & treatment of leg varicose veins|Transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg varicose veins
3307989|NCT01901731|Active Comparator|Endovenous treatment of leg varicose veins alone|Endovenous treatment of legs varicose veins only
3307990|NCT01901744|Experimental|Patients undergoing cataract surgery|
3307991|NCT01901757|Experimental|HCP1201, Fasted followed by fed|HCP1201 dosing in the fasted state followed by fed dosing
3307992|NCT01901757|Experimental|HCP1201, Fed followed by fasted|HCP1201 dosing in the fed state followed by fasted dosing
3307993|NCT01901770|Experimental|Arm I-HPV vaccine education|"The educational intervention is that parents and providers receive materials about HPV by mail including HPV/ cervical cancer videos and brochures, fact sheets, HPV/cervical cancer resource lists. Clinics receive posters, brochures, tabletop/reminder cards, resource lists, newsletters, and invitation to be vaccinated letters for parents."
3307994|NCT01901770|Active Comparator|Arm II- Flu vaccine education|The educational intervention is that parents and providers receive materials about Flu by mail including Flu brochures, fact sheets, Flu resource lists. Clinics receive posters and brochures.
3307995|NCT01901783|Active Comparator|With primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will be primarily closed.
3448477|NCT04064151|Experimental|"My Guide (psychoeducation & self-management program)"|Smartphone-based program plus standard clinical care.
3307996|NCT01901783|Experimental|Without primary closure|The ridge augmentation graft will be covered with a barrier membrane and the soft tissue will not be primarily closed.
3307997|NCT01901796|Experimental|Screening and CBT|Screening and Cognitive Behavioral Therapy. The intervention group will be screened and if they need criteria they will complete the 6, 30-minute online, interactive CBT modules over 6 weeks.
3307998|NCT01901796|No Intervention|Usual care|Usual prenatal care
3307999|NCT01901822|Active Comparator|Sutured separately|The soft tissue and the allograft will each be sutured separately using a continuous sling suture.
3308000|NCT01901822|Experimental|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
3308001|NCT01901835|Experimental|Arm I (humorous followed by non-humorous movies)|Participants are provided headphones and a tablet and choose among a selection of humorous movies. Upon the third course of chemotherapy, participants are provided a selection of non-humorous movies.
3308002|NCT01901835|Experimental|Arm II (non-humorous followed by humorous movies)|Participants are provided headphones and a tablet and choose among a selection of non-humorous movies. Upon the third course of chemotherapy, participants are provided a selection of humorous movies.
3308003|NCT01901861|Active Comparator|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
3308004|NCT01901861|Placebo Comparator|Placebo|Placebo is given before meal ingestion
3308005|NCT01901887|Experimental|Study Juice|"3,300 mg of Omega-3 HUFAs per day for 6 months~Other names: none"
3308006|NCT01901887|Placebo Comparator|Placebo Juice|"3,300 mg of macadamia nut oil per day for 6 months~Other names: none"
3308007|NCT01901913|Experimental|MD-bolus calculator for pre meal bolus|closed loop session with MD-bolus calculator for pre-meal bolus.
3308008|NCT01901913|Active Comparator|No MD-bolus calculator for pre-meal bolus|closed loop session without MD-bolus calculator for pre-meal bolus
3308009|NCT01901926|Active Comparator|Periodontal Treatment|"Periodontal Treatment in the form of Full mouth scaling and root planning will be given at one time only i.e. at baseline after full mouth dental checkup.~Checkup will be repeated at 3, 6 & 9 month interval along with HbA1C levels"
3308010|NCT01901926|No Intervention|Non treatment group|this group will only receive detailed dental check ups at the specified time 0, 3, 6 and 9 months respectively and there will be no scaling done. HbA1C levels will be estimated at the above specified times
3308011|NCT01901939|Experimental|exercise|daily bedside tailored low intensity pedaling exercise
3308012|NCT01901952|Active Comparator|Standard of care|
3308013|NCT01901952|Experimental|Intensive education and support|
3308014|NCT01901965|Experimental|NMES|neuromuscular electrical stimulation (NMES) of the quadriceps muscle with Kneehab
3308015|NCT01901965|Experimental|eccentric training|unilateral eccentric resistance exercises
3308016|NCT01901965|Sham Comparator|sham NMES|neuromuscular electrical stimulation of the quadriceps muscle with intensity which causes no visible contraction or displacement of the leg (activation below motor threshold)
3308017|NCT01901978|Experimental|Weight Loss|Caloric restrictive diet
3308018|NCT01901991|Experimental|Radioactive seed localization (RSL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have RSL performed. The radioactive seed is introduced through a gauge needle using standard ultrasound guidance. Once guided to the nonpalpable breast lesion, the seed is deployed into the breast tissue by advancing a stilette in the needle. The exact location is confirmed by mammography. The nonpalpable lesion is located during the operation with a handheld gamma probe, identical to the one used for the sentinel node procedure. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
3308019|NCT01901991|Active Comparator|Wire-guided localization (WGL)|"Patients are randomised for preoperative lesion localization with either radioactive seed localization (RSL) or wire-guided localization (WGL).~In this arm 205 patients will have WGL performed. Guided by ultrasound or mammography a flexible wire is introduced into the breast by the radiologist just before the operation. The tip of the wire must mark the nonpalpable lesion, and correct localization is verified by mammography. The surgeon uses the wire and mammography as a guide during the operation. The surgical specimen is orientated and examined at the Department of Radiology and Pathology in accordance with the existing guidelines of WGL."
3308020|NCT01902017|Experimental|Operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
3308021|NCT01902017|Experimental|Non-operative, Ketotifen|Ketotifen 5mg orally twice per day for 6 weeks.
3308022|NCT01902017|Placebo Comparator|Operative, Placebo|Placebo oral medication twice daily for 6 weeks.
3308023|NCT01902017|Placebo Comparator|Non-operative, Placebo|Placebo oral medication twice daily for 6 weeks.
3308024|NCT01902030||Proven/Probable IA Patients|Case Population
3308025|NCT01902030||possible/No IA Patients|Control population
3308026|NCT01902056|Active Comparator|one layer allograft|One layer allograft as a positive control
3308027|NCT01902056|Experimental|Two layer allograft|Two layer allograft as the test group.
3308028|NCT01902069|Experimental|Phosholean dietary supplement|Subjects in the PhosphoLean group will receive two capsules of PhosphoLEAN orally daily (total of 55 mg of NOPE and 100 mg of EGCG), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
3308029|NCT01902069|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule), one capsule consumed 60 minutes prior to lunch and one capsule 60 minutes prior to dinner.
3308030|NCT01902082|Experimental|Mesenchymal stem cell arm|Patients received one dose of 1x 10^6 allogeneic adipose-derived mesenchymal stem cells/kg body weight intravenously within 48 hours of enrollment.
3308031|NCT01902082|Placebo Comparator|Placebo|Patients received one dose of normal saline.
3308032|NCT01902095|Experimental|Tooth powder (test) arm|Experimental arm: tooth powder
3308033|NCT01902095|Active Comparator|Tooth Paste (control)|Tooth Paste
3308034|NCT01902108|Experimental|Clonidine|Clonidine 150μg added to bupivacaine in a local infiltration before wound incision
3308035|NCT01902108|Active Comparator|Bupivacaine|Bupivacaine 0.25 % alone in the wound infiltration
3308036|NCT01902121|Experimental|TI 30 units (10 unit + 20 unit|Technosphere® Insulin 30 units given as 2 cartridges: one 10 unit cartridge + one 20 unit cartridge
3308037|NCT01902121|Experimental|TI 30 units (30 unit cartridge|Technosphere® Insulin 30 units given as one 30 unit cartridge
3308038|NCT01902147||Elective major abdominal, thoracic, and arthroplasty surgery|All consenting patients scheduled for elective major abdominal, thoracic, and arthroplasty surgery will be followed for 8 weeks after surgery to measure the quality of recovering using the PQRS.
3308039|NCT01902160|Experimental|Treatment (temsirolimus, brentuximab vedotin)|Patients receive temsirolimus IV over 30-60 minutes on days 1 and 8 or days 1, 8, and 15 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
3308040|NCT01902186|Experimental|raltegravir|raltegravir and atazanavir and ritonavir
3308041|NCT01902186|Active Comparator|tenofovir/emtricitabine|tenofovir/emtricitabine and atazanavir and ritonavir
3308042|NCT01902199|Active Comparator|TRAA|participants will be given the active TRAA intervention where landscape images are linked with a push motion, and portrait images linked with a pull motion. Pictures will exclusively be related to smoking.
3308043|NCT01902199|Placebo Comparator|Control|participants will be given a mix of landscape and portrait pictures, equally divided into push or pull. the images will be a mix of smoking related pictures and non smoking pictures.
3308044|NCT01902212|Experimental|Oral Nutritional Supplement|2 servings a day
3308045|NCT01902225|Experimental|Istodax, Doxil|"Istodax; Intravenous; 8-14 mg/m2; Days 1, 8, and 15; over 4 hours~Doxil; Intravenous; 20 mg/m2; Day 1; over 1 hour"
3308046|NCT01902238|Experimental|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol/lipiodol (1:1 mixture), typically 1 to 1.5 ml.
3308047|NCT01902251|Experimental|Enzalutamide tablet|Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks
3308048|NCT01902251|Active Comparator|Enzalutamide capsule|Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks
3308049|NCT01902264|Experimental|EE20/DRSP/L-5-MTHF|
3308050|NCT01902277||Adult critically ill patients|All adult patients treated within study time frame on Intensive Care Units across Norfolk, Suffolk, and Cambridgshire, UK
3308051|NCT01902290|Placebo Comparator|Placebo|Administered by subcutaneous (SC) injections until week 24.
3308052|NCT01902290|Experimental|210 mg brodalumab|Administered by subcutaneous (SC) injections until week 24.
3308053|NCT01902329|Experimental|SGN-CD33A + HMA|SGN-CD33A with hypomethylating agent
3308054|NCT01902329|Experimental|SGN-CD33A Monotherapy|SGN-CD33A
3308055|NCT01902342|Experimental|CES1 gene variant group|Oseltamivir 75 mg 1 cap
3308056|NCT01902342|Experimental|CES1 gene wild type group|Oseltamivir 75 mg 1 cap
3308057|NCT01902355|Experimental|modified Seldinger technique|Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
3308058|NCT01902355|Active Comparator|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
3308059|NCT01902368|Other|screen detected, early diagnosis cohort|Subjects will be informed they have celiac disease and will be started on the gluten free diet.
3308060|NCT01902368|No Intervention|screen detected, delayed diagnosis cohort|Subjects will not be told they have celiac disease and will not start the gluten free diet.
3308061|NCT01902381|Experimental|Treatment (6, 8-bis(benzylthio) octanoic acid)|Patients receive treatment 6,8-bis(benzylthio)octanoic acid IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3308062|NCT01902394|Experimental|Whole grain rich diet|Participants in the whole grain (WG) group will receive a diet providing 100% of energy requirements in a diet rich in whole grains.
3308063|NCT01902394|Placebo Comparator|Refined grain rich diet|Participants in the refined grain (RG) group will receive a diet providing 100% of energy requirements in a diet rich in refined grains.
3308064|NCT01902394|No Intervention|Negative control|Subjects randomized to the negative control group will consume their own usual diet (i.e. not receive foods and beverages from the study).
3308065|NCT01902407||Diagnostic MRI and CT scan of the airway|"All patients seen at CCHMC (up to 90 years of age) who are scheduled to have a clinical sleep MRI or CT scan for their OSA airway or lung disease.~Scheduled for both Sleep diagnostic tests (Sleep MRI and CT scans)."
3308066|NCT01902420||patients with acromegaly|patients with acromegaly caused by a growth hormone secreting pituitary adenoma
3308067|NCT01902420||healthy control|healthy volunteers without a personal or family history of pituitary adenoma
3308068|NCT01902433|Experimental|Astym|A form of soft tissue mobilization using instruments
3308069|NCT01902433|Active Comparator|Eccentric Exercise|Eccentric exercise is a form of exercise where the benefit comes from applying a controlled lengthening stress to the muscle and tendon.
3308070|NCT01902446||Chlorhexidine gluconate|Intubated subjects transported by one air service will be treated with 5 mL chlorhexidine gluconate 0.12% applied for at least 30 seconds during helicopter transport.
3308071|NCT01902446||Normal saline (placebo)|Intubated subjects assigned transported by another air service will not have any additional treatment (in addition to usual care) during helicopter transport.
3308072|NCT01902472||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender) who seroconvert while taking FTC/TDF for PrEP
3308073|NCT01902485|Active Comparator|Quickstart|Immediate start
3308074|NCT01902485|Active Comparator|Afterstart|Delayed start
3308075|NCT01902498|Experimental|Aspirin 162mg twice daily|Patients will receive 162mg twice daily during the postoperative period, until day 7 postop or the end of hospitalization.
3308076|NCT01902498|Active Comparator|Aspirin 325mg daily|Patients will receive 325mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3308077|NCT01902498|Active Comparator|Aspirin 81mg daily|Patients will receive 81mg daily during the postoperative period, until day 7 postop or the end of hospitalization.
3308078|NCT01902511|Experimental|G-CSF + Erythropoietin|
3308079|NCT01902511|Active Comparator|G-CSF|
3308080|NCT01902524|Experimental|Fentanyl-TTS|Study drug administered in a form of one patch, either 21.0 cm2 or 10.5 cm2.
3308081|NCT01902537||Participants With Constipation|Participants with constipation receiving prucalopride will be observed for for the health related quality of life (QoL).
3308082|NCT01902550|Experimental|Metoprolol plus placebo then Metoprolol plus JNJ-54452840|Metoprolol tartrate immediate-release (metoprolol IR) will be administered as single oral dose of 100 milligram (mg) tablet or capsule. After two hours, placebo (normal saline) will be administered intravenously over 1 minute on Day 1.
3308083|NCT01902550|Experimental|Metoprolol plus JNJ-54452840 then Metoprolol plus placebo|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule. After two hours, JNJ-54452840 (12 milliliter [ml] solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
3308084|NCT01902589||Patients with Helicobacter pilorii in biopsy|Patients with Helicobacter pylori in biopsy, cultures will be obtained and subsequently sensitivity to antibiotics studied.
3308085|NCT01902615||Cohort|
3308086|NCT01902641|Active Comparator|Succinylcholine|Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.
3308087|NCT01902641|Active Comparator|Rocuronium/Sugammadex|Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)
3308088|NCT01902641|Active Comparator|Rocuronium|Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.
3308089|NCT01902654||Knee osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had knee osteoarthritis.
3308090|NCT01902654||Hand osteoarthritis|Patients over 50 years who presented to an outpatient rheumatology for 1 year and who had hand osteoarthritis.
3308091|NCT01902654||Soft tissue disease|All patients over 50 years who presented during the same period of time of other cohorts, to an outpatient rheumatology and who had soft tissue disease with no other rheumatic condition.
3308092|NCT01902667||Curative intent surgery alone|Patients with retroperitoneal sarcoma randomised into surgery alone arm.
3308093|NCT01902667||Pre-operative radiotherapy plus surgery|Patients with retroperitoneal sarcoma randomised to Arm 2: pre-operative radiotherapy plus surgery.
3308094|NCT01902680|Experimental|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
3308095|NCT01902693||HIV & chemotherapy|"Participants will be aged ≥ 18 years, aware of their HIV status and the diagnosis of malignancy, have a plasma viral load of < 50 HIV-1 RNA copies/ml (on suppressive HAART) at enrolment and be designated to receive cytotoxic chemotherapy including one or more of the following agents: R-CHOP, ABVD, Liposomal doxorubicin (Caelyx) or liposomal daunorubicin (Daunoxome) or Paclitaxel.~There is no intervention for this study. Blood samples will be taken and if available from routine care surplus cerebrospinal fluid."
3308096|NCT01902719|Experimental|Community Health Worker (CHW) Intervention|Participants randomized to this arm will receive the Community Health Worker Intervention that will include training in the use of home blood pressure machine, education on diet and exercise, and one-on-one support to assist with overcoming barriers to hypertension control (e.g., accessing healthcare, social and community services).
3308097|NCT01902719|Experimental|CHW Intervention and Communication Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and a communication skills training to partner with their physician providers in a way that encourages their greater involvement and shared decision-making with their physicians about hypertension care.
3308098|NCT01902719|Experimental|CHW and Problem Solving Skills Training|Participants randomized to this arm will receive the Community Health Worker Intervention and the Problem Solving Skills Training Intervention, a 9-week peer based self-management intervention to help patients improve their hypertension self-management by learning and employing skills to overcome their self-identified barriers to self-management.
3308099|NCT01902732|Other|Implantation of valves (IBV)|Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
3308100|NCT01902745|Active Comparator|Fatigue Reduction Diet|"The FRD maintains a participant on a diet with their typical caloric intake and replaces some of their calories with the following foods on a daily basis; whole grains, vegetables (one leafy green, one tomato, and on yellow/orange), fruit (one high in vitamin C), fatty fish and nuts and/or seeds.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
3308101|NCT01902745|Active Comparator|General Health Curriculum|"Counseling sessions on oral health, healthy eyesight, over-the-counter drug disposal, skin and hair health, cell phone and health, hearing loss, colorectal cancer screening, and preventing colds and flu.~A social cognitive theory intervention method will take place that motivates the participant to change their behavior and lifestyle for overall well being."
3308102|NCT01902771|Experimental|DC Vaccine + Lysate|"Leukapheresis: Baseline, post-surgery;~Dendritic Cell Vaccine (DC Vaccine): Post-Leukapheresis, administered intradermally once weekly via intradermal injection, for 4 weeks for a total of four vaccinations;~Tumor Lysate (Lysate): Post-DC Vaccine therapy. Administered intradermally during weeks 8, 12, 16, and 28;~Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations."
3308103|NCT01902784|Experimental|Storytelling Interview|"Participants assigned to receive the intervention will participate in an interview with a trained interventionist who will facilitate the telling of their 'story' - the personal experience they went through as a surrogate decision-maker for a loved one in the intensive care unit (ICU), who subsequently died after decisions were made to limit life-sustaining treatments (LST).~These participants will be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient)."
3381196|NCT03879109|Experimental|Arm A: Induction Chemotherapy followed by Pelvic reirradiation|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)~Protocol of reirradiation consists in conformational intensity modulated external irradiation, delivering a 30.6 Gy dose (1.8 Gy/day), with concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week."
3448478|NCT04064151|No Intervention|Standard Medical Care|Standard clinical care with no smartphone intervention.
3308104|NCT01902784|No Intervention|Monitoring of well-being|Participants assigned to the Monitoring of well-being group will receive follow up phone calls from study staff and be evaluated with questionnaires at baseline, 3 months, and 6 months after the death of their loved one (ICU patient).
3308105|NCT01902797|Experimental|Household|In each camp, the camp residences are divided into different sections (as clusters for sampling) by camp registration. In the first stage, sections are selected using Population-proportion-to size (PPS) method. In the second stage, households are randomly selected from the household list in each section provided by NGO and local committee. When a household is not responding, a nearest household on the north will be used as replacement. All family members and overnight guests aged above 5 years in the selected household will be invited for venous blood sample (2 ml); for children aged 1-5 years old, the blood sample (100 microL) will be obtained by finger prick; children younger than 1 year old are excluded. The head of household will be invited for a short questionnaire.
3308106|NCT01902810|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization
3308107|NCT01902810|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization
3308108|NCT01902823|No Intervention|No Nurse Navigator Services|
3308109|NCT01902823|Experimental|Services from a Nurse Navigator|
3308110|NCT01902836|Experimental|Conventional Treatment plus DLE|"Conventional treatment plus DLE~Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;~Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month."
3308111|NCT01902836|Placebo Comparator|Conventional treatment plus placebo|"Conventional treatment plus placebo:~oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month."
3308112|NCT01902849||Group 1 - TIVA-TCI|"include 35 patients with colorectal cancer undergoing surgery~anaesthesia is induced and maintained with total intravenous target-controlled infusion ( TIVA-TCI) of propofol and remifentanil.~for propofol initial target plasma concentration (Cp) is set to 4 micrograms/ml (modified Marsh model)( Base Primea™, Fresenius, France) and then adjusted in steps 0.2 micrograms/ml to maintain the BIS values between 40-55 during surgery.~for Remifentanil initial Cp is set at induction at 4 ng/ml and then the Cp is maintained between 3-8 ng/mL(increments of 0.5 ng/ml in case of inadequate anesthesia).~intervention:blood sampling for IL measurement"
3308113|NCT01902849||Group II- ISOFLURANE|"include 35 patients with colorectal cancer undergoing surgery~anesthesia is induced with propofol bolus 1,5-2 mg/kg and remifentanil TCI mode (Minto model) (Base Primea™, Fresenius, France) with an initial Cp 4 ng/ml~maintenance of anesthesia is achieved with isoflurane 1-1.5 MAC in order to maintain the BIS value between the values of 40-55 and remifentanil TCI with Cp between 3-8 ng/mL (increments of 0.5 ng/ml in case of inadequate anesthesia)~intervention:blood sampling for IL measurement"
3308114|NCT01902862|Experimental|Bortezomib plus rituximab|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3. Rituximab will be administered as intravenous infusion as 375 mg per m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
3308115|NCT01902875||TP regimen + CIK group|This group are treated with Preconditioning Chemotherapy （Paclitaxel + Cisplatin） Combined with Cytokine Induced Killer Cell Immunotherapy （CIK cell therapy）.
3308116|NCT01902875||TP regimen group|This group are treated with Chemotherapy （Paclitaxel + Cisplatin） only.
3308117|NCT01902914|Experimental|Hearing Aids, Model P02|A body-worn, local made, digital hearing aids Hearing Aids evaluation
3308118|NCT01902914|Active Comparator|Other hearing aids|Other Hearing Aids, Hearing Aids Evaluation
3308119|NCT01902927|Experimental|COPD patients|COPD patients will perform a constant workrate treadmill exercise test until exhaustion with positve/neutral/negative visual distraction images during the exercise test assigned in a randomized order
3308120|NCT01902940||Natural History|Assessment of natural history in IBM and CCFDN
3308121|NCT01902979|Experimental|Lifestyle intervention|In Weeks 1 and 6, people in the intervention group will meet with a Registered Dietitian and an Exercise Physiologist for personalized sessions. They will receive a pedometer and instructions on how to log in to the e-health site (https://sspanli.mtroyal.ca). They will wear the pedometer daily and log in to the website each week for a nutrition education session, a weekly step goal, and tips.
3308122|NCT01902979|No Intervention|Usual Care|
3308123|NCT01902992|Experimental|Depiquick® Birch|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
3308124|NCT01902992|Placebo Comparator|Placebo|At the screening visit (Visit 1), patients will be instructed how to complete the eDiary. Eligible patients will return for visit 2 as soon as they experience significant allergic symptoms. Significant allergic symptoms are defined by a symptom score ≥ 2. If the patients' eligibility has been confirmed according to inclusion/exclusion criteria checklist, randomization to one of the 2 treatment arms will be conducted. Patients will receive two consecutive subcutaneous injections of study medication (0,2 and 0,3 ml) with a time lag of ≥ 30 minutes. Patients return to the study site in weekly intervals for visit 3, visit 4, visit 5, visit 6, and visit 7 to receive study medication injections (0,5 ml each). If treatment is completed before the end of the tree pollen season, patients will be followed-up by telephone calls every 4 weeks until the end of the tree pollen season. The study completion visit will take place 4 weeks after the end of the tree pollen season.
3308125|NCT01903018|Experimental|P276-00|
3308126|NCT01903044|Experimental|BM-MNC injection|Injection of autologous bone marrow-derived mononuclear cells
3308127|NCT01903057|Experimental|Combination treatment|"Combination treatment with azithromycin, ivermectin and albendazole on day 1, followed by placebo on day 8~Placebo has same appearance and dosing as azithromycin."
3308128|NCT01903057|Placebo Comparator|Control (Standard of Care)|"Standard treatment with placebo, ivermectin and albendazole on day 1, followed by azithromycin on day 8~Placebo has same appearance and dosing as azithromycin."
3308129|NCT01903070|Experimental|Linagliptin in TD2 subjects|Linagliptin in TD2 subjects with normal renal function
3308130|NCT01903070|Experimental|Linagliptin in TD2 subjects with impaired renal function|Linagliptin in TD2 subjects with impaired renal function
3308131|NCT01903083|Experimental|Immunochemoradiotherapy|Immunotherapy with oral tadalafil daily; three doses of chemotherapy with IV Gemcitabine in 21-day cycles for up to 4 cycles; three fractions of external beam radiation to the pancreas and and regional lymph nodes; pancreaticoduodenectomy (surgical resection) for eligible patients.
3308132|NCT01903096|Experimental|Cognitive Behavioral Treatment (CBT)|Cognitive Behavioral Treatment. Seven 90-minute sessions of group treatment along 24 weeks.
3308133|NCT01903096|Active Comparator|Treatment-As-Usual (TAU)|Primary Care Treatment As Usual
3308134|NCT01903109|Active Comparator|Cevimeline first, the Evoxac|Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
3308135|NCT01903109|Active Comparator|First Evoxac, then cevimeline|Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
3308136|NCT01903122|Active Comparator|Cevimeline|Single Dose 30 mg Capsule
3308137|NCT01903122|Active Comparator|Evoxac|Single dose 30 mg capsule
3308138|NCT01903135|Other|[HCO3-] >= 27 mmol/L (Group 1)|All obese patients with plasmatic[HCO3-] >= 27 mmol/L will be addressed to a pneumologist. The pneumology investigations will establish(or not) the diagnosis of OHS
3308139|NCT01903135|Other|[HCO3-]< 27mmol/L+pneumologist (Group 2)|Among obese patients with serum [HCO3-]< 27 mmol/L, 300 randomized patients will be addressed to a pneumologist. The pneumology investigations will refute(or not)the diagnosis of OHS.
3308140|NCT01903135|Other|[HCO3-]< 27 mmol/L (Group 3)|Obese patients with a [HCO3-]<27 mmol/L randomized to group 3 will receive usual medical follow-up (end of study)
3308141|NCT01903161|Experimental|delayed remote ischemic preconditioning|applying pneumatic cuff on upper extremity (5 minutes cycles of limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times)
3308142|NCT01903161|Placebo Comparator|control|All the procedures were the same in the control group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
3308143|NCT01903174|Experimental|AeroForm Tissue Expansion|AeroForm Breast Tissue Expander placed after mastectomy
3308144|NCT01903200|Experimental|FK949E Fed Group|FK949E is administered after breakfast
3308145|NCT01903200|Experimental|FK949E Fasted Group|FK949E is administered in the morning under fasting conditions
3308146|NCT01903213||Kiklin group|Oral
3308147|NCT01903226|Experimental|High intensity training|Patients in this group will perform high aerobic intensity training, in 30 minutes, twice a week, in a 12 week period.
3308148|NCT01903226|Experimental|Moderate intensity training|Patients in this group will perform moderate aerobic intensity training, in 45 minutes, three times a week, in a 12 week period.
3308149|NCT01903226|No Intervention|controll|Patients in this group will perform no (additional) training.
3308150|NCT01903239|Other|Low-Risk BCC Excisional Margins|This is a study investigating the efficiency of 1-2 mm margins for the excision of low-risk basal cell carcinoma.
3308151|NCT01903278|Experimental|PEG-IFN-SA /RBV T1(Genotype2,3)|PEG-IFN-SA/RBV, 1.5μg/kg/week im and RBV 1000mg-1200mg/d po bid（BW<75kg,1000mg/d; BW≥75kg, 1200mg/d）,24 weeks
3308152|NCT01903278|Active Comparator|Pegasys /RBV C1(Genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 24 weeks
3308153|NCT01903278|Experimental|PEG-IFN-SA /RBV T2(Non-genotype 2,3)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
3308154|NCT01903278|Active Comparator|Pegasys /RBV C2(Non-genotype 2,3)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）for 48 weeks
3308155|NCT01903291||dimethyl fumarate|To be taken according to the United States Prescribing Information (USPI)
3308156|NCT01903304|Experimental|olive oil|intervention with olive oil for 3 months
3308157|NCT01903304|Placebo Comparator|Placebo|Intervention with placebo for 3 months
3308158|NCT01903317||Topical Therapy|Subjects who use topical therapy as the standard treatment of care for their psoriasis.
3308159|NCT01903317||Phototherapy and Systemic Therapy|Subjects who use phototherapy and systemic therapy as the standard treatment of care for their psoriasis.
3308160|NCT01903317||Biologic Therapy|Subjects who use biologic therapy as the standard treatment of care for their psoriasis.
3308161|NCT01903330|Experimental|(ERC1671/GM-CSF/Cyclophosphamide)+bevacizumab/bevacizumab biosimilar|"ERC1671 and GM-CSF will be intradermally administered, while cyclophosphamide is orally administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day. Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10 mg/kg every 2 weeks.~The treatment will be repeated every 28 days until progression of disease or intolerance."
3308162|NCT01903330|Placebo Comparator|(Placebo Injection/Placebo Pill) +Bevacizumab/bevacizumab biosimilar|"The control group will have the same study schedule except that the patients will be receiving the Oral Control on the Cyclophosphamide treatment days and the Injectable control on the GM-CSF + ERC1671 treatment days. The control group will receive bevacizumab or approved bevacizumab biosimilar just as the active treatment group above.~The treatment will be repeated every 28 days until progression of disease or intolerance."
3308163|NCT01903343||Healthy Volunteers|Single group of healthy male medical students at Ninewells Hospital & Medical School, Dundee.
3308164|NCT01903369||Elective orthopaedic surgery patients|All patients presenting for elective orthopaedic surgery >16 years of age.
3308165|NCT01903382||Adult patients|All patients undergoing general anesthesia between January 2006 and December 2013
3308166|NCT01903395|Experimental|Nurse-led counselling|First-degree relatives of patients undergoing active treatment for colorectal cancer are offered a nurse-led counselling by telephone regarding emotional and cognitive barriers to screening utilization.
3308167|NCT01903395|No Intervention|Usual Care|Usual print media, offered standardly by the recruiting centres.
3308168|NCT01903408|Other|Arm 1: Boost to prostate|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate (76.5 Gy) in 34 fractions Arm finished recruitment and follow-up
3308169|NCT01903408|Other|Arm 2: Boost to prostate and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate (76.5 Gy) & pelvic lymph node mets (61.2 Gy) in 34 Fx
3308170|NCT01903408|Other|Arm 3: Boost to prostate bed|IMRT of the pelvic lymphatic drainage (51 Gy) and integrated boost to the prostate bed (68 Gy) in 34 fractions Arm finished recruitment and follow-up and is published
3308171|NCT01903408|Other|Arm 4: Boost to prostate bed and lymph node metastases|IMRT of the pelvic lymphatic drainage (51 Gy), SIB to the prostate bed 68 Gy) & lymph node metastases (61.2 Gy) in 34 Fx
3308172|NCT01903408|Other|Arm 5: Boost to lymph node metastases|Patients with previous irradiation of the prostate bed: IMRT of the pelvic lymphatic drainage (46.8 Gy) above the previous treatment fields, SIB to lymph node metastases (63.2 Gy) in 26 Fx
3308173|NCT01903421|Active Comparator|Spinal anesthesia group|Spinal anesthesia group will receive bupivacaine 10-15mg anesthesia according to the standard practice. Supplemental sedation with intravenous anesthetics (midazolam/propofol) will be optional.
3308174|NCT01903421|Active Comparator|General anesthesia group|Induction of anesthesia will be achieved with propofol 1.5-2mg/kg and fentanyl 1-3g/kg. Anesthesia will be maintained with inhalational anesthesia (isoflurane or sevoflurane) at the discretion of anesthesiologist in charge of the case. A mixture of Air/O2 will be used to maintain adequate oxygenation. Nitrous oxide will not be used.
3308175|NCT01903447|Active Comparator|SSRI|sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg
3308176|NCT01903447|Active Comparator|CBT|12 weeks of individual cognitive behavioral therapy
3308177|NCT01903473|Experimental|Donor Treg infusion arm|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be first treated with Rapamycin while CNI (if any) will be discontinued and infused whith Treg cells 60-90 days after.
3308178|NCT01903473|Active Comparator|Control|Condition:Patients treated with steroids for a chronic GVHD occurring after allogeneic cell transplantation. Patients who have refractory chronic GVHD will be eligible. Patients in this arm will be treated with Rapamycin which is an alternative immunosupression strategy allowing to fight againt GVHD and CNI (if any) will be discontinued.
3308179|NCT01903499|Active Comparator|Bean patty|Bean Patty
3308180|NCT01903499|Active Comparator|Beef patty|Beef patty
3308181|NCT01903512||arthrocentesis in TMJ internal derangement|30 patients with TMJ internal derangement and pain with history of failed conservative management.
3308182|NCT01903538|Experimental|Cathodal transcranial direct current stimulation|
3308183|NCT01903538|Sham Comparator|Sham transcranial direct current stimulation|
3308184|NCT01903551|Experimental|Loco-regional catheter|A suprafascial catheter will be positioned at the end of cardiac intervention during the thoracotomy closure. The catheter will be connected to a elastomeric pump, which delivers the analgesic drug (ropivacaine).
3308185|NCT01903551|No Intervention|Intravenous analgesia|At the end of the cardiac intervention each patient will receive intravenous analgesia with morphine at 0.8 mg/h.
3308186|NCT01903577|Experimental|Novice Laparoscopic and Robotic Surgeons|"Students and surgical trainees with less than 100 laparoscopic and less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3308187|NCT01903577|Experimental|Expert Laparoscopists, Novice Roboticists|"Surgeons with more than 100 laparoscopic cases, less than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3308188|NCT01903577|Experimental|Expert robotic and laparoscopic surgeons|"Surgeons with greater than 100 laparoscopic and greater than 50 robotic cases.~Will participate in Robotic Task Performance and Laparoscopic Task Performance"
3308189|NCT01903590|Active Comparator|Transvaginal Tape Surgery|Randomized 50 patients undergoing TVT
3308190|NCT01903590|Experimental|Transobturator tape surgery|Randomized 50 patients undergoing TOT
3308191|NCT01903603||Healthy Children|Inclusion criteria for healthy children were as follows: ages of 4-20 y/o ; good cognition and cooperation; and healthy children.
3308192|NCT01903603||CP subjects|Inclusion criteria for subjects with brain damage by CP were as follows: a diagnosis of CP and aged 4-20 years old.
3308193|NCT01903629|Experimental|magnetic-controlled capsule endoscocpy (MCE)|patients were assigned to swallow MCE first, followed by the gastroscopy
3308194|NCT01903642|Other|Patients with inflammatory syndrome|
3308195|NCT01903655|Other|patients with a first episode of major depressive disorder|a group of patients with a first episode of major depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features
3308196|NCT01903655|Other|patients with recurrent depressive disorder|a group of patients with recurrent depressive disorder according to DSM-IV-TR including depressive episodes with melancholic features (at least three episodes of depression)
3308197|NCT01903655|Other|control group|patient with no depressive disorder during the study period and no psychiatric history
3308198|NCT01903681|Active Comparator|Circadin 10 mg|Second arm higher dose
3308199|NCT01903681|Active Comparator|Circadin 2 mg|First arm lower dose
3308200|NCT01903694|Active Comparator|sorafenib|800 mg of sorafenib twice daily orally.
3308201|NCT01903694|Experimental|sorafenib-pravastatin|800 mg of sorafenib twice daily oral doses associated with 40 mg of pravastatin in a taken per os. Pravastatin will be taken during dinner.
3308202|NCT01903707|Experimental|Cognitive Remediation Therapy|Participants will undertake approximately 30 minutes of computerized CRT training for 8 weeks, 5 days per week. They will meet a therapist once per week to discuss any difficulties, help motivation.
3308203|NCT01903707|Placebo Comparator|Placebo Comparator|Participants will meet therapist once per week but will not undertake the Computerized Cognitive remediation training.
3308204|NCT01903746||Patients in septic shock|
3308205|NCT01903759|Other|Patients with spontaneous rupture of the fetal membranes|
3308206|NCT01903772|Experimental|Inspiratory Muscle Training|Procedure: Inspiratory Muscle Training Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
3308207|NCT01903772|Sham Comparator|Sham Inspiratory Muscle Training|Twice daily inspiratory muscle training (3x30 breaths) at an intensity of 5 centimeters of water (H2O)
3308208|NCT01903785|Experimental|Salbutamol|400ug of salbutamol (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 1600ug salbutamol and placebo.
3308209|NCT01903785|Placebo Comparator|Placebo|400ug of placebo (one single inhalation) will be inhaled 60min prior to the begin of a time trial. Mean power output during the following 10km time trial will be described to 400ug and 1600ug salbutamol.
3308210|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, 125 μg, placebo|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 in each of the dose options: 5, 25 and 125 μg, and one dose that only contains the placebos.)
3308211|NCT01903824|Experimental|CEP-26401 5 μg, 25 μg, placebo, donepezil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 25 μg, and donepezil at 10mg and one dose that only contains the placebos.)
3308212|NCT01903824|Experimental|CEP-26401 5 μg, 125 μg, placebo, modafinil|Participants are dosed four times during this cross-over study. This group takes three active interventions (CEP-26401 at 5 and 125 μg, and modafinil at 200mg) and one dose that only contains the placebos.)
3308213|NCT01903850|Experimental|spray cryotherapy|spray cryotherapy: 4 -5 second sprays at Baseline (possible additional tx. to be determined at follow up)
3308214|NCT01903889|Active Comparator|Clinic based intervention|basic intervention is introduced, whereby HIV/AIDS providers are trained on contraception for HIV-positive women. They are charged with counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
3308215|NCT01903889|Experimental|clinic and community based intervention|The basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services. This includes training of C&T providers on gender-based influences on health behaviors; provision of couples' HIV testing and FP counseling services; and community-based education for men to promote gender equitable norms and male participation in health services.
3308216|NCT01903902|Experimental|Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting SeQuent Please drug-eluting balloon in native small coronary artery (vessel diameter > 2.25 mm and ≤ 2.75 mm)
3308217|NCT01903915||Patients|Schizophrenia group
3308218|NCT01903915||Control|Healthy control group
3308219|NCT01903928|Experimental|ASP0113 group|Participants receive 1 mL of ASP0113 intramuscularly 5 times, on days -14 to -3, 14 to 40, 60 ± 5, 90 ± 10, and 180 ± 10, counting from the transplantation (stem cell transfusion) day (day 0)
3308220|NCT01903941|Experimental|Training|Aerobic
3308221|NCT01903941|Placebo Comparator|Control|Not exercise
3308222|NCT01903954|Active Comparator|Active Comparator|Pplacebo in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
3308223|NCT01903954|Experimental|Setrobuvir|Setrobuvir (800 mg orally b.i.d loading dose followed by 200 mg orally .b.i.d.) in combination with standard of care Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)
3308224|NCT01903967||"Control Group"|Patients cured with no evidence of disease up to 5 years will be the controls.
3308225|NCT01903967||"Case Group"|Patients, in recurrence or progression before 5 years will be the cases
3308226|NCT01903980||EFN Cases|Cases of patients with epipericardial fat necrosis CT findings
3308227|NCT01904006|Experimental|New Culture Condition|Intervention group embryos cultured grouped under low oxygen tension in benchtop incubators.
3308228|NCT01904006|Active Comparator|Standard Culture Condition|Control group embryos cultured individually under atmospheric oxygen tension in large-box incubators.
3308229|NCT01904032|Experimental|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
3308230|NCT01904032|Active Comparator|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
3308231|NCT01904084|Active Comparator|Volar locked plating|One group with distal radius fracture is operated with Locking plate
3308232|NCT01904084|Active Comparator|Hoffman external fixator|One group with distal radius fracture is operated with Hoffman external fixator
3308233|NCT01904097|Sham Comparator|Pregabalin, Sham tDCS|Patients will receive pregabalin 150 mg oral (PO) twice per day (BID), and sham transcranial direct current stimulation (sham tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
3308234|NCT01904097|Experimental|Pregabalin, tDCS|Patients will receive pregabalin 150 mg oral(PO) twice per day (BID), and transcranial direct current stimulation (tDCS) five times per week during 2 weeks, and then twice per week until week 8th. The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
3308235|NCT01904110|Experimental|Risenex M|Patients who were treated with Resenex M (Risendronate/Cholecalciferol combination in one tablet) once a month for 12months
3308236|NCT01904110|Active Comparator|Risenex Plus|Patients who were treated with Risenex plus (Risendronate/Cholecalciferol combination in one tablet) once a week for 12months
3308237|NCT01904123|Experimental|Treatment (STAT3 inhibitor WP1066)|Patients receive STAT3 inhibitor WP1066 PO BID on Monday, Wednesday, and Friday of weeks 1 and 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3308238|NCT01904136|Experimental|Treatment (NK cells, allogeneic stem cell transplant)|"MYELOABLATIVE CONDITIONING REGIMEN: Patients receive high-dose melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and NK cells IV over 30 minutes on day -2 or -1.~NON-MYELOABLATIVE CONDITIONING REGIMEN: Patients receive melphalan IV over 30 minutes on day -7, fludarabine IV over 1 hour on days -7 to -4, undergo TBI on day -3, and receive NK cells IV over 30 minutes on day -2 or -1.~TRANSPLANT: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.~POST-TRANSPLANT CYCLOPHOSPHAMIDE AND GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 3 hours on days 3 and 4, tacrolimus IV beginning on day 5 for 2 weeks and then PO for approximately 4 months, and mycophenolate mofetil PO TID beginning on day 5 for approximately 6-7 months.~NK CELLS: Patients receive NK cells IV over 30 minutes on days 7 and 28-90."
3308239|NCT01904162|Experimental|healthy young adult males|healthy young adult males receiving 400 mg finafloxacin single dose
3308240|NCT01904162|Experimental|healthy young adult females|healthy young adult females receiving 400 mg finafloxacin single dose
3308241|NCT01904162|Experimental|healthy elderly adult males|healthy elderly adult males receiving 400 mg finafloxacin single dose
3308242|NCT01904162|Experimental|healthy elderly adult females|healthy elderly adult females receiving 400 mg finafloxacin single dose
3308243|NCT01904175||Reduced Intensity Allogeneic Transplant|Subjects undergoing a reduced intensity allogeneic stem cell transplant
3308244|NCT01904188||SIRS positive|Adult (> or = 18 years) patients with 3 of 4 systemic inflammatory response syndrome (SIRS) characteristics (1. tachycardia, 2. fever or hypothermia, 3. tachypnea, 4. leukocytosis), who have blood cultures drawn and urine collected for the evaluation of suspected sepsis, along with any other bodily fluid suspected to be the source of infection. May also include others without SIRS criteria but with bodily fluid production or infection of a bodily fluid
3308245|NCT01904214|Experimental|severe renal impairmnt|
3308246|NCT01904214|Experimental|moderate renal impairment|
3308247|NCT01904214|Experimental|mild renal impairment|
3308248|NCT01904214|Experimental|healthy subjects|
3308249|NCT01904227|Experimental|Inpatient Adaptation of DBT|"Patients are in treatment 5 days a week, during 12 weeks. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.~Patients also receive daily mindfulness classes, 2 hours of drama therapy, psycho educational classes about sexuality, substance abuse and medication, and the possibility to get help in applying principles of validation and behavioral analysis skills."
3308250|NCT01904227|Active Comparator|Outpatient DBT|Control condition: Standard outpatient DBT
3308251|NCT01904240||Parkinson's disease patients|Patients with Parkinson's disease
3308252|NCT01904240||Subjects without Parkinson's disease|Control subjects without Parkinson's disease
3308253|NCT01904253|Experimental|TAS-102|
3308254|NCT01904253|Active Comparator|Investigator Choice of Amrubicin or Topotecan|Investigator Choice of Amrubicin (Japan only) or Topotecan (Europe and Japan)
3308255|NCT01904266|Sham Comparator|GA + sham block|Patients will receive general anesthetic plus a sham paravertebral block
3308256|NCT01904266|Experimental|GA + paravertebral block|Patients will receive general anesthetic plus a paravertebral block
3308257|NCT01904279|Experimental|TCZ SC 162 mg Q3W|Participants with body weight less than (<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks.
3308258|NCT01904279|Experimental|TCZ SC 162 mg Q2W|Participants with body weight greater than or equal to (>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.
3308259|NCT01904292|Experimental|Tocilizumab|Participants will receive SC dose of tocilizumab based on body weight; participants with <30 kg will receive 162 milligrams (mg) of tocilizumab Q2W and those participants =>30 kg will receive 162 mg of tocilizumab QW, for 52 weeks.
3308260|NCT01904305||Patients receiving bronchoscopy|Patients suspected of having pneumonia received bronchoscopy to examine the lungs and to capture alveolar lavage culture
3308261|NCT01904318|Experimental|IDP-73152 mesylate 40 mg|
3308262|NCT01904318|Experimental|IDP-73152 mesylate 80 mg|
3308263|NCT01904318|Experimental|IDP-73152 mesylate 160 mg|
3308264|NCT01904318|Experimental|IDP-73152 mesylate 320 mg|
3308265|NCT01904318|Experimental|IDP-73152 mesylate 640 mg|
3308266|NCT01904318|Experimental|IDP-73152 mesylate 1280 mg|
3308267|NCT01904318|Placebo Comparator|Placebo|
3308268|NCT01904331||Breast cancer patients|Women who were curatively treated with chemo- and/or radiotherapy for breast cancer
3381197|NCT03879109|Active Comparator|Arm B: Chemotherapy alone|"Protocol of chemotherapy FOLFIRINOX*, 6 cycles :~oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
3308269|NCT01904331||Controls|Women matched on age and general practitioner with the breast cancer patients
3308270|NCT01904344|Other|Sensor testing and validation|
3308271|NCT01904357|Active Comparator|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
3381198|NCT03874351|Experimental|Active tDCS|Twenty minutes of direct current at intensity of 1.5 milliamperes (mA).
3381199|NCT03874351|Sham Comparator|Sham tDCS|Thirty seconds of direct current at 1.5 mA, followed by 0 mA for the remaining time of the 20-minute stimulation period.
3381200|NCT03871608||DTM Disorders|Patient with DTM Disorders with Examination of functional etiologies on DTM Disorders and Assessment of symptoms on DTM Disorders
3381202|NCT03860883|Experimental|Arm A (Wide Local Excision = 1cm Margin)|1cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
3308272|NCT01904357|Active Comparator|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
3308273|NCT01904396|Experimental|CarnitineDeficient|Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
3308274|NCT01904409|Placebo Comparator|Placebo|Placebo tablets once daily.
3308275|NCT01904409|Experimental|Rifaximin SSD 40 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 40 mg immediate release (IR) tablet once daily.
3381203|NCT03860883|Active Comparator|Arm B (Wide Local Excision = 2cm Margin)|2 cm Wide Local Excision margin + Sentinel Lymph Node Biopsy +/- Reconstruction
3381204|NCT03856359|Experimental|Rifaximin|rifaximin 550 milligrams (mg) orally twice daily for 3 months
3381208|NCT03846505|Experimental|Oxytocin|"A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
3381209|NCT03846505|Placebo Comparator|Placebo|"A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.~All participants will receive 12 weekly, 90-minute ABCT therapy sessions delivered by trained Masters or Doctoral-level clinicians consistent with the published manual."
3381210|NCT03843125|Experimental|Baricitinib High Dose|Baricitinib administered orally.
3381211|NCT03843125|Experimental|Baricitinib Low Dose|Baricitinib administered orally.
3381212|NCT03837717|Experimental|Holding First|Holding will occur on the second day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
3381213|NCT03837717|Experimental|No Holding First|Holding will occur on the third day of hypothermia treatment. Saliva will be collected on Day 2 and Day 3
3381214|NCT03837015|Active Comparator|Estring alone|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention.
3381215|NCT03837015|Active Comparator|Estring and vaginal RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will also be instructed to insert one RepHresh Pro-B capsule vaginally twice daily, morning and night, until day 30
3381216|NCT03837015|Active Comparator|Estring and oral RepHresh Pro-B|Participants will be given a single packet containing one Estring vaginal ring. Participants will begin using the vaginal ring on day 0 and keep it in place until day 30. Estring should not be removed during the one-month study intervention. Participants will be instructed to take one RepHresh Pro-B capsule orally twice daily until day 30.
3381217|NCT03837015|Active Comparator|Vaginal RepHresh Pro-B|Participants will be given a 30 days supply of RepHresh Pro-B and instructed to insert one capsule vaginally twice daily until day 30.
3381218|NCT03826264||Korea Centers|Seoul, Korea All Patients undergoing TAVR
3381219|NCT03826264||Stanford University|California, USA All Patients undergoing TAVR
3381220|NCT03826264||Northwestern University|Evanston, Illinois, USA All Patients undergoing TAVR
3381221|NCT03826264||Cheng-Hsin Hospital|Taipei, Taiwan All Patients undergoing TAVR
3448479|NCT04063774|Experimental|Dengue diagnostic algorithm|single arm of consecutive enrolled subjects with fever in whom the dengue diagnostic algorithms were applied by study physician and blood sample taken for hemogram and dengue reference tests (gold standard)
3448480|NCT04063683|Experimental|Anlotinib with chemotherapy|
3448481|NCT04063618|Experimental|Osteopathic Manipulative Therapy (OMT) Treatment Group|Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
3448482|NCT04063618|Active Comparator|Standard of care concussion treatment group|Standard of care concussion treatment without OMT
3448483|NCT04063605|Experimental|Clinical Pilates|Participants in this group will receive twice a week, total 8 weeks of clinical pilates exercise program. Each session will take 45 minutes.
3448484|NCT04063605|Active Comparator|Classic Physiotherapy|Participants in this group will receive twice a week, total 8 weeks of classic physiotherapy exercise program. Each session will take 45 minutes.
3448485|NCT04063527|Active Comparator|Standard therapy|combination of paclitaxel and carboplatin
3448486|NCT04063527|No Intervention|Observation|Observation
3308276|NCT01904409|Experimental|Rifaximin SSD 80 mg IR tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet once daily.
3308277|NCT01904409|Experimental|Rifaximin SSD 40 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 40 mg sustained extended release (SER) tablet once daily.
3308278|NCT01904409|Experimental|Rifaximin SSD 80 mg SER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg sustained extended release(SER) tablet once daily.
3308279|NCT01904409|Experimental|Rifaximin SSD 80mgIR/80mgSER tablet|Rifaximin soluble solid dispersion (SSD) 80 mg immediate release (IR) tablet + rifaximin SSD 80 mg sustained extended release (SER) tablet once daily.
3308280|NCT01904422|Experimental|conventional periodontal treatment|Treatment group by quadrant in five weeks. Patients in this group will receive periodontal treatment including plaque control instructions, supragingival and subgingival debridement and root planing. This treatment is done in 5 sessions with a periodicity of 1 session per week. In the first session patients will receive hygiene instruction and supragingival debridement performed with and ultrasonic device. In the following session, there will be done the scaling and root planing to one quadrant per session, using site specific hand curettes. In case of being partially edentulous patients will be implemented at least 3 teeth per quadrant in each session.
3448487|NCT04063475|Experimental|cyanoacrylate beside sutures for FGG fixation|butyl cyanoacrylate
3448488|NCT04063657|Active Comparator|External fixation|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in external fixator until the patient is deemed clinically appropriate for definitive surgical fixation.
3308281|NCT01904422|Experimental|Intensive periodontal treatment|Intensive treatment group in 24 hours: Patients in this group will receive periodontal treatment including: plaque control instructions, supragingival and subgingival debridement and scaling and root planing. This treatment is carried out in 2 sessions within 24 hours. In the first session hygiene instruction and supragingival and scaling and root planing of the teeth in right side at the upper jaw and mandible will be performed. The implementation of each upper and lower hemiarcade will be made until the periodontist treating check manually the removal of all subgingival calculus deposit and feel the smoothness of the root surface. In the second session, there will be an identical procedure in the arch left.
3308282|NCT01904461|Experimental|Vacuum device surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses the innovative vacuum device to obtain wounds hemostasis
3308283|NCT01904461|Active Comparator|Conventional surgery|At first the surgeon proceed to the dissection of children tonsils and at last he uses a bipolar forceps to obtain wounds hemostasis
3308284|NCT01904474|Experimental|Next.Step|"Experimental group participants, in addition to the standard treatment program are invited to get restricted access to the e-therapeutic platform (Next.Step), which includes a diverse set of resources, such as: educational resources (videos, brochures, menus, weekly tips, access to other links), self-monitoring (food, weight and physical activity records), social support (chats, discussion forums and personalized messages), interactive training modules (self-assessment quizzes, making their own diets) and motivational tools (personal goals planning, treatment progression registry, positive reinforcement).~Intervention length will be 36 weeks (24 weeks of direct intervention with a follow-up of 12 weeks), being based on case management methodology."
3308285|NCT01904474|Active Comparator|Standard protocol|The control group will follow the POC/HSM standard treatment protocol, which includes a baseline evaluation session with a paediatrician for initial screening, followed by appointments with the nutritionist and exercise physiologist. The second set of appointments will take place one month after for adjustments. After this, the adolescent will have appointments at 3, 6, 9 and 12 months. These adolescents will join a waiting list and nine months (36 weeks) after having started the standard treatment, they will receive the personal codes for accessing Next.Step.
3448489|NCT04063657|Active Comparator|Splinting|Adults diagnosed with an acute (<2 days from injury) calcaneal fracture recommended for operative treatment will be placed in a short leg splint until the patient is deemed clinically appropriate for definitive surgical fixation.
3308286|NCT01904487|Experimental|PET scans|Both alcoholics and healthy controls will undergo two [11C]flumazenil PET scans: one at baseline and one post administration of 0.2 mg/kg Tiagabine.
3308287|NCT01904500|Other|Cefazolin 2 grams|
3308288|NCT01904500|Active Comparator|Cefazolin 3 grams|
3308289|NCT01904513|Experimental|Probiotic|Daily consumption of yogurt supplemented with L. rhamnosus GR-1 at ~10^10 CFU/day
3308290|NCT01904513|Other|Milk|Daily consumption of pasteurized whole milk
3308291|NCT01904539|Experimental|Healthy Volunteer|Healthy volunteers receiving a single dose of obeticholic acid 10 mg.
3308292|NCT01904539|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment defined as Child-Pugh class A receiving a single dose of obeticholic acid 10mg.
3308293|NCT01904539|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment defined as Child-Pugh class B receiving obeticholic acid 10mg.
3308294|NCT01904539|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment defined as Child-Pugh class C receiving obeticholic acid 10 mg.
3308295|NCT01904552|Experimental|apical periodontitis (AP)|clinical pulp necrosis periapical index scores of 3, 4 or 5
3308296|NCT01904552|Experimental|normal periapex (NP)|clinical pulp vitality periapical index score of 1
3308297|NCT01904565|Experimental|Thermoradiotherapy|Patients subjected to the planned therapeutic intervention of local hyperthermia and proton beam therapy
3308298|NCT01904578|Experimental|true acupressure|Massage the effective pressure points as a self-care method at home [ Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the centre line between the ends of the eyebrows] for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
3308299|NCT01904578|Sham Comparator|sham acupressure|Massage the sham pressure points as a self-care method at home for 10 minutes. It was done 1 to 2 hours before sleeping, each night (except Fridays) by circular massage with a 1 Cm circle diameter.
3308300|NCT01904578|No Intervention|control|The control group only received the weekly control of blood pressure and speech communication .
3308301|NCT01904591|Experimental|Selenium and Vitamin E|single arm, all subjects receive both vitamins for 1 year from time zero.
3308302|NCT01904617|Experimental|D5NS at 125 mL/hr|5% dextrose in normal saline at 125 mL/hr
3308303|NCT01904617|Experimental|D2.5NS at 250mL/hr|2.5% dextrose in normal saline at 250 mL/hr
3308304|NCT01904617|Experimental|NS at 250mL/hr|Normal saline at 250mL/hr
3308305|NCT01904630||CRC high risk|Participants belong to a family with increased risk for CRC, will be analyzed with gene sequencing
3448490|NCT04063540|Other|placebo-amiloride|Patients will be treated for 12 weeks with placebo and then after a 4 week wash-out period, will be treated for 12 weeks with amiloride.
3308306|NCT01904643|Experimental|Treatment (lenalidomide, combination chemotherapy)|"LENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days.~RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming.~LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy.~CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity."
3308307|NCT01904656|Experimental|Arm I|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
3308308|NCT01904656|Active Comparator|Arm II|"Participants are exposed to a Healthy Eating Peaches!- media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
3308309|NCT01904669||Women who are trying to conceive|Women ages 18-44 without a history of fertility problems who are in a stable relationship with a male partner who have regular access to the Internet and have been trying to conceive <3 months.
3308310|NCT01904682|Experimental|Oral rigosertib|Patients will take 560 mg oral rigosertib (two 280 mg capsules) in the morning and 280 mg (one 280 mg capsule) in the afternoon, in fasting conditions, for 21 consecutive days of 21-day cycle (continuous regimen).
3308311|NCT01904695|Experimental|Antihypertensive drugs & Herbs|Thiazide diuretics and ACE inhibitor and β-blocker & Herbs for 8 weeks
3308312|NCT01904695|Active Comparator|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker for 8 weeks
3308313|NCT01904708|No Intervention|Sedentary Visit|Subjects will do quiet, sedentary activities for 8 hours. Hourly blood draws and breath sampling will be collected. Bolus C13-Lysine will be given at hour 4.
3308314|NCT01904708|Active Comparator|Exercise Visit|Subjects will do quiet, sedentary activities until hour 5. Blood and breath samples will be collected. At hour 4, subject will consume a bolus of C13-Lysine and immediately walk on a treadmill at a moderate intensity (exercise at 75% of max heart rate) for 45 minutes.
3308315|NCT01904734|Active Comparator|No previous male hormone treatment|Clomiphene
3308316|NCT01904734|Active Comparator|Previously treated with testosterone|Clomiphene
3308317|NCT01904747|Experimental|Palbociclib given to healthy volunteers|
3308318|NCT01904786|Experimental|Melatonin|Melatonin 40 mg every 8 hours for a total of six doses given over 48 hours orally (per nasogastric tube).
3308319|NCT01904786|Placebo Comparator|Placebo|Placebo consists of the solvent solution without melatonin. Solvent solution consists of 5 mL of saline/alcohol mixture in a ratio of 90:1
3308320|NCT01904799|Other|Cognitive Assessment|
3308321|NCT01904812|Other|Lupus erythematosus|
3308322|NCT01904838||Patients in Pittsburgh, Pennsylvania|persons receiving treatment at integrative and conventional medicine clinics in Pittsburgh, Pennsylvania
3308323|NCT01904838||Internet sample|internet sample of persons reporting that they receive, or have received in the past year, integrative medicine or conventional medical treatments.
3308324|NCT01904851||Stent|The patient received one or more stents to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in AT LEAST one of the lesions treated during the course of the procedure.
3308325|NCT01904851||Non-Stent|The patient did not receive a stent to the superficial femoral, popliteal, peroneal, anterior tibial, or posterior tibial arteries in ANY of the lesions treated during the course of the procedure.
3308326|NCT01904877||HIV testing|Enhancing HIV testing: By partnering with the local CDC and the gay community, we will use SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing.
3308327|NCT01904877||Phase II: 367 HIV positive MSM|"Linking to care:~Providing enhanced HIV care."
3308328|NCT01904890|Experimental|CRC Prevention and Screening Education|Intervention Lay Health Workers (LHWs) will be taught to teach their participants about CRC screening through 2 outreach sessions and 2 telephone calls aimed at increasing their CRC screening receipt.
3308329|NCT01904890|Active Comparator|Nutrition Education|LHWs and participants in the comparison group will receive a bilingual CRC brochure as well as 2 lectures on healthy nutrition for cardiovascular health delivered by a health educator and an optional post- intervention LHW outreach session on CRC screening.
3308330|NCT01904916|Other|Histological biopsy procedure|This is a diagnostic multicenter study combining histological biopsy of tumor material with DNA sequencing using Ion Torrent®, Next Generation Sequencing (NGS) platform. The study aims improve stratification of cancer patients by obtaining fresh tumor biopsies for next-generation sequencing for participation in clinical trials.
3308331|NCT01904929|Experimental|Reconditioning in the effort|
3308332|NCT01904968||Colon cancers in patients living the Cote D'or area|
3308333|NCT01904981|Experimental|Atenolol|Atenolol group
3308334|NCT01904981|Experimental|Valsartan|Valsartan group
3308335|NCT01904994|No Intervention|Standard of Care|Participants will be managed per standard of care following prevailing Swaziland Ministry of Health guidelines.
3308336|NCT01904994|Experimental|Combined Intervention Strategy|Point-of-care (POC) CD4+ (cluster of differentiation 4) Count Accelerated ART initiation for ART eligible participants Basic care and prevention package Cellular Appointment Reminders and Follow-Up Financial Incentives
3308337|NCT01905007|Active Comparator|Defibrillation testing|Defibrillation testing at initial ICD implantation
3308338|NCT01905007|No Intervention|No defibrillation testing|No defibrillation testing at initial ICD implantation
3308339|NCT01905020|Active Comparator|Conventional insulin pump therapry|Subjects will use conventional pump therapy to regulate their glucose levels.
3308340|NCT01905020|Active Comparator|Single-hormone closed-loop system|Variable subcutaneous insulin infusion rate will be used to regulate glucose levels. Insulin Aspart (Novorapid) will be infused using a subcutaneous infusion pump. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer-generated recommendations of infusion rates.
3308341|NCT01905020|Active Comparator|Dual-hormone closed-loop system|Insulin Aspart (Novorapid) and glucagon (Paladin) will be infused using two separate subcutaneous infusion pumps. The glucose levels as measured by the real time sensor will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated-recommendation delivery levels.
3308344|NCT01905059|Active Comparator|monoPI - boosted lopinavir or boosted darunavir|"boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)~This arm has been stopped on advise of DSMB (approved by Scientific Committee), patients are switched to standard second line triple therapy and followed until the end of the study at week 96."
3308345|NCT01905059|Active Comparator|bi therapy - (boosted lopinavir or darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD
3308346|NCT01905072|Experimental|Education Home Visits|The intervention group will receive the full intervention delivered by community health workers (CHWs) through home visits. CHWs will deliver the intervention in the subjects' homes. Home visits will be arranged at subjects' convenience and occur on a planned schedule. The intervention content will be based on the Institute of Medicine recommendations.
3308347|NCT01905072|No Intervention|Control Group|The control group will receive only measurement visits, with no intervention or interaction during the home visits. They will receive only support from their WIC clinic.
3308348|NCT01905098|Experimental|Observation-First Arm|"A group that first attends 4 observation visits without sauna, and then attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
3308349|NCT01905098|Active Comparator|Sauna-First Arm|"A group that first attends sauna sessions 5 times a week for 3.5 hours per visit for 3 weeks and then attends 4 observation visits without sauna.~Participants in this Arm will undergo both listed interventions: Observation and Sauna Protocols."
3308350|NCT01905111|Experimental|BI 853520|BI 853520 once daily in a dose escalation schedule
3308351|NCT01905124|Experimental|Drug: CF101|CF101 1 mg q12 hours
3308352|NCT01905124|Placebo Comparator|Placebo tablets of CF101|Placebo tablets q12 hours
3308353|NCT01905137|Active Comparator|Botulinum Toxin Type A|Patients in the treatment group will receive 200 Units of Botulinum toxin diluted in 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
3308354|NCT01905137|Placebo Comparator|Saline|Patients in the placebo group will receive 20 mL of saline injected globally into their pelvic floor muscles followed by 8 treatments of pelvic floor physical therapy.
3308355|NCT01905150|Experimental|G-FLIP+VitaminC, then G-FLIP-DM+VitaminC|G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C
3308356|NCT01905150|Active Comparator|G-FLIP, then G-FLIP-DM|G-FLIP alone, then G-GLIP-DM alone
3308357|NCT01905163|Experimental|laparoscopic management|Tumor Debulking Surgery by laparoscopy
3308358|NCT01905176|Experimental|Predischarge educational intervention|In person education on heart failure topics before discharge
3308359|NCT01905176|Experimental|Telephone educational intervention|Telephone support and education post-discharge
3308360|NCT01905176|Experimental|Combination|Pre-discharge in person education and post-discharge telephone education and support
3308361|NCT01905176|No Intervention|Usual care (control group)|Patients receive the routine care provided by the hospital which does not involve protocol driven discharge-planning
3308362|NCT01905189|Experimental|Hemodynamic study, cardiac pacing|We propose to study the hemodynamic response to a temporary atrio-dual right ventricular stimulation in pulmonary arterial hypertension subjects.Patients will be is own comparator.
3308363|NCT01905202|Experimental|Secretrol|Secretrol Capsules 80/80 once daily for 6 months
3308364|NCT01905215|Experimental|Group A|Subjects in this group will receive a single dose of formulation 1 of RSV vaccine
3308365|NCT01905215|Experimental|Group B|Subjects in this group will receive a single dose of formulation 2 of RSV vaccine
3308366|NCT01905215|Experimental|Group C|Subjects in this group will receive a single dose of formulation 3 of RSV vaccine
3308367|NCT01905215|Experimental|Group D|Subjects in this group will receive a single dose of formulation 4 of RSV vaccine
3308368|NCT01905215|Experimental|Group E|Subjects in this group will receive a single dose of formulation 5 of RSV vaccine
3308369|NCT01905215|Experimental|Group F|Subjects in this group will receive a single dose of formulation 6 of RSV vaccine
3308370|NCT01905215|Placebo Comparator|Group Placebo 1|Subjects in this group will receive a single dose of placebo
3308371|NCT01905215|Placebo Comparator|Group Placebo 2|Subjects in this group will receive a single dose of placebo
3308372|NCT01905228|Experimental|CBL0137|"Dose Level 9: 150 mg/m2, IV~Dose Level 10: 180 mg/m2, IV~Dose Level 11: 240 mg/m2, IV~Dose Level 12: 320 mg/m2, IV~Dose Level 13: 400 mg/m2, IV~Dose Level 14: 540 mg/m2, IV~Dose Level 15: 700 mg/m2, IV~Dose Level 16: 920 mg/m2, IV~Dose Level 17: 1200 mg/m2, IV~Dose Level 18: 1600 mg/m2, IV~Dose Level 19: 2100 mg/m2, IV~Dose Level 20: 2700 mg/m2, IV"
3308373|NCT01905280|Experimental|Acellular dermal matrix|A ridge preservation graft will be performed and then covered using acellular dermal matrix as a membrane.
3308374|NCT01905280|Active Comparator|Non-resorbable membrane|A ridge preservation graft will be performed and then covered using a non-resorbable PTFE membrane.
3308375|NCT01905293|Experimental|100% portion size|100% portion size condition
3308376|NCT01905293|Experimental|150% portion size|150% portion size condition
3308377|NCT01905293|Experimental|200% portion size|200% portion size condition
3308378|NCT01905306|Experimental|computer guided implant planning|radiographic and clinical evaluation of full-arch dental implant rehabilitation
3308379|NCT01905306|Experimental|free hand implants placement|radiographic and clinical evaluation of full-arch dental implant rehabilitation
3308380|NCT01905319||Subsequent new juvenile arthritis cases|During years 1998-2000, all new subsequent cases of juvenile idiopathic arthritis diagnosed in Estonia were included in the study group.
3308381|NCT01905332|Experimental|Literacy promoting home based program|Those 4 year old children who fall below the cutoff score on the literacy screening will be randomized to either receive standard of care (literacy toolkit) or will be given a referral to a home -based literacy promoting program through the Columbus Metropolitan Library.
3308382|NCT01905332|Active Comparator|Literacy Toolkit|Children who fall below the cut off score on the GRTR-R will be randomized to either receive a literacy toolkit (current standard of care) or a referral to a home based literacy promoting program. The toolkit will contain age-appropriate books and games.
3308383|NCT01905345|Experimental|Endurance and Resistance Training|Endurance and resistance exercise
3308384|NCT01905345|Experimental|Resistance Training|resistance exercise (12wk)
3308385|NCT01905345|Experimental|Resistance and resistance Training|resistance exercise (24 wk)
3308386|NCT01905371|Experimental|Dextroamphetamine + Physical therapy (PT)|"Treatment with d-amphetamine + physical therapy administered under two regimens administered sequentially:~10 mg of d-amphetamine combined with 1 hr PT session beginning 1 hr after drug administration every 4 days, for a total of 6 or 10 sessions"
3308387|NCT01905371|Placebo Comparator|Placebo + Physical Therapy (PT)|"Treatment with placebo + physical therapy administered under two regimens administered sequentially:~Regimen 1: 10 mg of placebo combined with 1 hr PT session beginning 1 hr after placebo administration every 4 days, for a total of 6 or 10 sessions"
3308388|NCT01905384|Active Comparator|U-SEMS group|Patients undergoing routine care ERCP and randomized to 10 mm diameter Uncovered Self-expanding metal biliary stents (U-SEMS) (Wallflex, Boston Scientific).
3308389|NCT01905384|Active Comparator|C-SEMS Group|Patients undergoing routine care ERCP and randomized to a 10 mm diameter Covered Self-Expanding metal biliary stents (C-SEMS) (Wallflex, Boston Scientific)
3308390|NCT01905397|Active Comparator|Negative Pressure Wound Therapy|The Prevena Incision Management System is a 510K cleared device that covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump (also 510K cleared) may be used in some cases with the Prevena dressings as to achieve the negative pressure
3308391|NCT01905397|Active Comparator|Conventional wound therapy|Traditional wound therapy (sterile bandages and dressing)
3308392|NCT01905410|Experimental|single treatment - VVZ-149 Injection|"single ascending dose escalation~0.25, 0.5, 1, 2, 4, 6, and 8 mg/kg Cohorts~4 hours IV infusion"
3308393|NCT01905410|Placebo Comparator|single treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion"
3308394|NCT01905410|Experimental|multiple treatment - VVZ-149 Injection|"Based on the results of SAD trials, low and high dosage are determined for MAD trials.~high and low dosage~4 hours IV infusion x 2 times/day x 3 days"
3308395|NCT01905410|Placebo Comparator|multiple treatment - placebo|"The matching volume of placebo (water for injection) to each experimental cohort~4 hours IV infusion x 2 times/day x 3 days"
3308396|NCT01905436||Annual Mass Drug Administration|This group will receive annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
3308397|NCT01905436||Semiannual Mass Drug Administration|This group will receive semi-annual mass drug administration (Albendazole 400 mg plus Ivermectin) provided by the Liberian Ministry of Health.
3308398|NCT01905449|Experimental|Ultrasound plus prosodic cues|One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)
3308399|NCT01905449|Experimental|Ultrasound vs Traditional treatment|One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.
3308400|NCT01905462||Exposed cohort|Women with the first day of LMP between 30 days before and 45 days after any Cervarix dose and between 30 days before and 90 days after any Cervarix dose.
3308401|NCT01905462||Non-exposed cohort|Women with the first day of LMP between 120 days and 18 months after their last Cervarix dose (and no further Cervarix dose before the outcome).
3308402|NCT01905475|Experimental|POL6326|POL6326 intravenous infusion
3308403|NCT01905475|Placebo Comparator|Placebo|Placebo intravenous infusion
3308404|NCT01905488||Group N|patients who didn't show internal jugula vein valve incompetency (IJVVI)
3308405|NCT01905488||Group PT|patients who showed IJVVI after pneumoperitoneum or Trendelenburg position
3308406|NCT01905488||Group S|patients who showed IJVVI in supine position
3308407|NCT01905501|Active Comparator|Total intravenous anesthesia|Total intravenous anaesthesia
3308408|NCT01905501|Experimental|Balanced anesthesia|
3308409|NCT01905514|No Intervention|control|using Medication event monitoring system
3308410|NCT01905514|Active Comparator|internet mobile application|using both mobile internet application and medication event monitoring system
3308411|NCT01905527||Standard Services of Group A (Group A1)|
3308412|NCT01905527||Customized Services of Group A (Group A2)|
3308413|NCT01905527||Group B|
3308414|NCT01905566|Active Comparator|Clopidogrel|clopidogrel: 75mg once a day
3308415|NCT01905566|Experimental|Ticagrelor|ticagrelor: 90mg twice a day
3448491|NCT04063540|Other|amiloride -placebo|Patients will be treated for 12 weeks with amiloride and then after a 4 week wash-out period, will be treated for 12 weeks with placebo.
3308416|NCT01905579|Experimental|patients with uveitis|Paracentesis of the anterior chamber in Paients with uveitis undergoing cataract surgery
3308417|NCT01905579|Experimental|patients without uveitis|Paracentesis of the anterior chamber in patients without uveitis undergoing routine cataract surgery
3308418|NCT01905605|Experimental|phosphatidylcholine supplementation|Phosphatidylcholine supplementation to be administered BID for 8 weeks
3308419|NCT01905605|Placebo Comparator|placebo supplementation|Placebo to be administered BID for 8 weeks
3308420|NCT01905618|Experimental|Multi Modal Education (MME)|Medical students in the medical schools randomized to the MME will receive four interventions during the course of their medical education. The four interventions/components are: 1) web-based curriculum on tobacco dependence treatment; 2)tobacco counseling role play; 3) preceptor training and teaching medical students, preceptor modeling the 5As, student observation, and student feedback; and 4)booster session.
3308421|NCT01905618|No Intervention|Traditional Education (TE)|Medical schools randomized to the Traditional Education (TE) will represent usual care and includes the current content and mode for tobacco teaching in the medical school.
3308422|NCT01905631|No Intervention|Untreated Control Group|Subjects will apply nothing for the entire three days of the trial. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
3308423|NCT01905631|Active Comparator|Treatment Group (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
3308424|NCT01905644|Experimental|With ultrasound|"Patients in this group will have perineal ultrasound for the detection of anal sphincter ruptures.~Intervention: Perineal ultrasound"
3308425|NCT01905644|No Intervention|Without ultrasound|Patients in this group will not have perineal ultrasound for the detection of anal sphincter ruptures.
3308426|NCT01905670|Experimental|Implant|Implant of the WiCS-LV system
3308427|NCT01905696|Experimental|N-Acetylcysteine (NAC)|After initial measurements of SNO-Hb level, forearm blood flow in response to exercise and hypoxia, subjects will take oral NAC 600 mg twice daily. Measurements will then be repeated.
3308428|NCT01905709|Experimental|All patients|150-500 ml of human fecal matter
3308429|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
3308430|NCT01905722|Experimental|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
3308431|NCT01905735|Placebo Comparator|placebo|1/2 ml of dispensing alcohol administered orally at every 7 day for 5 month .
3308432|NCT01905735|Active Comparator|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
3308433|NCT01905748|Experimental|Patients during Migraine attacks|Patients with Migraine before, during and after Migraine attacks. Acute phase reaction profile, and activation of the coagulation system will be investigated together with thrombophilia profile.
3308434|NCT01905748|Experimental|Control group|Patients with acute neurologic events like convulsions not related to fever or central nervous system (CNS) infections will be studied including acute phase reaction laboratory tests, thrombophilia and activation of the coagulation system
3308435|NCT01905774||Deferasirox|The patients will be treated by the primary physician according to clinical status. The Deferasirox dose range is between 20 to 40 mg/kg/day once daily dose. The treatment is a continuous treatment and not a single course.
3308436|NCT01905787||Group 2 - Dana group|50 patients will be included in the study.
3308437|NCT01905787||Group 3 - Schneider group|50 patients will be included in the study
3308438|NCT01905787||Group 4 - Detroit group|100 patients will be included in the study, Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+) will be included).
3308439|NCT01905787||Group 1 - Emek group|100 patients will be included in the study, including Homozygous SCA patients and Sickle Cell β Thalassemia Patients (β0 and β+ patients will be included).
3308440|NCT01905800|Active Comparator|Barbecue treatment without acceleration|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
3308441|NCT01905800|Experimental|Barbecue treatment with acceleartion|Treatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
3308442|NCT01905800|Placebo Comparator|Placebo treatment|Positional examination of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying a rotation towards the other side.
3308443|NCT01905813|Experimental|INCB040093|
3308444|NCT01905813|Experimental|INCB040093 in combination with itacitinib (INCB039110)|
3308448|NCT01905878|Experimental|single dose DLBS1033|Before taking the drug, blood samples will be collected from subject to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take three tablets enteric coated of DLBS1033 in front of investigator. After take the medicine blood sample will be collected on 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
3308449|NCT01905878|Experimental|steady state of DLBS1033|On day 1 blood samples will be collected to assess PAP complex level, serum creatinine, SGOT, SGPT, PT and aPTT. After that, subjects will instructed to take one tablet of DLBS1033 in front of investigator. Study drug packages (that consist of 8 tablets) will dispense to the subjects at day-1 and instructed to take the drug 3 times daily 30 minutes before meals. Subjects also will instructed to record any adverse events and concomitant medication prescribed in diary card. Subjects have to take the drug on 3 days (day 1, 2, and 3). On day 4, blood sample will be collected on 0 minutes, 30 minute, 60 minute, 90 minute, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 10 hour, 12 hour, and 24 hour to evaluate serial PAP complex. Subjects will undergo a clinical assessment including vital signs and the presence of adverse events at the time of blood sampling. On this trial, subjects are only permitted to eat food from investigator.
3308450|NCT01905891|Other|Subjects at risk of skin cancer|Subjects at risk of skin cancer (sun-damaged skin) a superficial shave biopsy will be performed.
3308451|NCT01905891|Other|Subjects with healthy skin|Subjects without sun-damaged skin a superficial shave biopsy will be performed.
3308452|NCT01905904|Active Comparator|sevorane|Sevorane 4% concentration during anesthesia induction
3308453|NCT01905904|Active Comparator|sevorane %7|Sevorane 7% concentration during anesthesia induction
3308454|NCT01905917|No Intervention|Control|Usual care
3308455|NCT01905917|Experimental|Tele-Rehabilitation|A tele-rehabilitation intervention involving weekly video-conferencing with a therapist, training exercise videos and use of wearable sensors to capture patient participation in exercises.
3308456|NCT01905930|Experimental|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
3308457|NCT01905930|Active Comparator|Ant. Cervical Discectomy & Fusion(ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
3308458|NCT01905969||Biomarker positive|NF-kB(+)/JNK(-) in curatively removed specimens
3308459|NCT01905969||Biomarker negative|NF-kB(-)/JNK(+) in curatively removed specimens
3308460|NCT01905982|Experimental|Conventional breathing therapy|first: conventional breathing therapy, second: reflectory breathing therapy
3308461|NCT01905982|Experimental|Reflectory breathing therapy|first: Reflectory breathing therapy second:Conventional breathing therapy
3308462|NCT01905995||Patients with advanced Parkinson's disease|no intervention - observational study
3308463|NCT01906021|Experimental|1|Intra-patient comparison of temperature map obtained during CT/CBCT with standard ablation temperature measurements
3308464|NCT01906034|Experimental|Exercise with supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
3308465|NCT01906034|Experimental|Home-based without supervision|The expert panel selected balance and strength / power exercises which can be performed with one's own bodyweight or with the help of small, low-cost exercise equipment (i.e., small weights, resistance bands, unstable surfaces). In this study, intensity during training will be regulated using the Borg Rating of Perceived Exertion scale (i.e., 6-20 points, maximal exertion at 20 points). According to the individual fitness level, exercises should be performed with a perceived exertion between 12 and 16 points (somewhat hard - hard) during balance and strength / power training. Exercise intensity will be progressed individually using the Borg Rating of Perceived Exertion scale and varying the balance and strength / power exercises in order to sufficiently stimulate the neuromuscular system. Strength / power exercises will be progressed from single to multiple joint, isometric to dynamic muscle contraction, short to long lever arm and slow to fast exercises.
3308466|NCT01906034|No Intervention|control group|The control group is a traditional waiting group and will receive a supervised training program after the completion of this study
3308467|NCT01906060|Experimental|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Intubation Laryngeal Mask and subsequently intubated with a commercially available endotracheal tube via the Intubation Laryngeal Mask.
3308468|NCT01906073|Experimental|intranasal fentanyl spray|Fentanyl for nasal administration (NF), is supplied as sprays containing a phosphate buffered solution of fentanyl citrate. NF is available in three strengths: 0.5 mg/ml, 1 mg/ml and 2 mg/ml in multiple-dose sprays. The corresponding doses are 50, 100 and 200 µg/puff. NF is applied as one puff in one nostril. One puff defines and equals one dose. Applying a puff to each nostril the upper dose can be increased to 400 µg. The doses used in this study are 50, 100, 200 ad 400µg. Fentanyl may be administered for up to 6 pain episodes/ 24 hours. For each pain episode, a dose of NF is self-administrated in one nostril. If pain relief is not achieved, another dose of NF could be administered in the opposite nostril after 15 minutes.
3308469|NCT01906073|Active Comparator|slow release morphine|The active substance is released gradually during its transit through the gastrointestinal tract. Slow release (SR) morphine is available in 5, 10, 30, 60, 100 and 200 mg. SR morphine is administered twice a day, usually every twelfth hour.
3308470|NCT01906086|Experimental|legume consumption|legume consumption, 4 servings per week, for 6 weeks
3308471|NCT01906086|Active Comparator|healthy dietary recommendations|no nutritional intervention
3308472|NCT01906099|Experimental|legume enriched diet|legume consumption, 4 servings per week, for 6 weeks
3308473|NCT01906099|Active Comparator|healthy dietary recommendations|no nutritional intervention
3308474|NCT01906112|No Intervention|Controlled|No surgery for primary breast tumor.
3308475|NCT01906112|Experimental|Study|Surgery for primary breast tumor.
3308476|NCT01906125|Experimental|Palbociclib given to Healthy Volunteers|
3308477|NCT01906138|Other|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
3308478|NCT01906151|Other|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
3308479|NCT01906164|Experimental|ALS-008176|
3308480|NCT01906164|Placebo Comparator|Placebo|
3308481|NCT01906190|Experimental|vaccinated group|Vaccinated group means that subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine.
3308482|NCT01906203|Experimental|ultramarathon|
3308483|NCT01906216|Active Comparator|Sorafenib|All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). Sorafenib may be taken either with a low/moderate fat meal or without food. Subjects are to continue sorafenib according to the study protocol if the adverse events could be safely controlled.
3308484|NCT01906216|Experimental|Sorafenib combined with TACE|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening). In addition, the subjects in this arm will receive the treatment of conventional transarterial chemoembolization. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents(doxorubicin) and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads.
3308485|NCT01906229||Acute respiratory distress syndrome (ARDS)|
3308486|NCT01906229||Systemic inflammatory response syndrome (SIRS)|
3308487|NCT01906229||ARDS+SIRS|
3308488|NCT01906242|Placebo Comparator|Water|Patients' dentures are treated with water (placebo) once a week for 10 min.
3308489|NCT01906242|Active Comparator|sodium hypochlorite|Patients' dentures are treated with a solution of sodium hypochlorite 0.5% once per week for 10 min
3308490|NCT01906242|Active Comparator|0.5% chlorhexidine|Patients' dentures are treated with 0.5% chlorhexidine once a week for 10 min.
3308491|NCT01906242|Active Comparator|0.12% sodium bicarbonate|Patients' dentures are treated with sodium bicarbonate 0.12% once a week for 10 min.
3308492|NCT01906255||FTC/TDF for PrEP|HIV-1 negative adults (any sex/gender, including transgender, pregnancy) who are participating in observational or clinical studies on FTC/TDF for PrEP
3308493|NCT01906268|Experimental|TAU + ABMT active|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - active"
3308494|NCT01906268|Sham Comparator|TAU + AMBT placebo|"Treatment as usual (TAU): selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor~Attention Bias Modification Treatment (ABMT) - placebo (sham)"
3308495|NCT01906281||Inflammatory knee osteoarthritis|One group of patients with inflammatory condition in physical evaluation. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
3308496|NCT01906281||Non-inflammatory knee osteoarthritis|Patients with no inflammatory condition in physical examination. We will make a blood analyse and arthrocentesis when synovial fluid were found in ultrasound examination. Ultrasound of affected knee and carotid artery will be performed.
3308497|NCT01906294||Type 2 Diabetes Mellitus|Patients with antidiabetic treatment for Type 2 Diabetes Mellitus
3308498|NCT01906307|Experimental|LJPC-501|LJPC-501, continuous infusion
3308499|NCT01906320|Experimental|Training group|
3308500|NCT01906320|No Intervention|Control Group|
3308501|NCT01906333|Experimental|Exercise & Glucose|2 hour exercise while getting glucose-supplementation
3308502|NCT01906333|Experimental|Exercise & Fasted|2 hour exercise while staying fasted
3308503|NCT01906359|Experimental|Dietary fat - PO|Native palm olein (IV56)
3308504|NCT01906359|Experimental|Dietary fat - IPO|Chemically interesterified palm olein (IV56)
3308505|NCT01906359|Experimental|Dietary fat - HOS|High oleic sunflower oil
3308506|NCT01906385|Experimental|Rhenium Liposome Treatment|
3308507|NCT01906398|Other|Experimental: ketogenic diet|Treatment will consist of KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction for patients with body mass index (BMI) of ≥ 21. The diet will be initiated with a 24 hour fast to induce ketosis. The diet will be supplemented with vitamins, calcium and phosphorus supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. If seizure frequency does not improve after 3 months of KD treatment, [fat]: [protein + carbohydrate] weight ratio will be increased to 4:1
3308508|NCT01906411||subjecst with different BMI|
3308509|NCT01906424|Other|Control Grp#1: Training w/ and w/o Stim|Control- Group #1: 4 weeks training without any transcutaneous electrical stimulation followed by 2 weeks of training plus transcutaneous electrical spinal cord stimulation applied to one or two locations of the cervical (neck) region of the spinal cord.
3308510|NCT01906424|Active Comparator|Grp#2: Training+Single Site Stimulation|Group #2: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to one location along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
3308511|NCT01906424|Active Comparator|Grp #3: Training + Two Site Stimualtion|Group #3: Four weeks of training plus transcutaneous electrical spinal cord stimulation applied to two locations along the cervical (neck) region of the spinal cord; followed by 2 weeks of training without stimulation
3308512|NCT01906437||Cardiac Magnetic Resonance|Cardiac Magnetic Resonance scan at visits 1 and 2
3308513|NCT01906450|Experimental|Scaling and root planing plus Azithromycin|Single session of scaling and root planning. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
3308514|NCT01906450|Placebo Comparator|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
3308515|NCT01906450|No Intervention|baselline screening only|Dental prophylaxis is offered
3308516|NCT01906489|Experimental|AKB-6548|
3308517|NCT01906489|Placebo Comparator|Placebo|
3308518|NCT01906502|Experimental|Device|Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization.
3308519|NCT01906528|Experimental|Males vs females|Constant-rate IV infusions of Mivacurium, range 1.0 - 3 micro/kg/min, duration 150 - 180 min
3308520|NCT01906541|Experimental|ex-vivo gene-therapy|transplantation of genetically modified autologous CD34+ cells
3308521|NCT01906554|Experimental|Egg Dose|
3308522|NCT01906567||severe preeclamptic women|"Severe preeclampsia is defined as the presence of 1 of the following symptoms or signs in the presence of preeclampsia:~• SBP of 160 mm Hg or higher or DBP of 110 mm Hg or higher on 2 occasions at least 6 hours apart~• Proteinuria of more than 5 g in a 24-hour collection or more than 3+ on 2 random urine samples collected at least 4 hours apart~• Pulmonary edema or cyanosis~• Oliguria (< 400 mL in 24 h)~• Persistent headaches~• Epigastric pain and/or impaired liver function~• Thrombocytopenia~• Oligohydramnios, decreased fetal growth, or placental abruption"
3308523|NCT01906567||mild preeclamptic women|Mild preeclampsia is defined as the presence of hypertension (BP ≥140/90 mm Hg) on 2 occasions, at least 6 hours apart, but without evidence of end-organ damage in the patient.
3308524|NCT01906567||Healthy Pregnant Women|healthy pregnant women at term who not developed any complication of pregnancy
3308525|NCT01906580|Experimental|Peg-IFNα-2a monotherapy|Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.
3308526|NCT01906580|Experimental|Sequential therapy|Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.
3308527|NCT01906580|Experimental|Combination therapy|Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.
3308528|NCT01906593||Tiantan biologial's vaccine|Tiantan Biological's vaccine group is the population injected with this vaccine.
3308529|NCT01906593||other group|Other vaccine group is the population injected with other manufacturers' vaccine except Tiantan Biological CO, Ltd.
3308530|NCT01906606|Experimental|Parenting Program|12 session community-based parenting program
3308531|NCT01906606|No Intervention|Control Group|received visual aids on nutrition
3308532|NCT01906619||Febrile illness WITH febrile seizure|The cohort comprises children aged between 3 months and 5 years who had a febrile seizure during the actual febrile disease.
3308533|NCT01906619||Febrile illness WITHOUT febrile seizure|The cohort comprises children aged between 3 months and 5 years with a febrile illness who had never a febrile seizure.
3308534|NCT01906632|Other|gene expression profile|
3308535|NCT01906645|No Intervention|Usual Care|Usual care consists of 1) a routine nurse intake 2) medication reconciliation performed by treating physicians. Given resource constraints (routine medication reconciliation did not include corroborating medication histories with outpatient pharmacies, routine use of pill cards or pill boxes, or review of Medicaid formularies) Uninsured patients were financially responsible for most medications at discharge. 3) Discharge patient education was performed by inpatient nurses and treating physicians at the time of discharge. 4) Patients without a usual source of primary care were often given a list of the fourteen area safety-net clinics, which have limited capacity for uncompensated care.
3308536|NCT01906645|Experimental|C-TraIn|Care Transitions Innovation (C-TraIn) was delivered in addition to usual care, and includes (1) transitional nurse coaching and education, including post-discharge phone calls and home visits for highest risk patients; (2) pharmacy care that includes patient education, medication reconciliation, guidance to inpatient providers to encourage low-cost medications, and provision of 30 days of medications after discharge for those without prescription drug coverage; (3) post-hospital primary care linkages; (4) and explicit efforts at system integration through monthly quality improvement meetings.
3308537|NCT01906671|Experimental|Puri-Nethol|Tablet formulation of 6-mercaptopurine
3308538|NCT01906671|Experimental|Xaluprine|Oral liquid formulation of 6-mercaptopurine
3308539|NCT01906684|Experimental|Acthar Gel|Acthar Gel is supplied as 5 mL multi-dose vial (63004-8710-1) containing 80 USP Units per mL. H.P. Acthar Gel (repository corticotropin injection). Acthar Gel will be administered as a subcutaneous daily dose of 80 units for up to 2 weeks.
3308540|NCT01906697|Active Comparator|group B|middle turbinate resection
3308541|NCT01906697|Active Comparator|group C|middle turbinate medialization
3308542|NCT01906697|Active Comparator|group A|middle turbinate Radio Frequency (RF) turbinoplasty
3308543|NCT01906710|Placebo Comparator|usual care|During admission patients receive standard, non - ward based, pharmaceutical care from a pharmacy team in taking responsibility for the appropriate, safe and cost-effective use of medication from a central hospital pharmacy. The pharmaceutical care consist of daily screening of generated alerts by the Computerized physician order entry (CPOE) system and consultation by phone. Dependent on the local situation the current medication reconciliation process is being performed by nursing and/or medical staff either protocolised or not.
3308544|NCT01906710|Active Comparator|integrated medicines management|"integrated medicines management consists of~patient centred medication reconciliation~intermediate medication review~discharge counseling~transfer of information to primary care"
3308545|NCT01906749|Placebo Comparator|Placebo|Placebo
3308546|NCT01906749|Active Comparator|Colchicine|Colchicine 0.5mg once daily for 24 months
3308547|NCT01906762|Experimental|Acetaminophen|Specified dosage for Acetaminophen was 15 mg/kg. so based on the patient's weight(averagely 70 kg), about 1gr Acetaminophen (one complete Apotel Ampule) was used.
3308548|NCT01906762|Experimental|Morphine|Specified dosage for Morphine was 0.1 mg/kg. so based on the patient's weight(averagely 70 kg), about 7 mg Morphine was used.
3308549|NCT01906775||Patients with PIT|Identification of patients with pacemaker-induced ventricular tachycardias
3308550|NCT01906788|Active Comparator|Group 1|Active comparator: Artemether Lumefantrine 6 dose regime orally
3308551|NCT01906788|Experimental|Group 2|Experimental: Artemether Lumefantrine 6 dose regime Plus single dose Primaquine (0.75/kg) on day 0
3308552|NCT01906788|Experimental|Group 3|Experimental: Artemether Lumefantrine 6 dose regimen plus single dose of Primaquine (0.75/kg) on day 2
3308553|NCT01906801|Experimental|Glucosamine sulfate & Diacerein|Glucosamine sulfate (sachet) 1500 mg and Diacerein 50 mg tablet by mouth once daily for 24 weeks
3308554|NCT01906801|Active Comparator|Glucosamine sulfate & Placebo|Glucosamine sulfate 1500 mg and Placebo (for Diacerein) 50 mg by mouth once daily for 24 weeks
3308555|NCT01906814|Experimental|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
3308556|NCT01906814|Active Comparator|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
3308557|NCT01906827||pregnant with ICP|pregnant with ICP
3308558|NCT01906840|Experimental|drug: turmeric capsule|Intervention is turmeric (one capsule with each meal containing 500 mg turmeric, of which 22.1 mg was the active ingredient curcumin; three capsules daily) for 8 weeks
3308559|NCT01906840|Placebo Comparator|Drug: placebo,capsule|Intervention is daily starch capsules 500 mg for 8 weeks
3308560|NCT01906853|No Intervention|No BCG|No BCG
3308561|NCT01906853|Experimental|BCG|Mycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
3308562|NCT01906879|Active Comparator|Triple therapy (A)|lansoprazole, 30mg, twice daily, for 14 days, po clarithromycin, 500mg, twice daily, for 14 days, po amoxicillin, 1gm, twice daily, for 14 days, po
3308563|NCT01906879|Experimental|non-bismuth quadruple therapy|Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid
3308564|NCT01906879|Experimental|bismuth quadruple therapy for 10 days|Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid
3308565|NCT01906892|Experimental|1a|6 weeks of group drumming workshops
3308566|NCT01906892|Experimental|1b|6 weeks of group drumming workshops
3308567|NCT01906892|Experimental|2a|2 weeks of active group drumming followed by 2 weeks of control activity involving a literary-based activity
3308568|NCT01906892|Active Comparator|2b|2 weeks of the literary-based comparative activity followed by 2 weeks of watching live group drumming
3308569|NCT01906892|Active Comparator|2c|2 weeks of listening to live group drumming followed by 2 weeks of listening to recordings of group drumming
3308570|NCT01906892|Active Comparator|2d|2 weeks of listening to recorded group drumming followed by 2 weeks of participation in group drumming
3308571|NCT01906892|Experimental|3a|10 weeks of participatory group drumming workshops
3308572|NCT01906892|Active Comparator|3b|10 weeks of engagement with other non-musical social activities
3308573|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation|Active TMS (1)
3308574|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 2|Active TMS (2)
3308575|NCT01906905|Active Comparator|Transcranial Magnetic Stimulation 3|Active TMS (3)
3308576|NCT01906918|Experimental|IRPC, Remote preconditioning|This group will be submitted to ischemic preconditioning
3308577|NCT01906918|Placebo Comparator|Control|This patients will be submitted to the standard surgery protocol in the institution. The patients will not be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion.
3308578|NCT01906931|Experimental|Portable Oxygen Concentrator first|
3308579|NCT01906931|Active Comparator|Portable oxygen cylinder first|
3308580|NCT01906944|Active Comparator|Trigger point injection|Trigger point injection under ultrasound guidance into the fascial layer above the external oblique or rectus muscle, whichever corresponds to patient's identifiable trigger point. The injectate will include 5 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
3308581|NCT01906944|Active Comparator|Transversus abdominis plane block|Injection into transversus abdominis plane layer under ultrasound guidance on the affected side along the mid-axillary line. The injectate will include 10 ml of bupivacaine 0.25% mixed with triamcinolone 20 mg.
3308582|NCT01906957|Experimental|Elderly healthy subjects|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3308583|NCT01906957|Experimental|Patients with metabolic syndrome|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3308584|NCT01906957|Experimental|coronary patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3308585|NCT01906957|Experimental|heart failure patients|"Randomization into :~high intensity interval training (HIIT)(n=20)~or~moderate intensity intensity continuous exercise (n=20)"
3308586|NCT01906983||Doppler ultrasound.|Doppler ultrasound will be performed to All patients 18 and up, admitted to Rambam Medical Center with diagnosis of blunt splenic trauma and agree to participate the study.
3308587|NCT01906996||proximal row carpectomy|patients were treated with a proximal row carpectomy
3308588|NCT01906996||four corner fusion|patients were treated with a four corner fusion
3308589|NCT01907009|Experimental|Registration.|"MELCAP study has only one arm. All suitable patients will receive 3 cycles of melphalan and lenograstim alternately.~Patient will start with a 3 day lenograstim (at 10mcg/kg/day) to boost up the blood cell count.~Upon reaching sufficient blood cell count, patients will undergo a venesection and roughly a pint of blood is taken. After this patients will receive first cycle of Melphalan (60mg/m2). The following day patient will receive back the previously given whole blood. A treament break of 6 days between the cycles is given. After the break the patient will be given Lenograstim (10mcg/kg/day)for 6 days (until sufficient).~The above regimen is repeated for cycle 2 and cycle 3 with only exception of Melphalan is given at 40mg/m2. After the cycle 3, Lenograstrim is given at 263 mcg/day for 10 days.~Upon treatment completion, patients will be followed for 2 years. If the patients show disease progression, they will start hormone therapy."
3308590|NCT01907022|Experimental|Left dorsolateral prefrontal cortex (DLPFC) Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
3308591|NCT01907035|Experimental|Cognitive-behavioral intervention|Cognitive-behavioral intervention: Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with practitioner plus routine therapy in the field of primary care in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
3308592|NCT01907035|Active Comparator|Usual care|Family practice attention without the psychologist support
3308593|NCT01907048||Group 1|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
3308594|NCT01907048||Group 2|Survey to measure patient awareness and understanding of the key messages in the patient card.
3308595|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo IV|600 mg N-acetylcysteine or placebo IV perfused over 15 minutes during the transplant procedure, prior to reperfusion,
3308596|NCT01907061|Active Comparator|600 mg N-acetylcysteine or placebo NG|600 mg NAC or placebo administered via NG tube starting at 12 hrs + 30 min post O.R. infusion,
3308597|NCT01907061|Active Comparator|N-acetylcysteine or placebo q 12 hour|600 mg NAC or placebo administered via NG tube every 12 hrs + 30 min for 3 additional doses (at 24, 36 and 48 hrs post O.R. infusion). The total administration will be 3000 mg over a 48 hr period.
3308598|NCT01907074|Experimental|Cholates Compound|
3308599|NCT01907126|Experimental|Women's Prison CoOp (WPC)|Will receive 5 group psychoeducation sessions plus individual pre-release and post-release goal planning sessions. Psychoeducation sessions will cover HIV risk and violence prevention, interpersonal violence-specific sexual safety skills, empowerment through knowledge and treatment, and skills for increasing affect regulation and social support.
3308600|NCT01907126|Placebo Comparator|Nutrition program (NP)|Participants in this condition will receive dose-matched nutrition education.
3308601|NCT01907139|Experimental|Distributed constraint-induced therapy (dCIT)|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks.
3308602|NCT01907139|Experimental|Robot-assisted therapy (RT)|The ArmeoSpring (Hocoma AG, Switzerland) will be adopted in this study. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. The ArmeoSpring g provides weight support for the arm across a large 3D workspace, enabling naturalistic movement across approximately 66% of the normal workspace in the vertical plane and 72% in the horizontal plane. Its main structure consists of an arm exoskeleton with elastic bands that relieve the weight of the limb and provide a sense of arm flotation at all positions in the available workspace. A custom grip sensor consisting of a water-filled cylindrical bladder detects grip pressure and finger movement and allows incorporation of grasp and release practice into arm training.
3308603|NCT01907139|Active Comparator|Dose-matched control therapy (DMCT)|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening.
3308604|NCT01907139|Experimental|RT + dCIT|In this combination therapy group, the participants will received 2 weeks of RT using the ArmeoSpring and followed by 2 weeks of distributed CIT. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively. This combined intervention group may integrate proximal (shoulder and elbow) to distal (wrist and hand) training of the UL and help transfer from motor ability gained to functional performance improvement. That is, it appears to associate with the advantages/effects of each RT and dCIT intervention.
3308605|NCT01907152|Experimental|Protein enriched yoghurt drink and bread|Yoghurt drink enriched with Whey Protein Concentrate Whole wheat bread enriched with cereal protein and soy
3308606|NCT01907152|No Intervention|Regular yoghurt drink and bread|Commercially available yoghurt drink and whole wheat bread
3308607|NCT01907165|Experimental|Maintenance Temozolomide + Disulfram|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months. Disulfiram (dose level 0 = 500 mg PO QD or dose level 1 1000 mg PO QD) on days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3308608|NCT01907165|Experimental|Maintenance Temozolomide + Disulfiarm + Copper Gluconate|"Beginning 4-6 weeks after completion of radiation therapy, patients receive maintenance temozolomide 150-200 mg/m2 PO QD on Days 1-5 every 28 days for 6 months, disulfiram 500 mg PO QD (dose of disulfiram determined to be the MTD) on Days 1-28, and copper gluconate 6 mg PO QD on Days 1-28. Treatment repeats every 28 days for 6 courses* in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients may receive additional maintenance temozolomide at the discretion of the treating medical oncologist."
3308609|NCT01907178||Postoperative pain management|The postoperative pain level will be assessed during hospitalization and at home, in patients undergoing total knee replacement
3308610|NCT01907191|Experimental|Liposomal bupivacaine|Ultrasound guided injection of liposomal bupivacaine
3308611|NCT01907191|Active Comparator|Bupivacaine|Bupivacaine (around the anterior, lateral and medial aspect of hip joint)
3308612|NCT01907204|Active Comparator|Oral|Oral drug (methylprednisolone) administration
3308613|NCT01907204|Experimental|Metered dose inhaler|
3308614|NCT01907204|Experimental|Nebulized|
3308615|NCT01907230|Experimental|Entecavir, Prophylactic group|Participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
3308616|NCT01907230|No Intervention|Control group (pre-emptive treatment)|Patients will start entecavir therapy, 0.5 mg/day orally, when reactivation of HBV (defined as detectable HBV viral loads for 2 consecutive visits with at least one month apart), and continued entecavir treatment until undetectable HBV viral loads for 1 year (consistent with current APASL recommendation).
3308617|NCT01907243|Active Comparator|spreader flap|Usage of spreader flap of upper lateral cartilage
3308618|NCT01907243|No Intervention|Control group|performing of rhinoplasty without spreader flap
3308619|NCT01907256|Active Comparator|group A|stair step incisions
3308620|NCT01907256|Active Comparator|Group B|inverted V incision
3308621|NCT01907282|Experimental|Family Focused Treatment|Family-Focused Treatment (FFT) consists of 18 sessions of psychoeducation, communication enhancement training, and problem-solving skills training in six months
3308622|NCT01907282|Active Comparator|Enhanced Care|Enhanced care is a 3-session family psychoeducational therapy focused on prevention of psychotic symptoms
3308623|NCT01907295||Patients|Patients diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH
3308624|NCT01907295||Relatives and controls|Relative has a family member diagnosed with idiopathic, anorexigen-induced, heritable PAH and PVOD/PCH Self declared healthy individuals
3308625|NCT01907308|Experimental|Combination of AMG 386 with Docetaxel|All treated patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
3308626|NCT01907347||ICU patients|
3308627|NCT01907373|Active Comparator|olmesartan medoxomil, PK of olmesartan|drug: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days
3308628|NCT01907373|Experimental|olmesartan medoxomil+probenecid, PK of olmesartan|drug1: olmesartan medoxomil; dosage form: oral tablet; dosage: 20mg/time; frequency: once a day; duration: 4 days; drug2: probenecid; dosage form: oral tablet; dosage: 500mg/time; frequency: 2 times/day; duration: 1 day
3308629|NCT01907386|Other|QSE-LSME and SSWI ultrasound|"QSE-LSME and SSWI ultrasound examinations combined with a clinically required CT-scan. We will screen 3 groups of 15 patients each, with at least one-year follow-up after EVAR, matched for sex, age and aneurysm diameter at baseline (before EVAR).~Group 1. Patients without endoleak and a maximal diameter reduction at one year of at least 10% and a volume reduction of 20%.~Group 2. Patients with a stable sac volume and diameter (less than 10% volume and 5% diameter variation within a year).~Group 3. Patients with type I, type II or type V endoleak (endotension) with more than 10% diameter progression and 20% volume progression."
3308630|NCT01907399|Other|obese patients|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)
3308631|NCT01907399|Other|obese patients with type 2 diabetes|(BMI> 30 kg/m2) androids (waist circumference> 102 cm in men and> 88 cm in woman)with diabetes
3308632|NCT01907399|Other|healthy volunteers|free of disease inflammatory or infectious and will have a BMI <25 Kg/m2et fasting glucose <1g / L
3308633|NCT01907412|No Intervention|Control Group|Couples in the Control group did not receive the Family Foundations Coparenting Program.
3308634|NCT01907412|Experimental|Intervention Group|Couples randomly assigned to the Intervention Group received the Family Foundations Coparenting Program.
3308635|NCT01907425|Other|Pre-natal Patient|
3308636|NCT01907438||non-carriers|Tissues from premenopausal women undergoing esthetic breast surgery with no family history of breast or ovarian cancers will be obtained.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3308637|NCT01907438||BRCA1 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA1 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3308638|NCT01907438||BRCA2 mutation carriers|Tissues from risk-reducing mastectomy in healthy premenopausal women with BRCA2 mutations undergoing.epithelial breast cells will be isolated, treated with estrogen for 48 h and then will be irradiated.
3308639|NCT01907451||The control group|"will receive support traditional10 hours per week: techniques called neuro-facilitators"
3308640|NCT01907451||test group|enjoy the same support as control group at 7 hours week, coupled with a personalized retraining effort ergometer for 3 hours per week: after a 5 minute warm to 50% of Heart Rate Maximum (HRmax) of the initial test effort (TE), continuous work of 20 minutes at an intensity corresponding to 70% HRmax, followed by a recovery period of 5 min between active 40 and 50% of maximum heart rate (5 times per week).
3308641|NCT01907464|Experimental|Patients with anorexia nervosa|This arm is the experimental arm composed of patients
3308642|NCT01907464|Active Comparator|controls subjects|This arm is composed of healthy volunteers
3308643|NCT01907477|Other|neutropenic patients|
3308644|NCT01907503|Other|Patients with Primary hip osteoarthritis|Patients with Primary hip osteoarthritis
3308645|NCT01907503|Other|Healthy volunteer|Healthy volunteer
3308646|NCT01907529|Experimental|Chemo plus Endostar|Docetaxel, epirubicin and cyclophosphamide plus endostar
3308647|NCT01907529|Active Comparator|Chemo only|docetaxel, epirubicin and cyclophosphamide
3308648|NCT01907542|Active Comparator|Monocryl suture skin closure|Monocryl skin suture
3308649|NCT01907542|Active Comparator|Stapled skin closure|stapled skin closure
3308650|NCT01907555||- Patients presenting Cohen syndrome and two VPS13B mutations|
3308651|NCT01907555||Patients presenting Cohen syndrome without a VPS13B mutation|
3308652|NCT01907555||Patients presenting neutropenia|
3308653|NCT01907568||Patients with schizophrenia|With and without hallucinations
3308654|NCT01907568||Patients with borderline personality disorder|With and without hallucinations
3308655|NCT01907568||Patients with hearing impairment|With and without hallucinations
3308656|NCT01907568||Patients with visual loss|With and without hallucinations
3308657|NCT01907568||Patients with Parkinson's Disease|With and without hallucinations
3308658|NCT01907568||Patients with Alzheimer's Disease|With and without hallucinations
3308659|NCT01907568||Patients with dementia with Lewy Bodies|With and without hallucinations
3308660|NCT01907568||Patients with Posttraumatic Stress Disorder|With and without hallucinations
3308661|NCT01907568||Patients with delirium|With and without hallucinations
3308662|NCT01907568||Healthy participants|With and without hallucinations
3308663|NCT01907568||Patients with mood disorder|With and without hallucinations
3308664|NCT01907581|Other|Patients admitted to an ICU|
3308665|NCT01907594|Active Comparator|D-cycloserine|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
3308666|NCT01907594|Placebo Comparator|Gelatin Capsule|The investigators will randomize participants to either DCS 250 mg or placebo, administered daily for four days.
3308667|NCT01907620|Other|Normal pregnancy|women pregnant
3308668|NCT01907620|Other|pregnancy complicated by pre-eclampsia|women with pregnancy complicated by pre-eclampsia
3308669|NCT01907633||Domperidone/ a proton pump inhibitor/metoclopramide users|Study patients had at least one prescription for domperidone, a proton pump inhibitor, or metoclopramide. Proton pump inhibitors observed in this study are: omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole.
3308670|NCT01907646|Experimental|Bladder training group|The patients of this group were submitted to passive vesical gymnastic during the second and third postoperative days, throughout the closure of the catheter for 3 h and open it for 15 min all day long.
3308671|NCT01907646|Experimental|No bladder training group|The patients of this group were not submitted to passive vesical gymnastic during the second and third postoperative days
3308672|NCT01907659|No Intervention|Standard of care|Standard of care for respiratory infections
3308673|NCT01907659|Experimental|Release of test results|Health care providers will receive viral PCR and PCT test results along with an algorithm recommending antibiotic treatment based on PCT level.
3308674|NCT01907672|Experimental|Rapid Diagnostic Test|Rapid Diagnostic Test for malaria to direct antimalarial dispensing decisions in Chemical Shops
3308675|NCT01907672|No Intervention|No RDT|Chemical sellers dispense antimalarials as per their own decisions without the benefit of test results
3308676|NCT01907685|Experimental|AVE8062 / Docetaxel|AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria
3308677|NCT01907698||Vaginal coitus group|Pregnant women assigned to have vaginal coitus at least twice a week
3308678|NCT01907698||Control group|Pregnant women assigned to have no vaginal intercourse
3308679|NCT01907711|Sham Comparator|Sham Acupuncture.|That through the center of the guide tube is inserted blunt rod, producing the sensation of a prick in each of the eight points that are not acupuncture points. No intervention is a completely inert as it involves some type of peripheral stimulus, but the technique is closer to a placebo and offers interesting option from a methodologic al point of view showing and ability to mimic real acupuncture The points are not used acupuncture points but are fictional points. The patient should remáis lying prone during the 20 minutes of the session, so the placebo technique remains hidden. Every five minutes the acupuncturist will repeat the action in the corresponding eigh points.
3308680|NCT01907711|Active Comparator|True acupuncture|The AV is an energy balance treatment with the aim of restoring health and well-being of the patient. Since each patient may have moré than three diagnoses of Traditional Chinese Medicine, will undertake a Major effort of synthesis of acupuncture points for treatment in a session, use the AV 8 - 12 needles, are held in place for 20 minutes with bidirectional rotation of the sleeve needle for one minute every five minutes (a total of four rotations for session). And in the AS 8 tube rod guides with blunt tip for 20 minutes. The same time be devoted to the patients in each treatment group similar, the time requested for the period of pre and post-treatment will be identical in all cases.
3308681|NCT01907724|Experimental|IDX719 + RTV|Participants take IDX719 150 mg once daily (QD) + ritonavir 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
3308682|NCT01907724|Experimental|Simeprevir/TMC647055 + RTV|Participants take simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 1-7, and then take IDX719 150 mg QD + simeprevir 75 mg QD + TMC647055 450 mg QD + RTV 30 mg QD on Days 8-14.
3308683|NCT01907750|Active Comparator|Transanastomotic tube|use of transanastomotic tube.
3308684|NCT01907750|Active Comparator|Transcystic tube|use of transcystic tube to drain bile duct
3308685|NCT01907763|Experimental|SOTB07 200mg|One tablet of SOTB07 200mg and One tablet of SOTB 400mg Placebo are administered twice a day.
3308686|NCT01907763|Experimental|SOTB07 400mg|One tablet of SOTB07 400mg and One tablet of SOTB 200mg Placebo are administered twice a day.
3308687|NCT01907763|Placebo Comparator|Placebo|One tablet of SOTB 200mg Placebo and One tablet of SOTB 400mg Placebo are administered twice a day.
3308688|NCT01907776|Experimental|ME1100|ME1100 inhalation solution (arbekacin for oral inhalation at 150 mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
3308689|NCT01907776|Placebo Comparator|Placebo|ME1100 placebo inhalation solution
3308690|NCT01907789|Experimental|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
3308691|NCT01907789|Experimental|Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
3308692|NCT01907789|Experimental|Risk-Reducing Salpingo-Oophorectomy (RRSO)|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
3308693|NCT01907802|Experimental|Treatment (dabrafenib)|Patients receive dabrafenib PO BID on days 1-28 (QD on day 1 of course 1). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3308694|NCT01907841|Experimental|Ischemic Preconditioning|IPC (4 x 5 minute cycles @ 220 mmHg) with 5 min reperfusion between trials.
3308695|NCT01907841|Placebo Comparator|Ischemic Preconditioning Placebo|Placebo (4 x 5 minute cycles @ 20mmHg) with 5 minutes between each cycle
3308696|NCT01907867|Experimental|Cohort 1|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 3 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 6 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3381227|NCT03809962||Ostenil® Plus|1-3 injections of sodium hyaluronate 2% (40 milligrams (mg) / 2,0 millilitres (ml)) in weekly interval.
3381228|NCT03808402||High dose surfactant|Infants who receive a first dose of surfactant between 170 and 200 mg/kg
3381229|NCT03808402||Low dose surfactant|Infants who receive a first dose of surfactant between 100 and 130 mg/kg
3381230|NCT03808064|Experimental|Intervention arm|After randomization, the FCHVs in the intervention arm will receive training, health education materials and a recording register. After receiving training, they will educate women of their respective ward on cervical cancer screening and prevention through home visits and maintain records in their service register.
3308697|NCT01907867|Experimental|Cohort 2|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 8 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3381231|NCT03808064|No Intervention|Control arm|There won't be any intervention in the control arm.
3381232|NCT03805789|Experimental|AAT (low dose)|Open label. Alpha-1 antitrypsin (AAT) is a lyophilized product for intravenous administration
3381233|NCT03805789|Experimental|AAT (medium dose)|Open label. AAT is a lyophilized product for intravenous administration
3381234|NCT03805789|Experimental|AAT (high dose)|Open label. AAT is a lyophilized product for intravenous administration
3381235|NCT03805789|Experimental|AAT (selected dose from open-label)|Double-blind. AAT is a lyophilized product for intravenous administration
3381236|NCT03805789|Placebo Comparator|Placebo|Albumin solution administered intravenously
3381237|NCT03795298|Experimental|WATCHMAN FLX|WATCHMAN FLX implant including modified post-implant drug regimen.
3381238|NCT03795298|Active Comparator|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
3381243|NCT03788642|Active Comparator|Control LED Shoe arm|Patients with DFU will wear LED shoe 30 minutes per day
3381244|NCT03788642|Active Comparator|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes per day
3381245|NCT03788213|Active Comparator|3 week RT|Adjuvant Radiotherapy delivered over 3 weeks
3381246|NCT03788213|Experimental|1 Week RT|Adjuvant Radiotherapy delivered over 1 week
3381247|NCT03786926|Experimental|Treatment|All patients take HMPL-689 taken daily
3381248|NCT03783884|Active Comparator|Treatment|Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation.
3308698|NCT01907867|Experimental|Cohort 3|"Day 1: Finafloxacin 800 mg will be administered as an oral dose once in the morning (first dose). Subjects will have plasma PK samples drawn at specified times around the first dose. Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 12 hours after the oral dose.~Day 2: Finafloxacin 800 mg will be administered as an oral dose once in the morning (second dose).~Day 3: Finafloxacin 800 mg will be administered as an oral dose once in the morning (third dose). Subjects will have plasma PK samples drawn at specified times around the third dose.~Bronchoscopic microsampling will be performed to obtain bronchial ELF samples in triplicate at 24 hours after the oral dose, followed immediately by BAL to obtain alveolar ELF samples."
3308699|NCT01907880|Active Comparator|Pamidronate and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Pamidronate and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
3308700|NCT01907880|Active Comparator|Zoledronic acid and placebo|Patients will receive two infusions simultaneously, at each study visit, one of Zoledronic acid and another of the placebo. After completing 3 cycles of study treatment, patients will resume their monthly intravenous pamidronate infusions as per current standard of care.
3308701|NCT01907893|Experimental|Trauma Collaborative Care Plus Treatment as Usual|Three components: (1) Services provided through the Trauma Survivors Network (TSN) Program; (2) Provider training to reinforce referral to and use of TSN programs; and (3) Enhancement of collaborative care through the use of a TSN Coordinator (TSN-C).
3308702|NCT01907893|No Intervention|Treatment as Usual|Study patients treated at Control Sites will have access to all services typically available to patients treated at these centers.
3308703|NCT01907919||conventional group,RM-GIC|1. Group A: Five teeth were treated with traditional rotating instruments, the cavities were prepared with diamond drills by turbine, multiple-blade drills by headpiece for removing the decayed dentine and, after cleaning and control of bleeding with cotton pellets with saline solution,RM-GIC (3M ESPE, USA) light-hardening paste was placed gently on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA).
3381249|NCT03783884|No Intervention|Control|Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation.
3381250|NCT03778229|Experimental|osimertinib + savolitinib|osimertinib + savolitinib
3381251|NCT03773965|Experimental|Baricitinib|Baricitinib given orally.
3381252|NCT03769519|No Intervention|Control (Group 1)|This group is considered the control group. This group will have scheduled texts and emails for the monthly surveys after the participant completes the baseline questionnaires.
3381253|NCT03769519|Experimental|ARICA Intervention (Group 2)|This group is considered the intervention group. Participants in this group will receive weekly texts and emails containing asthma facts and myths. They will also complete monthly surveys and participate in asthma education sessions.
3381254|NCT03763838|Experimental|Acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are known to affect physiology. Participants will also receive standard of care.
3381255|NCT03763838|Sham Comparator|Sham acupressure plus standard of care|Using AcuWand, participants will apply acupressure to points that are not known to affect physiology. Participants will also receive standard of care.
3381256|NCT03763838|Other|Standard of care|Participants will receive standard of care only.
3381259|NCT03756792|Active Comparator|First Time Control|Patients with no prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
3381260|NCT03756792|Experimental|First Time Intervention|Patients with no prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
3381261|NCT03756792|Active Comparator|Previous Experience Control|Patients with prior experience of Mohs surgery will be randomly assigned to the control group. The control group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology, then fill out a brief survey.
3381262|NCT03756792|Experimental|Previous Experience Intervention|Patients with prior experience of Mohs surgery will be randomly assigned to the intervention group. The intervention group will receive the normal education material that MMS patients receive from Wake Forest Baptist Health Dermatology and read a vignette about the typical experience of a Mohs patient, then fill out a brief survey.
3381263|NCT03754790|Experimental|Fitusiran|Participants will be administered fitusiran as an subcutaneous injection once monthly or every other month for 48 months.However, for participants enrolled in the lower-dose cohort, duration of fitusiran administration may exceed 48 months, to ensure a minimum of 18-month administration at this dose level.
3381264|NCT03745651|Placebo Comparator|Vehicle Control (VC) Period: Vehicle Cream BID|Participants received ruxolitinib matching vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3381265|NCT03745651|Experimental|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3308704|NCT01907919||Diode 808 nm laser-assisted group|"2. Group B : Five teeth cavities were prepared as the same with group one with traditional rotating instruments, hemostatic and cavities sterilization were achieved by a diode 808 nm (Picasso- AMD, USA) laser using following parameters:~Hemostatic: 1.5 W, CW, fiber diameter 400µm, in contact, 2s per 1mm, vertical and horizontal scanning movement on exposure site.~Cavity sterilization: 1W, CW, fiber diameter 400µm, in contact, 2mm per s, circular movement.~After hemostatic and cavity sterilization, RM-GIC (3M ESPE, USA) light-hardening paste was placed on the exposed part of the pulp and cavity floor next final restoration with composite z350 flow able and p60 (3M ESPE, USA)."
3308705|NCT01907932|Experimental|normal and various degrees splenomegaly|"VScan Ultrasound (GE Healthcare, USA) all subjects will be measured by 5 different medical residents~Each resident will complete questionaire:~Adequacy of image quality~What is best view obtained~Greatest Longitudinal Measure~Diagnosis~Diagnostic Certainty~Time to Complete exam"
3308706|NCT01907945|Experimental|Intervention|Participant households in this arm are eligible for participation in the social network-based water treatment education program (referred to as the Microclinic Water Program). Participant households who do not enroll in the Microclinic Water Program receive household-based education identical to that of the 'comparison' arm.
3308707|NCT01907945|Active Comparator|Comparison|Participant households in this arm receive household drinking water treatment education at the household level.
3308708|NCT01907971||Ebstein anomaly|Patients with Ebstein anomaly
3308709|NCT01907984|Experimental|Diclofenac and Midazolam|Diclofenac 100 mg tablet and Midazolam 7.5 mg tablet were administered by mouth as premedication 30 minutes before surgical interventions.
3308710|NCT01907984|Active Comparator|Midazolam|Midazolam 7.5 g tablet was administered as premedication by mouth 30 minutes before surgical interventions.
3308711|NCT01907997|Experimental|Group L|Intravenous lidocaine infusion group
3308712|NCT01907997|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
3308713|NCT01908010|Experimental|Group 1, low dose|ABT-354
3308714|NCT01908010|Experimental|Group 2, high dose|ABT-354
3308715|NCT01908023|Experimental|exercise|
3308716|NCT01908049|Experimental|Probiotic|A probiotic (Saccharomyces boulardii) 2 caps/ 8h for 12 weeks.
3308717|NCT01908049|Placebo Comparator|Placebo|No active substance is given.
3308718|NCT01908075||BDP/FOR|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD): Change their therapy to BDP/FOR (Fostair®) at same or lower BDP-equivalent ICS dose
3308719|NCT01908075||FP/SAL|Patients receiving ICS/LABA therapy as FP/SAL (Seretide®) who, at an index prescription date (IPD) : Remain on FP/SAL at the same BDP-equivalent ICS dose
3308720|NCT01908088|Experimental|fibroblast transplant|Transplantation of autologous cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hand deformity
3308721|NCT01908114|No Intervention|Group A|Routine Polio Program activities will be carried out with out any active intervention
3308722|NCT01908114|Experimental|Group B|"Expanded intervention with following components~Community support groups for both male and female at village/community level~Enhanced communication package and involvement of local social networks for group counseling on promotion of nutrition, hygiene and Expanded Program of Immunization (EPI) vaccinations~Involvement of Private sector (General Physicians,health care providers etc.) through advocacy and inclusion in Supplementary Immunization activities (SIAs)~Delivery of interventions & commodities through low cost health camps during National Immunization days (NIDs) and SIAs (will also assist in mop-up campaigns)"
3308723|NCT01908114|Experimental|Group C|All Interventions of Group A and B Plus combined bOPV/IPV strategy in the SIAs during the project
3308724|NCT01908153||Overweight/Obese|Children with BMI percentile of 85 or above.
3308725|NCT01908153||Healthy Weight|Children with BMI percentile between 15 and 85.
3308726|NCT01908166|Experimental|Diagnostic (ultrasound elastography)|Patients undergo ultrasound elastography.
3308727|NCT01908192|Experimental|NaBen®|NaBen® is a white oral tablet (500 mg), which will be taken twice daily at a total dose of 1000 mg/day during this study.
3308728|NCT01908192|Placebo Comparator|Placebo|The control treatment is placebo.
3308729|NCT01908218||ULBT group|344 adult patients undergoing general anesthesia with orotracheal intubation
3308730|NCT01908231||Pulmonary Embolism|Consecutive adult patients (minimum age eighteen) who presented to the ED of the hospitals participating in the study with clinical suspicion of PE will be considered for the study. We excluded patients with life expectancies of less than 3 months, and patients with first symptoms 15 days or more before inclusion.
3308731|NCT01908244|No Intervention|Control|No pentatonic music
3308732|NCT01908244|Experimental|Music|
3308733|NCT01908257|Experimental|Sequence 1 fasted|"Day 1: Lesinurad 400 mg once daily (qd)~Day 5: Ranitidine 150 mg twice daily (bid)~Day 6: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad.~Day 7: Ranitidine 150 mg (bid)"
3308734|NCT01908257|Experimental|Sequence 2 fasted|"Day 1: Ranitidine 150 mg (bid)~Day 2: Lesinurad 400 mg (qd) + ranitidine 150 mg (bid). Ranitidine dosed at -2 hours predose and 12 hours postdose of lesinurad~Day 3: Ranitidine 150 mg (bid)~Day 7: Lesinurad 400 mg (qd)"
3308735|NCT01908270|Experimental|Yoga|Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
3308736|NCT01908270|Other|Usual care|Patients continue usual care by their practitioner
3308737|NCT01908283|Experimental|Patient non immunosuppressed|Group 1 : patient without immunosuppressive treatment
3308738|NCT01908283|Experimental|Patient immunosuppressed|Group 2 : patient with immunosuppressive treatment
3308739|NCT01908296|Experimental|FK949E group|receiving FK949E with and without fluvoxamine
3308740|NCT01908309|Active Comparator|Iodixanol|Patients randomized to coronary angiography/angioplasty with Iodixanol 320
3308741|NCT01908309|Active Comparator|Iobitridol|Patients randomized to coronary angiography/angioplasty with Iobitridol 350
3308742|NCT01908322||Group 1|
3308743|NCT01908335|Experimental|A (PEG-IFN-SA /RBV low dose)|PEG-IFN-SA 0.75μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
3308744|NCT01908335|Experimental|B (PEG-IFN-SA /RBV middle dose)|PEG-IFN-SA 1.5μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
3308745|NCT01908335|Experimental|C (PEG-IFN-SA /RBV high dose)|PEG-IFN-SA 2.0μg/kg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
3308746|NCT01908335|Active Comparator|D (Pegasys /RBV)|Pegasys 180μg/week and RBV 1000mg-1200mg/d bid depending on body weight(BW),（BW<75kg，1000mg/d；BW≥75kg，1200mg/d）
3308747|NCT01908348|Experimental|Erythritol|Orange-flavored beverage containing 6, 12, or 18 grams of erythritol
3308748|NCT01908361|Experimental|Unilateral Hybrid (InMotion3 plus CIT) Intervention|Participants will receive 3 weeks of robot-assisted therapy (RT) using the InMotion3 Wrist Robot, followed by 3 weeks of CIT training.
3308749|NCT01908361|Experimental|Bilateral Hybrid (BMT plus BAT) Intervention|Participants in this bilateral treatment group will receive 3 weeks of RT using the Bi-Manu-Track (BMT) robot (Reha-Stim Co., Berlin, Germany), followed by 3 weeks of therapist-based BAT.
3308750|NCT01908361|Active Comparator|Conventional Rehabilitation (CR)|The CR intervention will be designed to match the duration and intensity of the hybrid interventions.
3308751|NCT01908374|Active Comparator|DHA-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish oil in triglyceride form (12 capsules/d providing 575 mg/d EPA; 1843 mg/d DHA; 259 mg/d n-3 DPA)
3308752|NCT01908374|Experimental|Phospholipid-rich fish oil|DHA-rich fish oil versus Phospholipid-rich fish oil Fish roe high in EPA/DHA phospholipids [(12 capsules/d providing 628 mg/d EPA; 1810 mg/d DHA; 137 mg/d n-3 docosapentaenoic acid (DPA)]
3308753|NCT01908387|Experimental|Oral azacitidine|
3308754|NCT01908400|Other|BMMNCs|Intravenous transfer of (BMMNCs)
3308755|NCT01908413|Experimental|CUDC-427|
3308756|NCT01908439|Experimental|Whole-body vibration|A new method for muscle reflex latency measurement
3308757|NCT01908452|Experimental|vitamin B6 (pyridoxine)|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
3308758|NCT01908452|Placebo Comparator|placebo|The 150 participating subjects will be randomized into 2 groups: 75 patients will receive vitamin B6 (1200 mg/day) and 75 patients will receive placebo, each for 12 weeks in a double-blind mode
3308759|NCT01908465|Active Comparator|Ebastine|Ebastine
3308760|NCT01908465|Placebo Comparator|placebo|Placebo
3308761|NCT01908478|Experimental|Combination: veliparib, gemcitabine, and IMRT|
3308762|NCT01908491|Active Comparator|IV PCA|hydromorphone with ketorolac
3308763|NCT01908491|Experimental|Continuous wound infusion|ON-Q Painbuster with ropivacaine
3308764|NCT01908504|Other|PET-CT|
3308765|NCT01908517|Experimental|HPV Vaccine Electronic Reminders|Parents in the intervention group will receive 1 electronic message per month in addition to the baseline and final assessments which equates to 8 contacts over a 7 month period. Specifically, intervention group participants will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey.
3308766|NCT01908543|Experimental|Iron treatment|"INTERVENTION: Ferrous sulphate 200mg oral tablet~This is a single arm study. Individuals in this arm will~have an additional 15 mls of supplementary research bloods taken with their usual clinic bloods~receive a single tablet of ferrous sulphate 200mg~fill in questionnaires that formally evaluate their nosebleed losses and dietary iron intake in the preceding 12 months~have a second blood sample later that day (20 mls of blood~Total number of participants in arm = 100"
3308767|NCT01908556|Experimental|Letrozol|All patients are treated with letrozole 2.5 mg for 5 years for the adjuvant treatment of postmenopausal patients with a hormone receptor positive primary breast cancer. Patients are treated according to the authorities' approval of the drug. Of all patients a germline DNA sample will be obtained before the treatment starts and serum samples will be taken at months 0, 6 and 12. Furthermore the paraffin embedded tissue block will be sent to a central pathology laboratory for central assessment of tumor biomarkers.
3308768|NCT01908569|Active Comparator|NO MACS + Time-lapse technology|The sperm capacitation will be performed through a density gradient. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
3308769|NCT01908569|Experimental|MACS + time-lapse technology|The sperm capacitation will be performed through a density gradient. After that, it will be subjected to the MACS technique in order to select the non-apoptotic spermatozoids. This sperm will be used in the IVF/ICSI treatment of the patient and the embryos obtained will be cultured using time-lapse technology (Embryoscope).
3308770|NCT01908595|Experimental|M518101|Proper quantity twice daily
3308771|NCT01908621|Active Comparator|G-CSF (filgrastim)|Patients will receive G-CSF(filgrastim) at 10 μg/kg per day (divided into two doses every 12 hours) subcutaneously for up to 7 days. On day 5, circulating CD34+ level will be determined. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease compared to the preceding day. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
3308772|NCT01908621|Active Comparator|Cytosine arabinoside + G-CSF (filgrastim)|Cytosine arabinoside will be administered as a 2-hour i.v. infusion at a dose of 0.4 g/m2 twice daily on days 1 and 2 (total dose 1.6 g/m2). G-CSF (filgrastim) 5-10 ug/kg will be started on day 5 and continued until last leukapheresis. The number of circulating CD34+ cells will be first evaluated after neutrophil recovery from nadir. Leukapheresis will be started when the CD34+ blood level will reach at least 10/µl. If the level will be not achieved, G-CSF administration will be continued until CD34+ level will decrease. Leukaphereses will be performed using Spectra-Optia Apheresis System (TherumoBCT Inc, Lakewood, CO, USA) according to the manufacturers protocols for mononuclear cell harvesting, processing 2 total blood volumes. In case of failing to harvest targeted number of stem cells (5 × 10^6 CD34+ cells/kg), next leukapheresis can be performed on following two days (maximum 3 leukaphereses) if circulating CD34+ cell level will remain as described above.
3308773|NCT01908647|Experimental|Exp RT fMRI/Exp Cognitive Training|Both experimental conditions.
3381266|NCT03745651|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID 8 hours apart from Day 1 up to Week 8. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3381267|NCT03745651|Experimental|Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381268|NCT03745651|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream during the VC Period were randomized at Week 8 to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381269|NCT03745651|Experimental|LTS Period: Ruxolitinib 0.75% Cream BID|Participants who applied ruxolitinib 0.75% cream during the VC Period, continued applying ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381270|NCT03745651|Experimental|LTS Period: Ruxolitinib 1.5% Cream BID|Participants who applied ruxolitinib 1.5% cream during the VC Period, continued applying ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID as needed from Week 8 up to Week 52. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381271|NCT03745638|Placebo Comparator|VC Period: Vehicle Cream BID|Participants received vehicle cream, applied topically to the affected areas as a thin film twice daily (BID) from Day 1 to Week 8 during the Vehicle Control (VC) Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3381272|NCT03745638|Experimental|VC Period: Ruxolitinib 0.75% Cream BID|Participants received ruxolitinib 0.75% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3381273|NCT03745638|Experimental|VC Period: Ruxolitinib 1.5% Cream BID|Participants received ruxolitinib 1.5% cream, applied topically to the affected areas as a thin film BID from Day 1 to Week 8 during the VC Period. Participants applied cream BID to areas identified at Baseline even if the areas improved.
3381274|NCT03745638|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 0.75% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the Long-term Safety (LTS) Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381275|NCT03745638|Experimental|LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID|Participants who applied vehicle cream BID during the VC Period, were randomized to apply ruxolitinib 1.5% cream, topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3308774|NCT01908647|Experimental|Exp RT fMRI/Ctrl Cognitive training|Experimental real-time fMRI and control cognitive training.
3308775|NCT01908647|Experimental|Ctrl RT fMRI/Exp Cognitive Training|Control RT fMRI (real-time functional MRI) and experimental cognitive training.
3308776|NCT01908647|Sham Comparator|Ctr RT fMRI/Ctr Cognitive Training|Control real-time fMRI and control cognitive training.
3308777|NCT01908660||Antiretroviral drugs|Pre-treated or treatment-naive HIV-infected patients with chronic hepatitis B and/or chronic hepatitis C who change an existing antiretroviral regimen or who start a new regimen.
3308778|NCT01908673|Active Comparator|HRV biofeedback|heart rate variability biofeedback
3308779|NCT01908673|Active Comparator|ASTM|Automatic Self Transcedental Meditation
3308780|NCT01908686|Active Comparator|Pivotal Response Training|Pivotal Response Training with children ages 4-35 years of age with an Autism Spectrum Disorder diagnosis
3308781|NCT01908686|No Intervention|Waitlist Control|Children in WL will be offered treatment following WL condition.
3308782|NCT01908712|Experimental|Lamazym|1 mg Lamazym/kg body weight
3308783|NCT01908725|Experimental|Lamazym|1 mg Lamazym/kg body weight
3308784|NCT01908738|Experimental|paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)|first groups receive paracervical block with 1%lidocaine and 0.9%NSS spray(placebo)
3308785|NCT01908738|Experimental|10%lidocaine spray and paracervical block with 0.9%NSS|the second groups receive 10%lidocaine spray and paracervical block with 0.9%NSS(placebo)
3308786|NCT01908738|Placebo Comparator|receive placebo both paracervical block and spray|the third groups receive placebo both paracervical block and spray
3308787|NCT01908764|Experimental|AL-60371/Posology 1|AL-60371 otic suspension, single dose of 200 µL following surgical insertion of tympanostomy tubes
3308788|NCT01908764|Experimental|AL-60371/Posology 2|AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes
3308789|NCT01908777|Experimental|high dose chemo w/asct + maintenance txt|High dose chemotherapy (Carmustine), VP-16 (etoposide, Vepesid®), Cytarabine (Ara-C), Melphalan (Alkeran)with autologous stem cell transplant followed by maintenance therapy with Romidepsin (Istodax)
3308790|NCT01908790||Heart Failure Patients|Acute and chronic heart failure patients already receiving right heart catheterization (RHC) as part of their usual care
3308791|NCT01908855|Experimental|ENCERT|ENCERT contains 1) psychoeducation (session1), 2) relaxation techniques for coping with stress (sessions 2-4), 3) non-judgmental awareness of body perceptions, (sessions 5-7), 4) modifying illness behavior and accepting unpleasant body perceptions (sessions 8-13), 5) attention defocusing on positive perceptions plus emotional self-support (sessions 14- 15), 6) analyzing interpretation processes to understand situational cues (sessions 16-17), and 7) change of behavior and interpretations (sessions 18-20). The innovative elements of ENCERT are: improving the awareness for the association of somatic symptoms with emotions, learning non-judgmental awareness and acceptance of unpleasant body perceptions, achieving high-frequent skill exercising with the emotion regulation audio training.
3308792|NCT01908855|Active Comparator|CBT|"This arm is based on traditional cognitive-behavioral therapy that can be considered the current treatment of choice, being the only intervention with an evidence grade 1a (Kroenke, 2007). As such, it presents the reference of efficacy and safety for new regimen. The strictly manualized program includes the following components focusing on the special needs of chronic somatoform patients: psychoeducation providing a framework for psychotherapy, attention defocusing, reduction of over-interpretation of symptoms, increase of physical activity, stress reduction."
3308793|NCT01908868|Experimental|EBUS-TBNA|EBUS-TBNA (with endobronchial and transbronchial lung biopsy)
3308794|NCT01908868|Active Comparator|Conventional TBNA|Conventional TBNA (with endobronchial and transbronchial lung biopsy)
3308795|NCT01908881|Active Comparator|Control (usual care)|"This arm receives usual care (control group) consisting in: home visits, evaluation by social worker and planning interventions according to multidisciplinary team usually done en Family Primary Health Care Centers"
3308796|NCT01908881|Experimental|Intervention (group workshop+usual care)|Group intervention (group workshop) described elsewhere
3308797|NCT01908894|Experimental|BIOD-123|SC administration of 0.20 U/kg
3308798|NCT01908894|Experimental|BIOD-125|SC administration of 0.20 U/kg
3308799|NCT01908894|Active Comparator|Humalog|SC administration of 0.20 U/kg
3381276|NCT03745638|Experimental|LTS Period: Ruxolitinib 0.75% Cream|Arm description: Participants who applied ruxolitinib 0.75% cream during VC Period, continued applying ruxolitinib 0.75% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381277|NCT03745638|Experimental|LTS Period: Ruxolitinib 1.5% Cream|Arm description: Participants who applied ruxolitinib 1.5% cream during VC Period, continued applying ruxolitinib 1.5% cream topically to the affected areas as a thin film BID from Week 8 to 52 during the LTS Period. Participants stopped treatment 3 days after lesions disappeared and restarted at the first sign of recurrence.
3381278|NCT03743662|Experimental|Recurrent Glioblastoma, No Surgery|One cohort is for patients with recurrent GBM who are not undergoing surgical debulking as part of their treatment plan
3381279|NCT03743662|Experimental|Recurrent Glioblastoma, Surgery|The second cohort is for patients with recurrent GBM who are undergoing surgery as part of their treatment.
3308800|NCT01908920|Other|OMT|Each osteopathic session is based on structural evaluation and treatment using indirect techniques.
3381280|NCT03743532|Experimental|JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes. They will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date.
3381281|NCT03743532|Experimental|Financial Incentives + JUUL/e-cigarette|Participants will be asked to completely switch from cigarettes to e-cigarettes, and they will receive a JUUL e-cigarette device and JUULpods during the first 4 weeks following a scheduled switch date. Participants will also receive weekly financial incentives for biochemically-verified cigarette abstinence during the first 4 weeks following the switch date.
3381282|NCT03739073|Experimental|Patient with coronary arterial indication|A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed for patients with intermediate stenosis of the left anterior descending artery (LDA).
3381285|NCT03737149|Experimental|mymobility with Apple Watch|Post-operative mobile application-guided education and exercise paired with accurate and sensitive activity monitoring.
3381286|NCT03737149|No Intervention|Standard of Care Physical Therapy|Standard of care patient education and post-operative physical therapy, as determined by local site guidelines and care pathways.
3308801|NCT01908920|Other|SHAM|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. A pre-determined protocol has been used. The practitioner's attention was distracted by subtracting calculation in silence."
3381287|NCT03734315||Ostenil®|3-5 injections of sodium hyaluronate 1 % (20 milligrams (mg) / 2.0 millilitres (ml)) in weekly interval.
3308802|NCT01908920|Other|CONTROL|No intervention
3308803|NCT01908933|Experimental|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
3308804|NCT01908946|Experimental|SMS Reminders|SMS reminders
3308805|NCT01908946|No Intervention|Standard verbal counseling|One time standard verbal counseling at the time of initial visit and timing for EPI vaccines at 6, 10 and 14 weeks
3308806|NCT01908959|Experimental|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received an Omron pedometer and learned to monitor walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks, in-group, to walk at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
3308807|NCT01908959|No Intervention|Attention-control|"Participants in the attention receive monthly brief telephone calls by research technicians and collection of study data on-site at the Maricopa Medical Center and other community based sites at baseline, 6, and 12 months (T1, T3, T5). The staff did not give advice or support specific to walking, which enabled a valid evaluation of the intervention effect. The content given to the attention-control group did not include the active ingredients of the Madres para la Salud intervention. The attention-control group received monthly mailings of health-related information regarding common postpartum or newborn concerns, such as breastfeeding, infant sleep, sibling rivalry, emotional support related to new parenthood, and early childhood development topics."
3308808|NCT01908998|Active Comparator|Sandal|
3308809|NCT01909024|Experimental|embolisation of pelvic veins & treatment of leg varicose veins|transjugular coil embolisation of pelvic veins followed by endovenous treatment of leg recurrent varicose veins
3308810|NCT01909024|Active Comparator|endovenous treatment of leg recurrent varicose veins alone|endovenous treatment of leg recurrent varicose veins alone
3308811|NCT01909037|Experimental|Flexofytol (bio-optimized curcumin)|
3308812|NCT01909050||refractory celiac disease|
3308813|NCT01909050||well-controlled celiac disease|
3308814|NCT01909050||uncontrolled celiac disease|either newly diagnosed with celiac disease or not on a gluten-free diet
3308815|NCT01909050||gluten-sensitivity|
3308816|NCT01909050||disorders other than celiac disease.|
3308817|NCT01909063|Experimental|Arm A|200 IU vitamin D and 700 mg of calcium per day in 2 glasses of juice per day for 2 weeks
3308818|NCT01909063|Experimental|Arm B|"200 IU vitamin D, 12 IU vitamin E, 2000 IU vitamin A as beta carotene, and 700 mg of calcium per day in 2 glasses of juice~Vitamin D, Vitamin E, and Vitamin A"
3308819|NCT01909063|Placebo Comparator|Arm C|"Control, 700 mg of calcium per day in 2 glasses of juice~Control, 700 mg Calcium"
3308820|NCT01909076|Active Comparator|Control PCPs and their patients|PCPs randomized to the control condition will receive electronic decision support tools. Patients of control PCPs will receive education materials that will be developed and made available to both control and intervention patients.
3308821|NCT01909076|Experimental|Intervention PCPs and patients|The Intervention Condition has three main components: access to nurse care management, access to the patient registry, and academic detailing for intervention PCPs. Intervention PCPs will also receive the control intervention of electronic decision support tools, and patients of intervention PCPs will receive the same patient education materials as patients of control PCPs.
3308822|NCT01909089|Experimental|Chloroprocaine|Up-down sequential allocation.
3308823|NCT01909102|Experimental|ACT-based intervention|The ACT-based intervention integrates educational topics on heart healthy behaviours with mindfulness and acceptance training regarding difficult thoughts and feelings, clarification of health-related values and commitment to behave in the valued direction while contacting difficult experiences.
3308824|NCT01909102|Active Comparator|Usual care|Usual care is based on current guidelines for the long-term multi-disciplinary rehabilitation and prevention of cardiac patients.
3308825|NCT01909115|Active Comparator|1000 IU of Vitamin D Daily|Participants randomized to take a 1000 IU capsule of Vitamin D every day for 6 months.
3308826|NCT01909115|Experimental|4000 IU of Vitamin D Daily|Participants randomized to take a 4000 IU capsule of Vitamin D capsule every day for 6 months.
3308827|NCT01909128|Experimental|fermented milk|
3308828|NCT01909128|Experimental|fermented rice|
3308829|NCT01909128|Placebo Comparator|placebo|
3308830|NCT01909167|Active Comparator|Treatment as usual (TAU)|Patients randomized to the treatment as usual arm will follow advice by their GP(general practitioner), mental health midwife or perinatal psychiatric team concerning treatment.
3308831|NCT01909167|Active Comparator|Online Cognitive Behavioral Therapy|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
3308832|NCT01909193|Experimental|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
3308833|NCT01909193|Experimental|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
3308834|NCT01909219|Active Comparator|Group A: standard regimen|Patients in the group A (standard regimen) will be instructed to take the two sachets of sodium picosulphate/magnesium citrate diluted in a glass of water 2-4 hours apart, starting at 5 pm the day before colonoscopy.
3308835|NCT01909219|Active Comparator|Group B|Patients in the group B (split regimen) will be instructed to take the first sachet of sodium picosulphate/magnesium citrate at 7 pm the day before colonoscopy and the second one at 6 am in the morning on the day of colonoscopy.
3308836|NCT01909232|Experimental|Active rTMS treatment|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
3308837|NCT01909232|Sham Comparator|Sham rTMS treatment|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
3308838|NCT01909245|Experimental|Single Arm Study|Allogenic Human Islet Cell Transplant with immunosuppression
3308839|NCT01909258||The study population.|"Healthy volunteers 20 to 40 years of age.~Intervention: Goniometric measure of pelvic extension reserve. Intervention: Photographic measure of pelvic extension reserve. Intervention: EOS measure of pelvic extension reserve."
3308840|NCT01909271|Experimental|Intervention Group|Participants will receive education through a novel program called Stroke Education Film Viewing.
3308841|NCT01909271|Other|Usual Care Group|Participants will receive education through Stroke Education Pamphlet Exposure.
3308842|NCT01909284|Experimental|Acupuncture & Epidural nerve block|acupuncture plus epidural block
3308843|NCT01909284|Active Comparator|Epidural nerve block|epidural block alone
3308844|NCT01909297|Active Comparator|ProSeal LMA|Supraglottic airway device
3308845|NCT01909297|Active Comparator|suprema LMA|Supraglottic airway device
3308846|NCT01909297|Active Comparator|I-gel LMA|Supraglottic airway device
3308847|NCT01909310|Active Comparator|with head support|patients are ventilated with their heads positioned on a support
3308848|NCT01909310|Sham Comparator|without head support|patients are ventilated without head support
3308849|NCT01909323|Placebo Comparator|sugary dessert cream|
3308850|NCT01909323|Experimental|maltitol alone|
3308851|NCT01909323|Experimental|maltitol 85% / FOS 15%|
3308852|NCT01909323|Experimental|maltitol 68% / FOS 32%|
3308853|NCT01909323|Experimental|maltitol 50% / FOS 50%|
3308854|NCT01909323|Experimental|FOS alone|
3308855|NCT01909349|No Intervention|Control Group|Control Group will gain access to the intervention after the intervention group has finished the program (>8 weeks after signing up)
3308856|NCT01909349|Experimental|Intervention Group I|Self-regulation support Behavior sequence: Physical activity, then fruit & vegetable intake
3308857|NCT01909362||Early recurrence (≤ 12 months)|Biospecimens from 25 patients who have had early recurrence (≤ 12 months) of their metastatic colorectal cancer
3308858|NCT01909362||Late recurrence (> 12 months)|Biospecimens from 25 patients who have had late recurrence (> 12 months) of their metastatic colorectal cancer
3308859|NCT01909388|Experimental|MRI-TRUS fusion guided real time HDR|Patients treated with dose escalation to Dominant Intraprostatic Lesions
3308860|NCT01909427|Placebo Comparator|Placebo/CNTO 6785 200 mg+Methotrexate (MTX)|
3308861|NCT01909427|Experimental|CNTO 6785 200 mg+MTX|
3308862|NCT01909427|Experimental|CNTO 6785 100 mg+MTX|
3308863|NCT01909427|Experimental|CNTO 6785 50 mg+MTX|
3308864|NCT01909427|Experimental|CNTO 6785 15 mg+MTX|
3308865|NCT01909440|Experimental|Arm I (RT + PS)|Patients undergo total body high-intensity RT thrice weekly and perform static stretching exercises after each session. Exercises progress from low intensity and high volume to higher intensity and lower volume over the course of the 12-week program. Patients also receive whey protein supplementation orally twice a day for 12 weeks.
3308866|NCT01909440|Experimental|Arm II (total body RT)|Patients undergo total body RT and stretching as in Arm I.
3308867|NCT01909440|Experimental|Arm III (protein supplementation)|Patients receive whey protein supplementation as in Arm I. Patients also undergo a home flexibility program 3 times per week, consisting of the same static stretching exercises performed after RT. After 12 weeks, patients may undergo the RT program as in Arm I.
3308868|NCT01909440|Active Comparator|Arm IV (attention control)|Patients undergo the home flexibility program as in Arm III. After 12 weeks, patients may undergo total body RT as in Arm I.
3308869|NCT01909479|Experimental|MOD-4023|
3308870|NCT01909479|Placebo Comparator|Placebo|
3308871|NCT01909492||Group 1|Group 1 will consist of 10 subjects with suspected MS, who have had a clinical attack within the last 12 weeks, have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within the prior 4 weeks, and for which they have not received any immunomodulating or immunosuppressant medication. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3308872|NCT01909492||Group 2|Group 2 will consist of 10 subjects with clinically stable definite MS, with no evidence of clinical relapse for at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for the Diagnosis of MS. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3308873|NCT01909492||Group 3|Group 3 will consist of 10 subjects without evidence of inflammatory systemic or inflammatory central nervous system disease, who require CSF removal for some other cause, such treatment of benign intracranial hypertension or as part of the procedure for insertion of an intrathecal medication delivery system. Patients will have a blood draw to provide serum and a CSF will be obtained through a lumbar puncture.
3308874|NCT01909505||Normal Males|Males with normal levels of serum testosterone
3308875|NCT01909505||Hypogonadal males|Males known to have low levels of serum testosterone
3308876|NCT01909518||pCLE examination|pCLE is used to distinguish the suspected lesions detected by I-SCAN in esophagus
3308877|NCT01909544|Experimental|Oxygen|
3308878|NCT01909544|Sham Comparator|Room air|
3308879|NCT01909557|Active Comparator|Acetyl-L-carnitine|Acetyl-L-carnitine 2 gr tablets
3308880|NCT01909557|Placebo Comparator|placebo|
3308881|NCT01909583|Active Comparator|STAGES PRE-GROUP|"INTERVENTION: this group will receive our STAGES booklet PRE-operatively"
3308882|NCT01909583|Placebo Comparator|STAGES POST-GROUP|INTERVENTION: This arm will only receive the STAGES-booklet POST-operatively
3308883|NCT01909596|Experimental|Knee osteoarthritis patients|Without orthoses 6° lateral wedge insoles 10° lateral wedge insoles Neutral customized foot orthoses 6° lateral customized foot orthoses 7° lateral customized foot orthoses 8° lateral customized foot orthoses 9° lateral customized foot orthoses 10° lateral customized foot orthoses Orthotist integrated lateral customized foot orthoses Orthotist lateral customized foot orthoses
3308884|NCT01909609|Sham Comparator|Parent Survival Guide|This arm of the study will focus on the document that is normally given to all parents of newborn infants. It contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
3308885|NCT01909609|Experimental|AAP Documents + Parent Survival Guide.|This arm of the study will focus on documents created based off of the American Academy of Pediatrics 2012 policy statement. They contain information on the potential risks and benefits of neonatal circumcision. The Parent Survival Guide contains information on newborn care such as feeding, cleaning of the baby's penis, etc.
3308886|NCT01909622|Experimental|Vitamin D-fortified milk|Skim milk fortified with 600 IU vitamin D3 / 250 mL
3308887|NCT01909622|Active Comparator|Vitamin D-unfortified milk|Unfortified skim milk
3308888|NCT01909635|Experimental|Food Feelings|If you are randomized to this group, you will be asked to think about your feelings of hunger, fullness, and the sensory qualities of the food (such as texture, smell, flavor) as you eat your meal.
3308889|NCT01909635|Experimental|Other Feelings|If you are randomized to this group, you will be asked to think about how hot or cold you feel, and how tired you are feeling as you eat your meal.
3308890|NCT01909648|Other|HbA2 Leuven|Presence of HbA2 Leuven mutation, demonstrated by molecular diagnosis on blood sample.
3308891|NCT01909661|Experimental|Damira/Celia peptide hydrolyzed casein|Extensively Hydrolyzed (EH)casein infant formula
3308892|NCT01909661|Experimental|Picot riz/Celia rice/Sanutri arroz|Picot riz/Celia rice/Sanutri arroz Extensively Hydrolyzed (EH) rice protein infant formula
3308893|NCT01909700|Experimental|Single Incision Mesh|intervention: single incision mesh implantation
3308894|NCT01909726||Interactive media|ScreenPlay
3308895|NCT01909726||Passive media|Silent nature video
3308896|NCT01909726||No media|Standard care
3308897|NCT01909739|Experimental|Statin group|
3308898|NCT01909739|Placebo Comparator|Placebo group|
3308899|NCT01909752|Experimental|DRibble Vaccine Alone|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3308900|NCT01909752|Experimental|DRibble vaccine with imiquimod|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4) and for four days following each vaccine cycle. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3308901|NCT01909752|Experimental|DRibble vaccine with GM-CSF|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy. DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43. GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. Immunization with HPV vaccine intramuscular injection at the time of the first and third vaccinations.
3308902|NCT01909765|Active Comparator|Dorsal slite|Skin and mucosa insicion made together
3308903|NCT01909765|Experimental|Double incision|Skin and mucosa incision made separately
3308904|NCT01909817||Routine coronary angiogram patients|
3308905|NCT01909830|Experimental|Arm A : Gemcitabine + Pemetrexed|"Arm A : Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
3308906|NCT01909843|Experimental|ALX-0171 Oral inhalation|
3308907|NCT01909856|Experimental|Arm1|1st cycle Palonosetron, 2nd cycle Granisetron
3308908|NCT01909856|Experimental|Arm2|1st cycle Granisetron, 2nd cycle Palonosetron
3308909|NCT01909869|Experimental|EXCEL-Ⅱ|A new Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions.
3308910|NCT01909882|Other|Family member's massage therapy|Family member's massage therapy
3308911|NCT01909895|Experimental|Anger induction|The participant will be asked to undergo a validated anger induction task.
3308912|NCT01909895|Experimental|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
3308913|NCT01909895|Experimental|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
3308914|NCT01909895|Other|Neutral emotion task|The participant will be asked to undergo a validated neutral task (i.e. count aloud by ones, starting with one and ending with 100, over and over, until the task period has ended).
3308915|NCT01909908|Experimental|ECM in Saline|
3308916|NCT01909908|Active Comparator|Blood Products|
3308917|NCT01909908|Experimental|ECM in Blood Products|
3308918|NCT01909934|Experimental|Brentuximab vedotin|1.8 mg/kg IV infusion
3308919|NCT01909947||Intubated extreme preterm infants|Infants with a birth weight ≤ 1250 grams and requiring endotracheal tube and mechanical ventilation
3308920|NCT01909960|Experimental|Surgery|Patients who will undergo flow imaging and neurosurgery (shunting). (25% of the studied population)
3308921|NCT01909960|Experimental|Clinical follow-up|Patients who will undergo flow imaging but not surgery (75% of the studied population)
3308922|NCT01909986|Experimental|E1|[14C]-ONO-4053
3308923|NCT01909999|Experimental|Immediate loading implants|The clinical and immunological comparisons compared implants that received Immediate loading prosthesis, i.e., full arch Branemark protocol prosthesis installed within 3 days after surgery, with unloaded implants.
3308924|NCT01909999|Active Comparator|Unloaded Implants|The variables, immunological and clinical, obtained in immediate loading groups were compared to unloaded implants, i.e., no prosthetic rehabilitation during osseointegration.
3308925|NCT01910012|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
3308926|NCT01910025|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethlene glycol
3308927|NCT01910038|Experimental|Prednisone+Tocilizumab|Prednisone (0.7 mg/Kg/d and then progressively tapered to reach 0.1 mg/Kg/d at W24) + tocilizumab 8mg/Kg/4 weeks for a total of 4 infusions (S0, S4, S8, S12).
3308930|NCT01910077|Experimental|Tacrobell capsule 1mg|Tacrolimus 1mg / 1 capsule
3308931|NCT01910077|Active Comparator|Prograf capsule 1mg|Tacrolimus 1mg / 1 capsule
3308932|NCT01910090|Experimental|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|FLURBIPROFEN, FAMOTIDINE 100/20 mg MULTI-LAYER TABLET one tablet, once
3308933|NCT01910090|Active Comparator|ANTADYS® and PEPCID®|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
3308934|NCT01910142|Active Comparator|calcium supplement with vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3 and 100 μg vitamin K. Additional 200 mg calcium in the form of carbonate
3308935|NCT01910142|Placebo Comparator|calcium supplement without vitamin K|Milk product supplying about 420 mg Ca and 7.5 μg vitamin D3. no vitamin K. Additional 200 mg calcium in the form of carbonate
3308936|NCT01910155|Experimental|Test|Ciprofloxacin/Dexamethasone
3308937|NCT01910155|Active Comparator|Reference|Ciprodex (R)
3308938|NCT01910155|Placebo Comparator|Placebo|Placebo
3308939|NCT01910168||Cohort|
3308940|NCT01910194|Other|Lyxumia|4 weeks Luxumia plus another 4 weeks combination
3308941|NCT01910194|Other|Lantus|4 weeks Lantus plus another 4 weeks combination
3308942|NCT01910220|Placebo Comparator|Group 1|placebo
3308943|NCT01910220|Experimental|Group 2|REGN1033 (SAR391786)
3308944|NCT01910220|Placebo Comparator|Group 3|placebo + exercise regimen
3308945|NCT01910220|Experimental|Group 4|REGN1033 (SAR391786) + exercise regimen
3308946|NCT01910233||adult patients with acute dyspnea in ED|
3308947|NCT01910246|Experimental|Metformin, Insulin Resistance, Cardiac Function,|Metformin Hydrochloride Tablets will be administered with a start dose of 500mg twice daily with meals.
3308948|NCT01910259|Experimental|Amiloride|Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks
3308949|NCT01910259|Experimental|Riluzole|Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks
3308950|NCT01910259|Experimental|Fluoxetine|Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks
3308951|NCT01910259|Placebo Comparator|Placebo|Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks
3308952|NCT01910285|Experimental|Remifentanyl- sufentanil placebo|3 mg/kg of propofol combined with 3 µg/kg of remifentanil
3308953|NCT01910285|Active Comparator|Sufentanil - remifentanyl placebo|3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil
3308954|NCT01910324|Experimental|Multidimensional Family Therapy Cross-Systems|In Stage 1 (in detention) Multidimensional Family Therapy Cross-Systems (MDFT-CS) consists of two major components: standard initial/engagement work with parents in the home and with adolescents in detention, plus a state-of-the-art HIV education prevention module. In Stage 2, MDFT-CS includes the standard MDFT components: 1) interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
3308955|NCT01910324|Other|Enhanced Services as Usual|In Stage 1 (in detention) ESAU includes two major components: standard drug treatment services delivered by detention staff, and state-of-the-art HIV education prevention intervention. In Stage 2, community drug treatment providers deliver high quality drug treatment on an outpatient basis.
3308956|NCT01910337||Screening|this first day, the patient will be evaluated with polar and blood pressure monitor. These data will be the basal one.
3308957|NCT01910337||Intervation|One week later the screening, the patient underwent to the surgery to remove his lower third molar. In this day, will be analyzed 4 points: basal, after the anesthesia, after the avulsion and 20 minutes after the surgery.
3308958|NCT01910337||Post operative|One week later the surgery, the patients will be evaluated again.
3308959|NCT01910350|Experimental|Cancer prevention intervention|Cancer prevention intervention: Experimental group receives intensive 2 hour education in each breast and cervical cancer risks and prevention intervention, and face to face reading of post intervention surveys by an community health worker.
3308960|NCT01910350|Active Comparator|Control group receives standard care|The control group receives reading materials and brochures on breast and cervical cancer such as one would receive in a doctors office and post condition surveys. All materials are read by the participant without the interaction or assistance of the community health worker.
3308961|NCT01910363|Experimental|A2NTX|single intramuscular injection of 300 units of A2NTX, a purified low molecular weight (150 kDalton) botulinum toxin preparation of type A2
3308962|NCT01910363|Active Comparator|BOTOX|single intramuscular injection of 300 units of BOTOX®, a commercially available botulinum toxin preparation of type A1
3308963|NCT01910376||Control cohort|Nursing home residents without cancer
3308964|NCT01910376||Cancer patient cohort|Patients in nursing homes with suspected or diagnosed active invasive cancer where a diagnostic or treatment decision has to be taken
3308965|NCT01910376||Biomarker cohort|Subgroup of individuals in the control cohort willing to provide a blood sample
3308966|NCT01910415|Experimental|Part A|"Will consist of up to 4 cohorts with subjects receiving lumacaftor or placebo for 7 days.~Cohort 1: 600 mg lumacaftor once a day Cohort 2: 1000 mg lumacaftor once a day Cohort 3: 1200 mg lumacaftor once a day"
3308967|NCT01910415|Experimental|Part B|"Will consist of 3 cohorts. All cohorts will be dosed in parallel. Cohort A will receive 600 mg Lumacaftor once a day plus 250 mg Ivacaftor twice a day for 7 days. From day 8-14 subjects will receive a supratherapeutic dose of Lumacaftor (TBD) plus 450 mg Ivacaftor twice a day.~Cohort B will receive lumacaftor and ivacaftor matching placebo for 14 days Cohort C will receive a single dose of 400 mg moxifloxacin on day 14"
3308968|NCT01910428|Experimental|L-asparaginase encapsulated in RBC|L-asparaginase encapsulated in RBC dose titration: 50, 100, 150 or 200 IU/kg
3308969|NCT01910454|Experimental|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|
3308970|NCT01910454|Active Comparator|Task Specific Training (TST)|
3308971|NCT01910467|Experimental|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
3308972|NCT01910467|Other|NIRS not visible and treatment as usual|NIRS measurements are not visible and the patients will be treated according to routine ('treatment as usual')
3308973|NCT01910480|Experimental|NBI-98854 followed by NBI-98854 with ketoconazole|50 mg NBI-98854 on Study Days 1 and 6 and 200 mg ketoconazole twice daily on Study Days 5 through 9.
3308974|NCT01910493|Active Comparator|ART no SMS reminders|control group
3308975|NCT01910493|Active Comparator|PMTCT no SMS reminders|control group
3308976|NCT01910493|Experimental|SMS reminders to PMTCT cohort|experimental group
3308977|NCT01910493|Experimental|SMS reminders to ART cohort|experimental group
3308978|NCT01910506|Experimental|RDEA3170|
3308979|NCT01910532|Experimental|Clevidipine|Using Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
3308980|NCT01910545|Experimental|OTS167IV|single arm
3308981|NCT01910558|Active Comparator|Alpha-cyclodextrin and digestible starch|Supplementation with three grams alpha cyclodextrin with three grams of digestible starch
3381291|NCT03731910|Experimental|HCC group|Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.
3308982|NCT01910558|Experimental|Alpha-cyclodextrin|Supplementation with six grams of alpha-cyclodextrin
3308983|NCT01910558|Placebo Comparator|Digestible Starch|Supplementation with six grams of digestible starch
3308984|NCT01910571|Experimental|P7435|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
3308985|NCT01910571|Placebo Comparator|Placebo|"In Part A, there will be up to 6 cohorts of 8 subjects each (for the 2 cohorts undergoing food effect study, there will be 12 subjects in each cohort). At each dose level, every subject will participate in two periods (one with active, P7435 and the second period with matching placebo or vice versa) separated by appropriate wash-out period between the two periods. The randomization scheme will ensure that no subject undergoes the placebo period twice.~In Part B, there will be up to 3 cohorts of 10 subjects each. Each of the 3 cohorts will participate in two study periods of 10 days of dosing in each (one period with active, P7435 and the other period with matching placebo or vice versa) separated by appropriate wash-out period."
3308986|NCT01910584||Novasure treated group|patients diagnosed menorrhea were treated with novasure endometrial ablation
3308987|NCT01910597|Experimental|SBG|
3308988|NCT01910610|Experimental|STRATEGY A|FOLFIRI-cetuximab, followed by oxaliplatin-based chemotherapy with bevacizumab
3308989|NCT01910610|Experimental|STRATEGY B|OPTIMOX-bevacizumab, followed by irinotecan-based chemotherapy with bevacizumab, followed by anti-EGFR mab with or without irinotecan
3308990|NCT01910623||Patients being studied|APL patients previously enrolled in GIMEMA AIDA 0493 and AIDA 2000 studies.
3308991|NCT01910649|Experimental|Drisapersen|Extension phase of treatment. Intravenous dosing of drisapersen will be investigated as an alternative route of administration
3308992|NCT01910662|Experimental|Part A:|Subjects in the Part A will receive an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the upper right forearm and an ID injection of 0.1 mL of buffer in the lower right forearm and lower and upper left forearm on Day 1.
3308993|NCT01910662|Experimental|Part B:Cohort 1A|Subjects in the Part B Cohort 1A arm will receive a SC immunisation of 5 mg KLH in the right deltoid. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH as 0.1 mL of KLH (1 mg/mL) in the lower right and lower left forearm. On Day 43, 0.1mL of KLH (1 mg/mL) will be injected ID into the upper left forearm and the upper right forearm (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
3308994|NCT01910662|Experimental|Part B:Cohort 1B|Subjects in the Part B Cohort 1B arm will receive a SC immunisation of 5 mg KLH in the right deltoid on Day 1. On Day 15 subjects will return to the unit for an ID injection of 0.1 mg KLH in the lower right and lower left forearm. On Day 43 subjects will then receive an ID injection of 0.1 mg KLH in the upper right and upper left forearms (The dose can be changed to either 5mg/1mg or 1mg/0.1mg depending on the results from the first 3 subjects in Cohort 1).
3308995|NCT01910662|Experimental|Part B:Cohort 2|Subjects in the Part B Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper right and upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 2 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
3308996|NCT01910662|Experimental|Part C: Cohort 1|Subjects in the Part C Cohort 1 will receive an ID injection of 0.1 mL PBS in the upper right forearm on Day 1. On Day 2 subjects will receive an ID injection of 0.1 ml PBS in the upper left forearm.
3308997|NCT01910662|Experimental|Part C: Cohort 2|Subjects in the Part C Cohort 2 will receive an ID injection of 2TU (0.04 microg/mL) PPD in the upper left forearms on Day 1. On Day 3 (48 hours post challenge) If the induration is less than 6 mm, the subject will be re-challenged with 10 TU (0.04 microg/mL) PPD at a site at least 4 cm away from another challenge site. On Day 29 the subjects will have 1 ID injections of 2 TU or 10 TU (the same dose that produced an induration of 6 mm or more).
3308998|NCT01910675|Experimental|PCC group|Twenty patients in the PCC group receive 15 IU/kg of Octaplex concentrate and 2 g of Riastap concentrate. Additional fibrinogen is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm.
3308999|NCT01910675|Active Comparator|FFP group|Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
3309000|NCT01910701|Experimental|Family Spirit Intervention|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
3309001|NCT01910714|Active Comparator|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
3309002|NCT01910714|Experimental|Focus on Youth Intervention (FOY)|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
3309003|NCT01910727|Experimental|Together on Diabetes-Hopkins|
3309004|NCT01910740|Experimental|Enhanced Physical Activity|Participants in the Enhanced Physical Activity group will receive a program of enhanced physical activity in addition to the usual care.
3309005|NCT01910740|Active Comparator|Usual Care|The Usual Care group will receive usual therapy provided by a multidisciplinary team and social interaction.
3309006|NCT01910753|Experimental|APA|Patient with neck cancer and accepting the physical activity program .
3309007|NCT01910766|Experimental|Coenzyme Q10/CC group|"Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration"
3309008|NCT01910766|Active Comparator|CC alone group|"Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6"
3309009|NCT01910779|Active Comparator|100 joule arm|100 joule as first biphasic shock energy
3309010|NCT01910779|Active Comparator|120 joule arm|120 joule as first biphasic shock energy
3309011|NCT01910805|Experimental|Lifestyle and Risk Awareness class|Women will attend a 3- and 9-month postpartum group nutrition and physical activity education class.
3309012|NCT01910805|No Intervention|Standard Care|Women will receive standard postpartum care for gestational diabetes mellitus.
3309013|NCT01910818|Experimental|Fractional CO2 laser Treatment|This is the area getting treated with CO2 laser.
3309014|NCT01910818|Experimental|No Treatment|This is the area receiving no treatment.
3309015|NCT01910844|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² from day 1 to day 3 every 3 weeks Metronomic Cyclophosphamide 150 mg from day 1 to day 14 every 3 weeks
3309016|NCT01910857|Experimental|Lifestyle counseling|Lifestyle counseling. 6 group meetings,facilitated by community health worker, focusing on lifestyle change, eg, weight loss, physical activity, low salt, stress reduction
3309017|NCT01910857|No Intervention|Control|Standard care
3309018|NCT01910870|Experimental|Cisplatin - Metronomic Cyclophosphamide|Cisplatin 25 mg/m² (day 1 to day 3) every 3 weeks Metronomic cyclophosphamide 150 mg (day 1 to day 14) every 3 weeks
3309019|NCT01910883|Experimental|Group 1|Single doses of 200, 400 and 600 mg finafloxacin i.v.
3309020|NCT01910883|Experimental|Group 2|Single doses of 800 and 1000 mg finafloxacin i.v.
3309021|NCT01910883|Experimental|Group 3|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v.
3309022|NCT01910883|Experimental|Group 4|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 600 mg i.v. (additional to Group 3)
3309023|NCT01910883|Experimental|Group 5|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 800 mg i.v.
3309024|NCT01910883|Experimental|Group 6|Multiple doses of finafloxacin once daily (o.d.) for 7 days at dose levels of 1000 mg i.v.
3309025|NCT01910896|Experimental|Overnight Intensive Patch|Overnight intensive patch (OIP), on polyolefin foam basis containing acrylate, extractum cepae and allantoin is a class I, CE (Conformité Européenne) marked medical device. Subjects will have their two scars randomized for Overnight Intensive Patch application versus no treatment.
3309026|NCT01910896|No Intervention|No treatment|Subjects serve as their own control. Eligible subjects have two comparable scars in same body regions, one scar will be treated with Overnight Intensive Patch, the second scar will not be treated.
3309027|NCT01910909|Experimental|Stereotactic body radiotherapy|Stereotactic body radiotherapy 60 Gy/3 fraction standard dose The highest allowable dose with maintain normal tissue constraints
3309028|NCT01910922||Repeated exposure Group (RE)|Exposure to basic salsify puree during E1-E8
3309029|NCT01910922||Flavour-flavour learning-salt (FFL-S)|Exposure to salty salsify puree during E1-E8
3309030|NCT01910922||Flavour-flavour learning-nutmeg (FFL-N)|Exposure to nutmeg-flavored salsify puree during E1-E8
3309031|NCT01910935|Experimental|Physical activity prescription|24 weeks physical activity program. 1 hour, 3 times a week, moderate to vigorous intensity.
3309032|NCT01910935|No Intervention|No physical activity prescription|Provide information to patients about the benefits of physical activity and how to increase it safely.
3309033|NCT01910948|Experimental|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
3309034|NCT01910961|Experimental|limb RIPC|limb RIPC protocol was applied after anesthetic induction and before the start of surgery. The limb RIPC was induced by placing a blood pressure cuff on the left upper arm of patient for three inflating-deflating cycles: 5 min inflating to 200 mmHg followed by a 5 min reperfusion with deflating the cuff.
3309035|NCT01910961|No Intervention|convention|Adult patients undergoing elective open abdominal aortic aneurysm repair received no treatment after induction of anaesthesia.The control group had an uninflated cuff placed on the left upper arm for 30 min.
3309036|NCT01910974|Experimental|endoscopic sub-mucosal dissection|
3309037|NCT01910987|Experimental|optimized retreatment, prolonged therapy|Patients will start therapy with retreatment with 6 cycles of bortezomib and dexamethasone (two 21-day cycles followed by four 35-day cycles) followed by a second randomization in a 1:1 ratio to 1 of 2 prolonged therapy schedules with bortezomib alone (Group A1: once weekly for the first 4 weeks in 35-day cycles; or Group A2: once every other week)
3309038|NCT01910987|Other|standard retreatment|Current Standard of Care: Patients will start retreatment with eight 21-day bortezomib and dexamethasone cycles, followed by posttreatment follow-up every 6 weeks.
3309039|NCT01911000|Experimental|RTHT|RT and hyperthermia after TACE in the unresectable HCC patients who combined with PVTT
3309040|NCT01911013|Active Comparator|Cage and Plate|anterior cervical discectomy and fusion surgery at one segment is performed using cervical cage and plate system
3309041|NCT01911013|Experimental|Cage alone|anterior cervical discectomy and fusion surgery at one segment is performed using only cervical cage without plate
3309042|NCT01911026|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus interventional instructions from reinforcement educated nurse such as 'Reinforcement Nurse Education'
3309043|NCT01911026|No Intervention|Standard preparation instructions|The control arm will receive written instructions on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
3309044|NCT01911039|Experimental|Regulatory T Cells|Cohort 1 at 1x105 Treg cells/kg, Cohort 2 at 5x105 Treg cells/kg and Cohort 3 at 1.5x106 Treg cells/kg with an extension phase at the MTD (or maximum administered dose if the MTD is not reached).
3309045|NCT01911052|Experimental|Intervention|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
3309046|NCT01911052|No Intervention|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care at Keimyung University Dongsan Medical Center
3309047|NCT01911052|Experimental|Interventional|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
3309048|NCT01911078|Other|Renal Denervation Group|Subjects receiving renal denervation procedure.
3309049|NCT01911078|No Intervention|Control Group|"Subjects not receiving renal denervation procedure.~Subjects are randomized in a 3:1 ratio to either Renal Denervation Group or Control Group."
3309050|NCT01911091|Experimental|Group 1 - Regular exercise|Alternate interval training and aerobic training and exercise
3309051|NCT01911091|No Intervention|Group 2 - Athlete exercise|Athletes are not given any intervention
3309052|NCT01911091|No Intervention|Group 3 - Obese No Exercise|The Obese group will not receive intervention
3309053|NCT01911104|Experimental|Exercise|10 weeks of aerobic exercise
3309054|NCT01911104|No Intervention|Active Control|Young athletes as a trained control
3309055|NCT01911117||Cardiac Surgical Patients|"Patients who undergo cardiac surgery will be included in this study.~Patients undergo cardiac surgery and are over 18 years of age.~Patients need bypass machine for their cardiac surgery and traditional CO measurement.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
3309056|NCT01911156|Other|Discontinue NA treatment|Subjects will not receive NA during the 72 week study period
3309057|NCT01911156|Other|NA treatment|Subjects will continue to receive their prescribed NA during the 72 week study period
3309058|NCT01911182|Experimental|Inhalation of low concentration of CO2|
3309059|NCT01911182|Active Comparator|caffeine only|
3309060|NCT01911195|Active Comparator|Control Group: Cognitive Testing|Control arm will receive cognitive testing only without undergoing general anesthesia
3309061|NCT01911195|Experimental|ISOFLURANE- Experimental Arm|Experimental arm will receive cognitive testing before and after general anesthesia
3309062|NCT01911208|Experimental|RECRUIT intervention|Clinical sites will work with the RECRUIT team to enhance and individualize their recruitment methods.
3309063|NCT01911208|Experimental|Control|Clinical sites can use which ever recruitment methods they prefer.
3309064|NCT01911234|Experimental|TNF-Kinoid|TNF Kinoid + ISA51
3309065|NCT01911234|Placebo Comparator|Placebo|Placebo + ISA51
3309066|NCT01911247|Experimental|Arm 1|
3309067|NCT01911286||Standard group|Apnea test according to the recommendation
3309068|NCT01911286||CPAP group|Apnea test with CPAP connection
3309069|NCT01911299|Experimental|Choline|Liquid glycerophosphocholine (GPC) supplement
3309070|NCT01911299|Placebo Comparator|Placebo|Liquid placebo supplement
3309071|NCT01911312|Experimental|Intervention|
3309072|NCT01911312|Active Comparator|Body Temperature Control|Stimulation performed with body temperature control
3309073|NCT01911325|Experimental|Phase Ib: Buparlisib + docetaxel|Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.
3309074|NCT01911325|Experimental|Phase II: Buparlisib + docetaxel|Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
3309075|NCT01911325|Placebo Comparator|Phase II: Placebo + docetaxel|Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.
3309076|NCT01911338|Experimental|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
3309077|NCT01911338|Active Comparator|Tradicional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8
3309078|NCT01911364|Experimental|BDP/FF/GB|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations b.i.d
3309079|NCT01911364|Active Comparator|Tiotropium|Tiotropium bromide 18 mcg
3309080|NCT01911364|Active Comparator|BDP/FF + Tiotropium|"BDP/FF pMDI 100/6/12.5 mcg 2 inhalations b.i.d and Tiotropium 18 mcg daily~BDP/FF/GB versus BDP/FF + Tiotropium"
3309081|NCT01911377|Active Comparator|Arm 1: Botulinum Toxin Type A|"200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections."
3309082|NCT01911377|Placebo Comparator|Arm 2: Normal Saline for Injection|Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.
3309083|NCT01911416|Experimental|All participants|All participants on study
3309084|NCT01911455|Active Comparator|acamprosate|The maximum dose of acamprosate to be used in this study is 666 mg three times daily (total 1998 mg/day) for subjects weight ≥ 50 kg and 1332mg for subjects that weigh < 50 kg.
3309085|NCT01911455|Placebo Comparator|Placebo|Placebo will be prescribed with the same frequency and duration as the acamprosate group.
3309086|NCT01911468|Active Comparator|metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os.
3309087|NCT01911468|Active Comparator|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3309088|NCT01911468|Active Comparator|metformin and liraglutide|In the metformin and liraglutide group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os. At the same time liraglutide was initiated at a dose of 0.6 mg injected sc once per day and increased to 1.2 mg/day after 1 week.
3309089|NCT01911481|Experimental|hydration|after recruitment the women in hydration group will be invited to drink 2 litres of water,in 2 hours
3309090|NCT01911481|No Intervention|control|
3309091|NCT01911494|Experimental|Intervention|"The CLIP intervention consists of (i) community engagement including community leaders, the women of the communities themselves, and their mothers, husbands, and mothers-in-law, regarding pre-eclampsia, its origins, symptoms, signs, and potential consequences, pre-permissions for maternal transport, and fundraising activities around transport and treatment costs; (ii) provision of HDP oriented antenatal care through CLIP visits and use of CLIP PIERS on the Move mHealth tool (for risk stratification), and (iii) use of the CLIP package for women with a CLIP 'trigger' (i.e., oral antihypertensive therapy (methyldopa) when indicated, intramuscular (i.m.) magnesium sulfate when indicated; and appropriate referral to an CEmOC facility when indicated)"
3309092|NCT01911494|No Intervention|Control|Current standard of antenatal care
3309093|NCT01911507|Experimental|Treatment ( INCB028, erlotinib)|Patients receive INC280 PO BID and erlotinib hydrochloride PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3309094|NCT01911520|Experimental|BMI < 50, Total Body Weight (TBW), 2mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
3309095|NCT01911520|Experimental|BMI < 50, TBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to total body weight.
3309096|NCT01911520|Experimental|BMI < 50, Ideal Body Weight (IBW), 2 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
3309097|NCT01911520|Experimental|BMI < 50, IBW, 4 mg/kg|Patients with a BMI < 50, who will be dosed according to ideal body weight.
3309098|NCT01911520|Experimental|BMI > 50, TBW, 2mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
3309099|NCT01911520|Experimental|BMI > 50, TBW, 4mg/kg|Patients with a BMI > 50, who will be dosed according to total body weight.
3309100|NCT01911520|Experimental|BMI >50, IBW, 2 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
3309101|NCT01911520|Experimental|BMI >50, IBW, 4 mg/kg|Patients with a BMI > 50, who will be dosed according to ideal body weight.
3309102|NCT01911533|Experimental|extracorporeal CO2|
3309103|NCT01911559||constipated quadriplegic CP children|In this study we included children with CP, in the manifestation of severe diplegia or quadriplegia, who do not currently use the standing-frame.
3309104|NCT01911572||Survivors|Individuals who have previously experienced an episode of invasive streptococcal infection or necrotising fasciitis.
3309105|NCT01911572||Family members|Parents of those survivors aged less than forty years without risk factors for streptococcal disease (forming mother-father-child trios), or first and second degree relatives of survivors from a family in which two or more individuals have been affected.
3309106|NCT01911585|Active Comparator|90 minute Prolonged Exposure Sessions|Prolonged Exposure Therapy for PTSD consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 90 minutes, with 40 to 60 minutes imaginal exposure.
3309107|NCT01911585|Experimental|60 minute Prolonged Exposure Sessions|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of 10 to 15 weekly or twice-weekly sessions, each lasting about 60 minutes, with 20 minutes imaginal exposure.
3309108|NCT01911598|Experimental|A: MEHD7945A+ Cisplatin + 5-FU|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 milligrams (mg) intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Cisplatin will be administered as 100 milligrams per square meter (mg/m^2) IV infusion on Day 1 of Cycles 1 to 6. 5-FU will be administered as 1000 mg/m^2/day administered as continuous infusion over Days 1-4 of Cycles 1 to 6.
3309109|NCT01911598|Experimental|B: MEHD7945A + Paclitaxel + Carboplatin|Participants with previously untreated R/M SCCHN will receive MEHD7945A 1650 mg IV infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or protocol violation. Carboplatin will be administered at a dose to achieve an area under the curve (AUC) of 6 milligrams/milliliter/minute (mg/mL/min) as an IV infusion on Day 1 of Cycles 1 to 6. Paclitaxel will be administered as 200 mg/m^2 IV infusion on Day 1 of Cycles 1 to 6.
3309110|NCT01911611|Placebo Comparator|Placebo|
3309111|NCT01911611|Experimental|RO6870868|
3309112|NCT01911624|Experimental|direct thrombin inhibition|dabigatran 110 mg BID, po argatroban (0.5 - 1 µg/kg/min) if peroral therapy is not possible
3309113|NCT01911624|Active Comparator|enoxaparin|enoxaparin 40 mg od, sc
3309114|NCT01911637|Experimental|VBY-036|VBY-036 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, or 900 mg
3309115|NCT01911637|Placebo Comparator|Placebo|Placebo
3309116|NCT01911650|Experimental|Autologous Platlet Rich Plasma|This subject arm will receive one injection of autologous platelet rich plasma for the treatment of Achilles tendinopathy. In addition, they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
3309117|NCT01911650|Other|Waitlist|Subjects in this arm will have already received standard of care interventions for Achilles tendinopathy with unsatisfactory outcomes. For this research they will be asked to undergo a palpatory exam of the Achilles tendon; complete Quality of Life Questionnaires at three different time points; and complete a 30 minute ultrasound imaging exam of the Achilles tendon.
3309118|NCT01911663|Experimental|KRG|500 mg Korea red ginseng (KRG)
3309119|NCT01911663|Placebo Comparator|Placebo|500 mg placebo (corn starch)
3309120|NCT01911676|Experimental|PF-03463275 Active Dose #1|Active dose between 40mg
3309121|NCT01911676|Experimental|PF-03463275 Active Dose #2|Active dose between 60mg
3309122|NCT01911676|Placebo Comparator|Placebo|Placebo- no active dose of PF-03463275.
3309123|NCT01911702|Active Comparator|Conventional Group|In this group patients receive volemic standard treatment (conventional)
3309124|NCT01911702|Active Comparator|Restrictive Group|In this group patients receive volemic small treatment (restrictive)
3309125|NCT01911715|Experimental|Single Oral MDV3100 dose|
3309126|NCT01911728|Experimental|Multiple doses of MDV3100|Multiple doses of MDV3100 and a single dose of pioglitazone and a single dose of cocktail containing -warfarin, omeprazole and midazolam
3309127|NCT01911741|Experimental|Treatment A|Single dose of 4 liquid-filled capsules of MDV3100 reference formulation
3309128|NCT01911741|Experimental|Treatment B|Single dose of 2 tablets of MDV3100 formulation tablet B
3309129|NCT01911741|Experimental|Treatment C|Single dose of 2 tablets of MDV3100 formulation tablet C
3309130|NCT01911754|Experimental|Influenza Vaccine|One dose of the vaccine will be administered at a volume of 0.5 mL by intramuscular injection on Day 1 and 22
3309131|NCT01911767||Dimethyl fumarate|Exposure to dimethyl fumarate since the first day of her last menstrual period (LMP) prior to conception or at any time during pregnancy
3309132|NCT01911767||Peginterferon beta-1a|Exposure to Peginterferon beta-1a since 17 days prior to the first day of her LMP prior to conception or at any time during pregnancy.
3309133|NCT01911767||Disease Modifying Therapy (DMT) Unexposed|Never received DMT therapy; discontinued treatment with any DMT at least more than 5× half-life prior to Day 1 of her LMP and throughout the entire pregnancy.
3309134|NCT01911806|Experimental|Back care pillow & standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks & back care pillow use during the day for 2 weeks
3309135|NCT01911806|Active Comparator|standard physical therapy treatment|standard physical therapy treatment for 6 sessions of treatment, each around 30 minutes, during a period of 2 weeks
3309136|NCT01911832|Experimental|Gastrectomy and subtotal gastrectomy|to compare the quality of life between esophagojejunostomy after total gastrectomy(TG group) and Roux-en-Y gastrojejunostomy after subtotal gastrectomy(SG group)
3309137|NCT01911832|Experimental|Wide and narrow reconstruction tube|to compare the quality of life between wide tube reconstruction after subtotal gastrectomy(WG group) and narrow tube reconstruction after subtotal gastrectomy(NG group) in Roux-en-Y gastrojejunostomy
3309138|NCT01911858|Experimental|Askina Calgitrol Paste|
3309139|NCT01911871||thalassemia|patients affected with thalassemia
3309140|NCT01911871||sickle cell disease|patients affected with sickle cell disease
3309141|NCT01911871||myelodysplasia|patients affected with myelodysplasia
3309142|NCT01911884|Other|Patients with a Rokitansky Syndrome|Patients with a Rokitansky Syndrome
3309143|NCT01911897|Experimental|MobiusHD|MobiusHD
3309144|NCT01911923|Active Comparator|No CPAP/PEEP and 100 % oxygen|This is the control group
3309145|NCT01911923|Experimental|CPAP/PEEP and 30 % oxygen|This is the intervention group
3309146|NCT01911936|Experimental|LJM716|
3309147|NCT01911949|Experimental|Single shot femoral nerve block|Ultrasound guided Femoral Nerve Block-40ml of bupivacaine 0.5% with epinephrine
3309148|NCT01911949|Placebo Comparator|Placebo femoral nerve block|Sterile normal saline solution
3309149|NCT01911962||transabdominal laparoscope surgery|transabdominal laparoscope surgery
3309150|NCT01911962||transvaginal laparoscopic surgery|transvaginal laparoscopic surgery
3309151|NCT01911975|Placebo Comparator|Placebo|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive placebo.
3309152|NCT01911975|Experimental|Lacosamide|Patients with gain-of-function Nav 1.7 related small fiber neuropathy in this arm will receive lacosamide.
3309153|NCT01911988||Colon&Rectal Stage II /Stage III|
3309154|NCT01912001|Other|Telephone follow-up.|A member of the Home Dialysis team will telephone patients to follow-up on their symptoms, dialysis and care.
3309155|NCT01912014|Experimental|Psychosocial support and counselling|There is only one arm as this is a pilot and feasibility study.
3309156|NCT01912027|Experimental|Arthroscopic Latarjet technique|Arthroscopic Latarjet technique
3309157|NCT01912027|Active Comparator|Open Latarjet technique|Open Latarjet technique
3309158|NCT01912040||Patients|Administration of 123Iodine MIBG to the patients referred .
3309159|NCT01912053|Experimental|Therasphere®|Therasphere® in association with Gemcitabine and Cisplatin
3309160|NCT01912066|Experimental|Stillen|Patients taking a tab of Stillen and a tab of placebo drug and a tab of NSAID
3309161|NCT01912066|Active Comparator|Cytotec|The subjects taking a tab of Cytotec, a tab of placebo drug, and a tab of NSAID
3309162|NCT01912092|Experimental|Askina Calgitrol Paste|
3381295|NCT03715764|Other|Physical therapy assessment|Patients allocated to the intervention group will be assigned to an assessment and evaluation by a physical therapist. If they are diagnosed with knee osteoarthritis they will get an offer to participate in a patient education program and physical training with an individualized exercise program made by a physical therapist. Patients will be offered individual treatment if they decline to participate in the education program, or if they have another diagnosis than osteoarthritis. Anytime after the first assessment by the physical therapist, the patient will be able to contact a physician if they want to.
3381296|NCT03715764|Other|Physician assessment|Allocation to the control group will involve an assessment and evaluation made by a physician. Further measures will then be determined by attending physician and the procedures that might get included are drug prescriptions, referral to x-ray examination, referral to a physical therapist or another health care provider. Anytime after the first assessment by the physician, the patient will be able to contact a physical therapist if they want to, even though if they have not been referred by the physician.
3381297|NCT03714308||Patients with nAMD_Treatment-naive (anti-VEGF naive)|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
3381298|NCT03714308||Patients with nAMD_Pre-treated with IVT-AFL|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
3381299|NCT03714308||Patients with nAMD_Pre-treated with any anti-VEGF|Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
3381300|NCT03706365|Experimental|A1. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
3381301|NCT03706365|Experimental|A2. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
3381302|NCT03706365|Active Comparator|B1. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
3381303|NCT03706365|Active Comparator|B2. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
3381304|NCT03706365|Experimental|A. Abiraterone plus Prednisone and Abemaciclib|Abiraterone plus prednisone administered orally and abemaciclib administered orally.
3381305|NCT03706365|Active Comparator|B. Abiraterone plus Prednisone and Placebo|Abiraterone plus prednisone administered orally and placebo administered orally.
3309163|NCT01912105|Experimental|treatment|Airway Medix Closed Suction System
3309164|NCT01912105|Active Comparator|control|standard closed suctioning systems
3381308|NCT03691584|Experimental|BAL PK study|Bronchoalveolar lavage procedure performed at either 2, 4, 8, or 24 hours after final dose of TP-6076 on Day 4
3381309|NCT03690011|Experimental|CD7.CAR/28zeta CAR T Cells|Three dose levels will be evaluated. The T cells will be administered following lymphodepleting chemotherapy with cyclophosphamide and fludarabine.
3381310|NCT03686228|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb and Aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
3381311|NCT03686228|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day and supportive treatment including wound care and pain killer drug.
3381312|NCT03683628|Active Comparator|PB-MNC therapy|The patientsin PB-MNC therapy group will be injected with G-CSF mobilized PB-MNC into calf or thigh muscle of ischemic limb, Aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
3381313|NCT03683628|Active Comparator|No PB-MNC therapy|In patients in No PB-MNC therapy, they will receive aspirin 81 mg/day, cilostazol 200 mg/day and walking exercise 3 times per week.
3381314|NCT03677596|Experimental|Dose Level 2|Inotuzumab ozogamicin at starting dose 1.2 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
3381315|NCT03677596|Active Comparator|Dose Level 1|Inotuzumab ozogamicin at starting dose 1.8 mg/m2/cycle (administered in 3 divided doses). Most patients expected to receive 2 or 3 cycles (cycle length 21 to 28 days)
3381316|NCT03677102|Active Comparator|higher chloride solutions|higher chloride crystalloid (Normal saline - chloride concentration 154 mmol/L)
3309165|NCT01912118|Experimental|PROPOFOL ONLY GROUP|In this study group measurements will be obtained before intubation or opioid administration. To that end plasma propofol concentration will be increased slowly from 0 to 4 μg/ml in steps of 0.5 μg/mL. After the highest target is reached, the propofol target concentration will be lowered to get a BIS value of 50. After 5-min, the laryngoscope will be inserted into the mouth. Next the laryngoscope will be removed. After 5-min the laryngoscope will be placed again and the patient will be intubated. This will be done without additional administration of muscle relaxant.
3309166|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET A|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 1 ng/ml remifentanil.
3309167|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET B|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 2 ng/ml remifentanil
3309168|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 3 ng/ml remifentanil.
3309169|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET D|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 4 ng/ml remifentanil.
3309170|NCT01912118|Experimental|PROPOFOL + REMIFENTANIL TARGET E|The subject will be intubated according to the design of group 1. The propofol concentration will be 2-5 μg/kg, aimed at a BIS of 50, with 5 ng/ml remifentanil.
3381317|NCT03677102|Active Comparator|lower chloride solutions|lower chloride crystalloid (Ringer's lactate - chloride concentration 110 mmol/L)
3381318|NCT03674827|Experimental|Dose escalation (Part 1)|Participants with NSCLC or TNBC were enrolled at escalating dose levels s of the VBIR-2 regimen.
3381319|NCT03674827|Experimental|Dose Expansion (Part 2)|Participants with metastatic NSCLC will be enrolled at the expansion dose level identified during Part 1 of the study.
3381320|NCT03672825|Experimental|RECLAIM|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
3381321|NCT03666754|Active Comparator|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
3381322|NCT03666754|Experimental|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
3381323|NCT03663855|Experimental|Cystinuria Patients|
3381324|NCT03659721|Experimental|FACAM|Intervention participants are assigned a support person (health nurse or a family therapist) who will offer support to the family until the child starts school at age 6. Intensity is up to 37 hours the first year followed by up to 10 hours of support each of the following years. The support person will offer individualized support to the family depending on the needs of the family. The support person will attend midwife consultations and help the pregnant woman to attend consultations with e.g. GP, midwife, or social worker. All intervention participants will also receive either an individual or group-based (COS-P)attachment based intervention during pregnancy and the first months of the child's life.
3381325|NCT03659721|Active Comparator|Care as Usual|Families in the control group receive the usual care that is offered to families in the target group. This includes consultations with e.g. a midwife, social worker, medical doctor, and health visitor. If needed, CAU families can receive e.g. extra home visits or family therapy.
3381326|NCT03657888|Experimental|Family Club Denmark (FCD)|Participation in FCD
3381327|NCT03657888|Other|Wait-list|Wait-list control
3381328|NCT03654729|Experimental|PledOx (2 µmol/kg)|Calmangafodipir (2 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
3381329|NCT03654729|Experimental|PledOx (5 µmol/kg)|Calmangafodipir (5 µmol/kg) on day 1 every two weeks to patients as an intravenous infusion, combined with mFOLFOX6 chemotherapy.
3381330|NCT03654729|Placebo Comparator|Placebo|Placebo will be given to patients as an intravenous infusion, on top of mFOLFOX6 chemotherapy.
3381334|NCT03633617|Experimental|Part A: Dupilumab or Placebo|Part A consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
3381335|NCT03633617|Experimental|Part B: Dupilumab or Placebo|Part B consists of a 24-week double-blind treatment period. Participants will be randomized to receive dupilumab dosing regimen 1, dupilumab dosing regimen 2 or placebo. At the end of the double-blind treatment visit (week 24), eligible participants may enter Part C. Participants who do not enter Part C will enter a 12-week follow-up period.
3381336|NCT03633617|Experimental|Part C: Dupilumab|Part C is a 28-week extended active treatment period. Participants will receive dupilumab dosing regimen 1, dupilumab dosing regimen 2. At the end of the treatment period (week 52), participants will enter a 12-week follow-up period.
3309171|NCT01912118|Experimental|PROPOFOL TARGET BIS 30 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS of 30.
3309172|NCT01912118|Experimental|PROPOFOL TARGET BIS 70 + REMIFENTANIL TARGET C|The subject will be intubated according to the design of group 1. The remifentanil target will be 3 ng/ml remifentanil. The propofol concentration will aim a BIS 70.
3309173|NCT01912131|Experimental|First 24 patients Cognitive interviewing|Part 1 - This first study phase will involve interviewing 24 patients to ask for their feedback on the appropriateness of questions being developed for use in the narrative interviewing in part 2 of the study. The cognitive interview will be audio-recorded. Demographics and ECOG performance status will be recorded prior to the cognitive interview.
3381337|NCT03630159|Experimental|Tisagenlecleucel+Pembrolizumab|
3381338|NCT03622879|Experimental|MT + TENS|The subject will adopt a semi-seated position on a bed while the mirror board is positioned between the legs perpendicular to the subject's midline. The paretic leg will be positioned behind the mirror, with the intact leg facing the reflective surface. All subjects will be reminded to focus on the image in the mirror during MT training. All subjects will receive concurrent TENS stimulation over the common peroneal nerve while practising bilateral lower limb exercises. After 15 minutes of priming with TENS + MT, all subjects will perform 60 minutes of lower limb task-oriented training.
3381339|NCT03622879|Placebo Comparator|Placebo-MT+TENS|In the Placebo-MT+TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group, except that the reflecting surface of the angle-adjustable mirror was covered with paper. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
3309174|NCT01912131|Active Comparator|usual care|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will neither be shown the goals-of-care (GOC) video nor undergo the narrative interview process - they will be contacted as per re-assessment.
3309175|NCT01912131|Experimental|video-only arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
3309176|NCT01912131|Experimental|combined narrative and video (P-COCC) arm|As outlined ECOG performance status will be recorded at the time of registration without the subject's involvement. Quality of life, treatment satisfaction, distress and peacefulness will also be recorded at baseline. subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences.
3309177|NCT01912144|Other|coffee|Coffee beverage
3309178|NCT01912157|Placebo Comparator|No Intervention|The control condition are 3 sessions writing about individual time-management (placebo).
3309179|NCT01912157|Active Comparator|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing).
3309180|NCT01912170|Experimental|fish oil|Patients will receive fish oil capsules, at a dose of 2g/day. Each 1g capsule will contain 220mg of EPA and 170mg of DHA
3309181|NCT01912170|Experimental|Flaxseed Oil|Patients will receive flaxseed oil capsule, at a dose of 2g/day. Each 1g capsule will contain 550mg of ALA
3309182|NCT01912170|Placebo Comparator|Placebo Supplementation|Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil
3309183|NCT01912183|Active Comparator|Monitoring device in PHR|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The Active Comparator group will not receive any feedback or communication outside of clinic visits from the clinical team regarding their goal progress.
3309184|NCT01912183|Experimental|Communication through PHR outside clinic|Both groups will receive routine clinical care in the pediatric weight management program at McMaster Children's Hospital. Children/youth in both groups will receive a physical activity and sleep monitor and access to their PHR. The experimental group will receive regular communication with /access to the clinical team through a secure portal within the PHR(i.e. 2 way communication, weekly feedback to the families on their goal progress).
3309185|NCT01912196|Experimental|MSI-195|"Patients randomized to the MSI-195 arm will receive treatment with 2 tablets (800 mg) of MSI-195 plus on-going antidepressant therapy (ADT).~MSI-195 800 mg (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)"
3309186|NCT01912196|Placebo Comparator|Placebo|"Patients randomized to the placebo arm will receive 2 tablets placebo plus on-going antidepressant therapy (ADT).~Placebo (two tablets) taken orally once a day in the morning on an empty stomach with water (food should be avoided for at least 1 hr after taking the study drug)."
3309187|NCT01912209|Experimental|My Everyday Health Group|Subjects in this group will be randomized to a web based diet and weight modification program (MyEveryday Health) and provided personal access codes. They will also continue to have access to the WebMD website provided as part of their employment with Baptist Health South Florida.
3309188|NCT01912209|No Intervention|WebMD Group|This group will continue to have access to a website that is available for use of all employees (WebMD) at Baptist Health South Florida. This is the care-as-usual arm.
3309189|NCT01912235|Active Comparator|Test Study 1: 2-15N glutamine|To determine the contributions make by glutamine to the provision of nitrogen for ornithine, citrulline and arginine syntesis in adults.
3309190|NCT01912235|Active Comparator|Test Study 2: 15N2 arginine &15N proline|administration of 15N2 arginine &15N proline to measure arginine and proline flux
3309191|NCT01912235|Active Comparator|Study Test 3: 1-13C glutamine|to determine to contribution of glutamine to the carbon skeleton of ornithine, citrulline and arginine in adults.
3309192|NCT01912248||Heart failure|strength training
3309193|NCT01912248||Heart Transplant recipients|strength training
3309194|NCT01912248||patients with ischemic heart disease|strength training
3309195|NCT01912261|Active Comparator|FeraMax|FeraMax Polysaccharide iron complex oral iron supplement 150mg one capsule orally daily
3309196|NCT01912261|Placebo Comparator|Placebo|one capsule orally daily
3309197|NCT01912300|Experimental|Lean adolescents|
3309198|NCT01912300|Experimental|Obese adolescents|
3309199|NCT01912313|Experimental|Rectal biopsy|
3309200|NCT01912326|Active Comparator|AF Suppression On|AF Suppression Algorithm On, optimized AF Pacemaker Programming
3309201|NCT01912326|Active Comparator|AF Suppression Off|AF Suppression programmed Off, Optimized Pacemaker Programming
3309202|NCT01912365||Above Elbow Cast + Collar/cuff|Participants randomized to this group will be treated with an Above Elbow Cast & collar/cuff for 3 weeks
3309203|NCT01912365||Long Arms Splint + Collar/Cuff|Participants randomized to this group will be treated with a long arm splint & collar/cuff for 3 weeks
3309204|NCT01912378|Experimental|Oxytocin Nasal Spray|40 IUs of Oxytocin nasal spray will be administered to both parents at one time during the lab visit.
3309205|NCT01912378|Placebo Comparator|Placebo nasal spray|40 IUs of Placebo nasal spray will be administered to both parents at one time during the lab visit.
3309206|NCT01912391|Experimental|Selegiline|Transdermal Selegiline 12 mg patch Apply (1) patch daily
3309207|NCT01912391|Placebo Comparator|Placebo (for Selegiline)|Transdermal Placebo patch Apply (1) patch daily
3309208|NCT01912417|Experimental|Hemodialysis session with exercise|Patients were included in a randomly crossover study design such that each patient received one HD session with exercise (intervention) and the next session without exercise (control), alternating for six consecutive HD sessions.
3309209|NCT01912417|No Intervention|hemodialysis session without exercise|Each patient received one hemodialysis session without exercise
3309210|NCT01912430|Experimental|ICC (Integrated Care Coaching)|Received evidence-based, protocol-driven integrated care coaching intervention to improve chronic illness health outcomes (clinical, financial).
3309211|NCT01912430|Experimental|Control Group|Matched cohort by age and chronic illness diagnoses - no intervention
3309212|NCT01912443||Bevacizumab Plus Chemotherapy|
3309213|NCT01912469|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
3309214|NCT01912469|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
3309215|NCT01912482|Experimental|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
3309216|NCT01912482|Active Comparator|Ventilatory Training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
3309217|NCT01912482|No Intervention|Crontrol Group|This condition will last six weeks, this period will be held six lectures sixty minutes long and periodization weekly.
3309218|NCT01912508||preterm labor|pregnant women with signs of preterm labor: uterine contractions or cervical shortening
3309219|NCT01912508||control|pregnant women with no signs or symptoms of preterm labor
3309220|NCT01912521|Experimental|Intervention|This arm is eligible for participation in the Mfangano Health Net Microclinic Program, a social network-based educational program.
3309221|NCT01912521|No Intervention|Comparison|This arm is not eligible for participation in the intervention. Participants still have access to usual care at the Sena Health Center or their health facility of choice.
3309222|NCT01912534|Active Comparator|Valsartan|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
3309223|NCT01912534|Placebo Comparator|Placebo|Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group. Treatment will continue for 2 years.
3309224|NCT01912547||Blood draw for TEG analysis|TEG analysis of blood from patients at different points in time
3309225|NCT01912560|Experimental|CAT-2003 or Placebo Dose 1|Daily for 28 days in patients with moderate hypertriglyceridemia
3309226|NCT01912560|Experimental|CAT-2003 or Placebo Dose 2|Daily for 28 days in patients with moderate hypertriglyceridemia
3309227|NCT01912560|Experimental|CAT-2003 or Placebo Dose 3|Daily for 28 days in patients with moderate hypertriglyceridemia
3309228|NCT01912560|Experimental|CAT-2003 or Placebo Dose 4|Daily for 28 days in patients with hypercholesterolemia who are on a statin
3309229|NCT01912573|Experimental|Intranasal (IN) naloxone|Intranasal (IN) naloxone as initial response to suspected opioid overdose
3309230|NCT01912573|Active Comparator|Standard of Care (TAU)|Standard of care (intravenous [IV], intramuscular [IM] or intraosseus [IO]delivery of naloxone) as initial response to suspected opioid overdose.
3309231|NCT01912586|No Intervention|Arm A|Patients receive no interventions for ED after laparoscopic surgery
3309232|NCT01912586|Experimental|Arm B|sildenafil 25mg/day nightly without vacuum erection device for 3 months after surgery within one or two weeks.
3309233|NCT01912586|Experimental|Arm C|sildenafil 25mg/day nightly and together with using vacuum erection device to make erections for 10-15 minutes/day for 3 months after surgery within one or two weeks.
3309234|NCT01912625|Experimental|Treatment (trametinib, chemotherapy, radiation therapy)|"CONCURRENT CHEMOTHERAPY: Patients undergo IMRT or 3D-CRT QD 5 days a week for 6 weeks. Patients receive trametinib PO QD and carboplatin IV over 30 minutes and paclitaxel IV over 1 hour once weekly. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients without disease progression after completion of chemoradiation proceed to consolidation chemotherapy.~CONSOLIDATION CHEMOTHERAPY: Beginning 3 weeks after completion of concurrent chemoradiation, patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on days 1 and 22. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity."
3309235|NCT01912638|Experimental|Implantation of Ologen in trabeculectomy|Ologen Collagen Matrix is implanted in primary limbal-based trabeculectomy. It should be placed on the top of the loosely-sutured scleral flap before suturing of the conjunctiva thus preventing the collapse of the subconjunctival space.
3309236|NCT01912638|Active Comparator|Provisc in trabeculectomy|Provisc is used in primary limbal-based trabeculectomy. At the end of the surgery cohesive viscoelastic (Provisc) is injected under the scleral flap to prevent early hypotony.
3309237|NCT01912651|No Intervention|No antibiotic treatment|Withholding post-operative antibiotics following reconstructive surgery necessitating skin grafting for defects of the face or nose.
3309238|NCT01912651|Experimental|Antibiotics|All patients will receive peri-operative antibiotics per standard practice. This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week).
3309239|NCT01912677|Active Comparator|Nifedipine|Women will receive an initial dose of oral nifedipine 10mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total).
3309240|NCT01912677|Experimental|Methyldopa|Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given.
3309241|NCT01912677|Experimental|Labetalol|Women will receive an initial dose of oral labetalol 200mg. If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total).
3309242|NCT01912690|Placebo Comparator|standard of care|
3309243|NCT01912690|Active Comparator|aerobic training only|
3309244|NCT01912690|Active Comparator|Aerobic and strength training|
3309245|NCT01912703||Preterm infants with IVH Grades I-II|Preterm infants (post-menstrual age 24-35 weeks) who were diagnosed with IVH Grades 1-2 in the neonatal intensive care unit (NICU).
3309246|NCT01912703||Control Group|Preterm infants (post-menstrual age 24-35 weeks) who had no imaging evidence of IVH in the neonatal intensive care unit (NICU).
3309247|NCT01912742|Experimental|Rapid weight loss group|The rapid weight loss group will follow a commercial very-low calorie diet (VLCD) during 4 weeks. The participants allocated to this group will follow a 550 (women) - 660 (men) kcal/day diet. The VLCD products provide 110kcal/pack and include a variety of milkshakes, smoothies and soups. In addition to VLCD products, calorie-free drinks and some low-starch vegetables (maximum 2 cups/day) will be allowed. Drinking at least 2.5 liters of non-caloric liquids will be recommended.
3309248|NCT01912742|Experimental|Slow weight loss group|The slow weight loss group will be prescribed an individualized low calorie diet (LCD) (1200-1500kcal/day), during 8 weeks, using meal replacements (such as smoothies, soups and cereal bars) and conventional foods. The macronutrient composition will be matched with that of the VLCD.
3309249|NCT01912755|Experimental|Articaine|injection of 1.8 mL buccal infiltrations of 4% articaine with 1:100,000 epinephrine in one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
3309250|NCT01912755|Active Comparator|Lidocaine|1.8 mL 2% lidocaine with 1:100,000 epinephrine injected as inferior alveolar nerve block in the mandible side with one tooth with a clinical diagnosis of symptomatic irreversible pulpitis.
3309251|NCT01912794|Experimental|Sensory Conditions|
3309252|NCT01912820|Experimental|Arm I (quercetin, green tea extract)|Patients receive GT extract PO BID and quercetin PO BID for 3-6 weeks before undergoing prostatectomy.
3309253|NCT01912820|Placebo Comparator|Arm II (GT extract, placebo)|Patients receive GT extract PO BID and placebo PO BID for 3-6 weeks before undergoing prostatectomy.
3309254|NCT01912846|Sham Comparator|Attention usual care intervention|"Interventions includes prognosis disclosure and discussions of EOL care as needed as in current clinical practices.~Interventions of the attention usual care arm include a consistent master prepared nurse on the study team will provide the attention portion of the care and a workbook and a video with educational materials. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department."
3309255|NCT01912846|Experimental|Interactive advance care planning|The intervention aims at facilitating patients, families, and primary physicians to discuss the patient's wishes for EOL care by clarifying a terminally ill cancer patient's understanding of his/her prognosis and treatment options and her/his readiness for engagement in ACP, appropriately weighting the benefits and burdens of medical treatments at EOL, and clearly defining and documenting the patient's preferences so as to be readily available later for the patient's primary physician to guide EOL care decision-making which will honor the patient's preferences for EOL care.
3309256|NCT01912859|Experimental|Nutrition/physical activity intervention|The intervention, Next Steps, comprises a network of community-led health maintenance programs offered to graduates of an initial intensive obesity course. These health maintenance programs will aim to help participants maintain and improve healthful behaviors and body mass indices.
3309257|NCT01912859|No Intervention|Usual care|"Participants in the No Intervention arm will not have access to the Next Steps programs and will receive only usual care through their health care clinic."
3309258|NCT01912885|Placebo Comparator|Group TENS 0-1|Electrodes will be fixated to one leg and sessions will be held once a week.
3309259|NCT01912885|Experimental|Group TENS 1-1|Electrical stimulation of the posterior tibial nerve of one leg once a week.
3309260|NCT01912885|Experimental|Group TENS 1-2|Electrical stimulation of the posterior tibial nerve of one leg twice a week.
3309261|NCT01912885|Experimental|Group TENS 2-1|Electrical stimulation of the posterior tibial nerve of two legs once a week.
3309262|NCT01912885|Experimental|Group TENS 2-2|Electrical stimulation of the posterior tibial nerve of two legs twice a week.
3309263|NCT01912898||1|
3309264|NCT01912937|Experimental|DCB Arm|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
3309265|NCT01912950|Experimental|Prowave LX IPL|"Prowave LX IPL, short pulse setting and snowflake mode On"
3309266|NCT01912950|No Intervention|No Treatment|No treatment administered.
3309267|NCT01912976|Experimental|Er:YAG AFL-PDT|Right leg on each patients was assigned a single session of Er:YAG AFL-PDT.
3309268|NCT01912976|Active Comparator|MAL-PDT|Left leg on each patient was selected to receive 2 sessions of MAL-PDT
3309269|NCT01912989|Experimental|Lifestyle counseling|NOURISH+ plus motivational interviewing
3309270|NCT01913002|Experimental|Treatment A|LX4211 800 mg
3309271|NCT01913002|Experimental|Treatment B|LX4211 2000 mg
3309272|NCT01913002|Active Comparator|Treatment C|moxifloxacin 400 mg
3309273|NCT01913002|Placebo Comparator|Treatment D|Placebo
3309274|NCT01913015|Experimental|Arm I (abiraterone acetate, low then high fat breakfast)|Patients receive standard dose abiraterone acetate PO QD (held on days 2, 3, 9, and 10), and low-dose abiraterone acetate PO QD on days 3 and 10. Patients eat a low fat breakfast on day 3 and a high fat breakfast on day 10.
3309275|NCT01913015|Experimental|Arm II (abiraterone acetate, high then low fat breakfast)|Patients receive abiraterone acetate as in Arm I. Patients eat a high fat breakfast on day 3, and a low fat breakfast on day 10.
3309276|NCT01913028|Experimental|MEDI9929|Solution of MEDI9929, SC
3309277|NCT01913028|Placebo Comparator|Placebo|Placebo solution for MEDI9929, SC
3309278|NCT01913054|Active Comparator|Fentanyl & Propofol|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg is given every time until the patient falls asleep. During the operation, 0.5 mg/kg is given when it is needed.
3309279|NCT01913054|Experimental|fentanyl, propofol & etomidate|0.02 ml/kg(1 μg/kg) fentanyl is diluted to 10 ml with normal saline and infused within 1 min, 4 min advance. 0.5 mg/kg(0.025 ml/kg) propofol is infused within 15 to 20 s. And then, depending on the randomized result, 0.5 mg/kg etomidate is given every time until the patient falls asleep. During the operation, 0.5 mg/kg etomidate is given when it is needed.
3309280|NCT01913067|Experimental|Cabazitaxel|Eligible patients will receive intravenous 25mg/m2 cabazitaxel every 3 weeks. Contrast-enhanced whole brain MRI will be performed every two cycles. Patients who show ≥50% volumetric reduction in the size of the brain lesion(s) will continue on cabazitaxel until disease progression or unacceptable toxicity. Patients who show evidence of disease progression and/or developed progressive neurological symptoms will be taken off study and offered whole brain irradiation. Patients who do not meet both criteria can have the choice either to continue on study drug or to be taken off study according to the investigator discretion.
3309281|NCT01913080|Active Comparator|Health Log|Patients who have a billing diagnosis RA (714.0)or seronegative inflammatory arthritis who are enrolled in the Brigham and Women's Rheumatoid Arthritis Sequential Study (BRASS)will be given the Health Log health management tool.
3309282|NCT01913080|No Intervention|Control Pill Box|Controls will be BRASS patients who continue to receive regular care and are also given a pill box instead of the Health Log health management tool.
3309283|NCT01913093||Leukemia survivors with neurocognitive deficit|"Leukemia survivors with neuro-cognitive deficit phenotype. Based on DIVERGET and other phenotyping tools, we will identify those with the deficit phenotype. This will be treated as case."
3309284|NCT01913093||Leukemia survivors without neurocognitive deficit|Leukemia survivors who did not show impaired neurocognitive function, compared to the Control group defined above.
3309285|NCT01913106|Experimental|HSV-tk + Valacyclovir and Brachytherapy|You will be given an antibiotic (Ciproflaxin) to take twice a day beginning the day before the procedure, and continuing for a total of 3 - 5 days. You will also be given 4 pills called (Valtrex) valacyclovir to take three times a day for 14 days, beginning the day before the procedure. You will be given a pill diary in which you will record each dose of valacyclovir that you take. You will receive brachytherapy (radioactive seed placement) the day after you begin taking your pills. After the radioactive seeds are placed, while you are still in the operating room, you will receive an injection into your prostate of 1 or 2 ml (one-fifth or two-fifths of a teaspoon) of a solution of the vector carrying the gene.
3309286|NCT01913119|Experimental|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
3309287|NCT01913132|No Intervention|Standard wound dressing OPEN|Standard wound dressing
3309288|NCT01913132|Experimental|PICO dressing OPEN|Negative pressure wound therapy with PICO (Smith & Nephew)
3309289|NCT01913132|No Intervention|Standard dressing EVAR|Standard wound dressing
3309290|NCT01913132|Experimental|PICO dressing EVAR|Negative pressure wound therapy with PICO (Smith & Nephew)
3309291|NCT01913145|Experimental|A1c, Self-collection, Blood sample|"Can a lay-persons safely and effectively self-collect a capillary blood sample of sufficient adequacy for A1c (HbA1c) testing in a clinical laboratory"
3309292|NCT01913158|Placebo Comparator|Placebo suppository|Hydrogenated palm kernel oil suppositories
3309293|NCT01913158|Active Comparator|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone Acetate suppositories
3309294|NCT01913171|Active Comparator|Walking|WALK. The participants were instructed to walk daily, at first week 12minutes/day, week II 16mins/day, week III 20mins/day, week IV 24 mins/day, week V 28mins/day, week VI 32mins/day at a pace that would moderately increase heart rate and result in sweating
3309295|NCT01913171|Active Comparator|Hula-hooping|HULA. The participants were instructed to hula hoop daily, at first week 6minutes/day, week II 8mins/day, week III 10mins/day, week IV 12 mins/day, week V 14mins/day, week VI 16mins/day
3309296|NCT01913184|Active Comparator|Continuous nebulization|Continuous nebulization with AKITA
3309297|NCT01913184|Experimental|Discontinuous nebulization|Discontinuous nebulization with AKITA
3309298|NCT01913197|Experimental|Pre-implant MRI images and planning|
3309299|NCT01913223|Experimental|submucosal dissection by dissector water jet|
3309300|NCT01913236|Experimental|Implementation intervention|Tailored implementation intervention to address determinants of practice in primary care
3309301|NCT01913236|No Intervention|Control|Treatment as usual provided by general practitioners to elderly patients with depression
3309302|NCT01913249|Experimental|Intervention|Seton through fistula 6 months prior to LIFT
3309303|NCT01913249|Active Comparator|Control|Seton through fistula 3 weeks prior to LIFT surgery
3309304|NCT01913262||IFH Patients on Depression Registry|Patients at the Institute for Family Health who have a diagnosis of depression active on their problem list or have had a diagnosis of depression used as an encounter diagnosis in the past year or patients with a PHQ-9 score greater than or equal to 10.
3309305|NCT01913275|Active Comparator|endoscopic stenting|endoscopic stenting to reduce preoperative jaundice
3309306|NCT01913275|Active Comparator|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
3309307|NCT01913288|Experimental|Biological Maternal Sounds|Daily Exposure to recorded mother's voice and heartbeat sounds via audio systems installed at the bedside
3309308|NCT01913288|Sham Comparator|Hospital Sounds|Exposure to standard hospital sounds; routine care.
3309309|NCT01913301|Experimental|Alagebrium|
3309310|NCT01913366|Experimental|CM-PST|If you are assigned to CM-PST, you will be working with the same care manager from your introductory session. The care manager will continue to work with you on your problem-solving plan. Additionally, you will receive case management services.
3309311|NCT01913366|Experimental|SG-PST|If you are assigned to SG-PST, you will continue to work on your problem-solving plan, using the self-guided materials provided to you during the introductory session. Additionally, you will be partnered with a senior peer counselor who will support you in your SG-PST efforts.
3309312|NCT01913379|Experimental|1: MDV3100|
3309313|NCT01913379|Experimental|2: MDV3100 and gemfibrozil|
3309314|NCT01913379|Experimental|3: MDV3100 and itraconazole|
3309315|NCT01913392||morbidly obese, chronic renal disease|adult patients (> 18 years) who have stage 4 or 5 chronic renal disease (CrCl < 30 ml/min) who are being considered for possible future kidney transplantation. The study inclusion criteria are an indication for laparoscopic sleeve gastrectomy (BMI > 40 kg/m2, or BMI > 35 with at least one co-morbidity such as hypertension, dyslipidemia or diabetes)
3309316|NCT01913418|Active Comparator|Suan-Zao-Ren Tang|The SZRT formula used in this study is manufactured as a herbal extract powder from the good manufacturing procedures (GMP) of the certified company Kaiser Pharmaceutical Co., Ltd. (Taiwan). Granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
3309317|NCT01913418|Placebo Comparator|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
3309318|NCT01913431|Experimental|Baracle Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
3309319|NCT01913431|Experimental|Baraclude Tab.®|(It can be also placebo) dosage: 2 tablets daily for 48 weeks
3309320|NCT01913444|Experimental|Recombinant Antithrombin Infusion|The initial loading dose and maintenance continuous infusion will be calculated according to the following equations which are based on the patient's baseline AT activity level prior to ECMO. Loading dose(IU)=(100-baseline AT activity)/2.3 x Wt(kg). Maintenance Dose(IU/hour)=(100-baseline AT activity)/10.2 x Wt(kg). The loading dose will be administered as a 15-minute IV infusion once the patient is on ECMO. This will be followed by the maintenance continuous infusion. AT levels will be checked 2hours after the initiation of treatment. For AT levels that are <80% or >100%, the infusion rate will be increased or decreased, respectively, by 30% and a follow-up level will be checked 2hours after the adjustment. If the AT level is within goal range (80-100%), follow-up AT levels will be checked every 6hours unless dose adjustments are made. Once the patient is off ECMO, the continuous infusion will be discontinued and AT levels will no longer be checked.
3309321|NCT01913457||Adults w/ PH|Subjects above 18y scheduled to undergo RHC for Doppler ultrasound external right chest wall tests
3309322|NCT01913457||Children w/ PH|Children 0-18y old scheduled to RHC
3309323|NCT01913457||Children control|Children 0-18y old w/o PH for Lung Doppler tests as controls
3309324|NCT01913496|Placebo Comparator|Standard care|standard care ,without the web application ebalance
3309325|NCT01913496|Active Comparator|ebalance|using the ebalance application for 14 weeks
3309326|NCT01913509|Experimental|Combined Therapy of FES and BAT|Patients with hemiplegic shoulder pain is applied functional electrical stimulation and bilateral arm training (FES-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected arm.
3309327|NCT01913509|Active Comparator|Conventional Rehabilitation|The stroke patients in CR group receive a structure protocol using electrical modality such as transcutaneous electrical nerve stimulation (TENS) and bilateral arm training (TENS-BAT) one hour daily, 3 days per week for 4 weeks and a total of 12 sessions.
3309328|NCT01913522|Experimental|Standard cryoablation|"Patients randomized to the standard group will undergo cryoablation with target duration of 240 seconds. Once PVI is achieved a single bonus application of 240 seconds will be delivered after the rewarming phase (to +20oC)."
3309329|NCT01913522|Active Comparator|Irrigated RF Ablation|Patients randomized to irrigated RF group will undergo standard wide circumferential PVI with an irrigated radiofrequency catheter
3309330|NCT01913522|Experimental|Short Cryoablation|"Patients randomized to the multiple-freeze group will undergo cryoablation with target duration of 120 seconds. Once PVI is achieved a single bonus application of 120 seconds will be delivered after the rewarming phase (to +20oC)."
3309331|NCT01913548||Sickle Cell Disease (SCD)|Patients with sickle cell diseases, 16 years or older with 10-20 years of transfusion (defined as 0.2-0.6mg Fe/kg/day exposure with annual ferritin levels greater than 2500 in at least 60% of years of chronic transfusion); 0 to 9 years old at the initiation of chronic transfusions; no exchange transfusions in the previous 6 months; and iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC (liver iron content) of greater than 7 mg/g dry wt in the previous 6 months or ferritin level greater than 1500mg/dl.
3309332|NCT01913548||Thalassemia Major (TM)|Patients with β-thalassemia major and transfusion-dependent E-beta THAL. 16 years or older with 10-20 years of chronic transfusion (defined above), 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3309333|NCT01913548||Diamond Blackfan Anemia (DBA)|Patients with DBA, 16 years or older with 10-20 years of transfusion, 0 to 9 years old at the initiation of chronic transfusions, iron overload documented by either liver biopsy, MRI or SQUID with estimated LIC of greater than 7 mg/g dry wt in the previous 6 months.
3309334|NCT01913561|Experimental|Master Caution Garment|"each patient will be connected simultaneously with two devices:~ECG gel electrodes~Master Caution Garment textile electrodes The two devices will be connected to hospital ECG telemetry."
3309339|NCT01913613|Experimental|Treatment|Treatment with the IASD device
3309340|NCT01913626|Experimental|cognitive group therapy|patient with subjective memory complains will participate in cognitive group therapy including eight meetings of practicing cognitive strategy to improve the memory .
3309341|NCT01913652|Experimental|Cabazitaxel|"INN: Cabazitaxel Cabazitaxel will be administered at a dose of 25 mg/m² by intravenous infusion, over 1 hour, on day 1 of each 21 day cycle.~Treatment should be administered until disease progression, unacceptable toxicity or patient's refusal."
3309342|NCT01913665|Active Comparator|B.Lactis|children with functional constipation
3309343|NCT01913665|Active Comparator|Inulin|children with functional constipation
3309344|NCT01913665|Active Comparator|B.Lactis+ınulin|children with functional constipation
3309345|NCT01913665|Placebo Comparator|plasebo|children with functional constipation
3309346|NCT01913678|Active Comparator|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
3309347|NCT01913678|Active Comparator|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
3309348|NCT01913678|Placebo Comparator|Complete diet|The participants will be given all dietary items in their diet.
3309349|NCT01913704|Placebo Comparator|Placebo device|"The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device.~The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
3309350|NCT01913704|Active Comparator|NatroxTM Device|"A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
3309351|NCT01913717|Experimental|External beam radiotherapy|External beam radiotherapy
3309352|NCT01913730|No Intervention|No prolonged therapy is scheduled|
3309353|NCT01913730|Experimental|Bortezomib Dexamethasone (Biochemical relapse)|Patients randomized in this group will be observed. At the occurrence of biochemical relapse, 4 VD cycles will be administered: Bortezomib (SC) and Dexamethasone (PO) weekly.
3309354|NCT01913743||MINDSETS|overweight/obese
3309355|NCT01913756|Experimental|Gouda-type cheese|80 g/day Gouda-type cheese
3309356|NCT01913756|No Intervention|Low cheese intake|
3309357|NCT01913756|Experimental|Gamalost (Norwegian traditional cheese)|50 g/day Gamalost
3309358|NCT01913769||Radiation therapy|Thoracic cancer patient s/p scheduled RT will be arranged to undergo Thallium-201 Myocardial Perfusion Study. The scheduled RT will be arranged by clinical judgments of radiation-oncologists. All of the patients will receive myocardial SPECT before and after the scheduled RT.
3309359|NCT01913782||patients with low back pain|"Patients with disc herniation or radiculitis who are over 18 years of age.~Patients with a history of chronic function-limiting low back pain and lower extremity pain for at least one months' duration.~Patients who are competent to understand the study and provide written informed consent and participate in outcome measurements."
3309360|NCT01913808|Experimental|Ferric carboxymaltose|Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit [mg] = 2.4 x patient's weight [kg] x (target Hb [13 g/dL] - current Hb [g/dL]) + 500 [mg iron stores]
3309361|NCT01913808|Active Comparator|Ferrous glycine sulphate|Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery
3309362|NCT01913834|Active Comparator|Forsteo|Synthetic PTH 1-34 Single dose Subcutaneous administration 20.0 micrograms
3309363|NCT01913834|Experimental|CP046 PTH CriticalSorb 22.5 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 22.5 micrograms
3309364|NCT01913834|Experimental|CP046 PTH CriticalSorb 45.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 45.0 micrograms
3309365|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 R|Synthetic PTH 1-34 Single dose Nasal administration rexam device 90.0 micrograms
3309366|NCT01913834|Experimental|CP046 PTH CriticalSorb 90.0 O|Synthetic PTH 1-34 Single dose Nasal administration 90 micrograms
3309367|NCT01913847|Experimental|Sildenafil|Sildenafil 20 mg
3309368|NCT01913847|Placebo Comparator|Placebo|Placebo
3309369|NCT01913860|No Intervention|Control|Control group will receive usual care
3309370|NCT01913860|Active Comparator|Improve GP prescribing behaviour|Improve GP prescribing behaviour will be promoted through personalised audit and feedback reports, delivered through face to face workshops within practice.
3309371|NCT01913860|Active Comparator|Improved delayed GP prescribing|Improved delayed GP prescribing will be promoted through the antibiotic prescribing guidelines and personalised audit and feedback reports. Additional scientific evidence will be provided related to delayed prescribing.
3309372|NCT01913873|Experimental|Cardiac biomarkers concentration changes|"In 2012 the Third Global MI Task Force has presented a third universal definition of MI implying that MI associated with CABG is arbitrarily defined by elevation of cardiac biomarkers values > 10x99th percentile URL in patients with normal baseline cTn values (≤ 99th percentile URL), in addition with either (i) new pathological Q waves or new LBBB (left bundle branch block), or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.~In this study we will measure the concentration changes over time of cardiac biomarkers (hs-cTN and CK-MB) and establish a threshold value for myocardial injury, diagnosed by ECG and approved -if necessary- by echocardiography."
3309373|NCT01913886|Experimental|MSCs injection|Injection of autologous bone marrow-derived mesenchymal cells
3309374|NCT01913899|Experimental|Mirror therapy|60 minutes of mirror therapy each day over a period of 14 days starting directly post surgically (24-48 hours after surgery)
3309375|NCT01913899|Active Comparator|Occupational/ physical therapy|60 minutes of occupational/ physical therapy each day over a period of 14 days starting 24-48 hours post surgically
3309376|NCT01913925|Active Comparator|Tyrosine-Containing Food Bar|150 mg/kg dose of tyrosine per administration, administered twice
3309377|NCT01913925|Placebo Comparator|Placebo bar|0 mg/kg dose of tyrosine per administration, administered twice
3309378|NCT01913938||patients with cytopenias|Patients with sepsis and concomitant cytopenias (leukopenia with thrombocytopenia and anemia) who are routinely treated with rhG-CSF will be followed for reconstitution of peripheral blood cell counts. In cooperation with the Department of Hematology, patients are examined for bone marrow cellularity and hemophagocytosis if G-CSF treatment does not result in leukocyte increase.
3381340|NCT03622879|Placebo Comparator|MT+placebo-TENS|In the MT+placebo-TENS group, the experimental set-up and protocol will be the same as in the MT+TENS group. The only difference is that placebo stimulation will be applied to the paretic limb from identical-looking TENS devices with the electrical circuit disconnected inside. After 15 minutes of priming, all subjects will perform 60 minutes of lower limb task-oriented training.
3381341|NCT03622879|Sham Comparator|control training|All subjects will perform 60 minutes of lower limb task-oriented training only.
3309379|NCT01913951|Experimental|Treatment (vosaroxin, azacitidine)|Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
3381342|NCT03611972|Experimental|Sugar-sweetened beverage (SSB)|SSB provided at 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 2 weeks
3381343|NCT03608579|Experimental|Single Injection|Single administration of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip by single ultrasound guided injection
3381344|NCT03608579|Experimental|Two Injections|Two-dose administration (2 x ultrasound guided injections) of Autologous Adipose Derived Mesenchymal Stromal Cells into the hip with one month interval between doses
3381349|NCT03598790|Experimental|Bimekizumab dose regimen 1|"Subjects are randomized to receive either dose regimen 1 or dose regimen 2, those on dose regimen 1 will switch to dose regimen 2 at Week 24 or later.~Intervention Name: Bimekizumab"
3381350|NCT03598790|Experimental|Bimekizumab dose regimen 2|Subjects will receive bimekizumab dose regimen 2. Intervention Name: Bimekizumab
3381351|NCT03584022|Experimental|Biopsy + Nerve Repair|Subjects will undergo standard sural nerve biopsy plus repair of the 6 cm nerve defect using a synthetic polymer (PCLF) nerve tube.
3381352|NCT03584022|Sham Comparator|Biopsy Only|Subjects will undergo the same standard sural nerve biopsy procedure as the Experimental Group, but will not include the nerve repair.
3381353|NCT03582176|Placebo Comparator|Lactose Placebo|Lactose Placebo by mouth twice per day
3309380|NCT01913964|Experimental|Acetyl-L-carnitine|2 g daily for 12 months
3309381|NCT01913964|Placebo Comparator|placebo|
3309382|NCT01913977|Experimental|Treatment with mechanical ventilation|Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy).
3309383|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|"The standard anti-emetic arm:~In this arm the treating medical oncologist will determine the choice of anti-emetic regimen that they perceive the patient would require and prescribe it. The treating physician will be blinded to result of the personalized composite emesis score. The physician may or may not choose to prescribe an NK-1 inhibitor as the study will not predetermine the type of anti-emetics used. In the event that the patient experienced chemo induced nausea and vomiting (CINV), modifications to the initial anti emetic regimen would be left to the treating physician."
3309384|NCT01913990|Experimental|Arm B: Dexamethasone, Ondansetron, Aprepitant|"The emesis risk model arm:~Prior to the start of intravenous chemotherapy an emesis risk score will be calculated for both acute and delayed emesis. The anti-emetic prophylaxis treatment will follow the emesis risk score. Whereby either an acute emesis score of ≥7 and/or a delayed emesis score of >16 will be considered high-risk. The anti-emetics will be prescribed reflecting this risk for pre-chemotherapy, 8 hrs post chemotherapy and day 2-3 post chemotherapy. Dexamethasone, Ondansetron and Aprepitant will be given in different combination and doses depending on what score the participant receives based on their responses to the diary. For subsequent cycle the anti-emetic score will be re-calculated prior to each cycle and the choice of anti-emetics adjusted if necessary."
3309385|NCT01914016|Other|prolonged walk|
3309386|NCT01914042|Experimental|Morphine|Morphine in changing dosages (range between 10-60 mg twice a day). Opioid titration proceeds as follows: starting at an oral dose of 10 mg twice per day, followed every 5 days by a dose increase of 10 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 120 mg per day had been reached.
3381354|NCT03582176|Active Comparator|Ketotifen Fumarate - 2mg|Ketotifen Fumarate 2 mg by mouth twice per day
3381355|NCT03582176|Active Comparator|Ketotifen Fumarate - 5mg|Ketotifen Fumarate 5 mg by mouth twice per day
3381356|NCT03575364||Primary Analytic|Patients with unilateral acute or subacute DVT of less than 6 weeks' duration.
3381357|NCT03575364||Registry|Patients with proximal lower extremity DVT.
3381358|NCT03573375|Experimental|Cancer Patients in Supportive Care Clinic (SCC)|
3381361|NCT03565640|Active Comparator|Capio Slim Device|Participants will be randomized to the sacrospinous ligament fixation with use of Capio Slim Device
3381362|NCT03565640|Experimental|Anchorsure Device|Participants will be randomized to the sacrospinous ligament fixation with use of Anchorsure Device
3381363|NCT03565107||Female Patients|ICSI treatment because of male subfertility
3381364|NCT03560466|Experimental|Dupilumab|Doses of dupilumab will be administered every 2 weeks or every 4 weeks added to current controller medications for 52 weeks
3309387|NCT01914042|Active Comparator|Milnacipran|Milnacipran (Ixel)- a serotonin-norepinephrine reuptake inhibitor (SNRI), will be administrated in changing dosages (range between 12.5-75 mg twice daily). SNRI titration proceeds as follows: starting at an oral dose of 12.5 mg twice per day, followed every 5 days by a dose increase of 12.5 mg twice per day until (1) adequate analgesia had been achieved (as determined by the patients), (2) side effects (severe sedation, nausea or vomiting, constipation, sleep disturbances) limited further titration, or (3) a total of 150 mg per day had been reached.
3309388|NCT01914055|Active Comparator|angio-guided thrombus aspiration|thrombus aspiration guided by angiography
3309389|NCT01914055|Experimental|OCT-guided thrombus aspiration|thrombus aspiration guided by optical coherence tomography
3309390|NCT01914068|No Intervention|Control|No in hospital exercise training and no exercise advice.
3309391|NCT01914068|Active Comparator|Exercise Intervention|In hospital exercise training
3309392|NCT01914081|Active Comparator|Resveratrol|500 mg (1 capsule BID) of resveratrol for 12 months
3309393|NCT01914081|Placebo Comparator|Placebo|500 mg (1 capsule BID) of placebo for 12 months.
3309394|NCT01914094|No Intervention|Standard care|Received current standard care.
3309395|NCT01914094|Experimental|Prehab|Received pre-operative exercise therapy plus education classes concerning management of their risk factors for coronary artery disease at a local medical fitness facility.
3309396|NCT01914107|Experimental|standard cancer pain care|the standard cancer pain care group: 1.will be follow-up by the cancer nurse once a week to acknowledge the cancer pain intensity, the current analgesic medication, and the side effects. and also give recommendations. 2.filled in the patient'diary and hand over to researchers.
3309397|NCT01914107|Experimental|real-time monitoring and instruction of cancer pain|"real-time monitoring and treatment instruction of cancer pain group~1.follow the same pattern of standard cancer pain care. 2. using the cloud computing concept system, install the software in the mobile phone of patients. the patients will fill in the content of brief pain inventory, medication and side effect, and upload to researchers every 2 days. 3. Researcher monitor the cancer pain treatment in realtime and give instructions."
3309398|NCT01914133|No Intervention|No Postprandial Hypotension (PPH)|Screening Meal Test performed and subject does not meet criteria for Postprandial Hypotension (PPH).
3309399|NCT01914133|Placebo Comparator|Placebo|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension (PPH). At second Meal Test subject will receive a placebo and will take a placebo with the first bite of the next 3 meals.
3309400|NCT01914133|Active Comparator|Acarbose|Screening Meal Test performed and subject meets criteria for Postprandial Hypotension. During the second Meal Test subject will receive Acarbose 50mg and will take Acarbose 25mg with first bite of each of the next 3 meals.
3309401|NCT01914146|Other|Before Initiation of Insulin Therapy|Study sessions will occur before the initiation of insulin therapy (no insulin). Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
3309402|NCT01914146|Other|After Initiation of Insulin Therapy|Study session will take place 2-4 weeks after the initiation of insulin therapy. Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
3309403|NCT01914172||Online web-based questionnaire|Up to 200 patients with KS/CHH will be recruited to complete an online web-based questionnaire (less than 30 minutes to complete)
3309404|NCT01914172||Patient focus group|Focus groups (90-120 minutes in duration) with 6-12 patients. Up to 36 patients total
3309405|NCT01914172||Online web-based evaluation of patient education materials|Up to 100 patients with KS/CHH will be recruited to complete an online web-based questionnaire to evaluate patient education materials (less than 15 minutes to complete)
3309406|NCT01914185|No Intervention|Comparison Schools|Regular health promotion activities
3309407|NCT01914185|Experimental|Comprehensive School Health (CSH)|Full time School Health Facilitator present in each school on a day-to-day basis for 3.5 years responsible for facilitating implementation of Comprehensive School Health
3309408|NCT01914198||Sleep study|Patients who are having a sleep study done at NCH to diagnose sleep apnea.
3309409|NCT01914211||Acute Normovolemic Hemodilution|Patients that receive acute normovolemic hemodilution prior to surgery.
3309410|NCT01914211||Tranexamic Acid|Patients that receive tranexamic acid during surgery.
3309411|NCT01914224|Experimental|Group 1|dietary education of low sodium and high potassium consumption
3309412|NCT01914224|Active Comparator|Group 2|dietary education of low sodium consumption only
3309413|NCT01914237|Experimental|Castor Stent Graft|To study the safety and efficacy of Castor single-branched stent graft system in endovascular repair of aortic dissection.
3309414|NCT01914250|Active Comparator|2|Topical Anesthetic, 2% Tetracaine oral gel - Group A Topical Anesthetic, 20% Benzocaine oral gel - Group B
3309415|NCT01914263|Experimental|cytokine induced killer cell|The eligible patients are infused a single dose of 8x10^9 CIK cells.
3309416|NCT01914263|No Intervention|Control|The eligible patients are followed up for 30 days without any treatment.
3309417|NCT01914289|Experimental|Resection|To observe prognosis of resection of icc
3309418|NCT01914289|Active Comparator|Radiotherapy|To observe the prognosis of radiotherapy treatment of icc
3309419|NCT01914302||Delica Lancing Device|Subjects in this group either use the Delica lancing device or a meter that requires 1.0 microliters of blood
3309420|NCT01914302||Freestyle Flash Lancing Device|Subjects in this group either use the Flash lancing device or a meter that requires 0.3/0.6 microliters of blood
3309421|NCT01914302||Easy Touch Lancing Device|Subjects in this group either use the Easy Touch lancing device or a meter that requires 0.3/0.6 microliters of blood
3309422|NCT01914302||Glucoject Lancing Device|Subjects in this group either use the Glucoject lancing device or a meter that requires 0.3/0.6 microliters of blood
3309423|NCT01914302||Microlet Lancing Device|Subjects in this group either use the Microlet lancing device or a meter that requires 0.3/0.6 microliters of blood
3309424|NCT01914302||Multiclix Lancing Device|Subjects in this group either use the Multiclix lancing device or a meter that requires 0.3/0.6 microliters of blood
3309425|NCT01914302||Fastclix Lancing Device|Subjects in this group either use the Fastclix lancing device or a meter that requires 0.3/0.6 microliters of blood
3381365|NCT03556202|Experimental|Mirikizumab Dose 1|Mirikizumab administered subcutaneously (SC).
3381366|NCT03556202|Experimental|Mirikizumab Dose 2|Mirikizumab administered SC.
3381367|NCT03550170|Active Comparator|Teleconference|Teleconference Intervention arm
3381368|NCT03550170|Active Comparator|Internet|Internet Intervention arm
3381369|NCT03550170|Active Comparator|I-to-1, in-person|1-to-1, in-person intervention arm
3309426|NCT01914302||Reli-On Lancing Device|Subjects in this group either use the Reli-On lancing device or a meter that requires 0.3/0.6 microliters of blood
3309427|NCT01914315|Experimental|Cardiac Rehabilitation|Patients randomized to the multidisciplinary cardiac management program at the cardiac rehabilitation center will undergo evaluation by a trained rehabilitation physician and physiologist. The evaluation will include medical history, physical examination, vitals, review of post discharge graded exercise stress test and nursing staff consultation. Exercise prescription will be based on a pre-specified protocol in accordance with ESC position paper on cardiac rehabilitation of patients with heart failure.
3309428|NCT01914315|Active Comparator|Internal Medicine|Following discharge, patients will return to the internal medicine (IM) outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated.
3309429|NCT01914341|Experimental|Music|pentatonic live music
3309430|NCT01914341|No Intervention|control|no intervention
3309431|NCT01914367|Active Comparator|Cervarix group|One sib of each twin pair will be given Cervarix according to the 0, 1, 6 month vaccination scheme.
3309432|NCT01914367|Active Comparator|Gardasil Group|One sib of each twin pair will be given Gardasil according to the 0, 1, 6 month vaccination scheme.
3309433|NCT01914380||Group 1|
3309434|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
3309435|NCT01914406|Active Comparator|continuous moderate training|Continued exercise 45 min.
3309436|NCT01914419|Active Comparator|IV infusion|Oxytocin 10 IU will be administered by IV infusion according to randomization assignment as soon as possible after delivery of the baby.
3309437|NCT01914419|Active Comparator|IV bolus|Oxytocin 10 IU will be administered by IV bolus according to randomization assignment as soon as possible after delivery of the baby.
3309438|NCT01914419|Active Comparator|IM injection|Oxytocin 10 IU will be administered by IM injection according to randomization assignment as soon as possible after delivery of the baby.
3309439|NCT01914432|Experimental|YH16410|PO, Once Daily, 8 weeks
3309440|NCT01914432|Active Comparator|Rosuvastatin|PO, Once Daily, 8 weeks
3309441|NCT01914432|Active Comparator|Telmisartan|PO, Once Daily, 8 weeks
3309442|NCT01914432|Placebo Comparator|Placebo|PO, Once Daily, 8 weeks
3309443|NCT01914445|Experimental|Indigo Carmine|Indigo Carmine (2 mg per kilo) and 2nd half of PEG dose will be orally administered to patients prior to colonoscopy.
3309444|NCT01914458|Experimental|Low-dose computed tomography (LDCT)|Patients will have one baseline LDCT scan.
3309445|NCT01914471|No Intervention|Control|These schools did not receive the intervention.
3309446|NCT01914471|Experimental|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
3309447|NCT01914484|Experimental|Nilotinib with Ruxolitinib|"Nilotinib: Given that recommended dose of Nilotinib for imatinib failed CML patients is 400mg twice daily, Nilotinib dose will remain fixed at 400mg bid throughout the cycles.~Ruxolitinib: In the phase I part of the study, dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose. Ruxolitinib will be given at one of 3 fixed dose levels for the duration of their treatment, either 10mg twice daily, 15mg twice daily or 20mg twice daily."
3309448|NCT01914497|Experimental|Acutus Medical System|Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.
3309449|NCT01914523|Placebo Comparator|Macintosh|tracheal intubation will be performed using a Macintosh
3309450|NCT01914523|Active Comparator|King Vision|tracheal intubation will be performed using a King Vision
3309451|NCT01914523|Active Comparator|Glidescope|tracheal intubation will be performed using a Glidescope
3309452|NCT01914523|Active Comparator|AirTraq|tracheal intubation will be performed using a AirTraq
3309453|NCT01914536||Pompe patients|Adult onset pompe patients being or not treated with enzyme therapy replacement
3309454|NCT01914562|Experimental|OCA 10 mg while fasted|OCA 10 mg orally in the fasting state
3309455|NCT01914562|Experimental|OCA 10 mg while Fed|OCA 10 mg orally in the fed state
3309456|NCT01914562|Experimental|OCA 25 mg while fasted|OCA 25 mg orally in the fasting state
3309457|NCT01914562|Experimental|OCA 25 mg while Fed|OCA 25 mg orally in the fed state
3309458|NCT01914575|Experimental|Dipole Density Mapping|
3309459|NCT01914588|Experimental|Telemonitoring + Standard care|
3309460|NCT01914588|Active Comparator|Standard care|
3309461|NCT01914601|Active Comparator|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
3309462|NCT01914601|Active Comparator|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
3309463|NCT01914614||Working Poor Survivors|Low Wage workers
3309464|NCT01914614||Non-Working Poor Survivors|Higher-Wage Salary Workers
3309465|NCT01914627|Experimental|Loion|
3309466|NCT01914627|Active Comparator|SA-Gel|
3309467|NCT01914640||Healthy adults living in Turkey|The group was enrolled from the 24 provinces of the 7 regions of Turkey. At least 3 provinces were selected from each region by a random sampling method. The populations of these 7 regions were obtained from the records of the 2000 census. The study sample included males and non-pregnant females aged between 20 and 83 years. The populations of city centers, districts, and villages were classified by using the stratified sampling method and then were selected from the data collected from the household identification forms by random sampling. The geography of Turkey was classified into three groups according to altitude. Sea level was accepted as zero. 0-300 m was taken as coastal, 300-900 m as moderate
3309468|NCT01914653|Experimental|Pre-radiated|
3309469|NCT01914653|Experimental|Not radiated|
3309470|NCT01914653|Experimental|Post-radiated|
3309471|NCT01914692|Experimental|Somatostatin group|Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.
3309472|NCT01914692|Placebo Comparator|Blank group|Use the normal saline instead of somatostatin.
3309473|NCT01914705|Active Comparator|Landmark Procedure|Using Landmarks to guide SCVC placement
3309474|NCT01914705|Active Comparator|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
3309475|NCT01914718|Experimental|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
3309476|NCT01914731|Experimental|Capsule|"Fecal microbiota transplant (stool transplant) from healthy, unrelated donor via frozen capsule"
3309477|NCT01914744|Experimental|entecavir|entecavir 0.5 mg/day PO
3309478|NCT01914744|Active Comparator|lamivudine|lamivudine 100 mg/day PO
3309479|NCT01914770||Adults with systemic lupus erythematosus (SLE)|Subjects with SLE receiving ongoing stable SLE treatment
3309480|NCT01914783|Experimental|ultrafine particles|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.
3309481|NCT01914783|Active Comparator|ultrafine particles and ozone|Subjects will be exposed to ultrafine particles for three hours in an exposure chamber. During that time participants will perform intermittent bicycle ergometer training. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. Blood pressure will be measured every 15 minutes. Ultrafine elemental carbon black particles are generated using a commercially available electric spark generator. Particle number, mass, and size distribution will be monitored during exposure.Ozone is generated from medical oxygen in order to maintain a concentration of 250 ppb.
3309482|NCT01914783|Placebo Comparator|clean air|Subjects will be exposed to clean air for three hours in an exposure chamber controlled for temperature, humidity, and gas/particle composition. During that time they will perform intermittent bicycle ergometer training for 15 minutes alternating with 15 minutes rest. Training intensity is adjusted individually to increase ventilation to 20 l/min/m². During exposure, heart rate will be monitored continuously via ECG. The blood pressure will be measured in time intervals of 15 minutes.
3309483|NCT01914796|Placebo Comparator|Single ascending doses|
3309484|NCT01914796|Placebo Comparator|Measurement of eye blink rate|
3309485|NCT01914809|Experimental|group with a preeclampsia before 34 SA|
3309486|NCT01914809|Other|group with a normal pregnancy|
3309487|NCT01914822|Experimental|methylphenidate hydrochloride|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
3309488|NCT01914822|Placebo Comparator|Sugar pill|The study will include two sessions which will be conducted at the same time of the day, one week apart from each other. Each session will last approximately 6 hours. In each session subjects will be exposed to baseline experimental pain models and auditory tests. Then they will receive either one MP SR 20 mg tablet or an identical looking placebo.
3309489|NCT01914835|Experimental|Motivational Chess & Active Control|Ten meetings of 90 minutes each.
3309490|NCT01914848|Active Comparator|Control Group|A routine care discharge planning with the social service
3309491|NCT01914848|Experimental|Advance Care Planning ACP|"Patient get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.~--------------------------------------------------------------------------------"
3309492|NCT01914861||Men/Women, 21-65, following exposure to a traumatice event|
3309493|NCT01914874|Experimental|Mindfulness Meditation|12 weekly sessions in group format
3309494|NCT01914874|No Intervention|Wait-list|Patients will receive the mindfulness intervention after a 12-week wait period
3309495|NCT01914887|Experimental|allogeneic ASCs|Treatment consists in a cell suspension (5 million cells/mL) in aseptic buffered solution containing human expanded adipose-derived stem cells (eASCs) of allogeneic origin in disposable vials with no preservative agents. The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
3309496|NCT01914900|Experimental|induction TPF chemotherapy|
3309497|NCT01914913|Other|BMMNCs|BMMNCs
3309498|NCT01914939|Experimental|Social Skills Focused CBT|Twelve weekly 60-minute sessions of social skills focused CBT
3309499|NCT01914939|Active Comparator|Stress Management/Relaxation Training|Twelve weekly 60-minute sessions of stress management training
3309500|NCT01914939|Experimental|Oxytocin|Intranasal administration of 24 IU of oxytocin
3309501|NCT01914939|Placebo Comparator|placebo drug|Intranasal placebo drug
3309502|NCT01914952|Active Comparator|CaHMB Capsule|
3309503|NCT01914952|Active Comparator|HMB free acid gelcap|
3309504|NCT01914952|Active Comparator|HMB free acid in water|
3309505|NCT01914952|Active Comparator|CaHMB powder in water|
3309506|NCT01914952|Active Comparator|HMB free acid (oral not in gelcap or water)|
3309507|NCT01914965|Active Comparator|Bupropion|First treatment group: 150 mg bupropion or placebo once daily for 2 weeks, followed by 300 mg bupropion or placebo once daily for subsequent 8 weeks (until week 10; visit 4) First tapering and washout: 150 mg bupropion or placebo once daily for 7 days followed by a washout phase of 1 week on placebo
3309508|NCT01914965|Placebo Comparator|Placebo|Second treatment group (crossover): placebo or 150 mg bupropion once daily for 2 weeks, followed by placebo or 300 mg bupropion once daily for subsequent 8 weeks (until week 22; visit 6) Second tapering placebo or 150 mg bupropion once daily for 7 days
3309509|NCT01914978|Experimental|Handbook|Food allergy handbook for parents
3309510|NCT01914978|Placebo Comparator|Treatment as usual|Food allergy treatment as usual
3309511|NCT01914991|Active Comparator|Control group|Conventional treatment: The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
3309512|NCT01914991|Experimental|Experimental group|dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
3309513|NCT01915004|Other|Standard Invididual Urotherapy|Educational Intervention. Standard individual urotherapy (bladder re-training) occurs in the pediatric urology clinic.
3309514|NCT01915004|Experimental|Bladder Training Video|Experimental Educational Intervention. Participants will watch a 7 minute animated bladder training video.
3309515|NCT01915017|Experimental|Cognitive Behavior Therapy for Psychosis|Cognitive behavior therapy for psychosis is a manual-driven collaborative talk-therapy designed to help the individual identify appraisal biases and cognitive distortion, identify alternative explanations for events, and find ways to cope with the distress caused by persistent psychotic symptoms.
3309516|NCT01915017|Experimental|Cognitive Adaptation Training|CAT is a manual driven treatment using environmental supports such as signs, alarms, checklists, electronic devices, and the organization of belongings to bypass cognitive and motivational impairments and to cue and sequence adaptive behavior.
3309517|NCT01915017|Experimental|Multi-modal Cognitive Therapy|Combines Cognitive Behavior Therapy for Psychosis and Cognitive Adaptation Training into one home-delivered intervention
3309518|NCT01915017|Active Comparator|Treatment as Usual|Medication follow up and limited case management provided by the local community mental health center
3309519|NCT01915030|Experimental|High protein diet|High protein diet during caloric restriction
3309520|NCT01915030|Placebo Comparator|Standard protein diet|Standard protein diet during caloric restriction
3309521|NCT01915043|Active Comparator|health education for lymphedema prevention|health education for lymphedema prevention
3309522|NCT01915043|Experimental|application smartphone-based group|Health education plus Smartphone-based application sample will have a reminder to do education everyday where patients will have to select if they have done or they haven´t done compliance
3309523|NCT01915056|No Intervention|Control Arm|Control Arm = Standard of Care. Patients who are randomized to the control arm will only have abnormal results on Geriatric Depression Scale (GDS) and cognitive evaluation communicated to their primary oncologist, as is customary. These results will be communicated to the primary team via electronic medical record and/or email communication. No other summary will be provided to oncologist.
3309524|NCT01915056|Experimental|Treatment Arm|Treatment Arm = Standard care plus GA results and recommendations. For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic (GA-driven intervention). The intervention consists of providing results of geriatric assessment in a summary to oncologists.
3309525|NCT01915069|Experimental|Cilostazol|The primary aim of the study is to assess the affects of oral Cilostazol taken at the FDA approved dose of 100mg PO bid on human oocyte maturation.
3309526|NCT01915082|Experimental|Azithromycin|"A first dose of azithromycin (25 mL po syrup = 1000 mg) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of azithromycin (6.25 mL = 250 mg) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
3309527|NCT01915082|Placebo Comparator|Ora-Plus|"A first dose of placebo (25 mL po syrup) will be given during preparation for subsequent lung transplantation (Day 0).~After lung transplantation, 'add on' treatment of placebo (6.25 mL) syrup will be given via (naso)gastric tube or per os every other day (days 1,3,5,7,9,11,13,15,17,19,21,23,25,27,29 and 31)."
3309528|NCT01915121|Active Comparator|Education Intervention|In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer.
3309529|NCT01915121|Placebo Comparator|Nutrition Intervention|In this session, participant will be provided with information about nutrition information directly related to bladder cancer recovery
3309530|NCT01915134|Experimental|EGP group|the group of participants who undergoing Recombinant Human Endostatin plus Gemcitabine and cisplatin chemotherapy
3309531|NCT01915134|Active Comparator|GP group|the group of participants who undergoing only Gemcitabine and cisplatin chemotherapy
3309532|NCT01915147|Experimental|OXN PR followed by OxyPR tablets|OXN PR followed by OxyPR tablets
3309533|NCT01915147|Experimental|OxyPR followed by OXN PR tablets|OxyPR followed by OXN PR tablets
3309534|NCT01915160|Active Comparator|treatment as usual|Trauma Focused- Cognitive Behavioral Therapy (TF-CBT)
3309535|NCT01915160|Experimental|tablet assisted therapy toolkit|electronically assisted Trauma Focused-Cognitive Behavioral Therapy (eTF-CBT)
3309536|NCT01915186|Experimental|Dihydroepiandrosterone (DHEA)|DHEA 25mg 3 times a day for 12 weeks
3309537|NCT01915186|Placebo Comparator|Placebo|Matched placebo capsules are given 3 times a day for 12 weeks
3309538|NCT01915199|Experimental|Intervention|Patients in this arm received a comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance.
3309539|NCT01915199|No Intervention|Control|Patients randomized in this group did not receive any intervention and treatment continued according to conventional practice.
3309540|NCT01915212|Experimental|HSV529|1 x 107 pfu/dose of HSV529 in 10 mM L-histidine buffer containing 50 mM potassium glutamate, 160 mM sodium chloride, and 10% (w/v) sucrose
3309541|NCT01915212|Placebo Comparator|Placebo|Sodium Chloride 0.9%
3309542|NCT01915264||Group 1|
3309543|NCT01915277|Experimental|Neonate dosing cohort 1|Neonate dexmedetomidine dosing cohort 1
3309544|NCT01915277|Experimental|Neonate dosing cohort 2|Neonate dexmedetomidine dosing cohort 2
3309545|NCT01915277|Experimental|Neonate dosing cohort 3|Neonate dexmedetomidine dosing cohort 3
3309546|NCT01915277|Experimental|Neonate dosing cohort 4|Neonate dexmedetomidine dosing cohort 4
3309547|NCT01915277|Experimental|Neonate dosing cohort 5|Neonate dexmedetomidine dosing cohort 5
3309548|NCT01915277|Experimental|Infant dosing cohort 1|Infant dexmedetomidine dosing cohort 1
3309549|NCT01915277|Experimental|Infant dosing cohort 2|Infant dexmedetomidine dosing cohort 2
3309550|NCT01915277|Experimental|Infant dosing cohort 3|Infant dexmedetomidine dosing cohort 3
3309551|NCT01915277|Experimental|Infant dosing cohort 4|Infant dexmedetomidine dosing cohort 4
3309552|NCT01915277|Experimental|Infant dosing cohort 5|Infant dexmedetomidine dosing cohort 5
3309553|NCT01915290||1600 elderly participants|Norwegian elderly population
3309554|NCT01915316||Prostate cancer|Men. Subjects have undergone primary and at least one secondary prostate biopsy with negative diagnostics. Elevated PSA (Prostate Specific Antigen), typically above 10 ng/mL.
3309555|NCT01915329|Experimental|Verum-RSS|RSS Stimulation with high frequency electric pulses
3309556|NCT01915329|Sham Comparator|Sham-RSS|Sham RSS Stimulation (no pulses are transmitted)
3309557|NCT01915342|Experimental|Focal muscle vibration|"Focal muscular vibration will be applied at mGCM of each subject for 10 minutes in each session.~Frequency: 40, 80, 120 Hz Amplitude: 0.1, 0.3, 0.5 mm"
3309558|NCT01915355|Experimental|Pulsed Dye Laser for fungus treatment|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
3309559|NCT01915368|Active Comparator|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
3309560|NCT01915368|Experimental|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
3309561|NCT01915368|Experimental|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
3309562|NCT01915381|Active Comparator|Control group|follow up detraining effect of multimodal intervention
3309563|NCT01915381|Experimental|application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder to do Phisical activity everyday where patients will have to select if they have done or they haven´t done physical activity.
3309564|NCT01915394||Hospitalized Respiratory Syncytial Virus Infected Newborns|All admitted newborns to the neonatal intensive care unit (NICU) will be enrolled in the study
3309565|NCT01915433|Experimental|Wahls Paleo Plus|Wahls Paleo Plus diet (ketogenic diet)
3309566|NCT01915433|Experimental|Wahls Diet|Wahls Diet (modified paleolithic diet)
3309567|NCT01915433|No Intervention|Usual Care|Control - usual care only.
3309568|NCT01915459|Experimental|Botulinum toxin type A(Botulax®)|Botulinum toxin type A
3309569|NCT01915459|Active Comparator|Botulinum toxin type A(Botox®)|Botulinum toxin type A
3309570|NCT01915472|Experimental|IMMU 130|
3309571|NCT01915485|Experimental|Lu 177|progressive metastatic medullary thyroid cancer
3309572|NCT01915498|Experimental|enasidenib|enasidenib administered orally. Multiple doses will be administered to determine the RP2D.
3309573|NCT01915524|Experimental|CV9202 and local radiation|"CV9202 consisting of 6 RNActive-derived molecules coding for 6 different NSCLC associated antigens.~local radiation (4x5 Gy)"
3309574|NCT01915537|Experimental|Infliximab group|Infliximab with MTX treatment
3309575|NCT01915537|Active Comparator|Classic DMARDs treatment group|Classic DMARDs treatment（MTX 、LEF 、HCQ 、 LEF ）
3309576|NCT01915550|Active Comparator|metformin|metformin was added without raising the insulin dose
3309577|NCT01915550|Active Comparator|Raising Insulin|insulin dose is raised
3309578|NCT01915576|Experimental|BAY1125976 [once daily, dose-esc.]|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
3309579|NCT01915576|Experimental|BAY1125976 [twice daily, dose-esc.]|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
3309580|NCT01915576|Experimental|BAY1125976 [MTD]|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
3309581|NCT01915589|Experimental|Refametinib (BAY86-9766)|For purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Death Unacceptable toxicity Subject withdraws consent Substantial non-compliance with the protocol Treating physician determines discontinuation of treatment is in the subject's best interest. Radiological progression as determined by RECIST (Version 1.1) or mRECIST criteria or clinical progression (e.g. Eastern Cooperative Oncology group performance status - ECOG PS ≥3) patients may continue to receive study treatment if identified as having continued clinical benefit as judged by the treating physician.
3381370|NCT03549468|Experimental|low level tragus stimulation (LLTS)|Patients with ischemic cardiomyopathy (left ventricular ejection fraction <35%) and heart failure who already have an implantable device with an atrial lead (dual chamber defibrillator or biventricular defibrillator) will undergo sequentially 1. Sham LLTS (5min), 2. Active LLTS at 5Hz (15min) and 20Hz (15min) and 3. Active LLTS group with atrial pacing at 100bpm at 5Hz (15min) and 20Hz (15min).
3309582|NCT01915602|Experimental|Refametinib and Sorafenib (Nexavar)|In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression [e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol
3309583|NCT01915615||Hypertrophic cardiomyopathy|"None - this is an observational study.~Patients with hypertrophic cardiomyopathy will be observed for up to 5 years after index cardiac magnetic resonance imaging and blood draw for genetics and biomarkers"
3309584|NCT01915628||BioMatrix Flex|percutaneous coronary intervention
3309585|NCT01915641|Active Comparator|group A|group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement
3309586|NCT01915641|Sham Comparator|group B|group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
3309587|NCT01915654||Study population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
3309588|NCT01915654||Reference population|The study involves patients operated in the cardiothoracic and cardio-vascular surgery department of Besançon University Hospital between December 2008 and May 2009 (study population) or between December 2007 and May 2008 and between December 2009 and May 2010 (reference population).
3309589|NCT01915667|Experimental|GLPG0634 capsule fasted|Single dose of GLPG0634 as capsules in fasted condition
3309590|NCT01915667|Experimental|GLPG0634 tablet fasted|Single dose of GLPG0634 as tablets in fasted condition
3309591|NCT01915667|Active Comparator|GLPG0634 tablet fed|Single dose of GLPG0634 as tablets in fed condition
3309592|NCT01915680||Glaucoma|
3309593|NCT01915680||Control|
3309594|NCT01915693|No Intervention|Arm A: Self-expanding metal stents (SEMS) (Control Arm)|SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.
3309595|NCT01915693|Experimental|Arm B: SEMS plus external beam radiotherapy (Intervention Arm)|External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.
3309596|NCT01915706|No Intervention|Observation|Patients randomized to observation will be observed during the post-operative period for spontaneous Baerveldt-350 tube opening. The ripcord will not be removed unless deemed medically necessary by the study physician.
3309597|NCT01915706|Experimental|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3.
3309598|NCT01915719|Experimental|Early non invasive ventilation|Early non invasive ventilation
3309599|NCT01915719|Active Comparator|Oxygen therapy only|Oxygen therapy only
3309600|NCT01915745|No Intervention|Usually health care|85 patients receive the usually health care. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
3309601|NCT01915745|Experimental|Short Message Service - SMS|85 patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in the Emergency Department emergencies. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
3309602|NCT01915758|Experimental|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel|occlusive patch 200 uL of clindamycin1%/tretinoin0.025% Gel
3309603|NCT01915758|Placebo Comparator|occlusive patch 200uL of vehicle gel|occlusive patch 200uL of vehicle gel
3309604|NCT01915784|Experimental|Group A|Genuair® (Pressair™) first; Breezhaler® (Neohaler™) second
3309605|NCT01915784|Experimental|Group B|Breezhaler® (Neohaler™) first; Genuair® (Pressair™) second
3309606|NCT01915797||Patient having a cancer and abnormal development|Patient having developed a cancerous pathology and presenting one or several anomalies of the development.
3309607|NCT01915810|Experimental|Arm I (pre-quit physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning 2 weeks before the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise activity per week for 5 weeks.
3309608|NCT01915810|Experimental|Arm II (quit day physical activity)|Participants receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks. Beginning on the assigned quit date, participants receive a Walking Program guide and engage in the SCwPA comprising brisk, self-paced walking with a goal of 150 minutes of exercise per week for 5 weeks.
3309609|NCT01915810|Active Comparator|Arm III (no physical activity)|Participants quit smoking on an assigned date and receive telephone-based cessation counseling over 15-20 minutes 1-2 weeks before assigned quit date and nicotine patch for 6 weeks.
3309610|NCT01915836|Experimental|Alpha game testers and questionaires|"This a video game designed to help smokers quit & remain non-smokers. Before the start the game,the participant will fill out a brief questionnaire.~It should take about 5 minutes to complete. Once this is done, the game play should last about 30 minutes & will present with different scenes. These scenes will show situations that may trigger smoking urges such as walking into a room where another person is smoking. In the game, the participant will be able to use different ways of coping with urges to smoke such as taking several deep breaths or listening to music. The participant will be asked to talk aloud about what they think of the game. The participant will be video &/or audio recorded while doing this. Once finished testing the game, we will then ask you a few questions about what you thought of the game. We will also ask you how relevant different situations are to you as a smoker or someone who is trying to avoid smoking. The entire visit is expected to last about 1.5 hours."
3309611|NCT01915875|Experimental|sophrology sessions|The sophrology is a dynamic method of physical and psychical relaxation
3309612|NCT01915888||Complete Rotarix vaccination cohort|Subjects had received 2 doses of Rotarix within the vaccination window and the observation time is from the end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario) to end of observation.
3381371|NCT03547973|Experimental|Cohort 1: Sacituzumab Govitecan-hziy|Participants with urothelial cancer (UC) previously treated with platinum-based and/or checkpoint inhibitors (CPIs) will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
3381372|NCT03547973|Experimental|Cohort 2: Sacituzumab Govitecan-hziy|Participants with UC who are ineligible for platinum-based therapy and failed therapy with previous immune CPI therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle.
3381373|NCT03547973|Experimental|Cohort 3: Sacituzumab Govitecan-hziy + Pembrolizumab|Participants who have had progression or recurrence of UC following a platinum-containing regimen in the metastatic setting, or progression or recurrence of UC within 12 months of completion of platinum-based therapy as neoadjuvant or adjuvant therapy will receive sacituzumab govitecan-hziy 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle and pembrolizumab at the standard approved dose (200 mg) only on Day 1 of a 21-day cycle. Lower doses of sacituzumab govitecan-hziy may be tested based on dose-limiting toxicities (DLTs) observed to determine the Recommended Phase 2 Dose (RP2D) of sacituzumab govitecan-hziy in combination with pembrolizumab.
3381374|NCT03547973|Experimental|Cohort 4: Sacituzumab Govitecan-hziy + Cisplatin + Avelumab|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy with maximum dose of 10 mg/kg intravenously on Days 1 and 8 of a 21-day cycle for up to 6 cycles. Based on DLTs observed, two additional lower doses may be tested to determine RP2D of sacituzumab govitecan-hziy in combination with cisplatin. If premature termination of 1 agent occurs due to toxicity, the other agent may be continued to complete up to 6 cycles of therapy. For participants who have not progressed, maintenance therapy will begin with infusions of avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks thereafter and sacituzumab govitecan-hziy 10 mg/kg on Days 1 and 8 every 21 days.
3381375|NCT03547973|Experimental|Cohort 5: Sacituzumab Govitecan-hziy + Cisplatin + Avelumab|Participants with UC who have never received therapy with platinum in the metastatic setting or for unresectable locally advanced disease will first receive cisplatin (either at 70 mg/m^2 on Day 1 of a 21-day cycle or at a split dose of 35 mg/m^2 on Days 1 and 8 of a 21-day cycle with a maximum body surface area of 2) and sacituzumab govitecan-hziy RP2D determined in Cohort 4 on Days 1 and 8 of a 21-day cycle, and avelumab 800 mg every 2 weeks beginning on Cycle 1, Day 1 and every 2 weeks. For participants who have not progressed after completion of up to 6 cycles of sacituzumab govitecan-hziy, cisplatin, and avelumab, maintenance therapy will be permitted with 800 mg of avelumab every 2 weeks and sacituzumab govitecan-hziy at the 10 mg/kg dose on Days 1 and 8 every 21 days. Maintenance therapy can start 4 to 6 weeks after the last dose of induction chemotherapy and will be permitted to continue until loss of clinical benefit.
3381379|NCT03535337|Active Comparator|CPS-Rsp-T|After 3 months of intervention, this group of CPS Rsp will receive 3 months of CPS-T intervention followed by SC.
3381380|NCT03535337|Active Comparator|CPS-Rsp-SC|After 3 months of intervention, this group of CPS Rsp's intervention will discontinue and they'll receive SC only
3381381|NCT03535337|Active Comparator|CPS-NRsp-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of CPS-I followed by 3 months of CPS-T and 3 months of SC.
3381382|NCT03535337|Active Comparator|CPS-NRsp-SMS-I|After 3 months of intervention, this group of CPS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
3309613|NCT01915888||Incomplete Rotarix vaccination cohort|Subjects had received one vaccination of Rotarix within the vaccination window and the observation time is from end of vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario)(if still observed) to end of observation.
3381383|NCT03535337|Active Comparator|SMS-Rsp-T|After 3 months of intervention, this group of SMS Rsp will receive 3 months of SMS tapered (SMS-T) intervention followed by SC.
3381384|NCT03535337|Active Comparator|SMS-Rsp-SC|After 3 months of intervention, this group of SMS Rsp, intervention will discontinue and they'll receive SC only
3381385|NCT03535337|Active Comparator|SMS-NRsp-CPS-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of CPS-I followed by 3 months CPS-T and 3 months SC
3381386|NCT03535337|Active Comparator|SMS-NRsp-I|After 3 months of intervention, this group of SMS NRsp will receive 3 months of SMS-I followed by 3 months of SMS-T and 3 months of SC
3381387|NCT03531112|Experimental|Appetite Awareness Treatment (AAT) + Lifestyle Modification (LM)|Participants will receive an 8-week Appetite Awareness Training (AAT) program using a group format, will be provided a smart scale (with bluetooth connection) and instructions to weigh themselves daily. Participants will also be provided with weekly tailored feedback on self-weighing frequency and weight change. Assessment will be conducted at 0, 2, and 6 months.
3309614|NCT01915888||Historical unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends on/before 12/31/2006) to end of observation.
3309615|NCT01915888||Contemporary unvaccinated cohort|Subjects did not receive any Rotarix vaccine dose within the vaccination window and the observation time is from end of the vaccination window (8 months old for ACIP scenario, or 6 months old for PI scenario, if vaccination window ends after 1/1/2007) to end of observation.
3309616|NCT01915901|Experimental|bismuth subsalicylate (Pepto-Bismol®) + DMF|Subjects will receive dimethyl fumarate (DMF) and bismuth subsalicylate (Pepto-Bismol®).
3309617|NCT01915901|Experimental|Placebo + DMF|Subjects will receive dimethyl fumarate (DMF) and placebo.
3309618|NCT01915927|Other|1|Only 1 arm: treatment with MSC-AFP
3309619|NCT01915953||anemia|Measuring Hb valuse on anemia patients
3309620|NCT01915966|Experimental|Cardamom, ginger and orange juice gelatin|Dietary Supplement
3309621|NCT01915966|Active Comparator|Camomile infusion with lemon juice|Dietary Supplement
3309622|NCT01915979|Experimental|Plasma rich in growth factors (PRGF)|This group will receive a total of three intraarticular injections of 6-8 ml. One injection every two weeks.
3309623|NCT01915979|Active Comparator|Celestone cronodose (bethametasone)|This group will receive a total of three intraarticular injections of 2ml. One injection every two weeks.
3309624|NCT01915992|Other|Volunteer healthy|
3309625|NCT01915992|Active Comparator|leukemia patient's|
3309626|NCT01916005|Experimental|endocarditis|
3309627|NCT01916018|Other|hypothyroid group|Clinical exams radiologic exams Blood sample
3309628|NCT01916031|Experimental|Education|Upper Respiratory Infection education in Fall
3309629|NCT01916031|No Intervention|Standard Curriculum|
3309630|NCT01916044|Experimental|Lower Uterine Segment Ultrasound|Measure of Uterine Segment by Ultrasound
3309631|NCT01916044|No Intervention|control|no measure of Uterine Segment Ultrasound
3309632|NCT01916057|Experimental|18F-FDG PET Scan|18F-FDG PET Scan at Day 0 and M3
3309633|NCT01916070||patients with syncope|
3309634|NCT01916070||patients with near syncope|
3309635|NCT01916096||Delica 28g Depth 3 vs Delica 30g Depth 3|30 subjects with diabetes
3309636|NCT01916096||Delica 28g Depth 5 vs Delica 30g Depth 5|30 subjects with diabetes
3309637|NCT01916096||Delica 28g Depth 7 vs Delica 30g Depth 7|30 subjects with diabetes
3309638|NCT01916096||Delica 28g Depth 3 vs Delica 33g Depth 3|30 subjects with diabetes
3309639|NCT01916096||Delica 28g Depth 5 vs Delica 33g Depth 5|30 subjects with diabetes
3309640|NCT01916096||Delica 28g Depth 7 vs Delica 33g Depth 7|30 subjects with diabetes
3309641|NCT01916122|Experimental|(FES) PET/CT for Imaging|"FES PET/CT studies will be performed as hybrid PET/CT examinations for attenuation correction and lesion localization. A bolus of 5 mCi (+/- 10%) of FES PET/CT will be injected intravenously. 60 (+/- 10) minutes following tracer injection, the patient will be positioned on a GE Discovery PET/CT scanner. A low milliampere CT of from the mid skull to mid thigh will be acquired first, 60-80mAs, 120-140kVp, with a 5mm slice thickness while the patient was free breathing. PET will be acquired at 3-5 minutes per bed position using the 3D mode, approximately 6-7 bed positions. FES PET/CT imaging will take less than 60 minutes. Scans will be reconstructed with iterative reconstruction.~If follow-up FES PT/CT scans are performed on a patient, then the same parameters will be used as the initial FES PET/CT scan."
3309642|NCT01916135|Experimental|[18F]-SKI- 249380 and PET/CT scanning|Patients will receive an injection of up to 7.5 (0.5-7.5) mCi of [18F]-SKI- 249380, followed by serial PET/CT scanning and blood draws, over a period of 3.5 hours, on a single day. PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. Each patient will be offered the opportunity to repeat the 18F-SKI-249380 injection and subsequent set of post-injection PET-CT scans, once, on a separate date. Each patient may or may not be receiving treatment with dasatinib therapy at the time of 18F-SKI-249380 PET, for their first PET study, as well as repeat PET study, at the discretion of their oncologist according to best clinical judgment.
3309643|NCT01916161||IBD patients|Ambulatory patients attending IBD clinics at Leeds Teaching Hospitals
3309644|NCT01916174|Experimental|Insulin degludec/liraglutide, B5|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
3309645|NCT01916174|Experimental|Insulin degludec/liraglutide, V2|Subjects will be randomly allocated to the two single dose administrations (one for each of the two IDegLira formulations) on the two separate dosing visits. The two administration days will be separated by a wash-out period of 7-15 days.
3309646|NCT01916187|Experimental|Imetelstat|285 mg/m2/dose, IV, for 2 hours. Days 1 and 8 every three weeks.
3309647|NCT01916200|Experimental|Paroxetine CR group|Paroxetine CR plus IBS regular treatment group
3309648|NCT01916200|No Intervention|Blank group|IBS regular treatment group
3309649|NCT01916213|Active Comparator|PICSI|PICSI dish ( MidAtlantic Diagnostics Inc) has been developed to select the specific sperm to be used for the ICSI procedure using the same principles as the Sperm Hyaluronan Binding Assay. HA-mediated ICSI sperm selection( PICSI) uses Falcon Petri dishes that feature three microdots of hyaluronan hydrogel attached to the interior bottom: mature, biochemically competent spermatozoa bind to hyaluronan, where they can be isolated and used for ICSI
3309650|NCT01916213|Active Comparator|ICSI|
3309651|NCT01916239|Experimental|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
3309652|NCT01916239|Experimental|Pomegranate extract formulation-1|New pomegranate extract formulation-1
3309653|NCT01916239|Experimental|Pomegranate extract formulation-2|New pomegranate extract formulation-2
3309654|NCT01916252|Active Comparator|MEL-200|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by high-dose melphalan-200 (MEL-200)
3309655|NCT01916252|Active Comparator|BUMEL|bortezomib/lenalidomide/dexamethasone (VRD-GEM) induction treatment followed by busulfan-melphalan (BUMEL) chemotherapy and consolidation with VRD-GEM
3309656|NCT01916265|Experimental|Glucagon level: 0,11 and 1 mg|Glucagon level: 0,11 and 1 mg
3309657|NCT01916265|Experimental|Glucagon level: 0,22 and 0,66 mg|Glucagon level: 0,22 and 0,66 mg
3309658|NCT01916265|Experimental|Glucagon level: 0,44 and 0,33 mg|Glucagon level: 0,44 and 0,33 mg
3309659|NCT01916278|Experimental|Emervel Lips Lidocaine|
3309660|NCT01916278|Experimental|Juvéderm Volbella with Lidocaine|
3309661|NCT01916291|Experimental|Propess insertion|
3309662|NCT01916317|No Intervention|Arm B:Control|: No peritumoral Local Anesthesia prior to excision
3309663|NCT01916317|Active Comparator|Arm A: Intervention|Arm A: 60mM of 0.5% Inj. Lignocaine will be injected peri tumoral prior to excision.
3309664|NCT01916343|Experimental|Study Laparoscopic Curriculum|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The residents in the intervention group will then complete the salpingectomy at the conclusion of the curriculum. Following the completion of the curriculum, residents in the intervention group will undergo a multiple-choice examination as well as a repeat skills examination.
3309665|NCT01916343|No Intervention|Standard Clinical Education|Residents will perform a salpingectomy in the operating room, which will be video-recorded through the laparoscopic camera. The standard clinical education residents will perform the procedure as per standard of care.
3309666|NCT01916356|Experimental|educational video|Change in participant's infertility knowledge before and after watching the educational video covering the topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
3309667|NCT01916369|Experimental|CTX DP|Human neural stem cell product, single dose administered once only, increasing doses
3309668|NCT01916382|Experimental|Nitisinone|Homogentisic acid lowering drug intervention
3309669|NCT01916382|No Intervention|No treatment|comparrator
3309670|NCT01916395||Imitrex and Treximet|Imitrex 100mg as needed Treximet 85/500mg
3309671|NCT01916408|Active Comparator|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
3309672|NCT01916408|Placebo Comparator|Placebo PL1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
3309673|NCT01916421|Active Comparator|EZ Shot|
3309674|NCT01916421|Active Comparator|Expect™|
3309675|NCT01916421|Active Comparator|EchoTip® Ultra|
3309676|NCT01916434|Experimental|High Pufa Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
3309677|NCT01916434|Experimental|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption
3309678|NCT01916434|Placebo Comparator|No salmon|The placebo group will continue to consume their habitual diet
3309679|NCT01916447|Experimental|TAS-102 and CPT-11 with or without Bevacizumab|
3309680|NCT01916460|Experimental|Gastroparetic patient 19G|Endoscopic Ultrasound Fine Needle Aspiration of the gastric wall prior to surgical placement of gastric neurostimulator with 19-gauge fine core needle used for aspiration
3309681|NCT01916473|Active Comparator|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
3309682|NCT01916473|Experimental|Continuous wound infusion|The continuous wound infusion consists of 0.376% ropivacaine infusion in the wound area at a rate 2 ml per hour.
3309683|NCT01916486|Experimental|Exercise training|Twice-weekly for the 6-month duration.
3309684|NCT01916486|Experimental|Complex mental and social activities|Twice-weekly for the 6-month duration.
3309685|NCT01916486|Active Comparator|Control: stretching and relaxation program|Twice-weekly for the 6-month duration.
3309686|NCT01916499||"Switch trap-door re-implantation of the coronaries"|"Re-implantation of the coronary arteries into the neo-aortic sinuses through a trap-door as far distally as possible on the neo-aorta"
3309687|NCT01916499||"Switch non-trap-door re-implantation of the coronaries"|Re-implantation of the coronary arteries into the neo-aortic sinuses through small incisions or excision in the sinuses
3309688|NCT01916525|Experimental|Exercise based cardiac rehabilitation|Patients will receive written instructions and a referral to the exercise-based rehabilitation unit. The patient will be taught to use fitness room. Each session of training will be controlled by heart rate. Instruction will also be given for at-home training and filling in a training diary, and training will be scheduled at Verve once a week. On the first visit the patient will receive a device that measures physical activity during the study. Training will also be monitored from the training diary. Structured questionnaires will be used to check compliance and implementation of care will be determined from medication and other health-related habits once a month (during the first 6 months) and finally after 12 months.
3309689|NCT01916525|No Intervention|Control|A conventional post-acute care group treated according to finnish guidelines.
3309690|NCT01916538||Cases|Individuals with a current or past diagnosis of anorexia nervosa
3309691|NCT01916538||Controls|Individuals who have never been diagnosed with an eating disorder
3309692|NCT01916564|Active Comparator|Same-morning whole-dose|2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy
3309693|NCT01916564|Active Comparator|Split-dose|1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy
3309694|NCT01916577|Active Comparator|Plerixafor (Mozobil) Control Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 normal control patients (volunteers) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells prior to the dose and then again 8 hours after the dose
3309695|NCT01916577|Experimental|Plerixafor (Mozobil) Experimental Arm|Plerixafor mobilization of autologous CD117 stem cells: Plerixafor will be given at 240mcg/kg subcutaneously once to 5 COPD, 5 Cystic Fibrosis, and 5 Pulmonary Fibrosis patients (awaiting lung transplantation) at time zero with blood collected for flow cytometric analysis for CD117+ peripheral blood cells just prior to the dose and then again 8 hours after the dose
3309696|NCT01916603|Experimental|Normative intervention|Normative intervention on diet & physical & breastfeeding: diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
3309697|NCT01916603|No Intervention|Routine care|Routine antenatal care according to national guidelines
3309698|NCT01916642|Placebo Comparator|Control|0.9% Normal Saline is given instead of Lidocaine in the same volume and duration. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3309699|NCT01916642|Active Comparator|Lidocaine 1mg/kg|Lidocaine 1mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3309700|NCT01916642|Active Comparator|Lidocaine 1.5mg/kg|Lidocaine 1.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3309701|NCT01916642|Active Comparator|Lidocaine 2mg/kg|Lidocaine 2mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3309702|NCT01916642|Active Comparator|Lidocaine 2.5mg/kg|Lidocaine 2.5mg/kg is given intravenously within 2 minutes. Then, Etomidate 2mg intravenously every 15 seconds is given until the complete loss of consciousness as detected as the complete loss of eyelash reflex.
3309703|NCT01916694|Experimental|Smart phone app glucose monitoring|Home blood glucose monitoring results directly transmitted via a bluetooth enabled smart phone app to a central database to be reviewed by clinicians
3309704|NCT01916694|Active Comparator|Standard glucose monitoring|Home blood glucose monitoring results recorded by hand in a paper diary by the patient and reviewed by the clinical team in the outpatient clinic.
3309705|NCT01916707|Active Comparator|Standard Dosing|Patients will receive standard VTE prophylaxis of enoxaparin SQ every 12 hours.
3309706|NCT01916707|Experimental|Weight Based Dosing|Patients will receive weight adjusted VTE prophylaxis of enoxaparin SQ every 12 hours.
3309707|NCT01916720|Experimental|SB-480848 40 mg|SB-480848 40 milligrams (mg) once a day (od) for 14 +/- 4 days followed by carotid endarterectomy. SB-480848 40 mg was administered as 2 SB-480848 20 mg tablets plus 2 placebo tablets.
3309708|NCT01916720|Experimental|SB-480848 80 mg|SB-480848 80 mg od for 14 +/- 4 days followed by carotid endarterectomy.SB-480848 80 mg was administered as 4 20 mg SB-480848 tablets.
3309709|NCT01916720|Placebo Comparator|Matching Placebo|Placebo for 14 +/- 4 days followed by carotid endarterectomy. Placebo was administered as 4 placebo tablets. Placebo tablets were identical in appearance to the SB-480848 20 mg tablets.
3309710|NCT01916733||Lower Extremity Bypass & open AAA|Lower Extremity Bypass (LEB) and open AAA patients will be placed on standard Fletcher Allen Health Care insulin protocol post op
3309711|NCT01916733||control|patients from the Vascular Study Group of New England centers without a defined program for glucose control after lower extremity bypass and open AAA repair will be used
3309712|NCT01916746|Experimental|transvaginal resection of pregnancy tissue|
3309713|NCT01916759|Other|HIV uninfected adults|25 HIV uninfected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3309714|NCT01916759|Other|HIV infected adults on HAART|25 HIV infected adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3309715|NCT01916759|Other|HIV-infected long-term non-progressors|10 HIV-infected long-term non-progressor adults enrolled at the Mulago National Referral Hospital complex in Kampala, Uganda will receive seasonal trivalent inactivated influenza vaccine (Vaxigrip®).
3309716|NCT01916772||cherubism patients|no interventions
3309717|NCT01916785|Experimental|A1|Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake
3309718|NCT01916785|Active Comparator|A2|Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake
3309719|NCT01916785|Active Comparator|B|Arm B : Dasatinib standard dose with Cmin < 3nM analysed on blood after 7-10 days dasatinib 100mg intake
3309720|NCT01916798|Active Comparator|Intralipid infusion|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
3309721|NCT01916798|No Intervention|Control group|100 Subfertile women aged 35-40 years with repeated implantation failure or recurrent miscarriage with positive natural killer cells undergoing ICSI cycle.
3309722|NCT01916837||Single arm|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery.
3309723|NCT01916850|Experimental|LX4211 Low Dose|400 mg of LX4211 administered once daily for 10 consecutive days
3309724|NCT01916850|Experimental|LX4211 High Dose|800 mg of LX4211 administered once daily for 10 consecutive days
3309725|NCT01916850|Placebo Comparator|Placebo|Identical placebo administered once daily for 10 consecutive days
3309726|NCT01916863|Experimental|LX4211|400 mg of LX4211
3309727|NCT01916863|Active Comparator|Canagliflozin|300 mg canagliflozin
3309728|NCT01916863|Placebo Comparator|Placebo|LX4211 placebo
3309729|NCT01916876|No Intervention|Standard Care|At discharge, patients will be given a discharge plan by their attending caregiver as deemed appropriate.
3309730|NCT01916876|Other|Integrative medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~Thereafter, if randomised to this study arm they will receive the intervention as outlined elsewhere.~Integrated Medical Follow-up package"
3309731|NCT01916889|Experimental|RACY test|"4-question RACY delirium screening tool"
3309732|NCT01916902|Active Comparator|Ticagrelor- Delayed Administration|Subjects receive 180 mg of ticagrelor during cardiac catheterization after diagnostic angiography and prior to stenting. OCT is performed prior to and after coronary artery stenting.
3309733|NCT01916902|Active Comparator|Ticagrelor- Immediate Administration|Subjects receive 180 mg of ticagrelor immediately after study enrollment. OCT is performed prior to and after coronary artery stenting.
3381388|NCT03531112|No Intervention|Control|Control group participants will receive no intervention in months 1-6, but will be offered the chance to receive an abbreviated form of AAT (4 weeks) following the 6-month assessment.
3381389|NCT03521154|Experimental|Osimertinib|Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
3381390|NCT03521154|Placebo Comparator|Placebo Osimertinib|Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
3381391|NCT03519945|Experimental|Mirikizumab|Mirikizumab administered subcutaneously (SC).
3381392|NCT03514498||Autism Spectrum Disorder|Children aged 4-12 years with a clinical diagnosis of mild-to-moderate Autism Spectrum Disorder undergoing dental surgery
3381393|NCT03514498||Typically Developed Controls|Children with no neurodevelopmental delays matched to Autism Spectrum Disorder participants according to age (within 6 months), gender, and ASA physical status level, scheduled to undergo dental surgery
3381394|NCT03511781|Experimental|Single Arm study|Hypofractionated Radiotherapy Schedule of 35 GY in 10 fractions is being administered in advanced Incurable Breast Cancer for female patients
3381395|NCT03507725|Experimental|Usual Care + Meditation|Usual care (local anaesthesia) + audio-recorded brief mind-dody intervention for 10 minutes before and for 10 minutes during the prostate biopsy procedure
3381396|NCT03507725|Active Comparator|Usual Care Group|Time-and-attention control group receiving usual care (local anesthesia) including optional background music in the biopsy procedure room
3381397|NCT03499236|Experimental|Treatment|Treatment arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
3381398|NCT03499236|Other|Control|Control arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility, but will not have transseptal catheterization or shunt implantation.
3381399|NCT03499236|Experimental|Roll in|Roll in arm patients will undergo a diagnostic right heart catheterization and invasive echocardiography to determine study eligibility followed by transseptal catheterization and V-Wave Shunt implantation
3309734|NCT01916915|Experimental|Tramadol 1|1 mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
3309735|NCT01916915|Experimental|Tramadol 2|2mg/kg tramadol + 0.25% levobupivacaine 4 ml/h infusion
3309736|NCT01916915|Placebo Comparator|Levobupivacaine|0.25% levobupivacaine 4ml/h infusion
3309737|NCT01916954|Active Comparator|3-day artemether-lumefantrine|Standard artemether-lumefantrine regimen (3-day treatment)
3309738|NCT01916954|Experimental|5-day artemether-lumefantrine|Artemether-lumefantrine extended regimen (5-day treatment)
3309739|NCT01916993|Experimental|Healthy Volunteers|single dose of NBI-98854 50 mg capsule
3309740|NCT01916993|Experimental|Mild Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3309741|NCT01916993|Experimental|Moderate Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3309742|NCT01916993|Experimental|Severe Hepatic Impairment|single dose of NBI-98854 50 mg capsule
3309743|NCT01917019|Placebo Comparator|Part A Placebo|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
3309744|NCT01917019|Experimental|Part A prolonged-release fampridine|Part A: All participants will receive placebo orally twice daily for the first 2 weeks and then be randomized to receive prolonged-release fampridine 10 mg or matching placebo tablets orally twice daily for up to 14 weeks.
3309745|NCT01917019|Experimental|Part B prolonged-release fampridine|Part B: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily for up to 52 weeks.
3309746|NCT01917019|Experimental|Part C prolonged-release fampridine|Part C: Eligible participants will receive open label treatment with prolonged-release fampridine 10mg orally twice daily until marketed product is available.
3309747|NCT01917032|Active Comparator|Sprinkles|Micronutrient Powder Sprinkles 1 gram orally on weekdays during 11 weeks
3309748|NCT01917032|Placebo Comparator|Placebo|Maltodextrin 1 gram orally on weekdays during 11 weeks
3309749|NCT01917045|Experimental|low body fat percentage|body fat percentage less than 30%
3309750|NCT01917045|Experimental|heigh body fat percentage|body fat percentage more than 30%
3309751|NCT01917058|Active Comparator|abatacept|
3309752|NCT01917058|Placebo Comparator|abatacept Subcutaneous vehicle|
3309753|NCT01917071|Experimental|Matched Group|Receives thoracic spine manipulation in the direction of motion limitation.
3309754|NCT01917097||Dexmedetomidine patients|Patients that received dexmedetomidine during their surgery.
3309755|NCT01917097||No Dexmedetomidine|Patients that didn't receive dexmedetomidine during surgery.
3309756|NCT01917110|Experimental|omafilcon A|Contact Lens Group
3309757|NCT01917110|Active Comparator|Spectacle Group|Prescription at Baseline
3309758|NCT01917123|Active Comparator|Stimol, Brachial Index, Powder agent|L-Citrulline malate,1gr,twice a day,2weeks
3309759|NCT01917123|Placebo Comparator|Placebo, Brachial Index, Powder agent|Placebo,1gr,twice a day,2weeks
3309760|NCT01917149|Experimental|Metoprolol|Patients in the metoprolol group were started on 11.875-23.75mg of metoprolol succinct extended-release tablet once daily (11.875mg was recommended for patients with NYHA functional classes III-IV), and then doses were doubled every 2 weeks to achieve asymptomatic bradycardia (50-60 bpm of heart rate) over 4-6 weeks. Investigators were encouraged to up-titrate metoprolol to a maximum dose of 190mg whenever possible.
3309761|NCT01917149|Experimental|Low-dose valsartan|Patients randomized to low dose valsartan receive valsartan 80 mg until study completion.
3309762|NCT01917149|Experimental|Low dose Benazepril|Patients randomized to low dose Benazepril receive Benazepril 10 mg until study completion.
3309763|NCT01917149|Experimental|High dose valsartan|Patients randomized to high-dose valsartan were started on valsartan 80mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of valsartan is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of valsartan 320mg, 480mg, 640mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
3309764|NCT01917149|Experimental|High dose Benazepril|Patients randomized to high-dose benazepril were started on benazepril 10mg twice daily, and uptitrated to target doses within 7 days under in-hospital observation. The target high doses of benazepril is determined by left-ventricular end-diastolic diameter (LVEDD) (the maximal value of anteroposterior and lateral diameters) obtained by ECG at the randomization visit. A target dose of benazepril 40mg, 60mg, 80mg daily were assigned to patients with LVEDD of 50-59, 60-69, ≥70 mm respectively.
3309765|NCT01917162|Other|Nelfilcon A/UltraFilcon B|Nelfilcon A contact lenses, followed by UltraFilcon B contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
3309766|NCT01917162|Other|UltraFilcon B/Nelfilcon A|UltraFilcon B contact lenses, followed by Nelfilcon A contact lenses. Each product worn bilaterally for one week in a daily wear, daily disposable modality.
3309767|NCT01917175||HIV+ patients with an estimated date of seroconversion|It was estimated that 564 individuals, will be enrolled at the Blood Bank Medical Centre, including 364 individuals already followed-up (former PRIMOCI ANRS 1220 cohort started in 1997) and 200 newly enrolled individuals in this study.
3309768|NCT01917201|Other|IVUS-guided group|The coronary stenting under IVUS-control (with VH or i-MAP) is carried out: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS (with VH or i-MAP) is being used, the optimality of stent implantation is also being assessed.If criteria of optimal implantation guided by IVUS were not achieved, additional impact is being made. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. An additional impact based on OCT data is not being used.
3309769|NCT01917201|Other|Non-IVUS group|The coronary stenting under angiography control is carried out. After postdilatation control OCT is carried out. An additional impact based on OCT data is not being used.
3309770|NCT01917227|Experimental|Video|
3309771|NCT01917240|Experimental|Monophasic Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
3309772|NCT01917240|Placebo Comparator|Sequential Media|Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo CCS & the best euploid embryo from each group will be transferred (DET). If there are only euploid embryos from one group, pt will have SET only (fresh or frozen)
3309773|NCT01917253|Experimental|standard length catheter|Standard Device for peripheral vein cannulation
3309774|NCT01917253|Experimental|Long catheter|Standard Device for peripheral vein cannulation
3309775|NCT01917266||Concordant|
3309776|NCT01917266||Discordant|
3309777|NCT01917279|Active Comparator|Intermittent Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3-week cycle.
3309778|NCT01917279|Experimental|Metronomic Capecitabine|Capecitabine 500 mg three times daily on days 1-21 of each 3-week cycle
3309779|NCT01917292|Other|Periodontal care|
3309780|NCT01917292|Experimental|One-Stage Full-Mouth Disinfection|
3309781|NCT01917305|Experimental|platform-switched implant|platform-switched implant
3309782|NCT01917305|Active Comparator|platform-matched implant|platform-matched implant
3309783|NCT01917318|Experimental|Iloperidone / Placebo|During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
3309784|NCT01917318|Experimental|Placebo / Iloperidone|During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.
3309785|NCT01917331|Experimental|Beclometasone/Formoterol/Glycopyrrolate|CHF 5993 pMDI 100/6/12.5 mcg 2 inhalations bid
3309786|NCT01917331|Active Comparator|Beclometasone/Formoterol|Foster® 100/6 mcg 2 inhalations bid
3309787|NCT01917357|Experimental|Quinvaxem in Uniject|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device"
3309788|NCT01917357|Active Comparator|Quinvaxem in single dose vials|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials"
3309789|NCT01917370||ICC patients|patients with intrahepatic cholangiocarcinoma treated by surgical treatment
3309790|NCT01917383|Experimental|Trabodenoson Plus Latanoprost|Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop
3309791|NCT01917383|Active Comparator|Timolol Plus Latanoprost|A Beta-blocker eye drop plus a prostaglandin analogue eye drop
3309792|NCT01917409|Experimental|conventional laryngoscopy|experimental conventional laryngoscopy group: laryngoscope is used to assist for nasotracheal intubation.
3309793|NCT01917409|Experimental|video-stylet|experimental video-stylet group:video-stylet is used to guide nasotracheal tube into trachea
3309794|NCT01917435|Experimental|fiberoptic bronchoscope|Experimental: fiberoptic bronchoscope fiberoptic bronchoscope is used to facilitate for nasotracheal intubation.
3309795|NCT01917435|Experimental|video-stylet|Experimental: video-stylet video-stylet is used to facilitate for nasotracheal intubation.
3309796|NCT01917448|Sham Comparator|Control|The skin will be injected with local anesthetic without spinal block
3309797|NCT01917448|Active Comparator|Spinal morphine|0.15 mg spinal morphine
3309798|NCT01917474|Experimental|Group A: Low-lipid diet|"Lifestyle counseling At the end of this run-in period all patients will be randomly attributed to one of the following two dietary regimens. Those in the experimental groupwill be given a low lipid diet with a lipid content < 20% of the total daily energy intake with the following composition:~Proteins (g) 77 (15% total energy intake) Lipids (g) 48 (22% total energy intake) Saturated (g) 9 (4% total energy intake) Monounsaturated (g) 31 (14% total energy intake) Polyunsaturated (g) 8 (4% total energy intake) Carbohydrates (g) 330 (63% total energy intake) Cholesterol (mg) 117 Fibres (g) 32 Total Energy (kcal) 1977"
3309799|NCT01917474|Active Comparator|normal lipid diet|"Patients in the active comparator will be given a diet with normal lipid intake and the following composition:~Proteins (g) 75 (15% total energy intake) Lipids (g) 67 (29% total energy intake) Saturated (g) 14 (6% total energy intake) Monounsaturated (g) 43 (19% total energy intake) Polyunsaturated (g) 10 (4% total energy intake) Carbohydrates (g) 307 (56% total energy intake) Cholesterol (mg) 128 Fibres (g) 32 Total Energy (kcal) 2048 lipid intake between 25-30% of the total daily energy intake."
3309800|NCT01917500||Cardiac ward 10 patients|10 patients from the cardiac ward.
3309801|NCT01917539|Sham Comparator|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment. All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
3309802|NCT01917539|Experimental|Pulsed Light Therapy|All subjects will come for their initial visit where evaluation and treatment #1 will take place. They will also attend 3 follow-up visits spaced approximately 3-4 weeks apart during which they will have subsequent treatments and/or evaluations for their dry eyes. The visit duration will range from approximately 60-90 minutes per clinic visit.
3309803|NCT01917552|Experimental|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
3309804|NCT01917552|No Intervention|observation|
3309805|NCT01917565||Airtraq laryngoscope group|The patients who will be intubated by using Airtraq laryngoscope
3309806|NCT01917565||Macintosh laryngoscope group|The patients who will be intubated by using Macintosh laryngoscope
3309807|NCT01917565||Fiberoptic bronchoscope group|The patients who will be intubated by using Fiberoptic bronchoscope
3309808|NCT01917578|Experimental|Half Cycles Group|Patients complete half of the whole cycles of neoadjuvant chemotherapy.
3309809|NCT01917578|Experimental|Whole Cycles Group|Patients complete whole cycles of neoadjuvant chemotherapy.
3309810|NCT01917591|Active Comparator|MariGen Wound|Fish derived extra cellular matrix
3309811|NCT01917591|Active Comparator|Oasis Sheet|Pig intestine derived extra cellular matrix
3309812|NCT01917604|Experimental|open exposure and control|● surgically uncover the canine tooth and bone removal exposing the largest diameter of the ectopic canine crown make a window in the palatal soft tissue and bond bracket after 10 days
3309813|NCT01917604|Experimental|closed exposure and control|raising a flap in the area of impacted canine,bonding an attachment and resuturing the flap
3309814|NCT01917617|Experimental|Oral rehydration group（Short Hydration）|"Gemcitabine； gemzer Cisplatin；Cispulan Oral Rehydration Solution(ORS)；OS-1~Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
3309815|NCT01917617|Active Comparator|Standard group（Long Hydration）|"Drug: Gemcitabine , Cisplatin~Other Names:~Gemcitabine； gemzer Cisplatin； Cispulan~Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
3309816|NCT01917630|Experimental|ALV003|
3309817|NCT01917630|Placebo Comparator|Placebo|
3309818|NCT01917643||Symbicort|BFC patients new to ICS/LABA and LAMA therapies
3309819|NCT01917643||Spiriva|Tiotropium bromide patients new to ICS/LABA and LAMA therapies
3309820|NCT01917669||Lean Non-Diabetic Group|Variables measured will also include serum analyses (HbA1c, adiponectin, cholesterol) and patient vital signs.
3309821|NCT01917669||Pre-diabetics|These patients are anticipated to have elevated BMI, yet not be diabetics.
3309822|NCT01917669||Diabetic Patients|These patients will have good glucose control.
3309823|NCT01917669||Diabetic patients with poor glucocontrol|These patients are anticipated to have poor glucose control. They are usually taking insulin.
3309824|NCT01917695|Active Comparator|Concurrent Radical Chemoradiation|Paclitaxel(175 mg/sq.m) + Cisplatin (75 mg/sq.m) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT + Brachytherapy (7Gy HDR x 3 doses) All to be completed within 8-10 weeks
3309825|NCT01917695|Experimental|Neoadjuvant Chemoradiation + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin(75 mg/m2) chemotherapy - 2 cycles of 3 weekly cycle Concurrent Radiotherapy - 50 Gy EBRT - completed within 5 weeks Radical Hysterectomy - 3 weeks after completion of RT All to be completed within 8-10 weeks
3309826|NCT01917695|Experimental|Neoadjuvant Chemotherapy + Radical Hysterectomy|Paclitaxel(175 mg/m2) + Cisplatin (75 mg/m2) chemotherapy - 3 cycles of 3 weekly cycle Radical Hysterectomy - 3 weeks after completion of chemotherapy All to be completed within 8-10 weeks
3309827|NCT01917708|Experimental|Abatacept|4 doses of abatacept 10 mg/kg/dose will be given on days -1, +5, +14, and +28.
3309828|NCT01917721|Experimental|Doxycycline|These patients will receive doxycycline at the acute phase of their disease
3309829|NCT01917721|Active Comparator|Placebo|The comparative arm of the study will receive standard care and placebo for Kawasaki disease, but not doxycycline
3309830|NCT01917734||IM-SAM|Children 6-59 months with bilateral pitting edema, and/or WHZ < - 3 and/or MUAC < 115 mm.
3309831|NCT01917786||Dexmedetomidine patients|Surgical patients receiving dexmedetomidine.
3309832|NCT01917786||Control patients|Surgical patients not receiving dexmedetomidine.
3309833|NCT01917799|Experimental|Aspirin|75mg tab of aspirin once daily
3309834|NCT01917799|Active Comparator|Aspirin + heparin|75mg tab of aspirin once daily + 0.4 mL/day of injection of low molecular weight heparin
3309835|NCT01917825|Experimental|MDT-15|The treatments will be administered to separate, sequential cohorts of 18 treated subjects in the following escalating doses:1 pellet, 3 pellets, and 6 pellets.
3309836|NCT01917838|Experimental|MFG plus MyMFG|"MFG plus MyMFG will be tested and the aim is:~Greater quality of the Design and Do process rated by therapists, parents, and independent coders.~Greater quantity and quality of HW assignments rated by therapists and parents.~Greater quality of the Review process as rated by therapists, parents, and independent coders.~Greater satisfaction with treatment as rated by the parent, target child, and therapists."
3309837|NCT01917864|Experimental|iPad Application|Student participants will use specialized iPad software under the supervision of a speech-language pathologist over the course of 12 months, approximately one session per week, one hour per session.
3309838|NCT01917877|Experimental|study group|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
3309839|NCT01917877|Active Comparator|control|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
3309840|NCT01917890|Experimental|Curcumin Group|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of curcumin (as 6 capsules 500 mg)"
3309841|NCT01917890|Placebo Comparator|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of placebo (as 6 capsules 500 mg)"
3309842|NCT01917903|Experimental|Identification of at risk variables|Individuals will come in for a single visit to perform all tasks / conditions. Measurements will be taken of spatial and temporal features of walking with and without a secondary task. In addition, cognitive tests of memory and attention will be performed. Outcomes will narrow measures to those most likely to show clinically significant change.
3309843|NCT01917903|Experimental|Gait-Cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
3309844|NCT01917916|Experimental|BI 655064 dose group 1|subject to receive BI 655064 dose group 1 single dose
3309845|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 1|subject to receive placebo
3309846|NCT01917916|Experimental|BI 655064 dose group 2|subject to receive BI 655064 dose group 2 single dose
3309847|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 2|subject to receive a placebo
3309848|NCT01917916|Experimental|BI 655064 dose group 4|Subject to receive BI 655064 dose group 4 single dose
3309849|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 4|Subject to receive placebo
3309850|NCT01917916|Experimental|BI 655064 dose group 3|Subject to receive BI 655064 dose group 3 single dose
3309851|NCT01917916|Placebo Comparator|Placebo to BI 655064 dose group 3|Subject to receive placebo
3309852|NCT01917929|Other|Secur-Fit Advanced|Secur-Fit Advanced Hip Stem
3309853|NCT01917942|Active Comparator|Standard of Care|Standard of Care
3309854|NCT01917942|Experimental|Humidification|Humidification
3309855|NCT01917981|Experimental|Personal Heart Rhythm Monitor|Intermittent cardiac monitoring with a Personal Heart Rhythm Monitor for three months.
3309856|NCT01917994|Experimental|Text Messages + Appointment Reminders|Participants in the intervention arm will receive supportive, informational, or motivational text messages three times a week for one year in addition to text message reminders about HIV primary care appointments.
3309857|NCT01917994|Active Comparator|Appointment Reminders|Participants in the control arm will receive text messages reminding them of HIV primary care appointments 48 hours before the scheduled appointment.
3309858|NCT01918007|Active Comparator|AT (adenotonsillectomy) Group|AT (adenotonsillectomy) immediately after the baseline study evaluation
3309859|NCT01918007|No Intervention|Control Group|No AT (adenotonsillectomy) for 3 months after the baseline study evaluation
3309860|NCT01918020|Experimental|Go Wild with Fruits and Veggies!|This group will receive nutrition education to learn about fruits and vegetables and physical activities right from the start of the experiment.
3309861|NCT01918020|Other|Go Wild with Fruits and Veggies! delayed|This group will only receive nutrition education about 4 months after the experiment starts.
3309862|NCT01918059|Experimental|Non-absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with non-absorbable suture (6-0 polypropylene) after repair of any deep component of the laceration.
3309863|NCT01918059|Experimental|Absorbable suture skin closure|The superficial eyelid skin will be repaired with simple interrupted sutures with absorbable suture (surgical gut) after repair of any deep component of the laceration.
3309864|NCT01918059|Experimental|Tissue Adhesive skin closure|The superficial eyelid skin will be repaired with layers of tissue adhesive (octyl-2-cyanoacrylate) after repair of any deep component of the laceration.
3309865|NCT01918098|Experimental|Oxycodone/naloxone prolonged release tablets|Dose strength:5/2.5 mg,10/5mg, 20/10mg,PO,q12h.daily dose from 10/5mg to 50/25mg.treatment duration:12 weeks
3309866|NCT01918098|Active Comparator|Oxycodone prolonged release tablets|Dose strength:5mg,10mg, 20mg,PO,q12h.daily dose from 10mg to 50mg.treatment duration:12 weeks
3309867|NCT01918111|Experimental|RD group|Renal denervation group
3309868|NCT01918111|Active Comparator|Control group|Control group
3309869|NCT01918124|Experimental|radiotherapy combined with chemotherapy|"Arm Label: radiotherapy combined with chemotherapy:~Radiotherapy:~Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.~Cisplatin:~Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.~Cisplatin and Doxorubicin and Cyclophosphamide： Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) given at 3 week intervals following completion of radiotherapy.~Paclitaxel and Carboplatin： Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy."
3309870|NCT01918137|Experimental|chocolate bar|
3309871|NCT01918137|Experimental|porridge|
3309872|NCT01918150|Experimental|TITAN 2 stent - Hexacath France|Patients receiving Titan 2 stents (percutaneous coronary intervention)
3309873|NCT01918150|Active Comparator|Cobalt-Chromium BMS - Any firm|Patients receiving Cobalt-Chromium Bare Metal Stents (free of any coating)(percutaneous coronary intervention)
3309874|NCT01918163|No Intervention|No Pills|Patients in this group will not receive Pomegranate pills.
3309875|NCT01918163|Active Comparator|Pomegranate pills|The reccruited patient will receive pomegranate pills every day for 12 weeks. The control group will not be exposed for the pills.
3309876|NCT01918176|Experimental|Fixed sequence crossover|All the subjects will undergo the treatment of Palbociclib alone first and then treatment of Palbociclib and Rabeprazole.
3309877|NCT01918202|Experimental|Cohort 1 - 20 mg|Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.
3309878|NCT01918202|Experimental|Cohort 2 ( adaptive dose, optional)|Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
3309879|NCT01918202|Experimental|Cohort 3 ( adaptive dose, optional)|"Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.~Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional"
3309880|NCT01918215|Other|Device Implantation|A prospective, blocked, randomised, placebo-controlled trial of primary prophylaxis ICD therapy or implantable loop recorder (ILR) insertion in patients with LVEF 36-50% and Late Gadolinium Enhancement(LGE)on CMR
3309881|NCT01918215|No Intervention|Observational Registry|A prospective observational registry of patients with LVEF 36-50% and no LGE on CMR
3309882|NCT01918228|Experimental|Intervention group|Talks on scientific status on back pain with the purpose of reducing LBP-related insecurity/fear, reducing the focus on the pain and providing participants with alternative explanation to their LBP. They were also provided with a folder (general stretching exercises) and had telephone access to health professional if they had questions about LBP during the follow-up year.
3309883|NCT01918228|No Intervention|Control group|No intervention will be provided by the study team.
3309884|NCT01918241|Experimental|pegfilgrastim,30mcg/kg|On the 3rd day and 6th day in Cycle 2, mean after 48h and 120h of chemotherapy, subjects will be received PEG-rhG-CSF(sc) in a fixed time(9:00±30 min), and the dosage is 30 mcg/kg.
3309885|NCT01918241|Experimental|pegfilgrastim, 60mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 60 mcg/kg.
3309886|NCT01918241|Experimental|pegfilgrastim,100mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to PEG-rhG-CSF(sc, single) in a fixed time(9:00±30 min), and the dosage is 100 mcg/kg.
3309887|NCT01918241|Experimental|filgrastim,5mcg/kg|On the 3rd day in Cycle 2, mean after 48h of chemotherapy, subjects will be assigned to controlled group with rhG-CSF(sc, once a day) in a fixed time(9:00±30 min), and the dosage is 5mcg/kg, rhG-CSF must be injected for a continous 14 days, or twice observed the results for ANC from the nadir to counts≥5.0×10^9/L, but at least 7 days.
3309888|NCT01918254|Experimental|Lumretuzumab Dose Escalation|Participants will receive escalating doses of lumretuzumab starting at 1000 mg IV (on Day 1, except Cycle 1 where lumretuzumab will be administered on Day 2) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
3309889|NCT01918254|Experimental|EPC1: Lumretuzumab (Prior Chemotherapy)|Extension phase Cohort 1 (EPC1): Participants will receive lumretuzumab 1000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 840 mg IV (on Day 1) initial dose followed by 420 mg IV, in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death.
3309890|NCT01918254|Experimental|EPC2: Lumretuzumab (Without Prior Chemotherapy)|Extension phase Cohort 2 (EPC2): Participants will receive lumretuzumab 2000 mg IV (on Day 1) along with paclitaxel 80 mg/m^2 IV (on Days 1, 8, and 15), and pertuzumab 420 mg IV (on Day 1), in each 21-day cycle. Participants will be treated until disease progression, unacceptable toxicities, and withdrawal from treatment for other reasons or death. Only participants with no prior chemotherapy for metastatic disease and/or a maximum of only one prior chemotherapy regimen in adjuvant or neoadjuvant setting will be enrolled in this cohort.
3309891|NCT01918267||Cohort|
3309892|NCT01918280|Experimental|Young group|Patient aged 15-22 years for seminal analyses and testicular biopsy
3309893|NCT01918280|Other|Adult group|Patient aged 23-55 years for seminal analyses and testicular biopsy
3309894|NCT01918293|Experimental|SMART arm|Using smartphone application for control of asthma
3309895|NCT01918293|No Intervention|conventional arm|non-using smartphone application for control asthma
3309896|NCT01918319|Experimental|Lifestyle intervention|The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
3309897|NCT01918319|No Intervention|Control|
3309898|NCT01918345|No Intervention|Standard Care (Control)|This group will receive a one-on-one counseling session during one visit with a Certified Diabetes Educator (CDE), who will provide standard advice on diabetes prevention and healthy lifestyle. They will receive a booklet on exercise and healthy diet as per current Canadian guidelines for healthy eating. This group will also receive a check-in telephone call from the Study Coordinator, half-way through the study. This group will not receive motivational interviewing, health coaching on low GI diet and/or exercise, or additional telephone follow-up.
3309899|NCT01918345|Experimental|Diet & Physical Activity Program with Health Coach|Participants assigned to this arm will receive a combination of the home-based physical activity program with health coach and the home-based low-GI diet program with health coach, as described in the respective individual arms. The Health Coach for this group will be a CDE.
3309900|NCT01918345|Experimental|Physical Activity Program with Health Coach|Participants will be counseled to follow physical activity recommendations for Canadians, which is at least 150 minutes of moderate physical activity per week. Participants will be asked to participate in aerobic, strength training and stretching activities. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their physical activity goals. More participants will be randomized to this group and the participants will either have CDE or a Registered Kinesiologist (R. Kin) as their health coach.
3309901|NCT01918345|Experimental|Diet Program with Health Coach|Participants will be counseled to follow recommendations for Canadians on healthy eating (Canada's Food Guide and Space on Your Plate. Low GI education will be layered on top of Canada's Food Guide recommendations. The goal for participants in the diet group is to lower their dietary GI by 8-10 units. Health Coaches will use motivational interviewing, goal-setting and problem solving to assist participants in meeting their dietary and low GI goals. The health coach for this group will be a CDE.
3309902|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-1|Fixed-dose combination VR 160/20 mg-1 is administered by mouth at Day 1, 8 and 15.
3309903|NCT01918358|Experimental|Fixed-dose combination VR 160/20 mg-2|Fixed-dose combination VR 160/20 mg-2 is administered by mouth at Day 1, 8 and 15.
3309904|NCT01918358|Experimental|Valsartan 160mg placebo + Rosuvastatin 20mg|Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered by mouth at Day 1, 8 and 15.
3309905|NCT01918384|Experimental|NPC-14|Intravenous drip, QW, 36 weeks, Dose will be adjusted and maintained by therapeutic drug monitoring of peak serum levels of NPC-14
3309906|NCT01918384|Placebo Comparator|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
3309907|NCT01918397|Active Comparator|Dose 1|Levofloxacin 11mg/kg daily + Optimized Background Regimen (OBR)
3309908|NCT01918397|Experimental|Dose 2|Levofloxacin 14mg/kg daily + Optimized Background Regimen (OBR)
3309909|NCT01918397|Experimental|Dose 3|Levofloxacin 17mg/kg daily + Optimized Background Regimen (OBR)
3309910|NCT01918397|Experimental|Dose 4|Levofloxacin 20mg/kg daily + Optimized Background Regimen (OBR)
3309911|NCT01918410|Active Comparator|Contact Lens with alginic acid|
3309912|NCT01918410|Placebo Comparator|Contact lens without alginic acid|
3309913|NCT01918423||Children of obese women from a RCT|Children born to obese women who were in the active intervention arm of the randomized controlled trial LiP. The lifestyle intervention during pregnancy consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
3309914|NCT01918423||Children of obese mothers from a RCT, controls|Children born to obese mothers who were in the control arm of the randomized controlled trial LiP.
3309915|NCT01918423||Children born to normal weight women|Children born to women with a pregestationally normal BMI and who were not part of a lifestyle intervention programme during pregnancy.
3309916|NCT01918436|Experimental|TEAMS intervention|"Pre-school children age 3-6, from Region Zealand in Denmark, diagnosed with ADHD as primary diagnosis are offered participation in the RCT study of the TEAMS program.~The intervention groups participate in eight weekly group sessions consisting of separate parent- and children's groups.~In the child group, the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development."
3309917|NCT01918436|Active Comparator|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
3309918|NCT01918449|No Intervention|Sleep Unit group|This group will have standard follow up in sleep unit at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
3309919|NCT01918449|Experimental|Primary Care group|This group will have standard follow up in primary care at 1, 3 and 6 month. These patients will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counseling.
3309920|NCT01918462||Alcoholic hepatitis|Patients with alcoholic hepatic; cases.
3309921|NCT01918462||Healthy controls|Persons undergoing hepatic resection; controls.
3309922|NCT01918475|Active Comparator|Carbetocin first|Subjects receive carbetocin 0.1 mg intravenously in the first session and placebo (NaCl 0.9%) in the second session
3309923|NCT01918475|Active Comparator|Placebo first|Subjects receive placebo (NaCl 0.9%) intravenously in the first session and carbetocin 0.1 mg in the second session
3309924|NCT01918488|Experimental|Nephropathy|Diabetics with diabetic nephropathy receiving first a standardized salt diet (200 mmol NaCl/day) for 4 days and then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
3309925|NCT01918488|Experimental|Control|Diabetics without nephropathy receiving a standardized salt diet (200 mmol NaCl/day) for 4 days, then amiloride tablet 20 mg two times daily (morning and afternoon) for 2 days.
3309926|NCT01918501|Experimental|Blood testing|Comparison of nutrition factors in MS patients and healthy volunteers as possibly source for the pathogenesis and for the remyelination process.
3309927|NCT01918527|Other|A, Conventional treatment|Operation + 4 or 8 cycles of adjuvant chemotherapy, if indicated.
3309928|NCT01918527|Other|B, Neoadjuvant chemotherapy|3 cycles of neoadjuvant chemotherapy + operation. Adjuvant chemotherapy only if indicated.
3309929|NCT01918540|Active Comparator|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
3309930|NCT01918540|Active Comparator|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer.
3309931|NCT01918553|Experimental|Subject in the study ALIENOR|
3309932|NCT01918566|Placebo Comparator|300ml tap water|Single intragastric instillation of 300ml tap water via nasogastric tube
3309933|NCT01918566|Active Comparator|Glucose|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
3309934|NCT01918566|Active Comparator|Glucose plus Lactisole|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole
3309935|NCT01918566|Active Comparator|Fructose|Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube
3309936|NCT01918566|Active Comparator|Glucose and Exendin|Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39
3381400|NCT03498716|Experimental|Atezolizumab + Chemotherapy|"Participants will receive atezolizumab (in combination with chemotherapy as described below) every 2 weeks for 10 doses, followed by atezolizumab maintenance therapy every 3 weeks to complete 1 year of treatment from the first dose~Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)"
3381401|NCT03498716|Active Comparator|Chemotherapy|Chemotherapy will consist of paclitaxel every week for 12 weeks, followed by dose-dense doxorubicin +cyclophosphamide or dose-dense epirubicin + cyclophosphamide every 2 weeks, for 4 doses supported with Granulocyte Colony-Stimulating Factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
3309937|NCT01918566|Sham Comparator|tap water, lactisole|Single intragastric instillation of 300ml tap water with 450ppm lactisole
3309938|NCT01918579|Experimental|CRP intervention|Patients will be tested by rapid POC CRP test
3381402|NCT03495895|Experimental|Minding the Baby|Families are visited weekly beginning in the mother's third trimester of pregnancy up through the child's first birthday, at which point visits take place biweekly up through the child's second birthday.
3381403|NCT03495895|Other|Control|Usual care control condition. Families in the control Group receive the usual care that is offered to families in the target group
3381404|NCT03489187||VTTS as standard of care|VTTS as standard of care.
3381405|NCT03486197|Experimental|Treatment (Pembrolizumab, neutron radiation therapy)|Participants receive pembrolizumab IV on days 1 and 22. On day 23, participants may undergo an optional tumor biopsy and receive 3-5 treatments of neutron radiation therapy over 2 weeks on days 23-42. Participants receive pembrolizumab IV on day 43 and continue per standard of care in the absence of disease progression or unacceptable toxicity.
3309939|NCT01918579|No Intervention|Control|Patients will not be tested by rapid POC CRP test
3309940|NCT01918592|Experimental|MRI/PET|
3381406|NCT03484923|Experimental|Arm 1: LAG525 + Spartalizumab in unselected patients|Spartalizumab and LAG525 will be administered intravenously
3381407|NCT03484923|Experimental|Arm 2: Capmatinib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Capmatinib will be administered orally.
3381408|NCT03484923|Experimental|Arm 3: Canakinumab+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Canakinumab will be administered subcutaneously.
3381409|NCT03484923|Experimental|Arm 4: Ribociclib+Spartalizumab in unselected patients|Spartalizumab will be administered intravenously. Ribociclib will be administered orally.
3309941|NCT01918605|Experimental|Diluted spacer|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
3309942|NCT01918605|Active Comparator|Non-diluted spacer|Single dose of DuraSeal product injected between rectum and prostate
3309943|NCT01918618||Levosimendan|study group
3309944|NCT01918618||No Levosimendan|Control group
3381410|NCT03484923|Experimental|Arm 1A: LAG525 + Spartalizumab in LAG-3 positive patients|Spartalizumab and LAG525 will be administered intravenously
3381413|NCT03474965|Experimental|Crizanlizumab|SEG101 (crizanlizumab) administered on Week 1 Day 1, Week3 Day 1 and Day 1 of every 4-week cycle
3381414|NCT03468608||Phase 1: Instrument Development|An initial set of questionnaire items will be created based on the questionnaires noted in the literature review as well as the semi-structured interviews conducted with parents and healthcare team members in our facility.
3309945|NCT01918631|Active Comparator|Entecavir|Entecavir 0.5mg QD for 48 weeks
3309946|NCT01918631|Active Comparator|tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300mg QD for 48 weeks
3309947|NCT01918644|Experimental|Treatment (SBRT, capecitabine, and surgery)|Patients undergo SBRT every other day over 2 weeks for a total of 5 fractions and receive capecitabine PO every 12 hours 5 days a week for 2 weeks. Patients then undergo definitive surgery after a minimum of 2 weeks from the completion of SBRT.
3309948|NCT01918657|Active Comparator|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded.
3381415|NCT03468608||Phase 2: Pre-Test Evaluation|Parents and healthcare team members will be asked to comment on the quality of the draft questionnaire created in phase 1 of this study.
3381416|NCT03468608||Phase 3: Pilot|"Parents will be asked to complete the questionnaire developed during phase 2 of this study. Upon completing the questionnaire, parents will be asked to rate the overall face validity of the tool using a 5-point Likert scale.~Healthcare team members will be asked to rate the content validity of each item on the questionnaire."
3381417|NCT03468608||Phase 4: Validation|Parents will be asked to complete the questionnaire developed during phase 3 of this study.
3381418|NCT03463239|Experimental|Autologous tissue engineered corpora|All subjects enrolled will undergo a corpora cavernosum biopsy. Endothelial and smooth muscle cells will be isolated and expanded, then seeded onto a scaffold that will later be implanted into the subject.
3381419|NCT03462290|Experimental|Botulinum toxin|
3381420|NCT03462290|Placebo Comparator|placebo|
3381421|NCT03450187|Active Comparator|Cohort A|50 mg TP-271 q24 (n=6), a novel, broad-spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
3381422|NCT03450187|Active Comparator|Cohort B|100 mg TLP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
3309949|NCT01918657|Placebo Comparator|placebo arm|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
3309950|NCT01918670||Pasteur|
3309951|NCT01918670||Grenoble|
3309952|NCT01918670||Nantes|
3309953|NCT01918670||Parly|
3309954|NCT01918670||Rennes|
3309955|NCT01918670||Rouen|
3309958|NCT01918696|Experimental|Anger Reduction Treatment|"This treatment consists of eight 15-minute sessions. Participants will read scenarios and imagine themselves in these situations: A driver does not let you over even though you have your blinker on. Next, another will appear to provide a less ambiguous interpretation. One letter will be missing from the key word of this sentence. The sentence will read They can't s_e you. The participant will fill in the missing letter (to form see). Next, this interpretation will be reinforced by requiring the participants to correctly answer yes or no to a comprehension question (Is the driver being disrespectful?). In each session 64 training scenarios will be presented. Participants will never see the same scenario twice over the course of the study."
3309959|NCT01918696|Active Comparator|Progressive Muscle Relaxation|"Participants will receive eight 15-minute sessions of PMR. They will listen to a PMR script (Kassinove & Tafrate, 2002). Participants will be asked to make sure they are sitting comfortably, close their eyes, and systematically tense and release 10 different muscle groups. At the end of this procedure, participants will create a plan for when they will use the exercise. They will then type out the sentence: When I feel [write the feeling you decided on], then I will use this relaxation technique. They will then be told, Now, go over what you have written and say it quietly to yourself until you can repeat it word for word without having to read what you have written."
3309960|NCT01918696|Placebo Comparator|Control Condition|To control for expectancy effects, participants assigned to the control condition will complete eight computerized sessions consisting of psychoeducation on healthy behaviors. These sessions will be matched for time with the active conditions, lasting 15 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep, and will be taken from protocols developed from our ongoing research. This psychoeducation is perceived as credible but has no detectable impact on behavior. After the post-treatment session, participants will be provided with the active ART treatment free of charge if they wish to receive it.
3309961|NCT01918709|Experimental|Valsartan 160mg, Rosuvastatin 20mg|Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 7 days.
3309962|NCT01918709|Experimental|Rosuvastatin 20mg|Rosuvastatin 20mg is administered daily by mouth once a day for 7 days.
3309963|NCT01918709|Experimental|Valsartan 160mg|Valsartan 160mg is administered daily by mouth once a day for 7 days.
3309964|NCT01918722|Experimental|ICH-1|herbal medicine with Hirudo, Tabanus,8 herbals, promote blood circulation function
3309965|NCT01918722|Active Comparator|ICH-2|herbal medicine without Hirudo, Tabanus,Only 6 herbals
3309966|NCT01918722|Placebo Comparator|placebo herbal medicine|Placebo ：granula，dose twice a day by Oral or nasogastric tube for 10 days
3309967|NCT01918735|Experimental|Group/dose level 1a|25 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3309968|NCT01918735|Placebo Comparator|Group/dose level 1b|Matching placebo for Group/dose level 1a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3309969|NCT01918735|Experimental|Group/dose level 2a|75 mg GWP42006 oral solution. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3309970|NCT01918735|Placebo Comparator|Group/dose level 2b|Matching placebo for Group/dose level 2a. As a safety precaution, subjects will be split into two sub-groups for sentinel dosing. On the first day of dosing , only two subjects will be dosed (randomisation schedule designed so that one placebo one active will be dosed on first day). Following a review of the safety data for the first set of subjects, the remaining subjects will be dosed.
3309971|NCT01918735|Experimental|Group/dose level 3a|200 mg GWP42006 oral solution (single dose) followed by an intravenous administration of 5 mg GWP42006 after the oral dose
3309972|NCT01918735|Placebo Comparator|Group/dose level 3b|Matching placebo for Group/dose level 3a
3309973|NCT01918735|Experimental|Group/dose level 4a|400 mg GWP42006 oral solution
3309974|NCT01918735|Placebo Comparator|Group/dose level 4b|Matching placebo for Group/dose level 4a
3309975|NCT01918735|Experimental|GWP42006 1, 2, or 3 times daily|Subjects will receive the selected dose of GWP42006 once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
3309976|NCT01918735|Placebo Comparator|Placebo 1, 2, or 3 times daily|Subjects will receive placebo once, twice or three times daily (the number of daily doses and actual dose will be decided upon based on results from Part 1 of the study) for a total of 5 days, with the final dose given on the morning of Day 5.
3381423|NCT03450187|Active Comparator|Cohort C|200 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
3381424|NCT03450187|Active Comparator|Cohort D|300 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
3381425|NCT03450187|Active Comparator|Cohort E|400 mg TP-271 q24 (n=6), a novel, broad spectrum tetracycline-class antibiotic or matching placebo (n=2) once daily for 7 days.
3381426|NCT03443908||CPAP therapy|CPAP therapy (minimum of 3-4 weeks)
3381427|NCT03432286|Experimental|Galcanezumab|"Galcanezumab administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
3381428|NCT03432286|Placebo Comparator|Placebo|"Placebo administered by SQ injection.~Participants may be eligible for optional open-label extension at the end of the double-blind period."
3381429|NCT03422198|Experimental|Short course vaginal cuff brachytherapy|Patients undergo short course vaginal cuff brachytherapy for 2 fractions with 1 week apart.
3381430|NCT03422198|Active Comparator|Vaginal cuff brachytherapy|Patients undergo standard of care vaginal cuff brachytherapy for 3-5 fractions over no more than 3 weeks.
3381434|NCT03393845|Experimental|Pembrolizumab + Fulvestrant|Pembrolizumab 200m IV q3W + Fulvestrant. Loading dose 500mg IV IM q2W x3 followed by 500mg IM q4W
3309977|NCT01918748|Experimental|MS & chronic stroke patients|"Intervention: 8 weeks of I-TRAVLE based training of proximal arm function, using the haptic master.~Each week participants will attend training sessions on 5 days per 2 weeks, during which they will train 2 times 30 minutes I-TRAVLE assisted therapy, of which 1x 30 minutes supervised self-training. The two times half an hour training sessions per day will be interspaced by at least half an hour to avoid (general) fatigue and overuse of the affected arm in the subjects."
3309978|NCT01918787|Experimental|repetitive TMS|repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control
3309979|NCT01918813|Experimental|Preoperative MRSA nasal colonization|Interventions in arm of preoperative MRSA nasal colonization consisted of antibiotic prophylaxis with a single dose of vancomycin 1g in addition to cephalosporins, and topical decolonization of MRSA with application of 2% mupirocin ointment twice daily to nares for 5 days
3309980|NCT01918826|Active Comparator|TENS active|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE
3309981|NCT01918826|Placebo Comparator|TENS placebo|NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO
3381435|NCT03386513|Experimental|Escalation and Expansion|"Escalation: IMGN632 was administered by IV on 2 different schedules for patients with relapsed/refractory AML or BPDCN.~Expansion: the study is currently enrolling in 2 BPDCN expansion cohorts at the RP2D:~Cohort 1: Relapsed or refractory BPDCN patients who have received 1-3 prior systemic therapies (incl. tagraxofusp-erzs and/or any other systemic therapy deemed appropriate for the treatment of BPDCN)~Cohort 6: Pivotal cohort for frontline BPDCN patients who have not received prior systemic therapy. Patients may have received local therapy (radiotherapy, surgical excision, photodynamic therapy). Eligible patients must have a recurrence or progression in the field of local therapy OR disease outside the field of local therapy.~Other expansion cohorts not currently enrolling:~• Cohort 2: Relapsed AML; Cohort 3: Relapsed or refractory ALL; Cohort 4: Other relapsed or refractory hematologic malignancies; Cohort 5: Relapsed or refractory AML at alternate dose or schedule"
3381436|NCT03379649|Experimental|PRP|Patient with recurrent implantation failure who receives intrauterine infusion of platelet rich plasma
3381437|NCT03379649|Placebo Comparator|Placebo|Patient with recurrent implantation failure who receives intrauterine infusion of embryo culture media
3381438|NCT03376763|Experimental|Group 1|Schizophrenia patients who are taking oral aripiprazole will be switched to Abilify maintena
3381439|NCT03376763|Experimental|Group 2|Schizophrenia patients who are taking other oral atypical antipsychotics will be switched to Abilify maintena
3381440|NCT03351387||SPY Intra-operative Angiography|The SPY Fluorescent Imaging System
3309982|NCT01918839|Experimental|VINCI Plus|One side has been treated with VINCI Plus
3309983|NCT01918839|Active Comparator|Restylane-L|One side has been treated with Restylane-L
3309984|NCT01918852|Active Comparator|Capecitabine|Capecitabine 1250 mg/m2 for patients < 70 years of age, and 1000 mg/m2 for patients ≥ 70 years of age, orally b.i.d. day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
3309985|NCT01918852|Experimental|S1|S-1 30 mg/m2 orally b.i.d. irrespective of age, day 1-14 with or without bevacizumab 7.5 mg/kg i.v. day 1.
3309986|NCT01918865|Experimental|ISIS-PTP1BRx|Weekly Dosing for 26 Weeks
3309987|NCT01918865|Placebo Comparator|Placebo|Weekly Dosing for 26 Weeks
3309988|NCT01918878|Experimental|Aflibercept (EYLEA)|Intravitreal injection of aflibercept (EYLEA) 2mg/0.05ml at enrolment (day 0), 4 weeks, 8 weeks, 16 weeks and 24 weeks. Aflibercept will be provided for total period of 24 weeks
3309989|NCT01918891|No Intervention|Usual Home Care|Regardless of study arm, all patients will receive usual home health services: a physician-ordered plan of care; skilled nursing and/or therapy services as prescribed by the MD; patient education, monitoring and hands-on care; and home health aide services depending on functional deficits and availability of unpaid caregivers.
3309990|NCT01918891|Experimental|Nurse Practitioner + Health Coach|The NP + HC arm will include the same protocol as the NP only arm plus 30 additional days of support. The HC will pick up the case after the initial 30 days and follow up with the plan of care jointly established by the patient, NP and HC. The focus will be on ongoing self-management coaching, providing preparation support for physician visits, and linking patient to additional community resources, as needed.
3309991|NCT01918891|Experimental|Nurse Practitioner Only|The NP only program will provide a 30 day intervention via in-home and telephone encounters for patients randomized to this group. In the first 30 days post-enrollment the NP will focus on medical case management and coordination with primary care providers and specialists, provide self-management coaching, and intervene if gaps in care are identified - all with a focus on BP reduction and preparing the patient for ongoing BP maintenance.
3309992|NCT01918904|Experimental|Sodium Thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
3309993|NCT01918904|Placebo Comparator|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
3309994|NCT01918917|Active Comparator|Levobupivacaine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml 0.9% sodium chloride administered. postoperative morphine administered for analgesia
3309995|NCT01918917|Active Comparator|Dexmedetomidine|Intraarticular 19 ml 0.5% levobupivacaine and 1 ml (100 mcg/ml) dexmedetomidine administered, postoperative morphine used for analgesia
3309996|NCT01918930|Experimental|MGA271|MGA271 (administered in main study CP-MGA271-01)
3309997|NCT01918943||PLIF and Aspen device patients|All patients will receive PLIF and Aspen device
3309998|NCT01918956|Active Comparator|conventional regimen of PURETHAL Birch|"Initial treatment:~6 incremental weekly subcutaneous doses of 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3, 4, 5, 6).~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in intervals according to registered scheme (week 8, 10, 12)."
3309999|NCT01918956|Experimental|rush regimen of PURETHAL Birch|"Initial treatment:~3 incremental weekly subcutaneous doses of 0.1, 0.3, and 0.5 ml PURETHAL Birch, 20.000 AUM/ml (week 1, 2, 3)~Maintenance treatment:~0.5 ml PURETHAL Birch, 20.000 AUM/ml, in 2-weekly intervals (week 5, 7, 9)."
3310000|NCT01918969||Blood donors|Blood donors with no exclusion criteria i.e with a very low probability to have an aortic aneurysm
3310001|NCT01918982||Aortic aneurysm|Patients with aortic aneurysm >30mm and < 50mm
3310002|NCT01918995|Experimental|Regadenoson low dose|Administered over approximately 10 seconds followed by 2 repeat low doses at 10 minute intervals
3310003|NCT01918995|Experimental|Regadenoson medium dose|Administered over approximately 10 seconds followed by 2 repeat medium doses at 10 minute intervals
3310004|NCT01918995|Experimental|Regadenoson high dose|Administered over approximately 10 seconds followed by 1 repeat high dose at 10 minute intervals
3310005|NCT01918995|Placebo Comparator|Placebo|Administered over approximately 10 seconds followed by 1 or 2 repeat doses at 10 minute intervals
3310006|NCT01919008|Experimental|Group 1 (FK949E low dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: Three FK949E low dose tablets~Days 7 to 10: One FK949E high dose tablet"
3310007|NCT01919008|Experimental|Group 2 (FK949E high dose tablet-first group)|"Days 1 and 2: One FK949E low dose tablet~Days 3 to 6: One FK949E high dose tablet~Days 7 to 10: Three FK949E low dose tablets"
3310008|NCT01919034||Patients undergoing abdominal surgery|Patients undergoing abdominal surgery and using morphine pain control analgesia (PCA) device will be involved. Pre- and Post- operative (after anesthesia and at the end of surgery) blood sampling (total 30 ml) plus normal liver tissue (10mm3) e will be harvested. Above protein(TM, IL-20, HD) amount change will be measured (ELISA for TM, IL-20 (serum) or flowcytometry (white cells) for TM, HD, IL-20 expression, stain or blotting for skin tissue). Patients will be included in this branch to check the correlation between morphine consumption and protein expression. Pain questionnaire (BPI, McGill) will be applied for pain evaluation. 2-D gel analysis will also be applied to screen further possible molecules.
3310009|NCT01919047||Betanis group|Patients receiving Betanis for Overactive Bladder
3310010|NCT01919060||lesions in colon|
3310011|NCT01919060||lesions in extra-colon|
3310012|NCT01919073|Experimental|Immediate Treatment Group|The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
3310013|NCT01919073|Active Comparator|Delayed Treatment Group|The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (in about 11-12 months from the initial appointment).
3310014|NCT01919086|Experimental|Patients with Multiple Myeloma|This is a phase II, single center clinical trial designed to evaluate the response rate and toxicity of a response-adapted, sequential therapy, using bortezomib and dexamethasone, followed by the addition of lenalidomide in non-responders, in patients with untreated MM.
3310016|NCT01919125|Experimental|Cohort 1: Child-Pugh Class A|Participants with mild hepatic impairment (Child-Pugh Class A score = 5-6) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3310017|NCT01919125|Experimental|Cohort 2: Child-Pugh Class B|Participants with moderate hepatic impairment (Child-Pugh Class B score = 7-9) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3310018|NCT01919125|Experimental|Cohort 3: Child-Pugh Class C|Participants with severe hepatic impairment (Child-Pugh Class C score = 10-15) will receive a single dose of 100 mg IDX719 by mouth on Day 1.
3310019|NCT01919138||severe sepsis, septic shock|
3310020|NCT01919151||Gastrointestinal cancer patients|Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
3310021|NCT01919177|Active Comparator|Nitrate rich beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of Nitrate-rich concentrated beetroot juice (containing 12 mmol of NO-3). This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
3310022|NCT01919177|Placebo Comparator|Nitrate depleted beetroot juice|Subjects with heart failure with preserved ejection fraction will receive 140 mL of nitrate-depleted beetroot juice (containing <0.01 mmol of NO-3).This will be a cross-over study. Therefore all subjects will receive both interventions, but the order of the interventions will be randomized.
3310023|NCT01919203|Experimental|group R|The starting dose of remifentanil is 0.5μg/kg and a step size was 0.05μg/kg.
3310024|NCT01919242||with morbidity|patients who suffered from any type of morbidity after surgery
3310025|NCT01919242||without morbidity|patients who did not suffer from any type of morbidity after surgery
3310026|NCT01919255|Active Comparator|Picolight + Coolprep (Day-Prior)|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior]
3310027|NCT01919255|Active Comparator|Picolight + Clicolon (Day-Prior)|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior]
3310028|NCT01919255|Active Comparator|Picolight + Coolprep (Split-Dose)|Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
3310029|NCT01919255|Active Comparator|Picolight + Clicolon (Split-Dose)|Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
3310030|NCT01919268|Experimental|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
3310031|NCT01919268|Active Comparator|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of six weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
3310032|NCT01919281|Experimental|strength training|The subjects will attend for supervised training three sessions per week for 10 weeks (9-12). The strength training program involves dynamic contraction at intensities of 60 - 70 % of 1 repetition maximum (RM) to improve strength and muscle hypertrophy. Each session will contain 8 exercises on the major muscle groups. Each drill consists of 10-12 repetitions (reps) x 3 sets separated by one minute rest between sets.
3310033|NCT01919281|Experimental|interval training|"High intensity interval training (HIT) three times per week. The three weekly supervised HIT sessions will include two 4x4 min interval sessions and one 10x1 min session. The HIT consist of uphill treadmill running/walking."
3310034|NCT01919281|No Intervention|control|Based on the Norwegian recommendation we will encourage the control group to perform 60 minutes of physical activity at moderate to high intensity on a daily basis.
3310035|NCT01919294|Experimental|testosterone undecanoate|Open label testosterone injection. Testosterone Undecanoate (1 g in 4 ml oily base) will be given as slow (2 minute) intramuscular injections (Nebido, manufactured by Bayer-Schering). These will be administered by the study investigator or designated research nurse at time zero (baseline visit 2) and after 6, 18, 30 and 42 weeks.
3310036|NCT01919320||CSS Console TAH-t Patients|All TAH-t patients implanted while supported with the CSS Console who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
3310037|NCT01919320||C2 Driver System TAH-t Patients|200 TAH-t patients implanted while supported by the Companion 2 (C2) Driver System who were enrolled in the INTERMACS Registry and implanted with the TAH-t on or after June 20, 2012.
3310038|NCT01919320||All TAH-t Patient Records|All records for TAH-t patients enrolled in the INTERMACS Registry will be reviewed to support Objective 2 of the protocol.
3310039|NCT01919333||laparoscopic ovarian cystectomy|the group who laparoscopic ovarian cystectomy are performed for endometrioma
3310040|NCT01919333||laparoscopic non- ovarian pelvic surgery|the group whom laparoscopic non- ovarian pelvic surgery are performed
3310041|NCT01919346|Experimental|Eculizumab|Eculizumab 1200 mg (diluted in Sodium Chloride (NaCl) to 5mg/mL, volume = 240 mL) will be given intraoperatively at the time of transplantation prior to reperfusion of the renal allograft and again at 900 mg (diluted in NaCl to 5mg/mL, volume = 180 mL) 12-24 hours post-transplantation
3310042|NCT01919346|Placebo Comparator|Normal Saline|Administered at same volume and time as Experimental arm
3310043|NCT01919359|Experimental|Facial filler w/vitamin,Placebo/Resurfacing w/vitamin, placebo|Multizyme 150C 2 caps 2 times/day between meals Day of tx for 30 days Cyruta Plus 90T 1 cap 3 times/day 30 days before and after tx or Multizyme 150C 2caps 2 times/day between meals Day of Tx for 30 days; SHEP 2caps 2 times/day 30 days before and after Tx Cellular Vitality 90C 1cap 3 times/day 30 days before and after Tx
3310044|NCT01919359|Placebo Comparator|Soft Tissue filler sugar pill|"Placebo Analog 2tabs 2 times/day between meals; Day of tx for 30 days; Placebo Analog 1tab 3 times/day 30 days before and after tx or Placebo Analog (A) 2~1cap 2 times/day between meals; Day of Tx for 30 days Placebo Analog (B) 2caps 2 times/day 30 days before and after Tx Placebo Analog (C) 1cap 3 times/day 30 days before and after Tx"
3310045|NCT01919372|Active Comparator|Conventional assistance|Usual treatment of obesity in terms of monitoring lifestyle habits
3310046|NCT01919372|Experimental|Telemedic assistance|telemedical assistance with a technological system to provide a continuous monitoring of lifestyle habits and individualized treatment of obesity
3310047|NCT01919385|Experimental|type 1 diabetes|Predictive Low Glucose Minimizer (PLGM) System
3310048|NCT01919424|Active Comparator|'The English-Wright nebulizer'|The English-Wright nebulizer will be used to perform a methacholine challenge.
3310049|NCT01919424|Active Comparator|Trudell AeroEclipse*II BAN nebulizer|The Trudell AeroEclipse*II BAN nebulizer will be used to perform a methacholine challenge
3310050|NCT01919437|Experimental|Web-Enabled Cognitive Neuropsychological Evaluation System|
3310051|NCT01919463|No Intervention|Control Group|Colonoscopy is completed without abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process.
3310052|NCT01919463|Experimental|Experimental Group 2 (Monitoring)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown to investigators for study but not to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression by his subjective judgement.
3381444|NCT03337698|Active Comparator|Stage 1: Cohort 1: Atezolizumab|"Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria."
3310053|NCT01919463|Experimental|Experimental Group 1 (Guiding)|Colonoscopy is completed with abdominal compression by GI assistants. Live image of magnetic endoscopic imaging system is shown both to investigators for study and to the colonoscopist for facilitating the intubation process. The colonoscopist directs GI assistants to conduct compression according to the guidance of magnetic endoscopic imaging system.
3310054|NCT01919476|Active Comparator|Control Meal: Bagel, cream cheese|Control meal consists of bagel with cream cheese and apple juice.
3310055|NCT01919476|Experimental|Almond Meal: Bagel, almond butter|Almond meal consists of bagel with almond butter and apple juice.
3310056|NCT01919502|Other|Semi-quantitative urine pregnancy test|Semi-quantitative urine pregnancy test (Quanti5 Multilevel hCG Pregnancy Test)
3381445|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381446|NCT03337698|Experimental|Stage 1: Cohort 1: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.~Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381447|NCT03337698|Active Comparator|Stage 1: Cohort 2: Docetaxel|"Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression.~Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381448|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Cobimetinib|"Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381449|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + CPI-444|"Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3310057|NCT01919515|Other|ZR Crown & Stainless Steel Crown|Each subject will have a maximum of one ZR Crown and one Stainless Steel Crown cemented on primary molars that are treatment planned for a crown.
3310058|NCT01919528|Experimental|axillary vein catheterization|central venous catheter placement into the axillary vein under ultrasound guidance
3310059|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program involving an individualized exercise and nutrition program 4 weeks before surgery. Whole body protein kinetics and insulin resistance will be determined at the beginning of the program and at the end of the program.
3381450|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + RO6958688|"Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381451|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Ipatasertib|"Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381452|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Docetaxel|"Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3310060|NCT01919554|Placebo Comparator|Placebo Sub Lingual Immunotherapy Tablets (SLIT)|Placebo tablets Matching the HDM allergen extract Sub Lingual Immunotherapy Tablets
3310061|NCT01919554|Experimental|SLIT of HDM allergen extracts|Sublingual Immunotherapy Tablets of House Dust Mite allergen extracts
3310062|NCT01919567||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
3310063|NCT01919567||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3310064|NCT01919567||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3310065|NCT01919580||Normal team|"Subjects who have problem at third molar of impacted tooth need to receive a surgery with general anesthesia.~Subjects must:~Should have a blood exam (20ml) before the surgery.~Site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample around third molar during the surgery."
3310066|NCT01919580||Oral dysplasia|"Subjects who are diagnosed with dysplasia of oral cavity.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3310067|NCT01919580||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3310068|NCT01919593|Experimental|2% Chlorhexidine Gluconate|apply 2% Chlorhexidine Gluconate in 70% Alcohol on skin before venipuncture
3310069|NCT01919593|Active Comparator|10% povidone iodine|apply 10% povidone iodine on the skin before venipuncture
3310070|NCT01919619|Experimental|Treatment (lenalidomide and ipilimumab)|Patients receive lenalidomide PO QD on days 1-21 of courses 1, 3, 5 and 7. Beginning 1-3 days after the last dose of lenalidomide patients receive one dose of ipilimumab IV over 90 minutes of courses 2, 4, 6 and 8. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
3310071|NCT01919632|Experimental|Lifestyle|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. (?) jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
3310072|NCT01919645|Experimental|Combined Training Group|"Combined Training - (strength + aerobics).~A combined training (CT)is performed, having aerobics exercises (AE)using a stationary bicycle and strength training in workout devices.~The strength training (ST) will be performed by isotonic exercises recruiting the main muscle groups. They exercises are: Chest Press, Leg Press, Vertical Traction, Leg Extension and Abdominal Crunch."
3310073|NCT01919645|Placebo Comparator|Control Group|The control group patients did not perform any intervention through physical exercises. They were oriented on Sleep Hygiene and were followed during the study. They were asked to come to the following visits (at weeks 8 and 16) and to 2 additional visits to get and then return the actigraph. During this period, they were followed through phone calls once a month and were asked for sleep hygiene and were reminded of their assessment dates.
3310074|NCT01919658|Active Comparator|proximal nerve block|The anesthesiologist will administer a proximal nerve block if specified in the randomization envelope.
3310075|NCT01919658|Active Comparator|distal nerve block|The anesthesiologist will administer a distal nerve block if specified in the randomization envelope.
3310076|NCT01919671|Experimental|Tongxinluo capsule|Tongxinluo capsule,4 granules,t.i.d. po,for 90 days
3310077|NCT01919671|Placebo Comparator|placebo capsule|placebo capsule,4 granules,t.i.d. po,for 90 days
3310078|NCT01919684|Active Comparator|Active|LGD-6972
3310079|NCT01919684|Placebo Comparator|Placebo (Captisol®)|Vehicle Control (Captisol®)
3310080|NCT01919710|Experimental|rHSA/GCSF for injection|rHSA/GCSF Start from 300mcg
3310081|NCT01919736|Active Comparator|Moderate gait retraining|a moderate 7 degree toe-in modification
3310082|NCT01919736|Active Comparator|Mild gait retraining|A 2 degree toe-in gait retraining
3310083|NCT01919749|Other|treatment|recommended treatment
3310084|NCT01919762||Bacteremia Positive Patients|"Symptomatic adult patients, confirmed via diagnostic blood culture and species identification followed by subsequent second blood culture results and species identification that are positive for each of the following species of bacteria (Target 6 Species).~Acinetobacter baumannii~Staphylococcus aureus~Klebsiella pneumonia~Pseudomonas aeruginosa~Enterococcus faecalis~Enterococcus faecium"
3310085|NCT01919762||Bacteremia Negative Patients|Adult patients confirmed via diagnostic blood culture and species identification and subsequent second blood culture and species identification as being negative for the Target 6 species
3310086|NCT01919788|Placebo Comparator|Control|"No insulin administered. Instead of insulin infusion, a small amount of saline is administered to keep the subject blinded.~Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism. Forearm pletysmography will be performed twice."
3310087|NCT01919788|Experimental|Insulin|Insulin (Insuman Rapid) is administered once as a bolus of 0,1 IU/kg. Three muscle biopsies and two fat biopsies will be obtained. A palmitic acid tracer will be given to estimate fatty acid metabolism Forearm pletysmography will be performed twice
3310088|NCT01919788|Experimental|Insulin and glucose|"Insulin (Insuman rapid) is administered once as a bolus injection of 0,1 IU/kg and glucose is given at the same time to avoid hypoglycemia in this arm.~Three muscle biopsies and to fat biopsies is obtained. A palmitic acid tracer is given to estimate fatty acid metabolism Forearm pletysmography will be performed twice"
3310089|NCT01919827|Experimental|MSC endobronchial infusion|
3310090|NCT01919840|Active Comparator|Group C|• conventional protocol, volume replacement with massive bleeding.
3310091|NCT01919840|Experimental|Group ROTEM|• Protocol according to the different tests to be performed with thromboelastography
3310092|NCT01919853|Experimental|Mindfulness-Based Stress Reduction|The MBSR intervention is an 8-week course meeting 2 hours weekly. The curriculum is based on MBSR manuals with a brief CRF education component incorporated into the first and second class sessions, drawing from information from the National Comprehensive Cancer Network clinical practice guidelines for CRF. In general, the MBSR class includes guided meditation practice; mindful, gentle movement (hatha yoga); didactic material on self-regulatory responses to stress; and group discussion that includes the participants' growing incorporation of mindfulness in adapting to life experiences. Along with class time, each participant is asked to commit 20 minutes per day, six days per week to formal meditation practice using compact disk recordings of the teacher's voice.
3310093|NCT01919853|Active Comparator|Attention Control|"The attention control is an 8-week class meeting 2 hours weekly. The group sessions are supportive in tone, focus on pre-designated topics relevant to fatigue management (e.g., sleep hygiene, nutrition, exercise, emotional regulation), and involve weekly readings and open group discussion about session topics. This condition contains non-specific factors similar to MBSR (e.g., facilitator offering participants compassionate attention, empathy, genuine caring, and an opportunity to discuss what is important to them in a supportive environment); however, mindfulness is not presented/practiced in the group."
3310094|NCT01919866|Experimental|Transplantation of CD3/CD19 depleted stem cells|Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW
3310095|NCT01919879|Experimental|Arm A: Cetuximab + Afatinib|Afatinib 40 mg daily Cetuximab 500 mg/m2 every 2 weeks until progression
3310096|NCT01919879|Active Comparator|Arm B : Cetuximab alone|Cetuximab 500mg/m2 every 2 weeks until progression After progression: Cetuximab 500mg/m2 + Afatinib 40 mg per day until progression
3310097|NCT01919892|Experimental|Lithium 450-900mg/day|An Open-Label, 6-week Pilot Study of Flexible Dose of Lithium in Bipolar Depression: The Effectiveness of Lower Lithium Levels
3310098|NCT01919905|Active Comparator|High dose|High dose vitamin D group receiving Mozzarella cheese/pizza with 28000 IU vitD/serving once a week
3310099|NCT01919905|Placebo Comparator|Low dose|Low dose vitamin D group receiving Mozzarella cheese/pizza with 200 IU vitD/serving once a week
3310100|NCT01919918|Other|Heart Failure Patients|Patients with heart failure will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
3310101|NCT01919918|Other|Control Participants|Healthy control participants will undergo intervention of muscle contraction with metabolite solution administration. Maximal voluntary muscle contraction exercise with varying metabolite solution administration of adenosine triphosphate, lactate, and protons with phosphate buffer.
3310102|NCT01919931||Candida Infection|Patients infected with Candida albicans
3310103|NCT01919931||No infection|Patients with no Candida albicans infection
3310104|NCT01919944|Experimental|VLY-686 20 mg|Single dose, 20 mg VLY-686, administered as two 10 mg VLY-686 oral capsules
3310105|NCT01919944|Experimental|VLY-686 50 mg|Single dose, 50 mg VLY-686, administered as one 50 mg VLY-686 oral capsule and one placebo capsule mimicking the VLY-686 50 mg capsule
3310106|NCT01919944|Experimental|VLY-686 100 mg|Single dose, 100 mg VLY-686, administered as two 50 mg VLY-686 oral capsules
3310107|NCT01919944|Placebo Comparator|Placebo|Single dose, placebo, administered as either two 10 mg oral capsules or two 50 mg oral capsules
3310108|NCT01919957|No Intervention|memory outcome|
3310109|NCT01919983||Primary Prevention of Sudden Cardiac Death|No intervention will be administered. This is an observational study testing the association of inflammation and cardiac sympathetic innervation using I-123-MIBG gamma scintigraphy
3310110|NCT01920009|Active Comparator|Pharmacy care group|patients in this group will receive two counseling sessions with a motivational interview.
3310111|NCT01920009|No Intervention|Controlgroup|patients in this group will receive usual care by pharmacists
3310112|NCT01920022|Experimental|Etonorgestrel and mifepristone|Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
3310113|NCT01920022|Active Comparator|mifepristone|Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion
3310114|NCT01920035|Experimental|Local cooling/hypothermia|These patients will have the UroCool device inserted prior to RARP to induce localized cooling/hypothermia of the pelvic region prior to and during RARP surgery.
3310115|NCT01920035|No Intervention|Control Group: RARP without hypothermia|These patients will receive standard of care only for RARP surgery. They will not receive the UroCool investigational device.
3310116|NCT01920048|Experimental|Percutaneous Coronary Intervention and Optimal Medical Therapy|
3310117|NCT01920048|Active Comparator|Optimal Medical Therapy alone|
3310118|NCT01920074|Experimental|Rectiv|
3310119|NCT01920087|Experimental|ATNC05|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
3310120|NCT01920087|Placebo Comparator|Placebo|Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.
3310121|NCT01920100||Memory clinic|People visiting a memory clinic at Ullevål University Hospital, St Olav Hospital or Innlandet Hospital Trust (n=400). The patients will be assessed three times over a three-year follow-up. Baseline inclusion started in January 2010. The final assessments will take place in spring 2014.
3310122|NCT01920100||Nursing homes|People admitted to a nursing home recruited from municipalities in Hedmark, Oppland, Nord-Trøndelag and Bergen (n=1000). Baseline assessments take place when the person is admitted to the nursing home. The patients will be assessed every six months over a three-year follow-up period. The first participant was included in March 2012, and baseline inclusion will be completed in December 2013.
3310123|NCT01920100||In-home care|People 70 years of age or older receiving in-home care recruited from municipalities in Hedmark, Oppland, Oslo, Østfold and Buskerud (n=995). The patients will be assessed three times over a three-year follow-up period. Baseline inclusion started in April 2009 and the final assessments will take place in December 2013.
3310124|NCT01920100||People without dementia|"People without dementia recruited from Nord-Trøndelag, Drammen and Oslo (n=400).~The participants will be assessed three times over a three-year follow-up period. Baseline inclusion will take place in autumn 2012 and the last follow-up will take place in autumn 2015."
3310125|NCT01920113|Experimental|DR group|In Group DR, a bolus dose of 0.5mcg/kg dexmedetomidine was injected intravenously 5 minutes before the start of the procedure (Precedex®, Abbott, Istanbul, Turkey). And a continuous infusion dose of 0.3-0.7mcg/hr/kg was started.
3310126|NCT01920113|Active Comparator|PR group|In Group PR, a bolus injection of 1 mg/kg of propofol was followed by a continuous infusion at a rate of 3-5mg/hr/kg(Pofol®, Dongkook Pharm. Co. Ltd., Seoul, Korea) using an infusion pump (Syringe Pump TE-331, Terumo Japan).
3310127|NCT01920126|Experimental|Sodium bicarbonate group|Sodium bicarbonate group
3310128|NCT01920126|Placebo Comparator|Saline group|Saline group
3310129|NCT01920139|Other|Breast cancer and Axillary Adenopathy|Women with breast cancer with abnormal appearing ipsilateral axillary nodes undergoing fine needle aspiration and core biopsy of a lymph node.
3310130|NCT01920165||Full cohort|The population at risk for each time point is the number of children living in England aged 0-14 year
3310131|NCT01920191|Experimental|IMA 950 and Poly ICLC|
3310132|NCT01920204|Experimental|Midostaurin|Treatment with Midostaurin, twice daily 100 mg orally for 6 months continuously.
3310133|NCT01920217||normal control|
3310134|NCT01920217||Sepsis group|
3310135|NCT01920230|Experimental|Mindfulness-ACT-intervention|Group meetings face-to-face and web-based program using principles of mindfulness and ACT.
3310136|NCT01920230|Experimental|Control|Control group, no intervention.
3310137|NCT01920243|Experimental|Health Mechanics- New Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals with new-onset traumatic spinal cord injuries are eligible for this group.
3310138|NCT01920243|No Intervention|Usual Care- New Injuries|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with new-onset traumatic spinal cord injuries.
3310139|NCT01920243|Experimental|Health Mechanics- Chronic Injuries|The Health Mechanics Program group receives the intervention. For this study, the Health Mechanics protocol is being applied to two areas of SCI management, bladder and bowel management, and administered over the telephone. The intervention will be administered as a series of modules delivered by a Health Coach (a health professional who works within the study team and is knowledgeable about SCI management). Individuals who have had traumatic spinal cord injuries for at least one year are eligible for this group.
3310140|NCT01920243|No Intervention|Usual Care- Chronics|This group will not receive the intervention. They will receive usual care. This group will be comprised of individuals with who have had traumatic spinal cord injuries for at least one year.
3310141|NCT01920256|Experimental|Personalized type 2 diabetes care.|Remote, personalized type 2 diabetes clinic provided by an endocrinologist using frequent remote contacts for medication adjustments.
3310142|NCT01920256|Active Comparator|Usual Endocrine Care|Usual Endocrine care will be provided by an endocrinologist.
3310143|NCT01920269|Active Comparator|Transurethral resection alone|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra-ie, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3310144|NCT01920269|Active Comparator|Intravesical passive diffusion mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin treatments. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy, biopsy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3310145|NCT01920269|Active Comparator|Intravesical electromotive mitomycin|Patients underwent urinary cytology, random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples. Patients are scheduled to receive an initial 6 intravesical mitomycin treatments at weekly intervals commencing 2 weeks after endoscopic procedures. Patients are placed on fluid restriction and oral sodium bicarbonate before intravesical mitomycin. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations. Response to treatment will be assessed with cystoscopy and urinary cytology at 3-month intervals for 2 years, 6-month intervals for 3 years and yearly thereafter.
3310146|NCT01920295|Experimental|Cryoballoon ablation|Cryoballoon ablation
3310147|NCT01920295|Active Comparator|Cryoballoon after medical therapy|Cryoballoon ablation
3310148|NCT01920295|Experimental|Cryoballoon as first-line therapy|Cryoballoon ablation
3310149|NCT01920295|Active Comparator|Cryoballoon after failed drug therapy|Cryoballoon ablation
3310150|NCT01920308||5 mm Bard LifeStent Vascular Stent|"The study population will be comprised of subjects who present with moderate lifestyle-limiting claudication to mild tissue loss (Rutherford Category 2-5) that are candidates for PTA and stenting.~Subjects with lesion(s) in the infra-inguinal segment (SFA and/or popliteal artery) will be considered for enrollment. The reference vessel diameter will be appropriate for treatment with available stent diameter of 5.0 mm (by visual estimate)."
3310151|NCT01920321|Experimental|Endoscopic lung volume reduction|After usual sedation, bronchoscope is introduce to the lung and palced in segmental wedge position then hot salineis instilled. Same procedure to others affected segments.
3310152|NCT01920334|Experimental|Zolpidem CR 12.5mg|Patients receive zolpidem CR 12.5mg at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
3310153|NCT01920334|Placebo Comparator|Placebo|Patients receive placebo at bedtime from the first night on the Cardiac Intensive Care Unit until their discharge from the hospital
3310154|NCT01920347||Neurological Pupil index|The NPi will be measured during treatment
3310155|NCT01920360|Experimental|SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
3310156|NCT01920360|Experimental|NOT SULPHUROUS WATERS IMMERSION BATHS|The baths will be held in individual tubs, properly disinfected, supplied with not sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
3310157|NCT01920360|Experimental|CONTROL GROUP|This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
3310158|NCT01920373|Active Comparator|Group A (corticosteroid injection group)|Group A will receive one intra-articular injection of 2 ml of solution containing 1ml of 10mg/ml Triamcinolone suspended in 1 ml of 0.5% Bupivacaine solution per affected joint
3310159|NCT01920373|Experimental|Group B (platelet rich plasma injection)|Group B will receive a 2 ml intra-articular injection of a platelet rich plasma preparation per affected joint
3310160|NCT01920386|Active Comparator|Tramadol hydrochloride/Acetaminophen Tab.|1tab PO within 5hours from teeth extraction
3310161|NCT01920386|Experimental|Tramadol hydrochloride/Acetaminophen SR Tab.|1tab PO within 5hours from teeth extraction and then 1tab more after 6hours
3310162|NCT01920399|Placebo Comparator|Placebo|IV infusions of 0.9% normal saline
3310163|NCT01920399|Experimental|CAZ-AVI|IV infusion of AVI 500 mg + CAZ 2000 mg.
3310164|NCT01920412|Experimental|Left Atrial Appendage Occluder|Adopted non-comparative arm on Left Atrial Appendage Occluder.
3310165|NCT01920425|Other|Hand-written diary first|Participants in this group will use the hand-written diary for the first two week and switch to Kinesia HomeView and the electronic diary for the second two weeks.
3310166|NCT01920425|Other|Kinesia HomeView first|Participants in this group will use Kinesia HomeView and the electronic diary for the first two week and switch to the hand-written diary for the second two weeks.
3310167|NCT01920438|Experimental|PEG|Percutaneous Endoscopic Gastrostomy
3310168|NCT01920438|Experimental|RIG|Radiologically-guided Insertion of Gastrostomy
3310169|NCT01920451|Experimental|Cognitive-Behavioral Therapy for Insomnia|Cognitive-Behavioral Therapy for Insomnia (CBTI) consists of an an individually-tailored sleep prescription intended to consolidate fragmented sleep; guidance on changing learned associations that are harmful to sleep using stimulus control theory; education on standard sleep hygiene and to correct unrealistic sleep expectations; and the identification and restructuring of maladaptive thoughts and beliefs about sleep.
3310170|NCT01920451|No Intervention|Wait List|Study participants who are randomized to the wait-list condition will not receive the intervention as part of this study protocol. They will, however, be offered the opportunity to receive CBTI at the end of their participation in this study. Wait-list participants will not be restricted in terms of additional therapies/treatments which they may seek for their sleep complaint.
3310171|NCT01920490|Experimental|GUILT-INCREASE-CORRELATION|Patients in this group will receive visual feedback that reinforces increasing the correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will reinforce stabilization of the preceding degree of correlation.
3310172|NCT01920490|Active Comparator|GUILT-STABILIZE-CORRELATION|Patients in this group will receive visual feedback that reinforces stabilization of the preceding degree of correlation in fMRI signal between the right superior anterior temporal and septal-subgenual regions during the retrieval of predefined guilt-related autobiographical episodes. During the indignation condition, visual feedback will also reinforce stabilization of the preceding degree of correlation.
3310173|NCT01920503||doxorubicin|"Day +1:~Lobar Infusion ( lobe with dominant disease) of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres.~Second lobar infusion of Doxorubicin preloaded into 2 ml of 70-150 µm M1 microspheres can be administered at the same time contralaterally or in a further TACE Day +30: The above procedure is repeated. Day +90: In case of response, a third administration following the above procedures will be repeated"
3310174|NCT01920516||Melphalan|"Day +1:~Intra femoral infusion of Melphalan at the dosage 1mg/ Kg~Intra femoral infusion of Melphalan Second ILI treatment can be repeated at side effects recovery ( following oncologist ' s planning of cure).~Day +30: The above procedure is repeated.~Day +90: In case of response, a third administration following the above procedures will be repeated."
3310175|NCT01920529|Experimental|aerobic exercise|The study will consist of two groups: Group Comparison (GC) will be submitted to two evaluations at the beginning of a week and end of 6 weeks, without receiving any kind of physical training intervention. Group Training (GT) will undergo two assessments at the beginning of the end of the 1st and 6th week, however will be submitted to aerobic training for six weeks. Supervised aerobic training will be held three times a week for six weeks,treadmill in four consecutive steps each (05 minutes stretching, 05 minutes heating, 20 training minutes (1 st and 2 nd week) and 30 minutes (3 rd to 6 weeks) and cool down 05 minutes). The exercise intensity will be maintained through a desired percentage of heart rate for training (x%) from 70% to 80%, obtaining then the optimal heart rate training.
3310176|NCT01920529|Placebo Comparator|control|Investigators evaluated the distance walked during the 6-minute walk test and recorded variables such as heart rate, respiratory frequency, pulse oxygen saturation and a scale of perceived exertion (Borg) in the moments before and after the test. There was only evaluation without intervention.
3310177|NCT01920542|Experimental|no dexmedetomidine|no administration of dexmedetomidine
3310178|NCT01920542|Active Comparator|dexmedetomidine|administration of 0.5ug/kg dexmedetomidine for 10 min and infusion of 0.5ug/kg/h of dexmedetomidine until weaning of cardiopulmonary bypass
3310179|NCT01920581||volunteers|
3310180|NCT01920607|Active Comparator|NMS|Implantation under general of local anesthesia of sacral nerve stimulation system (Interstim Therapy)
3381453|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Bevacizumab|"Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria."
3381454|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin|Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381455|NCT03337698|Experimental|Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin|Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381456|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + RO6958688|Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381457|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Docetaxel|"Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.~Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2."
3381458|NCT03337698|Experimental|Stage 2: Cohort 2: Atezolizumab + Linagliptin|Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381459|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan|Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381460|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + bevacizumab + Radiotherapy|Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
3381461|NCT03337698|Experimental|Stage 1: Cohort 2: Atezolizumab + Evolocumab|Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
3381462|NCT03336203|Active Comparator|Hyperurecemia with gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) with gout (EULAR's criteria) are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
3381463|NCT03336203|Active Comparator|Hyperurecemia without gout|90 patients with high SUA level (>8 mg/dL; 480 µmol/L) withot gout (EULAR's criteria) but with CKD are going to be treated with allopurinol 300 mg oral tab or febuxostat 80 vg oral tab to achive target SUA levels as 5 mg/dL (300 µmol/L) and ultralow SUA <3 mg/dL (180 µmol/L)
3381464|NCT03327649|Sham Comparator|Sham control|Patients will receive 1 hour of sham transcutaneous low level vagal stimulation daily for 3 months
3381465|NCT03327649|Experimental|Active treatment|Patients will receive 1 hour of active transcutaneous low level vagal stimulation daily for 3 months
3310181|NCT01920607|Experimental|SAM|Implantation under general anesthesia of magnetic anal sphincter (Fenix)
3381469|NCT03300817|Experimental|Prevention (MUC1 peptide-Poly-ICLC vaccine)|Patients receive MUC1 peptide-Poly-ICLC vaccine SC at weeks 0, 2, and 10.
3381470|NCT03298178||all aortic stenosis|
3381471|NCT03296033|Active Comparator|24 Hours group|Group one will be instructed to administer their last dose of enoxaparin at 07:00 in the morning on the day prior to their scheduled surgery date. This will mean that patients who have their surgery scheduled for 07:00 the following day will be 24-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, however this is currently considered normal clinical practice.
3310182|NCT01920620|Experimental|Intervention Arm|Inpatient weight loss counseling Motivational interviewing and troubleshooting via phone
3310183|NCT01920620|No Intervention|Usual Care Arm|Participants in the usual care group were not provided with any specific instructions regarding weight loss, diet or exercise prior to discharge. Follow-up phone calls for usual care subject were used only to obtain weight and assess for changes in medications or health condition.
3310184|NCT01920633||People with Down syndrome|
3310185|NCT01920646|Experimental|ALV|"300 gram cooked African leafy vegetables and school meal starch as daily school meal (5 days/weeks) for 3 months.~Selected African leafy vegetables:Amaranthus cruentus (amaranth), Vigna unguiculata (cowpea), Cleome gynandra (spiderplant), and Cucurbita maxima (pumpkin)."
3310186|NCT01920646|No Intervention|Control|normal school meal as daily meal (5 days/weeks) for 3 months
3310187|NCT01920659|Experimental|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
3310188|NCT01920659|Experimental|REHIT|6 weeks of HIT, 3 times a week (20sec)
3310189|NCT01920659|No Intervention|control|control
3310190|NCT01920672|Experimental|Timed Planned Activity (TPA)|The TPA provides meaningful activities delivered at specific times in the daily diurnal cycle; it is theory-based, its components have been tested in pilot work; and it is portable and replicable (e..g, protocols are standardized). It involves involved 8 contacts (6 home visits and 2 phone calls) over 4 days. At baseline the CG completes the Pleasant Event Activity Survey. From the survey a careplan of meaningful activities are developed for the CG to administer. The suggested activities match the capabilities of an individual with moderate stage AD ie., based on repetitive motion (e.g., folding towels) and integrating multi-sensory stimulation (e.g., soft music, objects pleasant to touch). CG are instructed to introduce these activities during the late morning and early evening.
3310191|NCT01920672|Active Comparator|Home Safety and Education Program|The active comparator intervention will be delivered by interventionists who will provide social attention, empathy and engagement similar to that afforded to the experimental group. The length of time spent will be comparable to the length of time spent in the treatment arm. The attention-control group will involve 6 in-home visits in the afternoon and 2 brief telephone education sessions in the morning. Control group subjects will be provided a copy of Mace and Rabins, The 36-Hour Day, a well-known practical guidebook for families caring for AD patients. Each contact will provide helpful education based on a specific book chapter including information about home safety, health promotion, and advanced care planning
3310192|NCT01920685|Experimental|Immediate therapy|6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered for a period of 8 weeks immediately after randomisation.
3310193|NCT01920685|Other|Delayed intervention|Therapy will be delayed until 12 weeks following randomisation, and then 6 sessions of talking therapy, targeting anxiety processes associated with paranoia, will be delivered over a period of 8 weeks.
3310194|NCT01920698|Experimental|MitraClip Device|Subjects randomized to the MitraClip Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
3310195|NCT01920698|Other|Control|Patients randomized to the Control group will receive optimal therapy alone
3310196|NCT01920724||wasting, obesity, stunting, normal|wasting (BMI for age Z-scores < -2 SD), normal (-1 SD ≤ BMI for age Z-scores ≤ +1 SD), obesity (BMI for age Z-scores > +2 SD), and stunting (HAZ < -2 SD).
3310197|NCT01920737|Experimental|Leukemia Patients|"The treatment plan has 6 treatment cycles. The cycle names are listed in the following order:~Induction Phase I - Induction Phase II - Intensification I - Re-induction I - Intensification II - Re-induction II Each cycle is given over a period of 4-6 weeks and the interval between them can range between 1-3 weeks. Based the patients medical condition, the doctor may decide to change the timing of the drugs, the interval between the drugs in a cycle, or the interval between the cycles. After receiving all cycles you will continue with a 36 months treatment part that is called Maintenance."
3310198|NCT01920750|Experimental|Group 2|5 subjects will receive d single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLCwA and one of mock antigen equally in two arms
3310199|NCT01920750|Experimental|Group 1|5 subjects received single 0.1 ml intracutaneous injections of 3 titrated doses (1, 10, and 25 grams/ml) of MLSA-LAM and one of mock antigen equally in two arms
3310200|NCT01920763||Surgical Patients|Patients with intracerebral hemorrhage who have been offered a parafascicular, minimally-invasive procedure for hematoma drainage, by the treating neurosurgeon.
3310201|NCT01920776|Experimental|Rutine treatment group, Ultrasound group|
3310202|NCT01920789|Experimental|Stereotactic radiotherapy|Arm A: Stereotactic radiotherapy to a dose of 66 Gy at the isocenter with 22 Gy per fraction in 3 fractions during one week with body frame fixation and a planning target volume with a 5 mm margin around the macroscopic tumour. A heterogeneous dose distribution is used so 45 Gy will cover the PTV.
3310203|NCT01920789|Active Comparator|Conventionally fractionated radiotherapy|Arm B: Conventionally fractionated radiotherapy to a dose of 70 Gy with 2 Gy per fraction in 35 fractions during 7 weeks with fixation in a vacuum pillow and a planning target volume with a 2 cm margin around the macroscopic tumour.
3310204|NCT01920815||Beta blocker therapy|Cohort will consist of those actively taking any beta blocker medication. Observation only.
3310205|NCT01920815||ARB therapy|Cohort will consist of those actively taking any angiotensin receptor blocker medication. Observation only.
3310206|NCT01920815||No therapy|Cohort will consist of those not taking either beta blocker nor angiotensin receptor blocker. Observation only.
3310207|NCT01920841|Experimental|Left (A), Right (B)|Cream A applied to left thigh and Cream B to right thigh
3310208|NCT01920841|Experimental|Left (B) Right (A)|Cream B applied to left thigh and Cream A to right thigh
3310209|NCT01920867|Active Comparator|RB, ST, IV|Injections of BMSC retrobulbar (RB), subtenon (ST) and intravenous (IV)
3310210|NCT01920867|Active Comparator|RB, ST, IV, IVIT|Injections of BMSC retrobulbar, subtenon, intravenous and intravitreal ( IVIT )
3310211|NCT01920867|Active Comparator|RB, ST, IV, IO|Injection of BMSC retrobulbar, subtenon, intravenous and intraocular (IO) with vitrectomy
3310212|NCT01920880||ACNES patients|Patients being treated in past for anterior cutaneous nerve entrapment syndrome
3310213|NCT01920880||Healthy controls|Healthy controls
3310214|NCT01920906|Experimental|Biopsy and blood tests|All subjects will undergo a skin biopsy and blood tests
3310215|NCT01920919|Experimental|Dexamethasone 1 mg|Dexamethasone 1 mg per day, for 180 days
3310216|NCT01920919|Placebo Comparator|Placebo|Placebo tablet, for 180 days
3310217|NCT01920932|Experimental|Treatment|Participants receive AEPA regimen (brentuximab vedotin, etoposide, prednisone, doxorubicin), and CAPDac regimen (cyclophosphamide, brentuximab vedotin, prednisone, dacarbazine(R)). Filgrastim may be given as clinically indicated. For those with lymph nodes that do not go into remission after 2 courses of AEPA chemotherapy, radiation therapy will be given. Some participants may volunteer to complete the quality of life assessment.
3310218|NCT01920945|Experimental|OnabotulinumtoxinA|
3310219|NCT01920971|Active Comparator|inferared therapy|hot pack therapy combined active infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
3310220|NCT01920971|Placebo Comparator|placebo infrared therapy|hot pack therapy combined placebo infrared therapy over the low back (wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2) followed by 20-min supervised therapeutic exercise, for 3 times per week for a 4-week duration. Patients will be assessed at before treatment and follow-up assessments, including after 2 week of treatment; after 4 weeks of treatment; and 1 and 3 months, respectively, after treatment is terminated.
3310221|NCT01920984|Experimental|pretreatment of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy due to diabetic retinopathy.
3310222|NCT01920984|No Intervention|No pretreatment of bevacizumab|Patients will not receive bevacizumab pretreatment before vitreous surgery.
3310223|NCT01920997||No drug intervention|The objective of this study is to investigate the expression of NEI network and urine metabolomics of healthy women with normal menstrual cycles.
3310224|NCT01921010|Active Comparator|Niaspan|Patients will be randomized to Niaspan 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of Niaspan will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
3310225|NCT01921010|Placebo Comparator|Control|patients will be randomized to placebo 1.5 g/d in addition to usual care statin lipid lowering agents. The dose of placebo will be titrated over a 4-week period and then patients will remain on study drug for additional 12 weeks. The dose of statin will be adjusted in a blinded fashion in both groups at week 10 to similarly achieve a LDL-C of less than 100mg/dl.
3310226|NCT01921036|Experimental|combined exercise|90 minutes combined endurance and resistance exercise once a week plus 90 minutes traditional cardiac rehabilitation once a week over six months
3310227|NCT01921036|Active Comparator|traditional cardiac rehabilitation|The group-based program is offered for 90 minutes twice a week and is a combination of gymnastics, coordination and flexibility exercises, and includes educational components targeting diet and nutrition, stress and relaxation, methods for coping with CVD and behavioral and lifestyle change.
3310228|NCT01921062|No Intervention|Control|Patients allocated to the control group only receive standard treatment.
3310229|NCT01921062|Experimental|Motor imagery|Patients allocated to this arm perform kinesthetic motor imagery during the immobilisation period.
3310230|NCT01921075||Volunteers|young (age<30), healthy, lean (BMI<25) volunteers
3310231|NCT01921088|Experimental|Contingent|Contingent RT-fMRI-NF of brain activity in the target region of interest
3310232|NCT01921088|Sham Comparator|Non-contingent|Sham RT-fMRI-NF of brain activity of previously recorded subject
3310233|NCT01921127||Symbicort|BFC patients new to ICS/LABA therapies
3310234|NCT01921127||Advair|FSC patients new to ICS/LABA therapies.
3310235|NCT01921153|Experimental|Short Intervention|All participants will be measured for (1) baseline, (2) two-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
3310236|NCT01921153|Experimental|Long Intervention|All participants will be measured for (1) baseline, (2) four-week environmental intervention: Healthy meal plates and trays, and (3) withdraw of intervention.
3310237|NCT01921192|Active Comparator|Folic Acid, vit B6 and B12|
3310238|NCT01921192|Placebo Comparator|Sugar pill|
3310239|NCT01921218|Experimental|Treatment|Belatacept (Nulojix) IV
3310240|NCT01921218|Active Comparator|Control|Calcineurin inhibitor based therapy (cyclosporine or tacrolimus)
3310241|NCT01921231|Experimental|Hyperbaric prilocaine 1%|Solution for injection. Intradural use. In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%). Administer 3 mL of syringe contains in two minutes.
3310242|NCT01921231|Active Comparator|Hyperbaric Bupivacaine 0.5%|Solution for injection. Intradural use. Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
3310243|NCT01921244|No Intervention|Usual Care|"Approximately 120 families will be asked to participate as usual care subjects and will complete surveys before and immediately after their visit, and approximately 3 months after the visit. These families will not receive the decision aid nor will their provider have been trained how to use the decision aid. All participating providers will have up to 10 usual care patients enrolled at baseline prior to allocation. During the trial, the control group [usual care providers] will have up to 10 additional patients enrolled for ongoing usual care data collection. After the trial is complete, the control group providers will cross over to the intervention arm."
3310244|NCT01921244|Experimental|Intervention|Approximately 80 families/patients with regularly scheduled clinic follow-up visits in the Division of Developmental and Behavioral Pediatrics (DDBP) at Cincinnati Childrens with providers trained on shared decision making will receive the decision aid prior to their index visit and complete surveys before and immediately after their visit, and approximately 3 months later.
3310245|NCT01921283|Experimental|BIS group|The BIS group (n=90) was monitored for sedation depth using BIS during ESD.
3310246|NCT01921283|Active Comparator|No-BIS group|The no-BIS group (n=90) was monitored by observer's assessment alertness/sedation scale (OAA/S).
3310247|NCT01921309|Experimental|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head and ceramic acetabular cup liner
3310248|NCT01921309|Active Comparator|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head and polyethylene acetabular cup liner
3310251|NCT01921361|Active Comparator|Intravenous|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous dexmedetomidine (dexmedetomidine diluted 1mcg/ml and than 1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
3381472|NCT03296033|Experimental|36 Hours Group|Group 2 will be instructed to administer their last dose of enoxaparin at 19:00 in the evening two days prior to their scheduled surgery date. Patients presenting for surgery at 07:00 two days later will be 36-hours removed from their last dose. Patients presenting for surgery later in the day would be slightly farther removed from their last dose, but again this mimics normal clinical practice in which the timing of the last dose of self-administered enoxaparin is not routinely adjusted based on the scheduled surgical start time.
3310252|NCT01921361|Active Comparator|Intrathecal|Intrathecal (3 ml) 15 mg levobupivacaine + (0.3 ml) 3 mcg dexmedetomidine (dexmedetomidine diluted 10 mcg/ml) and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion)
3310253|NCT01921361|Placebo Comparator|Control|Intrathecal (3 ml) 15 mg levobupivacaine + 0.3 ml 0.9% Sodium chloride and intravenous 0.9% Sodium chloride (1ml/kg/10 minutes and 0.5 ml/kg/hour infusion).
3381475|NCT03269032|Experimental|Phase 1 Healthy Volunteers|Healthy volunteers will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks.
3381476|NCT03269032|Experimental|Phase 2 IBS Patients|Participants with IBS will eat a typical American diet for 2 weeks and then eat a Mediterranean-style diet for 2 weeks
3381477|NCT03267758|Experimental|Goodbelly First|Subjects in this arm will consume 1 serving of lactobacillus plantarum 299v daily for first 6 weeks.
3381478|NCT03267758|Placebo Comparator|Placebo|Subjects in this arm will consume 1 serving of heat-killed placebo daily for first 6 weeks.
3381479|NCT03258658|Experimental|Autologous Engineered Urethral Construct|All subjects enrolled will undergo a full-thickness bladder biopsy as an out-patient surgical procedure. Urothelial and Smooth Muscle Cells recovered from the biopsy will be isolated and expanded over the next 4-6 weeks, and then seeded onto a tubular scaffold to create the autologous engineered urethral construct. Subjects will undergo a second surgical procedure to excise the urethral stricture and implant the urethral construct. All subjects will be followed for 3 years for safety and efficacy.
3310254|NCT01921374|Experimental|sleep parameters|To assess the sleep parameters.
3310255|NCT01921374|Other|cardiovascular parameters|To assess the cardiovascular profile of control mothers and caregivers-mothers.
3381480|NCT03250663|Active Comparator|Arm 1 - Standard of Care|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and follow standard of care
3381481|NCT03250663|Experimental|Arm 2 - Online Treatment Response|Subjects receive study medication, EUCRISA (crisaborole) ointment 2%, and electronic treatment response emails
3381482|NCT03237286|Experimental|Ketamine + Cognitive Training|
3310256|NCT01921374|Experimental|imflammatory and immunological profile|To assess the inflammatory profile of caregivers-mothers and control mothers
3310257|NCT01921374|Experimental|hormonal profile|To assess the hormonal profile of caregivers-mothers and control mothers.
3381483|NCT03237286|Sham Comparator|Ketamine + Sham Training|
3381484|NCT03237286|Placebo Comparator|Saline + Cognitive Training|
3310258|NCT01921374|Experimental|metabolic profile|To assess the health profile of caregivers-mothers and control mothers.
3310259|NCT01921400||HCV-infected mothers|in situ hybridization
3310260|NCT01921400||Uninfected mothers|in situ hybridization
3310261|NCT01921426|Experimental|GC4419|Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
3381485|NCT03226808|Other|Vivacit-E Liner|All subjects enrolled receive the study implant.
3381487|NCT03216122|Active Comparator|Control group (CG)|The implant will be loaded after 3-4 months of placement (Conventional/Delayed Loading)
3381488|NCT03216122|Active Comparator|Test group (TG)|The implant will be loaded non-occlusally within 3-4 days of placement (Immediate Loading)
3381489|NCT03212170|Experimental|FFNP PET/MRI|18F-Fluorofuranylnorprogesterone (FFNP) administration for PET/MRI imaging to assess biopsy-proven primary PR+ breast malignancies.
3381490|NCT03205137||Telmisartan and hydrochlorothiazide group|
3381491|NCT03205137||Telmisartan and amlodipine group|
3381492|NCT03205137||Telmisartan+hydrochlorothiazide double-pill combination group|
3381493|NCT03205137||telmisartan+amlodipine double-pill combination group|
3381494|NCT03201640|Other|slideshow|Participant receives traditional slideshow presentation for preoperative preparation
3310262|NCT01921439|Active Comparator|Feedback|Participants in this group will receive individualized feedback based on their stage of change. Feedback will include health effects of smoking, money spent per month and per year on cigarettes, time spent smoking compared with time spent doing other daily tasks, and how the participant compares to past study participants in average number of cigarettes per day used and level of addiction.
3310263|NCT01921439|No Intervention|No Feedback- Treatment as Usual (TAU)|Participants will take the computer based survey, but will only receive a number to the Oklahoma Tobacco Helpline (Treatment-as-usual condition) instead of feedback.
3381495|NCT03201640|Other|virtual|Participant receives virtual reality presentation for preoperative preparation
3310264|NCT01921465||multiparas having a planned cesarean section|elective cesarean section
3310265|NCT01921478||Cohort|
3310266|NCT01921491|Other|Standard of Care|Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient. Patient will practice Offloading. Reassessment weekly at office visit.
3310267|NCT01921491|Active Comparator|Other Commercially Available Product|Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
3310268|NCT01921491|Experimental|dHACM|Application of dHACM with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
3310269|NCT01921504|Experimental|Acupuncture|Participants in this group are given twice-a-week acupuncture treatment for 4 weeks.
3310270|NCT01921504|No Intervention|No treatment|The participants in this group are supposed to wait without any intervention for first 4 weeks. Then they receive the identical acupuncture treatments as in the treatment group for the following 4 weeks.
3310271|NCT01921530|Active Comparator|Interbody Fusion|
3310272|NCT01921530|Active Comparator|Posterolateral Fusion|
3310273|NCT01921543|Experimental|CI/BNST stimulation on|
3310274|NCT01921543|Experimental|CI/BNST vs stimulation off|randomized, double blind, 1 week crossover
3310275|NCT01921543|Experimental|ITP stimulation on|
3310276|NCT01921543|Experimental|CI/BNST vs ITP vs stimulation off|randomized, double blind, two month crossover
3310277|NCT01921556|Active Comparator|QualiCCare education|"QualiCCareeducation is a training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
3310278|NCT01921556|No Intervention|usual care|The practices randomized to the control group apply care as usual
3310279|NCT01921569|Experimental|dHACM|Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
3310280|NCT01921569|Placebo Comparator|Saline Injection|Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
3310281|NCT01921582|Experimental|Methylphenidate|"Methylphenidate (TEVA-METHYLPHENIDATE ER-C)~Dosage: 18 mg/day at Week 1; 36 mg/day at Week 2; 54 mg/day at Week 3; 72 mg/day at Week 4. Dosage levels may be maintained or decreased to manage medication side effects.~Dosage form: tablet~Dosage frequency: daily~Duration: 12 weeks total"
3310282|NCT01921582|Active Comparator|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy~12 individual 50-minute appointments over the course of up to 14 weeks~According to Fairburn, Marcus, and Wilson (1993)"
3310283|NCT01921595|Experimental|Valanced salt colloid group|
3310284|NCT01921595|Active Comparator|Valanced salt crystalloid group|
3310285|NCT01921608|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3310286|NCT01921621|No Intervention|Group A|Control: Group of Orthopedic Residents who receive arthroscopic surgery training at the Orthopedic Learning Center during a standard week-end Resident Arthroscopic Training Course
3310287|NCT01921621|Active Comparator|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
3310288|NCT01921621|Experimental|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
3310289|NCT01921647|Experimental|YH4808, amoxicillin, clarithromycin|single administration of YH4808 or amoxicillin or clarithromycin or YH4808 + amoxicillin + clarithromycin
3310290|NCT01921647|Experimental|YH4808, amoxicillin and clarithromycin|7 days repeat administration of YH4808, amoxicillin and clarithromycin for H.pylori eradication
3310291|NCT01921647|Experimental|YH4808 and amoxicillin|7 days repeat administration of YH4808 and amoxicillin for H.pylori eradication
3310292|NCT01921647|Active Comparator|nexium, amoxicillin and clarithromycin|BID, 7 days repeat administration of nexium, amoxicillin and clarithromycin for H.pylori eradication
3310293|NCT01921673|Experimental|Dovitinib plus docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
3310294|NCT01921686||Gastroesophageal Reflux Disease (GERD)|"History of troublesome symptoms (e.g. heartburn, chest pain, acid regurgitation) secondary to reflux of gastric contents at least three times per week~AND, At least one of the following:~Mucosal breaks on endoscopy (at least Grade-A esophagitis based on Los Angeles classification)~Abnormal pH index (pH less than 4 for greater than 6% of study)~Abnormal MII-pH (greater than 73 episodes of total reflux per 24 hours)"
3310295|NCT01921686||Eosinophilic Esophagitis (EoE)|"History of troublesome esophageal symptoms (e.g. dysphagia, food impaction, vomiting, upper abdominal or chest pain)~Greater than or equal to 15 eosinophils in at least one high powered field (HPF) from distal OR proximal esophageal biopsy~Lack of histological response to 6-8 weeks of high dose Proton Pump Inhibitor (PPI) OR negative pH probe (pH less than 4 for less than 6% of study). Subjects with greater than 15 eosinophils/HPF and abnormal pH results may have an overlap syndrome and will be excluded from the primary analysis."
3310296|NCT01921686||Control|Patients with no history of troublesome esophageal symptoms or esophageal disease AND normal esophagoscopy (for example, patients undergoing evaluation for chronic abdominal pain, inflammatory bowel disease, celiac disease).
3310297|NCT01921699|Other|irrelevant|
3310298|NCT01921712|Experimental|PUR0200 low dose|PUR0200 low dose, single dose inhalation
3310299|NCT01921712|Experimental|PUR0200 mid dose|PUR0200 mid dose, single dose inhalation
3310300|NCT01921712|Experimental|PUR0200 high dose|PUR0200 high dose, single dose inhalation
3310301|NCT01921712|Placebo Comparator|Placebo|PUR0200 matched placebo, single dose, inhalation
3310302|NCT01921712|Active Comparator|Active Comparator|Active Comparator, single dose, inhalation
3310303|NCT01921725|Experimental|Hydrophilic-based dressing (KoCarbonTM)|The wound is first cleansed with normal saline, and then applied with hydrophilic-based dressing (KoCarbonTM) and covered by sterile gauze. The frequency of dressing chang is depend on the amount of exudate.
3310304|NCT01921738|Experimental|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
3310305|NCT01921738|Experimental|Azithromycin capsule|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
3310306|NCT01921738|Placebo Comparator|Placebo Gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
3310307|NCT01921738|Placebo Comparator|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
3310308|NCT01921764|Experimental|Workplace physical exercise|Physical exercise (kettlebells, elastic bands, exercise balls) performed at the workplace with coaching
3310309|NCT01921764|Active Comparator|Home physical exercise|Physical exercise performed at home with elastic bands and bodyweight exercises with instruction to follow the exercises at http://www.jobogkrop.dk/Oevelser-til-nakke-og-ryg/Oevelser
3310310|NCT01921777|Experimental|Traumeel|Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets
3310311|NCT01921777|Placebo Comparator|Placebo|The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets
3310312|NCT01921790|Experimental|Avastin+ GemAOD|Avastin+ GemAOD means Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone
3310313|NCT01921803|Experimental|Arm 1|16 fractions à rato of 4 fractions a week over 4 weeks
3310314|NCT01921803|Experimental|Arm 2|25 fractions à rato of 5 fractions a week over 5 weeks
3310315|NCT01921816|Other|Prismocitrate 18/0|citrate-containing replacement solution (Prismocitrate 18/0, Gambro) will be administered at pre-filter port during continuous hemodiafiltration, for the purpose as replacement solution and anticoagulation
3310316|NCT01921842|Experimental|Nutrition and Physical Activity Training|NAP-SACC Child Care Wellness program administered in year 1 of study
3310317|NCT01921842|Other|Delayed Intervention Group|NAP-SACC Child Care Wellness Program is administered in year 2 of study.
3310318|NCT01921855|Experimental|BAY Factor VII (6.5 µg/kg) / Placebo|n = 4, randomized 3:1; 6.5 µg/kg BAY 86-6150 (B0189):Placebo
3310319|NCT01921855|Experimental|BAY Factor VII (20 µg/kg) / Placebo|n = 4, randomized 3:1; 20 µg/kg BAY 86-6150 (B0189):Placebo
3310320|NCT01921855|Experimental|BAY Factor VII (50 µg/kg) / Placebo|n = 4, randomized 3:1; 50 µg/kg BAY 86-6150 (B0189):Placebo
3310321|NCT01921855|Experimental|BAY Factor VII (90 µg/kg) / Placebo|n = 4, randomized 3:1; 90 µg/kg BAY 86-6150 (B0189):Placebo
3310322|NCT01921868|Experimental|Acetyl-L-Carnitine|Open-label administration of Acetyl-L-Carnitine, up to 2 g/day for 24 months.
3310323|NCT01921881|Experimental|St John's wort|"Subjects will undergo 3 oral glucose tolerance tests:~Without taking any St John's wort~After 3 weeks pretreatment with St John's wort~Minimum 6 weeks after last St John's wort ingestion"
3310324|NCT01921907|Experimental|Active|topical treatment
3310325|NCT01921907|Placebo Comparator|Placebo|topical treatment
3310326|NCT01921920|Active Comparator|Omeprazole 20mg aqueous|Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)
3310327|NCT01921920|Active Comparator|Omeprazole 20mg organic|Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)
3310328|NCT01921920|Active Comparator|Omeprazole 40mg aqueous|Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)
3310329|NCT01921920|Active Comparator|Omeprazole 40mg organic|Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)
3310330|NCT01921933|Experimental|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
3310331|NCT01921946|Other|Part A|Fimasartan (7 days) → Fimasartan + Rosuvastatin (7 days)
3310332|NCT01921946|Other|Part B|Rosuvastatin (7 days) → Fimasartan + Rosuvastatin (7 days)
3310333|NCT01921959||Partners of intervention women|Partners of women randomized to intervention
3310334|NCT01921959||Partners of no intervention women|Partners of women randomized to control
3310335|NCT01921972|Active Comparator|Galantamine and Placebo|Subjects in this group will receive 4 weeks of 8 mg/day galantamine CR, followed by 4 weeks of 16 mg/day and from week 9 up to the end of the trial of 24 mg/day.
3310336|NCT01921972|Experimental|Galantamine and Memantine|Galantamine titration will be performed as described above. Memantine titration will be performed over 4 weeks in steps of 5 mg/day up to 20mg/day (10 mg b.i.d.). 50 % of this group will receive galantamine first, 50 % of the group will receive memantine first to allow for differential qualitative evaluation of tolerability of a combination therapy.
3310337|NCT01921985|Active Comparator|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
3310338|NCT01921985|Placebo Comparator|NaCl|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
3310339|NCT01921998||Biomarker and health economics|Biomarkers will be taken throughout cycle 1. Health economics will be recorded using a patient side effect diary, a details of admission form, and a patient survey of healthcare use.
3310340|NCT01922063|Experimental|Physiotherapy Intervention|20 treatment sessions of a comprehensive physiotherapy program, 12 weeks' duration, with custom tailored instructions by the supervising physician; physicians discussed the course of therapy with the physiotherapist 1x/week. Patients had been treated by physiotherapist according to written prescriptions. Duration of treatment 30 min/ session. Patients were encouraged to practice regular home exercise.
3310341|NCT01922063|Sham Comparator|Sham neck massage|"received twenty sessions sham neck massage of 30 minutes' duration each with the patients lying in supine position on a massage bed and the head of the patient resting on the therapist's knees"
3310342|NCT01922063|No Intervention|No therapy|"no further therapy, patients were asked to wait and see for the first three months after operation, and no particular treatment was planned"
3310343|NCT01922128|Active Comparator|Drug, MC-1101|One eye drop of Active comparator, 0.5% MC-1101, 2 times per day, 28 days; followed by one drop of 1% MC-1101, 2 times per day, 28 days.
3310344|NCT01922128|Placebo Comparator|Placebo|One eye drop of Placebo comparator to MC-1101. Placebo contains all components of MC-1101 except for the active ingredient.
3310345|NCT01922141|Experimental|Aliskiren monotherapy|Aliskiren 150 mg, once a day, force titrated to Aliskiren 300 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3310346|NCT01922141|Experimental|Aliskiren dual therapy|Aliskiren 150 mg plus amlodipine 5 mg, once a day, force titrated to Aliskiren 300 mg plus amlodipine 5 mg after 8 weeks in 50% of patients. Optional titration of amlodipine 5 mg to 10 mg and optional addition/titration of hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3310347|NCT01922141|Active Comparator|Ramipril monotherapy|Ramipril 5 mg, once a day, force titrated to Ramipril 10 mg after 8 weeks in 50% of patients. Optional addition/titration of amlodipine 5 mg/10 mg and hydrochlorothiazide 12.5/25 mg based on systolic BP control in sequential steps
3310348|NCT01922154|Experimental|intravitreal ranibizumab|Ranibizumab was injected into vitreous cavity in the study eye once (0.5 mg/0.05 ml) at least 1 week before performing trabeculectomy with mitomycin C.
3310349|NCT01922167|Experimental|Leucine|2.5 g doses of leucine isolate three times per day (7.5 g total) of leucine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
3310350|NCT01922167|Placebo Comparator|Alanine|2.5 g doses of alanine isolate three times per day (7.5 g total) of alanine, taken by mouth in powder form mixed with liquid for 12 consecutive weeks.
3310351|NCT01922180||COPD Exacerbation|COPD patients aged 18 years or more, were included at the time of an exacerbation episode leading to admission in our hospital, which corresponds to a severe episode. There were no exclusion criteria. Patients underwent chest CT scans and PFT. After a minimum of two weeks free of any acute symptom after discharge, CT scans and PFT were redone.
3310352|NCT01922193|Experimental|Test Group|
3310353|NCT01922193|Active Comparator|Control Group|
3310354|NCT01922206|No Intervention|Wait-list Control|Participants in the wait-list control condition will receive a group-based version of the TRACK intervention after their 15-month follow up appointment.
3310355|NCT01922206|Experimental|TRACK Intervention|3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child
3310356|NCT01922245|Experimental|anodal tDCS|Soterix 1x1 device: anodal tDCS administered to the left hemisphere
3310357|NCT01922284|Experimental|Group 1 - Combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 1 will receive 5 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8 16 and 20.~At weeks 16 and 20, individuals in group 1 will be given MVAC in a volume of 0.5mls into the upper left arm and also 100ug CN54rgp140 mixed with 5ug GLA-AF in a total volume of 0.4mls into the muscle of the upper right arm."
3310358|NCT01922284|Active Comparator|Group 2 - Non-combination arm|"All participants will receive DNA vaccines at 0,4 and 8 weeks. These will be administered in 2 separate injections of 1ml (CN54ENV into the muscle of the upper right arm and ZM96GPN into the muscle of upper left arm). Participants in group 2 will receive 7 immunisations (DNA, MVA and CN54rgp140 in GLA-AF vaccines) at weeks 0, 4, 8, 16, 20, 24 and 28.~At weeks 16 & 20 group 2 will receive only 0.5mls of MVAC into the muscle of the upper left arm. At weeks 24 and 28 they will receive injections of 100ug CN54rgp140 mixed with 5ugGLAAF in a total volume of 0.4mls into the muscle of the upper right arm."
3310359|NCT01922297|Experimental|Day Treatment MDFT-HIV|Multidimensional Family Therapy (MDFT)is an integrative treatment approach that has blended family therapy, individual therapy, drug counseling, and multiple systems oriented intervention approaches (Liddle 1999). DT-MDFT-HIV includes a state-of-the-art family-based HIV prevention component into the core MDFT intervention specifically targeting high-risk sexual behavior in clinical sample teens.
3310360|NCT01922297|Other|Day Treatment SAU|The DT-Services as Usual (SAU) condition is primarily a peer group-based and individual approach that uses cognitive-behavioral principles and interventions. It is an adolescent substance abuse treatment and services consistent with those recommended for juvenile justice-involved drug abusing youth (Cooper & Bartlett 1998; National Institute of Justice, 2001).
3310361|NCT01922310|Other|Communication intervention|This study uses a single arm design with current 'controls' to explore an intervention, the procedure for providing information and requesting consent for donation, that uses new agreed best practice procedures led by specially trained intensive care health professionals. The study intervention is a staff education and training module intended to provide a framework and preparation for select critical care staff to conduct organ donation discussions in line with best practice.
3310362|NCT01922362|Experimental|Negative pressure drainage system|Negative pressure drainage system
3310363|NCT01922362|Active Comparator|Indirect wet dressing group|Indirect wet dressing
3310364|NCT01922375|Experimental|Naftopidil dose 2|PO administration
3310365|NCT01922375|Placebo Comparator|Placebo|PO administration
3310366|NCT01922375|Experimental|Naftopidil dose 1|PO administration
3310367|NCT01922388||Early Motor Complication|This group is composed of PD patients with motor complications of 3 years or less. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
3310368|NCT01922388||Late Motor Complication|This group is composed of PD patients with motor complications of more than 3 years. All subjects receive bilateral deep brain stimulation of the subthalamic nucleus and best medical treatment.
3310369|NCT01922401|Experimental|inverse ratio ventilation|in one group change the I:E ratio during pneumoperitoneum 1:2-1:2-2:1
3310370|NCT01922414|Active Comparator|Laser|Patients will undergo Laser lithotripsy
3310371|NCT01922414|Active Comparator|Ultrasonic|Patients will undergo ultrasonic lithotripsy
3310372|NCT01922440||Chronic Hypoparathyroidism|A rare disease with a duration of longer than 6 months characterized by insufficient parathyroid hormone (PTH) secretion, which can result in hypocalcemia, hyperphosphatemia, and associated clinical findings.
3310373|NCT01922453|Experimental|Music and Sound|Music and Sound applied to maternal abdomen through a special device for pregnant women.
3310374|NCT01922453|No Intervention|no music and sound|
3310375|NCT01922466|Experimental|Bee Venom Acupuncture|
3310376|NCT01922466|Experimental|Loxoprofen|
3310377|NCT01922466|Experimental|EWCT : Bee Venom Acupucture and Loxoprofen|
3310378|NCT01922479|Experimental|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
3310379|NCT01922479|Active Comparator|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
3310380|NCT01922492|Experimental|Autologous islet transplantation|Autologous islet transplantation arm: autologous islet transplantation
3310381|NCT01922492|Active Comparator|Oral anti-diabetic drugs|Metformin (starting from 500mg qd with dose adjustment thereafter) with or without vildagliptin (starting from 50mg qd with dose adjustment thereafter)
3310382|NCT01922505||PPI triple therapy|7-day PPI triple therapy regimen: PPI (esomeprazole 40 mg or omeprazole 20 mg or lansoprazole 30 mg or pantoprazole 40 mg or rabeprazole 20 mg) plus amoxicillin (1000mg) and clarithromycin (500mg) twice daily for 7 days.
3310383|NCT01922518|Active Comparator|Septal pacing group|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
3310384|NCT01922518|Active Comparator|Apex pacing group|Put RV lead around the apex
3310385|NCT01922531||Mild Traumatic Brain Injury|These were patients who presented to the ER within 6 hours of a witnessed head injury. Patients were also eligible if the patient had a self-reported head injury with evidence of head trauma.
3310386|NCT01922531||Orthopedic Injury|Patients were eligible as an orthopedic injured control who presented to the ER within 6 hours of an isolated extremity trauma that radiography and an Abbreviated Injury Scale (AIS) of less than or equal to 3.
3310387|NCT01922544||Conventional group|In this group CS lead was implanted in a conventional manner.
3310388|NCT01922544||EP-catheter group|In this group coronary sinus was canulated using a steerable electrophysiology catheter.
3310389|NCT01922557||NICOM|
3310390|NCT01922570|Experimental|Dietary supplements:parenteral nutrition|supplemental parenteral nutrition and enteral nutrition in case of failure (intake below 60% of energy needs) of enteral nutrition by day 3 after admission in the ICU or enteral nutrition only.
3310391|NCT01922583|Experimental|Vial|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
3310392|NCT01922596|Experimental|Active FNB, placebo ACB|FNB with 30 ml of ropivacaine 0,2% and ACB with 30 ml of placebo (saline). The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
3310393|NCT01922596|Experimental|Active ACB, placebo FNB|ACB with 30 ml of ropivacaine 0,2% and FNB with 30 ml of placebo (saline.The ACB will be performed just prior to the FNB. The blockades will be performed just after obtaining the baseline values (outcome measures) at time 0.
3310394|NCT01922609||Normal cerebrovascular reserve|Patients without preprocedural TCD signs of impaired cerebrovascular reserve
3310395|NCT01922609||Impaired cerebrovascular reserve|Patients with preprocedural TCD signs of impaired cerebrovascular reserve
3310396|NCT01922622||Bipolar hemiarthroplasty.|Group of patients who will stay in lateral position during whole surgery.
3310397|NCT01922622||Dynamic hip screw.|Group of patients who will be supine during surgery.
3310398|NCT01922635|Other|1|
3310399|NCT01922648||2-4 months|Infants aged between 2 and 4 months (Group 1), who have not yet been exposed to RSV
3310400|NCT01922648||6 - 12 months|Infants aged between 6 and 12 months (Group 2), who will have had exposure to one single RSV season in the winter of 2011/12
3310401|NCT01922648||3 - 6 years|Children aged between 3 and 6 years (Group 3), who have been exposed to RSV over several winter seasons
3310402|NCT01922661|Experimental|Cohort 1|Dose 1 of REGN1908-1909 or placebo
3310403|NCT01922661|Experimental|Cohort 2|Dose 2 of REGN1908-1909 or placebo
3310404|NCT01922661|Experimental|Cohort 3|Dose 3 of REGN1908-1909 or placebo
3310405|NCT01922674|No Intervention|Watchful Waiting|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that do not have surgery
3310406|NCT01922674|Active Comparator|Standard open tension-free inguinal hernia repair with mesh|Assess pain, physical function, and other outcomes in men with asymptomatic or minimally symptomatic inguinal hernia that undergo a standard open tension-free repair with mesh.
3310407|NCT01922687|Experimental|Amlodipine Plus Atorvastatin (Caduet)|amlodipine plus atorvastatin in a single tablet (Caduet, Pfizer, USA) was given once daily
3310408|NCT01922687|Active Comparator|Amlodipine (Norvasc)|amlodipine(Norvasc, Pfizer, USA) given once daily
3310409|NCT01922713|Placebo Comparator|white maize|white maize and a corn oil capsule
3310410|NCT01922713|Experimental|orange maize|orange maize and a corn oil capsule
3310411|NCT01922713|Active Comparator|vitamin A|white maize and a vitamin A capsule
3310412|NCT01922765|Experimental|AOC group|AOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days
3310413|NCT01922765|Experimental|AOM group|AOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days
3310414|NCT01922765|Experimental|Sequential group|Sequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days
3310415|NCT01922765|Experimental|concomitant group|concomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days
3310416|NCT01922778|Experimental|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD device can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting. If the biopsy cannot be performed due to technical difficulty (cervical stenosis) or inadequate sampling, we will try again on a different day after a trial of vaginal misoprostol (Cytotec) 400 or 600 mcg per vagina the night before."
3310417|NCT01922791|Active Comparator|Probiotic|Comparison of probiotics, fish oil and their combination to placebo
3310418|NCT01922791|Active Comparator|Fish oil|Comparison of probiotics, fish oil and their combination to placebo
3310419|NCT01922791|Active Comparator|Probiotics and Fish oil|Comparison of probiotics, fish oil and their combination to placebo
3310420|NCT01922791|Placebo Comparator|Placebo|Comparison of probiotics, fish oil and their combination to placebo
3310421|NCT01922804|Experimental|K2 vitamin|K2 vitamin 375 microgram a day for 3 years
3310422|NCT01922804|Placebo Comparator|placebo|1 tablet a day for 3 years
3310423|NCT01922817|Active Comparator|Saxagliptin|5mg once daily in addition to insulin therapy
3310424|NCT01922817|Placebo Comparator|Placebo|Crossover Placebo once daily
3310425|NCT01922830|Experimental|Bio-25 (Supherb)|"Bio-25 (Supherb) once daily (2 capsules -50 billion bacteria) for 6 months (or 4 weeks for healthy participants).~The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines."
3310426|NCT01922830|Placebo Comparator|Placebo|"Identical placebo once daily (2 capsules) for 6 months (or 4 weeks for healthy participants).~The placebo supplementation is identical-looking to the Bio-25 supplement."
3310427|NCT01922843|Experimental|DP001|DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
3310428|NCT01922843|Placebo Comparator|Placebo|Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks
3310429|NCT01922856|Experimental|Challenge (Vaccinated)|"The vaccine will be administered via the ID route to alternating upper arms on days 0, 21, and 42.~On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu)."
3310430|NCT01922856|Experimental|Challenge (Unvaccinated)|On the morning of challenge, subjects will drink 120 mL of bicarbonate buffer. Approximately 1 minute later, subjects will drink a solution of virulent H10407 bacteria suspended in the remaining 30 mL of bicarbonate buffer (2 x 10P7P cfu).
3310431|NCT01922869|Experimental|COB mixture|One time ingestion of flavonoid mixture from chocolate (80 g), orange juice (500 ml)and blackberries (160 g), also known as the 'COB mixture' providing approximately 640 mg of flavan-3-ols, 390 mg of anthocyanins and 342 mg of flavanones respectively.
3310432|NCT01922882|Experimental|Amagugu Counseling Intervention|"The 'Amagugu' intensive 6 session home-based intervention. All 6 visits will be undertaken by a lay counsellor over a period of 8-10 weeks. The intervention includes 3 stages linked to the outcomes of the intervention:~family engagement, personal preparation, disclosure practice using intervention materials~health promotion training and a mother-child visit~play-for-communication and custody care planning"
3310433|NCT01922882|No Intervention|Standard of Care|"There is currently no Standard of Care in the South African DoH addressing the issue of parental disclosure of HIV status to HIV-uninfected children, beyond a recommendation to 'counsel to disclose'.~Therefore, for women who are randomized to the control group, we will ensure a Standard of Care for all mothers including a one-hour counselling session, focused specifically on disclosure, delivered at the primary health care facility as part of the HIV Programme.~We will orientate all health professionals in the enrolment clinic, including nurses, counsellors and community health care workers, on parental HIV disclosure, and provide a one-day training workshop (including training manual, role-plays and competency testing."
3310434|NCT01922908|Active Comparator|MSC infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
3310435|NCT01922908|Placebo Comparator|SHAM infusion|Infusion of normal saline placebo
3310436|NCT01922921|Active Comparator|Arm I (placebo)|Patients receive HER2 ICD peptide-based vaccine ID once monthly for 3 months, trastuzumab (or trastuzumab and pertuzumab) per standard of care, and placebo PO BID for 4 months.
3310437|NCT01922921|Experimental|Arm II (polysaccharide-K)|Patients receive HER2 ICD peptide-based vaccine ID and trastuzumab (or trastuzumab and pertuzumab) as in Arm I and polysaccharide-K PO BID for 4 months.
3310438|NCT01922947|Active Comparator|Motivational Interviewing w/Social Network Counseling|Motivational Interviewing integrated with Social Network Counseling, 20-minute session.
3310439|NCT01922947|Sham Comparator|Health Counseling|
3310440|NCT01922960|Other|micro-imaging|"Sublingual or subconjunctival micro-imaging of the microcirculation taken for 3 minute intervals at certain timepoints.~Timepoints for burn/trauma subjects: Day0, Day1,Day2,Day6 & Day7 Timepoints for general surgery population: post-induction, prior to resection, after resection,& closing of surgical wound."
3310441|NCT01922973||normal men and women|normal volunteers: young and older men and women studied under fed and fasting (62.5h) conditions with frequent blood sampling for ghrelin and related hormones
3310442|NCT01922999|Active Comparator|Placebo controlled|comparison of placebo controlled to 1mg melatonin or 3mg melatonin
3310443|NCT01922999|Active Comparator|Melatonin|comparison of melatonin 1mg or melatonin 3mg
3310444|NCT01923012|Experimental|Vitamin K2|
3310445|NCT01923025|Experimental|RO5545965|
3310446|NCT01923038|Active Comparator|Patients ventilated with zero end expiratory pressure (ZEEP)|patients undergoing gynecologic laparoscopic surgery ventilated at zero end expiratory pressure
3310447|NCT01923038|Active Comparator|Patients ventilated with positive end expiratory pressure|patients undergoing gynecologic laparoscopic surgery ventilated at PEEP
3310448|NCT01923038|Active Comparator|recruitment plus PEEP|patients undergoing gynecologic laparoscopic surgery undergoing recruitment plus PEEP
3310449|NCT01923064|Active Comparator|NBCA-lipiodol|Patients will receive injection of a mixture of cyanoacrylate and lipiodol to treat gastric varices
3310450|NCT01923064|Experimental|NBCA-lauromacrogol|Patients will receive injection of the mixture of cyanoacrylate and lauromacrogol to treat gastric varices
3310451|NCT01923077|Placebo Comparator|Conventional|Conventional treatment with simvastatin
3310452|NCT01923077|Active Comparator|Rosuvastatin|loading dose of rosuvastatin 80 mg at randomization followed by 40 mg daily in 12 month.
3310453|NCT01923090|Experimental|Finasteride|Finasteride treatment 5mg for 3 weeks
3310454|NCT01923090|Experimental|Dutasteride|Dutasteride treatment 0.5mg for 3 weeks
3310455|NCT01923116|Experimental|HPV-16 vaccine|
3310456|NCT01923142|Experimental|Outer-Root-Sheath Melanocytes Suspension|This arm includes all patients sides (left or right) treated with autologous outer-root-sheath melanocytes suspension followed by targeted UVB phototherapy
3310457|NCT01923142|Placebo Comparator|Placebo|This arm includes all patients sides (left or right) treated with placebo followed by targeted UVB phototherapy
3310458|NCT01923155|Active Comparator|Nurse endoscopists|Colonoscopy performed by nurse endoscopists supervised by senior medical endoscopists
3310459|NCT01923155|Active Comparator|Medical endoscopists|Colonoscopy performed by senior medical endoscopists
3310460|NCT01923168|Experimental|Alpelisib + Letrozole|Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.
3310461|NCT01923168|Experimental|Buparlisib + Letrozole|Participants took buparlisib 100 mg once daily or 5 days on/2 days off plus letrozole 2.5 mg once daily.
3310462|NCT01923168|Placebo Comparator|Placebo + Letrozole|Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.
3310463|NCT01923194|Experimental|Test Group|
3310464|NCT01923194|Active Comparator|Comparator Group|
3310465|NCT01923207|Experimental|DX-2930|DX-2930 administered by subcutaneous route
3310466|NCT01923207|Placebo Comparator|placebo|inactive formulation of DX-2930
3310467|NCT01923220|Experimental|HO/02/02|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
3310468|NCT01923220|Sham Comparator|Aloe Vera Jel|To be applied topically
3310469|NCT01923233|Experimental|Treatment|Intradermal AlloStim(TM) (1ml) on day 0 and 3 in same location Intradermal AlloStim(TM) (1ml) on day 7 and day 10 in same location Radiofrequency ablation on day 14 followed by intralesional AlloStim (3ml) Intralesional AlloStim(TM)(3ml) on day 17 in same ablated lesion Intravenous AlloStim(TM)(5ml) on days 21, 49 and 78
3310470|NCT01923246|Experimental|Single WEB intervention|Web intervention recieved once.
3310471|NCT01923246|Experimental|Repeated WEB intervention|Web intervention recieved twice.
3310472|NCT01923246|Experimental|Single IVR intervention|IVR intervention recieved once
3310473|NCT01923246|Experimental|Repeated IVR intervention|IVR intervention recieved twice
3310474|NCT01923246|No Intervention|Control group|Untreated Control Group.
3310475|NCT01923259|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
3310476|NCT01923259|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
3310477|NCT01923272|Sham Comparator|Sham Device|inactive AlphaCore device
3310478|NCT01923272|Active Comparator|AlphaCore|Active AlphaCore device
3310479|NCT01923298|Experimental|Estradiol|ESTRING® (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days.
3310480|NCT01923324|Experimental|Physician telephone consultation|Received direct telephone consultation with pain physician about index patient
3310481|NCT01923324|Active Comparator|Usual family physician care|Usual family physician care (without direct telephone consultation with pain physician)
3310482|NCT01923337|Experimental|Treatment (irinotecan, alisertib)|Patients receive irinotecan hydrochloride IV over 30 minutes on days 1 and 8 and alisertib PO BID on days 1-3 and 8-10. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3310483|NCT01923350|Experimental|Weight Reduction Intervention|
3310484|NCT01923350|Active Comparator|Weight Reduction Control Arm|
3310485|NCT01923350|Active Comparator|Tested for diabetes|
3310486|NCT01923350|Active Comparator|Not tested for diabetes|
3310487|NCT01923376|Other|Lactulose|per standard of care
3310488|NCT01923376|Active Comparator|polyethylene glycol 3350 (Golytely)|
3310489|NCT01923402||Exclusive cigarette smokers|
3310490|NCT01923402||Exclusive moist snuff consumers|
3310491|NCT01923402||Non-tobacco consumers|
3310492|NCT01923415||Group 1: SLE|>=10 participants with systemic lupus erythematosus (SLE)
3310493|NCT01923415||Group 2: DLE|>=10 participants with discoid lupus erythematosus (DLE)
3310494|NCT01923415||Group 3: SCLE|>=10 participants with subacute cutaneous lupus erythematosus (SCLE)
3310495|NCT01923441||Highschool athletes|
3310496|NCT01923441||midschool athletes|
3310497|NCT01923454|Experimental|Paracentesis|"Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma"
3310498|NCT01923480|Experimental|15% CLINISOL 0.04 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.04 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3310499|NCT01923480|Experimental|15% CLINISOL 0.08 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.08 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3310500|NCT01923480|Experimental|15% CLINISOL 0.13 g/kg/hr|15% CLINISOL- Sulfite-Free (Amino Acid)Injection 0.13 g/kg/hr to be administered. Each treatment session is expected to last 7 hours with the first 3 hours of basal infusion followed by 4 hours of 15% CLINISOL - Sulfite-Free (Amino Acid) Injection.
3310501|NCT01923493|Active Comparator|no intervention waiting list|Patients in the no intervention waiting list group will not receive a study intervention.
3310502|NCT01923493|Experimental|tuina|tuina treatment
3310503|NCT01923506|Experimental|Treatment (SBRT)|Patients receive 5 fractions of SBRT over 1.5 weeks.
3310504|NCT01923519|Experimental|allergic rhinitis|
3310505|NCT01923519|Experimental|allergic rhinitis and asthma|
3310506|NCT01923519|Experimental|witnesses|
3310507|NCT01923545|Experimental|DA-3031 3.6mg|PEG-G-CSF
3310508|NCT01923545|Experimental|DA-3031 6mg|PEG-G-CSF
3310509|NCT01923545|Active Comparator|Leucostim®|G-CSF
3310510|NCT01923558|Experimental|Donepezil Hydrochloride Tablets, 23 mg|Donepezil Hydrochloride Tablets, 23 mg of Dr.Reddy's Laboratories Ltd
3310511|NCT01923558|Active Comparator|Aricept|Aricept® 23 mg tablet of Eisai Inc
3310512|NCT01923571||Normoglycemia|patients with intraoperative BGC in the 80-180 mg/dl range
3310513|NCT01923571||Hyperglycemia|patients with intraoperative BGC exceeding 180 mg/dl
3310514|NCT01923584|Active Comparator|EPI-743 400mg|EPI-743 at a dose of 400 mg three times daily
3310515|NCT01923584|Active Comparator|EPI-743 200mg|EPI-743 at a dose of 200 mg three times daily
3310516|NCT01923597|Active Comparator|Green tea extract|Patients will receive four capsules ( one capsula = 200mg of epigallocatechin gallate) of green tea extract per day for 3 months.
3310517|NCT01923597|Placebo Comparator|Placebo (celulose)|Patients will receive four capsules of placebo (celulose) daily for 3 months.
3310518|NCT01923610|Experimental|Main|MVA HIV-B
3310519|NCT01923623|Experimental|Block|Popliteal and saphenous Block with Ropivacaine
3310520|NCT01923623|Placebo Comparator|NaCl|
3310521|NCT01923636|Other|detection of CMV|Cohort of neonates less than 1 month with congenital CMV infection at birth objectified by the detection of CMV in a urine sample, in saliva or blood (fresh or Guthrie card) obtained in the first 10 days life
3310522|NCT01923649|Experimental|Lanreotide slow release 90 mg|Patients receive lanreatide slow release (Somatuline autogel) 90 mg every four weeks via a deep subcutaneous injection, three times. After a wash out period of 4 weeks they receive a similar placebo every for weeks, three times.
3310523|NCT01923649|Placebo Comparator|Placebo|Patients receive a deep subcutanous injection of placebo every four weeks, three times. After a wash out of three weeks, they will receive somatuline 90 mh via a deep subcutanous injection every four weeks, three times.
3310524|NCT01923662|Experimental|Neuroprosthesis|Eligible subjects will receive an implanted device (IRS-8 or IST-16) and surgically implanted electrodes to excite muscles that move paralyzed muscles. These electrodes are connected to the implanted stimulator that delivers electrical pulses to the nerves. These pulses cause the muscles to contract to perform functional movements or to exercise.
3310525|NCT01923675|Experimental|color blocking tint|Spectacles with red-blocking tint subjects will wear glasses daily for 6 months and have
3310526|NCT01923675|Other|holographic diffuser|Spectacles with color neutral tint subjects will wear glasses daily for 6 months and have
3310527|NCT01923675|Other|diffuser & color blocking tint|Spectacles with holographic diffuser and red-blocking tint subjects will wear glasses daily for 6 months and have
3310528|NCT01923675|Other|holographic diffuser and neutral tint|Spectacles with holographic diffuser and color neutral tint subjects will wear glasses daily for 6 months and have
3310529|NCT01923688|Experimental|Informatics Real-Time Alert|Alert/Nurse and Physician Intervention
3310530|NCT01923688|No Intervention|control-no intervention|
3310531|NCT01923701|Experimental|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy group receives group, individual, and family Cognitive Behavioral Therapy in addition to standard care.
3310532|NCT01923701|No Intervention|Monitoring|This group receives standard care only.
3310533|NCT01923714||Glaucoma|Patients with open-angle glaucoma (OAG) that require topical intraocular pressure lowering therapy and that were scheduled to switch current therapy to preservative-free DTFC.
3310534|NCT01923727|Experimental|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in mass doses of either 10 mg, 20 mg or 50 mg (optional).
3310535|NCT01923753|Experimental|Aerosure 15 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure. Order of presentation is randomised."
3310536|NCT01923753|Active Comparator|Aerosure 25 Hz|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
3310537|NCT01923753|Sham Comparator|Aerosure sham|"All subjects receive an active device operating at a specific frequency, active device operating at another specific frequency and sham device (disabled):~Aerosure at 15 Hz; Aerosure at 25 Hz; Sham Aerosure."
3310538|NCT01923766|Experimental|Cytotoxic T lymphocytes (CTLs)|Cytotoxic T lymphocytes (CTLs). CMV/AdV /EBV specific T cells will be given by slow intravenous injection over 1-2 minutes. Four dose levels will be explored. The lowest dose level will be 5x106cells/m2 and the highest will be 2.5x107/m2. During the dose escalation phase two to six patients will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval.
3310539|NCT01923779||TG002 Subjects|Subjects previously randomised in study TG002
3310540|NCT01923792||Placebo|Subjects previously randomised to receive placebo in study TH002
3310541|NCT01923792||ToleroMune HMD Group 1|Subjects previously randomised to receive ToleroMune HDM in study TH002
3310542|NCT01923792||ToleroMune HDM Group 2|Subjects previously randomised to receive ToleroMune HDM in study TH002
3310543|NCT01923818|Active Comparator|aspirin|Receiving a 100-mg dose of aspirin and placebo rivaroxaban from day 1 to day 30
3310544|NCT01923818|Experimental|Rivaroxaban 5mg|Receiving a 5-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
3310545|NCT01923818|Experimental|rivaroxaban 10mg|Receiving a 10-mg dose of rivaroxaban and placebo aspirin from day 1 to day 30
3310546|NCT01923831|Experimental|Magnesium group|
3310547|NCT01923831|Active Comparator|Dexamethasone group|
3310548|NCT01923844|Experimental|poractantalfa|preterm infants who received poractantalfa for respiratory distress syndrome
3310549|NCT01923844|Experimental|beractant|preterm infants who received beractant for respiratory distress syndrome
3310550|NCT01923844|No Intervention|Control|Preterm infants without respiratory distress syndrome
3310551|NCT01923857|Experimental|Healthy Volunteers|Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.
3310552|NCT01923857|Experimental|Mild Renal Impairment|Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).
3310553|NCT01923857|Experimental|Moderate Renal Impairment|Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).
3310554|NCT01923857|Experimental|Severe renal impairment|
3310555|NCT01923870|Experimental|Moderate Hepatic Impairment|Males age 18-70 with a BMI between 25-42 kg/m^2 with moderate hepatic impairment (Child-Pugh Class B)
3310556|NCT01923870|Experimental|Healthy Volunteers|Males age 18-70 with a BMI between 25-42 kg/m^2
3310557|NCT01923883|Active Comparator|Negative-pressure syringe|EUS-FNA with negative-pressure suction with syringe
3310558|NCT01923883|Experimental|Capillary sampling with slow-pull|EUS-FNA with capillary sampling with stylet slow-pull technique
3310559|NCT01923909|Active Comparator|Intra-articular corticosteroid|Intra-articular corticosteroid injections Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the suprapatellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
3310560|NCT01923909|Experimental|Intra-articular platelet-rich plasma|IA PRP procedure This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the suprapatellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
3310561|NCT01923922|Other|CT Perfusion|Participants with suspected Glioblastoma Multiforme undergo CT perfusion prior to surgery or biopsy.
3310562|NCT01923935|Experimental|BUSULFEX®, Alkeran®|"BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)~Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)"
3310563|NCT01923948|Active Comparator|Pregabalin|Single, 150 mg pre-operative oral dose of Pregabalin
3310564|NCT01923948|Placebo Comparator|Sugar Pill|Single, placebo pre-operative dose
3310565|NCT01923974|Placebo Comparator|Placebo|IV formulation
3310566|NCT01923974|Active Comparator|Melatonin 10 mg|IV formulation, Melatonin 10 mg
3310567|NCT01923974|Active Comparator|Melatonin 100 mg|IV formulation, Melatonin 100 mg
3310568|NCT01923987|Experimental|SCRT/ChemoTx with Delayed Surgery|Short course radiotherapy (25 Gy in 5 fractions) followed by intensive chemotherapy, compromising of FOLFOX of FOLFIRI (+-Bevacizumab or Cetuximab), with delayed surgery for rectal cancer with synchronous distant metastasis
3310569|NCT01924000|Experimental|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
3310570|NCT01924000|Placebo Comparator|Placebo|Placebo is applied twice daily to the other eyebrow.
3310571|NCT01924013|Placebo Comparator|Group A|"Prenatal Period 0 IU; Postpartum Period 0 IU (placebo)~Overall:The Prenatal Period will start at enrolment (17-24 weeks gestation) and last until delivery. The Postpartum Period will last from delivery until 6 months postpartum."
3310572|NCT01924013|Experimental|Group B|Prenatal Period 4,200 IU/week of vitamin D3 (=600 IU/d); Postpartum Period 0 IU/week (placebo)
3310573|NCT01924013|Experimental|Group C|Prenatal Period 16,800 IU/week of vitamin D3 (=2,400 IU/d); Postpartum Period 0 IU/week (placebo)
3310574|NCT01924013|Experimental|Group D|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 0 IU/week (placebo)
3310575|NCT01924013|Experimental|Group E|Prenatal Period 28,000 IU/week of vitamin D3 (=4,000 IU/d); Postpartum Period 28,000 IU/week(=4,000 IU/d)
3310576|NCT01924026||Affected MHP|With Phe between 360 and 600 micromoles/L
3310577|NCT01924026||Unaffected Siblings|With normal Phe levels
3310578|NCT01924039|Experimental|Brief Motivational Enhancement Therapy|
3310579|NCT01924039|Other|treatment as usual|
3310580|NCT01924052|Active Comparator|Migraine patients with high genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
3310581|NCT01924052|Active Comparator|Migraine patients with low genetic load|CGRP intravenous infusion 1.5 microgram/min for 20 min
3310582|NCT01924065|Active Comparator|Transesophageal Echocardiography group|This arm includes the patients with atrial fibrillation who undergo transesophageal echocardiography-guided cardioversion
3310583|NCT01924065|Active Comparator|Oral anticoagulant Group|This arm includes the patients with atrial fibrillation who take warfarin or new oral anticoagulant agents three weeks before electrical cardioversion.
3310584|NCT01924078|Experimental|Metronomic Capecitabine and AI|Postmenopausal Hormone receptor positive breast cancer patients who wanted to conserve breast were enrolled to receive capecitabine 500mg/tid p.o plus one of the aromatase inhibitors (AIs):Anastrozole 1mg/day p.o, and who had first line or second line Letrozole therapy failure were switched to capecitabine 500mg/tid p.o plus Exemestane 25mg/day p.o；or Exemestane therapy failure were switched to capecitabine 500mg/tid p.o plus Letrozole 2.5mg/day p.o.
3310585|NCT01924091|Experimental|Dapivirine Gel|"As outlined above, multiple gel formulations of dapivirine have been developed for vaginal use.~Three formulations, Dapivirine Gel-001 (Gel-001), Dapivirine Gel-002 (Gel-002), and Dapivirine Gel 4750 (Gel 4750) are no longer in development. Dapivirine Gel 4789, which has been tested in one clinical trial (IPM012), and Dapivirine Gel 4759 were recently evaluated in clinical trials, IPM 014A and IPM 020. This trial will use Dapivirine Gel 4759."
3310586|NCT01924091|Experimental|Dapivirine Film|Dapivirine film is formulated in a polyvinyl alcohol (PVA) based vaginal film containing hydroxypropyl methyl cellulose (HPMC) E5 (5 cp), polyethylene glycol 8000 (PEG), propylene glycol, and glycerin. PVA constituted 55.1% (w/w) of the film. The target loading dose for the film is 1.25 mg dapivirine per film based on phase I studies using dapivirine gels at concentrations of 0.01%, 0.02% and 0.05%30-33. The quantity of gel administered in these studies was 2.5 mL. Consequently the administered dose corresponds to 0.25, 0.5 and 1.25 mg dapivirine, respectively.
3310587|NCT01924104|Active Comparator|Low Molecular Weight Heparin|Low molecular weight heparin, 2500 milli-International unit/day, subcutaneously
3310588|NCT01924104|Active Comparator|Low dose aspirin|Low dose aspirin, 75mg/day, orally
3310589|NCT01924104|Active Comparator|Heparin & Aspirin|Heparin (40 mg/day, subcutaneously) and aspirin (70 mg/day, orally)
3310590|NCT01924104|Placebo Comparator|Sodium chloride (NaCl)|Equivalent volume of NaCl 0.9%, subcutaneously
3310591|NCT01924117|No Intervention|Linear Array HPV Genotyping assay|Women submitted to colposcopy with a suspicion of squamous intraepithelial lesion were programmed a clinical follow up to cervical swab in order to extract DNA and perform a Linear Array HPV Genotyping assay (Roche®, Mannheim, Germany).
3310592|NCT01924130|Experimental|One Healthy Breakfast Program|Classroom feeding, nutrition education lessons, social marketing, and parent outreach.
3310593|NCT01924130|No Intervention|Control|Only receive assessments.
3310594|NCT01924143|Experimental|TD-9855|
3310595|NCT01924156|Experimental|adenovirus-transfected DC + CIK|adenovirus-transfected autologous DC vaccine plus CIK cells
3310596|NCT01924195|Active Comparator|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
3310597|NCT01924195|Placebo Comparator|Placebo Capsule|Placebo capsule QD po and it should be continued until disease progression or patients withdrawal of consent
3310598|NCT01924208|Active Comparator|Timothy|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
3310599|NCT01924208|Active Comparator|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
3310600|NCT01924208|Active Comparator|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
3310601|NCT01924208|No Intervention|No intervention|No intervention (n=60, 50:50 atopic:non-atopic).
3310602|NCT01924221||CRT|Patients with implanted cardiac resynchronization therapy defibrillator
3310603|NCT01924234|Active Comparator|morphine|Volunteers are given morphine injection
3310604|NCT01924234|Active Comparator|remifentanil|Volunteers are given remifentanil infusion
3310605|NCT01924247|Other|Interventional Arm|Interventional Arm
3310606|NCT01924247|Other|Control Arm|Control Arm: Standard treatment by family physician
3310607|NCT01924260|Experimental|Treatment (alisertib, gemcitabine)|Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3310608|NCT01924273|Other|Port Wine Stain Birthmarks|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
3310609|NCT01924286|Experimental|Prednisone|Prednisone oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
3310610|NCT01924286|Placebo Comparator|Placebo|Placebo oral tablets 40mg daily for 2 weeks followed by 20mg daily for 2 weeks
3310611|NCT01924312|Placebo Comparator|No Intervention|A placebo cohort of 40 subjects with MCI related to vascular risk factors (MCI-CVD) will be followed longitudinally with cognitive, imaging, blood and optional spinal fluid biomarkers providing insight into the natural disease course of MCI-CVD. This natural history group will serve as the control group for the treatment arm described below.
3310612|NCT01924312|Experimental|Treatment Group|A cohort of 40 subjects with MCI-CVD will be treated with a nursing-based educational program (Heart Health Intervention) including aggressive symptom monitoring and treatment of vascular risks in a 6 visit intervention block over 12 weeks after baseline and thereafter for every 6 months for the study duration of 3 years. These subjects will be followed identically to the subjects in the natural history arm described in the control group above with cognitive testing, imaging, blood, and optional spinal fluid testing.
3310613|NCT01924325|Active Comparator|Dual-antiplatelet Therapy|Receiving a 75 mg dose of clopidogrel and 75mg dose of aspirin from day 1 to day 21, with placebo apixaban twice daily
3310614|NCT01924325|Experimental|Apixaban 2.5mg|Receiving a 2.5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
3310615|NCT01924325|Experimental|Apixaban 5mg|Receiving a 5-mg twice daily of apixaban, with placebo clopidogrel and placebo aspirin from day 1 to day 21
3310616|NCT01924338|Experimental|Skin types I and II|"Volunteers classified as skin types I and II according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3310617|NCT01924338|Experimental|Skin type III|"Volunteers classified as skin type III according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3310618|NCT01924338|Experimental|Skin type IV|"Volunteers classified as skin type IV according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3310619|NCT01924338|Experimental|Skin types V and VI|"Volunteers classified as skin types V and VI according to the Fitzpatrick Scale~Procedures: dental cast creation, MRI scan, laser scan"
3310620|NCT01924351|Other|HER2-positive Breast Cancer with Brain Metastasis|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis
3310621|NCT01924377|Other|standard circumferential pulmonary vein isolation (CPVI)|standard circumferential pulmonary vein isolation by radiofrequenvy ablation
3310622|NCT01924377|Experimental|CPVI + Rotor|standard circumferential pulmonary vein isolation + rotors' identification and ablation'
3310623|NCT01924403|Experimental|Staple Closure|Staple closure will be one technique employed to close the wound in primary total knee arthroplasty.
3310624|NCT01924403|Experimental|Running Subcuticular Closure|Running subcuticular closure will be one technique employed to close the wound in primary total knee arthroplasty.
3310625|NCT01924403|Experimental|Vertical Mattress Closure|Vertical mattress closure will be one technique employed to close the wound in primary total knee arthroplasty.
3310626|NCT01924416|Experimental|Enhanced Care|Enhanced Care: Decision aid; QL-PRO immediate summary results; chemotherapy cycles and imaging studies as needed
3310627|NCT01924416|Active Comparator|Usual Care|Usual Care: Routine chemotherapy cycles and imaging studies
3310628|NCT01924455||HBV-HIV coinfected subjects|HBV-HIV coinfected subjects seen at one of 7 participating centers.
3310629|NCT01924481|Experimental|low theobromine & low caffeine|Drink 1
3310630|NCT01924481|Experimental|low theobromine & high caffeine|Drink 2
3310631|NCT01924481|Experimental|high theobromine & low caffeine|Drink 3
3310632|NCT01924481|Active Comparator|no theobromine & high caffeine|Drink 4
3310633|NCT01924494||Endoscopy procedures|Patients undergoing elective flexible gastrointestinal endoscopy procedures
3310634|NCT01924507|Experimental|CPAP|Patients with apnea will be treated with CPAP during the night.
3310635|NCT01924507|No Intervention|Control|One arm group will be control and will not receive CPAP treatment during the ICU admission.
3310636|NCT01924520|Experimental|Group 1 (FK949E lower dose)|Oral
3310637|NCT01924520|Experimental|Group 2 (FK949E middle dose)|Oral
3310638|NCT01924520|Experimental|Group 3 (FK949E higher dose)|Oral
3310639|NCT01924546|Experimental|Supplementary water|This arm receives up to 3 L of supplemental water during the course of the testing day plus encouragement to drink water.
3310640|NCT01924546|No Intervention|Control|No additional water provided during the day. Additional water provided at the end of the school day.
3310641|NCT01924572|No Intervention|Immediate cord clamping|provider clamps and cuts the cord within 10 seconds after birth
3310642|NCT01924572|Experimental|cord clamping at 2 minutes|Provider places infant on maternal abdomen and cuts cord at 2 minutes after birth
3310643|NCT01924572|Experimental|cord clamping at 5 minutes|Provider places the infant on maternal abdomen and clamps and cuts cord at 5 minutes
3310644|NCT01924572|Experimental|cord milking|provider milks the cord 5 times from placenta to infant
3310645|NCT01924585||Frail patient|Patients will be stratified into groups frail and non-frail based on pre-operative frailty and disability.
3310646|NCT01924598|Experimental|DBS surgery|
3310647|NCT01924611|Active Comparator|Control Group|Atraumatic Restorative Technique using cotton rolls.
3310648|NCT01924611|Experimental|Experimental Group|Atraumatic Restorative Technique using rubber dam.
3310649|NCT01924624|Experimental|Thalidomide|Thalidomide 100mg per day after the radical resection HCC
3310650|NCT01924624|Active Comparator|Control|No adjuvant Thalidomide treatment after curative hepatic resection
3310651|NCT01924637|Experimental|FIASP|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
3310652|NCT01924637|Active Comparator|NovoRapid®|Each treatment period consists of 1 dosing visit during which the subject will receive a single dose of either insulin aspart or FIAsp at a predefined fixed dose level (in random sequence) in connection to intake of a standardised meal.
3310653|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM|
3310654|NCT01924650|Experimental|PH-797804 PARTICLE SIZE 9-11UM WITH SLS|
3310655|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM|
3310656|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 20UM WITH SLS|
3310657|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM|
3310658|NCT01924650|Experimental|PH-797804 PARTICLE SIZE <= 5UM WITH SLS|
3310659|NCT01924676|Experimental|Treatment A|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3310660|NCT01924676|Experimental|Treatment B|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3310661|NCT01924676|Experimental|Treatment C|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
3310662|NCT01924702|Active Comparator|anodal tDCS|Intensive language therapy with anodal transcranial direct current stimulation
3310663|NCT01924702|Sham Comparator|sham tDCS|Intensive language therapy with Sham-tDCS
3310664|NCT01924715||ISTDP|Patients provided Intensive Short term Dynamic Psychotherapy
3310665|NCT01924715||Control Group|Patients referred for ISTDP but never seen for any reason
3310666|NCT01924728|Active Comparator|Magnetic stimulation|Active magnetic stimulation delivered to the pelvic floor muscles
3310667|NCT01924728|Sham Comparator|Sham magnetic stimulation|Sham magnetic stimulation delivered to the pelvic floor muscles
3310668|NCT01924741||ALPPS|ALPPS is the most recent modification of the techniques developed for Two-stage hepatectomies. ALPPS allows to remove an extensive part of the liver in two steps. In the first step the liver parenchyma is transected along the intended line of resection and the future liver remnant cleaned by partial resections from all tumor tissue in the case of bilobar tumors. To this a portal ligation of the larger liver lobe that will have to be removed is added. After a waiting period of 1-2 weeks the second step is performed in which the deportalized liver is removed to render the patient completely tumor-free. (Ann Surg 2012; 255(3):405-14.)
3310669|NCT01924780|Active Comparator|NEMOS device stimulation 10 minutes|Subject will be stimulated in the cymba concha with a vibro-tactile mechanical device for 10 minutes
3310670|NCT01924780|Active Comparator|NEMOS device 60 minutes stimulation|Subjects will be stimulated in the cymba concha with a vibro-tactile mechanical device for 60 minutes
3310671|NCT01924780|Sham Comparator|Sham 10 minutes|10 minutes of t-VNS stimulation by rotating the NEMOS ear electrode 180 degrees within the pinna, which will position the electrode on the earlobe
3310672|NCT01924793|Experimental|Formulation of DAS181-F02 Dry Powder in Bulk|"The DAS181-F02 nebulized formulation includes 10mL of normal saline to prepare a liquid solution referred to as DAS181-F02 nebulized.~Dry Powder Inhaled Dose:~Non-ventilated subjects, capable of using a cyclohaler, will be treated by Dry Powder Inhalation. Each subject will receive a targeted daily dose of 10mg for 7 days for a total of 70mg of DAS181-F02. If a subject requires ventilation, the subject will be allowed to continue dosing following the Nebulized formulation instruction."
3310673|NCT01924793|Experimental|Nebulized Formulation Inhaled Dose|"Subjects unable to use the Dry Powder Inhaler (as determined by site Investigator) on continuous positive airway pressure (CPAP), Bi-level positive airway pressure (BIPAP) or requiring mechanical ventilation will be treated by Nebulized formulation. The subject will remain on the nebulized formulation for the duration of the study regardless of ventilation status. DAS-F02 10 mg will be utilized to prepare the nebulized solution per the Study Reference Manual.~Multiple methods (T piece, face mask, direct to ET tube) will be allowed for the nebulized dose administration. Detailed specification for nebulized dose administration will be defined in the Study Reference Manual."
3310674|NCT01924819|Experimental|Preoperative chemoradiotherapy|"2 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 3 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~5 weeks preoperative chemoradiotherapy.~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
3310675|NCT01924819|Active Comparator|Preoperative chemotherapy|"3 cycles preoperative chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine).~OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel~Gastric resection.~3 cycles adjuvant chemotherapy with: epirubicin + cisplatin + 5-fluorouracil. (5-fluorouracil may be replaced with capecitabine) OR epirubicin + oxaliplatin + capecitabine OR 4 cycles of 5-fluorouracil +Leucovorin + oxaliplatin + docetaxel"
3310676|NCT01924832|Experimental|BG00012 Part 1|BG00012 120 mg delivered to varying locations of the GI tract
3310677|NCT01924832|Experimental|BG00012 Part 2|BG00012 240 mg delivered to varying locations of the GI tract
3310678|NCT01924858|Experimental|GSK2647544 oral and [18F]GSK2647544 IV bolus|All subjects will receive a single oral dose of GSK2647544 100 milligram (mg) approximately 2 hours before administration of [18F] GSK2647544 and a dynamic PET scan. [18F]-GSK2647544 will be administered to the subject as an IV bolus during the PET scan, which will be conducted for up to 120 minute post the injection of [18F]GSK2647544
3310679|NCT01924884||Prospective|Patients newly referred to the Principal Investigator for intra-abdominal surgery and for whom the Principal Investigator anticipates using Negative-Pressure Wound Therapy.
3310680|NCT01924884||Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 will be identified through patient medical records. Living patients will be contacted via letter from the Principal Investigator introducing the study along with the study's consent form for the patients' review. Interested patients will be consented either in person at the patient's next clinic visit or via telephone by a member of the study staff.
3310681|NCT01924884||Historical Controls|Patients who underwent intra-abdominal surgery without Negative-Pressure Wound Therapy by the Principal Investigator prior to January 1, 2011 will be enrolled as Historical Controls.
3310682|NCT01924884||De-Identified Retrospective|Patients who underwent intra-abdominal surgery by the Principal Investigator between January 1, 2011 and May 9, 2013 and are deceased or do not consent to be in the study will be enrolled in the De-Identified Retrospective Case Cohort.
3310683|NCT01924897|Experimental|Exercise Training Arm|"Patients randomised to exercise training will be offered three sessions of aerobic interval exercise per week over the subsequent 4 weeks prior to their procedure. Each session will comprise 6 x 5 min repetitions at 60-80% peak VO2, with 2.5 min rest intervals. The aim will be to quickly progress patients to exercise intensities that correspond to and exceed the individual AT. Heart rate, clinical signs, blood pressure and perceived exertion will be recorded regularly throughout exercise.~Repeat CPET testing will then take place 4 weeks from the baseline test in the exercise laboratory (on the day prior to surgery) to determine changes (if any) in AT, VO2, VE/VCO2."
3310684|NCT01924897|No Intervention|No Exercise Training Arm|The patients in the non-exercise arm of the study will not undergo any exercise intervention but will be CPET tested in the exercise laboratory at the same time points as the exercise arm patients.
3310685|NCT01924910|Placebo Comparator|Placebo Pill|Received identical pills that do not contain vitamin D. Blood levels of 25(OH)D determined at 10 days, 3 months, and 1 year following placebo dose.
3310686|NCT01924910|Active Comparator|Vitamin D|250,000 IU cholecalciferol as single, oral dose. Blood levels 25(OH)D measured at 10 days, 3 months, and 1 year following dose.
3310687|NCT01924923||Uveal Melanoma|Scheduled for enucleation surgery
3310688|NCT01924936|Placebo Comparator|Email|Caring email (based on the caring letters literature) sent via secure email messaging. Of the interventions, it is by far the most minimal in clinical intensity and human resources needs for delivery.
3310689|NCT01924936|Experimental|DBT program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
3310690|NCT01924936|Experimental|Email + DBT program & Coach|"Caring Email + DBT online program & Coach: in addition to the DBT online program, will include personalized outreach and support for use of the program. An intervention coach will deliver this support exclusively via secure email messaging. The intervention coach will not provide psychotherapy, but instead provide reinforcement and contingency management surrounding completion of the three lessons. This intervention will utilize significantly greater ongoing clinical resources for its maintenance and offer greater clinical intensity for patients."
3310691|NCT01924962|No Intervention|medical therapy|patients are treated with medical therapy only, intervention (stent) of other than (chronic occluded) target-vessel is allowed.
3310692|NCT01924962|Active Comparator|revascularisation|revascularisation and stent-implantation of chronic occluded coronary artery
3310693|NCT01925001|Experimental|MP4CO|Escalating doses of MP4CO, administered intravenously
3310694|NCT01925001|Active Comparator|Sodium chloride solution|Normal saline (0.9% Sodium Chloride Injection USP)administered intravenously
3310695|NCT01925027|Experimental|NANO+ DES|The Nano+ Polymer-free Sirolimus-Eluting Coronary Stent System is device/drug combination products consisting of a drug-coated stent and a balloon expandable delivery system. The stent is coated with a formulation containing rapamycin, the active ingredient, adhered to 316L stainless bare stent scaffold with submicron micropores, and is approved by State Food and Drug Administration of China in 2011(No. 3460037).
3310696|NCT01925040|Experimental|Venus Pearl|Placement of restoration using Venus Pearl in carious teeth or as a replacement of a defective previous restoration.
3310697|NCT01925040|Active Comparator|control resin-based filling material|Placement of restoration using a control resin-based filling material in carious teeth or as a replacement of a defective previous restoration.
3310698|NCT01925053|Placebo Comparator|Ref meal|"The reference meal (REF) is based on WHO dietary guidelines for protein, fat and carbohydrate. It comprises everyday modern ingredients such as white rice."
3310699|NCT01925053|Active Comparator|PAL meal|Palaeolithic meal (PAL) is based on WHO dietary guidelines for protein, fat and carbohydrate but only uses ingredients that would have been available in Palaeolithic times (e.g. no cereals or dairy).
3310700|NCT01925066|Experimental|Aerosolized Vancomycin|
3310701|NCT01925079|Experimental|Intensive Educational Group|The Intensive Educational Group will receive 5 visits, including 2 visits via phone contacts. The expected dates for each visit will be stamped on the follow-up brochure for convenience. Patient education in this group includes routine education at discharge; 4 educational brochures, a calendar with health tips, and follow-up brochure with medical expert letter sent to patients at the day for discharge (baseline); and educational short messages through message platform once a week. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded.
3310702|NCT01925079|Sham Comparator|Control Group|The Control Group will receive 3 visits and receive care as per usual practice by the treating doctor and a follow-up brochure without medical expert letter. Dosage and adjustment of statins, and concomitant medications in all the treated patients will be recorded. Blood lipid panel (4 items), hepato-renal functions, and creatine kinase will be examined; while, Morisky 8-item questionnaire will be used to evaluate medication compliance at outpatient visits. In addition, the occurrence of major cardiovascular events and AE/SAE will be collected during the study.
3310703|NCT01925092|Experimental|mifepristone|Daily doses of mifepristone over 84 days.
3310704|NCT01925105|Experimental|Optimization of treatment|Optimization of treatment of diseases and symptoms
3310705|NCT01925105|Placebo Comparator|Control|Treatment as usual
3310706|NCT01925118|Experimental|High-dose IL-2|
3310707|NCT01925131|Experimental|Treatment (combination chemotherapy and inotuzumab ozogamicin)|Patients receive cyclophosphamide IV on day 1, vincristine sulfate IV on day 1, prednisone PO on days 1-5, and inotuzumab ozogamicin IV over 1 hour on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
3310708|NCT01925157|Experimental|LY3090106 (Healthy)|Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ).
3310709|NCT01925157|Placebo Comparator|Placebo (Healthy)|Healthy participants will receive a single dose of placebo matching LY3090106 SQ.
3310710|NCT01925157|Experimental|LY3090106 (RA)|Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV).
3310711|NCT01925157|Placebo Comparator|Placebo (RA)|Participants with RA will receive a single dose of placebo matching LY3090106 SQ.
3310713|NCT01925222||PCV-vaccinated infant, 3+1 schedule|
3310714|NCT01925222||PCV-vaccinated infant, 2+1 schedule|
3310715|NCT01925222||Control-vaccinated infant|
3310716|NCT01925222||PCV-vaccinated child, catch-up schedule|
3310717|NCT01925222||Control-vaccinated child, catch-up schedule|
3310718|NCT01925235||Control|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure
3310719|NCT01925235||RIPC|patients with impaired renal function and a high risk of developing acute kidney injury undergoing TAVI and receiving standard care including pre-hydration 12 hours prior and 12 hours post procedure plus ischemic preconditioning (intermittent arm ischemia through 4 cycles of 5-minute inflation and 5-minute deflation of a blood pressure cuff)
3310720|NCT01925248|Active Comparator|Whey protein group|Patients will be randomized to receive whey protein
3310721|NCT01925248|Placebo Comparator|Placebo group|Patients will be randomized to receive placebo
3310722|NCT01925261|Placebo Comparator|TPX-100 Cohort 1|Cohort 1 will be 20mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3310723|NCT01925261|Placebo Comparator|TPX-100 Cohort 2|Cohort 2 will be 50mg dose of TPX-100 in one randomized knee compared to placebo treated knee
3310724|NCT01925261|Placebo Comparator|TPX-100 Cohort 3|Cohort 3 will be 100mg dose of TPX-100 in one randomized knee compared to placebo treated knee
3310725|NCT01925261|Placebo Comparator|TPX-100 Cohort 4|Cohort 4 will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3310726|NCT01925261|Placebo Comparator|Part B|Part B will be 200mg dose of TPX-100 in one randomized knee, compared to placebo treated knee
3310727|NCT01925287|Active Comparator|Native curcumin powder|500 mg curcumin as native powder
3310728|NCT01925287|Experimental|Micronized curcumin powder|500 mg curcumin as micronized powder
3310729|NCT01925287|Experimental|Curcumin micelles|500 mg curcumin incorporated into liquid micelles
3310730|NCT01925300|Experimental|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab, qd|Single administration : 6 days, per oral
3310731|NCT01925300|Experimental|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab, qd|Single administration : 6 days, per oral
3310732|NCT01925300|Experimental|Concor 5mg 2T and Crestor 20 mg 1Tab, qd|Combination administration : 6 days, per oral
3310733|NCT01925313|Experimental|CJ-30044|
3310734|NCT01925313|Active Comparator|TALION TAB. 10mg|
3310735|NCT01925352|Experimental|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection in patients with ischemic heart disease into five left ventricular sites once.
3310736|NCT01925365|Experimental|Wholegrain cereal oats|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period.
3310737|NCT01925365|Placebo Comparator|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
3310738|NCT01925378|Experimental|Nelfinavir|This is a single arm intervention trial of nelfinavir in women with grade 2/3 or grade 3 cervical intraepithelial neoplasia
3310739|NCT01925391|Active Comparator|Sevoflurane, oxygen, intraocular pressure|Intraocular measurements under induction with Sevoflurane in oxygen
3310740|NCT01925391|Active Comparator|Nitrous oxide/O2/tetracaine|intraocular pressures in children undergoing inhalation induction with nitrous oxide in oxygen
3310741|NCT01925430||Comparative product|A device which monitors sleep/wake states
3310742|NCT01925430||Screening device|This device will screen for sleep-breathing disorders
3310743|NCT01925443|Experimental|low level laser therapy|individuals will be subject to the application of low level laser therapy, but this group will have three subdivisions related to dose in joules that will be administered to the individual, and J 4, J 6, 8 J. To be administered in the quadriceps muscle.
3310744|NCT01925443|No Intervention|Control Group|will consist of individuals diagnosed with diabetes mellitus non-insulin-dependent, however, will not perform low level laser therapy, participate only in the evaluations
3310745|NCT01925443|Experimental|Placebo group|individuals will be subject to the application of low level laser therapy but with a dose of 0 Joules.
3310746|NCT01925456|Other|Toviaz|Patients willingness to take Toviaz 4mg and 8mg
3310747|NCT01925482|Other|Group 1 -- no history of otitis media|no history of otitis media
3310748|NCT01925482|Other|Group 2 --patent tympanostomy tube|at least 1 patent tympanostomy tube
3310749|NCT01925495|Experimental|healthy adults|Experiment 1 -- variation of ear-canal pressure; Experiment 2 -- varied middle-ear gas compositions; Experiment 3 -- variation of middle-ear pressure
3310750|NCT01925521|Experimental|Part1 : OPS-2071|Single dose, OPS-2071 30,60,120,240,300,600,900,1200mg/day
3310751|NCT01925521|Placebo Comparator|Part1 : Placebo of OPS-2071|Single dose, Placebo
3310752|NCT01925521|Experimental|Part2 : OPS-2071|Multiple dose
3310753|NCT01925521|Placebo Comparator|Part2 : Placebo of OPS-2071|Multiple doses, Placebo
3310754|NCT01925534|Experimental|Optiflow|High-flow humidified nasal oxygen delivery system
3310755|NCT01925534|Active Comparator|Oxygen therapy|Standard oxygen therapy
3310756|NCT01925547|Experimental|Micellar curcumin|Subjects receive three times per day four capsules of curcumin micelles. One capsule contains 20 mg of curcumin. At the beginning, after three and six weeks of intake, blood samples are collected.
3310757|NCT01925547|Placebo Comparator|Placebo|Subjects receive three times per day four capsules of placebo preparation. At the beginning, after three and six weeks of intake, blood samples are collected.
3310758|NCT01925560|Experimental|Group A- agave inulin or placebo|Participant in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo.
3310759|NCT01925560|Experimental|Group B- agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
3310760|NCT01925560|Experimental|Group C-agave inulin or placebo|Participants in this group will receive Agave Inulin dose of 5 or 7.5 grams per day or placebo
3310761|NCT01925573|Other|Optune+RT+Bevacuzimab|"Part 1:~Bevacizumab every 2 weeks plus Optune daily for 4 week cycles.~Part 2:~RT will begin post 3 round of Bevacizumab (hypofractionated radiotherapy: 30 Gy in 5 fractions or 35 Gy in 10 fractions) per physician choice.~Part 3:~Adjuvant Bevacizumab and Optune"
3310762|NCT01925625|No Intervention|Control|participants monitored for 10 years for lung cancer incidence.
3310763|NCT01925625|Active Comparator|Early CDT Lung Test|Early CDT lung blood test
3310764|NCT01925638|Experimental|BAY86-9766|The study will be conducted in two parts and study treatments will be administered as follows: •Part A: Three subjects will be enrolled and will receive 10 mg of refametinib on Day 1. Once daily dosing of ketoconazole 400 mg will be initiated on Day 5 and will continue until Day 12 with 10 mg of refametinib administered concomitantly on Day 8 •Part B: Fifteen subjects will be enrolled and will receive refametinib doses of 10 mg, 20 mg or 30 mg on Days 1 and 8 with the same dose administered on both days. Refametinib dose for Part B will be based on safety and refametinib pharmacokinetics in Part A. Ketoconazole 400 mg will be administered once daily on Days 5 to 12. Subjects will stay in the investigational site for a total period of 15 consecutive days
3310765|NCT01925651|Other|Low Risk - No bolus|No Bolus
3310766|NCT01925651|Other|Low- Risk Alternate Bolus|Alternate Bolus
3310767|NCT01925651|Other|High Risk - Alternate Bolus|Alternate Bolus
3310768|NCT01925651|Other|High Risk - Continuous bolus|Continuous bolus
3310769|NCT01925664|Experimental|Doula|Mothers received doula home visiting services in addition to normal prenatal and obstetric clinical care and had access to social work case management.
3310770|NCT01925664|No Intervention|Usual Care|Mothers received normal prenatal and obstetric clinical care and had access to social work case management.
3310771|NCT01925690|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
3310772|NCT01925690|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
3310773|NCT01925716|Experimental|Corn oil/olive oil|Corn oil 56 g per day for 21 days followed by olive oil 56 g for 21 days
3310774|NCT01925716|Experimental|Olive Oil/Corn Oil|olive oil, 56g per day for 21 days followed by corn oil, 56 g for 21 days
3310775|NCT01925729|Experimental|ragweed|ragweed -- 1000PNU intranasal spray
3310776|NCT01925729|Experimental|histamine|5 mg intranasal spray
3310777|NCT01925729|Experimental|pseudoephedrine|pseudoephedrine -- 60 mg orally
3310778|NCT01925729|Experimental|oxymetazoline|oxymetazoline 0.05% solution intranasal spray
3310779|NCT01925742|Experimental|Low Risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics)
3310780|NCT01925742|Experimental|High risk of aneuploidy|Integrated prenatal screening for Down's syndrome (with follow-up fetal karyotype if positive); Serum QUAD Assay for aneuploidy screening; Semiconductor MPSS NIPT assay using ccfDNA in maternal blood; Optical-based MPSS NIPT assay using ccfDNA in maternal blood; Harmony™ Test (Ariosa Diagnostics) (subset)
3310781|NCT01925755||Group 1|
3310783|NCT01925807|Experimental|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
3310784|NCT01925820|Experimental|Arm 1|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks
3310785|NCT01925820|Active Comparator|Arm 2|Entecavir daily for 144 weeks.
3310786|NCT01925820|Active Comparator|Arm 3|180 mcg Peg-IFN alfa-2a once a week for 48 weeks
3310787|NCT01925833|Experimental|Both insertion and withdrawal|
3310788|NCT01925833|Active Comparator|Only withdrawal|
3310789|NCT01925859|Experimental|EryDex System|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)
3310790|NCT01925885|Active Comparator|PVI Ablation|Standard of care arm-pulmonary vein isolation (PVI)-involving moving the ablation catheter from point to point in a continuous line to surround the the orifices of the pulmonary veins in order to eliminate electrical conduction between the veins and left atrium.
3310791|NCT01925885|Experimental|FIRM Ablation|FIRM ablation for paroxysmal atrial fibrillation at sites of rotors or focal impulse formation as designated by using the mapping algorithm of RhythmView
3310792|NCT01925898|Experimental|Ketamine|Oral ketamine
3310793|NCT01925898|Active Comparator|Midazolam|Oral Midazolam
3310794|NCT01925924|Experimental|Resin-modified glass ionomer cement|Resin-modified glass ionomer cement is used to attach the fixed orthodontic brackets (brace) to the teeth.
3310795|NCT01925924|Active Comparator|Composite resin|Composite resin is used to attach fixed orthodontic brackets (brace)to the teeth.
3310796|NCT01925937|Experimental|Coenzyme Q10 & Atorvastatin|10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
3310797|NCT01925937|Active Comparator|Atorvastatin & placebo|10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
3310798|NCT01925963||Normal cohort|Normal, healthy adults without history of brain injury
3310799|NCT01925976|Other|Individualized dietetic intervention|Behavioral: Individualized dietetic intervention-eating habits.
3310800|NCT01926002|Experimental|Low-Dose MK-8351|Low-dose MK-8351 administered as single inhaled dose.
3310801|NCT01926002|Experimental|High-Dose MK-8351|High-dose MK-8351 administered as a single inhaled dose.
3310802|NCT01926002|Placebo Comparator|Placebo to MK-8351|Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose.
3310803|NCT01926041|Experimental|Intervention|A 16-week FIT2 program that combines smoking cessation therapy with individualized behavior coaching in diet and physical activity for PCWG restriction.
3310804|NCT01926041|No Intervention|Control|Usual care
3310805|NCT01926054|Active Comparator|Acthar Gel 80 IU SC BIW|80 IU administered subcutaneously BIW for 6 months
3310806|NCT01926054|Active Comparator|Acthar Gel 80 IU SC TIW|80 IU administered subcutaneously TIW for 6 months
3310807|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU- Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
3310808|NCT01926080|No Intervention|Standard Bereavement Care|Those randomized to control group (no DVD) Standard Bereavement Care Arm receive the bereavement materials given to families as standard-practice of care in the NICU at SLCH following the death of an infant
3310809|NCT01926106|Experimental|nIPPV|the infants in the arm were supported by Nasal Intermittent Positive-Pressure Ventilation(nIPPV)
3310810|NCT01926106|Active Comparator|nCPAP|the infants in the arm were supported by Nasal Continuous Positive Airway Pressure(nCPAP)
3310811|NCT01926132|Experimental|ascorbic acid 10g/20ml|Normal Saline 130ml+ ascorbic acid 10g/20ml , covered bottle for the blind allocation
3310812|NCT01926132|Active Comparator|Normal Saline 150ml|Normal Saline 150ml, covered bottle
3310813|NCT01926158|Experimental|Denosumab|Subcutaneous injection of denosumab 60 mg 4 weeks before surgery and 22 weeks after surgery
3310814|NCT01926158|Placebo Comparator|Placebo|Subcutaneous injection of placebo 4 weeks before surgery and 22 weeks after surgery
3310815|NCT01926171|Experimental|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus concurrent icotinib, which was administered orally three times per day.
3310816|NCT01926184|Experimental|ARTEMIS+CM|This is a 5-session, individually delivered intervention that is designed to enhance positive affect. It is designed to boost and extend the effectiveness of contingency management (CM).
3310817|NCT01926184|Placebo Comparator|Attention-Control+CM|Attention-matched, 5-session control condition consisting of brief-self report psychological measures and neutral writing exercises. Contingency management (CM) is also administered to this arm.
3310818|NCT01926197|Active Comparator|mFFX|mFOLFIRINOX
3310819|NCT01926197|Experimental|mFFX+SBRT|mFOLFIRINOX + SBRT
3310820|NCT01926210|Experimental|mild ovarian stimulation|Patients are stimulated with mild ovarian stimulation protocol,i.ed, from cycle day 3 to 7, letrozole 5mg per day are administrated and recombinant FSH 150 IU are given on day 4 and 6 . On cycle day 8, serum FSH LH, and estradiol levels are measured, and after then, the dose of recombinant FSH is adjusted according to the ovarian response and the maxim recombinant FSH dose is 150 IU/d. The GnRH-antagonist (Cetrotide) 0.25mg per day is administrated when the estradiol level reaches 200 pg/ml and the serum LH level rises above 2 times of basal LH level.
3310821|NCT01926210|Active Comparator|controlled ovarian stimulation|Patients are stimulated using controlled ovarian stimulation protocol,i.e., from cycle day 18-22 (day 7 after ovulation) of previous cycle, all participants are given short-acting GnRH agonist (Triptorelin 0.05mg/d) for 14 days, then after checking serum FSH, LH and estradiol to make sure that complete downregulation is achieved, exogenous gonadotropin (recombinant FSH) 300 IU/d is given for 5 days, then the dose of recombinant FSH is adjusted according to ovarian response.
3310822|NCT01926223|Experimental|Home visiting Group|
3310823|NCT01926223|No Intervention|Control Group|
3310824|NCT01926236|Active Comparator|Arm A: Active symptom control (ASC)|Active Symptom Control
3310825|NCT01926236|Experimental|Arm B: ASC with OxMdG chemotherapy|Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid & 5FU)
3310826|NCT01926249||Individuals at high risk of developing Alzheimer's dementia|"2000 participants with a newly identified cognitive deficit defined as performing worse than one standard deviation to the mean in one or more cognitive domain (memory, language, praxis, visuospatial abilities, attention and executive functions), not demented.~300 participants with an isolated cognitive complaint and an age of 60 years or more."
3310827|NCT01926262|Experimental|Physical Exercise Group|Specific Strength Training for the Neck and Shoulder muscles
3310828|NCT01926262|No Intervention|Reference group|No Specific Strength Training
3310829|NCT01926275|Experimental|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
3310830|NCT01926275|Active Comparator|NPPV|noninvasive positive pressure ventilation
3310831|NCT01926275|Active Comparator|IMT|inspiratory muscle training
3310832|NCT01926275|Placebo Comparator|LTOT|Long time oxygen therapy
3310833|NCT01926288|Other|HBeAg positive group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
3310834|NCT01926288|Other|HBeAg-negative group|"Entecavir maleate tablets (1) + blank Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks .~Blank maleate entecavir tablets (1) + Baraclude tablets (1),once a day Empty stomach (at least 2 hours after a meal or fasting), treatment for 48 weeks, then enter the open-label trial extended to 240 weeks ."
3310835|NCT01926301||Hemodialysis|Patients with severe sepsis or septic shock with acute renal failure and requirement of continuous veno-venous hemodialysis
3310836|NCT01926301||No hemodialysis|Patients with severe sepsis or septic shock without acute renal failure and no requirement of continuous veno-venous hemodialysis
3310837|NCT01926314|Experimental|device|Patients in this group will be offered pelvic floor muscle rehabilitation program using PHENIX Neuromuscular Stimulation Therapy System device. The participants will start therapy once a week 42 days after delivery, and last 8 weeks.
3310838|NCT01926314|Active Comparator|usual home care without device|Patients in this group will receive usual home care without device.
3310839|NCT01926327|Active Comparator|platelet reach plasma|The patients with osteoarthritis who underwent PRP injection.
3310840|NCT01926327|Placebo Comparator|placebo|The patients with osteoarthritis who underwent Normal Saline injection.
3310841|NCT01926340||Early maintenance treatment group|Drug (quetiapine, 400mg/d) during the 12-month randomized phase of the study
3310842|NCT01926340||Early discontinuation group|Drug (placebo) during the 12-month randomized phase of the study
3310843|NCT01926353||Vantris|Patient who categorized as who underwent endoscopic correction procedure, were patients who under general anesthesia performed by a single experienced surgeon using a 10Fr Storz® cystoscope with PPC (Vantris®) subureteral or intraureteral injection, or a combination of both techniques, depending on the anatomy of the ureteral meatus and VUR grade.
3310844|NCT01926353||Cohen reimplantation|Patient underwent surgical management were all had ureteral re-implatation with Cohen technique done by single experienced pediatric urologist.
3310845|NCT01926353||Continuous Antibiotic Prophylaxis|Group of patient treated with conservative management were children treated with culture guided antibiotics and maintained on 1st or 2nd generation cephalosporin as continuous antibiotic prophylaxis until time of 1 year follow-up.
3310846|NCT01926366|Experimental|Experimental: AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
3310847|NCT01926366|Placebo Comparator|Placebo to match AZD6423|Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo.
3310848|NCT01926379|Experimental|Combination Intervention Package (CIP)|Patients who enrolled in HIV care at a CIP site on or after January 1, 2013 and initiate Isoniazid Prevention Therapy (IPT) on or after study initiation on July 1, 2013 will receive the combination intervention components that is a part of the Combination Intervention Package (CIP).
3310849|NCT01926379|Other|Standard Of Care (IPT alone)|Patients are screened for tuberculosis (TB) at enrollment in HIV care at a HIV clinic and during each routine clinic visit using a simple symptom questionnaire. Eligible patients will receive the standard of care intervention, Isoniazid Prevention Therapy (IPT), per national guidelines. After IPT initiation, patients return to the HIV clinic monthly for monitoring of side effects, TB symptoms, self-reported 30-day adherence, and to receive a 30-day supply of isoniazid. If adherence problems are noted at any time, the nurse counsels the patient, and if the patient still wants to take IPT, it is continued.
3310850|NCT01926392|Experimental|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
3310851|NCT01926392|Active Comparator|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
3310852|NCT01926405|Other|Subjects with narcolepsy or with idiopathic hypersomnia|
3310853|NCT01926405|Other|Control patients with no sleeping disorder|
3310854|NCT01926418|No Intervention|Control|The control group receives the TPB questionnaires but receives no intervention
3310855|NCT01926418|Experimental|Implementation intentions|Participants are asked to specify when, where and how they will use condoms in the future. They will be sent weekly email reminders of their implementation intentions.
3310856|NCT01926418|Experimental|Planning task|Participants will be asked to practice the Tower of Hanoi task four times per week for ten to fifteen minutes.
3310857|NCT01926431|Experimental|Exercise|60 minutes of high intensity treadmill running
3310858|NCT01926431|Experimental|Rest|60 minutes of seated rest (control trial)
3310859|NCT01926457|Experimental|First Trimester Treatment of Prediabetes|"Patients randomized to first trimester treatment will receive the following intervention immediately initiated upon diagnosis of prediabetes at <15 weeks 0 days gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
3310860|NCT01926457|Active Comparator|Third Trimester Treatment of Prediabetes|"Patients randomized to third trimester treatment will receive the following intervention to be initiated at 28 weeks of gestation~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
3310861|NCT01926470|Experimental|anteroposterior approach group|anteroposterior approach group
3310862|NCT01926470|Active Comparator|oblique approach group|oblique approach group
3310863|NCT01926483|Experimental|Neoadjuvant Treatment|Neoadjuvant Chemoradiotherapy
3310864|NCT01926522|Experimental|Technological Rehabilitation|Experimental group receives a treatment of: 20 minutes of analyzing treadmill with feedback focused on symmetry and length of stride; 20 minutes of isokinetic dynamometric muscle strengthening of flexor and extensor muscles of tibiotarsal joint; 20 minutes of balance retraining on dynamic balance platform. Each patient receives 20 sessions over a period of 4 weeks (5 sessions per week).
3310865|NCT01926522|Active Comparator|Control Rehabilitation|Control group receives the same number of treatment sessions of same duration as those in the experimental group: activities targeted to improve the endurance (instead of analyzing treadmill ), manual exercises of lower limb muscle strengthening, stretching exercises (instead of dynamometer), gait retraining on the floor for 20 minutes and static and dynamic balance exercises in upright position (instead of dynamic balance platform).
3310866|NCT01926535|Experimental|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
3310867|NCT01926535|Active Comparator|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
3310868|NCT01926548|Experimental|CJ Imatinib 200mg|1 tablet(200mg) a day,PO,QD
3310869|NCT01926548|Active Comparator|Gleevec 100mg|2 tablet(100mg) a day,PO,QD
3310870|NCT01926561||Hypotensive bradycardic event|The participants are assigned to hypotensive bradycardic event (HBE) group when they experience signs or symptoms associated with syncope, hypotension, or bradycardia, which are treated with vasopressors or inotropics following sitting position after interscalene brachial plexus block is done. Otherwise, they are assigned to non-HBE group.
3310871|NCT01926574|Experimental|long rehabilitation|a 3.5-week, in-patient rehabilitation program, organized as a 7-hour workday with weekends off, simulating a close to normal summer work-week in Norway, and mainly group-based with maximum 8 participants per group. Focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving.
3310872|NCT01926574|Experimental|short rehabilitation|4+4 full days of rehabilitation at Hysnes Rehabilitation Center, separated by 2 weeks living at home. Group-based with 8 participants per group, focus on mental training (aimed at increasing motivation and self-efficacy), physical training and work-related problem solving. A workplace visit will be included in addition to the 4 + 4 rehabilitation days, if considered relevant.
3310873|NCT01926574|Active Comparator|Acceptance and commitment therapy|6 dynamic processes (committed action, self-as-context, presence in the moment, values, defusion and acceptance) are targeted both in group-sessions and individual meetings. Only the psychological part of the experimental interventions is applied, in an outpatient setting.
3310874|NCT01926574|No Intervention|Untouched|this group will be followed in registers at group level and not be aware of their participation in the study
3310875|NCT01926587|Experimental|Oral rigosertib plus azacitidine|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle. Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
3310876|NCT01926600||PO|administrated by per oral
3310877|NCT01926600||IV|Administrated by intravenous
3310878|NCT01926600||SL|administrated by sublingual
3310879|NCT01926613|Active Comparator|Supported Employment Only|Supported employment is an evidence based practice designed to help people with serious mental illness obtain competitive work. This vocational model adheres to the principles of zero inclusion, rapid job search, no prevocational training, attention to client preferences and integration with clinical services.
3310880|NCT01926613|Experimental|Thinking Skills for Work|The Thinking Skills for Work Program includes 5 components delivered by a Cognitive Specialist who works collaboratively with the consumer's Employment Specialist: a) assessing the consumer's strengths and weaknesses in cognitive functioning, and analysis of the contribution of cognitive impairments and other factors to job losses and difficulties obtaining a job; b) teaching coping strategies for dealing with cognitive challenges associated with job search or maintaining a job; c) computer cognitive training involving cognitive exercises with a commercially available software program, which is designed to improve the broad range of cognitive skills through a combination of practice and strategy coaching by the Cognitive Specialist; d) job search planning; and e) job support consultation.
3310881|NCT01926639|Experimental|Radiotherapy , rituximab and DC|Treatment repeated 3 times and targeting different lymph nodes
3310882|NCT01926652|Experimental|candesartan|Single administration : candesartan cilexetil 32mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
3310883|NCT01926652|Experimental|amlodipine|Single administration : amlodipine 10mg, qd. Combination administration : candesartan cilexetil 32mg and amlodipine 10mg, qd
3310884|NCT01926665|Experimental|Carfilzomib|Carfilzomib given in four doses, days 1, 2, 15 and 16, every 28 days for 6 months starting within 6 months post ASCT. Doses given in an escalated phase 1 design, starting at 20/20 mg/m2, later increased to 20/27 mg/m2, 20/36 mg/m2 and 20/45 mg/m2. CFZ dose based on actual body surface area at baseline (cycle 1). Patients with a body surface area (BSA) greater than 2.2 m2 receive dose based upon a 2.2 m2 BSA. Adjustments are not made if weight gains or losses are less than or equal to 20% from baseline. Dexamethasone 4 mg by vein or mouth prior to each CFZ dose in cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, then it should be restarted and administered prior to subsequent doses for reactions.
3310885|NCT01926678|Experimental|Swedish massage therapy|Swedish massage therapy once per week for 6 weeks
3310886|NCT01926678|Active Comparator|Light touch therapy|Light touch therapy once per week for 6 weeks
3310887|NCT01926678|Other|Wait list|A 6 week wait list, followed by randomization to massage therapy or light touch therapy once per week for 6 weeks
3310888|NCT01926691||Acute First-ever Stroke|Patients over 50 years and without pre-stroke dementia, displaying an ischemic first-ever stroke or transient ischemic attack (TIA), onset within the last 72 hours, Israeli residents.
3310889|NCT01926704||healthy, young subjects|
3310890|NCT01926717||Single Roux-y of Pancreaticojejunostomy-choledochojejunostomy|
3310891|NCT01926717||Pancreaticoduodenectomy|
3310892|NCT01926730|No Intervention|Usual diet|Patients will follow a usual diet and consume at least 16 oz of water per day
3310893|NCT01926730|Experimental|Restriction diet|Participants will follow a diet that limits intake of selected food items. Patients will consume at least 16 oz of water per day.
3310894|NCT01926743|Experimental|NIR with ICG group|
3310895|NCT01926756|Other|Straight catheterization (control)|The control arm is the current practice at our hospital (to perform straight catheterization for short procedures).
3310896|NCT01926756|Active Comparator|No straight catheterization|The experimental arm will void preoperatively and will not be straight catheterized intraoperatively. This is a change from the current practice at our hospital.
3310897|NCT01926769|Experimental|FOLFOX6+Metformin/FOFIRI+Metformin|
3310898|NCT01926795|Active Comparator|Short Leg Cast|Patient will be placed in a short leg cast for approximately 3 weeks or until radiographic union
3310899|NCT01926795|Experimental|No immobilization|No cast or splint will be applied to the injured extremity
3310900|NCT01926795|Other|Observational|Patient will be treated based on the parents comfort. This arm will consist of individuals in which the parent/guardian did not agree to randomization, but did consent for observational follow-up regardless of treatment.
3310901|NCT01926808||Vitamin D supplementation|
3310902|NCT01926821|Experimental|sonifilan|Group who get sonifilan
3310903|NCT01926821|No Intervention|control|No Sonifilan administered
3310904|NCT01926834|Experimental|Erigeron Injection|Erigeron Injection, 30ml,qd,i.v., for 7 days
3310905|NCT01926834|Placebo Comparator|placebo|normal saline, 500ml,i.v.,qd, for 7 days
3310906|NCT01926834|No Intervention|health volunteers|health volunteers, no drug to be given.
3310907|NCT01926847|Experimental|Riociguat+Placebo|Randomization order 1: first single oral dose of 2 mg BAY63-2521, then matching placebo
3310908|NCT01926847|Experimental|Placebo+Riociguat|Randomization order 2: first matching placebo, then single oral dose of 2 mg BAY63-2521
3310909|NCT01926860|Experimental|Study group - Prevenar®13 and Hepatitis A vaccines|Study group (group 1) - Prevenar®13 and Hepatitis A: one dose of each vaccine administered on Day 0
3310910|NCT01926860|Active Comparator|Pneumococcal conjugate vaccine -Control group - Prevenar®13|PCV -Control group (group 2) - Prevenar®13: one vaccine injection administered on Day 0
3310911|NCT01926860|Active Comparator|HepA -Control group - Hepatitis A vaccine|HepA -Control group (group 3) - Hepatitis A vaccine: one vaccine injection administered on Day 0
3310912|NCT01926873||Healthy volunteers|
3310913|NCT01926899|Experimental|Bortezomib administration|0.7 milligrams per meter squared given on Day 0 and Day +3
3310914|NCT01926912||Participants with schizophrenia|
3310915|NCT01926925||1|Overweight Hispanic children/adolescents
3310916|NCT01926925||2|Lean Hispanic children/adolescents
3310917|NCT01926938||adults at risk|Latino adults with family history of type 2 diabetes
3310918|NCT01926938||controls|Latino adults without family history of type 2 diabetes and normal glucose tolerance
3310919|NCT01926951|Experimental|Renal Denervation|Renal Denervation using the Kona Surround Sound Externally Focused Therapeutic Ultrasound therapy.
3310920|NCT01926964||Early breast cancer patients|Patients with ER-positive, HER2 negative, pN0 or pN1a and resected primary breast cancer R0 resection.
3310921|NCT01927003|Experimental|Surgical flap|Dorsal digito-metacarpal flap is based on the dorsal digital artery and dorsal metacarpal artery.
3310922|NCT01927016||Esophagectomy for cancer|Patients operated on for a cancer of the esophagus, a Siewert I or II cancer of the oesophago-gastric junction
3310923|NCT01927029|Experimental|Progesterone|Daily administration of vaginal progesterone, 180mg, in gel, from 18 weeks to 34 weeks.
3310924|NCT01927029|Placebo Comparator|Placebo|Placebo Gel, for daily use from 18 weeks to 34 weeks.
3310925|NCT01927042|Experimental|Expert Cares Helping Others plus Treatment as Usual|The experimental treatment (ECHOs plus TAU) will consist of the standard treatment consisting of group psychotherapy and skills training, nutritional counselling, and meal support, PLUS self-help unguided DVD series for carers, providing education about eating disorders and coping strategies for supporting those living with eating disorders.
3310926|NCT01927042|Active Comparator|Treatment as Usual|Treatment as usual (TAU) consists of group psychotherapy and skills training, nutritional counselling, and meal support.
3310927|NCT01927068|Experimental|Global Cohort 1|All subjects to be treated with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTX PTA) Balloon Catheter in Cohort 1.
3310928|NCT01927068|Experimental|Global ISR Cohort 2|"For Cohort 2, the same device was commercially available, and subjects were to be treated with the CE Marked, renamed device Stellarex 0.035 OTW drug-coated angioplasty balloon (Stellarex 035 DCB)"
3310929|NCT01927081|Active Comparator|discussion group|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain
3310930|NCT01927081|Active Comparator|discussion group + exercise|Eight weekly group sessions in which participants will engage in discussions regarding issues related to coping with advanced cancer and pain and learn gentle exercise and breathing techniques
3310931|NCT01927094|Active Comparator|Probiotic|"Saccharomyces boulardii 1 x 250 mg per day for 5 days, PO or Lactobacillus GG 1 x 10(9) CFU per day for 5 days or~Lactobacillus reuteri 1 x 10(8) CFU per day for 5 days"
3310932|NCT01927094|Active Comparator|Control|ORS-ad libitum
3310933|NCT01927107|Active Comparator|Probiotic mixture|Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach
3310934|NCT01927107|Active Comparator|Control|Standard diet therapy
3310935|NCT01927133||FIBROFRANCE Project|
3310936|NCT01927146||Resectable gastric cancer|No intervention
3310937|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine (QFT-)|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant. This group limited to adults with negative Quantiferon Gold TB (QFT) test.
3310938|NCT01927159|Experimental|2 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. Low dose of antigen and low dose of adjuvant.
3310939|NCT01927159|Experimental|10 mcg ID93 + 2 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and low dose of adjuvant.
3310940|NCT01927159|Experimental|10 mcg ID93 + 5 mcg GLA-SE Vaccine|Three intramuscular injections of ID93 + GLA-SE at Days 0, 28, and 112. High dose of antigen and high dose of adjuvant.
3310941|NCT01927159|Placebo Comparator|Saline|Three intramuscular injections of saline at Days 0, 28, and 112.
3310942|NCT01927172|Other|AirSonea|Use of AirSonea to detect wheeze sounds.
3310943|NCT01927185|Active Comparator|Long Axis strategy|The central venous catheterization will be performed by the long axis approach
3310944|NCT01927185|Active Comparator|Short Axis Strategy|The central venous catheterization will be performed by the short axis approach
3310945|NCT01927198|Experimental|RDEA3170 5 mg qd|No titration.
3310946|NCT01927198|Experimental|RDEA3170 10 mg qd|Increase from RDEA3170 5 mg to RDEA3170 10 mg qd at Week 2.
3310947|NCT01927198|Experimental|RDEA3170 12.5 mg qd|Increase from RDEA3170 10 mg to RDEA3170 12.5 mg qd at Week 4.
3310948|NCT01927198|Placebo Comparator|Placebo|Placebo group
3310949|NCT01927224|Experimental|Nifurtimox (Group 1)|Descriptive pharmacokinetic group
3310950|NCT01927224|Experimental|Nifurtimox (Group 2)|The assessment of bioequivalence of the two formulation (30mg vs.120mg)
3310951|NCT01927237|Experimental|HLR-first|"Patients in this arm will have the hypercapnia with low respiratory rate (HLR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, no additional changes will be made to the ventilator. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the EHR strategy per the cross-over design."
3310952|NCT01927237|Experimental|EHR-first|"Patients in this arm will have the eucapnia with high respiratory rate (EHR) strategy first. Once hypercapnia is achieved via inspired carbon dioxide, respiratory rate will be increased until PetCO2 returns to baseline or up to 35 breaths per minute, as limited by the National Heart Lung and Blood Institute (NHLBI) ARDS Network protocol. fraction of inspired oxygen inspired oxygen fraction and set tidal volume will be maintained. Once steady-state is achieved, physiological measurements will be taken. The patient will be returned to baseline settings for a 15-minute rest period before starting the HLR strategy per the cross-over design."
3310953|NCT01927250|Experimental|Okada Health and Wellness program|12,166 Japanese volunteers with/without illness, who were interested in practicing Okada Health and Wellness program for 3 consecutive months.
3310954|NCT01927263|Experimental|NI-071|
3310955|NCT01927263|Active Comparator|Infliximab|
3310956|NCT01927276|Placebo Comparator|Gluten Free Flour (Control)|Gluten Free Flour 10 grams daily
3310957|NCT01927276|Active Comparator|Wheat Flour|Wheat Flour 10 grams daily
3310958|NCT01927289|Active Comparator|Proximal Brachial Plexus block|15 mls of 1.5% Mepivacaine injected in the supraclavicular approach and 15 mls of saline injected in the distal forarm nerve blocks
3310959|NCT01927289|Active Comparator|Distal Forearm block|15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach
3310960|NCT01927302|Experimental|Naming Deficits|Language treatment will focus on improving naming deficits in people who have aphasia. An experimental group will receive treatment focusing on naming objects and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3310961|NCT01927302|Experimental|Spelling and/or Writing Deficits|Language treatment will focus on improving writing and/or spelling deficits in people who have aphasia. An experimental group will receive treatment focusing on improving spelling abilities and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3310962|NCT01927302|Experimental|Sentence Processing|Language treatment will focus on improving sentence comprehension and production deficits in people who have aphasia. An experimental group will receive treatment focusing on improving sentence processing and a control/natural history group will receive no treatment. Both groups will be assessed at baseline (week 0), at week 12, and at week 24.
3310963|NCT01927315|Experimental|Fenofibrate|Fenofibrate 145 mg (Fulcrosupra) oral tablets daily for 12 weeks
3310964|NCT01927315|Placebo Comparator|Placebo|Placebo oral tablets daily for 12 weeks
3310965|NCT01927328|No Intervention|Control|Standard Care as determined by the clinical team
3310966|NCT01927328|Active Comparator|Iron isomaltoside 1000|Intravenous Iron Isomaltoside 1000 (Monofer®)will be administered in line with the summary of product characteristics.
3310967|NCT01927354||Head and neck cancer|Subjects who suffer from oral cancer. Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.
3310968|NCT01927380||brachytherapy|males undergoing elective laparoscopic radical prostatectomy steep trendelenburg position with pneumoperitoneum
3310969|NCT01927393|Experimental|Arm I (PCPI)|Patients undergo a comprehensive physical, psychological, social, and spiritual palliative care assessment. Patients also receive a workbook that covers physical and psychological well-being and social and spiritual well-being, delivered over 2 educational sessions.
3310970|NCT01927393|Active Comparator|Arm II (standard care plus attention control)|Patients receive standard care plus attention comprising two telephone contacts.
3310971|NCT01927406|Experimental|Prostaglandin Analog vs Timolol|In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.
3310972|NCT01927406|Experimental|Prostaglandin Analog|In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.
3310973|NCT01927432||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles.
3310974|NCT01927432||Irregular menstrual cycles|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, including women with a pre-existing diagnosis of PCOS.
3310975|NCT01927445|No Intervention|Usual care|No standardized intervention for management of patients with atrial fibrillation. Instead participants receive interventions for management of chronic kidney disease.
3310976|NCT01927445|Experimental|quality improvement toolkit|The toolkit includes provider-focused strategies (education, audit and feedback, electronic decision support and reminders) plus patient-directed strategies (educational letters and reminders).
3310977|NCT01927458|Experimental|anodal tDCS with treadmill training|Each subject will receive 4 weeks gait treadmill training at least 3 days per week in combination with anodal transcranial Direct Current Stimulation over the primary motor cortex up to 20 min
3310978|NCT01927471||Regular menstrual cycles|Adult women will be assigned to this category if they report a history of regular menstrual cycles. We will aim to recruit 120 women in this category.
3310979|NCT01927471||Irregular menstrual cycles, no PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles, without a pre-existing diagnosis of PCOS. We will aim to recruit 120 women in this category.
3310980|NCT01927471||Irregular menstrual cycles, with PCOS|Adult women will be assigned to this category if they report a history of irregular menstrual cycles with a pre-existing diagnosis of PCOS by a physician. We will aim to recruit 120 women in this category.
3310981|NCT01927484|Experimental|methotrexate|25mg oral methotrexate tablets
3310982|NCT01927484|Placebo Comparator|placebo|25 mg/week placebo tablets
3310983|NCT01927510|Experimental|early mobilisation|intervention of early mobilisation
3310984|NCT01927510|No Intervention|Control|Standard care
3310985|NCT01927523|No Intervention|Control group|These youth will not receive the non-academic cognitive behavioral programming nor the intensive academic mathematics tutoring.
3310986|NCT01927523|Experimental|BAM Group Therapy & Match Math Tutoring|These youth will receive both the non-academic cognitive behavioral programming and the intensive academic mathematics tutoring.
3310987|NCT01927523|Experimental|BAM Group Therapy|These youth will receive the non-academic cognitive behavioral programming.
3310988|NCT01927523|Experimental|Match Math Tutoring|These youth will receive the intensive academic mathematics tutoring.
3310989|NCT01927536||Night Vision|White LED Flashlight, Red/Green Green Dominant LED Flashlight
3310990|NCT01927549|Active Comparator|Immediate multivessel PCI|After diagnostic angiography the culprit lesion is identified and PCI should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All additional lesions in other major coronary arteries defined by a diameter >2 mm with high grade stenoses (>70% by visual assessment) should be intervened using standard techniques. Other major coronary arteries are defined by stenoses of other vessels and are not confined to a diagonal branch if the left anterior descending coronary artery was identified as the culprit lesion.
3310991|NCT01927549|Active Comparator|Culprit lesion only PCI|After diagnostic angiography the culprit lesion is identified and PCI of the culprit lesion should be performed using standard techniques. The use of drug-eluting stents is recommended but not mandatory. All other lesions should be left untreated in the acute setting. Complete revascularization of the non-culprit lesions may be performed at a later time point as staged procedure depending on remaining ischemia (as per guideline recommendations either by PCI or CABG).
3310992|NCT01927588|Experimental|Everolimus+Tacrolimus+Prednisone|Certican 3mg/daily for 12 months TACreduced 0,15mg/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
3310993|NCT01927588|Active Comparator|Mycophenolate+Tacrolimus+Prednisone|Myfortic 720mg twice daily for 12 months TACreduced full dose/Kg/daily for 12 months Steroids 1mg/Kg/daily for 12 months
3310994|NCT01927614||Cohort 1|20 patients 1-year post heart transplant will undergo standard of care invasive cardiac catheterization but will also have intravascular ultrasound performed to measure the maximal intimal thickness of the proximal left anterior descending artery. Patients will be dichotomized into those with MIT <0.5mm (10 patients) and those with MIT >0.5mm (10 patients). All 20 patients will undergo both cardiac CT and cardiac MRI with perfusion imaging.
3310995|NCT01927614||Cohort 2|10 patients 1 year post heart transplant classified as CAV grade 0 by standard cardiac catheterization will undergo both cardiac CT and cardiac MRI with perfusion imaging.
3310996|NCT01927614||Cohort 3|10 patients with a diagnosis of CAV grade 1 as assessed by routine coronary angiogram at any time point post heart transplantation, will undergo cardiac CT and cardiac MRI with perfusion imaging
3310997|NCT01927640|Experimental|Dexmedetomidine and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Dexmedetomidine (0.3-0.6 mcg/kg) infusion
3310998|NCT01927640|Placebo Comparator|Normal saline and intranasal cocaine|Intranasal cocaine administration (2 mg/kg) then Saline (over 10 minutes I.V. infusion)
3310999|NCT01927653||The patients with amnestic MCI|"The patients with single domain amnestic MCI have a Clinical Dementia Rating score of 0.5 with isolated memory impairment without deficits in other cognitive domains. A cutoff scores below 1.5 Standard Deviation (SD) (or 7 percentile) of one of the tests in domains of cognitions employed psychometric tests; They should meet the following criteria:~memory complaint~normal general cognition~normal activities of daily living~not demented"
3311000|NCT01927653||The patients with dysexecutive MCI|"The patients of dMCI have relatively focal dysfunction in executive domain with the tests of memory, language and visuospatial skills within normal limits. The patients with single domain dysexecutive MCI should meet the following criteria:~relatively focal executive dysfunction~Within reference range on tests of memory, language and visuospatial skills~normal general cognition~normal activities of daily living~not demented"
3311001|NCT01927653||The healthy volunteers|"The healthy volunteers should be normal neuropsychological assessments as well as CDR=0 without significant neuropsychiatric disorder, right-handed, gender balanced and meet the following criteria:~Age and gender matched healthy subjects without significant neuropsychiatric disorder~Able to understand and provide signed informed consent"
3311002|NCT01927666|Experimental|dietary intervention|To measure the variation in extent of ITC excretion in urine from a capsule delivered dose of 100mg glucoraphanin
3311003|NCT01927679|Other|Antioxidant (LB) + control (UB)|Antioxidant will be weighed and applied to an area on the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
3311004|NCT01927679|Other|Antioxidant (UB) and Control (LB)|Antioxidant will be weighed and applied to an area on the upper back (UB) to be exposed with visible light at a concentration of 2 mg/cm^2. Control will also be weighed and applied to an area of the lower back (LB) to be exposed with visible light at a concentration of 2 mg/cm^2. These will be applied according to the randomization scheme.
3311005|NCT01927692||MG subjects|MG subjects will have serum acetylcholine receptor (AChR) antibodies
3311006|NCT01927705|Experimental|Treatment|"FURESTEM-AD Inj. 1. 2.5 x 10^7 stem cells after registration.~FURESTEM-AD Inj. 2. 5.0 x 10^7 stem cells after registration."
3311007|NCT01927731|Experimental|Arm I (cord blood transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day -1.
3311008|NCT01927731|Experimental|Arm II (haploidentical donor stem cell transplant patients)|Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.
3311009|NCT01927744|Experimental|Chemotherapy + Erlotinib|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus Erlotinib 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
3311010|NCT01927744|Experimental|Chemotherapy + Placebo|Docetaxel 75 mg/m2 by vein followed by Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles, plus placebo 150 mg by mouth daily continuously until the day before surgery. Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery. Phone call made to patient 1 time each year after the end of treatment visit.
3311011|NCT01927822||Pregnancy|Women who underwent termination of pregnancy at second trimester due to a variety of causes
3311012|NCT01927835|Experimental|Group 1A: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311013|NCT01927835|Experimental|Group 1B: Treatment|Participants will receive the DNA-HIV-PT123 vaccine administered as 1 mL intramuscularly (IM) and placebo (sodium chloride for injection, 0.9%) administered as 1 mL each in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311014|NCT01927835|Experimental|Group 2A: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311015|NCT01927835|Experimental|Group 2B: Treatment|Participants will receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine, each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive the NYVAC-HIV-PT1 vaccine and the NYVAC-HIV-PT4 vaccine; each will be administered as 1 mL IM in the left deltoid, and the AIDSVAX B/E vaccine administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311016|NCT01927835|Placebo Comparator|Group 3A: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311017|NCT01927835|Placebo Comparator|Group 3B: Placebo|Participants will receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid at Months 0 and 1. They will then receive two injections of placebo (sodium chloride for injection, 0.9%) each administered as 1 mL IM in the left deltoid, and 1 injection of placebo (sodium chloride for injection, 0.9%) administered as 1 mL IM in the right deltoid at Months 3 and 6.
3311018|NCT01927848|Experimental|Rosehip|Dosage: 3 capsules once daily with meals (daily dose: 2.25 g powder).
3311019|NCT01927848|Placebo Comparator|Placebo|Dosage: 3 capsules once daily with meals
3311020|NCT01927874|Active Comparator|Infiltration, analgesic effect|10ml 0.5% bupivacaine each side Block Injection of local anesthetic at pudendal nerve
3311021|NCT01927874|Active Comparator|Spinal block|10 mg of hyperbaric 0.5% bupivacaine Injection of anesthetic at subarachnoidal space
3311022|NCT01927900|Active Comparator|HMO1|HMO diluted in water
3311023|NCT01927900|Placebo Comparator|Glucose|Glucose diluted in water
3311024|NCT01927900|Active Comparator|HMO2|HMO diluted in water
3311025|NCT01927900|Active Comparator|HMO3|HMO diluted in water
3311026|NCT01927900|Active Comparator|HMO4|HMO diluted in water
3311027|NCT01927900|Active Comparator|HMO5|HMO diluted in water
3311028|NCT01927900|Active Comparator|HMO6|HMO diluted in water
3311029|NCT01927900|Active Comparator|HMO7|HMO diluted in water
3311030|NCT01927900|Active Comparator|HMO8|HMO diluted in water
3311031|NCT01927900|Active Comparator|HMO9|HMO diluted in water
3311032|NCT01927913|Experimental|SPD602|
3311033|NCT01927913|Active Comparator|Deferasirox|
3311034|NCT01927926|Experimental|Whey-protein & polydextrose snack|Whey-protein & polydextrose snack bar.
3311035|NCT01927926|Placebo Comparator|Control snack|Control snack bar containing minimal protein and not polydextrose.
3311036|NCT01927939||Histological proven breast cancer with bone lesion|
3311037|NCT01927952|Active Comparator|Kirschner wire|surgical fixation using a Kirschner wire
3311038|NCT01927952|Active Comparator|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
3311039|NCT01927952|Active Comparator|Stryker Smart-Toe implant|surgical fixation utilizing the Stryker Smart-Toe implant
3311040|NCT01927965|Experimental|Minnelide™ 001|A Phase 1, Multi-Center, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™ given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
3311041|NCT01927978||esophageal cancer, 18F-FDG PET|
3311042|NCT01927991|Experimental|iCBT with therapeutic support|Participants work with the online self-help and receive additional therapeutic support on demand
3311043|NCT01927991|Active Comparator|iCBT without therapeutic support|Participants work with the online self-help on their own and do not receive additional therapeutic support
3311044|NCT01928004|Experimental|implant placement|insertion of 2 interforaminal mandibular implants and conversion of the lower complete denture to an implant-overdenture
3311045|NCT01928004|Active Comparator|denture reline|conventional reline of mandibular complete denture
3311046|NCT01928017||Hematooncology patients|No intervention
3311047|NCT01928043|Experimental|adjunctive curcumin|Curcumin will be added to their current medications for 8 weeks. Starting dose will be 500mg daily, increased to 500mg twice daily in week 2, then increased to 1000mg twice daily during weeks 3-8. A slower titration will be used for subjects who demonstrate tolerability problems.
3311048|NCT01928095||Carotid Endocardectomy Patients|Subsequent analyses will be performed on the basis of the pathological grading provided by UK Pathology (e.g do readouts of the Dicer pathway correlate with pathological plaque characteristics).
3311049|NCT01928108||iPhone Application|"Participants using an iPhone will download the waterlogged application and use this to track daily water intake for 1 week."
3311050|NCT01928108||Android Application|"Participants using an Android cell phone will download the water your body application and use this to track daily water intake for 1 week."
3311051|NCT01928121|Experimental|AF expert program|Care provided by the interdisciplinary, nurse-coordinated AF expert program
3311052|NCT01928121|No Intervention|Usual care|
3311053|NCT01928134|Experimental|A|Vit K2+ Vit D3+ calcium carbonate (CaCO3)
3311054|NCT01928134|Active Comparator|B|Vit K2+CaCO3
3311055|NCT01928147|Experimental|PPI-383 single dose escalation in healthy volunteers|There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations; a food effect cohort will be included.
3311056|NCT01928147|Experimental|PPI-383 multiple doses in healthy volunteers|Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days; up to additional cohorts may receive multiple doses of different formulations or different regimens
3311057|NCT01928147|Experimental|PPI-383 multiple dose escalation in HCV Subjects|Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients
3311058|NCT01928160|Experimental|Arm I (chemotherapy, erlotinib hydrochloride)|Patients receive erlotinib hydrochloride PO QD on days 1-21, pemetrexed disodium IV and carboplatin IV or cisplatin IV on day 1. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance erlotinib hydrochloride PO QD on days 1-21 and pemetrexed disodium IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3311059|NCT01928160|Experimental|Arm II (chemotherapy)|Patients receive pemetrexed disodium and carboplatin or cisplatin as in Arm I. Treatment repeats every 21 days for 4 courses. Patients then receive maintenance pemetrexed disodium as in Arm I. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3311060|NCT01928173|Active Comparator|Abbreviated cognitive behavioral therapy|Arm 1 is a multi-component package including sleep hygiene, stimulus control, cognitive therapy, and passive relaxation.
3311061|NCT01928173|Active Comparator|Sleep education/sleep hygiene|Arm 2 consists of education about sleep and fatigue as well as sleep hygiene recommendations (e.g., avoiding nicotine and caffeine late in the day).
3311062|NCT01928212||healthy control|Sex- and agematched healthy subjects
3311063|NCT01928212||Parkinson group|Patients with Parkinson's disease
3311064|NCT01928238|Experimental|Arm 1|"Patients will have two 20-minute noninvasive periods :~Noninvasive neurally adjusted ventilatory assist (NIV-NAVA) and then Noninvasive pressure support ventilation (NPSV)"
3311065|NCT01928238|Experimental|Arm 2|"Patients will have two 20-minute noninvasive periods :~Noninvasive pressure support ventilation (NPSV) and then Noninvasive neurally adjusted ventilatory assist (NIV-NAVA)"
3311066|NCT01928251|Experimental|Informed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days at 3-month follow-up and pass the 3-month biochemical validation (Exhaled carbon monoxide level < 4 ppm, saliva cotinine level < 10 ng/ml) (Group A-Q). Participants will be informed about the incentives through telephone follow-up at 1 week and 1 month. Those who have not quitted at 3 months (Group A-N) or those self-reported quitters who refuse to participate in biochemical validation will be informed again that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
3311067|NCT01928251|Experimental|Uninformed early monetary incentive|Incentives of abstinence will be given to those who self-report abstinence for the past 7 days and pass the 3-month biochemical validation (Group B-Q), but they will not be informed about the incentive at the 1-week and 1-month follow-up. Those who have not quitted at 3 months (Group B-N) or those self-reported quitters who refuse to participate in the biochemical validation will be informed that they will be given the same incentive if they have quitted at 6 months and the quitting is validated.
3311068|NCT01928251|No Intervention|Uninformed late monetary incentive|Incentives for the self-reported and biochemically-validated abstinence at 6-month follow-up will be given after the 6-month biomedical validation. They would not be informed about the incentive at the 1-week, 1-month and 3-month follow-up. Group C also has two subgroups, those who have quitted at 3 months (Group C-Q) and those who have not (Group C-N).
3311069|NCT01928264|Experimental|Physical activity|Physical activity group program over 12 weeks; 1 hour sessions, 2 times a week
3311070|NCT01928264|No Intervention|Leisure time activities|Predominantly sedentary leisure time group activities, like playing board games, doing handicrafts, etc.; 12 weeks, 1 hour sessions, 2 times a week
3311071|NCT01928277||ICU-patients|ICU-patients weaning form mechanical ventilation
3311072|NCT01928303||Chronic Pain Patients taking opioid medications|Oral fluid, blood and urine samples will be obtained from chronic pain patients who are taking pain medications from the opioid class of drugs.
3311073|NCT01928303||Negative controls|At least 10% of the total subject population. Chronic pain patients who are not taking pain medication from the opioid class of drugs.
3311074|NCT01928316|Experimental|Sequence A|Healthy male volunteers will receive single oral dose of 10 mg imported mizolastine tablet on Day 1 and single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 8.
3311075|NCT01928316|Experimental|Sequence B|Healthy male volunteers will receive single oral dose of 10 mg domestic (made in China) mizolastine tablet on Day 1 and single oral dose of 10 mg imported mizolastine tablet on Day 8.
3311076|NCT01928342|Experimental|Coenzyme A 400mg|Coenzyme A 400mg per day
3311077|NCT01928342|Placebo Comparator|Placebo|Capsule without coenzyme A.
3311078|NCT01928355||metabolically healthy|
3311079|NCT01928355||Unhealthy|
3311080|NCT01928368|Active Comparator|Experimental Arm|
3311081|NCT01928368|Placebo Comparator|Placebo Arm|
3311082|NCT01928407|Experimental|ATAZANAVIR|The patient included in this Group 1 will receive their first antiretroviral regimen included : ATV + TDF/FTC (or Abacavir/Lamivudine, [ABC/3TC], if contre indicated of TDF/FTC) The dose : atazanavir/ritonavir 300/100mg/day and TDF/FTC 245 /200 mg day, 3 pills once a day, during 48 weeks during a meal
3311083|NCT01928407|Experimental|DARUNAVIR|The patients included in this Group 2 will receive their first antiretroviral regimen included Group 2 : DRV+ TDF/FTC (or ABC/3TC if contre-indicated of TDF/FTC) The dose : darunavir/ritonavir 800/100mg/day and TDF/FTC 245 /200 mg day, 4 pills once a day, during 48 weeks during a meal
3311084|NCT01928420|Experimental|NIC5-15|Subjects with Alzheimer's Disease Intervention: Drug: NIC5-15
3311085|NCT01928420|Placebo Comparator|Placebo|Subjects with Alzheimer's Disease Intervention: Drug: Placebo
3311086|NCT01928459|Experimental|Metastatic breast cancer|Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.
3311087|NCT01928459|Experimental|Solid tumor arm 1|Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.
3311088|NCT01928459|Experimental|Solid tumor arm 2|Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3
3311089|NCT01928459|Experimental|Dose escalation|To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.
3311090|NCT01928498|Experimental|Paclitaxel Eluting Balloon|Paclitaxel Eluting Balloon Angioplasty
3311091|NCT01928498|Active Comparator|Conventional uncoated balloon|Percutaneous Transluminal Angioplasty (PTA)
3311092|NCT01928511|Active Comparator|Continued oral nucleos(t)ide therapy|Patients assigned to this arm will continue their nucleos(t) analogue
3311093|NCT01928511|Experimental|Add on peg-interferon|Patients assigned to this arm will continue their existing nucleos(t)ide therapy and also be assigned peg-interferon alpha 2b 1.5mcg/kg sc weekly
3311094|NCT01928511|Experimental|switch to peg-interferon|Patients assigned to this arm will stop their existing nucleos(t)ide therapy after one month overlap after starting peg-interferon alpha 2b 1.5mcg/kg sc weekly
3311095|NCT01928537|Experimental|rigosertib sodium|Rigosertib sodium will be administered as a 72-hr continuous intravenous infusion consisting of 3 consecutive doses of 1800 mg over 24 hours on Days 1, 2, and 3 of a 14-day cycle for the first 8 cycles and then on Days 1, 2, and 3 of a 28-day cycle for the following cycles.
3311096|NCT01928550||PDR patients|Patients suspected to have Proliferative Diabetic Retinopathy or PDR
3311097|NCT01928563|Experimental|Dapoxetine|Dapoxetine is administered
3311098|NCT01928563|Experimental|Udenafil|Udenafil is administered
3311099|NCT01928563|Experimental|Udenafil and Dapoxetine|Udenafil and Dapoxetine are co-administered
3311100|NCT01928576|Experimental|Arm C|Nivolumab 3mg/kg every 2 weeks until progression
3311101|NCT01928576|Experimental|Arm D|"Anti-PD-1/PD-L1 treatment naïve patients only~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
3311102|NCT01928576|Experimental|Arm E|"Patients must have had refractory (Arm E=less than 24 weeks from first dose of anti-PD-1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
3311103|NCT01928576|Experimental|Arm F|"Patients must have had recurrent (Arm F=more than 24 weeks from first dose of anti-PD1/PD-L1) disease during or after anti-PD-1 or anti-PD-L1 therapy and, in the opinion of the investigator, must be unlikely to benefit from nivolumab monotherapy.~Every 28 days for 6 cycles Azacitidine 40mg/m2 days 1-5 and 8-10 Entinostat 5mg Days 3 and 10 Nivolumab 3mg/kg Days 1 and 15~Followed by:~Nivolumab 3mg/kg every 2 weeks until progression~After a patient has completed 6 months of nivolumab, they can receive nivolumab every 4 weeks instead of every 2 weeks. The dose for Nivolumab every 4 weeks is 480mg."
3311104|NCT01928589|Active Comparator|PBI|270 cGy (centigray) x 15
3311105|NCT01928589|Experimental|PBI with chemotherapy|270 cGy (centigray) x 15 concurrent with chemotherapy of the treating medical oncologist's choice
3311106|NCT01928602|Experimental|Expressive Aphasia Group A|"Behavioral: TherAppy Language App~Behavioral: Mind-Games"
3311107|NCT01928602|Experimental|Expressive Aphasia Group B|"Behavioral: Mind-Games~Behavioral: TherAppy Language App"
3311108|NCT01928628|Active Comparator|Lercanidipine 10mg|1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
3311109|NCT01928628|Experimental|Lercanidipine10mg /Valsartan 80mg|1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
3311110|NCT01928628|Experimental|Lercanidipine 10mg /Valsartan 160mg|1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
3311111|NCT01928641||Discrepancy in stroke onset|Patients with discrepancy in stroke symptom onset based on the diagnosis of the first neurologist who evaluated the patient at emergency room and the next day after admission
3311112|NCT01928654|Experimental|Micropulse laser treatment|Sub-threshold laser treatment covering the area of retinal thickening with a dense pattern
3311113|NCT01928654|Active Comparator|Laser modified ETDRS|Macular treatment using the modified ETDRS protocol, with barely visible laser burns to close microaneurysms, or with a grid pattern in the area of retinal thickening.
3311114|NCT01928667||Microscopic Colitis|Group consists of subjects diagnosed with either collagenous of lymphocytic colitis between January 1, 2000 and December 31, 2012
3311115|NCT01928667||Healthy Controls|Control group consists of subjects with no history of microscopic colitis. Group is age and sex matched with the case-group
3311116|NCT01928706|Experimental|Denture liner Mucopren Soft; Group 1|The existing mandibular dentures were relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22).
3311117|NCT01928706|Active Comparator|Denture liner Kooliner; Group 2|The existing mandibular dentures were relined with a a hard acrylic resin based denture liner (Kooliner; Group 2 n=22).
3311118|NCT01928732|Active Comparator|CPT|Cognitive Processing Therapy (CPT) - a type of cognitive therapy for treating PTSD.
3311119|NCT01928732|Active Comparator|PE|Prolonged Exposure (PE) - a type of exposure therapy for treating PTSD.
3311120|NCT01928745||CABG patients|15 patient who underwent a CABG will be submitted in this study
3311121|NCT01928745||Sepsis patients|15 patients with a severe sepsis will be admitted in this study
3311122|NCT01928784|Experimental|Specific pain spot|Radial Extracorporeal Shock Wave Therapy 2000 impulses, Patients with specific pain spot for low back pain
3311123|NCT01928784|Experimental|No specific pain spot|Radial Extracorporeal Shock Wave Therapy 4000 impulses, Patients without specific pain spot for low back pain
3311124|NCT01928810|Experimental|70% VO2max|"Cognitive Behavioural Therapy (CBT)~+ aerobic exercise (30 minutes, 70% VO2max) prior to 5 in-vivo exposure sessions"
3311125|NCT01928810|Active Comparator|30% VO2max|"Cognitive Behavioural Therapy (CBT)~+ placebo exercise (30 minutes, 30% VO2max) prior to 5 in-vivo exposure sessions"
3311126|NCT01928823|Experimental|D-Cycloserine + CBT|Patients receiving CBT (cognitive behavioral therapy) and D-Cycloserine (3 times, 50 mg, oral) directly after an exposure
3311127|NCT01928823|Placebo Comparator|Placebo + CBT|Patients receiving CBT (cognitive behavioral therapy) and a placebo pill (3 times, looking identical to the DCS pill) directly after an exposure
3311128|NCT01928836||Non-suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung nodule lesion in the chest (based on local CT result);~Without the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
3311129|NCT01928836||Suspected lung cancer group|"Aged 40 to 75 years;~Male smoker (≥400 cig/year), female smoker or non-smoker;~Visible lung cancer lesion in the chest (based on local CT result);~With the indication of biopsy (bronchoscope or percutaneous transthoracic) or surgery."
3311130|NCT01928875|Experimental|Adequacy of Anesthesia (AoA) Monitoring|Adequacy of Anesthesia monitoring with SPI and Entropy
3311131|NCT01928875|Active Comparator|Routine (Standard) Anesthesia Monitoring|
3311132|NCT01928888|Experimental|Arm HFP|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Famotidine, 3rd heartburn episode Placebo
3311133|NCT01928888|Experimental|Arm HPF|1st heartburn episode Intervention Hydrotalcid, 2nd heartburn episode Placebo, 3rd heartburn episode Famotidine
3311134|NCT01928888|Experimental|Arm FHP|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Placebo
3311135|NCT01928888|Experimental|Arm FPH|1st heartburn episode Intervention Famotidine, 2nd heartburn episode Placebo, 3rd heartburn episode Hydrotalcid
3311136|NCT01928888|Experimental|Arm PHF|1st heartburn episode Intervention Placebo, 2nd heartburn episode Hydrotalcid, 3rd heartburn episode Famotidine
3311137|NCT01928888|Experimental|Arm PFH|1st heartburn episode Intervention Placebo, 2nd heartburn episode Famotidine, 3rd heartburn episode Hydrotalcid
3311138|NCT01928901|Experimental|administration of Bronchipret|7 days of administration of Bronchipret, 2 FCT t.i.d
3311139|NCT01928901|Experimental|administration of Sinupret|7 days of administration of Sinupret, 2 CT t.i.d
3311140|NCT01928901|Placebo Comparator|administration of Bronchipret Placebo|7 days of administration of Bronchipret Placebo, 2 FCT t.i.d
3311141|NCT01928901|Placebo Comparator|administration of Sinupret Placebo|7 days of administration of Sinupret Placebo, 2 CT t.i.d
3311142|NCT01928914|Placebo Comparator|Group 1|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
3311143|NCT01928914|Experimental|Group 2|Subjects in group 2 receive 400mg of tafenoquine and placebo for moxifloxacin on three consecutive days of dosing
3311144|NCT01928914|Active Comparator|Group 3|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for tafenoquine and 400mg moxifloxacin.
3311145|NCT01928914|Experimental|Group 4|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 300mg of tafenoquine
3311146|NCT01928914|Experimental|Group 5|Subjects in group 1 receive placebo for tafenoquine and placebo for moxifloxacin on days 1 and 2. On day 3, subjects receive placebo for moxifloxacin and 600mg of tafenoquine
3311147|NCT01928966|Active Comparator|Group I - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four weeks of study: receive 1.5 ounces of pumpkin seeds per day for consumption; Third four weeks of the study: consume their perceived normal diet.
3311148|NCT01928966|Active Comparator|Group II - Pumpkin Seeds|First four weeks of study: consume perceived normal diet; Second four week period: consume perceived normal diet; Third four week period: receive 1.5 ounces of pumpkin seeds per day for consumption.
3311149|NCT01928979||Group 1|
3311150|NCT01928992||3D|Subjects that undergo 3D mammography
3311151|NCT01928992||2D|Subjects that undergo 2D mammography
3311152|NCT01929005|No Intervention|Standard of Care|If patients are randomized to standard of care, they are not assigned to a Comprehensive Care Physician. They are asked to continue receiving their care as they normally would.
3311153|NCT01929005|Experimental|Comprehensive Care|Patients randomized to the Comprehensive Care group are assigned to a Comprehensive Care physician and are asked to see their assigned CCP for their primary care. The patients will receive their care by the CCP in the outpatient clinic and also if they were to be hospitalized.
3311154|NCT01929070|Experimental|Group 1|"R1: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap in the fasting state~R2: Coadministration of Crestor 5mg 4tab and Omacor capsupe 1g 4cap on the high-fat diet~T1: Single-dose of HCP1007 1g/5mg 4 cap in the fasting state~T2: Single-dose of HCP1007 1g/5mg 4 cap on the high-fat diet~R1 -> T2 -> R2 -> T1"
3311155|NCT01929070|Experimental|Group 2|R2 -> R1 -> T1 -> T2
3311156|NCT01929070|Experimental|Group 3|T1 -> R2 -> T2 -> R1
3311157|NCT01929070|Experimental|Group 4|T2 -> T1 -> R1 -> R2
3311158|NCT01929096|Experimental|Low-dose group|Compound Edaravone Injection, 12.5mg/dose (Edaravone 10mg, (+)-Borneol 2.5mg), one dose every 12 hours, continue for 14 days
3311159|NCT01929096|Experimental|Medium-dose group|Compound Edaravone Injection, 37.5mg/dose (Edaravone 30mg, (+)-Borneol 7.5mg), one dose every 12 hours, continue for 14 days
3311160|NCT01929096|Experimental|High-dose group|Compound Edaravone Injection, 62.5mg/dose (Edaravone 50mg, (+)-Borneol 12.5mg), one dose every 12 hours, continue for 14 days
3311161|NCT01929096|Active Comparator|Control group|Edaravone Injection，30 mg/dose, one dose every 12 hours, continues for 14 days
3311162|NCT01929122|Placebo Comparator|Placebo-Control|Randomized participants consume 1 meal and 1 snack per day that does not include either rice bran or navy bean powder for 28 days.
3311163|NCT01929122|Experimental|Cooked Navy Bean Powder|Randomized participants consume 1 meal and 1 snack per day containing cooked navy bean powder (35 g/day) for 28 days.
3311164|NCT01929122|Experimental|Rice Bran|Randomized participants consume 1 meal and 1 snack per day containing rice bran (30 g/day) for 28 days.
3311165|NCT01929148|Experimental|Laparoscopic myomectomy plus PBS|A Laparoscopic myomectomy plus Prophylactic bilateral salpingectomy will be performed in women which have accomplished their reproductive desire
3311166|NCT01929148|Active Comparator|Laparoscopic myomectomy without PBS|A standard laparoscopic myomectomy without any prophylactic salpingectomy will be performed
3311167|NCT01929161|Experimental|Oxytocin|Oxytocin intranasal spray, 6 intranasal sufflations which deliver a total of 24 international units of oxytocin
3311168|NCT01929161|Placebo Comparator|Placebo (for oxytocin)|Intranasal spray with all equivalent ingredients except oxytocin
3311169|NCT01929161|Experimental|Lovingkindness Meditation|Lovingkindness guided meditation experienced in the laboratory and 6 additional LKM meditations taken home on the iPod.
3311170|NCT01929161|Placebo Comparator|Mindfulness Meditation|Mindfulness guided meditation experienced in the laboratory and 6 additional Mindfulness meditations taken home on the iPod.
3311171|NCT01929174||Controls|Patients undergoing catheterization for other reasons who have a normal biventricular heart.
3311172|NCT01929174||Single ventricle Fontan|"Patients with a single functional ventricle (excluding hypoplastic left heart syndrome) palliated with a Fontan type operation involving passive blood flow to the lungs."
3311173|NCT01929187|Active Comparator|Phytonail|Phytonail is a mixture of herbal active ingredients including tea tree oil, lavender oil and Australian blue cypress (ABC) oil with BioEqual carrier system.
3311174|NCT01929187|Active Comparator|amorolfine 5% nail lacquer|5% amorolfine
3311175|NCT01929200|Experimental|1-year treatment with icotinib|Patients will receive 1-year treatment with icotinib after operation.
3311176|NCT01929200|Experimental|2-year treatment with icotinib|Patients will receive 2-year treatment with icotinib after operation.
3311177|NCT01929213|Experimental|Udenafil|
3311178|NCT01929213|Experimental|Bosentan|
3311179|NCT01929213|Experimental|Udenafil/Bosentan|
3311180|NCT01929239|Experimental|Anti PSMA Designer T Cells|Open Label, subjects receive anti PSMA designer T cells, plus IL2, low or moderate dose.
3311181|NCT01929252|Active Comparator|Dexmedetomidine|%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.
3311182|NCT01929252|Active Comparator|Levobupivacaine|%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.
3311183|NCT01929265|Experimental|Rituximab - Bendamustine (RB)|"1 arm: Rituximab - Bendamustine (RB)~1 arm for all patients"
3311184|NCT01929278|Experimental|CT Gel patch|CT Gel is a reformulation of VELAC Gel that contains the same active ingredients (clindamycin 1% and tretinoin 0.025%) in a modified vehicle. The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
3311185|NCT01929278|Placebo Comparator|Vehicle gel patch|The test article was placed on a separate occlusive patch at volumes of 200 µL per patch.
3311186|NCT01929278|Experimental|Blank patch|Blank patches did not contain CT Gel or vehicle gel.
3311187|NCT01929304||Video|Patients in this group will be shown an informational video, narrated in English.
3311188|NCT01929304||Text|Patients in this group will read a single-page printed information sheet in English.
3311189|NCT01929330|Experimental|Sequence AB|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A), in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subject will receive or 5 x 0.1mg oral dose of dutasteride (Sequence B) in similar fashion as that of Sequence A. The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
3311190|NCT01929330|Experimental|Sequence BA|Subjects will be hospitalized to the clinical unit on the evening of Day -1. All subjects will receive 5 x 0.1mg oral dose of dutasteride (Sequence B) in the morning; Subjects will remain in the clinical unit until completion of all assessments at 24 hours post-dose on Day 2 including collection of the 24 hour post-dose PK sample. Subjects will return to the unit for the remaining PK samples at 36, 48 and 72 hours. The subjects will receive 1 x 0.5mg oral dose of dutasteride (Sequence A) in similar fashion as that of Sequence B, The two treatment sequences will be separated by a minimum washout period of 28 days to ensure that dutasteride is effectively eliminated from the subject between dosing occasions.
3311191|NCT01929356|Experimental|chest physiotherapy|session of 20 minutes chest physiotherapy with physiotherapist, use of airway clearance techniques, PEP (positive expiratory pressure) device
3311192|NCT01929369||CONTROL GROUP|Control group: index intervention guided by DSA; IVUS post-intervention only (50 patients)
3311193|NCT01929369||TEST GROUP|Test group: index intervention guided by IVUS + DSA (50 patients
3311194|NCT01929382|Active Comparator|Actimmune (interferon gamma 1b)|Subjects > 0.5m2 BSA will receive 50 mcg/m2 BSA and subjects ≤ 0.5m2 BSA will receive 1.5mcg/kg/dose, as SC injections three times weekly, from week 1 to week 3.
3311195|NCT01929382|Experimental|Actimmune(interferon gamma 1b) titration|30% of the recommended dose as SC injections three times weekly in week 1, 60% the recommended dose as SC injections three times weekly in week 2, and at the recommended dose as SC injections three times weekly in week 3
3311196|NCT01929421|Experimental|Gemcitabine/ s-1|
3311197|NCT01929434|Active Comparator|rehabilitation|Patients in the group accept rehabilitation for three weeks in hospital and other eleven months in their home under the guidance of physical therapist.
3311198|NCT01929434|No Intervention|control|Patients receive no professional treatment in hospital or rehabilitation centre.
3311199|NCT01929434|Experimental|stem cell injection|Patients in the group accept cell therapy including four times stem cells transplant via intrathecal injection.
3311200|NCT01929486|Experimental|<Phase Ia> Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg|<Phase Ia> Dose-escalation method with Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg. Mogamulizumab will be administered 8 times every week.
3311201|NCT01929486|Experimental|<Phase Ib> Mogamulizumab of the tolerated dose|<Phase Ib> Mogamulizumab of the tolerated dose in Phase Ia will be administered 8 times every week.
3311202|NCT01929486|Experimental|<Phase Ib> Mogamulizumab 0.1mg/kg|<Phase Ib> Mogamulizumab 0.1mg/kg will be administered 8 times every week.
3311203|NCT01929499|Experimental|synchronous CIK group|"After colectomy, patients will accept chemotherapy combined with cytokine-induced killer cells (CIK) therapy synchronously for 6 months.~For CapeOx regimen:~3×109 CIK cells on days 1-3; Oxaliplatin 130mg/m2 on day 7; Capecitabine 1000mg/m2 twice daily on days 7-20; Repeat every 3 weeks for 6-8 cycles.~For mFolfox6 regimen:~Oxaliplatin 85mg/m2 IV over 2 hours on day 1; Leucovorin 400mg/m2 IV over 2 hours on day 1; 5-FU 400mg/m2 IV bolus on day 1, then 2400mg/m2 IV continuous infusion over 46-48 hous; 3×109 CIK cells on days 9-11; Oxaliplatin 85mg/m2 IV over 2 hours on day 15; Leucovorin 400mg/m2 IV over 2 hours on day 15; 5-fluorouracil (5-FU) 400mg/m2 IV bolus on day 15, then 2400mg/m2 IV continuous infusion over 46-48 hours; Repeat every 4 weeks for 5-6 cycles."
3311204|NCT01929499|Experimental|sequence CIK group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens(the same as those in arm A), followed by 6-8 cycles of cytokine-induced killer cells (CIK) therapy at least 2 weeks later.
3311205|NCT01929499|No Intervention|control group|After colectomy, patients will accept adjuvant chemotherapy for 6 months, that is 6-8 cycles of CapeOX regimens (the same as those in arm A), or 10-12 cycles of mFolfox6 regimens （the same as those in arm A）.
3311206|NCT01929512|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 750/20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3311207|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3311208|NCT01929512|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 750/20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3311209|NCT01929512|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 750mg and Rosuvastatin 20mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3311210|NCT01929525||Silver Nitrate|Irrigation of fistula tract with 1% silver nitrate solution for all patients who accepts the study and signed the written informed consent form.
3311211|NCT01929538|Active Comparator|Covered biliary metal stent, 12 mm|ERCP and placement of a covered self-expanding biliary metal stent, 12mm in diameter
3311212|NCT01929538|Active Comparator|covered Biliary metal stent, 10 mm|ERCP and placement of a covered self-expanding biliary metal stent, 10 mm in diameter
3311213|NCT01929551|Other|Mango puree and pear juice beverage|Participants will drink 450 milliliters of the juice at time 0.
3311214|NCT01929551|Other|Commercial mango juice|Participants will drink 450 milliliters of the juice at time 0.
3311215|NCT01929551|Other|Fresh natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3311216|NCT01929551|Other|Frozen natural mango|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3311217|NCT01929551|Other|Processed natural mango pulp|Participants will eat 400 to 500 grams of frozen mango pulp, along with 250 milliliters of water at time 0.
3311218|NCT01929551|Other|Mix of natural mango and pear|Participants will eat 400 to 500 grams of a mixture of fresh natural fruit containing mango (73%) and pear (27%), along with 250 milliliters of water at time 0.
3311219|NCT01929551|Other|50 grams glucose load|Participants will drink 250 milliliters of the standard glucose load at time 0.
3311220|NCT01929564|Active Comparator|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
3311221|NCT01929564|Placebo Comparator|Parthenon broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet.
3311222|NCT01929577|Experimental|ASP015K Test Tablet - Fasting Conditions|ASP015K administered as a single tablet under fasting conditions.
3311223|NCT01929577|Experimental|ASP015K Reference Tablet - Fasting Conditions|ASP015K administered via multiple tablets under fasting conditions
3311224|NCT01929577|Experimental|ASP015K Test Tablet -Fed Conditions|ASP015K administered as a single tablet under fed conditions
3311225|NCT01929590|Active Comparator|PEG-3350 group 3|group 3: low-volume 2 L PEG-3350 solution (same day of the procedure 06:00-08:00 am).
3311226|NCT01929590|Active Comparator|PEG-3350 group 1|group 1 single dose (PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h)
3311227|NCT01929590|Experimental|PEG-3350 group 2|group 2: split-dose (PEG-3350 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
3311228|NCT01929603|Experimental|Olaparib alone, olaparib+rifampicin|Sequential treatments of olaparib alone followed by olaparib+rifampicin, with a washout period inbetween.
3311229|NCT01929616|Experimental|Regorafenib|A treatment cycle is defined as a 4 weeks period. Regorafenib will be administered once a day orally at a dose of 160 mg (4 tablets of 40 mg), for 3 weeks.
3311230|NCT01929629|Placebo Comparator|Placebo fasting|Single or multiple dosing placebo
3311231|NCT01929629|Experimental|Active fed condition|AZD0914 given as single dose
3311232|NCT01929655|Experimental|Radium-223 dichloride|
3311233|NCT01929668|Active Comparator|polyethylene glycol|4L polyethylene glycol
3311234|NCT01929668|Experimental|polyethylene glycol with ascorbic acid|2L polyethylene glycol and ascorbic acid
3311235|NCT01929694|Active Comparator|Berocca Boost|Guarana and vitamin and mineral complex, one tablet dissolved in 250ml water taken once.
3311236|NCT01929694|Placebo Comparator|Placebo|Matched placebo tablet, one tablet dissolved in 250ml water taken once.
3311237|NCT01929720|Experimental|Arm I (CBT for worry, uncertainty & insomnia)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. Patients participate in a Behavioral Intervention (cognitive-behavioral therapy) in which they receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5.
3381498|NCT03195478|Experimental|Nivo/Ipi Combination Therapy A|Specified Dose of Nivolumab and Ipilimumab on specified days
3381499|NCT03195478|Experimental|Nivo/Ipi Combination Therapy B|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
3381500|NCT03195478|Experimental|Nivo/Ipi Combination Therapy C|Specified Dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
3381501|NCT03195478|Experimental|Nivo/Ipi Combination Arm D|Specified dose of Nivolumab and Ipilimumab Combination Therapy on specified days followed by specified dose of Nivolumab Monotherapy on specified days
3381502|NCT03182244|Experimental|ASP2215|ASP2215 will be administered orally once daily.
3381503|NCT03182244|Active Comparator|Salvage chemotherapy|Options for salvage chemotherapy are limited to the following: Low-dose Cytarabine (LoDAC) will be administered twice daily by subcutaneous or intravenous injection for 10 days. Mitoxantrone, Etoposide, Cytarabine (MEC Induction Chemotherapy) will each be administered intravenously for 5 days (days 1 through 5). Granulocyte colony-stimulating factor (G-CSF) will be administered intravenously for 5 days (days 1 through 5) and also recommended 7 days after completing chemotherapy, Fludarabine and Cytarabine administered intravenously for 5 days (days 2 through 6) (FLAG Induction Chemotherapy). Based on the outcome of interim analysis, participants will be evaluated for eligibility for crossover extension (COE). In COE participants will be administered ASP2215 orally once daily.
3311238|NCT01929720|Active Comparator|Arm II (wait-list control)|Patients wear a wrist actigraph and complete a sleep diary and worry record daily in weeks 1 and 5. This is a wait-list comparison, so after six weeks, patients in the control group complete the behavioral (cognitive-behavioral therapy)intervention for worry, uncertainty, and insomnia.
3311239|NCT01929746|Experimental|BIIB019, 75 mg|BIIB019 delivered via Subcutaneous Injection
3381504|NCT03182244|Experimental|ASP2215 PK in Chinese population|PK samples will be collected after single and multiple doses in Chinese subjects.
3381505|NCT03179631|Experimental|Ataluren|10, 20 milligrams per kilogram (mg/kg)
3311240|NCT01929746|Experimental|BIIB019, 150 mg|BIIB019 delivered via Subcutaneous Injection
3311241|NCT01929772||severe sepsis or septic shock|patients with severe sepsis or septic shock
3311242|NCT01929785||Pre and Post Transplant|Research blood samples will be drawn pre-transplant, and at monthly post transplant visits at times corresponding to post-transplant, standard of care ImmKnowo and AlloMap clinical testing. A minimum of 12 visits per patient is expected
3311243|NCT01929785||One year post transplant|The second group will include heart transplant recipients at one year post transplant who consent to participate in the study. Research blood samples will be drawn at quarterly post transplant visits (standard of care in Year 2 post transplant) corresponding to ImmunKnow and AlloMap testing. A minimum of 4 visits per patient is expected.
3311244|NCT01929798|Experimental|Optimized basal/bolus with artificial pancreas|Portable artificial pancreas with optimization
3381506|NCT03179631|Placebo Comparator|Placebo|10, 20 mg/kg
3381507|NCT03171025|Experimental|Nivolumab, all patients|
3311245|NCT01929798|No Intervention|Nominal basal/bolus treatment|Portable artificial pancreas without optimization.
3311246|NCT01929811|Experimental|Metformin arm|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6 Metformin: 500mg tid, orally (500mg daily in first cycle)
3311247|NCT01929811|Other|TEC|Docetaxel: 75mg/m2, d1, q3w*6 Epirubicin: 75mg/m2, d1, q3w*6 Cyclophosphamide: 500mg/m2, d1, q3w*6
3311248|NCT01929837|Experimental|E-fied navigated rTMS|Electrical field navigated transcranial magnetic stimulation
3311249|NCT01929837|Sham Comparator|sham E-field navigated rTMS|Sham electrical field navigated rTMS
3311250|NCT01929837|Experimental|non-navigated rTMS|non-navigated rTMS
3311251|NCT01929837|Experimental|Experimental, Navigated rTMS|Navigated rTMS,
3311252|NCT01929850|Active Comparator|Surgery|Sleeve gastrectomy laparoscopic surgery plus Weight Watchers for morbidly obese patients
3381508|NCT03170362|Experimental|Intervention group|Pharmacogenetic test results will be provided to the provider within 72 hours of randomization in order to facilitate choice in selecting antidepressants.
3311253|NCT01929850|Other|Control|Weight Watchers Program for morbidly obese patients.
3311254|NCT01929902||Surgical Patients|
3311255|NCT01929915|Active Comparator|Epidural patient controlled analgesia|Epidural patient controlled analgesia
3311256|NCT01929915|Sham Comparator|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia for post operative pain control
3311257|NCT01929928||Surgical Patients|
3311258|NCT01929941|Experimental|Group 1 INCB047986|
3311259|NCT01929941|Experimental|Group 2 Experimental: INCB047986, gemcitabine, nab-paclitaxel|
3311260|NCT01929954|Experimental|Gintuit|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The test treatment GINTUIT will be inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. An additional single layer of GINTUIT will cover the entire surface of the extraction socket at approx. 2-3 mm beyond the margins of the wound and fixed with non-resorbable sutures. The lower layer of this additional layer should be in contact with the previously applied GINTUIT.
3311261|NCT01929954|Active Comparator|Bio-Gide|Subjects with a posterior tooth (molar or premolar) socket created by atraumatic extraction will be grafted with freeze-dried bone allograft (ie, MinerOss™). The primary wound bed will consist of exposed alveolar bone and bone graft imbedded in coagulum of blood from the socket for both treatments. The control treatment will be a collagen membrane (ie, Bio-Gide, applied per the Package Insert) inlayed within the defect over the socket graft material, and stabilized with resorbable tacking sutures. Crossed suspensory type sutures should also be placed over Bio-Gide, depending on the degree of stabilization needed. In all subjects, care should be taken in suturing to avoid advancement of the buccal gingival flap.
3311262|NCT01929967||Heterotaxy syndrome|Patients with a diagnosis of heterotaxy syndrome, as objectively defined by visceral heterotaxy (malrotation, interrupted inferior vena cava) with either documented polysplenia or asplenia by radiological imaging
3311263|NCT01930006|Experimental|MGCD265|
3311264|NCT01930019|Experimental|OE|OE - obese patients (BMI>40) in which etomidate was used,
3311265|NCT01930019|Other|NE|NE - patients with normal body mass (BMI<25), in which etomidate was used,
3311266|NCT01930019|Experimental|OT|OT - obese patients in which thiopental was used,
3311267|NCT01930019|Other|NT|NT - patients with normal body mass, in which thiopental was used
3311268|NCT01930032||All subjects|
3311269|NCT01930071|Experimental|PQ Bypass Guide Wire Delivery System|PQ Bypass Guide Wire Delivery System to complete percutaneous Fem-pop bypass
3311270|NCT01930084|Experimental|Combination intervention + incentives|"Point of care CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders~Non-cash financial incentives (FI)"
3311271|NCT01930084|Experimental|Combination intervention strategy(CIS)|"Point of care (POC) CD4+ after HIV diagnosis~Accelerated ART initiation~SMS appointment reminders"
3311272|NCT01930084|No Intervention|Standard of care (SOC)|Standard of care, no intervention
3311273|NCT01930097|Active Comparator|CHO-dependant bolus|"An insulin bolus dependant of carbohydrate content will be given after each meal.~Each subject insulin-to-carbohydrate ratio (U per 10g CHO) will be used to calculate the insulin bolus to be given. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings."
3311274|NCT01930097|Active Comparator|CHO-independent bolus|An insulin bolus independent of carbohydrate content will be given after each meal. The dual-hormone closed-loop strategy will give the remaining insulin needed based on the sensor readings.
3311275|NCT01930097|Active Comparator|Conventional treatment|Patients will use conventional pump therapy to regulate glucose levels
3311276|NCT01930110|Active Comparator|Single-hormone closed-loop system|In single-hormone closed-loop system, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
3311277|NCT01930110|Active Comparator|Dual-hormone closed-loop system|In dual-hormone closed-loop system, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
3311278|NCT01930123|Experimental|Patients with NAFLD|70 subjects with biopsy-proven NAFLD; subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
3311279|NCT01930123|Placebo Comparator|Health controls|15 healthy controls for comparison with NALFD patients.The 15 subjects will be challenged with a fructose infusion after a period for 12 hours fasting.
3311280|NCT01930136|Experimental|Calorie restriction (25%)|CR will correspond to a reduction of 25% from the total daily calorie expenditure calculated as Total Daily Energy Expenditure (TDEE) (kcal/d) using the formula from the validated Seven-Day Physical Activity Recall (PAR) Questionnaire (RMR x activity levels).
3311281|NCT01930136|Active Comparator|Ad libitum health diet|
3311282|NCT01930149|Experimental|Mailed patient outreach intervention|Participants randomized to this arm will receive mailed letter from health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
3311283|NCT01930149|No Intervention|Usual Care Control Group|Participants randomized to this arm will receive usual care.
3311284|NCT01930201||Standard general anesthesia|Patients receiving standard of care.
3311285|NCT01930201||Caudal Epidural Block|Patients receiving a caudal epidural block in addition to standard of care.
3311286|NCT01930227|Experimental|TEAS Treatment|Patients were given 30min of TEAS at PC6 after spinal anesthesia
3311287|NCT01930227|Sham Comparator|Non-acupoint stimulation|Patients were given 30min of electrical stimulation at shoulder after spinal anesthesia
3311288|NCT01930227|No Intervention|Control|No stimulation was given
3311289|NCT01930240|Placebo Comparator|TRIA-662 Placebo|Single dose of nine placebo capsules matching TRIA-662 drug capsules
3311290|NCT01930240|Experimental|TRIA-662 Low Dose|Single-dose of TRIA-662 administered as three 30 mg TRIA-662 capsules and six matching placebo capsules
3311291|NCT01930240|Experimental|TRIA-662 High Dose|Single dose of TRIA-662 administered as nine 30mg TRIA-662 capsules
3311292|NCT01930266|No Intervention|Observational|Patients will receive general dietary instructions with an annual follow-up. At this follow up, a repeat BMD, dietary and laboratory evaluation will be performed.
3311293|NCT01930266|Active Comparator|Interventional.|Patients will receive detailed dietary instructions with periodic (3 month) follow up. At the follow-up patients will be assessed whether they reached their calcium intake goals both quantitatively and whether appropriate calcium sources were utilized.
3311294|NCT01930266|Experimental|Active interventional|Patients will receive detailed dietary instructions and active follow up with diary and email reports. Inclusion in group C will be predicated upon intake of 100% DRI of calcium primarily by food sources, with the addition of Calcium Carbonate 600 mg, if necessary
3311295|NCT01930279||surface markers on T cells as assessed by FACS|
3311296|NCT01930292|Experimental|Part A: Debio 1143|Eligible participants receive Part A: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle according to dose escalation rules (in combination with Paclitaxel and Carboplatin standard of care)
3311297|NCT01930292|Experimental|Part B: Lung Cancer|Participants with Lung Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3311298|NCT01930292|Experimental|Part B: Ovarian Cancer|Participants with Ovarian Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3311299|NCT01930292|Experimental|Part B: Breast Cancer|Participants with Breast Cancer receive Part B: Debio 1143 once daily for 5 consecutive days in each 21-day treatment cycle (in combination with Paclitaxel and Carboplatin standard of care)
3311300|NCT01930318|Placebo Comparator|PCA,Placebo,Placebo|PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery
3311301|NCT01930318|Placebo Comparator|PCA,placebo,tramadol|PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol in the day 3 to day 5 after surgery
3311302|NCT01930318|Experimental|PCA,parecoxib,placebo|PCA for 2 days after operation, i.v parecoxib in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery
3311303|NCT01930318|Experimental|PCA,parecoxib,celecoxib|PCA for 2 days after operation,i.v parecoxib in 2 days after surgery and oral celecoxib in the day 3 to day 5 after surgery
3311304|NCT01930331|Experimental|ARCO treatment|Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision.
3311305|NCT01930331|Active Comparator|Eurartesim treatment|Patients in this treatment arm will receive a dose of dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision.
3311306|NCT01930344|Active Comparator|3D laparoscopic visual system|Laparoscopic cholecystectomy to be performed with 3D laparoscopic imaging system
3311307|NCT01930344|Placebo Comparator|2D Laparoscopic Visual System|Laparoscopic cholecystectomy to be performed using normal, 2D, laparoscopic visual system
3311308|NCT01930357|Experimental|VRVg Group|Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)
3311309|NCT01930357|Active Comparator|Imovax® Rabies Group|Participants will receive receive 3 vaccinations of Human Diploid Cell Vaccine (HDCV), Imovax® Rabies
3311310|NCT01930370|Experimental|Hemodialysis patients|Each patient will be evaluated during a total of 3.5 weeks correlating to routine dialysis treatment appointments. Each participant will start with low bicarbonate, followed by the washout phase (standard bicarbonate), then high bicarbonate, finishing with the follow up period. Dialysis prescription is standardized for each patient throughout the entire 3.5 week study period.
3311311|NCT01930383||Arm A|HCC patients who receive curative surgery or radiofrequency ablation therapy
3311312|NCT01930383||Arm B|patients who receive trans-arterial chemoembolization
3311313|NCT01930383||Arm C|patients who receive systemic therapy
3311314|NCT01930396|Experimental|Tinzaparin|
3311315|NCT01930396|Active Comparator|Unfractionated Heparin|
3311316|NCT01930409|Active Comparator|Education Only|"A 1 hour education session in the acute setting~A toolkit with education, exercise and self management instructions for after hip fracture"
3311317|NCT01930409|Experimental|Education + Telephone Follow-up|"A 1 hour education session in the acute setting~A telephone delivered self management program , including a toolkit (education, exercise and self management instructions for after hip fracture), support to take an active role in recovery, including setting and monitoring goals, problem solving mobility barriers, and guidance on the recovery process following a hip fracture."
3311318|NCT01930422|Experimental|Real tDCS|Direct transcranial electrical stimulation (tDCS procedure)
3311319|NCT01930422|Sham Comparator|Placebo tDCS|Sham procedure
3311320|NCT01930448||gastric bypass|Surgical group of obese patients with type 2 diabetes undergoing gastric bypass surgery
3311321|NCT01930448||gastric banding|surgical group of obese patients with type 2 diabetes undergoing gastric banding
3311322|NCT01930461|Experimental|SLIT (A)|SLIT tablets of HDM allergen extracts, 3 different doses (A)
3311323|NCT01930461|Experimental|SLIT (B)|SLIT tablets of HDM allergen extracts, 3 different doses (B)
3311324|NCT01930461|Experimental|SLIT (C)|SLIT tablets of HDM allergen extracts, 3 different doses (C)
3311325|NCT01930461|Placebo Comparator|Placebo|Placebo matching the SLIT tablets of HDM allergen extracts
3311326|NCT01930500|Experimental|Individual neuropsychological rehabilitation|12 times 90 minutes, once per week or once per two weeks, during 5 months
3311327|NCT01930500|Experimental|Group based neuropsychological rehabilitation|12 times 120 minutes + a brake, once per week or once per two weeks, during 5 months
3311328|NCT01930500|No Intervention|Control group|Control group does not receive neuropsychological rehabilitation or any other intervention during the first 5 months. After the control period they will be randomized to receive either individual or group based rehabilitation.
3311329|NCT01930526|Experimental|Pulmonary Rehabilitation|Patients will undergo the usual pulmonary rehabilitation programme but instead of two-legged cycling they will undergo single leg cycling where they cycle with one leg for 10-15mins and then the other in the same session.
3311330|NCT01930539|Experimental|Ultraviolet B lamp|Intervention arm: Patients in the Ultraviolet B lamp group will continue vitamin D2/D3 daily and will receive 3 treatment sessions of Ultraviolet B light once a week for 12 weeks. Patients will receive Ultraviolet B light from Ultraviolet B lamp at a distance of 14 inches for duration of 5 minutes each area while wearing an Ultraviolet eye shield. Areas of skin exposure will include 3 different areas amounting to 27% of body surface area. 9% body surface area will include front of abdomen, lower back, each arm, each leg is 18%, each thigh. Ultraviolet B light sessions will be supervised and conducted by study personnel or Center for Clinical and Translational Research staff. A food questionnaire will be reviewed at each visit to assess dietary intake of calcium. Skin exam will be conducted at the beginning and end of the session.
3311331|NCT01930539|No Intervention|Control|Patients in control group will continue with their current dose of Vitamin D2/D3 for 12 weeks.Patients will remain on the same steady dose for the duration of the study.These patients will not receive Ultraviolet B light sessions.
3311332|NCT01930552|Experimental|Cohort 1|aflibercept IV infusion for 1 hour followed by FOLFIRI IV infusion every 2 weeks
3311333|NCT01930565|Experimental|LFCO application|We made LFCO application(Lactobacillus Fermented Chamaecypris obtusa) containing cream to one side of patients' face to monitor effectiveness and safety in acne treatment.
3381509|NCT03170362|No Intervention|Delay results group|The comparator arm will not receive results at the time of randomization but will get results after the 24 week assessment (thus the results are delayed).
3381510|NCT03168347|Active Comparator|Anecdotal Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on anecdotal evidence.
3381511|NCT03168347|Active Comparator|Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence.
3381512|NCT03168347|Active Comparator|Anecdotal + Research Study Evidence|Scenario describes a medication's (biologic's) therapeutic effect results based on research study evidence and anecdotal evidence.
3381513|NCT03168347|Placebo Comparator|No Evidence|Scenario describes a medication's (biologic's) therapeutic effect with no mention on anecdotal nor research study evidence.
3381514|NCT03160365|Other|ACQUISITION OF IMAGES|4 MRIs were performed at Day 0, day 1, day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
3381515|NCT03158857||Hepatitis C monoinfection|"Sofosbuvir 400 mg tablet once a day + Daclatasvir 60mg tablet once a day~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
3381516|NCT03158857||Hepatitis C and HIV co-infection|"Sofosbuvir tablet 400 mg once a day + Daclatasvir tablet 90 mg once a day (increased dose in patients receiving efavirenz. Patients on an alternative HIV drug regimen will receive standard dose i.e. 60 mg)~Patients with evidence of cirrhosis will be offered treatment for 24 weeks, those who are not cirrhotic will be offered 12 weeks of treatment."
3381517|NCT03157128|Experimental|LOXO-292|Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)
3381518|NCT03155061|Experimental|Part A (Dose Escalation Part): ONO-4578 monotherapy|ONO-4578 specified dose on specified days in advanced or metastatic solid tumors
3381519|NCT03155061|Experimental|Part B: ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in advanced or metastatic solid tumors
3381520|NCT03155061|Experimental|Part C (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent gastric cancer
3381521|NCT03155061|Experimental|Part D (Expansion Part): ONO-4578 in combination with ONO-4538|ONO-4578+ONO-4538 specified dose on specified days in unresectable, advanced or recurrent colorectal cancer
3381522|NCT03141424|No Intervention|Group A|Usual care. Unchanged asthma medication during the entire study period.
3381523|NCT03141424|Experimental|Group B|Tapering of ICS over 8 weeks. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
3381524|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 1|This is a triple cross-over with a sham control condition; the standard tACS administered first, then Nested, then sham.
3381525|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 1|This is a double cross-over with a sham control condition; the tACS administered first, then the sham
3381526|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 1|This is a cross-over with a sham control condition; the standard tACS administered first, then sham.
3381527|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 2|This is a triple cross-over with a sham control condition; the standard tACS administered first, then sham, then nested tACS.
3381528|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 3|This is a triple cross-over with a sham control condition; the sham tACS administered first, then nested tACS, then standard tACS.
3311334|NCT01930565|Active Comparator|TTO application|To compare effectiveness and safety of new LFCO, we applied existing TTO containing cream to the other side of face in the same patients
3311335|NCT01930578|Experimental|Treatment with 0.9% normal saline|1 litre of normal saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3381529|NCT03112902|Active Comparator|Effects of tACS during SWS- Older Adults Active 2|This is a double cross-over with a sham control condition; the sham administered first, then the tACS.
3381530|NCT03112902|Active Comparator|Effects of tACS during SWS- MCI Active 2|This is a cross-over with a sham control condition; the sham administered first, then standard tACS.
3311336|NCT01930578|Experimental|Treatment with D5, 0.45 saline|1 litre of D5, 0.45 saline infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3311337|NCT01930578|Experimental|Treatment with D5|1 litre of D5 infused over minutes and BIS performed at baseline, and 5 minute intervals during infusion, then 5 minute interval readings for 15 minutes after the stop of the infusion.
3311338|NCT01930591|Active Comparator|Clopidogrel arm|Clopidogrel 300 mg before PCI followed by 75 mg po OD
3311339|NCT01930591|Experimental|Ticagrelor arm|Ticagrelor 180 mg before PCI followed by 90 mg po BID
3311340|NCT01930604|Active Comparator|Palmar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3311341|NCT01930604|Placebo Comparator|Palmar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3311342|NCT01930604|Active Comparator|Plantar hyperhidrosis, Botox (onabotulinumtoxinA)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3311343|NCT01930604|Placebo Comparator|Plantar hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3311344|NCT01930604|Active Comparator|Inguinal (groins/buttocks) hyperhidrosis, Botox (ona...)|Solution for injection, individual dosing, maximum dose 400 units, single treatment session.
3311345|NCT01930604|Placebo Comparator|Inguinal (groins/buttocks) hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3311346|NCT01930604|Active Comparator|Craniofacial hyperhidrosis, NeuroBloc/Myobloc (rima...)|Solution for injection, individual dosing, maximum dose 2500 units, single treatment session.
3311347|NCT01930604|Placebo Comparator|Craniofacial hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3311348|NCT01930604|Active Comparator|Truncal hyperhidrosis, NeuroBloc/Myobloc (rimabotulinumtoxinB)|Solution for injection, individual dosing, maximum dose 5000 units, single treatment session.
3311349|NCT01930604|Placebo Comparator|Truncal hyperhidrosis, NaCl|Solution for injection, individual dosing, injection volume corresponding to active comparator, single treatment session.
3311350|NCT01930617||Trondheim|Burr hole surgery with passive subdural drainage
3311351|NCT01930617||Tromsø|Burr hole surgery with continuous irrigation
3311352|NCT01930617||Stockholm|Burr hole surgery with active subgaleal drainage
3311353|NCT01930630|Experimental|Extraesophageal saline injection (ESI)|Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
3311354|NCT01930656||Group A, B, C|Group A- American cut-point Group B- Translational approach cut-point Group C- Cost-effectiveness cut-point
3311355|NCT01930669|Other|All patients|To measure the autonomic nervous system activity elicited by a gravitational sympathetic stimulus in critically ill
3311356|NCT01930682|Experimental|Early post-fibrinolytic catheterisation|For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
3311357|NCT01930682|Other|Primary PCI|For STEMI Patients,primary PCI is performed without fibrinolytic therapy.
3311358|NCT01930708|Experimental|DMF|120 mg capsule oral twice daily (BID) during the first week and 240 mg BID thereafter.
3311359|NCT01930721|Experimental|incision angle of 60 degrees|episiotomy incision angle will be defined as 60 degree as measured before cutting.
3311360|NCT01930721|Experimental|incision angle 40 degree episiotomy|incision angle of episiotomy will be defined as 40 degree as measured before cutting.
3311361|NCT01930734|Placebo Comparator|Normal Saline|"Normal Saline Placebo infusion containing Normal Saline NaCl 0.9% twice a week for a total duration of 6 months.~Placebo will be given at the same rate as the Dobutamine infusion, under the same measures."
3311362|NCT01930734|Experimental|Dobutamine|Twice weekly, IV Dobutamine infusion up to 5mcg/Kg/min infusion, for the duration of 6 months. Medication will be administered under medical supervision and continues ECG and vital sign monitoring. Routine electrolyte and renal function testing will be performed and electrolytes corrected as indicated.
3311363|NCT01930760|Experimental|Educational Intervention Group|
3311364|NCT01930760|Experimental|Behavioural Intervention Group|
3311365|NCT01930773|Experimental|Genotyping Arm|Rapid genotyping to select optimal P2Y12-inhibitor for PCI.
3311366|NCT01930773|Experimental|Phenotying Arm|The use of platelet function testing to select the optimal P2Y12-inhibitor for PCI.
3311367|NCT01930773|No Intervention|Conventional Arm|Regular approach for performing elective PCI.
3311368|NCT01930786||onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
3311369|NCT01930812|Experimental|18F-NaF PET Imaging for Bone Scintigraphy|All participants will receive PET/CT Imaging using the investigational drug 18F-NaF and a 99mTc-medronate whole body bone scan with SPECT to compare the diagnostic ability of the two methods for the presence of bone metastases.
3311370|NCT01930838||Controls|Matched on age, sex and body mass index
3311371|NCT01930838||Gastric bypass operation|Patients with gastric bypass operation between 2006 and 2011 in The Central Denmark Region
3311372|NCT01930851||Gastric bypass|All gastric bypass operated patients in the Central Denmark Region 2006-2011
3311373|NCT01930864|Experimental|metfomin + irinotecan|Irinotecan 350mg/m² q21d + metformin up to 2500mg/d until disease progression, prohibitive toxicity or consent withdrawal
3311374|NCT01930877|Active Comparator|Lidocaine|Intravenous Lidocaine bolus of 1.5 mg/kg followed by infusion of 1.5 mg/kg/hr
3311375|NCT01930877|Placebo Comparator|Placebo|Normal saline placebo infusion
3311376|NCT01930916|Other|Not interventionnal|INR capillary measurement with INRatio 2 device antiphospholipid antibodies and lupus anticoagulant
3311377|NCT01930929||Bariatric surgery operated patients|All patients who have operated in the Central and North Denmark Region 2006-2011
3311378|NCT01930942|Experimental|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
3311379|NCT01930955|Active Comparator|Amoxicillin|Amoxicillin were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
3311380|NCT01930955|No Intervention|control|Non-antibiotics were given to the children with acute upper respiratory tract infection characterized by fever and vomiting.
3311381|NCT01930968||Ultrasound measurement|There is only 1 arm in this study. The ocular tumors will be imaged using ultrasound and the contrast agent. The patient's history will be noted, lung and heart auscultation will be performed, and blood pressure readings will be obtained to ensure the patient has no contraindications to using Definity®. If there are no contraindications, routine ocular ultrasonography, both A and B scans, will be performed using an Ellex Eye Cubed ultrasound machine. Definity® (the microbubble contrast agent) will be prepared per package instruction and the dose calculated according to the following formula: Patient weight (kg) X 10 microliters = Definity® dose. If necessary, a second 10 microliter/kg dose may be given 30 minutes after the first IV injection.
3311382|NCT01930994||Cohort 1|Twenty Sino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 6-month insertion anniversary.
3311383|NCT01930994||Cohort 2|TwentySino-implant (II) and twenty Jadelle users enrolled 1-3 months before their 12-month insertion anniversary;
3311384|NCT01930994||Cohort 3|Twenty Sino-implant (II) and twenty Jadelle) users enrolled 1-3 months before their 24-month insertion anniversary
3311385|NCT01930994||Cohort 4|Twenty Sino-implant(II) and twenty Jadelle users enrolled 1-3 months before their 36-month insertion anniversary;
3311386|NCT01930994||Cohort 5|Forty Sino-implant (II) and forty Jadelle users enrolled 1-3 months before their 48-month insertion anniversary;
3311387|NCT01930994||Cohort 6|Forty Jadelle users enrolled 2-6 months before their 60-month insertion anniversary.
3311388|NCT01931007|Experimental|Autologous bone marrow concentrate|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the autologous bone marrow aspirate concentrate. The contralateral knee will be injected with only sterile saline for placebo.
3311389|NCT01931007|Placebo Comparator|Placebo|Subjects with symptomatic mild to moderate bilateral knee osteoarthritis will be enrolled in this study. Bone marrow will be aspirated from the patient's iliac crests and the cellular rich portion will be concentrated. Randomly, one knee will be injected with the bone marrow concentrate. The contralateral knee will be injected with only sterile saline for placebo.
3311390|NCT01931020|Active Comparator|Sucrose|1ml of 24%sucrose will be administered prior to heel lance
3311391|NCT01931020|Experimental|Glucose|1ml of 25% glucose will be administered prior to heel lance
3311392|NCT01931033|Experimental|Oxytocin|Intranasal Oxytocin (brand name Syntocinon) will be administered daily (for a total daily dose of 48 IU) for 8 weeks.
3311393|NCT01931046|Experimental|Part 1|Treatment at one of three dose levels of Ad5-SGE-REIC/Dkk-3 in a sequential dose-escalating design with 4 cycles of therapy at each dose level permitted.
3311394|NCT01931046|Experimental|Part 2|Treatment with Ad5-SGE-REIC/Dkk-3 every 6-weeks for up to 4 cycles of therapy and may continue therapy if they have stable disease or are responding.
3311395|NCT01931072|Experimental|High-intensity interval training|The High-intensity interval training group was instructed to complete exercise sessions of 4x4-minutes intervals at 85-95% of maximal heart rate, 3 times a week for 8 weeks. This type of exercise include 10 minutes warm-up, followed by four intervals of four minutes high-intensity (85-95% of HRmax), with three minutes active breaks (70% of HRmax) between each interval, and ending with seven minutes cool-down. An exercise session last for 42 minutes, where the participants should breathe heavily and feel exhausted four times.
3311396|NCT01931072|Active Comparator|Moderate training|The moderate training group was instructed to complete exercise sessions of 50 minutes at 70% of maximal heart rate, 3 times a week for 8 weeks.
3311397|NCT01931072|No Intervention|Control|The control group followed the baseline and follow-up tests, and was asked to live normally and not change their dietary pattern or exercise habits during their participation in this project. Based on the well-known beneficial effects of exercise on general health, it was regarded unethical to demand the control group to desist from any types of physical activity during the project period. They got no further follow-up on exercise.
3311398|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With No Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
3311399|NCT01931098|Experimental|Glioblastoma or Gliosarcoma With Prior Bevacizumab Exposure|Topotecan .25 mg and pazopanib 600 mg are administered orally daily until progression, up to one year.
3311400|NCT01931111||Norwegian Elderly Population|
3311401|NCT01931124|Experimental|High Intensity Training|training at high intensities ranging from 85-95% of maximal heart rate
3311402|NCT01931124|Experimental|Moderate Intensity Training|training at intensities of 65-75% of maximal heart rate
3311403|NCT01931137|Experimental|Coating A|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3311404|NCT01931137|Experimental|Coating B|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3311405|NCT01931137|Experimental|Coating C|Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET® I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)
3311406|NCT01931176|Experimental|rDEN2Δ30-7169 vaccine|Participants will receive a single injection of the rDEN2Δ30-7169 vaccine at study entry.
3311407|NCT01931176|Placebo Comparator|Placebo|Participants will receive a single injection of placebo at study entry.
3311408|NCT01931189|Experimental|NI-071|
3311409|NCT01931189|Active Comparator|Infliximab|
3311410|NCT01931215|Active Comparator|morphine group|spinal anesthesia with intrathecal morphine
3311411|NCT01931215|Experimental|TAP group|TAP-block with ropivacaine and clonidine
3311412|NCT01931228|Experimental|MI-E plus manually assisted coughing|
3311413|NCT01931228|Experimental|Manually assisted coughing only|
3311414|NCT01931241|Experimental|Cohort 1, 500 mg|Cohort 1 receives SDD 500 mg AHRO-001; one week later receives MDD of 500 mg bid 7 days, then 500 mg tid 7 days
3311415|NCT01931241|Experimental|Cohort 2, 750 mg|Cohort 2 receives SD of 750 AHRO-001, then 7 days of 750 mg BID AHRO-001, then 7 days of 750 mg TID AHRO-001.
3311416|NCT01931241|Experimental|Cohort 3, 1000 mg|Cohort 3 identical design as Cohorts 1 and 2, but SD is 1000 mg AHRO-001.
3311417|NCT01931241|Experimental|Cohort 4, 21 day dosing|Cohort 4 receives 21 days tid administration of AHRO-001 using the best tolerated dose as determined by cohorts 1, 2 & 3
3311418|NCT01931241|Experimental|Cohort 5, 12 weeks dosing|Cohort 5 receives 12 weeks tid administration of AHRO-001 using the best tolerated dose as determined by the first 4 cohorts.
3311419|NCT01931267|Experimental|Tablet Computer Motivated Instruction|Using Tablet Computer Motivated Instruction to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects.
3311420|NCT01931267|Active Comparator|systematic instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
3311421|NCT01931280|Experimental|Lifestyle Counseling|Participants will obtain access to an internet-based educational intervention.
3311422|NCT01931280|No Intervention|Usual Care (Self-Directed)|Participants receive information via email on health related topics that surround pregnancy, physical activity, nutrition, and gestational diabetes.
3311423|NCT01931293|Experimental|HLA-DR and DQ antigens|Isolation of patient's lymphocytes from 10 cc of blood to determine the HLA-DR and DQ antigens at the first visit.
3311424|NCT01931319|Experimental|Intravenous Baclofen|Three single doses were evaluated using three cohorts (N=12 per cohort). Subjects received single doses of baclofen: 7.5, 11.5 or 15mg 10-minute intravenous infusion administered over 10 minutes by an infusion pump and 10, 15, or 20mg taken orally with a 48-hour washout phase between oral and intravenous arms of the study. Initially, 3 subjects received study drug at a given dose, after assessing the safety and tolerance of baclofen the additional 9 subjects received study drug.
3311425|NCT01931332|Active Comparator|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) was performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hertz (Hz) with pulse width 0.1ms. Once a quadriceps muscle twitch was identified at a stimulated current between 0.2 and 0.5milliamperes (mA), 20mls of 0.375% levobupivacaine (75mg) was injected in fractionated amounts after negative aspiration
3311426|NCT01931332|Active Comparator|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
3311427|NCT01931345|Experimental|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
3311428|NCT01931345|Active Comparator|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
3311429|NCT01931358|Experimental|Group Ia|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
3311430|NCT01931358|Placebo Comparator|Group Ib|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
3311431|NCT01931358|Experimental|Group IIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12, 24 and 48
3311432|NCT01931358|Placebo Comparator|Group IIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12, 24 and 48
3311433|NCT01931358|Experimental|Group IIIa|ALVAC-HIV at Weeks 0 and 4; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24; AIDSVAX B/E at Week 48
3311434|NCT01931358|Placebo Comparator|Group IIIb|ALVAC-HIV Placebo at Weeks 0 and 4; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24; AIDSVAX B/E Placebo at Week 48
3311435|NCT01931358|Experimental|Group IVa|ALVAC-HIV at Weeks 0, 4 and 48; ALVAC-HIV + AIDSVAX B/E at Weeks 12 and 24
3311436|NCT01931358|Placebo Comparator|Group IVb|ALVAC-HIV Placebo at Weeks 0, 4 and 48; ALVAC-HIV Placebo + AIDSVAX B/E Placebo at Weeks 12 and 24
3311437|NCT01931371|Active Comparator|Recurrent anal fistula|Patients with a complex anal fistula that recurred after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
3311438|NCT01931371|Active Comparator|No recurrence of anal fistula|Patients with a complex anal fistula that did not develop recurrence after surgery with an Anal Fistula Plug or and Endorectal Advancement Flap
3311439|NCT01931384|Experimental|Intervention group|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
3311440|NCT01931384|Placebo Comparator|control group|normal saline (placebo) intramuscular injection will be given on the day of FET and 6 days later
3311441|NCT01931410|Placebo Comparator|sublingual|400 microgram mısoprostol will be administered sublıngually before elective caesarean
3311442|NCT01931410|Placebo Comparator|rectal|rectal 600 mgr misoprostol will be administered
3311443|NCT01931410|No Intervention|synpitan|
3311444|NCT01931423|Placebo Comparator|Drainage Group|early placental drainage plus cord traction
3311445|NCT01931423|No Intervention|Controlled Group|spontaneous removal placenta
3311446|NCT01931436|Experimental|Qing'E pill|Administered twice a day, and each 9 g
3311447|NCT01931449|Experimental|Modified digestive reconstruction|Modified method of digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract with an independent intestinal loop and pancreas end.
3311448|NCT01931449|Active Comparator|Routine pancreatoduodenectomy|Routine digestive tract reconstruction: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes;Reconstruct the common bile duct-jejunum and pancreatic duct-jejunum respectively.
3311449|NCT01931488|Other|MIBG label with I123 or I124|evaluate the added value of PET-CT with 124I-MIBG tracer, compared to planar and SPECT imaging with the routine 123I-MIBG tracers/
3311450|NCT01931540|Experimental|Exercise Training - 17 offspring of OM|4 months exercise training, OM: Obese mothers
3311451|NCT01931540|No Intervention|11 non-frail controls (9 LM)|Studied only at baseline
3311452|NCT01931540|Experimental|Exercise Training - 20 offspring of LM|4 months exercise training, LM:Lean/Normal Mothers
3311453|NCT01931553|Experimental|Standardized attending morning rounds|"Pre-rounds discretion~Pre-rounds huddle~Bedside RN integration~Patient-centered rounding~Real-time order writing"
3311454|NCT01931553|No Intervention|Usual rounding practice|Usual rounding practice (as defined by each clinical team)
3311455|NCT01931579|Experimental|confocal endo-microscopy|confocal endo-microscopy : CELLVIZIO endo-microscopy procedure is performed in every patient using the same extended working channel as for navigational bronchoscopy.
3311456|NCT01931592|Active Comparator|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
3311457|NCT01931592|Placebo Comparator|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
3311458|NCT01931605|Experimental|Embolization procedure|selective prostatic arterial embolization using BeadBlock (Terumo) particules
3311459|NCT01931618|Active Comparator|Usual care|"Receives two interventions:~Online screening and feedback.~Online booklet."
3311460|NCT01931618|Experimental|Extended follow-up|"Receives two interventions:~Online screening and feedback.~Online multi session follow-up."
3311461|NCT01931631|Experimental|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
3311462|NCT01931631|Active Comparator|ADA diet|American Diabetes Association diet
3311463|NCT01931644||Health Condition|Collect blood and other optional biospecimens from participants with a diagnosed health condition
3311464|NCT01931644||Healthy Control|Collect blood and other optional biospecimens from participants that have not been diagnosed with a health condition
3311465|NCT01931657|Experimental|Mifepristone prior to Mirena|Pretreatment with mifepristone prior to Mirena insertion
3311466|NCT01931657|Placebo Comparator|Placebo prior to Mirena|Pretreatment with placebo prior to Mirena insertion
3311467|NCT01931683|Experimental|remifentanil|LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods.
3311468|NCT01931696|Experimental|Verum acupuncture|Verum acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
3311469|NCT01931696|Sham Comparator|Sham acupuncture|Sham acupuncture treatment once every two days + Albuterol sulfate HFA (Ventolin®™ 100 mcg Inhalation Aerosol) as needed + Prednisone Acetate Tablets(H31020675, 5 mg oral tablet) for exacerbation
3311470|NCT01931722|Active Comparator|Branched chain amino acid|Branched chain amino acid as food supplement
3311471|NCT01931722|Active Comparator|Weight training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1RM (repetition maximum). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
3311472|NCT01931748|Experimental|UNCNT|6 times/ 12 days
3311473|NCT01931748|Active Comparator|MELSMON|6 times/ 12 days
3311474|NCT01931761|Experimental|[C14] selumetinib 75mg single dose|[C14] selumetinib 75mg single dose
3311475|NCT01931774||Acne Patients|
3311476|NCT01931774||Control Subjects|From General Population
3311477|NCT01931787|Experimental|Treatment (CPI-613)|Patients receive CPI-613 IV over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
3311478|NCT01931800||Presenting patients a pneumonia pneumococcique|
3311479|NCT01931800||Patients presenting a bacteremia pneumococcique|
3311480|NCT01931800||Patients affected by pneumococcique meningitis|
3311481|NCT01931813||Infants likely to present febrile convulsions|
3311482|NCT01931826|Active Comparator|Endoscopic treatment alone|3 to 5 sessions of sclerotherapy till eradication of esophageal varices.
3311483|NCT01931826|Active Comparator|Total EGDS + endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
3311484|NCT01931852|Experimental|CMR-guided care|Participants in this group will receive a cardiac MRI
3311485|NCT01931852|Active Comparator|Invasive-based guideline-adherent care|Participants will receive care adherent with current ACC/AHA guideline recommendations. ( ACC/AHA Guideline adherent care )
3311486|NCT01931891||prreclampsia|
3311487|NCT01931904||Trabeculectomy or Tube Shunt Patients|46 glaucoma patients undergoing trabeculectomy or tube shunt surgery to lower IOP
3311488|NCT01931917|Experimental|IY Parents and Babies Program|In the Incredible Years Parents and Babies Program, parents learn how to help their babies feel loved, safe, and secure. They learn how to encourage their babies' physical and language development. The parenting group format fosters peer support networks and shared learning. Trained Incredible Years facilitators use video clips of real-life situational vignettes to support the training and stimulate parenting group discussions and practice exercises with their babies. The program is group based with 6-8 mothers and partners attending 8 2 hour sessions with their babies.
3311489|NCT01931917|Active Comparator|Usual Care|Usual care consists of the elements that are being offered to all mothers in the participating municipalities which is 5 home visits by health visitors, a mothers group, a health nurse station and extra visits if needed.
3311490|NCT01931930|Experimental|Perilla extract|Experimental arm: Perilla extract
3311491|NCT01931930|Placebo Comparator|Maltodextrin|Placebo arm: Maltodextrin
3311492|NCT01931943|Experimental|Selatinib Ditosilate Tablets|Selatinib Ditosilate either at 450,750,1000,1250mg, p.o. once daily
3311493|NCT01931969||IJVC intervention|
3311494|NCT01931982|Active Comparator|victoza|The study is a cross over study. Patients randomised to start with victoza are treated with victoza for 10 weeks. After a wash out period of 2 weeks they cross over to 10 weeks of no treatment
3311495|NCT01931982|No Intervention|No treatment|
3311496|NCT01932021|Experimental|adipose tissue grafting|
3311497|NCT01932034||Standard dosing|Vancomycin dosed and monitored according to standard practice
3311498|NCT01932034||BestDose Computer Software|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations
3311499|NCT01932034||BestDose Computer Software 2|Vancomycin dosed using BestDose computer software, targeting AUC rather than trough concentrations and with computer-generated suggested optimal blood sampling times
3311500|NCT01932073|No Intervention|Control Group|Receives institutional skin care protocol
3311501|NCT01932073|Experimental|Treatment Group|Receives institutional skin care protocol and, when applicable (if skin reactions develop), Low-Level Laser Therapy
3311502|NCT01932086|Experimental|White rice|
3311503|NCT01932086|Experimental|Brown rice|
3311504|NCT01932086|Experimental|Black rice|
3311505|NCT01932086|Active Comparator|Bread|
3311506|NCT01932086|Active Comparator|Glucose solution|
3311507|NCT01932099|Experimental|Single arm feasibility study|Prospective, multi-center, single arm feasibility study. Subjects will include patients with severe aortic valve stenosis who require replacement of their native aortic valve. The intervention is transcatheter aortic valve replacement.
3311508|NCT01932138|Experimental|Enhanced CHW intervention|CHWs will 1) identify pregnant women through home visits and refer them to ANC; 2) inform pregnant women on antenatal care ANC and PMTCT; 3) visit women at home to ascertain ANC attendance; and 4) follow up women who have missed ANC or PMTCT appointments.
3311509|NCT01932138|Other|Standard of care|Clinic-based health workers follow-up patients who have missed scheduled PMTCT appointments (through telephone calls and/or in-person visits). The standard of care does not include any specific interventions to improve ANC attendance.
3311510|NCT01932151|Other|Terlipressin and albumin|Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
3311511|NCT01932177|Active Comparator|Schedule A|Everolimus run-in period followed by continuous administration of everolimus and sorafenib
3311512|NCT01932177|Active Comparator|Schedule B|Sorafenib run-in period followed by continuous administration of everolimus and sorafenib
3311513|NCT01932177|Experimental|Schedule C|Everolimus and sorafenib in alternance
3311514|NCT01932177|Experimental|Schedule D|Continuous administration of everolimus and intermittent administration of sorafenib
3311515|NCT01932190|Experimental|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
3311516|NCT01932190|Experimental|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria"
3311517|NCT01932203|Active Comparator|aspirin|aspirin 100mg by mouth once a day for 104 weeks
3311518|NCT01932203|Experimental|Cilostazol|Pletaal SR 200mg by mouth once a day for 104 weeks
3311519|NCT01932216|Active Comparator|Single-site robotic cholecystectomy|Single-site cholecystectomy using da Vinci robotic assisted surgery
3311520|NCT01932216|Active Comparator|Multi-port laparoscopic cholecystectomy|Multi-port cholecystectomy using laparoscopic surgery
3311521|NCT01932229|Experimental|Afatinib treatment|
3311522|NCT01932255||prophylactic spinal tap|Microvascular decompression surgery approach at the Karolinska University Hospital, i.e. a small craniectomy (removal of bone without putting it back), and postoperatively serial prophylactic lumbar tap
3311523|NCT01932255||no prophylactic spinal tap|Microvascular decompression surgery approach at St Olavs Hospital Trondheim University Hospital and the University Hospital of North Norway, i.e. not comprising a policy of preventing CSF leak by performing prophylactic lumbar taps or its equivalents
3311524|NCT01932268|Experimental|Rifampicin|experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin
3311525|NCT01932281|Experimental|SierraSil|SierraSil will be given in a dosage of 3 to 5, 667 mg capsules, according to body weight, daily for 3 weeks.
3311526|NCT01932281|Placebo Comparator|Placebo|This is a sugar pill and will be given in a dosage of 3 to 5 capsules daily for 3 weeks.
3311527|NCT01932307|Experimental|PGY1 General Surgery Residents|All first year general surgery residents at the University of British Columbia
3311528|NCT01932320|Experimental|Part 1|Participants will receive single dose of all the 3 formulations of JNJ-40411813 (Formulation A: hard gelatin capsule filled with beads; Formulation B: immediate release tablet, and Formulation C: Nanosuspension formulation) without food in 3 periods (Period 1, Period 2, and Period 3). The sequences will be based on a computer-generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period (no treatment) of at least 1 week.
3311529|NCT01932320|Experimental|Part 2|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 without food and with food in 2 periods (Period 1 and Period 2). The sequences will be based on a computer generated randomization schedule prepared by the sponsor before the study. Each period will be separated by a wash out period of at least 1 week.
3311530|NCT01932320|Experimental|Part 3|Participants will receive single dose of the selected solid dose formulation of JNJ-40411813 (Formulation A or Formulation B) from Part 1 on two occasions (Day 1 and Day 10) without food along with ketoconazole from Day 6 to Day 14 with food.
3311531|NCT01932333|Experimental|Cohort 1|
3311532|NCT01932333|Experimental|Cohort 2|
3311533|NCT01932359|Active Comparator|rapidly absorbable suture (Vicryl Rapide)|
3311534|NCT01932359|Active Comparator|non-absorbable suture (Ethilon)|
3311535|NCT01932372||Tofacitinib (Xeljanz)|Tablets 5 mg BID
3311536|NCT01932372||Standard of Care|Standard of Care for Rheumatoid Arthritis
3311537|NCT01932385|Experimental|sorafenib|sorafenib 400mg, oral, twice a day until disease progression defined by RECIST.
3311538|NCT01932385|Active Comparator|Best Supportive Care|treatment mainly on nutrition and symptoms control
3311539|NCT01932398||ADHD|A diagnosis of ADHD, classified by the DSM-IV.
3311540|NCT01932398||no ADHD|No diagnosis of ADHD, classified by the DSM-IV.
3311541|NCT01932424|Experimental|Single arm|The intervention in this study involves taking blood sample from an existing arterial line for measurement of blood propofol levels. The drug in evaluation is Propofol 2% (Diprivan 2%, Astra Zeneca UK) administered as a target controlled infusion using the commercially available paediatric TCI models (Paedfusor and Marsh models). The dose range is usually between a target concentration of 3-8 mcg/ml. However the anaesthetic management is not changed for the study. The blood concentrations of propofol will be measured using Pelorus 1500 (Sphere Medical, UK), a CE marked device. The anaesthetist will be blinded from the measurements, unless the measured value was outside the safe limit ( < 3 mcg/ml or > 10mcg/ml).
3311542|NCT01932450|Experimental|renal sympathetic denervation|One-time standard bilateral renal sympathetic denervation by catheter-based radiofrequency ablation and using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).
3311543|NCT01932450|Active Comparator|antihypertensive drugs|Blood pressure control in ADPKD patients with hypertension only using antihypertensive drugs which at least include an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)
3311544|NCT01932463|Experimental|ExAb;ate MRgFUS|
3311545|NCT01932476|Experimental|Celiac Disease Alone Gluten Challenge|
3311546|NCT01932476|Sham Comparator|Celiac Disease Alone Sham Challenge|
3311547|NCT01932476|Experimental|Celiac Disease and T1D Gluten Challenge|
3311548|NCT01932476|Sham Comparator|Celiac Disease and T1D Sham Challenge|
3311549|NCT01932489|Other|Sequencing of a metastatic lesion.|Biopsy of a metastatic lesion followed by a targeted cancer gene screen.
3311550|NCT01932502|Experimental|clonazepam conversion to clobazam (Onfi)|Subject's clonazepam will be converted to clobazam (Onfi). This is an open label study without placebo control.
3311551|NCT01932515|No Intervention|Screening|
3311552|NCT01932528|Experimental|500 mg LX606|All subjects will receive a single oral 500 mg dose of [14C]-LX1606.
3311553|NCT01932541|Experimental|Latuda (Lurasidone)|
3311554|NCT01932554|Experimental|Abciximab|"Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
3311555|NCT01932554|Placebo Comparator|Placebo|"Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission.~Patients will receive standard supportive care, including intravenous hydration, supplemental oxygen, incentive spirometry, ibuprofen, and parenteral narcotic pain medications (morphine, hydromorphone or fentanyl)"
3311556|NCT01932567|Experimental|Positive expiratory pressure|Use of positive expiratory pressure during 3 minutes
3311557|NCT01932567|Experimental|Incentive spirometry|Use of incentive spirometry during 3 minutes
3311558|NCT01932567|Experimental|manual airway clearance technique|Use of manual airway clearance technique during 3 minutes
3311559|NCT01932580|Other|FLOT chemotherapy|"Chemotherapy to be administered every 2 weeks for 4 cycles, before surgery. Then 4 more cycles will be given after surgery, at 2-week intervals.~5-FU 2600 mg IV/m2 in continuous infusion Leucovorin 200 mg IV/m2 Oxaliplatin 85 mg IV/m2 Docetaxel 50 mg IV/m2"
3311560|NCT01932593|Experimental|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
3311561|NCT01932593|Placebo Comparator|Placebo|
3311562|NCT01932632|No Intervention|Usual Care|This group will receive care as similar as possible to care that they received prior to the study beginning. Their attending MDs will be instructed and reminded to avoid making parallel changes in the prescribing for the control patients unless there is a specific medical indication to which they would normally respond with a medication reduction. No other reminders or prompts about the study will be provided for these patients.
3311563|NCT01932632|Experimental|Medication Minimization|"Initial Medication Review (IMR) Completed by Attending MD and identifies potential medications to be considered for minimization as well as those UNSUITABLE (as per usual MD opinion)~Orders-Medication Update (OMU) (ref form) The attending MD will have identified one or more medications to be considered for minimization and in the IMR suggested a time when a reduced dose will be reviewed (recommended every 4 weeks). Each review will generate an OMU. This process will be repeated for every participant in the Medication Minimization arm until all medications are marked as having no further changes, ie no need for further OMU. At that time a participant's record will be marked as having completed medication minimization."
3311564|NCT01932645||Prostatitis patients|We will enroll patients from the outpatient clinic who are suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation). Patients with these symptoms and identified as having prostatitis will be approached to enroll.
3311565|NCT01932645||Controls|Male patients seen in the outpatient clinic who do not have prostatitis (not suffering from pelvic pain (perineal, suprapubic, testicular, penile etc), and do not have urinary symptoms and sexual dysfunction (primarily pain associated with ejaculation)) will be approached to enrol as controls.
3311566|NCT01932658|Experimental|Hematopoietic stem cell transplantation|Lymphoablation followed by autologous hematopoietic stem cell transplantation rescue.
3311567|NCT01932671||SMART|The SMART (Second Manifestation of ARTerial disease) cohort comprises patients at high-risk for or who have clinically manifest cardiovascular disease, including transient ischemic attack, cerebrovascular disease, peripheral artery disease, aneurysma aorta abdominalis, myocardial infarction, coronary ischemia for which coronary intervention is required, renal artery stenosis, diabetes mellitus, hyperlipidemia, hypertension, patients diagnosed with human immunodeficiency virus, pre-eclampsia, HELLP syndrome, abruption placentae and Intrauterine growth restriction in medical history. Participants are re-invited after 4 years for a second screening. This screening is performed to study the progression of atherosclerosis and evaluate the effects of the advice of the multidisciplinary team.
3311568|NCT01932684|Experimental|Incentive spirometry|Was utilized an incentive spirometer volume in this group.
3311569|NCT01932684|No Intervention|Control Group|
3311570|NCT01932684|Experimental|Breath Stacking|We used a face mask silicone connected to a check valve allowing only inspiration and is connected to a spirometer showed that the volume inspired by the individual.
3311571|NCT01932710|Experimental|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment is tolerated. Patient receives a transfusion every 3-4 days (at least 2 a week) for up to 6 weeks.
3311572|NCT01932723|Experimental|Lumbar Stabilization Exercises & Control|Lumbar stabilization exercises daily, 10 repetitions each (three times a day) for three months consecutively. All exercises were performed to a count of 7 seconds.
3311573|NCT01932736|Experimental|healthy volunteers|healthy volunteers undergo pressure changes in ear canal
3311574|NCT01932749|Active Comparator|bilateral repetitive transcranial magnetic stimulation|"Bilateral protocol:~Motor threshold 100% /LDLPFC/10Hz/5 second duration/10 second intertrain/ Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain/"
3311575|NCT01932749|Active Comparator|unilateral repetitive transcranial magnetic stimulation|"Unilateral protocol:~Motor threshold 120% /RDLPFC/1Hz/10 second duration/2second intertrain"
3311576|NCT01932775|Experimental|GlucoTab System|
3311577|NCT01932801|No Intervention|Assessment-only|Assessment-only control condition
3311578|NCT01932801|Active Comparator|HRC|Harm reduction counseling, which entails provision of feedback and support of harm reduction goals and safer drinking provided at one-month intervals over a 3-month period.
3311579|NCT01932801|Experimental|XR-NTX+HRC|3 doses of active medication (380 mg injection/month) + Harm reduction counseling at one-month intervals over three months.
3311580|NCT01932801|Placebo Comparator|Placebo+HRC|3 doses of placebo + harm reduction counseling at one-month intervals over a three-month period
3311581|NCT01932814||Aminoglycosides|have received aminoglycosides
3311582|NCT01932814||No Aminoglycosides|did not receive aminoglycosides
3311583|NCT01932827||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is a online consumer monitor panel which answers surveys every 8-10 weeks about diet and health.
3311584|NCT01932840||Canadian Consumer Monitor Panel|Canadian Consumer Monitor Panel is an online panel which answer surveys every 8-10 weeks about diet and health
3311585|NCT01932853||Hemodialysis patients|Patients > 18y hemodialysis for at least 6 months at any center of Spain Fresenius Medical Care (FMC) meeting the inclusion criteria.
3311586|NCT01932866|Active Comparator|Control - diabetes risk score|the participants in the control group did not receive their diabetes risk score at the beginning of the trial, but did receive their scores to include baseline at the 12 and 24 week points.
3311587|NCT01932866|Experimental|Intervention - diabetes risk score|the subjects in the intervention arm received their diabetes risk scores at the beginning of the trial, 12 weeks and 24 weeks.
3311588|NCT01932879|Experimental|Blackberry|Participants will consume blackberries twice/day as part of a 1-week controlled diet.
3311589|NCT01932879|Other|Control|Participants will consume jello twice/day as part of a 1-week controlled diet.
3311590|NCT01932892||Transhumeral prosthesis user|Transhumeral body-powered prosthesis user
3311591|NCT01932905|Active Comparator|deep rTMS-active doble coil|patients undergoing of deep rTMS real with doble coil
3311592|NCT01932905|Sham Comparator|deep rTMS-sham|patients undergoing to placebo deep rTMS
3311593|NCT01932905|Active Comparator|deep rTMS-active: H-coil|patients undergoing of deep rTMS real with H-coil
3311594|NCT01932918||PCA with morphine in liver transplant|Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
3311595|NCT01932918||PCA with ketorolac in liver transplant|Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
3311596|NCT01932918||Intravenous PCA in thoracic surgery|Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
3311597|NCT01932918||PCEA in thoracic surgery|Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
3311598|NCT01932931|Active Comparator|Cholecalciferol supplement (50ug)|Cholecalciferol supplement is given for 1 year through randomisation of both MDD patients and healthy controls.
3311599|NCT01932931|Placebo Comparator|Placebo|Placebo treatment (tablet) is given for 1 year through randomisation of both MDD patients and healthy controls.
3311600|NCT01932944||No treatment|
3311601|NCT01932957|Other|Laparotomy arm|Standard treatment
3311602|NCT01932957|Experimental|Laparoscopy arm|Treatment by laparoscopy
3311603|NCT01932983||TOF test|TOF - train of four test performed on patiens undergoing lumbar spine surgery where introperative neurophysiologic monitoring is applied. Stimulation of peripheral nerve - ulnar nerve resulting with muscle contractions and evaluation of responses by anesthesiologist and neurophysiologists. Stimulation with group of 0.2 millisecond pulses, spaced 500 millisecond apart, at a 2 Hz rate, current 20-60 mA to deliver four muscle contractions. Eligibility criteria included patients for study where subjective visual interpretation and quantitative interpretation of Adductor pollicis muscle responses is followed.
3311604|NCT01933022|Other|Single Arm: Eligard|Single Arm
3311605|NCT01933035||Immune Thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made among individuals with known ITP . Those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy induced thrombocytopenia, and myelodysplastic thrombocytopenia, and a control population.
3311606|NCT01933035||Hypo-proliferative thrombocytopenics|The study shall be a single institution prospective cohort study. Comparison will be made between individuals with known ITP versus those with known hypo-proliferative forms of thrombocytopenia [aplastic anaemia, chemotherapy--induced thrombocytopenia, and myelodysplastic thrombocytopenia], and a control population.
3311607|NCT01933035||Control Pupulation|comprised of healthy individuals with normal platelet counts, to confirm normal values for MPC and MPM
3311608|NCT01933061|Experimental|Abraxane 150 mg/m² Intravenous (IV)|
3311609|NCT01933061|Experimental|CC-486 orally plus Abraxane IV|
3311610|NCT01933087|No Intervention|Control with no hand hygiene promotion|no implementation of hand hygiene promotion
3311611|NCT01933087|Experimental|Hand hygiene promotion|Intervention to promote hand hygiene which is based on the WHO multimodal hand hygiene improvement strategy.
3311612|NCT01933100|Experimental|Brown Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3311613|NCT01933100|Experimental|Polished Rice Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3311614|NCT01933100|Experimental|Wheat Based-Meal|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
3311615|NCT01933126|Experimental|HCG administration|Intrauterine HCG injection
3311616|NCT01933126|Placebo Comparator|Placebo|G2 Medium
3311617|NCT01933139|Experimental|Audio-visual presentation|The intervention group will watch a 10-minute scripted video explaining the procedure, risks, benefits, expectations, and long term complications that relate to hysterectomies before face-to-face interaction with the surgeon. Patients in both arms will then sign the same standard pre-surgical informed consent form before undergoing the procedure.
3311618|NCT01933139|No Intervention|Control|standard physician interaction (control arm)
3311619|NCT01933152||Group 1|
3311620|NCT01933165|Other|LipiView|
3311621|NCT01933178|Other|Cirrus AS-OCT|
3311622|NCT01933191|Experimental|physical acticity|Experimental: Aerobic treadmill exercise (30 minutes, 70% VO2max)
3311623|NCT01933191|Placebo Comparator|placebo exercise|Aerobic treadmill exercise (30 minutes, 20% VO2max)
3311624|NCT01933204|Experimental|Acupuncture|Using basic points combined with additional points. Basic points are fixed, while additional points will be selected from a list of points categorized by syndrome differentiation.
3311625|NCT01933204|Active Comparator|Climen 21 Tablets|COMPOSITION 11 white tablets each containing estradiol-17-valerate 2 mg, plus 10 pink tablets each containing estradiol-17-valerate 2 mg and cyproterone acetate 1 mg.
3311626|NCT01933256|Experimental|600mg HIP2B|600mg HIP2B
3311627|NCT01933256|Placebo Comparator|Placebo|Placebo
3311628|NCT01933256|Experimental|400mg HIP2B|400mg HIP2B
3311629|NCT01933269|Experimental|FACBC|
3311630|NCT01933282|Experimental|MESA chemotherapy|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4 dexamethasone 20mg/ m2，VD d2，d3，d4，d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
3311631|NCT01933295|Active Comparator|Sleep Education|Weekly educational emails sent to participants with information about sleep science and tips for better sleep.
3311632|NCT01933295|Experimental|Cognitive Behavioral Therapy for Insomnia|Behavioral treatment (5 component)
3311633|NCT01933295|Experimental|Sleep Restriction Therapy|Brief sleep restriction therapy.
3311634|NCT01933308|Experimental|Continuous high intensity training-CT80|All arms will receive standardized comprehensive self-management teaching from health care practitioners. At program completion, all subjects will receive the same standardized exercise recommendations. The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CT80 will consist of exercising at 80% of peak work rate (target training intensity) for 25 minutes, for a total session duration of 40 minutes.
3311635|NCT01933308|Experimental|Training at ventilatory threshold-CTVT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The duration of the training phase will be adjusted such that the total amount of work performed per session will be comparable between the three interventions. The training phase for the CTVT will consist of exercising at the ventilatory threshold for a duration that will result in a total amount of work equivalent to the work that each patient would have done if he/she had been assigned to the CT80 arm. This approach has been used successfully in the past to isolate the effect of training intensity from that of total training dose.
3311636|NCT01933308|Experimental|Interval training-IT|The exercise training program will consist of cycling on a calibrated cycle ergometer at the target intensity, three sessions per week for 12 weeks. Sessions will include a 10-minute warm-up, a training phase at the target intensity, and a 5-minute cool-down. The training phase for the IT will consist of intervals of 30 seconds of exercise at 100% of work peak interspersed with intervals of 30 seconds of rest. This approach to IT was selected because it was successfully used by Vogiatzis et al. [33] and was shown to be as effective as continuous exercise training at a moderate intensity. As with the CTVT and CT80 arms, the duration of the training phase will be adjusted for the IT arm such that the total amount of work will be equivalent.
3311637|NCT01933321|Experimental|Intrathecal autologous stem cells|Intrathecal stem cells will be administered to patients that fulfill the inclusion criteria.
3311638|NCT01933347|Experimental|Gefitinib 250mg/d|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression, perform scheduled visits in investigational sites at interview day and complete related examinations during follow-up period.
3311639|NCT01933360|Active Comparator|Misoprostol sublingual,1h|Administration of misoprostol sublingually 1h prior to surgery
3311640|NCT01933360|Active Comparator|Misoprostol sublingual. 3h|Administration of misoprostol sublingually 3h prior to surgery
3311641|NCT01933360|Active Comparator|Misoprostol vaginal,1h|Administration of misoprostol vaginally 1h prior to surgery
3311642|NCT01933360|Active Comparator|Misoprostol vaginal,3h|Administration of misoprostol vaginally 3h prior to surgery
3311643|NCT01933373|Active Comparator|Toupet|Laparoscopic Myotomy + Toupet 180 degree partial posterior fundoplication.
3311644|NCT01933373|Experimental|Dor|Laparoscopic Myotomy + Dor anterior partial fundoplication. 90 degree partial fundoplication being the standard of care.
3311645|NCT01933386|Other|SoundBite|SoundBite will be used for the first 30 days
3311646|NCT01933386|Other|Surgically Implanted BCD|The subject's own surgically implanted bone conduction device will be used for the first 30 days.
3311647|NCT01933412|Experimental|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
3311648|NCT01933412|Active Comparator|Engerix B Hepatitis B Vaccine|Engerix B Hepatitis B Vaccine
3311649|NCT01933438|Experimental|Sup-ER protocol|Early shoulder repositioning (Sup-ER Splint)
3311650|NCT01933438|Active Comparator|Control|Standard treatment
3311651|NCT01933451|Experimental|Restrictive intraoperative fluid therapy|To Keep intraoperative pulse pressure variation above 18%.
3311652|NCT01933451|Other|Liberal intraoperative fluid therapy|To keep intraoperative pulse pressure variation below 13%.
3311653|NCT01933477|No Intervention|Local Standard of Care|Arm A: Referral of post-partum women from the antenatal clinic to general adult ART services at approximately 4-8 weeks postpartum (the local current standard of care in this setting)
3311654|NCT01933477|Active Comparator|MCH-focused ART services|Arm B: Continued receipt of MCH-focused ART services based at the antenatal clinic throughout the period of breastfeeding. Post-partum women will only be referred to general adult ART services after the end of breastfeeding and once infants' final HIV status is determined.
3311655|NCT01933490|Other|a high carbohydrate test meal (control condition)|a high carbohydrate test meal (control condition)
3311656|NCT01933490|Active Comparator|high carbohydrate test meal after pre-treatment|a high carbohydrate test meal after pre-treatment with rapid acting aspart insulin (insulin condition)
3311657|NCT01933490|Active Comparator|high fructose low glucose test meal|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal (fructose condition)
3311658|NCT01933503|Experimental|OCA 5 mg|OCA 5 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 5 mg by mouth for 14 days.
3311659|NCT01933503|Experimental|OCA 10 mg|OCA 10 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 10 mg by mouth for 14 days.
3311660|NCT01933503|Experimental|OCA 25 mg|OCA 25 mg, 1 mg by mouth followed by 2 days of no investigational product (IP); then OCA 25 mg by mouth for 14 days.
3311661|NCT01933516|Experimental|GP2013|
3311662|NCT01933529|Experimental|ARA 290|ARA 290, 4.0 mg, injected subcutaneously once every morning during 28 days.
3311663|NCT01933529|Placebo Comparator|Placebo|Placebo, injected subcutaneously once every morning during 28 days,
3311664|NCT01933542|Active Comparator|Chlorzoxazone|"Oral administration of chlorzoxazone 500 mg (two 250 mg tablets)~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
3311665|NCT01933542|Placebo Comparator|Placebo|"Oral administration of two placebo tablets~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed"
3311666|NCT01933555|Experimental|Empowerment program|The hour intervention, delivered over a 11-week period, consisted of an empowerment and additional components adapted from Freedom program run to support domestic abused women.
3311667|NCT01933555|No Intervention|Control group|Standard care, which was routine check ups and care provided by health care professionals.
3311668|NCT01933568|Experimental|Radiation|combined CFRT and SABR with concurrent cisplatin
3311669|NCT01933581||ACS undergoing CA and PCI|Patients with Acute Coronary Syndrome undergoing coronary angiography and PCI
3311670|NCT01933607|Other|TOPS System|Post Marketing Study
3311672|NCT01933633|Experimental|Exercise|Regular exercise training for 10 weeks prior to assisted fertilisation
3311673|NCT01933633|No Intervention|Control|Standard care
3311674|NCT01933646||Cohort 1|
3311675|NCT01933659|Experimental|group A: DSW group|ingesting DSW 200 cc four times a day (one hour before meal and bed time);
3311676|NCT01933659|Placebo Comparator|group B: non-DSW group|ingesting non-DSW drinking water 200 cc four times a day (one hour before meal and bed time).
3311677|NCT01933685|Experimental|AIDSVAX B/E|AIDSVAX B/E at Weeks 0, 4, 24 and 48
3311678|NCT01933685|Placebo Comparator|AIDSVAX B/E Placebo|AIDSVAX B/E Placebo at Weeks 0, 4, 24 and 48
3311679|NCT01933698|Active Comparator|Amoxi-Ped|Single dose of 500 mg amoxicillin - AMOXI-PED - was administered after a 12-hour overnight fast.
3311680|NCT01933698|Active Comparator|Amoxil|Single dose of 500 mg amoxicillin - AMOXIL - was administered after a 12-hour overnight fast.
3311681|NCT01933711|Experimental|Rituximab maintenance|maintenance therapy with rituximab (375 mg/m2) administered every 3 months for 2 years.
3311682|NCT01933711|No Intervention|Observation|observational arm, no intervention
3311683|NCT01933724|Experimental|5 mg prednisone|Subjects will be randomized to 5 mg per day of prednisone for a 6 month period.
3311684|NCT01933724|Experimental|0 mg prednisone|Subjects will be randomized to 0 mg per day of prednisone dose for a 6 month period.
3311685|NCT01933737|Experimental|Kinesio Taping Group|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
3311686|NCT01933737|Experimental|Placebo tape group|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
3311687|NCT01933750|No Intervention|Randomized/Control|7 patients randomized to deferred treatment/control cohort at the 3 sub-study control sites = 21
3311688|NCT01933750|Experimental|Non-Randomized/Treatment|Patients are non-randomized and if meet inclusion criteria receive the implantation of the PresVIEW device
3311689|NCT01933763|Experimental|Group A|Participants in Group A will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
3311690|NCT01933763|Experimental|Group B|Participants in Group B will consist of up to 6 sequential ascending dose cohorts. Each cohort will therefore receive 1 of 6 ascending dosing levels of the study drug (REGN1193) or placebo.
3381531|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 4|This is a triple cross-over with a sham control condition; the sham tACS administered first, then standard tACS, then nested tACS.
3381532|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 5|This is a triple cross-over with a sham control condition; the nested tACS administered first, then sham, then standard tACS.
3381533|NCT03112902|Active Comparator|Effects of tACS during SWS- Standard/Nested 6|This is a triple cross-over with a sham control condition; the nested tACS administered first, then standard tACS, then sham.
3381534|NCT03108638||R3 Supervisor Strategy Region 1|First cohort to be trained and monitored with remote coaching in the R3 model
3311691|NCT01933802|Experimental|autologous MSC-NP|intrathecal administration of autologous MSC-NP in three doses at three month intervals
3381535|NCT03108638||R3 Supervisor Strategy Region 2|Second cohort to be trained and monitored with remote coaching in the R3 model
3381536|NCT03108638||R3 Supervisor Strategy Region 3|Third cohort to be trained and monitored with remote coaching in the R3 model
3381537|NCT03108638||R3 Supervisor Strategy Region 4|Fourth cohort to be trained and monitored with remote coaching in the R3 model
3381538|NCT03108456|Active Comparator|Orbital Atherectomy (OA)|The Diamondback 360® Coronary Orbital Atherectomy System (OAS) will be used for orbital atherectomy (OA) vessel preparation prior to implantation of a drug-eluting stent.
3381539|NCT03108456|Active Comparator|Conventional Balloon Angioplasty|Coronary balloons cleared or approved for commercial use by the Food and Drug Administration will be used for conventional balloon angioplasty prior to implantation of a drug-eluting stent.
3381540|NCT03106688|Active Comparator|Low-risk group|Individuals in the low-risk group are not in a risk of developing obesity according to traditional risk criteria.
3381541|NCT03106688|Active Comparator|High-risk group|Individuals in the high-risk group are in a risk of developing obesity according to traditional risk criteria.
3381542|NCT03105700|Experimental|Low Frequency TMS Intervention|Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
3381543|NCT03090191|Experimental|Clostridium difficile vaccine|
3381544|NCT03090191|Placebo Comparator|Placebo|
3381545|NCT03080259|Active Comparator|Stimulant Diversion Prevention|Providers will be trained in methods to prevent or decrease the likelihood of stimulant diversion by their adolescent patients (education and counseling, strategies for use by patients and parents, and treatment adjustments).
3381546|NCT03080259|No Intervention|Treatment As Usual|Standard clinical care
3381549|NCT03069378|Experimental|Talimogene Laherparepvec (T-VEC) Administered with Pembrolizu|Patients will initiate treatment with talimogene laherparepvec given intralesionally and pembrolizumab.
3381550|NCT03064750|Experimental|Pre-surgery exercise|pelvic floor exercises individually and in groups
3381551|NCT03064750|Other|Waiting list|wait as usual until surgery
3381552|NCT03060096|Experimental|Moderate Anxiety/depression: Low Intensity Stepped care|participants with moderate symptoms (PHQ-9-14; GAD-7: 10-14) will be randomized to either low-intensity stepped care or enhanced usual care. Stepped care consist of a self-guided cognitive behavioral therapy (CBT) workbook to reduce anxiety and depressive symptoms and biweekly (every two weeks) check-in calls from research staff to assess changes in symptom severity/immediate need for psychiatric treatment and provide minimal support.
3381553|NCT03060096|Experimental|Severe Anxiety/depression: High Intensity Stepped Care|Participants with severe symptoms (PHQ-9: 15-27; GAD-7: 15-21) will be randomized to high intensity stepped care (consist of a CBT workbook with accompanying psychotherapy by a Master's-level therapist delivered by telephone) or EUC. EUC consist of information about referrals/resources locally and nationally.
3381554|NCT03060096|Active Comparator|Enhanced Usual Care Control (EUC)|"Participants randomized to EUC will receive information about local referrals/resources (support groups, mental health providers, etc.). They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the NCI to assist with transition from active treatment to survivorship. Participants will receive information on self-help workbooks for anxiety & depressive symptoms. EUC control will receive a copy of the CBT workbook on completion of the study."
3381555|NCT03032601|Active Comparator|N-acetyl Cysteine Cohort|Intravenous N-acetyl Cysteine - 50mg in 200ml of D5W over one hour 1 x per week Oral N-acetyl Cysteine - 1 500mg tablet 2 x per day (on days IV N-acetyl cysteine is not administered)
3381556|NCT03032601|No Intervention|Control Cohort|Standard of Care Treatment
3381557|NCT03032328|Experimental|vitamin D supplement|patient's will be given a vitamin D
3381558|NCT03029000|Experimental|Tbo-filgrastim (GRANIX)|"Participants will receive tbo-filgrastim 10 mcg/kg of body weight, subcutaneously on the morning of Days 1 to 5.~The actual dose of tbo-filgrastim administered to each, individual participant will be calculated at baseline according to his or her body weight and that specific dose (10 mcg/kg of body weight) for each, individual participant will remain the same for all consecutive daily doses.~If the collection goal will not meet after the first apheresis on Day 5, tbo-filgrastim 10 mcg/kg of body weight will be administered subcutaneously for up to 3 additional days (Days 6 to 8) followed by daily apheresis to reach the cumulative collection goal."
3381559|NCT03014414|Experimental|Fun First|If randomized to the 12-month Fun First program, participants will attend weekly interactive small-group sessions led by health coaches for 6 months, then receive monthly phone calls from coaches for 6 months. The first 6 months consists of a 2-month module promoting enjoyment of key maintenance skills before losing weight, followed by a 4-month behavioral weight-loss program.
3381560|NCT03014414|Active Comparator|Weight Watchers|If randomized to the 12-month Weight Watchers program, participants are provided with study-paid access to weekly ongoing Weight Watchers meetings led by peer meeting leaders for 12 months at Weight Watchers locations convenient to participants as well as study-paid access to Weight Watchers personalized online tools. [The study and investigative team have no financial relationship with Weight Watchers].
3311692|NCT01933815|Experimental|TPI 287 + bevacizumab|"All subjects in phase 1 & subjects randomized to the TPI 287 + bevacizumab arm in phase 2 will be administered a 1-hour IV infusion of TPI 287 once every 3 weeks (Days 1 & 22 of 42-day cycle) & a 30-90 minute IV infusion of bevacizumab once every 2 weeks (Days 1, 15, & 29).~In phase 1, the dose of TPI 287 will be escalated in sequential dose cohorts of 3 to 6, while the dose of bevacizumab remains constant (10 mg/kg). The first 5 dose levels will be 140, 150, 160, 170, & 180 mg/m2. Dose levels beyond 180 mg/m2 will be increased in increments of 20 mg/m2. Three subjects will be treated at a dose level halfway between the dose level that exceeds the MTD and the dose level immediately prior to further refine the MTD.~In phase 2, the dose of TPI 287 will be the MTD determined in phase 1, & the dose of bevacizumab will be the same as phase 1 (10 mg/kg).~Subjects may continue on treatment unless they meet one or more of the protocol discontinuation criteria."
3311693|NCT01933815|Active Comparator|Bevacizumab|"All subjects randomized to the bevacizumab alone arm in phase 2 will be administered bevacizumab as a 30 to 90 minute IV infusion once every 2 weeks (Days 1, 15, and 29 of a 42-day cycle). The dose of bevacizumab will be 10 mg/kg.~Subjects will be withdrawn from the study if they meet one or more of the discontinuation criteria outlined in the protocol; however, treatment with bevacizumab may continue under the FDA approved labeling for bevacizumab at the discretion of the subject's doctor.~All subjects in phase 1 will be administered TPI 287 in combination with bevacizumab (i.e., there will be no bevacizumab alone arm during phase 1)."
3311694|NCT01933828|Active Comparator|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
3311695|NCT01933828|Active Comparator|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
3311696|NCT01933828|Other|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
3311697|NCT01933841||Days 1-30|Adult surgery patients whose operations occurred during Days 1-30 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3311698|NCT01933841||Days 31-60|Adult surgery patients whose operations occurred during Days 31-60 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3311699|NCT01933841||Days 61-90|Adult surgery patients whose operations occurred during Days 61-90 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3311700|NCT01933841||Days 91-120|Adult surgery patients whose operations occurred during Days 91-120 after monitoring is introduced in the PACU. Patients will have their TOF ratio measured and recorded using a TOF-Watch SX. The nurse will monitor the patient and notify the provider of the patient's TOF-ratio if appropriate.
3311701|NCT01933854||Riverside group|Women aged 20 years or over who are not pregnant living riverside area of the Amapa State Brazil.
3311702|NCT01933854||urban group|women aged 20years or over not pregnant and living urban area
3311703|NCT01933867|Experimental|Water immersion colonoscopy|Water immersion during colonoscope insertion and room air insufflation during colonoscope withdrawal.
3311704|NCT01933867|Active Comparator|Air insufflation colonoscopy|Standard room air insufflation during both colonoscope insertion and withdrawal.
3311705|NCT01933906|Experimental|P1101|"P1101 50µg s.c. will be administered every 2 weeks in addition to preexisting imatinib treatment. In the absence of dose limiting toxicities after 12 weeks, the dose will be escalated to 100µg every 2 weeks.~Maximum treatment duration will not expand 18 months."
3311706|NCT01933945||TACE + early Nexavar|Patients with early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility to choose Sorafenib as the next treatment option (regardless of whether TACE treatment is continued or not).
3311707|NCT01933945||TACE without early Nexavar|Patients without early start of Sorafenib treatment. This cohort comprises all patients where the physician decides at the time of TACE non-eligibility not to choose Sorafenib as the next treatment option. This cohort also includes patients with TACE non-eligibility for whom the decision to treat with Sorafenib is made at a later point in time, patients who are never treated with Sorafenib as well as patients for whom another systemic cancer treatment has been chosen be the physician either at time of TACE non-eligibility or at a later point in time.
3311708|NCT01933971|Other|Group 1: filgrastim 2.5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
3311709|NCT01933971|Other|Group 2: filgrastim 5 µg/kg/day for 7 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh~th injection: abdomen with the exception of the umbilical area~th injection: upper part of the same upper arm, posterior surface as for the 1st injection."
3311710|NCT01933971|Other|Group 3: filgrastim 10 µg/kg/day for 5 consecutive days|"The test investigational product is BK0023. The reference product is Neupogen® 30, by Dompé Biotec S.p.A., Italy.~Both study treatments were administered according to a cross-over design in 2 subsequent periods separated by wash-out periods of at least 28 days.~The sites, where the injections are to be performed, are planned as follows:~st injection: upper part of the upper arm, posterior surface~nd injection: upper part of the thigh~rd injection: abdomen with the exception of the umbilical area~th injection: upper part of the contra-lateral upper arm, posterior surface~th injection: upper part of the contra-lateral thigh."
3311711|NCT01933997|Experimental|MG01CI 1400 mg|
3311712|NCT01934023|Active Comparator|Varenicline|FDA approved smoking cessation medication
3311713|NCT01934023|Placebo Comparator|Placebo Sugar Pill|sugar pill
3311714|NCT01934036|Experimental|Obex, a nutritional supplement|Obex will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
3311715|NCT01934036|Placebo Comparator|Placebo|Placebo will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during two months. Patients will be recommended to comply with a healthy lifestyle through diet and exercise.
3311716|NCT01934049|Active Comparator|Dexmedetomidine|Dexmedetomidine in dex group is administered as 1ug/kg by intravenous infusion 10 min and then 0.6 ug/kg until 30 minutes before the operation finishes.
3311717|NCT01934049|Placebo Comparator|Saline|Participants in con group receive placebo(saline) as the same dose at the same time as dex group.
3311718|NCT01934062||Surgical patients|Pediatric patients having surgery at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
3311719|NCT01934075|Experimental|Mental health treatment|Participants will receive twice-weekly exposure to 6 sessions of individual mental health treatment in a private room. Sessions will follow the intervention manual and be delivered by a full-time nurse facilitator who has a counseling background and receives supervision by a trained therapist.
3311720|NCT01934075|No Intervention|Standard of Care|Participants in the control condition will receive counseling that is the current standard of care for fistula patients at KCMC.
3311721|NCT01934088|Experimental|Propofol|Propofol in refract doses. Induction: 10-60 mg supplemented with 10-30 mg following an age correlated algorithm. Maintenance with refract bolus of 10-20 mg every 1-2 minutes after assessed need and condition
3311722|NCT01934088|Active Comparator|Fentanyl and Midazolam|0.025-0.05 mg of Fentanyl i.v. minimum 5 minutes before procedure as a single shot. Midazolam 1-2 mg i.v. for induction and 0.5-1 mg i.v. for maintenance after assessing needs and condition
3311723|NCT01934101|Experimental|CHR-5154|CHR-5154
3311724|NCT01934101|Placebo Comparator|Placebo|Placebo
3311725|NCT01934114||Under Treatment|Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
3311726|NCT01934114||Normal Cohort|Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
3311727|NCT01934127|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
3311728|NCT01934127|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
3311729|NCT01934127|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
3311730|NCT01934127|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
3311731|NCT01934127|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
3311732|NCT01934127|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3311733|NCT01934153|Experimental|Cohort A|Single dose of topical [14C]Umeclidinium was applied to the unoccluded axilla, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3311734|NCT01934153|Experimental|Cohort B|Single dose of topical [14C]Umeclidinium was applied to the occluded axilla, and the drug which will be applied to the test site has remain on the application site for 8 hrs
3311735|NCT01934153|Experimental|Cohort C|Single dose of topical [14C]Umeclidinium was applied to the unoccluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3311736|NCT01934153|Experimental|Cohort D|Single dose of topical [14C]Umeclidinium was applied to the occluded palm, and the drug which will be applied to the test site has to remain on the application site for 8 hrs
3311737|NCT01934166|Experimental|Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3311738|NCT01934179||Ancillary-correlative (real-time PCR)|Patients undergo blood collection for analysis via real-time PCR at baseline, 3 months, and 6 months.
3311739|NCT01934205|Experimental|Part A(Cohort1)|Study BTZ116666 has two parts. Each part will consist of a maximum of 6 cohorts. Part A will be initiated with 4 initial cohorts/timepoints in order to minimize the number of healthy volunteers that undergo bronchoscopy in this study. After review of data from Cohorts 1 through 4 of Part A, the study team will determine if additional cohorts are needed to be studied in Part A and/ or if Part B is needed. If the study team determines that additional cohorts are needed, then only the necessary cohorts in Parts A and/or B will be executed. In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 2 hours x 1 dose
3311740|NCT01934205|Experimental|Part A (Cohort2)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 4 hours x 1 dose
3311741|NCT01934205|Experimental|Part A (Cohort3)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 8 hours x 1 dose
3311742|NCT01934205|Experimental|Part A (Cohort4)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion over 12 hours x 1 dose
3311743|NCT01934205|Experimental|Part A (Cohort5)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311744|NCT01934205|Experimental|Part A (Cohort6)|In Part A, participants will receive GSK2140944 1000 mg intravenous (IV) infusion. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311745|NCT01934205|Experimental|Part B (Cohort1)|In Part B, participants will receive GSK2140944 1000 mg IV infusion, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311746|NCT01934205|Experimental|Part B (Cohort2)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311747|NCT01934205|Experimental|Part B (Cohort3)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311748|NCT01934205|Experimental|Part B (Cohort4)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311749|NCT01934205|Experimental|Part B (Cohort5)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311750|NCT01934205|Experimental|Part B (Cohort6)|In Part B, participants will receive GSK2140944 1000 mg IV infusion over, q12h x 5 doses. Optional Cohort or Part and will only be used if necessary. Sampling times are to be determined based on the review of preliminary PK results from prior study parts and/or cohorts.
3311751|NCT01934244||Per Protocol|All enrolled patients in which all inclusion/exclusion criteria were met and the NovaSure endometrial ablation was completed.
3311752|NCT01934244||Primary|All enrolled patients in whom the Novasure device was inserted.
3311753|NCT01934244||Intent to treat|All enrolled patients in which NovaSure device was attempted.
3311754|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
3311755|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
3311756|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
3311757|NCT01934270|Experimental|Anaerobic Test|
3311758|NCT01934283|No Intervention|operated patients|small bowel obstrucion patients who needed surgery for treatment of obstruction.
3311759|NCT01934296|Experimental|chronic brain recording|This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.
3311760|NCT01934309|Experimental|TB reminders|Receive existing reminders plus new patient-specific reminders about TB screening, prevention, and treatment
3311761|NCT01934309|No Intervention|No TB reminders|Only receive existing reminders; no TB reminders
3311762|NCT01934322|Experimental|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
3311763|NCT01934322|No Intervention|Control|Patients randomized to control group (usual care) will receive standard emergency care by physicians (resident or attending physician) and nurses, without the case manager been involved. Nevertheless, the mobile team will take contact with each patient of the control group, giving them short information through a flyer (flyer) which will underline the existence of the mobile team, its addresses and telephone numbers.
3311764|NCT01934348|Experimental|Psychological First Aid|Behavioral intervention delivered to crime victims during 2-3 in-person interactions within 1 month of the assault.
3311765|NCT01934348|Active Comparator|Usual victim advocacy services|Standard victim advocacy services delivered to crime victims within 1 month of the assault.
3311766|NCT01934361|Experimental|Lomustine+ buparlisib (Phase Ib)|
3311767|NCT01934361|Experimental|carboplatin+ buparlisib (Phase Ib)|
3311768|NCT01934361|Experimental|lomustine+ buparlisib (Phase II)|
3311769|NCT01934361|Placebo Comparator|lumustine + placebo (Phase II)|
3311770|NCT01934361|Experimental|carboplatin+ buparlisib (Phase II)|
3311771|NCT01934374|Experimental|Stroke|On the 30th day post stroke (D30), the exjperimental group will start to receive the task-oriented lower extremity strengthening training (TOLEST) program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
3311772|NCT01934374|No Intervention|Control|The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
3311773|NCT01934413|Active Comparator|Technology-Enhanced TPC|In addition to receiving usual palliative care service in the hospital setting, Technology-Enhanced Transitional Palliative Care patients will receive Transitional Care from the Palliative Care consulting team beginning in the hospital within 24 hours of study enrollment and continuing post discharge for eight weeks in their homes in rural locations by means of video visits with the Palliative Care consulting team.
3311774|NCT01934413|Other|Usual standard of care|The control group will receive only the current standard palliative care service in the hospital setting, which includes standard in-hospital palliative care consultation and standard discharge planning.
3311775|NCT01934426||Admission High Risk|Admission High Risk
3381563|NCT02994459||Metabolically Normal Obese (likely insulin sensitive)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
3311776|NCT01934439|Experimental|PAAD (Proximal Arm AMES Device)Treatments|"The PAAD flexes and extends the elbow, and it abducts and adducts the shoulder, where abduction is away from the side of the body, and adduction is towards it. Elbow extension occurs simultaneously with shoulder abduction, and elbow flexion occurs simultaneously with shoulder adduction. At the same time as the movements, vibrators are utilized to activate muscle spindle Ia receptors in the muscles of the arm to exaggerate the perception of movement."
3311777|NCT01934452||Complete Remission|Complete remission arm in mRCC patients treated with sunitinib.
3311778|NCT01934452||Non Complete Remission|Non complete remission arm in mRCC patients treated with sunitinib.
3311779|NCT01934465||Avastin regimens|Patients who have either received or who are going to receive chemotherapy plus Avastin (bevacizumab)
3311780|NCT01934491|Experimental|Cognitive Training A|emotional memory training exercise
3311781|NCT01934491|Active Comparator|Cognitive Training B|memory training exercise
3311782|NCT01934530|Active Comparator|Connective Tissue Graft - Control|The donor tissue was harvested from tissue palatal to maxillary premolars and anterior to the mesial of the first molars. A horizontal incision corresponding to the width of the recipient bed plus 4mm was made 3 mm apical to the gingival margin. A small secondary vertical incision was tolerated on the mesial aspect of the surgical site to allow for a split thickness technique. The flap was then positioned over the graft and sutured with attempts to cover the grafted tissue to 2mm coronal to the implant/abutment interface pending flap tension. Follow up was monitored over 6 months at various time-points.
3311783|NCT01934530|Experimental|Alloderm - Test|ADM graft was prepared according to the manufacturer's instructions. The preparation requires rehydration in 50ml sterile saline or Ringers Solution for five minutes and repeated twice. The graft was then transferred to the recipient bed with the basement membrane side facing up and connective tissue on the periosteum. The allograft was trimmed to cover the defect dimensions up to the implant-abutment interface. There was a 4mm margin added to the width on each side to account for lateral contraction as with the connective tissue. With sterile moist gauze, pressure was applied to the graft for proper adaptation to the wound bed. The graft was sutured with a single sling and the flap with a double sling. Simple interrupted sutures were used to close vertical releases.
3311784|NCT01934543|Experimental|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
3311785|NCT01934543|Experimental|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
3311786|NCT01934569|Experimental|Active tratment|Pravastatin, midazolam, losartan, omeprazole, caffeine single dose alone or in combination with PF-05089771
3311787|NCT01934595|Experimental|Varying amounts of Beneprotein|1.5grams/kg/day, 2.0 grams/kg/day, and 2.5 grams/kg, day
3311788|NCT01934595|Active Comparator|1 Gram - Standard Therapy given in ICU|1 gram/kg/day of protein
3311789|NCT01934608|Experimental|Refill synch|Participants in this group will have their medication refill schedule synchronized.
3311790|NCT01934608|No Intervention|Control|Participants in this arm will receive usual care
3311791|NCT01934621|Experimental|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice. Participants use printed workbooks to learn and apply this method.
3311792|NCT01934621|Placebo Comparator|Attention Control|The attention control intervention will control for the non-specific effects of strategy training. The therapists will administer the standardized and dose-matched protocol, using scripted open-ended questions to facilitate participants' reflections on their rehabilitation activities and experiences. In lieu of the strategy training workbook materials, participants will complete a daily journal, and discuss their entries during attention control sessions.
3311793|NCT01934634|Experimental|LCL161 +Gemcitabine +nab-Paclitaxel|LCL161 (tablets): 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days nab-paclitaxel IV: 100 or 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
3311794|NCT01934673||Subjects with diabetes (type 2)|
3311795|NCT01934686||Subjects with diabetes mellitus (type 2)|
3311796|NCT01934699|Active Comparator|MRI-Arm|Myocardial vitality determination based on MRI diagnostics.
3311797|NCT01934699|Experimental|Echo-Arm|Myocardial vitality determination using echocardiography in combination with 2D-Strain Analysis.
3311798|NCT01934712|Experimental|FIAsp|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
3311799|NCT01934712|Active Comparator|NovoRapid®|Each subject will be randomly allocated to one of the two treatment sequences consisting of 2 dosing visits
3311800|NCT01934725||Patients w/ cryptogenic ischemic stroke|Patients aged 15 to 49 years with unexplained first-ever ischemic stroke
3311801|NCT01934725||Stroke-free control subjects|Stroke-free subjects age- and gender-matched to patients
3311802|NCT01934738|Experimental|Group 1: Cohort 1|
3311803|NCT01934738|Experimental|Group 1: Cohort 2|
3311804|NCT01934738|Experimental|Group 1: Cohort 3|
3311805|NCT01934738|Experimental|Group 2: Cohort 4|
3311806|NCT01934738|Experimental|Group 1: Cohort 5|
3311807|NCT01934738|Experimental|Group 2: Cohort 6|
3311808|NCT01934751|Other|Opioid dependent|Subjects with a possible opioid use disorder, as determined by positive responses on the eligibility form: has used opioids within the past 30 days, opioid use has been a problem, and at least one harmful consequence of opioid use has been present (eg. withdrawal symptoms, or problems with family, friends, work, money etc.).
3311809|NCT01934751|Other|Alcohol dependent|Patients who indicate they have a problem with alcohol will be asked to complete the AUDIT, a validated, 10-item instrument that measures the severity of an alcohol problem. The AUDIT enquires about core features of alcohol dependence, such as failure to fulfill obligations. A score of 8 or more indicates possible alcohol dependence.
3311810|NCT01934764||autoimmune disease|
3311811|NCT01934777|Experimental|TREATED GROUP|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg by mouth every day in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
3311812|NCT01934777|Placebo Comparator|PLACEBO GROUP|placebo: this group will treated with identical placebo pearls given orally in association with lifestyle intervention [hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity] for 6 months
3311813|NCT01934803|Active Comparator|Zinc gluconate|Study participants will receive zinc gluconate supplements (15 mg for men and 12 mg for women) and will be instructed to take one pill daily for 18 months.
3311814|NCT01934803|Placebo Comparator|Placebo|Study participants will receive identically packaged placebo (sucrose) pills and will be instructed to take one pill daily for 18 months.
3311815|NCT01934816|Experimental|Glimepiride|4mg of Glimepiride once only before vascular testing and intradermal injections of GLP-1 and its analogues
3311816|NCT01934816|Placebo Comparator|Placebo tablet|Placebo tablet is given in the morning of the intradermal injections of GLP-1 and its analogues
3311817|NCT01934816|Active Comparator|Glyburide|10mg of Glyburide before study visit and intradermal injections of GLP-1 and its analogues
3311818|NCT01934829|Experimental|urea-based cream|Advanced HCC throughout China were treated with 10% urea-based cream 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for up to 12 weeks
3311819|NCT01934829|Placebo Comparator|best supportive care|BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator
3311820|NCT01934842|Experimental|TAP20-C|TAP20-C
3311821|NCT01934842|Active Comparator|SAFE-T-FILL|SAFE-T-FILL
3311822|NCT01934868|Experimental|Prolotherapy Injections|"Each patient will be evaluated clinically and the spinal levels to be injected will be decided upon during each visit. The levels to be injected will largely depend on the pain referral patterns. All prolotherapy injections will be performed under ultrasound guidance.~A prolotherapy solution of 20% dextrose combined with 1% lidocaine will be injected to facet capsular ligaments and interspinous ligaments of the lumbar spine and the posterior sacroiliac ligaments. Six points will be injected in each treatment session. These sessions will be 4 weeks apart."
3311823|NCT01934868|Active Comparator|Epidural Steroid Injections (ESI)|Those patients assigned to the ESI group will receive epidural steroid injections with 80mg methylprednisolone and 10mg buvicaine to the interlaminar space. These will be performed 4 weeks apart and under fluoroscopy. The level that will be injected will depend both on the clinical presentation as well as the size of the interlaminar space seen under fluoroscopy.
3311824|NCT01934881|Experimental|group I|Voltage adjustment only
3311825|NCT01934881|Experimental|group II|Combined parameters adjustment
3311826|NCT01934907|Experimental|washed RBC|Packed RBCs are Washed and then, transfused.
3311827|NCT01934907|No Intervention|pack RBC|Packed RBCs are transfused.
3311828|NCT01934933|Active Comparator|celebrex|celebrex capsule, 0.2 gram bid, 52 weeks
3311829|NCT01934933|Active Comparator|Enbrel|etanercept injection, 25mg per injection, 50mg/week, 52 weeks
3311830|NCT01934933|Active Comparator|Enbrel plus Celebrex|50mg/week Enbrel by hypodermic injection plus Celebrex 0.2 gram bid, 52 weeks
3311831|NCT01934946|Experimental|comprehensive rehabilitation 10 days|comprehensive rehabilitation PT OT once per day for 10 times within 14 days hospitalization
3311832|NCT01934946|Placebo Comparator|home rehabilitation|home rehabilitation 6 times of PT home visit within 3 months after discharge
3311833|NCT01934959|Experimental|Probiotics|
3311834|NCT01934985||Group 1|Patients scheduled to have clinically indicated stress MPI with low pre-test likelihood (0-15%) of coronary disease based on criteria of Diamond and Forrester. And those who have already had a clinical indicated stress MPI in the last three years with a low likelihood of having active coronary disease with no significantly narrowed coronary arteries.
3311835|NCT01934985||Group II|Patients in Group II who will have the dynamic imaging protocol studies after SCA, patients will be selected for protocol enlistment only if the decision is made by the patient's physician, based totally on clinical and social factors, that any considered revascularization intervention would not be performed on the day of diagnostic selective coronary angiography (SCA) and will be performed electively, at least 4 to 7 days later. Viability will be assessed in these patients only in the presence of WM abnormalities, and with serial analysis of WM, as described above. Patients will be followed for death or infarction or other events more than 3 months after study, for up to 3 years following participation in the protocol.
3311836|NCT01934985||Group III|"Patients found at SCA to have lesions of borderline clinical significance, preferably in the absence of other associated lesions."
3311837|NCT01934985||Group IV|Patients who were diagnosed with advanced heart failure including patients who had or will have cardiac resynchonization therapy (CRT) or a heart transplant.
3311838|NCT01934998||SCA6 and control|SCA6 and control
3311839|NCT01934998||SCA6 or controls|Twelve SCA6 patients and 8 controls to be studied
3311840|NCT01935011||PD DBS 60 Hz, 130 Hz or DBS off|PD DBS on 60 Hz stimulation, 130 Hz stimulation or DBS off
3311841|NCT01935024|No Intervention|Normal Activity level|
3311842|NCT01935024|Active Comparator|Personalized Exercise Regimen|
3311843|NCT01935050|Experimental|Guided Cognitive-Behavioral Self-Help|All participants will receive the experimental intervention: Guided Cognitive-Behavioral Self-Help. The 10 patient treatment modules will incorporate exercise, behavioral activation, thought monitoring and restructuring, relaxation training, worry control, and sleep hygiene. The four caregiver educational modules will provide caregivers with the skills needed to facilitate patients' practice of treatment techniques learned in session. For example, caregivers will be taught to help patients identify negative thoughts and replace them with more balanced alternatives and will be given tools to assist patients complete therapy goals (i.e., exercise, socializing).
3311844|NCT01935063|Experimental|Cognitive Behavioral Couple Therapy|CBCT is a 12-session therapy that includes the following: re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviours and couple interactions; psychoeducation about PVD and its impact upon sexuality, defining/working the sexual script, mindfulness techniques, communication skills training, and sexual approach/avoidance goals work, defusion and acceptance approaches to coping with pain, among others.
3311845|NCT01935063|Active Comparator|Topical lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (Zolnoun, Hartmann, & Steege, 2003).
3311846|NCT01935076||Obese mother/ Macrosomic baby|Obese mother that delivers a macrosomic neonate to understand the effects neonatal exposure to maternal obesity.
3311847|NCT01935076||Obese mother/ normal weight baby|Obese mother that delivers a normal weight neonate to understand effects neonatal exposure to maternal obesity.
3311848|NCT01935076||Normal weight mother/ Macrosomic baby|Normal weight mother that delivers a macrosomic neonate
3311849|NCT01935076||Normal weight mother/ Normal weight baby|Normal weight mother who delivered a normal weight neonate
3311850|NCT01935089|Experimental|Interferon alpha|pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks
3311851|NCT01935102||Chemotherapy|MBC patients treated with a first-line chemotherapy including paclitaxel without bevacizumab
3311852|NCT01935102||bevacizumab+chemotherapy|histologically confirmed HER2-negative MBC, treated with a first-line therapy including bevacizumab 10 mg/m2 i.v. on days 1 and 15 combined with first-line paclitaxel 90 mg/m2 i.v. on days 1, 8 and 15, every 4 weeks
3311853|NCT01935115|Active Comparator|Propofol|The control group will receive propofol 1 mg/kg and remifentanil 1 mcg/kg intravenously
3311854|NCT01935115|Experimental|Ketamine|Study group will receive ketamine 0.75 mg/kg and remifentanil 1 mcg/kg intravenously
3311855|NCT01935128|Experimental|Arm 1 Everolimus/Reduced dose tacrolimus|In this arm, the myfortic® will be weaned off quickly and everolimus (Zortress®) initiated to achieve a target level of 3-8 ng/ml with a mean of 6 ng/ml. Once achieving a therapeutic dose of everolimus (Zortress®) the tacrolimus (Prograf® or Hecoria®) dose will be reduced a target level of 3-5 ng/ml.
3311856|NCT01935141|Experimental|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
3311857|NCT01935141|Active Comparator|Full-Dose IV Contrast|A single intravenous dose of 100ml of Visipaque 320 non-ionic isoosmolar contrast agent will be given for each CT scan. The CT scan will be performed using a Siemens Sensation 64-MDCT scanner.
3311858|NCT01935154|Placebo Comparator|Placebo|Placebo will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
3311859|NCT01935154|Experimental|Vx-001|Vx-001 will be administered evey 3 weeks from w0 to W15 than every 12 weeks until disease progression.
3311860|NCT01935167|Experimental|A Group|DW1029M 600mg for 24 weeks
3311861|NCT01935167|Experimental|B Group|DW1029M 1200mg for 24 weeks
3311862|NCT01935167|Placebo Comparator|C Group|Placebo for 24 weeks
3311863|NCT01935193|Experimental|asa resistant|asa resistant patients receive endovenous infusion of lysine acetylsalicylate 288 mg and if asa resistance has been reversed they have been prescribed oral soluble salt of lysine acetylsalicylate.
3311864|NCT01935206|Placebo Comparator|Placebo|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
3311865|NCT01935206|Experimental|Naloxone (2 mg/kg)|The effect of naloxone (2 mg/kg) on secondary hyperalgesia 168 hours after a first-degree burn-injury is compared to the placebo effect.
3311866|NCT01935219|Experimental|Goal Management Training + Processing Speed Training|Group receives both Goal Management Training and as well as Processing Speed Training using DriveSharp software.
3311867|NCT01935219|Active Comparator|Processing Speed Training + Brain Health Workshop|Group receives both Processing Speed Training (using DriveSharp) and participates in a Brain Health Workshop that is matched to Goal Management Training for session length and contact with trainer.
3311868|NCT01935219|Placebo Comparator|Brain Health Workshop + computer assignments|Group participates in Brain Health Workshop and is provided with computer assignments to match for time spent on the computer in the other arms.
3311869|NCT01935232||Men|140 Men
3311870|NCT01935232||Female|500 Female
3311871|NCT01935245|Experimental|Mini extracorporeal circulation|Patients undergoing coronary artery bypass surgery on minimal extracorporeal circulation
3311872|NCT01935245|Active Comparator|Conventional extracorporeal circulation|Patients undergoing coronary artery bypass surgery on conventional extracorporeal circulation
3311873|NCT01935258|Experimental|Psychosomatic therapy|Psychosomatic therapy consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS. Psychosomatic therapy delivered by a psychosomatic therapist.
3311874|NCT01935258|Other|care as usual|Usual care of the general practitioner
3311875|NCT01935271|Experimental|Muscle Armor Supplement|Treatment with a commercially available over the counter nutritional supplement
3311876|NCT01935271|Placebo Comparator|Placebo|Sugar-based placebo drink mix
3311877|NCT01935284||Healthy Volunteers|
3311878|NCT01935297|Active Comparator|Exercise|8 weeks of supervised, structured, combined endurance and resistance training
3311879|NCT01935297|No Intervention|Control|Patients receive usual care, regular exercise is not recommended but also not prohibited
3311880|NCT01935310|Experimental|imiquimod use in photoaging|Evaluate the efficacy and safety of imiquimod as a treatment option for photoaging photoaging equal to or greater than 3.
3311881|NCT01935323|Experimental|High Intensity Interval Training|Participants will perform the HIIT protocol on an electronically-braked cycle ergometer (Quinton Excalibur, Quinton Instrument Company, Bothell, WA). Participants will perform a 20-minute protocol, consisting of four minutes of cycling at 15% of maximum anaerobic power (Max-AP) followed by 30 seconds at 85% of Max-AP. These workloads will be based upon pre-trial Wingate tests. This cycle was repeated four times within each protocol, ending with two minutes at 15% of Max-AP. This will be performed 3d/wk for 6wks, with at least 24 hrs between each session.
3311882|NCT01935323|Active Comparator|Moderate Intensity Training|Participants will perform 45-60 min (graduated over time to 60) of continuous cycling at 65% of VO¬2peak on a Monark cycle ergometer. Workload will be based upon pre-trial VO¬2peak testing. MIT exercise will be performed 5d/wk for 6wks.
3311883|NCT01935336|Experimental|Ponatinib|Patients receive ponatinib hydrochloride taken by mouth once or twice a day. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3311884|NCT01935349||Diabetes mellitus (DM) and hypertension (HT)|Diabetes mellitus (DM) and/or hypertension (HT) patients in Hong Kong
3311885|NCT01935362|Placebo Comparator|placebo|Placebo administered to participant
3311886|NCT01935362|Active Comparator|Citrus supplement|Citrus supplement administered to participant
3311887|NCT01935375|Experimental|CNM Interpersonal Psychotherapy|CNM Interpersonal psychotherapy
3311888|NCT01935375|Active Comparator|Treatment as Usual|Treatment as Usual is psychotherapy with a mental health provider
3311889|NCT01935388|Experimental|Common canister|Use of a single MDI (instead of assigning each patient an individual MDI) for multiple mechanically ventilated patients. Inhalers will undergo a stringent cleaning protocol between administrations and storage.
3311890|NCT01935388|No Intervention|Control|Each patient will be assigned an individual inhaler as per standard of care practice.
3311891|NCT01935401||Women with Bulimia Nervosa|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
3311892|NCT01935401||Healthy Controls|"fNIR~- Functional near-infrared spectroscopy measured-brain activity"
3311893|NCT01935414|Experimental|geko™|geko™ use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
3311894|NCT01935414|Active Comparator|TEDS stockings|TEDS use continually post-surgery for 48hrs and then a minimum of 4hrs/day until discharge
3311895|NCT01935427||Volunteer test subjects|Healthy volunteer with no cardiovascular disease
3311896|NCT01935440|Active Comparator|Prevention & Testing Control|The comparison condition is focused on basic HIV risk reduction , safety and preventing drug overdose.
3311897|NCT01935440|Experimental|Prevention & Testing Intervention|The intervention condition is training on peer outreach skills which includes talking to HIV positive social network members about HIV care, medication adherence and HIV risk reduction.
3311898|NCT01935453|Experimental|Recombinant HSV-1 Injection|Intratumoral injection Single dose: 4 groups -- 106 pfu, 107 pfu, 108 pfu and 4×108 pfu Multiple dose (three injections, every 2 weeks): 2 groups -- 108, 108, 108pfu and 4×108, 4×108, 4×108pfu Continuous treatment: Upon 4 weeks follow-up after administration, if the investigator deems that continuous treatment will benefit subjects, continuous intratumoral injection may be given, and the interval between each injection will be 2 weeks.
3311899|NCT01935466||Pioglitazone|Ever users of Pioglitazone
3311900|NCT01935466||Other drugs|Never users of pioglitazone
3311901|NCT01935479|Experimental|AK159 SD 1|Single administration of AK159 dose level 1
3311902|NCT01935479|Experimental|AK159 SD 2|Single administration of AK159 dose level 2
3311903|NCT01935479|Experimental|AK159 SD 3|Single administration of AK159 dose level 3
3311904|NCT01935479|Experimental|AK159 SD 4|Single administration of AK159 dose level 4
3311905|NCT01935479|Active Comparator|MN-10-T SD|Single administration of teriparatide acetate
3311906|NCT01935479|Experimental|AK159 MD 1|Multiple administration of AK159 dose level 1
3311907|NCT01935479|Experimental|AK159 MD 2|Multiple administration of AK159 dose level 2
3311908|NCT01935479|Experimental|AK159 MD 3|Multiple administration of AK159 dose level 3
3311909|NCT01935479|Experimental|AK159 MD 4|Multiple administration of AK159 dose level 4
3311910|NCT01935479|Active Comparator|MN-10-T MD|Multiple administration of MN-10-T
3311911|NCT01935479|Placebo Comparator|Placebo MD|Multiple administration of placebo AK159
3311912|NCT01935492|Active Comparator|8 cycles of Paclitaxel & bevacizumab|8 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
3311913|NCT01935492|Active Comparator|2 x 4 cycles of Paclitaxel & bevacizumab|intermittent 2x4 cycles of Paclitaxel: 90 mg/m2 IV on days 1, 8 and 15 every 28 days & Bevacizumab: 10 mg/kg IV on days 1 and 15 every 28 days
3311914|NCT01935505||Consulting group|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
3311915|NCT01935505||Drug intervention group|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
3311916|NCT01935505||Telephone intervention group|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
3311917|NCT01935505||Consulting+Telephone+Drug intervention|All the interventions above are include in this group
3311918|NCT01935518|Experimental|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
3311919|NCT01935531|Experimental|Diclofenac|3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is applied twice daily in the treatment area. 3 % diclofenac in 2.5% hyaluronic acid gel (Solaraze® 3% gel) is to be applied 1cm beyond the single AK.
3311920|NCT01935544|Experimental|botulinum toxin injections|The main objective is to compare the efficiency of botulinum toxin injections depending on the localization technique: ultrasound vs. electrical stimulation.
3311921|NCT01935544|Other|ultrasound guidance|The secondary objective is to demonstrate less painful localization associated to ultrasound-guidance
3311922|NCT01935557|Active Comparator|Continuous heparin infusion group|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
3311923|NCT01935557|Active Comparator|Intermittent heparin infusion group|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
3311924|NCT01935570|Experimental|Magnesium|
3311925|NCT01935583|Experimental|Resilience/Adjustment Counseling|Intervention to promote resilience and adjustment (RAI) - The RAI was developed based upon considerable clinical experience and research review. The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment to injury. The RAI is implemented in seven, 60-minute, in-person sessions.
3311926|NCT01935583|No Intervention|Waitlist Control|Individuals are randomly assigned to the treatment group or waitlist control (WLC) group. Individuals will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC participants will then be offered the opportunity to participate in the intervention.
3311927|NCT01935596|Active Comparator|ropivacaïne 0,5%,|intrathecal administration of 15mg of ropivacaine 0.5%.
3311928|NCT01935596|Active Comparator|lévobupivacaïne 0,5%|intrathecal administration of 15mg of levobupivacaine 0.5%
3311929|NCT01935609|Experimental|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
3311930|NCT01935609|No Intervention|Waitlist Control|Couples are randomly assigned to the treatment group or waitlist control (WLC) group. Couples will complete the study measures on 2 occasions, 5 weeks apart. In fairness, WLC couples will then be offered the opportunity to participate in the intervention.
3311931|NCT01935635|Experimental|HPDCs-T immune therapy combined with IFN|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
3311932|NCT01935635|Experimental|HPDCs-T immune therapy combined with ETV|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3311933|NCT01935635|Experimental|HPDCs-T immune therapy combined with LdT|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3311934|NCT01935635|No Intervention|IFN treatment|IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks
3311935|NCT01935635|No Intervention|ETV treatment|Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3311936|NCT01935635|No Intervention|LdT treatment|Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region
3311937|NCT01935648||Ropivacaine|Injection of local anaesthetic (ropivacaine) into the knee joint following hip arthroplasty. Total dose 200mls of 0.2% ropivacaine or 400mg at the time of surgery. This will be followed by a continuous infusion of 10mls/hour 0.2% ropivacaine for the subsequent 24 hours.
3311938|NCT01935674|Experimental|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
3311939|NCT01935674|Experimental|Continue ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
3311940|NCT01935687|Experimental|Using of instrumented wheel and ergometer roller|The same patient will receive two types of tests: instrumented wheel and ergometer roller.
3311941|NCT01935713|Experimental|Electronic Cigarette|Participants received the electronic cigarette for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3311942|NCT01935713|Experimental|Dissolvable Tobacco Lozenge|Participants received the dissolvable tobacco lozenge for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3311943|NCT01935713|Experimental|Dissolvable Nicotine Lozenge (Nicorette)|Participants received the dissolvable nicotine lozenge (Nicorette) for use instead of cigarettes when in the presence of their child(ren) for up to 8 weeks.
3311944|NCT01935726||Pulmonary fibrosis patients or their caretaker/supporter|Patients with pulmonary fibrosis of any cause (idiopathic, related to connective tissue disease [e.g., rheumatoid arthritis, systemic sclerosis/scleroderma, dermato-/polymyositis, sjogren's syndrome], familial or genetic) or the primary supporter/caregiver of a patient with pulmonary fibrosis
3311945|NCT01935739||Primary Breast Tumor|Primary breast tumor were test for HER2/neu status.
3311946|NCT01935739||Axillary Lymph Nodes.|Axillary Lymph Nodes were tested for HER2/neu status.
3311947|NCT01935752|Other|Fibromuscular dysplasia|Fibromuscular dysplasia:blood samples & vascular echotracking
3311948|NCT01935752|Other|healthy volunteer|healthy volunteer:blood samples & vascular echotracking
3311949|NCT01935752|Other|hypertensive patients|hypertensive patients:blood samples & vascular echotracking
3311950|NCT01935765|Experimental|Diabetes people|99 Type 1 diabetic patients aged 18 to 60 years, diagnosed since at least a year
3311951|NCT01935765|Experimental|healthy volunteers (controll group)|46 healthy volunteers matched by age, gender and body mass index
3311952|NCT01935778|Active Comparator|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
3311953|NCT01935778|Experimental|Docetaxel and capecitabine and oxaliplatin|"Docetaxel 60 mg/m² will be intravenously infused over at least 1 hour on Day 1 every 3 weeks.~Oxaliplatin 100 mg/m² will be intravenously infused over at least 2 hours on Day 1 every 3 weeks.~Capecitabine 800 mg/m² will be orally administered twice daily from Day 1 evening to Day 15 morning every 3 weeks. (Total 1,600 mg/m² daily)"
3311954|NCT01935804|Experimental|Experimental: 1|Pioglitazone given 30mg/once daily for 12 months.
3311955|NCT01935804|Active Comparator|Active comparator: 2|Metformin given 850 mg/twice daily for 12 months.
3311956|NCT01935817|Active Comparator|Silybin + vitamin E + phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill per day for 12 months
3311957|NCT01935817|Placebo Comparator|sugar pill|one placebo pill per day for 12 months
3311958|NCT01935830|Experimental|LAAM arm|"[11C]LAAM 15-20 mCi (maximum administered mass of 10 ug)~Efavirenz, oral capsules, 600 mg~Ritonavir, oral capsules, 100 mg"
3311959|NCT01935843|Experimental|Anti-tumor responses of CART-HER-2|
3311960|NCT01935856|Experimental|KHK7580|
3311961|NCT01935869|Experimental|LEO 90100|
3311962|NCT01935869|Placebo Comparator|Vehicle|
3311963|NCT01935869|Other|Petrolatum ointment|
3311964|NCT01935882|Active Comparator|Artemether-Lumefantrine|Artemether-Lumefantrine combination
3311965|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.25|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
3311966|NCT01935882|Experimental|Artemether-Lumefantrine-Primaquine 0.4|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
3311967|NCT01935895||Exercise on Blood Pressure Reactivity|To test the hypothesis of the present study, volunteers were invited to participate in two randomly assigned visits in distint days, as follows: 1) combined resistance and aerobic exercises performed in a circuit mode; and 2) a control session without exercise. In both visits, blood pressure was measured at rest and at each 15 minutes post-session during 1 hour of recovery following the exercise and non exercise control sessions. In addition, blood pressure reactivity was evaluated using a cardiovascular stressor protocol (Cold Test Pressor) before and after the experimental sessions. The relationship between post-exercise blood pressure and blood pressure reactivity to stressor test was also examined.
3311968|NCT01935908|No Intervention|Control Group|The control group will not receive levetiracetam as seizure prophylaxis.
3311969|NCT01935908|Active Comparator|Treatment Group|levetiracetam 500mg in adults, twice daily, administered by mouth, per tube, or IV. The route of administration will be dependent upon the patient's clinical status and ability to tolerate each form. In descending order of preference, route of administration will be: oral, per tube, IV.
3311971|NCT01935960|Experimental|Arm I (retinoid 9cUAB30)|Participants receive retinoid 9cUAB30 PO QD on days 1 and 8-36. Treatment continues in the absence of unacceptable toxicity.
3311972|NCT01935960|Placebo Comparator|Arm II (placebo)|Participants receive a placebo PO QD on days 1 and 8-36.
3311973|NCT01935973|Active Comparator|Arm I (trametinib)|Patients receive trametinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
3311974|NCT01935973|Experimental|Arm II (trametinib and Akt inhibitor GSK2141795)|Patients receive trametinib PO QD and Akt inhibitor GSK2141795 PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3311975|NCT01935986|Experimental|probiotic|dietary supplement
3311976|NCT01935986|Placebo Comparator|placebo|dietary supplement without probiotic
3311977|NCT01935999|Other|One piece closed pouch|One piece closed pouch
3311978|NCT01936012|Experimental|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Dexa Medica was given to each of study subjects.
3311979|NCT01936012|Active Comparator|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg lisinopril dihydrate that equal to 10 mg lisinopril. A single dose of lisinopril tablet of PT Boehringer Ingelheim Indonesia was given to each of study subjects.
3311980|NCT01936025|Active Comparator|Sitagliptin|Placebo dextromethorphan + sitagliptin 100 mg
3311981|NCT01936025|Experimental|Dextromethorphan 30 mg + sitagliptin|Dextromethorphan 30 mg + sitagliptin 100 mg
3311982|NCT01936025|Experimental|Dextromethorphan 60 mg + sitagliptin|Dextromethorphan 60 mg + sitagliptin 100 mg
3311983|NCT01936025|Experimental|Dextromethorphan 90 mg + sitagliptin|Dextromethorphan 90 mg + sitagliptin 100 mg
3311984|NCT01936025|Experimental|Dextromethorphan 30 mg + placebo|Dextromethorphan 30 mg + placebo (sitagliptin)
3311985|NCT01936025|Experimental|Dextromethorphan 60 mg + placebo|Dextromethorphan 60 mg + placebo (sitagliptin)
3311986|NCT01936025|Experimental|Dextromethorphan 90 mg + placebo|Dextromethorphan 90 mg + placebo (sitagliptin)
3311987|NCT01936025|Placebo Comparator|Placebo|Placebo (dextromethorphan)+ placebo (sitagliptin)
3311988|NCT01936038|Placebo Comparator|Control Group|CPAP
3311989|NCT01936038|Experimental|EXPERIMENTAL GROUP|Upper Airway Toning for Improve the Compliance of CPAP
3311990|NCT01936051||OCD patients|OCD patients being treated with any dose of escitalopram
3311991|NCT01936064|Active Comparator|Jobelyn + Cyclophosphamide-Epirubicin6|Cyclophosphamide- Epirubicin 6 course regimen to be used with Jobelyn
3311992|NCT01936064|Active Comparator|Placebo + Cyclophosphamide- Epirubicin 6|Routine drugs for treatment of Breast Cancer used with Placebo
3311993|NCT01936077|Experimental|GnRH antagomnist hyper-responders|Those defined as hyper-responders will be given recombinant LH.
3311994|NCT01936090|Experimental|Treatment (bortezomib, TBI, melphalan, stem cell transplant)|"Conditioning regimen: Patients receive bortezomib IV on days -5 and -2, TBI BID on days -5 and -2, and melphalan IV over 1 hour on days -4 and -3.~Transplant: Patients undergo autologous bone marrow or peripheral blood stem cell transplant on day 0."
3311995|NCT01936103|Active Comparator|standard group|patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .
3311996|NCT01936103|Experimental|intensive group|patients in this group received intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation , and thereafter 20mg / night .
3311997|NCT01936116|Experimental|patients with intrauterine balloon catheter placement|In this group, during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
3311998|NCT01936116|Active Comparator|patients with intracervical balloon catheter placement|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
3311999|NCT01936129|Active Comparator|Copaxone|COPAXONE (glatiramer acetate) will be administered as a subcutaneous dose (20mg) once, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
3312000|NCT01936129|Placebo Comparator|Placebo|Placebo (buffered normal saline w/v)will be administered as a subcutaneous dose, one injection no later than 7 days from the initiation of the attack, and 1 more injection administered one week after the first injection.
3312001|NCT01936142|No Intervention|No RenalGuard|Control group will undergo CRT implantation without using RenalGuard
3312002|NCT01936142|Experimental|RenalGuard|Use of the RenalGuard system during CRT implantation
3312003|NCT01936155|Experimental|Oedema, Joint Mobility, Skin Oxygenation|Neuromuscular electrical stimulation (NMES) is to be applied using a custom-built, two-channel stimulator, Bioelectronics Research Cluster, National University of Ireland, Galway) with a frequency of 36 Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms. Stimulation is to be applied every 20 seconds over a period of 90 minutes. Its affect on oedema reduction, joint mobility and skin oxygenation will be assessed both before and after its application.
3312004|NCT01936168|Active Comparator|RFA|Radiofrequency Ablation (RFA)
3312005|NCT01936168|Experimental|MOCA|Mechanochemical Endovenous Ablation (MOCA)
3312006|NCT01936194|Experimental|Docosahexaenoic Acid (DHA)|infants receiving capsule containing DHA.
3312007|NCT01936194|Other|High Olive Oil|infants receiving capsule without DHA and EPA.
3312008|NCT01936194|Experimental|DHA+EPA|infants receiving capsule containing DHA and EPA.
3312009|NCT01936207||One Group|
3312010|NCT01936220|Experimental|Continuity of specialized care|Continuity of specialized inpatient and outpatient care (relapse prevention)
3312011|NCT01936220|Experimental|Continuity of specialized care and parent groups|Continuity of specialized care combined with Parent groups
3312012|NCT01936220|Active Comparator|Treatment as usual|Discontinuity of care, relapse prevention as usual
3312013|NCT01936233|Experimental|Aspirin AND Lamivudine|
3312014|NCT01936233|Active Comparator|Lamivudine|
3312015|NCT01936246|Experimental|Increased protein|Full term infants will be on 4 g/kg/day of protein. Preterm infants will be on 4.5 g/kg/day of protein until term corrected age. Beneprotein powder will be used; if this is not tolerated, Complete Amino Acids will be used. Max protein will be 30 g/day. Increased protein will be given until 12 months corrected age.
3312016|NCT01936246|No Intervention|Standard diet|Infants will be given a usual diet. If infants in this arm have poor growth, protein or caloric supplementation may be given per the discretion of the clinical team.
3312017|NCT01936272|Active Comparator|Chhabra Shunt Placement|The shunting arm will comprise a standard frontal approach ventriculoperitoneal shunt using a silastic Chhabra system.
3312018|NCT01936272|Active Comparator|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) arm will comprise a standard frontal approach with flexible endoscopy.
3312019|NCT01936285|Placebo Comparator|Control group|Patients taking placebo
3312020|NCT01936285|Experimental|Colchicine|Active treatment group
3312021|NCT01936298|Experimental|A-ROM Continuous Passive Rehabilitation|The group of patients with Active Range Of Motion (A-ROM) is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
3312022|NCT01936298|Experimental|P-ROM Continuous Passive Rehabilitation|The group of patients with Passive Range Of Motion (P-ROM), i.e. without active movements of the hand at the baseline, is subjected to two session per day in the morning and in the afternoon over a period of two weeks (5 days per week). Each session is composed by 30 min of continuous passive motion rehabilitation and 60 min of physical and occupational therapy.
3312023|NCT01936311|No Intervention|Control Group|This group will receive usual care.
3312024|NCT01936311|Experimental|Self-Management Goal Elicitation|This group will receive usual care alongside a form that helps elicit self-management goals as well as preferred treatment modalities.
3312025|NCT01936337|Active Comparator|DLX105 Hydrogel|
3312026|NCT01936337|Placebo Comparator|Placebo Hydrogel|
3312027|NCT01936350|Experimental|Sildenafil|12 patients will be in this group. They will take a sildenafil 50mg.
3312028|NCT01936350|Placebo Comparator|Placebo|12 patients will be in this group, they will take placebo
3312029|NCT01936376||head & neck cancer patients, cisplatin treatment|
3312030|NCT01936376||cancer patients, no cisplatin, no nephrotoxic agent|
3312031|NCT01936402|Experimental|5-6cm Chest compression depth|"Control group is trained for 5-6cm Chest compression depth during education.~Depth 5-6cm, Rate 100-120/min, Full chest recoil"
3312032|NCT01936402|Experimental|6-7cm chest compression depth|"Experimental group is trained for 6-7cm Chest compression depth during education.~Depth 6-7cm, Rate 100-120/min, Full chest recoil"
3312033|NCT01936415|Experimental|Regenerex|One of the two prosthesis investegated
3312034|NCT01936415|Active Comparator|Vanguard|
3312035|NCT01936428|Other|interview|
3312036|NCT01936441|Experimental|Cognitive Behavioral Therapy-Insomnia (CBT-I)|"Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women unable to attend the in-person session will receive a phone call. All in-person and telephone consultations will be 20-30 minutes.~Participants will receive reading materials before each phone call relating to menopausal changes, menopausal changes in sleep and strategies for lessening menopause related sleep disturbances. A daily sleep diary will be completed each week during the 8-week intervention period. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading and materials will be discussed and the sleep diary will be reviewed."
3312037|NCT01936441|Placebo Comparator|Menopause Education Control (MEC)|Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
3312038|NCT01936454||Cohort 1|n=20 women with insertion dates 3-5months prior to enrollment and followed for 2-6 months
3312039|NCT01936454||Cohort 2|n=20 women with insertion dates 9-11 months prior to enrollment and followed for 2-6 months
3312040|NCT01936454||Cohort 3|n=250 women with insertion dates 21-24 months prior to enrollment and followed through month 36
3312041|NCT01936454||Cohort 4|n=300 women with insertion dates 33-36 months prior to enrollment and followed through month 6
3312042|NCT01936480|Experimental|Moxifloxacin group|Healthy volunteers with QT genotype score in the highest or lowest quintile
3312043|NCT01936480|Placebo Comparator|Placebo Group|Healthy volunteers with QT genotype score in the highest or lowest quintile
3312044|NCT01936493||Females with uterine fibroids|Participants will be females age of 18 or older who have be diagnosed with uterine leiomyoma. Study Subjects will be asked if mothers or siblings also have diagnosis of uterine leoimyoma (either past or present diagnosis) and these family members will be invited to participate in this trial. All participants will provide blood samples for serum aliquots for hormonal analysis and genomic DNA analysis, and will answer a baseline genetic epidemiology questionnaire.
3312045|NCT01936506|Experimental|Cognitive Training A|emotional memory training exercise
3312046|NCT01936506|Active Comparator|Cognitive Training B|memory training exercise
3312047|NCT01936532|Experimental|assessment of treatment lenalidomide, dexamethasone,MLN9708|
3312048|NCT01936545|Experimental|propofol|The anesthesia was maintained with propofol during liver transplantation.
3312049|NCT01936545|Active Comparator|Desflurane|The anesthesia was maintained with desflurane during liver transplantation.
3312050|NCT01936558||Amputees|Amputee with one arm or one leg amputated/ Far infrared ray to the phantom limb site
3312051|NCT01936558||Healthy subjects|Healthy subjects under 30 years old/ Far infrared ray to the sole
3312052|NCT01936571||NSCLC|The cohort consists of approximately 250 patients. As a rule of thumb 5-10 events per variable are needed to avoid overfitting a model. To model 6 clinical variables + 9 biomarker variables 75-150 events are needed. Assuming a two-year survival of 40%, the calculated (constant) hazard rate is 0.46 per year. With an inclusion rate of 50 patients per year, and a follow-up time varying between 0.5 and 4 year, at the time of analysis (November/December 2013) it is expected that there will be 138 events available for analysis.
3312053|NCT01936584||TAPP repair|TAPP repair for inguinal hernia
3312054|NCT01936584||TEP repair|TEP repair for inguinal hernia
3312055|NCT01936597|Active Comparator|Single set (control Arm)|method of external cardiac massage incentive based on a single set. Intervention : Therapeutic and preventive strategies
3312056|NCT01936597|Experimental|Controller|Audio continuous guidance method by the controller. Intervention : Therapeutic and preventive strategies
3312057|NCT01936597|Experimental|Audio|Audio continuous guidance method by the controller relayed by an audio. Intervention : Therapeutic and preventive strategies
3312058|NCT01936610|Experimental|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section .
3312059|NCT01936610|Experimental|lecture|describe the advantages and disadvantages of normal delivery and cesarian section
3312060|NCT01936636||Cancer patients treated for BTcP|"All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.~Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires."
3312061|NCT01936675|No Intervention|Framingham Risk Score|Patients in this arm will receive their Framingham Risk Score of having a heart attack.
3312062|NCT01936675|Active Comparator|Framingham and Genetic Risk Score|Patients in this arm will receive their Framingham Risk Score as well as their Genetic Risk Score of having a heart attack.
3312063|NCT01936688|Experimental|MK-3222 200 mg + Placebo to Etanercept|MK-3222 200 mg subcutaneously (SC) on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
3312064|NCT01936688|Experimental|MK-3222 100 mg + Placebo to Etanercept|MK-3222 100 mg SC on Weeks 0, 4, 16, and 28 and, optionally, every 12 weeks thereafter until Week 220, plus etanercept placebo twice weekly up to Week 12, and then once weekly through Week 28.
3312065|NCT01936688|Placebo Comparator|Placebo to MK-3222 + Placebo to Etanercept|Placebo to MK-3222 administered SC on Weeks 0 and 4 plus etanercept placebo twice weekly up to Week 12, then once weekly up to Week 28. Participants will be re-randomized 1:1 at Week 12 to receive MK-3222 high dose or MK-3222 low dose on Weeks 12, 16, and 28 and, optionally, every 12 weeks thereafter through Week 220.
3312066|NCT01936688|Active Comparator|Placebo to MK-3222 + Etanercept 50 mg|Matching placebo to MK-3222 SC on Weeks 0 and 4 and etanercept 50 mg twice weekly up to Week 12 and then once weekly through Week 28.
3312067|NCT01936701|Other|acrylic 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-XS in one eye
3312068|NCT01936701|Other|silicone 3-piece IOL|same-day bilateral cataract surgery with implantation of intraocular lens Domilens KS-3Ai in one eye
3312069|NCT01936714|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
3312070|NCT01936714|Other|LF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 20ml/min, vacuum 400 mmHg, bottle height 100cm.
3312071|NCT01936727|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3312072|NCT01936727|Other|infusion asissted easyTip|The phacoemulsifications tip used was an infusion assisted easyTip 2.2mm (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3312073|NCT01936740|Other|HF easyTip 2.2mm|The phacoemulsifications tip used was the easyTip 2.2mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 45ml/min, vacuum 600 mmHg, bottle height 100cm.
3312074|NCT01936740|Other|HF easyTip 2.8mm|The phacoemulsifications tip used was the easyTip 2.8mm tip (Oertli Instruments, Berneck, Switzerland). The cristaline lens was divided into four quadrants using an aspiration flow rate of 10ml/min and vacuum of 70 mmHg. The quadrants were aspirated using the following linear power and fluidic settings: aspiration flow rate 50ml/min, vacuum 600 mmHg, bottle height 100cm.
3312075|NCT01936753|Experimental|Mentor Mother Peer Support|This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
3312076|NCT01936753|No Intervention|Routine Peer Support|Pregnant HIV-positive women receive standard-of-care PMTCT services (drugs, appointments, tests). These women are, per routine, assigned peer counselors who are also HIV-positive women with PMTCT experience but who do receive little or no standardized formal training, and are not closely supervised.
3312077|NCT01936779|Active Comparator|Dietary supplement: fatty acid active|4g/day n-3 fatty acids for 8 weeks
3312078|NCT01936779|Placebo Comparator|Dietary supplement: fatty acid placebo|4g/day olive oil for 8 weeks
3312079|NCT01936792||mild traumatic brain injury|Subjects with mild traumatic brain injury
3312080|NCT01936792||Controls|Controls with no premorbid health conditions
3312081|NCT01936805|Active Comparator|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
3312082|NCT01936805|Placebo Comparator|Control|A loading dose of placebo was administrated 24 h before the PCI.
3312086|NCT01936883|Active Comparator|LDR boost|After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy
3312087|NCT01936883|Active Comparator|HDR boost|Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.
3312088|NCT01936922|Experimental|Virtual reality device (GaitAid®)|This will be a within-subjects design. Each subject will first walk in a controlled laboratory setting as she or he would in daily life. After this, each participant will walk while using the virtual reality device (GaitAid®) for a brief period of time. The session will end with walking as usual.
3312089|NCT01936935|Experimental|Low-fat dairy|3 servings/d of low-fat dairy
3312090|NCT01936935|Placebo Comparator|Sugar-sweetened beverages|3 servings/d of sugar-sweetened foods
3312091|NCT01936961|Experimental|CTLA-4 Antibody + hypofractionated radiotherapy|Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
3312092|NCT01937013|Experimental|Intranasal Oxytocin|Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3
3312093|NCT01937013|Placebo Comparator|Saline Nasal Mist|Participants will be randomized to receive intranasal saline mist (placebo) on opposite visits from the interventional drug visit 2 or 3
3312094|NCT01937039||Breast cancer patients|Participants have a known diagnosis of breast cancer and are receiving a breast cancer evaluation and/or treatment, who agree to sample collection, access, and follow-up as part of the repository.
3312095|NCT01937039||Benign breast disease|Participants have benign breast disease and are receiving a diagnostic procedure and/or evaluation, who agree to sample collection, access, and follow-up as part of the repository.
3312096|NCT01937039||Healthy volunteer|Participants have no known diagnosis of breast disease or abnormality and are undergoing routine screening or diagnostic breast imaging procedures and/or other clinical evaluation, who agree to sample collection, access, and follow-up as part of the repository.
3312097|NCT01937052||Breast cancer patients|All patients planned to initiate hormonal therapy with either Tamoxifen, Raloxifene (Evista®), Anastrozole (Arimidex®), Letrozole (Femara®) or Exemestane (Aromasin®) are eligible to participate in sample collection and data for patient-reported outcomes/questionnaires.
3312098|NCT01937065||No treatment|
3312099|NCT01937078|Active Comparator|active|Famotidine will be administered at total daily doses of 80, 120mg, or 160mg per day. Each patient will be randomized to receive each active dose of famotidine (80, 120, or 160mg/d and placebo). Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo.
3312100|NCT01937091||Participants in trials|Participated in a trial of HAART for duration of > 48 weeks.
3312101|NCT01937091||Non-participants in trials|Never participated in clinical trials of HAART Must have been offered participation in a clinical trial and declined
3312102|NCT01937104|Experimental|Group 1|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust minimum alveolar concentration (MAC) to maintain bispectral index (BIS) between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Trendelenburg position - 30 degree"
3312103|NCT01937104|Experimental|Group 2|"Drug: Desflurane Anesthesia with desflurane in both Group 1 and Group 2 - adjust MAC to maintain BIS between 40-60~Drug: Remifentanil Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%~Device: Ultrasonographic measurement of ONSD~Procedure/Surgery: Mechanical ventilation Maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.~Reverse Trendelenburg position - 30 degree"
3312104|NCT01937143|Placebo Comparator|Control|General information about infant immunizations at birth of a newborn infant
3312105|NCT01937143|Active Comparator|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
3312106|NCT01937143|Active Comparator|High intensity intervention|Pamphlet and video with information about pain management during infant immunizations at birth of a newborn infant
3312107|NCT01937156|Experimental|SP-01|
3312108|NCT01937156|Active Comparator|Granisetron Hydrochloride Tablet|
3312109|NCT01937169|Experimental|Drug + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep.This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
3312110|NCT01937169|Placebo Comparator|Placebo + motor task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Placebo pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a motor task (e.g., walking) for 30 minutes."
3312111|NCT01937169|Sham Comparator|Dopicar + Sham task|"Each participant will undergo physical examination by an doctor. Then, the participant will receive the Fitbit device with instructions for proper use. The next stages will take place at the participant's home environment.~Each participant will monitor motor activity in hours prior to sleep and at night for assessing baseline activity level. After 3 nights of monitoring, each participant will be administered with a quarter of a Dopicar pill (4th night) and half a Dopical pill (5th night), measuring different dose effect on motor activity during sleep. This group will be administered with a quarter of a Dopicar pill, 1 hour prior to sleep. After 15 minutes, participants in this group will perform a non-motor task (e.g., crossword puzzle) for 30 minutes."
3312112|NCT01937182|Active Comparator|Selective Serotonin Reuptake Inhibitors|Intervention Drug: Citalopram
3312113|NCT01937182|Placebo Comparator|Placebo|Intervention Drug: Placebo
3312114|NCT01937208|Experimental|high-dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：60Gy/30F/6W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 75mg/m2 D1+docetaxel 75mg/m2 D1, Q3W
3312115|NCT01937208|Active Comparator|standard dose|concurrent chemoradiation:CT:DDP 25mg/m2 D1+Docetaxel 25mg/m2 D1,Weekly for 5 wks;RT：50Gy/25F/5W(3D-CRT or IMRT).Then,2 cycles consolidation chemotherapy were used:DDP 5mg/m2 D1+Docetaxel75mg/m2 D1, Q3W
3381564|NCT02994459||Metabolically Abnormal Obese (likely insulin resistant)|i) BMI ≥30.0 but <45.0 kg/m2; maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
3312116|NCT01937221||mild cognitive impairment|
3312117|NCT01937221||mild to moderate cognitive impairment|
3312118|NCT01937221||normal or control group|
3312119|NCT01937234|Active Comparator|Metoclopramide|Intravenous injection of 10mg metoclopramide
3312120|NCT01937234|Placebo Comparator|Placebo|Intravenous injection of 0.9% sodium chloride
3312121|NCT01937247|Placebo Comparator|Standard process|The control group is placebo group and this is our standard practice. Patients will be induced in the operating room and at the end of surgery will be reversed with neostigmine 50µg/kg and glycopyrrolate 10µg/kg. Once extubated and rolled out of the room, the house keeper team will start cleaning the operating room
3312122|NCT01937247|Active Comparator|Redesigned process|Patients will be inducted in the induction room. At the end of surgery and after placement of the surgical dressing, the registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room. The patient will be reversed with sugammadex 4mg/kg IV
3312123|NCT01937325|Active Comparator|Ivacaftor|150mg orally twice daily
3312124|NCT01937325|Placebo Comparator|Placebo|Matching placebo
3312125|NCT01937338|Experimental|AZD7624|
3312126|NCT01937338|Placebo Comparator|Placebo|
3312127|NCT01937416|Experimental|autologous bone marrow mononuclear cells|Bone marrow come from the patients himself/herself. With a conventional method and reagent,Ficoll, mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation.
3312128|NCT01937429|Experimental|Colonoscopy with blue indigo Carmin®|Patients undergoing from a colonoscopy with instillation of tepid water (30°C) tinged with indigo Carmin® (0,08/1000) during the endoscope insertion from the anus to the caecum, and with insufflation of air only during withdrawal from the caecum to the anus.
3312129|NCT01937429|Active Comparator|Standard colonoscopy|Standard colonoscopy with insufflation of air
3312130|NCT01937442|Experimental|Thalidomide Celgene™ 200mg once daily|5-day period of thalidomide treatment
3312131|NCT01937455|Experimental|Group A|rAAV1-PG9DP or placebo (v:p = 3:1)
3312132|NCT01937455|Experimental|Group B|rAAV1-PG9DP or placebo (v:p = 3:1)
3312133|NCT01937455|Experimental|Group C/C1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group C, and v:p = 9:3 in Group C1)
3312134|NCT01937455|Experimental|Group D/D1|rAAV1-PG9DP or placebo (v:p = 3:1 in Group D, v:p = 4:1 in Group D1)
3312135|NCT01937468|Experimental|Treg-enriched infusion plus 8-week low-dose Interleukin-2|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema. Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
3312136|NCT01937481|Experimental|Nutrition and Physical Activity|The Food Friends programs
3312137|NCT01937481|No Intervention|Control|Control group
3312138|NCT01937494|Experimental|asthma patients|patients who show a positive response at the first dos of histamine challenge test will be enrolled
3312139|NCT01937533||Cervical Cancer|Patients with presumed early cervical cancer being considered for curative surgery
3312140|NCT01937546|Active Comparator|Anterior shoulder|Primary delivery of the anterior shoulder of the fetus
3312141|NCT01937546|Experimental|Posterior shoulder|Primary delivery of the posterior shoulder of the fetus
3312142|NCT01937572|Experimental|Computer-aided TKA|The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
3312143|NCT01937572|Other|Conventional TKA|A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.
3312144|NCT01937585|Active Comparator|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
3312145|NCT01937585|Experimental|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
3312146|NCT01937611|Experimental|Dexmedetomidine|dexmedetomidine 1μg•kg-1
3312147|NCT01937611|Active Comparator|midazolam|midazolam 0.03 mg•kg-1
3312148|NCT01937637|Other|Behavioral Intervention for Dyspnea|"In the first intervention session, enrolled participants will learn breathing and relaxation exercises designed to relieve breathlessness. The nurse practitioner will also provide handouts with directions for these exercises, an audio-recording with the relaxation exercises, and worksheets for daily home practice. During the second session, participants will again meet with the nurse practitioner to review the study exercises and to address any difficulties participants may have experienced in practicing the skills.~All participants will complete questionnaires before and after the study intervention as well as a brief follow-up interview with the research assistant to obtain feedback about ways to improve the intervention to relieve breathlessness in patients with lung cancer."
3381565|NCT02994459||Metabolically Normal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) fasting blood glucose: <100 mg/dl; iv) blood glucose 2 h after an OGTT: <140 mg/dl; v) HbA1c <5.7 %; vi) fasting insulin: <20 µU/mL.
3312149|NCT01937650|Active Comparator|Radiotherapy plus metronidazole|Participants in the intervention arm received 1gm (2 suppositories) of metronidazole per rectum 30 minutes before radiotherapy for every other radiotherapy session with two rest days of Saturday and Sunday. The standard radiotherapy regimen for advanced cancer of the cervix composed of two phases of radiotherapy was used; phase 1 was tele-therapy via parallel-opposed portals from Co-60 radiation source, with a total dose of 50 Gy given in 25 fractions of 2 Gy/day for five weeks. The patients were then given a break of 1-4 weeks before getting the second phase of treatment. Phase 2 was brachy-therapy from a Cs-137 source, whereby a single dose of 30Gy was delivered at point A at a rate of 2.55 Gy/ hour for 7 hours and 50 minutes, via a uterine Tandem and two vaginal Ovoids.
3312150|NCT01937650|Placebo Comparator|Radiotherapy alone|Participants in the control arm received 500mg (two suppositories) of paracetamol as a placebo on similar days. This was in addition to the standard radiotherapy administration in two phases as described above.
3312151|NCT01937663|Experimental|KWA-0711 Dose1|
3312152|NCT01937663|Experimental|KWA-0711 Dose2|
3312153|NCT01937663|Experimental|KWA-0711 Dose3|
3312154|NCT01937663|Experimental|KWA-0711 Dose4|
3312155|NCT01937676||Adults admitted to ER|All adult patients admitted to emergency department during the study period.
3312156|NCT01937689|Experimental|Pyrotinib|Each subject will receive a single dose of pyrotinib on day 1, followed by 4-day observation period, and then subject will receive pyrotinib once daily for 28 days during cycle 1.Each cycle will consists of 28 days.
3312157|NCT01937702|Experimental|Anti-diabetes medication|Insulin
3312158|NCT01937728|Active Comparator|A: Peg-interferon alpha-2a & Ribavirin|Arm A: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
3312159|NCT01937728|Experimental|B: Peg-interferon alpha-2a & Ribavirin|"Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
3312160|NCT01937728|Experimental|C: Peg-interferon alpha-2a & Ribavirin|"Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1)"
3312161|NCT01937728|Active Comparator|D: Peg-interferon alpha-2a & Ribavirin|"Arm D: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment)"
3312162|NCT01937728|Experimental|E: Peg-interferon alpha-2a & Ribavirin|"Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
3312163|NCT01937728|Experimental|F: Peg-interferon alpha-2a & Ribavirin|"Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks.~(Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F a ratio of 1:1)"
3312164|NCT01937754|Active Comparator|Nitric Oxide supplement|
3312165|NCT01937754|Placebo Comparator|Placebo|
3312166|NCT01937767|Active Comparator|Propofol|Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.
3312167|NCT01937767|Experimental|Remimazolam 6 mg/kg/hr|Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
3312168|NCT01937767|Experimental|Remimazolam 12 mg/kg/hr|Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.
3312169|NCT01937793|Active Comparator|effortful swallowing exercise|Subjects in the arm are asked to do the effortful swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
3312170|NCT01937793|Active Comparator|Mendelsohn swallowing exercise|Subjects in the arm are asked to do the Mendelsohn swallowing exercise at home for 8 weeks. The training frequency is to exercise 3-4 days/week, 3 times/day, 10 repetitions per time. Besides the at home exercise, each subject is scheduled to meet the investigator at the hospital at weekly basis to discuss and review his/her exercise practice.
3312171|NCT01937806|Experimental|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
3312172|NCT01937806|Active Comparator|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
3312173|NCT01937819|Experimental|SMART arm|Using SMARTPHONE application for self judging bowel preparation
3312174|NCT01937819|No Intervention|Conventional arm|Non-using SMARTPHONE application for bowel preparation
3312175|NCT01937832|Active Comparator|Ertapenem|
3312176|NCT01937832|Experimental|Faropenem|
3312177|NCT01937858||Normal renal function|
3312178|NCT01937858||Stage 2 and 4 and 5 chronic kidney disease|
3312179|NCT01937858||End stage renal disease on hemodialysis|
3312180|NCT01937897|Experimental|Left-Sided Massage|Unilateral massage on the left side of the body.
3312181|NCT01937897|Active Comparator|Right-Sided Massage|Unilateral massage on the right side of the body.
3312182|NCT01937897|Sham Comparator|Bi-Lateral Massage|Traditional massage on the back of the body.
3312183|NCT01937910|Experimental|Stroke Group|Participants in the stroke group will complete 10 training sessions of the TRAIT task.
3312184|NCT01937910|Active Comparator|Matched Healthy Control Group|Participants in the Matched Healthy Control group will complete 10 sessions of the TRAIT task
3312185|NCT01937936|Experimental|CBT|Cognitive Behavioral Therapy (CBT)
3312186|NCT01937936|Active Comparator|Education|Health Education
3312187|NCT01937949|Other|Endovascular|"The study will include patients treated by endovascular aortic repair of juxtarenal, suprarenal and type IV thoracoabdominal aortic aneurysms using custom-made Cook Zenith® Fenestrated AAA Endovascular Graft. The graft includes combinations of scallops, holes (fenestrations) or cuffs (side branches) . These small holes or branches are the investigational part of this research study. The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches.~Other names:~Endovascular stent Stent-graft"
3312188|NCT01937988|Experimental|Doula Arm|Women in the doula arm will have standard procedure protocol with addition of doula support at the time of the procedure.
3312189|NCT01937988|No Intervention|Control Group|Women in the control arm will have standard procedure protocol at the time of the procedure.
3312190|NCT01938027|Experimental|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
3312191|NCT01938053|Other|Reminder card with no number|Patients receive a card to remind them of the time frame for results but no number is listed.
3312192|NCT01938053|Other|Card with number|Patients receive a card to remind them of the time frame for results but and a number to call for results is listed
3312193|NCT01938092|Active Comparator|Diazepam|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
3312194|NCT01938092|Placebo Comparator|Placebo|Participated will be instructed to insert one 10mg tablet vaginally 1-2 times per day as needed for pain.
3312195|NCT01938105|Experimental|Nimotuzumab+chemoradiotherapy|
3312196|NCT01938118|Experimental|Obesity Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote healthy lifestyle behaviors for prevention of excessive weight gain between birth to 15 months of life. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver to actively participate in the program with her.
3312197|NCT01938118|Active Comparator|Injury Prevention Group|Mothers and families receive a developmentally appropriate educational intervention designed to promote automobile and home safety behaviors for prevention of childhood injury. Educational content is delivered through eight home visits, five newsletters and twice weekly text messages. At several time points the mother identifies another family member/caregiver, who is only asked to complete surveys/assessments.
3312198|NCT01938131|Placebo Comparator|placebo|Patients in this group will be subjected to a treatment with muscle released in which the probe of CroSystem instrument will be approached to the quadriceps, without making contact. The instrument in these conditions emits a buzz but not provokes muscle vibration
3312199|NCT01938131|Experimental|repeated Muscle Vibration|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
3312200|NCT01938144|Experimental|Treatment A|IBU 200 mg/ PE 10 mg
3312201|NCT01938144|Experimental|Treatment B|IBU 200 mg/ PE 10 mg/CHLOR 4 mg
3312202|NCT01938144|Active Comparator|Treatment C|Acetaminophen 500 mg
3312203|NCT01938157|Experimental|High Risk Breast Cancer Patients|High Risk Breast Cancer Patients (all subjects)
3312204|NCT01938183|Placebo Comparator|Full-mouth PD+placebo gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of placebo gel (semi-solid suspension containing carbopol), overnight, during seven days.
3312205|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole tablet|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + single oral dose of 750 mg tablets/day at night, during seven days.
3312206|NCT01938183|Active Comparator|Full-mouth PD+Metronidazole benzoate gel|Full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour + trays with 3 g of 15% Mtz benzoate gel (semi-solid suspension containing carbopol), overnight, during seven days.
3312207|NCT01938196|Experimental|KWA-0711 Dose1|
3312208|NCT01938196|Experimental|KWA-0711 Dose2|
3312209|NCT01938196|Experimental|KWA-0711 Dose3|
3312210|NCT01938196|Experimental|KWA-0711 Dose4|
3312211|NCT01938196|Placebo Comparator|Placebo|
3312212|NCT01938209|Experimental|seated general thoracic spine manipulation|seated general thoracic spine manipulation
3312213|NCT01938209|Experimental|supine specific thoracic spine manipulation|Specific supine manipulation
3312214|NCT01938222||Short Stitch|Short stitch suture technique (6:1) for abdominal all closure stitch interval < 0,5 cm and lateral 0,5-0,8 cm
3312215|NCT01938235|Experimental|Exenatide|"o Exenatide at a dose of 1.5 µg IV over 30 min followed by 1.2 µg/hr IV for 1.5 h (Rate1), followed by 1.9 µg/hr IV* for 22 h (Rate 2)~*Once the creatinine clearance is available, if the value is <60 mL/min, the rate at 2 hours will be maintained at Rate 1 for the duration of the infusion. If the value becomes available after the 2-hour point, and the rate has already been changed to Rate 2, the infusion will be titrated back down to Rate 1 if the creatinine clearance is <60 mL/min.~If the creatinine clearance is <30 mL/min, the infusion will be discontinued and the patient will otherwise continue with all study procedures.~A bolus administration of study medication is initiated preferably prior to reperfusion, or, if not possible, up to 30 minutes after the start of reperfusion to avoid delays in door-to-door balloon times."
3312216|NCT01938235|Placebo Comparator|Placebo|o Placebo bolus over 30 min followed by placebo infusion at 'Rate 1' for 1.5 h, followed by 'Rate 2' for 22 hours*.
3312217|NCT01938248|Active Comparator|Control|Aspirin 81 mg once daily
3312218|NCT01938248|Experimental|Intervention|Apixaban, 5 mg twice daily (or 2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
3312219|NCT01938261|Experimental|Paracetamol effect on ductus|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
3312220|NCT01938261|Experimental|Paracetamol effect on pain|The first drug dose is given before 24 hours of age. Masked study drug is paracetamol infusion solution 10 mg/mL (PERFALGAN ®) or placebo, 0.45% saline solution. The loading dose is 20 mg/kg and the maintenance dose 7.5 mg kg every 6 hours for 4 days.
3312221|NCT01938274|Experimental|Educational intervention|Patients in this group will receive a brief educational intervention to assist them in setting the appropriate expectations for leisure activity after surgery with respect to the type, amount, intensity, and duration of activity.
3312222|NCT01938274|No Intervention|Control group|No intervention will be received. Patients will receive a written version of the education intervention at the end of the study.
3312223|NCT01938287|Experimental|SENSIMED Triggerfish|
3312224|NCT01938300|Experimental|Magnesium|"Magnesium sulfate infusion during a operation period.~Infusion regimen:~Bolus 50 mg/kg of magnesium sulfate in 100 ml normal saline over 15 minutes~Infusion 15 mg/kg/h of magnesium sulfate throughout the operation"
3312225|NCT01938300|Placebo Comparator|Control|administration of normal saline as a same volume of magnesium sulphate as a same method.
3312226|NCT01938313|Active Comparator|ERAS perioperative cares|Patients planned to undergoing laparoscopic gastrectomy, following the ERAS protocols.
3312227|NCT01938313|Active Comparator|Conventional perioperative cares|Patents will be managed by our hospital's critical pathways.
3312228|NCT01938326|Active Comparator|TLDG|No mini-laparotomy in the epigastrium Reconstruction by the uncut Roux-en Y gastrojejunostomy
3312229|NCT01938326|Active Comparator|SIDG|SIDG : pure single incision laparoscopic distal gastrectomy Reconstruction by the uncut Roux-en Y gastrojejunostomy
3312230|NCT01938339|Experimental|PET/MR|Multi-radiotracer PET/MR will be performed to compare the accuracy of tumor detection in patient with primary prostate cancer
3312231|NCT01938352|Experimental|CR8020|CR8020 administered as a single 2-hour intravenous infusion
3312232|NCT01938352|Placebo Comparator|Placebo|Placebo administered as a single 2-hour intravenous infusion
3312233|NCT01938365||Diabetes|
3312234|NCT01938365||Normal glucose regulation|
3312235|NCT01938404||Octaplas|Patients receiving Octaplas for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
3312236|NCT01938404||standard plasma products|Patients receiving standard plasma products (e.g., FFP, etc) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP) undergoing therapeutic plasma exchange (TPE) procedures
3312237|NCT01938417||adult patients treated with Osteoset® T (tobramycin sulfate)|10 g or 20 g of Osteoset® T
3312238|NCT01938443|Experimental|Part 1|Part 1 will determine the MTD and RP2D based on the safety and tolerability of GSK2256098 administered with trametinib. Subject will be administered starting dose of 1.0 mg OD trametinib combined with 500 mg BID GSK2256098. Dose escalation will continue until the MTD is established.
3312239|NCT01938443|Experimental|Part 2|Based on determination of combination dose regimen in Part 1, dose expansion cohorts for Part 2 will be opened.
3312240|NCT01938456|Experimental|Trametinib + Docetaxel + Filgrastim|Participants will receive Trametinib once daily for 21 days of each cycle + Intravenous Docetaxel once every three weeks over at least a one-hour infusion + Filgrastim (growth factor) subcutaneous injection once daily for prophylactic use.
3312241|NCT01938469|Other|Solid Meal|Participants in this group will be administered only solid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
3312242|NCT01938469|Other|Liquid Meal|Participants in this group will be administered only liquid meals on both study visits completed before surgery (T0) and 12-15 months after (T1).
3312243|NCT01938482|Experimental|Part 1|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as a single App 24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
3312244|NCT01938482|Experimental|Part 2|Subjects will receive 0.3% or 1% GSK1940029 (or matching vehicle), as 14 daily App24h (22.5h) application to 400 cm^2 (0.3%), 400 cm^2 (1%) or 1200 cm^2 (1%), respectively, in each of three sequential cohorts
3312245|NCT01938495|Experimental|NeuRx® Diaphragm Pacing System™ (DPS)|Patients randomized to the experimental arm will receive The NeuRx® Diaphragm Pacing System™ (DPS) device. Under general anesthesia, the intramuscular electrodes are surgically implanted in the diaphragm.
3312246|NCT01938495|No Intervention|Standard of Care|patients randomized to the standard of care arm will not have the Diaphragm Pacing System surgically implanted but will receive standard medical care.
3312247|NCT01938508|Experimental|Test|Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
3312248|NCT01938508|Experimental|Reference|Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
3312249|NCT01938521|Experimental|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
3312250|NCT01938521|Placebo Comparator|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) similar powder to mimic 1000 mg of Red Grape Cells (RGC), once daily by mouth for three month
3312251|NCT01938534|Experimental|Experimental|"Omeprazole 30mg twice Clarithromycin 500mg twice Amoxicillin 1000mg twice~for 10 days"
3312252|NCT01938534|Active Comparator|Control|Tetracycline 500mg four times Omeprazole 30mg twice Bismuth 600mg twice Metronidazole 500mg three times for 10 days
3312253|NCT01938547|Experimental|clevidipine|"An initial clevidipine IV infusion dose for the adolescent cohort has been specified per protocol. The initial dose for each of the subsequent age cohorts will be modified if necessary, based on the recommendation of the Data and Safety Monitoring Board (DSMB).~Following the initial dose, clevidipine will be up-titrated every 1.5 minutes, according to participant need, to achieve a systolic blood pressure (SBP) within the pre-specified SBP target range. Doses may be increased by less than doubling, and the time between dose adjustments may be lengthened, as the target blood pressure is approached. The infusion rate may be maintained for up to 96 hours, once the participant's SBP is within the target range, and titrated as necessary to maintain blood pressure within the range."
3312254|NCT01938560||Physicians|Retigabine Physicians (e.g. neurologists/epileptologists/neurosurgeons) who have prescribed retigabine at least once in the last 12 months.
3312255|NCT01938560||Pharmacists|Pharmacists who have dispensed an anti-epileptic drug (AED) at least once in the last 3 months.
3312256|NCT01938586||Surgical excision|
3312257|NCT01938599|Experimental|AM001|AM001 Cream, 7.5%. 2x daily for 12 weeks.
3312258|NCT01938599|Placebo Comparator|Vehicle|Placebo of AM001 Cream. 2x daily for 12 weeks.
3312259|NCT01938612|Experimental|MEDI4736 Q2W|Evaluate MEDI4736 given every 2 weeks
3312260|NCT01938612|Experimental|MEDI4736 Q3W|Evaluate MEDI4736 given every 3 weeks
3312261|NCT01938612|Experimental|MEDI4736 Dose Expansion|evaluate MEDI4736 given every 2 weeks
3312262|NCT01938612|Experimental|MEDI4736 Q4W|Evaluate MEDI4736 given every 4 weeks
3312263|NCT01938612|Experimental|MEDI4736 combined with another drug|evaluate MEDI4736 in combination with another drug given every 4 weeks
3312264|NCT01938638|Experimental|BAY1143572 [continuous]|BAY1143572 will be administered from cycle 1, day 1 (C1D1) onwards once daily continuously
3312265|NCT01938638|Experimental|BAY1143572 [on/off]|BAY1143572 will be administered from C1D1 in a 3 days on/4 days off schedule
3312266|NCT01938651|Experimental|Diagnostic (7T ultra high-field MRI/MRS)|Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.
3312267|NCT01938677|Experimental|Initial Gamma knife|Patients with VS and preserved hearing, randomized to initial gamma knife radiosurgery will receive this treatment within a few months after enrollment
3312268|NCT01938677|No Intervention|Initial conservative|Patients with VS and preserved hearing, randomized to initial conservative treatment will initially be followed with repeated MRI and audiometry. If MRI show progression of VS requiring intervention, patients will receive treatment but still belong to the initial treatment arm, according to intention to treat.
3312269|NCT01938690|Sham Comparator|Sham stimulation|Sham stimulation on the scalp of unaffected brain
3312270|NCT01938690|Experimental|transcranial magnetic stimulation|transcranial magnetic stimulation on unaffected brain
3312271|NCT01938729|Experimental|HAI with FLOXURIDINE & DEXAMETHASONE & GEMCITABINE|"This is an open-label single arm study. multi-institution phase I dose escalating trial of adjuvant HAIP FUDR and Gemcitabine chemotherapy after curative resection of ICC. Hepatectomy with or without bile duct reconstruction and pump placement are performed. The patients will start therapy 4 weeks postoperatively. They will receive HAI FUDR/Dex and systemic gemcitabine in the following dose escalation levels of gemcitabine. The dose of HAI FUDR will be fixed. A classic 3+3 cohort dose escalation scheme will be used to identify the MTD of the combination.~Level 1: Systemic gemcitabine 650mg/m^2 Day 1 and 15 and HAI FUDR/Dex 0.12mg/kg/day Day 1-14 Level 2.Systemic gemcitabine 800mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14 Level 3. Systemic gemcitabine 1000mg/m^2 Day 1 and 15 HAI FUDR/Dex 0.12 mg/kg/day Day 1-14"
3312272|NCT01938742|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3312273|NCT01938742|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3312274|NCT01938742|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 21
3312275|NCT01938742|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
3312276|NCT01938742|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus Novartis MF59 adjuvant on Day 21
3312277|NCT01938742|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
3312278|NCT01938742|Experimental|Group 7|100 subjects receive 45mcg sanofi A/H7N9 antigen on Day 0 and 21
3312279|NCT01938755|Experimental|levobupivacaine I|group that was administered levobupivacaine plus 60mg dextrose
3312280|NCT01938755|Experimental|levobupivacaine II|group that was administered levobupivacaine plus 80 mg dextrose
3312281|NCT01938755|Experimental|levobupivacaine III|group that was administered levobupivacaine plus 100 mg dextrose
3312282|NCT01938768||Tranexamic acid|patients with multiple trauma who received tranexamic acid on the scene
3312283|NCT01938768||Non tranexamic acid|patients with multiple trauma who did not receive tranexamic acid on the scene
3312284|NCT01938781|Active Comparator|Entecavir monotherapy|entecavir, 0.5mg, qd, oral, for 2 years.
3312285|NCT01938781|Experimental|Entecavir plus peg-IFN Therapy|entecavir combined peg-IFN in the middle 1 year.
3312286|NCT01938807|Experimental|Intervention|The intervention group receives the CareCoach mobile application
3312287|NCT01938807|Active Comparator|Control|The control group receives standard care.
3312288|NCT01938820|Active Comparator|Entecavir Therapy|"Entecavir monotherapy:~entecavir, 0.5mg, qd, oral, for 2 years."
3312289|NCT01938820|Experimental|Entecavir plus Thymosin-α|entecavir plus Thymosin-α 1.6μg, Twice a week, ih, in the middle of 1 year.
3312290|NCT01938859|Experimental|Lithium combined with SGAs|SGAs (Second Generation Antipsychotics), quetiapine adjunctive to lithium therapy
3312291|NCT01938859|Experimental|lithium combined with TCM|TCM (Traditional Chinese Medicine), Shuganjieyu capsule adjunctive to lithium therapy.
3312292|NCT01938859|Active Comparator|Lithium monotherpy|Lithium monotherapy
3312293|NCT01938872||PEB angioplasty|paclitaxel eluting balloon angioplasty in below-the-knee lesions
3312294|NCT01938898|Other|Potential NICOLA Participants|All potential participants identified through the sampling strategy and contacted to take part in the NICOLA study
3312295|NCT01938911|Experimental|Hypertensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312296|NCT01938911|Experimental|Hypertensives with oxytocin without social support|80 normotensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312297|NCT01938911|Experimental|Hypertensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312298|NCT01938911|Placebo Comparator|Hypertensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312299|NCT01938911|Experimental|Normotensives with oxytocin and social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312300|NCT01938911|Experimental|Normotensives with oxytocin without social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312301|NCT01938911|Experimental|Normotensives without oxytocin with social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312302|NCT01938911|Placebo Comparator|Normotensives without oxytocin or social support|80 hypertensive non-smoking medication-free men will be randomly assigned to receive intranasal OT (24 IU) or placebo 50 min before stress, and either social support (SS) from their best friend during the preparation period of the stress protocol or no social support.
3312303|NCT01938924|No Intervention|No intervention|No intervention
3312304|NCT01938924|Active Comparator|GekoTM|geko applied to bypass limb
3312305|NCT01938937|Experimental|Transcranial bright light exposure|Transcranially administered bright light exposure for 12 minutes
3312306|NCT01938937|Sham Comparator|Transcranial sham exposure|Transcranially administered sham exposure for 12 minutes
3312307|NCT01938950|Active Comparator|Aerobic Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals at 40-65% of VO2peak, three times per week, for 60 minutes/session.
3312308|NCT01938950|Active Comparator|Resistance Exercise|Participants will perform 2 sets (8-12 repetitions per set) of 8 exercises to the point of failure using weight stack equipment, three times per week, for 60 minutes/session. 2 sets of push-ups and sit-ups will also be performed.
3312309|NCT01938950|Active Comparator|Aerobic and Resistance Exercise|Participants will perform aerobic exercise using treadmills and/or ellipticals for 30 min at 40-65% of VO2peak and thereafter, perform 1 set of each of the above 10 resistance exercise for 30 min.
3312310|NCT01938963|No Intervention|Care as usual|
3312311|NCT01938963|Experimental|Collaborations in Health (COACH)|COACH integrates the care provided by the older person's primary care provider (PCP) with that delivered by an Aging Worker (AW; a lay member of the village's Aging Association), supervised by a psychiatrist consultant. Based on chronic disease management principles, the PCP is trained to use evidence based practice guidelines for treatment of both HTN and depression, and provided with access to mental health consultation regarding optimal management of the patient's depression. The AW is trained to conduct a systematic assessment of the older person's social context to identify and reduce social and environmental barriers to treatment adherence and response. AWs participate with the PCP in developing multi-disciplinary care plans for their shared patients, reinforce treatment adherence and adoption of healthy behaviors, and emphasize activation and engagement of the older person in activities designed to improve their connectedness to others and to the community.
3312312|NCT01938976|Experimental|Adolescent Asthma Action|Adolescent Asthma Action in Jordan (TAJ) Plus the added class smoke free pledge will be implemented in high schools in Jordan and will be compared to the TAJ alone for its efficacy in decreasing smoking rates, lowering CO1 levela and nicotine dependence.
3312313|NCT01938976|Experimental|TAJ|TAJ Plus the class smoke free pledge will be implemented in high schools in Jordan and compared to TAJ alone
3312314|NCT01939015|Active Comparator|Standard titanium miniplate- single non compression miniplate|fixation will be perform by A single non compression miniplate with 4-hole 2-mm using 2-mm monocortical screws at superior border of the mandible according to ideal lines of osteosynthesis.
3312315|NCT01939015|Experimental|three dimensional titanium miniplate|3D curved strut miniplate* (Universal Mandible System, Stryker-Lei binger, Freiburg, Germany) , installed and stabilized with monocortical screws. The 3D plate will be place in such a way that a horizontal bar is perpendicular and a vertical bar is parallel to the fracture line.
3312316|NCT01939041|Experimental|Robot-assisted therapy with InMotion3 (IMT)|We will use the InMotion3 Wrist Robot (Figure 1) for the IMT group. During the InMotion3 therapy (IMT) session, participants will receive 5-minute of muscle tone normalization preparation and passive range of motion, then a 70-minute robot-assisted training followed by a 15-minute functional training. During the robot-assisted training, only the paretic hand will be trained and the participant will rest the forearm and hand on a cradle and the wrist and hand in a fixed positions. During the practice, a visual display will provide online visual feedback of accuracy and coordination success. And summary scores regarding movement accuracy and movement smoothness will be shown on the display periodically. After each IMT session, a 15 min functional task practice will be provided as described in the previous paragraph.
3312317|NCT01939041|Experimental|Robot-assisted therapy with Bi-Manu-Track (BMT)|During the Bi-Manu-Track training (BMT), participant will use both nonparetic and paretic hands. Participants will receive 5-munite of muscle tone normalization preparation and passive range of motion, then will practice about 5-minute in Mode 1, 25-minute in Mode 2, and 5-minute in Mode 3 in wrist and forearm respectively. The training repetitions of each mode fall within the range of the protocols used in previous studies which would not cause adverse events (Hesse et al., 2005). The total minutes of each robot-assisted will be 70 minutes. After each BMT session, a 15 min functional task practice will be provided based on the same principles as the one in the IMT group.
3312318|NCT01939041|Active Comparator|Control intervention group (CI)|The control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
3312319|NCT01939054|Experimental|Nimotuzumab,docetaxel,capecitabine|Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
3312320|NCT01939054|Active Comparator|docetaxel,capecitabine|Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14
3312321|NCT01939067|Other|HHHFNC|"Treatment of respiratory distress by Heated Humidified High Flow Nasal Cannula (HHHFNC).~Escalation of the ventilatory support per protocol and the attending physician."
3312322|NCT01939067|Other|NCPAP|"Treatment of respiratory distress by nasal continuous positive airway pressure (NCPAP).~Escalation of the ventilatory support per protocol and the attending physician."
3312323|NCT01939080|Active Comparator|Medical supervision|Exercise training with supervised sessions Classics training
3312324|NCT01939080|Active Comparator|No medical supervision|Exercise training without supervised sessions Classics training
3312325|NCT01939093|Experimental|Quetiapine|Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
3312326|NCT01939093|Active Comparator|Haloperidol|Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.
3312327|NCT01939106|Other|One Piece Drainable Pouch|This is a one piece drainable pouch designed for the purpose of collecting stool from subjects with an ileostomy stoma
3312328|NCT01939119||retinal vascular occlusion|Patients with retinal vascular occlusion undergo a hematocrit dependent 5 day hemodilution
3312329|NCT01939132|Experimental|H.P. Acthar Gel SQ injection|Open-label H.P. Acthar Gel 80 units subcutaneously twice weekly for 12 weeks with a 12 week extension.
3312330|NCT01939171|Placebo Comparator|Non treated|Cadaver donor is cared and treated as usual protocol
3312331|NCT01939171|Experimental|TREATED|Cadaver donor receives one dose of thymoglobulin of 3 mg/kg iv in 2 hours after ganglia extraction and 3- 6 hours prior to organ procurement.
3312332|NCT01939184|Experimental|WC3055-01F|WC3055 12.5 mg tablet once daily for 12 weeks
3312333|NCT01939184|Experimental|WC3055-02F|WC3055 25 mg tablet once daily for 12 weeks
3312334|NCT01939184|Experimental|WC3055-03F|WC3055 50 mg tablet once daily for 12 weeks
3312335|NCT01939184|Experimental|WC3055-04F|WC3055 75 mg tablet once daily for 12 weeks
3312336|NCT01939184|Placebo Comparator|WC3055-07P|Placebo tablet once daily for 12 weeks
3312337|NCT01939210|Experimental|Arm I (breathing training sessions)|Patients participate in 3 50-minute breathing training sessions, including a psycho-educational component and meditation-based breathing training, over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
3312338|NCT01939210|Active Comparator|Arm II (control)|Patients receive standard care over 10 days. Patients then undergo 4D-CT on day 14 and undergo image-guided SBRT or standard radiation therapy 5 times a week for up to 5 fractions or 25 fractions, respectively.
3312339|NCT01939236|Experimental|traditional Chinese medicine|Subjects were treated with TCM 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
3312340|NCT01939236|Placebo Comparator|placebo (gummeline)|Subjects were treated with placebo 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient with chronic heart failure is qi deficiency and blood stasis. He will take drug of qi deficiency and blood stasis 2 times per day for 28 days.
3312341|NCT01939249|Active Comparator|Abbott Laboratories Xience|Subjects assigned to Abbott Laboratories Xience can be treated with either the Xience Prime or Xience Xpedition drug eluting stent (DES).
3312342|NCT01939249|Experimental|Biotronik Orsiro|Subjects assigned to Biotronik Orsiro will be treated with Biotronik Orsiro
3312343|NCT01939262|Experimental|Vegan Diet|Limitation of Animal Fat and Protein in the Diet. Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
3312344|NCT01939262|Placebo Comparator|Control|Subjects maintained their existing diet without modification.
3312345|NCT01939327|Experimental|Lenalidomide/Rituximab|Association of Lenalidomide and Rituximab
3312346|NCT01939379|Active Comparator|15ml ropivacaine|Depending on what dose of ropivacaine the subject is randomized to he/she could receive the 15ml dose injected into the catheter every 6 hours
3312347|NCT01939379|Active Comparator|30ml ropivacaine|If the subject is randomized to 30ml ropivacaine he/she will be injected through the catheter every 6 hours.
3312348|NCT01939392|Experimental|Renal Denervation|Subjects randomized to the Renal Denervation arm will receive bilateral renal ablation with the OneShot system and be maintained on antihypertensive medication.
3312349|NCT01939392|No Intervention|Optimal Medical Therapy|Subjects randomized to the control arm will be maintained on antihypertensive medications.
3312350|NCT01939418|Experimental|RAD001|gemcitabine 800mg/m2, D1 and D8 iv. every 3 weeks. cisplatin 30mg/m2, D1 and D8 iv. every 3 weeks. RAD001 5mg QD. po.
3312351|NCT01939431||Advanced|advanced stage podoconiosis
3312352|NCT01939431||Control|non-podoconiosis controls
3312353|NCT01939431||Early|early stage podoconiosis
3312354|NCT01939444|Experimental|naloxone intranasal|2.0 mg by the nasal route
3312355|NCT01939444|Active Comparator|naloxone intravenous|1.0 mg intravenous
3312356|NCT01939457|Experimental|misoprostol|400 mcg misoprostol sublingually
3312357|NCT01939470||Native American Women|Native American Women over the age of 50 yrs
3312358|NCT01939483|Experimental|Treatment (irinotecan hydrochloride)|"Patients receive irinotecan hydrochloride IV over 90 minutes on days 1, 8, 15, 22, and 29. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.~This arm also includes laboratory biomarker analysis as an intervention."
3312359|NCT01939509|Experimental|Atenolol-Bisoprolol|
3312360|NCT01939522|Experimental|Prevenar13® (13-valent pneumococcal conjugate vaccine)|Prevenar13 administered as a single dose, 0.5ml Intramuscular liquid form intervention at baseline.
3312361|NCT01939535||Women with endometriosis|Women with endometriosis with the intention of surgery - no intervention
3312362|NCT01939561|Active Comparator|Lamotrigine|Participants are taken oral tablets Lamotrigine once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300mg during the period of 8 weeks.
3312363|NCT01939561|Placebo Comparator|Placebo|Participants are taken oral tablets placebo once daily. The dosis is escalating every other weeks, from 25 mg - 50 mg - 150 mg- 300 mg during the period of 8 weeks.
3312364|NCT01939574|Experimental|Chemoradiation & Adjuvant Therapy:|"Concurrent chemoradiation Therapy:~Radiation therapy:2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg.~Adjuvant Therapy:~Temozolomide once per day for 5 consecutive days of a cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg."
3312365|NCT01939587|Experimental|PBF-680 5 mg|5 mg of PBF-680
3312366|NCT01939587|Experimental|PBF-680 20 mg|20 mg of PBF-680
3312367|NCT01939587|Placebo Comparator|Placebo|Placebo
3312368|NCT01939600|Experimental|All subjects|All subjects will undergo all 4 treatments, starch-free breakfast, Hi-Maize 260, Hylon VII and Amioca in randomized order
3312369|NCT01939613||Parkland group|Extensive burn patients are resuscitated with Parkland formula.In the first 24h of resuscitation,crystalloids were infused as the main fluid.
3312370|NCT01939613||TMMU group|Extensive burn patients are resuscitated with Third Military Medical University (TMMU) formula as a modified EVANS formula routinely used in China. In the first 24h of resuscitation, crystalloids and colloids were infused together.
3312371|NCT01939626|Experimental|Single-step medium|embryos will be cultured in a single-step medium for 5 days with no change
3312372|NCT01939626|Other|Control|Embryos cultured in two Culture media for 5 Days.
3312373|NCT01939639|Experimental|Oxytocin|24 IU Oxytocin, intranasal application 30 min prior to the experiment
3312374|NCT01939639|Placebo Comparator|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
3312375|NCT01939652|Active Comparator|Drag: Crystalloids and Colloids|Drag: Crystalloids and Colloids Intraoperative 10 ml/kg/per hour, postoperative 70-100 ml/per hour
3312376|NCT01939652|Experimental|Standard fluid regime|Drag: Crystalloids and Colloids Intraoperative 15 ml/kg/per hour, postoperative 150-200 ml/per hour
3312377|NCT01939665|Experimental|Irreversible electroporation|Single arm study: Percutaneous irreversible electroporation of locally advanced pancreatic carcinoma
3312378|NCT01939691|Experimental|Difluprednate|Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3312379|NCT01939691|Experimental|Nepafenac plus Prednisolone acetate|Nepafenac 0.1% 3 times a day until resolution; prednisolone acetate 1% 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at Week 4, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until Week 6, then decrease to 1 drop per day until Week 8, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3312380|NCT01939691|Experimental|Difluprednate plus Nepafenac|Nepafenac 0.1% 3 times a day until resolution; Difluprednate 0.05% ophthalmic emulsion 4 times a day until Week 4, then decrease according to protocol (if resolution of edema at 4 weeks, decrease to 1 drop per day until Week 6, then stop; if not resolved, continue at 4 times a day until 6 weeks and then decrease to 1 drop per day until Week 8 if resolved, then stop). If macular edema not resolved (or reoccurs) by Week 8, treat per best medical judgement.
3312381|NCT01939704|No Intervention|Pediatric Primary Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
3312382|NCT01939704|No Intervention|Pediatric Urgent Care Control|Baseline survey with a social needs assessment, health care status, health care satisfaction and health care utilization assessment and two telephone-based follow up surveys at 3 and 6 months.
3312383|NCT01939704|Experimental|Pediatric Primary Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
3312384|NCT01939704|Experimental|Pediatric Urgent Care Intervention|Baseline survey that includes social needs assessment, health care status, health care satisfaction and health care utilization assessment; 30 minute on-site intervention, twice monthly follow-up phone calls for up to 3 months to help address social needs
3312385|NCT01939717|Other|Dance group|Participants allocated to this group will continue with their usual care and participate in a set dancing class.
3312386|NCT01939717|No Intervention|Control group|Participants allocated to this group will act as a control group and continue to receive their usual care only.
3312387|NCT01939730|Experimental|Rituximab + GM-CSF|All patients receive one (1) course of therapy consisting of four (4) doses of rituximab, a single dose 375 mg/m^2 administered once weekly for 4 weeks along with GM-CSF 250 mcg subcutaneously three times weekly (tiw) for 8 weeks, starting 1 hour before the first dose of rituximab. In selected cases, the GM-CSF starts 1 week before, or 1 day after, the first rituximab dose.
3381566|NCT02994459||Metabolically Abnormal Lean|i) BMI ≥18.5 but <25.0 kg/m2; ii) maximum body circumference <165 cm to ensure subjects fit into the PET/CT and MR scanners; iii) iii) fasting blood glucose: ≥100 mg/dl or blood glucose 2 h after an OGTT: ≥140 or fasting insulin: >20 µU/mL.
3312388|NCT01939743|Experimental|diclofenac suppository plus lidocaine gel|Intervention Drug with local anaesthetic
3312389|NCT01939743|Other|Lidocaine gel only|Used as local aneaethetic as a part of institutional prostate biopsy protocol
3312390|NCT01939756|Experimental|Intravesical baobab oil|Intravesical instillation of 50 ml sterile Baobab natural oil. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 60 min, followed by emptying of the bladder and removal of the catheter.
3312391|NCT01939782|Experimental|Type 2 diabetic patients (T2D)|"In type 2 diabetic patients (T2D), the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
3312392|NCT01939782|Active Comparator|Healthy No Diabetics|"In healthy No Diabetics,: the investigators will evaluate the metabolic clock gene expression in PBC and serum glucose, insulin, triglycerides, free fatty acids (FFA), cortisol intact GLP-1, triglycerides ,cortisol, plasma free fatty acids (FFA l and DPP4 plasma activity in two different occasions:~No Breakfast (NoB): fasting until lunch at 12:00~Yes Breakfast (YesB): eating breakfast at 8:30 and lunch at 12:00 In both occasions the blood samples for glucose and insulin, cortisol and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch)."
3312393|NCT01939795|No Intervention|Healthy People|Control group
3312394|NCT01939795|Experimental|Untrained CRT|Untrained CRT patients
3312395|NCT01939795|Experimental|Exercise trained + CRT|Exercise-trained CRT patients
3312396|NCT01939808|Other|Wrist splinted in extended position|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
3312397|NCT01939808|Other|Wrist Splinted in the Neutral postion|We propose to carry out a study to compare the outcomes (grip strength and range of movement) of flexor tendon repair in two groups of patients: one with wrists splinted in a neutral position and the other splinted in an extended position during their postoperative rehabilitation
3312398|NCT01939821|Experimental|Educational and counselling program|In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach
3312399|NCT01939821|Active Comparator|Educational program|The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level.
3312400|NCT01939821|No Intervention|Control group|The control group will not receive any educational program. It represents the present real life in nursing homes.
3312401|NCT01939834|Experimental|AAA Control|"Subjects will use their home insulin pump along with a continuous glucose monitor (CGM) receiver. A CGM will be worn for 7 days prior to the study admission. Four fingersticks completed each day and carbohydrates will be recorded in bolus calculator of their insulin pump prior to each meal.~Subjects will be asked to provide the study team their insulin pump data on Day 2 or 3 to ensure accuracy of data collection. Subjects will be asked to submit insulin pump, glucometer, and CGM data 1-2 days prior to their admission and again the evening prior to the study admission at a Research House.~During the Experimental Admission, the AAA system will be tested using the DiAs platform. Subjects will participate in 45 minutes of exercise during the 40 hour admission (n=36). A subset (n=5-7) will continue with 5 nights of consecutive closed loop control (23:00-07:00)."
3312402|NCT01939834|Active Comparator|CGM + insulin pump at home|"The experimental and control admissions (40hr admissions) are exactly the same except for the study admission. During the Control Admission, subjects will use their home insulin pump along with a continuous glucose monitor receiver without running any specialized mathematical equations.~The active comparator for subjects participating in 5 consecutive nights of closed loop control will be the sensor-augmented pump therapy at home."
3312403|NCT01939847|Experimental|Molecular prolfiling in tissue|Participant's tumor will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology to provide a molecular profile for a possible treatment suggestion
3312404|NCT01939847|No Intervention|Molecular prolfiling in blood|Participant's blood sample will be analyzed by Foundation Medicine on their FoundationOne platform - a targeted whole exome sequencing of 182 cancer related genes (3,230 exons) as well as 37 introns from 14 genes commonly rearranged or altered in cancer via next-generation sequencing technology; however, this is just being done to see if it is possible to generate similar results in blood samples. We do not yet know if blood sample results may be used for treatment decision (this will be tested in a future study) and results will not be given to participants; therefore, no treatment suggestion will be given.
3312405|NCT01939860|No Intervention|Usual pharmacy care|Participants will not receive any structured written education on hypertension and its treatment
3312406|NCT01939860|Experimental|usual pharmacy care plus structured information|Participants will be provided with validated verbal and written information on hypertension and its treatment, including information about class (es) of anti-hypertensive medication(s) used by each patient, and their common side-effects. The written material will be based on validated patient information leaflets from the British Heart Foundation and the Blood Pressure Association.
3312407|NCT01939873|Experimental|KRISTELLER|Uterine fundal pressure
3312408|NCT01939873|No Intervention|Control group|
3312409|NCT01939886|Experimental|Artemether- Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania Other Name: Coartem;
3312410|NCT01939886|Active Comparator|Drug: Mefloquine-Artesunate, an alternative ACT|Treatment with the paediatric fixed dose combination Mefloquine-Artesunate (MQ-AS; Artequin; Mepha, Aesch, Basel, Switzerland, artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, given in three daily doses. The weight range of enrolled children is chosen to be recommended for this fixed dose combination. MQ-AS is available in Kenya as Artequin and has been extensively tested in uncomplicated malaria in children.
3381567|NCT02976038|Experimental|elamipretide|Open-label once daily subcutaneous injection of 40mg elamipretide
3312411|NCT01939912|Experimental|Stimulation of carotid body chemoreceptors|Adenosine boluses will be administered through an intravascular catheter used to administer the contrast agent during the carotid artery arteriography.
3312412|NCT01939925|Experimental|New plain language summary format|New plain language summary format of a Cochrane systematic review
3312413|NCT01939925|Active Comparator|Current plain language summary format|Plain Language Summary format for the public currently in use in Cochrane systematic reviews
3312414|NCT01939951|Active Comparator|Activation Energy Serum|Activation Energy Serum 7 or 21 drops twice daily for 4 weeks
3312415|NCT01939951|Placebo Comparator|Placebo|sugar pill
3312416|NCT01939964|Active Comparator|Activation Mist|Liquid mist preparation to be sprayed topically on wrinkle areas
3312417|NCT01939964|Placebo Comparator|Placebo|sugar pill
3312418|NCT01939990|Active Comparator|Nebivolol|Group A will be given Nebivolol 5 to 10mg per day
3312419|NCT01939990|Placebo Comparator|Placebo|Group B will be given Placebo.
3312420|NCT01940003|No Intervention|Control|Usual care of service Institute of Medicine Professor Fernando Figueira(IMIP) prenatal
3312421|NCT01940003|Experimental|Aquatic exercise|Pool-based exercise classes will be completed in groups of 4 to 6 participants under the instruction of a physiotherapist. The exercise program will be conducted three times per week and each session lasting 45 minute. This will be conducted since GDM diagnosis (26-28th gestational week) to the end of the third trimester (38-39th gestational week). Thus, an average of 30 training sessions will be planned for each pregnant woman.
3312422|NCT01940016|Experimental|Arm I (health coach)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and from a health coach. Participants in this arm of the study, interacted with the IVR system and had the option of interacting with the health coach.
3312423|NCT01940016|Active Comparator|Arm II (no coach condition)|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system. Participants in this arm of the study only interacted with the IVR system.
3312424|NCT01940042|Experimental|maneuver group|In the intervention group, CO2 was removed by means of Trendelenburg position (30 degrees) and a pulmonary recruitment maneuver consisting of five manual inflations of the lung.
3312425|NCT01940042|No Intervention|clasical group|no additional action will be taken after the operation
3312426|NCT01940055|Experimental|Experimental group|Dual Task Treadmill Walking Exercise Program
3312427|NCT01940055|Active Comparator|Control group|Dual task recumbent cycling exercise program
3312428|NCT01940068|Experimental|New Thickened Amino acid based formula|
3312429|NCT01940068|Active Comparator|Amino acid based formula|
3312430|NCT01940081||Group A: Nonischemic cardiomyopathy - not admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%) or~intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)~who are not admitted for cardiac surgery"
3312431|NCT01940081||Group B: Nonischemic cardiomyopathy -admitted for surgery|"Patients with nonischemic cardiomyopathy with:~documented ventricular arrhythmia or~suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or~high risk for ventricular arrhythmia (LVEF ≤ 35%)~who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)"
3312432|NCT01940081||Group C: Controls|"Patients without nonischemic cardiomyopathy (controls) who are admitted for:~Coronary artery bypass graft surgery and who do not have prior myocardial infarction~Aortic valve replacement"
3312433|NCT01940094|Experimental|5 mg Prednisone|Subjects will be randomized to a prednisone dose of 5 mg per day for a 6 month period.
3312434|NCT01940094|Experimental|0 mg Prednisone|Subjects will be randomized to taper their prednisone dose from 5 mg per day to 0 mg per day for a 6 month period.
3312435|NCT01940107|Other|Control Group (CG)|Control Group, which were subjected only to evaluations and to no exercise
3312436|NCT01940107|Experimental|Study Group (SG)|Study group (SG), was oriented to perform domiciliary exercises for the upper limbs.
3312437|NCT01940133|Experimental|PQR309|Different dose evaluation
3312438|NCT01940159|Active Comparator|Active Comparator: SEP-363856|Dosing will be initiated at 25 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 50, 100, and 150 mg of SEP-363856
3312439|NCT01940159|Placebo Comparator|Placebo|Matched placebo.
3312440|NCT01940172|Experimental|Birinapant with Conatumumab|
3312441|NCT01940185||LINX device|Patients implanted with the LINX® Reflux Management System.
3312442|NCT01940224|Active Comparator|Pregabalin & Morphine|Administration of pregabalin 300 mg to patients undergo laparoscopic colorectal surgery.Patients receive oral Pregabalin 150 mg the night before surgery, and another one dose of 150 mg 1 hour prior to surgery. Postoperative administration of morphine via PCA pump for 48 hours
3312443|NCT01940224|Placebo Comparator|Placebo & Morphine|Administration of placebo to patients undergo laparoscopic colorectal surgery.Patients receive oral Placebo the night before surgery, and another one dose 1 hour prior to surgery.Postoperative administration of morphine via PCA pump for 48 hours
3312444|NCT01940237|Experimental|Interpersonal Psychotherapy (IPT)|Interpersonal psychotherapy (IPT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) in several controlled trials. This study will test the efficacy of IPT in a group of prostate, colorectal, lung and pancreatic cancer patients with a diagnosis of major depressive disorder.
3312445|NCT01940250|Placebo Comparator|Sterile water|"Sterile water will be packaged identically to the active comparator.~Each patient randomized to the placebo arm of the trial will receive a loading dose of 0.5ml/kg intravenous over 20 minutes , followed by a maintenance dose of 0.3 ml/kg/hr to 0.5 ml/kg/hr randomly adjusted by an independent doctor to mimic adjustments made in the active comparator arm for 72 hrs."
3312446|NCT01940250|Active Comparator|Magnesium sulphate|"Each patient randomized to the treatment arm of the trial will receive a loading dose of 50mg/kg intravenous over 20 minutes (0.5ml/kg), followed by a maintenance dose of 30-50 mg/kg/hr (0.3 ml/kg/hr to 0.5 ml/kg/hr) for 72 hrs.~The maintenance dose will be determined by increasing the loading infusion dose 0.1 ml/kg/hr (10mg/kg/hr) every 15 minutes to a maximum dose of 0.5 ml/kg/hr (50 mg/kg/hr), with the following caveats:~If the systolic BP decreases to < 90th percentile for age, gender and length the dose will be reduced by 1 stage every 15 mins~If the systolic BP increases to the levels detailed in the study protocol for treatment failure, action will be taken as indicated~If the systolic BP decrease rapidly more than 25% over 15 minutes~If the plasma Mg level > 2.5 mmol/l or < 1.8 mmol/l a 25% increase or decrease in the infusion rate will be implemented as appropriate."
3312447|NCT01940263|Placebo Comparator|Placebo|placebo 320 mg daily for twelve weeks
3312448|NCT01940263|Experimental|Anthocyanin|Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.
3312449|NCT01940289|Active Comparator|asymptomatic subjects attending podiatry clinic for nail care|Algometric meter readings for perception of pain These subjects will have an algometric pressure threshold meter reading taken during their routine treatment visit to establish Algometric meter readings for perception of pain
3312450|NCT01940289|Active Comparator|forefoot pain|Algometric meter readings for perception of pain forefoot pain severity measured by both VAS and algometric pressure meter
3312451|NCT01940302|Experimental|LEHEL multi-nutrients supplement|75 g/d of LEHEL supplementation along with oral hypoglycemic agents such as glibenclamide and/or metformin.
3312452|NCT01940302|No Intervention|Control|Received only oral hypoglycemic agents.
3312453|NCT01940315|Active Comparator|rBV A/B|0.5 mL dose of rBV A/B (40 µg) will be administered intramuscularly (IM) in a three-dose dosing schedule given at Days 0, 28 ± 5 days, and 182 ± 9 days
3312454|NCT01940315|Placebo Comparator|Placebo|0.5 mL dose of placebo will be administered intramuscularly (IM) given at Days 0, 28 ± 5 days, and 182 ± 9 days
3312455|NCT01940328||Decompensated CHF|patients with acute pulmonary congestion or pulmonary edema
3312456|NCT01940328||Compensated CHF|patients with significant stable left HF (NYHA II-III) who are on optimal medical treatment for CHF, and are without clinical or laboratory evidence of pulmonary congestion
3312457|NCT01940328||Non CHF patients|patients without CHF and without uncontrolled hypertension.
3312458|NCT01940367|Active Comparator|PTNS Arm|Subjects randomized to the PTNS arm will undergo PTNS treatment once weekly for 30 minutes for 12 weeks total. If at 12 weeks they are considered to have a positive response to therapy, they will continue maintenance therapy in a tapered fashion: subjects will come in every 2 weeks for the next 8 weeks for 30 minute treatments (4 visits total), then every 3-4 weeks for 30 minute treatments for the remaining 32 weeks of the year (8-10 visits).
3312459|NCT01940367|Active Comparator|TENS Arm|Subjects randomized to the TENS arm of the study will begin therapy after their baseline evaluation is complete. They will be issued a home TENS device (EMPI TENS Select) and will administer self-treatment daily for 2 hours per day (1 hour in the morning and 1 hour in the evening) for a total of 12 weeks. If they are considered to have a positive response with TENS treatment, subjects will continue by weaning use over a three-month time period. They will begin with 3 x per week for 1 month, then 2 x per week for 1 month, then 1 x per week for 1 month, all at 2 hours per day.
3312460|NCT01940393|Active Comparator|Cetirizine|Cetirizine
3312461|NCT01940393|Active Comparator|Desloratadine|desloratadine
3312462|NCT01940393|Active Comparator|Fexofenadine|Fexofenadine
3312463|NCT01940393|Active Comparator|Ebastine|ebastine
3312464|NCT01940393|Active Comparator|Bilastine|bilastine
3312465|NCT01940406|Experimental|Stimulation procedure|Stimulation procedure
3312466|NCT01940419|Active Comparator|Tranexamic Acid|1g Tranexamic acid iv just before surgery
3312467|NCT01940419|Placebo Comparator|Placebo|sterile sodium chloride 9mg/ml iv
3312468|NCT01940432|Experimental|electroacupuncture group|Bilateral BL33 are given acupuncture of 50-60mm with 30-45°angle to inward and downward. Bilateral BL35 are given acupuncture of 50-60mm to outward and upward. The electric stimulator is applied to bilateral BL33 and BL35.Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
3312469|NCT01940432|Experimental|pelvic floor muscle training group|Standing/sitting/lying on back, knees bent to chest. A set consists of three contractions, each lasting 10s, with a 10s break between contractions. Counting or measuring the duration of contractions and breaks is accomplished without effort by taking advantage of the duration of normal breaths. As most men take about 10 breaths per minute, each breath can be used as 6s timing device.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all.
3312470|NCT01940445|Experimental|ResurFX treatment|Fractional Non Ablative (NA) treatment on one side of the face with the M22 ResurFX module
3312471|NCT01940445|Experimental|M22 ResurFX and QS treatment|Fractional NA treatment with the M22 ResurFX followed by Q-Switched (QS) laser treatment (SST) on one side of the face
3312472|NCT01940536|Active Comparator|Tranexamic Acid|1g tranexamic acid, intravenous, at time of sudy enrollment and again a surgical incision
3312473|NCT01940536|Placebo Comparator|Placebo Injection|Placebo injection (normal saline) a time of study enrollment and again at time of surgical incision
3312474|NCT01940549|Sham Comparator|Trauma Focused Therapy + Sham tDCS|Trauma Focused Therapy will be conducted during the delivery of sham Transcranial Direct Current Stimulation
3312475|NCT01940549|Active Comparator|Trauma Focused Therapy + active tDCS|Trauma focused therapy will be conducted while active Transcranial Direct Current Stimulation is applied
3312476|NCT01940562|Experimental|Eltrombopag|"Pediatric patients undergoing allogeneic UCB transplantation will receive eltrombopag from day +1 until platelet count has exceeded 50,000/microliter for 14 consecutive days without platelet transfusion.~Starting doses are 100 mg/d for children >40 kg body weight (BW), 50 mg/d for children 20-40 kg BW, and 2 mg/kg/d for children <20 kg BW.~If unsupported platelet count has not reached the threshold of 20,000/microliter, doses will be escalated every 2 weeks up to maximal doses of 200 mg/d for children ≥ 40 kg BW, 150 mg/d for children 20-40 kg BW and 3.5 mg/kg for children <20 kg BW."
3312477|NCT01940575|Active Comparator|Restylane®|Inject Restylane® on right or left nasolabial fold
3312478|NCT01940575|Experimental|SkinPlus-Hyal®|Inject SkinPlus-Hyal® on right or left nasolabial fold
3312479|NCT01940588||Neuropsychoanalytic treatment|Outpatient detoxification, intensive neuropsychoanalytic therapy, low dose naltrexone, monthly evaluations for six months - case series approach.
3312480|NCT01940601|Experimental|Balugrastim 300 ug/kg|Balugrastim 300 μg/kg subcutaneously (SC) administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
3312481|NCT01940601|Experimental|Balugrastim 670 μg/kg|Balugrastim 670 μg/kg (maximum 40 mg) SC administration once per chemotherapy cycle, approximately 24 h after chemotherapy, up to 4 cycles
3312482|NCT01940601|Active Comparator|Filgrastim 5 μg/kg|Filgrastim will be administered at a dose of 5 μg/kg SC once a day for at least 5 consecutive days or until absolute neutrophil count (ANC) has returned to ≥2*10^9/L for each chemotherapy cycle up to 4 cycles. The maximum period of filgrastim administration is 14 days in each cycle.
3312483|NCT01940627|Experimental|Ubiquinol|Firemen consuming 200 mg ubiquinol/day during two weeks
3312484|NCT01940627|Placebo Comparator|Control|Firemen consuming placebo capsules during two weeks
3312485|NCT01940640|Experimental|DHA supplementation|mothers consuming 900 mg DHA/day and their neonates.
3312486|NCT01940640|Active Comparator|Control|follow on capsules without probiotics
3312487|NCT01940653|Other|Progesterone|Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International). On the 5th (group A) of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
3312488|NCT01940653|Active Comparator|progesterone 3 days|Group B receives 3 days of micronized progesterone vaginally. On the 3rd day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred.
3312489|NCT01940666||Controls|patients who have all androgens (TT, A4, FAI, and DHEA-S) lower than their cut-off values
3312490|NCT01940666||Total Testosterone >= 2.39|Patients who have only total testosterone higher than its cut-off value; (TT) >=2.39
3312491|NCT01940666||Androstenedione >= 2.99|Patients who have only androstenedione higher than its cut-off value; (A4) >=2.99
3312492|NCT01940666||Free Androgen Index >= 6.53|Patients who have only free androgen index higher than its cut-off value; (FAI) >=6.53
3312493|NCT01940666||DHEAs >= 181.55|Patients who have only dehyroepiandrosterone sulfate higher than its cut-off value; (DHEA-S)>=181.55
3312494|NCT01940679|Experimental|Fresh meat stick|Fresh meat stick w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
3312495|NCT01940679|Experimental|Stored meat stick|Stored meat stick with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production
3312496|NCT01940679|Experimental|Fresh pound cake|Fresh pound cake w/ encapsulated 600 mg EPA/DHA; product frozen immediately after production.
3312497|NCT01940679|Experimental|Stored pound cake|Stored pound cake with encapsulated 600 mg EPA/DHA; stored at 100F for 3 months after production.
3312498|NCT01940692|Active Comparator|Intravenous tranexamic acid|Will receive 1.5g intravenous tranexamic acid preoperatively
3312499|NCT01940692|Experimental|Intra-articular tranexamic acid|Will receive 3g intra-articular tranexamic acid after wound closing
3312500|NCT01940718|Experimental|Transdermal Testosterone|Transdermal Androgel 1.62% (20.25 mg testosterone = 1 pump actuations) to be applied once daily for 3.5 months. Initial dose will be at lowest level, 20.25 mg testosterone with dosing adjustments given in 20.25 mg testosterone increments.
3312501|NCT01940731|Experimental|Colistimethate sodium|
3312502|NCT01940744|Experimental|Prescriptive Mobilization|"The prescriptively applied non-thrust manipulation will be involve a central lumbar posterior-anterior directed at L4 and L5. The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Patients will be seen for 4 visits."
3312503|NCT01940744|Active Comparator|Pragmatic Mobilization|The pragmatically applied non-thrust manipulation will be based on the original concepts outlined by Maitland and will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
3312504|NCT01940757|Experimental|25 Necator americanus Hookworm Larvae|
3312505|NCT01940757|Experimental|50 Necator americanus Hookworm Larvae|
3312506|NCT01940757|Experimental|75 Necator americanus Hookworm Larvae|
3312507|NCT01940783|Other|Intervention|All participants in the study will receive one pre-operative MRI, prior to cochlear implantation, and two cone-beam computed tomography scans, after cochlear implantation
3312508|NCT01940796|Experimental|Brentuximab Vedotin|The dose of brentuximab Vedotin will be based on the cohort the participant is enrolled on. Dosing will be based on the participant's weight prior to each dose. Actual weight will be used except for participants weighing > 100 kg. The dose for participants weighing > 100 Kg will be calculated based on a weight of 100 kg. The dose should be rounded to the nearest whole number of milligrams. Brentuximab vedotin will be administered over approximately 30 minutes IV.Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
3312517|NCT01940822|Experimental|Energy drink first, then placebo drink|Participants will receive an energy drink at the first study visit, and a placebo drink at the second study visit.
3312518|NCT01940822|Experimental|Placebo drink first, then energy drink|Participants will receive a placebo drink at the first study visit and an Energy Drink at the second study visit.
3312519|NCT01940835||Type 1 Diabetes|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
3312520|NCT01940835||Healthy Control Group|Subjects will have an upper endoscopy with small bowel biopsies and brushings. Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC). Stool samples will be collected at baseline for future microbiome and virome studies.
3312521|NCT01940848|Experimental|STW5|2/3 patients with irritable bowel syndrome will be randomized in this arm
3312522|NCT01940848|Placebo Comparator|Placebo|1/3 patients with irritable bowel syndrome will be randomized in this arm
3312523|NCT01940861||Traumatic brain injury|
3312524|NCT01940874||Cerebral oximetry|
3312525|NCT01940913|Active Comparator|Probiotics|
3312526|NCT01940913|Placebo Comparator|Placebo|
3312527|NCT01940926|Experimental|68Ga-BNOTA-PRGD2|In patients with RA, single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 will be given at 30 minutes before PET/CT scanning to determine 68Ga-BNOTA-PRGD2 uptake in joints.
3312528|NCT01940952|Active Comparator|Zydena 50mg|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
3312529|NCT01940952|Placebo Comparator|Placebo|Placebo + Donepezil 5mg or 10mg
3312530|NCT01940952|Active Comparator|Zydena 100mg|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
3312531|NCT01940965|Experimental|Lixisenatide + Biguanide|52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)
3312532|NCT01940965|Experimental|Lixisenatide + TZD|52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)
3312533|NCT01940965|Experimental|Lixisenatide + alpha-GI|52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)
3312534|NCT01940965|Experimental|Lixisenatide + Glinide|52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)
3312535|NCT01940978|Placebo Comparator|Control|Methylphenidate ER QD placebo BID
3312536|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 2.5mg|Methylphenidate ER QD cyproheptadine hydrochloride 2.5mg BID
3312537|NCT01940978|Active Comparator|Methylphenidate ER, cyproheptadine 5mg|Methylphenidate ER QD cyproheptadine hydrochloride 5.0mg BID
3312538|NCT01940991|Placebo Comparator|Dose B|Dose B: Placebo
3312539|NCT01940991|Experimental|Dose A|Dose A: Botulinum Toxin Type A
3312540|NCT01941004|Experimental|double blinded Fingolimod 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
3312541|NCT01941004|Placebo Comparator|Placebo 6 mos + open label fingolimod 6 mos|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
3312542|NCT01941017||Minimal or mild endometriosis|Patients with minimal or mild endometriosis diagnosed via laparoscopy.
3312543|NCT01941017||Tubal obstruction without endometriosis|Patients with tubal obstruction due to infection or adhesion with absent evidence for endometriosis on laparoscopy
3312544|NCT01941043|Experimental|CERC-301, Treatment Sequence 1|Treatment Sequence 1 - 7 days on placebo and 28 days on study drug (either 12mg or 8mg)
3312545|NCT01941043|Experimental|CERC-301, Treatment Sequence 2|Treatment Sequence 2 - Placebo for 7 days and study drug for 28 days (8 mgs)
3312546|NCT01941043|Placebo Comparator|Placebo, Treatment Sequence 3|Treatment Sequence 3 - Placebo for 35 Day treatment period
3312547|NCT01941056|Experimental|Treatment (CMV-MVA Triplex vaccine)|Participants receive multi-CMV epitope modified vaccinia Ankara vaccine IM followed by a booster injection 28 days later in the absence of unacceptable toxicity.
3312548|NCT01941069|Active Comparator|Internalizing Disorders|Students identified as being at-risk for or meeting criteria for Internalizing Disorders will assigned to this intervention arm. They will receive the FRIENDS for Life intervention. FRIENDS is a group Cognitive Behavioral Therapy (CBT) intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
3312549|NCT01941069|Active Comparator|Externalizing Disorders|Students identified as being at-risk for or meeting criteria for Externalizing Disorders will be assigned to this intervention arm. They will receive the Coping Power Program (CPP) intervention. CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
3312550|NCT01941082|Experimental|Part A: RO6867461|Single doses
3312551|NCT01941082|Experimental|Part B: RO6867461|Multiple doses
3312552|NCT01941108|No Intervention|Standard HIV Care Arm|Patients in the standard HIV care arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will not receive any additional intervention regarding their care after that. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months.
3312553|NCT01941108|Experimental|Peer Navigation Arm|Patients in the peer navigation arm will be escorted to their first HIV care appointment at the Moore Clinic at Johns Hopkins University Hospital. They will be assigned to a peer navigator who can assist them in overcoming obstacles to their HIV care. They will be given a smartphone with specialized software to help with their navigation. Participants in this arm will be followed up by the study coordinator every 3 months for 9 months and interact with their navigator when necessary.
3312554|NCT01941121|Experimental|Linkage to PrEP or Care|Subjects screened for HIV at any CCTG consortium site will be offered Linkage to PrEP or Care, depending on HIV status. After results are received, HIV testers will obtain verbal consent from the subject to connect with the ALERT Specialist, or otherwise offer the subject the ALERT Specialist contact information. When contacted, the ALERT Specialist will coordinate with the subject the scheduling of the PrEP or Care visit, and remain in contact to ensure linkage.
3312555|NCT01941134|Experimental|Gastric bypass COC|"This is a before-and-after comparison. Women will enroll prior to planned gastric bypass surgery and complete one cycle of oral contraceptive use and evaluation. There will then be no more study procedures/interventions until 3-4 months after surgery. At that time, women will complete the second cycle of OC use and evaluation. Study participation is then complete.~Intervention: Ethinyl estradiol-levonorgestrel(EE 20mcg/LNG 150mcg)"
3312556|NCT01941147|Experimental|Pulsed ELF-MF|Nine patients will be treated daily for 5 consecutive days, starting within 48 h from the onset of stroke. Three dose cohorts of three patients each, will be stimulated with pulsed ELF-MF at increasing daily exposure (45, 120, 240 min).
3312557|NCT01941160|Experimental|Amoxicillin/Clavulanic Acid and Lacidofil® STRONG|Participants are provided in double blinded fashion Lacidofil® STRONG to take with antibiotics
3312558|NCT01941160|Placebo Comparator|Placebo|Participants are provided in double blinded fashion placebo to take with antibiotics
3312559|NCT01941173|Experimental|Treatment (ziv-aflibercept, FOLFIRI)|Patients receive ziv-aflibercept IV over 15-30 minutes followed by FOLFIFRI chemotherapy comprising leucovorin calcium IV over 2 hours, irinotecan hydrochloride IV over 90 minutes, and fluorouracil IV over 46 hours on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
3312560|NCT01941199|Experimental|D → M → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312561|NCT01941199|Experimental|D → D+M → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312562|NCT01941199|Experimental|M → D → D+M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312563|NCT01941199|Experimental|M → D+M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312564|NCT01941199|Experimental|D+M → M → D|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312565|NCT01941199|Experimental|D+M → D → M|D : DA-1229 5mg qd, M : metformin 1000mg bid
3312566|NCT01941212|Active Comparator|Music therapy and Behavioral therapy|Music and behavioral therapy
3312567|NCT01941212|Active Comparator|Music only|Music therapy without behavioral therapy
3312568|NCT01941212|No Intervention|Control|Patients will not listen to music neither will get music therapy
3312569|NCT01941225|Placebo Comparator|Placebo|Nebulized normal saline. Single administration
3312570|NCT01941225|Experimental|Inhaled iloprost 5.0 mcg|Single administration
3312571|NCT01941238||Insulin pump|
3312572|NCT01941238||MDI|
3312573|NCT01941251|Active Comparator|Navigated individualized αTMS|navigated Transcranial Magnetic Stimulation
3312574|NCT01941251|Sham Comparator|Sham TMS|navigated Transcranial Magnetic Stimulation using sham coil
3312575|NCT01941264|Active Comparator|community based screening and treatment|CHWs will identify pregnant women in the village and encourage to go to the antenatal care clinic, furthermore, once a month the community health worker will screen the pregnant women for malaria with a rapid diagnostic test and treat with artemether-lumefantrine in case of a positive test result.
3312576|NCT01941264|No Intervention|Control|All pregnant women will be identified in the study area and asked for participation to the study. No intervention will take place.
3312577|NCT01941277|Experimental|Intensive Exercise Group|Behavioral
3312578|NCT01941277|Experimental|Current Recommendations Exercise Group|Behavioral
3312579|NCT01941290||Orsiro|
3312580|NCT01941303||Advanced stage non-small cell lung cancer patients|
3381568|NCT02966873|Experimental|N-Acetylcysteine (NAC) Treatment Group|"Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication at a time from the study physician or the study coordinator. The study medication provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
3381569|NCT02966873|Placebo Comparator|Placebo Group|"Participant will receive 12 weeks of inactive placebo comparator daily, as well as weekly cognitive-behavioral therapy, medication management, and Adverse Event (AE) monitoring.~Participant will receive one week of study medication (placebo) at a time from the study physician or the study coordinator. The study medication (placebo) provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening."
3381570|NCT02951767|Experimental|Cohort 1: Treatment-naive Cisplatin Ineligible Participants|Participants with advanced disease who are treatment-naive for advanced urothelial carcinoma and cisplatin ineligible will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
3381571|NCT02950415|Other|virtual + coaching|Parent is present virtually via an internet pad (iPad) and has received coaching about how best to verbally soothe child
3381572|NCT02950415|Other|virtual + no coaching|Parent is present virtually via an internet pad (iPad) and has not received coaching about how best to verbally soothe child
3381573|NCT02950415|Other|physical + coaching|Parent is physically present and has received coaching about how best to verbally soothe child
3381574|NCT02950415|Other|physical + no coaching|Parent is physically present and has not received coaching about how best to verbally soothe child
3381575|NCT02898181|Experimental|Tragus Stimulation|In this group patients will receive tragus stimulation for 8 hours per day during hospital stay.
3381576|NCT02898181|No Intervention|Control group|No tragus stimulation will be done
3381577|NCT02838836||Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
3312581|NCT01941316|Experimental|Phase II|"Phase II: Stratified, single arm trial using a starting dose of 20/36 mg/m2 of carfilzomib and 125 mg/m2 of irinotecan, in small cell lung cancer patients who have relapsed on a prior platinum regimen.~Stratification for phase II component:~Platinum sensitive disease: initial response to platinum-based chemotherapy with progression > 90 days after last treatment.~Platinum refractory disease: No response to platinum-based chemotherapy or progression within 90 days of completing platinum-based therapy. Subjects that progressed during or within one month of completion of platinum-based chemotherapy will be excluded."
3312582|NCT01941329|Experimental|Ranimizumab + Panretinal photocoagulation (PRP)|3 Intravitreous injections of ranibizumab combined with standard PRP (2 ± 1 weeks after injection), at month-0, month-1 and month-2 that can be repeated after month-3, with always at least 1 month of interval between injections.
3312583|NCT01941329|Active Comparator|Panretinal photocoagulation (PRP)|"Panretinal photocoagulation treatment (PRP) between month-0 and month-2, with 1 mandatory laser session in month-0 and more laser sessions as needed until Month-2 to complete the PRP treatment.~After completing the PRP treatment, PRP sessions can be repeated from Month-3 to Month-11."
3312584|NCT01941342|Active Comparator|Pancreatoduodenectomy|Instant pancreatoduodenectomy within one week after diagnosis including: Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract.
3381578|NCT02836600|Experimental|LY3039478|LY3039478 given orally TIW (3 times per week) in 28 day cycles. Treatment will continue until disease progression, development of unacceptable toxicity, or any other discontinuation criteria are met.
3381579|NCT02783664||Questionnaires to Evaluate Patient Stress Levels|
3381580|NCT02777762|Experimental|Fun First|Strategies to promote enjoyment of physical activity
3381581|NCT02777762|Active Comparator|Close at Hand|Strategies to promote tracking of physical activity
3312585|NCT01941342|Experimental|ENBD and Pancreatoduodenectomy|"Consistent ENBD (Endoscopic Nasobiliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3381582|NCT02763033|Experimental|Bob's Red Mill®|"Patients will follow the standard BMT (bone marrow transplant) diet and add potato-starch produced by Bob's Red Mill® beginning on day -7 and continuing through day +100.Patients will consume 20 g of Bob's Red Mill®, Potato-based dietary starch, orally twice daily.~Initially, subjects will take 20g daily for first three days prior to increasing dose to 20 g BID."
3381583|NCT02763033|Placebo Comparator|Starch Placebo|Patients will receive an iso-caloric, non-resistant starch placebo.
3381584|NCT02757222|Active Comparator|Standard dose|Patients receive a radiation dose of 66Gy in 30 fractions to the planning target volume 1 (PTV1) and 54 Gy in 30 fractions to the PTV2 concurrent with platinum chemotherapy weekly
3381585|NCT02757222|Experimental|Escalated dose|Patients receive a radiation dose of 73.5 Gy in 30 fractions to the boost target volume (BTV), 63Gy in 30 fractions to PTV1 and 54 Gy in 30 fractions to PTV2 concurrent with platinum chemotherapy weekly
3312586|NCT01941342|Experimental|EBD and Pancreatoduodenectomy|"Consistent EBD (Endoscopic Biliary Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3381586|NCT02754557|Experimental|Breath-Focused Meditation|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation.
3381587|NCT02754557|Experimental|Breath-Focused Meditation + Physiological Feedback|Women with post traumatic stress disorder (PTSD) will receive breath-focused meditation and physiological feedback.
3381588|NCT02717455|Experimental|Treatment (STRATUM 1)|Patients with recurrent/progressive DIPG will be enrolled at the time of progression. All patients will take the study drug panobinostat (LBH589).
3381589|NCT02717455|Experimental|Treatment (STRATUM 2)|Patients with non-progressed DIPG will be enrolled. All patients will take the study drug panobinostat (LBH589).
3312587|NCT01941342|Experimental|PTCD and Pancreatoduodenectomy|"Consistent PTCD (Percutaneous Transhepatic Cholangial Drainage) for 3 weeks or drainage until bilirubin level decreases to 200μmol per liter or below then perform pancreatoduodenectomy including:~Evaluate the resectability; Remove pancreas head, gastric pyloric antrum, duodenum, distal common bile duct and regional lymph nodes; Reconstruct digestive tract."
3312588|NCT01941355|Experimental|Exercise training, psycho-educative|
3312589|NCT01941355|Experimental|Psycho-educative component|
3312590|NCT01941355|Experimental|Exercise training component|
3312591|NCT01941355|No Intervention|Usual care|
3312592|NCT01941368|No Intervention|Control|Individuals assigned to Control Group will undergo baseline testing and then be asked to continue their normal exercise routine for 4 weeks and will undergo post-testing (visits 16 and 17) after this time period.
3312593|NCT01941368|Placebo Comparator|Placebo + High-Intesnity Interval Training (HIIT)|On training days, individuals will consume 1 gram of placebo 30 min prior to training, 1gram placebo 1 hour post training, and 1gram placebo 3 hours post training. On non-training days, individuals will consume placebo 3 times per day (8am, 12pm and 4pm).
3312594|NCT01941368|Active Comparator|HMB-FA + HIIT|On training days, individuals will consume 1 gram HMB-FA 30 min prior to training, 1gram HMB-FA 1 hour post training, and 1gram HMB-FA 3 hours post training. On non-training days, individuals will consume HMB-FA 3 times per day (8am, 12pm and 4pm).
3312595|NCT01941381||Type B tympanogram|Patients with a clinical diagnosis of acute otitis media and a B type curve with tympanometry.
3312596|NCT01941381||Type A/C tympanogram|Patients with a clinical diagnosis of acute otitis media and a type A or C curve with tympanometry
3312597|NCT01941394|Experimental|With MSC|infusion of Mesenchymal stem cells at dose 1 mln cells per kg
3312598|NCT01941394|No Intervention|Without MSC|Without MSC infusion
3312599|NCT01941407|Experimental|Association eribulin and bevacizumab|Drug: eribulin 1,23mg/m²; d1 and d8 in IV, all 3 weeks until 6 cycles or progression Drug: bevacizumab 15m/kg ; d1 in IV, all 3 weeks until 6 cycles or progression or toxicity
3312600|NCT01941420||1 Blood cardioplegia|Blood cardioplegia
3312601|NCT01941420||2 Crytalloid Cardioplegia|Crytalloid Cardioplegia
3312602|NCT01941433|Experimental|Arthritis Health Journal|Participants in this group will use the Arthritis Health Journal in the first 6 months of study.
3312603|NCT01941433|Other|Control|Participants in this group will receive a delayed intervention. They will receive usual care for the first 6 months of study, during which time they will contribute control data, and they will use the Arthritis Health Journal in the second 6 months of study, during which time they will contribute intervention data.
3312607|NCT01941459||1 Custodiol|Custodiol
3312608|NCT01941459||2 Blood cardioplegia|Blood cardioplegia
3312609|NCT01941511|Experimental|Rivipansel/Placebo/Moxifloxacin|Rivipansel 4.8 gA IV infusion over 20 minutes Phosphate Buffered Saline (PBS) IV infusion over 20 minutes Moxifloxacin (Avelox) 400 mg single oral dose
3312610|NCT01941524|Active Comparator|Poractant goup|Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation.
3312611|NCT01941524|Active Comparator|Beractant group|Newborns who will be monitored by aEEG and NIRS during beractant instillation
3312612|NCT01941550|Other|Cabazitaxel chemotherapy|"Patients undergo 6 cycles Cabazitaxel chemotherapy. Cabazitaxel suspension is given once per cycle as infusion intravenously, 1 mg/square meter.~For max. 6 times at all."
3312613|NCT01941563|Experimental|SI-6603|SI-6603 is administrated into the nucleus pulposus of the intervertebral disc
3312614|NCT01941563|Sham Comparator|Control|Sham injection
3312615|NCT01941576|Experimental|rhBNP Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a rhBNP infusion 24 hours after operation. The dose of recombinant human brain natriuretic peptide (rhBNP) will be 1.5 mcg/kg for loading, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
3312616|NCT01941576|Placebo Comparator|Placebo Group|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
3312617|NCT01941589|Active Comparator|present 5-ASA arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
3312618|NCT01941589|Active Comparator|5-ASA naive arm 1|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone
3312619|NCT01941589|Active Comparator|present 5-ASA arm 2|IV corticosteroids only / PO Methylprednisolone
3312620|NCT01941589|Active Comparator|5-ASA naive arm 2|IV corticosteroids only / PO Methylprednisolone
3312621|NCT01941602||prophylactic|Prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Department of neurosurgery at Karolinska Hospital, Stockholm, Sweden
3312622|NCT01941602||non-prophylactic|No use of prophylactic treatment with drugs to prevent venous thromboembolism in patients operated with open surgery for intracranial meningioma at the Departments of neurosurgery at University Hospital North Norway (UNN) and St.Olavs University Hospital (Tromsø and Trondheim respectively, both Norway)
3312623|NCT01941641|Experimental|neoadjuvant FOLFOXIRI|
3312624|NCT01941654|Experimental|preemptive local ablative therapy|
3312625|NCT01941667|Experimental|Daily Messages, virtual home visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
3312626|NCT01941667|Placebo Comparator|Usual Care|Infants will have usual care as defined by cardiology.
3312627|NCT01941680||ZPI|Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week
3312628|NCT01941680||ZPI+CHOP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~CHOP-21 Day1 = day 21 (3 cycles)~Day 1 Cyclophosphamide : 750 mg/m2, Doxorubicine : 50 mg/m2, Vincristine : 1,4mg/m2, Prednisone : 100mg/day PO.~day 2-Day 5 Prednisone~1mg/kg/day PO."
3312629|NCT01941680||ZPI +DHAP-21|"Zidovudine 1000mg/day : Retrovir® 250mg/day) PegINF (Pegasys®) 180μg x1 injection/week~DHAP Day 1= day 21 (3 cycles) Day 1 : Cisplatina 100 mg/m2 Day 2 and day 3 : Aracytine 2000mg/m2/day Day 1-day 4 : Dexamethasone 40mg"
3312630|NCT01941693|Experimental|Integrated care|"Integrated care:~Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders."
3312631|NCT01941693|Active Comparator|Usual care|Usual care
3312632|NCT01941706|Experimental|Project UPLIFT (Treatment)|Participants randomly assigned to the Treatment group receive the UPLIFT Intervention immediately after completing the Baseline Assessment. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
3312633|NCT01941706|Experimental|Project UPLIFT (TAU Waitlist Control)|Participants randomly assigned to the Treatment-as Usual (TAU) Waitlist Control group will also receive the UPLIFT intervention. However, TAU Waitlist Control participants will begin the Intervention 8 weeks after completing the Baseline Assessment. During the initial 8 weeks, participants in this group will continue whatever treatment they are currently undergoing to prevent or treat mild depressive symptoms. Participants can chose to participate in the Web- or phone-delivery of UPLIFT.
3312636|NCT01941732|Experimental|Sildenafil|motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h
3312637|NCT01941758|Experimental|Basic science (trivalent influenza vaccine)|Patients receive trivalent influenza vaccine on day 1.
3312638|NCT01941771|Active Comparator|Arm A|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
3312639|NCT01941771|Experimental|Arm B|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
3312640|NCT01941784|Experimental|Supportive care (health education program)|See Detailed Description.
3312641|NCT01941797|Experimental|Peri-implant mucosa|
3312642|NCT01941797|Active Comparator|periodontal mucosa|
3312643|NCT01941810|Experimental|Supportive care (bovine lactoferrin supplement)|Patients receive bovine lactoferrin supplement PO TID for 1 month.
3312644|NCT01941823||Carnitine CRRT, prospective|CRRT patients given carnitine in TPN as part of clinical protocol. Will evaluate total and free, carnitine and acylcarnitine profile as well as cardiac function by standard and speckle tracking echo weekly during CRRT.
3312645|NCT01941823||CRRT Control, retrospective|Retrospective control group, CRRT patients who did not receive carnitine supplementation during CRRT and had carnitine levels measured and echo performed during CRRT.
3312646|NCT01941823||ICU Control (non-CRRT), prospective|Critically ill ICU patients not receiving any exogenous carnitine, and not receiving CRRT, will have total and free carnitine and acylcarnitine profile measured weekly during CRRT.
3312647|NCT01941836|Experimental|ETC-1002 120 mg/day|Orally, once daily in morning as capsules
3312648|NCT01941836|Experimental|ETC-1002 180 mg/day|Orally, once daily in morning as capsules
3312649|NCT01941836|Active Comparator|ezetimibe 10mg/day|Orally, once daily in morning as capsules
3312650|NCT01941836|Experimental|ETC-1002 120 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
3312651|NCT01941836|Experimental|ETC-1002 180 mg/day + ezetimibe 10mg/day|Orally, once daily in morning
3312652|NCT01941849|Experimental|Vandetanib + 131I-mIBG|"Vandetanib (100, 200 or 300 mg once daily) in combination with 131I-mIBG radiation therapy (activity to be prescribed to deliver whole body absorbed dose of 0.5 Gy) on day 1 of each 12-weekly cycle.~Patients will receive up to 4 cycles of vandetanib in combination with 131I-mIBG."
3312653|NCT01941862|Experimental|Anxiety Risk Reduction|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
3312654|NCT01941862|Experimental|Mood Risk Reduction|The mood risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for perceived burdensomeness and thwarted belongingness. The psychoeducational component will focus on dispelling myths related to burdensomeness and belongingness and describe their role in the development of mood symptoms.
3312655|NCT01941862|Experimental|Combined Risk Reduction|The combined intervention will involve all of the interventions in the anxiety and mood risk reduction conditions and thus will not be matched for length.
3312656|NCT01941862|No Intervention|Repeated Contact Control|"Participants assigned to the repeated contact group will be assigned a personal study coordinator. The coordinator will contact them at specific intervals during the study. The rationale for these contacts will be provided (e.g., checking in on their status and helping to administer some brief measures). During the three weeks (corresponding to treatment session intervals for those in one of the active treatment conditions), the study coordinator will contact the participant once per week for a brief phone check in where suicide risk will be evaluated. Participants in the control group will also meet with their study coordinator during each of the scheduled follow-up visits."
3312657|NCT01941875|No Intervention|No Luteal Support|Control group: No luteal phase support or medication will be used
3312658|NCT01941875|Experimental|Luteal Vaginal Progesterone|Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
3312659|NCT01941888|Experimental|propofol|Patients in Group Propofol(n=70) were seated with propofol target concentration 1.2-1.6 µg/ml. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
3312660|NCT01941888|Active Comparator|midazolam|Control Group: patients in Group midazolam (n=70) were sedated with midazolam 0.04 mg/kg if aged< 70 - 0.03 mg/kg if aged> 70. Patients in both groups undergoing CS received also iv fentanyl (1μg/Kg) for pain control.
3312661|NCT01941901|Experimental|Calcium electroporation|"The metastases will be treated with intratumoral injection of calcium chlorid followed by electrotransfer.~It is a once-only treatment. Calcium chlorid concentration: 9mg/ml. Total dose: 0,5ml/cm3 tumor volume."
3312662|NCT01941901|Active Comparator|Electrochemotherapy with bleomycin|"The metastases will be treated with intratumoral injection of bleomycin followed by electrotransfer.~It is a once only treatment. bleomycin concentration: 1000 IU/ml. Total dose: o,5 ml/cm3 tumor volume."
3312663|NCT01941914|Experimental|Calcium electroporation|"The keloid will be treated with intratumoral injection of calcium chloride followed by electrotransfer. It is a once only treatment.~Calcium chlorid concentration is 9 mg/ml Total dose is 0,5ml/cm3 tumor volume."
3312664|NCT01941953|Experimental|Metformin and Flourouracil|
3312665|NCT01941966|Experimental|Chemo-radiotherapy|Capecitabine, PO, 825mg/m2 Mitomycin C, IV, 15 mg/m2 Radiotherapy - 50,4 - 54 Gy
3312666|NCT01941979|Experimental|Adjuvant therapy|"5-FU, Leucovorin and Oxaliplatine (FLOX) OR Capecitabine and Oxaliplatin (CAPOX)~NOTE: If the patient was randomized for the arm experimental, the investigator can choose between intravenous (IV) treatment or oral treatment (PO). Both are considered equal by the principal investigator."
3312667|NCT01941979|No Intervention|Observation|
3312668|NCT01941992|Experimental|SAMITAL® sachets, oral suspension|SAMITAL® sachets for oral suspension, 20 mL, four times a day.
3312669|NCT01941992|Placebo Comparator|Placebo sachets|Placebo sachets for oral suspension, 20 mL, four times a day.
3312670|NCT01942018|Experimental|EGOO|Patients presenting with symptomatic gastroesophageal junction outflow obstruction (EGOO)who will be treated with Per oral endoscopic myotomy (POEM)
3312671|NCT01942031|Experimental|structured collegial feed back|Structured feed back and information about stroke to the primary care center, to physicians and head of the center
3312672|NCT01942031|No Intervention|Control group|No structured feed back on stroke prevention. Ordinary educational activities only.
3312673|NCT01942044|Experimental|Promus element|Promus element is a thin struts, 2-link design, evelolimus-eluting stents.
3312674|NCT01942044|Active Comparator|Xience Prime|Xience Prime is a thin struts, 3-link design, evelolimus-eluting stents.
3312675|NCT01942044|Active Comparator|Nobori|Nobori is a thick struts, 2-link design, biolimus-eluting stents.
3312676|NCT01942057||School Grades 1+2|Children currently enrolled in grades 1 and 2
3312677|NCT01942057||School Grades 6+7|Children currently enrolled in grades 6 and 7
3312678|NCT01942057||School Grades 11+12|Children currently enrolled in grades 11 and 12
3312679|NCT01942070|Experimental|Bioresorbable vascular scaffold|Bioresorbable vascular scaffold (BVS)
3312680|NCT01942070|Active Comparator|Everolimus-eluting stent|Durable polymer everolimus-eluting metallic stent (EES)
3312681|NCT01942083|Experimental|OPB-111077|orally, once daily
3312682|NCT01942096||Competitive swimmers|Swimmers performing at national or international level
3312683|NCT01942096||Competitive indoor athletes|Indoor athletes performing at national or international level
3312684|NCT01942096||Healthy control individuals|Individuals performing sports at a recreational level
3312685|NCT01942109|Active Comparator|Furosemide|This group will receive furosemide as a diuretic treatment
3312686|NCT01942109|Experimental|Torasemide|This group will receive torasemide as a diuretic treatment
3312687|NCT01942122|Experimental|DLBS1442 100|DLBS1442 capsules 3x100 mg daily, taken every day along the study period
3312688|NCT01942122|Experimental|DLBS1442 200|DLBS1442 capsules 3x200 mg daily, taken every day along the study period
3312689|NCT01942122|Active Comparator|Mefenamic acid|Mefenamic acid tablets 3 x 500 mg daily, only taken for five (5) days during the menstrual period, i.e. day 1st to day 5th of menstrual period.
3312690|NCT01942174|Other|Immediate group|"For these patients, the methotrexate treatment is initiated in the same time that the antipneumococcal vaccination by Prevenar13. A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination.~Interventions : biological/vaccine and drug"
3312691|NCT01942174|Experimental|period group|"Methotrexate treatment is initiated 1 month later the first antipneumococcal vaccination by Prevenar13.~A revaccination by Pneumo23/Pneumovax is administred 2 months after the first vaccination~Interventions : biological/vaccine and drug"
3312692|NCT01942187|Active Comparator|Medication Augmentation|Medication augmentation with aripiprazole (Abilify) starting at 5mg/day, and increasing weekly in 5mg increments to a maximum of 15mg (10mg/day is the target dose). Under conditions of nonresponse after 6 weeks, aripiprazole will be switched for bupropion (Wellbutrin), starting at 150mg, and possibly increasing to 300mg after 2 weeks.
3312693|NCT01942187|Active Comparator|Problem Solving Therapy|Treatment for 12 weeks with weekly sessions of Problem Solving Therapy, with a trained therapist.
3312694|NCT01942200||Carcinoma, Oxaliplatin onkovis (Oxaliplatin)|Treatment in combination therapy for adjuvant treatment of colon carcinoma of stage III (Dukes C) after complete removal of the primary tumor, as well as for treatment of metastasizing colorectal carcinoma.
3312695|NCT01942213||Subjects receiving Ranibizumab|150 Subjects diagnosed with Neovascular Age-Related Macular Degeneration receiving Ranibizumab 0.5 mg administered by intravitreal injection.
3312696|NCT01942213||Subjects receiving Aflibercept|150 Subjects diagnosed with Age-related Macular Degeneration receiving Aflibercept 2 mg administered by intravitreal injection
3312697|NCT01942239|Active Comparator|CGM-group|CGM-group: the intervention(s) to be administered is Continuous glucose monitoring with real time glycemia each 5 minutes
3312698|NCT01942239|No Intervention|IGM-group|IGM-group: the intervention(s) to be administered is intermittent capillary glucose testing (IGM-group) associated with a blind-CGMS to detect retrospectively missed hypoglycemia
3312699|NCT01942265|Experimental|Group 4|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen on Day 21
3312700|NCT01942265|Experimental|Group 3|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3312701|NCT01942265|Experimental|Group 1|100 subjects receive 3.75mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3312702|NCT01942265|Experimental|Group 2|100 subjects receive 7.5mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 21
3312703|NCT01942265|Experimental|Group 5|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
3381591|NCT02685735|Active Comparator|Gabapentin|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
3381592|NCT02685735|Placebo Comparator|Placebo|Subjects will be randomized, stratifying for norepinephrine serotonin reuptake inhibitor (NSRI) use, to equal number to receive gabapentin or placebo pills. Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards.
3381593|NCT02680171|Experimental|Prism adaptation treatment|Prism Goggles with ten-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.
3381594|NCT02680171|Sham Comparator|Sham prism adaptation treatment|Non-Shifting Goggles (sham) will be worn by patients in the control condition. These goggles do not shift the patients visual field.
3312704|NCT01942265|Experimental|Group 9|100 subjects receive 15mcg sanofi A/H7N9 antigen on Day 0 and 21
3312705|NCT01942265|Experimental|Group 8|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 21
3312706|NCT01942265|Experimental|Group 7|100 subjects receive 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 21
3312707|NCT01942265|Experimental|Group 6|100 subjects receive 15mcg sanofi A/H7N9 antigen plus GSK AS03 adjuvant on Day 0 and 15mcg sanofi A/H7N9 antigen plus NVD MF59 adjuvant on Day 21
3312708|NCT01942265|Experimental|Group 10|100 subjects receive 45 mcg sanofi A/H7N9 antigen on Day 0 and 21
3312709|NCT01942278|No Intervention|Usual Care|Care is delivered according to baseline standard practice
3312710|NCT01942278|Experimental|BHOMA|Care is delivered according to the BHOMA intervention
3312711|NCT01942291|Experimental|Niacin/Laropiprant|Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
3312712|NCT01942291|Experimental|Niacin|Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
3312713|NCT01942304|Active Comparator|Anorganic bovine bone mineral in direct sinus augmentation|Anorganic bovine bone mineral
3312714|NCT01942304|Experimental|Alloplastic bone putty in direct sinus augmentation|Alloplastic bone putty
3312715|NCT01942317|Experimental|Balneotherapy|16 balneotherapy treatments, each of 45 minutes, twice a week, for 8 consecutive weeks
3312716|NCT01942317|No Intervention|Physiotherapy|16 physiotherapy treatments (no balneotherapy), each of 45 minutes, twice a week, for 8 consecutive weeks
3312717|NCT01942330|No Intervention|Traditional Laparoscopic-Assisted Colectomy|
3312718|NCT01942330|Experimental|Transvaginal Laparoscopic-Assisted Colectomy|Laparoscopic-Assisted Natural Orifice Surgery
3312719|NCT01942343|Active Comparator|Arm 1 : Droperidol 1,25 mg|
3312720|NCT01942343|Active Comparator|Arm 2 : Droperidol 0,625 mg|
3312721|NCT01942343|Active Comparator|Arm 3 : Odansetron 4 mg|
3312722|NCT01942356|Experimental|RL-TIVA Group|Propofol, ketamine and sufentanil administration for a TIVA (total intravenous anesthetic) will be administered using a Harvard 33 syringe pump connected via a RS 232 interface to the study computer running the RL (Reinforcement Learning) control software. This software platform will collect real time vitals and BIS valises and steer the target controlled infusion pumps and the closed loop controllers. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
3312723|NCT01942356|Active Comparator|Manual TIVA Group|Manually titrated TIVA (total intravenous anesethetic) with proposal, ketamine and sufentanil will be administered using an Alaris infusion pump titrated by the anesthesiologist based on blood pressure and heart-rate as is traditionally done and is standard of care with intravenous anesthetics. The anesthesiologist will provide interventions based on protocol for TIVA - Hypotension, TIVA - Hypertension, TIVA - Bradycardia and TIVA - Tachycardia .
3312724|NCT01942356|Active Comparator|Inhaled Sevofluorane Group|An inhaled anesthetic with Sevofluorane will be titrated between 0.8-1.5 MAC (minimum alveolar concentration) by the anesthesiologist based on heart rate and blood pressure which is standard of care for inhaled anesthetics. The anesthesiologist will provide interventions based on protocol for INH - Hypotension, INH - Hypertension, INH - Bradycardia and INH - Tachycardia .
3312725|NCT01942369||Deep Infiltrating Endometriosis (DIE)|
3312726|NCT01942382|Experimental|Treatment A|Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
3312727|NCT01942382|Experimental|Treatment B|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
3312728|NCT01942382|Experimental|Treatment C|Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
3312729|NCT01942395|Active Comparator|DASH/Sodium-Restricted Diet Intervention|Each patient will eat 3 weeks of the provided DASH/SRD diet for 21 days. The diet is patterned after the intervention in the DASH-Sodium trial (Sacks FM et al. New Engl J Med 2001;344(1):3-10). The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
3312730|NCT01942395|Active Comparator|Control Diet Intervention|Patients will consume 3 weeks of a specially prepared diet that will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study. The diet is designed, prepared, and packaged by research dietitians and all food and beverages are provided for study participants. At enrollment patients will be randomized to the DASH/SRD or Control Diet for 21 days and then cross over to the other for 21 days. Immediately following the provided DASH/SRD and Control Diet, patients will be instructed to adhere to the DASH/SRD for an additional eight weeks with dietary support.
3312731|NCT01942395|No Intervention|Healthy Control|Fifteen healthy age-matched and 10 young healthy control patients will be recruited. Age-matched healthy control subjects will undergo testing before and after 3 weeks of eating their habitual diet. Young healthy control subjects will only require 1 study visit with no dietary intervention.
3312732|NCT01942408|No Intervention|Standard care group|Patients will undergo an initial PVI procedure. Further management will be determined by AF recurrences at the responsible Consultant's discretion as per standard care.
3312733|NCT01942408|Active Comparator|Repeat study group|Following an initial PVI procedure, all patients (regardless of early AF recurrence) will undergo a repeat electrophysiology (EP) study at 8-10 weeks post-initial PVI, with repeat PVI of any PV reconnection identified
3312734|NCT01942421|Experimental|Cultivated mucosal epithelial transplant|Cultivated mucosal epithelial transplantaion to limbal deficiency patients
3312735|NCT01942447|Experimental|FMT|FMT
3312736|NCT01942447|Active Comparator|Standard|Vancomycin
3312737|NCT01942460|Experimental|Ferumoxytol|
3312738|NCT01942473|Experimental|Automated FiO2 control|Infants will be changed to a specific ventilator device approved for clinical use in neonates in Germany (Avea, Carefusion 234 GmbH Hoechberg, Germany), which is capable to automatically adjust the FiO2 based on readings of an incorporated SpO2 monitoring device. Infants will be allowed to adjust for at least 2h using the ventilator settings as chosen by the clinical team responsible. Thereafter, data will be recorded for 24h experimental time.
3312739|NCT01942473|Placebo Comparator|Manual Adjustment|Infants will be exposed to the first study phase (clinical routine or automated FiO2 adjustment) for 24 h and then will be switched to the alternate mode (automated FiO2 adjustment or clinical routine) for another 24 h.
3312740|NCT01942499|Other|Community Exercise Group|Community-based exercise program for one year
3312741|NCT01942499|No Intervention|Usual Care|
3312742|NCT01942512||ARETA|All patients with intracranial aneurysms, ruptured or unruptured, treated by endovascular treatment
3312743|NCT01942525||Intrauterine growth restriction|birth weight <10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
3312744|NCT01942525||Appropriate for gestation age|control group with birth weight >10th percentile first intervention: aEEG second intervention: assessment of neurodevelopmental follow-up
3312745|NCT01942538|Experimental|rTMS-rTMS|subjects receiving real rTMS treatment and real rTMS maintenance sessions
3312746|NCT01942538|Sham Comparator|sham - sham|subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
3312747|NCT01942538|Sham Comparator|rTMS-sham|subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
3312748|NCT01942538|Experimental|rTMS|real rTMS for 3 weeks but without clinical improvement
3312749|NCT01942538|Sham Comparator|sham|sham treatment for 3 weeks without clinical improvement
3312750|NCT01942551|Experimental|tadalafil, dutasteride|
3312751|NCT01942551|Experimental|dutasteride, tadalafil|
3312752|NCT01942564||Case Subjects|"Age 18 years or older~Had a head injury that occurred at least 6 months prior to entering study~Have found lights more bothersome since injury"
3312753|NCT01942564||Control Subjects|"Age 18 years or older~Have not had a previous head injury~Have had a full eye examination at Ohio State University College of Optometry during last 6 months."
3312754|NCT01942577|No Intervention|No treatment|
3312755|NCT01942577|Active Comparator|NoSting|
3312756|NCT01942603||Observation|
3312757|NCT01942603||Complete Lymfnode Dissection|
3312758|NCT01942616|Experimental|Condition 1|"Each study arm contains different scenarios presented to the participant.~Condition 1 is a Perpetrator Positive scenario.~The content of the Condition 1 group is as follows:~Framing: Episodic Labeling: DV label Extraneous Information: Perpetrator positive non relevant Victim/Perp Characteristic: Negative victim"
3312759|NCT01942616|Experimental|Condition 2|"Each study arm contains different scenarios presented to the participant.~Condition 2 is a Perpetrator Negative scenario.~The content of the Condition 2 group is as follows:~Framing: Thematic Labeling: Assault label Extraneous Information: Perpetrator neutral non relevant Victim/Perp Characteristic: Negative Perpetrator"
3312760|NCT01942616|Placebo Comparator|Condition 3|"Each study arm contains different scenarios presented to the participant.~The content of the Condition 3 group is as follows:~Framing: Neither Labeling: No label Extraneous Information: None Victim/Perp Characteristic: None"
3312761|NCT01942629||Lung adenocarcinoma|"This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3312762|NCT01942629||Breast adenocarcinoma|"This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3312763|NCT01942629||Pancreatic ductal adenocarcinoma|"This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.~at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
3312764|NCT01942655|Experimental|Patients with recto-colic biopsies prescribed|45 patients
3312765|NCT01942681|Other|Propiverine Hydrochloride Administration|Administration of Propiverine Hydrochloride for 12 weeks
3381595|NCT02657434|Experimental|Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed|Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
3381596|NCT02657434|Active Comparator|Arm B (Carboplatin or Cisplatin + Pemetrexed)|Participants received IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
3312766|NCT01942746|Active Comparator|Blueberry Juice|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue'). Volunteers consumed 300 mls of juice/day (247-271 mg anthocyanins (as C3G) daily) while on this intervention, for either 3 weeks (Blueberry Juice S2) or 12 weeks (Blueberry Juice L1).
3312767|NCT01942746|Active Comparator|Blueberry Capsules|Commercially prepared single strength blueberry juice which was composed of a 50:50 blend of two highbush blueberry species (Vaccinium corymbosum L. 'Rubel' and V. ashei Reade 'TifBlue')was freeze dried to a powder and encapsulated in gelatin capsules (Blueberry Capsules S2). Volunteers consumed 3 capsules/daily (7.11mg anthocyanin (as C3G eq) for 3 weeks.
3381597|NCT02646475|Experimental|Angiotensin-(1-7)|Subjects will receive intravenous infusion of three ascending doses of Angiotensin-(1-7). The doses are 4, 8, and 16 ng/kg/min. Each dose will be maintained for 10 minutes. The highest dose of Angiotensin-(1-7) will be maintained for an additional 120 minutes during the hyperinsulinemic-euglycemic clamp, for a total of 150 minutes of infusion.
3381598|NCT02646475|Placebo Comparator|Saline|Subjects will receive an intravenous infusion of saline that is matched in volume to the Angiotensin-(1-7) study day. The saline infusion will also be maintained for a total of 150 minutes.
3312768|NCT01942746|Placebo Comparator|Placebo|Volunteers consumed in S2 three placebo capsules daily for 3 weeks. In L1 volunteers consumed 300ml placebo juice for twelve weeks. Placebo products contained no anthocyanins.
3312769|NCT01942746|No Intervention|Washout (S2 and L1)|Washout periods involved no study products. Washout was 3 weeks in S2 and or 8 weeks (L1) in duration.
3312770|NCT01942759||Histologic grade|According to the modified criteria of Bloom and Richardson grading system: grade 1, 2 and 3
3312771|NCT01942759||Axillary metastasis|Group A: axillary lymph node metastasis Group B: no axillary lymphatic metastasis
3312772|NCT01942759||Modified Nottingham prognostic index|"NPI = pathological tumour size (cm) × 0.2 + lymph node stage (1, 2 or 3) + histological grade (1, 2 or 3)~The cut-off points of the index were 3.4 and 5.4 to divide patients into the good (≤3.4), moderate (3.41-5.4) and poor (>5.4) prognostic groups"
3312773|NCT01942759||Oestrogen receptor status|Negative Positive
3381602|NCT02631070|Experimental|Experimental Arm - Luspatercept (ACE-536)|Starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks
3381603|NCT02631070|Placebo Comparator|Control Arm: Placebo|Subcutaneous injection every 3 weeks
3312774|NCT01942759||Progesterone receptor status|Negative Positive
3312775|NCT01942759||HER-2 neu status|Negative Positive
3312776|NCT01942772|Experimental|experimental test of healthy subjects|wearing experiment，motion experiment
3381604|NCT02630641||Prostate cancer patients|
3381605|NCT02616185|Experimental|Dose Escalation|PF-06753512
3381606|NCT02606305|Experimental|Regimen A (Mirvetuximab soravtansine + Bevacizumab)|Mirvetuximab soravtansine + Bevacizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
3381607|NCT02606305|Experimental|Regimen B (Mirvetuximab soravtansine + Carboplatin)|Mirvetuximab soravtansine + Carboplatin administered on Day 1 of each 21-day cycle in Dose Escalation phase.
3381608|NCT02606305|Experimental|Regimen C (Mirvetuximab soravtansine + Pegylated liposomal doxorubicin)|Mirvetuximab soravtansine + Pegylated liposomal doxorubicin administered on Day 1 of each 28-day cycle in Dose Escalation Phase.
3381609|NCT02606305|Experimental|Regimen D (Mirvetuximab soravtansine + Pembrolizumab)|Mirvetuximab soravtansine + Pembrolizumab administered on Day 1 of each 21-day cycle in Dose Escalation and Dose Expansion phase.
3381610|NCT02606305|Experimental|Regimen E (Mirvetuximab soravtansine + Bevacizumab + Carboplatin)|Mirvetuximab soravtansine + Bevacizumab + Carboplatin administered on Day 1 of each 21-day cycle in Dose Expansion phase.
3381611|NCT02589938|Active Comparator|Standard Oral Hygiene|All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.
3381612|NCT02589938|Experimental|Standard Oral Hygiene + True Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The True acupuncture points will be at 3 sites on each ear, a site on the chin, on each forearm, a site on each hand, a site on each leg, and one placebo needle for a total of 14 sites. All sites will be applied for 20 minutes."
3312777|NCT01942798|Active Comparator|Cognitive Games|"The Cognitive Games group will receive 40 minute supervised group training three times per week for a period of four weeks. The group for the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely using a tablet with video conferencing capability. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~Subjects in the control group will play cognitive oriented video games using Wii Big Brain Academy Degree program. BigBrain™ is a video gaming system which has games and exercises to improve cognitive function(identify, memorize, analyze, compute, and visualize). Subjects use the Wii handheld remote to participate in the games by pointing and clicking the remote to select on-screen answers in response to on-screen questions."
3312778|NCT01942798|Experimental|WiiNWALK Intervention|"The intervention group will also receive 40 minute supervised group training three times per week for a period of four weeks. Interventions conducted over the first week will be held at the clinic, while the remaining three weeks be conducted at the subject's home and supervised by the Trainer remotely. At the end of the four-week Supervised Phase, subjects will retain the Wii units and they will be encouraged to use the program on their own for an additional period of four weeks (Unsupervised Phase).~The WiiNWALK protocol consists of performing Nintendo WiiFit activities. Subjects stand on the WiiFit balance board and interact with the WiiFit games through weight shifting or by using the Wii handheld remote control. The intervention protocol will include selected exercises consisting of: 1) Yoga 2) Balance Tasks 3) Strength training and 4) Aerobics.~At the in-clinic sessions in Vancouver, a motion-sensing device will also record video and skeleton data of the participant."
3312779|NCT01942811|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
3312780|NCT01942811|No Intervention|Control|Usual care and a health education booklet and video on cancer prevention
3312781|NCT01942824|Experimental|Intervention|Text Message
3312782|NCT01942824|No Intervention|Usual Care|
3312783|NCT01942837|Experimental|Enzalutamide|Participants will be treated with four 40 mg capsules (160 mg) once daily of enzalutamide taken orally. All participants without orchiectomy will be maintained on LHRH agonist/antagonist therapy. Participants will be evaluated clinically and with laboratory studies on day 1 of every 28 day cycle. Participants will maintain a drug diary from time of initiation of study treatment to time of discontinuation from the study (Appendix C).
3312784|NCT01942850||No Treatment|Collect pilot data on the performance of the ICARS in patients younger than 10 years of age, as well as to introduce definitions for the various clinically defined stages of AT, and attempt to develop descriptors of change that could help in the assessment of patients longitudinally.
3312785|NCT01942863|Experimental|water exchange single balloon enteroscopy|
3312786|NCT01942863|Active Comparator|CO2 insufflation single balloon enteroscopy|
3312787|NCT01942876|Experimental|Intervention|The Quit Using Drugs Intervention Trial (QUIT) experimental arm includes: screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
3312788|NCT01942876|Sham Comparator|Control|This arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
3312789|NCT01942889|Active Comparator|Antioxidant Supplementation|Vitamin antioxidant and trace elements combination that won't exceed the maximal nutritional dose recommended in France (Vit E, vit C, Selenomethionine, Zinc gluconate).
3312790|NCT01942889|Placebo Comparator|Placebo|Placebo
3312791|NCT01942902|Experimental|Continuous Glucose Monitoring System|
3312792|NCT01942915|Experimental|umbilical cord blood mononuclear cells|Umbilical Cord blood come from healthy puerpera. Erythrocyte in umbilical cord blood was separated and deleted through sedimentation. Mononuclear cells in umbilical cord blood were then isolated with a conventional method and reagent,Ficoll,by density gradient centrifugation.
3312793|NCT01942928|Active Comparator|Usual NHS care|
3312794|NCT01942928|Active Comparator|Usual NHS Care plus Osteopathic Manipulative Therapy|
3312795|NCT01942941|Experimental|geko™ electrical stimulation|Applied to stimulate peroneal nerve unilaterally
3312796|NCT01942954|Experimental|Mobile health cognitive stimulation|Experimental group
3312797|NCT01942954|No Intervention|Treatment-as-usual|This group consists of treatment-as-usual for alcohol abstinence according to the Minnesota Model.
3312798|NCT01942967||Preterm ≤ 32 weeks GA, on CPAP|Preterm infants less than 32 weeks gestational age requiring CPAP as a mode of respiratory support and admitted in the NICU.While the baby is on CPAP,tissue oxygen saturation monitoring will be started by applying NIRS(Near Infrared Spectroscopy Monitoring) sensors to the forehead and the abdomen. After 3 hours,echocardiography(including Superior Mesenteric Artery Doppler) will be done while the baby is on CPAP. Then, using the same machine, the mode of respiratory support will be changed to TrPA. After another three hours,another echocardiography will be done,then NIRS monitoring will be stopped and the mode of respiratory support will be changed back to CPAP.
3312799|NCT01942980|Other|conventional postoperative whole-brain radiation therapy|conventional postoperative whole-brain radiation therapy (40 Gy in 20 fractions of 2 Gy)
3312800|NCT01942980|Other|whole-brain radiation therapy with hippocampal avoidance|Radiation therapy with hippocampal avoidance
3312801|NCT01943006|Experimental|Hirudoid cream|"Patient treated with Hirudoid cream 0.3% Mucopolysaccharide polysulfate~Twice daily"
3312802|NCT01943006|Placebo Comparator|Placebo|"Patients treated with placebo cream without active substance~Twice daily"
3312803|NCT01943019|Experimental|Linagliptin|Linagliptin daily
3312804|NCT01943032||Primary Breast Tumor|Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
3312805|NCT01943032||Axillary Lymph Nodes.|Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
3312806|NCT01943045|Experimental|NGM282 Dose 1|NGM Dose 1
3312807|NCT01943045|Experimental|NGM282 Dose 2|NGM Dose 2
3312808|NCT01943045|Experimental|NGM282 Dose 3|NGM Dose 3
3312809|NCT01943045|Placebo Comparator|Placebo|Placebo
3312810|NCT01943058|Experimental|Arm A (megestrol acetate)|Patients receive megestrol acetate PO BID for up to 18 months in the absence of disease progression or unacceptable toxicity.
3312811|NCT01943058|Experimental|Arm B (levonorgestrel-releasing IUS)|Patients receive levonorgestrel-releasing IUS with continuous release for up to 18 months in the absence of disease progression or unacceptable toxicity.
3312812|NCT01943071|Experimental|Day care for patients with dementia|Day care for patients with dementia
3312813|NCT01943071|No Intervention|Care as usual|Care as usual
3312814|NCT01943084|Experimental|Norditropin®|
3312815|NCT01943084|Active Comparator|Genotropin®|
3312816|NCT01943123|Experimental|probiotic drink|experimental group (30 subjects) were given 50 ml of probiotic drink for 6 months on daily basis
3312817|NCT01943123|Placebo Comparator|plain, unsweetend, unflavored pasturised milk|control group/ placebo group (30 subjects) were given pasteurized milk (50 ml) for 6 months on regular basis
3312818|NCT01943136|Experimental|papaya 1% extract ointment|papaya 1% extract ointment twice a day for 1 week
3312819|NCT01943136|Active Comparator|mupirocin 2% ointment|mupirocin 2% ointment twice a day for 1 week
3312820|NCT01943162|Experimental|SMART-CPT|CPT with additional elements of cognitive rehabilitation
3312821|NCT01943162|Active Comparator|CPT|Standard Cognitive Processing Therapy
3312822|NCT01943175||Genetic High Risk|
3312823|NCT01943175||Healthy Control|
3312824|NCT01943188|Experimental|Treatment (SBRT, autologous PBMC infusion)|"SBRT: Patients undergo standard of care SBRT over 1-2 weeks according to tumor volume and location.~LYMPHODEPLETION: Beginning 3 weeks later, patients receive cyclophosphamide PO BID for 3 days.~REINFUSION OF PBMC: Within 3-14 days of completing lymphodepletion with cyclophosphamide , patients undergo autologous PBMC infusion."
3312825|NCT01943201|Experimental|new bedsheet|new bedsheet
3312826|NCT01943201|Placebo Comparator|conventional bedsheet|conventional bedsheet
3312827|NCT01943214||Type II DM body constitution|Type II diabetes mellitus, body constitution
3312828|NCT01943240|Experimental|Group A|Paravertebral peripheral nerve blockade with with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of 0.375% ropivacaine for pectoral nerve block
3312829|NCT01943240|Active Comparator|Group S|Paravertebral peripheral nerve blockade with 4 mL of 0.5% ropivacaine at each of six levels, plus 10 cc of normal saline for pectoral nerve block.
3312830|NCT01943253|Active Comparator|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
3312831|NCT01943253|Active Comparator|Hybridknife ESD|"Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)~Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)"
3312832|NCT01943266|Experimental|protein intake|protein intake randomly fed from deficient to excess
3312833|NCT01943279|Active Comparator|Standard Follow-up (SFU)|Women selecting SFU at either site (BCBC or CIHC) will schedule their in-person follow-up appointment before leaving the BCBC clinic on Study Day 1, when they receive their medication. In-person follow-up appointment will be scheduled for Study Day 15 (± 3 days)where, as per usual care, includes a history and a Post-abortion Checklist, transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
3312834|NCT01943279|Experimental|Remote Follow-up (RFU)|On Study Day 1 in both sites, women selecting RFU will receive 3 laboratory requisition forms for serum β-hCG testing and will be instructed to have testing done at a laboratory site of her choice on Study Day 10-12. The follow-up telephone appointment will be scheduled to take place on Study Day 15 (±3 days). For the follow-up telephone appointment, the research nurse/nurse practitioner will calculate the percentage fall in the β-hCG value. She will contact the subject by phone at the specified time, take a history of the timing of misoprostol use, resulting symptoms and complete the symptom Post-abortion Check-list. The research nurse/nurse practitioner, in consultation with the clinic physician if necessary, will confirm the information, determine whether other follow-up is required.
3312835|NCT01943305|Experimental|Test arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 75 subjects in the test arm will received 2 doses of inactivated Japanese Encephalitis vaccine and 1 dose of Yellow Fever vaccine.
3312836|NCT01943305|Experimental|Control arm|A total of 100 healthy adults, pre-screened to be negative for anti-dengue antibodies will be enrolled upon written informed consent. 25 subjects in the control arm will not receive Japanese Encephalitis vaccine but will receive 1 dose of Yellow Fever vaccine.
3312837|NCT01943318||Alcohol|"Alcoholic Liver Cirrhosis~Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement."
3312838|NCT01943318||Hepatitis B virus|Hepatitis B virus (HBV) Liver Cirrhosis
3312839|NCT01943318||Hepatitis C virus|Hepatitis C virus (HCV) Liver Cirrhosis
3312840|NCT01943318||Autoimmune|Autoimmune Cirrhosis
3312841|NCT01943318||Biliary|Primary or secondary biliary cirrhosis
3312842|NCT01943318||Toxic|Medication related cirrhosis
3312843|NCT01943318||Others|Hepatic venous pressure gradient (HVPG) measurement
3312844|NCT01943331||patients admitted to ICU|
3312845|NCT01943357|Experimental|Diabetes Self-Management Program|Behavioral: Diabetes Self Management Program. Consists of either a six-week small-group face-to-face program with two peer leaders or an six-week peer-facilitated Internet-based program.
3312846|NCT01943370|Experimental|Early saline irrigation|Initiation of early saline irrigation
3312847|NCT01943370|Active Comparator|Late or Routine Saline Irrigation|Routine initiation of saline irrigation
3312848|NCT01943383||Diuretic|Patients who received a diuretic drug during the parent trial are eligible for participation.
3312849|NCT01943396|Experimental|Rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. Best-corrected visual acuity, electroretinography and drusenoid retinal pigment epithelium detachment area will be examined. Changes of selected special immunologic parameters will be measured.
3312850|NCT01943396|No Intervention|without rheohemapheresis|Into the group the patients will be randomized with the same disease but without rheohemapheresis
3312851|NCT01943409|Active Comparator|Intralipid|Patients will receive Intralipid, which is the standard lipid emulsion used in the hospital
3312852|NCT01943409|Experimental|ClinOleic|Patients that are randomized to receive ClinOleic as a lipid emulsion in their PN, instead of Intralipid. ClinOleic is approved by Health Canada. The amount of calories from the lipid emulsion will be equivalent in the standard of care group and in the ClinOleic group.
3312853|NCT01943422|Experimental|Vemurafenib + IFNα-2b (10 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (10 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3312854|NCT01943422|Experimental|Vemurafenib + IFNα-2b(15 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (15 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3312855|NCT01943422|Experimental|Vemurafenib + IFNα-2b (20 MU/m2/d)|"Vemurafenib + High-dose Interferon alfa-2b (20 MU/m2/d)~IFNα-2b will be administered intravenously for 5 consecutive days (Monday through Friday) every week for 4 weeks (induction)~Vemurafenib will be dosed continuously at the standard Food and Drug Administration (FDA) approved dose of 960mg twice a day orally without dose interruption except for toxicities attributable to this agent."
3312856|NCT01943487|Experimental|1: verapamil + EC905|
3312857|NCT01943500||Cancer or no prior history of cancer|Confirmed patients with breast, prostate, or colorectal cancer (OR) subjects with no prior history of cancer
3312858|NCT01943513|Experimental|BIIB023|Participants receive intravenous (IV) infusions of BIIB023
3312859|NCT01943513|Placebo Comparator|Placebo|Participants receive intravenous (IV) infusions of placebo
3312860|NCT01943578||lung cancer patients|Non Small Cell Lung Cancer, Small Cell Lung Cancer
3312861|NCT01943604|Experimental|Experimental|"Nutella Breakfast~Waffle Breakfast"
3312862|NCT01943617|Active Comparator|Entecavir Therapy|Entecavir, 0.5mg, qd, oral, for 2 years
3312863|NCT01943617|Experimental|Entecavir plus thymosin therapy|Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
3312864|NCT01943630|Active Comparator|AS101|Topical 15% AS101 gel, once a day (overnight)
3312865|NCT01943630|Placebo Comparator|Vehicle|Vehicle, Once a day topical application (Overnight)
3312866|NCT01943643|Experimental|CT angiography, coronary bifurcations|
3312867|NCT01943656|Experimental|Tobii™ Eyegaze System|Single arm, open label study.
3312868|NCT01943669|Experimental|ReWalk™ device|Self-controlled group; single cohort.
3312869|NCT01943682|Experimental|CPX-351|CPX-351 is made up of two chemotherapy drugs that patients may have already received called cytarabine and daunorubicin that are now packaged together. Subjects will receive a single course of CPX-351 administered on Days 1, 3, and 5.
3312870|NCT01943708|Active Comparator|Continuous positive airway pressure (CPAP) device.|Standard CPAP therapy
3312871|NCT01943708|Experimental|Auto-CPAP device (SPAP).|Novel Auto-CPAP algorithm
3312872|NCT01943721|Experimental|VISION5 Product|VISION5 Product in both eyes
3312873|NCT01943734|Experimental|Lifestyle counseling|Information passed on anthropometric assessment
3312874|NCT01943760|Active Comparator|tramadol wound infiltration|2 mg / kg of tramadol diluted in 5 ml of 0.9% saline solution wound infiltration 20ml of 0.9% saline solution intravenously
3312875|NCT01943760|Experimental|tramadol intravenous administration|2 mg / kg of tramadol diluted 20ml of 0.9% saline solution intravenously 5 ml of 0.9% saline solution wound infiltration
3312876|NCT01943773|Experimental|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions. Sessions will occur three times weekly at the patient's home.
3312877|NCT01943773|Experimental|No Prehabilitation|The control group will undergo routine pre-operative management.
3312878|NCT01943786||FOLFIRI + Cetuximab|Patients with advanced colorectal cancer and wild-type KRAS will receive FOLFIRI + Cetuximab according to regular clinical practice
3312879|NCT01943812|Experimental|Substituted FET cycle and GnRHa|Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg
3312880|NCT01943812|Active Comparator|Substituted FET cycle|substituted FET cycle Estradiol Progesterone
3312881|NCT01943838|Experimental|SAR245408 polymorph E tablets|Escalating doses of SAR245408 polymorph E tablets, once daily dosing with morning meal every day for two 28-days cycles
3312882|NCT01943877|Experimental|Propolis|
3312883|NCT01943877|Sham Comparator|scaling and root planing|
3312884|NCT01943890|Experimental|Physiotherapy and hypertonic saline|Chest physiotherapy integrated with inhalation of hypertonic saline
3312885|NCT01943903||Cohort 1 - Standard of Care|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of each subject considered for percutaneous coronary intervention (PCI) and/or coronary artery bypass grafting (CABG), the investigator and the institution's heart team will review clinical data and results of the diagnostic tests to recommend a treatment strategy, according to the institution's standard practice. Cohort 1 of the study is an observational evaluation of resource utilization and outcomes based on standard practice for diagnosis and treatment of subjects with symptomatic suspected CAD and intermediate likelihood of obstructive CAD. Subjects will be followed for one year after enrollment.
3312886|NCT01943903||Cohort 2 - FFRCT-guided|Subjects will be referred for non-invasive and/or invasive testing and evaluation. Prior to treatment of subjects considered for PCI and/or CABG, the investigator and the institution's heart team will review the results of all available diagnostic tests, including cCTA and FFRCT, and will recommend a treatment strategy accordingly. FFRCT is a non-invasive method to evaluate the hemodynamic significance of coronary artery lesions. FFRCT calculates FFR from subject-specific cCTA data using computational fluid dynamics under rest and simulated maximal coronary hyperemic conditions. FFRCT values range between 0 and 1, and values ≤0.80 are considered hemodynamically (HD)-significant.
3312887|NCT01943942|Experimental|A (reference)/ B (test)|initial administration of reference and cross-over to test
3312888|NCT01943942|Experimental|B (test)/ A (reference)|initial administration of test and cross-over to reference
3312889|NCT01943955|Experimental|home-based computer gaming|computer gaming, balance exercises carried out at home for 20 minutes 5 days/week and monitored by a physical therapist.
3312890|NCT01943968|Other|Systemic sclerosis patients|Systemic sclerosis patients will have blood tested for fibrotic enzyme levels
3312891|NCT01943981||Optimal/inappropriate exercise response|
3312892|NCT01943994|Experimental|Psilocybin-assisted treatment|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a high dose of psilocybin (30mg / 70kg) to be administered on the Target Quit Date in week 5.
3312893|NCT01943994|Active Comparator|Nicotine Replacement Therapy (NRT)|Participants will receive a 13-week cognitive behavioral intervention for smoking cessation, with a standard 8 to 10-week regimen of NRT to be administered beginning on the Target Quit Date in week 5. NRT for this study will be a transdermal nicotine patch administered according to recommended label usage (For individuals who smoke more than 10 cigarettes per day: 21mg daily weeks 1-6, 14mg daily weeks 7-8, 7mg daily weeks 9-10. For individuals who smoke 10 or less cigarettes per day: 14mg daily for weeks 1-6, 7mg daily for weeks 7-8).
3312894|NCT01944007|Experimental|CLP 15 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3312895|NCT01944007|Experimental|CLP 25 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3312896|NCT01944007|Experimental|CLP 7.5 g Fed|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d just before each of 4 standardized meals/snack
3312897|NCT01944007|Experimental|CLP 15 g fasted|Cross-Linked Polyelectrolyte (CLP) Study medication delivered q.i.d 1 hour prior to 4 standardized meals/snack
3312898|NCT01944020|Experimental|CPAP|Active CPAP will be a therapeutic dose of positive airway pressure each night for 2 months
3312899|NCT01944020|No Intervention|Control|Control will be no use of CPAP for 2 months
3312900|NCT01944033|Active Comparator|Group Terbutaline|Group Terbutaline received 5 mg Terbutaline sulfate (2ml) and 3ml serum saline in nebulization repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
3312901|NCT01944033|Experimental|Group Terbutaline/IB|Group Terbutaline/Ipratropium Bromide received combination of 5 mg Terbutaline (2ml) and 0.5 mg Ipratropium bromide (2ml) and 1ml serum saline in nebulization repeated threeand every 4 hours during the first 24 hour protocol
3312902|NCT01944072|Other|60%|aerobic exercise training intensity of 60%Wmax
3312903|NCT01944072|Other|80%|aerobic exercise training intensity of 80%Wmax
3312904|NCT01944085|Active Comparator|Acetaminophen|Acetaminophen was administered 1 hour prior to pin removal (weight dependent dose)
3312905|NCT01944085|Active Comparator|Ibuprofen|Ibuprofen was administered 1 hour prior to pin removal (weight dependent dose)
3312906|NCT01944085|Placebo Comparator|Vitamin C (Placebo)|Vitamin C was administered 1 hour prior to pin removal (weight dependent dose)
3312907|NCT01944111|Experimental|Plication|Prospective clinical trial comparing Standard Adustable Gastric Banding versus experimental Adjustable Gastric Banding
3312908|NCT01944124|Experimental|Exercise Prescription + Mobile Health|Received a tailored exercise prescription and mobile health technology kit to track blood pressure, blood glucose, physical activity and body weight.
3312909|NCT01944124|Active Comparator|Exercise Prescription|Received a tailored exercise prescription only.
3312910|NCT01944137|No Intervention|Standard Care|Participant will receive standard cancer care
3312911|NCT01944137|Experimental|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy
3312912|NCT01944150|Active Comparator|TENS|Patients with only transcutaneous electrical nerve stimulation (TENS),
3312913|NCT01944150|Experimental|TENS and hypnosis.|Patients with transcutaneous electrical nerve stimulation (TENS) and hypnosis simultaneously
3312914|NCT01944163|No Intervention|Usual care|GP provide care as usual to their CLBP patients.
3312915|NCT01944163|Other|Referral arm|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
3312916|NCT01944176|Experimental|Simvastatin|simvastatin 20 mg/d is randomized to treat COPD patients for 4 weeks
3312917|NCT01944176|Placebo Comparator|B1-6-12|B1-6-12 one tablet a day is randomized to give to COPD patients for 4 weeks
3312918|NCT01944189|Experimental|Food Supplement|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
3312919|NCT01944189|Experimental|Food Supplement Arm|"Population PK Study will enroll 70 children receiving standard AL dose at 0, 8, 24, 36, 48, 60 hour with recommended milk or maize porridge plus oil. Both foods contain sufficient fat therefore will contribute to pool evaluations as a single cohort.~A subset, 48 children will have participated in nested comparative bio-availability study as follows Standard arm children receiving single dose with milk (12) Standard arm children receiving double dose with milk (12) Experimental arm children receiving single dose with maize porridge plus oil (12) Experimental arm children receiving double dose with maize porridge plus oil (12) The rest, 22 children will have participated exclusively in PPK, receiving appropriate single or double dose with milk similar to those in standard arm"
3312920|NCT01944202|Experimental|Educational Intervention|"Physicians in the intervention arm receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes the Appropriate Use Criteria (AUC) for echocardiography and highlights common clinical scenarios for which outpatient TTEs are ordered, 2) an electronic pocket card via email that provides tips on appropriate ordering of TTEs, and 3) an individualized monthly feedback report that categorized TTEs ordered over the preceding month. The feedback reports contains the number of TTEs ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
3381613|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|"All patients will receive standard oral hygiene patient teaching information that includes instructions regarding mouth rinses, use of lip balms, use of mild fluoride toothpaste, the importance of adequate oral hydration, and other standard advice. Each participating site determines the standard oral hygiene recommendations used at their site.~The Sham acupuncture points will be given according to the same schedule as the active acupuncture points, except the Sham needles will be placed below, above or between true active points."
3312921|NCT01944202|No Intervention|Control group|Physicians in the control arm have their TTE orders tracked and classified, but do not receive any feedback on their ordering behavior.
3312922|NCT01944215|Active Comparator|Arm 4 - Fast vs Fast + External Heating|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will receive the usual Mayo gown for breast imaging. A skin temperature sensor will be taped to the anterior of one breast and skin temperature will be recorded. The subject will be asked to sit for 15 minutes in the waiting room prior to injection of the Tc-99m sestamibi. Just prior to injection, skin temperature will be recorded again. After completion of the first study the subject will then be given a warm towel robe and a small heating pad to be placed over the chest area. After 30 minutes, skin temperature will be recorded again immediately prior to injection of the second dose of Tc-99m sestamibi. The second MBI study will then be performed.
3312923|NCT01944215|Active Comparator|Arm 3 - Fasting vs. Fasting + Caffeine|MBI will be performed in 52 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. The subject will then be instructed to consume 200 mg caffeine in tablet form. This is equivalent to the caffeine content of an 8 oz brewed coffee from Starbucks. After 45 minutes after consumption of the caffeine tablet, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3312924|NCT01944215|Active Comparator|Arm 2-Resting vs. Exercising|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be asked to perform moderate exercise on a treadmill for 6-10 minutes at a level of 70%-80% of maximum predicted heart rate. At ~10 minutes, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3312925|NCT01944215|Active Comparator|Arm 1-Fasting vs. Fed|MBI will be performed in 25 subjects after an overnight fast with 4-6 mCi Tc-99m sestamibi. Patients will then be instructed to consume 8-16 fluid oz of Ensure (350-700 calories). At 30 minutes after consumption of the meal, patients will receive a second injection of 4-6 mCi Tc-99m sestamibi and a repeat MBI study will be performed.
3312926|NCT01944228|Experimental|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
3312927|NCT01944228|Sham Comparator|Sham stimulation|Catheter placed in the IJV without stimulation
3312928|NCT01944241||Women with cervical surgery|The cases will include women who have had cervical surgery, either LLETZ or cone biopsy
3312929|NCT01944241||women with no surgery|controls will be women who have attended colposcopy but who have not had surgery.
3312930|NCT01944254|Active Comparator|random to respiration|Cardiac output measurement at random to respiration
3312931|NCT01944254|Experimental|timed with expiration start|Cardiac output measurement synchronised at start of expiration.
3312932|NCT01944254|Experimental|timed to instructed exhalation|Cardiac output measurement timed to instructed exhalation. The patient will receive instructions to exhale slowly using a peak expiratory flow (PEF)-flute and the cardiac output measurement will be started (i.e bolus given) at the start of expiration.
3312933|NCT01944267|Active Comparator|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
3312934|NCT01944267|Active Comparator|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
3312935|NCT01944267|Active Comparator|Apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
3312936|NCT01944280|Experimental|intervention|The intervention group will receive a 20 minute massage during each hemodialysis treatment for 2 weeks. Most patients receive dialysis 3 times per week resulting in 6 massage sessions. The massage will include both feet and legs up to and including the knee. Massage will include general light centripetal friction and point compression to bellies and myotendinous junction of muscles of the foot and calf not to exceed a perceived pain of 6 on a scale of 1 to 10, 10 being most severe and 1 being no pain.
3312937|NCT01944280|No Intervention|control|usual care
3312938|NCT01944306||Low birth-weight, obese|
3312939|NCT01944306||Low birth-weight, normal body weight|
3312940|NCT01944306||Normal birth-weight, obese|
3312941|NCT01944306||Normal birth-weight, normal body weight|
3312942|NCT01944332|Experimental|gamete treatment- oocytes and sperm|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The injected oocytes will be then exposed to the previously mentioned activating agents for the purpose of inducing embryo development. The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI.
3312943|NCT01944358||Taiwan AIDS study group|
3312944|NCT01944384|Experimental|aldactone|aldactone 25 mg for 6 months
3312945|NCT01944384|No Intervention|without aldactone|
3312946|NCT01944397||Atrial fibrillation|Patients with a diagnosis of atrial fibrillation recorded in primary or secondary care during the study period.
3312947|NCT01944410|Experimental|traumatic bone cyst|Patients with traumatic bone cyst defect are injected with PRP
3312948|NCT01944436||Parkinson's Disease Dementia|"Participants in the Parkinson's Disease Dementia group:~Must be taking a stable parkinsonian medication~Must have a diagnosis of clinically definite Parkinson's disease >1 year prior to cognitive deficit with at least two of the following symptoms: asymmetric resting tremor, rigidity or bradykinesia, and definite motor response to dopaminergic agents.~Response to cholinesterase inhibitor over a period of six months will be monitored."
3312949|NCT01944436||Dementia with Lewy Bodies|"Participants in the Dementia with Lewy Bodies group:~Diagnosis of clinically probable or possible Dementia with Lewy bodies with at least 1 of the following: Marked fluctuations in cognition, visual hallucinations or spontaneous parkinsonism.~Response to cholinesterase inhibitor over a period of six months will be monitored."
3312950|NCT01944449|Experimental|Whey Protein (WPC) at breakfast|The subjects in Whey Protein (WPC) group will consume WPC (35gr) powder in bottles mixed with 250 ml milk, making a total of 42 g protein, at breakfast, for 12 weeks.
3312951|NCT01944449|Experimental|Other Protein Sources at breakfast|The subjects will consume also 42 g protein at breakfast but from different source, for 12 weeks.
3312952|NCT01944449|Active Comparator|Low Protein at breakfast|The subjects will consume 17 g protein breakfast namely from soy for 12 weeks.
3312953|NCT01944488|Experimental|GnRH intervention|All participating subjects are assigned to receive an intravenous GnRH agonist injection.
3312954|NCT01944501|Active Comparator|Transcranial Magnetic Stimulation|Patients receiving real transcranial magnetic stimulation
3312955|NCT01944501|Placebo Comparator|Sham TMS|Patients receiving sham transcranial magnetic stimulation
3312956|NCT01944501|Active Comparator|Transcranial Direct Current Stimulation|Patients receiving real transcranial direct current stimulation
3312957|NCT01944501|Placebo Comparator|Sham TDCS|Patients receiving sham transcranial direct current stimulation
3312958|NCT01944514||Ischaemic cardiomyopathy group|Patients with ischaemic cardiomyopathy attending for ICD implantation / Ventricular tachycardia stimulation testing as part of ICD risk stratification
3312959|NCT01944514||Non-ischaemic cohort|Patients attending for ICD implantation / ventricular tachycardia stimulation test who do not have ischaemic cardiomyopathy.
3312960|NCT01944514||Control group|Patients attending for electrophysiological study with no conditions that place them at risk of sudden cardiac death.
3312961|NCT01944540|Active Comparator|conventional ESD|Conventional ESD arm indicates the group in which conventional ESD method is applied for the dissection of colorectal neoplasm.
3312962|NCT01944540|Experimental|Optimized ESD with snaring|Optimized ESD with snaring arm indicates the group in which optimized ESD with snaring method is applied for the dissection of colorectal neoplasm.
3312963|NCT01944553|Experimental|prospective|Single Arm
3312964|NCT01944579|Experimental|Control-Blackberry|Participants will receive a controlled diet with the control food (jello) first and then cross over to the controlled diet with blackberries.
3312965|NCT01944579|Experimental|Blackberry-Control|Participants will receive a controlled diet with blackberries first and then cross over to the controlled diet with the control food (jello).
3312966|NCT01944592|Experimental|Gynaecology Training Associates (GTA's)|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination with GTA's
3312967|NCT01944592|Active Comparator|Manikin training|Final year (Year 5) medical undergraduates embarking upon their O&G clinical placement trained in pelvic examination on manikins.
3312968|NCT01944605||Cardiac Arrest patients undergoing Therapeutic Hypothermia|Cardiac Arrest subjects with Return Of Spontaneous Circulation (ROSC) and undergoing treatment with Therapeutic Hypothermia will undergo sampling of blood, stool, and expired gas data at physiologically predetermined time points.
3312969|NCT01944618||T2DM patients newly prescribed Forxiga|A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.
3312970|NCT01944657|Active Comparator|Standard Medication Monotherapy Group|A group of 15 patients will receive only standard antidepressant medication treatment.
3312971|NCT01944657|Active Comparator|Supplemental TMS plus Medication Group|A group of 15 patients will receive supplemental transcranial magnetic stimulation (TMS) plus standard antidepressant medication.
3312972|NCT01944683|Experimental|GGF2|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
3312973|NCT01944683|Placebo Comparator|Placebo|"Patients will be randomized to receive GGF2 or Placebo and on study day 3 administered a single IV infusion.~Each patient will receive 5 oral doses of Midazolam syrup on study day 1 and days 4 through 7 respectively."
3312974|NCT01944696|Active Comparator|continuous (uninterrupted) phototherapy|standard phototherapy
3312975|NCT01944696|Experimental|15 minute per hour cycled phototherapy|15 minute per hour cycled phototherapy
3312976|NCT01944735|Experimental|Active|Once daily oral capsule containing 50 or 100 mg of CTX-4430
3312977|NCT01944735|Placebo Comparator|Placebo|Once daily oral capsule containing mannitol, visibly identical to CTX-4430 capsules
3312978|NCT01944748|Experimental|Family Mediation|Families receive FARS family mediation program after completing baseline survey.
3312979|NCT01944748|No Intervention|Wait-list control|Families receive FARS family mediation program after completing baseline, 6-week and 12-week surveys.
3312980|NCT01944761|Experimental|Immediate Group|The 15 patients in this group will be randomized to start the 12 week exercise intervention without delay (immediate condition).
3312981|NCT01944761|Experimental|Delayed Intervention|The 15 patients in this group will be randomized to start the intervention after the first group has completed the exercise intervention (delayed condition)
3312982|NCT01944787|Active Comparator|Routine|IV Hydration at 125 cc hour
3312983|NCT01944787|Experimental|Intervention|IV Hydration at 250 cc hour
3312984|NCT01944800|Experimental|Ticagrelor|
3312985|NCT01944800|Active Comparator|Prasugrel|
3312986|NCT01944813|Experimental|Intervention: ACP conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
3312987|NCT01944813|No Intervention|No intervention: usual care|No intervention just usual care
3312988|NCT01944826||Tako-Tsubo And Cancer Registry|
3312989|NCT01944852|Experimental|2 icodextrin bags/day|2 icodextrin bags + 1 glucose per day
3312990|NCT01944852|Active Comparator|1 icodextrin bag/day|1 icodextrin bag + 2 glucose bags per day
3312991|NCT01944865|Experimental|Interval Training|The INTV consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, and in the last 30 s of each repetition was performed a maximal sprint, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
3312992|NCT01944865|Experimental|Intermittent Training|The riders completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery (10-15 on the CR100 scale).
3312993|NCT01944904|Placebo Comparator|Sugar Pill|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
3312994|NCT01944904|Active Comparator|XOS 2.8|Subjects will be asked to take the dietary supplement daily for 8 weeks. Blood samples will be taken at screen, baseline and week 8. An oral glucose tolerance test will be taken at baseline and week 8. Additionally subjects will be asked to collect their stool samples at Baseline, week 4, and 8. Subjects will also undergo a test to determine their body composition at baseline and week 8. Subjects will be asked to keep a diary of their bowel habits and any symptoms that might be related to the supplement. Subjects will be asked to recall the foods that they have eaten in the past 24 hours and to avoid any foods that contain XOS and probiotic bacteria during the study.
3312995|NCT01944917||Chronic musculoskeletal pain|Chronic musculoskeletal pain - treated with electromagnetic field Chronic musculoskeletal pain - placebo
3312996|NCT01944943|Experimental|Vismodegib|Vismodegib 150 mg will be administrated orally at a dosage of 150 mg (1 capsule) once a day during 12 months.
3312997|NCT01944982|Experimental|Activated natural killer cells|Activated natural killer cells
3312998|NCT01944995|Experimental|group B|
3312999|NCT01944995|Experimental|group A|
3313000|NCT01945008||Hepatitis-C infected patients|Patients with Hepatitis-C infection untreated at the enrolment
3313001|NCT01945021|Experimental|Crizotinib|Single-arm trial whereby all consented, enrolled, eligible patients receive crizotinib
3313002|NCT01945047|Experimental|Ketamine|During Phase 1 patients will be randomly assigned to receive ketamine or active placebo.
3313003|NCT01945047|Active Comparator|Midazolam|In phase 1 patients will be randomized to receive active placebo
3313004|NCT01945060|Experimental|heart rate Control to Range System (hrCTR) using DiAs Platform|The Diabetes Assistant (DiAs) Control-to-Range system is notified of heart rate during exercise. The study team member will activate and deactivate a heart rate button when the subject's heart rate exceeds and then returns below 140 beats per minute.
3313005|NCT01945060|Placebo Comparator|DiAs Control-to-Range System not informed for heart rate|Using the DiAs Platform, the Control-to-Range system is not notified of the heart rate during exercise. Heart rate not of interest in this arm.
3313006|NCT01945073|No Intervention|Control (RC)|Routine clinical care with no intervention
3313007|NCT01945073|Experimental|Educational Booklet (BK)|Routine clinical care and educational booklet (BK) given
3313008|NCT01945073|Experimental|Educational Booklet and Counselling (CB)|Routine clinical care, aided by formal counselling and active discussions from the educational booklet (CB)
3313009|NCT01945099|Active Comparator|ePID closed loop system without hyaluronidase|Hyaluronidase will not be given while subject uses ePID closed loop system
3313010|NCT01945099|Experimental|ePID closed loop system with hyaluronidase at infusion site|Hyaluronidase will be injected at insulin pump infusion site prior to the time that subject uses ePID closed loop system
3313011|NCT01945099|Experimental|ePID closed loop system with hyaluronidase co-formulation|Hyaluronidase-insulin co-formulation will be used in study pump while subject uses ePID closed loop system
3313012|NCT01945125|No Intervention|THW Group|Patients under THW stimulation for RIT
3313013|NCT01945125|Other|rhTSH Group|Patients under rhTSH stimulation for RIT
3313014|NCT01945151|Experimental|Group 1 (G1) NMES is applied in the spastic antagonist muscle|The parameters considered for the application of NMES are: frequency of 50Hz, the wavelength of 350m / s, 10 seconds of contraction of 20 seconds of rest to total 15 minutes. During the application of NMES patients will be positioned supine on the bed with knees flexed semi supported on roller positioning. The G1 apply NMES on the motor point of the tibialis anterior and triceps surae lengthening held along with the contraction (reciprocal inhibition).
3313015|NCT01945177|No Intervention|white light endoscopy|white light endoscopy
3313016|NCT01945177|Active Comparator|narrow band imaging|narrow band imaging
3313017|NCT01945190|Experimental|True before sham electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
3313018|NCT01945190|Experimental|Sham before true electroacupuncture|Crossover design, individuals randomized to receive either true or sham acupuncture in first study day, and on the second study day whichever intervention was not administered on the first study day.
3313019|NCT01945203||PD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years."
3313020|NCT01945229||Hyperthyroid patients|Patients with hyperthyroidism admitted for treatment with radioiodine or antithyroid drugs
3313021|NCT01945255||HD-ABI|"Patients at National Taiwan University Hospital (NTUH)~Patients who have received PD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
3313022|NCT01945268|Experimental|influenza vaccine|Participants at high risk for adverse vascular events will be immunized with 0.5 ml dose of inactivated trivalent influenza vaccine
3313023|NCT01945268|Placebo Comparator|placebo vaccination|Participants at high risk for adverse vascular events will be immunized with a 0.5 ml dose of sterile saline inactivated during the influenza season.
3313024|NCT01945307||Healthy adults|Healthy adults aged 18 to 70 years
3313025|NCT01945320||HD-BCM|"Patients at National Taiwan University Hospital~Patients who have received HD more than 3 months~Patients who sign the informed consents~Patients who aged between 20-90 years"
3313026|NCT01945333|Active Comparator|Brain Basics for Impaired Tone Matchers|Cognitive remediation includes sensory processing training
3313027|NCT01945333|Active Comparator|Brain Basics for Intact Tone Matchers|Cognitive remediation includes sensory processing training
3313028|NCT01945333|Active Comparator|Brain Training for Impaired Tone Matcher|Cognitive remediation does not include sensory processing training
3313029|NCT01945333|Active Comparator|Brain Training for Intact Tone Matchers|Cognitive remediation does not include sensory processing training
3313030|NCT01945346|Experimental|PRX167700|
3313031|NCT01945346|Placebo Comparator|Placebo|
3313032|NCT01945359||Relapsing Remitting MS (RRMS)|
3313033|NCT01945372|Experimental|EEG NeuroFeedback - real feedback|Thw women in the experimental group will receive accurate realtime feedback corresponding to their performance on the task.
3313034|NCT01945372|Sham Comparator|EEG NeuroFeedback - sham feedback|The women in the sham group will receive neural feedback from another person in the study, thus unrelated to their mental practice
3313035|NCT01945385|Experimental|Video intervention|Participants will view a seven - minute theory-based video of patient testimonials about their own postabortal LARC uptake.
3313036|NCT01945385|No Intervention|Control|Patients will view a 7 minute video about stress management delivered by local psychologist.
3313037|NCT01945398|Experimental|Inspiratory Muscle Training (IMT)|Patients from the inspiratory muscle training group will utilize a linear pressoric resistance equipment with an inspiratory charge of 30% of maximum inspiratory pressure (adjusted weekly), during 7 days of the week, session duration of 30 minutes, during 8 weeks.
3313038|NCT01945398|Placebo Comparator|Sham IMT|Patients in the placebo group will be submitted to inspiratory muscle training with the same equipment as the intervention group, however without a resistance generating spring.
3313039|NCT01945411|Experimental|Experimental|the length between incisor and mandible angle
3313040|NCT01945411|Active Comparator|Active comparator|the length between mouth corner-mandible angle
3313041|NCT01945424||Pregnancy Cases|Pregnant women exposed to Sanofi Pasteur's Quadrivalent Influenza Vaccine (QIV)
3313042|NCT01945437|Placebo Comparator|Control|Control group receive same volume of normal saline as in the magnesium group
3313043|NCT01945437|Experimental|magnesium|This group receive magnesium sulfate perioperatively.
3313044|NCT01945450|Active Comparator|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
3313045|NCT01945450|No Intervention|No treatment|No antibiotics
3313046|NCT01945476|Experimental|midazolam|midazolam group
3313047|NCT01945476|Active Comparator|normal saline|control group
3313048|NCT01945502||nasal packing with dry packs|
3313049|NCT01945502||nasal packing with wet packs|
3313050|NCT01945502||nasal packing with Benzidamin-Clorhexsidin damped packs|
3313051|NCT01945502||no nasal packing|
3313052|NCT01945515|Experimental|Robot + anodal tDCS|Robotic-assisted gait training for 45 min after anodal tDCS on impaired motor cortex for 20 min
3313053|NCT01945515|Sham Comparator|Robot + sham tDCS|Robotic-assisted gait training for 45 min after sham tDCS on impaired motor cortex for 20 min
3313054|NCT01945528|Experimental|US-guided tenotomy with PRP|ultrasound guided percutaneous tenotomy with PRP injection each alternate week for a total of two interventions
3313055|NCT01945528|Active Comparator|US-guided tenotomy with lidocaine|ultrasound-guided percutaneous needle tenotomy with lidocaine injection each alternate week for a total of two interventions
3313056|NCT01945541|No Intervention|standard fluid management|postoperative BMC measurements
3313057|NCT01945541|Active Comparator|body composition monitoring preoperative|pre and postoperative BCM measurements
3313058|NCT01945554|Experimental|Cervical disc herniation|Patients with cervical disc herniation and compression of nerve roots C3-C8.
3313059|NCT01945554|Experimental|Lumbar disc herniation|Patients with lumbar disc herniation and compression of nerve roots L1-S1.
3313060|NCT01945567|Experimental|Dorsal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
3313061|NCT01945567|Experimental|Caudal zona incerta|Up to 3 mA, 60 us, 130 Hz deep brain stimulation
3313062|NCT01945567|Experimental|Empirical deep brain stimulation|Empirical unblinded deep brain stimulation programming using any posterior subthalamic area electrode contact(s) and stimulation parameters to optimise clinical outcome.
3313063|NCT01945606|Experimental|Placebo and BAY1067197|Patients will get both treatment 1 and 2
3313064|NCT01945632|No Intervention|no treatment|Control group with no treatment.
3313065|NCT01945632|Experimental|root planing (gracey curettes)|treatment with root planing using conventional gracey curettes
3313066|NCT01945632|Experimental|Vertically oscillating ultrasonic device|Treatment done with vertically oscillating ultrasonic device
3313067|NCT01945632|Experimental|Device: piezoelectric ultrasonic scraper|Treatment using a piezoelectric ultrasonic scraper
3313068|NCT01945645|Experimental|Intervention|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
3313069|NCT01945684|Experimental|Botulinum toxin type A (DWP450)|DWP450: Botulinum toxin type A
3313070|NCT01945684|Active Comparator|Botulinum toxin type A (Botox®)|Botox®: Botulinum toxin type A
3313071|NCT01945697||normal oral mucosa|
3313072|NCT01945697||oral precancerous lesion or oral cancer|
3313073|NCT01945723||Healthy volunteers|Healthy volunteers
3313074|NCT01945736||Cohort 1|> or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.
3313075|NCT01945736||Cohort 2|2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
3313076|NCT01945736||Cohort 3|6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.
3313077|NCT01945749|Experimental|Intraarticular steroid + Exercise|Intra-articular corticosteroid treatment with subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
3313078|NCT01945749|Active Comparator|Intraarticular saline+Exercise|Combined intra-articular saline injection and subsequent exercise therapy. Exercise therapy is commenced 2 weeks after injection
3313079|NCT01945762||1. patient cohorts (40 patients/cohort)|RET positive patient cohorts
3313080|NCT01945762||2. patient cohorts (40 patients/cohort)|RET negative patient cohorts
3313081|NCT01945788|Active Comparator|Teriparatide Forteo|20 micrograms/day plus calcium and vitamin D
3313082|NCT01945788|Experimental|Teriparatide Osteofortil|20 micrograms/day plus calcium and vitamin D
3313083|NCT01945801|Active Comparator|Lasilactone|Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
3313084|NCT01945801|Placebo Comparator|placebo pill|One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
3313085|NCT01945801|Active Comparator|Sodium-Restricted Diet|The diet group will receive a regimen with a prescribed intake of three grams of sodium per day
3313086|NCT01945814|Experimental|CTL for CMV seropositive donors|CTL for CMV seropositive donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors- three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
3313087|NCT01945814|Experimental|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)for CMV naïve donors-each group will undergo an identical dose escalation. Three different dose levels are selected, starting with 5 x 106 (a T cell number more than an order of magnitude lower than that administered at the time of an unmanipulated marrow infusion), followed by 1 x 107 and a final dose 2 x 107 mCTLs/m2. Two additional doses (at the same level)will be administered 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.
3313088|NCT01945827||DeltaMaxx treated Patients|
3313089|NCT01945840|Active Comparator|Roux en Y Gastric Bypass|Participants will be those already scheduled to undergo Roux en Y Gastric Bypass Surgery
3313090|NCT01945840|Experimental|Gut hormone infusion|"Infusion of three gut hormones (GLP-1, PYY and oxyntomodulin) subcutaneously for 4 weeks as below:~Combination of GLP-1/OXM/PYY (GOP)~Single GLP-1~Single OXM~Single PYY~Combination of GLP-1 and OXM~Combination of GLP-1 and PYY~Combination of OXM and PYY"
3313091|NCT01945840|Placebo Comparator|Placebo infusion|Saline infusion given subcutaneously for 4 weeks.
3313092|NCT01945840|Active Comparator|Very low calorie diet|Participants will be asked to follow a very low calorie diet for 4 weeks.
3313093|NCT01945853|Experimental|7 Tesla MRI|7T MRI will be done on ALS patients at baseline and at 6 month intervals.
3313094|NCT01945879|Experimental|GFFC + LMWH|gemcitabine/ 5-flourouracil/folinic acid/ cisplatin as chemotherapeutic treatment plus enoxaparine as experimental addition
3313095|NCT01945892||Irvine Gass Syndrome|"Patients older than 18 years who develop macula edema secondary to cataract surgery.~Group may receive intravitreal Ozurdex medication in case of persistent macular edema."
3313096|NCT01945905|Experimental|Extramural|Extramural medication delivery and supervision
3313097|NCT01945905|Active Comparator|Intramural|Intramural medication delivery and supervision
3313098|NCT01945918|Active Comparator|Self-management support education|Project staff will meet onsite with practice clinicians for a two-hour session to discuss what self-management support (SMS) is, why it is important, how primary care plays a role in this process, how others have approached it, and how it can be time and cost efficient for them to engage in SMS as part of standard diabetes care. Practices will have access to a website displaying general and local SMS resources. Discussion of the implementation of these resources into the practice will be facilitated. Two additional academic detailing visits will be made to check on progress on SMS adoption, provide additional information as needed, and answer questions. No input will be provided regarding how unique practice characteristics might be utilized for more effective implementation of SMS, and CTH will not be introduced.
3313099|NCT01945918|Active Comparator|Connection to Health Interactive Behavior Change Technology|Connection to Health (CTH) Arm: The number and length of staff visits to these practices will be the same as for the SMS Education Arm, but the content of the visits will center on the implementation and use of the CTH program as a way to implement SMS. Clinicians and selected staff members will be given hands-on experience using the system and will be provided with scenarios that will highlight the effective use of CTH as a tool for diabetes SMS. The practices will then implement CTH, using protocols selected from several suggested by the research team. Additional technical assistance with implementing CTH will also be provided as needed.
3313100|NCT01945918|Experimental|Connection to Health plus Coaching|"Connection to Health plus Coaching (CTH+C) Arm: This arm adds practice coaching as described above to CTH. The active coaching phase focuses on meetings of the practice improvement team, scheduled every other week for approximately 40 minutes each. The improvement team will consist of 6 - 10 diverse representatives of the practice (e.g., front office, medical assistants, physicians). The coach will assist the team in developing a CTH adoption plan and then help them break it down into small bites for rapid cycle change using the Plan-Do-Study-Act quality improvement (QI) model. Active coaching will last for 3 months, followed by monthly calls by the coach to review data regarding the practice's use of CTH and brief booster coaching to deal with problems."
3313101|NCT01945931|Experimental|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The safe delivery smartphone application will be introduced to health workers in the intervention clusters.
3313102|NCT01945931|No Intervention|Control|Health workers in the control clusters will not have access to the Safe Delivery App
3313103|NCT01945957|Experimental|OT (24 IU)|Phase I Aim 1a. (fMRI) Will determine the effect of oxytocin dose (24 IU) on neural activation and connectivity compared to placebo. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin in an eye-tracking task (social vs. non-social image).
3313104|NCT01945957|Experimental|OT (8 IU and 40IU)|Each phase will require a separate subject consent. Phase II Aim 2a. (fMRI) Will determine the effect of oxytocin dose (8 or 40 IU) on neural activation and connectivity. Aim 1 b (eye-tracking) will occur on a separate visit from fMRI scanning and will also assess response to oxytocin (8 or 40 IU) in an eye-tracking task (social vs. non-social image).
3313105|NCT01945983|Active Comparator|Early norepinephrine|Norepinephrine 4 mg in 5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour, adjusted according to patient's body weight to achieve norepinephrine 0.05microgram/kg/min Continuous drip for 48 hours.
3313106|NCT01945983|Placebo Comparator|Placebo|5% dextrose water 250 ml Intravenous infusion rate range from 8 to 15 ml/hour. Adjust rate of infusion according to patient's body weight to achieve dosage of norepinephrine comparable to 0.05 microgram/kg/min Continuous drip for 48 hours.
3313107|NCT01946009|Experimental|Cidofovir 1%|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
3313108|NCT01946022|Active Comparator|GnRH Agonist|GnRH long agonist protocol of invitro fertilization
3313109|NCT01946022|Active Comparator|GnRH Antagonist|GnRH fixed antagonist protocol of in vitro fertilization
3313110|NCT01946035|Placebo Comparator|Placebo|Participants will take 1 capsule placebo each evening
3313111|NCT01946035|Experimental|Doxazosin XL|Participants will take 1 capsule Doxazosin 4mg XL each evening
3313112|NCT01946048|Experimental|mesenchymal stem cells|Stem cells implantation Patients with severe coronary artery disease with ischemic cardiomyopathy managed with intramyocardial administration of allogeneic mesenchymal stem cells.
3313113|NCT01946061|Experimental|Treatment group|
3313114|NCT01946074|Experimental|Monotherapy|ABT-165 will be administered at escalating dose levels in 28-day dosing cycles (2 doses per cycle). Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-165
3313115|NCT01946074|Experimental|Cohort A|ABT-165 plus paclitaxel
3313116|NCT01946074|Experimental|Cohort B|ABT-165 plus FOLFIRI
3313117|NCT01946074|Experimental|Cohort C|ABT-165 plus ABBV-181
3313118|NCT01946074|Experimental|Cohort D|ABT-165 plus ABBV-181 plus paclitaxel
3313119|NCT01946087|Experimental|RIPC group|
3313120|NCT01946087|Placebo Comparator|Control group|
3313122|NCT01946113||Retrospektive Cohort|Patients requiring renal replacement therapy from 2011 to 2012 on intensive care unit
3313123|NCT01946113||Prospektive Cohort|Patients requiring renal replacement on intensive care unit in 2013 and 2014
3313124|NCT01946139|Experimental|Screening (HSIL detection)|Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months.
3313125|NCT01946217||Observational (questionnaire administration)|Participants complete the IMPACTS survey comprising questions about socio-demographic information and clinical trial participation.
3313126|NCT01946256|Active Comparator|Amoxicillin|Amoxicillin 500mg three times in a day for 1 week
3313127|NCT01946256|Placebo Comparator|Erythromycin|Erythromycin 500mg four times in a day for 1 week
3313128|NCT01946269|Active Comparator|Standard group|
3313129|NCT01946269|Active Comparator|Goal-directed therapy (GDT) protocol|
3313130|NCT01946295|Experimental|Famotidine|Famotidine 100mg x 2 orally
3313131|NCT01946295|Placebo Comparator|Placebo|Placebo control
3313132|NCT01946308|Experimental|conformational positioner & mattress|conformational positioner & mattress, five hours on each
3313133|NCT01946321|Other|Post-amputation functional rehab|Patients will continue with their rehabilitation programme, as specified by their clinical team, following amputation. A series of functional outcome measures will be carried out at 3 or 4 time points during the first 3 months following delivery of their artificial limb.
3313134|NCT01946334|Experimental|patients|
3313135|NCT01946347|Experimental|Patients with type 2 diabetes|30 individuals with type 2 diabetes Intervention: mixed meal, acute in vivo induced hyperinsulinemia
3313136|NCT01946347|Active Comparator|Healthy subjects|30 healthy men and women with no metabolic syndrome Intervention: mixed meal, acute in vivo induced hyperinsulinemia
3313137|NCT01946360|No Intervention|ACLF and Acute Liver Failure (ALF)..|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
3313138|NCT01946373|Experimental|Chemotherapy + T cells + IL-2|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
3313139|NCT01946373|Experimental|Chemotherapy + T cells + IL-2 + DCV|Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses. After completion of the IL-2 treatment 3-5 doses of weekly intradermal vaccinations with up to 1.5 x 10^7 Dendritic cells pulsed with autologous tumor lysate and NY-ESO-1 peptide.
3313140|NCT01946386|Experimental|LEO 90100|
3313141|NCT01946399|Other|Ozurdex implant|Intravitreal injection of Ozurdex implant
3313142|NCT01946451||Idiophatic ERMs|
3313143|NCT01946451||Secondary ERMs|
3313144|NCT01946464||undergoing surgery with general anesthesia|pts: edentulous, bearded, obstructive sleep apnea, Mallampati Class III or IV
3313145|NCT01946464||Mallampati I and II|Control group Mallampati I visualization of tonsils, uvula and soft palate Mallampati II visualization of hard and soft palate, and upper portion of tonsils and uvula.
3313146|NCT01946477|Experimental|Pomalidomide + dexamethasone|Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
3313147|NCT01946477|Experimental|Pomalidomide + Dexamethasone + Daratumumab|"Each subject enrolled in the study will take oral pomalidomide (4 mg) once daily on Days 1-21 and dexamethasone 40 mg/day (< 75 years old) or 20 mg/ day (>75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle and daratumumab administered intravenously (IV) at a starting dose of 16 mg/kg at following schedule:~Days 1, 8, 15, and 22 of a 28-day cycle for Cycle 1 and Cycle 2~Days 1 and 15 for Cycle 3 through Cycle 6~Day 1 for Cycle 7 and each cycle thereafter until disease progression"
3313148|NCT01946490||Radiotherapy in 2001|
3313149|NCT01946490||Radiotherapy in 2004|
3313150|NCT01946490||Radiotherapy in 2006|
3313151|NCT01946490||Radiotherapy in 2010|
3313152|NCT01946503||Short bowel syndrome|Patients followed in a clinic for short bowel syndrome
3313153|NCT01946503||Healthy controls|Patients seen in a general pediatric clinic without chronic or acute diseases
3313154|NCT01946555||Worst pain, Average pain|"It is necessary that patients are treated for their baseline pain with opioid medications 3rd step (WHO guidelines), having seven different provisions molecules (morphine, methadone, fentanyl, buprenorphine, oxycodone, hydromorphone and tapentadol), and that they receive opioid rescue medication, based on free choice among the options available on the market (in the form of transmucosal fentanyl: OTFC - lollipop, buccal buccal tablets, sublingual tablets, nasal spray in aqueous solution, with pectin nasal spray, morphine or other opioid oral immediate release or intravenously)."
3313155|NCT01946568|Experimental|Single dose Dalbavancin|
3313156|NCT01946581||Cataract Surgery|
3313157|NCT01946594|Active Comparator|Acetaminophen Arm|"Acetaminophen Suspension 160 mg / 5 mL:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
3313158|NCT01946594|Placebo Comparator|Placebo Arm|"Placebo Suspension:~Oral dose immediately following IIV and every 4-6 hours up to 24 hours (Maximum 5 oral doses)"
3313159|NCT01946607|Active Comparator|Citalopram|20 mg citalopram capsule, 1/ day, after breakfast (approximately 8am), for 7 days
3313160|NCT01946607|Placebo Comparator|Placebo|Placebo capsule 1/ day, after breakfast (approximately 8am), for 7 days
3313161|NCT01946620|Experimental|Flutiform 250/10 micrograms|Flutiform 250/10 µg (2 puffs twice daily)
3313162|NCT01946620|Experimental|Flutiform 125/5 micrograms|Flutiform 125/5 µg (2 puffs twice daily)
3313163|NCT01946620|Active Comparator|Formoterol 12 micrograms|Formoterol 12 µg 1 puff twice daily
3313164|NCT01946633|Experimental|Esophagogastroduodenoscopy（ECG）|n=15
3313165|NCT01946646|Experimental|S-1-CCRT|There are five dose levels and one arm only. Level 1: S-1, 25 mg/m2, bid, Day 1-14; RT 25 Gy/10 fx, Day 1-5, 8-12 Level 2: S-1, 25 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 3: S-1, 30 mg/m2, bid, Day 1-14; RT 30 Gy/10 fx, Day 1-5, 8-12 Level 4: S-1, 30 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 Level 5: S-1, 35 mg/m2, bid, Day 1-16; RT 36 Gy/12 fx, Day 1-5, 8-12, 15-16 All dose levels are followed by Gemcitabine/S-1 (G 1000 mg/m2, iv, D1 and 15 plus S-1 60/80/100 mg/day based on BSA, po, D1-7, D15-21, q4w) after the CCRT
3313166|NCT01946659|Experimental|Adherence to Sleep Apnea Treatment|The intervention arm of the study receives tailored education regarding Sleep Apnea by the study health educator via telephone.
3313167|NCT01946659|Other|Standard Care Group|The standard care group gets the standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine.
3313168|NCT01946672|Experimental|isotopic intraoperative detection|Lower-limb drainage isotopic intraoperative detection
3313169|NCT01946698||Fertility patients|Women with endometriosis compared to women without endometriosis. Different samples will be collected (blood, follicular fluid, cells from the uterus)
3313170|NCT01946711|Experimental|Buparid; Treatment A|Buparid 1 mg budesonide/2 ml nebuliser solution
3313171|NCT01946711|Active Comparator|Budes; Treatment B|Budes® Nasal Spray 50 µg budesonide/pump
3313172|NCT01946737|Active Comparator|Invasive coronary angiography (ICA)|Routine diagnostic ICA
3313173|NCT01946737|Experimental|HD-CTCA with ASIR|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)within 4 weeks of routine diagnostic ICA
3313174|NCT01946750|Experimental|Case|Hospitalized patient with clinical signs of Clostridium Difficile Infection and specific detection in stools of Clostridium Difficile toxins
3313175|NCT01946750|Other|Non-diarrheal control|Hospitalized patient and asymptomatic carrier of Clostridium Difficile
3313176|NCT01946763|No Intervention|safety of Anesthesia|No pre operative education
3313177|NCT01946763|Experimental|Behavioral : pre operative education|Behavioral pre operative education
3313178|NCT01946776|Other|Reveal XT|People with drug-resistant epilepsy whose heart rhythm will be monitored continuously for 2 years using Reveal XT, an implantable heart rate monitor.
3313179|NCT01946789|Experimental|ALT-803|
3313180|NCT01946815|Experimental|Atorvastatin|Atorvastatin (Lipitor) will be prescribed with 20mg,40mg,or 80mg by the unit of 28 tablets upon the result of lipid profile. Besides Clinical and lab test, follow-up CAG, IVUS(optional) and FFR will be performed in 12 months.
3313181|NCT01946828|Experimental|FIM|safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use
3313182|NCT01946841|Experimental|RealDiet®Renal enteral nutrition|
3313183|NCT01946854|Other|Observation Arm|Patients observed for 6 months, then will receive chemotherapy for 6 months.
3313184|NCT01946854|Active Comparator|Chemotherapy Group|Patients receive chemotherapy for 6 months, then observed for 6 months. The exact type of fluoropyrimidine-based chemotherapy is not mandated and final treatment decisions will be left to the medical oncologist who is administering the chemotherapy. All chemotherapy adjustments will be done by the treating medical oncologist according to standard of care.
3313185|NCT01946867|Experimental|NBTXR3 IntraTumoral injection (IT)|Single intratumor injection
3313186|NCT01946893|Experimental|Mindfulness Meditation|One session per week for 6 weeks online through study iPAD. The intervention is a standardized and structured program. The objectives are to: 1) help participants understand their personal reactions to stress, 2) teach them skills to modify their stress reactions, and 3) promote their desire for self-care and feelings of competence and mastery.
3313187|NCT01946893|Active Comparator|Education|Education sessions- 1 session per week for 6 weeks on study iPAD.
3313188|NCT01946906|No Intervention|No treatment|patient receive no active treatment
3313189|NCT01946906|Experimental|Rifaximin|Patient takes Rifaximin 550mg twice daily for 14 days
3313190|NCT01946919||cinepazide|Inpatient using the cinepazide in department of neurology
3313191|NCT01946932|Active Comparator|Cardiac Arrest 33°|survivors with temperature treatment 33°
3313192|NCT01946932|Active Comparator|Cardiac Arrest survivors 36°|survivors with temperature treatment 36°
3313193|NCT01946945|No Intervention|Control - Standard ART treatment|
3313194|NCT01946945|Experimental|Test - PGS|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5,/6. Embryos will be vitrified. Patients will have a single hatching euploid blastocyst (*) replaced on a thawed cycle.
3313195|NCT01946958|Experimental|Trained in Primary Care (PC) Triple P|This group received standardized training in Primary Care (PC) Triple P.
3313196|NCT01946958|Experimental|Care as Usal|This group provided care as usual. This group was not trained in PC Triple P interventions.
3313197|NCT01946971|Experimental|PL|Placebo once a day orally for 7 days, then lansoprazole 1mg/kg once a day orally for 7 days
3313198|NCT01946971|Experimental|LP|Lansoprazole 1mg/kg orally once a day for 7 days, then placebo orally once a day for 7 days
3313199|NCT01946984|Active Comparator|Diclofenac,75 mg, 3 ml,|patients were given Diclofenac IM before ERCP.
3313200|NCT01946984|Placebo Comparator|Normal Saline, 3ml, IM|patients were given normal saline 3 ml before ERCP
3313201|NCT01946997||Group 1: Non Diabetic|Normal retina
3313202|NCT01946997||Group 2: Diabetes with no retinopathy|Diabetic patients without diabetic retinopathy
3313203|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine|Vaccination with PPV23 or Vaccination with PCV 13
3313204|NCT01947010|Active Comparator|Crohn's patients treated with Azathioprine and TNFa inhibitors|Vaccination with PPV23 or Vaccination with PCV 13
3313205|NCT01947010|Active Comparator|Crohn's disease patients without treatment|Vaccination with PPV23 or Vaccination with PCV 13
3313206|NCT01947023|Experimental|Treatment (lapatinib, dabrafenib)|"Patients receive dabrafenib* PO BID on days 1-28 and lapatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.~NOTE: *Patients also receive dabrafenib PO for 2 weeks prior to beginning treatment with lapatinib."
3313207|NCT01947036||Healthy Subjects|Healthy adult controls (no auto-immune disease)
3313208|NCT01947036||Subjects with Crohn's Disease|Diagnosed with or suspected of having Crohn's disease (CD)
3313209|NCT01947036||Subjects with Rheumatoid Arthritis|Diagnosed with or suspected of having rheumatoid arthritis (RA)
3313210|NCT01947036||Subjects with Type 1 diabetes|Diagnosed with or suspected of having type 1 diabetes mellitus (T1D, T1DM)
3313211|NCT01947036||Subjects with Multiple Sclerosis (MS)|Diagnosed with or suspected of having MS
3313212|NCT01947036||Subjects with Psoriasis|Diagnosed with or suspected of having psoriasis (Ps)
3381617|NCT02557139|Experimental|Regimen A|Single-dose belumosudil 200 mg tablet in the fasted state
3381618|NCT02557139|Experimental|Regimen B|Single-dose belumosudil 200 mg tablet in the fed state
3381619|NCT02557139|Experimental|Regimen C|Single-dose belumosudil capsules (administered as two 100-mg capsules) in the fed state
3381620|NCT02547337||Type 1 diabetes|
3381621|NCT02547337||Healthy subjects|
3313213|NCT01947049|No Intervention|Control Arm|Participants in this arm will receive usual care (influenza testing and treatment)
3313214|NCT01947049|Experimental|Rapid Testing|Participants in this arm will receive rapid influenza testing with Xpert Flu.
3313215|NCT01947062|Active Comparator|Standard intravenous chemotherapy|Patients will receive standard intravenous chemotherapy based on cisplatin and etoposide.
3381622|NCT02513667|Experimental|ALK-inhibitor naive patients|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
3381623|NCT02513667|Experimental|Patients recieved prior ALK inhibitor|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR (Stereotactic ablative body radiation). They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination). The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months. At Follow-Up treatment, patients will be contacted every 3 months for 9 months.
3381624|NCT02513329|Active Comparator|Bupivicaine|Stellate Ganglion Block injection with bupivacaine
3381625|NCT02513329|Sham Comparator|Saline|Saline injection
3381626|NCT02510417|Experimental|VSTs against three viruses|Patients will receive 2 x 107 partially HLA-matched VSTs/m2 as a single infusion. In the rare case where insufficient banked cell product is available, a lower number of cells may be infused after discussion with the principal investigator, patient and/or guardian and the treatment team. If participants have a partial response (as defined by a 50% fall in viral load) they are eligible to receive up to 4 additional doses from day 28 after the initial infusion and at 2 weekly intervals thereafter.
3381627|NCT02486042|Active Comparator|Standard of Care (Standard Nutrition)|Infants in this group will receive standard lipids (predominantly Omega-6 fatty acids).
3381628|NCT02486042|Experimental|Omegaven|Infants in this group will receive lipid supplementation with omega-3 fatty acids.
3313216|NCT01947062|Experimental|Intravenous with metronomic chemotherapy|Patients will receive both intravenous (cisplatin and etoposide based) and metronomic chemotherapy (with oral cyclophosphamide).
3313217|NCT01947075||Adults with fever|Every adult with fever will be screened for different infectious diseases and for nasopharyngeal respiratory viruses and bacteria
3313218|NCT01947075||Healthy volonteers|For every adult with fever included with a diagnosis of pneumonia, a healthy volunteer will be included. These healthy volunteers will be screened for nasopharyngeal respiratory viruses and bacteria.
3313219|NCT01947088|Experimental|Music Therapy Arm|Music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.) Pre-study and post-study scores from the neuropsychological assessments will be compared to determine if music therapy has a significant effect on the child's cognitive recovery. Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for music therapy (treatment group) for about 45 minutes, twice per week, for Weeks 1-8. CThe Music Therapy group will partake in interventions such as singing and playing musical instruments.
3313220|NCT01947088|Active Comparator|Unstructured Play Arm|Child life programs provide children with opportunities to engage in normal play and recreational activities that promote growth, development and feelings of success and fulfillment.All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). This is the standard of care for all brain surgery patients. The results of this assessment and will be used in this research study. In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
3313221|NCT01947101|Experimental|Ulcerative Colitis|Fecal Microbiota Transplant
3313222|NCT01947114|Active Comparator|Group Propofol|
3313223|NCT01947114|Active Comparator|Group Ketamine|
3313224|NCT01947140|Experimental|Phase I: Schedule A|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle
3313225|NCT01947140|Experimental|Phase I: Schedule B|Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle
3313226|NCT01947140|Experimental|Phase II|Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle
3313227|NCT01947179|No Intervention|Physical Health Training|The Physical Health Training condition will include information on the importance and benefits of a healthy lifestyle. Additionally, the program will discuss guidelines for a healthy lifestyle including information on diet, water consumption, exercise, and sleep.
3313228|NCT01947179|Experimental|Anxiety Risk Reduction|The anxiety risk reduction intervention will include psychoeducation focused on the nature of stress and its effect on the body. Interoceptive exposure exercises that were designed to correct the conditioned fear of bodily sensations will be explained and practiced.
3313229|NCT01947192|Experimental|Chlorhexidine|Dentin pre-treatment with a experimental solution (chlorhexidine), after the dentin acid etching
3313230|NCT01947192|Placebo Comparator|Water|Application of water (placebo) after dentin acid etching.
3313231|NCT01947205|Active Comparator|paracetamol|Duration
3313232|NCT01947205|Active Comparator|without drug|Control group
3313233|NCT01947205|Active Comparator|dexketoprofen trometamol|Study group
3313234|NCT01947205|Active Comparator|two puff xylocain administration on cervical surface|Study group
3313235|NCT01947205|Active Comparator|paracervical block with ultracaine|study group
3313236|NCT01947218|Experimental|smoking COPD|
3313237|NCT01947218|Experimental|smoking without COPD|
3313238|NCT01947218|Other|No Smoking Control|
3313239|NCT01947218|Experimental|severe asthma|
3313240|NCT01947231|Experimental|Global Postural Re-education|Global Postural Re-education is delivered in a single treatment session each week for nine weeks.
3313241|NCT01947231|Active Comparator|Standard manual physical therapy|Standard manual physical therapy is delivered in a single treatment session each week for 9 weeks.
3313242|NCT01947244|Experimental|Doula Home Visiting|Participants assigned to the intervention group receive prenatal and short-term postpartum home visitation from doulas, and support from doulas at the hospital during labor, delivery, and with early breastfeeding. Additionally, these participants receive longer-term home visiting services from family support workers during pregnancy and after the birth.
3313243|NCT01947244|Active Comparator|Case Management|Mothers in the comparison group receive low intensity case management services during pregnancy and following the birth.
3313244|NCT01947257|Other|ventilated patients|
3313245|NCT01947270||Control group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is not implemented in the medical department. Drug prescriptions are conducted under usual care in the department.
3313246|NCT01947270||Intervention group|Patients of this group are hospitalized in a time frame where the multidisciplinary intervention program is implemented in the medical department.
3313247|NCT01947296||"Group  coordinated care"|"Patient living in place covered by cancer network participating to the study is in the group coordinated care"
3313248|NCT01947296||"Group  usual care "|"Patient living in place covered by cancer network non participating to the study or without cancer network is in the group usual care"
3313249|NCT01947309||Multiple Myeloma Patients Treated with Revlimid (lenalidomide)|Single Cohort of Multiple Myeloma Patients Treated with Revlimid
3313250|NCT01947322|Experimental|Allogenic NK cells infusion|
3313251|NCT01947348|Experimental|treatment with A3 SVF|These patients that have been treated. The control patients that have not been treated.
3313252|NCT01947374|Experimental|Chondrocyte implantation|From a previous biopsy, articular cartilage matrix is digested and chondrocytes are cultured in 2 passages until implants with at least 6,000,000 cells are constructed. These constructus of 8 mm in diameter are implanted arthroscopically by means of biodegradable anchor (MINILOK QUICKANCHOR TM from DePuy-Mitek ) located at the defect and tied securely.
3313253|NCT01947374|Experimental|Microfractures|Subchondral bone perforations that allow a clot to be formed, and subsequent scar at the cartilage defect area.
3313254|NCT01947387||Integra|
3313255|NCT01947387||Integra + NPWT (short-inpatient use only)|
3313256|NCT01947387||Integra + NPWT (long-all other durations)|
3313257|NCT01947387||Integra + STSG|
3313258|NCT01947387||Integra + Dermoinductive Agent|
3313259|NCT01947387||Free Flap|
3313260|NCT01947387||Local Tissue Flap|
3313261|NCT01947387||NPWT|
3313262|NCT01947387||NPWT then Integra (on same admission)|
3313263|NCT01947400||Hospitalists|AIDET Training
3313264|NCT01947413|Experimental|iTBS group|In intermittent theta burst stimulation (iTBS group), they received iTBS (80% of active motor threshold) on affected hemisphere.
3313265|NCT01947413|Experimental|cTBS group|In continuous theta burst stimulation (cTBS group), they received cTBS (80% of active motor threshold) on unaffected hemisphere.
3313266|NCT01947413|Sham Comparator|sham TBS group|In sham theta burst stimulation (sham TBS group), they received sham TBS stimulation.
3313267|NCT01947426|Experimental|DHA supplementation|mother consuming 400 mg/day of DHA and tehir neonates
3313268|NCT01947426|Placebo Comparator|Control (milk without DHA)|Mothers comsuming placebo and their neonates
3313269|NCT01947439|Experimental|Biolimus A9 eluting stent|biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.
3313270|NCT01947439|Active Comparator|Zotarolimus-eluting stent|zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.
3313271|NCT01947452|Experimental|Jobs Only|Youth will be offered a 5-hour per day, 5-day per week employment opportunity over 7 weeks. They will be paid the Illinois minimum wage of $8.25 per hour.
3313272|NCT01947452|Experimental|Jobs plus Social-Emotional Learning|Youth will be offered a 3-hour per day, 5-day per week employment opportunity over 7 weeks. They will also be offered 2-hour per day, 5-day per week social-emotional learning programming, for which they will be paid the same hourly wage as their job ($8.25/hour).
3313273|NCT01947465||Healthy controls|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 319 healthy controls will be enrolled and will receive hepatitis A and/or tetanus vaccination
3313274|NCT01947465||Patients with rheumatoid arthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with rheumatoid arthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3313275|NCT01947465||Patients with axial spondylarthritis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with axial spondylarthritis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3313276|NCT01947465||Patients with vasculitis|If a vaccination is indicated according to the recommendations by the Swiss Federal Office of Public Health: 142 patients with vasculitis will be enrolled and will receive hepatitis A and/or tetanus vaccination.
3313277|NCT01947478|Experimental|MDT-2113 Drug-Eluting Balloon|Paclitaxel drug-eluting angioplasty balloon
3313278|NCT01947478|Active Comparator|Standard angioplasty balloon|Standard PTA balloon without Paclitaxel drug-elution
3313279|NCT01947504|Experimental|education and support intervention|education and support intervention
3313280|NCT01947504|No Intervention|waiting list|waiting list and regular medical follow-up
3313281|NCT01947530|Active Comparator|Navigational Bronch/Standard Bronch|Patient will have first the Navigational Bronchoscopy then the standard bronchoscopy completed.
3313282|NCT01947530|Active Comparator|Standard Bronch/Navigational Bronch|Patient will first have a standard bronchoscopy then a navigational bronchoscopy completed.
3313283|NCT01947543||Ventricular tachycardia|Patients with ventricular tachycardia of unknown origin treated with an ICD.
3313284|NCT01947543||Family members|Family members (parents, siblings and children) for patients with results showing mutations in the calmodulin genes.
3313285|NCT01947556|Other|insujet is tested first|first procedure: experiment with the investigational product (Insujet pen)containing insulin aspart; second procedure: control device (conventional Novopen III insulin pen) contains insulin aspart.
3313286|NCT01947556|Other|insujet is tested second|first procedure: experiment with the conventional Novopen III insulin pen containing insulin aspart; second procedure: investigational device (Insujet) contains insulin aspart.
3313287|NCT01947569|Experimental|iDC recipients|iDC cells modified by in vitro engineering.
3313288|NCT01947569|Active Comparator|Control DC recipients|DC cells which have not been modified.
3313289|NCT01947569|Placebo Comparator|Placebo recipients|Saline injections.
3313290|NCT01947595|Active Comparator|high risk non-responder, intensified lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
3313291|NCT01947595|Active Comparator|hight risk non responder, normal lifestyle intervention|"high risk non-responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~A+B or A+C or B+C or A+B+C"
3313292|NCT01947595|Active Comparator|Responder, normal lifestyle intervention|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
3313293|NCT01947595|Active Comparator|Responder, single lifestyle advice (control group)|"Responder:~A) reduced Insulin secretion (disposition index: (IGI * ISI-Matsuda)< 760)~B) insulin resistance (ISI-Matsuda < 9,2)~C) elevated liver fat ( MRT > 5,56%)~No A, only B or C"
3313294|NCT01947634|Experimental|ResMed Apnea Link plus|Overnight respiratory polygraphy is performed in Fabry patients
3313295|NCT01947660|Experimental|Continuous regional anesthesia|
3313296|NCT01947660|Active Comparator|Systemic analgesia|
3313297|NCT01947673|Experimental|Modified Mindfulness Based Stress Reduction (MBSR) Program|After individual instruction, participants in this arm will perform meditation by following a series of mindfulness meditation (MM) recordings during hemodialysis for the next 4 to 8 weeks.The MM instructor will also meet with the participants weekly to provide continued instruction. Participants will also be encouraged to perform MM using a digital audio (MP3) player at home on non-dialysis days, and asked to keep a log of these sessions.
3313298|NCT01947673|Placebo Comparator|Health Education|Participants randomized to the control condition will undergo a 4 to 8 week health education series, with a parallel protocol as the MBSR intervention. Monitoring of adherence will be same as above.
3313299|NCT01947686||Patellofemoral Knee Arthroplasty|Patient who have received a robotically guided isolated patellofemoral implant.
3313300|NCT01947699|Experimental|Glyburide once daily|Timing of glyburide dosing will be changed, glucose will be monitored using continuous a glucose monitor.
3313301|NCT01947699|Experimental|Glyburide twice daily|Dose interval and timing of glyburide dose will be changed, glucose will be monitored using continuous a glucose monitor.
3313302|NCT01947699|Experimental|Mixed meal tolerance test.|Subjects will be admitted to the Clinical Translational Research Center, receive a Mixed meal tolerance test and have timed blood draws to assess the effect of glyburide on glucose and insulin metabolism.
3313303|NCT01947712|Placebo Comparator|milk chocolate|dosage form: orally given dosage:40 g milk chocolate (≤35% cocoa) frequency and duration: 40 g/day for one month
3313304|NCT01947712|Active Comparator|dark chocolate|dosage form: orally given dosage:40 g dark chocolate (≥85% cocoa) frequency and duration: 40 g/day for one month
3313305|NCT01947738|Experimental|VBY-891|VBY-891
3313306|NCT01947738|Placebo Comparator|Placebo|Capsules containing excipient but no active drug
3313307|NCT01947751|Active Comparator|CVC exchange|The CVC will be removed immediately.
3313308|NCT01947751|Experimental|CVC maintenance|The CVC will be maintained, and exchanged only if confirmed catheter-related infection or worsening of sepsis
3313309|NCT01947764|No Intervention|Usual Care|"The Usual Care components for the control clinics will include the following:~All clinicians (pediatricians, medical officers, clinical officers, and nurses) caring for children undergo the existing 3-day disclosure training~Chart materials to guide and document disclosure counseling and visits~The presence of the AMPATH SOP mandating disclosure to children ages 10 and older.~In Usual Care clinics, no specific personnel will be dedicated to disclosure."
3313310|NCT01947764|Experimental|HADITHI Intervention|"In addition to the Usual Care components, the HADITHI Intervention clinics will include:~Modified materials to guide disclosure sessions~Videotaped narratives for parental counseling~Dedicated disclosure counselors to initiate and conduct the disclosure process~Post-disclosure support groups for children~The disclosure counselors will avail themselves for conducting disclosure with any families referred to them by the AMPATH clinicians. They will post fliers that describe their services for parents and caregivers so that families can self-refer for disclosure counseling. Similarly, the post-disclosure support groups for children will be available for anyone enrolled in the clinic and families will be able to self-refer or to be referred by the clinicians."
3313311|NCT01947790|Experimental|Pioglitazone group|Pioglitazone 15 mg/day will be given in this group for 9 months
3313312|NCT01947790|Active Comparator|Metformin group|Metformin 0.85 twice daily will be given in this group for 9 months as control.
3313313|NCT01947803|Experimental|Paliperidone Palmitate|
3313314|NCT01947829||Chronic Hemodialysis|
3313315|NCT01947842|Experimental|Smartphone App|The pharmacist will download and configure the Dosecast smartphone application to remind the patient to take their medication in addition to pharmacist counseling on the importance of adherence.
3313316|NCT01947842|No Intervention|Counseling Alone|This arm will receive only counseling from the pharmacist with no other intervention.
3313317|NCT01947881||Patients with DME|Patients with DME who need treatment with anti-VEGF injections of Lucentis.
3313318|NCT01947920|Experimental|1: Tramadol HCl 200 mg daily or placebo|Participants will receive one capsule of Tramadol hydrochloride (HCl) every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3313319|NCT01947920|Experimental|2: Tramadol HCl 400 mg daily or placebo|Participants will recieve two capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3313320|NCT01947920|Experimental|3: Tramadol HCl 600 mg daily or placebo|Participants will receive three capsules of Tramadol HCl every 6 hours. Participants assigned to placebo will receive matching placebo capsules. A total of 9 doses will be administered.
3313321|NCT01947933|Placebo Comparator|Placebo IV|Participants with psoriasis will receive a single dose of placebo matching mirikizumab intravenously (IV)
3313322|NCT01947933|Experimental|Mirikizumab IV|Participants with psoriasis will receive a single escalating dose of 5 milligram (mg), 20 mg, 60 mg, 120 mg, 200 mg, 350 mg, or 600 mg mirikizumab, IV
3313323|NCT01947933|Experimental|Mirikizumab SC|Healthy participants will receive a single dose of 120 mg mirikizumab subcutaneously (SC).
3313324|NCT01947959||Rivaroxaban|Patients who have been prescribed Rivaroxaban for the first time
3313325|NCT01947959||Standard of care|Patients who have been prescribed Standard of care for the first time
3313326|NCT01947972|Other|protein intake of 4g/kg/d|Tailored protein fortification and nutritional status of preterm neonate. 4.5g protein per kg for preterms with body weight less than 1000g and 4g protein per kg for preterms with body weight more than 1000g, after human milk analysis. Intervention regards protein supplementation to fulfil the exact protein needs of preterms
3313327|NCT01947985||Rivaroxoban|Patients who have been prescribed Rivaroxaban for the first time
3313328|NCT01947985||Standard of care|Patients who have been prescribed standard of care for the first time
3313329|NCT01947998||Rivaroxaban / Cohort 1|Patients who have been prescribed Rivaroxaban for the first time
3313330|NCT01947998||Standard of care / Cohort 2|Patients who have been prescribed Standard of care for the first time
3313331|NCT01948011|Experimental|Racecadotril 10mg suspension|single oral dose
3313332|NCT01948011|Experimental|Racecadotril 30mg suspension|single oral dose
3313333|NCT01948011|Experimental|Racecadotril 60mg suspension|single oral dose
3313334|NCT01948011|Active Comparator|Racecadotril 60mg granules|single oral dose
3313335|NCT01948024|Active Comparator|Reference Arm - SAPHRIS|10 mg BID sublingual tablet
3313336|NCT01948024|Experimental|Test Arm - Asenapine|10 mg BID sublingual tablet
3313337|NCT01948037|Active Comparator|hydrotherapy|
3313338|NCT01948037|Other|hot spring|30-minutes/per day;4weeks
3313339|NCT01948089|Experimental|Variable Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
3313340|NCT01948089|Experimental|Constant Structured Cognitive Exercise|This training group will consist of 10 randomly assigned participants who will begin the adaptive working memory training task immediately after baseline assessment. Each participant will receive 30 minutes of cognitive exercise per day, 3 days a week for 10 weeks.
3313341|NCT01948102||subjects with ALS|subjects with ALS who are undergoing a percutaneous endoscopic gastrostomy
3313342|NCT01948102||subjects without ALS|subjects without ALS who are undergoing a percutaneous endoscopic gastrostomy
3313343|NCT01948115|Placebo Comparator|Medical air|
3313344|NCT01948115|Experimental|equimolar mixture of oxygen and nitrous oxide|
3313345|NCT01948128|Experimental|Vitamin D3|Vitamin D3 40,000 iu per day by mouth
3381629|NCT02480972|Other|Magnetic resonance imaging|multiparametric MRI including perfusion, diffusion, MR fat quantification and MR elastography
3313346|NCT01948128|Placebo Comparator|Placebo|Placebo taken daily by mouth
3313347|NCT01948154||children with CP|Cerebral palsy (CP) encompass a group of non-progressive, non-contagious motor conditions that cause physical disability in human development. 2-12 years old (n=60-80)
3313348|NCT01948154||normal child|normal child 2-12 years old (50 subjects)
3313349|NCT01948167|Experimental|Interpersonal Psychotherapy- Adolescent Skills Training|Interpersonal Psychotherapy- Adolescent Skills Training
3313350|NCT01948167|Experimental|Coping with Stress|Coping with Stress
3313351|NCT01948180|Experimental|baltaleucel-T|"Treatment consists of 2 infusions of 2x10E7 cells/m2 given on Days 1 and 15 intravenously via a peripheral or central line over a 1 to 10 minute period.~Subjects who tolerate the study treatment well and who do not require treatment with an alternative chemotherapeutic agent will be eligible for up to 3 additional infusions of 2x10E7 cells/m2 administered at week 8, month 3 and month 6."
3313352|NCT01948206||Prolonged paced QRS group|Patients with implantable cardioverter-defibrillators with Prolonged Paced(>=150ms) QRS duration
3313353|NCT01948206||Narrow paced QRS group|Patients with Implantable Cardioverter-Defibrillators with Narrow Paced(<150ms) QRS duration
3313354|NCT01948219|Experimental|ENTegral Artificial Larynx implant|ENTegral Artificial Larynx implantation
3313355|NCT01948232|Experimental|Perindopril|
3313356|NCT01948245|Active Comparator|TaurolockTMHep100|"2-4 ml of TaurolockTMHep100 will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of TaurolockTMHep100 administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
3313357|NCT01948245|Placebo Comparator|Heparin 100 IE/ml|"2-4 ml of Heparin 100 IE/mk will be instilled into the central venous access device (CVAD)after each infusion of parenteral nutrition/intravenous fluids. The instillation varying between twice per week to once daily depending on the patients individual HPN programme. The catheter lock solution is kept in situ in the lumen to the next infusion.~The duration of Heparin 100 IE/ml administration will be maximum 24 month or until occurence of primary outcome(CRBSI)."
3313358|NCT01948271|Experimental|TSO 7500|Subjects in this arm will receive doses of 7500 trichuris suis ova every two weeks, starting at the baseline visit, for a total of 8 doses.
3313359|NCT01948284|Active Comparator|maximal suction pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
3313360|NCT01948284|Active Comparator|half-maximal pressure|The pressure level of the suction unit will be set at the half-maximal (-35 cm Hg).
3313361|NCT01948297|Experimental|Part A|Adaptive doses of Debio1347 (CH5183284) - (10 mg to 210 mg/day) until the recommended dose (RD) is determined.
3313362|NCT01948297|Experimental|Part B|Participants with various tumours receive Debio1347 (CH5183284) orally at the recommended dose established during Part A.
3313363|NCT01948323|Other|.HEDUAfrica IT package+ std care info|"The HEDUAfrica IT package website aims to target disadvantaged gravid women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, SA). A healthcare worker will assist women with the touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes. Patients participating in the IT package also receive std car info~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
3313364|NCT01948323|No Intervention|Health awareness brochure + std care|Participants in the non-intervention group at another clinic in Soweto, will receive an enhanced form of standard care. This will include, in conjunction with the normal form of care at each clinic,a health awareness brochure that will focus specifically on health information relating to obesity, diabetes, diet, exercise and breastfeeding at each follow-up sessions. These participants will also be asked to fill out the 24 hour dietary recall assessment and short messaging service technology questionnaire (exactly the same as the intervention group) with help from a healthcare worker.
3313365|NCT01948336|Placebo Comparator|Control|The patients in group C (control) (n=30) were bolused with 1 mg kg-1 ketamine (Ketalar®, Eczacibasi, Luleburgaz, Turkey) (IV) and 1 mg kg-1 propofol (Propofol 1% Fresenius, Fresenius Kabi Deutschland, Bad Homburg, Germany) (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 ml kg-1 D5 0.3% NaCl IV given over 10 minutes, followed by 0.5 ml kg-1 hour-1 IV D5 0.3% NaCl infusion were administered.
3313366|NCT01948336|Active Comparator|Dexmedetomidine|The patients in group D (dexmedetomidine) (n=30) were bolused with 1mg kg-1 ketamine (IV), 1mg kg-1 propofol (IV) followed by 1 mg kg-1 hour-1 ketamine (IV) and 50 µg kg-1 min-1 propofol (IV) infusion. Additionally a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
3313367|NCT01948349|No Intervention|Non-tongue scraping and twin brackets|Patients in this subgroup will be instructed to follow standard at-home oral hygiene protocols. They will be instructed by the study coordinators to utilize the traditional Bass brushing technique [31], brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
3313368|NCT01948349|Experimental|Tongue scraping with standard twin brackets|Patients allocated to this group will receive the same oral hygiene protocol as the non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
3313369|NCT01948349|Experimental|No tongue scraping with self-ligating brackets|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). They will be instructed to use the traditional Bass brushing technique, brushing twice daily (morning and night) for 2 minutes each time. Patients will all be given the same toothbrush and toothpaste to use during the study. They will also be instructed on the method of flossing and be shown how to use interdental brushes to clean around the orthodontic appliances.
3313370|NCT01948349|Experimental|Tongue scraping with SLB|Patients in this group are treated with passive self-ligating Carrier brackets (Ortho Organizer). Patients allocated to this group will receive the same oral hygiene protocol as non-tongue scraping subjects. However, they will also be in instructed and asked to use the tongue-scraping method of cleaning the tongue as part of their oral hygiene regimen. Patients will be instructed to scrape the tongue once during their nighttime oral hygiene session of brushing and flossing. All patients in this subgroup will be given the same tongue scraper.
3313371|NCT01948362|Active Comparator|Sulforadex|Active compound
3313372|NCT01948362|Experimental|alpha Cyclodextrin|Placebo control arm
3313373|NCT01948401|Experimental|Controlled asthma|
3313374|NCT01948401|Experimental|Uncontrolled asthma with additional OCS|
3313375|NCT01948401|Experimental|Uncontrolled asthma without additional OCS|
3313376|NCT01948414|Other|obese women with eating disorders|Obese women with eating disorders : women with BMI higher or equal 35 and disinhibition score to TFEQ strictly higher to 8
3313377|NCT01948414|Other|Obese women without eating desorders|Obese women without eating disorders : women with BMI higher or equal to 35 and disinhibition score to TFEQ lower or equal to 8
3313378|NCT01948414|Other|Lean women|Lean women : women with BMI from 18.5 to 24.5 and disinhibition score to Three-Factor Eating Questionnaire (TFEQ)lower or equal to 8
3313379|NCT01948440|Experimental|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
3313380|NCT01948440|No Intervention|Treatment as Usual|The Control group participants will complete the ASI-MV and receive their normal course of treatment. The Control group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
3313381|NCT01948453|Active Comparator|Garlic|daily consumption of two odor controlled garlic tablets
3313382|NCT01948453|Placebo Comparator|Placebo|daily consumption of placebo
3313383|NCT01948466|Experimental|Commercials|Schools Administered Commercials
3313384|NCT01948466|No Intervention|Control|Schools not Administered Commercials
3313385|NCT01948479|Experimental|Insole optimised with inshoe analysis|
3313386|NCT01948479|Active Comparator|Routine insole provision|
3313387|NCT01948492|Experimental|protein|varying protein intake in random order from deficient to excess
3313388|NCT01948505|Active Comparator|Intervention group|IV acetaminophen: 1000mg IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
3313389|NCT01948505|Placebo Comparator|Placebo Group|IV Normal Saline: 100ml IV q 8 hrs (scheduled) until: a) tolerating PO and IV saline-locked or b) 48 hours reached on medication
3313390|NCT01948531|Experimental|Gynomunal® gel|The study will be conducted on 33 healthy volunteers of female sex aged between 35 and 65 years old; each subject will apply a fixed quantity of the Gynomunal gel on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage.
3313391|NCT01948544||chronic obstructive pulmonary disease|"More than 12 million adults are diagnosed with COPD~COPD is the 4th leading cause of death in the U.S.~Breathing difficulty is the major reason patients seek medical attention~COPD patients requiring hospitalization were associated with higher costs~Oximetry is an important tool for assessing need for Long-term oxygen therapy~LTOT has been proven to improve survival and quality of life~Patients will be provided a lightweight portable oxygen concentrator to:~support increased activity~improve quality of life~increase functional capacity"
3313392|NCT01948557|Other|Infant feeding counselling and support|All mothers provided with counselling. Subsequent support interventions depended on mothers' selection of feeding practice
3313393|NCT01948570||not in therapy (GROUP 1)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0).
3313394|NCT01948570||in therapy (GROUP 2)|A fixed quantity of the medical device will be applied on the face twice a day, in the morning and in the evening (always at the same hour), with a mild massage according to the instructions received by the investigator during the baseline visit (T0). Group 2 will continue also the standardised treatment with topical or systemic retinoids, benzoyl peroxide, clindamycin or AHA until the end of the study
3313395|NCT01948583|Active Comparator|Arm I: vaginal gel new formulation|"Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid)."
3313396|NCT01948583|Active Comparator|Arm II: vaginal gel on the market|"Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid).~One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid)."
3313397|NCT01948596|Experimental|Omega-3 polyunsaturated fatty acids|1200mg eicosapentaenoic acid (EPA) and 600mg docosahexaenoic acid (DHA) daily
3313398|NCT01948609||Treated with RRSO|Women with the BRCA gene 1/2 mutation who choose to undergo risk reducing salpingo-oophorectomy (RRSO) treatment.
3313399|NCT01948609||No RRSO treatment|Women with the BRCA gene 1/2 mutation who choose non-surgical treatment.
3313400|NCT01948622|Active Comparator|Mulungu|500 mg Mulungu Matusa® (Erytrina mulungu, 2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
3313401|NCT01948622|Placebo Comparator|placebo|500 mg of starch (2 capsules of 250 mg) administered v.o., one hour before the surgical procedure.
3313402|NCT01948635|Experimental|tapered PVC-cuffed tracheal tubes|Patients in this arm will be intubated with tapered PVC-tracheal tubes
3313403|NCT01948635|Active Comparator|Standard PVC-cuffed tracheal tube|Patients in this arm will be intubated with standard (barrel-shape cuffed) PVC tracheal tubes
3313404|NCT01948648|Active Comparator|Colesevelam|3.75g/day for 6 weeks
3313405|NCT01948648|Active Comparator|Fish Oil|1g/day for 6 weeks
3313406|NCT01948648|Active Comparator|Combination of Fish Oil and Colesevelam|3.75g/day of colesevelam and 1g/day of fish oil for 6 weeks
3313407|NCT01948661|Experimental|Anthocyanins+Phospholipidic Curcumin|Mirtoselect ® 500 mg tablet, 1000 mg (two oral tablets) per day and Meriva ®, 500 mg tablet, 1000 mg (two oral tablets) per day for 28 days
3313408|NCT01948661|Placebo Comparator|placeboA + placeboB|placeboA + placeboB per day for four weeks
3313409|NCT01948674|Experimental|computerized tasks- adaptive|
3313410|NCT01948674|Active Comparator|computerized tasks - nonadaptive|
3313411|NCT01948687||1. the control group|healthy adult volunteers
3313412|NCT01948687||2. patients with chronic hepatitis|patients with chronic hepatitis B or C (defined by the presence of serum anti hepatitis C antibody or serum hepatitis B surface antigen)
3313413|NCT01948687||3. liver cirrhosis type B or C|patients with liver cirrhosis type B or C
3313414|NCT01948700|Other|Brief Intervention|Motivational Interviewing (MI)
3313415|NCT01948700|Other|Standard Intervention|Education
3313416|NCT01948713|Experimental|Group 1|Strengthening of pelvic floor muscles.
3313417|NCT01948713|Experimental|Group 2|Strengthening of pelvic floor muscles associated with strengthening of hip muscles.
3313418|NCT01948726|Experimental|Hypofractionation with SIB|
3313419|NCT01948752|No Intervention|Menu - no nutrition information (control)|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included a normal menu with no nutrition information."
3313420|NCT01948752|Experimental|Calorie labels|Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with the calorie amounts displayed.
3313421|NCT01948752|Experimental|Calorie Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts in green/amber/red traffic lights to signify low/medium/high amounts."
3313422|NCT01948752|Experimental|Multi-Traffic Light|"Participants were randomized to receive one of four menus that each contained different type of nutrition information. This condition included menus with calorie amounts as well as sodium, fat, and sugar amounts in green/amber/red traffic lights to signify low/medium/high amounts."
3313423|NCT01948765|Active Comparator|Xenon and propofol|
3313424|NCT01948765|Placebo Comparator|propofol|
3313425|NCT01948778|Experimental|oXiris™ filter|oXiris™ filter
3313426|NCT01948778|Experimental|Toraymyxin Filter|Toraymyxin Filter
3313427|NCT01948778|Other|Standard of Care|Standard of Care CRRT if necessary
3313428|NCT01948804|Experimental|IVF patients|patients that has applied to Yeditepe University Hospital assisted reproduction center
3313429|NCT01948817|Experimental|Deferasirox|Deferasirox 20mg/kg taken BID
3313430|NCT01948843|Experimental|ADI-PEG 20|arginine deiminase formulated with polyethylene glycol
3313431|NCT01948856|Experimental|J022X ST|
3313432|NCT01948856|Placebo Comparator|Placebo|
3313433|NCT01948869|Experimental|Phoenix II|Application over 29 days twice daily
3313434|NCT01948869|Active Comparator|Phoenix I|Application over 29 days twice daily
3313435|NCT01948869|No Intervention|Untreated skin|Untreated skin areas of subjects will be observed over 29 days
3313437|NCT01948895|Experimental|Single-arm study|Desvenlafaxine 50mg/day Desvenlafaxine 100mg/day
3313438|NCT01948921|Placebo Comparator|placebo|1 ml normal saline will be given 5 minutes before EGD
3313439|NCT01948921|Active Comparator|meperidine|25 mg intramuscular meperidine will be given 5 minutes before EGD
3313440|NCT01948934|Experimental|amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
3313441|NCT01948960|No Intervention|standard care|everolimus dose is continued independently of everolimus AUC
3313442|NCT01948960|Active Comparator|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
3313443|NCT01948973|Active Comparator|OFF, subsensory, suprasensory|Here the stimulator is turned OFF for the first 2 weeks, then set subsensory (90% of sensory threshold) for the next 2 weeks and finally set suprasensory for the last 2 weeks.
3313444|NCT01948973|Active Comparator|Subsensory, OFF, suprasensory|Here the stimulator is set subsensory (90% of sensory threshold), then turned OFF for the next 2 weeks and finally set suprasensory in the last 2 weeks.
3313445|NCT01948999|Active Comparator|ECT|Electroconvulsive Therapy Anesthesia and concomitant muscular paralysis
3313446|NCT01948999|Sham Comparator|SHAM ECT|Anesthesia and concomitant muscular paralysis
3313447|NCT01949012|No Intervention|Control|Standard monitoring
3313448|NCT01949012|Experimental|Capnography|Standard monitoring and capnography
3313449|NCT01949025|Experimental|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
3313450|NCT01949025|No Intervention|Control group|
3313451|NCT01949038|Placebo Comparator|Oral placebo|Patients receive one oral dose of placebo least 30 minutes before the procedure.
3313452|NCT01949038|Placebo Comparator|Sublingual placebo|Patients receive one oral dose of placebo at least 30 minutes before the procedure.
3313453|NCT01949038|Active Comparator|Sublingual alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
3313454|NCT01949038|Active Comparator|Oral alprazolam|Patients receive one oral dose of alprazolam 0.5 mg at least 30 minutes before the procedure.
3313455|NCT01949064|Active Comparator|Michigan-type occlusal splint|Occlusal splint, Michigan-type
3313456|NCT01949064|Active Comparator|Grindcare|Biofeedback device
3313457|NCT01949077||Sustained virological response|Patients who achieve sustained virological response (SVR) are defined as undetectable HCV RNA in serum obtained 12 weeks or beyond the end of antiviral therapy.
3313458|NCT01949077||Non-responders|Non-responders are defined as patients who have not achieved virological milestones during therapy or who have relapsed with detectable HCV RNA in serum after cessation of treatment.
3313459|NCT01949103|Experimental|TD-1607 or placebo (Dose1)|TD-1607 or placebo administered intravenously
3313460|NCT01949103|Experimental|TD-1607 or placebo (Dose 2)|TD-1607 or placebo administered intravenously
3313461|NCT01949103|Experimental|TD-1607 or placebo (Dose 3)|TD-1607 or placebo administered intravenously
3313462|NCT01949103|Experimental|TD-1607 or placebo (Dose 4)|TD-1607 or placebo administered intravenously
3313463|NCT01949103|Experimental|TD-1607 or placebo (Dose 5) [Optional]|TD-1607 or placebo administered intravenously
3313464|NCT01949103|Experimental|TD-1607 or placebo (Dose 6) [Optional]|TD-1607 or placebo administered intravenously
3313465|NCT01949129|Experimental|Flu/Thio/Treo|"Fludarabine/Thiotepa/Treosulfan is for conditioning before HSCT from MSD or MD. ATG Thymo or Grafalon is used for patients who receive stem cells from unrelated donors.~Fludarabine/Thiotepa/Treosulfan with either ATG Thymo or Grafalon is also used for HSCT from MMD with in vitro T-Cell Depletion (TCD) or with CD34+ selection.~Fludarabine/Thiotepa/Treosulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
3313466|NCT01949129|Active Comparator|TBI/VP16|"TBI (Total Body Irradiation) / VP16 is used for conditioning for HSCT with MSD or MD graft with patients who are older than 48 months at the time of conditioning.~TBI/VP16 is also used with Post TX-Cyclophosphamide for MMD-graft without in vitro T-Cell Depletion.~TBI/VP16 with either ATG Thymo or Grafalon is used for MMD-HSCT with in vitro T-Cell Depletion or with CD34+ selection."
3313467|NCT01949129|Experimental|Flu/Thio/ivBu|"Fludarabine/Thiotepa/iV Busulfan is used for conditioning before HSCT from MSD or MD.~Fludarabine/Thiotepa/iBu with either ATG Thymo or Grafalon is also used for HSCT from MMD-HSCT with T-Cell Depletion (TCD) or haplo with CD34+ selection.~Fludarabine/Thiotepa/iV Busulfan with Post Tx-Cyclophosphamide is used for MMD-graft without in vitro TCD."
3313468|NCT01949168|Active Comparator|Boceprevir triple therapy with 5-day lead in|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) for 5 days, followed by boceprevir plus • Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection plus • Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy (week 5 from baseline), and maintain an undetectable plasma HCV RNA at week 20 of triple therapy (week 21 from baseline), treatment will stop at week 25. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 23 weeks (stopping at week 48).
3313469|NCT01949168|Active Comparator|Boceprevir triple therapy|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets) plus Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg, by mouth daily for 24 weeks. In patients who achieve an undetectable plasma HCV RNA level at week 4 of triple therapy, and maintain an undetectable plasma HCV RNA at week 20 of triple therapy, treatment will stop at week 24. Patients who have a detectable plasma HCV RNA at week 4 of triple therapy, but an undetectable plasma HCV RNA at week 20, will continue a with follow-on peginterferon-α-2b plus ribavirin for a further 24 weeks (stopping at week 48).
3313470|NCT01949168|Active Comparator|Standard of Care|48 weeks of Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection and Rebetol® (ribavirin), 1000/1200mg by mouth daily (200mg tablets)
3313471|NCT01949181|Experimental|Pulmonary cancer|
3313472|NCT01949194|Experimental|Regorafenib|Single-agent regorafenib
3313473|NCT01949207|Experimental|EVLA, phlebectomies & Trlop closure of incompetent perforators|endovenous laser ablation (EVLA) of great saphenous vein (GSV) plus phlebectomies plus TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
3313474|NCT01949207|Experimental|EVLA & phlebectomies|endovenous laser ablation (EVLA) of great saphenous vein (GSV) + phlebectomies.
3313475|NCT01949220||Von Willebrand factor deficient patient|Inherited von Willebrand disease
3313476|NCT01949233|Experimental|Irbesartan 150-300mg (and doxycycline placebo)|Irbesartan 150-300mg capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
3313477|NCT01949233|Experimental|Doxycycline 100-200mg (and irbesartan placebo)|Doxycycline 100-200mg capsules daily for 6 months Irbesartan placebo capsules daily for 6 months
3313478|NCT01949233|Experimental|Irbesartan 150-300mg and doxycycline 100-200mg|Irbesartan 150-300mg capsules daily for 6 months Doxycycline 100-200mg capsules daily for 6 months
3313479|NCT01949233|Placebo Comparator|irbesartan and doxycycline placebo|Irbesartan placebo capsules daily for 6 months Doxycycline placebo capsules daily for 6 months
3313480|NCT01949246||CRT patients|Patients undergoing CRT device implantation
3313481|NCT01949246||Healthy patients|Healthy controls
3313482|NCT01949259||Retrospective collection|Retrospective collection of data from included lung cancer patients.
3313483|NCT01949272||ARDS|ARDS patients achieving stades II and III of Berlin 2011 Classification
3313484|NCT01949285|Sham Comparator|Grp#1: sham stimulation|"Group #1: Baseline clinical assessment; followed by two weeks training with no stimulation; then four weeks training + sham Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment; then four weeks training + effective non-sham Transcutaneous Spinal Cord Stimulation; repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
3381634|NCT02400190|Experimental|Endocrine therapy alone|Patients receive endocrine therapy alone without radiotherapy
3381635|NCT02396199|Experimental|Endovascular|Endovascular treatment using the Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
3381636|NCT02375841||Physicians, Patients, and Caregivers|This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.
3381637|NCT02310321|Experimental|Phase 1 Dose Evaluation Part|In the dose-evaluation part in Phase 1 part, subjects will receive ASP2215 at assigned single dose for determination of MTD and/or RED. Treatment of AML in this study is composed of 3 periods of therapy: remission induction (42-day cycles x 2 at maximum), consolidation (28-day cycles x 3 at maximum), and maintenance (28-day cycles x 26 at maximum). The decision of whether or not to proceed to the next dose will be made based on the occurrence of DLT during Cycle 1 of the induction period.
3381638|NCT02310321|Experimental|Phase 1 Dose Expansion Part|In the dose expansion part in Phase 1 part, subjects will receive ASP2215 at RED that has been determined in the dose-evaluation part, and the safety will be assessed based on the onset of DLTs during Cycle 1 of the induction and consolidation periods.
3381639|NCT02310321|Experimental|Phase 2 Part|Subjects will receive ASP2215 at the recommended dose established in Phase 1 part.
3381640|NCT02297139|Experimental|Dasatinib|This is a continuation roll-over study for patients receiving benefit from prior dasatinib protocols. All subjects will receive dasatinib as per previous protocol
3313485|NCT01949285|Active Comparator|Grp#2: Control|"Group #2: Baseline clinical assessment; followed by two weeks training with no Transcutaneous Electrical Spinal Cord Stimulation; then four weeks training + effective Transcutaneous Electrical Spinal Cord Stimulation; followed by repeat clinical assessment.~Secondary outcome measurements: assess ability to stand with and without stimulation using a stance frame support; assess trunk function (core stability) with and without stimulation"
3313486|NCT01949298|Experimental|Immediate implant loading|The test group had implant immediately loaded by means of a implant supported mandibular denture connected with locator abutment.
3313487|NCT01949298|Active Comparator|Delayed implant loading group|The control group had implant loaded after 3 months of submerged healing by means of a implant supported mandibular denture connected with locator abutment.
3381641|NCT02281955|Experimental|De-escalated Radiation and Chemotherapy|Patients will receive Intensity Modulated Radiotherapy Treatments (IMRT), 60 Gy at 2 Gy/fx. The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history. Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
3313488|NCT01949311|Experimental|Dupilumab|Participants will receive repeat doses of dupilumab
3313489|NCT01949324|Experimental|NT-501 Implant procedure|The investigational product is the NT-501 encapsulated cell system which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that were derived from the NTC-200 cell line by genetic modification so as to secrete recombinant human ciliary neurotrophic factor (CNTF).
3381642|NCT02245230|Active Comparator|Intact Study Day|Subjects will receive saline infusion for 60 minutes followed by five ascending doses of Angiotensin (1-7) ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
3381643|NCT02245230|Experimental|Autonomic Blockade Study Day|Autonomic blockade will be induced by continuous intravenous infusion of trimethaphan starting at 0.5-1.0 mg/min and increasing by 1.0 mg/min every 2 to 6 minutes up to an infusion rate of 5 mg/min. Blood pressure will be restored to pre-trimethaphan levels with intravenous phenylephrine infusion at individually titrated doses, starting with 0.1 ug/kg/min. Angiotensin (1-7) will then be infused in five ascending doses ranging from 0.5 to 20 ng/kg/min. Each dose will be maintained for 10 minutes with hemodynamic measurements and blood samples collected at the end of each dosing period.
3313490|NCT01949324|Sham Comparator|Sham procedure|Non-penetrating sham procedure to mimic implant procedure
3313491|NCT01949350|Active Comparator|Carbohydrate|CHO loaded test:
3313492|NCT01949350|Active Comparator|Carbohydrate protein|CHO-P loaded test:
3313493|NCT01949350|Active Comparator|Water|Starved as for surgery
3313494|NCT01949363|Experimental|Stage 2 (Cohorts C and D)|Cohort C will first be given 1200mg cefixime orally once; Cohort D will be given 800mg cefixime orally three times (every 8 hours); 6 subjects in each cohort
3313495|NCT01949363|Experimental|Stage 1 (Cohorts A and B)|Cohort A will be given 400mg of cefixime orally once; Cohort B will be given 800mg of cefixime given orally once; 6 subjects in each cohort
3313496|NCT01949376||HT Patients|any stage of breast cancer without brain metastasis, will undergo hormonal therapy without chemotherapy
3313497|NCT01949376||CT and HT Patients|any stage of breast cancer without brain metastasis, will undergo chemotherapy and hormonal therapy
3313498|NCT01949376||CT Patients|any stage of breast cancer without brain metastasis, has undergone surgery prior to screening, will undergo chemotherapy without hormonal therapy
3313499|NCT01949376||RT or NT Patients|any stage of breast cancer without brain metastasis, will not undergo chemotherapy or hormonal therapy; may undergo radiation therapy or have no therapy
3313500|NCT01949376||Controls|healthy, cognitively normal subjects
3313501|NCT01949402||Haemodialysis|Patients with end-stage renal failure (ESRF) requiring long-term regular haemodialysis.
3381644|NCT02202434|Experimental|Lotus Valve System - Randomized|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3381645|NCT02202434|Active Comparator|CoreValve TAVR System - Randomized|Transcatheter aortic valve replacement (TAVR) with CoreValve/Evolut R Transcatheter Aortic Valve Replacement System
3313502|NCT01949402||Chronic Obstructive Pulmonary Disease|Patients with a confirmed diagnosis of COPD based on clinical history, obstructive spirometry (FEV1/VC ratio <70%) and radiology (e.g. hyperexpansion on plain chest radiograph; evidence of small airways disease or emphysema on cross-sectional imaging).
3313503|NCT01949402||Interstitial Lung Disease|Patients with a confirmed diagnosis of ILD based on clinical history and radiology (evidence of ILD on cross-sectional imaging).
3313504|NCT01949402||Control|Age-matched healthy volunteers with no history of cardiac, respiratory or renal disease.
3313505|NCT01949428||HDM-Induced Rhinoconjunctivitis Subjects|
3313506|NCT01949441|Experimental|ToleroMune HDM|
3313507|NCT01949441|Placebo Comparator|Placebo|
3313508|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt bid x4weeks|Fluorometholone 0.1% 1 drop two times daily for four weeks
3313509|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt bid x4 weeks|
3313510|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 4 weeks|Fluorometholone 0.1% 1 drop four times daily for four weeks
3313511|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x4 weeks|
3313512|NCT01949454|Experimental|Fluorometholone 0.1% 1 gtt qid x 8 weeks|Fluorometholone 0.1% 1 drop four times daily for eight weeks
3313513|NCT01949454|Placebo Comparator|Artificial Tears 1 gtt qid x8 weeks|
3313514|NCT01949467|Other|TDHS|20 Patients with Treated Dysmetabolic Hepatosiderosis (TDHS)
3313515|NCT01949467|Other|UDHS|20 patients with untreated Dysmetabolic Hepatosiderosis (UDHS)
3313516|NCT01949467|Other|TFPD|20 patients with treated Ferroportin Disease (TFPD)
3313517|NCT01949467|Other|UFPD|20 patients with untreated Ferroportin Disease (UFPD)
3313518|NCT01949467|Other|HV|20 Healthy volunteers (HV) patients
3313519|NCT01949493|Other|Care as usual|The patient will receive the usual care provided by the neurologists at VieCuri Medical Center. This may include an expectant strategy, a wrist splint, corticosteroid injection or carpal tunnel release surgery.
3313520|NCT01949493|Experimental|Mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus.
3313521|NCT01949506|Other|Stereotactic Body Radiation Therapy|Arms: Stereotactic Body Radiation Therapy (SBRT) with Adaptive Radiation Therapy (ART) for all patients. A non-randomized study. Patients must have 1-5 pulmonary metastases all less than 5 cm in size. Pathologic confirmation of primary soft tissue sarcoma. All lesions to receive 3-5 fractions to each tumor. Treatments delivered with > 10 Gy per fraction will have a minimum of 48 hour interfraction interval. For treatments with ≤ 10 Gy per fraction will have a minimum 24 hour interfraction interval. Treatments will be ideally completed over 14 days for 3 fraction treatments and over 21 days for >5 fraction treatment schedules.
3313522|NCT01949519|Experimental|Docetaxel and Lycopene|
3313523|NCT01949558|No Intervention|Control group|The control group receives a brochure on healthy dietary habits according to regular care.
3313524|NCT01949558|Experimental|Dietary intervention|12 week individual intervention based on a cognitive behavioral approach. It includes dietary restriction under guidance by a dietitian. Thereafter monthly follow-up takes place via email during the following 9 mo.
3313525|NCT01949571|Experimental|Mirtazapine|During the first and second phase of the study, subjects assigned to the control group received one tablet of placebo under daily basis, whereas the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, placebo group received same tablet under daily basis, whereas the mirtazapine group received 15 mg of mirtazapine.
3313526|NCT01949597||Patients with symptomatic endometriosis|
3313527|NCT01949610|Experimental|14C-JNJ26489112|
3313528|NCT01949623||RP patients|Retinitis Pigmentosa patients
3313529|NCT01949623||Controls|Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
3313530|NCT01949636||lean adolescents|
3313531|NCT01949649|Active Comparator|Peer-Led Group Intervention|In the Peer-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by peer leaders.
3313532|NCT01949649|Active Comparator|Clinician-Led Group Intervention|In the Clinician-Led Group Intervention, participants voluntarily engage in verbal, written, and behavioral exercises in which they critique the thin-ideal ideal during 4 1-hr sessions and in homework activities which are led by University clinicians.
3313533|NCT01949649|Active Comparator|Internet-Based Intervention|The Internet-Based Intervention consists of 6 40-min modules involving user-driven self-education activities and games (e.g., role-plays), writing/video contests, and off-line exercises designed to induce dissonance regarding pursuit of the thin-ideal, mirroring activities from the group Body Project.
3313534|NCT01949649|Active Comparator|Education Video|The Education Video describes eating disorders, their adverse effects, and the need for treatment, which is key information to provide to young women at elevated risk for eating disorders due to body dissatisfaction.
3313535|NCT01949675|Experimental|Study Group 1|Participants aged 1 through 4 years at enrollment
3313536|NCT01949675|Experimental|Study Group 2|Participants aged 5 through 14 years at enrollment
3313537|NCT01949675|Experimental|Study Group 3|Participants aged 15 years and above at enrollment
3313538|NCT01949688|Experimental|HLA-A*2402 restricted peptides|HLA-A*2402 restricted peptides with adjuvant
3313539|NCT01949688|Experimental|HLA-A*0201 restricted peptides|HLA-A*0201 restricted peptides with adjuvant
3313540|NCT01949701|Experimental|Vaccine|HLA-A*0201restricted URLC10 peptides
3313541|NCT01949714||Pheochromocytoma patients|Pheochromocytoma patients
3313542|NCT01949714||Incidentaloma patients|Incidentaloma patients
3313543|NCT01949727||AIM 1/AIM 2: AECOPD Admitted Patients|"AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.~AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health."
3313544|NCT01949740||Observational (patient preferences)|Patients participate in a 45-minute interview comprising assessment of priorities and quality of life at baseline, 1, 6, and 12 months.
3313545|NCT01949753|Experimental|Nutritional supplement Pregnenolone|Exposure therapy, exposure with response prevention and pharmacological facilitation (nutritional supplement pregnenolone), orally two hours before exposure therapy.
3381646|NCT02202434|Experimental|Lotus Valve Sytem - Single-arm 21mm Cohort|Transcatheter aortic valve replacement (TAVR) with 21mm Lotus Valve System
3313546|NCT01949753|Placebo Comparator|Placebo|Exposure therapy, exposure with response prevention without pharmacological facilitation (Placebo), orally two hours before exposure therapy.
3313547|NCT01949792|Active Comparator|270 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
3313548|NCT01949792|Active Comparator|3x90 microg/kg rFVIIa|Each subject will receive one single injection of 270 microg/kg and three injections of 90 microg/kg rFVIIa (one injection every 3 hours) in a randomised order. The two administration days will be separated by a wash-out period of at least 48 hours
3313549|NCT01949805|Active Comparator|Hydroxyurea|Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
3313550|NCT01949805|Experimental|Peg-P-IFN-alpha-2b (AOP2014)|Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
3313551|NCT01949818|Experimental|Yangzhengxiaoji Capsule combined with CHOP regimen|Yangzhengxiaoji Capsule combined with CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3313552|NCT01949818|Experimental|CHOP regimen|CHOP(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) regimen
3313553|NCT01949831|No Intervention|Control|Usual care
3313554|NCT01949831|Experimental|Functional assessment|Assessment of functional ability in combination with follow-up at home
3313555|NCT01949857|Experimental|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-15 years \6.50 lgCCID50/ml in adults aged 16 up to 65 years old
3313556|NCT01949857|Experimental|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
3313557|NCT01949857|Experimental|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
3313558|NCT01949857|Experimental|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
3313559|NCT01949883|Experimental|CPI-0610|
3313560|NCT01949896|Other|Intervention: NPO|"Infants in this group will be made NPO approximately 4 hours prior to receiving a blood transfusion and will remain NPO until approximately 24 hours after the blood transfusion.~Pro-inflammatory cytokine response will be monitored at 3 times points."
3313561|NCT01949896|Other|Control: Continue feedings|"Infants in this group will be allowed to continue feedings during the transfusion at the discretion of the medical team.~Pro-inflammatory cytokine response will be monitored at 3 times points."
3313562|NCT01949909|Experimental|Alhydrogel CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
3313563|NCT01949909|Experimental|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
3313564|NCT01949909|Placebo Comparator|Control rabies vaccine Verorub TM TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
3313565|NCT01949909|Experimental|Alhydrogel TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
3313566|NCT01949909|Experimental|GLA-SE TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
3313567|NCT01949909|Experimental|GLA-SE TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
3313568|NCT01949909|Experimental|GLA-SE TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
3313569|NCT01949922|Experimental|Injection of autologous muscle fibers in the anal sphincter|All patients, that still have relevant symptoms after completion of three months with individualized pelvic floor muscle training and dietary intervention to control defecatory function, will be offered injection of autologous muscle fiber fragments in the anal sphincter. A myscle biopsy will be taken from the leg, cut into small pieces in a saline solution and injected in the anal sphincter.
3313570|NCT01949935|Placebo Comparator|Control|Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.
3313571|NCT01949935|Experimental|Mupirocin|Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.
3313572|NCT01949948|Active Comparator|Tenecteplase|0.4 mg/kg single bolus intravenously
3313573|NCT01949948|Active Comparator|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
3313574|NCT01949961|Active Comparator|Ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The groups are separately randomised to 2 megahertz (MHz) transcranial ultrasound treatment for one hour.
3313575|NCT01949961|Placebo Comparator|Sham ultrasound|Patients eligible (NOR-SASS A/B) and ineligible (NOR-SASS C) for intravenous thrombolysis all receive intravenous ultrasound contrast (microbubbles). The two groups are separately randomised to sham ultrasound treatment for one hour.
3313576|NCT01949974|Experimental|Integral Attention Program (PAI)|"The key points of the PAI are:~To assess and manage pain and other symptoms resulting from disease progression.~To evaluate the information needs that may arise and to address them.~To encourage patient and family adaptation to the situation of advanced disease and in the terminal phase of it.~To provide guidance in decision-making while respecting patient autonomy.~To establish a plan of care and treatment, adapted to the evolution and needs of the patient.~To promote continuity of care."
3313577|NCT01949974|Active Comparator|Standard Palliative Chemotherapy and PAI|Standard palliative chemotherapy will be administered, depending on type of cancer, as well as PAI as been defined above.
3313578|NCT01949987|Active Comparator|2 hours after surgery|the investigators permit the patients to resume oral intake two hours after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
3313579|NCT01949987|Experimental|1 hour after surgery|the investigators permit the patients to resume oral intake one hour after surgery and observe child's behavior and score; cry, facial expression, verbal expression, torso, legs, activity, and consolability
3313580|NCT01950000|Placebo Comparator|Placebo|Placebo Treatment: A sterile sodium chloride injection 0.9% 10 ml
3313581|NCT01950000|Experimental|Fentanest|"For this study Fentanest doses were adjusted based on published guidelines from the values recommended media to a whole number and differentiating two groups of patients (multiple trauma / surgical or medical) The maximum dose is 100 mcg Fentanest. The multiple trauma patients / surgical 1.5 mcg / kg and in medical patients 1.0 mcg / kg were given a single bolus Fentanest / Placebo by type of patient (surgical / multiple trauma or physician) 5 'before turning mobilization with personal hygiene.~The bolus is given slowly (30'') intravenously, to be preferred by a peripheral without vasoactive drugs (only with fluid therapy).~Pharmaceutical form:~Sterile solution for injection. Each mL of injectable solution contains the equivalent of 0.05 mg of Fentanest; Excipients: sodium chloride and water for injection."
3313582|NCT01950026|Experimental|white|cryotherapy application
3313583|NCT01950026|Experimental|black|cryotherapy application
3313584|NCT01950026|Experimental|Brown|cryotherapy application
3313585|NCT01950026|Experimental|asian|cryotherapy application
3313586|NCT01950052|No Intervention|Control group|No special diet, patients will continue with a normal diet
3313587|NCT01950052|Experimental|Diet group|Pre-operative liver shrinking diet of 800 Kcal diet is administered for 4 weeks
3313588|NCT01950065|Experimental|Immediate Treatment with iovera|Immediate treatment with iovera
3313589|NCT01950065|Active Comparator|Delayed Treatment with iovera|Delayed Treatment with iovera
3313590|NCT01950091|Experimental|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
3313591|NCT01950091|Active Comparator|Alternative website control|Intervention is a Menu of links to 4 popular Websites offering back pain education
3313592|NCT01950091|No Intervention|Usual care control group|No contact; Control group
3313593|NCT01950104|Active Comparator|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development
3313594|NCT01950104|Experimental|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development (day 5 or 6)
3313595|NCT01950117|Active Comparator|Conventional polypectomy|Colorectal polyps from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was not performed for polypectomy. The snare used for polypectomy was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for conventional polypectomy. Prophylactic clipping after polyp removal was routinely performed.
3313596|NCT01950117|Experimental|Endoscopic mucosal resection|Colorectal polyp from 10 mm to 25 mm was found. Submucosal injection of saline solution before removal was performed for EMR. The snare used for EMR was a dual loop wire snare with a loop size of 33/16 mm (SN-3316LX, Medico's Hirata Inc., Osaka, Japan). An ERBE ICC200 (Amco, Tokyo, Japan) was used in the Endocut mode with the effect 3 current set at output limit 120W and forced coagulation current set at output limit 35W for EMR. Prophylactic clipping after polyp removal was routinely performed.
3313597|NCT01950143|Active Comparator|Standard broccoli soup|26 volunteers
3313598|NCT01950143|Experimental|Beneforte broccoli soup|26 volunteers
3313599|NCT01950143|Experimental|Beneforte extra broccoli soup|26 volunteers
3313600|NCT01950156|Experimental|Vaccine|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant
3313601|NCT01950182|Active Comparator|Palliative chemotherapy|Chemotherapy combined with trastuzumab. Chemotherapy could use the following drugs such as capecitabine , Vinorelbine, or Gemcitabine.
3313602|NCT01950182|Experimental|Palliative endocrine therapy|Endocrine therapy combined with trastuzumab. Endocrine therapy could use tamoxifen or aromatase inhibitors including anastrozole, letrozole, or exemestane.
3313603|NCT01950195|Experimental|Brain|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
3313604|NCT01950195|Experimental|Spine|"A cohort of six (6) patients will be treated at Dosing Schedule 1. If the observed dose limiting toxicity (DLT) rate is less ≤33%, the dose cohort will be expended to a total of 15 patients. Brain and spine metastases will be evaluated as two separate cohorts.~If the first schedule produces DLTs in >33% of patients, the Second Dosing schedule will be implemented. If the second dosing schedule produces DLTs in >33% of patients, the Third Dosing schedule will be implemented.~After 6 patients were enrolled in a cohort, their safety and toxicity will be continuously monitored till 12 weeks (3 months) after the initial dose of Ipilimumab is given for evaluating dose-limiting toxicities."
3313605|NCT01950208||knee pain|patients suffering from knee injury
3313606|NCT01950221|Experimental|POMx|POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract.
3313607|NCT01950221|Placebo Comparator|Placebo|Composition of the Drug Placebo Component/Function/Weight/Percentage of Fill Weight = Cellulose/Bulk agent/658 mg/64.5% Caramel/Colorant/79mg/7.8% Beet root/Flavor Ingredient/263mg/25.8% Magnesium stearate/USP Lubricant/10mg/1.0% Silica Dioxide/FCC Glidant/10mg/1.0% Total = 1020 mg/100% The method of manufacture of the placebo is identical to that of the drug product, except cellulose, caramel, and beet root are added in place of the active ingredient.
3313608|NCT01950234|Experimental|ACTH|ACTH administered subcutaneously as a pulsed regimen of 3 consecutive days per month
3313609|NCT01950234|Placebo Comparator|Placebo|Placebo subcutaneous injections administered on 3 consecutive days per month
3313610|NCT01950247|Experimental|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
3313611|NCT01950247|Active Comparator|IV Iron Standard of Care (SOC)|At a dose and administration regimen as determined by the study site investigator
3313612|NCT01950312|Experimental|gevokizumab|Solution for subcutaneous injection
3313613|NCT01950325|Experimental|Group 1|1mg/kg IV
3313614|NCT01950325|Experimental|Group 2 or Group 3|5 mg/kg IV (Group 2) or 5 mg/kg SC (Group 3)[only portion of the study that is randomized]
3313615|NCT01950325|Experimental|Group 4|20 mg/kg IV
3313616|NCT01950325|Experimental|Group 5|40 mg/kg IV
3313617|NCT01950338|Experimental|Dry needling group|The experimental group will receive a single session of DDN with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the gastrocnemius and tibialis anterior muscles.
3313618|NCT01950338|No Intervention|Control group|The control group will not receive any intervention.
3313619|NCT01950351|Experimental|Treatment (proton beam radiation therapy)|Patients undergo proton beam radiation therapy in 15 fractions over 5-6 weeks.
3313623|NCT01950403|Experimental|Arm I (linaclotide acetate)|Participants receive linaclotide acetate PO QD on days 1-7.
3313624|NCT01950403|Placebo Comparator|Arm II (placebo)|Participants receive placebo PO QD on days 1-7.
3313625|NCT01950416|Experimental|Ticagrelor|Ticagrelor 180mg loading dose (LD), followed by a 90mg x2 maintenance dose (MD) starting 12±6 hours post LD, until discharge.
3313626|NCT01950416|Active Comparator|Clopidogrel|Clopidogrel 600mg loading dose (LD), followed by a 150mg once daily maintenance dose (MD) starting 12±6 hours post LD, until discharge.
3313627|NCT01950455|Experimental|NAV5001|
3313628|NCT01950468|Experimental|NAV5001|
3313629|NCT01950468|Active Comparator|DaTscan|
3313630|NCT01950481|Experimental|Normal Hepatic Function|Subjects with normal hepatic function
3313631|NCT01950481|Experimental|Mild Hepatic Impairment|Subjects with mild hepatic impairment
3313632|NCT01950481|Experimental|Moderate Hepatic Impairment|Subjects with moderate hepatic impairment
3313633|NCT01950481|Experimental|Severe Hepatic Impairment|Subjects with severe hepatic impairment
3313634|NCT01950494|Experimental|fiteBac Hand Sanitizer|Blinded fitBac Hand sanitizer
3313635|NCT01950494|Placebo Comparator|Blinded emollient therapy|Blinded emollient therapy
3313636|NCT01950507|Experimental|Cohort 1|subjects may be on fluconazole or micafungin at study entry or be on no antifungal prophylaxis.
3313637|NCT01950507|Experimental|Cohort 2|subjects are on voriconazole at study entry. Voriconazole will continue throughout days O to 7.
3313638|NCT01950507|Experimental|Cohort 3|subjects are on fluconazole at study entry. Fluconazole will continue throughout days O to 7.
3313639|NCT01950520|Experimental|Cohort 2|Interventions, in random order, will be administered during one of the six one-day stays
3313640|NCT01950520|Experimental|Cohort 3|Interventions, in random order, will be administered during one of the four overnight inpatient stays
3313641|NCT01950520|Experimental|Low Temperature 1st|Low temperature before 27c (Cohort 1 only)
3313642|NCT01950520|Experimental|Low Temperature 2nd|Low temperature after 27c (Cohort 1 only)
3313643|NCT01950533||Peanut allergic|Subjects allergic to peanuts by oral food challenge
3313644|NCT01950533||Milk allergic|Subjects allergic to milk by oral food challenge
3313645|NCT01950533||Egg allergic|Subjects allergic to egg by oral food challenge
3313646|NCT01950546|Experimental|Nanosilver fluoride|This product is a solution composed of: 390 mg / ml 9nm silver nanoparticles ;21 mg / ml chitosan ; 22 mg / ml NaF.The cariostatic agent, nanosilver fluoride, was formulated in a similar way to silver diamine fluoride, so that this new formulation contained 5% nanosilver fluoride, while commercial diamine silver fluoride contains 30% silver fluoride. It will be applied once with a microbrush on tooth surfaces to check if it prevents the growth of S. mutans biofilms on dental surfaces.
3313647|NCT01950559||Subjects who are allergic to Soy|Subject allergy to soy is determined by an oral food challenge or history of positive soy food challenge.
3313648|NCT01950598|Active Comparator|Fresh carrier graft for KPro|KPro implanted using fresh cornea, preserved in optisol GS
3313649|NCT01950598|Experimental|Frozen carrier graft for KPro|KPro implanted using frozen cornea, which was supplied as a whole globe cryopreserved at -80°C in gramicidin 0.025 mg/mL and polymyxin B sulfate 10 000 U/mL ophthalmic solution.
3313650|NCT01950611|Experimental|Bortezomib in treatment|
3313652|NCT01950637||Patients with type 2 diabetes mellitus (T2DM)|
3313653|NCT01950637||Healthcare professionals (HCPs)|
3313654|NCT01950650||Patients with diabetes|
3313655|NCT01950650||Physicians|
3313656|NCT01950676|No Intervention|Control|Individuals in the control group will not use the smart phone application
3313657|NCT01950676|Experimental|Intervention|Individuals in the intervention group will use the smart phone application in insulin titration
3313658|NCT01950689|Placebo Comparator|Placebo|Placebo given in parallel with radiotherapy for 6 weeks.
3313659|NCT01950689|Experimental|Nimorazole|Nimorazole given in parallel with radiotherapy for 6 weeks
3313660|NCT01950702|Active Comparator|Lightwand intubation|"After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, traditional lightwand intubation was done by pre-specified anesthesiologist who experienced more than 100 times of lightwand intubation.~Patient's head were fixed at neutral position during all intubation period."
3313661|NCT01950702|Experimental|Laryngoscope assisted lightwand intubation|After standard total intravenous anesthesia using propofol and remifentanil continuous infusion, lightwand intubation using specific device(Macintosh laryngosope, female:3/Male:4) was done by pre-specified anesthesiologist who experienced more than 100 times of laryngoscope assisted lightwand intubation.
3313662|NCT01950715|Other|sacral nerve stimulation|A single armed study to evaluate the on the gastro-colic response in IBS patients treated with sacral nerve stimulation
3313663|NCT01950728|No Intervention|Control group|This group will not receive electrical stimulation. Volunteers will rest during 30 minutes.
3313664|NCT01950728|Active Comparator|Interferential current group|Interferential current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3313665|NCT01950728|Active Comparator|TENS Group|TENS will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3313666|NCT01950728|Active Comparator|Aussie current group|Aussie current will be applied during 30 minutes to volunteer's forearm. Intensity will be increase until volunteers fell a strong but comfortable paresthesia.
3313667|NCT01950754|Other|depressive patients|
3313668|NCT01950754|Other|nondepressed controls|
3313669|NCT01950793|Active Comparator|steroid|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
3313670|NCT01950793|Experimental|Hyaluronic acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
3313671|NCT01950806|Active Comparator|Pecan-containing diet|Test diet containing 1.5 oz pecans/2000 kcal/day for 28 days
3313672|NCT01950806|Placebo Comparator|Nut-free diet|Placebo diet containing no nuts or nut products, and identical in total fat and fiber as the test diet, for 28 days
3313673|NCT01950832||polycystic ovary syndrome (PCOS) group|Patients who were diagnosed as PCOS according to 2003 Rotterdam Criteria.
3313674|NCT01950832||Control|60 healthy volunteers
3313675|NCT01950845|Experimental|Automated fluid management system (Closed-loop system)|cardiac output Vigileo® (Edwards Lifesciences) monitoring is connected to the closed loop system that will automatically provide per operative fluid bolus to optimize cardiac output by automated detection of fluid responsiveness state.
3313676|NCT01950845|Sham Comparator|Current practice manual fluid management|cardiac output Vigileo® (Edwards Lifesciences) monitoring will be used to help the anesthesiologist team to detect fluid responsiveness state for the manual fluid management optimization
3313677|NCT01950858|Experimental|Biological|6 weeks of HBO treatment as well as non weight bearing
3313678|NCT01950858|Active Comparator|Control|non weight bearing
3313679|NCT01950871|Other|single arm study|Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.
3313680|NCT01950884|Experimental|Ezetimibe|Ezetimibe tablets plus lifestyle
3313681|NCT01950884|Active Comparator|lifestyle|lifestyle
3313682|NCT01950897||subjects dx'd clinically w/ muscular dystrophy|subjects with muscular dystrophy from whom muscle samples are obtained for clinical diagnosis or for any other medical purpose
3313683|NCT01950897||normal controls|subjects who do not have muscular dystrophy and from whom muscle samples are obtained for any medical purpose
3313684|NCT01950910||subjects w/ non-motor neurodegenerative disease|subjects with ALS or with non-motor neurodegenerative disease
3313685|NCT01950910||subjects w/out motorneuron degenerative dis|subjects without motorneuron degenerative disease
3313686|NCT01950923|Experimental|Arm I (sildenafil citrate)|Patients receive sildenafil citrate PO before the initiation of standard robotic partial nephrectomy.
3313687|NCT01950923|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO before the initiation of standard robotic partial nephrectomy.
3313688|NCT01950936|Experimental|Procalcitonin-guidance|Discontinuation of Antibiotics. Procalcitonin is measured on day 1/2, day 3, day 5 and day 7 (all days where the patient is still admitted to hospital and antibiotics are discontinued, whenever Procalcitonin is <0.15 ng/ml and dis-encouraged whenever Procalcitonin is <0.25 ng/ml
3313689|NCT01950936|No Intervention|Control - Standard of Care|Antibiotics are administered according to current guidelines
3313690|NCT01950949|Experimental|change respiratory parameters, volume expanding|
3313691|NCT01950962|Other|slight periodontal disease|
3313692|NCT01950962|Other|moderate periodontal disease|
3313693|NCT01950962|Other|severe periodontal disease|
3313694|NCT01950975|Other|Parents|2 parents of child
3313695|NCT01950975|Other|infant|
3313696|NCT01950988|Other|Children|
3313697|NCT01950988|Other|Adults|
3313698|NCT01950988|Other|Elderly people|
3313699|NCT01951001|Active Comparator|group 1|Fixed-dose Prasugrel of 10 mg/d
3313700|NCT01951001|Active Comparator|group 2|Fixed-dose Prasugrel of 5 mg/d
3313701|NCT01951001|Active Comparator|group 3|"Phenotype-based prasugrel dose~If patients show PRU < 85, prasugrel dose will be reduced by 5 mg/d.~If patients show PRU ≥ 85, prasugrel dose will continue 10 mg/d."
3313702|NCT01951014|Experimental|Teen Social Media Education|See description under intervention description
3313703|NCT01951014|No Intervention|Healthcare Provider Insights|Healthcare providers providing care to pregnant adolescents will serve as key informants to provide an additional perspective for adolescent health beliefs and behaviors.
3313704|NCT01951027|Experimental|Cohort 1|GX-G3 12.5 μg/kg or Placebo
3313705|NCT01951027|Experimental|Cohort 2|GX-G3 25 μg/kg or Placebo
3313706|NCT01951027|Experimental|Cohort 3|GX-G3 50 μg/kg or Placebo
3313707|NCT01951027|Experimental|Cohort 4|GX-G3 100 μg/kg or Placebo
3313708|NCT01951040||Oxytocin|Oxytocin was administered during labor
3313709|NCT01951040||No Oxytocin|Oxytocine was not administered during labor
3313710|NCT01951053|Experimental|Sequence 1|Participants will receive the study medications in the sequence of placebo, citalopram, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313711|NCT01951053|Experimental|Sequence 2|Participants will receive the study medications in the sequence of placebo, JNJ-40411813, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313712|NCT01951053|Experimental|Sequence 3|Participants will receive the study medications in the sequence of citalopram, placebo, and JNJ-40411813, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313713|NCT01951053|Experimental|Sequence 4|Participants will receive the study medications in the sequence of citalopram, JNJ-40411813, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313714|NCT01951053|Experimental|Sequence 5|Participants will receive the study medications in the sequence of JNJ-40411813, placebo, and citalopram, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313715|NCT01951053|Experimental|Sequence 6|Participants will receive the study medications in the sequence of JNJ-40411813, citalopram, and placebo, in 3 treatment periods. Each treatment period has 3 days and subsequent treatment period will be separated by 7 days.
3313716|NCT01951079|Experimental|second trimester abortion , feticide|all patients admitting to second trimester abortion above 22 weeks will be injected intra-amniotic DIGOXIN for feticide .
3313717|NCT01951144|Experimental|Cohort 1:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3313718|NCT01951144|Experimental|Cohort 2:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3313719|NCT01951144|Experimental|Cohort 3:|Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.
3313720|NCT01951144|Experimental|Cohort 4 (optional cohort):|Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.
3313721|NCT01951183|Placebo Comparator|Placebo|
3313722|NCT01951183|Experimental|RO6811135|
3313723|NCT01951196||Chronic kidney disease, CKD III+IV|150 patients with Chronic kidney disease, CKD stage III+IV.
3313724|NCT01951196||Healthy subjects|75 healthy subjects.
3313725|NCT01951209|Experimental|Rifaximin/Placebo|Rifaximin 550mg po bid for 12 weeks followed by crossover to matched placebo po bid x 12 weeks
3313726|NCT01951209|Experimental|Placebo/Rifaximin SSD|Matched placebo po bid for 12 weeks followed by crossover to Rifaximin 550mg po bid x 12 weeks
3313727|NCT01951222|Experimental|V0162 dose1|
3313728|NCT01951222|Experimental|V0162 dose2|
3313729|NCT01951222|Placebo Comparator|placebo|Placebo
3313730|NCT01951235|Experimental|Imeglimin (Dose 1)|
3313731|NCT01951235|Experimental|Imeglimin (Dose 2)|
3313732|NCT01951235|Experimental|Imeglimin (Dose 3)|
3313733|NCT01951235|Experimental|Imeglimin (Dose 4)|
3313734|NCT01951235|Placebo Comparator|Placebo|
3313735|NCT01951248|Experimental|CPAP treatment|Patients with chronic kidney disease and moderate to severe obstructive sleep apnea is treated 3 months with CPAP treatment
3313736|NCT01951274|Experimental|0.25 mg VPD-737|0.25 mg of VPD-737 daily by mouth for 42 days
3313737|NCT01951274|Experimental|1 mg VPD-737|1 mg VPD-737 taken daily by mouth for 42 days
3313738|NCT01951274|Experimental|5 mg VPD-737|5 mg tablets of VPD-737 to be taken daily by mouth for 42 days
3313739|NCT01951274|Placebo Comparator|Placebo|placebo tablets to be taken daily by mouth for 42 days
3313740|NCT01951287|Experimental|Acute beverage (Water) consumption|Acute beverage (Water)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points.
3313741|NCT01951287|Experimental|Acute beverage (Black Coffee) consumption|Acute beverage (Black Coffee)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3313742|NCT01951287|Experimental|Acute beverage (Orange Juice) consumption|Acute beverage (Orange Juice)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3313743|NCT01951287|Experimental|Acute beverage (Whole Milk) consumption|Acute beverage (Whole Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3313744|NCT01951287|Experimental|Acute beverage (2% Milk) consumption|Acute beverage (2% Milk) consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3313745|NCT01951287|Experimental|Acute beverage (Skim Milk) consumption|Acute beverage (Skim Milk)consumption with breakfast measuring blood glucose and insulin levels at specific time points. consumption with breakfast measuring blood glucose and insulin levels at specific time points
3313746|NCT01951300|Other|Gallium-68 citrate|Intravenous bolus injection of 200 MBq of Gallium-68 citrate
3313747|NCT01951313|Experimental|Egg consumption|No egg 75g of scrambled eggs 150g of scrambled eggs
3313748|NCT01951365||Growing schwannoma|Overall volumetric growth rate more over than 10%
3313749|NCT01951365||Stable schwannoma|Overall volumetric growth rate less than 10%
3313750|NCT01951404|Active Comparator|Allopurinol|Participants in this arm will be given allopurinol with the dose gradually increasing weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
3313751|NCT01951404|Placebo Comparator|Placebo|Participants in this arm will be given placebo with the dose appearing to gradually increase weekly as tolerated up to the dose determined in the first phase of the study. The drug dose will be given orally 3 times weekly after dialysis for 1 year.
3313752|NCT01951430||Myelodysplastic syndrome patients|Patients affected by myelodysplastic syndrome enrolled in the observational study
3313753|NCT01951443|Experimental|Ginseng|Encapsulated 400mg Rg3-KRG extract
3313754|NCT01951443|Placebo Comparator|Wheat Bran|400mg Wheat Bran capsule
3313755|NCT01951456|Experimental|Resistance training|Participants will attend two, 45-60-minute progressive, moderate intensity resistance training sessions per week for 12 weeks. The program will maintain a format of a 5-minute warm-up, 35-50 minutes of resistance training and a 5-minute cool-down with flexibility and abdominal exercises.
3313756|NCT01951456|Active Comparator|Health and Wellness|Participants in this group will be required to attend the exact same number of sessions as those in the Resistance Training group. Each session will last approximately 45-60 minutes. Sessions will include a practical component/demonstration, an informational video, and a handout on a pertinent healthy lifestyle topic for adults.
3313757|NCT01951469|Experimental|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
3313758|NCT01951469|Active Comparator|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
3313759|NCT01951482|Experimental|Bevacizumab and Pemetrexed/cisplatin|Bevacizumab 7.5mg/kg d1+Pemetrexed/cisplatin q21d
3313760|NCT01951482|Active Comparator|Pemetrexed/cisplatin|Pemetrexed/cisplatin q21d
3313761|NCT01951508|Other|Methylphenidate, Modafinil, MDMA, Placebo|Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but four treatment conditions in the same subject.
3313762|NCT01951521|Experimental|Boost|Boost radiation consists of 5 fractions of 3 Gy (total 15 Gy) delivered to the tumor (Gross Tumor Volume) additional to standard chemoradiation of 50 Gy with Capecitabine.
3313763|NCT01951521|No Intervention|Standard chemoradiation|Standard chemoradiation consisting of 25 x 2 Gy (total 50 Gy) with Capecitabine.
3313764|NCT01951534|Experimental|Breast Reconstruction Decisional Aid (BRDA)|In the BRDA arm, participants will be provided with a website address for using the Breast Reconstruction Decisional Aid, a secure password, and instructions for using the website for the decisional aid.
3313765|NCT01951534|Other|Usual Care (UC)|In the UC Condition, the participant will not be given the web-based decisional aid but will be given the Cancer Support Community pamphlet. This 56-page pamphlet contains information about the types of Breast Reconstruction, lists reasons why women choose reconstruction, key factors to considering when deciding, how to plan for surgery, possible risks, and a glossary of terms. The pamphlet is primarily informational. It is not customized, not interactive.
3313766|NCT01951547|Experimental|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy given at baseline
3313767|NCT01951547|Active Comparator|Oral hygiene instructions|Oral hygiene instructions given at baseline
3313768|NCT01951560|Experimental|valproic acid (Depacon)|Valproic acid by IV infusion over one hour
3313769|NCT01951560|Placebo Comparator|Isotonic saline solution|The placebo administered by IV infusion over 1 hour
3313770|NCT01951599|Experimental|AZD9291 20mg (oral capsule fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.
3313771|NCT01951599|Experimental|AZD9291 20mg (oral solution fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.
3313772|NCT01951599|Experimental|AZD9291 20mg (oral tablet fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.
3313773|NCT01951599|Experimental|AZD9291 20mg (oral fasted)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.
3313774|NCT01951599|Experimental|AZD9291 20mg (oral fed)|Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.
3313775|NCT01951612|Experimental|Executive Function Training Program|Participants in this group will receive the novel intervention training.
3313776|NCT01951612|Active Comparator|Psychoeducational Training Program|Participants in this group will receive the control intervention training.
3313777|NCT01951664|Experimental|Modified Yoga Program for HNC Survivors|Following the completion of baseline study measures, participants will be randomized to either do go directly into a Yoga program or to an 8 week wait-list control group. Those in the yoga program will undergo an initial Yoga Evaluation. Patients will receive customized yoga guided practice program, a home practice plan with ongoing modifications. Instructors will assess compliance. A satisfaction assessment is conducted at study-end.
3313778|NCT01951664|Active Comparator|Wait list control|Those in the wait list group will have the same assessments as those in the yoga program over the same period of time.
3313779|NCT01951677|Active Comparator|HBsAg + alum adjuvant|HBsAg + standard alum adjuvant
3313780|NCT01951677|Experimental|HBsAg + Advax-1(TM)|HBsAg + Advax-1
3313781|NCT01951677|Experimental|HBsAg + Advax-2(TM)|HBsAg + Advax-2
3313782|NCT01951677|Experimental|HBsAg + Advax-3(TM)|HBsAg + Advax-3
3313783|NCT01951677|Active Comparator|preS HBsAg + alum adjuvant|preS HBsAg + alum adjuvant
3313784|NCT01951677|Experimental|preS HBsAg + Advax-1(TM)|preS HBsAg + Advax-1
3313785|NCT01951677|Experimental|preS HBsAg + Advax-2(TM)|preS HBsAg + Advax-2
3313786|NCT01951677|Experimental|preS HBsAg + Advax-3(TM)|preS HBsAg + Advax-3
3313787|NCT01951677|Active Comparator|high dose preS HBsAg + alum adjuvant|high dose preS HBsAg + alum adjuvant
3313788|NCT01951677|Experimental|high dose preS HBsAg + Advax-1(TM)|high dose preS HBsAg + Advax-1
3313789|NCT01951677|Experimental|high dose preS HBsAg + Advax-2(TM)|high dose preS HBsAg + Advax-2(TM)
3313790|NCT01951677|Experimental|high dose preS HBsAg + Advax-3(TM)|high dose preS HBsAg + Advax-3
3313791|NCT01951690|Experimental|VS-6063 (defactinib)|Administered orally BID in a 21 day cycle
3313792|NCT01951716|Experimental|Truncal Vagotomy|Healthy participants without diabetes who have undergone a complete truncal vagotomy
3313793|NCT01951716|Experimental|No Vagotomy|Healthy participants without diabetes who have not had a complete truncal vagotomy
3313794|NCT01951729|Experimental|Pre-diabetes|Otherwise healthy individuals exhibiting hemoglobin A1c levels between 6.0% - 7.0%
3313795|NCT01951742|Placebo Comparator|Vehicle|vehicle without ANT-1401
3313796|NCT01951742|Experimental|Dose 1|lowest dose
3313797|NCT01951742|Experimental|Dose 2|second lowest dose
3313798|NCT01951742|Experimental|Dose 3|mid-level dose
3313799|NCT01951742|Experimental|Dose 4|second highest dose
3313800|NCT01951742|Experimental|Dose 5|highest dose
3313801|NCT01951781|Other|NEOCD64|NEOCD64 : dosage of CD64 blood marker in preterm newborn who are suspected of nosocomial infection (blood sample)
3313802|NCT01951807|Experimental|Coping & Communication Skills|The CCI intervention focuses on bolstering stress management and problem solving abilities, identifying and expressing support needs constructively, facilitating the ability to cope with unchangeable issues, cognitive restructuring, and dealing effectively with body image and sexuality issues over seven weekly 60 minute sessions.
3313803|NCT01951807|Experimental|Supportive Counseling (SC)|The SC intervention incorporates a supportive, non-directive counseling approach in seven weekly 60 minute sessions
3313804|NCT01951807|No Intervention|Usual Care (UC)|Patients receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
3313805|NCT01951833||Cystic fibrosis (Ecomedics vs NDD)|No treatment, observational
3313806|NCT01951833||Healthy (Ecomedics vs NDD)|"Free of respiratory symptoms for at least two weeks and will not have any chronic or recurrent chest problem.~No treatment, observational"
3313807|NCT01951846|Experimental|BIBF 1120|
3313808|NCT01951859|Experimental|Topical Neuropathy/Ulcer Cream|an anti-inflammatory topical cream that contains homeopathic ingredients
3313809|NCT01951859|Placebo Comparator|Placebo Cream|
3313810|NCT01951872|Experimental|Immediate treatment|Immediate manual-based treatment for caffeine dependence: administered within approximately one week following intake.
3313811|NCT01951872|Experimental|Delayed treatment|Delayed manual-based treatment for caffeine dependence: administered within approximately six weeks following intake.
3313812|NCT01951885|Active Comparator|Group A (tacrolimus, methotrexate)|Participants receive tacrolimus IV over 24 hours beginning on day -1 (or tacrolimus orally beginning on day -3) and then PO BID after engraftment with a taper from day 100 to day 180 (in the absence of GVHD). Patients also receive methotrexate IV on days 1, 3, 6, and 11.
3313813|NCT01951885|Experimental|Group B (tacrolimus, methotrexate, mycophenolate mofetil)|Patients receive tacrolimus as in group A and methotrexate (low dose) IV on days 1, 3, and 6. Patients also receive oral mycophenolate mofetil BID beginning on day 1, with a taper from day 45 to day 100 (in the absence of GVHD).
3313814|NCT01951898|Active Comparator|Montelukast|
3313815|NCT01951898|Sham Comparator|Vitamin B6|
3313816|NCT01951911|Active Comparator|Ketamine|Ketamine 1 mg per kg per 24 hours as subcutaneous infusion via syringe driver for 48 hours.
3313817|NCT01951911|Placebo Comparator|Placebo|Sodium chloride 0.9% administered as a subcutaneous infusion via syringe driver for 48 hours.
3313818|NCT01951924|Experimental|Group A: I10E then Kiovig®|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
3313819|NCT01951924|Experimental|Group B : Kiovig® then I10E|1 g/kg for 1-3 days up to 2 g/kg for 2-5 days every 4 to 8 weeks (±7 days)
3313820|NCT01951937|Active Comparator|Fish Meals|3 Fish meals per week for 4 months
3313821|NCT01951937|Placebo Comparator|Placebo|Habitual diet
3313822|NCT01951976|Experimental|Intervention Condition|"Questionnaires and yoga classes.~Group will attend a series of 90-minute yoga classes twice a week for 12 weeks."
3313823|NCT01951989|Experimental|Imiglucerase|"Primary purpose: to evaluate the pharmacokinetics of Imiglucerase activity into target cellular compartment depending on dose and frequency of infusions.~Secondary purposes : 1) to establish a possible relationship between the intra-monocytic activity of glucocerebrosidase and the clinical and biological activity of Gaucher disease and to define a possible threshold value of enzyme activity; 2) to establish a better correlation with known biomarkers of disease (routine markers and markers recently identified), which would better predict and / or monitor response to treatment ; 3) to compare the residual and natural rate of activity enzyme intra-monocytic for untreated patients (low severity disease)."
3313824|NCT01952002||IMT - Inspiratory Muscle Training|21 (16 males/5 femalesen) with a mean age of 73 ± 7.4 years were studied. Among the 21 study participants, the most prevalent clinical condition was coronary artery disease (11 cases); four individuals showing a diagnosis of chronic obstructive pulmonary disease and/or asthma, two presented congestive heart failure and the last four had other diseases
3313825|NCT01952067|Experimental|line-to-line reaming|Corail cemented femoral stem using line-to-line reaming and cementing technique, 28mm Alumine Biolox forte femoral head, Marathon cup
3313826|NCT01952067|Active Comparator|standard over-reaming|Corail cemented femoral stem using standard over-reaming with 2 broach sizes, 28mm Alumine Biolox forte femoral head, Marathon cup
3313827|NCT01952093||Usual care program|VLBW preterm infants who received usual medical care during hospitalization after birth.(in the previous study)
3313828|NCT01952093||Clinic-based intervention program|VLBW preterm infants who received specific early intervention program delivered at clinic before 1 year of corrected age (in the previous study)
3313829|NCT01952093||Home-based intervention program|VLBW preterm infants who received specific early intervention program delivered at home before 1 year of corrected age (in the previous study)
3313830|NCT01952093||Term control group|Healthy term infants
3381647|NCT02202434|Experimental|Lotus Valve System - Single-arm Continued Access Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3381648|NCT02202434|Experimental|Lotus Valve System - Single-arm Roll-in Cohort|Transcatheter aortic valve replacement (TAVR) with Lotus Valve System
3313831|NCT01952106|Experimental|distraction|use the computer game to distract children's pain and anxiety during venepuncture
3313832|NCT01952119|No Intervention|Routine Care|Routine care, no intervention
3381649|NCT02202434|Experimental|LOTUS Edge Valve System - Single-arm Edge Nested Registry|Transcatheter aortic valve replacement (TAVR) with 23mm, 25mm and 27mm LOTUS Edge Valve System.
3313833|NCT01952119|Active Comparator|Secure message reminder|Will receive a secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
3313834|NCT01952132|Experimental|OMS643762 Low Dose|Orally administering OMS643762 low dose daily for 14 days
3313835|NCT01952132|Experimental|OMS643762 High Dose|Orally administering OMS643762 high dose daily for 14 days
3313836|NCT01952132|Placebo Comparator|Placebo|Orally administering placebo daily for 14 days
3313837|NCT01952132|Experimental|OMS643762 Medium Dose|Orally administering OMS643762 medium dose daily for 14 days
3313839|NCT01952184|Active Comparator|closed vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryo Bio Systems High Security vitrification (CBSvit HS) device; the standard device in our lab.
3313840|NCT01952184|Experimental|open vitrification with closed storage|Half of the oocytes of every donor will be vitrified with the Cryotop closed system (Cryotop SC).
3313841|NCT01952197|Experimental|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
3313842|NCT01952210|Experimental|nutrition consultation and exercise program|individual nutritional consultation and exercise
3313843|NCT01952210|Active Comparator|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
3313844|NCT01952223|Experimental|ADT + pelvic RT|"ADT for a total duration of 3 years i.e. luteinizing hormone-releasing hormone (LHRH) agonist or LHRH antagonist +/-Peripheral anti-androgen~Pelvic RT (by IMRT or IGRT protocol):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3313845|NCT01952223|Experimental|ADT + Cabazitaxel + prostate RT|"ADT Cabazitaxel: 4 CT cycles~Prostate-only RT (IMRT or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3313846|NCT01952223|Experimental|ADT + cabazitaxel + pelvic RT|"ADT Cabazitaxel: 4 CT cycles~Pelvic RT (IMRT or IGRT):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3313847|NCT01952223|Active Comparator|ADT + prostate radiotherapy|"ADT for a total duration of 3 years: LHRH agonist or LHRH antagonist +/- anti-androgen~Prostate-only RT (IMRt or IGRT):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
3313848|NCT01952236|Experimental|Web+Mobile|A best-practices Web-based smoking cessation program integrated with a tailored treatment program delivered using a smartphone application.
3313849|NCT01952236|Active Comparator|Web Only|A best-practices Web-based smoking cessation program.
3313850|NCT01952249|Experimental|Demcizumab|Demcizumab will be administered prior to paclitaxel by intravenous (IV) infusion.
3313851|NCT01952249|Experimental|Taxol|demcizumab combined with weekly paclitaxel
3313855|NCT01952314|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics.
3313856|NCT01952314|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
3313857|NCT01952327|Other|plueurapump|Implantation of pleurapump system
3313858|NCT01952340|Experimental|Flaxseed|30 grams of milled flaxseed on its own or baked into food products (ie: bagels, muffins, and snack bars)
3313859|NCT01952340|Placebo Comparator|Wheat/Mixed Dietary Oils|A combination of wheat, pecans, and/or mixed dietary oils on its own or baked into food products (ie: bagels, muffins, and snack bars)
3313860|NCT01952353|Experimental|Preoperation TACE arm|In the preoperative TACE arm (Arm 2), patients underwent TACE followed by surgical resection. Preoperative TACE sessions were repeated once at 4-week intervals unless patients showed either PD or PVTT PD. Then, the patients were prepared for surgical resection, with the exception of those with unresectable disease after TACE For patients who had unresectable disease after TACE, plans for surgical resection were abandoned and the subsequent treatment course was determined by his/her attending oncologist
3313861|NCT01952353|Active Comparator|Resection arm|Liver resection Plus Thrombectomy
3313862|NCT01952379||Melasma|Women affected by symmetric facial malar melasma.
3313863|NCT01952392||Control group|Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
3313864|NCT01952392||Case group|Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary
3313865|NCT01952405|Experimental|Dialectical behavior therapy|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
3313866|NCT01952405|Placebo Comparator|alternative psychotherapy|The therapists of the alternative psychotherapy in the comparison group are asked to provide the type and dose of therapy that they believed is most suited to the patient, with a minimum of 1 scheduled individual session per week. Ancillary treatment could be prescribed as needed. Case management strategies are also available in the comparison group (alternative psychotherapy group). No restrictions are placed on ancillary pharmacotherapy in either condition.
3381650|NCT02173353||Pancreas cancer|Develope a stand, cradle or robotic arm to hold the ultrasound probe, to obtain an ultrasound just before a standard radiation therapy treatment is given.
3381651|NCT02152982|Experimental|Arm I (temozolomide, veliparib)|Patients receive temozolomide PO QD on days 1-5 and veliparib PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
3381652|NCT02152982|Placebo Comparator|Arm II (temozolomide, placebo)|Patients receive temozolomide as in Arm I and placebo PO BID on days 1-7. Treatment repeats every 28 days for 6 cycles in the absence of disease progression (confirmed progression) or unacceptable toxicity.
3381653|NCT02135302|Experimental|Impaired hepatic function|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each hepatically impaired subject.
3381654|NCT02135302|Experimental|Healthy subjects|A single 1.5 mg/kg dose of eravacycline will be administered intravenously on Day 1 as a 60 minute infusion to each healthy subject.
3381655|NCT02135276|Experimental|End stage renal disease (ESRD) subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
3381656|NCT02135276|Experimental|Normal healthy subjects|A single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes
3381657|NCT02108652|Experimental|Cohort 2: Participants With Second-line or Beyond Treatments|Participants with advanced disease who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting will receive atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.
3381658|NCT02097134|Experimental|Treatment (melphalan)|Patients receive melphalan IA on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
3313867|NCT01952431|Experimental|PulmOne MiniBox PFT|Total Lung Capacity (TLC) testing with PulmOne MiniBoxPFT
3381664|NCT02038725||TIA in last 2 weeks|
3381665|NCT02028884|Experimental|Satralizumab + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive satralizumab in addition to baseline treatment. The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
3381666|NCT02028884|Placebo Comparator|Placebo + Baseline Treatment|Participants randomized to this arm for the double-blind period will receive placebo in addition to baseline treatment.The double-blind period ends when either the participant has a treated relapse or the total number of protocol-defined relapses confirmed by the Clinical Endpoint Committee (CEC) reaches 26. In the open-label extension period, the participant will receive (with or without baseline treatment) an SC injection of satralizumab at Weeks 0, 2, and 4, and Q4W thereafter, with the last study drug administration on or before 31 December 2021.
3381667|NCT02016378|Sham Comparator|sham retraining|Participants in this condition will participate in a computerized task wherein the size of pictures of drug and non-drug related stimuli are increased or decreased based on the tilt (left or right) of the pictures, but without regard to the content (i.e., drug or non-drug).
3381668|NCT02016378|Active Comparator|Bias retraining|Participants in this condition will participate in 6 sessions of a computerized bias retraining.
3381669|NCT01989949|Experimental|TP-434 (Eravacycline) via IV infusion|TP-434 (Eravacycline) reconstituted and administered via IV infusion at a dose of 1 mg/kg, every 12 hours, for 7 doses over 4 days.
3381670|NCT01799915||REM sleep behavior disorder, RBD|Patients that have rapid eye movement sleep behavior disorder.
3381671|NCT01799915||multiple system atrophy|is a neurodegenerative disorder charaterized by abnormal alpha-synuclein deposition in the cytoplasm of oligodendroglial cells in the CNS, and typically sparing peripheral autonomic nerves.
3381672|NCT01799915||Pure Autonomic failure|A neurodegenerative disorder characterized by loss of peripheral noradrenergic fibers, with low levels of plasma norepinephine.
3381673|NCT01799915||Parkinson disease|A degenerative disorder of the central nervous system that leads to termors, difficulty walking, movement and coordination.
3381674|NCT01799915||Dementia with Lewy bodies|A neurodegenerative disorder similar to PAF and PD with the accumulation of Alpha-synuclein in the CNS however DLB patients develop dementia.
3313868|NCT01952431|Active Comparator|ZAN500|Total Lung Capacity (TLC) testing with ZAN500.
3313869|NCT01952457|Experimental|Zilver PTX|Patients in the Zilver PTX arm have to be treated by placement of the Zilver PTX drug-eluting stent (Cook), according to standard procedures based on the Instructions for Use. The only pre-treatment allowed prior to placement of the Zilver PTX drug-eluting stent (Cook) is standard PTA. Diameter measurements must be performed of the healthy vessel proximal and distal to the previously stented area. Diameter selection of the Zilver PTX drug-eluting stent (Cook) should result in minimal oversizing. The target lesion needs to be completely covered by using as few stents possible. Post-dilatation can be performed according to the Instructions of Use.
3313870|NCT01952457|Active Comparator|prosthetic bypass|Patients in the bypass arm have to be treated with a prosthetic bypass graft according to the institution's standard of care and the Instructions for Use of the prosthetic bypass graft.
3313871|NCT01952483||vitamin D deficient,|Vitamin D deficiency (serum level <20ng/ml)
3313872|NCT01952483||Vitamin D normal|Serum level >35 ng/ml
3313873|NCT01952496|Other|Force-measuring platform|"A force-measure platform will be placed under each foot of the subject to record the time course of load borne by each of the lower extremities during weight-bearing training in an assisted standing device.~Intervention: Assisted Standing Treatment Program. Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months."
3313874|NCT01952509||Cohort|
3313875|NCT01952535|Experimental|HMS5552 dose 1|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313876|NCT01952535|Experimental|HMS5552 dose 2|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313877|NCT01952535|Experimental|HMS5552 dose 3|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313878|NCT01952535|Experimental|HMS5552 dose 4|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313879|NCT01952535|Experimental|HMS5552 dose 5|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313880|NCT01952535|Experimental|HMS5552 dose 6|A single dose of HMS5552 tablets (5~50mg) taken orally.
3313881|NCT01952548|Experimental|Dose 1 Active|
3313882|NCT01952548|Experimental|Dose 2 Active|
3313883|NCT01952548|Experimental|Dose 3 Active|
3313884|NCT01952548|Experimental|Dose 4 Active|
3313885|NCT01952548|Experimental|Dose 5 Active|
3313886|NCT01952548|Experimental|Dose 6 Active|
3313887|NCT01952548|Experimental|Dose 7 Active|
3313888|NCT01952548|Placebo Comparator|Dose 1 Placebo|
3313889|NCT01952548|Placebo Comparator|Dose 2 Placebo|
3313890|NCT01952548|Placebo Comparator|Dose 3 Placebo|
3313891|NCT01952548|Placebo Comparator|Dose 4 Placebo|
3313892|NCT01952548|Placebo Comparator|Dose 5 Placebo|
3313893|NCT01952548|Placebo Comparator|Dose 6 Placebo|
3313894|NCT01952548|Placebo Comparator|Dose 7 Placebo|
3313895|NCT01952561|Experimental|2 weeks|
3313896|NCT01952561|Experimental|1 week|
3313897|NCT01952561|Experimental|4 weeks|
3313898|NCT01952561|Experimental|8 weeks|
3313899|NCT01952561|Experimental|12 weeks|
3313900|NCT01952587|Other|HIV-infected women|A peripheral blood sample will be collected from HIV-infected women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed.
3313901|NCT01952587|Other|Healthy control women|A peripheral blood sample will be collected from healthy women to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
3313902|NCT01952613|Experimental|Stroke - FES|Stroke population currently prescribed a FES orthotic device (< week)
3313903|NCT01952626|Active Comparator|ondansetron|Intravenous administration of ondansetron 4mg 15 minutes before spinal anesthesia
3313904|NCT01952626|Experimental|palonosetron|Intravenous administration of palonosetron 0.075mg 15 minutes before spinal anesthesia
3313905|NCT01952639|Experimental|30 g of wheat protein|Subjects will consume 30 g of wheat protein protein type and amount
3313906|NCT01952639|Experimental|30 g of wheat protein hydrolysate|Subjects will consume 30 g of wheat protein hydrolysate protein type and amount
3313907|NCT01952639|Active Comparator|30 g of whey protein|Subjects will consume 30 g of whey protein protein type and amount
3313908|NCT01952639|Active Comparator|30 g of casein|Subjects will consume 30 g of casein protein type and amount
3313909|NCT01952639|Experimental|60 g of wheat protein hydrolysate|Subjects will consume 60 g of wheat protein hydrolysate protein type and amount
3313910|NCT01952652|Active Comparator|Group Naproxen sodium (Group N)|Group N received naproxen sodium 550 mg 60 minutes before surgery.
3313911|NCT01952652|Active Comparator|Group Naproxen sodium codeine phosphate (Group NC)|Group NC received naproxen sodium 550 mg+30 mg codeine 60 minutes before surgery.
3313912|NCT01952704|Experimental|Aerobic exercise|30 minutes x 3 times/week x 12 weeks of stationery cycling
3313913|NCT01952704|Placebo Comparator|Non-aerobic exercise|30 minutes x 3 times/week x 12 weeks of gentle non-aerobic stretching
3313914|NCT01952730|Experimental|Experimental Treatment Arm|GVAX, up to 6 vaccinations, administered via injection
3313915|NCT01952743|Active Comparator|AF Ablation alone|Clinical AF ablation performed as deemed appropriate by operator
3313916|NCT01952743|Experimental|AF ablation with Renal Denervation|Renal denervation performed using the same ablation catheter after clinical AF ablation
3313917|NCT01952756|Active Comparator|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
3313918|NCT01952756|Placebo Comparator|Dummy Placebo|One tablet twice per day for 12 weeks
3313919|NCT01952769|Experimental|treatment of DIPG with MDV9300|treatment of diffuse pontine glioma with MDV9300 with the combination of radiation and low dose cyclophosphamide
3313920|NCT01952782|Experimental|Naloxone, Kisspeptin, GnRH|"The study will involve 3 visits:~Outpatient screening visit~Inpatient admission where subjects receive an intravenous infusion of naloxone, intravenous doses of kisspeptin 112-121, and intravenous doses of Gonadotropin Releasing Hormone (GnRH)~Outpatient follow-up visit"
3313921|NCT01952795|Active Comparator|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day. 3 sessions per week on a bicycle ergometer or on a treadmill (according to body fat distribution and other parameters) modifications carried out weekly, with a gradual increase as to exercise until maximal oxygen consumption 60 - 70% would always preceded by heating 5 minutes.
3313922|NCT01952795|No Intervention|No intervention|Usual diet and exercise
3313923|NCT01952808|Experimental|Intervention Group|Participants randomly assigned to this group will receive the intervention immediately.
3381675|NCT01789983||Breast Cancer Patients 60+|Breast Cancer Patients age 60 and older who have histologically confirmed stage I, II or III disease.
3313924|NCT01952808|No Intervention|Control Group|Participants randomly assigned to this group will not receive the intervention until one year after enrollment.
3313925|NCT01952821||Test Group|This group will receive all listed outcome measures on 2 testing visits.
3313926|NCT01952847|Placebo Comparator|mTOR Inhibitor Patient Group - Placebo|Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
3313927|NCT01952847|Experimental|mTOR Inhibitor Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
3313928|NCT01952847|Placebo Comparator|Radiation Therapy to Esophagus Patient Group - Placebo|Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
3313929|NCT01952847|Experimental|Radiation Therapy to Esophagus Patient Group - Glutamine|Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times.
3381676|NCT01789983||Lung Cancer Patients 60+|Lung Cancer Patients age 60 and above who have stage I, II or III disease
3313930|NCT01952860|Experimental|Hatha Yoga|Participants receive 18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home. Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
3313931|NCT01952873|Active Comparator|Rapid|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
3313932|NCT01952873|Experimental|Prolonged|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
3313933|NCT01952886|Experimental|Granisetron patch|Granisetron transdermal delivery system (supplied as a 52 cm^2 patch containing 34.3 mg of granisetron - 3.1 mg/day) is applied once per week.
3313934|NCT01952886|Active Comparator|Ondansetron tablet|Ondansetron 8 mg oral tablet is prescribed for once a day.
3313935|NCT01952899||Albert Schweitzer Hospital|
3313936|NCT01952899||Erasmus MC Academic Hospital|
3313937|NCT01952899||Ikazia Hospital|
3313938|NCT01952899||IJsselland Hospital|
3313939|NCT01952899||Maasstad Hospital|
3313940|NCT01952899||Sint Franciscus Gasthuis Hospital|
3313941|NCT01952912|Active Comparator|PkEP|
3313942|NCT01952912|Active Comparator|OP|
3313943|NCT01952925|Experimental|Combined afib ablation and RA denervation|Patients with atrial fibrillation and resistant hypertension will be enrolled and undergo a single procedure consisting of pulmonary vein isolation and renal artery denervation.
3313944|NCT01952938||LINK SL|Patients
3313945|NCT01952938||EnduRo|Patients
3313946|NCT01952951|Experimental|chemoradiation followed by CapOx|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by 2 cycles of chemotherapy (Capecitabine Oxaliplatin - CapOx) and surgery (total mesorectal excision)
3313947|NCT01952951|Active Comparator|chemoradiation|preoperative chemoradiation 50.4Gy with capecitabine or 5-fluorouracil/leucovorin (pelvic radiation capecitabine 5-fluorouracil) followed by rest for 8 weeks and surgery (total mesorectal excision)
3313948|NCT01952964|Experimental|JUC spray dressing|
3313949|NCT01952977|Active Comparator|MCT|MCT oil (20 g) was included in the test breakfast
3313950|NCT01952977|Placebo Comparator|LCT|Corn oil (20 g) was included in the test breakfast
3313951|NCT01952990|Experimental|Kovacaine Mist|"Tetracaine HCl 3% and Oxymetazoline HCl 0.05% - Total dose is based on weight. Subjects weighing 10 to <20 kg will receive 1 intranasal spray of 100 μL. Subjects weighing 20 to <40 kg will receive 2 intranasal sprays of 100 μL (total dose 200 μL.~Subjects weighing 40 kg or more will receive 2 intranasal sprays of 200 μL (total dose 400 μL)."
3313952|NCT01953029||non obstructive coronary disease|non obstructive coronary disease
3313953|NCT01953042|No Intervention|Waitlist as Per Usual|Wait list as per usual with no additional information sessions
3313954|NCT01953042|Active Comparator|Waitlist and Psychoeducation|Patients remain on waitlist but also receive 4 additional educational sessions (8 hours each)
3313955|NCT01953055|Experimental|Stereotactic ablative radiotherapy|40 Gy in 5 fractions over 4 weeks to prostate; 25 Gy in 5 fractions over 4 weeks to pelvic lymph nodes given simulataneously.
3313956|NCT01953094|Other|Anal Screening Pap Smear - Negative|Anal Pap Smear with no High Resolution Anoscopy
3313957|NCT01953094|Other|Anal Pap Smear - Positive Result - High Resolution Anoscopy|Patient who have a positive anal pap smear will go on to have a high resolution anoscopy.
3313958|NCT01953107|Experimental|Ferrous Fumarate 300 mg + Vitamin C|300 mg once a day of Oral Ferrous Fumarate
3313959|NCT01953107|Placebo Comparator|Placebo + Vitamin C|300 mg of Placebo
3313960|NCT01953120|Experimental|Belatacept|Survival and rejection in patients switched to belatacept.
3313961|NCT01953133|No Intervention|Control|"Couples do not receive intervention (counseling sessions) during study period. They do undergo one group-based session.~Upon completion of 9 month follow-up, participants in this arm can undergo a condensed, 2 session version of the intervention."
3313962|NCT01953133|Experimental|Couples' Counseling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
3381677|NCT01789983||Colon Cancer Patients 60+|Colon cancer patients age 60 and above who have stage II or III disease.
3313963|NCT01953146||PCOS criteria|nfertile patients undergoing assisted reproduction were consecutively recruited at the Fertility Clinic, Arhus University Hospital from February 2011 to May 2013. Women aged < 38 years without endometriosis where more than > 8 oocytes were retrieved were eligible. Patients were categorized in PCOS and non-PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.
3313964|NCT01953159||Patients with severe neuropathy|Patients with severe neuropathy after treatment with paclitaxel. Blood samples and patient questionnaires will be collected.
3313965|NCT01953159||Patients without neuropathy|Patients will be enrolled to this cohort and matched to a specified subject with neurotoxicity based on age (within 10 years), tumor type, chemotherapy regimen or total paclitaxel dosage, race, and ethnicity
3313966|NCT01953172|Placebo Comparator|Placebo capsules|Placebo capsules
3313967|NCT01953172|Experimental|AMP-886 (alpha-tocotrienol) in capsules|AMP-886 (alpha-tocotrienol) in capsules
3313968|NCT01953185|Experimental|Manual diaphragm release technique|
3313969|NCT01953185|Sham Comparator|Control group|
3313970|NCT01953198||All study participants|A total of 44 healthy and trained volunteers, age between 18 and 70 years. Subjects must have basic mountaineering experience.
3313971|NCT01953250||Infiltrating endometriosis|272 patients that underwent laparoscopic sigmoid and/or rectum resection with the indication of deep infiltrating endometriosis, in the department of Abdominal Surgery, University Hospital Leuven, between the year 1997 and September 2011.
3313972|NCT01953263|Experimental|Autologous Muscle Fiber Fragments|Autologous Muscle Fiber Fragments administered via a single,direct injection into the bladder neck sphincter region
3313973|NCT01953276||Serial Electrocardiogram Arm|All study participants will receive serial electrocardiograms.
3313974|NCT01953289||Appendicitis|Free fluid in perforated or non-perforated appendicitis
3313975|NCT01953302|Experimental|"modified open mesh technique"|"We performed an open intraperitoneal mesh technique in all patients: we placed surgical mesh of appropriate size intraperitoneally with transfascial fixation and drainage."
3313976|NCT01953315|Experimental|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
3313977|NCT01953341|Experimental|AMG 333|Subjects will receive a single oral dose of AMG 333 .
3313978|NCT01953341|Placebo Comparator|Placebo|Subjects will receive a single oral dose of placebo.
3313979|NCT01953367|Experimental|Vantobra; Treatment A|Vantobra, 170 mg tobramycin/1.7 mL nebulizer solution
3313980|NCT01953367|Active Comparator|TOBI; Treatment B|TOBI, 300 mg tobramycin/5 mL nebulizer solution
3313981|NCT01953380|Active Comparator|extended information|Extended information on specific allergy
3313982|NCT01953380|No Intervention|Information according to clin. routine|Information according to clinical routine
3313983|NCT01953406|Experimental|The 5-fluorouracil/mitomycin group|Systemic chemotherapy with 5-fluorouracil/mitomycin 5-fluorouracin 15mg/kg/day D1-6 civ + Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
3313984|NCT01953419|Experimental|Treatment group|received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity
3313985|NCT01953445|Experimental|Treatment (PI3K inhibitor BKM120, paclitaxel)|Patients receive PI3K inhibitor BKM120 PO QD on days 1-28 and paclitaxel IV over 60 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity.
3313986|NCT01953458||hepatitis C and/or B|
3313987|NCT01953471||Allergic rhinitis|
3313988|NCT01953484|Experimental|Acute Respiratory Distress Syndrome|Acute hypoxemia, bilateral pulmonary infiltrates and no evidence of primary left atrial hypertension
3313989|NCT01953484|Experimental|Chronic Obstructive Pulmonary Disease|Acute-on-Chronic Respiratory Insufficiency (patients with Chronic Obstructive Pulmonary Disease)
3313990|NCT01953484|Experimental|Bridge to Lung Transplant|Acute-on-Chronic Respiratory Insufficiency (patients awaiting lung transplant)
3313991|NCT01953497|Placebo Comparator|Placebo|Placebo
3313992|NCT01953497|Active Comparator|URC102|URC102
3313993|NCT01953510|Active Comparator|A: 3+1 PCV10|PCV10 administered at 2, 3, 4 and 9 months of age
3313994|NCT01953510|Experimental|B: 3+0 PCV10|PCV10 administered at 2, 3 and 4 months of age
3313995|NCT01953510|Experimental|C: 2+1 PCV10|PCV10 administered at 2, 4 and 9 months of age
3313996|NCT01953510|Experimental|D: 1+1 PCV10|PCV10 administered at 2 and 6 months of age
3313997|NCT01953510|Experimental|E: 2+1 PCV13|PCV13 administered at 2, 4 and 9 months of age
3313998|NCT01953510|No Intervention|F: control|No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
3313999|NCT01953510|No Intervention|G: control|Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age
3314000|NCT01953523|Experimental|Deployment of stromal vascular fraction|Administration of autologous adipose derived SVF
3314001|NCT01953536|Experimental|Vintafolide|Participants receive intravenous (IV) vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of a 28-day cycle.
3314002|NCT01953536|Experimental|Vintafolide + Paclitaxel|Participants receive IV vintafolide 2.5 mg on Days 1, 3, 5, 15, 17, and 19 of one 28-day cycle and receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
3314003|NCT01953536|Active Comparator|Paclitaxel|Participants receive IV paclitaxel on Days 1, 8, 15, and 22 of a 28-day cycle.
3314004|NCT01953549|Experimental|physical fitness training|aerobic physical fitness training
3314005|NCT01953549|Active Comparator|relaxation|non-aerobic training
3314006|NCT01953562||Intubated infants|
3314007|NCT01953588|Active Comparator|Arm I (anastrozole)|Patients receive anastrozole daily for 6 cycles followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3314008|NCT01953588|Active Comparator|Arm II (fulvestrant)|Patients receive fulvestrant on days 1 and 15 of cycle 1 and day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3314009|NCT01953588|Active Comparator|Arm III (anastrozole and fulvestrant)|Patients receive anastrozole daily in combination with fulvestrant on days 1 and 15 of cycle 1, and on day 1 of cycles 2-6 followed by surgery. A treatment cycle is 4 weeks in length. After completion of analysis of endocrine resistant data, patients will continue treatment as defined in the protocol.
3314010|NCT01953614|Sham Comparator|Placebo group|Ten people. Participants will receive what appears to be a chiropractic adjustment but which actually is not. This is the sham adjustment. Participants will also fill out Achenbach questionnaire. There will be a follow up in 7 days.
3314011|NCT01953614|Active Comparator|Chiropractic adjustment|Ten people. Group will be getting chiropractic adjustments. Participants will be filling out Achenbach questionnaire. There will be a follow up in 7 days.
3314012|NCT01953614|No Intervention|Control group|Ten people. This group will simply have their EEG recorded at baseline and after 7 days. There will be an Achenbach questionnaire like the two other groups.
3314013|NCT01953627|Experimental|Surgical procedure with the system Kymerax|
3314014|NCT01953640||Ancillary-correlative (gene expression with CYP-17 inhibition)|Laboratory Biomarker Analysis: Tissue, blood, and urine samples are collected at baseline and after 12-14 weeks of treatment and assessed for circulating tumor cells, genome-wide SNP, and exome sequencing. Subjects will also receive a Quality-of-Life Assessment.
3314015|NCT01953653|Other|A: Begin with Interactive Voice Response (IVR) System|Group A participants are randomized the IVR system as Modality #1. After 33 days of diary completion using IVR, they switch to the interactive web response system (IWR)as Modality #2.
3314016|NCT01953653|Other|B: Begin with Interactive Web Response (IWR) System|Group B participants are randomized to the IWR system as Modality #1. After 33 days of diary completion using IWR, they switch to the interactive voice response (IVR)system as Modality #2.
3314017|NCT01953666|Experimental|Rehabilitation Group|People with spinal cord injury who have a rehabilitation program on a word prediction software with an occupational therapist.
3314018|NCT01953666|Active Comparator|Self Training at Home Group|People with spinal cord injury who don't have a rehabilitation program with an occupational therapist but who have instructions for learning at home on a word prediction software
3314019|NCT01953666|No Intervention|No treatment Group|People with spinal cord injury who don't have instructions, rehabilitation programm on word prediction software. They have no treatment.
3314020|NCT01953679|Active Comparator|5mg UPA|Continuous regimen of oral daily 5 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
3314021|NCT01953679|Active Comparator|10mg UPA|Continuous regimen of oral daily 10 mg of ulipristal acetate (UPA) versus a cyclic regimen of 5 mg UPA for 24 days followed by a 4 day hormone free interval.
3314022|NCT01953705|Experimental|omega 3 polyunsaturated fatty acids|1.65 grams of EPA+DHA taken daily over 3 years
3314023|NCT01953705|Placebo Comparator|Soybean oil|1.65 grams of soybean oil taken daily over 3 years
3314024|NCT01953731|Experimental|Single-Arm Fixed-Sequence|Subjects will receive two different interventions in fixed-sequence two-period study. In the first period the subjects will receive a single-dose of palbociclib. In the second period, subjects will receive 12 days of rifampin and a single dose of palbociclib on day 8. In both periods, subjects will undergo pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
3314025|NCT01953744|Experimental|Fluconazole|Fluconazole will be administered by oral route at 6-8mg/kg/day during 28 days.
3314026|NCT01953744|Active Comparator|Meglumine Antimoniate|Meglumine Antimoniate will be administered by intravenous route at 20mg/kg/day during 20 days.
3314027|NCT01953757|Experimental|Vegan diet and vitamin B12 supplement|The diet/supplement group will be asked to follow a low-fat, vegan diet for 20 weeks, and take a vitamin B12 supplement daily.
3314028|NCT01953757|Active Comparator|Vitamin B12 supplement|The supplement group will be asked to take a daily vitamin B12 supplement, and to make no changes to their current diet.
3314029|NCT01953770|Active Comparator|Cranial irradiation|Consolidation therapy with cranial irradiation in intermediate risk group patients
3314030|NCT01953770|Experimental|Additional TIT|Consolidation therapy with additional triple intrathecal therapy (N6) and without cranial irradiation in intermediate risk group patients
3314031|NCT01953770|Experimental|MTX 2,000 mg/m2|Consolidation therapy with High-dose Methotrexate 2,000 mg/m2/24 h i.v. biweekly in intermediate risk group patients
3314032|NCT01953770|Active Comparator|MTX 30 mg/m2|Consolidation therapy with Low-dose Methotrexate 30 mg/m2 i.m. weekly in intermediate risk group patients
3314033|NCT01953770|Experimental|PEG-asp 1,000 U/m2|Consolidation therapy with PEG-L-asparaginase cons 1,000 U/m2 biweekly in standard risk group patients
3314034|NCT01953770|Active Comparator|L-asp 5,000 U/m2|Consolidation therapy with E.coli L-asparaginase 5,000 U/m2 weekly in standard risk group patients
3314035|NCT01953770|Active Comparator|PEG-DNR+|Induction therapy without PEG-L-asparaginase and with Daunorubicin 45 mg/m2 in standard and intermediate risk group patients
3314036|NCT01953770|Experimental|PEG+DNR+|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy)and daunorubicin 45 mg/m2 in standard and intermediate risk group patients
3314037|NCT01953770|Experimental|PEG+DNR-|Induction therapy with PEG-L-asparaginase ind (1,000 U/m2 on day 3 of therapy) without daunorubicin on day 8 in standard risk group patients
3314038|NCT01953796|Experimental|Study of Stair-step Clomiphene Protocol|50 mg clomiphene given for 5 days beginning on day 2 of the cycle. Tv USS done at days 11-14. When there is no response (no follicle >10 mm), 100 mg clomiphene is initiated immediately for 5 days, and U/S is repeated 1 week after the first tvUSS at day 21. If there is no response, another 150 mg clomiphene is initiated immediately for 5 days and U/S is performed 1week after the second U/S (day28). Ovulation for the stair-step cycles was confirmed by folliculometry (follicle tracing) by tvUSS.
3314039|NCT01953796|Active Comparator|Traditional Protocol.|Clomiphene medication was initiated at day two of the cycle. The starting dose was 50 mg/day for 5 consecutive days. In case of absent response, the patient was treated with 10 mg medroxyprogesterone acetate (MPA) for10 days. Daily doses of clomiphene citrate were increased by 50 mg in the next cycle up to 3 treatment cycle. In each cycle monitoring of follicular growth was done by tvUSS at day 11-14 of each cycle. First ovulation was used as the endpoint and the duration of follow-up was three treatment cycles (up to 150mg). Ovulation was assessed by tvUSS monitoring of follicle growth.
3314040|NCT01953809|Experimental|Run-in Period|All subjects will receive EE/NE for first 21 days and EE/NE matching placebo for next 7 days before start of treatment phase
3314041|NCT01953809|Experimental|Group 1|Subjects upon completion of 28 days of run-in period will receive GSK1322322/Placebo + EE/NE in period 1 and only EE/NE in period 2 and 3 of treatment phase. Each period will be of 7 days
3314042|NCT01953809|Experimental|Group 2|Subjects upon completion of 28 days of run-in period will receive only EE/NE in period 1, GSK1322322/Placebo + EE/NE in period 2 and again EE/NE only in period 3 of treatment phase. Each period will be of 7 days
3314043|NCT01953809|Experimental|Group 3|Subjects upon completion of 28 days of run-in period will receive only OC in period 1 and 2, and GSK1322322/Placebo + EE/NE in period 3 of treatment phase. Each period will be of 7 days
3314044|NCT01953822||Cervarix vaccinated (exposed) female cohort|Female subjects vaccinated with at least one dose of Cervarix® between the ages of 9 to 25 years.
3314045|NCT01953822||Unexposed historical female cohort|Unexposed female subjects identified from historical data, will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
3314046|NCT01953822||Unexposed concurrent male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®.
3314047|NCT01953822||Unexposed historical male cohort|Male population is composed of 9- to 25-year-old male subjects not vaccinated with Cervarix®. Comparison of the unexposed concurrent male cohort with the unexposed historical male cohort will be used as an internal control for changes over time in Clinical Practice Research Datalink (CPRD) GOLD in reporting New Onset of Autoimmune Diseases (NOAD). The male subjects will be frequency matched for age and practice region identifier to the subjects included in the vaccinated (exposed) cohort.
3314048|NCT01953835|Experimental|Cohort A|Cohort A is a single-sequence, open-label study in which each subject will receive Simvastatin 10 mg single dose oral tablet on Days 1 and 10, Rosuvastatin 10 mg single dose oral tablet on Days 3 and 12 and GSK2586184 standard formulation 400 mg twice daily oral tablet from Day 6 to Day 14 immediately after food. At Day 10 GSK2586184 and Simvastatin and at Day 12, GSK2586184 and Rosuvastatin will be co-administered.
3314049|NCT01953835|Experimental|Cohort B|Cohort B is a three-way crossover study in which each subject will receive a single dose of GSK2586184 standard formulation 400 mg oral tablet with food and two doses of a new formulation of GSK2586184 400 mg oral tablet, once with food and once in a fasted state, on Day 1, 4 and 7 according to their treatment sequence, with a 3-day wash out between doses.
3314050|NCT01953848|Experimental|1: Low dose EC905|
3314051|NCT01953848|Experimental|2: High dose EC905|
3314052|NCT01953861|Experimental|1: fasted|EC905 + fasted
3314053|NCT01953861|Experimental|2: low-fat breakfast|EC905 + low-fat breakfast
3314054|NCT01953861|Experimental|3: high-fat breakfast|EC905 + high-fat breakfast
3314055|NCT01953887|Experimental|1 combination tablet EC905|
3314056|NCT01953887|Experimental|2: solifenacin|
3314057|NCT01953887|Experimental|3: tamsulosin|
3314058|NCT01953900|Experimental|GD2 T cells plus VZV vaccine|In this study we will be administering from 1 x 10^6 to 1 x 10^9 transduced autologous VZV-specific CTLs, derived from VZV-specific memory T cells, so there will be no risk of alloreactivity. 6.1.1 Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m2/day followed by Fludarabine 30 mg/m2/day.
3314059|NCT01953939|Experimental|Prosthetic Limb Users|Single lower limb amputees who are wearing their artificial limb all day and are using them outdoors for the majority of the time will be enrolled into this reliability study.
3314060|NCT01953952|Experimental|Arm I (surgery, risk-based adjuvant therapy)|Patients undergo eHNS. Depending on post-operative pathology findings, patients may undergo IMRT QD five days a week for 6 weeks, beginning within 6 weeks after surgery. High-risk patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
3314061|NCT01953952|Active Comparator|Arm II (chemoradiotherapy)|Patients undergo IMRT QD five days a week for 7 weeks. Patients also receive cisplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy.
3314062|NCT01953978|Active Comparator|Dexamethasone|"Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
3314063|NCT01953978|Placebo Comparator|Placebo|"Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation~Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.~Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed~Tablet Paracetamol 1 g orally and tablet Ibuprofen 400 mg orally. Both 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours."
3314064|NCT01953991|Active Comparator|Cobalt chrome dentures|Cobalt chrome dentures are used as part of standard care for patients
3314065|NCT01953991|Active Comparator|PEEK dentures|PEEK dentures will be used as a comparator denture for patients
3314066|NCT01954030|Experimental|CTO and Bevacizumab (Phase 1)|The combination of CTO with the standard dosing of bevacizumab of 10 mg/kg every 2 weeks among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have previously failed bevacizumab
3314067|NCT01954030|Experimental|Phase 2: CTO alone (Phase 2)|The first 25 patients will be treated with CTO alone at the maximum tolerated dose (MTD) established in the Phase 1 portion of the study.
3314068|NCT01954030|Experimental|CTO and Bevacizumab (Phase 2)|The second group of 25 patients will be treated with the combination of CTO at the MTD established in the Phase 1 portion of this study and standard dosing of bevacizumab.
3314069|NCT01954043|Experimental|Arm A|Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).
3381678|NCT01727011|Experimental|IPAS|Once the patient recorded in the trial, and after completion of a post-implant dosimetry scanner to analyze the dose distribution within the target volume and organs at risk, the patient is treated by irradiation and partial accelerated breast brachytherapy using high dose rate, delivering a total dose of 16 Gy in one fraction
3381681|NCT01712308|Experimental|Treatment (sotatercept)|Patients receive sotatercept SC once every 3 weeks. Cycles repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients unable to achieve anemia-response after 8 cycles will be taken off study.
3381682|NCT01588431|Experimental|(TPE-A) Followed by Concurrent RT(XPE-A), surgery|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
3314070|NCT01954069|Other|Semi-quantitative pregnancy test|Semi-quantitative urine pregnancy test (SQPT) (dBest One Step hCG Panel Test Kit)
3314071|NCT01954095||Group 1: No prior preterm birth & normal cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had one or more term births (no prior preterm births) and have a normal cervical length (> 25 mm). These women will serve as gestational age controls for all groups.
3314072|NCT01954095||Group 2: No prior preterm birth & short cervix length|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have no prior preterm births and have a short cervical length (20mm or less). These women may receive treatment (e.g. vaginal progesterone, cerclage, pessary, NSAIDs, or a combination thereof) or no treatment.
3381686|NCT01564537|Experimental|Ixazomib + Lenalidomide + Dexamethasone|Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to end of treatment (EOT) projected at 80 months.
3314073|NCT01954095||Group 3: Prior preterm birth, normal cervix length, 17-OHPC|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length and will receive 17-OHPC treatment.
3314074|NCT01954095||Group 4: Prior preterm birth, normal cervix length, no treat|Pregnant women at 16 0/7 - 23 6/7 weeks gestation who have had prior preterm birth, have a normal cervical length, and will not receive any treatment. These women will serve as controls for Group 3.
3381687|NCT01564537|Placebo Comparator|Placebo + Lenalidomide + Dexamethasone|Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until progressive disease (PD) or unacceptable toxicity, whichever occurred first up to EOT projected at 80 months.
3381690|NCT01483664||initial survivorship planning consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
3381691|NCT01483664||initial wellness rehabilitation consultation|The overall design follows a cluster-randomized, clinical trial design. Although an apparently statistically-efficient design would have us randomize patients, the CST intervention must be delivered to physicians at four participating sites (MSKCC, Maimonides, MD Anderson, and Moffitt/TGH). Therefore, participating sites will be stratified by size and randomized to either experimental (initial survivorship planning consultation) or control (initial wellness rehabilitation consultation) in a multiple-level, cluster-randomized design, which protects against physician contamination of the experimental intervention within any site.
3381692|NCT01260961|Active Comparator|Docosa Hexanoic Acid|
3381693|NCT01260961|Placebo Comparator|Placebo|
3381694|NCT01237093|Experimental|1. Meat, no fish or soda|weight maintaining diet with meat but no fish or soda for 12 weeks
3381695|NCT01237093|Experimental|2. Meat and soda, no fish|weight maintaining diet with meat and soda but no fish for 12 weeks
3381696|NCT01237093|Experimental|4. Meat and fish and soda|weight maintaining diet with meat, fish, and soda for 12 weeks
3381697|NCT01237093|Experimental|5. Fish, no meat or soda|weight maintaining diet with meat, fish, and soda for 12 weeks
3381698|NCT01237093|Experimental|6. Fish and soda, no meat|weight maintaining diet with fish and soda but no meat for 12 weeks
3381699|NCT01237093|Experimental|7. No meat, fish, or soda|no fish, and no soda (vegetarian) for 12 weeks
3381700|NCT01237093|Experimental|8. Soda, no meart or fish|weight maintaining diet with soda but no meat or fish (vegetarian + soda) for 12 weeks
3314075|NCT01954108|Other|ESWT (Extracorporal Shock Wave Therapy)|Three applications in weekly interval.
3314076|NCT01954108|Active Comparator|hyaluronic acid sodium salt|Two injections of 2% (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
3314077|NCT01954134||thyroid cancer, healty|Thyroid cancer group: patients with differentiated or dedifferentiated thyroid cancer Healty: control group
3314078|NCT01954147|Experimental|SC-GLP-1|Umbilical Cord Mesenchymal Stem Cell Infusion Combined With Liraglutide
3314079|NCT01954147|Experimental|SC|Umbilical Cord Mesenchymal Stem Cell Infusion
3314080|NCT01954147|Experimental|GLP-1|Liraglutide
3314081|NCT01954147|Active Comparator|Control|Standard Medical Treatment
3314082|NCT01954173|Experimental|3D conformal radiation therapy|Within 24 weeks of surgical resection, patients undergo conformal radiation therapy once daily 5 days per week for 28 fractions. Treatment continues in the absence of disease progression or unacceptable toxicity.
3314083|NCT01954186|Experimental|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
3314084|NCT01954186|Active Comparator|after delivery & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
3314085|NCT01954199|Experimental|Neurodynamic group|Patients allocated to this group will receive three different neurodynamic techniques: a lumbar foramen dynamic opener; a side-lying slider and a slider in the slump position. Patients will be asked to perform home exercises (a slider and a tensioner technique). Treatment will receive four treatments during two weeks (two sessions/week).
3314086|NCT01954199|No Intervention|Control Group|"Patients allocated to Control Group (CG) will receive no intervention and will be advised according to the best evidence available; i.e, advice to remain active and to resume activities of daily living~Upon trial completion, treatment will be offered."
3314087|NCT01954212|Experimental|Enhanced complex oral health care intervention|The complex oral health care (OHC) intervention (SOCLE intervention) includes patient, staff and service level interventions.
3314088|NCT01954212|No Intervention|Usual oral health care|"Oral health care (OHC) will be provided in the standard manner, with no change to usual care.~Provision of this standard OHC will be sampled monthly. Surveys suggest that standard oral health care (OHC) in stroke care settings comprise poorly supported OHC interventions delivered by staff that lacked access to specialist training, products, equipment, assessments, protocols and dental services."
3314089|NCT01954225|Other|Udumbara sutra|The Udumbara Sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
3314090|NCT01954238|Active Comparator|Rivaroxaban|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease
3314091|NCT01954238|Placebo Comparator|Placebo|GCC-4401C matching placebo capsule
3314092|NCT01954238|Experimental|GCC-4401C|Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease. It is a novel molecule with a structural similarity to Rivaroxaban.
3314093|NCT01954277|Experimental|Electroacupuncture|All patients will receive 10 electroacupuncture sessions.
3314094|NCT01954277|Sham Comparator|Placebo Sham|All patients will receive 10 placebo sham sessions.
3314095|NCT01954290|Active Comparator|Hypertonic Saline (3%) and/or Mannitol arm|"The subjects in this arm will be given hypertonic saline and/or Mannitol.~For hypertonic saline,various concentrations are used clinically,up to 30-mL boluses of 23.4% saline.Rapid increases in sodium in this context do not appear to cause other neurologic complications observed with rapid correction of hyponatremia.Sodium levels up to 160 mmol/L may be acceptable,beyond which it may lead to worsening delirium,seizures,and overall poor outcome.~For Mannitol,every 4 hours serum osmolarity,serum glucose,urea,sodium and potassium will be measured till the therapy is given.Major complications include hypovolemia and hypotension.Strict fluid goals and volume replacement are essential.Impaired mannitol clearance may manifest as nephrotoxicity.Common practice includes repeating measurements of serum osmolarity and withholding repeat doses of mannitol when osmolarity exceeds 320 milliosmol(mOsm).Monitoring the osmole gap may be a more sensitive method for discerning mannitol clearance."
3314096|NCT01954290|Experimental|Conivaptan arm|The subjects in this arm will be given infusion of Conivaptan.
3314097|NCT01954303||Troponin status|"Patients are divided into troponin positive (if hsTnT on first presentation is <14 ng/L) and troponin negative (if hsTnT on first presentation is >=14 ng/l)."
3314098|NCT01954303||Progress of CHD|
3314099|NCT01954316|Experimental|CFI-400945 fumarate Schedule A|CFI-400945 fumarate tablets daily dosing expansion at 64mg
3314100|NCT01954316|Experimental|CFI-400945 fumarate Schedule B|CFI-400945 fumarate tablets intermittent dosing schedule, 2 days on/5 days off. Escalation at following levels: 96mg, 128mg
3314101|NCT01954316|Experimental|CFI-400945 fumarate Schedule C|CFI-400945 fumarate tablets intermittent dosing schedule, 1 day on/6 days off. Escalation will start at MTD of Schedule B
3314102|NCT01954329||Patients suspected of TIA by the GP|
3314103|NCT01954355|Experimental|LDE225 & Paclitaxel|"Phase I, Part A: LDE225: dose escalation in cohorts of 3-6 patients (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)~Phase I, Part B and C: LDE225: RP2D established in Part A (days 1-28) and Paclitaxel 80 mg/m2 (days 1, 8, 15)"
3314104|NCT01954368|Placebo Comparator|Intranasal placebo|Patients receiving intranasal placebo at ED admission
3314105|NCT01954368|Experimental|Intranasal sufentanil|Patients receiving intranasal sufentanil at ED admission
3314106|NCT01954381|Other|control|
3314107|NCT01954381|Experimental|patient|
3314108|NCT01954407|No Intervention|Control: No Smoking-Related Messages|Respondents will answer questions about smoking-related beliefs and intentions to smoke before receiving the treatment smoking-related messages (they will still receive them at the end to make the groups comparable and still expose them to anti-smoking messages).
3314109|NCT01954407|Experimental|Promising Smoking-Related Messages|Respondents will receive one of the possible sets of promising smoking-related messages and these should affect smoking-related intentions to a greater extent (make respondents less likely to smoke) than less-promising smoking-related messages.
3314110|NCT01954407|Experimental|Less-Promising Smoking-Related Messages|Respondents will receive one of the possible sets of less-promising smoking-related messages and these should affect their intentions to a lesser extent than the promising smoking-related messages.
3314111|NCT01954420|Other|Attention Control|"Standard care + cancer education~Participants receive a single session with a research nurse to discuss the importance of understanding cancer and cancer treatment strategies, and to introduce educational recordings available on an MP3 player. The educational recordings provide a selection of publicly available American Cancer Society patient information materials addressing topics related to cancer and cancer treatment strategies. Participants are asked to listen to at least one recording per day, or more frequently as desired."
3314112|NCT01954420|Experimental|Cognitive-Behavioral Intervention|"Standard care + Patient-Controlled Cognitive Behavioral Intervention~Participants will receive a single training session with a research nurse including: 1) Information about the causes of cancer-related pain, fatigue, and sleep disturbance. 2) An explanation of how cognitive-behavioral interventions may affect symptoms. 3) Review of the specific cognitive-behavioral strategies provided on the MP3 player. 4) Individualized recommendations for using the cognitive-behavioral strategies. The nurse interventionist and patient will develop a written plan for practicing the strategies with recommendations to use a strategy at least once a day, or more frequently as needed."
3314113|NCT01954433||Operated TSA Patients|Patients with glenohumeral arthritis and/or rotator cuff tear arthropathy who were operated and received a total shoulder prosthesis
3314114|NCT01954433||Non-operated TSA Patients|TSA-patients, indicated for treatment with a total shoulder prosthesis, who decided not to operate
3314115|NCT01954433||Operated RCR Patients|Patients with rotator cuff tear who were operated and received a rotator cuff reconstruction by arthroscopy
3314116|NCT01954433||Non-operated RCR Patients|RCR-patients, indicated for rotator cuff reconstruction by arthroscopy, who decided not to operate
3314117|NCT01954433||Operated TMC OA Patients|Patients with trapeziometacarpal (TMC) osteoarthritis who were operated and received a resection interposition suspension arthroplasty of the TMC joint
3314118|NCT01954433||Non-operated TMC OA Patients|TMC OA-patients, indicated for surgical treatment (resection interposition suspension arthroplasty), who decided not to operate
3314119|NCT01954446|Experimental|ContiPress vs. 3M|ContiPress vs. 3M passive and during exercise
3314120|NCT01954446|Experimental|ContiPress vs. Mobil-O-Graph|ContiPress vs. Mobil-O-Graph passive, then oscillometric passive, then oscillometric for 24 hrs every 15 mins.
3314121|NCT01954459|Active Comparator|Sensor alone|Glucose sensor site will not have Insupatch
3314122|NCT01954459|Experimental|Sensor with Insupatch|Glucose sensor site with Insupatch
3314123|NCT01954472|Experimental|Enhanced Portfolio plus structured exercise|Diet: The dietary portfolio advice: to limit saturated fat to <7% of total calories and cholesterol to <200 mg/d) plus inclusion of viscous fibres, soy protein, plant sterols and nuts, 5% extra monounsaturated fat, and selection of low glycemic index foods and will emphasize current recommendations for fruit and vegetable intakes (5-10 servings/d).
3314124|NCT01954472|Active Comparator|High fiber diet plus routine exercise|A diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); reduced meat consumption; lower fat dairy foods and a control margarine
3314125|NCT01954485|Experimental|LaserLok abutment|Laser microtexturing dental implant abutment
3314126|NCT01954485|Active Comparator|3inOne abutment|Standard dental implant abutment
3314127|NCT01954498|Experimental|Walnuts|2 ounces whole-shelled walnuts per day for 12 weeks
3314128|NCT01954498|Active Comparator|OTC (over-the-counter) multivitamin|OTC multivitamin tablet 2 per day for 12 weeks
3314129|NCT01954511|No Intervention|Manual therapy|Upper cervical flexion mobilization, C5 central posterior-anterior mobilization, Pressure biofeedback device
3314130|NCT01954524|Experimental|IV bolus injection of Sildenafil|CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil.
3314131|NCT01954537||Professional football players|Offensive and defensive professional football players ranging in age from 22 to 30 years old.
3314132|NCT01954537||Collegiate Football Players|Division III collegiate football players ranging in age from 20 to 23 years old.
3314133|NCT01954537||High School Football Players|High school football players ranging in age from 16 to 18 years old.
3314134|NCT01954550|Experimental|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
3314135|NCT01954550|Sham Comparator|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
3314136|NCT01954563|Experimental|Group 1|Receive 5x10^7 MVA85A by aerosol at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
3314137|NCT01954563|Experimental|Group 2|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost aerosol vaccination of 5x10^7 MVA85A at day 28.
3314138|NCT01954563|Experimental|Group 3|Receive 5x10^7 MVA85A by intradermal injection at day 0, followed by boost intradermal vaccination of 5x10^7 MVA85A at day 28.
3314139|NCT01954589|Experimental|ACT-462206 5 mg/Placebo|6 subjects received a single, 5 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3314140|NCT01954589|Experimental|ACT-462206 25 mg/Placebo|6 subjects received a single, 25 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3314141|NCT01954589|Experimental|ACT-462206 100mg/Placebo|6 subjects received a single, 100 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3314142|NCT01954589|Experimental|ACT-462206 200mg/Almorexant 400mg/Placebo|"Subjects were assigned to one of two possible treatment sequences: A/B or B/A with a washout period of 14 days between treatment periods.~Treatment A: Single oral dose of ACT-462206 200 mg or placebo. Treatment B: Single oral dose of almorexant 400 mg or placebo. In each sequence 6 subjects received ACT-462206 or almorexant & 2 subjects received placebo"
3314143|NCT01954589|Experimental|Experimental: ACT-462206 400mg/Placebo|6 subjects received a single, 400 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3314144|NCT01954589|Experimental|ACT-462206 1000 mg|6 subjects received a single, 1000 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3314145|NCT01954589|Experimental|ACT-462206 1500mg/Placebo|6 subjects received a single, 1500 mg, oral dose of ACT-462206 and 2 subjects received a single, oral dose of placebo
3381701|NCT01237093|Experimental|Meat and fish, no soda|weight maintaining diet with meat and fish but no soda for 12 weeks
3381702|NCT01230242|Experimental|Mirena IUD Placement Immediately Post-delivery|Participants enrolling in this study agree to have the IUD placed immediately post-delivery versus waiting the standard 6 weeks.
3381703|NCT01200680||chordoma cohort|Chordoma patients
3381708|NCT01116648|Experimental|Arm I (cediranib maleate and olaparib)|Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3381709|NCT01116648|Active Comparator|Arm II (olaparib)|Patients receive olaparib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3381710|NCT00983437|Experimental|Armodafinil|Armodafinil tablets 150 mg or 250 mg administered orally, once daily in the morning.
3381713|NCT00965757|Experimental|1|
3381714|NCT00965757|Placebo Comparator|2|
3381715|NCT00928447|Experimental|rHuPH20|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the nickel sulfate concentration (NSC) (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing rHuPH20 (3,000 Units [U]) will be administered once daily (QD) for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with drug rHuPH20 (3,000 U) at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing rHuPH20 will be then administered QD for 5 days.
3381716|NCT00928447|Placebo Comparator|Placebo|Participant's upper back will be divided into 2 equal spaces and will receive Regimen 1 and 2 in 4 spaces respectively. In Regimen 1, a single row of 4 patches, each with the NSC (1, 2.5, or 5%) determined at screening, will be applied to the upper space at Day 1. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. An ID injection containing placebo will be administered QD for 5 days at the center of each area of reaction. In Regimen 2, a single row of 4 sites in the lower space will be injected intradermally with placebo at Day 1. Ten minutes after the injections, patches with the NSC (1, 2.5, or 5%) determined at screening will be applied to the injection sites. After 48 hours, the patches will be removed and the reactions will be graded on the ICDRG scale. As during pretreatment, an ID injection containing placebo will be then administered QD for 5 days.
3381723|NCT00893789|Experimental|1|Armodafinil 50 mg/day
3381724|NCT00893789|Experimental|2|Armodafinil 150 mg/day
3381725|NCT00893789|Experimental|3|Armodafinil 250 mg/day
3381726|NCT00893789|Placebo Comparator|4|Placebo
3381727|NCT00852943||Patients|Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation or mast cell homeostasis or activation, will be eligible for enrollment.
3314146|NCT01954602|Active Comparator|Touch group|Sphincterotome assisted guide-wire cannulation
3381728|NCT00805129|Experimental|Everolimus|Everolimus will be administered at a dose of 10 mg orally once daily continuously.
3381729|NCT00708448|Experimental|All patients|All participants enrolled.
3381730|NCT00442195||1|Healthy Volunteers
3314147|NCT01954602|Experimental|No touch group|Guide-wire cannulation
3314148|NCT01954615|Experimental|Group A 5 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 5 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
3314149|NCT01954615|Experimental|Group B 20 mg ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of 20 mg ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state.
3314150|NCT01954615|Experimental|Group C ACT-281959 prodrug formulation I/placebo|Group C: 6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-B.
3314151|NCT01954615|Experimental|Group D ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-C.
3314152|NCT01954615|Experimental|Group E ACT-281959 prodrug formulation I/placebo|6 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Dose selection will be based on pharmacokinetic data derived from Groups A-D.
3314153|NCT01954615|Experimental|Group F ACT-281959 prodrug formulation I/placebo|Food effect dose group: 6 subjects to receive a single, oral dose ACT-281959 prodrug formulation I and 2 subjects to receive a single, oral dose of matching placebo. Medication to be administered in the fasted state. Following a 7-10 day washout period, subjects will receive the identical treatments administered in the first period. Medication to be administered in the fed state. Dose selection will be based on pharmacokinetic data derived from Groups A-E.
3314154|NCT01954615|Experimental|Group G ACT-281959 prodrug formulation I & II/ACT-246475|9 subjects to receive a single, oral dose of ACT-281959 prodrug formulation I (Treatment A), a single, oral dose of ACT-281959 prodrug formulation II (Treatment B), and a single, oral dose of ACT-246475 (Treatment C). Subjects will be equally randomized to one of 3 treatment sequences: ABC, BCA, and CAB. Treatments will be separated by 7-10 day washout periods. Medication to be administered in the fasted state. Data from Groups A-E will be used for pharmacometric modeling to guide the selection of doses to be used in Group G.
3314155|NCT01954641|Experimental|ACCURE Navigator|For those patients assigned to the ACCURE Navigator, the ACCURE Real-Time Registry is programmed to automatically alert the Navigator when a patient misses a scheduled treatment appointment and to require the Navigator to include details as to how she addressed and resolved that missed appointment, ensuring the ACCURE Navigator's proactive approach to addressing such issues. In addition, a warning message will be produced if no follow-up appointments or procedures are scheduled within 21 days of the index visit.
3314156|NCT01954641|Active Comparator|Usual Care by Cancer Center Care Team|A list of registry warnings about all patients enrolled in the study will be delivered securely to a designated representative at the clinic.
3314157|NCT01954654|Experimental|Accelerated treatment|
3314158|NCT01954654|Active Comparator|Standard treatment|
3314159|NCT01954667||obese and overweight|Group1 (n=30): overweight and obese (BMI ≥25 and/ or WHtR≥0.5)
3314160|NCT01954667||average body weight|Group2 (n=30): normal weight (BMI ≥ 18 to < 25 and/or WHtR ≥0.4 to <0.5)
3314161|NCT01954667||Control group|Control Group (n= 20): healthy subjects, matched for age and gender, were included in this study. All included controls had average weight (BMI ≥ 18 to < 25 and/ or WHtR ≥0.4 to <0.5)
3314162|NCT01954680|Experimental|COGFLEX-skill building levels|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
3314163|NCT01954680|Experimental|COGFLEX-control condition|In the R33, children will be randomized to receive either COGFLEX with skill-building levels or the control condition--which is just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
3314164|NCT01954693|Experimental|Everolimus (RAD001)|2x2.5mg daily
3314165|NCT01954693|Placebo Comparator|Placebo|2x2.5mg daily
3314166|NCT01954706|Experimental|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
3314167|NCT01954706|Active Comparator|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
3314168|NCT01954719|Experimental|cervix dilated after surgery|Digital cervical dilatation performed by surgeon
3314169|NCT01954719|No Intervention|control group|cervix not dilated after surgery
3314170|NCT01954732|No Intervention|Group I (observation)|Patients undergo observation.
3314171|NCT01954732|Experimental|Group II (metformin hydrochloride)|Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity.
3314172|NCT01954732|Experimental|Group III (metformin hydrochloride)|Patients receive metformin hydrochloride as in Group II.
3314173|NCT01954758|Experimental|Personalized embryo transfer (pET)|Patients will undergo a cycle of endometrial preparation following hormone replacement therapy (HRT) and an endometrial biopsy in a substituted cycle after 5 days (around 120 hours) of progesterone administration. The ERA test will determine the window of implantation (WOI) for each patient and will recommend the best time for embryo transfer thereby increasing the chances of a successful outcome. In some specific cases (≤ 10%) a second biopsy will be required to help the bioinformatic predictor to ensure the most appropriated moment for the embryo transfer. In a different cycle, patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI and vitrified. In a subsequent cycle, following the ERA result, a personalized embryo transfer (pET) will be carried out following the same conditions in which the ERA test was obtained, using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage)
3314174|NCT01954758|Active Comparator|Frozen embryo transfer (FET)|Patients will undergo a cycle of controlled ovarian stimulation (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In a subsequent cycle, following hormone replacement therapy (HRT), a frozen embryo transfer (FET) will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
3314175|NCT01954758|Active Comparator|Fresh embryo transfer (ET)|Patients will undergo a controlled ovarian stimulation cycle (COS) to obtain oocytes which will be fertilized by IVF/ICSI. In the same cycle, a fresh embryo transfer will be performed using 1 or 2 viable blastocysts previously obtained (day 5 or 6 stage).
3314176|NCT01954784|Experimental|Treatment (nonmyeloablative alloHSCT, lenalidomide)|"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate on days -5 to -3 and undergo TBI on day -1.~TRANSPLANT: Patients undergo allogeneic hematopoietic SCT on day 0.~GVHD PROPHYLAXIS: Patients receive standard GVHD prophylaxis comprising cyclosporine PO BID beginning on day -1 with taper beginning on day 100, mycophenolate mofetil PO BID on days 1-56, and bortezomib SC weekly from day 1 to day 91.~MAINTENANCE THERAPY: Beginning on day 100, patients receive lenalidomide PO daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3314177|NCT01954797||Physical Fitness|Patients from this group underwent 4 weeks of aerobic fitness training additional to normal supportive care, 5 times a week, for 50 minutes
3314178|NCT01954797||Relaxation|Patients of this group received 4-weeks of relaxation sessions additional to normal supportive care, 5 times a week, for 50 minutes.
3314179|NCT01954810|No Intervention|Japanese encephaltis chimerix vaccine|This is a single-arm study. Japanese encephalitis chimeric vaccine (JECV) will be administered to all subjects and check for antibody response 4 weeks after vaccination.
3314180|NCT01954823|Experimental|e-diary|The study group will have assess to an e-diary developed for people with MS, through the Internet and/or smart-phones. In addition, participants will continue to receive regular care at the MS clinic
3314181|NCT01954823|No Intervention|no use of e-diary|Participants of the control group will receive regular care at the MS clinic and will and no use of the e-diary
3314182|NCT01954836|Experimental|Initial fasting|Fasting during chemotherapy of the first half of chemotherapy cycles (1 and 2 of four or 1 to 3 of six cycles)
3314183|NCT01954836|Active Comparator|Secondary fasting|Fasting during the second half of chemotherapy cycles (3 and 4 of four cycles or 4 to 6 of six cycles)
3314184|NCT01954849|Experimental|Probiotic formulation|Probiotic dissolving lozenge, at least 1 billion total CFU, taken at a certain prescribed regimen for 28 days.
3314185|NCT01954849|Placebo Comparator|Placebo|Placebo dissolving lozenge, with the exact same appearance as the treatment lozenge (including flavour, colour, shape and texture), and formulated with all the same ingredients except for the live bacteria, taken for 28 days at the same prescribed regimen as the probiotic lozenge.
3314186|NCT01954862|Active Comparator|Air insufflation method.|Colonoscopy performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
3314187|NCT01954862|Experimental|CO2 insufflation|Colonoscopy performed with CO2 insufflation using the insufflation unit, allowing for washing as needed.
3314188|NCT01954862|Experimental|Water Immersion/CO2|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using CO2 insufflation.
3314189|NCT01954862|Experimental|Water Exchange/CO2|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using CO2 insufflation.
3314190|NCT01954862|Experimental|Water Immersion/AI|Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal. Insufflation not used until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Withdrawal phase done using room air insufflation.
3314191|NCT01954862|Experimental|Water Exchange/AI|Insufflation not used until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned. Withdrawal phase done using room air insufflation.
3314192|NCT01954875||Subjects with ALS|subjects diagnosed with amyotrophic lateral sclerosis
3314193|NCT01954875||subjects with non-ALS neurodegenerative disease|subjects diagnosed with non-ALS neurodegenerative disease
3314194|NCT01954875||healthy controls|healthy subjects as controls
3314195|NCT01954888|Active Comparator|Blind technique|Stellate ganglion block using the anterior paratracheal approach using surface landmarks.
3314196|NCT01954888|Active Comparator|Ultrasound-guided technique|Stellate ganglion block using the ultrasound-guided lateral approach at the sixth cervical vertebral level.
3314197|NCT01954901|Experimental|Standard treatment plus Hyperbaric Oxygen|The study treatment group will be compressed on air in the hyperbaric chamber to 2.0 atmospheres absolute (ATA), then placed on 100% oxygen by a head tent for 90 minutes.
3314198|NCT01954901|Placebo Comparator|Standard treatment with Hyperbaric Room Air|The study control group will be compressed to 2.0 ATA on air, then breath 21% oxygen and 79% nitrogen through the hood for 90 minutes.
3314199|NCT01954914|Experimental|Plerixafor, Mozobil|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
3314200|NCT01954940|Experimental|Whole Body Vibration Therapy|Group will receive daily whole body vibration therapy for up to 9 minutes maximum at a maximum of 18 Hz.
3314201|NCT01954940|No Intervention|Control group|Group will not receive whole body vibration therapy. This group will conduct all other tests and outcomes except whole body vibration therapy.
3314202|NCT01954953||no intervention|
3314203|NCT01954966|Active Comparator|Progesterone 200 mg capsules|Subjects will be prescribed progesterone 200 mg capsules by the study Principal Investigator. Subjects will take 200 mg of progesterone daily for four days.
3314204|NCT01954966|Placebo Comparator|Progesterone 200 mg look-alike capsules|Subjects will be prescribed progesterone 200 mg look-alike placebo capsules by the study Principal Investigator. Subjects will take look-alike placebo capsules daily for four days.
3314205|NCT01954979|Experimental|Abatacept|Abatacept will be administered for a total of 6 doses. Doses 1-3 will be administered at two week intervals (+/-2 days). One month following Dose 3, abatacept will be administered, and given at four-week intervals (+/-2 days) for three doses (Doses 4-6.) Patients will be followed for toxicity for 28 days following last dose of Abatacept. Patients will then be seen monthly for six months.
3314206|NCT01954992|Experimental|glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours on Day 1 of each 21-day cycle
3314207|NCT01954992|Active Comparator|5-FU|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
3314208|NCT01955018|Experimental|VeoTM|A new algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA) decreases the image noise up to 70% compared with the gold standard FBP model. Moreover, Veo improves spatial resolution with excellent detection of low and high contrast objects from a CT Dose Index (CTDIvol) equal to 0.3 mGy
3314209|NCT01955018|Other|gold standard FBP model|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality
3314210|NCT01955031|Experimental|Telemonitoring|Patient with type 2 diabetes randomized in telemonitoring group have a telemonitoring device with educational Tools at their home
3314211|NCT01955031|Sham Comparator|Usual care|patient randomized in this group have a usual care
3314212|NCT01955057||Smokers with lung cancer|
3314213|NCT01955070|Experimental|Implementation|Multimedia Presentation for Ketamine sedation
3314214|NCT01955070|Experimental|Intervention|Multimedia Presentation for Ketamine sedation
3314215|NCT01955070|No Intervention|Control|Patients that received the standard consent with signed consent form
3314216|NCT01955096|Experimental|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
3314217|NCT01955096|Other|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
3314218|NCT01955109|Experimental|Viaskin Peanut 250 mcg|
3314219|NCT01955135|Active Comparator|sedation|The sedation group (Group S, n=30), received 1 mg/kg ketamine and 1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol and 0.25mg/kg/h of ketamine for maintenance.
3314220|NCT01955135|Active Comparator|general anesthesia|In the general anesthesia group (Group G, n=30), anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; endotracheal intubation was facilitated without use of a neuromuscular blocker agent. Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen.
3314221|NCT01955148||Prior sPTB or PROM|Women who have had a previous delivery of a live born singleton between 20 weeks, 0 days and 36 weeks, 6 days due to spontaneous preterm premature labor or preterm rupture of fetal membranes
3314222|NCT01955148||Short cervical length|Short cervical length (≤25 mm) determined by transvaginal ultrasound
3314223|NCT01955148||Twin Pregnancy|Current twin pregnancy
3314224|NCT01955148||Prior cervicdal surgeries|Cervical cerclage in a prior pregnancy or prior cone biopsy or prior LEEP
3314225|NCT01955174|Experimental|Botulinum toxin injection|Esophageal endoscopic injection of botulinum toxin
3314226|NCT01955174|Sham Comparator|No injection|No injection of botulinum toxin
3314227|NCT01955187|Experimental|Sequential therapy: Tacrolimus-Rituximab|Tacrolimus: Initial dose of 0.05 mg/Kg/day PO, adjusted to blood levels (5- 7 ng/ml) for six months. Starting at the end of month 6, tacrolimus will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
3314228|NCT01955187|Active Comparator|Cyclical therapy: Corticosteroids and Cyclophosphamide|Month 1, 3 and 5: 1g IV methylprednisolone daily for three doses, oral methylprednisolone (0.5mg/kg/day) Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day)
3314229|NCT01955200|Experimental|CLOP-150|clopidogrel 150mg once daily
3314230|NCT01955200|Experimental|CLOP+CILOST|clopidogrel 75mg once daily plus cilostazol 100mg twice daily
3314231|NCT01955200|Experimental|TICAG|ticagrelor 90mg twice daily
3314232|NCT01955200|Active Comparator|CON(conventional DAPT)|clopidogrel 75mg once daily
3314233|NCT01955200|Active Comparator|Non-HOPR|clopidogrel 75mg once daily
3314234|NCT01955213||Morphine Sulphate|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3314235|NCT01955213||Fentanyl|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3314236|NCT01955213||Oxycodone|Patient groups are defined by the type of opioid used, being either morphine sulphate, fentanyl or oxycodone.Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
3314237|NCT01955226|Experimental|Tegaderm CHG clear dressing|Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
3314238|NCT01955226|Active Comparator|Standard clear Tegaderm dressing|Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
3314239|NCT01955239|Active Comparator|Standard IMRT|Standard IMRT in which the mean dose to both whole parotid glands is minimized.
3314240|NCT01955239|Experimental|Stem-cell Sparing IMRT|Stem-cell Sparing IMRT in which the mean dose to the stem cell containing region of the parotid gland is minimized
3314241|NCT01955252|Experimental|Azithromycin|"All participants older than 2 months (population 18,000) will be offered a single oral dose of oral azithromycin (tablets) 30 mg per Kg up to a maximum dose of 2g.~Women who tell the investigators they are pregnant and people with known allergy to macrolides will be offered benzathine benzylpenicillin.~This will be a single arm study. Study participants who met the inclusion criteria and agree to sign the consent form will be managed with proposed drug and systematically observed to measure outcomes of interest."
3314242|NCT01955265|Experimental|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
3314243|NCT01955265|Active Comparator|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
3314244|NCT01955278|Experimental|Creation of defitinive end colostomy|Patients undergoing elective laparoscopy assisted colorectal surgery, with the creation of a permanent end colostomy
3314245|NCT01955291|Experimental|Reinforced Feedback in Virtual Environment|During the experiment, patients in the RFVE training group (Reinforced Feedback in Virtual Environment) will receive 1 hour of virtual reality-based therapy by means of RFVE and 1 hour of TNR treatment (Traditional Neuromotor Rehabilitation). Both treatments will last 1 hour a day, five days weekly for four weeks. The treatment is focused on motor function impairment of the upper extremity.
3314246|NCT01955291|Other|Traditional Neromotor Rehabilitation|The TNR training group (Traditional Neuromotor Rehabilitation) patients will be treated totally for two hours daily by means of a TNR programme. The treatment will last 4 weeks.
3314247|NCT01955304|Experimental|A-fasted dosing followed by fed dosing|Experimental: Fasted dosing of fruquintinib followed by fed dosing; Dosing in the fasted state followed by fed dosing
3314248|NCT01955304|Experimental|B-fed dosing followed by fasted dosing|Experimental: Fed dosing of fruquintinib followed by fasted dosing; Dosing in the fed state followed by fasted dosing
3314249|NCT01955317|Experimental|chlorhexidine intervention|The intervention arm will also receive hand hygiene counselling with chlorhexidine and a pump bottle with chlorhexidine lotion along with mothers and neonatal health counseling.
3314250|NCT01955317|Active Comparator|Control|This arm will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
3314251|NCT01955330||Hybrid robotic cabg patients|Postoperative (5-7 years)Hybrid CABG robotically assisted surgical revascularization patients
3314252|NCT01955343||Lung cancer|Newly diagnosed and untreated non small cell lung cancer patients who underwent surgical resection for NSCLC (pathological stage I-III)
3314253|NCT01955343||Control|Subjects who will have surgery due to recurrent spontaneous pneumothorax Patients without lung cancer or other malignancies
3314254|NCT01955356|Experimental|Scratching|induced endometrial injury
3314255|NCT01955356|No Intervention|No scratching|None intervention
3314256|NCT01955395|Active Comparator|Immediate Group|If the participant is assigned to the Immediate Group, the participant will immediately receive the Relaxation Response Resiliency Program (3RP) intervention (3 months), followed by 3 months of continuing to practice what the participant learned during the intervention.
3314257|NCT01955395|Active Comparator|Waitlist Group|If the participant is assigned to the Waitlist Group, the participant will wait for 3 months and then receive the full Relaxation Response Resiliency Program (3RP) intervention (3 months).
3314258|NCT01955408||Overactive bladder after Synergo|
3314259|NCT01955421|Experimental|Erlotinib100|Patients will be randomized to buy and receive erlotinib 100mg qd.
3314260|NCT01955421|Experimental|Gefitinib250|Patients will be randomized to buy and receive gefitinib 250mg qd.
3314261|NCT01955447|Placebo Comparator|Reference|no added plant-based ingredients
3314262|NCT01955447|Active Comparator|Low level plant-based ingredients|Low level addition of plant-based ingredients
3314263|NCT01955447|Active Comparator|Medium level plant-based ingredients|Medium level addition of plant-based ingredients
3314264|NCT01955447|Active Comparator|High level plant-based ingredients|High level addition of plant-based ingredients
3314265|NCT01955460|Experimental|Treatment (chemotherapy, autologous T-cell immunotherapy)|Patients receive cyclophosphamide IV over 2 hours on days -7 and -6, fludarabine phosphate IV daily over 15-30 minutes on days -5 to -1, and TGFb DNRII-transduced autologous TIL and NGFR-transduced autologous T lymphocytes IV over up to 4 hours on day 0. Patients then receive high-dose aldesleukin IV over 15 minutes every 8-16 hours on days 1-5 (up to 15 doses) and 22-26 (up to 15 doses).
3314266|NCT01955486|Experimental|flight simulation|flight simulation in pressure chamber
3314267|NCT01955499|Experimental|Treatment (lenalidomide, ibrutinib)|Patients receive lenalidomide PO on days 1-21 and ibrutinib PO on days 1-28 (days 2-28 of cycle 1). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3314268|NCT01955512|Placebo Comparator|Placebo|Arm given placebo
3314269|NCT01955512|Experimental|Clopidogrel|Group given clopidogrel
3314270|NCT01955525||Acute coronary patients|Patients aged 18 and above who have been hospitalised with an ACS during the period of 2011 to 2013.
3314271|NCT01955538|Active Comparator|Control|Psychiatric treatment as usual for 6 months according to best clinical practice: 10 consultations with a medical doctor (medication and psycho-education) as well as 16 consultations with a psychologist.
3314272|NCT01955538|Experimental|Basic Body Awareness Therapy|Standard psychiatric treatment + Basic Body Awareness Therapy for 20 weeks, 1 hour/week.
3314273|NCT01955538|Experimental|Mixed physical activity|Standard psychiatric treatment + Mixed physical activity for 20 weeks, 1 hour/week.
3314274|NCT01955551|Experimental|Motiv. Interviewing|In the MI (motivational interviewing) study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
3314275|NCT01955551|Active Comparator|Anticipatory Guidance|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
3314276|NCT01955577|Experimental|Vitamin D3 cholecalciferol|1000IU x3 daily in a period of 14 days. After 14 days 1000IU x 1 daily.
3314277|NCT01955577|Placebo Comparator|Placebo orally everyday|One placebo pill x3 daily in a period of 14 days. After 14 days x1 placebo pill daily.
3314278|NCT01955590|Experimental|Metacognitive therapy|The focus of metacognitive therapy (MCT) is on metacognitive beliefs thought to underlie the development and maintenance of posttraumatic symptomatology.
3314279|NCT01955590|Active Comparator|EMDR|Eye movement desensitization reprocessing (EMDR): participant is asked to focus on trauma-related imagery, negative cognitions and body sensations while simultaneously focusing attention to a bilateral physical stimulation.
3314280|NCT01955590|Active Comparator|Treatment as usual|A group of 30 patients matched for age, gender and personality disorders receiving treatment as usual (TaU) in an outpatient setting will be included as a non-randomized comparative control condition.
3314281|NCT01955603|Experimental|Dose level 1|
3314282|NCT01955603|Experimental|Dose level 2|
3314283|NCT01955603|Experimental|Dose level 3|
3314284|NCT01955616|Active Comparator|RM-131|RM-131 100 µg by subcutaneous injection daily in the morning
3314285|NCT01955616|Placebo Comparator|Placebo|by subcutaneous injection daily in the morning
3314286|NCT01955642||AVC|Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications
3314287|NCT01955655|Active Comparator|Baclofen|The starting dose was 0.75 mg/kg in four divided doses daily and was cautiously increased at three-day intervals until crying subsided or symptoms of over dosage or side effects appeared. The usual maximum dose was two mg/kg in four divided doses daily.
3314288|NCT01955655|Placebo Comparator|placebo|Placebo contained fructose powder in equal quantity in packets mimicking those of Baclofen.
3314289|NCT01955668|Experimental|AZD6738|Patients will receive a single dose on day 1 followed by ongoing multiple dosing until MTD or MFD is reached.
3314290|NCT01955694|Experimental|BAY94-8862 (2.5 mg)|2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
3314291|NCT01955694|Experimental|BAY94-8862 (5 mg)|5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium
3314292|NCT01955694|Active Comparator|Eplerenone|25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium
3314293|NCT01955694|Experimental|BAY94-8862 (7.5 mg)|7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting).
3314294|NCT01955694|Experimental|BAY94-8862 (10 mg)|10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
3314295|NCT01955694|Experimental|BAY94-8862 (15 mg)|15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study.
3314296|NCT01955746||Type 1 DM|
3314297|NCT01955759|Experimental|beta blocker and amiodarone|The inteventin will be that patients will receive beta blocker Bisoprolol in adjusted dose + Amiodarone per os starting 7 days before coronary by-pass surgery, 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
3314298|NCT01955759|Experimental|beta blocker and statin|The intervention will be that patients will receive beta blocker (Bisoprolol tab in adjusted dose)+ Rosuvastatin 20 mg. x 1 starting 7 days before coronary by-pass surgry untill discharge.
3314299|NCT01955759|Placebo Comparator|beta blocker|Patients will receive beta blocker (Bisoprolol tab in adjusted dose).
3314300|NCT01955772|Experimental|EN (Enteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
3314301|NCT01955772|Other|PN (Parenteral Nutrition)|"NE group: According to the HAS and SFNEP recommendations and the good practice rules, a polyurethane or silicone NGT, 8 to 10 French units, will be inserted and its positioning will be controlled by radiography before the EN beginning. Polyurethane and silicone are very well tolerated by nasal and oesophagus mucosa and have a long life duration allowing keeping the same tube during 2 to 3 months.~PN group: PN will be administrated by a central venous catheter, which is usually inserted in allo-HSCT patients to allow the administration of chemotherapy and of the different parenteral treatments."
3314302|NCT01955785|Active Comparator|PC ventilation|Intervention with pressure controlled ventilator
3314303|NCT01955785|Active Comparator|PRVC ventilation|Intervention with Pressure Regulated Volume Controlled Ventilator
3314304|NCT01955798|Experimental|Trocar|Pyramidal tip reusable 11mm trocar
3314305|NCT01955798|Active Comparator|Veress needle|Veress needle
3314306|NCT01955811|Other|Platelet concentrate transfusion and Human Fibrinogen|Blood samples will be collected directly before the start of transfusion and 1 hour after the end of transfusion. These samples will be spiked with Human Fibrinogen and clotting tests will be performed. After 24 h after end of transfusion a clotting test will be performed again.
3314307|NCT01955824|Experimental|1% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
3314308|NCT01955824|Active Comparator|2% lignocaine|"Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients."
3314309|NCT01955850|Experimental|Internet-delivered CBT for insomnia|Online Cognitive behavioral treatment for insomnia
3314310|NCT01955850|Experimental|Face-to-face CBT for insomnia|Face-to-face Cognitive behavioral treatment for insomnia
3314311|NCT01955850|No Intervention|Waiting-list|Waiting-list
3314312|NCT01955863|Active Comparator|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
3314313|NCT01955863|Experimental|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
3314314|NCT01955863|Experimental|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
3314315|NCT01955876||Group 1|
3314316|NCT01955889|Experimental|Mobile Health Technology|Stretching and strengthening exercises provided via video using mobile health technology; walk daily using a pedometer; interact with a physical therapist remotely through an exercise application on a tablet device over 12 month period
3314317|NCT01955889|Active Comparator|Control|Stretching and strengthening exercises provided using printed photographs; walk daily using a pedometer; interact with a physical therapist at the beginning of the 12 month study; no use of mobile technology
3314318|NCT01955902||Opioid addicts|Opioid addicts undergoing bup/nal maintenance therapy
3314319|NCT01955915||Choroidal Tumor Group|15 patients diagnosed with small posterior choroidal tumors will be considered and evaluated for enrollment into this study
3314320|NCT01955928|Experimental|Online Cognitive behavioral treatment for insomnia|Online Cognitive behavioral treatment for insomnia
3314321|NCT01955928|No Intervention|Waiting-list|Waiting-list
3314322|NCT01955941||Cohort A|Patients with uveal melanoma for which brachytherapy is recommended will be considered and evaluated for enrollment into this study in order to describe the association between radiation treatment and changes in vision and blood flow within these treated eyes. Changes in vision and blood flow will be monitored at yearly intervals over a 5-year period. Up to 60 subjects will be recruited for this group.
3314323|NCT01955941||Cohort B|Patients with uveal melanoma who have previously undergone I-125 plaque brachytherapy will be considered for enrollment into this study to evaluate blood flow in eyes with more advanced radiation-induced changes. This group will only undergo a one-time study session. Up to 40 subjects will be recruited for this group.
3314324|NCT01955967|Other|Lidocaine|
3314325|NCT01955980|Experimental|Buparid; Treatment A|Buparid 1mg budesonide/2 ml nebulizer solution
3314326|NCT01955980|Active Comparator|Budes; Treatment B|Budes Nasal Spray 50 µg budesonide/pump
3314327|NCT01955993||Fentanyl use for surgical pain|Adolescent patient having surgery
3314328|NCT01956006|Experimental|MIlrinone|ER milrinone
3314329|NCT01956019|Experimental|MRI scanning|patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
3314330|NCT01956045||Decision making|
3314331|NCT01956058|Experimental|brachytherapy remedial|
3314332|NCT01956084|Experimental|LMP1/2 CTLs (Group A)|Patients receiving CTLs as adjunctive therapy following allogeneic stem transplant
3314333|NCT01956084|Experimental|LMP1/2 CTLs (Group B)|Patients receiving CTLs in relapse following allogeneic stem cell transplant
3314334|NCT01956136|Experimental|Arm 1|The patients receive 10 weeks of Music-based Neurological Rehabilitation (MBNR) and Standard Care (SC) followed by 10 weeks of SC only.
3314335|NCT01956136|Experimental|Arm 2|The patients receive 10 weeks of Standard Care (SC) only followed by 10 weeks of Music-based Neurological Rehabilitation (MBNR) and SC.
3314336|NCT01956149|Experimental|Cabazitaxel|Cabazitaxel 20 mg/m2 over 1 hour i.v., repeated on day 22
3314337|NCT01956162|Experimental|"Group Orthèse Diabète"|"Using Orthèse Diabète, a new customized removable device with rocker sole for plantar off-loading"
3314338|NCT01956162|Active Comparator|Control Group|"Using Conventional devices, removable off-loading systems among the devices available in France"
3314339|NCT01956175|Experimental|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation once daily for 10 minutes on three consecutive days.
3314340|NCT01956175|Sham Comparator|Sham stimulation|Sham stimulation once daily for 10 minutes on three consecutive days. If the subject cannot be decannulated after three days of sham stimulation, another three days of real electrical pharyngeal stimulation will be delivered.
3314341|NCT01956188|Experimental|EPA and DHA supplementation|EPA (1800mg/d) and DHA (1200mg/d) supplementation
3314342|NCT01956188|Placebo Comparator|Placebo|Soy oil (3000 mg/d)
3314343|NCT01956201|Experimental|Atorvastatin 20mg, Fenofibrate 160mg|Atorvastatin 20mg, Fenofibrate 160mg: po, q.d.
3314344|NCT01956201|Active Comparator|Atorvastatin 20mg, Placebo|Atorvastatin 20mg, Placebo for Fenofibrate 160mg po, q.d.
3314345|NCT01956214|Experimental|FES exercise|Participants will receive FES
3314346|NCT01956214|Sham Comparator|Mock FES exercise|participant will receive Mock FES
3314347|NCT01956227|Experimental|Home-based Exercise|Participants will be taught a series of exercises targeting balance and lower limb strength in four instructional sessions. They will be asked to complete exercises 3 times a week for 12 weeks. Exercise compliance will be recorded with a diary.
3314348|NCT01956227|Experimental|Education|Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
3314349|NCT01956227|Experimental|Exercise plus education|Participants will attend 2 instructional exercise sessions as well as 2 education sessions. Participants will be asked to complete exercises at home 3 times per week and engage in behavior to minimize fall risk.
3314350|NCT01956227|No Intervention|Control|Participants will not receive any treatment.
3314351|NCT01956266|Experimental|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate.
3314352|NCT01956292||Intraparenchimal cerebral haemorrhage|
3314353|NCT01956305|Experimental|Cohort A 10mg DS-7309|DS-7309 10 mg twice daily
3314354|NCT01956305|Experimental|Cohort B 20mg DS-7309|DS-7309 20 mg twice daily
3314355|NCT01956305|Experimental|Cohort C DS-7309 40 mg|DS-7309 40 mg twice daily
3314356|NCT01956305|Experimental|Cohort D DS-7309 75 mg|DS-7309 75 mg twice daily
3314357|NCT01956305|Experimental|Cohort E DS-7309 150 mg|DS-7309 150 mg twice daily
3314358|NCT01956305|Experimental|Cohort F DS-7309 150 mg with escalating metformin doses|DS-7309 150 mg twice daily with escalating metformin doses
3314359|NCT01956305|Placebo Comparator|Placebo|placebo to match DS-7309
3314360|NCT01956318|Experimental|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Patients are also delivered a booklet with advice on lifestyle.
3314361|NCT01956318|No Intervention|control group|patients are allowed to continue their usual drugs, compression therapy and are delivered a booklet with advice on lifestyle.
3314362|NCT01956344|Experimental|Immediate Treatment|Cognitive-behavioral therapy
3314363|NCT01956344|No Intervention|Delayed Treatment|This group will receive the cognitive-behavioral therapy after a 16 week delay
3314364|NCT01956344|No Intervention|Healthy Control|This group is matched to the immediate treatment group on age and gender. They do not receive an active treatment and will be used a a healthy comparator group.
3314365|NCT01956357|Experimental|Aquatic exercise|"The aquatic aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in deep water at low intensity for three minutes. The main part was intended to aerobic training in deep water, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in deep water at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
3314366|NCT01956357|Experimental|Land exercise|"The land aerobic training had a duration of 12 weeks and adopted the interval-training method, with intensities ranging between 85 and 100% of second ventilatory threshold (VT2) and total duration of 45 minute per session.~The sessions consisted of warm up, main part and calm down. The warm-up consisted of a walk in athletic track at low intensity for three minutes. The main part was intended to aerobic training in athletic track, in which subjects walked and / or ran, depending on your fitness level found in pre-training test. The calm down consisted of walking in athletic track at low intensity for two minutes and stretching standardized, emphasizing the muscles worked in the main part of the session, with a total duration of approximately five minutes."
3314367|NCT01956370|Experimental|PrePex™ device|Intervention 'PrePex™ device for adult male circumcision
3314368|NCT01956370|Active Comparator|Surgical|Adult male surgical circumcision
3314369|NCT01956383|Experimental|PrePex™ device|Adult male circumcision by the PrePex™ device
3314370|NCT01956396|Experimental|Experimental: PrePex™ device|Adult male circumcision by the PrePex™ device
3314371|NCT01956409|Experimental|diagnostic accuracy of PET and MR spectroscopy|To investigate the diagnostic accuracy of 18F-Fluorocholine PET and proton MR spectroscopy of breast lesions, using pathology as gold standard.
3314372|NCT01956422|Experimental|Continuous Positive Airway Pressure(CPAP)|In the first 24 hours after laparoscopic prostatectomy patients undergo 3 CPAP cycles (PEEP 7.5, FIO2 40% delivered with Helmet)lasting 2 hours.
3314373|NCT01956422|Active Comparator|Venturi Mask FiO2 40%|In the first 24 hours after laparoscopic prostatectomy patients breathe Oxygen 40% delivered with Venturi Mask
3314374|NCT01956448|Experimental|Drug eluting stent (BioMatrix Flex)|Device: Percutaneous coronary intervention with implantation of drug eluting stent (BioMatrix Flex)
3314375|NCT01956448|Experimental|Drug eluting stent (Resolute Integrity)|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
3314376|NCT01956474|Other|Theralight crosslinking and Riboflavin|ultraviolet-A (UVA)-induced cross-linking of corneal collagen (CXL) using UVA light and the photo- mediator riboflavin
3314377|NCT01956487|Other|Propafenone|Open label comparison of 2 formulations
3314378|NCT01956500|Experimental|Instaflex|Instaflex Joint Support supplement (3 capsules per day for 8 weeks)
3314379|NCT01956500|Placebo Comparator|Placebo|Placebo (3 capsules per day for 8 weeks)
3314380|NCT01956526|Experimental|CORolla™ TAA Stand Alone|Single arm study design including with patients with isolated HFpEF, in NYHA f. Cl. III-IV. These patients will receive the CORolla™ TAA device. For assessments of results, intra-patient comparisons of pre-procedure and follow-up data will be performed;
3314381|NCT01956526|Experimental|AVR and CORolla™ TAA Add On group|patients who require aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction will receive the CORolla™ TAA device.
3314382|NCT01956526|No Intervention|AVR and CORolla ADD On - Control|patients who require only the aortic valve replacement (AVR) due to aortic stenosis and have diastolic dysfunction.
3314383|NCT01956539||Heart Failure|All patients over 18 years with chronic heart failure, and all patients hospitalized for acute heart failure de novo or not. The diagnosis of heart failure is the responsibility of the cardiologist including patient.
3314384|NCT01956565|Experimental|Inspiratory muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
3314385|NCT01956565|No Intervention|Declining Inspiratory muscle training|No intervention. Interview and baseline assessment only.
3314386|NCT01956578|Experimental|Breathing Exercise Cohort|All patients enrolled will be asked to wear an external respiration band while performing a series of breathing exercises.
3314387|NCT01956591||Axillary hyperhidrosis|Patients whose major complaint is excessive sweating in the axillary region (i.e, sweating in the armpit). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., palmar hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3314388|NCT01956591||Palmar hyperhidrosis|Patients whose major complaint is excessive sweating in the palmar region (i.e, sweating in the hands). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3314389|NCT01956591||Plantar hyperhidrosis|Patients whose major complaint is excessive sweating in the plantar region (i.e, sweating in the feet). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3314390|NCT01956591||Cranio-facial hyperhidrosis|Patients whose major complaint is excessive sweating in the cranio-facial region (i.e, sweating in the face). Patients that also have hyperhidrosis - but that are less bothersome on other sites (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3314391|NCT01956591||Other sites hyperhidrosis|Patients whose major complaint is excessive sweating in other sites of the body (e.g., on the chest, on the abdomen). Patients that also have hyperhidrosis - but that are less bothersome on other sites previously grouped (e.g., axillary hyperhidrosis) are not excluded, but are accounted for accordingly to their main complaint.
3314392|NCT01956604|Experimental|Clonidine|"Clonidine administered orally:~Day 1/loading doses: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
3314393|NCT01956604|Placebo Comparator|Placebo (sugar pill)|"Placebo administered orally (identical capsula as for expirimental drug):~Day 1/loading doases: 75µg every 3rd hour until maximum 4 doses. Day 2-7/maintenance doses: 75µg BID. Duration of treatment is maximum 7 days."
3314394|NCT01956617|Other|injection volume|block success or failure determines a 5 ml decrease or increase for the subsequent patient, respectively
3314395|NCT01956630|Experimental|Genetically modified DCs plus CIK cells|Patients received four subcutaneous injections of 2-5×10e7 cells of DCs at the groin, axilla, and neck respectively on days 7, 9, 11, and 13 and i.v. infusions of 2-15×10e9 CIK on days 11 and 13 per cycle. The cycle was repeated until Wilms' tumor 1(WT1) turned negative by polymerase chain reaction(PCR) or graft-versus-host disease(GVHD) appeared.
3314396|NCT01956630|Active Comparator|Donor leukocyte infusions (DLI)|Patients received DLI at a dose of 2×10e7/kg, 5×10e7/kg and 1×10e8/kg cluster of differentiation 3(CD3)+ cells at months 1, 2 and 3 respectively unless GVHD appeared.
3314397|NCT01956643|Experimental|gum chewing|"Gum type was standardized with all subjects receiving sugar-free xylitol gum.~The patients in the chewing gum group, gum chewing began the morning of postoperative day 1. Patients chewed gum (two tablets) 3 times daily in the morning, afternoon, and evening for 15 min. The administration of the therapy was implemented by ICU nurses and recorded in the clinical report form file. All gum-chewing patients completed their course of gum chewing until gas out."
3314398|NCT01956643|Placebo Comparator|Control|Routine care during NPO
3314399|NCT01956656|Placebo Comparator|lotus leaf mouthwash|10 ml mouthwash to be used for 4days twice daily
3314400|NCT01956656|Placebo Comparator|placebo mouthwash|10 ml mouthwash to be used for 4 days twice daily
3314401|NCT01956669|Experimental|Pazopanib|All subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m^2/dose or as a powder in suspension at a dose of 225 mg/m^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m^2/dose was not tolerated (>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m^2/dose. A cycle was defined as 28 days with no rest periods between cycles.
3314402|NCT01956682|Active Comparator|Infant formula|HA formula + starch + L. reuteri
3314403|NCT01956682|Placebo Comparator|Standard Formula|Standard Infant Formula
3314404|NCT01956695|Experimental|Lenalidomide & Rituximab|"Induction treatment : Lenalidomide 20 mg capsule on days 1 to 21 days of a 28 days cycle for the first cycle followed by 25 mg on daily on days 1 to 21 of a 28 days cycle for cycles 2 to 8 (in the absence of hematologic toxicity. Rituximab at day 1 of each induction course 375 mg/m² intravenous.~Maintenance : Lenalidomide 10 mg capsule on days 1 to 21 days of a 28 days cycle for 1 year or until progression or intolerance."
3314405|NCT01956708|Active Comparator|Remote ischemic preconditioning|"Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: 3 cycles of 5 minutes left upper arm ischemia by inflation of a blood pressure cuff to 200mmHg and 5 minutes of reperfusion Anesthesia is with isoflurane (0.7-0.8% end-tidal) +sufentanil"
3314406|NCT01956708|Placebo Comparator|Placebo|"No Remote ischemic preconditioning (RIPC) protocol before coronary artery bypass surgery (CABG):~after induction of anesthesia and before surgery: the cuff is left uninflated"
3314407|NCT01956721|Experimental|Patients with heart failure (FEVG ≥ 50%)|Patients with heart failure (FEVG ≥ 50%)
3314408|NCT01956721|Experimental|Patients with heart failure (FEVG ≤ 35%),|Patients with heart failure (FEVG ≤ 35%),
3314409|NCT01956721|Other|Healthy Volunteers|Healthy Volunteers with no heart failure
3314410|NCT01956734|Experimental|DNX2401 and Temozolomide|"DNX2401: Virus injection in the brain parenchyma. Total dose will be 3x1010 vp suspended in 1 ml for all cases.~Temozolomide: 14 (window 14-28 days) days after the virus injection, patients will begin therapy with temozolomide in a dose of 150mg/m2 in days 1-7 and 15 -21 of a 28 days cycle, (dose dense scheme 7 days on, 7 days off), until a maximum of 2 x 28 days cycles in absence of toxicity."
3314411|NCT01956747||standard anticancer treatment|Patients older than 70 years of age with advanced malignancies of colorectum, breast or prostate, who will start with full standard anticancer treatment as decided by their oncologist.
3314412|NCT01956760|Experimental|Acupuncture|Acupuncture and intradermal acupuncture The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
3314413|NCT01956760|Placebo Comparator|Placebo Acupuncture|Placebo acupuncture and placebo intradermal acupuncture The acupuncture was applied 3 times in a week at 2 sham points on the wrist and 3 sham points on the ankle, approximately 1cm lateral to the acupoints. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same sham points, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
3314414|NCT01956786|Active Comparator|Amlodipine|5mg amlodipine,once daily for 8 weeks
3314415|NCT01956786|Experimental|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg of folic acid (FA),once daily for 8 weeks.
3314416|NCT01956786|Experimental|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg of folic acid (FA),once daily for 8 weeks.
3314417|NCT01956812|Experimental|Arm A IMMU-107 and gemcitabine|IMMU-107 and low dose gemcitabine
3314418|NCT01956812|Active Comparator|Arm B Placebo and low dose gemcitabine|Placebo and low dose gemcitabine
3314419|NCT01956825|Placebo Comparator|water|just water
3314420|NCT01956825|Experimental|"L-CARNITINE AND MAGNESIUM (slim water product)"|"The experimental arm will receive a product slim water, which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo."
3314421|NCT01956838|Experimental|Umami|intraduodenal infusion of umami
3314422|NCT01956838|Experimental|sweet|intraduodenal infusion of sweet tastant
3314423|NCT01956838|Experimental|bitter|intraduodenal infusion of bitter tastant
3314424|NCT01956838|Experimental|combination|intraduodenal infusion of a combination of tastants (umami, bitter and sweet)
3314425|NCT01956838|Placebo Comparator|placebo|intraduodenal infusion of placebo (tap water)
3314426|NCT01956851||Normal Healthy|Normal Healthy: includes healthy patients eligible for enrolment,
3314427|NCT01956851||Diabetics on Oral Hypoglycemic Agents|Diabetics on Oral Hypoglycemic Agents: includes diabetic patients on oral diabetic drug therapy with all eligibility criterion fulfilled,
3314428|NCT01956851||Diabetics on Insulin Therapy|Diabetics on Insulin Therapy: includes diabetic patients on insulin therapy with all eligibility criterion fulfilled
3314429|NCT01956864|Experimental|Dose VD 1|Vitamin D
3314430|NCT01956864|Experimental|Dose VD 2|Vitamin D
3314431|NCT01956864|Experimental|Dose VD 3|Vitamin D
3314432|NCT01956864|Experimental|Dose VD 4|Vitamin D
3314433|NCT01956864|Experimental|Dose VD 5|Vitamin D
3314434|NCT01956864|Experimental|VD 6 Month Treatment|Vitamin D
3314435|NCT01956877||Healthy volunteers|
3314436|NCT01956890|Other|diagnostic accuracy|diagnostic accuracy of PET and MRI for breast cancer diagnosis.
3314437|NCT01956903|Experimental|Allogenic Mesenchymal Stem Cell|Sequential Infusion of Expanded in-Vitro Allogenic Mesenchymal Stem Cell (MSC). Dosage 0,7 x 10e6 MSC/Kg/dose (cumulative minimum dose: 2,8 x 10e6 CSM/Kg.
3314438|NCT01956916|Experimental|Probiotics|Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die of Lactobacillus rhamnosus GG (LGG)
3314439|NCT01956916|Placebo Comparator|Placebo|Capsules containing maltodextrin
3314440|NCT01956929|Experimental|Metformin|2 weeks of Metformin use. First week 1000mg/day, Second week Max dose of 2000 mg/day.
3314441|NCT01956929|Placebo Comparator|Placebo|2 weeks of Placebo (lactulose pills)
3314442|NCT01956942|Experimental|Micropulse Laser Trabeculoplasty|Patient's randomized to MLT would be treated with the following settings: 300 micron spot size, 0.3 second duration, 15% duty cycle, and 1000 milliWatt power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative intraocular pressure (IOP) spikes as per standard pre-laser trabeculoplasty protocol.
3314443|NCT01956942|Active Comparator|Selective Laser Trabeculoplasty (SLT)|Patient's randomized to SLT would be treated with the following settings: 400 micron spot size, 0.3 second duration, and 1.00 milliWatt (mW) power. They would be treated with confluent laser spots across the entire 360 degrees of the trabecular meshwork. Each patient would receive pre-treatment with a drop on iopidine or brimonidine to prevent post-operative IOP spikes as per standard pre-laser trabeculoplasty protocol.
3314444|NCT01956955|Active Comparator|enoxaparin and alteplase|After alteplase therapy , 4-6 hour later, activated partial thromboplastin time (APTT) was checked. According to initial SC LMWH use time, fixed dose SC LMWH, enoxaparin, was administered subcutaneous every 12 hours.
3314445|NCT01956955|Active Comparator|Unfractionated heparin and alteplase|After thrombolytic treatment, a bolus of 10 mg of alteplase followed by 90 mg over 2-h infusion, patients either administered a constant heparin infusion (18 U/Kg per hour) adjusted to maintain an activated partial thromboplastin time of 46-70 s.
3314446|NCT01956981|Placebo Comparator|Magnesium|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
3314447|NCT01956981|Active Comparator|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
3314448|NCT01956994|Experimental|Whey protein supplement|Subjects will be instructed to consume 40 g whey protein each day for 12 weeks.
3314449|NCT01956994|Active Comparator|Carbohydrate supplement|Subjects will be instructed to consume a carbohydrate supplement (iso-caloric to the whey supplement) each day for 12 weeks.
3314450|NCT01957007|Experimental|Docetaxel|Drug: Docetaxel - administered intravenously
3314451|NCT01957007|Experimental|vantictumab|Drug: vantictumab - administered intravenously
3314452|NCT01957033|Experimental|Duration 6 weeks, frequency 3/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for 6 weeks
3314453|NCT01957033|Experimental|Duration 6 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for 6 weeks
3314454|NCT01957033|Experimental|Duration 6 weeks, Frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 6 weeks
3314455|NCT01957033|Experimental|Duration 3 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks Manual therapy 3 times/week for first 3 weeks
3314456|NCT01957033|Experimental|Duration 3 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks Manual therapy twice/week for first 3 weeks
3314457|NCT01957033|Experimental|Duration 3 weeks, frequency once/week|Exercise and education once/week for 6 weeks Manual therapy once/week for first 3 weeks
3314458|NCT01957033|Experimental|Duration 0 weeks, Frequency 3 times/week|Exercise and education 3 times/week for 6 weeks No manual therapy
3314459|NCT01957033|Experimental|Duration 0 weeks, Frequency twice/week|Exercise and education twice/week for 6 weeks. No manual therapy
3314460|NCT01957033|Experimental|Duration 0 weeks, Frequency once/week|Exercise and education once/week for 6 weeks No manual therapy
3314461|NCT01957046|Other|Oral Laxative|
3314462|NCT01957059|Experimental|Dose escalation phase|In the dose-escalation phase, following screening assessment, two cohorts of three subjects each receive two single doses of BMN 053 in two study periods (i.e., four single doses in total per subject). In each study period they will receive BMN 053 by IV infusion and by SC injection (separated by one week). The proposed doses are 1 mg/kg (Cohort 1, study period 1), 3 mg/kg (Cohort 2, study period 1), 6 mg/kg (Cohort 1, study period 2) and 9 mg/kg (Cohort 2, study period 2). The actual doses may be amended or repeated based on emerging data from previous doses.
3314463|NCT01957059|Experimental|Regimen selection|After completion of the dose-escalation period of Cohort 1, the safety data of the subjects will be reviewed by a DSMB and if no safety concerns these subjects will continue to receive 6 mg/kg BMN053 weekly by SC injection for 48 weeks. 3 more treatment-naïve subjects will be entered into this Group. These 6 subjects will form Group 1 of the Regimen Selection phase who received 6 mg/kg SC. At the time of this amendment (4) this part of the study has been completed. Following completion of the dose-escalation study period of Cohort 2 (9 mg/kg), the planned review of the preliminary plasma PK data from the dose-escalation phase showed a relative bioavailability of 50% for BMN053 with SC dosing (50% lower plasma AUC after SC dosing compared to IV dosing). Taking into consideration the risk of injection site reactions noted with similar compounds when administered SC over longer term, the planned 9 mg/kg BMN053 weekly by SC injection will be discontinued to be replaced by an IV regimen.
3314464|NCT01957059|Experimental|48-week Treatment Phase|"Thirty additional treatment-naïve subjects will be recruited for the primary evaluation and will receive treatment at the recommended regimen for a total of 48 weeks. Subjects dosed initially in the dose escalation phase and/or the regimen selection phase of the study will not be included in the primary analysis.~Following completion of the 2nd study period for Cohort 2, the safety data will be reviewed by the DSMB and in the absence of safety concerns the subjects may enter the 48 week treatment phase and receive 9 mg/kg PRO053 once weekly by SC injection. Three new subjects will enter cohort 2 (i.e. 6 subjects in total at this dose level).~After the initial 12 subjects have completed 12 weeks of dosing the dose for the Treatment group (30 new subjects) will be selected based on the totality of the 12-week data from those initial 12 subjects. The initial 12 subjects will also be dosed on the selected dose (i.e. continue on their dose or [down-]titrate)."
3314465|NCT01957059|Experimental|Dosing extension|All subjects who have completed the dose escalation and regimen selection phase of the study (N=15), and subjects who have complete the treatment phase of the study who have tolerated the treatment will be offered to continue dosing in the dosing extension with ongoing assessment of efficacy, safety, and tolerability of BMN 053. Safety, efficacy, PK/PD and biomarker assessments will be performed at scheduled visits; adverse events (AEs) and concomitant medications and therapies will be continuously monitored. The dose extension phase will provide BMN 053 treatment for 48 weeks.
3314466|NCT01957072|Experimental|Behaviour change intervention|Intensive behaviour change intervention for 3 months, followed by a maintenance phase for 3 months
3314467|NCT01957072|Other|Wait-list Control|Usual care for 3 months, followed by intensive behaviour change intervention for 3 months
3381741|NCT00001406||1|Volunteers with elevated eosinophil counts in the peripheral blood or tissues; or a relative of a volunteer with eosinophilia
3314468|NCT01957098|Placebo Comparator|0% pentose|Pure sucrose without pentoses added.
3314469|NCT01957098|Active Comparator|4% D-xylose|Sucrose drink supplemented with 4% D-xylose
3448492|NCT04063423||hemodialysis study session|"4h hemodialysis session using standard polysulphone dialyzer and Nikkiso dialysis monitors~Minimal dose of unfractionated heparin (UFH) with loading dose 500IE and maintenance 500IE/h, stopped 60 minutes before session end in case of AVF use.~Standard bicarbonate-based ultrapure dialysate. Na, K, Ca, bicarbonate concentrations according to the patient's routine dialysis prescription.~The blood flow rate maximized as per routine nursing care.~Dialysate flow rate fixed at 500 ml/min.~Dialysate temperature between 35.5°C and 36.5°C.~Ultrafiltration according to patient's dry weight and supported ultrafiltration rate.~At the end of the dialysis session the blood will be returned (100ml/min) to the patient."
3448493|NCT04063267|Experimental|E cigarettes|
3448494|NCT04063267|Active Comparator|Nicotine Replacement Therapy|
3448495|NCT04063449|Experimental|Experimental:group A|endostar,210 mg,CIV 72h,d1-d3; sintilimab,200mg,IV,d1; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar plus sintilimab for maintenance therapy until PD or intolerable toxicity ;
3448496|NCT04063449|Active Comparator|control:group B|endostar,210 mg,CIV 72h,d1-d3; carboplatin,5/AUC,IV,d1; Pemetrexed,500mg/m2 ,IV,d1； 3 weeks for a cycle;4-6 cycles; after the treatment for 4-6 cycles,endostar for maintenance therapy until PD or intolerable toxicity ;
3448497|NCT04063332||GROUP A|Absolutely healthy individuals without any comorbidities, working at the same environment with the rest of groups (doctors are excluded as belong to one of the special categories) patients with sepsis as defined by the Sepsis-3 classification criteria3
3448498|NCT04063332||GROUP B|Control patients without sepsis or infection and with the same exactly comorbidities (ideally ≤2 suffering organ systems) , i.e. identical Charlson score, identical mental status and age difference ≤ 5 years with group A
3448499|NCT04063332||GROUP C|Patients with sepsis as defined by the Sepsis-3 classification criteria3
3448500|NCT04063293|Experimental|PRP injection|PRP is prepared using a special device (VS-400, Genesis Comp, Korea). For each application a kit (e+ PRP, Genesis Comp, Korea) will be used. 18 cc of venous blood will be collected from the patient into the syringe with 2 cc of anticoagulant, and will be gently inverted. The sample will be slowly injected into the e+ PRP kit. The kit will be centrifuged under 1,500G for 4 minutes, which will separate the blood components into 3 different layers. The rot at the top of the kit will be pressed until the bottom of the piston will touch the red blood cell layer, and the rot will be turned clockwise to close it. The cap will be opened and the small syringe will be connected to the cap for extracting PRP. The injection will be performed in operation room under general anesthesia with either IV sedation of laryngeal mask airway (LMA) sedation. 10 cc of PRP will be directly injected in external muscles at 8 locations under the guidance of endoanal ultrasound
3448501|NCT04063631||1/Birth cohort|Prospective, longitudinal cohort of 1000 healthy infants. Recruited at birth and followed for 3 years. Samples to be collected at 5-10 days old, 1 and 3 years old. 100 participants with additional samples collected at 3 and 6 months of age. Approximately 300 participants to have samples collected at time of active wheezing and during convalescence.
3448502|NCT04063631||2/mild wheezers and controls|Children under 5 years old undergoing elective general surgical procedure. Some will have mild-to-moderate wheeze while others will be non-wheezing controls
3448503|NCT04063631||3/pre-school aged severe wheezers|50 children aged 1-6 years undergoing clinically indicated bronchoscopy due to recurrent wheezing.
3448504|NCT04063631||4/school aged severe asthmatics|50 kids aged 6-16 undergoing clinically indicated bronchoscopy due to asthma.
3448505|NCT04063345|Experimental|IVUS-guided PCI|Percutaneous intervention under IVUS-guidance
3448506|NCT04063345|Active Comparator|Angiography-guided PCI|Percutaneous intervention under angiograhy-guidance only
3448507|NCT04063319|Experimental|High-fidelity simulation|The participants in the intervention group will receive an high-fidelity simulation intervention
3448508|NCT04063319|No Intervention|Control|The participants in the control group will not receive any instructional intervention
3314470|NCT01957098|Active Comparator|8% D-xylose|Sucrose drink supplemented with 8% D-xylose
3314471|NCT01957098|Active Comparator|8% L-arabinose|Sucrose drink supplemented with 8% L-arabinose
3448509|NCT04063579|Experimental|Patients with heart failure with preserved ejection fraction|
3314472|NCT01957124|Experimental|PRF application|
3314473|NCT01957176|Experimental|Cohort A|Cohort A consists of subjects who had completed their treatment with eltrombopag (ELT) during their participation in a parent study for Myelodysplastic syndrome (MDS)/ Acute myeloid leukemia (AML). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 50 to 300 mg once daily (OD) for subjects of non- East Asian heritage. The dose ranges for subjects of East Asian heritage (i.e. Japanese, Chinese, Taiwanese, Thai and Korean) will be 25 to 150 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3448510|NCT04063579|Experimental|Non-heart failure patients|
3448511|NCT04063579|Experimental|Normal Volunteers|
3448512|NCT04063410|Experimental|Screening (pPCA)|Patients undergo standard of care CTA and undergo pPCA MRI for up to 60 minutes before surgery.
3448513|NCT04063670|Active Comparator|Control|Routine, standard-of-care treatment
3314474|NCT01957176|Experimental|Cohort B|Cohort B consists of adult subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3314475|NCT01957176|Experimental|Cohort C|Cohort C consists of pediatric subjects who have completed study treatment with ELT during their participation in a parent study for Idiopathic thrombocytopenic purpura (ITP). All subjects in this cohort will receive ELT at the dose that they were receiving at the time of the transition visit, except in the case where the subject required a dose modification. The range of doses of ELT that will be used in this cohort are from 12.5 to 75 mg. Dose adjustments (if required) will be done depending on each subject's platelet counts.
3314476|NCT01957189|Experimental|Dutasteride with/ without Tamsulosin|All subjects will be assigned to the same treatment group
3314477|NCT01957228|Experimental|bone biopsies|
3314478|NCT01957241||Hepatocellular Carcinoma and Esophageal Cancer|
3314479|NCT01957254||Severe Sepsis|Patient with severe sepsis
3314480|NCT01957267||Glaucoma Group|Patients with clinically confirmed glaucomatous ONH or NFL defects, with or without VF abnormalities
3314481|NCT01957267||Normal Group|Volunteers with healthy eyes
3314482|NCT01957280|Experimental|Process 2 patritumab|Process 2 patritumab 18 mg/kg (loading dose) on Day 1 of Cycle 1 followed by Process 2 patritumab 9 mg/kg (maintenance dose) once every 21 days starting on Day 1 of Cycle 2 through Cycle 5.
3314483|NCT01957293|Experimental|Salbutamol|
3314484|NCT01957293|Placebo Comparator|Sugar Syrup|
3314485|NCT01957306|Experimental|Dr. Tagliaferri's Menoapause Formula|Administered as 2 grams PO BID.
3314486|NCT01957319|Active Comparator|Silybin - vitamin E - phospholipids complex|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg in one pill for 12 months.
3314487|NCT01957319|Placebo Comparator|placebo|sugar pill
3314488|NCT01957332|Experimental|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET. On the same day or the day after 18F-FES injection 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
3314489|NCT01957345|Other|bleeding disorder|"Blood punction at patients with bleeding disorder definitely other than of platelet origin (e.g. low von Willebrand)"
3314490|NCT01957345|Other|constitutional platelet disorder|Blood punction at patients with constitutional platelet disorder (e.g. Glanzmann thrombasthenia)
3314491|NCT01957345|Other|defect of platelet function|Blood punction at patients with defect of platelet function of unknown origin, potentially defective in signalling pathway.
3314492|NCT01957358|Experimental|Lifestyle counselling using the Grief Recovery Method|Volunteers will participate in a series of weekly and twice-weekly sessions with a counselor who has obtained special training in the Grief Recovery Method.
3314493|NCT01957371|Experimental|Mindful Yoga Therapy|12 sessions of Mindful Yoga Therapy delivered two times per week for 75 minutes each.
3314494|NCT01957423|Experimental|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
3314495|NCT01957423|Active Comparator|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
3314496|NCT01957436|Active Comparator|Arm A|androgen deprivation therapy + docetaxel
3314497|NCT01957436|Experimental|Arm B|androgen deprivation therapy + docetaxel + abiraterone acetate + prednisone
3314498|NCT01957436|Experimental|Arm C|Arm A + radiotherapy
3314499|NCT01957436|Experimental|Arm D|Arm B + radiotherapy
3314500|NCT01957449|Active Comparator|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
3314501|NCT01957449|Placebo Comparator|Sugar Pill|Placebo by mouth given daily throughout hospitalization for up to 12 months
3314502|NCT01957501||Major Depressive Disorder Participants|
3314503|NCT01957501||Bipolar Disorder Participants:|
3314504|NCT01957501||Healthy Control Participants|
3314505|NCT01957514||Ancillary-Correlative (sample collection)|Patients undergo collection of tissue biopsy, blood, buccal swab, saliva, and urine at baseline.
3314506|NCT01957527||Ticagrelor discontinuation|
3314507|NCT01957540|Experimental|Ticagrelor|Ticagrelor 90mg bid for 15 days
3314508|NCT01957540|Active Comparator|Prasugrel|Prasugrel 10mg od for 15 days
3314509|NCT01957566|Experimental|APS|
3314510|NCT01957592||Subjects with diabetes mellitus (type 2)|
3314511|NCT01957605||prone position|Patient scheduled for surgery in the prone position
3314512|NCT01957618||Treatment group|liver cirrhosis group who received indefinite anti-viral treatment
3314513|NCT01957618||Historical control group|Liver cirrhotic patients who were enrolled before 2004 and did not receive treatment during the follow-up
3314514|NCT01957631|Active Comparator|Corticosteroid injection|Corticosteroid injection
3314515|NCT01957631|Experimental|Platelet rich plasma injection|Platelet rich plasma injection
3314516|NCT01957670|Experimental|Treatment with Lacrima medical device|
3314517|NCT01957683|Experimental|Single Arm|
3314518|NCT01957696||Pancreas-Tx recipients; single cohort|This is a prospective, single cohort observational study, aimed at using a historical control group as comparison. It will be conducted at our single, national centre for organ transplantation in Oslo. All pancreas recipients > 18 years of age, who fulfill the inclusion criteria, will prior to transplantation be asked for inclusion.
3314519|NCT01957722|Experimental|NOVOCART 3D|Scaffold assisted autologous chondrocyte Implant
3314520|NCT01957722|Active Comparator|Microfracture|considered a typical treatment for articular cartilage repair
3314521|NCT01957735|Experimental|BP31510 monotherapy|"Starting dose level of BPM31510 will be 66 mg/kg administered by IV infusion over 48 hours 2 times per week of each 28-day cycle.The 2 doses will be administered over 4 consecutive days.The study drug will be administered undiluted via a central venous access device and the infusion rate will be controlled by a programmable ambulatory infusion pump.~first dose of each week of the cycle a loading dose will be infused over 1 hour with the remainder of the dose volume infused over 47 hours.At each dose level of Arm 1 and Arm 2, patients will be treated for either 8 hours at minimum of outpatient monitoring or inpatient monitoring for the first 24-hrs of the first infusion of Cycle 1.~second dose of each week of the cycle, the total dose volume given over 48 hours with no loading dose."
3314522|NCT01957735|Active Comparator|BP31510 in combination with chemotherapy|"standard 3+3 design will be used for Arm 2 of the study. BPM31510 will be started at one dose level below the dose that has been studied and determined to be safe in the monotherapy portion of the trial. Arm 2 patients will be enrolled onto one of 3 chemotherapies, gemcitabine, 5-FU, or docetaxel according to the dose levels below:~Gemcitabine IV once weekly at a starting dose of 600 mg/m2 ;~5-Fluorouracil (5-FU) IV once weekly at a starting dose of 350 mg/m2 with leucovorin (LV) 100 mg/m2; OR~Docetaxel IV once weekly at a starting dose of 20 mg/m2.~Note:Both BPM31510 and the chemotherapy agent can escalate simultaneously in Cohorts 3 and 4 only if there are no DLTs observed in the previous cohorts. If one or more DLTs are observed, then intermediate dose levels will be added where one agent is escalated."
3314525|NCT01957774|Experimental|THR-18|
3314526|NCT01957774|Placebo Comparator|Placebo|matching placebo; look-alike with no active ingredients
3314527|NCT01957800|Experimental|Website|Group will be asked to complete a daily plan online for specific situations that tempt people to overeat. The website can be accessed online using a computer or smart phone and will allow participants to view others' plans. Participants will also be asked to enter their weight online every week.
3314528|NCT01957800|Active Comparator|Usual Care|Group will be given access to the online intervention after the 3-month study ends.
3314529|NCT01957813|Other|Standard Health Services|Service currently being provided to FSW in Naivasha include peer education and health services delivered through a drop-in center (DIC) staff by a counselor and a nurse. For peer education, there are six modules that the peer educators walk all peers through with sessions being held once a week.
3314530|NCT01957813|Experimental|LifeStyle Counseling|A package of enhancements to the current package of services delivered to FSW will be implemented and evaluated.
3314531|NCT01957826|Placebo Comparator|placebo comparator|transendocardial injection of placebo solution
3314532|NCT01957826|Experimental|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
3314533|NCT01957839|No Intervention|pretreatment group|doppler evaluation at pretreatment period
3314534|NCT01957839|Experimental|posttreatment group|doppler evaluatıon in normoprolactinemia women who given cabergoline treatment
3314535|NCT01957852||FloSeal +|Routine use of Floseal during cytoreductive and HIPEC surgery
3314536|NCT01957852||FloSeal -|FloSeal not used during CRS and HIPEC procedure
3314537|NCT01957878|Experimental|HPV therapeutic vaccine|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
3314538|NCT01957878|Placebo Comparator|Placebo matching ProCervix|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
3314539|NCT01957904|Other|ArterX Surgical Sealant|
3314540|NCT01957917|Experimental|NAC + Food Assistance|Arm 1 participants will receive NAC (nutritional assessment and counseling), plus a food ration once a month for 6 months if they continue their regular HIV care.
3314541|NCT01957917|Experimental|NAC + Cash Transfer|Arm 2 participants will receive NAC (nutritional assessment and counseling), plus a cash transfer equivalent in value to the food transfer once a month for 6 months if they continue their regular HIV care.
3314542|NCT01957917|Active Comparator|NAC Only|Arm 3 participants will receive NAC (nutrition assessment and counseling) only, which is the standard of care at the selected health facilities.
3314543|NCT01957943|Placebo Comparator|Control|38 patients Will receive standard oral diet 3 days before the operation will receive similar volume of 10% glucose solution Will receive same solution for 5 days postoperatively
3314544|NCT01957943|Active Comparator|OMEGA_PRE|38 patients Will receive standard oral diet 3 days before the operation will receive lipid supplementation 2 days before the operation with omega 3 enriched lipid emulsion (SMOFlipid) Will receive omega 3 enriched lipid emulsion (SMOFlipid) supplementation for 5 days postoperatively
3314545|NCT01957943|Active Comparator|OMEGA_POST|38 patients Will receive standard oral diet 3 days before the operation will receive glucose 10% solution 2 days before the operation Will receive omega 3 enriched lipid emulsion (SMOFlipid 20%) supplementation for 5 days postoperatively
3314546|NCT01957956|Experimental|Treatment (vaccine therapy and temozolomide)|"COURSE 1: Patients receive temozolomide PO daily on days 1-5.~COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5.~COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1.~Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
3314547|NCT01957969||Principal Population|Patients who undergo a definitive neuro-stimulator implantation.
3314548|NCT01957969||Annex Population|Patients who do not respond to the temporary test for the neurostimulator implantation
3314549|NCT01957995|Experimental|Arm I (lowest dose NDLS)|Patients receive lowest dose nanosomal docetaxel lipid suspension IV over 1 hour.
3314550|NCT01957995|Experimental|Arm II (low dose NDLS)|Patients receive low dose nanosomal docetaxel lipid suspension IV over 1 hour.
3314551|NCT01957995|Experimental|Arm III (high dose NDLS)|Patients receive high dose nanosomal docetaxel lipid suspension IV over 1 hour.
3314552|NCT01957995|Experimental|Arm IV (highest dose NDLS)|Patients receive highest dose nanosomal docetaxel lipid suspension IV over 1 hour.
3314553|NCT01958034|Experimental|Dietary supplement with bilberry extract|Billberry powder 3 times daily for 2 months.
3314554|NCT01958034|No Intervention|Control|No dietary supplement with bilberry extract
3314555|NCT01958047|Experimental|ASP3652|One single dose
3314556|NCT01958086|Experimental|Neural Communication System|The Neural Communication System consists of two Neuroport Multi-Port Arrays, which are descried in detail in the intervention description. One Neuroport Multi-Port Array is inserted into the posterior parietal cortex, an area of the brain used in reach planning. The second Neuroport Multi-Port Array is inserted into the motor cortex, which is primarily responsible for controlling movement. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to use thought to control a simple computer environment or a tablet computer.
3314557|NCT01958099|Other|Injury Prevention Specialist|
3314558|NCT01958099|Experimental|Kiosk Intervention|
3314559|NCT01958138|Experimental|propofol with Isoflurane|Propofol with Isoflurane, Group-I is the intervention arm with combination of two drugs such as low dose propofol and Isoflurane MAC awake.
3314560|NCT01958138|Active Comparator|alone isoflurane|The group-II is the control arm of study by using the only Isoflurane 1.2 MAC
3314561|NCT01958151||Sedated colonoscopy|"Planned colonoscopies for screening under propofol sedation titrated to reach a bispectal index value of 60.~Anxiety levels are assessed before the procedure with State-Trait Anxiety Inventory Scores."
3314562|NCT01958177|Other|BMMNC|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
3314563|NCT01958190|Active Comparator|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
3314564|NCT01958190|Experimental|combination Tacrolimus and Sirolimus|Patients receive combination of low-dose extended release Tacrolimus and low-dose Sirolimus
3314565|NCT01958216|Other|Trans-intestinal cholesterol excretion in vivo|Measuring trans-intestinal cholesterol excretion in vivo in bile diverted patients
3314566|NCT01958229||CHB patients without cirrhosis|
3314567|NCT01958242|No Intervention|Preoperative blood harvesting|
3314568|NCT01958255|Other|Tobacco cessation counseling|planned intervention for tobacco cessation counseling
3314569|NCT01958307|Experimental|Intervention|Lifestyle intervention
3314570|NCT01958307|No Intervention|No intervention|Standard prenatal care, short information leaflet about healthy lifestyle in pregnancy
3314571|NCT01958333|Experimental|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
3314572|NCT01958333|Experimental|Exercise 2|Medium-intensity, medium-volume cardiorespiratory exercise and strength training
3314573|NCT01958333|Experimental|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
3314574|NCT01958359|Experimental|Short IVR|IVR-based alcohol diary with feedback
3314575|NCT01958359|Experimental|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
3314576|NCT01958359|No Intervention|Control|Untreated control group
3314577|NCT01958372|Experimental|Group I (squamous cell histology)|Patients receive etoposide IV over 1 hour on days 1-5 and 29-33, cisplatin IV over 1 hour on days 1, 8, 29, and 36, and undergo RT 5 days a week for 6.6 weeks. Within 48 hours of initiating treatment, patients receive soy isoflavones PO daily on days 1-90.
3314578|NCT01958372|Experimental|Group II (non-squamous cell histology)|Patients receive pemetrexed disodium IV over 10 minutes on days 1, 22, and 43 and cisplatin IV over 1 hour on days 1, 22, and 43. Patients also undergo RT and receive soy isoflavones as in Group I.
3314579|NCT01958385|Active Comparator|Treatment group|The treatment of obese patients with the placement of g-Cath EZ suture anchors along with Diet and Exercise
3314580|NCT01958385|Sham Comparator|Sham Group|The treatment of obese patients with the sham procedure along with Diet and Exercise
3314581|NCT01958398|Experimental|Promillekoll|Smartphone app monitoring alcohol use with feedback.
3314582|NCT01958398|Experimental|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
3314583|NCT01958398|No Intervention|Control|Untreated control group
3314584|NCT01958411||18FDG-PET/CT|
3314585|NCT01958424||women with metabolic syndrome|women undergoing ivf treatment who have BMI>25 and meet the criteria for metabolic syndrome
3314586|NCT01958424||women without metabolic syndrome|women undergoing ivf treatment who have BMI>25 and who do not meet the criteria for metabolic syndrome
3314587|NCT01958450|Experimental|Er:YAG laser|acne scar treatment using Er:YAG laser
3314588|NCT01958450|Active Comparator|Bipolar radiofrequency with diode laser|Bipolar radiofrequency with diode laser
3314589|NCT01958463|Experimental|Fecal microbiota transplantation|Fecal microbiota transplantation during colonoscopy.
3314590|NCT01958502|Experimental|mesenchymal stem cell|stem cells drived from iliac bone marrow with centrifuge and ficoll method then implant in collagenic 3-D scaffold with BMP-2 and put in non union site by surgical approach under general or spinal anesthesia as deemed appropriate by the anesthetist.
3314591|NCT01958515||Chemoradiation with Research Samples|Standard of care chemoradiation therapy will be given as clinically indicated by the treating physicians. 4 research blood and tissue samples will be obtained. One before treatment starts, 2 while treatments are being received and finally one after treatments are completed.
3314592|NCT01958528||Cohort 1 Progressors|
3314593|NCT01958528||Cohort 2 - Non-Progressors|
3314594|NCT01958541|Experimental|Behavioral Intervention I|This non-medication group treatment (Sleep Intervention I) consists of four 90-minute sessions.
3314595|NCT01958541|Active Comparator|Behavioral Intervention II|This non-medication group treatment (Sleep Intervention II) consists of four 90-minute sessions.
3314596|NCT01958554|Experimental|Intervention Group|The integrated intervention consisted of 12 week of program and group support, based on the freedom program by pet craven. The former component was provided covering beliefs held and tactics used by the domestic violence abusers and took about 45 minutes. It included protection and enhanced choice-making and problem-solving skills.
3314597|NCT01958554|No Intervention|Wait list control group|The group was listed in wait list and were offered the same intervention and support on completion of study period.
3314598|NCT01958567|Experimental|Patients with clinical signs of scleritis or episcleritis|Optical Coherence Tomography for patients with scleral inflammation
3314599|NCT01958567|Experimental|Normal subjects with normal sclera|Optical Coherence Tomography on eyes with normal scleral
3314600|NCT01958580|Experimental|Treatment (gemcitabine, docetaxel, brachytherapy/IMRT, EBRT)|"CHEMOTHERAPY: Patients receive gemcitabine hydrochloride IV over 90 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.~RADIATION THERAPY: Beginning week 10, patients undergo 3 fractions of brachytherapy or IMRT over 3 weeks. Patients then undergo EBRT QD 5 days a week for 5 weeks."
3314601|NCT01958632||N|nerve suture
3314602|NCT01958632||NT|nerve transplantation
3314603|NCT01958632||VM|vein-in-muscle conduit
3314604|NCT01958684||Group 1|The MIRENA intrauterine delivery system (initial release rate: 20 μg LNG /24 h)
3314605|NCT01958684||Group 2|Copper IUDs with different shape and with or without drugs
3314606|NCT01958697||AG-BMI < 10 pct|Patients who's peroperative BMI is less than the 10th centile
3314607|NCT01958697||AG-BMI >= 10th pct|Patients who's peroperative BMI equals or is greater than the 10th centile
3314608|NCT01958710||Embolisation|(preoperative) embolisation of the bronchial circulation
3314609|NCT01958710||Surgery|Any surgically treated patient with a functional lung resection (at least wedge resection)
3314610|NCT01958723||Hospitalists|Introduction of Problem Specific Templates
3314611|NCT01958736|Experimental|Experimental|Ballistic Strength Training
3314612|NCT01958736|Active Comparator|Control|Usual care Physiotherapy
3314613|NCT01958749|No Intervention|Fat graft without Platelet Rich Plasma|"Step 1. Under Local Anaesthetic (or General Anaesthetic if the patient is unable to tolerate this), a fat graft is taken from just behind the mastoid process, or more posteriorly just beneath the hairline if necessary. The graft is kept moist in 0.9% saline.The ear canal is injected with local anaesthetic and the edges of the perforation are freshened. Gelfoam is placed into the middle ear and the fat graft placed on top of this until it touches the underside of the TM and slightly bulges through. In an attempt to achieve standardisation of surgical technique between sites, surgeons will be provided with an operative video to watch beforehand.~Step 2. The fat graft will simply be covered with a piece of saline-soaked Gelfoam cut to completely cover the perforation and graft."
3314614|NCT01958749|Experimental|Fat graft with Platelet Rich Plasma|"Procedure as for as for Fat graft without PRP, but at Step 2 the Gelfoam will instead be soaked in PRP derived from the patient's own whole blood. The generation of PRP is descibed below: -~10-20 mL of autologous blood collected from an antecubital vein is placed in an adenosine citrate dextrose-acid (ACD-A) collection tube to prevent premature activation~Blood immediately placed in the centrifuge at 1100g for 10 minutes (once)~Supernatant removed and collected into syringe~Injected onto surface of fat graft~Rest added to piece of gelfoam~Place gelfoam + PRP on the TM perforation"
3314615|NCT01958762|Other|Screening for cancers in the oral cavity|
3314616|NCT01958775|Experimental|GLP=2|active treatment with a single dose of GLP-2 (1500mcg)
3314617|NCT01958775|Placebo Comparator|Placebo|placebo
3314618|NCT01958801|Active Comparator|Interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
3314619|NCT01958801|Experimental|Supraclavicular block|Supraclavicular block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral supraclavicular fossa visualizing the brachial plexus located lateral to the subclavian artery. Using in-plane technique, nerve stimulation needle is advanced into the brachial plexus sheath, into which 25 ml of 1.5% mepivacaine is injected.
3314620|NCT01958814|Experimental|Salbutamol - Placebo|salbutamol at M0 and M60 placebo administration
3314621|NCT01958814|Experimental|Placebo - Salbutamol|placebo at M0 and M60 salbutamol administration
3314622|NCT01958840|Experimental|Behavioral Activation Treatment for Depression|Behavioral Activation Condition - 10 sessions
3314623|NCT01958840|Active Comparator|Supportive Counseling|Supportive Counseling Condition - 10 sessions
3314624|NCT01958853|Experimental|12-week RINCE|RINCE - active RINCE therapy involving 24 total treatment applications from the NeuroPoint device
3314625|NCT01958866|Active Comparator|Acetaminophen|Acetaminophen administer 1000 mg every 4-6 hours when fever is presented
3314626|NCT01958866|Experimental|Tinospora Crispa-extract Product|Tinospora Crispa-extract tablet administer 500 mg every 4-6 hours when fever is presented
3314627|NCT01958866|Placebo Comparator|Placebo|Placebo 2 tablets will be administered every 4 hours when fever is presented
3314628|NCT01958879|Experimental|ringer with corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups .In this group patients received 1mg dexamethasone after finishing the irrigation .
3381752|NCT05164614|Experimental|RT-102 Group 1|In 15 subjects, a RaniPill capsule containing 20 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
3314629|NCT01958879|Placebo Comparator|Ringer with out corticosteroid|Intra-articular irrigation was performed under local anesthesia with subcutaneous injection of 1%lidocaine solution (0.6 to 0.9 mL anaesthetic solution )was injected to block the auriculotemporal nerve. Then the skin on the TMJ was penetrated with a 21-gauge needle at the articular fossa followed by the injection of 3 mL Ringer solution to distend the joint space, pumping it in and out repeatedly. Another 21-gauge needle was inserted into the distended compartment in the area of the articular eminence, and the superior joint space was irrigated with 200 mL Ringer solution, allowing a free flow through the first needle in the both groups
3314630|NCT01958892||TURP|
3314631|NCT01958892||TUERP|
3314632|NCT01958905|Experimental|Artemether-Lumefantrine|All patients will receive Artemether-Lumefantrine and the endpoints will be compared between the two populations of severely malnourished and non-severely malnourished children
3314633|NCT01958931||Patients Suspicious for Lung Cancer|Subjects are symptomatic of lung cancer and have one or more lung nodules or lung masses suspicious for lung cancer.
3314634|NCT01958944|Experimental|Nitric oxide + standard treatment|Inhalation of 160 ppm NO for 30 minutes, 3 times daily, for a duration of 10 working days with the exclusion of weekend days (Friday & Saturday) in which no treatment under this study will be provided.
3314635|NCT01958957|Experimental|Ginkgolides Meglumine Injection|Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.
3314636|NCT01958970|Experimental|PINTA 745|
3314637|NCT01958970|Placebo Comparator|Placebo|
3314638|NCT01958983|Experimental|Music Therapy Group Session|Participants will receive 60-minute group session twice a week over 2 months of period. Each session will be led by a music therapist. The contents of the music therapy session include drumming, rhythm imitation, score reading, lyrics comprehension, singing, and song discussion.
3314639|NCT01958983|No Intervention|No Music Therapy Session|Participants will receive pre- and post-assessments and evaluations at 0 and 2 months. No intervention will be provided. Music therapy sessions will be offered to participants in completion of their study participation.
3314640|NCT01958996|Experimental|idarubicin|
3314641|NCT01959009|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3314642|NCT01959009|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min~Ti = 1s~Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3314643|NCT01959022|Experimental|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin XL based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
3314644|NCT01959061|Experimental|Raltitrexed and Oxaliplatin|Raltitrexed and Oxaliplatin were mixed with 10-15 ml lipiodol by arterial chemoembolization on day 1 and during each 28-day cycle.
3314645|NCT01959074|Active Comparator|Naftopidil|This interventional group will receive analgesics and naftopidil 75mg po qd.
3314646|NCT01959074|Placebo Comparator|Control groups with only analgesics|Control groups will receive only analgesics
3314647|NCT01959100|Experimental|Azithromycine|250 mg x 3/week during a meal for a period of 2 years
3314648|NCT01959100|Placebo Comparator|Placebo|250 mg x 3/week during a meal for a period of 2 years.
3314649|NCT01959126|Experimental|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment.
3314650|NCT01959152|Experimental|HiRes90K™ Advantage Cochlear Implant|HiRes90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with a moderate level of hearing loss in the low frequencies and severe-to-profound hearing loss in the mid-to-high frequencies.
3314651|NCT01959191||Low platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
3314652|NCT01959191||high platelet reactivity group|"Platelet reactivity will be measured after 7-days treatment of clopidogrel by VerifyNow system and the cohort will be divided by two group according to P2Y12 reactivity unit (PRU) cutoff value. Receiver operating characteristic (ROC) curves will be plotted to assess the optimal PRU cutoff value for differentiating between patients with and without subsequent MACEs after 1 year of follow-up. Low platelet reactivity indicates good response to clopidogrel and high platelet reactivity, resistance to clopidogrel. Groups will be Low platelet reactivity group and High platelet reactivity group"
3314653|NCT01959204|Other|Active|Open label pharmacokinetic study of oxycodone.
3314654|NCT01959217|Experimental|PM Component Text Reminders|There will be a a single face-to-face intervention followed by tailored text reminders. The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text message reminders will be determined by Phase 1.
3314655|NCT01959256|Experimental|Learning|Visual perceptual learning (VPL) group
3381753|NCT05164614|Experimental|RT-102 Group 2|In 15 subjects, a RaniPill capsule containing 80 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
3314656|NCT01959256|No Intervention|Control|Control group
3314657|NCT01959269||Regorafenib|Patients treated with Stivarga as 3rd or 4th line treatment, no intervention
3381754|NCT05164614|Experimental|RT-102 Group 3|In 15 subjects, a RaniPill capsule containing 60 µg of PTH will be administered and serial blood samples will be collected for PK analysis.
3381755|NCT05164614|Active Comparator|SC Group|In 10 subjects, 20 µg of Forteo will be administered subcutaneously and serial blood samples will be collected for PK analysis.
3381756|NCT05164614|Experimental|Part 2; Group 1|In 10 subjects, once-a-day repeat dosing with RT-102 (dose to be determined after Part 1) for 7 days in healthy post-menopausal or surgically sterile with bilateral oophorectomy women.
3381757|NCT05164614|Experimental|Part 2; Group 2|In 10 subjects, once-a-day repeat dosing with 20 µg dose of Forteo for 7 days in healthy post-menopausal or surgically sterile with bilateral oophorectomy women.
3381758|NCT05164601||Observation group|
3314658|NCT01959282|Placebo Comparator|Placebo|Participants will receive placebo once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive placebo through Week 32. Participants not in clinical response at Week 8 will receive treatment with 150 mg JNJ-54781532 orally once daily from Week 8 to Week 16. Participants who achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) at Week 16 can continue receiving 150 mg JNJ-54781532 orally once daily through Week 32
3381759|NCT05164575|Experimental|eRP-LOw Intensity (eRP-LO)|an 8-week intervention that includes FOUR virtual visits with a physiotherapist
3381760|NCT05164575|Experimental|eRP-HIgh Intensity (eRP-HI)|an 8-week intervention that includes EIGHT virtual visits with a physiotherapist
3381761|NCT05164562||type 1 diabetes|"type 1 diabetes group: patients with type 1 diabetes"
3381762|NCT05164549|Experimental|XR-Bup|Extended-Release Buprenorphine, monthly, 300mg or 100mg
3381763|NCT05164549|Active Comparator|Bup/Met|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference).
3381764|NCT05164549|Experimental|XR-Bup + PSI|Extended-Release Buprenorphine, monthly, 300mg or 100mg + Personalised Psychosocial Intervention (PSI)
3381765|NCT05164549|Active Comparator|Bup/Met + PSI|Standard of Care; either Buprenorphine (including Subutex, Suboxone & Espranor) or Methadone (Participant Preference) + Personalised Psychosocial Intervention (PSI)
3381766|NCT05164536|Experimental|[18F]Florbetapir|Participants will undergo amyloid PET imaging with an approved amyloid radiotracer (ie, [18F]Florbetapir (Amyvid™)) to assess β-amyloid neuritic plaque density.
3381767|NCT05164523||Patients with type 2 diabetes treated with SGLT2 inhibitors|metformin using patients with type 2 diabetes who were recently prescribed an SGLT2 inhibitor
3381768|NCT05164523||Patients with type 2 diabetes treated with other oral agents|metformin using patients with type 2 diabetes who were recently prescribed a pre-defined antidiabetic medication other than SGLT2 inhibitors
3381769|NCT05164510|Experimental|ct-DNA test in MPC|treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
3381770|NCT05164497|Experimental|Deliberate practice training|The experimental condition consists of deliberate practice training of non-specific psychotherapy skills using role-play and Theravue, an online skill-building system with therapy videos.
3381771|NCT05164497|Active Comparator|Theoretical teaching|The control condition will consist of theoretical teaching of non-specific psychotherapy skills.
3381772|NCT05164484|Other|Transpulmonary thermodilution in patients implanted with VV-ECMO during standard care for ARDS|Standard of care procedure for patient with severe ARDS
3381773|NCT05164471|Experimental|FLT180a|A single dose of FLT180a will be administered. Dose will be determined by enrollment cohort. The first 3 patients will receive 7.7 x 10e11 vg/kg. The dose in subsequent cohorts will be determined by the DMC based on review of data from the prior cohort(s).
3381774|NCT05164458|Experimental|IBI389|A dose escalation stage of IBI 389 monotherapy.
3381775|NCT05164458|Experimental|IBI 389 + sintilimab|A dose escalation stage of IBI 389 in combination with sintilimab.
3381776|NCT05164445|Active Comparator|Transbronchial forceps biopsy|Patients, whose transbronchial forceps biopsy was performed
3381777|NCT05164445|Active Comparator|Transbronchial forceps biopsy+Transbronchial cryobiopsy|Patients, whose transbronchial forceps biopsy and transbronchial cryobiopsy were performed as well
3381778|NCT05164432|Experimental|High risk of preterm birth|Women at high risk of preterm birth
3381779|NCT05164432|Active Comparator|Women with low risk pregnancies|Women with uncomplicated pregnancies anticipated to deliver at term
3381780|NCT05164419||Wide margin|Patients who underwent surgery with a final pathologic margin of more than 5mm.
3381781|NCT05164419||Close margin|Patients who underwent surgery with a final pathologic margin of less than 5mm
3381782|NCT05164406||With blood salvage|Patients undergoing oncologic liver surgery with systematic use of blood salvage therapy
3381783|NCT05164406||Without blood salvage|Patients undergoing oncologic liver surgery without any blood salvage therapy
3314659|NCT01959282|Experimental|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 25 mg once daily through Week 32
3314660|NCT01959282|Experimental|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg once daily through Week 32
3314661|NCT01959282|Experimental|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 150 mg once daily through Week 32
3314662|NCT01959282|Experimental|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily from Week 0 to Week 8. Participants in clinical response at Week 8 will continue to receive the same dosage through Week 32 and participants not in clinical response at Week 8 will continue to receive the same dosage through Week 16. At Week 16, participants who do not achieve a partial Mayo score response (ie, a change from baseline of ≥3 in the partial Mayo score) will be discontinued from study medication, and participants who achieve a partial Mayo score response at Week 16 can continue receiving JNJ 54781532 75 mg twice daily through Week 32
3314663|NCT01959295|Experimental|ASP2151|
3314664|NCT01959295|Placebo Comparator|ASP2151 placebo|
3314665|NCT01959308||Immunosuppressive therapy|Liver Transplant recipients who are receiving various doses and types of immunosuppressive therapy
3314666|NCT01959360|Active Comparator|direct lateral|
3314667|NCT01959360|Experimental|minimal invasive|
3314668|NCT01959360|Experimental|modified minimal invasive|
3314669|NCT01959373|Experimental|patients|
3314670|NCT01959373|Experimental|healthy volunteers|
3314671|NCT01959386||HER2 Positive Breast Cancer Participants|Participants with HER2 positive tumors who are considered for treatment with trastuzumab SC according to the judgement of physician and according to the actual summary of product characteristics will be observed for a period of approximately 1 year and will be followed for an additional 2 years.
3314672|NCT01959399|Experimental|ASP015K + rosuvastatin|
3314673|NCT01959438|Experimental|Selenite treatment|In the first part of the study, cohorts of 3 patients receive sodium selenite iv, starting with a dose of 0.5 mg/m2. If no serious adverse event the next cohort is treated according to a dose escalation schedule and this part has been completed. In the modified protocol, a continuous infusion over 2 days will be administered.
3314674|NCT01959451|Active Comparator|Prasugrel|Prasugrel 5 mg or 10mg daily for 12 months.
3314675|NCT01959451|Experimental|Prasugrel/Clopidogrel|Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months
3314676|NCT01959477|Experimental|Treatment (busulfan, etoposide, cyclophosphamide, transplant)|Patients receive busulfan IV over 3 hours on days -9 to -6, etoposide IV continuously over 24-36 hours on days -5 and -4, and cyclophosphamide IV over 4 hours on days -3 and -2. Patients then undergo autologous stem cell transplant on day 0.
3314677|NCT01959555||Retrospective collection of data|
3314678|NCT01959568|Experimental|Double tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation. After that the surgeon replaces ½ of perfluorodecalin volume by silicone oil.
3314679|NCT01959568|Active Comparator|Silicone oil tamponade|Vitrectomy and tamponade: subtotal vitrectomy, epiretinal membrane removal, perfluorodecalin tamponade, retinal photocoagulation and perfluorodecalin-silicone oil exchange.
3314680|NCT01959594|Experimental|Cohort 1|
3314681|NCT01959594|Experimental|Cohort 2|
3314682|NCT01959594|Experimental|Cohort 3|
3314683|NCT01959594|Experimental|Optional Cohort 4|
3314684|NCT01959594|Experimental|Optional Cohort 5|
3314685|NCT01959620|No Intervention|Assessment only|Participants will receive assessment only.
3314686|NCT01959620|Experimental|1-session exposure intervention|Participants will receive one session of exposure therapy.
3314687|NCT01959620|Experimental|3-session exposure intervention|Participants will receive three sessions of exposure therapy.
3314688|NCT01959633|Experimental|Vemurafenib+Cobimetinib + Peg-interferon|Vemurafenib 960 mg b.i.d. + Cobimetinib 60 mg o.d.(21 days on followed by 7 days off) + Peg-interferon 1/2/3 micrograms/Kg once weekly
3314689|NCT01959646|Placebo Comparator|Placebo|Placebo Group
3314690|NCT01959646|Experimental|Aged Garlic Extract Supplementation|Aged Garlic Extract Supplementation Group
3314691|NCT01959659||Cohort|
3314692|NCT01959711|Experimental|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
3314693|NCT01959711|Active Comparator|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
3314694|NCT01959724|Other|Vitrectomy|Vitreous surgery to treat macular detachment
3314695|NCT01959737|No Intervention|visual contact|After initial assessment/stabilization of the VLBW infant, visual contact of mother and infant is permitted for 5 minutes.
3314696|NCT01959737|Experimental|skin-to-skin contact|After initial stabilization mother and preterm infant are cared for skin-to-skin for 60 minuter. SSC is supervised by the attending neonatologist.
3314697|NCT01959750|Experimental|Intervention Group|
3381784|NCT05164393|Experimental|AVX001 1%|Application of AVX001 1% gel to treatment field once daily
3314698|NCT01959750|No Intervention|Control Group|
3314699|NCT01959763|Experimental|weight loss counseling|Cognitive behavioral therapy-based weight loss counseling program including 8 group visits
3314700|NCT01959763|Experimental|ELVIRA-based weight loss counseling|Weight loss counseling program based on 2 group visits of ELVIRA counseling method
3314701|NCT01959763|Experimental|ICT-based weight loss counseling|ICT-based weight loss counseling program with 52 weekly tasks and information packages.
3314702|NCT01959776|Other|Vitrectomy|
3314703|NCT01959789||Control|Standard treatment
3314704|NCT01959789||2 days|bleaching treatments made in 2 days
3314705|NCT01959802|Other|Vitrectomy|Vitrectomy for macular pseudo hole
3314706|NCT01959828|Experimental|inhaled nitric oxide|"Adults: IK-3001 at start dose 20 ppm; may be increased to 40 ppm at the investigator's or subinvestigator's discretion (up to ~ 24 hrs).~Children: IK 3001 at start 10 dose ppm; may be increased to 20 ppm at the investigator's or subinvestigator's discretion (up to ~24 hrs).~Treatment with IK-3001 will continue until it is clinically indicated to begin the weaning process from IK-3001."
3314707|NCT01959854|Active Comparator|carboxymethylcellulose|1 drop in each eye four times a day for 30 days
3314708|NCT01959854|Experimental|xanthan gum|1 drop in each eye four times a day for 30 days
3314709|NCT01959867|Experimental|SurgiMend® PRS (ADM)|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
3314710|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
3314711|NCT01959906||R0|Complete resection
3314712|NCT01959906||R1|Incomplete resection, microscopical tumor residu left behind
3314713|NCT01959906||CRM<1mm|complete resection (R0), however tumor spreads till less than 1 mm from the section pane.
3314714|NCT01959958||Sickle cell disease|In this study, children and adolescents with sickle cell disease ages 6-18 years and their parents/guardians will complete a questionnaire/interview.
3314715|NCT01959971|Experimental|Placebo - Alirocumab|Injection through subcutaneous (SC) administration, placebo for 4 weeks then, alirocumab for 10 weeks
3314716|NCT01959984|Experimental|100g Standard Noodles|100g Standard Noodles
3314717|NCT01959984|Experimental|75g Oral Glucose|75g Oral Glucose
3314718|NCT01959997|Active Comparator|Redo PVI|Therapeutic anticoagulation will be required for at least 3 weeks prior to ablation. An MRA will be performed to define cardiac and PV anatomy. Standard ablation technique will be employed. After gaining venous access, double transseptal puncture will be performed to permit left atrial access, guided by intracardiac ultrasound. A circular mapping catheter will be placed in each PV and any reconnections will be ablated by delivery of RF energy. Confirmation of re-isolation of all PVs will be performed at the conclusion of the procedure.
3314719|NCT01959997|Active Comparator|PVI + RDN|"All patients who are randomized to Group II will undergo redo PVI exactly as described above.~At the conclusion of PVI, RDN will be performed. Real-time 3-dimensional aorta-renal artery maps will be constructed with the use of the same navigation system and catheter used for PVI after femoral artery access. Both mapping and ablation will performed under the same modified sedation. RF ablations of 8 to 10 watts will be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium, for 2 min, and up to 6 lesions (separated by ≥ 5 mm). Lesions will be made both longitudinally and rotationally within each renal artery. To confirm renal denervation, high-frequency stimulation (HFS) will be used before the initial and after each RF delivery within the renal artery. RDN will be considered to have been achieved when the sudden increase of blood pressure (≥ 15 mm Hg from invasive arterial monitoring) is absent."
3314720|NCT01960010|Active Comparator|1% MIM-D3|1% MIM-D3 Ophthalmic Solution
3314721|NCT01960010|Placebo Comparator|Vehicle|Vehicle
3314722|NCT01960023|Experimental|Arm 1: Cetuximab and Neratinib|Cetuximab 400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV plus neratinib per oral daily until disease progression
3314723|NCT01960036|No Intervention|Treatment as usual (TAU)|Usual intensive outpatient treatment for substance use disorders
3314724|NCT01960036|Experimental|Mindful Awareness in Body-oriented Therapy (MABT)|A mind-body intervention to teach interoceptive skills for self-care.
3314725|NCT01960036|Active Comparator|Womens Health Education|A comparative arm to control for time and attention that involves education about the human body relevant to women's health.
3314726|NCT01960049|Placebo Comparator|MOTAP Catheter with Saline and IV PCA|Control group will have saline 20cc of 0.9% normal saline injected into the catheters and then run at 5ml/hr for 72 hours
3314727|NCT01960049|Active Comparator|MOTAP catheter with ropivocaine and IV PCA|20cc of 0.2% ropivacaine will be injected in two equal divided doses through the two catheters then run at 5ml/hr for 72 hours
3314728|NCT01960062|No Intervention|Control|Diabetes care with primary care practitioner supplemented with clinical pharmacy specialist
3314729|NCT01960062|Experimental|Intervention|Diabetes care with primary care practitioner and clinical pharmacy specialist, with the aid of a diabetes software and device to upload glucometer results from home
3314730|NCT01960088||Adolescents and their parents|Pharmacy demonstration project: HPV vaccine delivery
3314731|NCT01960101|Experimental|Lactoxeros milk product|Patient will take the milk product orally for 14 days as many times as needed per day(but not more than 6 times daily).
3314732|NCT01960101|Other|Aequasyal|Patients will take the oral spray for 14 days. The Aequasyal ® Oral Spray is a solution of oxidized glycerol triesters. The oral spray is applied by spraying on the inside of each cheek, 3-4 times per day. After each administration, users are instructed to gently spread the product around the mouth with the tongue. The Aequasyal ® Oral Spray is a Class I medical device, and is CE-marked.
3314733|NCT01960127|Experimental|Aerobic Exercise|Supervised aerobic training 3 times per week for 8 weeks (30-60 minute sessions)
3314734|NCT01960127|Placebo Comparator|Usual Care Group|These patients will continue with their normal daily activity ad will not be provided with supervised aerobic exercise training during the study period.
3314735|NCT01960153|Experimental|Tadalafil|Tadalafil is supplied in 20 mg tablets. Subjects will take 20 mg (one tablet) once per day and will be titrated to 40 mg (two tablets once per day) after one week. Subjects are on study drug for the duration of the trial.
3314736|NCT01960153|Placebo Comparator|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
3314737|NCT01960166|Experimental|Active distraction|Child will use Ipad as active distraction
3314738|NCT01960166|Experimental|Passive Distraction|Child will watch movie as passive distraction (control)
3314739|NCT01960179|Experimental|lixisenatide|lixisenatide monotherapy by group (Group 1: 52-week treatment; Group 2: 24-week treatment)
3314740|NCT01960192|Experimental|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
3314741|NCT01960192|Experimental|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles.
3314742|NCT01960205|Experimental|Standarddose Saxagliptin|Saxagliptin 5 mg (tablet) ,5mg a day and lifestyle intervention for 6 months
3314743|NCT01960205|Active Comparator|Lifestyle intervention|Lifestyle intervention for 6 months
3314744|NCT01960205|Active Comparator|Metformin|Metformin 500 mg (tablet) ,500mg three times a day and lifestyle intervention for 6 months
3314745|NCT01960205|Experimental|low dose Saxagliptin|Saxagliptin 5 mg (tablet) ,2.5 mg a day and lifestyle intervention for 6 months
3314746|NCT01960218||acute decompensated heart failure|Adult subjects anticipating discharge from a hospitalization where the primary discharge diagnosis is acute decompensated heart failure and who are not excluded due to existing conditions.
3314747|NCT01960231||pancreas specific MODY-2|
3314748|NCT01960244||hypercholesterolemia|familial hypercholesterolemia
3314749|NCT01960270|Experimental|Alone controlateral stimulation|"Device: INTERSTIM II~Stimulator II activated~Stimulator I not activated~Measure of efficacy on bladder hyperactivity"
3314750|NCT01960270|Experimental|2 sides-stimulation|"Device: INTERSTIM II~Stimulator I and II activated~Measure of efficacy on bladder hyperactivity"
3314751|NCT01960283|Active Comparator|Group I|"The group I will receive the intervention :~Methotrexate + anti-H1"
3314752|NCT01960283|Placebo Comparator|Group II|The intervention in group II will include : placebo + anti-H1
3314753|NCT01960309|Experimental|1. TnI elevation|TnI 0.06-0.60ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3314754|NCT01960309|Experimental|2. TnI elevation|TnI 0.61-6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3314755|NCT01960309|Experimental|3. TnI elevation|TnI>6.00 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3314756|NCT01960309|Experimental|4. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb<5.1. Intervention: minimal invasive cardiac imaging
3314757|NCT01960309|Experimental|5. TnI elevation|TnI >6.00 ng/ml, ischemia on ECG and Hb>5.0. Intervention: minimal invasive cardiac imaging
3314758|NCT01960309|Active Comparator|Control|TnI <0.06 ng/ml, no ischemia on ECG. Intervention: minimal invasive cardiac imaging
3314759|NCT01960322|Experimental|Telemetric|Enrolled patients will be followed for 12 months during which they will receive the study telemetry intervention.
3314760|NCT01960335|Active Comparator|Whey Protein Only|Ingestion of whey protein only (20 grams per serving) consumed 3X/day along with ad libitum diet for a total of 60 grams per day. One serving was consumed within 1 hour of waking in the morning; a second serving was consumed mid-afternoon; and a third serving was consumed within 2 hours of going to sleep at night.
3314761|NCT01960335|Experimental|Whey Protein and Resistance Exericse|Ingestion of whey protein (20 grams per serving) 3X/day: one serving within an hour of waking in morning; a second serving mid-afternoon or within 1 hour immediately following a resistance exercise bout on exercise days; and a third serving within 2 hours of going to bed at night.
3314762|NCT01960335|Experimental|Whey Protein and RISE exercise routine|Ingestion of whey protein (20 gram serving) 3X/day: one serving within an hour of waking in the morning; a second serving mid-afternoon or within 1 hour immediately following the RISE exercise bout; and a third serving within 2 hours of going to bed at night.
3314763|NCT01960361|Experimental|ICE dental implant|Subjects implanted with ICE implant
3314764|NCT01960374|Experimental|Japanese Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
3314765|NCT01960374|Experimental|Non-Japanese Asian Arm|3 cohorts of 9 subjects. Each cohort will receive oral 25 mg, 50 mg (anticipated) or 75 mg (anticipated) selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate).
3314766|NCT01960426|Active Comparator|Empiric Dose Intensification|Intensify treatment with the existing drug
3314767|NCT01960426|Active Comparator|Testing based strategy|Measurement of drug (Adalimumab/Infliximab) Testing-based strategy for the management of secondary loss of response that is based on drug/ ADA measurement
3314768|NCT01960439||Endoscopic evaluation|The study population contained a broad spectrum of endoscopic disease and clinical activity. At entry to the trial patients had active disease defined by the presence of a modified UCDAI score between 4 and 10.1 Only patients who had a MMCS endoscopy subscale score according to a single central reader (n= 194 of 281 participants) were eligible for assessment in the current study.
3314769|NCT01960452||Primary insomnia|
3314770|NCT01960452||Healthy sleeping controls|
3314771|NCT01960478|Other|bood test|
3314772|NCT01960491|Experimental|Device Closure of Atrial Septal Defect|
3314773|NCT01960504|Experimental|Drug Eluting Absorbable Metal Scaffold|DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold
3314774|NCT01960517|Experimental|Catheter placed|
3314775|NCT01960543|Active Comparator|Bupivacaine|"Intrathecal administration of bupivacaine 0.5%~Doses:~Bupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Bupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
3314776|NCT01960543|Active Comparator|Levobupivacaine|"Intrathecal administration of levobupivacaine 0.5%:~Doses:~Levobupivacaine 7 mg plus fentanyl 15 ug for patients shorter than 160 cm. Levobupivacaine 9 mg plus fentanyl 15 ug for patients equal or taller than 160 cm or hip replacement."
3314777|NCT01960556||Simulation|Simulation Training part of education
3314778|NCT01960556||Non-Simulation Based Education|Did not receive simulation based education
3314779|NCT01960569|Active Comparator|Arm 1 : active product (Thrombexx)|100 patients will have the active product(Thrombexx), their visits on days 1,4,8 and 16 for target parameters assessment
3314780|NCT01960569|Placebo Comparator|Arm 2 : Placebo|100 patients will have placebo , their visits on days 1,4,8 and 16 for target parameters assessment
3314781|NCT01960582|Experimental|New Practice Strategy|Structured strategy for assessment and evaluation before and after intervention
3314782|NCT01960582|No Intervention|Ordinary practice|Ordinary practice, not structured
3314783|NCT01960595|Experimental|IV fentanyl PCA|The patient receives post-OP IV fentanyl PCA
3314784|NCT01960595|Active Comparator|post-OP IV fentanyl PCA and local infiltration|pretreatment of local infiltration 0.25% bupivacaine 5 ml and post-OP IV fentanyl PCA
3314785|NCT01960595|Active Comparator|nerves block and post-OP IV fentanyl PCA|pretreatment of peroneal nerves 0.25% bupivacaine 10 ml and post-OP IV fentanyl PCA
3314786|NCT01960608||low sodium group|24_hours_urine_sodium < 100 mEq/L
3314787|NCT01960608||mid sodium group|24_hours_urine_sodium >= 100 mEq/L and < 200 mEq/L
3314788|NCT01960608||high sodium group|24_hours_urine_sodium >= 200 mEq/L
3314789|NCT01960608||low income group|the income 25% below the quartile
3314790|NCT01960608||low mid income group|the income 25% - 50% below the quartile
3314791|NCT01960608||mid income group|the income 50% - 75% below the quartile
3314792|NCT01960608||high income group|the income 75% over the quartile
3314793|NCT01960621|Experimental|2|
3314794|NCT01960647|Other|Uncoated PTA balloon catheter|Dilatation with uncoated PTA balloon catheter
3314795|NCT01960647|Active Comparator|Freeway Paclitaxel balloon catheter|Dilatation with Freeway Paclitaxel (3 µg/mm2) coated balloon catheter
3314796|NCT01960660|Experimental|Investigational Product|Omega-3 fatty acids in the form of triglycerides
3314797|NCT01960660|Active Comparator|Comparator Product 1|Omega-3 fatty acids in the form of ethyl esters.
3314798|NCT01960660|Active Comparator|Comparator Product 2|Omega-3 fatty acids in the form of phospholipids from krill oil.
3314799|NCT01960660|Active Comparator|Comparator Product 3|Omega-3 fatty acids from salmon oil.
3314800|NCT01960673|Experimental|LMA proseal|"The investigator will use proseal LMA in this study. The cuff of the proseal LMA could be inflation. It is thought to fix the larynx shape.~The investigator wants to test the efficacy during 30,45,60 degree of head and neck position."
3314801|NCT01960673|Experimental|igel LMA|"igel LMA did not have cuff. The shape, softness and contours accurately mirror the perilaryngeal anatomy.~The investigator want to test the efficacy of the igel at 30,45,60 degree of head and neck position."
3314802|NCT01960673|Experimental|air Q LMA|"The air-Q LMA should be used routinely as a classic passive airway. It is user-friendly, placement in patients is easy and air movement is outstanding. It has the added benefit of allowing for intubation using standard ET Tubes.~It also has the cuff and the contour of the mask is thought to mimic the the shape of the perilaryngeal region.~The investigator want to test the efficacy of the air Q LMA at 30,45,60 degree of the head and neck position."
3314803|NCT01960673|Experimental|ambu LMA|ambu LMA is also an cuff device LMA. The investigator wanted to test the efficacy about the leak pressure and the view at 30,45,60 degree of head and neck position.
3314804|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 1 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 1 of aluminum adjuvant Day 28: Placebo
3314805|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant Day 28: Low dose RSV F Antigen content with Dose 2 of aluminum adjuvant
3314806|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 3 of aluminum adjuvant
3314807|NCT01960686|Experimental|Low dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant Day 28: Low dose RSV F Antigen with Dose 4 of aluminum adjuvant
3314808|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 2 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 2 of aluminum adjuvant Day 28: Placebo
3314809|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 3 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen with Dose 3 of aluminum adjuvant Day 28: Placebo
3314810|NCT01960686|Experimental|High dose RSV F Vaccine with Dose 4 of Aluminum Adjuvant|Day 0: High dose RSV F Antigen content with Dose 4 of aluminum adjuvant Day 28: Placebo
3314811|NCT01960686|Placebo Comparator|Placebo|Day 0: Placebo Day 28: Placebo
3314812|NCT01960699||CPC < 3|Good neurological outcome
3314813|NCT01960699||CPC >/= 3|Unvavourable neurologic outcome
3314814|NCT01960712|No Intervention|Continued external drainage|Continued external drainage alone.
3314815|NCT01960712|Active Comparator|Continued external drainage + transpapillary stent|External drainage + transpapillary plastic stent (7-10 Fr).
3314816|NCT01960738|Experimental|Intervention|The intervention group received a pre-dive checklist and a post-dive log
3314817|NCT01960738|No Intervention|Control|The control group received the post-dive log only.
3314818|NCT01960751|Other|neurocognitive tests|neurocognitive tests battery (MMSE, SDS, SF-36, HAD, BPRS, RAVLT, FACT-Cog, MoCA)
3314819|NCT01960764|Experimental|Pre-Treatment|Prior to receiving the transplant, this arm will be washed with an antimicrobial regimen
3314820|NCT01960764|Placebo Comparator|Control|This arm will still be transplanted with the autologous microbiome transplant cream, however it will not be pre-treated with an antimicrobial regimen
3314821|NCT01960777|Experimental|Onstep|Participants in this group will have an inguinal hernia repair ad modum Onstep.
3314822|NCT01960777|Active Comparator|Laparoscopic repair|Participants in this group will receive an inguinal hernia repair by use of a laparoscopic approach.
3381785|NCT05164393|Experimental|AVX001 3%|Application of AVX001 3% gel to treatment field once daily.
3381786|NCT05164393|Placebo Comparator|AVX001 Vehicle|Application of AVX001 vehicle gel to treatment field once daily
3314823|NCT01960803|Experimental|IOERT arm|Intraoperative electron radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on a mobile self-shielded magnetron-driven X-band linear accelerator specifically developed for use in the operating room. This machine produces megavoltage electron beams of energy ranging between 4 and 12 MeV. The radiation is delivered from the device to the tumor bed through an attached applicator. A single dose of 21 Gy calculated to the 90% depth posterior to the tumor bed will be administered and will last approximately 2.5 minutes.
3314824|NCT01960829|Experimental|Everolimus|
3314825|NCT01960868|Experimental|patients|
3314826|NCT01960868|Other|control group|
3314827|NCT01960881||Prostate Cancer Patients|Prostate Cancer Patients
3314828|NCT01960920|Active Comparator|Healthy Volunteers|Dilute diesel exhaust Filtered diesel exhaust Filtered air
3314829|NCT01960920|Experimental|Heart Failure patients|Dilute diesel exhaust Filtered diesel exhaust Filtered air
3314830|NCT01960933|Active Comparator|Culprit lesion revascularization|Only the culprit lesion is treated whereas other study lesions are left un-treated.
3314831|NCT01960933|Active Comparator|Full revascularization|Culprit lesion is treated initially and all other lesions with diameter stenosis angiographically >50% and FFR <0.80 are treated in a separate procedure within the index hospitalization. Stenoses > 90% are treated without prior FFR.
3314832|NCT01960946|Active Comparator|Modified Citrus Pectin (MCP)|Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day
3314833|NCT01960946|Placebo Comparator|Placebo|Matched placebo 5 grams by mouth three times a day
3314834|NCT01960972|Experimental|Salt substitute|"As described by Brown, in a stepped wedge design, an intervention is rolled-out sequentially to the trial participants (either as individuals or clusters of individuals) over a number of time periods. The order in which the different individuals or clusters receive the intervention is determined at random and, by the end of the random allocation, all individuals or groups will have received the intervention. Stepped wedge designs incorporate data collection at each point where a new group (step) receives the intervention.~Thus, the salt substitute will be implemented in each cluster (village) in a randomized fashion. Not arms are needed since the 6 randomly-selected villages will be implemented in some moment of the protocol."
3314835|NCT01960985|Experimental|Physicaltherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
3314836|NCT01960985|Experimental|physiotherapy|Exprerimental group I - motor training balance training Exprerimental group II - motor training associated with visual and auditory cues on the balance training Control group - recived general orientations.
3314837|NCT01961011||Cohort #1: Bilateral carpal tunnel release|Cohort #1: Patients undergoing simultaneous bilateral carpal tunnel release for treatment of bilateral carpal tunnel syndrome. Inclusion criteria includes any adult patient indicated for bilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, any protected patient population, and the lack of assistance at home during the early postoperative period.
3314838|NCT01961011||Cohort #2: Unilateral carpal tunnel release|Cohort #2: Patients undergoing unilateral carpal tunnel release fir bilateral carpal tunnel syndrome. Patients will chose which hand they wish to have operated on. Patient will plan on undergoing carpal tunnel release on the unoperated side at a later date. Inclusion criteria include any adult patient indicated for unilateral carpal tunnel release. Exclusion criteria include age less than 18, pregnancy, and any protected patient population.
3314839|NCT01961024||Type 2 diabetic men|
3314840|NCT01961024||Age- and weight-matched controls|
3314841|NCT01961037|Experimental|Physical activity intervention|Tai Chi: Moving for Better Balance exercise program
3314842|NCT01961050|Experimental|Intervention|Dual-Focused Brief Physician Intervention (DFBPI)
3314843|NCT01961050|Other|Standard care|Services as usual including standard OB/GYN clinic visits; no experimental intervention is provided.
3314844|NCT01961063|Experimental|Treatment (gene therapy)|Patients receive busulfan IV over 3 hours on day -2 followed by lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells IV on day 0.
3314845|NCT01961076|Experimental|uncooked corn starch|Patients receive uncooked corn starch before bed-time
3314846|NCT01961076|Experimental|modified corn starch|Patients receive modified corn starch before bed-time
3314847|NCT01961076|Experimental|other carbohydrate (starch) containing meal|Patients receive a carbohydrate (starch) containing meal before bed-time
3314848|NCT01961128|Experimental|Exercise Intervention|220 minutes of exercise per week, including 2-3 supervised sessions for 6 weeks
3314849|NCT01961154|Other|Medication reduction|All participants undergo similar type of asthma medical reduction. Thus, there is only one arm.
3314850|NCT01961180|Active Comparator|active comparator|Drug: Cipralex
3314851|NCT01961180|Placebo Comparator|placebo comparator|Drug: Placebo
3314852|NCT01961193|Experimental|bandage contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
3314853|NCT01961193|Experimental|punctal plug|A punctal plug (Painless Silicon Plugs),will be inserted into each eye. Lubricant drops will be instilled four times daily into each eye. The punctal plug will remain in- situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
3314854|NCT01961193|No Intervention|Control group|Hydroxyethylcellulose drops will be inserted into each eye four times a day and erythromycin ophthalmic ointment will be applied three times a day as well.
3314855|NCT01961206||Case Patients|Case Patients with Community-Onset Bacteremia Due toESBL producing E.coli or K.pneumoniae
3314856|NCT01961206||control group|bacteremia caused by ESBL producing E.coli or K.pneumoniae
3314857|NCT01961219|Active Comparator|Adhesive Capsulitis with MUA|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment closed manipulation under anesthesia."
3314858|NCT01961219|Active Comparator|Adhesive Capsulitis with Arthroscopy|"Subjects with idiopathic adhesive capsulitis in the frozen or thawing phase who have failed pain management and failed improvement in range of motion after at least 3 months of supervised, regimented conservative treatment; or who after less than 3 months of conservative treatment demand a quicker return to function. Treatment Arthroscopic Capsular Release"
3314859|NCT01961232||Pulmonary Hypertension & WHO group I|Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
3314860|NCT01961232||Pulmonary Hypertension & WHO group II|Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
3314861|NCT01961232||Without Pulmonary Hypertension|Participants without Pulmonary Hypertension
3314862|NCT01961232||Connective Tissue Disease|Participants without PH, but with connective tissue disease
3314863|NCT01961245|Active Comparator|nocturnal non-invasive ventilation|patients will undergo 12 nights of non-invasive ventilation during pulmonary rehabilitation
3314864|NCT01961245|No Intervention|no nocturnal non-invasive ventilation|patients will undergo pulmonary rehabilitation without nocturnal non-invasive ventilation
3314865|NCT01961258||Sever asthmatics in the comminity|Computerized data base analysis and sampling of patients for outpatient clinic evaluation.
3314866|NCT01961284|Active Comparator|Zygomatic Implants|2-4 zygomatic implants inserted into edentulous maxilla with no augmentation/grafting prior to providing patient with dental prosthesis
3314867|NCT01961284|Active Comparator|Bone Graft and Conventional implants|Edentulous maxilla which is deficient in bone is first grafted using bone grafting material derived from cows and then ordinary implants are placed into the augmented jaw bone approximately 6 monhts after grafting. Patients will be provided with a dental prosthesis following osseointegration.
3314868|NCT01961310||RA patients|"This group is composed of 25 patients with RA. The diagnosis of RA is based upon the American College of Rheumatology criteria.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
3314869|NCT01961310||Healthy voluteers|"This group is composed of 25 healthy volunteers.~Intervention: Plasma analysis for bacterial translocation~Intervention: Stool analysis"
3314870|NCT01961336|Experimental|Testosterone|"Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.~10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI."
3314871|NCT01961336|No Intervention|Control|Long depot follicular GnRH agonist protocol. On day 21 initiation of ovarian stimulation with recombinant FSH for ICSI. If necessary downregulation will be achieved with additional daily agonist s.c.
3314872|NCT01961388||Group 1|Acarbose_BAY G5421
3314873|NCT01961388||Group 2|Metformin
3314874|NCT01961401|Experimental|High intensity exercise|High intensity, short duration exercise on bike
3314875|NCT01961401|Experimental|Moderate exercise|Moderate intensity exercise training on bike
3314876|NCT01961401|No Intervention|No exercise|No exercise, resting in the lab
3314877|NCT01961414|Experimental|Aflibercept|All patients will receive aflibercept 2.0mg intravitreal injection
3314878|NCT01961427|Active Comparator|sodium Nitrate 12mmol|Ingestion of a solution of inorganic nitrate, dosage: 12mmol
3314879|NCT01961427|Active Comparator|sodium Nitrate (6mmol)|ingestion of inorganic nitrate (6mmol solution)
3314880|NCT01961427|Active Comparator|sodium nitrate 3mmol|ingestion of inorganic nitrate (3mmol solution)
3314881|NCT01961427|Active Comparator|sodium nitrate (0mmol)|Ingestion of water as a placebo
3314882|NCT01961427|Active Comparator|Beetroot juice (12mmol)|ingestion of 170ml of concentrated beetroot juice (12mmol)
3314883|NCT01961427|Active Comparator|beetroot juice (6mmol)|ingestion of 85ml concentrated beetroot juice (6mmol)
3314884|NCT01961427|Active Comparator|Beetroot juice (3mmol)|Ingestion of 42.5ml of concentrated beetroot juice (3mmol)
3314885|NCT01961453|Active Comparator|Isosorbide Mononitrate, sustained release|One tablet containing 60 mg (Titration Stage 1) OR 120 mg (Titration Stage 2) of sustained-release ISMN administered at 8 AM.
3314886|NCT01961453|Placebo Comparator|Placebo capsule|One capsule of placebo administered once daily at 8 AM
3314887|NCT01961466||Diabetic patients|
3314888|NCT01961479|Experimental|Internet-based CBT for patients with PMS|The therapeutical intervention follows a treatment manual consisting of 14 modules. Patients work on up to two modules every week for eight weeks in a row. Modules comprise a) psychoeducation (e.g., information about PMS and its treatment); b) cognitive strategies (e.g., identifying and modifying dysfunctional cognitions, or coping with negative affects); and c) suggestions for lifestyle changes (e.g., sports, stress reduction, or balanced diet). Aim of the iCBT is to improve coping and thus to reduce the impairment due to premenstrual symptoms.
3314889|NCT01961479|Other|waiting list|During the waiting period, patients receive no treatment. After a waiting time of 2 months, patients of the waitlist receive the same iCBT treatment as the experimental group.
3314890|NCT01961492|Active Comparator|Fecal microbiota transplantation|A single fecal microbiota transplantation via colonoscope as an adjunct therapy to standard medical treatment
3314891|NCT01961492|No Intervention|Standard medical treatment|Standard medical treatment as recommended by the ECCO Guidelines of UC therapy.
3314892|NCT01961505|Experimental|Topical Tripterygium group|Patients were treated with topical compound tripterygium for 1 hour, twice per day. Area dosages were as followed that each 1st to 5th metacarpophalangeal joints (MCPJs), 1st to 5th proximal interphalangeal joints (PIPJs) and wrist was 3 ml, each elbow and ankle was 5 ml, each knee was 10 ml.
3314893|NCT01961505|Placebo Comparator|Topical Placebo group|Patients were treated with topical placebo for 1 hour, twice per day. The dosage was the same as the topical tripterygium group.
3381787|NCT05164380||PWA|Persons with Aphasia
3381788|NCT05164380||CG|Control Group healthy adults without aphasia
3381789|NCT05164367|Experimental|0.1 mg of atropine|1 gram of gel by topical application in the oral cavity once.
3314894|NCT01961557|Experimental|Feasibility Arm|All participants will be evaluated using the different configurations of the EA-KAFO (see Table 1 in the protocol), which includes the configuration that contains the Active Motorized KAFO and the configuration that contains the Powerwalk Knee Exoskeleton. Each subject will serve as their own control to assess the effect of each configuration of the EA-KAFO interventions.
3314895|NCT01961583|Experimental|Drug; 18F-Fluciclatide|18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration
3314896|NCT01961596|Experimental|cooling ice|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
3314897|NCT01961596|Placebo Comparator|water|"A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.~After 2 days the measurements will be repeated with the other application."
3314898|NCT01961622|Experimental|Florence D2A Closed Loop Glucose control|Subjects glucose levels are controlled by Florence D2A or similar closed loop insulin delivery system
3381790|NCT05164354|Experimental|Aromatherapy|Aromatherapy will be performed in the form of a 15-minute application period for three days
3381791|NCT05164354|Experimental|music concert|"Music concert will be performed in the form of a 15-minute daily practice period for three days, starting the day after the first measurement."
3381792|NCT05164341|Active Comparator|metreleptin|Metreleptin [Recombinant-methionyl human Leptin; r-metHuLeptin] for daily injection is a sterile, white, solid lyophilised cake
3381793|NCT05164341|Placebo Comparator|placebo|Placebo for daily injection is a sterile, white, solid lyophilised cake
3314899|NCT01961622|Active Comparator|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (FreeStyle Navigator CGM)
3314900|NCT01961635|Experimental|Zirconia Abutments|Place zirconia one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3381794|NCT05164328||Athletes|"Males and females aged 14-23 years old~Athletes competing in endurance sports at national or international level for at least 2 years. Sports include:~Triathlon~Cycling~Distance running (≥ 1500 meters)~Rowing~Swimming"
3381795|NCT05164328||Non-athletes|"Males and females aged 14-23 years old~Non athletes engaged in < 3 hours per week of physical activity"
3381796|NCT05164315|Experimental|Tailored surgery|Arm 1 will receive tailored surgery. If there are no cancer cells or the margin is negative in the local excision/biopsy during surgery, the operation will be terminated. And if the final pathology result is T2-4, or cancer cells and margin are positive in the frozen section during surgery, or the result of digital rectal examination and visual examination using anoretractor under general anesthesia is not suitable for local excision (visible and palpable tumor nodules), a total mesorectal excision will be performed.
3381797|NCT05164315|Active Comparator|Total mesorectal excision (TME)|Arm 2 will receive TME. Surgery including high ligation of the inferior mesenteric artery and total mesorectal excision will be performed under the lithotomy position. After pelvic dissection, double-stapled anastomosis or transanal anastomosis will be performed, followed by diverting stoma. Abdominoperineal resection with permanent stoma is included.
3381798|NCT05164302|Experimental|Group A: LO1 point (Tooth)|Participant received auricular acupuncture and sham acupuncture at LO1 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
3381799|NCT05164302|Experimental|Group B: LO3 point (Jaw)|Participant received auricular acupuncture and sham acupuncture at LO3 point in each side of the ear. In each session, temperature of skin surface at the pinna and lower jaw will be recorded.
3381800|NCT05164289||Control group|Patients in the control group will have simple consultations on D15, D30, D45, D60 and D75
3381801|NCT05164289||EMDR group|Patients in the EMDR group will have EMDR session on D15, D30, D45, D60 and D75
3448514|NCT04063670|Experimental|Video Intervention|Routine, standard-of-care PLUS peri-operative video series
3314901|NCT01961635|Experimental|Titanium Abutments|Place titanium one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3314902|NCT01961635|Experimental|Cad-Cam Acrylic abutments|Place cad-cam acrylic one-time one-abutment in subcrestal platform-switch dental implants on the day of implant installation, torque 20 n/cm2
3314903|NCT01961648|Active Comparator|Dead space|Participant will sleep connected to a mask with added dead space half of the night
3314904|NCT01961648|Sham Comparator|room air|Participant will sleep connected to a mask open to rrom air, half of the night
3314905|NCT01961661|Experimental|probiotic|Lactobacillus rhamnosus GG 5x10^9 colony forming units (CFU)per day
3314906|NCT01961661|Placebo Comparator|placebo|maltodextrins
3314907|NCT01961674|Experimental|Capsinoid arm|On capsinoids
3314908|NCT01961674|Placebo Comparator|Placebo arm|Placebo
3314909|NCT01961700|Experimental|Physiotherapy|Physiotherapy (breathing exercises, mobilisation, exercises for upper limbs, advice on physical activity and exercise) provided daily during hospitalization.
3314910|NCT01961700|No Intervention|Control group|No physiotherapy.
3314911|NCT01961713||Prostatectomy|Subjects with prostate cancer diagnosed on prostate biopsy who undergo radical prostatectomy at Massachusetts General Hospital
3314912|NCT01961726|Placebo Comparator|Placebo|
3314913|NCT01961726|Experimental|30 mg dose of JVS-100|
3314914|NCT01961726|Experimental|45 mg dose of JVS-100|
3314915|NCT01961739|Experimental|2% lidocaine|topical application, two times per day for 15 consecutive days
3314916|NCT01961739|Placebo Comparator|placebo|vaseline base applied topically, two times per day for 15 consecutive days
3314917|NCT01961752|Placebo Comparator|Control group|
3314918|NCT01961752|Experimental|Bupivacaine only group|
3314919|NCT01961752|Active Comparator|Bupivacaine with triamcinolone group|
3314920|NCT01961765|Experimental|cabozantinib|Cabozantinib will be administered at a dose of 40mg daily by mouth in the first cohort. Dose escalation will occur in subsequent patient cohorts. We will evaluate 3-6 patients per dose level.
3314923|NCT01961791||TNM 7th edition|staged by the current TNM 7th edition of AJCC/UICC
3314924|NCT01961791||new TNM stage|staged by new TNM stage with new lymph node staging concept
3314925|NCT01961804|Other|Actual recommendations|Current guidelines recommend to perform a CT scan and realise the anticoagulation reversion only in case of intracranial bleeding diagnosed.
3314926|NCT01961804|Experimental|Preventive reversion|Realise a preventive reversion before performing any CT scan.
3314927|NCT01961817|Other|Retromolar|"Patients in whom the vocal cord visualisation starts with the retromolar method, which has been randomized determined preoperatively.~The second visualization then will be performed with the conventional method."
3314928|NCT01961817|Other|Convenvtional|"Patients in whom the vocal cord visualisation starts with the conventional method, which has been randomized determined preoperatively.~The second visualization then will be performed with the retromolar method."
3314929|NCT01961830|Experimental|ME1100|ME1100 inhalation solution 0.6 mL for 90 mg, Single Dose ME1100 inhalation solution 3.0 mL for 450 mg, Single Dose
3314930|NCT01961843|Experimental|Abiraterone acetate with Prednisone|1000 mg Abiraterone daily by mouth, 4 x 250 mg tablets Prednisone administered as 5 mg orally twice a day
3314931|NCT01961856|Active Comparator|Ticagrelor|Ticagrelor 180mg loading dose
3314932|NCT01961856|Experimental|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by a Ticagrelor 180mg loading dose 2 hours later
3314933|NCT01961869|Experimental|Arm I (Fast release BRB confection 4g)|Participants receive one fast release BRB confection (4g) PO 4-6 hours apart thrice daily (TID) for 2 weeks.
3314934|NCT01961869|Experimental|Arm II (Fast release BRB confection 8g)|Participants receive two fast release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3314935|NCT01961869|Experimental|Arm III (Intermed release BRBconfection 4g)|Participants receive one intermediate release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
3314936|NCT01961869|Experimental|Arm IV (Intermed release BRBconfection 8g)|Participants receive two intermediate release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3314937|NCT01961869|Experimental|Arm V (Prolong release BRB confection 4g)|Participants receive one prolonged release BRB confection (4g) PO 4-6 hours apart TID for 2 weeks.
3314938|NCT01961869|Experimental|Arm VI (Prolong release BRB confection 8g)|Participants receive two prolonged release BRB confection (8g) PO 4-6 hours apart TID for 2 weeks.
3314939|NCT01961895|Active Comparator|Intravenous patient-controlled analgesia|Intravenous morphine solution 0.2 mg / ml in PCA mode without basal infusion, 1mg bolus demand and lockout of 8 minutes.
3314940|NCT01961895|Experimental|Continuous lumbar plexus (LP) block analgesia|"Continuous lumbar plexus (LP) block analgesia. Continuous infusion of a solution of 0.1% bupivacaine in PCA mode, programmed at 8 ml / h.~Rescue bolus 5 ml and 30 minutes lockout"
3314941|NCT01961908|Experimental|12 mg Proellex|12 mg capsules, orally, once daily for 8 months, including off-drug interval
3314942|NCT01961934|Experimental|Sodium Acetate C11 PET/CT Imaging|
3314943|NCT01961947|Experimental|ASP7374 group|
3314944|NCT01961947|Active Comparator|TIV group|
3314945|NCT01961960|Experimental|ASP7374 group|
3314946|NCT01961973|Active Comparator|Cultured chondrocytes|"Cultured chondrocytes:~This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery."
3314947|NCT01961973|Active Comparator|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
3314948|NCT01961986|Active Comparator|TSR: traditional subscap release|"TSR - traditional subscapularis release approach~Subscapularis tendon release technique TSR"
3314949|NCT01961986|Experimental|TSR: rotator cuff sparing|Rotator cuff sparing technique TSR
3314950|NCT01961999|Active Comparator|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
3314951|NCT01961999|Active Comparator|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5 ml/Kg/h >12h), despite therapy~refractory extravascular fluid overload~azotemia > 40mmol/L or 240 mg/dL~metabolic acidosis (pH<7,2)~hyperkaliemia (k+>6 mmol/L)"
3314952|NCT01962012|Experimental|AcceleDent Aura|AcceleDent Aura device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
3314953|NCT01962012|Sham Comparator|Sham Device|Sham devices will look identical to active devices but will not deliver vibration to the patient.
3314954|NCT01962038|Active Comparator|Combined Aerobic and Resistance Exercise/Cognitive Training|
3314955|NCT01962038|Active Comparator|Stretching Exercises/Cognitive Training|
3314956|NCT01962051||Delivery system Entry|
3314957|NCT01962064|Experimental|Semantic demantia|cognitive assessment and Brain imaging examination MRI of patient with the semantic variant of primary progressive aphasia
3314958|NCT01962064|Experimental|Frontotemporal dementia|cognitive assessment and Brain imaging examination MRI of patients with the behavioral variant of frontotemporal lobar degeneration
3448515|NCT04063358|Experimental|Lucentis injected Pre-operatively|Lucentis injected 2 weeks before cataract surgery
3448516|NCT04063358|Active Comparator|Lucentis injected intra-operatively|Lucentis injected during the course of the surgery by cataract surgeon.
3448517|NCT04063358|Experimental|Lucentis injected post-operatively|Lucentis injected 2 weeks after cataract surgery
3448518|NCT04063384|Active Comparator|Alcohol|Participants will be dosed to a 0.08g% blood alcohol concentration.
3448519|NCT04063384|Placebo Comparator|Placebo|Participants will receive a low dose of alcohol (placebo condition).
3448520|NCT04063254|Experimental|High-Dose Stereotactic Radiotherapy|
3314959|NCT01962064|Experimental|Elderly|cognitive assessment and Brain imaging examination MRI of healthy elderly subjects
3314960|NCT01962064|Experimental|Young|cognitive assessment and Brain imaging examination MRI of young subjects
3314961|NCT01962077|Experimental|MedCem MTA pulpotomies|
3314962|NCT01962090|Experimental|Thoracic Spine Thrust in Seated Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in a seated position.
3314963|NCT01962090|Experimental|Thoracic Spine Thrust in Supine Position|Thoracic spine thrust manipulation will be applied two times at each of two treatment sessions while the participant is in the supine position.
3314964|NCT01962116|Placebo Comparator|Heparin lock|
3314965|NCT01962116|Experimental|Citrate lock|
3314966|NCT01962129||Patients affected by a syndrome OFD|
3314967|NCT01962129||Patients AFFECTED BY A SEVERE MENTAL RETARDATION SYNDROMIQUE|
3314968|NCT01962142||Exacerbated asthma patients|
3314969|NCT01962155||chronic infected with hepatitis B virus|patients infected with hepatitis B virus for at least 6 months and agreed with liver biopsy
3314970|NCT01962168||Evolution® Biliary Stent - Uncovered|
3314971|NCT01962181|Active Comparator|Ritalin|Ritalin treatment at different doses
3314972|NCT01962181|Placebo Comparator|Placebo|Two meetings, one of which will be given a placebo and the other will be given a low dose of Ritalin, randomly.
3314973|NCT01962194|Experimental|PD and OCD paients for DBS intervention|Parkinson's disease (PD; n=5) and obsessive-compulsive disorder (OCD; n=5) patients that are candidates for treatment with STN DBS will be recruited over a period of two years.
3314974|NCT01962220|No Intervention|Standard of Care|"Routine ANC, Delivery and Postpartum Care: All consenting women will receive routine ANC/Delivery and Postpartum care offered to pregnant women in Kenya as per national guidelines at the MCH of the respective facility.~Routine PMTCT and HIV Care: All newly diagnosed HIV-infected pregnant women are enrolled into HIV care in the MCH and receive PMTCT/HIV care per Kenya national guidelines (Revised 2012 PMTCT Guidelines)."
3314975|NCT01962220|Experimental|Study Intervention for Retention (APFU)|Participants randomized to the experimental arm of the study will receive routine antenatal and HIV services as described above per Kenya national guidelines. In addition each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri), who will perform numerous tasks described in the intervention. In addition to the Mama Mshauri, this arm will receive phone/SMS appointment reminders, and default patient tracking if participants miss an appointment.
3314976|NCT01962233|Experimental|mesenchymal stem cells|Umbilical Cord Derived Mesenchymal Stem Cells at a dose of 100-800 million by intravenous infusion
3314977|NCT01962246|Active Comparator|postoperative chemotherapy,XELOX|
3314978|NCT01962246|Experimental|Preoperative Concurrent Chemoradiotherapy|
3314979|NCT01962259|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3314980|NCT01962259|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3314981|NCT01962259|Experimental|Active commuting|Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km
3314982|NCT01962259|No Intervention|Control|Receives no intervention.
3314983|NCT01962272|Experimental|Nutritional counseling and Forticare®|Weekly nutritional counseling and Forticare®. The goal being an intake that met the protein and energy requirements according to Harris-Benedict equation multiplied with an individual activity factor (1,1-1,5) and a stress factor (1,0-1,1). Daily protein requirements were estimated to 1,5 g/kg per day. In addition to the counseling, the patients in the intervention group were offered a high-protein nutrition supplement containing n-3 fatty acids (Forticare®, Nutricia). The recommended daily dose contained 2531 kJ, 33.8 g protein and 2.2 g EPA.
3314984|NCT01962272|Active Comparator|Control|"The control group was nutritionally instructed by the nurses with the possibility to call for a dietician not related to the study if needed. No fixed schemes.~Apart from the nutritional element the patients had the same care and therapy, including treatment of pain and side-effects to the treatment."
3314985|NCT01962285|Experimental|propofol slow infusion|"(healthy volunteers, non invasive monitoring and O2 supply via nasal cannula) Target controlled infusion of propofol using Schnider´s pharmacokinetic parameters in a slow, stepped fashion. beginning at Cp 0.5 mcg/ml and increasing in 0.5 mcg/ml every 7 minutes until LOC occurred, then a prolonged step of 14 minutes (2 samples), increase 2 steps further and then decrease in 0.5 mcg/ml steps until ROC and a 7 minute registry after ROC.~Blood sampling for propofol plasma level every 7 minutes (at the end of each step, allowing for pseudo-equilibrium condition.~32 channel-EEg and BIS continuous monitoring"
3314986|NCT01962311|Experimental|All patients|lumbar puncture
3314987|NCT01962324|Experimental|SIB Dose-Escalation radiotherapy|Simultaneous integrated boost to intraprostatatic tumor and lymph nodes
3314991|NCT01962350|Experimental|Active H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~18Hz Active H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
3314992|NCT01962350|Experimental|Sham H1-Coil deep brain rTMS|"Deep Brain Transcranial Magnetic Stimulation~Sham H1-Coil deep brain rTMS for 4-weeks over the cortex prefrontal. n=25"
3314993|NCT01962363|Experimental|EPI-743|EPI-743, oral, 400mg three times daily for 3 months
3314994|NCT01962376|Active Comparator|Bevacizumab,postoperative chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.~placebo:Physiological saline"
3314995|NCT01962376|Experimental|Preoperative Chemotherapy|"Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.~Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline"
3314996|NCT01962389|Experimental|Winsor Laser Catheter|
3314997|NCT01962402|Experimental|Lorcaserin with intensive diet counseling|Patients will be taking lorcaserin 10mg tablet by mouth twice daily. In addition, patients will be provided with intensive dietary counseling to promote weight loss.
3314998|NCT01962415|Experimental|UCBT:transfusion dependent anemias or increased rejection risk|Day -21 to -19: Alemtuzumab + Hydroxyurea; Day -18 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
3314999|NCT01962415|Experimental|BMT, PBSCT and not transfusion dependent UCBT|Start of conditioning to Day -15: Hydroxyurea; Day -14 to -13: Alemtuzumab + Hydroxyurea; Day -12 to -10: Hydroxyurea; Day -9 to -5: Fludarabine + Hydroxyurea; Day -4 to -3: Melphalan; Day -2: Thiotepa; Day -1: Rest; Day 0: Transplant
3315000|NCT01962454|Experimental|Arm 1|Run-in Phase: All participants will receive oral deuterated water (D2O) for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50mL 70% D2O three times per day (TID) for 7 days, followed by a 50ml 70% D2O dose twice daily (BID) for the next 2 weeks. Treatment Phase: Subjects will receive testosterone matching placebo IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks.
3315001|NCT01962454|Placebo Comparator|Arm 2|Run-in Phase: All participants will receive oral D2O for 3 weeks prior to the Treatment Phase of the study. The participants will consume 50 mL 70% D2O TID for 7 days, followed by a 50mL 70% D2O dose BID for the next 2 weeks. Treatment Phase: Subjects will receive testosterone IM injection one per week and 50 mL 70% D2O dose BID for 3 weeks
3315002|NCT01962467|Experimental|Arm 1|Each subject will receive 7 once daily doses of one of the 3 treatments (FF/LEV FDC or FF or LEV) administered as two 50 µL sprays per nostril in the morning, during each of the 3 treatment periods, as per one of the 6 possible randomization sequences. Each treatment period will be separated by a minimum washout period of 14 days
3315003|NCT01962480|Active Comparator|sutured closure of the hernia gap|The hernia gap is sutured intracorporally
3315004|NCT01962480|No Intervention|No closure of the hernia gap|Physiomesh is placed with at least 5 cm overlap of the gap and fixated with double crown technique
3315005|NCT01962519|Experimental|Early oral feeding|Early oral feeding starting with liquids on postoperative day (POD) 1, followed by a soft diet on POD 2, and solid foods on day 3
3315006|NCT01962519|No Intervention|Delayed oral feeding|Delayed oral feeding starting with liquids on postoperative day (POD) 4, followed by a soft diet on POD 5, and solid foods on day 6
3315007|NCT01962532|Experimental|Part 1: Dose Escalation (Daily Dosing)|Dose escalation of JNJ-42756493 is to occur until a dose at which <33 percent of participants experience a dose-limiting toxicity, the maximum concentration of JNJ-42756493 is less than the protocol-defined cardiovascular threshold, and JNJ-42756493 is biologically active. Participants will receive study drug once day on Day 1 of Cycle 1 followed by a 2-day drug-free period (Days 2 and 3 of Cycle 1) and continues throughout the 21 day cycle. For all subsequent cycles once a day for 21 days.
3315008|NCT01962532|Experimental|Part 1: Dose Escalation (Intermittent Dosing)|Intermitting dosing regimen will be 28 days (7 days on and 7 days off). Participants will receive JNJ-42756493 on Days 1 to 7 and Days 15 to 21 of each cycle; JNJ-42756493 will not be administered on Days 8 to 14 and Days 22 to 28 of each cycle.
3315009|NCT01962532|Experimental|Part 2: Dose Expansion|Participants will receive the recommended Phase 2 JNJ-42756493 dose determined in Part 1 as Intermitting dosing regimen (28 days, 7 days on and 7 days off). Participants who are tolerating study drug treatment and achieve clinical responses or stable disease will continue to receive study drug at the same dose until disease progression, unacceptable toxicity, or withdrawal of consent.
3315010|NCT01962545|Experimental|OAC alone|OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target international normalized ratio (INR) range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.
3315011|NCT01962545|No Intervention|OAC plus single APT|"OAC includes warfarin or NOAC. The dose of warfarin should be adjusted with the target INR range of 2.0-3.0 for those <70 years and 1.6-2.6 for those =>70 years, which is recommended in the Japanese guidelines. NOAC includes dabigatran 150mg or 110mg twice daily, rivaroxaban 15mg daily with the reduced dose of 10mg daily, apixaban 5mg twice daily with the reduced dose of 2.5mg twice daily, and edoxaban 60mg daily with the reduced dose of 30mg daily.~Single APT includes aspirin or clopidogrel. The dose of aspirin is 81-324mg/day and the dose of clopidogrel is 75mg/day."
3315012|NCT01962571|Experimental|Erythropoietin alfa|Recombinant human EPO (Epoetin alfa HEXAL®) will be given as an i.v. bolus injection on days 1, 2 and 3. The dosage per day will be 33.000 IU in accordance with previous trials.
3315013|NCT01962571|Placebo Comparator|Placebo|As matched placebo for this study, sterile normal saline (0.9% sodium chloride for i.v. administration) will be used. It will be given as a bolus injection in the same manner as EPO.
3315014|NCT01962584||SAM|patients with suspected acute myocarditis
3315015|NCT01962584||HC|Healthy controls
3315016|NCT01962597|Active Comparator|aerobic exercise|patients will undergo supervised exercise on a bike ergometer for 30 minutes three times per week during hemodialysis
3315017|NCT01962597|Active Comparator|resistance training|patients will undergo supervised lower extremity strength training three times per week pre-hemodialysis
3315018|NCT01962597|Experimental|aerobic exercise and resistance training|patients will undergo a combination of aerobic exercise and resistance training on an alternating schedule three time per week
3381802|NCT05164276|Active Comparator|Sniffing group|Before intubation, the patient's shoulder is supported by a 5cm pillow to make neck flexion with extension of atlanto-occipital joint, confirming that the external auditory meatus and sternal notch plane are horizontal and aligned. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Ahtolone, Ireland) using AceScope®.
3315019|NCT01962610|Experimental|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
3315020|NCT01962610|No Intervention|Usual Care|No study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit
3315021|NCT01962623|Active Comparator|Treatment as Usual (TAU)|Participants who are not randomly assigned to the IPT-MBD group will continue with treatment at usual, which is considered routine care.
3315022|NCT01962623|Other|IPT-MBD|Weekly Interpersonal Therapy for SMD/DMDD (IPT-MBD) sessions, which emphasizes building skills in managing relationships, helping with problem solving, strengthening communication skills and other skills.
3315023|NCT01962636|Experimental|Umbilical Cord Blood Transplant|The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI)followed by umbilical cord blood transplant. Immunosuppressive Cyclosporine and Mycophenylate Mofetil (MMF) will be administered pre- and post UCBT.
3381803|NCT05164276|Experimental|Neurtral group|Before intubation, the patient's head is placed without a pillow on the bed. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Ahtolone, Ireland) using AceScope®.
3381804|NCT05164276|Experimental|Flexed group|Before intubation, the patient's neck is flexed with pads until the chin touches the chest. Then, nasotracheal intubation is performed with a reinforced tube (Mallinckrodt Medical, Ahtolone, Ireland) using AceScope®.
3381806|NCT05164237|Experimental|group A|17 subjects will receive multimodal approach of electrotherapy (LLLT , US and IFC) with conventional physical therapy modalities in the form of ( splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
3381807|NCT05164237|Experimental|group B|17 subjects will receive NFT with conventional physical therapy modalities in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
3381808|NCT05164237|Experimental|group C|17 subjects will receive with conventional physical therapy modalities only in the form of (splint and therapeutic exercises ) 3 sessions every week for 8 weeks.
3381809|NCT05164224||No secondary suture|The participants who will develop post-cesarean surgical site infection and follow-up only antibiotic treatment for their wound care.
3381810|NCT05164224||secondary suture|The participants who will develop post-cesarean surgical site infection and need a secondary suture for their wound care
3381811|NCT05164211|Experimental|Didgeridoo|The children will have 6 didgeridoo lessons given by a teacher spread over 3 months.They will have a didgeridoo at home to practice with.
3381812|NCT05164211|No Intervention|Absence|The children will have nothing to do.
3381813|NCT05164198|Experimental|Open-label reduced-dose TNFi|"Participants in the experimental arm will receive one of the intervention below according to the TNFi agent used at baseline:~Adalimumab 40mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48.~Etanercept 50mg subcutaneous every 10 days (Q10D) from week 0 to week 48.~Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 5 weeks (Q5W) from week 0 to week 48.~Remsima SC 120mg subcutaneous every 3 weeks (Q3W) from week 0 to week 48."
3381814|NCT05164198|Active Comparator|Open-label full-dose TNFi|"Participants in the comparator arm will receive one of the intervention below according to the TNFi agent used at baseline:~Adalimumab 40mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48.~Etanercept 50mg subcutaneous every week (QW) from week 0 to week 48.~Golimumab 50mg (100mg if a participant's body weight ≥ 100kg) subcutaneous every 4 weeks (Q4W) from week 0 to week 48.~Remsima SC 120mg subcutaneous every 2 weeks (Q2W) from week 0 to week 48."
3381815|NCT05164185|Active Comparator|Ischemia reperfusion +remote ischemic conditioning|Active administration of short cykcles of ischemia.
3381816|NCT05164185|Sham Comparator|Ischemia reperfusion +sham|Placebo experiment without remote ischemic conditioning.
3381817|NCT05164172|Experimental|Eptinezumab 300 mg|Participants will receive 3 intravenous (IV) infusions of eptinezumab 300 mg (weight adjusted) at Weeks 0, 12, and 24.
3381818|NCT05164172|Experimental|Eptinezumab 100 mg|Participants will receive 3 IV infusions of eptinezumab 100 mg (weight adjusted) at Weeks 0, 12, and 24.
3448521|NCT04063254|Active Comparator|Standard-Dose Stereotactic Radiotherapy|
3448522|NCT04063462|Experimental|Cohort 1|Previously treated patients with EGFR exon 20 insertion mutant positive NSCLC
3448523|NCT04063462|Experimental|Cohort 2|Previously treated patients with HER2 exon 20 insertion mutant positive NSCLC
3315024|NCT01962649|Experimental|ICG & Optical Molecular Imaging|All patients will receive a dose of ICG 0.5mg/kg, with a maximum dose of 40mg, one day prior to the scheduled procedure. The patients will then undergo a routine image-guided biopsy on the day of the procedure; immediately prior to obtaining the biopsy sample, fluorescence intensity within the target lesion will be measured by a handheld optical molecular imaging device, which will be passed through the biopsy needle. Once the core sample is obtained using a standard biopsy needle, the specimen will be imaged using an epifluorescence, point-of-care imaging system and will then be submitted for standard pathologic analysis.
3315025|NCT01962662|Experimental|variable practice|EMG biofeedback training on force control muscle the goal of force level control training is 25%, 50%, 75%, and 100% of maximal strength.
3315026|NCT01962662|Experimental|constant practice group|EMG biofeedback training on force control muscle the goal of force level control training is 100% of maximal strength.
3315027|NCT01962662|Other|control group|U/E exercise
3315028|NCT01962701||OCT-group|OCT prior to C-section
3315029|NCT01962701||None-OCT-group|No OCT prior to C-section
3315030|NCT01962740|Active Comparator|Xience EES|This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3315031|NCT01962740|Active Comparator|Resolute Integrity ZES|This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3381819|NCT05164159|Active Comparator|propofol group|During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 ~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.
3381820|NCT05164159|Experimental|remimazolam group|Arm Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
3381821|NCT05164146|Active Comparator|propofol group|During the induction, propofol was controlled according to sedline (Psi target 40)
3381822|NCT05164146|Experimental|remimazolam group|During induction, remimazolam dose was controlled according to sedline (Psi target 40)
3381823|NCT05164133|Experimental|All Participants|Participants who are hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation will receive a single dose of TCZ on Day 1, with the option to receive a second dose 8-24 hours later if clinically indicated.
3381824|NCT05164120|Experimental|Interventional|900mg dose TID Administration Total: 2700mg
3315032|NCT01962740|Active Comparator|Promus Element EES|This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging
3315033|NCT01962753|Experimental|18FAV45|
3315034|NCT01962766|Active Comparator|complete myofunctionnal therapy|complete therapy (at least 5 sessions) to correct their swallowing pattern and tongue position
3315035|NCT01962766|Experimental|instructions|instructions to modify their tongue position (1 session)
3315036|NCT01962779|Experimental|Continuous positive airway pressure|Moderate to severe SDB subjects will be offered a 6-month therapy with continuous positive airway pressure (CPAP).
3315037|NCT01962779|No Intervention|No intervention|Subjects that refuse treatment with CPAP or that have a poor long-term compliance will be considered controls.
3381825|NCT05164120|Placebo Comparator|Placebo|900mg dose TID Administration Total: 2700mg
3381827|NCT05164094|Experimental|mRNA-1189 Dose Level 1|Participants will receive 3 intramuscular (IM) injections of mRNA-1189 at Dose Level 1 on Days 1, 57, and 169.
3381828|NCT05164094|Experimental|mRNA-1189 Dose Level 2|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 2 on Days 1, 57, and 169.
3381829|NCT05164094|Experimental|mRNA-1189 Dose Level 3|Participants will receive 3 IM injections of mRNA-1189 at Dose Level 3 on Days 1, 57, and 169.
3381830|NCT05164094|Placebo Comparator|Placebo|Participants will receive 1 IM injection of study drug-matching placebo on Days 1, 57, and 169.
3315041|NCT01962805|Experimental|Proellex Schedule A|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
3381831|NCT05164081|Experimental|Dual antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using dual antibiotic loaded bone cement (gentamicin+clindamycin) COPAL G+C (Heraeus).
3381832|NCT05164081|Active Comparator|Single antibiotic impregnated cement|Patients treated with a cemented hip hemiarthroplasty using single antibiotic loaded bone cement (gentamicin) Paladins R+G (Heraeus) or Refobacin (Biomet).
3381833|NCT05164068|Experimental|Information video|The experimental group likewise consisted of 60 individuals that received information about the biopsy procedure in video format
3381834|NCT05164068|No Intervention|Information face-to -face|The control group consisted of 60 patients that received face-to-face verbal information in a homogeneous and reproducible manner
3381835|NCT05164055|Experimental|Avalglucosidase alfa|Administered intravenously every other week
3381836|NCT05164042|Experimental|Treatment group|Subjects who meet the enrollment conditions will receive intravenous infusion of allogeneic CD19 CAR-T cells after pretreatment.
3381837|NCT05164029||ART couples|Couples in reproductive age undergoing ART treatment
3315042|NCT01962805|Experimental|Proellex Schedule B|Proellex vaginal capsule, 12 mg, once a day for up to 7 days
3315043|NCT01962818|Experimental|HFOV-sigh at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3381838|NCT05164029||natural pregnancy couples|Couples who get pregnant naturally
3381839|NCT05164003|Experimental|CORETOX®|
3381840|NCT05164003|Active Comparator|BOTOX®|
3381841|NCT05163990|Experimental|TEAS group|15 minutes before intraspinal anesthesia, bilateral Neiguan points and Zusanli points are given dense wave transcutaneous acupoint electrical stimulation with the frequency of 10/50Hz. The intensity is based on the maximum tolerance of the participant, and the stimulation last until 30 minutes after subarachnoid administration.
3381842|NCT05163990|No Intervention|Control group|Electrodes are connected at bilateral Neiguan points and Zusanli points 15 minutes before intraspinal anesthesia, but no transcutaneous acupoint electrical stimulation is given, the duration is the same as that of the TEAS group.
3381843|NCT05163977|Active Comparator|Cattell Warren Anastomosis|
3381844|NCT05163977|Experimental|Blumgart Anastomosis|
3381845|NCT05163964||Control Group|Prediabetes patients aged 18-65 years old, who plan to continue healthcare services at a community clinic in Malacca, no literacy barries
3381846|NCT05163951|Active Comparator|Trabeculectomy|Forty-four patients with advanced primary angle closure glaucoma will receive trabeculectomy.
3315044|NCT01962818|Experimental|HFOV-only at start|"Each patient will be exposed to either HFOV alone (HFOV-only) or HFOV combined with sigh breaths (HFOV-sigh), but in different order.~MAP=mean airway pressure.~DURING HFOV-SIGH:~Frequency 3 breaths/min Ti = 1s Peak inspiratory pressure (PIP) = 30 cm H2O~For patients already on HFOV-sigh at study start:~• MAP-set will be left unchanged at pre-trial settings.~For patients on HFOV-only at study start:~• During periods with superimposed sigh breaths, MAP-set will be reduced in accordance with a calculation of MAP aiming to keep average mean airway-pressure (MAP) unchanged. (MAP=(PIP*Tinsp+PEEP*Texp)/(Tinsp+Texp)~DURING HFOV-ONLY~For patients on HFOV-sigh at study start:~• During HFOV-only, the MAP-set will be increased in accordance with a calculation of MAP, aiming to keep average mean airway-pressure (MAP) unchanged.~For patients on HFOV-only at study start:~• MAP-set will be left unchanged at pre-trial settings."
3315045|NCT01962831|Experimental|dinoprostone|Group of women that will receive dinoprostone for induction of labour dinoprostone 10 mg in vagina to be reassessed every 24 hours
3315046|NCT01962831|Experimental|Single balloon foley catheter|Group of women that will have a single balloon foley catheter inserted for induction of labour
3381847|NCT05163951|Experimental|SPI+GSL+GT|Forty-four patients with advanced primary angle closure glaucoma will receive surgical peripheral iridectomy (SPI) combined with goniosynechialysis (GSL) and goniotomy (GT).
3315047|NCT01962844|Other|Nutritional treatment|All patients received an individualized diet plan and balanced. The diet was calculated according to the nutritional status and the protein 15-20% of total energy value, lipids 25-30% of daily energy intake and carbohydrate 50-60% of of total energy value
3315048|NCT01962844|Experimental|extra virgim coconut oil group|Oil from coconuts (cocos nucifera L.) contains a high proportion of medium chain fatty acids, principally the lauric acid (12:0), in proportions that range from 45 to 50%
3315049|NCT01962857|Experimental|Exercise|4 week supervised high-intensity shuttle running intervention, with 3 sessions per week (12 sessions in total)
3315050|NCT01962857|No Intervention|Control|No intervention - participants maintain usual lifestyle
3315051|NCT01962883|No Intervention|Control group|Osteopathic evaluation Cognitive and Physical Rest
3315052|NCT01962883|Experimental|Osteopathic Treatment Group|4 osteopathic treatments following a set protocol to which only the osteopathic lesions found within the subjects assessment will be treated.
3315053|NCT01962909|Experimental|PTP-01|single IV bolus dose 24 hours prior to surgery
3315054|NCT01962935|Experimental|Part A AZD4721|Part A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
3315055|NCT01962935|Placebo Comparator|Placebo|Part A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
3315056|NCT01962935|Active Comparator|AZD5069, then AZD4721|Part B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.
3315057|NCT01962948|Experimental|Treatment (paclitaxel, ganetespib)|Patients receive paclitaxel IV over 1 hour and ganetespib IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3315058|NCT01963000||CAP|A patient with CAP was identified by encoding pneumonia without severe immunosuppression (HIV infection, solid organ or bone marrow/stem cell transplants, severe neutropenia) as the main diagnosis (ICD 10 GM) of hospital admission.
3315059|NCT01963013|Experimental|Non-returning catheter valve|Non-returning catheter valve (UnometerTM SafetiTM Plus) was used in experimental group only.
3315060|NCT01963013|Active Comparator|Conventional urine bag|Conventional urine bag hasn't the non-returning catheter valve.
3315061|NCT01963026|Experimental|ToCUEST (constant or variable practice)|After therapy as usual (intervention A), the Task-oriented Client-centred Upper Extremity Skill Training (ToCUEST) module (Spooren et al., 2011) will be given. In this program individual goals will be extracted using the COPM (Canadian Occupational Performance Measure) and the training program is based on a task-analysis and uses principles of training physiology and motor learning. Intervention B will consist of the ToCUEST program, including the component 'practice variability' (ToCUEST variability). Intervention C will consist of a modified ToCUEST program in which the component 'practice variability' will be replaced by 'constant practice' (ToCUEST constant) in order to evaluate the contribution of these components. Intervention A' will be therapy as usual.
3315062|NCT01963039|Active Comparator|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement (PMMA) is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the cement reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
3315063|NCT01963039|Sham Comparator|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the bone cement(PMMA) is prepared to simulate the odor associated with mixing of polymethacrylate , but the needle is not placed and cement is not injected.
3315064|NCT01963052|Experimental|Part A: AGS-15E Dose Escalation (Dose Levels 1-6)|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Additional subjects may be enrolled for expansion of these dose levels to further evaluate the safety and efficacy, as recommended by a data review team (DRT).
3315065|NCT01963052|Experimental|Part B: AGS-15E Cisplatin Therapy -ineligible Expansion|Urothelial subjects who have not received any prior lines of therapy an who are unfit for Cisplatin therapy (Cis-ineligible) will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will initially be dosed one dose level below the preliminary recommended phase 2 dose (RP2D).
3315066|NCT01963052|Experimental|Part C: AGS15E Immune Checkpoint Inhibitor Treated Expansion|Subjects previously treated with immune checkpoint inhibitors (CPI) in the metastatic setting will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks. Subjects will be dosed at the RP2D.
3315067|NCT01963052|Experimental|Part A: AGS15E Dose Expansion|Subjects will receive a single 30 minute intravenous (IV) infusion of AGS15E once weekly for 3 weeks of every 4 weeks (Days 1, 8, and 15). A cycle is 4 weeks.
3315068|NCT01963065||Moderately pre-term infants and their mothers|cohort of moderately pre-term infants and their mothers
3315069|NCT01963104|Experimental|Automated hearing test|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
3315070|NCT01963104|Experimental|Pure-tone Screener test|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow-up.
3315071|NCT01963104|Experimental|Digits-in-noise test|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.
3315072|NCT01963104|Experimental|No screening test|This group of subjects will not receive a screening test.
3315073|NCT01963104|Experimental|Automated hearing test/Motivation video|Subjects will take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3315074|NCT01963104|Experimental|Pure-tone Screener/Motivation video|Subjects will take a pure-tone hearing screening test and then receive recommendations for hearing healthcare follow- up. They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3315075|NCT01963104|Experimental|Digits-in-noise test/Motivational video|Subjects will take a digits-in-noise test and then receive recommendations for hearing healthcare follow-up.They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss.
3315076|NCT01963104|Experimental|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss
3315077|NCT01963104|Experimental|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.
3315078|NCT01963104|Experimental|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test, take an abbreviated automated hearing test and then receive recommendations for hearing healthcare follow-up.~They will then watch a brief video that shows how hearing works and learn about the different types of hearing loss."
3315079|NCT01963130||drug (metformin and gliclazide)|The first group (Group 1) consisted of patients that used metformin (1000 mg bid) and gliclazide (60 mg qd).
3315080|NCT01963130||drug (metformin, gliclazide and vildagliptin)|The second group (Group 2) consisted of patients that used vildagliptin (50 mg bid) in addition to the same amount of metformin and gliclazide since their HbA1c were detected 7 % or over.
3315081|NCT01963156|Experimental|Prescription synchronization|
3315082|NCT01963156|No Intervention|Control|
3315083|NCT01963182|Experimental|irinotecan dose based on genetic polymorphism of UGT1A1|
3315084|NCT01963195|Experimental|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicity occurred. The overall study period takes about 24 months
3315085|NCT01963208|Experimental|ganaxolone|active
3315086|NCT01963208|Placebo Comparator|Placebo|placebo, non-active
3315087|NCT01963221|Other|fluodeoxyglucose (18f)|
3315088|NCT01963247||Healthy Athletes|
3315089|NCT01963247||Concussed Athletes|
3315090|NCT01963273|Experimental|pilonidal sinuses|All consecutive patients with diagnosis of chronic sacrococcygeal pilonidal sinus will be screened for the enrollment in our study.
3315091|NCT01963286|Other|Enhanced SVT discriminators|Patients with activated enhanced SVT discriminators (in accordance with predefined mandatory study settings)
3315092|NCT01963299|Active Comparator|Ropivacaine alone group|
3315093|NCT01963299|Experimental|Ropivacaine/Clonidine group|
3315094|NCT01963312|Experimental|Transarterial Supraselective Embolization|Transarterial supraselective embolization of prostatic arteria with Bead Block 300-500 μm
3315095|NCT01963312|Active Comparator|Transurethral Resection|Surgery to remove part of the prostate gland
3315096|NCT01963325|Experimental|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
3315097|NCT01963338|Experimental|Intradermal group|These group participants received two intradermal injections with the newly developed device, one in the forearm and one in the upper arm (deltoid region).
3315098|NCT01963338|Experimental|Intramuscular group|These group participants received one intramuscular injection in the upper arm(deltoid region) using needle and syringe and one intradermal injection in the forearm using the newly developed device.
3315099|NCT01963351||Locally advanced and metastatic nsclc|non squamous
3315100|NCT01963364|Experimental|Intervention group|All healthy volunteers
3315101|NCT01963377|Experimental|1. Nasal Cannulae / 2. Bronchoscope channel|Supplementation of O2 through will take place first through the aspiration channel of the bronchoscope, in second phase of the study O2-supplementation will be done through nasal cannulae.
3315102|NCT01963377|Experimental|1. Bronchoscope channel / 2. Nasal Cannulae|Supplementation of O2 through will take place first through nasal cannulae, in second phase of the study O2-supplementation will be done through the aspiration channel of the bronchoscope.
3315103|NCT01963390||Testosterone therapy|The study population is a cohort of testosterone deficient men who are planning on undergoing testosterone therapy at an outpatient men's health clinic.
3315104|NCT01963416|Placebo Comparator|Control|macro- and micro-nutrient matched control (240 ml)
3315105|NCT01963416|Experimental|Orange juice|commercial orange juice (240 ml)
3315106|NCT01963416|Experimental|whole orange|whole orange fruit (240 ml)
3315107|NCT01963416|Experimental|processed whole orange|processed whole orange (240 ml)
3315108|NCT01963429|Experimental|A(radiofrequency ablation )|radiofrequency ablation
3315109|NCT01963429|Experimental|B(Proton)|hypofractionated proton beam therapy
3315110|NCT01963442|Active Comparator|Amoxicillin/Clavulanic acid treatment|after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid. Chest X-ray performed at admission and Day 30 and replapses. 'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
3315111|NCT01963442|Placebo Comparator|placebo treatment|after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo. Chest X-ray performed at admission and Day 30 and replapse. blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
3315112|NCT01963455|Experimental|MDCs transplant|The women who have stress urinary incontinency.
3315113|NCT01963468|Experimental|Early language intervention|"Children will receive 6 months of weekly parent-implemented intervention sessions.~Children will be assessed monthly via audio recordings and language checklists to monitor language development more closely."
3315114|NCT01963468|No Intervention|Monthly language check-ups|Children will be assessed monthly via home observations and parents will complete a language checklist to monitor language development more closely.
3315115|NCT01963494|Experimental|Dyadic planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, randomly selected target persons form action plans to increase daily physical activity together with their partners.
3315116|NCT01963494|Active Comparator|Individual planning intervention|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons form action plans individually to increase daily physical activity and partners receive a distraction task.
3315117|NCT01963494|Active Comparator|No-planning control condition|A general motivational treatment is provided to each participant. For randomly assigned couples, target persons do not receive instructions for action planning, but perform a distraction task together with their partners.
3315118|NCT01963507|Experimental|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
3315119|NCT01963507|No Intervention|Control|
3315120|NCT01963546|Other|Intravenous anesthesia|We use total intravenous anesthesia to assess the stress response.
3315121|NCT01963546|Other|Intravenous and Inhalation anesthesia|We use intravenous and inhalation anesthesia during the surgery.
3315122|NCT01963546|Other|Inhalation anesthesia|We use inhalation anesthesia during the surgery.
3315123|NCT01963546|Experimental|Dexmedetomidine|"the effect of dexmedetomidine on the stress responses generated by patients with diabetic given gastric-bypass surgery : Group A group given the best anesthetic technique from preliminary work + dexmedetomidine Dexmedetomidine as a inducer was given intravenous infusion loading dose 1.0μg/kg for 10min, maintained intravenous infusion by 0.4μg/kg/h.~Group B group given the best anesthesia method from preliminary work(not using dexmedetomidine)."
3315124|NCT01963559|Other|Diabetic patients with MPP|
3315125|NCT01963559|Other|Diabetic patients without MPP|
3315126|NCT01963572|Experimental|surveillance group (SG)|SG will have health education brochure and free class from the first visit post-operatively but CG will only have the brochure. Moreover, SG will be screened every time when they visit the clinics. If there is any early sign of impairment, professional advice and counseling will be given additionally.
3315127|NCT01963572|No Intervention|general care group (CG)|CG raises any health-related question, they can be answered.
3315128|NCT01963585||Negative metacholine|Healthy control
3315129|NCT01963585||Positive metacholine|Hyperreactive airway disease - study group
3315130|NCT01963598|Experimental|Group 1|Dosing regimen 1
3315131|NCT01963598|Experimental|Group 2|Dosing regimen 2
3315132|NCT01963598|Experimental|Group 3|Dosing regimen 3
3315133|NCT01963598|Experimental|Group 4|Dosing regimen 4
3315134|NCT01963624||Breast masses detected with screening US|Those assessed with conventional B-mode US alone and those assessed with combined elastography and color doppler ultrasonography along with B-mode US.
3315135|NCT01963637|Experimental|Patients with morbid obesity|Patients with morbid obesity and who requires a gastric bypass or a Sleeve gastrectomy as a 1st bariatric procedure.
3315136|NCT01963650||No treatment|
3315137|NCT01963663|Active Comparator|Metformin|patients receiving fixed dose metformin 1000 mg daily
3315138|NCT01963663|Active Comparator|Pioglitazone|patients receiving fixed dose pioglitazone 30 mg daily
3315139|NCT01963689|Placebo Comparator|Intervention Group 2|Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
3315140|NCT01963689|Experimental|Intervention Group 1|Individuals belonging to Group 1 received a bottle containing aromatic gel enriched with essential oil of ylang ylang in a concentration of 2% and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
3315141|NCT01963689|Experimental|Intervention Group 3|The subjects in Group 3 were responsible for before the beginning of their working, put a drop of essential oil of ylang ylang in cotton located within the freshener personal and should be used throughout your work shift
3315142|NCT01963702|Experimental|Docetaxol ＆Capecitabine (TX)|Docetaxol: 75 mg/m2 d1, (From MAY 15th 2013, the dose was reduced to 60mg/m2 for high incidence of G3/4 myelosuppression after approved by institute Ethics Committee) ; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
3315143|NCT01963702|Active Comparator|Oxaliplatin ＆Capecitabine (XELOX)|Oxaliplatin: 130 mg/m2 d1; Capecitabine 1000 mg/m2 bid ×14d; Repeat every 3 weeks, until disease progression or intolerable toxicity or patients withdrawal of consent,or total 8 cycles
3315144|NCT01963715|Experimental|EGFR+ Solid Tumor|EGFR+ Solid Tumor
3315145|NCT01963728|Active Comparator|insulin isophane|daily dose will be titrated based on fasting morning glucose values
3315146|NCT01963728|Active Comparator|insulin glargine|daily dose will be titrated based on fasting morning glucose values
3315147|NCT01963741|Experimental|leukotriene D4|Nasal provocation test was induced by leukotriene D4 with a stepwisely concentration method (4 mcg/ml, 8 mcg/ml, 16 mcg/ml).
3315148|NCT01963741|Experimental|histamine|Nasal provocation test was induced by histamine with a stepwisely concentration method (0.4 mg/ml, 0.8 mg/ml, 1.6 mg/ml, 3.2mg/ml).
3315149|NCT01963754|Experimental|Subepriosteal Articaine|Administer Subperiosteal 1:100.000 Articaine 4% epinephrine, buccal and lingually, for Dental Implants in Posterior mandible
3315150|NCT01963754|Active Comparator|Loco-regional Articaine|Administer Loco-regional 1:100.000 articaine 4% epinephrine, for Dental Implants in Posterior Mandible
3315151|NCT01963780|Experimental|OCS Lung Tx.|
3315152|NCT01963806|Experimental|Smartphone-supplemented iCBT with therapist support|n = 50
3315153|NCT01963806|Experimental|Smartphone-supplemented iCBT without therapist support|n = 50
3315154|NCT01963806|Active Comparator|Active waiting list control group with delayed treatment|n = 50
3315155|NCT01963819|No Intervention|Control|Standard treatment
3315156|NCT01963819|Experimental|Intervention|Endometrial biopsy before standard treatment
3315157|NCT01963832|Experimental|eCMIT and Fluoxetine|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)
3315158|NCT01963832|Experimental|eCIMT and placebo|expanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo
3315159|NCT01963832|Experimental|Usual care and fluoxetine|Ususal physical care combined with Fluoxetine (FLX)
3315160|NCT01963832|Experimental|Usual care and placebo|Usual physical care combined with placebo
3315161|NCT01963858|Experimental|Functional relaxation|Functional relaxation
3315162|NCT01963858|Active Comparator|No relaxation|No relaxation
3315163|NCT01963871|Experimental|Yoga in Chronic Low Back Pain|12 weeks of no yoga followed by 12 weeks of yoga, 2 times per week for individuals with chronic low back pain
3315164|NCT01963884||Alveolar Socket Below Basal Bone|Tooth and the alveolar socket are positioned below basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3315165|NCT01963884||Alveolar Socket in Basal Bone (imbedded)|Tooth and alveolar socket are positioned in basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3315166|NCT01963884||Alveolar Socket Buccal to Basal Bone|Tooth and alveolar socket are positioned buccally in relation to maxillary basal bone. Measure Alveolar Socket remodeling, after Tooth Extraction with cone-beam technology evaluation
3315167|NCT01963910|Active Comparator|Mannitol in vehicle cream|Once the capsaicin has been removed, .2 mL of 30% mannitol in vehicle cream will be applied to one half of the upper lip and kept there for 10 minutes.
3315168|NCT01963910|Placebo Comparator|Vehicle Cream|Once the capsaicin has been removed, .2 mL of vehicle cream will be applied to the other half of the upper lip and kept there for 10 minutes.
3315169|NCT01963936|Experimental|Supreme LMA|
3315170|NCT01963936|Active Comparator|Facial mask|
3315171|NCT01963949||Primary Liver Cancer|Patients that have liver masses suspicious for primary liver cancer.
3315172|NCT01963962||Copper IUD|Women selecting the copper IUD for emergency contraception and to use for contraception after
3315173|NCT01963962||Levonorgestrel IUD|Women who select oral levonorgestrel for emergency contraception and begin the levonorgestrel IUD for ongoing contraception at the same time.
3315174|NCT01963988||Transurethral Coagulation (TUC)|This cohort patients will be managed with Transurethral Coagulation (TUC) of IC ulcer lesion
3315175|NCT01963988||Transurethral Resection(TUR)|This cohort patients will be managed with transurethral resection(TUR) of IC ulcer lesion
3315176|NCT01964001|Placebo Comparator|Placebo|starch
3315177|NCT01964001|Experimental|Dietary supplements|Vitamin B-6/Coenzyme Q10/vitamin B6+Coenzyme Q10
3315178|NCT01964014|Experimental|advagraf|The same capacity advagaf + sirolimus
3315179|NCT01964027|Experimental|Irinotecan plus epirubicin|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
3315180|NCT01964040|Placebo Comparator|group B: control bupivacaine group|Patient in this group will receive 25 ml bupivacaine 0.5% plus 0.5 ml normal saline peri-neurally and 0.5 ml subcutaneous normal saline.
3315181|NCT01964040|Experimental|Group B-peri-DEX: Peri-neural Dexmedetomidine|Patients in this group will receive 25 ml of 0.5% bupivacaine plus 0.5 ml (50 microgram) Dexmedetomidine peri-neurally and 0.5 ml subcutaneous normal saline
3315182|NCT01964040|Active Comparator|Group B-sys-DEX:Systemic Dexmedetomidine|Patients in this group will receive 25 ml bupivacaine plus 0.5 ml saline peri-neurally and 0.5 ml (50 microgram) subcutaneous Dexmedetomidine.
3315183|NCT01964053|Experimental|PATCH Intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
3315184|NCT01964053|Active Comparator|Usual Care|The usual care group will receive standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen. No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
3315185|NCT01964066|Experimental|ERCP & Thoracic epidural analgesia|Used thoracic epidural analgesia (ropivacaine 0.5% -10ml) for pain relief ERCP.
3315186|NCT01964066|Active Comparator|ERCP & Premedication|Used Premedication (trimeperidine 2% -1ml intravenously) for pain control ERCP.
3315187|NCT01964079|Active Comparator|CCB (amlodipine)|For patients who fail to respond to 5 mg oral amlodipine daily, the dose will be titrated up to 10 mg amlodipineh. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
3315188|NCT01964079|Active Comparator|ARB (losartan)|For patients who fail to respond to 50 mg oral losartan daily, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
3315189|NCT01964118|Other|Control group|The participants randomized to the crossover group begin study participation as a control group (no changes in food intake) for the first 6 months and switch to IF for the remaining 6 months of the study.
3315190|NCT01964118|Experimental|Intermittent Fasting group|Participant with a BMI between 28 and 35 kg/m2 will fast 3 non-consecutive days per week, whereas participant with a BMI between 24 and 27.9 kg/m2 will fast 2 non-consecutive days per week. Individuals following intermittent fasting (IF) will work with the study dietitian to design their weekly meal plans and menus for the non-fasting days. The subjects following IF will be asked to skip breakfast, lunch, dinner, snacks, and calorie-containing beverages on the fast days, but we will give them the option to consume at dinner a big salad (i.e. non-starchy raw and/or cooked vegetables dressed with 2 tablespoons of salad dressing prepared with vegetable oil, vinegar and seasonings).
3315191|NCT01964131|Experimental|D961H sachet 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets
3315192|NCT01964131|Other|D961H HPMC capsule 20 mg|Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule
3315193|NCT01964144|Experimental|Dovitinib arm|
3315194|NCT01964157|Experimental|LDK378 arm|
3315195|NCT01964170|Experimental|ASP3550 PART 1 and PART 2|Part 1 for 1 year treatment and Part 2 for an extended period of treatment
3315196|NCT01964170|Active Comparator|Goserelin|part 1 for 1 year treatment
3315197|NCT01964183|Experimental|treatment group|
3315198|NCT01964196|Experimental|ASP1517 low dose group|Oral
3315199|NCT01964196|Experimental|ASP1517 middle dose group|Oral
3315200|NCT01964196|Experimental|ASP1517 high dose group|Oral
3315201|NCT01964196|Placebo Comparator|Placebo group|Oral
3315202|NCT01964209||No treatment|This is a psychometric study of a screening tool for ADHD, so we will not be administering any treatments or interventions.
3315203|NCT01964235|Experimental|INC280 plus best supportive care|Approximately 46 patients will be treated with INC280 600 mg twice a day plus best supportive care.
3315204|NCT01964235|Placebo Comparator|Placebo plus best supportive care|Approximately 23 patients will be treated with matching placebo twice a day plus best supportive care.
3315205|NCT01964248|Experimental|Lidocaïne/prilocaïne|"Lidocaine/prilocaine eutectic mixture 5% incorporated in a cream base~Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
3315206|NCT01964248|Placebo Comparator|Placebo|"Single dose: 2 grams (one tube of cream)~Cream applied 2 hours before blood sample"
3315207|NCT01964261|Experimental|Neural Prosthetic System 2|The Neural Prosthetic System 2 consists of three Neuroport Arrays, which are described in detail in the intervention description. Two of the three Neuroport Arrays are inserted into the posterior parietal cortex, an area of the brain used in reach and grasp planning. The third Neuroport Array is inserted into somatosensory cortex, specifically S1 which represents sensory feedback for the hand and fingers. The arrays are inserted and the percutaneous pedestal is attached to the skull during a surgical procedure. Following surgical recovery the subject will participate in study sessions 3-5 times per week in which they will learn to control an end effector by thought augmented with sensory feedback via intracortical microstimulation. They will then use the end effector to perform various reach and grasp tasks.
3315208|NCT01964274||Surgical patients|Adult male and female patients undergoing surgery
3315209|NCT01964287|Experimental|Gembrax followed by Folfirinox|"Gembrax:~Albumin-bound paclitaxel followed by Gemcitabine Day 1,8,15 followed by 2 weeks of rest~Folfirinox:~Oxaliplatin, irinotecan, leucovorin, 5FU bolus and continuous"
3315210|NCT01964313||ACS cohort|Patients diagnosed with acute coronary syndrome.
3315211|NCT01964339||BMI greater than or equal to 30kg/m2 -venous|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
3315212|NCT01964339||BMI greater than or equal to 30kg/m2 - arterial|BMI greater than or equal to 30kg/m2 scheduled for PSG as part of routine clinical care. Participants will undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
3315213|NCT01964365|Experimental|Rosuvastatin|multiple dose of Rosuvastatin 20mg
3315214|NCT01964365|Experimental|Fenofibric acid|multiple dose of Fenofibric acid 135mg
3315215|NCT01964365|Experimental|Rosuvastatin + Fenofibric acid|multiple dose of the combination of Rosuvastatin 20mg and Fenofibric acid 135mg
3315216|NCT01964391|Experimental|Trastuzumab|In adjuvant setting trastuzumab will be administered in the following treatment regimens: (a) trastuzumab following surgery, chemotherapy (neo-adjuvant or adjuvant) and radiotherapy (if applicable); (b) trastuzumab following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; (c) trastuzumab in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. In neo-adjuvant setting, trastuzumab will be administered in combination with neo-adjuvant chemotherapy followed by adjuvant trastuzumab, for locally advanced (including inflammatory) breast cancer or tumors greater than (>) 2 centimeters (cm) in diameter.
3315217|NCT01964404|Experimental|Marijuana cigarette and placebo capsule|3-5% tetrahydrocannabinol cannabis cigarette smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
3315218|NCT01964404|Experimental|Dronabinol and placebo cigarette|Dronabinol 15mg 3-5% by mouth taken approximately 2.75 hours prior to the second functional MRI and a placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI.
3315219|NCT01964404|Placebo Comparator|Placebo cigarette and placebo capsule|Placebo cigarette (for marijuana) smoked immediately prior to the second functional MRI and a placebo capsule (for dronabinol) by mouth taken approximately 2.75 hours prior to the second functional MRI.
3315220|NCT01964417|Active Comparator|4L-split Dose of PEG Solution|4L-split Dose of PEG Solution for bowel preparation
3315221|NCT01964417|Active Comparator|Low-volume PEG Plus Ascorbic Acid|Low-volume PEG Plus Ascorbic Acid for bowel preparation
3315222|NCT01964443||all included patients|Men and women, 18 years of age and older, who have had the onset of the first symptoms of plaque psoriasis less than 10 years before study entry, are naïve or experienced to topical treatment, and are eligible for phototherapy or systemic treatment
3315223|NCT01964456|Active Comparator|Patients|Patients suffering of anorexia
3315224|NCT01964456|Placebo Comparator|Control|Subjects controls (not suffering of anorexia)
3315225|NCT01964469|Placebo Comparator|Written self-management action plan|Usual Care: Evidence-based best practice within the primary care asthma program including written self-management action plan and regular clinical review.
3315226|NCT01964469|Experimental|mobile & web based action plan|Evidence-based best practice within the primary care asthma program, replacing the written action plan with the Breathe mobile health and web-based application.
3315227|NCT01964469|No Intervention|Administrative data set|Health services use will be evaluated comparatively against our intervention population and our control and we will include health services utilization data from one year prior randomization.
3315228|NCT01964482|Experimental|Strength training|Supervised strength training daily during hospitalization and 3 times per week for 4 weeks after discharge in the participant's home
3315229|NCT01964482|No Intervention|Usual care|Usual care
3315230|NCT01964495|Active Comparator|Common clinical practice|Treatment according to current guidelines. Often a 7 day course of antibiotics. Initial treatment should be broad spectrum antibiotics and can be narrowed down if a specific pathogen is identified.
3315231|NCT01964495|Experimental|CRP-guided treatment|Treatment according to CRP levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
3315232|NCT01964495|Experimental|PCT guided treatment|Treatment according to PCT levels. Patients will be started on broad spectrum antibiotics for at least 3 days, treatment can be switched to small-spectrum antibiotics if a specific pathogen is identified. From day 4 to 7 daily blood tests will be performed in order to evaluate whether or not treatment can be discontinued. If treatment is discontinued, no more blood tests will be performed.
3315233|NCT01964508||Thyroid nodule|Patients with thyroid nodules undergoing FNA.
3315234|NCT01964534|Active Comparator|ARM 1 ABI-007 + Gemcitabine|ABI-007 : 125mg/m² IV / 30min (day 1, day 8, day 15) Gemcitabine : 1000mg/m² IV /30 min (day 1, day 8, day 15) One cycle every four weeks treatment until progression or limiting toxicity
3315235|NCT01964534|Experimental|Arm 2 ABI-007 + simplified LV5FU2|ABI-007 : 125mg/m² IV /30 min (day 1, day 15) folinic acid : 400mg/m² IV /2h (day 1, day 15) Bolus 5-FU : 400mg/m² IV /15min 5-FU infusion : 2400mg/m² IV / 46h (day 1-2, day 15-16) One cycle every four weeks Treatment until progression or limiting toxicity
3315237|NCT01964573|Experimental|Rotigotine group|
3315238|NCT01964573|Placebo Comparator|Placebo group|Placebo matched to rotigotine will be administered in the same way as within the Rotigotine group.
3315239|NCT01964586|Active Comparator|Lidocaine plus Adrenaline|Lidocaine and adrenaline diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes from the surgery.
3315240|NCT01964586|Active Comparator|Dexmedetomidine|2 mcg/kg dexmedetomidine diluted to 10 ml with normal salin and infiltrated to both side of the nasal septum before 10 minutes the surgery.
3315241|NCT01964599|Other|PF-RS|14 days consuming the PF-RS containing 30 g fiber and then 14 days consuming the control containing no fiber
3315242|NCT01964599|Other|PF-RO1|14 days consuming the PF-RO1 containing 30 g fiber and then 14 days consuming the control containing no fiber
3315243|NCT01964599|Other|PF-RO2|14 days consuming the PF-RO2 containing 30 g fiber and then 14 days consuming the control containing no fiber
3315244|NCT01964625|Experimental|PET-CT|Patients who have a negative routine PET-CT evaluation followed by onset and confirmation in accordance with NIH guidelines, will receive another PET-CT scan prior to initiation of therapy for chronic GvHD.
3315245|NCT01964638|Other|Targeted Biopsy|Men being evaluated for prostate cancer based upon standard of care clinical parameters (e.g. elevated PSA levels, abnormal DRE, mpMRI) will be considered for enrollment. Men who have undergone prostate mpMRI that has revealed an area(s) of suspicion for prostate cancer are eligible for enrollment. All men enrolled in the study undergo fusion targeted biopsy, visual estimation biopsy, and systematic biopsy. As a result the study includes a single arm with direct comparison of biopsy techniques.
3315246|NCT01964651|Experimental|Cohort A (Part 1)|Healthy male participants, 18 to 55 years of age.
3315247|NCT01964651|Experimental|Cohort B (Part 1)|Healthy male participants, 18 to 55 years of age.
3315248|NCT01964651|Experimental|Cohort C (Part 2)|Healthy female participants of nonchildbearing potential (surgically sterile or postmenopausal), 18 to 58 years of age.
3315249|NCT01964651|Experimental|Cohort D (Part 2)|Healthy elderly male or female participants, from 65 to 85 years of age.
3315250|NCT01964664|Experimental|Mindfulness meditation training|6-week, one-on-one, mindfulness meditation intervention based on Mindfulness-Based Cognitive Therapy program
3315251|NCT01964664|Active Comparator|Audio Group|6 weeks of listening to podcasts daily (same length as guided meditations), and discussing podcast content with research assistant during weekly study visits
3315252|NCT01964677|Experimental|MR-HIFU of painful bone metastases|
3315253|NCT01964703|Placebo Comparator|control|
3315254|NCT01964703|Active Comparator|Rubus occidentalis extract 900mg|taking Rubus occidentalis extract 900mg/day for 12weeks
3315255|NCT01964703|Active Comparator|Rubus occidentalis extract 1800mg|taking Rubus occidentalis extract 1800mg/day for 12weeks
3315256|NCT01964729|Sham Comparator|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
3315257|NCT01964729|Experimental|Transcranial Magnetic Stimulation|We will deliver high frequency rTMS at 10 Hz rate was over right M1 in sessions consisting of of 4 seconds of stimulation followed by 26 second intervals, with a total of 1600 pulses per session.
3315258|NCT01964742|Experimental|HIV-HCV co-infected patients|
3315259|NCT01964781|Experimental|topical tranexamic acid|tranexamic acid to be smeared on surgical wounds before closure
3315260|NCT01964781|Experimental|topical adrenaline|adrenaline solution to be smeared on surgical wounds before closure
3315261|NCT01964781|Experimental|topical bupivacaine|bupivacaine to be smeared on surgical wounds before closure
3315262|NCT01964781|Experimental|topical adrenaline plus tranexamic acid|tranexamic acid and adrenaline to be smeared on surgical wounds before closure
3315263|NCT01964781|Placebo Comparator|placebo control|saline to be smeared on surgical wounds before closure
3315264|NCT01964781|Placebo Comparator|tranexamic acid and placebo control|tranexamic acid and saline to be smeared on surgical wounds before closure
3315269|NCT01964820|Experimental|Positive affect skills intervention|Participants receive a 5-week intervention providing training in 8 skills for generating positive affect.
3315270|NCT01964820|No Intervention|Emotion reporting|Participants report emotions on the same regular basis as intervention participants, but receive no intervention.
3315271|NCT01964833|Sham Comparator|Periodontal treatment|Conventional periodontal treatment with hygiene orientation, calculus removal and root scaling and planing. Sham PDT.
3315272|NCT01964833|Experimental|Periodontal Treatment and PDT|Conventional periodontal treatment with hygiene orientation, calculus removal, root scaling and planing. Active PDT with diode laser and methylene blue photosensitizer
3315273|NCT01964846|Experimental|Resveratrol, curcumin|Subjects will take 2 capsules of resveratrol and curcumin. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
3315274|NCT01964846|Placebo Comparator|Placebo|Subjects will take 2 capsules of Placebo. Thirty (30) minutes later, subjects will be given an oral lipid tolerance test in the form of a fat-rich meal. Blood samples will be collected at different time points.
3315275|NCT01964859|Experimental|autologous skin fibroblasts|we are comparing 3 injection sites in the same individual
3315276|NCT01964872|Experimental|JNJ-38877618|
3315277|NCT01964872|Placebo Comparator|Placebo|
3315278|NCT01964885|Active Comparator|IQP-AS-105|One tablet daily
3315279|NCT01964885|Placebo Comparator|Placebo|One tablet daily
3315280|NCT01964911|Experimental|Ropivacaïne|
3315281|NCT01964937|Experimental|Group 1|"At Months 0 and 1, participants in Group 1 will receive one injection of AIDSVAX B/E ® administered intramuscularly (IM) in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid.~At Months 3 and 6, participants will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
3315282|NCT01964937|Experimental|Group 2|"At Months 0 and 1, participants in Group 2 will receive two injections of NYVAC vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive the AIDSVAX ® B/E vaccine administered IM in the right deltoid and two injections of placebo vaccine administered IM in the left deltoid."
3315283|NCT01964937|Experimental|Group 3|"At Months 0 and 1, participants in Group 3 will one injection of the AIDSVAX B/E vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid.~At Months 3 and 6, participants will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid."
3315284|NCT01964937|Experimental|Group 4|"At Months 0 and 1, participants in Group 4 will receive one injection of the DNA-HIV-PT123 vaccine administered IM in the left deltoid and one injection of placebo vaccine administered IM in the right deltoid.~At Months 3 and 6, participants will receive one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid and one injection of placebo vaccine administered IM the left deltoid."
3315285|NCT01964937|Experimental|Group 5|At Months 0, 1, 3, and 6, participants in Group 5 will receive one injection of the DNA-HIV-PT123 vaccine administered in the left deltoid and one injection of the AIDSVAX B/E ® vaccine administered IM in the right deltoid.
3315286|NCT01964989|Experimental|aQIV|flu vaccine
3315287|NCT01964989|Active Comparator|non-adjuvanted comparator|flu vaccine
3315288|NCT01965015|Experimental|V-Wave shunt implant|Implantation of the V-Wave inter-atrial shunt
3315289|NCT01965028|Experimental|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
3315290|NCT01965041|Experimental|Eyelea, ophthalmic exam, photgraphy|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaCl
3315291|NCT01965054|Experimental|Fish Oil Supplement Group|Receive the daily DHA pill and given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter
3315292|NCT01965054|No Intervention|Control Group|Given a validated Itching Survey to assess maternal symptoms on admission and then weekly thereafter.
3315293|NCT01965080|Experimental|Exemestane|Exemestane 25 mg daily
3315294|NCT01965093||perioperative desaturation|children aged 0-5 years who received general anesthesia and developed perioperative desaturation
3315295|NCT01965093||no perioperative desaturation|children aged 0-5 years who received general anesthesia and did not developed perioperative desaturation
3315296|NCT01965106|Active Comparator|QPI-1007 Injection|single intravitreal (IVT) injection of QPI-1007
3315297|NCT01965106|Sham Comparator|Control|Placebo (Sham injection procedure)
3315298|NCT01965119|Experimental|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
3315299|NCT01965132||Biologic DMARD|Korean patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis who will initiate, restart or switch to a biologic agent (etanercept, adalimumab, infliximab, golimumab, tocilizumab, abatacept, rituximab, ustekinumab, secukinumab)
3315300|NCT01965145|Experimental|Gevokizumab|Solution for subcutaneous injection, Dose 1
3315301|NCT01965145|Placebo Comparator|Placebo|Solution for subcutaneous injection, placebo
3315302|NCT01965184|Experimental|Cognitive-Behavioral Therapy for Anger and Aggressive Behavior|CBT is a behavioral intervention that consists of 12 weekly sessions. During CBT children are taught various skills for coping with frustration and parents are taught various strategies for managing situations that can be anger provoking for their child.
3315303|NCT01965184|Active Comparator|Supportive Psychotherapy (SPT)|SPT consists of 12 sessions that are focused on discussing peer relationships and family functioning with a goal of enhancing subjective well-being
3315304|NCT01965210|Experimental|Rye + high dose inulin + low dose gluten|Rye porridge supplemented with a high dose of the fermentable dietary fibre inulin and low dose of the plant protein gluten.
3315305|NCT01965210|Experimental|Rye + equal doses of inulin & gluten|Rye porridge supplemented with equal doses of the fermentable dietary fibre inulin and the plant protein gluten.
3315306|NCT01965210|Experimental|Rye + low dose inulin + high dose gluten|Rye porridge supplemented with a low dose of the fermentable dietary fibre inulin and a high dose of the plant protein gluten.
3315307|NCT01965210|Experimental|Large non-supplemented rye|Large portion of rye porridge without supplements.
3315308|NCT01965210|Experimental|Small non-supplemented rye|Small portion of rye porridge without supplements.
3315309|NCT01965210|Active Comparator|Refined wheat bread|Refined wheat bread.
3315310|NCT01965223|Experimental|Multi-fraction SABR|Radiotherapy: 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
3315311|NCT01965223|Experimental|Single fraction SABR|Radiotherapy: 28Gy delivered in 1 fraction
3315312|NCT01965236|Experimental|Group 1|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
3315313|NCT01965236|Experimental|Group 2|Patients are given 5 placebo (microcrystalline cellulose) pills per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 pills (1 g per pill) of sodium chloride per day.
3315314|NCT01965249|Active Comparator|Long stitch group|Long stitch suture technique Stitch interval > 10mm; Lateral > 10mm
3315315|NCT01965249|Experimental|Short stitch group|Short stitch technique for AWC stitch interval < 5 mm; Lateral 5 - 8 mm
3315316|NCT01965275|Experimental|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
3315317|NCT01965301|Experimental|BP1.5375|Single oral administration ranging from 0.5 mg to 100 mg
3315318|NCT01965301|Active Comparator|Diphenhydramine|Single oral dose of diphenhydramine 50mg
3315319|NCT01965301|Placebo Comparator|Placebo|Single oral dose
3315320|NCT01965314|Placebo Comparator|Traditional Training Group|These subjects will be offered multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
3315321|NCT01965314|Active Comparator|Simulation Training Group|In addition to traditional training the SG group will participate in a period of simulator based training. Following initial familiarization with the simulator these participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which these participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same simulator.
3315322|NCT01965340|Experimental|Patients with systematic TDM of anti-infective agents|Patients with systematic TDM of anti-infective agents and dosages adapted accordingly
3315323|NCT01965340|No Intervention|Patients treated as usual|
3315324|NCT01965353|Experimental|Panobinostat|"Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.~Bortezomib - subcutaneous injection twice a week during the first two weeks of each 21 day cycle.~Dexamethasone oral dose on the days of and after bortezomib administration during Cycles 1-8, and on days 1, 8 and 15 for Cycles 9 and beyond.~Lenalidomide - oral dose once daily on days 1-14 of each cycle. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle.~Each cycle of treatment will consist of 21 days. Accrual to the next higher dose level will not occur until the safety and tolerability of the prior dose level(s) has been determined at the end of the first cycle"
3315325|NCT01965379|Active Comparator|Intervention|Restriction on food containing phosphorus additives.
3315326|NCT01965379|Placebo Comparator|Control|Standard care.
3315327|NCT01965392|Experimental|healtn education|one group received an educational program
3315328|NCT01965405|Experimental|Phase 1: Standard of Care (A)|Brief counseling and bupropion
3315329|NCT01965405|Experimental|Phase 1: Standard of Care (B)|Brief counseling, bupropion, and brief high-magnitude prize contingency management.
3315330|NCT01965405|Experimental|Phase 2a Non-Responders (A)|Bupropion, continued counseling, monitored support to quit smoking.
3315331|NCT01965405|Experimental|Phase 2a: Non-Responders (B)|Bupropion, monitored support to quit smoking, prize contingency management for abstinence.
3315332|NCT01965405|Experimental|Phase 2b: Responders (A)|Bupropion, no additional treatment.
3315333|NCT01965405|Experimental|Phase 2b: Responders (B)|Bupropion, continued monitoring and low intensity prize contingency management.
3315334|NCT01965418|Active Comparator|Fufang Biejia Ruangan Tablet|Fufang Biejia Ruangan Tablet will be administered to all of subjects in this arm.
3315335|NCT01965418|Placebo Comparator|placebo|placebo of Fufang Biejia Ruangan Tablet
3315336|NCT01965470|Experimental|Combination Prevention|"Scale-up of HTC services during 2 annual HTC campaigns, with a target of >90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.~Scale-up of universal ART for all HIV-infected adults, with a target of >93% of HIV positive adults receiving ART.~Scale-up of retention in care and adherence interventions, with a target of ensuring that >95% of HIV-infected adults are virally suppressed with HIV-1 RNA <400 copies per ML..~Scale-up of linkage to MC services, with a target of ensuring >60% of HIV-negative men are circumcised.~Rapid strengthening of PMTCT services, with a target of >90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery."
3315337|NCT01965470|Active Comparator|Enhanced Care|Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.
3315338|NCT01965483|Experimental|Weekly radiation|once-weekly breast irradiation
3315339|NCT01965496|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 14 weeks
3315340|NCT01965496|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 200 microgram qw for the 10 weeks.
3315341|NCT01965496|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication start form 100 microgram qw for 4 weeks and then increased to 300 microgram qw for the 10 weeks.
3315342|NCT01965509|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 12 weeks
3315343|NCT01965509|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 12 weeks
3315344|NCT01965509|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
3315345|NCT01965522|Experimental|Melatonin and Vitamin D|
3315346|NCT01965522|Experimental|Placebo and Vitamin D|
3315347|NCT01965522|Experimental|Melatonin and Placebo|
3315348|NCT01965522|Placebo Comparator|Placebo and Placebo|
3315349|NCT01965548||Splenic injury|All patients admitted at the University Hospital North Norway Tromsø with a splenic injury following trauma, are included in the study.
3315350|NCT01965574|Experimental|Single arm|
3315351|NCT01965587|Active Comparator|novasure mirena IUS combined|novasure mirena IUS combined therapy
3315352|NCT01965587|Active Comparator|novasure alone|Sole treatment with Novasure
3315353|NCT01965613|Experimental|open label-Xilonix|Open label-Xilonix
3315354|NCT01965626|Active Comparator|Oseltamivir Combining HD-DXM|"Oseltamivir 75 mg twice per day, 10consecutive days~HD-DXM (orally at 40 mg daily for 4d )"
3315355|NCT01965626|Active Comparator|HD-DXM|HD-DXM (orally at 40 mg daily for 4d )
3315356|NCT01965639|Experimental|High Risk group|Extension of Care
3315357|NCT01965678|Experimental|OMT|
3315358|NCT01965691|Experimental|Protein intake|Protein intake- Dietary supplement
3315359|NCT01965704|Experimental|Ondansetron|Pregnant Women: ondansetron 8mg intravenously (IV) within 4 hours of delivery. Neonates: ondansetron 0.07 mg/kg given orally every 24 hours starting 4-8 hours after delivery, for up to 5 days (if IV line available in neonate, ondansetron 0.04 mg/kg IV every 24 hours for up to 5 days).
3315360|NCT01965704|Placebo Comparator|Placebo|"Pregnant Women: placebo given intravenously prior to delivery (volume to mimic the IV volume of the ondansetron group).~Neonates: placebo given orally every 24 hours, starting 4-8 hours after delivery, for up to 5 days with volume to mimic the oral volume of the ondansetron group (if IV line available, placebo may be given IV)."
3315361|NCT01965730|Active Comparator|epsilon-aminocaproic acid (EACA)|75mg/kg loading dose with infusion 15mg/kg/hr
3315362|NCT01965730|Experimental|EACA|125mg/kg loading dose of EACA followed by an infusion of EACA at 25mg/kg/hr for length of cardiac surgery.
3315363|NCT01965743|Other|Contraception Information Packet|Everyone in the study will receive the intervention, which is an information packet designed to facilitate conversations among peers about intrauterine contraception.
3381848|NCT05163938|Experimental|REThink therapeutic game|"Game based Cognitive-Behavioral Therapy: REThink therapeutic game is an online therapeutic game developed by David and collaborators (2018).~The seven levels of the game were developed based on the REBT model and each level trains an ability:~Level 1: identify the emotional reactions, and differentiating between basic emotions, complex emotions, and functional and dysfunctional emotions; Level 2: identify cognitive processes.~Level 3: identify the relation between cognitive processes, emotions, and behavioral reactions; Level 4: change irrational cognitions into rational cognitions; Level 5: build problem-solving skills; Level 6: build relaxation skills; Level 7: consolidate of the previous skills and building happiness skills. A new level will be unlocked once every three days. In order for a level to be unlocked, the previous one must have been completed.~Duration of the intervention: 21 days (a total of seven levels unlocked every three days)"
3381849|NCT05163938|Active Comparator|Treatment as usual|In the treatment as usual group the child/adolescent benefits from a free trial version of the REThink game which means a shorter version of each level of the game.
3381850|NCT05163925||EUROSETS ECMOLIFE SYSTEM|"Thirty consecutive patients that require ECLS and who receive the EUROSETS ECMOLIFE SYSTEM will be included. ECMOLIFE System is a perfusion system enabling operation and monitoring of extracorporeal circulation. ECMOLIFE System operates, powers, controls and regulates ECMOLIFE Centrifugal Pump which represents the disposable blood pump. ECMOLIFE System, when used in combination with ECMOLIFE Centrifugal Pump, is suitable for full or partial cardiac, circulatory and pulmonary support.~ECMOLIFE System is composed by an active programmable console (ECMOLIFE Console), a bearing-less motor driver (ECMOLIFE Motor driver), and sensors for blood parameters detection (flow rate, pressure, temperature, SvO2 and Hb). The console is equipped with an integrated back-up which in case of primary unit failure may be operated in combination with a back-up motor driver and flowmeter (besides, the ECMOLIFE system includes an Heater cooler device)."
3315364|NCT01965769|Experimental|no gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding
3315365|NCT01965769|No Intervention|gastric residual evaluation|Infants will receive routine gastric residual evaluation
3381851|NCT05163912|Experimental|Intervention|Virtual home intervention
3381852|NCT05163899|Active Comparator|Surgery|Filum release
3315366|NCT01965795|Placebo Comparator|Nutrim|"Nutrim will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottle will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
3381853|NCT05163899|No Intervention|Observation|Medical Management only
3381856|NCT05163873|No Intervention|Trans-peritoneal|Surgery technique in the formation of permanent end colostomy
3381857|NCT05163873|Experimental|Extra-peritoneal|Surgery technique in the formation of permanent end colostomy
3381858|NCT05163860||Youth|TGGD youth age 12-17 will answer a survey regarding demographics (gender identity, sex assigned at birth, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism, degree of family conservatism/liberalism, ethnicity), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (ADO-BED, previous Eating Disorder diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (ARQ), adequacy of physical activity (PACE+), bodyweight (BMI, BMI%ile, %mBMI), and previously diagnosed psychiatric and neurodevelopmental disorders
3381859|NCT05163860||Young Adults|TGGD young adults age 18-25 will answer a survey regarding demographics (gender identity, sex assigned at birth, country of residence, ethnicity, age, religion, degree of religiosity, degree of family religiosity, degree of conservatism/liberalism), age at which they revealed their gender identity, family gender environment (FGE), eating disorder risk (SCOFF, ADO-BED, previous ED diagnosis), food insecurity (HVS), perceived support of healthy eating and physical activity (SheL), risk taking behavior (RRBQ), bodyweight (BMI), malnutrition risk (MST), and previously diagnosed psychiatric and neurodevelopmental disorders.
3381860|NCT05163860||Parents|Parents of TGGD youth will answer a survey with information regarding demographics (religion, degree of religiosity, degree of conservatism/liberalism, country of residence, ethnicity, gender identity, sex assigned at birth, sexual orientation, education, marital status, household size, income), anxiety (GAD-7), depression (PHQ-9), family gender environment (FGE), food insecurity (HVS), height and bodyweight (BMI).
3381865|NCT05163834|Experimental|Efgartigimod-1|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 22
3381866|NCT05163834|Experimental|Efgartigimod-2|Weekly efgartigimod infusions and the pneumovax 23 vaccine on day 36
3381867|NCT05163834|Placebo Comparator|Placebo|Weekly placebo infusions and the pneumovax 23 vaccine on day 22
3381868|NCT05163821||Participants|Somali migrants in UK, aged over 50.
3381869|NCT05163808|Active Comparator|Low Dose Arm|Subjects will receive a low dose of BPN14770
3381870|NCT05163808|Active Comparator|High Dose Arm|Subjects will receive a high dose of BPN14770
3381871|NCT05163808|Placebo Comparator|Placebo Arm|Subjects will receive Placebo
3381872|NCT05163782|Experimental|People with foot drop|People with left or right foot drop
3448524|NCT04063501||Advanced stage unresectable Non-Small Cell Lung Cancer|Adult patients with a diagnosis of advanced stage unresectable Non-Small Cell Lung Cancer and indication for PD-1 blockade treatment (either as monotherapy or combined with chemotherapy)
3448525|NCT04063241|No Intervention|Parent: Pre-implementation|Parents in the pre-implementation group will receive standard care: verbal counseling by the doctor/nurse using text-based instructions they have prepared (not standardized).
3448526|NCT04063241|Experimental|Parent: Post-Implementation|Doctors and nurses will be able to customize the web-based disease-specific instructions with the research team's help. They will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.
3448527|NCT04063241|Other|Provider|Baseline measures will be assessed for providers. They will then take part in a 20-minute training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data. At the end of the study, assessments will be performed for those who use the health literacy-informed tool at least once during the study period.
3315367|NCT01965795|Experimental|Whole Coffee Fruit Concentrate (WCFC)|"WCFC is in powder form, and will be capsulated in size 1 gelatin capsules, white and blue, distributed in brown plastic bottles (28 caps/bottle: enough for 14 days of treatment). The first bottle will be provided at the time of randomization, and the second bottle will be provided on day 14 for dosing on days 15-28. The bottles will be labeled with the ABC logo and treatment code.~A dose of 100 mg will be administered twice daily (once before breakfast and again before dinner)."
3315368|NCT01965808|Experimental|LY2157299 (Fasted)|Single dose of 150 mg LY2157299 administered orally in fasted state in one of two study periods.
3315369|NCT01965808|Experimental|LY2157299 (Fed)|Single dose of 150 mg LY2157299 administered orally in fed state in one of two study periods.
3315370|NCT01965821|Other|Continuous control of Pcuff followed by manual control|Patients receive continuous control of cuff pressure with Mallinckrodt electronic device for 24h, followed by discontinuous control (every 8 hours) with a manual manometer for 24h.
3315371|NCT01965821|Other|Manual control of Pcuff followed by continuous control|Patients receive the reverse sequence (manual control followed by continuous control of Pcuff)
3315372|NCT01965847|Active Comparator|AM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to MORNING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
3315373|NCT01965847|Experimental|PM dosing|The study student pharmacist will perform medication therapy management with a focus on antihypertensive medications and specifically on the once daily antihypertensive assigned to EVENING dosing. Medication therapy management will take place in the clinic or by phone. Medication therapy management will include review of antihypertensive medications, patient empowerment and education, and provision of a personal medication record to the participant with specific instructions regarding the once daily antihypertensive medication assigned to morning versus evening. If a patient is taking more than one antihypertensive medication, only one will be used for the current study.
3315374|NCT01965873|Experimental|Enteral nutrition|In the enteral nutrition group a nasojejunal feeding tube will be placed via esophagogastroduodenoscopy and the position confirmed radiographically. Nutritional support will be started within 24 hours of enrollment, supplying daily 105 kJ (25 kcal)/kg, and 1.5 g/kg of protein based on ideal body weight. An elemental product for enteral nutrition will be infused at a rate of 25 ml/h, and increased by 10 ml/h every 6 hours, until the target rate of 100 ml/h will be achieved within 24-48 hours.
3315375|NCT01965873|No Intervention|Nil-by-mouth treatment|The nil-by-mouth treatment consists intravenous fluid replacement according to assessed needs via peripheral veins. This will include crystalloid (0.9% saline and 5% glucose), and colloid (10% hydroxyethyl starch and 3.5% plasma expander - haemaccel) solutions.
3315376|NCT01965886|Active Comparator|Medial approach|Medial parapatellar approach (classic approach)
3315377|NCT01965886|Experimental|Keblish approach|Lateral parapatellar approach (Keblish approach)
3315378|NCT01965925|Experimental|Modafinil|Modafinil will be administered at baseline with a single dose of 100 mg/day QAM increased at week 1 to a single dose 200mg/day QAM. Patients will take drug upon waking with no adjustment in sleep schedule. Dosing will be flexible based on side effects with a maximum dose of 200 mg/day. Subjects will be discontinued if 100mg/day is not tolerated.
3315379|NCT01965925|Placebo Comparator|Placebo|Subjects will take placebo upon waking once per day.
3315380|NCT01965951|Experimental|Experimental Treatment|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
3315381|NCT01965951|Active Comparator|Active Comparator|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
3315382|NCT01965977|Experimental|Bortezomib|bortezomib 1.3mg/m2 subcutaneous on day 1 and15
3315383|NCT01965990||NEP|Patients undergoing the administration of a homemade very low-calorie protein-based formula (2000 mL per day) by enteral route for 14 days
3315384|NCT01966016|Experimental|biventricular pacing|The first configuration will be biventricular pacing (RV and postero-lateral branch of CS for LV pacing), as accepted
3315385|NCT01966016|Experimental|triventricular pacing|The second configuration will be triventricular pacing (RV+ postero-lateral branch of CS for LV pacing+ antero-lateral branch of CS for LV pacing) i.e. multisite LV pacing
3315386|NCT01966029|Experimental|Treatment|All patients receive treatment with BMN 110
3315387|NCT01966055|Experimental|Solithromycin|
3315388|NCT01966081|Other|Cases|
3315389|NCT01966081|Other|controls|
3315390|NCT01966094||HIV+ subjects with HAND|Human immunodeficiency virus (HIV) positive subjects with HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
3315391|NCT01966094||HIV+ subjects without HAND|Human immunodeficiency virus (HIV) positive subjects without HIV-associated neurocognitive disorder (HAND) and either antiretroviral therapy (ART) naïve or ART-experienced off treatment for at least 6 months
3315392|NCT01966133|No Intervention|Control|no interventions were assigned
3315393|NCT01966133|Active Comparator|TACE('Ethiodized Oil + Doxorubicin)|TACE using Ethiodized Oil + Doxorubicin mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4-6 weeks after surgery.
3315394|NCT01966146|Experimental|TAVI|Echocardiography after TAVI
3315395|NCT01966146|Experimental|MitraClip|Echocardiography after MitraClip procedure
3315396|NCT01966172|Experimental|Multimodal|oral Ibuprofen 400mg 4 times daily oral Gabapentin 300mg twice daily oral Paracetamol 1000mg 4 times daily
3315397|NCT01966172|Active Comparator|Morphine|oral Morphine 10mg 4 times daily oral paracetamol 1000mg 4 times daily
3315398|NCT01966185|No Intervention|Tutor function off|The tutor function will be off for 12 out of 12 repeat simulations.
3315399|NCT01966185|Experimental|Tutor function on|The group will have the tutor function on for the 5 first out of 12 repeat simulation sessions.
3315400|NCT01966198|Experimental|all patients|tilt
3381873|NCT05163769|Experimental|Multimodal Physical and Neurocognitive Training|The participants in the Multimodal Physical and Neurocognitive training arm (mBCI) will undergo 48 sessions over 24 weeks (three times a week for the first 12 weeks; once a week for the subsequent 12 weeks; sessions spaced at least one day apart; 1 hour per session) of training on the NeeuroCycle BCI Physical and Cognitive training system. The mBCI training protocol consists of cognitive training modules that will be administered in tandem with a stationary cycling regime. The cognitive training program consists of six different gamified tasks that target attention, immediate/working and delayed memory, decision-making, and visuospatial abilities delivered on an electronic tablet. The cycling regime is divided into seven non-consecutive sections. The participant will be tasked to complete a cognitive training activity that will last about 2-3 minutes between each cycling session. The participant will stop all physical activity before starting on a cognitive training task.
3381874|NCT05163769|Experimental|Neurocognitive-Training only|The participants in the Neurocognitive training-only arm (nBCI) will undergo 48 sessions over 24 weeks (three times a week for the first 12 weeks; once a week for the subsequent 12 weeks; sessions spaced at least one day apart; 1 hour per session) of training on the NeeuroCycle BCI Cognitive training system. Participants in the nBCI arm will undergo the same cognitive training program as the participants in the mBCI arm previously described without participating in the cycling component. They will navigate the virtual space of the cognitive training program by using arrow keys on the tablet instead of paddling on the stationary bicycle.
3381875|NCT05163769|No Intervention|Active Control|The participants in the Active Control arm (AC) will undergo 48 sessions over 24 weeks (three times a week for the first 12 weeks; once a week for the subsequent 12 weeks; sessions spaced at least one day apart; 1 hour per session). Participants in this arm will not undergo any form of training on the NeeuroCycle training system. Instead, they will view informative documentaries on the same tablet as the other two arms and answer related questions.
3315401|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 1|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 1, who were skin test negative at Day 0 and remained negative at Day 132.~Group 1: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered by Intramuscular injection (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
3315402|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 2|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 2, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 2: These subjects will be re-vaccinated with one dose of 2mg Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study. These subjects will receive the same batch vaccine used in Phase 1A."
3381876|NCT05163756|Experimental|DW1903(Test)|once a day, q.d. PO / DW1903 + Placebo of DW1903-R1
3381877|NCT05163756|Active Comparator|DW1903-R1(Reference)|once a day, q.d. PO / Placebo of DW1903 + DW1903-R1
3381878|NCT05163743|Experimental|Ketogenic Diet-obese|LCKD (1200-1400kcal/day) low in carbohydrates (<50g per day) with a moderate protein intake (1-1.5g/kg of ideal body mass) but otherwise no other dietary restrictions. The participants will be counselled by a trained nutritionist at baseline and every two weeks, and compliance will be assessed through a 3-day dietary recall at each follow up visit and capillary beta hydroxybutyrate levels as well as urinary acetoacetate levels. The follow up visits take place at the time of the first vaccine dose, two weeks after the first vaccine dose, one week after the second vaccine dose. Then, gradual reintroduction of carbohydrates will take place following the second vaccine dose.
3381879|NCT05163730|Other|Panbio™ COVID-19/ Flu A&B Rapid Panel|"One nasal swab sample will be collected from both nostrils by operators and will be used to perform the Panbio™ COVID-19/ Flu A&B Rapid Panel test either in a laboratory or in a non-laboratory setting (e.g. GP centre or hospital clinic). Each Panbio™ COVID-19/ Flu A&B Rapid Panel result will be photographed by the observer at the time of test interpretation.~Nasopharyngeal samples will be collected and used for RT-PCR testing as per local procedures.~Nasal samples must always be collected prior to the Nasopharyngeal sampling."
3381880|NCT05163717|Experimental|INP105|POD-olanzapine (INP105), 5 mg, single dose, to be delivered to each participant
3381881|NCT05163717|Placebo Comparator|Placebo|POD-placebo, single dose, to be delivered to each participant
3381882|NCT05163704|Other|MRI Dexmedetomidine sedation|"Drug used: Dexmedetomidine. Given in increments of 0.2 ml at the time with atomizer (MAD Nasal™, Wayne Pennsylvania). Administered by radiology staff.~Dose 1 of nasal dexmedetomidine: 4 mcg/kg max 200 mcg Dose 2 of nasal dexmedetomidine: 2 mcg/kg max 100 mcg"
3381883|NCT05163691|Experimental|Group A - 6 mg single-dose|A single, inhaled dose of GH001 6 mg or placebo (randomized as 8 active and 2 placebo subjects)
3381884|NCT05163691|Experimental|Group B - 12 mg single-dose|A single, inhaled dose of GH001 12 mg or placebo (randomized as 8 active and 2 placebo subjects)
3381885|NCT05163691|Experimental|Group C - 18 mg single-dose|A single, inhaled dose of GH001 18 mg or placebo (randomized as 8 active and 2 placebo subjects)
3381886|NCT05163691|Experimental|Group D - Individualized Dosing Regimen, 1-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 1-hour dose interval (8 subjects)
3381887|NCT05163691|Experimental|Group E - Individualized Dosing Regimen, 2-hour interval|Administration of up to 3 inhaled doses of GH001 within a single day (6 mg, followed by 12 mg, followed by 18 mg) with a 2-hour dose interval (8 subjects)
3381888|NCT05163678||patient group|"All adolescents or young adults presenting for a consultation in the FSEF Relais systems.~They will be assessed upon entry into the device (T0), at the end of the follow-up (T1) and 6 months after the end of the follow-up (T6)."
3381889|NCT05163665|Active Comparator|Through-the-Scope clip group|Standard-of-Care clipping equipment and technique performed in closure of GI defect area after polyp removal.
3381890|NCT05163665|Experimental|X-Tack suturing group|Use of Endoscopic Helix Tacking System (X-Tack) by Apollo Endosurgery for the closure of GI defect after polyp removal.
3448528|NCT04063592|Experimental|Intervention|Subjects undergoing the proposed operative intervention. Intervention patients will serve as their own control for all outcome measures
3381891|NCT05163652|Experimental|3 months after two doses|group 1：the third does was given 3 months after two doses CoronaVac group 2：the third does was given 3 months after two doses BBIBP-CorV group 3：the third does was given 3 months after one does CoronaVac and one does BBIBP-CorV
3381892|NCT05163652|Experimental|4 months after two doses|group 1：the third does was given 4 months after two doses CoronaVac group 2：the third does was given 4 months after two doses BBIBP-CorV group 3：the third does was given 4 months after one does CoronaVac and one does BBIBP-CorV
3381893|NCT05163652|Experimental|5 months after two doses|group 1：the third does was given 5 months after two doses CoronaVac group 2：the third does was given 5 months after two doses BBIBP-CorV group 3：the third does was given 5 months after one does CoronaVac and one does BBIBP-CorV
3381894|NCT05163652|Experimental|6 months after two doses|group 1：the third does was given 6 months after two doses CoronaVac group 2：the third does was given 6 months after two doses BBIBP-CorV group 3：the third does was given 6 months after one does CoronaVac and one does BBIBP-CorV
3381895|NCT05163639|Experimental|1. Uninjured participants - Immediate and lasting effects of non-invasive paired stimulation|Participants will take part in the following to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
3381896|NCT05163639|Experimental|2. Intraoperative participants - Immediate effects of paired stimulation|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery to examine the immediate effects of combining cortical and spinal stimulation: A) Non-invasive pairing of cortical and spinal stimulation; B) Intraoperative pairing of cortical and spinal stimulation.
3381897|NCT05163639|Experimental|3. Intraoperative participants - Lasting effects of SCAP|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP).
3315403|NCT01966224|Experimental|2mg CryJ2-DNA-LAMP plasmid vaccine Group 3|"Healthy male and female subjects 18 to 63 years of age that participated in the previous Phase 1A study, from Group 3, who were skin test positive at Day 0 and remained positive or converted to negative for any JRC-related allergens at Day 132.~Group 3: These subjects will be re-vaccinated with one dose 2mg of Biological/Vaccine: CryJ2-DNA-LAMP plasmid vaccine administered Intramuscularly (IM) approximately 200-250 days after the last of the 4 vaccinations administered under the Phase IA study."
3315404|NCT01966237||Acute kidney injury|AKI defined by an elevation in urinary AKI biomarkers
3315405|NCT01966237||No acute kidney injury|No AKI defined by normal urinary AKI biomarkers
3381898|NCT05163639|Experimental|4. Chronic cervical SCI participants - Lasting effects of non-invasive SCAP|Participants with chronic cervical SCI will take part in the following, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP).
3381899|NCT05163639|Experimental|5. Intraoperative participants - Lasting effects of SCAP at or below myelopathic region|Participants will take part in the following if they have been scheduled for a clinically indicated cervical surgery, to examine the lasting effects of repeated cortical and spinal stimulation: A) Non-invasive repeated pairing of cortical and spinal stimulation (SCAP); B) Intraoperative repeated pairing of cortical and spinal stimulation (SCAP) at or below myelopathic region.
3381900|NCT05163626|Experimental|Combined aerobic exercise and cognitive training program|
3381901|NCT05163626|No Intervention|Standard health counseling at baseline|
3315406|NCT01966250|Experimental|Electroacupuncture and Usual care|15 minutes of electroacupuncture and usual care. Usual care contains 15 minutes ICT(Interferential Current Therapy), 10 minutes hot pack or ice pack and education of patients.
3315407|NCT01966250|Active Comparator|usual care|15 minutes ICT, 10 minutes hot pack or ice pack and education of patients
3315408|NCT01966263|Active Comparator|Local Infiltration Analgesia (LIA)|local infiltration analgesia is an anesthetic technique that consists of the infiltration of operated tissue with a long acting local anesthetic during surgery to achieve postoperative pain relieve. In this study LIA of the knee will exist of: 1. local infiltration analgesia (LIA) of the posterior capsule of the knee, 2. LIA of the anterior capsule of the knee and 3. LIA of the subcutaneous tissue of the knee
3315409|NCT01966263|Active Comparator|Femoral Nerve Block (FNB)|"a femoral nerve block is an anaesthetic technique that consists of anesthetizing the femoral nerve proximal of the operating area to achieve numbness distal of the block puncture site. A catheter can be placed, so the nerve can be anesthetized continuously or repeatedly for post-operative pain relieve.~In this study the FNB with catheter will be combined with local infiltration analgesia (LIA) of the posterior capsule of the knee"
3315410|NCT01966276|Experimental|Methyl-P plus Nutrient Formula|"Methylphenidate hydrochloride plus a CFS Nutrient Formula, both taken twice daily.~The CFS Nutrient Formula is a broad-spectrum CFS-specific dietary supplement that provides CFS patients with cellular fuel and cofactors (amino acids, antioxidants, and mitochondrial cofactors) while the low-dose CNS stimulant (methylphenidate hydrochloride) provides a metabolic catalyst to enhance cellular metabolism."
3315411|NCT01966276|Placebo Comparator|Methyl-P plus Nutrient matched placebos|Methylphenidate matched placebo + CFS Nutrient Formula matched placebo, both taken twice daily.
3315412|NCT01966289|Experimental|Cohort 1:CY/GVAX concurrently with SGI-110|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2, the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 Granulocyte macrophage-colony stimulating factor (GM-CSF) secreting cells, and SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3315413|NCT01966289|Experimental|Cohort 2: CY/GVAX after SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2, Cyclophosphamide (CY) is administered on Day 8 at 200 mg/m2, and the colon cancer tumor vaccine (GVAX) is administered on Day 9 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3315414|NCT01966289|Experimental|Cohort 3: CY/GVAX|During each of the four cycles, Cyclophosphamide (CY) is administered on Day 1 at 200 mg/m2 and the colon cancer tumor vaccine (GVAX) is administered on Day 2 at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3315415|NCT01966289|Experimental|Cohort 4: SGI-110|During each of the four cycles, SGI-110 is administered on Days 1-5 at 60 mg/m2. Each cycle is 28 days. Enrollment will begin first in Cohort 1 and 2. If a response to the treatment is seen in Cohorts 1 and 2, enrollment in Cohort 3 and 4 will begin.
3315416|NCT01966302|Experimental|Beraprost open label|Compassionate use access to open label BPS-314d-MR
3315417|NCT01966315||Dexmedetomidine group|"Dexmedetomidine group is the patients who sedated with dexmedetomidine in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of dexmedetomidine will be 0.2-0.7ug/kg/hr."
3315418|NCT01966315||Midazolam group|"Midazolam group is the patients who sedated with midazolam in intensive care unit. We will randomly allocate using www.randomizer.org.~They will sedate at the level of RASS -2. The dose of midazolam will be 0.05-0.1 mg/kg/hr."
3315419|NCT01966328|Experimental|36% Resolvine|Patients in this arm will be given one dose of 36% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
3315420|NCT01966328|Active Comparator|9% Resolvine|Patients in this arm will be given one dose of 9% Resolvine intravitreal injection, with the possibility of a second dose at Day 30
3315421|NCT01966341|Active Comparator|Routine Management|All patients will be given a prescription for the use of antispasmodics. If patients demonstrate symptoms consistent with constipation predominant IBS they will be treated with laxatives. If symptoms are more consistent with diarrhea predominant IBS they will be treated with bulking agents (fiber) +/- antibiotics. Patient will be called every week while enrolled in the study in order to titrate doses, and answer questions.
3315422|NCT01966341|Experimental|CBT/ Hypnotherapy|The CBT (cognitive behavior therapy) program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
3315423|NCT01966367|Experimental|CliniMACS PLUS followed by chemotherapy|"Patients will receive a pre-transplant conditioning regimen of Busulfan Fludarabine and Alemtuzumab. For patients with pre-transplant hepatic dysfunction, Melphalan will be substituted for the Busulfan. For patients receiving a second transplant or a boost, pre-transplant conditioning based on the clinical condition of the patient will be determined by the Principal Investigator and the patient's bone marrow transplantation (BMT) physician. The donor peripheral blood stem cells will undergo CD34+ selection (Biological/Vaccine: CD34 Stem Cell Selection Therapy). The CliniMACS (PLUS) Reagent System will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD)."
3315424|NCT01966393|Active Comparator|Dual-hormone closed-loop strategy|In dual-hormone closed-loop strategy, variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels
3315425|NCT01966393|Active Comparator|Single-hormone closed-loop strategy|In single-hormone closed-loop strategy, variable subcutaneous insulin infusion rate will be used to regulate glucose levels
3315426|NCT01966393|Active Comparator|Conventional insulin pump therapy|In control visit, subjects will use conventional pump therapy to regulate glucose levels.
3315427|NCT01966406|Experimental|No nasogastric tube insertion before pancreaticoduodenectomy|The patients receiving pancreaticoduodenectomy will not undergo NG tube insertion before operation
3315428|NCT01966406|Active Comparator|Pre-operative NG tube use|The patients receiving pancreaticoduodenectomy will undergo NG tube insertion before operation
3315429|NCT01966471|Active Comparator|Anthracycline Followed by Trastuzumab, Pertuzumab, and Taxane|Trastuzumab and pertuzumab will be administered concurrently for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) with the taxane (docetaxel or paclitaxel) component of chemotherapy following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
3315430|NCT01966471|Experimental|Anthracycline Followed by Trastuzumab Emtansine and Pertuzumab|Trastuzumab emtansine and pertuzumab will continue for up to a total duration of 1 year (up to 18 cycles [1 Cycle = 21 days]) following anthracycline [5 fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin and cyclophosphamide (EC) or doxorubicin and cyclophosphamide (AC)] based chemotherapy.
3315431|NCT01966484|Active Comparator|Succinylcholine|Patient receive succinylcholine as a muscle relaxant (0,5mg/kg) after induction of general anaesthesia for rigid bronchoscopy.
3315432|NCT01966484|Active Comparator|Mivacurium|Patients receive mivacurium (0,08mg/kg) as a muscle relaxant after induction of general anaesthesia for rigid bronchoscopy. At the end of the procedure and a twitch of 25% mivacurium was reversed with neostigmine (50 microg/kg) and atropin (10 microg/kg)
3315433|NCT01966497||Core study therapy|"idarubicin for both induction and consolidation courses~if Cr, two cycles of IDAC alone (1.5g/m2 per infusion every 12hours, on D1, 3 and 5 of each cycle)"
3315434|NCT01966510|Experimental|Cord blood transplantation|Two cord blood units containing both together more than 3x10^7 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients.
3315435|NCT01966523|Experimental|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
3315436|NCT01966523|Other|Usual Care|Residents will receive usual care for infections
3315437|NCT01966536|Experimental|Poor ovarian reserve|Autologous transplantation of CD133+ cells into ovarian artery
3315438|NCT01966549|Experimental|CNTO 6785|
3315439|NCT01966549|Placebo Comparator|Placebo|
3315440|NCT01966562|Experimental|WBV TRAINING|WHOLE-BODY VIBRATION TRAINING
3315441|NCT01966562|Active Comparator|MC TRAINING|MULTICOMPONENT TRAINING
3315442|NCT01966562|No Intervention|CG|Control group
3315443|NCT01966575|Experimental|No withdrawal bleed|No progestin prior to ovulation induction with clomiphene citrate
3315444|NCT01966575|No Intervention|Withdrawal Bleed|Progestin prior to beginning ovulation induction with clomiphene citrate (standard care)
3315445|NCT01966588||Metabolic Arm|Blood samples for whole genomic/transcriptomic sequencing; administration of the UKU Side Effect Rating Scale.
3315446|NCT01966588||Neutropenia/Immune System Arm|Blood samples for whole genomic/transcriptomic sequencing
3315447|NCT01966601|Experimental|TRV027 dose #1|TRV027 dose #1 via continuous IV infusion
3315448|NCT01966601|Experimental|TRV027 dose #2|TRV027 dose #2 via continuous IV infusion
3315449|NCT01966601|Experimental|TRV027 dose #3|TRV027 dose #3 via continuous IV infusion
3315450|NCT01966601|Placebo Comparator|Placebo|Placebo via continuous IV infusion
3315451|NCT01966614|Experimental|PRX302|PRX302 injection
3315452|NCT01966614|Placebo Comparator|Placebo|Placebo (Vehicle-only injection)
3315453|NCT01966627||Pediatric NAFLD Cohort|Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
3315454|NCT01966640|Experimental|Child food allergy suspicion|Basophil Activation Test realized in case of Child food egg and peanut allergy suspicion
3315455|NCT01966653|Active Comparator|nitrofurantoin|Nitrofurantoin will be given orally at a dose of 100 mg three times daily for 5 days.
3315456|NCT01966653|Active Comparator|fosfomycin|A single 3g dose of oral fosfomycin will be given.
3315457|NCT01966666|Experimental|TPI-287 low dose|2 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3315458|NCT01966666|Experimental|TPI-287 moderate dose|6.3 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3315459|NCT01966666|Experimental|TPI-287 high dose|20 mg/m2 of TPI-287 administered as a 1-hour intravenous infusion once every 3 weeks for 9 weeks (for a total of 4 infusions)
3315460|NCT01966666|Placebo Comparator|Placebo|
3315461|NCT01966679|Active Comparator|Double-blind (active versus placebo)|AZD7325 versus placebo
3315462|NCT01966679|Placebo Comparator|Placebo|
3315463|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 1|"Fluticasone Propionate Drug formulation 1 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3315464|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 2|"Fluticasone Propionate Drug formulation 2 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3315465|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3|"Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose.~See Formulation Development in Detailed Description for details regarding differences in formulations"
3315466|NCT01966692|Active Comparator|Fluticasone Propionate Formulation 3*|Fluticasone Propionate Drug formulation 3 administered via Plastiape Monodose Dry powder Inhaler , 500mcg single dose. * (The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation.
3315467|NCT01966705|Experimental|Therapist-guided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, supported self-help
3315468|NCT01966705|Experimental|Unguided Internet-based Cognitive Behavior Therapy|Cognitive Behavior Therapy delivered via the Internet: 12 weeks, self-help only
3315469|NCT01966705|Experimental|Cognitive Behavior Therapy-based bibliotherapy|Cognitive Behavior Therapy delivered in book form: 12 weeks, self-help only
3315470|NCT01966705|No Intervention|Waiting-list condition|No intervention: 12 weeks
3315471|NCT01966744||Clinicians/Nurses|Clinicians and nurses who treat patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3315472|NCT01966744||Patients|Patients age 11-18 years diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3315473|NCT01966744||Caregivers|Caregivers of patients diagnosed with IBD will be recruited to interact with and use the SMART portal to provide feedback on optimization.
3315474|NCT01966757||Neuronal ceroid lipofuscinosis patients|Caregiver of patient with NCL to provide information regarding patient's sleep habits
3315475|NCT01966783|Experimental|Budesonide dosage 1|Budesonide 2 mg suppository
3315476|NCT01966783|Experimental|Budesonide dosage 2|Budesonide 4 mg suppository
3315477|NCT01966783|Active Comparator|Mesalazine|Mesalazine 1g suppository
3315478|NCT01966783|Experimental|Combination|Budesonide 2 mg suppository/Mesalazine 1 g suppository
3315479|NCT01966822|Experimental|Dolutegravir 50mg|Dolutegravir 50mg every 24 hours + Kivexa (ABC+3TC)
3315480|NCT01966822|Active Comparator|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir + Kivexa (ABC+3TC)
3315481|NCT01966835|Experimental|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
3315482|NCT01966835|No Intervention|control group|no exercise intervention
3315483|NCT01966848|Active Comparator|Vanguard CR|Patients will receive the posterior cruciate retaining Vanguard CR prosthesis
3315484|NCT01966848|Active Comparator|Vanguard XP|Patients will receive the bi-cruciate retaining Vanguard xp prosthesis
3315485|NCT01966861|No Intervention|usual care|Weaning as protcolised by the units' daily practice (SBT)
3315486|NCT01966861|Experimental|Weaning guided by lung ultrasound|Predictive early signs of respiratory distress are assessed by lung ultrasound and if found will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis)
3315487|NCT01966874||Study population|"All study participants will receive 200 mg of the mifepristone product Zacafemyl, followed 24-48 hours later by 800 mcg of misoprostol."
3315488|NCT01966887|Experimental|MYDICAR-single intracoronary infusion|Genetic / AAV1 Serca2a (MYDICAR)
3315489|NCT01966887|Placebo Comparator|Placebo; single intracoronary infusion|Placebo comparator
3315490|NCT01966913|Experimental|bevacizumab|"Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:~A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.~The ICE chemotherapy regimen:~Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,~Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,~Ifosfamide, 2400 mg/m²/d,~For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle"
3315491|NCT01966939||Surgery|Craniotomy or Craniectomy
3315492|NCT01966939||Control|age, gender and teeth condition matched
3315493|NCT01966952||Resistant Hypertension|Resistant hypertension as described as; patients with uncontrolled hypertension on 3 or more antihypertensive medications with no secondary causes for hypertension (i.e. hyperaldosteronism, renal artery stenosis)
3315494|NCT01966965|Experimental|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
3315495|NCT01966965|Active Comparator|NEDAX|FOLLOWING THE LEAFLET TREATMENT
3315496|NCT01966991||Surveyed DNAFirst users|Women who opted for DNAFirst testing and who provided written permission (attested by signature and provision of telephone number)for DNAFirst Study staff to telephone them and conduct a brief telephone survey about their experiences.
3315497|NCT01967004|Experimental|Functional Assessment|Participant will be asked to perform a series of tasks involving their prosthesis. These tasks can involve switching grips as well as moving objects.
3315498|NCT01967017|Experimental|Lidocaine|Paracervical block using 15 mL of 1 % lidocaine
3315499|NCT01967017|Placebo Comparator|Placebo|paracervical block using 15 mL of bacteriostatic saline
3315500|NCT01967030||Women with recent GDM pregnancy|The study cohort includes women who had gestational diabetes mellitus (GDM) in their index pregnancy for study enrollment. There are two pre-defined groups: 1) women who breastfeed intensively during the first 4 months postpartum, and 2) women who mostly fed formula during the first 4 months postpartum. The study enrolled women into these pre-defined groups, but some women transitioned into mixed feeding groups after enrollment.
3315501|NCT01967043|Experimental|Oraxol Arm 1|"HM30181AK-US tablet administered as a single oral dose of xmg on Days x, y, and z of each cycle~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
3315502|NCT01967043|Experimental|Oraxol Arm 2|"HM30181AK-US tablet administered as a single oral dose of xmg daily with each dose of Paclitaxel~Paclitaxel administered as a fixed oral daily dose of xmg (nine xmg capsules) starting on Days x, y, and z of each cycle. Depending on the cohort, subjects will receive 2, 3, 4, or 5 consecutive days of paclitaxel per week."
3315503|NCT01967082|Experimental|Prevention (focus group, APPSPIRE app, survey)|Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
3315504|NCT01967095|Experimental|erlotinib|"This protocol is a phase 1, single arm, open label study of combination daily low dose erlotinib plus twice weekly high dose erlotinib in patients with EGFR-Mutant lung cancer who have not yet received erlotinib or gefitinib. Six dose levels are planned for escalation, with the pulse dose erlotinib increasing.~Expansion cohort A: Treat an additional 19 pts at the MTD with CNS involvement at diagnosis"
3315505|NCT01967108|Experimental|chest physiotherapy|chest physiotherapy in patient's bed, including deep breathing, directed cough, arm movment and more.
3315506|NCT01967108|No Intervention|control group|This patients will not recive chest physiotherapy after extubation, unless developing respiratory deterioration
3315507|NCT01967160||XGEVA inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with XGEVA at any time during the treatment cohort identification period
3315508|NCT01967160||Zoledronic acid inception cohort|Patients with cancer who are naïve to oral or IV bisphosphonate treatment at the dose indicated for SRE prevention and who begin treatment with IV zoledronic acid at any time during the treatment cohort identification period
3315509|NCT01967160||XGEVA-switch cohort|Patients with cancer who switch to XGEVA during treatment cohort identification period after having started antiresorptive therapy at the dose indicated for SRE prevention of no more than 2 years duration with bisphosphonates (<24 IV infusions or <24 monthly oral prescriptions)
3315510|NCT01967186|Experimental|Intraportal islet transplantation|Subject randomized to the protocol with intraportal islet transplantation and kidney transplantation
3315511|NCT01967186|Experimental|Intramuscular islet transplantation|Subject randomized to the protocol with intramuscular islet transplantation and kidney transplantation
3315512|NCT01967186|Experimental|Intramuscular transpl with stemcells|Subject randomized to the protocol with intramuscular islet transplantation and where islets have been incubated autologous mesenchymal stemcells. Will also receive kidney transplant
3315513|NCT01967186|Active Comparator|Kidney transplantation only|Subject that only undergoes kidney transplantation
3315514|NCT01967199|Active Comparator|Drug Eluting Stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
3315515|NCT01967199|Experimental|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
3315516|NCT01967212|Experimental|Game-based swallow biofeedback|swallowing training combined with game-based biofeedback in stroke dysphagia patient.
3315517|NCT01967212|Active Comparator|Swallow training without biofeedback|
3315518|NCT01967238|Active Comparator|Biologic/Vaccine, Age 18-64 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3315519|NCT01967238|Active Comparator|Biologic/Vaccine, Age 65-80 cohort|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3315520|NCT01967238|Active Comparator|Vaccine, healthy adults|Vaccination. IM Pneumococcal, meningococcal, or flu vaccine
3315521|NCT01967251|Experimental|Udenafil 25 mg|Udenafil 25 mg, tablets, orally, once daily for 12 weeks.
3315522|NCT01967251|Experimental|Udenafil 50 mg|Udenafil 50 mg, tablets, orally, once daily for 12 weeks.
3315523|NCT01967251|Experimental|Udenafil 75 mg|Udenafil 75 mg, tablets, orally, once daily for 12 weeks.
3315524|NCT01967251|Placebo Comparator|Placebo|Udenafil placebo-matching tablets, orally, once daily for 12 weeks.
3315525|NCT01967264|Experimental|Udenafil 150 mg + Udenafil 150 mg|Udenafil 150 mg, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
3315526|NCT01967264|Experimental|Udenafil 150 mg + Placebo|Udenafil 150 mg, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
3315527|NCT01967264|Experimental|Placebo + Udenafil 150 mg|Placebo, tablet, orally, once on Day 1, followed by udenafil 150 mg, tablet, orally, once on Day 3.
3315528|NCT01967264|Placebo Comparator|Placebo + Placebo|Placebo, tablet, orally, once on Day 1, followed by placebo, tablet, orally, once on Day 3.
3315529|NCT01967290|Experimental|Hand-to-mouth task - vibratory feedback|Hand-to-mouth task under vibratory feedback and 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis and provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed a vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
3315530|NCT01967290|Active Comparator|Hand-to-mouth task - no vibratory feedback|Hand-to-mouth task in the same conditions as the experimental arm but without vibratory feedback, only 3D movement analysis. The SWORD device is in place over the patient arm, performs continuous 3D movement analysis but does not provides vibratory feedback according to quality performance settings established by the clinician after patient assessment. If movement is of lower amplitude or slower than prescribed NO vibratory stimulus is delivered at the wrist of the patient. The intervention is repeated on the hemiparetic and normal sides and the duration of the task is defined according to the patient cardiovascular status.
3315531|NCT01967303||Patients with stroke or transient ischemic attack|Interview regarding restless legs syndrome
3315532|NCT01967303||Subjects without stroke or transient ischemic attack|Interview regarding restless legs syndrome
3315533|NCT01967329|Active Comparator|Standard Triple, treatment naive|"Standard Triple Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik"
3315534|NCT01967329|Active Comparator|Sequential, treatment naive|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to treatment naive participants in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3315535|NCT01967329|Active Comparator|Quadruple, treatment naive|"Quadruple Thearpy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to treatment naive participants in Old Crow, Tuktoyaktuk & Fort McPherson"
3315536|NCT01967329|Active Comparator|Sequential, previous failure(s)|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants who previously failed one or more treatments in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3315537|NCT01967329|Active Comparator|Quadruple, previous failure(s)|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants who previously failed treatment in Aklavik, Old Crow, Tuktoyaktuk & Fort McPherson"
3315538|NCT01967329|Active Comparator|Sequential, clarithromycin-resistant|"Sequential Therapy for H. pylori:~Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
3315539|NCT01967329|Active Comparator|Quadruple, clarithromycin-resistant|"Quadruple Therapy for H. pylori:~Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily~One of two treatments randomly assigned to participants with known clarithromycin resistance in Aklavik"
3315540|NCT01967355|Experimental|Lipid apheresis|Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.
3315541|NCT01967368|Experimental|Intanza|intradermal injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Intanza, single dose injection
3315542|NCT01967368|Active Comparator|Vaxigrip|intramuscular injection (15ug hemagglutinin 2013/2014 trivalent influenza vaccine) delivered with the Vaxigrip, single dose injection
3315543|NCT01967381|Placebo Comparator|Arm 1|Subjects will be maintained on oral placebo.
3315544|NCT01967381|Experimental|Arm 2|Subjects will be maintained on oral oxazepam (Serax®).
3315545|NCT01967381|Experimental|Arm 3|Subjects will be maintained on oral naltrexone (Revia®).
3315546|NCT01967381|Experimental|Arm 4|Subjects will be maintained on oral naltrexone (Revia®) and oral oxazepam (Serax®).
3315547|NCT01967394|Experimental|Intervention County|Use of internet based social marketing intervention
3315548|NCT01967394|Placebo Comparator|Control County|No use of social media
3315549|NCT01967407|Experimental|renal tumor <4cm, suspected RCC|Intervention/ Time point: Irreversible Electroporation at day 0 of each patient.
3315550|NCT01967420|Experimental|Cognitive remediation plus social cognition training|A combined intervention of 60 minutes of computerised cognitive remediation and 30 minutes of computerised social cognition training.
3315551|NCT01967420|Active Comparator|Cognitive remediation alone|An active control condition consisting of 60 minutes of computerised cognitive remediation and 30 minutes of free computer time.
3315552|NCT01967459|Active Comparator|High dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 300 000 IU, in the form of 3 ml D-cura drink 100 000 IU/ml
3315553|NCT01967459|Active Comparator|Low dose vitamin D|Volunteers assigned to this arm will receive a single dose of oral cholecalciferol 75000 IU, in the form of 3 ml D-cura drink 25 000 IU/ml
3315554|NCT01967472|Active Comparator|co-formulated Amodiaquine-Artesunate|"Sanofi Coarsucam Infant dose (2-12 months/4.5-8kg), amodiaquine:67.5mg/artesunate 25mg; 1 tablet once a day for 3 days.~Sanofi Coarsucam Young Child (13-59 months/9-17kg), amodiaquine: 136mg/artesunate 50mg; 1 tablet once a day for 3 days."
3315555|NCT01967472|Active Comparator|artemether-lumefantrine|"Novartis coartem infant dose (2-11 months/5-14kg), artemether 20mg/lumefantrine 120mg; 1 tablet twice a day for 3 days.~Novartis coartem child dose (12-59 months/15-24kg), artemether 20mg/lumefantrine 120mg; 2 tablets twice a day for 3 days"
3315556|NCT01967485|Experimental|Text Messaging|Text messaging to the parents of children. Children will receive open treatment for Attention Deficit/Hyperactivity Disorder (ADHD) with stimulant medication.
3315557|NCT01967485|Active Comparator|No Text Messaging|Children will receive open treatment for ADHD with stimulant medication. This group will not get the text messaging intervention, but will receive treatment as usual.
3315558|NCT01967498|Experimental|montelukast|this arm will receive montelukast as the active intervention of the study
3315559|NCT01967498|Placebo Comparator|placebo|
3315560|NCT01967511||FMD subjects|patients who fulfill standard diagnostic criteria for FMD
3315561|NCT01967511||SCAD subjects|patients who fulfill standard diagnostic criteria for SCAD
3315562|NCT01967511||CvAD subjects|patients who fulfill standard diagnostic criteria for CvAD
3315563|NCT01967511||Healthy control subjects|
3315564|NCT01967524|Experimental|botulinum toxin A + ropivacaïne|
3315565|NCT01967524|Active Comparator|Ropivacaïne|
3315567|NCT01967589|Experimental|DC (dosing condition)|Escalation design.
3315568|NCT01967589|Experimental|Oral A|Escalation design. Planned end-dose is 5 mg.
3315569|NCT01967589|Experimental|Oral B|Escalation design. Planned end-dose is 10 mg.
3315570|NCT01967589|Experimental|Oral C|Escalation design. Planned end-dose is 20 mg.
3315571|NCT01967654|Experimental|Technical assistance, training, plus clinical reminder system|To assess the contextual factors of the intervention settings (district level policies and organizational level characteristics) that may influence tobacco use treatment in CHCs and to inform additional modifications to the proposed implementation strategies.
3315572|NCT01967654|Experimental|TTC + referral to community health workers|To compare the effectiveness and cost effectiveness of two multi component implementation strategies.
3315573|NCT01967667|Experimental|Liposomal glutathione|dose steps
3315574|NCT01967667|Placebo Comparator|Placebo|dose steps
3315575|NCT01967680|Active Comparator|Sedation with daily wake-up trial|The control group is sedated with continuous infusion to Ramsay score 3-4. During daytime, the patient is awakened as the intravenous infusion of sedatives is discontinued. After a successful wake-up, the infusion of sedative is resumed, starting on half of the pre-wake-up dose. If the patient becomes uncomfortable or agitated during the awakening, sedation is resumed, again starting with half the dosage. The infusion of sedatives is then adjusted to Ramsey score 3-4.
3315576|NCT01967680|Experimental|Non-sedation|"This group will not receive sedatives. Patients are thoroughly and repeatedly informed by the staff of where they are, what have happened, and what type of treatment they are going to receive.~Participants in the non-sedated group are awake and have a natural sleep rhythm. In case these patients develop and outward delirium, it is necessary to have a nurse or other caregiver at the bedside in order to calm the patient. Patients with delirium are treated with haloperidol according to the U.S. guidelines, 2002 and the Danish national guidelines.~If, despite these measures, it is necessary to sedate an agitated patient more than twice, or where sedation might be necessary to ensure sufficient oxygenation or prone position, the patient is sedated and treated like the control-group. Every day during the wake-up trial it is evaluated whether the patient is able to continue the intervention of non-sedation."
3315577|NCT01967745||laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars, placed in the periumbilical area, right midabdomen, and forceps.
3315578|NCT01967745||open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
3315579|NCT01967758|Experimental|Cohort 1|Patients in Cohort 1 will receive ADU-623 at a dose of 3 x 10^7cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3315580|NCT01967758|Experimental|Cohort 2|Patients in Cohort 2 will receive ADU-623 at a dose of 3 x 10^8cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3315581|NCT01967758|Experimental|Cohort 3|Patients in Cohort 3 will receive ADU-623 at a dose of 3 x 10^9cfu by intravenous infusion (IV) over 2 hours on Day 0, Day 21, Day 42, and Day 63. Each dose is followed by a 3-day course or antibiotics. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
3381902|NCT05163613|Experimental|Patients hospitalized due to PCR-confirmed SARS-Cov-2 infection.|Patients hospitalized due to PCR-confirmed SARS-Cov-2 infection, who were treated with magnetostimulation in addition to a standard therapy. In the study groups, the patients were subjected to magnetic field - magnetostimulation with the use of apparatus Viofor JPS System. The control group included patients receiving a comprehensive treatment without magnetostimulation.
3381903|NCT05163600|Experimental|COPD|Diagnosed COPD according to GOLD-guidelines
3381904|NCT05163600|Experimental|Healthy|Age ≥ 18 years Clinically healthy
3381905|NCT05163587|Placebo Comparator|Control|control group will be provided with the commercially available whole-wheat flour for their consumption during the study period.
3381906|NCT05163587|Experimental|Intervention|intervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day.
3381907|NCT05163574|Experimental|High dose|20 patients
3381908|NCT05163574|Active Comparator|Low dose|20 patients
3381909|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot A
3315582|NCT01967771|Experimental|DTG/CBZ|All subjects will be assigned to a single-sequence of three treatment periods without washout. Subjects will receive DTG 50 mg once daily (OD) for 5 days (Period 1), followed by CBZ 100 mg twice daily (BID) for 3 days (days 1-3 of Period 2), CBZ 200 mg BID for 3 days (days 4-6 of Period 2), CBZ 300mg BID for 10 days (days 7-16 of Period 2), followed by DTG 50 mg OD in combination with CBZ 300mg BID for 5 days (Period 3).
3315583|NCT01967797|Experimental|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
3381910|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot B
3381911|NCT05163561|Experimental|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C|SII Inactivated Salk Polio Vaccine (Adsorbed) Lot C
3315584|NCT01967797|No Intervention|Control|Though the controls will have knowledge of the '5A's of Obesity Management', they will not be receiving 5As Team Intervention.
3315585|NCT01967810|Experimental|Arm 1|ANG1005 administered to bevacizumab-naive recurrent GBM participants
3315586|NCT01967810|Experimental|Arm 2|ANG1005, with or without bevacizumab, administered to bevacizumab-refractory recurrent GBM participants
3381912|NCT05163561|Active Comparator|Sii Licensed IPV|Sii Licensed IPV
3381913|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 1200 mg, 1200 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 1200 mg, 1200 mg) during daily therapy with 2NRTIs for 12 weeks
3381914|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 900 mg, 900 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 900 mg, 900 mg) during daily therapy with 2NRTIs for 12 weeks
3381915|NCT05163535|Experimental|VM-1500A-LAI (1200 mg, 600 mg, 600 mg)|VM-1500A-LAI 3 i / m injections with an interval of 4 weeks (1200 mg, 600 mg, 600 mg) during daily therapy with 2NRTIs for 12 weeks
3381916|NCT05163535|Other|ELPIDA®|ELPIDA®, 20 mg capsules and 2NRTIs, daily therapy for 12 weeks
3381917|NCT05163522|Experimental|Part 1 (SAD): Participants receiving VH4004280|
3381918|NCT05163522|Placebo Comparator|Part 1 (SAD): Participants receiving placebo|
3381919|NCT05163522|Experimental|Part 2 (MAD): Participants receiving VH4004280|
3381920|NCT05163522|Placebo Comparator|Part 2 (MAD): Participants receiving placebo|
3381921|NCT05163509|Experimental|MR-Linac Guided Adaptive Radiotherapy|Patients will receive Adaptive Radiotherapy on the MR-Linac treatment machine.
3315587|NCT01967810|Experimental|Arm 3|ANG1005 administered to recurrent WHO Grade III anaplastic glioma participants
3315588|NCT01967823|Experimental|1/Cyclophosphamide & Fludarabine + Anti-ESO murine TCR transduced PBL + HD Aldesleukin|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + anti-ESO murine T-cell receptor (TCR) transduced PBL + high-dose (HD) aldesleukin
3315589|NCT01967849|Other|Obese/overweight chldren/adolescents|Obese or overweight children and adolescents between ages 7-21 that are at risk for developing type 2 diabetes will undergo an Oral Glucose Tolerance test (OGTT) to asses glucose status.
3315590|NCT01967849|Other|Lean children/adolescents|Lean children/adolescents between the ages of 7-21. This cohort should have family members that have type 2 diabetes or was the result of a gestational diabetes pregnancy. They will undergo an Oral Glucose Tolerance Test to assess glucose status.
3315591|NCT01967875|Active Comparator|H-A: ERCC1 High Expression Group A|XP：Capecitabine+Cisplatin
3315592|NCT01967875|Experimental|H-B: ERCC1 High Expression Group B|DX：Docetaxel+Capecitabine
3315593|NCT01967875|Active Comparator|L: ERCC1 Low Expression Group|XP：Capecitabine+Cisplatin
3315594|NCT01967901|Active Comparator|Sequence: ABBA A=usual care, B=self-care|"The usual care consists of patients' follow up by their usual nephrologist and endocrinologist or general practitioner.~Self-care management consists of a the addition of a multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.~In this sequence, patients will receive the usual care for 3 months. Then, they will cross-over to receive a multidisciplinary self-management for the following 6 months and then cross-over to a 3 months of usual care."
3315595|NCT01967901|Active Comparator|Sequence BAAB|Patients will receive the multidisciplinary self-management program for 3 months. Then, they will cross-over to usual care for the following 6 months and then cross-over to 3 months of multidisciplinary self-management
3315596|NCT01967901|Active Comparator|Sequence AABB|Patients will receive the usual care for two periods of three months, then they will cross-over to a period of 6 months of a multidisciplinary self-management
3315597|NCT01967901|Active Comparator|Sequence BBAA|Patients will receive the multidisciplinary self-management for two periods of three months, then they will cross-over to a period of 6 months of usual care.
3315598|NCT01967914||Women undergoing cesarean delivery under spinal anesthesia|
3315599|NCT01967927|Experimental|GRID 18F-MISO|
3315600|NCT01967953|No Intervention|Standard Group|"Recipients of lungs procured from brain death donors deemed suitable for transplantation according to standard criteria.~Events: lung procurement, cold storage on ice, transplantation."
3315601|NCT01967953|Experimental|EVLP Group|"Recipients of marginal lungs procured from brain death donors and reconditioned with ex-vivo lung perfusion (EVLP).~Events: lung procurement, cold storage on ice, reconditioning by EVLP, cold storage on ice, transplantation."
3315602|NCT01967966|Experimental|Bioavailability|
3315603|NCT01967966|Experimental|Elimination & PK|
3315604|NCT01967979|Experimental|Cohort 1 (Itraconazole DDI)|
3315605|NCT01967979|Experimental|Cohort 2 (Fluoxetine DDI)|
3315606|NCT01967992|Active Comparator|American Diabetes Association recommended diet|"Participants in the American Diabetes Association (ADA) diet group will receive standard ADA advice. The diet includes high-fiber foods (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, fresh fish, and foods low in saturated fat. They will be asked to use the plate method to guide their nutritional choices."
3315607|NCT01967992|Experimental|Low Carbohydrate Diet|"Participants will be instructed to follow a low carbohydrate, ketogenic diet: carbohydrate intake 20-35 grams a day not including fiber. Foods permitted include: meats, poultry, fish, eggs, cheese, cream, some nuts and seeds, green leafy vegetables, and most other non-starchy vegetables. Because most individuals self-limit caloric intake, no calorie restriction will be recommended.~Participants will also be taught information about mindfulness and positive affect practices. The mindfulness-based curriculum will focus on the following elements: training on topics such as mindful meditation, mindful eating, awareness of fullness and hunger signals, and taste satiety. The positive emotion curriculum will include: training on topics such as noticing and savoring positive events, gratitude, positive reappraisal, personal strengths, attainable goals, and acts of kindness."
3315608|NCT01968005|Placebo Comparator|Placebo|Therapy with placebo
3315609|NCT01968005|Experimental|Etoreat®(Etodolac-Lidocaine Topical Patch)|Therapy with experimental drug
3315610|NCT01968018|Experimental|Tramadol HCI + acetaminophen|
3315611|NCT01968044|Experimental|Gemigliptin|Participant will remain gemigliptin 50mg throughout entire study (52 weeks).
3315612|NCT01968044|Other|Placebo to linagliptin|Participant who is randomized to placebo will be switched to linagliptin after 12 week and administered linagliptin by week 52.
3315613|NCT01968083|Experimental|RSV cps2 Vaccine|Participants will receive one dose of the RSV cps2 vaccine administered as nose drops at study entry.
3315614|NCT01968083|Placebo Comparator|Placebo|Participants will receive one dose of placebo administered as nose drops at study entry.
3315615|NCT01968096|No Intervention|SCI subjects|Stage 1 subjects: pilot study:understand post activation depression with spinal cord injury to avoid the influence of the suprasegmental level.
3315616|NCT01968096|No Intervention|Incomplete SCI subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
3315617|NCT01968096|No Intervention|Health subjects|Stage 2 subjects: pilot study:The strength of depression will be evaluated in individuals with and without SCI.
3315618|NCT01968096|Experimental|SCI subjects with high muscle tone (High frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(High frequency) will be executed .
3315619|NCT01968096|Experimental|SCI subjects with high muscle tone(low frequency)|Stage 3 subjects:A rehabilitation program of machine driven passive stretch(Low frequency) will be executed.
3315620|NCT01968096|No Intervention|SCI subjects with high muscle tone|Stage 3 subjects:Control subjects
3315621|NCT01968109|Experimental|Relatlimab|Relatlimab (BMS-986016) specified dose on specified days
3315622|NCT01968109|Experimental|Relatlimab + Nivolumab|Relatlimab (BMS-986016) + Nivolumab (BMS-936558) specified dose on specified days
3315623|NCT01968109|Experimental|BMS-986213|Relatlimab (BMS-986016) + Nivolumab (BMS-936558)
3315624|NCT01968122||aggressive medical treatment|administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for more than 5d before the operation (but Clopidogrel of loading dose 200mg in case of emergency operation for TIA); administer Aspirin (100mg/d) + Clopidogrel (75mg/d) for 90d and subsequent monoclonal antibody after the operation; control the primary risk factors (e.g. hypertension and high LDL); control the secondary risk factors (e.g. diabetes, blood lipid of not high LDL, smoking, obesity and hypomotility); and intervene the life style. Primary risk factors: target systolic pressure of <140mmHg (or <130mmHg in the diabetes patients); and LDL <70mg/dl (1.81mmol/L) or drop by 50%.
3315625|NCT01968161|Other|Asenapine|Open label switch to asenapine: asenapine will be introduced at the target dose (5 mg bid)
3315626|NCT01968174||eyelid displacement|patients suffering from eyelid disposition due to ptosis, blepharochalasis and are registered for eyelid surgeries will be assigned for the study
3315627|NCT01968187|Experimental|FE 992097|
3315628|NCT01968187|Placebo Comparator|Placebo|
3315629|NCT01968200|Experimental|Enalapril concomitant|Enalapril started concomitantly to AC-containing treatments
3315630|NCT01968200|Experimental|Enalapril after injury|Enalapril prescribed to selected patients showing laboratory evidences of injury after chemotherapy at follow-up visits.
3315631|NCT01968239|Experimental|OCT guided group|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab if the morphological macular changes for recurrence of macular edema (microcystic changes with or without increase of central retinal thickness) will be detected by OCT.
3315632|NCT01968239|Active Comparator|Standard treatment|Patients randomized to this group will get the intravitreal injection of 0.5 mg ranibizumab according to the in SmPC defined re-treatment criteria (re-injection if decrease of BCVA will be detected).
3315633|NCT01968252||Intraoperative Patient|All patients in the cohort will be scheduled to undergo a planned surgical procedure in which the subject will undergo general anesthesia and the procedure and/or the patient will require transesophageal echocardiographic monitoring for the procedure.
3315634|NCT01968265|Placebo Comparator|Placebo|
3381922|NCT05163496|Experimental|Psilocybin arm|psychedelic assisted psychotherapy + 25mg psilocybin
3381923|NCT05163496|Active Comparator|Placebo|Psychedelic assisted psychotherapy + 250mg niacin
3381924|NCT05163483|Experimental|Tucidinostat (chidamide) and PD-1 inhibitor （Toripalimab）|"Tucidinostat (chidamide), 30mg, biw, q3w~Toripalimab, 240mg, d1, q3w~approximately 2 years"
3381925|NCT05163470|Experimental|On Fi.RE. framework|Men football profesional players
3381926|NCT05163470|Active Comparator|Traditionnal rehabilitation|Men football profesional players
3315635|NCT01968265|Active Comparator|ISIS-GCCRRx|
3315636|NCT01968278|Experimental|Baked milk group|BM (baked milk)
3315637|NCT01968278|No Intervention|Control|IgE-cow's milk allergic patients not treated with OIT
3315638|NCT01968291|Experimental|Teach-back|Patients are prompted to state back in their own words their comprehension of the information given to them at discharge.
3315639|NCT01968291|No Intervention|Standard Discharge Instructions|Patient receives usual discharge instructions as administered by the nurse assigned to the patient.
3315640|NCT01968304|No Intervention|Iron status follow up|
3315641|NCT01968330|Experimental|Go!®to sleep|Patients in the sleep intervention arm will undergo a sleep wellness program entitled Go!®to sleep as part of their group prenatal visits. This intervention is a six-week online program developed by the Cleveland clinic for non-pregnant patients suffering from insomnia. In collaboration with the Cleveland clinic sleep disorders center researchers will modify the program to fit the specific needs of a pregnant population. Subjects will receive access to the program and instructed on its use at their initial group prenatal visit. In subsequent visits subjects will be able to discuss their experience with the program.
3315642|NCT01968330|No Intervention|Routine prenatal care|Patients in the routine prenatal care arm will complete prenatal care in a group setting and will not complete the sleep intervention.
3315643|NCT01968343|Experimental|Group cognitive-behavioral therapy|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group cognitive-behavioral therapy.
3315644|NCT01968343|Active Comparator|Group supportive therapy (control)|22 subjects, all of whom met the criteria for a diagnosis of trichotillomania established in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Subjects receive 22 sessions of group supportive therapy (control).
3315645|NCT01968369|Active Comparator|tomato sauce (+/- high fat meal)|80 gr for 7 days= total load 560 mg (+/- high fat meal)
3315646|NCT01968369|Placebo Comparator|diet without tomato (+/- high fat meal)|diet without tomato (+/- high fat meal)
3315647|NCT01968395|Other|Caspofungin 70 mg|Infusion of one dose of Caspofungin 70 mg
3315648|NCT01968408|Active Comparator|L. reuteri DSM 17938|"Lactobacillus reuteri DSM 17938,10(9)CFU/daily (for the duration of hospitalization)~ARM I: Rotavirus vaccinated patients~ARM II: Non-rotavirus vaccinated patients"
3315649|NCT01968408|Placebo Comparator|Placebo|"Placebo consists of an identical formulation in all respects except that the live probiotic bacteria were excluded~for the duration of hospitalization"
3315650|NCT01968460|Experimental|P2B001 Treatment A|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily.
3315651|NCT01968460|Experimental|P2B001 Treatment B|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
3315652|NCT01968460|Placebo Comparator|Placebo|Placebo once daily for 12 weeks.
3315653|NCT01968473|Experimental|NMES Device comfort|NMES Device comfort, establishing Sensory, Motor and Pain thresholds. Max Pain tolerance is also established.
3315654|NCT01968486|Experimental|PDT Standard Fluence, ranibizumab|verteporfin (6 mg/m2) SF (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 milliwatt(mW)/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
3315655|NCT01968486|Experimental|PDT Reduced Fluence, ranibizumab|verteporfin (6 mg/m2) RF ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s) plus 0.5 mg intravitreal ranibizumab
3315656|NCT01968486|Experimental|ranibizumab|0.5 mg (10 mg/ml) intravitreal ranibizumab.
3315657|NCT01968499||All recruited patients|Patients who receive stent implantation and aged >18 years.
3315658|NCT01968512|Experimental|Transcranial Direct Current Stimulation|Subjects will undergo to Transcranial Direct Current Stimulation with anode in left dorsolateral prefrontal cortex and cathode in right supra orbicular region. The stimulus will be 1mA for 20 minutes.
3315659|NCT01968512|Sham Comparator|TDCS-Sham|Subjects will undergo to procedure similar to the Transcranial Direct Current Stimulation with anode in dorsolateral prefrontal cortex and left cathode region supraorbicular right. They will receive a stimulus of 1mA only in initial 30 seconds and it will change the electrical charge for 0mA after this time, however the electrodes will be kept for 20 minutes as the active arm.
3315660|NCT01968525|Experimental|Group A|the hemoglobin is >12g/L in patients from group A.
3315661|NCT01968525|Experimental|Group B|Hb 9-12g/L
3315662|NCT01968525|Experimental|Group C|Hb<9g/L
3315663|NCT01968538||Prostate Cancer Patients|Prostate cancer patients who underwent radiation therapy
3315664|NCT01968538||Healthy control|age-matched male who has no known prostate cancer
3315665|NCT01968564|Experimental|High-dose curcumin pill|
3315666|NCT01968564|Experimental|Low-dose curcumin pill|
3315667|NCT01968564|Placebo Comparator|Placebo pill|
3315668|NCT01968577|Experimental|Rosuvastatin 40 mg|Administration of rosuvastatin 40 mg 2 to 6 hours before percutaneous coronary intervention
3315669|NCT01968577|No Intervention|Control group|The group of patients that do not receive rosuvastatin, 40 mg, before percutaneous coronary intervention.
3315670|NCT01968590|Active Comparator|cholecalciferol 600 IU|cholecalciferol in Ddrops form at either 600 International units per day versus 4,000 IU per day
3315671|NCT01968590|Active Comparator|cholecalciferol 4,000 IU|Cholecalciferol at 4,000 IU per day in the form of liquid Ddrops
3315672|NCT01968616|Other|Intravitreal Lucentis 0.5mg|One arm
3315673|NCT01968629|Experimental|Eovist at 24 Hour Delayed Imaging|This study will evaluate uptake of the hepatobiliary magnetic resonance imaging (MRI) contrast agent gadolinium ethoxybenzyl dimeglumine, or Eovist (Bayer Imaging, Wayne, NJ) within hepatocellular carcinomas (HCCs) at delayed, 24 hour imaging. The recommended dose of Eovist is 0.1 mL/kg, or 0.025 mmol/kg.
3381927|NCT05163457||aged of 75 and more living at home|"aged of 75 and more living at home group: patients aged of 75 and more living at home"
3315674|NCT01968642|Experimental|Educational Intervention|"Attending physicians in the intervention arm will receive the following multi-faceted educational intervention on transthoracic echocardiogram appropriateness: 1) a lecture at the beginning of the study period, which describes Appropriate USe Criteria (AUC) and highlights common clinical scenarios for which outpatient echocardiograms are ordered, 2) an electronic pocket cared via email that provides tips on appropriate ordering of echocardiograms, and 3) an individualized monthly feedback report that categorizes echocardiograms ordered over the preceding month. The feedback report will contain the number of echocardiograms ordered during the month and how many are classified as appropriate, inappropriate, or uncertain based on the 2011 AUC."
3381928|NCT05163444|Experimental|Rolling can|Gait analysis with rolling cane
3315675|NCT01968642|No Intervention|Control Group|Attending physicians in the control arm will have their echocardiogram orders tracked and classified, but will not receive any feedback on their ordering behavior.
3315676|NCT01968668|Experimental|BAY94-8862 (1.25 mg)|
3315677|NCT01968668|Experimental|BAY94-8862 (2.5 mg)|
3315678|NCT01968668|Experimental|BAY94-8862 (5 mg )|
3315679|NCT01968668|Experimental|BAY94-8862 (7.5 mg)|
3315680|NCT01968668|Experimental|BAY94-8862 (10 mg)|
3315681|NCT01968668|Placebo Comparator|Placebo|
3315682|NCT01968668|Experimental|BAY 94-8862 (15 mg)|
3315683|NCT01968668|Experimental|BAY 94-8862 (20 mg)|
3315684|NCT01968681|Experimental|Alexandrite laser treatment|
3381929|NCT05163444|Active Comparator|Quadripod can|Gait analysis with quadripod cane
3315685|NCT01968720|Experimental|CAT-2003 or Placebo|All patients will receive placebo for a 14 day treatment period and CAT-2003 for a 28 day treatment period.
3315686|NCT01968733|Active Comparator|Moxifloxacin|Intravenous with the potential step-down to oral moxifloxacin
3315687|NCT01968733|Experimental|Solithromycin|Intravenous with potential step-down to oral solithromycin
3315688|NCT01968746||ED patients with suspected infection|
3315689|NCT01968759|Active Comparator|Ramipril and Irbesartan|Best available therapy including dual RAS blockade with Ramipril and Irbesartan
3315690|NCT01968759|Experimental|Sevelamer|Two tablets of Sevelamer carbonate 800 mg will be orally administered three times per day during the meals for 3 months.
3315691|NCT01968772|Other|Transdermal Magnesium Chloride|This is a clear, odorless liquid that dries rapidly on the skin and leaves no oily residue. Its ingredients are water, magnesium chloride, and a proprietary blend of less than two-tenths of 1% trace minerals (Boron, Selenium, and Manganese).
3315692|NCT01968785|Active Comparator|Radiation dose 25 Gy|• 25 Gy: Subjects will be treated with beta radiation dosage of 25 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
3315693|NCT01968785|Active Comparator|Radiation dose 50 Gy|• 50 Gy: Subjects will be treated with beta radiation dosage of 50 Gy during renal denervation procedure. Subjects are to maintain baseline anti-hypertensive medications and will undergo follow-up for 24 months.
3315694|NCT01968798|Active Comparator|Aspirin|100 mg enteric-coated aspirin
3315695|NCT01968798|Placebo Comparator|Placebo|Placebo
3315696|NCT01968824|No Intervention|General Anesthesia|general anesthesia only
3315697|NCT01968824|Experimental|Brachial Plexus Nerve Block|brachial plexus nerve block
3315698|NCT01968837|No Intervention|Cervical cancer screening|
3315699|NCT01968850|No Intervention|no bone anti-resorptive therapy|(standard of care)
3315700|NCT01968850|Experimental|24-week tx of alendronate/vitamin D|Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D
3315701|NCT01968850|Experimental|Delayed 24-week tx of alendronate/vitamin D|a 24 week delay in initiation of a 24 week course of alendronate/vitamin D
3315702|NCT01968876|No Intervention|Standard Care|The control group will not use the medication adherence app
3315703|NCT01968876|Experimental|Medication Adherence Smartphone App|The experimental group will receive the medication adherence app on their smartphone and will have their entire outpatient medication list pushed to the application. Text message reminders will be sent to their phones at the appropriate times.
3315704|NCT01968889||Critical illness neuromyopthy|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
3315705|NCT01968902|Active Comparator|incabotulinumtoxinA|intramuscular injection, 200 to 400 units, 1 injection visit only
3315706|NCT01968902|Placebo Comparator|Placebo|intramuscular injection, saline 200 - 400 units , 1 injection visit only
3315707|NCT01968915|Experimental|LCL161|Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1.
3315708|NCT01968928||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients.
3315709|NCT01968928||normal|specimens come from normal bladder urothelial carcinoma patients.
3315710|NCT01968928||non-tumoral|specimens come from non-tumoral patients.
3315713|NCT01968993|Experimental|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
3315714|NCT01969006|Experimental|Injection of Marcaine ½ %|Injection of 40 ml of Marcaine ½ % 2 cm medial, 2 cm downwards from the Anterior Iliac Spine
3315715|NCT01969006|Placebo Comparator|Needle prick|Needle prick 2 cm medial and 2 cm downwards from the Anterior Iliac spine
3315716|NCT01969019|Active Comparator|methylprednisolone|intravenous MP: 0.5g weekly for six weeks followed by 0.25g weekly for six weeks
3381930|NCT05163431|Experimental|Painful Hallux Valgus|
3315717|NCT01969019|Active Comparator|methylprednisolone plus prednisone|intravenous MP 0.5g daily for three days per week, twice, followed by 0.25g daily for three days per week, twice, and followed by tapering oral prednisone (starting with 60mg/d, then10 mg less/week than each previous week for the next 3 weeks, then20mg/week at the 5th week followed with 5mg less/week than each previous week for the next 3 weeks)
3315718|NCT01969032|Experimental|2 consequent anthracycline-taxane based chemotherapy regimens|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
3315719|NCT01969045|Experimental|Working channel|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3315720|NCT01969045|Experimental|Enk Fiberoptic Atomizer|Patients will receive the local anaesthetics for the flexible bronchoscopy via the nebulizer Enk Fiberoptic Atomizer.
3315721|NCT01969071|Active Comparator|Levosimendan, inotropic agent|In the levosimendan group, levosimendan will be used in addition to standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)for 24 hours.Levosimendan dosage; a loading dose of levosimendan (6 μg kg-1) will be administered after removal of the aortic cross-clamp, followed by an infusion of levosimendan at a dose of 0.1 μg kg-1 min-1.
3315722|NCT01969071|Active Comparator|Control|In the control group, only standard inotropic therapy (one or more agent including; dopamine, dobutamine, noradrenaline, adrenaline)will be administered
3315723|NCT01969097|Experimental|Dual tDCS + motor training|Motor training of the affected upper extremity combined with dual transcranial direct current stimulation (tDCS).
3315724|NCT01969097|Active Comparator|Anodal tDCS + motor training|Motor training of the affected upper extremity combined with anodal tDCS.
3315725|NCT01969097|Sham Comparator|Sham tDCS + motor training|Motor training of the affected upper extremity combined with sham tDCS.
3315726|NCT01969110|Active Comparator|Perioperative|Oral IMPACT (1 L/day) for 5 days before surgery and by enteral feeding after surgery
3315727|NCT01969110|Active Comparator|Preoperative|Oral IMPACT 1000ml/day for 5 days (1 L/day) before surgery
3315728|NCT01969123|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3315729|NCT01969123|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3315730|NCT01969123|Placebo Comparator|EVP-6124 Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
3315731|NCT01969136|Experimental|Experimental: EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3315732|NCT01969136|Experimental|Experimental: EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3315733|NCT01969136|Placebo Comparator|EVP-6124, Placebo|Placebo, Tablet, Once Daily, Day 1 through Day 182
3315734|NCT01969149|Experimental|Exenatide group|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
3315735|NCT01969149|Active Comparator|Insulin group|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
3315736|NCT01969175|Experimental|Intervention Diet|
3315737|NCT01969175|Placebo Comparator|Control|
3315738|NCT01969188||SpA in RA|Patients with SpA with psoriatic arthritis (PsA), ankylosing spondylitis (AS), no biologic therapy for 3 months, over 18 yrs old.
3315739|NCT01969227|Experimental|Cohort|Adult mechanically ventilated patients who are deemed eligible for a spontaneous breathing trial and are candidates to receive subanesthetic ketamine by the primary critical care team.
3315740|NCT01969266|Experimental|PCI-32765|PCI-32765 840 mg will be administered as capsule (Treatment A in Period 1) and solution (Treatment B in Period 2) formulations. All participants will receive both treatments with a 7-day washout period between doses.
3315741|NCT01969292|Experimental|Colometer|Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
3315742|NCT01969292|Sham Comparator|Sham Software|An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
3315743|NCT01969292|No Intervention|Control|Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.
3315744|NCT01969305|Experimental|Kazakhstani Family Together (KFT)|Usual Care Plus KFT: Family-based multi-media HIV and drug abuse prevention intervention
3315745|NCT01969305|Experimental|Health education curriculum|Usual Care Alone: Health education curriculum on HIV and drug use prevention
3315746|NCT01969318|Placebo Comparator|Placebo/Metformin|
3315747|NCT01969318|Experimental|SP2086 (50mg q.d)/Metformin|
3315748|NCT01969318|Experimental|SP2086 (100mg q.d.)/Metformin|
3315749|NCT01969331|Placebo Comparator|Placebo|"maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171) Placebo as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy.~Two weeks after the end of PPI therapy subjects are seen at the follow up visit."
3315750|NCT01969331|Active Comparator|Normia|Lactobacillus rhamnosus GG, LGG® and Bifidobacterium, BB-12® Normia® probiotic as an addition to standard H. Pylori eradication therapy 7 days of initial therapy (2 antibiotics + PPI), followed by 21 days of PPI only therapy. One capsule twice per day/14 days Two weeks after the end of PPI therapy subjects are seen at the follow up visit.
3315751|NCT01969344||Smokers without COPD|Current or former smokers with at least a 20 pack-year history with normal lung function based on post-bronchodilator spirometry (n=944).
3315752|NCT01969344||Severe COPD|Current and former smokers with at least a 20 pack-year history with severe COPD based on post-bronchodilator spirometry (n=625).
3315753|NCT01969344||Mild/Moderate COPD|Current and former smokers with at least a 20 pack-year history with mild to moderate COPD based on post-bronchodilator spirometry (n=1210).
3315754|NCT01969344||Non-smokers|Never-smokers with normal lung function on spirometry without use of bronchodilators (n=201).
3315755|NCT01969357|Placebo Comparator|Placebo|
3315756|NCT01969357|Experimental|50 mg SP2086|
3315757|NCT01969357|Experimental|100 mg SP2086|
3315758|NCT01969357|Experimental|200 mg SP2086|
3315759|NCT01969357|Active Comparator|100 mg Sitagliptin|
3315760|NCT01969370|Experimental|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
3315761|NCT01969370|No Intervention|Control|No option to request non-medically actionable incidental information
3315762|NCT01969383|Experimental|heated pool|After selection, all volunteers will be asked to attend two exercise protocols performed on the ground and in the heated pool and the minimum interval of 24 hours between each protocol. Data collection will be performed only with the dominant member of each volunteer.
3315763|NCT01969396|Experimental|SonoBiopsy Catheter|
3315764|NCT01969396|Active Comparator|Endometrial biopsy catheter|
3315765|NCT01969422||observation group|observation
3315766|NCT01969461|Experimental|Healthy Choices: MET CHW Clinic|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the CLINIC by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
3315767|NCT01969461|Active Comparator|Healthy Choices: MET CHW Home|The 4-session Motivational Enhancement Therapy (MET) intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the HOME by a CHW (outreach worker, etc) already providing services in the clinic. The intervention is based on Motivational Interviewing (MI) techniques, building motivation for change by eliciting and reinforcing change talk.
3315768|NCT01969474|Experimental|Cannabis|Treatment with a Cannabis capsule
3315769|NCT01969474|Placebo Comparator|Placebo|Placebo
3315770|NCT01969487|Experimental|Preoperative warm-up on simulator|Trainees perform standard practice tasks programmed into a robotic surgical simulator immediately before the surgery.
3315771|NCT01969487|No Intervention|No preoperative warm-up|
3315772|NCT01969513|Experimental|INTERVENTION ARM|Patients meeting the inclusion criteria will be randomly assigned to the experimental group. They will receive Epley's manoeuvre plus betahistine 8mg three times a day until they no longer have symptoms. The Epley's manoeuvre will be performed only on the first visit.
3315773|NCT01969513|Sham Comparator|CONTROL GROUP|Patients meeting the inclusion criteria will be randomly assigned to the control group. These patients will receive sham manoeuvre (simulated Epley manoeuvre) plus betahistine 8mg three times a day until they no longer have symptoms. Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
3315774|NCT01969526|Experimental|Multifactorial Intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication.
3315775|NCT01969526|No Intervention|No intervention|Usual care
3315776|NCT01969552||Thyroid testing|Adult subjects presenting for thyroid testing or treatment
3315777|NCT01969578|Active Comparator|Chemotherapy|"Chemotherapy = either Cisplatin + Doxorubicin or Carboplatin + Paclitaxel~Patients from cohort A (chemonaïve) may be randomized in this arm to receive chemotherapy"
3315778|NCT01969578|Experimental|Androgen Deprivation Therapy (ADT)|"ADT = bicalutamide + triptorelin~Patients from cohort A (chemonaive) may be randomized to receive ADT, and patients from cohort B (pre-treated) will receive ADT without having been randomized."
3315779|NCT01969591|Experimental|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
3315780|NCT01969591|Other|convontional postoperative care|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
3315781|NCT01969604|Experimental|Motivational lifestyle counselling|This arm will include 1) Three individual motivational counselling sessions including handouts of four key messages regarding reduction of daily sitting time in combination with 2) Individual Short Text Message (SMS) reminders.
3315782|NCT01969604|No Intervention|Control Group|A control group will be encouraged to maintain their usual lifestyle during the 16-week intervention period.
3315783|NCT01969617|Experimental|Nalmefene 18 mg, then placebo|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3315784|NCT01969617|Placebo Comparator|Placebo, then Nalmefene 18 mg|18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride
3315785|NCT01969630|Active Comparator|PEB|PEB angioplasty plus provisional nitinol stent implantation
3315786|NCT01969630|Experimental|PES|Systematic PES angioplasty
3315790|NCT01969656|Placebo Comparator|Placebo|
3315791|NCT01969656|Active Comparator|Calcitriol|
3315792|NCT01969656|Experimental|50 ng 2MD|
3315793|NCT01969656|Experimental|110 ng 2MD|
3315794|NCT01969656|Experimental|170 ng 2MD|
3315795|NCT01969656|Experimental|220 ng 2MD|
3315796|NCT01969656|Experimental|440 ng 2MD|
3315797|NCT01969669|Experimental|Arm A (ABT-199 and ketoconazole)|
3315798|NCT01969682|Experimental|Arm A (ABT-199 and rifampin)|
3315799|NCT01969695|Experimental|ABT-199|ABT-199 monotherapy
3315800|NCT01969734|Experimental|Endobronchial valves|All subjects will have endobronchial valves inserted into the target lobe of the lung with the aim of complete lobar exclusion.
3315801|NCT01969760|No Intervention|Wait-list control|Wait-list control. No intervention delivered until post follow-up assessment. Upon completion of the follow-up, the family was offered the full intervention.
3315802|NCT01969760|Experimental|Healthy Families DC Program|Healthy Families DC Program
3315803|NCT01969773|Experimental|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
3315804|NCT01969773|Placebo Comparator|Control arm-Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
3315805|NCT01969786|Experimental|Corneal ulcer prevention program|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to the corneal ulcer prevention arm will be trained to diagnose and treat corneal abrasions with antifungal (itraconazole) and antibiotic (chloramphenicol) ointments. FCHVs will promote their new services to their communities and encourage villagers who experience ocular trauma to present to them within 24 hours.
3315806|NCT01969786|No Intervention|Control|Female community health volunteers (FCHV) residing in Village Development Committees (VDC) randomized to control (no intervention) will not receive additional training and will not undertake a promotional campaign in their communities.
3315807|NCT01969825|Experimental|Massage|Professional Swedish massage less than 15 minutes prior to semen collection for intrauterine insemination.
3315808|NCT01969825|No Intervention|No massage|Normal protocol for semen collection prior to intrauterine insemination.
3315809|NCT01969838|Experimental|Momelotinib|Participants will receive momelotinib plus placebo to match ruxolitinib.
3315810|NCT01969838|Active Comparator|Ruxolitinib|Participants will receive ruxolitinib plus placebo to match momelotinib.
3315811|NCT01969864|Experimental|HRSA Video Intervention|5-minute video on organ donation from U.S. Department of Health and Human Services
3315812|NCT01969864|Experimental|PI Video Intervention|5-minute video on organ donation created in part by the principal investigator.
3315813|NCT01969864|Placebo Comparator|CDC Health Website Intervention|This control intervention will include text from the CDC website on health and wellness.
3315814|NCT01969877|Experimental|Arm 1|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).
3315815|NCT01969877|Experimental|Arm 2|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).
3315816|NCT01969877|Experimental|Arm 3|Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).
3315817|NCT01969877|Experimental|Arm 4|Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).
3315818|NCT01969890|Experimental|G-CSF administration|Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days
3315819|NCT01969890|No Intervention|standard therapy|Standard therapy
3315820|NCT01969903|Experimental|No dexmedetomidine injected|Control group in which will be used only lidocaine for brachial plexus block
3315821|NCT01969903|Experimental|0.3 microgs/kg of dexmedetomidine|Experimental group, in which 0.3 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
3315822|NCT01969903|Experimental|0.6 microgs/kg of dexmedeomidine|Experimental group, in which 0.6 microgs/kg dexmedetomidine will be added to lidocaine for brachial plexus block
3315823|NCT01969929|Active Comparator|20G|20G vitrectomy with scleral and conjunctival sutures for closure
3315824|NCT01969929|Active Comparator|23G|23G transconjunctival sutureless vitrectomy
3315825|NCT01969942|Experimental|allogeneic stem cell transplantation Plan A|Subjects will receive the vaccine, Busulfan and Melphalan.
3315826|NCT01969942|Experimental|allogeneic stem cell transplantation Plan B|If subject have already received a stem cell transplant using Busulfan and Melphalan, they will receive Clysophosohamide and Fludarabine.
3315827|NCT01969955|Experimental|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
3315828|NCT01969968|Other|sleeve bariatric surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy
3315829|NCT01969968|Other|morbidly obese adults with by pass surgery|morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass
3315830|NCT01969968|Other|non obese|non obese patients
3315831|NCT01969981||PICC placement|
3315832|NCT01969994|Experimental|Controlled dietary background & (-)-[2-14C]epicatechin intake|
3315833|NCT01970020|Experimental|JNJ-38518168|
3315834|NCT01970033|Placebo Comparator|Placebo|
3315835|NCT01970033|Experimental|SP2086 50 mg b.i.d|
3315836|NCT01970033|Experimental|SP2086 100 mg q.d.|
3315837|NCT01970046|Placebo Comparator|Placebo/Metformin|
3315838|NCT01970046|Experimental|SP2086 (50mg b.i.d)/Metformin|
3315839|NCT01970046|Experimental|SP2086 (50mg q.d.)/Metformin|
3315840|NCT01970059|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
3315841|NCT01970059|Active Comparator|Sustained-release Metoprolol Succinate|47.5-190mg/d,po
3315842|NCT01970072|Experimental|1.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.01 mg/kg body weight
3315843|NCT01970072|Experimental|2.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.02 mg/kg body weight
3315844|NCT01970072|Experimental|3.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.05 mg/kg body weight
3315845|NCT01970072|Experimental|4.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.075 mg/kg body weight
3315846|NCT01970072|Experimental|5.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.1 mg/kg body weight
3315847|NCT01970072|Experimental|6.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.15 mg/kg body weight
3315848|NCT01970072|Experimental|7.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.2 mg/kg body weight
3315849|NCT01970072|Experimental|8.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.25 mg/kg body weight
3315850|NCT01970072|Experimental|9.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.3mg/kg body weight
3315851|NCT01970072|Experimental|10.Remimazolam Tosylate|Single IV bolus of Remimazolam Tosylate over 1 minute at 0.35 mg/kg body weight
3315852|NCT01970072|Active Comparator|11.Midazolam|Single IV bolus of Midazolam over 1 minute at 0.075 mg/kg body weight
3315853|NCT01970098|Experimental|KPS-0373|
3315854|NCT01970098|Placebo Comparator|Placebo|
3315855|NCT01970111|Experimental|KPS-0373|
3315856|NCT01970124|Experimental|KPS-0373|
3315857|NCT01970137|Experimental|KPS-0373|
3315858|NCT01970150|Experimental|1|In this intervention patients receive 5 days a week for 4 weeks of rTMS treatment with real coil
3315859|NCT01970163|Experimental|DermACELL|DermACELL acellular dermal matrix will be used to treat subjects diagnosed with an ulcer of the lower extremity (diabetic foot ulcer or venous stasis ulcer).
3315860|NCT01970163|Placebo Comparator|Conventional care dressings|Currently accepted standard of care wound management including Conventional care dressings will be utilized in subjects with a diagnosis of either diabetic foot ulcer or venous stasis ulcer.
3315861|NCT01970163|Active Comparator|GraftJacket|GraftJacket acellular dermal matrix will be used in those subjects diagnosed with a diabetic foot ulcer.
3315862|NCT01970189||Primary Immune Thrombocytopaenia|Recently-diagnosed (i.e. < 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
3315863|NCT01970202|Active Comparator|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
3315864|NCT01970202|Active Comparator|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
3315865|NCT01970202|Other|Control|no treatment
3315866|NCT01970215|Placebo Comparator|Group 1|TA-8995 0mg (placebo) & placebo statin
3315867|NCT01970215|Experimental|Group 2|TA-8995 1mg & placebo statin
3315868|NCT01970215|Experimental|Group 3|TA-8995 2.5mg & placebo statin
3315869|NCT01970215|Experimental|Group 4|TA-8995 5mg & placebo statin
3315870|NCT01970215|Experimental|Group 5|TA-8995 10mg & placebo statin
3315871|NCT01970215|Active Comparator|Group 6|TA-8995 0mg (placebo) & atorvastatin 20mg
3315872|NCT01970215|Active Comparator|Group 7|TA-8995 10mg & atorvastatin 20mg
3315873|NCT01970215|Active Comparator|Group 8|TA-8995 0mg (placebo) & rosuvastatin 10mg
3315874|NCT01970215|Active Comparator|Group 9|TA-8995 10mg & rosuvastatin 10mg
3315875|NCT01970228|Active Comparator|Adverse reaction to metal debris|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with adverse tissue reactions to metal debris
3315876|NCT01970228|Active Comparator|Periprosthetic joint infection|68Ga-citrate and 19F-FDG PET/CT imaging of hip replacement patients with periprosthetic joint infection
3315877|NCT01970228|Active Comparator|Aseptic mechanical implant loosening|68Ga-citrate and 19F-FDG PET/CT imaging of patients with aseptic mechanical loosening of hip prosthesis
3315878|NCT01970254||Screening (hepatitis B screening)|Patients with unknown HBV infection status undergo 3 HBV screening tests (HBsAg, anti-HBc, and anti-HBs) before chemotherapy. Patients with known HBV infection status undergo either HBsAg or anti-HBc screening tests if there is no evidence of HBV testing in the last 3 months. All patients complete HBV risk assessment survey.
3315879|NCT01970267|Active Comparator|Laser Treated|Laser will direct the laser at vitreous opacities. The power of the laser will be adjusted from 0.3-12 millijoules (mJ) with the end point being laser induced optical breakdown and the production of a small gas bubble 50% of the time. The treatment will attempt to reduced or eliminate symptomatic floaters in the visual axis. Each treatment session will be limited to 300 laser applications. Participants will be retreated based on continued symptoms for up to 5 sessions
3315880|NCT01970267|Sham Comparator|Not Treated|
3315881|NCT01970280|Active Comparator|Enoxaparin|Following a first AV graft thrombosis and successful thrombolysis with angioplasty, patients on chronic hemodialysis will be randomized to s.c Enoxaparin (Clexane) 0.5 mg/1kg of body weight per day or control group (not on Clexane).
3315882|NCT01970280|No Intervention|Observation|
3315883|NCT01970293|Other|Introduction to AA volunteer|
3315884|NCT01970293|No Intervention|AA materials offered|
3315885|NCT01970306|Experimental|Surgical intervention|Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
3315886|NCT01970319||Diabetic with nephropathy|
3315887|NCT01970319||Diabetics without nephropathy|
3315888|NCT01970332|No Intervention|No Exercise Therapy or Revascularization operation|The patient is evaluated but no intervention
3315889|NCT01970332|Experimental|Revascularization Surgery|The patient undergoes surgery to revascularize the ischemic, symptomatic limb(s)
3315890|NCT01970332|Experimental|Exercise Therapy|The patient undergoes supervised exercise therapy for 6 months
3315891|NCT01970345|Experimental|IGF-1|"Randomized, placebo-controlled, crossover format with 12 weeks in each treatment arm (IGF-1 and placebo), separated by a four-week wash-out phase.~Dose titration will be initiated at 0.04 mg/kg twice daily by subcutaneous injection, and increased, as tolerated, every week by 0.04 mg/kg per dose to a maximum of 0.12 mg/kg twice daily. Doses may be decreased according to tolerability by 0.04 mg/kg per dose. Medication will be administered twice daily with meals, and preprandial glucose monitoring will be performed by parents at treatment initiation, prior to each injection, and until a well tolerated dose is established."
3315892|NCT01970345|Placebo Comparator|Placebo|Placebo
3315893|NCT01970358|Experimental|Personalized NeoAntigen Cancer Vaccine|"- NeoVax (peptides + poly-ICLC)~Poly-ICLC: 4 x 0.5 mg (total dose 2 mg) given on days Days 1, 4, 8, 15, 22, 78, and 162~Peptides: 4 x 300 mcg per peptide given on days Days 1, 4, 8, 15, 22, 78, and 162"
3315894|NCT01970384|Experimental|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
3315895|NCT01970384|Sham Comparator|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
3315896|NCT01970410|Experimental|Teriflunomide|Teriflunomide 14 mg oral teriflunomide daily
3315897|NCT01970423|Other|CRT|After randomization and polysomnography the CRT will get activated. After 3-5 months cross over to conventional right ventricular stimulation.
3315898|NCT01970423|Other|Right Ventricular Stimulation|After randomization and polysomnography the conventional right ventricular stimulation will get activated. After 3-5 months cross over to CRT activation.
3315899|NCT01970436|Experimental|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
3315900|NCT01970436|No Intervention|Usual Prenatal Care|Usual, in-person prenatal care.
3315901|NCT01970449|Experimental|Group 1: study vaccines with Nat-B env insert|Participants in this arm will receive DNA Nat-B env vaccine injections on Day 0 and Day 28 followed by NYVAC Nat-B env vaccine injections on Day 84 and Day 164.
3315902|NCT01970449|Placebo Comparator|Group 1: placebo vaccines with Nat-B env insert|Participants in this arm will receive placebo injections of DNA Nat-B env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Nat-B env vaccine on Day 84 and Day 164.
3315903|NCT01970449|Experimental|Group 2: study vaccines with CON-S env insert|Participants in this arm will receive DNA CON-S env vaccine injections on Day 0 and Day 28 followed by NYVAC CON-S env vaccine injections on Day 84 and Day 164.
3315904|NCT01970449|Placebo Comparator|Group 2: placebo vaccines with CON-S env insert|Participants in this arm will receive placebo injections of DNA CON-S env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC CON-S env vaccine on Day 84 and Day 164.
3315905|NCT01970449|Experimental|Group 3: study vaccines with Mosaic env insert|Participants in this arm will receive DNA Mosaic env vaccine injections on Day 0 and Day 28 followed by NYVAC Mosaic env vaccine injections on Day 84 and Day 164.
3315906|NCT01970449|Placebo Comparator|Group 3: placebo vaccines with Mosaic env insert|Participants in this arm will receive placebo injections of DNA Mosaic env vaccine on Day 0 and Day 28 followed by placebo injections for NYVAC Mosaic env vaccine on Day 84 and Day 164.
3315907|NCT01970501|Experimental|bucindolol hydrochloride|"bucindolol hydrochloride (bucindolol)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 6.25mg, 12.5mg, 25mg, 50mg, and 100mg."
3315908|NCT01970501|Active Comparator|metoprolol succinate|"metoprolol succinate (Toprol-XL)~Capsules are available in the following dosage strengths to be taken twice daily (with or without food): 25mg, 50mg, 100mg, 200mg and/or matching placebo oral capsule to maintain blinded dosing."
3315909|NCT01970514|Experimental|ARO Spinal System|ARO Spinal System
3315910|NCT01970553|Experimental|lurbinectedin (PM01183) / gemcitabine|"Patients will consecutively receive the following on Days 1 and 8 q3wk (three weeks = one treatment cycle):~- Gemcitabine: intravenous infusion of 800 mg/m2/day over 30 minutes,~immediately followed by:~- PM01183: intravenous infusion over one hour at a starting dose of 2.5 mg/day, flat dose (FD), both on Days 1 and 8 every 3 weeks"
3315911|NCT01970566|Experimental|IE-MCR|Intense Exercise/Moderate Calorie Restriction
3315912|NCT01970566|Active Comparator|TP-CBT|Topiramate-Phentermine plus cognitive behavioral therapy
3315913|NCT01970566|Active Comparator|CBT|cognitive behavioral therapy
3315914|NCT01970579|Experimental|Paclitaxel coated balloon|
3315915|NCT01970579|Active Comparator|uncoated PTA catheter|
3315916|NCT01970605||Patients with PAOD or aneurysms|"Patients~in Fontaine class > IIa,~in need of aneurysm repair,~with defined cardiovascular risk factors or~graft infections.~Surgical reconstruction with defined Silver Graft vascular prosthesis."
3315917|NCT01970618|Experimental|Part A: single dose escalation (healthy subjects)|
3315918|NCT01970618|Experimental|Part B: 7 day repeat dose (healthy subjects)|
3315919|NCT01970618|Experimental|Part C: 14 day repeat dose (COPD patients)|
3315920|NCT01970631|No Intervention|Usual Care|Participants randomized to the Usual Care group will receive the current standard post-operative TKR care.
3315921|NCT01970631|Active Comparator|Motivational Interviewing (MI)|Participants randomized to the MI Intervention group will receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
3315922|NCT01970631|Active Comparator|Financial Incentives (FI)|Participants randomized to the FI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals over the course of the study.
3315923|NCT01970631|Active Comparator|Motivational Inverterviewing (MI) + Financial Incentives (FI)|Participants randomized to the FI + MI Intervention group will receive financial incentives for completing physical activity logs weekly/bi-weekly and achieving pre-specified physical activity goals as well as receive up to 14 telephone calls from a Health Educator for 9 months post-TKR.
3315924|NCT01970644||Brain metastases (>= 4)|Patients with pathologically proven solid tumour malignancy who have >=4 brain metastases will be treated with gamma knife radiosurgery.
3315925|NCT01970657||HP802-247 in prior study|Observational safety follow up study, no treatment specified
3315926|NCT01970657||Vehicle Control in prior study|Observational safety follow up study, no treatment specified
3315927|NCT01970683|Experimental|VSL #3|probiotics given orally BID
3315928|NCT01970683|Other|placebo|Near-identically appearing placebo
3315929|NCT01970696||Ovarian Stromal Tumors|
3315930|NCT01970696||Testicular Stromal Tumors|
3315931|NCT01970696||Ovarian Small Cell Carcinoma|
3381931|NCT05163418|Experimental|Flat feet|People with flat feet according to foot posture index (validated by clinical assessment)
3381932|NCT05163418|Experimental|High arches feet|People with high arches feet according to foot posture index (validated by clinical assessment)
3315932|NCT01970722|Experimental|Treatment (surgery, HIPEC cisplatin)|"Patients undergo surgery and receive hyperthermic cisplatin IP over 60 minutes.~Beginning at least 3 weeks after surgery, patients may receive carboplatin, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or gemcitabine hydrochloride IP or IV at the discretion of the medical and gynecologic oncologists."
3381933|NCT05163418|No Intervention|Normal arches feet (control group)|Control group
3381934|NCT05163392|Experimental|SilverD|"The SIlverD arm includes:~For standard dressing: a silverlon antimicrobial patch, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be weekly.~For sensitive skin dressing: a silverlon antimicrobial patch, Providone/iodine swabs for cleaning, an occlusive dressing with window, and sensitive driveline anchors. The driveline dressing change frequency will be weekly."
3381935|NCT05163392|Active Comparator|ControlD|"The ControlD arm includes:~For standard dressing: No antimicrobial barrier, CHG swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96 hours.~For sensitive skin dressing: No antimicrobial barrier, Providone/iodine swabs for cleaning, an occlusive dressing with window, and driveline anchors. The driveline dressing change frequency will be every 96hr."
3381936|NCT05163379||INTENSIVE CARE PATIENTS|EARLY MOBILIZATION OF INTUBE PATIENTS
3315933|NCT01970735|Experimental|FSHD patient|
3315934|NCT01970748|Placebo Comparator|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
3315935|NCT01970748|Active Comparator|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy. After eradication, follow-up endoscopy every 3 months and variceal ligation again if recurrence.
3381937|NCT05163366|Experimental|GROUP A|Group A will receive rectal ketamine(Ket)
3381938|NCT05163366|Active Comparator|GROUP B|Group B will receive only traditional standard of care protocols.
3315936|NCT01970761||scar, Fat Graft, Visual Analogue Scale|patients received autologous fat grafting in scar areas
3315937|NCT01970774|Experimental|MTM and PGx|Participants attend two MTM sessions and have PGx testing
3315938|NCT01970800|Experimental|Growth hormone, injections|Growth hormone injection 0.3mg/kg/week dailY
3315939|NCT01970813|Active Comparator|Study group|acupuncture and bee venom acupuncture point injection
3315940|NCT01970813|Sham Comparator|Control group|sham acupuncture and normal saline injections
3381939|NCT05163353|Experimental|Treatment with diluted Radiesse|Injection of Décolleté Wrinkles with diluted Radiesse
3381940|NCT05163353|Other|Delayed treatment with diluted Radiesse|Delayed injection of Décolleté Wrinkles with diluted Radiesse
3315941|NCT01970813|No Intervention|Waiting group|no additional intervention
3315942|NCT01970826|Experimental|Sterilized Clean Full-Mouth|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Full-mouth dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3381941|NCT05163327||Healthy Volunteer|10 Volunteers (Male or Female), aged18 or over, with no known history of Coronary Artery Disease
3381942|NCT05163327||Known Coronary Artery Disease|10 Volunteers (Male orFemale), aged 18 or over,with a known significant (defined as => 70% stenosis) single or 2 vessel Coronary Artery Disease
3381943|NCT05163314|Experimental|Soticlestat Dravet Syndrome (DS)|"Participants weighing <45kg: Soticlestat, mini-tablets/tablets, increase from lower dose level (60mg to 140mg) to higher dose level (100mg to 200mg) twice daily (BID), based on body weight, orally/via gastrostomy tube (G-tube) or percutaneous endoscopic gastrostomy (PEG) tube, up to 2 weeks in Titration Period. Participants will continue to receive dose that they are on at the end of Titration Period, for approximately 4 years in Maintenance Period. Dose will be tapered down to lower dose (not less than the lowest dose level based on weight) every 3 days until study drug is discontinued (up to 1 week) in Taper Period.~Participants weighing ≥45kg: Soticlestat mini-tablets or tablets with starting dose of 200 mg BID followed by 300 mg BID, up to 2 weeks in Titration Period. Participants will continue to receive 300 mg BID for approximately 4 years in Maintenance Period. Dose will be tapered down up to 100 mg every 3 days until study drug is discontinued (up to 1 week) in Taper Period."
3381944|NCT05163314|Experimental|Soticlestat Lennox Gastaut Syndrome (LGS)|"Participants weighing <45 kg: Soticlestat, mini-tablets/tablets, increase from lower dose level (60mg to 140mg) to higher dose level (100mg to 200mg) BID, based on body weight, orally/via G-tube or PEG tube, up to 2 weeks in Titration Period. Participants will continue to receive dose that they are on at the end of Titration Period, for approximately 4 years in Maintenance Period. Dose will be tapered down to a lower dose (not less than the lowest dose level based on weight) every 3 days until the study drug is discontinued (up to 1 week) in the Taper Period.~Participants weighing ≥45 kg: Soticlestat mini-tablets/tablets with a starting dose of 200 mg BID followed by 300 mg BID, up to 2 weeks in Titration Period. Participants will continue to receive 300 mg BID for approximately 4 years in Maintenance Period. Dose will be tapered down up to 100 mg every 3 days until study drug is discontinued (up to 1 week) in Taper Period."
3381945|NCT05163301|Experimental|Computer delivered RPI|2 session computer delivered counseling to prevent relapse to hazardous drinking
3315943|NCT01970826|Active Comparator|Sterilized Aseptic Full-Mouth|"The operatory room will be prepared with sterilized aseptic clean instruments. Full-mouth dental implants placement will be performed and involves meticulous hand washing, use of a sterile field, use of sterile gloves for application of a sterile dressing, and use of sterile instruments and fluid only. Involves the use of only sterile instruments and materials in dressing.~There is no contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
3381946|NCT05163301|Experimental|Person delivered RPI|2 session counselor delivered counseling to prevent relapse to hazardous drinking
3381947|NCT05163301|No Intervention|Treatment as Usual|Counseling for alcohol use available in clinic as treatment as usual
3381948|NCT05163288|Experimental|N-acetyl-L-leucine (IB1001)|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
3381949|NCT05163288|Placebo Comparator|Placebo comparator|Oral administration (granule in a sachet for suspension in water, orange juice, or almond milk). Patients ≥13 years old will receive a total daily dose of 4 g/day (administered as 3 doses per day); patients <13 will receive weight-tiered doses.
3381951|NCT05163262|Experimental|experimental|Addition of a sexuality questionnaire during patient follow-up within 3 months after inclusion, 6 months after and at one year
3381952|NCT05163249|Active Comparator|Cohort 1: osimertinib, 80mg, daily, P.O.|"Patients will continue to receive study medication in 28 day cycles until objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients who progress on first-line treatment of osimertinib monotherapy will have the opportunity to receive second-line treatment of osimertinib plus savolitinib after confirmation of MET status at disease progression."
3381953|NCT05163249|Experimental|Cohort 2: osimertinib 80mg daily, P.O. and savolitinib 300mg BID, P.O.|"All eligible patients will be randomized to receive treatment with osimertinib (80 mg daily) or osimertinib (80 mg daily) in combination with savolitinib (300 mg BID) in this study. Treatment will continue until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.~Patients in Cohort 2 can continue on savolitinib monotherapy (if osimertinib was stopped earlier) or osimertinib monotherapy (if savolitinib was stopped earlier) until objective disease progression or meet any of the discontinuation criteria."
3381954|NCT05163236||CRC in excluded population|CRC diagnosed in the population excluded from screening
3381955|NCT05163236||Screen-detected colorectal cancers (SD-CRCs)|CRC diagnosed after a positive fecal immunochemical test (FIT)
3381956|NCT05163236||Colorectal cancers (CRCs) with delayed diagnosis|CRCs diagnosed after a positive fecal immunochemical (FIT) test, but without colonoscopy or > 2 years after a positive fecal immunochemical test
3381957|NCT05163236||Fecal immunochemical test interval colorectal cancers (FIT IC)|CRCs diagnosed 2 years after a negative FIT
3315944|NCT01970826|Experimental|Sterilized Clean Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or products.~It will be evaluated the duration of surgery."
3315945|NCT01970826|Active Comparator|Sterilized Aseptic Single|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~Single dental implants placement will be made, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3381958|NCT05163236||colorectal cancers (CRCs) in non-responders|CRCs diagnosed in the FIT non-responders population
3381959|NCT05163236||Post-colonoscopy interval cancers|CRCs diagnosed within 5 years after a colonoscopy performed following a positive test that did not find colorectal cancer
3381960|NCT05163223|Experimental|AST-301(pNGVL3-hICD)+Chemotherapy|"AST-301/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (AST-301/rhuGM-CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
3381961|NCT05163223|Active Comparator|Placebo + Chemotherapy|"Placebo/rhuGM-CSF (q 3 weeks, 3 cycles) + Standard adjuvant therapy*~A booster (Placebo/rhuGM CSF) at 24 weeks post the third vaccination~Standard adjuvant therapy will be pembrolizumab or capecitabine (q 3 weeks)"
3381962|NCT05163210|Experimental|AO+VR|Participants of the experimental group will undergo a treatment based on observation of actions followed by their immediate reproduction in VR (AO+VR treatment).
3381963|NCT05163210|Placebo Comparator|CO+VR|Participants randomly assigned to the control group will receive an equal number of rehabilitation sessions, as the experimental group. Differently from the latter, patients of the control group will be required to observe videos depicting naturalistic scenes, without motor contents, for 1.5 min. Then, they will receive a motor training in the VR environment, performing the same type of exercises included in the above-described experimental treatment, prompted by the verbal instructions of an expert therapist.
3381965|NCT05163171||patient consulting or hospitalized in addiction structure|patient consulting or hospitalized in addiction structure
3381966|NCT05163158|Experimental|Central BP target|Participants randomized to central BP target will be treated with anti-hypertensive agents to achieve a clinic central SBP < 130 mmHg.
3381967|NCT05163158|Active Comparator|Brachial BP target (standard of care)|Participants randomized to a brachial BP target will be treated with anti-hypertensive drugs to achieve a clinic brachial SBP <130 mmHg.
3381968|NCT05163119|No Intervention|Control Group|Commercial cell-phone blocking app installed on smartphone, but app will be inactive.
3315946|NCT01970826|Experimental|Sterilized Clean - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3315947|NCT01970826|Active Comparator|Sterilized Aseptic - Partial|"The operatory room will be prepared with clean instruments but with no aseptic preparation.~One or more dental implants will be made for partial rehabilitation, Clean technique involves meticulous hand-washing, maintaining a clean environment by preparing a clean field, using clean gloves and sterile instruments, and preventing direct contamination of materials and supplies.~There is contact between : non-sterile material in any change procedures and contact between sterile instruments or materials and any non-sterile surface or product.~It will be evaluated the duration of surgery."
3315948|NCT01970839|Other|Tourniquet, pain, nerve injury, sensory nerve function|
3315949|NCT01970852|Experimental|Standard tablet computer|Patient will receive tablet computer within 18 hours of admission and will continue to have access to it for the rest of his/her stay. Tablet has typical applications including access to the internet and entertainment.
3315950|NCT01970852|No Intervention|Usual Care|Patients will receive usual care and will answer surveys during the usual time-frame specified.
3315951|NCT01970852|Experimental|Enhanced tablet computer|Patients will receive a tablet computer within 18 hours of admission. Tablet will give access to a personalized inpatient personal health record portal. Will also provide access to standard tablet applications (e.g. video calling, streaming movies, etc.)
3315952|NCT01970891|Experimental|Freezing of Gait amelioration|Effect of neuromuscular stimulation device will be assessed on Freezing of Gait amelioration
3315953|NCT01970904|Experimental|200 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 200 mg twice daily (BID) and Ribavirin (RBV) for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3315954|NCT01970904|Experimental|300 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 300mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3315955|NCT01970904|Experimental|400 mg BID|Dual-therapy with a response-guided treatment duration with Alisporivir 400 mg BID and RBV for 12 or 24 weeks (Treatment period 1). Patients who were considered treatment failures were to be treated with peg-IFNα2a/RBV 800 mg daily for 24 weeks in Treatment period 2 (Roll-over treatment arm).
3315956|NCT01970917|Other|Healthy volunteers right eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
3315957|NCT01970917|Other|Healthy volunteers left eye|The medical device will be randomly assigned to the right or left eye on the study day (randomization 1:1) whereas the fellow eye will receive placebo.
3315958|NCT01970930||PV or ET|subject who has polycythemia vera or essential thrombocythemia
3315959|NCT01970969||Cardiac arrhythmia symptoms|All subjects enrolled in the study will have an iRhythm Zio patch placed and a blood sample obtained.
3315960|NCT01971008|Placebo Comparator|Placebo binder|"Patients in this arm will be invited to wear a placebo binder (Clima Care Body warmer, Bort Medical) for 2 hours"
3315961|NCT01971008|Active Comparator|Elastic abdominal binder|"Patients in this arm will be invited to wear an elastic abdominal binder (Abdosyncro Abdominalbandage, Syncro Med GmbH) for 2 hours"
3315962|NCT01971021|Active Comparator|PICC-line|PICC line insertion.
3315963|NCT01971021|Active Comparator|PORT|Subcutaneous venous port insertion
3315964|NCT01971034|Experimental|Paclitaxel and Metformin|
3315965|NCT01971047|Active Comparator|Group 1-Regular Insulin|Intravenous Regular Insulin will be administered for a preoperative Blood glucose of greater than 180.
3315966|NCT01971047|Active Comparator|Group 2-Humalog|Subcutaneous Humalog will be administered for a preoperative Blood glucose of greater than 180
3315967|NCT01971060|Experimental|V-Loc suture|Laparoscopic surgery utilizing V-Loc suture
3315968|NCT01971073|Experimental|bilateral Anodal-L/R Cathodal-R/L tDCS|"bilateral Anodal-left and cathodal-right tDCS over DLPFC or bilateral Anodal-right and cathodal-left tDCS over DLPFC.~Intervention: Device: transcranial direct current stimulation"
3315969|NCT01971073|Sham Comparator|Sham tDCS|Sham tDCS
3315970|NCT01971099|Placebo Comparator|Placebo|patients will use placebo for 120 days
3315971|NCT01971099|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
3315972|NCT01971112|Experimental|Multivitamins and minerals|Experimental: X: Multivitamins and minerals (MVM) Arm X: 1X US-RDA of vitamins A, D,E,B6,B12, folate, copper and iron plus 500 mg vitamin C, and 14 mg of Zinc
3315973|NCT01971112|Placebo Comparator|Placebo|
3315974|NCT01971125||No treatment|"Patients with:~diabetes mellitus type 2~absence of heart disease previously reported~age >45 years~Informed Consent~Patients without:~presence of heart disease previously reported~diabetes type 1~serious systemic disease, with an expected lifetime lower than 2 years~no willingness to participate to the screening~inadequate compliance to study procedure~participation to other study"
3315975|NCT01971138||Surgical site infection registration|Is there a routine for SSI registration
3315976|NCT01971151|Experimental|Exposure with safety-seeking behavior|Patients receive exposure therapy. In the current condition, exposure is offered while patients are allowed to use their own safety-seeking behaviors (i.e., behavior believed to be necessary to prevent a feared catastrophe).
3315977|NCT01971151|Experimental|Exposure without safety-seeking behavior|Patients receive exposure therapy.In the current condition, exposure is offered while patients are instructed to omit their safety-seeking behavior.
3315978|NCT01971151|Active Comparator|Exposure therapy only|Patients receive exposure therapy. In the current condition, exposure is offered while patients do not receive any specific instructions about what to do with their safety-seeking behavior.
3315979|NCT01971164|Experimental|Dose 1 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3315980|NCT01971164|Experimental|Dose 2 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3315981|NCT01971164|Experimental|Dose 3 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3315982|NCT01971164|Experimental|Dose 4 JTZ-951 or Placebo|Tablets, 1 dose per day for 15 days
3315983|NCT01971177|Experimental|Femtosecond laser cataract surgery|"Laser group: a pre-fragmentation of the ocular lens will be performed by VICTUS femtosecond laser lens fragmentation procedure."
3315984|NCT01971177|Active Comparator|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are performed manually without femtosecond laser assisted lens fragmentation"
3315985|NCT01971190|Sham Comparator|Sham injection|Sham injection at baseline, at 1 month, and at 2 month
3315986|NCT01971190|Active Comparator|Intravitreal Aflibercept injection|2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month
3315987|NCT01971216|No Intervention|Control|Breastfeeding mothers who are not randomised to relaxation intervention
3315988|NCT01971216|Experimental|Relaxation|Breastfeeding mothers randomised to use relaxation tape at 2 weeks post-partum
3315989|NCT01971229|Sham Comparator|Carbohydrate|Patients in this arm will drink a 425 mL 100% clear apple juice (carbohydrate 50 g, 700 mOsmol). 1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
3315990|NCT01971229|Active Comparator|Whey Protein|Patients in this arm will drink a 330 mL Boost fruit flavoured clear beverage (whey protein 12.2 g, carbohydrate 50 g, 700 mOsmol).1.5 g of acetaminophen will be dissolved in the beverage for determination of gastric emptying.
3315991|NCT01971242|Active Comparator|Exenatide|Bydureon- 2mg administered subcutaneously once weekly
3315992|NCT01971242|Placebo Comparator|Placebo|Placebo, 2mg administered subcutaneously once weekly
3315993|NCT01971268||Platform-Switch Group|T3 dental implant, with platform-switch dental implant platform concept, measure marginal bone loss
3315994|NCT01971268||Platform-Matched Group|T3 dental implant, platform-matched dental implant platform concept, measure marginal bone loss
3315995|NCT01971281|Experimental|TTFilelds + gemcitabine|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine.
3315996|NCT01971281|Experimental|TTFields + gemcitabine+ nab-paclitaxel|Patients will be treated continuously with the NovoTTF-100L device, in addition to Gemcitabine plus nab-paclitaxel
3315997|NCT01971294||Systemic sclerosis|Adult suffering from systemic sclerosis included in the EUSTAR network of Brescia (I), Geneva (CH), Padova (I) and Paris (F).
3315998|NCT01971307|Experimental|SGE-PsyScan|The SGE-PsyScan is an internet application to which the General Practitioner (GP) refers the patient, which includes the distress screener, the 4-Dimensional Symptom Questionnaire (4DSQ) and a series of additional questions for differentiating between stress, depressive, anxious and somatization symptoms. Based on the 4DSQ patients and GPs receive advices for possible treatments.
3315999|NCT01971307|No Intervention|Usual care|Usual care for persons with psychosocial symptoms and disorders in Dutch primary care includes all usual care procedures; preventive, screening, diagnostic, (non-)pharmacological or therapeutic procedures which are routinely used in everyday care.
3316000|NCT01971320|Experimental|active stimulation|"sensitive electrical stimulation applied during meals with Urostim I for 6 weeks~Urostim I stimulation will be done during meals for 6 weeks"
3316001|NCT01971320|Placebo Comparator|fake stimulation|"Urostim I stimulation will be done during meals for 6 weeks~Fake sensitive electrical stimulation applied during meals with modified Urostim I who not deliver stimulation for 6 weeks"
3316002|NCT01971333||Liver transplantation|"Compare intraoperative change of dynamic parameters after fluid loading:~pulse pressure variation~stroke volume variation~plethysmographic variation index"
3316003|NCT01971359||Retrospective|
3316004|NCT01971398|Experimental|Positive Brochure|"Women receive a positive FASD education brochure with positive images and are asked to read this brochure in the presence of a data collector."
3316005|NCT01971398|Experimental|Negative Brochure|"Women receive a negative FASD education brochure with negative, vivid images and are asked to read this brochure in the presence of a data collector."
3316006|NCT01971398|Active Comparator|A general women's health brochure|Women receive a brochure on general aspects of women's health and pregnancy that is available in the Russian language and are asked to read this brochure in the presence of a data collector.
3316007|NCT01971411||Community dwelling elderly black females|
3316008|NCT01971424|Experimental|Mg oxide|Participants were supplemented for 12-weeks with 300 mg of daily oral magnesium oxide.
3316009|NCT01971424|No Intervention|Controls|The control group was educated by a trained dietician to follow a healthy diet.
3316010|NCT01971437|Experimental|Cystodistension & Cystoscopy Arm|This is the Arm receiving cystodistension and cystoscopy due to refractory OAB.
3316011|NCT01971437|Placebo Comparator|Cystoscopy Arm|This is the arm that receives cystoscopy only in women with refractory OAB.
3316012|NCT01971450||Iloprost|The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion.
3316013|NCT01971489|Experimental|Treatment (buparlisib, gemcitabine hydrochloride, cisplatin)|Patients receive buparlisib PO QD on days 1-21, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and cisplatin IV over 2 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
3316014|NCT01971502|Experimental|BI 1060469 single rising dose part|single rising doses given as tablet
3316015|NCT01971502|Experimental|BI 1060469 food effect part|given as tablet fasted and fed
3316016|NCT01971515|Experimental|MSC2363318A|
3316017|NCT01971515|Experimental|MSC2363318A plus Trastuzumab|
3316018|NCT01971515|Experimental|MSC2363318A plus Tamoxifen|
3316019|NCT01971528|No Intervention|Stage 1: Health control|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
3316020|NCT01971528|No Intervention|Stage 1: PD subjects|pilot study: Establishing the central and peripheral contributing factors to the voluntary muscle strength loss during a fatiguing exercise in young and PD groups.
3316021|NCT01971528|No Intervention|Stage 2: Health subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
3316022|NCT01971528|No Intervention|Stage 2: PD subjects|pilot study: Finding optimal sensory stimulation parameters for PD individuals.
3316023|NCT01971528|Experimental|Stage 3: PD subjects|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
3316024|NCT01971528|No Intervention|Stage 3: PD subjects (Control Subjects)|Investigating the long-term effects of combined sensory stimulating strengthening program on the activation level and central fatigue in PD individuals.
3316025|NCT01971541|Experimental|Mindfulness-Based Stress Reduction (MBSR)|An 8-week program designed to teach mindfulness skills
3316026|NCT01971541|Active Comparator|Cognitive Processing Therapy|A group-administered PTSD treatment program.
3316027|NCT01971606|Experimental|Rosuvastatin group|Rosuvastatin group
3316028|NCT01971606|Placebo Comparator|Placebo group|Placebo group
3316029|NCT01971619||SACS cohort|patients with acute myocardial infarction at Severance hospital
3316030|NCT01971632|Active Comparator|Oxycodone/Naloxone|
3316031|NCT01971632|Placebo Comparator|Placebo oxycodone/naloxone|
3316032|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)|"Arm A:~Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested"
3316033|NCT01971658|Active Comparator|VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)|"For arm B:~Induction therapy : 4 cycles of VCD (21 days)~Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15~Velcade® and Dexamethasone identical treatment to Arm A~Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested"
3316034|NCT01971671||Chinese lactating mother|no intervention.
3316035|NCT01971684||Refractory Pediatric ITP Patients|Pediatric ITP patients, ages 1-18, starting a new second line ITP therapy, defined as not IVIG, steroids, anti-D, or aminocaproic acid.
3316036|NCT01971710|Other|Community Leader Engagement|Trained formal and informal community leaders conducting community dialogues and advocacy, and developing community action plans
3316037|NCT01971710|Other|Community Days|Community gatherings involving participatory dialogue, guided discussion, and the provision of education and selected health services.
3316038|NCT01971710|Other|Community Peer Groups|Pregnant women attend 4 weekly peer-led classes in community peer groups. Men attending 4 peer-led education sessions in community peer groups
3316039|NCT01971736||1064nm laser, laxity|split-face single-blind randomized placebo-controlled trial evaluating improvement in facial skin laxity of the side of the face with placebo versus laser
3316040|NCT01971749||Unprotected left main coronary artery stenosis patients|
3316041|NCT01971762||Patients diagnosed bacteremia by S. aureus|
3316042|NCT01971775|Active Comparator|Ultrasonically Activated Shear|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
3316043|NCT01971775|Active Comparator|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
3316044|NCT01971788|Experimental|Prolonged bivalirudin infusion|Bivalirudin infusion is prolonged after the end of primary PCI
3316045|NCT01971788|Active Comparator|Intra-procedural bivalirudin infusion|Bivalirudin infusion is stopped at the end of primary PCI
3316046|NCT01971801|Active Comparator|Vitamin D|Vitamin D3, 50,000 IU, weekly
3316047|NCT01971801|Placebo Comparator|Placebo|Placebo comparator, weekly
3316048|NCT01971814|Experimental|Early infliximab monitoring group.|A consecutive sample of patients hospitalized with severe ulcerative colitis who are eligible to receive infliximab at 10mg/kg IV.
3316049|NCT01971827|No Intervention|Control|No intervention
3316050|NCT01971827|Experimental|MOVI-KIDS Program|Intervention group
3316051|NCT01971840|Experimental|MOVI-KIDS Program|Intervention group
3316052|NCT01971840|No Intervention|Control|No intervention
3316053|NCT01971879|Sham Comparator|Control|
3316054|NCT01971879|Active Comparator|Remote preconditioning|
3316055|NCT01971892|Experimental|Non invasive ventilation (NIV)|Experimental arm = non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O) NIV will intermittently delivered to the patients for at least six hours (cumulative tme of all trials which lasted at least 30 min) during the first 24h after the initiation of treatment. Between each NIV period, the patient will received supplemental oxygen through facial mask to achieve an oxygen saturation level above 94%.
3316056|NCT01971892|Active Comparator|standard oxygen therapy with facial mask|Patients assigned to standard medical therapy will received supplemental oxygen via a facial Venturi mask at a rate of up to 15 liters per minute with in order to maintain peripheral oxygen saturation above 94%.
3316057|NCT01971905||Oben label|There is no intervention on this descriptive study
3316058|NCT01971918|Experimental|early switch|"early switch of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
3316059|NCT01971918|Experimental|therapeutic intensification|"therapeutic intensification of monoclonal antibodies anti-TNF~anti drug antibodies dosage"
3316060|NCT01971931||Patients undergoing TKR.|
3316061|NCT01971944||Patients achieving steady state concentrations of carvedilol|Patients achieving steady state concentrations of carvedilol who receive a trial of dobutamine followed by milrinone.
3316062|NCT01971944||Patients achieving steady state concentrations of metoprolol|Patients achieving steady state concentrations of metoprolol who receive a trial of dobutamine followed by milrinone.
3316063|NCT01971944||Patients not receiving beta blocker|Patients not receiving beta blocker who receive a trial of dobutamine followed by milrinone.
3316064|NCT01971957||Sjogren-Larsson syndrome|There are no cohorts for this study.
3316065|NCT01971970||Pediatric IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
3316066|NCT01971970||Adult IBD patients|Anti-TNF naive patients with either Crohn's disease or ulcerative colitis will be treated with either Infliximab or Adalimumab
3316067|NCT01971983|Experimental|HVLA|The subjects allocated to this group will receive a 'High-velocity, low-amplitude (HVLA) technique over the lumbar spine.
3316068|NCT01971983|Experimental|ME|Subjects allocated to this group will receive a muscle energy (ME) technique.
3316069|NCT01971983|Sham Comparator|Sham group|"The individuals allocated to this group received an intervention of the sham. The sample of this group will consist of subjects with history of dysfunctions of the lumbar spine."
3316070|NCT01971996||Lumbar spine surgical patients|Patients undergoing lumbar spine surgery in the prone position
3316071|NCT01972009||Subjects without pulmonary hypertension|Patients with normal pulmonary pressures will be recruited amongst patients who are on the waiting list awaiting routine cardiac catheterisation for the investigation of shortness of breath and chest pain.
3316072|NCT01972009||Subjects with pulmonary hypertension|Patients with pulmonary hypertension will be recruited from the National Pulmonary Hypertension Service who are awaiting right and left heart catheterisation studies as part of their routine diagnostic work-up.
3316073|NCT01972022|Experimental|EES SYNERGY™|coronary artery lesions treated with Bioabsorbable Polymer EES
3316074|NCT01972022|Active Comparator|ZES, RESOLUTE Integrity™|coronary artery lesions treated with ZES, RESOLUTE Integrity™ stent system
3316075|NCT01972035|Experimental|ValAcyclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValA or ValG in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
3316076|NCT01972035|Active Comparator|ValGanciclovir|Kidney recipients who give informed consent will be randomly assigned to receive ValG or ValA in a 1:1 ratio. Duration of therapy is 3-12 months depending on risk and age of recipient. Dosing is based on glomerular filtration rate.
3316077|NCT01972048|Active Comparator|Control group|Participants in the control group will receive the mailed print brochure about breast cancer screening and community resources.
3316078|NCT01972048|Experimental|Intervention group|Participants will receive the mMammogram intervention.
3316079|NCT01972087|No Intervention|Control|Participants randomized to the control arm receive no telephone simulation training.
3316080|NCT01972087|Experimental|Simulation Training|Participants randomized to the intervention arm receive telephone simulation training.
3316081|NCT01972100|Active Comparator|Low-level laser therapy (LLLT)|Use of low-level laser therapy (LLLT) to induce a muscle fatigue resistance in intense exercises
3316082|NCT01972100|Active Comparator|Placebo low-level laser therapy (Placebo)|Use of low-level laser therapy (LLLT) placebo to induce a muscle fatigue resistance
3316083|NCT01972113|Placebo Comparator|Placebo-Control|The placebo-control group will take one placebo softgel capsules every day for 8 weeks.
3316084|NCT01972113|Active Comparator|Low-Dose Vitamin K2 (45 mcg/d)|The low-dose vitamin K2 group will take one 45-mcg vitamin K2 softgel capsule and one placebo softgel capsule every day for 8 weeks.
3316085|NCT01972113|Active Comparator|High-Dose Vitamin K2 (90 mcg/d)|The high-dose vitamin K2 group will take one 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
3316086|NCT01972126||AMI patients with LVEF 36% - 50%|Acute myocardial infarction patients with left ventricular ejection fraction between 36% and 50%
3316087|NCT01972139|Experimental|Renal Denervation|Subjects are treated with the renal denervation procedure after randomization.
3316088|NCT01972139|Other|Control|Subjects randomized prior to enrollment closure were treated with sham renal denervation (angiography only). Once enrollment was closed and the protocol revised, no control subjects crossed-over.
3316089|NCT01972165|Experimental|Group I|Mini-incision carpal tunnel release group
3316090|NCT01972165|Active Comparator|Group II|Endoscopic carpal tunnel release group
3316091|NCT01972178|Experimental|PRC-4016|PRC-4016, oral administration once daily, capsule
3316092|NCT01972178|Placebo Comparator|Placebo|Placebo, oral administration once daily, capsule
3316093|NCT01972191||Group 1|Group 1 : Bare eye marking group
3316094|NCT01972191||Group 2|Group 2 : Pendulum attached marker group
3316095|NCT01972191||Group 3|Group 3 : Horizontal slit beam assisted marker group
3316096|NCT01972230|Experimental|Bilanced group|"Sevofluorane adjusted to obtain an Et-Sevo of 1.8-2%, for all the time of the surgical procedure.~Remifentanyl TCI adjusted according to protocol to maintain the range of 1-3 ng / ml."
3316097|NCT01972230|Active Comparator|TCI group|Propofol 3-4 mg / ml and remifentanyl 1-3 ng / ml according to protocol TCI
3316098|NCT01972243||venous thromboembolism|
3316099|NCT01972256||Previous transsacral fusion|Subject candidates are those who had required a transsacral fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
3316100|NCT01972256||Previous transforaminal lumbar interbody fusion|Subject candidates are those who had required transforaminal lumbar interbody fusion at L4-L5-S1 where these were the only lumbar levels treated for pseudoarthrosis, spinal stenosis, spondylolisthesis, or degenerative disc disease (DDD).
3316101|NCT01972269|Active Comparator|bupivacaine-fentanyl 4|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316102|NCT01972269|Active Comparator|bupivacaine-fentanyl 6|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316103|NCT01972269|Active Comparator|bupivacaine-fentanyl 8|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316104|NCT01972269|Active Comparator|bupivacaine-fentanyl 10|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316105|NCT01972269|Active Comparator|bupivacaine-fentanyl 12|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316106|NCT01972269|Active Comparator|bupivacaine-fentanyl 14|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316107|NCT01972269|Active Comparator|bupivacaine-fentanyl 16|Test dose: 3mL of 0.125% bupivacaine-fentanyl 5mcg/mL. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316108|NCT01972269|Active Comparator|lidocaine 4|Test dose: 3mL of 2% lidocaine. Loading dose: 4mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316109|NCT01972269|Active Comparator|lidocaine 6|Test dose: 3mL of 2% lidocaine. Loading dose: 6mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316110|NCT01972269|Active Comparator|lidocaine 8|Test dose: 3mL of 2% lidocaine. Loading dose: 8mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316111|NCT01972269|Active Comparator|lidocaine 10|Test dose: 3mL of 2% lidocaine. Loading dose: 10mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316112|NCT01972269|Active Comparator|lidocaine 12|Test dose: 3mL of 2% lidocaine. Loading dose: 12mL of 0.125% bupivacaine-fentanyl 5mcg/mL.
3316113|NCT01972269|Active Comparator|lidocaine 14|Test dose: 3mL of 2% lidocaine. Loading dose: 14mL of 0.125% bupivacaine-fentanyl 5mcg/mL
3316114|NCT01972269|Active Comparator|lidocaine 16|Test dose: 3mL of 2% lidocaine. Loading dose: 16mL of 0.125% bupivacaine-fentanyl 5mcg/mL
3316115|NCT01972321|Experimental|Technology supported supervision|The technology supported supervision intervention will support the CHWs in providing quality case management for the under-fives who suffer from diarrhea, pneumonia and malaria through unlimited communication with their health facility supervisors and colleagues through closed-user-groups. It will enhance timely reporting of patient data and targeted support supervision on the CHWs who need support from their supervisors. With the CHWs receiving the above support and feedback messages, this will potentially increase CHW motivation, performance and retention. Data reported by CHWs can be used by the district planners to forecasting of medicine procurements and react to drug stock-outs or unusual data trends (e.g. disease outbreaks).
3316116|NCT01972321|Experimental|Community supported supervision|The community supported supervision intervention will set up village health clubs with the aim to improve child health through a community led forum with the CHW as the main focus point. Village health club meetings will provide a forum where CHWs and community members who are part of the club can work together to identify child health and CHW challenges. They will use village networks, knowledge, creativity and other assets.
3316117|NCT01972321|Active Comparator|Control arm|The CHWs in the control arm will be receiving the standard Ministry of Health designed package to integrated community case management support and supervision.
3316118|NCT01972334|Experimental|FMT or fecal microbial transplant|intervention is fecal microbial transplant done through endoscopy, subjects will be randomized 1:1 to receive either FMT or placebo
3316119|NCT01972334|Placebo Comparator|placebo|1:1 randomization to FMT versus placebo (which is saline or salt water)
3316120|NCT01972347|Experimental|Dabrafenib and Trametinib|Dabrafenib 150mg bid orally and Trametinib 2mg od orally for 52 weeks
3316121|NCT01972360||Diagnosis|Group 3: 99mTCSPECT plus stress echocardiography
3316122|NCT01972360||group 1 : diagnosis|Group 1: 99mTcSPECT plus CMR
3316123|NCT01972360||Group 2: diagnosis|Group 2: 99mTcSPECT plus CT
3316124|NCT01972373|Experimental|NIR endoscopy with Bevacizumab-IRDye800CW|In this non-randomized, non-blinded, prospective, feasibility study, bevacizumab-IRDye800CW will be administered to a total of 30 patients with proven locally advanced rectal cancer.
3316125|NCT01972386||Spectrum Image Analysis|
3316126|NCT01972399|Experimental|Laser|A laser will be used to clean out the area around the diseased implant to try to regain bone.
3316127|NCT01972399|Active Comparator|Mechanical|Mechanical debridement will be used to clean out the area around the diseased implant to try to regain bone.
3316128|NCT01972412|Other|Telephone support|Intervention type: Telephone support for four months.
3316129|NCT01972425|Experimental|Biomarker-based diagnostic|Analyse sample on arrival
3316130|NCT01972425|No Intervention|Routine use of antibiotics|Do not analyse the sample on arrival
3316131|NCT01972451|Placebo Comparator|Colonoscopy without enhanced dye|no enhanced dye
3316132|NCT01972451|Active Comparator|Colonoscopy with enhanced dye|enhanced dye
3316133|NCT01972477|Experimental|DLBS1449, 1x75 mg|DLBS1449 softcapsule 1x75 mg daily, taken every day along the study period.
3316134|NCT01972477|Experimental|DLBS1449, 1x150 mg|DLBS1449 softcapsule 1x150 mg (2 softcapsules 75 mg) daily, taken every day along the study period
3316135|NCT01972477|Placebo Comparator|Placebo|Placebo once daily, taken every day along the study period
3316136|NCT01972490|Experimental|ARM A|patients received avastin in combination with mFOLFOX6
3316137|NCT01972490|Active Comparator|ARM B|Patients received mFOLFOX6 alone
3316138|NCT01972503|Experimental|ARM A|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In ARM A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg + curative resection+mFOLFOX6.
3316139|NCT01972503|Active Comparator|ARM B|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm B, patients accepted curative resection + mFOLFOX6 alone.
3316140|NCT01972542|Active Comparator|Type 2 DM|"Intervention : Oral fat tolerance test~well or moderately controlled type 2 diabetes mellitus (HbA1c < 10%) No dipeptidyl peptidase-4 -inhibitor, Glucagon-like peptide-1 agonist, thiazolidinediones"
3316141|NCT01972542|Active Comparator|Prediabetes|"Intervention : Oral fat tolerance test~Glucose 140-199 mg/dL after 75g oral glucose tolerance test HbA1c 5.7-6.4%"
3316142|NCT01972542|Sham Comparator|Normal glucose tolerance|"Intervention : Oral fat tolerance test~No impaired fasting glucose and impaired glucose tolerance"
3316143|NCT01972555|Experimental|Minimally invasive aortic valve replacement|Minimally invasive AVR with either ministernotomy or anterior right-sided minithoracotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
3316144|NCT01972555|Active Comparator|Conventional aortic valve replacement|Conventional AVR through a standard median sternotomy will be performed according to current standard of care practices. Transthoracic echocardiography will be performed preoperatively and at day 1, 4, and 40.
3316145|NCT01972581|Experimental|Reaction Time Training|
3316146|NCT01972581|No Intervention|Control|
3316147|NCT01972594|No Intervention|Control group.|Natural progession based on Step count is recorded with a pedometer for 12 weeks.
3316148|NCT01972594|Experimental|Targeted protocol with Pedometer|A step based targeted protocol is given along with a pedometer for 12 weeks post surgery.
3316149|NCT01972607|No Intervention|CONTROL|This group will receive the same treatment of the experimental group after the test-retest measurements.
3316150|NCT01972607|Experimental|EXERCISE|This group will receive the treatment with aerobic exercise training
3316151|NCT01972620|Active Comparator|Multi-modal analgesia|Thirty-one patients were enrolled in this arm. Standard analgesia according to institutional standard and 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume = 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the 4 laparoscopic port sites (2 ml per port site) prior sutured closure.
3316152|NCT01972620|No Intervention|Control|Thirty-two patients were enrolled in this arm. They received standard analgesia according to institutional standard of practice consisted of non-narcotic analgesia with narcotic analgesic rescue after laparoscopic cholecystectomy.
3316153|NCT01972633|Active Comparator|1470nm Laser|Patient with varicose vein treated with 1470nm Laser (Biolitec)
3316154|NCT01972633|Active Comparator|VNUS Closure Fast|Patient with varicose vein treated with VNUS Closure Fast (Radiofrequency System)
3316155|NCT01972646||Adult patients (≥ 18 years) with uncomplicated cellulitis|Adult patients (≥ 18 years) whose chief complaint was consistent with a skin or soft tissue infection (key words included cellulitis, abscess, infection, insect bite, ulcer, or rash) were screened for eligibility by ED staff or trained research assistants and invited to participate in this study once an emergency physician confirmed a cellulitis infection.
3316156|NCT01972672|Experimental|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
3316157|NCT01972685|Other|Cryo vs Transbronchial vs VATS biopsy|Each patient will be brought to the operating room and will undergo transbronchial, cryoprobe and VATS biopsy of the lung.
3316158|NCT01972698|Experimental|Self-directed and simulation-assisted training|
3316159|NCT01972698|Active Comparator|Traditional apprenticeship training|
3316160|NCT01972711|Experimental|SEP-363856|Single-dose SEP-363856 50 mg
3316161|NCT01972711|Active Comparator|Amisulpride|Single-dose Amisulpride 400 mg.
3316162|NCT01972711|Placebo Comparator|Placebo|Matched placebo
3316163|NCT01972737|Experimental|Ad5-hGCC-PADRE Vaccine|Active vaccine
3316164|NCT01972750|Experimental|Dovitinib|IMP: Dovitinib (TKI258) Manufacturer: Novartis Dose: 500 mg/day Mode of application: orally Duration of treatment: 5 days / week (5 days on / 2 days off) of a 28-days cycle until progression of disease
3316165|NCT01972763|Active Comparator|Ranibizumab 1 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 1), patients will receive 1 mg of Ranibizumab monthly for the remainder of the study, if persistent or worse subretinal fluid with or without intraretinal cysts on SD-OCT is present.
3316166|NCT01972763|Active Comparator|Ranibizumab 0.5 mg|Subjects will receive Ranibizumab 0.5 mg for 3 doses and then be separated into 2 arms based on initial response. In this Arm (Arm 2), patients will receive 0.5 mg of Ranibizumab monthly for the remainder of the study, if complete resolution of subretinal fluid on SD-OCT is present.
3316167|NCT01972828|Experimental|PRELOAD DEPENDENCE|in this arm, fluid loading is administered with an algorithm using preload dependence indexes (variation in cardiac output in response to passive leg raising).
3316168|NCT01972828|Active Comparator|CONTROL|
3316169|NCT01972854|Experimental|riboflavin solution and KXL System|The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
3316170|NCT01972854|Placebo Comparator|placebo solution and KXL System|The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.
3316171|NCT01972880|Experimental|tablet-1|
3316172|NCT01972880|Active Comparator|tablet-2|
3316173|NCT01972893|Experimental|ZYD1|Tablet ZYD1 5 to 50 mg subcutaneously Once a day (OD) or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
3316174|NCT01972893|Placebo Comparator|Placebo|Tablet Placebo 5 to 50 mg subcutaneously OD or BID depending upon the pharmacokinetic profile obtained in Plan I (Single dose study)
3316175|NCT01972906|Experimental|Moxibustion treatment group|Apply traditional acupuncture to prevent the dysmenorrhea according to traditional Chinese medicine theory
3316176|NCT01972906|Active Comparator|Medicine control group|Ibuprofen Sustained Release Capsules will be penetrated for dysmenorrhea
3316177|NCT01972932|Placebo Comparator|Placebo|Placebo 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
3316178|NCT01972932|Active Comparator|Bio K+®|Bio K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
3316179|NCT01972945|Experimental|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
3316180|NCT01972945|Active Comparator|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
3316181|NCT01972958|Experimental|comprehensive care|comprehensive assessment, physical activity training, community resources referral, health education, health promotion activity.
3316182|NCT01972958|No Intervention|usual care|control group with usual care
3316183|NCT01972971|Other|pharmacist care|
3316184|NCT01972984|Experimental|Anastrozole|All qualifying women will receive anastrozole at the usual dose of 1mg daily for 2-6 weeks leading up to their surgery
3316185|NCT01972997|Experimental|SENSIMED Triggerfish|There is only 1 arm in the study. SENSIMED Trigerfish lens sensors with different base curves are placed on subjects in random and double-blinded manner in sequential sessions.
3316186|NCT01973010|Experimental|Massage|To treat low back pain with massage
3316187|NCT01973010|Active Comparator|Ibuprofen|Medicine control group
3316188|NCT01973023||Chronic spastic stroke patients|Chronic spastic stroke patients treated regularly with botulinum toxin injection in lower limb muscles
3316189|NCT01973049|Experimental|A1: DCV/ASV/BMS-791325+Placebo matching RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0mg tablet orally twice a day for 12 weeks"
3316190|NCT01973049|Experimental|A2: DCV/ASV/BMS-791325 + RBV (naive)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200mg tablet orally twice a day for 12 weeks"
3316191|NCT01973049|Experimental|A3: DCV/ASV/BMS-791325+Placebo matching RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Placebo matching Ribavirin 0 mg tablet orally twice a day for 12 weeks"
3316192|NCT01973049|Experimental|A4: DCV/ASV/BMS-791325 + RBV (experienced)|"Triple fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg, BMS-791325 75 mg) tablet orally twice a day for 12 weeks~Ribavirin 200 mg tablet orally twice a day for 12 weeks, Weight based dosing: If < 75 kg, 1000 mg per day (two 200 mg tablets in AM and three 200 mg tablets in PM); if ≥ 75 kg, 1200 mg per day (three 200 mg tablets in AM and three 200 mg tablets in PM), AM=in the morning, PM=in the evening"
3316193|NCT01973075||premature ovarian Insufficiency|4ml whole blood sample is going to collect from premature ovarian Insufficiency group for the assessment of genetic abnormalities
3316194|NCT01973075||healthy control group|4 ml of whole blood is going to taken from healthy control group
3316195|NCT01973088||non-urate calculus|
3316196|NCT01973088||non-calculus|
3316197|NCT01973088||urate calculus|
3316198|NCT01973101|Experimental|Chemo-induction|Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy
3316199|NCT01973101|Active Comparator|Chemoradiotherapy|Cisplatin, radiotherapy and brachytherapy
3316200|NCT01973114|Experimental|Group 1|One intratympanic injection of latanoprost (Day1)
3316201|NCT01973114|Placebo Comparator|Group 2|One intratympanic injection of placebo
3316202|NCT01973114|Experimental|Group 3|Three intratympanic injections of latanoprost (Day 1, 2 and 3)
3316203|NCT01973114|Placebo Comparator|Group 4|Three intratympanic injections of placebo (Day 1, 2 and 3)
3316204|NCT01973127|Experimental|Verum rTMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of verum rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at baseline and 2,4,8 and 12 weeks after start treatment."
3316205|NCT01973127|Sham Comparator|Sham TMS|"n=15. After detoxification of alcohol (maximum 4 days) rTMS treatment will start : 20 sessions (5 times during 4 weeks)of sham rTMS on the right dorsolateral prefrontal cortex.~Measurements of all objectives at basleine and 2,4,8 and 12 weeks after start treatment."
3316206|NCT01973140|Other|Tolvaptan and Hypertonic saline infusion|Tolvaptan 60 mg or 30 mg tablet by mouth for the first part of the study. A week later, infusion of hypertonic saline.
3316207|NCT01973153|Active Comparator|Brief Motivational Counseling (BMC)|
3316208|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Phone Calls (BMC+Phone)|
3316209|NCT01973153|Active Comparator|Brief Motivational Counseling Plus Home Visits (BMC+Home)|
3316210|NCT01973166|Experimental|Picosecond Q-switched Laser Treatment|Picosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
3316211|NCT01973166|Active Comparator|Nanosecond Q-switched Laser Treatment|Nanosecond Q-switched Nd:YAG (1064 nm and 532 nm) laser
3316212|NCT01973179||Radiation therapy|Radiotherapy with protons in patients with head and neck carcinoma
3316213|NCT01973244|Experimental|NNC0195-0092 (somapacitan)|
3316214|NCT01973244|Active Comparator|Norditropin®|
3316215|NCT01973257|Experimental|select from the option menu|select from the option menu
3316216|NCT01973270|Experimental|Targeted Cognitive Training - TCT|Neuroadaptive cognitive training
3316217|NCT01973270|Experimental|General Cognitive Exercises (GCE)|Neuroadaptive cognitive training
3316218|NCT01973270|No Intervention|Treatment as Usual|Treatment as Usual
3316219|NCT01973296|Experimental|ED to home care transition|The ED to home care transition intervention is a 4-week program that uses a Area Agency on Aging coach to conduct a home visit and three follow up phone calls to help patients develop the skills needed for self-management and to communicate with healthcare providers.
3316220|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
3316221|NCT01973309|Experimental|Vantictumab combined with paclitaxel|Drug: vantictumab combined with paclitaxel - administered intravenously
3316222|NCT01973322|Experimental|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
3316223|NCT01973322|Experimental|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
3316224|NCT01973322|Experimental|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
3316225|NCT01973322|Experimental|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
3316226|NCT01973361|Experimental|Ultrasound debridement|Participants receiving ultrasound assisted debridement in addition to best practice wound care.
3316227|NCT01973361|Active Comparator|Best Practice wound care|Participants receiving best practice wound care alone
3316228|NCT01973374|No Intervention|Routine Care|
3316229|NCT01973374|Experimental|Text Message Intervention|The text message intervention group receives usual prenatal and diabetic care in addition to two text messages per week throughout the pregnancy and a reminder text message prior to the postpartum visit. The text message intervention group also fills out a survey about the intervention after delivery.
3316230|NCT01973400|Experimental|Tocotrienol|200 mg, twice a day, 12 months
3316231|NCT01973400|Placebo Comparator|Placebo|200 mg, twice a day, 12 months
3316232|NCT01973426||Children with limited control of their thumb|Children afflicted by hemiplegic stroke or hemiplegic cerebral palsy who have lost the ability to actively (and accurately) control the thumb.
3316235|NCT01973465|Experimental|Fecal Microbiota Therapy|
3316236|NCT01973478|Experimental|DBS|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is on during 6 months (between Month 1 and Month 7). Stimulation will also be on after Month 7."
3316237|NCT01973478|Sham Comparator|SHAM|"The medical device includes:~Either a pacemaker ACTIVA PC (Ref 37601) two-channel (Medtronic USA) or two pacemakers Activa SC (Ref 37603) to a channel (Medtronic USA)~Two DBS electrodes with four contacts (type Medtronic DBS 3389). Patients will be operated with the usual stereotactic surgical procedure.~The target is the Accumbens nucleus.~The two electrodes are implanted in a single session under local anaesthesia or intermittent sedation (propofol parenteral without intubation early intervention). Day 0 is defined by the surgery.~The DBS is off during 6 months (between Month 1 and Month 7). Possibility to active the stimulation after Month 7."
3316238|NCT01973504|Experimental|MP4OX 500-mL|500-mL dose of MP4OX
3316239|NCT01973504|Experimental|MP4OX 750-mL|750-mL dose of MP4OX
3316240|NCT01973504|Sham Comparator|Control|Standard crystalloid Keep Vein Open (KVO) infusion
3316241|NCT01973517||Relapsing Remitting MS|Patients with relapsing remitting multiple sclerosis will be imaged under high-field (7T) MRI prior to and following administration of gadolinium-based contrast (0.1 mmol/kg IV). Afterwards, they will be administered Feraheme 5mg/kg IV via slow push, and they will return 24 hours or later after pharmaceutical administration for post-Feraheme MR imaging.
3316242|NCT01973530|Active Comparator|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
3316243|NCT01973530|Other|continuous femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
3316244|NCT01973543|Experimental|VY-AADC01 Dose 1|7.5 x 10^11 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3316245|NCT01973543|Experimental|VY-AADC01 Dose 2|1.5 x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3316246|NCT01973543|Experimental|VY-AADC01 Dose 3|4.7x 10^12 vector genomes of VY-AADC01; Single dose, neurosurgically infused, bilaterally into the striatum.
3316247|NCT01973556|Experimental|Pharmacist-Physician Collaborative Medication Management|Pharmacist-Physician Collaborative Medication Management
3316248|NCT01973556|No Intervention|Usual Care|
3316249|NCT01973634|Active Comparator|Minimal surgical margin 1 mm, conventional arm: seq boost|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost).
3316250|NCT01973634|Experimental|Minimal surgical margin of 1 mm, experimental arm with SIB|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
3316251|NCT01973634|Active Comparator|Minimal surgical margin <1 mm, conventional arm: seq boost|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
3316252|NCT01973634|Experimental|Minimal surgical margin < 1 mm, experimental arm with SIB.|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
3316253|NCT01973647|Experimental|Cognitive Behavioral Therapy (CBT-I)|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia
3316254|NCT01973647|Experimental|CBT-I + COPD-ED|Six weekly sessions of Cognitive Behavioral Therapy for Insomnia plus COPD Education
3316255|NCT01973647|Experimental|COPD Education (COPD-ED)|Six weekly sessions of COPD education
3316256|NCT01973647|Placebo Comparator|Attention Control (AC)|Six weekly sessions of non-sleep, non-COPD health education
3316257|NCT01973660|Experimental|Dual HER2 blockade|For a total of 18 weeks, HR-negative patients will be given dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
3316258|NCT01973660|Experimental|Dual HER2 blockade plus endocrine therapy|For a total of 18 weeks, HR-positive patients will be given letrozole (2.5 mg daily) or tamoxifen (20 mg daily) with concurrent dual blockade consisting of daily lapatinib at 1000 mg and trastuzumab at a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks.
3316259|NCT01973673|Active Comparator|Bone health educational materials|Bone health written educational materials, Bone health prescription,verbal counselling
3316260|NCT01973673|No Intervention|Usual care|Usual clinical care to be provided by oncologists.
3316261|NCT01973686|Experimental|Vigorous intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3316262|NCT01973686|Experimental|Moderate intensity LTPA|Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week
3316263|NCT01973686|No Intervention|Control|Receives no intervention
3316264|NCT01973699|Placebo Comparator|With Epinephrine|Patients undergoing shoulder arthroscopy with epinephrine in their irrigation as standardly performed
3316265|NCT01973699|Experimental|Without Epinephrine|Patients undergoing shoulder arthroscopy without epinephrine in their irrigation fluid as typically done
3316266|NCT01973712|Experimental|Locked Compression Plating|A direct lateral approach to the distal femur will be employed utilizing minimally invasive and indirect reduction techniques. After fracture reduction is achieved with the use of intra-operative fluoroscopy, a locking plate will be provisionally implanted. Following confirmation of placement, definitive fixation will follow with multiple locking screws in the distal fragment and bicortical screw fixation proximally. A standard layered closure will follow
3316267|NCT01973712|Experimental|Retrograde Intramedullary Nailing (RIMN)|The previous midline knee incision will be employed to access to the knee joint, allowing exposure of the femoral start point via the open box in the femoral component. Following reaming of the canal, an appropriately sized retrograde nail will be inserted. Intra-operative fluoroscopy will be used to confirm reduction. Both proximal and distal locking screws will be used to transfix the nail. A standard layered closure will follow.
3316268|NCT01973725|Experimental|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
3316269|NCT01973751|No Intervention|Healthy controls|Healthy controls who will be studied at baseline and serve as a control group for the bronchoscopy, induced sputum and peripheral blood collection.
3316270|NCT01973751|Active Comparator|Asthmatics (treatment)|Steroid-naïve asthma, randomized to inhaled budesonide, 2 puffs (200mcg) twice a day for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks after treatment with inhaled corticosteroids.
3316271|NCT01973751|No Intervention|Asthmatics (no treatment)|Steroid-naïve asthmatics randomized to no treatment for 8 weeks. These subjects will undergo bronchoscopy and induced sputum collection at baseline, undergo pulmonary function testing and peripheral blood collection at baseline, 4 and 8 weeks of no treatment.
3316272|NCT01973764|Other|Ultrasound guided arm|
3316273|NCT01973764|Other|Landmark-based arm|
3316274|NCT01973790|Experimental|Z-338|100mg TID
3316275|NCT01973816|Experimental|Medical treatment|The patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months.
3316276|NCT01973816|Active Comparator|Surgical|The patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months.
3316277|NCT01973829|Other|Baseline arm|baseline data (50 patients or 3 months per center)
3316278|NCT01973842|Active Comparator|0.2 mg triptorelin|0.2 mg triptorelin compared with 0.1 mg triptorelin and 0.4 mg triptorelin
3316279|NCT01973842|Active Comparator|0.1 mg triptorelin|0.1 mg triptorelin compared with 0.2 mg triptorelin and 0.4 mg triptorelin
3316280|NCT01973842|Active Comparator|0.4 mg triptorelin|0.4 mg triptorelin compared with 0.1 mg triptorelin and 0.2 mg triptorelin
3316281|NCT01973855|Experimental|TCM and Western Medicine|TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine：Ribavirin 10-15mg per kg every time
3316282|NCT01973855|Placebo Comparator|Western Medicine|Western Medicine：Ribavirin 10-15mg per kg every time
3316283|NCT01973868|Experimental|Regorafenib|"Regorafenib will be administered once daily on Days 1-21 of each 28-day Cycle (3 weeks on / 1 week off). The starting dose of regorafenib is 120 mg q.d., if this is tolerable in combination with cetuximab the dose will be escalated to 160 mg q.d.; if it is not tolerated the dose will be de-escalated to 80 mg q.d.~Subjects will receive an initial i.v. infusion of cetuximab (loading dose of 400 mg/ m2 BSA) on Pre-cycle Day -7.~The treatment of regorafenib in combination with cetuximab maintenance dose (250 mg/m2 BSA) starts on Cycle 1 Day 1.~Cetuximab infusions will be given in a once-weekly dosing-regimen as approved."
3316284|NCT01973881||T1 weighted MRI (magnetic resonance imaging)|For the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis. Quantitative MRI parameters for diffusion of water and/or fat content in bone marrow will determine extent of disease in patients with myelofibrosis, and changes in these parameters will predict response to therapy. To investigate this hypothesis, the researchers will perform this pilot clinical study of diffusion and fat content (T1 weighted imaging) in patients before and during treatment for myelofibrosis. The researchers expect to identify MRI parameters that determine the extent and severity of bone marrow disease in these patients and determine response to therapy at earlier time points than currently used clinical parameters.
3316285|NCT01973894||Midazolam|"Patients will be enrolled within 24h from the beginning of continuous Midazolam perfusion.~Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine.~Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
3316286|NCT01973907|No Intervention|Usual Care Resuscitation Strategy|Decisions regarding the IV/IO administration of isotonic fluid boluses and/or the initiation and escalation of vasoactive medication infusions are left to the discretion of the treating physician and medical team. We ask that vasoactive medications not be initiated until at least 60 mL/kg (3 litres for children ≥ 50 kg) of isotonic fluid bolus therapy has been administered. The treating physician and medical team are advised to follow ACCM guidelines for the resuscitation of neonatal and pediatric septic shock and to target ACCM recommended therapeutic endpoints.
3316287|NCT01973907|Experimental|Fluid Sparing Resuscitation Strategy|The treating physician and medical team are advised to follow the assigned Fluid Sparing Resuscitation Strategy to guide decisions regarding the IV/IO administration of further isotonic fluid boluses, and the timing of initiation and escalation of vasoactive medication infusions to target the therapeutic endpoints recommended in the ACCM guidelines for the resuscitation of neonatal and pediatric septic shock.
3316288|NCT01973920|Experimental|Oshadi Icp|Oshadi Icp oral insulin,
3316289|NCT01973933|Experimental|Metformin and Pyrimethamine|Metformin 750mg(D1), Metformin 500mg(D2)/Metformin 750mg+Pyrimethamine 50mg(D7), Metformin 500mg+Pyrimethamine 50mg(D8)
3316290|NCT01973946|No Intervention|Usual Care|Patients in the usual care group called the automated monitoring system daily to report presence, severity, and distress for 11 common symptoms. The attentional control group received equivalent contact time with the automated system including identical voice and assessment questions. Patients did not hear self-care messages during the call and the data were not available for clinical action by the study nurse practitioner. Patients were told on every phone call to call their oncology providers if they had concerns about their symptoms which is usual care for symptom follow up in oncology.
3316291|NCT01973946|Experimental|Symptom Alert and Coaching|"Patients in the Symptom Alert and Coaching arm called the automated monitoring system daily to report presence, severity, and distress on 11 symptoms. The system provided automated self care coaching based on the symptoms reported and automatically generated alerts to the study NP if symptoms exceeded preset thresholds. Two thresholds were set: a simple alert when severity or distress was 4 or greater on a 10 point scale and trend alerts based on a pattern of moderate severity over several days.~The alerts went into a case management site. The study NP logged into the system daily and responded to the alerts within 24 hours by calling patients to further assess the symptoms and to intensify symptom treatment using evidence based guidelines."
3316292|NCT01974011|Experimental|Dorsal penile nerve block according to Dalens' technique|Two injections at the dorsum penis according to Dalens' technique.
3316293|NCT01974011|Active Comparator|DPNB with additional infiltration of the ventromedial penis|"Modified procedure:~Two injections at the dorsum penis according to Dalens' technique plus on subcutaneous injection in the ventral midline of the penis at the transition between the penis and the scrotum."
3316294|NCT01974024|Experimental|Methylprednisolone|Dexamethasone was replaced with methylprednisolone as an antiemetic.
3316295|NCT01974024|Active Comparator|Dexamethasone|Dexamethasone was re-administered in the cycle.
3316296|NCT01974037|Active Comparator|Capsaicin_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water with capsaicin.
3316297|NCT01974037|Experimental|Capsaicin_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl with capsaicin.
3316298|NCT01974037|Experimental|Capsaicin_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl with capsaicin.
3316299|NCT01974037|No Intervention|Capsaicin_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
3316300|NCT01974037|No Intervention|Salt_effect subgroup 1|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of water.
3316301|NCT01974037|Experimental|Salt_effect subgroup 2|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 100 mmol/L NaCl.
3316302|NCT01974037|Experimental|Salt_effect subgroup 3|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 150 mmol/L NaCl.
3316303|NCT01974037|Experimental|Salt_effect subgroup 4|The volunteers allocated to the arm will perform neuroimaging detection with buccal administration of 200 mmol/L NaCl.
3316304|NCT01974063||A. Nonsmokers|Subjects have smoked <100 cigarettes or <10 shisha pipes per lifetime and whose urine nicotine <2 ng/mL and/or urine cotinine <5 ng/mL, at entry into the study.
3316305|NCT01974063||B.Current cigarette smokers|Defined by self-report and urine nicotine >30 ng/mL and/or urine cotinine >50 ng/ml.
3316306|NCT01974063||C. Current shisha smokers|Defined by self-report of smoking >4 pipes/wk and carboxyhemoglobin >2.5.
3316307|NCT01974063||D. smokers willing to quit|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Subjects must be a current smoker willing to stop smoking. Subjects will stop smoking after the baseline bronchoscopy, and switch to taking a smoking cessation medication called varenicline. We will provide subjects with the smoking cessation medication as part of this study. They will also receive phone calls to help with smoking cessation counseling.
3316308|NCT01974063||E. Smokers switching to E-cigarettes|Defined by self-report and urine nicotine >30 ng/ml and/or urine cotinine >50 ng/ml. Must be willing to switch from tobacco cigarettes to electronic cigarettes. The switch will occur after the baseline bronchoscopy. The nicotine dose that will be given to each subject will be determined by the study physician based on the urine smoking metabolite test. It will be adjusted depending on whether the subject is a light smoker or heavy smoker (Light smoker defined as having either a urine nicotine value from 2ng/ml-1000ng/ml or a urine cotinine value from 5ng/ml-1000ng/ml. Heavy smoker is defined as having either a urine nicotine or cotinine value of over 1000ng/ml.) We will provide the subjects with the electronic cigarettes to use as part of this study.
3316309|NCT01974076|Active Comparator|Active tDCS|
3316310|NCT01974076|Sham Comparator|Sham tDCS|
3316311|NCT01974115|Active Comparator|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
3316312|NCT01974154||Cohort I|A. Healthy nonsmokers B. Healthy smokers C. Healthy smokers/quit smoking D. COPD smokers E. COPD smokers/ quit smoking
3316313|NCT01974154||Cohort II|A. Smokers with normal spirometry and normal DLCO B. Smokers, normal spirometry, low DLCO
3316314|NCT01974167|Experimental|Eldecalcitol group|Eldecalcitol 0.75 microgram once daily orally
3316315|NCT01974167|Active Comparator|Alfacalcidol group|Alfacalcidol 1 microgram once daily orally
3316316|NCT01974193|Experimental|Floseal|application of floseal to one side of pelvis after pelvic lymphadenectomy
3316317|NCT01974193|No Intervention|Control|counter-site of pelvis; no intervention after pelvic lymphadenectomy
3316320|NCT01974219||Healthy nonsmokers|Healthy nonsmokers
3316321|NCT01974219||Healthy smokers|Healthy smokers
3316322|NCT01974219||COPD smokers|COPD smokers
3316323|NCT01974232||Romiplostim group|
3316324|NCT01974232||Eltrombopag group|
3316325|NCT01974258|Experimental|Dose-expansion: onartuzumab + cobimetinib|
3316326|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib|
3316327|NCT01974258|Experimental|Dose-expansion: onartuzumab + vemurafenib + cobimetinib|
3316328|NCT01974258|Experimental|Dose-finding: onartuzumab + vemurafenib + cobimetinib|
3316329|NCT01974271||Cohort|
3316330|NCT01974297|Active Comparator|Atorvastatin 20mg, monotherapy|Atorvastatin 20mg/day PO for 12weeks
3316331|NCT01974297|Experimental|Atorvastatin 10mg, Fenofibric acid 135mg|Atorvastatin 10mg, Fenofibric acid 135mg per day PO for 12weeks
3316332|NCT01974310|Active Comparator|Face-down positioning|Patients advised face-down positioning after surgery for macular hole.
3316333|NCT01974310|Experimental|Non-face-down positioning|Patients advised non-face-down positioning after surgery for macular hole.
3316334|NCT01974336|Experimental|UDCA+placebo group|15-30mg/kg/d UDCA for 2 months + placebo for 2 months
3316335|NCT01974336|Experimental|placebo+UDCA|placebo for 2 months+15-30mg/kg/d UDCA for 2 months
3316336|NCT01974349|Experimental|selumetinib 75mg (oral capsule fasted)|Volunteers will recieve selumetinib 75mg administered by mouth, as a capsule, in a fasted state.
3316337|NCT01974349|Experimental|selumetinib 75mg (oral capusle fed)|Volunteers will receive selumetinib 75mg administered by mouth, as a capsule, in a fed state.
3316338|NCT01974362||Cad/Cam Monolithic Zirconia|Patients that have a full-mouth (maxilla and mandible) dental implant supported rehabilitation restored with monolithic zirconia biomaterial
3316339|NCT01974362||Zirconia-Feldspathic|Patients that have a full-mouth (maxilla and mandible) implant supported rehabilitation restored with zirconia substructure and feldspathic veneered biomaterial
3316340|NCT01974375|Experimental|micafungin|micafungin sodium IV (Mycamine®)
3316341|NCT01974375|Active Comparator|Fluconazole|Fluconazole IV (use same brand in each hospital)
3316342|NCT01974388|Active Comparator|LSG started 2 cm from the pylorus|laparoscopic sleeve gastrectomy starting 2 cm from the pylorus
3316343|NCT01974388|Active Comparator|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
3316344|NCT01974401|Active Comparator|water jet irrigator|patients used supra-gingival irrigators as an oral health measure
3316345|NCT01974401|No Intervention|control group|patients in this group received routine oral health care protocols.
3316346|NCT01974414|Active Comparator|cedar honey|The two study groups were provided with standard treatment(dexamethasone and Fluconazole).The Case group(A) received cedar honey, 20 ml 3 times daily by swish and swallow technique, in addition to the standard treatment .
3316347|NCT01974414|No Intervention|control group|the control group (B) only received standard treatment(Dexametazone and Fluconazole).
3316350|NCT01974453||Right transradial|Procedures performed through right transradial approach
3316351|NCT01974453||Left transradial|Procedures performed through left transradial approach
3316352|NCT01974453||Femoral|Procedures performed through transfemoral approach
3316353|NCT01974466|Active Comparator|Goal A|"controled fluid therapy: 5~10ml/kg/hr fulfillment of two or more of four criteria:~heart rate <120 beats/min,~mean arterial blood pressure 65-85 mm Hg,~urine output ≥1 ml/kg /h~Hematocrit ≤35%."
3316354|NCT01974466|Other|Goal B|"controled fluid therapy: 5~10ml/kg/hr fulfillment of all of the following criteria:~1 central venous pressure8-12 mmHg , 2.mean arterial pressure 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
3316355|NCT01974479|Experimental|anti-CD19 redirected NK cells|This is a single arm study. Intravenous Infusion of activated NK cells bearing anti-CD19-BB-zeta receptors at cell dose of 0.5 - 5 x 10^7 CD56+ cells/kg, and up to 1 x 10^8 CD56+ cells/Kg
3316356|NCT01974492|Active Comparator|Upper leg vein|Upper leg vein harvesting
3316357|NCT01974492|Active Comparator|Lower leg vein|Lower leg vein harvesting
3316358|NCT01974505|Experimental|intubation using optiscope|The investigators are novice on optiscope. They will perform intubation using optiscope to patients scheduled elective surgery.
3316359|NCT01974518|Active Comparator|Rituximab|Inj Rituximab 1 gram IV given on day 0 and day 15
3316360|NCT01974518|Active Comparator|Combination of Rituximab and Cyclophosphamide IV|IV Rituximab 1gram on day 0 and 15 750 mg IV cyclophosphamide in 250 ml of NS over 2-3 hr on day 1 and day 16
3316361|NCT01974531||Preterm birth/ Timely birth|
3316362|NCT01974531||Women/men|
3316363|NCT01974544|Experimental|Best medical treatment|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will will be treated using the American Diabetes Association protocol. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3316364|NCT01974544|Experimental|gastric bypass surgery|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo gastric bypass surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3316365|NCT01974544|Experimental|sleeve gastrectomy|Fifty obese patients with kidney damage or high risk of kidney damage secondary to T2DM will undergo sleeve gastrectomy surgery, in the conventional procedure. Also this arm will be treated like: General interventions for all groups: blood presure, General interventions for all groups: dysilipidemia and General interventions for all groups: lifestyle establishes.
3316366|NCT01974570|Experimental|Marealis refined peptide concentrate|Participants are provided in double blinded fashion to Marealis refined peptide concentrate
3316367|NCT01974570|Placebo Comparator|Placebo|Participants are provided in double blinded fashion to Placebo
3316368|NCT01974583||the treatment group A|The people in treatment group were regrafted with thin split-thickness skin graft
3316369|NCT01974583||the control group B|The group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
3316370|NCT01974583||the control group C|Group C were covered with paraffin gauze
3316371|NCT01974596|Experimental|Probiotic Lactobacillus reuteri Vs Placebo|patients with full arch with dental implant received a tablet of Lactobacillus reuteri every day during 28 days, and after a wash-up, the same patients receive a tablet of placebo every day during 28 days
3316372|NCT01974609|Experimental|Narcotic|Hydrocodone + acetaminophen 4 times per day 1 week after surgery
3316373|NCT01974609|Active Comparator|non-narcotic|ibuprofen + acetaminophen 4 times per day 1 week after surgery
3316374|NCT01974622|Experimental|Visudyne|Visudyne half fluence- 1 treatment with the possibility of a second treatment.
3316375|NCT01974648|Active Comparator|propofol|In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
3316376|NCT01974648|Experimental|propofol and remifentanil|In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.
3316377|NCT01974661|Experimental|COMBIG-DC|COMBIG-DC (allogeneic dendritic cells) Cancer Vaccine 3 vaccinations: 5, 10 or 20 million cells per injection
3316378|NCT01974674|Experimental|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet number required for insulin independence of obtaining, with a threshold dose of 9,000 IEQ/kg body weight of the recipient and a maximum sequence number of 3 infusions. The patient will receive after transplantation immunosuppressive therapy with Thymoglobulin for induction, Prograf and Cellcept, both of which are given throughout the duration of the study
3316379|NCT01974726|Other|affected, intact tympanic membranes|History of middle-ear disease, ears with no holes/perforations/patent tympanostomy tubes in eardrum
3316380|NCT01974726|Other|affected, non-intact tympanic membranes|History of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
3316381|NCT01974726|Other|controls, intact tympanic membranes|No history of middle-ear disease, ears with no hole/perforation/patent tympanostomy tube in eardrum
3316382|NCT01974726|Other|controls, non-intact tympanic membranes|No history of middle-ear disease, ears with hole/perforation/patent tympanostomy tube in eardrum
3316383|NCT01974739|Active Comparator|hydrochloorthiazide|once a day 25 mg
3316384|NCT01974739|Placebo Comparator|placebo|once a day placebo
3316385|NCT01974778|Experimental|Active|Meal
3316386|NCT01974778|Placebo Comparator|Control|Water
3316387|NCT01974791|Experimental|GET Living Treatment|
3316388|NCT01974804||Pts having an MRI|Patients will undergo a 20 minute pretreatment MRI scan and a 30 minute post treatment MRI scan with contrast agent administration. Ten patients with brain metastasis will be recruited in the study. All the patients will be undergoing SRS (Stereotactic Radiosurgery). Patients will have 1 pretreatment evaluation and 2 post treatment evaluations [1-72 hours post treatment and 8 weeks (+/- 2 weeks) post treatment] for early response. Patients are to be administered contrast prior to obtaining MRI scans. These research scans are estimated to take 20 minutes of scan time (+/- 10 minutes), which includes patient set up and conducting the research sequences..
3316389|NCT01974830||Adult Alpha-1 Patients|Adult Alpha-1 patients receiving augmentation therapy in the home through Coram
3316390|NCT01974843||Group BT|Bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg
3316391|NCT01974843||Group LT|Levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg, resulting in a total volume of 1 ml/kg.
3316392|NCT01974869||Inflammatory bowel diseases-1|Treatment with anti-tumor necrosis factor alpha agents
3316393|NCT01974869||Inflammatory bowel diseases-2|Controls
3316394|NCT01974882|Experimental|Cryotherapy|Patients in the cryotherapy study group will have ice packs placed on their abdominal wound for the first hour following surgery.
3316395|NCT01974882|No Intervention|Control|No adjunctive therapy following abdominal surgery.
3316396|NCT01974908|Experimental|Ventricular Tachycardia (VT)|Patients with VT will undergo a clinically indicated ablation of their VT
3316397|NCT01974921|Experimental|Bronchial thermoplasty|ALAIR Catheter. Radiofrequency system.
3316398|NCT01974934|Experimental|Desvenlafaxine Succinate|
3316399|NCT01974947||Infertile men|Man partner of an infertile couple. Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
3316400|NCT01974973|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
3316401|NCT01974986|Placebo Comparator|Placebo|Water with flavoring and non-nutritive sweetener.
3316402|NCT01974986|Experimental|High-Na low-CHO beverage|Beverage containing sodium concentration of 40 to 50 mEq/L and carbohydrate concentration between 310 and 350 mmol/L.
3316403|NCT01974986|Experimental|Low-Na high-CHO beverage|Beverage containing sodium concentration of 15 to 25 mEq/L and carbohydrate concentration between 120 and 160 mmol/L.
3316404|NCT01975012|Experimental|Cohort 1: 6 to less than 12 years of age|Participants in this arm will be at least 6 but younger than 12 years of age; they will receive the study drug RPV together with 2 other NRTIs.
3316405|NCT01975012|Experimental|Cohort 2: 2 to less than 6 years of age|Participants in this arm will be at least 2 but younger than 6 years of age; they will receive the study drug RPV together with 2 other NRTIs.
3316406|NCT01975025|Experimental|All study participants|Short daily dialysis for 2 weeks
3316407|NCT01975038||A convenience sample|The characteristics of the sample will be monitored to assure that each category of skin type (I- VI) is accrued in sufficient size to support analysis. In addition, the sample will have equal representation from 4 ethnic groups within each skin type category: African American, Asian, Hispanic, or non-Hispanic White. Participants will self-identify as being Asian, Black, Hispanic Black, Hispanic White, or non-Hispanic White.
3316408|NCT01975051|Experimental|Miltefosine|Tablet Miltefosine 100 mg daily in two divided doses for 12 weeks.
3316409|NCT01975064|Active Comparator|Propofol|Propofol for maintenance of anesthesia
3316410|NCT01975064|Active Comparator|Sevoflurane|Sevoflurane for maintenance of anesthesia
3316411|NCT01975077|Experimental|A- 4mg QD|arm A- fruquintinib 4mg once daily, p.o.,continuous;given in 28-days cycles until disease progress, intolerable toxicity or patients withdrawal of consent
3316412|NCT01975077|Experimental|B- 5mg once daily, 3wks on/1wk off|arm B-fruquintinb 5mg once daily,p.o.,3 weeks on/1 week off, given in 28-day cycles until disease progress,intolerable toxicity or patients withdrawal of consent
3316413|NCT01975103|Experimental|Topcon Endpoint management|Active laser treatment
3316414|NCT01975103|Sham Comparator|Control|Powerless (sham) laser treatment
3316415|NCT01975116|Experimental|Treatment: p28|Pts receive azurin-derived cell-penetrating peptide p28 IV over 15 min 3x/week for 4 wks. Tx repeats every 6 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.
3316416|NCT01975129|Experimental|Vagitocin (Oxytocin)|
3316417|NCT01975142|Experimental|TDM-1|
3316418|NCT01975155||Celiac|patients with celiac disease filling the questionnaire and undergoing urinary test
3316419|NCT01975155||healthy controls|healthy patients filling the questionnaire and undergoing urinary test
3316420|NCT01975168|Experimental|Group 1|arrange laser acupuncture intervention for 12 weeks, then cross over to sham laser acupuncture intervention for 12 weeks
3316421|NCT01975168|Sham Comparator|Group 2|arrange sham laser acupuncture for 12 weeks, then cross over to laser acupuncture for 12 weeks
3316422|NCT01975194|Experimental|Rosuvastatin|Patients that receive rosuvastatin
3316423|NCT01975207|No Intervention|Group 1|"Patients will have information collected on their quality of life (QOL) at baseline (EuroQual 5-item measure - EQ-5D). Patients will be followed up at week 12 for a repeated measure of QOL and a score on the depression rating scale being used in this study (Patient Health Questionnaire-9 item version - PHQ-9). Individuals will also be asked on their health care access frequency (HCAF) at baseline and follow up."
3316424|NCT01975207|Experimental|Group 2|"Group #2. Screening for depression followed by treatment as usual: Patients will complete baseline measurements of their score on the PHQ-9, self-reported HCAF and QOL (EQ-5D) score.~The PHQ-9 score will be given to the clinic staff who will then follow up with treatment as usual. Patients will be followed up at week 12 for self-reported HCAF,PHQ-9 and QOL scores."
3316425|NCT01975207|Experimental|Group 3|Group #3 is Internet intervention: At baseline patients will complete QOL (EQ-5D), PHQ-9 scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered a guided internet-based intervention for the treatment of depression by the study staff. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL scores.
3316426|NCT01975207|Experimental|Group 4|Depression Treatment Pathway: At baseline patients will complete PHQ-9, QOL (EQ-5D) scores, and self-reported HCAF. Those who score 10 or more on the PHQ-9 will be offered the specific treatment as determined by the Depression Pathway by the clinic physician. Whenever possible, this pathway will be integrated into the local clinic's electronic medical record system, for ease of administration by the clinic. Patients will be followed up at week 12 for self-reported HCAF, PHQ-9 and QOL (EQ-5D) scores.
3316427|NCT01975233||WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 75 years requiring treatment for intracranial aneurysms.
3316428|NCT01975259||Cystic Fibrosis|"Adult patients with confirmed cystic fibrosis who are clinically stable. Interventions:~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich) Continuous Glucose Monitoring"
3316429|NCT01975259||Controls|"Adult Non-CF subjects matched for age and body mass index with normal glucose tolerance.~Oral Glucose Tolerance test (75g 2-hour) Modified Oral Glucose Tolerance Test (50g 4-hours) Matched isoglycemic clamp Hyperglycemic clamp with concurrent GLP-1 infusion Hyperglycemic Clamp with concurrent GIP infusion Hyperglycemic clamp with placebo infusion Liquid Meal Test (Carbohydrate-rich)"
3316430|NCT01975272|Active Comparator|Ferinject|Once an infusion of Ferinject 1000 mg, 1 day after surgery
3316431|NCT01975272|Active Comparator|Ferrous fumarate|2 times a day 200 mg ferrous fumarate, starting 24-48 hours after surgery
3316432|NCT01975272|Placebo Comparator|Placebo infusion and tablets|Patient will get a once a placebo infusion (250 ml NaCl), one day after surgery, and 60 placebo tablets for 30 days (2 tablets a day), starting 24-48 hours after surgery
3316433|NCT01975311|Experimental|Lumbopelvic Manipulation|Participants in this group will receive lumboplevic manipulation twice within a week.
3316434|NCT01975311|Placebo Comparator|Passive lumbar spine flexion and extension|Participants in this group will receive passive lumbar spine flexion and extension for 1 min twice within a week.
3316435|NCT01975324|Experimental|dalfampridine (ampyra)|Dalfampridine (ampyra) 10mgs twice a day (b.i.d.)for two weeks
3316436|NCT01975324|Placebo Comparator|Placebo|placebo (sugar Pill) twice a day (b.i.d.)for two weeks
3316437|NCT01975337|Experimental|End stage renal disease participants|End stage renal disease (ESRD) participants received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food at any time during the 2 hours after completion of hemodialysis on Day 1.
3316438|NCT01975337|Active Comparator|Matched healthy participants|Healthy participants (matched to those with end stage renal disease by sex, age, weight, and smoking status), received a single 400 mg (2 x 200 mg capsules) oral dose of alisporivir with food on Day 1.
3316439|NCT01975350||Colistimethate sodium inhalation|"Colistimethate sodium inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.~Additional intravenous colistimethate sodium for patients with ventilator-associated pneumonia"
3316440|NCT01975350||saline inhalation|saline inhalation for patients with ventilator-associated tracheobronchitis, pneumonia or lower respiratory tract colonization by multidrug resistant Gram-negative bacteria.
3316441|NCT01975363|Experimental|Arm I (lower dose curcumin)|Participants receive 50 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Assessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
3316442|NCT01975363|Experimental|Arm II (higher dose curcumin)|Participants receive 100 mg dose curcumin PO BID for 3 months. Biomarker analyses of breast adipose tissue and plasma samples will be obtained at baseline and 3 months. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin and also stored at -80°C for biomarker analysis. Asssessment of dietary intake by food frequency questionnaires and 24 hour dietary recalls will be used to assess usual dietary habits. All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
3316443|NCT01975415||Experienced Meditators|Self-identified participants who confirm to having a regular meditation practice for at least 3 months and practiced at least 70 minutes per week.
3316444|NCT01975415||Novice meditators|Self-identified participant who confirm to either having never seriously tried meditation, or who have not meditated more than once a week for at least 3 months
3316445|NCT01975441|Active Comparator|standard treatment|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg administered annually (at 0, 12, and 24 months).
3316446|NCT01975441|Experimental|DEC 6 mg/kg + Alb 400 mg x 1|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg given once
3316447|NCT01975441|Experimental|DEC + ALB + IVM|Diethylcarbamazine 6 mg/kg + Albendazole 400 mg + Ivermectin 200 µg/kg administered once only at the beginning of the RCT (0 month)
3316448|NCT01975454|Active Comparator|chemotherapy|Patients receive chemotherapy until disease progression or unacceptable toxicity
3316449|NCT01975454|Experimental|Herbal therapy plus chemotherapy|Patients receive herbal therapy plus chemotherapy until disease progression or unacceptable toxicity
3316450|NCT01975480|Experimental|Desvenlafaxine|At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.
3316451|NCT01975493||Amoxicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3316452|NCT01975493||Ampicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months)"
3316453|NCT01975493||Benzylpenicillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3316454|NCT01975493||Co-amoxiclav|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3316455|NCT01975493||Flucloxacillin|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3316456|NCT01975493||Piperacillin/tazobactam|"Group subdivided into age categories:~Preterm newborn infants Term newborn infants (0-27 days) Infants and toddlers (1 month to 23 months) Children (2 - 11 years) Adolescents (12 - 16 years)"
3316457|NCT01975506||head start practitioners|
3316458|NCT01975545|Active Comparator|Fluor varnish|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein)
3316459|NCT01975545|Experimental|Fluor varnish with nanoparticles|Fluor dental varnish (Fluor Protector, Ivoclar Vivadent, Principality of Liechtenstein) plus 25% 50 nm silver nanoparticles.
3316460|NCT01975558||Control group A|Control group. The group will undergo blood, urine, sebum, and saliva sampling.
3316461|NCT01975558||Breast cancer B|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling within the irradiation field.
3316462|NCT01975558||Breast cancer C|Breast cancer (60 Gy). The group will undergo blood, urine, sebum, and saliva sampling outside of the irradiation field, e.g. at the arm.
3316463|NCT01975571|Experimental|Adult|"Population 1: 15 Adults who have a severe sensorineural hearing loss with a pure-tone average (PTA) between 60-90 dB HL between 125-1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
3316464|NCT01975571|Experimental|Children and adolescents (L24)|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold >90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid L24 cochlear implant."
3316465|NCT01975571|Experimental|Children and adolescents S12|"Children (ages 5-12 years) and adolescents (ages 13-15 years) who have a sensorineural hearing loss with a pure-tone average (PTA) between 70-90 dB HL between 125-1500 Hz, a hearing threshold hearing threshold between 70-90 dB HL at 1500 Hz and profound loss at higher frequencies.~Intervention: These patients will receive a Hybrid S12 cochlear implant."
3316466|NCT01975584|Experimental|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
3316467|NCT01975597||Bone marrow aspirates and biopsy|
3316468|NCT01975610|Experimental|CC-292 375mg|Treatment
3316469|NCT01975610|Placebo Comparator|Placebo|Control
3381969|NCT05163119|Experimental|Commercial Cellphone-Blocking App|Commercial cellphone-blocking app that blocks handheld cellphone use while driving, but allows emergency calls and phone use after pressing the passenger button will be installed on smartphone.
3316470|NCT01975623|Experimental|Intervention Group|Pulmonary artery Energy Sealing with HARMONIC ACE+ Shears (HS) ex-vivo
3316471|NCT01975636|Experimental|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
3316472|NCT01975649|Experimental|Tribulus Terrestris|patients will use Tribulus terrestris (750 mg/day) during 120 days
3316473|NCT01975649|Placebo Comparator|Placebo|patients will use placebo for 120 days
3316474|NCT01975662|Experimental|Daptomycin|"Daptomycin will be dosed intravenously at 6-8mg/kg every 24 hours.~Patients with uncomplicated bacteremia will receive a dose of 6mg/kg every 24 hours. Patients with suspected complicated bacteremia or endocarditis, or receipt of at least two doses of vancomycin in the last 90 days (apart from vancomycin received for their current MRSA bacteremia) will receive a dose of 8mg/kg every 24 hours.~In patients with a creatinine clearance less than 30ml/min, or on intermittent or continuous hemodialysis, daptomycin will be dosed at 6-8mg/kg every 48 hours. The same criteria as above applies as to whether they receive 6mg/kg or 8mg/kg every 48hours. Daptomycin will be administered after hemodialysis in patients undergoing intermittent hemodialysis."
3316475|NCT01975662|Active Comparator|Vancomycin|Vancomycin will be dosed at 15mg/kg every 12 hours with appropriate dose adjustments by a pharmacist in patients with a creatinine clearance less than 50 ml/min, so as to achieve a vancomycin trough level of 15-20ug/ml.
3316476|NCT01975688|Experimental|Sativex: pre-treatment (Grade 0)|The PKs of a single dose of Sativex are investigated in subjects with mucositis of Radiation Therapy Oncology Group (RTOG) Grade 0 (i.e. at baseline, pre-induction of mucositis).
3316477|NCT01975688|Experimental|Sativex: mild mucositis (Grade 1)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 1 (mild).
3316478|NCT01975688|Experimental|Sativex: moderate mucositis (Grade 2)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 2 (moderate).
3316479|NCT01975688|Experimental|Sativex: severe mucositis (Grade 3)|The PKs of a single dose of Sativex are investigated in the same subjects when their mucositis is RTOG is Grade 3 (severe).
3316480|NCT01975714|Experimental|Latanoprost (Period I) + Bimatoprost (Period II)|"Preservative-free latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free bimatoprost 0.03% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
3316481|NCT01975714|Experimental|Bimatoprost (Period I) and Latanoprost (Period II)|"Preservative-free bimatoprost 0.03% Unit Dose (LUDPF) (Monoprost) eye drops will be administered every day at 21:00 for the first 3 months.~After the follow-up visit, patient will start Preservative-free latanoprost 0.005% Unit Dose (BUDPF) eye drops every day at 21:00 for the last 3 months."
3316482|NCT01975727|Placebo Comparator|Injection of Placebo|Intravenous Saline 0.9% 10 ml
3316483|NCT01975727|Active Comparator|Dexamethasone 3 mg|Intravenous Dexamethasone 3mg diluted in saline 0.9% up to 10 ml
3316484|NCT01975727|Active Comparator|Dexamethasone 6 mg|Intravenous Dexamethasone 6mg diluted in saline 0.9% up to 10 ml
3316485|NCT01975727|Active Comparator|Dexamethasone 12 mg|Intravenous Dexamethasone 12mg diluted in saline 0.9% up to 10 ml
3316486|NCT01975740|Experimental|Manual diaphragm release technique|
3316487|NCT01975740|Other|Sham manual diaphragm release technique|
3316488|NCT01975753|Active Comparator|Intravenous morphine|one bolus of intravenous morphine
3316489|NCT01975753|Experimental|nebulized morphine|"one nebulized bolus of morphine"
3316490|NCT01975753|Active Comparator|fentanyl|"one nebulized bolus of fentanyl"
3316491|NCT01975766|Experimental|Ketogenic diet|Ketogenic diet designed to sustain ketone levels through treatment.
3316492|NCT01975779|Experimental|Cohort A1: Lu AE58054 or placebo|
3316493|NCT01975779|Experimental|Cohort A2: Lu AE58054 or placebo|
3316494|NCT01975779|Experimental|Cohort B1: Lu AE58054|
3316495|NCT01975792||Preterm Admits|Women who are admitted for preterm labor observation and management
3316496|NCT01975805|Experimental|Chlorhexidine Gluconate|Use of Chlorhexidine Gluconate as skin disinfectant for cesarean section.
3316497|NCT01975805|Experimental|Povidone Iodine|Use of Povidone Iodine as skin disinfectant for cesarean section.
3316498|NCT01975818|Experimental|Molidustat (BAY 85-3934)(25mg)|Starting dose of 25 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits. Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
3316499|NCT01975818|Experimental|Molidustat (BAY 85-3934)(50mg)|Starting dose of 50 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.
3316500|NCT01975818|Experimental|Molidustat (BAY 85-3934) (75mg)|Starting dose of 75 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100,150 and 200 mg once daily.,
3316501|NCT01975818|Experimental|Molidustat (BAY 85-3934) (150mg)|Starting dose of 150 mg of BAY85-3934 as once-daily oral tablets. Regular titrations at dose control visits Titration occuring every 4-weeks will be based on the subject's Hb response and tolerability of the prior dose. Total treatment time is 16 weeks. Planned doses include 15, 25, 50, 75, 100, 150 and 200 mg once daily
3316502|NCT01975818|Active Comparator|Epoetin alfa/beta|Starting dose at the subject's current weekly dose. Administered IV or SC 3 times per week. Doses will be titrated at the scheduled dose control visits according to the local label. Titration will be based on the subject's Hb response and tolerability of the prior dose. Epoetin alfa may be administered in either the United States (US) or Japan; epoetin beta will only be administered in Japan.
3316503|NCT01975844|Experimental|Individualized Anemia Mangement Protocol|"Single arm study, therefore all patients will participate in the following:~Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
3316504|NCT01975857|Experimental|Mind-Body Bridging Program|The Mind-Body Bridging Program (MBBP) is an awareness training program (ATP) to help individuals improve their health condition and attain a state of well-being. Bridging is the primary technique that facilitates the healing process, by bringing one back to the present moment to experience thoughts, emotions and physical sensations. Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
3316505|NCT01975857|Active Comparator|Supportive Education|Supportive Education program will provide educational lectures on disability, sleep hygiene, and current research on depression and non-directive, supportive discussions about these topics.
3316506|NCT01975870|Experimental|intervention group|use of application on smartphone for lifestyle counseling
3316507|NCT01975870|No Intervention|control group|no use of application on smartphone
3316508|NCT01975883||Spine surgical patients|Sequential patients scheduled for spine surgery, including degenerative, deformative, tumoral and traumatologic indications are eligible to participate. Exclusion criteria are the following : infection or history of infection of surgical site, past medical history of diabetes mellitus, defined as chronic glucose intolerance either insulin-dependent or non insulin-dependent at the time of operation, and patients with preoperative random BG levels greater than 126 mg/dl considering they could also represent undiagnosed diabetes
3316509|NCT01975896|Experimental|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
3316510|NCT01975896|No Intervention|Health Education|The health education curriculum will be informed by: 1) the dietary and PA didactic units and materials developed as part of our school based trial, adapted for adolescents from the Diabetes Prevention Program (DPP) and 2) the standard curricula for school-based health education programs with particular attention to the unique needs of adolescents:increasing fruits and vegetables, reducing sugar sweetened drinks, and decreasing foods high in fat, unhealthy carbohydrates, and calories. The PA component will be based on current recommendations of engaging in at least 1 hour of moderate-to-vigorous physical activity (MVPA) most days of the week, building PA into the teen's lifestyle,and reducing sedentary behavior.
3316511|NCT01975961|Experimental|FDC YH16410|"Drug: Test treatment: FDC YH16410 (Telmisartan 80mg/ Rosuvastatin 20mg).~Subjects will receive single oral dose of 1 tablet of FDC containing Telmisartan 80mg and Rosuvastatin 20mg in fasted state"
3316512|NCT01975961|Active Comparator|Co-administration|"Drug: Reference Treatment: Co-administration(Telmisartan 80mg and Rosuvastatin 20mg).~Subjects will receive 1 x Telmisartan 80mg with 1 x Rosuvastatin 20mg tablet administered orally in fasted state as a single dose"
3316513|NCT01975987|Experimental|Intubation with the Bonfils fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope~Intubation will be performed with the Bonfils fiberscope with the patient in supine position with head and neck in neutral position~Bonfils fiberscope will be inserted from the right side of the patient's mouth, alongside the molars and advanced underneath the epiglottis. With the tip of the Bonfils in satisfactory position, the endotracheal tube will be advanced into the trachea using gentle rotary motions. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
3316514|NCT01976000||Group A|the surgeons were able to view 3D reconstructions before and during surgery
3316515|NCT01976000||Group B|the surgeons were only able to view 3D reconstructions after the surgery
3316516|NCT01976013|Other|Coaguchek|infants will receive sequential coagulation checks
3316517|NCT01976026|Experimental|Endovascular treatment with flow diversion|"Endovascular treatment with flow diversion, including standard management of thrombo-embolic risk. The goal of the treatment procedure is (as usual) to prevent rebleeding, while keeping treatment-related risks as low as possible.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. It is imperative that the allocated procedure is conducted in the safest possible manner. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
3316518|NCT01976026|Active Comparator|Best standard therapy|"May be any of the following:~Conservative management when no surgical or endovascular treatment is considered possible or reasonable~Conventional endovascular options including coiling with or without high-porosity stenting, and stent-in stent techniques~Parent vessel occlusion, with or without bypass~Surgical clipping or clip-wrapping (including parent vessel occlusion as a salvage procedure).~Choice of best option is based on the location, anatomy, and particular circumstances, before randomization for this patient's aneurysm.~This trial permits the interventionist or surgeon to use any device, technique or drug judged important to the safety and success of the endovascular or surgical procedure, at his/her discretion at any time during the procedure. The interventionist or surgeon may switch to an alternative BST or cross-over to the alternative treatment group, if it is in the best interest of the patient."
3316519|NCT01976039|Other|RRC|rhinopharyngeal retrograde clearance (RRC) isolated: First patient sits in a chair. Second: patient inhales air deeply and exhales making noise and vibration in the upper airway to facilitate swalling. Third patients finishes with another deep inhalation. This technique is new, simple to use and with no cost. No need of any material or equipment.
3316520|NCT01976039|Experimental|RRC+S|retrograde rhinopharyngeal retrograde clearance combined with saline instillation (RRC+S): patient sits in a chair and inhaled air and make noise and vibrate the upper airway at the same instills saline into the nare to facilitate nose washing and swalling. This technique is new, simple to use and with low cost (only saline).
3316521|NCT01976052||Obstructive sleep apnea patients|Patients with obstructive sleep apnea that has not received CPAP treatment
3316522|NCT01976052||Matched volunteers with non OSA|Matched volunteers without OSA. Matched in respect to age and BMI
3316523|NCT01976052||Matched normal controls with normal BMI|Volunteers that are matched according to age but has a normal BMI
3316524|NCT01976065|Other|Mineral Trioxide Aggregate (MTA)|Standard Treatment group consisting of placement of Mineral Trioxide Aggregate (MTA), an FDA approved dental material at the end of an immature root followed by a composite restoration (crown).
3316525|NCT01976065|Experimental|Revascularization Treatment (REVASC)|Consists of standard treatment procedure PLUS disinfection of the canal space with Triple Antibiotic Paste study medication followed by placement of Collaplug, an FDA approved material to help promote clotting. A composite restoration in then placed.
3316526|NCT01976065|Experimental|Regeneration Treatment (REGENDO)|Consists of standard treatment procedure PLUS Triple Antibiotic Paste study medication PLUS use of Emdogain, an FDA approved medication used in an FDA approved manner, that is a growth factor to help surrounding tissues to grow together and heal.
3316527|NCT01976078||Midazolam/Ranitidine/Esomeprazole|All enrolled subjects will have a study pharmacokinetic visit where they will be given the above cocktail of drugs along with their clinically indicated voriconazole dose, followed by blood sampling over the next 12 hours.
3316528|NCT01976091|Experimental|Cohort 1A|Two (n=2) adult LGMD2D wheelchair-dependent subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via single-limb perfusion at the low dose. Subjects will receive a dose of 1 x 10 12th vg/kg in a single limb with delivery to the whole limb.
3316529|NCT01976091|Experimental|Cohort 1B|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA via bilateral whole limb perfusion at low dose of 1 x 10 12th vg/kg.
3316530|NCT01976091|Experimental|Cohort 2|Three (n=3) LGMD2D subjects will receive self-complementary scAAVrh74.tMCK.hSGCA bilateral whole limb perfusion at high dose.Subjects will receive a total dose of 3 x 10 12th vg/kg per limb delivered to both extremities
3316531|NCT01976117|Experimental|enose|
3316532|NCT01976130|Experimental|bronchoscopy|Procedure
3316533|NCT01976143|Experimental|NKTR-102|A single 90 minute IV infusion of 220 mg/m2 NKTR-102
3316534|NCT01976156|Experimental|Phopsholean dietary supplement|Subjects in the Phospholean group will receive six capsules of PhosphoLean orally daily (total of 180 mg of NOPE and 120 mg of EGCG), ); two capsules consumed one hour before lunch, two capsules one hour prior to dinner, and two capsules two hours after dinner.
3316535|NCT01976156|Placebo Comparator|Placebo (rice flour) group|The control (placebo) group will receive a placebo (identical in appearance, but containing 100 mg of rice flour per capsule).
3316536|NCT01976169|Experimental|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
3316537|NCT01976182|Active Comparator|METHOTREXATE|"In step 1, 55 patients will receive methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with methotrexate at the same dosage.~Non responders at Month 4 will be randomized and treated either by:~Cyclophosphamide delivered at 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take between Month 5 and Month 8, decreased to 50 mg orally once daily beyond Month 8 for responders at Month 8;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
3316538|NCT01976182|Active Comparator|CYCLOPHOSPHAMIDE|"In step 1, 55 patients will receive cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take.~In step 2, responders at Month 4 (CR or PR) will be treated during 8 additional months with cyclophosphamide (at 50 mg orally once daily);~Non responders at Month 4 will be randomized and treated either by:~Methotrexate administered at 10 mg/m2 orally once a week (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take;~Ciclosporine A delivered at 3 mg/kg per day (at split doses of 1.5 mg/kg in the morning and 1.5 mg/kg at night) orally administered."
3316539|NCT01976195|Experimental|Thalidomide plus HD-Dexmamethasone|Thalidomide 150mg per day, 15 consecutive days Dexamethasone 40 mg per day, 4 consecutive days
3316540|NCT01976195|Active Comparator|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
3316541|NCT01976208|Experimental|Omalizumab|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
3316542|NCT01976208|Placebo Comparator|placebo|During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.
3316543|NCT01976221||Prioritization|Team-based multifaceted interactive training
3316544|NCT01976234|Active Comparator|Fresh group|Fresh group will receive RBC stored for less than 14 days
3316545|NCT01976234|Active Comparator|Old group|Old group will receive RBC stored for 14 days or more
3316548|NCT01976325|No Intervention|Standard Care|This arm will receive no intervention; only standard medical care.
3316549|NCT01976325|Experimental|Decision Aid + Standard Care|This group will receive the intervention (the Ottawa Malaria Decision Aid), in addition to standard medical care.
3316550|NCT01976351||Barrett's esophagus|Patients were eligible for the study if they were scheduled for endoscopic examination at the National Taiwan University Hospital and its Yun-Lin branch, because of a BE, with or without a previous history of dysplasia. Exclusion criteria included patients who are younger than 20 years of age or patients with esophageal or cardiac varices or pregnant women.
3316551|NCT01976377||Stage I, II, III, IV HNSCC|Stage I, II, III, IV HNSCC reveive treatment in NTUH
3316552|NCT01976403|Experimental|Pain booklet|
3316553|NCT01976403|No Intervention|standard care|
3316554|NCT01976429|Other|asymptomatic on flight/dive|individuals who experience no middle-ear problems on flying or diving
3316555|NCT01976429|Other|symptomatic on flying/diving|individuals who have experienced middle-ear problems on flying or diving
3316556|NCT01976455||20% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
3316557|NCT01976455||40% calorie depletion|During each 11-day stays the volunteer will have 9 days of calorie depletion (20% one stay and 40% the other).
3316558|NCT01976468||SCC metastasis|organ transplant recipients
3316559|NCT01976481|Experimental|Sunbed|sunbed exposure
3316560|NCT01976481|No Intervention|Observation|only observation of subjects recruited after randomization
3316561|NCT01976494|Experimental|domestic PCA equipment|Patient controlled analgesia by the domestic PCA equipment
3316562|NCT01976494|Active Comparator|imported PCA equipment|Patient controlled analgesia by imported PCA equipment
3316563|NCT01976520|Experimental|Oncoquest-CLL vaccine treatment|Patients receive Oncoquest-CLL vaccine subcutaneously on Day 1 and 15, and then monthly for 3 months in the absence of disease progression or unacceptable toxicity.
3316564|NCT01976533||Advanced therapy, Heart-lung transplantation, dead|
3316565|NCT01976546||airway|Patients with one or more predictors of diffucult airway
3316566|NCT01976559|Experimental|Hydrocephalus / Shunt Malfunction|Patients between the ages of 18-80 years with suspected hydrocephalus, shunt malfunction, or disorders of CSF circulation who are recommended by their doctor based on standard clinical criteria to undergo CSF infusion testing. The interventions include tympanic membrane displacement (TMD) and DPOAE.
3316567|NCT01976585|Experimental|rhuFlt3L/CDX-301|intratumoral injections on days 1-5 and 8-11. and Poly-ICLC intratumoral injection weekly, weeks 2-8
3316568|NCT01976598||Spinal Cord Stimulation: Sub-Sensory|Patients implanted with a Boston Scientific Spinal Cord Stimulation System for the treatment of chronic back and/or leg pain using Sub-Sensory Stimulation.
3316569|NCT01976611||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for chronic migraine as per local standard of care in clinical practice.
3316570|NCT01976637|Experimental|no compression|no compression stockings worn during a 3 weeks period
3316571|NCT01976637|Active Comparator|compression stockings|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
3316572|NCT01976676|Experimental|5-methyltetrahydrofolate|1 mg 5-methyltetrahydrofolate per day
3316573|NCT01976676|Active Comparator|folic acid|1 mg Folic acid per day
3316574|NCT01976689||Patients with New-onset Diabetes|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
3316575|NCT01976689||Patients without NODAT|New-onset diabetes after transplantation was defined as a fasting plasma glucose (FPG) level ≥ 126 mg/dL (7 mmol/L) or symptoms of diabetes plus casual plasma glucose concentrations ≥200 mg/dL (11.1 mmol/L), confirmed by repeat testing on a different day. According to these criteria, 63 patients were diagnosed as NODAT between years 2007-2010 but after the exclusion criteria of our study 57 patients with and 102 patients without NODAT were included in the study.
3316576|NCT01976702|Experimental|Enhanced Behavioral Skills Training|The Enhanced Behavioral Skills Training (E-BST) will include four 90-minute group sessions and two 60-minute individual sessions regarding HIV prevention and diminishing risk behavior, enhancing communication skills, improving the use of support services, and enhancing the use of resources in their community.
3316577|NCT01976702|Active Comparator|Health Promotion Comparison|The Health Promotion Comparison (HPC)condition will receive one video-based HIV prevention session, 3 video-based 90-minute group sessions and an additional 2 60-minute sessions with discussions on relevant topics unrelated to HIV.
3316579|NCT01976754|Other|dexmedetomidine,sepsis,ED50|Intervention Name: dexmedetomidine dosage form: intravenous injection dosage：0.2-0.7μg/kg/h frequency: 1 duration:12 hours
3316580|NCT01976767||Cohort A|Adults: severe asthmatics on high dose ICS and / or OCS
3316581|NCT01976767||Cohort B|Adults: current smokers or ex-smokers, severe asthmatics on high dose ICS and / or OCS
3316582|NCT01976767||Cohort C|Adults: non-smokers, mild to moderate asthmatics on regular inhaled corticosteroids (ICS)
3316583|NCT01976767||Cohort D|Adults: healthy volunteers, non-smokers, non-asthmatic with pre bronchodilator FEV1 > 80% predicted
3316584|NCT01976780|Active Comparator|AS/MQ|Treatment of P.falciparum mono-infection with 4 mg/kg of Artesunate daily for three days followed by 25mg/kg of Mefloquine split over two days.
3316585|NCT01976780|Active Comparator|AL|Treatment of P. falciparum mono-infection with Artemether Lumefantrine administered at the standard dosage according to pre-defined weight bands (5-14 kg: 1 tablet; 15-24 kg: 2 tablets; 25-34 kg: 3 tablets; and > 34 kg: 4 tablets) given twice a day for 3 days.
3316586|NCT01976793||patients with major depression|Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week
3316587|NCT01976832|Experimental|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-weeks music with movement (MWM) intervention protocol.
3316588|NCT01976832|Active Comparator|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
3316589|NCT01976858|Experimental|PEX168 50 microgram|PEX168 50 microgram qw sc. and the medication continued for 8 weeks
3316590|NCT01976858|Experimental|PEX168 100 microgram|PEX168 100 microgram qw sc. and the medication continued for 8 weeks
3316591|NCT01976858|Experimental|PEX168 200 microgram|PEX168 200 microgram qw sc. and the medication continued for 8 weeks
3316592|NCT01976858|Experimental|PEX168 300 microgram|PEX168 300 microgram qw sc. and the medication continued for 8 weeks
3316593|NCT01976858|Placebo Comparator|Placebo|Placebo qw sc. and the medication continued for 12 weeks
3316594|NCT01976884||Severe sepsis|Patients with severe sepsis
3316595|NCT01976884||Infectious kidney stone|Patients with sepsis after PCNL for infectious kidney stone
3316596|NCT01976884||Tumor|Patients with pancreatic cancer
3316597|NCT01976884||Volunteer|
3316598|NCT01976897||The study population|"Only one group is included. See inclusion/exclusion criteria.~Intervention: Knee flexion measurement 1~Intervention: Knee flexion measurement 2~Intervention: Heel - interface pressure measurements"
3316599|NCT01976910|Experimental|4-DM-CHOC-PEN|"DM-CHOC-PEN is an intervention and will be dosed @ 39 mg/M2,escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
3316600|NCT01976923|Active Comparator|Study arm|Intravitreal bevacizumab Small-gauge pars plana vitrectomy
3316601|NCT01976923|Sham Comparator|Control arm|Small-gauge pars plana vitrectomy
3316602|NCT01976936|Experimental|High Dose Lovastatin|High dose lovastatin (640 mg daily for three days) will be administered orally
3316603|NCT01976936|Active Comparator|Low Dose Lovastatin|Lovastatin 80 mg daily for three days will be administered orally to patients who were taking statin therapy at the time of enrolment
3316604|NCT01976936|Placebo Comparator|Placebo|Placebo will be administered orally to patients who were NOT taking statin therapy at the time of enrolment
3316605|NCT01976949|Active Comparator|Social-networking intervention|Individuals interested in participating in the study will be randomized to receive access to a 12-week internet-based treatment group. Subjects assigned to the treatment group will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
3316606|NCT01976949|Active Comparator|Control group|12 week wait-list control subjects will be able to join a group after they complete the 12-week assessment and will be asked to complete a 24-week assessment in order to measure change over time. Subjects will have access to a group discussion board, a structured 12-week coping-skills training course, professional facilitation of the group, a real-time chat board, and personal profiles established by other group members. Subjects will be asked to complete online self-report measures of distress, mood disturbance, and quality of life at baseline and again after participation in the 12-week group.
3316607|NCT01976962|Experimental|Prostate stereotactic body RT with MR-guided boost|Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.
3316608|NCT01977001||Primary Headache|Treatment with MigraineBoxTM
3316609|NCT01977014||Patient with LenusPro pump|
3316610|NCT01977027|Other|Stroke & age-matched Controls|"Alternate Hand Training or Affected Hand Training:~40 patients with stroke and 40 control subjects will participate over 7 visits. After completion of informed consent, subjects will undergo clinical assessments (Visit 1) which will involve testing for kinesthetic, visual, tactile and motor impairments and upper limb function. Visit 2, subjects will undergo no contrast MRI to identify lesion location. Healthy controls will not be imaged.~Visits 3-7 will involve psychophysical experiments to test adaptation with short-term Alternate Hand Training and Affected Hand Training. During 5 visits the subjects will grasp and lift an instrumented grip device of different weights, textures and shapes while data is being collected via surface electrodes from, upper arm and back muscles."
3316611|NCT01977027|Other|Phase 2 - Stroke ONLY|"Alternate Hand Training or Affected Hand Training:~Subjects will be randomized into two groups one receiving Alternate Hand Training and the other receiving Affected Hand Training. The groups will be matched by age, gender, handedness, side of lesion, extent of motor impairment and lesion location. They will complete 17 Study visits.~Visits 1 and 2 will involve clinical assessments and MRI. Visit 3. Pre-intervention assessments involving grasping and lifting objects of different weights, textures and shapes while fingertip forces, finger and arm movements. Muscle activity and performance is measured.~Visits 4-15. Subjects will participate in 12 training visits for 1 hour a day, twice a week for 6 weeks.~Visits 16-17. Recovery of hand function will be measured by repeating the pre-intervention clinical and grasping assessments (in 2 visits) immediately after 6-weeks of training, and another 6 weeks later."
3316612|NCT01977053|No Intervention|A: Standard medical care|Arm A: standard supervision and medical care during an adjuvant chemotherapy treatment in France
3316613|NCT01977053|Experimental|B: telephonic monitoring|Arm B: telephonic monitoring during inter-treatment intervals + personalized medical care.
3316614|NCT01977066|Experimental|Six months supervised exercise training|
3316615|NCT01977066|Experimental|Six months home-based exercise training|
3316616|NCT01977066|No Intervention|Control group|
3381970|NCT05163119|Experimental|Driving Mode|Driving mode blocks handheld phone use while driving or facilitates hands free use (exact functionality dependent on smartphone type and service provider).This group will also have the commercial cell-phone blocking app installed on smartphone, but app will be inactive.
3381971|NCT05163106|Experimental|Ribociclib and Letrozole Arm|Patients entered into this study will be given letrozole (FemarTM) in combination with ribociclib (KisqaliTM) for at least 6 months. Premenopausal women will also receive treatment with goserelin 3.6 mg s.c. every 4 weeks.
3381972|NCT05163093||Angle closure glaucoma patients with or without abnormal zonular.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
3316617|NCT01977079|Other|Premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
3316618|NCT01977079|Other|Not premature birth|"At the end of the study patients will be divided into two groups: Premature delivery versus No premature delivery. Prematurity is defined as a birth before 37.~In each group, the procalcitonin rate be estimated with a confidence interval of 95% and compared from a logistic regression."
3316619|NCT01977105|Experimental|Pilot Intervention Group|Mothers who are screened and determined to be eligible for this single-group pilot study will be enrolled along with their infants in the Grow Together peer group intervention.
3381973|NCT05163093||Patients with age-related cataract.|We observe the zonular during surgery, and divide patients into two groups according to their zonular, including with or without abnormal zonular.
3381974|NCT05163080|Active Comparator|Arm A|Peptide Vaccine (SurVaxM) in emulsion with Montanide given together with locally administered Sargramostim plus adjuvant oral Temozolomide
3381975|NCT05163080|Placebo Comparator|Arm B|Saline-Montanide emulsion with locally administered saline (instead of sargramostim) plus adjuvant oral temozolomide
3381976|NCT05163067|Experimental|Combined aerobic exercise and cognitive training program|
3381977|NCT05163067|No Intervention|Standard health counseling at baseline|
3381978|NCT05163041|Experimental|BT7480 monotherapy dose escalation|Participants will receive increasing doses of BT7480. It is expected that approximately 40 patients will participate in this dose escalation arm.
3381979|NCT05163041|Experimental|BT7480 and nivolumab dose escalation|Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.
3381980|NCT05163041|Experimental|BT7480 monotherapy dose expansion|Participants will receive a selected dose of BT7480. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
3381981|NCT05163041|Experimental|BT7480 and nivolumab dose expansion|Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 20 patients will participate in this dose expansion arm in Phase 1 plus an additional 45 patients in Phase 2.
3381982|NCT05163041|Experimental|BT7480 monotherapy in patients with renal insufficiency|Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.
3381983|NCT05163028|Experimental|Dose Escalation and Expansion|HBI-2376 will be given orally in ascending doses (escalation cohort), until the maximum tolerated dose or recommended Phase 2 dose is reached. Up to 6 patients will then be enrolled in the expansion cohort at the recommended dose.
3381984|NCT05163015||with oncogeriatric consultation|"with oncogeriatric consultation group: patients aged 75 and more with cancer with oncogeriatric consultation"
3381985|NCT05163015||without oncogeriatric consultation|"without oncogeriatric consultation group: patients aged 75 and more with cancer without oncogeriatric consultation"
3381986|NCT05162989|Experimental|iCare HOME2 vs iCare IC200|Measurement of intraocular pressure (IOP) with iCare IC200 reference tonometer compared to iCare HOME2 test tonometer. Measurement will be performed to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (>16 to <23 mmHg), or High IOP (≥23 mmHg).
3316620|NCT01977118|Experimental|Group B [streptokinase]|50000U of injection streptokinase dissolved in 100ml of normal saline instilled in to the pancreatic and/or peripancreatic collections via the percutaneous catheters and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of normal saline. This procedure will be done thrice daily for five days
3316621|NCT01977118|Placebo Comparator|Group A [placebo]|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
3316622|NCT01977131|Experimental|stromal cells modified HGF|
3316623|NCT01977144|Other|Embryo Transfer with CCS|Patients will have either a single or double embryo transfer with CCS tested embryos
3316624|NCT01977144|No Intervention|Embryo Transfer without CCS|Patients in this group will not have CCS performed on their embryo(s)
3316625|NCT01977157||bioimpedance measurements while trinking alcohol|Bioimpedance spectroscopy (BIS) measurements on 12 healthy subjects were performed while they were drinking alkohol until reaching a BAC of 0.8 ‰.
3316626|NCT01977170|Experimental|Hib/PRP-T vaccine|"One dose, correspond to 0.5 ml, composed of:~PRP-T 10ug NaCl 0.85%~Frequency: 1 injection"
3316627|NCT01977183|Experimental|Elderly adults with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3316628|NCT01977183|Placebo Comparator|Elderly adults with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid or or non-heated semi-solid food. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3316629|NCT01977183|Experimental|General adult population with MSPrebiotic|30 g of MSPrebiotic (potato resistant starch) per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3316630|NCT01977183|Placebo Comparator|General adult population with Placebo|30 g of corn starch per day taken with 1 glass (approximately 250 mL) of non-heated fluid. If the participant is taking any medications, they will be advised to either take the product 2 hours before or 2 hours after any medications.
3316631|NCT01977196|Experimental|DTP/HepatitisB/Hib vaccine|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3316632|NCT01977209|Experimental|Arm A|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Gossypol 20mg from day 1 to day 14. repeat Q 3weeks. Four cycles.
3316633|NCT01977209|Placebo Comparator|Arm B|Docetaxel 75mg/m2/iv over 90min and cisplatin 75mg/m2/iv over 90min on day 1. Placebo from day 1 to day 14. repeat Q 3weeks. Four cycles.
3316634|NCT01977235|Experimental|Arm A|Irinotecan 90mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
3316635|NCT01977235|Active Comparator|Arm B|Irinotecan 65mg/m2/iv over 90min and cisplatin 30mg/m2/iv over 60min on day 1 and 8, repeat Q 3weeks. Four cycles.
3316636|NCT01977248|Experimental|SMART therapy|The Sensorimotor Affect Relationship-based Therapy (SMART) program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
3316637|NCT01977261|Experimental|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu-plate
3316638|NCT01977261|Active Comparator|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with 2 staples
3316639|NCT01977274|Experimental|gynecological cancer|blood and tumor samples
3316640|NCT01977287||Functional Electrical Stimulation|The Functional Electrical Stimulation (FES) group will be asked to use their clinically prescribed FES unit (either ODFS III or Pace) to the dorsiflexors to treat foot drop for a period of 12 weeks.
3316641|NCT01977287||Ankle Foot Orthosis|The people in the Ankle Foot Orthosis group (AFO) will be asked to use their clinically prescribed AFO to treat drop foot for a period of 12 weeks.
3316642|NCT01977300|Placebo Comparator|Mood stabilizer & Placebo|Patients will receive lithium or valproate plus placebo for 52 weeks (risperidone or olanzapine tapering will begin on the day of randomization with discontinuation of the drug within 2 weeks).
3316643|NCT01977300|Experimental|"'24 week  arm"|Continuation of the lithium or valproate plus risperidone or olanzapine for 24 weeks followed by mood stabilizer plus placebo for another 28 weeks. Dosages: 1 to 6 mg of risperidone, 5 to 20 mg olanzapine.
3316644|NCT01977300|Active Comparator|"52 week arm"|Continuation of the atypical antipsychotic, risperidone or olanzapine, plus lithium or valproate for 52 weeks.
3316645|NCT01977313||All study participants|All study participants
3316646|NCT01977326|Experimental|counseling intervention|Each woman recruited into the intervention arm will undergo 6 sessions of basic counselling by lay-health workers
3316647|NCT01977326|Active Comparator|Enhanced usual care|usual antenatal care with additional 3 - 4 monthly phone calls.
3316648|NCT01977339|Experimental|Liposome Bupivacaine|Single injection femoral nerve block of 10 cc of 266 mg liposome bupivacaine with 10 cc of normal saline
3316649|NCT01977339|Active Comparator|Bupivacaine|Single shot femoral nerve block with 20cc of 0.25% bupivacaine
3316650|NCT01977365|Experimental|Growth promotion based on child centered approach|
3316651|NCT01977365|No Intervention|Control|
3316652|NCT01977378|Experimental|Sustained-Release Desvenlafaxine Hydrochloride|50-100mg/d
3316653|NCT01977378|Active Comparator|Sustained-Release Venlafaxine Hydrochloride|75-225mg/d
3316654|NCT01977417|Experimental|Salsalate|3.0 grams/day salsalate (1.5 g twice per day)
3316655|NCT01977417|Placebo Comparator|Placebo|Placebo capsule twice per day
3316656|NCT01977430|Experimental|Diuretics arm|The diuretic arm's patients will receive combined thiazide-furosemide therapy for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
3316657|NCT01977430|No Intervention|Control Arm|
3316658|NCT01977443|Active Comparator|APD-209 Eye drops|APD-209 Eye drops
3316659|NCT01977443|Placebo Comparator|APD-209 Placebo Eye drops|APD-209 Placebo Eye drops
3316660|NCT01977469|Experimental|Low intensity resistance training|Low intensity resistance training + aerobic training
3316661|NCT01977469|Experimental|High intensity resistance training|High intensity resistance training + aerobic training
3316662|NCT01977495|Active Comparator|Opt-in Enrollment|Opt-in enrollment: patient will be sent a recruitment letter, in which they must call the study team to take part in the study. During that call, the study team will schedule the participant for an intake visit.
3316663|NCT01977495|Active Comparator|Opt-out enrollment|Opt-out enrollment: patient will be sent a letter communicating to them that they have been enrolled into a research program at their doctor's office. After 10 days, the study team will contact the opt-out participants to schedule an intake visit.
3316664|NCT01977508||haemodialysis vascular access using ePTFE grafts|
3316665|NCT01977521|Experimental|Treatment|transcranial direct current stimulation (2mA)
3316666|NCT01977521|Sham Comparator|Sham|Sham stimulation
3316667|NCT01977534||Absorb BVS|Subjects receiving Absorb BVS
3316668|NCT01977560|Other|Standard Care|This arm will receive standard care for Type 2 diabetes: exercise and diet counseling according to the American Diabetes Association recommendations.
3316669|NCT01977560|Experimental|Optimum Lifestyle intervention|This arm will be participate in weekly visits with a dietitian and 4 weekly supervised exercise sessions. They will be advised to follow a high-protein, low-carbohydrate diet.
3316670|NCT01977586|Experimental|Metastatic renal cell carcinoma|Patients with clear cell renal cell carcinoma treated with anti-angiogenic therapies
3316671|NCT01977638|Experimental|CXD101|Dose escalation study of CXD101 administered orally twice daily for 5 consecutive days in every 21 day cycle. Starting dose 1mg twice daily (2mg/day).
3316672|NCT01977664||oocyte maturation failure|no intervention
3316673|NCT01977703|Active Comparator|Traditional ICD Programming|ICD will be set to pre-LVAD settings post LVAD implant.
3316674|NCT01977703|Experimental|Ultra Conservative ICD Programming|ICD will be set to ultra conservative settings post LVAD implant.
3316675|NCT01977716||Incident peritoneal dialysis patients|Patients with chronic kidney disease incident to peritoneal dialysis treatment
3316676|NCT01977742|Active Comparator|Initiate with SEP but without RTTE|Initiate supervised exercise (SEP) program but without rest-exercise transition training (RTTE)to improve cardiac vagal tone at same time; will stop RTTE after 8 weeks.
3316677|NCT01977742|Active Comparator|Initiate with RETT and SEP|"Supervised exercise program (aerobic, strength and flexibility exercises) and a specific sudden rest-exercise training protocol, three times a week. After 8 weeks, the sudden rest-exercise training protocol will be discontinued.~The cardiac vagal index will be measured at every 8 weeks."
3316678|NCT01977755|Active Comparator|danegapetide high dose|7,5 mg bolus injection, followed by 22,5 mg infused over 6 hours
3316679|NCT01977755|Active Comparator|danegaptide low dose|2,5 mg bolus injection, followed by 7,5 mg infused over 6 hours
3316680|NCT01977755|Placebo Comparator|Placebo|bolus injection, followed by infused over 6 hours
3316681|NCT01977768|Experimental|V7: Heat-inactivated M. vaccae pill|Daily pill of V7 together with standard tuberculosis therapy
3316682|NCT01977768|Placebo Comparator|Placebo pill|one pill of placebo pill once per day together with standard of care TB drugs
3316683|NCT01977807|Experimental|Myopia|Myopia Lasik treatment of virgin eyes.
3316684|NCT01977807|Experimental|Hyperopia|Hyperopia Lasik treatment of virgin eyes.
3316685|NCT01977833|Experimental|High Calorie Breakfast (BTdiet)|High Calorie Breakfast (BTdiet): The subject will consume High caloric breakfast, average lunch and reduced in calories dinner (BTdiet)
3316686|NCT01977833|Active Comparator|High Calorie Dinner (DTdiet)|High Calorie Dinner (DTdiet): The subject will consume High caloric dinner, average lunch and reduced in calories breakfast (DTdiet)
3316687|NCT01977859|Placebo Comparator|Saline|Saline infusion
3316688|NCT01977859|Active Comparator|Nesiritide 1.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 1.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3316689|NCT01977859|Active Comparator|Nesiritide 2.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 2.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3316690|NCT01977859|Active Comparator|Nesiritide 4.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 4.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3316691|NCT01977859|Active Comparator|Nesiritide 8.0|Nesiritide infused for 90 minute, initially at 0.5 pmol/kg/min and doubled every 15 minutes to achieve a target infusion rate of 8.0 pmol/kg/min, followed by a steady state infusion at the target rate for an additional 150 minutes (4 hours total).
3316692|NCT01977872|Experimental|A worksite activity-diet intervention|A 12 month intensive program that includes individual sessions, interactive group sessions and online activities.
3316693|NCT01977872|No Intervention|Motiva Program|The Motiva Program is the internal corporate wellness program offered to all BCBSIL employees.
3316694|NCT01977885|Experimental|High Protien Diet + Exercise|All participants will participate in both interventions (High Protein Diet and Exercise).
3316695|NCT01977911|Experimental|Tissue engineered airway construct|"Stem cell based tissue engineered partial laryngeal implants:~The final experimental product is a highly tested, recellularised, stem cells based tissue engineered product (airway construct) for operative partial laryngeal implantation into patients with severe laryngotracheal stenosis"
3316696|NCT01977924|Experimental|polyphenols|600 mg polyphenols (grape extract)
3316697|NCT01977924|Placebo Comparator|Placebo|microcrystalline cellulose
3316698|NCT01977963||Agranulocytosis|
3316699|NCT01977976|Experimental|Endometrial Aspirate (EA) group|Endometrial aspirate by pipelle
3316700|NCT01977976|No Intervention|Control group|No intervention prior to scheduled IVF
3316701|NCT01977989|No Intervention|No Vancomycin Powder|Patients who only receive IV Vancomycion prior to surgery. No Vancomycin powder is administered.
3316702|NCT01977989|Active Comparator|Vancomycin Powder|Patients who receive Vancomycin powder in the surgical site following surgery.
3316703|NCT01978002||Group 1 (Clinic Patients)|Women who have documented urinary status from surveys completed.
3316704|NCT01978002||Group 2 (Community Sample)|Women who have a clinical diagnosis of IC/BPS or OAB, and who have undergone urodynamic testing within the preceding 6 months as part of their routine clinical care.
3316705|NCT01978015|Experimental|latanoprost and timolol maleate fixed combination|Latanoprost 0.005% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3316706|NCT01978015|Experimental|bimatoprost and timolol maleate fixed combination|bimatoprost 0.03% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3316707|NCT01978015|Placebo Comparator|dextran and hypromellose|A control group of patients with POAG and pseudophakic after trabeculectomy without medication. These patients received a lubricant drop twice daily at 8 a.m. and 8 p.m. for 6 months
3316708|NCT01978015|Experimental|travoprost and timolol maleate fixed combination|Travoprost 0.004% and timolol maleate 0,5% fixed combination was dropped once daily at 8 p.m. for 6 months
3316709|NCT01978028|Active Comparator|ferric carboxymaltose|ferric carboxymaltose
3316710|NCT01978028|Placebo Comparator|placebo|placebo
3316711|NCT01978041|Experimental|Meal prepared with non fluoridated water (<0.1 ppm F)|
3316712|NCT01978041|Experimental|Meal prepared with fluoridated water (1 ppm F)|
3316713|NCT01978041|Experimental|Non fluoridated water (<0.1 ppm F)|
3316714|NCT01978041|Experimental|Fluoridated water (1 ppm F)|
3316715|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 60 ug F/kg|
3316716|NCT01978041|Experimental|Pilot study: Meal providing a fluoride dose of 120 ug F/kg|
3316717|NCT01978054|Experimental|Dissemination|Dissemination of public health knowledge: Participating states will help develop and choose 3-5 dissemination strategies they prefer for their state health department chronic disease units to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, and information on ways to enhance organizational climates favorable to evidence-based chronic disease prevention.
3316718|NCT01978054|No Intervention|Comparison|Comparison state health department chronic disease units will be provided links to preexisting sources of public health evidence-based information such as the Community Guide, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network, with Evidence-based Tools), and NCI Research to Reality.
3316719|NCT01978067||transvaginal resection of Uterine Scar|transvaginal resection of Uterine Scar From Previous Cesarean Delivery
3316720|NCT01978080|Experimental|Tremor reports provided|Kinesia HomeView utilized to monitor tremor at home and reports provided to treating clinician
3316721|NCT01978080|Active Comparator|Tremor reports not provided|Kinesia HomeView utilized to monitor tremor at home and reports not provided to treating clinician
3316722|NCT01978106||a WTR corneal astigmatism group|Corneal astigmatism was defined as WTR when the steep corneal cylinder axis was within 30 degrees of the horizontal axis.
3316723|NCT01978106||an ATR corneal astigmatism group|Corneal astigmatism was defined as ATR when the cylinder axis was within 30 degrees of the vertical axis.
3316724|NCT01978132|Active Comparator|Primary hyperaldosteronism|"patients with primary hyperaldosteronism will be subjected to the intervention forearm ischemia and reperfusion (20 minutes of forearm ischemia and 20 minutes of reperfusion).~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
3316725|NCT01978132|Placebo Comparator|Primary hypertension|"Patients with primary hypertension (PHA excluded)will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.~Primary endpoint is the reduction in brachial FMD by forearm ischemia-reperfusion, as a measure of endothelial ischemia-reperfusion injury"
3316726|NCT01978158|Experimental|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
3316727|NCT01978158|Experimental|Hyperoxia|Subjects will be breathing 100% of oxygen
3316728|NCT01978158|Active Comparator|Normoxia|Subjects wil be breathing room air (21%)
3316729|NCT01978171||breast cancer patients|Postmenopausal women with estrogen receptor (ER) positive advanced breast cancer whose disease is refractory to non steroidal aromatase inhibitors, and are eligible for treatment with exemestane and everolimus.
3316730|NCT01978210|Experimental|Wireless Moisture Pager|Parent(s) of subjects will participate in training and follow-up sessions in a manualized toilet training intervention for their child that incorporates use of a wireless moisture pager.
3316731|NCT01978210|Active Comparator|Standard Behavioral Treatment|Parent(s) of subjects will participate in training and follow-up sessions in a toilet training intervention for their child that incorporates use of the Autism Treatment Network's Toilet Training Tool Kit. The Tool Kit is a publication widely available to parents and clinicians that is designed to serve as an aid in the toilet training of children with autism. In this study, it is being used as a standard treatment control.
3316732|NCT01978223||Cases|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ED stay and whose stool samples test positive for RV by enzyme linked immunosorbent assay (ELISA) at a GSK designated laboratory.
3316733|NCT01978223||Controls|Children hospitalised for SGE, aged 12 weeks to < 5 years at the time of hospital admission/ ED stay, whose stool samples test negative for RV by enzyme linked immunosorbent assay at a GSK designated laboratory and who will be matched to the cases by date of birth and the hospital of admission/ ED stay.
3316734|NCT01978249|Experimental|Chemotherapy first without primary tumor resection|Patients will receive chemotherapy first without primary tumor resection.
3316735|NCT01978249|Active Comparator|Primary tumor resection followed by chemotherapy|Patients will receive primary tumor resection followed by chemotherapy.
3316736|NCT01978275|Experimental|stimulating catheters group|Lumbar plexus block performed through stimulating catheter
3316737|NCT01978275|Active Comparator|nonstimulating catheters|lumbar plexus block through nonstimulating catheters
3316738|NCT01978288||Cohort 1 Newborns with asthmatic mothers|Infants born to mothers who have diagnosis of Asthma that were enrolled in study from 5/7/14 to 6/1/16.
3316739|NCT01978288||Cohort 2 Newborns with asthmatic mothers|Infants born to mothers who have a diagnosis of Asthma with enrollment from June 2, 2016 going forward.
3316740|NCT01978288||Cohort 3 Newborns with healthy parents|Infants born to healthy parents without atopy (asthma, eczema, seasonal allergies) from June 2, 2016 going forward.
3316741|NCT01978301|Active Comparator|Triamcinolone acetonide|Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence
3316742|NCT01978301|Placebo Comparator|Placebo|Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.
3316743|NCT01978301|No Intervention|No treatment|Keloid(s) assigned 'No Treatment' will not receive any treatment.
3316744|NCT01978327|Experimental|GSK2647544|The planned repeat doses of GSK2647544 are 80 mg bid, 200 mg bid, and 350 mg bid
3316745|NCT01978327|Placebo Comparator|Placebo|Matching placebo
3316746|NCT01978327|Experimental|simvastatin|for drug-drug interaction
3316747|NCT01978327|Experimental|simvastatin co-dosed with GSK2647544|for drug-drug interaction
3316748|NCT01978340||sleeplab|Sleep Lab examined, usualy with some obesity or sleeping disorders.
3316749|NCT01978353|Experimental|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
3316750|NCT01978353|Active Comparator|Psychoeducation|Participants receive information about memory functioning and aging
3316751|NCT01978366|Experimental|Cohort 1: HT-100 tablet, Dose 1|• Multiple dose administration: Dose 1
3316752|NCT01978366|Experimental|Cohort 2: HT-100 tablet, Dose 2|• Multiple dose administration: Dose 2
3316753|NCT01978366|Experimental|Cohort 3: HT-100 tablet, Dose 3|• Multiple dose administration: Dose 3
3316754|NCT01978366|Experimental|Cohort 4: HT-100 tablet, Dose 4|• Multiple dose administration: Dose 4
3316755|NCT01978366|Experimental|Cohort 5: HT-100 tablet, Dose 5|• Multiple dose administration: Dose 5
3316756|NCT01978392|Experimental|Self-management group workshops|Self-management group workshops: Participants randomized to the intervention arm will be asked to participate in group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months.
3316757|NCT01978392|No Intervention|No treament (wait-list control)|Wait-list control: Participants randomized to the control arm will receive no intervention during the one-year period of data collection, but they will be invited to attend a full-day Saturday workshop after all study data collection is complete). The intent of the full-day workshop will be to provide the same self-management information as in the intervention arm, but on a delayed basis and in a more condensed format.
3316758|NCT01978405|Experimental|alpha-lipoic acid group|Alpha lipoic acid 600 mg in 0.9% sodium chloride 250 ml was given before and after contrast agent was administrated.
3316759|NCT01978405|Placebo Comparator|Placebo intervention group|Only 0.9% sodium chloride 250 ml was given for this group.
3316760|NCT01978418|Placebo Comparator|Placebo|Placebo is administered once, at 30-60 minutes of age
3316761|NCT01978418|Active Comparator|Intervention|Salbutamol 0,4 mg inhalation, given once at 30-60 minutes of age
3316762|NCT01978431|Experimental|Stimulant|Cocaine and Methylphenidate
3316763|NCT01978431|Placebo Comparator|Placebo|methylphenidate
3316764|NCT01978444|Experimental|laparoscopic D2 lymphadenectomy plus CME|Laparoscopic D2 lymphadenectomy plus CME will be performed for the treatment of patients assigned to this group.
3316765|NCT01978444|Active Comparator|laparoscopic D2 lymphadenectomy|Laparoscopic D2 lymphadenectomy will be performed for the treatment of patients assigned to this group.
3316766|NCT01978457|Experimental|cocaine hydrochloride|cocaine hydrochloride
3316767|NCT01978457|Experimental|propranolol|propranolol
3316768|NCT01978457|Placebo Comparator|placebo|placebo
3316769|NCT01978470|Experimental|Active|Trigeminal nerve stimulation
3316770|NCT01978483|Other|DPCP alone (Cohort 1)|Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3316771|NCT01978483|Experimental|UVB and denosumab group (Cohort 2)|Denosumab 60mg subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3316772|NCT01978483|Placebo Comparator|UVB and placebo group (Cohort 2)|Normal saline 1mL subcutaneous injection once. Broadband UVB exposure once. Diphenylcyclopropenone sensitization patches applied for 48hours. Diphenylcyclopropenone elicitation patches applied for 48hours.
3316773|NCT01978496|Placebo Comparator|Placebo|
3316774|NCT01978496|Experimental|Eletriptan 20 mg|
3316775|NCT01978496|Experimental|Eletriptan 40 mg|
3316776|NCT01978496|Experimental|Eletriptan 80 mg|
3316777|NCT01978522|Experimental|NICOLA Participants|All participants enrolled in the NICOLA cohort
3316778|NCT01978548|Experimental|JNJ-54861911 10 mg|From Day 1 to Day 28 inclusive, patients will self-administer once daily study drug (JNJ-54861911 or placebo) with a glass of non-carbonated water (approximately 200 mL).
3316779|NCT01978548|Experimental|JNJ-54861911 50 mg|
3316780|NCT01978548|Placebo Comparator|Placebo|Patients will receive matching placebo.
3316781|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 1|Follow-Up after dosing with NT100 Dose 1
3316782|NCT01978561|Experimental|Follow-Up after dosing with NT100 Dose 2|Follow-Up after dosing with NT100 Dose 2
3316783|NCT01978561|Placebo Comparator|Follow-Up after dosing with Placebo|Follow-Up after dosing with Placebo
3316784|NCT01978574|Active Comparator|Documentary videos|In the placebo control condition, participants watch daily videos.
3316785|NCT01978574|Experimental|Intellectual Enrichment|Daily activities that encourage intellectual enrichment, including games, reading/writing, and hobby activities.
3316786|NCT01978587|Experimental|Dose 1 JTZ-951|Tablets, 1 dose on Day 1 before hemodialysis
3316787|NCT01978587|Experimental|Dose 2 JTZ-951|Tablets, 1 dose on Day 8 after hemodialysis
3316788|NCT01978613|Experimental|Oral B (DC)|Escalation design. Planned end dose level is 5 mg alternative dosing condition (fasting for 30 minutes post-dosing)
3316789|NCT01978613|Experimental|Oral D|Escalation design. Planned end dose level is 20 mg standard dosing condition (fasting for 120 minutes post-dosing)
3316790|NCT01978613|Experimental|Oral C|Escalation design. Planned end dose level is 10 mg standard dosing condition (fasting for 120 minutes post-dosing)
3316791|NCT01978613|Experimental|Oral B|Escalation design. Planned end dose level is 5 mg standard dosing condition (fasting for 120 minutes post-dosing)
3316792|NCT01978613|Experimental|Oral A|Escalation design. Planned end dose level is 2.5 mg standard dosing condition (fasting for 120 minutes post-dosing)
3316793|NCT01978626|Experimental|Smart phone Apps|"1st year: Electronic sleep diary module: an app with electronic sleep diary and message reminder~2nd year: Social persuasion system module: an app of smart phone that encourages participants with each others~3rd year: Tai-chi module: a multi-media oriented app that helps participants practice Tai-Chi"
3316794|NCT01978626|Active Comparator|Control|"1st year: traditional paper-pencil diary~2nd year: no social persuasion is given beyond sessions~3rd year: Tai-chi teaching by Digital Video Disc only"
3316795|NCT01978652|Experimental|Peginterferon Beta-1a administered to Japanese participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
3316796|NCT01978652|Experimental|Peginterferon Beta-1a administered to Caucasian participants|A single dose of Peginterferon Beta-1a 125 μg subcutaneous (SC) injection administered by pre-filled syringe
3316797|NCT01978665|Placebo Comparator|prednisone and Solumedrol|placebo arm versus prednisone
3316798|NCT01978665|Placebo Comparator|solumedrol|placebo versus solu medrol
3316799|NCT01978665|Other|placebo|measurement of fitness
3316800|NCT01978678||Pulmicort|ICS and LABA - based on ACQ and FeNO
3316801|NCT01978691|Active Comparator|Probiotic|Bifidobacterium animalis ssp. lactis 420 (10^10 colony-forming units (CFU)/day in 12 g of microcrystalline cellulose), once per day for six months in a sachet mixed into a smoothie drink
3316802|NCT01978691|Active Comparator|Prebiotic|Polydextrose, 12 g once per day for six months in a sachet mixed into a smoothie drink
3316803|NCT01978691|Active Comparator|Synbiotic|B. lactis 420 (10^10 CFU/day) in 12 g of polydextrose, once per day for six months in a sachet to be mixed into a smoothie drink
3316804|NCT01978691|Placebo Comparator|Control|12 g of microcrystalline cellulose once per day for six months in a sachet to be mixed into a smoothie drink
3316805|NCT01978704|Experimental|Glycaemic load|
3316806|NCT01978704|Active Comparator|Carbohydrates content|
3316807|NCT01978717|Experimental|general anesthesia & epidural anesthesia|26 patients received general anesthesia combined with epidural anesthesia for surgery, and patient-controlled epidural analgesia for 2 days after surgery
3316808|NCT01978717|Experimental|general anesthesia|27 patients received general anesthesia for surgery, and patient-controlled intravenous analgesia for 2 days after surgery
3316809|NCT01978730|Experimental|high dose group of SaiLuoTong capsule|take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
3316810|NCT01978730|Experimental|low dose group of SaiLuoTong capsule|take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
3316811|NCT01978730|Placebo Comparator|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
3316812|NCT01978756||Outpatient clinic|All patients treated for breast cancer with curative intent in MAASTRO clinic in 2002-2003 who are still alive, who respond to our invitation letter and are willing to participate to visit the outpatient clinic. These patients will be sent a questionnaire with both basic and more detailed questions on their disease-status and on quality of life related outcome. In addition they will be asked to come to MAASTRO clinic for a more detailed evaluation of late side effects of the treatment. Patients are seen by a physician or a physician assistant at the outpatient clinic.
3316813|NCT01978769||Preadolescents with ADHD|preadolescents with prior diagnosis of ADHD and without any other psychiatric or neurological diagnosis.
3316814|NCT01978769||Preadolescents with out any diagnosis|Preadolescents with out any diagnosis
3316815|NCT01978782|Active Comparator|raltegravir alone|raltegravir 400 mg BID for 5 days
3316816|NCT01978782|Active Comparator|citalopram alone|citalopram 10 mg QD for 3 days, followed by citalopram 20 mg QD for 13-14 days
3316817|NCT01978782|Experimental|raltegravir + citalopram|raltegravir 500 mg BID and citalopram 20 mg QD for 5 days
3316818|NCT01978795|Experimental|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
3316819|NCT01978795|Active Comparator|Control|
3316820|NCT01978821|Experimental|stem cell|autologous bone marrow mononuclear cell transplantation
3316821|NCT01978860|Experimental|NovaCross, CTO|assess the safety and technical feasibility, deployment and withdrawal characteristics of the NovaCross™ micro-catheter during an interventional coronary angioplasty procedure and evaluating the CTO penetration rate.
3316822|NCT01978873|Experimental|Arm A:|"Cabazitaxel 25 mg / m² / day on day 1 every 3 weeks continued if the patient has stable disease or responding to up to 10 cycles. Cabazitaxel will be administered in combination with oral prednisone or prednisolone (Prednisolon 10mg 1x1)~Hormones will be initiated in conjunction with the last cycle of chemotherapy. Consists of the administration of a luteinizing hormone-releasing hormone (LHRH) agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device. G-CSF treatment according to ASCO guidelines is recommended."
3316823|NCT01978873|Active Comparator|Arm B:|-Hormone: LHRH agonist antiandrogens for 30 days + OR surgical castration OR CAB complete androgen blockade by LHRH agonist + antiandrogen device.
3316824|NCT01978886||Patient with diabetes|Patients who have been diagnoses with diabetes.
3316825|NCT01978886||Patients without diabetes|Patients who have not previous been diagnosed with diabetes.
3316826|NCT01978899|Active Comparator|Immediate Weight Loss Program Group|"Immediate Weight Loss Program Group~The weight loss Program Group will include weekly in-person sessions comprised of dietary counseling and increased physical activity. Patients will also be provided with exercise and dietary goals each week to implement at home.~Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks."
3316827|NCT01978899|Active Comparator|Delayed Weight Loss Program Group|The Delayed Weight Loss Program Group will take part in the weight loss intervention after the 16-week control period. Assessments will occur at baseline (pre-randomization), at the end of the 16-week intervention or control period and at 32 weeks
3316828|NCT01978925|Experimental|Pharmaceutical care|In the ED, immediately after discharge, participants randomized to the pharmaceutical care group will receive intervention coordinated by the study pharmacist.
3316829|NCT01978925|No Intervention|Usual care|In addition to counseling provided by a physician and by the nursing staff during their stay in the ED (usual care), patients randomized to the control group will receive the same printed material information on hypertension and/or diabetes medications and lifestyle interventions in order to keep patients masked.
3316830|NCT01978951|Experimental|Integrated Chronic Kidney Disease care|standard guidelines of CKD treatment + Integrated CKD care consisting of multidisciplinary team care and home visit by community care network
3316831|NCT01978951|Active Comparator|Conventional CKD care|standard guidelines of CKD treatment
3316832|NCT01978964|Experimental|ONT-10 Vaccine|
3316833|NCT01978977||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
3316834|NCT01978990||Diabetes Management System , blood glucose|
3316836|NCT01979042||patients with stones|80 men and women with a normal creatinine for the past year that present in the ER with renal colic and a stone in their ureter according to imaging
3316837|NCT01979042||patients without stones|20 men and women that presented in our department for elective surgery that is not related to stones or bladder outlet obstruction
3316838|NCT01979055|Experimental|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
3316839|NCT01979055|Placebo Comparator|Control group|3 telephone calls to assess any additional questions regarding asthma
3316840|NCT01979081||People with chronic disease|Participants greater than or equal to 44 years of age with a chronic disease (diabetes, heart disease, stroke, hypertension, osteoporosis, osteoarthritis, rheumatoid arthritis, chronic obstructive pulmonary disease, back pain, Multiple Sclerosis, Parkinson's Disease).
3316841|NCT01979081||People without chronic disease|Participants greater than or equal to 65 years of age without a chronic disease.
3316842|NCT01979094||spinal arthrodesis and/or arthroplasty procedures|
3316843|NCT01979107|Experimental|Proactive action by the general practitioner|Proactive action by the general practitioner inviting to preventive health check.
3316844|NCT01979107|No Intervention|Control group|The participants will be treated as usual by the general practitioner.
3316845|NCT01979120||only 1 cohort!|All patients already got an ICD implanted which includes an algorithm for screening of sleep-disordered breathing and will be examined by an portable polygraphy monitor in order to compare the Apnea-Hypopnea-Index.
3316846|NCT01979146|Experimental|Provider Unrelieved Symptom Alert|Patients in the intervention arm called the automated monitoring system daily to report presence, severity and distress on a 1-10 scale for nine symptoms. The system immediately sent an emailed symptom alert report to their oncologist and oncology nurse if symptoms exceeded preset thresholds (moderate to severe levels). Two thresholds were set: a simple alert when severity or distress was 4 or greater on the 10 point scale and trend alerts based on a pattern of moderate severity over several days.
3316847|NCT01979146|No Intervention|Attentional Control Usual Care Group|Patients in the usual care group called the automated monitoring system daily to report presence, severity and distress (1-10 scale) on 9 symptoms and also measured symptom interference with daily activities, functional status, work attendance, and unscheduled provider visits, urgent care and emergency department visits, and unscheduled hospitalizations. The usual care group received equivalent contact time with the automated system including identical voice and assessment questions. Data were not available for clinical action and not reported to the oncology providers. On every call, usual care participants were reminded to call their oncology provider if they had symptom concerns, which is the usual practice in oncology settings to address unrelieved symptoms.
3316848|NCT01979198||fusion group|close reduction with posterior short-segment transpedicular screw fixation with posterior fusion
3316849|NCT01979198||non-fusion group|close reduction with posterior short-segment transpedicular screw fixation without posterior fusion
3316850|NCT01979211|Experimental|Cetuximab and Radiation|Cetuximab 400 mg/m2 IV over 120 minutes loading dose > 4 days prior to initiation of radiation; Cetuximab 250 mg/m2 IV over 60 minutes weekly weeks 2-7 concurrent with Radiation therapy 60-66 Gy in 2 Gy daily fractions
3316851|NCT01979224|No Intervention|treatment and routine counseling|Parents attend regular consultation and receive regular medical guidance
3316852|NCT01979237|Experimental|SPASO method, FARES method|Reduction method: SPASO method, FARES method
3316853|NCT01979250|No Intervention|Normal corneas|Normal corneas from patients that undergo cataract surgery.
3316854|NCT01979250|Other|DSAEK surgery|Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK).
3316855|NCT01979263|Active Comparator|Attention Bias Modification|Attention Bias Modification computer task
3316856|NCT01979263|Placebo Comparator|Placebo Computer Task|Placebo computer task
3316857|NCT01979289|Experimental|Computer Treatment: Active|Computerized Cognitive Remediation: Targeted to underlying cerebral networks associated with remission.
3316858|NCT01979289|Active Comparator|Computer Treatment: Control|Computerized Cognitive Remediation: Non-targeted
3316859|NCT01979302|Experimental|Depression CAREPATH|Patients receiving care from Nurses trained in depression care management
3316860|NCT01979302|Other|Usual Care|Patients under the care of nurses who were trained in depression assessment and usual care
3316861|NCT01979328|Experimental|Study arm|geko neuromuscular electrostimulation
3316862|NCT01979341|Active Comparator|Dual trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG) plus 0.2mg triptorelin acetate (GnRH agonist)
3316863|NCT01979341|Active Comparator|hCG trigger|final oocyte maturation trigger using 6500 IU Ovitrelle (hCG)
3316864|NCT01979341|Active Comparator|agonist trigger|final oocyte maturation trigger using 0.2mg triptorelin acetate (GnRH agonist)
3316865|NCT01979354|Active Comparator|Spinal morphine|0.15 mg spinal morphine
3316866|NCT01979354|No Intervention|Control|No spinal morphine
3316867|NCT01979380|Experimental|KD101|
3316868|NCT01979380|Placebo Comparator|placebo|
3316869|NCT01979393|Experimental|Cabozantinib|Cabozantinib maintenance 60 mg daily for 2 years or until withdrawal criterion After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving cabozantinib shall be further treated at the investigator discretion.
3316870|NCT01979393|Experimental|Placebo|Placebo daily for 2 years or until withdrawal criterion. After documented disease progression (according to RECIST 1.1), the treatment will be unblinded. Subjects receiving placebo shall be offered the option of receiving cabozantinib up to further progression. This is not mandatory and treatment is at the investigator decision.
3316871|NCT01979406|Active Comparator|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
3316872|NCT01979406|Experimental|Ad4-PA-1|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Day 1 + oral placebo on Day 15 + AVA boost at Day 29"
3316873|NCT01979406|Experimental|Ad4-PA-2|"Given at 10^9, 10^10 and 10^11 vp~Ad4-PA at Days 1, 15 and 29"
3316874|NCT01979406|Experimental|Ad4-PA-3|"Ad4 given at 10^9, 10^10 and 10^11 vp~Ad4 PA-GPI at Day 1 + AVA boost at Day 15 + placebo on Day 29"
3316875|NCT01979406|Experimental|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
3316876|NCT01979406|Experimental|Ad4 PA-GPI-2|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + placebo on Day 15 + AVA boost at Day 29"
3316877|NCT01979406|Experimental|Ad4-PA-GPI -3|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4-PA-GPI at Days 1, 15 and 29"
3316878|NCT01979419||cognitively normal|MRI scans, PET scans, lumbar puncture
3316879|NCT01979419||mild cognitive impairment|MRI scans, PET scans, lumbar puncture
3316880|NCT01979419||Alzheimer's Disease|MRI scans, PET scans, lumbar puncture
3316881|NCT01979419||vascular MCI|MRI scans, PET scans, lumbar puncture
3316882|NCT01979419||subcortical ischemic vascular dementia|MRI scans, PET scans, lumbar puncture
3316883|NCT01979432|Other|Cardiovascular evaluation|Measure of the index of systolic pressure Echo doppler Echography Measure of the speed of the wave of pulse and the central pressure
3316884|NCT01979458|Experimental|PSE|Patients whose distal colon is imaged using the PSE device. This is a pilot trial of 30 patients.
3316885|NCT01979471|Other|Advanced care|For all the patients randomized to the advanced care group the pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA)
3316886|NCT01979471|No Intervention|Usual Care|"Patients randomized to the usual care group will receive:~Usual pharmacy care with no specific interventions for 3 months~At the end of the 3 months of the usual care period, all patients will cross over to receive the advanced care outlined above for 3 months"
3316887|NCT01979484|Experimental|PPI-668 capsule followed by tablet|On day 1 two 100 mg PPI-668 capsules will be administered; on day 8 one 200 mg PPI-668 tablet will be administered
3316888|NCT01979484|Experimental|PPI-668 tablet followed by capsule|On day 1 one 200 mg PPI-668 tablet will be administered; on day 8 two 100 mg PPI-668 capsules will be administered
3316889|NCT01979497|Active Comparator|Suture with Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then steri-strips for the adhesive stripped half of the scar is applied.
3316890|NCT01979497|Active Comparator|Suture without Adhesive Stripping|Buried dissolving subcuticular sutures are sued for both sides of the wound to approximate wound edges and then no closure material for the half of the scar is applied.
3316891|NCT01979510|Experimental|MK-0663B|MK-0663B (etoricoxib 90 mg immediate release [IR]/tizanidine 6 mg modified release [MR]) capsules once daily for 8 days.
3316892|NCT01979510|Experimental|DOLOCAM PLUS®|DOLOCAM PLUS® (meloxicam 7.5mg/methocarbamol 215mg) capsules once daily for 8 days.
3316895|NCT01979549||Sedation|patients underwent upper gastrointestinal endoscopy with sedation
3316896|NCT01979549||non-sedation|patients underwent upper gastrointestinal endoscopy without sedation
3316897|NCT01979562||100 runners|Male runners between 18-60 years.
3316898|NCT01979588|Placebo Comparator|Control|Providers do not have access to What's Going Around Tool but receive an instructional video explaining tool
3316899|NCT01979588|Active Comparator|What's Going Around Tool|Provider has access to What's Going Around Tool. Provider also shown a video explaining how to use Tool
3316900|NCT01979601|Experimental|Patient: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3316901|NCT01979601|Experimental|Patient: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3316902|NCT01979601|Experimental|Patient: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3316903|NCT01979601|Experimental|Patient: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3316904|NCT01979601|Experimental|Patient: LGT209 20 mg/kg|20 mg/kg LGT209 intravenous administration in patients on stable doses of statins
3316905|NCT01979601|Experimental|Healthy Volunteers: LGT209 0.3 mg/kg|0.3 mg/kg LGT209 intravenous administration in healthy volunteers
3316906|NCT01979601|Experimental|Healthy Volunteers: LGT209 1 mg/kg|1 mg/kg LGT209 intravenous administration in healthy volunteers
3316907|NCT01979601|Experimental|Healthy Volunteers: LGT209 3 mg/kg|3 mg/kg LGT209 intravenous administration in healthy volunteers
3316908|NCT01979601|Experimental|Healthy Volunteers: LGT209 10 mg/kg|10 mg/kg LGT209 intravenous administration in healthy volunteers
3316909|NCT01979601|Experimental|Healthy Volunteers: 20 mg/kg|20 mg/kg LGT209 intravenous administration in healthy volunteers
3316910|NCT01979601|Placebo Comparator|Patient: Placebo|Matching intravenous placebo in patients on stable doses of statins
3316911|NCT01979601|Placebo Comparator|Healthy Volunteers: Placebo|Matching intravenous placebo in healthy volunteers
3316912|NCT01979627|Experimental|transulnar approach group|Patients in transulnar group received interventional procedure through ulnar artery
3316913|NCT01979627|Other|transradial approach group|patients in transradial group received interventional procedure through radial artery
3316914|NCT01979640|Experimental|39 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3316915|NCT01979640|Experimental|37 Fr double lumen group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3316916|NCT01979640|Experimental|35 Fr double lumen tube group|patients are assigned to 35 Fr, 37 Fr, 39 Fr double lumen tube group according to their left main bronchus diameter measured by preoperative chest CT, to minimize difference between main bronchus diameter and bronchial tip diameter of double lumen tube
3316917|NCT01979653|Experimental|dexmedetomidine alone|dexmedetomidine 0.5 mcg/kg for 10 min + normal saline (volume-matched) bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
3316918|NCT01979653|Experimental|dexmedetomidine + midazolam|normal saline (volume-matched) for 10 min + midazolam 0.2 mg/kg bolus + dexmedetomidine 0.2-0.4 mcg/kg/hr infusion
3316919|NCT01979666|Experimental|study group|the patients that will get a nitrate patch
3316920|NCT01979666|Placebo Comparator|control group|the patients that will get the placebo patch
3316921|NCT01979679|Active Comparator|Lurasidone 80 mg per day|Lurasidone 80 mg per day
3316922|NCT01979679|Active Comparator|Lurasidone 120 mg per day|Lurasidone 120 mg per day
3316923|NCT01979679|Active Comparator|Lurasidone 160 mg per day|Lurasidone 160 mg per day
3316924|NCT01979692|Experimental|One arm ; CLM use in TTNB|"to determine the feasibility of using the CLM in performing TTNB of thoracic and mediastinal lesions~to obtain imaging criteria for distinguishing viable from non viable (necrotic) tissue and normal versus abnormal (inflammatory/malignant) lesions. On site rapid cytological examination (ROSE) will be the standard of biopsy quality.~the results will be compared to historic data of standard biopsies as to yield and quality of sampling"
3316925|NCT01979718|Experimental|Full term intervention|"random selection~composed of the daily standard physical treatment and 1 session per one day over two weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality simulating the surgeried knee."
3316926|NCT01979718|Active Comparator|Half term intervention|"random selection~composed of the daily standard physical treatment over two weeks and 1 session per one day over one weeks with a break on Saturday and Sunday (1 session is consisted of 50 repetitions of voluntary simultaneous flexion and extension of the both knees, taking a look at the mirrored virtual reality stimmulating the surgeried knee )"
3316927|NCT01979731|Experimental|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
3316928|NCT01979731|Active Comparator|Guidelines Ergonomics|Manual material handling Orientation posture Orientation furniture Orientation in general
3316929|NCT01979744|Experimental|Resolute Integrity - IVUS|Resolute Integrity - IVUS arm
3316930|NCT01979744|Active Comparator|Resolute Integrity - Angio|Resolute Integrity - Angio arm
3316931|NCT01979744|Active Comparator|Promus - Angio|Promus - Angio arm
3316932|NCT01979744|Active Comparator|Promus - IVUS|Promus - IVUS arm
3316933|NCT01979757|Active Comparator|Centrifugation|Patients recieved fatgraft processed by Centrifugation
3316934|NCT01979757|Active Comparator|Puregraft|Patients recieved fatgraft processed by Puregraft
3316935|NCT01979770||Adolescents|Adolescents who participated in an intervention trial of iron and zinc supplementation and a follow-up study at 9 years of age in 3 rural districts in Khon Kaen province, northeast of Thailand.
3316936|NCT01979783||LBP|group of subjects with low back pain
3316937|NCT01979783||nonLBP|group without low back pain
3316938|NCT01979796|Experimental|Ecig 24 mg nicotine|Ecig 24 mg nicotine
3316939|NCT01979796|Sham Comparator|Ecig 0 mg nicotine|Ecig 0 mg nicotine
3316940|NCT01979796|Placebo Comparator|Nicotine free inhalator|Nicotine free inhalator
3316941|NCT01979809|Sham Comparator|Arm 1|Untailored control website designed to support increase in fruit and vegetables with no age targeting used in previously funded MENU Choices study
3316942|NCT01979809|Active Comparator|Arm 2|MENU GenY age-targeted and tailored interactive website including 8 information sessions over 4 months, and options to visit over 185 recipes, videos, 4 bloggers, and information articles on dietary change topics
3316943|NCT01979809|Active Comparator|Arm 3|"Web intervention that is age targeted and tailored, identical to Arm 2, with the addition of personalized e-coaching support via email."
3316944|NCT01979822||PH patients with LenusPro pump|"Patient Inclusion Criteria:~Patient aged ≥ 18 years;~diagnosed with Pulmonary Arterial Hypertension (WHO) Category Group 1~Patient is in stable clinical condition and~the previous specific PH medication has been retained unchanged during the past 3 weeks"
3316945|NCT01979848||MRI Mapping Group|After Subjects arrive at the MRI facility, subjects will fill out a medical questionnaire that will be used to determine whether a MRI study can be performed. The investigators will determine whether there are any problems that make the subject not suitable for participating in this study.
3316946|NCT01979861|Experimental|vapor endometrial ablation|endometrial ablation using the AEGEA Vapor System
3316947|NCT01979874|Experimental|Pro-Omega|High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)
3316948|NCT01979874|Placebo Comparator|Placebo|Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
3316949|NCT01979887||Non-MGD Participants|Participants without MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3316950|NCT01979887||Mild-Moderate MGD Participants|Participants with Mild-Moderate MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3316951|NCT01979887||Severe MGD Participants|Participants with Severe MGD who have meibum expressed as per protocol. No investigational drug is administered in this study.
3316952|NCT01979900|Experimental|Vaccae|Experiment group:One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
3316953|NCT01979900|Placebo Comparator|Placebo|Placebo group:One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally
3316954|NCT01979913|Experimental|Patients with POAG or OHT|Patients with primary open angle glaucoma or ocular hypertension
3316955|NCT01979926|Experimental|N02RS1 200mg|Combination of Broussonetia spp and Lonicera spp
3316956|NCT01979926|Experimental|N02RS1 400mg|Combination of Broussonetia spp and Lonicera spp
3316957|NCT01979926|Placebo Comparator|Placebo|Sugar pill
3316958|NCT01979939|Experimental|A 1: DCV/ASV/BMS-791325 in treatment-naive subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
3316959|NCT01979939|Experimental|A 2: DCV/ASV/BMS-791325 in treatment-experienced subjects|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day for 12 weeks
3316960|NCT01979965|Active Comparator|Active drug|Ranolazine therapy for three months
3316961|NCT01979965|Placebo Comparator|Sugar Pill|sugar pill therapy for three months
3316962|NCT01979978|Experimental|Healthy Buddies Curriculum|Healthy buddies curriculum delivered by older peers weekly covering three components of healthy living: Physical activity, healthy eating and a healthy body image.
3316963|NCT01979978|No Intervention|Control|This group received standard school curriculum.
3316964|NCT01979991|Experimental|CT Imaging and Reconstruction|To develop a MBIR (model-based image reconstruction) method that will improve X-ray CT lung imaging by improving image quality and reducing dose.
3316965|NCT01980004|Experimental|Dietary Education|Participants in this treatment arm will undergo dietary counseling for the prevention of kidney stone formation.
3316966|NCT01980004|Experimental|Potassium Citrate and Dietary Education|Participants in this treatment arm will undergo potassium citrate supplementation and dietary counseling for the prevention of kidney stone formation.
3316967|NCT01980017|No Intervention|Wait-Listed Control Group|Usual care for smoking cessation
3316968|NCT01980017|Experimental|Ottawa Model for Smoking Cessation|Ottawa Model for Smoking Cessation
3316969|NCT01980030|Experimental|Romiplostim|Weekly Romiplostim for 12 weeks with intra-patient weekly dose escalation from 1µg/Kg to a maximum dose of 10 µg/Kg with a dose reduction schema in case of platelet overshoot
3316970|NCT01980043|Other|Rectal Prolapse|endoluminal rectal prolapse repair under sedation and local anesthesia using CO2 colonoscopy to fix the rectum with sutures to the abdominal wall under needlescopic control.
3316971|NCT01980069|Experimental|Neostigmine arm|Neostigmine arm
3316972|NCT01980069|Active Comparator|Sugammadex arm|Sugammadex arm
3316973|NCT01980082|Active Comparator|Cefazolin|"Cefazolin~1 gram/2 gram if body mass index > 40 - one time dose, 30-60 min prior to incision."
3316974|NCT01980082|Placebo Comparator|Placebo|1 dose of placebo - NaCl 0.9% with no drugs added to it.
3316975|NCT01980108|No Intervention|empty stomach|No fluid will be given to the patient prior to scanning.
3316976|NCT01980108|Experimental|50mL|50mL of water will be given to the patient prior to scanning
3316977|NCT01980108|Experimental|100mL|100mL of water will be given to the patient prior to scanning
3316978|NCT01980108|Experimental|200mL|200mL of water will be given to the patient prior to scanning
3316979|NCT01980108|Experimental|300mL|300mL of water will be given to the patient prior to scanning
3316980|NCT01980108|Experimental|400mL|400mL of water will be given to the patient prior to scanning
3316981|NCT01980121||Term pregnant patients|Term pregnant patients for scheduled elective cesarean section will be examined using a portable ultrasound machine to evaluate gastric contents.
3316982|NCT01980147|Experimental|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT). This integrated model focuses on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The model and techniques are adapted to an age range of 9 to 17 years, with more visual material and child friendly language options for the younger part of the age range (9-12) and more teen-relevant and interpersonal content options for the older part of the age range (13-17). The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
3316983|NCT01980147|No Intervention|Comparison|Naturalistic comparison arm: No intervention offered, no intervention prohibited.
3316984|NCT01980160|Active Comparator|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
3316985|NCT01980160|Sham Comparator|Unactivated Nometex Device|The Nometex device will not be activated and therefore have no effect on the nausea/vomiting associated with chemotherapy.
3316986|NCT01980173|Experimental|With Bakri balloon|"Patients randomized to this arm will be treated using the Bakri balloon.~Intervention: Bakri balloon"
3316987|NCT01980173|Active Comparator|Without Bakri balloon|"Patients randomized to this arm will receive routine care not including the Bakri Balloon.~Intervention: Routine Care"
3316988|NCT01980186||Individuals with autism|Both individuals with autism and their siblings will be evaluated with (TUS)transcranial 2D ultrasound.
3316989|NCT01980186||Siblings of individuals with autism|Non-autistic siblings with no other obvious health issues will be screened
3316990|NCT01980199|Experimental|Fexinidazole|"600mg tablets~3 tablets once a day for 4 days continued by 2 tablets once a day for 6 days"
3316991|NCT01980212||first line advanced non-small cell lung cancer|patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital
3316992|NCT01980225|Experimental|Collapse|This arm includes the patients where laser-induced collapse (=artificial shrinkage) of all blastocysts is performed before vitrification
3316993|NCT01980225|No Intervention|control|This control arm includes the patients of which the blastocysts are vitrified without performing collapse
3316994|NCT01980238|Experimental|cannula ileostomy|After LAR, experimental group will accept cannula ileostomy. Operation has described in the Detailed Description.
3316995|NCT01980238|Active Comparator|loop ileostomy|After LAR, active comparator group will accept loop ileostomy. This operation is well known by colorectal surgeons.
3316996|NCT01980264|Experimental|Diagnostic imaging|Harmonic Generation Microscopy
3316997|NCT01980277|Experimental|LY2780301 + paclitaxel|"The following dose-levels will be investigated:~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 70 mg/m²/week~Continuous daily PO LY2780301 400 mg QD + weekly paclitaxel 80 mg/m²/week~Continuous daily PO LY2780301 500 mg QD + weekly paclitaxel 80 mg/m²/week~A dose reduction could be explored:~- Continuous daily PO LY2780301 300 mg QD + weekly paclitaxel 70 mg/m²/week"
3316998|NCT01980303|Experimental|Cohort 1: Treatment A|Japanese participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
3316999|NCT01980303|Experimental|Cohort 1: Treatment B|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
3317000|NCT01980303|Experimental|Cohort 1: Treatment C|Japanese participants will receive 1 spray of esketamine solution in each nostril at time 0, 5, and 10 minutes (total dose: 84 mg).
3317001|NCT01980303|Experimental|Cohort 2: Treatment A|Caucasian participants will receive 1 spray of esketamine solution in each nostril (total dose: 28 mg).
3317002|NCT01980303|Experimental|Cohort 2: Treatment B|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0 and 5 minutes (total dose: 56 mg).
3317003|NCT01980303|Experimental|Cohort 2: Treatment C|Caucasian participants will receive 1 spray of esketamine solution in each nostril at time 0, 5 and 10 minutes (total dose: 84 mg).
3317004|NCT01980316|Experimental|Argatroban group|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
3317005|NCT01980316|Experimental|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
3317006|NCT01980329|Experimental|Maraviroc|single oral administration of 300 mg maraviroc
3317007|NCT01980355|Experimental|Tranexamic Acid|1000mg tranexamic acid; given over 15 minutes into the vein once prior to surgery.
3317008|NCT01980355|Placebo Comparator|Placebo|Placebo given over 15 minutes into the vein once prior to surgery.
3317009|NCT01980368|Experimental|Group I (Tai Chi Easy)|Patients attend Tai Chi Easy class for 60 minutes once a week for 6 weeks. Patients also receive a DVD and exercise manual of Tai Chi Easy exercises and are encouraged to practice at home for 30 minutes most days per week for 6 weeks.
3317010|NCT01980368|Active Comparator|Group II (educational control)|Patients receive readings each week and attend a book club to discuss the readings for 60 minutes once a week for 6 weeks.
3317011|NCT01980381|Experimental|Tree Theme Method ® (TTM) intervention|The TTM involves storytelling and story making, in which the patient draws tree maps representing certain periods of his/her life.
3317012|NCT01980381|No Intervention|Control group|Treatment as usual, with focus on the present everyday occupations
3317013|NCT01980394|Other|prospective cohort study|
3317014|NCT01980407|Experimental|SOL, single arm|S-1 combined with leucovorin and oxaliplatin
3317015|NCT01980420|Other|Sleeve gastrectomy|All patients will undergo sleeve gastrectomy
3317016|NCT01980433|Experimental|Active rTMS|Repetitive Transcranial Magnetic stimulation: 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
3317017|NCT01980433|Sham Comparator|Sham rTMS|Placebo Transcranial Magnetic stimulation delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
3317018|NCT01980446|Other|1:Mismatch negativity|Presence of the mismatch negativity during the cortical auditory-evoked potential would predict a favorable outcome in comatose survivors after cardiac arrest.
3317019|NCT01980459|Experimental|Magnesium Lactate|Patients will receive 2 tablets twice a day of Magnesium Lactate for 3 months.
3317020|NCT01980472|Experimental|bevacizumab, carboplatin and paclitaxel|bevacizumab, carboplatin and paclitaxel
3317021|NCT01980498|Experimental|PecFent nasal spray|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
3317022|NCT01980498|Active Comparator|Physician choice-Usual Care (PC-UC)|"Patients that have signed the ICF and met inclusion and exclusion criteria are randomly assigned 1:1 to receive one of the following IP-BTP treatments:~Fentanyl pectin nasal spray (FPNS)~Physician choice-Usual Care (PC-UC)"
3317023|NCT01980537|Experimental|Stereotaxis|Magnetic wire navigation
3317024|NCT01980537|Active Comparator|Conventional|Conventional wire navigation
3317025|NCT01980550|Experimental|sublingual nicotine，placebo|sublingual nicotine：one or two tablets per hour, up to a maximum of 20 tablets per day Subjects were advised to use the full treatment dose for 4 weeks
3317026|NCT01980563|Active Comparator|ultrasound|
3317027|NCT01980563|Active Comparator|combined monitoring|
3317028|NCT01980576||Pre-operative pain measurement|Patients with low back pain
3317029|NCT01980602|Experimental|Supervised Exercise Program|
3317030|NCT01980615|Experimental|BGF MDI (PT010) Dose 1|BGF MDI Dose 1 taken as 2 inhalations
3317031|NCT01980615|Experimental|BGF MDI (PT010) Dose 2|BGF MDI Dose 2 taken as 2 inhalations
3317032|NCT01980615|Experimental|BGF MDI (PT010) Dose 3|BGF MDI Dose 3 taken as 2 inhalations
3317033|NCT01980615|Active Comparator|GFF MDI (PT003)|GFF MDI (PT003) taken as 2 inhalations
3317034|NCT01980615|Active Comparator|Symbicort MDI Dose 1|Symbicort MDI taken as 2 inhalations
3317035|NCT01980615|Active Comparator|Symbicort MDI Dose 2|Symbicort MDI Dose 2 taken as 2 inhalations
3317036|NCT01980641|No Intervention|Control group|Assessment of each participant's home and his or her performance of ADL.
3317037|NCT01980641|Experimental|Experimental group|Educational intervention: Assessment of each participant's home and his or her performance of ADL and the therapist will provide to the participants of the experimental group a list of advice related to the HTAS items that are evaluated negatively.
3317038|NCT01980641|Experimental|Application smartphone-based group|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
3381987|NCT05162976|Experimental|Treatment (CC-486, nivolumab)|Patients receive azacitidine PO QD on days 1-7 and nivolumab IV over 30 minutes on day 8. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
3317039|NCT01980641|No Intervention|Non Application smartphone-based group|Non Smartphone-based application group (NSG) sample won't have a reminder
3317040|NCT01980667|Experimental|lurbinectedin (PM01183) / cisplatin|Patients will receive cisplatin as a 90-min i.v. infusion. In addition, patients will receive PM01183 as an i.v. infusion over 1-hour.
3317041|NCT01980680|Experimental|Agonist trigger|Agonist trigger Buserelin 0,5 mg and Pregnyl (hCG)
3317042|NCT01980680|Active Comparator|hCG|hCG trigger Pregnyl (hCG) and Progesterone and Estradiol
3317043|NCT01980693|Other|bone age assessment by ultrasound|The aim of this phase is to collect the ultrasound reading values of Speed of Sound (SOS) and Distance (DIS) of all participants by performing a one time measurement of the left hand by the SonicBone's BA device. Each measurement will be performed on three sites of the hand: the wrist the phalanx and the metacarpal bones.
3317044|NCT01980719||Healthy, Age-Matched|
3317045|NCT01980719||Fatigued|
3317046|NCT01980719||Not Fatigued|
3317047|NCT01980745|Active Comparator|Chloroquine diphosphate|chloroquine diphosphate 250mg/day
3317048|NCT01980745|Placebo Comparator|sugar pill|sugar pill
3317049|NCT01980758|Experimental|Surgery|Laparoscopic Gastric Plication
3317050|NCT01980797||Bicuspid aortic valve disease|"Group/Cohort Label - Bicuspid aortic valve~Group/Cohort Description -~Patients diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
3317051|NCT01980797||Tricuspid aortic valve control patients|"Group/Cohort Label - Tricuspid aortic valve control patients~Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched.~Patients not diagnosed with bicuspid aortic valve~All ages ≥8 years~Able to provide fully informed consent"
3317052|NCT01980810|Experimental|albumin-bounded paclitaxel plus S-1|arm 1:albumin-bounded paclitaxel 200mg iv d1 and S-1 80mg/m2/d po d1-10, repeated every 2 weeks,up to 9 cycles,then S-1 as single agent to treat to disease progression
3317053|NCT01980823|Experimental|Metformin-Atorvastatin combination|Patients will receive metformin and atorvastatin for approximately 2 weeks prior to breast surgery.
3317054|NCT01980836|Active Comparator|Seasonal influenza vaccine in tocilizumab treated RA patients|RA patients treated with tocilizumab
3317055|NCT01980836|Active Comparator|Seasonal influenza vaccine to Healthy controls|Healthy controls will be vaccinated against seasonal influenza
3317056|NCT01980849|Experimental|Long term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
3317057|NCT01980849|Active Comparator|Short-term prophylaxis|Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
3317058|NCT01980862||Heart Failure patients|No interventions for this study. Blood draw provided by patients.
3317059|NCT01980901||Ovation™/Ovation Prime™ Abdominal Stent Graft System|Adult male and female patients.
3317060|NCT01980927|Experimental|NUCCA atlas correction|NUCCA atlas correction for migraine patients
3317061|NCT01980953|Experimental|Part 1: Food Effect|GDC-0032 will be administered orally over 3-Treatment Period (TP) in 6-sequence as one 3 milligrams (mg) capsule in TP-A after 10 hour fasting from food, one 3 mg Phase III tablet in TP-B after 10 hour fasting from food and one 3 mg Phase III tablet in TP-C following the start of standard Food and Drug Administration (FDA) high-fat breakfast. Washout period o 14 to 20 days will be given between each TP.
3317062|NCT01980953|Experimental|Part 2: Tablet Formulation Comparison|Different formulations of tablets (Tablet A and Tablet B) of GDC-0032 will be administered orally over 2-TP having 10 hour fasting from food. Participants will receive one 3 mg Tablet A in TP-A and one 3 mg Tablet B in TP-B after 14 to 20 days washout period.
3317063|NCT01980953|Experimental|Part 3: Capsule API Lot Comparison|Two different lots of GDC-0032 active pharmaceutical ingredient (API) capsule formulation will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 3 mg capsule in TP-B after 14 to 20 days washout period.
3317064|NCT01980953|Experimental|Part 4: Tablet Relative Bioavailibity|GDC-0032 will be administered orally in crossover fashion over 2-TP to 20 participants having 10 hour fasting from food. Participants will receive one 3 mg capsule in TP-A and one 2 mg Phase III tablet in TP-B after 14 to 20 days washout period.
3317065|NCT01980966|Experimental|MHAA4549A|
3317066|NCT01980966|Placebo Comparator|Placebo|
3317067|NCT01980966|Active Comparator|Tamiflu|
3317068|NCT01980979|Experimental|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
3317069|NCT01981005|Experimental|RO5424802|
3317070|NCT01981018|Experimental|Imagery-focused Cognitive Therapy|"10 sessions of imagery-focused Cognitive Therapy delivered approximately weekly by two co-therapists, divided in 4 assessment, 4 treatment and 4 consolidation sessions; additional 2 blip management sessions during therapy and 3 blip management and booster session during follow up can be delivered if necessary."
3317071|NCT01981031|Experimental|A|Drug: BioChaperone® Combo
3317072|NCT01981031|Active Comparator|B|Drug: Humalog® Mix25
3317073|NCT01981044|Experimental|SERI® Surgical Scaffold|It is a prospective, multicenter, single-arm, post-market on-label clinical study of a 510(k)-cleared device.
3317074|NCT01981070|Other|Mindfulness Intervention for Parents|"The mindfulness intervention program incorporates the same structure as the Support and Information for Parents intervention (orientation session, six 2-hour sessions over 6 weeks, co-facilitated by two leaders) but different content. Instead of presentations by experts and open-ended discussions and peer support, sessions will offer experiential training in meditation practice (sitting meditation, gentle yoga, and walking meditation), as outlined in the MBCT Program (Segal et al., 2012). Each week, parents will be required to practice a mindfulness skill, and also participate in a mindful parenting exercise as homework, such as joining their child in an activity of the child's choice."
3317075|NCT01981070|Active Comparator|Support and Information for Parents|This 6-week program includes orientation session, six 2-hour sessions, held weekly. Parents will be provided with information on existing services in the region, and strategies to be strong advocates and plan and access services for their child. Each session will include a presentation by an expert, with a question answer period, a break, and facilitated discussion with other parents. The sessions will be co-facilitated by clinicians from the Disability Services Ontario (DSO) and Centre for Addiction and Mental Health (CAMH).
3317076|NCT01981083|Experimental|Egg albumin-based protein supplement|Powder form, dosage 30 g daily, duration 6 months
3317077|NCT01981083|Active Comparator|Renal-specific oral supplement|Liquid form, dosage 237 ml (one can) daily, duration 6 months
3317078|NCT01981135|Sham Comparator|Clean Air|Exposure to clean air will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3317079|NCT01981135|Experimental|Ozone|Exposure to ozone will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
3317080|NCT01981148||Healthy patients|Healthy patients
3317081|NCT01981148||Patients with various retinal diseases|Various retinal diseases (vascular, hereditary, degenerative)
3317082|NCT01981161||Fingolimod|patients treated by Fingolimod will have biological samples and clinical data
3317083|NCT01981161||Natalizumab|patients treated by Natalizumab will have biological samples and clinical data
3317086|NCT01981200|Experimental|Resistance training in AECOPD|The patients conduct daily training during admission with weight cuff 3 set of 10 rep.
3317087|NCT01981226|Experimental|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
3317088|NCT01981239|Experimental|LPC analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and linear voice analyses using LPC method are performed to calculate LPC index, residual variance, coefficiency mean, coeffiency variance, and coeffiency skewness.
3317089|NCT01981239|Active Comparator|spectral analysis group|Voice sampling is executed before and immediately after drinking of 20ml N/S and spectral voice analyses using Dr. Speech program are performed to calculate HNR (dB), RAP (%: Jitter), Mean and SD Fundamental Frequency (Hz: Fo), Shimmer (%) and SNR (dB).
3317090|NCT01981252|Experimental|Ulthera® System Treatment|Ulthera® System treatment of the peri-orbital and peri-oral regions.
3317091|NCT01981265||Hand osteoarthritis|
3317092|NCT01981278|Experimental|Treatment A|Tapentadol ER 250-mg tamper-resistant formulation (TRF) tablet will be administered as a single oral dose under fasted condition.
3317093|NCT01981278|Experimental|Treatment B|Tapentadol ER 250-mg prolonged-release formulation 2 (PR2) tablet will be administered as a single oral dose under fasted condition.
3317094|NCT01981291|Active Comparator|Perineural|Patients in this group will receive a perineural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
3317095|NCT01981291|Experimental|Intraneural|Patients in this group will receive an intraneural injection of mepivacaine for subgluteal sciatic nerve block, in addition to a femoral nerve block and patient-controlled postoperative analgesia.
3317096|NCT01981304||DES with a biodegradable polymer coating|Patients receiving the first carbonized bio-absorbable coated rapamycin-eluting coronary stent at time of percutaneous coronary intervention
3317097|NCT01981317|Experimental|Stepped Care CBT|"All participants in this arm receive Step One which includes 3-in-office sessions lasting 1 hour each over 6 weeks and 6 weekly phone calls lasting 15 minutes or less. The in-office sessions are devoted to psychoeducation, cognitive therapy, and hierarchy development. These sessions will include all procedures of the standard therapist-delivered CBT but will be parent-led, therapist guided; thus, the parent is delivering evidence-based strategies with clinician guidance.~Children are then stepped up to Step Two of SC-CBT if it is determined that more therapy is needed following the post assessment. Step Two is a continuation of therapy and will include 9 additional in-office weekly session lasting 1 hour each over 9 weeks. These sessions will be therapist-led and are devoted to exposure and response prevention."
3317098|NCT01981317|Active Comparator|Standard CBT|All patients in this arm will receive 12 sessions of therapy over 12 weeks using the evidence-based cognitive behavioral therapy protocol in POTS (2004). Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-12 involve exposure and response prevention exercises specific to each youth.
3317099|NCT01981330|Experimental|aMSC with and without hyaluronan gel|autologous mesenchymal stem cells (aMSC) injected into the vocal folds in 8 patients and aMSC mixed with hyaluronan gel in 8 patients
3317100|NCT01981343|Experimental|A-F Betafood|Two A-F Betafood tablets taken with a meal, 3 times daily for 12 weeks
3317101|NCT01981343|Placebo Comparator|Placebo|2 Placebo tablets taken with a meal, 3 times daily for 12 weeks
3317102|NCT01981369|Active Comparator|Propofol sedation.|This group will have infraclavicular block and sedation during surgery with intravenous Propofol. Patients will receive intravenous Propofol sedation 50-100 mcg/kg/min infusion. The infusion will be stopped 15 minutes before the end of surgery.
3317103|NCT01981369|Experimental|Dexmedetomidine sedation.|This group will have infraclavicular block and sedation with intravenous Dexmedetomidine. Patients will receive intravenous Dexmedetomidine sedation bolus 0.5mcg/kg in 10 minutes and then 0.2-0.5 mg/kg/hr infusion. The infusion will be stopped 15 minutes before the end of surgery.
3317104|NCT01981382||Incident cases|Persistent nonspecific low back pain
3317105|NCT01981382||Controls|Acute low back pain that resolves in <6 months
3317106|NCT01981395|Experimental|Treatment regimn 1|150 mg Fenobam Orally - once
3317107|NCT01981395|Placebo Comparator|Treatment Regimen 2|Placebo orally - once
3317108|NCT01981408|Experimental|[^14C]-LY2801653|Single oral dose of LY2801653 containing 100 micro curies of radioactivity
3317109|NCT01981421||Liver fibrosis|patients who had chronic liver disease
3317110|NCT01981434|Active Comparator|Video game based obesity education|This is the intervention group. They will be given the opportunity to play an interactive educational video game for teaching health and nutrition.
3317111|NCT01981434|No Intervention|No intervention|This is the control group that will receive only printed information about health and nutrition and will not be given the opportunity to play the educational video game.
3317112|NCT01981447|Active Comparator|Group A|IV Lacosamide administered (intravenously) over 30 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1 mg/ kg and 2.9 mg/kg over 30 minutes.
3317113|NCT01981447|Active Comparator|Group B|IV Lacosamide to be administered (intravenously) over 15 minutes: 0.7mg/kg, 1.4 mg/kg, 2.1mg/kg, 2,4 mg/kg
3317114|NCT01981460|No Intervention|Chloroprep and biopatch|Both arms are cleaned with chloroprep and a biopatch is placed on each arm.
3317115|NCT01981460|Experimental|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
3317116|NCT01981486|Placebo Comparator|Placebo|Placebo tablets
3317117|NCT01981486|Experimental|PF-05180999|Modified-release tablets of PF-05180999
3317118|NCT01981499|Experimental|Arm A1|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999
3317119|NCT01981499|Placebo Comparator|Arm A2|Part A of study to assess safety, tolerability, and pharmacokinetics of PF-05180999 relative to placebo
3317120|NCT01981499|Experimental|Arm B1|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
3317121|NCT01981499|Experimental|Arm B2|Part B of study to assess effects of PF-05180999 on histamine-induced wheal
3317122|NCT01981499|Experimental|Arm B3|Positive control to ensure histamine-induced wheal assay integrity
3317123|NCT01981499|Experimental|Arm B4|Placebo control
3317124|NCT01981525|Experimental|Arm 1|Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose.
3317126|NCT01981577||Patients with Parkinson's Disease|
3317127|NCT01981577||Healthy volunteers|
3317128|NCT01981603|Experimental|navigator|Kidney transplant recipients will serve as navigators to educate and assist other patients with the transplant process.
3317129|NCT01981603|No Intervention|usual care|usual care
3317130|NCT01981629||Shock|Defined by systolic blood pressure less than 95 mmHg or shock index (heart rate/systolic blood pressure) greater than 0.9
3317131|NCT01981642|Experimental|Patients with a LVAD implanted.|Recording of LVAD data during routine visits and daily life. Recording of daily activity using wristwatch accelerometers.
3317132|NCT01981655|Experimental|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg body weight (BW) is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
3317133|NCT01981655|Active Comparator|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes. There is NO continuous infusion infused thereafter; i.e. in total 3 ml per kg over 24 hours
3317134|NCT01981668|Experimental|Cabazitaxel, Eligard and Radiotherapy|This study utilizes a conventional phase I study design with a '3+3 cohort expansion' design(15), to determine the MTD of 1) Cabazitaxel, in Part A, and 2) Radiotherapy, in Part B. The determination of the MTD is given in Section 5.2, Definition of Dose - Limiting Toxicity. All patients who enter the study, and begin concurrent chemo-radiation are analyzable for the primary endpoint of the study.
3317135|NCT01981681|Experimental|Cohort 1 Experimental Arm|
3317136|NCT01981681|Experimental|Cohort 2 Experimental Arm|
3317137|NCT01981681|Experimental|Cohort 3 Experimental Arm|
3317138|NCT01981681|Placebo Comparator|Cohort 3 Placebo Arm|
3317139|NCT01981681|Experimental|Cohort 4 Experimental Arm|
3317140|NCT01981681|Placebo Comparator|Cohort 4 Placebo Arm|
3317141|NCT01981694|Experimental|Single ascending doses|
3317142|NCT01981694|Experimental|Measurement of eye blink rate|
3317143|NCT01981707|Experimental|F-Choline PET|The F-Choline-PET will be performed before and at 6 weeks of the beginning of treatment by abiraterone acetate or enzalutamide.
3317144|NCT01981720|Experimental|1.0 mg/kg|PRX-102 (pegunigalsidase alfa) 1.0 mg/kg IV every 2 weeks (+/- 3 days)
3317145|NCT01981733|Experimental|Device|
3317146|NCT01981746|Experimental|30 ml|30 ml ropivacaine 0.1%, single bolus
3317147|NCT01981746|Experimental|10 ml|10 ml 0.1% ropivacaine, single bolus
3317148|NCT01981785||Immune deficiencies/Immune disorders|Patients with abnormal immune responses or potential primary immune deficiencies or immune disorders (allergies, autoimmune diseases) will be enrolled as the study group.
3317149|NCT01981785||No prior immune abnormalities|Patients with no prior immune abnormalities will be enrolled as the control group.
3317150|NCT01981798|Active Comparator|Training group|Physiotherapy and occupational therapy: Training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour.
3317151|NCT01981798|No Intervention|Control Group|Members of the control group were referred to their general practitioner or specialist for further care.
3381988|NCT05162963|Active Comparator|Patients treated with fixed implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Fixed denture is considered the standard protocol.
3381989|NCT05162963|Experimental|Patients treated with removable implant denture|Patients quality of life will be compared when using a removable implant denture and a fixed implant denture, in a cross-over design. Removable denture is considered the experimental protocol.
3381990|NCT05162950||SW CAH|Patients with 21-hydroxylase deficiency, salt wasting form.
3381991|NCT05162950||SV CAH|Patients with 21-hydroxylase deficiency, simple virilising form.
3381992|NCT05162950||NC CAH|Patients with 21-hydroxylase deficiency, non-classic form.
3381993|NCT05162950||Carrier CAH|Healthy individuals, heterozygous carriers a mutation in the CYP21A2 gene. Recruited among parents of patients with CAH.
3381994|NCT05162950||Control|Healthy sex and age matched controls
3381995|NCT05162937|Experimental|Treatment group 1|Drug：GR1501 100mg
3381996|NCT05162937|Experimental|Treatment group 2|Drug：GR1501 200mg
3381997|NCT05162937|Experimental|Treatment group 3|Drug：GR1501 300mg
3317152|NCT01981811|Active Comparator|Aripiprazole and Ingestible Event Marker (IEM)|All subjects will continue to receive their previously prescribed dose of aripiprazole (10 mg, 15 mg, 20 mg, or 30 mg) through the trial. Subjects will discontinue dosing of the conventional oral aripiprazole tablet and will begin taking MIND1 (aripiprazole embedded with an Ingestible Event Marker) tablet once-daily for 12 weeks.
3317153|NCT01981837|Experimental|ALN-TTRSC (revusiran)|
3317154|NCT01981850|Experimental|Stage 1: Cohort 1 Weekly|Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
3317155|NCT01981850|Experimental|Stage 1: Cohort 1 Every 4 Weeks|Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
3381998|NCT05162937|Placebo Comparator|Treatment group 4|Drug：placebo
3381999|NCT05162924|Experimental|Spinal manipulation|Group receiving 12 sessions of spinal manipulative therapy in the lumbar area
3382000|NCT05162924|Placebo Comparator|Placebo|Group receiving 12 sessions of placebo spinal manipulative therapy in the lumbar area
3382001|NCT05162924|No Intervention|Healthy controls|A healthy control population will receive no treatment during the same time period (4 weeks) to measure the same physiological variables and their evolution.
3382002|NCT05161611|Experimental|Zinc sulfate|Patients will receive 10mg/day zinc sulfate along with phototherapy after being diagnosed to have hyperbilirubinemia
3382003|NCT05161611|Placebo Comparator|Placebo|Patients will receive placebo in addition to phototherapy
3317156|NCT01981850|Experimental|Stage 1: Cohort 2 Weekly|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.
3317157|NCT01981850|Experimental|Stage 1: Cohort 2 Every 4 Weeks|Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.
3317158|NCT01981850|Experimental|Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
3317159|NCT01981850|Experimental|Stage 2: Cohort 2 3mg/kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
3382004|NCT05160727|Experimental|Treatment group|"Concurrent Chemoradiotherapy:~Radiation: The dose is determined according to the treatment site and the purpose of treatment.~Irinotecan: 80mg/m2/w (UGT1A1*28 and *6: 6/6+GG) or 65mg/m2/w (UGT1A1*28 and *6: 6/7+GG or 6/6+GA) or 50mg/m2/w (UGT1A1*28 and *6: 7/7+GG or 6/6+AA or 6/7+GA) Tislelizumab: 200mg ivgtt d1 q3w~Consolidation therapy: 2 weeks after the completion of chemoradiotherapy. Irinotecan: 200mg/m2 ivgtt d1 q3w. Tislelizumab: 200mg ivgtt d1 q3w. Efficacy assessment every 3 cycles."
3382005|NCT05159414|Experimental|Glaucoma patients|Duration of study period(per participant): Screening period(0-4weeks), Intervention period(16weeks) Patient needs to visit site at least 5 times(Screening, V2, V3, V4, V5). V2 can be done with screening visit. Visit 3, 4, 5 is 2weeks, 6weeks, and 16weeks after visit 2(Baseline).
3382006|NCT05159180||patients with atrial arrhythmias undergoing catheter ablation of these|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
3382007|NCT05158296|Experimental|QR-421a 180/60 µg|180 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
3382008|NCT05158296|Experimental|QR-421a 60/60 µg|60 µg loading dose administered on Day 1, 60 µg maintenance dose administered at Month 3 and every 6 months thereafter
3382009|NCT05158296|Sham Comparator|Sham-procedure|Sham-procedure (no experimental drug administered) on Day 1, Month 3 and every 6 months thereafter
3382010|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort A|Eligible participants will receive BIVV020 and SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
3382011|NCT05156710|Other|Standard of Care (SOC) Cohort A|SOC immunosuppression including induction therapy, tacrolimus, and mycophenolate.
3382012|NCT05156710|Experimental|BIVV020 with Standard of Care (SOC) Cohort B|Eligible participants will receive BIVV020 and SOC which includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
3382013|NCT05156710|Other|Standard of Care (SOC) Cohort B|SOC includes plasmapheresis, IVIg, corticosteroids, rixutimxab.
3317160|NCT01981850|Experimental|Stage 2: Cohort 3 10mg /kg Every 4 Weeks|Participants will be treated with single agent PRM-151 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.
3317161|NCT01981889|Other|Prednisone|Participants who are started on Prednisone 40 mg per day for 2 weeks and then tapered.
3317162|NCT01981902||Dehydration|Non-Invasive Optical Spectroscopic monitoring method for dehydration
3317163|NCT01981915|Experimental|Lung Insufflation Volume|Measurement of the lung volume after hyperinsufflation with positive pressure by IPPB or LIAM
3317164|NCT01981915|Experimental|Peak Cough Flow|Measurement of the peak cough flow after hyperinsufflation with positive pressure by IPPB or LIAM
3317165|NCT01981928|Experimental|ASP7962|Each dose level group will include 8 subjects, of which 6 will be randomized to receive active ASP7962
3317166|NCT01981928|Placebo Comparator|Placebo|Each dose level group will include 8 subjects, of which 2 will be randomized to receive placebo
3317167|NCT01981941|Experimental|Treatment group|Oral
3317168|NCT01981980|Experimental|Carboxytherapy|It was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
3317169|NCT01981980|Experimental|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
3317170|NCT01981993||patients at ICU with sepsis|
3317171|NCT01982006|Active Comparator|Phaco|Cataract surgery by phacoemulsification
3317172|NCT01982006|Experimental|Femto|Corneal incision, anterior capsulorhexis and lens fragmentation by femtosecond laser
3317173|NCT01982019|Other|Obese patients with type 2 diabetes|Meal test taking and hormones measure including 26RFa
3317174|NCT01982019|Other|Obese patients witout diabetes|Meal test taking and hormones measure including 26RFa
3317175|NCT01982019|Other|healthy volonteers|Meal test taking and hormones measure including 26RFa
3317176|NCT01982032|Active Comparator|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
3317177|NCT01982032|Active Comparator|Medtronic CoreValve® system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
3317178|NCT01982045|Experimental|AttraX condition|8-10cc of AttraX® Putty per spinal level at the randomized allocation side of the spine (left or right).
3317179|NCT01982045|Active Comparator|Autograft condition|8-10cc autologous bone graft per spinal level at the control side of the spine. This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
3317180|NCT01982058|Experimental|Intimacy-Enhancing Couples|Patients and their partners receive communication and intimacy-enhancing intervention (IEC) once a week comprising the following five 90-minute sessions: Orientation and Stories of the Cancer Experience; Communication and Listening to Partner's concerns; Communication and Coping with Cancer Issues as a Team; Being Supportive to Solve Concerns; and Reflecting on Changes and Future Adaptation.
3317181|NCT01982058|Active Comparator|General Health and Wellness|Patients and their partners receive a General Health and Wellness intervention focusing on nutrition and physical activity once a week comprising of five 90-minute sessions: Introduction and Nutrition Basics; Nutrition and Prevention of Recurrence; Nutritional Review and Introduction to Relaxation; Physical Activity Basics; Aerobics and Resistance Exercises and Wrap up.
3317182|NCT01982058|Other|Usual Care|Patients and their partners receive standard psychological and emotional care (usual care [UC]) (i.e., social work consultations and referral to a psychiatrist or psychologist, if requested or deemed necessary by the attending physician).
3317183|NCT01982071|Experimental|Treatment group|Intravenous (IV)
3317184|NCT01982097||Group 1|
3317185|NCT01982110|Experimental|Mindfulness Based Therapy|Craving to Quit mobile application is provided for participants
3317186|NCT01982110|Active Comparator|Behavioral Smoking Cessation|NCI Quit Pal via a mobile phone application is provided for participants
3317187|NCT01982136||Urethral stricture|patients requiring surgery for urethral stricture
3317188|NCT01982149||Group 1|Non-smokers (n=20)
3317189|NCT01982149||Group 2|Non-smokers (n=20), Smokers (n=20) and Individuals with lung cancer (n=20)
3317190|NCT01982149||Group 3|Subjects with abnormalities (nodules) detected on CT (n=20)
3317191|NCT01982162||Cohort A|severe school aged asthma cohort
3317192|NCT01982162||Cohort B|mild to moderate school aged asthma cohort
3317193|NCT01982162||Cohort C|Severe pre school wheeze cohort
3317194|NCT01982162||Cohort D|Mild to moderate pre school wheeze cohort
3317195|NCT01982175|Experimental|Alemtuzumab|Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first.
3317196|NCT01982188||Single incision sling|
3317197|NCT01982201|Experimental|Lesinurad and Tums|Day 1: 240 mL water or 240 mL water and Tums Day 2: Lesinurad 400 mg or Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg
3317198|NCT01982201|Experimental|Lesinurad and MINTOX|Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg
3317199|NCT01982214|Sham Comparator|sedentary|No intervention
3317200|NCT01982214|Experimental|Vibration|Subjects in this group will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week while 12 months. The training included light squats at 35-50 Hz and ended up by stretching and relaxation exercises.
3317201|NCT01982227||patients|Patients (Aged 18 to 70 inclusive) with progressive colorectal cancer in intra-abdominal surgery requiring resection +/- Chemotherapy Hyperthermic Intraperitoneal
3317202|NCT01982266|Experimental|GRADION™ Hip Total Cartilage Replacement (TCR)™|
3317203|NCT01982305|Experimental|Simulator|One training session with the simulator.
3317204|NCT01982305|Active Comparator|Cadaver|One training session with a cadaver.
3317205|NCT01982318|Active Comparator|VitroGro®ECM|A topical application of synthetic extracellular matrix (ECM) protein formulation to the wound bed) plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
3317206|NCT01982318|Placebo Comparator|Dulbecco's Phosphate Buffered Saline|Dulbecco's Phosphate Buffered Saline plus Standard Care (moisture retentive dressing and multi-layer compression therapy).
3317207|NCT01982344|Experimental|mini-exchange-room (G2)|the other group will utilize disposable mini-exchange-room group
3317208|NCT01982344|No Intervention|usual care (G1)|The one group perform traditional PD procedure (G1)
3317209|NCT01982357||premature infant|Laser Speckle Imaging and Diffuse Optical Spectroscopy
3317210|NCT01982396|Active Comparator|Twice daily|
3317211|NCT01982396|Experimental|Once daily|
3317212|NCT01982409|Experimental|Live Attenuated Varicella Vaccine|use the arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
3317213|NCT01982422|Experimental|Dietary Intervention|A whole food, nutrient-dense dietary intervention which restricts processed foods high in food additives and optimizes micronutrient intake.
3317214|NCT01982422|Placebo Comparator|Standard-of Care Group|This group will receive normal standard-of-care for pregnancy.
3317215|NCT01982461|Experimental|Rosuvastatin|One Rosuvastatin tablet 10mg taken once daily.
3317216|NCT01982461|Active Comparator|Crestor®|One Crestor® tablet 10mg taken once daily.
3317217|NCT01982474|Experimental|Grass pollen extract injection|Grass pollen extract injected intralymphatically q 4 weeks x 3
3317218|NCT01982474|Placebo Comparator|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
3317219|NCT01982474|No Intervention|Observational group|Subjects already receiving traditional subcutaneous allergy immunotherapy for grass pollen, being observed for safety of their subcutaneous injections. Not receiving active intervention during this study.
3317220|NCT01982487|No Intervention|Arm A (no treatment)|Patients receive no treatment.
3317221|NCT01982487|Experimental|Arm B (IDO1 inhibitor INCB024360)|Patients receive IDO1 inhibitor INCB024360 PO BID on days 1-28.
3317222|NCT01982487|Experimental|Arm C (vaccine, IDO1 inhibitor INCB024360)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1 and IDO1 inhibitor INCB024360 PO BID on days 1-28.
3317223|NCT01982487|Experimental|Arm D (vaccine)|Patients receive ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine SC on day 1.
3317224|NCT01982500||Avastin regimens|Patients who are going to receive chemotherapy plus Avastin (bevacizumab)
3317225|NCT01982513||Term pregnant patients|"ASA I-II term (36-40 weeks) non-laboring women with singleton pregnancies who are admitted at MSH for induction of labor, elective cesarean section or for observation for any medical reason.~These patients will be examined in 4 positions with the ultrasound."
3317226|NCT01982526||Endmetrioma surgery|
3317227|NCT01982565|Experimental|Treatment Arm|NOx dressing applied and changed at least every 2 days for 12 weeks or until ulcer is healed.
3317228|NCT01982565|Active Comparator|Control Arm|Standard of Care
3317229|NCT01982578|Experimental|Product: Genistein|60 mg of genistein BID for 360 days. Intervention: Product: Genistein
3317230|NCT01982578|Placebo Comparator|Product: Placebo|1 placebo capsule BID for 360 days. Intervention: Product: Placebo
3317231|NCT01982591||Ancillary-Correlative (heavy metal and neurotoxicity)|Patients undergo serum and urine sample collection for heavy metal analysis by ICP-MS at baseline and at the completion of treatment. Patients also complete neurotoxicity assessment questionnaire at baseline and at the completion of treatment.
3317232|NCT01982604|Experimental|Sequence (Group) 1|"Subjects randomized to Sequence 1 will receive TI in the following sequence:~TI-Inhalation Powder A TI-Inhalation Powder B~*30 units (10 units + 20 units)"
3317233|NCT01982604|Experimental|Sequence (Group) 2|"Subjects randomized to Sequence 2 will receive TI in the following sequence:~TI-Inhalation Powder B TI-Inhalation Powder A~*30 units (10 units + 20 units)"
3317234|NCT01982617|Experimental|Motivational Interviewing|The Cognitive Behavioral Therapy/Motivational Interviewing group consisted of four group sessions focused on using motivational interviewing to enhance motivation to quit smoking and on presenting cognitive-behavioral techniques for preparing to cut down or quit smoking. The following four topics were covered in this program: 1) Positive and Negative Aspects of Smoking, 2) Concerns and Hopes about Cutting Down or Quitting, 3) Small Changes that Can Help You Get Motivated, and 4) Planning for the Future.
3317235|NCT01982617|Experimental|Psychoeducation|The education group also consisted of four group sessions that were co-led by a doctoral-level clinical psychologist and at bachelors-level research assistant. However, the focus of the education group was to present factual information about health risks of smoking, benefits of quitting, pharmacological smoking cessation aides, and smoking cessation programs in the area. The four group topics included: 1) Health Risks of Smoking, 2) Benefits of Quitting, 3) Nicotine Replacement Therapy and Bupropion (Zyban), and 4) Options for Treatment Programs.
3317236|NCT01982656|Experimental|Massage technique|In addition to standard medical care and pharmacologic interventions, massage technique for 20 minutes for 5 to 14 days while in the ICU will be provided to help alleviate pain and anxiety in the patient.
3317237|NCT01982656|Placebo Comparator|No intervention|Patients with an aneurysmal subarachnoid hemorrhage will receive standard medical care to include pharmacologic interventions prescribed by the primary physician and nonpharmacologic interventions provided by the bedside RN such as ice or heat to address their pain and anxiety needs.
3317238|NCT01982669||Different degree of spicy food intake|
3317239|NCT01982721|Experimental|Transfemoral amputees|Locking mechanism for prosthetic knee (no trade mark provided)
3317240|NCT01982721|No Intervention|Healthy volunteers|
3317241|NCT01982734|Active Comparator|Native curcumin|80 mg curcumin as native powder
3317242|NCT01982734|Experimental|Native curcumin plus phytochemicals|80 mg curcumin as native powder plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid and 40 mg xanthohumol
3317243|NCT01982734|Experimental|Curcumin micelles|80 mg curcumin incorporated into liquid micelles
3317244|NCT01982734|Experimental|Curcumin micelles plus phytochemicals|80 mg curcumin incorporated into liquid micelles plus 80 mg sesamin, 40 mg naringenin, 40 mg ferulic acid, 40 mg xanthohumol incorporated into micelles
3317245|NCT01982747|Other|MGN - Placebo|Subjects of the MGN-Placebo arm will receive 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 1 and physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 2
3317246|NCT01982747|Other|Placebo-MGN|Subjects of the Placebo-MGN arm will receive physiological saline solution as Placebo as 2 s.c. injections of 2 ml each during period 1 and 60mg MGN1703 as 2 s.c. injections of 2 ml each during period 2
3317247|NCT01982760|Experimental|DDAVP|Arm receiving DDAVP prior to the operation. Drug is administered intravenously at .3mcg per kg, over 30 minutes prior to the operation.
3317248|NCT01982760|No Intervention|No DDAVP|Patients Will not receive DDAVP prior to Rhinoplasty
3317249|NCT01982799|Experimental|Endododontic Tx + Long acting local anesthetic|long acting local anesthetic
3317250|NCT01982799|Experimental|Endodontic Tx plus local anesthetic|local anesthetic
3317251|NCT01982825|Experimental|Online intervention arm|Bi-weekly (MTh) for 6 weeks, participants will receive an email asking them to report number of cigarettes smoked, alcoholic drinks, engagement in physical activity, and overall mood the two-three days before. Upon answering, they will be launched to the site which will contain health messaging focused on smoking and other health topics.
3317252|NCT01982825|Active Comparator|Online control arm|Control participants will receive bi-weekly emails (MTh) over 6 weeks but in the context of a standard smoking cessation website. Because we are primarily testing the check-ins, tailored feedback, and market research-based mini-drama and other web content, we feel that this control group will isolate the hypothesized active elements of our program.
3317253|NCT01982838|Active Comparator|Group E|Epidural de novo technique
3317254|NCT01982838|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
3317255|NCT01982838|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
3317256|NCT01982851|Active Comparator|Group E|Epidural de novo technique
3317257|NCT01982851|Active Comparator|Group BF|Combined spinal epidural (CSE) technique with intrathecal 0.5% Bupivicaine 2.5mg + Fentanyl 15mcg
3317258|NCT01982851|Active Comparator|Group F|Combined spinal epidural (CSE) technique with intrathecal fentanyl 25mcg
3317259|NCT01982864|Experimental|hemodialysis patients|The administration of gentamicin at the beginning of the hemodialysis.
3317260|NCT01982877|Experimental|Family Support Intervention|Multifaceted family support intervention as well as ICU educational component.
3317261|NCT01982877|Experimental|Educational Control|ICU educational component
3317262|NCT01982890||Normal human controls|"Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.~Subjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
3317263|NCT01982903||Kidney transplant recipients|Adult recipients of a primary or secondary cadaveric or living donor single renal allograft at the University Hospitals Leuven between July 2014 and June 2016
3317264|NCT01982916|Experimental|AGR & Placebo|AGR tablet by qd and Placebo by bid for 4 weeks
3317265|NCT01982916|Placebo Comparator|Placebo|Placebo by bid for 4 weeks
3317266|NCT01982916|Active Comparator|Active comparator|Active Comparator and Placebo by bid for 4 weeks
3317267|NCT01982929|Sham Comparator|Sham block & Oral Meds|Definition intervention. Sham procedure. Blocks mimicked the TAP blocks, but neither needle nor injectate was used. Patients had bilateral ultrasound scans over the lateral aspect of the abdomen. To mimic the injection of medicine, a blunt needleless syringe was firmly pressed on either side of the abdomen. An adhesive bandage was applied over the injection or sham injection sites.
3317268|NCT01982929|Experimental|TAP block & Oral Meds|Definition intervention. TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc). TAP blocks were placed using ultrasound-guided identification of the transversus abdominis fascial plane, and in-plane needle guidance. Injection sites were near the Triangle of Petit, located at the lateral edge of the mid-abdomen, near the iliac crests. After negative aspiration for blood, the local anesthetic was injected in 5 cc aliquots. The total dosage injected never exceeded 0.25 mg/kg of 0.25% bupivacaine with epinephrine 1:400,000.
3317269|NCT01982981|No Intervention|control|The control group only be assessed
3317270|NCT01982981|Experimental|water provision|The experimental group get water every 15 days
3317271|NCT01982994|Experimental|Education/Daily Planning|Physical Activity Education and Daily Planning Tool
3317272|NCT01982994|No Intervention|No Education/Daily Planning|No Physical Activity Education/ Daily Planning Tool
3317273|NCT01983007|Experimental|high-intensity exercise group|Patients undergoing high-intensity exercise group. Intervention: high-intensity exercise.
3317274|NCT01983007|Experimental|low-intensity exercise group|Patients undergoing low-intensity exercise group Intervention: low-intensity exercise
3317275|NCT01983033|Experimental|active treatment condition (ATC)|training protocol 'drop it'
3317276|NCT01983033|Other|waiting list control|no treatment other than treatment as usual
3317277|NCT01983046|Placebo Comparator|placebo|placebo
3317278|NCT01983046|Active Comparator|high acetate ratio|high acetate ratio
3317279|NCT01983046|Active Comparator|high butyrate ratio|high butyrate ratio
3317280|NCT01983046|Active Comparator|high propionate ratio|high propionate ratio
3317281|NCT01983059||Patients with Liver Venous Thrombosis|
3317282|NCT01983072|Active Comparator|Infant starter formula|standard infant formula
3317283|NCT01983072|Experimental|Infant starter formula + prebiotics + probiotics|infant formula
3317284|NCT01983072|Other|Breastfeeding group|reference group
3317285|NCT01983085|Other|SPT Burn Wound|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
3317286|NCT01983085|Other|SPT graft donor site|Each wound will be divided into 2 with half the wound being treated with the NOx dressing and the other half with standard of care
3317287|NCT01983124|Experimental|Fotemustine + Vemurafenib|Fotemustine 100 mg/m2 q21 + Vemurafenib gelatin capsules supplied as 240-mg strengths. Vemurafenib will be administered continuous oral dosing at 960 mg twice daily or dose administered at time of disease progression with Vemurafenib previous treatment.
3317288|NCT01983150|Experimental|Crush the Crave Application|Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
3317289|NCT01983150|Active Comparator|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting(45) that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
3317290|NCT01983163|Active Comparator|ketogenic diet|ketogenic diet (2.5 to 4:1)
3317291|NCT01983163|Active Comparator|Modifid Atkin's diet|Modified Atkin's Diet
3317292|NCT01983189|Experimental|Low frequency rTMS|low frequency, repetitive transcranial magnetic stimulation (rTMS) for 20 minutes daily, 5 times a week for 3 weeks
3317293|NCT01983202||Women with PCOS|208 women diagnosed with PCOS and giving birth after singleton pregnancies at Odense University Hospital during 2003-2011.
3317294|NCT01983202||Controls|1040 women giving birth after singleton pregnancies at Odense University Hospital during 2003-2011, matched 1:5 to women with PCOS according to date-of-childbirth.
3317295|NCT01983215|Experimental|negative pressure dressing vs. standard of care|single arm study- randomized Prevena vac or standard of care
3317296|NCT01983267|Active Comparator|cannabis|Patient using cannabis during chemotherapy treatment
3317297|NCT01983267|No Intervention|control|Patients under chemotherapy treatment
3317298|NCT01983280|Experimental|Healing Touch|
3317299|NCT01983306|Experimental|SP-333 1 mg|1 mg SP-333 orally once daily for 4-week Treatment Period
3317300|NCT01983306|Experimental|SP-333 3 mg|3 mg SP-333 orally once daily for 4-week Treatment Period
3317301|NCT01983306|Experimental|SP-333 6 mg|6 mg SP-333 orally once daily for 4-week Treatment Period
3317302|NCT01983306|Placebo Comparator|Placebo|Placebo orally once daily for 4-week Treatment Period
3317303|NCT01983319|Experimental|CIMT + active anodal tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving active anodal transcranial Direct Current Stimulation 1,5 mA for 30 min.
3317304|NCT01983319|Sham Comparator|CIMT + sham tDCS|Subjects in this group will be trained with constraint-induced movement therapy for the hand (10 consecutive sessions Monday- Friday) while concurrently receiving sham transcranial Direct Current Stimulation
3317305|NCT01983319|No Intervention|Healthy control subjects|20 healthy age-matched control subjects will undergo MRI spectroscopy of the brain.
3317306|NCT01983332||occupational therapists|Occupational Therapists
3317307|NCT01983345|No Intervention|Control|No prenatal surgical repair of myelomeningocele
3317308|NCT01983345|Experimental|Case - open surgical repair|Prenatal surgical repair of fetal myelomeningocele
3317309|NCT01983358|Experimental|JPI-289|Each cohort, volunteers will be infused JPI-289 through I.V for 30 min.(6 volunteers per each cohort, total 7 cohort)
3317310|NCT01983358|Placebo Comparator|Placebo|Each cohort, volunteer will be infused placebo through I.V for 30 min.(2 volunteers per each cohort, total 7 cohort)
3317311|NCT01983371|Experimental|Ferumoxytol-enhanced MRI|This is a single-arm study. All enrolled patients will have a ferumoxytol-enhanced MRI scan.
3317312|NCT01983384|Placebo Comparator|Anesthetic Depth: standard care|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive routine anesthetic management not guided by the processed electroencephalogram
3317313|NCT01983384|Experimental|Anesthetic Depth: interventional|A cohort of older patients undergoing major non-cardiac surgery will be randomized to receive anesthetic management guided by the processed electroencephalogram (processed EEG-guided anesthetic depth)
3317314|NCT01983397|Experimental|Resistance training|Resistance training
3317315|NCT01983397|Experimental|Multicomponent training|Multicomponent training
3317316|NCT01983397|No Intervention|Control Group|The Control Group did not realize any intervention.
3317317|NCT01983410||BRCAmut carrier relatives of a BRCAmut PDAC patient|Who themselves have no known prior or active personal history of non-PDAC malignancy (e.g. breast , ovarian cancer or prostate cancer)
3317318|NCT01983410||BRCAmut carrier relatives of a BRCA mutation PDAC|Patient who themselves have a known prior or active breast, ovarian cancer or prostate cancer
3317319|NCT01983410||BRCAmut carriers|who are not related to a BRCAmut PDAC patient
3317320|NCT01983410||AJ PDAC patients|who are proven non-BRCAmut carriers.
3317321|NCT01983423|Experimental|Endometrial Biopsy|Endometrial biopsy performed within 5-10 days prior to starting controlled ovarian stimulation, as part of in vitro fertilization treatment.
3317322|NCT01983423|No Intervention|Without Biopsy|Those proceeding with in vitro fertilization routinely, without an endometrial biopsy.
3317323|NCT01983436|Experimental|Manual Lymphatic Drainage|"9 daily sessions of manual lymphatic drainage (except on Saturday/Sunday) starting at Day 1 after surgery.~4 more sessions (one every two days)."
3317324|NCT01983436|No Intervention|Control|No session of manual lymphatic drainage
3317325|NCT01983449|Experimental|Adventitial Dexamethasone|In patients receiving either angioplasty or atherectomy-based revascularization (pre-stratified to each by 50% of the total study), dexamethasone will be delivered to the adventitia following revascularization.
3317326|NCT01983462|Experimental|Clonidine|Oral 0.2 mg/day (0.1 mg bid)for 4 weeks
3317327|NCT01983462|Active Comparator|Hydrochlorothiazide|Oral, 12.5 mg/day qd, 4 weeks
3317328|NCT01983462|Placebo Comparator|Placebo|Placebo
3317329|NCT01983475|Placebo Comparator|Placebo|A group of participants will be randomized to the placebo group and will receive the identical volume of normal saline at parallel time points.
3317330|NCT01983475|Experimental|Denosumab|A group of participants will be randomized to the experimental group and will have Denosumab (Prolia, 60 mg SC) administered at baseline, 6 and 12 months.
3317331|NCT01983488||Uveitis|Patient with a clinical diagnosis of Uveitis.
3317332|NCT01983501|Experimental|Tucatinib (ONT-380) in combination with T-DM1|
3317333|NCT01983514|Active Comparator|1 international unit (IU) intravenous oxytocin|Using a double-dummy design participants will be administered 1 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) slow infusion with varying infusion rate over 20 minutes and placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device. Subject to pilot data this may be increased to 2 IU oxytocin (mixed in 200 ml 0.9% sodium chloride) and the infusion time/rate may change to best match the pharmacokinetic profile of intranasally administered oxytocin.
3317334|NCT01983514|Placebo Comparator|Placebo|Using a double-dummy design participants will be administered Placebo delivered with the OptiNose Breath Powered Bi-Directional liquid device and placebo delivered intravenously (0.9% sodium chloride 200 ml slow infusion for 20 minutes)
3382020|NCT05152576|Placebo Comparator|Placebo|Placebo will be injected into the forehead on Day 1.
3382021|NCT05152576|Experimental|OnabotulinumtoxinA X Dose A|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
3382022|NCT05152576|Experimental|OnabotulinumtoxinA X Dose B|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
3382023|NCT05152576|Experimental|OnabotulinumtoxinA X Dose C|OnabotulinumtoxinA X will be injected into the forehead on Day 1.
3317335|NCT01983514|Experimental|8IU intranasal oxytocin|Using a double-dummy design participants will be administered 8IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
3382028|NCT05147181||Participants With HAE|Participants with type 1 or type 2 HAE when treated with lanadelumab in real life in accordance with Summary of Product Characteristics (SmPC) and NDP requirements will be observed in this prospective observational study for 36 months
3382029|NCT05146388|No Intervention|Pre-Implementation - Usual Care|In pre-implementation phase, patient e-Rxs will be generated by the EHR in the usual fashion.
3382030|NCT05146388|Experimental|Post-Implementation - EHR-Based Approach|
3382033|NCT05145803||College Students|"Collegiate students tested positive for SARS-CoV-2 by a molecular reference test (PCR test or antigen test) (index patients).~Collegiate students known to be contacts of the index patients."
3317336|NCT01983514|Experimental|24IU intranasal oxytocin|Using a double-dummy design participants will be administered 24IU oxytocin liquid delivered with the OptiNose Breath Powered Bi directional liquid device and IV placebo (0.9% sodium chloride, 200 ml slow infusion for 20 minutes)
3317337|NCT01983527|Experimental|Arthrographic distention + intra-articular corticosteroid|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension), 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
3317338|NCT01983527|Active Comparator|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
3317339|NCT01983527|Active Comparator|Intra-articular corticosteroid|Arthrographic pseudodistention of the glenohumeral joint with injection of 5 ml contrast and 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension).
3317340|NCT01983540|Experimental|Study Group 1|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3317341|NCT01983540|Experimental|Study Group 2|Participants who received 3 doses of DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of Infanrix hexa vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3382034|NCT05145322|Experimental|Group 1|Group 1: Lesion-specific cavity design with 90 degree cavosurface angle throughout the cavity margins
3382035|NCT05145322|Experimental|Group 2|Lesion-specific cavity design with wide bevel throughout the cavity margins
3382038|NCT05144490|Experimental|Bodyweight Exercise|"A standardized 11-minute bodyweight exercise session that involves a 1-minute warm-up followed by 5, 1-minute bouts of exercise at a self-selected challenging pace, interspersed with 1-minute periods of low-intensity exercise for recovery."
3382039|NCT05144490|No Intervention|Non-Exercise Control|An 11-minute period of quiet sitting.
3317342|NCT01983540|Active Comparator|Study Group 3|Participants who received 3 doses of Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar (PCV7) and Rotarix (2 doses at 2 and 4 months of age), and a booster of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study.
3382040|NCT05144347|Experimental|XL114 Dose-Escalation Cohorts|Subjects (Cohort A1-An) will accrue in cohorts of 3-12 subjects in a i3+3 design.
3382041|NCT05144347|Experimental|XL114 Expansion Cohorts|The recommended dose from the Dose-Escalation stage, will be used in subjects with activated B-cell-like diffuse large B-cell lymphoma [ABC-DLBCL] (Cohort B), mantle cell lymphoma [MCL] (Cohort C), chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] (Cohort D). Subjects will also be enrolled in a Biomarker cohort (Cohort E).
3382042|NCT05143918||Hypothyroid patients as a cases|"Inclusion criteria:~age ranges will be 18 - 60 years~both genders~previously confirmed diagnosed~Exclusion criteria:~pregnancy~other comorbidities (hypertension, diabetes, malignancy,,,etc)"
3382043|NCT05143918||Control group|Healthy people without chronic disease
3317343|NCT01983579|Experimental|Anti-VEGF substance|At the first study visit patients receive anti-VEGF injection with the standard substance (comparator) and at the second visit with an alternative anti-VEGF substance.
3382044|NCT05143788|Experimental|New surgical plan group|The investigators use monopolar stimulators to determine and retain the tumor margin within 5mm from the posterior limb of the inner capsule in type III motor area glioma patients.
3382045|NCT05143788|Active Comparator|Traditional surgical plan group|The investigators use bipolar stimulator according to the current standard surgery plan. After the positive points are identified by stimulator, the positive points are retained in order to preserve the motor function while all the non-positive points of the tumor are resected.
3382046|NCT05143710||PRES in PE or E|patients diagnosed with PRES in PE or E
3382047|NCT05143333||Post acute COVID-19|Severity of COVID-19 will be determined based on patient classification within the PACT (Johns Hopkins Post-acute COVID-19 Team) clinic. Specifically, patients followed in the PACT-ICU clinic required ICU stays of ≥48 hours and high-flow nasal cannula/non-invasive ventilation or mechanical ventilation. Those followed in the PACT-Base clinic have less severe disease that does not necessitate ≥48 hours in the ICU but does qualify for PACT clinic referral based on either (1) ongoing pulmonary and/or rehabilitation needs at the time of hospital discharge, or (2) persistent pulmonary or functional deficits at 4-6 weeks post infection without hospitalization.
3317344|NCT01983579|Experimental|Sclerotomy occlusion|In the first session patients receive anti-VEGF injection without occlusion of the injection hole, while in the second session no occlusion is done.
3317345|NCT01983579|Experimental|Injection volume|In the first session patients receive anti-VEGF injection with the standard injection volume, while in the second session they receive anti-VEGF injection with a modified injection volume.
3382048|NCT05142059|Experimental|Experimental cohort|Participants will be involved in an evaluation program combining physical tests and self-administered questionnaires. Participants will be followed for 1 year with evaluations taking place at 6 months (occurrence of a fall) and at 1 year (the same evaluation, as initial).
3382049|NCT05142046||Pediatric cardiac surgery|The group consists of all the children who undergo cardiac surgery in our institution from 2008 to 2018. The age limit was from birth to 16 years old.
3382050|NCT05141422|Experimental|Treatment group|SHR2150+ efavirenz
3382053|NCT05140239||AbroSkib Cohort|Adult patients with moderate to severe atopic dermatitis who are eligible for and will receive systemic therapy with abrocitinib by their treating dermatologist as part of standard healthcare. The choice of therapy is strictly done by the treating dermatologist only, and the reasons for the choice will be captured by a structured documentation.
3382054|NCT05140148|Placebo Comparator|Placebo|placebo pill, twice daily
3382055|NCT05140148|Active Comparator|Amantadine|100 mg amantadine twice daily, or if 65 years or older once daily
3382056|NCT05140005|Other|15 subjects testing themselves|15 subjects will use the Glow Test Kit to test themselves for Covid 19.
3382057|NCT05140005|Other|15 subjects testing someone else|15 subjects will use the Glow Test Kit to test someone else (a child) for Covid 19.
3317346|NCT01983592|Active Comparator|Homeopathic medicine|The study medication will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
3382062|NCT05139381|Other|Treated with Mepolizumab|
3317347|NCT01983592|Placebo Comparator|Unmedicated lactose/sucrose globule|The placebo will be administered in one of two forms: (1) 3.5 mm diameter lactose/sucrose globule to be administered sublingually; or (2) 3.5 mm diameter lactose/sucrose globule dissolved in 250 ml spring water and administered orally. The medication will be administered as either 1 globule sublingual or 5 mL oral remedy/water up to 3 times per day. The dosage regimen is varialble at the discretion of the study clinician.
3317348|NCT01983605|Experimental|Treatment|LAA exclusion with the LARIAT Suture Delivery Device
3317349|NCT01983618|Placebo Comparator|Interscalene catheter|No block will be performed prior to surgery. An interscalene catheter will be inserted under ultrasound guidance by the anesthesiologist before the induction of anesthesia. Local anesthetics will only be administered once all TCD assessments are completed but prior to the end of surgery.
3317350|NCT01983618|Experimental|Interscalene nerve block and catheter|The anesthesiologist will perform the interscalene nerve block and insert an interscalene catheter under ultrasound guidance before induction of anesthesia. A standardized mixture of bupivacaine, lidocaine and epinephrine will be administered prior to surgery.
3317351|NCT01983631|Experimental|WBV group|Stage 1: Short-term Whole body vibration(3 minutes in half-squatting position)
3317352|NCT01983631|No Intervention|Non-WBV group|Stage 1 : Controlled group
3317353|NCT01983631|Experimental|training group|Stage 2: Long-term WBV training (3 sessions per week for 4 weeks)
3317354|NCT01983631|No Intervention|non-training group|Stage 2: Controlled group
3317355|NCT01983644|Experimental|RECO thrombectomy|IA thrombectomy is executed by RECO flow restoration device which is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
3317356|NCT01983644|Active Comparator|Solitaire FR thrombectomy|IA thrombectomy is executed by Solitaire FR flow restoration device
3317357|NCT01983657|Experimental|D1|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~If the treatment is effective, participants may be entered into low-dose group(D1)(rhGM-CSF administration 1.25 ug/kg/d, qd, sc, for 2 months，then rhGM-CSF administration 1.25 ug/kg/d, qod, sc, for 3 months), when the chest CT absorption≥25% , and /or the PaO2 elevated by 5 mm Hg."
3317358|NCT01983657|Experimental|D2|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was optimal, that dose is continued for 3 months, and defined as group 2(D2)."
3317359|NCT01983657|Experimental|D3|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level ≥1:1000，the dose will be increased to 2.5 ug/kg/d. After 2 months, if the clinical response was not optimal, the patients will receive whole lung lavage(WLL), who are defined as group 3(D3)."
3317360|NCT01983657|Active Comparator|D4|"Patients diagnosed with PAP will be received rhGM-CSF 1.25 ug/kg/d subcutaneously for 1 month, before evaluation on the 30th day (±3 day).~When the treatment is ineffective, and anti-GM-CSF antibody titers level <1:1000，the patients will receive whole lung lavage(WLL), then give rhGM-CSF administration (1.25 ug/kg/d) for 3 months, which belong to group4(D4)."
3317361|NCT01983670|Experimental|health group 1|Health subjects received 30 mins delay antagonist activation temporal ES.
3317362|NCT01983670|Experimental|SCA group 1|SCA subjects received four weeks temporal ES assisted home training program.
3317363|NCT01983670|No Intervention|health group 2|health subjects controlled group
3317364|NCT01983670|No Intervention|SCA group 2|SCA subjects controlled group
3317365|NCT01983696|Experimental|5% oxygen|the oocytes and embryos are cultured in 5% oxygen concentration after oocytes retrieval until Day 6 (counting from fertilization)
3317366|NCT01983696|No Intervention|20% oxygen|the oocytes and embryos are cultured in 20% oxygen concentration (in atmosphere) after oocytes retrieval until Day 6(counting from fertilization)
3317367|NCT01983709|Experimental|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV."
3317368|NCT01983735|Experimental|TELMINUVO Tab. (80/2.5mg, 80/5mg)|
3317369|NCT01983735|Active Comparator|S-Amlodipine 2.5, 5mg|
3317370|NCT01983748|Experimental|A|Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA
3317371|NCT01983748|No Intervention|B|Control, Standard of care, which is clinical control every 3 months
3317372|NCT01983761|Experimental|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|"Fludarabine, Clofarabine, Busulfan, Anti-thymocyte Globulin (ATG), Total Body Irradiation (TBI) (Myeloablative) Day Treatment~Day0 Admit, IV hydration, rituximab 375 mg/m2 (B cell malignancy)~Day 1 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day2 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day3 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000~Day4 Fludarabine 10 mg/m2, clofarabine 30 mg/m2, busulfan AUC 5,000, rabbit ATG 1.25 mg/kg~Day5 Low-dose TBI 2 Gy in AM, rabbit ATG 1.75 mg/kg~Day6 Rest~Day7 Rest~Day8 Cord blood infusions"
3317373|NCT01983761|Experimental|Fludarabine, Melphalan, ATG (Reduced Intensity)|"Day Treatment~Day0 Admit, hydration~Day1 Fludarabine 40 mg/m2 IV~Day2 Fludarabine 40 mg/m2 IV, rabbit ATG 1.25 mg/kg~Day3 Fludarabine 40 mg/m2 IV, rabbit ATG 1.75 mg/kg~Day4 Fludarabine 40 mg/m2 IV and Melphalan 140 mg/m2 IV~Day5 Rest Day6 Cord blood infusions"
3317374|NCT01983774|Placebo Comparator|Placebo|A matching placebo (sugar pill) to esomeprazole 40mg twice daily
3317375|NCT01983774|Active Comparator|Esomeprazole|Esomeprazole 40mg twice daily
3317376|NCT01983800|Active Comparator|intravenous propofol/midazolam|Sedation using intravenous propofol/midazolam, sedation will be titrated to a Riker Agitation Sedation Score
3317377|NCT01983800|Active Comparator|isoflurane|Sedation using inhaled isoflurane, sedation will be titrated to a Riker Agitation Sedation Score
3317378|NCT01983813|Experimental|PHCVRS intervention|Each participant will receive communication with a clinical pharmacist for 12 months to decrease risk of developing cardiovascular disease.
3317379|NCT01983813|Other|Usual care/Personal Health Record|Will receive usual medical care plus access to an online Personal Health Record, where the participant can document medications and diagnosed conditions.
3317380|NCT01983852||1|Children during End of Life Care
3317381|NCT01983865|Other|Exposure to birch pollen|
3317382|NCT01983891|Experimental|Intervention|6-week nutrition education and cooking course
3317383|NCT01983904|Experimental|Long Pulse Width|deep brain stimulation with short & long pulse width
3317384|NCT01983904|Experimental|Short Pulse Width|deep brain stimulation with short & long pulse width
3317385|NCT01983917|Other|Use of the Diabetes Application|
3317386|NCT01983943|Experimental|Hydroxytyrosol|Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months.
3317387|NCT01983943|Placebo Comparator|Placebo|Placebo 40mg will be taken once per day for 6 months.
3317388|NCT01983956|Experimental|Experimental arm|The structured approach intervention with the SENS model is based on the bio-psycho-social-spiritual model of care and the WHO definitions of palliative care as well as the NCCN Practice Guidelines for Palliative Care. It supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
3317389|NCT01983956|No Intervention|Control arm|Patients in the usual care group will receive routine oncology care throughout the study. This incorporates a routine assessment according to the standard SAKK - protocol which assesses overall symptoms. Patients are not seen by nurses during a routine visit to the outpatient clinic unless they need a blood withdrawal or any intravenous or subcutaneous treatment. Only nursing staff of the palliative care unit is familiar with using the SENS-assessment instrument. Participants assigned to usual care may meet with the palliative care service on request according to established practice.
3317390|NCT01983982||Adjuvant chemotherapy|Subjects will undergo pain testing, then receive standard of care chemotherapy, and then undergo pain testing.
3317391|NCT01983995||Actigraphy|Postmenopausal women starting aromatase inhibitor therapy will undergo assessment with questionnaires and actigraphy before starting AI therapy and after 3 months of treatment.
3317392|NCT01984008|Experimental|picosulfate,MgO, citric acid, bowel preparation, powder|colonoscopy picosulfate,MgO, citric acid, bowel preparation, powder
3317393|NCT01984008|Active Comparator|polyethylene glycol, bisacodyl,|colonoscopy polyethylene glycol,powder bisacodyl,tablet
3317394|NCT01984021|Experimental|traditional acupuncture (tACP)|In the upper trapezius muscle with the greatest area pain and lowest PPT score will be chosen for acupuncture. Sterile acupuncture needles measuring 0.25 x 13 mm (Suzhou Huanqiu Acupuncture Medical Appliance Co. Ltd.®) will be inserted in TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and LI-11 (located at the outermost point of the skinfold of elbow flexion in the direction of the lateral epicondyle of the elbow).
3317395|NCT01984021|Placebo Comparator|sham acupuncture (sACP)|The needles will be inserted 1 cm to the side of TE-5 (located on the dorsal face of the forearm between the radius and ulna 3 cm above the joint line of the wrist) and 1 cm to the side of LI-11 (in the direction of the styloid process of the radius).The acupuncture needles are positioned at different acupoints.
3317396|NCT01984034|Experimental|Educational Outreach Visits|The intervention is three educational outreach visits, one per prescription guideline. During each 15 to 20 minutes visit an academic detailer will promote one of the guidelines to a family doctor (up to three physicians may be present in each visit if they wish to, but one to one visits will be preferred and encouraged). The detailer will also distribute a point of care summary highlighting the main messages. The detailers will be mainly Family Physicians and family medicine residents.
3317397|NCT01984034|Active Comparator|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
3317398|NCT01984047|Experimental|GSK3050002 0.1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects (i.e. 1 subject will be dosed with GSK3050002 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.
3317399|NCT01984047|Experimental|GSK3050002 0.5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 0.5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3317400|NCT01984047|Experimental|GSK3050002 1 mg|Six subjects in this cohort will receive a single dose of GSK3050002 1 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort
3317401|NCT01984047|Experimental|GSK3050002 5 mg|Six subjects in this cohort will receive a single dose of GSK3050002 5 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3317402|NCT01984047|Experimental|GSK3050002 10 mg|Six subjects in this cohort will receive a single dose of GSK3050002 10 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3317403|NCT01984047|Experimental|GSK3050002 20 mg|Six subjects in this cohort will receive a single dose of GSK3050002 20 mg and two subjects will receive a single dose of placebo intravenously. Sentinel subjects will be used in the cohort.
3317404|NCT01984060|Other|HOME-EX|"Motivational Counseling: Six patient-centered motivational counseling sessions based on the self-determination theory (SDT) of behavior change will be conducted with the patients in the HOME-EX group over 12 weeks.~Exercise Intervention: an individually tailored home-based exercise program performed 5-7 days a week that consists of walking prescription, and individualized strength training exercise designed to provide moderately intense progressive resistance exercise. Subjects will be given a set of 3 color-coded therapeutic resistance bands representing varying levels of resistance and they will start with a number of sets which is customized for each individual and they will be encouraged to progressively increase from their individual baseline sets."
3317405|NCT01984060|No Intervention|Control|Subjects are instructed to maintain their usual activities during the study period. This group did not receive any PA counseling or recommendations.
3317406|NCT01984073|Active Comparator|ER Niacin Oral Fat Challenge|ER Niacin (Niaspan) 2000mg one hour prior to Oral Fat Challenge using fresh cream at a dose of 50 g fat per square meter of body surface area. This is followed by frequent plasma and urine collections for next 12 hours to assess markers of fat metabolism and inflammation.
3317407|NCT01984073|Active Comparator|IR Niacin Oral Fat Challenge|Immediate-Release Niacin (Nialor) 500 mg one hour prior to Oral Fat Challenge and again 1, 3 and 5 hours after the oral fat load for a total dose of 2 grams.Subjects will undergo plasma and urine collections for 12 hours to assess markers of fat metabolism and inflammation.
3317408|NCT01984073|Placebo Comparator|Placebo Oral Fat Challenge|Placebo one hour before and 1,3, and 5 hours after oral fat load using heavy cream at 50 grams of fat per square meter of body surface area. Plasma and urine collections for 12 hours
3317409|NCT01984086|Experimental|Part A|Subjects will receive following six treatments each in six period, with a 3-days minimum wash-out period, between each treatment period: 1) Single dose (SD) salbutamol (200mcg per blister from 1.6% blend) delivered via the UD-DPI by inhalation of 3 Blisters (BTR) giving a total dose of 600mcg; 2) SD salbutamol sulphate (200mcg per BTR from a 1.0% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 600mcg; 3) SD salbutamol (150mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 450mcg; 4) SD salbutamol (250mcg per BTR from a 1.6% blend) delivered via the UD-DPI by inhalation of 3 BTR giving a total dose of 750mcg; 5) SD of salbutamol (200mcg per BTR) delivered via the Diskus by inhalation of 3 BTR giving a total dose of 600mcg; 6) SD salbutamol (100mcg per actuation) delivered via the MDI giving a total dose of 600mcg
3317410|NCT01984086|Experimental|Part B|Prior to the start of Part B, a decision will be made regarding the UD-DPI products to be used in Part B. Subjects will receive following 6 treatments each in 6 period, with a 3-days minimum wash-out period, between each treatment period: 1) SD salbutamol (selected from Part A) delivered via the UD-DPI without activated charcoal (AC) by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 2) SD salbutamol (selected from Part A) delivered via the UD-DPI with AC by inhalation of 3 BTR (total dose dependant on UD-DPI formulation chosen); 3) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus without AC (total dose 600mcg); 4) SD salbutamol by inhalation of 3 BTR (200mcg per BTR) delivered via the Diskus with AC (total dose 600mcg); 5) SD salbutamol 6 inhalations (100mcg) delivered via the MDI without AC (total dose 600mcg); 6) SD salbutamol 6 inhalations (100mcg) delivered via the MDI with AC (total dose 600mcg)
3317411|NCT01984099|Active Comparator|Chemoprohylaxis Group|Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
3317412|NCT01984099|Placebo Comparator|Control Group|Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
3317413|NCT01984112|Experimental|Intramedullary Locked Nail|
3317414|NCT01984112|Active Comparator|Locked Plate|
3317415|NCT01984125|Experimental|Point-of-Care Prompt|A prompt, either electronically or by a nurse, will notify a provider if an adolescent is due for a vaccination. This prompt will appear at any type of visit where the patient is seen by a health provider.
3317416|NCT01984125|No Intervention|Control|
3317417|NCT01984138|Experimental|Estring|ESTRING
3317418|NCT01984138|Active Comparator|REPLENS|Replens
3317419|NCT01984177||cocaine-dependent (CD)|cocaine-dependent individuals
3317420|NCT01984177||healthy control (HC)|healthy age and sex-matched individuals who do not use cocaine
3317421|NCT01984190||Lower Extremity Joint Arthroplasty|Postoperative venous thromboembolism incidence in lower extremity joint arthroplasty using only the mobile compression device with or without aspirin for venous thromboembolism prevention. Sub-analysis of Total Hip Arthroplasty and Total Knee Arthroplasty will be included.
3317422|NCT01984203|Experimental|Progressive Heavy Strength Exercises|"The Progressive Heavy Load Exercise group gradually increases the external load from 60%RM to 90%RM and correspondently decreases the number of performed repetitions pr. set for the two rotator cuff exercises. Furthermore 4 sets is performed.~A progressive exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
3317423|NCT01984203|Active Comparator|Low Load Exercises|"Active exercises comparator continuously training with 60%RM through 12 weeks.~An exercise program consisting of 6 active exercises. Two exercises for the rotator cuff: Full Can and Sidelying external rotation Two exercises for the scapulae stabilizing muscles: Low Row and Push-Up Plus Two glenohumeral/postural corrective exercises: Posterior GH stretch and Scapular Retraction."
3317424|NCT01984216|Experimental|Roux-en-Y|Roux-en-Y for the gastrojejunostomy reconstruction
3317425|NCT01984216|Active Comparator|Billroth II|Billroth II for the gastrojejunostomy reconstruction
3317426|NCT01984255|Active Comparator|A- Bavituximab plus Ipilimumab|Arm A-Interventions Drug: Bavituximab Dose:3mg/kg IV over 90 minutes weekly x 2 followed by Bavituximab 3mg/kg IV over 90 minutes weekly Duration-x 12 weeks plus Drug :Ipilimumab 3mg/kg IV over 90 minutes every 3 weeks Duration-x 4.weeks
3317427|NCT01984255|Experimental|Arm B Ipilimumab|Arm B-Interventions Drug- I3mg/kg IV over 90 minutes day 1 followed three weeks later by Drug: Ipilimumab every 3 weeks x 3weeks. Total number of treated patients will be 8.
3317428|NCT01984281|Experimental|Pedometer-based prescription|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes) and a pedometer-based physical activity prescription, consisting of targets to be achieved (in terms of steps per day).
3317429|NCT01984281|No Intervention|Control|After baseline assessments, the control group will receive a educational session, regarding important aspects of asthma (symptoms, treatment, exacerbations, triggers, etc) plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes).
3317430|NCT01984320|Active Comparator|Coasting|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 to 3 days until drop of estradiol to a safe level to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3317431|NCT01984320|Active Comparator|Cabergoline|In their ICSI cycle patients will take 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3317432|NCT01984320|Active Comparator|Coasting and Cabergoline|In their ICSI cycle patients will continue their agonist treatment while stopping the human menopausal gonadotropin (hMG) injections for 1 day plus receiving 0.25 mg of cabergoline daily for 8 days from HCG triggering day to prevent OHSS. Early OHSS is assessed at day of embryo transfer and 7 days after this date. Late OHSS is assessed 14 days after embryo transfer.
3317433|NCT01984333|Experimental|Online cognitive training|Online cognitive training will provides eight sessions of a computerized training game. Each session will last about 30-40 minutes, and participants will undergo 2 sessions each week over a 4-week period.
3317434|NCT01984333|No Intervention|Waitlist control|This is a 1-month waitlist control to be compared with the active online cognitive training intervention. This is a no intervention control group.
3317435|NCT01984346|Experimental|Convergent Procedure|Convergent Procedure using EPi-Sense-AF Guided Coagulation System with Endocardial Catheter Ablation Treatment
3317436|NCT01984346|Active Comparator|Standalone Endocardial Catheter Ablation|Endocardial Catheter Ablation Treatment
3317437|NCT01984359|Other|Single arm|Biosamples will be obtained at multiple time-points for all participants
3317438|NCT01984372||Tresiba® users|
3317439|NCT01984385||Patients with a hip fracture|
3317440|NCT01984411|Experimental|Radial Technical|Radial technical is the procedure for catheterization
3317441|NCT01984411|Active Comparator|Femoral Technical|Vascular Access for cardiac catheterization
3317442|NCT01984450|Active Comparator|ACIC|The patients in this group will be treated by the ACIC technique, which uses autologous collagen to regenerate articular cartilage. ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation.
3317443|NCT01984450|Active Comparator|MCIC|The patients in this group will be treated by the MCIC technique, which uses concentrated BMAC to regenerate articular cartilage. MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation.
3317444|NCT01984463|Active Comparator|Fentanyl|Patients will be randomized to receive by the epidural catheter a bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL.
3317445|NCT01984463|Experimental|Morphine|Patients will be randomized to receive by the epidural catheter a bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL.
3317446|NCT01984476||Older Able-Bodied Controls|Subjects must be between the age of 55 and 65 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3317447|NCT01984476||Spinal Cord Injured|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must be injured between 5 to 10 years, level of injury between C1-T12, non-ambulatory (wheelchair dependent), and AIS grade of A or B. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3317448|NCT01984476||Age-Matched Able-Bodied Controls|Subjects must be between the age of 25 and 49 years old, be English-literate and able to provide informed consent. They must score at least 20/60 minimum acuity in their worst eye on the Snell Eye Exam, and score at least 24 on the Montreal Cognitive Assessment. Subjects MUST NOT HAVE: an acute illness or infection, history of stroke, recent illicit drug abuse (<6 months), controlled or uncontrolled hypertension or diabetes mellitus, history of epilepsy or other seizure disorder, history of Traumatic Brain Injury (as determined by TBI screening tool), any significant history of neurological disease/disorder, and diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder.
3317449|NCT01984489|Placebo Comparator|Placebo/Metformin|patients are administered oral tablets of placebo once daily and 500mg TID for 4 weeks at the run-in period. After randomized ,patients administer the drugs too.
3317450|NCT01984489|Experimental|SHR117887 (50mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks.
3317451|NCT01984489|Experimental|SHR117887 (100mg q.d)/Metformin|patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised,patients adminitered SHR117887 100mg QD and metformin 500mg TID for 12 weeks.
3317452|NCT01984502|Experimental|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
3317453|NCT01984528|Experimental|Prick Test|Alternaria alternata allergen extract Positve control Negative control
3317454|NCT01984541|Experimental|1|Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
3317455|NCT01984554||Ferric Carboxymaltose (FCM)|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician.
3317456|NCT01984554||Iron Sucrose|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3317457|NCT01984554||Iron Dextran|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3317458|NCT01984554||Ferumoxytol|Dosing levels, treatment choice, number and scheduling of infusions are all at the discretion of the subject and the subject's prescribing physician
3317459|NCT01984567|Experimental|Vitamin E|
3317460|NCT01984567|Experimental|Lipoic acid|
3317461|NCT01984567|Placebo Comparator|Control|
3317462|NCT01984580|Experimental|Zinc|
3317463|NCT01984580|Placebo Comparator|sodium|
3317464|NCT01984593|No Intervention|Control|No changes will be made for the participants in the control group, but they will undergo the same measurements and evaluations as the intervention group.
3317465|NCT01984593|Active Comparator|yoga|Two yoga exercises to perform at home 15 minutes twice daily.
3317466|NCT01984606|Experimental|Empagliflozin|Empagliflozin once daily
3317467|NCT01984606|Active Comparator|Sitagliptin|Sitagliptin once daily
3317468|NCT01984619||Blunt Tip Cannula|
3317469|NCT01984632|Experimental|Single-port laparoscopic myomectomy|We will use barbed suture (V-Loc) under intervention of single-port laparoscopic myomectomy
3317470|NCT01984632|Active Comparator|Multi-port laparoscopic myomectomy|We will use barbed suture(V-Loc) under intervention of multi-port laparoscopic myomectomy.
3317471|NCT01984645|Experimental|Notification|Providers in this arm will receive a secure online notification whenever their patients are visited in the emergency department or admitted as an inpatient.
3317472|NCT01984645|No Intervention|No intervention|Providers in this arm will not get a secure online notification about their patient's visit to the emergency department or inpatient admission.
3317473|NCT01984658|Experimental|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
3317474|NCT01984671|Experimental|Mobile Pain Coping Skills Training|Pain coping skills training
3317475|NCT01984671|No Intervention|Standard Care Control|
3317476|NCT01984710|Experimental|DBS for Treatment Resistant Depression|"DBS for TRD: Exploration of LFP with the Medtronic Activa PC+S Brain Radio system"
3317477|NCT01984723|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
3317478|NCT01984736|Experimental|EVP-6124, single dose|Single dose, Tablet, single administration, Day 1
3317479|NCT01984749|Experimental|Febuxostat treatment group|Once daily after breakfast (generally within 30 minutes after eating)
3317480|NCT01984749|No Intervention|Non-febuxostat treatment group|No febuxostat treatment
3317481|NCT01984762|Active Comparator|RYGBP|Roux-en-Y gastric bypass
3317482|NCT01984762|Active Comparator|SG|sleeve gastrectomy
3317483|NCT01984775|Experimental|GSK2894512 0.5%|Each subject will receive a topical application of GSK2894512 0.5% under semi-occlusive patch conditions once daily (OD) for 21 days.
3317484|NCT01984775|Experimental|GSK2894512 1%|Each subject will receive a topical application of GSK2894512 1% under semi- occlusive patch conditions OD for 21 days.
3317485|NCT01984775|Experimental|GSK2894512 2%|Each subject will receive a topical application of GSK2894512 2% under semi-occlusive patch conditions OD for 21 days.
3317486|NCT01984775|Placebo Comparator|Vehicle|Each subject will receive a topical application of Vehicle cream under semi-occlusive patch conditions OD for 21 days.
3317487|NCT01984775|Active Comparator|Sodium lauryl sulfate 0.1%|Each subject will receive a topical application of 0.2 milliliter (mL) of Sodium lauryl sulfate under semi-occlusive patch conditions OD for 21 days. This will serve as a positive control.
3317488|NCT01984775|Active Comparator|Petrolatum|Each subject will receive a topical application of 0.2 mL of Petrolatum under semi-occlusive patch conditions OD for 21 days. This will serve as a negative control.
3317489|NCT01984788|Active Comparator|BCX4161|400 mg TID for 28 days
3317490|NCT01984788|Placebo Comparator|Placebo|TID for 28 days
3317491|NCT01984801|Experimental|Part 1|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.5% SLS in sterile distilled water, Each treatment will be applied using individual patches, daily for 2 days
3317492|NCT01984801|Experimental|Part 2|Each of the following 6 treatments will be randomized to one of 6 designated locations on either upper arm or other locations, such as the lower or upper back, within each healthy subject: (A) 200 mg of 0.3% GSK1940029 gel, (B) 200 mg of 1% GSK1940029 gel, (C) 200 mg of 0.3%/1% vehicle gel only, (D) 200 µL of sterile distilled water, (E) Patch only, and (F) 200 µL of 0.1% SLS in sterile distilled water. Each treatment will be applied using individual patches, daily for 21 days
3317493|NCT01984801|Experimental|Part 3|Each acne patient will apply a thin coat of one or two concentration of GSK1940029 gel or vehicle to acne affected facial/neck skin by hand, once daily for 28 days
3317494|NCT01984814|Experimental|Stem cell|Autologous bone marrow mononuclear cells intrathecal and intramuscular transplantation
3317495|NCT01984814|No Intervention|Control|No cell transplantation was done
3382070|NCT05137678|Experimental|Experimental group|Glibenclamide was given orally or through nasogastric tube, 1.25 mg every 8 hours for 7 days
3382071|NCT05137678|No Intervention|Control group|No glibenclamide treatment
3382072|NCT05137223||Adolescent Only Focus Groups|20 early adolescents (ages 10-14) with physician-diagnosed persistent asthma (i.e., prescribed a controller medication) receiving care at a FQHC
3382073|NCT05137223||Caregiver Only Focus Groups|20 informal caregivers (e.g., parent, grandparent) of early adolescents with physician-diagnosed persistent asthma receiving care at a FQHC
3382074|NCT05137223||Adolescent and Caregiver Focus Groups|20 adolescents with physician-diagnosed persistent asthma receiving care at a FQHC and caregivers (both of whom did not participate in either previous group)
3382075|NCT05135000|Experimental|LTP001|Participants will receive LTP001 orally once daily in the morning for approximately 24 weeks
3317496|NCT01984827|Experimental|hyper-glycaemic clamp:|hyper-glycaemic clamp: intra-venous Glucose as an initial bolus of 250mg/kg followed by a variable maintenance infusion for 4 hours
3317497|NCT01984827|Experimental|Moxifloxacin|Single oral dose of 400 mg Moxifloxacin
3382076|NCT05135000|Placebo Comparator|Placebo|Participants will receive LTP001 placebo capsules matching LTP001 orally once daily in the morning for approximately 24 weeks
3382079|NCT05131490|Experimental|Experimental|Experimental group intervention consists two months a mobile application intervention developed for gynecological cancer patients receiving chemotherapy
3382080|NCT05131490|No Intervention|No intervention|Control group receive routine care.
3382081|NCT05130437|Experimental|mRNA-3927|Participants will receive the applicable dose identified during Study mRNA-3927-P101 (NCT04159103) on Day 1. The dose can be adjusted based on Sponsor recommendation.
3382082|NCT05129787|Active Comparator|Surgical resection|Liver resection
3382083|NCT05129787|Experimental|Thermal ablation|Thermal ablation (Microwave or radiofrequency)
3382084|NCT05126459|Active Comparator|Regimen 1|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Meperidine (1.5 -2 mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
3382085|NCT05126459|Experimental|Regimen 2|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration- Meperidine (1.5 -2 mg/kg) Inhalation - Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) -
3382086|NCT05126459|Experimental|Regimen 3|Oral administration - Hydroxyzine (1.5 - 2mg/kg) Oral administration - Midazolam (0.5- 0.75 mg/kg) Inhalation- Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2)
3382087|NCT05125952|Experimental|Acute Respiratory Failure|Patients with acute respiratory failure managed with pressure-support ventilation.
3382088|NCT05125471|Experimental|Investigational Drug|Cobimetinib will be administered at a maximal dose of 60 mg daily for 21 days on, then 7 days off, in a 28-Day treatment cycle for 12 cycles (approximately 12 months). Cobimetinib should be taken once daily at approximately the same time each day, and no later than 4 hours after the scheduled time. Cobimetinib can be taken with or without a meal. Cobimetinib tablets should never be chewed, cut, or crushed. Therapy may continue for up to 12 cycles provided the subject meets the criteria for starting subsequent cycles and does not meet any of the criteria for cobimetinib discontinuation. At least 7 days off cobimetinib (within +7 days) is required prior to starting a new treatment cycle.
3317498|NCT01984827|Placebo Comparator|Placebo|Placebo
3317499|NCT01984840|Active Comparator|Telemedicine|A tablet (a Samsung GALAXY TAB 2 (10.1)) that holds information on handling COPD in general and software that automatically instructs the patient in handling COPD during exacerbations. The device can also collect and transmit relevant disease-specific data, which are indicative of their current state of health, via an attached Fingertip Pulse Oximeter (Nonin, Onyx II % SpO2), a Digital Blood Pressure Monitor (Model UA-767, plus BT-C) and a scale. The device can measure four vital signs, which are transferred wirelessly: blood pressure, pulse, blood oxygen saturation and weight. The tablet can be activated and give a sound, when it is time for taking measurements again.
3382089|NCT05125016|Experimental|Module 1- Monotherapy|REGN4336
3382090|NCT05125016|Experimental|Module 2-Combo Therapy|REGN4336 + Cemiplimab
3382091|NCT05123742||DHCW Subjects in POC Offices|Dental Health Care Workers recruited in point of care offices.
3382092|NCT05123742||Patient Subjects in POC Offices|Dental patients recruited in point of care offices.
3382093|NCT05123742||DHCW Subjects in LAB Offices|Dental Health Care Workers recruited for lab-based testing.
3382094|NCT05123742||Patient Subjects in LAB Offices|Dental patients recruited for lab-based testing.
3382095|NCT05123196|Experimental|MT-8554|MT-8554 will be started from a low dose, and gradually increase the dose in order.
3382096|NCT05123196|Placebo Comparator|Placebo|
3382097|NCT05120037|Experimental|Active|
3382098|NCT05120037|Sham Comparator|Sham|
3382099|NCT05118789|Experimental|Phase 1 dose escalation|NVL-520 oral daily dosing
3382100|NCT05118789|Experimental|Cohort 2a|ROS1+ NSCLC naïve to TKI therapy
3317500|NCT01984840|No Intervention|Usual care|In Denmark, usual practice for treating, monitoring and caring for patients with COPD are the responsibility of the patient's general practitioner (treatment and monitoring) and the municipalities (practical help and nursing care). COPD patients can make appointments with their general practitioner or practice nurse free of charge in order to get help in managing COPD. Community based care and practical help varies. As a rule community care comes at regular intervals based on a clinically based estimate of the patients' needs, but the personnel are not necessarily certified nurses and often not fully educated in COPD and definitely not on call
3317501|NCT01984853||OBSERVATIONAL REGISTRY|Individuals presenting with signs and/or symptoms of Acute Coronary Syndrome at the Henry Ford Hospital Emergency Department (ED).
3317502|NCT01984866||Breast tumors sensitive to neoadjuvant|"Treated patients as usual clinical practice with unicentered tumors in stages II or III and good response determined by MR after 6 cycles of treatment (less than 2 cm apparent residual injury) will be consecutively subjected to radiofrequency biopsy and the surgery previously established for each case (Tumorectomy or mastectomy). Before surgery, the sentinel node will be biopsied in order to define the surgical treatment on the axilla (none in case of negative sentinel node, axillary lymphadenectomy if positive).~The tumor samples obtained by percutaneous radiofrequency and mastectomy-Tumorectomy biopsy will be studied thoroughly to define the correlation between the two."
3317503|NCT01984879||Inflammatory bowel diseases|Patients who have inflammatory bowel diseases and who give consent to participate in the survey
3317504|NCT01984918|Active Comparator|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
3317505|NCT01984918|No Intervention|Non-SMS reminder|No text message reminder via Short Message Service (SMS) will be sent
3317506|NCT01984931|Experimental|Trimebutine Maleate 300 mg Tab|A single dose of NEWBUTIN SR 300 mg Tab will be given orally one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
3317507|NCT01984931|Active Comparator|Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A|Anti-emetic medication protocol of Chungmu Hospital includes MACPERAN (Metoclopramide hydrochloride monohydrate 8.46 mg/2ml/A)thru IV twice in a day
3317508|NCT01984944|Other|Autistic Patient|"50 adults~25 childs"
3317509|NCT01984944|Other|Controls|"50 adults~25 childs"
3317510|NCT01984957|Other|disease (ALS, SMA or SBMA)|muscle biopsy
3317511|NCT01984970||videolaryngoscope|The patients received videolaryngoscope for double-lumen tube intubation
3317512|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3317513|NCT01984983|Experimental|VEEV DNA Vaccine 0.5 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3317514|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intramuscular|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3317515|NCT01984983|Experimental|VEEV DNA Vaccine 2.0 mg/ml Intradermal|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate
3317516|NCT01984983|Placebo Comparator|Placebo: 0.9% saline|0.9% saline
3317517|NCT01984996|Experimental|Freedom ProFlor Inguinal Hernia Implant|
3317518|NCT01985009|Other|Fibroscan®|Single arm study. See intervention item for détails..
3317519|NCT01985022|Experimental|PII with IES|The treatment condition that this group receives is PII with IES for 9 months.
3317520|NCT01985022|Experimental|IES|The treatment condition that this group receives is IES for 9 months.
3317521|NCT01985035|Experimental|Obese Apneic carbohydrate diet|Obese apneic individuals will be subject to a energy restriction diet rich in carbohydrates
3317522|NCT01985035|Experimental|Obese Apneic protein diet|Obese apneic individuals will be subject to a energy restricted diet rich in protein
3317523|NCT01985035|Experimental|Obese Non Apneic carbohydrate diet|Obese individuals without Obstructive sleep apnea will be subjected to a energy restricted diet rich in carbohydrates
3317524|NCT01985035|Experimental|Obese Non Apneic protein diet|Obese individuals without Obstructive Sleep Apnea will be subjected to a energy restricted diet rich in protein
3317525|NCT01985061|Active Comparator|BX2|Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2
3317526|NCT01985061|Experimental|BX3|Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
3317527|NCT01985061|Active Comparator|BX4-Suspended|Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2
3317528|NCT01985074|Experimental|Case-management intervention|Receiving nurse-managed intervention
3317529|NCT01985074|No Intervention|Control arm|Control group not receiving any intervention
3317530|NCT01985087|Experimental|Hypofractionated radiotherapy and temozolomide|All subjects will receive treatment as is a single arm study. Two weeks of combined hypofractionated radiotherapy with concurrent temozolomide followed by up to 6 cycles of adjuvant temozolomide treatment.
3317531|NCT01985100|Experimental|single group|single group of 6 patients will be treated with hyperbaric oxygen at 2 atmospheres absolute (ATA) for 90 minutes 5 days per week for 4 weeks (20 treatments) to see if the previously reported increase in cell metabolism following such treatment can be better documented by the more sensitive and precise method for assessing this, i.e. PET/MRI, than the previously reported SPECT/CT method
3317532|NCT01985113||early staged non-small cell lung cancers|patients who diagnosed as early staged non-small cell lung cancer after surgery
3317533|NCT01985113||lung benign mass patients|patients who diagnosed as lung benign mass after surgery
3317534|NCT01985139|Experimental|Obese patients|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
3317535|NCT01985139|Experimental|Normal-weight healthy volunteers|Computer-based tasks evaluating size and time discrimination capacities Blood sampling for the determination of plasma endocannabinoids levels
3317536|NCT01985152|Experimental|1.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 8.75mg,orally
3317537|NCT01985152|Experimental|2.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 17.5mg,orally
3317538|NCT01985152|Experimental|3.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 35mg,orally
3317539|NCT01985152|Experimental|4.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 70mg,orally
3317540|NCT01985152|Experimental|5.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 140mg,orally
3317541|NCT01985152|Experimental|6.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 210mg,orally
3317542|NCT01985152|Experimental|7.Azilsartan Trimethylethanolamine|Single dose of Azilsartan Trimethylethanolamine with 280mg,orally
3317543|NCT01985152|Placebo Comparator|Placebo|Placebo-matching tablets, orally
3317544|NCT01985165|Experimental|Imrecoxib|0.1g,BID,po
3317545|NCT01985178|Experimental|Omega-3 Fatty Acid Supplement|
3317546|NCT01985191|Experimental|Arm 1|SAR405838 and pimasertib in escalating doses
3382101|NCT05118789|Experimental|Cohort 2b|ROS1+ NSCLC treated with 1 prior ROS1 TKI and no prior platinum-based chemotherapy or immunotherapy
3382102|NCT05118789|Experimental|Cohort 2c|ROS1+ NSCLC treated with 1 prior ROS1 TKI and 1 prior platinum-based chemotherapy with or without immunotherapy
3382103|NCT05118789|Experimental|Cohort 2d|ROS1+ NSCLC treated with ≥2 prior ROS1 TKIs and up to 1 prior platinum-based chemotherapy with or without immunotherapy
3317547|NCT01985204|Placebo Comparator|Placebo|Placebo tablet
3382104|NCT05118789|Experimental|Cohort 2e|ROS1+ solid tumor and progressed on any prior therapy
3382105|NCT05118516|Experimental|Experimental|ASC43F for all subjects under the fasted state.
3317548|NCT01985204|Experimental|Intervention|Iodine tablet
3317549|NCT01985230|Experimental|ReActiv8 Implant|
3317550|NCT01985243|Experimental|Nutrition and agriculture|Intervention arm with integrated nutrition and agriculture education, skill building, and animal husbandry promotion
3317551|NCT01985243|Experimental|Iron-rich food & business literacy|Integrated business literacy and food supplementation program to promote school retention among female adolescents
3317552|NCT01985243|No Intervention|IYC Comparison|Comparison group of infants and young children for the nutrition-agriculture intervention
3317553|NCT01985243|No Intervention|Adolescent comparison|Comparison group for the adolescent business-food supplement intervention
3317554|NCT01985256|Experimental|Single Arm|Toca 511 vector/Toca FC
3317555|NCT01985269|Active Comparator|Home visits|Minimal physical examination at home Drug adherence/pill counts
3317556|NCT01985269|No Intervention|Control|Normal standard of care
3317557|NCT01985282||Nutrition Status and Physical Function|Nutrition questionnaire will be administered Physical functional status will be tested
3317558|NCT01985295|Other|cohort|"Dose level Dose of pazopanib orally, once daily, # patients -1 200 mg --~(starting) 400 mg 3~600 mg 3~(maximum) 800 mg 3"
3317559|NCT01985308|Experimental|MRT-Active|Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
3317560|NCT01985308|Sham Comparator|MRT-SHAM|Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
3317561|NCT01985347|Active Comparator|Obstructive Sleep Apnoea|Patients with newly diagnosed obstructive sleep apnoea and who have anxiety and depression would be given continuous positive airway pressure (CPAP) treatment.
3317562|NCT01985347|No Intervention|Chronic obstructive pulmonary disease and western population|(For this group no intervention needed).Patients with COPD, who have anxiety and depression & normal population in Western Adelaide who also have anxiety and depression their prevalence would be compare with patients of Obstructive sleep apnoea.
3317563|NCT01985373|Experimental|Intravenous immunoglobulin infusion|One intravenous infusion with Nanogam 50 mg/ml and 4 with Nanogam 100 mg/ml (0.2-0.8 g/kg)
3317564|NCT01985386|Experimental|GDS (gastric delivery system), meal|GDS capsule with meal
3317565|NCT01985386|Active Comparator|Ferrous sulfate, meal|Ferrous sulfate with meal
3317566|NCT01985399||EFV containing ARV regimen|Pts on Efavirenz containing ARV regimen will have neuropsychological testing performed
3317567|NCT01985399||Non -EFV ontaning ARV regimen|Pts on a Non-Efavirenz containing ARVregimen will have neuropsychological testing measures performed
3317568|NCT01985412||Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant and are followed at Stanford Hospital
3317569|NCT01985412||Pediatric Heart Transplant Recipients|Patients <18 yrs old that received a heart-only transplant and are followed at Lucile Packard Hospital
3317570|NCT01985412||Adult Lung Transplant Recipients|Patients >18 yrs old that received a lung-only transplant and are followed at Stanford Hospital
3317571|NCT01985412||Pediatric Lung Transplant Recipients|Patients <18 yrs old that received a lung-only transplant and are followed at Lucile Packard Hospital
3317572|NCT01985412||Kaiser Adult Heart Transplant Recipients|Patients >18 yrs old that received a heart-only transplant at Stanford Hospital but are followed at Kaiser Permanente in Santa Clara
3317573|NCT01985438|Active Comparator|percutaneous endoscopic gastrostomy tube|Percutaneous endoscopic gastrostomy tube placement - A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion
3317574|NCT01985438|Active Comparator|nasogastric tube|Nasogastric tube placement - All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
3317575|NCT01985451|Experimental|Pemetrexed and Temozolomide|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m2) and temozolomide (200mg/m² day 1-5, 28 day cycle).
3317576|NCT01985464|Experimental|Umbilical cord mesenchymal stem cells|
3382106|NCT05115721||Pre-ductal SpO2|
3382107|NCT05115721||Post-ductal SpO2|
3382108|NCT05113966|Experimental|Trilaciclib + Sacituzumab Govitecan-hziy|During the Treatment Phase patients will receive trilaciclib + sacituzumab govitecan-hziy on days 1 & 8 of a 21 day cycle. Trilaciclib is administered first, followed by sacituzumab govitecan-hziy. Administer diluted trilaciclib solution as a 30-minute IV infusion to be completed within 4 hours prior to the start of sacituzumab govitecan-hziy.
3317577|NCT01985477|Experimental|Lenalidomide + Dexamethasone + All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21. Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22. ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment. Dexamethasone starting dose: Dose previously on when progressing prior to study entry. ATRA starting dose: MTD from Phase I.~Maintenance Therapy Group A: Lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days, with ATRA at dose determined in Phase I for 14/28 days, and Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22. After 3 months on therapy at MTD in Phase I study, patients must be switched to this dose schedule. Patients unable to tolerate either Dexamethasone during maintenance phase may dose reduce Dexamethasone as needed."
3382109|NCT05113797|Active Comparator|Control Group|Subjects will perform YBT-LQ practice tests using standardized set of verbal instructions provided in the YBT-LQ online manual prior to the testing condition.
3382110|NCT05113797|Experimental|OPTIMAL Motor Learning Group|Subjects will perform the YBT-LQ with the practice period altered to implement aspects of the three pillars of the OPTIMAL motor learning theory (promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task).
3382111|NCT05113082||Participants with SBS-IF|Participants with SBS-IF who as part of standard or routine clinical practice, that underwent intestinal transplantation over the last 10 years (both dead and alive at the time of study enrollment) will be observed in this retrospective observational study for 10 months.
3382112|NCT05112965|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression or beyond if the participant continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; participant non-compliance; or study termination by the Sponsor, whichever occurs first.
3382113|NCT05110014|Other|Primary Care Office Visits|"The limited use dataset will contain the following data elements for each completed patient visit:~Date of clinic visit (where each date is indicated by a number relative to the clinic's Launch Date)~Clinic (designated by a unique study clinic identifier)~Type of visit completed (for example, new patient visit, return patient visit, annual exam)~Patient age~Patient gender~Patient race/ethnicity~Patient primary insurance~Nursing staff who roomed the patient (designated by a unique study identifier)~Whether patient used mPATH-CheckIn program (Y/N)~Whether nursing staff used mPATH Nursing Module to transmit mPATH data to electronic health record (Y/N)~Whether patient has a diagnosis of depression in the problem list in the EHR (Y/N)~Whether patient has an antidepressant medication listed in the active medication list ( (Y/N)~Results of depression screening items~Results of fall risk screening items~Results of safety at home screening items"
3382114|NCT05108896|Other|Aspiration in Acute Respiratory Failure Survivors|All participants will receive a tracheal ultrasound within 72 hours prior to extubation, collection of demographic and hospital clinical information, administration of 3 screening tests (study defined algorithm test, 3-ounce water swallow test, TOR-BSST) addressing swallowing function within 24 hours post-extubation, and a fiberoptic endoscopic examination of swallowing (FEES) exam.
3382115|NCT05107245||COVID-19 patients|Hospitalised COVID-19 patients
3382116|NCT05107245||Controls|Exposed medical staff
3382117|NCT05106764||Part A: Retrospective Database Analysis Cohort|Participant's data will be collected retrospectively using epidemiological methods.
3382118|NCT05106764||Part B: Prospective Diagnostic Study Cohort|Participants with a high likelihood of having FD as identified by the algorithm will have a single blood drawing for laboratory and/or genetic testing to confirm diagnosis of FD.
3382119|NCT05106725||Neurological patients|This cohort will include patients having been diagnosed with a neurological condition.
3382120|NCT05106725||Control|This cohort will include patients who have not been diagnosed with a neurological disorder.
3382121|NCT05106426|Experimental|HC2 intervention Group|Participants in this group will receive the Healthy Caregivers-Healthy Children (HC2) intervention for 24 months
3382122|NCT05106426|Active Comparator|Jump Start Control Group|Participants in this group will receive the Jump Start intervention for 24 months
3382123|NCT05106426|No Intervention|Parents/Caregivers of Participants receiving HC2 intervention|Parents/caregivers of participants receiving the HC2 program will not be receiving any intervention.
3382124|NCT05106426|No Intervention|No Intervention: Parents/Caregivers of participants receiving Jump Start Intervention|Parents/caregivers of participants receiving the Jump Start program will not be receiving any intervention.
3382127|NCT05101148|Experimental|selumetinib single arm|This is a sequential study consisting of a screening period lasting up to 28 days, a 28 day (1 cycle) treatment period (T1) in a fed state, a 7 day washout period, a further 1 cycle treatment period (T2) in a fasted state and an extension to T2 until results from the primary analysis are available. During Treatment Period 1 and 2 all participants will receive selumetinib (25 mg/m2 bid). If a third treatment period (T3) is required, participants will enter a 7 day washout period followed by a treatment period in a fed state at an adjusted dose for 3 cycles.
3382128|NCT05101018|Experimental|Romosozumab Baseline to Month 11 followed by Denosumab Month 12 to Month 24|"Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive romosozumab (210mg SQ) once a month for 12 months.~After 12 months the same twenty (20) individuals will receive denosumab (60mg SQ) at month 12 and 18."
3317578|NCT01985477|Experimental|Lenalidomide + All-Trans Retinoic Acid (ATRA)|"Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent Lenalidomide prior to study enrollment. All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy: Maintenance therapy consists of lenalidomide at the dose level tolerated at the completion of cycle 3 for 21/28 days, with ATRA at the dose determined in the phase I portion of the trial for 14/28 days. Dexamethasone will not be administered. After 3 months on therapy at the MTD in the phase 1 study, patients must be switched to this dose schedule."
3317579|NCT01985490|Experimental|epiretinal membrane|
3382129|NCT05101018|Active Comparator|Denosumab Baseline to Month 24|Of the forty (40) individuals with subacute spinal cord injury (SCI) enrolled in this study, twenty (20) participants will be randomly selected to receive denosumab (60 mg SQ) at baseline and 6, 12, and 18 months.
3317580|NCT01985503||Phase 1 group|Subjects were studied in 2009 and their follow-up is in 2014.
3317581|NCT01985503||Phase 2 group|Subjects were studied in 2011 and their follow-up is in 2016.
3317582|NCT01985516|Experimental|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
3317583|NCT01985516|Active Comparator|Pouring the gel on the tip of the catheter|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally)
3317584|NCT01985529|Experimental|Exercise|Enrollment in pulmonary rehabilitation
3317585|NCT01985529|No Intervention|Control|
3317586|NCT01985555|Experimental|Volitinib(HMPL-504)|There are 5 dose cohorts,including600 QD,800QD and 400BID mg,500BID in the dose escalation stage and HMPL-504 will be administered orally to patients once daily for each dose cohort., in the dose expansion stage 500BID will be administered orally to patients.
3317587|NCT01985568|Active Comparator|Standard Behavioral Therapy (Standard BT)|Standard BT: This group will follow a traditional model of initiating exercise concurrently with a dietary intervention for weight loss within an 18 month behavioral weight loss program.
3317588|NCT01985568|Experimental|Sequential Behavioral Therapy (Sequential BT)|Sequential BT: This group will receive diet and exercise interventions delivered sequentially within an 18 month behavioral weight loss program.
3317589|NCT01985594|Active Comparator|Utrogestan|oral tablet Utrogestan 400mg daily for 2 days
3317590|NCT01985594|Placebo Comparator|Nifedipine|tablet Nifedipine 20 mg stat then 20 mg after 30 minutes then another 20 mg after 30 minutes followed by 10 mg three times daily for 2 days
3317591|NCT01985607|Experimental|Thickened|
3317592|NCT01985607|Active Comparator|Control|
3317593|NCT01985620|Active Comparator|study group|Educational intervention with the parents
3317594|NCT01985620|No Intervention|control group|
3317595|NCT01985633|Experimental|Mesenchymal stem cell, PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 10 ml of Mesenchymal stem cell suspension and 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle
3317596|NCT01985633|Active Comparator|platelet rich plasma|About 100 ml of venous blood would be drawn with aseptic technique from the antecubital vein with an 18g needle , in order to avoid irritation and trauma to the platelets which are in a resting state. The blood would be collected in a 100 ml paediatric bag with CPDA(citrate phosphate dextrose adenine) as anti coagulant. A leucocyte filter will be also used to filter off the leucocytes. The blood will be then centrifuged for 15 min at 1300 rpm. This separates blood in to RBC( packed red blood cells) and platelet rich plasma. Next the PRP will be passed through a leucocyte filter to obtain leucocyte poor platelet rich plasma. 10 ml of PRP will be dispensed in a sterile syringe. The PRP would be used for injection.
3317597|NCT01985646|Experimental|surgery treatment|one stage pull through left-colectomy
3317598|NCT01985646|Experimental|conservative treatment|anal dilation, colonic lavage, oral probiotic
3317599|NCT01985659||open thoracotomy|In the first cohort(20007-2009) almost all patients where operated through a thoracotomy.
3317600|NCT01985659||Early VATS|In a second cohort, (2010-2011) the experience with vats was early.
3317601|NCT01985659||Standardized VATS|In the third period (2012-2013), a standardized vats technique with extensive intrapulmonary and mediastinal lymphadenectomy was used.
3317602|NCT01985672||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
3317603|NCT01985672||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels >20ng/L undergoing Frozen embryo transfer (vitamin D levels are measured on the day of embryo transfer)
3317604|NCT01985698|Experimental|Robotic-assisted resection|patients with low rectal cancer receiving robotic-assisted abdominoperineal resection.
3317605|NCT01985698|Active Comparator|Laparoscopic resection|patients with low rectal cancer receiving laparoscopic abdominoperineal resection.
3317606|NCT01985711|Experimental|web-based,CBT,MI,TTM, outpatient|Participants in web-based collaborative care group will receive 24 weekly 40-minute web-based Cognitive Behavioral Therapy (CBT) sessions, undergo structured Transtheoretical Model of Behavior Change or Motivational interviewing to set up proper life-style and healthy behavior to improve their live quality，conducted on the web. Besides, they will receive usual diabetes outpatient care and web-based diabetes care.
3317607|NCT01985711|Other|waitlist, usual diabetes outpatient|Participants assigned to the wait-list group will be given usual diabetes outpatient service (diabetic medication guidance and appointment to see doctor as routine, without specific anti-depression therapy). After 6 months, they will receive web-based collaborative care for 6 months too.
3317608|NCT01985724|Active Comparator|A|FEC -> TXT
3317609|NCT01985724|Experimental|B|Docetaxel/Cyclophosphamide (TC)
3317610|NCT01985737||Infants with infected PICC line|After informed consent the subjects that develop a PICC line infection in the NICU will serve as the cases.
3317611|NCT01985737||Infants without infected PICC line|After informed consent the subjects that do not develop a PICC line infection in the NICU will serve as the controls.
3317612|NCT01985750|Placebo Comparator|Drug: d-cycloserine or placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
3317613|NCT01985750|Active Comparator|D-cycloserine|"Placebo Comparator: Drug: d-cycloserine or placebo~Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
3317614|NCT01985776|Active Comparator|Exercise intervention|Patients will functional stabilisation exercise for the trunk.
3317615|NCT01985776|Active Comparator|Exercise and e-stim|Patients will receive exercise intervention and electrical stimulation simultaneously.
3317616|NCT01985776|No Intervention|Patients control|Patients will not receive any treatment but could use compression belt as per usual.
3317617|NCT01985776|No Intervention|Healthy control|Healthy asymptomatic participants who will not receive any treatment.
3317618|NCT01985789|Active Comparator|diphenhydramine|50mg dose given as two 25mg capsules
3317619|NCT01985789|Active Comparator|cetirizine|10mg dose given as 1 10mg capsule and 1 placebo capsule
3317620|NCT01985789|Active Comparator|desloratadine|5mg dose given as 1 5mg capsule and 1 placebo capsule
3317621|NCT01985789|Placebo Comparator|placebo|given as 2 placebo capsules
3317622|NCT01985802|Other|Pacing - Cross-over|Pacing will be conducted in 3 different ways (atrial, dual chamber and His-bundle pacing) at 2 different rates (basal and 100 bpm).
3317623|NCT01985815|Experimental|VC/VS stimulation ON followed by OFF|triple blind, randomised, two periods of three months
3317624|NCT01985815|Experimental|VC/VS stimulation OFF followed by ON|triple blind, randomised, two periods of three months
3317625|NCT01985828|Experimental|Intermediate Risk|"Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy~OR~Short term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)"
3317626|NCT01985828|Experimental|High Risk|Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost
3317627|NCT01985841|Experimental|Bevacizumab/FEC/Docetaxel|Bevacizumab plus 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) -> Bevacizumab plus Docetaxel
3317628|NCT01985854|Active Comparator|Propofol|Propofol target-controlled infusion will be kept 2-4μg /ml plasma concentration throughout procedure.
3317629|NCT01985854|Experimental|Desflurane|After taking off the electrophysiological monitoring from the patients, discontinue propofol and start desflurane from 6% (dialed concentration) at flow rate of 4L/min for 2 minutes in desflurane group. When achieve end tidal concentration of 4-5%, decrease the flow rate to 2L/min.
3317630|NCT01985867|Experimental|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 8×10^8 colony forming units (CFU), twice daily, orally for 4 weeks
3317631|NCT01985867|Placebo Comparator|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
3317632|NCT01985880||Hunner's ulcer interstitial cystitis|Hunner's ulcer interstitial cystitis
3317633|NCT01985880||non-ulcer interstitial cystitis|non-ulcer interstitial cystitis
3317634|NCT01985880||Control|Control
3317635|NCT01985893|Other|Lapatinib plus trastuzumab|Drug intervention: Lapatinib IMP, Trastuzumab on prescription. Lapatinib 1000 mg p.o. once daily for 21 days. Trastuzumab i.v. infusion 8 mg/kg loading dose; 6 mg/kg on Day 1 of each subsequent 3 weekly cycle.
3317636|NCT01985893|Other|Lapatinib plus Capecitabine|Drug intervention: Lapatinib and Capecitabine on prescription. Lapatinib 1250 mg p.o. once daily. Capecitabine 2000 mg/m2 p.o. in two divided doses on days 1 to 14 of a 21 day cycle.
3317637|NCT01985906|Experimental|Pararenal aortic aneurysm|"The aneurysm is adjacent to (proximal/distal landing zone < 15mm) or involving vital branches, including the celiac artery, superior mesenteric artery, or renal artery.~The intervention is endovascular management of the aneurysms with multiple overlapping uncovered stents"
3317638|NCT01985919||Bone marrow aspirate/biopsy and blood specimens|Collection of blood and bone marrow specimens for research purposes and increase the successful acquisition of correlative bone marrow samples to improve translational research in bone marrow diseases
3317639|NCT01985945|Other|Yoga|
3317640|NCT01985945|No Intervention|Without Yoga|
3317641|NCT01985984||H&N cancer patients|"Patients with Head and Neck Cancer, treated with curative intent~Any tumor site~Stage I-IV, M0~Treated with radiotherapy alone or in combination with systemic therapy~Definitive radiotherapy or postoperative radiotherapy~Interventions:~Radiation alone~Radiation in combination with systemic therapy"
3317642|NCT01986023|Experimental|SMS Short Message Service Arm plus Prescription|"Intervention is as follows: Drug reminder SMS will be sent to the participants in the intervention arm customised to their stroke prescription. These SMS will be interactive in a way that the participants will have to answer back if they have taken their medicine or not in a Yes/No format. Moreover behaviour change SMS will also be sent to the intervention arm twice weekly. In addition , Participants will be encouraged to take medication using a taxonomy of behavioral change intervention techniques."
3317643|NCT01986023|No Intervention|Standard Prescriptions and Counselling|The usual care arm will undergo standard treatment and counselling regarding their treatment and the education regarding their medication as per standard of care. They will receive a standard written prescription and no SMS
3317644|NCT01986036|Sham Comparator|CONTROL|Control breakfast low in protein and calcium. Porridge-based breakfast.
3317645|NCT01986036|Active Comparator|PROTEIN|High-protein breakfast.
3317646|NCT01986036|Active Comparator|CALCIUM|High-calcium breakfast.
3317647|NCT01986036|Experimental|PRO-CAL|High-protein and calcium breakfast.
3317648|NCT01986049|Experimental|Bupivicaine 0.5%|Drug Bupivacaine 0.5%
3317649|NCT01986049|Experimental|Bupivicaine 0.25%|Drug Bupivacaine 0.25%
3317650|NCT01986049|Placebo Comparator|Normal Saline|Saline Normal
3317651|NCT01986075|Active Comparator|Computer-assisted Therapy alone|Computer-assisted behavior therapy based on the Community Reinforcement Approach (CRA) to treating cocaine dependence. CRA is skills based treatment program that incorporates coping skills development and contingency management. Participants will attend the clinic 3x per week and receive counseling 2x per week when receiving Behavioral: Computer assisted therapy alone.
3317652|NCT01986075|Experimental|Computer-assisted CBT + Adderall-XR|Patients who are randomized to the computer-assisted behavior therapy plus mixed amphetamine salts (extended release) arm will have their dose titrated to 80 mg or the maximum tolerated extended release mixed amphetamine salts daily. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
3317653|NCT01986075|Placebo Comparator|Computer-assisted CBT plus placebo|Patients who are randomized to the Computer-assisted CBT plus placebo arm will have their medication dose titrated in a fix-flexible dose schedule matching the active medication arm. Participants will be asked to take the medication once per day in the morning or early afternoon and will be maintained on this schedule through week 14 of the trial.
3317654|NCT01986088|Placebo Comparator|Placebo|
3317655|NCT01986088|Experimental|Eletriptan 40 mg|
3317656|NCT01986088|Experimental|Eletriptan 80 mg|
3317657|NCT01986088|Experimental|Sumatriptan 50 mg|
3317658|NCT01986088|Experimental|Sumatriptan 100 mg|
3317659|NCT01986127|Experimental|Adalimumab|single administration of Adalimumab 80mg diluted in 5ml saline
3317660|NCT01986127|Placebo Comparator|saline|5 ml of saline
3317661|NCT01986153||Home parenteral nutrition patients|Patients who receive home parenteral nutrition.
3317662|NCT01986153||Healthy controls|Those who don't receive home parenteral nutrition and consume a normal diet.
3317663|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 1|Patients will receive MEHD7945A 1100 milligrams (mg) intravenous (IV) infusion every 2 weeks (q2w) in combination with cobimetinib. Cobimetinib will be administered at a starting dose of 80 mg oral tablet q2w. Cobimetinib doses will be escalated to establish maximum tolerated dose (MTD) of MEHD7945A+cobimetinib combination for Stage 2.
3317664|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (CRC)|CRC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
3317665|NCT01986166|Experimental|MEHD7945A + Cobimetinib - Stage 2 (NSCLC)|NSCLC patients will receive MEHD7945A in combination with cobimetinib until disease progression or unacceptable toxicity. The doses and schedule of the combination treatment will be according to the MTD established in Stage 1.
3317666|NCT01986179|Active Comparator|Telephone Interpretation|These families will be assigned to use telephone interpretation throughout the ED visit.
3317667|NCT01986179|Experimental|Video Interpretation|These families will be assigned to use video interpretation throughout the ED visit.
3317668|NCT01986192|Experimental|rivaroxaban|Rivaroxaban 15mg bid for 3 weeks and 20mg qd for 6 months
3317669|NCT01986192|Active Comparator|warfarin|Enoxaparin 1mg/kg bid overlapping with warfarin (target PT INR 2.0-3.0) for 6 months
3317670|NCT01986205|Experimental|Hyperbaric Oxygen|100% oxygen at 1.5 atmospheres absolute for 60 minutes, 40 sessions
3317671|NCT01986205|Placebo Comparator|Minimal pressure air|Regular air at minimal pressurization for 60 minutes, 40 sessions
3317672|NCT01986218|Experimental|Arm A: Dose Escalation (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
3317673|NCT01986218|Experimental|Arm A: Dose Expansion (BMS-986115)|Continuous daily dosing until disease progression or unacceptable toxicity
3317674|NCT01986218|Experimental|Arm B: Dose Escalation (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
3317675|NCT01986218|Experimental|Arm B: Dose Expansion (BMS-986115)|Twice weekly dosing until disease progression or unacceptable toxicity
3317676|NCT01986244||STAR Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the STAR
3317677|NCT01986244||Salto Talaris Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the Salto Talaris
3317678|NCT01986244||In-Bone Total Ankle Replacement|Procedure: Total Ankle Replacement Surgery using the In-Bone
3317679|NCT01986257|Experimental|Emotion Regulation Group Therapy (ERGT).|
3317680|NCT01986270|Placebo Comparator|Placebo|
3317681|NCT01986270|Experimental|Eletriptan 40 mg|
3317682|NCT01986270|Experimental|Eletriptan 80 mg|
3317683|NCT01986270|Experimental|Sumatriptan 25 mg|
3317684|NCT01986270|Experimental|Sumatriptan 50 mg|
3317685|NCT01986283|Placebo Comparator|Treatment A|Placebo solution +placebo capsule + placebo capsule chewed.
3317686|NCT01986283|Experimental|Treatment B|PF-00345439 taken whole + placebo solution + placebo chewed
3317687|NCT01986283|Experimental|Treatment C|PF-00345439 chewed + placebo solution + placebo taken whole
3317688|NCT01986283|Active Comparator|Treatment D|Oxycodone HCl immediate-release 40 mg tablets (eg, 2 x 5 mg + 1 x 30 mg) + placebo taken whole + placebo chewed
3317689|NCT01986296|Experimental|ExAblate Treatment|
3317690|NCT01986309|Active Comparator|Group L|Group L Lidocaine load dose 1.5 mg / kg over 5 minutes, followed by continuous infusion of 2 mg / kg / h, which is maintained until the end of surgical procedure
3317691|NCT01986309|Placebo Comparator|Group P|Normal saline solution administered under the same regimen
3317692|NCT01986322|Experimental|DTP/HB/Hib vaccine|"Group A will receive DTP/HB/Hib combination vaccine at 6-11, 10-15 and 14-19 weeks of age.~DTP/HB/Hib component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal"
3317693|NCT01986322|Active Comparator|DTP/HB and Hib vaccine|"Group B will receive DTP/HB and Hib Vaccines separately at 6-11,10-15, 14-19 weeks of age~DTP/HB component:~Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis rHbsAg Aluminum phosphate Natrium Chloride Thimerosal~Hib component:~Purified Haemophilus influenzae type b polysaccharide 10 mcg"
3317694|NCT01986335|Experimental|DTP/HB/Hib Vaccine (Batch: A)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3317695|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: B)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3317696|NCT01986335|Experimental|DTP/HB/Hib vaccine (Batch: C)|Purified diphteria toxoid Purified tetanus toxoid Inactivated Bordetella pertussis HbsAg PRP-TT Aluminum phosphate Natrium Chloride Thimerosal
3382130|NCT05097651|Experimental|CBD|Participants will receive oral liquid cannabidiol
3382131|NCT05097651|Placebo Comparator|Placebo|Participants will receive an inert oral liquid
3382132|NCT05097040|Experimental|Acceptance and commitment therapy (ACT) group|A total of 7 ACT sessions individually guided by a trained coach through Zoom videoconferencing
3382133|NCT05097040|No Intervention|Control group|Care as usual
3382134|NCT05096286|Experimental|Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy|"A diagnostic MRI-only, simulation-free plan will be generated from diagnostic brain MRI imaging, using a semi-automated, AI-assisted plan template within the Ethos Therapy system.~The radiation prescription dose twill be 3.0 Gy daily over approximately 2 weeks for a total of 30.0 Gy (10 fractions)."
3382136|NCT05094128||Participants Receiving Upadacitinib|
3382137|NCT05093959|Active Comparator|Metformin|20 weeks of metformin 1500 mg daily. Metformin is a widely used medication with an excellent safety profile. Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks. An extended release formulation will be used which improves compliance and reduces GI side effects.
3382138|NCT05093959|Placebo Comparator|Placebo|20 weeks of placebo 1500 mg daily. Placebo is a biologically inert substance placed in capsules to match appearance of active intervention (metformin). Dosing will be escalated during the first 3 weeks of treatment. Dosing will be initiated with 500 mg taken orally once daily in the evening for 1 week. After one week, the participant will be called to assess tolerance and will be asked to increase dose to two capsules per day for a total 1000 mg per day for one week. At the end of the second week, participants will be called again and if they tolerated the increased dose will be instructed to increase to three capsules (1500 mg/day) per day for the remainder of the 20 weeks.
3317697|NCT01986374|Experimental|HCG is introduced with small catheter.|phase 1 non randomized pilot
3317698|NCT01986387|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with chronic pain aged 16-25 years who have learned to function successfully with their chronic pain to the mentored participants).
3317699|NCT01986387|No Intervention|Waitlist Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
3317700|NCT01986400|Experimental|Virtual Peer-to-Peer Support Mentoring|In addition to standard medical care, adolescents in the experimental group will receive the VP2P support program, a manualized peer-mentorship program that will provide modeling and reinforcement by peers (young adults with JIA aged 16-25 years who have learned to function successfully with their JIA to the mentored participants).
3317701|NCT01986400|No Intervention|Wait-list Control|The control group will receive usual care but without the mentorship intervention. They will be offered the VP2P support program after completion of outcome measures (T1 - to be completed online prior to randomization; T2 - at program completion).
3317702|NCT01986413|Active Comparator|BIPAP ST|one night, NIV with pressure controlled ventilation (BIPAP ST) with individually titrated pressure parameters.
3382143|NCT05091580|Experimental|Intervention: Interpersonal Counseling for Depression|New adult TB patients with depressive symptoms (PHQ-9 > 10) will be offered 4 sessions of Interpersonal Counseling delivered by a trained lay counsellor.
3382144|NCT05091580|Other|Control: Enhanced Treatment as Usual|"New adult TB patients will be screened for depression and those with significant symptoms (PHQ-9 > 15 and/or suicidal ideation) will be referred to the clinic nurse for evaluation and referral to specialized mental health care as needed. Routine screening for depression is not a standard practice for TB patients; therefore assessment and referral is considered enhanced treatment as usual. Individuals will be interviewed at baseline and treatment completion."
3382145|NCT05091567|Experimental|Arm A: Atezolizumab+Lurbinectedin|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle in combination with lurbinectedin on Day 1 of each 21-day cycle."
3317703|NCT01986413|Experimental|IVAPS|one night, NIV with volume assured pressure support (IVAPS).The pressure parameters will be adjusted according to the BIPAP pressure levels.
3317704|NCT01986426|Experimental|Arm A: LTX-315 monotherapy singe lesion|"Cohort 1-3: First induction treatment (6 weeks): In week 1 the first index lesion will be injected Twice daily on 3 consecutive days. During week 2-6 the injection will be once a week.~Second induction treatment (6 weeks) and Maintenance treatment (20 weeks)- At week 7 the second index lesion will be injected with same dosing schedule as the first index lesion.~Cohort 4 and above: Once daily on 3 consecutive days week 1. Week 2-6 one injection per week. From week 8, one dosing days every 2 weeks."
3317705|NCT01986426|Experimental|Arm B: LTX-315 monotherapy in multiple concurrent lesions|"Patients with at least one injectable lesion and one bystander lesion will receive LTX-315 to one or more lesions:~Once daily on 2 consecutive days week 1-3."
3317706|NCT01986426|Experimental|Arm C|Patients with melanoma and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with ipilimumab given for 4 cycles every 3 weeks.
3317707|NCT01986426|Experimental|Arm D|Patients with TNBC and at least one injectable lesion will receive LTX-315 to one or more lesions on two consecutive days week 1-3 in combination with pembrolizumab given every 3 weeks.
3382146|NCT05091567|Active Comparator|Arm B: Atezolizumab|"Induction phase: participants will receive standard of care atezolizumab on Day 1 of each 21-day cycle in combination with carboplatin on Day 1 and etoposide on Days 1, 2, and 3 of each 21-day cycle for 4 cycles.~Maintenance phase: participants will receive atezolizumab on Day 1 of each 21-day cycle."
3382147|NCT05091346|Experimental|E7386|Participants will receive E7386 twice daily (BID) along with pembrolizumab 200 mg intravenous (IV) infusion once every 3 weeks (Q3W) in 21-day treatment cycle until RP2D is determined in Phase 1b. The recommended dose for Phase 2 part of the study will be based on Phase 1b result. Participants will continue to receive study treatment in Phase 2 part until disease progression, development of unacceptable toxicity, withdrawal of consent, or termination of the study.
3382148|NCT05090800|Experimental|Definity contrast agent|
3317708|NCT01986452|Active Comparator|Unattended CPAP therapy|Therapy data will be examined by reading out the CPAP device after 6 months. Patients can obtain help on own request, corresponding to the standard CPAP prescription routine.
3317709|NCT01986452|Experimental|Telemonitoring and support|CPAP device therapy data will be downloaded by the study site via GSM modules once a week. In case of poor therapy adherence (defined by a minimum average usage of 3h/night over the week) a contact call will be initiated to motivate patients or solve problems identified by telemonitoring. If active home intervention is required, the study site will inform the healthcare provider to visit the patient in a timely manner.
3317710|NCT01986465|Experimental|Depomedrol|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
3317711|NCT01986465|Placebo Comparator|Placebo|The trial pharmacist prepares a series of similar vials containing either 4 mg of Depomedrol or Normal Saline and coded them either 1, 2, 3 or 4, the group assignments are not decoded until the end of the trial when the final analysis is due to take place. Patients take their envelopes to the trial pharmacist who give them a coded vial which they take to the orthopaedic surgeon who make the injection. After the injection the trial clerk take the patients to a technician who give patients in groups 1 and 3 long arm splints.
3382149|NCT05089162|Experimental|Patients with chronic HF with reduced ventricular ejection fraction coming for scheduled day|
3382150|NCT05088980|Experimental|VOLBELLA with Lidocaine|Participants will receive VOLBELLA with Lidocaine on Day 1 and followed for 12 months.
3382151|NCT05088980|Placebo Comparator|Control Group|Participants will be followed for 3 months. Participants can opt to receive VOLBELLA with Lidocaine after 3 months and followed for 9 months.
3382152|NCT05083442|Active Comparator|Group 1 - LLLT|Subject receive Laser treatments and Lifestyle Modifications
3382153|NCT05083442|Sham Comparator|Group 2 - SHAM|Subject receives Sham Laser treatments and Lifestyle Modifications
3382154|NCT05080764|Experimental|1h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
3382155|NCT05080764|Experimental|3h incubation BF-200 ALA|Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
3382156|NCT05080764|Placebo Comparator|1h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.
3382157|NCT05080764|Placebo Comparator|3h incubation vehicle|Topical application of vehicle to BF-200 ALA red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 3h incubation.
3317713|NCT01986491|Experimental|Part 1; Period 1|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid X, 120 mg of solid Y, 30 mg of solid Y, and 120 mg of solid X.
3317714|NCT01986491|Experimental|Part 1; Period 2|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks. 30 mg of solid Y, 30 mg of solid X, 120 mg of solid X and 120 mg of solid Y.
3317715|NCT01986491|Experimental|Part 1; Period 3|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid X, 30 mg of solid Y, 120 mg of solid Y, and 30 mg of solid X.
3382161|NCT05074446|Experimental|Stereotype Threat Group|Stereotype threat manipulation will be performed on the participants in the experimental group just before they are taken into the testing room.
3382162|NCT05074446|No Intervention|Control Group|The other group (Control Group) will not be given any prior information.
3382163|NCT05073575|Experimental|Hyaluronic acid Group|Hyaluronic acid gel will be applied to exposed dental roots surfaces, after scaling and root planing therapy
3382164|NCT05073575|Active Comparator|No-hyaluronic acid Group|Only scaling and root planning will be performed on the exposed dental roots surfaces
3382165|NCT05073133|Experimental|OAV101|A single IV infusion at 1.1e14 vg/kg over approximately 60 minutes
3317716|NCT01986491|Experimental|Part 1; Period 4|Three participants will receive JNJ 39393406 of 2 different solid formulations (X and Y) with 2 different doses (30 mg and 120 mg) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 120 mg of solid Y, 120 mg of solid X, 30 mg of solid X, and 30 mg of solid Y.
3317717|NCT01986491|Experimental|Part 2; Period 1|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solid formulation, and 30 mg of solution.
3317718|NCT01986491|Experimental|Part 2; Period 2|Four participants will receive 30 mg of JNJ 39393406 of 2 different formulations (solid formulation selected from Part 1 and solution) in following sequence (on Day 1 of each sequence) with a washout period of 1-2 weeks: 30 mg of solution, and 30 mg of solid formulation.
3317719|NCT01986491|Experimental|Part 3|Eight participants (same participants from Part 2) will receive JNJ 39393406 (dose will likely be 30 mg, or another multiple of the 30 mg solid dose form selected in Part 1, but not higher than 210 mg) from Days 1 to 7.
3317720|NCT01986517|Experimental|Feedback|Therapists assigned to this group will receive standardized feedback on their psychotherapeutic competency after every fourth treatment session with a patient for a period of 20 therapy sessions. The feedback will be given by two experienced raters who are licensed as psychological psychotherapists.
3317721|NCT01986517|Experimental|No feedback|Therapists assigned to this group will receive no feedback
3317722|NCT01986530||Healthy individuals|Participants will be healthy volunteers of both sexes recruited from the Greek Military Medical School personnel, Thessaloniki, Greece.
3317723|NCT01986530||Boost Subgroup|After an overnight fast, 40 participants will be provided a standardized mixed meal in two different quantities (125 ml, n=20 and 250 ml, n=20) and blood samples will be obtained before as well as 30 min after mixed meal ingestion
3317724|NCT01986530||Aerobic exercise|After an overnight fast, 20 participants will be subjected to aerobic exercise for 30 min and blood samples will be obtained at baseline and at 30 min
3317725|NCT01986530||Circadian variation Subgroup|20 of the participants will be hospitalized and closely monitored for 24 hours. A catheter will be inserted in a vein and blood samples will be obtained every 3 hours through the 24-hour period.
3317726|NCT01986530||Seasonal variation Subgroup|20 of the participants will be monitored for one year and blood samples will be obtained every 3 months (at the middle of month January - April - July - October). Subjects will be instructed to maintain their normal exercise routine and dietary habits.
3317727|NCT01986543|Experimental|Arm 1|8 weeks R20mg/Kg + HZE and efavirenz 600mg
3317728|NCT01986543|Experimental|Arm 2|8 weeks R20mg/Kg + HZE and efavirenz 800mg
3317729|NCT01986543|Active Comparator|Standard arm|8 weeks R10mg/Kg + HZE and efavirenz 600mg
3317730|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
3317731|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot A)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot A) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot A)
3317732|NCT01986556|Experimental|Lesinurad 400 mg Fasted (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
3317733|NCT01986556|Experimental|Lesinurad 400 mg Fed (Site 1 and Site 2, Lot B)|Day 1: Lesinurad 400 mg (Site 1 or Site 2, Lot B) Day 5: Lesinurad 400 mg (Site 1 or Site 2, Lot B)
3317734|NCT01986569|Experimental|[18F]fluoroestradiol (FES)|The injectable radioactive dose of 111-222 megabecquerel. One single IV injection over 1-2 min. [18F]FES PET/CT for imaging.
3317735|NCT01986582|Active Comparator|Group A|One puff of oxymetazoline immediately followed by one puff of hydroxyl-propyl-methyl cellulose powder, morning & evening, for 8 days.
3317736|NCT01986582|Placebo Comparator|Group B|One puff of oxymetazoline immediately followed by one puff of placebo, morning & evening, for 8 days.
3317737|NCT01986608|Experimental|Lacosamide 30-minute iv|A 30-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
3317738|NCT01986608|Experimental|Lacosamide 60-minute iv|60-minute intravenous constant infusion of Lacosamide (LCM) 200 mg (200 mg/20 mL single-use vial).
3317739|NCT01986608|Experimental|Lacosamide oral tablet|Oral administration of Lacosamide (LCM) 200 mg (2 x 100 mg film-coated tablet) with 200 mL of water.
3317740|NCT01986621||Patients undergoing elective PCI|
3317741|NCT01986634|Other|Laser Treatment|Patients enrolled will have split face laser treatment. Patients will serve as their own control.
3317742|NCT01986660|Experimental|Ibuprofen Cream (SST-0225)|
3317743|NCT01986673|Experimental|5% Sildenafil Cream (SST-6006)|5% Sildenafil Cream
3317744|NCT01986673|Active Comparator|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
3317745|NCT01986699||Standard Therapy|Patients are treated as per current standard of care
3317746|NCT01986699||Laparoscopic Assisted Polypectomy|Patients treated with Laparoscopic Assisted Colonoscopic Polypectomy
3317747|NCT01986712||Intron A, HDI|High-dose interferon alfa (Intron A, HDI)
3317748|NCT01986712||Sylatron|Pegylated alfa-interferon 2b (Sylatron, PEG IFN)
3317749|NCT01986725|Active Comparator|Standardized care|During treatment and routine follow-up consultations, patients randomized to standardized care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.
3317750|NCT01986725|Active Comparator|Standardized care + WOMAN-PRO II program|During treatment and routine follow-up consultations, patients randomized to standardized care + WOMAN-PRO II program will be provided with usual care and nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments.
3317751|NCT01986738||Radiation Treatment|Patients undergoing standard of care radiation treatment with Active Breathing Control (ABC)
3317752|NCT01986764|Active Comparator|lisdexamfetamine|lisdexamfetamine 20 mg/d to 60 mg/d for 12 weeks
3317753|NCT01986764|Active Comparator|Estradiol|Estradiol 1 mg/d to 3 mg/d for 12 weeks
3317754|NCT01986764|Placebo Comparator|Placebo|
3382168|NCT05070247|Experimental|Dose Escalation: TAK-500 Single Agent (SA) (dosed Q3W)|TAK-500 dose escalation starting at 8 microgram per kilogram (mcg/kg), infusion, intravenously, once on Day 1 of each 21-days treatment cycle, once every 3 weeks (Q3W), for up to 1 year.
3317755|NCT01986777|Active Comparator|lisdexamfetamine|Participants will have a 50% chance of receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 10 weeks.
3317756|NCT01986777|Placebo Comparator|Placebo|Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
3317757|NCT01986803|Experimental|PCI with ABSORBTM bioresorbable vascular scaffold system (BVS)|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the Abbott Vascular ABSORB TM everolimus eluting bioresorbable vascular scaffold system (BVS)
3317758|NCT01986803|Active Comparator|PCI with XIENCE Xpedition stent|All patients assigned to the experimental arm will be treated with a primary Percutaneous Coronary Intervention using the XIENCE Everolimus Eluting Coronary Stent System (XIENCE Xpedition) (commercial product)
3317759|NCT01986842|Experimental|Low protein|Subject will receive a low protein diet (0.7 g/kg BW/day) for 14 days prior to the experimental trial
3317760|NCT01986842|Experimental|High protein|Subjects will receive a high protein diet (1.5 g/kg BW/day) for 14 days prior to the experimental trial
3317761|NCT01986868|Other|Coronary MR Angiography (CMRA)|Coronary MR Angiography(CMRA). A gadolinium-based contrast (Optimark or MultiHance) will be administered as well as a beta blocker which will be assigned based upon heart rate.
3317762|NCT01986894|Placebo Comparator|Treatment 1 (placebo)|Five placebo capsules matching the appearance of the 4 mg pomalidomide capsule will be administered orally on the morning of Day 1
3317763|NCT01986894|Experimental|Treatment 2 (4 mg pomalidomide)|Five capsules (one 4 mg pomalidomide capsule and four placebo capsules matching the appearance of the 4 mg pomalidomide capsule) will be administered orally on the morning of Day 1
3317764|NCT01986894|Experimental|Treatment 3 (20 mg pomalidomide)|Five 4 mg pomalidomide capsules will be administered orally on the morning of Day 1
3317765|NCT01986894|Active Comparator|Treatment 4 (moxifloxacin)|One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1
3317766|NCT01986959|Experimental|Surgery with Periodontal dressing|After the Surgical crown lengthening, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
3317767|NCT01986959|Other|Surgery without Periodontal dressing|After surgery, the patients were randomly allocated to the periodontal dressing group (PDG) and control group (CG - non-placement of periodontal dressing).
3317768|NCT01986972|Active Comparator|Toothbrushing With Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing with common dentifrice.
3317769|NCT01986972|Experimental|Toothbrushing Without Dentifrice|After 72 hours of absence oral hygiene, patients performed toothbrushing without dentifrice.
3317770|NCT01986998|Active Comparator|oMP 1250 mg: Group A|Methylprednisolone 1250 mg/24h x3 days
3317771|NCT01986998|Active Comparator|oMP 625 mg: Group B|Methylprednisolone oral 625 mg/24h x3 days
3317772|NCT01987011|Experimental|MG1109|MG1109 0.5 mL Intramuscularly injection, twice at an interval of 21 days
3317773|NCT01987011|Placebo Comparator|Placebo|Placebo(for MG1109) 0.5 mL Intramuscularly injection, twice at an interval of 21 days
3317774|NCT01987024|Active Comparator|group A-usual procedure|
3317775|NCT01987024|Experimental|groupB- actim partus|
3317776|NCT01987037||tests evaluation|children with autism spectrum disorder subjected to the NP-MOT tests
3317777|NCT01987063||pregnant woman with twins|pregnant woman with twins
3317778|NCT01987076|Active Comparator|Corticosteroids per os: Prednisone + Emollient|
3317779|NCT01987076|Experimental|Topical corticosteroid: Clobetasol + Emollient|
3317780|NCT01987115|Experimental|Fascial Manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
3317781|NCT01987115|Active Comparator|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
3317782|NCT01987128|Experimental|Intraneural injection|All patients in the arm will receive a single intraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, in the sciatic nerve under echographic guidance.
3317783|NCT01987128|Active Comparator|extraneural injection|All patients in the arm will receive a single extraneural injection of 12 ml Ropivacaine 1% BBraun, Germany, around the sciatic nerve under echographic guidance.
3317784|NCT01987141|Experimental|EMR intervention|Patients will have an electronic medical record popup/highlight in their chart, displaying the recommended guidelines for weight gain in pregnancy.
3317785|NCT01987141|No Intervention|Control|The patient's medical record will be displayed as usual, with no flag or highlight for weight gain recommendations
3317786|NCT01987154|Active Comparator|Marketed cow milk-based premature infant formula|
3317787|NCT01987154|Experimental|Marketed extensively hydrolyzed casein infant formula|
3317788|NCT01987167|Experimental|-ACHTHAR|Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU
3317789|NCT01987180||Usual standard care|Parents will be provided with the usual standard of care in the NICU. Discharge information will be provided to parents as is typically done in the NICU for VLBW infants getting ready to go home. Typical handouts are given to parents that describe their child's care and needs specifically as well as general guidelines. The project coordinator for the research study will verify that parents received information prior to discharge from the NICU staff. Parents will determine how you use this information.
3382169|NCT05070247|Experimental|Dose Escalation: TAK-500 (dosed Q3W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Day 1 of each 21-days treatment cycle (Q3W), along with pembrolizumab 200 milligram (mg) infusion, intravenously, once on Day 1 of each 21-days treatment cycle (Q3W), for up to 1 year. The exact starting dose of TAK-500 will be determined from the results of the TAK-500 SA arm dose escalation.
3382170|NCT05070247|Experimental|Dose Expansion: TAK-500 (dosed Q3W and/or Q2W) + Pembrolizumab (dosed Q3W)|TAK-500, infusion, intravenously, once on Days 1 and 22 (Q3W), and/or once on Days 1, 15, and 29, once every 2 weeks (Q2W), in a 42-days treatment cycle with pembrolizumab 200 mg infusion, intravenously, once on Days 1 and 22 (Q3W), in a 42-days treatment cycle for up to 1 year. The dose of TAK-500 for the Dose Expansion arm will be based on the results of the TAK-500 in combination with pembrolizumab Dose Escalation arm.
3382171|NCT05068973|Experimental|Luciola|Bronchoscopic implantation of the fiducial marker NOVATECH® LUCIOLA™ EB prior to radiotherapy treatment.
3382172|NCT05063331|Active Comparator|Sacrocolpopexy|Minimally invasive supracervical hysterectomy with sacrocolpopexy (MI-SCP+SCH)
3382173|NCT05063331|Active Comparator|Uterosacral Ligament Suspension|Total vaginal hysterectomy with uterosacral ligament suspension (TVH+USLS)
3382175|NCT05061134|Experimental|Main study: Ceralasertib + Durvalumab|Participants will receive ceralasertib on Days 15 to 28 plus durvalumab Day 1, once in 28 days (Q28D), until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
3382176|NCT05061134|Experimental|Main study: Ceralasertib|Participants will receive ceralasertib on Days 1 to 14, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
3382177|NCT05061134|Experimental|Biopsy Sub-study: Ceralasertib + Durvalumab|From Cycle 1, participants will receive combination of ceralasertib twice daily (BD) Days 15 to 28 plus durvalumab Day 1, Q28D, until progressive disease, unacceptable toxicity, withdrawal of consent, or a study treatment discontinuation criterion is met.
3382178|NCT05061134|Experimental|Biopsy study: Ceralasertib|During Cycle 0, participants will receive ceralasertib on Days 1 to 14, Q28D, followed by an off-treatment period between Days 15 to 28.
3382179|NCT05058638|Experimental|Aquamin®|
3317790|NCT01987180||NICU-2-Home mobile app user|Parents will receive smartphone and unique NICU-2-Home app for their use. A pair of parents will be given two smartphones and will be asked to use the devices in their preferred way. Within the given app there is a baby tracking tool (baby-connect.com) that enables parents to keep track of the baby's feeding, diapers, sleep, health, medicines, vaccines, photos, etc. The objective in doing this is not to monitor the growth and development of the child; rather, it is to observe what tools within the app parents use and how frequently they use them.
3317791|NCT01987206|Active Comparator|PID algorithm with HMS|"The control algorithm, at its core, is a Proportional-Integral-Derivative (PID)controller that incorporates an Internal Model Control (IMC) based tuning rule using an explicit model of human T1DM glucose-insulin dynamics. Parameters of the model are personalized based on a priori easily available subject parameters. This controller divides the control action into three components - the proportional distance between the current measurement and the target setpoint, the accumulated integral error as expressed by the area between the current state curve and the target set point over time, and the derivative rate of change of the current measurement.~The Health Monitoring System algorithm uses the same glucose monitoring (CGM) data as the PID control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
3382180|NCT05057494|Experimental|Arm A: Acalabrutinib plus Venetoclax (AV)|Participants will receive acalabrutinib and venetoclax orally.
3382181|NCT05057494|Experimental|Arm B: Venetoclax plus Obinutuzumab (VO)|Participants will receive Venetoclax orally and Obinutuzumab via IV infusion.
3382182|NCT05054803|Experimental|WJ-MSC (XCEL-UMC-BETA)|Pre-filled syringe with 4 ± 1 mL containing WJ-MSC in a balanced saline solution supplemented with human albumin.
3382183|NCT05054803|Placebo Comparator|Placebo|Pre-filled syringe with 4 ± 1 mL containing a balanced saline solution supplemented with human albumin
3382184|NCT05053763|Other|Experimental: age<65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
3382185|NCT05053763|Other|Active Comparator:age ≥65 group|The 90% effective dose of remimazolam for duodenoscopy insertion with alfentanil 10µg/kg
3382191|NCT05046184|No Intervention|Healthy Controls|Healthy controls will undergo clinician assessments and fMRI to compare to MDD group.
3382192|NCT05046184|Active Comparator|MDD - Ketamine|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four ketamine infusions.
3382193|NCT05046184|Placebo Comparator|MDD - Midazolam|Participants with MDD who have completed all baseline assessments including pre-treatment fMRI scan randomly allocated to receive four midazolam infusions.
3382194|NCT05045378|Active Comparator|1. Two 0.045mg/kg midazolam infusions|Two 0.045mg/kg midazolam infusions as active placebo
3382195|NCT05045378|Experimental|2. First 0.045mg/kg midazolam infusion and Second 0.5mg/kg ketamine infusion|Single ketamine infusion + Single midazolam placebo infusion
3382196|NCT05045378|Experimental|3. Two 0.5mg/kg ketamine infusions|Repeated (Two) ketamine infusions: Two 0.5mg/kg ketamine infusions
3317792|NCT01987206|Experimental|MPC algorithm with HMS|"The first control strategy is a flavor of Model Predictive Control (MPC) algorithm. MPC employs an explicit model of the process to be controlled when optimizing the input. Specifically, MPC controllers for glycemia control use a model of a human's T1DM insulin-glucose dynamics to predict the evolution of the blood glucose values over a so-called prediction horizon of controller steps, and optimize a predicted insulin input trajectory in order to optimize a specified cost objective that penalizes unsafe glycemic values, and also insulin usage.~The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values. Using a redundant and independent algorithm is an important safety feature of the overall AP device."
3317793|NCT01987258|No Intervention|Control|No exercise (control experiment)
3317794|NCT01987258|Experimental|Interval Walking|A one hour interval walking exercise bout
3317795|NCT01987258|Experimental|Continuous walking|A one hour continuous walking exercise bout
3317796|NCT01987271|Experimental|With noninvasive ventilation|When patients do the six minute walk test with the noninvasive ventilation.
3317797|NCT01987271|No Intervention|Without noninvasive ventilation|When patients do the six minute walk test without noninvasive ventilation.
3317798|NCT01987284|Experimental|SER100|SER100 10 mg s.c. twice daily
3317799|NCT01987284|Placebo Comparator|Placebo|Placebo administered s.c. twice daily
3317800|NCT01987297|Experimental|ATRA+Arsenic|All low- and intermediate-risk patients receive retinoic acid and arsenic trioxide based consolidation. High-risk patients receive ATRA+Arsenic+Anthracycline consolidation.
3317801|NCT01987297|Active Comparator|ATRA+chemo|All low-risk and intermediate-risk patients receive retinoic acid and chemotherapy with idarubicin or daunorubicin as consolidation. High-risk patients receive ATRA+anthracycline and cytarabine as consolidation.
3317802|NCT01987310|Active Comparator|Statin|statin therapy (atorvastatin 20 mg/d) for 6 months
3317803|NCT01987310|No Intervention|usual care|follow up group with no intervention
3317804|NCT01987310|Active Comparator|lifestyle counseling|lifestyle modification by dietician counseling and follow-up
3317805|NCT01987323|Experimental|Lipolat|Subconjunctival injection of Lipolat into the superior bulbar conjunctiva of all enrolled participants
3317806|NCT01987362|Experimental|RO6870810 (Part 1)|Participants will receive escalated doses of RO67870810 SC. RO6870810 will be escalated at a starting dose of 0.03 milligrams per kilogram (mg/kg) to a maximum of 0.85 mg/kg. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
3317807|NCT01987362|Experimental|RO6870810 (Part 2)|Participants will receive RO6870810 at doses up to the MTD or up to the highest dose tested if the MTD is not defined. Treatment will be administered in treatment cycles of either 21 days or 28 days and continued until PD, adverse events which justify treatment withdrawal, non-adherence, non-compliance, investigator decision, lost to follow-up, enrollment in other clinical study, or unacceptable toxicity.
3317808|NCT01987375|Experimental|Cetuximab-IRDye800 Participants|Participants who received the study drug cetuximab-IRDye800, following a loading dose of unlabeled cetuximab
3317809|NCT01987388|Experimental|High Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
3317810|NCT01987388|Experimental|High Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs high intensity exercise (85% of VO2 max), while in the calorimeter.
3317811|NCT01987388|Experimental|Low Intensity Exercise, High Carbohydrate Beverage|Study participant consumes a high carbohydrate beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
3317812|NCT01987388|Experimental|Low Intensity Exercise, High Fat Beverage|Study participant consumes a high fat beverage as part of the day's meals, and performs low intensity exercise (65% of VO2 max), while in the calorimeter.
3317813|NCT01987440|Experimental|Lubricating Gel|The speculum was warmed, and patients were informed about what was going to happen. The labia were spread from below to introduce the speculum, which was inserted at a 45-degree angle pointing downward then rotated horizontally as the insertion continued. A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the gel group , a doctor placed 6,5 mL mL sterile lubricating gel on the top and bottom blades of the speculum. Length of the vagina was measured by the index finger.
3317814|NCT01987440|Placebo Comparator|water|A VAS score (insertion) was obtained at this point. Next, the bill of the speculum was opened up until the vaginal cuff could be seen, and the speculum was secured by turning the thumbnut. A second VAS score (dilation) was recorded. During speculum examination, cervical smear with cervical brush was obtained for pathologic assessment if necessary. The speculum was withdrawn slightly, which allowed the bill to close together, and at this stage (extraction) the final VAS score was obtained. In the water group the speculum's top and bottom blades were moistened with 6,5 mL tap water previously loaded into a syringe kept at room temperature.After the speculum examination, pelvic examination was performed and length of the vagina (defined as distance from vaginal cuff to vaginal apex) was measured by the index finger.
3317815|NCT01987466||Post cardiac arrest patient|
3317816|NCT01987492|Experimental|Lebrikizumab High Dose|Participants will receive lebrikizumab at high dose level as subcutaneous (SC) injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
3317817|NCT01987492|Experimental|Lebrikizumab Low Dose|Participants will receive lebrikizumab at low dose level as SC injection every 4 weeks during the 44-week DBPC period, followed by a 32-week ATE period, and during the LTE period.
3382203|NCT05043441|Experimental|Acceptance and commitment therapy (ACT) group|10 weekly ACT sessions individually guided by a trained coach through Zoom videoconferencing with psychoeducation materials provided
3317818|NCT01987492|Placebo Comparator|Placebo|Participants will receive placebo matching to lebrikizumab SC injection every 4 weeks during the 44-week DBPC period. Participants will then be randomized to receive either high- or low-dose lebrikizumab every 4 weeks during the 32-week ATE period and will continue same treatment in the LTE period.
3317819|NCT01987518||digestive polyposis|Family adenomatous polyposis (APC or MYH genes) Peutz Jeghers Disease Cowden Disease Festooned Polyposis Juvenile Polyposis Hyperplastic Polyposis
3317820|NCT01987531|Experimental|left ventricular epicardial pacing lead|Enrolled patients will have a temporary left ventricular epicardial pacing lead placed in addition to the standard right ventricular and right atrial temporary epicardial pacing leads after open cardiac chamber cardiac surgery.
3317821|NCT01987544|Active Comparator|Self-Control|3 months of ergometer training under self control at home without any interventional motivation.
3317822|NCT01987544|Experimental|Motivation|3 months of ergometer training at home with telemonitoring and motivation phone calls once a week when training sessions drop below 20 minutes per day.
3317823|NCT01987570|Experimental|Allopurinol|One tablet of allopurinol is administrated orally at a dose of 300 mg/24 hours, during the time that the patient remains immobilized for 15 days.
3317824|NCT01987570|Placebo Comparator|Placebo|One tablet/24 hours of placebo orally, during the time that the patient remains immobilized for 15 days.
3317825|NCT01987622|Experimental|Acupuncture|A series of acupuncture sessions within six weeks from the baseline
3317826|NCT01987622|Active Comparator|Usual care|An intervention consisting of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed.
3317827|NCT01987635|Experimental|MEMO 3D anuloplasty ring|MEMO 3D anuloplasty ring
3317828|NCT01987635|Active Comparator|rigid ring|rigid ring
3317830|NCT01987661|Active Comparator|bilevel ventilation BIPAP ST|one night, BIPAP ST ventilation with individually optimised pressure parameters and supplemental oxygen if necessary.
3317831|NCT01987661|Experimental|BIPAP ST plus Airtrap|"one night, BIPAP ST ventilation with Airtrap control, same pressure parameters and oxygen."
3317832|NCT01987674|Experimental|Pre-meal protein drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
3317833|NCT01987674|Placebo Comparator|Water drink|A dose of 100 ml is taken just before breakfast, lunch and dinner.
3317834|NCT01987687|Active Comparator|Rest|Breakfast followed by a rest period prior to OGTT.
3317835|NCT01987687|Experimental|Exercise-immediate|Breakfast followed by exercise and an immediate OGTT
3317836|NCT01987687|Experimental|Exercise-delay|Breakfast followed by exercise and a delayed (1 h) OGTT.
3317837|NCT01987700|Active Comparator|FLEX-HD (underlay)|FLEX-HD human acellular dermal matrix applied using an underlay technique
3317838|NCT01987700|Active Comparator|FLEX-HD (overlay)|FLEX-HD human acellular dermal matrix applied using an overlay technique
3317839|NCT01987700|Active Comparator|Strattice (underlay)|Strattice porcine acellular dermal matrix applied using an underlay technique
3317840|NCT01987700|Active Comparator|Strattice (overlay)|Strattice porcine acellular dermal matrix applied using an overlay technique
3317841|NCT01987713|Experimental|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
3317842|NCT01987726||Observational (NGS, FMI testing)|"PART I: Within 10 weeks of beginning a treatment regimen, tumor tissue samples, Blood Collection and CTCs(Circulating tumor cell)from patients are collected for NGS and FMI testing, respectively. Patients remain on current line of therapy until a change in treatment is warranted. The physician's treatment recommendation is documented prior to the release of the FMI results.~PART II: Physicians are furnished with FMI test results when patients become eligible for a change in therapy and new treatment recommendations are documented. Treatment is dependent on preferences of the physician, patient, and/or results of the FMI test."
3317843|NCT01987739|Experimental|Arm 1|Subjects were randomized to receive single, oral doses of study medication in the sequence ABFCED, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317844|NCT01987739|Experimental|Arm 2|Subjects were randomized to receive single, oral doses of study medication in the sequence BCADFE, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317845|NCT01987739|Experimental|Arm 3|Subjects were randomized to receive single, oral doses of study medication in the sequence CDBEAF, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317846|NCT01987739|Experimental|Arm 4|Subjects were randomized to receive single, oral doses of study medication in the sequence DECFBA, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317847|NCT01987739|Experimental|Arm 5|Subjects were randomized to receive single, oral doses of study medication in the sequence EFDACB, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317848|NCT01987739|Experimental|Arm 6|Subjects were randomized to receive single, oral doses of study medication in the sequence FAEBDC, where, Treatment A was: 200 mg almorexant; Treatment B was 400 mg almorexant; Treatment C was 1000 mg almorexant; Treatment D was 20 mg zolpidem; Treatment E was 40 mg zolpidem; and Treatment F was placebo. The duration of each Treatment Visit was 1 day/2 nights. Study drug was administered on Day 1 of each Treatment Visit. Each treatment was separated by a washout period of at least 10 days.
3317849|NCT01987778|Experimental|Resistance training|The resistance training will be supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
3317850|NCT01987778|No Intervention|Control group|No intervention for 15 weeks but the same registrations, diaries and forms as the intervention group. The control group will however be omitted from muscle strength testing.
3317851|NCT01987804|Experimental|Oxytocin 100 i.u.|N=24 patients are administrated Oxytocin 100 i.u. vaginally
3317852|NCT01987804|Experimental|Oxytocin 400 i.u.|N=24 patients are administrated Oxytocin 400 i.u. vaginally
3317853|NCT01987804|Placebo Comparator|Placebo|N=16 patients are administrated placebo vaginally
3317854|NCT01987843|Experimental|MT-1303-Low|MT-1303-Low Dose
3317855|NCT01987843|Experimental|MT-1303-Middle|MT-1303-Middle Dose
3317856|NCT01987843|Experimental|MT-1303-High|MT-1303-High Dose
3317857|NCT01987843|Placebo Comparator|Placebo|Placebo
3317858|NCT01987856|Active Comparator|aCGH screen|aCGH screen; euploid blastocyst chosen on 23 plus XY chromosome screening plus blastocyst morphology
3317859|NCT01987856|Placebo Comparator|Blastocyst morphology|blastocysts chosen on morphological criteria only; scaled assessment of blastocyst expansion, inner cell mass and trophectoderm morphology
3317860|NCT01987882||"A. Natural History or Watchful Waiting"|
3317861|NCT01987882||B. Serial Botulinum Toxin Injections +/- Abduction Bracing|
3317862|NCT01987882||C. Adductor (+/- psoas) Muscle Releases Alone|
3317863|NCT01987882||D. Hip Reconstructive Surgery|
3317864|NCT01987882||E. Salvage Hip Surgery|
3317865|NCT01987921||Pediatric Intensive Care Unit Patients|All patients will be included in a single cohort initially (admission to the PICU) and then cohorted into groups based on development of severe AKI (Stage 2-3 KDIGO by either Cr or UOP criteria) within the first seven days, renal angina risk strata, medical admission diagnoses, and outcomes.
3317866|NCT01987934||Normal or Control group|Those subjects with normal oral epithelium will be included in this group.
3317867|NCT01987934||Study Group|Those subjects with oral squamous cell carcinoma will be included in this group.
3317868|NCT01987947|Placebo Comparator|Placebo|
3317869|NCT01987947|Active Comparator|Quilizumab|
3317870|NCT01987973|Active Comparator|Partial Repair / Debridement|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair. This is the control group."
3317871|NCT01987973|Experimental|Allograft Reconstruction|"Subjects in this arm of the study will receive the intervention Partial Rotator Cuff Repair with Allograft Augmentation"
3317872|NCT01987999|Experimental|Acetogenins|Acetogenins twice (BID) per day for 12 months
3317873|NCT01988038||No treatment|
3317874|NCT01988064|Experimental|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting pulse abnormalities performed by the nurse.
3317875|NCT01988064|Experimental|Group training|Group training using a tutorial film on calculating the pulse rate and detecting pulse abnormalities.
3317876|NCT01988077|Other|Adoptive cell transfer combined with Ipilimumab|Adoptive cell transfer combined with Ipilimumab
3317877|NCT01988116|Experimental|Oral Calcitriol|Oral Calcitriol 0.5 mcg once daily for 6 weeks
3317878|NCT01988116|Placebo Comparator|Placebo Arm|Placebo capsule 1 Capsule once daily for 6 weeks
3317879|NCT01988142|Experimental|SCI|
3317880|NCT01988155|Active Comparator|Eccentric Exericse|
3317881|NCT01988155|Experimental|Astym|
3317882|NCT01988168|Experimental|Suture closure|Closure of skin with a running subcuticular, absorbable monofilament suture.
3317883|NCT01988168|Active Comparator|Staples closure|Closure of skin with stainless-steel surgical staples.
3317884|NCT01988181|Active Comparator|Best clinical practice HD|All study patients will be dialyzed with the Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany) using high flux dialyzers. For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
3317885|NCT01988181|Experimental|Best clinical practice plus BVM-guided UF biofeedback|Patients in the BVM-guided UF biofeedback (intervention) phase will have the same prescription as the control group but will also have the ultrafiltration rate automatically adjusted by the Fresenius 5008 HD machine based on the changes in the relative blood volume.
3317886|NCT01988194|No Intervention|Usual care|Participants will receive usual care in the hospital.
3317887|NCT01988194|Experimental|Usual care with acupuncture|Participants will receive usual care with acupuncture treatments up to four days per week for the duration of their hospital stay.
3317888|NCT01988207|Experimental|12 Exercise Sessions|Patients will receive 12 treatment sessions with flow phonation exercises, as well as education on vocal hygiene.
3317889|NCT01988207|Active Comparator|6 Hygiene and 6 Exercise|Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
3317890|NCT01988220|Experimental|sensory retraining|sensory identification and discrimination training. using different attention and sensation modalities for sensory retraining
3317891|NCT01988220|Active Comparator|repeated exposure to sensory input|
3317892|NCT01988233|Experimental|BAILAMOS© Dance Program|BAILAMOS© Dance Program + Maintenance Program: includes a 4-month twice-weekly adoption phase and a 4-month twice-weekly maintenance phase. Each month during adoption a new dance style is introduced by a professional dance instructor. During the 4-month maintenance phase an indigenous dance leader, trained by the professional dance instructor, will lead dance with participants twice per week
3317893|NCT01988233|Experimental|Health Education Control Group|Health Education Control Group: Sedentary older Latinos randomly assigned to the health education control group will participate in classes developed for older adults and offered by the University of Illinois Extension. All classes are conducted in Spanish by extension staff using Spanish-language materials. Classes will meet one day per week for two hours, to provide equitable social contact as the treatment group.
3317894|NCT01988259|Active Comparator|Bilateral approach for laminoplasty|Open approach for laminoplasty
3317895|NCT01988259|Active Comparator|Unilateral approach for laminoplasty|Minimally invasive approach for laminoplasty
3317896|NCT01988259|Active Comparator|Subperiosteal approach for foraminotomy|Open approach for foraminotomy
3317897|NCT01988259|Active Comparator|Transmuscular approach for foraminotomy|Minimally invasive approach for foraminotomy
3317898|NCT01988285||Dysphagia and GERD controls|"The cross-sectional arm will consist of patients who are having a clinically indicated endoscopy for reflux and/or dysphagia.~Cross-sectional participants will have specimens collected and complete a questionnaire."
3317899|NCT01988285||Prospective Longitudinal EoE Cases|"The prospective longitudinal group will be subjects who have a positive EoE diagnosis during initial endoscopy. This prospective group will be followed up at their clinically indicated endoscopy after their standard of care clinical therapy of swallowed steroids.~Prospective longitudinal participants will have specimens collected and complete questionnaires s prior to their standard of care clinical therapy of swallowed steroids and at their clinically indicated follow up upper endoscopy."
3317900|NCT01988298|Experimental|Ibuprofen|Experimental: Ibuprofen 400 mg each 8 hours for 2-3 days.
3317901|NCT01988298|Active Comparator|Acetaminophen|Acetaminophen 1 g oral each 6 hours, 2-3 days.
3317902|NCT01988311|Experimental|Drug Only|psilocybin dose manipulation as described in the protocol
3317903|NCT01988311|No Intervention|Cognitive/Behavioral Tasks Only|
3317904|NCT01988311|No Intervention|Imaging Only|
3317905|NCT01988324|Experimental|FES/FDHT-PET|
3317906|NCT01988337|Experimental|Resin infiltration|"One proximal caries lesion (split mouth design) per patient will be treated using the resin infiltrant Icon (DMG, Hamburg, Germany) according to manufactures´ instructions."
3317907|NCT01988337|Sham Comparator|Mock treatment|"A second proximal caries lesion of each patient (split mouth design) will recieve a placebo treatment to mimic resin infiltration."
3317908|NCT01988350||Non-smokers|
3317909|NCT01988350||Smokers|
3317910|NCT01988363|Other|GON injection at C2 location|A 25 gauge, 2 inch spinal needle will be inserted into the symptomatic side after locating the GON via US at the level of C2. Subjects will receive an injection of 4 ml of injectate consisting of 1 ml of 2% Lidocaine, 3 mg betamethasone and 2.5 ml of 0.25% Bupivicaine to the greater occipital nerve at the novel, proximal C2 location.
3317911|NCT01988389|Experimental|whole apples|Subjects are asked to consume 2 apples a day for 8 weeks in addition to their habitual diet
3317912|NCT01988389|Other|apple juice squash|Subjects are asked to consume 100 ml of apple juice squash (recommended dilution with water up to 500 ml) for 8 weeks in addition to their habitual diet. The apple juice is used as a sugar matched control.
3317913|NCT01988428|No Intervention|standard care|"standard care~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
3317914|NCT01988428|Experimental|Antibiotics|"ceftriaxone 2000 mg (after taking bloodcultures)~training of ambulance personnel in recognizing sepsis and initiating pre-hospital treatment"
3317915|NCT01988467|Experimental|nasal breathing|"At the time that the exposure took place with nasal breathing, the study was as follows:~Before the exposure: rhinomanometry, IOS , FeNO , spirometry, plethysmography, P.100.~Exposure to second hand smoking:Each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: rhinomanometry, IOS , FeNO , spirometry,plethysmography , P.100."
3317916|NCT01988467|Experimental|oral breathing|"At the time that the exposure took place with oral breathing, the study was as follows:~Before the exposure: IOS, exhaled nitric oxide (FeNO), spirometry, plethysmography and P.100.~Exposure to second hand smoking: each volunteer was exposed to secondhand smoking twice, for 20 minutes, once with nasal breathing and once with oral breathing, with 3 days interval and in random sequence.~After the exposure: IOS, FeNO, spirometry,plethysmography and P.100."
3317917|NCT01988480|Experimental|Image-guided surgery|Image-guided implant placement
3317918|NCT01988480|Sham Comparator|sinus graft|Sinus lift surgery : Patients receive sinus graft before implant placement
3317919|NCT01988506|Experimental|Interleukin 2|Interleukin 2, 1MUI.= Proleukin®, RhIL-2
3317920|NCT01988519|Active Comparator|Closed suction drain|Two closed suctions drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
3317921|NCT01988519|Active Comparator|Closed gravity drain|Two closed gravity drains will be placed near the pancreatic anastomosis or suture line. The drains will be removed on the 4th or 5th day if the amylase activity is not increased.
3317922|NCT01988532||Adult PWH|
3317923|NCT01988545|Active Comparator|GLP-1|1,5 nmol/kg,GLP-1 sc injection
3317924|NCT01988545|Active Comparator|GLP-1 9-36amide|1,5 nmol/kg GLP-1 9-36amide, sc injection
3317925|NCT01988545|Active Comparator|Exendin-4|Exendin-4 ;10 ug,sc injection
3317926|NCT01988545|Placebo Comparator|isotonic saline|2 ml of isotonic saline, sc injection
3317927|NCT01988558|Experimental|Treated Group|Children diagnosed as suffering from recurrent Tonsillitis (at least 4 episodes per year) to receive DL-Lactic acid syrup twice a day for a month.
3317928|NCT01988558|Placebo Comparator|Placebo Group|
3317931|NCT01988584|Active Comparator|Umbilical Cord Blood (UCB) Arm|Children who have banked UCB with CBR will receive an umbilical cord blood stem cell infusion at the baseline/treatment visit.
3317932|NCT01988584|Active Comparator|Bone Marrow Stem Cells (BMMNC's)|Children in the BMMNC group will undergo bone marrow harvest and stem cell infusion at the baseline/treatment visit.
3317933|NCT01988584|Placebo Comparator|Placebo (inactive substance) Group|Five children in each group will be randomly assigned to receive an inactive substance (placebo) at the baseline/treatment visit. Parents will be given the opportunity to cross-over to either the umbilical cord blood or bone marrow harvest group at the one year visit.
3317934|NCT01988597||Dry Eyes|
3317935|NCT01988610|Experimental|Intervention Group|Open-label trial to assess the effects of Mifepristone on mood and cognition in people with a history of depression.
3317936|NCT01988623|Experimental|Pivotal Response Treatment (PRT)|
3317937|NCT01988636|Experimental|Group 1|Pilot Safety Group- 135000 PfSPZ + 270000 PfSPZ; staggered at Day 0 and 2 weeks
3317938|NCT01988636|Active Comparator|Group 4|Group to start at week 4 after Group 1 is deemed safe - 5 immunizations of 270000 PfSPZ at weeks 4, 8, 12, 16 and 24
3317939|NCT01988636|Placebo Comparator|Group 5|Group to receive placebo at same points as Group 4 - 5 immunizations of normal saline at weeks 4, 8, 12, 16 and 24
3317940|NCT01988649|Active Comparator|Intranasal Oxytocin|Administration of 32 units of Oxytocin administered intranasally
3317941|NCT01988649|Placebo Comparator|Placebo (saline)|Administration of 4 sprays intranasally of normal saline.
3317942|NCT01988675||Partial Brain Irradiation|Patients will receive partial brain irradiation for malignant or benign brain tumors as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
3317943|NCT01988675||Whole Brain Irradiation|Patients will receive whole brain irradiation for brain metastases as standard of care. Patients will also have MRI (Magnetic Resonance Imaging) scans and neuropsychological/QOL (Quality of Life Questionnaire) tests prior during and after RT (Radiation Therapy).
3317944|NCT01988688|Experimental|Bilateral DBS placement in area LC|Bilateral DBS placement in area LC. Devices include Medtronic Activa DBS model 3387 and 3389; Medtronic DBS extension; Medtronic Activa PC or Activa RC neurostimulator; Medtronic Patient Programmer; Medtronic Test Stimulator; Medtronic N/Vision Clinician Programmer
3317945|NCT01988701||Allogeneic SCT Groups|Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
3317946|NCT01988701||Autologous SCT group|Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
3317947|NCT01988714|Experimental|(TCT) plus evidence-based SE|(TCT) plus evidence-based SE
3317948|NCT01988714|Placebo Comparator|(CG) plus evidence-based SE|(CG) plus evidence-based SE
3317949|NCT01988753||Subjects with Liver Fibrosis|"Shearwave elastography is a non-invasive procedure for assessing liver status. Measurements of liver tissue elasticity will be obtained in the right lobe of the liver by using a curvilinear transducer (C5-1, Philips Healthcare) through intercostal spaces.~Biomarker Analysis~A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the purposes of the serum biomarker study. If subjects return for an additional liver biopsy in the future or a standard of care visit they may be asked to provide an additional sample for biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during the liver biopsy to be stained for additional biomarker analysis."
3317950|NCT01988766||Thrombosis|incidence of thrombosis in subjects who had PICC line placement
3317951|NCT01988766||No Thrombosis|no incidence of thrombosis in subjects who had PICC line placement
3317952|NCT01988792|Active Comparator|Fortification at 20 ml/kg/day feeding volume|Human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 20 ml/kg/day.
3317953|NCT01988792|Active Comparator|Fortification at 100 ml/kg/day feeding volume|human milk fortifiers will be added to the human milk when neonates reach to feeding volume of 100 ml/kg/day.
3317954|NCT01988805||Blood Draw|Normal healthy individuals will be consented and their blood drawn at the time of their visit.
3317955|NCT01988818|Active Comparator|Standard wound dressing|As comparator will be used a standard Cosmopor E®adhesive, island wound dressing (Paul Hartmann LTD)after hip or knee arthroplasty or spinal surgery
3317956|NCT01988818|Experimental|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
3317957|NCT01988831|Placebo Comparator|Placebo|"113 patients will be enrolled in the placebo group with respect to randomization.~Placebo group will be prescribed placebo pills in the same packaging as propranolol treated group.~The frequency and duration of the treatment is the same as propranolol arm. The placebo group will have the same cardiology consultation as propranolol treated group to ensure the respect of blindness."
3317958|NCT01988831|Experimental|Betablocker|"drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the Propranolol Group and treated with propranolol.~The dosage will be determined by the cardiologist as the maximum tolerated dose to a maximum of 160mg/day.~One long acting pill a day until an evidence of disease progression or the end of the study."
3317959|NCT01988844||Children with cerebral palsy|Children diagnosed with cerebral palsy are included in this group. An assessment and an intervention will be carried out.
3317960|NCT01988870|Experimental|Intra-operative Radiation Therapy (IORT)|Following breast conserving surgery, a CT-based plan will be prepared to deliver highly conformal IORT and the treatment will be administered.
3317961|NCT01988883|Placebo Comparator|Placebo|Patients will receive two inactive placebo pills filled with microcrystalline cellulose on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3317962|NCT01988883|Experimental|Modafinil|Patients will receive single doses of modafinil (200 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3317963|NCT01988883|Experimental|Propranolol|Patients will receive single doses of propranolol (20 mg, oral) and placebo on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3317964|NCT01988883|Experimental|Modafinil plus Propranolol|Patients will receive single doses of modafinil (200 mg, oral) and propranolol (20 mg, oral) on a randomized study day. Medications will be dummy blinded to the patient and investigators.
3317965|NCT01988896|Experimental|Dose-Escalation: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 milligrams (mg) of atezolizumab IV infusion on Day 1, 15 and 29 of Cycle 1 (cycle length=42 days [14-day run-in period + 28-day concomitant dosing period]), thereafter with atezolizumab IV dosing every 2 weeks (q2w) in all subsequent treatment cycles (28 days each). Combination with cobimetinib will begin on Cycle 1 Day 15 and will be given at increasing dose levels during Stage 1. During Stage 1, cobimetinib will be administered once daily (QD) orally for 21 consecutive days out of 28 days (21/7 dosing schedule) at a starting dose of 20 mg with escalation of 20 mg until the maximum tolerated dose (MTD; not more than 60 mg) for the two-drug combination.
3317966|NCT01988896|Experimental|Dose-Expansion: Cobimetinib, Atezolizumab|Participants will receive single dose of 800 mg of atezolizumab IV infusion q2w in all subsequent treatment cycles (28 days each). Participants will receive cobimetinib at the selected recommended RP2D on Days 1-14 of each 28-day cycle during Stage 2.
3317967|NCT01988909|Experimental|WR 279,396|All patients with the same Study drug: WR 279,396 (Topical Paromomycin and Gentamicin Cream)
3317968|NCT01988935|Experimental|Prolonged Exposure + Smoking Cessation|Prolonged Exposure therapy plus smoking cessation intervention
3317969|NCT01988935|Active Comparator|Smoking Cessation|Smoking cessation intervention
3317970|NCT01988948|Other|student cohort|"Various biological sampling~blood sampling,~oral, vulvar, vaginal and anal sampling for women,~oral and genital sampling for men"
3317971|NCT01988961|Experimental|Golimumab|Participants will receive the approved induction subcutaneous (SC) dose regimen of 200 mg at Week 0 followed by 100 mg at Week 2. At Week 6 and thereafter through Week 50, participants will receive the SC maintenance dosage of golimumab that has been approved for UC in the country in which the study is being conducted. In countries where golimumab is not approved for UC, a maintenance dosage of 100 mg every 4 weeks will be used.
3317972|NCT01988974|Experimental|Alert for AF Program|1) participation in the Alert for Atrial Fibrillation program ) .
3317973|NCT01988974|Active Comparator|Attention control condition|2) participation in the healthy sleep program
3317974|NCT01988987||Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
3317975|NCT01989000|Active Comparator|Neoadjuvant radiochemotherapy|Patients elected for neoadjuvant radiochemotherapy undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before start of the chemoradiation and again after radiochemotherapy (Gemcitabine/Radiotherapy), within two weeks before surgery (Pancreaticoduodenectomy).
3317976|NCT01989000|Active Comparator|Primary Surgery|Patients elected for primary surgery undergo DWI-MRI, DCE-MRI (Gadobutrol),T2*-MRI and [F-18]HX4 PET/CT imaging within two weeks before surgery (Pancreaticoduodenectomy).
3317977|NCT01989013|Other|biweekly intervention|biweekly intervention
3317978|NCT01989026|Active Comparator|BCG at admission to NICU|These children will receive the BCG (and OPV) vaccines at admission to the Neonatal Intensive Care Unit (NICU).
3317979|NCT01989026|No Intervention|BCG at discharge (as usual)|These children will only receive the BCG (and OPV) vaccines at discharge, as per current standard of care.
3317980|NCT01989052|Experimental|Phase 1: CTO and lomustine|The combination of CTO with the standard dosing of 100 mg/m2 of lomustine among patients with recurrent malignant glioma (World Health Organization (WHO) grade III or IV) that have not previously received bevacizumab as treatment for their disease
3317981|NCT01989052|Experimental|Phase 2: CTO alone|CTO alone at the MTD established in the Phase 1 portion of this study
3317982|NCT01989052|Experimental|Phase 2: CTO and lomustine|CTO at the same daily dose of as in the CTO alone arm in combination with 110 mg/m2 oral lomustine every 6 weeks
3317983|NCT01989052|Experimental|Phase 2: Lomustine alone|Oral lomustine alone at 110 mg/m2 every 6 weeks
3317984|NCT01989065|Active Comparator|Lifestyle counseling|The Duke Healthy Lifestyles program is a comprehensive childhood obesity treatment program. Standard of care is active engagement and Lifestyle Counseling of families by nutritionist, physician, mental health provider, and physical therapist. Monthly visits for 1 year are recommended.
3317985|NCT01989065|Experimental|Lifestyle counseling PLUS text messaging|Patients in this arm will receive full standard of care as described for the Active Comparison group. In addition, parents will be texted daily with a motivational message that provides information and support for healthy behaviors.
3317986|NCT01989078|Experimental|Losartan|Participants taking losartan, in addition to taking hydroxyurea therapy, as prescribed per standard of care
3317987|NCT01989091|Experimental|B-Lock (IMD)|Investigational Medical Device (IMD)
3317988|NCT01989091|Active Comparator|Heparin 5,000 U/mL (ACH)|Active Comparator Heparin (ACH)
3317989|NCT01989104||Children|6-12 years of age
3317990|NCT01989104||Adolescents|13-17 years of age
3317991|NCT01989104||Young adults|18-20 years of age
3317992|NCT01989117||Osteopathy|
3317993|NCT01989117||No osteopathy|
3317994|NCT01989143|Experimental|SAD Cohorts 1-8 Experimental Arm|
3317995|NCT01989143|Placebo Comparator|SAD Cohorts 1-8 Placebo Arm|
3317996|NCT01989143|Experimental|MAD Cohorts 9-11 Experimental Arm|
3317997|NCT01989143|Placebo Comparator|MAD Cohorts 9-11 Placebo Arm|
3317998|NCT01989143|Experimental|MAD Cohort 12 Experimental Arm|
3317999|NCT01989143|Placebo Comparator|MAD Cohort 12 Placebo Arm|
3318000|NCT01989182|Experimental|Treatment with Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. Subjects assigned to this group will also receive medical management.
3318001|NCT01989182|Active Comparator|Medical Management|The control group for this study will receive medical management. This medical management group will be evaluated and followed in the same manner as the treatment group, but without having a bronchoscopic procedure.
3318002|NCT01989234|Placebo Comparator|Placebo Comparator|Placebo Comparator
3318003|NCT01989234|Experimental|YKP10811 High Dose|YKP10811 High Dose
3318004|NCT01989234|Experimental|YKP10811 Mid Dose|YKP10811 Mid Dose
3318005|NCT01989234|Experimental|YKP10811 Low Dose|YKP10811 Low Dose
3318006|NCT01989247|Experimental|Self-management program|Seven weekly sessions of a group-based self-management programme for people with anxiety and depressive symptoms
3318007|NCT01989247|No Intervention|Control group|
3318008|NCT01989260|Other|Anti-adhesive gel|An anti-adhesive gel will be administered to one ovary (randomised at the time of laparoscopic surgery to severe endometriosis). The coated ovary will be compared to the non-coated ovary 3 months after surgery to assess for the presence of post-operative ovarian adhesions. Neither the patient nor the person performing the ultrasound scan assessing for the presence of ovarian adhesions will know which was the ovary coated in the anti-adhesive gel.
3318009|NCT01989273||IVC Collapsibility >50% or IVC < 12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility >50% or IVC diameter less than or equal to 12mm
3318010|NCT01989273||IVC Collapsibility <50% or IVC >12mm|Major Trauma Victims admitted at Level I Trauma Center with an inferior vena cava collapsibility <50% or IVC diameter >12mm
3318011|NCT01989286||Plagiocephaly group-Assessment|Children (3-5 years) who were diagnosed and treated because of positional plagiocephaly are included in this group. An asssessment of posture will be performed.
3318012|NCT01989312|Active Comparator|supraclavicular block|A supraclavicular block with 32 mL of lidocaine 1.5% + epinephrine 5µg/mL was performed for the anaesthetic management of the forearm and hand.
3318013|NCT01989312|Active Comparator|Supraclavicular and median, ulnar, radial blocks|Patients in this group received 20 mL of lidocaine 1.5% + epinephrine 5µg/mL for supraclavicular block and after the supraclavicular block they recieved a distal median, radial, and ulnar nerve blocks using 50:50 mixture of lidocaine 2% + levobupivacaine 0.5% (4 mL/nerve).
3318014|NCT01989325|Experimental|Carfilzomib + Filanesib|"Single agent + Carfilzomib arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information.~Filgrastim to be administered per the approved product prescribing information and institutional guidelines."
3318015|NCT01989325|Experimental|Carfilzomib|"Single agent arm.~Patients will be hydrated prior to and following carfilzomib administration and will be premedicated with dexamethasone, per the carfilzomib prescribing information."
3318016|NCT01989338||Hallux valgus patients|Females patients with hallux valgus asses for pain, function, and quality of life
3318017|NCT01989351||VAS<4|
3318018|NCT01989351||VAS>4|
3318019|NCT01989403||Lumbar disc herniation patients|LBP with sciatica, with a numeral rating scale (NRS) leg pain intensity of 5 or higher and onset within 1 year; (2) LDH confirmed by MRI
3318020|NCT01989416|Placebo Comparator|Soap bathing|ICU patients will be bathing with soap at least once daily
3318021|NCT01989416|Experimental|2% chlorhexidine wipes|Use 2% chlorhexidine wipes to clean the patient at least once daily
3318022|NCT01989429|Active Comparator|Daivonex|topical application
3318023|NCT01989429|Placebo Comparator|vehicle|topical application
3318024|NCT01989429|Experimental|M518101|topical application
3318025|NCT01989442|Experimental|Nasal Mask|patients who receive NIV by nasal mask interface after randomization
3318026|NCT01989442|Active Comparator|nasal prong|patients who receive NIV by nasal prongs as interface after randomization
3318027|NCT01989494||Attendings|Anesthesiology Attendings who will wear a pedometer for five days while at work
3318028|NCT01989494||CA1 Residents|Anesthesiology residents in their first year of anesthesiology residency who will wear a pedometer for five days while at work
3318029|NCT01989494||CA2 and CA3 Residents|Anesthesiology residents in their second year of anesthesiology residency who will wear a pedometer for five days while at work
3318030|NCT01989507|Experimental|Very low nicotine content cigarettes|Cigarettes with Nicotine Yield 0.07 ± 0.02
3318031|NCT01989507|Active Comparator|Conventional nicotine content cigarettes|Cigarettes with Nicotine Yield 0.8 ± 0.15
3318032|NCT01989520|Experimental|Treatment A|Phase IIb formulation
3318033|NCT01989520|Experimental|Treatment B|Putative phase III formulation
3318034|NCT01989520|Experimental|Treatment C|Slow dissolution variant 1
3318035|NCT01989520|Experimental|Treatment D|Slow dissolution variant 2
3318036|NCT01989520|Experimental|Treatment E|Optional treatment that may use one of 3 45 mg (intermediate dissolution variant) of AZD5069
3318037|NCT01989533|Placebo Comparator|A|Placebo controlled (blinded)
3318038|NCT01989533|Active Comparator|B|Intranasal Randomized
3318039|NCT01989533|Experimental|C|Oral Open label
3318040|NCT01989533|Experimental|D|Intranasal Open Label
3318041|NCT01989559|Experimental|Treatment (vaccine therapy)|Patients receive gp100:209-217(210M) peptide vaccine and HPV 16 E7:12-20 peptide vaccine with Montanide ISA 51 VG or Montanide ISA 51 SC on day 1 and between days 25-30. After 6 months, patients free of disease receive booster injections every 6 months for 3 years in the absence of unacceptable toxicity or disease progression.
3318042|NCT01989598|Experimental|Treatment (trametinib, Akt inhibitor GSK2141795)|Patients receive trametinib orally PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with progressive disease or who achieve less than PR after 4 courses may also receive Akt inhibitor GSK2141795 PO daily on days 1-28.
3318043|NCT01989611|Other|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year.
3318044|NCT01989624||Pancreatic Adenocarcinoma|
3318045|NCT01989637|Experimental|Strawberry Meal|40 g freeze-dried strawberries included in test meal
3318046|NCT01989637|Placebo Comparator|Control Meal|Control consisting of matched test meal with strawberry flavoring instead of freeze-dried strawberry powder
3318047|NCT01989650|Active Comparator|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
3318048|NCT01989650|No Intervention|No break|No break will be provided
3318049|NCT01989663|Experimental|1% vaginally applied tenofovir gel|1% vaginally applied tenofovir gel administered for 7 daily doses
3318050|NCT01989663|Placebo Comparator|HEC placebo vaginal gel|HEC placebo vaginal gel administered for 7 daily doses
3318051|NCT01989663|Experimental|Tenofovir film- 10mg|Tenofovir Film 10mg inserted vaginally, administered for 7 daily doses
3318052|NCT01989663|Experimental|Tenofovir Film-40 mg|Tenofovir Gel 40 mg inserted vaginally, administered for 7 daily doses
3318053|NCT01989663|Placebo Comparator|Placebo Film|Placebo Film inserted vaginally, administered for 7 daily doses
3318054|NCT01989676|Experimental|PF-05280014|
3318055|NCT01989676|Active Comparator|Herceptin®|
3318056|NCT01989702|Active Comparator|Fermented blueberry product|
3318057|NCT01989702|Placebo Comparator|Placebo|
3318058|NCT01989702|Active Comparator|Probiotic bacteria|
3318059|NCT01989715|Experimental|adult patients waiting for orthognathic surgery|
3318060|NCT01989728|Active Comparator|care as usual|
3318061|NCT01989728|Experimental|psychiatric examination and feedback|
3318062|NCT01989741|Other|sleep restriction|Longitudinal study of response to sleep restriction. Comparison between baseline values and sleep restriction values
3318063|NCT01989767|Active Comparator|control|Rehabilitation as usual
3318064|NCT01989767|Experimental|education|education of rehabilitation officers in psychiatric topics plus rehabilitation as usual
3318065|NCT01989780|Active Comparator|Arm A|weekly paclitaxel + bevacizumab
3318066|NCT01989780|Experimental|Arm B|"weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice)* + bevacizumab then back to weekly paclitaxel + bevacizumab~* Letrozole, Anastrozole, Exemestane, Fulvestrant, Goserelin, leuprorelin or LHRH Analogs + Aromatase inhibitors."
3318067|NCT01989806|Active Comparator|Robotic-assisted body weight supported treadmill training|Robotic assisted body weight supported treadmill training with conventional PT training
3318068|NCT01989806|Placebo Comparator|Passive lower limbs mobilization training|Passive lower limbs mobilization training with conventional PT training
3318069|NCT01989819||patients with Sjögren's syndrome|A skin biopsy will be performed in patients
3318070|NCT01989819||control group|A skin biopsy will be performed in control group
3318071|NCT01989819||non auto-immune small fiber neuropathies|
3318072|NCT01989832||Biological and clinical Data collected|
3318073|NCT01989845|Experimental|oral rivaroxaban in cancer-associated VTE|
3318074|NCT01989858|Experimental|peri-operative CHT (Arm A)|In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
3318075|NCT01989858|Active Comparator|post-operative CHT (Arm B)|In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
3318076|NCT01989858|Experimental|peri-operative CHT + post-operative CHT-RTX (Arm C)|CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
3318077|NCT01989858|Active Comparator|post-operative CHT + post-operative CHT-RTX (Arm D)|surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
3318078|NCT01989871|No Intervention|protocol feeding|Feeding of preterm infants according to current unit protocol: every 3 hours a prescribed amount
3318079|NCT01989871|Experimental|Adjusted individual feeding|Feeding every 2-4 hours, starting with que of hunger and finished upon infant signs.
3318080|NCT01989884|Experimental|Ortataxel|75 on day 1 every 21 days mg/m2 milligram(s)/square meter (intravenous use)
3318081|NCT01989897|Experimental|diluents|Negative control = diluent, saline with HSA--phenol Positive control = saline with 1mg/ml Histamine base
3318082|NCT01989923|Active Comparator|Nicotine replacement therapy|"Women in this arm of the study will receive 24-hour Nicotine Patches - either 21 mg patches (for 1 pack per day smokers), or 14 mg patches (for 1/2 pack per day smokers) smokers). Patients will use one patch per day for 6 weeks for a total of 42 patches. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.~Women will also receive nicotine gum or lozenges (subject choice)- these will be 2 mg pieces of nicotine gum or lozenge (approximately 210 pieces). This will account for using 8-10 per day at the beginning of the study and tapering to 2-3 pieces per day by the end of the study."
3318083|NCT01989923|Active Comparator|Electronic Cigarettes|"Women in this arm of the study will receive one Blu Cig Electronic Nicotine Delivery Device (E-cigarette) along with 2 electronic cigarette batteries, 1 wall charger and 1 USB charger, cartridges/refills in menthol or regular (patient choice). The number of cartridges is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation."
3318084|NCT01989936|Placebo Comparator|Placebo|
3318085|NCT01989936|Experimental|Eletriptan 40 mg|
3318086|NCT01989936|Experimental|Eletriptan 80 mg|
3318088|NCT01989962|Experimental|E4E Intervention Group|E4E Intervention Group is a group of family physicians who will participate in the first wave of E4E intervention.
3318089|NCT01989962|Sham Comparator|E4E Late Intervention Control Group|E4E Late Intervention Control Group is a group of family physicians who will participate in the second wave of E4E intervention 12 month later after the completion of the first wave of E4E intervention.
3318090|NCT01989988|Active Comparator|LRYGB|20 subjects Randomized will undergo LRYGB surgery
3318091|NCT01989988|Active Comparator|SADJB|20 subjects will undergo SADJB surgery
3318092|NCT01989988|Active Comparator|LMGB|20 subjects will undergo LMGB surgery
3382204|NCT05043441|Sham Comparator|Psychoeducation control group|Care as usual with psychoeducation materials provided
3382207|NCT05040360|Experimental|Arm I (capecitabine, temozolomide)|Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
3382208|NCT05040360|No Intervention|Arm II (surveillance)|Patients undergo surveillance with no active treatment.
3382211|NCT05036148||Patients indicated for MH screening|Patients referred to MH center for MH diagnostic
3382214|NCT05031624|Experimental|CDX-0159|Subjects will receive a single dose of CDX-0159
3382215|NCT05031624|Placebo Comparator|Normal Saline|Subjects will receive a single dose of normal saline
3318093|NCT01990001|Experimental|Office enrollment in the online contraceptive reminder system|Members of this arm were enrolled in the reminder system during their visit.
3318094|NCT01990001|No Intervention|Control|Members in the control group were not enrolled in the reminder system
3318095|NCT01990014||craniectomy|Adult subjects who experienced a cerebral infarction extended the sylvian area, and having received treatment by decompressive craniectomy.
3318096|NCT01990027||SKSC Patients group|"A group a 1000 subjects affected by kidney stone as described in the eligibility criteria will be recruited in the period 2014-2024 and the same exams will be repeated for each participants for a period of 3 years.~No intervention will be undertaken."
3318097|NCT01990027||SKSC Control group|"A group of 250 stone-free participants will be recruited and analysed with the same protocol as the patients but in a single visit. This group will be used for comparison with the patients group in future studies.~No intervention will be undertaken."
3318098|NCT01990040||Teduglutide treated|SBS participants who have been treated with teduglutide.
3382217|NCT05028660||Cohort 1|At least 76 patients with MIBC and elected for NAC
3382218|NCT05028634|Experimental|Cohort 1 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
3382219|NCT05028634|Experimental|Cohort 1 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), Pneumococcal polysaccharide vaccine (PPSV23), and the seasonal inactivated influenza vaccine.
3382220|NCT05028634|Experimental|Cohort 2 - Ozanimod|Comprises of participants received oral ozanimod will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap), and pneumococcal polysaccharide vaccine (PPSV23).
3382221|NCT05028634|Experimental|Cohort 2 - non-pegylated interferon-β or no disease modifying therapy|Comprises of participants received either non-pegylated interferon-β (IFN-β) or no disease modifying therapy (DMT) will be administered tetanus, diphtheria, and acellular pertussis vaccine (Tdap) and Pneumococcal polysaccharide vaccine (PPSV23).
3382234|NCT05024994|Experimental|E7820|Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
3382237|NCT05020990|Experimental|Lens A (Test)|Subjects will be randomized to wear Lens A (Test) toric lens for one week.
3318099|NCT01990040||Non-teduglutide treated|SBS participants who have not been treated with teduglutide.
3318100|NCT01990053|Experimental|Beating the Blues|Beating the Blues plus helper support.
3382238|NCT05020990|Active Comparator|Lens B (Control)|Subjects will be randomized to wear Lens B (control) toric lens for one week.
3318101|NCT01990053|No Intervention|Waitlist Condition|Eight week waitlist condition group parallel to the immediate treatment condition with optional entrance into the Beating the Blues after the first eight weeks
3318102|NCT01990066|Experimental|Intervention|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
3318103|NCT01990066|No Intervention|Observation|Subjects randomized to observation will only have physical therapy assessment using the Berg Balance Test and 6min Walk Test at baseline and end point. These subjects will not receive any exercise teaching.
3318104|NCT01990079|Experimental|QUIT4Ever|QUIT4EVER is an intervention that combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, mobile contingency management, and the smart-phone application Stay Quit Coach.
3318105|NCT01990079|Active Comparator|Control Contact Condition|This intervention combines 4 guideline-based smoking cessation counseling sessions, bupropion and nicotine replacement therapy, and mobile contingency management.
3318106|NCT01990092|Experimental|Metanx|Subjects will take 2 Metanx tablets once daily for 48 weeks.
3318107|NCT01990092|Placebo Comparator|Placebo|Subjects will take 2 placebo tablets once daily for 48 weeks.
3318108|NCT01990105||Patients with AF in the ER|All patients with ECG-diagnosed AF who attend emergency clinics for examination or treatment of arrhythmia or other cardiac diseases during the study period will be included.
3318109|NCT01990118|Active Comparator|Neoral|Patients who continued to be treated with the drug Neoral.
3318110|NCT01990118|Experimental|Gengraf arm|Patients were randomly selected to be converted to 'Gengraf® capsule containing 25mg or 100mg cyclosporine'
3318111|NCT01990131|Experimental|Intervention|The anxiety risk reduction condition will be a combination of psychoeducation plus Cognitive Bias Modification (CBM-I) for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
3318112|NCT01990131|Placebo Comparator|Control|The control condition will be a combination of information about general health and wellness (e.g. diet, exercise etc.) plus an inert Cognitive Bias Modification (CBM-I) task.
3318113|NCT01990144|Experimental|Bendamustine|Bendamustine is a novel chemotherapeutic agent, a hybrid of a purine analogue and an alkylator. It shows only partial in vitro cross-resistance with other alkylating agents and it is clinically well tolerated. In fact it has shown to be active in vitro against cell lines which are resistant to other alkylating agents. Preclinical data demonstrate that bendamustine acts in two distinct ways to kill cancer cells: it damages the DNA in cancer cells, which leads to cell death by a process known as apoptosis (programmed cell death) as well as by an alternate cell death pathway known as mitotic catastrophe (a disruption of normal cell division). This dual-effect may be attributable to its unique chemical structure.Bendamustine has demonstrated clinical activity in patients with chronic lymphocytic leukaemia, patients with relapsed indolent NHL, mantle cell lymphoma, multiple myeloma and several solid tumors.
3318114|NCT01990157|Experimental|TAB08|Multiple TAB08 administrations as intravenous infusions.
3318115|NCT01990170||ultrasound-guided foam sclerotherapy|This project is ongoing from an original study conducted by our research group looking at short- and mid-term clinical outcomes after UGFS. The original patient cohort from the aforementioned study was made up of 132 patients who underwent UGFS between 1 March 2005 and 31 December 2009 for treatment of a chronic venous ulcer (CEAP classification C5 or C6 disease) with significant (>0.5s) SVR confirmed with duplex ultrasound.
3318116|NCT01990183|Experimental|CareToy|CareToy intervention
3318117|NCT01990183|Other|Standard Care|Standard Care
3318118|NCT01990196|Active Comparator|AR inhibition only|"AR inhibition only Group 1: degarelix + enzalutamide~Endocrine therapy with degarelix and enzalutamide will continue for a minimum of 6 weeks and a maximum of 8 weeks in all groups prior to the planned prostatectomy."
3318119|NCT01990196|Active Comparator|AR inhibition plus MEK inhibition|"AR inhibition plus MEK inhibition Group 2: trametinib + degarelix + enzalutamide~In Group 2, treatment with trametinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, trametinib will be administered for no less than two weeks and no more than four weeks."
3318120|NCT01990196|Active Comparator|AR inhibition plus SRC inhibition|"AR inhibition plus SRC inhibition Group 3: dasatinib + degarelix + enzalutamide~In Group 3, treatment with dasatinib will begin on Day 29 (i.e. four weeks after initiation of androgen deprivation). Thus, dasatinib will be administered for no less than two weeks and no more than four weeks."
3318121|NCT01990209|Experimental|Orteronel|The planned dose of orteronel is 300mg orally (PO) twice daily (BID), for a total daily dose of 600mg.
3318122|NCT01990235|Experimental|PREPARE intervention|The PREPARE arm will review the PREPARE website plus the easy-to-read advance directive (AD). Participants will review PREPARE on their own for ≥ 20 minutes with staff present to answer questions. During PREPARE, participants answer preference questions and make an action plan (i.e., commitment to engage in advance care planning). To ensure home access to PREPARE content, participants will be given a website login and PREPARE content in digital video disc (DVD), booklet, and pamphlet format as well as the action plan and AD. One to three days before a primary care visit, the PREPARE arm will receive a reminder to come to their appointment and to bring their action plan.
3318123|NCT01990235|No Intervention|Control|The Control arm will review an easy-to-read AD. Controls will review the AD for ≥ 15 minutes with study staff present to answer questions and will take the AD home to complete if desired. One to three days before a primary care visit, controls will receive a reminder to come to their appointment.
3318124|NCT01990248||Cohort|
3318125|NCT01990274|Experimental|Novel|Patients in this arm will receive 3 sputum samples for GeneXpert MTB/RIF assay and MGIT liquid TB culture.
3318126|NCT01990274|Active Comparator|Standard|Patients in this arm will receive 2 sputum samples for fluorescence smear microscopy and MGIT liquid TB culture.
3318127|NCT01990287|Experimental|SCS and PNfS|Eon or Eon Mini IPG with epidural leads in the spinal column and subcutaneous leads in the peripheral field
3382240|NCT05010694|Experimental|Monotherapy Dose Escalation.|Treatment with GH35 alone, conducted until disease progression, intolerance or end of study.
3318128|NCT01990287|Active Comparator|SCS Alone|Eon or Eon Mini IPG with epidural leads in the spinal column
3382242|NCT05009862|Placebo Comparator|Control|Participants will receive 81mg daily of aspirin + placebo for 30 days.
3382243|NCT05009862|Experimental|Intervention|Participants will receive 81mg of aspirin + rivaroxaban 2.5mg twice daily for 30 days.
3382244|NCT05008835|Experimental|Drug - ACP-044 Dose A|ACP-044 Dose A
3318129|NCT01990326|Experimental|XAF5 Gel|The patient will apply XAF5 Gel to the skin of the submental area once a night.
3382245|NCT05008835|Experimental|Drug - ACP-044 Dose B|ACP-044 Dose B
3382246|NCT05008835|Placebo Comparator|Placebo|Placebo
3382247|NCT05008055|Experimental|Capivasertib monotherapy|Participants with R/R FL, R/R MZL, and R/R MCL will receive capivasertib orally until progression of disease (PD) or unacceptable toxicity.
3318130|NCT01990326|Placebo Comparator|Placebo Gel|The patient will apply a Placebo Gel to the skin of the submental area once a night.
3382256|NCT05006573|Experimental|Benralizumab|Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
3382257|NCT05006573|Placebo Comparator|Placebo|Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
3318131|NCT01990352|Experimental|Pegylated liposomal doxorubicin|
3382258|NCT05006456||Cohort 1|Cohort 1 consists of 2000 subjects undergoing catheter ablation with STSF catheter, in which AI is used to guide the ablation lesion creation.
3382259|NCT05006456||Cohort 2|Cohort 2 consists of 2000 subjects who undergoing catheter ablation using QDOT or HELIOSTAR catheter.
3382261|NCT05005390|Experimental|Group A (TTIP ventilation then mask ventilation )|Subjects will first be ventilated with the TTIP technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1).Subjects will then be ventilated with mask ventilation (Step 2).In Step 1, if ventilation fails with the TTIP technique for all of the first three consecutive breaths, the subject will be crossed over to the mask ventilation. If ventilation fails again with all the first three consecutive breaths after crossover,the study will be terminated.The routine care is resumed including tracheal intubation or laryngeal mask airway (LMA) insertion.
3318132|NCT01990391|Placebo Comparator|Cassava flavored flour|The placebo group (cassava flour flavored) received 9g/day of cassava flour flavored during three months (12 weeks)
3318133|NCT01990391|Experimental|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months (12 weeks)
3318134|NCT01990404|Active Comparator|Premixed 50% nitrous oxide and oxygen|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. Premixed 50% nitrous oxide and oxygen is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
3382262|NCT05005390|Active Comparator|Group B (mask ventilation, then TTIP ventilation)|Subjects will first be ventilated with the mask technique. If the subjects are adequately ventilated, as defined by carbon dioxide measured during exhalation in at least one of the first three consecutive breaths, ventilation will continue until completion of 10 breaths, for 1 min (Step 1).Subjects will then be ventilated with TTIP technique (Step 2).In Step 1, if ventilation fails for all of the first three consecutive breaths, the subject will be crossed over to the TTIP ventilation. If ventilation fails again with all the first three consecutive breaths after crossover,the study will be terminated.The routine care is resumed including tracheal intubation or LMA insertion.
3382263|NCT05002803|Experimental|Otago Exercise Program|Older adults will receive the Arabic Otago Exercise Program for 8 weeks plus health awareness videos.
3318135|NCT01990404|Placebo Comparator|Medical air|The patient will be taken care by the physician SMUR or home emergency. Upon acceptance of participation in the study, the clock will be started at the time of the establishment of the face mask. The medical air is administered for 30 minutes and an opioid titration is started 10 minutes after the introduction of gas, unless the patient expresses pain score EN <3/10.
3382264|NCT05002803|No Intervention|Control group|Older adults will receive only health awareness videos every 2 weeks.
3382265|NCT04996901||derivation cohort|Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital，and Wuhan Third Hospital will be used as a derivation cohort.
3382266|NCT04996901||validation cohort|Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.
3382267|NCT04995237|Experimental|Prescription Produce Plan (PPP)|PPP provides access to fresh produce along with individual goal setting and education
3318136|NCT01990417|Experimental|Passive stretching|After evaluation, the participants were randomly divided into four groups: A, B, C and D. Group A. stretched before and after workout ; group B stretched only before workout; group C stretched only after workout; and group D did not stretch at all.
3318137|NCT01990430|Experimental|Exercise Intervention|"The exercise program was designed and conducted by a qualified exercise physiologist with oncologic training. The exercise program consisted in a twice weekly supervised training program developed in a social framework. The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation.~The nutrition program consisted of three theoretical and practice classes, where specific terms of nutrition and diet were explained. Teachers did not promote avoiding any group of aliments and a Mediterranean diet was encouraged to be followed."
3318138|NCT01990430|No Intervention|Control|Patients will be asked to maintain their usual life style, without special changes
3382268|NCT04991467|Experimental|Parents of children receiving mental health treatment at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app .
3382269|NCT04991467|Experimental|Parents of children being treated for autoimmune disorders at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
3382270|NCT04991467|Experimental|Healthcare workers at Montefiore|Participants will either CARE program alone; b) Valera Health app; c) CARE program and Valera Health app.
3318139|NCT01990443|Experimental|Reslizumab IV|Reslizumab 220-mg administered Intravenously (IV)
3318140|NCT01990443|Experimental|Reslizumab SC|Reslizumab 220-mg administered Subcutaneously (SC)
3318141|NCT01990456|Experimental|PHASE 1: impact of tidal ventilation on VILI|In the first phase we will test whether administering a distending inspiratory pressure to produce tidal ventilation is superior to a strategy where only continuous positive airway pressure (CPAP) is applied for ventilation induced lung injury (VILI) mitigation, as assessed by its impact on biotrauma (serum cytokines) and physiologic measurements.
3318142|NCT01990456|Experimental|PHASE 2: impact of PEEP on VILI|In the second phase we will gain more insight as to whether a strategy that utilizes a PEEP level that correspond to best compliance is beneficial over Zero End-Expiratory Pressure (ZEEP). We will test the impact of both strategies on biotrauma (serum cytokines), physiologic parameters, and right ventricular function (transesophageal echocardiographic assessment).
3318143|NCT01990469|Experimental|Gemigliptin|Gemigliptin 50mg qd
3318144|NCT01990469|Placebo Comparator|Placebo|Gemigliptin placebo
3318145|NCT01990482|Experimental|coffee|coffee
3318146|NCT01990482|Placebo Comparator|water group|water
3318147|NCT01990508|Experimental|Targeted beverage education and financial incentives|Study subjects receive monthly letters with beverage education and financial incentives for not purchasing sugar-sweetened beverages
3318148|NCT01990508|Sham Comparator|Control|Monthly letters with generic nutrition information only
3318149|NCT01990521|Experimental|MS3TMRI / TRUS Guided Biopsy|
3318150|NCT01990547||Healthy Veterans|Healthy veterans, who have been deployed in support of OIF/OEF who do not have blast exposure or PTSD
3318151|NCT01990547||Veterans with history of blast exposure|OIF/OEF veterans with a history of blast exposure who do not meet criteria for PTSD
3318152|NCT01990547||Veterans with PTSD receiving usual care|OIF/OEF veterans with PTSD (with or without blast exposure) only who receive usual care (i.e., pharmacotherapy and/or supportive or psychodynamic individual or group therapy, not involving exposure therapy)
3318153|NCT01990547||Veterans with PTSD receiving Virtual Reality Exposure Therapy|"OIF/OEF veterans with PTSD (with or without blast exposure) that will receive Virtual Reality Exposure Therapy through the WRNMMC IRB approved protocol entitled Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure with Cognitive Enhancer ClinicalTrials.gov Identifier: NCT01352637, which is also open to new enrollment"
3318154|NCT01990599|Other|Nasopharyngeal Tube|Every patient undergoing trigeminal thermal coagulation of the Gasserian ganglion will be ventilated by a nasopharyngeal placed ID 5mm tube during the whole neurosurgical intervention.
3318155|NCT01990625|Experimental|Ultrasound scan|The group is pregnant women who reside in an intervention cluster who receive at least one antenatal ultrasound scan during antenatal care during the study time period.
3318156|NCT01990625|No Intervention|Routine antenatal care|The group is pregnant women that reside in the control clusters during the study time period. The group received routine antenatal care.
3318157|NCT01990638||DM group|
3318158|NCT01990638||non-DM group|
3318159|NCT01990690|Active Comparator|anti oxidant omega 3|The patients were randomized to receive either a daily dose of omega-3 plus as antioxidant once daily for two weeks or a daily placebo then stored in envelopes numbered from 1 to 140
3318160|NCT01990690|Placebo Comparator|placebo|"Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.~Group 2 was given a placebo once daily for two weeks."
3318161|NCT01990716|Other|IBD patients|Patients (diagnosed with IBD) having a screening colonic biopsy
3318162|NCT01990716|Other|Control Group|individuals undergoing screening colonic biopsy for colon cancer or polyp detection, who have not been diagnosed with any intestinal pathology.
3318163|NCT01990729||ARTRA|Patients with low back pain treated with ARTRA.
3318164|NCT01990755|Active Comparator|CBT (Cognitive Behavioral Therapy)|"Investigates the effects of cognitive-behavioral therapy (CBT), on the secretion of brain dopamine (DA), noradrenalin (NE) and serotonin (5-HT) in a group of 50 female inpatients, 14 with AN restricter type (AN-R), 14 with the bingeing-purging type (AN-BP), and 22 with BN.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
3318165|NCT01990755|Active Comparator|IBPP (IP brief psychotherapy )|"Investigates the effects in 15 AN and 17 BN patients of an individual psychology brief psychotherapy (IBPP) on psychological alterations and DA secretion measured as peripheral blood values of HVA before and after treatment.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation."
3318166|NCT01990755|Active Comparator|CBT + OLANZAPINE (5 MG)|"The study evaluated in 18 AN-R and 12 AN-BP patients the effects of CBT and of CBT associated with orally administered 5 mg olanzapine on the psychopathological aspects of the disease and on the secretion of HVA.~Associated intervention (non of interest): psychiatric management (with tranquillizer: delorazepam), nutritional rehabilitation"
3318167|NCT01990781|Experimental|Group LD: Lidocaine and Dexamethasone|lidocaine 1.5 mg/kg and dexamethasone (dexona) 8 mg iv prior to induction of anesthesia
3318168|NCT01990781|Active Comparator|Group L: Lidocaine|Group L: lidocaine 1.5 mg/kg iv prior to induction of anesthesia
3318169|NCT01990781|Active Comparator|D: Dexamethasone|Dexamethasone 8 mg iv prior to induction of anesthesia
3318170|NCT01990781|Placebo Comparator|N: normal saline|N: normal saline (placebo): 2 ml
3318171|NCT01990807|Active Comparator|Idarubicin(IDA)|philadelphia negative high -risk ALL : Induction therapy: IDA(6mg/m2/time) one time for each week,altogether 3 times
3318172|NCT01990846|Experimental|Flufirvitide-3 dose level 1|Single dose administration for dose level 1
3318173|NCT01990846|Experimental|Flufirvitide 3-Dose level 2|Single dose administration for Dose Level 2
3318174|NCT01990846|Placebo Comparator|Placebo|Single Dose administration Placebo for Flufirvitide-3
3318175|NCT01990846|Experimental|Flufirvitide-3 Dose level 1- Repeat dose|Repeat dose administration for five days
3318176|NCT01990846|Experimental|Flufirvitide-3-Dose level 2 Repeat dose|Repeat dose administration for 5 days
3318177|NCT01990846|Placebo Comparator|Placebo for Flufirvitide-3 Repeat dose|Repeat dose administration for 5 days
3318178|NCT01990872|Placebo Comparator|Placebo in high calcium group|Placebo + habitual dietary calcium intake (>1000 mg/d)
3318179|NCT01990872|Active Comparator|Vitamin D3 in low/moderate calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake <700 mg/d
3318180|NCT01990872|Placebo Comparator|Placebo in low/moderate calcium group|Placebo + habitual calcium intake <700 mg/d
3318181|NCT01990872|Active Comparator|Vitamin D3 in high calcium group|Vitamin D3 (20 microgram/day) + habitual calcium intake (>1000 mg/d)
3318182|NCT01990885|Experimental|Cohort A|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
3318183|NCT01990885|Experimental|Cohort B|Each subject will receive a single administration of either BL-7010 (at different amounts) or matching Placebo on 3 treatment occasions in a randomized double-blind fashion
3318184|NCT01990885|Experimental|Cohort C|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from Cohorts A and B) in a randomized double-blind fashion
3318185|NCT01990885|Experimental|Cohort D|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
3318186|NCT01990885|Experimental|Cohort E|Each Subject will receive either BL-7010 or Placebo 3 times a day for 14 days(amount to be based on results from previous cohorts) in a randomized double-blind fashion
3318187|NCT01990911|Experimental|Renal denervation|Renal denervation: both renal arteries are denervated by applying radio-frequency energy at application points moving in a helical fashion starting in the distal renal artery and moving to the proximal junction with the abdominal aorta.
3318188|NCT01990911|Sham Comparator|Medical therapy|This group will not receive renal sympathetic denervation
3318189|NCT01990924|Experimental|7.5 FPS|Low rate fluoroscopy at 7.5 frames per second (FPS)
3318190|NCT01990924|Active Comparator|15 FPS|Conventional rate fluoroscopy at 15 FPS
3318191|NCT01990937|Active Comparator|Oral midazolam|Oral midazolam (5 mg) in 15 mL of apple juice was drunk 30 minutes before EGD
3318192|NCT01990937|Placebo Comparator|Apple juice|15 mL of apple juice was drunk 30 minutes before EGD
3318193|NCT01990976||FSHD training|Only the patients who have participated to the FSHD1 study (NCT01116570) and the FSHD2 study (NCT01689480) can be included in this study.
3318194|NCT01990989||Clopidogrel treated patients|A consecutive cohort with 500 cases treated with 75mg/day maintenance dose of clopidogrel.
3318195|NCT01991002|Other|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
3318196|NCT01991028|Experimental|Radiolabelled OligoG CF-5/20 DPI|Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
3318197|NCT01991028|Active Comparator|Radiolabelled OligoG CF-5/20 6% Solution|Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
3318198|NCT01991041||Rufinamide|
3318199|NCT01991041||Anti-Epileptic Drugs|Includes those used off label as part of local clinical practice
3318200|NCT01991054|Experimental|vitamin D3 supplementation|The study group participants will receive vitamin D3 supplementation (120,000 I.U per month)for 6 months
3318201|NCT01991054|Placebo Comparator|placebo group|placebo group, 15 ml per month for 6 months
3318202|NCT01991080|Active Comparator|Wheatgerm juice|patients will drink Wheatgerm juice
3318203|NCT01991080|Active Comparator|Biofeedback|The patients will undergo biofeedback relaxation therapy
3318204|NCT01991106|Experimental|High intensity interval training|10-minute warm up at 60-70% of maximal heart rate (HRmax). Then walking, running or cycling at 85-95% of maximal heart rate at intervals of 4 x 4 minutes, with 3 minute active breaks (50-70% of HRmax) between intervals. A 5-minute cool down period.
3318205|NCT01991106|Experimental|Moderate intensity continuous training|walking, running or cycling continuously at 60-70% HRmax for 44 minutes.
3318206|NCT01991106|Active Comparator|nutritional advice|10 individual nutrition consultations with an accredited dietitian over the 12 month period. Content of consultations will include healthy food choices, portion sizes and regular mealtimes.
3318207|NCT01991106|No Intervention|non-obese children|100 healthy non-obese children aged 7-16 (controls)
3318208|NCT01991119|Active Comparator|Propafenone|Propafenone group
3318209|NCT01991119|Active Comparator|Dronedarone|Dronedarone group
3318210|NCT01991132|Other|MediView 2.0 software|
3318211|NCT01991145|Experimental|UCB and EPO|UCB + EPO + Rehabilitation
3318212|NCT01991145|Active Comparator|UCB and placebo EPO|UCB + placebo EPO + Rehabilitation
3318213|NCT01991145|Active Comparator|placebo UCB and EPO|placebo UCB + EPO + Rehabilitation
3318214|NCT01991145|Placebo Comparator|placebo UCB and placebo EPO|placebo UCB + placebo EPO + Rehabilitation
3318215|NCT01991158|Experimental|GAD-M regimen|GAD-M regimen means High dose of methotrexate combined with gemcitabine, pegaspargase and dexamethasone
3318216|NCT01991171|Experimental|Kinesio Taping|Participant will receive application of Kinesiotaping in their thigh on quadriceps muscle
3318217|NCT01991171|Placebo Comparator|Kinesio Taping Placebo|Participant will receive application of placebo Kinesiotaping in their thigh on quadriceps muscle
3318218|NCT01991171|No Intervention|Control Group|This participants will not receive intervention
3318220|NCT01991210|Experimental|DNIB0600A|DNIB0600A will be administered on Day 1 of each cycle (1 cycle = 21 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
3318221|NCT01991210|Active Comparator|PLD|PLD will be administered on Day 1 of each cycle (1 cycle = 28 days) until significant toxicity, disease progression, or withdrawal from the study (overall up to approximately 2.5 years).
3318222|NCT01991223|Placebo Comparator|Placebo group|NS infusion will be done during surgery.
3318223|NCT01991223|Experimental|Dex group|DEX infusion will be done during surgery.
3318224|NCT01991236|Experimental|Video|An educational video discussing the benefits and risk associated with long term usage of systemic corticosteroids.
3318225|NCT01991236|Other|Standard script|Standard scripted discussion of risks and benefits of systemic corticosteroids read to participants.
3318226|NCT01991249|Experimental|blood sample|
3318227|NCT01991262||Group 1 phone call and SMS reminder.|cloosed no one enrolled
3318228|NCT01991262||Group 2 phone call only.|cloosed no one enrolled
3318229|NCT01991262||Group 3 SMS reminder only .|cloosed no one enrolled
3318230|NCT01991262||Group 4 (Control) no support|cloosed no one enrolled
3318231|NCT01991275|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia.
3318232|NCT01991275|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia.
3318233|NCT01991288|Experimental|SNB Saphenous Nerve block|Patients received SNB preoperatively at mid thigh level with ultrasound guidance. 10 mls 0.5% bupivacaine was administered for nerve block by the anesthetist. All patients also received peri operative Local Infiltration Analgesia by the surgeon. All patients will receive preoperative oxycontin, peri operative paracetamol and diclofenac. Post operatively all patients received regular paracetamol 1g 6 hourly, Diclofenac sodium 12 hourly and oxycontin 10-20 mg 12 hourly. All patients received standardized spinal block by the same anesthetist, post nerve block for surgery.
3318234|NCT01991288|Active Comparator|NSNB Non Saphenous Nerve Block|Patients only received Local Infiltration Analgesia. As per protocol all patients received the same pre, peri and post operative analgesia as described in the experimental group. All patients had a standardized spinal block for surgery.
3318235|NCT01991301|Experimental|carfilzumib|Carfilzomib at a dose of 20mg/m2 I.V. will be administrated at day 1, 2 post infusion of the stem cell (SC) graft to the first 10 patients. If no > grade II toxicity* the next 10 patients will receive Carfilzomib (27 mg/m2) at day 1,2 and 8, 9, 15 and 16. If no > grade II toxicity* the next 10 patients will receive 2-3 cycles of Carfilzomib (27 mg/m2) administered at day 1,2 8,9,15 and 16 post SC graft infusion.
3318236|NCT01991327|Experimental|Androxal|Androxal 25 mg capsules once a day for 7 days
3382281|NCT04973150|Experimental|the children were given gauze covering training in one eye or both eyes|According to the operation method, the children were given gauze covering training in one eye or both eyes.
3382282|NCT04973150|No Intervention|Using regular tablet computer to play cartoon animation video|
3318237|NCT01991327|Active Comparator|Placebo Androxal|
3382293|NCT04969250|Experimental|Group I1|Immediate, one dose. Vaccination at study entry
3382294|NCT04969250|Experimental|Group I2|Immediate, two doses. Vaccination at study entry and Week 4
3382295|NCT04969250|Experimental|Group D1|Deferred, one dose. Vaccination at Week 12 only
3382296|NCT04969250|Experimental|Group D2|Deferred, two doses. Vaccination at Week 12 and Week 16
3382297|NCT04968574|Experimental|ENV-101|taladegib, 200 mg tablet, once daily for 12 weeks
3382298|NCT04968574|Placebo Comparator|placebo|placebo, tablet, once daily for 12 weeks
3382299|NCT04967885|Experimental|Immediate Intervention|Participants in the Immediate Intervention condition will create their Implementation Intention (II) messages before the two-week EMA + EMI-II period begins. During the EMA + EMI-II period, participants will complete five daily EMAs, and they will also complete weekly assessments reporting their past week cigarette smoking as a distal outcome and rating intervention acceptability. Following the EMA + EMI-II period, participants will enter a two-week follow-up period. During this time, participants will not receive any messages, but will report past week smoking on a weekly basis.
3382300|NCT04967885|Active Comparator|Waitlist|Participants randomized to the Waitlist control condition will begin with a two-week no intervention condition during which they will report past week smoking on a weekly basis but will not receive any other intervention components. At the end of the two-week waitlist control period, participants will begin the two-week EMA plus EMI-II period. During the EMA plus EMI-II active study period, participants will complete five daily EMAs and weekly assessments to report their past week cigarette smoking and rate intervention acceptability. No follow-up is planned for the wait list control condition.
3382301|NCT04965064|Experimental|Experimental: Capecitabine and Neratinib.|"Neratinib 240 mg PO QD Daily On-going~Capecitabine 750 mg/m2 PO bid Days 1-14, 7 days off On-going"
3318238|NCT01991340||Cohort|
3318239|NCT01991353|Experimental|With PRP|Standardized meniscal repair with PRP (platelet rich plasma) in the meniscal healing bed.
3318240|NCT01991353|Active Comparator|Without PRP|Standardized meniscal repair without PRP (platelet rich plasma).
3318241|NCT01991366||Eptifibatide Pre PCI|Receive eptifibatide pre PCI
3318242|NCT01991366||Eptifibatide during PCI|Receive eptifibatide during PCI
3382305|NCT04959903|Experimental|Adult patients affected by acute leukemia (AML, ALL)|
3382306|NCT04959903|Experimental|Pediatric patients affected by acute leukemia (AML, ALL)|
3382307|NCT04959760|Experimental|BinaxNow Covid-19 Antibody test|The BinaxNOW™ Antibody Tests measure SARS-CoV-2 S-IgG antibodies.
3382308|NCT04959266|Experimental|Arm A|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with itraconazole.
3382309|NCT04959266|Experimental|Arm B|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with rifampicin.
3382310|NCT04959266|Experimental|Arm C|Patients will receive a single oral dose of adavosertib alone, and a single oral dose of adavosertib concomitantly with omeprazole.
3318243|NCT01991366||No Eptifibatide|Receive no eptifibatide
3318244|NCT01991379|Experimental|MEK162 in Combination With Imatinib Mesylate|Pts will be treated with the combination therapy of MEK162 & imatinib. The phase Ib portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the standard 3+3 escalation doses. Phase Ib expansion cohort, pts will receive the RP2D: imatinib 400 mg once daily (standard of care first line imatinib dose) & MEK162 at the RP2D twice daily. The phase II portion of the study, pts will receive imatinib at 400 mg once daily & MEK162 at the RP2D. The MEK162 RP2D was originally determined based on the phase Ib escalation data & it was established as 45 mg BID. After the completion of the phase Ib dose expansion & initiation of phase II, the MEK162 RP2D was reduced to 30 mg BID30 for better long term tolerability. Patient's will now begin MEK162 at the revised RP2D of 30 mg BID. 1 cycle is 28 days. If no progression of the tumor is seen, pts will continue on therapy. Pts who have progression of disease will proceed directly to second line therapy as per standard of care.
3318245|NCT01991392|Active Comparator|Maintaining tube|Maintain nasogastric tube after extubation following pancreaticoduodenectomy
3318246|NCT01991392|Experimental|Non-tube|Remove nasogastric tube after extubation following pancreaticoduodenectomy
3318247|NCT01991405|Sham Comparator|Computerized Working Memory Training.|The Working Memory Training, includes both auditive and visual tasks, administrated on a computer, under guidance. 5 x 45 minutes per week, for 5 weeks. The placebo group will train at an fixed level (non-adaptive), but with otherwise identical computer programs.
3318248|NCT01991418||early staged non-small cell lung cancer|patients diagnosed as early staged non-small cell lung cancer and received surgery in HunanPTH
3318249|NCT01991431||TAVI|All Patients undergoing transaortic transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve with the Ascendra+ Delivery-System in participating sites
3318250|NCT01991444||TAVI patients of > 79 years|"All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.~Routine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
3318251|NCT01991457|Other|Treatment|Fludarabine, Total Body Irradiation (TBI)
3318252|NCT01991509|Experimental|LBR-101 IV Dose 1|LBR-101 Dose 1 Administered Intravenously
3318253|NCT01991509|Experimental|LBR-101 SC Dose 1|LBR-101 Dose 1 Administered Subcutaneously
3318254|NCT01991509|Placebo Comparator|Placebo IV|Placebo Administered Intravenously
3318255|NCT01991509|Placebo Comparator|Placebo SC|Placebo Administered Subcutaneously
3318256|NCT01991509|Experimental|LBR-101 Dose 2 IV|LBR-101 Dose 2 Administered Intravenously
3318257|NCT01991509|Experimental|LBR-101 Dose 2 SC|LBR-101 Dose 2 Administered Subcutaneously
3318258|NCT01991561|Experimental|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
3318259|NCT01991561|Experimental|Med dose H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine + Alhydrogel, 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
3318260|NCT01991561|Experimental|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
3318261|NCT01991561|Experimental|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
3318262|NCT01991561|Experimental|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
3318263|NCT01991561|Placebo Comparator|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
3318264|NCT01991574|Placebo Comparator|Methylcellulose|On one of the study days: ingest one methylcellulose capsule with a test meal rich in phosphate.
3318265|NCT01991574|Active Comparator|Calcium Acetate|On one of the study days: ingest 667 mg calcium acetate, equivalent to 169 mg elemental calcium, with a test meal rich in phosphate.
3318266|NCT01991574|Experimental|Iron Hydroxide Adipate|On one of the study days: ingest 800 mg ferric hydroxide adipate, equivalent to 175 mg elemental iron, with a test meal rich in phosphate.
3318267|NCT01991587|Experimental|Low dose of quadrivalent VLP vaccine|Biological: A single low dose of quadrivalent VLP vaccine
3318268|NCT01991587|Experimental|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
3318269|NCT01991587|Experimental|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
3318270|NCT01991587|Placebo Comparator|Placebo|A single dose of Placebo
3318271|NCT01991600|Active Comparator|Ferrous Sulphate|The active comparator was the standard-of-care therapy for iron deficiency anaemia (namely ferrous sulphate). Generic uncoated ferrous sulphate tablets BP 300 mg containing 60mg elemental iron were purchased from a local pharmacy. The route of administration was oral. Each participant ingested one ferrous sulphate tablet (60 mg Fe) on one of the study visits.
3318272|NCT01991600|Experimental|ferric iron oxide-organic acid (Fe-OA)|Fifteen different ferric iron oxide-organic acid preparations were investigated. Most organic acids used were generally recognised as safe (GRAS) and all were used at dietary equivalent levels. The dosage was 58 ± 6 mg elemental iron equivalent (average of all compounds). The route of administration was oral using methyl-cellulose capsules. On one of the study visits, each participant ingested a single dose, equivalent to ca. 60 mg iron, of the Fe-OA preparation allocated to her.
3318273|NCT01991613|Experimental|liquid protein supplement|Study subjects will receive standard of care nutrition with the addition of a liquid protein supplement when the baby is able to tolerate an enteral feeding volume of 40mL/kg/day.
3318274|NCT01991613|No Intervention|Control group|Study subjects will receive standard of care nutrition
3318275|NCT01991626|Other|LNS|Maize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
3318276|NCT01991626|Other|FePP-Emulsion mixed|Fat emulsion mixed to the meal containing FePP
3318277|NCT01991626|Other|FeSO4-Mixed|meals containing FeSO4 mixed with a fat emulsion
3318278|NCT01991626|Other|FePP-Emulsion before|Fat emulsion taken before a meal containing FePP
3318279|NCT01991626|Other|FeSO4- Emulsion before|Fat emulsion taken before a maize meal containing FeSO4
3318280|NCT01991626|Other|LNS-Phytase|Maize meal mixed with LNS containing micronutrient powder and phytase
3318281|NCT01991626|Other|phytase|Maize meal containing micronutrient powder and phytase
3318282|NCT01991626|Other|MNP-control|maize meal containing micronutrient powder (MNP)
3318283|NCT01991626|Other|FePP control|Maize meal containing FePP
3318284|NCT01991626|Other|FeSO4 control|Maize meal containing FeSO4
3318285|NCT01991639|No Intervention|cognitive training|Participants are visited twice a week by buddies, but they do not specifically monitor the nutritional status or perform physical training in the first 10-12 weeks. Instead of that buddies are provided with a portfolio of possible activities, especially cognitive training, which they could perform together with the frail, malnourished subjects.
3318286|NCT01991639|Experimental|nutritional & physical activity|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
3318287|NCT01991652||Wilms tumour|"Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy (= standard care).~One group of patients."
3318288|NCT01991665|Other|Group A|Digital examination before instrumental delivery to determine fetal head station and position
3318289|NCT01991665|Other|Group B|Digital examination before instrumental delivery to determine fetal head station and position + sonography evaluation of fetal head position
3318290|NCT01991678|Experimental|normal hepatic function|12 Patients will receive a 90-minute IV infusion
3318291|NCT01991678|Experimental|mild hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
3318292|NCT01991678|Experimental|severe hepatic dysfunction|6 Patients will receive a 90-minute IV infusion
3318293|NCT01991691|Experimental|Tablet-based reported outcome|With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.
3318294|NCT01991717|Experimental|Victus Group|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
3318295|NCT01991717|Other|Conventional Group|The Conventional Group acts as a control group where the capsulotomy as well as the lens fragmentation is performed manually
3318296|NCT01991756||AAA|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm will be treated with the Altura Endograft System.
3318297|NCT01991769|Experimental|exercise diabetes type 2|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
3318298|NCT01991769|Active Comparator|exercise healthy volunteers|4x4 min interval training, 47 min moderate intensity training, or no exercise preceding an 'unhealthy' meal.
3318299|NCT01991782|No Intervention|Control|Control patients with all follow-up visits in person at the Vanderbilt Orthopaedic Trauma clinic (2 weeks, 6 weeks, 3 months, and 6 months post-operative).
3318300|NCT01991782|Experimental|Telemedicine|Experimental cohort with two follow-up visits (6 weeks and 6 months) occurring via telemedicine video calls and two follow-up visits (2 weeks and 3 months) occurring in person.
3318301|NCT01991834|Placebo Comparator|Placebo|Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
3318302|NCT01991834|Active Comparator|Cefazolin|Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
3318303|NCT01991847|Experimental|Physical activity|Physical activity
3318304|NCT01991873|Experimental|Maintenance Chemotherapy + Panitumumab|"Maintenance therapy:~Panitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
3318305|NCT01991873|Experimental|Maintenance Chemotherapy w/o Panitumumab|"Maintenance therapy:~Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15~Re-induction upon progression:~Panitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.~mFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
3318306|NCT01991886|Experimental|nasal High Flow applied|Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
3318307|NCT01991899|Experimental|MMR Bio-Manguinhos|Arm 1:1170 children will receive MMR Bio-Manguinhos, 3 diferents lots
3318308|NCT01991899|Active Comparator|MMR GlaxoSmithKline|Arm 2:390 children will receive MMR GlaxoSmithKline
3318309|NCT01991912|Experimental|irrigation endoscopic decompression|endoscopic decompression is performed for cases of lumbar spinal stenosis.Portals 0.5cm in size are used for the introduction of the instruments and the endoscope. Saline under pump pressure is used to open a potential working space. This is followed by performing an ipsilateral hemilaminotomy and contralateral decompression under the midline structure
3318310|NCT01991925||quality of life, quality of care|
3318311|NCT01991938|Experimental|VS-5584|Oral VS-5584 administered once daily on Day 1, 3, 5, 8, 10, 12, 15, 17 and 19 of each cycle
3318312|NCT01991951|Experimental|Short term warfarin group|taking warfarin for only 2 weeks after catheter ablation of atrial fibrillation
3318313|NCT01991951|Active Comparator|Conventional therapy arm|conventional warfarin therapy of 3 weeks before and 8 weeks after catheter ablation of AF
3318314|NCT01991964|Experimental|laryngeal ultrasound stridor|During the study period, infants referred for FLB and bronchoscopy due to congenital stridor at the Department of Pediatric Pulmonology, Critical Care and Sleep Medicine at the Tel Aviv Sourasky Medical Centre will undergo an awake US of the larynx prior to performing the Flexible bronchoscopy.
3318315|NCT01991964|Other|laryngeal ultrasound -control|Infants matched for age referred for flexible bronchoscopy for reasons other than stridor will undergo an awake US of the larynx.
3318316|NCT01992003||Patients undergoing spine surgery|
3318317|NCT01992029||ALS Patients|
3318318|NCT01992029||Control patients suffering from neuropathy|
3318319|NCT01992029||Control patients suffering from myopathy|
3318320|NCT01992029||Control subjects|control patients without any neurological disease having an orthopedic surgery for shoulder disease
3318321|NCT01992042|Experimental|Fluvastatin/Pimonidazole|Patients will take 40mg BID of fluvastatin. The day before surgery patients will take a single dose of pimonidazole that will be calculate based on body surface area.
3382314|NCT04958954||Cohort 1: Pre-COVID|All participants meeting eligibility criteria in the Pre-COVID-19 period (immediately preceding the emergence of COVID-19) (Time Period 1) from 01 December 2018 to 30 November 2019
3382315|NCT04958954||Cohort 2: Active-COVID|All participants meeting eligibility criteria in the Active-COVID-19 period, Pre-Emergency Use Authorization (EUA) period (following the emergence of COVID-19 but before the first COVID-19 vaccine EUA) (Time Period 2) from 01 December 2019 to 10 December 2020 (1 day prior to first United States SARS-CoV-2 vaccine EUA)
3382316|NCT04958954||Cohort 3: Post-EUA|All mRNA-1273 vaccinated participants meeting eligibility criteria in the Post-EUA period (Time Period 3) from date of first United States SARS-CoV-2 vaccine EUA to 31 December 2022
3382317|NCT04958174||Users|Users of the web-application
3318322|NCT01992055|Experimental|Goal Management Training|The modified GMT intervention will consist of seven group sessions and, similar to van Hooren et al (2007), an individual session with a neuropsychologist on Session 5. Sessions will be held twice weekly. The manualized group sessions will include: (1) structured psychoeducation introducing participants to the brain and executive functioning, the relationship between stress and cognitive functioning, and relaxation training; (2) stepwise learning of GMT, including education regarding attentional lapses and goal neglect, as well as in-session practice targeting individual everyday functional deficits with the goal of maximizing generalization. Homework assignments targeting individual functional deficits will be assigned following each session.
3318323|NCT01992055|Active Comparator|Education & relaxation training|Education and relaxation training control group
3318324|NCT01992068||Lung cancer patients ≥ 18 years of age|"Lung cancer patients age ≥ 18 years or older who have:~Histologically confirmed lung cancer scheduled to undergo conventionally fractionated radiation treatment~Absence of any severe disorders of esophageal motility (patients with reflux and/or a hiatal hernia are eligible)"
3318325|NCT01992081|Experimental|Telecoaching|Participants will receive daily coaching by an automated telehealth system and coaching by the investigator during study visits, in addition to the usual care.
3318326|NCT01992081|Other|Control|Participants will receive the usual care but will NOT receive daily coaching by telehealth system.
3382320|NCT04956575|Experimental|Phase 1/2: mRNA-1010 Dose Level A|Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.
3382321|NCT04956575|Experimental|Phase 1/2 and Phase 2 NH: mRNA-1010 Dose Level B|Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
3382322|NCT04956575|Experimental|Phase 1/2 and Phase 2 NH: mRNA-1010 Dose Level C|Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.
3382323|NCT04956575|Experimental|Phase 1/2: Placebo|Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.
3318327|NCT01992120|Experimental|Debriefing of high-fidelity sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment focusing on perceptions of their knowledge and ability in the recognition and management of sepsis in hospitalized patient~Subjects will be specifically exposed to high-fidelity simulated sepsis scenarios and be debriefed on their performance in these scenarios (intervention)~Subjects will take a written test focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
3382324|NCT04956575|Active Comparator|Phase 2 NH: Active Comparator|Participants will receive active comparator by IM injection on Day 1.
3382325|NCT04956575|Experimental|Phase 2 NH: mRNA-1010 Dose Level D|Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
3382326|NCT04955808||Ancillary-correlative (biospecimen collection)|Patients undergo collection of tumor tissue during surgery. Patients also undergo blood samples. Samples collected may undergo genetic analysis including whole exome sequencing.
3382327|NCT04952701|Active Comparator|Control Lens|All subjects will wear control lenses for two weeks and then will wear Test lenses for two weeks.
3382328|NCT04952701|Experimental|Test Lens|After wearing control lenses for two weeks, all subjects will wear test lenses for two weeks.
3382330|NCT04949620|Experimental|REThink game, then responder monitoring|Participants in this group will have access to the REThink game for four weeks; based on their response to the intervention, they will be monitored for an additional period of four weeks.
3318328|NCT01992120|Placebo Comparator|Debriefing of high-fidelity non-sepsis simulation scenarios|"First visit:~Subjects will fill out a self-assessment survey of their perceptions of their knowledge and ability in the recognition and management of sepsis in the hospitalized patient~Subjects will be exposed to high-fidelity simulation scenarios (non-sepsis) and be debriefed in terms of their performance in these scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will receive a didactic teaching session focusing on recognition and management of early sepsis in the hospitalized patient~In the second visit:~Subjects will be exposed to a number of high-fidelity simulated sepsis scenarios and be scored on their performance in management of the scenarios~Subjects will take a written test of knowledge focusing on early recognition and management of sepsis~Subjects will then be debriefed specifically on their performance in the simulation scenarios"
3318329|NCT01992133|Experimental|Vitamin D3|Vitamin D3 at 4000 iu per day for 6 months
3318330|NCT01992133|Placebo Comparator|Placebo|matching placebo- capsules containing soya oil at 4 capsules a day for 6 months
3318331|NCT01992146|Placebo Comparator|Placebo|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.
3318332|NCT01992146|Experimental|Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)|Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.
3318333|NCT01992198|Experimental|cefoperazone + metronidazole|cefoperaozone 2g q8h + MDZ 0.5g q8h Oral care Somatostatin 3-6mg per 24h enteral nutrition
3318334|NCT01992198|Active Comparator|meropenem|Meropenem 0.5g q6h or adapted with renal function. Oral care Somatostatin 3-6mg per 24h enteral nutrition
3318335|NCT01992211|Experimental|Treatment Sequence 1(ABC)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
3318336|NCT01992211|Experimental|Treatment Sequence 2(ACB)|"Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
3318337|NCT01992211|Experimental|Treatment Sequence 3(BAC)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 15Day."
3318338|NCT01992211|Experimental|Treatment Sequence 4(BCA)|"Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
3318339|NCT01992211|Experimental|Treatment Sequence 5(CAB)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 8Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 15Day."
3318340|NCT01992211|Experimental|Treatment Sequence 6(CBA)|"Participant will be administered a single oral dose of BCWP_C003 under Fed condition on 1Day.~Participant will be administered a single oral dose of BCWP_C003 under Fasting condition on 8Day.~Participant will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition on 15Day."
3318341|NCT01992224|Experimental|early mechanical ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation~Abbreivation: PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SvO2, venous oxygen saturation"
3318342|NCT01992224|Experimental|conventional mechanical ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
3318343|NCT01992237||ALI patients|Patients with ARDS by Berlin definition and with or without clinical indication for ECMO treatment.
3318344|NCT01992250|Other|Low Risk - Age 70+|Age 70+. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
3318345|NCT01992250|Other|Moderate Risk - Age 50-69|Age between 50-69. Patients treated with the Visica 2 Treatment System, followed by adjuvant therapies
3318346|NCT01992263|Experimental|Vitamin D (600 IU)|
3318347|NCT01992263|Experimental|Vitamin D (2000 IU)|
3318348|NCT01992263|Experimental|Vitamin D (4000 IU)|
3318349|NCT01992263|Placebo Comparator|Placebo|
3318350|NCT01992276|Experimental|CR8020|Investigational monoclonal antibody against influenza A viruses
3318351|NCT01992276|Experimental|CR6261|Investigational monoclonal antibody against influenza A viruses
3318352|NCT01992276|Placebo Comparator|Placebo|Dextrose: 5% in water
3318353|NCT01992289||No treatment|This is a long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002.
3318354|NCT01992302||Rapid Cycling Group|Patients who develop a rapid cycling course during the follow-up period.
3318355|NCT01992302||Non Rapid Cycling Group|Patients who do not develop a rapid cycling course during the follow-up period.
3318356|NCT01992315|Experimental|Adipose-Derived ECM|
3318357|NCT01992328|Experimental|Immune Globulin|Immunoglobulin G Deficiency Associated with persistent asthma subtypes
3318358|NCT01992341|Experimental|AMG 386 15mg/kg and paclitaxel 80mg/m2|
3318359|NCT01992367|Placebo Comparator|Placebo|placebo arm
3318360|NCT01992367|Other|ASLAN003|Active drug
3318361|NCT01992393|Experimental|TIME|This arm will receive the TIME intervention.
3318362|NCT01992393|No Intervention|Treatment as Usual (TAU)|This arm will receive treatment as usual.
3318363|NCT01992406||Transrectal hybrid-NOTES anterior resection|
3318364|NCT01992432||Single-group study: chemotherapy|Single-group study: chemotherapy
3318365|NCT01992445||Suicidal|
3318366|NCT01992445||Other mental health|
3318367|NCT01992445||Control (non suicidal, non mental health)|
3318368|NCT01992471||history of breast cancer who have undergone BRCA1/2 testing|This is a single-arm observational study. Subjects with a history of breast cancer who have undergone BRCA1/2 testing and have received uninformative findings will enroll in this study, and then receive pre-test counseling for multiplex testing.
3318369|NCT01992497|Placebo Comparator|Formula + placebo|
3318370|NCT01992497|Experimental|Formula + probiotic|Formula + probiotic
3318371|NCT01992497|Experimental|Breastfed + probiotic|Breastfed + probiotic
3318372|NCT01992497|Placebo Comparator|Breastfed + placebo|
3318373|NCT01992510||silicone oil fiiled eye|those with a condition
3318374|NCT01992510||fellow eye|the contralateral eye in the same patient
3318375|NCT01992562|Experimental|Treatment|5 mcg ziconotide in 1ml of normal saline bolus intrathecal injection
3318376|NCT01992562|Placebo Comparator|Placebo|1ml of normal saline bolus intrathecal injection
3318377|NCT01992575||Retinal Vein Occlusion Group|Up to 35 patients diagnosed with retinal vein occlusions will be considered and evaluated for enrollment in this study.
3318378|NCT01992588|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3318379|NCT01992588|Experimental|NovoRapid® followed by FIAsp|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3318380|NCT01992601|Experimental|1|This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
3318381|NCT01992601|Experimental|2|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2.
3318382|NCT01992601|Experimental|3|This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2.
3318383|NCT01992601|Experimental|4|This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2.
3318384|NCT01992614|Experimental|Cohort 1|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3318385|NCT01992614|Experimental|Cohort 2|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3318386|NCT01992614|Experimental|Cohort 3|Single ascending doses of PF-06678552 or placebo to investigate the safety, tolerability, PK, and PD.
3318387|NCT01992627|Experimental|High Intensity Laser Therapy|High Intensity Laser Therapy (HILTERAPIA HIRO 3.O)will be used among diagnosed patients with elbow epicondylosis. A five minutes duration of HILTERAPIA HIRO 3.0 along the epicondyle area in a targeted manner will be use on the initial treatment, one week after the initial treatment, two weeks after the initial treatment and four weeks after the initial treatment thereafter.
3318388|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
3318389|NCT01992653|Experimental|Polatuzumab Vedotin (1.0mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3318390|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
3318391|NCT01992653|Experimental|Polatuzumab Vedotin (1.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3318392|NCT01992653|Experimental|Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3318393|NCT01992653|Experimental|Polatuzumab Vedotin (2.4mg) + R-CHP|Dose Escalation: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3318394|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + R-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with R-CHP.
3318395|NCT01992653|Experimental|Expansion: Polatuzumab Vedotin (1.8mg) + G-CHP|Dose Expansion: Participants will receive a total of six to eight 21-day cycles of polatuzumab vedotin in combination with G-CHP.
3318396|NCT01992666|Experimental|Blood sampling|
3318397|NCT01992679|No Intervention|Control|Participants in the control group will undergo the same assessments but receive no exercise stimulus and be asked to maintain current physical levels
3318398|NCT01992679|Experimental|Exercise group|The exercise program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training.
3318399|NCT01992692||PD group|Parkinsonian patients undergoing deep brain stimulator insertion and pulse generator placement
3318400|NCT01992692||non-PD group|Non-Parkinsonian patients undergoing intracranial surgery
3318401|NCT01992705|Other|Chemotherapy+SBRT prior to surgery if applicable|"FOLFIRINOX Drugs:~Calcium Folinate (Folinic Acid) 400 mg IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles.~Stereotactic Body Radiotherapy (SBRT):~30 Gy in 5 fractions given to radiographically defined pancreatic mass alone"
3318402|NCT01992718|Active Comparator|Evaluation of MRI, US for pelvic conditions|MRI and ultrasound imaging will be used clinically to evaluate pelvic pain and abnormal uterine bleeding. The goal is to determine which exams are most helpful to the clinician in providing an accurate diagnosis as well as evaluating patient preference.
3318403|NCT01992718|Active Comparator|Patient preference MRI vs. US|We are asking subjects to evaluate patient preference between MRI (magnetic resonance imaging) and ultrasound to determine which they would rather undergo.
3318404|NCT01992731|Active Comparator|IUI group|"Group 1: Patients undergo a standard treatment with 3 consecutive gonadotrophin stimulated IUI cycles Intervention: treatment choice and drug:(Follitropine Bèta, Puregon, MSD).~vs."
3318405|NCT01992731|Active Comparator|IVF/ICSI arm|"Group 2: 1 Patients start immediately with IVF/ICSI instead of IUI. A standard antagonist protocol with treatment with a recombinant FSH (Follitropine Bèta, Puregon, MSD) is used.~Intervention: treatment choice and drug: recombinant FSH (Follitropine Bèta, Puregon,"
3318406|NCT01992744||Healthy Pregnant Women|Participants 8 to 12 weeks gestational age as determined by their physician.
3318407|NCT01992770|Experimental|Tailored behavioural medicine|After having received a minimal intervention (step 1) comprising 'stay-active advice', participants scoring >90 on the Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) are randomly allocated to an eight-week treatment in step 2, depending on risk profile. The experimental condition includes supervised physical exercises integrated with either (a) graded activity, or (b) hierarchical graded exposure depending on risk profile, i.e. absence or presence of pain catastrophizing and fear-avoidance beliefs.
3318408|NCT01992770|Active Comparator|Control group|"Participants will be scheduled for supervised, regular Physical exercises twice a week during eight weeks 8. Participants with a moderate to high disability risk profile will receive: Tailored graded activities training."
3318409|NCT01992783|Experimental|Hi-maize resistant starch|13.5 g/day
3318410|NCT01992783|Placebo Comparator|Maltodextrin|13.5 g/day
3318411|NCT01992796|Experimental|irbesartan|"Irbesartan (total dose of 75 mg) or placebo administered every 24 hrs for 15 days. Moreover, the sepsis management will follow standard international guidelines (Crit Care Med.2008 Jan;36(1):296-327. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock).~Duration of treatment: Irbesartan 75 mg daily for 15 days; only one cycle. Follow up will last 90 days both for treatment and control arm.~Route of administration : oral by nasogastric tube.~Medication permitted and not permitted during the trial:~all the therapeutic interventions for sepsis management as indicated by international guidelines are admitted. During the trial are not permitted: ACE inhibitors, ARBs different from Irbersartan, angiotensin I synthesis inhibitors"
3318412|NCT01992796|Placebo Comparator|Placebo|Packaging and labelling for blinding purposes: tablets of placebo looking like the study drug
3318413|NCT01992809|Active Comparator|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
3318414|NCT01992809|Placebo Comparator|placebo mineral oil|placebo mineral oil 3 ml/day
3318415|NCT01992822|Experimental|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm
3318416|NCT01992835|Placebo Comparator|measurement of mediators in biological fluids|
3318417|NCT01992835|Experimental|Grass pollen allergen extract|
3318418|NCT01992848|Experimental|All participants|"Venous blood sampling 4-day food diary~1 week UV Dosimeter Peripheral Quantitative Computed Tomography of the radius"
3318419|NCT01992861||Diagnostic (DCE MRI, DW MRI, MR spectroscopy, FDG PET/CT)|Patients undergo radiation therapy and receive chemotherapy per standard of care. Patients undergo DCE MRI, DW MRI, and MR spectroscopy at baseline, 2-2.5 weeks, 4-5 weeks, and 1 month following radiation therapy completion, and FDG PET/CT at baseline, 2-2.5 weeks, and 4-5 weeks.
3318420|NCT01992887||In-depth Interview|Up to 20 in-depth interviews will be conducted among adult ART naïve patients, balanced by gender, site and reason for ART naiveté (determined ineligible or eligibility not yet determined) as much as possible. Up to 4 in-depth interviews will be conducted with health care providers.
3318421|NCT01992887||Focus Group Participants|Up to 40 patients ineligible or not yet eligible for ART will be invited to join a focus group discussion. Patients will be eligible for selection for either in-depth interviews or focus group discussions if they have made at least one prior visit to the clinic. Selected patients will be balanced as much as possible by gender and by pre-ART status (e.g. roughly half pre-ART eligibility determined, and roughly half pre-ART eligibility indeterminate).
3318422|NCT01992887||Prospective Cohort|Based on historical patient data from the four study CTCs, we expect that approximately 1,000 patients will enroll in HIV care at these clinics during the study period and be determined not eligible for ART or of unknown eligibility. Assuming a 10% refusal rate, approximately 900 patients would then enroll in this study and complete baseline interviews. These 900 patients will be prospectively monitored using routinely collected patient care data for up to 24 months. Outreach workers will attempt to trace all of the enrolled patients who are observed to be LTF during the study period, and complete a defaulter tracing survey.
3318423|NCT01992900|Experimental|Eurartesim dispersible oral tablets|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: 1 tablet containing 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
3318424|NCT01992900|Active Comparator|Eurartesim film coated tablet|Each patient will receive a specific amount of drug according to his/her body weight, once a day for three consecutive days (from 5 to <7 kg: half tablet equal to 80 mg PQP and 10 mg DHA; from 7 to < 13 kg: 1 tablet containing 160 mg PQP and 20 mg DHA).
3318425|NCT01992913|Experimental|iCBT|integrated CBT with computerized cognitive remediation
3318426|NCT01992913|Other|UC|usual care
3318427|NCT01992926|Active Comparator|interactive educational intervention|Physicians will use an interactive educational worksheet during the standard-of-care clinic visit.
3318428|NCT01992926|No Intervention|control group|Physicians will conduct the standard-of-care clinic visit as usual.
3318429|NCT01992939|Active Comparator|Non-Healthy Subjects arm|Subjects in this arm will have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack
3318430|NCT01992939|Active Comparator|Healthy Subjects Arm|Subjects who do not have peripheral vascular disease (PVD), vasoconstriction, or hypothermic extremities will be considered healthy subjects and they will receive two pulse oximetry probes. One probe will be a standard of care pulse oximetry probe and the second probe is the specialized pulse oximetry probe with external heat pack.
3318431|NCT01992952|Experimental|AZD5363 plus fulvestrant|Fulvestrant 500mg and AZD5363 4 days on 3 days off at dose determined in safety run in (maximum 480mg and minimum 320mg bd)
3382331|NCT04949620|Experimental|REThink game, then online parent intervention for non-responders|Participants who are allocated to the REThink game and do not respond to the four-week intervention will be allocated to the online
3382332|NCT04949620|No Intervention|Monitoring|Participants in this arm will be monitored for a total of eight weeks, for comparison with the REThink game intervention (after four weeks) and the online parenting program (after an additional four weeks).
3382333|NCT04947800|Experimental|Arm A: 12 week intervention, 8 week control|Electro acupuncture (EA) intervention will be administered for 12 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 8 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
3382334|NCT04947800|Experimental|Arm B: 8 week intervention, 12 week control|Electro acupuncture (EA) intervention will be administered for 8 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 12 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
3382335|NCT04947800|Experimental|Arm C: 4 week intervention, 16 week control|Electro acupuncture (EA) intervention will be administered for 4 weeks to the Lung Mu-Shu points and St36 which are related to lung function and general function. The EA control intervention will be administered for 16 weeks and will use Lv7 and Gb 26 which are near the other points but not traditionally related to lung function or general function.
3382342|NCT04945720|Experimental|Hepatic artery infusion chemotherapy（HAIC） plus Durvalumab|The therapeutic scheme was modified FOLFOX6 regimens including oxaliplatin (130 mg/m2 infusion for 3 hours on day 1), leucovorin (200 mg/m2 from hour 3 to 5 on day 1) and Fluorouracil (400 mg/m2 in bolus, and then 2,400 mg/m2 continuous infusion 46 hours). All chemo-drugs were given by HAI.Patients received anti-PD-L1 agents will begin no earlier than 7 days following the first HAIC procedure. Anti-PD-L1 agents were used intravenously at the standard dose: Durvalumab was given every 3 weeks during HAIC treatment (Q3W) and every 4 weeks after HAIC treatment (Q4W).
3318432|NCT01992952|Active Comparator|Placebo plus fulvestrant|Fulvestrant 500mg D1, D15 (cycle 1) and D1 of a 28 cycle thereafter. AZD5363 placebo 4 days on 3 days off
3318433|NCT01992965|Experimental|Continuous Glucose Monitoring Group|"Continuous Glucose Monitoring Group:~Different methods of blood glucose monitoring between groups, and this group will use real-time continuous glucose monitoring system with alarm limits（high and low limit is 10 mmol/L and 8 mmil/L , respectively ) up to five days for glucose control, the target mean glucose level is between 8 and 10 mmol/L."
3382349|NCT04939597|Experimental|Arm I (memantine hydrochloride)|Patients receive memantine hydrochloride PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
3382350|NCT04939597|Placebo Comparator|Arm II (placebo)|Patients receive placebo PO BID for 24 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete cognitive testing over 20-30 minutes at baseline, end of radiation therapy, and at 3, 6, 12, 30, and 60 months.
3318434|NCT01992965|Active Comparator|Conventional Group|"Conventional Group：~Different methods of blood glucose monitoring between groups, and this group will use finger prick blood glucose measurements for glucose control with the same target mean glucose level of 8 -10 mmol/L. Patients also wear real-time continuous glucose monitoring system to collect glucose measurements. The values of real-time continuous glucose monitoring system are blinded to investigator and patients."
3318435|NCT01992978|Experimental|radiofrequency-assisted resection group（RF-R)|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
3318436|NCT01992978|Active Comparator|conventional liver resection group（CLR-R）|Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical.
3318437|NCT01992991|Experimental|Transcranial direct current stimulation|Anodal stimulation
3318438|NCT01992991|Sham Comparator|Sham stimulation|30 sek of Transcranial direct current stimulation
3318439|NCT01993004||Healthy subjects|Self-explanatory
3318440|NCT01993004||Untreated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who are not on any disease-modifying treatment approved for MS
3318441|NCT01993004||Treated patients|Patients diagnosed with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome (CIS) who were prescribed Glatiramer acetate prior to enrollment
3318442|NCT01993056|Experimental|warm-up with 11+|"The FIFA 11+ is a complete warm up program aiming on reduce common soccer injuries"
3318443|NCT01993056|Placebo Comparator|control|the control group follows its regular training routine
3318444|NCT01993069|Experimental|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
3318445|NCT01993082|Experimental|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
3318446|NCT01993082|No Intervention|Activity Maintenance Group|Participants randomized into the waitlist control group receive no aerobic training. Wait-list control participants will receive monthly check-in phone calls to establish that they have not significantly increased activity engagement. Participants in this group will receive a free gym membership at the end of the study, monthly phone calls with a fitness coach support provider for 6 months, and 2 coaching text messages per week.
3318447|NCT01993095|Experimental|Experimental: FlexToBa physical activity DVD|Participants in this arm will receive a physical activity program delivered by DVD that focuses on exercises targeting flexibility, toning and balance. These exercises will be progressive in nature throughout the six months and will also focus on modifications for all ability levels. Participants will be provided with three DVDs including: an Introduction to physical activity, Sessions 1-3, and Sessions 4-6, which they will be asked to watch and participate in over the course of six months.
3318448|NCT01993095|Active Comparator|Usual care-Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
3318449|NCT01993121|Experimental|Three-month exercise training program|All subjects will perform three months of supervised exercise training.
3318450|NCT01993134|Experimental|Cefazolin|2g of Cefazolin, 20minutes before sugery. After surgery, 1g of cefazolin 06/06h.
3318451|NCT01993134|Active Comparator|Cefazolin Single Dose|2g of Cefazolin, 20minutes before sugery. After surgery, no drugs.
3318452|NCT01993147|Other|Dual Task Paradigm|This arm does not involve any drug intervention, it is an experimental type consisting of 80 subjects to study the dual task paradigm implemented during the fMRI scanning session. 80 subjects will perform the fMRI scan but will not undergo any drug intervention.
3318453|NCT01993160|Experimental|18F-FCH PET MR|Integrated whole body PET-MR or PET-CT and separate whole body MRI with use of 18F-FCH as the molecular probe
3318454|NCT01993173|Experimental|ADACEL Vaccine Group|Children, adolescents and adults randomized to receive a single booster dose of ADACEL (Tdap vaccine)
3318455|NCT01993173|Active Comparator|Local DT/Td Vaccine Group|Participants randomized to receive either a single booster dose of local DT vaccine (children aged 4 through 11 years) or local Td vaccine (adolescents and adults aged 12 through 64 years)
3318456|NCT01993199|Active Comparator|deep biopsy|
3318457|NCT01993212|Placebo Comparator|Placebo|Androxal Placebo and Gel Placebo
3318458|NCT01993212|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
3318459|NCT01993212|Experimental|Androxal Treatment|Androxal 12.5 mg or 25mg and Placebo Gel
3318460|NCT01993225|Placebo Comparator|Placebo|Placebo Gel and Placebo capsules
3318461|NCT01993225|Experimental|Androxal Treatment|Androxal 12.5mg/25 mg and Placebo gel
3318462|NCT01993225|Active Comparator|AndroGel Treatment|AndroGel 1.62% and Placebo Capsules
3318463|NCT01993251|Active Comparator|melatonin 0.5mg|
3318464|NCT01993251|Active Comparator|melatonin 2mg|
3318465|NCT01993251|Active Comparator|melatonin 6mg|
3318466|NCT01993251|Placebo Comparator|placebo|
3318467|NCT01993277|Active Comparator|Fischer Wallace Stimulator|30 20-minute sessions of the Fischer Wallace Stimulator administered twice-per-day within a 3-week time-frame;
3318468|NCT01993277|Active Comparator|Nexalin Brain Stimulator|15 40-minute sessions of Nexalin Brain Stimulator adminsitered once-per-day within a 3-week time-frame
3318469|NCT01993277|Active Comparator|DAVID Delight Stimulator|15 40-minute sessions of the DAVID Delight administered once-per-day within a 3-week time-frame
3318470|NCT01993277|Active Comparator|Relaxation Therapy|15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame
3318471|NCT01993290|Active Comparator|USG Supraclavicular block|20 ml of ropivacaine 0,75% is administered to brachial plexus at supraclavicular level.
3318472|NCT01993290|Active Comparator|Lateral infraclavicular block|20 ml of ropivacaine 0,75 % is administered to brachialis plexus at lateral infraclavicular level
3318473|NCT01993290|Active Comparator|USG Axillaris block|20 ml of ropivacaine 0,75% is administered to plexus brachialis at axillaris level
3318474|NCT01993303||Single Cohort|Population: 19 subjects, mean age 65 years, mean BMI 30 kg/m2, 79% male. Radionuclide Dosage: Rb-82 doses were rest 53+/-5 mCi and stress 53+/-6 mCi All were stress with Dipyridamole.
3318475|NCT01993316|Experimental|neurofeedback training|Subjects will undergo neurofeedback training to either the right primary motor cortex or the right superior parietal gyrus. The EEG measurements will be analyzed using LORETA.
3318476|NCT01993342||Inflammatory knee osteoarthritis|We recruited patients with osteoarthritis and synovial effusion to diagnostic the effusion and to confirm that this this synovial fluid had mechanical characteristics. Now we are going to determine the adipocytokines and traditional parameters of inflammation in this synovial fluid to correlate it, and we will associate it with the ultrasound explanation of the knee that we have in our database.
3318477|NCT01993355|Active Comparator|TAU|Control group. Treatment as usual (TAU): Physiotherapy program for CLBP.
3318478|NCT01993355|Experimental|Intervention 1 Relaxation techniques-sophrology|Intervention group 1: TAU + relaxation techniques-sophrology program.
3318479|NCT01993355|Experimental|Intervention 2 Cognitive-behavioral therapy|Intervention group 2: TAU + cognitive-behavioral therapy.
3318480|NCT01993368|Other|chronic periodontitis|biopsy of periodontal granulation tissue (surgical waste)
3318481|NCT01993368|Other|aggressive periodontitis (AP)|biopsy of periodontal granulation tissue (surgical waste)
3318482|NCT01993368|Other|controls|necessitating an extraction of wisdom teeth
3318483|NCT01993381||CINV of FOLFOX, FOLFIRI|moderate emetogenic chemotherapy
3318484|NCT01993394|Experimental|ventilation|hypergravity gas mixture
3318485|NCT01993407|Experimental|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
3318486|NCT01993407|Placebo Comparator|Pure Task Training|Participants will complete four, one-hour training sessions in which they will perform a single task each session, alternating tasks between but not within sessions.
3318487|NCT01993420|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3318488|NCT01993420|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3318489|NCT01993433|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3318490|NCT01993433|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3318491|NCT01993446|Experimental|DRM02|DRM02 Topical Gel, 0.25%
3318492|NCT01993446|Placebo Comparator|Vehicle|DRM02 Topical Gel, Vehicle
3318493|NCT01993459|Experimental|Midazolam intravenous|3mg/ml midazolam given intravenously
3318494|NCT01993459|Placebo Comparator|NaCl (sodium chloride) 0,9%|NaCl (sodium chloride) 0,9% given intravenously 3ml.
3318495|NCT01993472|Experimental|Andrographolides with Capecitabine|Capecitabine1250mg/m2 , bid，d1-14，q3w, Andrographolides 500mg，qd，d1-14，q3w;
3318496|NCT01993472|Active Comparator|Capecitabin alone|Capecitabine1250mg/m2 , bid，d1-14，q3w,
3318497|NCT01993498|Other|breast cancer treatment + blood sampling|Standard treatment of breast cancer with intervention : samples collection
3318498|NCT01993511||RYGB patients with type 2 diabetes|Preoperative oral glucose tolerance test with 2 h P-glucose >11.1 mmol/L
3318499|NCT01993511||RYGB patients with IGT|Preoperative oral glucose tolerance test with 2 h p-glucose >7.8 and <11.1 mmol/L
3318500|NCT01993511||RYGB patients with NGT|Preoperative oral glucose tolerance test with 2 h p-Glucose <7.8 mmol/L
3318501|NCT01993524|Experimental|probiotic|At I visit standard treatment(500mg oral metronidazole twice daily for 7 days) and probiotic twice daily for 10 days. At II visit, participants were checked for signs of vaginal infection; if they were still present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with probiotic twice daily for 10 days. Participants showing positive response to metronidazole treatment on the II visit were given only the probiotic once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
3318502|NCT01993524|Placebo Comparator|placebo|At I visit standard treatment (500mg oral metronidazole twice daily for 7 days) and placebo twice daily for 10 days. At the II visit, participants were checked for signs of vaginal infection; if they were present they were given a targeted antibiotic according to the microbiological analysis. Antibiotic was taken together with placebo twice daily for 10 days. Participants showing positive responses to metronidazole on the II visit were given only placebo once daily for 10 days in the peri-menstrual period for the next 3 months. Participants with targeted antibiotic were to come to the visit IIbis, and if treatment was successful they were to proceed for the next 3 months in the same manner as those successfully treated with metronidazole, as described above.
3318503|NCT01993537|No Intervention|Sufficeint|In this arm the participants have a Vitamin D level of greater than 75 ng/ml. They will continue to be monitored throughout the study but will not receive any intervention.
3318504|NCT01993537|No Intervention|Mild Insufficiency|In this arm the participants have a Vitamin D level between 37.5 - 75 ng/ml. The participants will be monitored throughout the study but will receive no intervention.
3318505|NCT01993537|No Intervention|Severe Deficiency no treatment|In this arm the participants have a low Vitamin D level of less than 37.5 ng/ml. The participants will be monitored but will receive no intervention.
3318506|NCT01993537|Experimental|Severe Deficiency - Treatment|In this arm the participants will be treated with Vitamin D. The participants will be prescribed a dose of 1000 IU a day (1 pill a day). At 6 weeks the dosage will increase to 2000 IU a day (2 pills a day).
3318507|NCT01993550|Experimental|Telephone counseling|Telephone counseling to enhance symptom management and reduce distress
3318508|NCT01993550|Active Comparator|Education|Overview of resources for psychosocial support and health information
3318509|NCT01993563|Experimental|Graded Motor Imagery|
3318510|NCT01993563|Active Comparator|Standard treatment|
3318511|NCT01993576|Experimental|indocyanine green|Indocyanine green is injected intravenously.
3318512|NCT01993589|No Intervention|Control group|Control group
3318513|NCT01993589|Active Comparator|Pain reliever|1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
3318514|NCT01993589|Active Comparator|Dexketoprofen trometamol|25 mg oral Dexofen Atabay ilaç Turkey
3318515|NCT01993589|Active Comparator|Lidocaine spray|2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
3318516|NCT01993589|Active Comparator|pethidine|Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
3318517|NCT01993589|Active Comparator|diclofenac sodium|Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey
3318518|NCT01993602|No Intervention|Control group|no intervention was performed in this group during postoperative period,
3318519|NCT01993602|Active Comparator|volumetric incentive spirometry|patients performed breathing exercises using volumetric incentive spirometer during five postoperative days
3318520|NCT01993602|Active Comparator|Flow oriented incentive spirometry|patients performed breathing exercises using flow oriented incentive spirometer during five postoperative days
3318521|NCT01993602|Active Comparator|Deep breathing group|patients performed deep breathing exercises without any device during five postoperative days
3318522|NCT01993602|Active Comparator|Continuous positive airway pressure group|patients performed breathing exercises using continuous positive airway pressure group during five postoperative days
3318523|NCT01993628|Experimental|Alzheimer's disease (AD)|Rey figure test and MRI
3318524|NCT01993628|Experimental|Lewy body's dementia (LBD)|Rey figure test and MRI
3318525|NCT01993641|Experimental|Pracinostat added to HMA|Pracinostat in combination with HMA treatment (either azacitidine or decitabine) used in initial single agent treatment for that patient
3318526|NCT01993654||Nevus|
3318527|NCT01993654||Racial Melanosis|
3318528|NCT01993654||Primary Acquired Melanosis|
3318529|NCT01993654||Malignant Melanoma|
3318530|NCT01993654||Normal|
3318531|NCT01993680|Experimental|Pyridostigmine bromide|14 days of active treatment followed by 21 days wash out
3318532|NCT01993680|Active Comparator|fludrocortisone|14 days of fludrocortisone treatment; 21 days wash out
3318533|NCT01993693|Experimental|Ultrasonic Diathermy Device|Therapeutic ultrasound used daily.
3318534|NCT01993693|Placebo Comparator|Sham Ultrasonic Diathermy Device|Sham device that does not deliver ultrasound
3318535|NCT01993719|Experimental|1/Arm 1 (CLOSED)|Standard preparative regimen + Young TIL Cells
3318536|NCT01993719|Experimental|1/Arm 1P|Standard preparative regimen + Young TIL Cells + possible retreatment with standard preparative regimen + Young TIL Cells +pembrolizumab
3318537|NCT01993719|Experimental|2/Arm 2 (CLOSED)|Lower dose preparative regimen + Young TIL Cells
3318538|NCT01993719|Experimental|3/Arm 1N|Standard preparative regimen + Young TIL Cells
3318539|NCT01993732|Experimental|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
3318540|NCT01993745||Study group|ECMO Patients survived
3318541|NCT01993745||Control|ECMO Patient died
3318542|NCT01993758|Active Comparator|Conventional tourniquet pressure|The patients in this group will undertake total knee arthroplasty under conventional tourniquet pressure, which will be set as the pressure added by 150mmHg on the last systolic blood pressure just before tourniquet inflation.
3318543|NCT01993758|Experimental|Low tourniquet pressure|The patients in this group will undertake total knee arthroplasty under low tourniquet pressure, which will be set as the pressure added by 120mmHg on the last systolic blood pressure just before tourniquet inflation.
3318544|NCT01993771||Males and females with alopecia|Males and females with alopecia scheduled for general anaesthesia.
3318545|NCT01993784|Experimental|Nimotuzumab|the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)
3318546|NCT01993797||Bronchiolitis|children presented with signs suggestive of bronchiolitis
3318547|NCT01993810|Active Comparator|Arm I (photon beam radiation therapy and chemotherapy)|"Patients undergo photon beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* IV over 1 hour and carboplatin* IV weekly during radiation therapy or etoposide IV on days 1-5 and 29-33 and cisplatin IV on days 1, 8, 29, and 36. Patients with non-squamous cell cancer may receive pemetrexed IV and carboplatin IV on every 21 days. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
3318548|NCT01993810|Experimental|Arm II (proton beam radiation therapy and chemotherapy)|"Patients undergo proton beam radiation therapy 5 days per week for a total of 35 fractions and receive either paclitaxel* and carboplatin*, etoposide and cisplatin, or pemetrexed and carboplatin (for non-squamous cell cancer patients only) as in Arm I. Patients who receive paclitaxel and carboplatin must complete 2 courses of consolidation therapy.~CONSOLIDATION THERAPY: Beginning 3-6 weeks after chemoradiotherapy, patients receive either paclitaxel IV over 3 hours and carboplatin IV on day 1 or durvalumab IV every 2 weeks. Treatment repeats every 21 days for 2 courses or every 2 weeks for up to 12 months for durvalumab in the absence of disease progression or unacceptable toxicity. Patients with non-squamous cell carcinoma may receive durvalumab or pemetrexed IV and carboplatin IV on day 1 every 21 days for up to 4 courses."
3318549|NCT01993862|No Intervention|Next Day Discharge|The patient will have a 23 hour standard of care observational stay in the hospital after an implantable cardioverter defibrillator implant procedure.
3318550|NCT01993862|Active Comparator|Same Day Discharge|The patient will be discharged from the hospital the same evening after an implantable cardioverter defibrillator implant procedure. Follow up after surgery will be done via remote device follow up (1) on the day of discharge and (2) 24 hours after surgery.
3318551|NCT01993901|Experimental|CSRT led telephone follow up|Patients in the experimental arm will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms.
3318552|NCT01993901|No Intervention|Standard Follow up|"Patients in the control group will have the standard follow up (CT of the chest, abdomen and pelvis prior to follow-up with the radiation oncologist 4 months after the completion of their treatment). In order to control for an attention effect that may be seen in the intervention group, patients in the control group will get a placebo or sham telephone call initiated by a research assistant 4-6 weeks after completion of their treatment. This telephone call will simply confirm their follow up appointment."
3318553|NCT01993953|Active Comparator|BodyPump|Resistance training in group, with one instructor. This pre-choreographed class contains 10 to 12 exercises with a barbell, weights and a step. Number of repetitions throughout the class varies between muscle groups, but is generally high (20-100).
3318554|NCT01993953|Active Comparator|Personal training|The PT will instruct proper technique to their clients, correct the training and technique, control the intensity and serve as a motivator at each training session.
3318555|NCT01993953|Active Comparator|Resistance training with instructor|Participants in this group are aimed to perform resistance training individually, based on two sessions with an instructor and a standarized training program given prior to the intervention. After six weeks, all participants in this group received a second instruction, as well as evaluation of the training protocol.
3318556|NCT01993953|No Intervention|Controlgroup|Control group - This group will be instructed to continue their activity and diet patterns. After the intervention period, they will be offered free exercise with BP at a fitness centre (12 weeks) and resistance training with a instructor at the Norwegian School of Sport Science.
3318557|NCT01993966||drug-resistant|specimens com from drug-resistant bladder urothelial carcinoma patients
3318558|NCT01993966||normal|specimens come from normal bladder urothelial carcinoma patients
3318559|NCT01993966||non-tumoral|specimens come from non-tumoral patients
3318560|NCT01993979|Other|Surveillance|Patients allocated to surveillance will be seen at 4, 7, 10 and 13 weeks post randomisation - equivalent to the end of cycle in patients receiving chemotherapy - in order to collect details of early treatment failure in this group and comparative data relating to toxicity and quality of life. Patients on surveillance will then be followed up for signs of recurrence at the same intervals as those who received chemotherapy
3318561|NCT01993979|Experimental|Chemotherapy|Patients allocated adjuvant chemotherapy will receive 4 x 21 day cycles of gemcitabine-cisplatin. Patients who have a sub-optimal renal function (GFR 30-49ml/min) will receive carboplatin instead of cisplatin.
3318562|NCT01994005|Placebo Comparator|Standard + Pamphlet|Subjects receiving standard counseling + ACOG pamphlets
3318563|NCT01994005|Active Comparator|Group 2: standard + facebook|Subjects receiving standard counseling + facebook education Intervention is 30 mins of use of facebook page
3318564|NCT01994018||Control Group (Vitamin D level)|Twenty (20) healthy individuals not on vitamin D supplementation will be used as controls to get a baseline vitamin D level.
3318565|NCT01994018||MS Group|RR-MS patients treated with a FDA approved immuno-modulatory drug with and without vitamin D supplementation for at least 2 years.
3318566|NCT01994031|Experimental|Dose level A|Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3318567|NCT01994031|Experimental|Dose level B|Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3318568|NCT01994031|Experimental|Dose level C|Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3318569|NCT01994031|Experimental|Dose level D|Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3318570|NCT01994031|Experimental|Dose level E|Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days
3318571|NCT01994031|Active Comparator|Comparator|Paclitaxel injection 175mg/m2 on day 1, each 21 days
3318572|NCT01994044|Active Comparator|Multimodal rehabilitation|
3318573|NCT01994044|Active Comparator|Cervical fusion|
3318574|NCT01994057||sensitive group; resistant group|"sensitive patients were defined as patients reached CR or PR after first month administration,SD after first three months administration.~resistant patients were defined as patients reached PD after first month administration and first three months administration"
3318575|NCT01994070|Active Comparator|Electrical-first|"Patients in atrial fibrillation for less than 48 hours will be administered procedural sedation and analgesia and an electrical current applied across their chest (cardioversion) to attempt conversion to normal sinus rhythm. If this does not succeed, they will be given intravenous procainamide (chemical cardioversion). If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion."
3318576|NCT01994070|Active Comparator|Chemical-first|"Patients in atrial fibrillation for less than 48 hours will be administered intravenous procainamide (chemical cardioversion) to attempt conversion to normal sinus rhythm. If procainamide is required, physicians will be informed as follows: 50% of patients convert to normal sinus rhythm within one hour and 90% of patients convert within two hours. Physicians can then proceed at their discretion. If this does not succeed, patients will be administered procedural sedation and analgesia and an electrical current applied across their chest (electrical cardioversion) to attempt conversion to normal sinus rhythm."
3318577|NCT01994083|Placebo Comparator|Placebo|Placebo
3318578|NCT01994083|Experimental|IX-01|Up to 4 different dose groups within 50 to 1,200 mg of IX-01 oral aqueous dispersion, administered once daily for 10 days
3318579|NCT01994096|Experimental|Caspofungin|1 arm, dose adjustment of caspofungin when exposure is inadequate
3318580|NCT01994122||People who have dropped out of school|
3318581|NCT01994122||College students (control group)|
3318582|NCT01994135|Active Comparator|Reference food|The reference food is white bread
3318583|NCT01994135|Experimental|Test food dose 1|Test food dose 1 response will be compared to reference test food
3318584|NCT01994135|Experimental|Test food dose 2|Test food dose 2 response will be compared to reference test food as well as to test food dose 1
3318585|NCT01994148|Experimental|Laparoscopy|Laparoscopy has been increasingly applied in patients with abdominal trauma , as an diagnostic and therapeutic modality. In this arm, we will include 100 Hemodynamically stable patients with gastrointestinal trauma, all of them will receive laparoscopic exploration,laparoscopic repair of the gastrointestinal injury will be attempted.
3318586|NCT01994161||Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
3318587|NCT01994187||CAS or CEA|CAS:the patient who accepted carotid angioplasty due to catotid artery stenosis CEA:the patient who accepted carotid endarterectomy due to catotid artery stenosis
3318588|NCT01994200|Experimental|Interdisciplinary Team-Based Approach|The delivered intervention will be to provide patients with an interdisciplinary team-based approach defined as care provided by a variety of professionals, each having their own domain of expertise, defined roles and responsibilities, who work together and meet to discuss patient needs and develop comprehensive treatment plans. Team composition will include physicians, a dedicated nurse, and allied professionals (e.g., dieticians, social workers, psychologists). The dedicated nurse will have a central integrative role in this interdisciplinary team and will provide patients with information about their illness and treatment, symptom management, emotional support, and reference to other resources when needed
3318589|NCT01994200|Other|Usual Care Control Group|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
3318590|NCT01994213|Experimental|Famitinib|Famitinib 25 mg qd p.o., 4 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent.
3318591|NCT01994239|Active Comparator|Radiation|"Pelvic radiotherapy~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy"
3318592|NCT01994239|Experimental|Radiation and Degarelix|"Radiotherapy:~46 Gy in 23 fractions of 2 Gy.~prostate only-boost up to 66 Gy~Associated with hormonal therapy by degarelix:~beginning in parallel to radiotherapy for 6 months~First dose of 240 mg~Maintenance dose of 80 mg"
3318593|NCT01994252|Active Comparator|Optimal Medical therapy plus ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy
3318594|NCT01994252|Active Comparator|Optimal Medical therapy plus CRT/ICD|Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy
3318595|NCT01994265|Active Comparator|Warfarin|Treatment with Warfarin once daily, taken at fast, to maintain INR between 2 and 3.
3318596|NCT01994265|Active Comparator|Dabigatran|Dabigatran 150 mg twice daily
3318597|NCT01994278|Experimental|Tooth brush|Periclean is a soft rubber gentle toothbrush
3318598|NCT01994304|No Intervention|No safe childbirth checklist|The selected control districts include Bharatpur, Pali, Jhunjhunu, and Nagaur
3318599|NCT01994304|Active Comparator|Safe Childbirth Checklist|The selected districts for SCC intervention include Alwar, Jalore, Sirohi, Sikar, Dausa, and Churu
3318600|NCT01994317|Active Comparator|Standard sedation dose|IV sedation dose calculated using current standard of care
3318601|NCT01994317|Experimental|Algorithm|IV sedation dose calculated by study algorithm
3318602|NCT01994330|Experimental|Desmopressin|"0,3 mcg per kilogram of desmopressin in 100 ml of saline, labeled as study drug and administered in 30 minutes a half hour before surgical incision"
3318603|NCT01994330|Placebo Comparator|placebo|"100 of saline labeled as study drug administered in 30 minutes a half hour before surgical incision"
3318604|NCT01994343|Experimental|Experimental group|Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
3318605|NCT01994343|No Intervention|Control group|Adult women aged over 18 years old without chronic pain. will receive no intervention.
3318606|NCT01994356|Active Comparator|Usual contraceptive counseling|subjects received usual contraceptive counseling
3318607|NCT01994356|Experimental|Physician self-disclosure of IUC use|subjects received usual contraceptive counseling plus intervention which was Physician self-disclosure of personal IUC use during the counseling
3318608|NCT01994369|Experimental|EC17 Injection group|This group with receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, they will be imaged with a camera and an imaging probe the investigators have developed.
3318610|NCT01994408|Experimental|default intensification arm (all)|all subjects will receive blister packs with weekly increasing blood pressure medications. There is no control arm for this study
3318611|NCT01994421|Sham Comparator|Kinesiotape|
3318612|NCT01994434|Other|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
3318613|NCT01994447|No Intervention|Traditional Nurse Enrollment|Research nurses will obtain verbal consent from patient/caregiver.
3318614|NCT01994447|Experimental|Student Enrollment|Trained research students will use digital video discs (DVD's) of primary investigators explaining study information to obtain informed consent
3318615|NCT01994460|Active Comparator|Arm 1 (control arm)|Standard treatment for drug-sensitive pulmonary TB using isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and ethambutol (2 months)
3318616|NCT01994460|Experimental|Arm 2 (experimental arm 1)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 2 weeks)
3318617|NCT01994460|Experimental|Arm 3 (experimental arm 2)|Isoniazid (6 months), rifampicin (6 months), pyrazinamide (2 months), and linezolid (600 mg/day, 4 weeks)
3318618|NCT01994473|Experimental|SEP-363856|Dosing will be initiated at 10 mg SEP-363856 as a single oral dose. Subsequent cohorts will be dosed at 25, 50, and 100 of SEP-363856.
3318619|NCT01994473|Placebo Comparator|Placebo|An oral of matched placebo
3318620|NCT01994473|Experimental|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
3318621|NCT01994499|Experimental|videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
3318622|NCT01994499|Active Comparator|Medical pleural drainage|Medical drainage
3318623|NCT01994512|Experimental|Decompression without fusion|Surgery of the stenotic spinal segments with decompression of the neural elements without concommitant fusion.
3318624|NCT01994512|Experimental|Decompression with fusion|Surgery of the stenotic spinal segments with decompression of the neural elements with concommitant fusion.
3318625|NCT01994525|Experimental|Cohort 1: PfRAS-infected|"5 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is 960 infectious bites.~Challenge occurs 3 weeks after final immunization."
3318626|NCT01994525|Placebo Comparator|Cohort 1: Noninfected|"Placebo immunization. 5 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated uninfected mosquitoes (mock-immunization). The target dose is 960 noninfected bites.~Challenge occurs 3 weeks after final immunization."
3318627|NCT01994525|Other|Cohort 1: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
3318628|NCT01994525|Experimental|Cohort 2: PfRAS-infected|"3 to 7 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
3318629|NCT01994525|Placebo Comparator|Cohort 2: Noninfected|"Placebo. 3 to 7 doses of approximately 200 noninfected bites (200-400 bites total) from irradiated, uninfected mosquitoes (true-immunization). The target dose is dependent on protection results in cohort 1.~Challenge occurs 3 weeks after final immunization."
3318630|NCT01994525|Other|Cohort 2: Nonimmunized|"No protective intervention given.~Challenge occurs directly after screening."
3318631|NCT01994525|Experimental|Hyperimmunity PfRAS-infected|"Cohort 1 sub-cohort~3 doses (immunizations) of approximately 200 infectious bites (200-400 bites total) from PfRAS-infected mosquitoes. This arm will receive the first 3 immunizations of Cohort 2.~Challenge occurs at the same time as Cohort 2 (3-20 weeks after the final immunization)"
3318632|NCT01994577||Adults (18+) presenting to the ED with symptoms of ACS|
3318633|NCT01994603|Experimental|Opt-in testing|"Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-in: Common barriers to HIV screening testing will be removed as much as possible (i.e., providing rapid testing, results shortly available, testing on-site, confidentiality). There is voluntary HIV testing available to all study participants if you wish to do it. "
3318634|NCT01994603|Experimental|Opt-out testing|Participants will be scheduled for a two-hour appointment to complete the written consent procedure, enroll in the study, and participate in the study activities, testing and a focus group. Opt-out multicomponent testing. Participants will be informed that a bundled routine health test is available on a voluntary basis to study participants, and the participant may elect to decline all or part of the testing.
3318635|NCT01994616||keloid or hypertrophic scars|All patient including all skin types with keloid or hypertrophic disease receiving Intralesional Cryotherapy
3318636|NCT01994642|Active Comparator|Reference|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)
3318637|NCT01994642|Placebo Comparator|Placebo|Placebo Sterile Otic Suspension
3318638|NCT01994642|Experimental|Test|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension
3318639|NCT01994655|Experimental|Doing exercise|We want to use Kupperman Index to assess the severity of climacteric symptoms,and assess the effect of doing exercise fof the climacteric symptoms
3318640|NCT01994668|Experimental|Lorazepam|
3318641|NCT01994668|Placebo Comparator|Placebo|
3318642|NCT01994681||Pancreatic Cancer|
3318643|NCT01994681||Healthy|
3318644|NCT01994694||adults with ADHD|adults with ADHD, without neurological and psychiatric comorbidities
3318645|NCT01994694||controls|people without ADHD, with no neurological and psychiatric disorders
3318646|NCT01994707|Active Comparator|Remote ischemic preconditioning|Left arm blood pressure cuff inflation for 5 min then deflation of cuff for 5 min- cycle repeated 3 times before coronary artery bypass grafting.
3318647|NCT01994707|Placebo Comparator|Placebo|Deflated cuff on arm for 30 minutes.
3318648|NCT01994733|Experimental|Intensive phosphate control|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice.
3318649|NCT01994733|Active Comparator|Liberalized phosphate control|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
3318650|NCT01994759|Active Comparator|Training|strengthening and stretching exercises.
3318651|NCT01994759|Active Comparator|Glucocorticosteroid injection|Injection of 40 mg methylprednisolone.
3318652|NCT01994759|Active Comparator|Training and Glucocorticosteroid injections|A combination treatment of the two above.
3318653|NCT01994772|Active Comparator|Targeted controlled temperature between 32.5 and 33.5°C|Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.
3318654|NCT01994772|Placebo Comparator|Targeted controlled temperature between 36.5 and 37.5°C|Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.
3318655|NCT01994824|Experimental|Intervention arm|"Transplant recipients will have IL15 and IL2Ra measured on day 7. If at risk for significant GVHD, the patient will get rabbit antithymocyte globulin, 3 mg/kg on day 8.~Patients from this intervention/experimental arm will be compared to historical and concurrent controls (no ATG on day 8)."
3318656|NCT01994915|Experimental|Occupational therapy group|35 patients diagnosed with chronic obstructive pulmonary disease attending to the Hospital because of an exacerbation are going to be included in this group.
3318657|NCT01994915|No Intervention|Control group|35 patients diagnosed with chronic obstructive pulmonary disease are going to be included in this group. They are not going to receive other than standard care (medical and physical therapy intervention).
3318658|NCT01994928|Active Comparator|Nose-mouth mask|Performance of intubation after preoxygenation using a nose-mouth mask.
3318659|NCT01994928|Experimental|High flow nasal cannula oxygen|Performance of intubation after preoxygenation using high flow nasal cannula oxygen.
3318660|NCT01994941|Experimental|Genotype guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol). Blood will be drawn for rapid genetic testing (Verigene) and results will be expected in 2-4 hours. If patients are intermediate or poor clopidogrel metabolisers, loading dose of ticagrelor 180mg are given to enhance the antiplatelet response.~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics). In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
3318661|NCT01994941|Active Comparator|Clinical guided group|"Patients are given standard doses of clopidogrel (either 300mg or 600mg according to clinical protocol).~Apart from the approach in guiding the use of P2Y12 receptor blocker, all patients will be treated according to usual clinical care including medications and coronary intervention. Blood will also be sent to standard laboratory for CYP2C19 genotyping using conventional polymerase chain reaction (PCR) method so as to confirm the accuracy of rapid genetic test. 24 hours after initial clopidogrel loading, blood will be taken to measure platelet reactivity by verifyNow P2Y12 assay (Accumetrics) which is an FDA approved, point-of-care device using light-transmission based optical detection which measures platelet aggregation. In case glycoprotein IIbIIIa inhibitor (Integrilin) is used, verifyNow P2Y12 assay will be performed 48 hours after cessation of Integrilin."
3318662|NCT01994967|Experimental|Levobupivacaine|"Presentation: injectable solution - ampoule of Levobupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
3318663|NCT01994967|Active Comparator|Bupivacaine|"Presentation: injectable solution - ampoule of Bupivacaine Hydrochloride~Indication: production of subarachnoid block (spinal/ spinal anesthesia)."
3318664|NCT01994980|Active Comparator|Default 4 days antibiotic therapy|Default 4 days antibiotic therapy
3318665|NCT01994980|No Intervention|Default 8 days antibiotic therapy|Default 8 days antibiotic therapy
3318666|NCT01995006|Experimental|Metamizole|Metamizole 1000mg TID Day 1 till Day 7
3318667|NCT01995006|Active Comparator|Naproxen|Naproxen 500 mg BID Day 1 till Day 7
3318668|NCT01995019|Placebo Comparator|Physiologic saline|Sodium chloride 9 mg/ml liquid for parental use
3318669|NCT01995019|Experimental|Methylprednisolone|Depo-Medrol 40 mg/ml, single dose, injection, intra-articular
3318670|NCT01995032|Experimental|750 mg metformin and 7.5 g L-citrulline daily p.o.|7.5 g L-citrulline p.o. and 750 mg metformin daily p.o. (3x 2.5 g, respectively 3x 250 mg) for 26 weeks
3318671|NCT01995032|Placebo Comparator|Placebo|metformin placebo and L-citrulline placebo 3 times daily p.o. for 26 weeks
3318672|NCT01995058|Experimental|Cabozantinib arm 1|Subjects randomized to this arm will receive cabozantinb 40 mg daily with abiratarone and prednisone
3318673|NCT01995058|Experimental|Cabozantinib arm 2|Subjects randomized to this arm will receive cabozantinib 20 mg daily with abiraterone and prednisone
3318674|NCT01995058|Experimental|Cabozantinib arm 3|Subjects randomized to this arm will receive cabozantinb 20 mg every other day with abiraterone and prednisone
3318675|NCT01995058|Active Comparator|Abiraterone only arm (4)|Subjects randomized to this arm will receive abiraterone with prednisone only
3318676|NCT01995084|Experimental|Optimization|Patients undergo a [F-18]HX4 PET/CT scan 2,3 and 4h after [F-18]HX4 injection.
3318677|NCT01995084|Experimental|Reproducibility|Patients undergo two [F-18]HX4 PET/CT scans 3.5h after [F-18]HX4 injection within a 10-day time frame.
3318678|NCT01995097|Experimental|SGR + Support Messages|scheduled gradual reduction text messages for first 3-5 weeks of participation; support text messages through 35th week of pregnancy
3318679|NCT01995097|Active Comparator|Support Messages Only|support text messages through 35th week of pregnancy
3318680|NCT01995110|Experimental|normal weight subjects|
3318681|NCT01995110|Experimental|obese subjects|
3318682|NCT01995149|Experimental|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
3318683|NCT01995162|Experimental|Free-living conditions|
3318684|NCT01995188|Experimental|Dose Escalation Cohort: DNIB0600A+Carboplatin|DNIB0600A at an initial dose of 1.2 milligrams per kilogram (mg/kg) will be administered via intravenous (IV) infusion further following a dose-escalation until DLT under consultation of the investigator in combination with Carboplatin fixed dose of area under the curve (AUC)=6 mg/milliliter(mL)*minute (min) administered by IV infusion on Day 1 of a 21-day cycle.
3318685|NCT01995188|Experimental|NSCLC Dose Expansion Cohort: DNIB0600A+Carboplatin|Recommended phase 2 dose (RP2D) of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with NSCLC until disease progression or death, whichever occurs first.
3318686|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin|RP2D of DNIB0600A administered via IV infusion in combination with AUC=6 mg/mL*min administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
3318687|NCT01995188|Experimental|PSOC Dose Expansion Cohort: DNIB0600A+Carboplatin+Bevacizumab|RP2D of DNIB0600A administered via IV infusion in combination with Carboplatin, AUC=6 mg/mL*min and Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle in participants with PSOC until disease progression or death, whichever occurs first.
3318688|NCT01995214|Experimental|P|Anesthesia maintenance with propofol+remifentanil
3318689|NCT01995214|Experimental|S|Anesthesia maintenance with sevoflurane+remifentanil
3318690|NCT01995227|Experimental|AlloVax Treatment|Intradermal injection (ID) of AlloStim(TM) (1ml) on day 4 and 7. AlloVax Treatment: ID injection of AlloSim(TM) (1 ml) followed immediately by the ID injection of CRCL (1ml) on day 11 and 14 in same location on the left arm and on day 18 and 21 in the same location on the right arm. Intravenous infusion of AlloStim(TM)(5ml) and a CRCL alone Intradermal injection on Day 27.
3382356|NCT04938765|Experimental|Magnesium sulfate arm|MgSo4 diluted to 20% will be administered at 40 mg/kg dosed to ideal body weight over 10min to the study arm followed by 10mg/kg/hr infusion.
3382357|NCT04938765|Placebo Comparator|Normal Saline|20 ml of normal saline bolus will be administered to the control group over 10 mins.
3382358|NCT04937790|Experimental|Core stabilization group (CSG)|This arm consists core stabilization exercises including abdominal hallowing, supine bride, bride dog, side plank, curl-up and modified push up exercise. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
3382359|NCT04937790|Experimental|Wobble board group ( WBG)|This arm consists balance training exercises which performed on computerized wobble board for primarily lower limb and anti- gravity muscle. Each session is going to begin with warm-up training which consist of stretching exercise for upper-limb, lower-limb and trunk muscles, and complete with cool down exercise (same with warm-up training). Patients are going to attend one session of patient education before the first session.
3382360|NCT04937790|No Intervention|Control group (CG)|This arm was planned as a control group. Therefore, any intervention will not be performed. Patients in this arm going to participate only one session of patient education at the beginning of the program
3318691|NCT01995240|Experimental|Optimization|For optimization of the protocol patients will undergo one DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scan.
3382361|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 1|Multiple doses of ALN-AGT01 administered by subcutaneous (SC) injection during the 12-month DB treatment period.
3382362|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 2|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
3318692|NCT01995240|Experimental|Reproducibility|For determination of the reproducibility patients will undergo two DCE-MRI (Gadobutrol), T2* MRI and DWI MRI scans within one week.
3318693|NCT01995253|Experimental|Controlled conditions|
3318694|NCT01995253|Experimental|Free-living conditions|
3318695|NCT01995279|Experimental|French ear acupuncture|Application of single session of French ear acupuncture at specific points used to reduce low back pain.
3318696|NCT01995279|Placebo Comparator|Sham Ultrasound|Sham ultrasound will be applied at lumbar spine.
3382363|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 3|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
3382364|NCT04936035|Experimental|ALN-AGT01 Dose Regimen 4|Multiple doses of ALN-AGT01 administered by SC injection during the 12-month DB treatment period.
3382365|NCT04936035|Placebo Comparator|Placebo + ALN-AGT01|Multiple doses of placebo administered by SC injection during the first 6 months of 12-month DB treatment period, followed by multiple doses of ALN-AGT01 administered by SC injection during the last 6 months of the 12-month DB treatment period.
3318697|NCT01995292|Experimental|bronchoscope|Patients will receive local anaesthetics via the working channel of the bronchoscope.
3318698|NCT01995292|Experimental|Enk Fiberoptic Atomizer|Patients will receive local anaesthetics for the awake fiberoptic intubation via the Enk Fiberoptic Atomizer.
3318699|NCT01995318|Placebo Comparator|Elastic bandage|Elastic bandage application as one of routine treatment choice of acute ankle sprains.
3318700|NCT01995318|Other|Kinesiotaping|Application of anti-edema kinesiotaping
3318701|NCT01995331|Other|moderate-dose cyclophosphomide|
3382369|NCT04932733|Experimental|Elderly isometric exercise|Quadriceps isometric exercise.
3318702|NCT01995344|Active Comparator|ARM A: High Dose Interleukin-2 (HD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous HD IL2
3318703|NCT01995344|Active Comparator|ARM B: Low Dose Interleukin-2 (LD IL2)|Eligible participants will undergo surgical tumour excision from which TIL will be derived, cultured and expanded. Participants will receive preconditioning chemotherapy with cyclophosphamide (60mg/kg) day -7 and day -6, followed by fludarabine (25mg/m2) day -5 to day -1. The autologous TILs will be re-infused on day 0 and the patients will receive up to 12 doses of intravenous LD-IL2
3318704|NCT01995370|Active Comparator|Monotherapy group|"Aspirin (81mg or 100mg) or clopidogrel (50mg or 75mg) will be orally administered once daily.~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
3318705|NCT01995370|Experimental|DAPT group|"Cilostazol (100mg twice daily) will be orally administered in combination with aspirin (81 or 100mg once daily) or clopidogrel (50 or 75mg once daily).~The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject."
3382370|NCT04932733|Active Comparator|Young isometric exercise|Quadriceps isometric exercise.
3382371|NCT04931342|Experimental|Ipatasertib + Paclitaxel|Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
3318706|NCT01995383|Placebo Comparator|Part 1: Placebo (PL)|
3318707|NCT01995383|Experimental|Part 1: Single Ascending Doses (SAD) of RO6836191|
3318708|NCT01995383|Placebo Comparator|Part 2: PL: Low-salt (LS) followed by normal-salt (NS) diet|
3318709|NCT01995383|Placebo Comparator|Part 2: PL: NS followed by LS diet|
3382372|NCT04931342|Experimental|Cobimetinib|Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
3382373|NCT04931342|Experimental|Trastuzumab Emtansine|Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.
3318710|NCT01995383|Experimental|Part 2: RO6836191: LS followed by NS diet|
3318711|NCT01995383|Experimental|Part 2: RO6836191: NS followed by LS diet|
3318714|NCT01995422|Experimental|Physical activity program|A 5-month follow-up including a 3-month period of supervised physical activity
3318715|NCT01995435|Experimental|Telemedicine refraction before traditional refraction|We will first refract an individual using telemedicine refraction, and then refract them using a traditional refraction method.
3318716|NCT01995435|Experimental|Traditional refraction before telemedicine refraction|We will first refract an individual using a traditional refraction, and then refract them using a telemedicine refraction method.
3318717|NCT01995448||SEPSIS Blood test|Patient with two criteria of systemic inflammatory response syndrome and a progressive infection which is clinically or microbiologically documented.
3318718|NCT01995474|Experimental|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
3318719|NCT01995474|Active Comparator|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
3318720|NCT01995500|Experimental|BioNIR|"The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil®~Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent)."
3318721|NCT01995500|Active Comparator|Resolute|"The Endeavor Resolute Zotarolimus-Eluting Coronary Stent System consists of four subsystems:~Endeavor Resolute Stent - a premounted cobalt alloy based stent~Delivery system - Rapid Exchange (RX) Coronary System~Polymer system~Zotarolimus - drug The Resolute has a nominal drug dose of 1.6 µg zotarolimus per mm2 of the stent surface area."
3318722|NCT01995578|Experimental|low dose 5'-azacitidine|This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse.
3318723|NCT01995604|Experimental|dHACM|UltraPulse laser therapy with application of dHACM
3318724|NCT01995604|Placebo Comparator|Sterile 0.9% Saline Solution|UltraPulse laser therapy with application of Sterile 0.9% Saline Solution
3318725|NCT01995617|Experimental|Low Dose (Cohort 1)|
3318726|NCT01995617|Experimental|Mid Dose (Cohort 2)|
3318727|NCT01995617|Experimental|High Dose (Cohort 3)|
3318728|NCT01995630|Experimental|Hypermetropic, spherical IOL|AMO Sensar AR40e
3318729|NCT01995630|Experimental|Hypermetropic, aspheric IOL|AMO Tecnis ZA9003
3318730|NCT01995630|Active Comparator|Emmetropic, spherical IOL|AMO Sensar AR40e
3318731|NCT01995630|Active Comparator|Emmetropic, aspheric IOL|AMO Tecnis ZA9003
3318732|NCT01995643|Active Comparator|Active Capsule|Grape Seed Extract Capsule: 300 mg
3318733|NCT01995643|Placebo Comparator|Placebo Capsule|Placebo Capsule: Maltodextrin
3318734|NCT01995656|Placebo Comparator|Placebo - Healthy|Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
3318735|NCT01995656|Experimental|LY3108743 - Healthy|Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
3318736|NCT01995656|Placebo Comparator|Placebo - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
3318737|NCT01995656|Experimental|LY3108743 - Diabetes|Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
3318738|NCT01995656|Placebo Comparator|Placebo - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
3318739|NCT01995656|Experimental|LY3108743 - Solution|Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.
3318740|NCT01995669|Experimental|Treatment (lenalidomide, obinutuzumab)|Patients receive lenalidomide PO QD on days on days 2-22 and obinutuzumab IV over 4-5 hours on days 1, 2, 8, 15, and 22 of cycle 1 and on day 1 of each subsequent cycle. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients not experiencing progression and who in the opinion of treating physician are deriving benefit from combination treatment may continue lenalidomide for an additional 6 cycles (up to cycle 12) and obinutuzumab on day 1 every 2 months for up to 2 years in the absence of disease progression or unacceptable toxicity.
3318741|NCT01995695|Experimental|Group 1: One Vaccine Dose and One Booster Vaccine Dose|Participants will receive one dose of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine at study entry. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
3318742|NCT01995695|Experimental|Group 2: Two Vaccine Doses and One Booster Vaccine Dose|Participants will receive two doses of live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine: one dose at study entry and one dose on Day 28. They will then receive one dose of inactivated subvirion H7N9 influenza vaccine on Day 98.
3318743|NCT01995721|Experimental|4-valent HPV vaccine|4-valent HPV vaccine administered in months 0., 2., 6.
3318744|NCT01995773||Healthy Controls|Healthy control women
3318745|NCT01995786|No Intervention|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour
3318746|NCT01995786|Experimental|GDT|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 2,5 ml/kg/h and boluses of crystalloids for values of stroke volume (SV) < SV TRIGGER. Every additional infusion of colloids, blood derivates, drugs must be recorded
3318747|NCT01995799|Experimental|USPIO timepoint 2-4 days|USPIO given 2-4 days post MI Ferumoxytol enhanced MRI
3318748|NCT01995799|Experimental|USPIO timepoint 5-7 days|USPIO given 5-7 days post MI Ferumoxytol enhanced MRI
3318749|NCT01995799|Experimental|USPIO tiempoint 11-21 days|USPIO given 11-21 days post MI Ferumoxytol enhanced MRI
3318750|NCT01995812|Experimental|Hula and heart health education|12 weeks of hula classes, 2 times a week for one hour. An additional 3 hours of heart health education was given to participants
3318751|NCT01995812|No Intervention|Control group|
3318752|NCT01995851||Intervention (LAIV)|Healthy children and adolescents between Junior Kindergarten (JK) and Grade 8 in the intervention schools will be immunized with LAIV (FluMist influenza vaccine) recommended for the 2013-14 the influenza season.
3318753|NCT01995851||Control (TIV)|Healthy children and adolescents between JK and Grade 8 in schools assigned to TIV will be immunized with inactivated influenza vaccine (Vaxigrip vaccine) recommended for the 2013-14 influenza season.
3318754|NCT01995864|Experimental|CTI-TS|CTI-TS is a time-limited, 9-month long intervention, provided at the critical time when a person is first offered services at a mental health clinic, or, at the similarly critical time when a person first seeks to reconnect with a mental health clinic after a long lapse.
3318755|NCT01995864|No Intervention|Usual Care|The Usual Care group will receive mental health services as provided by the local mental health services clinic.
3318756|NCT01995877||Subjects scheduled for IVC filter placement|A filter may be needed to be placed in the IVC (inferior vena cava) to prevent blood clots from traveling from legs to lungs. Patients who have had a pelvic fracture, or have blood clots in the leg(s) may need an IVC. Filter placement may be ordered when a patient is scheduled for major surgery and extensive bed rest.
3318757|NCT01995890|Experimental|nepafenac|Nepafenac 0.1% eye drops, 3 times a day
3318758|NCT01995890|No Intervention|control|No intervention in the control arm
3318759|NCT01995903|Experimental|Amyotrophic lateral sclerosis|Clinical examination for ALS(amyotrophic lateral sclerosis) and subjects with lower motor neuron signs will be completed. These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to assess neurological conditions.
3318760|NCT01995903|Active Comparator|Healthy controls (MRI)|These subjects will undergo MRI (magnetic resonance imaging) scans of the brain to compare against diseased subjects.
3318761|NCT01995916|Experimental|Mindfulness Intervention|Mindfulness Based Stress Reduction Intervention
3318762|NCT01995916|Active Comparator|Social Support Group|Social Support Group Intervention
3318763|NCT01995929||neurogenic dysphagia|Patients suffering from neurogenic dysphagia due to several reasons (e.g. Parkinson´s disease).
3318764|NCT01995942||Group 1|Patients with mrEMVI positive rectal cancer
3318765|NCT01995942||Group 2|Patients with mrEMVI negative rectal cancer
3318766|NCT01995955|Experimental|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
3318767|NCT01995968||SGA stillbirths (Cases)|Stillbirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2012-13, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
3318768|NCT01995968||SGA livebirths (Controls)|Livebirths, SGA births (below the 10th percentile of French customised birthweight curves), born in 2013, at or after 24 completed weeks of gestational age, without lethal congenital anomalies, to mothers residents in Isère, Savoie or Haute-Savoie
3318769|NCT01995981||Advanced soft tissue sarcoma patients|Advanced soft tissue sarcoma patients, who have an indication for pazopanib treatment.
3318770|NCT01995994||RT-CGM|
3318771|NCT01996007||Children|Pneumococcal nasopharyngeal carriage and immunogenicity in children aged 6-48 months who have previously received PCV13
3318772|NCT01996007||Parents|Pneumococcal nasopharyngeal carriage and immunogenicity in parents of children also participating in the study
3318773|NCT01996046||Bone mets|Patients will undergo an [18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
3318774|NCT01996059|Experimental|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
3318775|NCT01996059|Active Comparator|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
3318776|NCT01996072|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3318777|NCT01996085|Experimental|Hemodynamic group|"The treatment choice based on hemodynamic parameters established with ICG method.~Monotherapy or combined therapy in case of 1/ complex hemodynamic disturbances and/or 2/ office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
3318778|NCT01996085|Active Comparator|Empiric Group|"The treatment choice based on current guidelines (blinded to ICG).~Monotherapy or combined therapy in case of office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg"
3318779|NCT01996098|Experimental|6-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 6 months
3318780|NCT01996098|Experimental|12-month icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months
3318781|NCT01996098|No Intervention|Chemotherapy alone|No intervention
3318782|NCT01996111|Experimental|• Group 2:|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension
3318783|NCT01996111|Experimental|• Group 3:|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension
3318784|NCT01996111|Experimental|• Group 4:|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension
3318785|NCT01996111|Placebo Comparator|• Group 1|• Injection of 1.0 cc of 0.9% Saline
3318786|NCT01996124|Experimental|Indacaterol|Indacaterol Fumarate 150 mcg Breezehaler,Onbrez Novartis International AG, Basel Switzerland. Once daily.
3318787|NCT01996124|Placebo Comparator|Placebo|Placebo Breezehaler
3318788|NCT01996137|Experimental|VASST II|Stroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
3318789|NCT01996150|Experimental|Dilute bleach bath|Subjects will take a diluted bleach bath (0.005% Sodium hypochlorite) for 5-10 minutes twice a week for 12 weeks.
3318790|NCT01996163||Male|
3318791|NCT01996163||Female|
3318792|NCT01996176|Experimental|Intervention group|Intervention group
3318793|NCT01996176|Placebo Comparator|Intervention control|Control group
3318794|NCT01996189|Experimental|Insulin|Arterial puncture with an insulin syringe followed by arterial puncture with standard needle.
3318795|NCT01996189|Active Comparator|Standard|Arterial puncture with standard needle followed by arterial puncture with insulin syringe.
3318796|NCT01996202|Other|Resected Melanoma|Subjects with resected melanoma.
3318797|NCT01996202|Other|Unresected Melanoma|Subjects with unresected melanoma.
3318798|NCT01996215||AMD controls|
3318799|NCT01996215||AMD cases|
3318800|NCT01996228|Experimental|Cord Blood-derived multipotent stem cells|Human cord blood-derived multipotent stem cells (CB-SC) display unique phenotypes, such as the expression of embryonic stem (ES) cell markers, multipotential of differentiations, very low immunogenecity, and immune modulations in patients.
3318801|NCT01996267|Active Comparator|FEC-T +Pertuzumab|Fluorouracil; 500 mg/m2; day 1 Epirubicine; 90 mg/m2; day 1 Cyclophosphamide; 500 mg/m2; day 1 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle is repeated every 21 days
3318802|NCT01996267|Active Comparator|PTC+Pertuzumab|Paclitaxel; 80 mg/m2; day 1,8 Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1 Carboplatin; AUC=6; day 1 Pertuzumab; 420 mg (loading dose 840 mg); day 1 Cycle repeated every 21 days
3318803|NCT01996280|Placebo Comparator|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hours that includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan. The MI is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
3318804|NCT01996280|Experimental|Culturally Tailored MI|The CTMI is a single brief motivational interview lasting 1.5 hours. It follows the same sequence of structured strategies as the MI, but the focus of the components is different. CTMI has augmented some of the components with culturally relevant material, including discussion about acculturation stress. The CTMI components are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback elements in the CTMI, such as ethnic normative feedback about drinking. To control for time across conditions, interventionists are instructed to select CTMI components based on participant interests, not the entire array of components.
3318805|NCT01996293||Lamotrigine for Bipolar|antepartum and peripartum women taking lamotrigine for Bipolar Disorder
3318806|NCT01996306|Active Comparator|FOLFIRI +/- Bevacizumab|Bevacizumab 5 mg/kg IV 90-30 min Day 1 CPT-11 180 mg/m2 (150 mg/m2) IV 90 min Day 1 l-LV (dl-LV) 200 mg/m2 (400 mg/m2) IV 120 min Day 1 5-FU - bolus 400 mg/m2 IV bolus Day 1 5-FU - infusional 2400 mg/m2 IV continuous (46 hours) Day 1 - 3
3318807|NCT01996306|Experimental|XELIRI +/- Bevacizumab|Bevacizumab 7.5 mg/kg IV 90-30 min Day 1 CPT-11 200 mg/m2 (150 mg/m2) IV 90 min Day 1 Capecitabine 800 mg/m2 p.o. twice daily 14 Days consecutively
3318808|NCT01996345|Experimental|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
3318809|NCT01996345|No Intervention|Expectant Managment|Each participant will have standard care for placenta previa. This is the same care that a patient with a placenta previa would ordinarily receive even if she were not participating in the trial. The trial's participating investigators agree that the management outlined in this section is standard management for placenta previa.
3318810|NCT01996358|Active Comparator|Succinylcholine|Succinylcholine 0,5mg/kg as muscle relaxant during induction of anaesthesia for rigid bronchoscopy
3318811|NCT01996358|Active Comparator|Rocuronium 0,3|Rocuronium 0,3 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
3318812|NCT01996358|Active Comparator|Rocuronium 0,6|Rocuronium 0,6 mg/kg during induction of anaesthesia for rigid bronchoscopy. At the end of procedure 2mg/kg sugammadex for reversal of neuromuscular block are applied.
3318813|NCT01996384|Experimental|Classical Acupuncture + Lidocaine|Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
3318814|NCT01996384|Active Comparator|Non-classical acupuncture + lidocaine|Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
3318815|NCT01996397|Other|CRT implantation|Standard CRT indication. Assessment of acute response to CRT.
3318816|NCT01996423|Experimental|Vitamin D3 supplementation|Subjects in the experimental arm will receive weekly vitamin D3 doses in oral suspension during 6 weeks. Weekly dose varies according to age group: VD3 8000 IU between ages 2-5.9 years, VD3 12000 IU between ages 6-11.9 years, VD3 16000 IU between ages 12-17.9 years.
3318817|NCT01996423|Placebo Comparator|Placebo|Subjects in the placebo arm will receive weekly placebo oral suspension during 6 weeks.
3318818|NCT01996436|Active Comparator|Nicardipine|Group 1 : Nicardipine 5mg per circulation intra-arterial injection, Pharmacological angioplasty
3318819|NCT01996436|Active Comparator|Verapamil|Group 3: Verapamil 10mg per circulation intra-arterial injection, Pharmacological angioplasty
3318820|NCT01996436|Active Comparator|Nicardipine + Verapamil + Nitroglycerin|Group 4 : Nicardipine 5mg + Verapamil 10mg + Nitroglycerin 200mcg in 4cc 5 % dextrose in water , intra-arterial injection, Pharmacological angioplasty
3318821|NCT01996449|Active Comparator|Initial treatment with Amlodipine|The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3318822|NCT01996449|Active Comparator|Initial treatment with Eplerenone|The subject will be started on Eplerenone 50 - 200 mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued. The subject will be started on Amlodipine 2.5-10 mg daily, which he or she will continue for a period of 8 weeks. Following the 8 week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
3318823|NCT01996462|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
3318824|NCT01996475|Experimental|Torrent's of Escitalopram Oxalate Tablet 20 mg|
3318825|NCT01996488|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
3318826|NCT01996501|Experimental|Torrent's Olanzapine Orally Disintegrating Tablets 5mg|
3318827|NCT01996514|Experimental|Sweetener, non-food advertisements|non-caloric sweetener with water followed by TV program with non-food advertisements while feeding at 30 min
3318828|NCT01996514|Experimental|Glucose, non-food advertisements|Glucose with water followed by TV program with non-food advertisements while feeding at 30 min
3318829|NCT01996514|Experimental|Sweetener, food advertisements|non-caloric sweetener with water followed by TV program with food advertisements while feeding at 30 min
3318830|NCT01996514|Experimental|Glucose, food advertisements|Glucose with water followed by TV program with food advertisements while feeding at 30 min
3318831|NCT01996527|Experimental|3-Tesla magnetic resonance imaging|Patients undergo 3-Tesla magnetic resonance imaging to measure tumor protein content (using CEST-MRI), cellularity (using DW-MRI), and blood flow (using DCE-MRI and DSC-MRI with IV administration of gadolinium-containing contrast agent) no more than 2 weeks before, and 2 and 4 weeks after, the initiation of treatment.
3318832|NCT01996540|Experimental|Interventional arm|Interventional arm
3318833|NCT01996540|No Intervention|Standard arm|Standard arm
3318834|NCT01996553||Transradial cardiac catheterization|Patients undergoing cardiac catheterization through the radial artery.
3318835|NCT01996579|Experimental|Lactoferrin|Patients randomized to the Lactoferrin arm will receive Lactoferrin delivered to the oral cavity as a mouth swab and Lactoferrin down a nasogastric tube; a total of 2 grams administered in 4 divided doses per day.
3318836|NCT01996579|Placebo Comparator|Placebo (sterile water)|Placebo (sterile water) will also be delivered down the nasogastric tube; administered in 4 divided doses per day.
3318837|NCT01996618|Experimental|Ranolazine|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
3318838|NCT01996618|Placebo Comparator|Placebo|Subjects will be consented by the study investigator and then randomly assigned in an allocation-concealed fashion to double-blinded treatment with either titrated doses of ranolazine or matched placebo. After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily or matching placebo) with the plan to then undergo a repeat 24-hour ambulatory electrocardiographic monitoring in 6 days. When the subject returns the monitor, subjects will enter the washout period (cessation of the study medication) for 6 days and have electrocardiographic monitoring prior to return to the subject's referring provider for care.
3318839|NCT01996670||<2h group|
3318840|NCT01996670||2-4h group|
3318841|NCT01996670||>4h group|
3318842|NCT01996683|Active Comparator|iron chelation|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will continue their chelation therapy.
3318843|NCT01996683|Placebo Comparator|blood transfusion only|Included 25 thalassemia patients with low serum ferritin (< 500) or downward ferritin trend inspite of reduction of chelation dose over the last 6 months. They will be subjected to discontinuation of their chelation therapy.
3318844|NCT01996696|Experimental|Metformin|Metformin 500 mg PO TID x 30-36 months
3318845|NCT01996696|Placebo Comparator|Placebo|Identical placebo TID x 30-36 months
3318846|NCT01996735|Active Comparator|Ticagrelor 180 mg single dose|Ticagrelor 180 mg single dose
3318847|NCT01996735|Placebo Comparator|Placebo|Placebo single dose
3318848|NCT01996761|Experimental|Study Group 1|Study Group 1: 30ml Cerebrolysin
3318849|NCT01996761|Placebo Comparator|Study Group 2|Study Group 2: Placebo (0.9% NaCl)
3318850|NCT01996774||Child, peanut/ nut allergy, no treatment|
3318851|NCT01996774||Child, peanut/nut allergy, tolerance|
3318852|NCT01996774||Non allergic child, without atopia|
3318853|NCT01996787|Active Comparator|Air Optix Aqua|Compare safety and efficacy of the lens using OptiFree Replenish solution
3318854|NCT01996787|Active Comparator|Clariti with Handling Tint|Compare safety and efficacy of the lens using OptiFree Replenish solution
3318855|NCT01996800|Experimental|Spinal Manipulative Therapy (SMT)|Patients will receive 12 weeks of chiropractic SMT
3318856|NCT01996800|Active Comparator|SMT and Neuromuscular Reeducation|"Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.~A neuromuscular re-education program will consist of repetitive movements, posturing, and stimulation designed to reinforce nerve signals for functional movements. It is theorized that when the nerve signals are retrained and appropriate muscle movements are repeated, movement patterns become automatic again. Neuromuscular re-education is usually done along with other types of treatment to promote functional muscle movement."
3318857|NCT01996865|Experimental|Arm A: Lenalidomide + rituximab followed by lenalidomide|Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but < 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by a Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses
3318858|NCT01996865|Active Comparator|Arm B: Lenalidomide + rituximab followed by rituximab|Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29
3318859|NCT01996878||Case (Parkinson's disease patients)|Clinical diagnosis of Parkinson's disease (cases are diagnosed by the presence of at least three of the five following primary signs: rest tremor, bradykinesia, rigidity, impaired postural refluxes, and the presence of a sustained L-dopa response.)
3318860|NCT01996878||Control (Healthy volunteers)|Healthy volunteers without Parkinson's disease
3318861|NCT01996891|Other|Anti-Inflammatory Diet First|For the first 6 weeks, subjects will receive the anti-inflammatory diet. For the second 6 weeks, subjects will consume their habitual diet.
3318862|NCT01996891|Other|Anti-Inflammatory Diet Second|For the first 6 weeks, subjects will consume their habitual diet. For the second 6 weeks, subjects will receive the anti-inflammatory diet.
3318863|NCT01996930|Active Comparator|Haelan tape (steroid impregnated tape)|"Haelan tape, medicated tape for cutaneous use, containing 4mcg Fludroxycortide per centimetre squared.~Maximum daily dosage of 0.1mg = 25cm squared per day. Application = once daily and left in situ for 24 hours Maximum duration of treatment = 28 days"
3318864|NCT01996930|Active Comparator|Silver nitrate|Avoca caustic applicator 95% w/w cutaneous stick Cautery with silver nitrate cutaneous stick undertaken twice weekly Maximum duration of treatment = 28 days
3318865|NCT01996956|Other|Volume loading|
3318866|NCT01996969|Other|Regorafenib|This study is a single arm study with biomarker analysis
3318867|NCT01996995|Experimental|Nd:YAG laser pulse therapy|Nd:YAG laser pulse therapy Patients are treated with laser session in week 0, 2, 4, and 12. The settings are; 1064 nm, spot size 3 mm, 20 J /cm2, 5 Hz, power 10 W, pulse duration 132 millisecond. A maximum of two sequential sessions (one session on the horizontal and one the vertical passing) will be applied to eliminate potential safety issues in those patients with a lack protective sensibility.
3318868|NCT01996995|Sham Comparator|Sham|Sham treatment Patients are treated with a sham session in week 0, 2, 4, and 12. The study settings are similar to the laser except the laser beam. Because the patient is also blinded, they can't see the procedure. The sound and the beeps are audible similar to the laser treatment.
3382374|NCT04931342|Experimental|Atezolizumab + Bevacizumab|Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.
3382375|NCT04929223|Experimental|Inavolisib + Cetuximab|"Participants will receive 9 milligrams (mg) of inavolisib by mouth once daily (QD) on Days 8-28 of Cycle 1, then QD on Days 1-28 from Cycle 2 onwards (1 cycle=28 days).~Participants will also receive cetuximab intravenous (IV) infusion 400 mg/m2 body surface area on Day 1 of Cycle 1. All subsequent weekly (QW) doses will be 250 mg/m2 each."
3382376|NCT04929223|Experimental|Inavolisib + Bevacizumab|Participants will receive 9 mg of inavolisib by mouth QD combined with bevacizumab 15 milligram/kilogram (mg/kg) IV once every three weeks (Q3W) on Day 1 of each cycle (1 cycle=21 days).
3382377|NCT04929223|Experimental|Atezolizumab + Tiragolumab + Bevacizumab|Participants will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle, combined with Tiragolumab at a dose of 600 mg IV infusion on Day 1 of each cycle and Bevacizumab IV infusion at a dose of 15 mg/kg on Day 1 of each cycle. (Cycle length=21 days)
3382378|NCT04929223|Experimental|Atezolizumab + Tiragolumab|Participants will receive 1200 mg of atezolizumab by IV infusion on Day 1 of each cycle combined with tiragolumab 600 mg IV infusion on Day 1 of each cycle. (Cycle length=21 days)
3382379|NCT04929223|Experimental|Atezolizumab + SY-5609|Participants will receive 1680 mg of atezolizumab by IV infusion on Day 1 of each cycle Q4W in repeated 28-day cycles combined with SY-5609 at a dose of 3, 4, or 5 mg by mouth for 7 days, followed by 7 days off. (Cycle length=28 days)
3318869|NCT01997008|Experimental|Intervention|"Participants receive a five week intervention providing the following activities:~EMA:~Ecological Momentary Assessment (EMA) of Emotion throughout the day.~Intervention:~Positive Events: Participants identify a positive event and then describe how they capitalized on this event.~Gratitude: Participants identify one more more things that make them feel grateful.~Mindfulness: Participants participate in a 30 minute guided mindfulness/meditation practice.~Positive Reappraisal: Participants identify how they reappraised a negative event making it into a positive event.~Personal Strengths: Participants identify one more more personal strengths. Attainable goals: Participants identify a short-term attainable goal. Participants will outline what they did that day to work toward attaining their week's goal.~Acts of Kindness: Participants will identify one more more acts of kindness that they engaged in and how it made them feel."
3318870|NCT01997008|No Intervention|Emotion reporting and EMA notification|"Participants report emotions and receive EMA (ecological momentary assessment) text messages on the same regular basis as intervention participants, but receive no interventions.~EMA detail:~Ecological Momentary Assessment (EMA) of Emotion throughout the day. We will assess current emotions via email or text message 4 times per day, 2 days per week (one randomly selected week/work day and one randomly selected weekend/non-work day) during the 8 week study period, for a total of 16 days of EMA reporting. Participants will be asked to rate how much they are currently feeling several positive and negative emotions that have been associated with mortality and health: happy, excited, content, appreciative, sad, worried, and fearful."
3318871|NCT01997021|Experimental|US/IW/CW|This is a 3 arm crossover design. Arm US/IW/CW corresponds to the group of participants randomized to uninterrupted sitting (US) first, then Intermittent Walking (IW) and then continuous walk (CW).
3382385|NCT04923594|Active Comparator|NLS-2 (mazindol extended release)|2 mg dosed orally, once daily for 1 week; followed by 3 mg dosed orally, once daily for up to 3 weeks (total of 4 weeks)
3382386|NCT04923594|Placebo Comparator|Placebo|Dosed orally, once daily for up to 4 weeks
3318872|NCT01997021|Experimental|IW/US/CW|This is a 3 arm crossover design. Arm IW/US/CW corresponds to the group of participants randomized to Intermittent Walking (IW) first, then uninterrupted sitting (US), and then continuous walk (CW).
3382393|NCT04917861|Experimental|mRNA-1893 Low Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a low dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
3382394|NCT04917861|Experimental|mRNA-1893 High Dose (2-Dose Regimen)|Participants will receive mRNA-1893 at a high dose level administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
3382395|NCT04917861|Experimental|mRNA-1893 High Dose (1-Dose Regimen)|Participants will receive placebo matching to mRNA-1893 on Day 1 and mRNA-1893 at a high dose level administered as a 1-dose regimen (administered on Day 29). There will be 28-day (-3/+7 days) interval between vaccinations.
3318873|NCT01997021|Experimental|IW/CW/US|This is a 3 arm crossover design. Arm IW/CW/US corresponds to the group of participants randomized to Intermittent Walking (IW) first, then Continuous Walk (CW) and then Uninterrupted Sitting (US).
3318874|NCT01997021|Experimental|CW/IW/US|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Intermittent Walking (IW) and then Uninterrupted Sitting (US).
3318875|NCT01997021|Experimental|CW/US/IW|This is a 3 arm crossover design. Arm CW/IW/US corresponds to the group of participants randomized to Continuous Walk (CW) first, then Uninterrupted Sitting (US), and then Intermittent Walking (IW).
3318876|NCT01997021|Experimental|US/CW/IW|This is a 3 arm crossover design. Arm US/CW/IW corresponds to the group of participants randomized to Uninterrupted Sitting (US) first, then Continuous Walk (CW), and then Intermittent Walking (IW).
3318877|NCT01997034||Intensive Lifestyle Intervention|Former participants of Ubberup Folk High Schools intensive lifestyle intervention programme.
3318878|NCT01997047||Tachypneic children|All tachypneic children under 5 yrs age presenting to study centres. No exclusions.
3318879|NCT01997060|Experimental|Intensive Lifestyle Intervention|Intensive Lifestyle Intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction (~-700KCal/day). Education within nutrition, exercise and healthy living in general.
3318880|NCT01997086|Active Comparator|Transforaminal discectomy|patients diagnosed as lumbar disc herniation undergoing percutaneous transforaminal endoscopic discectomy (PTED).
3382396|NCT04917861|Placebo Comparator|Placebo|Participants will receive placebo matching to mRNA-1893 administered as a 2-dose regimen with 28-day (-3/+7 days) interval between vaccinations (administered on Day 1 and Day 29).
3318881|NCT01997086|Active Comparator|Microendoscopic discectomy|Patients diagnosed as lumbar disc herniation undergoing microendoscopic discectomy (MED).
3318882|NCT01997099||Library Creation|Individuals responsible for creating the drug library
3318883|NCT01997099||Pump Programming|Individuals responsible for programming ambulatory infusion pumps
3318884|NCT01997099||Home Implementation|Individuals responsible for implementing ambulatory infusion pumps in patients' homes
3318885|NCT01997099||Workflow|Individual at the facility responsible for describing the workflow of processing and implementing an ambulatory infusion pump prior to and after introducing the CADD®-Solis VIP System.
3318886|NCT01997099||Ambulatory Infusion Pump Patients|Patients that receive a prescription requiring use of the CADD®-Solis VIP pump
3318887|NCT01997112|Active Comparator|Paracetamol|paracetamol 1g (500mg x2) four times daily for 14 day period
3318888|NCT01997112|Placebo Comparator|Placebo|Matched placebo control: hard gelatin placebo capsules containing Lactose Ph Eur. Taken for 14 days
3318889|NCT01997138|Experimental|Anakinra|Anakinra 100 mg in 2 ml saline IA
3318890|NCT01997138|Placebo Comparator|Placebo|Saline 2 ml IA
3318891|NCT01997151|Experimental|Healthy Pregnancy: Step by Step|Pregnant women interacted with a multiple behavior change iPad- delivered program at federally funded health centers. The 20-30 minute program offered onscreen assessments of Transtheoretical Model strategies of change, and then provided individually tailored feedback messages matched to their readiness to change for relevant target behaviors. The program addressed smoking cessation and relapse prevention, stress management, and fruit and vegetable consumption. The feedback screens were interactive and engaging. The messages were written at a 4th-5th grade level and were reviewed for multicultural relevancy. Participants in the treatment group interacted with the program up to 3 times during pregnancy. A printed multiple behavior change guide also was distributed. All program components are available in English and Spanish.
3318892|NCT01997151|No Intervention|Usual Care|Pregnant women received regular prenatal care as delivered by the health care center from where they were receiving care. Standard informational March of Dimes brochures related to the target behaviors were distributed to usual care participants.
3318893|NCT01997164|Experimental|Cohorts 1 through 4|Participants in cohorts 1 through 4 will receive IVT REGN910-3 and IAI
3318894|NCT01997164|Experimental|Cohort 5|Participants in cohort 5 will receive IVT REGN910 and IAI
3318895|NCT01997177||novices|novice endoscopists, fellows of gastroenterology
3318896|NCT01997177||experienced endoscopist|consultant doctors of gastroenterology
3318897|NCT01997190|Experimental|Study Arm|AdV-tk + valacyclovir
3318898|NCT01997203|Experimental|HCV patients under treatment|"Fifty patients study group administered vitamin D were compared with 50 patients control group without vitamin D.~Dose of vitamin D 15,000 IU/week"
3318899|NCT01997203|No Intervention|HCV without Vit D|
3318900|NCT01997242||stenting undergoing surgery|Patients with prior coronary stenting undergoing urgent or elective surgical/endoscopic procedures
3318901|NCT01997255|Experimental|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
3318902|NCT01997268|Placebo Comparator|Placebo|Placebo 6 capsules (1.24 g each) daily for 12 weeks
3318903|NCT01997268|Experimental|SC401B 2 capsules|SC401B 2 capsules (1.24 g each) + 4 placebo capsules daily for 12 weeks
3318904|NCT01997268|Experimental|SC401B 4 capsules|SC401B 4 capsules (1.24 g each) + 2 placebo capsules daily for 12 weeks
3318905|NCT01997268|Experimental|SC401B 6 capsules|SC401B 6 capsules (1.24 g each) daily for 12 weeks
3318906|NCT01997294|Active Comparator|sequential therapy group|80mg atorvastatin before primary PCI (PPCI) followed by 40mg/d for 7 days after PPCI followed by 20mg/d for 1 year
3318907|NCT01997294|Placebo Comparator|Usual Therapy of atorvastatin|20mg/d before and after PPCI for 1 year
3318908|NCT01997307||Stratification by gender and age, including 4 age categories|>=55-64 years
3318909|NCT01997307||Age >=65 to 74|
3318910|NCT01997307||Age >=75 to 84|
3318911|NCT01997307||Age >=85|
3318912|NCT01997320|Experimental|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks combined with nutrient supplementation twice daily each containing 20g of milk protein.
3318913|NCT01997320|Active Comparator|Nutrition supplement|Nutrient supplementation twice daily for 12 weeks. Each supplement contains 20g of milk protein.
3318914|NCT01997346||Key Informant Interviews|We will conduct interviews with 4 clinic personnel (16 across the 4 sites) to learn about practices and provider perspectives in the HIV clinic or ancillary clinics such as VCT. The 4 clinic personnel in each site will include: the physician-in-charge, a nurse, one peer educator, and a nurse or community counselor from the VCT clinic. A semi-structured interview guide will be used to query respondents about: procedures for enrolling new clients, conducting active testing, identifying and initiating patients on ART, CD4 monitoring, tracking clients who have missed appointments, support programs, and peer education. We will also aim to understand how each respondent views her/his role, how s/he counsels patients on pre-ART care, and the challenges faced from each one's perspective.
3318915|NCT01997359||Key Informant Interviews|Eligible patients will undergo a one hour structured interview about barriers and facilitators to early ART initiation.
3318916|NCT01997359||Prospective Cohort|The prospective cohort will include all patients initiating ART at one of the six study sites, estimated at 1,200 patients. Cases will be adults initiating ART with either: CD4 count <150 cells/µL. Controls will be adults who initiate ART with CD4≥200 . Individuals initiating ART with CD4 counts of 150-199 cells per µL and at WHO Stage I-III will be excluded from the case-control analysis in order to ensure meaningful distinction between the two groups. We will enroll 720 patients for the case control study nested in the prospective cohort, which will include 360 cases and 360 controls, who will be frequency matched by sex, month of ART initiation, and clinic.
3318917|NCT01997372|Experimental|high dose ATG,low dose ATG|
3318918|NCT01997385|Active Comparator|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
3318919|NCT01997385|Experimental|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
3318920|NCT01997450||Q/LAIV|FluMist Quadrivalent
3318921|NCT01997450||Inactivated Influenza Vaccine|Inactivated Influenza Vaccine
3318922|NCT01997463|No Intervention|Regular Therapy|Regular Asthma Therapy
3318923|NCT01997463|Experimental|Supervised Therapy|Supervised asthma therapy in schools
3318924|NCT01997476|Experimental|Combined EUS, e-PFT and sEUS Testing|"Establish the advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
3318925|NCT01997489|Experimental|Fabry patients during treatment|39 patients with Fabry disease having had baseline examinations of the eyes were assessed also at follow-up 10 years after enzyme replacement therapy
3318926|NCT01997528|Experimental|Extracorporeal CO2 elimination by ILA Activve(R)|
3318927|NCT01997541||plain tube|
3318928|NCT01997541||reinforced tube|
3318929|NCT01997554|Experimental|less than 60 years old with clinical symptom of hypothyroidism|Group of patients less than 60 years old, with at least one clinical symptom of hypothyroidism
3318930|NCT01997554|Experimental|less than 60 years old without clinical symptoms|Group of patients less than 60 years old, without clinical symptoms of hypothyroidism
3318931|NCT01997554|Experimental|more than 60 years old|Group of patients more than 60 years old at recruitment.
3318932|NCT01997580|Experimental|Escitalopram|depressed patients receiving escitalopram treatment
3318933|NCT01997580|No Intervention|Control|healthy controls matched for age, gender, and BMI
3318934|NCT01997593|Experimental|ropivacaine|Preincisional wound intraperitoneal infiltration of 1% ropivacaine 0.3ml/kg was performed in group I patients before surgery.
3318935|NCT01997606|Experimental|Purotex|use of Purotex treated bedding covers
3318936|NCT01997606|Placebo Comparator|Placebo|no use of Purotex treated bedding covers
3318937|NCT01997632|Active Comparator|control vaccine: Imovax Polio®|
3318938|NCT01997632|Experimental|investigational vaccine|
3318939|NCT01997645|Active Comparator|Rectal advanced mucosal flap|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~In RAF procedure, internal opening will identified and after infiltration with saline-adrenalin solution (1/100000) the mucosal flap will be mobilized proximally. The external tract and internal opening will be excised and the defect will be sutured. After that, the flap will be advanced from both sides with absorbable suture and overlapped over the internal opening. External openings will be left open."
3318940|NCT01997645|Active Comparator|Ligation of intersphincteric fistula tract|"Procedure will be performed in general anesthesia without mechanical bowel preparation. Antibiotic prophylaxis (Metronidazole 1g) will be applied intravenously 60 minutes prior the surgery.~Before LIFT procedure the fistula tract will be identified with small probe. The intersphincteric space will be reached by dissection from small (2-4cm) incision. The fistula tract will be divided and ligated on both sides with Polydioxanone (PDS) suture. The external and internal openings will be left open to drain."
3318941|NCT01997658|Experimental|Methylprednisolone|Injection, 500 mg, single use, over 15 to 20 minutes.
3318942|NCT01997658|Placebo Comparator|Control|In Control arm, patients will receive the standardized surgical treatment without receiving methylprednisolone preoperatively (placebo).
3318943|NCT01997671|Experimental|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering.
3318944|NCT01997671|No Intervention|Control group|Routine clinical practice
3318945|NCT01997684|Experimental|Colonic Stenting with Elective Surgery|"In the experimental group, the patients will undergo colonic stenting within 24 h of inclusion. For this study, the WallFlex ™ Colonic Stent (Boston Scientific, Natick, MA) will be employed.~Candidates for elective surgery, after clinical success of colonic stenting, will be preferably operated on 5-14 days after inclusion, and no later than 4 weeks. Type and extent of the elective surgery will be selected by the surgeon.~In this group, unplanned emergency surgery will be indicated in case of technical failure of colonic stenting, iatrogenic morbidity, or clinical failure.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
3382399|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.
3382400|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-6231 by subcutaneous injection on Day 1.
3318946|NCT01997684|Active Comparator|Emergency Surgery|"In the comparator group, patients will be undergo emergency surgery. Surgical options including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.~In case of a primary colostomy, restoration of bowel continuity was attempted within 3-6 months."
3318948|NCT01997710|Experimental|all-ceramic inlay-retained RBFDP|Treatment with an all-ceramic inlay-retained RBFDP
3318949|NCT01997710|Active Comparator|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
3318950|NCT01997736|Experimental|Ablation|
3318951|NCT01997749|Experimental|Ketogenic diet|Acute stroke patients will receive a ketogenic diet (Ketocal 4:1 and ketogenic meals) for the first week after inclusion
3318952|NCT01997749|Active Comparator|Control diet|Acute stroke patients will receive a control diet (the regular diet, enteral or oral, offered at the hospitals) for the first week after inclusion.
3318953|NCT01997762|Placebo Comparator|Placebo|Corn starch capsules, 1 capsule twice a day for 3 months
3318954|NCT01997762|Experimental|Resveratrol|Resveratrol capsules, 250 mg twice a day for 3 months
3318955|NCT01997775|Experimental|METFORMIN|For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
3318956|NCT01997788|Experimental|The ITM group|The postoperative pain management includes both the intrathecal morphine injection and the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
3318957|NCT01997788|Placebo Comparator|The IV-PCA group|The postoperative pain management includes only the intravenous patient-controlled analgesia. Demerol on demand will be injected intravenously.
3318958|NCT01997801|Placebo Comparator|C group|In C group, NS infusion will be done intraoperatively.
3318959|NCT01997801|Experimental|KET group|In KET group, ketamine infusion will be done intraoperatively(0.25 mg/kg bolus injection following 100 mcg/kg/hr till the end of surgery).
3318960|NCT01997814|Active Comparator|Test Group|Patients in Test Group were given Herbal Immunomodulators (SeptilinTM) 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3318961|NCT01997814|Placebo Comparator|Control Group|Patients in Control Group were given placebo drug 2 tablets twice daily for 3 weeks then medications were stopped and changes in all parameters were again checked after 6 weeks.
3318962|NCT01997827|Active Comparator|metal-ceramic RBFDP|Treatment with a metal-ceramic RBFDP
3318963|NCT01997827|Experimental|all-ceramic RBFDP|Treatment with an all-ceramic RBFDP
3318964|NCT01997840|Experimental|ACY-1215 in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
3318965|NCT01997853|Active Comparator|Test Group|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks
3318966|NCT01997853|Placebo Comparator|Control Group|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks
3318967|NCT01997866|Other|Patients with Congestive Heart Failure|"STOP-BANG Scoring Model~Polysomnogram Sleep Study"
3318968|NCT01997879|Experimental|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
3318969|NCT01997944|Experimental|Human Serum Albumin/interferon alpha2a|Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.
3318970|NCT01997944|Active Comparator|Pegasys|Peginteferon 180 mcg multiple dose S.C.
3318971|NCT01997957|Experimental|TACE+HAIC-OXA+S-1|
3318972|NCT01997957|No Intervention|TACE+HAIC-OXA|
3318973|NCT01997970|Experimental|Treadmill workstation|Will receive a health talk with recommendations about diet and physical activity habits and will also receive a treadmill workstation at regular office site for 12 months.
3318974|NCT01997970|Experimental|Control group|Will receive a health talk with recommendations about diet and physical activity habits. Will continue to work with conventional office work at their regular desk.
3318975|NCT01997983|Experimental|TC-3 Gel with Botox|open label observational study
3318976|NCT01997996||PROLIFT+M|Patients that undergo surgery due to prolapse POP ≥ stage II with PROLIFT+M device having had ≥ 2x/4 weeks sexual intercourse before surgery.
3318977|NCT01998009|Other|Fecal occult blood tests|Each patient will perform one guaiac and two immunochemical fecal occult blood tests at home.
3318978|NCT01998035|Experimental|R/O: Level -1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)
3318979|NCT01998035|Experimental|R/O: Level 1|Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3318980|NCT01998035|Experimental|R/O: Level 2|Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3318981|NCT01998035|Experimental|R/O: Level 3|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3318982|NCT01998035|Experimental|R/O: Level 4|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)
3318983|NCT01998035|Experimental|R/O: Level 5|Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
3318984|NCT01998035|Experimental|R/O: Level 6|Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)
3318985|NCT01998048|Active Comparator|Latarjet|60 patients treated with open Latarjet operation
3318986|NCT01998048|Active Comparator|Bankart|60 patients treated with arthroscopic Bankart operation
3318987|NCT01998061|Experimental|Arm A|TKI alone until rapid progression
3318988|NCT01998061|Experimental|Arm B|TKI combined with investigator's choice of chemotherapy regimen and subsequent line of treatment until rapid progression.
3318989|NCT01998074|Experimental|Study formula|
3318990|NCT01998087|Experimental|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three standardized phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following birth of the baby.
3318991|NCT01998087|Active Comparator|General Support|The active control group of mothers will receive a brochure in pregnancy covering general pregnancy and parenting issues and follow-up phone calls but breastfeeding issues will not be specifically addressed. If a mother raises any breastfeeding issue she will be referred to appropriate support.
3318992|NCT01998087|No Intervention|Standard Care|This group will receive standard antenatal care provided by their chosen gynaecologist and obstetrician, consisting of regular antenatal visits. No written materials or telephone calls are routinely provided to pregnant women in Croatia.
3318993|NCT01998100|Experimental|Prolonged Exposure + Exercise|
3318994|NCT01998100|Active Comparator|Prolonged Exposure Alone|
3318995|NCT01998113||Glyburide (Glyburide vs Insulin)|Glyburide vs Insulin trials
3318996|NCT01998113||Insulin (Glyburide vs Insulin)|Glyburide vs Insulin trials
3318997|NCT01998113||Metformin (Metformin vs Insulin)|Metformin vs Insulin trials
3318998|NCT01998113||Insulin (Metformin vs Insulin)|Metformin vs Insulin trials
3318999|NCT01998113||Metformin (Metformin vs Glyburide)|Metformin vs Glyburide trials
3319000|NCT01998113||Glyburide (Metformin vs Glyburide)|Metformin vs Glyburide trials
3319001|NCT01998126|Experimental|EGFR patients with ipilimumab|ipilimumab and erlotinib in EGFR mutated patients
3319002|NCT01998126|Experimental|ALK patients plus ipilimumab|ipilimumab and crizotinib in ALK mutated patients
3319003|NCT01998126|Experimental|EGFR patients with nivolumab|nivolumab and erlotinib in EGFR mutated patients
3319004|NCT01998126|Experimental|ALK patients plus nivolumab|nivolumab and crizotinib in ALK mutated patients
3319005|NCT01998139||Test Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria. The subjects without sepsis will form the Test Cohort.
3319006|NCT01998139||Validation Cohort|EMP levels will be measured at ICU admission in subjects with physician-suspected sepsis. For each subject, the final diagnosis of sepsis or non-sepsis critical illness will be adjudicated using standard criteria.The subjects determined to have sepsis will serve as the Validation Cohort .
3319007|NCT01998152|Experimental|Nutritional counseling|Individualized nutritional counselling by a registered dietitian
3319008|NCT01998152|No Intervention|No intervention|Usual nutritional care by the oncologist. A dietitian is only involved when serious nutritional problems occur.
3319009|NCT01998165|Experimental|Remifentanil (0.25 µg/kg/min)|
3319010|NCT01998191|Active Comparator|Implicit Case note review (nurse)|"Notes to be reviewed using the implicit method by a nurse~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3319011|NCT01998191|Active Comparator|Implicit Case note review (MDT)|"Notes to be reviewed using the implicit method by an expert physician and nurse team.~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3319012|NCT01998191|Active Comparator|Implicit Case note review (physician)|"Notes to be reviewed using the implicit method by an expert physician~to be compared with interventions: 'Explicit case note review checklist (nurse)' 'Explicit case note review checklist (physician)' 'Explicit case note review checklist (MDT)' and the other two implicit arms"
3319013|NCT01998204||PD group|Patients with Parkinson's disease undergoing deep brain stimulator implantation and pulse generator placement
3319014|NCT01998204||non-PD group|Patients without Parkinson's disease undergoing intracranial surgery
3319015|NCT01998217|Active Comparator|Rem group|Patients in this group receive single infusion of remifentanil with target concentration infusion.
3319016|NCT01998217|Experimental|Flur group|Patients in this group receive both infusion of flurbiprofen and remifentanil
3319017|NCT01998230|Experimental|Early oral feeding group|In this goup patients with esophagectomy are encouraged to begin the oral intake carefully and adjust according to tolerance on post operative day 1.
3319018|NCT01998230|No Intervention|Delayed oral feeding group|In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
3319019|NCT01998256|Sham Comparator|Group I|All patients were programmed in the same nominal AV delay settings (sensed AV delay 120ms, paced AV delay 150 ms) before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
3319020|NCT01998256|Active Comparator|Group II|All patients were programmed in the same nominal AV delay settings before randomization. Patients in group I received a sham AV optimization; patients in group II received a real AV optimization. Baseline echocardiography measurements were repeated after (sham)optimization. At 4 weeks cross-over was done by AV optimization in group I and resetting pacemaker settings to nominal values in group II. At 8 weeks patients were evaluated with the same investigations as at week 4; every pacemaker was programmed in the most optimal AV setting. All optimizations were performed by 2 unblinded echocardiographists with experience in the field.
3319021|NCT01998282||Household water filter and improved cook stove|Vestergaard-Frandsen LifeStraw Family 2.0 filter and Ecozoom stove
3319022|NCT01998282||Control|Traditional water management practices and cooking stoves
3382401|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.
3319023|NCT01998295|Active Comparator|Artemether/lumefantrine|"Artemether/lumefantrine tablets, 6 doses, for 3 days~Dosage:~tablet for body weight between 5-14.9 Kilograms.~tablets for body weight between 15-24.9 Kilograms.~tablets for body weight between 25-34.9 Kilograms."
3319024|NCT01998308||Group 1|50 Knees will have single injection of Crespine gel
3319025|NCT01998308||Group 2|50 Knees will have single injection of 2 ampules of intragel
3319026|NCT01998308||Group 3|50 knees will have single injection of crespine plus gel
3319027|NCT01998308||Group 4|50 knees will have single injection of Monovisc
3319028|NCT01998321|Experimental|TKA using PSI|Total Knee Arthroplasty using Patient Specific Instrument
3319029|NCT01998321|Experimental|2 TKA using conditional technique.|Total Knee Arthroplasty using conditional technique.
3319030|NCT01998334|Experimental|CVVH 6h|CVVH 6h for first three days
3319031|NCT01998334|Experimental|CVVH 10h|CVVH 10h for first three days
3319032|NCT01998334|Experimental|CVVHDF|CVVHDF 6h for first three days
3319033|NCT01998347|Experimental|Paclitaxel liposome and Cisplatin|"Drug: paclitaxel liposome 175mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles:up to 6 cycles.~Drug: cisplatin 37.5 mg/m2, IV (in the vein) on day 1~2 of each 21 day cycle. Number of Cycles: up to 6 cycles."
3319034|NCT01998347|Active Comparator|Cisplatin plus 5-fluorouracil|"Cisplatin:~37.5 mg/m2, IV (in the vein) on day 1-2 of each 21 day cycle. Number of Cycles: up to 6 cycles.~5-fluorouracil: 200mg/m2, CIV (continuous intravenous infusion) on day 1~5 of each 21 day cycle. Number of Cycles: up to 6 cycles."
3319035|NCT01998373|Experimental|patient training and patient without training|Experimental group 1: patient education intervention group (PIGE) Experimental group 2: patient without intervention group (PWIG)
3319036|NCT01998373|No Intervention|control without education|this group did not receive an education
3319037|NCT01998386|Placebo Comparator|Placebo gel without hydrogen peroxide|The volunteers of this group will receive a placebo gel without hydrogen peroxide for whitening treatment.
3319038|NCT01998386|Experimental|6.0% hydrogen peroxide - White Class|Volunteers of this group will receive a gel with 6.0% hydrogen peroxide - White Class with calcium for whitening treatment.
3319039|NCT01998386|Experimental|7.5% hydrogen peroxide - White Class|The volunteers of this group will receive a gel with 7.5% hydrogen peroxide -White Class with calcium for whitening treatment.
3319040|NCT01998386|Experimental|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive disposable whitening strips - Oral-B 3D White for whitening treatment.
3319041|NCT01998425||Non-small cell lung cancer|The cohort data of patients with NSCLC will follow up from diagnosis, treatment response and final survival. Fibrocytes will be checked on the date of diagnsis (before treatment), re-staing (3months after treatment) and disease progression.
3319042|NCT01998451|Experimental|Double sphincter group|patients from double sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
3319043|NCT01998451|Other|general gallbladder sphincter group|patients from general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
3319044|NCT01998464||Retinal Vasculitis Group|Up to 35 patients diagnosed with retinal vasculitis will be considered and evaluated for enrollment in this study.
3319045|NCT01998490|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
3319046|NCT01998490|Experimental|Robot-assisted activity|30 minutes group session with robot-assisted activity with the robot seal Paro twice a week for 12 weeks in groups of 4-6 participants
3319047|NCT01998490|No Intervention|Control|Control group with treatment as usual
3319048|NCT01998503|Active Comparator|BD induction followed by ASCT|The BD regimen included bortezomib 1.3 mg/m2 i.v. and dexamethasone 40 mg p.o. on days 1, 4, 8 and 11 of the 21 day cycle. This process was repeated for 2 cycles. After two cycles of BD therapy, the collection of peripheral blood stem cells (PBSC) should be completed within 4 weeks. Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. Patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
3319049|NCT01998503|Experimental|ASCT alone|the patients who assigned to this arm will receive ASCT alone as an initial treatment. At first, patients receive the collection of peripheral blood stem cells (PBSC), Patients receive filgrastim (G-CSF) on days 1 to 5 and undergo autologous hematopoietic stem cell (HSC) collection. After then patients will receive ASCT therapy in 8 weeks after collection of PBSC (Recorded as day 0), while melphalan (day -2) with a dose of 140 or 200 mg/m2 (choosing a dose according to the degree of risk for patients). Melphalan will be administered by central venous catheter.
3319050|NCT01998516||Schizophrenia Patients|
3319051|NCT01998516||Bipolar I Patients|
3319052|NCT01998516||Siblings of Schizophrenia Patients|
3319053|NCT01998516||Siblings of Bipolar I Patients|
3319054|NCT01998516||Healthy Controls|
3319055|NCT01998529|Experimental|Cisplatin|After cytoreductive surgery, possible pneumonectomy, and possible diaphragm resection, the chest cavity will be closed in layers, leaving inflow and outflow chest tubes in place. Catheters connected to an extracorporeal perfusion circuit. Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C). In order to limit the systemic toxicity of cisplatin, amifostine administered intravenously over 15 minutes beginning 30 minutes after cisplatin perfusion. Patient response to amifostine continuously monitored by anesthesiologist. Infusion may be stopped and/or restarted based on blood pressure.
3319056|NCT01998542|Experimental|AlloStim+CRCL|AlloStim priming followed by AlloStim+CRCL priming and AlloStim IV. 3 cycles
3319057|NCT01998555|Other|CAD-CBT group therapy|CAD receive web-based CBT group therapy
3319058|NCT01998555|Other|CAD-CBT group therapy waiting list|CAD waiting list will receive web-based CBT group therapy later
3319059|NCT01998568||Corneal edema|Intraocular pressure measurement
3319060|NCT01998594|Active Comparator|Arthroplasty without HADM|Three - five (3 - 5) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure without using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of twenty-five (25) similar subjects who received the arthroplasty procedure with the use of the HADM spacer.
3382402|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-6231 by subcutaneous injection on Day 1.
3382403|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.
3319061|NCT01998594|Experimental|Arthroplasty with HADM|Twent-five (25) subjects with Eaton stage III-IV thumb CMC osteoarthritis undergo the basilar joint arthroplasty procedure with an interposition arthroplasty technique using a spacer constructed from human acellular matrix (HADM). Their postoperative DASH scores, grip strength, pinch strength, pain scale scores and quality of life questionnaires are compared to their preoperative scores. These subjects will be compared with a group of three - five (3 - 5) similar subjects who received the arthroplasty procedure without the use of the HADM spacer.
3319062|NCT01998607||Round 1|Survey of 210 oncologists 12 - 18 months after commercial availability of XGEVA® in the respective country
3319063|NCT01998607||Round 2|Survey of 210 oncologists 24 - 30 months after commercial availability of XGEVA® in the respective country
3319064|NCT01998620|Experimental|Ademetionine 1|Ademetionine 2000mg
3319065|NCT01998620|Experimental|Ademetionine 2|Ademetionine 1000mg
3319066|NCT01998620|Active Comparator|Ademetionine 3|no treatment in first 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
3319067|NCT01998646|Experimental|ASP4058 Tablet Dose Escalation Cohort|
3319068|NCT01998646|Experimental|ASP4058 Tablet - Fasting conditions|
3319069|NCT01998646|Experimental|ASP4058 Tablet - Fed conditions|
3319070|NCT01998646|Placebo Comparator|Placebo|
3319071|NCT01998659|Active Comparator|Px-102|Px-102 drinking solution, single dose
3319072|NCT01998659|Placebo Comparator|Placebo|Placebo drinking solution, single dose
3319073|NCT01998672|Active Comparator|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
3319074|NCT01998672|Placebo Comparator|Placebo|Oral drinking solution
3319075|NCT01998685|Experimental|Balanced (BAL) anaesthesia|In the BAL group anaesthesia is induced with midazolam 0.1mg kg-1 and fentanyl 1.5 μg kg- 1 Anaesthesia is maintained with sevoflurane 2.0% , oxygen 40% and air 70% with positive pressure ventilation in a circle system, in order to achieve normocapnia.
3319076|NCT01998685|Active Comparator|Totally Intravenous Anesthesia (TIVA-TCI)|In the TIVA-TCI group anaesthesia is induced with propofol 6 microg ml-1 and remifentanyl 0.4-1 microg kg-1 min, simultaneously administered using two separate modules of a continuous computer-assisted TCI system. Anaesthesia is maintained with propofol 4 microg ml-1 and remifentanil 0.25 microg Kg-1 min. This infusion is modified by 0.05 microg kg-1 min steps according to analgesic needs.
3319077|NCT01998698|Active Comparator|Monovision Group|Phacoemulsification surgery with intraocular lens implantation (monovision correction)
3319078|NCT01998698|Active Comparator|Multifocal Group|Phacoemulsification surgery with intraocular lens implantation (multifocal lens insertion)
3319079|NCT01998711|Experimental|Memory group|Memory training
3319080|NCT01998711|No Intervention|Control|Standard care
3319081|NCT01998724|No Intervention|Standard Care|No intervention
3319082|NCT01998724|Experimental|Tai Chi Exercise|24 week Tai Chi intervention designed for individuals with COPD
3319083|NCT01998724|Experimental|Group Walking Exercise|24 week group walking intervention
3319084|NCT01998750||Early-onset severe obesity|The study will enroll children and young adults up to 21 years of age with early onset severe obesity (BMI > 99th percentile noted at an age < 6 years of age).
3319085|NCT01998763|Placebo Comparator|Placebo|5 placebo pills per day, 20 weeks
3319086|NCT01998763|Experimental|2000 IU/d Vitamin D3|5 vitamin D3 pills per day, 20 weeks
3319087|NCT01998776|Active Comparator|Misoprostol|ASA 100 mg daily + misoprostol 200 four times daily (misoprostol group)
3319088|NCT01998776|Placebo Comparator|Placebo misoprostol|ASA 100 mg daily + placebo misoprostol four times daily (placebo group)
3319089|NCT01998789|Experimental|Everolimus Conversion Arm|"Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day). Therapeutic Drug Monitoring will be performed throughout the study. Tacrolimus should be eliminated when the everolimus target range has been reached. Complete tacrolimus elimination will not occur earlier than 90 days post transplant and no later than 120 days post transplant. Enteric coated mycopenolic acid will be maintained for the duration of the study. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Everolimus doses will be adjusted based on local lab results of everolimus trough levels."
3319090|NCT01998789|Active Comparator|Standard Tacrolimus Immunosuppresion Arm|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
3319091|NCT01998802|Active Comparator|Active Comparator: EBI-005|Drug: EBI-005 The investigational drug EBI-005, is an intervention to one of two study arms: 5 mg/mL topical administered 3 times per day.
3319092|NCT01998802|Placebo Comparator|Placebo Comparator|One of two study arms: placebo topical administered 3 times per day.
3319094|NCT01998828|Experimental|Momelotinib 100 mg PV|Participants with polycythemia vera will receive 100 mg of momelotinib.
3319095|NCT01998828|Experimental|Momelotinib 200 mg PV|Participants with polycythemia vera will receive 200 mg of momelotinib.
3319096|NCT01998828|Experimental|Momelotinib 100 mg ET|Participants with essential thrombocythemia will receive 100 mg of momelotinib.
3319097|NCT01998828|Experimental|Momelotinib 200 mg ET|Participants with essential thrombocythemia will receive 200 mg of momelotinib.
3319101|NCT01998854||VizAblate treatment|VizAblate System with subject serving as her own control
3319102|NCT01998932||Chronic Venous Ulcer|Patients with a chronic venous ulcer defined as a wound of greater than four weeks in duration between the foot and the ankle with an Ankle Brachial Pressure Index greater than 0.85 and a colour venous duplex evidence of chronic venous insufficiency showing either reflux or obstruction.
3319103|NCT01998945|Experimental|Exposure-based Cognitive Behavioral Therapy (ET)|Participants will receive exposure-based cognitive behavioral therapy
3319104|NCT01998945|Active Comparator|Relaxation Training (RT)|Participants will receive relaxation training
3319105|NCT01998971|Experimental|Daratumumab + VD|Daratumumab will be administered with Velcade-dexamethasone (VD).
3319106|NCT01998971|Experimental|Daratumumab + VMP|Daratumumab will be administered with Velcade-melphalan-prednisone (VMP).
3319107|NCT01998971|Experimental|Daratumumab + VTD|Daratumumab will be administered with Velcade-thalidomide-dexamethasone (VTD).
3319108|NCT01998971|Experimental|Daratumumab + Pom-dex|Daratumumab will be administered with pomalidomide-dexamethasone (Pom-dex).
3319109|NCT01998971|Experimental|Daratumumab + CFZ-dex|Daratumumab will be administered with carfilzomib (CFZ)-dexamethasone (CFZ-dex) regimen.
3319110|NCT01998971|Experimental|Daratumumab + KRd|Daratumumab will be administered with carfilzomib- lenalidomide-dexamethasone (KRd) regimen.
3319111|NCT01998997|Active Comparator|Family educational intervention|A family educational, non-pharmacologic intervention will be administered to educate family members on how to prevent delirium. Family members will be encouraged to actively participate in this non-pharmacologic intervention.
3319112|NCT01998997|Placebo Comparator|general health education|The placebo group will be given a brochure on good health habits
3319113|NCT01999010|No Intervention|"Treatment as usual (A Stage)"|The treatment as usual (TAU) group will continue to receive their usual treatment from their current treatment team - i.e. MHT will not be introduced during this phase.
3319114|NCT01999010|Experimental|"MHT (B Stage)"|Patients will be given software for Mental Health Telemetry (MHT), which allows them to record symptom intensity, hospital / ER visits, life events, etc., and to visualize their MHT data. Patients will be encouraged to make MHT entries once daily at a pre-determined time while in this arm, and will be prompted via text message by the MHT software to do so.
3319115|NCT01999010|Experimental|"Choice (A'  Stage)"|Patients exiting the MHT arm will be given the choice to continue with MHT for a further two months or whether to resume TAU (i.e., no further use of MHT) for the remaining two months.
3319116|NCT01999023|No Intervention|Observational group|No intervention
3319117|NCT01999023|Experimental|Dietary supplement|Low protein formula formula (28.5 g) twice a day
3319118|NCT01999036||Resuscitation of OHCA|Resuscitation of out-of-hospital cardiac arrest
3319119|NCT01999062|Experimental|IMRT + CT + MR scan|
3319120|NCT01999075|Placebo Comparator|Conventional Treatment|Conventional Treatment
3319121|NCT01999075|Active Comparator|Lung Volume Recruitment|Conventional treatment plus the use of Lung Volume Recruitment (LVR) twice per day
3319122|NCT01999088|Experimental|Functional meat|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
3319123|NCT01999088|Placebo Comparator|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
3319124|NCT01999101|Experimental|Px-104|Px-104 capsules, 5 mg
3319125|NCT01999140||Primary prevention|
3319126|NCT01999153|Experimental|DRUG : ROPIVACAINE|20 mL topically used during alginate dressing
3319127|NCT01999153|Placebo Comparator|PLACEBO : NaCl 0.9 %|20 mL topically used during alginate dressing
3319128|NCT01999166||Osteoarthritis|
3319130|NCT01999205|Experimental|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees
3319131|NCT01999244|Experimental|SC|Self-guided self-monitoring condition. Participants will receive standard self-monitoring tools and information on weight regulation.
3319132|NCT01999244|Experimental|TECH|Technology condition. Participants will receive self-monitoring technology and information regarding weight regulation.
3319133|NCT01999244|Experimental|TECH+INT|Technology plus interventionist contact arm. Participants will receive self-monitoring technology, information regarding weight regulation, and interventionist contact via telephone.
3319134|NCT01999257|No Intervention|In-person counselling|Similar to standard of care, wherein Ashkenazi Jewish individuals seeking carrier genetic screening meet a genetic counsellor for an in-person education and counselling session.
3319135|NCT01999257|Active Comparator|Online pre-test genetic education tool|Use of a web-based pre-test education program, wherein the information from a typical genetic counselling session for carrier screening in Ashkenazi Jewish individuals is presented.
3319136|NCT01999270|Experimental|Irinotecan, Bevacizumab and FDOPA-PET/MRI imaging|Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
3319137|NCT01999283|Active Comparator|Yoga Group Exercise|Yoga group exercise will be taught by a licensed Physical Therapist. Groups consist of 4-8 individuals with 12 sessions once weekly over 12 weeks.
3319138|NCT01999283|Active Comparator|Pilates Group Mat Exercise|Pilates mat exercise will be taught by a licensed Physical Therapist with additional Rehabilitation Pilates certification.
3319139|NCT01999283|No Intervention|Control|Wait Listed control group. Participants complete the same testing and were offered the option of attending the exercise classes on completion. The controls were not included in the exercise groups after completion.
3319140|NCT01999296||Patients undergoing laparoscopic surgery|
3319141|NCT01999309|Experimental|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
3319142|NCT01999309|Placebo Comparator|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
3319143|NCT01999361|Experimental|Myfortic treatment|Treatment with Myfortic
3319144|NCT01999387||Completed OIT|Patients who completed OIT >6 months prior to enrollment
3319145|NCT01999413|Experimental|OMEGAVEN - Daunorubicin - Cytarabine|"If WBC ≥ 30 G/L, chemotherapy the induction cycle :~Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~Cytarabine 200 mg/m²/day D1 to D7~OMEGAVEN® 2 ml/kg D1 to D9,~If WBC ≤ 30 G/L, OMEGAVEN during 48 hours~Induction cycle :~OMEGAVEN® 2 ml/kg D-2 to D7 Daunorubicin 60 mg/m²/day IV on D1, D2, and D3~- Cytarabine 200 mg/m²/day IV D1 to D7~bone marrow aspirate at D15: If BM blasts are > 5% or if second induction course :~Daunorubicin 35 mg/m²/day IV D17 and D18~OMEGAVEN® 2 ml/kg~Cytarabine 1000 mg/m²/12h IV on D17, D18, and D19~For all patients: G-CSF 5 µg/kg/day subcutaneously from D21 to hematopoietic recovery (PMN > 1 G/L or > 0.5 G/L during 3 days).~Consolidation will be administered at investigator's discretion"
3319146|NCT01999426|Experimental|Airway clearance intervention|Non-respiratory on-call physiotherapy treatment using airway clearance techniques
3319147|NCT01999426|Active Comparator|Airway clearance intervention 2|Specialist respiratory physiotherapy intervention using airway clearance techniques
3319148|NCT01999439|Experimental|Eosinophilic Esophagitis with Dysphagia|To assess quantitative magnetic resonance imaging(MRI)as a potential diagnostic tool for evaluating esophageal wall thickness and stiffness and response to treatment in children and adolescents with a diagnosis of eosinophilic esophagitis (EoE) presenting with difficulty swallowing(dysphagia)and food impaction.
3319149|NCT01999452|Experimental|Paleolithic diet first|Starting with Paleolithic diet and then switching to Diabetes diet
3319150|NCT01999452|Experimental|Diabetes diet first|Starting with Diabetes diet and then switching to Paleolithic diet
3319151|NCT01999478||Patients undergoing colonoscopy|Patients undergoing colonoscopy per standard of care.
3319152|NCT01999504|Experimental|PAL-2|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times (e.g. no cereals, no dairy).
3319153|NCT01999504|Experimental|TFH-1|Based on WHO dietary guidelines for protein, fat and carbohydrate but made with ingredients that would have been available in palaeolithic times, (e.g. no cereals, no dairy).
3319154|NCT01999504|Placebo Comparator|Reference|Meal based on WHO dietary guidelines for protein, fat and carbohydrate.
3319155|NCT01999543|Other|Reference food format|reference food format with and without plant-based ingredient added
3319156|NCT01999543|Experimental|Food format one|Food format one with and without plant-based ingredient added
3319157|NCT01999543|Experimental|Food format two|Food format two with and without plant-based ingredient added
3319158|NCT01999543|Experimental|Food format three|Food format three with and without plant-based ingredient added
3319159|NCT01999582|Experimental|Intravenous Dose Group 1, 2, and 3|Intravenous Dose Group 1 starting at 0.1 mg/kg and escalated in Dose Groups 2 (0.2 mg/kg) and Dose Group 3 (0.1, 0.2, 0.3, 0.4 mg/kg, titrated based on titration rules, administered every 14 days)
3319160|NCT01999582|Experimental|Subcutaneous Dose Group 1, 2, and 3|Subcutaneous Dose Group 1 starting at 0.13 mg/kg and escalated in Dose Groups 2 (0.26 mg/kg) and Dose Group 3 (0.4 to 0.5 mg/kg, titrated based on titration rules, administered every14 days)
3319167|NCT01999608||Vitamin D deficient patients|Serum 25-OH Vitamin D levels <20ng/L
3319168|NCT01999608||Vitamin D sufficient patients|Serum 25-OH Vitamin D levels ≥20ng/L
3319169|NCT01999621||lung cancer|Each lung cancer patient with organ failure, admitted in emergency, thoracic oncology or directly in ICU
3319170|NCT01999634|Experimental|cma microdialysis catheter placement|At the end of the surgery the cma microdialysis catheter is placed near the anastomosis
3319171|NCT01999647|Active Comparator|Perineural|Patients in this group will receive a perineural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
3319172|NCT01999647|Experimental|Intraneural|Patients in this group will receive an intraneural injection for subgluteal sciatic nerve block under real-time, short-axis, in-plane ultrasound guidance, in addition to a femoral nerve block and patient-controlled postoperative analgesia. Ropivacaine will be used for the sciatic nerve block, whereas the choice of agent for the femoral nerve block is left to the attending anesthesiologist.
3319173|NCT01999660||SpaceOAR™|prostate cancer patient prophetically treated by SpaceOAR™
3319174|NCT01999673|Experimental|bavituximab plus docetaxel|Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
3319175|NCT01999673|Placebo Comparator|placebo plus docetaxel|Six 21-day cycles of docetaxel plus weekly placebo. Patients who have not experienced disease progression will continue to receive placebo weekly until progression.
3319176|NCT01999686|Experimental|Treatment I : DLBS3233|DLBS3233 100 mg capsule once daily, and Placebo metformin caplet twice daily; orally, for 6 months
3319177|NCT01999686|Active Comparator|Treatment II : Metformin|Metformin XR 750 mg caplet twice daily, and Placebo DLBS3233 once daily; orally, for 6 months
3319178|NCT01999686|Experimental|Treatment III : Combination DLBS3233 and Metformin|DLBS3233 100 mg capsule once daily, and Metformin XR 750 mg caplet twice daily; orally, for 6 months.
3319179|NCT01999699|Experimental|HEPLISAV|
3319180|NCT01999712||LVAD recipients|Patients who are scheduled for LVAD implantation will undergo preoperative echocardiography
3319181|NCT01999725|Experimental|EDP-788|Single doses with dose escalation to continue in successive cohorts
3319182|NCT01999725|Placebo Comparator|Placebo|Single dose with matching placebo
3319183|NCT01999738|Experimental|Part A - MTD (Treatment 1)|"Treatment 1 is BIW on Days 1, 4, 8, and 11 of a 3-week schedule (BIW).~Intervention: EC1456 and EC20"
3319184|NCT01999738|Experimental|Part A - MTD (Treatment 2)|"Treatment 2 is EC1456 QW on Days 1 and 8 of a 3-week schedule (QW).~Intervention: EC1456 and EC20"
3319185|NCT01999738|Experimental|Part A - MTD (Treatment 3)|"Treatment 3 is EC1456 QW on Days 1, 8, and 15 of a 3-week schedule (CWD).~Intervention: EC1456 and EC20"
3319186|NCT01999738|Experimental|Part A - MTD (Treatment 4)|"Treatment 4 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule (QIW).~Intervention: EC1456 and EC20"
3319187|NCT01999738|Experimental|Part B - Efficacy (Treatment 5)|"Treatment 5 is EC1456 BIW. Once a dose is determined in Part A, Part B will begin with 3-6 subjects who will receive consecutive day dosing on Days 1, 2, 8, and 9 of a 3-week schedule. If this is not tolerated, the BIW cohort will continue with dosing on Days 1, 4, 8, and 11 of a 3-week schedule.~Intervention: EC1456 and EC20"
3319188|NCT01999738|Experimental|Part B - Efficacy (Treatment 6)|"Treatment 6 is EC1456 QW on Days 1 and 8 of a 3-week schedule or CWD on Days 1, 8 and 15 of a 3-week schedule.~Intervention: EC1456 and EC20"
3319189|NCT01999738|Experimental|Part B - Efficacy (Treatment 7)|"Treatment 7 is EC1456 QIW on Days 1, 2, 3, 4, 8, 9, 10, and 11 of a 3-week schedule for at least two cycles. If the patient is eligible to continue treatment (based upon treatment response and tolerability), he/she may opt to continue on the QIW schedule or change to the Treatment 6 regimen schedule (once its MTD and schedule have been determined).~Intervention: EC1456 and EC20"
3319190|NCT01999751||MRI Scan|Patients with implantable cardioverter-defibrillator or pacemaker who undergo an MRI scan
3319191|NCT01999764|Placebo Comparator|Placebo (for QLT091001)|Placebo is supplied to mimic QLT091001 oral solution.
3319192|NCT01999764|Experimental|QLT091001 - first oral dose|Subjects will receive an oral dose of 10mg/m2 of QLT091001.
3319193|NCT01999764|Experimental|QLT091001 - second oral dose|Subjects will receive an oral dose of 40 mg/m2 of QLT091001.
3319194|NCT01999790|Experimental|Blepharothomy|Patients treated with blepharotomy to correct upper lid retraction secondary to Grave's orbitopathy
3319195|NCT01999790|Experimental|posterior approach|Patients treated with a posterior approach to correct upper lid retraction secondary to Grave's orbitopathy
3319196|NCT01999803|Experimental|sNN0029 (VEGF)|4 µg/d of sNN0029 administered by continuous intracerebral infusion during12 weeks
3319197|NCT01999803|Placebo Comparator|Placebo|Placebo administered by continuous intracerebral infusion during12 weeks
3319198|NCT01999816|Experimental|Lifestyle Redesign|Occupational therapist led lifestyle redesign program to prevent pressure ulcers
3319199|NCT01999816|No Intervention|Control|Usual care
3319200|NCT01999829|Experimental|citrate of caffeine|
3319201|NCT01999829|Placebo Comparator|placebo|
3319202|NCT01999842|Experimental|Formulation 1 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 1 at a 21 day interval
3319203|NCT01999842|Experimental|Formulation 2 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 2 at a 21 day interval
3319204|NCT01999842|Experimental|Formulation 3 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 3 at a 21 day interval
3319205|NCT01999842|Experimental|Formulation 4 Group|Subjects in this group will receive two doses of GSK3206641A H7N9 vaccine formulation 4 at a 21 day interval
3319206|NCT01999842|Experimental|Formulation 5 Group|Subjects in this group will receive two doses of GSK3206640A H7N9 vaccine formulation 5 at a 21 day interval
3319207|NCT01999842|Placebo Comparator|Placebo Group|Subjects in this group will receive two doses of placebo at a 21 day interval
3319208|NCT01999855|Active Comparator|control group|"the Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
3319209|NCT01999855|Experimental|Asthmatic patients|"The Phonatory Maximum Time~Vocal Handicap Index~Scale GRBAS of Hirano~Videolaryngoscopy"
3319210|NCT01999881|Experimental|Arm A (aerobic and exercise training)|Patients and their support persons undergo a supervised combined aerobic exercise comprising walking, cycling, or video-based aerobics and strength training using resistance bands for 40 minutes 2 days a week at the UWHC and 3 days a week at home over 8 weeks.
3319211|NCT01999881|Active Comparator|Arm II (usual care)|Patients and their support persons undergo the usual care over 8 weeks.
3319212|NCT01999907|Placebo Comparator|Placebo|bolus placebo given in a 2ml dose by mouth at baseline. This group receives daily vitamin D supplement by mouth for the 6 month study (400IU cholecalciferol per day).
3319213|NCT01999907|Active Comparator|Vitamin D|Vitamin D (100,000IU) bolus in a 2ml dose by mouth given at baseline. This group receives a daily vitamin D supplement by mouth for 6 months (400IU cholecalciferol per day).
3319214|NCT01999933|Active Comparator|CCRT with cisplatin(DDP) weekly|concurrent chemotherapy: cisplatin（DDP） weekly, 40mg/m2, begin with radiation
3319215|NCT01999933|Experimental|CCRT with TP|concurrent TP tri-weekly, docetaxel plus cisplatin tri-weekly (75mg/m2), begin with radiation
3319216|NCT01999933|Experimental|concurrent and adjuvant TP|2 cycles of concurrent TP, docetaxel plus cisplatin tri-weekly (75mg/m2),begin with radiation; and 4 cycles of adjuvant TP, the same regimen, after radiation
3319217|NCT01999959|Experimental|Pertubation performed|Study group had pertubation and insemination
3319218|NCT01999959|No Intervention|Pertubation not performed|Study group had insemination only
3319219|NCT01999998|Experimental|Pilot|
3319220|NCT02000011|Other|standard strategy|
3319221|NCT02000011|Experimental|experimental strategy|
3319222|NCT02000024|Experimental|Lifestyle coaching|The existing Weight Watchers lifestyle modification program including the online support tools.
3319223|NCT02000024|Active Comparator|Lifestyle counseling|Brief advice regarding risk factors and strategies to reduce them by lifestyle modification guided by National Diabetes Education Program (NDEP) materials.
3319224|NCT02000037|Active Comparator|Dietary care|Treatment is composed of a dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille).
3319225|NCT02000037|Experimental|IR reflexotherapy + dietary care|"Treatment is composed of :~IR reflexotherapy sessions given by a trained professional ;~dietary care (with advices on physical activity) given by a professional (dietician of the Nutrition Department of the Institut Pasteur de Lille)."
3319226|NCT02000037|Experimental|IR Reflexotherapy|Treatment is composed of IR reflexotherapy sessions given by a trained professional.
3319227|NCT02000050|Experimental|Single Arm|"Neoadjuvant therapy: FOLFOX4 2 cycles + Tomotherapy + FOLFOX4 2 cycles~Surgery~Adjuvant therapy: FOLFOX4 8 cycles~TME (Total Mesorectal Excision)"
3319228|NCT02000076|Experimental|Sleep deprivation|Partial sleep deprivation allowing 3 h sleep at night
3319229|NCT02000076|Experimental|Full sleep|Sleep with no restriction
3319230|NCT02000089|Active Comparator|Familial pancreas cancer relatives|"High Risk Group 2 (familial pancreatic cancer relatives):~> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and~come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and~have a first-degree relationship with at least one of the relatives with pancreatic cancer.~If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
3319231|NCT02000089|Active Comparator|Group 1 germline mutation carrier|"High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed BRCA2, or PALB2 mutation, and there is 1 or more pancreatic cancer diagnoses in the family, one of whom is a first- or second-degree relative of the subject to be screened.~The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), age 40 years or older, regardless of family history of pancreas cancer."
3319232|NCT02000089|Active Comparator|Group 2 germline mutation carrier|"High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):~> 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and~The patient is a carrier of a confirmed BRCA1, ATM or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
3319233|NCT02000089|Active Comparator|Hereditary pancreatitis|High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger.
3319234|NCT02000089|Active Comparator|Peutz-Jeghers Syndrome|"At least 30 years old, and~at least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,~known STK11 gene mutation carrier"
3319235|NCT02000089|Active Comparator|Negative control|"are undergoing routine EGD or Colonoscopy; or Endoscopic Ultrasound (EUS) and/or Endoscopic Retrograde Cholangiopancreatography (ERCP) for non-pancreatic indications as part of their standard medical care, and~have no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
3319236|NCT02000089|Active Comparator|Chronic Pancreatitis|"are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,~have no clinical or radiologic suspicion of pancreatic cancer"
3319237|NCT02000089|Active Comparator|Pancreas cancer|a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)
3319238|NCT02000089|Active Comparator|Pancreas cyst, IPMN evaluation|are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system).
3319239|NCT02000102||Diabetic Macular Edema Patients Switched to Aflibercept|
3319240|NCT02000128|Experimental|bioimpedance monitoring group|patients whose fluid status will be monitored and guided by bioimpedance analysis
3319241|NCT02000128|Other|clinical monitoring group|patients whose fluid status will be monitored and guided by clinical experience
3319242|NCT02000141||Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of Colonic Advanced Mucosal Lesions
3319243|NCT02000167||Phelan-McDermid Syndrome only|Diagnosed with Phelan-McDermid Syndrome; 50 subjects to be recruited. 1-21 years of age
3319244|NCT02000167||Co-morbid Phelan-McDermid Syndrome & Mitochodrial Disorder|1-21 years of age; Diagnosed with Phelan-McDermid Syndrome AND diagnosed with Mitochondrial Disorder; 50 subjects to be recruited.
3319245|NCT02000193|Experimental|1|"drug: Fulvestrant treatment : Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, 29, then every 28 days.~The treatment will continue until disease progression or intolerable adverse event"
3319246|NCT02000206|Active Comparator|propofol + alfentanil|"Patients from the Propofol / Alfentanil group will receive in addition:~A loading dose of 10-15 mcg/kg Alfentanil + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) throughout the procedure if required"
3319247|NCT02000206|Active Comparator|propofol + ketamine|"Patients from the Propofol / Ketamine group will receive in addition:~A loading dose of 0.2-0.3 mg/kg Ketamine + 0.4 mg/kg Propofol, 2 minutes prior to the beginning of the procedure.~Additional boluses of Propofol (aliquots of 10-50 mg) and/or Ketamine (aliquots of 5-25 mg) throughout the procedure if required."
3319249|NCT02000232||Diagnosis with Gout and use of colchicine|Observational study age 18+
3319250|NCT02000245|Active Comparator|verbal expression for compassion|verbal expression for compassion
3319251|NCT02000245|Active Comparator|verbal expression and touch|verbal expression and touch
3319252|NCT02000245|No Intervention|control|control
3319253|NCT02000258|Other|Double-bundle ACL reconstruction|Double-bundle ACL reconstruction
3319254|NCT02000258|Other|Magnetic resonance imaging (MRI)|MRI of the ACL double-bundle reconstructed knee was done at 2 years after surgery.
3319255|NCT02000271|Other|Vaginal packing|Vaginal packing will be placed as is typical following vaginal reconstructive surgery.
3319256|NCT02000271|Experimental|No vaginal packing|No vaginal packing will be used following vaginal reconstructive surgery.
3319257|NCT02000284||General ASD|150 general ASD children
3319258|NCT02000284||ASD/MD|50 children Diagnosed with an Autism Spectrum Disorder and a Mitochondrial Disorder
3319259|NCT02000284||ASD/noMD|50 children with ASD that have been r/o as having a mitochondrial disorder
3319260|NCT02000284||MD/noASD|50 children with a mitochondrial disorder and without an ASD
3319261|NCT02000284||Developmental Delay|50 children without a mitochondrial disorder or autism spectrum disorder, but with general developmental delays
3319262|NCT02000284||Typically Developing|100 children with no history of medical, behavioral, or immunological disorders
3319263|NCT02000297|Active Comparator|Allogenic bone graft group|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
3319264|NCT02000297|Experimental|Synthetic bone substitute (geneX®) group|Patients in this arm is treated with synthetic bone substitute(geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
3319265|NCT02000323|Active Comparator|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Standard enteral nutrition liquid regimen （Peptisorb Liquid）will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
3319266|NCT02000323|Active Comparator|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through Naso-gastro-Jejunal tube until 2 or more followed requirements were met mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
3319267|NCT02000336|Experimental|Prednisolone 10|Prednihexal (Prednisolon), daily oral tablet, 10 mg during week one to four, 7,5 mg during week five to eight. Finally 5 mg for four weeks.
3319268|NCT02000336|Experimental|Prednisolone 60|Prednihexal (Prednisolon), daily oral tablet, 60 mg during the first week, weekly tapering: 40 mg, 20mg, 15mg, 10mg, 7,5mg. 7,5mg continued for one more week. Finally 5 mg for four weeks
3319269|NCT02000336|Placebo Comparator|Placebo|daily oral tablet
3319270|NCT02000349|Experimental|Frozen Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5 or day 6, embryos will then be vitrified, analyzed by NGS, and will have one or two euploid embryo(s) thawed and transferred on a FET cycle, before noon. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*).
3319271|NCT02000349|Experimental|Fresh Embryo Transfer with PGD|All embryos will be hatched on day 3. Patients will have hatching blastocysts (*) biopsied on day 5, analyzed by NGS, and will have one or two euploid embryo transferred on day 6, in the am. If more than two euploid blastocysts are available the one(s) to be transferred will be selected based on morphology (*). Any morulas developing to hatching blastocyst on day-6 will be also analyzed but vitrified for use in a future cycle.
3319272|NCT02000362|Experimental|Treatment|"cohort 1. 5.0 x 10^7 stem cells after registration~cohort 2. 1.0 x 10^8 stem cells after registration"
3319273|NCT02000375|Experimental|DHEA|Daily oral administration of DHEA at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
3382404|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-6231 by subcutaneous injection on Day 1.
3382405|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.
3319274|NCT02000388|Other|Ketorolac tromethamine (SPRIX)|A SPRIX dose will be one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs as needed for post vasectomy pain with a maximum daily dose of 126 mg to be continued for up to 5 days.
3319275|NCT02000388|Other|Standard of care|The intervention used will be standard of care
3319276|NCT02000401|Other|Ketorolac Tromethamine|Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.
3319277|NCT02000414|Experimental|intraperitoneal daptomycin|3 first patients : 200mg/day 3 following patients : 300mg/day
3319278|NCT02000453|Experimental|GSK2586184|A total of 15 subjects to be administered 400 mg GSK2586184 Tablet (200 mg X 2) twice daily for up to 56 days
3319279|NCT02000466||Exposed cohort|
3319280|NCT02000479|Experimental|training|12 weeks (2 x 6 weeks) of combined exercise training programme (supervised)
3319281|NCT02000479|No Intervention|Control|Continued usual care, habitual lifestyle
3319282|NCT02000492|Experimental|Training|Football, circuit training or running 5x12 minutes or 3x 40 minutes
3319283|NCT02000492|No Intervention|Control|
3319284|NCT02000505|No Intervention|Control|5 minutes chest-compression-only CPR, without any support
3319285|NCT02000505|Experimental|PocketCPR|5 minutes chest-compression-only CPR, with support
3319286|NCT02000505|Experimental|Metronome|5 minutes chest-compression-only CPR, with support
3319287|NCT02000505|Experimental|110bpm Song|5 minutes chest-compression-only CPR, with support
3319288|NCT02000518||external beam radiotherapy|emergency radiotherapy within 12 hours after neurological deficit due to MSCC
3319289|NCT02000544|Other|Modular Cardiopulmonary Bypass Circuit|Patients undergoing open heart surgery with a modular hybrid extracorporeal circulation circuit.
3319290|NCT02000557||Class II Malocclusion|
3319291|NCT02000570|Experimental|sitting position|
3319292|NCT02000596|Experimental|Cohort 1: T+P|Trastuzumab plus Pertuzumab as first line treatment for HER2 overexpressed Metastatic Breast Cancer (without hormonal therapy or chemotherapy)
3319293|NCT02000596|Experimental|Cohort 2 - Arm A|Hormonal Therapy with Anastrozole and Fulvestrant in addition Trastuzumab plus Pertuzumab for women who progressed on T+P alone, and who are ER/PR +
3319294|NCT02000596|Experimental|Cohort 2 - Arm B|Chemotherapy with Eribulin in addition to Trastuzumab plus Pertuzumab for women who progressed on T+P alone and who are ER/PR -
3319295|NCT02000609|Active Comparator|CHF 1535 NEXThaler 800/48 ug|single dose administration of CHF 1535 100/6 NEXThaler DPI, total dose: 800ug BDP, 48 ug Formoterol Fumarate
3319296|NCT02000609|Placebo Comparator|CHF 1535 NEXThaler PLACEBO|single dose administration of placebo via NEXThaler DPI
3319297|NCT02000609|Active Comparator|CHF 1535 pMDI 200/12|single dose administration of CHF 1535 100/6 pMDI , total dose: 200 ug BDP, 12 ug Formoterol Fumarate
3319298|NCT02000609|Active Comparator|CHF 1535 100/6 pMDI 800/48|single dose administration of CHF 1535 100/6 pMDI total dose: 800ug BDP, 48 ug Formoterol Fumarate
3319299|NCT02000609|Active Comparator|CHF 1535 NEXThaler 200/12|single dose administration of CHF 1535 100/6 pMDI, total dose: 200 ug BDP, 12 ug Formoterol Fumarate
3319300|NCT02000635||Leptospirosis|Patient with a diagnosis of leptospirosis confirmed by PCR in the five first day
3319301|NCT02000648||Patients diagnosed with chronic rhinitis or chronic urticaria|Patients diagnosed with chronic rhinitis/urticaria and followed-up at Allergy Clinics, Chulalongkorn University
3319302|NCT02000661|Experimental|Routine use of FFR|Fractional Flow Reserve (FFR) used in most cases to guide PCI
3319303|NCT02000661|Active Comparator|Selective use of FFR|Fractional Flow Reserve (FFR) used at investigator discretion (Current practice)
3319304|NCT02000674|Active Comparator|Administration of Succinylcholine|Intubation after IV administration of Succinylcholine 1mg/kg
3319305|NCT02000674|Experimental|Administration of Rocuronium|Intubation after IV administration of Rocuronium 1.2 mg/kg
3319306|NCT02000700|Experimental|Canagliflozin (Dose Group 1)|Participants will receive 100 mg (as 1 x 100-mg tablet) of canagliflozin daily for 14 days.
3319307|NCT02000700|Experimental|Canagliflozin (Dose Group 2)|Participants will be enrolled into Dose Group 2 to receive either 50 mg (as 1 x 50-mg tablet) or 300 mg (as 1 x 300-mg tablet) of canagliflozin daily for 14 days.
3319308|NCT02000713|Experimental|Amyotrophic Lateral Sclerosis|All subjects will be interviewed and administered a brief questionnaire to determine current disease severity. A brief neurological examination will be given to determine reflexes. Subjects will also have magnetic resonance imaging(MRI)scans of the cervical spine (neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. The clinical examinations will take approximately 30 minutes to complete. Subject participation in this study will be complete following the MRI and clinical examinations.
3319309|NCT02000713|Active Comparator|Healthy controls (MRI)|Subjects will also have magnetic resonance imaging (MRI) scans of the cervical spine(neck). Women of child-bearing potential will need to have a urine pregnancy test immediately prior to the MRI scan. Mri scan will take approximately 60 minutes to complete. Subject participation in this study will be complete following the MRI.
3319310|NCT02000726|Experimental|Placebo and Citalopram|4 weeks of 1 placebo pill/day and 12 weeks of citalopram 20-40 mg/day
3319311|NCT02000739|Other|Genetically Informed Therapy|"The treatment participants get will depend on the results of the DNA sequencing and the availability of targeted therapies that match the genetic profile of the tumor identified by the DNA sequencing.~If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant."
3319312|NCT02000765|Experimental|GSK2140944 for Injection and Capsule|Each subject will receive a single 1000 milligram (mg) IV dose of GSK2140944 containing [14C]-GSK2140944 of approximately 22.5 microcurie [μCi] (approximately 0.8 megabecquerel [MBq]) of radioactivity given as a 2 hour infusion on Day 1 of treatment period 1 and 2000 mg oral dose of GSK2140944 containing [14C]-GSK2140944 of approximately 45 μCi (approximately 1.7 MBq) of radioactivity on Day 1 of treatment period 2. Each treatment period will be followed with washout of atleast 8 Days.
3319313|NCT02000778|Experimental|EC17 Injection Group|The group will receive a single dose of EC17, infused over 10 minutes, prior to surgery. Then, during surgery, the EC-17 will be imaged with a camera that the investigators have developed.
3382406|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-6231 by subcutaneous injection on Day 1.
3382407|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.
3319314|NCT02000791|Experimental|cLMA insertion via laryngoscopic technique|Comparison of cLMA insertion via laryngoscope view by fiberscope
3382408|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-6231 by subcutaneous injection on Day 1.
3382409|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 6|Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.
3382410|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 6|Participants will receive 1 dose of Dose Level 6 of mRNA-6231 by subcutaneous injection on Day 1.
3382411|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 7|Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.
3382412|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 7|Participants will receive 1 dose of Dose Level 7 of mRNA-6231 by subcutaneous injection on Day 1.
3382413|NCT04916431|Experimental|Sentinel Group - mRNA-6231 Dose Level 8|Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.
3382414|NCT04916431|Experimental|Expansion Group - mRNA-6231 Dose Level 8|Participants will receive 1 dose of Dose Level 8 of mRNA-6231 by subcutaneous injection on Day 1.
3382420|NCT04907799|Experimental|Daily Caloric Restriction|The daily caloric restriction group will participate in a 2-year, group-based, behavioral weight loss intervention based on a 30% reduction in caloric intake and increased physical activity.
3382421|NCT04907799|Other|Standard Advice Control|The standard advice control group will receive an initial consultation with a registered dietician regarding current clinical recommendations for ADPKD without subsequent counseling sessions.
3382422|NCT04897451||Women with cervical ripening in the context of artificial labor induction|
3319315|NCT02000791|Active Comparator|cLMA insertion via standart technique|Comparison of cLMA insertion via standart technique view by fiberscope
3319316|NCT02000804|Experimental|darapladib 160mg|drug
3319317|NCT02000830||Placebo|Participants received placebo during the earlier study
3319318|NCT02000830||Stannsoporfin 3.0 mg/kg|Participants received Stannsoporfin 3.0 mg/kg during the earlier study
3319319|NCT02000830||Stannsoporfin 4.5 mg/kg|Participants received Stannsoporfin 4.5 mg/kg during the earlier study
3319320|NCT02000843|Other|perichondrium graft perforation|tympanoplasty -- conchal cavum approach is used.
3319321|NCT02000856|Active Comparator|Nitrate rich beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo) twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
3319322|NCT02000856|Placebo Comparator|Nitrate depleted beetroot juice|Eligible subjects will be randomised, in a double-blind crossover design, to receive treatment with either nitrate rich beetroot juice (70 ml containing approximately 8 mmol nitrate - active comparator) or nitrate depleted beetroot juice (70 ml - placebo)twice daily for 7 days (treatment period 1) followed by a 7 day washout period followed by treatment twice daily with the active comparator or placebo depending on initial treatment for another 7 days (treatment period 2) .
3319324|NCT02000882|Experimental|BKM120 plus Capecitabine|"BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off.~For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120."
3319325|NCT02000934|Experimental|TAK-659 60 mg (Dose Escalation)|TAK-659 60 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 49 cycles).
3319326|NCT02000934|Experimental|TAK-659 80 mg (Dose Escalation)|TAK-659 80 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 4 cycles).
3319327|NCT02000934|Experimental|TAK-659 100 mg (Dose Escalation)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 32 cycles).
3319328|NCT02000934|Experimental|TAK-659 120 mg (Dose Escalation)|TAK-659 120 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities (up to 41 cycles).
3319329|NCT02000934|Experimental|TAK-659 CCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with chronic lymphocytic leukemia (CCL) (up to 6 cycles).
3319330|NCT02000934|Experimental|TAK-659 DLBCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with diffuse large B-cell lymphoma (DLBCL) (up to 49 cycles).
3319331|NCT02000934|Experimental|TAK-659 iNHL (Dose Expansion)|Single dose TAK-659 100 mg, tablet, orally in pharmacokinetic (PK) Run-in prior to Cycle 1 followed by TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with indolent non-hodgkin lymphoma (iNHL) (up to 32 cycles).
3319332|NCT02000934|Experimental|TAK-659 MCL (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with mantle cell lymphoma (MCL) (up to 6 cycles).
3319333|NCT02000934|Experimental|TAK-659 PTLD (Dose Expansion)|TAK-659 100 mg, tablet, orally, once daily in 28-day cycles until disease progression or unacceptable toxicities in participants with post-transplant lymphoproliferative disorder (PTLD) (up to 1 cycle).
3319334|NCT02000947|Experimental|Dose Escalation|MEDI4736 and tremelimumab received by intravenous infusion.
3319335|NCT02000947|Experimental|Arm A|Medi4736 and tremelimumab received by intravenous infusion
3319336|NCT02000947|Experimental|Arm B|MEDI4736 and tremelimumab received by intravenous infusion
3319337|NCT02000947|Experimental|Arm C|MEDI4736 and tremelimumab received by intravenous infursion
3319338|NCT02000960|Experimental|Triheptanoin|All subjects will receive the study treatment which includes adding triheptanoin to the ketogenic diet with a goal intake of 35% total calories provided by triheptanoin (max 100 ml oil/day.
3319339|NCT02000986|Experimental|Specimen Collection/Risk Factor Assessment -> Diet/Exercise ->|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy
3319340|NCT02000999||Patients with bile duct strictures|
3319341|NCT02001012|Active Comparator|Artemether-lumefantrine|"Artemether-lumefantrine.~1 tablet = 20mg arthemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; >35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, >10-15kg = 1 tablet."
3319342|NCT02001012|Active Comparator|Chloroquine|"Chloroquine.~1 tablet contains 155mg chloroquine base. Adult dose (>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.~Child dose (>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours."
3319343|NCT02001025||Absorb scaffold|Bioresorbable vascular scaffold implanted in coronary arteries, which are completely resorbed over a period of approximately two years
3319344|NCT02001025||Xience stent|Second generation drug-eluting stent to treat coronary artery lesions
3319345|NCT02001038||Orthopaedic surgeons|Orthopaedic surgeons who perform surgical procedures for foot deformities in CMT patients at participants centres.
3319346|NCT02001077|Active Comparator|CBT-I|Participants will complete 8 weekly therapy sessions focused on improving sleep. A multicomponent CBT-I (Cognitive Behavioral Therapy for Insomnia) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, and cognitive restructuring.
3319347|NCT02001077|Active Comparator|CBT-P|Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
3319348|NCT02001077|No Intervention|Waitlist Control (WLC)|Participants in the WLC group will not receive any treatment between the baseline and post-treatment assessments. After the final follow-up assessment, they will be offered the opportunity to receive therapy which combines aspects of both CBT-I and CBT-P.
3319349|NCT02001090||CABG patients|Patients undergoing cardiac surgery for coronary artery disease with the use of heart-lung machine in St Olavs Hospital Trondheim University Hospital.
3319350|NCT02001103|Active Comparator|Memantine 10 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3319351|NCT02001103|Active Comparator|Memantine 20 mg/day|Dosing titration with 5 mg incremental each week Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3319352|NCT02001103|Placebo Comparator|Placebo|Clinical follow-up/assessment at week 1, 2, 4, 8, and 12 Treatment duration: 12 weeks
3319353|NCT02001116|Experimental|Pilot Hospitals|
3319354|NCT02001116|No Intervention|Control Hospitals|
3319355|NCT02001129|Experimental|Automated Telephone System|In addition to a standardized reminder letter, participants also received a telephone call from an automated system to remind them of a recommended follow-up appointment.
3319356|NCT02001129|Experimental|Personalized Telephone Call|In addition to the usual care letter, a staff member called participants one month prior of recommended follow-up appointment. During this call, participants were given the option to schedule an appointment.
3319357|NCT02001129|Active Comparator|Usual Care|"Participants randomized to this arm receive a usual care letter which is a standard reminder letter from the primary eye care office. This is usual practice in many primary eye care facilities."
3319360|NCT02001155||Trabeculectomy|Individuals in this group will have undergone a trabeculectomy for the treatment of glaucoma.
3319361|NCT02001155||Tube Shunt|Individuals in this group will have undergone a tube shunt for the treatment of glaucoma.
3319362|NCT02001168|Experimental|Pemetrexed &Cis-platinum|Pemetrexed d1＋Cis-platinum , d1, 21 d as a cycle.
3319363|NCT02001168|Experimental|Pemetrexed & Cis-platinum & rh-Endostatin|Pemetrexed d1＋Cis-platinum , d1； rh-Endostatin d1-14; 21 d as a cycle.
3319364|NCT02001168|Experimental|Docetaxel & Cis-platinum|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
3319365|NCT02001168|Experimental|Docetaxel & Cis-platinum & rh-Endostatin|Docetaxel ＋ Cis-platinum ＋ rh-Endostatin，21 d as a cycle.
3319366|NCT02001207||MICU patients|
3319367|NCT02001220|Active Comparator|Once daily screening|Patients will undergo assessments to determine readiness to undergo an SBT once daily.
3319368|NCT02001220|Experimental|At least twice daily screening|Patients will undergo assessments to determine readiness to undergo an SBT at least twice daily.
3319369|NCT02001233||EV71 Vaccine|Inactivated vaccine (vero cell) against EV71 of 400U /0.5ml in 5000 infants aged 6-35 months old on day0,28
3319370|NCT02001233||Placebo|placebo in 5000 infants aged 6-35 months old on day0,28
3319371|NCT02001246|Active Comparator|Real Deal program for Anger Management|"The Real Deal Anger Management Program is a structured, video-based intervention, which is an easy-to-implement, plug and play program that engages students in: (a) cognitive exercises for learning to recognize and correct thinking errors that lead to anger, (b) active practice of social-behavioral skills through role-playing, and (c) participation in progressive muscle relaxation exercises. The program features three training videos that focus on specific skills for controlling conflict."
3319372|NCT02001246|Experimental|Mind-body Bridging program|The Mind-Body Bridging program for anger management, includes experiential awareness activities, in which individuals learn to become aware of their thoughts, feelings, emotions, and bodily sensations, to help them identify and deal with ruminative and negative thoughts that might be associated with their anger. MBB helps participants use their senses to listen to sounds, and experience visual or tactile input, to calm their minds and relax their bodies. Written 'mapping' exercises enable them to recognize and defuse requirements, which are expectations of how they or the world should be. For the MBB anger management program, participants will be provided with a variety of mapping exercises to identify the source of their anger, and how they can effectively control it.
3319373|NCT02001259|Active Comparator|Epidural lidocaine|epidural lidocaine: 3 mL of 1% lidocaine with adrenaline and 3 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
3319374|NCT02001259|Experimental|epidural triamsinolone|epidural triamsinolone: 40 mg of triamsinolone (1 mL), 2.5 mL of 1% lidocaine with adrenaline and 2.5 mL of 1% lidocaine without adrenaline into epidural catheter at 48 hr after surgery
3319375|NCT02001272|Experimental|A:Paclitaxel + Carboplatin every 3 weeks|Patients randomized to the arm A receive 6 courses the following regimen: Paclitaxel 175 mg/m²/3 hours, I.V. and carboplatin AUC 5, I.V. every 3 weeks (1 cycle = 21 days).
3319376|NCT02001272|Experimental|B:Carboplatin monotherapy every 3 weeks|Patients randomized to the arm B receive 6 courses the following regimen: Carboplatin monotherapy AUC 5 or 6 every 3 weeks (1 cycle = 21 days).
3319377|NCT02001272|Experimental|C:Weekly Paclitaxel and Carboplatin|Patients randomized to the arm C receive 6 courses the following regimen: weekly paclitaxel 60 mg/m²/1 hour and weekly carboplatin AUC 2 (d1, d8, d15 ; d1=d29) (1 cycle = 28 days).
3319378|NCT02001285|Experimental|Double lumen tube|This arm contains patients who are needed endobronchial intubation with double lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
3319379|NCT02001285|Active Comparator|single lumen tube|This arm contains patients who are needed endotracheal intubation with single lumen tube for general anesthesia. After propofol infusion of effect site concentration 4 μg/ml, remifentanil infusion will be started with effect site concentration of 3.5 ng/ml. According to change arterial blood pressure and heart rate from baseline value, next remifentanil concentration will be regulated using up-and-down method. Step size of dose is 0.5 ng/ml.
3319380|NCT02001298|Experimental|nitroprusside|After induction of anesthesia, controlled hypotension was induced with continuous infusion of nitroprusside. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
3319381|NCT02001298|Experimental|remifentanil|After induction of anesthesia, controlled hypotension was induced with continuous infusion of remifentanil. Cardiac index, stroke volume index, and total peripheral resistance index were continuously measured using noninvasive cardiac output monitor (Cheetah NICOM, Cheetah Medical Inc, UK).
3319382|NCT02001311|Experimental|chlorhexidine gel|anti microbial agent that prevents the formation of plaque and reduces caries risk
3319383|NCT02001324|Active Comparator|Paper-based data collection|Paper-based data collection
3319384|NCT02001324|Active Comparator|Web-based data collection|Web-based data collection
3319385|NCT02001350||Resistant hypertension|
3319386|NCT02001363|Experimental|liraglutide|drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
3319387|NCT02001363|Placebo Comparator|liraglutide placebo|drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
3319388|NCT02001376|Experimental|Intensive exercise & home exercise|Intensive exercise group Home exercise group
3319389|NCT02001376|Experimental|Intensive exercise & control|Intensive exercise group Control group
3319390|NCT02001376|Experimental|Home exercise & control group|Home exercise Control group
3319391|NCT02001389|Experimental|EVP-6308; Arm 1|low dose, Capsule, Twice Daily, Day 1 through Day 3
3319392|NCT02001389|Experimental|EVP-6308; Arm 2|low intermediate dose, Capsule, Twice Daily, Day 1 through Day 3
3319393|NCT02001389|Experimental|EVP-6308; Arm 3|high intermediate dose, Capsule, Once Daily, Day 1 through Day 3
3319394|NCT02001389|Experimental|EVP-6308; Arm 4|high dose, Capsule, Once Daily, Day 1 through Day 3
3319395|NCT02001415|Active Comparator|Spectacles|Spectacles are the most common lens treatment to correct myopia. This arm is set to be as a control group for the other two arms. Myopia patients who enter in this group will wear a normal pair of glasses after the baseline examinations (axial length, refraction...).
3319396|NCT02001415|Active Comparator|Myovison|Myovision is a kind of specially designed, commercially available spectacle lenses that could control the peripheral refraction of myopia patients. Latest studies have changed the understanding of myopia--correcting both central and peripheral vision during lens treatment is indicating to be an effective way of slowing down eye growth. Patients who entered this group will wear a pair of Myovision after baseline examinations.
3319397|NCT02001415|Active Comparator|Ortho-K|Orthokeratology has recently been reported as an effective way to control eye growth for myopia adolescents. Patents who enter this group will wear ortho-K lenses during sleep after baseline examinations.
3319398|NCT02001428|Experimental|Intermittent Screening and Treatment|Infants enrolled at Village health posts will be randomly allocated to receive intermittent screening and treatment (IST) on every scheduled immunization visit at 2, 3, 4 and 9 months of age. Infants in this group will be screened for malaria by Rapid Diagnostic Test (RDT), and if positive, treated with dihydroartemisinin-piperaquine (DHP). Infants will also receive follow up home visits at 6 and 12 months.
3319399|NCT02001428|No Intervention|Passive Case Detection|Infants in the control arm will only be checked for malaria if they have fever, or history of fever in the 24 hours prior to the scheduled immunization visit at 2,3,4 and 9 months of age, or at a follow up home visit at 6 and 12 months. Infants with malaria will be treated with DHP once daily for 3 days according to local treatment guidelines.
3319400|NCT02001441||No treatment|
3319401|NCT02001454||Patients in pain|There is no intervention, only questionnaires for the patient
3319402|NCT02001454||Attending Physicians and Nurses|The staff physicians and nurses will also fill out a questionnaire
3319403|NCT02001467|Active Comparator|Simulation-based training|Simulation-based training to an expert criterion followed by clinical training until proficiency and certification.
3319404|NCT02001467|No Intervention|Control|No training is provided the control group participants.
3319405|NCT02001480|Other|Echocardiography|"12 lead holter for 7 days~CGM = continuous Glucose Monitoring"
3319406|NCT02001506|Active Comparator|FEC3-D3|"3 cycles of FEC followed by 3 cycles of Docetaxel~Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
3319407|NCT02001506|No Intervention|AC4-D4|"4 cycles of Adriamycin plus Cyclophosphamide (AC) followed by 4 cycles of Docetaxel~Adriamycin 60 mg/m2, every 3 weeks Cyclophosphamide 600 mg/m2, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
3319408|NCT02001519|Experimental|adriamycin,cytoxan, cisplatin|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks followed by 4 cycles of cisplatin 75 mg/m2 every 3 weeks
3319409|NCT02001532||Diabetes type 2|Patients diagnosed with type 2 diabetes within 5 years from baseline (i.e. 10 years at follow-up)
3319410|NCT02001532||Healthy controls|Sex and age-matched healthy controls
3319411|NCT02001545||Patients with STEMI and NSTEMI|Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.
3319412|NCT02001571|Experimental|Cohort 1|Mild Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3319413|NCT02001571|Experimental|Cohort 2|Moderate Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3319414|NCT02001571|Experimental|Cohort 3|Normal Hepatic participants administered to four 250 mg tablets (1000 mg) orally on Day 1.
3319415|NCT02001584|Experimental|Healthy Volunteers|
3319416|NCT02001584|Experimental|Obese, Otherwise Healthy Volunteers|
3319417|NCT02001597||Surgery patients|
3319418|NCT02001610|Active Comparator|Hard shell gelatin capsules|"Comparison delivery vehicle in the form of gelatin capsule~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
3319419|NCT02001610|Experimental|Acidophilus pearls|"Encapsulated using patented process~One capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
3319421|NCT02001636|Experimental|Protein group|"Patient group which takes daily protein supplements after bariatric surgery over 6 months.~Protein product: Resource Instant Protein 88, Nestlé Health Nutrition"
3319422|NCT02001636|Placebo Comparator|Control group|"Patient group which takes daily isocaloric placebo after bariatric surgery over 6 months and thus can be compared to the protein group.~Placebo product: Resource Maltodextrin, Nestlé Health Nutrition"
3319423|NCT02001649|Other|Inpatient group SNP Genotyping|"Patients will be recruited from pediatric departments in which 13 -17 y old adolescents are hospitalized for a suicide attempt. Data will be collected through self-administered questionnaires and face to face interview. DNA will be extracted from saliva sample.~Individuals will be genotyped at a total of 96 SNPs"
3319424|NCT02001649|Other|Control group SNP Genotyping|Control subjects are young adults without suicide attempt and without mental disorders
3319425|NCT02001662|Experimental|Intervention group, block no. 1 - Ropivacain|"Adductor-Canal-Block no.1: 30mL ropivacaine (7.5 mg/ml) when postoperative VAS-score is > 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL isotonic saline."
3319426|NCT02001662|Sham Comparator|Control group, block no. 1 - saline|"Adductor-Canal-Block no.1: 30mL isotonic saline when postoperative VAS-score is above 40mm (on a 0-100 mm VAS-scale) during a 45 degree active flexion of the knee.~Adductor-Canal-Block no.2: after 45 min (t45) - 30mL ropivacaine (7.5 mg/ml)"
3319427|NCT02001675|Experimental|Volunteer healthy|
3319428|NCT02001701|Experimental|Intravitreal Gas|Intravitreal injection of sulfahexafluoride gas
3319429|NCT02001727|Active Comparator|Hp-screened group|Screened for Helicobacter Pylori and eradication therapy (1998-99)
3319430|NCT02001727|Other|Control group|primarily unscreened group
3319431|NCT02001740|Placebo Comparator|lidocaine|frequency = once
3319432|NCT02001740|Experimental|Triamcinalone (steroid) and lidocaine|frequency = once
3319433|NCT02001753|Experimental|CMR group|Endothelial function, oxidative stress and inflammation were measured before and after CMR.
3319434|NCT02001753|Placebo Comparator|Placebo group|"The subjects keep supine position the MR machine as same time as experimental group when the MR machine is power off. The endothelial function, oxidative stress and inflammation were measured before and after this procedure. This group is called the non-CMR group or sham CMR group."
3319435|NCT02001753|No Intervention|health subject group|Healthy subjects (30) will be enrolled as controls at baseline.
3319436|NCT02001766|Experimental|High intensity exercise|3 times per week in a total of 12 weeks
3319437|NCT02001766|Experimental|Low intensity exercise|3 times per week in a total of 12 weeks
3319438|NCT02001766|Experimental|Control|Normal lifestyle for 12 weeks
3319439|NCT02001779|Experimental|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
3319440|NCT02001779|Active Comparator|Conventional biliary SEMS|A self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
3319441|NCT02001792|Sham Comparator|Controll group|Patients lying in a supine position during colonoscopy
3319442|NCT02001792|Active Comparator|Intervention|Patients lying in a left lateral position during colonoscopy
3319443|NCT02001805||Marathon runners|Very active runners that have been running > 10 marathons, 2 within the last year, or an amount of 50 km/week for the last 5 years
3319444|NCT02001805||Control subjects|Healthy normal weight control subjects, with a low activity level < 1 hour phsyical activity pr. week. They are matched with runners on age, BMI and gender
3319445|NCT02001818|Experimental|Nilotinib or Imatinib with Peginterferon|"Nilotinib 300mg twice daily for 24 months. Pegylated interferon alpha-2b 30-50 micrograms subcutaneously once weekly for maxium 21 months (3 months after trial registration).~Patients intolerant of nilotinib may be switched to appropriate doses of imatinib"
3319446|NCT02001831|Experimental|Supplement|"Liquid nutrient support (quantity 200 mL per day; energy 200 kcal per day):~Carbohydrate 28.5 g~Protein 8 g as Whey Protein Isolate~ω-3 PUFA 3000 mg, as DHA 1500mg, as EPA 1500mg~Vitamin D3 10 μg~Resveratrol 150 mg"
3319447|NCT02001831|Placebo Comparator|Control|"Placebo control~Liquid nutrient support~Quantity 200 mL per day - fruit juice only i,e. in absence of bioactives present in the supplement (whey protein, omega 3, vitamin D and resveratrol)."
3319448|NCT02001844|Placebo Comparator|Control|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
3319449|NCT02001844|Experimental|Trial Group|"Trial Group:~children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
3319450|NCT02001857|Experimental|TachoSil|TachoSil
3319451|NCT02001857|No Intervention|No TachoSil|No TachoSil
3319452|NCT02001870|Experimental|In Vitro Fecundation (IVF)|Couples will be treated by In Vitro Fecundation (IVF)
3319453|NCT02001870|Active Comparator|Intra Uterine Insemination (IUI)|Couples will be treated by Intra Uterine Insemination (IUI)
3319454|NCT02001883|Active Comparator|Association low-dose statin and nutraceuticals|Patients will receive the association between low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin) and a commercially available nutraceutical combined pill (1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg).
3319455|NCT02001883|Active Comparator|Low-dose statin|Patients will receive low-dose statin (10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin)
3319456|NCT02001896|Experimental|erlotinib combine with chemotherapy|Drug: gemcitabine 1000mg/m2 iv on days 1 of each 4 week cycle for 6 cycles Drug: Platinum chemotherapy (cisplatin or carboplatin) cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles Drug: Erlotinib[Tarceva] po on days 15-28 of each 4 week cycle until disease progression
3319457|NCT02001896|Active Comparator|erlotinib along|Drug: erlotinib [Tarceva] 150mg/day po until disease progression
3319458|NCT02001909|Experimental|Regorafenib|
3319459|NCT02001909|Experimental|Neomycin|
3319460|NCT02001922|Experimental|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
3319461|NCT02001922|No Intervention|Usual care|Usual COPD care
3319462|NCT02001935|Other|theophylline|
3319463|NCT02001948|Active Comparator|intrathecal morphine 0.1 mg|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive a spinal anaesthesia with 0.1 mg morphine combined with 7.5 mg heavy bupivacaine
3319464|NCT02001948|Active Comparator|0.4 mg of intrathecal morphine|After routine monitorisation, intravenous cannulation and premedication, patients in this group will receive spinal anesthesia with 0.4 mg of morphine combined with 7.5 mg of heavy bupivacaine.
3319465|NCT02001961||Heart failure|Patients will be recruited from the heart failure clinic by their consultant. These will include patients who are due to have a MRI scan for clinical reasons and those who volunteer to participate. Voluntary subjects will be over 8 years.
3319466|NCT02001961||Control|Control subjects will be identified after being referred for an MRI scan and being allocated to a non-cardiac MRI with gadolinium contrast.
3319467|NCT02001974|Experimental|Group 1|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 400 mg three times daily (t.i.d.) three weeks on one week off (three to six patients)
3319468|NCT02001974|Experimental|Group 2|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 100% increase to 800 mg t.i.d. if no toxicity in previous group (400 mg) three weeks on one week off (three to six patients)
3319469|NCT02001974|Experimental|Group 3|Paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15 of 28-day cycle) + reparixin oral 50% increase to 1200 mg t.i.d. if no toxicity in previous group (800 mg) three weeks on one week off (three to six patients).
3382427|NCT04895813|Experimental|Group 1:|The patient will be given training on the day the appointment is made for colonoscopy, educational material will be given as a reminder, information will be given on the phone and the training will be reminded on the day he should start diet for colonoscopy. No different application will be made on the day and after the colonoscopy.
3319470|NCT02002000|Experimental|vitamin D|Patients receiving 3 doses of vitamin D (cholecalciferol)
3319471|NCT02002000|Experimental|Placebo|Patients receiving 3 doses of placebo according to the same schedule as experimental arm
3319472|NCT02002013||Adult ICU patient receiving Fluid resus|Adult patients present in the ICU at the start of the study day or admitted during the 24-hour study period will be included in the study sample.
3382428|NCT04895813|No Intervention|Group 2|Routine information in the service will be made
3382431|NCT04895202||Siponimod|Patients administered Siponimod as per Swiss label
3319473|NCT02002026|Active Comparator|Ligation group|Uterine artery ligation will be done for patients in this group
3319474|NCT02002026|Placebo Comparator|Control group|Conventional CS
3382436|NCT04888585|Experimental|Dose A of ABBV-154|Participants in this group will receive dose A of ABBV-154 subcutaneously (SC) every other week (eow) for 12 weeks in the placebo-controlled period and 66 weeks in the long term extension (LTE) period.
3319475|NCT02002039|Active Comparator|erythropoietin, perinatal asphyxia,|Treatment group
3382437|NCT04888585|Experimental|Dose B of ABBV-154|Participants in this group will receive dose B of ABBV-154 SC eow for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.
3382438|NCT04888585|Experimental|Dose C of ABBV-154 EOW|Participants in this group will receive dose C of ABBV-154 SC eow for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.
3382439|NCT04888585|Experimental|Dose C of ABBV-154 E4W|Participants in this group will receive dose C of ABBV-154 SC every 4 weeks (e4w) for 12 weeks in the placebo-controlled period and 66 weeks in the LTE period.
3382440|NCT04888585|Experimental|Placebo|Participants in this group will receive placebo SC eow for 12 weeks in the placebo-controlled period and will be re-randomized in 1:1 ratio to receive ABBV-154 dose B or C respectively SC eow for 66 weeks in the LTE period.
3382441|NCT04884360|Experimental|Group A: Olaparib tablets 300 mg oral twice daily (n=280).|Participants in Group A will receive olaparib tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
3319476|NCT02002039|Placebo Comparator|Normal saline, perinatal asphyxia|Normal saline on alternate days for 5 doses starting from first 6 hours of life
3319477|NCT02002052|Active Comparator|Standard Arm|Standard platinum-based chemoradiotherapy, total radiation dose 60 Gy in 30 fractions
3319478|NCT02002052|Experimental|Experimental Arm|Functional-lung avoidance radiotherapy, total dose 60 Gy in 30 fractions, with concurrent platinum-based chemotherapy
3319479|NCT02002065||Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
3319480|NCT02002065||Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
3319481|NCT02002078|No Intervention|Methylprednisolone, caustic burns|
3319482|NCT02002104||EPCs|No proliferation and no differentiation on the ePTFEs
3319483|NCT02002104||Modified ePTFE|EPCs adherence, proliferation and differentiation on the ePTFEs.
3319484|NCT02002117||DNA mass spectrometry|DNA mass spectrometry
3319485|NCT02002143|Active Comparator|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
3382442|NCT04884360|Placebo Comparator|Group B: Placebo tablets 300 mg oral twice daily (n=140)|Participants in Group B will receive matching placebo tablets taken orally at a dose of 300 mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator, whichever is earlier, and as long as in the investigator's opinion they are benefiting from treatment and do not meet any other discontinuation criteria.
3382443|NCT04878640|Active Comparator|Group A|patients with morbid obesity and gall bladder stone underwent concomitant laparoscopic cholecystectomy in the same setting during laparoscopic sleeve gastrectomy
3319486|NCT02002143|Experimental|Group Appointments (GAs)|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
3382444|NCT04878640|Active Comparator|Group B|patients with morbid obesity and gall bladder stone underwent laparoscopic sleeve gastrectomy without concomitant laparoscopic cholecystectomy
3319487|NCT02002156|Experimental|BCG at birth and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
3382447|NCT04871711|Experimental|Delgocitinib cream 20 mg/g|Twice-daily topical application for 16 weeks
3382448|NCT04871711|Placebo Comparator|Cream vehicle|Twice-daily topical application for 16 weeks
3319488|NCT02002156|Experimental|BCG at 3 months old and routine vaccines|BCG, NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
3382449|NCT04869644|Experimental|Intervention: Behavioral Change Techniques to encourage Habit Formation|Individuals will receive daily text messages with the goal of increasing daily walking by 2,000 more steps 5 days per week. Participants will be enrolled for a baseline period lasting 2 weeks where their average daily activity level will be assessed using a Fitbit device to generate an average daily step counts. Following completion of baseline, participants will be asked to generate a walking plan with the goal of walking an additional 2,000 steps above their baseline activity level on 5 days per week. This walking plan will include details about day of the week, time of day, and location of walking. Once participants have completed their walking plan, they will receive daily texts based on the 5 identified BCTs for the duration of the 10-week intervention. All BCTs will be delivered daily. The goal of the text messages will be to encourage habit formation for walking behavior.
3319489|NCT02002156|Experimental|Routine vaccines|NeisVac-C®, Pediacel®, Infanrix™, Prevenar-13®, Menitorix®, Priorix®, Rotarix®
3382455|NCT04860349|Experimental|High Intensity Interval Training|20 minutes of High Intensity Interval Training for experimental group.
3382456|NCT04860349|No Intervention|Control|No intervention for the control group.
3382457|NCT04858425|Experimental|Niclosamide|Niclosamide tablets 400 mg 3 times daily for 14 days
3382458|NCT04858425|Placebo Comparator|Placebo|Matching placebo tablets 3 times daily for 14 days
3382463|NCT04851119|Experimental|Treatment (tegavivint)|Tegavivint will be administered IV over 4 hours on days 1, 8, and 15 of each cycle. Administer D5W flush after completion of each tegavivint infusion. A cycle of therapy is considered to be 28 days. A cycle may be repeated for a total of 26 cycles, up to a total duration of therapy of approximately 24 months. Drug doses should be adjusted based on the weight (height and BSA will also be captured) measured within 7 days prior to the beginning of each cycle. The starting dose will be 5 mg/kg with dose levels for subsequent cohorts increasing to 6.5 mg/kg and 8 mg/kg if excessive toxicity does not occur. If the MTD has been exceeded at the first dose level, then the subsequent cohort of patients will be treated at a dose of 4 mg/kg.
3382464|NCT04847232|Experimental|Sodium Zirconium Cyclosilicate|
3382465|NCT04847232|Placebo Comparator|Placebo|
3382466|NCT04845035|Experimental|BFM + Tyrosine Kinase Inhibitor|This study has 2 cohorts: participants aged 18 - 59 years and participants aged 60 or more years. Both cohorts receive the same study intervention with dosage adjusted for age. Participants receive the Berlin-Frankfurt-Münster (BFM) protocol plus dasatinib during a two-phase induction and a delayed re-induction. Participants receive the BFM protocol plus ponatinib during post-induction consolidations and maintenance.
3319490|NCT02002169|Experimental|Shower Technique Protocol (STP)|Participants will be given a minimum 30 minute personalized educational session by the study coordinator. They will be taught safe and clean techniques for showering with their CVC. If the participant passes the Shower Technique Test, they will be provided a pamphlet on the STP, not to be shared with other participants, to be kept as a reference and placed in their bathroom/household. They will also be given the necessary supplies for the STP.
3319491|NCT02002169|Active Comparator|Standard CVC care|Standard CVC Care consists of cleansing with chlorhexidine 2% or povidone (if allergic to chlorhexidine) at the CVC exit site by trained HD nurses followed by placement of a dry gauze dressing by the HD nurse 1x/week or when clinically indicated. In order to participate in the standard CVC care arm, participating sites must have in their policy that it is trained HD nurses who will apply the Polysporin Triple Ointment after standard cleansing with chlorhexidine 2% or povidone during HD, according to guideline recommendations or as per hospital patient care standards and nursing regulations.
3319492|NCT02002195||modified folfox|Oxaliplatin 85 mg/m2 in 2 hours intravenous infusion, + S-leucovorin 200 mg/m2, + 5-FU 2,400 mg/m2 as a 46 hours continuous infusion. The cycles are repeated every 2 weeks for a total of 8 cycle, if tumor response is stable disease, partial or complete response, then maintenance with Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
3319493|NCT02002234|Other|Medical Treatment Arm|Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
3319494|NCT02002234|Other|Surgery with Medical Treatment Arm|Aside from receiving standardized medical therapy, decompressive hemicraniectomy was performed by removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank. Cranioplasty was performed during a separate admission on an elective basis not earlier than 6 months from the initial surgery.
3319495|NCT02002247|Placebo Comparator|Placebo|Normal saline will be administered to subjects intravenously pre-operatively, upon admission to the ICU, then daily up to post-operative day 10 or ICU discharge, whichever occurs first.
3319496|NCT02002247|Active Comparator|sodium selenite|"High-dose sodium-selenite will be administered to subjects intravenously:~1) pre-operatively (2000 ug); 2) upon admission to the ICU (2000 ug), 3) then daily (1000 ug) up to post-operative day 10 or ICU discharge, whichever occurs first."
3319497|NCT02002260|Active Comparator|Levonorgestrel intrauterine system|levonorgestrel intrauterine system with 52 mg of levonorgestrel, levonorgestrel is released at a rate of approximately 20 μg/day. Inserted once, duration 5 years.
3319498|NCT02002260|Active Comparator|Combined oral contraceptives|A combined ethinyl estradiol (ee) and progestin oral contraceptive pill chosen by the participants' primary gynecologic care provider. Monophasic with 30 or 35 mcg ee administered according to pill pack instructions (21 days active pills, 7 placebo pills)
3319499|NCT02002273|Experimental|Patients with regulated suction mode|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
3319500|NCT02002273|Experimental|regulated seal mode (-8 cmH2O).|On the morning of each postoperative day (starting with POD#1) patients of group 1 are switched for 4 hours to -8 cm H2O and patients of group 2 are switched to -20 cm H2O. After this period of 4 hours both groups are switched back to their original pressure levels, with the effect on air leak and fluid leak measured. Pts are then left on their original pressure level until the next day, when the switch to -8 or - 20 cm H2O is again made.
3319501|NCT02002286|Experimental|TwHF extract + cART|Use Tripterygium Wilfordii Hook F extract (TwHF extract) and continue current cART regimen
3319502|NCT02002286|Other|cART control|Continue current cART regimen
3319503|NCT02002312|Experimental|Lu-177-DOTA-girentuximab|Patients in receive 10 mg of girentuximab coupled to DOTA and labeled with 65 mCi/m2 of Lu-177 if targeting of In-111-DOTA-girentuximab is observed in at least 1 lesion. Patients may be retreated no sooner than 12 weeks after the prior treatment with a dose of no more than 75% of the previous dose, for a total of not more than three treatments.
3319504|NCT02002325|Experimental|Alteplase|Intravenous tissue-type plasminogen activator (alteplase)
3319505|NCT02002325|Other|Standard Care|Standard treatment for acute stroke
3319506|NCT02002338||Pterygium|Patients who were operated of pterygium
3319507|NCT02002351||Pulmonary disease|
3319508|NCT02002364|Active Comparator|Single use flexible optical scope|Single use flexible optical scope , Ambu aScope
3319509|NCT02002364|Active Comparator|Multiple use flexible optical scope|Multiple use flexible optical scope
3319510|NCT02002377|Experimental|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
3319511|NCT02002390|Experimental|Fingolimod (FTY720) group|Drug: Fingolimod capsules will be administered as 0.5mg/day over a course of 3 consecutive days after stroke onset.
3319512|NCT02002390|Placebo Comparator|Control group|Patients will receive usual care and drug use in hospital.
3319513|NCT02002403|Placebo Comparator|Placebo|
3319514|NCT02002403|Experimental|Optina Low Dose|Optina, 15 mg orally, twice daily
3319515|NCT02002403|Experimental|Optina - High Dose|Optina, 45 mg orally, twice daily
3319516|NCT02002416||Metastatic gastric cancer patients|Selecte 100 cases of eligible metastatic gastric cancer patients with primary and metastatic lesion (1:1). Use the immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH) to detect the status of C-met.
3319517|NCT02002416||Early stage gastric cancer|Selected 100 cases of eligible gastric cancer patients with previously early stage gastric cancer
3319518|NCT02002429|Experimental|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
3319519|NCT02002429|Active Comparator|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine
3319520|NCT02002429|Sham Comparator|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline
3319521|NCT02002442|Active Comparator|0.12% Chlorhexidine|Alcohol-free Chlorhexidine Gluconate Oral Rinse USP, 0.12% from GUM®
3319522|NCT02002442|Active Comparator|Essential oil|LISTERINE® ZERO™ Mouthwash
3319523|NCT02002442|Active Comparator|0.07% Cetylpyridinium Chloride|Crest Pro-Health Multi-Protection Rinse - Refreshing Clean Mint (Procter and Gamble)
3319524|NCT02002442|Placebo Comparator|Saline|
3319525|NCT02002455|Experimental|Multimodality imaging|PET/CT, PET/MRI, mpMRI
3319526|NCT02002468|Experimental|Test result sent by letter|The pap-smear test result is sent by letter directly to the women. Women in need of follow up are in the letter recommended to contact their general practitioner.
3319527|NCT02002468|Active Comparator|Test result conveyed by general practitioners|In Denmark it is a standard procedure that general practitioners convey the pap-smear test results to the women.
3319528|NCT02002481|No Intervention|Control|10 minutes ALS-CPR in a normal environment
3319529|NCT02002481|Experimental|Transport|10 minutes ALS-CPR during a transport
3319530|NCT02002507||park bench position|Comparing jugular venous flow in supine and park bench position in neurosurgical patients requiring their surgery in park bench position
3319531|NCT02002507||prone position|Comparing the jugular venous flow in the supine and prone position in patients requiring their surgery to be done in the prone position.
3319532|NCT02002520||case group|patients undergo third molar surgery
3319533|NCT02002520||control group|subjects do not require surgery
3319534|NCT02002546||ED chest pain presenting patients|
3319535|NCT02002559||NBI Magnify Endoscopy|Detection of esphageal neoplasia through recognition of brownish discolored area via NBI and characterize the lesion using IPCL upon magnifying endoscopy
3319536|NCT02002559||Lugol Chromoendoscopy|Detection of esophageal neoplasia through recognition of discolored area
3319537|NCT02002572|Experimental|Mimic facial muscle from 3T MRI data|
3319538|NCT02002585|Experimental|RDN and optimal medical therapy|Renal denervation will be performed using the available denervation device with a european approval according to current guidelines. The same device will be used for all patients in this arm to avoid efficacy bias.
3319539|NCT02002585|No Intervention|optimal medical therapy alone|Group of patients who will be treated only with optimal medical therapy and will not be denervated. Subsequently, the patients will be followed in our cardiology and nephrology department according to the study flowchart for 3 years according to the standard of care in our institution for patients with chronic renal insufficiency.
3319540|NCT02002598|Experimental|CFZ with bendamustine and dexamethasone|Subjects will receive Carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days with dose escalation from 27, 36, 45 to 56 mg/ m2 . No matter what target dose the subject will receive, days 1 and 2 doses in the first cycle will always be 20 mg/m2, followed by target dose for all subsequent dates and cycles. Bendamustine will be given IV on days 1 and 2 with dose escalation up to 90 mg/m2 and dexamethasone 20 mg orally or intravenously on 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle. Study treatment will be given until 8 cycles of treatment are completed or until disease progression, whichever comes first.
3319541|NCT02002611|Experimental|Lobeglitazone|Subjects received Lobeglitazone 0.5 mg daily for 12 days in one period and in the other period, Subjects don't receive Lobeglitazone.
3319542|NCT02002611|Experimental|Warfarin|Subjects received Warfarin 25 mg once at period 1 and 2.
3319543|NCT02002624|Active Comparator|Conventional|Conventional instrumentation
3319544|NCT02002624|Experimental|PSI|Patient specific instrumentation
3319545|NCT02002637|Experimental|Latella Knee Implant System|
3319546|NCT02002663|Experimental|ropivacaine + methylprednisolone|Continuous infusion of Ropivacaine 0.2% and methylprednisolone 1mg/kg 10ml/h through intralesional catheter for 24 hours
3319547|NCT02002663|Placebo Comparator|saline|Continuous infusion of saline through intralesional catheter for 24 hs
3319548|NCT02002715|Active Comparator|Inhaled budesonide for 4 weeks|inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
3319549|NCT02002715|Active Comparator|Inhaled budesonide for 8 weeks|inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
3319550|NCT02002715|Active Comparator|Inhaled budesonide for 16 weeks|inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
3319551|NCT02002741|Active Comparator|Ibuprofen + Paracetamol|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Intravenous Paracetamol : Loading dose 20mg/kg --> 10 mg/kg q6h for total of 12 doses"
3319552|NCT02002741|Placebo Comparator|Ibuprofen + Placebo|"Ibuprofen 10mg/kg once --> 5mg/kg twice, q 24h for total of 3 doses~+ Placebo (NaCl 0.9%) , Intravenous , at equal volume to the paracetamol in the paracetamol arm, total of 12 doses given q 6h."
3319553|NCT02002754|Active Comparator|Eosinophilic bronchitis|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
3319554|NCT02002754|Active Comparator|cough variant asthma|Bambuterol Hydrochloride tablets 10mg,QN,for 3 days
3319555|NCT02002780|Experimental|Subjects|"Children identified during the screening phase of the project as having elevated, but not clinically defined, levels of psychosocial stress will be invited to participate in the intervention phase of this research if they are between 8 and 11 years of age.~Screening will identify 6 girls and 6 boys eligible and willing to participate in the intervention phase of the project."
3319556|NCT02002780|No Intervention|Control|All families that were screened during the screening phase of this study will complete the final screening instrument assessment, whether or not the child participated in the day camp intervention. The control group will be comprised of those families that did not participate in the intervention.
3319557|NCT02002793|Other|Early stage abdominal drainage|SAP patients who matches one of the following criteria:1．Intravesical pressure≥20cmH2O or 2.CT images:acute peripancreatic liquid collection should have early stage abdominal drainage immediately;
3319558|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT images:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
3319559|NCT02002806|Experimental|Alcohol Injection|Celiac plexus neurolysis by alcohol injection One time administration during surgery 20 ml of alcohol injection on each side of aorta at level of celiac axis
3319560|NCT02002806|Placebo Comparator|Placebo Injection|Celiac plexus injection - placebo injection
3319561|NCT02002819|Experimental|Levetiracetam-Placebo|This group receives levetiracetam for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives placebo for 4 weeks.
3319562|NCT02002819|Experimental|Placebo-Levetiracetam|This group receives placebo for 4 weeks twice daily, then has a break where no treatment is given for 4 weeks, and then receives levetiracetam for 4 weeks.
3319563|NCT02002845||Robotic arm|Patient who have undergone benign non-tumor TORS procedures using the da Vinci Surgical System
3319564|NCT02002858|Experimental|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
3319565|NCT02002858|Active Comparator|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
3319566|NCT02002897|Experimental|Fractional carbon dioxide laser|Single session of fractional laser is done using DEKA machine , for 3 months .
3319567|NCT02002897|Active Comparator|Ultraviolet A1 phototherapy (UVA1)|24 sessions of UVA 1 phototherapy are give at a rate of 3 sessions per week , at a dose of 30 joules using a Waldman targeted machine.
3319568|NCT02002923|Active Comparator|PVI only|
3319569|NCT02002923|Active Comparator|PVI+BT injection|
3319570|NCT02002949|Experimental|Short daily hemodialsysis|Short Daily Hemodialysis (SDHD) - 5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
3319571|NCT02002949|Active Comparator|Conventional hemodialysis|Conventional Hemodialysis (CHD) - 3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
3319572|NCT02002962|Active Comparator|RFA+BT injection|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
3319573|NCT02002962|Active Comparator|RFA|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
3319574|NCT02002988|Experimental|BT injection|
3319575|NCT02003001|Experimental|BT injection|
3319576|NCT02003027|Experimental|BT injection|
3319577|NCT02003040||St. Michael's Hospital Patients|Patients admitted to the Cardiology ward at St Michael's Hospital with a main diagnosis of acute decompensated heart failure
3319578|NCT02003066|Experimental|Standard|
3319579|NCT02003066|Active Comparator|Conservative|
3319580|NCT02003079||Diagnosed with or without Chronic Rhinosinusitis|
3319581|NCT02003092|Experimental|RX-5902|RX-5902 will be taken daily for 4 weeks in each 4 week cycle. Subjects will be fasting for 8 hours before and food may be ingested approximately 3 hours after the dose has been administered.
3319582|NCT02003118|Experimental|AKR 202|
3319583|NCT02003118|Placebo Comparator|Placebo|
3319584|NCT02003131|Other|Intra-articular knee injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered intra-articularly.
3319585|NCT02003131|Other|Subcutaneous injection of MTF|Trophic factors from umbilical cord mesenchymal stem cells administered subcutaneously once per week for 12 weeks.
3319586|NCT02003144|Experimental|Eculizumab|Eculizumab intravenous infusion every two weeks.
3319587|NCT02003157|Active Comparator|hypnosis|embryo transfer procedure with hypnosis
3319588|NCT02003157|Active Comparator|usual|embryo transfer usual procedure
3319589|NCT02003170||Neurodevelopmental Disorders|Children who present to various Arkansas Children's Hospital clinics for standard care related to neurodevelopmental disorders.
3319590|NCT02003209|Active Comparator|Arm I (combination chemotherapy, surgery, radiation)|"NEOADJUVANT: Patients receive docetaxel IV over 60 minutes, carboplatin IV over 30-60 minutes, trastuzumab IV over 30-90 minutes, and pertuzumab IV over 30-60 on day 1. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
3319591|NCT02003209|Experimental|Arm II (chemo, estrogen deprivation, surgery, radiation)|"NEOADJUVANT: All patients receive docetaxel, carboplatin, trastuzumab, and pertuzumab as in arm I. Premenopausal patients also receive goserelin acetate SC every 28 days until surgery and aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Postmenopausal patients receive aromatase inhibition therapy at the investigator's discretion daily until 1 day before surgery. Patients enrolled after Amendment #4 undergo 2 core biopsies prior to course 3 of treatment.~SURGERY: Patients undergo lumpectomy or mastectomy.~RADIATION: Patients undergo whole breast irradiation within 8 weeks following surgery.~ADJUVANT: Patients receive trastuzumab IV over 30-60 minutes every 21 days for up to 1 year."
3319592|NCT02003222|Experimental|Arm I (blinatumomab, chemotherapy)|See Detailed Description
3319593|NCT02003222|Active Comparator|Arm II (chemotherapy)|See Detailed Description
3319594|NCT02003235|Experimental|Single Arm|Daily watching videos using Reviview™, a dichoptic video display device
3319595|NCT02003248|Experimental|dyskinesia of PD|The proposed study is to evaluate the safety and initial effectiveness of the ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with dyskinesia of Parkinson's Disease (PD)
3319596|NCT02003261|Experimental|Unified Protocol with Treatment As Usual|Unified Protocol is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. During this treatment period, the participants continue the Treatment As Usual.
3319597|NCT02003261|Other|Waitlist Control with Treatment As Usual|Waitlist participants will not receive treatment during a 20-week waitlist period, but will receive the unified protocol immediately following the 20 week waiting period. During the waitlist period, the waitlist participants continue the treatment as usual.
3319598|NCT02003274|Other|Clamp-Mixed Meal Arm|Twenty adult patients with type 1 diabetes, regularly attending the Division of Endocrinology and Metabolic Diseases of University of Verona School of Medicine, using continuous subcutaneous fast insulin analogue infusion (CSII) through a permanent pump and on subcutaneous glucose sensing will be enrolled.
3319599|NCT02003274|Other|IVGTT-Mixed Meal Arm|Twenty healthy adult volunteers will be recruited.
3319600|NCT02003287|Experimental|FEES|Swallowing evaluation with the Fiberoptic Endoscopic Evaluation of Swallowing
3319601|NCT02003287|Active Comparator|VFSS|Swallowing evaluation with the Videofluoroscopic Swallowing Study
3319602|NCT02003313|Experimental|Group T|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
3319603|NCT02003313|Active Comparator|Group C|Participants of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine.
3319604|NCT02003326|Other|Inflammatory markers|All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat <30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.
3319605|NCT02003339|Experimental|RMIs|
3319606|NCT02003378|Active Comparator|Minute Ventilation (MV)|Pacemaker sensor set to MV (Cross over study)
3319607|NCT02003378|Active Comparator|Accelerometer (XL)|Pacemaker sensor set to XL (Cross over study)
3319608|NCT02003417||Non-metastatic prostate cancer patients|Histologically-confirmed, non-metastatic prostate cancer patients who received external beam radiation treatment with androgen deprivation therapy (total ADT duration > 3 months) for definitive treatment.
3319609|NCT02003430||≥65 years old|20 patients greater than or equal to 65 years of age
3319610|NCT02003430||<65 years old|20 patients less than 65 years of age
3319611|NCT02003443|Placebo Comparator|Sham Acupressure|Participants assigned to sham acupressure will receive similar instruction as those assigned to pain-relief acupressure, except that they will be taught to apply pressure to 10 acupoints that are unrelated to pain. That is, they will conduct self-administered acupressure 5 days/week for 8 weeks, as the pain-relief acupressure group does, but on 'sham' acupoints.
3319612|NCT02003443|No Intervention|Usual Care|Participants assigned to the UC group will receive no intervention.
3319613|NCT02003443|Experimental|Pain-Relief Acupressure|Participants assigned to pain-relief acupressure will be taught to apply physical pressure, using a wooden hand-held device designed for acupressure, to 10 acupoints on their body.That is, they will conduct self-administered acupressure 5 days/week for 8 weeks,on acupoints that are relevant to pain reduction.
3319614|NCT02003456|Experimental|Cardiac PET scan|To evaluate methods that could allow the use of two radiotracers(rubidium-82/18F-fluorodeoxyglucose(FDG)and rubidium-82, that are used in cardiac positron emission tomography(PET)imaging scans to be performed at one time instead of the current method which involves being imaged at separate times, several hours apart.
3319615|NCT02003469|Experimental|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
3319616|NCT02003482||Postop IMRT for Head/Neck cancer|CT for Radiation Treatment Planning
3319617|NCT02003482||Chemo/IMRT for bulky Head/Neck cancer|CT for Radiation Treatment Planning
3319618|NCT02003495|Experimental|MCV-ACYW135 Vaccine Group|"Participants at age 2 to 6 years of enrollment will receive 1 dose on Meningococcal ( A, C, Y and W 135) conjugate vaccine.~Participants at age 6 to 23 months of enrollment will receive 2 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 3 months apart.~Participants at age 3 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 1 month apart.~Participants at age 2 to 5 months of enrollment will receive 3 doses on Meningococcal ( A, C, Y and W 135) conjugate vaccine at 2 months apart."
3319619|NCT02003495|Active Comparator|MPV-ACYW135 Vaccine Group|Participants at age 2 to 6 years of enrollment will receive 1 dose on Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
3319620|NCT02003495|Active Comparator|MPV-A Vaccine Group|Participants at age 6 to 23 months of enrollment will receive 2 doses on Group A Meningococcal Polysaccharide vaccine at 3 months apart.
3319621|NCT02003495|Active Comparator|MCV-AC Vaccine Group|Participants at age 3 to 5 months of enrollment will receive 3 doses on Group A and C Meningococcal conjugate vaccine at 1 month apart.
3319622|NCT02003495|Placebo Comparator|Hib Vaccine Group|Participants at age 2 to 5 months of enrollment will receive 3 doses on Haemophilus Influenzae Type b Conjugate Vaccine at 2 months apart.
3319623|NCT02003521||Intervension|Lung Flute
3319624|NCT02003547|Experimental|AMA0076 Formulation A|Topical Ocular Drop BID X 1 wk
3319625|NCT02003547|Experimental|AMA0076 Formulation B|Topical Ocular Drop BID X 1wk
3319626|NCT02003547|Experimental|AMA0076 Formulation C|Topical Ocular Drop BID X 1 wk
3319627|NCT02003547|Placebo Comparator|Placebo|Topical Ocular Drop BID X 1 wk
3319628|NCT02003560|Experimental|Accelerated partial breast irradiation|Accelerated partial breast irradiation delivered by 3 dimensional conformal radiotherapy or intensity modulated radiotherapy
3319629|NCT02003586|Other|Plant-based ingredient to a starchy meal|Plant-based ingredient
3319630|NCT02003586|Other|Starchy meal alone|No plant-based ingredient
3319631|NCT02003599|Placebo Comparator|Placebo|"In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .~Both arm will use institutional skin care protocol."
3319632|NCT02003599|Experimental|Laser therapy|"In the intervention group, 26 patients will be submitted a laser therapy .The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2. It will be administrated five days a week before radiotherapy.~Both arm will use institutional skin care protocol."
3319633|NCT02003612||All subjects|All subjects
3319634|NCT02003651|Experimental|Quick Defense|250 mg E. purpurea root and 83 mg E.angustifolia root standardized to 10 mg alkylamides, and 210 mg of a proprietary synergistic extract blend containing andrographis paniculata leaf, black elderberry berries, sambucus nigra, ginger root, and zingiber officinale
3319635|NCT02003651|Placebo Comparator|Placebo|Placebo will contain the excipients vegetable glycerin and olive oil. Placebo and echinacea capsules will be colored green and contain the same proportions of inert ingredients.
3319636|NCT02003664|Active Comparator|Baclofen ER versus Placebo|Baclofen ER versus Placebo (sugar pill)
3319637|NCT02003664|Placebo Comparator|Placebo versus Baclofen ER|Participants will receive either placebo (sugar pill) or Baclofen ER
3319638|NCT02003677|Experimental|FIAsp followed by NovoRapid®|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3319639|NCT02003677|Active Comparator|NovoRapid® followed by Insulin aspart|Each subject will be randomly allocated to a treatment sequence consisting of 2 dosing visits separated by a wash-out period of 3-12 days
3319640|NCT02003690|Experimental|Dialectical Behavior Therapy + Pharmacotherapy|Dialectical Behavior Therapy + Pharmacotherapy
3319641|NCT02003690|Active Comparator|Standard of Care Psychotherapy + Pharmacotherapy|Standard of Care Psychotherapy + Pharmacotherapy
3319642|NCT02003703|Experimental|Recombinant Hepatitis B Virus Vaccine (High Dose)|Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
3319643|NCT02003703|Active Comparator|Recombinant Hepatitis B Virus Vaccine (Standard Dose)|Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
3319644|NCT02003716||No treatment|
3319645|NCT02003729|Active Comparator|Portable Sleep Monitor|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from portable monitor sleep studies.
3319646|NCT02003729|No Intervention|Polysomnography|The clinical diagnosis of OSA will be done according to the American Academy of Sleep Medicine criteria, a combination of data from clinical examination, presenting symptoms, risk factors and results from polysomnography from the sleep clinic.
3319647|NCT02003742|Experimental|NX-1207|Subjects randomised to the NX-1207 group will receive a single NX-1207 (2.5 mg) TRUS-guided intraprostatic injection (under antibiotic prophylaxis), followed by a placebo QD oral treatment for 12 months.
3319648|NCT02003742|Active Comparator|Comparator|Subjects randomised to the comparative arm will undergo TRUS only (under placebo prophylaxis) and will continue the tamsulosin 0.4 mg QD oral treatment for 12 months
3319649|NCT02003755|Experimental|Spastic CP|continuous passive motion training
3319650|NCT02003768|Experimental|TIVA|2% Propofol (Fresofol®), Remifentanil 20mcg/cc (Ultiva®)
3319651|NCT02003768|Active Comparator|Des|Desflurane (Suprane®), Remifentanil continuous infusion (20mcg/cc)
3319652|NCT02003781||cardiovascular disease|high risk cardiovascular disease patients and their relatives
3319653|NCT02003794|Experimental|IV Fluid|0.9% NaCl solution infusion: 100 ml/hr for three days.
3319654|NCT02003794|No Intervention|No IV Fluid|Not receive any intravenous fluid but can consume oral fluid normally for three days.
3319655|NCT02003807||Diverticulitis patients (case)|Cases were the patients who admitted to hospital because of acute diverticulitis attack.
3319656|NCT02003807||Non-diverticulitis patients (control)|Controls were the patients who admitted to hospital due to non-gastrointestinal disorder.
3319657|NCT02003820|Experimental|Group 1|Group 1 will receive plaque index exam and immediately start their three week intervention of watching a dental hygiene video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
3319658|NCT02003820|Experimental|Group 2|Group 2 will receive plaque index exam and immediately start their three week intervention of watching a control video immediately before brushing twice per day. Plaque index exams will be completed at start, t-10 days, and t-21 days. Parental surveys will be completed at each plaque index exam and 6 weeks after start.
3319659|NCT02003833|Experimental|Poly-L-lactic acid|Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
3319660|NCT02003833|Placebo Comparator|Placebo|Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
3319661|NCT02003846||Premature infant|Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours
3319662|NCT02003872|Experimental|Spattz 3 intragastric balloon|obese patients, . BMI ≥ 35 kg/m² or BMI ≥ 30 kg/m² and hypertension or diabetes mellitus. All will have the intragastric balloon
3319663|NCT02003885|Experimental|Desflurane increment|increment of desflurane 0.5-1.5 MAC in remifentanil anesthesia for cardiac surgery
3319664|NCT02003937|Experimental|12 weeks of aerobic conditioning|12 weeks of aerobic conditioning, a total 42 sessions of 30min exercise on a stationary cycle ergometer
3319665|NCT02003950|Other|Chocolate pre-restriction|
3319666|NCT02003950|Other|Chocolate Baseline|
3319667|NCT02003950|Other|Chocolate post-restriction|
3319668|NCT02003950|Other|Salty Snacks|
3319669|NCT02003950|Other|Sweet Non-Chocolate Snacks|
3319670|NCT02003950|Other|Dried Fruit|
2792952|NCT00914251|Active Comparator|Hesperidin, 500 mg per day|500 mg daily of oral Hesperidin for 3 weeks
2792956|NCT00914251|Placebo Comparator|Placebo|
3319671|NCT02003976|Experimental|Non-Surgical Treatment plus HTO|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will undergo a medial opening wedge high tibial osteotomy (HTO). They will continue with their home program and will be followed up for 2 years after baseline.
3319672|NCT02003976|Active Comparator|Non-Surgical Treatment|The optimized non-surgical treatment program consists of medications, physiotherapy and nutritional seminars. The 12-week program will include an assessment by a primary care physician, physiotherapist and orthopaedic surgeon, one supervised physiotherapy session per week, one body recomposition session per week, and a home program. After the 12-week program is completed, patients randomized to this group will continue with their home program and will be followed up for 2 years after baseline.
3319673|NCT02003989||patients|HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI
3319674|NCT02003989||control|non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI
3319675|NCT02004002|Active Comparator|Weight maintenance with normal protein intake|Control group will consume 1.4 g protein/kg body wt/d; consistent with the average protein intake in the US population.
3319676|NCT02004002|Experimental|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
3319677|NCT02004015|Experimental|Atracurium|injection of NMBA 0.5 mg/kg milligram(s)/kilogram in Intravenous bolus use
3319678|NCT02004015|Experimental|ROCURONIUM|injection of NMBA 0.6 mg/kg milligram(s)/kilogram in Intravenous bolus
3319679|NCT02004015|Placebo Comparator|placebo|injection of placebo Injection in Intravenous bolus use
3319680|NCT02004028|Experimental|VS-6063 (defactinib)|Administered orally (BID) for 12, 21 or 35 days (+/- 2 days)
3319681|NCT02004041|Experimental|VLY-686 x mg|Single dose, X mg VLY-686, administered as X 50 mg VLY-686 oral capsule(s)
3319682|NCT02004041|Placebo Comparator|Placebo|Single dose, placebo, administered as X 50 mg oral capsule(s)
3319683|NCT02004054||optic neurotis|measure of pupil diameter
3319684|NCT02004067|Active Comparator|Refresh Endura|Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months.
3319685|NCT02004067|Experimental|Restasis|Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months
3319686|NCT02004080||TBI admitted to ICU|Intensive Care treatment
3319687|NCT02004106|Experimental|Part 1: RO6895882 Single Ascending Dose|Participants will receive RO6895882 at ascending doses (</= 6 mg) as a single intravenous (IV) infusion.
3319688|NCT02004106|Experimental|Part 2: RO6895882 Dose Escalation Monotherapy|Participants in different cohorts will receive RO6895882 at ascending doses as IV infusion qw, q2w or q3w. After completion of Part 2 all participants have the option to receive the recommended RO6895882 dose once defined in Part 2 at the discretion of investigator.
3319689|NCT02004106|Experimental|Part 3: RO6895882 MTD Expansion|Participants will receive RO6895882 at MTD determined in Part 2 as IV infusion qw, q2w or q3w.
3319690|NCT02004119|Placebo Comparator|Placebo|
3319691|NCT02004119|Experimental|KHK4577|
3319692|NCT02004145|Experimental|Positive Psychology|"The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Gratitude for positive events~Gratitude letter~Performing acts of kindness~Using personal strengths~Enjoyable and meaningful activities:~Repeating one of the previous exercises."
3319693|NCT02004145|Sham Comparator|Organizational Skills|"The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.~Exercises:~Daily Events~Health Events~Morning and Evening Events~Interactions with Others~Leisure Time Activities~Repeating one of the previous exercises."
3319694|NCT02004171|Experimental|electronic cigarette|electronic cigarette 24mg cartridges; 1-2 cartridges daily
3319695|NCT02004171|Active Comparator|nicotine inhaler|nicotine inhaler 10mg cartridge; max 16 cartridges daily
3319696|NCT02004184|Experimental|maintenance pemetrexed|maintenance pemetrexed immediately after induction chemotherapy
3319697|NCT02004184|Active Comparator|pemetrexed at progression|observation and pemetrexed therapy at disease progression
3319698|NCT02004197|Experimental|Pylorex plus|Pylorex plus consisting of medicinal plants.
3319699|NCT02004197|Active Comparator|Quadruple therapy|Omeprazole, Amoxicillin, Metronodazole and TRITEC (ranitidine bismuth citrate)
3319700|NCT02004210|Experimental|The TARE group|transarterial radioembolization group
3319701|NCT02004210|Experimental|The TACE group|Transarterial chemoembolization group
3319702|NCT02004223|Experimental|Dose escalation using stereotactic boost|Dose level allocation - Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level
3319703|NCT02004275|Experimental|Arm I (pomalidomide, dexamethasone)|Patients receive pomalidomide PO QD on days 1-21 and dexamethasone PO QD on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving disease progression may cross over to Arm II.
3319704|NCT02004275|Experimental|Arm II (pomalidomide, dexamethasone, ixazomib)|Patients receive pomalidomide, dexamethasone, and ixazomib as in Phase I. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3319705|NCT02004301|Experimental|Radiolabelled T4 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 4 h radiolabelled with 4 MBq 99mTc
3319706|NCT02004301|Experimental|Radiolabelled T6 Tablet|Single dose of delayed release diclofenac potassium (25 mg) tablet with time delay of 6 h radiolabelled with 4 MBq 99mTc
3319707|NCT02004314|Other|Chloroquine|This will be a single arm, pilot study with each subject as his/her own control. The study will last 44 weeks, with 8 weeks observation period on ART alone to assess stability of activated CD8CD38 T cells, followed by 24 weeks chloroquine treatment with ART and a 12-week follow-up period on ART alone. Twenty ART treated patients will be recruited. To maximize chances of demonstrating a treatment effect, the chloroquine will be administrated for 24 weeks.
3319708|NCT02004327|Experimental|A Group|"1st administration - DW1029M300mg PO Once~2nd administration - DW1029M600mg PO Once~3rd administration - DW1029M1200mg PO Once"
3319709|NCT02004327|Experimental|B Group|"1st administration - DW1029M600mg PO Once~2nd administration - DW1029M1200mg PO Once~3rd administration - DW1029M300mg PO Once"
3319710|NCT02004327|Experimental|C Group|"1st administration - DW1029M1200mg PO Once~2nd administration - DW1029M300mg PO Once~3rd administration - DW1029M600mg PO Once"
3319711|NCT02004340|Active Comparator|Transcutaneous auricular vagal stimulation|Transcutaneous stimulation at auricular concha
3319712|NCT02004340|Sham Comparator|Transcutaneous auricular non-vagal stimulation|Transcutaneous stimulation at auricular edge
3319713|NCT02004340|No Intervention|control|No transcutaneous stimulation is given
3319714|NCT02004379||Patients with hepatitis C, genotype 1|Patients with hepatitis C, genotype 1, treated with telaprevir or boceprevir
3319715|NCT02004392|Experimental|EVP-6124, low dose|low dose, Tablet, Once Daily, Day 1 through Day 182
3319716|NCT02004392|Experimental|EVP-6124, high dose|high dose, Tablet, Once Daily, Day 1 through Day 182
3319717|NCT02004405|Experimental|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
3319718|NCT02004405|Active Comparator|Flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
3319719|NCT02004418|Experimental|C-Choline PET Scans|Radioactive doses of 11C-Choline: 400 MBq ± 10% per injection, pre-radiation treatment and following treatment at 3 and 6 months
3319720|NCT02004431||Pain (experimental)|The cases are patients with significant pain on day one after surgery
3319721|NCT02004431||No pain (control)|The controls are sex, age and operation matched individuals without pain.
3319722|NCT02004444||Natalizumab 18 months|10 patients on continuous natalizumab monotherapy for 18 months
3319723|NCT02004444||Natalizumab 24 months|10 patients on continuous natalizumab monotherapy for 24 months
3319724|NCT02004444||Natalizumab 36 months|10 patients on continuous natalizumab monotherapy for 36 months
3319725|NCT02004444||IFN-beta 36 months|10 patients on continuous interferon-beta monotherapy for 36 months
3319726|NCT02004444||Untreated|10 untreated patients
3319727|NCT02004457|Experimental|Acceptance-based behavior therapy (ABBT)|ABBT will consist of 2 sessions. The first session will be used to introduce the concept of acceptance and its possible benefits in the context of life values and patient-identified barriers to care engagement. Following a discussion of life values will be a discussion of which, if any, of these values are currently misaligned with the participant's HIV self-care. At the second session, acceptance-based coping skills will be practiced and a behavioral plan will be developed to targets barriers identified in the first session. These discussions will help the participant clarify how best to align their values with decisions on how to manage his/her HIV (e.g. when and how to disclose, what to expect at appointments).
3319728|NCT02004457|Placebo Comparator|Treatment-as-usual (TAU)|TAU will consist of the standard sessions all individuals receive as they enter HIV care and attend their first follow-up visit to review lab results. TAU includes identification of environmental barriers to care, assessment of needs for additional care and corresponding referrals (i.e., for depression, substance abuse), and recommendations to attend HIV support groups.
3319729|NCT02004470|No Intervention|Passive exsufflation|Will not actively suction carbon dioxide from abdomen. Open laparoscopic trocars and allow C02 to passively empty from abdomen.
3319730|NCT02004470|Experimental|Active lavage and suction|This step is already employed in many ongoing surgeries where normal saline will be used to lavage the right upper quadrant and then will be suctioned out to remove as much Carbon dioxide from the patient's abdomen and to therefore decrease postoperative pain.
3319731|NCT02004483|Experimental|Percutaneous Coronary Intervention|Each patient will get elective percutaneous coronary angioplasty with balloon inflation(PCI). During and after PCI 2D-echography (strain) will be performed.
3319732|NCT02004496|No Intervention|Group A: no app|no use of an mobile application while treatment
3319733|NCT02004496|Active Comparator|Group B: only app|Patients, who use independently the mobile application named Consilium without involvement of the physician.
3319734|NCT02004496|Active Comparator|Group C: app and physician|Patients use the mobile application named Consilium in collaboration with the physician.
3319735|NCT02004509|Active Comparator|anticoagulant|Prescription of oral anticoagulation for patients with silent AF (detected by the pacemaker).
3319736|NCT02004509|No Intervention|Control|Patients with silent FA detected only by the pacemaker will no receive oral anticoagulation.
3319737|NCT02004535|Experimental|Cochlear implantation|Cochlear implantation of the ear with severe to profound hearing loss
3319738|NCT02004548|Experimental|Metatinib Tromethamine|"Dose escalation is in accordance with the traditional 3 +3 design, and dose groups are subsequently set as: 25, 50, 100, 200, 300, 450, 600, 800 mg/d."
3319739|NCT02004561||Gastric Banding|Patients chose Gastric banding
3319740|NCT02004561||Gastric Bypass|Patients chose gastric bypass surgical operation
3319741|NCT02004574|Experimental|PRN treatment|Group 1: PRN treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily as needed (PRN)
3319742|NCT02004574|Experimental|Continuous treatment|Group 2: Continuous treatment Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel)once daily
3319743|NCT02004574|Experimental|Weekends treatment|Group 3: Weekends treatment (twice weekly) Apply Xamiol® gel (Calcipotriol/betamethasone dipropionate gel) once daily at weekends (on Saturdays and Sundays)
3319744|NCT02004587|Experimental|Mild hepatic impairment group|Mild hepatic impairment group by Child-Pugh scores
3319745|NCT02004587|Experimental|Moderate hepatic impairment group|Moderate hepatic impairment group by Child-Pugh scores
3319746|NCT02004587|Active Comparator|Healthy volunteers|Gemigliptin dosing in Healthy subjects
3319747|NCT02004600|Experimental|patient receiving one PDT session|patient receiving one photodynamic therapy (PDT) session
3319748|NCT02004626|Active Comparator|Collagenase|"Each gram of ointment contains :~Collagenase ...0.6 U~Vehicle qs ... 1 g~Presentation:~Topic use. 5 g tube of ointment containing smooth, lump-free , pale white to slightly brown with faint characteristic odor .~Dosage The ointment should have full contact with the entire injured area, and uniformly applied twice a day."
3319749|NCT02004626|Active Comparator|Kollagenase|"Each gram of ointment contains :~Collagenase ... 0.6 U~Vehicle qs ... 1 g~Presentation~Topic use. 5 g tube of ointment containing brownish clear, fat and weak characteristic odor.~Dosage The ointment should have full contact with all the injured area, being uniformly applied twice a day."
3319750|NCT02004639|Active Comparator|Mastictors sparing group|Using IMRT or HT to do masticators sparing techniques and physical therapy to prevent trismus.
3319751|NCT02004639|No Intervention|Masticators not sparing group|The patients do not receive masticators sparing technique as traditional techniques but still receive physical therapy after radiotherapy to prevent trismus.
3319752|NCT02004639|Active Comparator|EA group|Using masticators sparing techniques and electro-acupunture stimulation to prevent trismus
3319753|NCT02004639|Sham Comparator|Sham-EA group|Using masticators sparing techniques but with sham EA stimulation.
3319754|NCT02004652|Experimental|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
3319755|NCT02004652|Placebo Comparator|Placebo|Vitamin C, 50mg, tablet
3319756|NCT02004665||acute coronary syndrome and delirium|patients with acute coronary syndrome and delirium
3319757|NCT02004678|Other|Cohort 1, 7.5 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 7.5 mg DS-1150b in Period 2; or~a single dose of 7.5 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
3319758|NCT02004678|Other|Cohort 2, 15 mg DS-1150b|"Dosing will occur over two periods. Subjects will receive either~a dose of placebo in Period 1 followed by a single dose of 15 mg DS-1150b in Period 2; or~a single dose of 15 mg DS-1150b in Period 1 followed by a dose of placebo in Period 2."
3319759|NCT02004691|Experimental|GZ402665|Olipudase alfa dose (3 mg/kg body weight) in saline administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
3319760|NCT02004691|Placebo Comparator|Placebo|Placebo (saline) administered intravenously once every 2 weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
3319761|NCT02004704|Experimental|GZ402665|GZ402665 administered intravenously once every 2 weeks for up to 9 years at the dose each patient was receiving at the end of their previous olipudase alfa study.
3319762|NCT02004717|Experimental|dose escalation then expansion|"Dose escalation of this study will follow a 3+3 study design with a starting intravenous (IV) dose of 0.1 mg/kg. Six dose levels are planned: level 1,0.1 mg/kg; level 2,0.3 mg/kg; level 3, 1.0 mg/kg; level 4,3.0 mg/kg; level 5,10 mg/kg; level 6,20 mg/kg.~Dose Expansion - Up to 20 subjects will be enrolled and treated at the dose determined in Dose Escalation arm."
3319763|NCT02004730|Experimental|long single vessel disease|ABSORB implantation for long single vessel disease
3319764|NCT02004730|Experimental|multivessel disease ABSORB only|multivessel disease treated with ABSORB implantation only
3319765|NCT02004730|Experimental|"multivessel disease hybrid"|multivessel disease treated with ABSORB implantation and other devices such as drug eluting stents
3319766|NCT02004743|Other|Control|Treatment as Usual
3319767|NCT02004743|Other|Intervention|Psychological management guidelines + patient education
3319768|NCT02004756|Experimental|Fontan Patients|Fontan patients who are monitored at the Hospital for Sick Children (SickKids) will undergo an exercise program
3319769|NCT02004756|No Intervention|Healthy Controls|Healthy age-matched adolescents
3319770|NCT02004769|Experimental|Trastuzumab, Capecitabine, Docetaxel|Trastuzumab(8 mg/kg loading dose followed by 6 mg/kg every 3 weeks) Capecitabine(2000mg/m2d, d1-14,every 3 weeks) Docetaxel (60mg/m2 every 3 weeks for 6 cycles).All patients will continue to receive trastuzumab and Capecitabine until either disease progression, occurrence of unacceptable toxicity or withdrawal from the study for another reason.
3319771|NCT02004782|Active Comparator|Prenisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
3319772|NCT02004782|Placebo Comparator|Placebo|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
3319773|NCT02004795|Experimental|BNCT+ IG-IMRT|single arm
3319774|NCT02004821|Experimental|Renutryl® Booster|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat).
3319775|NCT02004834|Active Comparator|0,5% levobupivacaine with 2% lidocaine|7,0 ml.of mixture 0,5% levobupivacaine with 2% lidocaine are given per level Th2,Th3,Th4 for ultrasound guided paravertebral blocks in breast surgery
3319776|NCT02004834|Active Comparator|0,5% levobupivacine|7,0 ml. 0,5% levobupivacaine are given per level Th2,Th3,Th4, given for ultrasound guided paravertebral blocks in breast surgery
3319777|NCT02004860|Experimental|Protopic Arm|Protopic® 0.1% ointment - 2 applications per week for 6 months
3319778|NCT02004860|Active Comparator|Mycoster Arm|2 applications per week for 6 months
3319779|NCT02004899|Active Comparator|F20|Patients randomized to this arm of the study receive 20 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
3319780|NCT02004899|Experimental|F50|Patients randomized to this arm of the study receive 50 mcg fentanyl with 8 mg bupivacaine as their epidural loading dose
3319781|NCT02004899|Experimental|F100|Patients randomized to this arm of the study receive 100 mcg fentanyl and 8 mg bupivacaine as their epidural loading dose
3319782|NCT02004912|Experimental|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
3319783|NCT02004912|No Intervention|No mentoring intervention|The no mentoring intervention arm does not have supportive visits and education to health center staff by nurse mentors.
3319784|NCT02004925||Pneumoperitoneum|Patients with a diagnosis of pneumoperitoneum by CT or surgery
3319785|NCT02004925||no pneumoperitoneum|patients with acute abdominal pain with a diagnosis other than pneumoperitoneum in whom pneumoperitoneum was excluded by CT or surgery
3319786|NCT02004938||normal respiratory function|This will include the 40 subjects enrolled in the study
3319787|NCT02004951|Other|Misago RX (Misago RX, Terumo Corp., Tokyo|The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
3319788|NCT02004951|Other|Zilver PTX (Cook Medical, Bloomington, IN, USA)|Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.
3319789|NCT02005003|Active Comparator|Probiotic|Probiotic pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
3319790|NCT02005003|Placebo Comparator|Placebo|Placebo pills given for 2 weeks, during one of the interventions that the participants is either randomized to as the first or second intervention period. At day 0 and following each intervention period (at week 2 and week 6), participants will be tested using Inhibitory task, Blood samples, Feces collection, Caloric preload, Food selection task, Memory task and Food consumption task.
3319791|NCT02005042|No Intervention|Accelerometer only|Wear accelerometer only to measure activity levels (steps)
3319792|NCT02005042|No Intervention|Accelerometer plus EMA|Wear accelerometer and complete Ecological Momentary Assessment (EMA) surveys on smartphone 5 times daily
3319793|NCT02005042|Experimental|Feedback on smartphone|Wear accelerometer, complete EMA surveys on smartphone 5 times daily, receive intervention
3319794|NCT02005055||Patients with recalcitrant keloid scars|All patients with keloids insensitive to other treatments
3319795|NCT02005068|Experimental|Acute Osteomyelitis - Non MRSA|For treatment of Acute osteomyelitis (< 6 months duration) Non MRSA isolate- Ceftaroline 600 MG (milligram) IV (intra-venous) every 8 hours for 6 weeks.
3319796|NCT02005068|Experimental|Acute osteomyelitis MRSA isolate|For treatment of Acute osteomyelitis (< 6 months duration) MRSA isolate- Ceftaroline 600 MG IV every 8 hours for 8 weeks.
3319797|NCT02005068|Experimental|Prosthetic joint infection|For treatment of prosthetic joint infection Ceftaroline 600 mg IV every 8 hours for 6 weeks.
3319798|NCT02005081|Other|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
3319799|NCT02005081|Other|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
3319800|NCT02005094||Healthy group|patients without MAC/MAB lung disease and colonization
3319801|NCT02005094||MAC/MAB colonization group|patients with pulmonary MAC/MAB colonization
3319802|NCT02005094||MAC/MAB lung disease group|Patient with MAC/MAB lung disease
3319803|NCT02005107|Experimental|venlafaxine|Venlafaxine IR and XR, single dosages of each separated by a wash-out period
3319804|NCT02005107|Other|Venlafaxine XR and Venlafaxine IR|Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period.
3319805|NCT02005120|Experimental|Arm A|Bevacizumab
3319806|NCT02005120|Experimental|Arm B|recombinant human endostatin
3319807|NCT02005133||VEGF inhibitor naïve|
3319808|NCT02005133||VEGF inhibitor prior treated|
3319809|NCT02005146||Patients with chronic hepatitis B treated with nRTI|Patients with chronic hepatitis B with HBsAg loss treated with nucleoside/nucleotide analogues (Lamivudine, Adefovir, Tenofovir, Telbivudine, Entecavir, Emtricitabine)
3319810|NCT02005159||Positive blood-culture to bacteremia by enterobacteria|Patients with positive blood-culture to bacteremia by enterobacteria
3319811|NCT02005172|Other|Alivecor device and event monitor|Both the Alivecor device (experimental) and the standard of care (event monitor) will be provided to all patients for the duration of the study
3319812|NCT02005185||6-11y/o anesthetized at 0-2y/o for >2hrs|6-11yr olds anesthetized for more than120 minutes before the age of 2.
3319813|NCT02005185||6-11y/o anesthetized @ 0-2y/o for <30min|6-11 year olds anesthetized for < 30min before the age of 2.
3319814|NCT02005185||6-11y/o anesthetized at 4-7y/o for >2hrs|6-11 year olds anesthetized for more than 120 min between the ages of 4-7.
3319815|NCT02005185||6-11 y/o healthy control|6-11 year olds that have never received general anesthesia.
3319816|NCT02005198||Survey|
3319817|NCT02005224|Other|LCHF diet and a bout of exercise|LCHF diet for 3 weeks, where E% 70 fat, E% 20-25 proteins and 20g or less carbohydrates. Oral glucose tolerance test on the morning of day 21 followed by a bout of exercise in the afternoon (indoor bicycle, 60min at 75% HFpeak). The following morning (day 22) a new oral glucose tolerance test. Oral glucose tolerance test results from pre-tests used to determine the effect of LCHF and a bout of exercise on insulin sensitivity.
3319818|NCT02005237|Experimental|Aerobic Exercise (12 Weeks)|Aerobic exercise on a bicycle ergometer, tailored to the individual's level of fitness. Duration: 12 weeks with 2-3 sessions per week.
3382467|NCT04844749|Experimental|Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day|32mg of VERU-111 26mg of VERU-11
3319819|NCT02005237|No Intervention|Waitlist Control Group|No intervention (patients randomized to this group will be offered access to the training program after completion of the trial)
3319820|NCT02005263|Experimental|Salpingography|Infusion of air bubbles through Fallopian tubes with hysteroscopic visualization; typically 1-2 mL is infused. This is less than that typically used in the established technique of sonosalpingography.
3319821|NCT02005289|Experimental|Cohorts 1-3Treatment (MOR00208, lenalidomide)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and lenalidomide PO daily on days 1-28 (days 9-28 of course 1 only). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
3319822|NCT02005289|Experimental|Cohort 4 Treatment (MOR00208, ibrutinib)|Patients receive anti-CD19 monoclonal antibody MOR00208 IV over 2 hours on day 1 (days 1, 2, 8, 15, and 22 of course 1 only) and ibrutinib PO daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Correlative studies will be collected for this trial and will focus on the effects of MOR00208 alone and in combination with ibrutinib on immune effector cell number and function.
3319823|NCT02005302|Experimental|Vitamin D2 Treatment|
3319824|NCT02005302|Active Comparator|1,25(OH)2 Vitamin D3|
3319825|NCT02005302|Experimental|low protein diet|
3319826|NCT02005302|Active Comparator|normal protein diet|
3319827|NCT02005315|Experimental|Vanctictumab (OMP-18R5)|Vantictumab will be administered by intravenous (IV) infusion.
3319828|NCT02005315|Experimental|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
3319829|NCT02005315|Experimental|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
3319830|NCT02005328|Experimental|cross-over|Four periods separated by a wash out lasting up to 3 days at maximum. At each period, application of one product (twice). Duration of treatment period: From 4 to 13 days.
3319831|NCT02005341|Active Comparator|Autograft bone|
3319832|NCT02005341|Experimental|nanOss with bone marrow aspirate|
3319833|NCT02005367|No Intervention|DAP-CP|512 patients who elected to participate in the Drug Abuse Core Program alone (DAP-CP).
3319834|NCT02005367|Experimental|Natural Recovery-Horticulture|Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
3319835|NCT02005367|Experimental|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using one module per week with a staff facilitator and also pursued four hours of their hobby on each weekend day for up to 14 weeks.
3319836|NCT02005380||Text-based Task|This group is required to do the text-based task
3319837|NCT02005380||Graphic-based Task|This group is required to do the graphic-based task
3319838|NCT02005406||wei group and control group|wei group(n=25) and control group(n=24)
3319839|NCT02005419|Placebo Comparator|gemcitabine + placebo|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; placebo at 2 g on days 1-28
3319840|NCT02005419|Experimental|gemcitabine + metformin|gemcitabine at 1000 mg/m^2 on days 1, 8, and 15; metformin at 2 g on days 1-28
3319841|NCT02005432|Active Comparator|SS-PRP arm|panfotocoagulation (PRP) single shoot (ETDRS) + 0,05ml intravitreal injection anti-VEGF (ranibizumabe)
3319842|NCT02005432|Experimental|MS-PRP arm|Multiple shoot panfotocoagulation (PASCAL) plus IVR
3319843|NCT02005432|Other|IVR arm|only IVR (intravitreal Ranibizumabe)
3319844|NCT02005458|Experimental|YPEG-rhG-CSF 20μg/kg|20μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3319845|NCT02005458|Experimental|YPEG-rhG-CSF 30μg/kg|30μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3319846|NCT02005458|Experimental|YPEG-rhG-CSF 45μg/kg|45μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3319847|NCT02005458|Active Comparator|PEG-rhG-CSF 100μg/kg|100μg/kg,single s.c. at 48hrs after chemotherapy for each experimental cycle
3319848|NCT02005497|Experimental|HealthLinks|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email to implement a worksite wellness program and adopt evidence-based practices.
3319849|NCT02005497|Active Comparator|HealthLinks+|Worksites in this arm will receive the standard HealthLinks intervention protocol, which includes on-site consulting, toolkits, and support via telephone and email plus support to form a worker wellness committee to implement a worksite wellness program and adopt evidence-based practices.
3319850|NCT02005497|No Intervention|Delayed Control|Worksites in this arm will not receive an intervention during the study. After they have provided their final follow-up data, they will receive the HealthLinks intervention.
3319851|NCT02005523|Experimental|RNS60|
3319852|NCT02005523|Placebo Comparator|Saline|
3319853|NCT02005575|Placebo Comparator|Group 1|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml normal saline)
3319854|NCT02005575|Active Comparator|Group 2|an intercostal nerve block with a solution consisting of 0.46% bupivicaine (19.5 ml of 0.5% bupivicaine + .5ml .4% dexamethasone)
3319855|NCT02005588|Active Comparator|amino acid chelated iron arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and pregnant 14-18 weeks. these pregnant women will be given amino acid chelated iron capsules (15 mg iron/capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules, and hemoglobin 9.1-11 g/dl will receive 1 capsule). complete blood picture and serum ferritin will be assessed at 22-23 weeks, 29-30 weeks and 36-37 weeks. possible side effects (colicky abdominal pains, constipation and metallic taste) will be asked about in each follow up visit.
3319856|NCT02005588|Active Comparator|iron salt arm|this arm will contain 150 pregnant women with proved iron deficiency anemia and 14-18 weeks gestation. these women will be given oral iron salt ferrous fumarate capsules (350 mg iron/ capsule containing about 70 mg elemental iron/ capsule) 1-2 capsules daily according to hemoglobin level (hemoglobin 7-9 g/dl will receive 2 capsules daily and hemoglobin 9.1-11 g/dl will receive 1 capsule daily. women will be followed up with complete blood picture and serum ferritin at 22-23 weeks, 29-30 weeks and 36-37 weeks. women will be asked about possible side effects (colicky abdominal pains, constipation, and metallic taste) in each visit.
3319857|NCT02005614|Experimental|Gamma Knife Radiosurgery|"Rational dose selection is a concept wherein doses used for stereotactic radiosurgery is selected based on tumor volume, prior irradiation with whole brain radiotherapy, and the relative radioresistance of the tumor (radioresistant = melanoma, renal cell carcinoma, sarcoma; radiosensitive = breast cancer, lung cancer, colorectal cancer, gastrointestinal cancers).~Dose may be altered for lesions in the brainstem, adjacent to the optic nerve, optic chiasm, or motor cortex, or other clinical scenarios as defined by the treating physician. Reason for dose alteration will be recorded at the time of treatment.~For patients with 10+ brain metastases with multimorbidity or difficulty in tolerating a supine position, doses may be modified by the treating physicians for patient comfort."
3319858|NCT02005640||MSCT-based prothesis sizing|
3319859|NCT02005640||Echocardiographic-based prothesis sizing|
3319860|NCT02005653|Experimental|DEC + ALB sequential|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
3319861|NCT02005653|Experimental|DEC + ALB co-admin|Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
3319862|NCT02005653|Experimental|DEC + DOXY co-admin|Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
3319863|NCT02005653|Active Comparator|Diethylcarbamazine (DEC)|Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days
3319864|NCT02005679|Experimental|deaf persons with potential dementia|
3319865|NCT02005705|Active Comparator|Outpatient|
3319866|NCT02005705|Active Comparator|Inpatient|
3319867|NCT02005718|Experimental|Vitamin D|Cholecalciferol 300,000 twice
3319868|NCT02005731||Shockwaves|Low intensity linear focused shockwave device ('Renova')
3319869|NCT02005744|Experimental|Child Pugh A|CKD-501 will be administered to patients who are included Child Pugh A
3319870|NCT02005744|Experimental|Child Pugh B|CKD-501 will be administered to patients who are included Child Pugh B
3319871|NCT02005744|Experimental|Subject who are matched Child Pugh A|CKD-501 will be administered to the Subjects who are matched Child Pugh A
3319872|NCT02005744|Experimental|Subject who are matched Child Pugh B|CKD-501 will be administered to the subjects who are matched Child Pugh B
3319873|NCT02005757|Experimental|Bredinin tablet 150mg|dosage form: Tablet, dosage: 150mg qd, Duration: for 6months
3319874|NCT02005757|Active Comparator|Bredinin tablet 50mg|dosage form: Tablet, dosage: 50mg tid, Duration: for 6months
3319875|NCT02005770|Experimental|Sevoflurane|General anesthesia using Sevoflurane
3319876|NCT02005770|Active Comparator|Propofol|General anesthesia using propofol TCI
3319877|NCT02005783|Experimental|DBD arm|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 DBD: one dose of medicine twice per day, orally
3319878|NCT02005783|Other|EC/TC|Epirubicin: 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4 OR; Docetaxel: 75mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
3319879|NCT02005796|Experimental|Blue-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
3319880|NCT02005796|Experimental|Yellow-fleshed potato tubers|Intervention: Steam cooked mashed potato tubers
3319881|NCT02005796|Experimental|Bilberries and potato starch|Intervention: A gel boiled with bilberries and potato starch
3319882|NCT02005809|Active Comparator|Second look endoscopy|This group is performed second look endoscopy about 24 hours later from endoscopic submucosal dissection.
3319883|NCT02005809|No Intervention|without second look endoscopy|This group is not performed second look endoscopy after ESD
3319884|NCT02005822|Experimental|Valganciclovir|Valganciclovir 32 mg/kg per day in two doses (16 mg/kg per dose) during 6 weeks in an oral solution.
3319885|NCT02005822|No Intervention|Control|"Refusal control group:~Infants in the control group receive no antiviral therapy. Counseling and treatment assigned by an audiological center remain unchanged.~Historical control group:~Infants with birth date 1-11-2011 till 1-07-2012 with sensorineural hearing loss and congenital CMV."
3319886|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support at facility~Weekly support groups provided in clinic~Phone call, SMS, or home visit for each missed appointment"
3319887|NCT02005835|Other|Community-based Peer Support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines~Mentor mothers provide education and psychosocial support in community prior to each visit~Monthly support groups in community~Home visits for each missed appointment"
3319888|NCT02005835|No Intervention|Standard of Care|The Standard of care as outlined in the Malawi HIV integrated Care Guidelines
3319889|NCT02005848|Experimental|Alpha1 Antitrypsin (Glassia)|60 mg/kg body weight
3319890|NCT02005848|Experimental|Alpha-1 Antitrypsin (Glassia)|120 mg/kg body weight
3319891|NCT02005848|Placebo Comparator|Placebo|Placebo
3319892|NCT02005861|Experimental|bone marrow cells transplantation|"surgical procedure :the day before the surgery: platelet gel production. The day of the surgery: bone marrow aspiration from the posterior iliac crest of the patient and concentration. After the bone marrow harvesting, ankle arthroscopy will be performed. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and implanted.~After that platelet gel will be loaded on the top of implant"
3319893|NCT02005874||Dry eye|
3319894|NCT02005874||Non-dry eye|
3319895|NCT02005900|Experimental|DHA|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART
3319896|NCT02005900|Placebo Comparator|PLACEBO|
3319897|NCT02005926|Experimental|negative FNA result of abnormal node|Axillary ultrasound examination was undergone for all breast cancer patients before sentinel lymph node biopsy (SLNB). If abnormal axillary lymph node was found, ultrasound-guided FNA cytology of these nodes were performed. The abnormal nodes were defined as completely hypoechoic node, asymmetric focal hypoechoic node, cortical lobulation and cortical thickness >3mm. Patients with negative results of FNA would undergo SLNB. Technetium-99m-labeled Rituximab was used for lymphatic mapping. Before the SLNB operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
3319898|NCT02005939|Experimental|Pomegranate extract capsule|All participants receive 1.1 g pomegranate extract capsule daily for 4 weeks
3319899|NCT02005939|Placebo Comparator|Placebo capsule|All participants receive a 1.1g placebo capsule daily for 4 weeks
3319900|NCT02005952||Spirometry, quality control, Pulmonary Function Laboratory|Performing spirometry, with control over the quality of the same, made from the pulmonary function laboratory of the Hospital de la Santa Creu i Sant Pau.
3319901|NCT02005952||Spirometry, quality control, software|Performing spirometry, with the support of software self-management quality of spirometry maneuvers incorporated therein
3319902|NCT02005952||Spirometry, quality control, control group|Performing spirometry in the way that is currently working in primary care (control group without any support).
3319903|NCT02005965||Staging and outcomes for patients with Low Rectal Cancer|Low Rectal Cancer defined on MRI as a cancer within 6cm of the anal verge
3319904|NCT02005978||Acromegaly1|Acromegalic patients treated with radiation therapy
3319905|NCT02005978||Healthy controls|Health controls matched for age, gender and BMI to the patients
3319906|NCT02005978||Acromegaly 2|Acromegalic patients treated with pituitary surgery
3319907|NCT02005991|Experimental|PF-05212377 70 mg|
3319908|NCT02005991|Experimental|PF-05212377 20 mg|
3319909|NCT02005991|Experimental|PF-05212377 10 mg|
3319910|NCT02006017|Experimental|Group A|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary plus a recommendation and a second scenario will be accompanied by an evidence summary alone
3319911|NCT02006017|Experimental|Group B|We will present to participants two general clinical scenarios. The first scenario will be accompanied by an evidence summary alone and a second scenario will be accompanied by an evidence summary plus a recommendation
3319912|NCT02006030|Experimental|ADI-PEG 20 + TACE|ADI-PEG 20 plus concurrent transarterial chemoembolization
3319913|NCT02006030|Active Comparator|Transarterial chemoembolization (TACE)|transarterial chemoembolization alone
3319914|NCT02006043|Experimental|Erlotinib 150mg/day taken orally|Erlotinib 150mg/day taken orally until disease progression or intolerable toxicities
3319915|NCT02006069|Experimental|MPP ON|MPP ON: feature is enabled
3319916|NCT02006069|No Intervention|MPP OFF|MPP OFF: feature not enabled
3319917|NCT02006082||COPD patients followed after TVC|All COPD patients living in the southern part of Rogaland county in Western Norway, with a habitual value of FEV1 < 50%, who were monitored at home by TVC following discharge after emergency hospitalization for COPD exacerbation at Stavanger University Hospital, or who had tele-monitoring at home under outpatient treatment for acute COPD deterioration during the pilot project period (16th April 2010 - 31st December 2011). The telemedicine equipment consisted of a computer with a web camera with a microphone, through which the patient at home and the specially trained nurse in hospital were able to communicate, and also comprised requisites to measure the patient's oxygen saturation and heart rate, and to perform a spirometry.
3319918|NCT02006095||Neuroimaging Correlates|
3319919|NCT02006134||PEDIATRIC VASCULITIS/PROSPECTIVE|Pediatric patients in this cohort are those diagnosed with vasculitis within 12 months from study entry. Clinical data, blood (RNA, plasma, serum), urine, and saliva (DNA) will be collected at 3 to 5 timepoints: time-of-diagnosis, post-induction, 12-month post diagnosis, disease flare, and remission/post-flare.
3319920|NCT02006134||PEDIATRIC VASCULITIS/RETROSPECTIVE|Patients in this cohort are those diagnosed with vasculitis more than 12 months from study entry and/or were previously enrolled in the ARChiVe or Brainworks registries. Clinical outcome data will be collected retrospectively. Blood (RNA & serum), urine, and saliva (DNA) will be collected at 2 timepoints: disease flare, and remission/post-flare.
3319921|NCT02006134||ADULT VASCULITIS/ COHORT 1|Adult patients in this cohort are those at or near the time of diagnosis of GPA, MPA, EGPA or unclassified vasculitis that are participants in DCVAS. Clinical data and blood (RNA, DNA) will be collected at the time-of-diagnosis only.
3319922|NCT02006134||ADULT VASCULITIS / COHORT 2|Adult patients in this cohort are those individuals that are participants in DCVAS and have any form of vasculitis. Clinical data and blood (DNA) collected at the time-of-diagnosis will be used for study.
3319923|NCT02006134||HEALTHY CHILDREN / PEDIATRIC CONTROL|Participants in this cohort are otherwise healthy children with no history of inflammatory disease. Children will provide a one time donation of blood (RNA, serum) and urine.
3319924|NCT02006134||HEALTHY ADULTS / ADULT CONTROL|Participants in this cohort are otherwise healthy adults with no history of inflammatory disease. Adults will provide a one time donation urine and will provide blood (RNA, serum) as many as 4 times.
3319929|NCT02006173|Placebo Comparator|Normal saline|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.
3319930|NCT02006173|Active Comparator|Lidocaine|Participants will be randomly assigned to nasolabial or nasolabial&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.
3319931|NCT02006186|Experimental|Bicycle Train Intervention|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
3319932|NCT02006186|No Intervention|Control|The control arm does not receive any intervention. All participants, regardless of group assignment, each receive a bicycle, safety equipment, and take a bicycle safety course.
3319933|NCT02006199|Experimental|relaxation with psychoeducation|after 8 weeks of relaxation with psychoeducation. subject take part in 8 weeks of the mindfulness meditation program
3319934|NCT02006199|Experimental|meditation|8 weeks of mindfulness meditation
3319935|NCT02006212|Other|cadiac surgical patient; One arm|All patients undergoing first or redo cardiac surgery with or without cardiopulmonary bypass necessitating general and/or local anesthesia. If they present any EEG abnormality intraoperatively an immediate cerebral CT scan will be performed and the necessary measures will be taken to reduce the neurologic damage.
3319936|NCT02006225|Experimental|Plerixafor|The use of plerixafor as additive measurment for the conventional stem cell collection protocol.
3319937|NCT02006238|Experimental|Farabloc|The participants will sleep on Farabloc fabric nightly for a week.
3319938|NCT02006238|Placebo Comparator|Nylon Fabric|The participants will sleep on Nylon fabric nightly for week.
3319939|NCT02006277|Experimental|Cohort 1|Cohort 1 will be an open label, randomized, 4 period, 4 treatment, 4 sequence, cross over sensory evaluation of three new prototype formulations (75 mg dose of crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres) and OS (75 mg dose of crizotinib)via use of a Crizotinib Taste Assessment - Questionnaire for Cohort 1 in healthy adults.
3319940|NCT02006277|Experimental|Cohort 2|This cohort will be an open label, randomized, 5 period, 5 treatment, 4 sequence, cross over single dose bioavailability study employing administration of four crizotinib formulations Treatments E, F, G and H (Crizotinib 250 mg dose Formulated Capsule and 250 mg dose crizotinib as prototypes 0.529 mg/mg, 0.470 mg/mg and 0.420 mg/mg Microspheres, respectively) in the fasted state to healthy adult subjects (Periods 1-4). In addition, Treatment I (250 mg dose of crizotinib OS) will be administered at Period 5, for a taste evaluation only (no pharmacokinetic (PK) sample collection after the dose), in the period immediately following the completion of Period 4 of Cohort 2. A Crizotinib Taste Assessment - Questionnaire for Cohort 2 will be filled by all subjects.
3319941|NCT02006290|Experimental|1|
3319942|NCT02006290|Placebo Comparator|2|
3319943|NCT02006303|Active Comparator|Green light PVP|The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
3319944|NCT02006303|Active Comparator|Prostatic Artery Embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
3319945|NCT02006316||varicoceles|men with clinical varicoceles underwent microsurgical varicocelectomy due to causes other than infertility such as testicular pain, discomfort or scrotal mass
3319946|NCT02006329|Experimental|Intervention group - dietary consultation - Medit|
3319947|NCT02006329|No Intervention|Control group - dietary consultation - Mediterranean diet|
3319948|NCT02006355|Active Comparator|Continuous femoral nerve bloc|Continuous femoral nerve bloc
3319949|NCT02006355|Experimental|Continuous local anesthesia|Continuous local infiltration of local anesthetic in the operated knee.
3319950|NCT02006368|Experimental|Storage Age|
3319951|NCT02006381||Age 3-6|This will include 10 typically developing boys age 3-6
3319952|NCT02006381||Age 7-12|This will include 10 typically developing boys age 7-12
3319953|NCT02006381||Age 13-17|This will include 10 typically developing boys age 13-17
3319954|NCT02006394|Experimental|Active Diet|Reduced glycemic index bread products, fish oil capsules, and polyphenol capsules.
3319955|NCT02006394|Placebo Comparator|Placebo Diet|Market variety bread products, corn oil capsules, and corn starch capsules.
3319956|NCT02006433|Experimental|Deep Brain Stimulation|"Deep brain stimulation (DBS) for the alleviation of chronic neuropathic pain in patients with spinal cord injury (SCI). The stimulation will be applied bilaterally or unilaterally in the midbrain periaqueductal/periventricular gray region (PAG/PVG).~Extended participation in the study, which will last approximately 2 more years, precisely 104 weeks.The purpose of this extended portion of the study is to obtain long-term follow-up information on safety and efficacy, in subjects that have opted to receive continuing brain stimulation. Investigators label weeks in terms of original enrollment. Thus the surgery occurs in weeks 7 and 8 and the original study finishes in week 52, with the extension lasting from week 53 to week 156."
3319957|NCT02006446||VATES|men with altered spermograms (isolated teratozoospermia or oligo-astheno-teratozoospermia)
3319958|NCT02006485|Experimental|Ublituximab + TGR-1202|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose
3319959|NCT02006485|Experimental|Ublituximab + TGR-1202 + ibrutinib|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose ibrutinib oral daily dose
3319960|NCT02006485|Experimental|Ublituximab + TGR-1202 + bendamustine|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Bendamustine at a fixed IV infusion on Days 1 & 2
3382468|NCT04844749|Active Comparator|Active control alternative androgen receptor targeting agent|The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.
3382469|NCT04843761|Experimental|Aviptadil + Remdesivir + SOC|
3382470|NCT04843761|Placebo Comparator|Aviptadil + Remdesivir Placebo + SOC|
3382471|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir + SOC|
3319961|NCT02006498|Experimental|Sillymarin|Active component study medication
3319962|NCT02006498|Placebo Comparator|Placebo|Placebo capsules
3319963|NCT02006511|Experimental|Incisional Neg Pressure Wound Therapy|Incisional negative pressure wound therapy dressings applied to the surgical site
3319964|NCT02006511|Active Comparator|Standard of care wound dressing|Standard of care wound dressing of gauze and tape or the equivalent applied to the surgical site
3319965|NCT02006524|Active Comparator|Screening with MyDiagnostick|All patients eligible for influenza vaccination are screened for atrial fibrillation with the MyDiagnostick, an easy to use and patient friendly device.
3319966|NCT02006537|Experimental|Cohort 1|Cohort 1 will enrol 8 healthy male volunteers, who will receive a single 10 mg dose of GSK225694 in the fasted state.
3319967|NCT02006537|Experimental|Cohort 2|Cohort 2 will enrol 20 healthy elderly male and female volunteers (10 males and 10 females), who will receive a single 10 mg dose of GSK225694 in the fasted or fed state according to the randomization schedule.
3319968|NCT02006589|Experimental|Arm 1 Test then Reference|Subjects will be randomized and receive the following two treatments administered orally in a fasting state A= Single dose of candesartan cilexetil (Test formulation) 8mg; B = Single dose of candesartan cilexetil (Reference treatment) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3319969|NCT02006589|Experimental|Arm 2 Reference then Test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 8mg; B= Single dose of candesartan cilexetil (Test formulation) 8mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3319970|NCT02006602|Experimental|Arm 1 reference then test|Subjects will be randomized and receive the following two treatments administered orally in a fasting state: A=Single dose of candesartan cilexetil (Reference treatment) 16mg; B= Single dose of candesartan cilexetil (Test formulation) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3319971|NCT02006602|Experimental|Arm 2 test then reference|Subjects will receive the following two treatments administered orally in a fasting state: A= Single dose of candesartan cilexetil (Test formulation) 16mg. B=Single dose of candesartan cilexetil (Reference treatment) 16mg. The two treatment periods will be separated by a washout period of at least 7 days and no more than 14 days.
3319972|NCT02006615|Experimental|High frequency rTMS plus fNIRS|rTMS with neuroimage assessment of functional near infrared spectroscopy
3319973|NCT02006615|Sham Comparator|Sham rTMS|Sham stimulation
3319974|NCT02006615|Experimental|High frequency rTMS|High frequency rTMS to modulate brain areas
3319975|NCT02006680||Children with Central Precocious Puberty|Children with Central Precocious Puberty will have hormonal testing of markers of puberty up to 30 days prior to placement of a Supprelin LA insert and 28-97 days after placement of the Supprelin LA insert.
3319976|NCT02006745|Other|Ribavirin|ARM 1: PEG-IFN and weight-based ribavirin (RBV)
3319977|NCT02006745|Other|Telaprevir|ARM 2: PEG-IFN and weight-based RBV plus telaprevir (TPV)
3319978|NCT02006771|Experimental|Southern Chinese meal|White rice (1 bowl), stir fried Choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
3319979|NCT02006771|Experimental|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
3319980|NCT02006771|Experimental|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil plus Coca-cola classic (21 fluid ounces)
3319981|NCT02006771|Experimental|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
3319982|NCT02006797|Experimental|intervention|patients with reconciliation procedure at discharge and included in the exchange process
3319983|NCT02006797|No Intervention|control|usual care
3319984|NCT02006810|Experimental|lipids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
3319985|NCT02006810|Other|flavonoids|The study will be randomized (on the order of taking the products: a single dose of lipids or a single dose of flavonoids), single-blinded, cross-over for each population (healthy and metabolic syndrome).
3319986|NCT02006849|Other|Acthar 40 units|Acthar 40 units subcutaneously three times a week for patients with sub-nephrotic proteinuria.
3319987|NCT02006849|Other|Acthar 80 units|Acthar 80 units subcutaneously twice a week for patients with nephrotic proteinuria.
3319988|NCT02006862||olanzapine, schizophrenia|
3319989|NCT02006875|Experimental|real rTMS|Experimental included the a daily real rTMS session for 15 mins followed by a physical therapy for 45 mins.
3319990|NCT02006875|Sham Comparator|sham rTMS|the control interventions included a daily sham rTMS session for 15 minutes followed by a physical therapy for 45 minutes.
3319991|NCT02006901||microdecompression|surgical microdecompression using a bilateral or unilateral approach depending on the surgeon's preference and the individual patient's anatomy and symptoms.
3319992|NCT02006901||laminectomy|the spinous process and the laminae of the involved level(s) as well as the medial aspects of the facet joints are resected
3319993|NCT02006914||Chromium Picolinate|Subjects who are HIV+ and insulin resistant
3319994|NCT02006914||Placebo|HIV+ and insulin resistant
3319995|NCT02006940|Experimental|Alveoflex, in vivo imaging miniprobe|All the patients will be examined using confocal laser endomicroscopy during bronchoscopy with a special minirobe Alveoflex before and after the treatment. Records will be done and analyzed prospectively with the included software for endomicroscopic system.
3319996|NCT02006953|Active Comparator|Bolus|"Bolus: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Volume of each bolus is determined by dividing the total volume of feeding by the desired number of feedings per day:~If child is less than 6 months: 8 feeds/day If child is 6-12 months 6 feeds/day If child is 12 months or greater: 5 feedings/day Rate of feeds is determine by the rate needed to infuse each bolus over 1 hour. Patient to remain NPO. Once at goal, if able to take PO, may offer orally first with remainder of goal volume over the remainder of the hour."
3319997|NCT02006953|Active Comparator|Continuous|Continuous: Total volume of feedings is determined by the amount of formula required to meet calorie and protein needs, which is determined by a Registered Dietitian. Rate of feeds is determined by dividing total volume of feedings by 24 hours. Patient is to remain NPO. Once at goal, if able to take PO, may offer hourly amount orally, but only 2x per day.
3319998|NCT02006966|Experimental|Group L|Intravenous lidocaine infusion group
3319999|NCT02006966|Active Comparator|Group C|Intravenous normal saline infusion - control group
3320000|NCT02006992|Active Comparator|RTF Infant Formula 1|a ready to feed (RTF) extensively hydrolyzed infant formula fed ad lib.
3320001|NCT02006992|Experimental|Powder Infant Formula 2|a powdered extensively hydrolyzed infant formula fed ad lib.
3320002|NCT02007005|Experimental|Dose escalation|intravesical instillation of abnobaVISCUM Fraxini
3382472|NCT04843761|Experimental|Aviptadil Placebo + Remdesivir Placebo + SOC|
3320003|NCT02007018|Experimental|Negative Pressure Wound Therapy|This group will receive the usual care of surgical wound AND Negative Pressure Wound Therapy (NPWT). The Prevena™ Incision Management System (PIMS) is placed in a sterile fashion over the closed surgical site prior to leaving the operating room. The PIMS is to remain in place until the completion of therapy at five days.
3320004|NCT02007018|Active Comparator|Usual Care of Surgical Wound|This group will receive the usual care of a surgical wound.
3320005|NCT02007031||Hypertensive subjects|Hypertensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
3320006|NCT02007031||Normotensive subjects|Normotensive subjects are exposed to brief cold exposure (-15 C for 15 min) mainly subjected to their facial region during which their cardiovascular responses are registered.
3320007|NCT02007044|Experimental|Arm I (ibrutinib)|Patients receive ibrutinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3320008|NCT02007044|Experimental|Arm II (ibrutinib, rituximab)|Patients receive ibrutinib as in Arm I beginning on day 1 or 2. Patients also receive rituximab IV over 3-8 hours on days 1, 8, 15, and 22 of course 1 and day 1 of courses 2-6. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3320009|NCT02007057|Active Comparator|Interscalene nerve block|"Interscalene block is performed preoperatively with ultrasound guidance and neurostimulation 0.8 milliampere. The block is performed using in-plane approach with a needle of 50 mm for a neurostimulation. During the injection, it is verified that the diffusion extends to the anterior and posterior space. If the posterior distribution is limited, the needle is remobilized to obtain an overall diffusion: a bolus of 20 mL of ropivacaine 0.75% is made by the anesthetist. The effectiveness of the nerve block is checked before the start of surgery."
3320010|NCT02007057|Experimental|Suprascapular nerve block|The suprascapular block is performed at the end of surgery when the incisions are closed but before the removal of the surgical drapes. The material used is a compound of a 10 cc syringe sterile equipment, a green intramuscular needle (14 gauge) and a bulb 10 cc of 0.75% Ropivacaine. The injection of 10 cc is realized by the technical princeps
3320011|NCT02007083|Active Comparator|Bilateral laminotomy (BL)|The multifidus muscles is detached from the spinous process bilaterally.The decompression of the spinal canal is performed by first doing a flavectomy. Thereby performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. This is performed bilaterally.
3320012|NCT02007083|Active Comparator|Unilateral laminotomy with crossover (UL)|The multifidus muscles is detached from the spinous process unilaterally. The laminotomy is first performed ipsilaterally. The decompression of the spinal canal is performed by first doing a flavectomy. Then, performing a laminotomy (about 1/3) of the the lower part of the superior lamina, and a laminotomy of the upper part (about 1/4) of the inferior lamina. Dura is then retracted, and the decompression is performed contralaterally.
3320013|NCT02007083|Active Comparator|Spinous process osteotomy (SPO)|The multifidus muscles is detached from the spinous process unilaterally. An osteotomy of the superior spinous process is performed at the basis, in the actual level. The spinous process with intact interspinal and supraspinal ligaments is then retracted to the contralateral side. The decompression is first performed in the midline. Then one goes laterally on both sides too perform the decompression. About 1/3 of the lower part of the superior lamina is removed, and about 1/4 of the upper part of the inferior lamina is removed.
3320014|NCT02007122|Experimental|IRRT|Ceftaroline levels are measured in patients receiving intermittent renal replacement therapy
3320015|NCT02007122|Experimental|CRRT|Ceftaroline levels are measured in patients receiving continuous renal replacement therapy
3320016|NCT02007135||Healthy|Healthy persons, without non-specific low back pain
3320017|NCT02007148|Experimental|micado|CAPECITABINE 500 mg twice a day, orally, continuously DOCETAXEL 60 mg/sqm i.v. over 1 hr on day 1 cycles repeated every 3 weeks Duration of treatment: Chemotherapy should be continued until: progressive disease; unacceptable toxicities; patients' refusal; or upon investigator's judgement is in the best interest for the patient.
3320018|NCT02007161|Active Comparator|Nutritional State|"Fed vs. Fasted State~Diclofenac potassium 50 mg"
3320019|NCT02007161|Active Comparator|Use of a PPI|"Nexiam (esomeprazole) 40 mg~Diclofenac potassium 50 mg"
3320020|NCT02007174||Bevacizumab injection|Three subconjunctival intralesional injections of bevacizumab. Bevacizumab injections were 2.5 mg/0.05 ml, subconjunctivally applied near to the pterygium recurrence. Application of bevacizumab was performed three times: basal, 2 and 4 weeks.
3320021|NCT02007174||Medical Treatment|In order to reduce the patient bias, the control eye received a sham laser treatment, under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mexico) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA). Post sham laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
3382476|NCT04837677|Experimental|PRT1419|PRT1419 will be administered by intravenous infusion
3320022|NCT02007174||Argon Laser Treatment|Argon laser therapies were performed on an outpatient basis only by one ophthalmologist. Under slit lamp, topical anesthesia using 0.5% tetracaine hydrochloride eye drops (Ponti-Ofteno, Laboratorios Sophia, Jalisco, Mex) and topical 1 mg fluorescein Sodium staining (Bio-Glo, Hub Pharmaceuticals, Rancho Cucamonga CA) was applied. Argon laser was applied along the vessels of the pterygium apex with power between 450mW to 780 mW, spot size of 100 u with 10 milliseconds duration. Additional grill pattern treatment was given to pterygium body using a 200 microns spot size. Treatments were given in one only session. Post laser care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, CA, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
3320023|NCT02007187|Experimental|Danhong injection|Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
3320024|NCT02007187|Placebo Comparator|Placebo|Based on the standard medical care, placebo was 40ml of 0.9% saline, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2-3 hours every day for 7 days.
3382478|NCT04831281|Experimental|Low Dose|Daily subcutaneous injection of Low Dose ATH-1017
3382479|NCT04831281|Experimental|High Dose|Daily subcutaneous injection of High Dose ATH-1017
3382480|NCT04831281|Placebo Comparator|Placebo|Daily subcutaneous injection of Placebo
3320025|NCT02007226||Spinal Cord Injury|Chronic SCI (Duration of Injury >5 years)
3320026|NCT02007239|Experimental|treatment|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
3382482|NCT04820179|Experimental|Cabozantinib 40mg + Atezolizumab 1200mg|Cabozantinib 40 mg, tablets, oral administration, once daily, continuously. Atezolizumab 1200 mg, administered intravenously, on Day 1 of every 21 day cycle.
3320027|NCT02007265||TIA and SPC outpatients|All consecutive patients attending outpatient TIA and Stroke Prevention Clinics at three regional stroke centres will be eligible to be screened.
3320028|NCT02007304|Experimental|Herbs|participants assigned to experimental arm will take 300mg panax ginseng and 300mg salvia miltiorrhiza extracts in capsules for 12 weeks along with eccentric exercise training
3320029|NCT02007304|Placebo Comparator|Placebo|parcipants in this group will take placebo capsule containing microcrystalline cellulose
3320030|NCT02007317|Experimental|Oshadi D and Oshadi R|Anti tumor agents
3320031|NCT02007330|Experimental|Group L|Intravenous lidocaine infusion group
3320032|NCT02007330|Placebo Comparator|Group C|Intravenous normal saline infusion - control group
3382483|NCT04816669|Experimental|Lyophilized SDV|
3382484|NCT04816669|Experimental|Frozen liquid MDV (control for lyo SDV)|Control for lyophilized SDV
3382485|NCT04816669|Experimental|Frozen-liquid with LNP size at the upper end of specification|
3382486|NCT04816669|Experimental|RTU|
3382487|NCT04816669|Experimental|Frozen liquid MDV (given as third dose following a primary series of lyophilized BNT162b2)|Additional vaccine dose, using the frozen-liquid formulation, offered to participants who originally received 2 doses of the lyophilized formulation of BNT162b2
3382490|NCT04813497|Other|Participants who refuse the SARS-CoV-2 vaccine|Participant who does not wish to be vaccinated against the SARS-CoV-2 virus and who wishes to perform the serological test during the vaccination campaign and the second 12-14 weeks after the first serological test.
3382491|NCT04813497|Other|Participants who received the first dose of SARS-CoV-2 vaccine before the first serological test|Participant who has received his first dose of vaccine and who performs his serological test when he receives the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity. The second serological test will be done 12 to 14 weeks after the second dose of the SARS-CoV-2 vaccine to determine its immunity.
3382492|NCT04813497|Other|Participants who start whit the serological test before SARS-CoV-2 vaccine|Participant who performed the serological test before the first dose of vaccine and 12 to 14 weeks after the second dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
3382493|NCT04813497|Other|Participants who received two doses of SARS-CoV-2 vaccine|Participant who has received their two doses of vaccine and who performs his serological test when he receives the third dose of vaccine against the SARS-CoV-2 virus to determine his immunity.
3382494|NCT04813263||Participants Treated With Venetoclax|Participants who are administrated venetoclax for treatment of AML under routine clinical practice.
3382495|NCT04812067|Experimental|TTHX1114 weekly x 5|TTHX1114 via IC injection weekly x 5
3382496|NCT04809623|Experimental|GS-5718|Participants will receive GS-5718 orally once daily for 4 weeks
3382497|NCT04809623|Experimental|Placebo|Participants will receive placebo orally once daily for 4 weeks
3320033|NCT02007343||Patients with gram-negative infections|"Sample (5/week/hospital) of all patients in a hospital that meet all of the following:~meeting the criteria of at least one infection entity based on (modified) definitions of the Center for Disease Control and Infection Prevention (CDC; Am J Infect Control 2008;36:309-32) (restricted to infections that have septic potential);~a culture with a gram-negative isolate (Enterobacteriaceae / Pseudomonas aeruginosa / Acinetobacter spp. / Stenotrophomonas maltophilia) with minimal inhibitory concentration (MIC) results from an automated system available that can be used to identify such an infection entity according to these criteria;~receipt of antibiotics (oral, intravenous or intramuscular) for this infection, the choice of which is determined by the culture with the gram-negative (i.e. this isolate is seen as the causative pathogen);~were admitted to the hospital during (part of) the infection episode.~Date of entry into cohort: date of index culture of infection episode"
3382498|NCT04809051|No Intervention|Condition 1: Combined Transplant Pictograph|"Participants randomized to baseline (control) arm Condition 1 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a survival rate pictograph corresponding to all patients at the center who received transplants."
3382499|NCT04809051|Experimental|Condition 2: Stratified Transplant Pictograph|"Participants randomized to Condition 2 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of survival rate pictographs corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
3382500|NCT04809051|Experimental|Condition 3: Combined Transplant SRTR|"Participants randomized to Condition 3 will view only combined transplant survival outcome information (e.g. transplant survival rate not stratified by number and quality of donor hearts accepted at each center) when making a choice between the two hospitals. The survival following transplant metric is displayed as a quintile score corresponding to all patients at the center who received transplants."
3382501|NCT04809051|Experimental|Condition 4: Stratified Transplant SRTR|"Participants randomized to Condition 4 will view only stratified transplant survival outcome information when making a choice between the two hospitals. The survival following transplant metric is displayed as a pair of quintile scores corresponding to two distinct groups of transplant patients at the center: those who received optimal donor organs and those who received adequate donor organs."
3320034|NCT02007343||Non-infected patients|"Matched sample of all patients that (1) were admitted to the hospital and (2) did not have a gram-negative infection according to the 4 criteria set out in the other group on the date used for matching. Selected by matching 1:1 to patients with gram-negative infections on (1) hospital, (2) length of hospital stay on the date the index culture for the infected patient was obtained, and (3) age.~Date of cohort entry: date of index culture of matched infected patient"
3320035|NCT02007356|Experimental|allogeneic HSCT|"The present study will evaluate and validate in a single-center, open-label, single arm fashion the safety and feasibility of direct infusions of donor-derived pathogen-specific IFN-γ positive T-cells in recipients of HSCT with post-transplant viral infection according to the previously clinically certified CCS® [3-6]. The Investigator will first generate and apply IFN-γ positive selected T-cells to recipients of HSCT with CMV, EBV or adenovirus as previously published. The Investigator aim is to include 6 patients from the University Hospital of Basel.~With confirmed safety the investigator will in the future perform an efficacy study and extend this treat-ment for other clinically relevant pathogens including human herpesvirus (HHV)-6, HHV-8, polyomaviruses JC and BK and fungi including Aspergillus fumigatus and Candida albicans, to other immunosuppressed patients such as solid organ transplant (SOT) recipients."
3320036|NCT02007395||colonoscopy population|
3320037|NCT02007408|Placebo Comparator|Placebo group|
3320038|NCT02007408|Active Comparator|Paracervical block plus lidocaine spray|Lidocaine injection+Lidocaine spray received PCB with 2 ampoules of lidocaine solution plus 2 pumps (20 mg=2 pumps) of 10% lidocaine spray
3320039|NCT02007408|Active Comparator|paracervical block plus isotonic saline spray|2 ampoules of lidocaine solution (20 mg Lidocaine HCl+0.0125 mg epinephrine/ml) plus isotonic spray
3320040|NCT02007408|Active Comparator|only lidocaine spray|paracervical block with saline solution plus 10% lidocaine spray
3320041|NCT02007421|Other|HIV positive homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
3382503|NCT04806035|Experimental|TG-1801|TG-1801 Single Agent
3382504|NCT04806035|Experimental|TG-1801 + Ublituximab|TG-1801 in combination with ublituximab
3320042|NCT02007421|Other|HIV negative homosexual men|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
3320043|NCT02007447|Active Comparator|OCYTOCINA - SPRAY NASAL|OCYTOCINA - SPRAY NASAL - 24Ui twice per day for 8 weeks
3320044|NCT02007447|Placebo Comparator|Placebo|Placebo - twice per day for 8 weeks
3320045|NCT02007460|Experimental|Exercise leg|
3320046|NCT02007460|No Intervention|Control leg|
3320047|NCT02007473||Patients requiring transfusion with plasma|Recipients, who have received a transfusion with Methylene Blue plasma produced using the THERAFLEX MB-Plasma procedure from MacoPharma.
3320048|NCT02007486||Heart Failure: NYHA functional class I|Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3320049|NCT02007486||Heart Failure: NYHA functional class II|Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3320050|NCT02007486||Heart Failure: NYHA functional class III|Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of <45%.
3320051|NCT02007486||Healthy Control Subjects|Healthy, sedentary, non-smoking, age- and sex-matched control subjects.
3320052|NCT02007499||Cardiac Arrest, Out of hospital|Pre-arrival Cardiopulmonary Resuscitation (CPR) instruction for bystander.
3320053|NCT02007525|Experimental|Yoga intervention|
3320054|NCT02007525|No Intervention|Wait list control|
3320055|NCT02007538||Thin Prep|Samples obtained from this group will be tested with thin prep
3320056|NCT02007538||Control Group|Samples obtained from this group will be tested with conventional procedure.
3320057|NCT02007551|Experimental|Mealtime Intervention|The mealtime intervention group will receive a trained peer volunteer to their home once weekly for 8 weeks to prepare and share a meal with them.
3320058|NCT02007564|Experimental|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
3320059|NCT02007564|No Intervention|Supportive Telephone Contact Control|Patients and caregivers each received three separate, structured emotional support telephone calls with research staff (M duration = 13 minutes; SD = 6.5 minutes) to minimize differential drop-out with the RSV intervention group. Control callers asked questions of participants and then engaged in supportive conversations using empathic listening and reflection. Topics discussed included family, intergenerational ties, and important aspects of the patient's life, but structured reminiscence and the creative and therapeutic nature of legacy activities were not discussed.
3320060|NCT02007590|Experimental|Aerosure 25 Hz|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3320061|NCT02007590|Sham Comparator|Aerosure sham|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3320062|NCT02007590|No Intervention|No device|All subjects receive an active device, sham device (disabled) and no device in a randomised sequence.
3320063|NCT02007603|Experimental|Ampicillin / sulbactam|Patients are randomized to the ampicillin / sulbactam arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
3320064|NCT02007603|Experimental|Amoxicillin / clavulanic acid|Patients are randomized to the amoxicillin / clavulanic acid arm. Pharmacokinetic samples will be taken during multiple hemodialysis sessions.
3320065|NCT02007616|Experimental|Non-action video game training|20 1-hour sessions of non-action video game training
3320066|NCT02007616|No Intervention|Control|Participants in the control group did not receive non-action video game training
3320067|NCT02007629|Experimental|Riociguat|Subjects received riociguat film coated immediate-release (IR) tablet 3 times a day (tid) with or without food at a starting dose of 1.0 milligram (mg) and increased by 0.5 mg increments at 2-weekly intervals to a maximum of 2.5 mg tid, until Week 8 (titration phase). An optimal dose was determined based on systolic blood pressure (SBP) and well-being. Thereafter, riociguat continued at the optimal individual dose until Week 24 (Main phase). Dose reductions or stop of study medication for safety reasons were allowed at any time. Increases or re-increases in 0.5 mg steps (maximum dose 2.5 mg) were possible at the investigator's discretion weighing the benefit with potential risks implied. Subjects were offered participation in EDSP and received riociguat 2.5 mg film coated IR tablet 3 tid with or without food for 18 months or until reimbursement.
3320068|NCT02007642||No study treatment|
3320069|NCT02007655||Eliquis on Nonvalvular Atrial Fibrilliation patients|Patients who are beginning to receive the treatment with Eliquis under the approved indications, dosage, and administration will be included in this study
3320070|NCT02007668|Experimental|Kinesio Taping|Patients will receive an application of Kinesio taping in their lumbar spine.
3320071|NCT02007668|Placebo Comparator|Kinesio Taping Placebo|Patients will receive an application of medical adhesive tape in their lumbar spine.
3320072|NCT02007668|No Intervention|Control|This participants will not receive intervention
3320073|NCT02007681|Experimental|Lifestyle change|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
3320074|NCT02007681|No Intervention|Control|Regular free week with no changes performed
3320075|NCT02007694|Active Comparator|VRET plus Yohimbine|Virtual Reality Exposure Therapy combined with the administration of yohimbine.
3320076|NCT02007694|Active Comparator|VRET plus propranolol|Virtual Reality Exposure Therapy combined with the administration of propranolol
3320077|NCT02007694|Placebo Comparator|VRET plus placebo|Virtual Reality Exposure Therapy combined with the administration of a non-active placebo pill
3320078|NCT02007707|Experimental|Tobacco LHW|Quit Smoking For a Healthy Family - family-based psycho-education intervention using lay health worker (LHW) outreach.
3320079|NCT02007707|Active Comparator|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach.
3320080|NCT02007733|Other|Single Arm|All children enrolled in this study will receive the same interventions, which include collection of regular weights to establish percent weight change with rehydration, clinical assessment of dehydration status, and ultrasound of the IVC and aorta.
3320081|NCT02007746||Subjects with sickle cell disease and iron overload|Patients will have blood tests done to evaluate liver function and general health, then have FibroScan and Ferriscan. A blinded (no access to laboratory parameters or available data) radiologist will interpret the Ferriscan. Liver biopsy will be also obtained (if not done within the previous year). Otherwise, the results of the recent liver biopsy will be collected.
3320082|NCT02007746||control patients with sickle cell disease|Patients 10 years and older with sickle cell disease without history of chronic transfusions (less than 4 transfusions in a lifetime) and without obvious liver disease. Will have liver function blood tests and general health check ups. Then will have FibroScan performed. No liver biopsy will be performed in control patients.
3320083|NCT02007759|Experimental|VitalStim|This group will be assigned to the active VitalStim unit.
3320084|NCT02007759|Sham Comparator|Sham VitalStim|This group will be assigned to the sham VitalStim unit.
3320085|NCT02007772|Active Comparator|BiPAP breathing support|BiPAP is used over a period of 6 weeks (outpatient)
3320086|NCT02007772|Experimental|nHF / TNI breathing support|nasal high-flow is used over a period of 6 weeks (outpatient)
3320087|NCT02007785|Experimental|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
3320088|NCT02007798|Experimental|low-dose group|S group : dexmedetomidine is infused intravenously at a dose of 0.4 ug/kg
3320089|NCT02007798|Experimental|middle-dose group|M group: dexmedetomidine is infused intravenously at a dose of 0.8 ug/kg
3320090|NCT02007798|Experimental|control group|P group: normal saline is infused intravenously
3320091|NCT02007811|Experimental|allogeneic donor derived B-lymphocytes|
3320092|NCT02007824|Experimental|ULSD-12D|ultrasound surgical device made by Ultech.
3320093|NCT02007824|Active Comparator|SONOCA-180|ultrasound surgical device made by Soering
3320094|NCT02007837|Experimental|Combined aspirin and multinutrient supplement|In a single capsule, the following will be combined: 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12
3320095|NCT02007837|Placebo Comparator|Placebo|5mg folic acid, cellulose filler
3320096|NCT02007850|Placebo Comparator|ropivacaine continuous mode|0.2% ropivacaine 8 ml/hr through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
3320097|NCT02007850|Active Comparator|ropivacaine patient controlled mode|0.2% ropivacaine patient controlled mode, basal rate 4 ml/hr, bolus 4 ml, lockout 60 minutes through femoral nerve block catheter for 2 days and they have patient controlled intravenous fentanyl
3320098|NCT02007876|Experimental|Mobility and Activity Training|"Pre-operative: Participants will receive weekly sessions of higher level, task-specific transfer training. All MAT participants will learn the GCS set of exercises chosen to activate core muscles and lessen decline in core strength. These sessions will be supplemented by a home-based walking and physical activity enhancement program of the participants' choosing, focusing on attaining a safe community-based rate of perceived exertion. A pedometer and home exercise log will be used to encourage compliance and advance activities.~Post-operative: Participants will be screened by physical therapy for standard physical therapy with focus on early mobilization. The GCS exercises taught pre-operatively will be reinstituted.~Post-discharge/home: Participants will continue the GCS program and begin to return to elements of their pre-operative home-based MAT program. The program physical therapist will call weekly to review progress."
3320099|NCT02007876|No Intervention|Normal activity|"Pre-operative: Participants will be given the National Institute on Aging guide to home-based exercise but no further instruction or incentive for walking or physical activity enhancement.~Post-operative: Participants will be screened by in-hospital physical therapy for standard physical therapy with focus on early mobilization. Those who do not receive physical therapy will not be given any additional training, as is standard for reimbursed hospital services.~Post-discharge: Program nurse will call weekly to provide health education but no instruction or incentives for mobility or physical activity enhancement."
3320100|NCT02007889|Active Comparator|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
3320101|NCT02007889|No Intervention|Control|control group received just antibiotic regimens without L-carnitine
3320102|NCT02007902||Very preterm babies|Observational model: cohort
3320103|NCT02007915|Experimental|Pamidronate Disodium|
3382510|NCT04795674|Experimental|ADHD EWM|Participants will receive EWM training sessions.
3320104|NCT02007928|Other|rispéridone, aripiprazole, olanzapine...|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
3320105|NCT02007941|Experimental|End Stage Renal Disease(ESRD)|"CKD-501 will be administered to patients who have required dialysis and non-dialysis eGFR(estimate glomerular filtration rate ) is Less than 15.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
3320106|NCT02007941|Active Comparator|normal renal function|"CKD-501 will be administered to normal renal function subject who have eGFR(estimate glomerular filtration rate ) of 90 or more.~First, ESRD Patient and normal renal function Subjects are conducted. After the interim analysis, Determine whether early termination or renal impaired subject's progress"
3320107|NCT02007941|Experimental|Mild renal impairment|CKD-501 will be administered to patients who have eGFR(estimate glomerular filtration rate ) is 60 to 89 that.
3382511|NCT04795674|Placebo Comparator|ADHD Placebo|Participants will receive placebo training sessions.
3382512|NCT04789083|Experimental|Group 1 (Propolis)|Medical therapy and propolis
3382513|NCT04789083|Experimental|Group 2 (Nurse Coaching/ Nursing education)|Medical treatment and nurse coaching
3382514|NCT04789083|Placebo Comparator|Group 3 (Plassebo)|Medical treatment and plassebo will be applied.
3382515|NCT04788901|Experimental|Online therapeutic game|Participants in this group will have access to the evaluation module of the REThink game.
3320108|NCT02007980||Patients with indwelling ureteral stent|Patients with existing indwelling ureteral stent, no additional treatment
3320109|NCT02007993|Active Comparator|Group 1|Treatment with a tongue scraper
3320110|NCT02007993|Experimental|Group 2|PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
3320111|NCT02007993|Experimental|Group 4|Tongue scraper + PDT wavelength = 660 nm Fluency = 320 J/cm2 Power = 100 milliwatt Energy = 9 J Time = 90 s
3320112|NCT02007993|Experimental|Group 3|PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
3320113|NCT02007993|Experimental|Group 5|Tongue scraper + PDT wavelength = 660 nm Fluency = 428 J/cm2 Power = 100 milliwatt Energy = 12 J Time = 120 s
3320114|NCT02008006|Experimental|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine~Etoposide~Cytarabine~Melphalan~HDT will be followed by an Autologous Stem Cell Transplantation"
3320115|NCT02008019|No Intervention|No treatment|No Everolimus treatment before surgery
3320116|NCT02008019|Experimental|Everolimus 2,5 mg/day|Everolimus treatment at 2,5 mg/day for 30 days
3320117|NCT02008019|Experimental|Everolimus 10 mg/day|Everolimus treatment at 10 mg/day for 30 days
3320118|NCT02008032|Experimental|All patients|Stationary Breast Tomosynthesis
3320119|NCT02008045||Neonates at Risk for Brian Injury|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
3320120|NCT02008045||Term Neonates|Magnetic Resonance Imaging Neurodevelopmental Testing - 18 Month
3320121|NCT02008058||Single Arm|Surveys, diaries, clinical assessments of men with metastatic castrate-resistant prostate cancer
3320122|NCT02008071|Experimental|Daily step goal financial incentive|
3320123|NCT02008071|Active Comparator|Control, Standard of Care|
3320124|NCT02008084|Sham Comparator|TRIA-662 single-blind baseline|Baseline, 6 to 8-week, dietary lead-in period
3320125|NCT02008084|Experimental|TRIA-662|Following successful completion of the Baseline randomized to active drug
3320126|NCT02008084|Placebo Comparator|Placebo|Following successful completion of the Baseline randomized to placebo drug
3320127|NCT02008097|Experimental|Liver transplant without a stent|Liver Transplant patients without a stent who are referred for liver ultrasound will have will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System .
3320128|NCT02008097|Experimental|Liver transplant with a stent|Liver transplant patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for liver ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3320129|NCT02008097|Experimental|Renal artery disease without a stent|Patients with hypertension or impaired renal function who are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3320130|NCT02008097|Experimental|Renal artery disease with a stent|Patients who are referred for angioplasty and stenting, or who have had angioplasty and stenting and are referred for renal ultrasound will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3320131|NCT02008097|Experimental|Pregnancy, Normal|Pregnant women referred for an obstetrical ultrasound to evaluate a normal pregnancy; for example, to determine gestation or gestational age will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System.
3382518|NCT04785677|Experimental|Comprehensive Trauma-Based Reentry Program|Participants will complete up to19 session comprehensive trauma-based reentry program.
3382519|NCT04785677|No Intervention|Treatment as usual (TAU)|Participants will be receive all reentry services normally eligible to receive by the state or the community to which they are released.
3320132|NCT02008097|Experimental|Pregnancy, High Risk|Pregnant women referred for an obstetrical ultrasound to evaluate a high risk pregnancy due to a medical condition present before or during pregnancy for either the mother or the baby will have a B-Flow ultrasound exam using the GE LOGIQ E9 Ultrasound System. Examples of risk factors include placenta previa, vaginal bleeding, suspected multiple gestation, suspected uterine abnormality, suspected fetal growth abnormality, advanced maternal age, a prior C-section, prior low birth weight baby, and prior preterm birth.
3320133|NCT02008110|Experimental|CA125 guided strategy|In this group, physician will be encouraged to maximize all treatment measures aimed to keep CA125≤35 U/ml (normal values).
3320134|NCT02008110|Active Comparator|Standard treatment strategy|Therapy is based on established european current guidelines
3320135|NCT02008123|Experimental|Primidone|Participants will receive primidone in addition to their clopidogrel regimen. For the first 3 days of the study, participants will take 125 mg of primidone (one-half tablet). After 3 days of 125 mg, the primidone dose will be increased to 250 mg (1 tablet) taken at bedtime for the next 17-25 days. The participant will then be asked to return and be retested.
3320136|NCT02008136|Experimental|botulinum toxin injected|Because this is an open label study, all subjects will receive one of two botulinum toxins based on their symptoms. Those will cervicalgia will receive Botox (botulinum toxin A) and those with lumbago or low back pain will receive Myobloc (botulinum toxin B)
3320137|NCT02008162||Bronchodilators|"Patients with severe heterogeneous emphysema selected as potential candidtes for lung volume reduction surgery.~Bronchodilators employed for the study include albuterol 200µg and tiotropium bromide 18 µg administered by puffs following a first spirometry and plethysmography performed after a washout period of 48h from all bronchodilators and subsequently repeated within 30 min after bronchodilators administration."
3320138|NCT02008175|Experimental|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/sq.cm with riboflavin and distilled water alternated every 2 minutes was used for the procedure.
3320139|NCT02008201|Experimental|Vitamin D dose 1|Vitamin D dose 1
3320140|NCT02008201|Experimental|Vitamin D dose 2|Vitamin D dose 2
3320141|NCT02008201|Experimental|Vitamin D dose 3|Vitamin D dose 3
3320142|NCT02008201|No Intervention|observational|No dose
3320143|NCT02008214|Experimental|PTX|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral PTX 400 mg each 12 h, oral
3320144|NCT02008214|Placebo Comparator|Placebo|IFN 180 micrograms subcutaneous weekly RBV 400 mg each 12 h, oral Placebo oral daily
3320145|NCT02008240|Experimental|Needle aspiration of hydrosalpinx|Aspiration of hydrosalpingeal fluid under ultrasound guidance
3320146|NCT02008240|Active Comparator|salpingectomy|Surgical removal of hydrosalpinx
3320147|NCT02008253||INTRASTROMAL CORNEAL RING SEGMENT|Forty-two eyes of 26 patients, 14 men and 12 women, with ectasia after refractive surgery were studied in a nonrandomized, retrospective, observational case series.
3320148|NCT02008266||Patients with Rheumatoid Arthritis|
3320149|NCT02008279|Experimental|Group 1A|100 mg CNTO 3157 or placebo in healthy male Japanese participants
3320150|NCT02008279|Experimental|Group 1B|100 mg CNTO 3157 or placebo in healthy male Caucasian participants
3320151|NCT02008279|Experimental|Group 2A|300 mg CNTO 3157 or placebo in healthy male Japanese participants
3320152|NCT02008279|Experimental|Group 2B|300 mg CNTO 3157 or placebo in healthy male Caucasian participants
3320153|NCT02008279|Experimental|Group 3A|600 mg CNTO 3157 or placebo in healthy male Japanese participants
3320154|NCT02008279|Experimental|Group 3B|600 mg CNTO 3157 or placebo in healthy male Caucasian participants
3320155|NCT02008279|Experimental|Group 4|300 mg CNTO 3157 in healthy male Caucasian participants
3320156|NCT02008292|Experimental|physostigmine and amphetamine|There is only one arm to the study. All subjects will receive physostigmine and amphetamine.
3320157|NCT02008305|Experimental|protocol of optimization ALARA|protocol of optimization ALARA protocol of optimization of doses
3320158|NCT02008305|Active Comparator|protocol of opimization Philips|protocol of optimization Philips usual protocol of optimization of doses
3320159|NCT02008331|Experimental|SYNBIOTIC|Patients of this group assumed Probinul-Neutro® po 5g three times a day for 30 days
3320160|NCT02008331|Placebo Comparator|PLACEBO|patients of this group received 5g of placebo 3 times a day for 30 days
3320161|NCT02008344|Active Comparator|favipiravir|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
3320162|NCT02008344|Placebo Comparator|placebo|Day 1: 1800 mg (1st loading dose), 1800 mg (2nd loading dose) Days 2-5: 800 mg BID (3rd to 10th dose)
3320163|NCT02008357|Experimental|Solanezumab|"Solanezumab (400-1600 milligrams) intravenously (IV) every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
3320164|NCT02008357|Placebo Comparator|Placebo|"Placebo IV every 4 weeks for 240 weeks.~Participants who enter the open-label extension will receive solanezumab IV."
3320165|NCT02008383|Experimental|Cabozantinib and Panitumumab|60 mg Cabozantinib PO daily and 6 mg/kg Panitumumab IV every 2 weeks.
3320166|NCT02008383|Experimental|Cabozantinib|60 mg Cabozantinib PO daily.
3320167|NCT02008409|Experimental|EndoLift Liver Retractor|"During surgery, the surgeon will use the new internal liver retractor device. The device will retract the subject's liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
3320168|NCT02008422|Experimental|Oxaliplatin & Endostar injection|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14; Endostar injection, 7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10; 21 d as a cycle.
3320169|NCT02008422|Active Comparator|Oxaliplatin|Oxaliplatin, 130 mg/m2 , iv, 3-4h, d1; Gimeracil and Oteracil Potassium Capsules, 40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
3320170|NCT02008435|Experimental|Enriched GLB|This arm aims to increase the effectiveness of the Group Lifestyle Balance (GLB) program by integrating habit formation techniques, namely if-then plans and their mental practice, into the program.
3320171|NCT02008435|Active Comparator|Standard GLB|This arm is the standard Group Lifestyle Balance (GLB) program, which is the group version of the Diabetes Prevention Program developed by the NIH.
3320172|NCT02008448|Active Comparator|PVI+LL|Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.
3320173|NCT02008448|Active Comparator|PVI+LL+BT injection|"Circumferential PVI was accomplished and then additional ablation lines were created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the LA between the two superior PVs (roof). Finally, patients underwent cavo-tricuspid isthmus ablation in the right atrium.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
3320174|NCT02008461|Active Comparator|RFA|Mapping and radiofrequency ablation are performed by using standard methods.
3320175|NCT02008461|Active Comparator|RFA+BT injection|"Mapping and radiofrequency ablation are performed by using standard methods.~Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster)."
3320176|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 3 months|
3320177|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 3 months|
3320178|NCT02008474|Active Comparator|Online weight loss + Incentives for behavior 12 months|
3320179|NCT02008474|Active Comparator|Online weight loss + Incentives for weight loss 12 months|
3320180|NCT02008487|Other|Wound powder|In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
3320181|NCT02008500|Placebo Comparator|Placebo Mouthwash Group|Group 1 (placebo mouthwash group) contained 51 individuals
3320182|NCT02008500|Active Comparator|Herbal Mouthwash Group|Group 2 ( Herbal mouthwash) contained 52 individual
3320183|NCT02008500|Sham Comparator|Non Herbal Mouthwash Group|Group 3 (Non Herbal mouthwash) contained 50 individuals
3320184|NCT02008513|Active Comparator|Group 1|AFF006 Placebo groups receive 6 AFFITOPE® AD02 vaccinations
3320185|NCT02008513|Active Comparator|Group 2|AFF006 verum groups receive 3 Placebo injections then followed by 3 AFFITOPE® AD02 vaccinations
3320186|NCT02008539|Experimental|treatment arm|
3320188|NCT02008578|Experimental|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|Adults with confirmed Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive 0.25g Flu-IVIG/kg of actual body weight, to a maximum dose of 25g Flu-IVIG.
3320189|NCT02008578|Placebo Comparator|Placebo|Adults with Influenza A or B and evidence of ongoing viral replication (as demonstrated by positive rapid Ag or PCR preferably within 24 hours and no later than 6 days from symptom onset) will receive placebo for Flu-IVIG (a comparable volume of saline).
3320190|NCT02008591|Active Comparator|Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
3320191|NCT02008591|Active Comparator|Combined Spinal Epidural Technique|Bupivacaine 2.5 mg with Fentanyl 25 mcg
3320192|NCT02008591|Active Comparator|Dural Puncture Epidural Technique|Bupivacaine 0.125% with Fentanyl 2 mcg/mL, 15 mL load over 5 min
3320193|NCT02008604||Stroke patients|
3320194|NCT02008604||TIA patients|patients with a transient ischemic attack (control group)
3320195|NCT02008630|Experimental|Animal-assisted activity|30 minutes group session with animal-assisted activity twice a week for 12 weeks in groups of 4-6 participants.
3320196|NCT02008630|Experimental|Animal-assisted therapy|30 minutes group session with animal-assisted therapy twice a week for 12 weeks in groups of 4-6 participants
3320197|NCT02008630|No Intervention|Control|Control group with treatment as usual
3320198|NCT02008643|Experimental|children with food allergy|Chidren aged 8-18 year with food allergy
3320199|NCT02008643|Active Comparator|children with chronic diseases|
3320200|NCT02008643|Active Comparator|witnesses|"Inclusion criteria Age between 8-18 year old Children attending schools of Nice City Signed informed consent of the two parents Signed informed consent of the child Health insurance recipient~Non inclusion criteria Association with another medical or psychiatric chronic disease No signed consent"
3320201|NCT02008669||Multiple Sclerosis cases|"All patients will undergo the following interventions~Gustatory sensitivity test using Taste strips~Blood sampling~Questionnaires"
3320202|NCT02008695|Active Comparator|Youth microfinance only|Youth receive loan
3320203|NCT02008695|Active Comparator|youth and adult micro finance|youth and adult receive loan
3320204|NCT02008695|Active Comparator|adult microfinance|adults receive loan
3320205|NCT02008708|Experimental|Livestock microfinance|Participants randomized to the microfinance intervention receive a female pig loan with ongoing support to manage health and care of the pig by trained agents.
3320206|NCT02008708|Active Comparator|Delayed Control Group|Participants randomized to delayed control group receives pig loan 12 months after the intervention group
3320207|NCT02008721|Active Comparator|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
3320208|NCT02008721|Placebo Comparator|Placebo|Placebo
3320209|NCT02008734|No Intervention|Control|
3320210|NCT02008734|Experimental|PD0332991|Patients will be randomized 3:1 to be treated with PD0332991 125mg/day orally for a total duration of 14 days (or 100 mg/day for a total duration of 21 days depending on results of interim analysis) with last treatment taken the day previous to the surgical procedure.
3382521|NCT04778410|Experimental|Safety Run-in Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab, venetoclax and azacitidine.
3320211|NCT02008747|Active Comparator|Magnesium sulphate|"The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium.~They also received 40mg/kg ideal body weight magnesium sulphate by bolus injection before the operation started, followed by a continuous application of 10mg/kg ideal body weight/hour for 24 hours."
3320212|NCT02008747|No Intervention|No treatment|The patients in this group underwent general anaesthesia with total intravenous anesthesia containing Remifentanyl (0,3 mg/kg ideal body weight/h), Propofol (4 mg/kg ideal body weight/h) and Atracurium. They received no additional medication.
3320213|NCT02008760|Placebo Comparator|vegetable oil with betacarotene|4 capsules vegetable oil with betacarotene
3320214|NCT02008760|Active Comparator|krill and vitamin D3|krill and vitamin D3. (72 mg), four capsules daily
3320215|NCT02008786|Experimental|Rosuvastatin, placebo|rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
3320216|NCT02008786|Experimental|Ramipril, placebo|ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo
3320217|NCT02008799|Experimental|Bone marrow stem cell injection|through special butterfly inject stem cell in testicular artery and inside tubules
3320218|NCT02008812|Experimental|Ad sensor|virus detection
3320219|NCT02008825|Experimental|ViSiGi|Utilization of ViSiGi calibration tube
3320220|NCT02008825|Active Comparator|Usual standard of care|Usual non suction Bougie
3320221|NCT02008838|Active Comparator|Synbiotic|Each synbiotic capsule (Protexin, UK) contained 2 × 108 CFU of seven strains of friendly bacteria (Lactobacillus casei, Lactobacillus rhamnosus, Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, Bifidobacterium longum, Lactobacillus bulgaricus), prebiotics (FOS [Fructooligosaccharide]), and probiotics culture (Magnesium stearate [source: mineral and vegetable], and vegetable capsule [hydroxypropyl methyl cellulose])
3320222|NCT02008838|Placebo Comparator|Placebo|250 mg Maltodexterin
3320223|NCT02008851|Experimental|Implantation of Neo-kidney Augment|Patients receiving one dose (implant) of NKA into the left kidney
3320224|NCT02008864|Placebo Comparator|Placebo|Wheat
3320225|NCT02008864|Active Comparator|Senna|Senna
3320226|NCT02008929|Other|MG4101|Ex vivo expanded allogeneic NK cell
3320227|NCT02008955|Experimental|lysine intake at different levels of intake|all subjects will receive all 7 of the lysine test levels, assigned in random order.
3320228|NCT02008968|Active Comparator|Uric acid ≥7 mg/dL|This arm will receive allopurinol treatment. 50 subjects will be recruited.
3320229|NCT02008968|Active Comparator|Uric acid ≥6 and <7|This arm will not receive allopurinol. 50 subjects will be recruited.
3320230|NCT02008968|Placebo Comparator|Normouricemic|This arm is healthy controls. 30 subjects will be recruited.
3320231|NCT02008981|Active Comparator|Angelica sinensis|Angelica sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
3320232|NCT02008981|Active Comparator|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
3320233|NCT02008981|Active Comparator|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
3320234|NCT02008994|Experimental|Genomic and Proteomic Profiling|"Reverse Phase Protein Microarray will be used to determine how often there are specific proteins that could make your tumor susceptible or resistant to treatment.~Immunohistochemistry will look for specific markers of disease in your DNA.~RNA sequencing will be used to help doctors and scientists understand how your genes are working.~Low pass whole genome and exome sequencing will be used to help identify variants in your DNA."
3320235|NCT02009007|Experimental|dopamine|dopamine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
3320236|NCT02009007|Experimental|phenylephrine|Phenylephrine is administered to maintain systolic blood pressure in the range of 80-120% of baseline during operation
3320237|NCT02009033|Experimental|Ringer's lactate|Fluid therapy during operation
3320238|NCT02009059||Non-invasive temperature in hypothermia|Adult patients undergoing elective thoracic surgery in deep hypothermia
3320239|NCT02009072|Experimental|Sutured limbal conjunctival autograft|Sutured limbal conjunctival autograft was done for patients of group 2 after pterygium excision
3320240|NCT02009072|Experimental|Suturless and glue free Limbal conjuctival autograft|Sutureless and glue free Limbal conjunctival autograft was done for patients of group 1 after pterygium excision
3320241|NCT02009085||Individuals undergoing skin excision.|Skin lesions are under suspicion for skin cancer.
3320242|NCT02009098|Active Comparator|præoperativ antibiotic|iv Cefuroxime 1,5g administered 15-60 minutes before incision
3320243|NCT02009098|Active Comparator|postoperativ antibiotic|iv Cefuroxime 1,5g administered after umbilical cord clamping
3320244|NCT02009111|Experimental|Couple CARE for Parents|Couple CARE for Parents is a couple-focused intervention that addresses interpersonal processes within relationships and promotes healthy relationship and parenting skills among couples with a newborn. Couple CARE for Parents uses a highly disseminable model (i.e., home-visitation and video- and telephone-assisted skills training) developed in Australia.
3320245|NCT02009111|Other|Wait-list control|The control group will be wait-listed until after the 24-month assessment, at which point they are eligible to receive Couple CARE for Parents (tailored for their children's ages).
3320246|NCT02009124|Experimental|Stem cell|autologous bone marrow mononuclear cell transplantation
3320247|NCT02009124|No Intervention|Control|Stem cell therapy is not done for this group of spinal cord injury patients
3320248|NCT02009137|Experimental|EVERA|EVERA- korean ESTES system, apply for 12 weeks
3320249|NCT02009137|Active Comparator|ESTES|ESTES apply for 12 weeks
3320250|NCT02009150||Women at high risk for breast cancer|Proven carriers of deleterious BRCA1 or BRCA2 mutations Or Women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on Tyrer-Cuzick, Gail or Clause risk models.
3320251|NCT02009176|Experimental|Laparoscop Anatomical Hepatectomy|Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound, hepatic segmental staining were used selectively.
3320252|NCT02009176|Active Comparator|Laparoscope Aon-anatomical Hepatectomy|Total laparoscopic aon-anatomical hepatectomy were performed, combined with cholecystectomy when necessary. The intraoperative ultrasound or hepatic segmental staining will be used to ensure the tumour was completely resected.
3320253|NCT02009189|Placebo Comparator|Control|Saline flush
3320254|NCT02009189|Active Comparator|2% Taurolidine lock|Catheter lock with 2% Taurolidine
3320255|NCT02009189|Active Comparator|1.35% Taurolidine with citrate|Catheter lock with 1.35% Taurolidine + citrate
3320256|NCT02009202|Active Comparator|picosulphate|Picosulphate is given orally
3320257|NCT02009202|Active Comparator|polyethylene glycol|Polyethylene glycol is given orally
3320258|NCT02009215|Experimental|Intermittent preventive treatment (IPT)|Dihydroartemisinin-piperaquine (DP)
3320259|NCT02009215|No Intervention|Control|No intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be given.
3320260|NCT02009228|Active Comparator|Single-port laparoscopy|The three-channel single-port: a 1.5-cm horizontal intraumbilical skin incision, a 1.5-cm to 2-cm rectus fasciotomy to open the peritoneal cavity, and the insertion of an Alexis small wound retractor (Applied Medical, Rancho Santa Margarita, CA). The wrist portion of a size 6.5 surgical glove was fixed to the outer ring of the wound retractor. A 12-mm trocar was inserted through a small hole made in one of the fingertips of the glove and advanced into the abdominal cavity. Two additional holes for the accessory channels were made in another fingertip of the glove, and two conventional 5-mm trocars were inserted through the holes.
3320261|NCT02009228|Active Comparator|Conventional laparoscopy|The 12-mm main troca was inserted via subumbilical incision after fully insufflation by verness needle and other 3 working 5-mm trocas were inserted under vision at right middle abdominal, left middle abdominal and suprapubic incisions.
3320262|NCT02009241|Active Comparator|Pulmonary Rehabilitation|The intervention group will perform a 12 week pulmonary rehabilitation program consisting of 30 minutes of treadmill aerobic exercise training and 30 minutes of muscle strength training.
3320263|NCT02009241|No Intervention|Control|
3320264|NCT02009254|Experimental|Mashed Potatoes (as produced)|
3320265|NCT02009254|Experimental|Mashed Potatoes (with no added butter during production)|
3320266|NCT02009254|Experimental|glucose control (50 g)|
3320267|NCT02009267||Patient controlled analgesia|Use of patient controlled analgesia (PCA) for the management of postoperative pain after the Nuss procedure.
3320268|NCT02009267||Continuous thoracic epidural infusion|Continuous thoracic epidural infusions (TE) for the management of postoperative pain after the Nuss procedure.
3320269|NCT02009267||Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) for the management of postoperative pain after the Nuss procedure.
3320270|NCT02009280|Experimental|Propofol group|Propofol group
3320271|NCT02009280|Active Comparator|Sevoflurane group|Sevoflurane group
3320272|NCT02009293||Cough IPF|Male and female with idiopathic pulmonary fibrosis and cough and about to start on Pirfenidone according to regular practice will be asked to wear a cough monitor 24 hours before starting Pirfenidone and twice 24 hours while using Pirfenidone. Patients will also be asked to fill in questionnaires about quality of life and cough.
3320273|NCT02009306|Experimental|PecFent and Epistatus|Medication administered by family / carer for symptoms
3320274|NCT02009306|Active Comparator|Standard subcutaneous medication|Standard subcutaneous medication - diamophine and / or midazolam administered by nursing staff
3320275|NCT02009306|Experimental|Epistatus Alone|"From 28/11/17 following approval from sponsor, ethics committee and MHRA a 3rd observational arm was introduced:~Epistatus administered PRN by family / carer for symptoms"
3320276|NCT02009358|Experimental|Mental health promotion group|
3320277|NCT02009371|Experimental|Light therapy|In this group, participants will be exposed to the LED treatment device (light box) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
3320278|NCT02009371|Placebo Comparator|Control group|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
3320279|NCT02009410|Experimental|Creon|
3320280|NCT02009410|Placebo Comparator|Placebo|
3320281|NCT02009423|Experimental|Masitinib|masitinib-treatment arm
3320282|NCT02009423|Placebo Comparator|Placebo|placebo-treatment arm
3320283|NCT02009436|Experimental|Treatment (azacitidine)|Patients receive azacitidine via nebulizer over 20 minutes QD on days 1-5 and 15-19. Treatment repeats every 28 days for up to 24 weeks in the absence of disease progression or unacceptable toxicity. Patients may continue treatment on a case-by-case basis at the discretion of principal investigator and Institutional Review Board.
3320284|NCT02009449|Experimental|Part A: Dose Escalation Cohort 1|Pegilodecakin (1 ug/kg) - Daily subcutaneous (SC) injections of pegilodecakin for up to 22 months
3320285|NCT02009449|Experimental|Part A: Dose Escalation Cohort 2|Pegilodecakin (2.5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
3320286|NCT02009449|Experimental|Part A: Dose Escalation Cohort 3|Pegilodecakin (5 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
3320287|NCT02009449|Experimental|Part A: Dose Escalation Cohort 4|Pegilodecakin (10 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
3320288|NCT02009449|Experimental|Part A: Dose Escalation Cohort 5|Pegilodecakin (20 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
3320289|NCT02009449|Experimental|Part A: Dose Escalation Cohort 6|Pegilodecakin (40 ug/kg) - Daily subcutaneous injections of pegilodecakin for up to 22 months
3382522|NCT04778410|Experimental|Safety Run-in Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab and MEC.
3382523|NCT04778410|Experimental|Safety Run-in Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab and CC-486.
3382524|NCT04778410|Experimental|Phase 2 Cohort 1 (1L Unfit AML Mag+Ven+Aza)|Participants with newly diagnosed untreated AML who are ineligible for intensive induction chemotherapy will receive magrolimab at the recommended Phase 2 dose (RP2D) determined in the Safety run-in cohort 1, venetoclax and azacitidine.
3382525|NCT04778410|Experimental|Phase 2 Cohort 2 (R/R AML Mag+MEC)|Participants with relapsed or refractory (r/r) AML will receive magrolimab at the RP2D determined in the Safety run-in cohort 2 and MEC.
3320290|NCT02009449|Experimental|Part A: Dose Expansion Cohort 1|at least 15 RCC participants will be dosed with pegilodecakin for up to 22 months
3320291|NCT02009449|Experimental|Part B: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3382526|NCT04778410|Experimental|Phase 2 Cohort 3 (Post-Chemo Maintenance Mag+CC-486)|Participants with newly diagnosed AML who are in complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with minimal residual disease (MRD) positivity following intensive chemotherapy will receive magrolimab at the RP2D determined in the Safety run-in cohort 3 and CC-486.
3382528|NCT04770896|Experimental|Atezolizumab + Lenvatinib or Sorafenib|Participants will receive atezolizumab plus lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3320292|NCT02009449|Experimental|Part B: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3320293|NCT02009449|Experimental|Part B: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3382529|NCT04770896|Active Comparator|Lenvatinib or Sorafenib|Participants will receive lenvatinib or sorafenib. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
3382530|NCT04770324|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
3382531|NCT04768296|Experimental|Berzosertib + Topotecan|In Japan, a Safety Run-in Part will be conducted. In case safety and tolerability is confirmed in the Safety Run-in part, Japanese participants will enroll in the Main Part of the Phase 2. Both in the Safety Run-in and Main Part of the Phase 2, participants will receive berzosertib and topotecan until disease progression or other criteria for study intervention discontinuation are met.
3382532|NCT04767997|Experimental|Experimental group|Participants in this group will be randomized to receive probiotic formulation for the following 12 weeks.
3382533|NCT04767997|Placebo Comparator|Control group|Participants in this group will be randomized to receive placebo for the following 12 weeks.
3382534|NCT04762186|Experimental|Dose escalation|SARS CoV-2 infected participants will receive a single infusion over 15 to 30 minutes
3382535|NCT04760730|Experimental|Group A: 1 intramuscular (IM) injection of AZD1222 on Day 1 followed by rAd26-S on Day 29|Subjects will receive 1 intramuscular (IM) injection of 5 × 10^10 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 29
3382536|NCT04760730|Experimental|Group B: 1 intramuscular (IM) injection of rAd26-S on Day 1 followed by AZD1222 on Day 29|Subjects will receive 1 intramuscular (IM) injection of rAd26-S (1.0±0.5) х 10^11 viral particles (vp) (nominal) on Day 1 followed by AZD1222 5 × 10^10 vp (nominal) on Day 29.
3320294|NCT02009449|Experimental|Part B: Dose Expansion Cohort|"Daily SC injection with pegilodecakin with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.~Day 1~Paclitaxel 200/175 mg/m2 IV, or~Docetaxel 75/65 mg/m2 IV And~Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or~Cisplatin 75mg/m2 IV"
3382537|NCT04759586|Active Comparator|Arm A (DA-EPOCH-R)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive etoposide phosphate, doxorubicin hydrochloride, and vincristine sulfate IV over 96 hours on days 1-4 and cyclophosphamide IV over 30-60 minutes on day 5. Beginning 24-72 hours after completing cyclophosphamide, patients receive filgrastim or pegylated filgrastim SC daily until ANC is >= 500/uL after the expected nadir. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity.
3320295|NCT02009449|Experimental|Part C: Dose Escalation Cohort 1|"Pegilodecakin (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3320296|NCT02009449|Experimental|Part C: Dose Escalation Cohort 2|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3320297|NCT02009449|Experimental|Part C: Dose Escalation Cohort 3|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3320298|NCT02009449|Experimental|Part C: Dose Expansion Cohort 1|"Daily SC injection with pegilodecakin with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;~Day 1~Oxaliplatin 85 mg/m2 IV over 2 hours~Leucovorin 200 mg/m2 IV over 2 hours followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours~Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by~5-FU 400 mg/m2 IV bolus and~5-FU 600 mg/m2/day IV over 22 hours"
3320299|NCT02009449|Experimental|Part D: Dose Escalation Cohort 1|"Pegilodecakin (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).~Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by~• Gemcitabine 1000 mg/m2 IV."
3320300|NCT02009449|Experimental|Part E: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).~• Capecitabine 1000 mg/m2 po BID"
3320301|NCT02009449|Experimental|Part F: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
3320302|NCT02009449|Experimental|Part G: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)~• Pazopanib 800 mg po QD"
3320303|NCT02009449|Experimental|Part H: Dose Escalation Cohort 1|"Pegilodecakin (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3320304|NCT02009449|Experimental|Part I: Dose Escalation Cohort 1|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).~• Nivolumab 3 mg/kg IV over 60 min"
3320305|NCT02009449|Experimental|Part H: Dose Escalation Cohort 2|"Pegilodecakin (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3320306|NCT02009449|Experimental|Part H: Dose Escalation Cohort 3|"Pegilodecakin (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).~• Pembrolizumab 2 mg/kg IV over 30 min"
3320307|NCT02009449|Experimental|Part J: Dose Escalation Cohort 1|Pegilodecakin (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes
3320308|NCT02009462|Experimental|Artefill|Four treatment visits using Artefill dermal filler
3320309|NCT02009475|Active Comparator|Continues aerobic training|Treadmill or exercise bike training with target heart rate of 50-70% of the heart rate reserve (or 50-60% of the peak VO2 reserve). Overall 45 minutes of exercise (including the 5-10 minute warm-up period).
3320310|NCT02009475|Experimental|Interval Exercse Training|Bouts of high intensity interval treadmill or exercise bike training, comprising of 85-95% of the heart rate reserve (or 80-90% of the peak VO2 reserve), for the duration of 4 minutes, separated by periods of low intensity activity until the heart rate reaches 50% of the peak heart rate. This set will be repeated 3 times.
3320311|NCT02009488|Experimental|Canagliflozin (JNJ-28431754)|Each patient will receive canagliflozin 100 mg once daily during the first 4 weeks of the 25 weeks double-blind period, then the dose may be increased to 300 mg once daily, till the end of the period.
3320312|NCT02009488|Placebo Comparator|Placebo|One placebo capsule taken orally (by mouth) once daily for approximately 28 days during the Pre-Treatment Run-In and the Baseline Periods, then during double-blind study for 178 days (approximately 24-25 weeks).
3320313|NCT02009527|Experimental|N-hydroxy-nor-arginine|N-hydroxy-nor-arginine 0.1 mg/ min i.a. for 20 min
3320314|NCT02009527|Placebo Comparator|NaCl|NaCl 0.9%, 6 ml/min i.a. for 20 min
3320315|NCT02009540|Placebo Comparator|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor.
3320316|NCT02009540|Active Comparator|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml).
3320317|NCT02009553||Information sheet, Applied|In this group, all patients will receive the information sheet one month before the procedure
3320318|NCT02009553||Information sheet, not applied|In this group, patients will not receive a pre-procedural information sheet
3320319|NCT02009566|Experimental|Abdominal radiographs with microfabricated tags|
3320320|NCT02009579|Active Comparator|Experimental arm|Nintedanib/vargatef
3320321|NCT02009579|Placebo Comparator|Comparator arm|Placebo
3320322|NCT02009592|Active Comparator|Hepatosteatosis|Rifaximin was given to patients with hepatosteatosis in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
3320323|NCT02009592|Active Comparator|Steatohepatitis|Rifaximin was given to patients with steatohepatitis patients in the doses of 3x2 daily, 200 mg tablets for 4 weeks.
3320324|NCT02009605|Experimental|one arm|Icotinib of routine dose Icotinib: 125mg, oral administration, three times per day.
3320325|NCT02009618|Placebo Comparator|Irritable bowel syndrome patients|placebo tablet was given to another group in same doses for 10 days
3320326|NCT02009618|Experimental|Rifaximin|"Irritable bowel syndrome patients~Rifaximin is given to patients 200 mg tablets, 3x2/daily, for 10 days"
3320327|NCT02009631|Experimental|Sequence Group A|200 mg Veliparib
3320328|NCT02009631|Experimental|Sequence Group B|400 mg Veliparib
3320329|NCT02009631|Placebo Comparator|Sequence Group C|Placebo
3320330|NCT02009644|Experimental|Treovance|Subjects who receive the Treovance stent-graft
3320331|NCT02009670|Experimental|13C inulin|13C inulin combined with an inulin load are administered orally
3320332|NCT02009670|Placebo Comparator|Placebo|A placebo is administered orally
3320333|NCT02009709|Active Comparator|9 mW/cm2|CCL-VARIO UV lamp Riboflavin 0.1% ophthalmic solution
3320334|NCT02009709|Active Comparator|18 mW/cm2|CCL-VARIO at 18 mW/cm2 Riboflavin 0.1% ophthalmic solution
3320335|NCT02009735|Experimental|virosensor|virus detection
3320336|NCT02009748|Active Comparator|Vitamin D supplementation|Colecalciferol 2.800 IU/day
3320337|NCT02009748|Placebo Comparator|Placebo|Vehicle (coconut oil)
3320338|NCT02009761|Experimental|BI 655064 subcutaneous|Escalating single dose as subcutaneous injection
3320339|NCT02009774||Controll group|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITHOUT using the NBI function of the scope.
3320340|NCT02009774||Intervention|Patients from the control group will be examined using a CF-HQ 190 EVIS Exera III Advanced Diagnostic Video Colonoscope. If colon polyps are detected optical diagnosis will be determined WITH THE HELP OF the NBI function of the scope.
3320341|NCT02009787|Experimental|Vitamin D supplementation group|drug: vitamin D3 tablets (Vigantoletten; Merck Pharma, Germany); the frequency: 2000 IU vitamin D3 tablets were taken daily; duration: 6 months.
3320342|NCT02009787|Placebo Comparator|Control group|drug: placebo tablets; the frequency: 2000 IU placebo tablets were taken daily; duration: 6 months.
3320343|NCT02009800|No Intervention|2 dose of quadrivalent HPV vaccine|The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.
3320344|NCT02009800|Experimental|3 doses of quadrivalent HPV vaccine|The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)
3320345|NCT02009826||Healthy controls|Healthy age- and sex-matched controls
3320346|NCT02009826||Schizophrenia patients|Young schizophrenia patients 18-40y
3320347|NCT02009839|Experimental|Meeky Mouse program|"14-week Meeky Mouse program consists of 8 training sessions (psychoeducation and anxiety management) followed by 6 practice sessions (exposure using social skills training)"
3320348|NCT02009839|Placebo Comparator|Computer Games|14 weeks of interactive session with the therapist while playing computer games
3320349|NCT02009852||Oral cancer|"Subjects who suffer from oral cancer.~Subjects must:~Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.~In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.~Before the surgery site staff must:~Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.~Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery."
3320350|NCT02009891||Control|Control couples who will not use predictive model
3320351|NCT02009891||Predictive model|Couples who will use predictive model
3320352|NCT02009904||Phenylketonuria (PKU); Healthy Controls|Children with PKU (5-18y); Age and Gender matched healthy subjects for comparison
3320353|NCT02009943|Experimental|Ferric carboxymaltose (FDA IND pending)|15 mg/kg, up to 750 mg IV x 1 on the day of study enrollment.
3320354|NCT02009943|Active Comparator|Iron sucrose (FDA IND 109,877)|"Iron sucrose 100 mg IV will be dosed daily using goal-direction up to a total of 700 mg over a 7-day period. Specifically, iron sucrose will be dosed daily if:~TSAT < 25%~Serum iron concentration < 150 ug/mL~Serum ferritin concentration < 1,500 ng/mL"
3320355|NCT02009943|No Intervention|Control|No iron supplementation
3320356|NCT02009956|Other|DESyne Novolimus Eluting CSS|Enrollment of up to 50 patients with up to two de novo native coronary artery lesions measuring between 2.5 and 4.0 mm in diameter and </= 34 mm in length receiving the DESyne Novolimus Eluting CSS.
3320357|NCT02009995|Active Comparator|Aerobic Training (AT) only|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
3320358|NCT02009995|Experimental|AT plus Primarily Home-Based Resistance Band Training|"Both of the bands + AT groups will engage in RBT 3 times per week, progressing to 3 sets of 8-12 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
3320359|NCT02010008|Experimental|Motivational Interviewing Intervention|Motivational Interviewing (MI) Intervention includes in -person home visit that elicits behavior change by helping participants explore and resolve ambivalence. A telephone follow-up call also uses MI technique.
3320360|NCT02010008|No Intervention|Comparison|Usual care
3320361|NCT02010034|Other|Compassionate use|This lipid preparation is only being used for compassionate use.
3320362|NCT02010047|Experimental|IHC, FISH and qPCR ALK assays|ALK testing by IHC and FISH will be compared to ALK qPCR testing on NSCLC FFPE tissue.
3320363|NCT02010060|No Intervention|Control|The goal of this group is to maintain their current lifestyle habits during the intervention. participants are asked to make no conscious changes to their physical activity or dietary habits.
3320364|NCT02010060|Experimental|Aerobic Exercise Training|The Aerobic training group will participate in 6 months of aerobic training and asked to make no conscious alterations in their physical activity outside of exercise session, or dietary habits
3320365|NCT02010060|Experimental|Aerobic Exercise+ Physical Activity|The goal of this group is to perform 6 months of aerobic exercise and increase the amount of physical activity outside of their training sessions. They will be asked to make no conscious changes to their dietary habits
3320366|NCT02010073||One Group|This is a prospective observational study, aimed at collecting an adequate dataset on a large cohort of patients admitted to a large number of ICUs.
3320367|NCT02010086|Experimental|Individual Cognitive Behavioral Therapy|
3320368|NCT02010086|Active Comparator|Standard Community Treatment|
3320369|NCT02010099|Experimental|PP110 Gel|PP110 Gel
3320370|NCT02010099|Experimental|PP110 medicated wipes|PP110 Medicated wipes
3320371|NCT02010099|Active Comparator|Preparation-H cream|Preparation-H cream
3320372|NCT02010112|Experimental|Initial Diagnosis Cohort|Subjects with clinical indication of H.pylori infection will undergo breath test compared to routine clinical standard of care- endoscopy
3320373|NCT02010125||Acute ACL injury|"Subjects with acute ACL injury will be recruited and enrolled within 28 days of injury Serum, urine, and synovial fluid will be collected at baseline, 6wks post-injury or post-surgery, 6 months, and 1 year Patients will have a quantitative MRI on both knees 7 days after initial visit, then at 6 months and 1 year.~Patients may or may not opt for ACL reconstruction Patients will have functional testing (One-legged hop tests and Star excursion balance test) at 6 months and 1 year Patients will fill out questionnaires (Knee Osteoarthritis Outcome Survey, Veteran Rand-12, Lysholm, International Knee Documentation Committee, Marx Questionnaire) at baseline, 6 weeks, 6 months, and 1 year"
3320374|NCT02010138|Active Comparator|Small Extent Group (SG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the SG. The small-extent peeling was performed in SG.
3320375|NCT02010138|Active Comparator|Large Extent Group (LG)|Patients who were scheduled for surgery for idiopathic macular hole were randomly assigned to the LG. The large-extent peeling was performed in LG.
3320376|NCT02010164|Experimental|Old-CoQ10|
3320377|NCT02010164|No Intervention|Old|
3320378|NCT02010164|No Intervention|Young|Young less than 33 years old participants
3320379|NCT02010190||Cancer Survivors|Participants will be survivors of a childhood cancer.
3320380|NCT02010190||Control Group|Control participants will consist of age- and gender-matched individuals who are non-first-degree relatives of the survivor group.
3320381|NCT02010229||women at high risk of placenta accreta|Parturient women with placenta praevia and at least one previous caesarean delivery
3320382|NCT02010242|Experimental|GKT137831|GKT137831 100 mg capsules twice a day
3320383|NCT02010242|Placebo Comparator|Placebo|Placebo capsule twice a day
3320384|NCT02010268|Experimental|preterm neonates|Preterm neonates (birth before 33 weeks of gestation)
3320385|NCT02010281|Experimental|rTMS of the motor cortex (Magventure)|experimental : rTMS of the motor cortex : repetitive magnetic stimulation targeting the motor cortex assisted by neuronavigation
3320386|NCT02010281|Placebo Comparator|rTMS placebo (magventure)|sham stimulation of the motor or prefrontal cortex with the placebo face of the device
3320387|NCT02010281|Experimental|rTMS prefrontal cortex (magventure)|Experimental : repetitive transcranial stimulation targeting the prefrontal cortex as indicated by neuronavigation
3320388|NCT02010294||Children hospitalized for invasive GAS infection|Children hospitalized for invasive GAS infection
3320389|NCT02010294||Children with non-invasive infection|Children with non-invasive infection such as pharyngitis, tonsillitis, proctitis or skin infection diagnosed by a positive test for rapid diagnosis of GAS performed at the site of infection with a positive GAS culture
3320390|NCT02010307|Experimental|aggressive periodontitis|25 patients with aggressive periodontitis blood extraction
3320391|NCT02010307|Experimental|chronic periodontitis|25 patients with chronic periodontitis blood extraction
3320392|NCT02010307|Experimental|healthy|25 healthy periodontal patients blood extraction
3320393|NCT02010320|Experimental|Computer dosed|Patients for which the computer model will calculate the individual doses
3320394|NCT02010320|Active Comparator|Control|Patients which will get their tacrolimus doses determined by experience transplant physicians
3320395|NCT02010333|Experimental|Ha44 Gel 0.74% w/w|Open label, one arm
3320396|NCT02010346|Experimental|Early headgear treatment|Headgear treatment is initiated at the age of 7-8 years and continued as long as Class I occlusion is achieved
3320397|NCT02010346|No Intervention|Later headgear treatment|Headgear treatment is initiated in the beginning of the growth spurt.
3320398|NCT02010372|Experimental|Reminder Recall Reports|Training in how to use reminder-recall reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
3320399|NCT02010372|Experimental|Audit-Feedback/Immunization Forecasting Reports|Training in how to use audit-feedback/immunization forecasting reports in the Immunization registry will be given to administrators who will then be asked to regularly run these reports for a period of one year.
3320400|NCT02010372|No Intervention|Control|No intervention will be administered to this group.
3320401|NCT02010385|Active Comparator|Octreotide|One subcutaneous injection - 1 mL
3320402|NCT02010385|Placebo Comparator|Saline|One subcutaneous injection - 1 mL
3320403|NCT02010398|Active Comparator|Cross-Training healthy subjects|A cohort of healthy subjects (N=15) will undergo a phase of intervention consisting of cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
3320404|NCT02010398|Active Comparator|Standard-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a standard-training of the more-impaired limb employing an isokinetic contraction regimen at maximal intensity.
3320405|NCT02010398|Experimental|Cross-Training multiple sclerosis|A cohort of patients with multiple sclerosis (N=15), presenting with a marked asymmetry in limb strength, will undergo a cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
3320406|NCT02010398|No Intervention|Healthy Control|A cohort of healthy subjects (N=15) will undergo baseline assessment and a second evaluation after one month of no-intervention
3320407|NCT02010411|Active Comparator|Prolastin|Prolastin 250 mg nebulized BID, 10 days
3320408|NCT02010424|Experimental|Individual culture|standard IVF protocol: half of the fertilized oocytes of the patient will be cultured individually in drops of 25 µl Cook cleavage medium till day 3 after fertilization and subsequently in drops of 25 µl Cook blastocyst medium till day 5 after fertilization
3320409|NCT02010424|Experimental|WOW|Half of the fertilized oocytes of the patient will be cultured in group in a WOW dish, each in a separate microwell but covered with one drop of 30 µl of Cook cleavage medium till day 3 after fertilization and subsequently all the embryos will be transferred to a new WOW dish (in the exactly the same position) covered with 30 µl of Cook blastocyst medium till day 5 after fertilization
3320410|NCT02010437|Active Comparator|Foam Sclerotherapy Group|"The axial vein will be cannulated under local anaesthesia and ultrasound guidance with the patient reclined in a supine position for GSV or ASV treatment, prone position if SSV or GV treatment.~The foam is then prepared by the Tessari technique by the surgeon. Two 2-ml syringes will be connected via a three way stop-cock tap and a 5 micron filter in series (Braun Medical, Sheffield, UK). The syringes will contain 1 part Sodium Tetradecyl Sulphate 3% and 3 parts air. In practice 0.5ml of 3% STS will be drawn up against 2 ml of air. The foam will be produced by at least 20 passages from syringe to syringe through the filter.~Up to 2ml of foam will be injected into each cannula under ultrasound control to observe venous spasm, followed by gentle massaging of the skin to propagate the foam through the segment of vein treated."
3320411|NCT02010437|Active Comparator|Catheter Directed Foam Sclerotherapy (CDS) Group|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and a guide-wire inserted to facilitate the placement of the catheter system.The appropriate Unifuse® catheter will be selected and deployed through the introducer sheath and advanced to within 2cm of the junction or perforator at the upper limit of incompetence or the top of the incompetent segment in the case of segmental reflux. A 1:3 foam of 3% STD will be produced as described for FS. At this point the patient will be repositioned into a Trendelenburg position (head up)
3320412|NCT02010437|Active Comparator|ClariVein Group (CV) Treatment|The straight segment of axial vein will be cannulated under local anaesthesia at the lowest point of demonstrable reflux and the ClariVein device 4-F micro sheath will be introduced up the vein via a guide wire as per manufacturer's instructions. Concentration of STD will depend on axial vein to be treated; if treating GSV or ASV 1.5% STD liquid will be used, if SSV or GV 1.0% STD liquid will be used. Volume of STD to be prepared for the CV treatment will be calculated using a dosage chart provided by the manufacturer
3320413|NCT02010450|Experimental|Wearable Blanket|subjects randomized to this group will receive a wearable blanket (sleep sack) that contains a safe sleep message.
3320414|NCT02010450|Active Comparator|Control Group|subjects randomized to this group will receive an incentive item (such as a University of Kansas Pediatrics water Bottle) that does not contain the safe sleep message.
3320415|NCT02010463|Other|Exercise Intervention|9-month exercise program involving four exercise education sessions
3320416|NCT02010476||Normal insulin sensitivity|cognitively normal men without insulin resistance
3320417|NCT02010476||Insulin resistance|cognitively normal men with insulin resistance
3320418|NCT02010489|No Intervention|Control|Following randomization, the control group will receive usual preoperative care consisting of two to four multidisciplinary visits over six months. During this time, patients will be provided with exercise counseling through the team kinesiologist. They will complete a behavior modification program called Craving ChangeTM and must achieve usual goals of lifestyle and dietary modification, along with modest weight loss of approximately 5%, in order to be scheduled for surgery. Patients will also complete a liquid diet consisting of 900 calories per day for two weeks prior to their procedure in order to reduce intra-abdominal obesity and facilitate the procedure.
3320419|NCT02010489|Other|12 Week Exercise Program|The intervention group will undergo standard pre-operative care and will also be enrolled in a 12-week exercise program at the Reh-Fit Centre in Winnipeg. The Reh-Fit Centre is a non-profit organization with the mission to enhance the health and wellbeing of its members and the community by providing innovative health and fitness services. The intervention will be offered at no cost to the patient. It will involve regular supervised exercise sessions at the Reh-fit centre three times per week. Most patients will complete the intervention prior to commencing the liquid diet but will otherwise discontinue the program while on the diet two weeks prior to surgery.
3320420|NCT02010502|Active Comparator|Concentrated Beet Root Juice|500ml per day for 6 days
3320421|NCT02010502|Active Comparator|Beet root powder|500ml per day for 6 days
3320422|NCT02010502|Placebo Comparator|Placebo juice|Negligible nitrate
3320423|NCT02010515||Sinus rhythm, first ICD implantation|
3320424|NCT02010528||Type 1 diabetes|Parents or caregivers of children and adolescents with type 1 diabetes
3320425|NCT02010528||Controls|Parents or caregivers of children and adolescents without diabetes
3320426|NCT02010541||insulin pump group|20 children below the age of 7 years who use an insulin pump for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin).
3320427|NCT02010541||RT (real time) -CGMS group|20 children below the age of 7 years who use an insulin pump and RT-CGMS on regular basis for at least 6 months, more than 6 months of duration of type 1 diabetes, complete remission, no associated disease (normal blood pressure for age, only therapy insulin). pump for at least 6 months, and children below the age of 7 years who use RT-CGMS on regular
3320428|NCT02010554|Active Comparator|Brief Education|Patients receive a brief educational packet along with treatment as usual
3320429|NCT02010554|Experimental|MI-CBT Treatment|Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.
3320430|NCT02010580||Osphena|Subjects will be randomized in a ratio of 1:1 to receive either 60 mg of ospemifene (Osphena, Shionogi, Florham, NJ) or placebo tablet.
3320431|NCT02010593|Experimental|Dapivirine Vaginal Ring|Safety study of a vaginal ring containing Dapivirine in a postmenopausal female population
3320432|NCT02010593|Placebo Comparator|Placebo|The placebo VR is a flexible, platinum-catalyzed-cured matrix ring, identical to Dapivirine Ring-004, containing no active-drug
3320433|NCT02010619|Experimental|Cognitive behavior therapy|
3320434|NCT02010619|Active Comparator|Supportive therapy|
3320435|NCT02010658|No Intervention|Memory|
3320436|NCT02010658|Experimental|Cognitive Aid|
3320437|NCT02010671||Women with a prior cesarean section|Survey of women who had a cesarean section with their last pregnancy and no other prior cesarean section deliveries
3320438|NCT02010710|Experimental|Decison support|"Decision-support - CTGs with the decision support software running that will alert clinicians to the presence of abnormalities in the CTG in real time."
3320439|NCT02010710|No Intervention|No Decision Support|"No decision-support - CTGs with no additional interpretation (UK standard care),"
3320440|NCT02010723|Active Comparator|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
3320441|NCT02010723|Experimental|sclerotherapy|foam sclerotherapy with aethoxysclerol foam
3320442|NCT02010736|Experimental|Spastic Hemiparetic Cerebral Palsy|Single treadmill gait training with additional loading
3320443|NCT02010749||Control|Control: Children who had received Standard formula (SF) as infants
3320444|NCT02010749||Experimental|Experimental: Children who had received lower protein formula as infants
3320445|NCT02010762|Active Comparator|Vitamin D|Weekly Vitamin D3 drops 25.000 IU for 6 months following ileocoecal resection
3320446|NCT02010762|Placebo Comparator|Placebo|Weekly placebo drops for 6 months following ileocoecal resection
3320447|NCT02010788||BOTOX®|Patients who receive botulinum toxin Type A (BOTOX®) treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
3320448|NCT02010801|Experimental|IRE for tumor before tumor resection|
3320450|NCT02010827||Patients|Patients
3320451|NCT02010827||healthy controls|healthy controls
3320452|NCT02010840|Experimental|Psychodeucation program|Both couples receive the father inclusive psychoeducation program which consists of a single 3-hour session during pregnancy and two telephone follow up at postpartum.
3320453|NCT02010840|Active Comparator|Mother only|Only the women receives the psychoeducation program.
3320454|NCT02010840|No Intervention|Control group|Receives usual perinatal care services only
3320455|NCT02010853|Experimental|patient|"each patient TGA will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
3320456|NCT02010853|Other|control|"each control will receive an evaluation in resting state IRMf during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
3320457|NCT02010866|Other|Counseling|in-person counseling through RFWP to distressed respondents on the ISP and patients who seek counseling without completing the ISP
3320458|NCT02010892||Watchful Waiting|Patients with aneurysms considered to be at low risk of rupture will remain under surveillance with annual CT / MRI scans and multi-disciplinary team review (as per local practice). These patients' data will contribute to the natural history component of the study.
3320459|NCT02010892||Best Medical Therapy|This refers to lifestyle modification (smoking cessation and dietary management) as well as medical management of hypercholesterolaemia and hypertension for patients who are considered unsuitable for, or who refuse, OSR / ESG.
3320460|NCT02010892||Open Surgery (OSR)|Replacement of the aneurysmal aorta with prosthetic conduit via a sternotomy or thoracotomy with circulatory support.
3320461|NCT02010892||Stenting (ESR)|Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid procedures that comprise a combination of a conventional surgical component and a transluminal repair are to be included in this group.
3320462|NCT02010905|Active Comparator|Losartan 150mg daily|Losartan: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
3320463|NCT02010905|Placebo Comparator|Placebo 150mg daily|Placebo: white film-coated biconvex tablet (50mg) with a diameter of 8mm. One time daily three tablets.
3320464|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate capsule|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
3320465|NCT02010918|Experimental|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
3320466|NCT02010918|Active Comparator|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
3320467|NCT02010931||primary|subjects who are 18 years or older, who have minimal residual disease detected by PCR at a level of 1/10-3 or higher, who are free form allogeneic stem cell transplantation until hematological relapse or until 18 months after minimal residual disease detection (whichever comes first)
3320468|NCT02010944|Experimental|1: FDC-SET-SET|Fixed Dose Combination followed by two periods of the Single Entity Tablets
3320469|NCT02010944|Experimental|2: SET-FDC-FDC|Single Entity Tablets followed by two periods of Fixed Dose Combination
3320470|NCT02010957|Experimental|FDG positron emission tomography and Iodometomidate imaging|Combined FDG PET and Iodometomidate imaging prior adrenal surgery of uncertain adrenal neoplasms
3320471|NCT02010970|Experimental|Group 1 AZD3293-itraconazole|Subjects from Group 1 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 1, itraconazole will be administered orally twice daily starting on Day 5 for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the morning dose of itraconazole. Group 1 subjects will be discharged on Day 14.
3320472|NCT02010970|Experimental|Group 2 AZD3293-diltiazem|Subjects from Group 2 will receive a single dose of AZD3293 as an oral solution on Day 1 . In Group 2, diltiazem will be administered orally once daily starting on Day 5, for 9 consecutive days (Days 5 to 13). On Day 8, a single dose of AZD3293 will be coadministered as an oral solution after the diltiazem dose. Group 2 subjects will be discharged on Day 14.
3320473|NCT02010970|Experimental|Group 3 AZD3293-midazolam|Subjects from Group 3 will receive a single dose of midazolam on Day 1 . AZD3293 will be administered as an oral solution once daily starting on Day 2 for 9 consecutive days (Days 2 to 10) followed by a 7 day wash-out period. On Day 8 and Day 17 a single dose of midazolam will be administered. Group 3 subjects will be discharged on Day 18
3320474|NCT02010983|Experimental|longstanding achalasia|
3320475|NCT02011009|Experimental|BLSE|The main objective of this study is to measure the carriage of antibiotic-resistant bacteria (enterobacteria ESBLs) in HIV seropositive patients looking for potential factors associated with sexual transmission. As a matter of fact, there is currently a worldwide community epidemic outbreak of enteric bacteria resistant to antibiotics for which the modes of transmission are still not fully known. There are many open questions about the possibility of sexual transmission and this study aims to find an answer.
3320476|NCT02011022|Experimental|3g group|The dose of MTX is 3 g/m2
3320477|NCT02011022|Experimental|5g group|The dose of MTX is 5g/m2
3320478|NCT02011048||Giant ventral incisional hernia|Patient with a giant ventral incisional hernia (> 10 cm fascial defect) scheduled to undergo endoscopic components separation.
3320479|NCT02011048||Control group|Patients scheduled to undergo surgery on other indications.
3320480|NCT02011087|Experimental|Diagnostic (bioelectric impedance analysis)|Patients undergo bioelectrical impedance phase angle measurement on day 1 of treatment.
3320481|NCT02011100|Experimental|CARNOSINE|3 months oral carnosine administration in a dose of 2 gram per day, twice a day 1 gram dose (1-0-1)
3320482|NCT02011100|Placebo Comparator|placebo|3 months placebo intake - taken twice a day (1-0-1)
3320483|NCT02011126|Experimental|Treatment (imetelstat sodium)|Patients receive imetelstat sodium IV over 2 hours on days 1 and 8. Treatment repeats every 21 days for up to 36 courses in the absence of disease progression or unacceptable toxicity.
3320484|NCT02011139|Active Comparator|Group A|12 sessions of Cognitive-behavioral group therapy in the first 12 weeks
3320485|NCT02011139|Active Comparator|Group B|12 sessions of Cognitive-behavioral group therapy in the second 12 weeks
3320486|NCT02011165||Tennis ball|Night with tennis ball fastened in the back of the night shirt. A positioning measuring device mounted.
3320487|NCT02011165||No tennis ball|Night without tennis ball fastened in the back of the night shirt. A positioning measure device mounted.
3320488|NCT02011178|Active Comparator|Optimal medical treatment and surgery|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol in combination with RYGB surgery.
3320489|NCT02011178|Other|Optimal medical treatment|In the study 50 obese patients with CKD 3 andT2DM will be treated using the European Association for Study of Diabetes protocol
3320490|NCT02011191|Active Comparator|Biotin|10,000 micrograms biotin daily for 8 weeks
3320491|NCT02011191|Placebo Comparator|Sugar pill|
3320492|NCT02011204||People with ALS|"People diagnosed with early ALS (possible, probable, probable-laboratory supported or definite ALS according to El Escorial criteria)~Intervention: Electrical Impedance Myography (EIM)."
3320493|NCT02011204||Other Neurological Diseases|People with a diagnosis of a disease that mimics ALS
3320494|NCT02011204||Healthy Controls|Healthy Volunteers that do not have ALS or another neurological disease that mimics ALS.
3320495|NCT02011217|Experimental|Rye crisp bread A|
3320496|NCT02011217|Experimental|Rye crisp bread B|
3320497|NCT02011217|Experimental|Wheat crisp bread C|
3320498|NCT02011230|No Intervention|Control|Patients in the control group will not be given any special fluids to take after surgery Patients will use their discretion to drink as needed following surgery
3320499|NCT02011230|Experimental|Hoist|Patients in the Hoist group will be given a 10 day supply of Hoist that they will self administer
3320500|NCT02011243||Professional players, men|This group includes professional, male, handball players meeting study inclusion criteria.
3320501|NCT02011243||Professional players, women|This group includes professional, female, handball players meeting study inclusion criteria.
3320502|NCT02011243||Junior players, men|This group includes junior, male, handball players meeting study inclusion criteria.
3320503|NCT02011243||Junior players, women|This group includes junior, female, handball players meeting study inclusion criteria.
3320504|NCT02011256|Experimental|Implantable loop-recorder|
3320505|NCT02011269|Active Comparator|7500 TSO|7500 active Trichuris suis ova will be provided in a15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
3320506|NCT02011269|Active Comparator|15000 TSO|15000 active Trichuris suis ova will be provided in two 15 mL of aqueous suspension (supplied in 30 mL glass containers) administered orally, once every 2 weeks for 10 weeks
3320507|NCT02011269|Placebo Comparator|Non-active treatment|The TSO placebo drug product is a non-sterile, 15 mL aqueous solution containing phosphate buffer, pH 5 and 0.05% potassium sorbate as antimicrobial preservative. The TSO placebo is supplied in two 30 mL glass containers that is identical to the container/closure described above for the active drug product.
3320508|NCT02011282|Experimental|Electro-Neuro-Muscular Stimulation|Patients will receive daily sessions of electrostimulation with a commercially available device (En-Stimulation 4, Netherlands) in the quadriceps muscle for 10 days
3320509|NCT02011282|No Intervention|Control|Patients in this arm will receive the usual standard treatment
3320510|NCT02011295|Other|Microfracture|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT
3320511|NCT02011295|Other|microfracture + injection of autologous BMAC|Procedure/Surgery: ankle arthroscopy with debridement and microfracture of the OLT plus injection of autologous Bone Marrow Aspirate Concentration
3320512|NCT02011308|Active Comparator|Green Light Laser|
3320513|NCT02011308|Active Comparator|TURP|Transurethral Resection of the Prostate
3320514|NCT02011321|Experimental|clevidipine|Four-hour infusion of low-dose intravenous clevidipine in patients with moderate vasospasm after aneurysmal subarachnoid hemorrhage
3320515|NCT02011334|Experimental|RoActemra/Actemra|
3320516|NCT02011347|Experimental|Ketamine|Patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and Ketamine (bolus dose of Ketamine (0.15 mg.kg-1) followed by an infusion of Ketamine (0.15 mg.kg-1 h-1) until the end of anesthesia)
3320517|NCT02011347|Experimental|Placebo|patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo (NaCl 9/00 (same volume as in the Ketamine group)
3320518|NCT02011360|Other|Low carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein. This will be administered over 72 hour hospital stay.
3320519|NCT02011360|Other|Low Fat diet|Low fat diet: 65%carb; 15%fat; 20% protein. This will be administered over a 72 hour hospital stay.
3320520|NCT02011373|Experimental|IFABOND|
3320521|NCT02011412||Intermountain Risk Score known|
3320522|NCT02011412||Intermountain Risk Score Unknown|
3320523|NCT02011425|Experimental|mandibular advancement appliance|mandibular advancement appliance (SomnoDent by SomnoMed)
3320524|NCT02011425|No Intervention|without mandibular advancement appliance|no therapy
3320525|NCT02011438|Experimental|UTalk Intervention|Active preventative intervention condition.
3382538|NCT04759586|Experimental|Arm B (DA-EPOCH-R, nivolumab)|Patients receive treatment as in Arm A. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity.
3320526|NCT02011438|No Intervention|Control|Education/Support Condition
3320527|NCT02011451|Experimental|95% Pure ECGC capsules 200mg|95% Pure ECGC capsules 200mg three times a day with food for 6 months
3320528|NCT02011451|Placebo Comparator|Sugar pill|Matched placebo capsules
3320529|NCT02011477|Experimental|Neural glide|This technique involves two movements, initial and final. It consists of going from one to the other constantly. The therapist took the subject's head by putting his hands on the suboccipital and front region. In the initial movement, the therapist perform craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject perform dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as perform plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject. The session lasted 7 minutes.
3320530|NCT02011477|Placebo Comparator|Placebo|The model of the ultrasound (ENRAF-NONIUS, P.O. Box 12080, 3004 GB Rotterdam, The Netherlands). The subject was placed in a prone position, with arms along the body and the head in the hole of the examining couch. The therapist applied a non-therapeutic dose of ultrasound for 7 minutes with no break all over the cervical area and trapezius, in circles.
3320531|NCT02011477|Active Comparator|Neural Stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject . In the final position, the therapist made the subject execute a craniocervical flexion while he pushed the subject's hands against the chest, in order to increase thoracic kyphosis. At the same time, the subject had to raise the elevated leg without separating the popliteal zone in the other knee, while maintaining dorsiflexion of the ankle and a maximum knee extension. The session lasted 7 minutes.
3320532|NCT02011503|Experimental|dHACM|Application of multi-layer compression therapy with application of dHACM.
3320533|NCT02011503|Other|Control|Application of multi-layer compression therapy without application of dHACM.
3320534|NCT02011529|Active Comparator|TEAMcare treatment of diabetes|
3320535|NCT02011529|No Intervention|Treatment as usual|Participants randomized to treatment as usual will receive their usual mental health treatment and primary care treatment
3320536|NCT02011568|Other|Moderate hypothermia|Therapeutic hypothermia at 31 degrees celsius
3320537|NCT02011568|Active Comparator|Mild Hypothermia|Therapeutic Hypothermia at 34 degrees Celsius
3320538|NCT02011594|Experimental|Arm A|Nimotuzumab
3320539|NCT02011594|Placebo Comparator|Arm B|Placebo (normal saline)
3320540|NCT02011620|Active Comparator|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
3320541|NCT02011620|No Intervention|Standard care|Standard care - no intervention with nitrates
3320542|NCT02011633|Experimental|HCP1201, Part 1|Participants received a single oral dose of the HCP1201 500/10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3320543|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part1|Participants received a single oral dose of coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg under fasting condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3320544|NCT02011633|Experimental|HCP1201, Part 2|Participants received a single oral dose of the HCP1201 500/10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3320545|NCT02011633|Active Comparator|Metformin and Rosuvastatin, Part 2|Participants received a single oral dose of coadministration of Metformin SR 500mg and Rosuvastatin 10mg under fed condition, on Period 1(for participants randomized to Sequence 1) or on Period 2(for participants randomized to Sequence 2).
3320546|NCT02011646|Experimental|Healthy Weight|intervention four times per week and consist of approximately 10 participants.
3320547|NCT02011646|Active Comparator|Controlled Intervention|Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web.
3320548|NCT02011659|Active Comparator|Ramosetron|
3320549|NCT02011672|Experimental|nutrient-enriched milk|consumption of 250 ml three times per day
3320550|NCT02011672|Placebo Comparator|regular milk|consumption of 250 ml three times per day
3320551|NCT02011685|Active Comparator|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening) for one week out of each month during the 12-month intervention.
3320552|NCT02011685|Experimental|HBPTM + Nurse Case Management (NCM)|Participants will complete the same Home BP Telemonitoring protocol and will also complete 20 counseling phone calls with a nurse case manager during the 12-month intervention.
3320553|NCT02011698|Experimental|absorbable sutures|mesh fixation with absorbable sutures in lichtenstein anterior inguinal herniorrhaphy
3320554|NCT02011698|Active Comparator|non absorbable sutures|mesh fixation with non absorbable sutures in lichtenstein anterior inguinal herniorrhaphy. This is the method to be considered the standard of care thus far.
3320555|NCT02011698|Experimental|fibrin biological glue|mesh fixation with fibrin biological glue in lichtenstein anterior inguinal herniorrhaphy
3320556|NCT02011711||Mirena|Women interested in beginning use of Mirena
3320557|NCT02011711||Depot-medroxyprogesterone acetate|Women interested in beginning use of depot-medroxyprogesterone acetate
3320558|NCT02011711||Oral Contraception|Women interested in beginning use of oral contraception
3320559|NCT02011724|Experimental|Apligraf|
3320560|NCT02011737|Active Comparator|Naftopidil|Naftopidil 75mg once daily
3320561|NCT02011737|Placebo Comparator|Placebo|Placebo once daily
3320562|NCT02011750|Experimental|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
3320563|NCT02011750|Placebo Comparator|Placebo|Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
3320564|NCT02011763|Experimental|Study Group|Toddlers, children and adolescents aged 12 months to 15 years
3320565|NCT02011776||Group 1|using the 0.1% fluorometholone eye drops combined with the 0.1% sodium hyaluronate eye drops
3320566|NCT02011776||Group 2|using the 0.5% cyclosporin A eye drops combined with 0.1% sodium hyaluronate eye drops
3320567|NCT02011789|Experimental|Group1|Group 1 consumes Placebo beverage for 56 days followed by Citrus Limonoid Beverage for 56 days.
3320568|NCT02011789|Active Comparator|Group 2|Group 2 consumes Citrus Limonoid Beverage for 56 days followed by Placebo beverages for 56 days
3320569|NCT02011802|Active Comparator|Algosteril TM|Calcium alginate dressings are made from seaweed. Calcium alginate dressings form a natural gel of the exudates against the healing tissue that keeps it moist and supple, aiding in healing and tissue growth. In addition, this gel material forms a natural barrier to bacteria that may complicate healing with secondary infections of the wound. Alginates are the reference of dressing after sinus pilonidal excision.
3320570|NCT02011802|Experimental|Sorbact TM|DACC (dialkylcarbamoyle chloride) is a main component of the bacterial binding wound dressing: Sorbact. DACC is a hydrophobic fatty acid derivative that can be used to coat dressing materials, resulting in a dressing with highly hydrophobic pathogen binding properties. This is a primary wound interface dressing and is effective when in close contact with the wound bed in a moist environment.
3320571|NCT02011815||Breast cancer|Diagnosed breast cancer patients who are getting chemotherapy for the first time.
3320572|NCT02011828|Experimental|Ergocalciferol, then Placebo|Participants first receive Ergocalciferol 50,000 international units (IU)/week for the first 12 weeks. After a 4 week wash-out period, they then receive matching placebo treatment for 12 weeks.
3320573|NCT02011828|Experimental|Placebo, then Ergocalciferol|Participants first receive placebo treatment (matching ergocalciferol 50,000 IU/week) for the first 12 weeks. After a 4 week wash-out period, they then receive ergocalciferol 50,000 IU/week treatment for 12 weeks.
3320574|NCT02011841|Experimental|Rifaximin group|Rifaximin 1200 mg/day orally for 6 months
3320575|NCT02011841|Active Comparator|Control group|Ciprofloxacin 500 mg/day orally for 6 months
3320576|NCT02011854|Experimental|Acupuncture with rehabilitation|Electric acupuncture,Chinese medicine,Chinese medicine cupping,rehabilitation,To treat five times a week,Total course is eight weeks
3320577|NCT02011854|Other|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
3320578|NCT02011867|Experimental|Cork Electrode|Using Cork Electrode for CSF leak prevention for inner ear malformations.
3320579|NCT02011906|Active Comparator|CAD, OMEGA 3|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains placebo of vitamin E
3320580|NCT02011906|Active Comparator|CAD, omega 3 and vitamin E|patients with CAD who receive 4 gr/day omega 3 in the form of 4 softgels each of them contains 1000 mg omega 3 and a softgel contains 400 IU vitamin E
3320581|NCT02011906|Placebo Comparator|CAD, placebo|patients with CAD who receive 4 softgels/day each of them contains placebo of omega 3 and a softgel/day contains placebo of vitamin E
3320582|NCT02011919|Other|Echopulse|Echopulse HIFU
3320583|NCT02011932||Healthy volunteers|
3320584|NCT02011932||Chronic hepatitis C|
3320585|NCT02011958|Experimental|Liposomal Amphotericin B / Miltefosine|"Liposomal Amphotericin B : 30mg/kg total dose: IV infusion 5mg/kg per day on day 1, 3, 5, 7, 9, 11~Miltefosine: orally taken every day during 28 days~1 x 50 mg capsule per day if patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg"
3320586|NCT02011958|Experimental|Liposomal Amphotericin B|Liposomal Amphotericin B: 40 mg/kg total dose : IV infusion of 5mg/kg per day on day 1 to 5, 10, 17, 24
3320587|NCT02011971|Active Comparator|Low dose|Vinpocetine 10 mg Healthy subjects
3320588|NCT02011971|Active Comparator|Mid-dose 1|Vinpocetine 20mg Healthy subjects
3320589|NCT02011971|Placebo Comparator|Placebo|0 dose of vinpocetine Healthy and Epilepsy subjects
3320590|NCT02011971|Active Comparator|High Dose|Vinpocetine 60 mg single dose Healthy Subjects & 20mg tid Epilepsy Subjects
3320591|NCT02011984||peripheral artery disease|de novo stenotic lesions in superficial femoral artery
3320592|NCT02011997|Experimental|segmentectomy|Patients undergo cVATS (complete Video-assisted Thoracoscopic Surgery) segmentectomy
3320593|NCT02011997|Active Comparator|Lobectomy|Patients undergo cVATS lobectomy
3320594|NCT02012010|Experimental|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
3320595|NCT02012010|Active Comparator|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
3320596|NCT02012023|Experimental|Controllable tube ileostomy|After LAR, the experimental group accepted controllable tube ileostomy.
3320597|NCT02012023|Active Comparator|Loop ileostomy|After LAR, the experimental group accepted loop ileostomy.
3320598|NCT02012036||TUR-B|TUR-B in patients suspected to have non-muscle-invasive bladder cancer (NMIBC).
3320599|NCT02012049|Experimental|Risperdal OD / Risperdal Quicklet|Risperdal OD (investigational drug) + Risperdal Quicklet (control drug)
3320600|NCT02012049|Experimental|Risperdal Quicklet / Risperdal OD|Risperdal Quicklet (control drug) + Risperdal OD (investigational drug)
3320601|NCT02012062|Active Comparator|Arm Cisplatin|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by cisplatin 40 mg/m2/week in concurrent with IMRT
3320602|NCT02012062|Experimental|Arm Nimotuzumab|Neoadjuvant TPF chemotherapy (docetaxel 75 mg/m2, cisplatin 75 mg/m2, 5-FU 2500 mg/m2 every 3 weeks for 3 cycles), followed by weekly nimotuzumab 200mg in concurrent with IMRT
3320603|NCT02012075|Experimental|Extended-Release Carvedilol Sulfate|18-72mg/d,po
3320604|NCT02012075|Active Comparator|Sustained-release Metoprolol Succinate|11.875-190mg/d,po
3320605|NCT02012088|Experimental|RCOMP|"R-COMP Regimen:~Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
3320606|NCT02012088|Active Comparator|RCHOP|"R-CHOP Regimen:~Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles"
3320607|NCT02012101|Experimental|niv plus oxygen therapy|oxygen therapy is given during the whole experimental process, niv is given at peak exercise until the borg scale reaches it's baseline point
3320608|NCT02012101|Active Comparator|oxygen therapy|oxygen therapy is given during the whole experimental process
3320609|NCT02012114|No Intervention|Cysteamine Bitartrate|Single arm study. Subjects receive their current oral form of cysteamine bitartrate treatment : Cystagon® or RP103
3320610|NCT02012127||Acromegalic patients|
3320611|NCT02012140|Experimental|Ticagrelor|As per ACC/AHA and ESC guidelines 180 mg is the recommended LD. The ticagrelor 90 mg BID dose, following the loading dose, has been selected for the clopidogrel naïve patients with stable angina, NSTEMI and STEMI patients undergoing PCI as the maintenance dose for this study since it is the FDA recommended dose.
3320612|NCT02012166|Experimental|MK-0893 40 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320613|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 10 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320614|NCT02012166|Experimental|Placebo→MK-0893 10 mg→MK-0893 40 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320615|NCT02012166|Experimental|MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320616|NCT02012166|Experimental|Placebo→MK-0893 1000 mg→MK-0893 200 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320617|NCT02012166|Experimental|MK-0893 200 mg→placebo→MK-0893 1000 mg|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320618|NCT02012166|Experimental|MK-0893 1000 mg→MK-0893 200 mg→placebo|In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs.
3320619|NCT02012179|Experimental|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
3320620|NCT02012179|No Intervention|Usual Care|General advice to limit dietary sodium as it is provided during routine clinic practice
3320621|NCT02012205|Experimental|wet cupping|patient will receive wet cupping
3320622|NCT02012205|No Intervention|control|not cupping
3320623|NCT02012231|Experimental|Dose Escalation|Cohort 1/Day -7 = 300 mg/day PLX8394; Cohort 1/Day 1 = 900 mg/day PLX8394
3320624|NCT02012244|Experimental|fentanyl-based analgesia|fentanyl intravenous patient-controlled analgesia + additional pethidine
3320625|NCT02012244|Experimental|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol intravenous patient-controlled analgesia + additional ketorolac or propacetamol
3320626|NCT02012257|Experimental|Anterior Site|AMSA nerve block injection
3320627|NCT02012257|Experimental|Common Site|AMSA nerve block injection
3320628|NCT02012257|Experimental|Posterior Site|AMSA nerve block injection
3320629|NCT02012270||Conventional Group|Group of patients in whom after open AAA repair abdominal wall will be closed by conventional technique by the operating surgeons. There will be a great variation in sutures and techniques used
3320630|NCT02012270||PRINCIPLES Group|Group of patients in whom after open AAA repair abdominal wall will be closed by PRINCIPLES technique by the operating surgeons.
3320631|NCT02012296|Active Comparator|Treatment (enzalutamide)|Patients receive enzalutamide PO per standard of care.
3320632|NCT02012296|Experimental|Treatment (enzalutamide, mifepristone)|Patients receive enzalutamide PO and mifepristone PO.
3320633|NCT02012309|Experimental|HIV-seronegative|HIV-seronegative subjects will receive Prevnar (PCV-13) at week 0.
3320634|NCT02012309|Experimental|HIV-infected|HIV-infected subjects will receive Prevnar (PCV-13) at week 0, and Pneumovax (PPSV-23) at week 8 per Advisory Committee on Immunization Practices (ACIP) guidelines.
3320635|NCT02012322|Other|Placebo vs. Q10 100mg vs. Q10 300mg|
3320636|NCT02012322|Other|Placebo vs. Q10 300mg vs. Q10 100mg|
3320637|NCT02012322|Other|Q10 100mg vs. Placebo vs. Q10 300mg|
3320638|NCT02012322|Other|Q10 100mg vs. Q10 300mg vs. Placebo|
3320639|NCT02012322|Other|Q10 300mg vs. Placebo vs. Q10 100mg|
3320640|NCT02012322|Other|Q10 300mg vs. Q10 100mg vs. Placebo|
3320641|NCT02012335|Placebo Comparator|ECT + saline|Brief pulse ECT with saline as placebo in each session
3320642|NCT02012335|Experimental|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
3320643|NCT02012361|Active Comparator|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target Fraction of inspired oxygen concentration (FiO2) of 0.25. During the course of the operation a small muscle biopsy will be collected.
3320644|NCT02012361|Active Comparator|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes prior to the inflation of the surgical tourniquet. During the course of the operation a small muscle biopsy will be collected.
3320645|NCT02012374|Experimental|"Intensive Language Action Therapy (constrained)"|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. Spoken responses are explicitly modeled and encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
3320646|NCT02012374|Experimental|Unconstrained Intensive Language Action Therapy|Following a phase of baseline pre-treatment testing, speech therapy sessions take place 5 days/week for 3 hours per session during two consecutive weeks. All communicative responses are encouraged during therapy. Following the intensive 2-week treatment, participants are trained in using individualized home practice programs on iPads. They practice approximately daily for six months, checking in weekly with an SLP via videoconferencing software and return for probes monthly. Six months post-treatment testing will take place following completion of the home practice phase and again at 12 months post-treatment.
3320647|NCT02012387|Active Comparator|Active|Omalizumab 300 mg Subcutaneous route 300 mg dose (independent from total IgE, weight or high)
3320648|NCT02012387|Placebo Comparator|Placebo|Placebo Saline serum Subcutaneous route 0.6 ml saline serum with same volume as an active treatment
3320649|NCT02012387|Active Comparator|Open labeled|After the double blinded period, all patients from both arms will receive the active drug for 8 more months.
3320650|NCT02012400|Experimental|Intervention group|
3320651|NCT02012400|No Intervention|Control group|
3320652|NCT02012413|Active Comparator|PST group|roughly 20 patients will be treated with PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
3320653|NCT02012413|Placebo Comparator|Control group|roughly 20 patients will be submitted to a placebo PST protocol, outcomes will be Kujala score improvement at 3, 6 and 12 months.
3320654|NCT02012426|Experimental|Intervention Group|Participants enrolled in commercial weight management program
3320655|NCT02012426|Active Comparator|Control group|Participants enrolled in standard care weight management provision
3320656|NCT02012439|Active Comparator|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy
3320657|NCT02012439|Active Comparator|Cognitive therapy|Cognitive Therapy
3320658|NCT02012465|Experimental|Insulin protocol|"For diabetic patients, as part of the initial chemotherapy orders on admission, the following will be calculated by the primary oncologist to determine the amount of neutral protamine Hagedorn (NPH) insulin needed to cover steroid use in prednisone equivalents (all insulin in this study is to be administered subcutaneously):~Use 0.1 (mg of prednisone equivalent - 20)/20 x weight (kg) to estimate total insulin in 24 hours (Total daily dose (TDD))~Total daily NPH dose will be divided equally based on the frequency of steroid administration, and given with each steroid dose.~For nondiabetic participants with hyperglycemia recruited during admission, the inpatient oncology team will consult the endocrine team within 24 hours of eligibility for NPH dosing as above."
3320659|NCT02012478|No Intervention|No intervention|baseline session - with surveys and HbA1C only
3320660|NCT02012478|Experimental|MI-informed SMS intervention|Baseline session with surveys & HbA1C MI baseline session Technology tutorial Intervention x 3 months
3320661|NCT02012504||Western medicine|venlafaxine or escitalopram
3320662|NCT02012504||Chinese medcine|Shuganjieyu capsule
3320663|NCT02012517|Active Comparator|short antibiotic course|Intravenous 2 gram cefazolin every 8 hours for 24 hours beginning at surgery
3320664|NCT02012517|Experimental|Prolonged antobiotic treatment|Intravenous 2 gram cefazolin every 8 hours for 48 hours starting at surgery followed by oral cefalexin 500 mg every 6 hours until removal of drains
3320665|NCT02012530|Active Comparator|HA|Patients in this arm will have hyaluronic acid (HA) injected into their knee along with 3 ml local anaesthetic. The HA injection is in the form of 2 ml aqueous sodium hyaluronate. The exact constituents of the HA change in a proprietary manner. All HA injections used will have the CE marking on them.
3320666|NCT02012530|Active Comparator|PRP|Patients in this arm will have platelet rich plasma (PRP) injected into their knee. The PRP sample will be produced at the time of the injection. 30 ml of blood is drawn fro the patient a few minutes before the injection. Using a CE marked differential centrifugation device, the platelets are isolated. This concentrated sample of platelets is injected into the knee after the skin around the injection site is anaesthetised with local anaesthetic.
3320667|NCT02012543|Experimental|Agar jelly, constipation|Subjects eat a cap of agar jelly (180g) shortly before eating dinner every day for 4 weeks.
3320668|NCT02012556|Experimental|Tesamorelin|
3320669|NCT02012569|Experimental|TT.173|It is applied directly to the bleeding of the donor site
3320670|NCT02012569|Placebo Comparator|placebo|It is applied directly to the bleeding of the donor site
3320671|NCT02012595||Parkinson's patients|Participants with Parkinson's Disease
3320672|NCT02012595||Healthy Controls|Healthy participants
3320673|NCT02012647|Active Comparator|People with Parkinsons Disease|Participants have been diagnosed with Parkinson's Disease, and as recommended by their physicians, have undergone DBS surgery for both sides of the brain. These participants will undergo TMS and motor physiology testing, and results will be compared to participants without Parkinson's Disease.
3320674|NCT02012647|Placebo Comparator|Healthy Controls|These participants do not have Parkinson's Disease, nor have they had DBS surgery, and are a healthy controls. These participants will undergo TMS and motor physiology testing, and results will be compared to participants with Parkinson's Disease.
3320675|NCT02012660||Hyponatremia, seasonality|Summer months = June, July, August Winter months = December, January, February
3320676|NCT02012673|Experimental|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system
3320677|NCT02012712|Experimental|Personal Health Record (PHR)|Subjects were sent an invitation to use an online Personal Health Record (PHR)
3320678|NCT02012712|No Intervention|Usual care|Subjects received usual care (no invitation or access to the study PHR)
3320679|NCT02012725||Arm 1 Mycardial Fibrosis|MRI with Intravenous administration of gadolinium
3320680|NCT02012725||Arm 2 Chronic Kidney Disease|MRI with no gadolinium administration
3320681|NCT02012738|Active Comparator|Assignment to FORNET|17 participants were randomly assigned to FORNET
3320682|NCT02012738|Active Comparator|Assignment to CBT|14 participants were randomly assigned to CBT
3320683|NCT02012738|Other|Waiting List Control Group (camp)|7 participants were randomly assigned to the Waiting List Control Group (camp)
3320684|NCT02012738|Other|Waiting List Control Group (no camp)|36 participants were assigned to the Waiting List Control Group (no camp)
3320685|NCT02012751|Experimental|Nevus doctor program|Use of Nevus doctor program to assess the diagnostic category of pigmented skin lesions
3320686|NCT02012764||Musculoskeletal symptoms - Pre diagnosis|Patients presenting with non-specific musculoskeletal complaints at risk of development of RA.
3320687|NCT02012777|Active Comparator|cohort 1 10mg propranolol|"first study arm will consist of 5 subjects who will be administered a dose of 10mg propanolol and followed 1-4 weeks.~Data safety and monitoring committee has reviewed the data for safety and instructed the study to continue based on the findings."
3320688|NCT02012777|Active Comparator|cohort 2 20mg propranolol|This cohort will involve the administration of 5 subjects with 20mg propanolol. The data safety and monitoring committee will review the data for safety when the 5 subjects are recruited and instruct the study to continue depending on the findings.
3320689|NCT02012777|Active Comparator|cohort 3 40mg propranolol|This cohort will involve the administration of 10 subjects with 40mg propanolol. The data safety and monitoring committee will review the data for safety when the 10 subjects are recruited and instruct the study to continue depending on the findings.
3320690|NCT02012790|Experimental|Diet A|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3320691|NCT02012790|Experimental|Diet B|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3320692|NCT02012790|Active Comparator|Diet C|Whole food diet modifies dietary fatty acids. Foods provided for 16 weeks; study oils provided for 22 weeks.
3320693|NCT02012803|Experimental|Operative treatment|
3320694|NCT02012803|Active Comparator|conservative treatment|
3320695|NCT02012816|Other|Uncircumcised men|The program allows each man coming for circumcision to refer up to 5 uncircumcised men in their social network for VMMC services and receive a monetary reward for each successful referral.
3320696|NCT02012829|No Intervention|control group|GPs from practices in the control group are asked to continue their usual care, as if they were not participating in this trial. They had to send their patients list to the research team to calculate their eligible population. They were also asked to list all the gaiac Fecal occult blood test ( gFOBT) delivered during the six months period of the study.
3320697|NCT02012829|Active Comparator|intervention|GPs communication skills and CRC screening :the intervention was a four hours educational training for GPs of the intervention group focused on communication skills with a patients' centered care approach to improve patients participation at CRC screening
3320698|NCT02012842|Active Comparator|Immediate periodontal treatment|Strict supragingival plaque control and non surgical periodontal treatment immediately after the baseline examination(test group).
3320699|NCT02012842|Other|Delayed periodontal treatment|Strict plaque control and non surgical periodontal treatment 6 months after the baseline examination (control group).
3320700|NCT02012855|Experimental|Exercise only|90 minutes of exercise
3320701|NCT02012855|Experimental|Exercise and high glycemic index meal|90 minutes of exercise followed by a high glycemic index meal matched for calories expended during the exercise
3320702|NCT02012855|Experimental|Exercise and low glycemic index meal|90 minutes of exercise followed by a low glycemic index meal matched for calories expended during the exercise
3320703|NCT02012855|No Intervention|No exercise and no meal|No exercise and no meal
3320704|NCT02012868||bariatric surgery, obstructive sleep apnoea|bariatric surgery
3320705|NCT02012881|Experimental|Physical activity intervention|60 minutes of physical activity on every school day
3320706|NCT02012881|Active Comparator|Control|Usual practice
3448529|NCT04063553|Other|Intervention arm|Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.
3320707|NCT02012894||Obese patients with preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy with preoperative GER at 24 H pH-monitoring (Group A)
3320708|NCT02012894||Obese patients without preoperative GER|Obese patients selected for laparoscopic sleeve gastrectomy without preoperative GER at 24 H pH-monitoring (Group B)
3320709|NCT02012920|Experimental|Single Failure of Abiraterone or Enzalutamide|Seviteronel: given orally once daily in 28 day cycles
3320710|NCT02012920|Experimental|Double Failure of Abiraterone and Enzalutimide|Seviteronel: given orally once daily in 28 day cycles
3320711|NCT02012946|Active Comparator|dobutamine|patient receiving dobutamine
3320712|NCT02012946|Active Comparator|Levosimendan|patient receiving levosimendan
3320713|NCT02012972||NCD Risks|Study subjects with NCD risks or disease at enrollment. Each of these subjects will have a Referral for NCD care
3320714|NCT02012972||No NCD Risks|Study subjects without NCD risks or disease at enrollment.
3320715|NCT02012985|Experimental|Oxabact OC5 capsules|The active study drug consists of Oxalobacter formigenes OC5 in enteric-coated size-4 capsules. The dose (not less than (NLT) 1E+09 colony forming units (CFU)) will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
3320716|NCT02012985|Placebo Comparator|Placebo capsules|The placebo study drug consists of microcrystalline cellulose in enteric-coated size-4 capsules. It has been manufactured to mimic the OC5 capsule. The dose will be administrated orally with breakfast and dinner as one capsule two times per day for 8 to 10 weeks.
3320717|NCT02012998|Experimental|HBVAXPRO Challenge dose|HBVAXPRO 5µg
3320718|NCT02013011|Active Comparator|recruitment maneuver and PEEP|apply recruitment maneuver and positive end expiratory pressure (PEEP) 5 centimeter of water (cmH2O) after induction of anesthesia
3320719|NCT02013011|Active Comparator|PEEP|apply positive end expiratory pressure (PEEP) 5 cmH2O after induction of anesthesia
3320720|NCT02013024|Active Comparator|cryopreservation technique|slow freezing cryopreservation technique
3320721|NCT02013024|Active Comparator|vitrification cryopreservation technique|vitrification cryopreservation technique
3320722|NCT02013076||Oral corticosteroids (OCS)|"All patients receive:~Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting prednisone/prednisolone: they receive dexamethasone (0.3 mg/kg, max. 10 mg)~2 to 3 doses of salbutamol within the first hour of therapy according to severity Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy."
3320723|NCT02013089|Experimental|Erlotinib or Gefitinib|Erlotinib 150 mg tablet or Gefitinib 250 mg tablet by mouth every day
3320724|NCT02013089|Experimental|Everolimus|Everolimus 10 mg orally once daily every day
3320725|NCT02013089|Experimental|Imatinib|Imatinib 400 mg tablet orally per day
3320726|NCT02013089|Experimental|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day
3320727|NCT02013089|Experimental|Vandetanib|Vandetanib 300 mg orally once daily
3320728|NCT02013089|No Intervention|Control|No intervention was performed for patients without any gene alternation or without any available target agents
3320729|NCT02013102|Experimental|Arm Ⅰ|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks.
3320730|NCT02013102|Experimental|Arm Ⅱ|Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
3320731|NCT02013115|No Intervention|Cursurf|The baby with respiratory distress syndrome was given Cursurf through intubation.
3320732|NCT02013115|Experimental|Cursurf and Budesonide|The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation.
3320733|NCT02013128|Experimental|Ublituximab + ibrutinib|Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions Ibrutinib: Fixed oral daily dose
3320734|NCT02013141|Experimental|Telavancin|Telavancin 10 mg/kg IV administered over one hour one time.
3320735|NCT02013154|Experimental|Part A: DKN-01 (Dose Escalation)|Escalating dose of 150 milligrams (mg) up to 300 mg of DKN-01 administered on days 1 and 15 and 80 milligrams per meter squared of body surface area (mg/m2) of paclitaxel administered on days 1,8,15, and 22
3320736|NCT02013154|Experimental|Part B: DKN-01 (Dose Confirmation)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3320737|NCT02013154|Experimental|Part C: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction adenocarcinoma patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3320738|NCT02013154|Experimental|Part D: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to esophageal squamous cell cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3320739|NCT02013154|Experimental|DKN-01 Monotherapy Substudy|Dose of DKN-01 determined in Part A will be administered to esophageal or gastro-esophageal junction cancer patients on Days 1 and 15
3320740|NCT02013154|Experimental|Part E: DKN-01 (Cohort Expansion)|Dose of DKN-01 determined in Part A will be administered to gastric adenocarcinoma with Wnt signaling alteration cancer patients on Days 1 and 15 and 80 mg/m2 of paclitaxel administered on Days 1,8,15,and 22
3320741|NCT02013154|Experimental|Part F DKN-01 (Dose Escalation+Expansion)|Escalating dose on 150mg up to 300 mg of DKN-01 administered to patients with recurrent or metastatic esophageal cancer, gastroesophageal junction cancer or gastric adenocarcinoma with Wnt signaling alterations on days 1 and 15 and 200 mg of pembrolizumab administered on day 1 of a 21 day cycle
3320742|NCT02013193|Experimental|Ranger(TM) Paclitaxel-coated balloon|Index lesion treated with Ranger(TM) Paclitaxel-coated PTA balloon catheter (Ranger DCB)
3320743|NCT02013193|Active Comparator|uncoated PTA balloon|Index lesion treated with an uncoated standard PTA dilatation balloon catheter selected upon investigator´s discretion
3320744|NCT02013219|Experimental|Stage 1: Alectinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycle) of each cycle thereafter along with alectinib at a starting dose of 600 mg PO BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless maximum tolerable dose (MTD) is exceeded. The combination will be given to treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC.
3320745|NCT02013219|Experimental|Stage 1: Erlotinib and Atezolizumab|In Stage 1, starting dose of atezolizumab will be 1200 mg IV q3w administered on Day 8 of Cycle 1 and on Day 1 (21-day cycles) of each cycle thereafter along with erlotinib at a starting dose of 150 mg PO QD, for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter; unless MTD is exceeded. The combination will be given to participants with EGFR TKI treatment-naive, locally advanced or metastatic NSCLC.
3320746|NCT02013219|Experimental|Stage 2: Alectinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or maximum allowed dose (MAD) of the combination treatment established in Stage 1. Treatment-naive participants with ALK-positive, locally advanced or metastatic NSCLC will be included.
3320747|NCT02013219|Experimental|Stage 2: Erlotinib and Atezolizumab|In Stage 2, participants received the RP2D on the basis of the MTD or MAD of the combination treatment established in Stage 1. Previously untreated (or with one prior treatment that was not an EGFR TKI), EGFR mutation positive, locally advanced or metastatic NSCLC participants will be included.
3320748|NCT02013232|Placebo Comparator|placebo|risperidone plus placebo
3320749|NCT02013232|Experimental|aripiprazole 5mg|risperidone treatment plus aripiprazole 5mg/day
3320750|NCT02013232|Experimental|aripiprazole 10mg|risperidone plus aripiprazole 10mg/day
3320751|NCT02013232|Experimental|aripiprazole 20mg|risperidone plus aripiprazole 20mg/day
3320752|NCT02013258|Active Comparator|Intranasal oxytocin|Intranasal oxytocin. 16 IU intranasal oxytocin x 5 days. One month interval between arms of treatment.
3320753|NCT02013258|Placebo Comparator|Placebo|Placebo will be administered via nasal spray - 1 spray in each nostril x5 days.
3320754|NCT02013271||Lutonix DCB|Lutonix Paclitaxel Drug Coated Balloon
3320755|NCT02013297|Experimental|SBRT treatment|According to the site to irradiate and to local constraints, SBRT consist in 1 to 8 fractions of 5 to 18 Gy
3320756|NCT02013310|Experimental|HT-0712 (50mg)|HT-0712 capsules administered once daily.
3320757|NCT02013310|Placebo Comparator|Placebo|Placebo capsules administered once daily.
3320758|NCT02013323|Active Comparator|Septilin Group|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing
3320759|NCT02013323|Placebo Comparator|Placebo Group|Subjects in placebo group received Placebo tablets thrice daily for 7 days after Scaling and root planing
3320760|NCT02013336|Experimental|MM-398 + cyclophosphamide|
3320761|NCT02013349|Other|DESyne Novolimus Eluting CSS|approved device continued access
3320762|NCT02013362|Experimental|Pralatrexate injection|Dietary Supplement: Vitamin B12, Folic Acid
3320763|NCT02013427|No Intervention|Observational|Subjects randomized to this arm will be asked to discontinue their current pain medications for the length of the study. This arm is not blinded, as both study staff and participants will be aware that they are not receiving a study treatment.
3320764|NCT02013427|Active Comparator|Naproxen & Omeprazole|Subjects randomized to this arm will be asked to discontinue their current pain medications and take one 500mg naproxen capsule and one 40mg omeprazole capsule twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
3320765|NCT02013427|Placebo Comparator|Placebo Only|Subjects randomized to this arm will be asked to discontinue their current pain medications and take two placebo capsules twice a day for the length of the study. This arm is double-blind, as neither participants nor study staff will know what medication the participants is receiving (blind to active versus placebo treatment).
3320766|NCT02013453|Active Comparator|Observational|Patients on the Observational arm are currently being treated with a proton pump inhibitor (PPIs) such as Omeprazole. They will receive standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3320767|NCT02013453|Active Comparator|Standard Chemo + Placebo|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive placebo along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3320768|NCT02013453|Experimental|Standard Chemo + Omeprazole|Patients on the Standard Chemo and Placebo arm are not currently being treated with a proton pump inhibitor (PPI). They will be randomized to receive Omeprazole along with standard of care chemotherapy. Standard treatment is the choice of the treating physician and may include Carboplatin in combination with either 5FU, Paclitaxel, or Pemetrexed.
3320769|NCT02013466|Other|Bolus ONS intake|Bolus ONS A Bolus ONS B Bolus ONS C Bolus ONS D ONS = oral nutritional supplement 4-way cross-over design: Determination of the product order is based on a Latin square design. 3 Latin squares (4x4) are used, resulting in 12 unique product orders. Subjects receive a randomisation number corresponding with 1 of the 12 product orders. Study product labels will contain randomisation number and appropriate visit number.
3320770|NCT02013479|Experimental|SelenoPRECISE|SelenoPRECISE
3320771|NCT02013479|Placebo Comparator|Placebo|Placebo
3320772|NCT02013492|Experimental|Treatment (propranolol hydrochloride)|Patients receive propranolol hydrochloride PO BID for 4 months in the absence of disease progression or unacceptable toxicity. Propranolol will be administered on an out-patient basis. Blood for correlative studies (30 ml - green top tube) will be drawn at baseline and at each clinic visit. Tumor tissue for analysis will be obtained via core needle biopsy (or other appropriate modality) pre-study and at approximately the two month time point.
3320773|NCT02013505|No Intervention|Instructions printed on a paper.|There will be no intervention.
3320774|NCT02013505|Experimental|Paper and video instructions|.Instructions printed on paper and a educational video.
3320775|NCT02013518|Experimental|Cognitive behavioural therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
3320776|NCT02013518|Other|Control group|Treatment as usual at the participating memory clinics
3320777|NCT02013557|Experimental|Intervention Group|Women in the intervention group will receive a test text-message reminder at the time of enrollment. They will then receive a text-reminder to schedule their oral glucose tolerance test at 6 weeks postpartum, with further reminders at 3 months and 6 months if they have not completed their testing.
3448530|NCT04063553|Other|Control arm|The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given
3320778|NCT02013557|No Intervention|Control group|This arm will only receive the test text-message reminder at the time of enrollment. Otherwise they will receive usual postpartum care.
3320779|NCT02013570|Active Comparator|Dexmedetomidine|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
3320780|NCT02013570|Placebo Comparator|Normal saline, postoperative pain|Group S peritonsillar 2ml normal saline (1 ml per tonsil) via peritonsillar infiltration.
3320781|NCT02013583||Glucose Transporter Type I Deficiency|No interventions
3320782|NCT02013596|No Intervention|Control|Patients were given no TEAS
3320783|NCT02013596|Experimental|TEAS Pretreatment|Patients were given 30min of TEAS before pneumoperitoneum
3320784|NCT02013596|Experimental|TEAS Treatment|Patients were given 30min of TEAS during pneumoperitoneum
3320785|NCT02013635||Cerebral Venous Thrombosis|patients over 16 years old with acute cerebral venous thrombosis
3320786|NCT02013648|Active Comparator|Standard arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day administered on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day administered by continuous IV infusion on days 1-7.~Patients achieving PR only at the end of cycle 1 will receive a second induction cycle with daunorubicin 50 mg/m2/day (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) administered on days 1-3 and cytarabine 200 mg/m2/day administered by cont. IV infusion daily on days 1-5.~Patients will receive 4 cycles of consolidation therapy. Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 administered intravenously over three hours.~Follow-up period: There is no maintenance therapy in the standard arm. Patients will be closely followed, in particular for molecular disease persistence or molecular relapse."
3320787|NCT02013648|Experimental|Investigational arm|"Patients will receive induction therapy with daunorubicin 60 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 12mg²/day on days 1,3,5) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-7. Patients will receive dasatinib 100 mg QD on days 8-21. Patients achieving PR only at the end of cycle 1 will receive a 2nd induction cycle with daunorubicin 50 mg/m2/day on days 1-3 (when daunorubicin is not available due to supply shortage: Idarubicin 10 mg²/day on days 1 and 3) and cytarabine 200 mg/m2/day by cont. IV infusion on days 1-5. Patients will receive dasatinib 100 mg QD on days 6-21.~Consolidation therapy (4 cycles). Treatment consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, days 1-3 iv over 3 hours. Patients will receive dasatinib 100 mg QD on days 4-21. Maintenance therapy: Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
3320788|NCT02013661||Suture in Periodontal resective surgery|Four types of suture including silk, polypropylene, PGA, and PTFE
3320789|NCT02013700|Experimental|20 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 2 x10^6 (20 million) cells delivered via peripheral intravenous infusion
3320790|NCT02013700|Placebo Comparator|Placebo|Patients will receive a matched placebo delivered via peripheral intravenous infusion
3320791|NCT02013700|Experimental|100 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 100 x10^6 (20 million) cells delivered via peripheral intravenous infusion
3320792|NCT02013700|Experimental|200 million hMSCs|Patients will receive a single administration of Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs): 200 x10^6 (200 million) cells delivered via peripheral intravenous infusion
3320793|NCT02013713||Family Hypercholesterolemia in cardiology|
3320794|NCT02013726|Experimental|MBI Scan & Tomosynthesis Scan|Patients will receive both scans.
3320795|NCT02013739||Patients with chronic heart failure|other
3320796|NCT02013739||Healthy volontiers|other
3320797|NCT02013752|Active Comparator|Perineal device during delivery|"Delivery should be managed by using the perineal protection device when the head was crowning and 5-6 cm of it was visible. One part the tongue was inserted between the head and the posterior vaginal wall and the two wings were held against the perineum and kept in place by the delivery attendant's hand."
3320798|NCT02013752|Other|Standard care|Standard care at delivery: Manual support of the perineum
3320799|NCT02013804|Experimental|Dose arms|Dose Escalation
3320800|NCT02013843|Other|Community-based treatment|"Overweight and obese children are seen on a regular basis by health care professionals in the 8 communities included in the project. The care providers are all trained thoroughly in using the Holbaek-method for treatment of pediatric obesity."
3320801|NCT02013856|Experimental|Low Epicatechin and procyanidin|Low epicatechin and procyanidin doses
3320802|NCT02013856|Experimental|High Epicatechin and procyanidin|High epicatechin and procyanidin doses
3320803|NCT02013856|Experimental|High Procyanidin|High procyanidin only
3320804|NCT02013856|Placebo Comparator|Placebo|No epicatechin and procyanidin
3320805|NCT02013869|Experimental|Flow-I|Wash in of desflurane in an anaesthesia machine without below
3320806|NCT02013869|Active Comparator|Asys|Wash in of desflurane in conventional anaesthesia machine Asys
3320807|NCT02013882||1-1-12 wash-in|wash-in using O2:N2O 1:1 L/min with desflurane 12%
3320808|NCT02013908|Active Comparator|Standard ED management alone|Radiographic and physical examinations to exclude fractures or other serious conditions will be performed for all patients before considering eligibility in the study. After completion of the examination, patients who have pain of at least a level 4, as measured by the Wong-Baker scale (ranges 0 to 10), will receive intravenous or intramuscular injections of non-steroidal anti-inflammatory drugs (NSAIDs) for immediate pain control. All patients will be observed 30 minutes after the administration of the NSAIDs. In patients with primary headaches who respond poorly to the initial NSAID injection, an intravenous injection of opioid analgesics will be provided. After these initial standard ED management interventions, patients who are still suffering from acute pain will be asked to participate in the trial. During the study, rescue medication for immediate pain control will be allowed for patients allocated to both groups.
3320809|NCT02013908|Experimental|Acupuncture plus standard ED management|The patients in this group will receive a single session of individualized acupuncture treatment delivered by a certified Korean Medicine Doctor (KMD) specialized (or in-training) in acupuncture and moxibustion medicine and with at least 3 years of clinical experience. The acupuncture formulas will be composed based on the individual patient's symptoms and at the KMD's discretion. Acupuncture treatments will be provided in line with standard ED management, the same as in the control group.
3320810|NCT02013921||Physical Activity|Patients with a breast cancer and are completing treatment
3320811|NCT02013934|Active Comparator|Probiotics|Dietary supplement
3320813|NCT02013947|Other|Moderate altitude group|2 weeks of exercise at 1900 meters sea level
3320814|NCT02013947|Other|low altitude group|2 weeks of exercise at 400 meters sea level
3320815|NCT02013960|Experimental|Laminaria|cytotec and laminaria
3320816|NCT02013960|Active Comparator|Cytotec|Cytotec only
3320817|NCT02013973|Experimental|AMH-group|The patients randomized to the AMH-group calculation of gonadotropin starting dose will be made from an algorithm including age, BMI, AFC and AMH-analysis.
3320812|NCT02013934|Placebo Comparator|Placebo|Dietary supplement
3320818|NCT02013973|No Intervention|Non-AMH-group|The patients randomized to the non-AMH-group, calculation of gonadotropin starting dose will be made from an algorithm including only age, BMI and AFC
3320819|NCT02013986|Experimental|etomidate & midazolam|a bolus of midazolam(Jiangsu Enhua Pharmaceutical Ltd.) 0.1mg/kg then a bolus of etomidate(Etomidate Fat Emulsion Injection, Jiangsu Enhua Pharmaceutical Ltd.)0.3 mg/kg and intravenously, during induction period, the other steps as usual.
3320820|NCT02013986|Active Comparator|midazolam & propofol|During induction period,use a bolus of midazolam injection 0.1mg/kg(Jiangsu Enhua Pharmaceutical Ltd.) and then a bolus of propofol injection 2mg/kg(Astrazeneca PLC.)intravenously, the other steps are as usual.
3320821|NCT02013999|Experimental|Virtual reality program|mobile device for virtual reality program
3320822|NCT02013999|Active Comparator|Control|standard occupuational therapy
3320823|NCT02014025|Experimental|laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept laparoscopic hepatectomy: tumors are totally resected through laparoscopic.
3320824|NCT02014025|Experimental|open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
3382539|NCT04759586|Active Comparator|Arm C (R-CHOP)|Patients receive prednisone or prednisolone PO QD on days 1-5 and rituximab IV or rituximab and hyaluronidase human SC over 5 minutes on day 1 or 5. Patients also receive cyclophosphamide IV over 30-60 minutes, doxorubicin hydrochloride IV over 1-15 minutes or up to 60 minutes, and vincristine sulfate IV over 1 or up to 60 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity.
3382540|NCT04759586|Experimental|Arm D (R-CHOP, nivolumab)|Patients receive treatment as in Arm C. Patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (5 if the patient had 1 prior cycle of treatment) in the absence of disease progression or unacceptable toxicity.
3382541|NCT04759586|Active Comparator|Arm E (R-CHOP, radiation therapy)|Patients receive treatment as in Arm C. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions.
3382542|NCT04759586|Experimental|Arm F (R-CHOP, nivolumab, radiation therapy)|Patients receive treatment as in Arm D. Within 6-8 weeks after completion of chemotherapy, patients undergo radiation therapy over 25 fractions.
3382544|NCT04753814|Other|Identyfication of prognostic factors in HFrEF|Selected prognostic factors will be analyzed in patients with LVEF ≤40%
3382545|NCT04753814|Other|Identyfication of prognostic factors in HFmrEF|Selected prognostic factors will be analyzed in patients with LVEF 41-49%
3382546|NCT04753814|Other|Identyfication of prognostic factors in HFpEF|Selected prognostic factors will be analyzed in patients with LVEF ≥50%
3382547|NCT04750954|Experimental|Treatment (peposertib, lutetium Lu 177 dotatate)|Patients receive peposertib PO QD or BID on days 1-21 and lutetium Lu 177 dotatate IV over 30 minutes on day 1. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
3382548|NCT04750213||Participants Receiving Humira (Adalimumab)|Participants receiving Adalimumab for Pyoderma Gangrenosum (PG).
3382549|NCT04745754|Experimental|Intervention Condition|The trial will test the efficacy of an embedded primary care provider (PCP) model (experimental condition) in which PCPs are trained in survivorship and then embedded within an oncology practice to care for low-risk, early stage breast and colorectal cancer survivors who will be transitioned at 6-12 months post-treatment for comprehensive survivorship care.
3382550|NCT04745754|No Intervention|Control Condition|Usual care for breast and colorectal cancer survivors (oncology-led model).
3382555|NCT04739059|Experimental|CSL312|Fully human immunoglobulin G subclass 4/lambda recombinant monoclonal antibody administered subcutaneously
3382558|NCT04727359||FIT64b model project|Patients being treated in FIT64b model project at UKT
3382559|NCT04727359||Standard care|Patients being treated in standard care (control hospitals)
3382563|NCT04724291|Other|MAGNET + EGD|Capsule endoscopy followed by traditional endoscopy
3382564|NCT04719663|Experimental|1. Congruent Rationale & Treatment: Biological/Pharmacol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
3382565|NCT04719663|Experimental|2. Incongruent Rationale & Treatment: Psychological/Pharmacol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo pill (Buscopan).
3382566|NCT04719663|Experimental|3. Congruent Rationale & Treatment: Psychological/Psychol.|Participants receive a psychological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
3382567|NCT04719663|Experimental|4. Incongruent Rationale & Treatment: Biological/Psychol.|Participants receive a biological illness explanation and treatment rationale. During treatment they receive a placebo psychological treatment (emotional writing).
3382568|NCT04719663|No Intervention|5. Natural course control|Participants receive no intervention and remain on the psychotherapy waiting list. Participants who are recruited externally and are not on a waiting list, will be offered the option to join the waiting list.
3382571|NCT04712643|Experimental|Arm A: atezolizumab + bevacizumab + TACE|Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.
3382572|NCT04712643|Active Comparator|Arm B: TACE alone|Participants will receive on-demand transarterial chemoembolization.
3382573|NCT04704336|No Intervention|Self-directed without Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and provided standard of care.
3382574|NCT04704336|Experimental|With Practice Facilitation (PF)|Participants will be identified from HIV clinics during routine visits and will receive the task-shifting strategy for HTN control (TASSH) protocol.
3382575|NCT04702425|Experimental|VOB560-MIK665 - Part 1a|Part 1a - Patients with relapsed/refractory non-Hodgkin lymphoma and relapsed/refractory multiple myeloma administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382576|NCT04702425|Experimental|VOB560-MIK665 - Part 1b|Part 1b - Patients with relapsed/refractory acute myeloid leukemia administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382577|NCT04702425|Experimental|VOB560-MIK665 - Part 2a|Part 2a - Patients with relapsed/refractory multiple myeloma with at least 10 patients with 1q gain cytogenetic abnormality and 10 patients with high risk R/R MM as defined in (Sonneveld et al 2016) administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382578|NCT04702425|Experimental|VOB560-MIK665 - Part 2b|Part 2b - Patients with relapsed/refractory non-Hodgkin lymphoma with at least 10 patients with double-hit (DH) lymphoma, based on the overall bad prognosis and limited therapeutic options for patients with DH NHL administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382579|NCT04702425|Experimental|VOB560-MIK665 - Part 2c|Part 2c - Patients with relapsed/refractory acute myeloid leukemia venetoclax refractory or insensitive with at least 6 patients M5 as proposed by French-American-British (FAB) group, based on the observation that venetoclax resistance in AML M5 can be caused by up-regulation of MCL1 administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382580|NCT04702425|Experimental|VOB560-MIK665 - Part 2d|Part 2d - Patients with relapsed/refractory acute myeloid leukemia venetoclax naive patients administered VOB560 and MIK665 as an intravenous (IV) infusion.
3382583|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose A|
3382584|NCT04698603|Experimental|Phase 1 (Part A): GH001 dose B|
3382585|NCT04698603|Experimental|Phase 2 (Part B): GH001 Individualized Dosing Regimen|
3382586|NCT04697628|Experimental|Tisotumab vedotin|Tisotumab vedotin monotherapy
3382587|NCT04697628|Active Comparator|Chemotherapy|Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
3382588|NCT04697173|No Intervention|Standard consent|This group will be consented for invasive procedures using standard Hospital policy. Informed consent will be obtained either in person or via telephone with a witness from the patient or his/her legal guardian for any/all procedures medically indicated at that time, at the discretion of the Attending Physician.
3382589|NCT04697173|Experimental|Bundled consent|"Upon admission, this group will received the document titled Common PICU Procedures Explained and encourage to read the document. They will then, within 24 hours of admission be consented using the Bundle Consent Document for the group of invasive procedures listed and explained in that document."
3382597|NCT04681092|Experimental|AKS-452 s.c.(A)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL) single-dose
3382598|NCT04681092|Experimental|AKS-452 s.c. (B)|Subcutaneous injection of pre-defined dose (22,5 ug, 125 uL), two-dose
3382599|NCT04681092|Experimental|AKS-452 s.c. (C)|Subcutaneous injection of pre-defined dose (45 ug, 205 uL), single-dose
3382600|NCT04681092|Experimental|AKS-452 s.c. (D)|Subcutaneous injection of pre-defined dose (45 ug, 250 uL), two-dose
3382601|NCT04681092|Experimental|AKS-452 s.c. (E)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), single-dose
3382602|NCT04681092|Experimental|AKS-452 s.c. (F)|Subcutaneous injection of pre-defined dose (90 ug, 500 uL), two-dose
3382603|NCT04681092|Experimental|Phase 2, single-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (90 ug, 500 uL)
3382604|NCT04681092|Experimental|Phase 2, two-dose injection|Subcutaneous injection of selected dose based on phase 1 data, dose (45 ug, 500 uL) twice.
3382605|NCT04678284|Experimental|D-Homes intervention|Behavioral treatments by a diabetes wellness coach as defined below.
3382606|NCT04667000|Experimental|lower extremities|the women's lower extremities will be heated with Forced Air Warming
3382607|NCT04667000|Experimental|upper extremities|the women's upper extremities will be heated with Forced Air Warming
3382608|NCT04667000|Experimental|whole body|the women's whole body will be heated with Forced Air Warming
3382609|NCT04667000|No Intervention|control group|there is no intervention for this group
3382610|NCT04663997|Experimental|177 Lu-PSMA-617|
3382611|NCT04663997|Active Comparator|Docetaxel|
3382612|NCT04662086|Experimental|Acebilustat|Participants are randomized to receive either active acebilustat or matching placebo for 28 days.
3382613|NCT04662086|Experimental|Camostat|Participants are randomized to receive either active camostat or matching placebo for 10 days.
3382614|NCT04662073|Experimental|Camostat|Participants are randomized to receive camostat for 10 days.
3382615|NCT04662073|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match camostat for 10 days.
3382616|NCT04662060|Experimental|Acebilustat|Participants are randomized to receive acebilustat for 28 days.
3382617|NCT04662060|Placebo Comparator|Matching Placebo|Participants are randomized to receive placebo to match acebilustat for 28 days.
3382618|NCT04658472|Experimental|SOC-Treated|"Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be administered SAR445088 with superimposing effects of standard of care (SOC) therapy; Weeks 13-24: SAR445088 administration.~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (at approximately week 98)."
3382619|NCT04658472|Experimental|SOC-Refractory|"Part A: Eligible participants will receive SAR445088 for 24 weeks.~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98)."
3382620|NCT04658472|Experimental|SOC-Naive|"Part A: Eligible participants will receive SAR445088 for 24 weeks.~Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46).~Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98)."
3382621|NCT04658173|Experimental|remimazolam-alfentanil combination|Group remimazolam-alfentanil combination received 10 µg/kg alfentanil and 0.3mg/kg remimazolam over 30 seconds, followed by an infusion of remimazolam at 0.2 to 1 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, remimazolam 0.1mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
3382622|NCT04658173|Active Comparator|propofol-alfentanil combination|Group propofol-alfentanil combination received 10 µg/kg alfentanil and 1.5 to 2mg/kg propofol over 30 seconds followed by an infusion of propofol at 2 to 6 mg/kg/hr and alfentanil at 0 to 1ug/kg/min. In case of the sudden patient movement, and difficulty in maneuvering the endoscope, propofol 0.5 mg/kg was used in the form of bolus, as rescue drugs, and alfentanil 5ug/kg when additional analgesia is needed
3382623|NCT04657991|Experimental|Triplet Arm|Encorafenib and Binimetinib in combination with Pembrolizumab
3382624|NCT04657991|Active Comparator|Control Arm|Pembrolizumab
3382626|NCT04656275|Experimental|BI 1323495 treatment group (part 1)|Part 1
3382627|NCT04656275|Experimental|BI 1323495 treatment group (part 2)|Part 2
3382628|NCT04656275|Placebo Comparator|Placebo group|Placebo
3382629|NCT04652895||Moderate-to-severe traumatic brain injury inpatients|Moderate-to-severe traumatic brain injury inpatients
3382630|NCT04651153|Experimental|UCB7853|Part 1: Single intravenous infusion of UCB7853 Part 2: Multiple intravenous infusions of UCB7853 at pre-specified time-points
3382631|NCT04651153|Placebo Comparator|Placebo|Part 1: Single intravenous infusion of Placebo Part 2: Multiple intravenous infusions of Placebo at pre-specified time-points
3382635|NCT04644744|Experimental|Hypothermic oxygenated perfusion (HOPE)|Application of end-ischemic Hypothermic machine perfusion (HOPE) for a minimum of 2 hours (until hepatectomy)
3382636|NCT04644744|Experimental|Normothermic machine perfusion (NMP)|Application of end-ischemic normothermic machine perfusion (NMP) for a minimum of 4 hours (up to 24 hours)
3382637|NCT04644744|Active Comparator|Conventional cold storage (CCS)|Conventional cold storage
3382640|NCT04639219|Experimental|T-DXd|T-DXd monotherapy
3382644|NCT04627285|Experimental|Lacosamide|Subjects in this arm will receive various single doses of lacosamide
3448531|NCT04063514|Experimental|Focused Ultrasound|The ultrasound treatment will last either 1 hour or 20 minutes total time for the DWL device or Brainsonix Focused Ultrasound Device, respectively.
3448532|NCT04063098|Other|All participants|Participants scheduled for endoscopic sleeve gastroplasty
3448533|NCT04063137|Active Comparator|Anthocyanin fortified bread|White bread is fortified with a 25% (w/w) black rice anthocyanin extract. Extract fortification is 4% w/w of bread flour.
3448534|NCT04063137|Placebo Comparator|White bread|
3448535|NCT04063228|Active Comparator|Standard of care|
3448536|NCT04063228|Active Comparator|Simple Skill Group|
3448537|NCT04063150|Active Comparator|IPV at 14 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 14 weeks and 9 months of age.
3448538|NCT04063150|Active Comparator|IPV at 6 weeks + 9 months|Participants in this arm will receive full doses (0.5 mL) of IPV at 6 weeks and 9 months of age.
3448539|NCT04063150|Active Comparator|fIPV ID at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
3448540|NCT04063150|Active Comparator|fIPV ID at 14 weeks + 9 months|Participants in this arm will receive intradermal fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
3448541|NCT04063150|Active Comparator|fIPV IM at 6 weeks + 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 6 weeks, 14 weeks, and 9 months of age.
3448542|NCT04063150|Active Comparator|fIPV 0.1mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.1 mL) of IPV at 14 weeks and 9 months of age.
3448543|NCT04063150|Active Comparator|fIPV 0.2mL IM at 14 weeks + 9 months|Participants in this arm will receive intramuscular fractional doses (0.2 mL) of IPV at 14 weeks and 9 months of age.
3448544|NCT04063644|Experimental|Vis Glyc Neo|"Vis glyc eye drops is administered.~Eye drops based on N-Acetylcoarnosine, Vaccinium myrtillus and Chondroitin sulfate"
3448545|NCT04063644|Active Comparator|physiological saline solution|Physiological saline solution ALVITA is administered.
3448546|NCT04062968|Experimental|Video education|"Women randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos .7 They will then complete the study related surveys at their initial obstetric visit."
3448547|NCT04062968|No Intervention|Usual care|Women randomized to the control group will receive routine prenatal care with no additional study intervention other than completion of the study related surveys at baseline (initial prenatal testing).
3448548|NCT04063202||Non-cases|Secondary school students (seventh to tenth years of education) without probable depression at baseline interview.
3448549|NCT04062929||Intervention|The investigators included 32 patients who participated to a monocentric 4-day program for secondary prevention in cardiovascular disease, between January 2017 and October 2018. Participation to the program was on a voluntary basis and individuals were referred by their own physician, cardiac rehabilitation center or spontaneously. Eligibility criteria included age 18 years and older, stable coronary artery disease with appropriate medical certificate of fitness and no current medical conditions affecting sports participation. Patients unable to give written constent, with impaired cognitive functions, chronic motor deficiency or severe medical disorder (other than heart disease) significantly affecting functional abilities and individuals with insufficient information about medical history of documented coronary disease were excluded.
3448550|NCT04063189|Experimental|First Relapsed Multiple Myeloma|
3448551|NCT04063072|No Intervention|Usual care|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to current hospital clinical practice.
3448552|NCT04063072|Experimental|ERAS protocol|Perioperative care for hysterectomy of benign or malignant tumors of the uterus is managed according to ERAS protocol.
3382655|NCT04625270|Experimental|Part A|To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the Expansion Phase (Part B)
3382656|NCT04625270|Experimental|Part B|To determine the efficacy of the optimal regimen identified from Part A
3382657|NCT04624243|Experimental|MK-8189 8 mg (Acute) - MK-8189 8 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 8 mg once daily (QD) in the acute treatment period from Week 1-6 followed by MK-8189 8 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
3382658|NCT04624243|Experimental|MK-8189 16 mg (Acute) - MK-8189 16 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 16 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 16 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
3382659|NCT04624243|Experimental|MK-8189 24 mg (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189 24 mg QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
3382660|NCT04624243|Active Comparator|Risperidone 6 mg (Acute) - Risperidone 6 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive risperidone 6 mg QD in the acute treatment period from Week 1-6 followed by risperidone 6 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive MK-8189-matching placebo QD from Week 1-12.
3382661|NCT04624243|Experimental|Placebo to MK-8189 (Acute) - MK-8189 24 mg (Extension)|Participants will be treated for a total of 12 weeks. Participants will receive MK-8189-matching placebo QD in the acute treatment period from Week 1-6 followed by MK-8189 24 mg QD in the extension treatment period from Week 7-12 and participants will simultaneously receive risperidone-matching placebo QD from Week 1-12.
3382662|NCT04617275|Experimental|Arm 1-PF-06882961 starting dose of 5 milligram (mg) BID titrated to 120 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 120 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
3382663|NCT04617275|Experimental|Arm 2-PF-06882961 starting dose of 10 mg BID titrated to 100 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 120 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID
3382664|NCT04617275|Experimental|Arm 3-PF-06882961 starting dose of 5 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 5 mg BID to reach the target dose of 80 mg BID. Titration steps include: 5 mg BID, 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
3382665|NCT04617275|Experimental|Arm 4-PF-06882961 starting dose of 10 mg BID titrated to 80 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 80 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID and 80 mg BID
3382666|NCT04617275|Placebo Comparator|Arm 5 - Placebo in subjects with T2DM and Obesity|Matching Placebo tablets taken twice a day (BID)
3382667|NCT04617275|Experimental|Arm 6-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with T2DM|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
3382668|NCT04617275|Experimental|Arm 7-PF-06882961 starting dose of 10 mg BID titrated to 200 mg in participants with Obesity|The dose will be titrated over 12 weeks, starting with a dose of 10 mg BID to reach the target dose of 200 mg BID. Titration steps include: 10 mg BID, 20 mg BID, 40 mg BID, 60 mg BID, 80 mg BID, 100 mg BID and 120 mg BID,140 mg BID, 160 mg BID, 180 MG BID, 200 mg BID
3382669|NCT04612751|Experimental|Datopotamab deruxtecan (Dato-DXd)|Dose Escalation and Dose Expansion: Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab with and without carboplatin in participants with advanced or metastatic NSCLC.
3382671|NCT04607850|Experimental|Lead-in Group A ChAdOx1-HPV low dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^7 pfu)
3382672|NCT04607850|Experimental|Lead-in Group B ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
3382673|NCT04607850|Experimental|Lead-in Group C ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10) vp and MVA-HPV (1 x 10^8 pfu)
3382674|NCT04607850|Experimental|Group 1 ChAdOx1-HPV mid dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^7 pfu)
3382675|NCT04607850|Experimental|Group 2 ChAdOx1-HPV high dose and MVA-HPV low dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^7 pfu)
3382676|NCT04607850|Experimental|Group 3 ChAdOx1-HPV low dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^8 vp) and MVA-HPV (1 x 10^8 pfu)
3382677|NCT04607850|Experimental|Group 4 ChAdOx1-HPV mid dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^9 vp) and MVA-HPV (1 x 10^8 pfu)
3382678|NCT04607850|Experimental|Group 5 ChAdOx1-HPV high dose and MVA-HPV high dose|Prime-boost vaccine doses: ChAdOx1-HPV (2 x 10^10 vp) and MVA-HPV (1 x 10^8 pfu)
3382679|NCT04607850|Placebo Comparator|Group 6 Placebo Saline|Sodium Chloride (0.9%)
3382680|NCT04606771|Experimental|Arm A|"Savolitinib 300 mg oral QD~Osimertinib 80 mg oral QD"
3382681|NCT04606771|Experimental|Arm B|"Savolitinib 300 mg oral QD~Placebo to Osimertinib 80mg oral QD"
3382686|NCT04598009|Experimental|Treatment (binimetinib, imatinib)|Patients receive binimetinib PO BID on days 1-28 and imatinib PO QD on days 1-28. Cycles repeat every 28 days
3382690|NCT04591015|Experimental|DD-CA|In the DD-CA arm, participants will be offered a proven digital texting platform in their language of preference (Spanish/English) as part of the diabetes transitions discharge program with added COVID support messages.
3382691|NCT04591015|Active Comparator|Usual Care (UC)|UC participants will not receive the added COVID support messages, both arms will have a referral placed to the Diabetes Transitions Service (DTS) as part of usual care at the time of discharge.
3382692|NCT04588480|Experimental|BNT162b2|BNT162b2 (intramuscular injection)
3382693|NCT04588480|Placebo Comparator|Placebo|Placebo (intramuscular injection)
3382694|NCT04588428|Experimental|Part 1: INO-4700 Group A|Participants will receive one ID injection of 0.6 milligram (mg) of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
3382695|NCT04588428|Experimental|Part 1: INO-4700 Group B|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
3382696|NCT04588428|Experimental|Part 1: INO-4700 Group C|Participants will receive one ID injection of 1.0 mg of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
3382697|NCT04588428|Experimental|Part 1: INO-4700 Group D|Participants will receive two ID injections (in an acceptable location on two different limbs) of 0.5 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
3382698|NCT04588428|Experimental|Part 1: INO-4700 Group E|Participants will receive two ID injections (in an acceptable location on two different limbs) of 1.0 mg each of INO-4700 followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
3382699|NCT04588428|Placebo Comparator|Part 1: Placebo Group F|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
3382700|NCT04588428|Placebo Comparator|Part 1: Placebo Group G|Participants will receive one ID injection of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
3382701|NCT04588428|Placebo Comparator|Part 1: Placebo Group H|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 8.
3382702|NCT04588428|Placebo Comparator|Part 1: Placebo Group I|Participants will receive two ID injections (in an acceptable location on two different limbs) of placebo followed by EP using the CELLECTRA™ 2000 device on Day 0 and Week 4.
3382703|NCT04588428|Experimental|Part 2: Parts 2A and 2B|Participants will receive ID injection of INO-4700 based on optimal dose and regimen selection in Part 1 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4 or Week 8 and a booster dose at Week 48 (only for Part 2B participants receiving a third dose).
3382704|NCT04587687|Experimental|Treatment (brentuximab vedotin, bendamustine)|Patients receive brentuximab vedotin IV over 30 minutes on day 1 and bendamustine IV over 60 minutes on days 1 and 2. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who respond to combination treatment and do not experience excessive toxicity may continue to receive brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
3382711|NCT04580940||Subjects with complex pancreaticobiliary disease|All subjects will undergo the percutaneous transhepatic cholangiopancreatoscopy with the SpyGlass Discover System.
3382712|NCT04579380|Experimental|Tucatinib + Trastuzumab (+ Fulvestrant)|Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
3382713|NCT04579250|Experimental|Group 1|20 mcg IM at Day 0
3382714|NCT04579250|Experimental|Group 2A|60 mcg IM at Day 0 and Week 16
3382715|NCT04579250|Experimental|Group 2B|60 mcg IM at Day 0 and Week 16
3382716|NCT04578600|Experimental|Treatment (lenalidomide, oral azacitidine, obinutuzumab)|Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
3382717|NCT04575870||Treatment Group 1: 90 min waiting period|Participants undergo their planned tracheobronchoscopy + 90 minute waiting period prior to modified functional endoscopic swallowing exam
3382718|NCT04575870||Treatment Group 2: 66 min waiting period|Participants undergo their planned tracheobronchoscopy + 66 minute waiting period prior to modified functional endoscopic swallowing exam
3382719|NCT04575870||Treatment Group 3: 46 min waiting period|Participants undergo their planned tracheobronchoscopy + 46 minute waiting period prior to modified functional endoscopic swallowing exam
3382720|NCT04575870||Treatment Group 4: 28 min waiting period|Participants undergo their planned tracheobronchoscopy + 28 minute waiting period prior to modified functional endoscopic swallowing exam
3382721|NCT04575870||Treatment Group 5: 13 min waiting period|Participants undergo their planned tracheobronchoscopy + 13 minute waiting period prior to modified functional endoscopic swallowing exam
3382724|NCT04570267|Experimental|CSL324 (Low dose)|One low dose of CSL324 administered subcutaneously on Day 1
3382725|NCT04570267|Experimental|CSL324 (High dose)|One high dose of CSL324 administered subcutaneously on Day 1
3382726|NCT04570267|Placebo Comparator|Placebo|One dose of placebo administered subcutaneously on Day 1
3382728|NCT04568122|Experimental|Saliva test|Participants perform each test assay, noting the results for comparison by technician, and completing survey questionnaires.
3382730|NCT04565392|Experimental|famotidine|A 20-milligram tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
3382731|NCT04565392|Placebo Comparator|Placebo|A placebo tablet to match a 20-milligram (mg) tablet of Pepcid in the morning and evening the first day, to be increased thereafter to one tablet every 8 hours if not improving
3382734|NCT04560179|Experimental|Treatment Arm|The phase 1 trial will last up to 14 days, with each infant receiving a specified dose of tobramycin solution for inhalation every 12 hours, administered via vibrating mesh nebulizer. The drug dosage (78mg, 150mg, 216mg, or 300mg) will be determined as per the inter-patient dose escalation 3+3 design protocol. During the trial, each infant will undergo blood and tracheal aspirate sampling and respiratory mechanics measurements at pre-specified time points to assess dose safety and potential efficacy. Clinical data will also be recorded daily throughout the trial.
3382735|NCT04560179|No Intervention|Observational Arm|Enrolled infants who are ineligible to participate in the phase-1 trial (lack of parental consent, research tracheal aspirate negative for a pathogenic GNR) will undergo collection of clinical and respiratory mechanics data for 14 days after ineligibility to participate in the phase-1 trial is established.
3382736|NCT04541433|Experimental|AZD9833 monotherapy|Dose escalation of AZD9833 monotherapy for patients with ER+ HER2- advanced breast cancer
3382737|NCT04541030||GPS Cohort 1|Samples and images from up to 277 evaluable patients diagnosed with NCCN low or intermediate risk prostate cancer, Gleason <= 7, managed with RP, and mpMRI within 6 months prior to prostatectomy
3382740|NCT04540042|Experimental|SelK2 (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
3382741|NCT04540042|Placebo Comparator|Placebo (Part 1)|I.V., multiple-dose (Day 1 and Day 22)
3382742|NCT04540042|Experimental|SelK2 (Part 2)|I.V., single-dose (Day 1)
3382743|NCT04540042|Placebo Comparator|Placebo (Part 2)|I.V., single-dose (Day 1)
3382744|NCT04538794|Experimental|CDX-0159|CDX-0159 every 4-8 weeks
3382745|NCT04538794|Placebo Comparator|Normal Saline|Normal saline every 4-8 weeks
3382755|NCT04524390|Experimental|Maralixibat|Maralixibat oral solution administered twice daily, up to 600 microgram per kilogram, for 26 weeks and in the OLE for all patients.
3382756|NCT04524390|Placebo Comparator|Placebo|Placebo oral solution for 26 weeks. All placebo participants who complete Week 26 and continue in the open label extension (OLE) will receive maralixibat after Week 26.
3382757|NCT04509050||Part A|Children with CF not on ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy.
3382758|NCT04509050||Part B|Children with CF planning to start ivacaftor or elexacaftor/tezacaftor/ivacaftor CFTR modulator therapy. Participants from the Part A cohort of this study may enroll into the Part B cohort if they become eligible for these CFTR modulator therapies and plan to start them.
3382759|NCT04506411|Experimental|TPG|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive Turmipure GOLD® product during 12 weeks
3382760|NCT04506411|Active Comparator|STE|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive standard turmeric extract 95% curcuminoids (STE) product during 12 weeks
3382761|NCT04506411|Placebo Comparator|Control|59 participants who meet the eligibility criteria will be randomized under experimental arm and will receive placebo (maltodextrin) product during 12 weeks
3382762|NCT04504669|Experimental|Monotherapy|Participants will receive AZD8701 intravenously, on Day 1, 3, 5 and 8 and then weekly for a maximum of 2 years.
3382763|NCT04504669|Experimental|Combination Therapy|Participants will receive AZD8701 (intravenously, on Day 1, 3, 5 and 8 and then weekly) and durvalumab (MEDI4736) intravenously monthly for a maximum of 2 years.
3382764|NCT04501978|Experimental|ACTIV-3 Drug plus SOC|Participants in this study will be randomized to receive one of the ACTIV-3 drug treatments plus Standard of Care (SOC) or placebo plus SOC
3382765|NCT04501978|Placebo Comparator|Placebo plus SOC|The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
3382766|NCT04499924|Experimental|Phase 2 Arm|Tucatinib + trastuzumab + ramucirumab + paclitaxel
3382767|NCT04499924|Experimental|Arm 3A|Tucatinib + trastuzumab + ramucirumab + paclitaxel
3382768|NCT04499924|Active Comparator|Arm 3B|Ramucirumab + paclitaxel + tucatinib placebo + trastuzumab placebo
3382769|NCT04499924|Experimental|Arm 3C|Tucatinib + ramucirumab + paclitaxel + trastuzumab placebo
3382771|NCT04489134|Experimental|A D B C|Period n°01: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
3382772|NCT04489134|Experimental|B A C D|Period n°01: Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®)
3448553|NCT04063085|Experimental|PROTAHERE group|The PROTAHERE group received intra-pelvic PROTAHERE Absorbable Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
3448554|NCT04063085|Active Comparator|Hyalobarrier group|The Hyalobarrier group received intra-pelvic Hyalobarrier Gel during the scheduled pelvic surgery and be followed for 24 months.
3448555|NCT04063085|Sham Comparator|No treatment group|The no treatment group did not receive any anti-adhesion agent during the scheduled pelvic surgery and be followed for 24 months.
3448556|NCT04063085|Active Comparator|Seprafilm group|The Seprafilm group received intra-pelvic Seprafilm Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
3448557|NCT04063085|Active Comparator|Interceed group|The Interceed group received intra-pelvic Gynecare Interceed (TC7) Absorbale Adhesion Barrier during the scheduled pelvic surgery and be followed for 24 months.
3448558|NCT04063163|Experimental|A|HLX 10+chemotherapy (Carboplatin-Etoposide)
3448559|NCT04063163|Placebo Comparator|B|Placebo+chemotherapy (Carboplatin-Etoposide)
3448560|NCT04062773|Experimental|TRF|Eating restricted to between midday and 6pm.
3448561|NCT04062773|Placebo Comparator|Normal timing of food intake.|Eating between 8am and 11pm.
3448562|NCT04063397||Preeclampsia|40 patients diagnosed with preeclampsia with or without severe features
3448563|NCT04063397||Control|20 Control group of patients without hypertensive disorders of pregnancy
3448564|NCT04063436|Experimental|Experimental|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
3448565|NCT04062981|Experimental|Cohort I|"Subjects ≥ 18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
3448566|NCT04062981|Experimental|Cohort II|"Subjects 12 to <18 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
3448567|NCT04062981|Experimental|Cohort III|"Subjects 6 to <12 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
3448568|NCT04062981|Experimental|Cohort IV|"Subjects 2 to <6 years of age~These subjects will reach maximum stable dose and continue onto YKP509C002."
3382773|NCT04489134|Experimental|C B D A|Period n°01: Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°02:Administration of a 2 mg dose of LCP-tacro (Envarsus®) Period n°03:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°04:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)
3382774|NCT04489134|Experimental|D C A B|Period n°01:Administration of a single 120 mg dose of immediate release verapamil (Isoptine®) and a 2 mg dose of LCP-tacro (Envarsus®) Period n°02:Administration of a single 120 mg dose of immediate-release verapamil (Isoptine®) and a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°03:Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®) Period n°04:Administration of a 2 mg dose of LCP-tacro (Envarsus®)
3382775|NCT04484142|Experimental|DS-1062a 6.0 mg/kg|Participants will receive 6.0 mg/kg of DS-1062a
3382776|NCT04478942|Active Comparator|oral misoprostol|At time of delivery, participants randomly assigned to either oral misoprostol will receive 50 mcg of Misoprostol every 4 hours up to 6 doses, OR until simplified Bishop score >6 (whichever is achieved first).
3382777|NCT04478942|Active Comparator|intravenous oxytocin|At time of delivery, participants randomly assigned to intravenous oxytocin, will be administered the drug per standard of labor and delivery titrations.
3382778|NCT04468321|Experimental|Apple Watch|Patients will be provided with the Apple Watch Series 6 with Irregular Rhythm Detection and ECG capabilities.
3382779|NCT04468321|Placebo Comparator|Withings Move|Patients will be provided with the Withings Move with activity tracking.
3382780|NCT04467593|Experimental|Cohort A1|Three patients with advanced solid cancer will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15)
3382781|NCT04467593|Experimental|Cohort A2|The highest whole-body hyperthermia duration with acceptable side effects from cohort A1 will be applied to three additional patients with advanced solid cancer, once a week and for 15 days in total.
3382782|NCT04467593|Experimental|Cohort B1|Three pancreatic cancer patients will be subjected to repetitive hyperthermia starting with 2 hours (day 1), 4 hours (day 8) and 6 hours (day 15) using the device and in combination with the standard of care chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nab-paclitaxel or gemcitabine alone).
3382783|NCT04467593|Experimental|Cohort B2|The highest whole-body hyperthermia duration with acceptable side effects from cohort B1 will be applied in combination with chemotherapy (FOLFIRINOX, FOLFOX, gemcitabine/nabpaclitaxel or gemcitabine alone) to three additional pancreatic cancer patients, once a week and for 15 days in total.
3382784|NCT04466800|Experimental|Intervention group_rehabilitation program|multidisciplinary and personalized rehabilitation program
3382785|NCT04466800|No Intervention|Control group|Usual care of each site, including delivery of an information sheet concerning recommended physical activity (based on WHO recommendations) and nutrition. One month after inclusion, patients of this group will be offered a rehabilitation program (as described in the intervention group, but with only one session with a physical activity educator at home) and one dietitian consultation.
3382786|NCT04464187||Participants exposed to Elagolix-containing products|Pregnant participants exposed to Elagolix from 14 days after last menstrual period (LMP) or at any point during pregnancy.
3382787|NCT04464187||Participants not exposed to Elagolix-containing products|Pregnant participants with endometriosis, uterine fibroids, or other conditions based on approved indications and prescribing patterns of Elagolix-containing products not exposed to Elagolix from 14 days after LMP or at any point during pregnancy.
3382788|NCT04463693|Experimental|Intervention|Insertion of the etonogestrel contraceptive implant subdermally over the non-dominant scapula
3382789|NCT04463680|Experimental|Intervention|Will receive 2 week regimen of rifampin 600mg per day
3382790|NCT04463498|Experimental|n=20, Sleep-school 8 weeks|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3382791|NCT04463498|Experimental|n=20, Sleep-school 8 weeks and additive bb-glasses|Patients receive treatment as usual in the psychiatric clinic combined with participation in the sleep school and additive treatment with bb-glasses. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3382792|NCT04463498|Active Comparator|n=40 8-week wait list for sleep-school|Patients receive treatment as usual in the psychiatric clinic while they wait for participation in the sleep school. They have already been given education on sleep regulation and sleep hygiene advice in the first meeting with the sleep-school facilitator.
3382793|NCT04453137|Active Comparator|Humira 40 mg/mL (Adalimumab Originator)|During the LeadIn Period, patients will receive Humira (initial dose of 80 mg [2 × 40 mg] administered subcutaneously [SC], followed by 40 mg SC given every other week starting 1 week after the initial dose). At Week 12, responsive patients (Psoriasis Area and Severity Index [PASI] ≥ 75 [PASI75]) will be randomly assigned in a 1:1 ratio to either of the following groups for participation in the Double-Blind Switching Module.
3382794|NCT04453137|Active Comparator|IC - Humira 40 mg/mL (Adalimumab Originator)|patients continue to receive Humira 40 mg every other week from Week 12 until Week 26 (8 injections)
3382795|NCT04453137|Experimental|IC - Humira/AVT02 40 mg/mL (Adalimimab Biosimilar)|"patients undergo repeated switches (Sw) of AVT02 and Humira from Week 12 until Week 26:~Sw1-AVT02 (40 mg every other week) for 4 weeks (2 injections),~Sw2-Humira (40 mg every other week) for 4 weeks (2 injections),~Sw3-AVT02 (40 mg every other week) for 8 weeks (4 injections)."
3382796|NCT04453137|Experimental|AVT02 40 mg/mL (Adalimimab Biosimilar)|At Week 28, after the EoS IC visit, responsive patients (PASI ≥ 50 [PASI50]) will be offered to continue with the optional open-label Extension Phase (Weeks 28 to 52). AVT02 40 mg will be administered every other week starting from Week 28 (after completing EoS IC assessments), ending with the final study drug administration at Week 50. The EoS visit is planned for Week 52.
3382797|NCT04446000|Experimental|CSL730 (dose 1 with premedication)|administered as a single dose by subcutaneous (SC) injection or by SC infusion
3382798|NCT04446000|Experimental|CSL730 (dose 2 with premedication)|administered as a single dose by SC injection or by SC infusion
3382799|NCT04446000|Experimental|CSL730 (dose 3 with premedication)|administered as a single dose by SC injection or by SC infusion
3382800|NCT04446000|Experimental|CSL730 (dose 1 without premedication)|administered as a single dose by SC injection or by SC infusion
3382801|NCT04446000|Experimental|CSL730 (dose 2 without premedication)|administered as a single dose by SC injection or by SC infusion
3382802|NCT04446000|Experimental|CSL730 (dose 3 without premedication)|administered as a single dose by SC injection or by SC infusion
3382803|NCT04446000|Experimental|CSL730 (dose 4 without premedication)|administered as a single dose by SC injection or by SC infusion
3382804|NCT04446000|Experimental|CSL730 (dose 5 without premedication)|administered as a single dose by SC injection or by SC infusion
3382805|NCT04446000|Experimental|CSL730 (dose 6 without premedication)|administered as a single dose by SC injection or by SC infusion
3382806|NCT04446000|Experimental|CSL730 (dose 7 without premedication)|administered as a single dose by SC injection or by SC infusion
3382807|NCT04446000|Placebo Comparator|Placebo|A solution matching the excipient profile of CSL730 without the active substance administered as a single dose by SC injection or by SC infusion
3382808|NCT04439552||CXL group|Patients who are about to undergo a corneal cross-linking (CXL) surgery to treat keratoconus.
3382809|NCT04439552||Control group|Healthy volunteers age and sex matched to the CXL group.
3382810|NCT04434196|Experimental|CC-99282 + obinutuzumab|Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B.
3382811|NCT04432350||Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
3382812|NCT04432350||Not Treated with Repurposed Drugs|This cohort will be for individuals who have tested positive for COVID-19 and were not treated with repurposed drugs. This will be tracked via drug claims data in a PrescribeWellness Pharmacy.
3382813|NCT04431453|Experimental|Remdesivir (RDV)|"Participants will receive RDV up to 10 days. The RDV dose administered in each cohort is as follows:~Cohort 1: intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg daily~Cohorts 2-5: IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily~Cohort 6-7: IV RDV at a dose to be determined based on RDV exposure data from Cohort 5~Cohort 8: IV RDV 200 mg on Day 1 followed by IV RDV 100 mg daily"
3382814|NCT04430738|Experimental|Cohort 1A|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
3382815|NCT04430738|Experimental|Cohort 1B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles
3382816|NCT04430738|Experimental|Cohort 1C|Tucatinib + trastuzumab + CAPOX given in 21-day cycles
3382817|NCT04430738|Experimental|Cohort 1D|Tucatinib + trastuzumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles and trastuzumab given every 21 days
3382818|NCT04430738|Experimental|Cohort 1E|Tucatinib + trastuzumab + pembrolizumab + FOLFOX. Tucatinib and FOLFOX given in 14-day cycles, trastuzumab given in 21-day cycles, and pembrolizumab given in 42-day cycles
3382819|NCT04430738|Experimental|Cohort 1F|Tucatinib + trastuzumab + pembrolizumab + CAPOX. Tucatinib, trastuzumab, and CAPOX given in 21-day cycles and pembrolizumab given in 42-day cycles.
3382820|NCT04430738|Experimental|Cohort 1G|Tucatinib + trastuzumab + pembrolizumab. Tucatinib and trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
3382821|NCT04430738|Experimental|Cohort 2A|Tucatinib + trastuzumab + pembrolizumab + (FOLFOX or CAPOX). Either (1) tucatinib and FOLFOX given in 14-day cycles or (2) tucatinib and CAPOX given in 21-day cycles. Trastuzumab given in 21-day cycles and pembrolizumab given in 42-day cycles.
3382822|NCT04430738|Experimental|Cohort 2B|Tucatinib + trastuzumab + FOLFOX given in 14-day cycles.
3382823|NCT04409418|Experimental|Experimental Group|If the patient is randomized to the experimental group (lower arm), the research staff will direct the insert to place the catheter into the forearm at least 10 cm away from the antecubital fossa.
3382824|NCT04409418|Active Comparator|Control Group|Control group (upper arm). If the patient is in the control group the research staff will direct the inserter to place the catheter into the upper arm vein at least 2 cm above the antecubital fossa.
3382827|NCT04397185|Experimental|Breast Cancer Locator (BCL)|Subject randomized to BCL surgical guidance to perform partial mastectomy
3382828|NCT04397185|Active Comparator|Wire Localization (WL)|Subject randomized to WL surgical guidance to perform partial mastectomy
3382834|NCT04382898|Experimental|Part 1 (mCRPC) - dose titration|W_pro1 monotherapy
3382835|NCT04382898|Experimental|Part 2 Arm 1A (mCRPC) - expansion cohort|W_pro1 in combination with cemiplimab
3382836|NCT04382898|Experimental|Part 2 Arm 1B [1] (mCRPC) - expansion cohort|W_pro1 monotherapy
3382837|NCT04382898|Experimental|Part 2 Arm 2 (LPC) - expansion cohort|W_pro1 in combination with cemiplimab
3382838|NCT04382898|Experimental|Part 2 Arm 3 (LPC) - expansion cohort|W_pro1 monotherapy
3382839|NCT04382898|Experimental|Part 2 Arm 1B [2] (mCRPC) - expansion cohort|Following progression after W_pro1 monotherapy, patients in Arm 1b have the option to be treated with cemiplimab monotherapy
3382840|NCT04375956|Experimental|Pembrolizumab|Pembrolizumab 200 mg d1 q 21 iv infusion, until disease progression of disease, unacceptable toxicity or patient's refusal. Pembrolizumab will be administered for a maximum of 2 years.
3382841|NCT04373707|Active Comparator|Low Prophylactic Dose of Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
3382842|NCT04373707|Experimental|Weight-Adjusted Prophylactic Dose Low Molecular Weight Heparin|Enoxaparin, Tinzaparin, Nadroparin, Dalteparin
3382843|NCT04372628|Active Comparator|Group 1 - Lopinavir/Ritonavir|Lopinavir/Ritonavir 400 mg/100 mg orally twice daily for twenty-eight doses (Days 1-14)
3382844|NCT04372628|Placebo Comparator|Control Group|Placebo unmatched orally twice daily for 14 days
3382847|NCT04363697|Experimental|Dapagliflozin|Dapagliflozin 10 mg administered orally once daily for 2 months
3382848|NCT04363697|Placebo Comparator|Placebo|Matching placebo administered orally once daily for 2 months
3382849|NCT04349150|Experimental|Virtual reality|Participants on this arm will have their colonoscopy initiated under virtual reality instead of standard sedatives and narcotics
3382853|NCT04334057||Patients with haemophilia A|New patients who have not previously been exposed to Esperoct® (Turoctocog alfa pegol or N8-GP in clinical trials) are eligible for this study.
3382857|NCT04323436|Experimental|Run-in part|capmatinib in combination with spartalizumab
3382858|NCT04323436|Experimental|Randomized part - Arm 1 spartalizumab|capmatinib in combination with spartalizumab
3382859|NCT04323436|Experimental|Randomized part - Arm 2 placebo|capmatinib in combination with placebo
3382862|NCT04317066|Experimental|Pembrolizumab in Participants with rrPMBCL|Participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) receive pembrolizumab 200 mg by intravenous (IV) infusion every 3 weeks (Q3W) for up to 24 months.
3382866|NCT04313881|Experimental|Magrolimab + Azacitidine|"Participants will receive the following magrolimab and azacitidine dosing regimens:~Magrolimab:~Cycle 1: 1mg/kg priming dose on Days 1 and 4; 15 mg/kg on Day 8; and 30 mg/kg on Days 11, 15, and 22~Cycle 2: weekly doses of 30 mg/kg on Days 1, 8, 15, and 22~Cycle 3 and onward: 30 mg/kg every 2 weeks on Days 1 and 15~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle"
3382867|NCT04313881|Placebo Comparator|Control Arm (Placebo + Azacitidine)|"Participants will receive the following placebo and azacitidine dosing regimens:~Placebo:~Cycle 1: Days 1, 4, 8, 11, 15, and 22~Cycle 2: Days 1, 8, 15, and 22~Cycle 3 and onward: Days 1 and 15~Azacitidine: 75 mg/m^2 on Days 1 to 7 (or Days 1 to 5 and 8 to 9) of each cycle"
3382868|NCT04313283|Experimental|Parents Taking Action|A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders for 12 weeks.
3382869|NCT04305496|Experimental|Capivasertib + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Capivasertib: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
3382870|NCT04305496|Placebo Comparator|Placebo + fulvestrant|"Fulvestrant: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.~Placebo: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle."
3382871|NCT04292470|Experimental|Amitriptyline|Amitriptyline 10 mg daily
3382873|NCT04289311|Experimental|Intervention arm|Single group study; all participants are in the intervention arm and receive the intervention
3382874|NCT04287959|Active Comparator|A: wean to 30%|wean to 30% oxygen on high flow and then turn off high flow support and place onto standard low flow oxygen.
3382875|NCT04287959|Active Comparator|B: wean to 21%|wean to 21% oxygen on high flow and then turn off high flow support and place directly into air.
3382876|NCT04287816|Experimental|Zero hard-boiled egg at 0 h|No eggs will be consumed on the test day. Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
3382877|NCT04287816|Experimental|One hard-boiled egg at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg prior to the 72-h pharmacokinetics trial.
3382878|NCT04287816|Experimental|Two hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 2 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
3382879|NCT04287816|Experimental|Three hard-boiled eggs at 0 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 3 hard-boiled eggs prior to the 72-h pharmacokinetics trial.
3382880|NCT04287816|Experimental|One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone at 0 h prior to the 72-h pharmacokinetics trial followed by 1 hard-boiled egg 3 hours after spinach consumption.
3382881|NCT04287816|Experimental|One hard-boiled egg at 0 h + One hard-boiled egg at 3 h|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested along with 1 hard-boiled egg at 0 h prior to the 72-h pharmacokinetics trial followed by 1 egg 3 hours after spinach consumption.
3382882|NCT04286321|Experimental|Zero hard-boiled egg|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested alone prior to the 72-h pharmacokinetics trial.
3382883|NCT04286321|Experimental|Two egg whites|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two egg whites (0 g fat) prior to the 72-h pharmacokinetics trial.
3382884|NCT04286321|Experimental|Two hard-boiled eggs|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with two whole eggs (9.6 g fat) prior to the 72-h pharmacokinetics trial.
3382885|NCT04286321|Experimental|Vegetable oil|Deuterium-labeled spinach containing 2 mg αT and 500 ug PQ will be ingested with vegetable oil (9.6 g fat) prior to the 72-h pharmacokinetics trial.
3382887|NCT04273243||Subjects who received AT-GTX-501 gene transfer|Subjects with CLN6 Batten disease who previously received AT-GTX-501 in the preceding study (Study AT-GTX-501-01).
3382888|NCT04258943|Experimental|Single Agent Bosutinib|Bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML). A treatment cycle is defined as 28 days
3382890|NCT04253236|Experimental|Cohort 1|Dosing Regimen A - 680 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
3382891|NCT04253236|Experimental|Cohort 2|Dosing Regimen B - 340 mg weekly for 12 weeks via once weekly subcutaneous (SC) injections
3382892|NCT04240210|No Intervention|To assess degree of adherence to ART in a real world seeting.|Part I of the study is a Cohort Survey of HIV+ outpatient clinic patients currently receiving ART to assess medication adherence and tolerability by determining a change in adherence and tolerability from baseline to 4 months, measured by standardized patient reported outcome and adherence surveys
3382893|NCT04240210|Experimental|Potential changes in ART adherence when switced to Symtuza.|Part 2 of the study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
3382894|NCT04235504|Active Comparator|Control Arm|The Control Arm will use individual subject's current diabetes therapy (MDI+FGM or MDI+CGM) for 6 months during the Study Phase. During the Continuation Phase of 6 months Control Arm will start using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0
3382895|NCT04235504|Experimental|Treatment Arm|The Treatment Arm will use the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0 for 6 months during the Study Phase and other 6 months during the Continuation Phase.
3382896|NCT04222101|Other|cardiomyopathy|only one arm, all participants undergo oral glucose tolerance testing and results are used to evaluate association with degree of cardiac dysfunction
3382899|NCT04220489|Experimental|Ketamine Group|Participants will receive a 1 mg/kg dose of intravenous ketamine 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr ketamine with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
3382900|NCT04220489|Placebo Comparator|Placebo Group|Participants will receive a 1 mg/kg dose of intravenous saline 15 minutes after induction of general anesthesia. Thereafter, a continuous infusion of 0.20 mg/kg/hr saline with a maximum dose of 20 mg/hr will be run to conclude at 48 hours after the end of the surgery (fascial closure).
3382901|NCT04219319|Experimental|Experimental: LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor|An open label, multi center, single arm Phase I study to evaluate the safety, tolerability, and efficacy of LCAR-T2C CAR-T cells in relapsed or refractory CD4+ T lymphocyte tumor.
3382902|NCT04218786|Active Comparator|Colchicine Group|This group will receive low dose colchicine, 0.5 mg.
3382903|NCT04218786|Placebo Comparator|Placebo group|This group will receive a placebo drug with a similar shape and mass as that to experimental drug
3382904|NCT04217473|Experimental|TILT-123|"Patients will receive administrations of TILT-123. Patients will also receive Tumor Infiltrating Lymphocytes (TILs) during the treatment phase.~Escalation to the next dose of TILT-123 level will occur when the safety data has been evaluated for all patients in the preceding dose level."
3382905|NCT04211389|Active Comparator|ARQ-151 cream 0.3%|Active comparator
3382906|NCT04211389|Placebo Comparator|ARQ-151 cream vehicle|Placebo comparator
3382909|NCT04209855|Experimental|mirvetuximab soravtansine (MIRV; IMGN853)|MIRV 6 mg/kg adjusted ideal body weight (AIBW) every 3 weeks (Q3W)
3382910|NCT04209855|Active Comparator|Investigator's choice of chemotherapy|"Paclitaxel (Pac; 80 mg/m2) administered once per week (QW) within a 4-week cycle~Pegylated liposomal doxorubicin (PLD; 40 mg/m2) administered every 4 weeks (Q4W)~Topotecan (Topo; 4 mg/m2) administered either on Days 1, 8, and 15 every 4 weeks or for 5 consecutive days (1.25 mg/m2 Days 1-5) every 3 weeks (Q3W)"
3382911|NCT04208087|Experimental|SI-722|
3382912|NCT04208087|Placebo Comparator|Placebo|
3382913|NCT04206813|Experimental|Intervention group|240 eligible women will receive a 2-dose regimen of Gardasil 9 at (0 and 6 months, followed by a rescue 3rd dose at month 12)
3382914|NCT04206813|Active Comparator|Control group|120 eligible women will receive the standard 3-dose regimen of Gardasil 9 at (0, 2, 6 months)
3382916|NCT04198870|Other|Control Arm|Mitral Valve Repair Surgery
3382917|NCT04198870|Experimental|Device Arm|MitraClip™ device implantation
3382921|NCT04190030|Experimental|Mindfulness|
3382922|NCT04190030|Active Comparator|Cognitive reappraisal|
3382923|NCT04188548|Experimental|Dose Escalation LY3484356|LY3484356 given orally.
3382924|NCT04188548|Experimental|Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI|LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
3382925|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E3: LY3484356|LY3484356 given orally.
3382926|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus|LY3484356 and everolimus given orally.
3382927|NCT04188548|Experimental|Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib|LY3484356 and alpelisib given orally.
3382928|NCT04188548|Experimental|Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib|LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
3382929|NCT04188548|Experimental|Part D: Dose Expansion: LY3484356 +/- Abemaciclib|LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
3382930|NCT04188548|Experimental|Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab|LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
3382931|NCT04185363|Experimental|Maralixibat|All subjects will receive Maralixibat oral solution
3382932|NCT04177940|Active Comparator|Denosumab (DMAB) to Alendronate (ALN)|Switch from Denosumab 60 mg administered subcutaneously (SC) to weekly oral alendronate (70 mg; started 6 months after last denosumab dose)
3382933|NCT04177940|Active Comparator|"DMAB to Early Zoledronic Acid (ZA)"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one early zoledronic acid infusion (5 mg; 6 months after last denosumab dose)"
3382934|NCT04177940|Active Comparator|"DMAB to Late ZA"|"Switch from Denosumab 60 mg administered subcutaneously (SC) to one late zoledronic acid infusion (5 mg; 9 months after last denosumab dose)"
3382935|NCT04172480||acute HIV1 infection|Patient infected by HIV1, prior treatment initiation
3382936|NCT04172480||chronic HIV1 infection|Patient infected by HIV1, untreated or without treatment since at least 3 months
3382937|NCT04172480||HIV2 infection|Patient infected by HIV2, untreated or without treatment since at least 3 months
3382938|NCT04165343||Non-Alcoholic Fatty Liver Disease (NAFLD)|"Cohort: Patients with known Non-Alcoholic Fatty Liver Disease (NAFLD)~All patients will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood test"
3382939|NCT04165343||Healthy Control Subjects|"Cohort: Healthy controls~All healthy subjects will undergo the following interventions:~Positron Emission Tomography (PET) on the EXPLORER scanner Magnetic Resonance Imaging (MRI) Echocardiogram and Electrocardiogram Blood tests"
3382940|NCT04160663|Experimental|Subjects with atrial fibrillation|Subjects with atrial fibrillation that have been clinically scheduled for an electrical cardioversion procedure will have carotid ultrasound testing done before and after the procedure
3382941|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 1|Participants will receive 1 dose of Dose Level 1 of mRNA-3927 by intravenous (IV) infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382942|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 2|Participants will receive 1 dose of Dose Level 2 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382943|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 3|Participants will receive 1 dose of Dose Level 3 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382944|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 4|Participants will receive 1 dose of Dose Level 4 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382945|NCT04159103|Experimental|Dose Optimization Stage: Dose Level 5|Participants will receive 1 dose of Dose Level 5 of mRNA-3927 by IV infusion on Day 1 of a 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382946|NCT04159103|Experimental|Dose Expansion Stage|Participant will receive the optimal dose of mRNA-3927 identified during the Dose Optimization Stage at 1 dose on Day 1 of each 21-day period for up to 10 doses during the approximate 30-week Treatment Period.
3382947|NCT04155450|Experimental|McKenzie Extension with External Limb Loading Protocol|"Moist Heat Pack for 10 mins~McKenzie Extension Exercise Protocol~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing~Limb loading for basic stabilization progression of the lumbar extensors. Begin in the quadruped position and progress the intensity by~Flexing one upper extremity~Extending one lower extremity with a leg slide~Extending one lower extremity by lifting it off the mat~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~Progress to prone position:~Extending one lower extremity~Extending both lower extremity"
3382948|NCT04155450|Active Comparator|McKenzie Extension Group|"Moist Heat Pack for 10 mins~McKenzie Extension Protocol Sequence~Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
3382949|NCT04153149|Experimental|Vutrisiran 25 mg|Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
3382950|NCT04153149|Placebo Comparator|Placebo|Participants will receive placebo during the double-blind period.
3382951|NCT04140344|Experimental|ARM 1: Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
3382952|NCT04140344|No Intervention|ARM 2: Control group|The control group will be given the standard post-op packet that includes detailed instructions on proper wound care and signs and symptoms of infection. They will not receive text messages. The same outcomes will be assessed in both groups through a 30-day post-operative phone call.
3382953|NCT04133701|Experimental|Time-Restricted Feeding|"Control (Baseline): Blood pressure and neurovascular control will be measured.~Post-Intervention: Blood pressure and neurovascular control will be measured."
3382954|NCT04133376|Experimental|Vascular Endothelial Function|Brachial artery flow-mediated dilation will be used to measure endothelial function
3382955|NCT04133376|Experimental|Biomarkers of oxidative stress and inflammation|Prooxidant and inflammatory plasma biomarkers will be used to assess oxidative stress and inflammatory status
3382956|NCT04133376|Experimental|Vascular endothelial cells|
3382957|NCT04130997|Experimental|Ublituximab Infusions|"RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 168.~RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 168.~For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 168 weeks, or until physician or participant decision to withdraw from the study"
3382959|NCT04110262|Experimental|High-low dietary sodium|High sodium diet (3400 mg/day) feeding period followed by low sodium diet (2300 mg/day) feeding period
3382960|NCT04110262|Experimental|Low-high dietary sodium|Low sodium diet (2300 mg/day) feeding period followed by high sodium diet (3400 mg/day) feeding period
3448569|NCT04062994||Intervention Group|All patients scheduled for surgery at a UCLA site in the one year period after go-live
3382961|NCT04103749|Experimental|Exalt DScope 02|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed using the Exalt single use duodenoscope study device. Subjects are considered enrolled after completing the study specific informed consent form.
3382967|NCT04101617|Experimental|Experimental group|Participants will receive previously designed educational material with recommendations for healthy habits and oral health recommendations. Also, pediatricians will give the parents oral health education. Parents and their children will receive toothbrushes as well as toothpaste.
3382968|NCT04101617|No Intervention|Control Group|Parents and their children will receive toothbrushes as well as toothpaste.
3382969|NCT04100200|Active Comparator|Mixed Berries|Strawberry and red raspberry composite served as a frozen drink
3382970|NCT04100200|Active Comparator|FOS|Non-polyphenol, carbohydrate-based fermentable fiber/pre-biotic served as a frozen drink
3382971|NCT04100200|Active Comparator|Combination|Mixed berry composite + FOS served as a frozen drink
3382972|NCT04100200|Placebo Comparator|Control|Placebo similar in color to mixed berry supplement without any polyphenols served as a frozen drink
3382973|NCT04093076|Experimental|INO-4500 Group A|Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device.
3382974|NCT04093076|Experimental|INO-4500 Group B|Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.
3382975|NCT04093076|Placebo Comparator|Placebo Group C|Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device.
3382976|NCT04093076|Placebo Comparator|Placebo Group D|Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit..
3382979|NCT04076280|Experimental|SWAP Intervention|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the Sodium Watcher Program.
3382980|NCT04076280|Active Comparator|Usual Care|The participants are randomized using a table of random numbers pre-generated by a computer assigning them to the usual care group.
3382981|NCT04074109|Experimental|Teleyoga|group will receive instruction via computer tablet
3382982|NCT04074109|Active Comparator|In-person yoga|group will receive instruction in-person
3382992|NCT04053842|Experimental|Multi-modality prostate cancer imaging|The study requires eligible patients to complete one imaging session at St. Joseph's Health Care to begin within 6 weeks of the scheduled Radical Prostatectomy. Imaging will consist of simultaneous multiparametric MRI (mpMRI), sodium MRI and positron emission tomography (PET) with a radio-labeled probe for prostate-specific membrane antigen (PSMA).
3382993|NCT04053673|Experimental|RBN-2397|Dose Escalation: Multiple doses of RBN-2397 for oral administration Dose Expansion: Oral dose of RBN-2397 as determined during Dose Escalation
3382994|NCT04052516|Placebo Comparator|Placebo|Placebo oral capsules taken one daily for 52 weeks
3382995|NCT04052516|Experimental|Icosabutate 300mg|Icosabutate 300mg oral capsule taken once daily for 52 weeks
3382996|NCT04052516|Experimental|Icosabutate 600mg|Icosabutate 600mg oral capsules taken once daily for 52 weeks
3382997|NCT04050085|Experimental|Treatment (SD-101, radiation therapy, nivolumab)|Patients receive TLR9 agonist SD-101 intratumorally on days 1 and 8 of cycle 1 and day 1 of cycles 2-5. Treatment repeats every 2 weeks for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo radiation therapy on days 1, 3, 5, 8, and 10 of cycle 1. Patients also receive nivolumab IV over 30 minutes on day 2. Cycles with nivolumab repeat every 2 weeks for 24 months in the absence of disease progression or unacceptable toxicity.
3382998|NCT04047979|Experimental|Younger Group|Participants between the ages of 50 to 60 years will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
3382999|NCT04047979|Experimental|Older Group|Participants who are ≥70 year old will receive two doses of Zoster vaccine recombinant, adjuvanted (Shingrix®)
3448570|NCT04062838|Experimental|Prolotherapy|Injection of 20% dextrose (50 % dextrose diluted with 0.5% lidocaine) into the rotator cuff tendinous insertions as well as into the tear. All injections are performed under ultrasound.
3448571|NCT04063046|Active Comparator|General anesthesia|General anesthesia involving intubation or supraglottic airway device insertion
3448572|NCT04063046|Experimental|peripheral nerve block|popliteal sciatic nerve block
3448573|NCT04063124|Experimental|Intermittent D+Q|Senolytic treatment in 5 individuals with early AD to determine levels of drug that reach the central nervous system (CNS) by collecting cerebral spinal fluid (CSF), and begin collecting initial data on target engagement of senescent cells, AD-related markers, and AD-relevant outcomes for future trials.
3448574|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for initiation and follow-up of the ketogenic diet
3448575|NCT04063020||Reconstructive plastic surgery procedure|Minors with ear aplasia and initiating a reconstructive plastic surgery procedure
3448576|NCT04062747|Active Comparator|I-gel LMA|After standard anesthesia i-Gel was placed into the patient.
3448577|NCT04062747|Active Comparator|Ambu Aura-i|After standard anesthesia Ambu Aura-i was placed into the patient.
3448578|NCT04062760|Active Comparator|Standard diuretic therapy (SDT)|Furosemide +/- spironolactone or potassium canrenoate
3448579|NCT04062760|Experimental|Early sequential nephron blockade (ESNB)|Furosemide + metolazone + acetazolamide +/- spironolactone or potassium canrenoate
3448580|NCT04062851|No Intervention|GRV group|Gastric residuals will be checked prior to feeds
3448581|NCT04062851|Experimental|NO GRV group|Gastric residuals will not be checked prior to feeds
3383000|NCT04029480|Experimental|Ertugliflozin 5 mg/5 mg|"All participants will initially receive ertugliflozin (ERTU) 5 mg once daily (QD) and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at Week 12 (WK12), all participants that do not meet the up-titration criteria will remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54. Approximately half the participants who meet the up-titration criteria at the second randomization at WK12 will also remain on ERTU 5 mg and placebo to ERTU 15 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a fasting fingerstick glucose (FFSG) of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
3383001|NCT04029480|Experimental|Ertugliflozin 5 mg/15 mg|"All participants will initially receive ERTU 5 mg QD and placebo to ERTU 15 mg QD for 12 weeks. At the second randomization at WK12, approximately half the participants who meet the up-titration criteria at the second randomization will up-titrate to ERTU 15 mg and placebo to ERTU 5 mg from WK12 to WK54.~Note: For participants not on insulin, the up-titration criterion at the second randomization at WK12 is HbA1C ≥7.0% (53 mmol/mol) and for participants on insulin, a FFSG of ≥110 mg/dL (6.1 mmol/L) will be required in addition to HbA1C ≥7.0% (53 mmol/mol). Participants will remain on their background metformin with/without insulin treatment throughout the study."
3383002|NCT04029480|Placebo Comparator|Placebo|At the first randomization, participants receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD for 12 weeks. Participants in the placebo group with HbA1C ≥7.0% (53 mmol/mol) at WK12 will be mock titrated. Note: The up-titration criteria for participants on insulin will include a FFSG of ≥110 mg/dL (6.1 mmol/L) in addition to HbA1C ≥7.0% (53 mmol/mol) at WK12. Participants will continue to receive placebo to ERTU 5 mg and placebo to ERTU 15 mg QD from WK24 to WK54. Participants will remain on their background metformin with/without insulin treatment throughout the study.
3383003|NCT04016805|Experimental|ublituximab + umbralisib + ibrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~ibrutinib: dose tolerated by subject; to be administered daily"
3383004|NCT04016805|Experimental|ublituximab + umbralisib + venetoclax|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~venetoclax: dose tolerated by subject; to be administered daily"
3383005|NCT04016805|Experimental|ublituximab + umbralisib + acalabrutinib|"ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter~umbralisib: 800 mg; to be administered daily~acalabrutinib: previously tolerated dose; to be administered every 12 hours"
3383006|NCT04010851|Experimental|Peer co-led educational group|The intervention delivered in a group format is added to treatment as usual. After the parents participate in the one day-intervention, they can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence.
3383007|NCT04010851|Other|Control group|The control goup will receive treatment as usual.
3383008|NCT04002362|Experimental|Children receiving triamcinolone acetonide|Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks.
3383009|NCT03993132||Patients with type 2 diabetes|
3383010|NCT03992352||Age 60+ with planned HCT for Hematologic Malignancy|Subjects 60 years or older with a planned allogeneic transplantation for a hematologic malignancy.
3383011|NCT03979495|No Intervention|Standard of care|standard of care
3383012|NCT03979495|Active Comparator|IT platform|Access to an IT platform for visit-based reminders about overdue abnormal cancer screening test results
3383013|NCT03979495|Active Comparator|IT platform with reminders|Access to an IT platform that will deliver both visit based and between visit reminders about abnormal cancer screening test results.
3383014|NCT03979495|Active Comparator|IT platform and patient navigation|the IT platform available in Arm 3 and navigation to help with scheduling and to address social barriers to care.
3383015|NCT03975647|Experimental|Tucatinib + T-DM1|Tucatinib + T-DM1
3383016|NCT03975647|Active Comparator|Placebo + T-DM1|Placebo + T-DM1
3383017|NCT03973151|Experimental|HL-085|HL-085 will be administered as BID with specified dose.
3383018|NCT03966989|Experimental|Performance Feedback|Feedback offline either via email or text
3383019|NCT03966989|No Intervention|Control|Standard practice control
3383020|NCT03963518||Control|chemotherapy
3383021|NCT03963518||Experimental|immune-checkpoint inhibitor
3383023|NCT03944772|Experimental|Module 1: Osimertinib + Savolitinib|The patients in this group will receive osimertinib taken in combination with savolitinib
3383024|NCT03944772|Experimental|Module 2: Osimertinib + Gefitinib|The patients in this group will receive osimertinib taken in combination with gefitinib
3383025|NCT03944772|Experimental|Module 3: Osimertinib + Necitumumab|The patients in this group will receive osimertinib taken in combination with necitumumab
3383026|NCT03944772|Experimental|Module 4: Carboplatin + Pemetrexed + Durvalumab)|The patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
3383027|NCT03944772|No Intervention|Observational Cohort: No study drug|"Patients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice.~With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib."
3383028|NCT03944772|Experimental|Module 5: Osimertinib + Alectinib|The patients in this group will receive osimertinib taken in combination with alectinib
3383029|NCT03944772|Experimental|Module 6: Osimertinib + Selpercatinib|The patients in this group will receive osimertinib taken in combination with selpercatinib
3383030|NCT03944772|Experimental|Module 7: Etoposide + Durvalumab + Carboplatin or Cisplatin|The patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.
3383031|NCT03944772|Experimental|Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.|The patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).
3383032|NCT03944772|Experimental|Module 9: Osimertinib + Selumetinib|The patients in this group will receive osimertinib taken in combination with selumetinib
3383035|NCT03940690|Experimental|Anti-VEGF injections (bevacizumab)|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9
3383036|NCT03940690|Active Comparator|Arm : laser only|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
3383037|NCT03933449|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of every 21-day (3-week) cycle for up to 35 administrations (up to approximately 2 years).
3383038|NCT03933449|Active Comparator|Chemotherapy|Participants receive Investigator's choice of chemotherapy: paclitaxel 80-100 mg/m^2 IV on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR docetaxel 75 mg/m^2 IV on Day 1 of every 21-day (3-week) cycle, OR irinotecan 180 mg/m^2 IV on Day 1 of every 14-day (2-week) cycle (up to approximately 2 years).
3383043|NCT03924466|Experimental|Cancer patients|"Cohort 1: locally advanced or metastatic breast cancer patients~Cohort 2: Patients with locally advanced, unresectable, or metastatic cancer disease of breast with low, intermediate or high HER2-expression, salivary gland; gastric body or gastro-esophageal junction; endometrium; uterus; lung; biliary tract; gallbladder; pacreas; colorectum; urothelium; prostate; other solid with intermediate or high HER2-expression~Cohort 3: Patients with local or locally advanced HER2-+ breast carcinoma, who are planned for neo-adjuvant treatment prior to surgery, and who are suspected for axillary lymph node invasion."
3383044|NCT03923790|Experimental|STOP model|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet and a blue tooth enabled BP monitor with an iPad. A video telehealth visit occurs 7 days after discharge attended by a nurse practitioner (NP) or MD , social worker (SW), and pharmacist. The NP and pharmacist review the BP data to determine the need for medication adjustment. The SW assesses the need for resources. BP is reviewed via an online portal every 2 weeks until average BP is < 130/80mmHg, then monthly. Uncontrolled BP prompts a call from the pharmacist to discuss medication adherence and titration. Subsequent video telehealth visits occur 1 month, 3 months, and 5 months after enrollment.
3383045|NCT03923790|Active Comparator|Usual Care|Pharmacist evaluates patient prior to discharge and a nurse navigator contacts patient 72 hours after discharge. Patient receives educational packet.
3383048|NCT03919162|Experimental|600 mg|First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID
3383049|NCT03919162|Experimental|300 mg|First 4 weeks 150 mg BID, week 5-24 300 mg BID
3383050|NCT03919162|Experimental|150 mg|24 weeks on 150 mg BID
3383051|NCT03919162|Placebo Comparator|Placebo|
3383060|NCT03901144|Experimental|Test cream (2% urea/20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
3383061|NCT03901144|Active Comparator|Reference cream 1: Miniderm® 20% cream (20% glycerol)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
3383062|NCT03901144|Active Comparator|Reference cream 2: Diprobase® cream (cream without humectants)|Topical cream, 1 Finger Tip Unit per treatment area on the lower volar forearms twice daily for 28 days
3383063|NCT03901144|No Intervention|Untreated|Untreated skin area on the volar forearm
3383064|NCT03897127|Active Comparator|Standard arm|
3383065|NCT03897127|Experimental|Investigational arm|
3383072|NCT03891355|Experimental|Carfilzomib (K) plus Lenalidomide (R) and Dexamethasone (D)|"Carfilzomib (K) (maximum period of treatment= 24 cycles)~K on days 1-2, 8-9, 15-16 during cycles 1-12. The dosage of K will be 20 mg/m2 10' iv infusion on day 1 and 2 during cycle 1 and then 27 mg/m2 10' iv infusion thereafter;~K: on days 1-2, 15-16 during cycles 13-24. The dosage of K will be 27 mg/m2 10' iv infusion. Lenalidomide (R) (maximum period of treatment= 24 cycles)~R: 25 mg/daily on day 1 to 21 of a 28 days course; for patients with creatinine clearance ≥ 30 mL/min but < 50 mL/min the dosage of R will be 10 mg/daily on day 1 to 21 of a 28 days course.~Dexamethasone (D) (maximum period of treatment= 24 cycles) PO or IV D on days 1-2, 8-9, 15-16, 22-23. The dosage will be 20 mg between 30 minutes and 4 hours prior to K. For patients older than 75 years the dosage may be reduced at 10 mg."
3383075|NCT03861273|Experimental|PF-06838435/ fidanacogene elaparvovec|
3383076|NCT03859336|Experimental|Transdermal Neuromodulation Stimulation|"Day 1 of Transdermal Neuromodulation Stimulation (TENS) is a one-day sham stimulation, consisting of: 30 seconds of sensation in which amplitude is increased up to the threshold of salient sensation, followed by 19 minutes of no stimulation (device is turned off), followed by 30 more seconds of salient stimulation. Day 1 is used to exclude those who cannot tolerate study procedures and placebo responders; it will also serve as baseline for anxiety measures. TENS treatment begins one day after sham, and lasts 3 days with 20 minutes of stimulation per day. One day following open label treatment all participants will once again receive sham stimulation following the same procedures utilized at Day 1.~Treatment amplitude is adjusted for each participant, in which the stimulation will be administered just below the participant's sensation threshold. Amplitude from the TENS device does not exceed 20mA. Frequency will be at 300hz."
3383077|NCT03850067|Experimental|CC-90011 in combination with Cisplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated.
3383078|NCT03850067|Experimental|CC-90011 in combination with Carboplatin and Etoposide|During the Chemotherapy Treatment Period, the dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design, administered orally Days 1 and 8, in combination with cisplatin intravenous (IV) 75 mg/m2, Day 1, and etoposide iv 100 mg/m2 on Days 1, 2, and 3, for 4 cycles of 21 days each. Subjects completing the chemotherapy and being responders as per RECIST 1.1 will enter the Maintenance Treatment Period. Subjects completing 6 cycles of maintenance treatment subject will be treated only with CC-90011 at RP2D (60 mg) and continuing on CC-90011 are only required to have clinic visits/assessments performed on Day 1 (± 3 days) of each subsequent cycle (Cycles 6 and higher) unless more frequent visits are clinically indicated
3383079|NCT03850067|Experimental|Nivolumab combination|"When the RP2D of CC-90011 in combination with cisplatin or carboplatin and etoposide is determined, the combination of CC-90011 at RP2D with cisplatin or carboplatin and etoposide plus nivolumab IV 240 mg Day 1 of each chemotherapy cycle, will be explored. For CC-90011 in combination with chemotherapy and nivolumab, the starting dose will be the RP2D of CC-90011 in combination with chemotherapy.~A maintenance therapy will be given to subjects responding to the combination of CC-90011 with chemotherapy or to chemotherapy with nivolumab, as per RECIST 1.1. These subjects will receive 60 mg or 40 mg (in case of combination with nivolumab) of CC-90011 orally once weekly on Days 1, 8, 15, and 22, during cycles of 28-day each and, in the case of the combination with nivolumab, nivolumab IV 480 mg on Day 1 during cycles of 28-day each."
3383084|NCT03828448|Experimental|ublituximab + umbralisib|"Ublituximab: 900 mg administered through Cycle 12, via IV infusion~Umbralisib: 800 mg administered through Cycle 24, via daily oral tablet"
3383091|NCT03818971|Experimental|alcohol consumption with alcohol use disorder (AUD)|subjects with regular alcohol consumption with AUD according to the DSM 5 without any other substance use disorder (except alcohol) without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
3383092|NCT03818971|Other|alcohol consumption without alcohol use disorder|subjects with regular alcohol consumption without AUD according to the DSM 5 without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
3383093|NCT03818971|Other|no alcohol consumption|subjects without alcohol consumption without any other substance use disorder without psychiatric, neurologic or ophthalmologic disease in progress with a negative drug check and Breathalyzer the day of the inclusion - only one visit is planned for this study : an electroretinogram will be realized
3383094|NCT03817463||Patients with T2DM|
3383099|NCT03809572|Experimental|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy (MBCT) adapted for pregnancy includes 8 sequential, weekly 2-hour group sessions co-led by two master's level therapists. Sessions include: 1) introducing new mindfulness skills through in-session practice, 2) reviewing mindfulness practices and troubleshooting barriers to practice, 3) reinforcing mindfulness skills through in-session practice and debriefing, 4) learning about how thoughts influence feelings and behaviors (not all sessions), 5) providing psychoeducational information to support skills, and 6) encouraging the establishment of social support.
3383100|NCT03809572|No Intervention|Treatment as usual (TAU)|All participants will receive routine prenatal care from an identified medical provider, which they have initiated on their own. They will be able to engage in any services recommended by their primary medical provider or that they voluntarily initiate. For ethical reasons, they are not prohibited from engaging in any type of therapeutic, complementary, or medication treatment (after enrollment). The TAU group will be offered a delayed treatment option, after the 6 month follow-up. This will be a 2 hour mindfulness psychoeducation session, offered between 6 and 9 months postpartum. Several core mindfulness concepts included in the full MBCT curriculum will be taught and participants will complete several brief mindfulness activities.
3383101|NCT03804996|Experimental|TG-1801|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. Subjects who experience disease progression after completing 6 months of single agent TG-1801 will be eligible for TG-1801 single-agent re-treatment at the discretion of the investigator.
3383102|NCT03804996|Experimental|TG-1101|Arm Description: TG-1801 will be administered once every 4 weeks (28-day) cycles. To explore the safety of TG-1801 in combination with ublituximab will be explored at doses below and up to the RP2D. TG-1801 intrapatient dose escalation will not be permitted in combination therapy.
3383103|NCT03804879|Experimental|LMB763|LMB763 capsules
3383104|NCT03804879|Placebo Comparator|Placebo|Placebo comparator
3383105|NCT03803774|Experimental|Treatment (IMRRT, birinapant)|Beginning on day 1, patients undergo IMRRT 5 days a week (Monday-Friday). Patients also receive birinapant IV over 30 minutes on days 2 and 9 of each cycle. Treatment repeats every 3 weeks for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
3383106|NCT03798093|Active Comparator|Umbilical Cord Milking|The delivering practitioner will place the newborn below the level of the incision (at the edge of the table) at C/S and a second team member will milk the cord four times. For vaginal delivery, the delivering obstetrician, midwife or perinatal provider will hold the infant against their body or place the infant on the mother's abdomen and the cord will be milked either four times by the obstetrical provider or by a second team member. For the cord milking procedure, the obstetrical provider will milk the entire length of umbilical cord over two seconds, repeating three additional times as described previously. This time is not significantly different from the time for ECC as we have demonstrated in our previous trials.
3383107|NCT03798093|Active Comparator|Early Cord Clamping|This will occur by clamping the umbilical cord as soon as possible. Since both ECC and UCM will occur after a brief assessment, it is important to note that the cord clamping time will be longer than in previously conducted preterm trials (average 20 seconds) which performed the intervention on all subjects regardless of whether or not they were vigorous. In all cases, the cord clamping time will be documented to ensure consistency.
3383111|NCT03788811||Control subjects|Control subjects who do not have a lifetime diagnosis of SZ, BP, other psychotic disorder, recurrent mood disorder or have not met criteria for a major depression episode in the last 12 months according to DSM-V criteria.
3383112|NCT03788811||Patients with schizophrenia (SZ)|Patient with a diagnosis of schizophrenia for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
3383113|NCT03788811||Patients with bipolar disorder Type I (BP1)|Patient with a diagnosis of bipolar disorder Type 1 for at least 12 months, that resulted in a diagnosis with a Structured Clinical Interview for DSM-5 (SCID-5-CT).
3383114|NCT03781986|Experimental|APG-115 monotherapy|APG-115 will be administered in an open label fashion until progression, intolerance, or patient preference.
3383115|NCT03781986|Experimental|APG-115 + Carboplatin [terminated]|APG-115 and Carboplatin will be administered in an open label fashion until progression, intolerance, or patient preference. [Phase 1 was terminated early and this arm was discontinued. An MTD was not established during Phase 1.]
3383116|NCT03778073|Experimental|Cohort A|Cosibelimab (TG-1501) single-agent
3383117|NCT03778073|Experimental|Cohort B|Cosibelimab + Ublituximab + Bendamustine combination
3383118|NCT03778073|Experimental|Cohort C|Cosibelimab + Ublituximab + Bendamustine combination
3383119|NCT03770741|Experimental|Monitoring of cerebral oxygenation|Modify cardio-respiratory support to avoid cerebral hypoxia
3383120|NCT03770741|Other|Treatment as usual|Treatment according local guidelines and practices.
3383121|NCT03768063|Experimental|Atezolizumab|Participants will continue to receive atezolizumab monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol, until disease progression, loss of clinical benefit as judged by the investigator, death, withdrawl of study consent, unacceptable toxicity, pregnancy, patient non-compliance, or study termination by the Sponsor, whichever occurs first.
3383122|NCT03766035||Consented, enrolled PSC patients undergoing ERCP + SpyGlass|Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician.
3383125|NCT03765632|Experimental|Gene Therapy|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
3383128|NCT03761173||FlowTriever|Mechanical thrombectomy for pulmonary embolism
3383129|NCT03761173||Conservative Therapy Sub-Study|Anticoagulation medication for pulmonary embolism (as directed by treating physician)
3383130|NCT03755687|Experimental|Art Therapy Intervention|Standardized mixed media art therapy directives (e.g. drawing/painting/collaging within a circle)
3383131|NCT03751137||Breast Feeding|Infants who, when enrolled, are exclusively breast feeding.
3383132|NCT03751137||Formula Feeding|Infants who, when enrolled, are exclusively formula feeding.
3383133|NCT03745924||Patients with haemophilia B|Patients with haemophilia B without current inhibitors
3383134|NCT03745820|Experimental|BIIB104 0.5 mg|Participants will receive 0.5 mg of BIIB104 twice a day, orally, for 12 weeks.
3383135|NCT03745820|Experimental|BIIB104 0.15 mg|Participants will receive 0.15 mg of BIIB104 twice a day, orally, for 12 weeks.
3383136|NCT03745820|Placebo Comparator|Matching Placebo|Participants will receive matching placebo twice a day, orally, for 12 weeks.
3383137|NCT03745287|Experimental|CTX001|CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Subjects will receive a single infusion of CTX001 through a central venous catheter.
3383138|NCT03739372|Experimental|Newly diagnosed HGG (Stratum A)|Children and young adults with newly diagnosed HGG receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
3383139|NCT03739372|Experimental|Diffuse midline HGG (Stratum B)|Children and young adults with diffuse midline high grade gliomas receive an individualized treatment plan. Each treatment is different and depends on what the Specialized Tumor Board recommends depending on the molecular profile of the patient's tumor.
3383140|NCT03737812|Placebo Comparator|Placebo|Participants randomized to receive double-blind placebo by intravenous infusion.
3383141|NCT03737812|Experimental|Elezanumab Dose 1|Participants randomized to receive double-blind elezanumab Dose 1 by intravenous infusion.
3383142|NCT03737812|Experimental|Elezanumab Dose 2|Participants randomized to receive double-blind elezanumab Dose 2 by intravenous infusion.
3383143|NCT03737643|Active Comparator|Arm 1|Platinum-based chemotherapy in combination with bevacizumab and durvalumab placebo (saline IV infusion) followed by maintenance bevacizumab, durvalumab placebo (saline IV infusion) and olaparib placebo (tablets).
3383144|NCT03737643|Experimental|Arm 2|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib placebo.
3383145|NCT03737643|Experimental|Arm 3|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib.
3383146|NCT03737643|Experimental|tBRCAm cohort|Platinum-based chemotherapy in combination with bevacizumab and durvalumab followed by maintenance bevacizumab, durvalumab and olaparib. Bevacizumab is optional according to local practice.
3383147|NCT03736655|Experimental|Interposition supraciliary implant|Any patients corresponding to inclusion / exclusion criteria
3383148|NCT03735121|Experimental|Atezolizumab (Part 2)|Atezolizumab
3383149|NCT03735121|Experimental|Cohort 1: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
3383150|NCT03735121|Experimental|Cohort 2: Atezolizumab+rHuPH20 (Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
3383151|NCT03735121|Experimental|Cohort 3: Atezolizumab+rHuPH20(Part 1)|Atezolizumab+rHuPH20, followed by Atezolizumab
3383152|NCT03735121|Experimental|Atezolizumab + rHuPH20 (Part 2)|Atezolizumab + rHuPH20
3383153|NCT03734107|Experimental|PREP-DC Intervention|50 participants will be randomized to the Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC) intervention. Participants will complete 3 intervention sessions with study interventionists and will receive text messages and other study resources during the active intervention period (3 months).
3383154|NCT03734107|No Intervention|Standard Care Comparison|50 participants will be randomized to standard care and will participate in regular diabetes clinic visits and receive standard materials on the transition to adult diabetes care, as they would have done without participation in this study.
3383157|NCT03729453||Intraoperative Pancreatoscopy|All subjects will undergo the intraoperative pancreatoscopy with SpyGlass procedure.
3383158|NCT03725345|Experimental|Alcohol Group|Participants will consume an alcoholic beverage consisting of a 1:5 ratio of 95% ethyl alcohol and orange juice
3383159|NCT03725345|Placebo Comparator|Placebo Group|Participants will consume a placebo beverage of orange juice
3383163|NCT03703297|Experimental|Durvalumab + Placebo|Durvalumab monotherapy: Durvalumab (1500 mg intravenous [IV]) q4w in combination with placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with placebo saline solution.
3383164|NCT03703297|Experimental|Durvalumab + Tremelimumab|Durvalumab in combination with tremelimumab: Durvalumab (1500 mg IV) q4w in combination with tremelimumab (75 mg IV) q4w for up to 4 doses/cycles each, followed by durvalumab 1500 mg q4w. The first durvalumab monotherapy 1500 mg dose q4w will be 4 weeks after the final dose of durvalumab in combination with tremelimumab.
3383165|NCT03703297|Placebo Comparator|Placebo + Placebo|Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
3383174|NCT03695250|Experimental|Treatment (BMS-986205 and nivolumab)|Patients receive IDO1 inhibitor BMS-986205 PO QD on days 1-14 and nivolumab IV over 30 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
3383175|NCT03685942|Experimental|active light therapy|Light therapy 1000 lux daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m., during 8 weeks in addition to usual treatment
3383176|NCT03685942|Placebo Comparator|placebo light therapy|People receive usual treatment and use a placebo light therapy device (175 lux) daily for 30 minutes, as soon as possible after awaking, in preference between 7 and 9 a.m. during 8 weeks.
3383177|NCT03681392|Experimental|Once daily then twice daily|One 6.5 cc scoop of S4S once a day for 7 days, then one 6.5 cc scoop of S4S twice a day for 7 days
3383178|NCT03681392|Experimental|Twice daily then once daily|One 6.5 cc scoop of S4S twice a day for 7 days, then one 6.5 cc scoop of S4S once a day for 7 days
3383179|NCT03671590|Experimental|Arm 1|TG-1701 oral daily dose
3383180|NCT03671590|Experimental|Arm 2|TG-1701 + Ublituximab + Umbralisib
3383181|NCT03663933|Experimental|1/RIC Arm|Reduced Intensity Conditioning Arm
3383182|NCT03663933|Experimental|2/IOC Arm|Immunosuppression Only Conditioning Arm
3383183|NCT03662386||Patients with suspicion of hereditary retinal dystrophy|
3383184|NCT03659136|Experimental|Xentuzumab/everolimus/exemestane|
3383185|NCT03659136|Placebo Comparator|Placebo/everolimus/exemestane|
3383187|NCT03648541|Experimental|All Patients|1 arm solution for injection Spesolimab will be used for all patients. Those who did not respond to previous induction treatment or experienced disease flare will need i.v. re-induction treatment also
3383188|NCT03645928|Experimental|Cohort 1A|LN-144 therapy in combination with pembrolizumab in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma with ≤ 3 prior lines of systemic therapy, excluding checkpoint inhibitors (CPI).
3383189|NCT03645928|Experimental|Cohort 1B|LN-145-S1 therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is proto-oncogene B-Raf (BRAF) V600 mutation positive, patients must have received a BRAF inhibitor or BRAF inhibitor with or without a mitogen-activated extracellular signal-related kinase (MEK) inhibitor.
3383190|NCT03645928|Experimental|Cohort 1C|LN-144 Generation 3 (Gen 3) therapy as a single agent in patients with Stage IIIC or Stage IV unresectable or metastatic melanoma, who have previously received systemic therapy with a PD-1 blocking antibody. If the tumor is BRAF V600 mutation positive, patients must have received BRAF inhibitor with or without a MEK inhibitor.
3383191|NCT03645928|Experimental|Cohort 2A|LN-145 therapy in combination with pembrolizumab in patients with advanced, recurrent, or metastatic HNSCC, with ≤ 3 prior lines of systemic therapy, excluding CPIs.
3383192|NCT03645928|Experimental|Cohort 3A|LN-145 therapy in combination with pembrolizumab in patients with locally advanced or metastatic (Stage III or Stage IV) non-small-cell lung cancer (NSCLC) with ≤ 3 prior lines of systemic therapy, excluding CPIs or ≤ 4 prior lines if 2 or more of the lines are TKI therapy for those with tumors that harbored actionable mutations (eg, EGFR, ALK, ROS).
3383193|NCT03645928|Experimental|Cohort 3B|LN-145 therapy as a single agent in patients with Stage III or Stage IV NSCLC, who have previously received 1-3 lines of prior systemic therapy. Patients with known oncogene drivers (eg, EGFR, ALK, ROS) who have mutations that are sensitive to targeted therapies are not required to have received prior systemic therapy with CPIs.
3383194|NCT03645928|Experimental|Cohort 3C|LN-145 therapy in combination with ipilimumab and nivolumab in patients with Stage III or Stage IV NSCLC who have previously received 1 line of approved CPI monotherapy as the only prior line of systemic therapy.
3383195|NCT03632941|Active Comparator|VRP-HER2 Vaccine|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)
3383196|NCT03632941|Active Comparator|Pembrolizumab|5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
3383197|NCT03632941|Experimental|VRP-HER2 Vaccine + Pembrolizumab|VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total (Cycle 1: Day 1 and Day 15 Cycle 2: Day 8)+ 5 administrations of Pembrolizumab 200 mg every 3 weeks for 5 total IV infusions (Day 1 of each 3 week cycle x 5 cycles)
3383198|NCT03629730|Experimental|High dose|Will receive the greatest duration of coordination intervention training.
3383199|NCT03629730|Experimental|Intermediate dose|Will receive a moderate duration of coordination intervention training.
3383200|NCT03629730|Experimental|Low dose|Will receive a short duration of coordination intervention training.
3383201|NCT03629730|Active Comparator|Active control|Will perform the same number and duration of physical exercises as the High Dose group, but while moving one body segment at a time.
3383202|NCT03621592|Experimental|Cutimed® Sorbact®|Participants in this group will receive the Cutimed Sorbact intervention for 6 weeks.
3383203|NCT03621592|Active Comparator|Acticoat®|Participants in this group will receive the Acticoat intervention for 6 weeks.
3383204|NCT03616912|Experimental|Baricitinib High Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3383205|NCT03616912|Experimental|Baricitinib Low Dose|Baricitinib administered orally. Placebo administered orally to maintain the blind.
3383206|NCT03616912|Placebo Comparator|Placebo|Placebo administered orally.
3383209|NCT03604978|Experimental|Cohort A (nivolumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes on day 1. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
3383210|NCT03604978|Experimental|Cohort B (nivolumab, ipilimumab, radiosurgery)|Patients receive nivolumab IV over 30 minutes every 2 weeks for 12 doses (6 months) and then every 4 weeks for additional 6 months. Patients also receive ipilimumab IV over 90 minutes on day 1. Treatment with ipilimumab repeats every 6 weeks for 4 doses in the absence of disease progression or unacceptable toxicity. Patients undergo multi-fraction stereotactic radiosurgery on days 1, 3, and 5.
3383211|NCT03604185|Experimental|Choir Singing Group|Choir participants will take part in weekly two-hour group choral sessions over the course of fourteen weeks, during which time they will receive pitch training and vocal direction. In addition to the weekly group choir sessions, participants will be offered optional individual online musical and vocal training exercises (up to one hour weekly).
3383212|NCT03604185|Active Comparator|Music Appreciation Group|Participants assigned to the music appreciation class will take part in a fourteen week course which will emphasize analytic listening to musical excerpts, which will match the choir class in terms of duration, homework demands, and instructor - both classes will be taught by the same person.
3383213|NCT03604185|No Intervention|Do-Nothing Control Group|The do-nothing control group will not receive any active training.
3383214|NCT03603912|No Intervention|Control|Written educational literature on healthy eating and exercise guideline
3383215|NCT03603912|Experimental|Metformin|Metformin ER up to 750 mg twice daily
3383216|NCT03603912|Experimental|Lifestyle/Risk Factor Modification|Lifestyle/Risk Factor Modification (LRFM): Diet/nutrition, exercise, and risk factor modification
3383217|NCT03603912|Experimental|Metformin + LRFM|Metformin ER up to 750 mg twice daily + Lifestyle/Risk Factor Modification (LRFM) diet/nutrition, exercise, and risk factor modification
3383218|NCT03603912|No Intervention|No Atrial Fibrillation|Written educational literature on healthy eating and exercise guideline
3383223|NCT03594955|Experimental|SAR440234|Participants received SAR440234 intravenous (IV) injection at a dose of 1 nanogram per kilogram (ng/kg) once weekly (except first week in which drug was administered 2 times: Day 1 and 4) i.e., on Days 1, 4, 8, 15, 22, 29 and 36 in a single Cycle of 42 days. Due to early study termination, no further treatment cycles were conducted.
3383224|NCT03587311|Experimental|GROUP I (anetumab ravtansine, bevacizumab)|Patients receive anetumab ravtansine IV over 1 hour on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3383225|NCT03587311|Experimental|GROUP II (paclitaxel, bevacizumab)|Patients receive paclitaxel on days 1, 8, 15, and 22 and bevacizumab over 30-90 minutes IV on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
3383226|NCT03581123|Experimental|Supported-Self management (SSM)|Supported-Self management
3383227|NCT03581123|Experimental|Spinal Manipulation Therapy (SMT)|Spinal Manipulation Therapy
3383228|NCT03581123|Experimental|SMT + SSM|Spinal Manipulation Therapy + Supported Self-Management
3383229|NCT03581123|Active Comparator|Standard Medical Care (SMC)|Standard Medical Care
3383230|NCT03577301|Active Comparator|Clinic-based Delivery|Participants will receive the intervention in person following HIV counseling and testing. The intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
3383231|NCT03577301|Active Comparator|Remote Delivery|Participants will receive the intervention by remote delivery following HIV counseling and testing. Just as the clinic-based participants, he intervention involves completion of the 4 YMHP sessions and the delivery of pre-exposure prophylaxis (PrEP) information and navigation services to interested participants. This arm is closed to enrollment.
3383232|NCT03577301|Active Comparator|Multi-modal Delivery|A 4 session MI intervention. Session 1 is always delivered in person immediately after baseline. Session 2-4 can be delivered in person or remotely based upon youth preference. This arm is open to enrollment as of 11/15/2019.
3383233|NCT03577301|No Intervention|Treatment as Usual|Treatment as usual control = individual HIV testing with referrals and link age to care as provided by the sites under routine circumstances. This arm is open to enrollment as of 11/15/2019.
3383234|NCT03574389|Experimental|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|"Participants in cohort 1 will receive each dose of 13vPnC in months 2, 4 and 6, and then a booster dose during months 12-15.~Participants in cohort 2 will receive first dose dose 13vPnC at the age of months 7(included) to months 12 (less than months 12), and the second dose will be given at least 28 days after first dose, and the third dose will be months 12 to 15 (and at least 56 days after the second dose).~Participants in cohort 3 will receive the first dose of 13vPnC during 1 (included) to 2 years (less than 2 years of age) of age, and the second dose will be given at least 56 days after first dose.~Participants in cohort 4 will receive only one dose at the age of 2 (included) to 6 (less than 6 years of age) years of age."
3383235|NCT03574389|Active Comparator|Haemophilus influenzae type b (Hib)|"No participants in cohort 1 will receive Hib vaccine.~Participants in cohort 2 will receive the first dose of Hib vaccine at the age of months 7 (included) to 12 (less than 12 months), and the second dose will be given at least 28 days after the first dose, the third dose will following local practice or national recommendation at the discretion of the investigator.~Participants in cohorts 3 and 4 will receive the only one dose Hib vaccine at the age of 1 (included) to 6 (less than 6 years) years of age."
3383236|NCT03569761|Experimental|Decision Aid Video Intervention|Participants randomized to the intervention group will view the AI culturally-adapted CRC screening decision aid in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer.
3383237|NCT03569761|Active Comparator|Control|Participants randomized to the control group will view an attention-control video about food safety in a private room at a RHCC clinic. The video will be viewed on an electronic tablet or laptop computer. The investigators chose the attention-control video so that the structure of the control arm mirrors the intervention arm. The food safety topic was chosen to provide information that is reasonably salient to the control arm participants but that would not be likely to affect encounters with healthcare providers.
3383238|NCT03561701|Experimental|Oteseconazole (VT-1161) 150mg capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
3383239|NCT03561701|Placebo Comparator|Placebo capsule|Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
3383240|NCT03558152|Experimental|Arm 1a: UTTR1147A Dose Level 1 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
3383241|NCT03558152|Experimental|Arm 1b: UTTR1147A Dose Level 1 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 1 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
3383242|NCT03558152|Experimental|Arm 2a: UTTR1147A Dose Level 2 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
3383243|NCT03558152|Experimental|Arm 2b: UTTR1147A Dose Level 2 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 2 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
3383244|NCT03558152|Experimental|Arm 3a: UTTR1147A Dose Level 3 (Part A) + UTTR1147A (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A maintenance dose and Vedolizumab Placebo."
3383245|NCT03558152|Experimental|Arm 3b: UTTR1147A Dose Level 3 (Part A) + Placebo (Part B)|"Part A: UTTR1147A dose level 3 and Vedolizumab Placebo.~Part B: UTTR1147A Placebo and Vedolizumab Placebo."
3383246|NCT03558152|Active Comparator|Arm 4: Vedolizumab|Parts A and B: Vedolizumab and UTTR1147A Placebo.
3383247|NCT03558152|Placebo Comparator|Arm 5: Placebo|Parts A and B: UTTR1147A Placebo and Vedolizumab Placebo.
3383248|NCT03549000|Experimental|NZV930 Monotherapy|Single Agent NZV930
3383249|NCT03549000|Experimental|NZV930 with PDR001 Doublet Therapy|Combination of NZV930 with PDR001
3383250|NCT03549000|Experimental|NZV930 with NIR178 Doublet Therapy|Combination of NZV930 with NIR178
3383251|NCT03549000|Experimental|NZV930 with NIR178 & PDR001 Triplet Therapy|Combination of NZV930 with NIR178 and PDR001
3383252|NCT03548246|Placebo Comparator|Placebo|Daily placebo, plus usual maintenance treatment with hydrocortisone and fludrocortisone.
3383253|NCT03548246|Experimental|Abiraterone acetate|Abiraterone acetate administered daily in dose determined in Phase 1, plus usual maintenance treatment with hydrocortisone and fludrocortisone..
3383254|NCT03540706|Experimental|Care with C-reactive protein assay in micro method|During a visit to the general practitioner for a clinical suspicion of respiratory infection, the doctor will practice a C-reactive protein assay in micro method. He will prescribe antibiotics according to the result of the dosage
3383255|NCT03540706|No Intervention|Care without C-reactive protein assay in micro method|Simple management of a patient coming for a suspicion of respiratory infection without dosage of the C-reactive protein in micro method
3383259|NCT03532542|Experimental|Casimersen|Patients amenable to exon 45 skipping who have completed a clinical trial evaluating casimersen will receive open-label casimersen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
3383260|NCT03532542|Experimental|Golodirsen|Patients amenable to exon 53 skipping who have completed a clinical trial evaluating golodirsen will receive open-label golodirsen intravenous (IV) infusions, weekly, at 30 mg/kg for up to 144 Weeks.
3383261|NCT03529799|Experimental|Injured Participants|Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles
3383262|NCT03529799|Active Comparator|Uninjured Participants|Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles
3383263|NCT03528642|Experimental|Treatment (telaglenastat, temozolomide, RT)|Patients receive telaglenastat PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
3383264|NCT03527277|Experimental|Naturally-sweetened orange juice|Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
3383265|NCT03527277|Active Comparator|Sugar-sweetened beverage|Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
3383266|NCT03525808|Experimental|AXIOS|Patients will receive the AXIOS stent for the treatment of walled-off pancreatic necrosis.
3383267|NCT03521596||Patient enrolled|Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
3383271|NCT03519464|Other|ICL and Healthy Volunteers|Biological/Vaccine
3383272|NCT03519295|Experimental|ARM A - mDCF + Atezolizumab|"MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.~Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks"
3383273|NCT03519295|Active Comparator|ARM B - mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks.
3383276|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383277|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383278|NCT03516981|Experimental|GEP low TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
3383279|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383280|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383281|NCT03516981|Experimental|GEP low TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
3383282|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383283|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383284|NCT03516981|Experimental|GEP hi TMB low: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
3383285|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Quavonlimab|Participants receive pembrolizumab 200 mg Q3W plus quavonlimab at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383286|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Favezelimab|Participants receive pembrolizumab 200 mg Q3W plus favezelimab 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years).
3383287|NCT03516981|Experimental|GEP hi TMB hi: Pembrolizumab + Lenvatinib|Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity.
3383288|NCT03507673||Progynova/Dydrogesterone|
3383289|NCT03507673||Spontaneous cycle|
3383290|NCT03507673||Progynova/Crinone|
3383291|NCT03507673||Others Medication|
3383292|NCT03506971|Experimental|Participants|"As part of this research, families will benefit from~pediatric nurse's interventions : home visits by a pediatric nurse who will center around three times: a time of observation of the development and progress of the baby, a time for play with the baby and a time to listening the parents.~psychologist's evaluation and joint home visits : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
3383293|NCT03506971|Other|Control|"psychologist's evaluation : home visits by the coordinating psychologist to evaluate three areas: child development, parenthood and parent-child interaction."
3383299|NCT03493945|Experimental|Arm 1.1|M7824 + N-803
3383300|NCT03493945|Experimental|Arm 2.1A|M7824 + BN-Brachyury
3383301|NCT03493945|Experimental|Arm 2.1B|M7824 + BN-Brachyury
3383302|NCT03493945|Experimental|Arm 2.2A|M7824 + BN-Brachyury + N-803
3383303|NCT03493945|Experimental|Arm 2.2B|M7824 + BN-Brachyury + N-803
3383304|NCT03493945|Experimental|Arm 2.3A|M7824 + BN-Brachyury + N-803 + Epacadostat
3383305|NCT03493945|Experimental|Arm 2.3B|M7824 + BN-Brachyury + N-803 + Epacadostat
3383306|NCT03492021|Experimental|Adequate Protein_Carbohydrate Post Therapy|Diet Intervention - Adequate Protein (1.0 g/kg/d) - Carbohydrate Post Therapy [AP-CPT]
3383307|NCT03492021|Experimental|Optimal Protein_Protein Post Therapy|Diet Intervention - Optimal Protein (2.0 g/kg/d) - Protein Post Therapy [OP-PPT]
3383315|NCT03462459|Experimental|Vancomycin|125 mg, oral capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
3383316|NCT03462459|Placebo Comparator|Placebo|125 mg placebo capsule by mouth, once daily, for the duration of standard-of-care antibiotic therapy plus 5 days
3383317|NCT03461211|Experimental|Teprotumumab|Eight infusions of teprotumumab every 3 weeks (q3W) for a total of 21 weeks: teprotumumab 10 mg/kg administered on Day 1 and teprotumumab 20 mg/kg administered q3W for the remaining 7 infusions.
3383318|NCT03457948|Experimental|Group I [pembrolizumab, 177Lu DOTATATE]|Patients will be treated with pembrolizumab and intravenous peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate (177Lu-DOTATATE, Lutathera®) for up to four (4) sessions. Patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3) and any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%. Patients who achieve progressive or stable disease response after cycle 4 may receive an additional 4 cycles of pembrolizumab and lutetium Lu-177 DOTATATE in the absence of disease progression or unacceptable toxicity.
3383319|NCT03457948|Experimental|Group II [pembrolizumab, TAE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo Arterial Embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
3383320|NCT03457948|Experimental|Group III [pembrolizumab, yttrium-90 microsphere RE]|Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere Radio Embolization (RE) 3-15 days following the first dose of pembrolizumab.
3383321|NCT03436550||Patients with Chronic Liver Disease|
3383322|NCT03436550||Control Group|
3383323|NCT03432364|Experimental|ST-400 Investigational product|ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene
3383324|NCT03426605|Experimental|LAM-003|Open label LAM-003 at three increasing dose levels of 200, 300 and 450 mg.
3383325|NCT03423628|Experimental|AZD1390 + Radiation Therapy|AZD1390 + Radiation Therapy
3383326|NCT03421340|Other|ERC Arm|After screening examination and confirmed presence of non-complex bile duct stone by image, patients will be randomly assigned by stratified randomization to Electroscopic Retrograde Cholangioscopy (ERC) treatment.
3383327|NCT03421340|Other|DSC Arm|After screening examination and confirmed presence of non-complex bile duct stone by imagine, patients will be randomly assigned by stratified randomization to fluoroscopy/radiation-free direct solitary cholangioscopy (DSC).
3383328|NCT03410927|Experimental|TAS0728|Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial)
3383329|NCT03401099|Active Comparator|Radiofrequency ablation of CTI|Radiofrequency ablation of CTI (cavo-tricuspid isthmus), which is the 'conventional' treatment of atrial flutter
3383330|NCT03401099|Active Comparator|Cryoballoon PVI|Cryoballoon PVI (Pulmonary Vein Isolation), which is the 'novel treatment'
3383331|NCT03396445|Experimental|Arm 1: MK-5890|Participants receive escalating doses of MK-5890 via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3383332|NCT03396445|Experimental|Arm 2: MK-5890 + Pembrolizumab|Participants receive escalating doses of MK-5890 via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years) PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3383333|NCT03396445|Experimental|Arm 3: MK-5890 + Pembrolizumab + Pemetrexed + Carboplatin|Participants receive MK-5890 at the selected dose via IV infusion PLUS pembrolizumab 200 mg via IV infusion PLUS pemetrexed 500 mg/m^2 via IV infusion PLUS carboplatin Area Under the Curve (AUC) 5 mg/mL/min via IV infusion, all given on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3383334|NCT03396445|Experimental|Arm 4: MK-5890 +Pembrolizumab + Nab-paclitaxel|Participants receive MK-5890 at the selected dose via IV infusion PLUS pembrolizumab via IV infusion PLUS nab-paclitaxel 100 mg/m^2 via IV infusion. MK-5890 and pembrolizumab will be given on Day 1 of each 6-week cycle (Q6W). Nab-paclitaxel will be given on a 3-week on (Days 1, 8 and 15)/ 1-week off schedule every 28 days. MK-5890 and pembrolizumab will be given for up to a total of 18 cycles (approximately 2 years).
3383335|NCT03381170|Experimental|Ublituximab|Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E
3383336|NCT03379051|Experimental|Ublituximab + Umbralisib + Venetoclax|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions TGR-1202 oral daily dose Venetoclax oral daily dose
3383337|NCT03379051|Experimental|Ublituximab + Umbralisib + Lenalidomide|Ublituximab at a fixed IV infusion dose Days 1, 8 and 15 followed by maintenance infusions; Umbralisib and Lenalidomide both administered days 1 - 21 of every 28 days
3383342|NCT03374202|Experimental|Group 1|5 x 10 (10) vg/kg IM
3383343|NCT03374202|Experimental|Group 2|5 x 10 (11) vg/kg IM
3383344|NCT03374202|Experimental|Group3|2.5 x 10 (12) vg/kg IM
3383345|NCT03371017|Experimental|Atezolizumab|Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
3383346|NCT03371017|Placebo Comparator|Placebo|Participants will receive Placebo on day 1 of each 3-week treatment cycle
3383348|NCT03364231|Experimental|Umbralisib|Umbralisib oral daily dose
3383349|NCT03354273|Experimental|1|Flurpiridaz PET MPI (following off-study SPECT MPI)
3383350|NCT03328273|Other|Arm A Part 1 and 2|DISCONTINUED (ceralasertib monotherapy)
3383351|NCT03328273|Experimental|Arm B Part 1 and 2|ceralasertib + acalabrutinib in combination
3383353|NCT03323398|Experimental|Arm A: mRNA-2416 Alone|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 for six 28-day cycles.
3383354|NCT03323398|Experimental|Arm B: mRNA-2416 in Combination with Durvalumab|Participants will be administered mRNA-2416 through an intratumoral injection at the applicable dose on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 6 in combination with durvalumab through an intravenous infusion at a fixed dose on Day 1 of Cycles 1 through 6. The duration for each cycle is 28 days.
3383359|NCT03299816|Active Comparator|Self-Shopping DASH group (S-DASH)|The Self-Shopping DASH group will receive printed patient-centered materials on the DASH diet and chronic kidney disease. Participants will also receive $30/week allowance for the purchase of food and drinks of their choosing from a local grocer (Klein's ShopRite stores of Maryland) during the first four months. During the remainder of the study (months 5-12), the participants in this group will be asked to continue to follow the dietary advice provided but will not receive the food allowance.
3383360|NCT03299816|Experimental|Coaching DASH group (C-DASH)|The C-DASH group intervention will be a patient-tailored program, delivered by a study coach that is trained by a dietitian, which emphasizes key self-management behaviors - diet and self-monitoring. This group will receive advice from the study coach and purchase $30 worth of fresh fruits, vegetables, nuts and beans that are high in potassium on a weekly basis for the first four months.
3383363|NCT03282123|Experimental|MDMA-assisted therapy|Three sessions of MDMA-assisted therapy with flexible dose of MDMA from 80 to 120 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
3383364|NCT03276780|Experimental|In vivo|Will receive 4 types of short-acting NRT medication to use in combination with the nicotine patch in each counseling session for four sessions. At the fifth session, participants will select their short acting NRT to use with the patch to make a cessation attempt.
3383365|NCT03276780|Active Comparator|Standard of care|Will receive 4 sessions of behavioral counseling around their smoking. At the fifth session, participants will select their short-acting NRT to use with the nicotine patch based on a product description of each product to make a cessation attempt.
3383366|NCT03275402|Experimental|131I-omburtamab|"One treatment cycle of 131I-omburtamab consists of 1 dose at 50mCi at week 1. For Japan only one treatment cycle of 131I-omburtamab consists of 2 doses: 2mCi at week 1 and 50mCi at week 2. First cycle is initiated right after confirmation of eligibility at week 1. At week 5 (week 6 for Japan) the participant will be evaluated for safety and if eligible, receive a second cycle of 131I-omburtamab.~Secondary efficacy endpoints will be evaluated at week 26 and primary efficacy endpoint will be evaluated at week 156."
3383367|NCT03232593||Participants who Receive Atezolizumab|Participants who are administered with atezolizumab as per the local label and standard of care at physician's discretion will be observed for approximately 6 years.
3383368|NCT03224819|Experimental|Exploration Phase|Dose finding phase of the study
3383369|NCT03224819|Experimental|Expansion Phase|Maximum Tolerated Dose identified by Exploration Phase administered to subjects
3383370|NCT03219333|Experimental|Enfortumab vedotin|Enfortumab vedotin on days 1, 8 and 15 every 28 days
3383371|NCT03207256|Experimental|TGR-1202|Oral TGR-1202 Daily
3383372|NCT03207256|Experimental|TGR-1202 + Ublituximab|Oral TGR-1202 in combination with Ublituximab intravenous administration
3383374|NCT03205553|Active Comparator|Standard of Care (SoC) Treatment Group|The SoC group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice and subsequently serially reduced in silo (staged silo reduction) until the bowel contents are at the level of fascia and deemed suitable for closure. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons.
3383375|NCT03205553|Experimental|Direct Peritoneal Resuscitation (DPR) Treatment Group|The DPR group will be placed in silo shortly after birth within 2 hours of admission to the NICU per standard practice. At the time of silo placement for staged procedure, the JP drain will be sterilely placed intra-abdominally through the top of the silo. Subjects will be treated with adjuvant direct peritoneal resuscitation (DPR) and subsequently serially reduced in silo until the abdomen is closed (during the entirety of silo placement), which is usually four to five days.
3383376|NCT03205072||ERCP & Spy Glass DS|Patients with cadaveric donor or live donor liver transplantation referred for ERCP in the setting of a clinical suspicion of post liver transplant bile duct strictures.
3383379|NCT03197922|Experimental|MIE Treatment for Two Weeks|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for two weeks. MIE consists of daily clinic appointments, each of which lasts until a continent bowel movement occurs or 3 hours elapse. These participants will discontinue the use of medication previously prescribed for the treatment of constipation, other than the suppositories used in the MIE treatment. During MIE, medical professionals resolve any constipation and oversee a regimen of over the counter medications that increase the predictability of a bowel movement.
3383380|NCT03197922|No Intervention|Treatment as Usual (TAU)|Participants randomized to the Treatment as Usual (TAU) group will continue to receive outpatient medical treatment of encopresis according to best practice guidelines by the pediatric gastroenterologist. In addition, participants in the TAU group will receive a 2-hour individual appointment in clinic with a doctoral level clinician with extensive experience in behavioral treatments for encopresis. During the appointment, the clinician will review strategies to increase continence by providing parent education on the following topics: how to collect and evaluate data on their child's bowel movements, how to establish and use a sit schedule, identifying behaviors that are precursors to bowel movements and how to use them to increase the probability of a bowel movement being continent, consequences for incontinence, and reinforcement for continence.
3383381|NCT03197922|Experimental|MIE Treatment for One Week|Participants in this arm will receive the Multidisciplinary Intervention for Encopresis (MIE) for one week. This study arm was discontinued in October 2019.
3383385|NCT03176004|Experimental|Attention Bias Modification|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a threatening word.
3383386|NCT03176004|Active Comparator|Active Control Condition|Participants play a game in which they can move up in levels by reducing their reaction time to targets presented in the location of a word with a specific color.
3383387|NCT03176004|No Intervention|Wait List|Participants simply return after 8 weeks.
3383388|NCT03166085|Experimental|PU-H71 With Nab-paclitaxel (Abraxane)|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle and nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1. Both drugs will be administered on the same day, in sequence, with nab-paclitaxel being administered first followed by administration of PU-H71 as close as possible to 6 hours later (+/-1 hour). PU-H71 will be administered intravenously over a 1 hour period; nab-paclitaxel will be administered per standard guidelines as a 30-minute intravenous infusion.
3383389|NCT03161054|Experimental|One arm for all patient|"Induction phase:~Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.~Super-frail patients will not receive etoposide during cycles 1 and 2.~Maintenance Phase:~Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.~Post Maintenance Phase:~Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance"
3383402|NCT03115333|Experimental|Diagnostic (DSC-MRI)|Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15.
3383403|NCT03104205|Experimental|Evaluate home-based MOWI|Conduct and assess the feasibility, acceptability, and potential effectiveness of home-based MOWI in improving physical function.
3383404|NCT03100149|Experimental|Part 1: RO7046015 High Dose|Participants will receive RO7046015 at high dose level as intravenous infusion every 4 weeks (Q4W) up to 52 weeks in Part 1.
3383405|NCT03100149|Experimental|Part 1: RO7046015 Low Dose|Participants will receive RO7046015 at low dose level as intravenous infusion Q4W up to 52 weeks in Part 1.
3383406|NCT03100149|Placebo Comparator|Part 1: Placebo|Participants will receive placebo as intravenous infusion Q4W up to 52 weeks in Part 1.
3383407|NCT03100149|Experimental|Part 2: RO7046015 High Dose|Part 1 RO7046015 high dose group participants and placebo group participants randomized to high dose level will receive RO7046015 at high dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
3383408|NCT03100149|Experimental|Part 2: RO7046015 Low Dose|Part 1 RO7046015 low dose group participants and placebo group participants randomized to low dose level will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 52 weeks in Part 2.
3383409|NCT03100149|Experimental|Part 3: RO7046015 Low Dose|Part 2 RO7046015 low dose group participants and high dose group participants will receive RO7046015 at low dose level as intravenous infusion Q4W for additional 5 years in Part 3.
3383410|NCT03099174|Experimental|Cohort A|Xentuzumab + Abemaciclib (Dose 1)
3383411|NCT03099174|Experimental|Cohort B|Xentuzumab + Abemaciclib + Letrozole (Dose 2)
3383412|NCT03099174|Experimental|Cohort C|Xentuzumab + Abemaciclib + Anastrozole (Dose 3)
3383413|NCT03099174|Experimental|Cohort D|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
3383414|NCT03099174|Experimental|Cohort E|Xentuzumab + Abemaciclib (Dose 1)
3383415|NCT03099174|Experimental|Cohort F|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
3383416|NCT03099174|Experimental|Cohort D1|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
3383417|NCT03099174|Experimental|Cohort D2|Xentuzumab + Abemaciclib + Fulvestrant (Dose 4)
3383419|NCT03073603|Active Comparator|Drug Continuation Arm|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
3383420|NCT03073603|Experimental|Drug Discontinuation Arm|Participants who will discontinue their Disease Modifying Therapies (DMTs). No other changes to their treatment occur. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
3383421|NCT03072862||Commercial Nucleus Cochlear Implant Systems|
3383422|NCT03050814|Active Comparator|Standard of Care (SOC) - Arm A|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine until disease progression.
3383423|NCT03050814|Experimental|Standard of Care (SOC) - Arm B + Lead in|Participants will receive leucovorin calcium (folinic acid), fluorouracil, and oxaliplatin (FOLFOX)- + bevacizumab + avelumab + Ad-CEA vaccine (given weeks 0,2,4,8,12,16 and then every 12 weeks) for up to 12 2-week cycles followed by maintenance therapy with bevacizumab + capecitabine + avelumab + Ad-CEA vaccine (following the every 12-week dosing schedule) until disease progression.
3383424|NCT03048201|Other|Physica KR|Subjects that receive the Physica Kinematic Retaining Knee System
3383425|NCT03048201|Other|Physica CR|Subjects that receive the Physica Cruciate Retaining Knee System
3383426|NCT03048201|Other|Physica PS|Subjects that receive the Physica Posterior Stabilized Knee System
3383427|NCT03030417|Experimental|Treatment Arm|LMP744 will be administered IV over 1 hour on days 1-5 of each 28-day cycle
3383428|NCT03030404||Cohort 1|Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.
3383430|NCT03016533|Experimental|Dolutegravir (Tivicay)|All participants will receive dolutegravir film-coated tablets or film-coated dispersible tablets at appropriate doses selected as per their age and weight bands. For those participants who were previously receiving dolutegravir in study P1093 (parent study), dolutegravir will be supplied as film-coated tablets containing 10 milligram (mg), 25 mg and 50 mg; and 5 mg film-coated dispersible tablets of dolutegravir. Participants will receive dolutegravir until age-appropriate formulations are available to them from some other source, or until participant is no longer deriving benefit from treatment, or participant is discontinued, or until development of dolutegravir is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
3383431|NCT03016533|Experimental|ABC/DTG/3TC|All participants will receive ABC/DTG/3TC immediate release tablets or film-coated dispersible tablets at appropriate doses selected as per their weight bands. For those participants who were previously receiving ABC/DTG/3TC in study P2019 (parent study), ABC/DTG/3TC will be supplied as immediate release tablets containing 600 mg, 50 mg and 300 mg of ABC, DTG, and 3TC respectively and film-coated dispersible tablets containing 60 mg, 5 mg and 30 mg of ABC, DTG, and 3TC respectively. Participants will receive ABC/DTG/3TC until age-appropriate formulations are available to them from some other source, until participant is no longer deriving benefit from treatment, or until participant is discontinued, or until development of ABC/DTG/3TC is terminated. The dose adjustment will be made if a participant's weight change requires a dose adjustment.
3383435|NCT02962128|Experimental|High Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a high LA diet (10% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
3383436|NCT02962128|Experimental|Low Linoleic Acid (LA) Diet|European Americans (genotypes: TT, GT & GG) and African Americans (genotypes: GT & GG) at rs173537will be randomly assigned to a low LA diet (2.5% energy) based on a randomized block design with 5 strata defined by race and genotype combinations.
3383437|NCT02916316||Chemo immunotherapy|All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
3383438|NCT02894658|Experimental|Lipiflow system|Treatment through the use of heat and pulsatile pressure.
3383439|NCT02894658|Active Comparator|Fellow eye warm compresses|Warm compresses to fellow eye and daily treatment with eyelid scrubs.
3383440|NCT02891798|Experimental|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Patients will receive a nerve block consisting of bupivacaine plus clonidine-buprenorphine-dexamethasone (Bupivacaine-CBD)
3383441|NCT02891798|Active Comparator|Bupivacaine Only (control arm)|Patients will receive a nerve block consisting of bupivacaine only.
3383445|NCT02861794|Other|GMK Sphere|Patients receive a GMK Sphere Total Knee Replacement.
3383446|NCT02827838|Experimental|Treatment (durvalumab, surgery)|Patients receive durvalumab IV over approximately 60 minutes on day 1. Treatment repeats every 2 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Within 3-17 days after last dose administration of durvalumab, patients undergo surgery. Patients may receive an additional dose of durvalumab if time to surgery is longer than 30 days.
3383447|NCT02810171|Active Comparator|Cognitive Behavioral Therapy|
3383448|NCT02810171|Other|Relaxation Therapy|
3383449|NCT02810171|No Intervention|No Intervention: Healthy youth only|Healthy control participants, matched to gender and age with anxiety patients, will be enrolled. These healthy participants will be scanned with fMRI before and after ~16 weeks, but without any intervention (i.e., no therapy).
3383450|NCT02803203|Experimental|osimertinib and bevacizumab|"Phase 1:~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks~Phase 2:~Use MTD determined during phase 1"
3383451|NCT02802020|Experimental|WallFlex FCSEMS Recipients|"The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent. Patients who meet all eligibility criteria will receive the WallFlex Pancreatic stent for up to 6 months stent indwell and 6 months follow-up after stent removal. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study."
3383452|NCT02797262|Experimental|Intervention|"Building on the available Proteus devices, the investigators will design and create a Proteus digital health feedback (PDHF) system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).~The investigators will test overall utility (including feasibility, acceptability and sustainability) of the PDHF system, its accuracy for measuring adherence and its impact on enhancing patients' level of adherence and the effect on virologic and clinical outcomes (exploratory), the retention of its impact on keeping up with adherence and improvement of plasma HIV RNA and CD4 cell count after the 16-week usage of the PDHF system."
3383453|NCT02797262|No Intervention|Control|UC is chosen as the control condition because it meets ethical and moral requirements to attempt treatment. Eligible patients will be randomized to one of the two conditions using a stratified urn randomization procedure to increase the likelihood of balanced allocation of prognostic variables at baseline.
3383454|NCT02795806||1|Everybody for whom a clinical narrative report is created.
3383455|NCT02793583|Experimental|Umbralisib + Ublituximab|Umbralisib oral daily dose in combination with Ublituximab intravenous administration
3383456|NCT02793583|Experimental|Umbralisib|Umbralisib oral daily dose
3383457|NCT02793583|Experimental|Umbralisib + Ublituximab + Bendamustine|Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration
3383458|NCT02791568||Pilot Study|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
3383459|NCT02791568||Main Study- Control Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
3383460|NCT02791568||Main Study- Study Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection"
3383461|NCT02791568||Main Study- Ferumoxytol Group|"Ultrasound Scan~MRI Scan~Blood/Urine collection~Ferumoxtyol Infusion"
3383462|NCT02742090|Experimental|TGR-1202|Oral daily dose of TGR-1202
3383463|NCT02724241|Experimental|nicotine|use of an e-cigarette filled with liquid with nicotine
3383464|NCT02724241|Experimental|no nicotine|Use of an e-cigarette filled with liquid without nicotine
3383465|NCT02724241|Sham Comparator|sham comparator|Use of empty e-cigarette (sham control)
3448582|NCT04062890|Active Comparator|Vigabatrin|Vigabatrin - Pill, 500 mg twice daily for 7 days (days 1-7), 1000 mg twice daily for 7 days (days 8-14), 1500 mg twice daily for 10 days (days 15-24), 1000 mg twice daily for 7 days (days 25-31), 500 mg twice daily for 7 days (days 32-38).
3448583|NCT04062890|Placebo Comparator|Placebo|Placebo - Pill, 1 pill twice daily for 7 days (days 1-7), 2 pills twice daily for 7 days (days 8-14), 3 pills twice daily for 10 days (days 15-24), 2 pills twice daily for 7 days (days 25-31), 1 pill twice daily for 7 days (days 32-38).
3448584|NCT04063059|Active Comparator|Intervention|Subjects will be randomized to the program intervention which is a female-specific, culturally relevant, self-regulation based in-person group sessions and telephone counseling intervention designed for African American women who are overweight or obese.
3448585|NCT04063059|No Intervention|Control|Usual care
3448586|NCT04062916||women with endometriosis|65 women whose main symptom was pain and who did not respond to medical treatment and underwent endometriosis surgery
3383469|NCT02656303|Experimental|Ublituximab + TGR-1202|Ublituximab IV treatment + TGR-1202 oral daily dose
3383470|NCT02639910|Experimental|Cohort A|tafasitamab (MOR208) in combination with idelalisib
3383471|NCT02639910|Experimental|Cohort B|tafasitamab (MOR208) in combination with venetoclax
3383476|NCT02628067|Experimental|Pembrolizumab 200 mg|Participants receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
3383477|NCT02628067|Experimental|Pembrolizumab 400 mg|Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).
3383478|NCT02625480|Experimental|Single Arm|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of chimeric antigen receptor (CAR) transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR+ T cells/kg or 1 x 10^6 anti-CD19 CAR+ T cells/kg
3383479|NCT02618980|Experimental|early endoscopy|endoscopic hemostasis
3383480|NCT02618980|No Intervention|without early endoscopy|Patients assigned to non-endoscopic treatment group receive high dose infusional PPI therapy. If UGI bleeding subsided after medical treatment alone, diagnostic EGD will be done under stable hemodynamic and 2 weeks after ACS to confirm UGI SRH. If the SRH is not located at UGI tract, the patients will be excluded. Troponin I or T and complete ECG will be checked every 8 hours within 24 hours of interventions. APACHE II score at intervention will be calculated for each patient.
3383482|NCT02613598|Experimental|Bortezomib and Ruxolitinib|Bortezomib on days 1, 4, 8, and 11 of a 21 day cycle in combination with Ruxolitinib (5, 10, 15, 20, or 25 mg) twice daily.
3383483|NCT02612311|Experimental|Ublituximab + TGR-1202|"Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions~TGR-1202: Fixed oral daily dose"
3383484|NCT02612311|Active Comparator|Obinutuzumab + Chlorambucil|"Obinutuzumab: IV infusion dose on Days 1, 8 and 15 in Cycle 1 followed by Day 1 infusion in Cycles 2 - 6~Chlorambucil: Oral dose on Days 1 and 15 of Cycles 1 - 6"
3383485|NCT02612311|Experimental|Ublituximab|- Ublituximab: IV infusion dose on Days 1, 8 and 15 followed by maintenance infusions
3383486|NCT02612311|Experimental|TGR-1202|- TGR-1202: Fixed oral daily dose
3383488|NCT02598557|Experimental|Arm I (exemestane)|Patients receive exemestane PO QD on days 1-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
3383489|NCT02598557|Experimental|Arm II (exemestane, placebo)|Patients receive exemestane PO QD on days 1, 3, and 5. Patients also receive placebo PO QD on days 2, 4, 6, and 7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
3383490|NCT02598557|Experimental|Arm III (exemestane, placebo)|Patients receive exemestane PO QD on day 1 and placebo PO QD on days 2-7. Cycles repeat every 7 days for 4-6 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo surgery on days 29, 36, or 43.
3383493|NCT02595320|Experimental|Group A|capecitabine, 1500 mg, twice a day for 7 days on then 7 days off
3383494|NCT02595320|Active Comparator|Group B|capecitabine, 1250 mg/m2 OR 1000 mg/m2, twice a day for 14 days on then 7 days off
3383495|NCT02594384|Experimental|Continuous monotherapy|All patients will take LAM-002A two times daily by mouth every day until cancer progression or intolerability.
3383496|NCT02594384|Experimental|Intermittent monotherapy|All patients will receive LAM-002A at escalating dose levels two times daily by mouth for 3 days on therapy followed by 4 days off therapy every week until cancer progression or intolerability.
3383497|NCT02594384|Experimental|LAM-002A + rituximab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and rituximab 375 mg/m2 by vein every week for 4 weeks and then every 8 weeks for 4 times (total of 8 infusions)
3383498|NCT02594384|Experimental|LAM-002A + atezolizumab|All patients will receive LAM-002A 125mg two times daily by mouth every day until cancer progression or intolerability and atezolizumab 1200 mg by vein every 3 weeks until cancer progression or intolerability
3383499|NCT02586623|Experimental|Open Label Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally. During the Open Label Titration Period, patients will first receive 100 mg TID and their dose will be raised (in 100 mg increments) at subsequent visits until optimal dose is determined. During the Open Label Treatment Period, patients will receive active droxidopa100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to the patient's individual dose at the end of the Open-Label Titration Period).
3383500|NCT02586623|Placebo Comparator|Randomized Period|Active droxidopa 100, 200, 300, 400, 500, or 600 mg three times daily (TID) orally (equal to patients individual dose at the end of the Open-Label Period) or matching placebo.
3383509|NCT02545283|Experimental|Idasanutlin plus Cytarabine|Participants will receive induction therapy idasanutlin and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or complete remission with incomplete blood count recovery (CRi), up to 28 additional days are allowed for blood count recovery, if needed.
3383510|NCT02545283|Placebo Comparator|Placebo plus Cytarabine|Participants will receive induction therapy idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in Cycle 1 (treatment cycle length=28 days). Responding participants may continue with consolidation therapy for a maximum of 2 additional cycles including idasanutlin matching placebo and cytarabine for 5 days followed by 23 days of rest in each cycle (treatment cycle length=28 days). After each cycle, for participants achieving CRp or CRi, up to 28 additional days are allowed for blood count recovery, if needed.
3448587|NCT04062903|Active Comparator|Immediate Appointment|Intervention group who receive the Social Prescription without delay. The effectiveness of the consultation and referral process will be assessed.
3448588|NCT04062903|Active Comparator|Delayed Appointment|Waitlist control group who receive social Prescribing after a delay of 20 working days. The effectiveness of the consultation and referral process will be assessed.
3448589|NCT04062942||DDD patients|All patients presenting to the neurosurgical department of the Kantonsspital St. Gallen (KSSG) or the Univesity Hospital Zürich (USZ) with DDD fulfilling the inclusion criteria and scheduled for ESI or TFESI will be considered for this study.
3448590|NCT04063033|Experimental|IV Iron treatment|Patients will be administered IV Iron for 3-5 days. 125 mg per day.
3448591|NCT04063033|No Intervention|No IV Iron treatment|Patients will receive standard treatment for heart failure without IV Iron.
3448592|NCT04062682|No Intervention|Controls|No changes in dietary habits
3448593|NCT04062682|Experimental|Healthy Diet|Changes in dietary habits only
3448594|NCT04063111|Active Comparator|group A|Group A will be treated with vacuum assistant closure
3448595|NCT04063111|Active Comparator|group B|Group B will be treated with conventional dressing
3448596|NCT04062955|Experimental|Prevention (dietary intervention)|"DIETARY INTERVENTION: Participants receive dietary counseling with a dietitian in person or via telephone to support adherence to a diet based on the AHEI guidelines once weekly for up to 12 weeks.~DXA ONLY STUDY: Participants undergo DXA scan for breast density measurement at baseline and at 12 weeks."
3448597|NCT04062487|Experimental|Lumbar pedicle screws implantation of traditional procedure|traditional method of lumbar pedicle screws implantation
3448598|NCT04062695|Active Comparator|Tofacitinib|5 mg oral BID
3448599|NCT04062695|Placebo Comparator|Placebo|matching Placebo BID
3448600|NCT04062721|Experimental|Chemotherapy + RFA + in situ immunotherapy|Patients with non-resectable CRC liver-only metastases.
3448601|NCT04062656|Experimental|B - Nivolumab|"Responders~6 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 postoperative cycles nivolumab (i.v., 240mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v., 240mg, q2w)~4 additional cycles nivolumab (i.v., 240mg, q2w)+FLOT (i.v., 240mg, q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480 mg, q4w)"
3448602|NCT04062656|Experimental|D - Nivolumab + relatlimab|"Responders~6 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 postoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)~Non-responders~2 preoperative cycles nivolumab (i.v.,240 mg, q2w) and relatlimab (i.v.,80 mg, q2w)~4 additional cycles nivolumab (i.v.,240 mg, q2w)+FLOT (i.v.,q2w) pre- and postoperative~followed by nivolumab monotherapy for up to one year (i.v., 480mg, q4w)"
3448603|NCT04062396|Active Comparator|Eurosets REMOWELL 2 oxygenator|
3448604|NCT04062396|Active Comparator|LivaNova INSPIRE oxygenator|
3448605|NCT04062383|Experimental|Positive Psychology + Motivational Interviewing|Participants will complete weekly positive psychology exercises and will systematically set goals related to physical activity. Study trainers will review the positive psychology exercises on the phone each week and will use motivational interviewing techniques to facilitate goal setting.
3383527|NCT02524171|Experimental|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
3383528|NCT02524171|No Intervention|Usual Care (UC)|Usual care provided by the mental health residential rehabilitation treatment programs, which patients in both groups are in.
3383532|NCT02497131|Experimental|Brentuximab Vedotin 16 cycles|Subjects will receive 1.8 mg/kg of brentuximab vedotin as an iv infusion administered on Day 1 of each 21-day cycle for a maximum of 16 cycles.
3383533|NCT02492867|Experimental|Response-driven Adaptive RT|Patients will receive treatment 5 days per week, in once daily fractions, for 30 treatments with dose per fraction individually adapted over the final 9 treatments. Patients may also receive concurrent chemotherapy with Carboplatin and Paclitaxel. Patients may receive consolidation chemotherapy (carboplatin and paclitaxel) or immunotherapy (durvalumab) at the discretion of the medical oncologist.
3448606|NCT04062643||Patients with obesity|Obesity in those with BMI ≥30 kg/m2
3448607|NCT04062643||Patients without obesity|Normal weight was considered in the patients with BMI <30 kg/m2
3448608|NCT04062435|Experimental|Interventional Group|"Peschke®TE 0.25 % application in the INFERIOR FORNIX~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
3448609|NCT04062435|Active Comparator|Control Group|"Peschke®TE 0.25 % application on the CORNEA~Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator."
3448610|NCT04062331|Placebo Comparator|Placebo group|This group will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) without any frequency (device doesn't running; it means, device turned off) but the same duration of sessions.
3448611|NCT04062331|Experimental|Group under TMS 1 Hertz treatment|1 Hertz group (1 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 1 Hertz.
3448612|NCT04062331|Experimental|Group under TMS 5 Hertz treatment|5 Hertz group (5 Hertz ) will be under standard therapy (natalizumab) plus Transcranial Magnetic Stimulation (TMS) running with a frequency of 5 Hertz .
3448613|NCT04062669|Experimental|Low dose (Ld-) RG SAM (CNE) group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) low dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)"
3448614|NCT04062669|Experimental|Medium dose (Md-) RG SAM (CNE) group|Healthy adults,18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) medium dose formulation vaccine in one arm and one intramuscular injection of saline solution in the opposite arm at Day 1.
3448615|NCT04062669|Experimental|Lower dose (Lrd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lower dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
3448616|NCT04062669|Experimental|Lowest dose (Ltd-) RG SAM (CNE) group|Healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RG SAM (CNE) lowest dose formulation vaccine in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)
3448617|NCT04062669|Placebo Comparator|Saline Placebo group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive two intramuscular injections of saline placebo, one in each arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age will receive one intramuscular injections of saline placebo in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
3448618|NCT04062669|Active Comparator|RabAvert group|"In Part 1 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm and one intramuscular injection of saline solution in the other arm, according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61).~In Part 2 of the study, healthy adults, 18 to 40 years of age, will receive one intramuscular injection of RabAvert in one arm according to a 0, 2, 6-month schedule (i.e. at Days 1 and 61)."
3448619|NCT04062526|Experimental|Patient with Parkinson Disease|"Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review.~Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment."
3448620|NCT04062526|Experimental|Healthy Control|Subject must be a Healthy.
3448621|NCT04062500||Patients with heart failure|patients treated in the hospital for acute heart failure in China
3448622|NCT04062253||HCV or HIV negative|Individuals who test negative for HCV or HIV are given information regarding ways of transmission.
3448623|NCT04062253||HCV and HIV positive|Individuals with a positive test for HCV o HIV are offered delivery or accompaniment to specialist health care.
3448624|NCT04062474|Experimental|Epidural Intervention with Steroids|Epidural Intervention with Steroids
3448625|NCT04062461|Experimental|self-care promotion|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
3448626|NCT04062461|Active Comparator|Control group|routinely management in the HF. Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
3448627|NCT04062175|Active Comparator|cephalosporin arm|72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision
3448628|NCT04062175|Active Comparator|cephalosporin +azithromycin arm|72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
3383572|NCT02458313|Experimental|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
3383573|NCT02458313|Placebo Comparator|Placebo|Placebo capsules b.i.d. for 12 weeks.
3383574|NCT02455193|Experimental|Exercise intervention|10 weeks of a moderate exercise intervention
3383575|NCT02455193|Active Comparator|Diet intervention|10 weeks of a diet intervention
3383576|NCT02435810||Family Member|A family member of a patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
3383577|NCT02435810||Patient|Patient with known or suspected infection or inflammation of the nervous system based on clinical or imaging data provided
3383578|NCT02426892|Experimental|ISA101 + Nivolumab|"HPV-16 vaccination (ISA 101) administered subcutaneously at 100 mcg for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.~Nivolumab administered intravenously at 3 mg/kg every 2 weeks beginning on day 8 after the first vaccine dose.~There are 3 weeks in Cycle 1 and 2 weeks in Cycles 2 and beyond."
3383580|NCT02409368|Experimental|Cohort A: Treatment - Nivolumab|Nivolumab IV infusion
3383584|NCT02375555|Experimental|Elotuzumab, lenalidomide, bortezomib, and dexamethasone|"Participants will receive therapy with the combination of lenalidomide, bortezomib, and dexamethasone and elotuzumab (E-RVD). Induction cycles (1 to 8) are 21-day cycles.~Elotuzumab will be administered by intravenous (IV) infusion~Bortezomib as a subcutaneous injection~Lenalidomide single daily oral dose~Dexamethasone as oral tablets and IV infusion~Stem cell mobilization will be performed for all subjects at the end of Cycle 4.~Subjects may elect to stop E-RVD Cycle 4 and proceed to autologous SCT. Subjects who do not proceed to SCT may receive 8 cycles of induction therapy.~- The maintenance schedule (28 days) will start after 8 cycles of induction regimen for subjects not proceeding with SCT, or after recovery from SCT for subjects proceeding with it.~Maintenance therapy with E-RVD will be administered to all patients, with the specific maintenance regimen determined by risk category."
3383585|NCT02369016|Experimental|Copanlisib (BAY 80-6946)|patients with rituximab-refractory iNHL
3383586|NCT02322593|Experimental|TAS-118/Oxaliplatin|TAS-118 plus Oxaliplatin
3383587|NCT02322593|Active Comparator|S-1/Cisplatin|S-1 plus Cisplatin
3383590|NCT02315521||Group 1|Fetuses with LUTO before 18 weeks
3383591|NCT02315521||Group 2|Fetuses with LUTO between 18 and 30 weeks
3383592|NCT02315521||Group 3|Fetuses with LUTO between 30 and 34 weeks
3383593|NCT02315521||Group 4|Fetuses with LUTO after 34 weeks
3383594|NCT02301156|Experimental|Ublituximab + ibrutinib|"Ublituximab: IV infusion dose Days 1, 8 and 15 followed by maintenance infusions~Ibrutinib: Fixed oral daily dose"
3383595|NCT02301156|Active Comparator|Ibrutinib|- Ibrutinib: Fixed oral daily dose
3383596|NCT02277119|Experimental|Normal Eyes|Subjects with no known ocular diseases will be scanned with the iVue and Maestro device
3383597|NCT02277119|Experimental|Glaucomatous Eyes|Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device
3383598|NCT02277119|Experimental|Eyes with Retinal Diseases|Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device
3383599|NCT02230891|Active Comparator|Carvedilol|Approximately 70 subjects will be randomized to carvedilol
3383600|NCT02230891|Active Comparator|Spironolactone|Approximately 70 subjects will be randomized to spironolactone
3383601|NCT02230891|Other|Usual care|Approximately 70 subjects will be randomized to usual care/ standard care by primary care providers
3383602|NCT02227251|Experimental|Part 1: Selinexor 60 mg|Participants received fixed dose of 60 mg selinexor orally, twice weekly (BIW) on Days 1 and 3 (e.g., Monday and Wednesday or Tuesday and Thursday, etc.) of Weeks 1-4 of each four week (each cycle of 28 days) cycle (total of 8 doses per cycle).
3383603|NCT02227251|Experimental|Part 2: Arm A-Selinexor 40 mg|Participants received selinexor 40 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles (28 days) until disease progression (total of 8 doses per cycle).
3383604|NCT02227251|Experimental|Part 2: Arm B-Selinexor 60 mg|Participants received selinexor 60 mg orally BIW on Days 1 and 3 of each week of 4-week treatment cycles) for 2 cycles (each cycle of 28 days) followed by 60 mg once weekly (QW) in the subsequent cycles until disease progression (total of 8 doses per cycle).
3383605|NCT02220894|Experimental|Pembrolizumab|Participants receive pembrolizumab 200 mg intravenous (IV) on Day 1 of every 21-day cycle (every 3 weeks, or Q3W) for up to 35 treatments.
3383606|NCT02220894|Active Comparator|SOC Treatment|Participants receive carboplatin target dose Area Under Curve (AUC) 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + paclitaxel 200 mg/m^2 IV on Day 1 of every 21-day cycle (Q3W) for a maximum of 6 cycles OR carboplatin target dose AUC 5 (maximum dose 750 mg) or AUC 6 (maximum dose 900 mg) + pemetrexed 500 mg/m^2 IV on Day 1 Q3W for a maximum of 6 cycles; participants with non-squamous histologies may go on to receive optional treatment with pemetrexed 500 mg/m^2 IV on Day 1 Q3W.
3383607|NCT02124824|Experimental|Arm 1: Control|Control
3383608|NCT02124824|Experimental|Arm 2: Heart Failure|Heart Failure
3383609|NCT02123823|Active Comparator|Everolimus 10mg + Exemestane 25mg|Phase II - Daily everolimus oral administration 10mg + daily exemestane 25 mg orally
3383610|NCT02123823|Experimental|BI836845 + Everolimus + Exemestane|Phase II - BI 836845 recommended dose will be administered intravenously once every week, in addition to daily everolimus (oral administration at recommended dose) + daily exemestane 25 mg orally
3383611|NCT02123823|Experimental|PhI - BI836845 + Everolimus + Exemestane|Phase I - Dose escalation (24-48 patients) BI 836845 low or high dose, Everolimus 5mg, 7,5mg or 10 mg and Exemestane 25mg
3383612|NCT02066636|Experimental|Cohort A: Nivolumab|Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent
3383613|NCT02066636|Experimental|Cohort B: Nivolumab|"Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).~Discontinue treatment and at progression, retreatment allowed"
3383614|NCT02052778|Experimental|Phase 1 Dose escalation|Phase 1 Dose escalation portion for once daily and thrice weekly dosing of futibatinib (TAS-120) in patients with solid tumors.
3383615|NCT02052778|Experimental|Phase 1 Dose expansion|Phase 1 Dose expansion portion for once daily dosing of futibatinib (TAS-120) in patients with tumors harboring FGF/FGFR aberrations
3383616|NCT02052778|Experimental|Phase 2|Phase 2 portion for once daily dosing of futibatinib (TAS-120) in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).
3383617|NCT02043678|Experimental|Radium-223 dichloride + Abi/Pred|Participants received 6 intravenous (IV) administrations of radium-223 dichloride 50 kiloBecquerel per kilogram (kBq/kg) (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update) body weight at intervals of 4 weeks, along with oral abiraterone acetate tablets 1000 milligrams (mg) every day plus prednisone/prednisolone 5 mg twice daily (abi/pred) for 6 cycles, followed by abi/pred until an on-study symptomatic skeletal event (SSE) occurred (or other withdrawal criteria were met)
3383618|NCT02043678|Placebo Comparator|Placebo + Abi/Pred|Participants received 6 IV administrations of placebo matched to radium-223 dichloride at intervals of 4 weeks, along with abi/pred for 6 cycles, followed by abi/pred until an on-study SSE occurred (or other withdrawal criteria were met)
3383620|NCT01936831|Experimental|Group 1: Participants with a TB strain that has an inhA mutation|"Participants who meet Step 2 entry criteria will be randomized 1:1:1 to receive the following treatments for 7 days:~5 mg cohort: Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily~10 mg cohort: Isoniazid 10 mg/kg daily plus vitamin B6 ≥25 mg daily~15 mg cohort: Isoniazid 15 mg/kg daily plus vitamin B6 ≥25 mg daily"
3383621|NCT01936831|Experimental|Group 2: Participants with TB without inhA nor katG mutations|Participants who meet Step 2 entry criteria will receive Isoniazid 5 mg/kg daily plus vitamin B6 ≥25 mg daily for 7 days
3383622|NCT01936831|Experimental|Group 3: Participants with an MTB isolate with a katG mutation with or without an inhA mutation|Participants with an M. tuberculosis isolate with a katG mutation with or without an inhA mutation who meet Step 2 entry criteria will be randomized to receive either Isoniazid 15 mg/kg or 20 mg/kg daily, plus vitamin B6 ≥25 mg daily for 7 days.
3383630|NCT01774019|Active Comparator|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Patients in this group will receive a fully covered or uncovered study SEMS (self-expanding metal stent)
3383631|NCT01774019|No Intervention|None (No Pre-Operative Biliary Drainage)|Patients in this group will not receive pre-operative biliary drainage with a study SEMS
3383632|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 1.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 1.0 milligrams per kilogram (mg/kg) once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or investigational medicinal product (IMP) occurs.
3383633|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 3.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 3.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383634|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383635|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 20.0 mg/kg|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 20.0 mg/kg once every 2 weeks in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383636|NCT01772004|Experimental|Dose Escalation Cohort: Avelumab 10.0 mg/kg Weekly|Participants with metastatic or locally advanced solid tumors received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once weekly for the first 12 weeks and once every 2 weeks starting Week 13 in dose escalation cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383637|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, Post-platinum Doublet|Participants with non-small cell lung cancer (NSCLC), who had progressed after 1 line of platinum-containing doublet chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383638|NCT01772004|Experimental|Primary Expansion Cohort: NSCLC, First Line|Participants with non-small cell lung cancer (NSCLC), first line received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383639|NCT01772004|Experimental|Primary Expansion Cohort: Metastatic Breast Cancer|Participants with metastatic breast cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383640|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who progressed on or after first line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383641|NCT01772004|Experimental|Primary Expansion Cohort: GC/GEJC Non Progressed|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who non-progressed on or after first-line chemotherapy received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in primary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383642|NCT01772004|Experimental|Secondary Expansion Cohort: Colorectal Cancer|Participants with colorectal cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383643|NCT01772004|Experimental|Secondary Expansion Cohort: Castrate-resistant Prostate Cancer|Participants with castrate-resistant prostate cancer received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383644|NCT01772004|Experimental|Secondary Expansion Cohort: Adrenocortical Carcinoma|Participants with adrenocortical carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383645|NCT01772004|Experimental|Secondary Expansion Cohort: Melanoma|Participants with melanoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383646|NCT01772004|Experimental|Secondary Expansion Cohort: Mesothelioma|Participants with mesothelioma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383647|NCT01772004|Experimental|Secondary Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383648|NCT01772004|Experimental|Secondary Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383649|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (First Line)|Participants with Renal cell carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a first-line therapy in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383650|NCT01772004|Experimental|Secondary Expansion Cohort: Renal Cell Carcinoma (Second Line)|Participants with Renal cell carcinoma who failed 1 prior systemic first-line regimen received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a second line treatment in secondary expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383651|NCT01772004|Experimental|Efficacy Expansion Cohort: Ovarian Cancer|Participants with ovarian carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383652|NCT01772004|Experimental|Efficacy Expansion Cohort: Urothelial Carcinoma|Participants with urothelial carcinoma received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383653|NCT01772004|Experimental|Efficacy Expansion Cohort: GC/ GEJC, Third Line|Participants with gastric (GC) and gastroesophageal junction cancer (GEJC) who have failed both a first-line chemotherapy regimen and subsequent ramucirumab therapy, received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks as a third-line treatment in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383654|NCT01772004|Experimental|Efficacy Expansion Cohort: HNSCC|Participants with head and neck squamous cell carcinoma (HNSCC) received intravenous infusion of Avelumab at a dose of 10.0 mg/kg once every 2 weeks in efficacy expansion cohort until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
3383655|NCT01750567|Experimental|Metformin (Glucophage)|The starting dose of metformin will be 500 mg po daily for one week. The dose can be escalated to 500 mg twice a day after one week, and further escalated to the final dose of 1000 mg twice a day in week 3 if the medication is tolerated without adverse side effects (refer to holding parameters described in section 9.3.3). All doses should be administered with food to decrease gastrointestinal upset.
3383656|NCT01748149|Experimental|Vemurafenib|"Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be crushed. If patients receiving crushed tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take crushed tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.~The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle."
3383659|NCT01721759|Experimental|Nivolumab, 3 mg/kg|Participants received nivolumab, 3 mg/kg, intravenously over 60 minutes every 2 weeks (on Day 1 of each cycle) until disease progression, discontinuation due to toxicity, withdrawal of consent, or end of study. Every 2-week treatment period was considered to be a cycle.
3383660|NCT01633541|Experimental|platinum/docetaxal + AT-101|"platinum/docetaxel + AT-101 The platinum will either be cisplatin or carboplatin as deemed best by the medical oncologist.~(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~(AT-101 Arm) Days #1-3: Patients will receive AT-101 40 mg orally twice daily On Day 23 (+/- 3 days), there will be a direct laryngoscopy (DL) with tumor biopsy and blood draw, repeat CT scan of the neck with perfusion within a week biopsy."
3383661|NCT01633541|Active Comparator|Active Comparator arm|"(Both Arms) Day #1: Patients will undergo induction chemotherapy with (TP) docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 (or Carboplatin AUC 6).~Day #23 (+/- 3 days): Patients will undergo a direct laryngoscopy (DL) with biopsy. Patients will also undergo a repeat CT scan of the neck with perfusion within a week (+/-) of their perspective biopsies."
3383670|NCT01539447|Active Comparator|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
3383671|NCT01539447|Placebo Comparator|Placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
3383673|NCT01511588||HH patients|Clinical patients with hypogonadotropic hypogonadism (HH)
3383674|NCT01498276||General Population|Members of the general population
3383675|NCT01498276||Members of under-resourced communities|Participant recruited from under-resourced communities in the Washington, DC area in the Southeastern US
3383676|NCT01498263||Alzheimers related dementias (family)|Enrollment was open to family members of persons diagnosed with Alzheimers (/related dementia) in specific communities around Memphis, TN.
3383677|NCT01498263||Inherited inflammatory condition (family)|Enrollment open to family members of persons diagnosed with inherited inflammatory conditions. Participation at NIH or remote (internet/phone); request referral of family for remote participation.
3383678|NCT01498263||Inherited metabolic conditions (family)|Enrolls family members of persons diagnosed with inborn errors of metabolism / mitochondrial disorders. Study at NIH or remote (internet/phone); request family-referrals for remote participation.
3383679|NCT01498263||Inherited neurodegenerative disorders (family)|Open to family members of persons diagnosed with genetically-defined neurodegenerative conditions. Study at NIH or (internet/phone); request referral of family members for remote participation.
3383680|NCT01498263||Typically developing (family) = Healthy Volunteers|Open to parents of typically-developing child/ren <18yrs (*when age-matched child is full-time resident of parent's home). Study at NIH; request family-referrals for remote participation.
3383681|NCT01498263||Undiagnosed conditions (family)|Enrollment open to family members referred in from the Undiagnosed Disease Network. Participation at NIH or remote (internet/phone); request referral of family members for remote participation
3383703|NCT01343459|Experimental|IOERT followed by hypofractionated WBRT|HIOB: IOERT of 11.1 Gy followed by WBRT with 15 times 2.7 Gy per fraction.
3383706|NCT01322971|Active Comparator|Metronidazole|Patients randomized to the metronidazole arm will receive metronidazole 500mg orally twice daily for seven days.
3383707|NCT01322971|Placebo Comparator|Placebo|Patients randomized to the placebo arm will receive placebo orally twice daily for seven days(control arm
3383708|NCT01285102|Experimental|Arm I|Patients receive irinotecan-eluting beads via hepatic artery embolization every 3 weeks for up to 3 (unilobar disease) or 4 (bi-lobar disease) courses in the absence of disease progression or unacceptable toxicity.
3383716|NCT01224704|Experimental|Lean: hypertonic first|Lean: Hypertonic solution at day 6 and water deprivation at day 10
3383717|NCT01224704|Experimental|Lean: water deprivation first|Lean: Water deprivation at day 6 and hypertonic solution at day 10
3383718|NCT01224704|Experimental|Obese: hypertonic first|Obese: Hypertonic solution at day 6 and water deprivation at day 10
3383719|NCT01224704|Experimental|Obese: water deprivation first|Obese: Water deprivation at day 6 and hypertonic solution at day 10
3383730|NCT01174121|Experimental|1/CD8+ Enriched TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young CDS+ enriched TIL + high-dose aldesleukin (CLOSED)
3383731|NCT01174121|Experimental|2/Unselected TIL (CLOSED)|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine +young unselected TIL + high-dose aldesleukin (CLOSED)
3383732|NCT01174121|Experimental|3/Unselected TIL + Pembro Prior to Cells|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin + pembrolizumab prior to cell administration and 3 additional doses every 3 weeks following cell infusion
3383733|NCT01174121|Experimental|4/Unselected TIL + Pembro at POD|Non-myeloablative, lymphodepleting preparative regimen of cyclophosphamide and fludarabine + young unselected TIL + high-dose aldesleukin +pembrolizumab within 4 weeks of progressive disease for up to 8 doses every 3 weeks
3383753|NCT01026220|Experimental|Regimen I (consolidation therapy)|Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
3383754|NCT01026220|Experimental|Regimen II (consolidation therapy)|Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
3383755|NCT01026220|Experimental|Induction: all patient|All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.
3383769|NCT00804713|Experimental|All study participants|Subjects administered the TB skin test, Battey skin test, QFT-GIT, and T-Spot
3383777|NCT00683631|Experimental|TheraSphere|TheraSphere
3383778|NCT00677560||3|"Mild-moderate asthma.~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
3383779|NCT00677560||4|"Severe Asthma~Within the asthma group, there were two sub-groups; mild-moderate asthma and severe asthma distinguished using the Global Initiative for Asthma (GINA) guidelines (GINA, 2009)."
3383780|NCT00677560||1|"Normal subjects~Normal subjects were a group made up of healthy subjects, with normal lung function, non-smokers at the time of the screening."
3383781|NCT00677560||2|"Healthy smokers~Healthy smokers were comprised of people who were current smokers and had normal lung function at the time of screening."
3383782|NCT00677560||5|"COPD (Gold stage I - III)~The COPD group included stage I to III patients, classified according to severity of airflow limitation (post bronchodilator FEV1), from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD, 2011)."
3383790|NCT00424099|Experimental|Group 1: Methylphenidate + NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Nursing Telephone Intervention (NTI). NTI calls from study nurse 3 times weekly to ask about side effects and other symptoms.
3383791|NCT00424099|Placebo Comparator|Group 2: Placebo + NTI|Placebo capsule orally as needed for 14 days + NTI, calls from study nurse 3 times weekly to ask about side effects and other symptoms.
3383792|NCT00424099|Experimental|Group 3: Methylphenidate + Non NTI|Methylphenidate 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days + Non NTI, calls from research staff 3 times weekly.
3383793|NCT00424099|Experimental|Group 4: Placebo + Non NTI|Placebo capsules as needed with Non NTI, calls from research staff 3 times weekly.
3383794|NCT00397111||Healthy Volunteer|Healthy Volunteer/control group
3383795|NCT00397111||Major Depressive Disorder|Individuals with Major Depressive Disorder
3383796|NCT00389649|Active Comparator|HR=60|Pacemaker set at 60
3383797|NCT00389649|Active Comparator|HR=75|Pacemaker set at 75
3383798|NCT00389649|Active Comparator|HR=90|Pacemaker set at 90
3383799|NCT00342654||1|Participants from two large, nutritional intervention trials that were conducted in Linxian, China between 1985-1991.
3383800|NCT00342446||Patients|Patients of all races with primary or secondary infertility, including women with recurrent miscarriages.
3383805|NCT00086567||patients|Patients in first remission from treatment of FIGO stage III/IV primary peritoneal, fallopian tube, or epithelial ovarian carcinoma
3383818|NCT00005917||Chediak-Higashi Syndrome|Confirmed or suspected patients with Chediak-Higashi Syndrome.
3383829|NCT00001521|Experimental|Investigational 1|boys/flutamide, letrozole, and reduced hydrocortisone dose or conventional treatment (with hydrocortisone and fludrocortisone ) until the age of 14
3383830|NCT00001521|Experimental|Investigational 2|girls/flutamide, letrozole, and reduced hydrocortisone dose, the Letrozole will discontinue at 13 y.o. and continue flutamide until 2 years after menarche or when final height is reached, whichever occurs first
3383832|NCT00001486||Normal Controls|Male and female adult healthy volunteers
3383833|NCT00001486||Parents|Parents of Probands and siblings for the purposes of DNA collection
3383834|NCT00001486||Probands|Adult Subjects with Schizophrenia Spectrum Disorders
3383835|NCT00001486||Siblings|Adult siblings of Probands
3383838|NCT00001465||LAM|Patients with tissue diagnosis of LAM may be admitted for evaluation every six months, or as deemed necessary for research
3448629|NCT04062240||Additional BIS sensor|Many providers caring for cardiovascular surgical patients utilizes BIS monitoring to gauge depth of anesthesia. The current practice involves placement of the BIS sensor on the patient's forehead per the manufacturer's recommendation on arrival to the operating room. The intervention in this study will add an additional BIS sensor to the patient's forehead. After syncing the two monitors for time, and ensuring appropriate skin contact and signal quality of both sensors, BIS monitoring will commence. BIS readings will be available every 12 seconds during the duration of the study, yielding up to 240 points of comparison per enrolled patient.
3448630|NCT04062604||Femur fracture|Stabilization of femur fracture according to the AO fundation guidelines
3448631|NCT04062604||Hip alloplasty|Endoprothesis
3448632|NCT04062604||Knee alloplasty|Endoprothesis
3448633|NCT04062604||Knee arthroscopy|Resection of the meniscus lesion or anterior cruciatus ligamentum reconstruction
3448634|NCT04062149|Active Comparator|Control Group|The control group will be the group where the participants receive only their normal physiotherapy treatment.
3448635|NCT04062149|Experimental|Experimental Group|The experimental group will be the group where participants receive physiotherapy aimed at improving their ability to stand on their weaker leg alongside their normal physiotherapy treatment.
3448636|NCT04062578|Experimental|CD Oliver|Female first team players of the club that plays in the National Second Division league.
3448637|NCT04062578|Active Comparator|SD Huesca|Female first team players who play in the Aragonese Territorial First league
3448638|NCT04062292||Obstructive lung diseases group|"Having been diagnosed with obstructive pulmonary disease,~No acute exacerbation or infection in the past 1 week, Being between the ages of 18 and 65,"
3448639|NCT04062292||Healthy group|Age and sex matched healthy subjects without orthopedic and chronic diseases
3448640|NCT04062513|Experimental|Olfactive stimulation intervention with familiarization|Participants will receive the olfactive stimulation intervention with mothers' milk odor during a previous period of nine hours and during heel prick. Sucrose will be also administered during heel prick.
3448641|NCT04062513|Experimental|Olfactive stimulation intervention|Participants will receive the olfactive stimulation intervention with mothers' milk odor during heel prick only. Sucrose will be also administered during heel prick.
3448642|NCT04062513|Other|Standard care|In the control arm, participants will receive the standard care for pain which is sucrose administration.
3448643|NCT04062318|Experimental|Tactile detection task with online TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over somatosensory cortex during the tactile detection task.
3448644|NCT04062318|Active Comparator|Tactile detection task with online control TMS-EEG|Participants receive perceptual threshold-level tactile stimuli to the third digit of the right hand and report detection or non-detection. EEG is recorded and TMS is applied over a control brain region during the tactile detection task. This control condition is intended to mimic the peripheral (e.g. cranial/facial muscle and/or nerve activation, auditory evoked response), but not biological effects of TMS specifically related to somatosensory perception.
3448645|NCT04062123|Experimental|Dexmedetomidine|Subjects in this group will receive dexmedetomidine during the drug portion of the experiment.
3448646|NCT04062123|Experimental|Propofol|Subjects in this group will receive propofol during the drug portion of the experiment.
3448647|NCT04062123|Experimental|Fentanyl|Subjects in this group will receive fentanyl during the drug portion of the experiment.
3448648|NCT04062591|Active Comparator|piroxicam|piroxicam group who received induction with piroxicam(0.4mg/kg) IM
3448649|NCT04062591|Sham Comparator|placebo|saline IM in the same dose of piroxicam
3448650|NCT04062344||Short oral drug provocation test|Minors performing a short (1-4 days) drug provocation test
3448651|NCT04062344||Prolonged oral drug provocation test|Minors performing a prolonged (5-8 days)drug provocation test
3448652|NCT04062565|Experimental|Experimental|Treprostinil and Riociguat
3448653|NCT04062136|Experimental|Stem cell transplantation|1 million umbilical Cord Mesenchymal Stem Cells per body kg will transplant via the intravenous at baseline, and the second transplantation will be performed 1 week after the first transplantation
3448654|NCT04062201|Experimental|Study Strategy|
3383848|NCT05166395|Experimental|Er:YAG laser Group|The study is a split-scar model. Participants will have half of their lesion receive a total of three sessions using 2940 nm Er:YAG laser spaced over a 4-week study participation interval.
3383849|NCT05166395|No Intervention|Control (No Intervention) Group|The study is a split-scar model. Participants will serve as their own control and have half of their lesion receive no intervention.
3383850|NCT05166382|Experimental|Group 1: SomaSignal Informed Medical Management (CVDT2D test, informed)|Blood draw for cardiovascular CVDT2D test at baseline and 6 months (+/- 30 days). SomaSignal Test results will be sent to the providers and then shared with study participants. Participants' medical record will be reviewed, and they may be contacted within 30 days after baseline and 6-month visits to review changes in treatment strategy (nothing, add/remove medication, etc.) made at visit.
3383851|NCT05166382|Placebo Comparator|Group 2: Standard of Care (CVDT2D test, uninformed)|Similar to group 1 but SomaSignal CV test results will not be provided to participants until after the intervention period.
3383852|NCT05166369|Experimental|Intervention targeted to healthcare providers (paediatricians, nurses and pharmacists) (ITHP)|"Professionals in the PC centres allocated to this group will receive a complex intervention, delivered remotely, which will include the following components:~i) Web based training that will include: communication skills training and optimal management of acute non-complicated RTI, including a specific training on delayed antibiotic prescription.~ii) By-monthly feedback about the rate of antibiotic prescription and consumption for RTI, center level and individual pediatrician level (information automatically gathered from electronic health records)."
3383853|NCT05166369|Experimental|Intervention targeted to parents (ITP)|PC centres allocated to this group will display posters and flyers to inform parents and/or caregivers about a mobile app. It will provide detailed information about respiratory tract infections and optimal use of antibiotics. The app will include information that will be of use before the consultation, but it will also allow the patient to interact with the physician during the consultation, potentially improving share decision-making. Importantly, the app will allow tailoring the guidance provided according to the type of infection or number of days with symptoms. The app will be accessible through an app store or directly using a QR (quick response) code to facilitate uptake. Professionals in the primary care centres allocated to this group will also receive a by-monthly feedback about the rate of antibiotic prescription and consumption for RTI, at center level and individual pediatrician level (information automatically gathered from electronic health records).
3383854|NCT05166369|Experimental|Intervention targeted to patients and/or patient´s parents and to the healthcare providers (ITHP*P)|Centres allocated to this group will receive the two interventions described above (intervention targeted to parents plus intervention targeted to providers).
3383855|NCT05166369|No Intervention|Control group|The centers allocated to this arm of the study will continue with their usual care. To avoid a potential Hawthorne effect (observer effect) these centers will not be informed about their participation as controls.
3383856|NCT05166356||Patients|A sample of patients who received the NOHARM intervention after their surgery.
3383857|NCT05166356||Care Team Members|Staff members who had patients on the NOHARM intervention
3383858|NCT05166343|No Intervention|Standard of Care|All POHCA events will be handled per standard of care of epinephrine administration via intravenous or intraosseous (IV/IO) based on patient estimated weight.
3383859|NCT05166343|Other|Intramuscular Epinephrine Dose|"POHCA events will be handled per standard of care, however, first dose epinephrine administration will be via intramuscular (IM) autoinjector. Dosing will be dependent on weight as follows:~3-5kg=0.3mg IM epinephrine 6-9kg=0.5mg IM epinephrine 10-24kg=1.0mg IM epinephrine~≥25kg=1.5mg IM epinephrine"
3383860|NCT05166330|Active Comparator|ketofol 1:1|0.15-0.2 mL/kg from of 5 mg/mL propofol and 5 mg/mL ketamine mixture
3383861|NCT05166330|Active Comparator|ketofol 1:3|0.15-0.2 mL/kg from of 7.5 mg/mL propofol and 2.5 mg/mL ketamine mixture
3383862|NCT05166317||Liver Cirrhosis|All the consecutive patients of cirrhosis admitted to Intensive care unit of Hepatology department of ILBS.
3383863|NCT05166304|Placebo Comparator|placepo|patients will receive the standard therapy (methotrexate) plus placebo tablets
3383864|NCT05166304|Experimental|rebamipide|100 mg rebamipide taken orally daily plus Methotrexate 7.5 mg weekly
3383865|NCT05166291|Experimental|traditional anesthesia (TA)|traditional anesthesia
3383866|NCT05166291|Experimental|comfort-in injection system (CIS)|comfort-in injection system (CIS)
3383867|NCT05166278|Experimental|EXPER|Deescalation training.
3383868|NCT05166278|No Intervention|CONTR|Management of aggressive behaviour as usual.
3383869|NCT05166265|Experimental|Sentio system|Prospective, open label, single-arm multi-centre investigation following clinical practice for bone conduction devices.
3383872|NCT05166239|Experimental|HAIC-Cola group|Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. 12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily after HAIC. 200 mg of Camrelizumab injection intravenously for 1h before 24h of HAIC every 4 week.
3383873|NCT05166239|Active Comparator|Cola group|12/8 mg (weight ≥ 60kg / < 60 kg) of Lenvatinib once daily. 200 mg of Camrelizumab injection intravenously for 1h every 4 week.
3383874|NCT05166213||Chronic back pain|
3383875|NCT05166213||Clinically significant menopausal complaints|
3383876|NCT05166213||Parkinson's disease|
3383877|NCT05166213||Migraine|
3383878|NCT05166213||Cancer-related emesis/nausea|
3383879|NCT05166200|Experimental|Experimental Formula|One 237 ml serving of study product
3383880|NCT05166200|Active Comparator|Test Meal|48 g Instant oatmeal
3383881|NCT05166187|Experimental|Intervention|Patients randomized to the intervention arm will have a Best Practice Advisory (BPA) displayed as part of the discharge order workflow. This BPA requires clinicians to choose an option before completing the discharge documentation. Options include ordering one of the appropriate statins or documenting that the medication is contraindicated, the patient declined, or the patient does not meet criteria for a high-intensity statin.
3383882|NCT05166187|No Intervention|Usual Care|Patients randomized to the usual care arm will have the identical set of windows displayed in the discharge workflow minus the BPA window.
3383883|NCT05166174||Pregnant women who underwent previous cesarean section with barbed suture|"This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed by using barbed suture (Fish-bone suture)."
3383884|NCT05166174||Pregnant women who underwent previous cesarean section with conventional smooth suture|This group includes pregnant women, who underwent a previous cesarean section. During the previous surgical procedure, the hysterotomy was closed conventional smooth suture.
3383885|NCT05166161|Experimental|PTC923|Participants will receive PTC923 7.5 milligrams (mg)/kilogram (kg (participants 0 to <6 months of age), 15 mg/kg (participants 6 to <12 months of age), 30 mg/kg (participants 12 months to <2 years of age), or 60 mg/kg (participants ≥2 years of age) orally once daily for a minimum of 12 months or until participant experiences lack of efficacy.
3383886|NCT05166148|Experimental|eccentric cycling compared to concentric cycling|Every participant will perform the same protocol and will participated to the 3 experimental sessions (a, b and c) of the assigned intervention.
3383887|NCT05166135||Acute Myeloid Leukemia|Patients ≥18 years old at diagnosis, with de novo AML diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for AML within the study period.
3383888|NCT05166135||Relapsed/Refractory Acute Lymphoid Leukemia|Patients ≥18 years old at diagnosis, with R/R ALL diagnosed between 01 January 2015 and 31 December 2019, as documented in the medical chart and according to the physician's notes, and with at least 1 line of treatment for R/R ALL within the study period.
3383889|NCT05166122|Active Comparator|AI workflow|In AI work flow, patients will be screened by taking normal retinal images and all images will be assessed for the severity of diabetic retinopathy by a computerized artificial intelligence system immediately after the photograph is taken via the Internet and retinal images will be sent to the retinal ophthalmologist for overreading.
3383890|NCT05166122|No Intervention|Manual workflow|Volunteers who have been screened by manual workflow will be screened by imaging the retina and image that are not normal will be sent to assess the severity of diabetic retinopathy by specialist staff.
3383891|NCT05166109|Experimental|Vamorolone 500mg/day [250mg if <50kg body weight]|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
3383892|NCT05166109|Placebo Comparator|Placebo|Subjects will be randomized to one of two treatment groups in a 1:2 ratio (placebo:vamorolone).
3383893|NCT05166096|Experimental|Rho-11 administered in Period 1, oral aspirin administered in Period 2|
3383894|NCT05166096|Experimental|Oral aspirin administered in Period 1, Rho-11 administered in Period 2|
3383895|NCT05166083||Trans man|"Trans man is assigned female at birth and identify as man"
3383896|NCT05166070|Experimental|Administration of RD133|"Three dose groups of 1.0×10^6 CAR-T/kg, 3.0×10^6 CAR-T/kg, and 6.0×10^6 CAR-T/kg RD133 are designed in this study. 3 to 6 subjects are expected to be enrolled in each dose group according to observed DLT.~RD133 will be intravenously infused at least 24 hours after lymphodepletion preconditioning. According to the assigned dose group, the designated dose of RD133 will be infused in a single infusion within 30 minutes on day 0."
3383897|NCT05166057|Experimental|Telerehabilitation Group (TG)|TGr will be given online exercises, synchronized 2 days a week, and a home program for 1 day, accompanied by a physiotherapist, via videoconference on the group smartphone.
3383898|NCT05166057|Experimental|Video Group (VGr)|After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent to them and the patients will be asked to do their exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling them once a week.
3383899|NCT05166057|Experimental|Standard pulmonary rehabilitation group (SGr)|The SGr group will be applied the pulmonary rehabilitation program with supervision in the hospital 2 days a week, and they will be asked to do their exercises at home for 1 day. The exercise period will be 8 weeks for both groups.
3383900|NCT05166044||Safety group|All of the participants(N=5000) received one dose of EV71 vaccine and one of other vaccines(such as MMR vaccine,encephalitis vaccine,mumps vaccine,inactivated poliomyelitis vaccine,influenza vaccine and so on ) at the same time.
3383901|NCT05166031|Active Comparator|bOPV dose|Naïve infants to receive two doses of bOPV at 2 and 3 months of age.
3383902|NCT05166031|Active Comparator|nOPV2 dose|Naïve infants to receive two doses of nOPV2 at 2 and 3 months of age.
3383903|NCT05166031|Experimental|bOPV + nOPV2 dose|Naïve infants to receive two doses of nOPV2 and bOPV at 2 and 3 months of age.
3383904|NCT05166018|Experimental|SuMO Patient|"92 data will be collected during the patient care episode. Among the 92 criteria, 63 are pre-operative, 29 are post-operative in order to provide an evolutionary prediction during the management of the patient.~Post-operative follow-up criteria making it possible to establish the scalability or non-scalability of the quality of life after the surgical procedure.~The results will be compared to the prediction proposed by the machine learning algorithm."
3383905|NCT05166005|Active Comparator|High dose|High dose Vitamin D therapy will initiate at a dosage of 50,000 IU on the first and second week of hospitalization
3383906|NCT05166005|Placebo Comparator|Low dose|Vitamin D therapy will prescribe at a dosage of 2,000 IU/day
3448655|NCT04062201|Active Comparator|Control Strategy|
3383907|NCT05165992|Active Comparator|Nebulized Fentanyl|Intervention group (n=100): Administration of nebulized Fentanyl (25 μg in 5 ml of normal saline) over 15 mins, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
3383908|NCT05165992|Placebo Comparator|Nebulized 0.9% Saline Solution|Control group (n=100): Administration of nebulized 0.9% saline solution (5 ml of normal saline), over 15 minutes, thrice daily using a traditional nebulizer. Treatment duration - 48 hours
3383909|NCT05165979||Hospitalized COVID-19 patients|Hospitalized COVID-19 patients
3383910|NCT05165966|Experimental|Experimental Group-High-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with high-dosage of COVID-19 vaccine (Vero cell), Inactivated.
3383911|NCT05165966|Experimental|Experimental Group-Medium-dosage of COVID-19 vaccine (Vero cell), Inactivated|170 participants will receive one dose of booster vaccination with medium-dosage of COVID-19 vaccine (Vero cell), Inactivated.
3383912|NCT05165953||Group 1: COVID-19 positive with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
3383913|NCT05165953||Group 2: COVID-19 positive with no asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
3383914|NCT05165953||Group 3: COVID-19 negative with asthma|"data were collected from medical records including: history of COVID -19 infection, presenting symptoms and clinical examination, hospitalization either ICU or ward. For asthma patients, their full data were collected regarding asthma control in last 3 months following GINA criteria for asthma control [8], Investigations included; CBC with differential count, WBC, lymphocytes, eosinophils, HGB and platelets, Inflammatory markers as d-dimer, LDH and ferritin level, electrolytes, BUN, serum creatinine, CXR, and old spirometry reports.~Diagnosis of COVID 19 infection was made by a positive nasopharyngeal and throat swabs COVID 19 polymerase chain reaction (PCR)."
3383915|NCT05165940|Active Comparator|TAU|Treatment As Usual with a VA mental health treatment coordinator
3383916|NCT05165940|Experimental|New Health Services Intervention|Novel health services intervention with a VA mental health treatment coordinator
3383917|NCT05165927|Experimental|BFR Group|BFR cuffs will be used for specific exercises and added to the current SOC for post hip scope PT.
3383918|NCT05165927|No Intervention|SOC Group|Current SOC for post hip scope PT will be assigned.
3383919|NCT05165914|Active Comparator|Midazolam group|In the midazolam group, patients double blindly received 0.03 mg.kg-1 midazolam intravenously just before emergence from general anesthesia.
3383920|NCT05165914|Placebo Comparator|Placebo group|In the placebo group, patients double blindly received normal saline of similar volume to midazolam just before emergence from general anesthesia.
3383921|NCT05165901|Experimental|Nociceptive pain|patients with joint pain (knee and shoulder), myofascial pain syndrome
3383922|NCT05165901|Experimental|Neuropathic pain|patients with postherpetic neuralgia, peripheral nerve injury (CRPS type II, brachial plexopathy, nerve entrapment syndrome)
3383923|NCT05165901|Experimental|Mixed pain|patients with spine or SIJ origin back and buttock pain or neck pain and SPINE-origin back pain과 neck pain, SIJ-origin back and buttock pain
3383924|NCT05165888|Experimental|Communication and Bias Mitigation Training|This is a communication training session based on a culturally-based program developed with rural, southern Black patients and families and modified for an urban, northern population. A strategy of bias mitigation successfully used with medical students will be adapted for practicing clinicians using results of phase 1. This strategy is based on transformational learning theory and incorporates critical reflection, guided dialogue, perspective taking exercises, role plays and strategy development. If specific communication behaviors are found related to bias and stereotyping in phase 1, these will be discussed and targeted using these techniques. Otherwise, these techniques will be used to address racial bias generally. The intervention will be incorporated within the communication training session.
3383925|NCT05165888|Active Comparator|Communication Training Only|This is a communication training session based on standard palliative care techniques to listen empathically, share prognostic information and treatment options, elicit patient and family goals and values related to their treatment, and facilitate shared decision-making regarding end-of-life treatment.
3383926|NCT05165875|Other|Randomized: Steroid injection|1ml injection of a mixture of 0.5ml triamcinolone acetonide (50mg/5ml) and 0.5ml 1% lignoacaine is given intra-thecally into the first extensor compartment.
3383927|NCT05165875|Other|Randomized: Splint|a long thumb spica thermoplastic splint (wrist neutral, 30º CMCJ flexion, 30º thumb abduction, IPJ free) will be customized and intermittent active range of motion exercises will be taught for 4 weeks
3383928|NCT05165849|Experimental|GFS101A+Toripalimab|Patient will be administrated with GFS101A IV in combination with Toripalimab IV. The duration of the treatment cycle is defined as 21 days.
3383929|NCT05165836|Placebo Comparator|Erector Spinae Plane block without Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL saline
3383930|NCT05165836|Experimental|Erector Spinae Plane block with Dexmedetomidine group|Patients received Ultrasound-guided Erector Spinae Plane block at T2 using 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg
3383931|NCT05165823|Experimental|Sodium restriction|Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.
3383932|NCT05165823|No Intervention|Usual diet|
3383933|NCT05165810|Active Comparator|Arm 1: standard ART initiation + government-based HIV care + routine adherence support|Participants randomized to Arm 1 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
3383934|NCT05165810|Experimental|Arm 2: same-day ART + government-based HIV care + routine adherence support|Participants randomized to Arm 2 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
3383935|NCT05165810|Experimental|Arm 3: standard ART initiation + community-based HIV care + routine adherence support|Participants randomized to Arm 3 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
3383936|NCT05165810|Experimental|Arm 4: standard ART initiation + government-based HIV care + enhanced adherence support|Participants randomized to Arm 4 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
3383937|NCT05165810|Experimental|Arm 5: same-day ART initiation + community-based-based HIV care + routine adherence support|Participants randomized to Arm 5 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive routine adherence support should they experience treatment failure at 6 months [usual care].
3383938|NCT05165810|Experimental|Arm 6: same-day ART initiation + government-based-based HIV care + enhanced adherence support|Participants randomized to Arm 6 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a government HIV clinic [usual care], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
3383939|NCT05165810|Experimental|Arm 7: standard ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 7 will i) initiate ART on a standard timeline [usual care], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
3383940|NCT05165810|Experimental|Arm 8: same-day ART initiation + community-based-based HIV care + enhanced adherence support|Participants randomized to Arm 8 will i) initiate ART on the day of enrollment [experimental], ii) receive ongoing care in a PWID-focused community-based site [experimental], and iii) receive enhanced adherence support should they experience treatment failure at 6 months [experimental].
3383941|NCT05165784|Active Comparator|V technique|Researcher will perform the V tecnique on the patient's inguinal area
3383942|NCT05165784|Active Comparator|palpation tecnique|Researcher will perform the V tecnique on the patient's inguinal area
3383943|NCT05165771|Experimental|GS-5718 Dose A|Participants will receive GS-5718 Dose A once daily + placebo to match (PTM) GS-5718 Dose B once daily + PTM tofacitinib twice daily for up to 12 weeks.
3383944|NCT05165771|Experimental|GS-5718 Dose B|Participants will receive GS-5718 Dose B once daily + PTM GS-5718 Dose A once daily + PTM tofacitinib twice daily for up to 12 weeks.
3383945|NCT05165771|Active Comparator|Tofacitinib|Participants will receive tofacitinib 5 mg twice daily + PTM GS-5718 (Dose A + Dose B) once daily for up to 12 weeks.
3383946|NCT05165771|Placebo Comparator|Placebo|Participants will receive PTM GS-5718 (Dose A + Dose B) once daily + PTM tofacitinib twice daily for up to 12 weeks.
3383947|NCT05165758||Diabetic subjects without foot ulcer|27 diabetic subjects without foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
3383948|NCT05165758||Diabetic subjects with foot ulcer|54 diabetic subjects presenting foot ulcer will answer to the SF-36 score (mental health items) and to a french precarit index (EPICES:Evaluation de la précarité et des inégalités de santé dans les Centres d'examens de santé)
3383949|NCT05165745|Other|Cisgender Women and Trans Individuals (CWTI)|Cisgender women and trans individuals (CWTI) who are taking PrEP, have considered and decided not to take PrEP, or who have discontinued PrEP.
3383950|NCT05165732|Experimental|Experimental Group 1|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
3383951|NCT05165732|Experimental|Experimental Group 2|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
3383952|NCT05165732|Experimental|Experimental Group 3|96 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd. will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Beijing institute of Biological Products Co.,Ltd.
3383953|NCT05165732|Experimental|Experimental Group 4|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Sinovac Research & Development Co.,Ltd.
3383954|NCT05165732|Experimental|Experimental Group 5|92 subjects who completed primary immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd will receive one dose of booster immunization with inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.
3383955|NCT05165719||Vaccinated|SARS-CoV-2 vaccination with 'Sputnik V' (Gam-COVID-Vac) in a period 7-14 days after the second vaccination before recruitment
3383956|NCT05165719||Convalescents|PCR (polymerase chain reaction) confirmed COVID-19 in a period 14-45 days before recruitment
3383957|NCT05165719||Healthy donors|No self-reported COVID-19 infection
3383958|NCT05165706|Experimental|Mediterranean Low Carbohydrate Diet|
3383959|NCT05165706|Experimental|Standard Low Carbohydrate Diet|
3383960|NCT05165706|Experimental|Low Fat, Healthy Carbohydrate Diet|
3383961|NCT05165693|Experimental|Experimental Formula|One 296 mL serving of study product
3383962|NCT05165693|Active Comparator|Test Meal|48 g Instant oatmeal
3383963|NCT05165680|Experimental|experimental group, group A|Thirty patients in this group will perform aerobic exercise in the form of walking on electric treadmill three times/ week day after day and low caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
3383964|NCT05165680|Active Comparator|healthy diet|ow caloric diet rich in iron, vitamin C and folate and iron supplement for 12 weeks.
3383965|NCT05165667|Experimental|team meeting|the team meeting will help to measure the effectiveness of rehabilitation team meeting on disability among stroke patinets in Functional Independent Measure (FIM) score
3383966|NCT05165667|Active Comparator|patient|they will be the subject
3383967|NCT05165654|Experimental|Active Stimulation with TDCS|10 tDCS; Two, twenty-minute sessions of tDCS to the rSTS for 5 days (10 total sessions).
3383968|NCT05165654|Sham Comparator|SHAM Stimulation|10 passive sham control; Two, twenty-minute sessions of passive sham control to the rSTS for a 30 second ramped up and down at the beginning and end of the 20 min period for 5 days (10 total sessions).
3383969|NCT05165641|Other|segmental spinal anesthesia|thoracic spinal anesthesia at T 10 level
3383970|NCT05165628|Experimental|Group 1 - CYP-006TK|Participants will receive CYP-006TK dressings
3383971|NCT05165628|No Intervention|Group 2 - Standard of Care|Participants will continue to be treated as per local standard of care
3383972|NCT05165615|Experimental|AndroidAPS versus Control-IQ|Patients with use of the Control-IQ system (closed-loop hybrid system) and previous users of AndroidAPS (closed-loop hybrid system)
3383973|NCT05165589|Experimental|Part 1: Initial data collection for device feasibility|3 subjects for 4 days included to collect initial data for algoritm development for device feasibility
3383974|NCT05165589|Experimental|Part 2: Device feasibility|10 subjects for 7 days included to evaluate device feasibility
3383975|NCT05165576|Experimental|Child-centered communication|The child's preparation for the MRI scanning is conducted using a child-centered communication type of interaction
3383976|NCT05165576|Active Comparator|Magnetic Resonance Imaging (MRI) Simulation Toy|The child's preparation for the MRI scanning is conducted through provision of general information about the MRI exam simulated with an MRI toy
3383977|NCT05165576|No Intervention|General information about the Magnetic Resonance Imaging (MRI) exam|The child's preparation for the MRI scanning is based on the provision of routine information about the MRI exam
3383978|NCT05165563|Experimental|Workflows|Digital and conventional workflows for treatment of implant single crowns
3383979|NCT05165563|Experimental|Materials|Materials for treatment of implant single crowns (polymer-infiltrated ceramic networks, PICNs and lithium disilicate, LS2).
3383980|NCT05165550|Experimental|Cohort 1|Elsulfavirine 20 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
3383981|NCT05165550|Experimental|Cohort 2|Elsulfavirine 40 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
3383982|NCT05165550|Experimental|Cohort 3|Elsulfavirine 80 mg. Eight (8) subjects (6 active, 2 placebo) per dose level will be enrolled
3383984|NCT05165524|Active Comparator|Laser|
3383985|NCT05165524|Active Comparator|Cream|
3383986|NCT05165524|No Intervention|Control|
3383987|NCT05165511|Experimental|Executive Function-Enhanced Parent-Based Behavioral Treatment (PBT-EF)|PBT-EF will integrate executive function training with family-based behavioral treatment (FBT) for obesity, the gold-standard behavioral treatment for childhood obesity. PBT-EF will include self-monitoring, calorie reduction, and dietary and physical activity recommendations in addition to planning, organization, and problem-solving skills.
3383988|NCT05165498||Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures|Patients undergoing elective thoracic surgery, abdominal surgery, or having rib fractures who will have placed a thoracic epidural catheter to manage their perioperative analgesia.
3383989|NCT05165485|Experimental|Revefenacin|Revefenacin DoseA administered with tiotropium placebo
3383990|NCT05165485|Active Comparator|Tiotropium|Tiotropium DoseB administered with revefenacin placebo
3383991|NCT05165472|Experimental|Intervention|Real transcranial magnetic stimulation applied
3383992|NCT05165472|Sham Comparator|Sahm-control|Sham transcranial magnetic stimulation applied
3383993|NCT05165459|Experimental|Cytori Celution System in Chronic Non-Healing venous Leg Ulcers|On the screening visit, the study physician will assign one eligible ulcer, as the target ulcer. Target ulcer will be treated and followed up during the whole study period. After liposuction investigational device will be applied on the target ulcer. After completion of Day1 visit all subjects enter the observation period and will come back to 3 on-site visits on day 7 day 14 and day 28
3383994|NCT05165433|Experimental|All cohorts|NG-350A and pembrolizumab
3383995|NCT05165420||RV4941A arm|RV4941A study product is applied twice a day (morning and evening) on the face, neck and eye contour during the whole study.
3383996|NCT05165407|Experimental|Sintilimab Combined With IBI310 and Surufatinib|Surufatinib at a dose of 250mg QD, with Sintilimab injected intravenously 200mg per 3 weeks and IBI310 injected intravenously 1mg/kg per 6 weeks until disease progresses or unacceptable tolerability occurs
3383997|NCT05165394|Placebo Comparator|Placebo|Participant follows Placebo schedule (57 days)
3383998|NCT05165394|Experimental|Antidepressant|Participant follows NBI-1065846 schedule (57 days)
3383999|NCT05165381||Contactless vital signs meassurement|Eligible participants will agree to have a 1.5-minute facial video recorded using an iPad. Video will be processed through a specialized algorithm to obtain BP, HR and RR measurements.
3384000|NCT05165355|Experimental|Experimental group|Furmonertinib (80 mg orally, once daily) for 3 years.
3384001|NCT05165342|Experimental|Treatment|This treatment is delivered by contact electrodes built in a mask, which is worn by the patient over closed eyes. The device setup is really easy and intuitive.
3384002|NCT05165342|Sham Comparator|Sham-intervention|The same device as treatment but the power of device will be set to ZERO power.
3384003|NCT05165329|Active Comparator|Probiotic and Peanut Oral Immunotherapy (PPOIT)|Probiotic and peanut oral immunotherapy taken daily for 18 months
3384004|NCT05165329|Active Comparator|Placebo Probiotic and Peanut Oral Immunotherapy|Placebo probiotic and peanut oral immunotherapy taken daily for 18 months
3384005|NCT05165329|Placebo Comparator|Placebo Probiotic and Placebo Oral Immunotherapy|Placebo probiotic and placebo oral immunotherapy taken daily for 18 months
3384006|NCT05165303|Experimental|lidocaine with propofol|
3384007|NCT05165290|Active Comparator|LAT, 0.005%|Commercially available FDA-approved generic latanoprost ophthalmic solution, 0.005%
3384008|NCT05165290|Experimental|TC-002|TC-002, TearClear latanoprost ophthalmic solution, 0.005%
3384009|NCT05165277|Experimental|Acidic phosphate buffer solution|pH5.2 phosphate buffer solution
3384010|NCT05165277|Placebo Comparator|Neutral phosphate buffer solution|pH7.4 phosphate buffer solution
3384011|NCT05165264||Cohort 1|Participants with previously untreated advanced or metastatic gastric cancer (GC), gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma (EAC)
3384012|NCT05165251|Experimental|Amlopine/atorvastatin|amlodipine/atorvastatin (5mg/10mg QD)
3384013|NCT05165251|Active Comparator|Amlodipine|amlodipine (5mg QD)
3384014|NCT05165251|Other|Lifestyle intervention|
3384015|NCT05165238|Experimental|Coaching program|Participants will complete a 4-week coaching program in an on-line group setting. The purpose of the program will be to help participants change dietary behaviors via a small changes approach.
3384016|NCT05165225|Experimental|Pyrotinib|Experimental: Patients will receive Pyrotinib combined with Epirubicin and Cyclophosphamide followed by Docetaxel
3384017|NCT05165212|Experimental|Patients receiving one dose of amoxicillin.|Patients receiving one dose of amoxicillin and then observed for one hour for signs/symptoms off allergic reaction.
3384018|NCT05165199|Experimental|Elobixibat|10mg Elobixibat administration for 4 weeks
3384019|NCT05165186|Experimental|Video Intervention Arm|For participants randomized to the video intervention arm, participants will be shown two videos about Advanced Care Planning, and then they will be asked questions regarding the usefulness of the video and their comfort with the video
3384020|NCT05165186|No Intervention|Control Arm|For participants randomized to the control group arm, participants will review an informational sheet, which covers the same information as the videos shown to the intervention arm.
3384021|NCT05165173|Experimental|Intervention|Based on estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the nanoparticle group.
3384022|NCT05165173|Active Comparator|Comparator|Based on the estimated glomerular filtration rate (eGFR) and vitamin D levels, participants will be placed into the microparticle group.
3384024|NCT05165147||physical examination population|From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
3384025|NCT05165134|Experimental|Experimental kinesiotape group A|Kinesiotape group
3384026|NCT05165134|Placebo Comparator|Placebo kinesiotape group B|Control group
3384027|NCT05165121|Other|Human Factors|The purpose of the human factor study was to verify the feasibility of self-fitting MDHearing Smart hearing aid by listeners with a mild to moderate sensorineural hearing loss.
3384028|NCT05165121|Other|Clinical Study|The clinical study included two groups of subjects (self-fit and professional-fit groups) with the main purpose to compare the fitting outcomes between the two fitting groups. The professional-fit group aimed to show whether the MDHearing Smart hearing aids can be fitted by audiology professional on each user reliably and if each user can benefit from using the MDHearing smart hearing aids. The self fit group intended to show whether the MDHearing Smart hearing aids can be fitted by each user reliably and if each user can use the MDHearing app on their smartphone or tablet to make adjustments to achieve a good aided benefit.
3384029|NCT05165108|Experimental|Non-Invasive VNS|Non-Invasive VNS will decrease inflammation in people with Crohn's disease leading to decrease in inflammatory markers and symptoms of disease.
3384030|NCT05165082|Experimental|Timolol plus cryotherapy|Apply topical timolol solution twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen every other week (at the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
3384031|NCT05165082|Placebo Comparator|Placebo plus cryotherapy|Apply placebo (normal saline) twice daily (since the beginning of the allocation and continue for 8 weeks) and cryotherapy with liquid nitrogen every other week (at the allocation day, at the 2nd week, 4th week and 6th week after the beginning of the trial).
3384032|NCT05165069|Experimental|Mecobalamin group|Mecobalamin (0.5mg / time, 3 times / day) for 6 months
3384033|NCT05165069|Placebo Comparator|Placebo group|placebo (0.5mg / time, 3 times / day) for 6 months
3384034|NCT05165056|Experimental|Treatment group|Patients allocated to the treatment group will receive institutional standard vaginal care in combined with twice weekly PBMT sessions during the radiotherapy course and until two weeks after the end of radiotherapy.
3384035|NCT05165056|No Intervention|Control group|Patients allocated to the control group will receive institutional standard vaginal care.
3384036|NCT05165043||PC group|"The patients who conducted position change due to massive EGVB resulting in poor visualization in the stomach were included. The patients were characterized in terms of age, sex, causes of liver cirrhosis, adverse events (AEs) during position change, additional findings after body position change, treatment regimens and follow-up information.~During position changing procedure, endoscopist withdrew the gastroscope from the stomach and patients changed from the left lateral position to the right lateral position with the help of the nurses. Then endoscopist reinserted the gastroscope into the stomach and tried to detect the addition varices after position change.~Bleeding varices were treated by injection of N-butyl-Cyanoacrylate glue (glub B or Beltran, Compex) or/and Lauromacrogol (Shanxi, Tianyu)."
3384037|NCT05165030|Experimental|Blood Sample|Blood Sample
3384038|NCT05165017|Active Comparator|Intervention Arm 1|AlloRx Stem Cells IV infusion treatment
3384039|NCT05165017|Placebo Comparator|Intervention Arm 2|IV infusion of normal saline
3384040|NCT05165004|Experimental|Kangaroo Mother Care|Researchers contacted the mother a day before applying KMC, and advised her to take shower and abstain from using perfumes before attending to the NICU. On days of KMC application, the researchers asked the mother to remove the upper clothes in a private room and put on an open-front gown and mask. The mother was assisted to sit in a comfortable chair with a soft backrest and footrest to prevent fatigue. Then, the preterm neonate was carefully put naked except for the head and diaper area on the mothers' bare chest with flexed arms and legs as in froglike position, and the head was turned sideways. The researchers wrapped and secured the mother's gown and put a blanket on the neonates' back to ensure neonatal thermal insulation. The mother was instructed to support the neonate's bottom with the right hand while supporting the head and neck with the other hand.
3384041|NCT05165004|Experimental|Hammock Positioning|Researchers made a hammock by using a rectangular cotton cloth with ropes that passed through the circular openings of the incubator and tied on the upper part of it. After one hour of feeding, the preterm neonate was placed in a supine fetal position in the hammock where the head was supported in a neutral midline position by using rolled towel without neck hyperflexion or hyperextension. Moreover, the spine of the preterm neonate was supported while arms and knees were flexed.
3384042|NCT05165004|Active Comparator|NICU Routine Care|The preterm neonates in the control group received the routine care of the NICU, which entails; encircling the neonate in a fetal position using rolled towel inside the incubator.
3384043|NCT05164991|Experimental|MR imaging|The experiment is aimed to induce a virtual rubber hand illusion, in which the individuals can potentially experience an embodiment illusion
3384044|NCT05164978|Experimental|DEP combine with PD-1 antibody|doxorubicin (doxorubicin hydrochloride liposome injection) 25 mg/m2 day 1; etoposide 100 mg/m2 was administered day1; methylprednisolone 1.5mg/kg days 1 to 3,then 0.25mg/kg day 4 to 14; sintilimab injection 200mg day 4. This regimen was repeated after 2 weeks.
3384045|NCT05164952|Experimental|Delayed use of zoledronic acid arm|delayed-ZOL patients will receive ZOL only if their T-score fall below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture will be detected by spinal X-ray at the 3- monthly assessment.
3384046|NCT05164952|Experimental|Immediate use of zoledronic acid arm|Immediate-ZOL patients will receive ZOL immediately after randomization
3384047|NCT05164926|Experimental|Experimental group, whose perineum was massaged with St. John's Wort oil during labor|St. John's Wort oil will be applied to this group during perineal massage during labor.
3384048|NCT05164913||Control group|No general anesthesia between 0-3 years old or 0-5 years old
3384049|NCT05164913||Single anesthesia group|Only once general anesthesia between 0-3 years old or 0-5 years old
3384050|NCT05164913||Multiple anesthesia group|More than once general anesthesia between 0-3 years old or 0-5 years old
3384051|NCT05164900|Experimental|patients with nasal pterygium.|
3384052|NCT05164887||MIRACLe patients|"Patient affected by colorectal cancer submitted to laparoscopic resection with MBP + OA + perioperative Probiotics administration.~MBP = oral polyphosphate 500ml preoperative OA = Amoxicillin/Clavulanic acid 1g x 2 + metronidazole 250mg x 3 Probiotics = Streptococcus thermophilus; Bifidobacterium breve; Bifidobacterium longum; Bifidobacterium infantis; Lactobacillus acidophilus; Lactobacillus plantarum; Lactobacillus paracasei; Lactobacillus delbrueckii subsp. Bulgaricus 4,4g x 2"
3384053|NCT05164874|Experimental|Intervention|"Women will receive a proposition for an appointment at the MMU in complement to the current screening invitation, keeping the choice of their place of screening.~Women will also receive the timetable of prevention actions with the invitation to participate in screening."
3384054|NCT05164874|No Intervention|Control|No change from the usual breast cancer screening organization
3384055|NCT05164861|Experimental|"Intervention/kombucha-based beverage Black currant with juniper"|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha Black currant with juniper, enriched with inulin and vitamins"
3384056|NCT05164861|No Intervention|Control|Subjects of this group will receive standard diet with similar quantity of water as in experimental group
3384057|NCT05164861|Experimental|"Intervention/kombucha-based beverage Strawberries with lime"|"Subjects randomized to this group will receive newly developed food product - non-alcoholic pasteurized beverage based on kombucha Strawberries with lime, enriched with inulin and vitamins"
3384058|NCT05164848|Experimental|Cohort A|"JMT101 combined with two dose levels of afatinib will be tested according to the 3 + 3 dose-escalation design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days)."
3384059|NCT05164848|Experimental|Dose Expansion Cohort|Once the safe and effective dose has been determined, an expansion cohort will be recruited to further evaluate the efficacy and safety of the selected dose.
3384060|NCT05164835|Experimental|Experimental|
3384061|NCT05164822||Necrotizing Vasculitis|Patient with an initial diagnosis of necrotizing vasculitis having a symptomatic peripheral neurological impairment, associated with systemic necrotizing vasculitis or isolated pure without further visceral impairment
3384062|NCT05164809||Tungsten/Teflon +|Dissection with novel electrodes (Tungsten needle electrode + Teflon coated Spatula electrode)
3384063|NCT05164809||Tungsten/Teflon -|Dissection without novel electrodes (Scalpel + Steel Spatula Electrode)
3384064|NCT05164796|Experimental|IVUS-guided|
3384065|NCT05164783|Experimental|Participants|Intervention: use of SCP
3384066|NCT05164770|Experimental|Zanubrutinib+R+chemotherapy|Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
3384067|NCT05164770|Active Comparator|R+chemotherapy|R-CHOP; R-DA-EPOCH; R-HD MTX
3384068|NCT05164744||Diagnosed with COVID-19|Participants in the study cohort will have been diagnosed with COVID-19 by a PCR (polymerase chain reaction) positive test
3384069|NCT05164731|Experimental|3 months after two doses|the third does was given 3 months after two doses
3384070|NCT05164731|Experimental|4 months after two doses|the third does was given 4 months after two doses
3384071|NCT05164731|Experimental|5 months after two doses|the third does was given 5 months after two doses
3384072|NCT05164731|Experimental|6 months after two doses|the third does was given 6 months after two doses
3384073|NCT05164718|Experimental|Exercise group|
3384074|NCT05164718|Other|Control group|
3384075|NCT05164705|Active Comparator|Intermittent Hypoxia|Participant will visit our center 2-4 times per week for three weeks to receive Acute Intermittent Hypoxia.
3384076|NCT05164705|Sham Comparator|Sham Intermittent Hypoxia|Participants will visit our center 2-4 times per week for three weeks to receive Sham Intermittent Hypoxia.
3384077|NCT05164692|Placebo Comparator|Control|"Control group receives the routine treatment and uses 0.9% NaCl physiological saline:~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
3384078|NCT05164692|Experimental|Navax|"Navax group receives the routine treatment and uses NaCl 0.9% plus B. subtilis and B. clausii at 5 billions CFU/5 mL (LiveSpo®️ Navax):~Routine treatment is as follows:~Oral administrative drugs: antipyretic paracetamol (Efferegant®️); anti-inflammatory corticosteroid methylprednisolon; antibiotics e.g. ampicillin and sulbactam complex (Ama-power®️), tobramycin (Medphatobra®️), or cefotaxim (Goldcefo®️), based on the results of antibiotic susceptibility test.~Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin ®️inhaler) or budesonide (Pulmicort ®️Respules)."
3384079|NCT05164679|Experimental|MMT|Intervention group performing multimodal training (MMT) 1-2 hours weekly
3384080|NCT05164679|No Intervention|CON|Sedentary control group
3384081|NCT05164666|Experimental|TAK-103 Cohort 1|TAK-103, 1 × 10^7 Chimeric antigen receptor (CAR) (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
3384082|NCT05164666|Experimental|TAK-103 Cohort 2|TAK-103, 1 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
3384083|NCT05164666|Experimental|TAK-103 Cohort 3|TAK-103, 5 × 10^8 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
3384084|NCT05164666|Experimental|TAK-103 Cohort 4|TAK-103, 1 × 10^9 CAR (+) cells/body as a starting dose, intravenous infusion, will be administered at approximately 5 mL/min.
3384087|NCT05164640|Other|assessment of coronary physiology|"This is a prospective, multicentric, non-randomized , single-arm , open label clinical study.~Included patients will be studied with invasive functional tests performed during index coronary angiography. These will include FFR, instantaneous Wave-Free Ratio (iFR), Resting Ful-Cycle Ra-tio (RFR), CFR, IMR and provocative Acetylcholine test.~After the diagnosis of vasospastic angina (VSA) or coronary microvascular dysfunction (CMD) is made, a stratified medical therapy will then be initiated according to the results of physiological assessment according to ESC guidelines and recent EAPCI expert consensus document ."
3384088|NCT05164627|Active Comparator|Group A|patients will receive Dexmedetomidine infusion (0.2 mcg/kg/hr) from the start of the surgery till the end of it.
3384089|NCT05164627|Active Comparator|Group B|patients will receive Magnesium infusion (10 mg/kg/hr) from the start of the surgery till the end of it.
3384090|NCT05164627|Placebo Comparator|Group C|Patients will receive Normal Saline 0.9% infusion
3384091|NCT05164263|Experimental|Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months|"Type 2 diabetic males & females between 18-65 years.~HbA1c: 7.0% - 10%~eGFR ˃60 mL/min/1.73m2.~Patient who will give informed consent"
3384092|NCT05161741|Experimental|Uncontrolled diabetes requiring Insulin|
3384093|NCT05161039|Other|Serranator|
3384094|NCT05161039|Other|POBA|
3384095|NCT05160415|Experimental|Treatment|"Drug: EDG-5506~All participants will receive EDG-5506."
3384096|NCT05156125|Experimental|VTX002 Dose A|VTX002 Dose A tablet administered orally once daily
3384097|NCT05156125|Experimental|VTX002 Dose B|VTX002 Dose B tablet administered orally once daily
3384098|NCT05156125|Placebo Comparator|Placebo|Placebo tablet administered orally once daily
3384099|NCT05155449|Active Comparator|Probiotics|Two capsules per day for 8 weeks
3384100|NCT05155449|Placebo Comparator|Placebo|Two capsules per day for 8 weeks
3384105|NCT05153590||Reimbursed|The reimbursed cohort includes only patients who received Saxenda® through mandatory basic insurance
3384106|NCT05153590||Non reimbursed|The non reimbursed cohort includes patients who received Saxenda® through additional private insurance or self-pay
3384107|NCT05153135||Ribociclib|Participants who initiated CDK4/6i therapy
3384108|NCT05153135||Palbociclib|Participants who initiated CDK4/6i therapy
3384109|NCT05153135||Abemaciclib|Participants who initiated CDK4/6i therapy
3384110|NCT05150704|Experimental|Experimental arm|Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care
3384111|NCT05150704|Placebo Comparator|Control arm|Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.
3384116|NCT05147298|Experimental|Environmental group intervention (E only)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment
3384117|NCT05147298|Experimental|Individual-level eHealth phone program intervention (I only)|An automated telephone-based physical activity program.
3384118|NCT05147298|Experimental|Combined group (E and I interventions)|Changing the environment surrounding the PHDs making it more amenable to walking and advocating for changes to the built environment and an automated telephone-based physical activity program.
3384119|NCT05147298|No Intervention|Control group (no interventions)|No interventions for residents to increase activity levels.
3384120|NCT05147246|Experimental|Intervention Schools - School Staff|
3384121|NCT05147246|Experimental|Intervention Schools - Parent-Child Pairs|
3384122|NCT05147246|No Intervention|Wait-List Control Schools - School Staff|
3384123|NCT05147246|No Intervention|Wait-List Control Schools - Parent-Child Pairs|
3384124|NCT05146479||Fluoride varnish (FA group)|Application of 5% NaF varnish onto first permanent molars
3384125|NCT05146479||Fluoride varnish + dental sealant (FA+S group)|Application of 5% NaF varnish plus pit and fissure sealant onto first permanent molars
3384126|NCT05145855||Anosognosia-positive group|Patients will be included in the anosognosia-positive group if they achieved at least one positive anosognosia score before rehabilitation. The anosognosia score for HN will be calculated by subtracting the patient's self-evaluation score from the score assigned by the rehabilitation nurse using the parallel Catherine Bergego Scale.
3384127|NCT05145855||Anosognosia-negative group|Patients will be included in the anosognosia-negative group if they achieved zero or negative anosognosia score before rehabilitation.
3384128|NCT05145829|Experimental|Melanoma patients|All patients will undergo lymphatic mapping with SPIO, 99mTc and PB.
3384129|NCT05145751||COVID-19 infection|Consecutive patients with polymerase chain reaction (PCR) confirmed SARS CoV-2 infection
3384130|NCT05145621|Active Comparator|Test|Fingolimod 0.5 mg capsules - (administered as 3 x Fingolimod 0.5 mg capsules)
3384131|NCT05145621|Active Comparator|Reference|Fingolimod 0.5 mg capsules -(administered as 3 x Fingolimod 0.5 mg capsules)
3384132|NCT05145361|Experimental|B001 injection|Subjects randomized to this arm will receive B001 twice, at day 1 and day 15, up to the end of the study.
3384133|NCT05145361|Placebo Comparator|Placebo|Subjects randomized to this arm will receive Placebo twice, at day 1 and day 15, up to the end of the study.
3384134|NCT05144555|Experimental|Group MET|Patients from this group will undergo orthodontic fixed treatment with stainless steel brackets.
3384135|NCT05144555|Active Comparator|Group CER|Patients from this group will undergo orthodontic fixed treatment with ceramic brackets.
3384136|NCT05144295|Experimental|Investigational Arm|"Patients will receive lubiprostone capsules (Amiprostone 8 and 24 mcg, or Lubicont 8 mcg)~Patients weighing <50 kg will be given lubiprostone at doses of 8 mcg/8 hours.~Patients weighing ≥ 50 kg will be given lubiprostone at doses of 24 mcg BID.~Patients and their parents/legal guardians will be instructed to administer the doses at least 5 hours apart with meals and a large volume of fluid."
3384137|NCT05144295|Active Comparator|Control Arm|"Subjects will receive the conventional therapy (one or a combination of the following):~Lactulose  Lactulose, or Duphalac syrup at a dose of 1 ml/kg once or twice daily (maximum 60 mL/day),~Bisacodyl tablets  Bisacodyl 5 mg/tablet in a dose of 2 tab/day for < 12 years or 3 tab/day for > 12 years, or~Sodium Picosulfate 0.75% drops (Picolax drops) in a daily dose of 2.5-20 mg/day."
3384138|NCT05143489|Active Comparator|Preservative Free Lidocaine Group|The patient will receive a 1mg/kg IV dose of preservative free lidocaine with a max dose of 40mg
3384139|NCT05143489|Active Comparator|Placebo Group|The patient will receive IV normal saline of 1mg/kg with a max of 40mg
3384140|NCT05140538|Active Comparator|Group 1|SRP + Biorepair Total Protective Repair toothpaste for home oral hygiene twice a day
3384141|NCT05140538|Experimental|Group 2|SRP + Biorepair Total Protective Repair toothpaste + Biorepair mouthwash (3 in 1) for home oral hygiene twice a day
3384142|NCT05140187|Experimental|CMV-TCR-T cells|The patients with CMV infection after HSCT will receive a single infusion of donor-derived CMV-TCR-T cells, with the escalated dose ranging from 1×10^4 to 1×10^7 CMV-TCR-T cells.
3384143|NCT05138575|Active Comparator|Empagliflozin + Potassium Chloride (KCl)|"Empagliflozin (10 mg daily) + Potassium Chloride (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
3384144|NCT05138575|Active Comparator|Empagliflozin + Potassium Nitrate (KNO3)|"Empagliflozin (10 mg daily) + Potassium Nitrate (6 mmol three times daily)~Active arm will be 6 weeks in duration followed by a 2 week washout period."
3384145|NCT05138575|Placebo Comparator|Potassium Chloride (KCl) + Placebo for Empa|"Potassium Chloride (6 mmol three times daily) + Placebo for Empagliflozin~Placebo arm will be 6 weeks in duration followed by a 2 week washout period."
3384146|NCT05138458|Experimental|Cohort 1 and Cohort 2|MT-101
3384147|NCT05138458|Experimental|Cohort 3|MT-101 preceded by conditioning (lymphodepleting) chemotherapy
3384148|NCT05137795|Experimental|Severe COVID-19 ZYESAMI™|Patients with Severe COVID-19 to be treated with inhaled ZYESAMI™ (aviptadil) by mesh nebulizer 100μg 3x daily
3384149|NCT05137795|Experimental|Severe COVID-19 Placebo|Patients with Severe COVID-19 to be treated with inhaled placebo 3x daily
3384150|NCT05132205|Experimental|Radiofrequency Ablation|Patients will receive RFA as a one-time intervention, with a possible second treatment after 6 months if adequate resolution is not noted on ultrasound.
3384151|NCT05125822|Experimental|Meal Replacement and Lifestyle Therapy|Participants in this study will have an 8-week meal replacement therapy period in which they are asked to reduce their BMI by 5% by following a prescribed eating regimen consisting of meal replacement shakes and/or frozen meals for breakfast and lunch. For dinner they will consume a pre-packaged frozen entree to be consumed with two servings of fruit and three servings of vegetables per day. Participants will also have lifestyle/behavioral modification counseling every 2 weeks throughout the entire study.
3384152|NCT05120232|Active Comparator|Unified Protocol (UP)|The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy that has been shown to be effective for treating emotional disorders. The UP targets negative emotions and helps people respond to their emotions in ways that are more helpful for them and in line with their goals. This will be delivered entirely on an online platform.
3384153|NCT05120232|Experimental|Modified Unified Protocol (UP+)|A modified version of the UP (called the UP+) delivered entirely on an online platform that will include exercises specifically designed to enhance positive emotions.
3384156|NCT05111743||Brolucizumab|Participants received brolucizumab injection during the index period
3384157|NCT05110209||Aflibercept|Patients/patient eyes who were treated only with aflibercept in 2019
3384158|NCT05110209||Ranibizumab|Patients/patient eyes who were treated only with ranibizumab in 2019
3384159|NCT05110209||Bevacizumab|Patients/patient eyes who were treated only with bevacizumab in 2019
3384160|NCT05110209||≥2 Different Anti- VEFGFs|Patients/patient eyes who were treated with ≥2 different anti-VEGFs in 2019
3384163|NCT05105048|Experimental|mRNA-1647|CMV-seronegative or CMV-seropositive participants will receive mRNA-1647 vaccine by intramuscular (IM) injection in a 0-, 2-, and 6-month schedule.
3384164|NCT05105048|Placebo Comparator|Placebo|CMV-seronegative or CMV-seropositive participants will receive placebo matching to mRNA-1647 vaccine by IM injection in a 0-, 2-, and 6-month schedule.
3384167|NCT05100225|Experimental|PTP-001 200 mg|A single intra-articular injection in the target knee of PTP-001 200 mg.
3384168|NCT05100225|Experimental|PTP-001 100 mg|A single intra-articular injection in the target knee of PTP-001 100 mg.
3384169|NCT05100225|Placebo Comparator|Placebo/saline|A single intra-articular injection in the target knee of 4mL of placebo control - physiological saline (0.9% sodium chloride injection, USP).
3384170|NCT05096832|Experimental|V-01 COVID-19 Vaccine|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
3384171|NCT05096832|Placebo Comparator|Placebo control|1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac).
3384172|NCT05096143||Naive Sacubitril/valsartan|Participants who were prescribed with Naive Sacubitril/valsartan
3384173|NCT05096143||Naive ACEi/ARB|Participants who were prescribed with Naive Angiotensin-converting enzyme inhibitors/Angiotensin II receptor antagonists (ACEi/ARB)
3384174|NCT05095727|Experimental|mRNA-3745|Participants will receive a single IV dose of mRNA-3745 on Day 1.
3384176|NCT05093335|Experimental|[68Ga]-Pentixafor|An intravenous bolus of 4.1 mCi (150 MBq) ± 10% of [68Ga]-Pentixafor will be injected in all participants that will be imaged on a hybrid PET/CT device. Any of the following factors may determine if imaging cannot be performed: tolerance/compliance in the PET/CT scanner; dose availability; dose quality control; availability of the PET/CT scanner or availability of study personnel. [68Ga]-Pentixafor uptake dynamics / pharmacokinetics will be evaluated by PET/CT performed with a low-dose CT component used for PET attenuation correction (1-2 mSv). [68Ga]-Pentixafor-PET/CT scan duration will be approximately 1.5 hours. Some patients will have two scans.
3384179|NCT05091749|Experimental|chronic coronary syndromes|
3384180|NCT05090982||Patients with Atopic dermatitis|150 patients with Atopic dermatitis
3384181|NCT05086237|Experimental|Basic reminder|Participants will be sent a basic text message reminder of their missed well-child visit. The exact wording of the text message will be finalized once the open trial is complete.
3384182|NCT05086237|Experimental|Detailed reminder|Participants will be sent a text message reminder of their missed well-child visit that mentions the importance of well-child visits and/or includes the provider/clinic name. The exact wording of the text message will be finalized once the open trial is complete.
3384183|NCT05086237|No Intervention|Treatment as usual|This group will receive treatment as usual, which involves no text messaging follow-up.
3384184|NCT05085184|Experimental|UI018|
3384185|NCT05085184|Active Comparator|UIC201806 and UIC201602|
3384186|NCT05082831|Active Comparator|microfracture surgery + HST003|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the study intervention (HST003). HST003 will be injected into the microfracture defects (interstices) and fill the remainder of the defect to the cartilage margin following surgery.
3384187|NCT05082831|No Intervention|microfracture surgery only|This is an Intervention Model where all patients who are identified/confirmed candidates for microfracture surgery will be enrolled to receive the microfracture surgery (standard of care). Ten (10) patients will be randomized to receive the microfracture surgery (standard of care).
3384188|NCT05079568|Experimental|Active VR Group|"Subjects will be provided an Oculus Go VR headset pre-loaded with a menu of virtual reality programs which have been designed specifically to treat both acute and chronic pain. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes."
3384189|NCT05079568|Sham Comparator|Sham VR Group|Subjects will be provided an Oculus Go VR headset pre-loaded two-dimensional nature video. Subjects are required to use the VR headset at home four times daily, prior to breakfast, lunch, dinner, and bedtime. Each session will last approximately 15 minutes.
3384195|NCT05072444|Experimental|QPX7728|Drug: QPX7728 beta lactamase inhibitor Other names: IV
3384196|NCT05072444|Experimental|QPX2014|Drug: QPX2014 antibiotic Other names: IV
3384197|NCT05068076|Experimental|Patients undergoing ablation for HCC|Pre-procedure CEUS will be performed on patients undergoing ablation followed by targeting of lesions for precise needle placement in the Kupffer phase. 2 hours post procedure USG with contrast will also be done for response assessment
3384198|NCT05063084|Experimental|OHD (HFNO)|High flow nasal oxygen
3384199|NCT05063084|Other|Control|Classic pre-oxygenation with facemask
3384201|NCT05061979|Experimental|Mild renal impairment|Participants with mild renal impairment will receive a single dose of BAY1747846.
3384202|NCT05061979|Experimental|Moderate renal impairment|Participants with moderate renal impairment will receive a single dose of BAY1747846.
3384203|NCT05061979|Experimental|Normal renal function|Participants with normal renal function will receive a single dose of BAY1747846.
3384204|NCT05056974|Experimental|UB-421 + chidamide|UB-421 + chidamide combination therapy
3384205|NCT05056727|Experimental|Sodium Zirconium Cyclosilicate (SZC)|SZC 5 g every other day to 15 g once daily + Lisinopril/Valsartan
3384206|NCT05056727|Placebo Comparator|Placebo|Placebo + Lisinopril/Valsartan
3384207|NCT05055128|Experimental|X842 25 mg BID|Patients will receive 2 tablets (X842 25mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 25 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
3384208|NCT05055128|Experimental|X842 50 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 dummy) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg + X842 dummy) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
3384209|NCT05055128|Experimental|X842 75 mg BID|Patients will receive 2 tablets (X842 50 mg + X842 25 mg) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
3384210|NCT05055128|Experimental|X842 100 mg BID|Patients will receive 2 tablets (X842 50 mg×2) and 1 capsule (Lansoprazole dummy) in the morning, and 2 tablets (X842 50 mg×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
3384211|NCT05055128|Active Comparator|Lansoprazole|Patients will receive 2 tablets (X842 dummy×2) and 1 capsule (Lansoprazole 30 mg) in the morning, and 2 tablets (X842 dummy×2) in the evening during 4-week double-blind treatment. Thereafter, patients will receive 1 capsule of Lansoprazole 30 mg QD for 4 weeks.
3384212|NCT05053659|Experimental|Loncastuximab tesirine & venetoclax|"Participants will receive a baseline disease assessment via PET/CT in FDG avid lymphomas; CT scan (chest, abdomen, pelvis; inclusion of neck in selected cases). Bome marrow biopsy in selected cases.~Premedication includes:~Allopurinol (to reduce uric acid) 300mg orally daily starting day -1 and continuing at least until day 7 of each cycle.~Dexamethasone (steroid pre-medication) 4mg orally twice daily on day -1, day 1 and day 2 of each cycle.~Adequate oral hydration starting on day -1 or -2, defined as 1 - 2 liters of oral intake of liquids in 24 hours~Study treatment to be given every 21 days.~Loncastuximab tesirine (50 - 150 μg/kg) intravenously (IV) on day 1 of each 21-day cycle~Venetoclax (400 - 800 mg) orally, every day on days 1 - 5 of each 21-day cycle. Dose ramp-up on cycle 1 (over days 1 - 5 for target dose 400mg, 1 - 6 for target dose 600mg and 1 - 7 for target dose 800mg"
3384215|NCT05051566|Experimental|LY3502970 Prototype (Part A)|Multiple doses of LY3502970 prototype administered orally.
3384216|NCT05051566|Experimental|LY3502970 Reference (Part A)|Multiple doses of LY3502970 reference administered orally.
3384217|NCT05051566|Experimental|LY3502970 Prototype (Part B)|Multiple doses of LY3502970 prototype administered orally.
3384218|NCT05051566|Experimental|LY3502970 Reference (Part B)|Multiple doses of LY3502970 reference administered orally.
3384219|NCT05051566|Active Comparator|Esomeprazole (Part B)|Multiple doses of Esomeprazole (Proton Pump Inhibitor) administered orally.
3384223|NCT05048342|Experimental|Arm 1|LOU064 open-label treatment taken orally for 52 weeks.
3384224|NCT05044923|Experimental|Targeted Epidural Spinal Stimulation|Participants will undergo surgery to implant devices that will be used for Targeted Epidural Spinal Stimulation (TESS).
3384225|NCT05044897|Experimental|Study treatment|"SI-B001 is a bispecific antibody targeting EGFR and HER3, which is administered weekly by intravenous infusion（QW）.~The 4-week cycle was maintained until disease progression or cessation due to intolerable toxicity or other reasons (e.g., withdrawal of informed consent or death). From C1D1, efficacy was evaluated every 8 weeks ±7 days in the first year and every 12 weeks ±7 days in the second year."
3384232|NCT05042648|No Intervention|Control group (Group A)|Group A will receive no intervention
3384233|NCT05042648|Experimental|Buprenorphine group (Group B)|Group B will receive buprenorphine patch of 10 mg (sustained release of 10 µg/h) applied either on chest or on outer side of arm 12 h before surgery. The transdermal buprenorphine patch should be applied to intact skin on the flat surfaces of the upper outer arm, upper chest, upper back, or the side of the chest.
3384236|NCT05039944|Experimental|SI-B001_A|Patients with unresectable or metastatic gastric cancer, HER2-negative and without standard treatment were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384237|NCT05039944|Experimental|SI-B001_B|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed conventional chemotherapy combined with EGFR mab were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384238|NCT05039944|Experimental|SI-B001_C|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed multiple lines of conventional chemotherapy (excluding EGFR monoclonal antibody) were treated with SI-B001 monotherapy.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384239|NCT05039944|Experimental|SI-B001 combined with irinetecan_D|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed to receive anti-PD-1 (L1) mab (excluding EGFR mab) in the first or second line were treated with SI-B001 in combination with irinetecan in the third line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384240|NCT05039944|Experimental|SI-B001 combined with FOLFIRI or FOLFOX_E|Patients with MSI-H KRASwt BRAFwt unresectable or metastatic colorectal cancer who had previously failed first-line anti-PD-1 (L1) mab were treated with SI-B001 in combination with FOLFIRI or FOLFOX for second-line treatment.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384241|NCT05039944|Experimental|SI-B001 combined with irinetecan_F|Patients with MSS KRASwt BRAFwt unresectable or metastatic colorectal cancer who had failed standard first-line treatment containing oxaliplatin or irinotecan plus fluorouracil plus or minus bevacizumab were treated with SI-B001 plus irinotecan in the second-line.SI-B001 is administered by intravenous drip twice weekly (Q2W).
3384242|NCT05039710|Experimental|Cohort 1: JNJ-75220795 or Placebo|Participants will receive single subcutaneous (SC) dose of JNJ-75220795 Dose 1 or matching placebo on Day 1 in Cohort 1.
3384243|NCT05039710|Experimental|Cohort 2: JNJ-75220795 or Placebo|Participants will receive single SC dose of JNJ-75220795 Dose 2 or matching placebo on Day 1 in Cohort 2.
3384244|NCT05037929|Experimental|Astegolimab Q2W|Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W).
3384245|NCT05037929|Experimental|Astegolimab Q4W|Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W).
3384246|NCT05037929|Placebo Comparator|Placebo|Participants will receive SC placebo Q2W.
3384247|NCT05035511|Experimental|Responders vs Non-responders|After the tDCS outcome recorded immediately after tDCS treatment, participants will be categorized into responders and non-responders based on the percentage of change in the total SRS score (primary outcome). Participants that show reductions of at least 10% in the total SRS scores as compared to baseline scores will be considered responders.
3384250|NCT05032157|Experimental|Arm 1: LOU064 (blinded)|LOU064A (blinded) taken orally b.i.d. for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
3384251|NCT05032157|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064A placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomised in 2:1 ratio (active vs placebo)
3384253|NCT05030311|Experimental|Arm 1: LOU064 (blinded)|LOU064 (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally open label for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
3384254|NCT05030311|Placebo Comparator|Arm 2: LOU064 placebo (blinded)|LOU064 placebo (blinded) taken orally for 24 weeks, followed by LOU064 (open-label) taken orally for 28 weeks. Randomized in a 2:1 ratio (arm 1:arm 2).
3384255|NCT05029102|Experimental|TAS-102 and Anlotinib|TAS-102: 35 mg/m2，per oral，twice daily, days 1-5 and 8-12 of each 28-day cycle Anlotinib: 10mg，per oral，once daily，days 1-14 of each 21-day cycle
3384263|NCT05027269|Experimental|Part A Single Dose: AOC 1001 Dose Level 1|AOC 1001 will be administered once.
3384264|NCT05027269|Placebo Comparator|Part A Single Dose: Placebo|Saline will be administered once.
3384265|NCT05027269|Experimental|Part B Multiple Ascending Dose: AOC 1001 Dose Levels 2-4|AOC 1001 will be administered three times.
3384266|NCT05027269|Placebo Comparator|Part B Multiple Ascending Dose: Placebo|Saline will be administered three times.
3384269|NCT05026047|Experimental|patients consulting in an infectious disease department|no comparator
3384270|NCT05023343|Active Comparator|Active|Unilateral transmuscular quadratus lumborum block using 30 mL 0.75% ropivacaine
3384271|NCT05023343|Placebo Comparator|Placebo|Unilateral transmuscular quadratus lumborum block using 30 mL isotonic saline
3384272|NCT05022654|Experimental|SI-B001 combined with irinotecan_A|Patients with recurrent metastatic esophageal squamous cell carcinoma who had failed first-line therapy with PD-1(L1) mab were enrolled.
3384273|NCT05022654|Experimental|SI-B001 combined with irinotecan_B|Patients with recurrent metastatic esophageal squamous cell carcinoma who had failed second-line treatment with PD-1(L1) mab were enrolled.
3384274|NCT05020769|Experimental|SI-B001 combined with osimertinib_A|Patients with locally advanced/metastatic NSCLC progressed on 3rd generation EGFR-TKI treatment.
3384275|NCT05020769|Experimental|SI-B001 combined with osimertinib_B|Patients with locally advanced/metastatic NSCLC progressed on prior EGFR-TKI treatment and with T790M negative mutation.
3384276|NCT05020769|Experimental|SI-B001 combined with osimertinib_C|Patients with locally advanced/metastatic NSCLC and with EGFR exon20ins mutation.
3384277|NCT05020457|Experimental|SI-B001 combined with AP or TP_A|SI-B001 combined with Platinum-based chemotherapy(AP or TP). Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant after first-line treatment with anti-PD-1 /L1 mab alone.
3384278|NCT05020457|Experimental|SI-B001 combined with Docetaxel_B|Patients with EGFRwt/ALKwt non-small cell lung cancer were included and progressed or were intolerant after first-line treatment with platinum-based two-drug chemotherapy plus anti-PD-1 /L1 mab.
3384279|NCT05020457|Experimental|SI-B001 combined with Docetaxel_C|Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant to treatment with anti-PD-1 /PD-L1 monoclonal antibody after first-line or above chemotherapy.
3384280|NCT05018104||Lower Limb Orthopedic Surgery Patients who Received Popliteal Sciatic Nerve Blocks|All patients undergoing lower limb surgery who received popliteal sciatic nerve blocks (with or without other peripheral nerve blocks) at St. Paul's Hospital from January 4, 2016 to November 1, 2019
3384295|NCT05008562||COVID-19 RELATED MUSCLE MASS CHANGE IN THE INTENSIVE CARE UNIT|"Patients over the age of 18 who are hospitalized in our intensive care unit with a diagnosis of COVID-19 will be included in the study.~The day the patients are admitted to the intensive care unit will be considered the 1st day of the study. SOFA, qSOFA, APACHE II, CRP, procalcitonin values will be recorded on the first day. On the first day of our patients, rectus femoris muscle thickness measurement will be done ultrasonographically (bilateral). In addition, bilateral thigh circumference will be measured anthropometrically (with a tape measure). It is planned to evaluate the muscle strength of the patients according to the MRC (Medical Research Council) scoring.~In addition to these measurements, the creatine kinase values in the routine clinical follow-up of the patients, the differences between the fluid intake and output values, inotropic supplements used in their treatment, diuretic needs, and neuromuscular blocker use will also be noted."
3384298|NCT05007145|Experimental|PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin|Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.
3384299|NCT05007145|Active Comparator|Albumin-bound paclitaxel+cisplatin+radiotherapy|Participants receive albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.
3384300|NCT05006339|Experimental|Dental Monitoring|Orthodontic retention review via dental monitoring only
3384301|NCT05006339|Active Comparator|Clinic Review|Orthodontic retention review via in-office visits as per routine care
3384302|NCT05006313|Experimental|Intraoperative fluorescence angiography|Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
3384303|NCT04993768|Experimental|TPN-101, Dose A|
3384304|NCT04993768|Experimental|TPN-101, Dose B|
3384305|NCT04993768|Experimental|TPN-101, Dose C|
3384306|NCT04993768|Placebo Comparator|Placebo|
3384307|NCT04992520|Experimental|Group 1A: S. sonnei 53G|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
3384308|NCT04992520|Experimental|Group 1B: S. flexneri 2a 2457T|"At least 3 months after challenging Group 1A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
3384309|NCT04992520|Experimental|Group 2A: S. flexneri 2a 2457T (1500 cfu)|"30 naïve participants will be challenged with 1500 colony forming units (cfu) of S. flexneri 2a~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
3384310|NCT04992520|Experimental|Group 2B: S. sonnei 53G|"At least 3 months after challenging Group 2A, 20 of those volunteers, along with 10 newly recruited naïve participants, will be challenged with 1500 cfu of S. sonnei 53G~Mode of Administration: After a 90 minute fast subjects will drink the 120 mL of sodium bicarbonate (to neutralize gastric acidity) and then drink the challenge suspension within 2 minutes."
3384311|NCT04991805||Benralizumab|Patients who have received Benralizumab.
3384312|NCT04991805||Other biologics|Patients who have received non benralizumab biologics.
3384313|NCT04991805||Non-biologic|Patients who have received non biologic drug.
3384314|NCT04990388|Experimental|Stage 1: UX053 Dose Level 1S|Participants to receive a single, peripheral intravenous (IV) infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
3384315|NCT04990388|Experimental|Stage 1: UX053 Dose Level 2S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
3384316|NCT04990388|Experimental|Stage 1: UX053 Dose Level 3S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
3384317|NCT04990388|Experimental|Stage 1: UX053 Dose Level 4S|Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.
3384318|NCT04990388|Experimental|Stage 2: UX053 Dose Level 1R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker every 2 weeks (Q2W) for 5 doses.
3384319|NCT04990388|Experimental|Stage 2: UX053 Dose Level 2R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
3384320|NCT04990388|Experimental|Stage 2: UX053 Dose Level 3R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
3384321|NCT04990388|Experimental|Stage 2: UX053 Dose Level 4R|Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
3384322|NCT04990388|Placebo Comparator|Stage 2: Placebo Dose|Participants randomized to receive a single, peripheral IV infusions of matching placebo, plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.
3384327|NCT04987203|Experimental|Tivozanib in Combination with Nivolumab|Subjects with refractory advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment [for nivolumab] whichever occurs first.
3384328|NCT04987203|Experimental|Tivozanib|Subjects with refractory advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.
3384329|NCT04983680|Experimental|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy (MBCT) is an 8-week group intervention (1.5-hour weekly sessions) that combines cognitive-behavioral therapy and mindfulness training to treat emotional problems.
3384335|NCT04975893|Other|CMV-seropositive and CMV-seronegative Participants|CMV-seropositive and CMV-seronegative participants who completed Study mRNA-1647-P202 will be followed every 6 months for 3 years in this study after the final visit in Study mRNA-1647-P202.
3384336|NCT04973228|Active Comparator|Experimental: ARQ-154 Foam 0.3%|
3384337|NCT04973228|Placebo Comparator|Placebo Comparator: ARQ-154 Vehicle Foam|
3384338|NCT04971785|Experimental|SEMA + CILO/FIR FDC|Participants will receive semaglutide (SEMA) 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and fixed-dose combination (FDC) of cilofexor and firsocostat (CILO/FIR 30 mg/20 mg) once daily for 72 weeks
3384339|NCT04971785|Experimental|SEMA + Placebo-To-Match (PTM) CILO/FIR|Participants will receive SEMA 0.24-2.4 mg once weekly (dose escalation every 4 weeks) and PTM CILO/FIR administered once daily for 72 weeks
3384340|NCT04971785|Experimental|PTM SEMA + CILO/FIR FDC|PTM Semaglutide once weekly and CILO/FIR 30 mg/20 mg FDC administered once daily for 72 weeks
3384341|NCT04971785|Placebo Comparator|PTM SEMA + PTM CILO/FIR|PTM Semaglutide once weekly and PTM CILO/FIR once daily for 72 weeks
3384346|NCT04968951|Active Comparator|FMT with Antibiotics|Participants will receive antibiotics before receiving Fecal Microbiota Transplantation
3384347|NCT04968951|Placebo Comparator|FMT with placebo|Participants will receive placebo before receiving Fecal Microbiota Transplantation
3384348|NCT04964544|Other|Open Label, Single Arm Technology-Assisted Cholesterol Trial|Open Label Single Arm study in All-comers population who self-report having concern about high cholesterol or heart health
3384352|NCT04962477||Pregnant|
3384353|NCT04962477||Non-pregnant|
3384357|NCT04958304||Moderna COVID-19 Vaccine in Pregnant Women|The Moderna COVID-19 Vaccine Pregnancy Registry will collect primary data from pregnant women who have received the Moderna COVID-19 vaccine and their healthcare providers (HCPs).
3384358|NCT04956068|Experimental|Unresectable PM group|Patients who have progressed on conventional systemic therapy and PIPAC is used as a palliative strategy.
3384359|NCT04956068|Experimental|Extensive PM group|Patients who have significant volume of peritoneal disease are treated with the intent for potential conversion to curative surgery. Role of PIPAC is as an adjunct to systemic chemotherapy to downstage peritoneal metastases.
3384360|NCT04953962|Experimental|Arm 1: CBP501 (25) + Cisplatin + Nivolumab|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
3384361|NCT04953962|Experimental|Arm 2: CBP501 (16) + Cisplatin + Nivolumab|CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
3384362|NCT04953962|Experimental|Arm 3: CBP501 (25) + Cisplatin|CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
3384363|NCT04953962|Experimental|Arm 4: Cisplatin + Nivolumab|Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
3384364|NCT04952857|Experimental|Intervention|Vitamn D 6 lakh IU oral stat
3384365|NCT04952857|Placebo Comparator|Placebo|Placebo equal volume/ weight
3384377|NCT04943445|Experimental|Treatment: Single Arm|"Induction chemo-immunotherapy:~Carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.~Concurrent radio-immunotherapy:~Radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles. Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.~Consolidation immunotherapy:~Pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses."
3384378|NCT04941365|Experimental|single arm|Blood samples will be collected at baseline(Visit 1), and during therapy at visit 2 (around one month after the treatment starting) and at Visit 3 (around three months after the treatment starting. And, optionally, in case of a disease progression (PD).
3384388|NCT04932018|Experimental|Interventional|The intervention group will participate in a round table educational session with a study facilitator/mentor farmer and occupational health nurse plus receive an invitation to participate in an interactive virtual community providing ongoing resources and support from community farmers and agriculture experts.
3384389|NCT04932018|Sham Comparator|Attention Control|The second group (attention control) will receive an invitation to participate in the virtual community without mentor interaction.
3384390|NCT04930432|Experimental|MCLA-129|In the dose escalation phase 1 part, MCLA-129 will be administered every two weeks with increasing doses to patients with advanced solid tumors. In Part 2, patients with NSCLC and other advanced solid tumors in each corhort will be dosed with MCLA-129 every two weeks at the RP2D.
3384391|NCT04928261|Experimental|De-escalated HER2 targeted treatment|Patients with early-stage HER2-positive breast cancer who demonstrate a pathological complete response at time of surgery.
3384396|NCT04923295|Experimental|Pre Treatment and post treatment|Patients on Peritoneal Dialysis will be evaluated by PET and transport status Patients on Peritoneal Dialysis will be evaluated by PET after treatment with Dapagliflozin
3384403|NCT04917614|Active Comparator|group teas|Patients in the TEAS group will receive preoperative TEAS for 30 min before the spinal anesthesia at Hegu (LI4), Neiguan (PC6), and Zusanli (St 36) with an electronic acupuncture device.
3384404|NCT04917614|Sham Comparator|Control Group|In the sham group, the patients were connected to the electronic acupuncture, but electronic stimulation was not applied.
3384405|NCT04916990|Active Comparator|CARES Intervention|All participants will complete surveys to assess Quality of Care and Patient Reported outcomes at baseline, 3 months and 6 months. The CARES intervention will include a maximum of 10 navigation and 10 counseling sessions delivered over approximately a 6- month period delivered by oncology nurse navigators and master's level counselors. Sessions will be scheduled to correspond with key transition points during treatment and may be held in person, virtually, or by phone.
3384406|NCT04916990|No Intervention|Usual Care|All participants will complete surveys to assess Quality of Care and Patient Reported Outcomes. Patients will receive a standardized list of resources.
3384407|NCT04915534|Other|Women - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
3384408|NCT04915534|Other|Men - low cuff pressure|A cuff pressure of 45 cm H2O is used to block the laryngeal mask
3384409|NCT04915534|Other|Women - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
3384410|NCT04915534|Other|Men - normal cuff pressure|A cuff pressure of 60 cm H2O is used to block the laryngeal mask
3384420|NCT04908163|Active Comparator|Nutritional education group (NEG)|"Participants in the nutritional education group will be given a leaflet with written nutrition educational information to follow a Mediterranean diet. Participants will be encouraged to adhere to this diet for one month. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured."
3384421|NCT04908163|Experimental|Culinary intervention group (CIG)|"Participants assigned to the culinary intervention group will receive a written nutrition educational information as well as eight online nutritional and cooking classes during the one-month intervention period. Four visits will be scheduled for participants assigned to this group:~(1) before randomization (T1); (2) after randomization and before the the beginning of the intervention (T2); and (3) (4) after the intervention (T3)(T4). In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Participants will receive 8 culinary workshops between visit 2 and visit 3. In all time-points, questionnaires will be registered and at T2 and T4 blood samples will be collected and advanced glycation end-products will be measured.~Volunteers will be also contacted by phone after 6 months of the end of the intervention to collect information about food and culinary habits."
3384422|NCT04908111|Experimental|Safety Run In|Six evaluable patients will receive the trial vaccines with standard of care treatment to confirm they are safe before opening the next stage of the trial. These patients will not be randomised.
3384423|NCT04908111|Experimental|Arm A: Trial vaccines with standard of care treatment|Approximately 40 patients will be randomised to receive the trial vaccines with standard of care treatment in this arm.
3384424|NCT04908111|Other|Arm B: Standard of care treatment|Approximately 40 patients will be randomised to receive standard of care treatment alone in this arm.
3384425|NCT04907240||Iliac|Subjects with de novo or restenotic lesions in the iliac arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384426|NCT04907240||Superficial Femoral Artery (SFA)|Subjects with de novo or restenotic lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384427|NCT04907240||Superficial Femoral Artery (SFA) In-Stent Restenosis (ISR)|Subjects with in-stent restenosis lesions in the SFA and proximal popliteal arteries treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384428|NCT04907240||AV access|Subjects with stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous (AV) access graft and in the venous outflow of dialysis access circuits, including the central veins treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384429|NCT04907240||Popliteal Artery Aneurysms|Subjects with popliteal artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384430|NCT04907240||Trauma/Injury|Subjects with traumatic or iatrogenic vessel injuries in arteries that are located in the chest cavity, abdominal cavity, or pelvis (except for aorta, coronary, innominate, carotid, vertebral, and pulmonary arteries) treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384431|NCT04907240||Visceral Artery Aneurysms|Subjects with isolated visceral artery aneurysms treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX)
3384432|NCT04907240||Others|Subjects treated with the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface (VSX) but do not fit any of the cohorts listed above.
3384433|NCT04904471|Experimental|Experimental|Three doses of recombinant SARS-CoV-2 vaccine (Sf9 Cell) on Day 0, Day 21and Day 42.
3384434|NCT04904471|Placebo Comparator|Placebo Comparator|Three doses of placebo on Day 0, Day 21and Day 42.
3384435|NCT04899310|Experimental|mRNA-3705|Treatment Period (during the Dose Optimization Stage and the Optional Dose Expansion Stage): 1 of up to 5 possible doses of mRNA-3705, administered intravenously (IV), once every 2 to 4 weeks (q2W to q4W), depending on participant's weight for up to 10 doses over approximately 40 weeks.
3384436|NCT04899232|Experimental|AT3 less than 100% with SOC plus AT3 supplement|Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.
3384437|NCT04899232|No Intervention|AT3 less than 100% with SOC only|Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.
3384438|NCT04899232|No Intervention|AT3 more than 100% with SOC only|Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.
3384444|NCT04893811|Experimental|Single Arm|Bivalent recombinant lipoprotein 2086 vaccine
3384445|NCT04891770|Experimental|Cohort 1: TAF + VIR-2218 + SLGN + Nivolumab|"Nucleos(t)ide(s) (NUC)-suppressed participants with chronic hepatitis B (CHB) will receive:~Tenofovir alafenamide (TAF) 25 mg once daily for 36 weeks (up to 84 weeks)~VIR-2218 200 mg once every 4 weeks for 24 weeks~At Week 12 the following will be added:~Selgantolimod (SLGN) 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Participants who are on TAF treatment and meet the criteria stopping at the end of trial (EOT) visit will stop all treatments, no later than follow-up (FU) Week 1 visit, and enter a treatment-free follow-up(TFFU) period"
3384446|NCT04891770|Experimental|Cohort 2 Group A: VIR-2218 + SLGN + Nivolumab|"Viremic participants with CHB will receive:~VIR-2218 200 mg once every 4 weeks for 24 weeks~At Week 12, the following will be added:~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
3384447|NCT04891770|Experimental|Cohort 2 Group B: SLGN + Nivolumab|"Viremic participants with CHB will receive:~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
3384448|NCT04891770|Experimental|VIR-2218 + SLN + Nivolumab|"Cohort 3 will be initiated at the discretion of the sponsor after Cohort 2 has completed enrollment.~Viremic participants with CHB will recieve:~VIR-2218 200 mg once every 4 weeks for 24 weeks~SLGN 3 mg once a week on the same day for 24 weeks~Nivolumab 0.3 mg/kg once every 4 weeks for 24 weeks~Viremic participants who meet criteria to initiate NUC treatment will receive TAF 25 mg once daily for up to 36 weeks during the study."
3384453|NCT04886258|Active Comparator|DFV890|DFV890
3384454|NCT04886258|Placebo Comparator|Placebo|Placebo
3384455|NCT04881045|Experimental|Dose Escalation (Part 1)|Participants will receive PF-07257876 at escalating dose levels.
3384456|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 1 (NSCLC)|Participants with non-small cell lung cancer (NSCLC) will receive PF-07257876 at the recommended dose from Part 1.
3384457|NCT04881045|Experimental|Dose Expansion (Part 2) - Cohort 2 (SCCHN)|Participants with squamous cell carcinoma of the head and neck (SCCHN) will receive PF-07257876 at the recommended dose from Part 1.
3384458|NCT04880850|Experimental|insulin icodec + insulin aspart|Participants will get once weekly injections in combination with 2-4 times daily injections of insulin aspart
3384459|NCT04880850|Active Comparator|Insulin glargine + insulin aspart|Participants will get once daily injections in combination with 2-4 times daily injections of insulin aspart
3384460|NCT04879940|Experimental|Prostatic Artery Embolization (PAE)|Participants who receive PAE with Merit Medical Embospheres.
3384461|NCT04877990|Experimental|Long-Term Extension Rollover Study: BMS-986165|
3384464|NCT04877652||ADHF patients|Patients with acute decompensated heart failure (ADHF) having insufficient response to diuretic therapy following a dose escalation protocol in keeping with AHA guidelines for the management of heart failure.
3384465|NCT04877054|Experimental|Intervention Arm|Intervention sessions will occur ~once per week, with all 4 sessions being completed within 4-8 weeks. Each session will include an education and motivational interviewing (MI) component.
3384466|NCT04877054|Active Comparator|Education only Arm|Participants in the education-only control arm will receive one education session. The education session will occur via telephone or telehealth. Education will include medication purpose and adherence strategy recommendations delivered in a single telehealth session.
3384467|NCT04876053|No Intervention|Standard Care|
3384468|NCT04876053|Experimental|Healthy Food Delivery Intervention|9000 calorie / week food box
3384469|NCT04871763|Experimental|Geldis® gel|Patients will brush their essix retainers with a toothbrush and with Geldis® gel.
3384470|NCT04871763|Active Comparator|Tablets|Patients will leave their essix retainers in a glass with water and Polident tablets.
3384471|NCT04871763|Active Comparator|Water|Patients will brush essix retainers with a toothbrush under running water.
3384472|NCT04870970||Tobacco Users|Participants in this group use some form of tobacco.
3384473|NCT04870970||Non-Tobacco Users|Participants in this group do not use tobacco products.
3384475|NCT04868500|Experimental|Clinical Pilot|Each participant will be asked to complete the symptoms log daily for up to 6 months. Additional surveys will be completed throughout the study by participants and MGH clinical staff.
3384478|NCT04861935|Placebo Comparator|ultrasound evaluation of sacral region in normal pediatric patients|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
3384479|NCT04861935|Active Comparator|ultrasound evaluation of sacral region in patients with sacral dimple|"Ultrasound evaluation of sacral region will be performed to detect spinal abnormality.~Dural sac level and its distance to estmated injection site, optimal entry angle for caudal block will be measured."
3384480|NCT04860297|Experimental|mRNA-1273|"All participants (healthy participants and SOT participants) will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.~All SOT participants will be offered the opportunity to receive a third dose of mRNA-1273 at Day 85.~SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the emergency use authorization (EUA) prior to enrollment will receive Dose 3 on Day 1."
3384481|NCT04858035|Experimental|Online Speech Training|"Participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. All participants will receive 12 sessions of perceptual training over 4 weeks. Finally, participants will complete a 3-session maintenance phase in which perception and production are probed but not treated. Perception will be measured using the identification and category goodness judgment.~Following completion of perception training all participants will complete two weeks of production training. The production training will consists of 4, 60-minute sessions. Each session will provide instruction and practice trials."
3384482|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 1|
3384483|NCT04857034|Experimental|Active Treatment: BMS-986165 Dose 2|
3384484|NCT04857034|Placebo Comparator|Placebo|
3384489|NCT04843319|Experimental|VERU-100 at various doses|150 mg, 200 mg, 300 mg or 400 mg of VERU-100
3384492|NCT04840693|Experimental|Excess of endogenous glucoglucocorticoids (group 1)|v
3384493|NCT04840693|Experimental|Exogenous hypercortisolisms (group 2)|a disease justifying the up-coming start of a glucocorticoid therapy
3384494|NCT04840693|Experimental|Adrenal insufficiency (group 3)|chronic adrenal insufficiency
3384495|NCT04840693|Other|Control (group 4)|without glucocorticoid excess
3384496|NCT04838743||IDegLira|Real-world adult population with type 2 diabetes mellitus in Japan.
3384498|NCT04829604|Experimental|HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory|"This global Phase 2 study is designed to assess anticancer activity and safety of ARX788 in HER2 positive metastatic breast cancer subjects whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.~The investigational medicinal product (IMP), ARX788, will be administered every 4 weeks (Q4W) by intravenous (IV) infusion."
3384501|NCT04828343|Experimental|Cohort 1 <50 kg|Study participants randomized to Cohort 1 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
3384502|NCT04828343|Experimental|Cohort 2 <50 kg|Study participants randomized to Cohort 2 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
3384503|NCT04828343|Experimental|Cohort 3 >=50 kg|Study participants randomized to Cohort 3 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered with a syringe driver.
3384504|NCT04828343|Experimental|Cohort 4 >=50 kg|Study participants randomized to Cohort 4 will receive a single dose of rozanolixizumab (RLZ) or placebo (PBO) subcutaneously administered by manual push.
3384505|NCT04825262|Experimental|Intervention genotyping group|"Patients who are scheduled to receive renal transplant from a living donor between January 2021 to January 2023. They will be assigned to receive the initial CYP3A5 genotype-based tacrolimus (FK) dose as determined by their CYP3A5 genotype.~CYP3A5 expresser (extensive or intermediate metabolizer) - 0.20mg/kg CYP3A5 non-expresser (poor metabolizer) - 0.15mg/kg~The starting dose of the intervention arm will be reviewed for every 10 patients recruited based on the drug levels achieved."
3384506|NCT04825262|No Intervention|Historical Control Group|Patients who received renal transplant from a living donor between January 2016 - December 2020 and received standard weight-based dosing of tacrolimus
3384510|NCT04822181|Experimental|Semaglutide OW (once weekly )|Semaglutide administrated subcutaneously once weekly
3384511|NCT04822181|Placebo Comparator|Placebo|Placebo administrated subcutaneously once weekly
3384512|NCT04821934|Experimental|Telerehabilitation (TR) at home + Telesurveillance program (TSu)|These COVID-19 patients will enter the usual telesurveillance program together with a specific remote rehabilitation program on exercise activity.
3384513|NCT04821934|Active Comparator|Telesurveillance (TSu) alone|These COVID-19 patients will enter the usual remote telesurveillance program
3384514|NCT04821830||Parkinson's disease patients who take levo-dopa as standard of care|Participants will undergo evaluation of the relationship between the LDR and movement vigor. All participants will undergo standard evaluation with standard clinical rating scales and three outcome measures: Tapping Speed Task - Measurement of Bradykinesia; Grip Strength Task - Measurement of Incentive-Outcome Coupling - Movement Vigor; Joystick Movement Task - Measurement of Incentive-Outcome Coupling - Movement Vigor. Some participants may opt in to an additional training and evaluation: Value Driven Attentional Oculomotor Capture.
3384515|NCT04821310|Active Comparator|Arm 1 Full Dose Pantoprazole and matching placebo|Full Healing Dose of pantoprazole
3384516|NCT04821310|Active Comparator|Arm 2 Half Dose Pantoprazole and matching placebo|Half Healing Dose of pantoprazole
3384517|NCT04819100|Experimental|Selpercatinib|Selpercatinib administered orally.
3384518|NCT04819100|Placebo Comparator|Placebo|Placebo administered orally.
3384519|NCT04819074||Patients with unruptured brain aneurysms|"We will